# RGD-PIPELINE: ftp-file-extracts # MODULE: cell lines build 2020-05-19 # GENERATED-ON: 2023/05/20 00:26:17 # CONTACT: rgd.data@mcw.edu # FORMAT: tab delimited text # NOTES: # This file provides cell line data in RGD. # The cell line data is either curated in RGD, or imported from Cellosaurus resource. # The file is in the tab-delimited format. # Multiple values in a single column are separated by ';' # COUNT: 145678 cell lines RGD ID Symbol Name Type Species Cellosaurus ID Description Source SO_ACC_ID Genomic Alteration Notes Origin Research Use Availability Gender Characteristics Phenotype Germline Competent Groups Caution 10053737 Crlj:WI-ES1/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced by mating Crlj:WI female with WI-Tg(L2-Venus)Nips male. has germ-line transmission Cryopreserved Female media used: 3i+LIF This ES cell line has ubiquitous venus gene expression. Yes 10053738 Crlj:WI-ES5/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced by mating Crlj:WI female with WI-Tg(L2-Venus)Nips male. has germ-line transmission Cryopreserved Female media used: 3i+LIF This ES cell line has ubiquitous Venus gene expression. Yes 10053739 Crlj:WI-ES10/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced by mating Crlj:WI female with WI-Tg(L2-Venus)Nips male. Cryopreserved Male media used: 3i+LIF This ES cell line has ubiquitous Venus gene expression. No 10053740 WI-Tg(CAG/Venus)Nips-ES4/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WI-Tg(CAG/Venus)Nips Cryopreserved Male media used: 3i+LIF This ES cell line has ubiquitous Venus gene expression. No 10053741 BN/CrlCrlj-ES4/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from BN/CrlCrlj has germ-line transmission Cryopreserved Male media used: 2i+LIF Yes 10053742 BN/CrlCrlj-ES6/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from BN/CrlCrlj Cryopreserved Female media used: 2i+LIF No 10053744 BN/CrlCrlj-ES3/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from BN/CrlCrlj Cryopreserved Male media used: 3i+LIF No 10053745 BN/CrlCrlj-ES5/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from BN/CrlCrlj has germ-line transmission Cryopreserved Male media used: 3i+LIF Yes 10054005 DA/Slc-ES1/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from DA/Slc has germ-line transmission Cryopreserved Male media used: 3i+LIF Yes 10054006 Crlj:WI-ES11/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from Crlj:WI has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054007 Crlj:WI-ES13/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from Crlj:WI has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054008 BN/CrlCrlj-ES7/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was electroporated with humanized Kusabira-Orange (huKO) gene (CAG/huKO-neo plasmid; 7.5 kb) into BN/CrlCrlj-ES4/Nips. has germ-line transmission Cryopreserved Male media used: 2i+rLIF This ES cell line has ubiquitous huKO gene expression. Yes 10054009 DA/Slc-ES2/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was electroporated with humanized Kusabira-Orange (huKO) gene (CAG/huKO-neo plasmid; 7.5 kb) into DA/Slc-ES1/Nips. has germ-line transmission Cryopreserved Male media used: 3i+LIF This ES cell line has ubiquitous huKO gene expression. Yes 10054010 WDB/Nips-ES1/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF This ES cell lines can participate in chimerae and transmit the characteristics through germline at high efficiency. Yes 10054011 WDB/Nips-ES41/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF Yes 10054012 WDB/Nips-ES47/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips Cryopreserved Male media used: 2i+LIF No 10054013 WDB/Nips-ES48/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054014 WDB/Nips-ES3/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054015 WDB/Nips-ES4/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054016 WDB/Nips-ES6/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+Forskolin Yes 10054017 WDB/Nips-ES7/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPANi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips Cryopreserved Male media used: 2i+Forskolin No 10054019 WDB/Nips-ES8/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPANi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i+Forskolin Yes 10054021 WDB/Nips-ES14/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i Yes 10054022 WDB/Nips-ES32/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i Yes 10054023 WDB/Nips-ES37/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB/Nips has germ-line transmission Cryopreserved Male media used: 2i Yes 10054025 WI-Tg(CAG/Venus)Nips-ES13/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WI-Tg(CAG/Venus)Nips Cryopreserved Male media used: 2i+LIF This ES cell line has ubiquitous Venus gene expression. No 10054026 WI-Tg(CAG/Venus)Nips-ES17/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WI-Tg(CAG/Venus)Nips Cryopreserved Male media used: 2i+LIF This ES cell line has ubiquitous Venus gene expression. No 10054027 F344/NSlc-ES37/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from F344/NSlc has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin Yes 10054029 WI-Tg(CAG/Venus)Nips-ES12/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WI-Tg(CAG/Venus)Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin This ES cell line has ubiquitous Venus gene expression. Yes 10054030 WI-Tg(CAG/Venus)Nips-ES20/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WI-Tg(CAG/Venus)Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin This ES cell line has ubiquitous Venus gene expression. Yes 10054032 WDB-Rosa26em1(RT2)Nips-ES2/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst produced from WDB-Rosa26em1(RT2)Nips has germ-line transmission Cryopreserved Male media used: 2i+LIF+Forskolin This ES cell line has ubiquitous tdTomato gene expression. Yes 10054033 WI-Tg(CAG/Venus)Nips-ES2/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst prepared by treatment of ovulated homozygote of WI-Tg(CAG/Venus)Nips female rat oocytes with ionomycin and cycloheximide. Cryopreserved Female Parthenogenetic ES cell line; media used: 2i+LIF+Forskolin This ES cell line has ubiquitous Venus gene expression. No 10054034 WI-Tg(CAG/Venus)Nips-ES5/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst prepared by treatment of ovulated homozygote of WI-Tg(CAG/Venus)Nips female rat oocytes with ionomycin and cycloheximide. has germ-line transmission Cryopreserved Female Parthenogenetic ES cell line; media used: 2i+LIF+Forskolin This ES cell line has ubiquitous Venus gene expression. Yes 10054035 WI-Tg(CAG/Venus)Nips-ES10/Nips embryonic stem cell Norway rat National Institute for Physiological Sciences, Okazaki Aichi, JAPAN CL:0000010 This ES cell line was made from blastocyst prepared by treatment of ovulated homozygote of WI-Tg(CAG/Venus)Nips female rat oocytes with ionomycin and cycloheximide. Cryopreserved Female Parthenogenetic ES cell line; media used: 2i+LIF+Forskolin This ES cell line has ubiquitous Venus gene expression. No 127227593 CVCL_A2JC MDCK-C09 transformed cell line dog CVCL_A2JC CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Transcriptome analysis by RNAseq Female Characteristics: Has a low tumorigenic potential 127227594 CVCL_A2JD MDCK-C35 transformed cell line dog CVCL_A2JD CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Transcriptome analysis by RNAseq Female Characteristics: Has a low tumorigenic potential 127227595 CVCL_A2JE MDCK-W73 transformed cell line dog CVCL_A2JE CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Has a high tumorigenic potential 127227596 CVCL_A8BA THP1-Dual KO-MAVS cancer cell line human CVCL_A8BA CL:0000010 Knockout cell: Method=Not specified; HGNC; 29233; MAVS; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227597 CVCL_A8BC THP1-Dual KO-RIG-I cancer cell line human CVCL_A8BC CL:0000010 Knockout cell: Method=Not specified; HGNC; 19102; RIGI; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227598 CVCL_A8BB THP1-Dual KO-MDA5 cancer cell line human CVCL_A8BB CL:0000010 Knockout cell: Method=Not specified; HGNC; 18873; IFIH1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227599 CVCL_A8BE THP1-HMGB1-Lucia cancer cell line human CVCL_A8BE CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4983; HMGB1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses a HMGN1-Lucia construct 127227600 CVCL_A8BD THP1-Dual KI-mSTING cancer cell line human CVCL_A8BD CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1919762; Sting1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227601 CVCL_A8BG THP1-Dual KI-hSTING-H232 cancer cell line human CVCL_A8BG CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Arg232His); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227602 CVCL_A8BF THP1-Dual KI-hSTING-A162 cancer cell line human CVCL_A8BF CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Ser162Ala); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227603 CVCL_A8AX THP1-Dual KO-TLR4 cancer cell line human CVCL_A8AX CL:0000010 Knockout cell: Method=Not specified; HGNC; 11850; TLR4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227604 CVCL_A8AW THP1-Dual KO-TLR2 cancer cell line human CVCL_A8AW CL:0000010 Knockout cell: Method=Not specified; HGNC; 11848; TLR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227605 CVCL_A8AZ THP1-Dual KO-IKKepsilon cancer cell line human CVCL_A8AZ CL:0000010 Knockout cell: Method=Not specified; HGNC; 14552; IKBKE; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227606 CVCL_A8AY THP1-Dual KO-TBK1 cancer cell line human CVCL_A8AY CL:0000010 Knockout cell: Method=Not specified; HGNC; 11584; TBK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227607 CVCL_A8AP THP1-KO-CASP4 cancer cell line human CVCL_A8AP CL:0000010 Knockout cell: Method=Not specified; HGNC; 1505; CASP4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227608 CVCL_A8AR THP1-KO-NLRC4 cancer cell line human CVCL_A8AR CL:0000010 Knockout cell: Method=Not specified; HGNC; 16412; NLRC4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227609 CVCL_A8AQ THP1-KO-GSDMD cancer cell line human CVCL_A8AQ CL:0000010 Knockout cell: Method=Not specified; HGNC; 25697; GSDMD; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227610 CVCL_A8AT THP1-ASC-GFP cancer cell line human CVCL_A8AT CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 16608; PYCARD; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses a PYCARD-GFP construct under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227611 CVCL_A8AS THP1-KO-NLRP3 cancer cell line human CVCL_A8AS CL:0000010 Knockout cell: Method=Not specified; HGNC; 16400; NLRP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227612 CVCL_A8AV THP1-Dual KO-IRF3 cancer cell line human CVCL_A8AV CL:0000010 Knockout cell: Method=Not specified; HGNC; 6118; IRF3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227613 CVCL_A8AU THP1-Dual KO-IFI16 cancer cell line human CVCL_A8AU CL:0000010 Knockout cell: Method=Not specified; HGNC; 5395; IFI16; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227614 CVCL_A8AH THP1-Dual KO-STING cancer cell line human CVCL_A8AH CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227615 CVCL_A8AG Raji-hVISTA cancer cell line human CVCL_A8AG CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 30085; VSIR; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227616 CVCL_A8AJ THP1-Dual KO-TREX1 cancer cell line human CVCL_A8AJ CL:0000010 Knockout cell: Method=Not specified; HGNC; 12269; TREX1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227617 CVCL_A8AI THP1-Dual KO-cGAS cancer cell line human CVCL_A8AI CL:0000010 Knockout cell: Method=Not specified; HGNC; 21367; CGAS; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227618 CVCL_A8AL THP1-Dual KO-IFNAR2 cancer cell line human CVCL_A8AL CL:0000010 Knockout cell: Method=Not specified; HGNC; 5433; IFNAR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227619 CVCL_A8AK THP1-Null2 cancer cell line human CVCL_A8AK CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227620 CVCL_A8AN THP1-KO-ASC cancer cell line human CVCL_A8AN CL:0000010 Knockout cell: Method=Not specified; HGNC; 16608; PYCARD; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127227621 CVCL_A8AM THP1-Dual KO-TRIF cancer cell line human CVCL_A8AM CL:0000010 Knockout cell: Method=Not specified; HGNC; 18348; TICAM1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227622 CVCL_A8CB RAW-Difluo mLC3 cancer cell line house mouse CVCL_A8CB CL:0000010 Transfected with: MGI; MGI:1914693; Map1lc3b; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Allows monitoring of autophagic flux in real time by detecting the appearance of dual red and green RFP:GFP:LC3 puncta or single red RFP:LC3 puncta by fluorescence microscopy Early in autophagy, both RFP and GFP signals are detected. As the fusion of the autophagosomes with the lysosomes progresses, the GFP fluorescence diminishes, leaving only the RFP fluorescence visible. The percentages of RFP-GFP positive and of RFP positive cells can be determined and these values can be used to assess autophagic flux (InVivoGen).; Characteristics: Stably expresses a RFP-GFP-Map1lc3b construct 127227623 CVCL_A8CA HeLa-Difluo hLC3 cancer cell line human CVCL_A8CA CL:0000010 Transfected with: HGNC; 13352; MAP1LC3B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Allows monitoring of autophagic flux in real time by detecting the appearance of dual red and green RFP:GFP:LC3 puncta or single red RFP:LC3 puncta by fluorescence microscopy Early in autophagy, both RFP and GFP signals are detected. As the fusion of the autophagosomes with the lysosomes progresses, the GFP fluorescence diminishes, leaving only the RFP fluorescence visible. The percentages of RFP-GFP positive and of RFP positive cells can be determined and these values can be used to assess autophagic flux (InVivoGen).; Characteristics: Stably expresses a RFP-GFP-MAP1LC3B construct 127227624 CVCL_A8CD 293-hMyD88 transformed cell line human CVCL_A8CD CL:0000010 Transfected with: HGNC; 7562; MYD88 (with p.Leu252Pro); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to study SARS-CoV-2-host cell fusion Upon transient transfection, with a spike expression plasmid, these cells become a SARS-CoV-2 mimic, which can then fuse with permissive reporter cells (InVivoGen). Group: SARS-CoV-2 research cell line 127227625 CVCL_A8CC THP1-Blue KI-IP10 cancer cell line human CVCL_A8CC CL:0000010 Knockout cell: Method=Not specified; HGNC; 10637; CXCL10; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: The coding sequence of CXCL10 has been replaced with the Lucia luciferase reporter gene under the control of the endogenous promoter and thus allows the direct study of CXCL10 induction; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 copies of the NF-kappaB consensus TRE and 3 copies of the c-Rel binding site 127227626 CVCL_A8CF HEK-Blue IL-10 transformed cell line human CVCL_A8CF CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5964; IL10RA; Transfected with: HGNC; 5965; IL10RB; Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human IL10 (and to a lesser extent mouse IL10) by monitoring the activation of the STAT3 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT3 promoter 127227627 CVCL_A8CE HEK-Blue CD40L transformed cell line human CVCL_A8CE CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11919; CD40; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive CD40L by monitoring the activation of the NF-kappaB pathway (InVivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127227628 CVCL_A8CH HEK-Blue IL-23 transformed cell line human CVCL_A8CH CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5971; IL12RB1; Transfected with: HGNC; 19100; IL23R; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse IL23 by monitoring the activation of the STAT3 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT3 promoter 127227629 CVCL_A8CG HEK-Blue IL-22 transformed cell line human CVCL_A8CG CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5965; IL10RB; Transfected with: HGNC; 13700; IL22RA1; Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse IL22 by monitoring the activation of the STAT3 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT3 promoter 127227630 CVCL_A8BY HEK-Blue STAT6-hSTING-R232 transformed cell line human CVCL_A8BY CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11368; STAT6; Transfected with: HGNC; 27962; STING1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a STAT6-responsive promoter 127227631 CVCL_A8BX HT29-Lucia AhR cancer cell line human CVCL_A8BX CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Female Characteristics: Used for the study of aryl hydrocarbon receptor (AhR) genomic signaling induction (InVivoGen); Characteristics: The Lucia luciferase reporter gene is under the control of a minimal promoter coupled with the human CYP1A1 gene entire regulatory sequence which contains 6 dioxin responsive elements (DRE) 127227632 CVCL_A8BZ THP1-Difluo hLC3 cancer cell line human CVCL_A8BZ CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 13352; MAP1LC3B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Allows monitoring of autophagic flux in real time by detecting the appearance of dual red and green RFP:GFP:LC3 puncta or single red RFP:LC3 puncta by fluorescence microscopy Early in autophagy, both RFP and GFP signals are detected. As the fusion of the autophagosomes with the lysosomes progresses, the GFP fluorescence diminishes, leaving only the RFP fluorescence visible. The percentages of RFP-GFP positive and of RFP positive cells can be determined and these values can be used to assess autophagic flux (InVivoGen).; Characteristics: Stably expresses a RFP-GFP-MAP1LC3B construct 127227633 CVCL_A8BQ HEK-Blue ISG transformed cell line human CVCL_A8BQ CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227634 CVCL_A8BP 293-Dual mSTING transformed cell line human CVCL_A8BP CL:0000010 Knockout cell: Method=Not specified; HGNC; 5434; IFNB1; Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1919762; Sting1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene expression depends on the activation of the endogenous IFNB1 promoter as the IFNB1 gene has been replaced by Lucia. 127227635 CVCL_A8BS HepG2-Dual cancer cell line human CVCL_A8BS CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 c-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227636 CVCL_A8BR HEK-Blue ISG-KO-STING transformed cell line human CVCL_A8BR CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227637 CVCL_A8BU HEK-Blue KO-ALPK1 transformed cell line human CVCL_A8BU CL:0000010 Knockout cell: Method=Not specified; HGNC; 20917; ALPK1; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127227638 CVCL_A8BT HepG2-Lucia AhR cancer cell line human CVCL_A8BT CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Used for the study of aryl hydrocarbon receptor (AhR) genomic signaling induction (InVivoGen); Characteristics: The Lucia luciferase reporter gene is under the control of a minimal promoter coupled with the human CYP1A1 gene entire regulatory sequence which contains 6 dioxin responsive elements (DRE) 127227639 CVCL_A8BW THP1-Dual KO-TLR8 cancer cell line human CVCL_A8BW CL:0000010 Knockout cell: Method=Not specified; HGNC; 15632; TLR8; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227640 CVCL_A8BV HEK-Blue KO-TIFA transformed cell line human CVCL_A8BV CL:0000010 Knockout cell: Method=Not specified; HGNC; 19075; TIFA; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127227641 CVCL_A8BI THP1-Dual KI-hSTING-R232 cancer cell line human CVCL_A8BI CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227642 CVCL_A8BH THP1-Dual KI-hSTING-M155 cancer cell line human CVCL_A8BH CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Val155Met); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227643 CVCL_A8BK 293-Dual Null transformed cell line human CVCL_A8BK CL:0000010 Knockout cell: Method=Not specified; HGNC; 5434; IFNB1; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene expression depends on the activation of the endogenous IFNB1 promoter as the IFNB1 gene has been replaced by Lucia. 127227644 CVCL_A8BJ THP1-Dual KI-hSTING-S154 cancer cell line human CVCL_A8BJ CL:0000010 Knockout cell: Method=Not specified; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Asn154Ser); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227645 CVCL_A8BM 293-Dual hSTING-H232 transformed cell line human CVCL_A8BM CL:0000010 Knockout cell: Method=Not specified; HGNC; 5434; IFNB1; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Arg232His); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene expression depends on the activation of the endogenous IFNB1 promoter as the IFNB1 gene has been replaced by Lucia. 127227646 CVCL_A8BL 293-Dual hSTING-A162 transformed cell line human CVCL_A8BL CL:0000010 Knockout cell: Method=Not specified; HGNC; 5434; IFNB1; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1 (with p.Ser162Ala); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene expression depends on the activation of the endogenous IFNB1 promoter as the IFNB1 gene has been replaced by Lucia. 127227647 CVCL_A8BN 293-Dual hSTING-R232 transformed cell line human CVCL_A8BN CL:0000010 Knockout cell: Method=Not specified; HGNC; 5434; IFNB1; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 27962; STING1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene expression depends on the activation of the endogenous IFNB1 promoter as the IFNB1 gene has been replaced by Lucia. 127227648 CVCL_A8AB Raji-Null cancer cell line human CVCL_A8AB CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227649 CVCL_A8AA Raji-hLAG3 cancer cell line human CVCL_A8AA CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6476; LAG3; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227650 CVCL_A8AD Raji-hPD-1 cancer cell line human CVCL_A8AD CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8760; PDCD1; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227651 CVCL_A8AC Raji-hOX40 cancer cell line human CVCL_A8AC CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11918; TNFRSF4; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227652 CVCL_A8AF Raji-hTIGIT cancer cell line human CVCL_A8AF CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 26838; TIGIT; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227653 CVCL_A8AE Raji-hPD-L1 cancer cell line human CVCL_A8AE CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227654 CVCL_A7ZZ Raji-hICOS cancer cell line human CVCL_A7ZZ CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5351; ICOS; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227655 CVCL_A7ZY Raji-HER2 cancer cell line human CVCL_A7ZY CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227656 CVCL_A7ZR A549-Dual KO-MDA5 hACE2-TMPRSS2 cancer cell line human CVCL_A7ZR CL:0000010 Knockout cell: Method=Not specified; HGNC; 18873; IFIH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Ideal for studying SARS-CoV-2 viral entry into host cells, the viral RNA sensing pathway, as well as screening small molecule inhibitors and neutralizing antibodies These cells are permissive to infection by SARS-CoV-2 Spike-pseudotyped viral particles (InVivoGen).; Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). Group: SARS-CoV-2 research cell line 127227657 CVCL_A7ZQ A549-Dual hACE2-TMPRSS2 cancer cell line human CVCL_A7ZQ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Ideal for studying SARS-CoV-2 viral entry into host cells, the viral RNA sensing pathway, as well as screening small molecule inhibitors and neutralizing antibodies These cells are permissive to infection by SARS-CoV-2 Spike-pseudotyped viral particles (InVivoGen).; Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). Group: SARS-CoV-2 research cell line 127227658 CVCL_A7ZT Jurkat-Lucia NFAT-CD16 cancer cell line human CVCL_A7ZT CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3619; FCGR3A; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter fused to 6 NFAT consensus transcriptional response elements 127227659 CVCL_A7ZS A549-Dual KO-RIG-I hACE2-TMPRSS2 cancer cell line human CVCL_A7ZS CL:0000010 Knockout cell: Method=Not specified; HGNC; 19102; RIGI; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Ideal for studying SARS-CoV-2 viral entry into host cells, the viral RNA sensing pathway, as well as screening small molecule inhibitors and neutralizing antibodies These cells are permissive to infection by SARS-CoV-2 Spike-pseudotyped viral particles (InVivoGen).; Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). Group: SARS-CoV-2 research cell line 127227660 CVCL_A7ZV Raji-h4-1BB cancer cell line human CVCL_A7ZV CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11924; TNFRSF9; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227661 CVCL_A7ZU Jurkat-Lucia NFAT-CD32 cancer cell line human CVCL_A7ZU CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3616; FCGR2A; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter fused to 6 NFAT consensus transcriptional response elements 127227662 CVCL_A7ZX Raji-hEGFR cancer cell line human CVCL_A7ZX CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227663 CVCL_A7ZW Raji-hCTLA4 cancer cell line human CVCL_A7ZW CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2505; CTLA4; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 127227664 CVCL_A7ZJ RAW-ASC KO-NLRC4 cancer cell line house mouse CVCL_A7ZJ CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:3036243; Nlrc4; Transfected with: MGI; MGI:1931465; Pycard; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Male 127227665 CVCL_A7ZI RAW-ASC KO-CASP11 cancer cell line house mouse CVCL_A7ZI CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:107700; Casp4; Transfected with: MGI; MGI:1931465; Pycard; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 127227666 CVCL_A7ZL RAW-Dual KO-TLR4 cancer cell line house mouse CVCL_A7ZL CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:1340094; Cxcl2; Knockout cell: Method=Not specified; MGI; MGI:96824; Tlr4; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression depends on the activation of the endogenous MIP-2/CXCL2 promoter as the Cxcl2 gene has been replaced by ALPP. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227667 CVCL_A7ZK RAW-Dual cancer cell line house mouse CVCL_A7ZK CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:1340094; Cxcl2; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase ALPP expression depends on the activation of the endogenous MIP-2/CXCL2 promoter as the Cxcl2 gene has been replaced by ALPP. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227668 CVCL_A7ZN A549-Dual KO-RIG-I cancer cell line human CVCL_A7ZN CL:0000010 Knockout cell: Method=Not specified; HGNC; 19102; RIGI; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227669 CVCL_A7ZM A549-Dual KO-MAVS cancer cell line human CVCL_A7ZM CL:0000010 Knockout cell: Method=Not specified; HGNC; 29233; MAVS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227670 CVCL_A7ZP A549-Dual KO-MDA5 cancer cell line human CVCL_A7ZP CL:0000010 Knockout cell: Method=Not specified; HGNC; 18873; IFIH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 127227671 CVCL_A7ZB RAW-Lucia ISG-KO-TRIF cancer cell line house mouse CVCL_A7ZB CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2147032; Ticam1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227672 CVCL_A7ZA RAW-Lucia ISG-KO-IRF1 cancer cell line house mouse CVCL_A7ZA CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96590; Irf1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227673 CVCL_A7ZD RAW-Lucia ISG-KO-IRF7 cancer cell line house mouse CVCL_A7ZD CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1859212; Irf7; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227674 CVCL_A7ZC RAW-Lucia ISG-KO-IRF5 cancer cell line house mouse CVCL_A7ZC CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1350924; Irf5; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227675 CVCL_A7ZF RAW-Lucia ISG-KO-MDA5 cancer cell line house mouse CVCL_A7ZF CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1918836; Ifih1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227676 CVCL_A7ZE RAW-Lucia ISG-KO-MAVS cancer cell line house mouse CVCL_A7ZE CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2444773; Mavs; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227677 CVCL_A7ZH RAW-ASC KO-GSDMD cancer cell line house mouse CVCL_A7ZH CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:1916396; Gsdmd; Transfected with: MGI; MGI:1931465; Pycard; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Male 127227678 CVCL_A7ZG RAW-ASC cancer cell line house mouse CVCL_A7ZG CL:0000010 Transfected with: MGI; MGI:1931465; Pycard; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 127227679 CVCL_A8JI 3G7 hybridoma house mouse CVCL_A8JI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227680 CVCL_A8JH 3G6 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227681 CVCL_A8JK 3H4 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227682 CVCL_A8JJ 3H2 hybridoma house mouse CVCL_A8JJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227683 CVCL_A8JM 5A1 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227684 CVCL_A8JL 3H6 hybridoma house mouse CVCL_A8JL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227685 CVCL_A8JN 9F2 hybridoma house mouse CVCL_A8JN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227686 CVCL_A8JA 3F1 hybridoma house mouse CVCL_A8JA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227687 CVCL_A8JC 3F4 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227688 CVCL_A8JB 3F2 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227689 CVCL_A8JE 3F6 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227690 CVCL_A8JD 3F5 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227691 CVCL_A8JG 3G2 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227692 CVCL_A8JF 3G1 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8JF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227693 CVCL_A8IX 3E1 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227694 CVCL_A8IW 3D7 hybridoma house mouse CVCL_A8IW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227695 CVCL_A8IZ 3E5 hybridoma house mouse CVCL_A8IZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227696 CVCL_A8IY 3E4 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227697 CVCL_A8IP 3C2 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227698 CVCL_A8IR 3C6 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227699 CVCL_A8IQ 3C4 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227700 CVCL_A8IT 3D2 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227701 CVCL_A8IS 3D1 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227702 CVCL_A8IV 3D5 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227703 CVCL_A8IU 3D3 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227704 CVCL_A8HG DHMi002-A induced pluripotent stem cell human CVCL_A8HG From: German Heart Center Munich; Munich; Germany CL:0000010 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227705 CVCL_A8HF DHMi001-A induced pluripotent stem cell human CVCL_A8HF From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127227706 CVCL_A8HI MLi004-A induced pluripotent stem cell human CVCL_A8HI From: Faculty of Medicine, University of Ljubljana; Ljubljana; Slovenia CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Arg682Ter (c.2044C>T); ClinVar=VCV001047976; Zygosity=Heterozygous (PubMed=34284275); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; c.6900+4A>G (IVS87+4A>G) (p.Gly2278_Gln2300del); ClinVar=VCV000374314; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=34284275) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 127227707 CVCL_A8HH DHMi003-A induced pluripotent stem cell human CVCL_A8HH From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127227708 CVCL_A8HK JHUi003-A induced pluripotent stem cell human CVCL_A8HK From: Johns Hopkins University; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 9305; PPP2R2B; Repeat_expansion; CAG[69]; ClinVar=VCV000005614; Zygosity=Heterozygous (PubMed=34087983); Sequence variation: Mutation; HGNC; 9305; PPP2R2B; Repeat_expansion_edited; CAG[72]; ClinVar=VCV000005614; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087983) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127227709 CVCL_A8HJ MUi023-A induced pluripotent stem cell human CVCL_A8HJ From: Mahidol University; Bangkok; Thailand CL:0000010 Discontinued: hPSCreg; MUi023-A; true. 127227710 CVCL_A8HM RCPFi005-A induced pluripotent stem cell human CVCL_A8HM From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Leu337Gln (c.1010T>A); Zygosity=Heterozygous (PubMed=34087982); Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Ala343Thr (c.1027G>A); ClinVar=VCV000159725; Zygosity=Heterozygous (PubMed=34087982) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227711 CVCL_A8HL RCPFi004-A induced pluripotent stem cell human CVCL_A8HL From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Glu786Lys (c.2356G>A); ClinVar=VCV001012262; Zygosity=Homozygous (PubMed=34087982) Population: Arab; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227712 CVCL_A8HA BJTTHi001-A induced pluripotent stem cell human CVCL_A8HA From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 127227713 CVCL_A8HC BJTTHi001-A-2 induced pluripotent stem cell human CVCL_A8HC From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10586; SCN1B Population: Chinese; Derived from sampling site: Peripheral blood. Male 127227714 CVCL_A8HB BJTTHi001-A-1 induced pluripotent stem cell human CVCL_A8HB From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10585; SCN1A Population: Chinese; Derived from sampling site: Peripheral blood. Male 127227715 CVCL_A8HE SCMCi001-A-1 induced pluripotent stem cell human CVCL_A8HE From: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127227716 CVCL_A8HD SCMCi001-A induced pluripotent stem cell human CVCL_A8HD From: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127227717 CVCL_A8GV ZIPi015-F induced pluripotent stem cell human CVCL_A8GV From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227718 CVCL_A8GU ZIPi015-E induced pluripotent stem cell human CVCL_A8GU From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227719 CVCL_A8GX ZIPi015-H induced pluripotent stem cell human CVCL_A8GX From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227720 CVCL_A8GW ZIPi015-G induced pluripotent stem cell human CVCL_A8GW From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227721 CVCL_A8GZ ZIPi015-J induced pluripotent stem cell human CVCL_A8GZ From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227722 CVCL_A8GY ZIPi015-I induced pluripotent stem cell human CVCL_A8GY From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227723 CVCL_A8GN CHO.DogSLAMtag spontaneously immortalized cell line CVCL_A8GN CL:0000010 Transfected with: VGNC; 46206; Dog SLAMF1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127227724 CVCL_A8GM CHO.CowSLAMtag spontaneously immortalized cell line CVCL_A8GM CL:0000010 Transfected with: VGNC; 34653; Bovine SLAMF1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127227725 CVCL_A8GP SAS-R cancer cell line human CVCL_A8GP CL:0000010 Population: Japanese; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Oral cavity; tongue. Female Characteristics: Radioresistant Can proliferate with daily exposure to 2 Gy X-rays for more than 30 days (PubMed=21716292). 127227726 CVCL_A8GR ZIPi015-B induced pluripotent stem cell human CVCL_A8GR From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227727 CVCL_A8GQ ZIPi015-A induced pluripotent stem cell human CVCL_A8GQ From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227728 CVCL_A8GT ZIPi015-D induced pluripotent stem cell human CVCL_A8GT From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227729 CVCL_A8GS ZIPi015-C induced pluripotent stem cell human CVCL_A8GS From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227730 CVCL_A8IH 3A2 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227731 CVCL_A8IG 3A1 hybridoma house mouse CVCL_A8IG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227732 CVCL_A8IJ 3A7 hybridoma house mouse CVCL_A8IJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227733 CVCL_A8II 3A6 hybridoma house mouse CVCL_A8II CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227734 CVCL_A8IL 3B3 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227735 CVCL_A8IK 3B1 hybridoma house mouse CVCL_A8IK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227736 CVCL_A8IN 3B6 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227737 CVCL_A8IM 3B4 [Mouse hybridoma against SARS-CoV-2 spike] hybridoma house mouse CVCL_A8IM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127227738 CVCL_A8IB ESi101-A induced pluripotent stem cell human CVCL_A8IB From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11782; TH; Simple; p.Arg233His (c.698G>A); ClinVar=VCV000016236; Zygosity=Homozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227739 CVCL_A8IA ESi084-A induced pluripotent stem cell human CVCL_A8IA From: El Instituto de Investigacion Biomedica de A Coruna, University of Coruna; Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227740 CVCL_A8ID ESi103-A induced pluripotent stem cell human CVCL_A8ID CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227741 CVCL_A8IC ESi102-A induced pluripotent stem cell human CVCL_A8IC From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11782; TH; Simple; p.Arg328Trp (c.982C>T); Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 11782; TH; Simple; p.Thr399Met (c.1196C>T) (p.Thr368Met, c.1103C>T); ClinVar=VCV000378729; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227742 CVCL_A8IF HepG2-N10 cancer cell line human CVCL_A8IF From: Xia N.-S.; Xiamen University; Xiamen; China CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Transfected with a hepatitis B virus (HBV) subtype adw2 genome 127227743 CVCL_A8IE M9-ENL1 transformed cell line human CVCL_A8IE CL:0000010 Transfected with: HGNC; 7132; KMT2A (KMT2A-MLLT1 fusion); Transfected with: HGNC; 7134; MLLT1 (KMT2A-MLLT1 fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: KMT2A-MLLT1; Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Characteristics: Expresses a transfected KMT2A-MLLT1 (MLL-ENL) fusion protein Mimics the features of primary human pro-B cell acute lymphoblastic leukemia (PubMed=22160482). 127227744 CVCL_A8HW IMT-KO9 conditionally immortalized cell line house mouse CVCL_A8HW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1349215; Abcd1 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J Abcd1-/- x H2kb-tsA58 transgenic. Male 127227745 CVCL_A8HV IMT-KO4 conditionally immortalized cell line house mouse CVCL_A8HV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1349215; Abcd1 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J Abcd1-/- x H2kb-tsA58 transgenic. Male 127227746 CVCL_A8HY ESi085-A induced pluripotent stem cell human CVCL_A8HY From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227747 CVCL_A8HX SBKMS-KS1 cancer cell line human CVCL_A8HX CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=19289832) Derived from metastatic site: Groin. Female 127227748 CVCL_A8HZ ESi083-A induced pluripotent stem cell human CVCL_A8HZ From: El Instituto de Investigacion Biomedica de A Coruna, University of Coruna; Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227749 CVCL_A8HN RCPFi006-A induced pluripotent stem cell human CVCL_A8HN From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Tyr790Ter (c.2370T>G); ClinVar=VCV000006195; Zygosity=Homozygous (PubMed=34087982) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227750 CVCL_A8HQ AND-1 EGFP-2A-SCL embryonic stem cell human CVCL_A8HQ From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Karyotypic information: 47,XY,-1,+der(1)dup(1q11->1qter::1q11->1qter)-7,+i(7)p,+13 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with a pRRL-EF1a-EGFP-2A-SCL-PGK-Neo construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227751 CVCL_A8HP CQ4ed-iPSC induced pluripotent stem cell human CVCL_A8HP From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 19693; COQ4; Simple_corrected; p.Glu161Asp (c.483G>C); ClinVar=VCV000380493; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28465093) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227752 CVCL_A8HS HS181 EGFP-2A-RUNX1c embryonic stem cell human CVCL_A8HS From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 10471; RUNX1 (isoform AML-1C); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Transduced with a pRRL-EF1a-EGFP-2A-RUNX1c-PGK-Neo construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227753 CVCL_A8HR HS181 EGFP-2A-SCL embryonic stem cell human CVCL_A8HR From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Karyotypic information: 46,XX [15]; 46,XX,der(5)t(q35;?)+der(12)t(q11;?) [7] (Spanish_Stem_Cell_Bank) Female Characteristics: Transduced with a pRRL-EF1a-EGFP-2A-SCL-PGK-Neo construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127227754 CVCL_A8HU IMT-KO2 conditionally immortalized cell line house mouse CVCL_A8HU CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1349215; Abcd1 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J Abcd1-/- x H2kb-tsA58 transgenic. Male 127227755 CVCL_A8HT K562/GM-CSF cancer cell line human CVCL_A8HT CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Pleural effusion. Biotechnology: Used for the production of the Sorento Therapeutics STI-6991 SARS-CoV-2 (COVID-19) vaccine candidate The cell line which is lethally irradiated is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation (PubMed=32289117). Female Characteristics: Does not express HLA class I or II antigens, potentially decreasing the magnitude of the alloresponses generated on repeated immunizations (PubMed=10466632) 127227756 CVCL_A8FE HT43 hybridoma house mouse CVCL_A8FE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227757 CVCL_A8FD HT41 hybridoma house mouse CVCL_A8FD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227758 CVCL_A8FG HT45 hybridoma house mouse CVCL_A8FG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227759 CVCL_A8FF HT44 hybridoma house mouse CVCL_A8FF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227760 CVCL_A8FI HT53 hybridoma house mouse CVCL_A8FI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227761 CVCL_A8FH HT52 hybridoma house mouse CVCL_A8FH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227762 CVCL_A8FK HT58 [Mouse hybridoma against human TLR4] hybridoma house mouse CVCL_A8FK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227763 CVCL_A8FJ HT55 hybridoma house mouse CVCL_A8FJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227764 CVCL_A8FA HT3 hybridoma house mouse CVCL_A8FA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227765 CVCL_A8FC HT40 hybridoma house mouse CVCL_A8FC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227766 CVCL_A8FB HT4 [Mouse hybridoma against human TLR4] hybridoma house mouse CVCL_A8FB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227767 CVCL_A8ET mTX11 hybridoma CVCL_A8ET CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227768 CVCL_A8ES 5A5 [Mouse/rat hybridoma against human CD14] hybridoma CVCL_A8ES CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127227769 CVCL_A8EV HT16 hybridoma house mouse CVCL_A8EV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227770 CVCL_A8EU HT11 hybridoma house mouse CVCL_A8EU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227771 CVCL_A8EX HT2 [Mouse hybridoma against human TLR4] hybridoma house mouse CVCL_A8EX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227772 CVCL_A8EW HT17 hybridoma house mouse CVCL_A8EW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y6Y9; Human LY96; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227773 CVCL_A8EZ HT29 hybridoma house mouse CVCL_A8EZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227774 CVCL_A8EY HT26 hybridoma house mouse CVCL_A8EY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y6Y9; Human LY96; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227775 CVCL_A8EL mTX12 hybridoma CVCL_A8EL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227776 CVCL_A8EK mTX10 hybridoma CVCL_A8EK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227777 CVCL_A8EN 1B12 [Mouse hybridoma against human CD14] hybridoma CVCL_A8EN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127227778 CVCL_A8EM GFP5 hybridoma CVCL_A8EM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42212; GFP (Note=With p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). 127227779 CVCL_A8EP 1E1 [Mouse hybridoma against human CD14] hybridoma CVCL_A8EP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127227780 CVCL_A8ER 1F1 [Mouse hybridoma against human CD14] hybridoma CVCL_A8ER CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127227781 CVCL_A8EQ 1E12 hybridoma CVCL_A8EQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127227782 CVCL_A8GF hLp4 hybridoma CVCL_A8GF CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18428; Human LBP. 127227783 CVCL_A8GE hLp1 hybridoma CVCL_A8GE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18428; Human LBP. 127227784 CVCL_A8GH CLC12N2 cancer cell line human CVCL_A8GH CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 16412; NLRC4 (with p.Leu152_Ala1024del, CARD domain, C12N2 construct); Transfected with: HGNC; 5331; NOD2 (with p.Met1_Ala216del, NACHT+LRR domains, C12N2 construct); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Ascites. Male 127227785 CVCL_A8GG HeLa-R cancer cell line human CVCL_A8GG CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Uterus; cervix. Female Characteristics: Radioresistant Can proliferate with daily exposure to 2 Gy X-rays for more than 30 days (PubMed=27681752). 127227786 CVCL_A8GJ MAIL8-19 transformed cell line human CVCL_A8GJ CL:0000010 Transfected with: HGNC; 16412; NLRC4 (with p.Leu152_Ala1024del, CARD domain, C12N2 construct); Transfected with: HGNC; 5331; NOD2 (with p.Met1_Ala216del, NACHT+LRR domains, C12N2 construct); Transfected with: HGNC; 16608; PYCARD; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127227787 CVCL_A8GI NUC12N2 cancer cell line human CVCL_A8GI CL:0000010 Transfected with: HGNC; 16412; NLRC4 (with p.Leu152_Ala1024del, CARD domain, C12N2 construct); Transfected with: HGNC; 5331; NOD2 (with p.Met1_Ala216del, NACHT+LRR domains, C12N2 construct) Population: Japanese; Derived from metastatic site: Paragastric lymph node. Female 127227788 CVCL_A8GL CHO.B95aSLAMtag spontaneously immortalized cell line CVCL_A8GL CL:0000010 Transfected with: UniProtKB; Q9GJT3; Saguinus oedipus SLAMF1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127227789 CVCL_A8GK Vero.DogSLAMtag spontaneously immortalized cell line green monkey CVCL_A8GK CL:0000010 Transfected with: VGNC; 46206; SLAMF1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 127227790 CVCL_A8GB M14-23 hybridoma CVCL_A8GB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227791 CVCL_A8GA M14-21 hybridoma CVCL_A8GA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227792 CVCL_A8GD M14-29 hybridoma CVCL_A8GD CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227793 CVCL_A8GC M14-26 hybridoma CVCL_A8GC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227794 CVCL_A8FU M14-9 hybridoma CVCL_A8FU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227795 CVCL_A8FT HepG2-R cancer cell line human CVCL_A8FT CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Liver. Male Characteristics: Radioresistant Can proliferate with daily exposure to 2 Gy X-rays for more than 30 days (PubMed=21716292). 127227796 CVCL_A8FW M14-11 hybridoma CVCL_A8FW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227797 CVCL_A8FV M14-10 hybridoma CVCL_A8FV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227798 CVCL_A8FY M14-16 hybridoma CVCL_A8FY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227799 CVCL_A8FX M14-14 hybridoma CVCL_A8FX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227800 CVCL_A8FZ M14-17 hybridoma CVCL_A8FZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10810; Mouse Cd14. 127227801 CVCL_A8FM HT60 hybridoma house mouse CVCL_A8FM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227802 CVCL_A8FL HT59 hybridoma house mouse CVCL_A8FL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y6Y9; Human LY96; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227803 CVCL_A8FN HT66 hybridoma house mouse CVCL_A8FN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227804 CVCL_A8FQ HTB1 hybridoma house mouse CVCL_A8FQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227805 CVCL_A8FP HT68 hybridoma house mouse CVCL_A8FP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227806 CVCL_A8FS HepG2-8960-R cancer cell line human CVCL_A8FS CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Liver. Male Characteristics: Radioresistant Can proliferate with daily exposure to 2 Gy X-rays for more than 30 days (PubMed=19215227). 127227807 CVCL_A8FR HTB2 hybridoma house mouse CVCL_A8FR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O00206; Human TLR4. 127227808 CVCL_A8DC Sf9 SARS-CoV-2 Spike S1 spontaneously immortalized cell line CVCL_A8DC CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S) (AA 1-685; S1) Derived from sampling site: Ovary. Female Group: Insect cell line; Group: SARS-CoV-2 research cell line 127227809 CVCL_A8DB HEK293T SARS-CoV-2 Spike transformed cell line human CVCL_A8DB CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: SARS-CoV-2 research cell line 127227810 CVCL_A8DE MUi028-A induced pluripotent stem cell human CVCL_A8DE From: Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227811 CVCL_A8DD Sf9 SARS-CoV-2 Spike S2 spontaneously immortalized cell line CVCL_A8DD CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S) (AA 816-1273; S2) Derived from sampling site: Ovary. Female Group: Insect cell line; Group: SARS-CoV-2 research cell line 127227812 CVCL_A8DG PCIi030-A induced pluripotent stem cell human CVCL_A8DG From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127227813 CVCL_A8DF PCIi029-A induced pluripotent stem cell human CVCL_A8DF From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Male 127227814 CVCL_A8DI WAe009-A-60 embryonic stem cell human CVCL_A8DI From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 9886; KDM5A (NUP98-KDM5 fusion); Transfected with: HGNC; 8068; NUP98 (NUP98-KDM5 fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 127227815 CVCL_A8DH PCIi031-A induced pluripotent stem cell human CVCL_A8DH From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127227816 CVCL_A8CZ HEK-Blue TGF-beta transformed cell line human CVCL_A8CZ CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 6769; SMAD3; Transfected with: HGNC; 6770; SMAD4; Transfected with: HGNC; 11772; TGFBR1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive TGF-beta by monitoring the activation of the TGF-beta/SMAD pathway (InVivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a beta-globin minimal promoter fused to 3 SMAD3/4-binding elements (SBE) 127227817 CVCL_A8CY HEK-Dual IFN-gamma transformed cell line human CVCL_A8CY CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11362; STAT1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Allows the detection of bioactive human IFN-gamma by monitoring the activation of the JAK/STAT1 pathway; Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line both genes are under the control of an ISG54 minimal promoter in conjunction with four IFN-gamma activated sites (GAS). 127227818 CVCL_A8DA HEK-Blue IL-4/IL-13 transformed cell line human CVCL_A8DA CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11368; STAT6; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human IL4 and human/murine IL13 by monitoring the activation of the STAT-6 pathway (InVivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a STAT6-responsive promoter 127227819 CVCL_A8CR HEK-Dual hTLR2 (NF/IL8) transformed cell line human CVCL_A8CR CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11848; TLR2; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227820 CVCL_A8CQ HEK-Dual Null transformed cell line human CVCL_A8CQ CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227821 CVCL_A8CT HEK-Dual hTLR5 (NF/IL8) transformed cell line human CVCL_A8CT CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11851; TLR5; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227822 CVCL_A8CS HEK-Dual hTLR3 (NF/IL8) transformed cell line human CVCL_A8CS CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11849; TLR3; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227823 CVCL_A8CV HEK-Dual mTLR4 (NF/IL8) transformed cell line human CVCL_A8CV CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:88318; Cd14; Transfected with: MGI; MGI:1341909; Ly96; Transfected with: MGI; MGI:96824; Tlr4; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227824 CVCL_A8CU HEK-Dual hTLR9 (NF/IL8) transformed cell line human CVCL_A8CU CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 15633; TLR9; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227825 CVCL_A8CX HEK-Dual TNF-alpha transformed cell line human CVCL_A8CX CL:0000010 Knockout cell: Method=Not specified; HGNC; 7562; MYD88; Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line both genes are under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 c-Rel binding sites. 127227826 CVCL_A8CW HEK-Dual mTLR7 (NF/IL8) transformed cell line human CVCL_A8CW CL:0000010 Knockout cell: Method=Not specified; HGNC; 6025; CXCL8; Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:2176882; Tlr7; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites. The Lucia luciferase reporter gene expression depends on the activation of the endogenous CXCL8/IL8 promoter as the CXCL8 gene has been replaced by Lucia. 127227827 CVCL_A8CJ HEK-Blue RANKL transformed cell line human CVCL_A8CJ CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11908; TNFRSF11A; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse TNFSF11/RANKL by monitoring the activation of the NF-kappaB and AP-1 pathway; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a promoter with NF-kappaB and AP-1-binding sites 127227828 CVCL_A8CI HEK-Blue TPO transformed cell line human CVCL_A8CI CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 7217; MPL; Transfected with: HGNC; 11367; STAT5B; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse TPO by monitoring the activation of the STAT5 pathway; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a STAT5 promoter 127227829 CVCL_A8CL HEK-Blue IL-1beta transformed cell line human CVCL_A8CL CL:0000010 Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse IL1B monitoring the activation of the NF-kappaB and AP-1 pathways In addition, the TNF-alpha, TLR3 and TLR5 responses have been blocked (InvivoGen).; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127227830 CVCL_A8CK HEK-Blue IL-17C transformed cell line human CVCL_A8CK CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5985; IL17RA; Transfected with: HGNC; 18439; IL17RE; Transfected with: HGNC; 1343; TRAF3IP2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and murine IL17C and IL17F by monitoring the activation of the NF-kappaB and AP-1 pathways (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the IFN-beta minimal promoter fused to five NF-kappaB and five AP-1 binding sites 127227831 CVCL_A8CN HEK-Lucia Null transformed cell line human CVCL_A8CN CL:0000010 Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227832 CVCL_A8CM HEK-Blue IL-1R transformed cell line human CVCL_A8CM CL:0000010 Knockout cell: Method=Not specified; HGNC; 11849; TLR3; Knockout cell: Method=Not specified; HGNC; 11851; TLR5; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:96545; Il1r1; Transfected with: MGI; MGI:104975; Il1rap; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse IL1A and IL1B by monitoring the activation of the NF-kappaB and AP-1 pathways In addition, the TNF-alpha, TLR3 and TLR5 responses have been blocked (InvivoGen).; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127227833 CVCL_A8CP HEK-Lucia RIG-I transformed cell line human CVCL_A8CP CL:0000010 Transfected with: HGNC; 19102; RIGI; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 127227834 CVCL_A8ED TES101 hybridoma house mouse CVCL_A8ED CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227835 CVCL_A8EC mTX6 hybridoma CVCL_A8EC CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227836 CVCL_A8EF mTES101-RP(N6035) hybridoma house mouse CVCL_A8EF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227837 CVCL_A8EE mTES101-RP(N6002) hybridoma house mouse CVCL_A8EE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227838 CVCL_A8EH mTX7 hybridoma CVCL_A8EH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227839 CVCL_A8EG Ts4 hybridoma house mouse CVCL_A8EG CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227840 CVCL_A8EJ mTX9 hybridoma CVCL_A8EJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227841 CVCL_A8EI mTX8 hybridoma CVCL_A8EI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227842 CVCL_A8DZ mTX3 hybridoma CVCL_A8DZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227843 CVCL_A8EB mTX5.2 hybridoma CVCL_A8EB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227844 CVCL_A8EA mTX4 hybridoma CVCL_A8EA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227845 CVCL_A8DS NCC-CC4-3 cancer cell line human CVCL_A8DS CL:0000010 Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Male 127227846 CVCL_A8DR NCC-CC4-2 cancer cell line human CVCL_A8DR CL:0000010 Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Male 127227847 CVCL_A8DU NCC-CC6-2 cancer cell line human CVCL_A8DU CL:0000010 Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Male 127227848 CVCL_A8DT NCC-CC6-1 cancer cell line human CVCL_A8DT CL:0000010 Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Male 127227849 CVCL_A8DW GFP2 hybridoma CVCL_A8DW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42212; GFP (Note=With p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). 127227850 CVCL_A8DV HeLa NEK1 KO cancer cell line human CVCL_A8DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7744; NEK1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127227851 CVCL_A8DY mTX1 hybridoma CVCL_A8DY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9JMI7; Mouse Tex101. 127227852 CVCL_A8DX mk34 hybridoma CVCL_A8DX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9CWP4; Mouse Ly6k. 127227853 CVCL_A8DK RCPCMi007-A-1 induced pluripotent stem cell human CVCL_A8DK From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227854 CVCL_A8DJ RCPCMi007-A induced pluripotent stem cell human CVCL_A8DJ From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227855 CVCL_A8DM UM281-1 PGD embryonic stem cell human CVCL_A8DM From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-21-0486. 127227856 CVCL_A8DL PS1 finite cell line human CVCL_A8DL CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2002; probable Female 127227857 CVCL_A8DN NCC-BD3 cancer cell line human CVCL_A8DN CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male 127227858 CVCL_A8DQ NCC-BD4-2 cancer cell line human CVCL_A8DQ CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male 127227859 CVCL_A8DP NCC-BD4-1 cancer cell line human CVCL_A8DP CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male 127227860 CVCL_A4SV UMGi079-A induced pluripotent stem cell human CVCL_A4SV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227861 CVCL_A4SU UMGi078-A induced pluripotent stem cell human CVCL_A4SU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227862 CVCL_A4SX UMGi081-A induced pluripotent stem cell human CVCL_A4SX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227863 CVCL_A4SW UMGi080-A induced pluripotent stem cell human CVCL_A4SW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227864 CVCL_A4SZ UMGi083-A induced pluripotent stem cell human CVCL_A4SZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227865 CVCL_A4SY UMGi082-A induced pluripotent stem cell human CVCL_A4SY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227866 CVCL_A4SN UMGi072-A induced pluripotent stem cell human CVCL_A4SN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227867 CVCL_A4SM UMGi071-A induced pluripotent stem cell human CVCL_A4SM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127227868 CVCL_A4SP UMGi073-A induced pluripotent stem cell human CVCL_A4SP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227869 CVCL_A4SR UMGi075-A induced pluripotent stem cell human CVCL_A4SR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127227870 CVCL_A4SQ UMGi074-A induced pluripotent stem cell human CVCL_A4SQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127227871 CVCL_A4ST UMGi077-A induced pluripotent stem cell human CVCL_A4ST From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127227872 CVCL_A4SS UMGi076-A induced pluripotent stem cell human CVCL_A4SS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127227873 CVCL_A4SF WT1-iPSC induced pluripotent stem cell human CVCL_A4SF CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 127227874 CVCL_A4SE ActiCre-B1 embryonic stem cell CVCL_A4SE CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Female Characteristics: Ubiquitously expresses the tamoxifen-inducible Cre-driver ERT2CreERT2 Using CRISPR/Cas9 a IRES-ERT2CreERT2-IRES-Hyg construct was introduced into the 3'UTR of ACTB (PubMed=33453576). Group: Non-human primate cell line 127227875 CVCL_A4SH WT3-iPSC induced pluripotent stem cell human CVCL_A4SH CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227876 CVCL_A4SG WT2-iPSC induced pluripotent stem cell human CVCL_A4SG CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127227877 CVCL_A4SJ SAA2-iPSC induced pluripotent stem cell human CVCL_A4SJ CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127227878 CVCL_A4SI SAA1-iPSC induced pluripotent stem cell human CVCL_A4SI CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127227879 CVCL_A4SL UMGi070-A induced pluripotent stem cell human CVCL_A4SL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127227880 CVCL_A4SK SAA3-iPSC induced pluripotent stem cell human CVCL_A4SK CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227881 CVCL_A5LN TMMR-1 hybridoma house mouse CVCL_A5LN CL:0000010 Monoclonal antibody isotype: IgG1. 127227882 CVCL_A5LM H14-YAP1 induced pluripotent stem cell human CVCL_A5LM CL:0000010 Transfected with: HGNC; 16262; YAP1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male 127227883 CVCL_A5LP TMMR-2 hybridoma house mouse CVCL_A5LP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 26 kDa protein on osteosarcoma cell lines. 127227884 CVCL_A5LR OSEV cancer cell line human CVCL_A5LR CL:0000010 Unspecified 127227885 CVCL_A5LQ TMMR-3 hybridoma house mouse CVCL_A5LQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human 97 kDa protein on osteosarcoma cell lines. 127227886 CVCL_A5LT OSFN cancer cell line human CVCL_A5LT CL:0000010 Unspecified 127227887 CVCL_A5LS OSFL cancer cell line human CVCL_A5LS CL:0000010 Unspecified 127227888 CVCL_A5LF FM3A AC2 cancer cell line house mouse CVCL_A5LF CL:0000010 Selected for resistance to: ChEBI; CHEBI:2766; Aphidicolin; Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 127227889 CVCL_A5LE FM3A AC1 cancer cell line house mouse CVCL_A5LE CL:0000010 Selected for resistance to: ChEBI; CHEBI:2766; Aphidicolin; Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 127227890 CVCL_A5LH BC3H1#1 cancer cell line house mouse CVCL_A5LH CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from metastatic site: Brain; Breed/subspecies: C3H. Unspecified Characteristics: Spontaneously fusing clone of BC3H1 Can form multinucleated myocytes (PubMed=10852349). 127227891 CVCL_A5LG FM3A AC3 cancer cell line house mouse CVCL_A5LG CL:0000010 Selected for resistance to: ChEBI; CHEBI:2766; Aphidicolin; Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 127227892 CVCL_A5LJ MF2S cancer cell line house mouse CVCL_A5LJ CL:0000010 127227893 CVCL_A5LI EUE6 cancer cell line human CVCL_A5LI CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (EUE) has been shown to be a HeLa derivative. 127227894 CVCL_A5LL H7-YAP1 embryonic stem cell human CVCL_A5LL CL:0000010 Transfected with: HGNC; 16262; YAP1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female 127227895 CVCL_A5LK H7v1,17q,i20 embryonic stem cell human CVCL_A5LK CL:0000010 Karyotypic information: 47,XX,+del(1)(p22p22),der(6)t(6;17)(q27;q1),t(12;20)(q13;q11.2),i(2)(q10)ish dup(20)(q11.21;q11.21). Female Characteristics: Aneuploid WA07 subline with gain of chromosome 1 that has an interstitial deletion at 1p22, gain of chromosome 17q and isochromosome of the long (q) arm of chromosome 20 127227896 CVCL_A5LB FM3A SR-01 cancer cell line house mouse CVCL_A5LB CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Revertant of parent cell line for cell growth at 39 Celsius (PubMed=1995072) 127227897 CVCL_A5LA FM3A G258 cancer cell line house mouse CVCL_A5LA CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature-sensitive Deficient in cell growth, asparagine glycosylation and synthesis of oligosaccharide-lipid. Selection is effected by tritium suicide selection. Mutagenized cells are bathed in tritiated mannose and stored so as to allow time for cells that had taken up the mannose to be killed by radiation damage (PubMed=1995072; PubMed=6725415). 127227898 CVCL_A5LD FM3A SR-12 cancer cell line house mouse CVCL_A5LD CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Revertant of parent cell line for cell growth at 39 Celsius (PubMed=1995072) 127227899 CVCL_A5LC FM3A SR-11 cancer cell line house mouse CVCL_A5LC CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Revertant of parent cell line for cell growth at 39 Celsius (PubMed=1995072) 127227900 CVCL_A5KU H14.BJ1 induced pluripotent stem cell human CVCL_A5KU CL:0000010 Karyotypic information: 48,XY,+12,+der(17)hsr(17)(p11.2) del(17)(p13.3). Male Characteristics: Aneuploid WA14 subline with gain of chromosome 12 and chromosome 17 that incorporates an hsr comprising amplification of chromosomal region 17p13.3 127227901 CVCL_A5KT H7v20q embryonic stem cell human CVCL_A5KT CL:0000010 Karyotypic information: 46,XX,ish dup(20)(q11.21;q11.21). Female Characteristics: Aneuploid WA07 subline with gain of a copy number variant 20q11.21 127227902 CVCL_A5KW H7.s6-GFP embryonic stem cell human CVCL_A5KW CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Karyotypic information: 48,XX, +del(1)(p22p22),der(6)t(6;17)(q27;q1),+12,ish dup(q11.21;q11.21) Female Characteristics: Aneuploid WA07 subline with gain of chromosome 1 that has an interstitial deletion at 1p22, gain of chromosome 17q, trisomy chromosome 12 and gain of copy number variant 20q11.21 127227903 CVCL_A5KV H14.s9 somatic stem cell human CVCL_A5KV CL:0000010 Male 127227904 CVCL_A5KY H7.s14-Tomato embryonic stem cell human CVCL_A5KY CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female 127227905 CVCL_A5KX H14.BJ1-GFP induced pluripotent stem cell human CVCL_A5KX CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Karyotypic information: 48,XY,+12,+der(17)hsr(17)(p11.2) del(17)(p13.3) Male Characteristics: Aneuploid WA14 subline with gain of chromosome 12 and chromosome 17 that incorporates an hsr comprising amplification of chromosomal region 17p13.3 127227906 CVCL_A5KZ ND15079 transformed cell line human CVCL_A5KZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15079; probable Male 127227907 CVCL_A5MN GM27925 induced pluripotent stem cell human CVCL_A5MN CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227908 CVCL_A5MQ GM27938 induced pluripotent stem cell human CVCL_A5MQ CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: The donor is mosaic for the disease causing KIF1A mutation, this cell line originate from a wildtype cell 127227909 CVCL_A5MP GM27937 induced pluripotent stem cell human CVCL_A5MP CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Arg203Ser (c.609G>T); Zygosity=Mosaic (Coriell) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: The donor is mosaic for the disease causing KIF1A mutation, this cell line originate from a diseased cell 127227910 CVCL_A5MS 77-1 cancer cell line human CVCL_A5MS CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 1.4 days (PubMed=7817386) 127227911 CVCL_A5MR GM27978 induced pluripotent stem cell human CVCL_A5MR CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ser181Cysfs*5 (c.542_543delCT); Zygosity=Heterozygous (Coriell) Population: Caucasian and Native North American; Alaskan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227912 CVCL_A5MU SNUe004-A-2 embryonic stem cell human CVCL_A5MU From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean. Male 127227913 CVCL_A5MT SNUe004-A-1 embryonic stem cell human CVCL_A5MT From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean. Male 127227914 CVCL_A5MG GM28029 finite cell line human CVCL_A5MG CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg230Ter (c.688C>T); ClinVar=VCV000280010; Zygosity=Heterozygous (Coriell) Population: Native North American; Cherokee, Caucasian and Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227915 CVCL_A5MF GM28026 transformed cell line human CVCL_A5MF CL:0000010 Sequence variation: Mutation; HGNC; 6408; MAFB; Simple; p.Pro71Arg (c.212C>G); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127227916 CVCL_A5MI GM28031 finite cell line human CVCL_A5MI CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian; Polish; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 127227917 CVCL_A5MH GM28030 finite cell line human CVCL_A5MH CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227918 CVCL_A5MK GM27901 transformed cell line human CVCL_A5MK CL:0000010 Sequence variation: Mutation; HGNC; 11497; SYNGAP1; Simple; p.Arg1240Ter (c.3718C>T); ClinVar=VCV000225077; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127227919 CVCL_A5MJ GM28032 finite cell line human CVCL_A5MJ CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 127227920 CVCL_A5MM GM27918 induced pluripotent stem cell human CVCL_A5MM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227921 CVCL_A5ML GM27957 induced pluripotent stem cell human CVCL_A5ML CL:0000010 Sequence variation: Mutation; HGNC; 11497; SYNGAP1; Simple; p.Arg1240Ter (c.3718C>T); ClinVar=VCV000225077; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127227922 CVCL_A5MA GM28019 finite cell line human CVCL_A5MA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu1366Lys (c.4096G>A); ClinVar=VCV000200036; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu90Pro (c.269T>C); ClinVar=VCV000381516; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127227923 CVCL_A5MC GM28021 finite cell line human CVCL_A5MC CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu90Pro (c.269T>C); ClinVar=VCV000381516; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227924 CVCL_A5MB GM28020 finite cell line human CVCL_A5MB CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu1366Lys (c.4096G>A); ClinVar=VCV000200036; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu90Pro (c.269T>C); ClinVar=VCV000381516; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227925 CVCL_A5ME GM28023 finite cell line human CVCL_A5ME CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu1366Lys (c.4096G>A); ClinVar=VCV000200036; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu90Pro (c.269T>C); ClinVar=VCV000381516; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127227926 CVCL_A5MD GM28022 finite cell line human CVCL_A5MD CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 127227927 CVCL_A5LV OSPR cancer cell line human CVCL_A5LV CL:0000010 Unspecified 127227928 CVCL_A5LU OSON cancer cell line human CVCL_A5LU CL:0000010 Unspecified 127227929 CVCL_A5LX OSSM cancer cell line human CVCL_A5LX CL:0000010 Unspecified 127227930 CVCL_A5LW OSSK cancer cell line human CVCL_A5LW CL:0000010 Unspecified 127227931 CVCL_A5LZ U2OS-ATRkd cancer cell line human CVCL_A5LZ CL:0000010 Transfected with: HGNC; 882; ATR (with p.Asp2494Glu = ATRkd); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 127227932 CVCL_A5LY OSWO cancer cell line human CVCL_A5LY CL:0000010 Unspecified 127227933 CVCL_A5JL ND15114 transformed cell line human CVCL_A5JL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15114; probable Male 127227934 CVCL_A5JK ND15099 transformed cell line human CVCL_A5JK CL:0000010 Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15099; probable Male 127227935 CVCL_A5JN ND15139 transformed cell line human CVCL_A5JN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15139; probable Female 127227936 CVCL_A5JM ND15118 transformed cell line human CVCL_A5JM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15118; probable Female 127227937 CVCL_A5JP ND15147 transformed cell line human CVCL_A5JP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15147; probable Male 127227938 CVCL_A5JR ND15149 transformed cell line human CVCL_A5JR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15149; probable Female 127227939 CVCL_A5JQ ND15148 transformed cell line human CVCL_A5JQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15148; probable Female 127227940 CVCL_A5JD ND14972 transformed cell line human CVCL_A5JD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14972; probable Male 127227941 CVCL_A5JC ND14970 transformed cell line human CVCL_A5JC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14970; probable Female 127227942 CVCL_A5JF ND14974 transformed cell line human CVCL_A5JF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14974; probable Female 127227943 CVCL_A5JE ND14973 transformed cell line human CVCL_A5JE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14973; probable Male 127227944 CVCL_A5JH ND15056 transformed cell line human CVCL_A5JH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15056; probable Male 127227945 CVCL_A5JG ND15001 transformed cell line human CVCL_A5JG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15001; probable Male 127227946 CVCL_A5JJ ND15096 transformed cell line human CVCL_A5JJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15096; probable Male 127227947 CVCL_A5JI ND15058 transformed cell line human CVCL_A5JI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15058; probable Male 127227948 CVCL_A5IZ ND14720 transformed cell line human CVCL_A5IZ CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14720; probable Male 127227949 CVCL_A5JB ND14883 transformed cell line human CVCL_A5JB CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14883; probable Female 127227950 CVCL_A5JA ND14761 transformed cell line human CVCL_A5JA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14761; probable Female 127227951 CVCL_A5IS MP 4112 hybrid cell line human CVCL_A5IS CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2128 127227952 CVCL_A5IR MP 4109 hybrid cell line human CVCL_A5IR CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2129 127227953 CVCL_A5IU UKAi004-A induced pluripotent stem cell human CVCL_A5IU From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Ser972Leu (c.2915C>T); ClinVar=VCV000133443; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7780; NFE2; Simple; p.Glu261Alafs*3 (c.782_785delAGAG); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Cys973Alafs*34 (c.2917delT); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A.G); ClinVar=VCV000135287; Zygosity=Homozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Heterozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male Characteristics: Established from a patient that has a KIT p.Asp816Val mutation, but this cell line does not contain this mutation 127227954 CVCL_A5IT MP 4126 hybrid cell line human CVCL_A5IT CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2615 127227955 CVCL_A5IW UKAi004-C induced pluripotent stem cell human CVCL_A5IW From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Ser972Leu (c.2915C>T); ClinVar=VCV000133443; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7780; NFE2; Simple; p.Glu261Alafs*3 (c.782_785delAGAG); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A.G); ClinVar=VCV000135287; Zygosity=Homozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Heterozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male 127227956 CVCL_A5IV UKAi004-B induced pluripotent stem cell human CVCL_A5IV From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Ser972Leu (c.2915C>T); ClinVar=VCV000133443; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7780; NFE2; Simple; p.Glu261Alafs*3 (c.782_785delAGAG); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Cys973Alafs*34 (c.2917delT); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A.G); ClinVar=VCV000135287; Zygosity=Homozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Heterozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male Characteristics: Established from a patient that has a KIT p.Asp816Val mutation, but this cell line does not contain this mutation 127227957 CVCL_A5IY UKAi004-E induced pluripotent stem cell human CVCL_A5IY From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Ser972Leu (c.2915C>T); ClinVar=VCV000133443; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7780; NFE2; Simple; p.Glu261Alafs*3 (c.782_785delAGAG); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A.G); ClinVar=VCV000135287; Zygosity=Homozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Heterozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male 127227958 CVCL_A5IX UKAi004-D induced pluripotent stem cell human CVCL_A5IX From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Ser972Leu (c.2915C>T); ClinVar=VCV000133443; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 7780; NFE2; Simple; p.Glu261Alafs*3 (c.782_785delAGAG); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A.G); ClinVar=VCV000135287; Zygosity=Homozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Heterozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male 127227959 CVCL_A5KM CHO-K1 mutant 29 spontaneously immortalized cell line CVCL_A5KM CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Defective in the incorporation of ethanolamine into phosphatidylethanolamine (PubMed=2684962) 127227960 CVCL_A5KL CHO-tsH1-C9D9 spontaneously immortalized cell line CVCL_A5KL CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Compared to the parent cell line, it has reduced system L transport activity Selection is effected by tritium suicide selection. Mutagenized cells are bathed in tritiated D-leucine and stored so as to allow time for cells that had taken up the D-leucine to be killed by radiation damage. 127227961 CVCL_A5KN CHO-K1 PSA-1 spontaneously immortalized cell line CVCL_A5KN CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Require exogenous phosphatidylserine for growth (PubMed=3084470) 127227962 CVCL_A5KQ CHO-K1 PSA-3 spontaneously immortalized cell line CVCL_A5KQ CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Require exogenous phosphatidylserine for growth (PubMed=3084470) Defective for phosphatidylserine synthase 1 (Ptdss1) (PubMed=1748687). 127227963 CVCL_A5KP CHO-K1 PSA-2 spontaneously immortalized cell line CVCL_A5KP CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Require exogenous phosphatidylserine for growth (PubMed=3084470) 127227964 CVCL_A5KS H7v17q embryonic stem cell human CVCL_A5KS CL:0000010 Miscellaneous: Cell line information from personal communication of Price C.J. Karyotypic information: 46,XX,der(6)t(6;17)(q27;q1) Female Characteristics: Aneuploid WA07 subline with gain of chromosome 17q 127227965 CVCL_A5KR H7v1q embryonic stem cell human CVCL_A5KR CL:0000010 Karyotypic information: 46,XX,dup(1)(q21;q42) (DOI=10.1101/854430). Female Characteristics: Aneuploid WA07 subline with gain of chromosome 1q 127227966 CVCL_A5KE CHO-K1 Mev-SM spontaneously immortalized cell line CVCL_A5KE CL:0000010 Transfected with: RGD; 2804; Hmgcs2 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Repairs the deficiency in mevalonate biosynthesis of the parent cell line (PubMed=7961793) 127227967 CVCL_A5KD CHO-K1 Mev-1 spontaneously immortalized cell line CVCL_A5KD CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient for mevalonate biosynthesis Lacks hydroxymethylglutaryl-CoA synthase activity (PubMed=4019518). 127227968 CVCL_A5KG CHO-tsH1-D10 spontaneously immortalized cell line CVCL_A5KG CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature-resistant revertant of CHO-tsH1 with constitutively elevated system L transport activity (PubMed=6863284) 127227969 CVCL_A5KF CHO-tsH1-C11 spontaneously immortalized cell line CVCL_A5KF CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature-resistant revertant of CHO-tsH1 with constitutively elevated system L transport activity (PubMed=6863284) 127227970 CVCL_A5KI CHO-tsH1-C11B6 spontaneously immortalized cell line CVCL_A5KI CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature-resistant revertant of CHO-tsH1 with constitutively elevated system L transport activity (PubMed=2777768) 127227971 CVCL_A5KH CHO-tsH1-F10 spontaneously immortalized cell line CVCL_A5KH CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature-resistant revertant of CHO-tsH1 with constitutively elevated system L transport activity (PubMed=6863284) 127227972 CVCL_A5KK CHO-tsH1-C5D9 spontaneously immortalized cell line CVCL_A5KK CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Compared to the parent cell line, it has reduced system L transport activity Selection is effected by tritium suicide selection. Mutagenized cells are bathed in tritiated D-leucine and stored so as to allow time for cells that had taken up the D-leucine to be killed by radiation damage. 127227973 CVCL_A5KJ CHO-tsH1-C4B4 spontaneously immortalized cell line CVCL_A5KJ CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Compared to the parent cell line, it has reduced system L transport activity Selection is effected by tritium suicide selection. Mutagenized cells are bathed in tritiated D-leucine and stored so as to allow time for cells that had taken up the D-leucine to be killed by radiation damage. 127227974 CVCL_A5KA A549-hACE2 [Invivogen] cancer cell line human CVCL_A5KA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Permissive to infection by SARS-CoV-2 and/or spike-pseudotyped lentiviral particles (InvivoGen) Group: SARS-CoV-2 research cell line 127227975 CVCL_A5KC HUES 17v12,17 embryonic stem cell human CVCL_A5KC CL:0000010 Miscellaneous: Cell line information from personal communication of Price C.J. Karyotypic information: 48,XY,+12,+17 Male Characteristics: Aneuploid HUES 17 subline with gain of chromosomes 12 and 17 127227976 CVCL_A5KB A549-hACE2-TMPRSS2 cancer cell line human CVCL_A5KB CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) and/or spike-pseudotyped lentiviral particles (InvivoGen) Group: SARS-CoV-2 research cell line 127227977 CVCL_A5JT ND15167 transformed cell line human CVCL_A5JT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15167; probable Male 127227978 CVCL_A5JS ND15150 transformed cell line human CVCL_A5JS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15150; probable Male 127227979 CVCL_A5JV K9STS cancer cell line dog CVCL_A5JV CL:0000010 Unspecified Doubling time: 35.04 +- 8.1 hours (PubMed=18562222); 18 hours (PubMed=27257868). 127227980 CVCL_A5JU ND15171 transformed cell line human CVCL_A5JU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND15171; probable Male 127227981 CVCL_A5JX FM3A tsFT5 cancer cell line house mouse CVCL_A5JX CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Stop growing at 39 Celsius. Defective in DNA replication. Contains a thermolabile Uba1 (PubMed=8344958). Doubling time: ~18 hours (PubMed=8344958) 127227982 CVCL_A5JW FM3A ts85R-MN3 cancer cell line house mouse CVCL_A5JW CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Revertant of parent cell line (ts85) 127227983 CVCL_A5JZ BW5147.PHAR2.1 cancer cell line house mouse CVCL_A5JZ CL:0000010 Selected for resistance to: UniProtKB; P05087; Phaseolus vulgaris leucoagglutinating phytohemagglutinin (PHA-L); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Deficient in alpha-mannoside beta-1,6-N-acetylglucosaminyltransferase (Mgat5) (PubMed=6216250) 127227984 CVCL_A5JY FM3A tsFT50 cancer cell line house mouse CVCL_A5JY CL:0000010 Sequence variation: Mutation; MGI; MGI:1927222; Diaph3; Simple; p.Gln668Ter (c.2002C>T); Zygosity=Homozygous (PubMed=33187357) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Cytokinesis is blocked at 39 Celsius. 127227985 CVCL_A5HJ UCLAi004-A induced pluripotent stem cell human CVCL_A5HJ From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCLAi001-A (Cellosaurus=CVCL_WT92), UCLAi001-B (Cellosaurus=CVCL_WT93) and UCLAi001-C (Cellosaurus=CVCL_WT94); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227986 CVCL_A5HI UCLAi003-C induced pluripotent stem cell human CVCL_A5HI From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi002-A (Cellosaurus=CVCL_A5HD), UCLAi002-B (Cellosaurus=CVCL_A5HE) and UCLAi002-C (Cellosaurus=CVCL_A5HF); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227987 CVCL_A5HL UCLAi004-C induced pluripotent stem cell human CVCL_A5HL From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCLAi001-A (Cellosaurus=CVCL_WT92), UCLAi001-B (Cellosaurus=CVCL_WT93) and UCLAi001-C (Cellosaurus=CVCL_WT94); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227988 CVCL_A5HK UCLAi004-B induced pluripotent stem cell human CVCL_A5HK From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCLAi001-A (Cellosaurus=CVCL_WT92), UCLAi001-B (Cellosaurus=CVCL_WT93) and UCLAi001-C (Cellosaurus=CVCL_WT94); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227989 CVCL_A5HN aMoS7 transformed cell line house mouse CVCL_A5HN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum; intestinal crypt Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 127227990 CVCL_A5HM aMoC1 transformed cell line house mouse CVCL_A5HM CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colon; intestinal crypt Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 127227991 CVCL_A5HP U-251MG IDH1 R132C cancer cell line human CVCL_A5HP CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 5382; IDH1 (with p.Arg132Cys); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127227992 CVCL_A5HB HES-3 NKX2.1GFP/w embryonic stem cell human CVCL_A5HB CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Using homologous recombination an EGFP reporter gene was introduced in one allele of the NKX2.1 locus 127227993 CVCL_A5HA ESIBIe003-A-6 embryonic stem cell human CVCL_A5HA From: Universite Libre de Bruxelles; Brussels; Belgium CL:0000010 Transfected with: HGNC; 11825; NKX2-1; Transfected with: HGNC; 8622; PAX8; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Transduced with a lentiviral cassette containing an NKX2.1-IRES-PAX8 construct under the control of a promoter inducible by doxycycline via a tetracycline response element; Characteristics: Using homologous recombination an EGFP reporter gene was introduced in one allele of the INS locus 127227994 CVCL_A5HD UCLAi002-A induced pluripotent stem cell human CVCL_A5HD From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi003-A (Cellosaurus=CVCL_A5HG), UCLAi003-B (Cellosaurus=CVCL_A5HH) and UCLAi003-C (Cellosaurus=CVCL_A5HI); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227995 CVCL_A5HC HOC-I cancer cell line human CVCL_A5HC CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: ~75 hours (PubMed=2723484) 127227996 CVCL_A5HF UCLAi002-C induced pluripotent stem cell human CVCL_A5HF From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi003-A (Cellosaurus=CVCL_A5HG), UCLAi003-B (Cellosaurus=CVCL_A5HH) and UCLAi003-C (Cellosaurus=CVCL_A5HI); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227997 CVCL_A5HE UCLAi002-B induced pluripotent stem cell human CVCL_A5HE From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi003-A (Cellosaurus=CVCL_A5HG), UCLAi003-B (Cellosaurus=CVCL_A5HH) and UCLAi003-C (Cellosaurus=CVCL_A5HI); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227998 CVCL_A5HH UCLAi003-B induced pluripotent stem cell human CVCL_A5HH From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi002-A (Cellosaurus=CVCL_A5HD), UCLAi002-B (Cellosaurus=CVCL_A5HE) and UCLAi002-C (Cellosaurus=CVCL_A5HF); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127227999 CVCL_A5HG UCLAi003-A induced pluripotent stem cell human CVCL_A5HG From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi002-A (Cellosaurus=CVCL_A5HD), UCLAi002-B (Cellosaurus=CVCL_A5HE) and UCLAi002-C (Cellosaurus=CVCL_A5HF); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228000 CVCL_A5GY IBMS-iPSC-068-02 induced pluripotent stem cell human CVCL_A5GY From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian. Male 127228001 CVCL_A5GX TBN spontaneously immortalized cell line CVCL_A5GX CL:0000010 Derived from sampling site: Brain Cell type=Neural cell.. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Optimal growth temperature is 32 Celsius Does not grow at 16 Celsius. Doubling time: 4.84 days (in 2.5% FBS), 2.66 days (in 7.5% FBS), 2.44 days (in 10% FBS), 2.59 days (in 15% FBS), 4.84 days (in 20% FBS) (PubMed=33258111) Group: Fish cell line 127228002 CVCL_A5GZ UNIBSi014-A induced pluripotent stem cell human CVCL_A5GZ From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127228003 CVCL_A5GQ UKAi001-A-1 induced pluripotent stem cell human CVCL_A5GQ From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5358; IRF8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228004 CVCL_A5GP UKAi001-C induced pluripotent stem cell human CVCL_A5GP From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228005 CVCL_A5GS UKAi001-C-1 induced pluripotent stem cell human CVCL_A5GS From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5358; IRF8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228006 CVCL_A5GR UKAi001-B-1 induced pluripotent stem cell human CVCL_A5GR From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5358; IRF8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228007 CVCL_A5GU ZZUi029-A induced pluripotent stem cell human CVCL_A5GU From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 127228008 CVCL_A5GT ZZUi027-A induced pluripotent stem cell human CVCL_A5GT From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 16499; RAB39B; Simple; p.Glu179fs*48 (c.536dupA); Zygosity=Hemizygous (PubMed=34247111) Population: Chinese; Han; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 127228009 CVCL_A5GW NOSCC1 cancer cell line human CVCL_A5GW CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Characteristics: Established from tumors in super-immunodeficient NSG (NOD.Cg-Prkdc(scid)Il2rg(tm1Wjl)/SzJ) mice subcutanously injected with the patient tumor pieces (PubMed=33300248) 127228010 CVCL_A5GV EZB-ICR cancer cell line human CVCL_A5GV CL:0000010 Population: Iranian; Derived from sampling site: Oral cavity; tongue. Female Doubling time: ~31 hours, at 25th passage (PubMed=33507685) 127228011 CVCL_A5IK ips#202 induced pluripotent stem cell house mouse CVCL_A5IK CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: Isl1:Cre/Rosa26-YFP transgenic. Unspecified 127228012 CVCL_A5IJ NCC-DDLPS2-C1 cancer cell line human CVCL_A5IJ CL:0000010 Population: Japanese; Derived from sampling site: Right thigh. Omics: SNP array analysis Female Doubling time: ~54 hours (PubMed=33555519) Part of: NCC sarcoma cell line panel 127228013 CVCL_A5IM ips#137 induced pluripotent stem cell house mouse CVCL_A5IM CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: Isl1:Cre/Rosa26-LacZ transgenic. Unspecified 127228014 CVCL_A5IL ips#231 induced pluripotent stem cell house mouse CVCL_A5IL CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: Isl1:Cre/Rosa26-YFP transgenic. Unspecified 127228015 CVCL_A5IN NS-(f)iPS Isl1C somatic stem cell house mouse CVCL_A5IN CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Isl1:Cre/Rosa26-YFP transgenic. Unspecified Characteristics: Neural stem cell 127228016 CVCL_A5IQ hTERT-1604-PMS134 telomerase immortalized cell line human CVCL_A5IQ CL:0000010 Transfected with: HGNC; 9122; PMS2 (with p.Arg134Ter = PMS134); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 127228017 CVCL_A5IP HEK293 HADH-/- transformed cell line human CVCL_A5IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4799; HADH Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127228018 CVCL_A5IC UM-Chor5C cancer cell line human CVCL_A5IC CL:0000010 Derived from metastatic site: Salivary gland; parotid gland. Male 127228019 CVCL_A5IB Vero-SCARB2 spontaneously immortalized cell line green monkey CVCL_A5IB CL:0000010 Transfected with: HGNC; 1665; SCARB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; epithelium. Female Virology: Highly susceptible to infection by enterovirus type 71 (EV71) and coxsackievirus A group type 16 (CA16) (PubMed=23919614) Group: Non-human primate cell line 127228020 CVCL_A5IE U-CH18 cancer cell line human CVCL_A5IE CL:0000010 Derived from sampling site: Bone; chest. Male Doubling time: ~7-8 days (Chordoma_Foundation) 127228021 CVCL_A5ID UM-Chor5D cancer cell line human CVCL_A5ID CL:0000010 Derived from sampling site: Bone; cranium; clivus. Male Doubling time: 4.632 days (Chordoma_Foundation) 127228022 CVCL_A5IG UM-Chor6 cancer cell line human CVCL_A5IG CL:0000010 Derived from sampling site: Bone; cranium; clivus. Male Doubling time: ~21 days (Chordoma_Foundation) 127228023 CVCL_A5IF U-CH19 cancer cell line human CVCL_A5IF CL:0000010 Derived from sampling site: Bone; sacrum. Male Doubling time: ~7 days (Chordoma_Foundation) 127228024 CVCL_A5II U-CHCF365 cancer cell line human CVCL_A5II CL:0000010 Derived from sampling site: Bone; cranium; clivus. Male Characteristics: Established from the CF365 patient-derived xenograft Doubling time: ~4 days (Chordoma_Foundation) 127228025 CVCL_A5IH U-CHCF359B cancer cell line human CVCL_A5IH CL:0000010 Derived from sampling site: Bone; cranium; clivus. Female Characteristics: Established from the CF359B patient-derived xenograft Doubling time: 5-6 days (Chordoma_Foundation) 127228026 CVCL_A5HZ 293-SCARB2 transformed cell line human CVCL_A5HZ CL:0000010 Transfected with: HGNC; 1665; SCARB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Virology: Highly susceptible to infection by enterovirus type 71 (EV71) and coxsackievirus A group type 16 (CA16) (PubMed=23919614) 127228027 CVCL_A5HY TS516 cancer cell line human CVCL_A5HY CL:0000010 Miscellaneous: Cell line has been lost (from personal communication of Weis-Garcia F.); Miscellaneous: Doubling time from MSKCC antibody and bioresource core facility Derived from sampling site: Brain. Doubling time: ~2 days (Direct_author_submission) 127228028 CVCL_A5IA RD-SCARB2 cancer cell line human CVCL_A5IA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1665; SCARB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Virology: Highly susceptible to infection by enterovirus type 71 (EV71) and coxsackievirus A group type 16 (CA16) (PubMed=23919614) 127228029 CVCL_A5HR U-251MG IDH1 WT cancer cell line human CVCL_A5HR CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 5382; IDH1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127228030 CVCL_A5HQ U-251MG IDH1 R132H cancer cell line human CVCL_A5HQ CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 5382; IDH1 (with p.Arg132His); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127228031 CVCL_A5HT NCH645 cancer cell line human CVCL_A5HT CL:0000010 Derived from sampling site: Brain. Group: Cancer stem cell line 127228032 CVCL_A5HS NCH620 cancer cell line human CVCL_A5HS CL:0000010 Derived from sampling site: Brain. Group: Cancer stem cell line 127228033 CVCL_A5HV NCH1681 cancer cell line human CVCL_A5HV CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=33504762) Derived from sampling site: Brain. Group: Cancer stem cell line 127228034 CVCL_A5HU NCH551b cancer cell line human CVCL_A5HU CL:0000010 Derived from sampling site: Brain. Group: Cancer stem cell line 127228035 CVCL_A5HX TS676 cancer cell line human CVCL_A5HX CL:0000010 Miscellaneous: STR profile and doubling time from MSKCC antibody and bioresource core facility Derived from sampling site: Brain. Male Doubling time: ~7 days (Direct_author_submission) 127228036 CVCL_A5HW TS603 cancer cell line human CVCL_A5HW CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous (PubMed=23558169; PubMed=33504762) Miscellaneous: STR profile and doubling time from MSKCC antibody and bioresource core facility Derived from sampling site: Brain. Doubling time: ~7 days (Direct_author_submission) 127228037 CVCL_A5FH IBBISTi001-D induced pluripotent stem cell human CVCL_A5FH From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ala1206Profs*4 (c.3612delA); ClinVar=VCV000037533; Zygosity=Heterozygous (PubMed=33631522) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228038 CVCL_A5FG IBBISTi001-C induced pluripotent stem cell human CVCL_A5FG From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ala1206Profs*4 (c.3612delA); ClinVar=VCV000037533; Zygosity=Heterozygous (PubMed=33631522) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228039 CVCL_A5FJ IBBISTi002-B induced pluripotent stem cell human CVCL_A5FJ From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228040 CVCL_A5FI IBBISTi002-A induced pluripotent stem cell human CVCL_A5FI From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228041 CVCL_A5FL IBBISTi003-B induced pluripotent stem cell human CVCL_A5FL From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Unexplicit; c.156_157insAlu; ClinVar=VCV000126018; Zygosity=Heterozygous (PubMed=34087993) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228042 CVCL_A5FK IBBISTi003-A induced pluripotent stem cell human CVCL_A5FK From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Unexplicit; c.156_157insAlu; ClinVar=VCV000126018; Zygosity=Heterozygous (PubMed=34087993) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228043 CVCL_A5FN IBBISTi003-D induced pluripotent stem cell human CVCL_A5FN From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Unexplicit; c.156_157insAlu; ClinVar=VCV000126018; Zygosity=Heterozygous (from autologous cell lines IBBISTi003-A, IBBISTi003-B and IBBISTi003-C) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228044 CVCL_A5FM IBBISTi003-C induced pluripotent stem cell human CVCL_A5FM From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Unexplicit; c.156_157insAlu; ClinVar=VCV000126018; Zygosity=Heterozygous (PubMed=34087993) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228045 CVCL_A5FB HPIi001-B induced pluripotent stem cell human CVCL_A5FB From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Arg185Ser (c.553C>A); ClinVar=VCV000420099; Zygosity=Heterozygous (PubMed=33740643) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228046 CVCL_A5FA HPIi001-A induced pluripotent stem cell human CVCL_A5FA From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Arg185Ser (c.553C>A); ClinVar=VCV000420099; Zygosity=Heterozygous (PubMed=33740643) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228047 CVCL_A5FD HPIi002-B induced pluripotent stem cell human CVCL_A5FD From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Asp179Asn (c.541G>A); Zygosity=Heterozygous (PubMed=34388489) Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228048 CVCL_A5FC HPIi002-A induced pluripotent stem cell human CVCL_A5FC From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Asp179Asn (c.541G>A); Zygosity=Heterozygous (PubMed=34388489) Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228049 CVCL_A5FF IBBISTi001-B induced pluripotent stem cell human CVCL_A5FF From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ala1206Profs*4 (c.3612delA); ClinVar=VCV000037533; Zygosity=Heterozygous (PubMed=33631522) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228050 CVCL_A5FE IBBISTi001-A induced pluripotent stem cell human CVCL_A5FE From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ala1206Profs*4 (c.3612delA); ClinVar=VCV000037533; Zygosity=Heterozygous (PubMed=33631522) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228051 CVCL_A5EW EHTJUi003-A induced pluripotent stem cell human CVCL_A5EW From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Leu460Trpfs*6 (c.1377delC); ClinVar=VCV000188548; Zygosity=Heterozygous (PubMed=34087980) Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis Female 127228052 CVCL_A5EV CRICKi002-A induced pluripotent stem cell human CVCL_A5EV From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 127228053 CVCL_A5EY FDCHi005-B induced pluripotent stem cell human CVCL_A5EY From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 3091; DYRK1A; Simple_corrected; p.Val577Asp (c.1730T>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33813175) Derived from sampling site: Peripheral blood. Male 127228054 CVCL_A5EX FDCHi005-A induced pluripotent stem cell human CVCL_A5EX From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 3091; DYRK1A; Simple; p.Val577Asp (c.1730T>A); Zygosity=Heterozygous (PubMed=33813175) Derived from sampling site: Peripheral blood. Male 127228055 CVCL_A5EZ GZHMCi005-A induced pluripotent stem cell human CVCL_A5EZ From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Derived from sampling site: Amniotic fluid. Male 127228056 CVCL_A5EN 2T9 transformed cell line house mouse CVCL_A5EN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Bmp2 promoter T-Ag-3 transgenic. Unspecified 127228057 CVCL_A5EQ WAe009-A-56 embryonic stem cell human CVCL_A5EQ From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6694; LRP2. Female 127228058 CVCL_A5EP WAe009-A-50 embryonic stem cell human CVCL_A5EP From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11167; SNTA1 Female Caution: There seems to be two H9SNTA1KO cell line established in China, this one and CVCL_C5TU. 127228059 CVCL_A5ES WTC-DMD-mEGFP-cl96 induced pluripotent stem cell human CVCL_A5ES CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 DMD has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 127228060 CVCL_A5ER MDA-MB-231 met2 cancer cell line human CVCL_A5ER CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Metastatic to lung Established from a lung tumor after injection of the parent cell line into the tail vein of athymic nude mice (PubMed=30337562). Group: Triple negative breast cancer (TNBC) cell line 127228061 CVCL_A5EU CRICKi001-A induced pluripotent stem cell human CVCL_A5EU From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Arg1203Cys (c.3607C>T); Zygosity=Heterozygous; Note=De novo mutation (PubMed=33799280) Population: Caucasian; Derived from sampling site: Hair root Cell type=Keratinocyte.. Male 127228062 CVCL_A5ET WTC-CLYBL-dCas9-TagBFP-KRAB-cl391 induced pluripotent stem cell human CVCL_A5ET CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Tyr66His and p.Tyr145Phe = BFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (deactivated version with KRAB domain; dCas9-KRAB) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a dCas9-TagBFP-KRAB construct is expressed from a CAGGS promoter edited into the 2nd intron of the CLYBL safe harbor Part of: Allen Cell Collection 127228063 CVCL_A5GI UNCi002-A induced pluripotent stem cell human CVCL_A5GI From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 127228064 CVCL_A5GK UMi030-A induced pluripotent stem cell human CVCL_A5GK From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Val37Ile (c.109G>A); ClinVar=VCV000017023; Zygosity=Homozygous (PubMed=34883447) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228065 CVCL_A5GJ UMGi156-A induced pluripotent stem cell human CVCL_A5GJ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 127228066 CVCL_A5GM UKAi001-A induced pluripotent stem cell human CVCL_A5GM From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228067 CVCL_A5GL WMUi021-A induced pluripotent stem cell human CVCL_A5GL From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10912; SLC12A3; Simple; p.Thr60Met (c.179C>T); ClinVar=VCV000101514; Zygosity=Homozygous (PubMed=33735743) Population: Chinese; Han; Derived from sampling site: Urine. Male 127228068 CVCL_A5GN UKAi001-B induced pluripotent stem cell human CVCL_A5GN From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Bone marrow. Male 127228069 CVCL_A5GA SCVI-19 induced pluripotent stem cell human CVCL_A5GA From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 127228070 CVCL_A5GC SCVI-273 induced pluripotent stem cell human CVCL_A5GC From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 127228071 CVCL_A5GB SCVI-15 induced pluripotent stem cell human CVCL_A5GB From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 127228072 CVCL_A5GE TIGETi003-A induced pluripotent stem cell human CVCL_A5GE From: San Raffaele Telethon Institute for Gene Therapy, Ospedale San Raffaele; Milan; Italy CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228073 CVCL_A5GD TIGETi001-A induced pluripotent stem cell human CVCL_A5GD From: San Raffaele Telethon Institute for Gene Therapy, Ospedale San Raffaele; Milan; Italy CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228074 CVCL_A5FX SCVIi004-A induced pluripotent stem cell human CVCL_A5FX From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Arg79Ter (c.235C>T); ClinVar=VCV000006754; Zygosity=Heterozygous (PubMed=33743362) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127228075 CVCL_A5FW SCVIi003-A induced pluripotent stem cell human CVCL_A5FW From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.His733Alafs*8 (c.2197_2202delinsG) (p.His689fs, c.2065_2070delinsG); ClinVar=VCV000045063; Zygosity=Heterozygous (PubMed=33743362) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228076 CVCL_A5FZ SCVI-114 induced pluripotent stem cell human CVCL_A5FZ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 127228077 CVCL_A5FY SCVIi005-A induced pluripotent stem cell human CVCL_A5FY From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Arg577Aspfs*5 (c.1725_1728dupGATG); ClinVar=VCV000406551; Zygosity=Heterozygous (PubMed=33743362) Population: East Asian; Derived from sampling site: Peripheral blood. Male 127228078 CVCL_A5FP MRIi025-A induced pluripotent stem cell human CVCL_A5FP From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228079 CVCL_A5FR MUNIe009-A embryonic stem cell human CVCL_A5FR From: Masaryk University; Brno; Czech Republic CL:0000010 Donor information: Embryo is sibling to that giving rise to MUNIe008-A (Cellosaurus=CVCL_A5FQ). Male 127228080 CVCL_A5FQ MUNIe008-A embryonic stem cell human CVCL_A5FQ From: Masaryk University; Brno; Czech Republic CL:0000010 Donor information: Embryo is sibling to that giving rise to MUNIe009-A (Cellosaurus=CVCL_A5FR). Female 127228081 CVCL_A5FT RCMGi005-A induced pluripotent stem cell human CVCL_A5FT From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=36067639) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228082 CVCL_A5FS NCKDi002-A induced pluripotent stem cell human CVCL_A5FS From: National Center of Kidney Diseases; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg363Gly (c.1087A>G) (p.Arg219Gly, c.655A>G); Zygosity=Heterozygous (PubMed=33780729) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228083 CVCL_A5FV SCVIi002-A induced pluripotent stem cell human CVCL_A5FV From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; c.3330+2T>G; ClinVar=VCV000008621; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33743363) Derived from sampling site: Peripheral blood. Female 127228084 CVCL_A5FU SCVIi001-A induced pluripotent stem cell human CVCL_A5FU From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; c.3330+2T>G; ClinVar=VCV000008621; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33743363) Derived from sampling site: Peripheral blood. Male 127228085 CVCL_A5TV U-251MG PAX6-/- 2A.28 cancer cell line human CVCL_A5TV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8620; PAX6; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127228086 CVCL_A5TU U-251MG PAX6-/- 2.10 cancer cell line human CVCL_A5TU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8620; PAX6; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127228087 CVCL_A5TX CEM/ara-G cancer cell line human CVCL_A5TX CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:73141; 9-beta-D-arabinofuranosylguanine (ara-G); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Doubling time: 21.4 hours (PubMed=25070259) 127228088 CVCL_A5TW U-251MG PAX6-/- 2A.3 cancer cell line human CVCL_A5TW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8620; PAX6; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 127228089 CVCL_A5TZ CCRF/CEM/ara-C/D cancer cell line human CVCL_A5TZ CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228090 CVCL_A5TY CCRF/CEM/ara-C/B cancer cell line human CVCL_A5TY CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228091 CVCL_A5TN UM-SCC-5PT cancer cell line human CVCL_A5TN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16020667) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Larynx; supraglottis. Male 127228092 CVCL_A5TM irPSCc3 transformed cell line Norway rat CVCL_A5TM CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Sprague Dawley. Unspecified 127228093 CVCL_A5TP UM-SCC-10BPT cancer cell line human CVCL_A5TP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16020667) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Submental lymph node. Male 127228094 CVCL_A5TR CalH2 cancer cell line human CVCL_A5TR CL:0000010 127228095 CVCL_A5TQ Ca1 cancer cell line human CVCL_A5TQ CL:0000010 127228096 CVCL_A5TT UK1 cancer cell line human CVCL_A5TT CL:0000010 127228097 CVCL_A5TS CalH3 cancer cell line human CVCL_A5TS CL:0000010 127228098 CVCL_A5TF sciCHO:hACE2:hTMPRSS2 spontaneously immortalized cell line CVCL_A5TF CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Adapted to growth in suspension (CLS) Doubling time: 18-22 hours (CLS) Group: SARS-CoV-2 research cell line; Group: Serum/protein free medium cell line 127228099 CVCL_A5TE sciCHO:hACE2 spontaneously immortalized cell line CVCL_A5TE CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Can be used for ACE2 binding assays, flow cytometry, screening of ACE2 antibodies (CLS); Characteristics: Adapted to growth in suspension (CLS) Doubling time: 18-22 hours (CLS) Group: SARS-CoV-2 research cell line; Group: Serum/protein free medium cell line 127228100 CVCL_A5TH imPSCc1 transformed cell line house mouse CVCL_A5TH CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 45 hours (PubMed=20847583) 127228101 CVCL_A5TG RLT-PSC transformed cell line human CVCL_A5TG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Unspecified Doubling time: 28.6 +- 2.5 hours (PubMed=30621293) 127228102 CVCL_A5TJ imPSCc3 transformed cell line house mouse CVCL_A5TJ CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 51 hours (PubMed=20847583) 127228103 CVCL_A5TI imPSCc2 transformed cell line house mouse CVCL_A5TI CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 45 hours (PubMed=20847583) 127228104 CVCL_A5TL irPSCc2 transformed cell line Norway rat CVCL_A5TL CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Sprague Dawley. Unspecified 127228105 CVCL_A5TK irPSCc1 transformed cell line Norway rat CVCL_A5TK CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Sprague Dawley. Unspecified 127228106 CVCL_A5TB HSC-Li transformed cell line human CVCL_A5TB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Unspecified Characteristics: Produces both HGF and TGFB1 in a time-dependent manner (PubMed=25678842) Doubling time: 8 hours (PubMed=25678842) 127228107 CVCL_A5TA ASHe spontaneously immortalized cell line CVCL_A5TA CL:0000010 Derived from sampling site: Heart Cell type=Cardiac endothelial cell.. Unspecified Group: Fish cell line 127228108 CVCL_A5TD sciCHO spontaneously immortalized cell line CVCL_A5TD CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Adapted to growth in suspension Optimized for the generation of stable populations and clones for high-yield recombinant protein production (CLS). Doubling time: 18-22 hours (CLS) Group: Serum/protein free medium cell line 127228109 CVCL_A5TC CAISMOV24 cancer cell line human CVCL_A5TC CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=29132324) Population: Brazilian; Derived from metastatic site: Ascites. Omics: Array-based CGH Female Doubling time: 71.2 hours (PubMed=29132324) 127228110 CVCL_A5UW JW18 spontaneously immortalized cell line fruit fly CVCL_A5UW CL:0000010 Transfected with: UniProtKB; P42212; GFP Omics: Transcriptome analysis by RNAseq. Characteristics: Expresses a Jupiter-GFP fusion protein; Characteristics: Constitutively infected with Wolbachia Group: Insect cell line 127228111 CVCL_A5UV S2-DGRC-attP-25C6 spontaneously immortalized cell line fruit fly CVCL_A5UV CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Breed/subspecies: Oregon-R. Male Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 25C6 locus (PubMed=33963853) Group: Insect cell line 127228112 CVCL_A5UY CCRF/CEM/ara-C/C cancer cell line human CVCL_A5UY CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228113 CVCL_A5UX JW18DOX spontaneously immortalized cell line fruit fly CVCL_A5UX CL:0000010 Characteristics: Expresses a Jupiter-GFP fusion protein; Characteristics: Cured of Wolbachia infection through doxycycline treatment. Group: Insect cell line 127228114 CVCL_A5UZ S2:DER2f spontaneously immortalized cell line fruit fly CVCL_A5UZ CL:0000010 Transfected with: FlyBase_Gene; FBgn0000434; Der; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228115 CVCL_A5UN S2R+-(FEx-10%) spontaneously immortalized cell line fruit fly CVCL_A5UN CL:0000010 Breed/subspecies: Oregon-R. Male Characteristics: Adapted to growth in M3 + 10% Fly Extract (FEx) medium Group: Insect cell line; Group: Serum/protein free medium cell line 127228116 CVCL_A5UQ Kc167-(M3-FEx-2.5%) spontaneously immortalized cell line fruit fly CVCL_A5UQ CL:0000010 Female Characteristics: Adapted to growth in M3 + 2.5% Fly Extract (FEx) medium. Group: Insect cell line; Group: Serum/protein free medium cell line 127228117 CVCL_A5UP Kc167-(M3) spontaneously immortalized cell line fruit fly CVCL_A5UP CL:0000010 Female Characteristics: Adapted to growth in M3 medium. Group: Insect cell line; Group: Serum/protein free medium cell line 127228118 CVCL_A5US Kc167-attP-25C6 spontaneously immortalized cell line fruit fly CVCL_A5US CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 25C6 locus (PubMed=33963853) Group: Insect cell line 127228119 CVCL_A5UR Kc167-(M3BPYE-FEx2.5%) spontaneously immortalized cell line fruit fly CVCL_A5UR CL:0000010 Female Characteristics: Adapted to growth in M3 + BPYE + 2.5% Fly Extract (FEx) medium. Group: Insect cell line; Group: Serum/protein free medium cell line 127228120 CVCL_A5UU S2R+-attP-99F8 spontaneously immortalized cell line fruit fly CVCL_A5UU CL:0000010 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228121 CVCL_A5UT Kc167-attP-99F8 spontaneously immortalized cell line fruit fly CVCL_A5UT CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 99F8 locus (PubMed=33963853) Group: Insect cell line 127228122 CVCL_A5UG S2R+-Apc-KO-E5 spontaneously immortalized cell line fruit fly CVCL_A5UG CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0015589; Apc; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228123 CVCL_A5UF S2R+-Moe-KO-21B4 spontaneously immortalized cell line fruit fly CVCL_A5UF CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0011661; Moe; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228124 CVCL_A5UI S2R+-Pex19-KO-A1 spontaneously immortalized cell line fruit fly CVCL_A5UI CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0032407; Pex19; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228125 CVCL_A5UH S2R+-TSC1-KO-C5 spontaneously immortalized cell line fruit fly CVCL_A5UH CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0026317; Tsc1; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228126 CVCL_A5UK S2R+-Slik-KO-22C2 spontaneously immortalized cell line fruit fly CVCL_A5UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0035001; Slik; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228127 CVCL_A5UJ S2R+-Pten-KO-1A4 spontaneously immortalized cell line fruit fly CVCL_A5UJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0026379; Pten; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228128 CVCL_A5UM S2R+-(FEx-2.5%) spontaneously immortalized cell line fruit fly CVCL_A5UM CL:0000010 Breed/subspecies: Oregon-R. Male Characteristics: Adapted to growth in M3 + 2.5% Fly Extract (FEx) medium Group: Insect cell line; Group: Serum/protein free medium cell line 127228129 CVCL_A5UL S2R+-Yki-KO-G7 spontaneously immortalized cell line fruit fly CVCL_A5UL CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0034970; yki; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 127228130 CVCL_A5UA CCRF/CEM/ara-C/G cancer cell line human CVCL_A5UA CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228131 CVCL_A5UC CCRF/CEM/ara-C/J cancer cell line human CVCL_A5UC CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228132 CVCL_A5UB CCRF/CEM/ara-C/I cancer cell line human CVCL_A5UB CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 127228133 CVCL_A5UE HFF-2 IRR finite cell line human CVCL_A5UE CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1042.1; true Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 6000 rads 127228134 CVCL_A5UD SACC-LM-KRT19-KD cancer cell line human CVCL_A5UD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6436; KRT19 Miscellaneous: Cell line information from personal communication of Kong L Population: Chinese; Derived from sampling site: Salivary gland; sublingual gland. Female 127228135 CVCL_A5RT CD#01 iPSC induced pluripotent stem cell human CVCL_A5RT CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu129Argfs*8 (c.382delC); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Arg168Cys (c.502C>T); ClinVar=VCV000813438; Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Tyr (c.693C>T); ClinVar=VCV000197621; Zygosity=Heterozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Male 127228136 CVCL_A5RS FFF0082001 induced pluripotent stem cell human CVCL_A5RS CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu129Argfs*8 (c.382delC); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Arg168Cys (c.502C>T); ClinVar=VCV000813438; Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Tyr (c.693C>T); ClinVar=VCV000197621; Zygosity=Heterozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Male 127228137 CVCL_A5RV HBLT-11 transformed cell line human CVCL_A5RV CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male Characteristics: Established from a tumor induced in nude mice by inoculation of late passage HBL-100 (PubMed=2840847) Problematic cell line: Misidentified Parent cell line (HBL-100) has been shown to have a Y chromosome while originally thought to be of female origin. 127228138 CVCL_A5RU CD#68T-13 iPSC induced pluripotent stem cell human CVCL_A5RU CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu285Ala (c.854A>C); ClinVar=VCV000002605; Zygosity=Homozygous (PubMed=33304759); Transfected with: HGNC; 756; ASPA; Transfected with: HGNC; 1633; CD19 (with p.Lys324_Arg556del = CD19t) Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male Characteristics: Using TALEN a EF1a promoter-ASPA-T2A-CD19t construct was introduced in the AAVS1 safe harbor locus (PubMed=33304759) 127228139 CVCL_A5RX HBLT-13 transformed cell line human CVCL_A5RX CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male Characteristics: Established from a tumor induced in nude mice by inoculation of late passage HBL-100 (PubMed=2840847) Problematic cell line: Misidentified Parent cell line (HBL-100) has been shown to have a Y chromosome while originally thought to be of female origin. 127228140 CVCL_A5RW HBLT-12 transformed cell line human CVCL_A5RW CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male Characteristics: Established from a tumor induced in nude mice by inoculation of late passage HBL-100 (PubMed=2840847) Problematic cell line: Misidentified Parent cell line (HBL-100) has been shown to have a Y chromosome while originally thought to be of female origin. 127228141 CVCL_A5RZ ARD-pUTX cancer cell line human CVCL_A5RZ CL:0000010 Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832); Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (from parent cell line); Transfected with: HGNC; 12637; KDM6A Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female Characteristics: KDM6A/UTX expression is inducible by doxycycline (PubMed=29045832) 127228142 CVCL_A5RY ARD-EZH2i-R cancer cell line human CVCL_A5RY CL:0000010 Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832); Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (from parent cell line) Selected for resistance to: ChEBI; CHEBI:167693; 1-isopropyl-N-((6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl)-6-(2-(4-methylpiperazin-1-yl)pyridin-4-yl)-1H-indazole-4-carboxamide (GSK343); Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 127228143 CVCL_A5RL CD#60 ipsC induced pluripotent stem cell human CVCL_A5RL CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Gly176Asp (c.527C>A); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Ala305Glu (c.914C>A); ClinVar=VCV000002607; Zygosity=Heterozygous (PubMed=33304759) Derived from sampling site: Brain Cell type=Fibroblast.. Male 127228144 CVCL_A5RK CD#59 ipsC induced pluripotent stem cell human CVCL_A5RK CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Gly176Asp (c.527C>A); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Ala305Glu (c.914C>A); ClinVar=VCV000002607; Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Arg249Trp (c.745C>T); ClinVar=VCV000126510; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228145 CVCL_A5RN FF08711992 finite cell line human CVCL_A5RN CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Met82Asnfs*7 (c.244dupA); Zygosity=Homozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Female 127228146 CVCL_A5RM CD#68 iPSC induced pluripotent stem cell human CVCL_A5RM CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu285Ala (c.854A>C); ClinVar=VCV000002605; Zygosity=Homozygous (PubMed=33304759) Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 127228147 CVCL_A5RP CD#92 iPSC induced pluripotent stem cell human CVCL_A5RP CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Met82Asnfs*7 (c.244dupA); Zygosity=Homozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Female 127228148 CVCL_A5RR CD#00 iPSC induced pluripotent stem cell human CVCL_A5RR CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.His244Arg (c.731A>G); ClinVar=VCV000371086; Zygosity=Homozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Male 127228149 CVCL_A5RQ FFF0282000 finite cell line human CVCL_A5RQ CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.His244Arg (c.731A>G); ClinVar=VCV000371086; Zygosity=Homozygous (PubMed=33304759) Derived from sampling site: Cell type=Fibroblast. Male 127228150 CVCL_A5RD KCLi013-A induced pluripotent stem cell human CVCL_A5RD From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 535; ANXA11; Simple; p.Arg235Gln (c.704G>A); dbSNP=rs765489119; Zygosity=Heterozygous (PubMed=33610019) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228151 CVCL_A5RC KCLi012-A induced pluripotent stem cell human CVCL_A5RC From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 535; ANXA11; Simple; p.Asp40Gly (c.119A>G); ClinVar=VCV000488353; Zygosity=Heterozygous (PubMed=33610019) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228152 CVCL_A5RF ICANi001-A-1 induced pluripotent stem cell human CVCL_A5RF From: INSERM U1166-Institute of Cardiometabolism and Nutrition; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple_corrected; p.Arg403Leu (c.1208G>T); ClinVar=VCV000014101; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33610018) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228153 CVCL_A5RE ICANi001-A induced pluripotent stem cell human CVCL_A5RE From: INSERM U1166-Institute of Cardiometabolism and Nutrition; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple_edited; p.Arg403Leu (c.1208G>T); ClinVar=VCV000014101; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33610018) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228154 CVCL_A5RH IEC6-Cdx2L1 finite cell line Norway rat CVCL_A5RH CL:0000010 Transfected with: MGI; MGI:88361; Cdx2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male Characteristics: Cdx2 can conditionally be expressed by addition of IPTG in the culture media This cell line was engineered with the LacSwitch system in this case composed of two plasmids, pOPRSVI-Cdx2 that contains a RSV LTR promoter, 2 lacO sites (lactose repressor), cdX2 and a neo gene and p3'SS that contains the LacI and hph genes. Thus when IPTG is added to the culture media, repression mediated by lacI is removed and Cdx2 is expressed (PubMed=8552090). 127228155 CVCL_A5RG THCE telomerase immortalized cell line human CVCL_A5RG CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Eye; cornea; epithelium. 127228156 CVCL_A5RJ IEC6-Cdx2MT15 finite cell line Norway rat CVCL_A5RJ CL:0000010 Transfected with: MGI; MGI:88361; Cdx2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male Characteristics: The transfected Cdx2 gene is under the csheep MT1 gene (PubMed=8552090) 127228157 CVCL_A5RI IEC6-Cdx2L2 finite cell line Norway rat CVCL_A5RI CL:0000010 Transfected with: MGI; MGI:88361; Cdx2; Transfected with: UniProtKB; P03023; Escherichia coli LacI; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male Characteristics: Cdx2 can conditionally be expressed by addition of IPTG in the culture media This cell line was engineered with the LacSwitch system in this case composed of two plasmids, pOPRSVI-Cdx2 that contains a RSV LTR promoter, 2 lacO sites (lactose repressor), cdX2 and a neo gene and p3'SS that contains the LacI and hph genes. Thus when IPTG is added to the culture media, repression mediated by lacI is removed and Cdx2 is expressed (PubMed=8552090). 127228158 CVCL_A5QZ KCLi009-A induced pluripotent stem cell human CVCL_A5QZ From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521His (c.1562G>A); ClinVar=VCV000016225; Zygosity=Heterozygous (PubMed=33610019) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228159 CVCL_A5RB KCLi011-A induced pluripotent stem cell human CVCL_A5RB From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 535; ANXA11; Simple; p.Gly38Arg (c.112G>A); ClinVar=VCV000488354; Zygosity=Heterozygous (PubMed=33610019) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228160 CVCL_A5RA KCLi010-A induced pluripotent stem cell human CVCL_A5RA From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg522Gly (c.1564A>G); ClinVar=VCV000540279; Zygosity=Heterozygous (PubMed=33610019) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228161 CVCL_A5SU KDM/JuB2 cancer cell line dog CVCL_A5SU CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Labrador Retriever. Female Characteristics: Established from the xenograft Ju Doubling time: 31.6 hours (PubMed=22839755) 127228162 CVCL_A5ST KDM/JuA1 cancer cell line dog CVCL_A5ST CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Labrador Retriever. Female Characteristics: Established from the xenograft Ju 127228163 CVCL_A5SW KDM/Re12 cancer cell line dog CVCL_A5SW CL:0000010 Derived from sampling site: Heart; right atrium; Breed/subspecies: Golden Retriever. Male Characteristics: Established from the xenograft Re 127228164 CVCL_A5SV KDM/JuB4 cancer cell line dog CVCL_A5SV CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Labrador Retriever. Female Characteristics: Established from the xenograft Ju 127228165 CVCL_A5SY KDM/Ud2 cancer cell line dog CVCL_A5SY CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Papillion. Female Characteristics: Established from the xenograft Ud Doubling time: 23.5 hours (PubMed=22839755) 127228166 CVCL_A5SX KDM/Re21 cancer cell line dog CVCL_A5SX CL:0000010 Derived from sampling site: Heart; right atrium; Breed/subspecies: Golden Retriever. Male Characteristics: Established from the xenograft Re 127228167 CVCL_A5SZ KDM/Ud6 cancer cell line dog CVCL_A5SZ CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Papillion. Female Characteristics: Established from the xenograft Ud 127228168 CVCL_A5SM Wilms11 finite cell line human CVCL_A5SM CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; None_reported; -; Zygosity=- (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Homozygous; Note=Somatic (PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Male 127228169 CVCL_A5SL Wilms10T finite cell line human CVCL_A5SL CL:0000010 Sequence variation: Gene deletion; HGNC; 12796; WT1; Zygosity=Homozygous; Note=Nested within a heterozygous 11p13 deletion (PubMed=27213811; PubMed=33379206); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Homozygous (PubMed=27213811; PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Female 127228170 CVCL_A5SN imWilms1 conditionally immortalized cell line human CVCL_A5SN CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser50Ter (c.149C>A); Zygosity=Homozygous (PubMed=33379206); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Female 127228171 CVCL_A5SQ imWilms6 conditionally immortalized cell line human CVCL_A5SQ CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Homozygous (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg390Ter (c.1168C>T) (p.Arg463Ter, c.1387C>T); ClinVar=VCV000003494; Zygosity=Homozygous (PubMed=33379206); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 127228172 CVCL_A5SP imWilms3 conditionally immortalized cell line human CVCL_A5SP CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; None_reported; -; Zygosity=- (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Val432Serfs*87 (c.1293_1294insA); Zygosity=Homozygous; Note=Somatic (PubMed=33379206); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 127228173 CVCL_A5SS PEC transformed cell line pig CVCL_A5SS CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) (PubMed=31426793) 127228174 CVCL_A5SR Y79/EDR cancer cell line human CVCL_A5SR CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Eye; globe. Omics: Transcriptome analysis by RNAseq Female Doubling time: 14.5 hours (DOI=10.3969/j.issn.1673-713X.2017.04.002) 127228175 CVCL_A5SE Wilms2 finite cell line human CVCL_A5SE CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Tyr (c.134C>A); ClinVar=VCV000375895; Zygosity=Heterozygous (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg362Ter (c.1084C>T) (p.Arg435Ter, c.1303C>T); ClinVar=VCV000003497; Zygosity=Homozygous (PubMed=20106868; PubMed=24619359; PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Male 127228176 CVCL_A5SD Wilms1-2r finite cell line human CVCL_A5SD CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Cys (c.134C>G); ClinVar=VCV000376242; Zygosity=Heterozygous (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser50Ter (c.149C>A); Zygosity=Homozygous (PubMed=33379206) Population: Caucasian; Donor information: Established from the right kidney of the recurrence (2nd tumor) of the patient; Derived from sampling site: Kidney. Female 127228177 CVCL_A5SG Wilms4 finite cell line human CVCL_A5SG CL:0000010 Sequence variation: Gene deletion; HGNC; 12796; WT1; Zygosity=Heterozygous (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.His438Profs*7 (c.1311_1312insC); Zygosity=Heterozygous (PubMed=20106868; PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Male 127228178 CVCL_A5SF Wilms3 finite cell line human CVCL_A5SF CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; None_reported; -; Zygosity=- (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Val432Serfs*87 (c.1293_1294insA); Zygosity=Homozygous; Note=Somatic (PubMed=20106868; PubMed=24619359; PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Male 127228179 CVCL_A5SI Wilms6 finite cell line human CVCL_A5SI CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Homozygous (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg390Ter (c.1168C>T) (p.Arg463Ter, c.1387C>T); ClinVar=VCV000003494; Zygosity=Homozygous (PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Male 127228180 CVCL_A5SH Wilms5 finite cell line human CVCL_A5SH CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; None_reported; -; Zygosity=- (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg433Profs*84 (c.1296_1299delGC); Zygosity=Homozygous; Note=Somatic (PubMed=20106868; PubMed=33379206) Population: Caucasian; Donor information: The patient has a germline WT1 p.Arg390Ter (c.1168C>T) mutation that was lost in the tumor; Derived from sampling site: Kidney. Male 127228181 CVCL_A5SK Wilms10M finite cell line human CVCL_A5SK CL:0000010 Sequence variation: Gene deletion; HGNC; 12796; WT1; Zygosity=Homozygous; Note=Nested within a heterozygous 11p13 deletion (PubMed=33379206); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Homozygous (PubMed=33379206) Population: Caucasian; Derived from metastatic site: Lung. Female 127228182 CVCL_A5SJ Wilms8 finite cell line human CVCL_A5SJ CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Ala (c.133T>G); ClinVar=VCV000376241; Zygosity=Heterozygous (PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg390Ter (c.1168C>T) (p.Arg463Ter, c.1387C>T); ClinVar=VCV000003494; Zygosity=Homozygous (PubMed=33379206) Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis Male 127228183 CVCL_A5SA KMS-34-SCC1 cancer cell line human CVCL_A5SA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Pleural effusion. Female 127228184 CVCL_A5SC Wilms1-2l finite cell line human CVCL_A5SC CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=20106868; PubMed=33379206); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser50Ter (c.149C>A); Zygosity=Homozygous (PubMed=20106868; PubMed=33379206) Population: Caucasian; Donor information: Established from the left kidney of the recurrence (2nd tumor) of the patient; Derived from sampling site: Kidney. Female 127228185 CVCL_A5SB KMS-34-SCC2 cancer cell line human CVCL_A5SB CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Pleural effusion. Female 127228186 CVCL_A5PR NB90-6 cancer cell line human CVCL_A5PR CL:0000010 127228187 CVCL_A5PQ NB90-4 cancer cell line human CVCL_A5PQ CL:0000010 127228188 CVCL_A5PT A2780/CP8 cancer cell line human CVCL_A5PT CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female Doubling time: 22.1 +- 0.7 hours (PubMed=3539322) 127228189 CVCL_A5PS A2780/CP20 cancer cell line human CVCL_A5PS CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Phe (c.517G>T); Zygosity=Unspecified (PubMed=8557231) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 127228190 CVCL_A5PV EG [Human ovarian carcinoma] cancer cell line human CVCL_A5PV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143fs (c.427_458del32); Zygosity=Unspecified (PubMed=8557231) Derived from sampling site: Ovary. Female 127228191 CVCL_A5PU EC [Human ovarian carcinoma] cancer cell line human CVCL_A5PU CL:0000010 Derived from sampling site: Ovary. Female 127228192 CVCL_A5PX NMH spontaneously immortalized cell line house mouse CVCL_A5PX CL:0000010 Karyotypic information: Near diploid karyotype; Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: CD-1. Male Doubling time: 19 hours (PubMed=7525051) 127228193 CVCL_A5PW ML3B transformed cell line human CVCL_A5PW CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 127228194 CVCL_A5PJ AAKIPSi001-A induced pluripotent stem cell human CVCL_A5PJ From: INSERM; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127228195 CVCL_A5PI LRVA-4 cancer cell line human CVCL_A5PI CL:0000010 Miscellaneous: Cell line has been lost (PubMed=14518029) Derived from sampling site: Prostate. Male 127228196 CVCL_A5PL AAKIPSi003-A induced pluripotent stem cell human CVCL_A5PL From: INSERM; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127228197 CVCL_A5PK AAKIPSi002-A induced pluripotent stem cell human CVCL_A5PK From: INSERM; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127228198 CVCL_A5PN BALB/3T3 clone A31T spontaneously immortalized cell line house mouse CVCL_A5PN CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 127228199 CVCL_A5PM N11 transformed cell line house mouse CVCL_A5PM CL:0000010 Transformant: Recombinant retrovirus 3RV/VN-11; Derived from sampling site: Embryonic brain Cell type=Microglial cell.; Breed/subspecies: CD-1. Unspecified 127228200 CVCL_A5PP PNET-1 cancer cell line human CVCL_A5PP CL:0000010 127228201 CVCL_A5PB GM25134 transformed cell line human CVCL_A5PB CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Gly156Asp (c.467G>A); Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228202 CVCL_A5PA GM25995 transformed cell line human CVCL_A5PA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228203 CVCL_A5PD GM25154 transformed cell line human CVCL_A5PD CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ter355Aspext*48 (c.1063delT) (X355D); Zygosity=Unspecified (Coriell) Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228204 CVCL_A5PC GM25153 transformed cell line human CVCL_A5PC CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ter355Aspext*48 (c.1063delT) (X355D); Zygosity=Unspecified (Coriell) Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228205 CVCL_A5PF GM25166 transformed cell line human CVCL_A5PF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228206 CVCL_A5PE GM25155 transformed cell line human CVCL_A5PE CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228207 CVCL_A5PH GM25170 transformed cell line human CVCL_A5PH CL:0000010 Sequence variation: Gene deletion; HGNC; 2928; DMD; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228208 CVCL_A5PG GM25168 transformed cell line human CVCL_A5PG CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Trp114Glnfs*7 (c.338-1G>A) (IVS4-1G>A) (Ex5del); Zygosity=Hemizygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228209 CVCL_A5QS UMi028-A-2 induced pluripotent stem cell human CVCL_A5QS From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 12393; TTC3; Simple_edited; p.Ser1038Cys (c.3113C>G); dbSNP=rs377155188; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33626494) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228210 CVCL_A5QR CEIi001-A induced pluripotent stem cell human CVCL_A5QR From: Cole Eye Institute, Cleveland Clinic; Cleveland; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29021; CEP290 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 127228211 CVCL_A5QU WAe001-A-55 embryonic stem cell human CVCL_A5QU From: University of Manchester; Manchester; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7. Male 127228212 CVCL_A5QT WAe001-A-54 embryonic stem cell human CVCL_A5QT From: University of Manchester; Manchester; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7. Male 127228213 CVCL_A5QW WAe001-A-30 embryonic stem cell human CVCL_A5QW From: University of Houston; Houston; USA. CL:0000010 Male 127228214 CVCL_A5QV WAe001-A-56 embryonic stem cell human CVCL_A5QV From: University of Houston; Houston; USA CL:0000010 Transfected with: HGNC; 7059; MGMT (with p.Gly180_Asn_207del and 19 mutations = SNAP-tag). Male Characteristics: Using CRISPR/Cas9 a SNAP-tag was in-frame inserted at the C-terminus of the SOD1 coding region following a 3 amino-acid linker (PubMed=34118566) 127228215 CVCL_A5QY KCLi008-A induced pluripotent stem cell human CVCL_A5QY From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Gln519Glu (c.1555C>G); ClinVar=VCV000650787; Zygosity=Heterozygous (PubMed=33610019) Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228216 CVCL_A5QX WAe014-A-1 embryonic stem cell human CVCL_A5QX From: Korea University Cell Function Regulation Lab; Seoul; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 61; ABCD1. Male 127228217 CVCL_A5QK WMUi022-A induced pluripotent stem cell human CVCL_A5QK From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (PubMed=33901818) Population: Chinese; Han; Derived from sampling site: Urine. Male 127228218 CVCL_A5QJ WMUi020-A induced pluripotent stem cell human CVCL_A5QJ From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 17985; ROBO4; Simple; p.Gln54Arg (c.161A>G); dbSNP=rs59648931; Zygosity=Heterozygous (PubMed=33631418) Population: Chinese; Han; Derived from sampling site: Thoracic aorta; smooth muscle. Female 127228219 CVCL_A5QM WMUi006-A induced pluripotent stem cell human CVCL_A5QM From: Wenzhou Medical University; Wenzhou; China. CL:0000010 127228220 CVCL_A5QL WMUi023-A induced pluripotent stem cell human CVCL_A5QL From: Wenzhou Medical University; Wenzhou; China. CL:0000010 127228221 CVCL_A5QN NUIGi040-B induced pluripotent stem cell human CVCL_A5QN From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228222 CVCL_A5QQ Ep-1 induced pluripotent stem cell human CVCL_A5QQ CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 127228223 CVCL_A5QP UMGi157-A induced pluripotent stem cell human CVCL_A5QP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228224 CVCL_A5QC ciPSC line 3 induced pluripotent stem cell dog CVCL_A5QC CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Beagle. Male 127228225 CVCL_A5QB JLUEYEi001-A induced pluripotent stem cell human CVCL_A5QB From: Eye Center of Second Hospital, Jilin University; Changchun; China CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Unexplicit; IVS22-1C>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=33647874) Population: Mongolian; Derived from sampling site: Peripheral blood. Female 127228226 CVCL_A5QE ciPSC P9 induced pluripotent stem cell dog CVCL_A5QE CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Beagle. Female 127228227 CVCL_A5QD ciPSC line 6 induced pluripotent stem cell dog CVCL_A5QD CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Beagle. Male 127228228 CVCL_A5QG UMGi041-B.3 induced pluripotent stem cell human CVCL_A5QG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Ala2254Val (c.6761C>T); Zygosity=Heterozygous (PubMed=33640691) Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228229 CVCL_A5QF JLUEYEi002-A induced pluripotent stem cell human CVCL_A5QF From: Eye Center of Second Hospital, Jilin University; Changchun; China CL:0000010 Population: Mongolian; Derived from sampling site: Peripheral blood. Male 127228230 CVCL_A5QI JMUi001-A-3 induced pluripotent stem cell human CVCL_A5QI From: Comprehensive Heart Failure Center, University Clinic Wurzburg; Wurzburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 127228231 CVCL_A5QH JMUi001-A-2 induced pluripotent stem cell human CVCL_A5QH From: Comprehensive Heart Failure Center, University Clinic Wurzburg; Wurzburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9024; PKP2 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 127228232 CVCL_A5PZ COS-7 1C7 transformed cell line CVCL_A5PZ CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Useful to study endothelin analogues for agonist or antagonist activity Group: Non-human primate cell line 127228233 CVCL_A5PY UOK85 cancer cell line human CVCL_A5PY CL:0000010 Derived from sampling site: Kidney. Unspecified 127228234 CVCL_A5QA COS-F2-130 transformed cell line CVCL_A5QA CL:0000010 Transfected with: HGNC; 2590; CYP11A1; Transfected with: HGNC; 3638; FDX1; Transfected with: HGNC; 3642; FDXR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Useful system for studying steroidogenesis Converts cholesterol to pregnenolone but lack downstream enzymes that catalyze other steroidogenic reactions (PubMed=11356706).; Characteristics: Transfected with the F2 construct that consist of the fusion of P450scc-adrenodoxin reductase-adrenodoxin (PubMed=11356706) Group: Non-human primate cell line 127228235 CVCL_A5NP GM25858 transformed cell line human CVCL_A5NP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228236 CVCL_A5NR GM25861 transformed cell line human CVCL_A5NR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228237 CVCL_A5NQ GM25860 transformed cell line human CVCL_A5NQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228238 CVCL_A5NT GM25873 transformed cell line human CVCL_A5NT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228239 CVCL_A5NS GM25872 transformed cell line human CVCL_A5NS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228240 CVCL_A5NV GM25929 transformed cell line human CVCL_A5NV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228241 CVCL_A5NU GM25886 transformed cell line human CVCL_A5NU CL:0000010 Population: Caucasian; English/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228242 CVCL_A5NH STF-4 finite cell line human CVCL_A5NH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228243 CVCL_A5NG STF-6 finite cell line human CVCL_A5NG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228244 CVCL_A5NJ H7-H2B-RFP embryonic stem cell human CVCL_A5NJ CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; A0A4V4ND72; mRFP1. Female Characteristics: The H2B-mRFP1 fusion construct is under the control of the CAG promoter 127228245 CVCL_A5NI STF-5 finite cell line human CVCL_A5NI CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228246 CVCL_A5NL HUES 17-H2B-RFP embryonic stem cell human CVCL_A5NL CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; A0A4V4ND72; mRFP1 Miscellaneous: Cell line information from personal communication of Price C.J. Male Characteristics: The H2B-mRFP1 fusion construct is under the control of the CAG promoter 127228247 CVCL_A5NK H14-H2B-RFP induced pluripotent stem cell human CVCL_A5NK CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; A0A4V4ND72; mRFP1 Miscellaneous: Cell line information from personal communication of Price C.J. Male Characteristics: The H2B-mRFP1 fusion construct is under the control of the CAG promoter 127228248 CVCL_A5NN GM25857 transformed cell line human CVCL_A5NN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228249 CVCL_A5NM GM25856 transformed cell line human CVCL_A5NM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228250 CVCL_A5NB UKAi008-A induced pluripotent stem cell human CVCL_A5NB From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Leu34Phe (c.100C>T); ClinVar=VCV000135308; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Val218Met (c.652G>A); ClinVar=VCV000135321; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A>G); ClinVar=VCV000135287; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.His1778Arg (c.5333A>G); ClinVar=VCV000135289; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Homozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male Characteristics: Established from a patient that has a KIT p.Asp816Val mutation, but this cell line does not contain this mutation 127228251 CVCL_A5NA UKAi007-B induced pluripotent stem cell human CVCL_A5NA From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Gly725Ser (c.2173G>A) (p.Gly706Ser, c.2116G>A); ClinVar=VCV000133445; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Val178Ile (c.532G>A); ClinVar=VCV000134520; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 10471; RUNX1; Simple; p.Met133Ile (c.399G>A); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 10783; SRSF2; Simple; p.Pro95_Arg102del (c.284_307del); dbSNP=rs766200080; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Arg1261Cys (c.3781C>T); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ser1292Arg (c.3876C>G); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Homozygous (PubMed=33512435) Derived from sampling site: Bone marrow. Male 127228252 CVCL_A5ND UKAi008-C induced pluripotent stem cell human CVCL_A5ND From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Leu34Phe (c.100C>T); ClinVar=VCV000135308; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Val218Met (c.652G>A); ClinVar=VCV000135321; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A>G); ClinVar=VCV000135287; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.His1778Arg (c.5333A>G); ClinVar=VCV000135289; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Homozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male 127228253 CVCL_A5NC UKAi008-B induced pluripotent stem cell human CVCL_A5NC From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Leu34Phe (c.100C>T); ClinVar=VCV000135308; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Val218Met (c.652G>A); ClinVar=VCV000135321; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ile1762Val (c.5284A>G); ClinVar=VCV000135287; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.His1778Arg (c.5333A>G); ClinVar=VCV000135289; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Homozygous (PubMed=33512435) Derived from sampling site: Peripheral blood. Male Characteristics: Established from a patient that has a KIT p.Asp816Val mutation, but this cell line does not contain this mutation 127228254 CVCL_A5NF BRE finite cell line human CVCL_A5NF CL:0000010 Sequence variation: Mutation; HGNC; 43; TAP1; Simple; p.Asp273fs (c.819delC); Zygosity=Homozygous (PubMed=10074495) Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228255 CVCL_A5NE STF-1 finite cell line human CVCL_A5NE CL:0000010 Sequence variation: Mutation; HGNC; 44; TAP2; Simple; p.Arg273Ter (c.817C>T) (R253*); ClinVar=VCV000013727; Zygosity=Homozygous (from autologous cell line ST-EMO) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228256 CVCL_A5MW SNUe003-A-2 embryonic stem cell human CVCL_A5MW From: Seoul National University; Seoul; South Korea CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Korean Male Characteristics: Using CRISPR/Cas9 a T2A-mCherry-polyA-PGKp-NeoR-polyA construct was introduced at the C-terminal end of one allele of Brachyury (PubMed=33878708) 127228257 CVCL_A5MV SNUe003-A-1 embryonic stem cell human CVCL_A5MV From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean; Karyotypic information: 47,XY,+12 (hPSCreg). Male 127228258 CVCL_A5MY UKAi006-A induced pluripotent stem cell human CVCL_A5MY From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ile859Thr (c.2576T>C) (p.Ile848Thr, c.2543T>C); ClinVar=VCV000006350; Zygosity=Heterozygous (PubMed=30720580) Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228259 CVCL_A5MX UKAi005-A induced pluripotent stem cell human CVCL_A5MX From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ile859Thr (c.2576T>C) (p.Ile848Thr, c.2543T>C); ClinVar=VCV000006350; Zygosity=Heterozygous (PubMed=30720580) Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228260 CVCL_A5MZ UKAi007-A induced pluripotent stem cell human CVCL_A5MZ From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Gly725Ser (c.2173G>A) (p.Gly706Ser, c.2116G>A); ClinVar=VCV000133445; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Val178Ile (c.532G>A); ClinVar=VCV000134520; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 10471; RUNX1; Simple; p.Val101Alafs*31 (c.302_318del); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 10783; SRSF2; Simple; p.Pro95_Arg102del (c.284_307del); dbSNP=rs766200080; Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ser1292Arg (c.3876C>G); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Arg1465Ter (c.4393C>T); Zygosity=Heterozygous (PubMed=33512435); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Homozygous (PubMed=33512435) Derived from sampling site: Bone marrow. Male Characteristics: Established from a patient that has a KIT p.Asp816Val mutation, but this cell line does not contain this mutation 127228261 CVCL_A5NX GM25933 transformed cell line human CVCL_A5NX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228262 CVCL_A5NW GM25932 finite cell line human CVCL_A5NW CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228263 CVCL_A5NZ GM25991 transformed cell line human CVCL_A5NZ CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: No OTC mutation found 127228264 CVCL_A5NY GM25944 finite cell line human CVCL_A5NY CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 127228265 CVCL_A4ZU ZZUNEUi019-A induced pluripotent stem cell human CVCL_A4ZU From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10259; RORB; Simple; c.94-1G>A; ClinVar=VCV001683646; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=33540281) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228266 CVCL_A4ZT ZZUNEUi018-A induced pluripotent stem cell human CVCL_A4ZT From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 127228267 CVCL_A4ZW Muntjak-T4 undefined cell line type CVCL_A4ZW CL:0000010 Discontinued: ATCC; CRL-6573; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 127228268 CVCL_A4ZV PoEKC spontaneously immortalized cell line CVCL_A4ZV CL:0000010 Unspecified Group: Fish cell line. 127228269 CVCL_A4ZY 250 MK finite cell line human CVCL_A4ZY CL:0000010 Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 127228270 CVCL_A4ZX Muntjak(Fe) undefined cell line type CVCL_A4ZX CL:0000010 Discontinued: ATCC; CRL-6572; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 127228271 CVCL_A4ZZ KIJ308T cancer cell line human CVCL_A4ZZ CL:0000010 Derived from sampling site: Kidney. 127228272 CVCL_A4ZM BGUi009-A induced pluripotent stem cell human CVCL_A4ZM From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Homozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Connective tissue. Male 127228273 CVCL_A4ZL BGUi008-A induced pluripotent stem cell human CVCL_A4ZL From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Heterozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228274 CVCL_A4ZN BGUi010-A induced pluripotent stem cell human CVCL_A4ZN From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Homozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228275 CVCL_A4ZQ ZZUNEUi015-A induced pluripotent stem cell human CVCL_A4ZQ From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 17574; ALPK3; Simple; p.Thr338lle (c.1013T>C); ClinVar=VCV000389853; Zygosity=Heterozygous (PubMed=33607470) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228276 CVCL_A4ZP BGUi014-A induced pluripotent stem cell human CVCL_A4ZP From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 127228277 CVCL_A4ZS ZZUNEUi017-A induced pluripotent stem cell human CVCL_A4ZS From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Glu12513fs (c.37537delG); Zygosity=Heterozygous (PubMed=33610015) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228278 CVCL_A4ZR ZZUNEUi016-A induced pluripotent stem cell human CVCL_A4ZR From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Ala355Thr (c.1063G>A); ClinVar=VCV000042820; Zygosity=Heterozygous (PubMed=33636496) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228279 CVCL_A4ZE UMGi014-C induced pluripotent stem cell human CVCL_A4ZE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228280 CVCL_A4ZD UMGi141-A induced pluripotent stem cell human CVCL_A4ZD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228281 CVCL_A4ZG UMGi092-A induced pluripotent stem cell human CVCL_A4ZG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228282 CVCL_A4ZF UMGi014-D induced pluripotent stem cell human CVCL_A4ZF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228283 CVCL_A4ZI UMGi099-B induced pluripotent stem cell human CVCL_A4ZI From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228284 CVCL_A4ZH UMGi099-A induced pluripotent stem cell human CVCL_A4ZH From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228285 CVCL_A4ZK BGUi007-A induced pluripotent stem cell human CVCL_A4ZK From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous (PubMed=34419746) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228286 CVCL_A4ZJ BGUi006-A induced pluripotent stem cell human CVCL_A4ZJ From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous (PubMed=34419746) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228287 CVCL_A4XZ WMUi018-A induced pluripotent stem cell human CVCL_A4XZ From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9208; POR; Simple; p.Arg454His (c.1361G>A) (p.Arg457His, c.1370G>A); ClinVar=VCV000016907; Zygosity=Homozygous (PubMed=33631521) Population: Chinese; Han; Derived from sampling site: Urine. Female 127228288 CVCL_A4YB WMUi016-A induced pluripotent stem cell human CVCL_A4YB From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2023; CLCN5; Simple; p.Arg718Ter (c.2152C>T); ClinVar=VCV000011797; Zygosity=Hemizygous (PubMed=33545640) Population: Chinese; Han; Derived from sampling site: Urine. Male 127228289 CVCL_A4YA WMUi019-A induced pluripotent stem cell human CVCL_A4YA From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10910; SLC12A1; Simple; p.Ala244Asp (c.731C>A); Zygosity=Homozygous (PubMed=33607471) Population: Chinese; Han; Derived from sampling site: Urine. Female 127228290 CVCL_A4XS SDQLCHi036-A induced pluripotent stem cell human CVCL_A4XS From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Unexplicit; Ex3-9del; Zygosity=Heterozygous (PubMed=33550136) Derived from sampling site: Peripheral blood. Male 127228291 CVCL_A4XR SDQLCHi035-A induced pluripotent stem cell human CVCL_A4XR From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Heterozygous (PubMed=33517119); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.His100Argfs*14 (c.299_300delAT); ClinVar=VCV000044736; Zygosity=Heterozygous (PubMed=33517119) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228292 CVCL_A4XU SDQLCHi040-A induced pluripotent stem cell human CVCL_A4XU From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 5964; IL10RA; Simple; p.Arg101Trp (c.301C>T); ClinVar=VCV000039432; Zygosity=Homozygous (PubMed=34530396) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228293 CVCL_A4XT SDQLCHi038-A induced pluripotent stem cell human CVCL_A4XT From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228294 CVCL_A4XW SDUBMSi009-A induced pluripotent stem cell human CVCL_A4XW From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 8108; OCRL; Simple; c.940-11G>A; ClinVar=VCV000279859; Zygosity=Hemizygous (PubMed=33540283) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228295 CVCL_A4XV SDQLCHi041-A induced pluripotent stem cell human CVCL_A4XV From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg203Gln (c.608G>A); ClinVar=VCV001029750; Zygosity=Heterozygous (PubMed=33550137); Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Glu446Lys (c.1336G>A); ClinVar=VCV000553423; Zygosity=Heterozygous (PubMed=33550137) Derived from sampling site: Peripheral blood. Male 127228296 CVCL_A4XY WMUi014-A induced pluripotent stem cell human CVCL_A4XY From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; c.2013insA; Zygosity=Hemizygous (PubMed=33472124) Population: Chinese; Han; Derived from sampling site: Urine. Male 127228297 CVCL_A4XX WMUi017-A induced pluripotent stem cell human CVCL_A4XX From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9330; PQBP1; Simple; p.Pro609Ala (c.1825C>G); Zygosity=Hemizygous (PubMed=33477035) Population: Chinese; Han; Derived from sampling site: Urine. Male 127228298 CVCL_A4XK SDQLCHi028-A induced pluripotent stem cell human CVCL_A4XK From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228299 CVCL_A4XJ SDQLCHi027-A induced pluripotent stem cell human CVCL_A4XJ From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228300 CVCL_A4XM SDQLCHi030-A induced pluripotent stem cell human CVCL_A4XM From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228301 CVCL_A4XL SDQLCHi029-A induced pluripotent stem cell human CVCL_A4XL From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228302 CVCL_A4XN SDQLCHi031-A induced pluripotent stem cell human CVCL_A4XN From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228303 CVCL_A4XQ SDQLCHi034-A induced pluripotent stem cell human CVCL_A4XQ From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 127228304 CVCL_A4XP SDQLCHi032-A induced pluripotent stem cell human CVCL_A4XP From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 5154; HPGD; Simple; p.Leu104Alafs*3 (c.308_309CT[1]) (c.310_311delCT); ClinVar=VCV000156027; Zygosity=Homozygous (PubMed=33550138) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228305 CVCL_A4XC UUMCBi002-A induced pluripotent stem cell human CVCL_A4XC From: Department of Medical Cell Biology, Biomedical Centre; Uppsala; Sweden CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228306 CVCL_A4XB UUMCBi001-A induced pluripotent stem cell human CVCL_A4XB From: Department of Medical Cell Biology, Biomedical Centre; Uppsala; Sweden CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228307 CVCL_A4XE FINCBi003-A induced pluripotent stem cell human CVCL_A4XE From: Fondazione IRCCS Istituto Neurologico C Besta; Milan; Italy. CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.8469_13460del; Zygosity=Heteroplasmic; Note=In 30% (PubMed=33434818) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 127228308 CVCL_A4XD FINCBi002-A induced pluripotent stem cell human CVCL_A4XD From: Fondazione IRCCS Istituto Neurologico C Besta; Milan; Italy. CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.9449_14550del; Zygosity=Heteroplasmic; Note=In 80% (PubMed=33434818) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 127228309 CVCL_A4XG SDQLCHi039-A induced pluripotent stem cell human CVCL_A4XG From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 1133; BTK; Simple; p.Tyr510_Glu513delGluTyrLeuGluinsGlu (c.1530_1538delATACCTGGA); Zygosity=Hemizygous (PubMed=33453577) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228310 CVCL_A4XF GWCMCi003-A induced pluripotent stem cell human CVCL_A4XF From: Guangzhou Women and Children's Medical Center; Guangzhou; China. CL:0000010 127228311 CVCL_A4XI PLAFMCi003-A induced pluripotent stem cell human CVCL_A4XI From: Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Gene deletion; HGNC; 9008; PKD1; Zygosity=Heterozygous (PubMed=33485185); Sequence variation: Gene deletion; HGNC; 12363; TSC2; Zygosity=Heterozygous (PubMed=33485185) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228312 CVCL_A4XH SDQLCHi037-A induced pluripotent stem cell human CVCL_A4XH From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Gln539Ter (c.1615C>T); ClinVar=VCV000488807; Zygosity=Heterozygous (PubMed=33465531) Derived from sampling site: Peripheral blood. Male 127228313 CVCL_A4ZA UMGi101-A induced pluripotent stem cell human CVCL_A4ZA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 127228314 CVCL_A4ZC UMGi140-A induced pluripotent stem cell human CVCL_A4ZC From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228315 CVCL_A4ZB UMGi132-A induced pluripotent stem cell human CVCL_A4ZB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228316 CVCL_A4YT SUi002-B induced pluripotent stem cell human CVCL_A4YT From: Semmelweis University; Budapest; Hungary CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228317 CVCL_A4YS SUi002-A induced pluripotent stem cell human CVCL_A4YS From: Semmelweis University; Budapest; Hungary CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228318 CVCL_A4YV SUi003-B induced pluripotent stem cell human CVCL_A4YV From: Semmelweis University; Budapest; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 6316; KHSRP; Simple; p.Gly403Cys (c.1207G>T) (Chr19:6416869C>A); Zygosity=Heterozygous; Note=De novo mutation (from autologous cell line SUi003-A); Sequence variation: Mutation; HGNC; 6329; KIR2DL1; Simple; c.412A>T (Chr19:g.55286658A>T); Zygosity=Heterozygous; Note=De novo mutation (from autologous cell line SUi003-A); Sequence variation: Mutation; HGNC; 18531; LRRC7; Simple; p.Val1158Ile (c.3472G>A) (Chr1:g.70505093G>A); Zygosity=Heterozygous; Note=De novo mutation (from autologous cell line SUi003-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228319 CVCL_A4YU SUi003-A induced pluripotent stem cell human CVCL_A4YU From: Semmelweis University; Budapest; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 6316; KHSRP; Simple; p.Gly403Cys (c.1207G>T) (Chr19:g.6416869C>A); Zygosity=Heterozygous; Note=De novo mutation (PubMed=33503521); Sequence variation: Mutation; HGNC; 6329; KIR2DL1; Simple; c.412A>T (Chr19:g.55286658A>T); Zygosity=Heterozygous; Note=De novo mutation (PubMed=33503521); Sequence variation: Mutation; HGNC; 18531; LRRC7; Simple; p.Val1158Ile (c.3472G>A) (Chr1:g.70505093G>A); Zygosity=Heterozygous; Note=De novo mutation (PubMed=33503521) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228320 CVCL_A4YX KRIBBi001-A induced pluripotent stem cell human CVCL_A4YX From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Population: Brazilian; Derived from sampling site: Bone marrow. Female 127228321 CVCL_A4YW IBMS-iPSC-070-02 induced pluripotent stem cell human CVCL_A4YW From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 15894; PANK2; Simple; p.Leu111Gln (c.332T>A); ClinVar=VCV000193506; Zygosity=Heterozygous (PubMed=33517123); Sequence variation: Mutation; HGNC; 15894; PANK2; Simple; c.1413-9_-14dupTTCCCC; Zygosity=Heterozygous (PubMed=33517123); Sequence variation: Mutation; HGNC; 15894; PANK2; Simple; p.Asn500Ile (c.1499A>T); dbSNP=rs759332123; Zygosity=Heterozygous (PubMed=33517123) Population: Chinese; Derived from sampling site: Peripheral blood. Female 127228322 CVCL_A4YZ UMGi150-A induced pluripotent stem cell human CVCL_A4YZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228323 CVCL_A4YY UMGi153-A induced pluripotent stem cell human CVCL_A4YY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228324 CVCL_A4YL BGUi012-A induced pluripotent stem cell human CVCL_A4YL From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228325 CVCL_A4YK BGUi011-A induced pluripotent stem cell human CVCL_A4YK From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4588; GRIN2D; Simple; p.Val667Ile (c.1999G>A); ClinVar=VCV000267211; Zygosity=Heterozygous (PubMed=33482465) Population: Jewish; Ashkenazi; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228326 CVCL_A4YN BGUi015-A induced pluripotent stem cell human CVCL_A4YN From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 127228327 CVCL_A4YM BGUi013-A induced pluripotent stem cell human CVCL_A4YM From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Derived from sampling site: Peritoneum. Female 127228328 CVCL_A4YP STBCi026-A-4 induced pluripotent stem cell human CVCL_A4YP From: StemBANCC; Oxford; United Kingdom CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a GFP tag was introduced at the C-terminus of PITX3 127228329 CVCL_A4YR SUi001-B induced pluripotent stem cell human CVCL_A4YR From: Semmelweis University; Budapest; Hungary CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127228330 CVCL_A4YQ SUi001-A induced pluripotent stem cell human CVCL_A4YQ From: Semmelweis University; Budapest; Hungary CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127228331 CVCL_A4YD UKWMPi002-A-1 induced pluripotent stem cell human CVCL_A4YD From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 1753; CDH13 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228332 CVCL_A4YC UKWMPi002-A induced pluripotent stem cell human CVCL_A4YC From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228333 CVCL_A4YF UKWMPi002-B induced pluripotent stem cell human CVCL_A4YF From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228334 CVCL_A4YE UKWMPi002-A-2 induced pluripotent stem cell human CVCL_A4YE From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1753; CDH13 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228335 CVCL_A4YH UKWMPi001-A induced pluripotent stem cell human CVCL_A4YH From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany. CL:0000010 127228336 CVCL_A4YG UKWMPi002-C induced pluripotent stem cell human CVCL_A4YG From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228337 CVCL_A4YJ ZZUi028-A induced pluripotent stem cell human CVCL_A4YJ From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Female 127228338 CVCL_A4YI UKWMPi001-B induced pluripotent stem cell human CVCL_A4YI From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany. CL:0000010 127228339 CVCL_A4VY 4.3-01 induced pluripotent stem cell house mouse CVCL_A4VY CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Zfp57-/- z (M+Z-) genotype 127228340 CVCL_A4VX 4.2-05 induced pluripotent stem cell house mouse CVCL_A4VX CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Zfp57+/- (M+Z+) genotype 127228341 CVCL_A4VZ 4.3-04 induced pluripotent stem cell house mouse CVCL_A4VZ CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Zfp57-/- z (M+Z-) genotype 127228342 CVCL_A4VQ PN1-iPSC induced pluripotent stem cell human CVCL_A4VQ From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 25792; USB1; Simple; c.693+1G>T; ClinVar=VCV000496749; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26987923) Derived from sampling site: Peripheral blood. Female 127228343 CVCL_A4VP M3O-lenti-iPSC-LIF(-) induced pluripotent stem cell house mouse CVCL_A4VP CL:0000010 Male 127228344 CVCL_A4VS D1902 embryonic stem cell house mouse CVCL_A4VS CL:0000010 Breed/subspecies: 129 x DBA/2. 127228345 CVCL_A4VR PN2-iPSC induced pluripotent stem cell human CVCL_A4VR From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 25792; USB1; Simple; c.693+1G>T; ClinVar=VCV000496749; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26987923) Derived from sampling site: Peripheral blood. Female 127228346 CVCL_A4VU D1904 embryonic stem cell house mouse CVCL_A4VU CL:0000010 Breed/subspecies: 129 x DBA/2. 127228347 CVCL_A4VT D1903 embryonic stem cell house mouse CVCL_A4VT CL:0000010 Breed/subspecies: 129 x DBA/2. 127228348 CVCL_A4VW D1911 embryonic stem cell house mouse CVCL_A4VW CL:0000010 Breed/subspecies: 129 x DBA/2. 127228349 CVCL_A4VV D1906 embryonic stem cell house mouse CVCL_A4VV CL:0000010 Breed/subspecies: 129 x DBA/2. 127228350 CVCL_A4VI FORTHi001A induced pluripotent stem cell human CVCL_A4VI From: Department of Biomedical Research, Foundation of Research and Technology-Hellas; Ioannina; Greece CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 127228351 CVCL_A4VH TLE3-447-D08-A01 embryonic stem cell human CVCL_A4VH From: Broad Institute of MIT and Harvard; Cambridge; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 11839; TLE3. Male 127228352 CVCL_A4VK FORTHi001C induced pluripotent stem cell human CVCL_A4VK From: Department of Biomedical Research, Foundation of Research and Technology-Hellas; Ioannina; Greece CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 127228353 CVCL_A4VJ FORTHi001B induced pluripotent stem cell human CVCL_A4VJ From: Department of Biomedical Research, Foundation of Research and Technology-Hellas; Ioannina; Greece CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 127228354 CVCL_A4VM iPSC(OCT4) 2 induced pluripotent stem cell human CVCL_A4VM From: McMaster Stem Cell and Cancer Research Institute, Michael G DeGroote School of Medicine, McMaster University; Hamilton; Canada. CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 127228355 CVCL_A4VL iPSC(OCT4) 1 induced pluripotent stem cell human CVCL_A4VL From: McMaster Stem Cell and Cancer Research Institute, Michael G DeGroote School of Medicine, McMaster University; Hamilton; Canada. CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 127228356 CVCL_A4VN iPSC(OCT4) 3 induced pluripotent stem cell human CVCL_A4VN From: McMaster Stem Cell and Cancer Research Institute, Michael G DeGroote School of Medicine, McMaster University; Hamilton; Canada. CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 127228357 CVCL_A4VA UMGi093-A induced pluripotent stem cell human CVCL_A4VA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228358 CVCL_A4VC GWCMCi002-A induced pluripotent stem cell human CVCL_A4VC From: Guangzhou Women and Children's Medical Center; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; c.1517-1G>T; ClinVar=VCV000024421; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=34088015) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228359 CVCL_A4VB UMGi094-A induced pluripotent stem cell human CVCL_A4VB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228360 CVCL_A4VE CREM040i-SA82-2 induced pluripotent stem cell human CVCL_A4VE CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=28111279) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 127228361 CVCL_A4VD CREM039i-SA108 induced pluripotent stem cell human CVCL_A4VD CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=28111279) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 127228362 CVCL_A4VG iPS-CTX-R395S induced pluripotent stem cell human CVCL_A4VG From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2605; CYP27A1; Simple; p.Arg395Ser (c.1183C>A); ClinVar=VCV000004261; Zygosity=Homozygous (PubMed=27879219) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228363 CVCL_A4VF CREM043i-SA210-1 induced pluripotent stem cell human CVCL_A4VF CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=28111279) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 127228364 CVCL_A4WZ IGIBi002-A [2021] induced pluripotent stem cell human CVCL_A4WZ From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+5G>C (IVS1,G>C,+5) (IVS1-5G>C); ClinVar=VCV000015447; Zygosity=Homozygous (PubMed=33338925) Population: Indian; Derived from sampling site: Peripheral blood. Male Caution: Two different cell lines were established by CSIR-IGIB with the same IGIBi002-A designation 127228365 CVCL_A4WY MCRIi019-A-1 induced pluripotent stem cell human CVCL_A4WY From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31612; MIR26B Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228366 CVCL_A4XA HUi002-A induced pluripotent stem cell human CVCL_A4XA From: Hanyang Biomedical Research Institute, Hanyang University; Seoul; South Korea CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228367 CVCL_A4WR LIBDi015-A induced pluripotent stem cell human CVCL_A4WR From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228368 CVCL_A4WQ LIBDi014-A induced pluripotent stem cell human CVCL_A4WQ From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11634; TCF4; Zygosity=Heterozygous (PubMed=32971458) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228369 CVCL_A4WT LIBDi017-A induced pluripotent stem cell human CVCL_A4WT From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228370 CVCL_A4WS LIBDi016-A induced pluripotent stem cell human CVCL_A4WS From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; c.922+3G>T; ClinVar=VCV001204043; Zygosity=Heterozygous (PubMed=32971458) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228371 CVCL_A4WV LIBDi019-A induced pluripotent stem cell human CVCL_A4WV From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11634; TCF4; Zygosity=Heterozygous (PubMed=32971458) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228372 CVCL_A4WU LIBDi018-A induced pluripotent stem cell human CVCL_A4WU From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228373 CVCL_A4WX SCSe001-A-3 embryonic stem cell human CVCL_A4WX From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP. Male Characteristics: Using homologous recombination an EGFP reporter gene was introduced in the INS locus and using CRISPR/Cas9 a tandem-dimer RFP was introduced in the SST gene (PubMed=33316598) 127228374 CVCL_A4WW LIBDi010-A induced pluripotent stem cell human CVCL_A4WW From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228375 CVCL_A4WJ MHHi019-A induced pluripotent stem cell human CVCL_A4WJ From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7853; NME5; Simple; p.Ile139Tyrfs*8 (c.415delA); Zygosity=Homozygous (PubMed=32950024) Derived from sampling site: Peripheral blood. Female 127228376 CVCL_A4WI MPIi007-A induced pluripotent stem cell human CVCL_A4WI From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 713; ARSA; Simple; p.Thr393Ser (c.1178C>G) (p.Thr391Ser, c.1172C>G); ClinVar=VCV000021184; Zygosity=Heterozygous (PubMed=32950023) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 127228377 CVCL_A4WL MHHi020-A induced pluripotent stem cell human CVCL_A4WL From: Hannover Medical School, LEBAO (MHH); Hannover; Germany. CL:0000010 127228378 CVCL_A4WK MHHi019-B induced pluripotent stem cell human CVCL_A4WK From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7853; NME5; Simple; p.Ile139Tyrfs*8 (c.415delA); Zygosity=Homozygous (PubMed=32950024) Derived from sampling site: Peripheral blood. Female 127228379 CVCL_A4WN LIBDi012-A induced pluripotent stem cell human CVCL_A4WN From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg385Ter (c.1153C>T); ClinVar=VCV000007372; Zygosity=Heterozygous (PubMed=32971458) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228380 CVCL_A4WM LIBDi011-A induced pluripotent stem cell human CVCL_A4WM From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg76Ter; Zygosity=Heterozygous (PubMed=32971458) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228381 CVCL_A4WP LIBDi013-A induced pluripotent stem cell human CVCL_A4WP From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228382 CVCL_A4WB WAe001-A-80 embryonic stem cell human CVCL_A4WB From: University of Wisconsin; Madison; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Male Characteristics: Using ZFN a 2A-PuroR-CD43_promoter-eGFP was introduced in the AAVS1 safe harbor locus and CDH5(CD144) promoter-tdTomato-Zeo construct was transferred using a PiggyBac transposon vector (PubMed=27879215) 127228383 CVCL_A4WA 7.2-02 induced pluripotent stem cell house mouse CVCL_A4WA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Zfp57-/- mz (M-Z-) genotype 127228384 CVCL_A4WD PH1-iPSC#2 induced pluripotent stem cell human CVCL_A4WD From: University of Bordeaux; Bordeaux; France CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Homozygous (PubMed=31151050) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228385 CVCL_A4WC PH1-iPSC#1 induced pluripotent stem cell human CVCL_A4WC From: University of Bordeaux; Bordeaux; France CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Homozygous (PubMed=31151050) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228386 CVCL_A4WF WT-iPSC#2 induced pluripotent stem cell human CVCL_A4WF From: University of Bordeaux; Bordeaux; France CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228387 CVCL_A4WE WT-iPSC#1 induced pluripotent stem cell human CVCL_A4WE From: University of Bordeaux; Bordeaux; France CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228388 CVCL_A4WH PH1-iPSC#2-TTRp-eGFP induced pluripotent stem cell human CVCL_A4WH From: University of Bordeaux; Bordeaux; France CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Homozygous (PubMed=31151050); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: The transduced eGFP gene expression is under the control of transthyretin promoter (TTRp) (PubMed=31151050) 127228389 CVCL_A4WG PH1-iPSC#2-TTRp-AGXT induced pluripotent stem cell human CVCL_A4WG From: University of Bordeaux; Bordeaux; France CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Heterozygous; Note=No longer homozygous because of transduced wild-type gene (PubMed=31151050); Transfected with: HGNC; 341; AGXT Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: The transduced AGXT gene expression is under the control of transthyretin promoter (TTRp) (PubMed=31151050) 127228390 CVCL_A4TW CALM1-F142L iPSC c2 induced pluripotent stem cell human CVCL_A4TW CL:0000010 Sequence variation: Mutation; HGNC; 1442; CALM1; Simple; p.Phe142Leu (c.426C>G) (c.9406C>G); ClinVar=VCV000183231; Zygosity=Heterozygous (PubMed=28158429) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228391 CVCL_A4TV CALM1-F142L iPSC c1 induced pluripotent stem cell human CVCL_A4TV CL:0000010 Sequence variation: Mutation; HGNC; 1442; CALM1; Simple; p.Phe142Leu (c.426C>G) (c.9406C>G); ClinVar=VCV000183231; Zygosity=Heterozygous (PubMed=28158429) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127228392 CVCL_A4TY WAe001-A-57 embryonic stem cell human CVCL_A4TY From: Institute for Cardiovascular Science of Soochow University; Suzhou; China CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Male Characteristics: Using CRISPR/Cas9 a 2A-mCherry cassette was integrated in front of the stop codon of EFNB2 in one allele (PubMed=33611045) 127228393 CVCL_A4TX WAe001-A-47 embryonic stem cell human CVCL_A4TX From: Wenzhou Medical University; Wenzhou; China CL:0000010 Transfected with: HGNC; 28966; VGLL4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Dox-inducible expression of VGLL4 The cell has been transfected with a PB-TRE6P-VGLL4-P2A-EGFP-3Flag-PA-EF1a-5'LTR-rtTA-T2A-puroR construct (PubMed=33385792). 127228394 CVCL_A4TZ WAe009-A-48 embryonic stem cell human CVCL_A4TZ From: Shenzhen People's Hospital; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Glu1784Lys (c.5350G>A) (p.Glu1783Lys, c.5347G>A); ClinVar=VCV000009377; Zygosity=Heterozygous; Note=By method not specified (PubMed=33517120). Female 127228395 CVCL_A4TN CCD2-iPS 9 induced pluripotent stem cell human CVCL_A4TN From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Gln67Ter (c.199C>T); Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228396 CVCL_A4TQ UMGi090-A induced pluripotent stem cell human CVCL_A4TQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228397 CVCL_A4TP CCD2-iPS 12 induced pluripotent stem cell human CVCL_A4TP From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Gln67Ter (c.199C>T); Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228398 CVCL_A4TS Rev1-iPSC induced pluripotent stem cell human CVCL_A4TS From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple_corrected; p.Arg391Ter (c.1171C>T); ClinVar=VCV000065625; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228399 CVCL_A4TR UMGi091-A induced pluripotent stem cell human CVCL_A4TR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228400 CVCL_A4TU UMGi130-A induced pluripotent stem cell human CVCL_A4TU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228401 CVCL_A4TT UMGi014-E induced pluripotent stem cell human CVCL_A4TT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Male 127228402 CVCL_A4TG IHLPC transformed cell line human CVCL_A4TG CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Pericyte.. Characteristics: Retains pericyte-specific characteristics, including normal pericyte morphology and expression of the commonly used pericyte markers, PDGFRB and NG2 (PubMed=33446892) 127228403 CVCL_A4TF UMGi148-A induced pluripotent stem cell human CVCL_A4TF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Male 127228404 CVCL_A4TI CCD1-iPS 4 induced pluripotent stem cell human CVCL_A4TI From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Arg391Ter (c.1171C>T); ClinVar=VCV000065625; Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228405 CVCL_A4TH CCD1-iPS 2 induced pluripotent stem cell human CVCL_A4TH From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Arg391Ter (c.1171C>T); ClinVar=VCV000065625; Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228406 CVCL_A4TK CCD2-iPS 4 induced pluripotent stem cell human CVCL_A4TK From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Gln67Ter (c.199C>T); Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228407 CVCL_A4TJ CCD1-iPS 6 induced pluripotent stem cell human CVCL_A4TJ From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Arg391Ter (c.1171C>T); ClinVar=VCV000065625; Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228408 CVCL_A4TM CCD2-iPS 8 induced pluripotent stem cell human CVCL_A4TM From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Gln67Ter (c.199C>T); Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228409 CVCL_A4TL CCD2-iPS 7 induced pluripotent stem cell human CVCL_A4TL From: Department of Biochemistry, Tokyo Dental College; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Gln67Ter (c.199C>T); Zygosity=Heterozygous (PubMed=29357927) Derived from sampling site: Oral cavity; oral mucosa. Female 127228410 CVCL_A4TA UMGi084-A induced pluripotent stem cell human CVCL_A4TA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228411 CVCL_A4TC UMGi086-A induced pluripotent stem cell human CVCL_A4TC From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228412 CVCL_A4TB UMGi085-A induced pluripotent stem cell human CVCL_A4TB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127228413 CVCL_A4TE UMGi154-A induced pluripotent stem cell human CVCL_A4TE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Urine. Female 127228414 CVCL_A4TD UMGi155-A induced pluripotent stem cell human CVCL_A4TD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Male 127228415 CVCL_A4UX UMGi102-A induced pluripotent stem cell human CVCL_A4UX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 127228416 CVCL_A4UW UMGi109-A induced pluripotent stem cell human CVCL_A4UW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228417 CVCL_A4UZ UMGi104-A induced pluripotent stem cell human CVCL_A4UZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 127228418 CVCL_A4UY UMGi103-A induced pluripotent stem cell human CVCL_A4UY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 127228419 CVCL_A4UP UMGi105-A induced pluripotent stem cell human CVCL_A4UP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228420 CVCL_A4UR UMGi106-B induced pluripotent stem cell human CVCL_A4UR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228421 CVCL_A4UQ UMGi106-A induced pluripotent stem cell human CVCL_A4UQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228422 CVCL_A4UT UMGi107-B induced pluripotent stem cell human CVCL_A4UT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228423 CVCL_A4US UMGi107-A induced pluripotent stem cell human CVCL_A4US From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228424 CVCL_A4UV UMGi108-B induced pluripotent stem cell human CVCL_A4UV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228425 CVCL_A4UU UMGi108-A induced pluripotent stem cell human CVCL_A4UU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 127228426 CVCL_A4UH UMGi128-A induced pluripotent stem cell human CVCL_A4UH From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228427 CVCL_A4UG UMGi127-A induced pluripotent stem cell human CVCL_A4UG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127228428 CVCL_A4UJ iMSMD-cohet.7 induced pluripotent stem cell human CVCL_A4UJ CL:0000010 Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; c.373+1G>T (p.Val68Lysfs*6); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29249666); Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; p.Ile187fs (c.561_564delACTC) (c.561del4); Zygosity=Heterozygous (PubMed=29249666) Derived from sampling site: Peripheral blood. Female 127228429 CVCL_A4UI iMSMD-cohet.5 induced pluripotent stem cell human CVCL_A4UI CL:0000010 Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; c.373+1G>T (p.Val68Lysfs*6); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29249666); Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; p.Ile187fs (c.561_564delACTC) (c.561del4); Zygosity=Heterozygous (PubMed=29249666) Derived from sampling site: Peripheral blood. Female 127228430 CVCL_A4UL iMSMD-het.4 induced pluripotent stem cell human CVCL_A4UL CL:0000010 Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; c.373+1G>T (p.Val68Lysfs*6); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29249666) Donor information: While obtained from a patient suffering from Mendelian susceptibility to mycobacterial diseases, this iPSC originates from the sister of this patient who was the donor for a hematopoietic stem cell transplantation; Derived from sampling site: Peripheral blood. Female 127228431 CVCL_A4UK iMSMD-cohet.17 induced pluripotent stem cell human CVCL_A4UK CL:0000010 Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; c.373+1G>T (p.Val68Lysfs*6); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29249666); Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; p.Ile187fs (c.561_564delACTC) (c.561del4); Zygosity=Heterozygous (PubMed=29249666) Derived from sampling site: Peripheral blood. Female 127228432 CVCL_A4UN ZZUNEUi020-A induced pluripotent stem cell human CVCL_A4UN From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg719Gln (c.2156G>A); ClinVar=VCV000014107; Zygosity=Heterozygous (PubMed=33453578) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228433 CVCL_A4UM iMSMD-het.9 induced pluripotent stem cell human CVCL_A4UM CL:0000010 Sequence variation: Mutation; HGNC; 5439; IFNGR1; Simple; c.373+1G>T (p.Val68Lysfs*6); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29249666) Donor information: While obtained from a patient suffering from Mendelian susceptibility to mycobacterial diseases, this iPSC originates from the sister of this patient who was the donor for a hematopoietic stem cell transplantation; Derived from sampling site: Peripheral blood. Female 127228434 CVCL_A4UB WAe009-A-47 embryonic stem cell human CVCL_A4UB From: Peking University Third Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2279; COX6A2. Female 127228435 CVCL_A4UA SPHi001-A induced pluripotent stem cell human CVCL_A4UA From: Shenzhen People's Hospital; Shenzhen; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127228436 CVCL_A4UD UMGi126-A.9 induced pluripotent stem cell human CVCL_A4UD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1250Gln (c.3749G>A); ClinVar=VCV000221068; Zygosity=Heterozygous (PubMed=31106349); Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1268Gln (c.3803G>A); ClinVar=VCV000240673; Zygosity=Heterozygous (PubMed=31106349) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi126-A) for a series of distinct clones 127228437 CVCL_A4UC WAe009-A-46 embryonic stem cell human CVCL_A4UC From: The Second People's Hospital of Liaocheng; Liaocheng; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7576; MYH6. Female 127228438 CVCL_A4UF UMGi126-A.13 induced pluripotent stem cell human CVCL_A4UF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1250Gln (c.3749G>A); ClinVar=VCV000221068; Zygosity=Heterozygous (PubMed=31106349); Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1268Gln (c.3803G>A); ClinVar=VCV000240673; Zygosity=Heterozygous (PubMed=31106349) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi126-A) for a series of distinct clones 127228439 CVCL_A4UE UMGi126-A.12 induced pluripotent stem cell human CVCL_A4UE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1250Gln (c.3749G>A); ClinVar=VCV000221068; Zygosity=Heterozygous (PubMed=31106349); Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg1268Gln (c.3803G>A); ClinVar=VCV000240673; Zygosity=Heterozygous (PubMed=31106349) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi126-A) for a series of distinct clones 127228440 CVCL_A5DF CTR4#5 induced pluripotent stem cell human CVCL_A5DF CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228441 CVCL_A5DE 11H4-1C7 hybridoma CVCL_A5DE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse osteocyte antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12397 127228442 CVCL_A5DH CTR8#14 induced pluripotent stem cell human CVCL_A5DH CL:0000010 127228443 CVCL_A5DG CTR2#6 induced pluripotent stem cell human CVCL_A5DG CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228444 CVCL_A5DJ MS-HIPS RR16#5 induced pluripotent stem cell human CVCL_A5DJ CL:0000010 Miscellaneous: Sampling site from personal communication of ISENET Biobanking Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228445 CVCL_A5DI MS-HIPS PP9#1 induced pluripotent stem cell human CVCL_A5DI CL:0000010 Miscellaneous: Sampling site from personal communication of ISENET Biobanking Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 127228446 CVCL_A5DL WFS2_3 finite cell line human CVCL_A5DL CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 127228447 CVCL_A5DK WFS2_4 finite cell line human CVCL_A5DK CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 127228448 CVCL_A5DB 9A3-2G8 hybridoma CVCL_A5DB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse osteocyte antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12395 127228449 CVCL_A5DA 2T3 transformed cell line house mouse CVCL_A5DA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Bmp2 promoter T-Ag-3 transgenic. Unspecified 127228450 CVCL_A5DD 9D9-2F5 hybridoma CVCL_A5DD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse osteocyte antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12396 127228451 CVCL_A5DC 9C11 [Rat hybridoma against mouse Pdpn] hybridoma CVCL_A5DC CL:0000010 Miscellaneous: This hybridoma was lost (Patent=US6358737). Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q62011; Mouse Pdpn 127228452 CVCL_A5CU HCCLM9 cancer cell line human CVCL_A5CU CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Established from pulmonary metastatic lesions produced in nude mice by 9 rounds of subcutaneous inoculation of parent cell line 127228453 CVCL_A5CT Hep-G2 VL-17A cancer cell line human CVCL_A5CT CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: MGI; MGI:87921; Adh1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Liver. Male 127228454 CVCL_A5CW AF22 somatic stem cell human CVCL_A5CW CL:0000010 Miscellaneous: Sex of donor from personal communication of ISENET Biobanking Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Long term self-renewing neuroepithelial-like stem cells with stable neurogenic properties (PubMed=22272239) 127228455 CVCL_A5CV CTR4#9 induced pluripotent stem cell human CVCL_A5CV CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127228456 CVCL_A5CY AF24 somatic stem cell human CVCL_A5CY CL:0000010 Unspecified Characteristics: Long term self-renewing neuroepithelial-like stem cells with stable neurogenic properties (PubMed=22272239). 127228457 CVCL_A5CX AF23 somatic stem cell human CVCL_A5CX CL:0000010 Female Characteristics: Long term self-renewing neuroepithelial-like stem cells with stable neurogenic properties (PubMed=22272239). 127228458 CVCL_A5CZ HEK293 APPswe transformed cell line human CVCL_A5CZ CL:0000010 Transfected with: HGNC; 620; APP (with p.Lys670Asn and p.Met671Leu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127228459 CVCL_A5CM CH12F3-2 cancer cell line house mouse CVCL_A5CM CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 127228460 CVCL_A5CL U87DND cancer cell line human CVCL_A5CL CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male Characteristics: Exhibits a remarkably low competence at producing ceramide de novo (PubMed=27894925) Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 127228461 CVCL_A5CN F180 finite cell line human CVCL_A5CN CL:0000010 Derived from sampling site: Cell type=Fibroblast. 127228462 CVCL_A5CQ Hep-G2 VA-13 cancer cell line human CVCL_A5CQ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: MGI; MGI:87921; Adh1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Liver. Male 127228463 CVCL_A5CP F184 finite cell line human CVCL_A5CP CL:0000010 Derived from sampling site: Cell type=Fibroblast. 127228464 CVCL_A5CS Hep-G2 VI-7 cancer cell line human CVCL_A5CS CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Control cell line for Hep-G2 VA-13 (Cellosaurus=CVCL_A5CQ) and Hep-G2 VA-28 (Cellosaurus=CVCL_A5CR) (PubMed=11981770) 127228465 CVCL_A5CR Hep-G2 VA-28 cancer cell line human CVCL_A5CR CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: MGI; MGI:87921; Adh1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Liver. Male 127228466 CVCL_A5EG HEK293T-GIGYF1/2-null transformed cell line human CVCL_A5EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9126; GIGYF1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11960; GIGYF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30-40 hours (DSMZ=ACC-874) 127228467 CVCL_A5EF HEK293T-DDX6-null transformed cell line human CVCL_A5EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2747; DDX6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30-40 hours (DSMZ=ACC-873) 127228468 CVCL_A5EI HEK293T-XRN1-null transformed cell line human CVCL_A5EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30654; XRN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~24-30 hours (DSMZ=ACC-876) 127228469 CVCL_A5EH HEK293T-HELZ-null transformed cell line human CVCL_A5EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16878; HELZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~24-30 hours (DSMZ=ACC-875) 127228470 CVCL_A5EK NS46C somatic stem cell house mouse CVCL_A5EK CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Neural stem cell; Breed/subspecies: 129P2/Ola. Male Characteristics: Expresses eGFP under the control of the Sox-1 promoter Doubling time: ~24 hours (PubMed=16086633) 127228471 CVCL_A5EJ Quad-GL261 cancer cell line house mouse CVCL_A5EJ CL:0000010 Transfected with: HGNC; 10880; PMEL (with p.Met1_Leu18del and p.Arg40_Val661del); Transfected with: MGI; MGI:95900; H2-Ea (with p.Met1_Leu70del and p.Glu100_Leu255del); Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14) (with p.Met1_Ser251del, p.Asn272_Ser317del and p.Glu347_Pro386del); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Brain; Breed/subspecies: C57BL/6. Characteristics: Transfected with the Quad Ag cassette encoding four peptides presented by H-2b class I or II molecules as a single coding sequence The peptides are human PMEL/gp100 AA 25-33 (presented by H-2Db), chicken OVA epitope OT-I (AA 258-265; presented by H-2Kb), chicken OVA epitope OT-II (AA 324-340; presented by I-Ab) and mouse H2-Ea/I-Ea AA 77-93(52-68) (presented by I-Ab). To facilitate processing, each peptide is flanked on both sides by the 6 amino acid residues that surrounded the peptide in the corresponding native protein. 127228472 CVCL_A5EM Cor1 somatic stem cell house mouse CVCL_A5EM CL:0000010 Miscellaneous: Sex of donor from personal communication of ISENET Biobanking Derived from sampling site: Embryonic brain; neocortex Cell type=Neural stem cell.. Male 127228473 CVCL_A5EL CGR8-NS somatic stem cell house mouse CVCL_A5EL CL:0000010 Derived from sampling site: Cell type=Neural stem cell; Breed/subspecies: 129P2/Ola. Male 127228474 CVCL_A5EA FAIK1-10 transformed cell line house mouse CVCL_A5EA CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: B6D2;C57BL6N-Tg(EPO::Cre)1Rhw x B6.Cg-Gt(ROSA)26Sor/J). Omics: Transcriptome analysis by RNAseq 127228475 CVCL_A5EC FAIK3-5 transformed cell line house mouse CVCL_A5EC CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: B6D2;C57BL6N-Tg(EPO::Cre)1hw x B6.Cg-Gt(ROSA)26Sor/J). Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces Epo under hypoxia Doubling time: ~20-30 hours (DSMZ=ACC-861) 127228476 CVCL_A5EB FAIK2-5 transformed cell line house mouse CVCL_A5EB CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: B6D2;C57BL6N-Tg(EPO::Cre)1Rhw x B6.Cg-Gt(ROSA)26Sor/J). Omics: Transcriptome analysis by RNAseq 127228477 CVCL_A5EE HEK293T-CAF40-null transformed cell line human CVCL_A5EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10445; CNOT9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30-40 hours (DSMZ=ACC-872) 127228478 CVCL_A5ED SB-28-Ohlfest cancer cell line house mouse CVCL_A5ED CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Brain; Breed/subspecies: C57BL/6. Omics: Deep exome analysis Characteristics: Glioma was induced by intraventricular transfection of pT2/C-Luc/PGK-SB100 and Sleeping Beauty (SB)-flanked pT2/CAG-NRasV12 and pT2/shp53/mPDGF Doubling time: ~30 hours (DSMZ=ACC-880) 127228479 CVCL_A5DV CB660SP somatic stem cell human CVCL_A5DV CL:0000010 Derived from sampling site: Fetal spinal cord Cell type=Neural stem cell.. Female 127228480 CVCL_A5DU Sai3 somatic stem cell human CVCL_A5DU CL:0000010 Derived from sampling site: Fetal brain; hindbrain. Characteristics: Neuroepithelial stem cell 127228481 CVCL_A5DX O4ANS somatic stem cell house mouse CVCL_A5DX CL:0000010 Derived from sampling site: Brain; subventricular zone Cell type=Neural stem cell.; Breed/subspecies: 129 x MF1. Female Doubling time: ~30 hours (PubMed=16766697) 127228482 CVCL_A5DW aNS-1 somatic stem cell house mouse CVCL_A5DW CL:0000010 Derived from sampling site: Brain; subventricular zone Cell type=Neural stem cell.; Breed/subspecies: CD-1. Male Doubling time: ~30 hours (PubMed=16766697) 127228483 CVCL_A5DZ JK-6L.39L cancer cell line human CVCL_A5DZ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Peripheral blood. Male Characteristics: Produces low quantity of IgG kappa; Characteristics: IL6 independent 127228484 CVCL_A5DY JK-6L.31H cancer cell line human CVCL_A5DY CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Peripheral blood. Male Characteristics: Produces high quantity of IgG kappa; Characteristics: IL6 independent 127228485 CVCL_A5DN WFS2_1 finite cell line human CVCL_A5DN CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 127228486 CVCL_A5DM WFS2_2 finite cell line human CVCL_A5DM CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 127228487 CVCL_A5DP MGM18004E finite cell line human CVCL_A5DP CL:0000010 Derived from sampling site: Abdomen; skin; dermis Cell type=Fibroblast.. Male 127228488 CVCL_A5DR F0075E finite cell line human CVCL_A5DR CL:0000010 Derived from sampling site: Abdomen; skin; dermis Cell type=Fibroblast.. Female 127228489 CVCL_A5DQ F0022E finite cell line human CVCL_A5DQ CL:0000010 Derived from sampling site: Abdomen; skin; dermis Cell type=Fibroblast.. Female 127228490 CVCL_A5DT Sai2 somatic stem cell human CVCL_A5DT CL:0000010 Miscellaneous: Sex of donor from personal communication of ISENET Biobanking Derived from sampling site: Fetal brain; hindbrain. Male Characteristics: Neuroepithelial stem cell 127228491 CVCL_A5DS Sai1 somatic stem cell human CVCL_A5DS CL:0000010 Derived from sampling site: Fetal brain; hindbrain. Male Characteristics: Neuroepithelial stem cell 127228492 CVCL_A5BD SW1573/S1neo cancer cell line human CVCL_A5BD CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 127228493 CVCL_A5BC SW1573/S1(MRP) cancer cell line human CVCL_A5BC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Transfected with: HGNC; 51; ABCC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 127228494 CVCL_A5BF MCTs transformed cell line house mouse CVCL_A5BF CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; cartilage Cell type=Chondrocyte.. 127228495 CVCL_A5BE SW1573/S1ou cancer cell line human CVCL_A5BE CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Transfected with: MGI; MGI:88105; Atp1a1. Selected for resistance to: ChEBI; CHEBI:472805; Ouabain Female 127228496 CVCL_A5BH Hepa 1-6/10R cancer cell line house mouse CVCL_A5BH CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Liver; Breed/subspecies: C57L. Female 127228497 CVCL_A5BG Vero 2.2 spontaneously immortalized cell line green monkey CVCL_A5BG CL:0000010 Transfected with: UniProtKB; Q9J0X9; Human herpesvirus 1 (isolate KOS) ICP27 (UL54); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 127228498 CVCL_A5BJ WIF-B9 hybrid cell line CVCL_A5BJ CL:0000010 Doubling time: 2.6 +- 0.1 days (PubMed=17276572). 127228499 CVCL_A5BI LS174T/R cancer cell line human CVCL_A5BI CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Colon. Female 127228500 CVCL_A5AZ GLC-4/ADRpr cancer cell line human CVCL_A5AZ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male Characteristics: Partial revertant of GLC-4/ADR obtained after culturing in drug-free medium for a number of months (3 according to PubMed=3040227 and 6 according to PubMed=7809167) 127228501 CVCL_A5BB SW1573/S1(MDR1) cancer cell line human CVCL_A5BB CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Transfected with: HGNC; 40; ABCB1. Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR) Female 127228502 CVCL_A5BA SW1573/S1 cancer cell line human CVCL_A5BA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Female 127228503 CVCL_A5AS B203L-CD80 cancer cell line human CVCL_A5AS CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Unspecified 127228504 CVCL_A5AR B1203L-CD80 cancer cell line human CVCL_A5AR CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Male 127228505 CVCL_A5AU Rosi EBV-B transformed cell line human CVCL_A5AU HLA typing: A*24:02,32:01; B*35:03,44:031; C*04:01,04:01 (PubMed=17131342) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228506 CVCL_A5AT B901L-CD80 cancer cell line human CVCL_A5AT CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Female 127228507 CVCL_A5AW HepG2.105 cancer cell line human CVCL_A5AW CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Virology: Expresses a hepatitis B virus (HBV) subtype AYW genome under the control of a tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Transcription of HBV pre-genomic RNA is induced upon doxycycline removal from the culture medium, leading to capsid assembly and DNA synthesis (PubMed=16935386). 127228508 CVCL_A5AV Huh7.93 cancer cell line human CVCL_A5AV CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Japanese Male Virology: Expresses a hepatitis B virus (HBV) subtype AYW genome under the control of a tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Transcription of HBV pre-genomic RNA is induced upon doxycycline removal from the culture medium, leading to capsid assembly and DNA synthesis (PubMed=16935386). 127228509 CVCL_A5AY HMR10-3 conditionally immortalized cell line Norway rat CVCL_A5AY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [U19tsa](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Holtzman. Characteristics: Grows at the permissive temperature (33 Celsius) Differentiates to a neuronal phenotype at the nonpermissive temperature (39 Celsius). 127228510 CVCL_A5AX HepG2.117 cancer cell line human CVCL_A5AX CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Virology: Expresses a hepatitis B virus (HBV) subtype AYW genome under the control of a tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Transcription of HBV pre-genomic RNA is induced upon doxycycline removal from the culture medium, leading to capsid assembly and DNA synthesis (PubMed=16935386). 127228511 CVCL_A5AK G613M cancer cell line human CVCL_A5AK HLA typing: A*24:02,11:01; B*52:01,55:02; C*12:02,12:03 (PubMed=17131342). CL:0000010 Unspecified 127228512 CVCL_A5AJ Rosi cancer cell line human CVCL_A5AJ CL:0000010 Miscellaneous: Age/sex of donor and cancer type from personal communication of van Baren N Derived from metastatic site: Not specified. Male 127228513 CVCL_A5AM A904L-CD80 cancer cell line human CVCL_A5AM CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Male 127228514 CVCL_A5AL A904-EBV-B transformed cell line human CVCL_A5AL HLA typing: A*24:02,26:03; B*07:02,39:01; C*07:02 (PubMed=15994973) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228515 CVCL_A5AN A904L-A26 cancer cell line human CVCL_A5AN CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: HGNC; 4931; HLA-A (allele A*26:03); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Lung. Male 127228516 CVCL_A5AQ A529L-CD80 cancer cell line human CVCL_A5AQ CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Male 127228517 CVCL_A5AP A904L-B39 cancer cell line human CVCL_A5AP CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: HGNC; 4932; HLA-B (allele B*39:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Lung. Male 127228518 CVCL_A5CE UNIPDi007-A induced pluripotent stem cell human CVCL_A5CE From: University of Padova; Padova; Italy. CL:0000010 127228519 CVCL_A5CD UNIPDi006-A induced pluripotent stem cell human CVCL_A5CD From: University of Padova; Padova; Italy. CL:0000010 127228520 CVCL_A5CG CV-1 D 5.2 transformed cell line CVCL_A5CG CL:0000010 Transfected with: MGI; MGI:88105; Atp1a1 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 127228521 CVCL_A5CF TEX transformed cell line human CVCL_A5CF CL:0000010 Transfected with: HGNC; 4010; FUS (FUS-ERG fusion); Transfected with: HGNC; 3446; ERG (FUS-ERG fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Expresses a transfected FUS-ERG (TLS-ERG) fusion protein Mimics the features of primary human acute myeloid leukemia and of leukemia-initiating cells (LIC) and are more than 90% CD34+. Underwent step-wise transformation and immortalization through acquisition of additional genetic changes, such as expression of TERT, expression of LIC markers CD34, CD44 and CD123 and the stem cell gene BMI1 (PubMed=16094415; PubMed=22160482). 127228522 CVCL_A5CI CV-1 D 7.3 transformed cell line CVCL_A5CI CL:0000010 Transfected with: MGI; MGI:88105; Atp1a1 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 127228523 CVCL_A5CH CV-1 D 6.1 transformed cell line CVCL_A5CH CL:0000010 Transfected with: MGI; MGI:88105; Atp1a1 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 127228524 CVCL_A5CK CV-1 E 5.5 transformed cell line CVCL_A5CK CL:0000010 Transfected with: MGI; MGI:88105; Atp1a1 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 127228525 CVCL_A5CJ CV-1 E 4.1 transformed cell line CVCL_A5CJ CL:0000010 Transfected with: MGI; MGI:88105; Atp1a1 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 127228526 CVCL_A5CA PCIi026-A induced pluripotent stem cell human CVCL_A5CA From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Female 127228527 CVCL_A5CC PCIi028-A induced pluripotent stem cell human CVCL_A5CC From: Phenocell SAS; Grasse; France. CL:0000010 127228528 CVCL_A5CB PCIi027-A induced pluripotent stem cell human CVCL_A5CB From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Male 127228529 CVCL_A5BT Bm7brm cancer cell line human CVCL_A5BT CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Taiwan; Derived from sampling site: Lung. Male Characteristics: Metastatic to brain Established from intracardiac injection of parent cell in SCID mice and cultured from brain tissue. 127228530 CVCL_A5BS Bm7 cancer cell line human CVCL_A5BS CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Taiwan; Derived from sampling site: Lung. Male Characteristics: Metastatic to brain Established from intracardiac injection of parent cell in SCID mice and cultured from brain tissue. 127228531 CVCL_A5BV Hki-8 transformed cell line human CVCL_A5BV CL:0000010 Transfected with: HGNC; 8022; NT5C2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127228532 CVCL_A5BU HKiG2 transformed cell line human CVCL_A5BU CL:0000010 Transfected with: HGNC; 8022; NT5C2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a NT5C2 fused to EGFP 127228533 CVCL_A5BX UMCGi008-B induced pluripotent stem cell human CVCL_A5BX From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 127228534 CVCL_A5BW U937-ASPI3K cancer cell line human CVCL_A5BW CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 795; ATM (anti-sense); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 127228535 CVCL_A5BZ UMCGi008-D induced pluripotent stem cell human CVCL_A5BZ From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 127228536 CVCL_A5BY UMCGi008-C induced pluripotent stem cell human CVCL_A5BY From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 127228537 CVCL_A5BL WIF-B9/Rev hybrid cell line CVCL_A5BL CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Characteristics: Established by culturing the parent cell line without cisplatin in the medium for 2 months Doubling time: 2.7 +- 0.1 days (PubMed=17276572) 127228538 CVCL_A5BK WIF-B9/R hybrid cell line CVCL_A5BK CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Doubling time: 2.9 +- 0.3 days (PubMed=17276572) 127228539 CVCL_A5BN WIF12 hybrid cell line CVCL_A5BN CL:0000010 127228540 CVCL_A5BM WIF12-1 TGdelta hybrid cell line CVCL_A5BM CL:0000010 Karyotypic information: Has lost the human chromosome X; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 127228541 CVCL_A5BP WIF12-6 hybrid cell line CVCL_A5BP CL:0000010 127228542 CVCL_A5BR CL1-5-F4-Luc cancer cell line human CVCL_A5BR CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Taiwan; Derived from sampling site: Lung. Male 127228543 CVCL_A5BQ SCC-25/CP cancer cell line human CVCL_A5BQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Oral cavity; tongue. Male 127228544 CVCL_A5AC A2780/m175 cancer cell line human CVCL_A5AC CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg175His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127228545 CVCL_A5AB A2780/cmv cancer cell line human CVCL_A5AB CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Control cell line for A2780/m175, A2780/m248 and A2780/m273 127228546 CVCL_A5AE A2780/m273 cancer cell line human CVCL_A5AE CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127228547 CVCL_A5AD A2780/m248 cancer cell line human CVCL_A5AD CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg248Trp); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127228548 CVCL_A5AG 76N finite cell line human CVCL_A5AG CL:0000010 Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 127228549 CVCL_A5AF Tera-CP cancer cell line human CVCL_A5AF CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lung. Male 127228550 CVCL_A5AI Mull cancer cell line human CVCL_A5AI CL:0000010 Miscellaneous: Age/sex of donor, exact cancer type and sampling site from personal communication of van Baren N Derived from metastatic site: Right buttock; hypodermis. Female 127228551 CVCL_A5AH 76N-F2V transformed cell line human CVCL_A5AH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with p.Phe9Val) Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis Female 127228552 CVCL_A5AA PK-15(CD163) spontaneously immortalized cell line pig CVCL_A5AA CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: A construct containing a CMV promoter-pig CD163 and EF1a promoter-GFP-T2-Pac was transferred using a PiggyBac transposon vector; Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus type 1 and type 2 (PRRSV-1/2) 127228553 CVCL_A6NN MANCHO18-3C1 hybridoma house mouse CVCL_A6NN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228554 CVCL_A6NQ MANCHO3-8A4 hybridoma house mouse CVCL_A6NQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228555 CVCL_A6NP MANCHO2-9G3 hybridoma house mouse CVCL_A6NP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228556 CVCL_A6NS MANCHO5-4F11 hybridoma house mouse CVCL_A6NS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228557 CVCL_A6NR MANCHO4-2G5 hybridoma house mouse CVCL_A6NR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228558 CVCL_A6NU MANCHO7-7F3 hybridoma house mouse CVCL_A6NU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228559 CVCL_A6NT MANCHO6-5A6 hybridoma house mouse CVCL_A6NT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228560 CVCL_A6NG MSH3MAB10-9B11 hybridoma house mouse CVCL_A6NG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228561 CVCL_A6NF MSH3MAB9-7A10 hybridoma house mouse CVCL_A6NF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228562 CVCL_A6NI MANCHO11-9F2 hybridoma house mouse CVCL_A6NI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228563 CVCL_A6NH MANCHO10-9E10 hybridoma house mouse CVCL_A6NH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228564 CVCL_A6NK MANCHO14-4E1 hybridoma house mouse CVCL_A6NK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228565 CVCL_A6NJ MANCHO13-2G12 hybridoma house mouse CVCL_A6NJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228566 CVCL_A6NM MANCHO17-4C8 hybridoma house mouse CVCL_A6NM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228567 CVCL_A6NL MANCHO15-5C3 hybridoma house mouse CVCL_A6NL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228568 CVCL_A6NA MSH3MAB4-8E6 hybridoma house mouse CVCL_A6NA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3 (Note=Also reacts with human). 127228569 CVCL_A6NC MSH3MAB6-5D6 hybridoma house mouse CVCL_A6NC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228570 CVCL_A6NB MSH3MAB5-7H12 hybridoma house mouse CVCL_A6NB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228571 CVCL_A6NE MSH3MAB8-2A9 hybridoma house mouse CVCL_A6NE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228572 CVCL_A6ND MSH3MAB7-9E11 hybridoma house mouse CVCL_A6ND CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228573 CVCL_A6MV MANFU11-3E4 hybridoma house mouse CVCL_A6MV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228574 CVCL_A6MU MANFU10-5H10 hybridoma house mouse CVCL_A6MU CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228575 CVCL_A6MX MSH3MAB1-1F6 hybridoma house mouse CVCL_A6MX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228576 CVCL_A6MW MANFU12-6B5 hybridoma house mouse CVCL_A6MW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228577 CVCL_A6MZ MSH3MAB3-5A5 hybridoma house mouse CVCL_A6MZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3 (Note=Also reacts with human). 127228578 CVCL_A6MY MSH3MAB2-2F11 hybridoma house mouse CVCL_A6MY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13705; Mouse Msh3. 127228579 CVCL_A6NW 45E10 hybridoma house mouse CVCL_A6NW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P35992; Drosophila melanogaster Ptp10D. 127228580 CVCL_A6NV 3B7B5 hybridoma house mouse CVCL_A6NV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9W266; Drosophila melanogaster wdp. 127228581 CVCL_A6NY 9D82B3 hybridoma house mouse CVCL_A6NY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16621; Drosophila melanogaster Lar. 127228582 CVCL_A6NX 4C71B7 hybridoma house mouse CVCL_A6NX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P35832; Drosophila melanogaster Ptp99A. 127228583 CVCL_A6NZ MANEX1A-4C7 hybridoma house mouse CVCL_A6NZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228584 CVCL_A6LM 6F9 hybridoma house mouse CVCL_A6LM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-1006 127228585 CVCL_A6LL 15G7 hybridoma house mouse CVCL_A6LL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 127228586 CVCL_A6LN U2OS OPTN KO cancer cell line human CVCL_A6LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17142; OPTN Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 127228587 CVCL_A6LQ U2OS TBK1 KO cancer cell line human CVCL_A6LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 127228588 CVCL_A6LP U2OS SQSTM1 KO cancer cell line human CVCL_A6LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 127228589 CVCL_A6LS MANSIX5A2-3B4 hybridoma house mouse CVCL_A6LS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228590 CVCL_A6LR MANSIX5A1-2A6 hybridoma house mouse CVCL_A6LR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228591 CVCL_A6LE 11/9 hybridoma house mouse CVCL_A6LE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127228592 CVCL_A6LD 182-D1106-362 hybridoma house mouse CVCL_A6LD CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized IMAB362 (claudiximab; zolbetuximab) therapeutic antibody Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2810 127228593 CVCL_A6LG 1D4 [Mouse hybridoma against Drosophila fas2] hybridoma house mouse CVCL_A6LG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P34082; Drosophila melanogaster fas2. 127228594 CVCL_A6LF 10C9 [Mouse hybridoma against Drosophila lmb] hybridoma house mouse CVCL_A6LF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q24188; Drosophila melanogaster lbm. 127228595 CVCL_A6LI BP102 hybridoma house mouse CVCL_A6LI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Drosophila melanogaster CNS axons. 127228596 CVCL_A6LH 23C7 hybridoma house mouse CVCL_A6LH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; M9PE88; Drosophila melanogaster wit. 127228597 CVCL_A6LK 15C12 hybridoma house mouse CVCL_A6LK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 127228598 CVCL_A6LJ MDA-MB-435S/1 cancer cell line human CVCL_A6LJ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 127228599 CVCL_A6LA 182-D1106-061 hybridoma house mouse CVCL_A6LA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2748 127228600 CVCL_A6LC 182-D1106-294 hybridoma house mouse CVCL_A6LC CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2809 127228601 CVCL_A6LB 182-D1106-279 hybridoma house mouse CVCL_A6LB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2808 127228602 CVCL_A6KT 182-D1106-058 hybridoma house mouse CVCL_A6KT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2740 127228603 CVCL_A6KS 182-D1106-057 hybridoma house mouse CVCL_A6KS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2739 127228604 CVCL_A6KV 182-D1106-062 hybridoma house mouse CVCL_A6KV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2742 127228605 CVCL_A6KU 182-D1106-059 hybridoma house mouse CVCL_A6KU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2741 127228606 CVCL_A6KX 182-D758-035 hybridoma house mouse CVCL_A6KX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2745 127228607 CVCL_A6KW 182-D1106-067 hybridoma house mouse CVCL_A6KW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2743 127228608 CVCL_A6KZ 182-D758-040 hybridoma house mouse CVCL_A6KZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2747 127228609 CVCL_A6KY 182-D758-036 hybridoma house mouse CVCL_A6KY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2746 127228610 CVCL_A6MN MANFU4-3C7 hybridoma house mouse CVCL_A6MN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228611 CVCL_A6MM MANFU3-4E6 hybridoma house mouse CVCL_A6MM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228612 CVCL_A6MP MANFU5-7H2 hybridoma house mouse CVCL_A6MP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228613 CVCL_A6MR MANFU7-1B5 hybridoma house mouse CVCL_A6MR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228614 CVCL_A6MQ MANFU6-4H8 hybridoma house mouse CVCL_A6MQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228615 CVCL_A6MT MANFU9-4E12 hybridoma house mouse CVCL_A6MT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228616 CVCL_A6MS MANFU8-2F5 hybridoma house mouse CVCL_A6MS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228617 CVCL_A6MF MANSIX5B3-10D2 hybridoma house mouse CVCL_A6MF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228618 CVCL_A6ME MANSIX5B2-10B3 hybridoma house mouse CVCL_A6ME CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228619 CVCL_A6MH MANSIX5C2a-6C1 hybridoma house mouse CVCL_A6MH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228620 CVCL_A6MG MANSIX5B4-9G10 hybridoma house mouse CVCL_A6MG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228621 CVCL_A6MJ DAG-6F4 hybridoma house mouse CVCL_A6MJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (alpha-dystroglycan) (Note=Also reacts with mouse). 127228622 CVCL_A6MI MANSIX5C2b-3A1 hybridoma house mouse CVCL_A6MI CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228623 CVCL_A6ML MANFU2-10F9 hybridoma house mouse CVCL_A6ML CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228624 CVCL_A6MK MANFU1-7A2 hybridoma house mouse CVCL_A6MK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75072; Human FKTN. 127228625 CVCL_A6MB MANSIX5A11-2H1 hybridoma house mouse CVCL_A6MB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228626 CVCL_A6MA MANSIX5A10-4H7 hybridoma house mouse CVCL_A6MA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228627 CVCL_A6MD MANSIX5B1-6E10 hybridoma house mouse CVCL_A6MD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228628 CVCL_A6MC MANSIX5A12-4E7 hybridoma house mouse CVCL_A6MC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228629 CVCL_A6LU MANSIX5A4-3E11 hybridoma house mouse CVCL_A6LU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228630 CVCL_A6LT MANSIX5A3-3D9 hybridoma house mouse CVCL_A6LT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5 127228631 CVCL_A6LW MANSIX5A6-1C11 hybridoma house mouse CVCL_A6LW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228632 CVCL_A6LV MANSIX5A5-10B12 hybridoma house mouse CVCL_A6LV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228633 CVCL_A6LY MANSIX5A8-7G4 hybridoma house mouse CVCL_A6LY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228634 CVCL_A6LX MANSIX5A7-3G10 hybridoma house mouse CVCL_A6LX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228635 CVCL_A6LZ MANSIX5A9-2G8 hybridoma house mouse CVCL_A6LZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. 127228636 CVCL_A6JK NU-RMESO-9 cancer cell line Norway rat CVCL_A6JK CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228637 CVCL_A6JJ NU-RMESO-2 cancer cell line Norway rat CVCL_A6JJ CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228638 CVCL_A6JM NU-RMESO-20 cancer cell line Norway rat CVCL_A6JM CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228639 CVCL_A6JL NU-RMESO-14 cancer cell line Norway rat CVCL_A6JL CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228640 CVCL_A6JN NU-RMESO-26 cancer cell line Norway rat CVCL_A6JN CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228641 CVCL_A6JQ NU-RMESO-79 cancer cell line Norway rat CVCL_A6JQ CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228642 CVCL_A6JP NU-RMESO-40 cancer cell line Norway rat CVCL_A6JP CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666). 127228643 CVCL_A6JC MUi022-A induced pluripotent stem cell human CVCL_A6JC From: Mahidol University; Bangkok; Thailand. CL:0000010 127228644 CVCL_A6JB MUi024-A induced pluripotent stem cell human CVCL_A6JB From: Mahidol University; Bangkok; Thailand. CL:0000010 127228645 CVCL_A6JE SDR-P-1D5 finite cell line Norway rat CVCL_A6JE CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Spontaneous dwarf rat (SDR). 127228646 CVCL_A6JD SDRL-2 finite cell line Norway rat CVCL_A6JD CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Spontaneous dwarf rat (SDR). 127228647 CVCL_A6JG IWT-1 cancer cell line human CVCL_A6JG CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=24587255) Population: Japanese; Derived from sampling site: Ascites. Male 127228648 CVCL_A6JF MSH-P3 finite cell line pig CVCL_A6JF CL:0000010 Derived from sampling site: Fetal pituitary gland; Breed/subspecies: Miniature pig. Unspecified Characteristics: Secretes prolactin (PubMed=29949606) 127228649 CVCL_A6JI bTS11 somatic stem cell human CVCL_A6JI CL:0000010 Male Characteristics: Trophoblast stem cell line Senescence: Senesces at 150 PDL (RCB=RCB4941); Doubling time: 21.7 +- 3.0 hours (PubMed=29249463). 127228650 CVCL_A6JH bTS5 somatic stem cell human CVCL_A6JH CL:0000010 Female Characteristics: Trophoblast stem cell line Senescence: Senesces at 150 PDL (RCB=RCB4940); Doubling time: 22.6 +- 2.5 hours (PubMed=29249463). 127228651 CVCL_A6IZ MUi026-A induced pluripotent stem cell human CVCL_A6IZ From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Gln1960Ter (c.5878C>T); ClinVar=VCV000562298; Zygosity=Heterozygous (PubMed=33799277) Population: Southeast Asian; Thai; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228652 CVCL_A6IY ZZUNEUi021-A induced pluripotent stem cell human CVCL_A6IY From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Arg140Cys (c.418C>T); ClinVar=VCV000043636; Zygosity=Heterozygous (PubMed=34929444) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127228653 CVCL_A6JA MUi027-A induced pluripotent stem cell human CVCL_A6JA From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; c.7946_7947delCT; Zygosity=Heterozygous (PubMed=35629189) Population: Southeast Asian; Thai; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127228654 CVCL_A6IR FA-AML1C cancer cell line human CVCL_A6IR CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (PubMed=12750298); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Glu (c.8503_8504TC>GA) (8731TC>GA); Zygosity=Heterozygous; Note=Reverted (PubMed=12750298) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: IL3 dependent 127228655 CVCL_A6IQ FA-AML1 cancer cell line human CVCL_A6IQ CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (PubMed=12750298); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Glu (c.8503_8504TC>GA) (8731TC>GA); Zygosity=Heterozygous; Note=Reverted (PubMed=12750298) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 and IL3 dependent 127228656 CVCL_A6IT IBL-SLO-7B spontaneously immortalized cell line CVCL_A6IT CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 20.8 hours, at 28 Celsius (DOI=10.1303/aez.32.179); 28.45 hours (DOI:10.6660/TESFE.1999004) Group: Insect cell line 127228657 CVCL_A6IS COL [Human plasma cell myeloma] cancer cell line human CVCL_A6IS CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 127228658 CVCL_A6IV SNU-899 R1 cancer cell line human CVCL_A6IV CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Larynx. Male 127228659 CVCL_A6IU PNUH-12 R1 cancer cell line human CVCL_A6IU CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Unspecified (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Pharynx; hypopharynx. Female 127228660 CVCL_A6IX ZZUNEUi022-A induced pluripotent stem cell human CVCL_A6IX From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 127228661 CVCL_A6IW MDCK-UT-A1 spontaneously immortalized cell line dog CVCL_A6IW CL:0000010 Transfected with: HGNC; 10919; SLC14A2 (isoform UT-A1); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Transfected with the pFRT/lacZeo and pcDNA5/FRT/UT-A1 plasmids 127228662 CVCL_A6KL 2E12 [Human/mouse hybridoma] hybridoma CVCL_A6KL CL:0000010 Monoclonal antibody isotype: IgM. 127228663 CVCL_A6KK TM-1 [Human leukemia] cancer cell line human CVCL_A6KK CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 127228664 CVCL_A6KN 3E9 [Human/mouse hybridoma against leukemia cell surface antigen] hybridoma CVCL_A6KN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human leukemia cell surface antigen. 127228665 CVCL_A6KM 3E10 [Human/mouse hybridoma] hybridoma CVCL_A6KM CL:0000010 Monoclonal antibody isotype: IgM. 127228666 CVCL_A6KP BD9-D12 hybridoma house mouse CVCL_A6KP CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: Human antigen on A-549 lung cancer cells. 127228667 CVCL_A6KR 182-D1106-056 hybridoma house mouse CVCL_A6KR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2738 127228668 CVCL_A6KQ 182-D1106-055 hybridoma house mouse CVCL_A6KQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56856; Human CLDN18 (isoform A2; CLDN18.2). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2737 127228669 CVCL_A6KD RF-S1 hybrid cell line CVCL_A6KD CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 127228670 CVCL_A6KC APM-3 hybridoma house mouse CVCL_A6KC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:34905; Paraquat. 127228671 CVCL_A6KF MAb-G2 hybridoma CVCL_A6KF CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). 127228672 CVCL_A6KE MAb-G1 hybridoma CVCL_A6KE CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). 127228673 CVCL_A6KH MAb-G4 hybridoma CVCL_A6KH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). 127228674 CVCL_A6KG MAb-G3 hybridoma CVCL_A6KG CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). 127228675 CVCL_A6KJ A4H12 cancer cell line human CVCL_A6KJ CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Group: Hybridoma fusion partner cell line 127228676 CVCL_A6KI MAb-G6 hybridoma CVCL_A6KI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). 127228677 CVCL_A6JZ PQXB2/2 hybridoma house mouse CVCL_A6JZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:34905; Paraquat. 127228678 CVCL_A6KB APM-2 hybridoma house mouse CVCL_A6KB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:34905; Paraquat. 127228679 CVCL_A6KA APM-1 hybridoma house mouse CVCL_A6KA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:34905; Paraquat. 127228680 CVCL_A6JS rasSFME transformed cell line house mouse CVCL_A6JS CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified Group: Serum/protein free medium cell line 127228681 CVCL_A6JR ChR2-C2C12 spontaneously immortalized cell line house mouse CVCL_A6JR CL:0000010 Transfected with: UniProtKB; Q8RUT8; Chlamydomonas reinhardtii channelrhodopsin-2 (cop4); Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 127228682 CVCL_A6JU r/mHM-SFME-1 transformed cell line house mouse CVCL_A6JU CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified Characteristics: Established after 7 passages of the original cell line into BALB/c mice; Characteristics: Spontaneously metastasize into the lungs of syngeneic mice when injected subcutaneously Group: Serum/protein free medium cell line 127228683 CVCL_A6JT ras/mycSFME transformed cell line house mouse CVCL_A6JT CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified Group: Serum/protein free medium cell line 127228684 CVCL_A6JW KDS 101-2 hybridoma house mouse CVCL_A6JW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02788; Human LTF. 127228685 CVCL_A6JV KDS 101-1 hybridoma house mouse CVCL_A6JV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02788; Human LTF. 127228686 CVCL_A6JY PQXB1/2 hybridoma house mouse CVCL_A6JY CL:0000010 Discontinued: ECACC; 89050503; true. Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:34905; Paraquat 127228687 CVCL_A6JX KDS 301-1 hybridoma house mouse CVCL_A6JX CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P24627; Bovine LTF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8852 127228688 CVCL_A6HI LO-DNP-68 hybridoma Norway rat CVCL_A6HI CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228689 CVCL_A6HH LO-DNP-66 hybridoma Norway rat CVCL_A6HH CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228690 CVCL_A6HK LO-DNP-9 hybridoma Norway rat CVCL_A6HK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228691 CVCL_A6HJ LO-DNP-7 hybridoma Norway rat CVCL_A6HJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228692 CVCL_A6HM LO-DNP-58 hybridoma Norway rat CVCL_A6HM CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228693 CVCL_A6HL LO-DNP-41 hybridoma Norway rat CVCL_A6HL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228694 CVCL_A6HN LO-DNP-67 hybridoma Norway rat CVCL_A6HN CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228695 CVCL_A6HA LO-DNP-47 hybridoma Norway rat CVCL_A6HA CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228696 CVCL_A6HC LO-DNP-49 hybridoma Norway rat CVCL_A6HC CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228697 CVCL_A6HB LO-DNP-48 hybridoma Norway rat CVCL_A6HB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228698 CVCL_A6HE LO-DNP-55 hybridoma Norway rat CVCL_A6HE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228699 CVCL_A6HD LO-DNP-51 hybridoma Norway rat CVCL_A6HD CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228700 CVCL_A6HG LO-DNP-62 hybridoma Norway rat CVCL_A6HG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228701 CVCL_A6HF LO-DNP-56 hybridoma Norway rat CVCL_A6HF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228702 CVCL_A6GX LO-DNP-39 hybridoma Norway rat CVCL_A6GX CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228703 CVCL_A6GW LO-DNP-3 hybridoma Norway rat CVCL_A6GW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228704 CVCL_A6GZ LO-DNP-44 hybridoma Norway rat CVCL_A6GZ CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228705 CVCL_A6GY LO-DNP-4 hybridoma Norway rat CVCL_A6GY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228706 CVCL_A6GP LO-DNP-10 hybridoma Norway rat CVCL_A6GP CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228707 CVCL_A6GR LO-DNP-34 hybridoma Norway rat CVCL_A6GR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228708 CVCL_A6GQ LO-DNP-30 hybridoma Norway rat CVCL_A6GQ CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228709 CVCL_A6GT LO-DNP-15 hybridoma Norway rat CVCL_A6GT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228710 CVCL_A6GS LO-DNP-40 hybridoma Norway rat CVCL_A6GS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228711 CVCL_A6GV LO-DNP-22 hybridoma Norway rat CVCL_A6GV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228712 CVCL_A6GU LO-DNP-20 hybridoma Norway rat CVCL_A6GU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228713 CVCL_A6IJ FRTL-5/T transformed cell line Norway rat CVCL_A6IJ CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified Characteristics: Established from tumor tissue of a xenograft obtained by subcutaneous injection of FRTL-5 in C3H nu/nu nude mice (PubMed=1694496) 127228714 CVCL_A6II FRT-L KiKi transformed cell line Norway rat CVCL_A6II CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 127228715 CVCL_A6IL FRTL-5/TP transformed cell line Norway rat CVCL_A6IL CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified Characteristics: Established from tumor tissue of a xenograft obtained by subcutaneous injection of FRTL-5/T in C3H nu/nu nude mice (PubMed=1694496) 127228716 CVCL_A6IK FRTL-5/TA transformed cell line Norway rat CVCL_A6IK CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified Characteristics: Established from tumor tissue of a xenograft obtained by subcutaneous injection of FRTL-5/T in C3H nu/nu nude mice (PubMed=1694496) 127228717 CVCL_A6IN 5UD5 transformed cell line Norway rat CVCL_A6IN CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10849 127228718 CVCL_A6IM FRA cancer cell line Norway rat CVCL_A6IM CL:0000010 Derived from sampling site: Thyroid gland Cell type=Epithelial cell.; Breed/subspecies: Fischer. 127228719 CVCL_A6IP HNTB-2K finite cell line human CVCL_A6IP CL:0000010 Derived from sampling site: Thyroid gland Cell type=Follicular cell.. Unspecified Doubling time: 69 hours, at 45th passage (PubMed=8090760) 127228720 CVCL_A6IB OM-B hybridoma house mouse CVCL_A6IB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human mucinous cystadenocarcinoma antigen. 127228721 CVCL_A6IA OM-A hybridoma house mouse CVCL_A6IA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human mucinous cystadenocarcinoma antigen. 127228722 CVCL_A6ID FRT-U10 spontaneously immortalized cell line Norway rat CVCL_A6ID CL:0000010 Transfected with: HGNC; 1706; CD8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thyroid gland. Unspecified 127228723 CVCL_A6IC OM-C hybridoma house mouse CVCL_A6IC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human mucinous cystadenocarcinoma antigen. 127228724 CVCL_A6IF CW39-1B10 hybridoma house mouse CVCL_A6IF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56202; Human CTSW. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2511 127228725 CVCL_A6IE FRT spontaneously immortalized cell line Norway rat CVCL_A6IE CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 127228726 CVCL_A6IH CW40-1B1 hybridoma house mouse CVCL_A6IH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P56202; Human CTSW. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2513 127228727 CVCL_A6IG CW39-2B6 hybridoma house mouse CVCL_A6IG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56202; Human CTSW. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2512 127228728 CVCL_A6HY HH09A3 hybridoma human CVCL_A6HY CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 127228729 CVCL_A6HX HH09A2 hybridoma human CVCL_A6HX CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 127228730 CVCL_A6HZ 71-5.2F9 hybridoma CVCL_A6HZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human gastric carcinoma cell surface carbohydrate epitope. 127228731 CVCL_A6HQ WIL2 AGr9 clone 35-1 transformed cell line human CVCL_A6HQ CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 127228732 CVCL_A6HP LO-DNP-65 hybridoma Norway rat CVCL_A6HP CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127228733 CVCL_A6HS WIL2 MTI-TG transformed cell line human CVCL_A6HS CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 127228734 CVCL_A6HR WIL2 MTIr-107 transformed cell line human CVCL_A6HR CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 127228735 CVCL_A6HU WIL2 H35.1.1 transformed cell line human CVCL_A6HU CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line 127228736 CVCL_A6HT WIL2 AGr9 clone 3-1 transformed cell line human CVCL_A6HT CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 127228737 CVCL_A6HW MAC 40/43 hybridoma human CVCL_A6HW CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human breast cancer cells 47 kDa glycoprotein. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 86111001 127228738 CVCL_A6HV 0467.3 transformed cell line human CVCL_A6HV CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Hybridoma fusion partner cell line 127228739 CVCL_A6VW MDCK-II Rab29-KO spontaneously immortalized cell line dog CVCL_A6VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45270; RAB29 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228740 CVCL_A6VV MDCK-II Rab28-KO spontaneously immortalized cell line dog CVCL_A6VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45269; RAB28 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228741 CVCL_A6VY MDCK-II Rab30-KO spontaneously immortalized cell line dog CVCL_A6VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45273; RAB30 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228742 CVCL_A6VX MDCK-II Rab3-KO spontaneously immortalized cell line dog CVCL_A6VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45282; RAB3A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45283; RAB3B; Knockout cell: Method=CRISPR/Cas9; VGNC; 45284; RAB3C; Knockout cell: Method=CRISPR/Cas9; VGNC; 45285; RAB3D Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228743 CVCL_A6VZ MDCK-II Rab32/38-KO spontaneously immortalized cell line dog CVCL_A6VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 53757; RAB32; Knockout cell: Method=CRISPR/Cas9; VGNC; 45280; RAB38 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228744 CVCL_A6VN MDCK-II Rab22-KO spontaneously immortalized cell line dog CVCL_A6VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45262; RAB22A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45274; RAB31 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228745 CVCL_A6VQ MDCK-II Rab24-KO spontaneously immortalized cell line dog CVCL_A6VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45264; RAB24 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228746 CVCL_A6VP MDCK-II Rab23-KO spontaneously immortalized cell line dog CVCL_A6VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45263; RAB23 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228747 CVCL_A6VS MDCK-II Rab26-KO spontaneously immortalized cell line dog CVCL_A6VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45266; RAB26 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228748 CVCL_A6VR MDCK-II Rab25-KO spontaneously immortalized cell line dog CVCL_A6VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45265; RAB25 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228749 CVCL_A6VU MDCK-II Rab27-KO spontaneously immortalized cell line dog CVCL_A6VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45267; RAB27A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45268; RAB27B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228750 CVCL_A6VT MDCK-II Rab26/37-KO spontaneously immortalized cell line dog CVCL_A6VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45266; RAB26; Knockout cell: Method=CRISPR/Cas9; VGNC; 45279; RAB37 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228751 CVCL_A6VG MDCK-II Rab19-KO spontaneously immortalized cell line dog CVCL_A6VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45258; RAB19 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228752 CVCL_A6VF MDCK-II Rab18-KO spontaneously immortalized cell line dog CVCL_A6VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45257; RAB18 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228753 CVCL_A6VI MDCK-II Rab1A-KO spontaneously immortalized cell line dog CVCL_A6VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45259; RAB1A Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228754 CVCL_A6VH MDCK-II Rab19/43-KO spontaneously immortalized cell line dog CVCL_A6VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45258; RAB19; Knockout cell: Method=CRISPR/Cas9; VGNC; 45289; RAB43 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228755 CVCL_A6VK MDCK-II Rab2-KO spontaneously immortalized cell line dog CVCL_A6VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45271; RAB2A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45272; RAB2B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228756 CVCL_A6VJ MDCK-II Rab1B-KO spontaneously immortalized cell line dog CVCL_A6VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 52037; RAB1B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228757 CVCL_A6VM MDCK-II Rab21-KO spontaneously immortalized cell line dog CVCL_A6VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45261; RAB21 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228758 CVCL_A6VL MDCK-II Rab20-KO spontaneously immortalized cell line dog CVCL_A6VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45260; RAB20 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228759 CVCL_A6VA MDCK-II Rab12-KO spontaneously immortalized cell line dog CVCL_A6VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 103700; RAB12 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228760 CVCL_A6VC MDCK-II Rab14-KO spontaneously immortalized cell line dog CVCL_A6VC CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45254; RAB14 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228761 CVCL_A6VB MDCK-II Rab13-KO spontaneously immortalized cell line dog CVCL_A6VB CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45253; RAB13 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228762 CVCL_A6VE MDCK-II Rab17-KO spontaneously immortalized cell line dog CVCL_A6VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45256; RAB17 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228763 CVCL_A6VD MDCK-II Rab15-KO spontaneously immortalized cell line dog CVCL_A6VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45255; RAB15 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228764 CVCL_A6WX ECCD-2 hybridoma CVCL_A6WX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09803; Mouse Cdh1/Cd324. 127228765 CVCL_A6WW ECCD-1 hybridoma CVCL_A6WW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09803; Mouse Cdh1/Cd324. 127228766 CVCL_A6WZ NCC-CAD-299 hybridoma house mouse CVCL_A6WZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22223; Human CDH3. 127228767 CVCL_A6WY HECD-1 hybridoma house mouse CVCL_A6WY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 127228768 CVCL_A6WP MDCK-II Rab6-KO spontaneously immortalized cell line dog CVCL_A6WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 59055; RAB6A; Knockout cell: Method=CRISPR/Cas9; VGNC; 59057; RAB6B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228769 CVCL_A6WR MDCK-II Rab7B-KO spontaneously immortalized cell line dog CVCL_A6WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45294; RAB7B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228770 CVCL_A6WQ MDCK-II Rab7A-KO spontaneously immortalized cell line dog CVCL_A6WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45293; RAB7A Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228771 CVCL_A6WT MDCK-II Rab9-KO spontaneously immortalized cell line dog CVCL_A6WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45297; RAB9A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45298; RAB9B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228772 CVCL_A6WS MDCK-II Rab8-KO spontaneously immortalized cell line dog CVCL_A6WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45295; RAB8A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45296; RAB8B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228773 CVCL_A6WV MDCK-II Rab7AB-KO spontaneously immortalized cell line dog CVCL_A6WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45293; RAB7A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45294; RAB7B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228774 CVCL_A6WU MDCK-II Rab7A/9-KO spontaneously immortalized cell line dog CVCL_A6WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45293; RAB7A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45297; RAB9A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45298; RAB9B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228775 CVCL_A6WH MDCK-II Rab39/42-KO spontaneously immortalized cell line dog CVCL_A6WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB39A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45281; RAB39B; Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB42 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228776 CVCL_A6WG MDCK-II Rab39-KO spontaneously immortalized cell line dog CVCL_A6WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB39A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45281; RAB39B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228777 CVCL_A6WJ MDCK-II Rab40-KO spontaneously immortalized cell line dog CVCL_A6WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB40B; Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB40C Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228778 CVCL_A6WI MDCK-II Rab4-KO spontaneously immortalized cell line dog CVCL_A6WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45290; RAB4A; Knockout cell: Method=CRISPR/Cas9; VGNC; 53756; RAB4B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228779 CVCL_A6WL MDCK-II Rab43-KO spontaneously immortalized cell line dog CVCL_A6WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45289; RAB43 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228780 CVCL_A6WK MDCK-II Rab42-KO spontaneously immortalized cell line dog CVCL_A6WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; -; RAB42 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228781 CVCL_A6WN MDCK-II Rab5C-KO spontaneously immortalized cell line dog CVCL_A6WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 55798; RAB5C Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228782 CVCL_A6WM MDCK-II Rab5AB-KO spontaneously immortalized cell line dog CVCL_A6WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45291; RAB5A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45292; RAB5B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228783 CVCL_A6WB MDCK-II Rab34-KO spontaneously immortalized cell line dog CVCL_A6WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45277; RAB34 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228784 CVCL_A6WA MDCK-II Rab33-KO spontaneously immortalized cell line dog CVCL_A6WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45275; RAB33A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45276; RAB33B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228785 CVCL_A6WD MDCK-II Rab35-KO spontaneously immortalized cell line dog CVCL_A6WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45278; RAB35 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228786 CVCL_A6WC MDCK-II Rab34/36-KO spontaneously immortalized cell line dog CVCL_A6WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45277; RAB34; Knockout cell: Method=CRISPR/Cas9; VGNC; 49953; RAB36 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228787 CVCL_A6WF MDCK-II Rab37-KO spontaneously immortalized cell line dog CVCL_A6WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45279; RAB37 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228788 CVCL_A6WE MDCK-II Rab36-KO spontaneously immortalized cell line dog CVCL_A6WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 49953; RAB36 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228789 CVCL_A6TT ED-40810(-) cancer cell line human CVCL_A6TT CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Lost its original IL2 dependency 127228790 CVCL_A6TW ED-70423C(-) cancer cell line human CVCL_A6TW CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Lost its original IL2 dependency 127228791 CVCL_A6TV ED-41214(-) cancer cell line human CVCL_A6TV CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 127228792 CVCL_A6TY T3 [Human LCL] transformed cell line human CVCL_A6TY CL:0000010 Population: Japanese; Karyotypic information: 46,XX,add(19)(p13) (PubMed=15262425); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228793 CVCL_A6TX N6803-2 transformed cell line human CVCL_A6TX CL:0000010 Population: Japanese; Karyotypic information: 47,XY,dup(1)(25q32),add(4)(q35),+12,add(18)(p11),add(20)(q13.3) (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228794 CVCL_A6TZ T3-2 [Human type 2 diabetes] transformed cell line human CVCL_A6TZ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228795 CVCL_A6TM Sez507 cancer cell line human CVCL_A6TM CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 127228796 CVCL_A6TL SezM3(-) transformed cell line human CVCL_A6TL CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Female Characteristics: Lost its original IL2 dependency 127228797 CVCL_A6TN ATL-72b(-) transformed cell line human CVCL_A6TN CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 127228798 CVCL_A6TQ ATL-21C(-)/3.8 transformed cell line human CVCL_A6TQ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency Cultured for 3.8 years without IL2. 127228799 CVCL_A6TP ATL-21C(-)/8.9 transformed cell line human CVCL_A6TP CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency Cultured for 8.9 years without IL2. 127228800 CVCL_A6TS CATL-3 transformed cell line human CVCL_A6TS CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Characteristics: IL2 dependent 127228801 CVCL_A6TR CATL-2 transformed cell line human CVCL_A6TR CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Characteristics: IL2 dependent 127228802 CVCL_A6TE ATL-72/2(-) transformed cell line human CVCL_A6TE CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228803 CVCL_A6TD ATL-45T transformed cell line human CVCL_A6TD CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228804 CVCL_A6TG Sez627(-) cancer cell line human CVCL_A6TG CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Lost its original IL2 dependency 127228805 CVCL_A6TF ATL-2(-) transformed cell line human CVCL_A6TF CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 127228806 CVCL_A6TI ATL-21C(-)/2 transformed cell line human CVCL_A6TI CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency Cultured for 2 years without IL2. 127228807 CVCL_A6TH ED-50823(-) transformed cell line human CVCL_A6TH CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood. Male Characteristics: Lost its original IL2 dependency 127228808 CVCL_A6TK SezM3 transformed cell line human CVCL_A6TK CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Female Characteristics: IL2 dependent 127228809 CVCL_A6TJ SezM transformed cell line human CVCL_A6TJ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Female Characteristics: IL2 dependent 127228810 CVCL_A6TA ATL-72/2 transformed cell line human CVCL_A6TA CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228811 CVCL_A6TC ATL-72T transformed cell line human CVCL_A6TC CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228812 CVCL_A6TB ATL-72b transformed cell line human CVCL_A6TB CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228813 CVCL_A6UV RMM-A1 cancer cell line Norway rat CVCL_A6UV CL:0000010 Derived from sampling site: Ear; pinna; Breed/subspecies: Fischer 344. Male Characteristics: Tumorigenic 127228814 CVCL_A6UU RMM-C cancer cell line Norway rat CVCL_A6UU CL:0000010 Derived from sampling site: Ear; pinna; Breed/subspecies: Fischer 344. Male Characteristics: Established from the transplantable tumor RMM Doubling time: 17.2 hours (at 10th passage), 14.8 hours (at 30th passage) (PubMed=26949998) 127228815 CVCL_A6UX MDCK-II Rab10-KO spontaneously immortalized cell line dog CVCL_A6UX CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45247; RAB10 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228816 CVCL_A6UW RMM-CAF cancer cell line Norway rat CVCL_A6UW CL:0000010 Derived from sampling site: Ear; pinna; Breed/subspecies: Fischer 344. Male Characteristics: Non-tumorigenic 127228817 CVCL_A6UZ MDCK-II Rab11/25-KO spontaneously immortalized cell line dog CVCL_A6UZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45248; RAB11A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45249; RAB11B; Knockout cell: Method=CRISPR/Cas9; VGNC; 45265; RAB25 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228818 CVCL_A6UY MDCK-II Rab11-KO spontaneously immortalized cell line dog CVCL_A6UY CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 45248; RAB11A; Knockout cell: Method=CRISPR/Cas9; VGNC; 45249; RAB11B Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 127228819 CVCL_A6UN COLO 320DM#3 SIRT1 KO cl.4 cancer cell line human CVCL_A6UN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228820 CVCL_A6UM COLO 320DM#3 SIRT1 KO cl.3 cancer cell line human CVCL_A6UM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228821 CVCL_A6UP COLO 320DM#3 SIRT1 KO cl.5 cancer cell line human CVCL_A6UP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228822 CVCL_A6UR NP-2/CD4/CCR6 cancer cell line human CVCL_A6UR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1607; CCR6; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 127228823 CVCL_A6UQ COLO 320DM#3 SIRT1 KO cl.6 cancer cell line human CVCL_A6UQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228824 CVCL_A6UT C8166/CCR5 transformed cell line human CVCL_A6UT CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood. Male 127228825 CVCL_A6US NP-2/CD4/FPRL1 cancer cell line human CVCL_A6US CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 3827; FPR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 127228826 CVCL_A6UF TD-2 fLuc-CXCR4 cancer cell line house mouse CVCL_A6UF CL:0000010 Transfected with: MGI; MGI:109563; Cxcr4; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6J x BALB/cJ TGFalpha/Trp53(+/-) transgenic. Male 127228827 CVCL_A6UE TD-2 fLuc-CCR7 cancer cell line house mouse CVCL_A6UE CL:0000010 Transfected with: MGI; MGI:103011; Ccr7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6J x BALB/cJ TGFalpha/Trp53(+/-) transgenic. Male 127228828 CVCL_A6UH EL16 embryonic stem cell CVCL_A6UH CL:0000010 Karyotypic information: 40,XX (30%); 39,X0 (70%) (PubMed=10192391); Breed/subspecies: Cast/EiJ x 129SvJae. Female 127228829 CVCL_A6UG 7C8 [Mouse hybridoma against rat Cav1] hybridoma house mouse CVCL_A6UG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P41350; Rat Cav1 (Note=Also reacts with human and mouse). 127228830 CVCL_A6UJ COLO 320DM#3 cancer cell line human CVCL_A6UJ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female Characteristics: Contains multiple DMs with amplified MYC (PubMed=3164477) 127228831 CVCL_A6UI EL16.7 embryonic stem cell CVCL_A6UI CL:0000010 Karyotypic information: 40,XX, one chromosome X from M.m.musculus and the other from M.m.castaneus (PubMed=10520993); Breed/subspecies: Cast/EiJ x 129SvJae. Female 127228832 CVCL_A6UL COLO 320DM#3 SIRT1 KO cl.2 cancer cell line human CVCL_A6UL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228833 CVCL_A6UK COLO 320DM#3 SIRT1 KO cl.1 cancer cell line human CVCL_A6UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 127228834 CVCL_A6UB T6 [Human LCL] transformed cell line human CVCL_A6UB CL:0000010 Population: Japanese; Karyotypic information: 47,XX,+2 (PubMed=15262425); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228835 CVCL_A6UA T5 [Human LCL] transformed cell line human CVCL_A6UA CL:0000010 Population: Japanese; Karyotypic information: 46,Y,add(X)(p22) (PubMed=15262425); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228836 CVCL_A6UD TD-2 fLuc cancer cell line house mouse CVCL_A6UD CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6J x BALB/cJ TGFalpha/Trp53(+/-) transgenic. Male 127228837 CVCL_A6UC TD-2 cancer cell line house mouse CVCL_A6UC CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6J x BALB/cJ TGFalpha/Trp53(+/-) transgenic. Male 127228838 CVCL_A6RS GEM-322 cancer cell line CVCL_A6RS CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Ryukin. Unspecified Group: Fish cell line 127228839 CVCL_A6RR GEM-49 cancer cell line CVCL_A6RR CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Comet. Unspecified Group: Fish cell line 127228840 CVCL_A6RU IP-B12 cancer cell line Norway rat CVCL_A6RU CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Fischer 344/DuCrj. Male Characteristics: Secretes PTHrP Doubling time: 17.9 hours (PubMed=12853701) 127228841 CVCL_A6RT IP-P cancer cell line Norway rat CVCL_A6RT CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Fischer 344/DuCrj. Male Characteristics: Established from the transplantable tumor IP Doubling time: 17.5 hours (PubMed=12853701) 127228842 CVCL_A6RW N0003 post-immortalized transformed cell line human CVCL_A6RW CL:0000010 Population: Japanese; Karyotypic information: 46,XX,add(7)(q22),+12,der(13;14)(q10;q10) (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228843 CVCL_A6RV N0003 pre-immortalized transformed cell line human CVCL_A6RV CL:0000010 Population: Japanese; Karyotypic information: 45,XX,der(13;14)(q10;q10) (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228844 CVCL_A6RY N0005 post-immortalized transformed cell line human CVCL_A6RY CL:0000010 Population: Japanese; Karyotypic information: 46,XY,add(3)(p25),add(8)(q24.3),del(17)(p11.2) (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228845 CVCL_A6RX N0005 pre-immortalized transformed cell line human CVCL_A6RX CL:0000010 Population: Japanese; Karyotypic information: 46,XY (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228846 CVCL_A6RK MFVD A5 transformed cell line house mouse CVCL_A6RK CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic vas deferens; Breed/subspecies: B10/CBA x Tag5 transgenic. Male 127228847 CVCL_A6RJ MFVD parental transformed cell line house mouse CVCL_A6RJ CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic vas deferens; Breed/subspecies: B10/CBA x Tag5 transgenic. Male 127228848 CVCL_A6RM MFVD E2 transformed cell line house mouse CVCL_A6RM CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic vas deferens; Breed/subspecies: B10/CBA x Tag5 transgenic. Male 127228849 CVCL_A6RL MFVD A6 transformed cell line house mouse CVCL_A6RL CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic vas deferens; Breed/subspecies: B10/CBA x Tag5 transgenic. Omics: Proteome analysis by 2D-DE/MS Male 127228850 CVCL_A6RN MSP.1 undefined cell line type human CVCL_A6RN CL:0000010 Discontinued: ATCC; CRL-2774; true. Unspecified 127228851 CVCL_A6RQ HuOS cancer cell line human CVCL_A6RQ CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Doubling time: 30 hours (PubMed=433590) 127228852 CVCL_A6RP 1A7 hybridoma house mouse CVCL_A6RP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 14.G2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11786 127228853 CVCL_A6RC TROMA-2 hybridoma CVCL_A6RC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05784; Mouse Krt18. 127228854 CVCL_A6RB MAO A-7E10 hybridoma house mouse CVCL_A6RB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21397; Human MAOB. 127228855 CVCL_A6RE 3C7.14 hybridoma house mouse CVCL_A6RE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21214; Bovine TGFB2. 127228856 CVCL_A6RD 2G1.1.12 hybridoma house mouse CVCL_A6RD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21214; Bovine TGFB2. 127228857 CVCL_A6RG 12H5 hybridoma house mouse CVCL_A6RG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01137; Human TGFB1. 127228858 CVCL_A6RF 2D7.20 hybridoma house mouse CVCL_A6RF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P21214; Bovine TGFB2. 127228859 CVCL_A6RI 4A11 hybridoma house mouse CVCL_A6RI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01137; Human TGFB1. 127228860 CVCL_A6RH 2G7 [Mouse hybridoma against human TFGB1/2/3] hybridoma house mouse CVCL_A6RH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01137; Human TGFB1; Monoclonal antibody target: UniProtKB; P61812; Human TGFB2; Monoclonal antibody target: UniProtKB; P10600; Human TGFB3. 127228861 CVCL_A6QZ MAO A-4F10 hybridoma house mouse CVCL_A6QZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21397; Human MAOB. 127228862 CVCL_A6QY MAO A-3C9 hybridoma house mouse CVCL_A6QY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21397; Human MAOB. 127228863 CVCL_A6RA MAO A-7B10 hybridoma house mouse CVCL_A6RA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21397; Human MAOB. 127228864 CVCL_A6ST ATL-23 transformed cell line human CVCL_A6ST CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228865 CVCL_A6SS ATL-20 transformed cell line human CVCL_A6SS CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228866 CVCL_A6SV ATL-6 transformed cell line human CVCL_A6SV CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228867 CVCL_A6SU ATL-26C transformed cell line human CVCL_A6SU CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228868 CVCL_A6SX ATL-41T transformed cell line human CVCL_A6SX CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228869 CVCL_A6SW ATL-40T transformed cell line human CVCL_A6SW CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228870 CVCL_A6SZ ATL-46T transformed cell line human CVCL_A6SZ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228871 CVCL_A6SY ATL-67T transformed cell line human CVCL_A6SY CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228872 CVCL_A6SL ATL-42T cancer cell line human CVCL_A6SL CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228873 CVCL_A6SK ED-50823 transformed cell line human CVCL_A6SK CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood. Male Characteristics: IL2 dependent 127228874 CVCL_A6SN ATL-13 transformed cell line human CVCL_A6SN CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 127228875 CVCL_A6SM ATL-11-6 transformed cell line human CVCL_A6SM CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228876 CVCL_A6SP ATL-14T transformed cell line human CVCL_A6SP CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228877 CVCL_A6SR ATL-18C transformed cell line human CVCL_A6SR CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 127228878 CVCL_A6SQ ATL-17C transformed cell line human CVCL_A6SQ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 127228879 CVCL_A6SD N6803 post-immortalized transformed cell line human CVCL_A6SD CL:0000010 Population: Japanese; Karyotypic information: 47,XY,dup(3)(q27;q13),+8 (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228880 CVCL_A6SC N6803 pre-immortalized transformed cell line human CVCL_A6SC CL:0000010 Population: Japanese; Karyotypic information: 46,XY (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228881 CVCL_A6SF LLKF undefined cell line type CVCL_A6SF CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male 127228882 CVCL_A6SE ASMF undefined cell line type CVCL_A6SE CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. 127228883 CVCL_A6SH ATL-48Tb(-) cancer cell line human CVCL_A6SH CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 127228884 CVCL_A6SG ATL-55T(-) cancer cell line human CVCL_A6SG CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 127228885 CVCL_A6SJ ED-70423C cancer cell line human CVCL_A6SJ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 127228886 CVCL_A6SI ED-41214 cancer cell line human CVCL_A6SI CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 127228887 CVCL_A6RZ N0005-A1 transformed cell line human CVCL_A6RZ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127228888 CVCL_A6SB N0013 post-immortalized transformed cell line human CVCL_A6SB CL:0000010 Population: Japanese; Karyotypic information: 46,XX,add(2)(q37),der(11)t(11;12)(p15;q13) (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228889 CVCL_A6SA N0013 pre-immortalized transformed cell line human CVCL_A6SA CL:0000010 Population: Japanese; Karyotypic information: 46,XX (PubMed=11520562); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127228890 CVCL_A6PQ MANDAG4-4G1 hybridoma house mouse CVCL_A6PQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (beta-dystroglycan). 127228891 CVCL_A6PP MANDAG3-4F7 hybridoma house mouse CVCL_A6PP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (beta-dystroglycan). 127228892 CVCL_A6PS MANHINGE1A-6F11 hybridoma house mouse CVCL_A6PS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 127228893 CVCL_A6PR MANHINGE4A-5C11 hybridoma house mouse CVCL_A6PR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228894 CVCL_A6PU MANHINGE1C-5D12 hybridoma house mouse CVCL_A6PU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228895 CVCL_A6PT MANHINGE1B-10F9 hybridoma house mouse CVCL_A6PT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228896 CVCL_A6PW MANHINGE2B-9C11 hybridoma house mouse CVCL_A6PW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228897 CVCL_A6PV MANHINGE2A-8B11 hybridoma house mouse CVCL_A6PV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228898 CVCL_A6PI MANDYS3-6A9 hybridoma house mouse CVCL_A6PI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 127228899 CVCL_A6PH 22Rv1-CabR2 cancer cell line human CVCL_A6PH CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Derived from sampling site: Prostate. Male Characteristics: Established from xenografts that were obtain by subcutaneously injecting 22Rv1 cells into the flanks of 8 weeks old, athymic male BALB/c nude mice and treating them with cabazitaxel (PubMed=31799745) 127228900 CVCL_A6PK MANEX7B-8E11 hybridoma house mouse CVCL_A6PK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 127228901 CVCL_A6PJ MANEX6-4H4 hybridoma house mouse CVCL_A6PJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228902 CVCL_A6PM MANDAG1-7A11 hybridoma house mouse CVCL_A6PM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (beta-dystroglycan). 127228903 CVCL_A6PL MANEX7C-6F7 hybridoma house mouse CVCL_A6PL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228904 CVCL_A6PN MANDAG2-7D11 hybridoma house mouse CVCL_A6PN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (beta-dystroglycan). 127228905 CVCL_A6PA MANEX1B-1D6 hybridoma house mouse CVCL_A6PA CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228906 CVCL_A6PC MANDYS10-2E10 hybridoma house mouse CVCL_A6PC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 127228907 CVCL_A6PB MANDYS1-3B7 hybridoma house mouse CVCL_A6PB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse, pig and rabbit). 127228908 CVCL_A6PE Sp1/7-2 hybridoma house mouse CVCL_A6PE CL:0000010 Anecdotal: Together with Sp2/3-3 (Cellosaurus=CVCL_A6PD) these are the first hybridomas to have been created. Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC) 127228909 CVCL_A6PD Sp2/3-3 hybridoma house mouse CVCL_A6PD CL:0000010 Anecdotal: Together with Sp1/7-2 (Cellosaurus=CVCL_A6PE) these are the first hybridomas to have been created. Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC) 127228910 CVCL_A6PG 22Rv1-CabR1 cancer cell line human CVCL_A6PG CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Derived from sampling site: Prostate. Male Characteristics: Established from xenografts that were obtain by subcutaneously injecting 22Rv1 cells into the flanks of 8 weeks old, athymic male BALB/c nude mice and treating them with cabazitaxel (PubMed=31799745) 127228911 CVCL_A6PF Sp1/HL hybridoma house mouse CVCL_A6PF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 127228912 CVCL_A6QR CK-5H5 hybridoma house mouse CVCL_A6QR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P05122; Chicken CKB. 127228913 CVCL_A6QQ CK-2A7 hybridoma house mouse CVCL_A6QQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05122; Chicken CKB. 127228914 CVCL_A6QT TROMA-3 hybridoma CVCL_A6QT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P19001; Mouse Krt19. 127228915 CVCL_A6QS TROMA-1 hybridoma CVCL_A6QS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11679; Mouse Krt8. 127228916 CVCL_A6QV ESC-BLC 1 T1 embryonic stem cell house mouse CVCL_A6QV CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129/Sv-ter/+. Male 127228917 CVCL_A6QU ESC-BLC 1 embryonic stem cell house mouse CVCL_A6QU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129/Sv-ter/+. Male 127228918 CVCL_A6QX MAO B-1C2 hybridoma house mouse CVCL_A6QX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27338; Human MAOB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8176 127228919 CVCL_A6QW ESC-BLC 1 T2/K26 embryonic stem cell house mouse CVCL_A6QW CL:0000010 Breed/subspecies: 129/Sv-ter/+. Male 127228920 CVCL_A6QJ CK-JAC hybridoma house mouse CVCL_A6QJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05122; Chicken CKB. 127228921 CVCL_A6QI CK-ART hybridoma house mouse CVCL_A6QI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00565; Chicken CKM. 127228922 CVCL_A6QL CK-JOE hybridoma house mouse CVCL_A6QL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05122; Chicken CKB. 127228923 CVCL_A6QK CK-JIL hybridoma house mouse CVCL_A6QK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05122; Chicken CKB. 127228924 CVCL_A6QN CK-1F7 hybridoma house mouse CVCL_A6QN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12277; Human CKB. 127228925 CVCL_A6QM CK-1B7 hybridoma house mouse CVCL_A6QM CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06732; Human CKM. 127228926 CVCL_A6QP CK-5D11 hybridoma house mouse CVCL_A6QP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06732; Human CKM. 127228927 CVCL_A6QB MANHINGE4B-9B1 hybridoma house mouse CVCL_A6QB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228928 CVCL_A6QA MANHINGE3C-10E12 hybridoma house mouse CVCL_A6QA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228929 CVCL_A6QD MANCHO1-2C7 hybridoma house mouse CVCL_A6QD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228930 CVCL_A6QC MANHINGE4C-10F2 hybridoma house mouse CVCL_A6QC CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228931 CVCL_A6QF MANCHO9-8C10 hybridoma house mouse CVCL_A6QF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228932 CVCL_A6QE MANCHO8-5C5 hybridoma house mouse CVCL_A6QE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228933 CVCL_A6QH MANCHO19-5D12 hybridoma house mouse CVCL_A6QH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228934 CVCL_A6QG MANCHO16-9C2 hybridoma house mouse CVCL_A6QG CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 127228935 CVCL_A6PY MANHINGE3A-6D6 hybridoma house mouse CVCL_A6PY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228936 CVCL_A6PX MANHINGE2C-8D11 hybridoma house mouse CVCL_A6PX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228937 CVCL_A6PZ MANHINGE3B-12D2 hybridoma house mouse CVCL_A6PZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 127228938 CVCL_A5ZT LERS-1 transformed cell line Norway rat CVCL_A5ZT CL:0000010 Miscellaneous: Cell line has been lost (PubMed=2788356) Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Spleen; Breed/subspecies: Lewis. Female 127228939 CVCL_A5ZS FIRT-1 transformed cell line Norway rat CVCL_A5ZS CL:0000010 Miscellaneous: Cell line has been lost (PubMed=2788356) Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Thymus; Breed/subspecies: Fischer 344. Female 127228940 CVCL_A5ZV HOZOT finite cell line human CVCL_A5ZV CL:0000010 Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Unspecified 127228941 CVCL_A5ZU LERT-1 transformed cell line Norway rat CVCL_A5ZU CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Thymus; Breed/subspecies: Lewis. Female 127228942 CVCL_A5ZX UHOMi003-A induced pluripotent stem cell human CVCL_A5ZX From: University Hospital of Montpellier; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127228943 CVCL_A5ZW JSNK-1 transformed cell line pig CVCL_A5ZW CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Unspecified 127228944 CVCL_A5ZZ UHOMi005-A induced pluripotent stem cell human CVCL_A5ZZ From: University Hospital of Montpellier; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228945 CVCL_A5ZY UHOMi004-A induced pluripotent stem cell human CVCL_A5ZY From: University Hospital of Montpellier; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127228946 CVCL_A5ZL HEL-N1 cancer cell line human CVCL_A5ZL CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Subline that does not expresses KIT (PubMed=7538619) Doubling time: 19.0 +- 0.8 hours (in serum-containing medium), 24.0 +- 1.1 hours (in serum-free medium) (PubMed=7538619) 127228947 CVCL_A5ZK U937/EVI1 cancer cell line human CVCL_A5ZK CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3498; MECOM; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Characteristics: Transduced with a MECOM/EVI1-IRES-EGFP construct 127228948 CVCL_A5ZN BCBL-2 cancer cell line human CVCL_A5ZN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296). Male 127228949 CVCL_A5ZM HEL-P1 cancer cell line human CVCL_A5ZM CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Subline that highly expresses KIT and GYPA (PubMed=7538619) Doubling time: 18.9 +- 1.4 hours (in serum-containing medium), 23.6 +- 0.9 hours (in serum-free medium) (PubMed=7538619) 127228950 CVCL_A5ZP SWI3a-26 spontaneously immortalized cell line CVCL_A5ZP CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Biotechnology: Cell line for recombinase mediated cassette exchange (RMCE) that was generated by random integration of a FRT-flanked GFP reporter It contains a single copy of the GFP reporter transgene at a genetic locus that is protected from silencing. The integrated GFP cassette contains a selection trap that allows for selection of recombinant cells upon RMCE (PubMed=25804355). Female Characteristics: Transduced with the pEFFS-EGFP-dneo vector that contains eGFP under the control of the EF1alpha promoter The eGFP gene is flanked by a wild type FRT site and a synthetic variant (F3). A selection trap, an ATG-deleted, promoterless neo (Dneo) gene is located downstream of eGFP. When eGFP is exchanged by Flp-mediated recombination against a cassette including a promoter and start codon, Dneo becomes complemented and the cell becomes resistant against the antibiotic G418, thus allowing for selection of recombinant cells (PubMed=22174749). 127228951 CVCL_A5ZR FIRS-1 transformed cell line Norway rat CVCL_A5ZR CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Spleen; Breed/subspecies: Fischer 344. Female 127228952 CVCL_A5ZQ LO-HM-7 hybridoma Norway rat CVCL_A5ZQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01871; Human immunoglobulin heavy chain mu. 127228953 CVCL_A5ZD HBCHU.15 transformed cell line human CVCL_A5ZD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228954 CVCL_A5ZC HBCHU.09 transformed cell line human CVCL_A5ZC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228955 CVCL_A5ZF HBCHU.18 transformed cell line human CVCL_A5ZF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228956 CVCL_A5ZE HBCHU.16 transformed cell line human CVCL_A5ZE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228957 CVCL_A5ZH Org MHH.1 hybrid cell line CVCL_A5ZH CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line 127228958 CVCL_A5ZG HBCHU.20 transformed cell line human CVCL_A5ZG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228959 CVCL_A5ZJ NH cancer cell line human CVCL_A5ZJ From: Suzukawa K.; University of Tsukuba; Tsukuba; Japan CL:0000010 Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 127228960 CVCL_A5ZI JOK-1/5.3 cancer cell line human CVCL_A5ZI CL:0000010 Transfected with: HGNC; 1685; CD5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood. Male 127228961 CVCL_A5XZ HE-30 transformed cell line CVCL_A5XZ CL:0000010 Transformant: Simian virus 40 (SV40) [tsA30](NCBI-Taxonomy; 1891767). 127228962 CVCL_A5XY HE-239 transformed cell line CVCL_A5XY CL:0000010 Transformant: Simian virus 40 (SV40) [tsA239](NCBI-Taxonomy; 1891767). 127228963 CVCL_A5YA PNK-86 finite cell line CVCL_A5YA CL:0000010 Derived from sampling site: Kidney. Virology: Susceptible to infection by herpes simplex virus, adenovirus type 7 (Ad7) and parainfluenza virus types 1 to 3 Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 27 127228964 CVCL_A5XR NCI-H460/TPT10 ABCG2 KO cancer cell line human CVCL_A5XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 74; ABCG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male Characteristics: Compared to the parent cell line, no longer resistant to topotecan (PubMed=33425914) 127228965 CVCL_A5XQ NCI-H460/TPT10 cancer cell line human CVCL_A5XQ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Pleural effusion. Male Doubling time: 22.46 +- 0.85 hours (PubMed=33425914) 127228966 CVCL_A5XT A4xS hybrid cell line pig CVCL_A5XT CL:0000010 Characteristics: Hybrid of pig embryonic kidney cells with pig splenocytes (Patent=RU2545720); Virology: Susceptible to infection by African swine fever virus (AFSV) (PubMed=26182658). Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 87 127228967 CVCL_A5XS AM-3 telomerase immortalized cell line human CVCL_A5XS CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11998; TP53 (with p.Met1_Ala159del) Population: Japanese; Derived from sampling site: Bone; jaw; mandible Cell type=Ameloblast.. Female 127228968 CVCL_A5XV M3-1 clone 650A spontaneously immortalized cell line CVCL_A5XV CL:0000010 Derived from sampling site: Bone marrow. Male 127228969 CVCL_A5XU PPK-66B finite cell line pig CVCL_A5XU CL:0000010 Derived from sampling site: Kidney. 127228970 CVCL_A5XX T91M cancer cell line human CVCL_A5XX CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Uterus; cervix. Female Characteristics: Derived from parent cell line after 800 rads of X-radiation (PubMed=5660764) Doubling time: 27-28 hours (DOI=10.2172/4683311) Problematic cell line: Contaminated Parent cell line (T-1) has been shown to be a HeLa derivative. 127228971 CVCL_A5XW M3-1 clone 650AB spontaneously immortalized cell line CVCL_A5XW CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Obtained after irradiation of parent cell line (650A) 127228972 CVCL_A5XJ ONS-99 cancer cell line human CVCL_A5XJ CL:0000010 Population: Japanese. Male 127228973 CVCL_A5XI ZK cancer cell line human CVCL_A5XI CL:0000010 Population: Japanese. 127228974 CVCL_A5XL MINT2 cancer cell line human CVCL_A5XL CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male Doubling time: ~45 hours (PubMed=15943790) 127228975 CVCL_A5XK MINT1 cancer cell line human CVCL_A5XK CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male Doubling time: ~45 hours (PubMed=15943790) 127228976 CVCL_A5XN ONS-20 cancer cell line human CVCL_A5XN CL:0000010 Population: Japanese. Unspecified 127228977 CVCL_A5XM MINT3 cancer cell line human CVCL_A5XM CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male Doubling time: ~45 hours (PubMed=15943790) 127228978 CVCL_A5XP ZK-2 cancer cell line human CVCL_A5XP CL:0000010 Population: Japanese. Unspecified 127228979 CVCL_A5XB NULC-1 cancer cell line human CVCL_A5XB CL:0000010 Population: Japanese. 127228980 CVCL_A5XA GC302 hybridoma house mouse CVCL_A5XA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 40 kDa stomach oncofetal antigen. 127228981 CVCL_A5XD CSTO-1 hybridoma house mouse CVCL_A5XD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human stomach adenocarcinoma-associated antigen. 127228982 CVCL_A5XC NULC-2 cancer cell line human CVCL_A5XC CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. 127228983 CVCL_A5XF LCT-6 cancer cell line human CVCL_A5XF CL:0000010 Population: Japanese; Derived from sampling site: Larynx. 127228984 CVCL_A5XE FU-GC-16 cancer cell line human CVCL_A5XE CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 127228985 CVCL_A5XH ZK-1 cancer cell line human CVCL_A5XH CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 26 hours (PubMed=22575259) 127228986 CVCL_A5XG OKK-1 cancer cell line human CVCL_A5XG CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 127228987 CVCL_A5YZ RUBHU.09 transformed cell line human CVCL_A5YZ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228988 CVCL_A5ZB RABHU.02 transformed cell line human CVCL_A5ZB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228989 CVCL_A5ZA RABHU.01 transformed cell line human CVCL_A5ZA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228990 CVCL_A5YS HAVCH.03 transformed cell line CVCL_A5YS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 127228991 CVCL_A5YR HAVCH.02 transformed cell line CVCL_A5YR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 127228992 CVCL_A5YU HBCHU.02 transformed cell line human CVCL_A5YU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228993 CVCL_A5YT HAVHU.01 transformed cell line human CVCL_A5YT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228994 CVCL_A5YW RUBHU.02 transformed cell line human CVCL_A5YW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228995 CVCL_A5YV HBCHU.01 transformed cell line human CVCL_A5YV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228996 CVCL_A5YY RUBHU.08 transformed cell line human CVCL_A5YY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228997 CVCL_A5YX RUBHU.03 transformed cell line human CVCL_A5YX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 127228998 CVCL_A5YK ARH-77 clone A5P3 transformed cell line human CVCL_A5YK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:1349162; Sdc1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Problematic cell line: Misclassified Parent cell line (ARH-77) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 127228999 CVCL_A5YJ BMEV transformed cell line CVCL_A5YJ CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Muscle Cell type=Epithelial cell.. Unspecified 127229000 CVCL_A5YM ACB-985 cancer cell line human CVCL_A5YM CL:0000010 Derived from sampling site: Bone marrow. Unspecified Characteristics: Produces IgG kappa 127229001 CVCL_A5YL MER cancer cell line human CVCL_A5YL CL:0000010 Derived from sampling site: Bone marrow. Unspecified 127229002 CVCL_A5YN C23/11 transformed cell line human CVCL_A5YN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 16-18 hours (at passage <10), 20-23 hours (at 42th passage) (CelloPub=CLPUB00607) Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (CelloPub=CLPUB00607). 127229003 CVCL_A5YQ HAVCH.01 transformed cell line CVCL_A5YQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 127229004 CVCL_A5YP HET-37 hybrid cell line CVCL_A5YP CL:0000010 Group: Hybridoma fusion partner cell line. 127229005 CVCL_A5YC KR-92 finite cell line CVCL_A5YC CL:0000010 Derived from sampling site: Intestine. 127229006 CVCL_A5YB KEK-92 finite cell line CVCL_A5YB CL:0000010 Derived from sampling site: Fetal intestine. Unspecified 127229007 CVCL_A5YE CGFR-Ca-1 spontaneously immortalized cell line dog CVCL_A5YE CL:0000010 Derived from sampling site: Fetal muscle. Unspecified 127229008 CVCL_A5YD CC0066 transformed cell line human CVCL_A5YD CL:0000010 Karyotypic information: 47,XY,r(14) (PubMed=16152642); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92063005; true Male Part of: ECACC chromosomal abnormality collection 127229009 CVCL_A5YG CGFR-Ca-3 telomerase immortalized cell line dog CVCL_A5YG CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal muscle. Unspecified 127229010 CVCL_A5YF CGFR-Ca-2 spontaneously immortalized cell line dog CVCL_A5YF CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Unexplicit; Not described; Zygosity=Unspecified (PubMed=15365251) Derived from sampling site: Fetal muscle. Unspecified 127229011 CVCL_A5YI BMET telomerase immortalized cell line CVCL_A5YI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Muscle Cell type=Epithelial cell.. Unspecified 127229012 CVCL_A5YH BMES spontaneously immortalized cell line CVCL_A5YH CL:0000010 Derived from sampling site: Muscle Cell type=Epithelial cell.. Unspecified 127229013 CVCL_A5VX NCL2 [Human lung carcinoma] cancer cell line human CVCL_A5VX CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male Characteristics: Established from a nude mouse xenograft of CL2 Doubling time: 30 hours (PubMed=1497905) 127229014 CVCL_A5VW F-49-1 cancer cell line human CVCL_A5VW CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (AV3) has been shown to be a HeLa derivative. 127229015 CVCL_A5VZ TruHD-Q43Q17M telomerase immortalized cell line human CVCL_A5VZ CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=30256717); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229016 CVCL_A5VY TruHD-Q21Q18F telomerase immortalized cell line human CVCL_A5VY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 127229017 CVCL_A5VP F9-11 spontaneously immortalized cell line house mouse CVCL_A5VP CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: The parent cell line was fused with yeast strain F9 (AB1380 with a neo gene integrated in ura3) spheroblasts (PubMed=8710496); Characteristics: Mixture of cells containing small integrations of yeast DNA (27% of cells), cells containing large numbers of small extrachromosomal elements (32% of cells, Fig 2C) and cells containing no yeast DNA (40% of cells) (PubMed=8710496). 127229018 CVCL_A5VR F9-13 spontaneously immortalized cell line house mouse CVCL_A5VR CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: The parent cell line was fused with yeast strain F9 (AB1380 with a neo gene integrated in ura3) spheroblasts (PubMed=8710496); Characteristics: Contains a single small integration of yeast DNA into a mouse chromosome (PubMed=8710496) 127229019 CVCL_A5VQ F9-12 spontaneously immortalized cell line house mouse CVCL_A5VQ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: The parent cell line was fused with yeast strain F9 (AB1380 with a neo gene integrated in ura3) spheroblasts (PubMed=8710496); Characteristics: Mixture of cells with small integrations of yeast DNA (23%), cells with large numbers of small extrachromosomal elements (17%), cells with very large integrations of yeast DNA (18%), cells with a large novel chromosome (14%) and cells with no signal (28%) (PubMed=8710496) 127229020 CVCL_A5VT F9-5 spontaneously immortalized cell line house mouse CVCL_A5VT CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: The parent cell line was fused with yeast strain F9 (AB1380 with a neo gene integrated in ura3) spheroblasts (PubMed=8710496); Characteristics: Contains a single small integration of yeast DNA into a mouse chromosome (PubMed=8710496) 127229021 CVCL_A5VS F9-15 spontaneously immortalized cell line house mouse CVCL_A5VS CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: The parent cell line was fused with yeast strain F9 (AB1380 with a neo gene integrated in ura3) spheroblasts (PubMed=8710496); Characteristics: Contains a single small integration of yeast DNA into a mouse chromosome (PubMed=8710496) 127229022 CVCL_A5VV ICGi029-A induced pluripotent stem cell human CVCL_A5VV From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Asn515del (c.1543_1545delAAC); ClinVar=VCV000181070; Zygosity=Heterozygous (PubMed=33892289) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127229023 CVCL_A5VU ICGi028-A induced pluripotent stem cell human CVCL_A5VU From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4801; HADHA; Simple; p.Glu510Gln (c.1528G>C); ClinVar=VCV000100085; Zygosity=Heterozygous (PubMed=33887580) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229024 CVCL_A5VH UT-SCC-91 cancer cell line human CVCL_A5VH CL:0000010 Derived from sampling site: Nose; skin. 127229025 CVCL_A5VG UT-SCC-115 cancer cell line human CVCL_A5VG CL:0000010 Derived from metastatic site: Not specified. 127229026 CVCL_A5VJ Tu-107 cancer cell line human CVCL_A5VJ CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 127229027 CVCL_A5VI UT-SCC-59A cancer cell line human CVCL_A5VI CL:0000010 Derived from metastatic site: Temple; skin. Male 127229028 CVCL_A5VL Tu-323 cancer cell line human CVCL_A5VL CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 127229029 CVCL_A5VK Tu-159 cancer cell line human CVCL_A5VK CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 127229030 CVCL_A5VN QZG undefined cell line type human CVCL_A5VN CL:0000010 Derived from sampling site: Fetal liver. 127229031 CVCL_A5VM Tu-325 cancer cell line human CVCL_A5VM CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 127229032 CVCL_A5VB U-2OSMR cancer cell line human CVCL_A5VB CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; tibia. Female 127229033 CVCL_A5VA S2:spi4 spontaneously immortalized cell line fruit fly CVCL_A5VA CL:0000010 Transfected with: FlyBase_Gene; FBgn0005672; Spi; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: Oregon-R. Male Group: Insect cell line 127229034 CVCL_A5VD UCLA-PL3 transformed cell line human CVCL_A5VD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229035 CVCL_A5VC U-2OSTR cancer cell line human CVCL_A5VC CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Bone; tibia. Female 127229036 CVCL_A5VF UT-SCC-105 cancer cell line human CVCL_A5VF CL:0000010 Derived from sampling site: Face; skin. 127229037 CVCL_A5VE UT-SCC-111 cancer cell line human CVCL_A5VE CL:0000010 Derived from sampling site: Face; skin. 127229038 CVCL_A5WY OUMS-16 transformed cell line human CVCL_A5WY CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a chronic lymphatic leukemia; Derived from sampling site: Peripheral blood. 127229039 CVCL_A5WX PC-5Ly transformed cell line human CVCL_A5WX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a lung carcinoma; Derived from sampling site: Lymph node. Male 127229040 CVCL_A5WZ FU-MK-1 hybridoma house mouse CVCL_A5WZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 127229041 CVCL_A5WQ GM16131 transformed cell line human CVCL_A5WQ CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16131; probable Male 127229042 CVCL_A5WP GM16126 transformed cell line human CVCL_A5WP CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 9 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16126; probable Female 127229043 CVCL_A5WS UM-UC-3 LLWO1 cancer cell line human CVCL_A5WS CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Urinary bladder. Male Characteristics: Transfected with the plasmid pUHD172-1neo which contains a rtTA under the control of the CMV promoter The reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 (PubMed=12914669). 127229044 CVCL_A5WR GM16330 transformed cell line human CVCL_A5WR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16330; probable Unspecified 127229045 CVCL_A5WU GM16345 transformed cell line human CVCL_A5WU CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16345; probable Female 127229046 CVCL_A5WT UM-UC-3 LLWO2F cancer cell line human CVCL_A5WT CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 9281; PPP1CA (with a N-terminal His6-HA tag); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Urinary bladder. Male Characteristics: Expresses PPP1CA induced by doxycycline Transfected with the plasmid 6-HA-PP1alpha-pTEP4m plasmid that express a 6His-HA tagged PP1C1 undert the control of a Teto/CMV promoter.; Characteristics: Transfected with the plasmid pUHD172-1neo which contains a rtTA under the control of the CMV promoter The reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 (PubMed=12914669). 127229047 CVCL_A5WW NPC-TY861 cancer cell line human CVCL_A5WW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 18 hours (DOI=10.11334/jibi1954.34.1Supplement1_329) 127229048 CVCL_A5WV NPC-204 cancer cell line human CVCL_A5WV CL:0000010 Population: Chinese; Taiwan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Doubling time: 24-30 hours (DOI=10.2183/pjab1945.46.453) 127229049 CVCL_A5WI GM16292 transformed cell line human CVCL_A5WI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16292; probable Female 127229050 CVCL_A5WH GM16291 transformed cell line human CVCL_A5WH CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16291; probable Female 127229051 CVCL_A5WK GM16294 transformed cell line human CVCL_A5WK CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16294; probable Female 127229052 CVCL_A5WJ GM16293 transformed cell line human CVCL_A5WJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16293; probable Female 127229053 CVCL_A5WM GM16333 transformed cell line human CVCL_A5WM CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16333; probable Female 127229054 CVCL_A5WL GM16295 transformed cell line human CVCL_A5WL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16295; probable Male 127229055 CVCL_A5WN GM16101 transformed cell line human CVCL_A5WN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16101; probable Female 127229056 CVCL_A5WA TruHD-Q50Q40F telomerase immortalized cell line human CVCL_A5WA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=30256717); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=30256717); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 127229057 CVCL_A5WC GM16286 transformed cell line human CVCL_A5WC CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16286; probable Female 127229058 CVCL_A5WB GM16285 transformed cell line human CVCL_A5WB CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16285; probable Female 127229059 CVCL_A5WE GM16288 transformed cell line human CVCL_A5WE CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16288; probable Male 127229060 CVCL_A5WD GM16287 transformed cell line human CVCL_A5WD CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16287; probable Male 127229061 CVCL_A5WG GM16290 transformed cell line human CVCL_A5WG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16290; probable Female 127229062 CVCL_A5WF GM16289 transformed cell line human CVCL_A5WF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16289; probable Female 127229063 CVCL_A6FG RG11/15 hybridoma house mouse CVCL_A6FG CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rat Ig kappa light chains (IgK-1b allotype). 127229064 CVCL_A6FF ONS-82 cancer cell line human CVCL_A6FF CL:0000010 Population: Japanese. Unspecified 127229065 CVCL_A6FI LO-MG1-15 hybridoma Norway rat CVCL_A6FI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01868; Mouse immunoglobulin heavy chain gamma-1. 127229066 CVCL_A6FH LO-MG1-13 hybridoma Norway rat CVCL_A6FH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01868; Mouse immunoglobulin heavy chain gamma-1. 127229067 CVCL_A6FK LO-MG2a-7 hybridoma Norway rat CVCL_A6FK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse Ig heavy chain gamma-2a. 127229068 CVCL_A6FJ LO-MG2a-3 hybridoma Norway rat CVCL_A6FJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse Ig heavy chain gamma-2a. 127229069 CVCL_A6FM MAR 80.2 hybridoma house mouse CVCL_A6FM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Rat Ig kappa light chains (allotype IgK-1a). 127229070 CVCL_A6FL LO-MG2b-1 hybridoma Norway rat CVCL_A6FL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01867; Mouse immunoglobulin heavy chain gamma-2b. 127229071 CVCL_A6FA UNESP-MM4 cancer cell line dog CVCL_A6FA CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Teckel. Female Doubling time: 10.28 hours (PubMed=33195606) 127229072 CVCL_A6FC NCC-SS4-C1 cancer cell line human CVCL_A6FC CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=33611700) Population: Japanese Omics: SNP array analysis. Male Doubling time: ~245 hours (PubMed=33611700) Part of: NCC sarcoma cell line panel 127229073 CVCL_A6FB NCC-DDLPS3-C1 cancer cell line human CVCL_A6FB CL:0000010 Population: Japanese; Derived from sampling site: Right thigh. Omics: SNP array analysis Female Doubling time: ~47 hours (PubMed=33677797) Part of: NCC sarcoma cell line panel 127229074 CVCL_A6FE ONS-86 cancer cell line human CVCL_A6FE CL:0000010 Population: Japanese. Unspecified 127229075 CVCL_A6FD ONS-84 cancer cell line human CVCL_A6FD CL:0000010 Population: Japanese. Unspecified 127229076 CVCL_A6EV UNESP-CM11 cancer cell line dog CVCL_A6EV CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Doubling time: 7.45 hours (PubMed=33195606) 127229077 CVCL_A6EU UNESP-CM9 cancer cell line dog CVCL_A6EU CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Doubling time: 8.95 hours (PubMed=33195606) 127229078 CVCL_A6EX UNESP-CM61 cancer cell line dog CVCL_A6EX CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Teckel. Female Doubling time: 13.06 hours (PubMed=33195606) 127229079 CVCL_A6EW UNESP-CM60 cancer cell line dog CVCL_A6EW CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Teckel. Female Doubling time: 11.79 hours (PubMed=33195606) 127229080 CVCL_A6EZ UNESP-MM3 cancer cell line dog CVCL_A6EZ CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Teckel. Female Doubling time: 34.17 hours (PubMed=33195606) 127229081 CVCL_A6EY UNESP-MM1 cancer cell line dog CVCL_A6EY CL:0000010 Derived from sampling site: Bone; Breed/subspecies: Poodle. Female Doubling time: 25.41 hours (PubMed=33195606) 127229082 CVCL_A6EN MARM-4 hybridoma house mouse CVCL_A6EN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat IgM heavy chain. 127229083 CVCL_A6EM MARL-5 hybridoma house mouse CVCL_A6EM CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rat Ig lambda light chains. 127229084 CVCL_A6EP MARM-7 hybridoma house mouse CVCL_A6EP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat IgM heavy chain. 127229085 CVCL_A6ER UNESP-CM1 cancer cell line dog CVCL_A6ER CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female Doubling time: 6.31 hours (PubMed=33195606) 127229086 CVCL_A6EQ MARG2a-7 hybridoma house mouse CVCL_A6EQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20760; Rat immunoglobulin heavy chain gamma-2A. 127229087 CVCL_A6ET UNESP-CM5 cancer cell line dog CVCL_A6ET CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Teckel. Female Doubling time: 7.5 hours (PubMed=33195606) 127229088 CVCL_A6ES UNESP-CM4 cancer cell line dog CVCL_A6ES CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Teckel. Female Doubling time: 5.1 hours (PubMed=33195606) 127229089 CVCL_A6GH LO-DNP-1 hybridoma Norway rat CVCL_A6GH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229090 CVCL_A6GG LO-DNP-45 hybridoma Norway rat CVCL_A6GG CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229091 CVCL_A6GJ LO-DNP-16 hybridoma Norway rat CVCL_A6GJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229092 CVCL_A6GI LO-DNP-2 hybridoma Norway rat CVCL_A6GI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229093 CVCL_A6GL LO-DNP-11 hybridoma Norway rat CVCL_A6GL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229094 CVCL_A6GK LO-DNP-61 hybridoma Norway rat CVCL_A6GK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229095 CVCL_A6GN LO-DNP-64 hybridoma Norway rat CVCL_A6GN CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229096 CVCL_A6GM LO-DNP-57 hybridoma Norway rat CVCL_A6GM CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 127229097 CVCL_A6GB LO-MA-10 hybridoma Norway rat CVCL_A6GB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01878; Mouse immunoglobulin heavy chain alpha. 127229098 CVCL_A6GA LO-MA-7 hybridoma Norway rat CVCL_A6GA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01878; Mouse immunoglobulin heavy chain alpha. 127229099 CVCL_A6GD LO-MG-7 hybridoma Norway rat CVCL_A6GD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Mouse Ig heavy chain gamma. 127229100 CVCL_A6GC MAR 103.6 hybridoma house mouse CVCL_A6GC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Rat Ig kappa light chains (allotype IgK-1b). 127229101 CVCL_A6GF LO-HA-9 hybridoma Norway rat CVCL_A6GF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1; Monoclonal antibody target: UniProtKB; P01877; Human immunoglobulin heavy chain alpha 2. 127229102 CVCL_A6GE MARG2c-5 hybridoma house mouse CVCL_A6GE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P20762; Rat immunoglobulin heavy chain gamma-2C. 127229103 CVCL_A6FW LO-MD-6 hybridoma Norway rat CVCL_A6FW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01881; Mouse immunoglobulin heavy chain delta. 127229104 CVCL_A6FV LO-MO-1 hybridoma Norway rat CVCL_A6FV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 127229105 CVCL_A6FY LO-MG2a-9 hybridoma Norway rat CVCL_A6FY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse Ig heavy chain gamma-2a. 127229106 CVCL_A6FX LO-MD-8 hybridoma Norway rat CVCL_A6FX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01881; Mouse immunoglobulin heavy chain delta. 127229107 CVCL_A6FZ LO-MG3-13 hybridoma Norway rat CVCL_A6FZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03987; Mouse immunoglobulin heavy chain gamma-3. 127229108 CVCL_A6FN LO-MK-2 hybridoma Norway rat CVCL_A6FN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse Ig kappa light chains. 127229109 CVCL_A6FQ LO-BG-1 hybridoma Norway rat CVCL_A6FQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Porphyromonas gingivalis (strain ATCC 33277). 127229110 CVCL_A6FP LO-MK-3 hybridoma Norway rat CVCL_A6FP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Mouse Ig kappa light chains. 127229111 CVCL_A6FS LO-SM-11 hybridoma Norway rat CVCL_A6FS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Streptococcus mutans cell wall antigens. 127229112 CVCL_A6FR LO-SM-2 hybridoma Norway rat CVCL_A6FR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Streptococcus mutans cell wall antigens. 127229113 CVCL_A6FU LO-CD2b hybridoma Norway rat CVCL_A6FU CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-802 127229114 CVCL_A6FT LO-panB-a hybridoma Norway rat CVCL_A6FT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Human leucocytes. 127229115 CVCL_A6DE EB-Y8 hybridoma Norway rat CVCL_A6DE CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Yersinia enterocolitica serogroup O:8 lipopolysaccharide. 127229116 CVCL_A6DD EB-A7 hybridoma Norway rat CVCL_A6DD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229117 CVCL_A6DG LO-MG2a-2 hybridoma Norway rat CVCL_A6DG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse Ig heavy chain gamma-2a. 127229118 CVCL_A6DF LO-MG1-2 hybridoma Norway rat CVCL_A6DF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01868; Mouse immunoglobulin heavy chain gamma-1. 127229119 CVCL_A6DI LO-MG3-7 hybridoma Norway rat CVCL_A6DI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03987; Mouse immunoglobulin heavy chain gamma-3. 127229120 CVCL_A6DH LO-MG2b-2 hybridoma Norway rat CVCL_A6DH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01867; Mouse immunoglobulin heavy chain gamma-2b. 127229121 CVCL_A6DK LO-MM-9 hybridoma Norway rat CVCL_A6DK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01872; Mouse immunoglobulin heavy chain mu. 127229122 CVCL_A6DJ LO-MK-1 hybridoma Norway rat CVCL_A6DJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse Ig kappa light chains. 127229123 CVCL_A6DA EB-A4 hybridoma Norway rat CVCL_A6DA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229124 CVCL_A6DC EB-A6 hybridoma Norway rat CVCL_A6DC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229125 CVCL_A6DB EB-A5 hybridoma Norway rat CVCL_A6DB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229126 CVCL_A6CT LO-CD4-a hybridoma Norway rat CVCL_A6CT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 89012101 127229127 CVCL_A6CS LO-CD2a hybridoma Norway rat CVCL_A6CS CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized siplizumab (MEDI-507) therapeutic antibody Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11423 127229128 CVCL_A6CV LO-CD6-a hybridoma Norway rat CVCL_A6CV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 127229129 CVCL_A6CU LO-CD4-b hybridoma Norway rat CVCL_A6CU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 89012102 127229130 CVCL_A6CX EB-A1 hybridoma Norway rat CVCL_A6CX CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229131 CVCL_A6CW LO-Tmat hybridoma Norway rat CVCL_A6CW CL:0000010 Monoclonal antibody isotype: IgG2a. 127229132 CVCL_A6CZ EB-A3 hybridoma Norway rat CVCL_A6CZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229133 CVCL_A6CY EB-A2 hybridoma Norway rat CVCL_A6CY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 127229134 CVCL_A6CL LO-PL3-a hybridoma Norway rat CVCL_A6CL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08514; Human ITGAB/CD41. 127229135 CVCL_A6CK LO-CD5-a hybridoma Norway rat CVCL_A6CK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06127; Human CD5. 127229136 CVCL_A6CN LO-PL4 hybridoma Norway rat CVCL_A6CN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21926; Human CD9. 127229137 CVCL_A6CM LO-PL3-b hybridoma Norway rat CVCL_A6CM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08514; Human ITGAB/CD41. 127229138 CVCL_A6CP LO-Tact-1 hybridoma Norway rat CVCL_A6CP CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. 127229139 CVCL_A6CR LO-DR-a hybridoma Norway rat CVCL_A6CR CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Human HLA-DR. 127229140 CVCL_A6CQ LO-Tact-2 hybridoma Norway rat CVCL_A6CQ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. 127229141 CVCL_A6EF MARG2b-8 hybridoma house mouse CVCL_A6EF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20761; Rat immunoglobulin heavy chain gamma-2B. 127229142 CVCL_A6EE MARG2b-3 hybridoma house mouse CVCL_A6EE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20761; Rat immunoglobulin heavy chain gamma-2B. 127229143 CVCL_A6EH MARG2c-3 hybridoma house mouse CVCL_A6EH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P20762; Rat immunoglobulin heavy chain gamma-2C. 127229144 CVCL_A6EG MARG2c-2 hybridoma house mouse CVCL_A6EG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20762; Rat immunoglobulin heavy chain gamma-2C. 127229145 CVCL_A6EJ MARK-2 hybridoma house mouse CVCL_A6EJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat Ig kappa light chains (allotype IgK-1a). 127229146 CVCL_A6EI MARK-1 hybridoma house mouse CVCL_A6EI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat Ig kappa light chains. 127229147 CVCL_A6EL MARL-4 hybridoma house mouse CVCL_A6EL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Rat Ig lambda light chains. 127229148 CVCL_A6EK MARL-15 hybridoma house mouse CVCL_A6EK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat Ig lambda light chains. 127229149 CVCL_A6EB MARG1-1 hybridoma house mouse CVCL_A6EB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20759; Rat immunoglobulin heavy chain gamma-1. 127229150 CVCL_A6EA MARE-1 hybridoma house mouse CVCL_A6EA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01855; Rat immunoglobulin heavy chain epsilon. 127229151 CVCL_A6ED MARG2a-8 hybridoma house mouse CVCL_A6ED CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20760; Rat immunoglobulin heavy chain gamma-2A. 127229152 CVCL_A6EC MARG1-2 hybridoma house mouse CVCL_A6EC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20759; Rat immunoglobulin heavy chain gamma-1. 127229153 CVCL_A6DU LO-VX-4 hybridoma Norway rat CVCL_A6DU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Potato virus X. 127229154 CVCL_A6DT LO-VX-10 hybridoma Norway rat CVCL_A6DT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Potato virus X. 127229155 CVCL_A6DW LO-VX-9 hybridoma Norway rat CVCL_A6DW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Potato virus X. 127229156 CVCL_A6DV LO-VX-6 hybridoma Norway rat CVCL_A6DV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Potato virus X. 127229157 CVCL_A6DY MARA-2 hybridoma house mouse CVCL_A6DY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Rat IgA heavy chain. 127229158 CVCL_A6DX MARA-1 hybridoma house mouse CVCL_A6DX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat IgA heavy chain. 127229159 CVCL_A6DZ MARD-3 hybridoma house mouse CVCL_A6DZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01883; Rat immunoglobulin heavy chain delta. 127229160 CVCL_A6DM LO-MM-8 hybridoma Norway rat CVCL_A6DM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01872; Mouse immunoglobulin heavy chain mu. 127229161 CVCL_A6DL LO-MM-3 hybridoma Norway rat CVCL_A6DL CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01872; Mouse immunoglobulin heavy chain mu. 127229162 CVCL_A6DN LO-ME-2 hybridoma Norway rat CVCL_A6DN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 127229163 CVCL_A6DQ LO-Ea-10 hybridoma Norway rat CVCL_A6DQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Erwinia amylovora. 127229164 CVCL_A6DP LO-ME-3 hybridoma Norway rat CVCL_A6DP CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 127229165 CVCL_A6DS LO-Ea-18 hybridoma Norway rat CVCL_A6DS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Erwinia amylovora. 127229166 CVCL_A6DR LO-Ea-15 hybridoma Norway rat CVCL_A6DR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Erwinia amylovora. 127229167 CVCL_A6BC LO-HL-4 hybridoma Norway rat CVCL_A6BC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human Ig lambda light chains. 127229168 CVCL_A6BB LO-HL-3 hybridoma Norway rat CVCL_A6BB CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: Human Ig lambda light chains. 127229169 CVCL_A6BE LO-HApoB-2 hybridoma Norway rat CVCL_A6BE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229170 CVCL_A6BD LO-HApoB-1 hybridoma Norway rat CVCL_A6BD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229171 CVCL_A6BG LO-HApoB-4 hybridoma Norway rat CVCL_A6BG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229172 CVCL_A6BF LO-HApoB-3 hybridoma Norway rat CVCL_A6BF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229173 CVCL_A6BI LO-HApoB-6 hybridoma Norway rat CVCL_A6BI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229174 CVCL_A6BH LO-HApoB-5 hybridoma Norway rat CVCL_A6BH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 127229175 CVCL_A6AZ LO-HG-23 hybridoma Norway rat CVCL_A6AZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human IgG (all 4 classes). 127229176 CVCL_A6AY LO-HG-22 hybridoma Norway rat CVCL_A6AY CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229177 CVCL_A6BA LO-HL-2 hybridoma Norway rat CVCL_A6BA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Ig lambda light chains. 127229178 CVCL_A6AR LO-HG-1 hybridoma Norway rat CVCL_A6AR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human IgG (all 4 classes). 127229179 CVCL_A6AQ LO-HD-3 hybridoma Norway rat CVCL_A6AQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01880; Human immunoglobulin heavy chain delta. 127229180 CVCL_A6AT LO-HG-6 hybridoma Norway rat CVCL_A6AT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229181 CVCL_A6AS LO-HG-3 hybridoma Norway rat CVCL_A6AS CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229182 CVCL_A6AV LO-HG-19 hybridoma Norway rat CVCL_A6AV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229183 CVCL_A6AU LO-HG-7 hybridoma Norway rat CVCL_A6AU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229184 CVCL_A6AX LO-HG-21 hybridoma Norway rat CVCL_A6AX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human IgG (all 4 classes). 127229185 CVCL_A6AW LO-HG-20 hybridoma Norway rat CVCL_A6AW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human IgG (all 4 classes). 127229186 CVCL_A6AJ LO-RK-1b-1 hybridoma Norway rat CVCL_A6AJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat Ig kappa light chains (IgK-1b allotype). 127229187 CVCL_A6AI LO-RK-1a-1 hybridoma Norway rat CVCL_A6AI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Rat Ig kappa light chains (IgK-1a allotype). 127229188 CVCL_A6AL LO-RG-1 hybridoma Norway rat CVCL_A6AL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Rabbit IgG heavy chain. 127229189 CVCL_A6AK LO-RK-1b-2 hybridoma Norway rat CVCL_A6AK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat Ig kappa light chains (IgK-1b allotype). 127229190 CVCL_A6AN LO-HM-8 hybridoma Norway rat CVCL_A6AN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01871; Human immunoglobulin heavy chain mu. 127229191 CVCL_A6AM LO-HM-2 hybridoma Norway rat CVCL_A6AM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01871; Human immunoglobulin heavy chain mu. 127229192 CVCL_A6AP LO-HD-1 hybridoma Norway rat CVCL_A6AP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01880; Human immunoglobulin heavy chain delta. 127229193 CVCL_A6CD LO-HRP-17 hybridoma Norway rat CVCL_A6CD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229194 CVCL_A6CC LO-HRP-16 hybridoma Norway rat CVCL_A6CC CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229195 CVCL_A6CF LO-HRP-19 hybridoma Norway rat CVCL_A6CF CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229196 CVCL_A6CE LO-HRP-18 hybridoma Norway rat CVCL_A6CE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229197 CVCL_A6CH LO-VG2 hybridoma Norway rat CVCL_A6CH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Xenopus laevis vitellogenin. 127229198 CVCL_A6CG LO-VG1 hybridoma Norway rat CVCL_A6CG CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: Xenopus laevis vitellogenin. 127229199 CVCL_A6CJ LO-CD1-a hybridoma Norway rat CVCL_A6CJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06126; Human CD1A. 127229200 CVCL_A6CI LO-VG3 hybridoma Norway rat CVCL_A6CI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Xenopus laevis vitellogenin. 127229201 CVCL_A6BZ LO-HRP-13 hybridoma Norway rat CVCL_A6BZ CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229202 CVCL_A6CB LO-HRP-15 hybridoma Norway rat CVCL_A6CB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229203 CVCL_A6CA LO-HRP-14 hybridoma Norway rat CVCL_A6CA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229204 CVCL_A6BS LO-HK-1 hybridoma Norway rat CVCL_A6BS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human Ig kappa light chains. 127229205 CVCL_A6BR LO-HE-7 hybridoma Norway rat CVCL_A6BR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01854; Human immunoglobulin heavy chain epsilon. 127229206 CVCL_A6BU LO-HL-1 hybridoma Norway rat CVCL_A6BU CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: Human Ig lambda light chains. 127229207 CVCL_A6BT LO-HK-3 hybridoma Norway rat CVCL_A6BT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Ig kappa light chains. 127229208 CVCL_A6BW LO-HRP-9 hybridoma CVCL_A6BW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229209 CVCL_A6BV LO-HRP-8 hybridoma CVCL_A6BV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229210 CVCL_A6BY LO-HRP-12 hybridoma Norway rat CVCL_A6BY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229211 CVCL_A6BX LO-HRP-10 hybridoma CVCL_A6BX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. 127229212 CVCL_A6BK LO-HA-1 hybridoma Norway rat CVCL_A6BK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1. 127229213 CVCL_A6BM LO-HA-3 hybridoma Norway rat CVCL_A6BM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1; Monoclonal antibody target: UniProtKB; P01877; Human immunoglobulin heavy chain alpha 2. 127229214 CVCL_A6BL LO-HA-2 hybridoma Norway rat CVCL_A6BL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1. 127229215 CVCL_A6BN LO-HA-4 hybridoma Norway rat CVCL_A6BN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1; Monoclonal antibody target: UniProtKB; P01877; Human immunoglobulin heavy chain alpha 2. 127229216 CVCL_A6BQ LO-HA-6 hybridoma Norway rat CVCL_A6BQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1; Monoclonal antibody target: UniProtKB; P01877; Human immunoglobulin heavy chain alpha 2. 127229217 CVCL_A6BP LO-HA-5 hybridoma Norway rat CVCL_A6BP CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P01876; Human immunoglobulin heavy chain alpha 1; Monoclonal antibody target: UniProtKB; P01877; Human immunoglobulin heavy chain alpha 2. 127229218 CVCL_A6AB UHOMi006-A induced pluripotent stem cell human CVCL_A6AB From: University Hospital of Montpellier; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229219 CVCL_A6AA UHOMi007-A induced pluripotent stem cell human CVCL_A6AA From: University Hospital of Montpellier; Montpellier; France CL:0000010 Population: Caucasian; Donor information: Established from a healthy heavy smoker; Derived from sampling site: Peripheral blood. Male 127229220 CVCL_A6AD 1E4-1D9 hybridoma house mouse CVCL_A6AD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 127229221 CVCL_A6AC Tet-293/Ins6 transformed cell line human CVCL_A6AC CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Secretes insulin induced by doxycyclin; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 127229222 CVCL_A6AF 1E2-1D11 hybridoma house mouse CVCL_A6AF CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Human heparan sulfate proteoglycans (HSPG). 127229223 CVCL_A6AE 1E4-1C2 hybridoma house mouse CVCL_A6AE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human heparan sulfate proteoglycans (HSPG). 127229224 CVCL_A6AH 1E2-2C9 hybridoma house mouse CVCL_A6AH CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Human heparan sulfate proteoglycans (HSPG). 127229225 CVCL_A6AG 1E2-2B8 hybridoma house mouse CVCL_A6AG CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Human heparan sulfate proteoglycans (HSPG). 127229226 CVCL_A7PP WS6KO finite cell line human CVCL_A7PP CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 19 PDL (PubMed=4083160) 127229227 CVCL_A7PR WS8KO finite cell line human CVCL_A7PR CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 19 PDL (PubMed=4083160) 127229228 CVCL_A7PQ WS7KO finite cell line human CVCL_A7PQ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229229 CVCL_A7PT WS10KO finite cell line human CVCL_A7PT CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (PubMed=4083160) 127229230 CVCL_A7PS WS9KO finite cell line human CVCL_A7PS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 12 PDL (PubMed=4083160) 127229231 CVCL_A7PV NHSF41 finite cell line human CVCL_A7PV CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 50 PDL (PubMed=4083160) 127229232 CVCL_A7PU WS12KO finite cell line human CVCL_A7PU CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (PubMed=4083160) 127229233 CVCL_A7PH WS10S finite cell line human CVCL_A7PH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229234 CVCL_A7PG MBC-1 cancer cell line human CVCL_A7PG CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Unspecified 127229235 CVCL_A7PJ WS1KO finite cell line human CVCL_A7PJ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (PubMed=4083160) 127229236 CVCL_A7PI WS11KO finite cell line human CVCL_A7PI CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (PubMed=4083160) 127229237 CVCL_A7PL WS3KO finite cell line human CVCL_A7PL CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 11 PDL (PubMed=4083160) 127229238 CVCL_A7PK WS2KO finite cell line human CVCL_A7PK CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229239 CVCL_A7PN WS5KO finite cell line human CVCL_A7PN CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (PubMed=4083160) 127229240 CVCL_A7PM WS4KO finite cell line human CVCL_A7PM CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 13 PDL (PubMed=4083160) 127229241 CVCL_A7PB K-TL-1 cancer cell line human CVCL_A7PB CL:0000010 Population: Japanese; Derived from sampling site: Hair follicle; outer root sheath. Female Doubling time: 10 days (PubMed=6165463) 127229242 CVCL_A7PA T3-2 [Rat tooth germ] telomerase immortalized cell line Norway rat CVCL_A7PA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Tooth bud; dental papilla; molar Cell type=Odontoblast.; Breed/subspecies: Sprague Dawley. 127229243 CVCL_A7PD AWT KoTa finite cell line human CVCL_A7PD CL:0000010 Population: Japanese; Karyotypic information: 46,XY,del(11)(p13) (JCRB); Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229244 CVCL_A7PC MGH9009-1 cancer cell line human CVCL_A7PC CL:0000010 Derived from metastatic site: Lymph node. Unspecified 127229245 CVCL_A7PF CFS414_1G10 transformed cell line CVCL_A7PF CL:0000010 Transfected with: UniProtKB; J7RUA5; Staphylococcus aureus Cas9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Continental Chestnut Flanked White. Male Characteristics: Constitutively expresses nuclear GFP (nGFP) and pac and conditionally expresses S.aureus Cas9 and mCherry in the presence of Cre recombinase; Characteristics: A FLEx-SaCas9-P2A-mCherry construct was transferred using a PiggyBac transposon vector Group: Bird cell line 127229246 CVCL_A7PE CFS414_F6 transformed cell line CVCL_A7PE CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Continental Chestnut Flanked White. Male Group: Bird cell line 127229247 CVCL_A7QQ U2OS EGFP-H2B cancer cell line human CVCL_A7QQ CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 127229248 CVCL_A7QP YTH 3.2.6 hybridoma Norway rat CVCL_A7QP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09564; Human CD7. 127229249 CVCL_A7QS LUMCi046-A induced pluripotent stem cell human CVCL_A7QS From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple; p.Met1Arg (c.2T>G); Zygosity=Heterozygous (PubMed=34688992) Population: Chilean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229250 CVCL_A7QR LUMCi045-A induced pluripotent stem cell human CVCL_A7QR From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple; p.Met1Arg (c.2T>G); Zygosity=Heterozygous (PubMed=34688992) Population: Chilean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229251 CVCL_A7QU LGLL-CL1 transformed cell line human CVCL_A7QU CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229252 CVCL_A7QT LUMCi039-A induced pluripotent stem cell human CVCL_A7QT From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg594Gln (c.1781G>A); ClinVar=VCV000053018; Zygosity=Heterozygous (PubMed=27470144) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229253 CVCL_A7QW M-2478 finite cell line human CVCL_A7QW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 127229254 CVCL_A7QV LGLL-2 transformed cell line human CVCL_A7QV CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Population: African; Ethiopian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229255 CVCL_A7QI B82CAPR spontaneously immortalized cell line house mouse CVCL_A7QI CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 127229256 CVCL_A7QH MIN6 rho0 transformed cell line house mouse CVCL_A7QH CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Unspecified Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with bis-4-piperidyle-dichloride (PubMed=8824267). 127229257 CVCL_A7QK A3D8 hybridoma house mouse CVCL_A7QK CL:0000010 Monoclonal antibody isotype: IgG1 (PubMed=2646376); IgM (PubMed=6466869; PubMed=6863545); Monoclonal antibody target: UniProtKB; P16070; Human CD44. 127229258 CVCL_A7QJ SHSY-5Y Tet-On SNCA cancer cell line human CVCL_A7QJ CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11138; SNCA; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Inducible expression of SNCA upon treatment with doxycycline Serves as a model for both dopaminergic neuronal biology and a-synuclein pathology (Millipore).; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 127229259 CVCL_A7QM ED-S/ADM cancer cell line human CVCL_A7QM CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 127229260 CVCL_A7QL Hermes-2 hybridoma CVCL_A7QL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 127229261 CVCL_A7QN YTH 66.9 hybridoma Norway rat CVCL_A7QN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P31358; Human CD52. 127229262 CVCL_A7QA ATL-2/ADM cl-1 transformed cell line human CVCL_A7QA CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 127229263 CVCL_A7QC RIN-AhGh cancer cell line Norway rat CVCL_A7QC CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 127229264 CVCL_A7QB ATL-2/ADM cl-2 transformed cell line human CVCL_A7QB CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 127229265 CVCL_A7QE RIN 1046-44 cancer cell line Norway rat CVCL_A7QE CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Does not secrete glucagon, nor insulin, nor somatostatin (PubMed=2879852) 127229266 CVCL_A7QD RIN-AhLh cancer cell line Norway rat CVCL_A7QD CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 127229267 CVCL_A7QG RIN-5AH-T2 cancer cell line Norway rat CVCL_A7QG CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 127229268 CVCL_A7QF RIN 1046-43 cancer cell line Norway rat CVCL_A7QF CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Secretes insulin and somatostatin (PubMed=2879852) 127229269 CVCL_A7PX NHSF63 finite cell line human CVCL_A7PX CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (PubMed=4083160) 127229270 CVCL_A7PW NHSF5 finite cell line human CVCL_A7PW CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 53 PDL (PubMed=4083160) 127229271 CVCL_A7PZ SALT-3/ADM cl-2 cancer cell line human CVCL_A7PZ CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Pleural effusion Cell type=T-cell.. Male 127229272 CVCL_A7PY NHSF64 finite cell line human CVCL_A7PY CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 37 PDL (PubMed=4083160) 127229273 CVCL_A7NN UTP-L12 cancer cell line human CVCL_A7NN CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG; Note=In frame (PubMed=8187069) Population: Japanese; Derived from sampling site: Bone marrow. Female 127229274 CVCL_A7NM IRTA21 cancer cell line human CVCL_A7NM CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG; Note=In frame (PubMed=7794765) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~99 hours (PubMed=7794765) 127229275 CVCL_A7NP CS-R cancer cell line human CVCL_A7NP CL:0000010 Unspecified 127229276 CVCL_A7NR NU-T1 hybridoma house mouse CVCL_A7NR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. 127229277 CVCL_A7NQ SALT-3 cancer cell line human CVCL_A7NQ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Pleural effusion Cell type=T-cell.. Male 127229278 CVCL_A7NT KOS-1 cancer cell line human CVCL_A7NT CL:0000010 Population: Japanese; Derived from sampling site: Bone; distal femur. Female Doubling time: 27.4 hours (PubMed=10948649) 127229279 CVCL_A7NS NU-T2 hybridoma house mouse CVCL_A7NS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29016; Human CD1B. 127229280 CVCL_A7NF IMS-BC2 cancer cell line human CVCL_A7NF CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9650450; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36 hours (PubMed=9650450) 127229281 CVCL_A7NE IMS-BC1 cancer cell line human CVCL_A7NE CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9650450; PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: 48 hours (PubMed=9650450) 127229282 CVCL_A7NH SZ-117 hybridoma house mouse CVCL_A7NH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08253; Human MMP2 (Note=Also recognizes filamin A). 127229283 CVCL_A7NG UACC-SARC1 cancer cell line human CVCL_A7NG CL:0000010 Omics: Array-based CGH. Female Characteristics: Obtained from a radiation-induced sarcoma Doubling time: 28.3 hours (PubMed=25644184) 127229284 CVCL_A7NJ 82.3 cancer cell line human CVCL_A7NJ CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Liver; intrahepatic bile duct. Male Characteristics: Shows cross-resistance to gemcitabine, 5-fluorouracil, carboplatin and oxaliplatin (PubMed=33922695); Characteristics: Established from a 4th generation xenograft maintained in NOD/SCID mice (PubMed=33922695) Doubling time: 48-53 hours (PubMed=33922695) 127229285 CVCL_A7NI 2XSB cancer cell line human CVCL_A7NI CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 19291; CSMD3; Simple; p.Trp3337Ter (c.10010G>A); Zygosity=Heterozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 2976; DNMT1; Simple; c.2586+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33707600); Sequence variation: Mutation; HGNC; 6697; LRP5; Simple; p.Arg428Ter (c.1282C>T); ClinVar=VCV000006269; Zygosity=Heterozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 7765; NF1; None_reported; -; Zygosity=- (PubMed=33707600); Sequence variation: Mutation; HGNC; 8059; NUMA1; Simple; p.Leu1167Alafs*39 (c.3499_3500delCT); Zygosity=Heterozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro38Ser (c.112C>T); ClinVar=VCV000127688; Zygosity=Homozygous (PubMed=33707600); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His178Asp (c.532C>G); ClinVar=VCV000482223; Zygosity=Homozygous (PubMed=33707600) Population: Caucasian; Derived from sampling site: Right brachial nerve. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 28.0 +- 3.09 hours (at 6th passage), 27.3 +- 4.06 hours (at 54th passage) (PubMed=33707600) 127229286 CVCL_A7NL IRTA17 cancer cell line human CVCL_A7NL CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG; Note=In frame (PubMed=7794765) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~79 hours (PubMed=7794765) 127229287 CVCL_A7NK RRBL1 cancer cell line human CVCL_A7NK CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=17675267) Population: Japanese; Derived from sampling site: Peripheral blood. Male 127229288 CVCL_A7NB Sf-21-CB spontaneously immortalized cell line CVCL_A7NB CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used for the production of the MSD Animal Health porcine circovirus type 2 (PCV2) vaccine Porcilis PCV Used to produce the PCV2 ORF2 capsid protein.; Biotechnology: Used for the production of the MSD Animal Health classical swine fever virus (CSFV) vaccine Porcilis Pesti Used to produce the CSFV envelope glycoprotein E2. Female Group: Insect cell line; Group: Recombinant protein production insect cell line; Group: Vaccine production cell line 127229289 CVCL_A7NA LSA-D6 cancer cell line CVCL_A7NA CL:0000010 Transformant: Feline sarcoma virus (strain Snyder-Theilen)(NCBI-Taxonomy; 11780); Derived from sampling site: Thymus. Unspecified Characteristics: Compared to the parent cell line, has increased interferon-alpha secretion activity 127229290 CVCL_A7ND GM28037 finite cell line human CVCL_A7ND CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Tyr117Ter (c.351T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127229291 CVCL_A7NC WAe009-A-58 embryonic stem cell human CVCL_A7NC From: Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 2207; COL4A5. Female 127229292 CVCL_A7MU SAEC-H7 embryonic stem cell CVCL_A7MU CL:0000010 Unspecified Doubling time: 1.7 days (PubMed=34044158). Group: Fish cell line 127229293 CVCL_A7MT BHK21-MERS-Rep spontaneously immortalized cell line CVCL_A7MT CL:0000010 Transfected with: UniProtKB; K9N7C7; Middle East respiratory syndrome-related coronavirus replicase polyprotein 1ab; Transfected with: UniProtKB; K9N4V7; Middle East respiratory syndrome-related coronavirus nucleoprotein (N); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Kidney. Male Characteristics: Transfected with a pBAC-CMV-MERS-CoV replicon construct The MERS-CoV replicon contains the genes encoding the MERS-CoV polyproteins 1a and 1b and the N protein, neo, and the renilla-type luciferase (Rluc) gene (PubMed=33616893). 127229294 CVCL_A7MW SAEC-C1 embryonic stem cell CVCL_A7MW CL:0000010 Unspecified Group: Fish cell line. 127229295 CVCL_A7MV SAEC-A3 embryonic stem cell CVCL_A7MV CL:0000010 Unspecified Doubling time: 1.7 days (PubMed=34044158). Group: Fish cell line 127229296 CVCL_A7MY LSA-D4-C cancer cell line CVCL_A7MY CL:0000010 Transformant: Feline sarcoma virus (strain Snyder-Theilen)(NCBI-Taxonomy; 11780); Derived from sampling site: Thymus. Unspecified Characteristics: Compared to the parent cell line, has increased interferon-alpha secretion activity 127229297 CVCL_A7MX SAEC-F1 embryonic stem cell CVCL_A7MX CL:0000010 Unspecified Group: Fish cell line. 127229298 CVCL_A7MZ LSA-D4-K17 cancer cell line CVCL_A7MZ CL:0000010 Transformant: Feline sarcoma virus (strain Snyder-Theilen)(NCBI-Taxonomy; 11780); Derived from sampling site: Thymus. Unspecified Characteristics: Compared to the parent cell line, has increased interferon-alpha secretion activity 127229299 CVCL_A7NV MCS-2 [Mouse hybridoma against human ANPEP] hybridoma house mouse CVCL_A7NV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15144; Human ANPEP/CD13. 127229300 CVCL_A7NU MCS-1 [Mouse hybridoma against sialyl Lewis X] hybridoma house mouse CVCL_A7NU CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 127229301 CVCL_A7NX WAe001-A-72 embryonic stem cell human CVCL_A7NX From: The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO. Male 127229302 CVCL_A7NW PRHC-1 cancer cell line human CVCL_A7NW CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Resistant of the cytopathogenic effect of poliovirus infection (PubMed=3037186) 127229303 CVCL_A7NZ RTG spontaneously immortalized cell line Norway rat CVCL_A7NZ CL:0000010 Derived from sampling site: Embryonic tooth bud; dental papilla; incisor; Breed/subspecies: Wistar. Unspecified Doubling time: ~19 hours (PubMed=293368) 127229304 CVCL_A7NY VMCs transformed cell line house mouse CVCL_A7NY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: BALB/c. Doubling time: ~15 hours (PubMed=8228520) 127229305 CVCL_A7LL RUCDRi002-A-10 induced pluripotent stem cell human CVCL_A7LL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229306 CVCL_A7LK RUCDRi002-A-9 induced pluripotent stem cell human CVCL_A7LK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229307 CVCL_A7LN RUCDRi002-A-12 induced pluripotent stem cell human CVCL_A7LN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229308 CVCL_A7LM RUCDRi002-A-11 induced pluripotent stem cell human CVCL_A7LM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229309 CVCL_A7LP RUCDRi002-A-13 induced pluripotent stem cell human CVCL_A7LP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229310 CVCL_A7LR RUCDRi002-A-15 induced pluripotent stem cell human CVCL_A7LR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 a dCas9-VPR-2A-tdTomato-WPRE construct containing dCas9 fused to heterotrimeric VPR transactivator consisting of VP64, p65, and RTA domains along with a tdTomato and a woodchuck hepatitis post-transcriptional regulatory element (WPRE) was introduced in the AAVS1 safe harbor locus (PubMed=34481190) 127229311 CVCL_A7LQ RUCDRi002-A-14 induced pluripotent stem cell human CVCL_A7LQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229312 CVCL_A7LD RUCDRi002-A-1 induced pluripotent stem cell human CVCL_A7LD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229313 CVCL_A7LC DMBi001-A-1 induced pluripotent stem cell human CVCL_A7LC From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6482; LAMA2 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229314 CVCL_A7LF RUCDRi002-A-3 induced pluripotent stem cell human CVCL_A7LF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229315 CVCL_A7LE RUCDRi002-A-2 induced pluripotent stem cell human CVCL_A7LE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229316 CVCL_A7LH RUCDRi002-A-6 induced pluripotent stem cell human CVCL_A7LH From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229317 CVCL_A7LG RUCDRi002-A-4 induced pluripotent stem cell human CVCL_A7LG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229318 CVCL_A7LJ RUCDRi002-A-8 induced pluripotent stem cell human CVCL_A7LJ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229319 CVCL_A7LI RUCDRi002-A-7 induced pluripotent stem cell human CVCL_A7LI From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229320 CVCL_A7KZ UNIMGi003-A induced pluripotent stem cell human CVCL_A7KZ From: Universita degli Studi Magna Graecia di Catanzaro; Catanzaro; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2482; CSTB; Repeat_expansion; c.-210CCCCGCCCCGCG[(2_3)]; ClinVar=VCV000008398; Zygosity=Unspecified (PubMed=33865103) Population: Caucasian; Italian; Derived from sampling site: Peripheral blood. Male 127229321 CVCL_A7LB CMC-hiPSC-022 induced pluripotent stem cell human CVCL_A7LB From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq 127229322 CVCL_A7LA UNIMGi004-A induced pluripotent stem cell human CVCL_A7LA From: Universita degli Studi Magna Graecia di Catanzaro; Catanzaro; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2482; CSTB; Repeat_expansion; c.-210CCCCGCCCCGCG[(2_3)]; ClinVar=VCV000008398; Zygosity=Unspecified (PubMed=33865103) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127229323 CVCL_A7KS WMUi031-A induced pluripotent stem cell human CVCL_A7KS From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8108; OCRL; Simple; p.Met876Asnfs (c.2626dupA); Zygosity=Hemizygous (PubMed=33765594) Population: Chinese; Han; Derived from sampling site: Urine. Male 127229324 CVCL_A7KR SCVIi011-A induced pluripotent stem cell human CVCL_A7KR From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Leu987Argfs*70 (c.2960delT); ClinVar=VCV000943648; Zygosity=Heterozygous (PubMed=34051449) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Female 127229325 CVCL_A7KU ZNHi001-B induced pluripotent stem cell human CVCL_A7KU From: Zhongnan Hospital of Wuhan University; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg180Cys (c.538C>T) (p.Arg223Cys, c.667C>T); ClinVar=VCV000128081; Zygosity=Heterozygous (PubMed=33780728) Population: Asian; Derived from sampling site: Peripheral blood. Male 127229326 CVCL_A7KT ZNHi001-A induced pluripotent stem cell human CVCL_A7KT From: Zhongnan Hospital of Wuhan University; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg180Cys (c.538C>T) (p.Arg223Cys, c.667C>T); ClinVar=VCV000128081; Zygosity=Heterozygous (PubMed=33780728) Population: Asian; Derived from sampling site: Peripheral blood. Male 127229327 CVCL_A7KW REGUi013-A induced pluripotent stem cell human CVCL_A7KW From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Array-based CGH Male 127229328 CVCL_A7KV REGUi012-A induced pluripotent stem cell human CVCL_A7KV From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Array-based CGH Male 127229329 CVCL_A7KY REGUi011-A induced pluripotent stem cell human CVCL_A7KY From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France. CL:0000010 127229330 CVCL_A7KX REGUi014-A induced pluripotent stem cell human CVCL_A7KX From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Array-based CGH Male 127229331 CVCL_A7MM IMGTi003-B induced pluripotent stem cell human CVCL_A7MM From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: We assigned the IMGTi003-B name for consistency with the IMGTi003-A cell line 127229332 CVCL_A7ML TAF11 finite cell line human CVCL_A7ML CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(8)(p23;q24.3); 45,XY,-8 (PubMed=33070101); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 127229333 CVCL_A7MN IMGTi003-C induced pluripotent stem cell human CVCL_A7MN From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: We assigned the IMGTi003-C name for consistency with the IMGTi003-A cell line 127229334 CVCL_A7MQ ICGi024-B induced pluripotent stem cell human CVCL_A7MQ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi024-B name for consistency with the ICGi024-A cell line 127229335 CVCL_A7MP IMGTi003-D induced pluripotent stem cell human CVCL_A7MP From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: We assigned the IMGTi003-D name for consistency with the IMGTi003-A cell line 127229336 CVCL_A7MS TAF12 finite cell line human CVCL_A7MS CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 127229337 CVCL_A7MR ICGi024-C induced pluripotent stem cell human CVCL_A7MR From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi024-C name for consistency with the ICGi024-A cell line 127229338 CVCL_A7ME PER.C6 TetR transformed cell line human CVCL_A7ME From: Johnson & Johnson Janssen; Beerse; Belgium CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina Cell type=Retinoblast.. Biotechnology: Used for the production of the Janssen SARS-CoV-2 (COVID-19) vaccine (Trade name: Ad26.COV2.S) (DrugBank; DB15857) In the context of the vaccine production, the tetR repressor blocks the expression of the SARS-CoV-2 spike protein gene during production of the recombinant adenoviral vector, thereby optimising vector production. Unspecified Group: Vaccine production cell line 127229339 CVCL_A7MD WTC-mEGFP-TERF2-cl25 induced pluripotent stem cell human CVCL_A7MD CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 TERF2 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 127229340 CVCL_A7MG ICGi025-B induced pluripotent stem cell human CVCL_A7MG From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi025-B name for consistency with the ICGi025-A cell line 127229341 CVCL_A7MF CCA-OF cancer cell line CVCL_A7MF CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis felineus(NCBI-Taxonomy; 147828). Male Characteristics: Obtained by both Opisthorchis felineus infection and N-nitrosodimethylamine treatment (PubMed=33862109) Doubling time: 23.2 +- 2.7 hours (PubMed=33862109) 127229342 CVCL_A7MI ICGi025-D induced pluripotent stem cell human CVCL_A7MI From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi025-D name for consistency with the ICGi025-A cell line 127229343 CVCL_A7MH ICGi025-C induced pluripotent stem cell human CVCL_A7MH From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi025-C name for consistency with the ICGi025-A cell line 127229344 CVCL_A7MK ICGi025-F induced pluripotent stem cell human CVCL_A7MK From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi025-F name for consistency with the ICGi025-A cell line 127229345 CVCL_A7MJ ICGi025-E induced pluripotent stem cell human CVCL_A7MJ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male Caution: We assigned the ICGi025-E name for consistency with the ICGi025-A cell line 127229346 CVCL_A7MA RUCDRi002-A-24 induced pluripotent stem cell human CVCL_A7MA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229347 CVCL_A7MC FAHZUi001-A induced pluripotent stem cell human CVCL_A7MC From: The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 22947; NLRP7; Simple; p.Gln421Ter (c.1261C>T); Zygosity=Homozygous (PubMed=34087990) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127229348 CVCL_A7MB RUCDRi002-A-25 induced pluripotent stem cell human CVCL_A7MB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229349 CVCL_A7LT RUCDRi002-A-17 induced pluripotent stem cell human CVCL_A7LT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 a CAG-dCas9-KRAB-T2A-tdTomato-WPRE construct was introduced in the AAVS1 safe harbor locus 127229350 CVCL_A7LS RUCDRi002-A-16 induced pluripotent stem cell human CVCL_A7LS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 a CAG-dCas9-KRAB-T2A-tdTomato-EF1alpha-puroR construct was introduced in the AAVS1 safe harbor locus 127229351 CVCL_A7LV RUCDRi002-A-19 induced pluripotent stem cell human CVCL_A7LV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 TTN was tagged at the C-terminus with mEGFP 127229352 CVCL_A7LU RUCDRi002-A-18 induced pluripotent stem cell human CVCL_A7LU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229353 CVCL_A7LX RUCDRi002-A-21 induced pluripotent stem cell human CVCL_A7LX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229354 CVCL_A7LW RUCDRi002-A-20 induced pluripotent stem cell human CVCL_A7LW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229355 CVCL_A7LZ RUCDRi002-A-23 induced pluripotent stem cell human CVCL_A7LZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229356 CVCL_A7LY RUCDRi002-A-22 induced pluripotent stem cell human CVCL_A7LY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 127229357 CVCL_A7JJ TMPi002-A induced pluripotent stem cell human CVCL_A7JJ From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 127229358 CVCL_A7JI TMPi001-B induced pluripotent stem cell human CVCL_A7JI From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229359 CVCL_A7JL TMPi003-A induced pluripotent stem cell human CVCL_A7JL From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229360 CVCL_A7JK TMPi002-B induced pluripotent stem cell human CVCL_A7JK From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 127229361 CVCL_A7JN TMPi004-A induced pluripotent stem cell human CVCL_A7JN From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 127229362 CVCL_A7JM TMPi003-B induced pluripotent stem cell human CVCL_A7JM From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229363 CVCL_A7JP TMPi004-B induced pluripotent stem cell human CVCL_A7JP From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 127229364 CVCL_A7JB IGIBi007-A induced pluripotent stem cell human CVCL_A7JB From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 9416; PRKG2; Simple; p.Asn164Lysfs*2 (c.491dup); Zygosity=Homozygous (PubMed=33887582) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229365 CVCL_A7JA VRISGi001-A induced pluripotent stem cell human CVCL_A7JA From: Vinmec Research Insitute of Stem Cell and Gene Technology; Hanoi; Vietnam CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Umbilical cord blood. Female 127229366 CVCL_A7JD JSPHi001-A induced pluripotent stem cell human CVCL_A7JD From: Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg335Trp (c.1003C>T); ClinVar=VCV000036473; Zygosity=Heterozygous (PubMed=33887581) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229367 CVCL_A7JC PLAFMCi004-A induced pluripotent stem cell human CVCL_A7JC From: Chinese PLA General Hospital; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229368 CVCL_A7JF SDUBMSi011-A induced pluripotent stem cell human CVCL_A7JF From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 20323; SMOC2; Simple; p.Leu359Arg (c.1076T>G); Zygosity=Heterozygous (PubMed=33892290) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229369 CVCL_A7JE HEBHMUi007-A induced pluripotent stem cell human CVCL_A7JE From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229370 CVCL_A7JH TMPi001-A induced pluripotent stem cell human CVCL_A7JH From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229371 CVCL_A7JG CIBi009-A induced pluripotent stem cell human CVCL_A7JG From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Leu414Arg (c.1241T>G); ClinVar=VCV000251747; Zygosity=Heterozygous (PubMed=33892292); Sequence variation: Mutation; HGNC; 603; APOB; Simple; p.Asp540Tyr (c.1618G>T); ClinVar=VCV000925431; Zygosity=Heterozygous (PubMed=33892292) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229372 CVCL_A7IY FLENIi001-A induced pluripotent stem cell human CVCL_A7IY From: Fundacion para la Lucha contra las Enfermedades Neurologicas de la Infancia; Buenos Aires; Argentina CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Thr119Ile (c.356C>T); ClinVar=VCV000625849; Zygosity=Heterozygous (PubMed=33839546) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229373 CVCL_A7IX HEBHMUi006-A induced pluripotent stem cell human CVCL_A7IX From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: hPSCreg; HEBHMUi006-A; true Male 127229374 CVCL_A7IZ PUMCHi014-A induced pluripotent stem cell human CVCL_A7IZ From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 23198; CYP4V2; Simple; c.802-8_810del17insGC (IVS6-8 del/insGC); ClinVar=VCV000039271; Zygosity=Heterozygous (PubMed=33857831); Sequence variation: Mutation; HGNC; 23198; CYP4V2; Simple; p.Trp340Ter (c.1020G>A); ClinVar=VCV000039248; Zygosity=Heterozygous (PubMed=33857831) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229375 CVCL_A7IQ SHCDNi005-A induced pluripotent stem cell human CVCL_A7IQ From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 18060; ARX; Simple; p.Gln503Alafs*28 (c.1507_1508del); Zygosity=Hemizygous (PubMed=34968892) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229376 CVCL_A7IP CSUASOi007-A induced pluripotent stem cell human CVCL_A7IP From: Central South University, Aier School of Ophthalmology; Changsha; China. CL:0000010 127229377 CVCL_A7IS CMES40-OC embryonic stem cell CVCL_A7IS CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: mCerulean3, a bright cyan fluorescent protein derived from GFP. Female Characteristics: Using CRISPR/Cas9 a P2A-mCerulean3-T2A-pac construct was knocked in at the c-terminus of one allele of POU5F1/OCT4 (PubMed=33799281) Group: Non-human primate cell line 127229378 CVCL_A7IR 46C-Dip2c KO embryonic stem cell house mouse CVCL_A7IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1920179; Dip2c; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 127229379 CVCL_A7IU UALGi002-A induced pluripotent stem cell human CVCL_A7IU From: Universidade do Algarve; Faro; Portugal CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Peripheral blood. Female 127229380 CVCL_A7IT SYSUe008-A embryonic stem cell human CVCL_A7IT From: Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24865; GPAM. Male 127229381 CVCL_A7IW PUMCSMi001-A induced pluripotent stem cell human CVCL_A7IW From: School of Basic Medicine, Peking Union Medical College; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127229382 CVCL_A7IV UALGi001-A induced pluripotent stem cell human CVCL_A7IV From: Universidade do Algarve; Faro; Portugal CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Peripheral blood. Male 127229383 CVCL_A7KK BCHi006-B induced pluripotent stem cell human CVCL_A7KK From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Asp471Glufs*37 (c.1412delA); Zygosity=Heterozygous (PubMed=33714067) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229384 CVCL_A7KJ BCHi006-A induced pluripotent stem cell human CVCL_A7KJ From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Asp471Glufs*37 (c.1412delA); Zygosity=Heterozygous (PubMed=33714067) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229385 CVCL_A7KM SCVIi007-A induced pluripotent stem cell human CVCL_A7KM From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg1712Gln (c.5135G>A); ClinVar=VCV000036642; Zygosity=Heterozygous (PubMed=34352619) Derived from sampling site: Peripheral blood. Male 127229386 CVCL_A7KL SCVIi006-A induced pluripotent stem cell human CVCL_A7KL From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Glu1356Lys (c.4066G>A); ClinVar=VCV000164294; Zygosity=Heterozygous (PubMed=34352619) Derived from sampling site: Peripheral blood. Male 127229387 CVCL_A7KN SCVIi008-A induced pluripotent stem cell human CVCL_A7KN From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg723Cys (c.2167C>T); ClinVar=VCV000014095; Zygosity=Heterozygous (PubMed=34352619) Derived from sampling site: Peripheral blood. Male 127229388 CVCL_A7KQ SCVIi010-A induced pluripotent stem cell human CVCL_A7KQ From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Ser624Cys (c.1870A>T); ClinVar=VCV000644725; Zygosity=Heterozygous (PubMed=34051449) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229389 CVCL_A7KP SCVIi009-A induced pluripotent stem cell human CVCL_A7KP From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Gly572Ser (c.1714G>A); ClinVar=VCV000067248; Zygosity=Heterozygous (PubMed=34051449) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 127229390 CVCL_A7KC BCHi002-B induced pluripotent stem cell human CVCL_A7KC From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Arg558Thrfs*9 (c.1671dupA) (c.1671_1672insA); ClinVar=VCV000156643; Zygosity=Heterozygous (PubMed=33714067) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229391 CVCL_A7KB BCHi002-A induced pluripotent stem cell human CVCL_A7KB From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Arg558Thrfs*9 (c.1671dupA) (c.1671_1672insA); ClinVar=VCV000156643; Zygosity=Heterozygous (PubMed=33714067) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229392 CVCL_A7KE BCHi003-B induced pluripotent stem cell human CVCL_A7KE From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Leu629Ter (c.1886T>A); Zygosity=Mosaic (PubMed=33714067) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229393 CVCL_A7KD BCHi003-A induced pluripotent stem cell human CVCL_A7KD From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Established from a patient that is mosaic for a CDKL5 p.Leu629Ter mutation, but this cell line does not contain this mutation 127229394 CVCL_A7KG BCHi004-B induced pluripotent stem cell human CVCL_A7KG From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Asp135Gly (c.404A>G); Zygosity=Mosaic (PubMed=33714067) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229395 CVCL_A7KF BCHi004-A induced pluripotent stem cell human CVCL_A7KF From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Established from a patient that is mosaic for a CDKL5 p.Asp135Gly mutation, but this cell line does not contain this mutation 127229396 CVCL_A7KI BCHi005-B induced pluripotent stem cell human CVCL_A7KI From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Arg550Ter (c.1648C>T); ClinVar=VCV000143780; Zygosity=Heterozygous (PubMed=33714067) Population: Latino or Hispanic; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229397 CVCL_A7KH BCHi005-A induced pluripotent stem cell human CVCL_A7KH From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Arg550Ter (c.1648C>T); ClinVar=VCV000143780; Zygosity=Heterozygous (PubMed=33714067) Population: Latino or Hispanic; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229398 CVCL_A7JZ BCHi001-A induced pluripotent stem cell human CVCL_A7JZ From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Simple; p.Val718Met (c.2152G>A); ClinVar=VCV000143796; Zygosity=Mosaic (PubMed=33714067) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229399 CVCL_A7JY TMPi009-B induced pluripotent stem cell human CVCL_A7JY From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229400 CVCL_A7KA BCHi001-B induced pluripotent stem cell human CVCL_A7KA From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Established from a patient that is mosaic for a CDKL5 p.Val718Met mutation, but this cell line does not contain this mutation 127229401 CVCL_A7JR TMPi005-B induced pluripotent stem cell human CVCL_A7JR From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229402 CVCL_A7JQ TMPi005-A induced pluripotent stem cell human CVCL_A7JQ From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229403 CVCL_A7JT TMPi006-B induced pluripotent stem cell human CVCL_A7JT From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229404 CVCL_A7JS TMPi006-A induced pluripotent stem cell human CVCL_A7JS From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229405 CVCL_A7JV TMPi007-B induced pluripotent stem cell human CVCL_A7JV From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229406 CVCL_A7JU TMPi007-A induced pluripotent stem cell human CVCL_A7JU From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 127229407 CVCL_A7JX TMPi009-A induced pluripotent stem cell human CVCL_A7JX From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229408 CVCL_A7JW TMPi008-A induced pluripotent stem cell human CVCL_A7JW From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229409 CVCL_A7XX 58F8dc1 hybridoma Norway rat CVCL_A7XX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P50489; Plasmodium falciparum (isolate Camp) apical membrane antigen 1 (AMA-1). 127229410 CVCL_A7XW 28G2dc1 hybridoma Norway rat CVCL_A7XW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P50489; Plasmodium falciparum (isolate Camp) apical membrane antigen 1 (AMA-1). 127229411 CVCL_A7XZ N1-2A8 hybridoma house mouse CVCL_A7XZ From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O96555; Plasmodium vivax ookinete surface protein (Pvs25). 127229412 CVCL_A7XY N1-1H10 hybridoma house mouse CVCL_A7XY From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O96555; Plasmodium vivax ookinete surface protein (Pvs25). 127229413 CVCL_A7XP BoMaMa-J2imm Tlr4-/- transformed cell line house mouse CVCL_A7XP From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229414 CVCL_A7XR BoMaMa-J2imm Tlr7-/- transformed cell line house mouse CVCL_A7XR From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2176882; Tlr7 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229415 CVCL_A7XQ BoMaMa-J2imm Tlr6-/- transformed cell line house mouse CVCL_A7XQ From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1341296; Tlr6 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229416 CVCL_A7XT BoMaMa-J2imm Tlr9-/- GFP transformed cell line house mouse CVCL_A7XT From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1932389; Tlr9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229417 CVCL_A7XS BoMaMa-J2imm Tlr9-/- transformed cell line house mouse CVCL_A7XS From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1932389; Tlr9 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229418 CVCL_A7XV 23A3dc1 hybridoma Norway rat CVCL_A7XV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50489; Plasmodium falciparum (isolate Camp) apical membrane antigen 1 (AMA-1). 127229419 CVCL_A7XU 19H8dc1 hybridoma Norway rat CVCL_A7XU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04934; Plasmodium falciparum (isolate Camp) merozoite surface protein 1 (MSP1). 127229420 CVCL_A7XH BoMaMa-J2imm Ticam2-/- transformed cell line house mouse CVCL_A7XH From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:3040056; Ticam2 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229421 CVCL_A7XG BoMaMa-J2imm Ticam1-/- Ticam2-/- transformed cell line house mouse CVCL_A7XG From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2147032; Ticam1; Knockout cell: Method=KO mouse; MGI; MGI:3040056; Ticam2 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229422 CVCL_A7XJ BoMaMa-J2imm Tlr1-/- transformed cell line house mouse CVCL_A7XJ From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1341295; Tlr1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229423 CVCL_A7XI BoMaMa-J2imm Tirap-/- transformed cell line house mouse CVCL_A7XI From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2152213; Tirap Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229424 CVCL_A7XL BoMaMa-J2imm Tlr2-/- Tlr4-/- transformed cell line house mouse CVCL_A7XL From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346060; Tlr2; Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229425 CVCL_A7XK BoMaMa-J2imm Tlr2-/- transformed cell line house mouse CVCL_A7XK From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346060; Tlr2 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229426 CVCL_A7XN BoMaMa-J2imm Tlr3-/- transformed cell line house mouse CVCL_A7XN From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2156367; Tlr3 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229427 CVCL_A7XM BoMaMa-J2imm Tlr2-/- Tlr9-/- transformed cell line house mouse CVCL_A7XM From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346060; Tlr2; Knockout cell: Method=KO mouse; MGI; MGI:1932389; Tlr9 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229428 CVCL_A7XB BoMaMa-J2imm Irf3-/- Irf7-/- transformed cell line house mouse CVCL_A7XB From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1859179; Irf3; Knockout cell: Method=KO mouse; MGI; MGI:1859212; Irf7 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229429 CVCL_A7XA BoMaMa-J2imm Irf3-/- transformed cell line house mouse CVCL_A7XA From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1859179; Irf3 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229430 CVCL_A7XD BoMaMa-J2imm Myd88-/- transformed cell line house mouse CVCL_A7XD From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229431 CVCL_A7XC BoMaMa-J2imm Irf7-/- transformed cell line house mouse CVCL_A7XC From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1859212; Irf7 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229432 CVCL_A7XF BoMaMa-J2imm Ticam1-/- transformed cell line house mouse CVCL_A7XF From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2147032; Ticam1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229433 CVCL_A7XE BoMaMa-J2imm Myd88-/- Ticam1-/- transformed cell line house mouse CVCL_A7XE From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88; Knockout cell: Method=KO mouse; MGI; MGI:2147032; Ticam1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229434 CVCL_A7YY 293/mNOD2 transformed cell line human CVCL_A7YY CL:0000010 Transfected with: MGI; MGI:2429397; Nod2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229435 CVCL_A7YX 293/hNOD2 transformed cell line human CVCL_A7YX CL:0000010 Transfected with: HGNC; 5331; NOD2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229436 CVCL_A7YZ HEK-Blue Null2-k transformed cell line human CVCL_A7YZ CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229437 CVCL_A7YQ HEK-Blue hNOD1 transformed cell line human CVCL_A7YQ CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 16390; NOD1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229438 CVCL_A7YP HEK-Blue Null1 transformed cell line human CVCL_A7YP CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229439 CVCL_A7YS HEK-Blue mNOD1 transformed cell line human CVCL_A7YS CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1341839; Nod1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229440 CVCL_A7YR HEK-Blue hNOD2 transformed cell line human CVCL_A7YR CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5331; NOD2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229441 CVCL_A7YU 293/Null transformed cell line human CVCL_A7YU CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229442 CVCL_A7YT HEK-Blue mNOD2 transformed cell line human CVCL_A7YT CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:2429397; Nod2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229443 CVCL_A7YW 293/mNOD1 transformed cell line human CVCL_A7YW CL:0000010 Transfected with: MGI; MGI:1341839; Nod1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229444 CVCL_A7YV 293/hNOD1 transformed cell line human CVCL_A7YV CL:0000010 Transfected with: HGNC; 16390; NOD1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229445 CVCL_A7YI 293-SARS2-S transformed cell line human CVCL_A7YI CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stable expression of the SARS-CoV-2 Spike protein For optimal expression, the C-terminal ER-retention signal has been removed. Has a functional furin cleavage site. Recommended for cell-cell fusion assays with ACE2-expressing cells (InVivoGen). Group: SARS-CoV-2 research cell line 127229446 CVCL_A7YH 297-17 hybridoma house mouse CVCL_A7YH CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Plasmodium sp thrombospondin-related anonymous protein (TRAP) (Note=Immunization with a synthetic peptide).. 127229447 CVCL_A7YK HEK-Blue hACE2 transformed cell line human CVCL_A7YK CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites Group: SARS-CoV-2 research cell line 127229448 CVCL_A7YJ 293-SARS2-S-dfur transformed cell line human CVCL_A7YJ CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stable expression of the SARS-CoV-2 Spike protein with an inactive furin (dfur) cleavage site facilitating improved surface expression and detection for flow cytometry For optimal expression, the C-terminal ER-retention signal has been removed (InVivoGen). Group: SARS-CoV-2 research cell line 127229449 CVCL_A7YM HEK-Blue Null2 transformed cell line human CVCL_A7YM CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229450 CVCL_A7YL HEK-Blue Null1-v transformed cell line human CVCL_A7YL CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229451 CVCL_A7YN HEK-Blue Null1-k transformed cell line human CVCL_A7YN CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 127229452 CVCL_A7YA N1-1A5 hybridoma house mouse CVCL_A7YA From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; A0A024V850; Plasmodium falciparum (isolate FVO) merozoite surface protein 1 (MSP1) (19 kDa fragment) (Note=Also reacts with isolate 3D7). 127229453 CVCL_A7YC S1-1G3 hybridoma CVCL_A7YC From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A024V850; Plasmodium falciparum (isolate FVO) merozoite surface protein 1 (MSP1) (42 kDa fragment). 127229454 CVCL_A7YB S1-1D7 hybridoma house mouse CVCL_A7YB From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A0A024V850; Plasmodium falciparum (isolate FVO) merozoite surface protein 1 (MSP1) (42 kDa fragment). 127229455 CVCL_A7YE S1-4A4 hybridoma house mouse CVCL_A7YE From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A024V850; Plasmodium falciparum (isolate FVO) merozoite surface protein 1 (MSP1) (42 kDa fragment). 127229456 CVCL_A7YD S1-3D6 hybridoma house mouse CVCL_A7YD From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A024V850; Plasmodium falciparum (isolate FVO) merozoite surface protein 1 (MSP1) (19 kDa fragment) (Note=Also reacts with isolate 3D7). 127229457 CVCL_A7YG 141-32 hybridoma house mouse CVCL_A7YG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium sp thrombospondin-related anonymous protein (TRAP) (Note=Immunization with a synthetic peptide).. 127229458 CVCL_A7YF 250-30 hybridoma house mouse CVCL_A7YF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium sp thrombospondin-related anonymous protein (TRAP) (Note=Immunization with a synthetic peptide).. 127229459 CVCL_A7VV N3-1D7 hybridoma house mouse CVCL_A7VV From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229460 CVCL_A7VU N3-1C8 hybridoma house mouse CVCL_A7VU From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229461 CVCL_A7VX N4-1F6 hybridoma house mouse CVCL_A7VX From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229462 CVCL_A7VW N3-2D9 hybridoma house mouse CVCL_A7VW From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229463 CVCL_A7VZ N4-2E3 hybridoma house mouse CVCL_A7VZ From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229464 CVCL_A7VY N4-1G6 hybridoma house mouse CVCL_A7VY From: Long C.A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KQK5; Plasmodium falciparum apical membrane antigen 1 (AMA-1). 127229465 CVCL_A7VN 4C1 [Mouse hybridoma against P.falciparum csp] hybridoma house mouse CVCL_A7VN CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229466 CVCL_A7VM 3D3 [Mouse hybridoma against P.falciparum csp] hybridoma house mouse CVCL_A7VM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229467 CVCL_A7VP 4C6 [Mouse hybridoma against P.falciparum csp] hybridoma house mouse CVCL_A7VP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229468 CVCL_A7VR 2F2 [Mouse hybridoma against P.vivax csp] hybridoma house mouse CVCL_A7VR CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08677; Plasmodium vivax circumsporozoite protein. 127229469 CVCL_A7VQ 2D4 [Mouse hybridoma against P.falciparum csp] hybridoma house mouse CVCL_A7VQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229470 CVCL_A7VT 2E10.2 hybridoma house mouse CVCL_A7VT CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08677; Plasmodium vivax circumsporozoite protein. 127229471 CVCL_A7VS LET1 transformed cell line house mouse CVCL_A7VS CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Virology: Supports spreading influenza virus infection in the absence of exogenous protease (PubMed=24243730) Doubling time: <24 hours (PubMed=24243730) 127229472 CVCL_A7VF SeGB spontaneously immortalized cell line CVCL_A7VF CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Can grow at temperatures ranging from 15 to 32 Celsius (DOI=10.3147/jsfp.56.22) Group: Fish cell line 127229473 CVCL_A7VE 3D11 [Mouse hybridoma against P.berghei csp] hybridoma house mouse CVCL_A7VE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06915; Plasmodium berghei circumsporozoite protein. 127229474 CVCL_A7VH SeGE-22 spontaneously immortalized cell line CVCL_A7VH CL:0000010 Unspecified Characteristics: Can grow at temperatures ranging from 25 to 32 Celsius (DOI=10.3147/jsfp.56.22). Group: Fish cell line 127229475 CVCL_A7VG SeGE-12 spontaneously immortalized cell line CVCL_A7VG CL:0000010 Unspecified Characteristics: Can grow at temperatures ranging from 25 to 32 Celsius (DOI=10.3147/jsfp.56.22). Group: Fish cell line 127229476 CVCL_A7VJ 2A10 hybridoma house mouse CVCL_A7VJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229477 CVCL_A7VI SeGF spontaneously immortalized cell line CVCL_A7VI CL:0000010 Derived from sampling site: Fin. Unspecified Characteristics: Can grow at temperatures ranging from 15 to 32 Celsius (DOI=10.3147/jsfp.56.22) Group: Fish cell line 127229478 CVCL_A7VL 3C2 [Mouse hybridoma against P.falciparum csp] hybridoma house mouse CVCL_A7VL CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229479 CVCL_A7VK 3C1 hybridoma house mouse CVCL_A7VK CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P02893; Plasmodium falciparum circumsporozoite protein. 127229480 CVCL_A7VB OUMS-15 transformed cell line human CVCL_A7VB CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. 127229481 CVCL_A7VA OUMS-14 transformed cell line human CVCL_A7VA CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 127229482 CVCL_A7VD 3D1 [Mouse hybridoma against monkeypox virus vCCI] hybridoma house mouse CVCL_A7VD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6YLY9; Monkeypox virus (strain MPXV_ZAI1979_005) CC-type chemokine-binding protein (vCCI). 127229483 CVCL_A7VC OUMS-17 transformed cell line human CVCL_A7VC CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a chronic lymphatic leukemia; Derived from sampling site: Peripheral blood. 127229484 CVCL_A7WW BrMi-J2imm Tlr9-/- transformed cell line house mouse CVCL_A7WW From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1932389; Tlr9 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229485 CVCL_A7WV BrMi-J2imm Tlr7-/- transformed cell line house mouse CVCL_A7WV From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2176882; Tlr7 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229486 CVCL_A7WY BoMaMa-J2imm Casp1-/- transformed cell line house mouse CVCL_A7WY From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96544; Casp1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229487 CVCL_A7WX BoMaMa-J2imm transformed cell line house mouse CVCL_A7WX From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229488 CVCL_A7WZ BoMaMa-J2imm Cd14-/- transformed cell line house mouse CVCL_A7WZ From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88318; Cd14 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. 127229489 CVCL_A7WN BrMi-J2imm Ticam1-/- transformed cell line house mouse CVCL_A7WN From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2147032; Ticam1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229490 CVCL_A7WQ BrMi-J2imm Tlr1-/- transformed cell line house mouse CVCL_A7WQ From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1341295; Tlr1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229491 CVCL_A7WP BrMi-J2imm Ticam2-/- transformed cell line house mouse CVCL_A7WP From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:3040056; Ticam2 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229492 CVCL_A7WS BrMi-J2imm Tlr3-/- transformed cell line house mouse CVCL_A7WS From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2156367; Tlr3 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229493 CVCL_A7WR BrMi-J2imm Tlr2-/- transformed cell line house mouse CVCL_A7WR From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346060; Tlr2 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229494 CVCL_A7WU BrMi-J2imm Tlr6-/- transformed cell line house mouse CVCL_A7WU From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1341296; Tlr6 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229495 CVCL_A7WT BrMi-J2imm Tlr4-/- transformed cell line house mouse CVCL_A7WT From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229496 CVCL_A7WG g12 hybridoma house mouse CVCL_A7WG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08505; Plasmodium berghei p23-like protein. 127229497 CVCL_A7WF c7 hybridoma house mouse CVCL_A7WF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium berghei 52 kDa phosphoprotein. 127229498 CVCL_A7WI L1.6 hybridoma house mouse CVCL_A7WI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q25645; Plasmodium berghei merozoite surface protein 1. 127229499 CVCL_A7WH F4.4 hybridoma house mouse CVCL_A7WH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q25645; Plasmodium berghei merozoite surface protein 1. 127229500 CVCL_A7WK BrMi-J2imm transformed cell line house mouse CVCL_A7WK From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229501 CVCL_A7WJ W3.5 hybridoma house mouse CVCL_A7WJ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Plasmodium berghei erythrocytic-stage exoantigen. 127229502 CVCL_A7WM BrMi-J2imm Myd88-/- Tirap-/- transformed cell line house mouse CVCL_A7WM From: Golenbock D.; The University of Massachusetts Medical School; Worcester; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88; Knockout cell: Method=KO mouse; MGI; MGI:2152213; Tirap Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229503 CVCL_A7WL BrMi-J2imm Myd88-/- Ticam1-/- transformed cell line house mouse CVCL_A7WL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88; Knockout cell: Method=KO mouse; MGI; MGI:2147032; Ticam1 Miscellaneous: As no real cell line name was provided, we assigned the name based on the abbreviation of its description Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.. 127229504 CVCL_A7WA em13.5 hybridoma house mouse CVCL_A7WA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P90574; Plasmodium chabaudi 93 kDa erythrocyte membrane protein (Pc(em)-93). 127229505 CVCL_A7WC em16.8 hybridoma house mouse CVCL_A7WC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium chabaudi 65 kDa erythrocyte membrane protein (Pc(em)-65). 127229506 CVCL_A7WB em16.3 hybridoma house mouse CVCL_A7WB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium chabaudi 65 kDa erythrocyte membrane protein (Pc(em)-65). 127229507 CVCL_A7WE b5 hybridoma house mouse CVCL_A7WE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08168; Plasmodium berghei 58 kDa phosphoprotein. 127229508 CVCL_A7WD em17.4 hybridoma house mouse CVCL_A7WD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium chabaudi 46 kDa erythrocyte membrane protein (Pc(em)-46). 127229509 CVCL_A7TT WIL2-A3 transformed cell line human CVCL_A7TT CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 127229510 CVCL_A7TS RPMI-7882 transformed cell line human CVCL_A7TS CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229511 CVCL_A7TV BA886 finite cell line CVCL_A7TV CL:0000010 Derived from sampling site: Aorta; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (CelloPub=CLPUB00632); Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) 127229512 CVCL_A7TU 1H8 [Mouse hybridoma against human BMSC] hybridoma house mouse CVCL_A7TU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human 80 kDa protein on bone marrow stromal cells. 127229513 CVCL_A7TX BPA987 finite cell line CVCL_A7TX CL:0000010 Derived from sampling site: Lung; artery; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (CelloPub=CLPUB00632) 127229514 CVCL_A7TW BA987 finite cell line CVCL_A7TW CL:0000010 Derived from sampling site: Aorta; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (CelloPub=CLPUB00632; PubMed=8300237) 127229515 CVCL_A7TZ Bushpig 1194 finite cell line CVCL_A7TZ CL:0000010 Derived from sampling site: Aorta; endothelium. Male Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=9577776) 127229516 CVCL_A7TY Buffalo 595 finite cell line CVCL_A7TY CL:0000010 Derived from sampling site: Aorta; endothelium. Female Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=9577776) 127229517 CVCL_A7TL RPMI-7712 transformed cell line human CVCL_A7TL CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229518 CVCL_A7TK RPMI-7662 transformed cell line human CVCL_A7TK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229519 CVCL_A7TN RPMI-7722 transformed cell line human CVCL_A7TN CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229520 CVCL_A7TM RPMI-7762 transformed cell line human CVCL_A7TM CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229521 CVCL_A7TP RPMI-7672 transformed cell line human CVCL_A7TP CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229522 CVCL_A7TR RPMI-7912 transformed cell line human CVCL_A7TR CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229523 CVCL_A7TQ RPMI-7822 transformed cell line human CVCL_A7TQ CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229524 CVCL_A7TD RPMI-7572 transformed cell line human CVCL_A7TD CL:0000010 Karyotypic information: 47,XY,+21; 48,XY,+21+C (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229525 CVCL_A7TC RPMI-7492 transformed cell line human CVCL_A7TC CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229526 CVCL_A7TF RPMI-7532 transformed cell line human CVCL_A7TF CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229527 CVCL_A7TE RPMI-7852 transformed cell line human CVCL_A7TE CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229528 CVCL_A7TH RPMI-7542 transformed cell line human CVCL_A7TH CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229529 CVCL_A7TG RPMI-7732 transformed cell line human CVCL_A7TG CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229530 CVCL_A7TJ RPMI-7592 transformed cell line human CVCL_A7TJ CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229531 CVCL_A7TI RPMI-7582 transformed cell line human CVCL_A7TI CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229532 CVCL_A7SZ RPMI-7462 transformed cell line human CVCL_A7SZ CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229533 CVCL_A7TB RPMI-8092 transformed cell line human CVCL_A7TB CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229534 CVCL_A7TA RPMI-7552 transformed cell line human CVCL_A7TA CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229535 CVCL_A7UU B-LCL-HROC68 transformed cell line human CVCL_A7UU HLA typing: A*02:01:01,29:02:01; B*13:02:01,47:03:01; C*06:02:01,16:01:01; DPB1*01:01:01,04:01:01; DQA1*02:01:01; DQB1*02:02:01; DRB1*07:01:01 (CLS=302078) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229536 CVCL_A7UT B-LCL-HROC60 transformed cell line human CVCL_A7UT HLA typing: A*02:01:01,11:01:01; B*20:02:01,55:01:01; C*03:03:01,05:01:01; DPB1*04:01:01; DQA1*01:01:01,01:03:01; DQB1*05:01:01,06:03:01; DRB1*01:01:01,13:01:01 (CLS=302004) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229537 CVCL_A7UW A549-hACE2 (HA-FLAG) cancer cell line human CVCL_A7UW From: Garcia-Sastre A.; The Icahn School of Medicine at Mount Sinai Medical School; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expresses ACE2 with C-terminal HA and FLAG tags under the control the CMV promoter (BEI_Resources) Group: SARS-CoV-2 research cell line 127229538 CVCL_A7UV A549-hACE2 [BEI resources] cancer cell line human CVCL_A7UV From: Baric R.; Department of Epidemiology, University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expresses ACE2 under the control of the EF1a promoter (BEI_Resources) Group: SARS-CoV-2 research cell line 127229539 CVCL_A7UY DBT piD-2 transformed cell line house mouse CVCL_A7UY CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: BALB/c x DBA/2. Female Virology: Persistently infected by mouse hepatitis virus (MHV) strain JHM (PubMed=8593285) 127229540 CVCL_A7UX DBT piD-10 transformed cell line house mouse CVCL_A7UX CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: BALB/c x DBA/2. Female Virology: Persistently infected by mouse hepatitis virus (MHV) strain JHM (PubMed=8593285) 127229541 CVCL_A7UZ DBT piD-3 transformed cell line house mouse CVCL_A7UZ CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: BALB/c x DBA/2. Female Virology: Persistently infected by mouse hepatitis virus (MHV) strain JHM (PubMed=8593285) 127229542 CVCL_A7UM B-LCL-HROC102 transformed cell line human CVCL_A7UM From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229543 CVCL_A7UL B-LCL-HROC278 transformed cell line human CVCL_A7UL HLA typing: A*01:03:01,25:01:01; B*07:02:01,18:01:01; C*07:02:01,12:03:01; DPB1*02:01:02,04:01:02; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:02:01; DRB1*04:01:01,15:01:01 (CLS=302051) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229544 CVCL_A7UN B-LCL-HROC43 transformed cell line human CVCL_A7UN HLA typing: A*01:01:01,02:01:01; B*15:01:01,37:01:01; C*03:03:01,06:02:01; DPB1*01:01:01,05:01:01; DQA1*01:05:01,05:05:01; DQB1*03:01:01,05:01:01; DRB1*10:01:01,12:01:01 (CLS=302067) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229545 CVCL_A7UQ B-LCL-HROC50 transformed cell line human CVCL_A7UQ HLA typing: A*02:01:01,03:01:01; B*07:02:01,27:01:01; C*06:02:01,07:02:01; DPB1*04:01:01; DQA1*01:02:01,02:01:01; DQB1*03:03:02,06:02:01; DRB1*07:01:01,15:01:01 (CLS=302069) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229546 CVCL_A7UP B-LCL-HROC46 transformed cell line human CVCL_A7UP HLA typing: A*01:01:01,02:01:01; B*07:02:01,08:01:01; C*07:01:01,07:02:01; DPB1*01:01:01,19:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01 (CLS=302068) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229547 CVCL_A7US B-LCL-HROC59 transformed cell line human CVCL_A7US HLA typing: A*03:01:01,24:02:01; B*01:02:01,27:05:02; C*02:02:02,07:02:01; DPB1*04:01:01,14:01:01; DQA1*01:02:01,03:03:01; DQB1*03:02:01,06:02:01; DRB1*04:01:01,15:01:01 (CLS=302073) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229548 CVCL_A7UR B-LCL-HROC57 transformed cell line human CVCL_A7UR HLA typing: A*01:01:01,02:01:01; B*08:01:01,27:01:01; C*06:02:01,07:01:01; DPB1*02:01:02,04:01:01; DQA1*02:01:01,05:01:01; DQB1*02:01:01,03:03:02; DRB1*03:01:01,07:01:01 (CLS=302072) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229549 CVCL_A7UE BPA593/1 finite cell line CVCL_A7UE CL:0000010 Derived from sampling site: Lung; artery; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=8300237) 127229550 CVCL_A7UD BPA291 finite cell line CVCL_A7UD CL:0000010 Derived from sampling site: Lung; artery; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=8300237) 127229551 CVCL_A7UG BSV-793 finite cell line CVCL_A7UG CL:0000010 Derived from sampling site: Limb; saphenous vein Cell type=Endothelial cell.. 127229552 CVCL_A7UF SBE-189 finite cell line CVCL_A7UF CL:0000010 Derived from sampling site: Brain; microvascular endothelium Cell type=Endothelial cell.. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (CelloPub=CLPUB00633) 127229553 CVCL_A7UI Vero-Luc2p spontaneously immortalized cell line green monkey CVCL_A7UI CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney; epithelium. Biotechnology: Used in a quantitative and sensitive luciferase-based assay for bacterial toxins that inhibit protein synthesis (PubMed=20585113) Female Characteristics: Stably expresses luciferase Luc2p which is tagged with a PEST sequence which promotes rapid turnover Therefore, luciferase activity reflects the current level of protein synthesis (PubMed=20585113).; Characteristics: Transduced with a Luc2P-IRES-eGFP construct Group: Non-human primate cell line 127229554 CVCL_A7UH E5 finite cell line CVCL_A7UH CL:0000010 Derived from sampling site: Umbilical cord Cell type=Endothelial cell.. Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=3329310; PubMed=3900854) 127229555 CVCL_A7UK HEK-293T-hACE2 transformed cell line human CVCL_A7UK CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses ACE2 under the control of the EF1a promoter (BEI_Resources) Group: SARS-CoV-2 research cell line 127229556 CVCL_A7UJ Vero E6-high ACE2 spontaneously immortalized cell line green monkey CVCL_A7UJ CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Obtained by sorting Vero E6 cells for cells expressing high levels of endogenous ACE2; Characteristics: Application in SARS-CoV-2 research Group: Non-human primate cell line 127229557 CVCL_A7UA Sable 1194 finite cell line CVCL_A7UA CL:0000010 Derived from sampling site: Lung; artery; endothelium. Female Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=9577776) 127229558 CVCL_A7UC BPA191 finite cell line CVCL_A7UC CL:0000010 Derived from sampling site: Lung; artery; endothelium. Unspecified Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=8300237) 127229559 CVCL_A7UB Eland 895 finite cell line CVCL_A7UB CL:0000010 Derived from sampling site: Aorta; endothelium. Female Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=9577776) 127229560 CVCL_A7RR FHNG-00 transformed cell line human CVCL_A7RR HLA typing: A*23:01:01,24:39; B*44:03:01:01,40:02:01; C*04:01:01:01,02:02:02:01; DPA1*01:03:01:01,02:01:01:02; DPB1*16:01:01,10:01:01; DQA1*03:01:01,05:05:01; DQB1*03:05:01,03:01:01:03; DRB1*04:03:01,11:01:01:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229561 CVCL_A7RQ FHSL-00 transformed cell line human CVCL_A7RQ HLA typing: A*30:02:01:01; B*07:02:01,35:01:01:02; C*07:02:01:03,04:01:01:01; DPA1*01:03:01:01,01:03:01:04; DPB1*04:01:01:01,02:01:02; DQA1*01:02:01; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229562 CVCL_A7RT FHNG-01 transformed cell line human CVCL_A7RT HLA typing: A*24:39,29:02:01:01; B*15:17:01:01,40:02:01; C*07:01:02,02:02:02:01; DPA1*01:03:01:01; DPB1*02:01:02,16:01:01; DQA1*01:02:01,05:05:01; DQB1*06:04:01,03:01:01:03; DRB1*13:02:01,11:01:01:01; DRB3*03:01:01,02:02:01:02 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229563 CVCL_A7RS FHES-00 transformed cell line human CVCL_A7RS HLA typing: A*02:01:01:01,24:02:01:01; B*35:01:01:02,35:12:01; C*04:01:01:01; DPA1*01:03:01:05; DPB1*04:02:01:02; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:07:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229564 CVCL_A7RV WAe009-A-62 embryonic stem cell human CVCL_A7RV From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6294; KCNQ1. Female 127229565 CVCL_A7RU FHES-01 transformed cell line human CVCL_A7RU HLA typing: A*68:03:01,02:01:01:01; B*40:02:01; C*03:05,02:02:02:01; DPA1*01:03:01:04,02:02:02; DPB1*02:01:02,05:01:01; DQA1*03:01:01,05:05:01; DQB1*03:02:01,03:01:01:03; DRB1*04:07:01,11:01:01:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229566 CVCL_A7RX WAe009-A-59 embryonic stem cell human CVCL_A7RX From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4808; HAND2. Female 127229567 CVCL_A7RW WAe009-A-61 embryonic stem cell human CVCL_A7RW From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12010; TPM1. Female 127229568 CVCL_A7RJ LEO-10 transformed cell line human CVCL_A7RJ HLA typing: A*03:01:01:01; B*07:02:01; C*07:02:01:03; DPA1*01:03:01:02; DPB1*04:01:01:01; DQA1*01:02:01; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229569 CVCL_A7RI AL-10 transformed cell line human CVCL_A7RI HLA typing: A*26:01:01:01; B*38:01:01; C*12:03:01:01; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:02:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229570 CVCL_A7RL FHBN transformed cell line human CVCL_A7RL HLA typing: A*02:01:01:01; B*15:01:01:01,44:03:01:01; C*03:03:01:01,04:09N; DPA1*01:03:01:01,01:03:01:02; DPB1*04:01:01:01(350:01),13:01:01; DQA1*02:01:01,01:02:01; DQB1*02:02:01:01,06:02:01; DRB1*07:01:01,15:01:01; DRB4*01:01:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229571 CVCL_A7RK FH90 transformed cell line human CVCL_A7RK HLA typing: A*11:01:01:01,26:01:01:01; B*35:01:01:02; C*08:01:01; C*03:03:01:01; DPA1*02:02:02,01:03:01:01; DPB1*05:01:01,02:01:02; DQA1*05:03,01:04:01; DQB1*03:01:01:01,05:03:01; DRB1*14:03:01,14:07:01; DRB3*01:01:02,02:02:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229572 CVCL_A7RN FHJQ-01 transformed cell line human CVCL_A7RN HLA typing: A*24:02:01:02L,01:01:01:01; B*37:01:01,08:01:01:01; C*01:02:01,07:01:01:01; DPA1*01:03:01:02,02:01:02; DPB1*04:01:01:01,01:01:01; DQA1*03:03:01:01,05:01:01:02; DQB1*03:01:01:01,02:01:01; DRB1*04:07:01,03:01:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229573 CVCL_A7RM FHJQ-00 transformed cell line human CVCL_A7RM HLA typing: A*24:02:01:02L,02:01:01:01; B*37:01:01,07:02:01; C*01:02:01,07:02:01:03; DPA1*01:03:01:01,01:03:01:02; DPB1*04:01:01:01,02:01:02; DQA1*03:03:01:01,05:05:01; DQB1*03:01:01:01,03:01:01:03; DRB1*04:07:01,11:01:01:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229574 CVCL_A7RP FHSL-01 transformed cell line human CVCL_A7RP HLA typing: A*11:01:01:01; B*07:02:01; C*07:02:01:03; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*01:02:01,03:03:01:01; DQB1*06:02:01,03:01:01:01; DRB1*15:01:01,04:01:01; DRB4*01:03:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229575 CVCL_A7RB FH81 transformed cell line human CVCL_A7RB HLA typing: A*01:01:01:01,02:01:01:01; B*40:02:01,07:05:01:01; C*02:02:02:01,15:23; DPA1*01:03:01:04,01:03:01:05; DPB1*04:02:01:01(105:01),04:01:01:01(126:01); DQA1*01:02:02,05:05:01; DQB1*05:02:01,03:01:01:03; DRB1*16:02:01:02,01:03; DRB5*02:02 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229576 CVCL_A7RA FH80 transformed cell line human CVCL_A7RA HLA typing: A*02:01:01:01,02:03:01; B*40:01:02; C*03:17,07:02:01:01; DPA1*02:02:02; DPB1*135:01,05:01:01; DQA1*01:04:01,03:02; DQB1*05:03:01,03:03:02; DRB1*14:54:01,09:01:02; DRB3*02:02:01:01; DRB4*01:03:02 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229577 CVCL_A7RD FH83 transformed cell line human CVCL_A7RD HLA typing: A*02:01:01:01; B*07:02:01,40:02:01; C*07:02:01:03,02:06:01; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*01:02:01; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229578 CVCL_A7RC FH82 transformed cell line human CVCL_A7RC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229579 CVCL_A7RF FH86 transformed cell line human CVCL_A7RF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229580 CVCL_A7RE FH85 transformed cell line human CVCL_A7RE HLA typing: A*03:01:01:01,32:01:01; B*18:01:01:02,40:02:01; C*07:01:01:01,15:02:01:02; DPA1*01:03:01:02,02:02:02; DPB1*04:02:01:02(105:01),04:01:01:01(126:01); DQA1*05:05:01,03:01:01; DQB1*03:01:01:03,03:02:01; DRB1*11:01:01:01,04:03:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229581 CVCL_A7RH FH89 transformed cell line human CVCL_A7RH HLA typing: A*02:01:01:01; B*15:01:01:01; C*03:04:01:01; DPA1*01:03:01:02,01:03:01:03; DPB1*03:01:01(124:01),04:01:01:01(350:01); DQA1*03:01:01; DQB1*03:02:01; DRB1*04:01:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229582 CVCL_A7RG FH87 transformed cell line human CVCL_A7RG HLA typing: A*02:01:01:01,01:01:01:01; B*40:02:01,08:01:01:01; C*15:02:01:02,07:01:01:01; DPA1*01:03:01:01; DPB1*02:01:02; DQA1*02:01:01,05:01:01:02; DQB1*02:02:01:01,02:01:01; DRB1*07:01:01,03:01:01; DRB3*01:01:02; DRB4*01:01:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229583 CVCL_A7QY M-4581 finite cell line human CVCL_A7QY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127229584 CVCL_A7QX M-3773 finite cell line human CVCL_A7QX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 127229585 CVCL_A7QZ FH79 transformed cell line human CVCL_A7QZ HLA typing: A*11:01:01:01,02:01:01:01; B*18:01:01:02,50:01:01; C*07:36,06:02:01:02; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*05:05:01,02:01:01; DQB1*03:01:01:03,02:02:01:01; DRB1*11:01:01:01,07:01:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 127229586 CVCL_A7SS UM-55 transformed cell line human CVCL_A7SS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229587 CVCL_A7SR UM-3 [Human LCL] transformed cell line human CVCL_A7SR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229588 CVCL_A7SU UM-39 transformed cell line human CVCL_A7SU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229589 CVCL_A7ST UM-56 transformed cell line human CVCL_A7ST CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229590 CVCL_A7SW UM-11 transformed cell line human CVCL_A7SW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229591 CVCL_A7SV UM-10 transformed cell line human CVCL_A7SV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229592 CVCL_A7SY RPMI-7402 transformed cell line human CVCL_A7SY CL:0000010 Karyotypic information: 47,XY,+21; 46,XY (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229593 CVCL_A7SX RPMI-7422 transformed cell line human CVCL_A7SX CL:0000010 Karyotypic information: 47,XY,+21 (PubMed=4266330); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229594 CVCL_A7SK OUMS-9 transformed cell line human CVCL_A7SK CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Lymph node. Male 127229595 CVCL_A7SJ OUMS-8 transformed cell line human CVCL_A7SJ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Male 127229596 CVCL_A7SM OUMS-11A transformed cell line human CVCL_A7SM CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from subacute myelo-optico-neuropathy; Derived from sampling site: Peripheral blood. Female 127229597 CVCL_A7SL OUMS-10 transformed cell line human CVCL_A7SL CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Lymph node. Male 127229598 CVCL_A7SN OUMS-11B transformed cell line human CVCL_A7SN CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from subacute myelo-optico-neuropathy; Derived from sampling site: Peripheral blood. Female 127229599 CVCL_A7SQ OUMS-13 transformed cell line human CVCL_A7SQ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from subacute myelo-optico-neuropathy; Derived from sampling site: Peripheral blood. Female 127229600 CVCL_A7SP OUMS-12 transformed cell line human CVCL_A7SP CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Peripheral blood. Male 127229601 CVCL_A7SC OUMS-21 [1972] transformed cell line human CVCL_A7SC CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Caution: Two cell lines named OUMS-21 have been created at Okayama University Medical School, one in 1972 from the peripheral blood of a normal adult donor (Cellosaurus=CVCL_A7SC) and one in 1993 from the SV40-transformed liver of a fetus (Cellosaurus=CVCL_9131) 127229602 CVCL_A7SB OUMS-20 transformed cell line human CVCL_A7SB CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229603 CVCL_A7SE OUMS-3 transformed cell line human CVCL_A7SE CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229604 CVCL_A7SD OUMS-22 [1972] transformed cell line human CVCL_A7SD CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Two cell lines named OUMS-22 have been created at Okayama University Medical School, one in 1972 from the peripheral blood of a normal adult donor (Cellosaurus=CVCL_A7SD) and one in 1993 from the SV40-transformed liver of a fetus (Cellosaurus=CVCL_9132) 127229605 CVCL_A7SG OUMS-5 transformed cell line human CVCL_A7SG CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229606 CVCL_A7SF OUMS-4 transformed cell line human CVCL_A7SF CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229607 CVCL_A7SI OUMS-7 transformed cell line human CVCL_A7SI CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from subacute myelo-optico-neuropathy; Derived from sampling site: Peripheral blood. Female 127229608 CVCL_A7SH OUMS-6 transformed cell line human CVCL_A7SH CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Lymph node. Male 127229609 CVCL_A7RZ LUMCi046-A-1 induced pluripotent stem cell human CVCL_A7RZ From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple_edited; c.-3A>G; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34688992); Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple_corrected; p.Met1Arg (c.2T>G); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34688992) Population: Chilean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229610 CVCL_A7RY LUMCi045-A-1 induced pluripotent stem cell human CVCL_A7RY From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple_corrected; p.Met1Arg (c.2T>G); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34688992); Sequence variation: Mutation; HGNC; 25947; KLHL24; Simple_edited; p.Val2Val (c.6A>C); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34688992) Population: Chilean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229611 CVCL_A7SA OUMS-18 transformed cell line human CVCL_A7SA CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229612 CVCL_A7AA HeLa M KIF13B-KO cancer cell line human CVCL_A7AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14405; KIF13B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229613 CVCL_A7AC R15_Spike hybridoma house mouse CVCL_A7AC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229614 CVCL_A7AB HeLa M KIF13A/B-DKO cancer cell line human CVCL_A7AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14566; KIF13A; Knockout cell: Method=CRISPR/Cas9; HGNC; 14405; KIF13B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229615 CVCL_A7AE R31_Spike hybridoma house mouse CVCL_A7AE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229616 CVCL_A7AD R22_Spike hybridoma house mouse CVCL_A7AD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229617 CVCL_A7AG S1D7_Spike hybridoma house mouse CVCL_A7AG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229618 CVCL_A7AF R52_Spike hybridoma house mouse CVCL_A7AF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229619 CVCL_A6ZZ HeLa M KIF13A-KO cancer cell line human CVCL_A6ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14566; KIF13A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229620 CVCL_A6ZS 40LB spontaneously immortalized cell line house mouse CVCL_A6ZS CL:0000010 Transfected with: MGI; MGI:1344376; Tnfsf13b; Transfected with: MGI; MGI:88337; Cd40lg; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Can be used as feeder cells for B cell culture Support efficient proliferation and survival of B cells (PubMed=21897376). 127229621 CVCL_A6ZR 3T3/40L spontaneously immortalized cell line house mouse CVCL_A6ZR CL:0000010 Transfected with: MGI; MGI:88337; Cd40lg; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 127229622 CVCL_A6ZU T49-25 hybridoma house mouse CVCL_A6ZU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15197; Human EPHB6. 127229623 CVCL_A6ZT ABC-31 cancer cell line human CVCL_A6ZT CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (PubMed=33829270) Population: Japanese; Derived from metastatic site: Pleural effusion. Female Characteristics: Resistant to the tyrosine kinase inhibitor osimertinib Has activated IGF1R (PubMed=33829270). 127229624 CVCL_A6ZW KM2048 hybridoma CVCL_A6ZW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15197; Human EPHB6. 127229625 CVCL_A6ZV KM1978 hybridoma CVCL_A6ZV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15197; Human EPHB6. 127229626 CVCL_A6ZY HeLa M Rab8-DKO cancer cell line human CVCL_A6ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Knockout cell: Method=CRISPR/Cas9; HGNC; 30273; RAB8B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229627 CVCL_A6ZX KM2051 hybridoma CVCL_A6ZX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15197; Human EPHB6. 127229628 CVCL_A6ZK id5P cancer cell line Norway rat CVCL_A6ZK CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male 127229629 CVCL_A6ZJ d5krm3 cancer cell line Norway rat CVCL_A6ZJ CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male Characteristics: Highly metastatic activity to lung by intracapsular transplantation (RCB) 127229630 CVCL_A6ZM id5krm7 cancer cell line Norway rat CVCL_A6ZM CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male Characteristics: Highly metastatic activity to lung by intracapsular transplantation (RCB) 127229631 CVCL_A6ZL id5krm3 cancer cell line Norway rat CVCL_A6ZL CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male Characteristics: Highly metastatic activity to lung by intracapsular transplantation (RCB) 127229632 CVCL_A6ZN BD1B hybridoma CVCL_A6ZN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9R100; Mouse Cdh17. 127229633 CVCL_A6ZQ MOMA-2 [Mouse/rat hybridoma against mouse macrophages and monocytes] hybridoma CVCL_A6ZQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse macrophages and monocytes intracellular antigen. 127229634 CVCL_A6ZP MOMA-1 [Mouse/rat hybridoma against mouse Siglec1] hybridoma CVCL_A6ZP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q62230; Mouse Siglec1/Cd169. 127229635 CVCL_A6ZC AQP4(E5505-3D12-129) hybridoma house mouse CVCL_A6ZC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229636 CVCL_A6ZB AQP4(E5504-2G2-105) hybridoma house mouse CVCL_A6ZB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229637 CVCL_A6ZE DP2(D5203-1D8-31) hybridoma house mouse CVCL_A6ZE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9Z2J6; Mouse Ptgdr2. 127229638 CVCL_A6ZD AQP4(E5507-3A1-113) hybridoma house mouse CVCL_A6ZD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229639 CVCL_A6ZF BLG-139-3 factor-dependent cell line house mouse CVCL_A6ZF CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: Transfected with a LexA-d1EGFP reporter that consists of 8 tandem copies of a LexA binding element, a minimal promoter from mouse Ifnb and d1EGFP (destabilized EGFP) (PubMed=15225556) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 127229640 CVCL_A6ZI d5krm7 cancer cell line Norway rat CVCL_A6ZI CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male Characteristics: Highly metastatic activity to lung by intracapsular transplantation (RCB) 127229641 CVCL_A6ZH rRCCd5 cancer cell line Norway rat CVCL_A6ZH CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Derived from sampling site: Kidney; renal tubule; Breed/subspecies: Wistar Crlj:WI. Male 127229642 CVCL_A6XY Cys-SN2(N3323) hybridoma house mouse CVCL_A6XY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9ULM6; Human CNOT6. 127229643 CVCL_A6XX Cys-SN2(N3316) hybridoma house mouse CVCL_A6XX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229644 CVCL_A6XZ Cys-SN2(N3331) hybridoma house mouse CVCL_A6XZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229645 CVCL_A6XQ LCHi002-B induced pluripotent stem cell human CVCL_A6XQ From: Lurie Children's Hospital of Chicago; Chicago; USA. CL:0000010 127229646 CVCL_A6XP LCHi002-A induced pluripotent stem cell human CVCL_A6XP From: Lurie Children's Hospital of Chicago; Chicago; USA CL:0000010 Discontinued: hPSCreg; LCHi002-A; true. 127229647 CVCL_A6XS UNINAi001-B induced pluripotent stem cell human CVCL_A6XS From: University of Naples Federico II; Napoli; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6297; KCNQ3; Simple; p.Phe534Ilefs*15 (c.1599dupT); ClinVar=VCV000205978; Zygosity=Homozygous (from autologous cell line UNINAi001-A) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229648 CVCL_A6XR UNINAi001-A induced pluripotent stem cell human CVCL_A6XR From: University of Naples Federico II; Napoli; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6297; KCNQ3; Simple; p.Phe534Ilefs*15 (c.1599dupT); ClinVar=VCV000205978; Zygosity=Homozygous (PubMed=33799276) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229649 CVCL_A6XU CCR4aN(Y6206) hybridoma house mouse CVCL_A6XU CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9ULM6; Human CNOT6. 127229650 CVCL_A6XT UNINAi002-A induced pluripotent stem cell human CVCL_A6XT From: University of Naples Federico II; Napoli; Italy CL:0000010 Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 127229651 CVCL_A6XW Cys-SN2(N3312) hybridoma house mouse CVCL_A6XW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229652 CVCL_A6XV Cys-SN2(N3306) hybridoma house mouse CVCL_A6XV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229653 CVCL_A6XI WTC-mEGFP-EZH2-cl18 induced pluripotent stem cell human CVCL_A6XI CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 EZH2 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 127229654 CVCL_A6XH WTC-mEGFP-POLR2A-cl74 induced pluripotent stem cell human CVCL_A6XH CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 POLR2A has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 127229655 CVCL_A6XK CSUi003-A induced pluripotent stem cell human CVCL_A6XK From: Central South University; Changsha; China CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229656 CVCL_A6XJ CSUi002-A induced pluripotent stem cell human CVCL_A6XJ From: Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (PubMed=33706202) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 127229657 CVCL_A6XM LCHi001-A induced pluripotent stem cell human CVCL_A6XM From: Lurie Children's Hospital of Chicago; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Ile900Phe (c.2698A>T); ClinVar=VCV000464801; Zygosity=Hemizygous (PubMed=34233262) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 127229658 CVCL_A6XL CSUi004-A induced pluripotent stem cell human CVCL_A6XL From: Central South University; Changsha; China CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 127229659 CVCL_A6XN LCHi001-B induced pluripotent stem cell human CVCL_A6XN From: Lurie Children's Hospital of Chicago; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Ile900Phe (c.2698A>T); ClinVar=VCV000464801; Zygosity=Hemizygous (PubMed=34233262) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 127229660 CVCL_A6XA NCD-2 hybridoma CVCL_A6XA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10288; Chicken CDH2 (Note=Also reacts with Xenopus). 127229661 CVCL_A6XC HAM1C transformed cell line human CVCL_A6XC CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Characteristics: IL2 dependent 127229662 CVCL_A6XB PCD-1 hybridoma CVCL_A6XB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10287; Mouse Cdh3. 127229663 CVCL_A6XE USFi002-A induced pluripotent stem cell human CVCL_A6XE From: University of South Florida; Tampa; USA CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Simple; p.Asp2116Argfs*37 (c.6345_6352del); ClinVar=VCV000959711; Zygosity=Heterozygous (PubMed=34088019) Population: African American; Derived from sampling site: Peripheral blood. Male 127229664 CVCL_A6XD USFi001-A induced pluripotent stem cell human CVCL_A6XD From: University of South Florida; Tampa; USA CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[781]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=34034220); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1092]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=34034220) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 127229665 CVCL_A6XG USFi004-A induced pluripotent stem cell human CVCL_A6XG From: University of South Florida; Tampa; USA CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Asp600Valfs*56 (c.1799delA); ClinVar=VCV000202020; Zygosity=Heterozygous (PubMed=34034221) Population: Caribbean; Haitian and Caucasian; Derived from sampling site: Peripheral blood. Female 127229666 CVCL_A6XF USFi003-A induced pluripotent stem cell human CVCL_A6XF From: University of South Florida; Tampa; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg541Cys (c.1621C>T); ClinVar=VCV000048046; Zygosity=Heterozygous (PubMed=34029931) Population: Hispanic; Derived from sampling site: Peripheral blood. Female 127229667 CVCL_A6YZ AQP4(E5415A-1H6-68) hybridoma house mouse CVCL_A6YZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229668 CVCL_A6YY AQP4(E5413-1G11-49) hybridoma house mouse CVCL_A6YY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229669 CVCL_A6ZA AQP4(E5415B-1H7-79) hybridoma house mouse CVCL_A6ZA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229670 CVCL_A6YR CHO hAQP4-M1 spontaneously immortalized cell line CVCL_A6YR CL:0000010 Transfected with: HGNC; 637; AQP4 (isoform M1); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127229671 CVCL_A6YQ AQP4(D15107-3D7-33) hybridoma house mouse CVCL_A6YQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P55087; Human AQP4 (isoform M23) (Note=Also reacts with mouse). 127229672 CVCL_A6YT CHO hAQP4-M23 spontaneously immortalized cell line CVCL_A6YT CL:0000010 Transfected with: HGNC; 637; AQP4 (isoform M23); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127229673 CVCL_A6YS CHO hAQP4-M1/M23 spontaneously immortalized cell line CVCL_A6YS CL:0000010 Transfected with: HGNC; 637; AQP4 (isoform M1); Transfected with: HGNC; 637; AQP4 (isoform M23); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 127229674 CVCL_A6YV AQP4(D12092-1C3-02) hybridoma house mouse CVCL_A6YV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55087; Human AQP4 (isoform M23). 127229675 CVCL_A6YU AQP4(C9401-A3-29) hybridoma house mouse CVCL_A6YU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55087; Human AQP4 (isoform M23). 127229676 CVCL_A6YX AQP4(E5209-1C8-22) hybridoma house mouse CVCL_A6YX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23). 127229677 CVCL_A6YW AQP4(E5206-1B10-8) hybridoma house mouse CVCL_A6YW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P55088; Mouse Aqp4 (isoform M23) (Note=Also reacts with human). 127229678 CVCL_A6YJ Glut1(D4418-30) hybridoma house mouse CVCL_A6YJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229679 CVCL_A6YI Glut1(D4402-6) hybridoma house mouse CVCL_A6YI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229680 CVCL_A6YL hTobC(Y5432) hybridoma house mouse CVCL_A6YL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P50616; Human TOB1. 127229681 CVCL_A6YK Glut1(D4404-9) hybridoma house mouse CVCL_A6YK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229682 CVCL_A6YN hTobC(Y5444) hybridoma house mouse CVCL_A6YN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P50616; Human TOB1. 127229683 CVCL_A6YM hTobC(Y5443) hybridoma house mouse CVCL_A6YM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P50616; Human TOB1. 127229684 CVCL_A6YP hTobC(Y5452) hybridoma house mouse CVCL_A6YP CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P50616; Human TOB1. 127229685 CVCL_A6YB Cys-SN2(N3349) hybridoma house mouse CVCL_A6YB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229686 CVCL_A6YA Cys-SN2(N3338) hybridoma house mouse CVCL_A6YA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229687 CVCL_A6YD Glut1(D3638-22) hybridoma house mouse CVCL_A6YD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229688 CVCL_A6YC Cys-SN2(N3372) hybridoma house mouse CVCL_A6YC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01037; Human CST1 (isoform SN2). 127229689 CVCL_A6YF Glut1(D4425-2) hybridoma house mouse CVCL_A6YF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229690 CVCL_A6YE Glut1(D3643-9) hybridoma house mouse CVCL_A6YE CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229691 CVCL_A6YH Glut1(D4417-14) hybridoma house mouse CVCL_A6YH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229692 CVCL_A6YG Glut1(D4416-3) hybridoma house mouse CVCL_A6YG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11166; Human SLC2A1. 127229693 CVCL_A7HH Ctrl. BS PBiPS37-Sv4F-1 induced pluripotent stem cell human CVCL_A7HH CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127229694 CVCL_A7HG WAe009-A-55 embryonic stem cell human CVCL_A7HG From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; p.Asn210Asn (c.630C>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243). Female 127229695 CVCL_A7HJ iPSC 09-25 induced pluripotent stem cell human CVCL_A7HJ CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Lys254Glu (c.760A>G); Zygosity=Heterozygous (PubMed=33862537); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Pro637Hisfs*25 (c.1910delC); Zygosity=Heterozygous (PubMed=33862537) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 127229696 CVCL_A7HI iPSC 08-46 induced pluripotent stem cell human CVCL_A7HI CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Arg490Trp (c.1468C>T); ClinVar=VCV000166790; Zygosity=Heterozygous (PubMed=33862537); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Arg788Serfs*14 (c.2362_2363delAGinsTCATCT); ClinVar=VCV000017618; Zygosity=Heterozygous (PubMed=33862537) Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 127229697 CVCL_A7HL iPSC 09-88 induced pluripotent stem cell human CVCL_A7HL CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 127229698 CVCL_A7HK ESi100-A induced pluripotent stem cell human CVCL_A7HK From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 127229699 CVCL_A7HN CalJa ESC 1 embryonic stem cell CVCL_A7HN CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XX,-20,+mar (PubMed=33711687) Female Group: Non-human primate cell line 127229700 CVCL_A7HM iPSC 11-03 induced pluripotent stem cell human CVCL_A7HM CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 127229701 CVCL_A7HB WAe009-A-49 embryonic stem cell human CVCL_A7HB From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243). Female 127229702 CVCL_A7HA UKAi003-A-2 induced pluripotent stem cell human CVCL_A7HA From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple_corrected; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Peripheral blood. Male 127229703 CVCL_A7HD WAe009-A-52 embryonic stem cell human CVCL_A7HD From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=By CRISPR/Cas9. Female 127229704 CVCL_A7HC WAe009-A-51 embryonic stem cell human CVCL_A7HC From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243). Female 127229705 CVCL_A7HF WAe009-A-54 embryonic stem cell human CVCL_A7HF From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; p.Asn210Asn (c.630C>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33845243). Female 127229706 CVCL_A7HE WAe009-A-53 embryonic stem cell human CVCL_A7HE From: Brown University; Providence; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple_edited; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Homozygous; Note=By CRISPR/Cas9. Female 127229707 CVCL_A7GW UKAi002-A-1 induced pluripotent stem cell human CVCL_A7GW From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8861; PF4 Derived from sampling site: Peripheral blood. Female Characteristics: Established from a patient that has a JAK2 p.Val617Phe mutation, but this cell line does not contain this mutation 127229708 CVCL_A7GV UKAi002-B induced pluripotent stem cell human CVCL_A7GV From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 127229709 CVCL_A7GY UKAi003-A induced pluripotent stem cell human CVCL_A7GY CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 127229710 CVCL_A7GX UKAi002-B-1 induced pluripotent stem cell human CVCL_A7GX From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8861; PF4; Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 127229711 CVCL_A7GZ UKAi003-A-1 induced pluripotent stem cell human CVCL_A7GZ From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 6192; JAK2; Simple_corrected; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Peripheral blood. Male 127229712 CVCL_A7GN MHHi009-A-4 induced pluripotent stem cell human CVCL_A7GN From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: RedStar(nuc), a red fluorescent protein Derived from sampling site: Umbilical cord blood. Male 127229713 CVCL_A7GQ IIMCBi001-A induced pluripotent stem cell human CVCL_A7GQ From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229714 CVCL_A7GP MHHi009-A-eGFP induced pluripotent stem cell human CVCL_A7GP From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 127229715 CVCL_A7GS SIGi001-A-14 induced pluripotent stem cell human CVCL_A7GS CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female Characteristics: Contains a HA tag at the C-terminal of both alleles of MAPT (hPSCreg) 127229716 CVCL_A7GR IIMCBi002-A induced pluripotent stem cell human CVCL_A7GR From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 127229717 CVCL_A7GU UKAi002-A induced pluripotent stem cell human CVCL_A7GU From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: Established from a patient that has a JAK2 p.Val617Phe mutation, but this cell line does not contain this mutation 127229718 CVCL_A7GT SIGi001-A-16 induced pluripotent stem cell human CVCL_A7GT CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Homozygous; Note=By method not specified (hPSCreg); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (hPSCreg) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female Characteristics: Contains a HA tag at the C-terminal of both alleles of MAPT (hPSCreg) 127229719 CVCL_A7II WAe001-A-60 embryonic stem cell human CVCL_A7II From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1494; ALX1. Male 127229720 CVCL_A7IH WAe001-A-63 embryonic stem cell human CVCL_A7IH From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1. Male 127229721 CVCL_A7IK WAe001-A-65 embryonic stem cell human CVCL_A7IK From: Nanfang Hospital, Southern Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 160; ACTL6B. Male 127229722 CVCL_A7IJ WAe001-A-58 embryonic stem cell human CVCL_A7IJ CL:0000010 Transfected with: UniProtKB; P0DTC9; Human SARS coronavirus 2 (SARS-CoV-2) nucleoprotein (N); Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Transduced with a pB-TRE-[SARS-CoV-2-N]-EF1a-rtTA-2A-puroR-2A-EGFP construct In the presence of doxycycline rtTA undergo conformational change, binds to the TRE and activates SARS-CoV-2 N protein expression (PubMed=33771478). Group: SARS-CoV-2 research cell line 127229723 CVCL_A7IM UOMi005-A induced pluripotent stem cell human CVCL_A7IM From: University of Manitoba; Winnipeg; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: While the patient has a a 7.3 kb deletion in her mitochondrial DNA, this cell line does not show this deletion (PubMed=33756177; PubMed=33807701) 127229724 CVCL_A7IL WAe009-A-39 embryonic stem cell human CVCL_A7IL From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK. Female 127229725 CVCL_A7IN UOMi006-A induced pluripotent stem cell human CVCL_A7IN From: University of Manitoba; Winnipeg; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: While the patient has a a 5 kb deletion in her mitochondrial DNA, this cell line does not show this deletion (PubMed=33807701; PubMed=33901817) 127229726 CVCL_A7IA CalJa ESC 13 embryonic stem cell CVCL_A7IA CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229727 CVCL_A7IC CalJa ESC 15 embryonic stem cell CVCL_A7IC CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229728 CVCL_A7IB CalJa ESC 14 embryonic stem cell CVCL_A7IB CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229729 CVCL_A7IE CalJa ESC 17 embryonic stem cell CVCL_A7IE CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Donor information: Embryo is sibling to that giving rise to CalJa ESC 16 (Cellosaurus=CVCL_A7ID) Male Group: Non-human primate cell line 127229730 CVCL_A7ID CalJa ESC 16 embryonic stem cell CVCL_A7ID CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XY [4/9]; 46,X,+19 [2/9]; 47,XY,+19 [3/9] (PubMed=33711687); Donor information: Embryo is sibling to that giving rise to CalJa ESC 17 (Cellosaurus=CVCL_A7IE) Male Group: Non-human primate cell line 127229731 CVCL_A7IG CPGHi003-A induced pluripotent stem cell human CVCL_A7IG From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 8768; AIFM1; Simple; p.Arg422Gln (c.1265G>A); ClinVar=VCV000162480; Zygosity=Hemizygous (PubMed=34088005) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229732 CVCL_A7IF CPGHi002-A-1 induced pluripotent stem cell human CVCL_A7IF From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 854; ATP6V1B2; Simple_corrected; p.Arg506Ter (c.1516C>T); ClinVar=VCV000203442; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33714068) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127229733 CVCL_A7HX CalJa ESC 10 embryonic stem cell CVCL_A7HX CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229734 CVCL_A7HW CalJa ESC 9 embryonic stem cell CVCL_A7HW CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Male Group: Non-human primate cell line 127229735 CVCL_A7HZ CalJa ESC 12 embryonic stem cell CVCL_A7HZ CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XY [2/7]; 46,XY,del(13p) [4/7]; 46,XY,del(3q),del(13p) [1/7] (PubMed=33711687) Male Group: Non-human primate cell line 127229736 CVCL_A7HY CalJa ESC 11 embryonic stem cell CVCL_A7HY CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Male Group: Non-human primate cell line 127229737 CVCL_A7HP CalJa ESC 2 embryonic stem cell CVCL_A7HP CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229738 CVCL_A7HR CalJa ESC 4 embryonic stem cell CVCL_A7HR CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XX [2/6]; 46,XX,-20,+mar [1/6]; 47,XX,+5 [2/6]; 47,XX,+5,del(5p),del(13p) [1/6] (PubMed=33711687) Female Group: Non-human primate cell line 127229739 CVCL_A7HQ CalJa ESC 3 embryonic stem cell CVCL_A7HQ CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XX,del(13p) (PubMed=33711687) Female Group: Non-human primate cell line 127229740 CVCL_A7HT CalJa ESC 6 embryonic stem cell CVCL_A7HT CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229741 CVCL_A7HS CalJa ESC 5 embryonic stem cell CVCL_A7HS CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Female Group: Non-human primate cell line 127229742 CVCL_A7HV CalJa ESC 8 embryonic stem cell CVCL_A7HV CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XX,del(13p) [5/8]; 46,XX,-1,+4,del(4q),del(13p) [1/8]; 46,XX,+4,-5,del(4q) [1/8]; 47,XX,+15,del(13p) [1/8] (PubMed=33711687) Female Group: Non-human primate cell line 127229743 CVCL_A7HU CalJa ESC 7 embryonic stem cell CVCL_A7HU CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Karyotypic information: 46,XY [2/5]; 46,XY,del(1p) [2/5]; 45,X,del(1p) [1/5] (PubMed=33711687) Male Group: Non-human primate cell line 127229744 CVCL_A7FF WS9001 transformed cell line human CVCL_A7FF CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229745 CVCL_A7FE WS8901 transformed cell line human CVCL_A7FE CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229746 CVCL_A7FH WS12101 transformed cell line human CVCL_A7FH CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229747 CVCL_A7FG WS9401 transformed cell line human CVCL_A7FG CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229748 CVCL_A7FJ WS14101 transformed cell line human CVCL_A7FJ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229749 CVCL_A7FI WS12701 transformed cell line human CVCL_A7FI CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229750 CVCL_A7FL WS6401 transformed cell line human CVCL_A7FL CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229751 CVCL_A7FK WS5802 transformed cell line human CVCL_A7FK CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229752 CVCL_A7FB 7B5 hybridoma house mouse CVCL_A7FB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14965; Human AURKA. 127229753 CVCL_A7FA 2E1 [Mouse hybridoma against human AURKA] hybridoma house mouse CVCL_A7FA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14965; Human AURKA. 127229754 CVCL_A7FD WS6104 transformed cell line human CVCL_A7FD CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229755 CVCL_A7FC WS10001 transformed cell line human CVCL_A7FC CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Homozygous (PubMed=10543396) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229756 CVCL_A7EU UT-SCC-122 cancer cell line human CVCL_A7EU CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229757 CVCL_A7ET UT-SCC-114 cancer cell line human CVCL_A7ET CL:0000010 Derived from sampling site: Oral cavity; lower lip. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229758 CVCL_A7EW HCC4006-OsiR cancer cell line human CVCL_A7EW CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291); Derived from metastatic site: Pleural effusion. Male 127229759 CVCL_A7EV PF130 cancer cell line human CVCL_A7EV CL:0000010 Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Glu102_Lys104delinsGln (c.303_310del8ins); Zygosity=Unspecified (PubMed=33669371) Derived from metastatic site: Pleural effusion. Male 127229760 CVCL_A7EY 35C1 hybridoma house mouse CVCL_A7EY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14965; Human AURKA (Note=Also reacts with mouse). 127229761 CVCL_A7EX NCI-H1975 CS cancer cell line human CVCL_A7EX CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Cys797Ser (c.2389T>A); ClinVar=VCV000376342; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=32928921); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 127229762 CVCL_A7EZ 1A3 [Mouse hybridoma against human AURKA] hybridoma house mouse CVCL_A7EZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14965; Human AURKA. 127229763 CVCL_A7EM UT-SCC-73 cancer cell line human CVCL_A7EM CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 127229764 CVCL_A7EL UT-SCC-72 cancer cell line human CVCL_A7EL CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229765 CVCL_A7EN UT-SCC-81 cancer cell line human CVCL_A7EN CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229766 CVCL_A7EQ UT-SCC-95 cancer cell line human CVCL_A7EQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Gly (c.428T>G); ClinVar=VCV000486556; Zygosity=Heterozygous (PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 127229767 CVCL_A7EP UT-SCC-87 cancer cell line human CVCL_A7EP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Phe (c.763A>T); ClinVar=VCV000376621; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 127229768 CVCL_A7ES UT-SCC-112 cancer cell line human CVCL_A7ES CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 127229769 CVCL_A7ER UT-SCC-99 cancer cell line human CVCL_A7ER CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229770 CVCL_A7GG SDUBMSi005-A induced pluripotent stem cell human CVCL_A7GG From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Thr560Arg (c.1679C>G); ClinVar=VCV000234554; Zygosity=Heterozygous (PubMed=33770698) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127229771 CVCL_A7GF SDUBMSi008-A induced pluripotent stem cell human CVCL_A7GF From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Arg266Ter (c.796C>T); ClinVar=VCV000024325; Zygosity=Hemizygous (PubMed=33878711) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229772 CVCL_A7GI SDUBMSi004-A induced pluripotent stem cell human CVCL_A7GI From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 Female 127229773 CVCL_A7GH SDUBMSi003-A induced pluripotent stem cell human CVCL_A7GH From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 Male 127229774 CVCL_A7GK MHHi021-A induced pluripotent stem cell human CVCL_A7GK From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg723Gly (c.2167C>G); ClinVar=VCV000042885; Zygosity=Heterozygous (PubMed=33578365) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: MYH7 mutation indicated incorrectly as being at c.2169C>G in PubMed=33578365 127229775 CVCL_A7GJ SIAISi013-A induced pluripotent stem cell human CVCL_A7GJ From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China. CL:0000010 127229776 CVCL_A7GM MHHi009-A induced pluripotent stem cell human CVCL_A7GM From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Umbilical cord blood. Male 127229777 CVCL_A7GL MHHi021-B induced pluripotent stem cell human CVCL_A7GL From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg723Gly (c.2167C>G); ClinVar=VCV000042885; Zygosity=Heterozygous (PubMed=33578365) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: MYH7 mutation indicated incorrectly as being at c.2169C>G in PubMed=33578365 127229778 CVCL_A7GA MHHi001-A-5 induced pluripotent stem cell human CVCL_A7GA From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: GCaMP6f, a green fluorescent calcium sensor; Transfected with: RedStar(nuc), a red fluorescent protein Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female Characteristics: Using TALEN two constructs, a CAG-promoter driven GCamP6f and a CAG-prpmoter driven RedStar(nuc) were introduced in both alleles of the AAVS1 safe harbor locus (PubMed=33571874) 127229779 CVCL_A7GC GZHMCi007-A induced pluripotent stem cell human CVCL_A7GC From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18078; ZBTB7A Derived from sampling site: Peripheral blood. Male 127229780 CVCL_A7GB GZHMCi006-A induced pluripotent stem cell human CVCL_A7GB From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Derived from sampling site: Amniotic fluid. Male 127229781 CVCL_A7GE SDUBMSi007-A induced pluripotent stem cell human CVCL_A7GE From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Arg266Ter (c.796C>T); ClinVar=VCV000024325; Zygosity=Hemizygous (PubMed=33878711) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 127229782 CVCL_A7GD SDUBMSi006-A induced pluripotent stem cell human CVCL_A7GD From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Gly1406Arg (c.4216G>A); Zygosity=Heterozygous (PubMed=33601099); Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Gly1415Arg (c.4243G>A); Zygosity=Heterozygous (PubMed=33601099) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 127229783 CVCL_A7FV 8H3 [Mouse hybridoma against human WRN] hybridoma house mouse CVCL_A7FV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14191; Human WRN. 127229784 CVCL_A7FU 4H12 [Mouse hybridoma against human WRN] hybridoma house mouse CVCL_A7FU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14191; Human WRN. 127229785 CVCL_A7FX JAWSII/EGFP spontaneously immortalized cell line house mouse CVCL_A7FX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6 Trp53-/-. 127229786 CVCL_A7FW HEC-LTT conditionally immortalized cell line human CVCL_A7FW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16; Characteristics: In the presence of doxycycline, hTERT and SV40-TAg expression are activated, resulting in high cell proliferation and unlimited expansion In the absence of the doxycycline, cells stop proliferating and can be maintained in a growth-arrested state that reflects the status of endothelial cells in vivo (PubMed=26345505). 127229787 CVCL_A7FZ C3-luc transformed cell line house mouse CVCL_A7FZ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Breed/subspecies: C57BL/6. Unspecified 127229788 CVCL_A7FY JAWSII/IL-12 spontaneously immortalized cell line house mouse CVCL_A7FY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: MGI; MGI:96539; Il12a; Transfected with: MGI; MGI:96540; Il12b Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6 Trp53-/-. 127229789 CVCL_A7FN WS12001 transformed cell line human CVCL_A7FN CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Tyr463Ter (c.1389T>A) (c.1620T>A); Zygosity=Homozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229790 CVCL_A7FM WS11701 transformed cell line human CVCL_A7FM CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; c.3460-7T>A (IVS29-7T>A); Zygosity=Homozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229791 CVCL_A7FP WS25401 transformed cell line human CVCL_A7FP CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Ala1306Serfs*13 (c.3915dupA) (c.4146insA); ClinVar=VCV000005448; Zygosity=Homozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229792 CVCL_A7FR 3D12 hybridoma house mouse CVCL_A7FR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14191; Human WRN. 127229793 CVCL_A7FQ NSYM transformed cell line human CVCL_A7FQ CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229794 CVCL_A7FT 4F8 [Mouse hybridoma against human WRN] hybridoma house mouse CVCL_A7FT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14191; Human WRN. 127229795 CVCL_A7FS 4D9 hybridoma house mouse CVCL_A7FS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14191; Human WRN. 127229796 CVCL_A7DD N0014 transformed cell line human CVCL_A7DD CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229797 CVCL_A7DC N0012 transformed cell line human CVCL_A7DC CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229798 CVCL_A7DF N0103 transformed cell line human CVCL_A7DF CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229799 CVCL_A7DE N0102 transformed cell line human CVCL_A7DE CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229800 CVCL_A7DH N4702 transformed cell line human CVCL_A7DH CL:0000010 Miscellaneous: Not immortalized Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229801 CVCL_A7DG N0104 transformed cell line human CVCL_A7DG CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229802 CVCL_A7DJ 1E7 [Mouse hybridoma against mouse Celf3] hybridoma house mouse CVCL_A7DJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8CIN6; Mouse Celf3. 127229803 CVCL_A7DI N7401 transformed cell line human CVCL_A7DI CL:0000010 Miscellaneous: Not immortalized Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229804 CVCL_A7CZ N0009 transformed cell line human CVCL_A7CZ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229805 CVCL_A7DB N0011 transformed cell line human CVCL_A7DB CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229806 CVCL_A7DA N0010 transformed cell line human CVCL_A7DA CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229807 CVCL_A7CS WS12301 transformed cell line human CVCL_A7CS CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229808 CVCL_A7CR WS11901 transformed cell line human CVCL_A7CR CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229809 CVCL_A7CU N0002 transformed cell line human CVCL_A7CU CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229810 CVCL_A7CT N0001 transformed cell line human CVCL_A7CT CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229811 CVCL_A7CW N0006 transformed cell line human CVCL_A7CW CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229812 CVCL_A7CV N0004 transformed cell line human CVCL_A7CV CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Senescence: Not immortalized 127229813 CVCL_A7CY N0008 transformed cell line human CVCL_A7CY CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229814 CVCL_A7CX N0007 transformed cell line human CVCL_A7CX CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Senescence: Not immortalized 127229815 CVCL_A7CK WS11601 transformed cell line human CVCL_A7CK CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229816 CVCL_A7CJ WS11301 transformed cell line human CVCL_A7CJ CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229817 CVCL_A7CM WS0702 transformed cell line human CVCL_A7CM CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229818 CVCL_A7CL WS0701 transformed cell line human CVCL_A7CL CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229819 CVCL_A7CN WS0801 transformed cell line human CVCL_A7CN CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229820 CVCL_A7CQ WS11801 transformed cell line human CVCL_A7CQ CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229821 CVCL_A7CP WS6201 transformed cell line human CVCL_A7CP CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Glu1149fs (c.3446delA) (c.3677delA); Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229822 CVCL_A7EE UT-SCC-79A cancer cell line human CVCL_A7EE CL:0000010 Derived from metastatic site: Parotid lymph node. Omics: Deep exome analysis Female 127229823 CVCL_A7ED UT-SCC-63A cancer cell line human CVCL_A7ED CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis Male 127229824 CVCL_A7EG UT-SCC-59B cancer cell line human CVCL_A7EG CL:0000010 Derived from metastatic site: Cervical lymph node. Male 127229825 CVCL_A7EF UT-SCC-59C cancer cell line human CVCL_A7EF CL:0000010 Derived from metastatic site: Parotid lymph node. Omics: Deep exome analysis Male 127229826 CVCL_A7EI UT-SCC-79B cancer cell line human CVCL_A7EI CL:0000010 Derived from metastatic site: Cervical lymph node. Female 127229827 CVCL_A7EH UT-SCC-63B cancer cell line human CVCL_A7EH CL:0000010 Derived from metastatic site: Not specified. Male 127229828 CVCL_A7EK UT-SCC-65 cancer cell line human CVCL_A7EK CL:0000010 Derived from sampling site: Oral cavity; soft palate and oral cavity; tonsil. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 127229829 CVCL_A7EJ UT-SCC-67 cancer cell line human CVCL_A7EJ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 127229830 CVCL_A7EA UT-SCC-76B cancer cell line human CVCL_A7EA CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Male Caution: UT-SCC-76A and UT-SCC-76B are supposed to originate from the same patient but have totally different STR profiles 127229831 CVCL_A7EC UT-SCC-126A cancer cell line human CVCL_A7EC CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Phe (c.388C>T); ClinVar=VCV000216466; Zygosity=Heterozygous (PubMed=29970484); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Lys (c.511G>A); ClinVar=VCV000141566; Zygosity=Heterozygous (PubMed=29970484) Derived from sampling site: Oral cavity; lower lip. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 127229832 CVCL_A7EB UT-SCC-110A cancer cell line human CVCL_A7EB CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 127229833 CVCL_A7DT SCCNij172 cancer cell line human CVCL_A7DT CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Unspecified Characteristics: Established from a xenograft maintained in mouse 127229834 CVCL_A7DS SCCNij167 cancer cell line human CVCL_A7DS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Unspecified Characteristics: Established from a xenograft maintained in mouse 127229835 CVCL_A7DV SCCNij202 cancer cell line human CVCL_A7DV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783-1G>T; ClinVar=VCV000634661; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Unspecified Characteristics: Established from a xenograft maintained in mouse 127229836 CVCL_A7DU SCCNij185 cancer cell line human CVCL_A7DU CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.His708Asn (c.2122C>A); Zygosity=Unspecified (PubMed=33802339); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=33802339); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Serfs*13 (c.457_469del); Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Unspecified Characteristics: Established from a xenograft maintained in mouse 127229837 CVCL_A7DX UT-SCC-74A cancer cell line human CVCL_A7DX CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 127229838 CVCL_A7DW UT-SCC-54C cancer cell line human CVCL_A7DW CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Caution: UT-SCC-54A, UT-SCC-54B and UT-SCC-54C are supposed to originate from the same patient but the STR profile of UT-SCC-54C is totally different from that of the two other cell lines 127229839 CVCL_A7DZ UT-SCC-76A cancer cell line human CVCL_A7DZ CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Caution: UT-SCC-76A and UT-SCC-76B are supposed to originate from the same patient but have totally different STR profiles 127229840 CVCL_A7DY UT-SCC-74B cancer cell line human CVCL_A7DY CL:0000010 Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis Male 127229841 CVCL_A7DL Anti-Dgcr14 hybridoma house mouse CVCL_A7DL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O70279; Mouse Ess2/Dgcr14. 127229842 CVCL_A7DK Anti-6330403k07Rik hybridoma house mouse CVCL_A7DK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8VBZ2; Mouse 6330403k07Rik. 127229843 CVCL_A7DN A5201A hybridoma house mouse CVCL_A7DN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q92542; Human NCSTN. 127229844 CVCL_A7DM KN7 hybridoma CVCL_A7DM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody TG40-BP1. 127229845 CVCL_A7DP A5226A hybridoma house mouse CVCL_A7DP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q92542; Human NCSTN. 127229846 CVCL_A7DR SCCNij153 cancer cell line human CVCL_A7DR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Unspecified (PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Unspecified Characteristics: Established from a xenograft maintained in mouse 127229847 CVCL_A7DQ HepG2-NIAS cancer cell line human CVCL_A7DQ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Can not only rapidly activate hepatic functions such as albumin secretion, urea synthesis and CYP3A4 activity but also induce the formation of bile canaliculus-like structures by utilizing a collagen vitrigel membrane as a culture substratum (RCB) 127229848 CVCL_A7BB CT30 somatic stem cell human CVCL_A7BB CL:0000010 Derived from sampling site: Trophoblast; cytotrophoblast. Female Characteristics: Trophoblast stem cell line Senescence: Senesces at 150 PDL (RCB=RCB4938); Doubling time: 19.4 +- 1.6 hours (PubMed=29249463) 127229849 CVCL_A7BA CT29 somatic stem cell human CVCL_A7BA CL:0000010 Derived from sampling site: Trophoblast; cytotrophoblast. Male Characteristics: Trophoblast stem cell line Senescence: Senesces at 150 PDL (RCB=RCB4937); Doubling time: 22.6 +- 2.5 hours (PubMed=29249463) 127229850 CVCL_A7BD MEF_Hsp47 KO-11 spontaneously immortalized cell line house mouse CVCL_A7BD CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88283; Serpinh1 Derived from sampling site: Cell type=Fibroblast. Unspecified 127229851 CVCL_A7BC MEF_Hsp47 WT-1 spontaneously immortalized cell line house mouse CVCL_A7BC CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Control cell line for MEF_Hsp47 KO-11 (Cellosaurus=CVCL_A7BD) and MEF_Hsp47 KO-13 (Cellosaurus=CVCL_A7BE) 127229852 CVCL_A7BF PSA4 cancer cell line house mouse CVCL_A7BF CL:0000010 Breed/subspecies: 129/Sv. 127229853 CVCL_A7BE MEF_Hsp47 KO-13 spontaneously immortalized cell line house mouse CVCL_A7BE CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88283; Serpinh1 Derived from sampling site: Cell type=Fibroblast. Unspecified 127229854 CVCL_A7BH eIF2ak(4KO) transformed cell line house mouse CVCL_A7BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353448; Eif2ak1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353449; Eif2ak2; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1341830; Eif2ak3; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353427; Eif2ak4 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229855 CVCL_A7BG PSA5-E cancer cell line house mouse CVCL_A7BG CL:0000010 Derived from sampling site: Visceral endoderm; Breed/subspecies: 129/Sv. 127229856 CVCL_A7AY HEK-DsupdeltaC transformed cell line human CVCL_A7AY CL:0000010 Transfected with: UniProtKB; P0DOW4; Ramazzottius varieornatus Dsup (with p.Lys360_Lys445del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 127229857 CVCL_A7AX HEK-DsupKD transformed cell line human CVCL_A7AX CL:0000010 Knockout cell: Method=shRNA knockdown; UniProtKB; P0DOW4; Dsup; Transfected with: UniProtKB; P0DOW4; Ramazzottius varieornatus Dsup; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses Dsup under the control of a constitutive CAG promoter 127229858 CVCL_A7AZ CT27 somatic stem cell human CVCL_A7AZ CL:0000010 Derived from sampling site: Trophoblast; cytotrophoblast. Female Characteristics: Trophoblast stem cell line Senescence: Senesces at 150 PDL (RCB=RCB4936); Doubling time: 24.0 +- 1.7 hours (PubMed=29249463) 127229859 CVCL_A7AQ MCC138c cancer cell line human CVCL_A7AQ CL:0000010 Derived from sampling site: Lung. Characteristics: Established from a xenograft induced in NOD/SCID/gammacnull (NOG) mice 127229860 CVCL_A7AP MCC121c cancer cell line human CVCL_A7AP CL:0000010 Derived from sampling site: Lung. Characteristics: Established from a xenograft induced in NOD/SCID/gammacnull (NOG) mice 127229861 CVCL_A7AS HeLa PRDX6 KO cancer cell line human CVCL_A7AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16753; PRDX6 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229862 CVCL_A7AR MCC148c cancer cell line human CVCL_A7AR CL:0000010 Derived from sampling site: Lung. Characteristics: Established from a xenograft induced in NOD/SCID/gammacnull (NOG) mice 127229863 CVCL_A7AU HeLa/Fucci(CA)5 cancer cell line human CVCL_A7AU CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Ser101_Leu546del and p.Arg68Ala, p.Arg69Ala and p.Leu70Ala); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; A0A6G7QPQ8; Montipora monasteriata AzaleaB5; Transfected with: Ricordea sp h2-3, a bright green fluorescent protein. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci(CA5) (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci(CA)5 probe which consist of the fusion of AzaleaB5 to the ubiquitination domain of human CDT1 (aa 1-100) but with the Cy motif 68-RRL-70 replaced by AAA and of h2-3 to the ubiquitination domain of human geminin (aa 1-110) 127229864 CVCL_A7AT CFS414 transformed cell line CVCL_A7AT CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Continental Chestnut Flanked White. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~23.9 hours (PubMed=35288582) Group: Bird cell line 127229865 CVCL_A7AW HEK-Dsup transformed cell line human CVCL_A7AW CL:0000010 Transfected with: UniProtKB; P0DOW4; Ramazzottius varieornatus Dsup; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses Dsup under the control of a constitutive CAG promoter 127229866 CVCL_A7AV HeLa/Fucci(SA)5 cancer cell line human CVCL_A7AV CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; A0A6G7QPQ8; Montipora monasteriata AzaleaB5; Transfected with: Ricordea sp h2-3, a bright green fluorescent protein. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci(SA5) (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci(SA)5 probe which consist of the fusion of AzaleaB5 to the ubiquitination domain of human CDT1 (aa 30-120) and of h2-3 to the ubiquitination domain of human geminin (aa 1-110) 127229867 CVCL_A7AI HeLa M Rab10-KO cancer cell line human CVCL_A7AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9759; RAB10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229868 CVCL_A7AH S3D8_Spike hybridoma house mouse CVCL_A7AH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). 127229869 CVCL_A7AK TSD-B4S cancer cell line Norway rat CVCL_A7AK CL:0000010 Derived from sampling site: Testis; Breed/subspecies: Sprague Dawley. Male Doubling time: 13.4 hours, at 5th passage (PubMed=24723111) 127229870 CVCL_A7AJ HeLa M Rab22-DKO cancer cell line human CVCL_A7AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9764; RAB22A; Knockout cell: Method=CRISPR/Cas9; HGNC; 9771; RAB31 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 127229871 CVCL_A7AM TSD-P cancer cell line Norway rat CVCL_A7AM CL:0000010 Derived from sampling site: Testis; Breed/subspecies: Sprague Dawley. Male Doubling time: 12.1 hours, at 25th passage (PubMed=24723111) 127229872 CVCL_A7AL TSD-F9R cancer cell line Norway rat CVCL_A7AL CL:0000010 Derived from sampling site: Testis; Breed/subspecies: Sprague Dawley. Male Doubling time: 15.7 hours, at 5th passage (PubMed=24723111) 127229873 CVCL_A7AN MS-K cancer cell line house mouse CVCL_A7AN CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. Male Doubling time: 9.4 hours (PubMed=2043753) 127229874 CVCL_A7CC WS10201 transformed cell line human CVCL_A7CC CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229875 CVCL_A7CB WS9801 transformed cell line human CVCL_A7CB CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229876 CVCL_A7CE WS10901 transformed cell line human CVCL_A7CE CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Caution: Indicated as originating from a 60 year old female in PubMed=9365237 and from a 43 year old female in PubMed=10543396 127229877 CVCL_A7CD WS10501 transformed cell line human CVCL_A7CD CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229878 CVCL_A7CG WS9601 transformed cell line human CVCL_A7CG CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229879 CVCL_A7CF WS11201 transformed cell line human CVCL_A7CF CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys168Alafs*10 (c.502_503delAA) (c.733_734delAA); ClinVar=VCV000403979; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Indicated as originating from a 49 year old female in PubMed=9365237 and from a 48 year old male in PubMed=10543396 127229880 CVCL_A7CI WS10801 transformed cell line human CVCL_A7CI CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229881 CVCL_A7CH WS10101 transformed cell line human CVCL_A7CH CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229882 CVCL_A7BZ WS24002 transformed cell line human CVCL_A7BZ CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229883 CVCL_A7BY WS10402 transformed cell line human CVCL_A7BY CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229884 CVCL_A7CA WS9101 transformed cell line human CVCL_A7CA CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229885 CVCL_A7BR WS5801 transformed cell line human CVCL_A7BR CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229886 CVCL_A7BQ WS6801 transformed cell line human CVCL_A7BQ CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229887 CVCL_A7BT WS0101 transformed cell line human CVCL_A7BT CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg1305Ter (c.3913C>T) (c.4144C>T); ClinVar=VCV000005444; Zygosity=Heterozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229888 CVCL_A7BS WS6501 transformed cell line human CVCL_A7BS CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229889 CVCL_A7BV WS11001 transformed cell line human CVCL_A7BV CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229890 CVCL_A7BU WS2101 transformed cell line human CVCL_A7BU CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 127229891 CVCL_A7BX WS23703 transformed cell line human CVCL_A7BX CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237; PubMed=10543396) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Indicated as originating from a 51 year old male in PubMed=9365237 and from a 39 year old male in PubMed=10543396 127229892 CVCL_A7BW WS23702 transformed cell line human CVCL_A7BW CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=9365237); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous (PubMed=9365237) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 127229893 CVCL_A7BJ eIF2ak(4KO+PERK) transformed cell line house mouse CVCL_A7BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353448; Eif2ak1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353449; Eif2ak2; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1341830; Eif2ak3; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353427; Eif2ak4; Transfected with: MGI; MGI:1353449; Eif2ak2 (FLAG-tagged) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229894 CVCL_A7BI eIF2ak(4KO+HRI) transformed cell line house mouse CVCL_A7BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353448; Eif2ak1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353449; Eif2ak2; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1341830; Eif2ak3; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353427; Eif2ak4; Transfected with: MGI; MGI:1353448; Eif2ak1 (FLAG-tagged) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229895 CVCL_A7BL eIF2ak(4KO+GCN2) transformed cell line house mouse CVCL_A7BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353448; Eif2ak1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353449; Eif2ak2; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1341830; Eif2ak3; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353427; Eif2ak4; Transfected with: MGI; MGI:1353427; Eif2ak4 (FLAG-tagged) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229896 CVCL_A7BK eIF2ak(4KO+PKR) transformed cell line house mouse CVCL_A7BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353448; Eif2ak1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353449; Eif2ak2; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1341830; Eif2ak3; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1353427; Eif2ak4; Transfected with: MGI; MGI:1341830; Eif2ak3 (FLAG-tagged) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229897 CVCL_A7BN TFL-21-7G hybridoma house mouse CVCL_A7BN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A2A288; Human ZC3H12D. 127229898 CVCL_A7BM WT(MEF) SV40-immortalized transformed cell line house mouse CVCL_A7BM CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified 127229899 CVCL_A7BP NP-2/CD4/RDC1 cancer cell line human CVCL_A7BP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 23692; ACKR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 150517732 CVCL_A0BH PS2C501 hybridoma house mouse CVCL_A0BH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4226 150517733 CVCL_A0BI PS1Z134 hybridoma house mouse CVCL_A0BI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4228 150517734 CVCL_A0BJ PS1Z125 hybridoma house mouse CVCL_A0BJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4229 150517735 CVCL_A0BK HK1A523 hybridoma house mouse CVCL_A0BK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20151; Human KLK2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11876 150517736 CVCL_A0BL HK1D106.4 hybridoma house mouse CVCL_A0BL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P20151; Human KLK2 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11937 150517737 CVCL_A0BM HK1G464.3 hybridoma house mouse CVCL_A0BM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P20151; Human KLK2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11983 150517738 CVCL_A0BN HK1G586.1 hybridoma house mouse CVCL_A0BN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P20151; Human KLK2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12026 150517739 CVCL_A0BA PSM773 hybridoma house mouse CVCL_A0BA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517740 CVCL_A0BB PS1P351 hybridoma house mouse CVCL_A0BB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517741 CVCL_A0BC PS1R163 hybridoma house mouse CVCL_A0BC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517742 CVCL_A0BD PS2C109 hybridoma house mouse CVCL_A0BD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4227 150517743 CVCL_A0BE PS2C807 hybridoma house mouse CVCL_A0BE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4223 150517744 CVCL_A0BF PS2C837 hybridoma house mouse CVCL_A0BF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4224 150517745 CVCL_A0BG PS2C634 hybridoma house mouse CVCL_A0BG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4225 150517746 CVCL_A0AW PR18 hybridoma house mouse CVCL_A0AW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P28906; Human CD34. 150517747 CVCL_A0AX PSA399 hybridoma house mouse CVCL_A0AX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517748 CVCL_A0AY PSB999 hybridoma house mouse CVCL_A0AY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517749 CVCL_A0AZ PSJ206 hybridoma house mouse CVCL_A0AZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 150517750 CVCL_A0AP NK92.39 hybridoma house mouse CVCL_A0AP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40200; Human CD96. 150517751 CVCL_A0AQ SKII.4 hybridoma house mouse CVCL_A0AQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15151; Human PVR/CD155. 150517752 CVCL_A0AR 12.2 hybridoma house mouse CVCL_A0AR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q95460; Human MR1. 150517753 CVCL_A0AS 26.5 hybridoma house mouse CVCL_A0AS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q95460; Human MR1 (Note=Also reacts with bovine, mouse and rat). 150517754 CVCL_A0AT CHO-S r34.1 (clone D8) spontaneously immortalized cell line CVCL_A0AT CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Expresses the murine 34.1 monoclonal antibody against the N-terminus of HSV-1 glycoprotein D (gD) (HIVReagentProgram) Doubling time: ~24 hours (PubMed=30502324) 150517755 CVCL_A0AU UCSC.PG128.CHO.S.F4 spontaneously immortalized cell line CVCL_A0AU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Expresses the PGT128 neutralizing monoclonal antibody against the HIV-1 gp120, specifically to the V3 glycan (HIVReagentProgram) 150517756 CVCL_A0AV K6.1 hybridoma house mouse CVCL_A0AV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P28906; Human CD34. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11085 150517757 CVCL_A0CI Pro104.C55.1 hybridoma house mouse CVCL_A0CI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9Y6M0; Human PRSS21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5277 150517758 CVCL_A0CJ Pro104.D9.1 hybridoma house mouse CVCL_A0CJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y6M0; Human PRSS21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6077 150517759 CVCL_A0CK Pro104.K81.15 hybridoma house mouse CVCL_A0CK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y6M0; Human PRSS21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6078 150517760 CVCL_A0CL CEMx174/SIVmac316 clone 3D8 hybrid cell line human CVCL_A0CL CL:0000010 Virology: Infected with simian immunodeficiency virus isolate SIVmac316 (HIVReagentProgram). 150517761 CVCL_A0CM 902 hybridoma house mouse CVCL_A0CM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04578; HIV-1 isolate HXB2 env (gp120). 150517762 CVCL_A0CN SCL1-CD4 clone 6 cancer cell line human CVCL_A0CN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val197Ter; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Face; skin. Female 150517763 CVCL_A0CP RCMGi006-A induced pluripotent stem cell human CVCL_A0CP From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Population: Caucasian; Russian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150517764 CVCL_A0CA 1G10 [Mouse hybridoma against HIV-1 rev] hybridoma house mouse CVCL_A0CA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04618; HIV-1 isolate HXB2 rev. 150517765 CVCL_A0CB 1G7 [Mouse hybridoma against HIV-1 rev] hybridoma house mouse CVCL_A0CB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04618; HIV-1 isolate HXB2 rev. 150517766 CVCL_A0CC 8E7 [Mouse hybridoma against HIV-1 rev] hybridoma house mouse CVCL_A0CC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04618; HIV-1 isolate HXB2 rev. 150517767 CVCL_A0CD 9G2 [Mouse hybridoma against HIV-1 rev] hybridoma house mouse CVCL_A0CD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04618; HIV-1 isolate HXB2 rev. 150517768 CVCL_A0CE 1D9 [Mouse hybridoma against HIV-1 isolate HXB2 tat] hybridoma house mouse CVCL_A0CE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04608; HIV-1 isolate HXB2 tat. 150517769 CVCL_A0CF 1C6.5 hybridoma house mouse CVCL_A0CF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P20881; HIV-2 isolate ST vpx. 150517770 CVCL_A0CG 6D2.6 hybridoma house mouse CVCL_A0CG CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20881; HIV-2 isolate ST vpx. 150517771 CVCL_A0CH Pro104.C25.1 hybridoma house mouse CVCL_A0CH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9Y6M0; Human PRSS21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6076 150517772 CVCL_A0BX VCaP-CR cancer cell line human CVCL_A0BX CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone; vertebra. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived after a passage of the parent cell line in castrated nude mice; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) Doubling time: ~60 hours (PubMed=34402095) 150517773 CVCL_A0BY CHO MGAT1- A244_N332-rgp120 5F spontaneously immortalized cell line CVCL_A0BY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Produces a gp120 from a modified A244 isolate (A244_N332-rgp120) where a glycosylation was moved from Asn-334 to Asn-332 It is enriched for mannose-5 glycans. The gp120 construct contains an N-terminal purification tag from HSV-1 glycoprotein D (gD) (PubMed=30071025). 150517774 CVCL_A0BP HK1H247 hybridoma house mouse CVCL_A0BP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P20151; Human KLK2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12162 150517775 CVCL_A0BQ S14-1 transformed cell line house mouse CVCL_A0BQ CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male Characteristics: Expresses transferrin and SGP-2, lacks a FSH response, and is capable of forming epithelial tumors in nude mice (PubMed=8214009) 150517776 CVCL_A0BR NCC-ssRMS2-C1 cancer cell line human CVCL_A0BR CL:0000010 Sequence variation: Mutation; HGNC; 7611; MYOD1; None_reported; -; Zygosity=- (PubMed=34164773) Population: Japanese; Derived from sampling site: Back. Omics: SNP array analysis Male Doubling time: ~41 hours (PubMed=34164773) Part of: NCC sarcoma cell line panel 150517777 CVCL_A0BT CHO MGAT1- TZ97008-rgp120 2D7 spontaneously immortalized cell line CVCL_A0BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q924C0; Mgat1; Transfected with: HIV-1 isolate TZ97008 env (gp120); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Produces a gp120 from a clade C isolate (TZ97008-rgp120) and enriched for mannose-5 glycans The gp120 construct contains an N-terminal purification tag from HSV-1 glycoprotein D (gD). Group: Serum/protein free medium cell line 150517778 CVCL_A0BU CHO MGAT1- TZ97008-rgp120 3E5 spontaneously immortalized cell line CVCL_A0BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q924C0; Mgat1; Transfected with: HIV-1 isolate TZ97008 env (gp120); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Produces a gp120 from a clade C isolate (TZ97008-rgp120) and enriched for mannose-5 glycans The gp120 construct contains an N-terminal purification tag from HSV-1 glycoprotein D (gD). Group: Serum/protein free medium cell line 150517779 CVCL_A0BV 34.1 hybridoma house mouse CVCL_A0BV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q05059; Human herpesvirus 1 (strain F) glycoprotein D (gD) (Note=Recognizes the p.Lys26_Gln52 N-terminal region used as a purification tag). 150517780 CVCL_A0BW LAPC4-CR cancer cell line human CVCL_A0BW CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived after 4 passages of the parent cell line in castrated nude mice; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) Doubling time: ~50 hours (PubMed=34402095) 150517781 CVCL_A0AG 183-H12-5C hybridoma house mouse CVCL_A0AG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03347; HIV-1 isolate BH10 gag (p24). 150517782 CVCL_A0AH 4B2 [Macaca B-cell transformed] transformed cell line CVCL_A0AH CL:0000010 Transformant: Rhesus lymphocryptovirus (Macacine herpesvirus 4)(NCBI-Taxonomy; 45455); Derived from sampling site: Lymph node. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; E7CWP5; Simian immunodeficiency virus (isolate SIVmac239) (SIV-mac) env (gp41) Group: Non-human primate cell line 150517783 CVCL_A0AI 6E6 [Macaca B-cell transformed] transformed cell line CVCL_A0AI CL:0000010 Transformant: Rhesus lymphocryptovirus (Macacine herpesvirus 4)(NCBI-Taxonomy; 45455); Derived from sampling site: Lymph node. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; E7CWP5; Simian immunodeficiency virus (isolate SIVmac239) (SIV-mac) env (gp41) Group: Non-human primate cell line 150517784 CVCL_A0AJ Cr24.1 hybridoma house mouse CVCL_A0AJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O95727; Human CRTAM/CD355. 150517785 CVCL_A0AK CR24.2.8 hybridoma house mouse CVCL_A0AK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O95727; Human CRTAM/CD355. 150517786 CVCL_A0AL 2.29 hybridoma house mouse CVCL_A0AL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95944; Human NCR2/CD336. 150517787 CVCL_A0AM 3.43 hybridoma house mouse CVCL_A0AM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95944; Human NCR2/CD336. 150517788 CVCL_A0AN 11A8 hybridoma house mouse CVCL_A0AN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 150517789 CVCL_A0AA 168B17-46-34 hybridoma house mouse CVCL_A0AA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517790 CVCL_A0AB 168B17-46-50 hybridoma house mouse CVCL_A0AB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517791 CVCL_A0AC 168B17-46-70 hybridoma house mouse CVCL_A0AC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517792 CVCL_A0AD 168B17-46-92 hybridoma house mouse CVCL_A0AD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517793 CVCL_A0AE 168A51-2 hybridoma house mouse CVCL_A0AE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517794 CVCL_A0AF 168A51-42 hybridoma house mouse CVCL_A0AF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03409; Human T-cell leukemia virus 1 (strain Japan ATK-1 subtype A) tax. 150517795 CVCL_A0JP JTUi005-A induced pluripotent stem cell human CVCL_A0JP From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 53924; NOTCH2NLC; Simple; c.-164GGC[(66_517)]; ClinVar=VCV000691867; Zygosity=Heterozygous; Note=62 GGC repeats (PubMed=36244083); Sequence variation: Mutation; HGNC; 53924; NOTCH2NLC; Simple; c.-164GGC[(66_517)]; ClinVar=VCV000691867; Zygosity=Heterozygous; Note=100 GGC repeats (PubMed=36244083) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150517796 CVCL_A0JQ OFi001-A induced pluripotent stem cell human CVCL_A0JQ From: OrganFactory; Kiheung; South Korea CL:0000010 Population: East Asian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 150517797 CVCL_A0JR OFi002-A induced pluripotent stem cell human CVCL_A0JR From: OrganFactory; Kiheung; South Korea CL:0000010 Population: East Asian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 150517798 CVCL_A0JS YCMi004-A induced pluripotent stem cell human CVCL_A0JS From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Arg23351Ter (c.70051C>T); ClinVar=VCV000405145; Zygosity=Heterozygous (PubMed=34952434) Population: Korean; Derived from sampling site: Peripheral blood. Male 150517799 CVCL_A0JT YCMi005-A induced pluripotent stem cell human CVCL_A0JT From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 12010; TPM1; Simple; p.Glu192Lys (c.574G>A); ClinVar=VCV000031882; Zygosity=Heterozygous (PubMed=35176663) Population: Korean; Derived from sampling site: Peripheral blood. Female 150517800 CVCL_A0JU IUFi001-A induced pluripotent stem cell human CVCL_A0JU From: Leibniz Research Institute For Environmental Medicine; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys337Ter (c.1009A>T) (A1088T); ClinVar=VCV000550722; Zygosity=Heterozygous (PubMed=34271225); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg857Ter (c.2569C>T); ClinVar=VCV000553383; Zygosity=Heterozygous (PubMed=34271225) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150517801 CVCL_A0JV SANi006-A induced pluripotent stem cell human CVCL_A0JV From: Sanquin; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 31928; NBEAL2; Simple; p.Cys2190Alafs*23 (c.6568delT); ClinVar=VCV000982280; Zygosity=Heterozygous (PubMed=34237592); Sequence variation: Mutation; HGNC; 31928; NBEAL2; Simple; p.Leu2646Pro (c.7937T>C); ClinVar=VCV000982281; Zygosity=Heterozygous (PubMed=34237592) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 150517802 CVCL_A0JW SANi007-A induced pluripotent stem cell human CVCL_A0JW From: Sanquin; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 3309; ELANE; Simple; c.614delG; Zygosity=Heterozygous (PubMed=34229202) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 150517803 CVCL_A0JH 31H12 hybridoma house mouse CVCL_A0JH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Salmonella enteritidis subserogroup E lipopolysaccharide (LPS) O:3 antigen. 150517804 CVCL_A0JI 45F6 hybridoma house mouse CVCL_A0JI CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Salmonella enteritidis subserogroup E lipopolysaccharide (LPS) O:3 antigen. 150517805 CVCL_A0JJ SDW18.1.1 hybridoma house mouse CVCL_A0JJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01375; Human TNF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9228 150517806 CVCL_A0JK 4C3 [Mouse hybridoma against human MSMB] hybridoma house mouse CVCL_A0JK CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08118; Human MSMB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9121; Registration: Upjohn Culture Collection; UC HB-17 150517807 CVCL_A0JL 7A5F9 hybridoma house mouse CVCL_A0JL CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08118; Human MSMB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9224; Registration: Upjohn Culture Collection; UC HB-18 150517808 CVCL_A0JM 8H4C7 hybridoma house mouse CVCL_A0JM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08118; Human MSMB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9225; Registration: Upjohn Culture Collection; UC HB-19 150517809 CVCL_A0JN 11C11B11 hybridoma house mouse CVCL_A0JN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08118; Human MSMB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9226; Registration: Upjohn Culture Collection; UC HB-20 150517810 CVCL_A0JA M32-8 hybridoma house mouse CVCL_A0JA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Gly719Cys). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012127 150517811 CVCL_A0JB M80-14 hybridoma house mouse CVCL_A0JB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Leu861Gln). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201315 150517812 CVCL_A0JC M85-13 hybridoma house mouse CVCL_A0JC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Leu858Arg). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012125 150517813 CVCL_A0JD 177E6 hybridoma house mouse CVCL_A0JD CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: Salmonella enteritidis subserogroup OD1 lipopolysaccharide (LPS) O:9 antigen (Note=Also reacts with subserogroup OD3). 150517814 CVCL_A0JE 178H11 hybridoma house mouse CVCL_A0JE CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: Salmonella enteritidis subserogroup OD1 lipopolysaccharide (LPS) O:9 antigen. 150517815 CVCL_A0JF 24E6 hybridoma house mouse CVCL_A0JF CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Salmonella enteritidis subserogroup E lipopolysaccharide (LPS) O:3 antigen. 150517816 CVCL_A0JG 29E1 hybridoma house mouse CVCL_A0JG CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Salmonella enteritidis subserogroup E lipopolysaccharide (LPS) O:3 antigen. 150517817 CVCL_A0IW M120 hybridoma house mouse CVCL_A0IW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Gly863Asp). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201304 150517818 CVCL_A0IX M121#1 hybridoma house mouse CVCL_A0IX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Asp761Tyr). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201303 150517819 CVCL_A0IY M122#1 hybridoma house mouse CVCL_A0IY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Val769Leu). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201316 150517820 CVCL_A0IZ M20-18 hybridoma house mouse CVCL_A0IZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Gly719Ser). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012118 150517821 CVCL_A0KQ UNIBSi016-A induced pluripotent stem cell human CVCL_A0KQ From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Glu1000Val (c.2999A>T); ClinVar=VCV000217604; Zygosity=Heterozygous (PubMed=34182252); Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Gly1213Alafs*7 (c.3638delG); Zygosity=Heterozygous (PubMed=34182252) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517822 CVCL_A0KR UNIBSi016-B induced pluripotent stem cell human CVCL_A0KR From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Glu1000Val (c.2999A>T); ClinVar=VCV000217604; Zygosity=Heterozygous (PubMed=34182252); Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Gly1213Alafs*7 (c.3638delG); Zygosity=Heterozygous (PubMed=34182252) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517823 CVCL_A0KS UNIBSi016-C induced pluripotent stem cell human CVCL_A0KS From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Glu1000Val (c.2999A>T); ClinVar=VCV000217604; Zygosity=Heterozygous (PubMed=34182252); Sequence variation: Mutation; HGNC; 29253; CC2D2A; Simple; p.Gly1213Alafs*7 (c.3638delG); Zygosity=Heterozygous (PubMed=34182252) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517824 CVCL_A0KT LANCEi020-A-1 induced pluripotent stem cell human CVCL_A0KT From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150517825 CVCL_A0KU LANCEi020-A-10 induced pluripotent stem cell human CVCL_A0KU From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3713-28_3833del (Ex31del); Zygosity=Heterozygous (PubMed=34174776); Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3713-30_3833del (Ex31del); Zygosity=Heterozygous (PubMed=34174776) Derived from sampling site: Peripheral blood. Male 150517826 CVCL_A0KV LANCEi020-A-2 induced pluripotent stem cell human CVCL_A0KV From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150517827 CVCL_A0KW LANCEi020-A-3 induced pluripotent stem cell human CVCL_A0KW From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150517828 CVCL_A0KX LANCEi020-A-4 induced pluripotent stem cell human CVCL_A0KX From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 3603; FBN1 Derived from sampling site: Peripheral blood. Male 150517829 CVCL_A0KI KUTTAMi002-A induced pluripotent stem cell human CVCL_A0KI From: Research Center for Translational Medicine, Koc Universitesi; Istanbul; Turkey CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150517830 CVCL_A0KJ KUTTAMi003-A induced pluripotent stem cell human CVCL_A0KJ From: Research Center for Translational Medicine, Koc Universitesi; Istanbul; Turkey CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150517831 CVCL_A0KK EMe-NH6W523S1 induced pluripotent stem cell human CVCL_A0KK From: Cincinnati Children's Hospital Medical Center Pluripotent Stem Cell Facility; Cincinnati; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 150517832 CVCL_A0KL EMe-NH6W523XS7 induced pluripotent stem cell human CVCL_A0KL From: Cincinnati Children's Hospital Medical Center Pluripotent Stem Cell Facility; Cincinnati; USA CL:0000010 Sequence variation: Mutation; HGNC; 11079; SLC9A6; Simple; p.Trp523Ter (c.1569G>A); Zygosity=Hemizygous (PubMed=34182254) Derived from sampling site: Peripheral blood. Male 150517833 CVCL_A0KM EMe-NH6W523K5 induced pluripotent stem cell human CVCL_A0KM From: Cincinnati Children's Hospital Medical Center Pluripotent Stem Cell Facility; Cincinnati; USA CL:0000010 Sequence variation: Mutation; HGNC; 11079; SLC9A6; Simple_corrected; p.Trp523Ter (c.1569G>A); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=34182254) Derived from sampling site: Peripheral blood. Male 150517834 CVCL_A0KN EMe-NH6W523K17 induced pluripotent stem cell human CVCL_A0KN From: Cincinnati Children's Hospital Medical Center Pluripotent Stem Cell Facility; Cincinnati; USA CL:0000010 Sequence variation: Mutation; HGNC; 11079; SLC9A6; Simple_corrected; p.Trp523Ter (c.1569G>A); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=34182254) Derived from sampling site: Peripheral blood. Male 150517835 CVCL_A0KP UNIBSi015-A induced pluripotent stem cell human CVCL_A0KP From: University of Brescia; Brescia; Italy. CL:0000010 150517836 CVCL_A0KA HEBHMUi009-A induced pluripotent stem cell human CVCL_A0KA From: Hebei Medical University; Shijiazhuang; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=34218115) Derived from sampling site: Peripheral blood. Male 150517837 CVCL_A0KB UCLi014-A induced pluripotent stem cell human CVCL_A0KB From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 19977; RDH12; Simple; p.Phe254Leufs*24 (c.759delC); ClinVar=VCV000812389; Zygosity=Heterozygous (PubMed=34216980) Population: Kurdistani and Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150517838 CVCL_A0KC UCLi015-A induced pluripotent stem cell human CVCL_A0KC From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 19977; RDH12; Simple; p.Asn207Asp (c.619A>G); ClinVar=VCV000805924; Zygosity=Homozygous (PubMed=34216980) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150517839 CVCL_A0KD UCLAi005-A induced pluripotent stem cell human CVCL_A0KD From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517840 CVCL_A0KE UCLAi005-B induced pluripotent stem cell human CVCL_A0KE From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517841 CVCL_A0KF UCLAi005-C induced pluripotent stem cell human CVCL_A0KF From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150517842 CVCL_A0KG CUIMCi003-A induced pluripotent stem cell human CVCL_A0KG From: Columbia University Irving Medical Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16876; ARNT2; Simple; p.Pro130Ala (c.388C>G); Zygosity=Heterozygous; Note=De novo mutation (PubMed=34214899; PubMed=35390757) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150517843 CVCL_A0KH KUTTAMi001-A induced pluripotent stem cell human CVCL_A0KH From: Research Center for Translational Medicine, Koc Universitesi; Istanbul; Turkey CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150517844 CVCL_A0JX SANi008-A induced pluripotent stem cell human CVCL_A0JX From: Sanquin; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Glu1441Valfs*11 (c.4322_4325delAGAG); ClinVar=VCV001173104; Zygosity=Heterozygous (PubMed=34224985); Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Asn3376Ser (c.10127A>G); ClinVar=VCV000065529; Zygosity=Heterozygous (PubMed=34224985) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 150517845 CVCL_A0JY SANi009-A induced pluripotent stem cell human CVCL_A0JY From: Sanquin; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; p.Lys59fs (c.177delA); ClinVar=VCV000224763; Zygosity=Heterozygous (PubMed=34182253); Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; c.1839_1842delTAGA; ClinVar=VCV000224764; Zygosity=Heterozygous (PubMed=34182253) Derived from sampling site: Peripheral blood. Female 150517846 CVCL_A0JZ SANi010-A induced pluripotent stem cell human CVCL_A0JZ From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood. Female 150517847 CVCL_A0HN 3G5 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517848 CVCL_A0HP 4C11 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HP CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517849 CVCL_A0HQ 4F6 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517850 CVCL_A0HR 7A5 hybridoma house mouse CVCL_A0HR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517851 CVCL_A0HS 8E4 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517852 CVCL_A0HU 9D8 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517853 CVCL_A0HF 1A1/B2 hybridoma house mouse CVCL_A0HF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Opisthorchis felineus 105 Kda excretory-secretory antigen. Group: Patented cell line 150517854 CVCL_A0HG 10E4 hybridoma house mouse CVCL_A0HG CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517855 CVCL_A0HH 16A3 hybridoma house mouse CVCL_A0HH CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517856 CVCL_A0HI 1B5 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HI CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517857 CVCL_A0HJ 1D2 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517858 CVCL_A0HK 21H1 hybridoma house mouse CVCL_A0HK CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517859 CVCL_A0HL 2H9 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HL CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517860 CVCL_A0HM 3E6 [Mouse hybridoma against human RPSA] hybridoma house mouse CVCL_A0HM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. 150517861 CVCL_A0HA THP18 cancer cell line human CVCL_A0HA CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 150517862 CVCL_A0HB THP18-deltaA3A cancer cell line human CVCL_A0HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17343; APOBEC3A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 150517863 CVCL_A0HC THP18-deltaA3A/B cancer cell line human CVCL_A0HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17343; APOBEC3A; Knockout cell: Method=CRISPR/Cas9; HGNC; 17352; APOBEC3B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 150517864 CVCL_A0HD 1D6 hybridoma house mouse CVCL_A0HD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; M1G6I5; Opisthorchis viverrini tetraspanin 2A (Ov-TSP-2). 150517865 CVCL_A0HE 3F5 [Mouse hybridoma against O.viverrini Ov-TSP-2] hybridoma house mouse CVCL_A0HE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; M1G6I5; Opisthorchis viverrini tetraspanin 2A (Ov-TSP-2). 150517866 CVCL_A0GU Mel-XY2 cancer cell line human CVCL_A0GU HLA typing: A*30,33; B*18,65 (PubMed=17448240) CL:0000010 Population: Caucasian; Derived from metastatic site: Axillary lymph node. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2831 150517867 CVCL_A0GV Mel-XY3 cancer cell line human CVCL_A0GV HLA typing: A*02:01,23; B*18,18 (PubMed=17448240) CL:0000010 Population: Caucasian; Derived from metastatic site: Axillary lymph node. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2832 150517868 CVCL_A0GW MGPK alphaVbeta6-C5 spontaneously immortalized cell line pig CVCL_A0GW CL:0000010 Transfected with: VGNC; 30323; Bovine ITGAV; Transfected with: VGNC; 30331; Bovine ITGB6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Virology: Combined treatment of the parent cell line with BVDV NS5A siRNA, interferon alpha and ribavirin has cured the cell line from bovine viral diarrhea virus (BVDV) infection (PubMed=34092457); Virology: Susceptible to infection by foot-and-mouth disease virus (PubMed=34092457) Problematic cell line: Misidentified Grand-parent cell line (LF-BK) was originally thought to be of bovine origin but originates from pig (PubMed=25617444). 150517869 CVCL_A0GX MB5 transformed cell line human CVCL_A0GX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S) 150517870 CVCL_A0GY MC8 transformed cell line human CVCL_A0GY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S) 150517871 CVCL_A0GZ 5210-87-13 hybridoma CVCL_A0GZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9UH17; Human APOBEC3B (Note=Also partially reacts with APOBEC3A and APOBEC3G). 150517872 CVCL_A0IP K5-116-2-1 hybridoma house mouse CVCL_A0IP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11253 150517873 CVCL_A0IQ K5-70 hybridoma house mouse CVCL_A0IQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11251 150517874 CVCL_A0IR T5-86 hybridoma house mouse CVCL_A0IR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11254 150517875 CVCL_A0IS T6-16 hybridoma house mouse CVCL_A0IS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11346 150517876 CVCL_A0IT M116 hybridoma house mouse CVCL_A0IT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Gly719Ala). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201301 150517877 CVCL_A0IU M117-10 hybridoma house mouse CVCL_A0IU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Asn826Ser). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201320 150517878 CVCL_A0IV M118#7 hybridoma house mouse CVCL_A0IV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR (with p.Ala839Thr). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201302 150517879 CVCL_A0IG 31-6-1 hybridoma house mouse CVCL_A0IG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02778; Human CXCL10. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00143 150517880 CVCL_A0IH JEV_1 hybridoma house mouse CVCL_A0IH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27395; Japanese encephalitis virus (JEV) polyprotein (AA 1-105; Capsid protein C). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00258 150517881 CVCL_A0II JEV_2 hybridoma house mouse CVCL_A0II CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27395; Japanese encephalitis virus (JEV) polyprotein (AA 1-105; Capsid protein C). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00259 150517882 CVCL_A0IJ 4G12 [Mouse hybridoma against ASFV CD2v] hybridoma house mouse CVCL_A0IJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0A7W5A6; African swine fever virus (ASFV) (isolate DB/LN/2018) CD2 homolog (CD2v). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.19947 150517883 CVCL_A0IK UN1 hybridoma house mouse CVCL_A0IK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16150; Human SPN/CD43. 150517884 CVCL_A0IL UMG1 hybridoma house mouse CVCL_A0IL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16150; Human SPN/CD43. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 16001 150517885 CVCL_A0IM CDina26 hybridoma house mouse CVCL_A0IM CL:0000010 Biotechnology: Was used to produce the monoclonal antibody begelomab (Begedina) which was evaluated as a therapeutic agent against steroid-resistant acute graft-versus-host disease Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 12002 150517886 CVCL_A0IN K5-107 hybridoma house mouse CVCL_A0IN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11252 150517887 CVCL_A0IA 1B-4971 hybridoma house mouse CVCL_A0IA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517888 CVCL_A0IB anti-MERS CoV P1 hybridoma house mouse CVCL_A0IB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; K9N4V7; Middle East respiratory syndrome-related coronavirus (MERS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00331 150517889 CVCL_A0IC anti-MERS CoV P3 hybridoma house mouse CVCL_A0IC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; K9N4V7; Middle East respiratory syndrome-related coronavirus (MERS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00332 150517890 CVCL_A0ID 124-11-2 hybridoma house mouse CVCL_A0ID CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02778; Human CXCL10. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00142 150517891 CVCL_A0IE 137-2-1 hybridoma house mouse CVCL_A0IE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02778; Human CXCL10. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00145 150517892 CVCL_A0IF 28-2-3 hybridoma house mouse CVCL_A0IF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02778; Human CXCL10. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00144 150517893 CVCL_A0HV 1A-3187 hybridoma house mouse CVCL_A0HV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517894 CVCL_A0HW 1A-4246 hybridoma house mouse CVCL_A0HW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517895 CVCL_A0HX 1B-3246 hybridoma house mouse CVCL_A0HX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517896 CVCL_A0HY 1B-3440 hybridoma house mouse CVCL_A0HY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517897 CVCL_A0HZ 1B-4863 hybridoma house mouse CVCL_A0HZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. Group: Patented cell line 150517898 CVCL_A0FL HCA-770H hybridoma house mouse CVCL_A0FL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517899 CVCL_A0FM HCA-784H hybridoma house mouse CVCL_A0FM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517900 CVCL_A0FN HCA-803H hybridoma house mouse CVCL_A0FN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517901 CVCL_A0FP HCA-805 hybridoma house mouse CVCL_A0FP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517902 CVCL_A0FQ HCA-805HDR hybridoma house mouse CVCL_A0FQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517903 CVCL_A0FR HCA-838H hybridoma house mouse CVCL_A0FR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517904 CVCL_A0FS HDA-202 hybridoma house mouse CVCL_A0FS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517905 CVCL_A0FD HCA-57HDR hybridoma house mouse CVCL_A0FD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517906 CVCL_A0FE HCA-627 hybridoma house mouse CVCL_A0FE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5284 150517907 CVCL_A0FF HCA-646HD hybridoma house mouse CVCL_A0FF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517908 CVCL_A0FG HCA-656 hybridoma house mouse CVCL_A0FG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517909 CVCL_A0FH HCA-660HD hybridoma house mouse CVCL_A0FH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517910 CVCL_A0FI HCA-671H hybridoma house mouse CVCL_A0FI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517911 CVCL_A0FJ HCA-69H hybridoma house mouse CVCL_A0FJ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517912 CVCL_A0FK HCA-713 hybridoma house mouse CVCL_A0FK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517913 CVCL_A0FA HCA-293HDR hybridoma house mouse CVCL_A0FA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517914 CVCL_A0FB HCA-350DHR hybridoma house mouse CVCL_A0FB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517915 CVCL_A0FC HCA-507HD hybridoma house mouse CVCL_A0FC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517916 CVCL_A0ES W112 6G-2 hybridoma house mouse CVCL_A0ES CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human T-cell receptor variable beta-5.3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9927 150517917 CVCL_A0ET 2D1 [Mouse hybridoma against human TcRv beta-8.1] hybridoma house mouse CVCL_A0ET CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human T-cell receptor variable beta-8.1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9928 150517918 CVCL_A0EU 79RD27 finite cell line human CVCL_A0EU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150517919 CVCL_A0EV AT3NG finite cell line human CVCL_A0EV CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser2860del (c.8575TCT[1]) (c.8578_8580delTCT) (Ser1512del); ClinVar=VCV000003018; Zygosity=Homozygous (PubMed=7792600) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. 150517920 CVCL_A0EW HCA-155H hybridoma house mouse CVCL_A0EW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517921 CVCL_A0EX HCA-212 hybridoma house mouse CVCL_A0EX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517922 CVCL_A0EY HCA-231H hybridoma house mouse CVCL_A0EY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517923 CVCL_A0EZ HCA-290 hybridoma house mouse CVCL_A0EZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517924 CVCL_A0GM 2A5 [Mouse hybridoma against human IL1RL1] hybridoma house mouse CVCL_A0GM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM ABP-10189 150517925 CVCL_A0GN FB9 hybridoma house mouse CVCL_A0GN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM ABP-10190 150517926 CVCL_A0GP HB12 hybridoma house mouse CVCL_A0GP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM ABP-10191 150517927 CVCL_A0GQ ST2-BA-1.1-07E04-02B07-02G06 hybridoma house mouse CVCL_A0GQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10431 150517928 CVCL_A0GR ST2-BA-1.1-09F08-02D04-01F05 hybridoma house mouse CVCL_A0GR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10432 150517929 CVCL_A0GS Mel-XX4 cancer cell line human CVCL_A0GS HLA typing: A*24,33; B*18,65 (PubMed=17448240) CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2829 150517930 CVCL_A0GT Mel-XY1 cancer cell line human CVCL_A0GT HLA typing: A*02:01,23; B*18,37 (PubMed=17448240) CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2830 150517931 CVCL_A0GE NCC-cOV1-C1 cancer cell line human CVCL_A0GE CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Omics: SNP array analysis Female Doubling time: 40 hours (DOI=10.2198/jelectroph.65.23) 150517932 CVCL_A0GF LK1 [Mouse ESC] embryonic stem cell house mouse CVCL_A0GF CL:0000010 Breed/subspecies: C57BL/6. Male 150517933 CVCL_A0GG GSI-1 embryonic stem cell house mouse CVCL_A0GG CL:0000010 Breed/subspecies: 129X1/SvJ. Unspecified 150517934 CVCL_A0GH HEK293-mST2L transformed cell line human CVCL_A0GH CL:0000010 Transfected with: MGI; MGI:98427; Il1rl1; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The expression of the luciferase reporter gene is under the control of a NF-kappaB-inducible promoter 150517935 CVCL_A0GI CNTO2549 hybridoma CVCL_A0GI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14719; Mouse Il1rl1. 150517936 CVCL_A0GJ CNTO8195 hybridoma CVCL_A0GJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14719; Mouse Il1rl1. 150517937 CVCL_A0GK CNTO9195 hybridoma CVCL_A0GK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14719; Mouse Il1rl1. 150517938 CVCL_A0GL CNTO9383 hybridoma CVCL_A0GL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14719; Mouse Il1rl1. 150517939 CVCL_A0GA 4B2 [Mouse/rat hybridoma against mouse Clec7a] hybridoma CVCL_A0GA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q6QLQ4; Mouse Clec7a/Cd369. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10151 150517940 CVCL_A0GB RH1 [Mouse/rat hybridoma against mouse Clec7a] hybridoma CVCL_A0GB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q6QLQ4; Mouse Clec7a/Cd369. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10152 150517941 CVCL_A0GC SC30 hybridoma CVCL_A0GC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q6QLQ4; Mouse Clec7a/Cd369. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10153 150517942 CVCL_A0GD CHO dhfr- Clone 20/1 spontaneously immortalized cell line CVCL_A0GD CL:0000010 Derived from sampling site: Ovary. Female 150517943 CVCL_A0FT HDA-676 hybridoma house mouse CVCL_A0FT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517944 CVCL_A0FU HDA-907 hybridoma house mouse CVCL_A0FU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5286 150517945 CVCL_A0FV HDA-1018 hybridoma house mouse CVCL_A0FV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517946 CVCL_A0FW HDA-1606 hybridoma house mouse CVCL_A0FW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517947 CVCL_A0FX HDA-1884 hybridoma house mouse CVCL_A0FX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517948 CVCL_A0FY HDA-1937 hybridoma house mouse CVCL_A0FY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517949 CVCL_A0FZ HDA-2003 hybridoma house mouse CVCL_A0FZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F7RNT6; Dog ANXA5; Monoclonal antibody target: UniProtKB; P08758; Human ANXA5. 150517950 CVCL_A0DJ PF1-6.1.1.3 hybridoma house mouse CVCL_A0DJ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5168 150517951 CVCL_A0DK PF1-11-2-1 hybridoma house mouse CVCL_A0DK CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6863 150517952 CVCL_A0DL PF1-11.2.1.4 hybridoma house mouse CVCL_A0DL CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5169 150517953 CVCL_A0DM EL-4 6.1 cancer cell line house mouse CVCL_A0DM CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 150517954 CVCL_A0DN RL119 hybridoma CVCL_A0DN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P18572; Mouse Cd147. 150517955 CVCL_A0DP RL388 hybridoma CVCL_A0DP CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P10852; Mouse Slc3a2/Cd98. 150517956 CVCL_A0DQ RL73 hybridoma CVCL_A0DQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P18572; Mouse Cd147. 150517957 CVCL_A0DB PF8-2-43-1 hybridoma house mouse CVCL_A0DB CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6575 150517958 CVCL_A0DC NC17 hybridoma CVCL_A0DC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. Group: Patented cell line 150517959 CVCL_A0DD TB13 hybridoma CVCL_A0DD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. Group: Patented cell line 150517960 CVCL_A0DE MCIR1 cancer cell line human CVCL_A0DE CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34214199); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34214199) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Characteristics: Obtained from a ibrutinib-resistant tumor clone Doubling time: 32 hours (PubMed=34214199) 150517961 CVCL_A0DF 293C18P transformed cell line human CVCL_A0DF CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201913 150517962 CVCL_A0DG PF1-4-1-1 hybridoma house mouse CVCL_A0DG CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6862 150517963 CVCL_A0DH PF1-4.1.1.1 hybridoma house mouse CVCL_A0DH CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5166 150517964 CVCL_A0DI PF1-4.13.1.1 hybridoma house mouse CVCL_A0DI CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5167 150517965 CVCL_A0CY PF8-1-66-1 hybridoma house mouse CVCL_A0CY CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6573 150517966 CVCL_A0CZ PF8-2-112-1 hybridoma house mouse CVCL_A0CZ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6574 150517967 CVCL_A0DA PF8-2-177-1 hybridoma house mouse CVCL_A0DA CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6576 150517968 CVCL_A0CQ RBME-6 spontaneously immortalized cell line CVCL_A0CQ CL:0000010 Unspecified Doubling time: ~63 hours (PubMed=34230000). Group: Tick cell line 150517969 CVCL_A0CR PF8-1-116-1 hybridoma house mouse CVCL_A0CR CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6566 150517970 CVCL_A0CS PF8-1-132-1 hybridoma house mouse CVCL_A0CS CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6567 150517971 CVCL_A0CT PF8-1-136-3 hybridoma house mouse CVCL_A0CT CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6568 150517972 CVCL_A0CU PF8-1-257-1 hybridoma house mouse CVCL_A0CU CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6569 150517973 CVCL_A0CV PF8-1-268-1 hybridoma house mouse CVCL_A0CV CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6570 150517974 CVCL_A0CW PF8-1-314-1 hybridoma house mouse CVCL_A0CW CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6571 150517975 CVCL_A0CX PF8-1-46-1 hybridoma house mouse CVCL_A0CX CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O14793; Human MSTN Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6572 150517976 CVCL_A0EK XMMPS-OP1 hybridoma house mouse CVCL_A0EK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Pseudomonas aeruginosa Fisher type 1 core lipopolysaccharide (LPS). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9384 150517977 CVCL_A0EL XMMPS-OP2 hybridoma house mouse CVCL_A0EL CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa Fisher type 2 core lipopolysaccharide (LPS). 150517978 CVCL_A0EM 5A6.E9 hybridoma house mouse CVCL_A0EM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04234; Human CD3D. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9772 150517979 CVCL_A0EN deltaTCAR-3 hybridoma house mouse CVCL_A0EN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B7Z8K6; Human TRDC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9578 150517980 CVCL_A0EP RS2A-2-H-7 hybridoma house mouse CVCL_A0EP CL:0000010 Characteristics: Isotype switched derivative of deltaTCAR-3; Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; B7Z8K6; Human TRDC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10110 150517981 CVCL_A0EQ 3A8 [Mouse hybridoma against human TRAC] hybridoma house mouse CVCL_A0EQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01848; Human TRAC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9900 150517982 CVCL_A0ER 3D6 hybridoma house mouse CVCL_A0ER CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01848; Human TRAC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9901 150517983 CVCL_A0EC Prost 185 hybridoma house mouse CVCL_A0EC CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11425 150517984 CVCL_A0ED Prost 30 hybridoma house mouse CVCL_A0ED CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human prostate epithelial-specific antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11424 150517985 CVCL_A0EE Prost C219 hybridoma house mouse CVCL_A0EE CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11893 150517986 CVCL_A0EF Prost C37 hybridoma house mouse CVCL_A0EF CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11892 150517987 CVCL_A0EG XMMEN-J5D hybridoma house mouse CVCL_A0EG CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9083 150517988 CVCL_A0EH XMMEN-LY1 hybridoma house mouse CVCL_A0EH CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Salmonella minnesota R595 core lipopolysaccharide (LPS). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9082 150517989 CVCL_A0EI XMMEN-LY2 hybridoma house mouse CVCL_A0EI CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Salmonella minnesota R595 core lipopolysaccharide (LPS). 150517990 CVCL_A0EJ XMMPS-605 hybridoma house mouse CVCL_A0EJ CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: Pseudomonas aeruginosa strain PAC 605 core lipopolysaccharide (LPS). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8909 150517991 CVCL_A0DZ IgM-8 hybridoma house mouse CVCL_A0DZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human IgM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201850 150517992 CVCL_A0EA Prost 130 hybridoma house mouse CVCL_A0EA CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11427 150517993 CVCL_A0EB Prost 16 hybridoma house mouse CVCL_A0EB CL:0000010 Monoclonal antibody isotype: IgG1. 150517994 CVCL_A0DR HSB.2-A7-D2 cancer cell line human CVCL_A0DR CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Produces high level of IL2 in response to IL1 150517995 CVCL_A0DS HSB.2-A7-D9 cancer cell line human CVCL_A0DS CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Produces high level of IL2 in response to IL1 150517996 CVCL_A0DT HSB.2-C5-B2 cancer cell line human CVCL_A0DT CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Produces high level of IL2 in response to IL1 150517997 CVCL_A0DU hIL1Rm10 hybridoma house mouse CVCL_A0DU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14778; Human IL1R1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10556 150517998 CVCL_A0DV ASE [Anopheles] spontaneously immortalized cell line CVCL_A0DV CL:0000010 Unspecified Group: Insect cell line. 150517999 CVCL_A0DW HeLa S3 AGO2KO cancer cell line human CVCL_A0DW CL:0000010 Knockout cell: Method=ZFN; HGNC; 3263; AGO2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: scRNAseq analysis Female 150518000 CVCL_A0DX RM3/1 hybridoma house mouse CVCL_A0DX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VB7; Human CD163. 150518001 CVCL_A0DY MAC 2-158 hybridoma house mouse CVCL_A0DY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q86VB7; Human CD163. 150518002 CVCL_A0RX 1E5 [Mouse hybridoma against human RB1] hybridoma house mouse CVCL_A0RX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518003 CVCL_A0RY 1G5 [Mouse hybridoma against human RB1] hybridoma house mouse CVCL_A0RY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518004 CVCL_A0RZ 4G2 hybridoma house mouse CVCL_A0RZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518005 CVCL_A0RP MS-3 hybridoma house mouse CVCL_A0RP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma salivarium. 150518006 CVCL_A0RQ MS-4 hybridoma house mouse CVCL_A0RQ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Mycoplasma salivarium. 150518007 CVCL_A0RR MS-5 [Mouse hybridoma against M.salivarium] hybridoma house mouse CVCL_A0RR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma salivarium. 150518008 CVCL_A0RS RB1-MAbP2 hybridoma house mouse CVCL_A0RS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10093 150518009 CVCL_A0RT TEC-11 hybridoma house mouse CVCL_A0RT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P17813; Human ENG/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12311 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5660827 and Patent=US5877289 and to be P3X63Ag8.653 (Cellosaurus=CVCL_4032) in PubMed=9815965. 150518010 CVCL_A0RU TEC-4 hybridoma house mouse CVCL_A0RU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P17813; Human ENG/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12312 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5660827 and Patent=US5877289 and to be P3X63Ag8.653 (Cellosaurus=CVCL_4032) in PubMed=9815965. 150518011 CVCL_A0RV 3C8 [Mouse hybridoma against human RB1] hybridoma house mouse CVCL_A0RV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06400; Human RB1 (Note=Binds to the C-terminal end) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12313 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518012 CVCL_A0RW 1D1 hybridoma house mouse CVCL_A0RW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518013 CVCL_A0RH MH-3 hybridoma house mouse CVCL_A0RH CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Mycoplasma hyorhinis. 150518014 CVCL_A0RI MO-1 hybridoma house mouse CVCL_A0RI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mycoplasma orale. 150518015 CVCL_A0RJ MO-2 hybridoma house mouse CVCL_A0RJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma orale. 150518016 CVCL_A0RK MO-3 hybridoma house mouse CVCL_A0RK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mycoplasma orale. 150518017 CVCL_A0RL MP-1 hybridoma house mouse CVCL_A0RL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma pneumoniae. 150518018 CVCL_A0RM MS-1 [Mouse hybridoma against M.salivarium] hybridoma house mouse CVCL_A0RM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mycoplasma salivarium. 150518019 CVCL_A0RN MS-2 [Mouse hybridoma against M.salivarium] hybridoma house mouse CVCL_A0RN CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Mycoplasma salivarium. 150518020 CVCL_A0RA AL-3 hybridoma house mouse CVCL_A0RA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Acholeplasma laidlawii. 150518021 CVCL_A0RB MA-1 [Mouse hybridoma against M.arginini] hybridoma house mouse CVCL_A0RB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mycoplasma arginini. 150518022 CVCL_A0RC MA-2 hybridoma house mouse CVCL_A0RC CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Mycoplasma arginini. 150518023 CVCL_A0RD MA-3 hybridoma house mouse CVCL_A0RD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Mycoplasma arginini. 150518024 CVCL_A0RE MA-4 hybridoma house mouse CVCL_A0RE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma arginini. 150518025 CVCL_A0RF MH-1 [Mouse hybridoma against M.hyorhinis] hybridoma house mouse CVCL_A0RF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma hyorhinis. 150518026 CVCL_A0RG MH-2 [Mouse hybridoma against M.hyorhinis] hybridoma house mouse CVCL_A0RG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma hyorhinis. 150518027 CVCL_A0SY MRIi027-A induced pluripotent stem cell human CVCL_A0SY From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518028 CVCL_A0SZ MRIi024-A induced pluripotent stem cell human CVCL_A0SZ From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518029 CVCL_A0TA MRIi016-A induced pluripotent stem cell human CVCL_A0TA From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518030 CVCL_A0SQ U2OS ATXN3 KO cancer cell line human CVCL_A0SQ From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7106; ATXN3 Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 150518031 CVCL_A0SR NCC-GCTB2-C1 cancer cell line human CVCL_A0SR CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=34304386) Population: Japanese; Derived from sampling site: Bone; proximal tibia. Omics: SNP array analysis Male Doubling time: 64 hours (PubMed=34304386) Part of: NCC sarcoma cell line panel 150518032 CVCL_A0SS NCC-GCTB3-C1 cancer cell line human CVCL_A0SS CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=34304386) Population: Japanese; Derived from sampling site: Bone; proximal tibia. Omics: SNP array analysis Female Doubling time: 26 hours (PubMed=34304386) Part of: NCC sarcoma cell line panel 150518033 CVCL_A0ST HL60/MRI cancer cell line human CVCL_A0ST CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Cell line established from the transplantable tumor of the same name 150518034 CVCL_A0SU LCPHi001-A induced pluripotent stem cell human CVCL_A0SU From: The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng People's Hospital; Liaocheng; China CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=34464855); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Ala495Pro (c.1483G>C) (A456P); ClinVar=VCV000093450; Zygosity=Heterozygous (PubMed=34464855); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Val499Val (c.1497G>C) (V460V); ClinVar=VCV000093451; Zygosity=Heterozygous (PubMed=34464855) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518035 CVCL_A0SV BIUi001-A induced pluripotent stem cell human CVCL_A0SV From: Bar Ilan University; Ramat Gan; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29456; TOR1AIP1; Simple; p.Arg321Ter (c.961C>T); ClinVar=VCV000804380; Zygosity=Homozygous (PubMed=34560421) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518036 CVCL_A0SW BIUi002-A induced pluripotent stem cell human CVCL_A0SW From: Bar Ilan University; Ramat Gan; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29456; TOR1AIP1; Simple; p.Arg321Ter (c.961C>T); ClinVar=VCV000804380; Zygosity=Homozygous (PubMed=34560421) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518037 CVCL_A0SX MRIi026-A induced pluripotent stem cell human CVCL_A0SX From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518038 CVCL_A0SI mHypoE-36 transformed cell line house mouse CVCL_A0SI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 150518039 CVCL_A0SJ mHypoE-43 transformed cell line house mouse CVCL_A0SJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 150518040 CVCL_A0SK mHypoA-Kiss/GFP-1 transformed cell line house mouse CVCL_A0SK CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: 129S6/SvEvTac x C57BL/6NCr Kiss-1tm1.1(cre/EGFP)Stei/J. Male 150518041 CVCL_A0SL mHypoA-Kiss/GFP-2 transformed cell line house mouse CVCL_A0SL CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: 129S6/SvEvTac x C57BL/6NCr Kiss-1tm1.1(cre/EGFP)Stei/J. Male 150518042 CVCL_A0SM mHypoA-Kiss/GFP-3 transformed cell line house mouse CVCL_A0SM CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; arcuate nucleus; Breed/subspecies: 129S6/SvEvTac x C57BL/6NCr Kiss-1tm1.1(cre/EGFP)Stei/J. Female 150518043 CVCL_A0SN mHypoA-Kiss/GFP-4 transformed cell line house mouse CVCL_A0SN CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; anteroventral periventricular nucleus; Breed/subspecies: 129S6/SvEvTac x C57BL/6NCr Kiss-1tm1.1(cre/EGFP)Stei/J. Female 150518044 CVCL_A0SP HEK293T ATXN3 KO transformed cell line human CVCL_A0SP From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7106; ATXN3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Laflamme C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518045 CVCL_A0SA 4H6 hybridoma house mouse CVCL_A0SA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518046 CVCL_A0SB 7F12 hybridoma house mouse CVCL_A0SB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06400; Human RB1 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5710255 and to be FO (Cellosaurus=CVCL_6972) in PubMed=7510760. 150518047 CVCL_A0SC mHypoE-2 transformed cell line house mouse CVCL_A0SC CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Belsham D.D.) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 150518048 CVCL_A0SD mHypoE-19 transformed cell line house mouse CVCL_A0SD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Belsham D.D.) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 150518049 CVCL_A0SE mHypoE-22 transformed cell line house mouse CVCL_A0SE CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Belsham D.D.) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 150518050 CVCL_A0SF mHypoE-20 transformed cell line house mouse CVCL_A0SF CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 150518051 CVCL_A0SG mHypoE-25 transformed cell line house mouse CVCL_A0SG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 150518052 CVCL_A0SH mHypoE-29 transformed cell line house mouse CVCL_A0SH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 150518053 CVCL_A0PV IIID5 spontaneously immortalized cell line CVCL_A0PV CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Bright, vacuoles; immovable, forms blastula-like sphere Group: Cnidaria cell line 150518054 CVCL_A0PW IIIB6 spontaneously immortalized cell line CVCL_A0PW CL:0000010 Miscellaneous: Cell line lost. Omics: Transcriptome analysis by RNAseq Characteristics: Bright, vacuoles; immovable, forms gastrula-like sphere Group: Cnidaria cell line 150518055 CVCL_A0PX EL4-Zbtb1 KO cancer cell line house mouse CVCL_A0PX CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:2442326; Zbtb1 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Omics: miRNA expression profiling Unspecified 150518056 CVCL_A0PY 18/1 hybridoma house mouse CVCL_A0PY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00746; Human CFD. 150518057 CVCL_A0PZ C18/3 hybridoma house mouse CVCL_A0PZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08603; Human CFH. 150518058 CVCL_A0PN GPC3-7C8 hybridoma house mouse CVCL_A0PN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201009 150518059 CVCL_A0PP IVB6 spontaneously immortalized cell line CVCL_A0PP CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Brilliant brown; forms cell aggregates; immovable Group: Cnidaria cell line 150518060 CVCL_A0PQ IIC5 spontaneously immortalized cell line CVCL_A0PQ CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Brilliant brown; forms filopodia; movable Group: Cnidaria cell line 150518061 CVCL_A0PR IVB4 spontaneously immortalized cell line CVCL_A0PR CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Dark, fattened; amorphous; forms lamellipodia; movable Doubling time: 4-5 days (PubMed=33899125) Group: Cnidaria cell line 150518062 CVCL_A0PS IVC4 spontaneously immortalized cell line CVCL_A0PS CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Dark, fattened; amorphous; forms lamellipodia; movable Doubling time: 4-5 days (PubMed=33899125) Group: Cnidaria cell line 150518063 CVCL_A0PT IVD1 spontaneously immortalized cell line CVCL_A0PT CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Dark, fattened; amorphous; forms lamellipodia; movable Doubling time: 4-5 days (PubMed=33899125) Group: Cnidaria cell line 150518064 CVCL_A0PU IVC6 spontaneously immortalized cell line CVCL_A0PU CL:0000010 Omics: Transcriptome analysis by RNAseq. Characteristics: Bright, vacuoles; immovable, forms cell sheet Group: Cnidaria cell line 150518065 CVCL_A0PF 2C9 [Mouse hybridoma against aflatoxin M1] hybridoma house mouse CVCL_A0PF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:78576; Aflatoxin M1 (AFM1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201018 150518066 CVCL_A0PG 4F12 [Mouse hybridoma against aflatoxin] hybridoma house mouse CVCL_A0PG CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518067 CVCL_A0PH 4F3 [Mouse hybridoma against aflatoxins] hybridoma house mouse CVCL_A0PH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518068 CVCL_A0PI 8E11 hybridoma house mouse CVCL_A0PI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518069 CVCL_A0PJ 8F6 hybridoma house mouse CVCL_A0PJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518070 CVCL_A0PK DE7 hybridoma house mouse CVCL_A0PK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1) (Note=Also reacts with AFB1, AFG2 and AFM1). 150518071 CVCL_A0PL 2G6 [Mouse hybridoma against aflatoxins G] hybridoma house mouse CVCL_A0PL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518072 CVCL_A0PM S-95-7 hybridoma house mouse CVCL_A0PM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A5P8NB39; Influenza A virus isolate A/California/7/2009 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201024 150518073 CVCL_A0PA 1C10 [Mouse hybridoma against aflatoxin G1] hybridoma house mouse CVCL_A0PA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1) (Note=Also reacts with AFG2). 150518074 CVCL_A0PB 1C11 [Mouse hybridoma against aflatoxins] hybridoma house mouse CVCL_A0PB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201013 150518075 CVCL_A0PC 1C8 [Mouse hybridoma against aflatoxin G1] hybridoma house mouse CVCL_A0PC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1) (Note=Also reacts with AFG2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201017 150518076 CVCL_A0PD 1D3 [Mouse hybridoma against aflatoxins] hybridoma house mouse CVCL_A0PD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518077 CVCL_A0PE 1E10 hybridoma house mouse CVCL_A0PE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518078 CVCL_A0QW ZN-5 hybridoma house mouse CVCL_A0QW From: Trevarrow B.; Institute of Neuroscience, University of Oregon; Eugene; USA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q90460; Danio rerio alcama/cd166a. 150518079 CVCL_A0QX ZN-8 hybridoma house mouse CVCL_A0QX From: Trevarrow B.; Institute of Neuroscience, University of Oregon; Eugene; USA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q90460; Danio rerio alcama/cd166a. 150518080 CVCL_A0QY AL-1 hybridoma house mouse CVCL_A0QY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Acholeplasma laidlawii. 150518081 CVCL_A0QZ AL-2 hybridoma house mouse CVCL_A0QZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Acholeplasma laidlawii. 150518082 CVCL_A0QP CGMCC-18525 hybridoma house mouse CVCL_A0QP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:189548; 3,5-dinitrosalicylic acid hydrazide (DNSH). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.18525 150518083 CVCL_A0QQ 30G8 hybridoma house mouse CVCL_A0QQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mycoplasma gallisepticum strain R. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-15207 150518084 CVCL_A0QR 34H1 hybridoma house mouse CVCL_A0QR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycoplasma gallisepticum strain R. 150518085 CVCL_A0QS 35A6 hybridoma house mouse CVCL_A0QS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; F8WJY4; Mycoplasma gallisepticum strain R MGC3 (crMA) (Note=Also reacts with other strains, but not avirulent strain F). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5244 150518086 CVCL_A0QT 35H5 hybridoma house mouse CVCL_A0QT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mycoplasma gallisepticum strain R. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-15206 150518087 CVCL_A0QU 38B7 hybridoma house mouse CVCL_A0QU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mycoplasma gallisepticum strain R. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-15205 150518088 CVCL_A0QV 39E8 hybridoma house mouse CVCL_A0QV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mycoplasma gallisepticum strain R. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-15208 150518089 CVCL_A0QG BRCA84D hybridoma house mouse CVCL_A0QG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line 150518090 CVCL_A0QH GB8 hybridoma house mouse CVCL_A0QH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518091 CVCL_A0QI OVCA22 hybridoma house mouse CVCL_A0QI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518092 CVCL_A0QJ PRCA157 hybridoma house mouse CVCL_A0QJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line 150518093 CVCL_A0QK SG27 hybridoma house mouse CVCL_A0QK CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518094 CVCL_A0QL TDH6 hybridoma house mouse CVCL_A0QL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518095 CVCL_A0QM TES7 hybridoma house mouse CVCL_A0QM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518096 CVCL_A0QN L20 hybridoma house mouse CVCL_A0QN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8913 150518097 CVCL_A0QA D10/4 hybridoma house mouse CVCL_A0QA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00746; Human CFD. 150518098 CVCL_A0QB L20/3 hybridoma house mouse CVCL_A0QB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08603; Human CFH. 150518099 CVCL_A0QC M13/12 hybridoma house mouse CVCL_A0QC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00751; Human CFB. 150518100 CVCL_A0QD P21/15 hybridoma house mouse CVCL_A0QD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00751; Human CFB. 150518101 CVCL_A0QE BRCA68D hybridoma house mouse CVCL_A0QE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 150518102 CVCL_A0QF BRCA69D hybridoma house mouse CVCL_A0QF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line 150518103 CVCL_A0NT 203E3 hybridoma house mouse CVCL_A0NT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKX5; Human ITGA11. 150518104 CVCL_A0NU 2H4 [Mouse hybridoma against human CALCA] hybridoma house mouse CVCL_A0NU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014232 150518105 CVCL_A0NV CGMCC-10417 hybridoma house mouse CVCL_A0NV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10417 150518106 CVCL_A0NW 277 34B3 20170123 hybridoma house mouse CVCL_A0NW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q5H943; Human CT83. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-02527 150518107 CVCL_A0NX LT006 hybridoma house mouse CVCL_A0NX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16552; Human IL17A Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017102 150518108 CVCL_A0NY LT007 hybridoma house mouse CVCL_A0NY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16552; Human IL17A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017165 150518109 CVCL_A0NZ 10C9 [Mouse hybridoma against aflatoxins] hybridoma house mouse CVCL_A0NZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). 150518110 CVCL_A0NL 7.10D7 hybridoma house mouse CVCL_A0NL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518111 CVCL_A0NM 7.10H2 hybridoma house mouse CVCL_A0NM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518112 CVCL_A0NN ZH68-2A4 hybridoma house mouse CVCL_A0NN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; B0F9T9; Trichinella spiralis serine protease Ts-ZH68. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.18317 150518113 CVCL_A0NP WN10-1H9 hybridoma house mouse CVCL_A0NP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; B0F9T2; Trichinella spiralis Ts-WN10. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.18316 150518114 CVCL_A0NQ C2C12-hITGA11 spontaneously immortalized cell line house mouse CVCL_A0NQ CL:0000010 Transfected with: HGNC; 6136; ITGA11; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 150518115 CVCL_A0NR 203E1H5 hybridoma house mouse CVCL_A0NR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKX5; Human ITGA11. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3318 150518116 CVCL_A0NS 234H11E8 hybridoma house mouse CVCL_A0NS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9UKX5; Human ITGA11. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3319 150518117 CVCL_A0ND 7.4A3 hybridoma house mouse CVCL_A0ND CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518118 CVCL_A0NE 7.7G5 hybridoma house mouse CVCL_A0NE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3899 150518119 CVCL_A0NF 7.8B3 hybridoma house mouse CVCL_A0NF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518120 CVCL_A0NG 7.8C9 hybridoma house mouse CVCL_A0NG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518121 CVCL_A0NH 7.8H12 hybridoma house mouse CVCL_A0NH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518122 CVCL_A0NI 7.9D4 hybridoma house mouse CVCL_A0NI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518123 CVCL_A0NJ 7.9G8 hybridoma house mouse CVCL_A0NJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518124 CVCL_A0NK 7.9H5 hybridoma house mouse CVCL_A0NK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518125 CVCL_A0NA 7.2A1 hybridoma house mouse CVCL_A0NA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518126 CVCL_A0NB 7.2F5 hybridoma house mouse CVCL_A0NB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518127 CVCL_A0NC 7.2H2 hybridoma house mouse CVCL_A0NC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. 150518128 CVCL_A0LR TRNDi012-H induced pluripotent stem cell human CVCL_A0LR From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518129 CVCL_A0LS TRNDi012-I induced pluripotent stem cell human CVCL_A0LS From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518130 CVCL_A0LT EURACi006-A induced pluripotent stem cell human CVCL_A0LT From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Gly548Valfs*15 (c.1643delG); ClinVar=VCV000202035; Zygosity=Heterozygous (PubMed=34134068) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518131 CVCL_A0LU EURACi006-A-1 induced pluripotent stem cell human CVCL_A0LU From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple_corrected; p.Gly548Valfs*15 (c.1643delG); ClinVar=VCV000202035; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34134068) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518132 CVCL_A0LV EURACi007-A induced pluripotent stem cell human CVCL_A0LV From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Asn346Leufs*12 (c.1035-5203_1171-13298del); Zygosity=Heterozygous (PubMed=34298432) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518133 CVCL_A0LW EURACi008-A induced pluripotent stem cell human CVCL_A0LW From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Asn346Leufs*12 (c.1035-5203_1171-13298del); Zygosity=Heterozygous (PubMed=34298432) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: While harboring the same PKP2 mutation as a family member from which EURACi007-A (Cellosaurus=CVCL_A0LV) was derived, the donor of this cell line did not show any symptom of arrhythmogenic right ventricular dysplasia 150518134 CVCL_A0LX EURACi009-A induced pluripotent stem cell human CVCL_A0LX From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518135 CVCL_A0LY AIBNi001-A induced pluripotent stem cell human CVCL_A0LY From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518136 CVCL_A0LJ TRNDi012-A induced pluripotent stem cell human CVCL_A0LJ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518137 CVCL_A0LK TRNDi012-B induced pluripotent stem cell human CVCL_A0LK From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (PubMed=34139597) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518138 CVCL_A0LL TRNDi012-C induced pluripotent stem cell human CVCL_A0LL From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518139 CVCL_A0LM TRNDi012-D induced pluripotent stem cell human CVCL_A0LM From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518140 CVCL_A0LN TRNDi012-E induced pluripotent stem cell human CVCL_A0LN From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518141 CVCL_A0LP TRNDi012-F induced pluripotent stem cell human CVCL_A0LP From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518142 CVCL_A0LQ TRNDi012-G induced pluripotent stem cell human CVCL_A0LQ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 150518143 CVCL_A0LB LANCEi020-A-8 induced pluripotent stem cell human CVCL_A0LB From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3713-28_3833del (Ex31del); Zygosity=Heterozygous (PubMed=34174776) Derived from sampling site: Peripheral blood. Male 150518144 CVCL_A0LC LANCEi020-A-9 induced pluripotent stem cell human CVCL_A0LC From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3603; FBN1 Derived from sampling site: Peripheral blood. Male 150518145 CVCL_A0LG MCRIi024-A induced pluripotent stem cell human CVCL_A0LG From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Gly148Asp (c.443G>A); Zygosity=Heterozygous (PubMed=34157503) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518146 CVCL_A0LH MCRIi024-A-1 induced pluripotent stem cell human CVCL_A0LH From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple_corrected; p.Gly148Asp (c.443G>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34157503) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518147 CVCL_A0LI BCHNi001-A induced pluripotent stem cell human CVCL_A0LI From: Department of Nephrology, Beijing Children's Hospital Affiliated to Capital Medical University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 18758; BBS7; Simple; p.Asp252Asn (c.754G>A); Zygosity=Heterozygous (PubMed=34146953); Sequence variation: Mutation; HGNC; 18758; BBS7; Simple; c.849+1G>C; ClinVar=VCV001507819; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=34146953) Population: Chinese; Derived from sampling site: Peripheral blood. Male 150518148 CVCL_A0KY LANCEi020-A-5 induced pluripotent stem cell human CVCL_A0KY From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 3603; FBN1 Derived from sampling site: Peripheral blood. Male 150518149 CVCL_A0KZ LANCEi020-A-6 induced pluripotent stem cell human CVCL_A0KZ From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 3603; FBN1 Derived from sampling site: Peripheral blood. Male 150518150 CVCL_A0LA LANCEi020-A-7 induced pluripotent stem cell human CVCL_A0LA From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3713-28_3833del (Ex31del); Zygosity=Heterozygous (PubMed=34174776) Derived from sampling site: Peripheral blood. Male 150518151 CVCL_A0MS 6.2E5 hybridoma house mouse CVCL_A0MS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3897 150518152 CVCL_A0MT 6.3G9 hybridoma house mouse CVCL_A0MT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3649 150518153 CVCL_A0MU 6.4B4 hybridoma house mouse CVCL_A0MU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. 150518154 CVCL_A0MV 6.6B5 hybridoma house mouse CVCL_A0MV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. 150518155 CVCL_A0MW 6.8B4 hybridoma house mouse CVCL_A0MW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. 150518156 CVCL_A0MX 6.8G6 hybridoma house mouse CVCL_A0MX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3645 150518157 CVCL_A0MY 7.1C5 hybridoma house mouse CVCL_A0MY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3900 150518158 CVCL_A0MZ 7.1G10 hybridoma house mouse CVCL_A0MZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Z0T9; Mouse Itgb6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3898 150518159 CVCL_A0MK SNUe003-A-3 embryonic stem cell human CVCL_A0MK From: Seoul National University; Seoul; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Population: Korean Male Characteristics: Using CRISPR/Cas9 a T2A-EGFP-polyA-PGKp-PuroR-polyA construct was introduced at the C-terminal end of MYH6 (PubMed=35427904) 150518160 CVCL_A0ML FDC-P1 Beta6 factor-dependent cell line house mouse CVCL_A0ML CL:0000010 Transfected with: MGI; MGI:96615; Itgb6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. 150518161 CVCL_A0MM NIH 3T3 Beta6 spontaneously immortalized cell line house mouse CVCL_A0MM CL:0000010 Transfected with: MGI; MGI:96615; Itgb6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 150518162 CVCL_A0MN 6.1A8 hybridoma house mouse CVCL_A0MN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3647 150518163 CVCL_A0MP 6.2A1 hybridoma house mouse CVCL_A0MP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3896 150518164 CVCL_A0MQ 6.2B1 hybridoma house mouse CVCL_A0MQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3646 150518165 CVCL_A0MR 6.2B10 hybridoma house mouse CVCL_A0MR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3648 150518166 CVCL_A0MC AUi001-A induced pluripotent stem cell human CVCL_A0MC From: Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6118; IRF3; Simple; p.Arg285Gln (c.854G>A); ClinVar=VCV000208454; Zygosity=Heterozygous Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518167 CVCL_A0MD AUi002-A induced pluripotent stem cell human CVCL_A0MD From: Aarhus University; Aarhus; Denmark. CL:0000010 150518168 CVCL_A0ME HRMSDUi001-A induced pluripotent stem cell human CVCL_A0ME From: Hospital for Reproductive Medicine Affiliated to Shandong University; Jinan; China CL:0000010 Population: Chinese; Han; Karyotypic information: 45,XY,der(13;14)(q10;q10) (PubMed=34284274); Derived from sampling site: Peripheral blood. Male 150518169 CVCL_A0MF KUMi002-A induced pluripotent stem cell human CVCL_A0MF From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Population: Korean; Donor information: Established from a patient suffering from chronic myeloid leukemia with BCR-ABL but has a normal karyotype; Derived from sampling site: Bone marrow. Male 150518170 CVCL_A0MG KUMi001-A induced pluripotent stem cell human CVCL_A0MG From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=34280890) Population: Korean; Derived from sampling site: Bone marrow. Male 150518171 CVCL_A0MH XMMPS-OP3 hybridoma house mouse CVCL_A0MH CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa Fisher type 3 core lipopolysaccharide (LPS). 150518172 CVCL_A0MI XMMPS-OP4 hybridoma house mouse CVCL_A0MI CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa Fisher type 4 core lipopolysaccharide (LPS). 150518173 CVCL_A0MJ XMMPS-OP7 hybridoma house mouse CVCL_A0MJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Pseudomonas aeruginosa Fisher type 7 core lipopolysaccharide (LPS). 150518174 CVCL_A0LZ AIBNi002-A induced pluripotent stem cell human CVCL_A0LZ From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518175 CVCL_A0MA NCUFi001-A induced pluripotent stem cell human CVCL_A0MA From: Niccolo Cusano University Foundation; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly314Ser (c.940G>A) (p.Gly187Ser, c.559G>A); ClinVar=VCV000003123; Zygosity=Heterozygous (PubMed=34130155) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518176 CVCL_A0MB UGOTSAi001-A induced pluripotent stem cell human CVCL_A0MB From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Female 150518177 CVCL_A0ZX MUSIi015-A induced pluripotent stem cell human CVCL_A0ZX From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4174; GATA6; Simple; p.Glu51Lys (c.151G>T); Zygosity=Heterozygous (PubMed=35853413); Sequence variation: Mutation; HGNC; 32058; ZYG11A; Simple; p.Leu475Pro (c.1424T>C); Zygosity=Heterozygous (PubMed=35853413) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 150518178 CVCL_A0ZY MUSIi001-A-1 induced pluripotent stem cell human CVCL_A0ZY From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Southeast Asian; Thai; Derived from sampling site: Abdomen; skin; dermis (Note=From a cesarean section scar). Female 150518179 CVCL_A0ZZ ZJUi005-A [Wrong name] induced pluripotent stem cell human CVCL_A0ZZ From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2245Tyr (c.6734G>A); ClinVar=VCV000968455; Zygosity=Heterozygous (PubMed=34298435) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: There are 2 cell lines generated by the same group with the same name This cell line should be renamed. 150518180 CVCL_A0ZP NCTC 2168 spontaneously immortalized cell line house mouse CVCL_A0ZP CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 150518181 CVCL_A0ZQ NCTC 1742 cancer cell line house mouse CVCL_A0ZQ CL:0000010 Derived from sampling site: Adipose tissue; hypodermis; Breed/subspecies: C3H/HeN. Male 150518182 CVCL_A0ZR NCTC 2049 spontaneously immortalized cell line house mouse CVCL_A0ZR CL:0000010 Derived from sampling site: Adipose tissue; hypodermis; Breed/subspecies: C3H/HeN. Male 150518183 CVCL_A0ZS PLAFMCi005-A induced pluripotent stem cell human CVCL_A0ZS From: Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 11630; HNF1B; Simple; c.544+3_544+6delAAGT; ClinVar=VCV000635668; Zygosity=Heterozygous (PubMed=34359001) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518184 CVCL_A0ZT UMi031-A induced pluripotent stem cell human CVCL_A0ZT From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518185 CVCL_A0ZU UMi031-A-2 induced pluripotent stem cell human CVCL_A0ZU From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple_edited; p.Leu64Pro (c.191T>C); ClinVar=VCV001006297; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34352618) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518186 CVCL_A0ZV MUSIi013-A induced pluripotent stem cell human CVCL_A0ZV From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Umbilical cord blood Cell type=Natural killer cell.. Female 150518187 CVCL_A0ZW MUSIi014-A induced pluripotent stem cell human CVCL_A0ZW From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 32058; ZYG11A; Simple; p.Leu475Pro (c.1424T>C); Zygosity=Heterozygous (PubMed=35193007) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 150518188 CVCL_A0ZH UWRBTi003-C induced pluripotent stem cell human CVCL_A0ZH From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (PubMed=34419748) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518189 CVCL_A0ZI UWRBTi004-A induced pluripotent stem cell human CVCL_A0ZI From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (PubMed=34419748) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518190 CVCL_A0ZJ UWRBTi004-B induced pluripotent stem cell human CVCL_A0ZJ From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (PubMed=34419748) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518191 CVCL_A0ZK UWRBTi004-C induced pluripotent stem cell human CVCL_A0ZK From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (from autologous cell lines UWRBTi004-A and UWRBTi004-B) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518192 CVCL_A0ZL HIHTFi001-A induced pluripotent stem cell human CVCL_A0ZL From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 21168; RHOT1; Simple_edited; p.Ser156Ala (c.466T>G); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34359002) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518193 CVCL_A0ZM HIHTFi001-B induced pluripotent stem cell human CVCL_A0ZM From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 21168; RHOT1; Simple_edited; p.Arg272Gln (c.815G>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34359002) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518194 CVCL_A0ZN HIHTFi001-C induced pluripotent stem cell human CVCL_A0ZN From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 21168; RHOT1; Simple_edited; p.Lys572Arg (c.1714_1716AAA>CGG); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34359002) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518195 CVCL_A0YA OSRi010-A induced pluripotent stem cell human CVCL_A0YA From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple; p.Ile871Thr (c.2612T>C); ClinVar=VCV000001031; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518196 CVCL_A0YB OSRi010-A-1 induced pluripotent stem cell human CVCL_A0YB From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple_corrected; p.Ile871Thr (c.2612T>C); ClinVar=VCV000001031; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518197 CVCL_A0YC AIBNi003-A induced pluripotent stem cell human CVCL_A0YC From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518198 CVCL_A0YD AIBNi004-A induced pluripotent stem cell human CVCL_A0YD From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518199 CVCL_A0YE AIBNi005-A induced pluripotent stem cell human CVCL_A0YE From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518200 CVCL_A0YF AIBNi006-A induced pluripotent stem cell human CVCL_A0YF From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518201 CVCL_A0XV ZMAC-4 factor-dependent cell line pig CVCL_A0XV CL:0000010 Derived from sampling site: Fetal lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace x Yorkshire x Duroc. Unspecified Characteristics: CSF1 dependent; Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) (PubMed=21191013); Virology: Supports high level of replication of African swine fever virus attenuated strain OURT88/3 (PubMed=32515659) Doubling time: 3.9 +- 0.3 days (PubMed=32515659) 150518202 CVCL_A0XW PCIi032-A induced pluripotent stem cell human CVCL_A0XW From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Female 150518203 CVCL_A0XX PCIi033-A induced pluripotent stem cell human CVCL_A0XX From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518204 CVCL_A0XY OSRi009-A induced pluripotent stem cell human CVCL_A0XY From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple; p.Asp868Asn (c.2602G>A); ClinVar=VCV000001032; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518205 CVCL_A0XZ OSRi009-A-1 induced pluripotent stem cell human CVCL_A0XZ From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple_corrected; p.Asp868Asn (c.2602G>A); ClinVar=VCV000001032; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518206 CVCL_A0XN 12 060 cancer cell line human CVCL_A0XN CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 6.6 days (PubMed=33251771) 150518207 CVCL_A0XP 12 073 cancer cell line human CVCL_A0XP CL:0000010 Derived from sampling site: Brain; right frontal lobe. Male Doubling time: 4.2 days (PubMed=33251771) 150518208 CVCL_A0XQ 12 075 cancer cell line human CVCL_A0XQ CL:0000010 Derived from sampling site: Brain; right frontal lobe. Female Doubling time: 13.6 days (PubMed=33251771) 150518209 CVCL_A0XR 12 079 cancer cell line human CVCL_A0XR CL:0000010 Derived from sampling site: Brain; left parieto-occipital lobe. Female Doubling time: 2.3 days (PubMed=33251771) 150518210 CVCL_A0XS 13 019 cancer cell line human CVCL_A0XS CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 1.6 days (PubMed=33251771) 150518211 CVCL_A0XT 13 025 cancer cell line human CVCL_A0XT CL:0000010 Derived from sampling site: Brain; left temporal lobe. Male Doubling time: 4.7 days (PubMed=33251771) 150518212 CVCL_A0XU CL2621 spontaneously immortalized cell line CVCL_A0XU From: Boehringer Ingelheim Animal Health, Inc.; St Joseph; USA. CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Non-human primate cell line Problematic cell line: Misidentified Parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 150518213 CVCL_A0XF 11 045 cancer cell line human CVCL_A0XF CL:0000010 Derived from sampling site: Brain; left temporal lobe. Male Doubling time: 2.3 days (PubMed=33251771) 150518214 CVCL_A0XG 11 068 cancer cell line human CVCL_A0XG CL:0000010 Derived from sampling site: Brain; right temporal lobe. Male Doubling time: 3.5 days (PubMed=33251771) 150518215 CVCL_A0XH 11 091 cancer cell line human CVCL_A0XH CL:0000010 Derived from sampling site: Brain; left fronto-parietal lobe. Female Doubling time: 13.4 days (PubMed=33251771) 150518216 CVCL_A0XI 12 040 cancer cell line human CVCL_A0XI CL:0000010 Derived from sampling site: Brain; right temporal lobe. Male Doubling time: 6.7 days (PubMed=33251771) 150518217 CVCL_A0XJ 12 041 cancer cell line human CVCL_A0XJ CL:0000010 Derived from sampling site: Brain; left parieto-occipital lobe. Female Doubling time: 2.2 days (PubMed=33251771) 150518218 CVCL_A0XK 12 046 cancer cell line human CVCL_A0XK CL:0000010 Derived from sampling site: Brain; right temporo-occipital lobe. Female Doubling time: 10.3 days (PubMed=33251771) 150518219 CVCL_A0XL 12 058 cancer cell line human CVCL_A0XL CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 8.5 days (PubMed=33251771) 150518220 CVCL_A0XM 12 059 cancer cell line human CVCL_A0XM CL:0000010 Derived from sampling site: Brain; left temporal lobe. Female Doubling time: 5.8 days (PubMed=33251771) 150518221 CVCL_A0ZA UWRBTi001-B induced pluripotent stem cell human CVCL_A0ZA From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518222 CVCL_A0ZB UWRBTi001-C induced pluripotent stem cell human CVCL_A0ZB From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518223 CVCL_A0ZC UWRBTi002-A induced pluripotent stem cell human CVCL_A0ZC From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518224 CVCL_A0ZD UWRBTi002-B induced pluripotent stem cell human CVCL_A0ZD From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518225 CVCL_A0ZE UWRBTi002-C induced pluripotent stem cell human CVCL_A0ZE From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518226 CVCL_A0ZF UWRBTi003-A induced pluripotent stem cell human CVCL_A0ZF From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (from autologous cell lines UWRBTi003-B and UWRBTi003-C) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518227 CVCL_A0ZG UWRBTi003-B induced pluripotent stem cell human CVCL_A0ZG From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Ser52Alafs*13 (c.153delC); ClinVar=VCV001074960; Zygosity=Hemizygous (PubMed=34419748) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518228 CVCL_A0YW 4TCYA1 hybridoma house mouse CVCL_A0YW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24522; Human GADD45A. 150518229 CVCL_A0YX MDA-MB-231bo cancer cell line human CVCL_A0YX CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Metastatic to bone Established after injection of the parent cell line in the left ventricle of the heart of female nude mice and retrieving the bone metastatic cells and repeating this procedure 11 times. Group: Triple negative breast cancer (TNBC) cell line 150518230 CVCL_A0YY MDA-MB-231br cancer cell line human CVCL_A0YY CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Metastatic to brain Established after injection of the parent cell line in the left ventricle of the heart of female nude mice and retrieving the brain metastatic cells and repeating this procedure 6 times. Group: Triple negative breast cancer (TNBC) cell line 150518231 CVCL_A0YZ UWRBTi001-A induced pluripotent stem cell human CVCL_A0YZ From: Faculty of Biotechnology, University of Wroclaw; Wroclaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518232 CVCL_A0YP MHHi022-A induced pluripotent stem cell human CVCL_A0YP From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.His533Arg (c.1598A>G); ClinVar=VCV000425962; Zygosity=Heterozygous (PubMed=34388490) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518233 CVCL_A0YQ MHHi023-A induced pluripotent stem cell human CVCL_A0YQ From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys84_Ser140del (c.248-1_418+1del171) (Ex3del); Zygosity=Heterozygous (PubMed=34388490) Population: Asian; Derived from sampling site: Peripheral blood. Female 150518234 CVCL_A0YR MHHi024-A induced pluripotent stem cell human CVCL_A0YR From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Arg491Trp (c.1471C>T); ClinVar=VCV000008802; Zygosity=Heterozygous (PubMed=34388490) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518235 CVCL_A0YS UKEi070-A induced pluripotent stem cell human CVCL_A0YS From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Asp770Asn (c.2308G>A) (p.Asp770Serfs*98); ClinVar=VCV000036604; Zygosity=Heterozygous; Note=Causes aberrant splicing (PubMed=34375846) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518236 CVCL_A0YT UKEi070-A-1 induced pluripotent stem cell human CVCL_A0YT From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple_corrected; p.Asp770Asn (c.2308G>A) (p.Asp770Serfs*98); ClinVar=VCV000036604; Zygosity=Heterozygous; Note=Causes aberrant splicing By CRISPR/Cas9 (PubMed=34375846). Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518237 CVCL_A0YU UKEi070-A-2 induced pluripotent stem cell human CVCL_A0YU From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Asp770Asn (c.2308G>A) (p.Asp770Serfs*98); ClinVar=VCV000036604; Zygosity=Heterozygous; Note=Causes aberrant splicing (PubMed=34375846); Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple_edited; p.Arg943Ter (c.2827C>T); ClinVar=VCV000037039; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34375846) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518238 CVCL_A0YV 30T.14 hybridoma house mouse CVCL_A0YV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P24522; Human GADD45A. 150518239 CVCL_A0YG AIBNi007-A induced pluripotent stem cell human CVCL_A0YG From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518240 CVCL_A0YH AIBNi008-A induced pluripotent stem cell human CVCL_A0YH From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518241 CVCL_A0YI AIBNi009-A induced pluripotent stem cell human CVCL_A0YI From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Male 150518242 CVCL_A0YJ AIBNi010-A induced pluripotent stem cell human CVCL_A0YJ From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518243 CVCL_A0YK AIBNi011-A induced pluripotent stem cell human CVCL_A0YK From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518244 CVCL_A0YL AIBNi012-A induced pluripotent stem cell human CVCL_A0YL From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Peripheral blood. Female 150518245 CVCL_A0YM NERCi001-A induced pluripotent stem cell human CVCL_A0YM From: National Engineering and Research Center of Human Stem Cell; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Arg599Gln (c.1796G>A); ClinVar=VCV000635412; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Ser947Pro (c.2839T>C); ClinVar=VCV000635413; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Glu1116Gln (c.3346G>C); ClinVar=VCV000635414; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Placenta. Male 150518246 CVCL_A0YN TJCi001-A induced pluripotent stem cell human CVCL_A0YN From: TJC Life; Seoul; South Korea CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 150518247 CVCL_A0WA A549-A2-ESO cancer cell line human CVCL_A0WA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 24198; CTAG1A; Transfected with: HGNC; 4931; HLA-A (allele A*2); Transfected with: CBG, click beetle green luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with both a CBG-T2A-GFP construct and a NY-ESO-1-T2A-HLA-A2 construct 150518248 CVCL_A0WB BT-IMF spontaneously immortalized cell line CVCL_A0WB CL:0000010 Derived from sampling site: Fetal intestine Cell type=Myofibroblast.. Unspecified 150518249 CVCL_A0WC GreenTad-HF1 spontaneously immortalized cell line CVCL_A0WC CL:0000010 Derived from sampling site: Cephalic region Cell type=Fibroblast.. Unspecified Group: Amphibian cell line 150518250 CVCL_A0WD GreenTad-HF2 spontaneously immortalized cell line CVCL_A0WD CL:0000010 Derived from sampling site: Cephalic region Cell type=Fibroblast.. Unspecified Group: Amphibian cell line 150518251 CVCL_A0VT ICGi030-A induced pluripotent stem cell human CVCL_A0VT From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Lys1013Glnfs*15 (c.3036dupC); ClinVar=VCV000495410; Zygosity=Heterozygous (PubMed=34736038); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (PubMed=34736038) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518252 CVCL_A0VU WAe001-A-73 embryonic stem cell human CVCL_A0VU From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30778; GATAD2B. Male 150518253 CVCL_A0VV WAe001-A-74 embryonic stem cell human CVCL_A0VV From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30778; GATAD2B. Male 150518254 CVCL_A0VW DT4994 cancer cell line house mouse CVCL_A0VW From: Tuveson D.; Cold Spring Harbor Laboratory; Cold Spring Harbor; USA CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: Tg(Pdx1-cre),LSL-Kras(G12D/+). 150518255 CVCL_A0VX DT6606 cancer cell line house mouse CVCL_A0VX From: Tuveson D.; Cold Spring Harbor Laboratory; Cold Spring Harbor; USA CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: Tg(Pdx1-cre),LSL-Kras(G12D/+). 150518256 CVCL_A0VY DT6606-OVA cancer cell line house mouse CVCL_A0VY CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas; Breed/subspecies: Tg(Pdx1-cre),LSL-Kras(G12D/+). 150518257 CVCL_A0VZ A549-CBG cancer cell line human CVCL_A0VZ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: CBG, click beetle green luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a CBG-T2A-GFP construct 150518258 CVCL_A0VL MS-EwS-3 cancer cell line human CVCL_A0VL CL:0000010 Miscellaneous: STR profile from personal communication of Rossig C Derived from metastatic site: Lung. Male 150518259 CVCL_A0VM MS-EwS-4 cancer cell line human CVCL_A0VM CL:0000010 Derived from metastatic site: Liver. Male 150518260 CVCL_A0VN MS-EwS-6 cancer cell line human CVCL_A0VN CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (Direct_author_submission) Miscellaneous: Gene fusion, site of sampling and age of donor from personal communication of Rossig C Derived from metastatic site: Thoracic cavity. Male 150518261 CVCL_A0VP MS-EwS-15 cancer cell line human CVCL_A0VP CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (Direct_author_submission) Miscellaneous: Gene fusion from personal communication of Rossig C Derived from metastatic site: Not specified. Male 150518262 CVCL_A0VQ MS-EwS-16 cancer cell line human CVCL_A0VQ CL:0000010 Derived from metastatic site: Bone; vertebra. Male 150518263 CVCL_A0VR MS-EwS-34 cancer cell line human CVCL_A0VR CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (Direct_author_submission) Miscellaneous: Gene fusion, site of sampling, sex and age of donor from personal communication of Rossig C Derived from metastatic site: Bone marrow. Male 150518264 CVCL_A0VS MS-EwS-5 cancer cell line human CVCL_A0VS CL:0000010 Miscellaneous: STR profile and sex of donor from personal communication of Rossig C Derived from metastatic site: Lung. Male 150518265 CVCL_A0VD 10B1A2 hybridoma house mouse CVCL_A0VD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. 150518266 CVCL_A0VE 12B2E1 hybridoma house mouse CVCL_A0VE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201761 150518267 CVCL_A0VF 12H6G1 hybridoma house mouse CVCL_A0VF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201762 150518268 CVCL_A0VG 14A12G11 hybridoma house mouse CVCL_A0VG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. 150518269 CVCL_A0VH 3T3-mB7-H4 spontaneously immortalized cell line house mouse CVCL_A0VH CL:0000010 Transfected with: MGI; MGI:3039619; Vtcn1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 150518270 CVCL_A0VI 3E8 [Mouse hybridoma against mouse Vtcn1] hybridoma house mouse CVCL_A0VI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q7TSP5; Mouse Vtcn1 (Note=Also reacts with human). 150518271 CVCL_A0VJ 4H8 hybridoma house mouse CVCL_A0VJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7TSP5; Mouse Vtcn1 (Note=Also reacts with human). 150518272 CVCL_A0VK MS-EwS-1 cancer cell line human CVCL_A0VK CL:0000010 Derived from metastatic site: Soft tissue. Male 150518273 CVCL_A0XA Wall cancer cell line dog CVCL_A0XA CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Glu273Lys (c.818C>T); Zygosity=Unspecified (PubMed=34079834) Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; rib; Breed/subspecies: Giant Schnauzer. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518274 CVCL_A0XB SRH cancer cell line human CVCL_A0XB CL:0000010 Sequence variation: Mutation; HGNC; 7611; MYOD1; Simple; p.Leu122Arg (c.365T>G); Zygosity=Homozygous (PubMed=33322555); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=33322555); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Unspecified (PubMed=33322555) Derived from sampling site: Left leg; skeletal muscle. Omics: Array-based CGH Female Doubling time: 34.3 +- 2.5 hours (PubMed=33322555) 150518275 CVCL_A0XC SHG-140 cancer cell line human CVCL_A0XC CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Val178Ile (c.532G>A); ClinVar=VCV000134520; Zygosity=Homozygous (PubMed=33391433); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg1968Ter (c.5902C>T) (p.Arg1947Ter, c.5839C>T); ClinVar=VCV000000343; Zygosity=Homozygous (PubMed=33391433); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (PubMed=33391433); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=33391433) Population: Chinese; Derived from sampling site: Brain. Male 150518276 CVCL_A0XD 11 029 cancer cell line human CVCL_A0XD CL:0000010 Derived from sampling site: Brain; right occipital lobe. Male Doubling time: 6.6 days (PubMed=33251771) 150518277 CVCL_A0XE 11 030 cancer cell line human CVCL_A0XE CL:0000010 Derived from sampling site: Brain; right temporo-parietal lobe. Female Doubling time: 1.8 days (PubMed=33251771) 150518278 CVCL_A0WU Dark cancer cell line dog CVCL_A0WU CL:0000010 Miscellaneous: Breed from personal communication of Gola C Derived from metastatic site: Lymph node; Breed/subspecies: Beauceron. Male 150518279 CVCL_A0WV Desmond cancer cell line dog CVCL_A0WV CL:0000010 Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; distal radius; Breed/subspecies: Greyhound. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518280 CVCL_A0WW Lord cancer cell line dog CVCL_A0WW CL:0000010 Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; distal tibia; Breed/subspecies: Cane corso. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518281 CVCL_A0WX Pedro cancer cell line dog CVCL_A0WX CL:0000010 Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; distal radius; Breed/subspecies: Labrador Retriever. Omics: Deep exome analysis Male 150518282 CVCL_A0WY Penny cancer cell line dog CVCL_A0WY CL:0000010 Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; tail; Breed/subspecies: Boxer. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518283 CVCL_A0WZ Sky cancer cell line dog CVCL_A0WZ CL:0000010 Miscellaneous: Sampling site and breed from personal communication of Gola C Derived from sampling site: Bone; proximal femur; Breed/subspecies: Boxer. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518284 CVCL_A0WM mes-c-myc A1 transformed cell line house mouse CVCL_A0WM CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Myc; Derived from sampling site: Embryonic brain; mesencephalon; Breed/subspecies: CD-1. Omics: Secretome proteome analysis Unspecified Characteristics: Cease to divide and undergo morphological differentiation after serum withdrawal or addition of cAMP (PubMed=10527628); Characteristics: Established by infection with a replication-defective retrovirus bearing the MYC and neo genes under the control of MLV LTR promoter 150518285 CVCL_A0WN CLC-1 spontaneously immortalized cell line dog CVCL_A0WN CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Unspecified Doubling time: 48.8 +- 3.3 hours (PubMed=34248270) 150518286 CVCL_A0WP BHSK finite cell line CVCL_A0WP CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 150518287 CVCL_A0WQ BHST finite cell line CVCL_A0WQ CL:0000010 Derived from sampling site: Fetal nose; nasal cavity; nasal turbinate. Unspecified 150518288 CVCL_A0WR BHSFL finite cell line CVCL_A0WR CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Fetal lung. Unspecified Virology: Susceptible to infection by bovine parainfluenza virus 3 (BPIV-3), bovine respiratory syncytial virus (BRSV), bovine viral diarrhea virus (BVDV) and bovine herpesvirus 1 (BoHV-1) (PubMed=20357964) 150518289 CVCL_A0WS DOUG cancer cell line dog CVCL_A0WS CL:0000010 Derived from metastatic site: Bone; right proximal humerus; Breed/subspecies: Rottweiler. Omics: Transcriptome analysis by single cell RNAseq Male 150518290 CVCL_A0WT FSCSC cancer cell line CVCL_A0WT CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Right hindlimb; synovium. Male 150518291 CVCL_A0WE GreenTad-HF3 spontaneously immortalized cell line CVCL_A0WE CL:0000010 Derived from sampling site: Cephalic region Cell type=Fibroblast.. Unspecified Group: Amphibian cell line 150518292 CVCL_A0WF GreenTad-HE4 spontaneously immortalized cell line CVCL_A0WF CL:0000010 Derived from sampling site: Cephalic region Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 150518293 CVCL_A0WG GreenTad-gill spontaneously immortalized cell line CVCL_A0WG CL:0000010 Derived from sampling site: Gill. Unspecified Group: Amphibian cell line 150518294 CVCL_A0WH WoodTad-HE1 spontaneously immortalized cell line CVCL_A0WH CL:0000010 Derived from sampling site: Cephalic region Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 150518295 CVCL_A0WI WoodTad-Bone spontaneously immortalized cell line CVCL_A0WI CL:0000010 Derived from sampling site: Bone; hindlimb. Unspecified Group: Amphibian cell line 150518296 CVCL_A0WJ WoodTad-rpe spontaneously immortalized cell line CVCL_A0WJ CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Unspecified Group: Amphibian cell line 150518297 CVCL_A0WK TOS1 finite cell line human CVCL_A0WK CL:0000010 Miscellaneous: Age/sex of donor, sampling site and doubling time from personal communication of Brandi M.L Derived from sampling site: Bone; femur. Male Doubling time: 125 hours (Direct_author_submission) 150518298 CVCL_A0WL TOS1-CSCs cancer cell line human CVCL_A0WL CL:0000010 Miscellaneous: Age/sex of donor and sampling site from personal communication of Brandi M.L Derived from sampling site: Bone; femur. Male Group: Cancer stem cell line 150518299 CVCL_A0TZ 32D.C10 factor-dependent cell line house mouse CVCL_A0TZ CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent; Characteristics: Does not express endogenous Csf3r 150518300 CVCL_A0UA 32D/G-CSF-R factor-dependent cell line house mouse CVCL_A0UA CL:0000010 Transfected with: HGNC; 2439; CSF3R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518301 CVCL_A0UB 32D/G-CSF-R p.Gln741Ter factor-dependent cell line house mouse CVCL_A0UB CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Gln741Ter); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518302 CVCL_A0TR G8B11 hybridoma house mouse CVCL_A0TR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03971; Human AMH. 150518303 CVCL_A0TS CHO-S/H9C2 spontaneously immortalized cell line CVCL_A0TS CL:0000010 Transfected with: HGNC; 3546; F8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014191 150518304 CVCL_A0TT WTH-1 hybridoma house mouse CVCL_A0TT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q63493; Rat Cd1d (Note=Also reacts with mouse). 150518305 CVCL_A0TU WTH-2 hybridoma house mouse CVCL_A0TU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q63493; Rat Cd1d (Note=Also reacts with mouse). 150518306 CVCL_A0TV GCLP hybridoma house mouse CVCL_A0TV CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014195 150518307 CVCL_A0TW 12H11 hybridoma house mouse CVCL_A0TW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014196 150518308 CVCL_A0TX HGrC1-YAP transformed cell line human CVCL_A0TX CL:0000010 Transfected with: HGNC; 16262; YAP1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 150518309 CVCL_A0TY HGrC1-YAP(S127A) transformed cell line human CVCL_A0TY CL:0000010 Transfected with: HGNC; 16262; YAP1 (with p.Ser127Ala); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 150518310 CVCL_A0TJ HEK293 FUS KO transformed cell line human CVCL_A0TJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 150518311 CVCL_A0TK N2A Psen1/Psen2 dKO cancer cell line house mouse CVCL_A0TK CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1202717; Psen1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:109284; Psen2 Breed/subspecies: A/J. Male 150518312 CVCL_A0TL RK-13/CD40L spontaneously immortalized cell line CVCL_A0TL CL:0000010 Transfected with: UniProtKB; G1SKP7; Rabbit CD40LG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018180 150518313 CVCL_A0TM C9F2-2 hybridoma house mouse CVCL_A0TM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03971; Human AMH. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018183 150518314 CVCL_A0TN 7D11-1 hybridoma house mouse CVCL_A0TN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03971; Human AMH. 150518315 CVCL_A0TP C17B10 hybridoma house mouse CVCL_A0TP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03971; Human AMH. 150518316 CVCL_A0TQ C8H3-2 hybridoma house mouse CVCL_A0TQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03971; Human AMH. 150518317 CVCL_A0TB MRIi017-A induced pluripotent stem cell human CVCL_A0TB From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 150518318 CVCL_A0TC MRIi020-A induced pluripotent stem cell human CVCL_A0TC From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 150518319 CVCL_A0TD MRIi021-A induced pluripotent stem cell human CVCL_A0TD From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 150518320 CVCL_A0TE MRIi022-A induced pluripotent stem cell human CVCL_A0TE From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 150518321 CVCL_A0TF MRIi023-A induced pluripotent stem cell human CVCL_A0TF From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 150518322 CVCL_A0TG MRIi019-A induced pluripotent stem cell human CVCL_A0TG From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 150518323 CVCL_A0TH MRIi028-A induced pluripotent stem cell human CVCL_A0TH From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Sequence variation: Mutation; HGNC; 25686; PPCS; Simple; p.Glu233Val (c.698A>T); ClinVar=VCV000590782; Zygosity=Homozygous (PubMed=35397396) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518324 CVCL_A0TI Huh-7.5 Tet-On cancer cell line human CVCL_A0TI CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 150518325 CVCL_A0VA 4D1C2 hybridoma house mouse CVCL_A0VA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. 150518326 CVCL_A0VB 6F9D5 hybridoma house mouse CVCL_A0VB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. 150518327 CVCL_A0VC 8H3C4 hybridoma house mouse CVCL_A0VC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201760 150518328 CVCL_A0US SP2/0-01-SPINK1-SUN hybridoma house mouse CVCL_A0US CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00995; Human SPINK1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018213 150518329 CVCL_A0UT PGGG spontaneously immortalized cell line CVCL_A0UT CL:0000010 Derived from sampling site: Gill. Unspecified Doubling time: 41.8 hours (at 20th passage), 41.4 hours (at 40th passage), 37.7 hours (at 60th passage) (PubMed=33396134) Group: Fish cell line 150518330 CVCL_A0UU 1C1H11 hybridoma house mouse CVCL_A0UU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201758 150518331 CVCL_A0UV MLA-144 clone E7T cancer cell line CVCL_A0UV CL:0000010 Transformant: Gibbon ape leukemia virus (GALV)(NCBI-Taxonomy; 11840); Derived from sampling site: Lymph node. Characteristics: Glucocorticoid sensitive clone Group: Non-human primate cell line 150518332 CVCL_A0UW MLA-144 clone 15T cancer cell line CVCL_A0UW CL:0000010 Transformant: Gibbon ape leukemia virus (GALV)(NCBI-Taxonomy; 11840); Derived from sampling site: Lymph node. Characteristics: Glucocorticoid sensitive clone Group: Non-human primate cell line 150518333 CVCL_A0UX MLA-144 clone 8T cancer cell line CVCL_A0UX CL:0000010 Transformant: Gibbon ape leukemia virus (GALV)(NCBI-Taxonomy; 11840); Derived from sampling site: Lymph node. Characteristics: Glucocorticoid resistant clone Group: Non-human primate cell line 150518334 CVCL_A0UY 2B12B6 hybridoma house mouse CVCL_A0UY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. 150518335 CVCL_A0UZ 3E5G7 hybridoma house mouse CVCL_A0UZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7Z7D3; Human VTCN1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201759 150518336 CVCL_A0UK 4D1 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_A0UK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200606 150518337 CVCL_A0UL 3G4 hybridoma house mouse CVCL_A0UL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200604 150518338 CVCL_A0UM 2F2 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_A0UM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200424 150518339 CVCL_A0UN 29A9 hybridoma house mouse CVCL_A0UN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018181 150518340 CVCL_A0UP A4-1B1 hybridoma house mouse CVCL_A0UP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017144 150518341 CVCL_A0UQ A4-6A2 hybridoma house mouse CVCL_A0UQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017143 150518342 CVCL_A0UR AT 36-38 hybridoma house mouse CVCL_A0UR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; A6NLP5; Human TTC36. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018196 150518343 CVCL_A0UC 32D/G-CSF-R p.Gln754Ter factor-dependent cell line house mouse CVCL_A0UC CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Gln754Ter); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518344 CVCL_A0UD 32D/G-CSF-R p.Gln739Ter factor-dependent cell line house mouse CVCL_A0UD CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Gln739Ter); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518345 CVCL_A0UE 32D/G-CSF-R p.Tyr727Phe factor-dependent cell line house mouse CVCL_A0UE CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Tyr727Phe); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518346 CVCL_A0UF 32D/G-CSF-R p.Tyr752Phe factor-dependent cell line house mouse CVCL_A0UF CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Tyr752Phe); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518347 CVCL_A0UG 32D/G-CSF-R p.Tyr767Phe factor-dependent cell line house mouse CVCL_A0UG CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Tyr767Phe); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518348 CVCL_A0UH 32D/G-CSF-R p.Tyr787Phe factor-dependent cell line house mouse CVCL_A0UH CL:0000010 Transfected with: HGNC; 2439; CSF3R (with p.Tyr787Phe); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male 150518349 CVCL_A0UI 8H5 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_A0UI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200607 150518350 CVCL_A0UJ 10F7 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_A0UJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200608 150518351 CVCL_A8RQ V-MG-6/STT cancer cell line human CVCL_A8RQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Ala (c.653T>C); Zygosity=Unspecified (PubMed=8934553). 150518352 CVCL_A8RP V-MG-33 cancer cell line human CVCL_A8RP CL:0000010 150518353 CVCL_A8RS WTC dual tagged TOMM20-mEGFP/mTagRFPT-TUBA1B-cl79 induced pluripotent stem cell human CVCL_A8RS CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 TOMM20 has been endogenously tagged in one allele at the C-terminus with mEGFP and TUBA1AB has been endogenously tagged in one allele at the N-terminus with mTagRFP-T Part of: Allen Cell Collection 150518354 CVCL_A8RR WISH-Mx2/EGFP cancer cell line human CVCL_A8RR CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency (PubMed=22549076) Female Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter (PubMed=22549076) Problematic cell line: Contaminated Parent cell line (WISH) has been shown to be a HeLa derivative. 150518355 CVCL_A8RU N1380 cancer cell line human CVCL_A8RU CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Virology: Not susceptible to infection by porcine sapelovirus Transduced with Cas9 and then with the GeCKO v2 whole genome CRISPR/Cas9 library of guide RNAs. The resulting cells were then infected with porcine sapelovirus (PSV) (PubMed=32496007). 150518356 CVCL_A8RT WTC-mEGFP-PCNA-cl83 induced pluripotent stem cell human CVCL_A8RT CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 PCNA has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 150518357 CVCL_A8RW SK-N-BE(1)s cancer cell line human CVCL_A8RW From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Male 150518358 CVCL_A8RV SK-N-BE(1)n cancer cell line human CVCL_A8RV From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11196202) Population: Caucasian; Karyotypic information: 46,XY,del(1)(p32),der(3)t(3;17)(p21;q21),der(4)t(1;4)(q21;q3?5),dmin (PubMed=11196202); Derived from metastatic site: Bone marrow. Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) 150518359 CVCL_A8RI MEL-11 cancer cell line human CVCL_A8RI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714). Unspecified 150518360 CVCL_A8RH TRNDi018-D induced pluripotent stem cell human CVCL_A8RH From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150518361 CVCL_A8RK B-LCL-HROC117 transformed cell line human CVCL_A8RK From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150518362 CVCL_A8RJ MEL-31 cancer cell line human CVCL_A8RJ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714). Unspecified 150518363 CVCL_A8RM V-MG-35/CE cancer cell line human CVCL_A8RM CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8934553). 150518364 CVCL_A8RL B-LCL-HROC313 transformed cell line human CVCL_A8RL HLA typing: A*01:01:01,02:01:01; B*08:01:01,40:01:02; C*03:04:01,07:01:01; DPA1*04:01:01G,05:01:01G; DQA1*04:01:01,05:01:01; DQB1*02:01:01,04:02:01; DRB1*03:01:01,08:01:01 (CLS=302058) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150518365 CVCL_A8RN V-MG-35/FTC cancer cell line human CVCL_A8RN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8934553). 150518366 CVCL_A8RA OX-133 hybridoma house mouse CVCL_A8RA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:189421; N-ethylmaleimide-cysteine. 150518367 CVCL_A8RC WAe001-A-67 embryonic stem cell human CVCL_A8RC From: Wenzhou Medical University; Wenzhou; China CL:0000010 Transfected with: HGNC; 11714; TEAD1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: Transduced with a TRE6P-TEAD1-P2A-EGFP construct Overexpression of TEAD1 is induced by doxycyclin. 150518368 CVCL_A8RB WAe001-A-64 embryonic stem cell human CVCL_A8RB From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2. Male 150518369 CVCL_A8RE TRNDi018-A induced pluripotent stem cell human CVCL_A8RE From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150518370 CVCL_A8RD WAe001-A-68 embryonic stem cell human CVCL_A8RD From: Wenzhou Medical University; Wenzhou; China CL:0000010 Transfected with: HGNC; 11717; TEAD4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: Transduced with a TRE6P-TEAD4-P2A-EGFP construct Overexpression of TEAD4 is induced by doxycyclin. 150518371 CVCL_A8RG TRNDi018-C induced pluripotent stem cell human CVCL_A8RG From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (PubMed=34051448); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (PubMed=34051448) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150518372 CVCL_A8RF TRNDi018-B induced pluripotent stem cell human CVCL_A8RF From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150518373 CVCL_A8QX MDS-L/GR-GFP-N cancer cell line human CVCL_A8QX CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Transfected with: HGNC; 2439; CSF3R; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Met, p.Ser65Gly and p.Gln69Leu = rsGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Transduced with a 5'LTR-CSF3R-CMV-rsGFP-Neo-3'LTR construct 150518374 CVCL_A8QW MDS-L/GFP-N cancer cell line human CVCL_A8QW CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Met, p.Ser65Gly and p.Gln69Leu = rsGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Transduced with a 5'LTR-CMV-rsGFP-Neo-3'LTR construct 150518375 CVCL_A8QZ MDS-LGF cancer cell line human CVCL_A8QZ CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29955132) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Characteristics: IL3 independent Has lost the H3C3 p.Lys28Met mutation of the parent cell line. 150518376 CVCL_A8QY MDS-L-2007 cancer cell line human CVCL_A8QY CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 4768; H3C3; Simple; p.Lys28Met (c.83A>T); Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29955132) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Characteristics: IL3 dependent 150518377 CVCL_A8SR WTC-mEGFP-CTCF-cl20 induced pluripotent stem cell human CVCL_A8SR CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 CTCF has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 150518378 CVCL_A8SQ CHO-gmt4D-EPO-GnT I spontaneously immortalized cell line CVCL_A8SQ CL:0000010 Knockout cell: Method=ZFN; UniProtKB; Q2MH30; Dhfr; Transfected with: HGNC; 3415; EPO; Transfected with: UniProtKB; Q2MH30; Cricetulus griseus Dhfr; Transfected with: UniProtKB; Q924C0; Cricetulus griseus Mgat1 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Ovary. Female Characteristics: Transfected with the pEGD vector containing CMV-EPO-IRES-GnTI-IRES-DHFR 150518379 CVCL_A8ST VUi031-A induced pluripotent stem cell human CVCL_A8ST From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518380 CVCL_A8SS ISFi002-A induced pluripotent stem cell human CVCL_A8SS From: Institute for Stem Cell Research, Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 150518381 CVCL_A8SV VUi033-A induced pluripotent stem cell human CVCL_A8SV From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518382 CVCL_A8SU VUi032-A induced pluripotent stem cell human CVCL_A8SU From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518383 CVCL_A8SX PmLyO-Sf9 hybrid cell line CVCL_A8SX CL:0000010 Characteristics: Fusion of Sf9 cells with shrimp lymphoid organ cells (PubMed=33826940); Virology: Susceptible to infection by white spot syndrome virus (WSSV) (PubMed=33264652). Group: Crustacean cell line; Group: Insect cell line 150518384 CVCL_A8SW TMOi001-A-4 induced pluripotent stem cell human CVCL_A8SW CL:0000010 Derived from sampling site: Umbilical cord blood. Female Characteristics: Using CRISPR/Cas9 a HA tag was inserted at the C-terminus of SPG11 (PubMed=34479069) 150518385 CVCL_A8SJ JR1Nmyc6 cancer cell line human CVCL_A8SJ CL:0000010 Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung. Female Characteristics: Expresses MYCN under the control of the CMV promoter 150518386 CVCL_A8SI JR1neo20 cancer cell line human CVCL_A8SI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung. Female 150518387 CVCL_A8SL JR1cmyc5 cancer cell line human CVCL_A8SL CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung. Female Characteristics: Expresses MYC under the control of the CMV promoter 150518388 CVCL_A8SK JR1Nmyc9 cancer cell line human CVCL_A8SK CL:0000010 Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung. Female Characteristics: Expresses MYCN under the control of the CMV promoter 150518389 CVCL_A8SM HCE-1(NM) cancer cell line human CVCL_A8SM CL:0000010 Derived from sampling site: Esophagus. Female Characteristics: Established from a tumor transplanted in nude mice 150518390 CVCL_A8SP CHO-gmt4D spontaneously immortalized cell line CVCL_A8SP CL:0000010 Knockout cell: Method=ZFN; UniProtKB; Q2MH30; Dhfr; Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Gln339Ter (c.1015C>T); Zygosity=Unspecified (from parent cell line) Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Ovary. Female Characteristics: Lacks N-acetylglucosaminyltransferase I activity 150518391 CVCL_A8SB CAP-pStbl-empty-Null transformed cell line human CVCL_A8SB CL:0000010 Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Transduced with a pStbl-CMV-bsd-Null vector and a pEGP-CMV-Null vector 150518392 CVCL_A8SA CAP-CD63-tGFP-Null transformed cell line human CVCL_A8SA CL:0000010 Transfected with: HGNC; 1692; CD63; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Overexpresses CD63-turboGFP Transduced with a pStbl-CMV-bsd-CD63-tGFP vector and a pEGP-CMV-Null vector. 150518393 CVCL_A8SD CAP-CD63-tGFP-miRNA-744 transformed cell line human CVCL_A8SD CL:0000010 Transfected with: HGNC; 1692; CD63; Transfected with: HGNC; 33658; MIR744; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Overexpresses CD63-turboGFP and MIR744 Transduced with a pStbl-CMV-bsd-CD63-tGFP vector and a pEGP-CMV-hsa-miRNA-744 vector. 150518394 CVCL_A8SC CAP-CD63-tGFP-miRNA-493 transformed cell line human CVCL_A8SC CL:0000010 Transfected with: HGNC; 1692; CD63; Transfected with: HGNC; 32082; MIR493; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Overexpresses CD63-turboGFP and MIR493 Transduced with a pStbl-CMV-bsd-CD63-tGFP vector and a pEGP-CMV-hsa-miRNA-493 vector. 150518395 CVCL_A8SF SJ-GBM3 cancer cell line human CVCL_A8SF CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Unspecified (PubMed=9802058). 150518396 CVCL_A8SE SJ-GBM5 cancer cell line human CVCL_A8SE CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=9802058) Derived from sampling site: Brain. Female 150518397 CVCL_A8SH IMR32.ODC.CE cancer cell line human CVCL_A8SH CL:0000010 Transfected with: UniProtKB; P12337; Rabbit liver carboxylesterase 1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Abdomen. Male Characteristics: Expresses the carboxylesterase (CE) gene under the control of an ornithine decarboxylase (ODC) promoter (PubMed=10933967) 150518398 CVCL_A8SG IMR32.CMV.neo cancer cell line human CVCL_A8SG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Abdomen. Male 150518399 CVCL_A8RY CAP-CD63-tGFP transformed cell line human CVCL_A8RY CL:0000010 Transfected with: HGNC; 1692; CD63; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Overexpresses CD63-turboGFP Transduced with a pStbl-CMV-bsd-CD63-tGFP vector. 150518400 CVCL_A8RX GPASE transformed cell line CVCL_A8RX CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Amnion Cell type=Epithelial cell.; Breed/subspecies: Hartley. 150518401 CVCL_A8RZ CAP-pStbl-empty transformed cell line human CVCL_A8RZ CL:0000010 Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Transduced with a pStbl-CMV-bsd-Null vector 150518402 CVCL_A8PN UCSFi001-A-51 induced pluripotent stem cell human CVCL_A8PN From: University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple_edited; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34536661) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 150518403 CVCL_A8PQ UCSFi001-A-53 induced pluripotent stem cell human CVCL_A8PQ From: University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 150518404 CVCL_A8PP UCSFi001-A-52 induced pluripotent stem cell human CVCL_A8PP From: University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 150518405 CVCL_A8PS UKEi001-B induced pluripotent stem cell human CVCL_A8PS From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518406 CVCL_A8PR UKEi001-A induced pluripotent stem cell human CVCL_A8PR From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518407 CVCL_A8PU UKEi003-B induced pluripotent stem cell human CVCL_A8PU From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518408 CVCL_A8PT UKEi003-A induced pluripotent stem cell human CVCL_A8PT CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518409 CVCL_A8PG UTA.00102.LQT1 induced pluripotent stem cell human CVCL_A8PG From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.1129-2A>G (IVS7-2A>G); dbSNP=rs768022350; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=28785673) Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518410 CVCL_A8PF UMILi009-A induced pluripotent stem cell human CVCL_A8PF From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12856; YY1; Simple; p.Asp129Ilefs*127 (c.385delG); ClinVar=VCV000817604; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 150518411 CVCL_A8PI UTA.04607.WT induced pluripotent stem cell human CVCL_A8PI From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518412 CVCL_A8PH UTA.00118.LQT1 induced pluripotent stem cell human CVCL_A8PH From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.1129-2A>G (IVS7-2A>G); dbSNP=rs768022350; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=28785673) Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518413 CVCL_A8PK SHCMDLi002-A induced pluripotent stem cell human CVCL_A8PK From: Shanghai Children's Hospital; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518414 CVCL_A8PJ SHCMDLi001-A induced pluripotent stem cell human CVCL_A8PJ From: Shanghai Children's Hospital; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 20456; TRAF7; Simple; p.Arg655Gln (c.1964G>A); ClinVar=VCV000587685; Zygosity=Heterozygous; Note=De novo mutation (PubMed=34088006) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 150518415 CVCL_A8PM UCSFi001-A-50 induced pluripotent stem cell human CVCL_A8PM From: University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple_edited; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34536661) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 150518416 CVCL_A8PL UCSFi001-A-49 induced pluripotent stem cell human CVCL_A8PL From: University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple_edited; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34536661) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 150518417 CVCL_A8PA UBi002-A induced pluripotent stem cell human CVCL_A8PA From: University of Barcelona; Barcelona; Spain. CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 150518418 CVCL_A8PC UBi004-A induced pluripotent stem cell human CVCL_A8PC From: University of Barcelona; Barcelona; Spain. CL:0000010 150518419 CVCL_A8PB UBi003-A induced pluripotent stem cell human CVCL_A8PB From: University of Barcelona; Barcelona; Spain. CL:0000010 150518420 CVCL_A8PE TRNDi031-A induced pluripotent stem cell human CVCL_A8PE From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Cys312Ter (c.936T>A); ClinVar=VCV001358138; Zygosity=Heterozygous (PubMed=34198154) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518421 CVCL_A8PD TRNDi030-A induced pluripotent stem cell human CVCL_A8PD From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Tyr36Cys (c.107A>G) (p.Tyr52Cys, c.155A>G); ClinVar=VCV000000093; Zygosity=Homozygous (PubMed=34088014) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518422 CVCL_A8QP LB919-SCCHN cancer cell line human CVCL_A8QP From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ile655Val (c.1963A>G); ClinVar=VCV000013873; Zygosity=Unspecified (PubMed=28765120). Unspecified 150518423 CVCL_A8QR UAMS-32P spontaneously immortalized cell line house mouse CVCL_A8QR CL:0000010 Transfected with: HGNC; 9608; PTH1R Derived from sampling site: Bone marrow; Breed/subspecies: SAMR1. Unspecified 150518424 CVCL_A8QQ GM27463 induced pluripotent stem cell human CVCL_A8QQ CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518425 CVCL_A8QT LF1 [Human lung myofibroblast] finite cell line human CVCL_A8QT CL:0000010 Derived from sampling site: Lung Cell type=Myofibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: ~2 days (PubMed=17986007) 150518426 CVCL_A8QS Me32A-DmATP7 finite cell line human CVCL_A8QS CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Unexplicit; 4bp deletion within exon 6; Zygosity=Unspecified (from parent cell line); Transfected with: FlyBase_Gene; FBgn0030343; ATP7 (with a N-terminal Myc tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. 150518427 CVCL_A8QV MDS-L cancer cell line human CVCL_A8QV CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 4768; H3C3; Simple; p.Lys28Met (c.83A>T); Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29955132) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Characteristics: IL3 dependent 150518428 CVCL_A8QU LF2 [Human lung myofibroblast] finite cell line human CVCL_A8QU CL:0000010 Derived from sampling site: Lung Cell type=Myofibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: ~3 days (PubMed=17986007) 150518429 CVCL_A8QH MIN6-cl4 transformed cell line house mouse CVCL_A8QH CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Retains glucose-stimulated insulin secretion even after long-term culture (PubMed=23560115) 150518430 CVCL_A8QG MIN6-K8 transformed cell line house mouse CVCL_A8QG CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Male Characteristics: Responsive to insulin, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (PubMed=24843422) 150518431 CVCL_A8QJ ZYM-SVEC01 telomerase immortalized cell line pig CVCL_A8QJ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Vein Cell type=Endothelial cell.. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200841 150518432 CVCL_A8QI MIN6-CB4 transformed cell line house mouse CVCL_A8QI CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C3/Hej x C57BL/6 IT6 transgenic. Omics: Transcriptome analysis by RNAseq Male Characteristics: Retains glucose-stimulated insulin secretion even after long-term culture (PubMed=33436850) 150518433 CVCL_A8QL Panc02-luc cancer cell line house mouse CVCL_A8QL CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6. Male 150518434 CVCL_A8QK CD126 spontaneously immortalized cell line house mouse CVCL_A8QK CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr1085_Ala1210del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 150518435 CVCL_A8QN KUL98-MELB cancer cell line human CVCL_A8QN CL:0000010 Unspecified 150518436 CVCL_A8QM KUL98-MELA cancer cell line human CVCL_A8QM CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=28765120). Unspecified 150518437 CVCL_A8QB HVRDe009-A-2 embryonic stem cell human CVCL_A8QB From: Arizona State University; Tempe; USA CL:0000010 Karyotypic information: 46,XX,inv(9)(p12;q13) (hPSCreg). Female Characteristics: Using CRISPR/Cas9 a 3xFLAG tag was introduced at the C-terminal region of CTNNB1 (PubMed=34736039) 150518438 CVCL_A8QA MRIi004-A induced pluripotent stem cell human CVCL_A8QA From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 150518439 CVCL_A8QD SCVI-112 induced pluripotent stem cell human CVCL_A8QD From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 150518440 CVCL_A8QC SCVI-113 induced pluripotent stem cell human CVCL_A8QC From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 150518441 CVCL_A8QF MIN6-K20 transformed cell line house mouse CVCL_A8QF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Male Characteristics: Responsive to insulin, but not to glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) (PubMed=24843422) 150518442 CVCL_A8QE HXWMF-1 cancer cell line house mouse CVCL_A8QE CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.; Breed/subspecies: BALB/c. Female Characteristics: Produced by subcutaneous injection of HXEX-ALL1 cells of BALB/c (nu/nu) nude mice (PubMed=33740980) Doubling time: 12-17 hours (PubMed=33740980) 150518443 CVCL_A8PW UMCGi010-A induced pluripotent stem cell human CVCL_A8PW From: University Medical Center Groningen; Groningen; Netherlands. CL:0000010 Male 150518444 CVCL_A8PV UKEi003-C induced pluripotent stem cell human CVCL_A8PV From: Uiversity Medical Center Hamburg-Eppendorf; Hamburg; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518445 CVCL_A8PY HighMan-S2 spontaneously immortalized cell line fruit fly CVCL_A8PY CL:0000010 Breed/subspecies: Oregon-R. Male Characteristics: Using CRISPR/Cas9 the parent cell line was engineered to produce proteins with high-mannose N-glycan structures Doubling time: 18-24 hours (ExpreS2ion) Group: Insect cell line; Group: Recombinant protein production insect cell line 150518446 CVCL_A8PX SMBCi008-A induced pluripotent stem cell human CVCL_A8PX From: Shandong Medical Biotechnological Center; Jinan; China. CL:0000010 Male 150518447 CVCL_A8PZ HeLa SOD1 KO cancer cell line human CVCL_A8PZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11179; SOD1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 150518448 CVCL_A8NM VUi026-A induced pluripotent stem cell human CVCL_A8NM From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 30348; POLR3B; Simple; p.Val523Glu (c.1568T>A); ClinVar=VCV000031166; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 30348; POLR3B; Simple; c.2084-6A>G; ClinVar=VCV000419962; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 150518449 CVCL_A8NL VUi025-A induced pluripotent stem cell human CVCL_A8NL From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 30348; POLR3B; Simple; p.Tyr596Ter (c.1788C>A); ClinVar=VCV001184064; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 30348; POLR3B; Simple; p.Leu727Ser (c.2180T>C); ClinVar=VCV001184068; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 150518450 CVCL_A8NN VUi027-A induced pluripotent stem cell human CVCL_A8NN From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 Male 150518451 CVCL_A8NQ VUi029-A induced pluripotent stem cell human CVCL_A8NQ From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 150518452 CVCL_A8NP VUi028-A induced pluripotent stem cell human CVCL_A8NP From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 Female 150518453 CVCL_A8NS TRNDi029-A induced pluripotent stem cell human CVCL_A8NS From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Arg465Arg (c.1395G>T) (Chr20:g.10629709C>A); Zygosity=Heterozygous; Note=Splice site mutation (PubMed=34087995) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518454 CVCL_A8NR VUi030-A induced pluripotent stem cell human CVCL_A8NR From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 Female 150518455 CVCL_A8NE SBRIi004-A induced pluripotent stem cell human CVCL_A8NE From: Stem Cell and Brain Research, U1208 INSERM; Bron; France. CL:0000010 150518456 CVCL_A8ND SBRIi003-A induced pluripotent stem cell human CVCL_A8ND From: Stem Cell and Brain Research, U1208 INSERM; Bron; France. CL:0000010 150518457 CVCL_A8NG SCVIi013-A induced pluripotent stem cell human CVCL_A8NG From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 150518458 CVCL_A8NF SCVIi012-A induced pluripotent stem cell human CVCL_A8NF From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 150518459 CVCL_A8NI SDQLCHi043-A induced pluripotent stem cell human CVCL_A8NI From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 150518460 CVCL_A8NH SDQLCHi042-A induced pluripotent stem cell human CVCL_A8NH From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 6677; LPL; Simple; c.88+1G>C; ClinVar=VCV000001542; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=34087978); Sequence variation: Mutation; HGNC; 6677; LPL; Simple; p.Leu279Arg (c.836T>G); ClinVar=VCV000851236; Zygosity=Heterozygous (PubMed=34087978) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518461 CVCL_A8NK iPSC-CB1RB9-WAS-GFP induced pluripotent stem cell human CVCL_A8NK CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Umbilical cord blood. Characteristics: Transduced with a lentiviral vector expressing GFP under the control of the WAS gene promoter (PubMed=28380349) 150518462 CVCL_A8NJ iPSC-CB1RB9 induced pluripotent stem cell human CVCL_A8NJ CL:0000010 Derived from sampling site: Umbilical cord blood. 150518463 CVCL_A8NA RCPCMi008-A induced pluripotent stem cell human CVCL_A8NA From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 11588; TBP; Repeat_expansion; CAG[47]; Zygosity=Heterozygous (PubMed=34171784) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518464 CVCL_A8NC SBRIi002-A induced pluripotent stem cell human CVCL_A8NC From: Stem Cell and Brain Research, U1208 INSERM; Bron; France. CL:0000010 Female 150518465 CVCL_A8NB SBRIi001-A induced pluripotent stem cell human CVCL_A8NB From: Stem Cell and Brain Research, U1208 INSERM; Bron; France. CL:0000010 150518466 CVCL_A8MT NUIGi038-C induced pluripotent stem cell human CVCL_A8MT From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518467 CVCL_A8MS NNIi002-A induced pluripotent stem cell human CVCL_A8MS From: National Neuroscience Institute; Singapore; Singapore. CL:0000010 150518468 CVCL_A8MV PENNi001-A-1 induced pluripotent stem cell human CVCL_A8MV From: University of Pennsylvania; Philadelphia; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13557; ACE2 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518469 CVCL_A8MU OGHFUi001-A induced pluripotent stem cell human CVCL_A8MU From: Obstetrics and Gynecology Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 18060; ARX; Simple; p.Arg330Leu (c.989G>T); Zygosity=Hemizygous (PubMed=34087996) Derived from sampling site: Peripheral blood. Male 150518470 CVCL_A8MX PUFHi003-A induced pluripotent stem cell human CVCL_A8MX From: Peking University First Hospital; Beijing; China. CL:0000010 150518471 CVCL_A8MW PUFHi002-A induced pluripotent stem cell human CVCL_A8MW From: Peking University First Hospital; Beijing; China. CL:0000010 150518472 CVCL_A8MZ QDMHi001-A induced pluripotent stem cell human CVCL_A8MZ From: Qingdao Municipal Hospital; Qingdao; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2258Arg (c.6772T>C); ClinVar=VCV000379489; Zygosity=Heterozygous (PubMed=34087733) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518473 CVCL_A8MY QBRIi012-A induced pluripotent stem cell human CVCL_A8MY From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 11006; SLC2A2; Simple; p.Arg301Ter (c.901C>T); ClinVar=VCV000016093; Zygosity=Homozygous (PubMed=34171785) Population: Palestinian; Derived from sampling site: Peripheral blood. Male 150518474 CVCL_A8NU TUSMi010-A induced pluripotent stem cell human CVCL_A8NU From: Tongji University School of Medicine; Wuhan; China. CL:0000010 150518475 CVCL_A8NT TUSMi009-A induced pluripotent stem cell human CVCL_A8NT From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Donor information: Established from a patient suffering from glioblastoma; Derived from sampling site: Peripheral blood. Female 150518476 CVCL_A8NW ZJUi007-A induced pluripotent stem cell human CVCL_A8NW From: The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Trp47Ter (c.140G>A); Zygosity=Hemizygous (PubMed=34365103) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518477 CVCL_A8NV SMUSHi001-A induced pluripotent stem cell human CVCL_A8NV From: Southern Medical University, Shenzhen Hospital; Shenzhen; China CL:0000010 Population: Chinese; Han; Karyotypic information: 46,XX; Derived from sampling site: Peripheral blood. Ambiguous 150518478 CVCL_A8NY UABi001-A induced pluripotent stem cell human CVCL_A8NY From: University of Alabama at Birmingham; Birmingham; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34392011) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150518479 CVCL_A8NX YCMi003-A induced pluripotent stem cell human CVCL_A8NX From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Asp364His (c.1090G>C); Zygosity=Heterozygous (PubMed=34438160) Population: Korean; Karyotypic information: 47,XYY (PubMed=34438160); Derived from sampling site: Peripheral blood. Male 150518480 CVCL_A8NZ UABi002-A induced pluripotent stem cell human CVCL_A8NZ From: University of Alabama at Birmingham; Birmingham; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34392011) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150518481 CVCL_A8LK BGUi023-A induced pluripotent stem cell human CVCL_A8LK From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518482 CVCL_A8LJ BGUi022-A induced pluripotent stem cell human CVCL_A8LJ From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518483 CVCL_A8LM BGUi025-A induced pluripotent stem cell human CVCL_A8LM From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518484 CVCL_A8LL BGUi024-A induced pluripotent stem cell human CVCL_A8LL From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518485 CVCL_A8LN IBTCMi001-A induced pluripotent stem cell human CVCL_A8LN From: Institute of Basic Theory for Chinese Medicine; Beijing; China CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 150518486 CVCL_A8LQ JTUi004-A induced pluripotent stem cell human CVCL_A8LQ From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518487 CVCL_A8LP JTUi003-A induced pluripotent stem cell human CVCL_A8LP From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518488 CVCL_A8LC BCHNEUi012-A induced pluripotent stem cell human CVCL_A8LC From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Asn73Lysfs*43 (c.218dupA); ClinVar=VCV000450739; Zygosity=Heterozygous (PubMed=34087981) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518489 CVCL_A8LB BCHNEUi011-A induced pluripotent stem cell human CVCL_A8LB From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Asn73Lysfs*43 (c.218dupA); ClinVar=VCV000450739; Zygosity=Heterozygous (PubMed=34087981); Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Tyr284Ser (c.851A>C); ClinVar=VCV000471069; Zygosity=Heterozygous (PubMed=34087981) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518490 CVCL_A8LE BGUi017-A induced pluripotent stem cell human CVCL_A8LE From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518491 CVCL_A8LD BGUi016-A induced pluripotent stem cell human CVCL_A8LD From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518492 CVCL_A8LG BGUi019-A induced pluripotent stem cell human CVCL_A8LG From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518493 CVCL_A8LF BGUi018-A induced pluripotent stem cell human CVCL_A8LF From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518494 CVCL_A8LI BGUi021-A induced pluripotent stem cell human CVCL_A8LI From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518495 CVCL_A8LH BGUi020-A induced pluripotent stem cell human CVCL_A8LH From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 150518496 CVCL_A8KZ BCHNEUi009-A induced pluripotent stem cell human CVCL_A8KZ From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; c.1025+2dupT; ClinVar=rs750223135; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=34087981); Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Thr69Pro (c.205A>C); ClinVar=VCV001306889; Zygosity=Heterozygous (PubMed=34087981) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518497 CVCL_A8KY BCHNEUi008-A induced pluripotent stem cell human CVCL_A8KY From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Glu232Glyfs*21 (c.694dupG); ClinVar=VCV000818030; Zygosity=Heterozygous (PubMed=34087981) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518498 CVCL_A8LA BCHNEUi010-A induced pluripotent stem cell human CVCL_A8LA From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; c.1025+2dupT; ClinVar=rs750223135; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=34087981) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518499 CVCL_A8KR EHTJUi004-A induced pluripotent stem cell human CVCL_A8KR From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Leu1563Glufs*63 (c.4687_4688delCT) (c.4683_4684delCT); ClinVar=VCV001072470; Zygosity=Heterozygous (PubMed=34087998) Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Female 150518500 CVCL_A8KQ CSSi012-A induced pluripotent stem cell human CVCL_A8KQ From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly376Asp (c.1127G>A); Zygosity=Heterozygous (PubMed=34087986) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518501 CVCL_A8KT ESi086-A induced pluripotent stem cell human CVCL_A8KT From: Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 150518502 CVCL_A8KS EHTJUi005-A induced pluripotent stem cell human CVCL_A8KS From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Female 150518503 CVCL_A8KV ESi086-A-2 induced pluripotent stem cell human CVCL_A8KV From: Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4171; GATA2; Simple_edited; p.Arg398Trp (c.1192C>T); ClinVar=VCV000029709; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34284273) Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 150518504 CVCL_A8KU ESi086-A-1 induced pluripotent stem cell human CVCL_A8KU From: Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4171; GATA2; Simple_edited; p.Arg396Gln (c.1187G>A); ClinVar=VCV000472437; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34284273) Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 150518505 CVCL_A8KX BCHNEUi007-A induced pluripotent stem cell human CVCL_A8KX From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Glu232Glyfs*21 (c.694dupG); ClinVar=VCV000818030; Zygosity=Heterozygous (PubMed=34087981); Sequence variation: Mutation; HGNC; 574; AP4M1; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000561150; Zygosity=Heterozygous (PubMed=34087981) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518506 CVCL_A8KW AMUFAHi001-A induced pluripotent stem cell human CVCL_A8KW From: The First Affiliated Hospital of Anhui Medical University; Anhui; China CL:0000010 Sequence variation: Mutation; HGNC; 18576; CCNO; Simple; p.Gln88Argfs*8 (c.253_257GGCCC[3]) (c.258_262dupGGCCC) (c.262_263insGGCCC); ClinVar=VCV000139600; Zygosity=Homozygous (PubMed=34088001) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 150518507 CVCL_A8ML METUi001-A induced pluripotent stem cell human CVCL_A8ML From: Middle East Technical University; Ankara; Turkey CL:0000010 Derived from sampling site: Peripheral blood. Male 150518508 CVCL_A8MK LEIi018-A induced pluripotent stem cell human CVCL_A8MK From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.5461-10T>C; ClinVar=VCV000092870; Zygosity=Heterozygous (PubMed=34214897); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Asn1868Ile (c.5603A>T); ClinVar=VCV000099390; Zygosity=Heterozygous (PubMed=34214897); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Leu2026Pro (c.6077T>C); ClinVar=VCV000236144; Zygosity=Heterozygous (PubMed=34214897) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518509 CVCL_A8MN MRIi003-A induced pluripotent stem cell human CVCL_A8MN From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518510 CVCL_A8MM MILi001-A induced pluripotent stem cell human CVCL_A8MM From: Miltenyi Biotec B.V.; Gladbach; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 150518511 CVCL_A8MP MRIi018-A induced pluripotent stem cell human CVCL_A8MP From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Sequence variation: Mutation; HGNC; 944; ADGRB2; Simple; p.Gly267Asp (c.800G>A); Zygosity=Unspecified; Note=De novo mutation (hPSCreg); Sequence variation: Mutation; HGNC; 28338; DENND5B; Simple; p.Lys799Arg (c.2396A>G); Zygosity=Unspecified; Note=De novo mutation (hPSCreg); Sequence variation: Mutation; HGNC; 26011; SYBU; Simple; p.Pro93Leu (c.278C>A); Zygosity=Unspecified; Note=De novo mutation (hPSCreg) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 150518512 CVCL_A8MR NNIi001-A induced pluripotent stem cell human CVCL_A8MR From: National Neuroscience Institute; Singapore; Singapore. CL:0000010 150518513 CVCL_A8MQ NMIi010-A induced pluripotent stem cell human CVCL_A8MQ From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 150518514 CVCL_A8MD LCSBi006-A induced pluripotent stem cell human CVCL_A8MD From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=34736041) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518515 CVCL_A8MC LCSBi005-B transformed cell line human CVCL_A8MC From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=34736041) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 150518516 CVCL_A8MF LCSBi007-B induced pluripotent stem cell human CVCL_A8MF From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=34826737) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 150518517 CVCL_A8ME LCSBi007-A induced pluripotent stem cell human CVCL_A8ME From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=34826737) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 150518518 CVCL_A8MH LEIi016-B induced pluripotent stem cell human CVCL_A8MH From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Ile852Thr (c.2555T>C); ClinVar=VCV000099883; Zygosity=Heterozygous (PubMed=34034222); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Asp1005Val (c.3014A>T); ClinVar=VCV000846589; Zygosity=Heterozygous (PubMed=34034222) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518519 CVCL_A8MG LEIi016-A induced pluripotent stem cell human CVCL_A8MG From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Ile852Thr (c.2555T>C); ClinVar=VCV000099883; Zygosity=Heterozygous (PubMed=34034222); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Asp1005Val (c.3014A>T); ClinVar=VCV000846589; Zygosity=Heterozygous (PubMed=34034222) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518520 CVCL_A8MJ LEIi017-B induced pluripotent stem cell human CVCL_A8MJ From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Arg152Gln (c.455G>A); ClinVar=VCV000099301; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Leu1388Pro (c.4163T>C); ClinVar=VCV000099254; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.5461-10T>C; ClinVar=VCV000092870; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Asn1868Ile (c.5603A>T); ClinVar=VCV000099390; Zygosity=Heterozygous (PubMed=34198153) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518521 CVCL_A8MI LEIi017-A induced pluripotent stem cell human CVCL_A8MI From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Arg152Gln (c.455G>A); ClinVar=VCV000099301; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Leu1388Pro (c.4163T>C); ClinVar=VCV000099254; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.5461-10T>C; ClinVar=VCV000092870; Zygosity=Heterozygous (PubMed=34198153); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Asn1868Ile (c.5603A>T); ClinVar=VCV000099390; Zygosity=Heterozygous (PubMed=34198153) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518522 CVCL_A8LZ LCSBi004-A induced pluripotent stem cell human CVCL_A8LZ From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=35378365) Population: Latino or Hispanic; Dominican; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 150518523 CVCL_A8MB LCSBi005-A transformed cell line human CVCL_A8MB From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=34736041) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518524 CVCL_A8MA LCSBi004-B induced pluripotent stem cell human CVCL_A8MA From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=35378365) Population: Latino or Hispanic; Dominican; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 150518525 CVCL_A8LS INSRMi011-A induced pluripotent stem cell human CVCL_A8LS From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Arg169Pro (c.506G>C); Zygosity=Heterozygous (PubMed=35245853) Derived from sampling site: Peripheral blood. Male 150518526 CVCL_A8LR KEIOi002-A induced pluripotent stem cell human CVCL_A8LR From: Keio University; Tokyo; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 150518527 CVCL_A8LU LCSBi002-B induced pluripotent stem cell human CVCL_A8LU From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (PubMed=35378365) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 150518528 CVCL_A8LT LCSBi002-A induced pluripotent stem cell human CVCL_A8LT From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518529 CVCL_A8LW LCSBi003-A induced pluripotent stem cell human CVCL_A8LW From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=34826737) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 150518530 CVCL_A8LV LCSBi002-C induced pluripotent stem cell human CVCL_A8LV From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (PubMed=35378365) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 150518531 CVCL_A8LY LCSBi003-C induced pluripotent stem cell human CVCL_A8LY From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=34826737) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 150518532 CVCL_A8LX LCSBi003-B induced pluripotent stem cell human CVCL_A8LX From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518533 CVCL_A8ZY SDZFYi001-A induced pluripotent stem cell human CVCL_A8ZY From: Shandong Academy of Occupational Health and Occupational Medicine; Jinan; China CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518534 CVCL_A8ZX QBRIi013-A induced pluripotent stem cell human CVCL_A8ZX From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Population: Egyptian; Derived from sampling site: Peripheral blood. Female 150518535 CVCL_A8ZZ UCSCi001-A induced pluripotent stem cell human CVCL_A8ZZ From: Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli; Rome; Italy. CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg518Ile (c.1553G>T); Zygosity=Heterozygous (PubMed=34303285) Population: Caucasian; Italian; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 150518536 CVCL_A8ZQ NIAi001-I induced pluripotent stem cell human CVCL_A8ZQ CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Asn1437His (c.4309A>C); ClinVar=VCV000039183; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518537 CVCL_A8ZP NIAi001-H induced pluripotent stem cell human CVCL_A8ZP CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518538 CVCL_A8ZS NIAi001-K induced pluripotent stem cell human CVCL_A8ZS CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Lys1906Met (c.5717A>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518539 CVCL_A8ZR NIAi001-J induced pluripotent stem cell human CVCL_A8ZR CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Asn1437His (c.4309A>C); ClinVar=VCV000039183; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518540 CVCL_A8ZU NIAi001-M induced pluripotent stem cell human CVCL_A8ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Derived from sampling site: Umbilical cord blood. Female 150518541 CVCL_A8ZT NIAi001-L induced pluripotent stem cell human CVCL_A8ZT CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Thr1348Asn (c.4043A>C); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518542 CVCL_A8ZW FAHZUe001-A embryonic stem cell human CVCL_A8ZW From: The First Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20822; ADGRL4. Male 150518543 CVCL_A8ZV NIAi001-N induced pluripotent stem cell human CVCL_A8ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Derived from sampling site: Umbilical cord blood. Female 150518544 CVCL_A8ZI NIAi001-B induced pluripotent stem cell human CVCL_A8ZI CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518545 CVCL_A8ZH NIAi001-A induced pluripotent stem cell human CVCL_A8ZH CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518546 CVCL_A8ZK NIAi001-D induced pluripotent stem cell human CVCL_A8ZK CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518547 CVCL_A8ZJ NIAi001-C induced pluripotent stem cell human CVCL_A8ZJ CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518548 CVCL_A8ZM NIAi001-F induced pluripotent stem cell human CVCL_A8ZM CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Tyr1699Cys (c.5096A>G); ClinVar=VCV000001937; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518549 CVCL_A8ZL NIAi001-E induced pluripotent stem cell human CVCL_A8ZL CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Tyr1699Cys (c.5096A>G); ClinVar=VCV000001937; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518550 CVCL_A8ZN NIAi001-G induced pluripotent stem cell human CVCL_A8ZN CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34087985) Derived from sampling site: Umbilical cord blood. Female 150518551 CVCL_A8ZA HVRDe008-A-1 embryonic stem cell human CVCL_A8ZA CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using CRISPR/Cas9, a P2A-Luc2-IRES-PuroR-pA construct was inserted at the 3'end of one allele of GAPDH (PubMed=34088000) 150518552 CVCL_A8ZC CUi001-A-1 induced pluripotent stem cell human CVCL_A8ZC From: Chiba University; Chiba; Japan CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=34087989); Sequence variation: Mutation; HGNC; 12791; WRN; Simple_corrected; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation By CRISPR/Cas9 (PubMed=34087989). Population: Japanese; Derived from sampling site: Peripheral blood. Male 150518553 CVCL_A8ZB CUi001-A induced pluripotent stem cell human CVCL_A8ZB From: Chiba University; Chiba; Japan CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=34087989) Population: Japanese; Derived from sampling site: Peripheral blood. Male 150518554 CVCL_A8ZE PSHi001-A induced pluripotent stem cell human CVCL_A8ZE From: Plastic Surgery Hospital of Chinese Academy of Medical Sciences; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518555 CVCL_A8ZD BCH001 induced pluripotent stem cell human CVCL_A8ZD From: Beijing Children's Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; c.2608-125C>T; Zygosity=Heterozygous (PubMed=34087988) Population: Chinese; Derived from sampling site: Peripheral blood. Male 150518556 CVCL_A8ZG PSHi002-A induced pluripotent stem cell human CVCL_A8ZG From: Plastic Surgery Hospital of Chinese Academy of Medical Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 11654; TCOF1; Simple; p.Ser657Trpfs*25 (c.1966_1969dup); Zygosity=Heterozygous (PubMed=34247110) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150518557 CVCL_A8ZF CiSB spontaneously immortalized cell line CVCL_A8ZF CL:0000010 Derived from sampling site: Swim bladder. Unspecified Virology: Susceptible to infection by grass carp reovirus (GCRV) genotype 2 (PubMed=33460745) Group: Fish cell line 150518558 CVCL_A8XW E01F finite cell line CVCL_A8XW CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518559 CVCL_A8XV NM-iPS induced pluripotent stem cell CVCL_A8XV CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518560 CVCL_A8XY OF35Y-iPS induced pluripotent stem cell dog CVCL_A8XY CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Omics: Transcriptome analysis by RNAseq Male 150518561 CVCL_A8XX RNA-iPSC #1 induced pluripotent stem cell CVCL_A8XX CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518562 CVCL_A8XZ K9 finite cell line dog CVCL_A8XZ CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518563 CVCL_A8XN FAFU&CU-Px-1 spontaneously immortalized cell line CVCL_A8XN CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 19 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518564 CVCL_A8XQ FAFU&CU-Px-3 spontaneously immortalized cell line CVCL_A8XQ CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 23 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518565 CVCL_A8XP FAFU&CU-Px-2 spontaneously immortalized cell line CVCL_A8XP CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 20 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518566 CVCL_A8XS FAFU&CU-Px-5 spontaneously immortalized cell line CVCL_A8XS CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 19 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518567 CVCL_A8XR FAFU&CU-Px-4 spontaneously immortalized cell line CVCL_A8XR CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 18 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518568 CVCL_A8XU Tn5B-40 spontaneously immortalized cell line CVCL_A8XU CL:0000010 Unspecified Doubling time: 22 hours (DOI=10.1111/j.1744-7917.2004.tb00236.x). Group: Insect cell line; Group: Recombinant protein production insect cell line 150518569 CVCL_A8XT FAFU&CU-Px-6 spontaneously immortalized cell line CVCL_A8XT CL:0000010 Breed/subspecies: Geneva 88. Unspecified Doubling time: 18 hours (DOI=10.1111/1744-7917.12533) Group: Insect cell line 150518570 CVCL_A8XG LaNCE hiPSC-57 induced pluripotent stem cell human CVCL_A8XG From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518571 CVCL_A8XF BGUi009-B induced pluripotent stem cell human CVCL_A8XF From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Homozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Connective tissue. Male 150518572 CVCL_A8XI BGUi008-B induced pluripotent stem cell human CVCL_A8XI From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Heterozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518573 CVCL_A8XH LaNCE hiPSC-60 induced pluripotent stem cell human CVCL_A8XH From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518574 CVCL_A8XK NEAU-Ds-950821 spontaneously immortalized cell line CVCL_A8XK CL:0000010 Unspecified Doubling time: 52.6 hours (DOI=10.1007/BF02855536). Group: Insect cell line 150518575 CVCL_A8XJ BGUi010-B induced pluripotent stem cell human CVCL_A8XJ From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 29131; PLEKHM2; Simple; p.Lys645Alafs*12 (c.1932_1933delAG) (c.2156_2157delAG); ClinVar=VCV000253148; Zygosity=Homozygous (PubMed=34088011) Population: Bedouin; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518576 CVCL_A8XM TMs7311 spontaneously immortalized cell line CVCL_A8XM CL:0000010 Transfected with: UniProtKB; P08160; Autographa californica nuclear polyhedrosis virus p35; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Unspecified Group: Insect cell line 150518577 CVCL_A8XL NEAU-Xc-920730 spontaneously immortalized cell line CVCL_A8XL CL:0000010 Unspecified Group: Insect cell line. 150518578 CVCL_A8XA LaNCE hiPSC-61 induced pluripotent stem cell human CVCL_A8XA From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518579 CVCL_A8XC LaNCE hiPSC-55 induced pluripotent stem cell human CVCL_A8XC From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518580 CVCL_A8XB LaNCE hiPSC-62 induced pluripotent stem cell human CVCL_A8XB From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518581 CVCL_A8XE LaNCE hiPSC-59 induced pluripotent stem cell human CVCL_A8XE From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518582 CVCL_A8XD LaNCE hiPSC-56 induced pluripotent stem cell human CVCL_A8XD From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518583 CVCL_A8YX F15553 induced pluripotent stem cell human CVCL_A8YX CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Leu (c.2149G>C); ClinVar=VCV000018105; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 150518584 CVCL_A8YW F12448 induced pluripotent stem cell human CVCL_A8YW CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518585 CVCL_A8YZ UOMELBi002-A induced pluripotent stem cell human CVCL_A8YZ CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_corrected; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34088002) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 150518586 CVCL_A8YY F16574 induced pluripotent stem cell human CVCL_A8YY CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 150518587 CVCL_A8YP I5061F B-3-15 iPSC induced pluripotent stem cell CVCL_A8YP CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518588 CVCL_A8YR CTXNS1 B-1 iPSC induced pluripotent stem cell CVCL_A8YR CL:0000010 Derived from sampling site: Fetal brain; cerebral cortex. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518589 CVCL_A8YQ I5061F B-3-3 iPSC induced pluripotent stem cell CVCL_A8YQ CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518590 CVCL_A8YT F11430 induced pluripotent stem cell human CVCL_A8YT CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.His163Arg (c.488A>G); ClinVar=VCV000018124; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518591 CVCL_A8YS CTXNS2 B-1 iPSC induced pluripotent stem cell CVCL_A8YS CL:0000010 Derived from sampling site: Fetal brain; cerebral cortex. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518592 CVCL_A8YV F12434 induced pluripotent stem cell human CVCL_A8YV CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Gly217Arg (c.649G>C); ClinVar=VCV000018159; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518593 CVCL_A8YU F12424 induced pluripotent stem cell human CVCL_A8YU CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala79Val (c.236C>T); ClinVar=VCV000018157; Zygosity=Heterozygous (PubMed=30045758) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518594 CVCL_A8YH E01F A-2-6 iPSC induced pluripotent stem cell CVCL_A8YH CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 150518595 CVCL_A8YG E01F A-2-2 iPSC induced pluripotent stem cell CVCL_A8YG CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518596 CVCL_A8YJ E02M finite cell line CVCL_A8YJ CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 150518597 CVCL_A8YI E01F A-2-7 iPSC induced pluripotent stem cell CVCL_A8YI CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 150518598 CVCL_A8YL CM421F finite cell line CVCL_A8YL CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518599 CVCL_A8YK E02M B-0-7 iPSC induced pluripotent stem cell CVCL_A8YK CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 150518600 CVCL_A8YN I5061F finite cell line CVCL_A8YN CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518601 CVCL_A8YM CM421F B-0-12 iPSC induced pluripotent stem cell CVCL_A8YM CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 150518602 CVCL_A8YB K9 iPSC #2 induced pluripotent stem cell dog CVCL_A8YB CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518603 CVCL_A8YA K9 iPSC #1 induced pluripotent stem cell dog CVCL_A8YA CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518604 CVCL_A8YD N01F finite cell line pig CVCL_A8YD CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518605 CVCL_A8YC K9 iPSC #3 induced pluripotent stem cell dog CVCL_A8YC CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518606 CVCL_A8YF N01F iPSC #2 induced pluripotent stem cell pig CVCL_A8YF CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518607 CVCL_A8YE N01F iPSC #1 induced pluripotent stem cell pig CVCL_A8YE CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518608 CVCL_A8VU SRTF spontaneously immortalized cell line CVCL_A8VU CL:0000010 Derived from sampling site: Fin; Breed/subspecies: Standard Ryukin Takafumi. Unspecified Virology: Susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=23999703) Group: Fish cell line 150518609 CVCL_A8VT RKF spontaneously immortalized cell line CVCL_A8VT CL:0000010 Derived from sampling site: Fin; Breed/subspecies: Ryukin. Unspecified Virology: Not susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=23999703) Group: Fish cell line 150518610 CVCL_A8VW PKW-LWHT transformed cell line CVCL_A8VW CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tail; skin; dermis Cell type=Fibroblast.. Male Doubling time: 14.41 hours (PubMed=29596530) Group: Cetacean cell line 150518611 CVCL_A8VV GFF spontaneously immortalized cell line CVCL_A8VV CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 150518612 CVCL_A8VY ZBE3 embryonic stem cell zebrafish CVCL_A8VY CL:0000010 Breed/subspecies: AB. Unspecified Characteristics: Grows at temperatures ranging from 20 to 32 Celsius The highest growth rate is obtained at 28 Celsius (PubMed=28833122). Group: Fish cell line 150518613 CVCL_A8VX SSK spontaneously immortalized cell line CVCL_A8VX CL:0000010 Derived from sampling site: Kidney. Unspecified Characteristics: Optimal growth temperature is 28 Celsius (DOI=10.21077/ijf.2017.64.special-issue.76212-14) Group: Fish cell line 150518614 CVCL_A8VZ JFSK_alb spontaneously immortalized cell line CVCL_A8VZ CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Albinos. Unspecified Characteristics: Capable of growing from 18 to 30 Celsius, the optimal temperature is 24 Celsius (PubMed=28698966) Group: Fish cell line 150518615 CVCL_A8VM B45 spontaneously immortalized cell line CVCL_A8VM CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone B45. Female Virology: Highly susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518616 CVCL_A8VL A36 spontaneously immortalized cell line CVCL_A8VL CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone A36. Female Virology: Susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518617 CVCL_A8VN B57 spontaneously immortalized cell line CVCL_A8VN CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone B57. Omics: Transcriptome analysis by RNAseq Female Virology: Not susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518618 CVCL_A8VQ HFB-ES embryonic stem cell CVCL_A8VQ CL:0000010 Unspecified Group: Fish cell line. 150518619 CVCL_A8VP BAASf spontaneously immortalized cell line CVCL_A8VP CL:0000010 Derived from sampling site: Bulbus arteriosus Cell type=Fibroblast.. Female Group: Fish cell line 150518620 CVCL_A8VS CSCVE spontaneously immortalized cell line CVCL_A8VS CL:0000010 Derived from sampling site: Heart; blood vessel Cell type=Endothelial cell.. Unspecified Characteristics: Capable of growing from 22 to 32 Celsius, the optimal temperature is 28 Celsius (PubMed=25194832) Doubling time: 68 hours (at 7th passage), 57 hours (at 15th passage), 47 hours (at 23th passage), 41 hours (at 37th passage), 39 hours (at 45th passage), 33 hours (at 64th passage) (PubMed=25194832) Group: Fish cell line 150518621 CVCL_A8VR HKM spontaneously immortalized cell line CVCL_A8VR CL:0000010 Derived from sampling site: Head kidney. Unspecified Characteristics: Can grow between 25 to 37 Celsius, with an optimal growth temperature of 28 Celsius (PubMed=25204072) Group: Fish cell line 150518622 CVCL_A8VE 9F8BO hybridoma house mouse CVCL_A8VE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NRN5; Human OLFML3. Group: Patented cell line 150518623 CVCL_A8VD 46A9BO hybridoma house mouse CVCL_A8VD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NRN5; Human OLFML3. Group: Patented cell line 150518624 CVCL_A8VG immKHC8 telomerase immortalized cell line human CVCL_A8VG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 150518625 CVCL_A8VF Z14A7 hybridoma house mouse CVCL_A8VF CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9NRN5; Human OLFML3. Group: Patented cell line 150518626 CVCL_A8VI A2 [Carp] spontaneously immortalized cell line CVCL_A8VI CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone A2. Female Virology: Not susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518627 CVCL_A8VH HeLa FUS KO cancer cell line human CVCL_A8VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 150518628 CVCL_A8VK A3 spontaneously immortalized cell line CVCL_A8VK CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone A3. Female Virology: Highly susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518629 CVCL_A8VJ A22 spontaneously immortalized cell line CVCL_A8VJ CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy derived homozygous clone A22. Omics: Transcriptome analysis by RNAseq Female Virology: Susceptible to infection by viral hemorrhagic septicemia virus (VHSV) (PubMed=22514610) Group: Fish cell line 150518630 CVCL_A8VA immFHC1 telomerase immortalized cell line human CVCL_A8VA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518631 CVCL_A8VC MW1C 6.3 cancer cell line human CVCL_A8VC CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Ter (c.702C>A); Zygosity=Unspecified (PubMed=1961733) Derived from metastatic site: Pleural effusion. Female 150518632 CVCL_A8VB immFHC2 telomerase immortalized cell line human CVCL_A8VB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518633 CVCL_A8WV ftiPSm-2 induced pluripotent stem cell CVCL_A8WV CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518634 CVCL_A8WU ftiPSm-1 induced pluripotent stem cell CVCL_A8WU CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518635 CVCL_A8WX ftiPSm-4 induced pluripotent stem cell CVCL_A8WX CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518636 CVCL_A8WW ftiPSm-3 induced pluripotent stem cell CVCL_A8WW CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518637 CVCL_A8WZ LaNCE hiPSC-58 induced pluripotent stem cell human CVCL_A8WZ From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 150518638 CVCL_A8WY ftiPSm-5 induced pluripotent stem cell CVCL_A8WY CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 150518639 CVCL_A8WN XACHi014-A induced pluripotent stem cell human CVCL_A8WN From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ile145Serfs*92 (c.431delC); Zygosity=Heterozygous (PubMed=34088017) Population: Chinese; Derived from sampling site: Peripheral blood. Female 150518640 CVCL_A8WM XACHi013-A induced pluripotent stem cell human CVCL_A8WM From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Trp392Ter (c.1175G>A) (p.Trp265Ter, c.794G>A); ClinVar=VCV000405268; Zygosity=Heterozygous (PubMed=34088017) Population: Chinese; Derived from sampling site: Peripheral blood. Male 150518641 CVCL_A8WP fiPS-1 induced pluripotent stem cell CVCL_A8WP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 150518642 CVCL_A8WR ftiPSf-19 induced pluripotent stem cell CVCL_A8WR CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 150518643 CVCL_A8WQ ftiPSf-1 induced pluripotent stem cell CVCL_A8WQ CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 150518644 CVCL_A8WT ftiPSf-4 induced pluripotent stem cell CVCL_A8WT CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 150518645 CVCL_A8WS ftiPSf-2 induced pluripotent stem cell CVCL_A8WS CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 150518646 CVCL_A8WF CP-94251 finite cell line human CVCL_A8WF CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=9453489) Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 150518647 CVCL_A8WE CP-52731 finite cell line human CVCL_A8WE CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu97Gln (c.290T>A); Zygosity=Unspecified (PubMed=9453489); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=9453489) Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 150518648 CVCL_A8WH HPCASRi002-A induced pluripotent stem cell human CVCL_A8WH CL:0000010 Sequence variation: Mutation; HGNC; 1514; CASR; Simple; p.Ile554Serfs*73 (c.1656delA); Zygosity=Heterozygous (PubMed=34111698); Sequence variation: Mutation; HGNC; 1514; CASR; Simple; p.Cys739Ter (c.2217T>A); Zygosity=Heterozygous (PubMed=34111698) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 150518649 CVCL_A8WG KR-42421 finite cell line human CVCL_A8WG CL:0000010 Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 150518650 CVCL_A8WJ HEBHMUi008-A induced pluripotent stem cell human CVCL_A8WJ From: Hebei Medical University; Shijiazhuang; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=34088020) Derived from sampling site: Peripheral blood. Male 150518651 CVCL_A8WI KUCFRi003-A induced pluripotent stem cell human CVCL_A8WI From: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 7427; MT-CYB; Simple; p.Asp171Asn (m.15257G>A); ClinVar=VCV000009674; Zygosity=Heteroplasmic (PubMed=34091428) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 150518652 CVCL_A8WL XACHi012-A induced pluripotent stem cell human CVCL_A8WL From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ile145Serfs*92 (c.431delC); Zygosity=Heterozygous (PubMed=34088017); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Trp392Ter (c.1175G>A) (p.Trp265Ter, c.794G>A); ClinVar=VCV000405268; Zygosity=Heterozygous (PubMed=34088017) Population: Chinese; Derived from sampling site: Peripheral blood. Male 150518653 CVCL_A8WK WAe007-A-1 embryonic stem cell human CVCL_A8WK From: Institute for Cardiovascular Science of Soochow University; Suzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 4173; GATA4; Simple_edited; p.Thr280Met (c.839C>T); ClinVar=VCV000030108; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34088018). Female 150518654 CVCL_A8WB EMB spontaneously immortalized cell line CVCL_A8WB CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Capable of growing from 18 to 30 Celsius, the optimal temperature is between 24 and 30 Celsius (PubMed=29333652) Group: Fish cell line 150518655 CVCL_A8WA JFSK_wt spontaneously immortalized cell line CVCL_A8WA CL:0000010 Derived from sampling site: Skin. Unspecified Characteristics: Capable of growing from 18 to 30 Celsius, the optimal temperature is 24 Celsius (PubMed=28698966) Group: Fish cell line 150518656 CVCL_A8WD CP-18821 finite cell line human CVCL_A8WD CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9453489); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser303Alafs*42 (c.906del); Zygosity=Unspecified (PubMed=9453489) Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 150518657 CVCL_A8WC ESCC-CL-Iran cancer cell line human CVCL_A8WC CL:0000010 Miscellaneous: As no cell line name was provided in the papers, we assigned the name based on the abbreviation of the cell line description Population: Iranian; Persian; Derived from sampling site: Esophagus. Omics: Proteome analysis by 2D-DE/MS Female 150518658 CVCL_A8TS JXQ-3D-1436R3 cancer cell line human CVCL_A8TS CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518659 CVCL_A8TR JXQ-3D-1436R2 cancer cell line human CVCL_A8TR CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518660 CVCL_A8TU JXQ-3D-1436R5 cancer cell line human CVCL_A8TU CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518661 CVCL_A8TT JXQ-3D-1436R4 cancer cell line human CVCL_A8TT CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518662 CVCL_A8TW JXQ-3D-902R1 cancer cell line human CVCL_A8TW CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518663 CVCL_A8TV JXQ-3D-1436R6 cancer cell line human CVCL_A8TV CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518664 CVCL_A8TY JXQ-3D-902R3 cancer cell line human CVCL_A8TY CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518665 CVCL_A8TX JXQ-3D-902R2 cancer cell line human CVCL_A8TX CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518666 CVCL_A8TK JXQ-3D-1279R9 cancer cell line human CVCL_A8TK CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518667 CVCL_A8TJ JXQ-3D-1279R8 cancer cell line human CVCL_A8TJ CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518668 CVCL_A8TM JXQ-3D-1405R2 cancer cell line human CVCL_A8TM CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518669 CVCL_A8TL JXQ-3D-1405R1 cancer cell line human CVCL_A8TL CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518670 CVCL_A8TN JXQ-3D-1405R3 cancer cell line human CVCL_A8TN CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518671 CVCL_A8TQ JXQ-3D-1436R1 cancer cell line human CVCL_A8TQ CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518672 CVCL_A8TP JXQ-3D-1405R4 cancer cell line human CVCL_A8TP CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518673 CVCL_A8TC JXQ-3D-1279R1 cancer cell line human CVCL_A8TC CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518674 CVCL_A8TB JXQ-3D-668R4 cancer cell line human CVCL_A8TB CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518675 CVCL_A8TE JXQ-3D-1279R3 cancer cell line human CVCL_A8TE CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518676 CVCL_A8TD JXQ-3D-1279R2 cancer cell line human CVCL_A8TD CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518677 CVCL_A8TG JXQ-3D-1279R5 cancer cell line human CVCL_A8TG CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518678 CVCL_A8TF JXQ-3D-1279R4 cancer cell line human CVCL_A8TF CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518679 CVCL_A8TI JXQ-3D-1279R7 cancer cell line human CVCL_A8TI CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518680 CVCL_A8TH JXQ-3D-1279R6 cancer cell line human CVCL_A8TH CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518681 CVCL_A8SZ JXQ-3D-668R2 cancer cell line human CVCL_A8SZ CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518682 CVCL_A8SY JXQ-3D-668R1 cancer cell line human CVCL_A8SY CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518683 CVCL_A8TA JXQ-3D-668R3 cancer cell line human CVCL_A8TA CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 150518684 CVCL_A8UT IMR/KAT100 cancer cell line human CVCL_A8UT CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=17974978) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2761; Dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate (Antimony potassium tartrate; Derived from metastatic site: Abdomen. Male 150518685 CVCL_A8US RIT-1b cancer cell line human CVCL_A8US CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.748_755del8; Zygosity=Unspecified (PubMed=1933904) Donor information: Established from a patient originally treated by radiation therapy for a pituitary adenoma (PubMed=1933904). Unspecified 150518686 CVCL_A8UV immKEB1 telomerase immortalized cell line human CVCL_A8UV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 150518687 CVCL_A8UU immFEB1 telomerase immortalized cell line human CVCL_A8UU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518688 CVCL_A8UX immKEB2 telomerase immortalized cell line human CVCL_A8UX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 150518689 CVCL_A8UW immFEB2 telomerase immortalized cell line human CVCL_A8UW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518690 CVCL_A8UZ immFEB4 telomerase immortalized cell line human CVCL_A8UZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518691 CVCL_A8UY immFEB3 telomerase immortalized cell line human CVCL_A8UY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518692 CVCL_A8UL HEK293-Survivin transformed cell line human CVCL_A8UL CL:0000010 Transfected with: HGNC; 593; BIRC5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 150518693 CVCL_A8UK JXQ-3D-4256R3 cancer cell line human CVCL_A8UK CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518694 CVCL_A8UN HOT cancer cell line human CVCL_A8UN HLA typing: A*26; B*35,60; C*07 (PubMed=7671230). From: Sato N.; Sapporo Medical College; Sapporo; Japan CL:0000010 Population: Japanese Female 150518695 CVCL_A8UM MaS-3 cancer cell line human CVCL_A8UM CL:0000010 Population: Caucasian; Karyotypic information: Hypotriploid to hypertriploid karyotype (PubMed=33727576); Derived from sampling site: Urinary bladder and kidney; renal pelvis. Omics: Deep proteome analysis Male Doubling time: 26 hours (PubMed=33727576); ~60-80 hours (DSMZ=ACC-901) 150518696 CVCL_A8UP OMYleb spontaneously immortalized cell line CVCL_A8UP CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 150518697 CVCL_A8UR hKC hTERT telomerase immortalized cell line human CVCL_A8UR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Age/sex of donor from personal communication of Gurskaya N.G Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 150518698 CVCL_A8UQ OMYsd spontaneously immortalized cell line CVCL_A8UQ CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 150518699 CVCL_A8UD JXQ-3D-902R8 cancer cell line human CVCL_A8UD CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518700 CVCL_A8UC JXQ-3D-902R7 cancer cell line human CVCL_A8UC CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518701 CVCL_A8UF JXQ-3D-4160R1 cancer cell line human CVCL_A8UF CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518702 CVCL_A8UE JXQ-3D-902R9 cancer cell line human CVCL_A8UE CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518703 CVCL_A8UH JXQ-3D-4160R3 cancer cell line human CVCL_A8UH CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518704 CVCL_A8UG JXQ-3D-4160R2 cancer cell line human CVCL_A8UG CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518705 CVCL_A8UJ JXQ-3D-4256R2 cancer cell line human CVCL_A8UJ CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518706 CVCL_A8UI JXQ-3D-4256R1 cancer cell line human CVCL_A8UI CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518707 CVCL_A8TZ JXQ-3D-902R4 cancer cell line human CVCL_A8TZ CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518708 CVCL_A8UB JXQ-3D-902R6 cancer cell line human CVCL_A8UB CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518709 CVCL_A8UA JXQ-3D-902R5 cancer cell line human CVCL_A8UA CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 150518710 CVCL_A8KJ A69 cancer cell line human CVCL_A8KJ CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 62 hours (PubMed=2910777) 150518711 CVCL_A8KI A175 cancer cell line human CVCL_A8KI CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 59 hours (PubMed=2910777) 150518712 CVCL_A8KL A121(A) cancer cell line human CVCL_A8KL CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 25 hours (PubMed=2910777) 150518713 CVCL_A8KK A90 cancer cell line human CVCL_A8KK CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 71 hours (PubMed=2910777) 150518714 CVCL_A8KN BRCi014-A-2 induced pluripotent stem cell human CVCL_A8KN CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Asian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 a 2A-tdTomato-EF1a-Ble construct was knocked-in at the 3'end of one allele of the ISL1 gene (PubMed=34087992) 150518715 CVCL_A8KM BRCi014-A-1 induced pluripotent stem cell human CVCL_A8KM CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Asian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 a 2A-tdTomato-EF1a-Ble construct was knocked-in at the 3'end of one allele of the ISL1 gene (PubMed=34087992) 150518716 CVCL_A8KP CHUVi001-A induced pluripotent stem cell human CVCL_A8KP From: Centre Hospitalier Universitaire Vaudois; Lausanne; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150518717 CVCL_A8KB HML-1 hybridoma house mouse CVCL_A8KB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103; Monoclonal antibody target: UniProtKB; P26010; Human ITGB7. 150518718 CVCL_A8KA RGL-1 hybridoma house mouse CVCL_A8KA CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Rat intestinal intraepithelial lymphocytes. 150518719 CVCL_A8KD HML-3 hybridoma house mouse CVCL_A8KD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103; Monoclonal antibody target: UniProtKB; P26010; Human ITGB7. 150518720 CVCL_A8KC HML-2 [Mouse hybridoma against human ITGAE/ITGB7] hybridoma house mouse CVCL_A8KC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103; Monoclonal antibody target: UniProtKB; P26010; Human ITGB7. 150518721 CVCL_A8KF HML-5 hybridoma house mouse CVCL_A8KF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103; Monoclonal antibody target: UniProtKB; P26010; Human ITGB7. 150518722 CVCL_A8KE HML-4 hybridoma house mouse CVCL_A8KE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103; Monoclonal antibody target: UniProtKB; P26010; Human ITGB7. 150518723 CVCL_A8KH A1 [Human ovarian carcinoma] cancer cell line human CVCL_A8KH CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 67 hours (PubMed=2910777) 150518724 CVCL_A8KG SPC-Gm-17 spontaneously immortalized cell line CVCL_A8KG CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 2.4 days (PubMed=12762839) Group: Insect cell line 150518725 CVCL_A8JY UACC-1273-4-3 cancer cell line human CVCL_A8JY CL:0000010 Transfected with: HGNC; 12784; WNT5A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Axillary lymph node. Male 150518726 CVCL_A8JX HeLa-LTRHIV-1-Luc cancer cell line human CVCL_A8JX CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: The expression of the luciferase reporter gene is under the control of the HIV-1 isolate BRU promoter (LTR from -454 to +338) (PubMed=17245432) 150518727 CVCL_A8JZ UACC-1273-4-7 cancer cell line human CVCL_A8JZ CL:0000010 Transfected with: HGNC; 12784; WNT5A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Axillary lymph node. Male 150518728 CVCL_A8JQ HEK293T SYT1 KO transformed cell line human CVCL_A8JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11509; SYT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Laflamme C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518729 CVCL_A8JP HEp-2-NS1 cancer cell line human CVCL_A8JP CL:0000010 Transfected with: UniProtKB; P0DOE9; Human respiratory syncytial virus A protein NS1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 150518730 CVCL_A8JS HES-3 NKX2.5eGFP/w embryonic stem cell human CVCL_A8JS CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Using homologous recombination an EGFP reporter gene was introduced at the first exon of one allele of the NKX2.5 locus 150518731 CVCL_A8JR CMT-7364 cancer cell line dog CVCL_A8JR CL:0000010 Derived from sampling site: Mammary gland. Female Characteristics: Tumorigenic in nude mice (PubMed=30309498) Doubling time: 21.12 hours (PubMed=30309498) Group: Triple negative breast cancer (TNBC) cell line 150518732 CVCL_A8JU PER-494 cancer cell line human CVCL_A8JU CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Bone marrow. Female 150518733 CVCL_A8JT HES-3 MESP1mCherry/w NKX2-5eGFP/w embryonic stem cell human CVCL_A8JT CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Characteristics: Useful for dissecting the molecular and cellular mechanisms related to the earliest steps in cardiac development in live cells (PubMed=25187301); Characteristics: Using homologous recombination an EGFP reporter gene was introduced at the first exon of one allele of the NKX2.5 locus; Characteristics: Using homologous recombination an mCherry reporter gene was introduced at the first exon of one allele of the MESP1 locus 150518734 CVCL_A8JW ASTC-a-1 SCAT3 cancer cell line human CVCL_A8JW CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Met1_Ser2insVal, p.Phe64Leu, p.Ser65Thr, p.Tyr66Trp, p.Asn146Ile, p.Met153Thr, p.Val163Ala and p.His231Leu = ECFP); Transfected with: Venus, a bright yellow fluorescent protein derived from YFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Chinese Characteristics: Transfected with the SCAT3 reporter for caspase activation SCAT3 comprises the ECFP (enhanced cyan fluorescent protein) and Venus proteins linked by an 18 amino acid peptide that includes DEVD, a CASP3 cleavage sequence. 150518735 CVCL_A8JV PER-910 cancer cell line human CVCL_A8JV CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Peripheral blood. Male 150518736 CVCL_A9NL 273 hybridoma house mouse CVCL_A9NL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Murine leukemia viruses (MuLV) gp70. 150518737 CVCL_A9NK 715 hybridoma house mouse CVCL_A9NK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Murine leukemia viruses (MuLV) gp70. 150518738 CVCL_A9NN Chessie 8 hybridoma house mouse CVCL_A9NN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03377; HIV-1 isolate BRU/LAI env (gp41). 150518739 CVCL_A9NM Chessie 6 hybridoma house mouse CVCL_A9NM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03377; HIV-1 isolate BRU/LAI env (gp120). 150518740 CVCL_A9NP Chessie 13-39.1 hybridoma house mouse CVCL_A9NP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03377; HIV-1 isolate BRU/LAI env (gp120). 150518741 CVCL_A9NR Rev-CEM-E7 cancer cell line human CVCL_A9NR CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Transfected with a pNL-GFP-RRE(SA) construct that results in the expression of the GFP gene under the control of the HIV-1 LTR promoter in HIV-1 infected cells when Tat and Rev are present 150518742 CVCL_A9NQ Rev-CEM-D4 cancer cell line human CVCL_A9NQ CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Transfected with a pNL-GFP-RRE(SA) construct that results in the expression of the GFP gene under the control of the HIV-1 LTR promoter in HIV-1 infected cells when Tat and Rev are present 150518743 CVCL_A9ND Een69 finite cell line human CVCL_A9ND CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 150518744 CVCL_A9NC AGH-OG3 embryonic stem cell house mouse CVCL_A9NC CL:0000010 Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by RNAseq Male 150518745 CVCL_A9NF FX1G5 hybridoma house mouse CVCL_A9NF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2993 150518746 CVCL_A9NE FW5H6 hybridoma house mouse CVCL_A9NE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2996 150518747 CVCL_A9NH 2-189-H-1 hybridoma house mouse CVCL_A9NH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZQ7; Human CD274. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015160 150518748 CVCL_A9NG FX7A7 hybridoma house mouse CVCL_A9NG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01258; Human CALCA (Note=Recognizes propeptide). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2997 150518749 CVCL_A9NJ 500 hybridoma house mouse CVCL_A9NJ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Murine leukemia viruses (MuLV) gp80. 150518750 CVCL_A9NI 55-2F12 hybridoma house mouse CVCL_A9NI CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05894; Simian immunodeficiency virus (isolate Mm142-83) (SIV-mac) gag (p24). 150518751 CVCL_A9MZ CL015 transformed cell line human CVCL_A9MZ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9097; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200716 150518752 CVCL_A9NB L6565 cancer cell line house mouse CVCL_A9NB CL:0000010 150518753 CVCL_A9NA CL016 transformed cell line human CVCL_A9NA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9098; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200717 150518754 CVCL_A9MS CL005 transformed cell line human CVCL_A9MS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9087; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200706 150518755 CVCL_A9MR CL004 transformed cell line human CVCL_A9MR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9086; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200705 150518756 CVCL_A9MU CL007 transformed cell line human CVCL_A9MU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9089; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200708 150518757 CVCL_A9MT CL006 transformed cell line human CVCL_A9MT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9088; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200707 150518758 CVCL_A9MW CL009 transformed cell line human CVCL_A9MW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9091; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200710 150518759 CVCL_A9MV CL008 transformed cell line human CVCL_A9MV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9090; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200709 150518760 CVCL_A9MY CL011 transformed cell line human CVCL_A9MY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9093; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200712 150518761 CVCL_A9MX CL010 transformed cell line human CVCL_A9MX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9092; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200711 150518762 CVCL_A9NT CHO-K1-UCSC spontaneously immortalized cell line CVCL_A9NT CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 150518763 CVCL_A9NS Rev-CEM-G2 cancer cell line human CVCL_A9NS CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Transfected with a pNL-GFP-RRE(SA) construct that results in the expression of the GFP gene under the control of the HIV-1 LTR promoter in HIV-1 infected cells when Tat and Rev are present; Characteristics: Expresses the mCherry gene under the control of a EF-1a promoter 150518764 CVCL_A9NV Sup-T1 CCR5+ L23 cancer cell line human CVCL_A9NV CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: Expresses low level of CCR5 (HIVReagentProgram) Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 150518765 CVCL_A9NU Sup-T1 CCR5+ H6 cancer cell line human CVCL_A9NU CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: Expresses high level of CCR5 (HIVReagentProgram) Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 150518766 CVCL_A9NX CHO C1s-/- MGAT1- spontaneously immortalized cell line CVCL_A9NX CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q924C0; Mgat1; Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GUR0; C1s Derived from sampling site: Ovary. Female Characteristics: This cell line minimizes proteolysis of clade B HIV-1 envelope proteins commonly observed in the production of monomeric gp120 and gp140 as well as gp140 trimers; Characteristics: This cell line can only produce N-linked carbohydrates with early oligomannose glycans (Man5-9) Group: Serum/protein free medium cell line 150518767 CVCL_A9NW Sup-T1 CCR5+ M10 cancer cell line human CVCL_A9NW CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: Expresses medium level of CCR5 (HIVReagentProgram) Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 150518768 CVCL_A9NZ CHO C1s-/- MGAT1- BaL-rgp120 spontaneously immortalized cell line CVCL_A9NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q924C0; Mgat1; Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GUR0; C1s; Transfected with: UniProtKB; Q78225; HIV-1 isolate BaL env; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Produces an unclipped gp120 from a clade B isolate (BaL-rgp120) and enriched for mannose-5 glycans The gp120 construct contains an N-terminal purification tag from HSV-1 glycoprotein D (gD) (PubMed=31087560). Group: Serum/protein free medium cell line 150518769 CVCL_A9NY CHO C1s-/- spontaneously immortalized cell line CVCL_A9NY CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GUR0; C1s Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 150518770 CVCL_A9DB RPMI-8226-mCherry cancer cell line human CVCL_A9DB CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 150518771 CVCL_A9DA RPMI-8226-Luc2-tdT cancer cell line human CVCL_A9DA CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 150518772 CVCL_A9DD PUMC-CRC1 cancer cell line human CVCL_A9DD CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1493fs (c.4476_4479delCACGinsACA); Zygosity=Heterozygous (PubMed=34162944); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=34162944); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Val506Glu (c.1517T>C); Zygosity=Homozygous (PubMed=34162944) Population: Chinese; Derived from sampling site: Cecum. Female Doubling time: 44 hours (PubMed=34162944); Microsatellite instability: Stable (MSS) (PubMed=34162944) 150518773 CVCL_A9DC RPMI-8226-tdT cancer cell line human CVCL_A9DC CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 150518774 CVCL_A9DF Daoy-luc2-tdT cancer cell line human CVCL_A9DF CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Brain; cerebellum. Male 150518775 CVCL_A9DE S1-IR20 cancer cell line human CVCL_A9DE CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from sampling site: Colon. Female 150518776 CVCL_A9DH COLO 205-Luc2-tdT cancer cell line human CVCL_A9DH CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from metastatic site: Ascites. Male 150518777 CVCL_A9DG COLO 205-EGFP cancer cell line human CVCL_A9DG CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Ascites. Male 150518778 CVCL_A9CY COLO 201-tdT cancer cell line human CVCL_A9CY CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from metastatic site: Ascites. Male 150518779 CVCL_A9CX COLO 201-mCherry cancer cell line human CVCL_A9CX CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from metastatic site: Ascites. Male 150518780 CVCL_A9CZ RPMI-8226-EGFP cancer cell line human CVCL_A9CZ CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 150518781 CVCL_A9CQ HCT-8-Luc2-tdT cancer cell line human CVCL_A9CQ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male 150518782 CVCL_A9CP 293T-Luc2-tdT transformed cell line human CVCL_A9CP CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518783 CVCL_A9CS HCT-8-tdT cancer cell line human CVCL_A9CS CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male 150518784 CVCL_A9CR HCT-8-mCherry cancer cell line human CVCL_A9CR CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Male 150518785 CVCL_A9CU RBE-Luc2-tdT cancer cell line human CVCL_A9CU CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Ser (c.394C>A); ClinVar=VCV000375893; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Japanese; Derived from sampling site: Liver. Female 150518786 CVCL_A9CT CCC-REPF-1 finite cell line Norway rat CVCL_A9CT CL:0000010 Derived from sampling site: Embryonic lung Cell type=Fibroblast.. Unspecified 150518787 CVCL_A9CW COLO 201-Luc2-tdT cancer cell line human CVCL_A9CW CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from metastatic site: Ascites. Male 150518788 CVCL_A9CV COLO 201-EGFP cancer cell line human CVCL_A9CV CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Ascites. Male 150518789 CVCL_A9CI DU145-Cas9-539 cancer cell line human CVCL_A9CI CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Brain. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518790 CVCL_A9CH H460/CIS cancer cell line human CVCL_A9CH CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male Doubling time: 1.9 days (PubMed=11551417) 150518791 CVCL_A9CK DU145-Cas9-541 cancer cell line human CVCL_A9CK CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Brain. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518792 CVCL_A9CJ DU145-Cas9-540 cancer cell line human CVCL_A9CJ CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Brain. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518793 CVCL_A9CM 293T-mCherry transformed cell line human CVCL_A9CM CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518794 CVCL_A9CL 293T-tdT transformed cell line human CVCL_A9CL CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518795 CVCL_A9CN 293T-EGFP transformed cell line human CVCL_A9CN CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150518796 CVCL_A9EC 110BH3 hybridoma house mouse CVCL_A9EC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P14174; Human MIF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11345 150518797 CVCL_A9EB 9.6 hybridoma house mouse CVCL_A9EB CL:0000010 Monoclonal antibody isotype: IgG2a (Patent=US6010902); IgG2b (PubMed=6969782); Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10267 150518798 CVCL_A9EE PK15-B1 spontaneously immortalized cell line pig CVCL_A9EE CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Can produce high titers of porcine circovirus type 2 (PCV2) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200936 150518799 CVCL_A9ED 205AD2 hybridoma house mouse CVCL_A9ED CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P14174; Human MIF. 150518800 CVCL_A9EG PK15-IFNgSB spontaneously immortalized cell line pig CVCL_A9EG CL:0000010 Transfected with: VGNC; 89040; Pig IFNG Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Contains a sleeping beauty (SB) integrated pTEG-IFNg-Fc vector containing a fusion of pig IFNG with pig IgG Fc domain; Virology: Highly susceptible to infection by porcine circovirus type 2 (PCV2) 150518801 CVCL_A9EF PK15-IFNgRan spontaneously immortalized cell line pig CVCL_A9EF CL:0000010 Transfected with: VGNC; 89040; Pig IFNG Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Contains a randomly integrated pTEG-IFNg-Fc vector containing a fusion of pig IFNG with pig IgG Fc domain; Virology: Highly susceptible to infection by porcine circovirus type 2 (PCV2) 150518802 CVCL_A9EI PK15-1E5 spontaneously immortalized cell line pig CVCL_A9EI CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Grows adherently; Virology: Can produce high titers of porcine circovirus type 2 (PCV2) 150518803 CVCL_A9EH PK15-1C8 spontaneously immortalized cell line pig CVCL_A9EH CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Grows adherently; Virology: Can produce high titers of porcine circovirus type 2 (PCV2) 150518804 CVCL_A9DZ LA9-IS11 EGF-2 spontaneously immortalized cell line house mouse CVCL_A9DZ CL:0000010 Transfected with: HGNC; 3229; EGF Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50057 150518805 CVCL_A9DY A31-IS11 EGF-2 spontaneously immortalized cell line house mouse CVCL_A9DY CL:0000010 Transfected with: HGNC; 3229; EGF Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50093 150518806 CVCL_A9EA L-IS11 IgE-9 spontaneously immortalized cell line house mouse CVCL_A9EA CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: Transfected with an IgE expression vector having the IL-2 leader sequence Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50056 150518807 CVCL_A9DR GBC-SD-Cas9-771 cancer cell line human CVCL_A9DR CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 150518808 CVCL_A9DQ GBC-SD-Cas9-770 cancer cell line human CVCL_A9DQ CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518809 CVCL_A9DT GBC-SD-Cas9-773 cancer cell line human CVCL_A9DT CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 150518810 CVCL_A9DS GBC-SD-Cas9-772 cancer cell line human CVCL_A9DS CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 150518811 CVCL_A9DV GBC-SD-Cas9-775 cancer cell line human CVCL_A9DV CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 150518812 CVCL_A9DU GBC-SD-Cas9-774 cancer cell line human CVCL_A9DU CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 150518813 CVCL_A9DX L-bFGF-6 spontaneously immortalized cell line house mouse CVCL_A9DX CL:0000010 Transfected with: HGNC; 3676; FGF2 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 150518814 CVCL_A9DW L-bFGF-5 spontaneously immortalized cell line house mouse CVCL_A9DW CL:0000010 Transfected with: HGNC; 3676; FGF2 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50092 150518815 CVCL_A9DJ COLO 205-tdT cancer cell line human CVCL_A9DJ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from metastatic site: Ascites. Male 150518816 CVCL_A9DI COLO 205-mCherry cancer cell line human CVCL_A9DI CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from metastatic site: Ascites. Male 150518817 CVCL_A9DL GBC-SD-Cas9-766 cancer cell line human CVCL_A9DL CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518818 CVCL_A9DK GBC-SD-Luc2-tdT cancer cell line human CVCL_A9DK CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Chinese; Derived from sampling site: Gallbladder. Male 150518819 CVCL_A9DN GBC-SD-Cas9-768 cancer cell line human CVCL_A9DN CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518820 CVCL_A9DM GBC-SD-Cas9-767 cancer cell line human CVCL_A9DM CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518821 CVCL_A9DP GBC-SD-Cas9-769 cancer cell line human CVCL_A9DP CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Gallbladder. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518822 CVCL_A9BB MDA-MB-231 NAT1 down cancer cell line human CVCL_A9BB CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7645; NAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a pcDNA5/FRT derived construct with a NATb promoter driving the expression of NAT1 (NATb/NAT1*4) Doubling time: 27.2 hours (PubMed=29315819) Group: Triple negative breast cancer (TNBC) cell line 150518823 CVCL_A9BA MDA-MB-231 NAT1 scrambled cancer cell line human CVCL_A9BA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a scrambled NAT1 shRNA, control cell line for other NAT1 cell lines Doubling time: 27.4 hours (PubMed=29315819) Group: Triple negative breast cancer (TNBC) cell line 150518824 CVCL_A9BD MDA-MB-231 NAT1+/- 2-12 cancer cell line human CVCL_A9BD CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 7645; NAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a scrambled NAT1 shRNA Group: Triple negative breast cancer (TNBC) cell line 150518825 CVCL_A9BC MDA-MB-231 NAT1 up cancer cell line human CVCL_A9BC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a pcDNA5/FRT derived construct with a NATb promoter driving the expression of NAT1 (NATb/NAT1*4) Doubling time: 23.4 hours (PubMed=29315819) Group: Triple negative breast cancer (TNBC) cell line 150518826 CVCL_A9BF MDA-MB-231 NAT1-/- 5-50 cancer cell line human CVCL_A9BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7645; NAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a scrambled NAT1 shRNA Doubling time: 29.8 + 0.7 hours (PubMed=29964355) Group: Triple negative breast cancer (TNBC) cell line 150518827 CVCL_A9BE MDA-MB-231 NAT1-/- 2-19 cancer cell line human CVCL_A9BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7645; NAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a scrambled NAT1 shRNA Doubling time: 29.3 + 1.1 hours (PubMed=29964355) Group: Triple negative breast cancer (TNBC) cell line 150518828 CVCL_A9AW LLC-M1 undefined cell line type house mouse CVCL_A9AW CL:0000010 Derived from sampling site: Lymph node. Unspecified 150518829 CVCL_A9AV LLC-AS180 undefined cell line type house mouse CVCL_A9AV CL:0000010 Unspecified 150518830 CVCL_A9AY LLC-MS180 cancer cell line house mouse CVCL_A9AY CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 150518831 CVCL_A9AX LLC-M3 undefined cell line type house mouse CVCL_A9AX CL:0000010 Unspecified 150518832 CVCL_A9AZ MDA-MB-231 CAPN2 KO cancer cell line human CVCL_A9AZ From: Greer P.A.; Queen's University; Kingston; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1479; CAPN2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 150518833 CVCL_A9AN HOS-SL cancer cell line human CVCL_A9AN CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=2531855) Population: Caucasian; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Female Characteristics: Non-tumorigenic 150518834 CVCL_A9AQ Detroit 98/AGR cancer cell line human CVCL_A9AQ CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=20143388). 150518835 CVCL_A9AP IGR/Cut40 cancer cell line human CVCL_A9AP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=21556589) Derived from sampling site: Uterus; cervix. Female Doubling time: ~28 hours (PubMed=21556589) 150518836 CVCL_A9AS GL PK/1 undefined cell line type human CVCL_A9AS CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of pig kidney origin but found to be a human cell line (PubMed=13881104; PubMed=13881105).. 150518837 CVCL_A9AR Detroit 98/Apt cancer cell line human CVCL_A9AR CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:22526; 4-aminofolic acid (Aminopterin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 150518838 CVCL_A9AU LLC-HE1 undefined cell line type human CVCL_A9AU CL:0000010 Derived from sampling site: Fetal torso. Unspecified 150518839 CVCL_A9AT GL RK/7 spontaneously immortalized cell line CVCL_A9AT CL:0000010 Derived from sampling site: Kidney. 150518840 CVCL_A9AG SDUBMSi013-A induced pluripotent stem cell human CVCL_A9AG From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 150518841 CVCL_A9AF SDUBMSi012-A induced pluripotent stem cell human CVCL_A9AF From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 150518842 CVCL_A9AI SCVIi014-A induced pluripotent stem cell human CVCL_A9AI From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg190Gln (c.569G>A) (p.Arg63Gln, c.188G>A); ClinVar=VCV000003117; Zygosity=Heterozygous (PubMed=34411974) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 150518843 CVCL_A9AH SDUBMSi010-A induced pluripotent stem cell human CVCL_A9AH From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 150518844 CVCL_A9AK SCVIi016-A induced pluripotent stem cell human CVCL_A9AK From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg192Cysfs*91 (c.573_577delGCGCT) (p.Arg65Cysfs*91, c.192_196delGCGCT); ClinVar=VCV000053072; Zygosity=Heterozygous (PubMed=34411974) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518845 CVCL_A9AJ SCVIi015-A induced pluripotent stem cell human CVCL_A9AJ From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Lys196Serfs*41 (c.585delG) (p.Lys69Serfs*41, c.204delG); ClinVar=VCV000053076; Zygosity=Heterozygous (PubMed=34411974) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518846 CVCL_A9AM CG3 cancer cell line human CVCL_A9AM CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu289His (c.866T>A); Zygosity=Unspecified (PubMed=1336431) Population: Chinese; Taiwan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 150518847 CVCL_A9AL CG2 cancer cell line human CVCL_A9AL CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236His (c.706T>C); ClinVar=VCV000216469; Zygosity=Unspecified (PubMed=1336431); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Val (c.709A>G); ClinVar=VCV000182934; Zygosity=Unspecified (PubMed=1336431); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1336431) Population: Chinese; Taiwan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 150518848 CVCL_A9CA PUMC-mips-C2 induced pluripotent stem cell house mouse CVCL_A9CA CL:0000010 150518849 CVCL_A9CC PUMC-mips-D2 induced pluripotent stem cell house mouse CVCL_A9CC CL:0000010 150518850 CVCL_A9CB PUMC-mips-C4 induced pluripotent stem cell house mouse CVCL_A9CB CL:0000010 150518851 CVCL_A9CE EAG3 cancer cell line human CVCL_A9CE CL:0000010 Population: Chinese; Derived from sampling site: Endometrium. Female 150518852 CVCL_A9CD PUMC-mips-D3 induced pluripotent stem cell house mouse CVCL_A9CD CL:0000010 150518853 CVCL_A9CG TR-LNN-1 cancer cell line human CVCL_A9CG CL:0000010 Population: Chinese; Derived from metastatic site: Lymph node. Male 150518854 CVCL_A9CF HCT-8/VCR cancer cell line human CVCL_A9CF CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Male 150518855 CVCL_A9BX PUMC-mips-B4 induced pluripotent stem cell house mouse CVCL_A9BX CL:0000010 150518856 CVCL_A9BW PUMC-mips-B2 induced pluripotent stem cell house mouse CVCL_A9BW CL:0000010 150518857 CVCL_A9BZ PUMC-mips-B6 induced pluripotent stem cell house mouse CVCL_A9BZ CL:0000010 150518858 CVCL_A9BY PUMC-mips-B5 induced pluripotent stem cell house mouse CVCL_A9BY CL:0000010 150518859 CVCL_A9BP Ecad-231-7 cancer cell line human CVCL_A9BP CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1748; CDH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 150518860 CVCL_A9BR K562/HHT cancer cell line human CVCL_A9BR CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; Derived from sampling site: Pleural effusion. Female 150518861 CVCL_A9BQ Ecad-231-9 cancer cell line human CVCL_A9BQ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1748; CDH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 150518862 CVCL_A9BT PUMC-mips-A4 induced pluripotent stem cell house mouse CVCL_A9BT CL:0000010 150518863 CVCL_A9BS PUMC-mips-A2 induced pluripotent stem cell house mouse CVCL_A9BS CL:0000010 150518864 CVCL_A9BV PUMC-mips-B1 induced pluripotent stem cell house mouse CVCL_A9BV CL:0000010 150518865 CVCL_A9BU PUMC-mips-A5 induced pluripotent stem cell house mouse CVCL_A9BU CL:0000010 150518866 CVCL_A9BH VCAF2B telomerase immortalized cell line human CVCL_A9BH CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Vulva Cell type=Fibroblast.. Female 150518867 CVCL_A9BG CerCAF telomerase immortalized cell line human CVCL_A9BG CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Uterus; cervix. Female 150518868 CVCL_A9BJ LT97 cancer cell line human CVCL_A9BJ CL:0000010 Sequence variation: Gene deletion; HGNC; 583; APC; Zygosity=Homozygous (PubMed=12204677); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12204677; PubMed=17708598); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu257Arg (c.770T>G); ClinVar=VCV000142134; Zygosity=Heterozygous (PubMed=17708598); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1100+30A>T; ClinVar=VCV000810938; Zygosity=Heterozygous (PubMed=17708598) Miscellaneous: STR profile mentioned in PubMed=27996158 but obtained from personal communication of Schlormann W Derived from sampling site: Colon. Female Characteristics: Contains 2 subpopulations of cells, one CD44+, the other CD44- (PubMed=17708598) 150518869 CVCL_A9BI VCAF8 telomerase immortalized cell line human CVCL_A9BI CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Vulva Cell type=Fibroblast.. Female 150518870 CVCL_A9BL DG6 cancer cell line house mouse CVCL_A9BL CL:0000010 Omics: Transcriptome analysis by microarray. Characteristics: Poorly metastatic to lung (PubMed=15845378) 150518871 CVCL_A9BK DD1 cancer cell line house mouse CVCL_A9BK CL:0000010 Omics: Transcriptome analysis by microarray. Characteristics: Highly metastatic to lung (PubMed=15845378) 150518872 CVCL_A9BN DG6-VAP33-GFP cancer cell line house mouse CVCL_A9BN CL:0000010 Transfected with: HGNC; 12648; VAPA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Transfected with a VAPA-GFP construct 150518873 CVCL_A9BM DG6-GFP cancer cell line house mouse CVCL_A9BM CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). 150518874 CVCL_A9AA JUCTCi017-A induced pluripotent stem cell human CVCL_A9AA From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 10806; SGCB; Simple; p.Leu287Serfs*14 (c.859delC); ClinVar=VCV000534946; Zygosity=Homozygous (PubMed=34087734) Population: Jordanian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 150518875 CVCL_A9AC JUCTCi017-C induced pluripotent stem cell human CVCL_A9AC From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 10806; SGCB; Simple; p.Leu287Serfs*14 (c.859delC); ClinVar=VCV000534946; Zygosity=Homozygous (from autologous cell line JUCTCi017-A) Population: Jordanian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 150518876 CVCL_A9AB JUCTCi017-B induced pluripotent stem cell human CVCL_A9AB From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 10806; SGCB; Simple; p.Leu287Serfs*14 (c.859delC); ClinVar=VCV000534946; Zygosity=Homozygous (from autologous cell line JUCTCi017-A) Population: Jordanian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 150518877 CVCL_A9AE LANCEi022-A induced pluripotent stem cell human CVCL_A9AE From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys617Terfs (c.1851_1852delTG); Zygosity=Heterozygous (PubMed=34062330) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Omics: SNP array analysis Male 150518878 CVCL_A9AD LANCEi021-A induced pluripotent stem cell human CVCL_A9AD From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Tyr2272Asp (c.6814T>G); Zygosity=Heterozygous (PubMed=34062330) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Omics: SNP array analysis Female 150518879 CVCL_A9LJ R456 embryonic stem cell CVCL_A9LJ CL:0000010 Female Group: Non-human primate cell line. 150518880 CVCL_A9LI R420 embryonic stem cell CVCL_A9LI CL:0000010 Female Group: Non-human primate cell line. 150518881 CVCL_A9LL R475 embryonic stem cell CVCL_A9LL CL:0000010 Female Group: Non-human primate cell line. 150518882 CVCL_A9LK R460 embryonic stem cell CVCL_A9LK CL:0000010 Male Group: Non-human primate cell line. 150518883 CVCL_A9LN YTH 24.5 hybridoma Norway rat CVCL_A9LN CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518884 CVCL_A9LM YAML 568.4 hybridoma Norway rat CVCL_A9LM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518885 CVCL_A9LP YTH 5.3 hybridoma Norway rat CVCL_A9LP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518886 CVCL_A9LB BHK-BTV-VP6 spontaneously immortalized cell line CVCL_A9LB CL:0000010 Transfected with: UniProtKB; G9JKG2; Bluetongue virus serotype 1 (Chinese isolate) protein VP6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male 150518887 CVCL_A9LA OPL spontaneously immortalized cell line CVCL_A9LA CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 150518888 CVCL_A9LD MDBK-Nectin-4 spontaneously immortalized cell line CVCL_A9LD CL:0000010 Transfected with: VGNC; 43719; Dog NECTIN4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male Virology: Susceptible to infection by peste des petits ruminants virus (PPRV) 150518889 CVCL_A9LC DF-1-AvBD2 spontaneously immortalized cell line CVCL_A9LC CL:0000010 Transfected with: UniProtKB; P46158; Chicken gallinacin-2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 150518890 CVCL_A9LF R366.4 embryonic stem cell CVCL_A9LF CL:0000010 Male Group: Non-human primate cell line. 150518891 CVCL_A9LE SMB [Scophthalmus] spontaneously immortalized cell line CVCL_A9LE CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 150518892 CVCL_A9LH R394.2 embryonic stem cell CVCL_A9LH CL:0000010 Female Group: Non-human primate cell line. 150518893 CVCL_A9LG R367B embryonic stem cell CVCL_A9LG CL:0000010 Male Group: Non-human primate cell line. 150518894 CVCL_A9KY FULA4 cancer cell line house mouse CVCL_A9KY CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: FVB. Omics: Transcriptome analysis by RNAseq Female 150518895 CVCL_A9KX FULA3 cancer cell line house mouse CVCL_A9KX CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: FVB. Omics: Transcriptome analysis by RNAseq Female 150518896 CVCL_A9KZ CHO Hu 164 SCF 17 spontaneously immortalized cell line CVCL_A9KZ CL:0000010 Transfected with: HGNC; 6343; KITLG (with p.Ser191_Val273) Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10557 150518897 CVCL_A9KQ BELA1 cancer cell line house mouse CVCL_A9KQ CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>C); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Female 150518899 CVCL_A9KS BULA1 cancer cell line house mouse CVCL_A9KS CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Female 150518900 CVCL_A9KR BELA2 cancer cell line house mouse CVCL_A9KR CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>C); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Female 150518901 CVCL_A9KU CULA cancer cell line house mouse CVCL_A9KU CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; None_reported; -; Zygosity=- (Direct_author_submission) Miscellaneous: Age/sex of donor and Kras mutation status from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by RNAseq Female 150518902 CVCL_A9KT BULA2 cancer cell line house mouse CVCL_A9KT CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Female 150518903 CVCL_A9KW FULA2 cancer cell line house mouse CVCL_A9KW CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: FVB. Female 150518904 CVCL_A9KV FULA1 cancer cell line house mouse CVCL_A9KV CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=30828726) Miscellaneous: Age/sex of donor from personal communication of Giotopoulou G Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: FVB. Omics: Transcriptome analysis by RNAseq Female 150518905 CVCL_A9MK SW620-Luc2-tdT cancer cell line human CVCL_A9MK CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male 150518906 CVCL_A9MJ SW620-EGFP cancer cell line human CVCL_A9MJ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Lymph node. Male 150518907 CVCL_A9MM SW620-tdT cancer cell line human CVCL_A9MM CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male 150518908 CVCL_A9ML SW620-mCherry cancer cell line human CVCL_A9ML CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from metastatic site: Lymph node. Male 150518909 CVCL_A9MN CL001 transformed cell line human CVCL_A9MN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9083; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200702 150518910 CVCL_A9MQ CL003 transformed cell line human CVCL_A9MQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9085; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200704 150518911 CVCL_A9MP CL002 transformed cell line human CVCL_A9MP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Reference control cell line for pharmacogenomics testing Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9084; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200703 150518912 CVCL_A9MC A549-Cas9-861 cancer cell line human CVCL_A9MC CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518913 CVCL_A9MB A549-Cas9-860 cancer cell line human CVCL_A9MB CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518914 CVCL_A9ME A549-Cas9-863 cancer cell line human CVCL_A9ME CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518915 CVCL_A9MD A549-Cas9-862 cancer cell line human CVCL_A9MD CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 150518916 CVCL_A9MG SW480-Luc2-tdT cancer cell line human CVCL_A9MG CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Colon. Male 150518917 CVCL_A9MF SW480-EGFP cancer cell line human CVCL_A9MF CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Colon. Male 150518918 CVCL_A9MI SW480-tdT cancer cell line human CVCL_A9MI CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Colon. Male 150518919 CVCL_A9MH SW480-mCherry cancer cell line human CVCL_A9MH CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Colon. Male 150518920 CVCL_A9LZ WWX-GEEC03 finite cell line CVCL_A9LZ CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014137 150518921 CVCL_A9LY MHCC97H-GFP-LC3 cancer cell line human CVCL_A9LY CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6838; MAP1LC3A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201097 150518922 CVCL_A9MA 12D7-MDR1 cancer cell line human CVCL_A9MA CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 40; ABCB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150518923 CVCL_A9LR YTH 65.3 hybridoma Norway rat CVCL_A9LR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518924 CVCL_A9LQ YTH 54.12 hybridoma Norway rat CVCL_A9LQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518925 CVCL_A9LT YTH 72.1 hybridoma Norway rat CVCL_A9LT CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518926 CVCL_A9LS YTH 68.2 hybridoma Norway rat CVCL_A9LS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518927 CVCL_A9LV YTH 79.6 hybridoma Norway rat CVCL_A9LV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518928 CVCL_A9LU YTH 75.6 hybridoma Norway rat CVCL_A9LU CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518929 CVCL_A9LX YTH 891.1 hybridoma Norway rat CVCL_A9LX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518930 CVCL_A9LW YTH 86.10 hybridoma Norway rat CVCL_A9LW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 150518931 CVCL_A9JH CWBR-L2 finite cell line CVCL_A9JH CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150518932 CVCL_A9JG HOS/GFP cancer cell line human CVCL_A9JG CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 150518933 CVCL_A9JJ CWBR-S2 finite cell line CVCL_A9JJ CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150518934 CVCL_A9JI CWBR-S1 finite cell line Norway rat CVCL_A9JI CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 150518935 CVCL_A9JL CWBR-T11 finite cell line CVCL_A9JL CL:0000010 Derived from sampling site: Tail; muscle Cell type=Fibroblast.. Male 150518936 CVCL_A9JK CWBR-T10 finite cell line CVCL_A9JK CL:0000010 Derived from sampling site: Tail; muscle Cell type=Fibroblast.. Male 150518937 CVCL_A9JN WB-S2 finite cell line CVCL_A9JN CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150518938 CVCL_A9JM WB-S1 finite cell line CVCL_A9JM CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Unspecified 150518939 CVCL_A9JB MDCK-XF04 spontaneously immortalized cell line dog CVCL_A9JB CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018192 150518940 CVCL_A9JA MDCK-XF03 spontaneously immortalized cell line dog CVCL_A9JA CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018191 150518941 CVCL_A9JD HepG2-CYP3A29 cancer cell line human CVCL_A9JD CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: VGNC; 103556; Pig CYP3A29; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 150518942 CVCL_A9JC P815 Hsp65-IL-2 cancer cell line house mouse CVCL_A9JC CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P9WPE7; Mycobacterium tuberculosis groL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male Characteristics: Transfected with a groL2/Hsp65-IL2 construct 150518943 CVCL_A9JF DC-L1 finite cell line CVCL_A9JF CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 150518944 CVCL_A9JE GSQ-S1 finite cell line CVCL_A9JE CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150518945 CVCL_A9IW BFR-K1 finite cell line CVCL_A9IW CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male 150518946 CVCL_A9IV BMU-S1 finite cell line CVCL_A9IV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518947 CVCL_A9IY BFR-S3 finite cell line CVCL_A9IY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518948 CVCL_A9IX BFR-L1 finite cell line CVCL_A9IX CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150518949 CVCL_A9IZ MDCK-XF02 spontaneously immortalized cell line dog CVCL_A9IZ CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Doubling time: <21 hours (DOI=10.3969/j.issn.1002-2694.2019.00.172) Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018190 150518950 CVCL_A9IN HBR-S2 finite cell line CVCL_A9IN CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150518951 CVCL_A9IQ BOS-3 finite cell line CVCL_A9IQ CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Brahman. Female 150518952 CVCL_A9IP RK1 finite cell line Norway rat CVCL_A9IP CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified 150518953 CVCL_A9IS BOS-2 finite cell line CVCL_A9IS CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 150518954 CVCL_A9IR BOS-4 finite cell line CVCL_A9IR CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Brahman. Female 150518955 CVCL_A9IU BOS-6 finite cell line CVCL_A9IU CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Unspecified 150518956 CVCL_A9IT BOS-5 finite cell line CVCL_A9IT CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Unspecified 150518957 CVCL_A9KI 3C3E2 hybridoma house mouse CVCL_A9KI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P60880; Human SNAP25 (with p.Arg198_Gly206del; SNAP25(197)). 150518958 CVCL_A9KH 2C9B10 hybridoma house mouse CVCL_A9KH CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P60880; Human SNAP25 (with p.Arg198_Gly206del; SNAP25(197)). 150518959 CVCL_A9KK 5C8H5 hybridoma house mouse CVCL_A9KK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 first 15 residues). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014173 150518960 CVCL_A9KJ BTL2013 spontaneously immortalized cell line CVCL_A9KJ CL:0000010 Knockout cell: Method=siRNA knockdown; VGNC; -; Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014116 150518961 CVCL_A9KM 10.2 hybridoma house mouse CVCL_A9KM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06127; Human CD5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10269 150518962 CVCL_A9KL 9.3 hybridoma house mouse CVCL_A9KL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10747; Human CD28. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10271 150518963 CVCL_A9KN SRA01/01 transformed cell line human CVCL_A9KN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5858 150518964 CVCL_A9KA MCA 67 hybridoma house mouse CVCL_A9KA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV) isolate Delaware. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11122 150518965 CVCL_A9KC MCA BK9 hybridoma house mouse CVCL_A9KC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV) isolate Delaware. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10157 150518966 CVCL_A9KB MCA 57 hybridoma house mouse CVCL_A9KB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV) isolate GLS. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10156 150518967 CVCL_A9KE MCA 8 hybridoma house mouse CVCL_A9KE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10174 150518968 CVCL_A9KD MCA 197 hybridoma house mouse CVCL_A9KD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10158 150518969 CVCL_A9KG 1D3B8 hybridoma house mouse CVCL_A9KG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P60880; Human SNAP25 (with p.Arg198_Gly206del; SNAP25(197)). 150518970 CVCL_A9KF DerP2 hybridoma house mouse CVCL_A9KF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49278; Dermatophagoides pteronyssinus allergen Der p 2 (DERP2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014112 150518971 CVCL_A9JX RM-1 [Macaca kidney] finite cell line CVCL_A9JX CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Group: Non-human primate cell line 150518972 CVCL_A9JW RM-3 finite cell line CVCL_A9JW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 150518973 CVCL_A9JZ MCA BK70 hybridoma house mouse CVCL_A9JZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Infectious bursal disease virus (IBDV). 150518974 CVCL_A9JY RM-2 [Macaca kidney] finite cell line CVCL_A9JY CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female Group: Non-human primate cell line 150518975 CVCL_A9JP WB-S3 finite cell line CVCL_A9JP CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 150518976 CVCL_A9JR WB-S5 finite cell line CVCL_A9JR CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 150518977 CVCL_A9JQ WB-S4 finite cell line CVCL_A9JQ CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150518978 CVCL_A9JT HBMSC finite cell line human CVCL_A9JT CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 150518979 CVCL_A9JS HSF2 finite cell line human CVCL_A9JS CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518980 CVCL_A9JV MM-S4 finite cell line CVCL_A9JV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 150518981 CVCL_A9JU RBMSC finite cell line Norway rat CVCL_A9JU CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Sprague Dawley. Unspecified 150518982 CVCL_A9HF TS-L3 finite cell line CVCL_A9HF CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150518983 CVCL_A9HE TS-K3 finite cell line CVCL_A9HE CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male 150518984 CVCL_A9HH C57/B6-L finite cell line house mouse CVCL_A9HH CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Male 150518985 CVCL_A9HG TS-R1 finite cell line CVCL_A9HG CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 150518986 CVCL_A9HJ C57/B6-SPL finite cell line house mouse CVCL_A9HJ CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C57BL/6. Male 150518987 CVCL_A9HI C57/B6-S finite cell line house mouse CVCL_A9HI CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 150518988 CVCL_A9HL PNA-T1 finite cell line CVCL_A9HL CL:0000010 Derived from sampling site: Testis Cell type=Epithelial cell.. Male 150518989 CVCL_A9HK PNA-M1 finite cell line CVCL_A9HK CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 150518990 CVCL_A9HB TS-EH-1 finite cell line CVCL_A9HB CL:0000010 Derived from sampling site: Fetal heart Cell type=Fibroblast.. Male 150518991 CVCL_A9HA HEH2 finite cell line human CVCL_A9HA CL:0000010 Derived from sampling site: Fetal heart Cell type=Fibroblast.. Male 150518992 CVCL_A9HD TS-S4 finite cell line CVCL_A9HD CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 150518993 CVCL_A9HC TS-ES-1 finite cell line CVCL_A9HC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150518994 CVCL_A9GU LPA-L1 finite cell line CVCL_A9GU CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150518995 CVCL_A9GT LPA-K1 finite cell line CVCL_A9GT CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male 150518996 CVCL_A9GW KMM-L2 finite cell line house mouse CVCL_A9GW CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Kunming. Male 150518997 CVCL_A9GV LPA-M1 finite cell line CVCL_A9GV CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 150518998 CVCL_A9GY GGA-E finite cell line CVCL_A9GY CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line 150518999 CVCL_A9GX BIN-S1 finite cell line CVCL_A9GX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519000 CVCL_A9GZ GGA-EH finite cell line CVCL_A9GZ CL:0000010 Derived from sampling site: Embryonic heart Cell type=Fibroblast.. Unspecified Group: Bird cell line 150519001 CVCL_A9GM LC-L4 finite cell line CVCL_A9GM CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519002 CVCL_A9GL LC-L3 finite cell line CVCL_A9GL CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519003 CVCL_A9GN LC-M4 finite cell line CVCL_A9GN CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 150519004 CVCL_A9GQ OCU-MSC1 finite cell line CVCL_A9GQ CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 150519005 CVCL_A9GP LC-S5 finite cell line CVCL_A9GP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519006 CVCL_A9GS LPA-H1 finite cell line CVCL_A9GS CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male 150519007 CVCL_A9GR OCU-MSC2 finite cell line CVCL_A9GR CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Unspecified 150519008 CVCL_A9IG SM-S1 finite cell line CVCL_A9IG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519009 CVCL_A9IF GRB-S1 finite cell line CVCL_A9IF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519010 CVCL_A9II RM-S1 finite cell line CVCL_A9II CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 150519011 CVCL_A9IH STB-S2 finite cell line CVCL_A9IH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519012 CVCL_A9IK GSnFB-L2 finite cell line CVCL_A9IK CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Group: Bat cell line 150519013 CVCL_A9IJ OAR-L1 finite cell line CVCL_A9IJ CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 150519014 CVCL_A9IM HBR-M1 finite cell line CVCL_A9IM CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 150519015 CVCL_A9IL GSnFB-S1 finite cell line CVCL_A9IL CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519016 CVCL_A9IA LHB-M4 finite cell line CVCL_A9IA CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Unspecified Group: Bat cell line 150519017 CVCL_A9IC MPC-L3 finite cell line CVCL_A9IC CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519018 CVCL_A9IB LHB-S3 finite cell line CVCL_A9IB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519019 CVCL_A9IE MPC-S3 finite cell line CVCL_A9IE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519020 CVCL_A9ID MPC-L4 finite cell line CVCL_A9ID CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 150519021 CVCL_A9HV DB-L1 finite cell line CVCL_A9HV CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Group: Bat cell line 150519022 CVCL_A9HU GH-M1 finite cell line CVCL_A9HU CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Female 150519023 CVCL_A9HX GHB-L3 finite cell line CVCL_A9HX CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Group: Bat cell line 150519024 CVCL_A9HW DB-M1 finite cell line CVCL_A9HW CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male Group: Bat cell line 150519025 CVCL_A9HZ LHB-L2 finite cell line CVCL_A9HZ CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Group: Bat cell line 150519026 CVCL_A9HY GHB-S3 finite cell line CVCL_A9HY CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male Group: Bat cell line 150519027 CVCL_A9HN CHB-S2 finite cell line CVCL_A9HN CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Group: Bat cell line 150519028 CVCL_A9HM MMY-S2 finite cell line CVCL_A9HM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Bat cell line 150519029 CVCL_A9HP CHP-M1 finite cell line CVCL_A9HP CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 150519030 CVCL_A9HR CHP-K3 finite cell line CVCL_A9HR CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Female 150519031 CVCL_A9HQ CHP-S1 finite cell line CVCL_A9HQ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519032 CVCL_A9HT FFB-S3 finite cell line CVCL_A9HT CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male Group: Bat cell line 150519033 CVCL_A9HS FFB-L3 finite cell line CVCL_A9HS CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Group: Bat cell line 150519034 CVCL_A9FD FCA-K1 finite cell line CVCL_A9FD CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male 150519035 CVCL_A9FC HSA-S4 finite cell line human CVCL_A9FC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519036 CVCL_A9FF HARA-B-GFP cancer cell line human CVCL_A9FF CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from metastatic site: Pleural effusion. Male 150519037 CVCL_A9FE LDG-2 finite cell line CVCL_A9FE CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: Jianzhou big-eared. Male 150519038 CVCL_A9FH MM-S7 finite cell line CVCL_A9FH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 150519039 CVCL_A9FG MM-S10 finite cell line CVCL_A9FG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 150519040 CVCL_A9FJ MM-E1 finite cell line CVCL_A9FJ CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Group: Non-human primate cell line 150519041 CVCL_A9FI MM-M7 finite cell line CVCL_A9FI CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male Group: Non-human primate cell line 150519042 CVCL_A9EZ OCU-L1 finite cell line CVCL_A9EZ CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 150519043 CVCL_A9FB SEP-L2 finite cell line pig CVCL_A9FB CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Miniature pig. Male 150519044 CVCL_A9FA SEP-L1 finite cell line pig CVCL_A9FA CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Miniature pig. Female 150519045 CVCL_A9ES 6/11 hybridoma house mouse CVCL_A9ES CL:0000010 Monoclonal antibody isotype: IgM, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9072 150519046 CVCL_A9ER MAKM-4.3.16 hybridoma house mouse CVCL_A9ER CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2158 150519047 CVCL_A9EU DG-S2 finite cell line CVCL_A9EU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519048 CVCL_A9ET BC18 hybridoma house mouse CVCL_A9ET CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. 150519049 CVCL_A9EW OCU-S1 finite cell line CVCL_A9EW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Black. Female 150519050 CVCL_A9EV OCU-S2 finite cell line CVCL_A9EV CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 150519051 CVCL_A9EY OCU-K4 finite cell line CVCL_A9EY CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female 150519052 CVCL_A9EX OCU-M1 finite cell line CVCL_A9EX CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 150519053 CVCL_A9EK PK15-1A6 spontaneously immortalized cell line pig CVCL_A9EK CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by classical swine fever virus (CSFV) 150519054 CVCL_A9EJ PK15-2F11 spontaneously immortalized cell line pig CVCL_A9EJ CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Grows adherently; Virology: Can produce high titers of porcine circovirus type 2 (PCV2) 150519055 CVCL_A9EM Ea1C-35 transformed cell line human CVCL_A9EM From: MultiCell Technologies, Inc.; Woonsocket; USA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5565 150519056 CVCL_A9EL PK15-3B1 spontaneously immortalized cell line pig CVCL_A9EL CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Low susceptibility to infection by classical swine fever virus (CSFV) 150519057 CVCL_A9EN HRP 16-1 hybridoma house mouse CVCL_A9EN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P00433; Armoracia rusticana PRXC1A. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute of Virology of the Slovak Academy of Sciences; Number_not_reported 150519058 CVCL_A9EQ MAKM-2.42.3 hybridoma house mouse CVCL_A9EQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2157 150519059 CVCL_A9EP MAKM-1.1.12 hybridoma house mouse CVCL_A9EP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2156 150519060 CVCL_A9GE GP-L2 finite cell line CVCL_A9GE CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519061 CVCL_A9GD GP-L1 finite cell line CVCL_A9GD CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519062 CVCL_A9GG GP-S2 finite cell line CVCL_A9GG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519063 CVCL_A9GF GP-M2 finite cell line CVCL_A9GF CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 150519064 CVCL_A9GI GP-S4 finite cell line CVCL_A9GI CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519065 CVCL_A9GH GP-S3 finite cell line CVCL_A9GH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519066 CVCL_A9GK LC-L2 finite cell line CVCL_A9GK CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 150519067 CVCL_A9GJ LC-L1 finite cell line CVCL_A9GJ CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 150519068 CVCL_A9GA BTA-S2 finite cell line CVCL_A9GA CL:0000010 Derived from sampling site: Scalp; skin Cell type=Fibroblast.. Male 150519069 CVCL_A9GC GP-K1 finite cell line CVCL_A9GC CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male 150519070 CVCL_A9GB GP-H2 finite cell line CVCL_A9GB CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male 150519071 CVCL_A9FT MM-L2 finite cell line CVCL_A9FT CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 150519072 CVCL_A9FS MM-L1 finite cell line CVCL_A9FS CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 150519073 CVCL_A9FV SVU-K1 finite cell line CVCL_A9FV CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male 150519074 CVCL_A9FU SVU-H1 finite cell line CVCL_A9FU CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male 150519075 CVCL_A9FX HAF finite cell line human CVCL_A9FX CL:0000010 Derived from sampling site: Aorta Cell type=Fibroblast.. Female 150519076 CVCL_A9FW SVU-L1 finite cell line CVCL_A9FW CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 150519077 CVCL_A9FZ CAM-S finite cell line CVCL_A9FZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Bird cell line 150519078 CVCL_A9FY CAM-M finite cell line CVCL_A9FY CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Female Group: Bird cell line 150519079 CVCL_A9FL DPLC1 somatic stem cell dog CVCL_A9FL CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.; Breed/subspecies: Corgi. Female 150519080 CVCL_A9FK MM-E2 finite cell line CVCL_A9FK CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Group: Non-human primate cell line 150519081 CVCL_A9FN SSC-S4 finite cell line pig CVCL_A9FN CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Unspecified 150519082 CVCL_A9FM SSC-S3 finite cell line pig CVCL_A9FM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Changbai Mountains wild boar. Female Group: Endangered species/breed cell line 150519083 CVCL_A9FP SSC-S5 finite cell line pig CVCL_A9FP CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 150519084 CVCL_A9FR MM-K3 finite cell line CVCL_A9FR CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female Group: Non-human primate cell line 150519085 CVCL_A9FQ MM-K2 finite cell line CVCL_A9FQ CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female Group: Non-human primate cell line 150519086 CVCL_RS80 SH-SY5YrDOX10 cancer cell line human CVCL_RS80 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 150519087 CVCL_B0H0 LB86 transformed cell line human CVCL_B0H0 CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Phe46Leu (c.138T>A); dbSNP=rs769378741; Zygosity=Homozygous (PubMed=10397714) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 38.25 hours (PubMed=10397714) 150519088 CVCL_B0GN SK-N-SH D cancer cell line human CVCL_B0GN CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Can naturally differentiate as neuron-like cells (Patent=US10591466) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-5010 150519089 CVCL_B0GQ HPS3918 induced pluripotent stem cell human CVCL_B0GQ CL:0000010 Population: Japanese; Donor information: Established from dizygotic twin of HPS3920 (Cellosaurus=CVCL_UP53); Derived from sampling site: Peripheral blood. Male 150519090 CVCL_B0H2 Sp2/0-Ag14 hEPO cancer cell line house mouse CVCL_B0H2 CL:0000010 Transfected with: HGNC; 3415; EPO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Characteristics: Produces human EPO with full in vitro biological activity, but low in vivo biological activity 150519091 CVCL_B0GP CSUi002-A-1 induced pluripotent stem cell human CVCL_B0GP From: Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 LMNB1 has been endogenously tagged in one allele at the N-terminus with EGFP (PubMed=34438319) 150519092 CVCL_B0H1 LB86-LUDSN11 transformed cell line human CVCL_B0H1 CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Phe46Leu (c.138T>A); dbSNP=rs769378741; Zygosity=Homozygous (PubMed=10397714); Transfected with: HGNC; 12591; UROD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 21.1 hours (PubMed=10397714) 150519093 CVCL_B0GS PUMCHi016-A induced pluripotent stem cell human CVCL_B0GS From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; c.8559-2A>G (p.Tyr2854_Arg2894del); ClinVar=VCV000048604; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=34419747) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519094 CVCL_B0H4 XMMLY-H65 hybridoma house mouse CVCL_B0H4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06127; Human CD5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9286 150519095 CVCL_B0H3 4A2 [Mouse hybridoma against human CD7] hybridoma house mouse CVCL_B0H3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09564; Human CD7. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8350 150519096 CVCL_B0GR PUMCHi015-A induced pluripotent stem cell human CVCL_B0GR From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys934Trp (c.2802T>G); ClinVar=VCV000143179; Zygosity=Heterozygous (PubMed=34419747); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Arg4187His (c.12560G>A); ClinVar=VCV000865757; Zygosity=Heterozygous (PubMed=34419747) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519097 CVCL_B0H6 4H7H7 hybridoma house mouse CVCL_B0H6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2847 150519098 CVCL_B0GU CHO-K1 hMCHR1 spontaneously immortalized cell line CVCL_B0GU CL:0000010 Transfected with: HGNC; 4479; MCHR1 Derived from sampling site: Ovary. Discontinued: Euroscreen; Catalog number ES-370-C Female 150519099 CVCL_B0H5 1F11E5 hybridoma house mouse CVCL_B0H5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2846 150519100 CVCL_B0GT XACHi015-A induced pluripotent stem cell human CVCL_B0GT From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Pro605Leu (c.1814C>T); ClinVar=VCV000067284; Zygosity=Heterozygous (PubMed=34438161) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519101 CVCL_B0GG 24/04-10B4-24-8-FACS 9-5 hybridoma CVCL_B0GG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8BRU4; Mouse Clec9a/Cd370 (Note=Also reacts with human). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08042901 150519102 CVCL_B0GF 24/04-10B4-24-8 hybridoma CVCL_B0GF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8BRU4; Mouse Clec9a/Cd370 (Note=Also reacts with human). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 07121101 150519103 CVCL_B0GI 42/04-42D2-66-4-1-Clone 4 hybridoma CVCL_B0GI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8BRU4; Mouse Clec9a/Cd370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08041902 150519104 CVCL_B0GH 42/04-42D2-66-4-1 hybridoma CVCL_B0GH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8BRU4; Mouse Clec9a/Cd370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 07121102 150519105 CVCL_B0GK 20/05-3A4-26-16-Clone 5 hybridoma CVCL_B0GK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UXN8; Human CLEC9A/CD370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08041903 150519106 CVCL_B0GJ 20/05-3A4-26-16 hybridoma CVCL_B0GJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UXN8; Human CLEC9A/CD370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 07121103 150519107 CVCL_B0GM 23/05-4C6-29-3-Clone 5 hybridoma CVCL_B0GM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UXN8; Human CLEC9A/CD370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08041904 150519108 CVCL_B0GL 23/05-4C6-29-3 hybridoma CVCL_B0GL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UXN8; Human CLEC9A/CD370. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 07121104 150519109 CVCL_B0GA NimoAb101 hybridoma CVCL_B0GA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00187; Human MASP2. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 03050904 150519110 CVCL_B0GC M0545YM035S2 hybridoma house mouse CVCL_B0GC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00187; Human MASP2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2660 150519111 CVCL_B0GB M0545YM029S2 hybridoma house mouse CVCL_B0GB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00187; Human MASP2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2657 150519112 CVCL_B0GE M0545YM048S2 hybridoma house mouse CVCL_B0GE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00187; Human MASP2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2659 150519113 CVCL_B0GD M0545YM046S2 hybridoma house mouse CVCL_B0GD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00187; Human MASP2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2658 150519114 CVCL_B0FV 1A4 hybridoma house mouse CVCL_B0FV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3947 150519115 CVCL_B0G7 ADx215 hybridoma house mouse CVCL_B0G7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 9679CB 150519116 CVCL_B0FU 11D12 hybridoma house mouse CVCL_B0FU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4116 150519117 CVCL_B0G6 ADx211 hybridoma house mouse CVCL_B0G6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 8348CB 150519118 CVCL_B0FX 427B7 hybridoma house mouse CVCL_B0FX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4518 150519119 CVCL_B0G9 MHG-8 hybridoma house mouse CVCL_B0G9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14392; Human LRRC32. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 10246CB 150519120 CVCL_B0FW 320G10 hybridoma house mouse CVCL_B0FW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4514 150519121 CVCL_B0G8 Sp2/neo cancer cell line house mouse CVCL_B0G8 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 150519122 CVCL_B0FZ 530C8 hybridoma house mouse CVCL_B0FZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4728 150519123 CVCL_B0FY 517F1 hybridoma house mouse CVCL_B0FY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4502 150519124 CVCL_B0I1 GM28025 finite cell line human CVCL_B0I1 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519125 CVCL_B0HP H6-2.5F7 hybridoma house mouse CVCL_B0HP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519126 CVCL_B0I0 GM28024 finite cell line human CVCL_B0I0 CL:0000010 Sequence variation: Mutation; HGNC; 21308; ELOVL5; Simple; c.246+3891C>T (p.Gln102Ter, c.304C>T); ClinVar=VCV000691282; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Met1_Ala5del (c-11_13delGGCCGGGTGCGATGGCGGCGGTGG) (c.-13_11del24); ClinVar=VCV000215241; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519127 CVCL_B0I3 GM28034 finite cell line human CVCL_B0I3 CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Trp278Ter (c.834G>A); ClinVar=VCV000928763; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519128 CVCL_B0HR H6-2.8A7 hybridoma house mouse CVCL_B0HR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519129 CVCL_B0I2 GM28033 finite cell line human CVCL_B0I2 CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Trp278Ter (c.834G>A); ClinVar=VCV000928763; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 150519130 CVCL_B0HQ H6-2.7C7 hybridoma house mouse CVCL_B0HQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12288 150519131 CVCL_B0I5 GM28036 finite cell line human CVCL_B0I5 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519132 CVCL_B0HT Prost J415 hybridoma house mouse CVCL_B0HT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12109 150519133 CVCL_B0I4 GM28035 finite cell line human CVCL_B0I4 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519134 CVCL_B0HS Prost E99 hybridoma house mouse CVCL_B0HS CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12101 150519135 CVCL_B0I7 GM28212 finite cell line human CVCL_B0I7 CL:0000010 Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519136 CVCL_B0HV Prost J591 hybridoma house mouse CVCL_B0HV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12126 150519137 CVCL_B0I6 GM28209 transformed cell line human CVCL_B0I6 CL:0000010 Population: Bangladeshi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519138 CVCL_B0HU Prost J533 hybridoma house mouse CVCL_B0HU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12127 150519139 CVCL_B0HH H6-2.12A5 hybridoma house mouse CVCL_B0HH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519140 CVCL_B0HG H6-2.10D1 hybridoma house mouse CVCL_B0HG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12290 150519141 CVCL_B0HJ H6-2.14H2 hybridoma house mouse CVCL_B0HJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12294 150519142 CVCL_B0HI H6-2.13C3 hybridoma house mouse CVCL_B0HI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519143 CVCL_B0HL H6-2.16A3 hybridoma house mouse CVCL_B0HL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12296 150519144 CVCL_B0HK H6-2.15B12 hybridoma house mouse CVCL_B0HK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12293 150519145 CVCL_B0HN H6-2.5E8 hybridoma house mouse CVCL_B0HN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12295 150519146 CVCL_B0HM H6-2.5D4 hybridoma house mouse CVCL_B0HM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12291 150519147 CVCL_B0HB H6-1.12F10 hybridoma house mouse CVCL_B0HB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519148 CVCL_B0HA 3B5H10 hybridoma house mouse CVCL_B0HA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2848 150519149 CVCL_B0HD H6-1.5E1 hybridoma house mouse CVCL_B0HD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519150 CVCL_B0HC H6-1.15D7 hybridoma house mouse CVCL_B0HC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 150519151 CVCL_B0HF H6-2.10A5 hybridoma house mouse CVCL_B0HF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12289 150519152 CVCL_B0HE H6-1.7H6 hybridoma house mouse CVCL_B0HE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12292 150519153 CVCL_B0H8 4F1B5 hybridoma house mouse CVCL_B0H8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2851 150519154 CVCL_B0GW LB44 transformed cell line human CVCL_B0GW CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Gly281Glu (c.842G>A); ClinVar=VCV000000066; Zygosity=Homozygous (PubMed=10397714); Transfected with: HGNC; 12591; UROD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 34.5 hours (PubMed=10397714) 150519155 CVCL_B0H7 3A2D3 hybridoma house mouse CVCL_B0H7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2849 150519156 CVCL_B0GV I3.4.2 cancer cell line human CVCL_B0GV CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from metastatic site: Abdomen. Male Characteristics: High expression of MCHR1 Responds to melanin-concentrating hormone (MCH) in Calcium-mobilization assays (PubMed=16524757). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5201 150519157 CVCL_B0GY LB45 transformed cell line human CVCL_B0GY CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Gly281Glu (c.842G>A); ClinVar=VCV000000066; Zygosity=Homozygous (PubMed=10397714) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 32.5 hours (PubMed=10397714) 150519158 CVCL_B0H9 3C4A6 hybridoma house mouse CVCL_B0H9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes expanded poly-Gln region). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2850 150519159 CVCL_B0GX LB44-LUDSN11 transformed cell line human CVCL_B0GX CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Gly281Glu (c.842G>A); ClinVar=VCV000000066; Zygosity=Homozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 19.4 hours (PubMed=10397714) 150519160 CVCL_B0GZ LB45-LUDSN11 transformed cell line human CVCL_B0GZ CL:0000010 Sequence variation: Mutation; HGNC; 12591; UROD; Simple; p.Gly281Glu (c.842G>A); ClinVar=VCV000000066; Zygosity=Homozygous (PubMed=10397714); Transfected with: HGNC; 12591; UROD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: 21 hours (PubMed=10397714) 150519161 CVCL_B0EM 3D5.1.10 hybridoma house mouse CVCL_B0EM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14763; Human TNFRSF10B/CD262 (Note=Also reacts with TNFRSF10A/CD261). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12536 150519162 CVCL_B0EL 3H3.14.5 hybridoma house mouse CVCL_B0EL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14763; Human TNFRSF10B/CD262. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12534 150519163 CVCL_B0F0 SZ-168 hybridoma house mouse CVCL_B0F0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86YL7; Human PDPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015185 150519164 CVCL_B0EN 38SB13 hybridoma house mouse CVCL_B0EN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7667 150519165 CVCL_B0EQ 38SB19 hybridoma house mouse CVCL_B0EQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7670 150519166 CVCL_B0F2 ZOSL-1 cancer cell line human CVCL_B0F2 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; right femur. Female Doubling time: 39.28 +- 3.04 hours (Patent=CN112080473B; PubMed=34221892) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202088 Problematic cell line: Probably contaminated The STR profile is identical to that of the HOS cell line. Originally thought to originate from the lung metastasis of a 12 year old female Chinese osteosarcoma patient. 150519167 CVCL_B0F1 2F6 [Mouse hybridoma against human CKB/CKM] hybridoma house mouse CVCL_B0F1 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P12277; Human CKB; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202086 150519168 CVCL_B0EP 38SB18 hybridoma house mouse CVCL_B0EP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7669 150519169 CVCL_B0ES 38SB31 hybridoma house mouse CVCL_B0ES CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7668 150519170 CVCL_B0F4 CGMCC-13827 hybridoma house mouse CVCL_B0F4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Aspergillus fumigatus (strain ATCC-1022) galactomannan antigen (GM). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.13827 150519171 CVCL_B0ER 38SB30 hybridoma house mouse CVCL_B0ER CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7666 150519172 CVCL_B0F3 BLAC-20 spontaneously immortalized cell line CVCL_B0F3 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Leukocyte.. Unspecified 150519173 CVCL_B0EE 4H6.17.8 hybridoma house mouse CVCL_B0EE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12455 150519174 CVCL_B0ED 4G7.18.8 hybridoma house mouse CVCL_B0ED CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-99 150519175 CVCL_B0EG 7C2 [Mouse hybridoma against human ERBB2] hybridoma house mouse CVCL_B0EG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12215 150519176 CVCL_B0EF 5G11.17.1 hybridoma house mouse CVCL_B0EF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12694 150519177 CVCL_B0EI 2C4 [Mouse hybridoma against human ERBB2] hybridoma house mouse CVCL_B0EI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12697 150519178 CVCL_B0EH 7F3 hybridoma house mouse CVCL_B0EH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12216 150519179 CVCL_B0EK 3H1.18.10 hybridoma house mouse CVCL_B0EK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14763; Human TNFRSF10B/CD262. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12535 150519180 CVCL_B0EJ 3F11.39.7 hybridoma house mouse CVCL_B0EJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14763; Human TNFRSF10B/CD262. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12456 150519181 CVCL_B0EA 2A2.16.7 hybridoma house mouse CVCL_B0EA CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3360 150519182 CVCL_B0EC 4E7.24.3 hybridoma house mouse CVCL_B0EC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11454 150519183 CVCL_B0EB 1H5.25.9 hybridoma house mouse CVCL_B0EB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12695 150519184 CVCL_B0DT 759E3 hybridoma house mouse CVCL_B0DT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10808; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10079 150519185 CVCL_B0E5 CA1 hybridoma house mouse CVCL_B0E5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 2C7. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11311 150519186 CVCL_B0DS 758G5 hybridoma house mouse CVCL_B0DS CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519187 CVCL_B0E4 PC3-EMT12 cancer cell line human CVCL_B0E4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray Male Characteristics: Transfected with a pLentilox-EV-Luc luciferase expression vector 150519188 CVCL_B0E7 3G9 hybridoma house mouse CVCL_B0E7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Neisseria gonorrhoeae lipo-oligosaccharide (LOS). 150519189 CVCL_B0DV 760C5 hybridoma house mouse CVCL_B0DV CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519190 CVCL_B0E6 2C7 [Mouse hybridoma against N.gonorrhoease LOS] hybridoma house mouse CVCL_B0E6 CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: Neisseria gonorrhoeae lipo-oligosaccharide (LOS) (Note=Binds to the inner 15253 LOS structure found within WG LOS). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11859 150519191 CVCL_B0DU 759G12 hybridoma house mouse CVCL_B0DU CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519192 CVCL_B0E9 1G11.14.7 hybridoma house mouse CVCL_B0E9 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3361 150519193 CVCL_B0DX 769E11 hybridoma house mouse CVCL_B0DX CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519194 CVCL_B0E8 1E10.16.4 hybridoma house mouse CVCL_B0E8 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; O00220; Human TNFRSF10A/CD261 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3359 150519195 CVCL_B0DW 761B10 hybridoma house mouse CVCL_B0DW CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519196 CVCL_B0DZ 788G6 hybridoma house mouse CVCL_B0DZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8692; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10080 150519197 CVCL_B0DY 770G4 hybridoma house mouse CVCL_B0DY CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519198 CVCL_B0FN ZZUi030-A induced pluripotent stem cell human CVCL_B0FN From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11237; SPG7; Simple; p.Arg398Ter (c.1192C>T); ClinVar=VCV000545964; Zygosity=Heterozygous (PubMed=34509920) Population: Chinese; Han; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 150519199 CVCL_B0FM NUIGi056-A induced pluripotent stem cell human CVCL_B0FM From: National University of Ireland Galway; Galway; Ireland. CL:0000010 150519200 CVCL_B0G1 535F7 hybridoma house mouse CVCL_B0G1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4510 150519201 CVCL_B0FP ZZUi031-A induced pluripotent stem cell human CVCL_B0FP From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 150519202 CVCL_B0G0 534G9 hybridoma house mouse CVCL_B0G0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4729 150519203 CVCL_B0G3 1023F10 hybridoma house mouse CVCL_B0G3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4507 150519204 CVCL_B0FR WAe009-A-69 embryonic stem cell human CVCL_B0FR From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7577; MYH7. Female 150519205 CVCL_B0G2 547A1 hybridoma house mouse CVCL_B0G2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4506 150519206 CVCL_B0FQ ZZUi032-A induced pluripotent stem cell human CVCL_B0FQ From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 150519207 CVCL_B0FT 1613F12 hybridoma house mouse CVCL_B0FT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4505 150519208 CVCL_B0G5 ADx210 hybridoma house mouse CVCL_B0G5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 8347CB 150519209 CVCL_B0G4 1614G5 hybridoma house mouse CVCL_B0G4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4519 150519210 CVCL_B0FS H9c2 Trpm4 KO spontaneously immortalized cell line Norway rat CVCL_B0FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; RGD; 620244; Trpm4 Derived from sampling site: Embryonic heart; cardiac muscle; Breed/subspecies: BDIX. Unspecified 150519211 CVCL_B0FF HYB-241 hybridoma house mouse CVCL_B0FF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519212 CVCL_B0FE HYB-195 hybridoma house mouse CVCL_B0FE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519213 CVCL_B0FH K562-R cancer cell line human CVCL_B0FH CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Pleural effusion. Female 150519214 CVCL_B0FG HYB-612 hybridoma house mouse CVCL_B0FG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519215 CVCL_B0FJ C219 hybridoma house mouse CVCL_B0FJ CL:0000010 Miscellaneous: The patent US4837306 claims a mAB against ABCB1 but does not seem to specifically claim hybridoma C219. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243 150519216 CVCL_B0FI G8-2 hybridoma house mouse CVCL_B0FI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519217 CVCL_B0FL F4 hybridoma house mouse CVCL_B0FL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11325 150519218 CVCL_B0FK JSB-1 hybridoma house mouse CVCL_B0FK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519219 CVCL_B0FB UIC2 hybridoma house mouse CVCL_B0FB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11027 150519220 CVCL_B0FA MRK17 hybridoma house mouse CVCL_B0FA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519221 CVCL_B0FD SK-N-MC-IXC/VCR cancer cell line human CVCL_B0FD CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Supra-orbital region. Female Problematic cell line: Misclassified Grand-parent cell line (SK-N-MC) was originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor. 150519222 CVCL_B0FC UIC2/A hybridoma house mouse CVCL_B0FC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11287 150519223 CVCL_B0F6 2C5D6 hybridoma house mouse CVCL_B0F6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O76093; Human FGF18. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202091 150519224 CVCL_B0EU COVID19-SRBD-8 hybridoma house mouse CVCL_B0EU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202167 150519225 CVCL_B0ET 38SB39 hybridoma house mouse CVCL_B0ET CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7671 150519226 CVCL_B0F5 LCZ8A3 hybridoma house mouse CVCL_B0F5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human prostatic exosomal protein (PSEP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2019144 150519227 CVCL_B0F8 4D8G7 hybridoma house mouse CVCL_B0F8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O76093; Human FGF18 (Note=Also reacts with FGF8 and FGF17). 150519228 CVCL_B0EW SZ-179 hybridoma house mouse CVCL_B0EW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04275; Human VWF. 150519229 CVCL_B0F7 3E4F7 hybridoma house mouse CVCL_B0F7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O76093; Human FGF18 (Note=Also reacts with FGF8 and FGF17). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202092 150519230 CVCL_B0EV SZ-176 hybridoma house mouse CVCL_B0EV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04275; Human VWF. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2019273 150519231 CVCL_B0EY SZ-125 hybridoma house mouse CVCL_B0EY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04275; Human VWF. 150519232 CVCL_B0F9 MRK16 hybridoma house mouse CVCL_B0F9 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. 150519233 CVCL_B0EX SZ-123 hybridoma house mouse CVCL_B0EX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04275; Human VWF. 150519234 CVCL_B0EZ SZ-163 hybridoma house mouse CVCL_B0EZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86YL7; Human PDPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201613 150519235 CVCL_B0CK RAO-2 telomerase immortalized cell line human CVCL_B0CK CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu); Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female Characteristics: Does not show anchorage-independent growth in soft agar and is not tumorigenic in nude mice (PubMed=16395697) 150519236 CVCL_B0CJ RAO-1 telomerase immortalized cell line human CVCL_B0CJ CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female Doubling time: 36 hours (PubMed=29022488) 150519237 CVCL_B0CM RAO-4 telomerase immortalized cell line human CVCL_B0CM CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu); Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female Characteristics: Tumorigenic Generates human mammary epithelial carcinoma when injected into nude mice (PubMed=16395697). 150519238 CVCL_B0CL RAO-3 telomerase immortalized cell line human CVCL_B0CL CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu); Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female Characteristics: Tumorigenic Generates human mammary spindle cell carcinomas when injected into nude mice (PubMed=16395697). 150519239 CVCL_B0D0 HUPEC 002 FSGS G0/G0 conditionally immortalized cell line human CVCL_B0D0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte-like epithelial cell.. Male 150519240 CVCL_B0CN PC3-EMT1 cancer cell line human CVCL_B0CN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Selected from a mesenchymal sub-population of the parent cell line; Characteristics: Transfected with a pLentilox-EV-Luc luciferase expression vector 150519241 CVCL_B0CQ 5E12.5 hybridoma house mouse CVCL_B0CQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human 125 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-994 150519242 CVCL_B0D2 BB11 hybridoma house mouse CVCL_B0D2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. Group: Patented cell line; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10220 150519243 CVCL_B0CP 8G1.7 hybridoma house mouse CVCL_B0CP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25063; Human CD24. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-993 150519244 CVCL_B0D1 VIIIC3.78 hybridoma house mouse CVCL_B0D1 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; C6C2D6; Borrelia burgdorferi (strain N40) outer surface protein A (ospA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10878; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10256 150519245 CVCL_B0CC ART [Human OVCAR-8 contaminated cell line] cancer cell line human CVCL_B0CC CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Female Characteristics: Engineered to overexpress the SV40 large T antigen; Virology: Can be used to evaluate the infectious entry of polyomaviruses (BKPyV, JCPyV, SV40, MCPyV) and human papillomaviruses Pathogenic variants of the JCPyV virus previously believed to be non-infectious can infect this cell line (ATCC). Doubling time: ~34 hours (ATCC=CRL-3468) Problematic cell line: Contaminated Parent cell line (NCI-ADR-RES) has been shown to be a OVCAR-8 derivative. 150519246 CVCL_B0CB PC3-epi cancer cell line human CVCL_B0CB CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Selected based on an epithelial cell morphology, bioluminescent intensity and expression of E-cadherin Selection was repeated twice and a stable epithelial population was obtained (PubMed=24124593).; Characteristics: Transfected with a pLentilox-EV-Luc luciferase expression vector 150519247 CVCL_B0CE MEL114433 cancer cell line house mouse CVCL_B0CE CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 BrafCA/+; Ptenflox/+; Cdkn2aflox/+; Tyr-CreERT2-tg. Omics: Deep exome analysis Female Doubling time: ~24 hours (ATCC=CRL-3473) 150519248 CVCL_B0CD SFT cancer cell line human CVCL_B0CD CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Thr116Leufs*8 (c.346_349delACTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Glufs*3 (c.1024delC); ClinVar=VCV000428885; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Brain; right temporo-parietal lobe. Female Virology: Can be used to evaluate the infectious entry of polyomaviruses (BKPyV, JCPyV, SV40) and human papillomaviruses Pathogenic variants of the JCPyV virus previously believed to be non-infectious can infect this cell line, especially in the presence of the chemical 3Fax-Peracetyl Neu5Ac (3Fax) (ATCC). Doubling time: ~30 hours (ATCC=CRL-3469) 150519249 CVCL_B0CG B2905 cancer cell line house mouse CVCL_B0CG CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 Hgftg. Omics: Deep exome analysis Male Doubling time: ~16 (ATCC=CRL-3476) 150519250 CVCL_B0CF HCmel1274 cancer cell line house mouse CVCL_B0CF CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 Cdk4R24C/R24C; Hgftg. Omics: Deep exome analysis Female Doubling time: ~16-20 hours (ATCC=CRL-3475) 150519251 CVCL_B0CI HMEC 2.6 telomerase immortalized cell line human CVCL_B0CI CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female Doubling time: ~3 days (PubMed=29022488) 150519252 CVCL_B0CH B9013HCB cancer cell line house mouse CVCL_B0CH CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 BrafCA/+; Cdkn2aflox/+; Tyr-CreERT2-tg; Hgftg. Omics: Deep exome analysis Female Doubling time: ~24-36 hours (ATCC=CRL-3474) 150519253 CVCL_B0BZ RCJ 3.1C5.25 spontaneously immortalized cell line Norway rat CVCL_B0BZ CL:0000010 Derived from sampling site: Embryonic bone; calvaria Cell type=Chondrocyte.. 150519254 CVCL_B0BY RCJ 3.1C5.18 spontaneously immortalized cell line Norway rat CVCL_B0BY CL:0000010 Derived from sampling site: Embryonic bone; calvaria Cell type=Chondrocyte.. 150519255 CVCL_B0CA HUPEC 005 FSGS G1/G2 conditionally immortalized cell line human CVCL_B0CA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte-like epithelial cell.. Male 150519256 CVCL_B0C3 BBG-30 hybridoma house mouse CVCL_B0C3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Porphyromonas gingivalis fimbriae. Group: Patented cell line; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10103 150519257 CVCL_B0BR N17A3 transformed cell line human CVCL_B0BR CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 150519258 CVCL_B0C2 BBG-25 hybridoma house mouse CVCL_B0C2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Porphyromonas gingivalis lipopolysaccharide (LPS). 150519259 CVCL_B0BQ D5-NP118 transformed cell line human CVCL_B0BQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Male 150519260 CVCL_B0C5 BBG-42 hybridoma house mouse CVCL_B0C5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Porphyromonas gingivalis. Group: Patented cell line; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10105 150519261 CVCL_B0BT NE6-E6E7 transformed cell line human CVCL_B0BT CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Esophagus. Male 150519262 CVCL_B0C4 BBG-31 hybridoma house mouse CVCL_B0C4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Porphyromonas gingivalis fimbriae. Group: Patented cell line; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10104 150519263 CVCL_B0BS N33B2 transformed cell line human CVCL_B0BS CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 150519264 CVCL_B0BV HAC-HPV16-E6/E7 transformed cell line human CVCL_B0BV CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Human papillomavirus type 16 (HPV16) [p16HHMo](NCBI-Taxonomy; 333760); Derived from sampling site: Articular cartilage Cell type=Chondrocyte.. Male 150519265 CVCL_B0C7 TDIII,IIIBB2 hybridoma house mouse CVCL_B0C7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Treponema denticola (strain ATCC 33520). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9967 150519266 CVCL_B0BU NE6-E6E7/hTERT transformed cell line human CVCL_B0BU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Esophagus. Male 150519267 CVCL_B0C6 TDII,IAA11 hybridoma house mouse CVCL_B0C6 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Treponema denticola (strain ATCC 33520). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9966 150519268 CVCL_B0C9 HUPEC 003 FSGS G0/G0 conditionally immortalized cell line human CVCL_B0C9 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte-like epithelial cell.. Male 150519269 CVCL_B0BX RCJ 3.1C5 spontaneously immortalized cell line Norway rat CVCL_B0BX CL:0000010 Derived from sampling site: Embryonic bone; calvaria Cell type=Chondrocyte.. Characteristics: Differentiates to form discrete cartilage nodules Nodule formation is regulated by Dex and vitamin D3 metabolites in a dose- and time-dependent manner (PubMed=2551636). 150519270 CVCL_B0C8 HUPEC 001 G0/G0 conditionally immortalized cell line human CVCL_B0C8 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte-like epithelial cell.. Male 150519271 CVCL_B0BW RCJ 3.1 spontaneously immortalized cell line Norway rat CVCL_B0BW CL:0000010 Derived from sampling site: Embryonic bone; calvaria. Characteristics: Differentiates into myotubes, adipocytes, chondrocytes and osteoblasts in the presence of the glucocorticosteroid dexamethasone (Dex) (PubMed=3384856) 150519272 CVCL_B0DL 451C3 hybridoma house mouse CVCL_B0DL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10810; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10081 150519273 CVCL_B0DK 451B7 hybridoma house mouse CVCL_B0DK CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519274 CVCL_B0DN 454A12 hybridoma house mouse CVCL_B0DN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10804; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10075 150519275 CVCL_B0DM 452E12 hybridoma house mouse CVCL_B0DM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer 240 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10803; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10074 150519276 CVCL_B0DP 457D7 hybridoma house mouse CVCL_B0DP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer 240 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10805; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10076 150519277 CVCL_B0E1 87H7 hybridoma house mouse CVCL_B0E1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer 230 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10788; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10059 150519278 CVCL_B0E0 871E3 hybridoma house mouse CVCL_B0E0 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10813; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10084 150519279 CVCL_B0DR 736G9 hybridoma house mouse CVCL_B0DR CL:0000010 Miscellaneous: This hybridoma was lost in a liquid nitrogen tank thaw (PubMed=2470501). Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340 150519280 CVCL_B0E3 PC3-EMT14 cancer cell line human CVCL_B0E3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray Male Characteristics: Transfected with a pLentilox-EV-Luc luciferase expression vector 150519281 CVCL_B0DQ 697B3 hybridoma house mouse CVCL_B0DQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10806; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10077 150519282 CVCL_B0E2 9C6 hybridoma house mouse CVCL_B0E2 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human breast/ovarian cancer 70 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10785; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10056 150519283 CVCL_B0DD 35E10 hybridoma house mouse CVCL_B0DD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human breast cancer 80 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10796; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10067 150519284 CVCL_B0DC 32A1 hybridoma house mouse CVCL_B0DC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10795; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10066 150519285 CVCL_B0DF 388D4 hybridoma house mouse CVCL_B0DF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10794; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10065 150519286 CVCL_B0DE 387H9 hybridoma house mouse CVCL_B0DE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer 40 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10802; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10073 150519287 CVCL_B0DH 421E8 hybridoma house mouse CVCL_B0DH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10793; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10064 150519288 CVCL_B0DG 41B4 hybridoma house mouse CVCL_B0DG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast cancer 240 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10786; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10057 150519289 CVCL_B0DJ 44F4 hybridoma house mouse CVCL_B0DJ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10787; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10058 150519290 CVCL_B0DI 44B2 hybridoma house mouse CVCL_B0DI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10797; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10068 150519291 CVCL_B0CZ KY-mBNP-I hybridoma house mouse CVCL_B0CZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P40753; Mouse Nppb. 150519292 CVCL_B0DB 254H9 hybridoma house mouse CVCL_B0DB CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human breast cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10792; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10063 150519293 CVCL_B0DA 219F3 hybridoma house mouse CVCL_B0DA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10801; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10072 150519294 CVCL_B0CS 106.3 hybridoma house mouse CVCL_B0CS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12044 150519295 CVCL_B0D4 106A10 hybridoma house mouse CVCL_B0D4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer 55 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10789; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10060 150519296 CVCL_B0CR 3-631-436 hybridoma house mouse CVCL_B0CR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6476 150519297 CVCL_B0D3 SGB3B4 hybridoma house mouse CVCL_B0D3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human 150 kDa protein 'CDX'. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10879; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10205 150519298 CVCL_B0D6 140A7 hybridoma house mouse CVCL_B0D6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human breast cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10798; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10069 150519299 CVCL_B0CU 8.1 hybridoma house mouse CVCL_B0CU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12050 150519300 CVCL_B0D5 120H7 hybridoma house mouse CVCL_B0D5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10790; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10061 150519301 CVCL_B0CT 201.3 hybridoma house mouse CVCL_B0CT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12045 150519302 CVCL_B0D8 203E2 hybridoma house mouse CVCL_B0D8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10799; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10070 150519303 CVCL_B0CW CHO 3-631-436 AM8 spontaneously immortalized cell line CVCL_B0CW CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Produces the heavy and light chains of monoclonal antibody 3-631-436 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8368 150519304 CVCL_B0D7 200F9 hybridoma house mouse CVCL_B0D7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10791; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10062 150519305 CVCL_B0CV CHO 3-631-436 AM5 spontaneously immortalized cell line CVCL_B0CV CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Produces the heavy and light chains of monoclonal antibody 3-631-436 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8369 150519306 CVCL_B0CY BC203 hybridoma house mouse CVCL_B0CY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-3515 150519307 CVCL_B0D9 204F4 hybridoma house mouse CVCL_B0D9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10800; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10071 150519308 CVCL_B0CX CHO 106.3 AM1 spontaneously immortalized cell line CVCL_B0CX CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Produces the heavy and light chains of monoclonal antibody 106.3 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6987 150519309 CVCL_B0AI CX16-RV7 Endo transformed cell line human CVCL_B0AI CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519310 CVCL_B0AH CX16-RV7 Ecto transformed cell line human CVCL_B0AH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519311 CVCL_B0AK CX16-RV8 Ecto transformed cell line human CVCL_B0AK CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519312 CVCL_B0AJ CX16-RV7 TZ transformed cell line human CVCL_B0AJ CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519313 CVCL_B0AM CX16-RV8 TZ transformed cell line human CVCL_B0AM CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519314 CVCL_B0AL CX16-RV8 Endo transformed cell line human CVCL_B0AL CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519315 CVCL_B0B0 HaCaT-16E6E7 transformed cell line human CVCL_B0B0 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519316 CVCL_B0AN CX16-RV9 Ecto transformed cell line human CVCL_B0AN CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519317 CVCL_B0AA CX16-RV2 TZ transformed cell line human CVCL_B0AA CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female Doubling time: ~30-40 hours (ATCC=CRL-3460) 150519318 CVCL_B0AC CX16-RV3 Endo transformed cell line human CVCL_B0AC CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519319 CVCL_B0AB CX16-RV3 Ecto transformed cell line human CVCL_B0AB CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519320 CVCL_B0AE CX16-RV5 Ecto transformed cell line human CVCL_B0AE CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519321 CVCL_B0AD CX16-RV3 TZ transformed cell line human CVCL_B0AD CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519322 CVCL_B0AG CX16-RV5 TZ transformed cell line human CVCL_B0AG CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519323 CVCL_B0AF CX16-RV5 Endo transformed cell line human CVCL_B0AF CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519324 CVCL_B0A9 CX16-RV2 Endo transformed cell line human CVCL_B0A9 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female Doubling time: ~30-40 hours (ATCC=CRL-3459) 150519325 CVCL_B0A8 CX16-RV2 Ecto transformed cell line human CVCL_B0A8 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female Doubling time: ~30-40 hours (ATCC=CRL-3458) 150519326 CVCL_B0A1 SGC7901/OXA cancer cell line human CVCL_B0A1 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (SGC-7901) has been shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 150519327 CVCL_B0A0 MDA-MB-231br/eGFP cancer cell line human CVCL_B0A0 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Metastatic to brain Established after injection of the parent cell line in the left ventricle of the heart of female nude mice and retrieving the brain metastatic cells and repeating this procedure 6 times. Group: Triple negative breast cancer (TNBC) cell line 150519328 CVCL_B0A3 hTERT FT190 transformed cell line human CVCL_B0A3 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female Doubling time: ~32 hours (ATCC=CRL-3444) 150519329 CVCL_B0A2 EO771.lmb cancer cell line house mouse CVCL_B0A2 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6. Female Characteristics: Metastatic to lung 150519330 CVCL_B0A5 HeLa IFITM2/3-KO cancer cell line human CVCL_B0A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 150519331 CVCL_B0A4 HeLa IFITM1/2/3-KO cancer cell line human CVCL_B0A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Facilitates the functional analysis of IFITMs and as well as their mechanisms of regulation Can also be used to identify other innate immunity factors and/or screen for new anti-infective drug candidates (ATCC). 150519332 CVCL_B0A7 U2OS DR-GFP cancer cell line human CVCL_B0A7 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a DR-GFP reporter construct The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Can be used to monitor homologous recombination efficiency using the DR-GFP reporter (ATCC) 150519333 CVCL_B0A6 A549 IFITM2/3-KO cancer cell line human CVCL_B0A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Has also reduced expression of IFITM1 150519334 CVCL_B0BJ HNPSV-5 transformed cell line human CVCL_B0BJ CL:0000010 Population: Japanese; Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Intervertebral disc; nucleus pulposus. Female 150519335 CVCL_B0BI HNPSV-1 transformed cell line human CVCL_B0BI CL:0000010 Population: Japanese; Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Intervertebral disc; nucleus pulposus. Male Senescence: Transformed but with a finite life span Senesces at 60-100 PDL (PubMed=15247572). 150519336 CVCL_B0BL D4-NP135 transformed cell line human CVCL_B0BL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Female 150519337 CVCL_B0BK D4-NP124 transformed cell line human CVCL_B0BK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Female 150519338 CVCL_B0BN D5-NP108 transformed cell line human CVCL_B0BN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Male 150519339 CVCL_B0BM D4-NP143 transformed cell line human CVCL_B0BM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Female 150519340 CVCL_B0C1 BBG-12 hybridoma house mouse CVCL_B0C1 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Porphyromonas gingivalis. Group: Patented cell line; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10102 150519341 CVCL_B0BP D5-NP113 transformed cell line human CVCL_B0BP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intervertebral disc; nucleus pulposus. Male 150519342 CVCL_B0C0 BgII,VF9/2d hybridoma house mouse CVCL_B0C0 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Porphyromonas gingivalis (strain ATCC 33277). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9968 150519343 CVCL_B0BB HaCaT-pLVX spontaneously immortalized cell line human CVCL_B0BB CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Control cell line for a series of HaCaT HPV E5, E6 and E7 transfected cell lines 150519344 CVCL_B0BA HaCaT-84E7 spontaneously immortalized cell line human CVCL_B0BA CL:0000010 Transfected with: UniProtKB; Q99FX2; Human papillomavirus type 84 protein E7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519345 CVCL_B0BD RK13-UL37 spontaneously immortalized cell line CVCL_B0BD CL:0000010 Transfected with: UniProtKB; Q911W0; Suid herpesvirus 1 (strain Kaplan) tegument protein UL37; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Characteristics: Expression of UL37 is under the control of the CMV promoter 150519346 CVCL_B0BC RK13-UL51 spontaneously immortalized cell line CVCL_B0BC CL:0000010 Transfected with: UniProtKB; Q85227; Suid herpesvirus 1 (strain Kaplan) tegument protein UL51; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Characteristics: Expression of UL51 is under the control of the CMV promoter 150519347 CVCL_B0BF 339.15.3.6 hybridoma house mouse CVCL_B0BF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16552; Human IL17A; Monoclonal antibody target: UniProtKB; Q96PD4; Human IL17F. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7987 150519348 CVCL_B0BE RK13-UL11 spontaneously immortalized cell line CVCL_B0BE CL:0000010 Transfected with: UniProtKB; Q85040; Suid herpesvirus 1 (strain Kaplan) cytoplasmic envelopment protein 3 (UL11); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Characteristics: Expression of UL11 is under the control of the CMV promoter 150519349 CVCL_B0BH Hu5 finite cell line human CVCL_B0BH CL:0000010 Derived from sampling site: Abdomen; muscle. Female Caution: Indicated as originating from a 44 year old female donor PubMed=12050145 and from a 42 year old in PubMed=16919240 150519350 CVCL_B0BG 339.15.5.3 hybridoma house mouse CVCL_B0BG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16552; Human IL17A; Monoclonal antibody target: UniProtKB; Q96PD4; Human IL17F. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7987 150519351 CVCL_B0AY HaCaT-16E5 spontaneously immortalized cell line human CVCL_B0AY CL:0000010 Transfected with: UniProtKB; P06927; Human papillomavirus type 16 protein E5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519352 CVCL_B0AX 184E6E7 transformed cell line human CVCL_B0AX CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium. Female 150519353 CVCL_B0B9 HaCaT-84E6 spontaneously immortalized cell line human CVCL_B0B9 CL:0000010 Transfected with: UniProtKB; Q99FX3; Human papillomavirus type 84 protein E6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519354 CVCL_B0AZ HaCaT-16E6 spontaneously immortalized cell line human CVCL_B0AZ CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519355 CVCL_B0AQ CX16-RV9 TZ transformed cell line human CVCL_B0AQ CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519356 CVCL_B0B2 HaCaT-18E5 spontaneously immortalized cell line human CVCL_B0B2 CL:0000010 Transfected with: UniProtKB; P06792; Human papillomavirus type 18 protein E5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519357 CVCL_B0AP CX16-RV9 Endo transformed cell line human CVCL_B0AP CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519358 CVCL_B0B1 HaCaT-16E7 spontaneously immortalized cell line human CVCL_B0B1 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519359 CVCL_B0AS CX16-8 Endo transformed cell line human CVCL_B0AS CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519360 CVCL_B0B4 HaCaT-18E7 spontaneously immortalized cell line human CVCL_B0B4 CL:0000010 Transfected with: UniProtKB; P06788; Human papillomavirus type 18 protein E7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519361 CVCL_B0AR CX16-8 Ecto transformed cell line human CVCL_B0AR CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519362 CVCL_B0B3 HaCaT-18E6 spontaneously immortalized cell line human CVCL_B0B3 CL:0000010 Transfected with: UniProtKB; P06463; Human papillomavirus type 18 protein E6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519363 CVCL_B0AU CX16-9 Ecto transformed cell line human CVCL_B0AU CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 150519364 CVCL_B0B6 HaCaT-62E6 spontaneously immortalized cell line human CVCL_B0B6 CL:0000010 Transfected with: UniProtKB; Q676V2; Human papillomavirus type 62 protein E6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519365 CVCL_B0AT CX16-8 TZ transformed cell line human CVCL_B0AT CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519366 CVCL_B0B5 HaCaT-62E5 spontaneously immortalized cell line human CVCL_B0B5 CL:0000010 Transfected with: Human papillomavirus type 62 protein E5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519367 CVCL_B0AW CX16-9 TZ transformed cell line human CVCL_B0AW CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; cervical transformation zone epithelium Cell type=Epithelial cell.. Female 150519368 CVCL_B0B8 HaCaT-84E5 spontaneously immortalized cell line human CVCL_B0B8 CL:0000010 Transfected with: Human papillomavirus type 84 protein E5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519369 CVCL_B0AV CX16-9 Endo transformed cell line human CVCL_B0AV CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 150519370 CVCL_B0B7 HaCaT-62E7 spontaneously immortalized cell line human CVCL_B0B7 CL:0000010 Transfected with: UniProtKB; Q676V1; Human papillomavirus type 62 protein E7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 150519371 CVCL_B0P8 BCHSCTi001-A induced pluripotent stem cell human CVCL_B0P8 From: Department of Hematopoietic Stem Cell Tranplatation, Beijing Children's Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Simple; p.Arg391Cys (c.1171C>T); ClinVar=VCV000010125; Zygosity=Hemizygous (PubMed=34496342) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519372 CVCL_B0P7 174-24-11 hybridoma house mouse CVCL_B0P7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99062; Human CSF3R. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12700 150519373 CVCL_B0P9 UKWMPi007-A induced pluripotent stem cell human CVCL_B0P9 From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 11007; SLC2A3; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150519374 CVCL_B0P0 A8G3.5 hybridoma house mouse CVCL_B0P0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3317 150519375 CVCL_B0P2 B3F6.17 hybridoma house mouse CVCL_B0P2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3319 150519376 CVCL_B0P1 A8H3.1 hybridoma house mouse CVCL_B0P1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3315 150519377 CVCL_B0P4 AHM-1 cancer cell line human CVCL_B0P4 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgA lambda Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8220 150519378 CVCL_B0P3 B6G7.10 hybridoma house mouse CVCL_B0P3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3313 150519379 CVCL_B0P6 163-93 hybridoma house mouse CVCL_B0P6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99062; Human CSF3R. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12699 150519380 CVCL_B0P5 AHM-3D3 cancer cell line human CVCL_B0P5 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8221 150519381 CVCL_B0PX 1-10 [Mouse hybridoma against ouabain] hybridoma house mouse CVCL_B0PX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:472805; Ouabain. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-812 150519382 CVCL_B0Q9 LCL-PI 17 transformed cell line human CVCL_B0Q9 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519383 CVCL_B0PW A23-A/D3 hybridoma house mouse CVCL_B0PW CL:0000010 Transfected with: UniProtKB; P02769; Bovine ALB. Monoclonal antibody isotype: IgG2a Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0004 150519384 CVCL_B0Q8 LCL-PI 16 transformed cell line human CVCL_B0Q8 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519385 CVCL_B0PZ 7-1 [Mouse hybridoma against ouabain] hybridoma house mouse CVCL_B0PZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:472805; Ouabain. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-814 150519386 CVCL_B0PY 5A12 hybridoma house mouse CVCL_B0PY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:472805; Ouabain. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-813 150519387 CVCL_B0Q1 Dig 26-10 hybridoma house mouse CVCL_B0Q1 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 150519388 CVCL_B0PP SCMCi004-A induced pluripotent stem cell human CVCL_B0PP From: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Population: Chinese; Karyotypic information: 45,XY,19,add(21)(p13) (PubMed=34298433); Derived from sampling site: Bone marrow. Male 150519389 CVCL_B0Q0 8E4 [Mouse hybridoma against ouabain] hybridoma house mouse CVCL_B0Q0 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:472805; Ouabain. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-815 150519390 CVCL_B0Q3 Dig 24-2F8 hybridoma house mouse CVCL_B0Q3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 150519391 CVCL_B0PR HMSCATi001-A induced pluripotent stem cell human CVCL_B0PR From: Stem Cell Application and Translation Laboratory, Hebei Medical University; Shijiazhuang; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 150519392 CVCL_B0Q2 Dig 26-20 hybridoma house mouse CVCL_B0Q2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 150519393 CVCL_B0PQ GLNNFi001-A induced pluripotent stem cell human CVCL_B0PQ From: GROW Laboratory; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 6938; CHST6; Simple; p.Val172Leu; Zygosity=Homozygous (PubMed=35472829) Population: Indian; Derived from sampling site: Peripheral blood. Male 150519394 CVCL_B0Q5 Dig 35-20 hybridoma house mouse CVCL_B0Q5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8113 150519395 CVCL_B0PT HMSCATi003-A induced pluripotent stem cell human CVCL_B0PT From: Stem Cell Application and Translation Laboratory, Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Female 150519396 CVCL_B0Q4 Dig 25-54 hybridoma house mouse CVCL_B0Q4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 150519397 CVCL_B0PS HMSCATi002-A induced pluripotent stem cell human CVCL_B0PS From: Stem Cell Application and Translation Laboratory, Hebei Medical University; Shijiazhuang; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 150519398 CVCL_B0PV KM-10 hybridoma house mouse CVCL_B0PV CL:0000010 Transfected with: UniProtKB; P02769; Bovine ALB. Monoclonal antibody isotype: IgG1 Group: Patented cell line 150519399 CVCL_B0Q7 LCL-PI 15 transformed cell line human CVCL_B0Q7 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519400 CVCL_B0Q6 Dig 40-50 hybridoma house mouse CVCL_B0Q6 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 150519401 CVCL_B0PU KSCBi015-A induced pluripotent stem cell human CVCL_B0PU From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg190Gln (c.569G>A) (p.Arg63Gln, c.188G>A); ClinVar=VCV000003117; Zygosity=Heterozygous (PubMed=34509919) Population: Korean; Derived from sampling site: Peripheral blood. Female 150519402 CVCL_B0PH KITi001-C-41 induced pluripotent stem cell human CVCL_B0PH From: Korea Institute of Toxicology; Daejeon; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Using CRISPR/cAS9 a EGFP-polyA-PGK promoter-neo construct was introduced at the C-terminus of one allele of ACTA2 (PubMed=34481189) 150519403 CVCL_B0PG UKWMPi012-B induced pluripotent stem cell human CVCL_B0PG From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene amplification; HGNC; 11007; SLC2A3; Duplication; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150519404 CVCL_B0PJ SCVIi017-A induced pluripotent stem cell human CVCL_B0PJ From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 11947; TNNI3; Simple; p.Arg145Trp (c.433C>T); ClinVar=VCV000012426; Zygosity=Heterozygous (PubMed=34798544) Derived from sampling site: Peripheral blood. Female 150519405 CVCL_B0PI TMOi001-A-3 induced pluripotent stem cell human CVCL_B0PI CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple_edited; p.Ala111Leufs*7 (c.331delG); Zygosity=Homozygous (PubMed=34419745) Derived from sampling site: Umbilical cord blood. Female 150519406 CVCL_B0PL SCVIi019-A induced pluripotent stem cell human CVCL_B0PL From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 11947; TNNI3; Simple; p.Arg79Cys (c.235C>T); ClinVar=VCV000043367; Zygosity=Heterozygous (PubMed=34798544) Derived from sampling site: Peripheral blood. Male 150519407 CVCL_B0PK SCVIi018-A induced pluripotent stem cell human CVCL_B0PK From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 11947; TNNI3; Simple; p.Arg204Cys (c.610C>T); ClinVar=VCV000177631; Zygosity=Heterozygous (PubMed=34798544) Derived from sampling site: Peripheral blood. Male 150519408 CVCL_B0PN SCMCi003-A induced pluripotent stem cell human CVCL_B0PN From: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Population: Chinese; Karyotypic information: 52,XY,t(9,22)(q34:q11.2),+11,14,17,21,22,Y (PubMed=34298433); Derived from sampling site: Bone marrow. Male 150519409 CVCL_B0PM SCMCi002-A induced pluripotent stem cell human CVCL_B0PM From: Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Population: Chinese; Karyotypic information: 47,XX,del(5)(q22q25),del(7)(q22),del(12)(p11.2),+13 (PubMed=34298433); Derived from sampling site: Bone marrow. Female 150519410 CVCL_B0PB UKWMPi008-A induced pluripotent stem cell human CVCL_B0PB From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 11007; SLC2A3; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150519411 CVCL_B0PA UKWMPi007-B induced pluripotent stem cell human CVCL_B0PA From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 11007; SLC2A3; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150519412 CVCL_B0PD UKWMPi011-A induced pluripotent stem cell human CVCL_B0PD From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene amplification; HGNC; 11007; SLC2A3; Duplication; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150519413 CVCL_B0PC UKWMPi008-B induced pluripotent stem cell human CVCL_B0PC From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 11007; SLC2A3; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150519414 CVCL_B0PF UKWMPi012-A induced pluripotent stem cell human CVCL_B0PF From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene amplification; HGNC; 11007; SLC2A3; Duplication; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 150519415 CVCL_B0PE UKWMPi011-B induced pluripotent stem cell human CVCL_B0PE From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene amplification; HGNC; 11007; SLC2A3; Duplication; Zygosity=Heterozygous (PubMed=34492570) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 150519416 CVCL_B0MU H-CB-P1 hybridoma CVCL_B0MU CL:0000010 Monoclonal antibody isotype: IgM, lambda. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2104; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0517 150519417 CVCL_B0N6 W8B2 hybridoma house mouse CVCL_B0N6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05186; Human ALPL. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2567 150519418 CVCL_B0N5 39D5 hybridoma house mouse CVCL_B0N5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13591; Human NCAM1/CD56. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2930 150519419 CVCL_B0MT B40-DE8 hybridoma house mouse CVCL_B0MT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0436 150519420 CVCL_B0MW H-CB-P3 hybridoma CVCL_B0MW CL:0000010 Monoclonal antibody isotype: IgM, kappa. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0519 150519421 CVCL_B0N8 HEK293T PRKN KO transformed cell line human CVCL_B0N8 From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Laflamme C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 150519422 CVCL_B0MV H-CB-P2 hybridoma CVCL_B0MV CL:0000010 Monoclonal antibody isotype: IgM, lambda. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0518 150519423 CVCL_B0N7 MDCK-15D3 spontaneously immortalized cell line dog CVCL_B0N7 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017155 150519424 CVCL_B0MY CB 63 hybridoma CVCL_B0MY CL:0000010 Monoclonal antibody isotype: IgM. Doubling time: 14 hours (PubMed=3343518) 150519425 CVCL_B0MX CB 15 hybridoma CVCL_B0MX CL:0000010 Monoclonal antibody isotype: IgM. Doubling time: 16 hours (PubMed=3343518) 150519426 CVCL_B0N9 Abcam SH-SY5Y PRKN KO cancer cell line human CVCL_B0N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 150519427 CVCL_B0MZ CB 84 hybridoma CVCL_B0MZ CL:0000010 Monoclonal antibody isotype: IgG. Doubling time: 26 hours (PubMed=3343518) 150519428 CVCL_B0MM B25-AD5 hybridoma house mouse CVCL_B0MM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0430 150519429 CVCL_B0ML B25-AB1 hybridoma house mouse CVCL_B0ML CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0429 150519430 CVCL_B0N0 CB 86 hybridoma CVCL_B0N0 CL:0000010 Monoclonal antibody isotype: IgM. Doubling time: 24 hours (PubMed=3343518) 150519431 CVCL_B0MN B25-BB1 hybridoma house mouse CVCL_B0MN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0431 150519432 CVCL_B0MQ B25-CF11 hybridoma house mouse CVCL_B0MQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0433 150519433 CVCL_B0N2 CB 79 hybridoma CVCL_B0N2 CL:0000010 Monoclonal antibody isotype: IgG. Doubling time: 28 hours (PubMed=3343518) 150519434 CVCL_B0MP B25-BI8 hybridoma house mouse CVCL_B0MP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0432 150519435 CVCL_B0N1 CB 87 hybridoma CVCL_B0N1 CL:0000010 Monoclonal antibody isotype: IgM. Doubling time: 36 hours (PubMed=3343518) 150519436 CVCL_B0MS B40-AE6 hybridoma house mouse CVCL_B0MS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0435 150519437 CVCL_B0N4 W7C5 hybridoma house mouse CVCL_B0N4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6YHK3; Human CD109. 150519438 CVCL_B0MR B40-AA3 hybridoma house mouse CVCL_B0MR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0434 150519439 CVCL_B0N3 PBG04 hybridoma CVCL_B0N3 CL:0000010 Monoclonal antibody isotype: IgM, lambda. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2577 150519440 CVCL_B0ME B9-AB9 hybridoma house mouse CVCL_B0ME CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds FSHB, LHB and TSHB). 150519441 CVCL_B0MD B27-AC9 hybridoma house mouse CVCL_B0MD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519442 CVCL_B0MG B9-AA4 hybridoma house mouse CVCL_B0MG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519443 CVCL_B0MF B9-BG4 hybridoma house mouse CVCL_B0MF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519444 CVCL_B0MI B32-BD11 hybridoma house mouse CVCL_B0MI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519445 CVCL_B0MH B9-AA1 hybridoma house mouse CVCL_B0MH CL:0000010 Monoclonal antibody isotype: Not determined; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds FSHB, LHB and TSHB). 150519446 CVCL_B0MK B32-BG4 hybridoma house mouse CVCL_B0MK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519447 CVCL_B0MJ B32-BF2 hybridoma house mouse CVCL_B0MJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519448 CVCL_B0MA B27-FG11 hybridoma house mouse CVCL_B0MA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519449 CVCL_B0MC B20-CA2 hybridoma house mouse CVCL_B0MC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P01229; Human LHB (Note=Also binds CGB). 150519450 CVCL_B0MB B32-BC11 hybridoma house mouse CVCL_B0MB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519451 CVCL_B0NV A17G12.1 hybridoma house mouse CVCL_B0NV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3314 150519452 CVCL_B0NU A10B2.18 hybridoma house mouse CVCL_B0NU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3311 150519453 CVCL_B0NX A27F6.1 hybridoma house mouse CVCL_B0NX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3310 150519454 CVCL_B0NW A18B3.11 hybridoma house mouse CVCL_B0NW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3312 150519455 CVCL_B0NZ A6F8.6 hybridoma house mouse CVCL_B0NZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3318 150519456 CVCL_B0NY A40G12.8 hybridoma house mouse CVCL_B0NY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13385; Human TDGF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3316 150519457 CVCL_B0NN G45-89 hybridoma house mouse CVCL_B0NN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519458 CVCL_B0NM G45-70 hybridoma house mouse CVCL_B0NM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519459 CVCL_B0NP 99-12-1 hybridoma house mouse CVCL_B0NP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q07021; Human C1QBP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11863 150519460 CVCL_B0NR 9C2C1A9 hybridoma house mouse CVCL_B0NR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11862 150519461 CVCL_B0NQ 11G5G1B11 hybridoma house mouse CVCL_B0NQ CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11861 150519462 CVCL_B0NT 169B hybridoma house mouse CVCL_B0NT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13349; Human ITGAD. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11906 150519463 CVCL_B0NS 169A [Mouse hybridoma against human ITGAD] hybridoma house mouse CVCL_B0NS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13349; Human ITGAD. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11907 150519464 CVCL_B0NF G3-42 hybridoma house mouse CVCL_B0NF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519465 CVCL_B0NE G3-299 hybridoma house mouse CVCL_B0NE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519466 CVCL_B0NH G3-519 hybridoma house mouse CVCL_B0NH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10747 150519467 CVCL_B0NG G3-508 hybridoma house mouse CVCL_B0NG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10748 150519468 CVCL_B0NJ G3-537 hybridoma house mouse CVCL_B0NJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519469 CVCL_B0NI G3-536 hybridoma house mouse CVCL_B0NI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519470 CVCL_B0NL G45-60 hybridoma house mouse CVCL_B0NL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10749 150519471 CVCL_B0NK G45-16 hybridoma house mouse CVCL_B0NK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519472 CVCL_B0NB 293.STAT1 BAX KO transformed cell line human CVCL_B0NB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Exhibits significantly increased adeno-associated virus (AAV) production capacity for gene therapy applications (ATCC) 150519473 CVCL_B0NA PK-15/A11 spontaneously immortalized cell line pig CVCL_B0NA CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 54 150519474 CVCL_B0ND G3-211 hybridoma house mouse CVCL_B0ND CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). 150519475 CVCL_B0NC 166-32 hybridoma house mouse CVCL_B0NC CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized Fab antigen binding domain of the therapeutic antibody lampalizumab (FCFD4514S; RG7417) which was developed as a potential treatment of geographic atrophy (atrophy of the retinal cells, retinal pigment epithelium, and choriocapillaris) secondary to age-related macular degeneration Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00746; Human CFD. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12476 150519476 CVCL_B0L4 7.159.2 hybridoma house mouse CVCL_B0L4 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Biotechnology: The monoclonal antibody produced by this hybridoma is tested as a potential therapeutic antibody with antineoplastic activity under the name dusigitumab (MEDI-573) Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; P01344; Human IGF2 (Note=Also binds to IGF1) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7424 150519477 CVCL_B0KS WT.5 hybridoma CVCL_B0KS CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; G3V8L7; Rat Itgam/Cd11b. 150519478 CVCL_B0L3 9E6 hybridoma house mouse CVCL_B0L3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Cryptococcus neoformans var neoformans non-capsular antigen.. 150519479 CVCL_B0KR HESC-1 transformed cell line human CVCL_B0KR CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ear; inner ear; endolymphatic sac Cell type=Epithelial cell.. Group: Patented cell line 150519480 CVCL_B0KU 3G12.7 hybridoma house mouse CVCL_B0KU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:6887; Methylphenidate (Ritalin). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202069 150519481 CVCL_B0L6 7.234.2 hybridoma house mouse CVCL_B0L6 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01344; Human IGF2 (Note=Also binds to IGF1) 150519482 CVCL_B0KT 2D11 hybridoma house mouse CVCL_B0KT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P40424; Human PBX1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201912 150519483 CVCL_B0L5 7.160.2 hybridoma house mouse CVCL_B0L5 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01344; Human IGF2 (Note=Also binds to IGF1) 150519484 CVCL_B0KW 3G12 [Mouse hybridoma against PCV2 Cap] hybridoma house mouse CVCL_B0KW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; V5N005; Porcine circovirus type 2 (PCV2) isolate Nanjing caspid protein (Cap). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014198 150519485 CVCL_B0L8 7.34.1 hybridoma house mouse CVCL_B0L8 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01344; Human IGF2 (Note=Also binds to IGF1) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7423 150519486 CVCL_B0KV 2F8 [Mouse hybridoma against PCV2 Cap] hybridoma house mouse CVCL_B0KV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; V5N005; Porcine circovirus type 2 (PCV2) isolate Nanjing caspid protein (Cap). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014199 150519487 CVCL_B0L7 7.251.3 hybridoma house mouse CVCL_B0L7 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01344; Human IGF2 (Note=Also binds to IGF1) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7422 150519488 CVCL_B0KY 34893 2L transformed cell line human CVCL_B0KY CL:0000010 Transfected with: HGNC; 1402; CACNB2; Transfected with: UniProtKB; P13806; Rabbit CACNA2D1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12108 150519489 CVCL_B0KX 3H11 [Mouse hybridoma against PCV2 Cap] hybridoma house mouse CVCL_B0KX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; V5N005; Porcine circovirus type 2 (PCV2) isolate Nanjing caspid protein (Cap). 150519490 CVCL_B0L9 8H9 [Mouse hybridoma against human CD276] hybridoma house mouse CVCL_B0L9 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized omburtamab potential therapeutic antibody against neuroblastoma Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10926 150519491 CVCL_B0KK CA4AF5 hybridoma house mouse CVCL_B0KK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZXP3; Legionella pneumophila subsp pneumophila (strain Philadelphia 1) groEL (Note=Also reacts with many other Legionella species).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10439 150519492 CVCL_B0KJ CE/F16 hybridoma house mouse CVCL_B0KJ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8048 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519493 CVCL_B0KM GB5BE8 hybridoma house mouse CVCL_B0KM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZXP3; Legionella pneumophila subsp pneumophila (strain Philadelphia 1) groEL (Note=Also reacts with many other Legionella species).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10459 150519494 CVCL_B0KL GB5AF6 hybridoma house mouse CVCL_B0KL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZXP3; Legionella pneumophila subsp pneumophila (strain Philadelphia 1) groEL (Note=Also reacts with many other Legionella species).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10453 150519495 CVCL_B0L0 4E2 [Mouse hybridoma against C.neoformans non-capsular antigen] hybridoma house mouse CVCL_B0L0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Cryptococcus neoformans var neoformans non-capsular antigen.. 150519496 CVCL_B0KN F4/CB5/K18 hybridoma house mouse CVCL_B0KN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Legionella pneumophila subsp pneumophila (strain Philadelphia 1).. 150519497 CVCL_B0L2 7C7 hybridoma house mouse CVCL_B0L2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Cryptococcus neoformans var neoformans non-capsular antigen.. 150519498 CVCL_B0KQ F4/JD3.8/K101 hybridoma house mouse CVCL_B0KQ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Legionella pneumophila subsp pneumophila (strain Philadelphia 1).. 150519499 CVCL_B0L1 5D9 [Mouse hybridoma against C.neoformans non-capsular antigen] hybridoma house mouse CVCL_B0L1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Cryptococcus neoformans var neoformans non-capsular antigen.. 150519500 CVCL_B0KP F4/CB5/K104 hybridoma house mouse CVCL_B0KP CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Legionella pneumophila subsp pneumophila (strain Philadelphia 1).. 150519501 CVCL_B0KC 4D8 hybridoma house mouse CVCL_B0KC CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12487 150519502 CVCL_B0KB 4D4 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0KB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12493 150519503 CVCL_B0KE CE/F11 hybridoma house mouse CVCL_B0KE CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8043 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519504 CVCL_B0KD 4E10-1.14 hybridoma house mouse CVCL_B0KD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12310 150519505 CVCL_B0KG CE/F13 hybridoma house mouse CVCL_B0KG CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8045 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519506 CVCL_B0KF CE/F12 hybridoma house mouse CVCL_B0KF CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8044 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519507 CVCL_B0KI CE/F15 hybridoma house mouse CVCL_B0KI CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8047 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519508 CVCL_B0KH CE/F14 hybridoma house mouse CVCL_B0KH CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P01574; Human IFNB1 Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8046 Caution: This hybridoma along with 5 other described in PubMed=6205971 seem to have been described in two US patent applications that seem to have been rejected by the USPTO (see the two web links). 150519509 CVCL_B0JZ 1G3 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0JZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12489 150519510 CVCL_B0JY hMBL1.2 hybridoma house mouse CVCL_B0JY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11226; Human MBL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12619 150519511 CVCL_B0KA 4C8B9 hybridoma house mouse CVCL_B0KA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12492 150519512 CVCL_B0LT 24B11 hybridoma house mouse CVCL_B0LT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (B chain). 150519513 CVCL_B0M5 B24-BF10 hybridoma house mouse CVCL_B0M5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519514 CVCL_B0LS 23D7 hybridoma house mouse CVCL_B0LS CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (A chain). 150519515 CVCL_B0M4 H-BL-IgG/1 hybridoma house mouse CVCL_B0M4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human IgG. Group: Patented cell line 150519516 CVCL_B0LV 33G2 hybridoma house mouse CVCL_B0LV CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (B chain). 150519517 CVCL_B0M7 B27-BH2 hybridoma house mouse CVCL_B0M7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519518 CVCL_B0LU 25A4 hybridoma house mouse CVCL_B0LU CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (A chain). 150519519 CVCL_B0M6 B9-BA8 hybridoma house mouse CVCL_B0M6 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB. 150519520 CVCL_B0LX 29/24 B11 hybridoma house mouse CVCL_B0LX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14174; Human MIF. Group: Patented cell line 150519521 CVCL_B0M9 B27-AD10 hybridoma house mouse CVCL_B0M9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519522 CVCL_B0LW 35H6 hybridoma house mouse CVCL_B0LW CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (B chain). 150519523 CVCL_B0M8 B27-CE8 hybridoma house mouse CVCL_B0M8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also binds LHB). 150519524 CVCL_B0LZ H-BL-IgE/1 hybridoma house mouse CVCL_B0LZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgE. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Karl-Marx-Universitat Leipzig, Zentralen Institut fur Molekularbiologie; DDR-0052 150519525 CVCL_B0LY H-BL-Ig kappa hybridoma house mouse CVCL_B0LY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human Ig kappa light chains. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Zentralinstitut fur Molekularbiologie; ZIM-0049 150519526 CVCL_B0LL 103B2 hybridoma house mouse CVCL_B0LL CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; Q04900; Human CD164. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2221 150519527 CVCL_B0LK RPDS-2M4 hybridoma house mouse CVCL_B0LK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 260310-03 150519528 CVCL_B0LN 40B8 hybridoma house mouse CVCL_B0LN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6YHK3; Human CD109. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2279 150519529 CVCL_B0LM 105A5 hybridoma house mouse CVCL_B0LM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q04900; Human CD164. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2222 150519530 CVCL_B0LP 12A07-A10 transformed cell line CVCL_B0LP CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Extraembryonic membrane. Unspecified Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2695 150519531 CVCL_B0M1 H-BL-IgE/3 hybridoma house mouse CVCL_B0M1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human IgE. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Karl-Marx-Universitat Leipzig, Zentralen Institut fur Molekularbiologie; DDR-0094 150519532 CVCL_B0M0 H-BL-IgE/2 hybridoma house mouse CVCL_B0M0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IgE. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Karl-Marx-Universitat Leipzig, Zentralen Institut fur Molekularbiologie; DDR-0053 150519533 CVCL_B0M3 H-BL-IgM/1 hybridoma house mouse CVCL_B0M3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IgM. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Karl-Marx-Universitat Leipzig, Zentralen Institut fur Molekularbiologie; DDR-0056 150519534 CVCL_B0LR UNIVAX 70 hybridoma house mouse CVCL_B0LR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (A chain). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12054 150519535 CVCL_B0LQ AGE1.CS.pIX transformed cell line CVCL_B0LQ From: ProBioGen AG; Berlin; Germany CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Somite; Breed/subspecies: ST4 compact. Unspecified Group: Bird cell line 150519536 CVCL_B0M2 H-BL-IgE/4 hybridoma house mouse CVCL_B0M2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgE. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Karl-Marx-Universitat Leipzig, Zentralen Institut fur Molekularbiologie; DDR-0095 150519537 CVCL_B0LD R604 hybrid cell line Norway rat CVCL_B0LD CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Characteristics: Produces the chimeric monoclonal antibody EMAB604 against human LDLR Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3692 150519538 CVCL_B0LC 4H2 [Mouse hybridoma against marinobufagenin] hybridoma house mouse CVCL_B0LC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:146151; Marinobufagenin (MBG). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6788 150519539 CVCL_B0LF RPDS-1M19 hybridoma house mouse CVCL_B0LF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 050210-02 150519540 CVCL_B0LE RPDS-1M20 hybridoma house mouse CVCL_B0LE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 050210-04 150519541 CVCL_B0LH RPDS-1M27 hybridoma house mouse CVCL_B0LH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 050210-01 150519542 CVCL_B0LG RPDS-1M21 hybridoma house mouse CVCL_B0LG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 050210-03 150519543 CVCL_B0LJ RPDS-2M2 hybridoma house mouse CVCL_B0LJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 260310-02 150519544 CVCL_B0LI RPDS-1M31 hybridoma house mouse CVCL_B0LI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 260310-01 150519545 CVCL_B0KZ 192C transformed cell line human CVCL_B0KZ CL:0000010 Transfected with: HGNC; 1402; CACNB2; Transfected with: HGNC; 1392; CACNA1E; Transfected with: UniProtKB; P13806; Rabbit CACNA2D1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 150519546 CVCL_B0LB 4G4 [Mouse hybridoma against marinobufagenin] hybridoma house mouse CVCL_B0LB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:146151; Marinobufagenin (MBG) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6725 150519547 CVCL_B0LA 3E9 [Mouse hybridoma against marinobufagenin] hybridoma house mouse CVCL_B0LA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:146151; Marinobufagenin (MBG) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6724 150519548 CVCL_B0J2 F97/8-11H2C hybridoma house mouse CVCL_B0J2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). 150519549 CVCL_B0IQ GM28092 finite cell line human CVCL_B0IQ CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519550 CVCL_B0J1 F98/5-10H.7G hybridoma house mouse CVCL_B0J1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). 150519551 CVCL_B0IP GM28091 finite cell line human CVCL_B0IP CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519552 CVCL_B0IS AG24459 transformed cell line human CVCL_B0IS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 150519553 CVCL_B0J4 F97/6-9A2C hybridoma house mouse CVCL_B0J4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). 150519554 CVCL_B0J3 F97/9-1A.6B hybridoma house mouse CVCL_B0J3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). 150519555 CVCL_B0IR GM28095 finite cell line human CVCL_B0IR CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Tyr133Asp (c.397T>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg192Profs*8 (c.574_575insCTGC); ClinVar=VCV000419973; Zygosity=Heterozygous (Coriell) Population: Caucasian; Austrian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150519556 CVCL_B0J6 AC6C3-2B12 hybridoma CVCL_B0J6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human 32 kDa protein on the surface of many cancer cells. 150519557 CVCL_B0IU AG24457 transformed cell line human CVCL_B0IU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 150519558 CVCL_B0J5 AC6C3 hybridoma CVCL_B0J5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human 32 kDa protein on the surface of many cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10305 150519559 CVCL_B0IT AG24460 transformed cell line human CVCL_B0IT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 150519560 CVCL_B0IW AG24444 transformed cell line human CVCL_B0IW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 150519561 CVCL_B0J8 Expi293F Inducible transformed cell line human CVCL_B0J8 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably expresses high levels of tetR When used with compatible inducible vectors the gene of interest is repressed with very low levels of basal expression until induction with tetracycline. Expression can be modulated by addition of different amounts of tetracycline (Thermofisher). Group: Serum/protein free medium cell line 150519562 CVCL_B0IV AG24447 transformed cell line human CVCL_B0IV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 150519563 CVCL_B0J7 Expi293F GnTI- transformed cell line human CVCL_B0J7 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Lacks N-acetylglucosaminyltransferase I activity and accordingly predominantly modifies glycoproteins with the Man5GlcNAc2 N-glycan Group: Serum/protein free medium cell line 150519564 CVCL_B0II GM28053 finite cell line human CVCL_B0II CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian/Russian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519565 CVCL_B0IH GM28257 finite cell line human CVCL_B0IH CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; c.173+1G>A; ClinVar=VCV000554440; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519566 CVCL_B0IK GM28077 finite cell line human CVCL_B0IK CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Tyr133Asp (c.397T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519567 CVCL_B0IJ GM28054 finite cell line human CVCL_B0IJ CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Gly195Asp (c.584G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Heterozygous (Coriell) Population: Caucasian/Russian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519568 CVCL_B0IM GM28079 finite cell line human CVCL_B0IM CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg192Profs*8 (c.574_575insCTGC); ClinVar=VCV000419973; Zygosity=Heterozygous (Coriell) Population: Caucasian; Austrian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 150519569 CVCL_B0IL GM28102 finite cell line human CVCL_B0IL CL:0000010 Sequence variation: Mutation; HGNC; 11042; SLC6A1; Simple; p.Asp52Asn (c.154G>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Norwegian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519570 CVCL_B0J0 F98/2-7C.6B hybridoma house mouse CVCL_B0J0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). 150519571 CVCL_B0IN GM28090 finite cell line human CVCL_B0IN CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Ser282Cysfs*9 (c.841_842CT[2]) (c.845_846delCT); ClinVar=VCV000012770; Zygosity=Homozygous (Coriell) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519572 CVCL_B0IA GM28206 transformed cell line human CVCL_B0IA CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous (Coriell) Population: Bangladeshi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519573 CVCL_B0IC GM28213 finite cell line human CVCL_B0IC CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Unexplicit; Ex10-11del; Zygosity=Mosaic (Coriell) Population: Caucasian; Romanian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519574 CVCL_B0IB GM28210 finite cell line human CVCL_B0IB CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous (Coriell) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519575 CVCL_B0IE GM28234 finite cell line human CVCL_B0IE CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Arg468Ter (c.1402C>T); ClinVar=VCV000565700; Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Arg625Thr (c.1874G>C); Zygosity=Heterozygous (Coriell) Population: Jewish; Syrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519576 CVCL_B0ID GM28214 finite cell line human CVCL_B0ID CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg75Ter (c.223C>T); ClinVar=VCV000048672; Zygosity=Heterozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519577 CVCL_B0IG GM28252 induced pluripotent stem cell human CVCL_B0IG CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; c.448+64T>C (IVS3+64T>C); ClinVar=VCV000683189; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 150519578 CVCL_B0IF GM28249 induced pluripotent stem cell human CVCL_B0IF CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Gly176Asp (c.527C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Ala305Glu (c.914C>A); ClinVar=VCV000002607; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Arg249Trp (c.745C>T); ClinVar=VCV000126510; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519579 CVCL_B0HX F89/160.1.5 hybridoma house mouse CVCL_B0HX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Also reacts with sheep, mule deer, elk and many other species; recognizes the epitope 'Ile-His-Phe-Gly'). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12403 150519580 CVCL_B0I9 GM28211 finite cell line human CVCL_B0I9 CL:0000010 Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 150519581 CVCL_B0HW F99/97.6.1 hybridoma house mouse CVCL_B0HW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Also reacts with sheep, mule deer, elk and many other species; recognizes the epitope 'Gln-Tyr-Gln-Arg-Glu-Ser'). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12696 150519582 CVCL_B0I8 GM28208 transformed cell line human CVCL_B0I8 CL:0000010 Population: Bangladeshi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519583 CVCL_B0HZ 28F11 hybridoma house mouse CVCL_B0HZ CL:0000010 Characteristics: Produces a catalytic antibody capable of cleaving a Gly-Phe bond when in presence of a metal ion cofactor. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9971 150519584 CVCL_B0HY F89/193.1.5 hybridoma house mouse CVCL_B0HY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Also reacts with sheep, mule deer and elk). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-114 150519585 CVCL_B0K3 3C4 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12494 150519586 CVCL_B0JR WAe009-A-71 embryonic stem cell human CVCL_B0JR From: Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 11190; SOX10. Female 150519587 CVCL_B0K2 3C2 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. 150519588 CVCL_B0JQ SHIPMi002-A induced pluripotent stem cell human CVCL_B0JQ From: Shanghai Institute of Precision Medicine, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519589 CVCL_B0K5 3C9 hybridoma house mouse CVCL_B0K5 CL:0000010 Monoclonal antibody isotype: IgG1 (Patent=US6150508); IgG2b (PubMed=9817391); Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12484 150519590 CVCL_B0JT H1975/OR [China Dongguan] cancer cell line human CVCL_B0JT CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291) Female 150519591 CVCL_B0K4 3C6 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12491 150519592 CVCL_B0JS H1975/OR [China Guangzhou] cancer cell line human CVCL_B0JS CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291) Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2019300 150519593 CVCL_B0K7 3E11 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K7 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12488 150519594 CVCL_B0JV 3F8 [Mouse hybridoma against human MBL2] hybridoma house mouse CVCL_B0JV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11226; Human MBL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12621 150519595 CVCL_B0K6 3D7-1.1 hybridoma house mouse CVCL_B0K6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12309 150519596 CVCL_B0JU GS17F1C4 hybridoma house mouse CVCL_B0JU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01032; Pig C5. 150519597 CVCL_B0JX 2A9 hybridoma house mouse CVCL_B0JX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11226; Human MBL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12620 150519598 CVCL_B0K9 3G6 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K9 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12485 150519599 CVCL_B0JW 1C10 [Mouse hybridoma against human MBL2] hybridoma house mouse CVCL_B0JW CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P11226; Human MBL2. 150519600 CVCL_B0K8 3E6 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12486 150519601 CVCL_B0JJ CR4E8E10E10 transformed cell line human CVCL_B0JJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgM Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10304 150519602 CVCL_B0JI Ba-6 hybridoma house mouse CVCL_B0JI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Brucella abortus strain S99 major outer membrane 36-38 kDa protein. 150519603 CVCL_B0JL QAU-Bd-E-2 spontaneously immortalized cell line CVCL_B0JL CL:0000010 Unspecified Virology: Susceptible to infection by Bactrocera dorsalis cripavirus (BdCV) Doubling time: 31.9 hours (PubMed=34435282). Group: Insect cell line 150519604 CVCL_B0JK NCI-H1975/AR cancer cell line human CVCL_B0JK CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291) Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201982 150519605 CVCL_B0JN EHTJUi005-A-3 induced pluripotent stem cell human CVCL_B0JN From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Female 150519606 CVCL_B0JM EHTJUi005-A-1 induced pluripotent stem cell human CVCL_B0JM From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1 Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Female 150519607 CVCL_B0K1 2C7 [Mouse hybridoma against human FOLH1] hybridoma house mouse CVCL_B0K1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12490 150519608 CVCL_B0JP SHIPMi001-A induced pluripotent stem cell human CVCL_B0JP From: Shanghai Institute of Precision Medicine, Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Leu460Trpfs*6 (c.1377delC); ClinVar=VCV000188548; Zygosity=Heterozygous (PubMed=34785479) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 150519609 CVCL_B0K0 1G9 hybridoma house mouse CVCL_B0K0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12495 150519610 CVCL_B0JB ID1-V-LUC hES embryonic stem cell human CVCL_B0JB CL:0000010 Transfected with: Venus, a bright yellow fluorescent protein derived from YFP; Transfected with: UniProtKB; P08659; Firefly luciferase. Female Characteristics: Stem cell model for screening drugs for pulmonary hypertension and to find a novel lead compound for the treatment of pulmonary hypertension using BMP signaling; Characteristics: Transduced with a Id1-Venus-Luc-MC1-DTA construct in which expression of the genes for Venus and luciferase are under the control of a full-length human ID1 promoter Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.11091 150519611 CVCL_B0JA C2C12-BRE spontaneously immortalized cell line house mouse CVCL_B0JA CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: Allows a sensitive, rapid and specific cell based assay for the simultaneous quantification of total and isoform specific BMP activity from biological samples (PubMed=19298647); Characteristics: Transfected with a construct in which the luciferase reporter gene is under the control of the BMP responsive element (BRE) of the Id1 promoter region 150519612 CVCL_B0JD Ba-1 hybridoma house mouse CVCL_B0JD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Brucella abortus strain S99 38-45 kDa component of smooth lipopolysaccharide (Note=Also reacts with Brucella melitensis 16M and Brucella suis). 150519613 CVCL_B0JC 4H12 [Mouse hybridoma against human MYH9] hybridoma house mouse CVCL_B0JC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35579; Human MYH9. 150519614 CVCL_B0JF Ba-3 hybridoma house mouse CVCL_B0JF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Brucella abortus strain S99 38-45 kDa component of smooth lipopolysaccharide. 150519615 CVCL_B0JE Ba-2 hybridoma house mouse CVCL_B0JE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Brucella abortus strain S99 38-45 kDa component of smooth lipopolysaccharide (Note=Also reacts with Brucella melitensis 16M and Brucella suis). 150519616 CVCL_B0JH Ba-5 hybridoma house mouse CVCL_B0JH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Brucella abortus strain S99 major outer membrane 25-27 kDa protein. 150519617 CVCL_B0JG Ba-4 hybridoma house mouse CVCL_B0JG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Brucella abortus strain S99 major outer membrane 25-27 kDa protein. 150519618 CVCL_B0IY UMi033-A induced pluripotent stem cell human CVCL_B0IY From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 150519619 CVCL_B0J9 Expi293F Inducible GnTI- transformed cell line human CVCL_B0J9 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Lacks N-acetylglucosaminyltransferase I activity and accordingly predominantly modifies glycoproteins with the Man5GlcNAc2 N-glycan; Characteristics: Stably expresses high levels of tetR When used with compatible inducible vectors the gene of interest is repressed with very low levels of basal expression until induction with tetracycline. Expression can be modulated by addition of different amounts of tetracycline (Thermofisher). Group: Serum/protein free medium cell line 150519620 CVCL_B0IX UMi032-A induced pluripotent stem cell human CVCL_B0IX From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 150519621 CVCL_B0IZ F98/5-3B.2C.4G hybridoma house mouse CVCL_B0IZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2 (Note=Recognizes AA 307-314 in activation peptide). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10291 150519622 CVCL_B0XB MAK16.1.39 hybridoma house mouse CVCL_B0XB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2590 150519623 CVCL_B0XA 5F7 [Mouse/sheep hybridoma against C.botulinum botA] hybridoma CVCL_B0XA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519624 CVCL_B0XD MAK18.4.34 hybridoma house mouse CVCL_B0XD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2592 150519625 CVCL_B0XC MAK17.3.1 hybridoma house mouse CVCL_B0XC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2591 150519626 CVCL_B0XF MAK1.21.3 hybridoma CVCL_B0XF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2650 150519627 CVCL_B0XE MAK18.29.23 hybridoma house mouse CVCL_B0XE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2593 150519628 CVCL_B0X8 4F7 [Mouse/sheep hybridoma against C.botulinum botA] hybridoma CVCL_B0X8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519629 CVCL_B0WW 6B2-2 hybridoma house mouse CVCL_B0WW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-969 150519630 CVCL_B0X7 2G11 [Mouse hybridoma against C.botulinum botA] hybridoma CVCL_B0X7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519631 CVCL_B0WV 4A2-4 hybridoma house mouse CVCL_B0WV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519632 CVCL_B0WY 6E10-10 hybridoma house mouse CVCL_B0WY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519633 CVCL_B0X9 5E2 hybridoma CVCL_B0X9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519634 CVCL_B0WX 6C2-4 hybridoma house mouse CVCL_B0WX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-970 150519635 CVCL_B0WZ 6E10-4 hybridoma house mouse CVCL_B0WZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519636 CVCL_B0X0 6E10-5 hybridoma house mouse CVCL_B0X0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519637 CVCL_B0WN HC11.208.1 hybridoma house mouse CVCL_B0WN CL:0000010 Monoclonal antibody isotype: IgG1. 150519638 CVCL_B0X2 6E9-1 hybridoma house mouse CVCL_B0X2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519639 CVCL_B0WQ B1.1 hybridoma house mouse CVCL_B0WQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P01210; Human PENK (Met-enkephalin). 150519640 CVCL_B0X1 6E10-8 hybridoma house mouse CVCL_B0X1 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519641 CVCL_B0WP A1.1 hybridoma house mouse CVCL_B0WP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01210; Human PENK (Met-enkephalin). 150519642 CVCL_B0X4 6E9-4 hybridoma house mouse CVCL_B0X4 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519643 CVCL_B0WS B3.1 hybridoma house mouse CVCL_B0WS CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: UniProtKB; P01210; Human PENK (Met-enkephalin). 150519644 CVCL_B0X3 6E9-3 hybridoma house mouse CVCL_B0X3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519645 CVCL_B0WR B2.1 hybridoma house mouse CVCL_B0WR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01210; Human PENK (Met-enkephalin). 150519646 CVCL_B0X6 16F9 hybridoma CVCL_B0X6 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519647 CVCL_B0WU 4A2-2 hybridoma house mouse CVCL_B0WU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-971 150519648 CVCL_B0WT 1C10 [Mouse/sheep heteromyeloma] hybrid cell line CVCL_B0WT From: Bioventix Ltd; Farnham; United Kingdom CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 150519649 CVCL_B0X5 1G4 [Mouse hybridoma against C.botulinum botA] hybridoma CVCL_B0X5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P0DPI0; Clostridium botulinum botulinum neurotoxin type A (botA). 150519650 CVCL_B0WG BCIRL-Sf4FB-0614-SGS spontaneously immortalized cell line CVCL_B0WG CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 150519651 CVCL_B0WF BCIRL-SfNS-0518B-YL spontaneously immortalized cell line CVCL_B0WF CL:0000010 Derived from sampling site: Nervous system. Unspecified Group: Insect cell line 150519652 CVCL_B0WI BCIRL-AtuNE-1129-SGS spontaneously immortalized cell line CVCL_B0WI CL:0000010 Unspecified Group: Insect cell line. 150519653 CVCL_B0WH BCIRL-AtuE-1127-SGS spontaneously immortalized cell line CVCL_B0WH CL:0000010 Unspecified Group: Insect cell line. 150519654 CVCL_B0WK 3B7 [Mouse hybridoma against FIV p24] hybridoma house mouse CVCL_B0WK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16087; Feline immunodeficiency virus (isolate Petaluma) (FIV) gag (p24). 150519655 CVCL_B0WJ 1C11 [Mouse hybridoma against FIV p24] hybridoma house mouse CVCL_B0WJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16087; Feline immunodeficiency virus (isolate Petaluma) (FIV) gag (p24). 150519656 CVCL_B0WM HC11.151.1 hybridoma house mouse CVCL_B0WM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 150519657 CVCL_B0WL HC11.13.1 hybridoma house mouse CVCL_B0WL CL:0000010 Monoclonal antibody isotype: IgG1. 150519658 CVCL_B0XP 5C1 hybridoma house mouse CVCL_B0XP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519659 CVCL_B0XR 293T/ACE2 [Japan 2021] transformed cell line human CVCL_B0XR CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33686154) Group: SARS-CoV-2 research cell line 150519660 CVCL_B0XQ LXVI-5A5-C7 hybridoma house mouse CVCL_B0XQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania mexicana venezuelensis. 150519661 CVCL_B0XS MRC5/ACE2 finite cell line human CVCL_B0XS CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Virology: Highly susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33686154) Group: SARS-CoV-2 research cell line 150519662 CVCL_B0XH Trk27 hybridoma house mouse CVCL_B0XH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519663 CVCL_B0XG MAK10.4.63 hybridoma house mouse CVCL_B0XG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16860; Human NPPB. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2654 150519664 CVCL_B0XJ Trk62 hybridoma house mouse CVCL_B0XJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7890 150519665 CVCL_B0XI Trk49 hybridoma house mouse CVCL_B0XI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8249 150519666 CVCL_B0XL 1F1 [Mouse hybridoma against human ACP5] hybridoma house mouse CVCL_B0XL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519667 CVCL_B0XK Trk73 hybridoma house mouse CVCL_B0XK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519668 CVCL_B0XN 4E6 hybridoma house mouse CVCL_B0XN CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519669 CVCL_B0XM 2H1 hybridoma house mouse CVCL_B0XM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13686; Human ACP5. 150519670 CVCL_B0VB CEM231.6.7 hybridoma house mouse CVCL_B0VB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9620 150519671 CVCL_B0VA CHB235 hybridoma house mouse CVCL_B0VA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:42433; 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA. Group: Patented cell line 150519672 CVCL_B0VD 263A17 hybridoma house mouse CVCL_B0VD CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 150519673 CVCL_B0VC ECH037.2 hybridoma house mouse CVCL_B0VC CL:0000010 Characteristics: Tetradoma obtained by the biological fusion of two hybridomas; Monoclonal antibody target: ChEBI; CHEBI:42433; 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA (Note=The antibody binds to the chelated In+++ metal ion); Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 150519674 CVCL_B0UU AX-EA1-G1 hybridoma house mouse CVCL_B0UU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P94217; Bacillus anthracis S-layer protein EA1 (eag). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2632 150519675 CVCL_B0V6 ICR-2A2 spontaneously immortalized cell line CVCL_B0V6 CL:0000010 Karyotypic information: Diploid. Unspecified Group: Amphibian cell line 150519676 CVCL_B0UT 12.5 hybridoma house mouse CVCL_B0UT CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q16206; Human ENOX2. 150519677 CVCL_B0V5 ICR-2A1 spontaneously immortalized cell line CVCL_B0V5 CL:0000010 Unspecified Group: Amphibian cell line; Group: Haploid karyotype cell line. 150519678 CVCL_B0UW 1hFT.1.6D4.1C8 hybridoma house mouse CVCL_B0UW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Mullerian duct-derived epithelial cell antigen PIPA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4220 150519679 CVCL_B0V8 2A81G5 hybridoma house mouse CVCL_B0V8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:42433; 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA (Note=The antibody binds to the chelated Cd++ metal ion). 150519680 CVCL_B0UV 23a-14G9 hybridoma house mouse CVCL_B0UV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Bacillus anthracis spore specific antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6004 150519681 CVCL_B0V7 ICR B9 spontaneously immortalized cell line CVCL_B0V7 CL:0000010 Karyotypic information: Diploid; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759). Unspecified Group: Amphibian cell line 150519682 CVCL_B0UY 306D326.26 hybridoma house mouse CVCL_B0UY CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized sonepcizumab (LT1009; Asonex) therapeutic antibody candidate for treatment of patients with cancer or ocular diseases Discontinued: ATCC; SD-5362; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:37550; Sphingosine 1-phosphate (S1P) 150519683 CVCL_B0V9 CHA255 hybridoma house mouse CVCL_B0V9 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:42433; 4-[N'-(2-hydroxyethyl)thioureido]-L-benzyl EDTA (Note=The antibody binds to the chelated In+++ metal ion). Group: Patented cell line 150519684 CVCL_B0UX mPA7 hybridoma house mouse CVCL_B0UX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15529; Human CD46. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3706 150519685 CVCL_B0UZ CHO LH1 275 transformed cell line CVCL_B0UZ CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Transfected with plasmid pATH1009 encoding the Ig heavy and light chains of humanized version (LT1009) of mAB (LT1002) produced by hybridoma 306D326.26 (Cellosaurus=CVCL_B0UY) Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8422 150519686 CVCL_B0UM NIKS-16 transformed cell line human CVCL_B0UM CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 150519687 CVCL_B0UL 2D4 [Mouse hybridoma against HPV18 E7] hybridoma house mouse CVCL_B0UL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06788; Human papillomavirus type 18 protein E7. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201402 150519688 CVCL_B0V0 1E12b hybridoma house mouse CVCL_B0V0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140691; Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/24:0) (Stage-specific embryonic antigen-3; SSEA-3). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-126149 150519689 CVCL_B0UN NIKS-16deltaE7 transformed cell line human CVCL_B0UN CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [With defective E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 150519690 CVCL_B0V2 487 finite cell line human CVCL_B0V2 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn235Ile (c.704A>T); Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Val (c.751A>G); Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Gly (c.773A>G); ClinVar=VCV000406590; Zygosity=Unspecified (PubMed=10446856) Derived from sampling site: Synovium Cell type=Fibroblast.. Unspecified 150519691 CVCL_B0UQ JTUi007-A induced pluripotent stem cell human CVCL_B0UQ From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2433; CSF1R; Simple; p.Ile794Thr (c.2381T>C); ClinVar=VCV000029813; Zygosity=Heterozygous (PubMed=34837774) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 150519692 CVCL_B0V1 339.15.6.16 hybridoma house mouse CVCL_B0V1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16552; Human IL17A; Monoclonal antibody target: UniProtKB; Q96PD4; Human IL17F. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7989 150519693 CVCL_B0UP NIKS-18 transformed cell line human CVCL_B0UP CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 150519694 CVCL_B0US 12.1 [Mouse hybridoma against human ENOX2] hybridoma house mouse CVCL_B0US CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q16206; Human ENOX2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4206 150519695 CVCL_B0V4 491 finite cell line human CVCL_B0V4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp207Asp (c.621T>C); Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe212Tyr (c.635T>A); Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg290Cys (c.868C>T); ClinVar=VCV000216472; Zygosity=Unspecified (PubMed=10446856) Derived from sampling site: Synovium Cell type=Fibroblast.. Unspecified 150519696 CVCL_B0V3 488 finite cell line human CVCL_B0V3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Arg (c.833C>G); ClinVar=VCV000376644; Zygosity=Unspecified (PubMed=10446856); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu289Leu (c.867C>T); ClinVar=VCV000233110; Zygosity=Unspecified (PubMed=10446856) Derived from sampling site: Synovium Cell type=Fibroblast.. Unspecified 150519697 CVCL_B0UR OMB-037 hybrid cell line CVCL_B0UR CL:0000010 Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11086. 150519698 CVCL_B0UE 3B7 [Mouse hybridoma against M.honghuensis shell valve protein] hybridoma house mouse CVCL_B0UE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Myxobolus honghuensis shell valve protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013189 150519699 CVCL_B0UD 1C7 [Mouse hybridoma against M.honghuensis polar filament] hybridoma house mouse CVCL_B0UD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Myxobolus honghuensis polar filament. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013188 150519700 CVCL_B0UG 2D12 [Mouse hybridoma against M.rotundus protein] hybridoma house mouse CVCL_B0UG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Myxobolus rotundus 91 kDa spore/trophozoite protein. 150519701 CVCL_B0UF 1A9 [Mouse hybridoma against M.rotundus 104 kDa spore protein] hybridoma house mouse CVCL_B0UF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Myxobolus rotundus 104 kDa spore protein. 150519702 CVCL_B0UI HepG2/TC155 cancer cell line human CVCL_B0UI CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P03146; Hepatitis B virus genotype D subtype ayw capsid protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with a hepatitis B virus capsid protein that contains a tetracysteine (TC) C-C-P-G-C-C insertion in position 115 The TC tag specifically reacts with a membrane-permeable biarsenical fluorescent dye (ReAsH) (PubMed=24373334). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013191 150519703 CVCL_B0UH HepG2.A64 cancer cell line human CVCL_B0UH CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Transfected with a plasmid pTriexHBV1.1 containing 1.1 copies of hepatitis B virus (HBV) DNA (GenBank: HQ638218.1) (PubMed=28382278) Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201163 150519704 CVCL_B0UK 2F10 [Mouse hybridoma against HPV16 E6] hybridoma house mouse CVCL_B0UK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03126; Human papillomavirus type 16 protein E6. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201401 150519705 CVCL_B0UJ S467 hybridoma house mouse CVCL_B0UJ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Grass carp reovirus strain GCRV-HZ08 protein S10. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013193 150519706 CVCL_B0WA HEK293-FT APEX1 KO clone 1C4 transformed cell line human CVCL_B0WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 587; APEX1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: 20.4 hours (PubMed=34529719) 150519707 CVCL_B0WC WAe001-A-66 embryonic stem cell human CVCL_B0WC From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Transfected with: Akaluciferase (Akaluc), a luciferase-derived fluorescent protein. Male Characteristics: Using CRISPR/Cas9 a construct containing the Akaluc gene under the control of a EF-1 alpha promoter was introduced in the AAVS1 safe harbor locus 150519708 CVCL_B0WB HEK293-FT APEX1 KO clone 2A9 transformed cell line human CVCL_B0WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 587; APEX1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: 19.4 hours (PubMed=34529719) 150519709 CVCL_B0WE SKOV3-TAX/CBP cancer cell line human CVCL_B0WE CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 150519710 CVCL_B0WD HO8910-TAX/CBP cancer cell line human CVCL_B0WD CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HO-8910) has been shown to be a HeLa derivative. 150519711 CVCL_B0VV 24-2-3 hybridoma house mouse CVCL_B0VV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 with pyro-Glu3; N3pE-42). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2926 150519712 CVCL_B0W7 SYSUi006-A induced pluripotent stem cell human CVCL_B0W7 From: Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University; Guangzhou; China. CL:0000010 150519713 CVCL_B0VU 17-4-3 hybridoma house mouse CVCL_B0VU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 with pyro-Glu3; N3pE-42). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2925 150519714 CVCL_B0W6 SYSUi005-A induced pluripotent stem cell human CVCL_B0W6 From: Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Pro77Ser (c.229C>T); Zygosity=Heterozygous (PubMed=34942479) Population: Chinese; Derived from sampling site: Peripheral blood. Male 150519715 CVCL_B0VX 6-1-6 hybridoma house mouse CVCL_B0VX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 with pyro-Glu3; N3pE-42). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2924 150519716 CVCL_B0W9 NCC-LGFMS1-C1 cancer cell line human CVCL_B0W9 CL:0000010 Sequence variation: Gene fusion; HGNC; 23720; CREB3L2 + HGNC; 4010; FUS; Name(s)=FUS-CREB3L2 (PubMed=34535876) Population: Japanese; Derived from sampling site: Rectus abdominis muscle. Omics: SNP array analysis Female Doubling time: ~149.9 hours (PubMed=34535876) Part of: NCC sarcoma cell line panel 150519717 CVCL_B0VW 5-5-6 hybridoma house mouse CVCL_B0VW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 with pyro-Glu3; N3pE-42). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2923 150519718 CVCL_B0W8 KMUGMCi001-A induced pluripotent stem cell human CVCL_B0W8 From: Kanazawa Medical University; Uchinada; Japan CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple; p.Phe259Lysfs*28 (c.772+3_772+4dup); Zygosity=Heterozygous (PubMed=35279593) Population: Japanese; Derived from sampling site: Peripheral blood. Female 150519719 CVCL_B0VZ CHO/CERT 2.41 spontaneously immortalized cell line CVCL_B0VZ CL:0000010 Transfected with: HGNC; 2205; CERT1 (with p.Ser132Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Has improved secretion characteristics in comparison to non-transgenic cell lines Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2990 150519720 CVCL_B0VY CHO/CERT 2.20 spontaneously immortalized cell line CVCL_B0VY CL:0000010 Transfected with: HGNC; 2205; CERT1 (with p.Ser132Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Has improved secretion characteristics in comparison to non-transgenic cell lines Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2989 150519721 CVCL_B0VN 4B1 hybridoma house mouse CVCL_B0VN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519722 CVCL_B0VM 1C12 [Mouse hybridoma against FeLV p15E] hybridoma house mouse CVCL_B0VM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (p15E). 150519723 CVCL_B0VP 6B2 [Mouse hybridoma against FeLV p15E] hybridoma house mouse CVCL_B0VP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (p15E). 150519724 CVCL_B0W1 9D11.2E8 hybridoma house mouse CVCL_B0W1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07333; Human CSF1R/CD115. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2920 150519725 CVCL_B0W0 10H2.2F12 hybridoma house mouse CVCL_B0W0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07333; Human CSF1R/CD115. 150519726 CVCL_B0W3 2DE9-BC1 hybridoma house mouse CVCL_B0W3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; K0BVN3; Middle East respiratory syndrome-related coronavirus (MERS-CoV) isolate EMC/2012 nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); KCTC 13003BP 150519727 CVCL_B0VR 6G3 hybridoma house mouse CVCL_B0VR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519728 CVCL_B0W2 2DE12-AE6 hybridoma house mouse CVCL_B0W2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; K0BVN3; Middle East respiratory syndrome-related coronavirus (MERS-CoV) isolate EMC/2012 nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); KCTC 13002BP 150519729 CVCL_B0VQ 6D4 hybridoma house mouse CVCL_B0VQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519730 CVCL_B0W5 506-2G10G5 hybridoma house mouse CVCL_B0W5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A0G3U597; Middle East respiratory syndrome-related coronavirus (MERS-CoV) isolate KOR/KNIH/002_05_2015 spike protein (S). 150519731 CVCL_B0VT 8F3 hybridoma house mouse CVCL_B0VT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519732 CVCL_B0W4 492-1G10E4E2 hybridoma house mouse CVCL_B0W4 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A0A0G3U597; Middle East respiratory syndrome-related coronavirus (MERS-CoV) isolate KOR/KNIH/002_05_2015 spike protein (S). 150519733 CVCL_B0VS 7B3 hybridoma house mouse CVCL_B0VS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519734 CVCL_B0VF 125M165DAAA hybridoma house mouse CVCL_B0VF CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10106 150519735 CVCL_B0VE 125M10AA hybridoma house mouse CVCL_B0VE CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10107 150519736 CVCL_B0VH 125N26F6AA hybridoma house mouse CVCL_B0VH CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10109 150519737 CVCL_B0VG 125M96ABA hybridoma house mouse CVCL_B0VG CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10108 150519738 CVCL_B0VJ 125Q54AAAA hybridoma house mouse CVCL_B0VJ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10105 150519739 CVCL_B0VI 125Q47BA hybridoma house mouse CVCL_B0VI CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10104 150519740 CVCL_B0VL 1C1 [Mouse hybridoma against FeLV gp70] hybridoma house mouse CVCL_B0VL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A6G7H0D3; Feline leukemia virus (strain Kawakami-Theilen) env (gp70). 150519741 CVCL_B0VK 125R5AAAA hybridoma house mouse CVCL_B0VK CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33 Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10103 150519742 CVCL_B0SZ 3D4 [Mouse hybridoma against hepatitis B virus HBsAG] hybridoma house mouse CVCL_B0SZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8170 150519743 CVCL_B0TB MAb 1-5-1-3 hybridoma house mouse CVCL_B0TB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33261; Human CYP2C19. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3969 150519744 CVCL_B0TA MAb 1-1-11-1 hybridoma house mouse CVCL_B0TA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33261; Human CYP2C19. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3971 150519745 CVCL_B0T4 1083-17-1A hybridoma house mouse CVCL_B0T4 CL:0000010 Biotechnology: Was used to produce the monoclonal antibody Edrecolomab (Panorex) which was evaluated as a therapeutic agent against stage III colorectal carcinoma Was never approved by FDA but was used in Germany in 1995. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 150519746 CVCL_B0SS DASm244-5B3C3C6 hybridoma house mouse CVCL_B0SS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine; Monoclonal antibody target: ChEBI; CHEBI:174315; Cocaethylene. 150519747 CVCL_B0SR DASm244-5A11H10A4 hybridoma house mouse CVCL_B0SR CL:0000010 Monoclonal antibody isotype: Not determined; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine; Monoclonal antibody target: ChEBI; CHEBI:174315; Cocaethylene. 150519748 CVCL_B0T3 SW1694 cancer cell line human CVCL_B0T3 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 150519749 CVCL_B0T6 48-1 transformed cell line CVCL_B0T6 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgM Group: Non-human primate cell line 150519750 CVCL_B0SU DS2D3 hybridoma house mouse CVCL_B0SU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Bacillus thuringiensis crystal proteins Cry1A to Cry1F. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015145 150519751 CVCL_B0T5 1116-56-2 hybridoma house mouse CVCL_B0T5 CL:0000010 Monoclonal antibody isotype: IgG1. 150519752 CVCL_B0ST M12353 cancer cell line CVCL_B0ST CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver. Male Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015142 150519753 CVCL_B0T8 #132 PL12 SC-D1 hybridoma house mouse CVCL_B0T8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47712; Human PLA3G4A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10563 150519754 CVCL_B0SW 5B8 hybridoma house mouse CVCL_B0SW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13945; Human ADRB3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016202 150519755 CVCL_B0SV 4G7 hybridoma house mouse CVCL_B0SV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13945; Human ADRB3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015147 150519756 CVCL_B0T7 KC-88 hybridoma house mouse CVCL_B0T7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HTLV-1, HTLV-2 (Note=Also bind to STLV-1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10562 150519757 CVCL_B0SY 5D9 [Mouse hybridoma against human ADRB3] hybridoma house mouse CVCL_B0SY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13945; Human ADRB3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016203 150519758 CVCL_B0T9 #132 PC3-1-SC-E8 hybridoma house mouse CVCL_B0T9 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P47712; Human PLA3G4A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10564 150519759 CVCL_B0SX 5D1 hybridoma house mouse CVCL_B0SX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13945; Human ADRB3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015146 150519760 CVCL_B0SK 6H6 [Mouse hybridoma against human THRB] hybridoma house mouse CVCL_B0SK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00734; Human THRB (Note=Recognizes an abnormal form called PIVKA-II). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10541 150519761 CVCL_B0SJ 2H4 [Mouse hybridoma against human THRB] hybridoma house mouse CVCL_B0SJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00734; Human THRB (Note=Recognizes an abnormal form called PIVKA-II). 150519762 CVCL_B0SM COC1501 hybridoma house mouse CVCL_B0SM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015136 150519763 CVCL_B0SL 3C10 [Mouse hybridoma against human THRB] hybridoma house mouse CVCL_B0SL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00734; Human THRB (Note=Recognizes an abnormal form called PIVKA-II). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9638 150519764 CVCL_B0T0 5D3 [Mouse hybridoma against hepatitis B virus HBsAG] hybridoma house mouse CVCL_B0T0 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9801 150519765 CVCL_B0SN GNC92H2 hybridoma house mouse CVCL_B0SN CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma as well as a humanized version are used in immunotherapeutical neutralization studies in rodents and human Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine. 150519766 CVCL_B0SQ DASm244-4D8A4A4 hybridoma house mouse CVCL_B0SQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine; Monoclonal antibody target: ChEBI; CHEBI:174315; Cocaethylene. 150519767 CVCL_B0T2 SW1687 cancer cell line human CVCL_B0T2 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 150519768 CVCL_B0T1 5C11 hybridoma house mouse CVCL_B0T1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8171 150519769 CVCL_B0SP DASm244-3B10D9E3 hybridoma house mouse CVCL_B0SP CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:27958; Cocaine; Monoclonal antibody target: ChEBI; CHEBI:174315; Cocaethylene. 150519770 CVCL_B0SC LCL-IDDM-PI440 transformed cell line human CVCL_B0SC CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519771 CVCL_B0SB LCL-IDDM-PI437 transformed cell line human CVCL_B0SB CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519772 CVCL_B0SE LCL-IDDM-PI444 transformed cell line human CVCL_B0SE CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519773 CVCL_B0SD LCL-IDDM-PI443 transformed cell line human CVCL_B0SD CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519774 CVCL_B0SG LCL-IDDM-PI446 transformed cell line human CVCL_B0SG CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519775 CVCL_B0SF LCL-IDDM-PI445 transformed cell line human CVCL_B0SF CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519776 CVCL_B0SI LCL-IDDM-PI450 transformed cell line human CVCL_B0SI CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519777 CVCL_B0SH LCL-IDDM-PI447 transformed cell line human CVCL_B0SH CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519778 CVCL_B0UA S18-1C3 hybrid cell line human CVCL_B0UA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018189 Problematic cell line: Probably contaminated Grand-parent cell line (CNE-2) has been shown to be a hybrid of HeLa and of cell line of unknown origin. 150519779 CVCL_B0UC SP2/0-02-AREG-SUN hybridoma house mouse CVCL_B0UC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15514; Human AREG. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018214 150519780 CVCL_B0UB S26 hybrid cell line human CVCL_B0UB CL:0000010 Group: Patented cell line Problematic cell line: Probably contaminated Parent cell line (CNE-2) has been shown to be a hybrid of HeLa and of cell line of unknown origin.. 150519781 CVCL_B0TT 3G3 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12615 150519782 CVCL_B0U5 HuS-1 hybridoma house mouse CVCL_B0U5 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P68871; Human HBB (Note=Recognizes Hb S, p.Glu7Val). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8660 150519783 CVCL_B0U4 1G7-2 hybridoma Norway rat CVCL_B0U4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10540 150519784 CVCL_B0TS 3E6 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TS CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. 150519785 CVCL_B0U7 11G7 hybridoma house mouse CVCL_B0U7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60603; Human TLR2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5014 150519786 CVCL_B0TV Ha1-1.16 hybridoma house mouse CVCL_B0TV CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6698 150519787 CVCL_B0TU 4A10 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12617 150519788 CVCL_B0U6 HuS-2 hybridoma house mouse CVCL_B0U6 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P68871; Human HBB (Note=Recognizes Hb S, p.Glu7Val). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8661 150519789 CVCL_B0TX Ha1-4.120 hybridoma house mouse CVCL_B0TX CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6700 150519790 CVCL_B0U9 S18 hybrid cell line human CVCL_B0U9 CL:0000010 Group: Patented cell line Problematic cell line: Probably contaminated Parent cell line (CNE-2) has been shown to be a hybrid of HeLa and of cell line of unknown origin.. 150519791 CVCL_B0U8 8H7 [Mouse hybridoma against A.lucorum EcR-A] hybridoma house mouse CVCL_B0U8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A0K0N8J0; Apolygus lucorum 20-hydroxy-ecdysone receptor (EcR-A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016206 150519792 CVCL_B0TW Ha1-4.117 hybridoma house mouse CVCL_B0TW CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6699 150519793 CVCL_B0TZ Ha1-4.37 hybridoma house mouse CVCL_B0TZ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6702 150519794 CVCL_B0TY Ha1-4.121 hybridoma house mouse CVCL_B0TY CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6701 150519795 CVCL_B0TL MAb 763-15-20 hybridoma house mouse CVCL_B0TL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds to alleles CYP2C9*1, CYP2C9*2 and CYP2C9*3 Also binds CYP2C8).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1078 150519796 CVCL_B0TK MAb 592-2-5 hybridoma house mouse CVCL_B0TK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds to alleles CYP2C9*1, CYP2C9*2, CYP2C9*3 Also binds to CYP2C18).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12646 150519797 CVCL_B0TN 1G8 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12612 150519798 CVCL_B0TM MAb 763-15-5 hybridoma house mouse CVCL_B0TM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds to alleles CYP2C9*1, CYP2C9*2 and CYP2C9*3). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1079 150519799 CVCL_B0U1 20G3-2 hybridoma Norway rat CVCL_B0U1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10541 150519800 CVCL_B0TP 2A2 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12613 150519801 CVCL_B0U0 Ha1-5.99 hybridoma house mouse CVCL_B0U0 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43653; Human PSCA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6703 150519802 CVCL_B0U3 28G12-2 hybridoma Norway rat CVCL_B0U3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10543 150519803 CVCL_B0TR 3C5 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12616 150519804 CVCL_B0U2 24D3-2 hybridoma Norway rat CVCL_B0U2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03375; HIV-1 isolate BH10 env (gp120). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10542 150519805 CVCL_B0TQ 2H9 [Mouse hybridoma against human PSCA] hybridoma house mouse CVCL_B0TQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43653; Human PSCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12614 150519806 CVCL_B0TD MAb 1-7-4-8 hybridoma house mouse CVCL_B0TD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33261; Human CYP2C19. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3970 150519807 CVCL_B0TC MAb 1-68-11 hybridoma house mouse CVCL_B0TC CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds to alleles CYP2C9*1, CYP2C9*2 and CYP2C9*3 Also binds to CYP2C8, CYP2C18 and CYP2C19).. 150519808 CVCL_B0TF MAb 281-1-1 hybridoma house mouse CVCL_B0TF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10632; Human CYP2C8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12648 150519809 CVCL_B0TE MAb 13-1-3 hybridoma house mouse CVCL_B0TE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10632; Human CYP2C8. 150519810 CVCL_B0TH MAb 327-8-3 hybridoma house mouse CVCL_B0TH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds to alleles CYP2C9*1 and CYP2C9*2 Also binds to CYP2C18).. 150519811 CVCL_B0TG MAb 292-2-3 hybridoma house mouse CVCL_B0TG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds and inhibits allele CYP2C9*2). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12645 150519812 CVCL_B0TJ MAb 5-7-5 hybridoma house mouse CVCL_B0TJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11712; Human CYP2C9 (Note=Binds also to CYP2C18 and CYP2C19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12647 150519813 CVCL_B0TI MAb 5-1-5 hybridoma house mouse CVCL_B0TI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10632; Human CYP2C8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12649 150519814 CVCL_B0QY LCL-IDDM-PI287 transformed cell line human CVCL_B0QY CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519815 CVCL_B0QX LCL-IDDM-PI286 transformed cell line human CVCL_B0QX CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519816 CVCL_B0R9 LCL-IDDM-PI298 transformed cell line human CVCL_B0R9 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519817 CVCL_B0QZ LCL-IDDM-PI288 transformed cell line human CVCL_B0QZ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519818 CVCL_B0QQ LCL-IDDM-PI260 transformed cell line human CVCL_B0QQ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519819 CVCL_B0R2 LCL-IDDM-PI291 transformed cell line human CVCL_B0R2 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519820 CVCL_B0QP LCL-IDDM-PI259 transformed cell line human CVCL_B0QP CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519821 CVCL_B0R1 LCL-IDDM-PI290 transformed cell line human CVCL_B0R1 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519822 CVCL_B0QS LCL-IDDM-PI269 transformed cell line human CVCL_B0QS CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519823 CVCL_B0R4 LCL-IDDM-PI293 transformed cell line human CVCL_B0R4 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519824 CVCL_B0QR LCL-IDDM-PI268 transformed cell line human CVCL_B0QR CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519825 CVCL_B0R3 LCL-IDDM-PI292 transformed cell line human CVCL_B0R3 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519826 CVCL_B0QU LCL-IDDM-PI271 transformed cell line human CVCL_B0QU CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519827 CVCL_B0R6 LCL-IDDM-PI295 transformed cell line human CVCL_B0R6 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519828 CVCL_B0QT LCL-IDDM-PI270 transformed cell line human CVCL_B0QT CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519829 CVCL_B0R5 LCL-IDDM-PI294 transformed cell line human CVCL_B0R5 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519830 CVCL_B0QW LCL-IDDM-PI285 transformed cell line human CVCL_B0QW CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519831 CVCL_B0R8 LCL-IDDM-PI297 transformed cell line human CVCL_B0R8 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519832 CVCL_B0QV LCL-IDDM-PI284 transformed cell line human CVCL_B0QV CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519833 CVCL_B0R7 LCL-IDDM-PI296 transformed cell line human CVCL_B0R7 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519834 CVCL_B0QI LCL-PI 186 transformed cell line human CVCL_B0QI CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519835 CVCL_B0QH LCL-PI 90 transformed cell line human CVCL_B0QH CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519836 CVCL_B0QK LCL-PI 201 transformed cell line human CVCL_B0QK CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519837 CVCL_B0QJ LCL-PI 196 transformed cell line human CVCL_B0QJ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519838 CVCL_B0QM LCL-PI 205 transformed cell line human CVCL_B0QM CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519839 CVCL_B0QL LCL-PI 202 transformed cell line human CVCL_B0QL CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519840 CVCL_B0R0 LCL-IDDM-PI289 transformed cell line human CVCL_B0R0 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519841 CVCL_B0QN LCL-IDDM-PI258 transformed cell line human CVCL_B0QN CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519842 CVCL_B0QA LCL-PI 24 transformed cell line human CVCL_B0QA CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519843 CVCL_B0QC LCL-PI 44 transformed cell line human CVCL_B0QC CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519844 CVCL_B0QB LCL-PI 43 transformed cell line human CVCL_B0QB CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519845 CVCL_B0QE LCL-PI 54 [From CVI female patient] transformed cell line human CVCL_B0QE CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Caution: There seem to be two distinct cell lines which were assigned by NCBI_Iran the name LCL-PI 54 150519846 CVCL_B0QD LCL-PI 50 transformed cell line human CVCL_B0QD CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519847 CVCL_B0QG LCL-PI 69 transformed cell line human CVCL_B0QG CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519848 CVCL_B0QF LCL-PI 64 transformed cell line human CVCL_B0QF CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519849 CVCL_B0RZ LCL-IDDM-PI323 transformed cell line human CVCL_B0RZ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519850 CVCL_B0RY LCL-IDDM-PI322 transformed cell line human CVCL_B0RY CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519851 CVCL_B0SA LCL-IDDM-PI427 transformed cell line human CVCL_B0SA CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519852 CVCL_B0RR LCL-IDDM-PI315 transformed cell line human CVCL_B0RR CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519853 CVCL_B0S3 LCL-IDDM-PI327 transformed cell line human CVCL_B0S3 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519854 CVCL_B0RQ LCL-IDDM-PI314 transformed cell line human CVCL_B0RQ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519855 CVCL_B0S2 LCL-IDDM-PI326 transformed cell line human CVCL_B0S2 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519856 CVCL_B0RT LCL-IDDM-PI317 transformed cell line human CVCL_B0RT CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519857 CVCL_B0S5 LCL-IDDM-PI329 transformed cell line human CVCL_B0S5 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519858 CVCL_B0RS LCL-IDDM-PI316 transformed cell line human CVCL_B0RS CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519859 CVCL_B0S4 LCL-IDDM-PI328 transformed cell line human CVCL_B0S4 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519860 CVCL_B0RV LCL-IDDM-PI319 transformed cell line human CVCL_B0RV CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519861 CVCL_B0S7 LCL-IDDM-PI401 transformed cell line human CVCL_B0S7 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519862 CVCL_B0RU LCL-IDDM-PI318 transformed cell line human CVCL_B0RU CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519863 CVCL_B0S6 LCL-IDDM-PI330 transformed cell line human CVCL_B0S6 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519864 CVCL_B0RX LCL-IDDM-PI321 transformed cell line human CVCL_B0RX CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519865 CVCL_B0S9 LCL-IDDM-PI421 transformed cell line human CVCL_B0S9 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519866 CVCL_B0RW LCL-IDDM-PI320 transformed cell line human CVCL_B0RW CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519867 CVCL_B0S8 LCL-IDDM-PI331 transformed cell line human CVCL_B0S8 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519868 CVCL_B0RJ LCL-IDDM-PI308 transformed cell line human CVCL_B0RJ CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519869 CVCL_B0RI LCL-IDDM-PI307 transformed cell line human CVCL_B0RI CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519870 CVCL_B0RL LCL-IDDM-PI310 transformed cell line human CVCL_B0RL CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519871 CVCL_B0RK LCL-IDDM-PI309 transformed cell line human CVCL_B0RK CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519872 CVCL_B0RN LCL-IDDM-PI312 transformed cell line human CVCL_B0RN CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519873 CVCL_B0RM LCL-IDDM-PI311 transformed cell line human CVCL_B0RM CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519874 CVCL_B0RP LCL-IDDM-PI313 transformed cell line human CVCL_B0RP CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519875 CVCL_B0S1 LCL-IDDM-PI325 transformed cell line human CVCL_B0S1 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519876 CVCL_B0S0 LCL-IDDM-PI324 transformed cell line human CVCL_B0S0 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519877 CVCL_B0RB LCL-IDDM-PI300 transformed cell line human CVCL_B0RB CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519878 CVCL_B0RA LCL-IDDM-PI299 transformed cell line human CVCL_B0RA CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519879 CVCL_B0RD LCL-IDDM-PI302 transformed cell line human CVCL_B0RD CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519880 CVCL_B0RC LCL-IDDM-PI301 transformed cell line human CVCL_B0RC CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519881 CVCL_B0RF LCL-IDDM-PI304 transformed cell line human CVCL_B0RF CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519882 CVCL_B0RE LCL-IDDM-PI303 transformed cell line human CVCL_B0RE CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 150519883 CVCL_B0RH LCL-IDDM-PI306 transformed cell line human CVCL_B0RH CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519884 CVCL_B0RG LCL-IDDM-PI305 transformed cell line human CVCL_B0RG CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 150519885 CVCL_W450 MMJ-2 cancer cell line human CVCL_W450 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 12-15 hours, at 6th passage (PubMed=8652447) 151357216 CVCL_B3EJ Abcam HEK293T PPP2R1B KO transformed cell line human CVCL_B3EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9303; PPP2R1B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357217 CVCL_B3EI Abcam HEK293T PPP1R16A KO transformed cell line human CVCL_B3EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14941; PPP1R16A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357218 CVCL_B3EL Abcam HEK293T PPP4R2 KO transformed cell line human CVCL_B3EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18296; PPP4R2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357219 CVCL_B3EK Abcam HEK293T PPP2R5C KO transformed cell line human CVCL_B3EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9311; PPP2R5C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357220 CVCL_B3EN Abcam HEK293T PPP6R1 KO transformed cell line human CVCL_B3EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29195; PPP6R1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357221 CVCL_B3EM Abcam HEK293T PPP5C KO transformed cell line human CVCL_B3EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9322; PPP5C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357222 CVCL_B3EP Abcam HEK293T PQBP1 KO transformed cell line human CVCL_B3EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9330; PQBP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357223 CVCL_B3F1 Abcam HEK293T PRPS1 KO transformed cell line human CVCL_B3F1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9462; PRPS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357224 CVCL_B3F0 Abcam HEK293T PRPF4B KO transformed cell line human CVCL_B3F0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17346; PRPF4B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357225 CVCL_B3EB Abcam HEK293T POU4F2 KO transformed cell line human CVCL_B3EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9219; POU4F2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357226 CVCL_B3EA Abcam HEK293T POP5 KO transformed cell line human CVCL_B3EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17689; POP5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357227 CVCL_B3ED Abcam HEK293T PPIF KO transformed cell line human CVCL_B3ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9259; PPIF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357228 CVCL_B3EC Abcam HEK293T PPHLN1 KO transformed cell line human CVCL_B3EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19369; PPHLN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357229 CVCL_B3EF Abcam HEK293T PPM1B KO transformed cell line human CVCL_B3EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9276; PPM1B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357230 CVCL_B3EE Abcam HEK293T PPIH KO transformed cell line human CVCL_B3EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14651; PPIH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357231 CVCL_B3EH Abcam HEK293T PPM1G KO transformed cell line human CVCL_B3EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9278; PPM1G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357232 CVCL_B3EG Abcam HEK293T PPM1F KO transformed cell line human CVCL_B3EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19388; PPM1F; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357233 CVCL_B3DY Abcam HEK293T PKN1 KO transformed cell line human CVCL_B3DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9405; PKN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357234 CVCL_B3DX Abcam HEK293T PIP5K1A KO transformed cell line human CVCL_B3DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8994; PIP5K1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357235 CVCL_B3E9 Abcam HEK293T POMK KO transformed cell line human CVCL_B3E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26267; POMK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357236 CVCL_B3DZ Abcam HEK293T PLCG1 KO transformed cell line human CVCL_B3DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357237 CVCL_B3DQ Abcam HEK293T PEA15 KO transformed cell line human CVCL_B3DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8822; PEA15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357238 CVCL_B3E2 Abcam HEK293T PLEKHJ1 KO transformed cell line human CVCL_B3E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18211; PLEKHJ1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357239 CVCL_B3DP Abcam HEK293T PDXK KO transformed cell line human CVCL_B3DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8819; PDXK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357240 CVCL_B3E1 Abcam HEK293T PLD6 KO transformed cell line human CVCL_B3E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30447; PLD6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357241 CVCL_B3DS Abcam HEK293T PHF23 KO transformed cell line human CVCL_B3DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28428; PHF23; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357242 CVCL_B3E4 Abcam HEK293T PLOD3 KO transformed cell line human CVCL_B3E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9083; PLOD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357243 CVCL_B3DR Abcam HEK293T PEX5 KO transformed cell line human CVCL_B3DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9719; PEX5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357244 CVCL_B3E3 Abcam HEK293T PLOD2 KO transformed cell line human CVCL_B3E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9082; PLOD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357245 CVCL_B3DU Abcam HEK293T PIGT KO transformed cell line human CVCL_B3DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14938; PIGT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357246 CVCL_B3E6 Abcam HEK293T PNP KO transformed cell line human CVCL_B3E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7892; PNP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357247 CVCL_B3DT Abcam HEK293T PHKA1 KO transformed cell line human CVCL_B3DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8925; PHKA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357248 CVCL_B3E5 Abcam HEK293T PLS3 KO transformed cell line human CVCL_B3E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9091; PLS3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357249 CVCL_B3DW Abcam HEK293T PINK1 KO transformed cell line human CVCL_B3DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357250 CVCL_B3E8 Abcam HEK293T POMGNT1 KO transformed cell line human CVCL_B3E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19139; POMGNT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357251 CVCL_B3DV Abcam HEK293T PIK3R2 KO transformed cell line human CVCL_B3DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357252 CVCL_B3E7 Abcam HEK293T POLE3 KO transformed cell line human CVCL_B3E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13546; POLE3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357253 CVCL_B3FK Abcam HEK293T RAB1A KO transformed cell line human CVCL_B3FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9758; RAB1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357254 CVCL_B3FJ Abcam HEK293T RAB14 KO transformed cell line human CVCL_B3FJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16524; RAB14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357255 CVCL_B3FM Abcam HEK293T RAB2A KO transformed cell line human CVCL_B3FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9763; RAB2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357256 CVCL_B3FL Abcam HEK293T RAB1B KO transformed cell line human CVCL_B3FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18370; RAB1B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357257 CVCL_B3G0 Abcam HEK293T RHOA KO transformed cell line human CVCL_B3G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 667; RHOA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357258 CVCL_B3FN Abcam HEK293T RAB5IF KO transformed cell line human CVCL_B3FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15870; RAB5IF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357259 CVCL_B3FQ Abcam HEK293T RAD23A KO transformed cell line human CVCL_B3FQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9812; RAD23A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357260 CVCL_B3G2 Abcam HEK293T RNASEH2A KO transformed cell line human CVCL_B3G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18518; RNASEH2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357261 CVCL_B3FP Abcam HEK293T RAB6A KO transformed cell line human CVCL_B3FP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9786; RAB6A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357262 CVCL_B3G1 Abcam HEK293T RHOG KO transformed cell line human CVCL_B3G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 672; RHOG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357263 CVCL_B3FC Abcam HEK293T PTPRF KO transformed cell line human CVCL_B3FC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9670; PTPRF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357264 CVCL_B3FB Abcam HEK293T PTPN11 KO transformed cell line human CVCL_B3FB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9644; PTPN11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357265 CVCL_B3FE Abcam HEK293T PUS1 KO transformed cell line human CVCL_B3FE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15508; PUS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357266 CVCL_B3FD Abcam HEK293T PTRH2 KO transformed cell line human CVCL_B3FD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24265; PTRH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266715; true Female 151357267 CVCL_B3FG Abcam HEK293T PXK KO transformed cell line human CVCL_B3FG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23326; PXK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357268 CVCL_B3FF Abcam HEK293T PVR KO transformed cell line human CVCL_B3FF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9705; PVR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357269 CVCL_B3FI Abcam HEK293T RAB13 KO transformed cell line human CVCL_B3FI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9762; RAB13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357270 CVCL_B3FH Abcam HEK293T PYM1 KO transformed cell line human CVCL_B3FH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30258; PYM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357271 CVCL_B3EZ Abcam HEK293T PRKRA KO transformed cell line human CVCL_B3EZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9438; PRKRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357272 CVCL_B3EY Abcam HEK293T PRKCZ KO 2 transformed cell line human CVCL_B3EY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9412; PRKCZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266681; true Female 151357273 CVCL_B3FA Abcam HEK293T PTK2 KO transformed cell line human CVCL_B3FA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9611; PTK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357274 CVCL_B3ER Abcam HEK293T PRDX1 KO transformed cell line human CVCL_B3ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357275 CVCL_B3F3 Abcam HEK293T PSAT1 KO transformed cell line human CVCL_B3F3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19129; PSAT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357276 CVCL_B3EQ Abcam HEK293T PRCC KO transformed cell line human CVCL_B3EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9343; PRCC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357277 CVCL_B3F2 Abcam HEK293T PRRC2B KO transformed cell line human CVCL_B3F2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28121; PRRC2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357278 CVCL_B3ET Abcam HEK293T PRDX4 KO transformed cell line human CVCL_B3ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17169; PRDX4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357279 CVCL_B3F5 Abcam HEK293T PSMD8 KO transformed cell line human CVCL_B3F5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9566; PSMD8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357280 CVCL_B3ES Abcam HEK293T PRDX2 KO transformed cell line human CVCL_B3ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9353; PRDX2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357281 CVCL_B3F4 Abcam HEK293T PSIP1 KO transformed cell line human CVCL_B3F4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9527; PSIP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357282 CVCL_B3EV Abcam HEK293T PRKCD KO transformed cell line human CVCL_B3EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9399; PRKCD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357283 CVCL_B3F7 Abcam HEK293T PSME3 KO transformed cell line human CVCL_B3F7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9570; PSME3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357284 CVCL_B3EU Abcam HEK293T PREP KO transformed cell line human CVCL_B3EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357285 CVCL_B3F6 Abcam HEK293T PSME1 KO transformed cell line human CVCL_B3F6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9568; PSME1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357286 CVCL_B3EX Abcam HEK293T PRKCZ KO 1 transformed cell line human CVCL_B3EX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9412; PRKCZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab265073; true Female 151357287 CVCL_B3F9 Abcam HEK293T PTGES3 KO transformed cell line human CVCL_B3F9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16049; PTGES3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357288 CVCL_B3EW Abcam HEK293T PRKCSH KO transformed cell line human CVCL_B3EW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9411; PRKCSH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357289 CVCL_B3F8 Abcam HEK293T PTDSS1 KO transformed cell line human CVCL_B3F8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9587; PTDSS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357290 CVCL_B3CH Abcam HEK293T NME4 KO 2 transformed cell line human CVCL_B3CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7852; NME4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357291 CVCL_B3CG Abcam HEK293T NME4 KO 1 transformed cell line human CVCL_B3CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7852; NME4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357292 CVCL_B3CJ Abcam HEK293T NOL7 KO transformed cell line human CVCL_B3CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21040; NOL7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357293 CVCL_B3CI Abcam HEK293T NME6 KO transformed cell line human CVCL_B3CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20567; NME6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357294 CVCL_B3CL Abcam HEK293T NOSIP KO transformed cell line human CVCL_B3CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17946; NOSIP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357295 CVCL_B3CK Abcam HEK293T NONO KO transformed cell line human CVCL_B3CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7871; NONO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357296 CVCL_B3CN Abcam HEK293T NPM3 KO transformed cell line human CVCL_B3CN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7931; NPM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357297 CVCL_B3CM Abcam HEK293T NPC2 KO transformed cell line human CVCL_B3CM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14537; NPC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357298 CVCL_B3CB Abcam HEK293T NFATC3 KO transformed cell line human CVCL_B3CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7777; NFATC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357299 CVCL_B3CA Abcam HEK293T NEIL1 KO 2 transformed cell line human CVCL_B3CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18448; NEIL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357300 CVCL_B3CD Abcam HEK293T NIBAN2 KO transformed cell line human CVCL_B3CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25282; NIBAN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357301 CVCL_B3CC Abcam HEK293T NFE2L1 KO transformed cell line human CVCL_B3CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7781; NFE2L1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357302 CVCL_B3CF Abcam HEK293T NME1 KO transformed cell line human CVCL_B3CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7849; NME1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357303 CVCL_B3CE Abcam HEK293T NIT2 KO transformed cell line human CVCL_B3CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29878; NIT2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357304 CVCL_B3BW Abcam HEK293T NCAPG2 KO transformed cell line human CVCL_B3BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21904; NCAPG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357305 CVCL_B3C8 Abcam HEK293T NEFM KO transformed cell line human CVCL_B3C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7734; NEFM; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357306 CVCL_B3BV Abcam HEK293T NASP KO transformed cell line human CVCL_B3BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7644; NASP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357307 CVCL_B3C7 Abcam HEK293T NDUFV1 KO transformed cell line human CVCL_B3C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7716; NDUFV1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357308 CVCL_B3BY Abcam HEK293T NCSTN KO transformed cell line human CVCL_B3BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17091; NCSTN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357309 CVCL_B3BX Abcam HEK293T NCOA2 KO transformed cell line human CVCL_B3BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7669; NCOA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357310 CVCL_B3C9 Abcam HEK293T NEIL1 KO 1 transformed cell line human CVCL_B3C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18448; NEIL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357311 CVCL_B3BZ Abcam HEK293T NDRG1 KO transformed cell line human CVCL_B3BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7679; NDRG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357312 CVCL_B3C0 Abcam HEK293T NDUFA11 KO transformed cell line human CVCL_B3C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20371; NDUFA11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357313 CVCL_B3BN Abcam HEK293T MYL6B KO transformed cell line human CVCL_B3BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29823; MYL6B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357314 CVCL_B3BQ Abcam HEK293T MZT2B KO transformed cell line human CVCL_B3BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25886; MZT2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357315 CVCL_B3C2 Abcam HEK293T NDUFA7 KO transformed cell line human CVCL_B3C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7691; NDUFA7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357316 CVCL_B3BP Abcam HEK293T MYSM1 KO transformed cell line human CVCL_B3BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29401; MYSM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357317 CVCL_B3C1 Abcam HEK293T NDUFA4 KO transformed cell line human CVCL_B3C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7687; NDUFA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357318 CVCL_B3BS Abcam HEK293T NACA KO transformed cell line human CVCL_B3BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7629; NACA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357319 CVCL_B3C4 Abcam HEK293T NDUFB1 KO transformed cell line human CVCL_B3C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7695; NDUFB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357320 CVCL_B3BR Abcam HEK293T NABP2 KO transformed cell line human CVCL_B3BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28412; NABP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357321 CVCL_B3C3 Abcam HEK293T NDUFAF8 KO transformed cell line human CVCL_B3C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33551; NDUFAF8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357322 CVCL_B3BU Abcam HEK293T NANS KO transformed cell line human CVCL_B3BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19237; NANS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357323 CVCL_B3C6 Abcam HEK293T NDUFS3 KO transformed cell line human CVCL_B3C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7710; NDUFS3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357324 CVCL_B3BT Abcam HEK293T NADK KO transformed cell line human CVCL_B3BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29831; NADK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357325 CVCL_B3C5 Abcam HEK293T NDUFC1 KO transformed cell line human CVCL_B3C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7705; NDUFC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357326 CVCL_B3DI Abcam HEK293T PCBD1 KO transformed cell line human CVCL_B3DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8646; PCBD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357327 CVCL_B3DH Abcam HEK293T PBK KO transformed cell line human CVCL_B3DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357328 CVCL_B3DK Abcam HEK293T PCNP KO transformed cell line human CVCL_B3DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30023; PCNP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357329 CVCL_B3DJ Abcam HEK293T PCCB KO transformed cell line human CVCL_B3DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8654; PCCB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357330 CVCL_B3DM Abcam HEK293T PDAP1 KO transformed cell line human CVCL_B3DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14634; PDAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357331 CVCL_B3DL Abcam HEK293T PCNT KO transformed cell line human CVCL_B3DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16068; PCNT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357332 CVCL_B3E0 Abcam HEK293T PLD3 KO transformed cell line human CVCL_B3E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17158; PLD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357333 CVCL_B3DN Abcam HEK293T PDCD6 KO transformed cell line human CVCL_B3DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8765; PDCD6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357334 CVCL_B3DA Abcam HEK293T PAK4 KO transformed cell line human CVCL_B3DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357335 CVCL_B3DC Abcam HEK293T PAPOLA KO transformed cell line human CVCL_B3DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14981; PAPOLA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357336 CVCL_B3DB Abcam HEK293T PANK4 KO transformed cell line human CVCL_B3DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19366; PANK4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357337 CVCL_B3DE Abcam HEK293T PARL KO transformed cell line human CVCL_B3DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18253; PARL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357338 CVCL_B3DD Abcam HEK293T PARK7 KO transformed cell line human CVCL_B3DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16369; PARK7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357339 CVCL_B3DG Abcam HEK293T PARP2 KO transformed cell line human CVCL_B3DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357340 CVCL_B3DF Abcam HEK293T PARP1 KO transformed cell line human CVCL_B3DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357341 CVCL_B3CX Abcam HEK293T NTPCR KO transformed cell line human CVCL_B3CX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28204; NTPCR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357342 CVCL_B3D9 Abcam HEK293T PAIP2 KO transformed cell line human CVCL_B3D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17970; PAIP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357343 CVCL_B3CW Abcam HEK293T NT5C KO transformed cell line human CVCL_B3CW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17144; NT5C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357344 CVCL_B3D8 Abcam HEK293T PAFAH1B3 KO transformed cell line human CVCL_B3D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8576; PAFAH1B3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357345 CVCL_B3CZ Abcam HEK293T NUDT1 KO transformed cell line human CVCL_B3CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8048; NUDT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357346 CVCL_B3CY Abcam HEK293T NUCKS1 KO transformed cell line human CVCL_B3CY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29923; NUCKS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357347 CVCL_B3CP Abcam HEK293T NPTN KO transformed cell line human CVCL_B3CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17867; NPTN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357348 CVCL_B3D1 Abcam HEK293T NUP210 KO transformed cell line human CVCL_B3D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30052; NUP210; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357349 CVCL_B3D0 Abcam HEK293T NUDT5 KO transformed cell line human CVCL_B3D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8052; NUDT5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357350 CVCL_B3CR Abcam HEK293T NRAS KO transformed cell line human CVCL_B3CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357351 CVCL_B3D3 Abcam HEK293T OCIAD1 KO transformed cell line human CVCL_B3D3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16074; OCIAD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357352 CVCL_B3CQ Abcam HEK293T NR2C2 KO transformed cell line human CVCL_B3CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7972; NR2C2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357353 CVCL_B3D2 Abcam HEK293T OAZ1 KO transformed cell line human CVCL_B3D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8095; OAZ1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357354 CVCL_B3CT Abcam HEK293T NSD1 KO transformed cell line human CVCL_B3CT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14234; NSD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357355 CVCL_B3D5 Abcam HEK293T OTUB1 KO transformed cell line human CVCL_B3D5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23077; OTUB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357356 CVCL_B3CS Abcam HEK293T NRDC KO transformed cell line human CVCL_B3CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7995; NRDC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357357 CVCL_B3D4 Abcam HEK293T OSTC KO transformed cell line human CVCL_B3D4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24448; OSTC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357358 CVCL_B3CV Abcam HEK293T NSUN2 KO transformed cell line human CVCL_B3CV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25994; NSUN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357359 CVCL_B3D7 Abcam HEK293T PACSIN3 KO transformed cell line human CVCL_B3D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8572; PACSIN3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357360 CVCL_B3CU Abcam HEK293T NSDHL KO transformed cell line human CVCL_B3CU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13398; NSDHL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357361 CVCL_B3D6 Abcam HEK293T OXA1L KO transformed cell line human CVCL_B3D6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8526; OXA1L; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357362 CVCL_B3AF Abcam HEK293T LYPLA2 KO transformed cell line human CVCL_B3AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6738; LYPLA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357363 CVCL_B3AE Abcam HEK293T LYPLA1 KO transformed cell line human CVCL_B3AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6737; LYPLA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357364 CVCL_B3AH Abcam HEK293T MACROH2A1 KO transformed cell line human CVCL_B3AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4740; MACROH2A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357365 CVCL_B3AG Abcam HEK293T M6PR KO transformed cell line human CVCL_B3AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6752; M6PR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266668; true Female 151357366 CVCL_B3AJ Abcam HEK293T MAP2K2 KO transformed cell line human CVCL_B3AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357367 CVCL_B3AI Abcam HEK293T MAF1 KO transformed cell line human CVCL_B3AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24966; MAF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357368 CVCL_B3AL Abcam HEK293T MAP3K7 KO transformed cell line human CVCL_B3AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6859; MAP3K7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357369 CVCL_B3AK Abcam HEK293T MAP3K10 KO transformed cell line human CVCL_B3AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6849; MAP3K10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357370 CVCL_B3AB Abcam HEK293T LRRC59 KO transformed cell line human CVCL_B3AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28817; LRRC59; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357371 CVCL_B3AA Abcam HEK293T LRP5 KO transformed cell line human CVCL_B3AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357372 CVCL_B3AD Abcam HEK293T LUC7L2 KO transformed cell line human CVCL_B3AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21608; LUC7L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357373 CVCL_B3AC Abcam HEK293T LTA4H KO transformed cell line human CVCL_B3AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6710; LTA4H; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357374 CVCL_B3A6 Abcam HEK293T LIN28B KO transformed cell line human CVCL_B3A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32207; LIN28B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357375 CVCL_B3A5 Abcam HEK293T LGALS1 KO transformed cell line human CVCL_B3A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6561; LGALS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357376 CVCL_B3A8 Abcam HEK293T LMAN2 KO transformed cell line human CVCL_B3A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16986; LMAN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357377 CVCL_B3A7 Abcam HEK293T LMAN1 KO transformed cell line human CVCL_B3A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6631; LMAN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357378 CVCL_B3A9 Abcam HEK293T LPAR3 KO transformed cell line human CVCL_B3A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14298; LPAR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357379 CVCL_B3A0 Abcam HEK293T LAMTOR4 KO transformed cell line human CVCL_B3A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33772; LAMTOR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357380 CVCL_B3A2 Abcam HEK293T LARP1 KO transformed cell line human CVCL_B3A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29531; LARP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266295; true Female 151357381 CVCL_B3A1 Abcam HEK293T LAPTM4A KO transformed cell line human CVCL_B3A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6924; LAPTM4A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357382 CVCL_B3A4 Abcam HEK293T LDHB KO transformed cell line human CVCL_B3A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6541; LDHB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357383 CVCL_B3A3 Abcam HEK293T LBR KO transformed cell line human CVCL_B3A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6518; LBR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357384 CVCL_B3BG Abcam HEK293T MTMR4 KO transformed cell line human CVCL_B3BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7452; MTMR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357385 CVCL_B3BF Abcam HEK293T MTHFD2 KO transformed cell line human CVCL_B3BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7434; MTHFD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357386 CVCL_B3BI Abcam HEK293T MTR KO transformed cell line human CVCL_B3BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7468; MTR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357387 CVCL_B3BH Abcam HEK293T MTOR KO transformed cell line human CVCL_B3BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3942; MTOR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357388 CVCL_B3BK Abcam HEK293T MTRNR2L8 KO transformed cell line human CVCL_B3BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37165; MTRNR2L8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357389 CVCL_B3BJ Abcam HEK293T MTRNR2L1 KO transformed cell line human CVCL_B3BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37155; MTRNR2L1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357390 CVCL_B3BM Abcam HEK293T MYC KO transformed cell line human CVCL_B3BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357391 CVCL_B3BL Abcam HEK293T MTX1 KO transformed cell line human CVCL_B3BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7504; MTX1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357392 CVCL_B3BA Abcam HEK293T MRPL50 KO transformed cell line human CVCL_B3BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16654; MRPL50; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357393 CVCL_B3BC Abcam HEK293T MT2A KO transformed cell line human CVCL_B3BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7406; MT2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266538; true Female 151357394 CVCL_B3BB Abcam HEK293T MRPS28 KO transformed cell line human CVCL_B3BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14513; MRPS28; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357395 CVCL_B3BE Abcam HEK293T MTHFD1L KO transformed cell line human CVCL_B3BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21055; MTHFD1L; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357396 CVCL_B3BD Abcam HEK293T MTCH2 KO transformed cell line human CVCL_B3BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17587; MTCH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357397 CVCL_B3AV Abcam HEK293T MATK KO transformed cell line human CVCL_B3AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6906; MATK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266171; true Female 151357398 CVCL_B3B7 Abcam HEK293T MPST KO transformed cell line human CVCL_B3B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7223; MPST; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357399 CVCL_B3AU Abcam HEK293T MAT2B KO transformed cell line human CVCL_B3AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6905; MAT2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357400 CVCL_B3B6 Abcam HEK293T MPP2 KO transformed cell line human CVCL_B3B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7220; MPP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357401 CVCL_B3AX Abcam HEK293T MDH2 KO transformed cell line human CVCL_B3AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6971; MDH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357402 CVCL_B3B9 Abcam HEK293T MRPL2 KO transformed cell line human CVCL_B3B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14056; MRPL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357403 CVCL_B3AW Abcam HEK293T MCL1 KO transformed cell line human CVCL_B3AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6943; MCL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357404 CVCL_B3B8 Abcam HEK293T MRFAP1 KO transformed cell line human CVCL_B3B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24549; MRFAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357405 CVCL_B3AZ Abcam HEK293T MEX3B KO transformed cell line human CVCL_B3AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25297; MEX3B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357406 CVCL_B3AY Abcam HEK293T MEA1 KO transformed cell line human CVCL_B3AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6986; MEA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357407 CVCL_B3AN Abcam HEK293T MAPK12 KO transformed cell line human CVCL_B3AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6874; MAPK12; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357408 CVCL_B3AM Abcam HEK293T MAP7D1 KO transformed cell line human CVCL_B3AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25514; MAP7D1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357409 CVCL_B3AP Abcam HEK293T MAPK14 KO transformed cell line human CVCL_B3AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357410 CVCL_B3B1 Abcam HEK293T MKNK2 KO transformed cell line human CVCL_B3B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7111; MKNK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357411 CVCL_B3B0 Abcam HEK293T MIX23 KO transformed cell line human CVCL_B3B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31136; MIX23; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357412 CVCL_B3AR Abcam HEK293T MAPK8IP1 KO transformed cell line human CVCL_B3AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6882; MAPK8IP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357413 CVCL_B3B3 Abcam HEK293T MMADHC KO transformed cell line human CVCL_B3B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25221; MMADHC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357414 CVCL_B3AQ Abcam HEK293T MAPK3 KO transformed cell line human CVCL_B3AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6877; MAPK3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357415 CVCL_B3B2 Abcam HEK293T MKRN1 KO transformed cell line human CVCL_B3B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7112; MKRN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357416 CVCL_B3AT Abcam HEK293T MAPKAPK5 KO transformed cell line human CVCL_B3AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6889; MAPKAPK5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357417 CVCL_B3B5 Abcam HEK293T MPP1 KO transformed cell line human CVCL_B3B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7219; MPP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357418 CVCL_B3AS Abcam HEK293T MAPK9 KO transformed cell line human CVCL_B3AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6886; MAPK9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357419 CVCL_B3B4 Abcam HEK293T MPDU1 KO transformed cell line human CVCL_B3B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7207; MPDU1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357420 CVCL_B3MR CHIpMSC3 somatic stem cell human CVCL_B3MR CL:0000010 Sequence variation: Mutation; HGNC; 59; ABCC8; Simple; p.Arg1493Gln (c.4478G>A) (R1494Q); ClinVar=VCV000370910; Zygosity=Homozygous (PubMed=31525223) Derived from sampling site: Pancreas Cell type=Mesenchymal stem cell.. Male 151357421 CVCL_B3N3 Sua-5B-IE8-Act::Cas9-2A-Neo spontaneously immortalized cell line CVCL_B3N3 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: Suakoko 2La. Unspecified Characteristics: Modified using a Minos mediated integration cassette (MiMIC) to deliver a recombination-mediated cassette (RMCE) acceptor, to add a docking site for recombination via the bacteriophage FC31 integrase; Characteristics: A N-3xFLAG-spCas9-T2A-Neo/Kan R construct was integrated in the Act5C locus Doubling time: ~20 hours (DGRC) Group: Insect cell line 151357422 CVCL_B3MQ CHIpMSC1 somatic stem cell human CVCL_B3MQ CL:0000010 Sequence variation: Mutation; HGNC; 59; ABCC8; Simple; p.Gly316Arg (c.1016G>A); Zygosity=Heterozygous (PubMed=31525223) Derived from sampling site: Pancreas Cell type=Mesenchymal stem cell.. Male 151357423 CVCL_B3N2 Sua-5B-IE8 spontaneously immortalized cell line CVCL_B3N2 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Suakoko 2La. Unspecified Characteristics: Modified using a Minos mediated integration cassette (MiMIC) to deliver a recombination-mediated cassette (RMCE) acceptor, to add a docking site for recombination via the bacteriophage FC31 integrase Doubling time: ~20 hours (DGRC) Group: Insect cell line 151357424 CVCL_B3N5 C6/36-HE8 spontaneously immortalized cell line CVCL_B3N5 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Unspecified Characteristics: Modified using a Minos mediated integration cassette (MiMIC) to deliver a recombination-mediated cassette (RMCE) acceptor, to add a docking site for recombination via the bacteriophage FC31 integrase Doubling time: ~24 hours (DGRC) Group: Insect cell line 151357425 CVCL_B3MT NCKDi003-A induced pluripotent stem cell human CVCL_B3MT From: National Center of Kidney Diseases; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 2023; CLCN5; Simple; p.Thr347Pro (c.1042A>C) (p.Thr277Pro, c.829A>C); Zygosity=Unspecified (PubMed=34547705) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female Caution: Mutation indicated as hemizygous in title of PubMed=34547705 but this cell line is from a normal X,X female patient so it can't be hemizygous 151357426 CVCL_B3MS JEI-001 telomerase immortalized cell line human CVCL_B3MS CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; c.515delG; Zygosity=Heterozygous (PubMed=34539995); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Peripheral nervous system; vestibular nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by RNAseq Male 151357427 CVCL_B3N4 NAMRU2-CQ-01-1.7 spontaneously immortalized cell line CVCL_B3N4 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Ovary. Female Characteristics: Modified using a Minos mediated integration cassette (MiMIC) to deliver a recombination-mediated cassette (RMCE) acceptor, to add a docking site for recombination via the bacteriophage FC31 integrase Doubling time: ~24 hours (DGRC) Group: Insect cell line 151357428 CVCL_B3MV 1C8 [Mouse hybridoma against N.fowleri NfCPB-L] hybridoma house mouse CVCL_B3MV CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; X5D911; Naegleria fowleri cathepsin B-like (NfCPB-L). 151357429 CVCL_B3N7 btl>Ras attP-L3 spontaneously immortalized cell line fruit fly CVCL_B3N7 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Characteristics: btl-Gal4 driving UAS-RasV12 and UAS-p35 (baculovirus anti-apoptotic factor p35) with an attP flanked cassette for RMCE Group: Insect cell line 151357430 CVCL_B3N6 BPT-1 spontaneously immortalized cell line CVCL_B3N6 CL:0000010 Derived from sampling site: Trophectoderm. Female Doubling time: ~96 hours (PubMed=15293218) 151357431 CVCL_B3MU SDPHi001-A induced pluripotent stem cell human CVCL_B3MU From: Shandong Provincial Hospital Affiliated to Shandong First Medical University; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 151357432 CVCL_B3MX 2C9 [Mouse hybridoma against N.fowleri NfCPB] hybridoma house mouse CVCL_B3MX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; X5D761; Naegleria fowleri cathepsin B (NfCPB). 151357433 CVCL_B3N9 ENTZ HLC 2 cancer cell line human CVCL_B3N9 CL:0000010 Derived from sampling site: Larynx. Unspecified 151357434 CVCL_B3MW 1D9 [Mouse hybridoma against N.fowleri NfCPB-L] hybridoma house mouse CVCL_B3MW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; X5D911; Naegleria fowleri cathepsin B-like (NfCPB-L). 151357435 CVCL_B3N8 ENTZ HLC 1 cancer cell line human CVCL_B3N8 CL:0000010 Derived from sampling site: Larynx. Unspecified 151357436 CVCL_B3MJ MK-31M finite cell line human CVCL_B3MJ CL:0000010 Population: Japanese. Female 151357437 CVCL_B3MI MK-31F finite cell line human CVCL_B3MI CL:0000010 Population: Japanese. Male 151357438 CVCL_B3ML HCC1419/TDR cancer cell line human CVCL_B3ML CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala74fs*47 (c.220_226delGCCCCTG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1); Derived from sampling site: Breast. Female 151357439 CVCL_B3MK Akata delta2 EBER1(+) cancer cell line human CVCL_B3MK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for EBER1 and EBER2 and which was knocked-in for EBER1 only 151357440 CVCL_B3MN SKBR3/TDR cancer cell line human CVCL_B3MN CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1); Derived from metastatic site: Pleural effusion. Female 151357441 CVCL_B3MM HCC1954/TDR cancer cell line human CVCL_B3MM CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line) Population: East Indian; Selected for resistance to: DrugBank; DB05773; Trastuzumab emtansine (T-DM1); Derived from sampling site: Breast. Female 151357442 CVCL_B3MP CHIpMSC2 somatic stem cell human CVCL_B3MP CL:0000010 Derived from sampling site: Pancreas Cell type=Mesenchymal stem cell.. Female 151357443 CVCL_B3N0 HEK293-mir122 transformed cell line human CVCL_B3N0 CL:0000010 Transfected with: HGNC; 31501; MIR122; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151357444 CVCL_B3MB DR-EcoScreen-HS cancer cell line house mouse CVCL_B3MB CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Used in a bioassay for the determination of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated biphenyls (DL-PCBs) in environmental and food samples Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs); Characteristics: Has higher responsiveness to TCDD than DR-EcoScreen (JCRB) 151357445 CVCL_B3MA Cx43KOM104-E7(+/+) spontaneously immortalized cell line house mouse CVCL_B3MA CL:0000010 Miscellaneous: The 3 cell lines Cx43KOM104-E7(-/-) (Cellosaurus=CVCL_B3MA), Cx43KOM104-E4(+/-) (Cellosaurus=CVCL_B3M8) and Cx43KOM104-E6(-/-) (Cellosaurus=CVCL_B3M9) originate from embryos of different Gja1 genotype which are the outcome of a cross betwee two Gja(+/-) mice Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 151357446 CVCL_B3MD MK-37b finite cell line human CVCL_B3MD CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2731; probable Ambiguous 151357447 CVCL_B3MC D21-iPSC#2 induced pluripotent stem cell human CVCL_B3MC CL:0000010 Derived from sampling site: Amniotic fluid. Female Characteristics: While originating from a Down syndrome patient, this cell line has lost the extra copy of chromosome 21 151357448 CVCL_B3MF MK-42 finite cell line human CVCL_B3MF CL:0000010 Population: Japanese. Female 151357449 CVCL_B3ME MK-37a finite cell line human CVCL_B3ME CL:0000010 Derived from sampling site: Gonad. Ambiguous 151357450 CVCL_B3MH MK-31 finite cell line human CVCL_B3MH CL:0000010 Population: Japanese. Female 151357451 CVCL_B3MG MK-36 finite cell line human CVCL_B3MG CL:0000010 Population: Japanese; Karyotypic information: 46,XY,inv(20)mat (JCRB); Derived from sampling site: Amniotic fluid. Male 151357452 CVCL_B3LY T21-iPSC#1 induced pluripotent stem cell human CVCL_B3LY CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=30760866); Derived from sampling site: Amniotic fluid. Female 151357453 CVCL_B3M9 Cx43KOM104-E6(-/-) spontaneously immortalized cell line house mouse CVCL_B3M9 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95713; Gja1 Miscellaneous: The 3 cell lines Cx43KOM104-E7(-/-) (Cellosaurus=CVCL_B3MA), Cx43KOM104-E4(+/-) (Cellosaurus=CVCL_B3M8) and Cx43KOM104-E6(-/-) (Cellosaurus=CVCL_B3M9) originate from embryos of different Gja1 genotype which are the outcome of a cross betwee two Gja(+/-) mice Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 151357454 CVCL_B3LX D21-iPSC#1 induced pluripotent stem cell human CVCL_B3LX CL:0000010 Karyotypic information: 46,XX [17/20]; 45,X [1/20]; 45,XX,-12 [1/20]; 90,XXXX,-14,-17 [1/20] (JCRB); Derived from sampling site: Amniotic fluid. Female Characteristics: While originating from a Down syndrome patient, this cell line has lost the extra copy of chromosome 21 151357455 CVCL_B3LZ T21-iPSC#5 induced pluripotent stem cell human CVCL_B3LZ CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=30760866); Derived from sampling site: Amniotic fluid. Female 151357456 CVCL_B3NS CHOPi007-A induced pluripotent stem cell human CVCL_B3NS From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 151357457 CVCL_B3NR CHOPi006-A induced pluripotent stem cell human CVCL_B3NR From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151357458 CVCL_B3NU CSUASOi008-A induced pluripotent stem cell human CVCL_B3NU From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 151357459 CVCL_B3NT CIBi010-A induced pluripotent stem cell human CVCL_B3NT From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Asian; Derived from sampling site: Urine Cell type=Epithelial cell.. Male Characteristics: Using CRISPR/Cas9 a T2A-mCherry construct was integrated in front of the stop codon of both alleles of ASGR1 (PubMed=35561459) 151357460 CVCL_B3NW DHMCi006-A induced pluripotent stem cell human CVCL_B3NW From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Arg2111Gly (c.6331A>G); Zygosity=Heterozygous (PubMed=34695767); Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Arg2573Cys (c.7717C>T); ClinVar=VCV000499806; Zygosity=Heterozygous (PubMed=34695767) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151357461 CVCL_B3NV CSUXHi006-A induced pluripotent stem cell human CVCL_B3NV From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China. CL:0000010 Male 151357462 CVCL_B3NY DMBi002-A induced pluripotent stem cell human CVCL_B3NY From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=34678665) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151357463 CVCL_B3NX DHMCi007-A induced pluripotent stem cell human CVCL_B3NX From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Asp2762Val (c.8285A>T); ClinVar=VCV000522472; Zygosity=Homozygous (PubMed=34688127) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151357464 CVCL_B3NK SIE-MSH-805-At spontaneously immortalized cell line CVCL_B3NK CL:0000010 Unspecified Group: Insect cell line. 151357465 CVCL_B3NJ SIE-MSH-805-F spontaneously immortalized cell line CVCL_B3NJ CL:0000010 Unspecified Group: Insect cell line. 151357466 CVCL_B3NM BBANTWi007-A induced pluripotent stem cell human CVCL_B3NM From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; c.4714+95GGGT[3] (c.4813+3_4813+6dupGGGT); ClinVar=VCV000254157; Zygosity=Heterozygous (PubMed=35247843) Population: Caucasian; Belgian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 151357467 CVCL_B3NL BBANTWi006-A induced pluripotent stem cell human CVCL_B3NL From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; c.4714+95GGGT[3] (c.4813+3_4813+6dupGGGT); ClinVar=VCV000254157; Zygosity=Heterozygous (PubMed=35247843) Population: Caucasian; Belgian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 151357468 CVCL_B3NN BCMi002-A induced pluripotent stem cell human CVCL_B3NN From: Baylor College of Medicine; Houston; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 151357469 CVCL_B3NQ CHOPi005-A induced pluripotent stem cell human CVCL_B3NQ From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151357470 CVCL_B3NP CCMi005-A induced pluripotent stem cell human CVCL_B3NP From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (PubMed=35961103) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 151357471 CVCL_B3NC SMG-hu-1 transformed cell line human CVCL_B3NC CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland. Female 151357472 CVCL_B3NB ENTZ HTC 2 cancer cell line human CVCL_B3NB CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 151357473 CVCL_B3NE IOZCAS-Ha-8 spontaneously immortalized cell line CVCL_B3NE CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 34.1 hours (Patent=CN112695010A) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.17690 151357474 CVCL_B3ND IOZCAS-Myse-1 spontaneously immortalized cell line CVCL_B3ND CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~34 hours (PubMed=34599689) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.17282 151357475 CVCL_B3NG SIE-MSH-805 spontaneously immortalized cell line CVCL_B3NG CL:0000010 Unspecified Group: Insect cell line. 151357476 CVCL_B3NF IOZCAS-Spex-IX telomerase immortalized cell line CVCL_B3NF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Ovary. Female Doubling time: 70.09 hours (Patent=CN102807969B) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4506 151357477 CVCL_B3NI AH9 hybridoma house mouse CVCL_B3NI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9F6Z8; Acinetobacter baumannii beta-lactamase IMP-4. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.20287 151357478 CVCL_B3NH 1AA4 hybridoma house mouse CVCL_B3NH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9F6Z8; Acinetobacter baumannii beta-lactamase IMP-4. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.20288 151357479 CVCL_B3MZ AF6 hybridoma house mouse CVCL_B3MZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Acanthamoeba castellanii galactose-binding protein. 151357480 CVCL_B3MY 2D6 hybridoma house mouse CVCL_B3MY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; X5D761; Naegleria fowleri cathepsin B (NfCPB). 151357481 CVCL_B3NA ENTZ HTC 1 cancer cell line human CVCL_B3NA CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 151357482 CVCL_B3KP Abcam HEK293T UBXN6 KO transformed cell line human CVCL_B3KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14928; UBXN6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357483 CVCL_B3L1 Abcam HEK293T USP33 KO transformed cell line human CVCL_B3L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20059; USP33; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357484 CVCL_B3L0 Abcam HEK293T USP24 KO transformed cell line human CVCL_B3L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12623; USP24; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266643; true Female 151357485 CVCL_B3KR Abcam HEK293T UCK1 KO transformed cell line human CVCL_B3KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14859; UCK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357486 CVCL_B3L3 Abcam HEK293T UTP11 KO transformed cell line human CVCL_B3L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24329; UTP11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357487 CVCL_B3KQ Abcam HEK293T UCHL1 KO transformed cell line human CVCL_B3KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12513; UCHL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357488 CVCL_B3L2 Abcam HEK293T USP7 KO transformed cell line human CVCL_B3L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12630; USP7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357489 CVCL_B3KT Abcam HEK293T UFL1 KO transformed cell line human CVCL_B3KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23039; UFL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357490 CVCL_B3L5 Abcam HEK293T VAT1 KO transformed cell line human CVCL_B3L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16919; VAT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357491 CVCL_B3KS Abcam HEK293T UFC1 KO transformed cell line human CVCL_B3KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26941; UFC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357492 CVCL_B3L4 Abcam HEK293T VAMP8 KO transformed cell line human CVCL_B3L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12647; VAMP8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357493 CVCL_B3KV Abcam HEK293T UFSP2 KO transformed cell line human CVCL_B3KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25640; UFSP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357494 CVCL_B3L7 Abcam HEK293T VDAC3 KO transformed cell line human CVCL_B3L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12674; VDAC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357495 CVCL_B3KU Abcam HEK293T UFM1 KO transformed cell line human CVCL_B3KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20597; UFM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357496 CVCL_B3L6 Abcam HEK293T VDAC1 KO transformed cell line human CVCL_B3L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12669; VDAC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357497 CVCL_B3KH Abcam HEK293T TYK2 KO transformed cell line human CVCL_B3KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357498 CVCL_B3KG Abcam HEK293T TXNRD3 KO transformed cell line human CVCL_B3KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20667; TXNRD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357499 CVCL_B3KJ Abcam HEK293T UBE2E1 KO transformed cell line human CVCL_B3KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12477; UBE2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357500 CVCL_B3KI Abcam HEK293T UBE2A KO transformed cell line human CVCL_B3KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12472; UBE2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357501 CVCL_B3KL Abcam HEK293T UBE2J2 KO transformed cell line human CVCL_B3KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19268; UBE2J2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357502 CVCL_B3KK Abcam HEK293T UBE2G1 KO transformed cell line human CVCL_B3KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12482; UBE2G1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357503 CVCL_B3KN Abcam HEK293T UBXN1 KO transformed cell line human CVCL_B3KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18402; UBXN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357504 CVCL_B3KM Abcam HEK293T UBE2S KO transformed cell line human CVCL_B3KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17895; UBE2S; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357505 CVCL_B3KB Abcam HEK293T TUBB4B KO transformed cell line human CVCL_B3KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20771; TUBB4B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357506 CVCL_B3KA Abcam HEK293T TUBB2A KO transformed cell line human CVCL_B3KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12412; TUBB2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357507 CVCL_B3KD Abcam HEK293T TXNDC5 KO transformed cell line human CVCL_B3KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21073; TXNDC5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357508 CVCL_B3KC Abcam HEK293T TWF2 KO transformed cell line human CVCL_B3KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9621; TWF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357509 CVCL_B3KF Abcam HEK293T TXNRD2 KO transformed cell line human CVCL_B3KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18155; TXNRD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357510 CVCL_B3KE Abcam HEK293T TXNL1 KO transformed cell line human CVCL_B3KE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12436; TXNL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357511 CVCL_B3JW Abcam HEK293T TOP2B KO transformed cell line human CVCL_B3JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11990; TOP2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357512 CVCL_B3K8 Abcam HEK293T TROAP KO transformed cell line human CVCL_B3K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12327; TROAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357513 CVCL_B3JV Abcam HEK293T TOP1MT KO transformed cell line human CVCL_B3JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29787; TOP1MT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357514 CVCL_B3K7 Abcam HEK293T TRMT1 KO transformed cell line human CVCL_B3K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25980; TRMT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357515 CVCL_B3JY Abcam HEK293T TPM3 KO transformed cell line human CVCL_B3JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12012; TPM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357516 CVCL_B3JX Abcam HEK293T TP53INP2 KO transformed cell line human CVCL_B3JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16104; TP53INP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357517 CVCL_B3K9 Abcam HEK293T TTLL12 KO transformed cell line human CVCL_B3K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28974; TTLL12; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357518 CVCL_B3JZ Abcam HEK293T TPM4 KO transformed cell line human CVCL_B3JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12013; TPM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357519 CVCL_B3LQ Abcam HEK293T ZYX KO 2 transformed cell line human CVCL_B3LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13200; ZYX; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357520 CVCL_B3M2 T21-iPSC#12 induced pluripotent stem cell human CVCL_B3M2 CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=30760866); Derived from sampling site: Amniotic fluid. Female 151357521 CVCL_B3LP Abcam HEK293T ZNRD2 KO transformed cell line human CVCL_B3LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11328; ZNRD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357522 CVCL_B3M1 T21-iPSC#9 induced pluripotent stem cell human CVCL_B3M1 CL:0000010 Karyotypic information: 47,XX,+21 (PubMed=30760866); Derived from sampling site: Amniotic fluid. Female 151357523 CVCL_B3M4 HeLa-TMPRSS2 cancer cell line human CVCL_B3M4 CL:0000010 Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Can be used to isolate human coronavirus 229E (HCoV-229E) (JCRB) 151357524 CVCL_B3LS Vero PVR1/2 DKO spontaneously immortalized cell line green monkey CVCL_B3LS CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9S1N4; PVR1; Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9S1L1; PVR2 Derived from sampling site: Kidney; epithelium. Female Virology: Not susceptible to infection by poliovirus Group: Non-human primate cell line 151357525 CVCL_B3M3 T21-KC-K4DT telomerase immortalized cell line human CVCL_B3M3 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Keratinocyte. Female 151357526 CVCL_B3LR Vero PVR1 KO spontaneously immortalized cell line green monkey CVCL_B3LR CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9S1N4; PVR1 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 151357527 CVCL_B3LU Akata EBER(-) EBV cancer cell line human CVCL_B3LU CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for EBER1 and EBER2 151357528 CVCL_B3M6 Akata EBER(+) EBV cancer cell line human CVCL_B3M6 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for EBER1 and EBER2 and which was knocked-in for both EBERs 151357529 CVCL_B3M5 BALM-24 cancer cell line human CVCL_B3M5 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Virology: EBV-negative 151357530 CVCL_B3LT Vero PVR2 KO spontaneously immortalized cell line green monkey CVCL_B3LT CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9S1L1; PVR2 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 151357531 CVCL_B3M8 Cx43KOM104-E4(+/-) spontaneously immortalized cell line house mouse CVCL_B3M8 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:95713; Gja1 Miscellaneous: The 3 cell lines Cx43KOM104-E7(-/-) (Cellosaurus=CVCL_B3MA), Cx43KOM104-E4(+/-) (Cellosaurus=CVCL_B3M8) and Cx43KOM104-E6(-/-) (Cellosaurus=CVCL_B3M9) originate from embryos of different Gja1 genotype which are the outcome of a cross betwee two Gja(+/-) mice Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 151357532 CVCL_B3LW HeLa-ACE2 cancer cell line human CVCL_B3LW CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151357533 CVCL_B3LV HeLa-ACE2-TMPRSS2 cancer cell line human CVCL_B3LV CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Can be used to isolate human coronavirus NL63 (HCoV-NL63) (JCRB) 151357534 CVCL_B3M7 TYEK-2 cancer cell line human CVCL_B3M7 CL:0000010 Population: Japanese; Derived from metastatic site: Esophagus. Male Doubling time: 21.9 hours (JCRB) 151357535 CVCL_B3LI Abcam HEK293T YIPF3 KO transformed cell line human CVCL_B3LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21023; YIPF3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357536 CVCL_B3LH Abcam HEK293T YIF1A KO transformed cell line human CVCL_B3LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16688; YIF1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357537 CVCL_B3LK Abcam HEK293T ZC3H15 KO transformed cell line human CVCL_B3LK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29528; ZC3H15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357538 CVCL_B3LJ Abcam HEK293T YWHAG KO transformed cell line human CVCL_B3LJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12852; YWHAG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357539 CVCL_B3LM Abcam HEK293T ZNF593 KO transformed cell line human CVCL_B3LM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30943; ZNF593; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357540 CVCL_B3LL Abcam HEK293T ZFR KO transformed cell line human CVCL_B3LL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17277; ZFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357541 CVCL_B3M0 T21-iPSC#6 induced pluripotent stem cell human CVCL_B3M0 CL:0000010 At 66th passage: 46,X0,+21 (JCRB) Karyotypic information: 47,XX,+21 (PubMed=30760866); Derived from sampling site: Amniotic fluid. Female 151357542 CVCL_B3LN Abcam HEK293T ZNHIT1 KO transformed cell line human CVCL_B3LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21688; ZNHIT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357543 CVCL_B3LA Abcam HEK293T WASF3 KO 1 transformed cell line human CVCL_B3LA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12734; WASF3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357544 CVCL_B3LC Abcam HEK293T WDR83OS KO transformed cell line human CVCL_B3LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30203; WDR83OS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357545 CVCL_B3LB Abcam HEK293T WASF3 KO 2 transformed cell line human CVCL_B3LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12734; WASF3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357546 CVCL_B3LE Abcam HEK293T WNK2 KO 2 transformed cell line human CVCL_B3LE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14542; WNK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357547 CVCL_B3LD Abcam HEK293T WNK2 KO 1 transformed cell line human CVCL_B3LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14542; WNK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357548 CVCL_B3LG Abcam HEK293T YDJC KO transformed cell line human CVCL_B3LG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27158; YDJC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357549 CVCL_B3LF Abcam HEK293T YBX3 KO transformed cell line human CVCL_B3LF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2428; YBX3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357550 CVCL_B3KX Abcam HEK293T UQCC2 KO transformed cell line human CVCL_B3KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21237; UQCC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357551 CVCL_B3L9 Abcam HEK293T VRK1 KO transformed cell line human CVCL_B3L9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12718; VRK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357552 CVCL_B3KW Abcam HEK293T ULK3 KO transformed cell line human CVCL_B3KW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19703; ULK3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357553 CVCL_B3L8 Abcam HEK293T VKORC1 KO transformed cell line human CVCL_B3L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23663; VKORC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357554 CVCL_B3KZ Abcam HEK293T USP16 KO transformed cell line human CVCL_B3KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357555 CVCL_B3KY Abcam HEK293T UQCRQ KO transformed cell line human CVCL_B3KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29594; UQCRQ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357556 CVCL_B3IN Abcam HEK293T SUCLG2 KO transformed cell line human CVCL_B3IN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11450; SUCLG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357557 CVCL_B3IM Abcam HEK293T SUCLG1 KO transformed cell line human CVCL_B3IM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11449; SUCLG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357558 CVCL_B3IP Abcam HEK293T SUFU KO transformed cell line human CVCL_B3IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357559 CVCL_B3J1 Abcam HEK293T TAOK2 KO transformed cell line human CVCL_B3J1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16835; TAOK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357560 CVCL_B3J0 Abcam HEK293T TALDO1 KO transformed cell line human CVCL_B3J0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11559; TALDO1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357561 CVCL_B3IR Abcam HEK293T SURF4 KO transformed cell line human CVCL_B3IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11476; SURF4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357562 CVCL_B3J3 Abcam HEK293T TBRG4 KO transformed cell line human CVCL_B3J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17443; TBRG4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357563 CVCL_B3IQ Abcam HEK293T SUPT20H KO transformed cell line human CVCL_B3IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20596; SUPT20H; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357564 CVCL_B3J2 Abcam HEK293T TAX1BP1 KO transformed cell line human CVCL_B3J2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357565 CVCL_B3IT Abcam HEK293T SYNGR2 KO transformed cell line human CVCL_B3IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11499; SYNGR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357566 CVCL_B3J5 Abcam HEK293T TEAD4 KO transformed cell line human CVCL_B3J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11717; TEAD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357567 CVCL_B3IS Abcam HEK293T SYAP1 KO transformed cell line human CVCL_B3IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16273; SYAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357568 CVCL_B3J4 Abcam HEK293T TCEAL9 KO transformed cell line human CVCL_B3J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30084; TCEAL9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357569 CVCL_B3IF Abcam HEK293T STK16 KO transformed cell line human CVCL_B3IF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11394; STK16; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357570 CVCL_B3IE Abcam HEK293T STK11 KO transformed cell line human CVCL_B3IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357571 CVCL_B3IH Abcam HEK293T STRADB KO transformed cell line human CVCL_B3IH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13205; STRADB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357572 CVCL_B3IG Abcam HEK293T STK35 KO transformed cell line human CVCL_B3IG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16254; STK35; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357573 CVCL_B3IJ Abcam HEK293T STT3A KO transformed cell line human CVCL_B3IJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6172; STT3A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357574 CVCL_B3II Abcam HEK293T STRAP KO transformed cell line human CVCL_B3II CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30796; STRAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357575 CVCL_B3IL Abcam HEK293T STX10 KO transformed cell line human CVCL_B3IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11428; STX10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357576 CVCL_B3IK Abcam HEK293T STT3B KO transformed cell line human CVCL_B3IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30611; STT3B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357577 CVCL_B3IB Abcam HEK293T SSNA1 KO transformed cell line human CVCL_B3IB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11321; SSNA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357578 CVCL_B3IA Abcam HEK293T SSBP4 KO transformed cell line human CVCL_B3IA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15676; SSBP4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357579 CVCL_B3ID Abcam HEK293T STAM KO transformed cell line human CVCL_B3ID CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11357; STAM; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357580 CVCL_B3IC Abcam HEK293T SSR4 KO transformed cell line human CVCL_B3IC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11326; SSR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357581 CVCL_B3HU Abcam HEK293T SNRNP40 KO transformed cell line human CVCL_B3HU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30857; SNRNP40; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357582 CVCL_B3I6 Abcam HEK293T SRP9 KO transformed cell line human CVCL_B3I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11304; SRP9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357583 CVCL_B3HT Abcam HEK293T SNCA KO transformed cell line human CVCL_B3HT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357584 CVCL_B3I5 Abcam HEK293T SRP68 KO transformed cell line human CVCL_B3I5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11302; SRP68; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357585 CVCL_B3HW Abcam HEK293T SOD2 KO transformed cell line human CVCL_B3HW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11180; SOD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357586 CVCL_B3I8 Abcam HEK293T SRSF5 KO transformed cell line human CVCL_B3I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10787; SRSF5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357587 CVCL_B3HV Abcam HEK293T SNX3 KO transformed cell line human CVCL_B3HV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11174; SNX3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266164; true Female 151357588 CVCL_B3I7 Abcam HEK293T SRSF10 KO transformed cell line human CVCL_B3I7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16713; SRSF10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357589 CVCL_B3HY Abcam HEK293T SPAG5 KO transformed cell line human CVCL_B3HY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13452; SPAG5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357590 CVCL_B3HX Abcam HEK293T SORBS3 KO transformed cell line human CVCL_B3HX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30907; SORBS3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357591 CVCL_B3I9 Abcam HEK293T SRSF6 KO transformed cell line human CVCL_B3I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10788; SRSF6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357592 CVCL_B3HZ Abcam HEK293T SPAG7 KO transformed cell line human CVCL_B3HZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11216; SPAG7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357593 CVCL_B3K0 Abcam HEK293T TRABD KO transformed cell line human CVCL_B3K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28805; TRABD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357594 CVCL_B3JN Abcam HEK293T TMEM259 KO transformed cell line human CVCL_B3JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17039; TMEM259; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357595 CVCL_B3JQ Abcam HEK293T TMEM97 KO transformed cell line human CVCL_B3JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28106; TMEM97; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357596 CVCL_B3K2 Abcam HEK293T TRAPPC2L KO transformed cell line human CVCL_B3K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30887; TRAPPC2L; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357597 CVCL_B3JP Abcam HEK293T TMEM59 KO transformed cell line human CVCL_B3JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1239; TMEM59; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357598 CVCL_B3K1 Abcam HEK293T TRAF2 KO transformed cell line human CVCL_B3K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357599 CVCL_B3JS Abcam HEK293T TMSB4X KO transformed cell line human CVCL_B3JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11881; TMSB4X; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357600 CVCL_B3K4 Abcam HEK293T TRIP10 KO transformed cell line human CVCL_B3K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12304; TRIP10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357601 CVCL_B3JR Abcam HEK293T TMSB10 KO transformed cell line human CVCL_B3JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11879; TMSB10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357602 CVCL_B3K3 Abcam HEK293T TRIO KO transformed cell line human CVCL_B3K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12303; TRIO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357603 CVCL_B3JU Abcam HEK293T TOMM7 KO transformed cell line human CVCL_B3JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21648; TOMM7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357604 CVCL_B3K6 Abcam HEK293T TRIP13 KO 2 transformed cell line human CVCL_B3K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12307; TRIP13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357605 CVCL_B3JT Abcam HEK293T TOMM6 KO transformed cell line human CVCL_B3JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34528; TOMM6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357606 CVCL_B3K5 Abcam HEK293T TRIP13 KO 1 transformed cell line human CVCL_B3K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12307; TRIP13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357607 CVCL_B3JG Abcam HEK293T TMEM106C KO transformed cell line human CVCL_B3JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28775; TMEM106C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357608 CVCL_B3JF Abcam HEK293T TMED9 KO transformed cell line human CVCL_B3JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24878; TMED9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357609 CVCL_B3JI Abcam HEK293T TMEM147 KO transformed cell line human CVCL_B3JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30414; TMEM147; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357610 CVCL_B3JH Abcam HEK293T TMEM126B KO transformed cell line human CVCL_B3JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30883; TMEM126B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357611 CVCL_B3JK Abcam HEK293T TMEM160 KO transformed cell line human CVCL_B3JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26042; TMEM160; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357612 CVCL_B3JJ Abcam HEK293T TMEM14B KO transformed cell line human CVCL_B3JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21384; TMEM14B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357613 CVCL_B3JM Abcam HEK293T TMEM208 KO transformed cell line human CVCL_B3JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25015; TMEM208; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357614 CVCL_B3JL Abcam HEK293T TMEM165 KO transformed cell line human CVCL_B3JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30760; TMEM165; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357615 CVCL_B3JA Abcam HEK293T TIPRL KO transformed cell line human CVCL_B3JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30231; TIPRL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357616 CVCL_B3JC Abcam HEK293T TLE1 KO transformed cell line human CVCL_B3JC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357617 CVCL_B3JB Abcam HEK293T TK1 KO transformed cell line human CVCL_B3JB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11830; TK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357618 CVCL_B3JE Abcam HEK293T TMED4 KO transformed cell line human CVCL_B3JE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22301; TMED4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357619 CVCL_B3JD Abcam HEK293T TMED10 KO transformed cell line human CVCL_B3JD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16998; TMED10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357620 CVCL_B3IV Abcam HEK293T SYP KO 2 transformed cell line human CVCL_B3IV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11506; SYP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357621 CVCL_B3J7 Abcam HEK293T TFDP2 KO transformed cell line human CVCL_B3J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11751; TFDP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357622 CVCL_B3IU Abcam HEK293T SYP KO 1 transformed cell line human CVCL_B3IU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11506; SYP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357623 CVCL_B3J6 Abcam HEK293T TECR KO transformed cell line human CVCL_B3J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4551; TECR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357624 CVCL_B3IX Abcam HEK293T TACC1 KO transformed cell line human CVCL_B3IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11522; TACC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357625 CVCL_B3J9 Abcam HEK293T TIMM17B KO transformed cell line human CVCL_B3J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17310; TIMM17B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357626 CVCL_B3IW Abcam HEK293T TAB1 KO transformed cell line human CVCL_B3IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18157; TAB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357627 CVCL_B3J8 Abcam HEK293T TIMM17A KO transformed cell line human CVCL_B3J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17315; TIMM17A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357628 CVCL_B3IZ Abcam HEK293T TAGLN2 KO transformed cell line human CVCL_B3IZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11554; TAGLN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357629 CVCL_B3IY Abcam HEK293T TACC3 KO transformed cell line human CVCL_B3IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11524; TACC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357630 CVCL_B3GL Abcam HEK293T SDHD KO transformed cell line human CVCL_B3GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10683; SDHD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357631 CVCL_B3GK Abcam HEK293T SDF4 KO transformed cell line human CVCL_B3GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24188; SDF4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357632 CVCL_B3GN Abcam HEK293T SEC13 KO transformed cell line human CVCL_B3GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10697; SEC13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357633 CVCL_B3GM Abcam HEK293T SEC11A KO transformed cell line human CVCL_B3GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17718; SEC11A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357634 CVCL_B3GP Abcam HEK293T SEC61B KO transformed cell line human CVCL_B3GP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16993; SEC61B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357635 CVCL_B3H1 Abcam HEK293T SIVA1 KO transformed cell line human CVCL_B3H1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17712; SIVA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357636 CVCL_B3H0 Abcam HEK293T SHPK KO transformed cell line human CVCL_B3H0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1492; SHPK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357637 CVCL_B3GR Abcam HEK293T SELENOH KO transformed cell line human CVCL_B3GR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18251; SELENOH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357638 CVCL_B3H3 Abcam HEK293T SLC25A10 KO transformed cell line human CVCL_B3H3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10980; SLC25A10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357639 CVCL_B3GQ Abcam HEK293T SEC61G KO transformed cell line human CVCL_B3GQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18277; SEC61G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357640 CVCL_B3H2 Abcam HEK293T SLC19A1 KO transformed cell line human CVCL_B3H2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10937; SLC19A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357641 CVCL_B3GD Abcam HEK293T RTL8C KO transformed cell line human CVCL_B3GD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2569; RTL8C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357642 CVCL_B3GC Abcam HEK293T RRAS2 KO transformed cell line human CVCL_B3GC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17271; RRAS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357643 CVCL_B3GF Abcam HEK293T S100A13 KO transformed cell line human CVCL_B3GF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10490; S100A13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357644 CVCL_B3GE Abcam HEK293T RTN3 KO transformed cell line human CVCL_B3GE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10469; RTN3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357645 CVCL_B3GH Abcam HEK293T SCO1 KO transformed cell line human CVCL_B3GH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10603; SCO1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357646 CVCL_B3GG Abcam HEK293T SARNP KO transformed cell line human CVCL_B3GG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24432; SARNP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357647 CVCL_B3GJ Abcam HEK293T SDF2L1 KO transformed cell line human CVCL_B3GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10676; SDF2L1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357648 CVCL_B3GI Abcam HEK293T SCYL1 KO transformed cell line human CVCL_B3GI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14372; SCYL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357649 CVCL_B3FZ Abcam HEK293T RFX5 KO transformed cell line human CVCL_B3FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9986; RFX5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357650 CVCL_B3GB Abcam HEK293T RRAGD KO transformed cell line human CVCL_B3GB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19903; RRAGD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357651 CVCL_B3GA Abcam HEK293T RRAGA KO transformed cell line human CVCL_B3GA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16963; RRAGA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357652 CVCL_B3FS Abcam HEK293T RBM3 KO transformed cell line human CVCL_B3FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9900; RBM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357653 CVCL_B3G4 Abcam HEK293T RNF167 KO transformed cell line human CVCL_B3G4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24544; RNF167; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357654 CVCL_B3FR Abcam HEK293T RANBP1 KO transformed cell line human CVCL_B3FR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9847; RANBP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357655 CVCL_B3G3 Abcam HEK293T RNF10 KO transformed cell line human CVCL_B3G3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10055; RNF10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357656 CVCL_B3FU Abcam HEK293T RBM42 KO transformed cell line human CVCL_B3FU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28117; RBM42; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357657 CVCL_B3G6 Abcam HEK293T RPE KO transformed cell line human CVCL_B3G6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10293; RPE; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357658 CVCL_B3FT Abcam HEK293T RBM4 KO transformed cell line human CVCL_B3FT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9901; RBM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357659 CVCL_B3G5 Abcam HEK293T RNF181 KO transformed cell line human CVCL_B3G5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28037; RNF181; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357660 CVCL_B3FW Abcam HEK293T RCN2 KO transformed cell line human CVCL_B3FW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9935; RCN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357661 CVCL_B3G8 Abcam HEK293T RPL22 KO transformed cell line human CVCL_B3G8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10315; RPL22; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357662 CVCL_B3FV Abcam HEK293T RCN1 KO transformed cell line human CVCL_B3FV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9934; RCN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357663 CVCL_B3G7 Abcam HEK293T RPF1 KO transformed cell line human CVCL_B3G7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30350; RPF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357664 CVCL_B3FY Abcam HEK293T REXO2 KO transformed cell line human CVCL_B3FY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17851; REXO2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357665 CVCL_B3FX Abcam HEK293T REPIN1 KO transformed cell line human CVCL_B3FX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17922; REPIN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357666 CVCL_B3G9 Abcam HEK293T RPL36AL KO transformed cell line human CVCL_B3G9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10346; RPL36AL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357667 CVCL_B3HM Abcam HEK293T SLX9 KO transformed cell line human CVCL_B3HM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15811; SLX9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357668 CVCL_B3HL Abcam HEK293T SLC9A3R2 KO transformed cell line human CVCL_B3HL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11076; SLC9A3R2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357669 CVCL_B3I0 Abcam HEK293T SPAST KO transformed cell line human CVCL_B3I0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11233; SPAST; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357670 CVCL_B3HN Abcam HEK293T SMAD9 KO transformed cell line human CVCL_B3HN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6774; SMAD9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357671 CVCL_B3HQ Abcam HEK293T SMARCB1 KO transformed cell line human CVCL_B3HQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11103; SMARCB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357672 CVCL_B3I2 Abcam HEK293T SPHK2 KO transformed cell line human CVCL_B3I2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18859; SPHK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357673 CVCL_B3HP Abcam HEK293T SMARCA4 KO transformed cell line human CVCL_B3HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357674 CVCL_B3I1 Abcam HEK293T SPCS1 KO transformed cell line human CVCL_B3I1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23401; SPCS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357675 CVCL_B3HS Abcam HEK293T SMO KO transformed cell line human CVCL_B3HS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357676 CVCL_B3I4 Abcam HEK293T SRP14 KO transformed cell line human CVCL_B3I4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11299; SRP14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357677 CVCL_B3HR Abcam HEK293T SMARCD1 KO transformed cell line human CVCL_B3HR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11106; SMARCD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357678 CVCL_B3I3 Abcam HEK293T SQSTM1 KO transformed cell line human CVCL_B3I3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357679 CVCL_B3HE Abcam HEK293T SLC35A4 KO transformed cell line human CVCL_B3HE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20753; SLC35A4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357680 CVCL_B3HD Abcam HEK293T SLC30A5 KO transformed cell line human CVCL_B3HD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19089; SLC30A5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357681 CVCL_B3HG Abcam HEK293T SLC38A10 KO transformed cell line human CVCL_B3HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28237; SLC38A10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357682 CVCL_B3HF Abcam HEK293T SLC35F2 KO transformed cell line human CVCL_B3HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23615; SLC35F2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357683 CVCL_B3HI Abcam HEK293T SLC41A3 KO transformed cell line human CVCL_B3HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31046; SLC41A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357684 CVCL_B3HH Abcam HEK293T SLC39A14 KO transformed cell line human CVCL_B3HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20858; SLC39A14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357685 CVCL_B3HK Abcam HEK293T SLC7A1 KO transformed cell line human CVCL_B3HK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11057; SLC7A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357686 CVCL_B3HJ Abcam HEK293T SLC5A6 KO transformed cell line human CVCL_B3HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11041; SLC5A6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357687 CVCL_B3HA Abcam HEK293T SLC25A40 KO transformed cell line human CVCL_B3HA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29680; SLC25A40; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357688 CVCL_B3HC Abcam HEK293T SLC27A4 KO transformed cell line human CVCL_B3HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10998; SLC27A4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357689 CVCL_B3HB Abcam HEK293T SLC25A46 KO transformed cell line human CVCL_B3HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25198; SLC25A46; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357690 CVCL_B3GT Abcam HEK293T SERBP1 KO transformed cell line human CVCL_B3GT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17860; SERBP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357691 CVCL_B3H5 Abcam HEK293T SLC25A22 KO transformed cell line human CVCL_B3H5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19954; SLC25A22; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357692 CVCL_B3GS Abcam HEK293T SEPHS1 KO transformed cell line human CVCL_B3GS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19685; SEPHS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357693 CVCL_B3H4 Abcam HEK293T SLC25A15 KO transformed cell line human CVCL_B3H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10985; SLC25A15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357694 CVCL_B3GV Abcam HEK293T SETD2 KO transformed cell line human CVCL_B3GV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357695 CVCL_B3H7 Abcam HEK293T SLC25A32 KO transformed cell line human CVCL_B3H7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29683; SLC25A32; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357696 CVCL_B3GU Abcam HEK293T SERP1 KO transformed cell line human CVCL_B3GU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10759; SERP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357697 CVCL_B3H6 Abcam HEK293T SLC25A23 KO transformed cell line human CVCL_B3H6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19375; SLC25A23; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357698 CVCL_B3GX Abcam HEK293T SH2B2 KO transformed cell line human CVCL_B3GX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17381; SH2B2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357699 CVCL_B3H9 Abcam HEK293T SLC25A39 KO transformed cell line human CVCL_B3H9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24279; SLC25A39; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357700 CVCL_B3GW Abcam HEK293T SGTA KO transformed cell line human CVCL_B3GW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10819; SGTA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357701 CVCL_B3H8 Abcam HEK293T SLC25A38 KO transformed cell line human CVCL_B3H8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26054; SLC25A38; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357702 CVCL_B3GZ Abcam HEK293T SH3GL1 KO transformed cell line human CVCL_B3GZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10830; SH3GL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357703 CVCL_B3GY Abcam HEK293T SH3BGRL3 KO transformed cell line human CVCL_B3GY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15568; SH3BGRL3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357704 CVCL_B2SY Abcam HEK293T BRCA2 KO 2 transformed cell line human CVCL_B2SY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1101; BRCA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357705 CVCL_B2SX Abcam HEK293T BRCA2 KO 1 transformed cell line human CVCL_B2SX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1101; BRCA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357706 CVCL_B2T9 Abcam HEK293T C1orf43 KO transformed cell line human CVCL_B2T9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29876; C1orf43; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357707 CVCL_B2SZ Abcam HEK293T BRD2 KO transformed cell line human CVCL_B2SZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357708 CVCL_B2SQ Abcam HEK293T BCL2L2-PABPN1 KO transformed cell line human CVCL_B2SQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 42959; ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357709 CVCL_B2T2 Abcam HEK293T BRPF1 KO transformed cell line human CVCL_B2T2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14255; BRPF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357710 CVCL_B2SP Abcam HEK293T BCKDHA KO transformed cell line human CVCL_B2SP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 986; BCKDHA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357711 CVCL_B2T1 Abcam HEK293T BRD9 KO transformed cell line human CVCL_B2T1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357712 CVCL_B2SS Abcam HEK293T BEX3 KO transformed cell line human CVCL_B2SS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13388; BEX3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357713 CVCL_B2T4 Abcam HEK293T BTBD1 KO transformed cell line human CVCL_B2T4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1120; BTBD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357714 CVCL_B2SR Abcam HEK293T BCR KO transformed cell line human CVCL_B2SR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1014; BCR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357715 CVCL_B2T3 Abcam HEK293T BSG KO transformed cell line human CVCL_B2T3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1116; BSG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357716 CVCL_B2SU Abcam HEK293T BLVRB KO transformed cell line human CVCL_B2SU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1063; BLVRB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357717 CVCL_B2T6 Abcam HEK293T BZW1 KO transformed cell line human CVCL_B2T6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18380; BZW1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357718 CVCL_B2ST Abcam HEK293T BLVRA KO transformed cell line human CVCL_B2ST CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1062; BLVRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357719 CVCL_B2T5 Abcam HEK293T BTRC KO transformed cell line human CVCL_B2T5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357720 CVCL_B2SW Abcam HEK293T BRAP KO transformed cell line human CVCL_B2SW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1099; BRAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357721 CVCL_B2T8 Abcam HEK293T C19orf48 KO transformed cell line human CVCL_B2T8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29667; C19orf48; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357722 CVCL_B2SV Abcam HEK293T BMI1 KO transformed cell line human CVCL_B2SV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1066; BMI1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357723 CVCL_B2T7 Abcam HEK293T C12orf57 KO transformed cell line human CVCL_B2T7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29521; C12orf57; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357724 CVCL_B2SI Abcam HEK293T ATRAID KO transformed cell line human CVCL_B2SI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24090; ATRAID; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357725 CVCL_B2SH Abcam HEK293T ATP5MF KO transformed cell line human CVCL_B2SH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 848; ATP5MF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357726 CVCL_B2SK Abcam HEK293T B2M KO transformed cell line human CVCL_B2SK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357727 CVCL_B2SJ Abcam HEK293T ATXN2L KO transformed cell line human CVCL_B2SJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31326; ATXN2L; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357728 CVCL_B2SM Abcam HEK293T BAMBI KO transformed cell line human CVCL_B2SM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30251; BAMBI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357729 CVCL_B2SL Abcam HEK293T B4GALT2 KO transformed cell line human CVCL_B2SL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 925; B4GALT2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357730 CVCL_B2T0 Abcam HEK293T BRD3 KO transformed cell line human CVCL_B2T0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357731 CVCL_B2SN Abcam HEK293T BCAP31 KO transformed cell line human CVCL_B2SN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16695; BCAP31; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357732 CVCL_B2SA Abcam HEK293T ATG3 KO transformed cell line human CVCL_B2SA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20962; ATG3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357733 CVCL_B2SC Abcam HEK293T ATOX1 KO transformed cell line human CVCL_B2SC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 798; ATOX1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357734 CVCL_B2SB Abcam HEK293T ATG4C KO transformed cell line human CVCL_B2SB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16040; ATG4C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357735 CVCL_B2SE Abcam HEK293T ATP5IF1 KO transformed cell line human CVCL_B2SE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 871; ATP5IF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357736 CVCL_B2SD Abcam HEK293T ATP2C1 KO transformed cell line human CVCL_B2SD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13211; ATP2C1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357737 CVCL_B2SG Abcam HEK293T ATP5MC3 KO transformed cell line human CVCL_B2SG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 843; ATP5MC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357738 CVCL_B2SF Abcam HEK293T ATP5MC2 KO transformed cell line human CVCL_B2SF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 842; ATP5MC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357739 CVCL_B2TZ Abcam HEK293T CDK10 KO transformed cell line human CVCL_B2TZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1770; CDK10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357740 CVCL_B2TY Abcam HEK293T CDH2 KO transformed cell line human CVCL_B2TY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1759; CDH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357741 CVCL_B2UA Abcam HEK293T CHCHD6 KO transformed cell line human CVCL_B2UA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28184; CHCHD6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357742 CVCL_B2TR Abcam HEK293T CD164 KO transformed cell line human CVCL_B2TR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1632; CD164; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357743 CVCL_B2U3 Abcam HEK293T CELF1 KO transformed cell line human CVCL_B2U3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2549; CELF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357744 CVCL_B2TQ Abcam HEK293T CCP110 KO transformed cell line human CVCL_B2TQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24342; CCP110; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357745 CVCL_B2U2 Abcam HEK293T CDV3 KO transformed cell line human CVCL_B2U2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26928; CDV3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357746 CVCL_B2TT Abcam HEK293T CD2BP2 KO transformed cell line human CVCL_B2TT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1656; CD2BP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357747 CVCL_B2U5 Abcam HEK293T CERS2 KO transformed cell line human CVCL_B2U5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14076; CERS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266198; true Female 151357748 CVCL_B2TS Abcam HEK293T CD276 KO transformed cell line human CVCL_B2TS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19137; CD276; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357749 CVCL_B2U4 Abcam HEK293T CERK KO transformed cell line human CVCL_B2U4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19256; CERK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357750 CVCL_B2TV Abcam HEK293T CDC14B KO transformed cell line human CVCL_B2TV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1719; CDC14B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357751 CVCL_B2U7 Abcam HEK293T CERT1 KO transformed cell line human CVCL_B2U7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2205; CERT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357752 CVCL_B2TU Abcam HEK293T CD47 KO transformed cell line human CVCL_B2TU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1682; CD47; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357753 CVCL_B2U6 Abcam HEK293T CERS6 KO transformed cell line human CVCL_B2U6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23826; CERS6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357754 CVCL_B2TX Abcam HEK293T CDC42 KO transformed cell line human CVCL_B2TX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1736; CDC42; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357755 CVCL_B2U9 Abcam HEK293T CHCHD3 KO transformed cell line human CVCL_B2U9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21906; CHCHD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357756 CVCL_B2TW Abcam HEK293T CDC16 KO transformed cell line human CVCL_B2TW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1720; CDC16; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab267254; true Female 151357757 CVCL_B2U8 Abcam HEK293T CHCHD2 KO transformed cell line human CVCL_B2U8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21645; CHCHD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357758 CVCL_B2TJ Abcam HEK293T CBL KO transformed cell line human CVCL_B2TJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357759 CVCL_B2TI Abcam HEK293T CASP1 KO transformed cell line human CVCL_B2TI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1499; CASP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266226; true Female 151357760 CVCL_B2TL Abcam HEK293T CCND2 KO transformed cell line human CVCL_B2TL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357761 CVCL_B2TK Abcam HEK293T CBX1 KO transformed cell line human CVCL_B2TK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1551; CBX1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357762 CVCL_B2TN Abcam HEK293T CCNI KO transformed cell line human CVCL_B2TN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1595; CCNI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357763 CVCL_B2TM Abcam HEK293T CCND3 KO transformed cell line human CVCL_B2TM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1585; CCND3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266518; true Female 151357764 CVCL_B2TP Abcam HEK293T CCNL2 KO transformed cell line human CVCL_B2TP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20570; CCNL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357765 CVCL_B2U1 Abcam HEK293T CDK5 KO transformed cell line human CVCL_B2U1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357766 CVCL_B2U0 Abcam HEK293T CDK11A KO transformed cell line human CVCL_B2U0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1730; CDK11A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357767 CVCL_B2TB Abcam HEK293T CA2 KO transformed cell line human CVCL_B2TB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1373; CA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357768 CVCL_B2TA Abcam HEK293T C20orf27 KO transformed cell line human CVCL_B2TA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15873; C20orf27; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357769 CVCL_B2TD Abcam HEK293T CAMK2D KO transformed cell line human CVCL_B2TD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1462; CAMK2D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357770 CVCL_B2TC Abcam HEK293T CALM3 KO transformed cell line human CVCL_B2TC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1449; CALM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357771 CVCL_B2TF Abcam HEK293T CANX KO transformed cell line human CVCL_B2TF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1473; CANX; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357772 CVCL_B2TE Abcam HEK293T CAMKK2 KO transformed cell line human CVCL_B2TE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1470; CAMKK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357773 CVCL_B2TH Abcam HEK293T CARM1 KO transformed cell line human CVCL_B2TH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357774 CVCL_B2TG Abcam HEK293T CAPN2 KO transformed cell line human CVCL_B2TG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1479; CAPN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357775 CVCL_B2QW Abcam A-549 TRIM34 KO 2 cancer cell line human CVCL_B2QW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10063; TRIM34; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357776 CVCL_B2R8 Abcam HEK293T ADRM1 KO transformed cell line human CVCL_B2R8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15759; ADRM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357777 CVCL_B2QV Abcam A-549 TRIM22 KO cancer cell line human CVCL_B2QV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16379; TRIM22; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357778 CVCL_B2R7 Abcam HEK293T ADPGK KO transformed cell line human CVCL_B2R7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25250; ADPGK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357779 CVCL_B2QY Abcam A-549 TRIM56 KO 2 cancer cell line human CVCL_B2QY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19028; TRIM56; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357780 CVCL_B2QX Abcam A-549 TRIM38 KO 2 cancer cell line human CVCL_B2QX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10059; TRIM38; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357781 CVCL_B2R9 Abcam HEK293T AGA KO transformed cell line human CVCL_B2R9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 318; AGA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357782 CVCL_B2QZ Abcam A-549 USP18 KO 2 cancer cell line human CVCL_B2QZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12616; USP18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357783 CVCL_B2R0 Abcam A-549 ZC3HAV1 KO 1 cancer cell line human CVCL_B2R0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23721; ZC3HAV1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357784 CVCL_B2QN Abcam A-549 TMEM140 KO 2 cancer cell line human CVCL_B2QN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21870; TMEM140; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357785 CVCL_B2QQ Abcam A-549 TNFAIP3 KO 2 cancer cell line human CVCL_B2QQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11896; TNFAIP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357786 CVCL_B2R2 Abcam HEK293T AADAT KO transformed cell line human CVCL_B2R2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17929; AADAT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357787 CVCL_B2QP Abcam A-549 TMEM64 KO 2 cancer cell line human CVCL_B2QP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25441; TMEM64; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357788 CVCL_B2R1 Abcam A-549 ZCCHC2 KO 1 cancer cell line human CVCL_B2R1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22916; ZCCHC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357789 CVCL_B2QS Abcam A-549 TRANK1 KO 2 cancer cell line human CVCL_B2QS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29011; TRANK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357790 CVCL_B2R4 Abcam HEK293T ACADVL KO transformed cell line human CVCL_B2R4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 92; ACADVL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357791 CVCL_B2QR Abcam A-549 TP53 KO cancer cell line human CVCL_B2QR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357792 CVCL_B2R3 Abcam HEK293T ABCF2 KO transformed cell line human CVCL_B2R3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 71; ABCF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357793 CVCL_B2QU Abcam A-549 TRIM21 KO 1 cancer cell line human CVCL_B2QU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11312; TRIM21; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357794 CVCL_B2R6 Abcam HEK293T ADARB1 KO transformed cell line human CVCL_B2R6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 226; ADARB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357795 CVCL_B2QT Abcam A-549 TRIM14 KO 1 cancer cell line human CVCL_B2QT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16283; TRIM14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357796 CVCL_B2R5 Abcam HEK293T ADAR KO transformed cell line human CVCL_B2R5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 225; ADAR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357797 CVCL_B2QG Abcam A-549 TENT5A KO 1 cancer cell line human CVCL_B2QG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18345; TENT5A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357798 CVCL_B2QF Abcam A-549 TEAD2 KO cancer cell line human CVCL_B2QF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11715; TEAD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357799 CVCL_B2QI Abcam A-549 TGFBR2 KO 1 cancer cell line human CVCL_B2QI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357800 CVCL_B2QH Abcam A-549 TGFB1 KO cancer cell line human CVCL_B2QH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11766; TGFB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357801 CVCL_B2QK Abcam A-549 THEMIS2 KO 1 cancer cell line human CVCL_B2QK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16839; THEMIS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357802 CVCL_B2QJ Abcam A-549 TGM2 KO 2 cancer cell line human CVCL_B2QJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11778; TGM2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357803 CVCL_B2QM Abcam A-549 TMEM106B KO cancer cell line human CVCL_B2QM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22407; TMEM106B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357804 CVCL_B2QL Abcam A-549 TLDC2 KO 1 cancer cell line human CVCL_B2QL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16112; TLDC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357805 CVCL_B2QA Abcam A-549 SPINK1 KO 2 cancer cell line human CVCL_B2QA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11244; SPINK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267205; true Male 151357806 CVCL_B2QC Abcam A-549 STAT2 KO 3 cancer cell line human CVCL_B2QC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357807 CVCL_B2QB Abcam A-549 STAT2 KO 1 cancer cell line human CVCL_B2QB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357808 CVCL_B2QE Abcam A-549 TDRD7 KO 2 cancer cell line human CVCL_B2QE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30831; TDRD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357809 CVCL_B2QD Abcam A-549 TAP2 KO cancer cell line human CVCL_B2QD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18655; SEC14L3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357810 CVCL_B2RX Abcam HEK293T ARAF KO transformed cell line human CVCL_B2RX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357811 CVCL_B2S9 Abcam HEK293T ARRB2 KO transformed cell line human CVCL_B2S9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 712; ARRB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357812 CVCL_B2RW Abcam HEK293T APRT KO transformed cell line human CVCL_B2RW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 626; APRT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357813 CVCL_B2S8 Abcam HEK293T ARPP19 KO transformed cell line human CVCL_B2S8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16967; ARPP19; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357814 CVCL_B2RZ Abcam HEK293T ARF5 KO transformed cell line human CVCL_B2RZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 658; ARF5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357815 CVCL_B2RY Abcam HEK293T ARF3 KO transformed cell line human CVCL_B2RY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 654; ARF3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357816 CVCL_B2RP Abcam HEK293T ANP32B KO transformed cell line human CVCL_B2RP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16677; ANP32B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357817 CVCL_B2S1 Abcam HEK293T ARHGDIA KO 1 transformed cell line human CVCL_B2S1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 678; ARHGDIA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357818 CVCL_B2S0 Abcam HEK293T ARFIP1 KO transformed cell line human CVCL_B2S0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21496; ARFIP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357819 CVCL_B2RR Abcam HEK293T AP1B1 KO transformed cell line human CVCL_B2RR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 554; AP1B1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357820 CVCL_B2S3 Abcam HEK293T ARHGEF1 KO transformed cell line human CVCL_B2S3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 681; ARHGEF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357821 CVCL_B2RQ Abcam HEK293T ANXA11 KO transformed cell line human CVCL_B2RQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 535; ANXA11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357822 CVCL_B2S2 Abcam HEK293T ARHGDIA KO 2 transformed cell line human CVCL_B2S2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 678; ARHGDIA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357823 CVCL_B2RT Abcam HEK293T APEH KO transformed cell line human CVCL_B2RT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 586; APEH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357824 CVCL_B2S5 Abcam HEK293T ARL6IP1 KO transformed cell line human CVCL_B2S5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 697; ARL6IP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357825 CVCL_B2RS Abcam HEK293T APBB1 KO transformed cell line human CVCL_B2RS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 581; APBB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357826 CVCL_B2S4 Abcam HEK293T ARID1A KO transformed cell line human CVCL_B2S4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357827 CVCL_B2RV Abcam HEK293T APP KO transformed cell line human CVCL_B2RV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357828 CVCL_B2S7 Abcam HEK293T ARPC5L KO transformed cell line human CVCL_B2S7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23366; ARPC5L; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357829 CVCL_B2RU Abcam HEK293T APEX2 KO transformed cell line human CVCL_B2RU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17889; APEX2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357830 CVCL_B2S6 Abcam HEK293T ARL6IP4 KO transformed cell line human CVCL_B2S6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18076; ARL6IP4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357831 CVCL_B2RH Abcam HEK293T ALDH9A1 KO transformed cell line human CVCL_B2RH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 412; ALDH9A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357832 CVCL_B2RG Abcam HEK293T ALDH18A1 KO transformed cell line human CVCL_B2RG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9722; ALDH18A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357833 CVCL_B2RJ Abcam HEK293T ALKBH5 KO transformed cell line human CVCL_B2RJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25996; ALKBH5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357834 CVCL_B2RI Abcam HEK293T ALKBH2 KO transformed cell line human CVCL_B2RI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32487; ALKBH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357835 CVCL_B2RL Abcam HEK293T ANAPC15 KO transformed cell line human CVCL_B2RL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24531; ANAPC15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357836 CVCL_B2RK Abcam HEK293T AMPD2 KO transformed cell line human CVCL_B2RK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 469; AMPD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357837 CVCL_B2RN Abcam HEK293T ANP32A KO transformed cell line human CVCL_B2RN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13233; ANP32A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357838 CVCL_B2RM Abcam HEK293T ANKRD52 KO transformed cell line human CVCL_B2RM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26614; ANKRD52; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357839 CVCL_B2RB Abcam HEK293T AK2 KO transformed cell line human CVCL_B2RB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 362; AK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357840 CVCL_B2RA Abcam HEK293T AIFM1 KO transformed cell line human CVCL_B2RA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8768; AIFM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357841 CVCL_B2RD Abcam HEK293T AKAP1 KO transformed cell line human CVCL_B2RD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 367; AKAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357842 CVCL_B2RC Abcam HEK293T AK3 KO transformed cell line human CVCL_B2RC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17376; AK3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357843 CVCL_B2RF Abcam HEK293T ALAS1 KO transformed cell line human CVCL_B2RF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 396; ALAS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357844 CVCL_B2RE Abcam HEK293T AKR1A1 KO transformed cell line human CVCL_B2RE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 380; AKR1A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357845 CVCL_B2P6 Abcam A-549 NR3C1 KO cancer cell line human CVCL_B2P6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7978; NR3C1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357846 CVCL_B2P5 Abcam A-549 NMI KO cancer cell line human CVCL_B2P5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7854; NMI; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357847 CVCL_B2P8 Abcam A-549 OAS1 KO 2 cancer cell line human CVCL_B2P8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8086; OAS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357848 CVCL_B2P7 Abcam A-549 NT5C3A KO 1 cancer cell line human CVCL_B2P7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357849 CVCL_B2P9 Abcam A-549 OAS2 KO 2 cancer cell line human CVCL_B2P9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8087; OAS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357850 CVCL_B2P0 Abcam A-549 MSX1 KO 2 cancer cell line human CVCL_B2P0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7391; MSX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357851 CVCL_B2P2 Abcam A-549 MYH2 KO 1 cancer cell line human CVCL_B2P2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7572; MYH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267027; true Male 151357852 CVCL_B2P1 Abcam A-549 MX2 KO 1 cancer cell line human CVCL_B2P1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7533; MX2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357853 CVCL_B2P4 Abcam A-549 NCOA7 KO 2 cancer cell line human CVCL_B2P4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21081; NCOA7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357854 CVCL_B2P3 Abcam A-549 NBN KO cancer cell line human CVCL_B2P3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7652; NBN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab276103; true Male 151357855 CVCL_B2PV Abcam A-549 RTP4 KO 2 cancer cell line human CVCL_B2PV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23992; RTP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357856 CVCL_B2Q7 Abcam A-549 SOCS1 KO cancer cell line human CVCL_B2Q7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19383; SOCS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357857 CVCL_B2PU Abcam A-549 RSAD2 KO cancer cell line human CVCL_B2PU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30908; RSAD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267130; true Male 151357858 CVCL_B2Q6 Abcam A-549 SMAD3 KO 2 cancer cell line human CVCL_B2Q6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6769; SMAD3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357859 CVCL_B2PX Abcam A-549 SAMD9 KO 1 cancer cell line human CVCL_B2PX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1348; SAMD9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357860 CVCL_B2Q9 Abcam A-549 SP140 KO 2 cancer cell line human CVCL_B2Q9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17133; SP140; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357861 CVCL_B2PW Abcam A-549 SAA1 KO 1 cancer cell line human CVCL_B2PW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10513; SAA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab266994; true Male 151357862 CVCL_B2Q8 Abcam A-549 SP110 KO cancer cell line human CVCL_B2Q8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5401; SP110; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357863 CVCL_B2PZ Abcam A-549 SECTM1 KO 1 cancer cell line human CVCL_B2PZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10707; SECTM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357864 CVCL_B2PY Abcam A-549 SAMD9L KO 1 cancer cell line human CVCL_B2PY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1349; SAMD9L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357865 CVCL_B2PN Abcam A-549 PVR KO cancer cell line human CVCL_B2PN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9705; PVR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357866 CVCL_B2PM Abcam A-549 PTPRK KO 1 cancer cell line human CVCL_B2PM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357867 CVCL_B2PP Abcam A-549 PYHIN1 KO 2 cancer cell line human CVCL_B2PP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28894; PYHIN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357868 CVCL_B2Q1 Abcam A-549 SFRP1 KO cancer cell line human CVCL_B2Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10776; SFRP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357869 CVCL_B2Q0 Abcam A-549 SERPING1 KO 1 cancer cell line human CVCL_B2Q0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1228; SERPING1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab266940; true Male 151357870 CVCL_B2PR Abcam A-549 RASGRP3 KO 1 cancer cell line human CVCL_B2PR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14545; RASGRP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267198; true Male 151357871 CVCL_B2Q3 Abcam A-549 SIDT1 KO 2 cancer cell line human CVCL_B2Q3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25967; SIDT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357872 CVCL_B2PQ Abcam A-549 RAB27A KO cancer cell line human CVCL_B2PQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9766; RAB27A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357873 CVCL_B2Q2 Abcam A-549 SHFL KO 2 cancer cell line human CVCL_B2Q2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25649; SHFL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357874 CVCL_B2PT Abcam A-549 RNF19B KO 1 cancer cell line human CVCL_B2PT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26886; RNF19B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357875 CVCL_B2Q5 Abcam A-549 SLC2A1 KO cancer cell line human CVCL_B2Q5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11005; SLC2A1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357876 CVCL_B2PS Abcam A-549 REC8 KO cancer cell line human CVCL_B2PS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16879; REC8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357877 CVCL_B2Q4 Abcam A-549 SLC25A28 KO 1 cancer cell line human CVCL_B2Q4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23472; SLC25A28; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357878 CVCL_B2PF Abcam A-549 PARP9 KO 1 cancer cell line human CVCL_B2PF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24118; PARP9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357879 CVCL_B2PE Abcam A-549 PARP14 KO 1 cancer cell line human CVCL_B2PE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29232; PARP14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357880 CVCL_B2PH Abcam A-549 PLAAT4 KO 2 cancer cell line human CVCL_B2PH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9869; PLAAT4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357881 CVCL_B2PG Abcam A-549 PDCD1LG2 KO cancer cell line human CVCL_B2PG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267019; true Male 151357882 CVCL_B2PJ Abcam A-549 PLSCR1 KO 2 cancer cell line human CVCL_B2PJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9092; PLSCR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357883 CVCL_B2PI Abcam A-549 PLEKHA4 KO 2 cancer cell line human CVCL_B2PI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14339; PLEKHA4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357884 CVCL_B2PL Abcam A-549 PSMB8 KO 2 cancer cell line human CVCL_B2PL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9545; PSMB8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357885 CVCL_B2PK Abcam A-549 PMAIP1 KO 2 cancer cell line human CVCL_B2PK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9108; PMAIP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357886 CVCL_B2PB Abcam A-549 OASL KO 2 cancer cell line human CVCL_B2PB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8090; OASL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357887 CVCL_B2PA Abcam A-549 OAS3 KO cancer cell line human CVCL_B2PA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8088; OAS3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357888 CVCL_B2PD Abcam A-549 PARP10 KO 2 cancer cell line human CVCL_B2PD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25895; PARP10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357889 CVCL_B2PC Abcam A-549 OTOP3 KO 2 cancer cell line human CVCL_B2PC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19658; OTOP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357890 CVCL_B2MS Abcam A-549 ERCC1 KO cancer cell line human CVCL_B2MS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3433; ERCC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab276106; true Male 151357891 CVCL_B2N4 Abcam A-549 HLA-E KO 1 cancer cell line human CVCL_B2N4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4962; HLA-E; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357892 CVCL_B2MR Abcam A-549 EPSTI1 KO 1 cancer cell line human CVCL_B2MR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16465; EPSTI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357893 CVCL_B2N3 Abcam A-549 HES4 KO cancer cell line human CVCL_B2N3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24149; HES4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357894 CVCL_B2MU Abcam A-549 ETV7 KO 2 cancer cell line human CVCL_B2MU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18160; ETV7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357895 CVCL_B2N6 Abcam A-549 HTR3D KO 2 cancer cell line human CVCL_B2N6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24004; HTR3D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357896 CVCL_B2MT Abcam A-549 ETV6 KO 2 cancer cell line human CVCL_B2MT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357897 CVCL_B2N5 Abcam A-549 HMOX1 KO cancer cell line human CVCL_B2N5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5013; HMOX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357898 CVCL_B2MW Abcam A-549 GBP3 KO cancer cell line human CVCL_B2MW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4184; GBP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357899 CVCL_B2N8 Abcam A-549 IFI16 KO 2 cancer cell line human CVCL_B2N8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5395; IFI16; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357900 CVCL_B2MV Abcam A-549 GBP2 KO 1 cancer cell line human CVCL_B2MV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4183; GBP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357901 CVCL_B2N7 Abcam A-549 IDO1 KO 2 cancer cell line human CVCL_B2N7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6059; IDO1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab266950; true Male 151357902 CVCL_B2MY Abcam A-549 GCH1 KO 2 cancer cell line human CVCL_B2MY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4193; GCH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357903 CVCL_B2MX Abcam A-549 GBP4 KO 2 cancer cell line human CVCL_B2MX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20480; GBP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357904 CVCL_B2N9 Abcam A-549 IFI35 KO cancer cell line human CVCL_B2N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5399; IFI35; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357905 CVCL_B2MK Abcam A-549 DDX60L KO cancer cell line human CVCL_B2MK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26429; DDX60L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357906 CVCL_B2MJ Abcam A-549 DDX58 KO 2 cancer cell line human CVCL_B2MJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19102; RIGI; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357907 CVCL_B2MM Abcam A-549 DSG2 KO 1 cancer cell line human CVCL_B2MM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357908 CVCL_B2ML Abcam A-549 DHX58 KO cancer cell line human CVCL_B2ML CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29517; DHX58; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357909 CVCL_B2N0 Abcam A-549 HAPLN3 KO 2 cancer cell line human CVCL_B2N0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21446; HAPLN3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357910 CVCL_B2MN Abcam A-549 DTX3L KO 1 cancer cell line human CVCL_B2MN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30323; DTX3L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357911 CVCL_B2MQ Abcam A-549 EIF2AK2 KO 2 cancer cell line human CVCL_B2MQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9437; EIF2AK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357912 CVCL_B2N2 Abcam A-549 HERC5 KO 2 cancer cell line human CVCL_B2N2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24368; HERC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357913 CVCL_B2MP Abcam A-549 DUSP4 KO cancer cell line human CVCL_B2MP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3070; DUSP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357914 CVCL_B2N1 Abcam A-549 HELZ2 KO 2 cancer cell line human CVCL_B2N1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30021; HELZ2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357915 CVCL_B2MC Abcam A-549 CFH KO cancer cell line human CVCL_B2MC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4883; CFH; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357916 CVCL_B2MB Abcam A-549 CEACAM1 KO 1 cancer cell line human CVCL_B2MB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1814; CEACAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357917 CVCL_B2ME Abcam A-549 CHEK2 KO cancer cell line human CVCL_B2ME CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16627; CHEK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357918 CVCL_B2MD Abcam A-549 CFHR3 KO 2 cancer cell line human CVCL_B2MD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16980; CFHR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357919 CVCL_B2MG Abcam A-549 CXCL10 KO 1 cancer cell line human CVCL_B2MG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10637; CXCL10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357920 CVCL_B2MF Abcam A-549 CMPK2 KO 1 cancer cell line human CVCL_B2MF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27015; CMPK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357921 CVCL_B2MI Abcam A-549 CYP24A1 KO cancer cell line human CVCL_B2MI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2602; CYP24A1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357922 CVCL_B2MH Abcam A-549 CXCL10 KO 3 cancer cell line human CVCL_B2MH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10637; CXCL10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357923 CVCL_B2LZ Abcam HeLa ZRANB1 KO cancer cell line human CVCL_B2LZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18224; ZRANB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151357924 CVCL_B2LY Abcam HeLa ZNHIT6 KO cancer cell line human CVCL_B2LY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26089; ZNHIT6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151357925 CVCL_B2MA Abcam A-549 CD274 KO 2 cancer cell line human CVCL_B2MA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17635; CD274; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357926 CVCL_B2NT Abcam A-549 LILRB4 KO cancer cell line human CVCL_B2NT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6608; LILRB4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357927 CVCL_B2NS Abcam A-549 LGALS9 KO cancer cell line human CVCL_B2NS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6570; LGALS9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357928 CVCL_B2NV Abcam A-549 MAP2K7 KO 2 cancer cell line human CVCL_B2NV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357929 CVCL_B2NU Abcam A-549 LRRK2 KO cancer cell line human CVCL_B2NU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab277993; true Male 151357930 CVCL_B2NX Abcam A-549 MAP3K15 KO 1 cancer cell line human CVCL_B2NX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31689; MAP3K15; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357931 CVCL_B2NW Abcam A-549 MAP3K11 KO 2 cancer cell line human CVCL_B2NW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357932 CVCL_B2NZ Abcam A-549 MLH1 KO cancer cell line human CVCL_B2NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357933 CVCL_B2NY Abcam A-549 MAP3K2 KO 1 cancer cell line human CVCL_B2NY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357934 CVCL_B2NL Abcam A-549 IRF7 KO 1 cancer cell line human CVCL_B2NL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357935 CVCL_B2NK Abcam A-549 IRF3 KO 1 cancer cell line human CVCL_B2NK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6118; IRF3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357936 CVCL_B2NN Abcam A-549 ISM1 KO 2 cancer cell line human CVCL_B2NN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16213; ISM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357937 CVCL_B2NM Abcam A-549 IRF9 KO cancer cell line human CVCL_B2NM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6131; IRF9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357938 CVCL_B2NP Abcam A-549 KDM7A KO 1 cancer cell line human CVCL_B2NP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22224; KDM7A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357939 CVCL_B2NR Abcam A-549 LAMP3 KO 2 cancer cell line human CVCL_B2NR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14582; LAMP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357940 CVCL_B2NQ Abcam A-549 KRT7 KO cancer cell line human CVCL_B2NQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6445; KRT7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357941 CVCL_B2ND Abcam A-549 IFIH1 KO 2 cancer cell line human CVCL_B2ND CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18873; IFIH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357942 CVCL_B2NC Abcam A-549 IFI6 KO 2 cancer cell line human CVCL_B2NC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4054; IFI6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357943 CVCL_B2NF Abcam A-549 IFIT5 KO 1 cancer cell line human CVCL_B2NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13328; IFIT5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357944 CVCL_B2NE Abcam A-549 IFIT2 KO 2 cancer cell line human CVCL_B2NE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5409; IFIT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357945 CVCL_B2NH Abcam A-549 IL15RA KO 2 cancer cell line human CVCL_B2NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5978; IL15RA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357946 CVCL_B2NG Abcam A-549 IFNL3 KO cancer cell line human CVCL_B2NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18365; IFNL3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357947 CVCL_B2NJ Abcam A-549 IRF2 KO 1 cancer cell line human CVCL_B2NJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357948 CVCL_B2NI Abcam A-549 IL6ST KO cancer cell line human CVCL_B2NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6021; IL6ST; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357949 CVCL_B2MZ Abcam A-549 GMPR KO 2 cancer cell line human CVCL_B2MZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4376; GMPR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357950 CVCL_B2NB Abcam A-549 IFI44L KO 2 cancer cell line human CVCL_B2NB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17817; IFI44L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357951 CVCL_B2NA Abcam A-549 IFI44 KO 2 cancer cell line human CVCL_B2NA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16938; IFI44; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151357952 CVCL_B2ZB Abcam HEK293T ILKAP KO transformed cell line human CVCL_B2ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15566; ILKAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357953 CVCL_B2ZA Abcam HEK293T IL4R KO transformed cell line human CVCL_B2ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6015; IL4R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357954 CVCL_B2ZD Abcam HEK293T IPO4 KO transformed cell line human CVCL_B2ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19426; IPO4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357955 CVCL_B2ZC Abcam HEK293T INVS KO transformed cell line human CVCL_B2ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17870; INVS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357956 CVCL_B2ZF Abcam HEK293T IRS1 KO transformed cell line human CVCL_B2ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6125; IRS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab267320; true Female 151357957 CVCL_B2ZE Abcam HEK293T IPPK KO transformed cell line human CVCL_B2ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14645; IPPK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357958 CVCL_B2YW Abcam HEK293T HNRNPA0 KO transformed cell line human CVCL_B2YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5030; HNRNPA0; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357959 CVCL_B2Z8 Abcam HEK293T IDH3G KO transformed cell line human CVCL_B2Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5386; IDH3G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357960 CVCL_B2YV Abcam HEK293T HMGN3 KO transformed cell line human CVCL_B2YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12312; HMGN3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357961 CVCL_B2Z7 Abcam HEK293T HSP90B1 KO transformed cell line human CVCL_B2Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12028; HSP90B1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357962 CVCL_B2YY Abcam HEK293T HNRNPA1L2 KO transformed cell line human CVCL_B2YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27067; HNRNPA1L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357963 CVCL_B2YX Abcam HEK293T HNRNPA1 KO transformed cell line human CVCL_B2YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5031; HNRNPA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357964 CVCL_B2Z9 Abcam HEK293T IKBKG KO transformed cell line human CVCL_B2Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5961; IKBKG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357965 CVCL_B2YZ Abcam HEK293T HNRNPA2B1 KO transformed cell line human CVCL_B2YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5033; HNRNPA2B1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357966 CVCL_B2Z0 Abcam HEK293T HNRNPA3 KO transformed cell line human CVCL_B2Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24941; HNRNPA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357967 CVCL_B2YN Abcam HEK293T HEY1 KO transformed cell line human CVCL_B2YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4880; HEY1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab267338; true Female 151357968 CVCL_B2YQ Abcam HEK293T HK1 KO transformed cell line human CVCL_B2YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4922; HK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357969 CVCL_B2Z2 Abcam HEK293T HNRNPR KO transformed cell line human CVCL_B2Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5047; HNRNPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357970 CVCL_B2YP Abcam HEK293T HINT2 KO transformed cell line human CVCL_B2YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18344; HINT2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357971 CVCL_B2Z1 Abcam HEK293T HNRNPAB KO transformed cell line human CVCL_B2Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5034; HNRNPAB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357972 CVCL_B2YS Abcam HEK293T HM13 KO transformed cell line human CVCL_B2YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16435; HM13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357973 CVCL_B2Z4 Abcam HEK293T HP1BP3 KO transformed cell line human CVCL_B2Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24973; HP1BP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357974 CVCL_B2YR Abcam HEK293T HLA-E KO transformed cell line human CVCL_B2YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4962; HLA-E; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357975 CVCL_B2Z3 Abcam HEK293T HNRNPUL1 KO transformed cell line human CVCL_B2Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17011; HNRNPUL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357976 CVCL_B2YU Abcam HEK293T HMGN2 KO transformed cell line human CVCL_B2YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4986; HMGN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357977 CVCL_B2Z6 Abcam HEK293T HSP90AB1 KO transformed cell line human CVCL_B2Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5258; HSP90AB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357978 CVCL_B2YT Abcam HEK293T HMGB2 KO transformed cell line human CVCL_B2YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5000; HMGB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357979 CVCL_B2Z5 Abcam HEK293T HSP90AA1 KO transformed cell line human CVCL_B2Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5253; HSP90AA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357980 CVCL_B2YG Abcam HEK293T H3-3B KO transformed cell line human CVCL_B2YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4765; H3-3B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357981 CVCL_B2YF Abcam HEK293T GTF3C6 KO transformed cell line human CVCL_B2YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20872; GTF3C6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357982 CVCL_B2YI Abcam HEK293T HCFC1R1 KO transformed cell line human CVCL_B2YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21198; HCFC1R1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357983 CVCL_B2YH Abcam HEK293T HADHA KO transformed cell line human CVCL_B2YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4801; HADHA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357984 CVCL_B2YK Abcam HEK293T HDAC2 KO 2 transformed cell line human CVCL_B2YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357985 CVCL_B2YJ Abcam HEK293T HDAC2 KO 1 transformed cell line human CVCL_B2YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357986 CVCL_B2YM Abcam HEK293T HDHD5 KO transformed cell line human CVCL_B2YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357987 CVCL_B2YL Abcam HEK293T HDAC2 KO 3 transformed cell line human CVCL_B2YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357988 CVCL_B2ZX Abcam HEK293T KRTCAP2 KO transformed cell line human CVCL_B2ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28942; KRTCAP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357989 CVCL_B2ZW Abcam HEK293T KNSTRN KO transformed cell line human CVCL_B2ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30767; KNSTRN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357990 CVCL_B2ZZ Abcam HEK293T L3MBTL3 KO transformed cell line human CVCL_B2ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23035; L3MBTL3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357991 CVCL_B2ZY Abcam HEK293T KXD1 KO transformed cell line human CVCL_B2ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28420; KXD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357992 CVCL_B2ZP Abcam HEK293T KDM6B KO transformed cell line human CVCL_B2ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357993 CVCL_B2ZR Abcam HEK293T KIAA0100 KO transformed cell line human CVCL_B2ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28960; BLTP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357994 CVCL_B2ZQ Abcam HEK293T KHK KO transformed cell line human CVCL_B2ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6315; KHK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357995 CVCL_B2ZT Abcam HEK293T KIF20A KO transformed cell line human CVCL_B2ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9787; KIF20A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357996 CVCL_B2ZS Abcam HEK293T KIF1C KO transformed cell line human CVCL_B2ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357997 CVCL_B2ZV Abcam HEK293T KLHDC3 KO transformed cell line human CVCL_B2ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20704; KLHDC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357998 CVCL_B2ZU Abcam HEK293T KIF22 KO transformed cell line human CVCL_B2ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6391; KIF22; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151357999 CVCL_B2ZH Abcam HEK293T JMJD6 KO transformed cell line human CVCL_B2ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19355; JMJD6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358000 CVCL_B2ZG Abcam HEK293T ITPA KO transformed cell line human CVCL_B2ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6176; ITPA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358001 CVCL_B2ZJ Abcam HEK293T JUP KO transformed cell line human CVCL_B2ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6207; JUP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358002 CVCL_B2ZI Abcam HEK293T JOSD1 KO transformed cell line human CVCL_B2ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28953; JOSD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358003 CVCL_B2ZL Abcam HEK293T KDELR2 KO transformed cell line human CVCL_B2ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6305; KDELR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358004 CVCL_B2ZK Abcam HEK293T KDELR1 KO transformed cell line human CVCL_B2ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6304; KDELR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358005 CVCL_B2ZN Abcam HEK293T KDM5C KO 2 transformed cell line human CVCL_B2ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11114; KDM5C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358006 CVCL_B2ZM Abcam HEK293T KDM5C KO 1 transformed cell line human CVCL_B2ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11114; KDM5C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358007 CVCL_B2XB Abcam HEK293T FTSJ1 KO transformed cell line human CVCL_B2XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13254; FTSJ1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358008 CVCL_B2XA Abcam HEK293T FTH1 KO transformed cell line human CVCL_B2XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3976; FTH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358009 CVCL_B2XD Abcam HEK293T FUS KO transformed cell line human CVCL_B2XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358010 CVCL_B2XC Abcam HEK293T FUCA2 KO transformed cell line human CVCL_B2XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4008; FUCA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358011 CVCL_B2WU Abcam HEK293T FAM136A KO transformed cell line human CVCL_B2WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25911; FAM136A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358012 CVCL_B2X6 Abcam HEK293T FLAD1 KO transformed cell line human CVCL_B2X6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24671; FLAD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358013 CVCL_B2WT Abcam HEK293T FAM120A KO transformed cell line human CVCL_B2WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13247; FAM120A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358014 CVCL_B2X5 Abcam HEK293T FKBP2 KO transformed cell line human CVCL_B2X5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3718; FKBP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358015 CVCL_B2WW Abcam HEK293T FAM174C KO transformed cell line human CVCL_B2WW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26073; FAM174C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358016 CVCL_B2X8 Abcam HEK293T FLOT2 KO transformed cell line human CVCL_B2X8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3758; FLOT2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358017 CVCL_B2WV Abcam HEK293T FAM162A KO transformed cell line human CVCL_B2WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17865; FAM162A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358018 CVCL_B2X7 Abcam HEK293T FLOT1 KO transformed cell line human CVCL_B2X7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3757; FLOT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358019 CVCL_B2WY Abcam HEK293T FANCG KO transformed cell line human CVCL_B2WY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3588; FANCG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358020 CVCL_B2WX Abcam HEK293T FAM83D KO transformed cell line human CVCL_B2WX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16122; FAM83D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358021 CVCL_B2X9 Abcam HEK293T FOXO3 KO transformed cell line human CVCL_B2X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3821; FOXO3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358022 CVCL_B2WZ Abcam HEK293T FANCI KO transformed cell line human CVCL_B2WZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25568; FANCI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358023 CVCL_B2WM Abcam HEK293T ERF KO transformed cell line human CVCL_B2WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3444; ERF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358024 CVCL_B2WL Abcam HEK293T EPHB4 KO 2 transformed cell line human CVCL_B2WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358025 CVCL_B2X0 Abcam HEK293T FCGRT KO transformed cell line human CVCL_B2X0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3621; FCGRT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358026 CVCL_B2WN Abcam HEK293T ERGIC3 KO transformed cell line human CVCL_B2WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15927; ERGIC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358027 CVCL_B2WQ Abcam HEK293T ESD KO transformed cell line human CVCL_B2WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3465; ESD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358028 CVCL_B2X2 Abcam HEK293T FGF13 KO transformed cell line human CVCL_B2X2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3670; FGF13; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358029 CVCL_B2WP Abcam HEK293T ERP29 KO transformed cell line human CVCL_B2WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13799; ERP29; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358030 CVCL_B2X1 Abcam HEK293T FCSK KO transformed cell line human CVCL_B2X1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29500; FCSK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358031 CVCL_B2WS Abcam HEK293T F2R KO transformed cell line human CVCL_B2WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3537; F2R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266398; true Female 151358032 CVCL_B2X4 Abcam HEK293T FKBP10 KO transformed cell line human CVCL_B2X4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18169; FKBP10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358033 CVCL_B2WR Abcam HEK293T ETFA KO transformed cell line human CVCL_B2WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3481; ETFA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358034 CVCL_B2X3 Abcam HEK293T FGFR1 KO transformed cell line human CVCL_B2X3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3688; FGFR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358035 CVCL_B2WE Abcam HEK293T EIF2D KO transformed cell line human CVCL_B2WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6583; EIF2D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358036 CVCL_B2WD Abcam HEK293T EIF2AK4 KO 2 transformed cell line human CVCL_B2WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358037 CVCL_B2WG Abcam HEK293T EIF4G2 KO transformed cell line human CVCL_B2WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3297; EIF4G2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358038 CVCL_B2WF Abcam HEK293T EIF3K KO transformed cell line human CVCL_B2WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24656; EIF3K; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358039 CVCL_B2WI Abcam HEK293T ELOF1 KO transformed cell line human CVCL_B2WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28691; ELOF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358040 CVCL_B2WH Abcam HEK293T EIF4H KO transformed cell line human CVCL_B2WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12741; EIF4H; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358041 CVCL_B2WK Abcam HEK293T EPHB4 KO 1 transformed cell line human CVCL_B2WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358042 CVCL_B2WJ Abcam HEK293T EMD KO transformed cell line human CVCL_B2WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3331; EMD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358043 CVCL_B2YA Abcam HEK293T GSK3A KO transformed cell line human CVCL_B2YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4616; GSK3A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358044 CVCL_B2YC Abcam HEK293T GSTK1 KO transformed cell line human CVCL_B2YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16906; GSTK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358045 CVCL_B2YB Abcam HEK293T GSS KO transformed cell line human CVCL_B2YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4624; GSS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358046 CVCL_B2YE Abcam HEK293T GTF2F1 KO transformed cell line human CVCL_B2YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4652; GTF2F1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358047 CVCL_B2YD Abcam HEK293T GSTO1 KO transformed cell line human CVCL_B2YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13312; GSTO1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358048 CVCL_B2XV Abcam HEK293T GNG4 KO transformed cell line human CVCL_B2XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4407; GNG4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358049 CVCL_B2Y7 Abcam HEK293T GRHPR KO transformed cell line human CVCL_B2Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4570; GRHPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358050 CVCL_B2XU Abcam HEK293T GNB2 KO transformed cell line human CVCL_B2XU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4398; GNB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358051 CVCL_B2Y6 Abcam HEK293T GPX1 KO transformed cell line human CVCL_B2Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4553; GPX1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358052 CVCL_B2XX Abcam HEK293T GNG8 KO transformed cell line human CVCL_B2XX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19664; GNG8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358053 CVCL_B2Y9 Abcam HEK293T GRN KO transformed cell line human CVCL_B2Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4601; GRN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358054 CVCL_B2XW Abcam HEK293T GNG5 KO transformed cell line human CVCL_B2XW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4408; GNG5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358055 CVCL_B2Y8 Abcam HEK293T GRK2 KO transformed cell line human CVCL_B2Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 289; GRK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358056 CVCL_B2XZ Abcam HEK293T GOLGA5 KO transformed cell line human CVCL_B2XZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4428; GOLGA5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358057 CVCL_B2XY Abcam HEK293T GNPDA1 KO transformed cell line human CVCL_B2XY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4417; GNPDA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358058 CVCL_B2XN Abcam HEK293T GHITM KO 2 transformed cell line human CVCL_B2XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17281; GHITM; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358059 CVCL_B2XM Abcam HEK293T GHITM KO 1 transformed cell line human CVCL_B2XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17281; GHITM; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358060 CVCL_B2XP Abcam HEK293T GIPC1 KO transformed cell line human CVCL_B2XP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1226; GIPC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358061 CVCL_B2Y1 Abcam HEK293T GOLM1 KO transformed cell line human CVCL_B2Y1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15451; GOLM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358062 CVCL_B2Y0 Abcam HEK293T GOLIM4 KO transformed cell line human CVCL_B2Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15448; GOLIM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358063 CVCL_B2XR Abcam HEK293T GLI4 KO transformed cell line human CVCL_B2XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4320; GLI4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358064 CVCL_B2Y3 Abcam HEK293T GPATCH4 KO transformed cell line human CVCL_B2Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25982; GPATCH4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358065 CVCL_B2XQ Abcam HEK293T GK KO transformed cell line human CVCL_B2XQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4289; GK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358066 CVCL_B2Y2 Abcam HEK293T GPAA1 KO transformed cell line human CVCL_B2Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4446; GPAA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358067 CVCL_B2XT Abcam HEK293T GNAI1 KO transformed cell line human CVCL_B2XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4384; GNAI1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358068 CVCL_B2Y5 Abcam HEK293T GPI KO transformed cell line human CVCL_B2Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4458; GPI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358069 CVCL_B2XS Abcam HEK293T GLYR1 KO transformed cell line human CVCL_B2XS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24434; GLYR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358070 CVCL_B2Y4 Abcam HEK293T GPC4 KO transformed cell line human CVCL_B2Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4452; GPC4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358071 CVCL_B2XF Abcam HEK293T FYN KO transformed cell line human CVCL_B2XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4037; FYN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358072 CVCL_B2XE Abcam HEK293T FXYD5 KO transformed cell line human CVCL_B2XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4029; FXYD5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358073 CVCL_B2XH Abcam HEK293T G6PC3 KO transformed cell line human CVCL_B2XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24861; G6PC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358074 CVCL_B2XG Abcam HEK293T FZR1 KO transformed cell line human CVCL_B2XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24824; FZR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358075 CVCL_B2XJ Abcam HEK293T GAK KO transformed cell line human CVCL_B2XJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4113; GAK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358076 CVCL_B2XI Abcam HEK293T GAA KO transformed cell line human CVCL_B2XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4065; GAA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358077 CVCL_B2XL Abcam HEK293T GDI2 KO transformed cell line human CVCL_B2XL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4227; GDI2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358078 CVCL_B2XK Abcam HEK293T GCN1 KO transformed cell line human CVCL_B2XK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4199; GCN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358079 CVCL_B2UZ Abcam HEK293T COQ8A KO transformed cell line human CVCL_B2UZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16812; COQ8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358080 CVCL_B2VB Abcam HEK293T CSTB KO transformed cell line human CVCL_B2VB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2482; CSTB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358081 CVCL_B2VA Abcam HEK293T CSF2 KO transformed cell line human CVCL_B2VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358082 CVCL_B2US Abcam HEK293T COA4 KO transformed cell line human CVCL_B2US CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24604; COA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358083 CVCL_B2V4 Abcam HEK293T CPNE1 KO transformed cell line human CVCL_B2V4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2314; CPNE1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358084 CVCL_B2UR Abcam HEK293T COA3 KO transformed cell line human CVCL_B2UR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24990; COA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358085 CVCL_B2V3 Abcam HEK293T COX8A KO transformed cell line human CVCL_B2V3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2294; COX8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358086 CVCL_B2UU Abcam HEK293T COL6A2 KO transformed cell line human CVCL_B2UU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2212; COL6A2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab266482; true Female 151358087 CVCL_B2V6 Abcam HEK293T CPT1A KO transformed cell line human CVCL_B2V6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2328; CPT1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358088 CVCL_B2UT Abcam HEK293T COL6A1 KO transformed cell line human CVCL_B2UT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2211; COL6A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358089 CVCL_B2V5 Abcam HEK293T CPSF7 KO transformed cell line human CVCL_B2V5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30098; CPSF7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358090 CVCL_B2UW Abcam HEK293T COMT KO transformed cell line human CVCL_B2UW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2228; COMT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358091 CVCL_B2V8 Abcam HEK293T CREBBP KO transformed cell line human CVCL_B2V8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358092 CVCL_B2UV Abcam HEK293T COLGALT1 KO transformed cell line human CVCL_B2UV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26182; COLGALT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358093 CVCL_B2V7 Abcam HEK293T CRAT KO transformed cell line human CVCL_B2V7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2342; CRAT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358094 CVCL_B2UY Abcam HEK293T COPS7B KO transformed cell line human CVCL_B2UY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16760; COPS7B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358095 CVCL_B2UX Abcam HEK293T COPS7A KO transformed cell line human CVCL_B2UX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16758; COPS7A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358096 CVCL_B2V9 Abcam HEK293T CRIM1 KO transformed cell line human CVCL_B2V9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2359; CRIM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358097 CVCL_B2UK Abcam HEK293T CMC2 KO 2 transformed cell line human CVCL_B2UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24447; CMC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358098 CVCL_B2UJ Abcam HEK293T CMC2 KO 1 transformed cell line human CVCL_B2UJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24447; CMC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358099 CVCL_B2UM Abcam HEK293T CNKSR3 KO transformed cell line human CVCL_B2UM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23034; CNKSR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358100 CVCL_B2UL Abcam HEK293T CNIH4 KO transformed cell line human CVCL_B2UL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25013; CNIH4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358101 CVCL_B2V0 Abcam HEK293T COQ9 KO transformed cell line human CVCL_B2V0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25302; COQ9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358102 CVCL_B2UN Abcam HEK293T CNOT1 KO transformed cell line human CVCL_B2UN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7877; CNOT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358103 CVCL_B2UQ Abcam HEK293T COA1 KO transformed cell line human CVCL_B2UQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21868; COA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358104 CVCL_B2V2 Abcam HEK293T COX7A2 KO transformed cell line human CVCL_B2V2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2288; COX7A2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358105 CVCL_B2UP Abcam HEK293T CNPY2 KO transformed cell line human CVCL_B2UP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13529; CNPY2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358106 CVCL_B2V1 Abcam HEK293T CORO1C KO transformed cell line human CVCL_B2V1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2254; CORO1C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358107 CVCL_B2UC Abcam HEK293T CIB1 KO transformed cell line human CVCL_B2UC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16920; CIB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358108 CVCL_B2UB Abcam HEK293T CHD1 KO transformed cell line human CVCL_B2UB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1915; CHD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358109 CVCL_B2UE Abcam HEK293T CIRBP KO transformed cell line human CVCL_B2UE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1982; CIRBP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358110 CVCL_B2UD Abcam HEK293T CIB2 KO transformed cell line human CVCL_B2UD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24579; CIB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358111 CVCL_B2UG Abcam HEK293T CKMT1A KO transformed cell line human CVCL_B2UG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31736; CKMT1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358112 CVCL_B2UF Abcam HEK293T CIT KO transformed cell line human CVCL_B2UF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1985; CIT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358113 CVCL_B2UI Abcam HEK293T CLUH KO transformed cell line human CVCL_B2UI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29094; CLUH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358114 CVCL_B2UH Abcam HEK293T CLTA KO transformed cell line human CVCL_B2UH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2090; CLTA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358115 CVCL_B2WA Abcam HEK293T EEF1E1 KO transformed cell line human CVCL_B2WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3212; EEF1E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358116 CVCL_B2WC Abcam HEK293T EIF2AK4 KO 1 transformed cell line human CVCL_B2WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358117 CVCL_B2WB Abcam HEK293T EIF1 KO transformed cell line human CVCL_B2WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3249; EIF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358118 CVCL_B2VT Abcam HEK293T DEGS1 KO transformed cell line human CVCL_B2VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13709; DEGS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358119 CVCL_B2W5 Abcam HEK293T DYRK1A KO transformed cell line human CVCL_B2W5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3091; DYRK1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358120 CVCL_B2VS Abcam HEK293T DCXR KO transformed cell line human CVCL_B2VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18985; DCXR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358121 CVCL_B2W4 Abcam HEK293T DYNC2I2 KO transformed cell line human CVCL_B2W4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28296; DYNC2I2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358122 CVCL_B2VV Abcam HEK293T DGUOK KO transformed cell line human CVCL_B2VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2858; DGUOK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358123 CVCL_B2W7 Abcam HEK293T ECH1 KO transformed cell line human CVCL_B2W7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3149; ECH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358124 CVCL_B2VU Abcam HEK293T DESI1 KO transformed cell line human CVCL_B2VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24577; DESI1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358125 CVCL_B2W6 Abcam HEK293T E2F4 KO transformed cell line human CVCL_B2W6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3118; E2F4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358126 CVCL_B2VX Abcam HEK293T DMPK KO transformed cell line human CVCL_B2VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2933; DMPK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358127 CVCL_B2W9 Abcam HEK293T EEF1B2 KO transformed cell line human CVCL_B2W9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3208; EEF1B2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358128 CVCL_B2VW Abcam HEK293T DIAPH1 KO transformed cell line human CVCL_B2VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2876; DIAPH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358129 CVCL_B2W8 Abcam HEK293T ECI2 KO transformed cell line human CVCL_B2W8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14601; ECI2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358130 CVCL_B2VZ Abcam HEK293T DNAJB1 KO transformed cell line human CVCL_B2VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5270; DNAJB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358131 CVCL_B2VY Abcam HEK293T DNAJA1 KO transformed cell line human CVCL_B2VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5229; DNAJA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358132 CVCL_B2VL Abcam HEK293T DAPK3 KO transformed cell line human CVCL_B2VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2676; DAPK3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358133 CVCL_B2VK Abcam HEK293T DAPK1 KO transformed cell line human CVCL_B2VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2674; DAPK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358134 CVCL_B2VN Abcam HEK293T DAZAP1 KO 2 transformed cell line human CVCL_B2VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2683; DAZAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358135 CVCL_B2VM Abcam HEK293T DAZAP1 KO 1 transformed cell line human CVCL_B2VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2683; DAZAP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358136 CVCL_B2VP Abcam HEK293T DAZAP2 KO transformed cell line human CVCL_B2VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2684; DAZAP2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358137 CVCL_B2W1 Abcam HEK293T DR1 KO transformed cell line human CVCL_B2W1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3017; DR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358138 CVCL_B2W0 Abcam HEK293T DNAJC2 KO transformed cell line human CVCL_B2W0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13192; DNAJC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358139 CVCL_B2VR Abcam HEK293T DCTPP1 KO transformed cell line human CVCL_B2VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28777; DCTPP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358140 CVCL_B2W3 Abcam HEK293T DROSHA KO transformed cell line human CVCL_B2W3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17904; DROSHA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358141 CVCL_B2VQ Abcam HEK293T DBI KO transformed cell line human CVCL_B2VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2690; DBI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358142 CVCL_B2W2 Abcam HEK293T DRG1 KO transformed cell line human CVCL_B2W2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3029; DRG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358143 CVCL_B2VD Abcam HEK293T CTDSP1 KO transformed cell line human CVCL_B2VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21614; CTDSP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358144 CVCL_B2VC Abcam HEK293T CTDNEP1 KO transformed cell line human CVCL_B2VC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19085; CTDNEP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358145 CVCL_B2VF Abcam HEK293T CTSL KO transformed cell line human CVCL_B2VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2537; CTSL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358146 CVCL_B2VE Abcam HEK293T CTSH KO transformed cell line human CVCL_B2VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2535; CTSH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358147 CVCL_B2VH Abcam HEK293T CYBA KO transformed cell line human CVCL_B2VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2577; CYBA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358148 CVCL_B2VG Abcam HEK293T CTTN KO transformed cell line human CVCL_B2VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3338; CTTN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358149 CVCL_B2VJ Abcam HEK293T DAG1 KO transformed cell line human CVCL_B2VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2666; DAG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358150 CVCL_B2VI Abcam HEK293T CYSTM1 KO transformed cell line human CVCL_B2VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30239; CYSTM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151358151 CVCL_B4GK WG4140 finite cell line human CVCL_B4GK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 68; ABCD4; Simple; c.542+1G>T; ClinVar=VCV000280107; Zygosity=Heterozygous; Note=Splice donor mutation (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 68; ABCD4; Simple; p.Gly486Cys (c.1456G>T); ClinVar=VCV000037322; Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874) Miscellaneous: Cell line no longer available Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358152 CVCL_B4GJ WG4066 finite cell line human CVCL_B4GJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 68; ABCD4; Simple; p.Tyr319Cys (c.956A>G); ClinVar=VCV000037319; Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 68; ABCD4; Simple; p.Glu583Leufs*9 (c.1746_1747insCT); ClinVar=VCV000037320; Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 6694; LRP2; Simple; p.Arg1311His (c.3932G>A); ClinVar=VCV000893877; Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 6694; LRP2; Simple; p.Arg3646His (c.10937G>A); ClinVar=VCV000074222; Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 24759; TPRG1; Simple; p.Ser141Ile (c.422G>T); Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874); Sequence variation: Mutation; HGNC; 24759; TPRG1; Simple; p.Tyr61Ter (c.183_192del); Zygosity=Heterozygous (CelloPub=CLPUB00670; PubMed=22922874) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 151358153 CVCL_B4GM WG4053 finite cell line human CVCL_B4GM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358154 CVCL_B4GL WG3897 finite cell line human CVCL_B4GL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358155 CVCL_B4H0 WG4042 finite cell line human CVCL_B4H0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Ala24_Lys82del (c.70-4298_246+2311del6785); Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=21303734); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358156 CVCL_B4GN IMBB spontaneously immortalized cell line house mouse CVCL_B4GN CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1097161; Bak1; Knockout cell: Method=KO mouse; MGI; MGI:99702; Bax Derived from sampling site: Whole embryo Cell type=Fibroblast.. Doubling time: ~24 hours (Patent=US8389276) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9386 151358157 CVCL_B4H2 NN10 cancer cell line house mouse CVCL_B4H2 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: ICFW. Characteristics: Constitutively synthesizes and secretes erythropoietin (PubMed=3861324) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-235 151358158 CVCL_B4GQ PV014 transformed cell line human CVCL_B4GQ CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Thr238Ter (c.712_713delAC) (T237X); Zygosity=Heterozygous (CelloPub=CLPUB00671); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671); Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: HGNC; 11730; TERT Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358159 CVCL_B4GP B-LCL-HROC10 transformed cell line human CVCL_B4GP From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151358160 CVCL_B4H1 IW32 cancer cell line house mouse CVCL_B4H1 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: ICFW. Characteristics: Constitutively synthesizes and secretes erythropoietin (PubMed=6578507; PubMed=6589018); Characteristics: One of the two copies of the EPO locus has undergone rearrangement and amplification (PubMed=2766927; PubMed=3561395) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-234 151358161 CVCL_B4GC RAC-5E cancer cell line house mouse CVCL_B4GC CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Doubling time: 9 hours (PubMed=3756929) 151358162 CVCL_B4GB RAC-1P cancer cell line house mouse CVCL_B4GB CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358163 CVCL_B4GE RAC-2C cancer cell line house mouse CVCL_B4GE CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358164 CVCL_B4GD RAC-4E cancer cell line house mouse CVCL_B4GD CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358165 CVCL_B4GG RAC-11P cancer cell line house mouse CVCL_B4GG CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358166 CVCL_B4GF RAC-10P cancer cell line house mouse CVCL_B4GF CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Doubling time: 23 hours (PubMed=3756929) 151358167 CVCL_B4GI WG3630 finite cell line human CVCL_B4GI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 68; ABCD4; Simple; p.Asn141Lys (c.423C>G); ClinVar=VCV001343599; Zygosity=Homozygous (PubMed=23141461); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Homozygous (PubMed=23141461) Miscellaneous: Cell line no longer available Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 151358168 CVCL_B4GH WG4095 finite cell line human CVCL_B4GH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358169 CVCL_B4FZ GM2300 cancer cell line human CVCL_B4FZ CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358170 CVCL_B4FY GM2217 cancer cell line human CVCL_B4FY CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Ser (c.488A>C); Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358171 CVCL_B4GA RAC-311C cancer cell line house mouse CVCL_B4GA CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358172 CVCL_B4FR 368BR finite cell line human CVCL_B4FR CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358173 CVCL_B4G3 GM2401 cancer cell line human CVCL_B4G3 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358174 CVCL_B4FQ 47N30A32 hybridoma house mouse CVCL_B4FQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-464 151358175 CVCL_B4G2 GM2345 cancer cell line human CVCL_B4G2 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358176 CVCL_B4FT GM139 cancer cell line human CVCL_B4FT CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358177 CVCL_B4G5 GM2493 cancer cell line human CVCL_B4G5 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358178 CVCL_B4FS GM133 cancer cell line human CVCL_B4FS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358179 CVCL_B4G4 GM2455 cancer cell line human CVCL_B4G4 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358180 CVCL_B4FV GM1592 cancer cell line human CVCL_B4FV CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358181 CVCL_B4G7 RAC-3C cancer cell line house mouse CVCL_B4G7 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Doubling time: 23 hours (PubMed=3756929) 151358182 CVCL_B4FU GM1578 cancer cell line human CVCL_B4FU CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358183 CVCL_B4G6 GM97 cancer cell line human CVCL_B4G6 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358184 CVCL_B4FX GM1600 cancer cell line human CVCL_B4FX CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358185 CVCL_B4G9 RAC-31C cancer cell line house mouse CVCL_B4G9 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Doubling time: 15 hours (PubMed=3756929) 151358186 CVCL_B4FW GM1596 cancer cell line human CVCL_B4FW CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220His (c.658T>C); ClinVar=VCV000376687; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358187 CVCL_B4G8 RAC-34E cancer cell line house mouse CVCL_B4G8 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Doubling time: 9.4 hours (PubMed=3756929) 151358188 CVCL_B4HL 4H11 hybridoma house mouse CVCL_B4HL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358189 CVCL_B4HK 4C9 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358190 CVCL_B4HN 6E6 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5433 151358191 CVCL_B4HM 5C12 [Mouse hybridoma against human HMGB1] hybridoma house mouse CVCL_B4HM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. 151358192 CVCL_B4HP 6H9 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1 (Note=Also recognizes human HMGB1 and human/rat Hmgb2). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5434 151358193 CVCL_B4I1 ML15-5F7.5B10 hybridoma house mouse CVCL_B4I1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7241 151358194 CVCL_B4I0 ML15-4B7.3A6 hybridoma house mouse CVCL_B4I0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7242 151358195 CVCL_B4HR 7H3 hybridoma house mouse CVCL_B4HR CL:0000010 Monoclonal antibody isotype: IgG1+IgG3; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358196 CVCL_B4I3 ML15-7E5.5E12 hybridoma house mouse CVCL_B4I3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7809 151358197 CVCL_B4HQ 7G8 hybridoma house mouse CVCL_B4HQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. 151358198 CVCL_B4I2 ML15-6A2-4B10 hybridoma house mouse CVCL_B4I2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7409 151358199 CVCL_B4HD 2E11 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1 (Note=Also recognizes human HMGB1 and human/rat Hmgb2). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5431 151358200 CVCL_B4HC 1C3 [Mouse hybridoma against human HMGB1] hybridoma house mouse CVCL_B4HC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. 151358201 CVCL_B4HF 2G7 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1 (Note=Also reacts with human). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5432 151358202 CVCL_B4HE 2G5 hybridoma house mouse CVCL_B4HE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358203 CVCL_B4HH 3E10 [Mouse hybridoma against human HMGB1] hybridoma house mouse CVCL_B4HH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. 151358204 CVCL_B4HG 3-5A6 hybridoma house mouse CVCL_B4HG CL:0000010 Monoclonal antibody isotype: IgG2a+IgG2b; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358205 CVCL_B4HJ 4A10 [Mouse hybridoma against human HMGB1] hybridoma house mouse CVCL_B4HJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. 151358206 CVCL_B4HI 3G8 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358207 CVCL_B4GZ WG4008 finite cell line human CVCL_B4GZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; c.1339-1G>T; ClinVar=VCV001323238; Zygosity=Heterozygous; Note=Splice acceptor mutation (CelloPub=CLPUB00671; PubMed=21303734) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358208 CVCL_B4HB 1A9 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358209 CVCL_B4HA 10D4 hybridoma house mouse CVCL_B4HA CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5435 151358210 CVCL_B4H4 NCC-MPNST6-C1 cancer cell line human CVCL_B4H4 CL:0000010 Population: Japanese; Derived from sampling site: Right thigh; hypodermis. Male Doubling time: ~75 hours (PubMed=34775549) Part of: NCC sarcoma cell line panel 151358211 CVCL_B4GS WG1908 finite cell line human CVCL_B4GS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Native North American; Dakelh; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358212 CVCL_B4H3 IW201 cancer cell line house mouse CVCL_B4H3 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795). 151358213 CVCL_B4GR WG3265 finite cell line human CVCL_B4GR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Thr172Argfs*10 (c.515_516delAC); ClinVar=VCV000000517; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358214 CVCL_B4GU WG1087 finite cell line human CVCL_B4GU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358215 CVCL_B4H6 Y12 hybridoma house mouse CVCL_B4H6 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa (PubMed=6180012); IgG3, kappa (PubMed=2295704); Monoclonal antibody target: UniProtKB; P27048; Mouse Snrpb. 151358216 CVCL_B4GT WG2432 finite cell line human CVCL_B4GT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358217 CVCL_B4H5 Y2 hybridoma house mouse CVCL_B4H5 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P27048; Mouse Snrpb. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8050 151358218 CVCL_B4H8 HeLa TUBA4A KO cancer cell line human CVCL_B4H8 From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12407; TUBA4A Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358219 CVCL_B4GW WG1903 finite cell line human CVCL_B4GW CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358220 CVCL_B4H7 E85 hybridoma house mouse CVCL_B4H7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P69905; Human HBA1 (Note=Glycated; N-deoxyfructosyllysine). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10616 151358221 CVCL_B4GV WG1173 finite cell line human CVCL_B4GV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358222 CVCL_B4GY WG1959 finite cell line human CVCL_B4GY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Lys281fs*4 (c.842_845delAGAG); Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19136951); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358223 CVCL_B4H9 DPH1.1 hybridoma house mouse CVCL_B4H9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1 (Note=Also reacts with mouse and rat). Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 10002 151358224 CVCL_B4GX WG1350 finite cell line human CVCL_B4GX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19136951) Population: El Salvadoran; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358225 CVCL_B4EI WG3599 finite cell line human CVCL_B4EI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala631Glnfs*17 (c.1891delG); ClinVar=VCV000242511; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358226 CVCL_B4EH WG3820 finite cell line human CVCL_B4EH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln624Arg (c.1871A>G); ClinVar=VCV001459267; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. 151358227 CVCL_B4EK WG3397 finite cell line human CVCL_B4EK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caribbean; Barbadian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358228 CVCL_B4EJ WG3564 finite cell line human CVCL_B4EJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro654_Arg655insTer (c.1962_1963delTC) (p.Pro654Profs*2); ClinVar=VCV000552144; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358229 CVCL_B4EM WG1220 finite cell line human CVCL_B4EM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Arg250Ter (c.748C>T); ClinVar=VCV000000767; Zygosity=Homozygous (PubMed=18385497) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358230 CVCL_B4EL WG3447 finite cell line human CVCL_B4EL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg727Ter (c.2179C>T); ClinVar=VCV000218998; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358231 CVCL_B4F0 WG3377 finite cell line human CVCL_B4F0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Thr238Ter (c.712_713delAC) (T237X); Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19136951); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19136951) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358232 CVCL_B4EN WG1437 finite cell line human CVCL_B4EN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Arg54Ter (c.160C>T); ClinVar=VCV000000765; Zygosity=Heterozygous (PubMed=18385497); Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Leu103_Ser108dup (c.307_324dup); ClinVar=VCV000000766; Zygosity=Heterozygous (PubMed=18385497) Miscellaneous: Cell line no longer available Population: Caribbean; Haitian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358233 CVCL_B4EA WG4027 finite cell line human CVCL_B4EA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Gln (c.683G>A); Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. 151358234 CVCL_B4EC WG3439 finite cell line human CVCL_B4EC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly427Asp (c.1280G>A); ClinVar=VCV000218990; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358235 CVCL_B4EB WG3426 finite cell line human CVCL_B4EB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; German/Polish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358236 CVCL_B4EE WG3664 finite cell line human CVCL_B4EE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Lys520Asn (c.1560G>C); Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. 151358237 CVCL_B4ED WG3482 finite cell line human CVCL_B4ED From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg474Ter (c.1420C>T); ClinVar=VCV000554873; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Middle Eastern; Derived from sampling site: Skin Cell type=Fibroblast.. 151358238 CVCL_B4EG WG3547 finite cell line human CVCL_B4EG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg581Ter (c.1741C>T); ClinVar=VCV000554675; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358239 CVCL_B4EF WG3705 finite cell line human CVCL_B4EF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Gly1167Val (c.3500G>T); ClinVar=VCV001444711; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Ile2071Val (c.6211A>G); ClinVar=VCV001478369; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala555Thr (c.1663G>A); ClinVar=VCV000203850; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Chinese/Asian ethnic group; Hmong; Derived from sampling site: Skin Cell type=Fibroblast.. 151358240 CVCL_B4DX WG3637 finite cell line human CVCL_B4DX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met266Tyrfs*7 (c.795_796insT); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358241 CVCL_B4E9 WG3721 finite cell line human CVCL_B4E9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val136Phe (c.406G>T); ClinVar=VCV001071892; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358242 CVCL_B4E8 WG3742 finite cell line human CVCL_B4E8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358243 CVCL_B4DW WG4169 finite cell line human CVCL_B4DW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.753+3A>G; dbSNP=rs776400008; Zygosity=Heterozygous; Note=Splice donor mutation (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1332+1delG; ClinVar=VCV000554656; Zygosity=Heterozygous; Note=Splice donor mutation (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358244 CVCL_B4DZ WG3760 finite cell line human CVCL_B4DZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala324Thr (c.970G>A); ClinVar=VCV000550893; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg616Cys (c.1846C>T); ClinVar=VCV000551499; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Caution: MMUT c.1846C>T mutation indicated incorrectly as being causative of p.Pro649Leu in CelloPub=CLPUB00669 and PubMed=27233228 (personal communication of Rosenblatt D.S.) 151358245 CVCL_B4DY WG3602 finite cell line human CVCL_B4DY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly312Val (c.935G>T); ClinVar=VCV000218988; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly637Arg (c.1909G>A); ClinVar=VCV001486406; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358246 CVCL_B4E1 WG3310 finite cell line human CVCL_B4E1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu394Phefs*30 (c.1181dupT); ClinVar=VCV000222930; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln659Ter (c.1975C>T); ClinVar=VCV000222939; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358247 CVCL_B4DP WG3972 finite cell line human CVCL_B4DP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro194Leu (c.581C>T); ClinVar=VCV001073632; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Portuguese and Mexican and Southeast Asian; Lao/Thai; Derived from sampling site: Skin Cell type=Fibroblast.. 151358248 CVCL_B4E0 WG3669 finite cell line human CVCL_B4E0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser354Trpfs*20 (c.1061delCinsGGA); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser357Metfs*5 (c.1065_1068dupATGG); ClinVar=VCV000280817; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Afghan; Derived from sampling site: Skin Cell type=Fibroblast.. 151358249 CVCL_B4DR WG3374 finite cell line human CVCL_B4DR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu414Lysfs*17 (c.1240delG); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358250 CVCL_B4E3 WG3794 finite cell line human CVCL_B4E3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val19Glyfs*39 (c.55dupG); ClinVar=VCV000222906; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. 151358251 CVCL_B4DQ WG3499 finite cell line human CVCL_B4DQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 16732; MCEE; Simple; p.Arg143His (c.428G>A); ClinVar=VCV000336936; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu211del (c.631_633delGAG); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: African or African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358252 CVCL_B4E2 WG3707 finite cell line human CVCL_B4E2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly427Asp (c.1280G>A); ClinVar=VCV000218990; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Unexplicit; Ex13 del; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 11653; TCN2; Simple; p.Arg170Gln (c.509G>A); ClinVar=VCV000341197; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358253 CVCL_B4E5 WG3325 finite cell line human CVCL_B4E5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg93His (c.278G>A); ClinVar=VCV000001880; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. 151358254 CVCL_B4DT WG3520 finite cell line human CVCL_B4DT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358255 CVCL_B4DS WG3556 finite cell line human CVCL_B4DS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1332+1delG; ClinVar=VCV000554656; Zygosity=Heterozygous; Note=Splice donor mutation (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358256 CVCL_B4E4 WG3784 finite cell line human CVCL_B4E4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro86Leu (c.257C>T); ClinVar=VCV000553773; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358257 CVCL_B4DV WG3329 finite cell line human CVCL_B4DV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu494Ter (c.1481T>A); ClinVar=VCV000551275; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. 151358258 CVCL_B4E7 WG3361 finite cell line human CVCL_B4E7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian and Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358259 CVCL_B4E6 WG3336 finite cell line human CVCL_B4E6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358260 CVCL_B4DU WG3965 finite cell line human CVCL_B4DU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr429Ter (c.1287C>G); ClinVar=VCV000554278; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358261 CVCL_B4FJ 30N47-1 hybridoma house mouse CVCL_B4FJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-463 151358262 CVCL_B4FI MODE-K.CD46 transformed cell line house mouse CVCL_B4FI CL:0000010 Transfected with: HGNC; 6953; CD46; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Female 151358263 CVCL_B4FL 47N30A35 hybridoma house mouse CVCL_B4FL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-465 151358264 CVCL_B4FK 47N3-6 hybridoma house mouse CVCL_B4FK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-466 151358265 CVCL_B4FN 47N48B22 hybridoma house mouse CVCL_B4FN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-469 151358266 CVCL_B4FM 47N38B27 hybridoma house mouse CVCL_B4FM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-468 151358267 CVCL_B4FP 47N9-11 hybridoma house mouse CVCL_B4FP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-467 151358268 CVCL_B4G1 GM2328 cancer cell line human CVCL_B4G1 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Ser (c.481G>T); Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358269 CVCL_B4G0 GM2313 cancer cell line human CVCL_B4G0 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=14961077) Derived from sampling site: Brain. Unspecified Characteristics: Early passage culture 151358270 CVCL_B4FB HC11/Twist spontaneously immortalized cell line house mouse CVCL_B4FB CL:0000010 Transfected with: MGI; MGI:98872; Twist1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 151358271 CVCL_B4FA HC11/MV7 spontaneously immortalized cell line house mouse CVCL_B4FA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female Characteristics: Control cell line for HC11/Twist and HC11/Wnt-1 151358272 CVCL_B4FD RAC/MV7 cancer cell line house mouse CVCL_B4FD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Characteristics: Control cell line for RAC/Wnt-1 151358273 CVCL_B4FC HC11/Wnt-1 spontaneously immortalized cell line house mouse CVCL_B4FC CL:0000010 Transfected with: MGI; MGI:98953; Wnt1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 151358274 CVCL_B4FF RAC/Wnt-1 #9 cancer cell line house mouse CVCL_B4FF CL:0000010 Transfected with: MGI; MGI:98953; Wnt1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female Characteristics: Expresses Wnt1 at a high level (PubMed=10197631) 151358275 CVCL_B4FE RAC/Wnt-1 cancer cell line house mouse CVCL_B4FE CL:0000010 Transfected with: MGI; MGI:98953; Wnt1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Breed/subspecies: BALB/c. Female 151358276 CVCL_B4FH MODE-K.CD150 transformed cell line house mouse CVCL_B4FH CL:0000010 Transfected with: HGNC; 10903; SLAMF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Female 151358277 CVCL_B4FG MODE-K transformed cell line house mouse CVCL_B4FG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Female Doubling time: 15 hours (PubMed=7693823) 151358278 CVCL_B4EY WG3298 finite cell line human CVCL_B4EY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358279 CVCL_B4F9 C57/Wnt-1 spontaneously immortalized cell line house mouse CVCL_B4F9 CL:0000010 Transfected with: MGI; MGI:98953; Wnt1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female 151358280 CVCL_B4EX WG3287 finite cell line human CVCL_B4EX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358281 CVCL_B4EZ WG3322 finite cell line human CVCL_B4EZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358282 CVCL_B4F2 WG3470 finite cell line human CVCL_B4F2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358283 CVCL_B4EQ WG3583 finite cell line human CVCL_B4EQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Ser228Ter (c.683C>G); Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19058814) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358284 CVCL_B4EP WG3280 finite cell line human CVCL_B4EP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Leu21Ilefs*2 (c.60_61insAT); ClinVar=VCV000219001; Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19058814); Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Cys153Metfs*10 (c.455dupC); ClinVar=VCV000219002; Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19058814) Miscellaneous: Cell line no longer available Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358285 CVCL_B4F1 WG3412 finite cell line human CVCL_B4F1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358286 CVCL_B4ES WG1191 finite cell line human CVCL_B4ES From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358287 CVCL_B4F4 WG3589 finite cell line human CVCL_B4F4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358288 CVCL_B4F3 WG3560 finite cell line human CVCL_B4F3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358289 CVCL_B4ER WG3745 finite cell line human CVCL_B4ER From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Asp246Gly (c.737A>G); ClinVar=VCV000839892; Zygosity=Homozygous (CelloPub=CLPUB00671; PubMed=19058814) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358290 CVCL_B4EU WG2951 finite cell line human CVCL_B4EU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358291 CVCL_B4F6 WG3732 finite cell line human CVCL_B4F6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358292 CVCL_B4ET WG2025 finite cell line human CVCL_B4ET From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358293 CVCL_B4F5 WG3728 finite cell line human CVCL_B4F5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358294 CVCL_B4F8 C57/MV7 spontaneously immortalized cell line house mouse CVCL_B4F8 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Characteristics: Control cell line for C57/Wnt-1 151358295 CVCL_B4EW WG3224 finite cell line human CVCL_B4EW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358296 CVCL_B4EV WG3185 finite cell line human CVCL_B4EV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358297 CVCL_B4F7 WG3646 finite cell line human CVCL_B4F7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 25221; MMADHC; Simple; p.Ser228Ter (c.683C>G); Zygosity=Homozygous (from autologous cell line WG3583) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358298 CVCL_B4CG WG2341 finite cell line human CVCL_B4CG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Cys560Tyr (c.1679G>A); ClinVar=VCV000554451; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.2125-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358299 CVCL_B4CF WG3233 finite cell line human CVCL_B4CF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly427Asp (c.1280G>A); ClinVar=VCV000218990; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1677-1G>A; ClinVar=VCV000550012; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358300 CVCL_B4CI WG2451 finite cell line human CVCL_B4CI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; MMUT p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available; Miscellaneous: Second MMUT mutation was not detected Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358301 CVCL_B4CH WG2658 finite cell line human CVCL_B4CH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln18Ter (c.52C>T); ClinVar=VCV000001877; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available; Miscellaneous: Second MMUT mutation was not detected Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358302 CVCL_B4CK WG2646 finite cell line human CVCL_B4CK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro86Leu (c.257C>T); ClinVar=VCV000553773; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic and Native North American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358303 CVCL_B4CJ WG2269 finite cell line human CVCL_B4CJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu451Ter (c.1351G>T); ClinVar=VCV000557114; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available; Miscellaneous: Second MMUT mutation was not detected Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358304 CVCL_B4CM WG2670 finite cell line human CVCL_B4CM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met186Val (c.556A>G); ClinVar=VCV000551460; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358305 CVCL_B4CL WG2910 finite cell line human CVCL_B4CL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro86Leu (c.257C>T); ClinVar=VCV000553773; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Trp105Arg (c.313T>C); ClinVar=VCV000001878; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358306 CVCL_B4CA WG3065 finite cell line human CVCL_B4CA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu443Phefs*5 (c.1328dupT); ClinVar=VCV000934454; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1956+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358307 CVCL_B4CC WG2083 finite cell line human CVCL_B4CC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln218His (c.654A>C); ClinVar=VCV000551243; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1677-1G>A; ClinVar=VCV000550012; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. 151358308 CVCL_B4CB WG2883 finite cell line human CVCL_B4CB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.753+2T>A; ClinVar=VCV000203856; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg581Ter (c.1741C>T); ClinVar=VCV000554675; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358309 CVCL_B4CE WG3017 finite cell line human CVCL_B4CE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ile412del (c.1230CAT[1]) (c.1233_1235delCAT); ClinVar=VCV000978689; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1957-2A>G; ClinVar=VCV000555787; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358310 CVCL_B4CD WG2219 finite cell line human CVCL_B4CD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1957-2A>G; ClinVar=VCV000555787; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ile697Valfs*4 (c.2089_2101del); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Danish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358311 CVCL_B4BV WG2153 finite cell line human CVCL_B4BV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358312 CVCL_B4C7 WG3218 finite cell line human CVCL_B4C7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg511Ter (c.1531C>T); ClinVar=VCV000556124; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly291Glu (c.870G>A); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Greek Cypriot; Derived from sampling site: Skin Cell type=Fibroblast.. 151358313 CVCL_B4C6 WG2634 finite cell line human CVCL_B4C6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg474Ter (c.1420C>T); ClinVar=VCV000554873; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian and African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358314 CVCL_B4BU WG2786 finite cell line human CVCL_B4BU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358315 CVCL_B4C9 WG0497 finite cell line human CVCL_B4C9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.753+2T>A; ClinVar=VCV000203856; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1332+1delG; ClinVar=VCV000554656; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358316 CVCL_B4BX WG2202 finite cell line human CVCL_B4BX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Metfs*3 (c.656delA); ClinVar=VCV001073471; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358317 CVCL_B4BW WG1512 finite cell line human CVCL_B4BW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg474Ter (c.1420C>T); ClinVar=VCV000554873; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358318 CVCL_B4C8 WG3031 finite cell line human CVCL_B4C8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu434Hisfs*3 (c.1301_1302delTC); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro615Arg (c.1844C>G); ClinVar=VCV000550276; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358319 CVCL_B4BZ WG2719 finite cell line human CVCL_B4BZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser594Argfs*11 (c.1778_1782delAAAGT); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358320 CVCL_B4BY WG2435 finite cell line human CVCL_B4BY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His386Arg (c.1157A>G); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358321 CVCL_B4BN WG2474 finite cell line human CVCL_B4BN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Gln (c.683G>A); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg467Ter (c.1399C>T); ClinVar=VCV000495778; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358322 CVCL_B4BM WG3170 finite cell line human CVCL_B4BM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Gln (c.683G>A); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly630Glu (c.1889G>A); ClinVar=VCV000426995; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358323 CVCL_B4C1 WG1784 finite cell line human CVCL_B4C1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Thr566Arg (c.1697C>G); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian and African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358324 CVCL_B4BP WG3191 finite cell line human CVCL_B4BP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asp244Leufs*39 (c.729_730insTT); ClinVar=VCV000552079; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu305Ser (c.914T>C); ClinVar=VCV000556865; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358325 CVCL_B4C0 WG1864 finite cell line human CVCL_B4C0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His386Asn (c.1156C>A); ClinVar=VCV000558672; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser389del (c.1166_1168delCTT); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358326 CVCL_B4BR WG2174 finite cell line human CVCL_B4BR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln383Pro (c.1148A>C); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358327 CVCL_B4C3 WG2683 finite cell line human CVCL_B4C3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly355Ilefs*8 (c.1062delTinsCATCCAGA); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358328 CVCL_B4C2 WG2271 finite cell line human CVCL_B4C2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly145Ser (c.433G>A); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358329 CVCL_B4BQ WG2871 finite cell line human CVCL_B4BQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly158Glufs*22 (c.459delT); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu347Arg (c.1040T>G); ClinVar=VCV000807633; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. 151358330 CVCL_B4BT WG2433 finite cell line human CVCL_B4BT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358331 CVCL_B4C5 WG3027 finite cell line human CVCL_B4C5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly427Asp (c.1280G>A); ClinVar=VCV000218990; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly544Ter (c.1630_1631delGGinsTA); ClinVar=VCV000203860; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. 151358332 CVCL_B4BS WG2077 finite cell line human CVCL_B4BS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr429Ter (c.1287C>G); ClinVar=VCV000554278; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358333 CVCL_B4C4 WG2454 finite cell line human CVCL_B4C4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln383His (c.1149G>T); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358334 CVCL_B4DH WG3863 finite cell line human CVCL_B4DH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln218His (c.654A>C); ClinVar=VCV000551243; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358335 CVCL_B4DG WG3337 finite cell line human CVCL_B4DG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln218His (c.654A>C); ClinVar=VCV000551243; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian and Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358336 CVCL_B4DJ WG3679 finite cell line human CVCL_B4DJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn189Ile (c.566A>T); ClinVar=VCV000222915; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian and Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358337 CVCL_B4DI WG3529 finite cell line human CVCL_B4DI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian and Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. 151358338 CVCL_B4DL WG3495 finite cell line human CVCL_B4DL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; English/Irish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358339 CVCL_B4DK WG2700 finite cell line human CVCL_B4DK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met186Val (c.556A>G); ClinVar=VCV000551460; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358340 CVCL_B4DN WG3869 finite cell line human CVCL_B4DN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.754-2A>G; ClinVar=VCV000552691; Zygosity=Heterozygous; Note=Splice acceptor mutation (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358341 CVCL_B4DM WG4055 finite cell line human CVCL_B4DM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Aboriginal Australian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358342 CVCL_B4DB WG3427 finite cell line human CVCL_B4DB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu10Phefs*39 (c.29dupT); ClinVar=VCV000553287; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val553Glyfs*17 (c.1658delT); ClinVar=VCV001069591; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358343 CVCL_B4DA WG3572 finite cell line human CVCL_B4DA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 16692; CD320; Simple; p.Gly220Arg (c.658G>A); ClinVar=VCV000136684; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met1Thr (c.2T>C); ClinVar=VCV000222903; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly544Ter (c.1630_1631delGGinsTA); ClinVar=VCV000203860; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Palestinian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358344 CVCL_B4DD WG3650 finite cell line human CVCL_B4DD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg31Ter (c.91C>T); ClinVar=VCV000092688; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu117Ter (c.349G>T); ClinVar=VCV000001882; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. 151358345 CVCL_B4DC WG3512 finite cell line human CVCL_B4DC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg31Ter (c.91C>T); ClinVar=VCV000092688; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108His (c.323G>A); ClinVar=VCV000100707; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 11653; TCN2; Simple; p.Leu30Arg (c.89T>G); ClinVar=VCV000529781; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: African or African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358346 CVCL_B4DF WG3654 finite cell line human CVCL_B4DF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.146_147ins279; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asp125_Asn126insGlu (c.372_374dupGGA) (p.K124_D125insE); ClinVar=VCV000203861; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358347 CVCL_B4DE WG3473 finite cell line human CVCL_B4DE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Trp43Ter (c.129G>A); ClinVar=VCV000222908; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr100Cys (c.299A>G); ClinVar=VCV000218991; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358348 CVCL_B4CW WG2209 finite cell line human CVCL_B4CW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Phe174Ser (c.521T>C); ClinVar=VCV000218986; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Phe573Ser (c.1718T>C); ClinVar=VCV000284235; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358349 CVCL_B4D8 WG2468 finite cell line human CVCL_B4D8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Dutch/German; Derived from sampling site: Skin Cell type=Fibroblast.. 151358350 CVCL_B4CV WG1186 finite cell line human CVCL_B4CV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg511Ter (c.1531C>T); ClinVar=VCV000556124; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His678Arg (c.2033A>G); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358351 CVCL_B4D7 WG3126 finite cell line human CVCL_B4D7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11450; SUCLG2; Simple; p.Arg91Ser (c.273A>T); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available; Miscellaneous: No MMUT mutations were not detected Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358352 CVCL_B4CY WG3246 finite cell line human CVCL_B4CY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Phe573Ser (c.1718T>C); ClinVar=VCV000284235; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358353 CVCL_B4CX WG2600 finite cell line human CVCL_B4CX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Thr370Pro (c.1108A>C); ClinVar=VCV000203847; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Phe573Ser (c.1718T>C); ClinVar=VCV000284235; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358354 CVCL_B4D9 WG3468 finite cell line human CVCL_B4D9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met1Val (c.1A>G); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358355 CVCL_B4CZ WG3369 finite cell line human CVCL_B4CZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.753+2T>A; ClinVar=VCV000203856; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Met700Lys (c.2099T>A); ClinVar=VCV000218997; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358356 CVCL_B4D0 WG3036 finite cell line human CVCL_B4D0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.753+1G>A; ClinVar=VCV000633322; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358357 CVCL_B4CN WG2679 finite cell line human CVCL_B4CN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln218His (c.654A>C); ClinVar=VCV000551243; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358358 CVCL_B4D2 WG1827 finite cell line human CVCL_B4D2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly215Cys (c.643G>T); ClinVar=VCV000418341; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358359 CVCL_B4CQ WG2456 finite cell line human CVCL_B4CQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr316Cys (c.947A>G); ClinVar=VCV000640484; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358360 CVCL_B4CP WG2958 finite cell line human CVCL_B4CP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn189Lys (c.567T>G); ClinVar=VCV000618734; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Thr230Ile (c.689C>T); ClinVar=VCV001512244; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. 151358361 CVCL_B4D1 WG3067 finite cell line human CVCL_B4D1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358362 CVCL_B4D4 WG1600 finite cell line human CVCL_B4D4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr231Asn (c.691T>A); ClinVar=VCV000218992; Zygosity=Heterozygous (PubMed=9285782; PubMed=16281286) Miscellaneous: Cell line no longer available; Miscellaneous: Second MMUT mutation was not detected Derived from sampling site: Skin Cell type=Fibroblast.. 151358363 CVCL_B4CS WG2983 finite cell line human CVCL_B4CS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala324Thr (c.970G>A); ClinVar=VCV000550893; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn341Lysfs*20 (c.1022dupA); ClinVar=VCV000553958; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358364 CVCL_B4D3 WG2190 finite cell line human CVCL_B4D3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369Cys (c.1105C>T); ClinVar=VCV000218989; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358365 CVCL_B4CR WG2429 finite cell line human CVCL_B4CR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala324Thr (c.970G>A); ClinVar=VCV000550893; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala631Glnfs*17 (c.1891delG); ClinVar=VCV000242511; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358366 CVCL_B4D6 WG2545 finite cell line human CVCL_B4D6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available; Miscellaneous: No MMUT mutations were not detected Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358367 CVCL_B4CU WG2606 finite cell line human CVCL_B4CU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Phe174Ser (c.521T>C); ClinVar=VCV000218986; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg467Ter (c.1399C>T); ClinVar=VCV000495778; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358368 CVCL_B4D5 WG2319 finite cell line human CVCL_B4D5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11449; SUCLG1; Simple; p.Glu145Lys (c.433G>A); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228); Sequence variation: Mutation; HGNC; 11449; SUCLG1; Simple; p.Asn171His (c.511A>C); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228) Miscellaneous: Cell line no longer available Population: Caucasian; Irish/Italian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358369 CVCL_B4CT WG2547 finite cell line human CVCL_B4CT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1083+2T>A; ClinVar=VCV000495775; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu443Phefs*5 (c.1328dupT); ClinVar=VCV000934454; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358370 CVCL_B4AE WG3127 finite cell line human CVCL_B4AE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358371 CVCL_B4AD WG2469 finite cell line human CVCL_B4AD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358372 CVCL_B4AG WG2622 finite cell line human CVCL_B4AG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg727Ter (c.2179C>T); ClinVar=VCV000218998; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358373 CVCL_B4AF WG2608 finite cell line human CVCL_B4AF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg581Ter (c.1741C>T); ClinVar=VCV000554675; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358374 CVCL_B4AI WG2672 finite cell line human CVCL_B4AI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg31Ter (c.91C>T); ClinVar=VCV000092688; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly284Ter (c.850G>T); ClinVar=VCV000553762; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358375 CVCL_B4AH WG2041 finite cell line human CVCL_B4AH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu443Phefs*5 (c.1328dupT); ClinVar=VCV000934454; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358376 CVCL_B4AK WG2187 finite cell line human CVCL_B4AK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg93His (c.278G>A); ClinVar=VCV000001880; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln514Argfs*24 (c.1541delA); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358377 CVCL_B4AJ WG2821 finite cell line human CVCL_B4AJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly87Glu (c.260G>A); ClinVar=VCV000558311; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg467Ter (c.1399C>T); ClinVar=VCV000495778; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358378 CVCL_B4AA WG2310 finite cell line human CVCL_B4AA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala732Trpfs*6 (c.2194_2197delGCCGinsTGGAA); ClinVar=VCV000222942; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358379 CVCL_B4AC WG2348 finite cell line human CVCL_B4AC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358380 CVCL_B4AB WG2325 finite cell line human CVCL_B4AB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358381 CVCL_B4A5 WG2312 finite cell line human CVCL_B4A5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358382 CVCL_B4A4 WG1800 finite cell line human CVCL_B4A4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=9452100; PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358383 CVCL_B4A7 WG2896 finite cell line human CVCL_B4A7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African; Nigerian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358384 CVCL_B4A6 WG2628 finite cell line human CVCL_B4A6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358385 CVCL_B4A9 WG3070 finite cell line human CVCL_B4A9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg727Ter (c.2179C>T); ClinVar=VCV000218998; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Palestinian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358386 CVCL_B4A8 WG3068 finite cell line human CVCL_B4A8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358387 CVCL_B4A1 WG2680 finite cell line human CVCL_B4A1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian and African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358388 CVCL_B4A0 WG3207 finite cell line human CVCL_B4A0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358389 CVCL_B4A3 WG1562 finite cell line human CVCL_B4A3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=9452100; PubMed=16281286) Miscellaneous: Cell line no longer available Population: African; Ghanaian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358390 CVCL_B4A2 WG2839 finite cell line human CVCL_B4A2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly642Arg (c.1924G>C); ClinVar=VCV000551102; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Irish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358391 CVCL_B4BF WG2798 finite cell line human CVCL_B4BF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val227Asnfs*16 (c.671_678dupAATTTATG); ClinVar=VCV000554641; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg616Cys (c.1846C>T); ClinVar=VCV000551499; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358392 CVCL_B4BE WG2638 finite cell line human CVCL_B4BE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val227Asnfs*16 (c.671_678dupAATTTATG); ClinVar=VCV000554641; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg727Ter (c.2179C>T); ClinVar=VCV000218998; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358393 CVCL_B4BH WG3040 finite cell line human CVCL_B4BH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu688Ter (c.2062G>T); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Southeast Asian; Vietnamese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358394 CVCL_B4BG WG2872 finite cell line human CVCL_B4BG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg511Ter (c.1531C>T); ClinVar=VCV000556124; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358395 CVCL_B4BJ WG3112 finite cell line human CVCL_B4BJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser262Asn (c.785G>A); ClinVar=VCV001499715; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358396 CVCL_B4BI WG3044 finite cell line human CVCL_B4BI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Glu224Ter (c.670G>T); ClinVar=VCV000552718; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358397 CVCL_B4BL WG2644 finite cell line human CVCL_B4BL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.1332+1delG; ClinVar=VCV000554656; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358398 CVCL_B4BK WG3210 finite cell line human CVCL_B4BK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly203Arg (c.607G>A); ClinVar=VCV000218987; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358399 CVCL_B4BB WG1608 finite cell line human CVCL_B4BB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His350Tyr (c.1048C>T); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358400 CVCL_B4BA WG2973 finite cell line human CVCL_B4BA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly215Ser (c.643G>A); ClinVar=VCV000001888; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu346del (c.1036_1038delCTT); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358401 CVCL_B4BD WG3071 finite cell line human CVCL_B4BD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val227Asnfs*16 (c.671_678dupAATTTATG); ClinVar=VCV000554641; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn341Lysfs*20 (c.1022dupA); ClinVar=VCV000553958; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358402 CVCL_B4BC WG3020 finite cell line human CVCL_B4BC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn720Serfs*14 (c.2159_2160delAT); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; English/French; Derived from sampling site: Skin Cell type=Fibroblast.. 151358403 CVCL_B4B6 WG2247 finite cell line human CVCL_B4B6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly203Arg (c.607G>A); ClinVar=VCV000218987; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358404 CVCL_B4AU WG2924 finite cell line human CVCL_B4AU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu281Ser (c.842T>C); ClinVar=VCV000203858; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358405 CVCL_B4B5 WG1605 finite cell line human CVCL_B4B5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro649Leufs*23 (c.1946delC); ClinVar=VCV000556782; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358406 CVCL_B4AT WG2659 finite cell line human CVCL_B4AT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Val (c.281G>T); ClinVar=VCV000657887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Trp105Arg (c.313T>C); ClinVar=VCV000001878; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358407 CVCL_B4B8 WG1693 finite cell line human CVCL_B4B8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn219Tyr (c.655A>T); ClinVar=VCV000001886; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358408 CVCL_B4AW WG3192 finite cell line human CVCL_B4AW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358409 CVCL_B4B7 WG2676 finite cell line human CVCL_B4B7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr429Ter (c.1287C>G); ClinVar=VCV000554278; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358410 CVCL_B4AV WG3158 finite cell line human CVCL_B4AV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gln589Ter (c.1765C>T); ClinVar=VCV000845401; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358411 CVCL_B4AY WG2515 finite cell line human CVCL_B4AY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108His (c.323G>A); ClinVar=VCV000100707; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358412 CVCL_B4B9 WG2597 finite cell line human CVCL_B4B9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala197Glu (c.594C>A); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly637Arg (c.1909G>A); ClinVar=VCV001486406; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358413 CVCL_B4AX WG3200 finite cell line human CVCL_B4AX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358414 CVCL_B4AZ WG1601 finite cell line human CVCL_B4AZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108His (c.323G>A); ClinVar=VCV000100707; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser594Argfs*11 (c.1778_1782delAAAGT); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358415 CVCL_B4AM WG2405 finite cell line human CVCL_B4AM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro86Leu (c.257C>T); ClinVar=VCV000553773; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358416 CVCL_B4AL WG2416 finite cell line human CVCL_B4AL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg93His (c.278G>A); ClinVar=VCV000001880; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu518Pro (c.1553T>C); ClinVar=VCV000218994; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358417 CVCL_B4B0 WG2717 finite cell line human CVCL_B4B0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108His (c.323G>A); ClinVar=VCV000100707; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg727Ter (c.2179C>T); ClinVar=VCV000218998; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. 151358418 CVCL_B4AN WG2873 finite cell line human CVCL_B4AN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Arg (c.280G>A); ClinVar=VCV000167312; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn341Lysfs*20 (c.1022dupA); ClinVar=VCV000553958; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358419 CVCL_B4B2 WG3050 finite cell line human CVCL_B4B2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg152Ter (c.454C>T); ClinVar=VCV000426467; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg629Lysfs*12 (c.1885dupA); ClinVar=VCV000568904; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358420 CVCL_B4AQ WG3140 finite cell line human CVCL_B4AQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Val (c.281G>T); ClinVar=VCV000657887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Thr370Pro (c.1108A>C); ClinVar=VCV000203847; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358421 CVCL_B4B1 WG2691 finite cell line human CVCL_B4B1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser135Ter (c.404C>A); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn341Lysfs*20 (c.1022dupA); ClinVar=VCV000553958; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358422 CVCL_B4AP WG3211 finite cell line human CVCL_B4AP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Val (c.281G>T); ClinVar=VCV000657887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg152Ter (c.454C>T); ClinVar=VCV000426467; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358423 CVCL_B4B4 WG2603 finite cell line human CVCL_B4B4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly161Ter (c.481G>T); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg694Trp (c.2080C>T); ClinVar=VCV000218996; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358424 CVCL_B4AS WG3205 finite cell line human CVCL_B4AS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Val (c.281G>T); ClinVar=VCV000657887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358425 CVCL_B4AR WG2838 finite cell line human CVCL_B4AR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly94Val (c.281G>T); ClinVar=VCV000657887; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly284Ter (c.850G>T); ClinVar=VCV000553762; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358426 CVCL_B4B3 WG3051 finite cell line human CVCL_B4B3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; c.385+3insTAAGGGT; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg152Ter (c.454C>T); ClinVar=VCV000426467; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358427 CVCL_B4P4 7BC9.1 hybridoma house mouse CVCL_B4P4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cell line BEN. 151358428 CVCL_B4P3 7B5.4 hybridoma house mouse CVCL_B4P3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358429 CVCL_B4P6 G523 cancer cell line human CVCL_B4P6 CL:0000010 Derived from sampling site: Brain. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Hi-C chromosome conformation analysis; Omics: Transcriptome analysis by RNAseq Male Group: Cancer stem cell line 151358430 CVCL_B4P5 E14 cancer cell line human CVCL_B4P5 CL:0000010 Unspecified 151358431 CVCL_B4P8 G583 cancer cell line human CVCL_B4P8 CL:0000010 Derived from sampling site: Brain. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Hi-C chromosome conformation analysis; Omics: Transcriptome analysis by RNAseq Male Group: Cancer stem cell line 151358432 CVCL_B4P7 G567 cancer cell line human CVCL_B4P7 CL:0000010 Derived from sampling site: Brain. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Hi-C chromosome conformation analysis; Omics: Transcriptome analysis by RNAseq Female Group: Cancer stem cell line 151358433 CVCL_B4P9 UCF0010 finite cell line human CVCL_B4P9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358434 CVCL_B4P0 7B17.7 hybridoma house mouse CVCL_B4P0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358435 CVCL_B4P2 7B3.5 hybridoma house mouse CVCL_B4P2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358436 CVCL_B4P1 7B24.4 hybridoma house mouse CVCL_B4P1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cell line BEN. 151358437 CVCL_B4NZ 4EAB8.2 hybridoma house mouse CVCL_B4NZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells. 151358438 CVCL_B4NY 4EAB3.7 hybridoma house mouse CVCL_B4NY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells. 151358439 CVCL_B4PT UCF0048 finite cell line human CVCL_B4PT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358440 CVCL_B4Q5 UCF0078 finite cell line human CVCL_B4Q5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358441 CVCL_B4PS UCF0047 finite cell line human CVCL_B4PS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358442 CVCL_B4Q4 UCF0075 finite cell line human CVCL_B4Q4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358443 CVCL_B4PV UCF0051 finite cell line human CVCL_B4PV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358444 CVCL_B4Q7 UCF0082 finite cell line human CVCL_B4Q7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358445 CVCL_B4PU UCF0049 finite cell line human CVCL_B4PU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358446 CVCL_B4Q6 UCF0079 finite cell line human CVCL_B4Q6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358447 CVCL_B4PX UCF0056 finite cell line human CVCL_B4PX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358448 CVCL_B4Q9 UCF0084 finite cell line human CVCL_B4Q9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358449 CVCL_B4PW UCF0052 finite cell line human CVCL_B4PW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358450 CVCL_B4Q8 UCF0083 finite cell line human CVCL_B4Q8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358451 CVCL_B4PZ UCF0058 finite cell line human CVCL_B4PZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358452 CVCL_B4PY UCF0057 finite cell line human CVCL_B4PY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358453 CVCL_B4PL UCF0033 finite cell line human CVCL_B4PL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358454 CVCL_B4PK UCF0029 finite cell line human CVCL_B4PK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358455 CVCL_B4PN UCF0039 finite cell line human CVCL_B4PN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358456 CVCL_B4PM UCF0034 finite cell line human CVCL_B4PM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358457 CVCL_B4PP UCF0040 finite cell line human CVCL_B4PP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358458 CVCL_B4Q1 UCF0062 finite cell line human CVCL_B4Q1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358459 CVCL_B4Q0 UCF0060 finite cell line human CVCL_B4Q0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358460 CVCL_B4PR UCF0043 finite cell line human CVCL_B4PR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358461 CVCL_B4Q3 UCF0070 finite cell line human CVCL_B4Q3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358462 CVCL_B4PQ UCF0042 finite cell line human CVCL_B4PQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358463 CVCL_B4Q2 UCF0068 finite cell line human CVCL_B4Q2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358464 CVCL_B4PD UCF0019 finite cell line human CVCL_B4PD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358465 CVCL_B4PC UCF0018 finite cell line human CVCL_B4PC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358466 CVCL_B4PF UCF0023 finite cell line human CVCL_B4PF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358467 CVCL_B4PE UCF0022 finite cell line human CVCL_B4PE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358468 CVCL_B4PH UCF0025 finite cell line human CVCL_B4PH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151358469 CVCL_B4PG UCF0024 finite cell line human CVCL_B4PG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151358470 CVCL_B4PJ UCF0028 finite cell line human CVCL_B4PJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358471 CVCL_B4PI UCF0026 finite cell line human CVCL_B4PI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358472 CVCL_B4PB UCF0012 finite cell line human CVCL_B4PB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151358473 CVCL_B4PA UCF0011 finite cell line human CVCL_B4PA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151358474 CVCL_B4MQ UCB1139 transformed cell line human CVCL_B4MQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358475 CVCL_B4N2 UCB1218 transformed cell line human CVCL_B4N2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358476 CVCL_B4MP UCB1136 transformed cell line human CVCL_B4MP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358477 CVCL_B4N1 UCB1216 transformed cell line human CVCL_B4N1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358478 CVCL_B4N4 AG03141.hTERT clone 8 telomerase immortalized cell line human CVCL_B4N4 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln748Ter (c.2242C>T) (2476C>T); ClinVar=VCV000835212; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358479 CVCL_B4MS UCB1196 transformed cell line human CVCL_B4MS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358480 CVCL_B4N3 C8 [Human colon adenocarcinoma] cancer cell line human CVCL_B4N3 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1307Lysfs*7 (c.3920_3921del); Zygosity=Unspecified (PubMed=9482574). Unspecified 151358481 CVCL_B4MR UCB1148 transformed cell line human CVCL_B4MR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis Female Part of: GenCord collection 151358482 CVCL_B4N6 SAL02 hybridoma house mouse CVCL_B4N6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11954 151358483 CVCL_B4MU UCB1200 transformed cell line human CVCL_B4MU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358484 CVCL_B4N5 S3(LD5G11F4) hybridoma house mouse CVCL_B4N5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358485 CVCL_B4MT UCB1199 transformed cell line human CVCL_B4MT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis Female Part of: GenCord collection 151358486 CVCL_B4N8 SAL04 hybridoma house mouse CVCL_B4N8 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358487 CVCL_B4MW UCB1206 transformed cell line human CVCL_B4MW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358488 CVCL_B4N7 SAL03 hybridoma house mouse CVCL_B4N7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358489 CVCL_B4MV UCB1203 transformed cell line human CVCL_B4MV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358490 CVCL_B4MI UCB1117 transformed cell line human CVCL_B4MI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis Female Part of: GenCord collection 151358491 CVCL_B4MH UCB1113 transformed cell line human CVCL_B4MH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358492 CVCL_B4MK UCB1120 transformed cell line human CVCL_B4MK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358493 CVCL_B4MJ UCB1119 transformed cell line human CVCL_B4MJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358494 CVCL_B4MM UCB1130 transformed cell line human CVCL_B4MM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358495 CVCL_B4ML UCB1129 transformed cell line human CVCL_B4ML CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358496 CVCL_B4N0 UCB1212 transformed cell line human CVCL_B4N0 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358497 CVCL_B4MN UCB1131 transformed cell line human CVCL_B4MN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358498 CVCL_B4MA UCB1101 transformed cell line human CVCL_B4MA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358499 CVCL_B4MC UCB1103 transformed cell line human CVCL_B4MC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358500 CVCL_B4MB UCB1102 transformed cell line human CVCL_B4MB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358501 CVCL_B4ME UCB1107 transformed cell line human CVCL_B4ME CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358502 CVCL_B4MD UCB1105 transformed cell line human CVCL_B4MD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358503 CVCL_B4MG UCB1112 transformed cell line human CVCL_B4MG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358504 CVCL_B4MF UCB1108 transformed cell line human CVCL_B4MF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358505 CVCL_B4LX UCB1079 transformed cell line human CVCL_B4LX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358506 CVCL_B4M9 UCB1100 transformed cell line human CVCL_B4M9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358507 CVCL_B4LW UCB1077 transformed cell line human CVCL_B4LW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358508 CVCL_B4M8 UCB1099 transformed cell line human CVCL_B4M8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358509 CVCL_B4LZ UCB1083 transformed cell line human CVCL_B4LZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358510 CVCL_B4LY UCB1080 transformed cell line human CVCL_B4LY CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358511 CVCL_B4NR M79 hybridoma house mouse CVCL_B4NR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 151358512 CVCL_B4NQ M77 hybridoma house mouse CVCL_B4NQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 151358513 CVCL_B4NT 3E11.5 hybridoma house mouse CVCL_B4NT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358514 CVCL_B4NS 3E10.2 hybridoma house mouse CVCL_B4NS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358515 CVCL_B4NV 3E19.8 hybridoma house mouse CVCL_B4NV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells. 151358516 CVCL_B4NU 3E14.5 hybridoma house mouse CVCL_B4NU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358517 CVCL_B4NX 4EAB10.4 hybridoma house mouse CVCL_B4NX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells. 151358518 CVCL_B4NW 3E22.1 hybridoma house mouse CVCL_B4NW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human lung cancer cells (Note=Also recognizes many other type of cells). 151358519 CVCL_B4NJ SAL23 hybridoma house mouse CVCL_B4NJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358520 CVCL_B4NI SAL22 hybridoma house mouse CVCL_B4NI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358521 CVCL_B4NL SAL25 hybridoma house mouse CVCL_B4NL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358522 CVCL_B4NK SAL24 hybridoma house mouse CVCL_B4NK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358523 CVCL_B4NN M72 hybridoma house mouse CVCL_B4NN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 151358524 CVCL_B4NP M74 hybridoma house mouse CVCL_B4NP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 151358525 CVCL_B4NB SAL07 hybridoma house mouse CVCL_B4NB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358526 CVCL_B4NA SAL06 hybridoma house mouse CVCL_B4NA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358527 CVCL_B4ND SAL09 hybridoma house mouse CVCL_B4ND CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358528 CVCL_B4NC SAL08 hybridoma house mouse CVCL_B4NC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358529 CVCL_B4NF SAL11 hybridoma house mouse CVCL_B4NF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358530 CVCL_B4NE SAL10 hybridoma house mouse CVCL_B4NE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358531 CVCL_B4NH SAL13 hybridoma house mouse CVCL_B4NH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358532 CVCL_B4NG SAL12 hybridoma house mouse CVCL_B4NG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358533 CVCL_B4MY UCB1208 transformed cell line human CVCL_B4MY CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358534 CVCL_B4N9 SAL05 hybridoma house mouse CVCL_B4N9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:80025; Salinomycin. 151358535 CVCL_B4MX UCB1207 transformed cell line human CVCL_B4MX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358536 CVCL_B4MZ UCB1210 transformed cell line human CVCL_B4MZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358537 CVCL_B4L0 WG0291 finite cell line human CVCL_B4L0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358538 CVCL_B4KN D11-M3 cancer cell line human CVCL_B4KN CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=22383533). Unspecified 151358539 CVCL_B4KQ D14-M2 cancer cell line human CVCL_B4KQ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Omics: Transcriptome analysis by RNAseq. Unspecified 151358540 CVCL_B4L2 Twin-N finite cell line human CVCL_B4L2 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Donor information: Twin-DS (Cellosaurus=CVCL_B4L1) and Twin-N originate from monozygotic twins discordant for trisomy 21; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by single cell RNAseq Female 151358541 CVCL_B4KP D14-M1 cancer cell line human CVCL_B4KP CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Unspecified 151358542 CVCL_B4L1 Twin-DS finite cell line human CVCL_B4L1 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Donor information: Twin-DS and Twin-N (Cellosaurus=CVCL_B4L2) originate from monozygotic twins discordant for trisomy 21; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by single cell RNAseq Female 151358543 CVCL_B4KS M408 cancer cell line human CVCL_B4KS CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25645078). Unspecified 151358544 CVCL_B4L4 UCF1014 finite cell line human CVCL_B4L4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by single cell RNAseq Female Part of: GenCord collection 151358545 CVCL_B4KR M311 [Human melanoma] cancer cell line human CVCL_B4KR CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=25645078; PubMed=27533468). Unspecified 151358546 CVCL_B4L3 Twin-N-iPSCs line#7 induced pluripotent stem cell human CVCL_B4L3 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Karyotypic information: 46,XX (PubMed=32739879); Donor information: Twin-DS-iPSC (Cellosaurus=CVCL_W088) and Twin-N-iPSC originate from monozygotic twins discordant for trisomy 21; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 151358547 CVCL_B4KU MM160113 cancer cell line human CVCL_B4KU From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Not specified. Male 151358548 CVCL_B4L6 UCB1001 transformed cell line human CVCL_B4L6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358549 CVCL_B4KT IGRMel1 cancer cell line human CVCL_B4KT CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=27533468) Derived from metastatic site: Not specified. Unspecified 151358550 CVCL_B4L5 UCB1014 transformed cell line human CVCL_B4L5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by single cell RNAseq Female Part of: GenCord collection 151358551 CVCL_B4KG D18 cancer cell line human CVCL_B4KG CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Gly414Val (c.1241G>T); Zygosity=Heterozygous (PubMed=22383533). Unspecified 151358552 CVCL_B4KF C003 cancer cell line human CVCL_B4KF CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Characteristics: Early passage culture 151358553 CVCL_B4KI C004-2 cancer cell line human CVCL_B4KI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Female Characteristics: Early passage culture 151358554 CVCL_B4KH C028-2 cancer cell line human CVCL_B4KH CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22250051; PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 151358555 CVCL_B4KK C045 cancer cell line human CVCL_B4KK CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Unspecified Characteristics: Early passage culture 151358556 CVCL_B4KJ C042-2 cancer cell line human CVCL_B4KJ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Unspecified Characteristics: Early passage culture 151358557 CVCL_B4KM D11-M2 cancer cell line human CVCL_B4KM CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=22383533) Omics: Transcriptome analysis by RNAseq. Unspecified 151358558 CVCL_B4KL C088-2 cancer cell line human CVCL_B4KL CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358559 CVCL_B4KA C016 cancer cell line human CVCL_B4KA CL:0000010 Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358560 CVCL_B4KC C076 cancer cell line human CVCL_B4KC CL:0000010 Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358561 CVCL_B4KB C074 cancer cell line human CVCL_B4KB CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358562 CVCL_B4KE C094 cancer cell line human CVCL_B4KE CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358563 CVCL_B4KD C088 cancer cell line human CVCL_B4KD CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358564 CVCL_B4JV 13G5-57 hybridoma house mouse CVCL_B4JV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11359 151358565 CVCL_B4K7 NOVOe001-A embryonic stem cell human CVCL_B4K7 From: Novo Nordisk A/S; Bagsvaerd; Denmark. CL:0000010 Female 151358566 CVCL_B4JU 13G5-52 hybridoma house mouse CVCL_B4JU CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11358 151358567 CVCL_B4K6 WG4152 finite cell line human CVCL_B4K6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358568 CVCL_B4JX 22H8-84 hybridoma house mouse CVCL_B4JX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11361 151358569 CVCL_B4K9 C006 cancer cell line human CVCL_B4K9 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358570 CVCL_B4JW 14A8-85 hybridoma house mouse CVCL_B4JW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11360 151358571 CVCL_B4K8 C001 cancer cell line human CVCL_B4K8 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 151358572 CVCL_B4JZ 55E7-79 hybridoma house mouse CVCL_B4JZ CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11363 151358573 CVCL_B4JY 49F2-30 hybridoma house mouse CVCL_B4JY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11362 151358574 CVCL_B4LP UCB1070 transformed cell line human CVCL_B4LP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358575 CVCL_B4M1 UCB1087 transformed cell line human CVCL_B4M1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358576 CVCL_B4M0 UCB1086 transformed cell line human CVCL_B4M0 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358577 CVCL_B4LR UCB1072 transformed cell line human CVCL_B4LR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358578 CVCL_B4M3 UCB1091 transformed cell line human CVCL_B4M3 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358579 CVCL_B4LQ UCB1071 transformed cell line human CVCL_B4LQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358580 CVCL_B4M2 UCB1089 transformed cell line human CVCL_B4M2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358581 CVCL_B4LT UCB1074 transformed cell line human CVCL_B4LT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358582 CVCL_B4M5 UCB1094 transformed cell line human CVCL_B4M5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358583 CVCL_B4LS UCB1073 transformed cell line human CVCL_B4LS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358584 CVCL_B4M4 UCB1092 transformed cell line human CVCL_B4M4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358585 CVCL_B4LV UCB1076 transformed cell line human CVCL_B4LV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358586 CVCL_B4M7 UCB1098 transformed cell line human CVCL_B4M7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358587 CVCL_B4LU UCB1075 transformed cell line human CVCL_B4LU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358588 CVCL_B4M6 UCB1096 transformed cell line human CVCL_B4M6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358589 CVCL_B4LH UCB1053 transformed cell line human CVCL_B4LH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358590 CVCL_B4LG UCB1052 transformed cell line human CVCL_B4LG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358591 CVCL_B4LJ UCB1058 transformed cell line human CVCL_B4LJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358592 CVCL_B4LI UCB1056 transformed cell line human CVCL_B4LI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358593 CVCL_B4LL UCB1064 transformed cell line human CVCL_B4LL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358594 CVCL_B4LK UCB1061 transformed cell line human CVCL_B4LK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358595 CVCL_B4LN UCB1069 transformed cell line human CVCL_B4LN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358596 CVCL_B4LM UCB1067 transformed cell line human CVCL_B4LM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358597 CVCL_B4LB UCB1025 transformed cell line human CVCL_B4LB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358598 CVCL_B4LA UCB1023 transformed cell line human CVCL_B4LA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358599 CVCL_B4LD UCB1029 transformed cell line human CVCL_B4LD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358600 CVCL_B4LC UCB1027 transformed cell line human CVCL_B4LC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358601 CVCL_B4LF UCB1048 transformed cell line human CVCL_B4LF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358602 CVCL_B4LE UCB1046 transformed cell line human CVCL_B4LE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358603 CVCL_B4KW CCLF-UPGI-0061-T cancer cell line human CVCL_B4KW CL:0000010 Derived from metastatic site: Not specified. 151358604 CVCL_B4L8 UCB1012 transformed cell line human CVCL_B4L8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358605 CVCL_B4KV CCLF-UPGI-0005-T cancer cell line human CVCL_B4KV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Pro (c.379T>C); ClinVar=VCV000934410; Zygosity=Homozygous (DepMap) Derived from metastatic site: Not specified. 151358606 CVCL_B4L7 UCB1011 transformed cell line human CVCL_B4L7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151358607 CVCL_B4KY WG0290 finite cell line human CVCL_B4KY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358608 CVCL_B4KX GM00301 finite cell line human CVCL_B4KX CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00301; probable 151358609 CVCL_B4L9 UCB1016 transformed cell line human CVCL_B4L9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151358610 CVCL_B4KZ WG0548 finite cell line human CVCL_B4KZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358611 CVCL_B4IM YTA1 finite cell line human CVCL_B4IM CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 151358612 CVCL_B4IL STH4 transformed cell line human CVCL_B4IL CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151358613 CVCL_B4J0 BEP2D H2B transformed cell line human CVCL_B4J0 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358614 CVCL_B4IN YTH3 transformed cell line human CVCL_B4IN CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 independent 151358615 CVCL_B4J2 BEP2D H2BT transformed cell line human CVCL_B4J2 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358616 CVCL_B4IQ YTA1H transformed cell line human CVCL_B4IQ CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 independent 151358617 CVCL_B4J1 BEP2D H2BFT transformed cell line human CVCL_B4J1 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358618 CVCL_B4IP YTH5 transformed cell line human CVCL_B4IP CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 independent 151358619 CVCL_B4IS BEP2D Fe60T1 transformed cell line human CVCL_B4IS CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Iron-56 ion irradiation(NCIt; C129641); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358620 CVCL_B4J4 BEP2D H3A transformed cell line human CVCL_B4J4 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358621 CVCL_B4IR BEP1B transformed cell line human CVCL_B4IR CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358622 CVCL_B4J3 BEP2D H2BT2L transformed cell line human CVCL_B4J3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=10426802) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358623 CVCL_B4IE 147BR finite cell line human CVCL_B4IE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358624 CVCL_B4ID LB188 transformed cell line human CVCL_B4ID CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151358625 CVCL_B4IG 78LO finite cell line human CVCL_B4IG CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female Doubling time: 36.0 hours (PubMed=6459055) 151358626 CVCL_B4IF 148BR finite cell line human CVCL_B4IF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358627 CVCL_B4II 791T/36 hybridoma house mouse CVCL_B4II CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08174; Human CD55. 151358628 CVCL_B4IH A206 transformed cell line human CVCL_B4IH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 151358629 CVCL_B4IK iChEC-1 transformed cell line human CVCL_B4IK CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Val62Ile (c.184G>A); ClinVar=VCV000016550; Zygosity=Homozygous (PubMed=30571950); Sequence variation: Mutation; HGNC; 13941; SLC44A4; Simple; p.Asp123Val (c.368A>T); dbSNP=rs12661281; Zygosity=Homozygous (PubMed=30571950); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; choroid Cell type=Endothelial cell.. Female 151358630 CVCL_B4IJ 791T/48 hybridoma house mouse CVCL_B4IJ CL:0000010 Monoclonal antibody isotype: IgG2b. 151358631 CVCL_B4IA MDCK-2B2 transformed cell line dog CVCL_B4IA CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201323 151358632 CVCL_B4IC ciChEnC conditionally immortalized cell line human CVCL_B4IC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; choroid Cell type=Endothelial cell.. Female Characteristics: Can be maintained in culture at the permissive temperature of 33 Celsius for up to 27 passages without signs of senescence 151358633 CVCL_B4IB 2CFSMEo-/6REP-CFTR transformed cell line human CVCL_B4IB CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln2Ter (c.4C>T); ClinVar=VCV000053980; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1884; CFTR Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 151358634 CVCL_B4HT 9G2 [Mouse hybridoma against rat Hmgb1] hybridoma house mouse CVCL_B4HT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358635 CVCL_B4I5 Myok9 transformed cell line dog CVCL_B4I5 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Sex of donor from personal communication of Nghiem P.P Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.; Breed/subspecies: Golden Retriever x Labrador Retriever. Female Doubling time: ~16 hours (PubMed=32246189) 151358636 CVCL_B4HS 9G1 hybridoma house mouse CVCL_B4HS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P63159; Rat Hmgb1. 151358637 CVCL_B4I4 KM162C14Q telomerase immortalized cell line human CVCL_B4I4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Muscle Cell type=Myoblast.. Unspecified 151358638 CVCL_B4I7 15303MN clone 3 telomerase immortalized cell line dog CVCL_B4I7 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Beagle. Male 151358639 CVCL_B4HV ML13-7C6.1D4.4A9.5G8 hybridoma house mouse CVCL_B4HV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7240 151358640 CVCL_B4I6 15303MN clone 2 telomerase immortalized cell line dog CVCL_B4I6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Beagle. Male 151358641 CVCL_B4HU ML13-4D10.3F3 hybridoma house mouse CVCL_B4HU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7405 151358642 CVCL_B4I9 CXMDJ clone 9 telomerase immortalized cell line dog CVCL_B4I9 CL:0000010 Sequence variation: Mutation; VGNC; 54134; DMD; Unexplicit; Ex7del; Zygosity=Hemizygous (PubMed=33567244); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Beagle. Male 151358643 CVCL_B4HX ML15-10F11.3D9 hybridoma house mouse CVCL_B4HX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7239 151358644 CVCL_B4I8 CXMDJ clone 8 telomerase immortalized cell line dog CVCL_B4I8 CL:0000010 Sequence variation: Mutation; VGNC; 54134; DMD; Unexplicit; Ex7del; Zygosity=Hemizygous (PubMed=33567244); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Beagle. Male 151358645 CVCL_B4HW ML15-10C1.5C6.3H4 hybridoma house mouse CVCL_B4HW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7810 151358646 CVCL_B4HZ ML15-3B10.2D5.3F1 hybridoma house mouse CVCL_B4HZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7851 151358647 CVCL_B4HY ML15-2F2.3E12 hybridoma house mouse CVCL_B4HY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 last 23 residues; Abeta(20-42)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7408 151358648 CVCL_B4JN BEP2D R30-5B transformed cell line human CVCL_B4JN CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358649 CVCL_B4JM BEP2D R30-4B transformed cell line human CVCL_B4JM CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358650 CVCL_B4JP BEP2D R30-6A transformed cell line human CVCL_B4JP CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358651 CVCL_B4K1 RBSV1A transformed cell line human CVCL_B4K1 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358652 CVCL_B4K0 BRL-5 spontaneously immortalized cell line Norway rat CVCL_B4K0 CL:0000010 Transfected with: RGD; 2687; Ghr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver; Breed/subspecies: Buffalo. 151358653 CVCL_B4JR AI206 hybridoma house mouse CVCL_B4JR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody YH206. 151358654 CVCL_B4K3 BRL-6005 cancer cell line human CVCL_B4K3 CL:0000010 Unspecified 151358655 CVCL_B4K2 RBSV3 transformed cell line human CVCL_B4K2 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358656 CVCL_B4JQ YH206 hybridoma house mouse CVCL_B4JQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human heavily glycosylated mucin-like antigen. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2001 151358657 CVCL_B4JT 10F7-38 hybridoma house mouse CVCL_B4JT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11357 151358658 CVCL_B4K5 WG3838 finite cell line human CVCL_B4K5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Gln27Arg (c.80A>G); ClinVar=VCV000552467; Zygosity=Heterozygous (PubMed=29302025); Sequence variation: Mutation; HGNC; 9352; PRDX1; Simple; c.515-2A>T; ClinVar=VCV000495210; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=29302025) Miscellaneous: Cell line no longer available Population: Japanese and Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: The mutation indicated in PubMed=29302025 for MMACHC (c.81G>A) is incorrect The correct mutation is c.80G>A (personal communication of Rosenblatt D.). 151358659 CVCL_B4JS 9H5-4 hybridoma house mouse CVCL_B4JS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q13332; Human PTPRS. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11356 151358660 CVCL_B4K4 BRL-6278 cancer cell line human CVCL_B4K4 CL:0000010 Unspecified 151358661 CVCL_B4JF BEP2D R30T3L transformed cell line human CVCL_B4JF CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358662 CVCL_B4JE BEP2D R30T1L2A transformed cell line human CVCL_B4JE CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Unspecified (PubMed=10426802) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358663 CVCL_B4JH BEP2D R30T5L2P transformed cell line human CVCL_B4JH CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Asn (c.417G>T); ClinVar=VCV000584923; Zygosity=Unspecified (PubMed=10426802) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358664 CVCL_B4JG BEP2D R30T5L2 transformed cell line human CVCL_B4JG CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Asn (c.417G>T); ClinVar=VCV000584923; Zygosity=Unspecified (PubMed=10426802) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358665 CVCL_B4JJ BEP2D R5D7A4C transformed cell line human CVCL_B4JJ CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358666 CVCL_B4JI BEP2D R5D7A2C transformed cell line human CVCL_B4JI CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358667 CVCL_B4JL BEP2D R30-3C transformed cell line human CVCL_B4JL CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358668 CVCL_B4JK BEP2D R30-2C transformed cell line human CVCL_B4JK CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358669 CVCL_B4JB BEP2D R3D7 transformed cell line human CVCL_B4JB CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358670 CVCL_B4JA BEP2D R30T5 transformed cell line human CVCL_B4JA CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358671 CVCL_B4JD BEP2D R30T1L transformed cell line human CVCL_B4JD CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358672 CVCL_B4JC BEP2D R5D7 transformed cell line human CVCL_B4JC CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358673 CVCL_B4IU BEP2D Fe60T3 transformed cell line human CVCL_B4IU CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Iron-56 ion irradiation(NCIt; C129641); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358674 CVCL_B4J6 BEP2D R30 transformed cell line human CVCL_B4J6 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358675 CVCL_B4IT BEP2D Fe60T2 transformed cell line human CVCL_B4IT CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Iron-56 ion irradiation(NCIt; C129641); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358676 CVCL_B4J5 BEP2D R2D6 transformed cell line human CVCL_B4J5 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358677 CVCL_B4IW BEP2D H1A transformed cell line human CVCL_B4IW CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358678 CVCL_B4J8 BEP2D R30T2 transformed cell line human CVCL_B4J8 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358679 CVCL_B4IV BEP2D Fe60T4 transformed cell line human CVCL_B4IV CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Iron-56 ion irradiation(NCIt; C129641); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358680 CVCL_B4J7 BEP2D R30T1 transformed cell line human CVCL_B4J7 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358681 CVCL_B4IY BEP2D H1ATN transformed cell line human CVCL_B4IY CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358682 CVCL_B4IX BEP2D H1ATBA1 transformed cell line human CVCL_B4IX CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=9214610); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358683 CVCL_B4J9 BEP2D R30T3 transformed cell line human CVCL_B4J9 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic in nude mice 151358684 CVCL_B4IZ BEP2D H1B transformed cell line human CVCL_B4IZ CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Helium-ion radiation(NCIt; C16098); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 151358685 CVCL_B3UZ 597 induced pluripotent stem cell human CVCL_B3UZ From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 151358686 CVCL_B3UY 595 induced pluripotent stem cell human CVCL_B3UY From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151358687 CVCL_B3VA SNUhES47 embryonic stem cell human CVCL_B3VA From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017005. 151358688 CVCL_B3UR 1013 induced pluripotent stem cell human CVCL_B3UR From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151358689 CVCL_B3V3 CHA-hES63 embryonic stem cell human CVCL_B3V3 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12021002. 151358690 CVCL_B3V2 CHA-hES62 embryonic stem cell human CVCL_B3V2 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12021001. 151358691 CVCL_B3UQ PEO1X cancer cell line human CVCL_B3UQ CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Ter (c.4965C>G) (5193C>G); ClinVar=VCV000037936; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (CelloPub=CLPUB00667) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female Doubling time: 47.84 hours (CelloPub=CLPUB00667) 151358692 CVCL_B3UT 1579 induced pluripotent stem cell human CVCL_B3UT From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 2153; CNGB3; Simple; p.Thr383Ilefs*13 (c.1148delC); ClinVar=VCV000005225; Zygosity=Heterozygous (PubMed=32011687); Sequence variation: Mutation; HGNC; 2153; CNGB3; Simple; chr8:g.87618576G>A; Zygosity=Heterozygous; Note=Incorporates cryptic exon 14b (PubMed=32011687) Derived from sampling site: Peripheral blood. Female 151358693 CVCL_B3V5 CHA-hES59 embryonic stem cell human CVCL_B3V5 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12018001. 151358694 CVCL_B3US 1096 induced pluripotent stem cell human CVCL_B3US From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151358695 CVCL_B3V4 CHA-hES64 embryonic stem cell human CVCL_B3V4 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12021003. 151358696 CVCL_B3UV 1581 induced pluripotent stem cell human CVCL_B3UV From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 2153; CNGB3; Simple; chr8:g.87618576G>A; Zygosity=Heterozygous; Note=Incorporates cryptic exon 14b (PubMed=32011687) Derived from sampling site: Peripheral blood. Male 151358697 CVCL_B3V7 CHA-hES61 embryonic stem cell human CVCL_B3V7 From: CHA University; Seongnam; South Korea CL:0000010 Karyotypic information: 70,XXX,+12. Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12018003 151358698 CVCL_B3UU 1580 induced pluripotent stem cell human CVCL_B3UU From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 2153; CNGB3; Simple; p.Thr383Ilefs*13 (c.1148delC); ClinVar=VCV000005225; Zygosity=Heterozygous (PubMed=32011687); Sequence variation: Mutation; HGNC; 2153; CNGB3; Simple; chr8:g.87618576G>A; Zygosity=Heterozygous; Note=Incorporates cryptic exon 14b (PubMed=32011687) Derived from sampling site: Peripheral blood. Female 151358699 CVCL_B3V6 CHA-hES60 embryonic stem cell human CVCL_B3V6 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12018002. 151358700 CVCL_B3UX 591 [Human iPSC] induced pluripotent stem cell human CVCL_B3UX From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151358701 CVCL_B3V9 SNUhES46 embryonic stem cell human CVCL_B3V9 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017006. 151358702 CVCL_B3UW 1582 induced pluripotent stem cell human CVCL_B3UW From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 151358703 CVCL_B3V8 SNUhES45 embryonic stem cell human CVCL_B3V8 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017004. 151358704 CVCL_B3UJ WG3332 finite cell line human CVCL_B3UJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; c.291-1G>A; ClinVar=VCV000219004; Zygosity=Heterozygous; Note=Splice acceptor mutation (CelloPub=CLPUB00662); Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Gln234Ter (c.700C>T); ClinVar=VCV000203820; Zygosity=Heterozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358705 CVCL_B3UI WG3293 finite cell line human CVCL_B3UI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; c.197-1G>T; ClinVar=VCV000219008; Zygosity=Homozygous; Note=Splice acceptor mutation (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358706 CVCL_B3UL WG2664 finite cell line human CVCL_B3UL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 18871; MMAA; Simple; p.Arg145Ter (c.433C>T); ClinVar=VCV000003160; Zygosity=Heterozygous (CelloPub=CLPUB00662); Sequence variation: Mutation; HGNC; 18871; MMAA; Simple; p.Thr198Serfs*6 (c.593_596delCTGA) (c.592_595del); ClinVar=VCV000203815; Zygosity=Heterozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358707 CVCL_B3UK WG1641 finite cell line human CVCL_B3UK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Gln234Ter (c.700C>T); ClinVar=VCV000203820; Zygosity=Homozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358708 CVCL_B3UN IV-A1-j spontaneously immortalized cell line CVCL_B3UN CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: DTaI; Derived from sampling site: Lung Cell type=Fibroblast.. Male Characteristics: Resistant to an insulin-diphtheria-A chain toxic conjugate (DTaI) 151358709 CVCL_B3UM WG3365 finite cell line human CVCL_B3UM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; c.916-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (CelloPub=CLPUB00671; PubMed=21303734); Sequence variation: Mutation; HGNC; 23038; LMBRD1; Simple; p.Asn353Ilefs*18 (c.1056delG) (L352fsX18); ClinVar=VCV000225048; Zygosity=Heterozygous (CelloPub=CLPUB00671; PubMed=19136951) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358710 CVCL_B3V1 KRIBBi004-A induced pluripotent stem cell human CVCL_B3V1 From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Karyotypic information: 46,XX,t(1;5)(p31.1;p35.1) (PubMed=34736040); Derived from sampling site: Bone marrow. Female 151358711 CVCL_B3UP LMH17 finite cell line CVCL_B3UP CL:0000010 Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female 151358712 CVCL_B3V0 KRIBBi003-A induced pluripotent stem cell human CVCL_B3V0 From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 8926; PHKA2; Simple; p.Ala1076Glufs*40 (c.3227_3231del); Zygosity=Hemizygous (PubMed=34740118) Population: Korean; Derived from sampling site: Urine. Male 151358713 CVCL_B3UB ICGi035-A induced pluripotent stem cell human CVCL_B3UB From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2183; VPS13B; Simple; c.3870+1G>T; ClinVar=VCV000559917; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=35026660) Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358714 CVCL_B3UA WG0614 finite cell line human CVCL_B3UA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358715 CVCL_B3UD MCH014 finite cell line human CVCL_B3UD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151358716 CVCL_B3UC ICGi035-B induced pluripotent stem cell human CVCL_B3UC From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2183; VPS13B; Simple; c.3870+1G>T; ClinVar=VCV000559917; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=35026660) Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358717 CVCL_B3UF WG2408 finite cell line human CVCL_B3UF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous (CelloPub=CLPUB00662; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358718 CVCL_B3UE WG2181 finite cell line human CVCL_B3UE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg31Ter (c.91C>T); ClinVar=VCV000092688; Zygosity=Homozygous (CelloPub=CLPUB00662; PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358719 CVCL_B3UH WG2147 finite cell line human CVCL_B3UH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Val188_Ala192dup (c.563_577dupTGTGCCGCCGGGCCG); ClinVar=VCV000203822; Zygosity=Homozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358720 CVCL_B3UG WG2662 finite cell line human CVCL_B3UG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Lys48Phefs*2 (c.141_142insTTTT); Zygosity=Homozygous (CelloPub=CLPUB00662; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Pacific; Derived from sampling site: Skin Cell type=Fibroblast.. 151358721 CVCL_B3VZ WG3163 finite cell line human CVCL_B3VZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg31Ter (c.91C>T); ClinVar=VCV000092688; Zygosity=Homozygous (CelloPub=CLPUB00662; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian and Native North American; Derived from sampling site: Skin Cell type=Fibroblast.. 151358722 CVCL_B3WB WG0103 finite cell line human CVCL_B3WB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358723 CVCL_B3WA WG0107 finite cell line human CVCL_B3WA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358724 CVCL_B3W4 C7788 transformed cell line human CVCL_B3W4 From: Institute for Basic Research in Developmental Disabilities; Staten Island; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C; ClinVar=VCV000002644; Zygosity=Heterozygous (PubMed=9295267); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=9295267) Derived from sampling site: Peripheral blood. 151358725 CVCL_B3VS WG0735 finite cell line human CVCL_B3VS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Thr227Met (c.680C>T); ClinVar=VCV000800827; Zygosity=Homozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: African and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358726 CVCL_B3W3 C7787 transformed cell line human CVCL_B3W3 From: Institute for Basic Research in Developmental Disabilities; Staten Island; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C; ClinVar=VCV000002644; Zygosity=Heterozygous (PubMed=9295267); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=9295267) Derived from sampling site: Peripheral blood. 151358727 CVCL_B3VR WG0670 finite cell line human CVCL_B3VR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Gly149Val (c.446_447delinsTT) (458_459GC>TT); ClinVar=VCV000848483; Zygosity=Homozygous (PubMed=8940272) Miscellaneous: Cell line no longer available Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358728 CVCL_B3W6 C7790 transformed cell line human CVCL_B3W6 From: Institute for Basic Research in Developmental Disabilities; Staten Island; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C; ClinVar=VCV000002644; Zygosity=Heterozygous (PubMed=9295267) Derived from sampling site: Peripheral blood. Male 151358729 CVCL_B3VU WG1654 finite cell line human CVCL_B3VU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358730 CVCL_B3W5 C7789 transformed cell line human CVCL_B3W5 From: Institute for Basic Research in Developmental Disabilities; Staten Island; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=9295267) Derived from sampling site: Peripheral blood. Female 151358731 CVCL_B3VT WG1396 finite cell line human CVCL_B3VT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg52Gln (c.155G>A); ClinVar=VCV000570071; Zygosity=Heterozygous (PubMed=7726158; PubMed=8940272); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg357Cys (c.1069C>T); ClinVar=VCV001452549; Zygosity=Heterozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358732 CVCL_B3W8 WG0229 finite cell line human CVCL_B3W8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358733 CVCL_B3VW WG1772 finite cell line human CVCL_B3VW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg51Pro (c.152G>C); Zygosity=Heterozygous (PubMed=8940272); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; c.237-1G>T (c.249-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=8940272) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358734 CVCL_B3W7 WG0109 finite cell line human CVCL_B3W7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358735 CVCL_B3VV WG1767 finite cell line human CVCL_B3VV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Leu323Pro (c.968T>C); ClinVar=VCV000003529; Zygosity=Heterozygous (PubMed=8940272); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg377Cys (c.1129C>T); ClinVar=VCV000003528; Zygosity=Heterozygous (PubMed=8940272) Miscellaneous: Cell line no longer available Population: African American and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358736 CVCL_B3VY WG0356 finite cell line human CVCL_B3VY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg325Cys (c.973C>T); ClinVar=VCV000975600; Zygosity=Homozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358737 CVCL_B3W9 WG0140 finite cell line human CVCL_B3W9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358738 CVCL_B3VX WG1886 finite cell line human CVCL_B3VX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358739 CVCL_B3VK WG0138 finite cell line human CVCL_B3VK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 93; ACAT1; Simple; p.Met1Lys (c.2T>A); ClinVar=VCV000002838; Zygosity=Homozygous (PubMed=8103405) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358740 CVCL_B3VJ NCC-GCTB4-C1 cancer cell line human CVCL_B3VJ CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=34731453) Population: Japanese; Derived from sampling site: Bone; left proximal tibia. Male Doubling time: 65.78 hours (PubMed=34731453) Part of: NCC sarcoma cell line panel 151358741 CVCL_B3VM WG0421 finite cell line human CVCL_B3VM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Tyr140Cys (c.419A>G); ClinVar=VCV000371634; Zygosity=Heterozygous (DOI=10.26502/acbr.50170022); Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg297Ter (c.889C>T); ClinVar=VCV000001562; Zygosity=Heterozygous (DOI=10.26502/acbr.50170022) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358742 CVCL_B3VL WG0026 finite cell line human CVCL_B3VL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 93; ACAT1; Simple; c.1163+2T>C (IVS11,T-C,+2); ClinVar=VCV000002837; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=8103405) Miscellaneous: Cell line no longer available Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358743 CVCL_B3W0 WG0305 finite cell line human CVCL_B3W0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Cys365Tyr (c.1094G>A); ClinVar=VCV000002642; Zygosity=Homozygous (PubMed=9295267) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358744 CVCL_B3VN WG0354 finite cell line human CVCL_B3VN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; c.780+1G>A (c.792+1G>A); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358745 CVCL_B3W2 C7786 transformed cell line human CVCL_B3W2 From: Institute for Basic Research in Developmental Disabilities; Staten Island; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=9295267) Derived from sampling site: Peripheral blood. 151358746 CVCL_B3VQ WG0458 finite cell line human CVCL_B3VQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg52Gln (c.155G>A); ClinVar=VCV000570071; Zygosity=Heterozygous (PubMed=7726158; PubMed=8940272); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg335Cys (c.1003C>T); Zygosity=Heterozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358747 CVCL_B3W1 WG0308 finite cell line human CVCL_B3W1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Cys365Arg (c.1093T>C); ClinVar=VCV000002641; Zygosity=Heterozygous (PubMed=9295267) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358748 CVCL_B3VP WG0355 finite cell line human CVCL_B3VP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; c.780+1G>A (c.792+1G>A); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358749 CVCL_B3VC SNUhES49 embryonic stem cell human CVCL_B3VC From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017008. 151358750 CVCL_B3VB SNUhES48 embryonic stem cell human CVCL_B3VB From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017007. 151358751 CVCL_B3VE CHA-hES57 embryonic stem cell human CVCL_B3VE From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017002. 151358752 CVCL_B3VD CHA-hES56 embryonic stem cell human CVCL_B3VD From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017001. 151358753 CVCL_B3VG CHA-FT-NT17 embryonic stem cell human CVCL_B3VG From: CHA University; Seongnam; South Korea CL:0000010 Female Characteristics: Produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 42-year-old female patient with central areolar choroidal dystrophy. 151358754 CVCL_B3VF CHA-hES58 embryonic stem cell human CVCL_B3VF From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12017003. 151358755 CVCL_B3VI CHA-FT-NT19 embryonic stem cell human CVCL_B3VI CL:0000010 Karyotypic information: 47,XYY (PubMed=32502464). Male Characteristics: Produced by somatic cell nuclear transfer from mononucleated cells from cord blood Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12019002 151358756 CVCL_B3VH CHA-FT-NT18 embryonic stem cell human CVCL_B3VH From: CHA University; Seongnam; South Korea CL:0000010 Male Characteristics: Produced by somatic cell nuclear transfer from mononucleated cells from cord blood. Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12019001 151358757 CVCL_B3SX HeLa-mCAT#8 TAL-CERS2#18 cancer cell line human CVCL_B3SX CL:0000010 Knockout cell: Method=TALEN (3 of 4 alleles); HGNC; 14076; CERS2; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358758 CVCL_B3T9 HHUUKDi009-A induced pluripotent stem cell human CVCL_B3T9 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151358759 CVCL_B3T8 C57M10 spontaneously immortalized cell line house mouse CVCL_B3T8 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Unspecified 151358760 CVCL_B3SW HeLa-mCAT#8 TAL-CERS2#16 cancer cell line human CVCL_B3SW CL:0000010 Knockout cell: Method=TALEN; HGNC; 14076; CERS2; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358761 CVCL_B3SZ HeLa-mCAT#8 TAL-CE#14 cancer cell line human CVCL_B3SZ CL:0000010 Knockout cell: Method=TALEN; HGNC; 2205; CERT1; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358762 CVCL_B3SY HeLa-mCAT#8 TAL-CE#1 cancer cell line human CVCL_B3SY CL:0000010 Knockout cell: Method=TALEN; HGNC; 2205; CERT1; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358763 CVCL_B3T1 HeLa-mCAT#8 TAL-CERS2#18-CERT#10 cancer cell line human CVCL_B3T1 CL:0000010 Knockout cell: Method=TALEN (3 of 4 alleles); HGNC; 14076; CERS2; Knockout cell: Method=TALEN; HGNC; 2205; CERT1; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358764 CVCL_B3SP II-II6B3 hybridoma house mouse CVCL_B3SP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02460; Chicken COL2A1. 151358765 CVCL_B3T0 HeLa-mCAT#8 TAL-CE#3 cancer cell line human CVCL_B3T0 CL:0000010 Knockout cell: Method=TALEN; HGNC; 2205; CERT1; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358766 CVCL_B3T3 HeLa-mCAT#8 TAL-UG#7 cancer cell line human CVCL_B3T3 CL:0000010 Knockout cell: Method=TALEN; HGNC; 12524; UGCG; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358767 CVCL_B3SR V-DH2 hybridoma house mouse CVCL_B3SR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Chicken type V collagen. 151358768 CVCL_B3T2 HeLa-mCAT#8 TAL-UG#3 cancer cell line human CVCL_B3T2 CL:0000010 Knockout cell: Method=TALEN; HGNC; 12524; UGCG; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358769 CVCL_B3SQ V-ABI2 hybridoma house mouse CVCL_B3SQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Chicken type V collagen. 151358770 CVCL_B3T5 HeLa-mCAT#8 TAL-B4G5#2 cancer cell line human CVCL_B3T5 CL:0000010 Knockout cell: Method=TALEN; HGNC; 928; B4GALT5; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358771 CVCL_B3ST MA-108 finite cell line CVCL_B3ST CL:0000010 Derived from sampling site: Fetal spleen. Unspecified Group: Non-human primate cell line 151358772 CVCL_B3SS FMC46 hybridoma house mouse CVCL_B3SS CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P14151; Human SELL/CD62L. 151358773 CVCL_B3T4 HeLa-mCAT#8 TAL-CE#14-UG#2 cancer cell line human CVCL_B3T4 CL:0000010 Knockout cell: Method=TALEN; HGNC; 2205; CERT1; Knockout cell: Method=TALEN; HGNC; 12524; UGCG; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358774 CVCL_B3SV HeLa-mCAT#8 TAL-CERS2#13 cancer cell line human CVCL_B3SV CL:0000010 Knockout cell: Method=TALEN (3 of 4 alleles); HGNC; 14076; CERS2; Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358775 CVCL_B3T7 KUMi003-A induced pluripotent stem cell human CVCL_B3T7 From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Population: Korean; Donor information: Established from a patient suffering from acute promyelocytic leukemia but as a normal karyotype; Derived from sampling site: Bone marrow. Male 151358776 CVCL_B3T6 GZHMCi008-A induced pluripotent stem cell human CVCL_B3T6 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 151358777 CVCL_B3SU HeLa-mCAT#8 cancer cell line human CVCL_B3SU CL:0000010 Transfected with: MGI; MGI:88117; Slc7a1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358778 CVCL_B3SH HeLa ANXA11 KO cancer cell line human CVCL_B3SH From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 535; ANXA11 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151358779 CVCL_B3SG TRA-8 hybridoma house mouse CVCL_B3SG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O14763; Human TNFRSF10B/CD262. 151358780 CVCL_B3SJ SMBCi013-A induced pluripotent stem cell human CVCL_B3SJ From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Ser975Tyr (c.2924C>A) (p.Ser768Tyr, c.2303C>A); ClinVar=VCV000862055; Zygosity=Heterozygous (PubMed=34995846); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Arg1319Ter (c.3955C>T) (p.Arg1112Ter, c.3334C>T); ClinVar=VCV000035728; Zygosity=Heterozygous (PubMed=34995846) Population: Chinese; Han; Derived from sampling site: Urine. Male 151358781 CVCL_B3SI SMBCi011-A induced pluripotent stem cell human CVCL_B3SI From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 151358782 CVCL_B3SL CMT-1026 cancer cell line dog CVCL_B3SL CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Teddy Bear. Female Doubling time: 23.95 hours (PubMed=34712723) Group: Triple negative breast cancer (TNBC) cell line 151358783 CVCL_B3SK SMCPGi001-A induced pluripotent stem cell human CVCL_B3SK From: The Seven Medical Center of PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 5042; HNRNPH2; Simple; p.Arg206Trp (c.616C>T); ClinVar=VCV000225760; Zygosity=Heterozygous; Note=De novo mutation (PubMed=34763229) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 151358784 CVCL_B3SN II-5B2 hybridoma house mouse CVCL_B3SN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02460; Chicken COL2A1. 151358785 CVCL_B3SM II-2B1 hybridoma house mouse CVCL_B3SM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02460; Chicken COL2A1. 151358786 CVCL_B3SB WAe009-A-72 embryonic stem cell human CVCL_B3SB From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2198; COL1A2. Female 151358787 CVCL_B3SA WAe009-A-75 embryonic stem cell human CVCL_B3SA From: Shenzhen People's Hospital; Shenzhen; China. CL:0000010 Female 151358788 CVCL_B3SD GM28007 finite cell line human CVCL_B3SD CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ile486Tyrfs*2 (c.1455dup); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358789 CVCL_B3SC HCC827-Luc-mCh-Puro cancer cell line human CVCL_B3SC CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Female 151358790 CVCL_B3SF MDCK-II Abcc1 spontaneously immortalized cell line dog CVCL_B3SF CL:0000010 Transfected with: RGD; 3112; Abcc1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 151358791 CVCL_B3SE GM28063 finite cell line human CVCL_B3SE CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Asn178Glufs*9 (c.532_535delAATA); ClinVar=VCV000372719; Zygosity=Heterozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358792 CVCL_B3TY CHO-hGluN1-hGluN2A spontaneously immortalized cell line CVCL_B3TY From: Evotec, Aptuit; Verona; Italy CL:0000010 Transfected with: HGNC; 4584; GRIN1; Transfected with: HGNC; 4585; GRIN2A; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female Characteristics: Upon induction by tetracycline expresses an heterodimeric human NMDA receptor GRIN1/GRIN2A 151358793 CVCL_B3TX MCH042 finite cell line human CVCL_B3TX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358794 CVCL_B3U9 WG0516 finite cell line human CVCL_B3U9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358795 CVCL_B3TZ CHO-hGluN1-hGluN2B spontaneously immortalized cell line CVCL_B3TZ From: Evotec, Aptuit; Verona; Italy CL:0000010 Transfected with: HGNC; 4584; GRIN1; Transfected with: HGNC; 4586; GRIN2B; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female Characteristics: Upon induction by tetracycline expresses an heterodimeric human NMDA receptor GRIN1/GRIN2b 151358796 CVCL_B3TQ NCC-DDLPS4-C1 cancer cell line human CVCL_B3TQ CL:0000010 Population: Japanese; Derived from sampling site: Retroperitoneal space. Omics: SNP array analysis Male Doubling time: 72.5 hours (PubMed=34834427) Part of: NCC sarcoma cell line panel 151358797 CVCL_B3U2 WG0067 finite cell line human CVCL_B3U2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358798 CVCL_B3U1 CHO-hGluN1-hGluN2D spontaneously immortalized cell line CVCL_B3U1 From: Evotec, Aptuit; Verona; Italy CL:0000010 Transfected with: HGNC; 4587; GRIN2C; Transfected with: HGNC; 4588; GRIN2D; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female Characteristics: Upon induction by tetracycline expresses an heterodimeric human NMDA receptor GRIN1/GRIN2D 151358799 CVCL_B3TP NCC-UPS1-C1 cancer cell line human CVCL_B3TP CL:0000010 Population: Japanese Omics: Deep proteome analysis. Male Doubling time: ~40.9 hours (DOI=10.11418/jtca.36.41) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358800 CVCL_B3TS NCC-CCS1B-C1 cancer cell line human CVCL_B3TS CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=29197033) Population: Japanese; Derived from metastatic site: Left thigh; hypodermis. Omics: Deep proteome analysis Female Doubling time: 20 hours (PubMed=29197033) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358801 CVCL_B3U4 WG0153 finite cell line human CVCL_B3U4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358802 CVCL_B3TR NCC-CCS1-X4-C1 cancer cell line human CVCL_B3TR CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=29197033) Population: Japanese; Derived from metastatic site: Left thigh; hypodermis. Omics: Deep proteome analysis Female Characteristics: Established from a fourth generation xenograft established by subcutaneous injection in female NOD/Shi-scid IL-2Rgammanull mice Doubling time: 17 hours (PubMed=29197033) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358803 CVCL_B3U3 WG0124 finite cell line human CVCL_B3U3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358804 CVCL_B3U6 WG0240 finite cell line human CVCL_B3U6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358805 CVCL_B3TU WG0674 finite cell line human CVCL_B3TU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 151358806 CVCL_B3TT NCC-CCS1B-X2-C1 cancer cell line human CVCL_B3TT CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=29197033) Population: Japanese; Derived from metastatic site: Left thigh; hypodermis. Omics: Deep proteome analysis Female Characteristics: Established from a second generation xenograft established by subcutaneous injection in female NOD/Shi-scid IL-2Rgammanull mice Doubling time: 20 hours (PubMed=29197033) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358807 CVCL_B3U5 WG0220 finite cell line human CVCL_B3U5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358808 CVCL_B3TW MCH033 finite cell line human CVCL_B3TW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151358809 CVCL_B3U8 WG0449 finite cell line human CVCL_B3U8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 151358810 CVCL_B3TV MCH012 finite cell line human CVCL_B3TV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151358811 CVCL_B3U7 WG0241 finite cell line human CVCL_B3U7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. 151358812 CVCL_B3TI COG-LL-329 cancer cell line human CVCL_B3TI CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 151358813 CVCL_B3TH COG-LL-319 cancer cell line human CVCL_B3TH CL:0000010 Karyotypic information: 46,XX,der(7)t(1;7)(q32;q36),del(9)(p11.2),der(19)t(1;19)(q23;p13.3) (COG); Derived from sampling site: Peripheral blood. Female 151358814 CVCL_B3TK COG-LL-355 cancer cell line human CVCL_B3TK CL:0000010 Derived from sampling site: Bone marrow. Male 151358815 CVCL_B3TJ COG-LL-332 cancer cell line human CVCL_B3TJ CL:0000010 Karyotypic information: 46,XY,t(1;9)(p34;q34) (COG); Derived from sampling site: Bone marrow Cell type=T-cell.. Male 151358816 CVCL_B3TM NCC-pRMS1-C1 cancer cell line human CVCL_B3TM CL:0000010 Population: Japanese; Derived from sampling site: Right thigh; muscle. Male Doubling time: 61 hours (DOI=10.11418/jtca.38.1) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358817 CVCL_B3TL COG-LL-356 cancer cell line human CVCL_B3TL CL:0000010 Derived from sampling site: Bone marrow. Male 151358818 CVCL_B3U0 CHO-hGluN1-hGluN2C spontaneously immortalized cell line CVCL_B3U0 From: Evotec, Aptuit; Verona; Italy CL:0000010 Transfected with: HGNC; 4584; GRIN1; Transfected with: HGNC; 4587; GRIN2C; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female Characteristics: Upon induction by tetracycline expresses an heterodimeric human NMDA receptor GRIN1/GRIN2C 151358819 CVCL_B3TN NCC-pRMS1-X4-C1 cancer cell line human CVCL_B3TN CL:0000010 Population: Japanese; Derived from sampling site: Right thigh; muscle. Male Characteristics: Established from a fourth generation xenograft established by subcutaneous injection in female NOD/Shi-scid IL-2Rgammanull mice Doubling time: 40 hours (DOI=10.11418/jtca.38.1) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 151358820 CVCL_B3TA HUSTTJi001-A induced pluripotent stem cell human CVCL_B3TA From: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 14539; RNF213; Simple; p.Arg4810Lys (c.14429G>A); ClinVar=VCV000039700; Zygosity=Heterozygous (PubMed=34749017) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151358821 CVCL_B3TC COG-LY-459 cancer cell line human CVCL_B3TC CL:0000010 Derived from sampling site: Peripheral blood. Female 151358822 CVCL_B3TB COG-LY-460 cancer cell line human CVCL_B3TB CL:0000010 Derived from sampling site: Ovary. Female 151358823 CVCL_B3TE COG-LY-457 cancer cell line human CVCL_B3TE CL:0000010 Derived from sampling site: Bone marrow. Female 151358824 CVCL_B3TD COG-LY-458 cancer cell line human CVCL_B3TD CL:0000010 Derived from sampling site: Peripheral blood. Female 151358825 CVCL_B3TG CHLA-233 cancer cell line human CVCL_B3TG CL:0000010 151358826 CVCL_B3TF CHLA-221 cancer cell line human CVCL_B3TF CL:0000010 151358827 CVCL_B3R7 EHD E2C5 hybridoma house mouse CVCL_B3R7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Epizootic hemorrhagic disease virus 2 (EHDV-2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021180 151358828 CVCL_B3QV PICALM6A transformed cell line house mouse CVCL_B3QV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2385902; Picalm; Transfected with: HGNC; 7132; KMT2A (KMT2A-MLLT1 fusion); Transfected with: HGNC; 7134; MLLT1 (KMT2A-MLLT1 fusion) Transformant: KMT2A-MLLT1; Derived from sampling site: Embryonic liver; Breed/subspecies: fit1 Picalmfit1-5R. Unspecified 151358829 CVCL_B3R6 5E8 hybridoma house mouse CVCL_B3R6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q14980; Human NUMA1. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10586 151358830 CVCL_B3QU LMM117 hybridoma house mouse CVCL_B3QU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. 151358831 CVCL_B3R9 A640-BB-3 transformed cell line house mouse CVCL_B3R9 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358832 CVCL_B3QX PICALM6D transformed cell line house mouse CVCL_B3QX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2385902; Picalm; Transfected with: HGNC; 7132; KMT2A (KMT2A-MLLT1 fusion); Transfected with: HGNC; 7134; MLLT1 (KMT2A-MLLT1 fusion) Transformant: KMT2A-MLLT1; Derived from sampling site: Embryonic liver. Unspecified 151358833 CVCL_B3R8 A640-BB-1 transformed cell line house mouse CVCL_B3R8 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358834 CVCL_B3QW PICALM6B transformed cell line house mouse CVCL_B3QW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2385902; Picalm; Transfected with: HGNC; 7132; KMT2A (KMT2A-MLLT1 fusion); Transfected with: HGNC; 7134; MLLT1 (KMT2A-MLLT1 fusion) Transformant: KMT2A-MLLT1; Derived from sampling site: Embryonic liver. Unspecified 151358835 CVCL_B3QZ 4T1.3 cancer cell line house mouse CVCL_B3QZ CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Metastasizes with high frequency to bone upon orthotopic injection into the mammary fat pad of immunocompetent female BALB/c mice (PubMed=27177471) 151358836 CVCL_B3QY 2G8D10 hybridoma house mouse CVCL_B3QY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; M4I2H9; Orf virus major core protein 4a (ORFV086). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201471 151358837 CVCL_B3QN ShK cancer cell line human CVCL_B3QN CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5853; IGL; Name(s)=IGL-BCL2 (PubMed=12967475); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=12967475). Population: Japanese 151358838 CVCL_B3QM MTX-TK cancer cell line human CVCL_B3QM CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Brain. Male 151358839 CVCL_B3R1 NOD-iPS#5 induced pluripotent stem cell house mouse CVCL_B3R1 CL:0000010 Derived from sampling site: Tail; tip Cell type=Fibroblast.; Breed/subspecies: NOD/Lt. Male 151358840 CVCL_B3QP OYB cancer cell line human CVCL_B3QP CL:0000010 Population: Japanese. 151358841 CVCL_B3R0 MY.1E12 hybridoma house mouse CVCL_B3R0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227 (Note=Recognizes the sialylalpha2-3Galactosylbeta1-3N-acetylgalactosaminide trisaccharide onto the Thr within the VTS repeats). 151358842 CVCL_B3R3 NOD-iPS#17 induced pluripotent stem cell house mouse CVCL_B3R3 CL:0000010 Derived from sampling site: Tail; tip Cell type=Fibroblast.; Breed/subspecies: NOD/Lt. Male 151358843 CVCL_B3QR RbM2 hybridoma house mouse CVCL_B3QR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rabbit 50 Kda lysosomal membrane antigen. 151358844 CVCL_B3R2 NOD-iPS#11 induced pluripotent stem cell house mouse CVCL_B3R2 CL:0000010 Derived from sampling site: Tail; tip Cell type=Fibroblast.; Breed/subspecies: NOD/Lt. Male 151358845 CVCL_B3QQ PCL2021 cancer cell line human CVCL_B3QQ CL:0000010 Unspecified 151358846 CVCL_B3R5 11A10 hybridoma house mouse CVCL_B3R5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q14980; Human NUMA1. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10585 151358847 CVCL_B3QT LMM111 hybridoma house mouse CVCL_B3QT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. 151358848 CVCL_B3R4 1G11 spontaneously immortalized cell line house mouse CVCL_B3R4 CL:0000010 Derived from sampling site: Lung; endothelium Cell type=Lung microvascular endothelial cell.; Breed/subspecies: C57BL/6NCrLBR. Female 151358849 CVCL_B3QS LMM102 hybridoma house mouse CVCL_B3QS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. 151358850 CVCL_B3QF LM cancer cell line human CVCL_B3QF CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307) Derived from sampling site: Liver. Female 151358851 CVCL_B3QE AS [Human rhabdoid tumor] cancer cell line human CVCL_B3QE CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from sampling site: Abdomen. Female 151358852 CVCL_B3QH A-20 hybridoma house mouse CVCL_B3QH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45 (isoform Ly5.1). Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2003-077 151358853 CVCL_B3QG MT [Human rhabdoid tumor] cancer cell line human CVCL_B3QG CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from metastatic site: Hypodermis. Male 151358854 CVCL_B3QJ PCNSL-MSK cancer cell line human CVCL_B3QJ From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Brain. Omics: Array-based CGH Male 151358855 CVCL_B3QI 104-2 hybridoma house mouse CVCL_B3QI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45 (isoform Ly5.2). Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2003-077 151358856 CVCL_B3QL MTX-RAJI cancer cell line human CVCL_B3QL CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151358857 CVCL_B3QK MTX-HKBML cancer cell line human CVCL_B3QK CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Brain. Male 151358858 CVCL_B3QB NPC-BM29 cancer cell line human CVCL_B3QB CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Bone marrow. Female Characteristics: Invasive subline of NPC-BM1 151358859 CVCL_B3QA NP550hTert telomerase immortalized cell line human CVCL_B3QA CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Male 151358860 CVCL_B3QD Rag2-/- pro-B cells finite cell line house mouse CVCL_B3QD CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97849; Rag2 Derived from sampling site: Bone marrow Cell type=Pro-B cell.; Breed/subspecies: 129S6/SvEvTac-Rag2tm1Fwa. Unspecified Characteristics: Rag2-/- pro-B cells maintained on OP42 stromal cells 151358861 CVCL_B3QC NPC-BM00 cancer cell line human CVCL_B3QC CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Bone marrow. Female Characteristics: Non-invasive subline of NPC-BM1 151358862 CVCL_B3RW CPG8 transformed cell line human CVCL_B3RW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151358863 CVCL_B3S8 MUPS-1 cancer cell line human CVCL_B3S8 CL:0000010 Population: African American; Derived from sampling site: Right mandible; hypodermis. Omics: Transcriptome analysis by RNAseq Male Doubling time: 93.14 hours (PubMed=32652895) 151358864 CVCL_B3RV CPG7 transformed cell line human CVCL_B3RV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151358865 CVCL_B3S7 WAe009-A-74 embryonic stem cell human CVCL_B3S7 From: Shenzhen People's Hospital; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple_edited; p.Tyr616Cys (c.1847A>G); ClinVar=VCV000067295; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35247842). Female 151358866 CVCL_B3RY ICGi034-A induced pluripotent stem cell human CVCL_B3RY From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=35007918) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151358867 CVCL_B3RX ICGi033-A induced pluripotent stem cell human CVCL_B3RX From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[77] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=35872525) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151358868 CVCL_B3S9 TT1 [Human thyroid carcinoma] cancer cell line human CVCL_B3S9 CL:0000010 Derived from sampling site: Thyroid gland. 151358869 CVCL_B3RZ SXMUi001-A induced pluripotent stem cell human CVCL_B3RZ From: Shanxi Medical University; Taiyuan; China CL:0000010 Sequence variation: Mutation; HGNC; 3551; F9; Simple; p.Arg75Ter (c.223C>T); ClinVar=VCV000010572; Zygosity=Hemizygous (Patent=CN113881637A; PubMed=35121195) Derived from sampling site: Urine. Male Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.22359 151358870 CVCL_B3S0 SIAISi014-A induced pluripotent stem cell human CVCL_B3S0 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China. CL:0000010 151358871 CVCL_B3RN NCC-UPS3-C1 cancer cell line human CVCL_B3RN CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=34665443); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (PubMed=34665443) Population: Japanese; Derived from metastatic site: Left buttock; hypodermis. Omics: SNP array analysis Female Doubling time: 61.6 hours (PubMed=34665443) Part of: NCC sarcoma cell line panel 151358872 CVCL_B3RQ ICGi031-A induced pluripotent stem cell human CVCL_B3RQ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151358873 CVCL_B3S2 SIAISi016-A induced pluripotent stem cell human CVCL_B3S2 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Derived from sampling site: Peripheral blood. Male 151358874 CVCL_B3S1 SIAISi015-A induced pluripotent stem cell human CVCL_B3S1 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China. CL:0000010 151358875 CVCL_B3RP WAe009-A-67 embryonic stem cell human CVCL_B3RP From: Institute of Health Service and Transfusion Medicine; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10852; SHMT2. Female 151358876 CVCL_B3RS CPG10 transformed cell line human CVCL_B3RS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151358877 CVCL_B3S4 SIAISi018-A induced pluripotent stem cell human CVCL_B3S4 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151358878 CVCL_B3RR ICGi032-A induced pluripotent stem cell human CVCL_B3RR From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151358879 CVCL_B3S3 SIAISi017-A induced pluripotent stem cell human CVCL_B3S3 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Population: Chinese/Asian ethnic group: Hui; Derived from sampling site: Peripheral blood. Male 151358880 CVCL_B3RU CPG18 transformed cell line human CVCL_B3RU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151358881 CVCL_B3S6 WAe009-A-73 embryonic stem cell human CVCL_B3S6 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10486; S100A1. Female 151358882 CVCL_B3S5 CIPi001-A induced pluripotent stem cell human CVCL_B3S5 From: Children's Hospital of Capital Institute of Pediatrics; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 151358883 CVCL_B3RT CPG166 transformed cell line human CVCL_B3RT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151358884 CVCL_B3RG SV-BB-5 transformed cell line house mouse CVCL_B3RG CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358885 CVCL_B3RF SV-BB-4 transformed cell line house mouse CVCL_B3RF CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358886 CVCL_B3RI 28-12 (Ara) transformed cell line house mouse CVCL_B3RI CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: ICR. Female 151358887 CVCL_B3RH 28-12 transformed cell line house mouse CVCL_B3RH CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: ICR. Female 151358888 CVCL_B3RK CQ8-A2D9 hybridoma house mouse CVCL_B3RK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P30556; Human AGTR1 (Note=Raised against the peptide 'AFHYESQ' and recognizes it). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017108 151358889 CVCL_B3RJ 2D9 [Mouse hybridoma against H.hepaticus cdtB] hybridoma house mouse CVCL_B3RJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7VG76; Helicobacter hepaticus cdtB. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021140 151358890 CVCL_B3RM NCC-MFS3-C1 cancer cell line human CVCL_B3RM CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=33990915); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (PubMed=33990915) Population: Japanese; Derived from sampling site: Thigh; hypodermis. Omics: SNP array analysis Female Doubling time: ~36 hours (PubMed=33990915) Part of: NCC sarcoma cell line panel 151358891 CVCL_B3RL NCC-MFS4-C1 cancer cell line human CVCL_B3RL CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=34383271); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (PubMed=34383271) Population: Japanese; Derived from sampling site: Lower leg; hypodermis. Omics: SNP array analysis Female Doubling time: ~64 hours (PubMed=34383271) Part of: NCC sarcoma cell line panel 151358892 CVCL_B3RA A640-BB-4 transformed cell line house mouse CVCL_B3RA CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358893 CVCL_B3RC SV-BB-1 transformed cell line house mouse CVCL_B3RC CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358894 CVCL_B3RB A640-BB-5 transformed cell line house mouse CVCL_B3RB CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358895 CVCL_B3RE SV-BB-3 transformed cell line house mouse CVCL_B3RE CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358896 CVCL_B3RD SV-BB-2 transformed cell line house mouse CVCL_B3RD CL:0000010 Transformant: Simian virus 40 (SV40) [SV68C](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 151358897 CVCL_B3P5 DRICUi007-A induced pluripotent stem cell human CVCL_B3P5 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 151358898 CVCL_B3P4 DRICUi006-A induced pluripotent stem cell human CVCL_B3P4 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 151358899 CVCL_B3P7 DRICUi009-A induced pluripotent stem cell human CVCL_B3P7 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 151358900 CVCL_B3P6 DRICUi008-A induced pluripotent stem cell human CVCL_B3P6 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 151358901 CVCL_B3P9 1BH3 hybridoma house mouse CVCL_B3P9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; A1Z0H6; Pseudomonas fluorescens G2 3-phosphoshikimate 1-carboxyvinyltransferase (aroA). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10494 151358902 CVCL_B3P8 HCT 116 SYT1 KO cancer cell line human CVCL_B3P8 From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11509; SYT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Cell line information from personal communication of Laflamme C Derived from sampling site: Colon. Male 151358903 CVCL_B3P1 DRICUi003-A induced pluripotent stem cell human CVCL_B3P1 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 151358904 CVCL_B3P0 DRICUi002-A induced pluripotent stem cell human CVCL_B3P0 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 151358905 CVCL_B3P3 DRICUi005-A induced pluripotent stem cell human CVCL_B3P3 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 151358906 CVCL_B3P2 DRICUi004-A induced pluripotent stem cell human CVCL_B3P2 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 151358907 CVCL_B3NZ DRICUi001-A induced pluripotent stem cell human CVCL_B3NZ From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 151358908 CVCL_B3Q6 NP446-CDK4R24C-hTert telomerase immortalized cell line human CVCL_B3Q6 CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Female 151358909 CVCL_B3PU SK-JHRCC-62-LN cancer cell line human CVCL_B3PU From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lymph node. Male 151358910 CVCL_B3Q5 NP361-cyclinD1-hTert telomerase immortalized cell line human CVCL_B3Q5 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Female 151358911 CVCL_B3PT SK-JHRCC-228 cancer cell line human CVCL_B3PT From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Male 151358912 CVCL_B3PW Dnmt1(Y495C)-1 embryonic stem cell house mouse CVCL_B3PW From: Birla Institute of Technology and Science Pilani, Hyderabad Campus; Hyderabad; India CL:0000010 Transfected with: MGI; MGI:94912; Dnmt1 (with p.Tyr501Cys, equivalent to human p.Tyr495Cys); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 151358913 CVCL_B3Q8 NP550-CDK4R24C-hTert telomerase immortalized cell line human CVCL_B3Q8 CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Male 151358914 CVCL_B3Q7 NP446-cyclinD1-hTert telomerase immortalized cell line human CVCL_B3Q7 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Female 151358915 CVCL_B3PV SK-JHRCC-219 cancer cell line human CVCL_B3PV From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=32359397) Derived from metastatic site: Bone. Male 151358916 CVCL_B3PY AIBNi014-A induced pluripotent stem cell human CVCL_B3PY From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.1236-3dupT; ClinVar=VCV000181847; Zygosity=Homozygous (PubMed=34507142); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2135_Arg2136insTer (c.6404_6405insTT) (p.Arg2136fs); ClinVar=VCV000220763; Zygosity=Heterozygous (PubMed=34507142) Population: Caucasian; Derived from sampling site: Nose; nasal cavity; olfactory mucosa. Female 151358917 CVCL_B3Q9 NP550-cyclinD1-hTert telomerase immortalized cell line human CVCL_B3Q9 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Male 151358918 CVCL_B3PX WAe009-A-70 embryonic stem cell human CVCL_B3PX From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3756; FLNC. Female 151358919 CVCL_B3PZ AIBNi013-A induced pluripotent stem cell human CVCL_B3PZ From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Derived from sampling site: Nose; nasal cavity; olfactory mucosa. Male 151358920 CVCL_B3PM CCLF-PEDS-0008-T cancer cell line human CVCL_B3PM CL:0000010 Derived from metastatic site: Hypodermis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358921 CVCL_B3PL CCLF-PEDS-0003-T cancer cell line human CVCL_B3PL CL:0000010 Derived from metastatic site: Hypodermis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358922 CVCL_B3Q0 SKOV3/MRP7 cancer cell line human CVCL_B3Q0 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 52; ABCC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Doubling time: 68.19 +- 1.53 hours (PubMed=34631561) 151358923 CVCL_B3PN CCLF-PEDS-0009-T cancer cell line human CVCL_B3PN CL:0000010 Derived from metastatic site: Pleural effusion. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358924 CVCL_B3Q2 CPGHi004-A induced pluripotent stem cell human CVCL_B3Q2 From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151358925 CVCL_B3PQ UOK353 cancer cell line human CVCL_B3PQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181His (c.542G>A); ClinVar=VCV000142320; Zygosity=Heterozygous (PubMed=32259323) Population: African American; Karyotypic information: 43,XX,-4,-9,-15,t(19;22)(p13.1;q11.2) (PubMed=32259323); Derived from sampling site: Kidney. Female Doubling time: ~72 hours (PubMed=32259323) 151358926 CVCL_B3PP CCLF-PEDS-0018-T undefined cell line type human CVCL_B3PP CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358927 CVCL_B3Q1 HEK293-MRP7 transformed cell line human CVCL_B3Q1 CL:0000010 Transfected with: HGNC; 52; ABCC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151358928 CVCL_B3Q4 NP361-CDK4R24C-hTert telomerase immortalized cell line human CVCL_B3Q4 CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Female 151358929 CVCL_B3PS RMC2C cancer cell line human CVCL_B3PS CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=32359397) Population: African American; Karyotypic information: Near hypertriploid karyotype (PubMed=32259323); Derived from sampling site: Kidney. Male 151358930 CVCL_B3Q3 NP361hTert telomerase immortalized cell line human CVCL_B3Q3 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Female 151358931 CVCL_B3PR UOK360 cancer cell line human CVCL_B3PR CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Ser258Valfs*23 (c.771insA); Zygosity=Homozygous (PubMed=32259323) Population: African American; Karyotypic information: Hypertriploid karyotype (PubMed=32259323); Derived from sampling site: Kidney. Female Doubling time: ~24 hours (PubMed=32259323) 151358932 CVCL_B3PE HCEM-1 telomerase immortalized cell line human CVCL_B3PE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Tooth; periodontal ligament Cell type=Cementoblast.. Unspecified 151358933 CVCL_B3PD TR-IL2-YT cancer cell line human CVCL_B3PD CL:0000010 Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion Cell type=Natural killer cell.. Male 151358934 CVCL_B3PG MS215 finite cell line human CVCL_B3PG CL:0000010 Derived from sampling site: Eye; choroid Cell type=Choroidal melanocyte.. Unspecified Doubling time: 20.5 hours (CelloPub=CLPUB00655) 151358935 CVCL_B3PF HCEM-2 telomerase immortalized cell line human CVCL_B3PF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Tooth; periodontal ligament Cell type=Cementoblast.. Unspecified 151358936 CVCL_B3PI BS153-ResE cancer cell line human CVCL_B3PI CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Brain. 151358937 CVCL_B3PH vCor.4U finite cell line human CVCL_B3PH From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Cardiomyocyte. Female 151358938 CVCL_B3PK CCLF-PEDS-0001-T cancer cell line human CVCL_B3PK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr107_Phe113del (c.320_340delACGGTTTCCGTCTGGGCTTCT); Zygosity=Heterozygous (DepMap) Derived from sampling site: Kidney. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358939 CVCL_B3PJ A375-RMR SCH 0.25 cancer cell line human CVCL_B3PJ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; Derived from sampling site: Skin. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 151358940 CVCL_B3PA 2EA2 hybridoma house mouse CVCL_B3PA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A1Z0H6; Pseudomonas fluorescens G2 3-phosphoshikimate 1-carboxyvinyltransferase (aroA). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10495 151358941 CVCL_B3PC TR-IL2-NK-92 cancer cell line human CVCL_B3PC CL:0000010 Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male 151358942 CVCL_B3PB ERMCL spontaneously immortalized cell line human CVCL_B3PB CL:0000010 Miscellaneous: As no cell line name was provided in the papers, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Eye; retina; neuroretina. Female 151358943 CVCL_B3ZA WG3357 finite cell line human CVCL_B3ZA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4839; HCFC1; Simple; p.Thr1481Met (c.4442C>T); ClinVar=VCV000382802; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358944 CVCL_B3ZC WG4142 finite cell line human CVCL_B3ZC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358945 CVCL_B3ZB WG4131 finite cell line human CVCL_B3ZB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 16692; CD320; Simple; p.Glu88del (c.256GAG[2]) (c.262_264delGAG); ClinVar=VCV000203643; Zygosity=Heterozygous (PubMed=31462756); Sequence variation: Mutation; HGNC; 16692; CD320; Simple; p.Gly220Arg (c.658G>A); ClinVar=VCV000136684; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358946 CVCL_B3ZE WG2046 finite cell line human CVCL_B3ZE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly215Cys (c.643G>T); ClinVar=VCV000418341; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358947 CVCL_B3ZD WG4190 finite cell line human CVCL_B3ZD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11529; EPCAM; Simple; p.Gln167Profs*21 (c.499dupC); ClinVar=VCV000012774; Zygosity=Homozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358948 CVCL_B3YV WG2686 finite cell line human CVCL_B3YV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358949 CVCL_B3Z7 WG3023 finite cell line human CVCL_B3Z7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4839; HCFC1; Simple; p.Pro1492Leu (c.4475C>T); Zygosity=Heterozygous (CelloPub=CLPUB00669; PubMed=27233228; PubMed=31462756) Miscellaneous: Cell line no longer available Population: Saudi Arabian and Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358950 CVCL_B3YU WG2625 finite cell line human CVCL_B3YU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Ser3329Leu (c.9986C>T); ClinVar=VCV000532212; Zygosity=Heterozygous (PubMed=31462756); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Glu584Ter (c.1749_1750delGGinsTT); Zygosity=Heterozygous (PubMed=31462756); Sequence variation: Mutation; HGNC; 8653; PCCA; Unexplicit; Ex21 intragenic 9-kb duplication; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Donor information: Established from a patient which had elevated level of methylmalonic acid thus was originally diagnosed as suffering from methylmalonic acidemia; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358951 CVCL_B3Z6 WG3099 finite cell line human CVCL_B3Z6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358952 CVCL_B3YX WG2716 finite cell line human CVCL_B3YX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358953 CVCL_B3Z9 WG3221 finite cell line human CVCL_B3Z9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358954 CVCL_B3YW WG2701 finite cell line human CVCL_B3YW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg445Trp (c.1333C>T); ClinVar=VCV000973456; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358955 CVCL_B3Z8 WG3162 finite cell line human CVCL_B3Z8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358956 CVCL_B3YZ WG2727 finite cell line human CVCL_B3YZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358957 CVCL_B3YY WG2718 finite cell line human CVCL_B3YY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358958 CVCL_B3YN WG2316 finite cell line human CVCL_B3YN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358959 CVCL_B3YM WG1606 finite cell line human CVCL_B3YM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly203Arg (c.607G>A); ClinVar=VCV000218987; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151358960 CVCL_B3YP WG2324 finite cell line human CVCL_B3YP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358961 CVCL_B3Z1 WG2740 finite cell line human CVCL_B3Z1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358962 CVCL_B3Z0 WG2731 finite cell line human CVCL_B3Z0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 27288; ACSF3; Simple; p.Pro285Leu (c.854C>T); ClinVar=VCV000381877; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358963 CVCL_B3YR WG2389 finite cell line human CVCL_B3YR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358964 CVCL_B3Z3 WG2837 finite cell line human CVCL_B3Z3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 27288; ACSF3; Simple; p.Arg558Trp (c.1672C>T); ClinVar=VCV000031134; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358965 CVCL_B3YQ WG2368 finite cell line human CVCL_B3YQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358966 CVCL_B3Z2 WG2823 finite cell line human CVCL_B3Z2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358967 CVCL_B3YT WG2575 finite cell line human CVCL_B3YT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358968 CVCL_B3Z5 WG3092 finite cell line human CVCL_B3Z5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358969 CVCL_B3YS WG2436 finite cell line human CVCL_B3YS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4268; CBLIF; Simple; p.Lys145del (c.432GAA[1]) (c.435_437delGAA); ClinVar=VCV000208192; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151358970 CVCL_B3Z4 WG3086 finite cell line human CVCL_B3Z4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Ser865Asn (c.2594G>A); ClinVar=VCV000265086; Zygosity=Heterozygous (PubMed=31462756); Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Asn2157Asp (c.6469A>G); ClinVar=VCV000695565; Zygosity=Heterozygous (PubMed=31462756) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151358971 CVCL_B3YF 3-11 hybridoma house mouse CVCL_B3YF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358972 CVCL_B3YE 2-6 hybridoma house mouse CVCL_B3YE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358973 CVCL_B3YH 3-9 hybridoma house mouse CVCL_B3YH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358974 CVCL_B3YG 3-5 hybridoma house mouse CVCL_B3YG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358975 CVCL_B3YJ 5-18 hybridoma house mouse CVCL_B3YJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358976 CVCL_B3YI 4-7 hybridoma house mouse CVCL_B3YI CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151358977 CVCL_B3YL WG2808 finite cell line human CVCL_B3YL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358978 CVCL_B3YK WG2842 finite cell line human CVCL_B3YK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Trp105Arg (c.313T>C); ClinVar=VCV000001878; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151358979 CVCL_B3ZW WG1612 finite cell line human CVCL_B3ZW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg467Ter (c.1399C>T); ClinVar=VCV000495778; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358980 CVCL_B3ZV WG1919 finite cell line human CVCL_B3ZV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu685dup (c.2053_2055dupCTC) (684insL); Zygosity=Homozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358981 CVCL_B3ZY WG3059 finite cell line human CVCL_B3ZY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly544Ter (c.1630_1631delGGinsTA); ClinVar=VCV000203860; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. 151358982 CVCL_B3ZX WG1727 finite cell line human CVCL_B3ZX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg474Ter (c.1420C>T); ClinVar=VCV000554873; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Canadian Dariusleut Hutterite; Derived from sampling site: Skin Cell type=Fibroblast.. 151358983 CVCL_B3ZZ WG3118 finite cell line human CVCL_B3ZZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg616Cys (c.1846C>T); ClinVar=VCV000551499; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358984 CVCL_B3ZN WG1797 finite cell line human CVCL_B3ZN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Asn388His (c.1162A>C); Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. 151358985 CVCL_B3ZQ WG1999 finite cell line human CVCL_B3ZQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358986 CVCL_B3ZP WG3122 finite cell line human CVCL_B3ZP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val399Glufs*24 (c.1196_1197delTG); ClinVar=VCV000578141; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Brazilian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358987 CVCL_B3ZS WG3026 finite cell line human CVCL_B3ZS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly427Asp (c.1280G>A); ClinVar=VCV000218990; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. 151358988 CVCL_B3ZR WG2562 finite cell line human CVCL_B3ZR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg403Ter (c.1207C>T); ClinVar=VCV000167310; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358989 CVCL_B3ZU WG1738 finite cell line human CVCL_B3ZU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Heterozygous (PubMed=9554742; PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Val633Gly (c.1898T>G); ClinVar=VCV000449393; Zygosity=Heterozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Irish/Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358990 CVCL_B3ZT WG1517 finite cell line human CVCL_B3ZT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg152Ter (c.454C>T); ClinVar=VCV000426467; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Gln (c.683G>A); Zygosity=Heterozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151358991 CVCL_B3ZG WG2503 finite cell line human CVCL_B3ZG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly215Ser (c.643G>A); ClinVar=VCV000001888; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358992 CVCL_B3ZF WG2419 finite cell line human CVCL_B3ZF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly215Ser (c.643G>A); ClinVar=VCV000001888; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. 151358993 CVCL_B3ZI WG2516 finite cell line human CVCL_B3ZI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ser306Phe (c.917C>T); ClinVar=VCV000553978; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. 151358994 CVCL_B3ZH WG2541 finite cell line human CVCL_B3ZH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000203855; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151358995 CVCL_B3ZK WG1510 finite cell line human CVCL_B3ZK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu346del (c.1036_1038delCTT); Zygosity=Homozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151358996 CVCL_B3ZJ WG1431 finite cell line human CVCL_B3ZJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly312Val (c.935G>T); ClinVar=VCV000218988; Zygosity=Homozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151358997 CVCL_B3ZM WG3056 finite cell line human CVCL_B3ZM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. 151358998 CVCL_B3ZL WG2377 finite cell line human CVCL_B3ZL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. 151358999 CVCL_B3XA WG2076 finite cell line human CVCL_B3XA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359000 CVCL_B3XC WG1719 finite cell line human CVCL_B3XC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Homozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; c.792_818del27; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359001 CVCL_B3XB WG3387 finite cell line human CVCL_B3XB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000381577; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359002 CVCL_B3X5 WG1176 finite cell line human CVCL_B3X5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359003 CVCL_B3WT WG2599 finite cell line human CVCL_B3WT From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359004 CVCL_B3WS WG2460 finite cell line human CVCL_B3WS From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr222Ter (c.666C>A); ClinVar=VCV000496436; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359005 CVCL_B3X4 WG3366 finite cell line human CVCL_B3X4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359006 CVCL_B3WV WG3072 finite cell line human CVCL_B3WV From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359007 CVCL_B3X7 WG3183 finite cell line human CVCL_B3X7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359008 CVCL_B3X6 WG2722 finite cell line human CVCL_B3X6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359009 CVCL_B3WU WG3014 finite cell line human CVCL_B3WU From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359010 CVCL_B3X9 WG1422 finite cell line human CVCL_B3X9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359011 CVCL_B3WX WG3480 finite cell line human CVCL_B3WX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668; PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (CelloPub=CLPUB00668; PubMed=19370762) Miscellaneous: Cell line no longer available Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359012 CVCL_B3X8 WG1539 finite cell line human CVCL_B3X8 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359013 CVCL_B3WW WG3130 finite cell line human CVCL_B3WW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359014 CVCL_B3WZ WG3514 finite cell line human CVCL_B3WZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668; PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr222Ter (c.666C>A); ClinVar=VCV000496436; Zygosity=Heterozygous (CelloPub=CLPUB00668; PubMed=19370762) Miscellaneous: Cell line no longer available Population: Caucasian; Italian and Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359015 CVCL_B3WY WG3281 finite cell line human CVCL_B3WY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr222Ter (c.666C>A); ClinVar=VCV000496436; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359016 CVCL_B3WL WG1496 finite cell line human CVCL_B3WL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359017 CVCL_B3WK WG1481 finite cell line human CVCL_B3WK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359018 CVCL_B3WN WG2113 finite cell line human CVCL_B3WN From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala191Glu (c.572C>A); ClinVar=VCV000203854; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Native North American; Cherokee; Derived from sampling site: Skin Cell type=Fibroblast.. 151359019 CVCL_B3WM WG1958 finite cell line human CVCL_B3WM From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Leu685Arg (c.2054T>G); ClinVar=VCV000218995; Zygosity=Homozygous (PubMed=9554742; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359020 CVCL_B3WP WG2328 finite cell line human CVCL_B3WP From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Tyr316Cys (c.947A>G); ClinVar=VCV000640484; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly426Ter (c.1276G>T); Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. 151359021 CVCL_B3X1 WG3686 finite cell line human CVCL_B3X1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359022 CVCL_B3X0 WG3665 finite cell line human CVCL_B3X0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359023 CVCL_B3WR WG2339 finite cell line human CVCL_B3WR From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359024 CVCL_B3X3 WG2452 finite cell line human CVCL_B3X3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359025 CVCL_B3WQ WG1692 finite cell line human CVCL_B3WQ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359026 CVCL_B3X2 WG2279 finite cell line human CVCL_B3X2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Homozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359027 CVCL_B3WD WG0370 finite cell line human CVCL_B3WD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359028 CVCL_B3WC WG0098 finite cell line human CVCL_B3WC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359029 CVCL_B3WF WG1127 finite cell line human CVCL_B3WF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359030 CVCL_B3WE WG1070 finite cell line human CVCL_B3WE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359031 CVCL_B3WH WG1135 finite cell line human CVCL_B3WH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000001424; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359032 CVCL_B3WG WG1129 finite cell line human CVCL_B3WG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359033 CVCL_B3WJ WG1404 finite cell line human CVCL_B3WJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg132Ter (c.394C>T); ClinVar=VCV000001423; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr222Ter (c.666C>A); ClinVar=VCV000496436; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359034 CVCL_B3WI WG1391 finite cell line human CVCL_B3WI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359035 CVCL_B3YB 1-9 hybridoma house mouse CVCL_B3YB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359036 CVCL_B3YA 1-6 hybridoma house mouse CVCL_B3YA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359037 CVCL_B3YD 2-2 [Mouse hybridoma against human TCN2] hybridoma house mouse CVCL_B3YD CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359038 CVCL_B3YC 2-13 hybridoma house mouse CVCL_B3YC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359039 CVCL_B3XU MBU-7 cancer cell line human CVCL_B3XU CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (PubMed=34707142); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (PubMed=34707142); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=34707142); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (PubMed=34707142) Miscellaneous: Doubling time from personal communication of Diesch J Population: Caucasian; Karyotypic information: Compared to the parent cell line, has a complete trisomy of chromosome 7 (PubMed=34707142); Derived from sampling site: Pleural effusion. Male Doubling time: 30-40 hours (Direct_author_submission) 151359040 CVCL_B3Y6 WG2860 finite cell line human CVCL_B3Y6 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Pro95Arg (c.284C>G); ClinVar=VCV000218985; Zygosity=Homozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Population: Iraqi; Derived from sampling site: Skin Cell type=Fibroblast.. 151359041 CVCL_B3XT PNL2 hybridoma house mouse CVCL_B3XT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanocyte-associated antigen. 151359042 CVCL_B3Y5 WG3199 finite cell line human CVCL_B3Y5 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151359043 CVCL_B3Y8 1-12 hybridoma house mouse CVCL_B3Y8 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359044 CVCL_B3XW WG3129 finite cell line human CVCL_B3XW From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg153Ter (c.457C>T); ClinVar=VCV000550539; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Ter (c.481C>T); ClinVar=VCV000095703; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Glu170Cysfs*36 (c.507_519del13); ClinVar=VCV000556017; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359045 CVCL_B3XV MBU-8 cancer cell line human CVCL_B3XV CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (PubMed=34707142); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (PubMed=34707142); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=34707142); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (PubMed=34707142) Miscellaneous: Doubling time from personal communication of Diesch J Population: Caucasian; Karyotypic information: Compared to the parent cell line, has a complete trisomy of chromosome 18 as well as a partial trisomy of 7 and tetrasomy of 8p (PubMed=34707142); Derived from sampling site: Pleural effusion. Male Doubling time: 30-40 hours (Direct_author_submission) 151359046 CVCL_B3Y7 WG3733 finite cell line human CVCL_B3Y7 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 16692; CD320; Simple; p.Glu88del (c.256GAG[2]) (c.262_264delGAG); ClinVar=VCV000203643; Zygosity=Homozygous (PubMed=20524213) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 151359047 CVCL_B3XY WG3561 finite cell line human CVCL_B3XY From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp157Ter (c.471G>A); ClinVar=VCV000553844; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr222Ter (c.666C>A); ClinVar=VCV000496436; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359048 CVCL_B3Y9 1-2 hybridoma house mouse CVCL_B3Y9 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20062; Human TCN2. 151359049 CVCL_B3XX WG3458 finite cell line human CVCL_B3XX From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Homozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359050 CVCL_B3XZ WG3580 finite cell line human CVCL_B3XZ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp203Ter (c.609G>A); ClinVar=VCV000030800; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Lys220del (c.658_660delAAG); ClinVar=VCV000095707; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359051 CVCL_B3XM UCSFi001-A-58 induced pluripotent stem cell human CVCL_B3XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 151359052 CVCL_B3XL WG3539 finite cell line human CVCL_B3XL From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Gly147Asp (c.440G>A); ClinVar=VCV000203829; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp157Valfs*24 (c.468_469delCT); Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359053 CVCL_B3Y0 WG2471 finite cell line human CVCL_B3Y0 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg153Ter (c.457C>T); ClinVar=VCV000550539; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359054 CVCL_B3XN UCSFi001-A-59 induced pluripotent stem cell human CVCL_B3XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 151359055 CVCL_B3XQ MM04H hybridoma house mouse CVCL_B3XQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28676; Human GCA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021182 151359056 CVCL_B3Y2 WG2322 finite cell line human CVCL_B3Y2 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151359057 CVCL_B3XP ATCi001-A induced pluripotent stem cell human CVCL_B3XP From: Aegicare (Shenzhen) Technology Co; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 30224; SLC52A2; Simple; p.Ala26Profs*42 (c.75_76insCCTGG); Zygosity=Heterozygous (PubMed=34736036); Sequence variation: Mutation; HGNC; 30224; SLC52A2; Simple; p.Cys278delinsCysLeuLeuGly (c.832_833insGCCTGCTGG); Zygosity=Heterozygous (PubMed=34736036) Population: Chinese; Derived from sampling site: Peripheral blood. Female 151359058 CVCL_B3Y1 WG1713 finite cell line human CVCL_B3Y1 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151359059 CVCL_B3XS HMB-50 hybridoma house mouse CVCL_B3XS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P40967; Human PMEL. 151359060 CVCL_B3Y4 WG3174 finite cell line human CVCL_B3Y4 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous PubMed=16281286) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. 151359061 CVCL_B3XR HMB-45 hybridoma house mouse CVCL_B3XR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40967; Human PMEL. 151359062 CVCL_B3Y3 WG2564 finite cell line human CVCL_B3Y3 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Cys (c.322C>T); ClinVar=VCV000001887; Zygosity=Homozygous PubMed=16281286) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. 151359063 CVCL_B3XE WG2711 finite cell line human CVCL_B3XE From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr130Cys (c.389A>G); ClinVar=VCV000297484; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 151359064 CVCL_B3XD WG1705 finite cell line human CVCL_B3XD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Leu116Pro (c.347T>C); ClinVar=VCV000001422; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359065 CVCL_B3XG WG3423 finite cell line human CVCL_B3XG From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp203Ter (c.608G>A); ClinVar=VCV000095706; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359066 CVCL_B3XF WG3676 finite cell line human CVCL_B3XF From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg189Valfs*21 (c.565delC); ClinVar=VCV000553238; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359067 CVCL_B3XI WG2636 finite cell line human CVCL_B3XI From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Asn110Aspfs*13 (c.328_331delAACC); ClinVar=VCV000203835; Zygosity=Homozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359068 CVCL_B3XH WG3496 finite cell line human CVCL_B3XH From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Tyr205Ter (c.615C>G); ClinVar=VCV000281007; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359069 CVCL_B3XK WG3308 finite cell line human CVCL_B3XK From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Asn110Aspfs*13 (c.328_331delAACC); ClinVar=VCV000203835; Zygosity=Homozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359070 CVCL_B3XJ WG2863 finite cell line human CVCL_B3XJ From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Asn110Aspfs*13 (c.328_331delAACC); ClinVar=VCV000203835; Zygosity=Homozygous (PubMed=19370762); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Ile190Tyrfs*13 (c.567dupT); ClinVar=VCV000556708; Zygosity=Heterozygous (PubMed=19370762) Miscellaneous: Cell line no longer available Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359071 CVCL_B5IL ICSSUi001-A induced pluripotent stem cell human CVCL_B5IL From: Institute for Cardiovascular Science of Soochow University; Suzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2633Gly (c.7897T>G); ClinVar=VCV000984411; Zygosity=Heterozygous (PubMed=35231796) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359072 CVCL_B5IK FDCHi007-A induced pluripotent stem cell human CVCL_B5IK From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2972; DNM1; Simple; p.Ala182Asp (c.545C>A); ClinVar=VCV000421787; Zygosity=Heterozygous; Note=De novo mutation (PubMed=35184021) Derived from sampling site: Peripheral blood. Female 151359073 CVCL_B5IN ICSSUi003-A induced pluripotent stem cell human CVCL_B5IN From: Institute for Cardiovascular Science of Soochow University; Suzhou; China. CL:0000010 151359074 CVCL_B5IM ICSSUi002-A induced pluripotent stem cell human CVCL_B5IM From: Institute for Cardiovascular Science of Soochow University; Suzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Homozygous (PubMed=35305471) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359075 CVCL_B5IP ITXi001-A induced pluripotent stem cell human CVCL_B5IP From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Omics: Transcriptome analysis by microarray Female 151359076 CVCL_B5J1 MDCi233-B induced pluripotent stem cell human CVCL_B5J1 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Leu369Pro (c.1106T>C); Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1768_Pro1776del (c.5302_5328delCGGCCCCTCTACAGCCCCCTGCAGCCA); Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 151359077 CVCL_B5J0 MDCi233-A induced pluripotent stem cell human CVCL_B5J0 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Leu369Pro (c.1106T>C); Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1768_Pro1776del (c.5302_5328delCGGCCCCTCTACAGCCCCCTGCAGCCA); Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 151359078 CVCL_B5IR MILi001-C induced pluripotent stem cell human CVCL_B5IR From: Miltenyi Biotec B.V.; Gladbach; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151359079 CVCL_B5IQ MILi001-B induced pluripotent stem cell human CVCL_B5IQ From: Miltenyi Biotec B.V.; Gladbach; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151359080 CVCL_B5ID ISMMSi039-A induced pluripotent stem cell human CVCL_B5ID From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359081 CVCL_B5IC ISMMSi038-A induced pluripotent stem cell human CVCL_B5IC From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359082 CVCL_B5IF ISMMSi041-A induced pluripotent stem cell human CVCL_B5IF From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359083 CVCL_B5IE ISMMSi040-A induced pluripotent stem cell human CVCL_B5IE From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359084 CVCL_B5IH ISMMSi043-A induced pluripotent stem cell human CVCL_B5IH From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: African American; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359085 CVCL_B5IG ISMMSi042-A induced pluripotent stem cell human CVCL_B5IG From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359086 CVCL_B5IJ FDCHi006-A induced pluripotent stem cell human CVCL_B5IJ From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 151359087 CVCL_B5II UKWNLi005-A induced pluripotent stem cell human CVCL_B5II From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Ser126Gly (c.376A>G); ClinVar=VCV000163547; Zygosity=Unspecified (PubMed=35325818) Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 151359088 CVCL_B5HZ ISMMSi027-A induced pluripotent stem cell human CVCL_B5HZ From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Karyotypic information: 46,XY,t(1;17)(p34;q23) (PubMed=34739849); Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359089 CVCL_B5IB ISMMSi037-A induced pluripotent stem cell human CVCL_B5IB From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359090 CVCL_B5IA ISMMSi036-A induced pluripotent stem cell human CVCL_B5IA From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359091 CVCL_B5HS ISMMSi020-A induced pluripotent stem cell human CVCL_B5HS From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359092 CVCL_B5I4 ISMMSi030-A induced pluripotent stem cell human CVCL_B5I4 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359093 CVCL_B5HR ISMMSi019-A induced pluripotent stem cell human CVCL_B5HR From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359094 CVCL_B5I3 ISMMSi029-A induced pluripotent stem cell human CVCL_B5I3 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359095 CVCL_B5HU ISMMSi022-A induced pluripotent stem cell human CVCL_B5HU From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359096 CVCL_B5I6 ISMMSi032-A induced pluripotent stem cell human CVCL_B5I6 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: African American; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359097 CVCL_B5HT ISMMSi021-A induced pluripotent stem cell human CVCL_B5HT From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359098 CVCL_B5I5 ISMMSi031-A induced pluripotent stem cell human CVCL_B5I5 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359099 CVCL_B5HW ISMMSi024-A induced pluripotent stem cell human CVCL_B5HW From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359100 CVCL_B5I8 ISMMSi034-A induced pluripotent stem cell human CVCL_B5I8 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359101 CVCL_B5HV ISMMSi023-A induced pluripotent stem cell human CVCL_B5HV From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359102 CVCL_B5I7 ISMMSi033-A induced pluripotent stem cell human CVCL_B5I7 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359103 CVCL_B5HY ISMMSi026-A induced pluripotent stem cell human CVCL_B5HY From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359104 CVCL_B5HX ISMMSi025-A induced pluripotent stem cell human CVCL_B5HX From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359105 CVCL_B5I9 ISMMSi035-A induced pluripotent stem cell human CVCL_B5I9 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359106 CVCL_B5IT MPIi008-A induced pluripotent stem cell human CVCL_B5IT From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg394Leu (c.181G>T); Zygosity=Heterozygous (PubMed=35667217) Population: Caucasian; Derived from sampling site: Testis; tunica albuginea Cell type=Fibroblast.. Male 151359107 CVCL_B5IS MNZTASi001-A induced pluripotent stem cell human CVCL_B5IS From: Menzies Institute for Medical Research, University of Tasmania; Hobart; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359108 CVCL_B5IV NCKDi005-A induced pluripotent stem cell human CVCL_B5IV From: National Center of Kidney Diseases; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 2206; COL4A4; Simple; p.Gly408Cysfs*29 (c.1221_1222insTGCAGGCATGATAGGACCCCCT); Zygosity=Homozygous (PubMed=34942480) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359109 CVCL_B5IU NCKDi004-A induced pluripotent stem cell human CVCL_B5IU From: National Center of Kidney Diseases; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Met1Ile (c.3G>A); Zygosity=Homozygous (PubMed=34626894) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359110 CVCL_B5IX NDi004-B induced pluripotent stem cell human CVCL_B5IX From: University of Notre Dame; Notre Dame; USA CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg4198Ter (c.12592C>T); ClinVar=VCV000158722; Zygosity=Heterozygous (PubMed=35550987) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359111 CVCL_B5IW NDi004-A induced pluripotent stem cell human CVCL_B5IW From: University of Notre Dame; Notre Dame; USA CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg4198Ter (c.12592C>T); ClinVar=VCV000158722; Zygosity=Heterozygous (PubMed=35550987) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359112 CVCL_B5IZ NYSCFi003-A induced pluripotent stem cell human CVCL_B5IZ From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151359113 CVCL_B5IY NDi004-C induced pluripotent stem cell human CVCL_B5IY From: University of Notre Dame; Notre Dame; USA CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg4198Ter (c.12592C>T); ClinVar=VCV000158722; Zygosity=Heterozygous (PubMed=35550987) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359114 CVCL_B5GJ TRNDi010-D-1 induced pluripotent stem cell human CVCL_B5GJ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (PubMed=34619643); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple_corrected; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34619643) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 151359115 CVCL_B5GI TRNDi010-D induced pluripotent stem cell human CVCL_B5GI From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (PubMed=34619643) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 151359116 CVCL_B5GL ZJUi008-A induced pluripotent stem cell human CVCL_B5GL From: Zhejiang University School of Medicine; Hangzhou; China. CL:0000010 151359117 CVCL_B5GK TRNDi010-D-2 induced pluripotent stem cell human CVCL_B5GK From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple_corrected; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34619643) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 151359118 CVCL_B5GN ZOCi004-A induced pluripotent stem cell human CVCL_B5GN From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10457; RS1; Simple; p.Glu72Lys (c.214G>A); ClinVar=VCV000009888; Zygosity=Hemizygous (PubMed=36270067) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359119 CVCL_B5GM ZOCi002-A induced pluripotent stem cell human CVCL_B5GM From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10457; RS1; Simple; p.Arg102Gln (c.305G>A); ClinVar=VCV000009896; Zygosity=Hemizygous (PubMed=34798543) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359120 CVCL_B5H1 FDZSi003-A induced pluripotent stem cell human CVCL_B5H1 From: Zhongshan Hospital of Fudan University; Shanghai; China. CL:0000010 151359121 CVCL_B5GP ZSYYDNi001-A induced pluripotent stem cell human CVCL_B5GP From: Department of Neurology, Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex51del; Zygosity=Hemizygous (PubMed=34619646) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359122 CVCL_B5H0 ULBi004-A induced pluripotent stem cell human CVCL_B5H0 From: Universite Libre de Bruxelles; Brussels; Belgium CL:0000010 Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Female 151359123 CVCL_B5GB OCUT-4 cancer cell line human CVCL_B5GB CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24357248) Population: Japanese; Derived from sampling site: Thyroid gland. Male 151359124 CVCL_B5GA OCUT-3 cancer cell line human CVCL_B5GA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24357248) Population: Japanese; Derived from metastatic site: Lymph node. Male 151359125 CVCL_B5GD OCUT-6 cancer cell line human CVCL_B5GD CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=24357248) Population: Japanese; Derived from sampling site: Thyroid gland. Female 151359126 CVCL_B5GC OCUT-5 cancer cell line human CVCL_B5GC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24357248) Population: Japanese; Derived from metastatic site: Lymph node. Female 151359127 CVCL_B5GF OCUT-1F cancer cell line human CVCL_B5GF CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24357248); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female 151359128 CVCL_B5GE OCUT-1C cancer cell line human CVCL_B5GE CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24357248); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female 151359129 CVCL_B5GH JTUi009-A induced pluripotent stem cell human CVCL_B5GH From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China. CL:0000010 151359130 CVCL_B5GG JTUi008-A induced pluripotent stem cell human CVCL_B5GG From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China. CL:0000010 151359131 CVCL_B5FY SYSUSCi002-A induced pluripotent stem cell human CVCL_B5FY From: Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 1663; CD36; Simple; p.Thr111Serfs*22 (c.332_333delCA) (c.329_330delAC); ClinVar=VCV000225309; Zygosity=Homozygous (PubMed=35305469) Population: Chinese; Derived from sampling site: Peripheral blood. Female 151359132 CVCL_B5G9 SYSUe011-A-1 embryonic stem cell human CVCL_B5G9 From: Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2892; DKK2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Male 151359133 CVCL_B5FX SYSUSCi001-A induced pluripotent stem cell human CVCL_B5FX From: Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 1040; BFSP1; Simple; p.Glu269Lys (c.805G>A); Zygosity=Heterozygous (PubMed=34995847); Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Leu125Pro (c.374T>C); Zygosity=Heterozygous (PubMed=34995847) Population: Chinese; Derived from sampling site: Peripheral blood. Male 151359134 CVCL_B5FZ UCLi020-A induced pluripotent stem cell human CVCL_B5FZ From: University College London; London; United Kingdom. CL:0000010 151359135 CVCL_B5G2 REF-WT1A transformed cell line Norway rat CVCL_B5G2 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Unspecified 151359136 CVCL_B5FQ SCVIi024-A induced pluripotent stem cell human CVCL_B5FQ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151359137 CVCL_B5G1 REF-WT10A transformed cell line Norway rat CVCL_B5G1 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Unspecified 151359138 CVCL_B5FP SCVIi025-A induced pluripotent stem cell human CVCL_B5FP From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151359139 CVCL_B5G4 REF-WT6A transformed cell line Norway rat CVCL_B5G4 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Omics: Proteome analysis by 2D-DE Unspecified 151359140 CVCL_B5FS SCVIi021-A induced pluripotent stem cell human CVCL_B5FS From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg377Cys (c.1129C>T); ClinVar=VCV000048031; Zygosity=Heterozygous (PubMed=34954454) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359141 CVCL_B5G3 REF-WT2A transformed cell line Norway rat CVCL_B5G3 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Omics: Proteome analysis by 2D-DE Unspecified 151359142 CVCL_B5FR SCVIi020-A induced pluripotent stem cell human CVCL_B5FR From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg377Cys (c.1129C>T); ClinVar=VCV000048031; Zygosity=Heterozygous (PubMed=34954454) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359143 CVCL_B5FU SCVIi023-A induced pluripotent stem cell human CVCL_B5FU From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151359144 CVCL_B5G6 ZZUi033-A induced pluripotent stem cell human CVCL_B5G6 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6470; L1CAM; Simple; p.Ile219Val (c.655A>G); Zygosity=Hemizygous (PubMed=35042084) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151359145 CVCL_B5G5 LCPHi002-A induced pluripotent stem cell human CVCL_B5G5 From: The Institute for Tissue Engineering and Regenerative Medicine, Liaocheng People's Hospital; Liaocheng; China CL:0000010 Sequence variation: Mutation; HGNC; 1908; VPS13A; Simple; p.Ala1428fs (c.4282_4289delinsA); Zygosity=Heterozygous (PubMed=35093716) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151359146 CVCL_B5FT SCVIi022-A induced pluripotent stem cell human CVCL_B5FT From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg377Cys (c.1129C>T); ClinVar=VCV000048031; Zygosity=Heterozygous (PubMed=34954454) Population: Native American; Derived from sampling site: Peripheral blood. Female 151359147 CVCL_B5FW SUSMi003-A induced pluripotent stem cell human CVCL_B5FW From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Male 151359148 CVCL_B5G8 ZZUi035-A induced pluripotent stem cell human CVCL_B5G8 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 151359149 CVCL_B5FV SHCHNDi001-A induced pluripotent stem cell human CVCL_B5FV From: Shanghai Children's Hospital; Shanghai; China. CL:0000010 151359150 CVCL_B5G7 ZZUi034-A induced pluripotent stem cell human CVCL_B5G7 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 151359151 CVCL_B5HK ISMMSi015-A induced pluripotent stem cell human CVCL_B5HK From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359152 CVCL_B5HJ ISMMSi014-A induced pluripotent stem cell human CVCL_B5HJ From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359153 CVCL_B5HM ISMMSi017-A induced pluripotent stem cell human CVCL_B5HM From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: African American; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 151359154 CVCL_B5HL ISMMSi016-A induced pluripotent stem cell human CVCL_B5HL From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359155 CVCL_B5I0 ISMMSi028-A induced pluripotent stem cell human CVCL_B5I0 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 151359156 CVCL_B5HN ISMMSi017-B induced pluripotent stem cell human CVCL_B5HN From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: African American; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 151359157 CVCL_B5HQ ISMMSi018-A induced pluripotent stem cell human CVCL_B5HQ From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359158 CVCL_B5I2 ISMMSi028-C induced pluripotent stem cell human CVCL_B5I2 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359159 CVCL_B5HP ISMMSi017-C induced pluripotent stem cell human CVCL_B5HP From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: African American; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 151359160 CVCL_B5I1 ISMMSi028-B induced pluripotent stem cell human CVCL_B5I1 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 151359161 CVCL_B5HC ISMMSi007-A induced pluripotent stem cell human CVCL_B5HC From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359162 CVCL_B5HB ISMMSi006-A induced pluripotent stem cell human CVCL_B5HB From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359165 CVCL_B5HG ISMMSi011-A induced pluripotent stem cell human CVCL_B5HG From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359166 CVCL_B5HF ISMMSi010-A induced pluripotent stem cell human CVCL_B5HF From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359167 CVCL_B5HI ISMMSi013-A induced pluripotent stem cell human CVCL_B5HI From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359168 CVCL_B5HH ISMMSi012-A induced pluripotent stem cell human CVCL_B5HH From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359169 CVCL_B5GZ UOWi010-A induced pluripotent stem cell human CVCL_B5GZ From: University of Wollongong; Wollongong; Australia. CL:0000010 151359170 CVCL_B5GY HGS4 cancer cell line house mouse CVCL_B5GY CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI:109337; Brca2; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mesentery; Breed/subspecies: B6.129P2-Trp53tm1Brn/J.Ptenfl/f x C57BL/6J-Brca2fl/fl. Female Characteristics: When injected i.p produces omental tumors and metastases to splenoportal fat, lesser omentum, and mesentery, with extensive disease established by 12-20 weeks (PubMed=31940494). 151359171 CVCL_B5HA ISMMSi005-A induced pluripotent stem cell human CVCL_B5HA From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151359172 CVCL_B5H3 HAD9 embryonic stem cell human CVCL_B5H3 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Unspecified 151359173 CVCL_B5GR XWHNi001-A induced pluripotent stem cell human CVCL_B5GR From: Department of Neurology, Xuan Wu Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Homozygous (PubMed=35149456) Population: Chinese; Derived from sampling site: Peripheral blood. Female 151359174 CVCL_B5H2 GENYOi007-A induced pluripotent stem cell human CVCL_B5H2 CL:0000010 Sequence variation: Mutation; HGNC; 3057; DTNA; Simple; p.Val742Phe (c.2224G>T); ClinVar=VCV000140609; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 151359175 CVCL_B5GQ ZJYYPHi001-A induced pluripotent stem cell human CVCL_B5GQ From: Yuyao People's Hospital of Zhejiang Province; Yuyao city; China CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Arg513Cys (c.1537C>T); ClinVar=VCV000201456; Zygosity=Heterozygous (PubMed=34678660) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 151359176 CVCL_B5H5 FAMRCi011-B induced pluripotent stem cell human CVCL_B5H5 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia.. CL:0000010 Male 151359177 CVCL_B5GT XACHi017-A induced pluripotent stem cell human CVCL_B5GT From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 151359178 CVCL_B5H4 FAMRCi011-A induced pluripotent stem cell human CVCL_B5H4 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia.. CL:0000010 Male 151359179 CVCL_B5GS XACHi016-A induced pluripotent stem cell human CVCL_B5GS From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 151359180 CVCL_B5H7 FAMRCi009-A induced pluripotent stem cell human CVCL_B5H7 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Simple; p.Val2297Met (c.6889G>A) (p.Val2264Met, c.6790G>A); ClinVar=VCV000641618; Zygosity=Heterozygous (PubMed=34971933) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359181 CVCL_B5GV HGS1 cancer cell line house mouse CVCL_B5GV CL:0000010 Knockout cell: Method=KO mouse; MGI:109337; Brca2; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Peritoneum; Breed/subspecies: B6.129P2-Trp53tm1Brn/J.Ptenfl/f x C57BL/6J-Brca2fl/fl. Female Characteristics: When injected i.p produces omental tumors and metastases to splenoportal fat, lesser omentum, and mesentery, with extensive disease established by 12-20 weeks (PubMed=31940494). 151359182 CVCL_B5H6 FAMRCi010-A induced pluripotent stem cell human CVCL_B5H6 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Simple; p.Gly2011Arg (c.6031G>A); ClinVar=VCV000472122; Zygosity=Heterozygous (PubMed=34971931) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151359183 CVCL_B5GU UUIGPi015-A induced pluripotent stem cell human CVCL_B5GU From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Gene deletion; HGNC; 10585; SCN1A; Zygosity=Heterozygous; Note=2,9 Mbp deletion that spans 10 genes (PubMed=35203050) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151359184 CVCL_B5GX HGS3 cancer cell line house mouse CVCL_B5GX CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI:109337; Brca2; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fallopian tube; Breed/subspecies: B6.129P2-Trp53tm1Brn/J.Ptenfl/f x C57BL/6J-Brca2fl/fl. Female Characteristics: When injected i.p produces omental tumors and metastases to splenoportal fat, lesser omentum, and mesentery, with extensive disease established by 12-20 weeks (PubMed=31940494). 151359185 CVCL_B5H9 ISMMSi004-A induced pluripotent stem cell human CVCL_B5H9 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151359186 CVCL_B5H8 HCPRi001-A induced pluripotent stem cell human CVCL_B5H8 From: Ryan A.L.; University of Southern California; Los Angeles; USA. CL:0000010 151359187 CVCL_B5GW HGS2 cancer cell line house mouse CVCL_B5GW CL:0000010 Knockout cell: Method=KO mouse; MGI:109337; Brca2; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fallopian tube and ovary; Breed/subspecies: B6.129P2-Trp53tm1Brn/J.Ptenfl/f x C57BL/6J-Brca2fl/fl. Female Characteristics: When injected i.p produces omental tumors and metastases to splenoportal fat, lesser omentum, and mesentery, with extensive disease established by 12-20 weeks (PubMed=31940494). 151359188 CVCL_B5EH BER-DSRCT cancer cell line human CVCL_B5EH CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex7-WT1 Ex8 fusion (PubMed=34841430); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro2139Leufs*9; Zygosity=Unspecified (PubMed=34841430). Karyotypic information: Near triploid karyotype (PubMed=34841430) Female Doubling time: 30.5 hours (PubMed=34841430) 151359189 CVCL_B5EG SK-DSRCT2 cancer cell line human CVCL_B5EG CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex9-WT1 Ex8 fusion (PubMed=34841430); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Asn564Asp (c.1690A>G); ClinVar=VCV000376261; Zygosity=Unspecified (PubMed=34841430); Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Val767Glyfs*76; Zygosity=Unspecified (PubMed=34841430) Derived from metastatic site: Abdomen. Male Doubling time: 59.5 hours (PubMed=34841430) 151359190 CVCL_B5EJ ICGi036-A induced pluripotent stem cell human CVCL_B5EJ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Ser177Leu (c.530C>T); ClinVar=VCV000003686; Zygosity=Heterozygous (PubMed=34999421); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys352Arg (c.1054T>C); ClinVar=VCV000251618; Zygosity=Heterozygous (PubMed=34999421) Derived from sampling site: Peripheral blood. Female 151359191 CVCL_B5EI BOD-DSRCT cancer cell line human CVCL_B5EI CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex7-WT1 Ex8 fusion (PubMed=34841430); Sequence variation: Mutation; HGNC; 14010; MGA; Simple; p.Leu2167Glyfs*27; Zygosity=Unspecified (PubMed=34841430). Doubling time: 46.6 hours (PubMed=34841430) 151359192 CVCL_B5EL ICGi034-B induced pluripotent stem cell human CVCL_B5EL From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line ICGi034-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151359193 CVCL_B5EK ICGi037-A induced pluripotent stem cell human CVCL_B5EK From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Trp443Arg (c.1327T>C); ClinVar=VCV000998052; Zygosity=Heterozygous (PubMed=35152179); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Glu714_Ile796del (c.2141-966_2390-330del); Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 151359194 CVCL_B5EN ICGi038-A induced pluripotent stem cell human CVCL_B5EN From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.940+3_940+6delGAGT; ClinVar=VCV000869390; Zygosity=Heterozygous (PubMed=35152178); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Arg416Trp (c.1246C>T); ClinVar=VCV000183110; Zygosity=Heterozygous (PubMed=35152178) Derived from sampling site: Peripheral blood. Female 151359195 CVCL_B5EM ICGi034-C induced pluripotent stem cell human CVCL_B5EM From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line ICGi034-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151359196 CVCL_B5EB CAM-45B spontaneously immortalized cell line CVCL_B5EB CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 151359197 CVCL_B5EA CAM-45A spontaneously immortalized cell line CVCL_B5EA CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 151359198 CVCL_B5ED ALL spontaneously immortalized cell line CVCL_B5ED CL:0000010 Derived from sampling site: Liver. Unspecified Virology: Susceptible to infection by viral hemorrhagic septicemia virus (VHSV), red-spotted grouper nervous necrosis virus (RGNNV) and largemouth bass virus (LMBV) (PubMed=34624134) Group: Fish cell line 151359199 CVCL_B5EC CAM-47A spontaneously immortalized cell line CVCL_B5EC CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 151359200 CVCL_B5EF SK-DSRCT1 cancer cell line human CVCL_B5EF CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex10-WT1 Ex8 fusion (PubMed=34841430); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Met1634Ter (c.4899delC); Zygosity=Unspecified (PubMed=34841430) Derived from sampling site: Ascites. Female Doubling time: 23.4 hours (PubMed=34841430) 151359201 CVCL_B5EE Sf-RVNLec1 spontaneously immortalized cell line CVCL_B5EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; H2BEB9; Mgat1 Derived from sampling site: Ovary. Female Characteristics: Produces immature, relatively minimally processed N-glycan precursors that can be removed from the polypeptide backbone using endo-beta-N-acetylglucosaminidase H (PubMed=34838817); Virology: Devoid of SfRV rhabdovirus (from parent cell line) Group: Insect cell line; Group: Recombinant protein production insect cell line 151359202 CVCL_B5E8 CAM-44A spontaneously immortalized cell line CVCL_B5E8 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 151359203 CVCL_B5DW HEK293 THAP7HBM #34 transformed cell line human CVCL_B5DW CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.His230Ala (c.688_689CA>GC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Tyr232Ala (c.694_695TA>GC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359204 CVCL_B5E7 CMAfin1 spontaneously immortalized cell line CVCL_B5E7 CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Doubling time: 11.8 +- 1.61 days (in 5% FBS), 6.3 +- 0.27 days (in 10% FBS), 4.6 +- 0.19 days (in 15% FBS), 4.1 +- 0.15 days (in 20% FBS) (PubMed=36349563) Group: Fish cell line 151359205 CVCL_B5DV HEK293 THAP7DCC #40 transformed cell line human CVCL_B5DV CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Lys241Ter (c.721A>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Arg242Ter (c.727_728CG>TA); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359206 CVCL_B5DY HEK293 THAP7null #29 transformed cell line human CVCL_B5DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23190; THAP7 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359207 CVCL_B5E9 CAM-44B spontaneously immortalized cell line CVCL_B5E9 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 151359208 CVCL_B5DX HEK293 THAP7HBM #76 transformed cell line human CVCL_B5DX CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.His230Ala (c.688_689CA>GC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Tyr232Ala (c.694_695TA>GC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359209 CVCL_B5DZ HEK293 THAP7null #32 transformed cell line human CVCL_B5DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23190; THAP7 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359210 CVCL_B5E0 HEK293 THAP7null #44 transformed cell line human CVCL_B5E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23190; THAP7 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359211 CVCL_B5DN CBW spontaneously immortalized cell line CVCL_B5DN CL:0000010 Derived from sampling site: Snout. Unspecified Doubling time: 28.05 +- 3.73 hours (PubMed=11330178) Group: Fish cell line 151359212 CVCL_B5DQ ART [Acipenser] spontaneously immortalized cell line CVCL_B5DQ CL:0000010 Derived from sampling site: Testis. Male Doubling time: 55.57 hours (PubMed=30484862) Group: Fish cell line 151359213 CVCL_B5E2 HEK293 THAP11HBM #1 transformed cell line human CVCL_B5E2 CL:0000010 Sequence variation: Mutation; HGNC; 23194; THAP11; Simple_edited; p.His244Ala (c.730_731AT>GC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23194; THAP11; Simple_edited; p.Tyr246Ala (c.736_737TA>GC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359214 CVCL_B5DP CrEK spontaneously immortalized cell line CVCL_B5DP CL:0000010 Derived from sampling site: Kidney. Unspecified Characteristics: Optimal growth at 28 Celsius (PubMed=34843633); Virology: Highly susceptible to infection by Chinese rice-field eels rhabdovirus (CrERV) (PubMed=34843633) Group: Fish cell line 151359215 CVCL_B5E1 HEK293 THAP11F80L #8 transformed cell line human CVCL_B5E1 CL:0000010 Sequence variation: Mutation; HGNC; 23194; THAP11; Simple_edited; p.Phe80Leu (p.240C>G); ClinVar=VCV000393304; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by RNAseq Female 151359216 CVCL_B5DS HEK293 THAP7DCC #7 transformed cell line human CVCL_B5DS CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Lys241Ter (c.721A>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Arg242Ter (c.727_728CG>TA); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359217 CVCL_B5E4 RTdi-MI spontaneously immortalized cell line CVCL_B5E4 CL:0000010 Derived from sampling site: Intestine (Note=Distal part). Unspecified Doubling time: 4.4 days (PubMed=34205481) Group: Fish cell line 151359218 CVCL_B5E3 GCK-84 spontaneously immortalized cell line CVCL_B5E3 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 151359219 CVCL_B5DR SCC-DF spontaneously immortalized cell line CVCL_B5DR CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201525 151359220 CVCL_B5DU HEK293 THAP7DCC #36 transformed cell line human CVCL_B5DU CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Lys241Ter (c.721A>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Arg242Ter (c.727_728CG>TA); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359221 CVCL_B5E6 pORF121-mAb-3D9 hybridoma house mouse CVCL_B5E6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; K7PC12; Cyprinid herpesvirus 2 ORF121. 151359222 CVCL_B5DT HEK293 THAP7DCC #27 transformed cell line human CVCL_B5DT CL:0000010 Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Lys241Ter (c.721A>T); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202); Sequence variation: Mutation; HGNC; 23190; THAP7; Simple_edited; p.Arg242Ter (c.727_728CG>TA); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31905202) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359223 CVCL_B5E5 RTpi-MI spontaneously immortalized cell line CVCL_B5E5 CL:0000010 Derived from sampling site: Intestine (Note=Proximal part). Unspecified Doubling time: 3.0 days (PubMed=34205481) Group: Fish cell line 151359224 CVCL_B5FI BabESC-4 embryonic stem cell CVCL_B5FI CL:0000010 Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: MeDIP-seq; Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 151359225 CVCL_B5FH biPS-160-5 induced pluripotent stem cell CVCL_B5FH CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 151359226 CVCL_B5FK M14939#3 induced pluripotent stem cell CVCL_B5FK CL:0000010 Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: MeDIP-seq; Omics: Transcriptome analysis by RNAseq. Group: Non-human primate cell line 151359227 CVCL_B5FJ BabESC-15 embryonic stem cell CVCL_B5FJ CL:0000010 Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: MeDIP-seq; Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 151359228 CVCL_B5FM SCVIi026-A induced pluripotent stem cell human CVCL_B5FM From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Glu1784Lys (c.5350G>A) (p.Glu1783Lys, c.5347G>A); ClinVar=VCV000009377; Zygosity=Heterozygous (PubMed=34856468) Population: East Asian; Derived from sampling site: Peripheral blood. Female 151359229 CVCL_B5FL SNUARTe003 embryonic stem cell pig CVCL_B5FL CL:0000010 Transfected with: DsRed2, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Landrace x Yorkshire x Duroc. Female Characteristics: Contains a porcine OCT4 upstream region-derived dual reporter system composed of two constructs, pOCT4-deltaPE-eGFP and pOCT4-deltaDE-DsRed2 (PubMed=34861590) 151359230 CVCL_B5G0 UCLi019-A induced pluripotent stem cell human CVCL_B5G0 From: University College London; London; United Kingdom. CL:0000010 151359231 CVCL_B5FN SCVIi027-A induced pluripotent stem cell human CVCL_B5FN From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Pro701Leu (c.2102C>T); ClinVar=VCV000067713; Zygosity=Heterozygous (PubMed=34856468) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 151359232 CVCL_B5FA MRIi003-A-2 induced pluripotent stem cell human CVCL_B5FA From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7568; MYH10 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359233 CVCL_B5FC MRIi003-A-3 induced pluripotent stem cell human CVCL_B5FC From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 17993; TRPM4 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359234 CVCL_B5FB MRIi002-A induced pluripotent stem cell human CVCL_B5FB From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany. CL:0000010 Female 151359235 CVCL_B5FE biPS-90-11 induced pluripotent stem cell CVCL_B5FE CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 151359236 CVCL_B5FD MRIi003-A-4 induced pluripotent stem cell human CVCL_B5FD From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17993; TRPM4 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359237 CVCL_B5FG biPS-160-2 induced pluripotent stem cell CVCL_B5FG CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: MeDIP-seq; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 151359238 CVCL_B5FF biPS-90-25 induced pluripotent stem cell CVCL_B5FF CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 151359239 CVCL_B5EX ICANi002-A induced pluripotent stem cell human CVCL_B5EX From: INSERM U1166-Institute of Cardiometabolism and Nutrition; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 151359240 CVCL_B5F9 MRIi003-A-1 induced pluripotent stem cell human CVCL_B5F9 From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 7568; MYH10 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151359241 CVCL_B5EW HEBHMUi011-A induced pluripotent stem cell human CVCL_B5EW From: Hebei Medical University; Shijiazhuang; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=35305470) Derived from sampling site: Peripheral blood. Male 151359242 CVCL_B5F8 UNCi009-A induced pluripotent stem cell human CVCL_B5F8 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359243 CVCL_B5EZ ICANi002-A-2 induced pluripotent stem cell human CVCL_B5EZ From: INSERM U1166-Institute of Cardiometabolism and Nutrition; Paris; France CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 10593; SCN5A Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 151359244 CVCL_B5EY ICANi002-A-1 induced pluripotent stem cell human CVCL_B5EY From: INSERM U1166-Institute of Cardiometabolism and Nutrition; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Unexplicit_edited; Ex42del; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=34883448) Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 151359245 CVCL_B5EP DHMi004-A induced pluripotent stem cell human CVCL_B5EP From: German Heart Center Munich; Munich; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11604; TBX5; Simple; p.Pro85Thr (c.253C>A); ClinVar=VCV000626359; Zygosity=Heterozygous; Note=De novo mutation (PubMed=34894535) Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male 151359246 CVCL_B5F1 UMi035-A induced pluripotent stem cell human CVCL_B5F1 From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 151359247 CVCL_B5F0 UMi034-A induced pluripotent stem cell human CVCL_B5F0 From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 151359248 CVCL_B5F3 UNCi004-A induced pluripotent stem cell human CVCL_B5F3 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359249 CVCL_B5ER ZZUPMCi001-A induced pluripotent stem cell human CVCL_B5ER From: Precision Medicine Center, Zhengzhou University; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8617; PAX3; Simple; p.Gly42fs (c.123delG); ClinVar=VCV001048553; Zygosity=Heterozygous (PubMed=34864221) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 151359250 CVCL_B5EQ DHMi005-A induced pluripotent stem cell human CVCL_B5EQ From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male 151359251 CVCL_B5F2 UNCi003-A induced pluripotent stem cell human CVCL_B5F2 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359252 CVCL_B5F5 UNCi006-A induced pluripotent stem cell human CVCL_B5F5 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359253 CVCL_B5ET ZZUNEUi024-A induced pluripotent stem cell human CVCL_B5ET From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 151359254 CVCL_B5F4 UNCi005-A induced pluripotent stem cell human CVCL_B5F4 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359255 CVCL_B5ES ZZUNEUi023-A induced pluripotent stem cell human CVCL_B5ES From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Arg26562Ter (c.79684C>T); ClinVar=VCV000222861; Zygosity=Heterozygous (PubMed=34883393) Population: Kazakh; Derived from sampling site: Peripheral blood. Male 151359256 CVCL_B5EV HEBHMUi010-A induced pluripotent stem cell human CVCL_B5EV From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 151359257 CVCL_B5F7 UNCi008-A induced pluripotent stem cell human CVCL_B5F7 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359258 CVCL_B5F6 UNCi007-A induced pluripotent stem cell human CVCL_B5F6 From: University of North Carolina at Chapel Hill; Chapel Hill; USA. CL:0000010 151359259 CVCL_B5EU ZZUNEUi025-A induced pluripotent stem cell human CVCL_B5EU From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; c.772+1G>A; ClinVar=VCV000042790; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=35257994) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151359260 CVCL_B5CF UCB1146 transformed cell line human CVCL_B5CF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359261 CVCL_B5CE UCB1143 transformed cell line human CVCL_B5CE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359262 CVCL_B5CH UCB1198 transformed cell line human CVCL_B5CH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359263 CVCL_B5CG UCB1197 transformed cell line human CVCL_B5CG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359264 CVCL_B5CJ UCB1204 transformed cell line human CVCL_B5CJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359265 CVCL_B5CI UCB1201 transformed cell line human CVCL_B5CI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359266 CVCL_B5CL UCB1211 transformed cell line human CVCL_B5CL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359267 CVCL_B5CK UCB1205 transformed cell line human CVCL_B5CK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359268 CVCL_B5CB UCB1138 transformed cell line human CVCL_B5CB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359269 CVCL_B5CA UCB1135 transformed cell line human CVCL_B5CA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359270 CVCL_B5CD UCB1140 transformed cell line human CVCL_B5CD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359271 CVCL_B5CC UCB1137 transformed cell line human CVCL_B5CC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359272 CVCL_B5BU UCB1085 transformed cell line human CVCL_B5BU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359273 CVCL_B5C6 UCB1124 transformed cell line human CVCL_B5C6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359274 CVCL_B5BT UCB1084 transformed cell line human CVCL_B5BT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359275 CVCL_B5C5 UCB1123 transformed cell line human CVCL_B5C5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359276 CVCL_B5BW UCB1090 transformed cell line human CVCL_B5BW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359277 CVCL_B5C8 UCB1126 transformed cell line human CVCL_B5C8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359278 CVCL_B5BV UCB1088 transformed cell line human CVCL_B5BV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359279 CVCL_B5C7 UCB1125 transformed cell line human CVCL_B5C7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359280 CVCL_B5BY UCB1104 transformed cell line human CVCL_B5BY CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359281 CVCL_B5BX UCB1093 transformed cell line human CVCL_B5BX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359282 CVCL_B5C9 UCB1128 transformed cell line human CVCL_B5C9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359283 CVCL_B5BZ BFSF_OMKS_1 induced pluripotent stem cell CVCL_B5BZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Unspecified 151359284 CVCL_B5BM UCB1057 transformed cell line human CVCL_B5BM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359285 CVCL_B5BL UCB1055 transformed cell line human CVCL_B5BL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359286 CVCL_B5C0 BFSF_OMKS_2 induced pluripotent stem cell CVCL_B5C0 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Unspecified 151359287 CVCL_B5BN UCB1030 transformed cell line human CVCL_B5BN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359288 CVCL_B5BQ UCB1063 transformed cell line human CVCL_B5BQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359289 CVCL_B5C2 UCB1109 transformed cell line human CVCL_B5C2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359290 CVCL_B5BP UCB1059 transformed cell line human CVCL_B5BP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359291 CVCL_B5C1 UCB1106 transformed cell line human CVCL_B5C1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359292 CVCL_B5BS UCB1078 transformed cell line human CVCL_B5BS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359293 CVCL_B5C4 UCB1116 transformed cell line human CVCL_B5C4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359294 CVCL_B5BR UCB1068 transformed cell line human CVCL_B5BR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359295 CVCL_B5C3 UCB1115 transformed cell line human CVCL_B5C3 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359296 CVCL_B5DG HeLa1.3 hTR-50-3xMS2 TCAB1-/- cancer cell line human CVCL_B5DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25522; WRAP53 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9 3 MS2 stem loops sequences flanked by homologous telomerase RNA (hTR) sequences were knocked in; Characteristics: Has exceptionally long telomeres of approximately 23 kb in length (from parent cell line) 151359297 CVCL_B5DF HeLa1.3 hTR-50-3xMS2 cancer cell line human CVCL_B5DF CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9 3 MS2 stem loops sequences flanked by homologous telomerase RNA (hTR) sequences were knocked in; Characteristics: Has exceptionally long telomeres of approximately 23 kb in length (from parent cell line) 151359298 CVCL_B5DI CAB-80 spontaneously immortalized cell line CVCL_B5DI CL:0000010 Karyotypic information: Heteroploid karyotype (CelloPub=CLPUB00673). Unspecified Characteristics: Optimal growth at 22 to 28 Celsius (CelloPub=CLPUB00673) Doubling time: 21-45 hours (CelloPub=CLPUB00673) Group: Fish cell line 151359299 CVCL_B5DH HeLa1.3 hTR-50-3xMS2 TERT-/- cancer cell line human CVCL_B5DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11730; TERT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9 3 MS2 stem loops sequences flanked by homologous telomerase RNA (hTR) sequences were knocked in; Characteristics: Has exceptionally long telomeres of approximately 23 kb in length (from parent cell line) 151359300 CVCL_B5DK AHZC 88 spontaneously immortalized cell line CVCL_B5DK CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Snout. Unspecified Characteristics: Capable of growing from 4 to 38 Celsius, the optimal temperature is 27 Celsius CelloPub=CLPUB00674) Group: Fish cell line 151359301 CVCL_B5DJ WM-9001 spontaneously immortalized cell line CVCL_B5DJ CL:0000010 Unspecified Characteristics: Optimal growth at 30 to 37 Celsius (PubMed=11229590) Doubling time: 19.71 +- 3.74 hours (PubMed=11229590; PubMed=11330178). Group: Fish cell line 151359302 CVCL_B5DM CBT spontaneously immortalized cell line CVCL_B5DM CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: 33.40 +- 20.08 hours (PubMed=11330178) Group: Fish cell line 151359303 CVCL_B5DL CBS [Piaractus] spontaneously immortalized cell line CVCL_B5DL CL:0000010 Derived from sampling site: Anal fin. Unspecified Doubling time: 27.00 +- 12.60 hours (PubMed=11330178) Group: Fish cell line 151359304 CVCL_B5DA HeLa1.3 cancer cell line human CVCL_B5DA CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has exceptionally long telomeres of approximately 23 kb in length (PubMed=19864690) 151359305 CVCL_B5DC U2OS RAD52 KO clone #1 cancer cell line human CVCL_B5DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9824; RAD52 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359306 CVCL_B5DB HeLa204 cancer cell line human CVCL_B5DB CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has telomeres of approximately 3-7 kb in length (from parent cell line) 151359307 CVCL_B5DE U2OS RAD52 KO clone #3 cancer cell line human CVCL_B5DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9824; RAD52 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359308 CVCL_B5DD U2OS RAD52 KO clone #2 cancer cell line human CVCL_B5DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9824; RAD52 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359309 CVCL_B5CV 2C6 [Mouse hybridoma against imazethapyr] hybridoma house mouse CVCL_B5CV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:82022; Imazethapyr (Pursuit) (Note=Also binds to imazamox and imazapic). 151359310 CVCL_B5D7 SU-LL-1 cancer cell line human CVCL_B5D7 CL:0000010 Karyotypic information: 49,XY,+ 1,-2,-5,+der(5)t(2;5)(p23;q35),+7,-21,+der(21q),+3mar (PubMed=8432193). Male 151359311 CVCL_B5CU 1D2 [Mouse hybridoma against imazethapyr] hybridoma house mouse CVCL_B5CU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:82022; Imazethapyr (Pursuit) (Note=Also binds to imazamox, imazamethabenz-methyl and imazapic). 151359312 CVCL_B5D6 Melu cancer cell line human CVCL_B5D6 CL:0000010 Karyotypic information: 56,X,-X,+2,+5,+7,+ 8,12q+,+15,+19,+20,+22,+3mar (PubMed=8432193); Derived from metastatic site: Not specified. Female 151359313 CVCL_B5CX 3A5 [Mouse hybridoma against imazamethabenz-methyl] hybridoma house mouse CVCL_B5CX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:2894; Imazamethabenz-methyl (Assert) (Note=Also binds to imazethapyr, imazamethabenz-methyl and imazapic). 151359314 CVCL_B5D9 HeLa1.2.11 cancer cell line human CVCL_B5D9 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has exceptionally long telomeres of approximately 23 kb in length (PubMed=10338214) 151359315 CVCL_B5CW 3A2 [Mouse hybridoma against imazaquin] hybridoma house mouse CVCL_B5CW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:5869; Imazaquin (Scepter) (Note=Also binds to imazethapyr, imazamox and imazapic). 151359316 CVCL_B5D8 SU-LyB.1 undefined cell line type human CVCL_B5D8 CL:0000010 Derived from sampling site: Bone marrow. Unspecified 151359317 CVCL_B5CZ SPL.IVB5 hybridoma house mouse CVCL_B5CZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). 151359318 CVCL_B5CY SPL.IID2 hybridoma house mouse CVCL_B5CY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). 151359319 CVCL_B5CN UCB1215 transformed cell line human CVCL_B5CN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359320 CVCL_B5CM UCB1214 transformed cell line human CVCL_B5CM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359321 CVCL_B5D1 SPL.IID2A2 hybridoma house mouse CVCL_B5D1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). 151359322 CVCL_B5CP UCB1217 transformed cell line human CVCL_B5CP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359323 CVCL_B5D0 SPL.IVA5 hybridoma house mouse CVCL_B5D0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). 151359324 CVCL_B5CR 14D7 hybridoma house mouse CVCL_B5CR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:6964; Molinate. 151359325 CVCL_B5D3 SPL.IVA5A1 hybridoma house mouse CVCL_B5D3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8535 151359326 CVCL_B5D2 SPL.IVB5A1 hybridoma house mouse CVCL_B5D2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human low density lipoprotein (LDL). 151359327 CVCL_B5CQ U2OS VGF KO cancer cell line human CVCL_B5CQ From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12684; VGF Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359328 CVCL_B5CT 1A5 [Mouse hybridoma against imazethapyr] hybridoma house mouse CVCL_B5CT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:82022; Imazethapyr (Pursuit) (Note=Also binds to imazaquin, imazamethabenz-methyl and imazapic). 151359329 CVCL_B5D5 HeLaII cancer cell line human CVCL_B5D5 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has telomeres of approximately 3-7 kb in length (PubMed=8432193) 151359330 CVCL_B5CS 16C11 hybridoma house mouse CVCL_B5CS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:6964; Molinate. 151359331 CVCL_B5D4 HeLaI cancer cell line human CVCL_B5D4 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has telomeres of approximately 25-30 kb in length (PubMed=8432193) 151359332 CVCL_B4WZ UCT0119 finite cell line human CVCL_B4WZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359333 CVCL_B4XB UCT0130 finite cell line human CVCL_B4XB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359334 CVCL_B4XA UCB0130 transformed cell line human CVCL_B4XA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359335 CVCL_B4WS UCB0115 transformed cell line human CVCL_B4WS CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359336 CVCL_B4X4 UCB0124 transformed cell line human CVCL_B4X4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359337 CVCL_B4WR UCT0114 finite cell line human CVCL_B4WR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359338 CVCL_B4X3 UCT0122 finite cell line human CVCL_B4X3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359339 CVCL_B4WU UCB0116 transformed cell line human CVCL_B4WU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359340 CVCL_B4X6 UCB0125 transformed cell line human CVCL_B4X6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359341 CVCL_B4WT UCT0115 finite cell line human CVCL_B4WT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359342 CVCL_B4X5 UCT0124 finite cell line human CVCL_B4X5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359343 CVCL_B4WW UCB0117 transformed cell line human CVCL_B4WW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359344 CVCL_B4X8 UCB0128 transformed cell line human CVCL_B4X8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359345 CVCL_B4WV UCT0116 finite cell line human CVCL_B4WV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359346 CVCL_B4X7 UCT0125 finite cell line human CVCL_B4X7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359347 CVCL_B4WY UCB0119 transformed cell line human CVCL_B4WY CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359348 CVCL_B4WX UCT0117 finite cell line human CVCL_B4WX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359349 CVCL_B4X9 UCT0128 finite cell line human CVCL_B4X9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359350 CVCL_B4WK UCT0110 finite cell line human CVCL_B4WK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359351 CVCL_B4WJ UCB0110 transformed cell line human CVCL_B4WJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359352 CVCL_B4WM UCT0112 finite cell line human CVCL_B4WM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359353 CVCL_B4WL UCB0112 transformed cell line human CVCL_B4WL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359354 CVCL_B4X0 UCB0121 transformed cell line human CVCL_B4X0 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359355 CVCL_B4WN UCB0113 transformed cell line human CVCL_B4WN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359356 CVCL_B4WQ UCB0114 transformed cell line human CVCL_B4WQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359357 CVCL_B4X2 UCB0122 transformed cell line human CVCL_B4X2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359358 CVCL_B4WP UCT0113 finite cell line human CVCL_B4WP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359359 CVCL_B4X1 UCT0121 finite cell line human CVCL_B4X1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359360 CVCL_B4WC UCT0100 finite cell line human CVCL_B4WC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359361 CVCL_B4WB UCB0100 transformed cell line human CVCL_B4WB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359362 CVCL_B4WE UCT0103 finite cell line human CVCL_B4WE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359363 CVCL_B4WD UCB0103 transformed cell line human CVCL_B4WD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359364 CVCL_B4WG UCT0105 finite cell line human CVCL_B4WG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359365 CVCL_B4WF UCB0105 transformed cell line human CVCL_B4WF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359366 CVCL_B4WI UCT0108 finite cell line human CVCL_B4WI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359367 CVCL_B4WH UCB0108 transformed cell line human CVCL_B4WH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359368 CVCL_B4YA UCB0187 transformed cell line human CVCL_B4YA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359369 CVCL_B4YC UCB0188 transformed cell line human CVCL_B4YC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359370 CVCL_B4YB UCT0187 finite cell line human CVCL_B4YB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359371 CVCL_B4XT UCB0167 transformed cell line human CVCL_B4XT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359372 CVCL_B4Y5 UCT0180 finite cell line human CVCL_B4Y5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359373 CVCL_B4Y4 UCB0180 transformed cell line human CVCL_B4Y4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359374 CVCL_B4XS UCT0164 finite cell line human CVCL_B4XS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359375 CVCL_B4XV UCB0169 transformed cell line human CVCL_B4XV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359376 CVCL_B4Y7 UCT0181 finite cell line human CVCL_B4Y7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359377 CVCL_B4Y6 UCB0181 transformed cell line human CVCL_B4Y6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359378 CVCL_B4XU UCT0167 finite cell line human CVCL_B4XU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359379 CVCL_B4XX UCB0172 transformed cell line human CVCL_B4XX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359380 CVCL_B4Y9 UCT0183 finite cell line human CVCL_B4Y9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359381 CVCL_B4Y8 UCB0183 transformed cell line human CVCL_B4Y8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359382 CVCL_B4XW UCT0169 finite cell line human CVCL_B4XW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359383 CVCL_B4XZ UCT0172 finite cell line human CVCL_B4XZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359384 CVCL_B4XY UCF0172 finite cell line human CVCL_B4XY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359385 CVCL_B4XL UCT0144 finite cell line human CVCL_B4XL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359386 CVCL_B4XK UCB0144 transformed cell line human CVCL_B4XK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359387 CVCL_B4XN UCT0152 finite cell line human CVCL_B4XN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359388 CVCL_B4XM UCB0152 transformed cell line human CVCL_B4XM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359389 CVCL_B4XP UCB0155 transformed cell line human CVCL_B4XP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359390 CVCL_B4Y1 UCT0176 finite cell line human CVCL_B4Y1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359391 CVCL_B4Y0 UCB0176 transformed cell line human CVCL_B4Y0 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359392 CVCL_B4XR UCB0164 transformed cell line human CVCL_B4XR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359393 CVCL_B4Y3 UCT0177 finite cell line human CVCL_B4Y3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359394 CVCL_B4Y2 UCB0177 transformed cell line human CVCL_B4Y2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359395 CVCL_B4XQ UCT0155 finite cell line human CVCL_B4XQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359396 CVCL_B4XD UCT0137 finite cell line human CVCL_B4XD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359397 CVCL_B4XC UCB0137 transformed cell line human CVCL_B4XC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359398 CVCL_B4XF UCT0139 finite cell line human CVCL_B4XF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359399 CVCL_B4XE UCB0139 transformed cell line human CVCL_B4XE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359400 CVCL_B4XH UCT0140 finite cell line human CVCL_B4XH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359401 CVCL_B4XG UCB0140 transformed cell line human CVCL_B4XG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359402 CVCL_B4XJ UCT0141 finite cell line human CVCL_B4XJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359403 CVCL_B4XI UCB0141 transformed cell line human CVCL_B4XI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359404 CVCL_B4UY UCT0041 finite cell line human CVCL_B4UY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359405 CVCL_B4UX UCF0041 finite cell line human CVCL_B4UX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359406 CVCL_B4V9 UCF0050 finite cell line human CVCL_B4V9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359407 CVCL_B4UZ UCB0042 transformed cell line human CVCL_B4UZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359408 CVCL_B4UQ UCB0024 transformed cell line human CVCL_B4UQ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359409 CVCL_B4V2 UCF0045 finite cell line human CVCL_B4V2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359410 CVCL_B4V1 UCB0045 transformed cell line human CVCL_B4V1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359411 CVCL_B4UP UCT0019 finite cell line human CVCL_B4UP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359412 CVCL_B4US UCB0025 transformed cell line human CVCL_B4US CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359413 CVCL_B4V4 UCB0048 transformed cell line human CVCL_B4V4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359414 CVCL_B4UR UCT0024 finite cell line human CVCL_B4UR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359415 CVCL_B4V3 UCT0045 finite cell line human CVCL_B4V3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359416 CVCL_B4UU UCB0034 transformed cell line human CVCL_B4UU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359417 CVCL_B4V6 UCB0049 transformed cell line human CVCL_B4V6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359418 CVCL_B4UT UCT0025 finite cell line human CVCL_B4UT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359419 CVCL_B4V5 UCT0048 finite cell line human CVCL_B4V5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359420 CVCL_B4UW UCB0041 transformed cell line human CVCL_B4UW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359421 CVCL_B4V8 UCB0050 transformed cell line human CVCL_B4V8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359422 CVCL_B4UV UCT0034 finite cell line human CVCL_B4UV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359423 CVCL_B4V7 UCT0049 finite cell line human CVCL_B4V7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359424 CVCL_B4UI PD42 transformed cell line human CVCL_B4UI HLA typing: A*02:06,24:02; B*07:02,55:01; C*01:02,07:02 (PubMed=28832583); HLA typing: DPA1*01:03,02:02; DPB1*04:01,05:01; DQA1*01:01,01:02; DQB1*05:01,06:02; DRB1*01:02,15:01; DRB5*01:01 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Unspecified 151359425 CVCL_B4UH GD149 transformed cell line human CVCL_B4UH HLA typing: A*01:01,24:02; B*38:01,44:03; C*06:02,12:03 (PubMed=28832583); HLA typing: DPA1*01:03,02:01; DPB1*03:01(124:01),04:01(350:01); DQA1*01:10,02:01; DQB1*02:02,06:03; DRB1*07:01,13:01; DRB3*01:01; DRB4*01:01 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Unspecified 151359426 CVCL_B4UK MD155 transformed cell line human CVCL_B4UK HLA typing: A*02:01,24:02; B*15:01,18:01; C*03:03,07:01 (PubMed=28832583); HLA typing: DQB1*03,06; DRB1*11,13 (Direct_author_submission) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Miscellaneous: HLA class II typing from personal communication of Bassani-Sternberg M Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics Unspecified 151359427 CVCL_B4UJ RA957 transformed cell line human CVCL_B4UJ HLA typing: A*02:20,68:01; B*35:03,39:01; C*04:01,07:02 (PubMed=28832583); HLA typing: DPA1*01:03; DPB1*04:01(105:01),04:02(126:01); DQA1*03:03,04:01; DQB1*03:01,04:02; DRB1*04:01,08:01; DRB4*01:03 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Unspecified 151359428 CVCL_B4UM UCT0018 finite cell line human CVCL_B4UM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359429 CVCL_B4UL UCB0018 transformed cell line human CVCL_B4UL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359430 CVCL_B4V0 UCT0042 finite cell line human CVCL_B4V0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359431 CVCL_B4UN UCB0019 transformed cell line human CVCL_B4UN CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359432 CVCL_B4UA UCF0305 finite cell line human CVCL_B4UA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359433 CVCL_B4UC UCF0275 finite cell line human CVCL_B4UC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359434 CVCL_B4UB UCF0285 finite cell line human CVCL_B4UB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359435 CVCL_B4UE BP455 transformed cell line human CVCL_B4UE HLA typing: A*02:01,31:01; B*39:06,40:01; C*03:04,07:02 (Direct_author_submission); HLA typing: DPA1*01:03; DPB1*02:01; DQA1*01:05,01:10; DQB1*05:01,06:03; DRB1*10:01,13:01; DRB3*01:01 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Miscellaneous: HLA class I typing from personal communication of Bassani-Sternberg M Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics Unspecified 151359436 CVCL_B4UD UCF0184 finite cell line human CVCL_B4UD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359437 CVCL_B4UG CM467 transformed cell line human CVCL_B4UG HLA typing: A*01:01,24:02; B*13:02,39:06; C*06:02,12:03 (PubMed=28832583); HLA typing: DPA1*01:03; DPB1*02:01,23:01; DQA1*01:02,02:01; DQB1*02:02,05:02; DRB1*07:01,16:01; DRB4*01:03; DRB5*02:02 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Unspecified 151359438 CVCL_B4UF CD165 transformed cell line human CVCL_B4UF HLA typing: A*02:05,24:02; B*15:01,50:01; C*03:03,06:02 (PubMed=28832583); HLA typing: DPA1*01:03; DPB1*04:01(105:01),04:02(126:01); DQA1*05:05; DQB1*03:01; DRB1*11:01; DRB3*02:02 (PubMed=31611696) From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Unspecified 151359439 CVCL_B4VZ UCT0087 finite cell line human CVCL_B4VZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359440 CVCL_B4VY UCB0087 transformed cell line human CVCL_B4VY CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359441 CVCL_B4WA UCT0097 finite cell line human CVCL_B4WA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359442 CVCL_B4VR UCB0081 transformed cell line human CVCL_B4VR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359443 CVCL_B4W3 UCT0093 finite cell line human CVCL_B4W3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359444 CVCL_B4W2 UCB0093 transformed cell line human CVCL_B4W2 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359445 CVCL_B4VQ UCT0079 finite cell line human CVCL_B4VQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359446 CVCL_B4W5 UCF0094 finite cell line human CVCL_B4W5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359447 CVCL_B4VT UCT0081 finite cell line human CVCL_B4VT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359448 CVCL_B4W4 UCB0094 transformed cell line human CVCL_B4W4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359449 CVCL_B4VS UCF0081 finite cell line human CVCL_B4VS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359450 CVCL_B4W7 UCB0095 transformed cell line human CVCL_B4W7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359451 CVCL_B4VV UCT0083 finite cell line human CVCL_B4VV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359452 CVCL_B4VU UCB0083 transformed cell line human CVCL_B4VU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359453 CVCL_B4W6 UCT0094 finite cell line human CVCL_B4W6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359454 CVCL_B4W9 UCB0097 transformed cell line human CVCL_B4W9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359455 CVCL_B4VX UCT0086 finite cell line human CVCL_B4VX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359456 CVCL_B4VW UCB0086 transformed cell line human CVCL_B4VW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359457 CVCL_B4W8 UCT0095 finite cell line human CVCL_B4W8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359458 CVCL_B4VJ UCT0062 finite cell line human CVCL_B4VJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359459 CVCL_B4VI UCB0062 transformed cell line human CVCL_B4VI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359460 CVCL_B4VL UCT0070 finite cell line human CVCL_B4VL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359461 CVCL_B4VK UCB0070 transformed cell line human CVCL_B4VK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359462 CVCL_B4VN UCT0078 finite cell line human CVCL_B4VN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359463 CVCL_B4VM UCB0078 transformed cell line human CVCL_B4VM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359464 CVCL_B4VP UCB0079 transformed cell line human CVCL_B4VP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359465 CVCL_B4W1 UCT0088 finite cell line human CVCL_B4W1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359466 CVCL_B4W0 UCB0088 transformed cell line human CVCL_B4W0 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359467 CVCL_B4VB UCB0051 transformed cell line human CVCL_B4VB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359468 CVCL_B4VA UCT0050 finite cell line human CVCL_B4VA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359469 CVCL_B4VD UCB0055 transformed cell line human CVCL_B4VD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359470 CVCL_B4VC UCT0051 finite cell line human CVCL_B4VC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359471 CVCL_B4VF UCT0055 finite cell line human CVCL_B4VF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359472 CVCL_B4VE UCF0055 finite cell line human CVCL_B4VE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359473 CVCL_B4VH UCT0060 finite cell line human CVCL_B4VH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359474 CVCL_B4VG UCB0060 transformed cell line human CVCL_B4VG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359475 CVCL_B4SW UCF0228 finite cell line human CVCL_B4SW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359476 CVCL_B4T8 UCF0247 finite cell line human CVCL_B4T8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359477 CVCL_B4SV UCF0227 finite cell line human CVCL_B4SV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359478 CVCL_B4T7 UCF0246 finite cell line human CVCL_B4T7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359479 CVCL_B4SY UCF0231 finite cell line human CVCL_B4SY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359480 CVCL_B4SX UCF0230 finite cell line human CVCL_B4SX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359481 CVCL_B4T9 UCF0249 finite cell line human CVCL_B4T9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359482 CVCL_B4SZ UCF0234 finite cell line human CVCL_B4SZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359483 CVCL_B4T0 UCF0235 finite cell line human CVCL_B4T0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359484 CVCL_B4SN UCF0217 finite cell line human CVCL_B4SN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359485 CVCL_B4SQ UCF0221 finite cell line human CVCL_B4SQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359486 CVCL_B4T2 UCF0239 finite cell line human CVCL_B4T2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359487 CVCL_B4SP UCF0218 finite cell line human CVCL_B4SP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359488 CVCL_B4T1 UCF0236 finite cell line human CVCL_B4T1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359489 CVCL_B4SS UCF0223 finite cell line human CVCL_B4SS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359490 CVCL_B4T4 UCF0243 finite cell line human CVCL_B4T4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359491 CVCL_B4SR UCF0222 finite cell line human CVCL_B4SR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359492 CVCL_B4T3 UCF0242 finite cell line human CVCL_B4T3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359493 CVCL_B4SU UCF0226 finite cell line human CVCL_B4SU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359494 CVCL_B4T6 UCF0245 finite cell line human CVCL_B4T6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359495 CVCL_B4ST UCF0225 finite cell line human CVCL_B4ST CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359496 CVCL_B4T5 UCF0244 finite cell line human CVCL_B4T5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359497 CVCL_B4SG UCF0202 finite cell line human CVCL_B4SG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359498 CVCL_B4SF UCF0201 finite cell line human CVCL_B4SF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359499 CVCL_B4SI UCF0205 finite cell line human CVCL_B4SI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359500 CVCL_B4SH UCF0204 finite cell line human CVCL_B4SH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359501 CVCL_B4SK UCF0211 finite cell line human CVCL_B4SK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359502 CVCL_B4SJ UCF0210 finite cell line human CVCL_B4SJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359503 CVCL_B4SM UCF0216 finite cell line human CVCL_B4SM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359504 CVCL_B4SL UCF0212 finite cell line human CVCL_B4SL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359505 CVCL_B4SA UCF0190 finite cell line human CVCL_B4SA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359506 CVCL_B4SC UCF0194 finite cell line human CVCL_B4SC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359507 CVCL_B4SB UCF0193 finite cell line human CVCL_B4SB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359508 CVCL_B4SE UCF0198 finite cell line human CVCL_B4SE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359509 CVCL_B4SD UCF0195 finite cell line human CVCL_B4SD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359510 CVCL_B4TX UCF0283 finite cell line human CVCL_B4TX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359511 CVCL_B4U9 UCF0304 finite cell line human CVCL_B4U9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359512 CVCL_B4TW UCF0282 finite cell line human CVCL_B4TW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359513 CVCL_B4U8 UCF0303 finite cell line human CVCL_B4U8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359514 CVCL_B4TZ UCF0288 finite cell line human CVCL_B4TZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359515 CVCL_B4TY UCF0284 finite cell line human CVCL_B4TY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359516 CVCL_B4TP UCF0272 finite cell line human CVCL_B4TP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359517 CVCL_B4U1 UCF0290 finite cell line human CVCL_B4U1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359518 CVCL_B4U0 UCF0289 finite cell line human CVCL_B4U0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359519 CVCL_B4TR UCF0274 finite cell line human CVCL_B4TR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359520 CVCL_B4U3 UCF0293 finite cell line human CVCL_B4U3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359521 CVCL_B4TQ UCF0273 finite cell line human CVCL_B4TQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359522 CVCL_B4U2 UCF0292 finite cell line human CVCL_B4U2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359523 CVCL_B4TT UCF0277 finite cell line human CVCL_B4TT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359524 CVCL_B4U5 UCF0295 finite cell line human CVCL_B4U5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359525 CVCL_B4TS UCF0276 finite cell line human CVCL_B4TS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359526 CVCL_B4U4 UCF0294 finite cell line human CVCL_B4U4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359527 CVCL_B4TV UCF0279 finite cell line human CVCL_B4TV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359528 CVCL_B4U7 UCF0300 finite cell line human CVCL_B4U7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359529 CVCL_B4TU UCF0278 finite cell line human CVCL_B4TU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359530 CVCL_B4U6 UCF0298 finite cell line human CVCL_B4U6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359531 CVCL_B4TH UCF0258 finite cell line human CVCL_B4TH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359532 CVCL_B4TG UCF0257 finite cell line human CVCL_B4TG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359533 CVCL_B4TJ UCF0266 finite cell line human CVCL_B4TJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359534 CVCL_B4TI UCF0262 finite cell line human CVCL_B4TI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359535 CVCL_B4TL UCF0268 finite cell line human CVCL_B4TL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359536 CVCL_B4TK UCF0267 finite cell line human CVCL_B4TK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359537 CVCL_B4TN UCF0271 finite cell line human CVCL_B4TN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359538 CVCL_B4TM UCF0270 finite cell line human CVCL_B4TM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359539 CVCL_B4TB UCF0251 finite cell line human CVCL_B4TB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359540 CVCL_B4TA UCF0250 finite cell line human CVCL_B4TA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359541 CVCL_B4TD UCF0253 finite cell line human CVCL_B4TD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359542 CVCL_B4TC UCF0252 finite cell line human CVCL_B4TC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359543 CVCL_B4TF UCF0255 finite cell line human CVCL_B4TF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359544 CVCL_B4TE UCF0254 finite cell line human CVCL_B4TE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359545 CVCL_B4QU UCF0112 finite cell line human CVCL_B4QU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359546 CVCL_B4R6 UCF0125 finite cell line human CVCL_B4R6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359547 CVCL_B4QT UCF0110 finite cell line human CVCL_B4QT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359548 CVCL_B4R5 UCF0124 finite cell line human CVCL_B4R5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359549 CVCL_B4QW UCF0114 finite cell line human CVCL_B4QW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359550 CVCL_B4R8 UCF0129 finite cell line human CVCL_B4R8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359551 CVCL_B4QV UCF0113 finite cell line human CVCL_B4QV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359552 CVCL_B4R7 UCF0128 finite cell line human CVCL_B4R7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359553 CVCL_B4QY UCF0116 finite cell line human CVCL_B4QY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359554 CVCL_B4QX UCF0115 finite cell line human CVCL_B4QX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359555 CVCL_B4R9 UCF0130 finite cell line human CVCL_B4R9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359556 CVCL_B4QZ UCF0117 finite cell line human CVCL_B4QZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359557 CVCL_B4QM UCF0101 finite cell line human CVCL_B4QM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359558 CVCL_B4QL UCF0100 finite cell line human CVCL_B4QL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359559 CVCL_B4R0 UCF0119 finite cell line human CVCL_B4R0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359560 CVCL_B4QN UCF0102 finite cell line human CVCL_B4QN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359561 CVCL_B4QQ UCF0105 finite cell line human CVCL_B4QQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359562 CVCL_B4R2 UCF0121 finite cell line human CVCL_B4R2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359563 CVCL_B4QP UCF0103 finite cell line human CVCL_B4QP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359564 CVCL_B4R1 UCF0120 finite cell line human CVCL_B4R1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359565 CVCL_B4QS UCF0108 finite cell line human CVCL_B4QS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359566 CVCL_B4R4 UCF0123 finite cell line human CVCL_B4R4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359567 CVCL_B4QR UCF0106 finite cell line human CVCL_B4QR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359568 CVCL_B4R3 UCF0122 finite cell line human CVCL_B4R3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359569 CVCL_B4QE UCF0090 finite cell line human CVCL_B4QE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359570 CVCL_B4QD UCF0089 finite cell line human CVCL_B4QD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359571 CVCL_B4QG UCF0093 finite cell line human CVCL_B4QG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359572 CVCL_B4QF UCF0092 finite cell line human CVCL_B4QF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359573 CVCL_B4QI UCF0097 finite cell line human CVCL_B4QI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359574 CVCL_B4QH UCF0095 finite cell line human CVCL_B4QH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359575 CVCL_B4QK UCF0099 finite cell line human CVCL_B4QK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359576 CVCL_B4QJ UCF0098 finite cell line human CVCL_B4QJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359577 CVCL_B4QA UCF0086 finite cell line human CVCL_B4QA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359578 CVCL_B4QC UCF0088 finite cell line human CVCL_B4QC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359579 CVCL_B4QB UCF0087 finite cell line human CVCL_B4QB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359580 CVCL_B4RV UCF0165 finite cell line human CVCL_B4RV CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359581 CVCL_B4S7 UCF0187 finite cell line human CVCL_B4S7 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359582 CVCL_B4RU UCF0164 finite cell line human CVCL_B4RU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359583 CVCL_B4S6 UCF0185 finite cell line human CVCL_B4S6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359584 CVCL_B4RX UCF0168 finite cell line human CVCL_B4RX CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359585 CVCL_B4S9 UCF0189 finite cell line human CVCL_B4S9 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359586 CVCL_B4RW UCF0167 finite cell line human CVCL_B4RW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359587 CVCL_B4S8 UCF0188 finite cell line human CVCL_B4S8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359588 CVCL_B4RZ UCF0171 finite cell line human CVCL_B4RZ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359589 CVCL_B4RY UCF0169 finite cell line human CVCL_B4RY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359590 CVCL_B4RN UCF0150 finite cell line human CVCL_B4RN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359591 CVCL_B4RM UCF0149 finite cell line human CVCL_B4RM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359592 CVCL_B4RP UCF0152 finite cell line human CVCL_B4RP CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359593 CVCL_B4S1 UCF0176 finite cell line human CVCL_B4S1 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359594 CVCL_B4S0 UCF0174 finite cell line human CVCL_B4S0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359595 CVCL_B4RR UCF0155 finite cell line human CVCL_B4RR CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359596 CVCL_B4S3 UCF0180 finite cell line human CVCL_B4S3 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359597 CVCL_B4RQ UCF0154 finite cell line human CVCL_B4RQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359598 CVCL_B4S2 UCF0177 finite cell line human CVCL_B4S2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359599 CVCL_B4RT UCF0161 finite cell line human CVCL_B4RT CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359600 CVCL_B4S5 UCF0183 finite cell line human CVCL_B4S5 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359601 CVCL_B4RS UCF0159 finite cell line human CVCL_B4RS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359602 CVCL_B4S4 UCF0181 finite cell line human CVCL_B4S4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359603 CVCL_B4RF UCF0138 finite cell line human CVCL_B4RF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359604 CVCL_B4RE UCF0137 finite cell line human CVCL_B4RE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359605 CVCL_B4RH UCF0140 finite cell line human CVCL_B4RH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359606 CVCL_B4RG UCF0139 finite cell line human CVCL_B4RG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359607 CVCL_B4RJ UCF0142 finite cell line human CVCL_B4RJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359608 CVCL_B4RI UCF0141 finite cell line human CVCL_B4RI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359609 CVCL_B4RL UCF0146 finite cell line human CVCL_B4RL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359610 CVCL_B4RK UCF0144 finite cell line human CVCL_B4RK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359611 CVCL_B4RB UCF0132 finite cell line human CVCL_B4RB CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359612 CVCL_B4RA UCF0131 finite cell line human CVCL_B4RA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359613 CVCL_B4RD UCF0134 finite cell line human CVCL_B4RD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Female Part of: GenCord collection 151359614 CVCL_B4RC UCF0133 finite cell line human CVCL_B4RC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: MicroRNAs array analysis; Omics: SNP array analysis Male Part of: GenCord collection 151359615 CVCL_B5AD SP-2 [Mouse hybridoma against human LGALS3BP] hybridoma house mouse CVCL_B5AD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08380; Human LGALS3BP. 151359616 CVCL_B5AC 465.12S hybridoma house mouse CVCL_B5AC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q08380; Human LGALS3BP. 151359617 CVCL_B5AF A-1-18 hybridoma house mouse CVCL_B5AF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma cancer cells. 151359618 CVCL_B5AE SK-MEL-25 subclone-5 cancer cell line human CVCL_B5AE CL:0000010 Derived from metastatic site: Not specified. Female 151359619 CVCL_B5AH A-1-27 hybridoma house mouse CVCL_B5AH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma cancer cells. 151359620 CVCL_B5AG A-1-19 hybridoma house mouse CVCL_B5AG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma cancer cells. 151359621 CVCL_B5AJ A-1-6 hybridoma house mouse CVCL_B5AJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma cancer cells. 151359622 CVCL_B5AI A-1-43 hybridoma house mouse CVCL_B5AI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma cancer cells. 151359623 CVCL_B5AB 225.28S hybridoma house mouse CVCL_B5AB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 151359624 CVCL_B5AA RCV58 transformed cell line human CVCL_B5AA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=IgG memory B cell.. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P03524; Rabies virus glycoprotein (G) 151359625 CVCL_B5A4 19G7-C10 hybridoma house mouse CVCL_B5A4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH) (Note=Also reacts with Plasmodium vivax). Group: Patented cell line 151359626 CVCL_B5A3 10D3G2 hybridoma house mouse CVCL_B5A3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359627 CVCL_B5A6 17E4-D6 hybridoma house mouse CVCL_B5A6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). Group: Patented cell line 151359628 CVCL_B5A5 7G9-G1 hybridoma house mouse CVCL_B5A5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). Group: Patented cell line 151359629 CVCL_B5A8 6C9(B)-G7 hybridoma house mouse CVCL_B5A8 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH) (Note=Also reacts with Plasmodium vivax). Group: Patented cell line 151359630 CVCL_B5A7 6C9(A)-D6 hybridoma house mouse CVCL_B5A7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH) (Note=Also reacts with Plasmodium vivax). Group: Patented cell line 151359631 CVCL_B5A9 RCV20 transformed cell line human CVCL_B5A9 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=IgG memory B cell.. Unspecified Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03524; Rabies virus glycoprotein (G) 151359632 CVCL_B5A0 10A5H5 hybridoma house mouse CVCL_B5A0 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359633 CVCL_B5A2 10C4D5 hybridoma house mouse CVCL_B5A2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359634 CVCL_B5A1 10B6D1 hybridoma house mouse CVCL_B5A1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359635 CVCL_B5BE UCB1022 transformed cell line human CVCL_B5BE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359636 CVCL_B5BD UCB1021 transformed cell line human CVCL_B5BD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359637 CVCL_B5BG UCB1028 transformed cell line human CVCL_B5BG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359638 CVCL_B5BF UCB1026 transformed cell line human CVCL_B5BF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359639 CVCL_B5BI UCB1040 transformed cell line human CVCL_B5BI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359640 CVCL_B5BH UCB1037 transformed cell line human CVCL_B5BH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359641 CVCL_B5BK UCB1047 transformed cell line human CVCL_B5BK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359642 CVCL_B5BJ UCB1045 transformed cell line human CVCL_B5BJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359643 CVCL_B5BA UCB1008 transformed cell line human CVCL_B5BA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359644 CVCL_B5BC UCB1015 transformed cell line human CVCL_B5BC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359645 CVCL_B5BB UCB1013 transformed cell line human CVCL_B5BB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359646 CVCL_B5AT S-17-52 hybridoma house mouse CVCL_B5AT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359647 CVCL_B5B5 UCB1000 transformed cell line human CVCL_B5B5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359648 CVCL_B5AS S-13-24 hybridoma house mouse CVCL_B5AS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359649 CVCL_B5B4 UCB0161 transformed cell line human CVCL_B5B4 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359650 CVCL_B5AV S-18-325 hybridoma house mouse CVCL_B5AV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359651 CVCL_B5B7 UCB1004 transformed cell line human CVCL_B5B7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359652 CVCL_B5AU S-18-24 hybridoma house mouse CVCL_B5AU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359653 CVCL_B5B6 UCB1002 transformed cell line human CVCL_B5B6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359654 CVCL_B5AX S-19-57 hybridoma house mouse CVCL_B5AX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen found in melanoma, neuroblastoma and teratoma cancer cells. 151359655 CVCL_B5B9 UCB1007 transformed cell line human CVCL_B5B9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359656 CVCL_B5AW S-19-352 hybridoma house mouse CVCL_B5AW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in all cell lines. 151359657 CVCL_B5B8 UCB1006 transformed cell line human CVCL_B5B8 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359658 CVCL_B5AY S-cl-57 hybridoma house mouse CVCL_B5AY CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen found in melanoma, neuroblastoma and teratoma cancer cells. 151359659 CVCL_B5AL A-10-365 hybridoma house mouse CVCL_B5AL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359660 CVCL_B5AK A-10-33-1 hybridoma house mouse CVCL_B5AK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359661 CVCL_B5AN A-11-352 hybridoma house mouse CVCL_B5AN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359662 CVCL_B5AM A-11-124 hybridoma house mouse CVCL_B5AM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma, neuroblastoma and teratoma cancer cells. 151359663 CVCL_B5AP A-8-125 hybridoma house mouse CVCL_B5AP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in melanoma, neuroblastoma and teratoma cancer cells. 151359664 CVCL_B5B1 BD1 hybridoma house mouse CVCL_B5B1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27827; Paraoxon. 151359665 CVCL_B5B0 S-cl-69 hybridoma house mouse CVCL_B5B0 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359666 CVCL_B5B3 0.5alpha transformed cell line human CVCL_B5B3 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03381; Human T-cell leukemia virus 1 (HTLV-1) env (gp46) 151359667 CVCL_B5AR S-13-16 hybridoma house mouse CVCL_B5AR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen found in melanoma, neuroblastoma and teratoma cancer cells. 151359668 CVCL_B5AQ A-8-17 hybridoma house mouse CVCL_B5AQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen found in many types of cancer cells. 151359669 CVCL_B5B2 CE3 hybridoma house mouse CVCL_B5B2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27827; Paraoxon. 151359670 CVCL_B4ZB UCB0282 transformed cell line human CVCL_B4ZB CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359671 CVCL_B4ZA UCT0277 finite cell line human CVCL_B4ZA CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359672 CVCL_B4ZD UCB0284 transformed cell line human CVCL_B4ZD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359673 CVCL_B4ZC UCT0282 finite cell line human CVCL_B4ZC CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359674 CVCL_B4YU UCT0234 finite cell line human CVCL_B4YU CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359675 CVCL_B4Z6 UCT0271 finite cell line human CVCL_B4Z6 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359676 CVCL_B4YT UCB0234 transformed cell line human CVCL_B4YT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359677 CVCL_B4Z5 UCB0271 transformed cell line human CVCL_B4Z5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359678 CVCL_B4YW UCT0243 finite cell line human CVCL_B4YW CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359679 CVCL_B4Z8 UCT0276 finite cell line human CVCL_B4Z8 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359680 CVCL_B4YV UCB0243 transformed cell line human CVCL_B4YV CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359681 CVCL_B4Z7 UCB0276 transformed cell line human CVCL_B4Z7 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359682 CVCL_B4YY UCT0251 finite cell line human CVCL_B4YY CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359683 CVCL_B4YX UCB0251 transformed cell line human CVCL_B4YX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359684 CVCL_B4Z9 UCB0277 transformed cell line human CVCL_B4Z9 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359685 CVCL_B4YZ UCB0253 transformed cell line human CVCL_B4YZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359686 CVCL_B4YM UCB0226 transformed cell line human CVCL_B4YM CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359687 CVCL_B4YL UCT0225 finite cell line human CVCL_B4YL CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359688 CVCL_B4Z0 UCT0253 finite cell line human CVCL_B4Z0 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359689 CVCL_B4YN UCT0226 finite cell line human CVCL_B4YN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359690 CVCL_B4YQ UCT0227 finite cell line human CVCL_B4YQ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359691 CVCL_B4Z2 UCT0255 finite cell line human CVCL_B4Z2 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359692 CVCL_B4YP UCB0227 transformed cell line human CVCL_B4YP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359693 CVCL_B4Z1 UCB0255 transformed cell line human CVCL_B4Z1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359694 CVCL_B4YS UCT0228 finite cell line human CVCL_B4YS CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359695 CVCL_B4Z4 UCT0270 finite cell line human CVCL_B4Z4 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359696 CVCL_B4YR UCB0228 transformed cell line human CVCL_B4YR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359697 CVCL_B4Z3 UCB0270 transformed cell line human CVCL_B4Z3 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359698 CVCL_B4YE UCB0217 transformed cell line human CVCL_B4YE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359699 CVCL_B4YD UCT0188 finite cell line human CVCL_B4YD CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359700 CVCL_B4YG UCB0218 transformed cell line human CVCL_B4YG CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359701 CVCL_B4YF UCT0217 finite cell line human CVCL_B4YF CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359702 CVCL_B4YI UCB0223 transformed cell line human CVCL_B4YI CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359703 CVCL_B4YH UCT0218 finite cell line human CVCL_B4YH CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359704 CVCL_B4YK UCB0225 transformed cell line human CVCL_B4YK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359705 CVCL_B4YJ UCT0223 finite cell line human CVCL_B4YJ CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359706 CVCL_B4ZV NIZEDSM1iT21-C13 induced pluripotent stem cell human CVCL_B4ZV CL:0000010 Karyotypic information: Trisomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359707 CVCL_B4ZU NIZEDSM1iT21-C6 induced pluripotent stem cell human CVCL_B4ZU CL:0000010 Karyotypic information: Trisomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359708 CVCL_B4ZX D7E hybridoma house mouse CVCL_B4ZX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q4PRK9; Plasmodium vivax lactate dehydrogenase (PvLDH). 151359709 CVCL_B4ZW D2H hybridoma house mouse CVCL_B4ZW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q4PRK9; Plasmodium vivax lactate dehydrogenase (PvLDH). 151359710 CVCL_B4ZZ 10A5H3 hybridoma house mouse CVCL_B4ZZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359711 CVCL_B4ZY 10A4E11 hybridoma house mouse CVCL_B4ZY CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13774; Plasmodium falciparum lactate dehydrogenase (PfLDH). 151359712 CVCL_B4ZN UCT0313 finite cell line human CVCL_B4ZN CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359713 CVCL_B4ZM UCF0313 finite cell line human CVCL_B4ZM CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359714 CVCL_B4ZP CM05287 finite cell line human CVCL_B4ZP CL:0000010 Karyotypic information: 60% trisomy 21, 40% normal karyotype (PubMed=25694335); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by single cell RNAseq 151359715 CVCL_B4ZR NIZEDSM1iD21-C7 induced pluripotent stem cell human CVCL_B4ZR CL:0000010 Karyotypic information: Disomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359716 CVCL_B4ZQ NIZEDSM1iD21-C3 induced pluripotent stem cell human CVCL_B4ZQ CL:0000010 Karyotypic information: Disomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359717 CVCL_B4ZT NIZEDSM1iT21-C5 induced pluripotent stem cell human CVCL_B4ZT CL:0000010 Karyotypic information: Trisomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359718 CVCL_B4ZS NIZEDSM1iD21-C9 induced pluripotent stem cell human CVCL_B4ZS CL:0000010 Karyotypic information: Disomic Chr21 cell line that originate from a mosaic Down syndrome individual; Derived from sampling site: Skin Cell type=Fibroblast.. 151359719 CVCL_B4ZF UCB0285 transformed cell line human CVCL_B4ZF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: GenCord collection 151359720 CVCL_B4ZE UCT0284 finite cell line human CVCL_B4ZE CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359721 CVCL_B4ZH UCB0295 transformed cell line human CVCL_B4ZH CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359722 CVCL_B4ZG UCT0285 finite cell line human CVCL_B4ZG CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Part of: GenCord collection 151359723 CVCL_B4ZJ UCB0304 transformed cell line human CVCL_B4ZJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: GenCord collection 151359724 CVCL_B4ZI UCT0295 finite cell line human CVCL_B4ZI CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359725 CVCL_B4ZL UCB0313 transformed cell line human CVCL_B4ZL CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359726 CVCL_B4ZK UCT0304 finite cell line human CVCL_B4ZK CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Female Part of: GenCord collection 151359727 CVCL_B1AH Abcam THP-1 LYZ KO cancer cell line human CVCL_B1AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6740; LYZ; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359728 CVCL_B1AG Abcam THP-1 LGALS9 KO cancer cell line human CVCL_B1AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6570; LGALS9; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359729 CVCL_B1AJ Abcam THP-1 RIPK1 KO cancer cell line human CVCL_B1AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10019; RIPK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359730 CVCL_B1AI Abcam THP-1 PTPN6 KO cancer cell line human CVCL_B1AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9658; PTPN6; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359731 CVCL_B1AL Abcam THP-1 TNF KO cancer cell line human CVCL_B1AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11892; TNF; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359732 CVCL_B1AK Abcam THP-1 STING1 KO cancer cell line human CVCL_B1AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359733 CVCL_B1AN Abcam HEK293 ACP1 KO transformed cell line human CVCL_B1AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 122; ACP1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359734 CVCL_B1AM Abcam THP-1 TREM2 KO cancer cell line human CVCL_B1AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17761; TREM2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359735 CVCL_B1AB Abcam THP-1 CHI3L1 KO cancer cell line human CVCL_B1AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1932; CHI3L1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359736 CVCL_B1AA Abcam THP-1 CCL3 KO cancer cell line human CVCL_B1AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10627; CCL3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359737 CVCL_B1AD Abcam THP-1 CXCR2 KO cancer cell line human CVCL_B1AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6027; CXCR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359738 CVCL_B1AC Abcam THP-1 CXCL10 KO cancer cell line human CVCL_B1AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10637; CXCL10; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359739 CVCL_B1AF Abcam THP-1 LATS1 KO cancer cell line human CVCL_B1AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359740 CVCL_B1AE Abcam THP-1 IL1B KO cancer cell line human CVCL_B1AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5992; IL1B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359741 CVCL_B1A8 Abcam THP-1 CASP1 KO cancer cell line human CVCL_B1A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1499; CASP1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359742 CVCL_B1A7 Abcam THP-1 BCL2 KO cancer cell line human CVCL_B1A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: Abcam; ab276113; true Male 151359743 CVCL_B1A9 Abcam THP-1 CASP9 KO cancer cell line human CVCL_B1A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1511; CASP9; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359744 CVCL_B1A0 Abcam MCF-7 TPBG KO cancer cell line human CVCL_B1A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12004; TPBG; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359745 CVCL_B1A2 Abcam THP-1 ATG12 KO cancer cell line human CVCL_B1A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 588; ATG12; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359746 CVCL_B1A1 Abcam THP-1 ANPEP KO cancer cell line human CVCL_B1A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 500; ANPEP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359747 CVCL_B1A4 Abcam THP-1 ATG16L1 KO cancer cell line human CVCL_B1A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359748 CVCL_B1A3 Abcam THP-1 ATG14 KO cancer cell line human CVCL_B1A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359749 CVCL_B1A6 Abcam THP-1 ATG7 KO cancer cell line human CVCL_B1A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16935; ATG7; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359750 CVCL_B1A5 Abcam THP-1 ATG5 KO cancer cell line human CVCL_B1A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 589; ATG5; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 151359751 CVCL_B1BI Abcam HEK293 SMAD5 KO transformed cell line human CVCL_B1BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6771; SMAD5 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359752 CVCL_B1BH Abcam HEK293 SIRT1 KO transformed cell line human CVCL_B1BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359753 CVCL_B1BK Abcam Raji CD27 KO cancer cell line human CVCL_B1BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11922; CD27; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151359754 CVCL_B1BJ Abcam HEK293 SMARCC1 KO transformed cell line human CVCL_B1BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359755 CVCL_B1BM Abcam Raji CD74 KO 2 cancer cell line human CVCL_B1BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151359756 CVCL_B1BL Abcam Raji CD74 KO 1 cancer cell line human CVCL_B1BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151359757 CVCL_B1C0 Abcam A-431 DDAH1 KO cancer cell line human CVCL_B1C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2715; DDAH1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151359758 CVCL_B1BN Abcam Raji CD80 KO cancer cell line human CVCL_B1BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1700; CD80; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151359759 CVCL_B1BA Abcam HEK293 PDCD6IP KO transformed cell line human CVCL_B1BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8766; PDCD6IP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359760 CVCL_B1BC Abcam HEK293 PHF6 KO transformed cell line human CVCL_B1BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359761 CVCL_B1BB Abcam HEK293 PHF10 KO transformed cell line human CVCL_B1BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18250; PHF10 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359762 CVCL_B1BE Abcam HEK293 PRMT6 KO transformed cell line human CVCL_B1BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18241; PRMT6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359763 CVCL_B1BD Abcam HEK293 PLXNB2 KO transformed cell line human CVCL_B1BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9104; PLXNB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359764 CVCL_B1BG Abcam HEK293 SESN2 KO transformed cell line human CVCL_B1BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20746; SESN2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359765 CVCL_B1BF Abcam HEK293 SDHA KO transformed cell line human CVCL_B1BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10680; SDHA Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359766 CVCL_B1AX Abcam HEK293 GJA1 KO transformed cell line human CVCL_B1AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4274; GJA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359767 CVCL_B1B9 Abcam HEK293 NKX2-5 KO transformed cell line human CVCL_B1B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2488; NKX2-5 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359768 CVCL_B1AW Abcam HEK293 GATA2 KO transformed cell line human CVCL_B1AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359769 CVCL_B1B8 Abcam HEK293 NDRG1 KO transformed cell line human CVCL_B1B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7679; NDRG1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359770 CVCL_B1AZ Abcam HEK293 HK2 KO transformed cell line human CVCL_B1AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4923; HK2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359771 CVCL_B1AY Abcam HEK293 GYS1 KO transformed cell line human CVCL_B1AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4706; GYS1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359772 CVCL_B1AP Abcam HEK293 ATP13A2 KO transformed cell line human CVCL_B1AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30213; ATP13A2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359773 CVCL_B1B1 Abcam HEK293 HOXA9 KO 2 transformed cell line human CVCL_B1B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5109; HOXA9 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359774 CVCL_B1B0 Abcam HEK293 HOXA9 KO 1 transformed cell line human CVCL_B1B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5109; HOXA9 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359775 CVCL_B1AR Abcam HEK293 DDX17 KO transformed cell line human CVCL_B1AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2740; DDX17 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359776 CVCL_B1B3 Abcam HEK293 IFNGR1 KO transformed cell line human CVCL_B1B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359777 CVCL_B1AQ Abcam HEK293 DCP1A KO transformed cell line human CVCL_B1AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18714; DCP1A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359778 CVCL_B1B2 Abcam HEK293 HRAS KO transformed cell line human CVCL_B1B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5173; HRAS Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359779 CVCL_B1AT Abcam HEK293 FGFR3 KO transformed cell line human CVCL_B1AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3690; FGFR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359780 CVCL_B1B5 Abcam HEK293 KMT5A KO transformed cell line human CVCL_B1B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29489; KMT5A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359781 CVCL_B1AS Abcam HEK293 E2F1 KO transformed cell line human CVCL_B1AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359782 CVCL_B1B4 Abcam HEK293 IRS2 KO transformed cell line human CVCL_B1B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6126; IRS2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359783 CVCL_B1AV Abcam HEK293 FOXO3 KO transformed cell line human CVCL_B1AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3821; FOXO3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359784 CVCL_B1B7 Abcam HEK293 MFN2 KO transformed cell line human CVCL_B1B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16877; MFN2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359785 CVCL_B1AU Abcam HEK293 FOXC1 KO transformed cell line human CVCL_B1AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3800; FOXC1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Abcam; ab269474; true Female 151359786 CVCL_B1B6 Abcam HEK293 LAMP2 KO transformed cell line human CVCL_B1B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6501; LAMP2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151359787 CVCL_B0ZB Abcam K-562 CSF3 KO cancer cell line human CVCL_B0ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2438; CSF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 151359788 CVCL_B0ZA Abcam K-562 ADAM17 KO cancer cell line human CVCL_B0ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 195; ADAM17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 151359789 CVCL_B0ZD Abcam PC-3 CXCL8 KO cancer cell line human CVCL_B0ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6025; CXCL8; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 151359790 CVCL_B0ZC Abcam Calu-3 TMPRSS2 KO cancer cell line human CVCL_B0ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11876; TMPRSS2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male 151359791 CVCL_B0ZF Abcam A-375 IL13RA2 KO cancer cell line human CVCL_B0ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5975; IL13RA2; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 151359792 CVCL_B0ZE Abcam SK-N-BE(2) GRM5 KO cancer cell line human CVCL_B0ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4597; GRM5; Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Discontinued: Abcam; ab273376; true Male 151359793 CVCL_B0ZH Abcam Hep-G2 ACE2 KO cancer cell line human CVCL_B0ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13557; ACE2; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359794 CVCL_B0ZG Abcam U-87MG MAPT KO cancer cell line human CVCL_B0ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6893; MAPT; Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Discontinued: Abcam; ab269490; true. Male 151359795 CVCL_B0YY Abcam U2OS CD40 KO cancer cell line human CVCL_B0YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11919; CD40 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359796 CVCL_B0Z9 Abcam Jurkat TAL1 KO cancer cell line human CVCL_B0Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11556; TAL1; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151359797 CVCL_B0YX Abcam U2OS ACO1 KO cancer cell line human CVCL_B0YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 117; ACO1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359798 CVCL_B0YZ Abcam U2OS FHL2 KO cancer cell line human CVCL_B0YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3703; FHL2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359799 CVCL_B0YQ Abcam SW480 ACAT1 KO cancer cell line human CVCL_B0YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 93; ACAT1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359800 CVCL_B0Z2 Abcam U2OS SUV39H2 KO cancer cell line human CVCL_B0Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17287; SUV39H2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359801 CVCL_B0YP Abcam RAW 264.7 Prkaa1 KO cancer cell line house mouse CVCL_B0YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:2145955; Prkaa1 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 151359802 CVCL_B0Z1 Abcam U2OS PICALM KO cancer cell line human CVCL_B0Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15514; PICALM Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359803 CVCL_B0YS Abcam SW480 DDIT3 KO cancer cell line human CVCL_B0YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2726; DDIT3; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359804 CVCL_B0Z4 Abcam U2OS TNC KO cancer cell line human CVCL_B0Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5318; TNC Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359805 CVCL_B0YR Abcam SW480 ALDH2 KO cancer cell line human CVCL_B0YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 404; ALDH2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359806 CVCL_B0Z3 Abcam U2OS THY1 KO cancer cell line human CVCL_B0Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11801; THY1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359807 CVCL_B0Z6 Abcam Jurkat IFNG KO cancer cell line human CVCL_B0Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5438; IFNG; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151359808 CVCL_B0YU Abcam SW480 ITGA6 KO cancer cell line human CVCL_B0YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6142; ITGA6; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359809 CVCL_B0Z5 Abcam Jurkat CD1C KO cancer cell line human CVCL_B0Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1636; CD1C; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151359810 CVCL_B0YT Abcam SW480 ELAVL1 KO cancer cell line human CVCL_B0YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3312; ELAVL1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359811 CVCL_B0Z8 Abcam Jurkat PTPN2 KO cancer cell line human CVCL_B0Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9650; PTPN2; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151359812 CVCL_B0YW Abcam SW480 SERPINA1 KO cancer cell line human CVCL_B0YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8941; SERPINA1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359813 CVCL_B0Z7 Abcam Jurkat IKZF1 KO cancer cell line human CVCL_B0Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13176; IKZF1; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 151359814 CVCL_B0YV Abcam SW480 LCN2 KO cancer cell line human CVCL_B0YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6526; LCN2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359815 CVCL_B0YI Abcam SH-SY5Y PDGFRB KO cancer cell line human CVCL_B0YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8804; PDGFRB; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 151359816 CVCL_B0YH Abcam SH-SY5Y PDGFRA KO cancer cell line human CVCL_B0YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 151359817 CVCL_B0YK Abcam SH-SY5Y PINK1 KO cancer cell line human CVCL_B0YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 151359818 CVCL_B0YJ Abcam SH-SY5Y DLG4 KO cancer cell line human CVCL_B0YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2903; DLG4; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 151359819 CVCL_B0YM Abcam RAW 264.7 Ccl7 KO cancer cell line house mouse CVCL_B0YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:99512; Ccl7 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 151359820 CVCL_B0YL Abcam Caco-2 ACE2 KO cancer cell line human CVCL_B0YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13557; ACE2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151359821 CVCL_B0Z0 Abcam U2OS HNRNPD KO cancer cell line human CVCL_B0Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5036; HNRNPD Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151359822 CVCL_B0YN Abcam RAW 264.7 Cd68 KO cancer cell line house mouse CVCL_B0YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:88342; Cd68 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 151359823 CVCL_B0ZZ Abcam MCF-7 TLE1 KO cancer cell line human CVCL_B0ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359824 CVCL_B0ZY Abcam MCF-7 PDE3B KO cancer cell line human CVCL_B0ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8779; PDE3B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359825 CVCL_B0ZR Abcam Hep-G2 SLC2A1 KO cancer cell line human CVCL_B0ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11005; SLC2A1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359826 CVCL_B0ZQ Abcam Hep-G2 NFKB2 KO cancer cell line human CVCL_B0ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7795; NFKB2; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359827 CVCL_B0ZT Abcam MCF-7 ATAD2 KO cancer cell line human CVCL_B0ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30123; ATAD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359828 CVCL_B0ZS Abcam Hep-G2 TFEB KO cancer cell line human CVCL_B0ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11753; TFEB; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359829 CVCL_B0ZV Abcam MCF-7 BMI1 KO cancer cell line human CVCL_B0ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1066; BMI1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359830 CVCL_B0ZU Abcam MCF-7 ATM KO cancer cell line human CVCL_B0ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359831 CVCL_B0ZX Abcam MCF-7 HES1 KO cancer cell line human CVCL_B0ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5192; HES1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151359832 CVCL_B0ZW Abcam MCF-7 BRD4 KO cancer cell line human CVCL_B0ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Abcam; ab282674; true Female 151359833 CVCL_B0ZJ Abcam Hep-G2 B2M KO cancer cell line human CVCL_B0ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359834 CVCL_B0ZI Abcam Hep-G2 ARRB2 KO cancer cell line human CVCL_B0ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 712; ARRB2; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359835 CVCL_B0ZL Abcam Hep-G2 CTNNB1 KO cancer cell line human CVCL_B0ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359836 CVCL_B0ZK Abcam Hep-G2 CD63 KO cancer cell line human CVCL_B0ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1692; CD63; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359837 CVCL_B0ZN Abcam Hep-G2 MTOR KO cancer cell line human CVCL_B0ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3942; MTOR; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Discontinued: Abcam; ab277829; true Male 151359838 CVCL_B0ZM Abcam Hep-G2 LRP6 KO cancer cell line human CVCL_B0ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6698; LRP6; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359839 CVCL_B0ZP Abcam Hep-G2 NF2 KO cancer cell line human CVCL_B0ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 151359840 CVCL_B1IP Abcam HeLa ABHD6 KO cancer cell line human CVCL_B1IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21398; ABHD6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359841 CVCL_B1J1 Abcam HeLa ADARB1 KO cancer cell line human CVCL_B1J1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 226; ADARB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359842 CVCL_B1J0 Abcam HeLa ADAM9 KO cancer cell line human CVCL_B1J0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 216; ADAM9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359843 CVCL_B1IR Abcam HeLa ACAD9 KO cancer cell line human CVCL_B1IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21497; ACAD9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359844 CVCL_B1J3 Abcam HeLa ADCY3 KO cancer cell line human CVCL_B1J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 234; ADCY3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359845 CVCL_B1IQ Abcam HeLa ABL1 KO cancer cell line human CVCL_B1IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 76; ABL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359846 CVCL_B1J2 Abcam HeLa ADCK2 KO cancer cell line human CVCL_B1J2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19039; ADCK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359847 CVCL_B1IT Abcam HeLa ACOT9 KO cancer cell line human CVCL_B1IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17152; ACOT9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359848 CVCL_B1J5 Abcam HeLa ADK KO cancer cell line human CVCL_B1J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 257; ADK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359849 CVCL_B1IS Abcam HeLa ACHE KO cancer cell line human CVCL_B1IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 108; ACHE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359850 CVCL_B1J4 Abcam HeLa ADCY7 KO cancer cell line human CVCL_B1J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 238; ADCY7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359851 CVCL_B1IV Abcam HeLa ACSL1 KO cancer cell line human CVCL_B1IV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3569; ACSL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359852 CVCL_B1J7 Abcam HeLa AGO1 KO cancer cell line human CVCL_B1J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3262; AGO1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359853 CVCL_B1IU Abcam HeLa ACOX3 KO cancer cell line human CVCL_B1IU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 121; ACOX3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359854 CVCL_B1J6 Abcam HeLa ADRB1 KO cancer cell line human CVCL_B1J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 285; ADRB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261831; true Female 151359855 CVCL_B1IH Abcam A-549 ZC3HAV1 KO 2 cancer cell line human CVCL_B1IH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23721; ZC3HAV1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359856 CVCL_B1IG Abcam A-549 VCAM1 KO cancer cell line human CVCL_B1IG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12663; VCAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359857 CVCL_B1IJ Abcam HeLa AAK1 KO cancer cell line human CVCL_B1IJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19679; AAK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359858 CVCL_B1II Abcam A-549 ZCCHC2 KO 2 cancer cell line human CVCL_B1II CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22916; ZCCHC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359859 CVCL_B1IL Abcam HeLa ABCC3 KO cancer cell line human CVCL_B1IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 54; ABCC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359860 CVCL_B1IK Abcam HeLa ABCC1 KO cancer cell line human CVCL_B1IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359861 CVCL_B1IN Abcam HeLa ABHD17A KO cancer cell line human CVCL_B1IN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28756; ABHD17A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359862 CVCL_B1IM Abcam HeLa ABCF3 KO cancer cell line human CVCL_B1IM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 72; ABCF3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359863 CVCL_B1IB Abcam A-549 TRIM21 KO 2 cancer cell line human CVCL_B1IB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11312; TRIM21; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359864 CVCL_B1IA Abcam A-549 TRIM14 KO 2 cancer cell line human CVCL_B1IA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16283; TRIM14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359865 CVCL_B1ID Abcam A-549 TRIM38 KO 1 cancer cell line human CVCL_B1ID CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10059; TRIM38; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359866 CVCL_B1IC Abcam A-549 TRIM34 KO 1 cancer cell line human CVCL_B1IC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10063; TRIM34; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359867 CVCL_B1IF Abcam A-549 USP18 KO 1 cancer cell line human CVCL_B1IF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12616; USP18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359868 CVCL_B1IE Abcam A-549 TRIM56 KO 1 cancer cell line human CVCL_B1IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19028; TRIM56; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359869 CVCL_B1HW Abcam A-549 TEAD1 KO cancer cell line human CVCL_B1HW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11714; TEAD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359870 CVCL_B1I8 Abcam A-549 TRANK1 KO 1 cancer cell line human CVCL_B1I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29011; TRANK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359871 CVCL_B1HV Abcam A-549 TDRD7 KO 1 cancer cell line human CVCL_B1HV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30831; TDRD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359872 CVCL_B1I7 Abcam A-549 TNFSF10 KO cancer cell line human CVCL_B1I7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11925; TNFSF10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359873 CVCL_B1HY Abcam A-549 TENT5A KO 2 cancer cell line human CVCL_B1HY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18345; TENT5A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359874 CVCL_B1HX Abcam A-549 TEAD4 KO cancer cell line human CVCL_B1HX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11717; TEAD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359875 CVCL_B1I9 Abcam A-549 TREX1 KO cancer cell line human CVCL_B1I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12269; TREX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359876 CVCL_B1HZ Abcam A-549 TGFBR1 KO cancer cell line human CVCL_B1HZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11772; TGFBR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359877 CVCL_B1JQ Abcam HeLa APH1A KO cancer cell line human CVCL_B1JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29509; APH1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359878 CVCL_B1K2 Abcam HeLa ARNTL KO cancer cell line human CVCL_B1K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 701; BMAL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359879 CVCL_B1JP Abcam HeLa AP1M2 KO cancer cell line human CVCL_B1JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 558; AP1M2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359880 CVCL_B1K1 Abcam HeLa ARL8B KO cancer cell line human CVCL_B1K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25564; ARL8B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359881 CVCL_B1JS Abcam HeLa APPL1 KO cancer cell line human CVCL_B1JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24035; APPL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359882 CVCL_B1K4 Abcam HeLa ASCC2 KO cancer cell line human CVCL_B1K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24103; ASCC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265781; true Female 151359883 CVCL_B1JR Abcam HeLa APLNR KO cancer cell line human CVCL_B1JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 339; APLNR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359884 CVCL_B1K3 Abcam HeLa ASAP1 KO cancer cell line human CVCL_B1K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2720; ASAP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359885 CVCL_B1JU Abcam HeLa ARAP3 KO cancer cell line human CVCL_B1JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24097; ARAP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359886 CVCL_B1K6 Abcam HeLa ASS1 KO cancer cell line human CVCL_B1K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 758; ASS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359887 CVCL_B1JT Abcam HeLa APTX KO cancer cell line human CVCL_B1JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15984; APTX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359888 CVCL_B1K5 Abcam HeLa ASH1L KO cancer cell line human CVCL_B1K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19088; ASH1L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359889 CVCL_B1JW Abcam HeLa ARFIP2 KO cancer cell line human CVCL_B1JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17160; ARFIP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265813; true Female 151359890 CVCL_B1K8 Abcam HeLa ATAD2 KO cancer cell line human CVCL_B1K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30123; ATAD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359891 CVCL_B1JV Abcam HeLa ARF1 KO cancer cell line human CVCL_B1JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 652; ARF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359892 CVCL_B1K7 Abcam HeLa ASXL1 KO cancer cell line human CVCL_B1K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18318; ASXL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359893 CVCL_B1JI Abcam HeLa ANKRD13A KO cancer cell line human CVCL_B1JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21268; ANKRD13A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359894 CVCL_B1JH Abcam HeLa ALPP KO cancer cell line human CVCL_B1JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 439; ALPP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261763; true Female 151359895 CVCL_B1JK Abcam HeLa ANTXR1 KO cancer cell line human CVCL_B1JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21014; ANTXR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359896 CVCL_B1JJ Abcam HeLa ANKRD17 KO cancer cell line human CVCL_B1JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23575; ANKRD17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359897 CVCL_B1JM Abcam HeLa ANXA6 KO cancer cell line human CVCL_B1JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 544; ANXA6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359898 CVCL_B1JL Abcam HeLa ANXA3 KO cancer cell line human CVCL_B1JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 541; ANXA3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359899 CVCL_B1K0 Abcam HeLa ARL2BP KO cancer cell line human CVCL_B1K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17146; ARL2BP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359900 CVCL_B1JN Abcam HeLa AP1M1 KO cancer cell line human CVCL_B1JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13667; AP1M1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359901 CVCL_B1JA Abcam HeLa AK1 KO cancer cell line human CVCL_B1JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 361; AK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359902 CVCL_B1JC Abcam HeLa AKAP11 KO cancer cell line human CVCL_B1JC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 369; AKAP11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359903 CVCL_B1JB Abcam HeLa AK4 KO cancer cell line human CVCL_B1JB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 363; AK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359904 CVCL_B1JE Abcam HeLa AKT3 KO cancer cell line human CVCL_B1JE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265687; true Female 151359905 CVCL_B1JD Abcam HeLa AKT1 KO cancer cell line human CVCL_B1JD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359906 CVCL_B1JG Abcam HeLa ALK KO cancer cell line human CVCL_B1JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 427; ALK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab266003; true Female 151359907 CVCL_B1JF Abcam HeLa ALDH3A2 KO cancer cell line human CVCL_B1JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 403; ALDH3A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359908 CVCL_B1IX Abcam HeLa ACTA2 KO cancer cell line human CVCL_B1IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 130; ACTA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359909 CVCL_B1J9 Abcam HeLa AIP KO cancer cell line human CVCL_B1J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 358; AIP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359910 CVCL_B1IW Abcam HeLa ACSL3 KO cancer cell line human CVCL_B1IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3570; ACSL3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359911 CVCL_B1J8 Abcam HeLa AGO3 KO cancer cell line human CVCL_B1J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18421; AGO3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359912 CVCL_B1IZ Abcam HeLa ADAM17 KO cancer cell line human CVCL_B1IZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 195; ADAM17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359913 CVCL_B1IY Abcam HeLa ACTN1 KO cancer cell line human CVCL_B1IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 163; ACTN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151359914 CVCL_B1GN Abcam A-549 NRP1 KO cancer cell line human CVCL_B1GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8004; NRP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359915 CVCL_B1GM Abcam A-549 NR1H2 KO cancer cell line human CVCL_B1GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7965; NR1H2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359916 CVCL_B1GP Abcam A-549 NT5C3A KO 2 cancer cell line human CVCL_B1GP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359917 CVCL_B1H1 Abcam A-549 PMAIP1 KO 1 cancer cell line human CVCL_B1H1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9108; PMAIP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359918 CVCL_B1H0 Abcam A-549 PLSCR1 KO 1 cancer cell line human CVCL_B1H0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9092; PLSCR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359919 CVCL_B1GR Abcam A-549 OAS2 KO 3 cancer cell line human CVCL_B1GR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8087; OAS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359920 CVCL_B1H3 Abcam A-549 PTGS2 KO cancer cell line human CVCL_B1H3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9605; PTGS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359921 CVCL_B1GQ Abcam A-549 OAS2 KO 1 cancer cell line human CVCL_B1GQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8087; OAS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359922 CVCL_B1H2 Abcam A-549 PSMB8 KO 1 cancer cell line human CVCL_B1H2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9545; PSMB8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359923 CVCL_B1GT Abcam A-549 OTOP3 KO 1 cancer cell line human CVCL_B1GT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19658; OTOP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359924 CVCL_B1H5 Abcam A-549 PYHIN1 KO 1 cancer cell line human CVCL_B1H5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28894; PYHIN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359925 CVCL_B1GS Abcam A-549 OASL KO 1 cancer cell line human CVCL_B1GS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8090; OASL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359926 CVCL_B1H4 Abcam A-549 PTPRK KO 2 cancer cell line human CVCL_B1H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359927 CVCL_B1GF Abcam A-549 MAP3K2 KO 2 cancer cell line human CVCL_B1GF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359928 CVCL_B1GE Abcam A-549 MAP3K15 KO 2 cancer cell line human CVCL_B1GE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31689; MAP3K15; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359929 CVCL_B1GH Abcam A-549 MX1 KO cancer cell line human CVCL_B1GH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7532; MX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267035; true Male 151359930 CVCL_B1GG Abcam A-549 MSX1 KO 1 cancer cell line human CVCL_B1GG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7391; MSX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359931 CVCL_B1GJ Abcam A-549 MYH2 KO 2 cancer cell line human CVCL_B1GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7572; MYH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267028; true Male 151359932 CVCL_B1GI Abcam A-549 MX2 KO 2 cancer cell line human CVCL_B1GI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7533; MX2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359933 CVCL_B1GL Abcam A-549 NLRC5 KO cancer cell line human CVCL_B1GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29933; NLRC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359934 CVCL_B1GK Abcam A-549 NCOA7 KO 1 cancer cell line human CVCL_B1GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21081; NCOA7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359935 CVCL_B1GB Abcam A-549 MAP2K7 KO 1 cancer cell line human CVCL_B1GB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359936 CVCL_B1GA Abcam A-549 LMO2 KO cancer cell line human CVCL_B1GA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6642; LMO2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267167; true Male 151359937 CVCL_B1GD Abcam A-549 MAP3K14 KO cancer cell line human CVCL_B1GD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6853; MAP3K14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359938 CVCL_B1GC Abcam A-549 MAP3K11 KO 1 cancer cell line human CVCL_B1GC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359939 CVCL_B1FU Abcam A-549 IFIH1 KO 1 cancer cell line human CVCL_B1FU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18873; IFIH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359940 CVCL_B1G6 Abcam A-549 KDM7A KO 2 cancer cell line human CVCL_B1G6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22224; KDM7A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359941 CVCL_B1FT Abcam A-549 IFI6 KO 1 cancer cell line human CVCL_B1FT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4054; IFI6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359942 CVCL_B1G5 Abcam A-549 JAK2 KO cancer cell line human CVCL_B1G5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6192; JAK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359943 CVCL_B1FW Abcam A-549 IFIT3 KO cancer cell line human CVCL_B1FW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5411; IFIT3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359944 CVCL_B1G8 Abcam A-549 LAP3 KO cancer cell line human CVCL_B1G8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18449; LAP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359945 CVCL_B1FV Abcam A-549 IFIT2 KO 1 cancer cell line human CVCL_B1FV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5409; IFIT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359946 CVCL_B1G7 Abcam A-549 LAMP3 KO 1 cancer cell line human CVCL_B1G7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14582; LAMP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359947 CVCL_B1FY Abcam A-549 IL15RA KO 1 cancer cell line human CVCL_B1FY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5978; IL15RA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359948 CVCL_B1FX Abcam A-549 IFIT5 KO 2 cancer cell line human CVCL_B1FX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13328; IFIT5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359949 CVCL_B1G9 Abcam A-549 LGALS9C KO cancer cell line human CVCL_B1G9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33874; LGALS9C; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359950 CVCL_B1FZ Abcam A-549 IL6 KO cancer cell line human CVCL_B1FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6018; IL6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359951 CVCL_B1I0 Abcam A-549 TGM2 KO 1 cancer cell line human CVCL_B1I0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11778; TGM2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359952 CVCL_B1HN Abcam A-549 SMAD6 KO cancer cell line human CVCL_B1HN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6772; SMAD6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359953 CVCL_B1HQ Abcam A-549 SP140 KO 1 cancer cell line human CVCL_B1HQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17133; SP140; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359954 CVCL_B1I2 Abcam A-549 THEMIS2 KO 2 cancer cell line human CVCL_B1I2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16839; THEMIS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359955 CVCL_B1HP Abcam A-549 SP100 KO cancer cell line human CVCL_B1HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11206; SP100; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359956 CVCL_B1I1 Abcam A-549 TGOLN2 KO cancer cell line human CVCL_B1I1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15450; TGOLN2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359957 CVCL_B1HS Abcam A-549 SPINK1 KO 3 cancer cell line human CVCL_B1HS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11244; SPINK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267206; true Male 151359958 CVCL_B1I4 Abcam A-549 TMEM140 KO 1 cancer cell line human CVCL_B1I4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21870; TMEM140; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359959 CVCL_B1HR Abcam A-549 SPINK1 KO 1 cancer cell line human CVCL_B1HR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11244; SPINK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267204; true Male 151359960 CVCL_B1I3 Abcam A-549 TLDC2 KO 2 cancer cell line human CVCL_B1I3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16112; TLDC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359961 CVCL_B1HU Abcam A-549 SYN1 KO cancer cell line human CVCL_B1HU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11494; SYN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab266917; true Male 151359962 CVCL_B1I6 Abcam A-549 TNFAIP3 KO 1 cancer cell line human CVCL_B1I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11896; TNFAIP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359963 CVCL_B1HT Abcam A-549 STAT2 KO 2 cancer cell line human CVCL_B1HT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359964 CVCL_B1I5 Abcam A-549 TMEM64 KO 1 cancer cell line human CVCL_B1I5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25441; TMEM64; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359965 CVCL_B1HG Abcam A-549 SECTM1 KO 2 cancer cell line human CVCL_B1HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10707; SECTM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359966 CVCL_B1HF Abcam A-549 SAMD9L KO 2 cancer cell line human CVCL_B1HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1349; SAMD9L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359967 CVCL_B1HI Abcam A-549 SHFL KO 1 cancer cell line human CVCL_B1HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25649; SHFL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359968 CVCL_B1HH Abcam A-549 SERPING1 KO 2 cancer cell line human CVCL_B1HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1228; SERPING1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab266941; true Male 151359969 CVCL_B1HK Abcam A-549 SLC15A3 KO cancer cell line human CVCL_B1HK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18068; SLC15A3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359970 CVCL_B1HJ Abcam A-549 SIDT1 KO 1 cancer cell line human CVCL_B1HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25967; SIDT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359971 CVCL_B1HM Abcam A-549 SMAD3 KO 1 cancer cell line human CVCL_B1HM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6769; SMAD3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359972 CVCL_B1HL Abcam A-549 SLC25A28 KO 2 cancer cell line human CVCL_B1HL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23472; SLC25A28; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359973 CVCL_B1HA Abcam A-549 RNF19B KO 2 cancer cell line human CVCL_B1HA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26886; RNF19B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359974 CVCL_B1HC Abcam A-549 S100A4 KO cancer cell line human CVCL_B1HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10494; S100A4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359975 CVCL_B1HB Abcam A-549 RTP4 KO 1 cancer cell line human CVCL_B1HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23992; RTP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359976 CVCL_B1HE Abcam A-549 SAMD9 KO 2 cancer cell line human CVCL_B1HE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1348; SAMD9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359977 CVCL_B1HD Abcam A-549 SAA1 KO 2 cancer cell line human CVCL_B1HD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10513; SAA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359978 CVCL_B1GV Abcam A-549 PARP12 KO cancer cell line human CVCL_B1GV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21919; PARP12; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359979 CVCL_B1H7 Abcam A-549 RAB29 KO cancer cell line human CVCL_B1H7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9789; RAB29; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359980 CVCL_B1GU Abcam A-549 PARP10 KO 1 cancer cell line human CVCL_B1GU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25895; PARP10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359981 CVCL_B1H6 Abcam A-549 RAB10 KO cancer cell line human CVCL_B1H6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9759; RAB10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359982 CVCL_B1GX Abcam A-549 PARP9 KO 2 cancer cell line human CVCL_B1GX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24118; PARP9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359983 CVCL_B1H9 Abcam A-549 RICTOR KO cancer cell line human CVCL_B1H9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28611; RICTOR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359984 CVCL_B1GW Abcam A-549 PARP14 KO 2 cancer cell line human CVCL_B1GW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29232; PARP14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359985 CVCL_B1H8 Abcam A-549 RASGRP3 KO 2 cancer cell line human CVCL_B1H8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14545; RASGRP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab267199; true Male 151359986 CVCL_B1GZ Abcam A-549 PLEKHA4 KO 1 cancer cell line human CVCL_B1GZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14339; PLEKHA4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359987 CVCL_B1GY Abcam A-549 PLAAT4 KO 1 cancer cell line human CVCL_B1GY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9869; PLAAT4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359988 CVCL_B1EL Abcam A-549 ATF3 KO cancer cell line human CVCL_B1EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359989 CVCL_B1EK Abcam A-549 APOL6 KO 2 cancer cell line human CVCL_B1EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14870; APOL6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359990 CVCL_B1EN Abcam A-549 BATF2 KO 1 cancer cell line human CVCL_B1EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25163; BATF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359991 CVCL_B1EM Abcam A-549 ATP10A KO cancer cell line human CVCL_B1EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13542; ATP10A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359992 CVCL_B1EP Abcam A-549 BRCA1 KO cancer cell line human CVCL_B1EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1100; BRCA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: Abcam; ab276099; true Male 151359993 CVCL_B1F1 Abcam A-549 DDX60 KO cancer cell line human CVCL_B1F1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25942; DDX60; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359994 CVCL_B1F0 Abcam A-549 DDX58 KO 1 cancer cell line human CVCL_B1F0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19102; RIGI; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359995 CVCL_B1ER Abcam A-549 CD274 KO 1 cancer cell line human CVCL_B1ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17635; CD274; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359996 CVCL_B1F3 Abcam A-549 DNAH5 KO cancer cell line human CVCL_B1F3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2950; DNAH5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359997 CVCL_B1EQ Abcam A-549 CA12 KO cancer cell line human CVCL_B1EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1371; CA12; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359998 CVCL_B1F2 Abcam A-549 DEPDC5 KO cancer cell line human CVCL_B1F2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18423; DEPDC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151359999 CVCL_B1ED Abcam HCT 116 UBE2H KO cancer cell line human CVCL_B1ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12484; UBE2H; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360000 CVCL_B1EC Abcam HCT 116 TUBB3 KO cancer cell line human CVCL_B1EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20772; TUBB3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360001 CVCL_B1EF Abcam HCT 116 ZFYVE16 KO cancer cell line human CVCL_B1EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20756; ZFYVE16; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360002 CVCL_B1EE Abcam HCT 116 UBE2K KO cancer cell line human CVCL_B1EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4914; UBE2K; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360003 CVCL_B1EH Abcam A-549 ABCG2 KO cancer cell line human CVCL_B1EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 74; ABCG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360004 CVCL_B1EG Abcam A-549 ABCC1 KO cancer cell line human CVCL_B1EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360005 CVCL_B1EJ Abcam A-549 APOL2 KO 2 cancer cell line human CVCL_B1EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 619; APOL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360006 CVCL_B1EI Abcam A-549 ANGPTL6 KO cancer cell line human CVCL_B1EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23140; ANGPTL6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360007 CVCL_B1DZ Abcam HCT 116 PLK2 KO cancer cell line human CVCL_B1DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360008 CVCL_B1EB Abcam HCT 116 TSPO KO cancer cell line human CVCL_B1EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1158; TSPO; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360009 CVCL_B1EA Abcam HCT 116 TRIB3 KO cancer cell line human CVCL_B1EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16228; TRIB3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360010 CVCL_B1DS Abcam HCT 116 KRAS KO cancer cell line human CVCL_B1DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6407; KRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360011 CVCL_B1E4 Abcam HCT 116 RXRA KO cancer cell line human CVCL_B1E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10477; RXRA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360012 CVCL_B1DR Abcam HCT 116 ITGB1 KO cancer cell line human CVCL_B1DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360013 CVCL_B1E3 Abcam HCT 116 RRM2B KO cancer cell line human CVCL_B1E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17296; RRM2B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360014 CVCL_B1DU Abcam HCT 116 MLST8 KO cancer cell line human CVCL_B1DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24825; MLST8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360015 CVCL_B1E6 Abcam HCT 116 SP3 KO cancer cell line human CVCL_B1E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11208; SP3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360016 CVCL_B1DT Abcam HCT 116 MELK KO cancer cell line human CVCL_B1DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16870; MELK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360017 CVCL_B1E5 Abcam HCT 116 SLC9A3R1 KO cancer cell line human CVCL_B1E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11075; SLC9A3R1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360018 CVCL_B1DW Abcam HCT 116 NFKB2 KO cancer cell line human CVCL_B1DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7795; NFKB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360019 CVCL_B1E8 Abcam HCT 116 TLE5 KO cancer cell line human CVCL_B1E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 307; TLE5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360020 CVCL_B1DV Abcam HCT 116 MORF4L2 KO cancer cell line human CVCL_B1DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16849; MORF4L2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360021 CVCL_B1E7 Abcam HCT 116 SQSTM1 KO cancer cell line human CVCL_B1E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360022 CVCL_B1DY Abcam HCT 116 PKN2 KO cancer cell line human CVCL_B1DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9406; PKN2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360023 CVCL_B1DX Abcam HCT 116 NR2F2 KO cancer cell line human CVCL_B1DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7976; NR2F2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360024 CVCL_B1E9 Abcam HCT 116 TMSB10 KO cancer cell line human CVCL_B1E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11879; TMSB10; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360025 CVCL_B1FM Abcam A-549 HTR3D KO 1 cancer cell line human CVCL_B1FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24004; HTR3D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360026 CVCL_B1FL Abcam A-549 HLA-E KO 2 cancer cell line human CVCL_B1FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4962; HLA-E; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360027 CVCL_B1G0 Abcam A-549 IRF1 KO cancer cell line human CVCL_B1G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6116; IRF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360028 CVCL_B1FN Abcam A-549 IDO1 KO 1 cancer cell line human CVCL_B1FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6059; IDO1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360029 CVCL_B1FQ Abcam A-549 IFI27 KO cancer cell line human CVCL_B1FQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5397; IFI27; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360030 CVCL_B1G2 Abcam A-549 IRF3 KO 2 cancer cell line human CVCL_B1G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6118; IRF3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360031 CVCL_B1FP Abcam A-549 IFI16 KO 1 cancer cell line human CVCL_B1FP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5395; IFI16; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360032 CVCL_B1G1 Abcam A-549 IRF2 KO 2 cancer cell line human CVCL_B1G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360033 CVCL_B1FS Abcam A-549 IFI44L KO 1 cancer cell line human CVCL_B1FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17817; IFI44L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360034 CVCL_B1G4 Abcam A-549 ISM1 KO 1 cancer cell line human CVCL_B1G4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16213; ISM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360035 CVCL_B1FR Abcam A-549 IFI44 KO 1 cancer cell line human CVCL_B1FR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16938; IFI44; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360036 CVCL_B1G3 Abcam A-549 IRF7 KO 2 cancer cell line human CVCL_B1G3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360037 CVCL_B1FE Abcam A-549 GCH1 KO 1 cancer cell line human CVCL_B1FE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4193; GCH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360038 CVCL_B1FD Abcam A-549 GBP4 KO 1 cancer cell line human CVCL_B1FD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20480; GBP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360039 CVCL_B1FG Abcam A-549 HAPLN3 KO 1 cancer cell line human CVCL_B1FG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21446; HAPLN3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360040 CVCL_B1FF Abcam A-549 GMPR KO 1 cancer cell line human CVCL_B1FF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4376; GMPR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360041 CVCL_B1FI Abcam A-549 HERC5 KO 1 cancer cell line human CVCL_B1FI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24368; HERC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360042 CVCL_B1FH Abcam A-549 HELZ2 KO 1 cancer cell line human CVCL_B1FH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30021; HELZ2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360043 CVCL_B1FK Abcam A-549 H1-2 KO cancer cell line human CVCL_B1FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4716; H1-2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360044 CVCL_B1FJ Abcam A-549 HERC6 KO cancer cell line human CVCL_B1FJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26072; HERC6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360045 CVCL_B1FA Abcam A-549 ETV7 KO 1 cancer cell line human CVCL_B1FA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18160; ETV7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360046 CVCL_B1FC Abcam A-549 GBP2 KO 2 cancer cell line human CVCL_B1FC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4183; GBP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360047 CVCL_B1FB Abcam A-549 GBP1 KO cancer cell line human CVCL_B1FB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4182; GBP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360048 CVCL_B1ET Abcam A-549 CEACAM1 KO 2 cancer cell line human CVCL_B1ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1814; CEACAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360049 CVCL_B1F5 Abcam A-549 DTX3L KO 2 cancer cell line human CVCL_B1F5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30323; DTX3L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360050 CVCL_B1ES Abcam A-549 CD9 KO cancer cell line human CVCL_B1ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1709; CD9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360051 CVCL_B1F4 Abcam A-549 DSG2 KO 2 cancer cell line human CVCL_B1F4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360052 CVCL_B1EV Abcam A-549 CHEK1 KO cancer cell line human CVCL_B1EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1925; CHEK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360053 CVCL_B1F7 Abcam A-549 EPAS1 KO cancer cell line human CVCL_B1F7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3374; EPAS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360054 CVCL_B1EU Abcam A-549 CFHR3 KO 1 cancer cell line human CVCL_B1EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16980; CFHR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360055 CVCL_B1F6 Abcam A-549 EIF2AK2 KO 1 cancer cell line human CVCL_B1F6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9437; EIF2AK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360056 CVCL_B1EX Abcam A-549 CMPK2 KO 2 cancer cell line human CVCL_B1EX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27015; CMPK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360057 CVCL_B1F9 Abcam A-549 ETV6 KO 1 cancer cell line human CVCL_B1F9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360058 CVCL_B1EW Abcam A-549 CHMP2B KO cancer cell line human CVCL_B1EW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24537; CHMP2B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360059 CVCL_B1F8 Abcam A-549 EPSTI1 KO 2 cancer cell line human CVCL_B1F8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16465; EPSTI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360060 CVCL_B1EZ Abcam A-549 CYP1B1 KO 1 cancer cell line human CVCL_B1EZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2597; CYP1B1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360061 CVCL_B1EY Abcam A-549 CXCL10 KO 2 cancer cell line human CVCL_B1EY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10637; CXCL10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360062 CVCL_B1CJ Abcam A-431 P4HB KO cancer cell line human CVCL_B1CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8548; P4HB; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360063 CVCL_B1CI Abcam A-431 NT5E KO cancer cell line human CVCL_B1CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8021; NT5E; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360064 CVCL_B1CL Abcam A-431 PPP2R5D KO cancer cell line human CVCL_B1CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9312; PPP2R5D; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360065 CVCL_B1CK Abcam A-431 PERP KO cancer cell line human CVCL_B1CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17637; PERP; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360066 CVCL_B1CN Abcam A-431 SOS1 KO cancer cell line human CVCL_B1CN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11187; SOS1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360067 CVCL_B1CM Abcam A-431 PXN KO cancer cell line human CVCL_B1CM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9718; PXN; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360068 CVCL_B1CP Abcam A-431 STK24 KO cancer cell line human CVCL_B1CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11403; STK24; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360069 CVCL_B1D1 IRCC-Neuromed-NULU cancer cell line human CVCL_B1D1 CL:0000010 Derived from sampling site: Brain; temporo-parietal lobe. Female 151360070 CVCL_B1D0 IRCC-Neuromed-IP cancer cell line human CVCL_B1D0 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 151360071 CVCL_B1CB Abcam A-431 KRT13 KO cancer cell line human CVCL_B1CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6415; KRT13; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360072 CVCL_B1CA Abcam A-431 IL1RN KO cancer cell line human CVCL_B1CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6000; IL1RN; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360073 CVCL_B1CD Abcam A-431 KRT15 KO cancer cell line human CVCL_B1CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6421; KRT15; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360074 CVCL_B1CC Abcam A-431 KRT14 KO cancer cell line human CVCL_B1CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6416; KRT14; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360075 CVCL_B1CF Abcam A-431 MYL9 KO cancer cell line human CVCL_B1CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15754; MYL9; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360076 CVCL_B1CE Abcam A-431 MMP14 KO cancer cell line human CVCL_B1CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7160; MMP14; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360077 CVCL_B1CH Abcam A-431 NEK9 KO cancer cell line human CVCL_B1CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18591; NEK9; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360078 CVCL_B1CG Abcam A-431 NBN KO cancer cell line human CVCL_B1CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7652; NBN; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360079 CVCL_B1BY Abcam A-431 CTNNB1 KO cancer cell line human CVCL_B1BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360080 CVCL_B1BX Abcam A-431 CLDN1 KO cancer cell line human CVCL_B1BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2032; CLDN1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360081 CVCL_B1C9 Abcam A-431 HSP90AB1 KO cancer cell line human CVCL_B1C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5258; HSP90AB1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360082 CVCL_B1BZ Abcam A-431 CTSD KO cancer cell line human CVCL_B1BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2529; CTSD; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360083 CVCL_B1C2 Abcam A-431 DPF2 KO cancer cell line human CVCL_B1C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9964; DPF2; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360084 CVCL_B1BQ Abcam Raji CXCR5 KO cancer cell line human CVCL_B1BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1060; CXCR5; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151360085 CVCL_B1C1 Abcam A-431 DHCR24 KO cancer cell line human CVCL_B1C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2859; DHCR24; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360086 CVCL_B1BP Abcam Raji CD86 KO cancer cell line human CVCL_B1BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1705; CD86; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 151360087 CVCL_B1BS Abcam A-431 B2M KO cancer cell line human CVCL_B1BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360088 CVCL_B1C4 Abcam A-431 EPCAM KO cancer cell line human CVCL_B1C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11529; EPCAM; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360089 CVCL_B1BR Abcam A-431 ADRB2 KO cancer cell line human CVCL_B1BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 286; ADRB2; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360090 CVCL_B1C3 Abcam A-431 DUSP6 KO cancer cell line human CVCL_B1C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3072; DUSP6; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360091 CVCL_B1BU Abcam A-431 CAV1 KO cancer cell line human CVCL_B1BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1527; CAV1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360092 CVCL_B1C6 Abcam A-431 GRB2 KO cancer cell line human CVCL_B1C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4566; GRB2; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360093 CVCL_B1BT Abcam A-431 BST2 KO cancer cell line human CVCL_B1BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1119; BST2; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360094 CVCL_B1C5 Abcam A-431 G3BP1 KO cancer cell line human CVCL_B1C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30292; G3BP1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360095 CVCL_B1BW Abcam A-431 CENPB KO cancer cell line human CVCL_B1BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1852; CENPB; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360096 CVCL_B1C8 Abcam A-431 HLA-A KO cancer cell line human CVCL_B1C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360097 CVCL_B1BV Abcam A-431 CBFB KO cancer cell line human CVCL_B1BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1539; CBFB; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360098 CVCL_B1C7 Abcam A-431 H1-0 KO cancer cell line human CVCL_B1C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4714; H1-0; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360099 CVCL_B1DK Abcam HCT 116 GNA13 KO cancer cell line human CVCL_B1DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4381; GNA13; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360100 CVCL_B1DJ Abcam HCT 116 GLI4 KO cancer cell line human CVCL_B1DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4320; GLI4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360101 CVCL_B1DM Abcam HCT 116 GRB2 KO cancer cell line human CVCL_B1DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4566; GRB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360102 CVCL_B1DL Abcam HCT 116 GNB1 KO cancer cell line human CVCL_B1DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4396; GNB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360103 CVCL_B1E0 Abcam HCT 116 PODXL KO cancer cell line human CVCL_B1E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360104 CVCL_B1DN Abcam HCT 116 HELLS KO cancer cell line human CVCL_B1DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4861; HELLS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360105 CVCL_B1DQ Abcam HCT 116 HK2 KO cancer cell line human CVCL_B1DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4923; HK2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360106 CVCL_B1E2 Abcam HCT 116 RBBP7 KO cancer cell line human CVCL_B1E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9890; RBBP7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360107 CVCL_B1DP Abcam HCT 116 HIF1A KO cancer cell line human CVCL_B1DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4910; HIF1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360108 CVCL_B1E1 Abcam HCT 116 POR KO cancer cell line human CVCL_B1E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9208; POR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360109 CVCL_B1DC Abcam HCT 116 CTNNB1 KO cancer cell line human CVCL_B1DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360110 CVCL_B1DB Abcam HCT 116 CSNK2A1 KO cancer cell line human CVCL_B1DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2457; CSNK2A1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360111 CVCL_B1DE Abcam HCT 116 DMPK KO cancer cell line human CVCL_B1DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2933; DMPK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360112 CVCL_B1DD Abcam HCT 116 DIAPH1 KO cancer cell line human CVCL_B1DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2876; DIAPH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360113 CVCL_B1DG Abcam HCT 116 EPHA2 KO cancer cell line human CVCL_B1DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3386; EPHA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360114 CVCL_B1DF Abcam HCT 116 EIF1 KO cancer cell line human CVCL_B1DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3249; EIF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360115 CVCL_B1DI Abcam HCT 116 FSCN1 KO cancer cell line human CVCL_B1DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11148; FSCN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360116 CVCL_B1DH Abcam HCT 116 FGFR4 KO 1 cancer cell line human CVCL_B1DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3691; FGFR4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360117 CVCL_B1CZ IRCC-Neuromed-VEM cancer cell line human CVCL_B1CZ CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 151360118 CVCL_B1CY IRCC-Neuromed-ZAR cancer cell line human CVCL_B1CY CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 151360119 CVCL_B1DA Abcam HCT 116 CDKN1A KO 1 cancer cell line human CVCL_B1DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360120 CVCL_B1CR Abcam A-431 VCL KO cancer cell line human CVCL_B1CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12665; VCL; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360121 CVCL_B1D3 IRCC-Neuromed-DA cancer cell line human CVCL_B1D3 CL:0000010 Derived from sampling site: Brain; central sulcus. Female 151360122 CVCL_B1CQ Abcam A-431 VAMP8 KO cancer cell line human CVCL_B1CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12647; VAMP8; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 151360123 CVCL_B1D2 IRCC-Neuromed-CG cancer cell line human CVCL_B1D2 CL:0000010 Derived from sampling site: Brain; temporo-insular lobe. Female 151360124 CVCL_B1CT Ham-2 cancer cell line CVCL_B1CT CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis viverrini(NCBI-Taxonomy; 6198). Male Characteristics: Obtained by both Opisthorchis viverrini infection and N-nitrosodimethylamine treatment (PubMed=34549357) Doubling time: 45.8 + 2.1 hours (PubMed=34549357) 151360125 CVCL_B1D5 IRCC-Neuromed-MI cancer cell line human CVCL_B1D5 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=33398536) Derived from sampling site: Brain; temporo-parietal lobe. Female 151360126 CVCL_B1CS Abcam A-431 NDRG1 KO cancer cell line human CVCL_B1CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7679; NDRG1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Discontinued: Abcam; ab277849; true Female 151360127 CVCL_B1D4 IRCC-Neuromed-FL cancer cell line human CVCL_B1D4 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=33398536) Derived from sampling site: Brain; cerebral cortex; insular lobe. Female 151360128 CVCL_B1D7 Abcam HCT 116 ADAM17 KO cancer cell line human CVCL_B1D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 195; ADAM17; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360129 CVCL_B1CV IRCC-Neuromed-CL cancer cell line human CVCL_B1CV CL:0000010 Derived from sampling site: Brain; frontal lobe. Male 151360130 CVCL_B1CU IRCC-Neuromed-COGI cancer cell line human CVCL_B1CU CL:0000010 Derived from sampling site: Brain; frontal lobe. Male 151360131 CVCL_B1D9 Abcam HCT 116 CD2BP2 KO cancer cell line human CVCL_B1D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1656; CD2BP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360132 CVCL_B1CX IRCC-Neuromed-DNA cancer cell line human CVCL_B1CX CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 151360133 CVCL_B1D8 Abcam HCT 116 ATF3 KO cancer cell line human CVCL_B1D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 151360134 CVCL_B1CW IRCC-Neuromed-PAP cancer cell line human CVCL_B1CW CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=33398536) Derived from sampling site: Brain; temporal lobe. Male 151360135 CVCL_B0YA XF27/28.43E2 hybridoma house mouse CVCL_B0YA CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4054 151360136 CVCL_B0YC XF3.10B8 hybridoma house mouse CVCL_B0YC CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3151 151360137 CVCL_B0YB XF27/28.55G4 hybridoma house mouse CVCL_B0YB CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 151360138 CVCL_B0YE XF3.6A2 hybridoma house mouse CVCL_B0YE CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3148 151360139 CVCL_B0YD XF3.5F1 hybridoma house mouse CVCL_B0YD CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3147 151360140 CVCL_B0YG Abcam HEK293 JUN KO transformed cell line human CVCL_B0YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6204; JUN Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151360141 CVCL_B0YF Abcam HEK293 SDHB KO transformed cell line human CVCL_B0YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10681; SDHB Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151360142 CVCL_B0XX XF11.1D8 hybridoma house mouse CVCL_B0XX CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3030 151360143 CVCL_B0Y9 XF27/28.36F11 hybridoma house mouse CVCL_B0Y9 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4053 151360144 CVCL_B0XW AAVpro 293T transformed cell line human CVCL_B0XW CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151360145 CVCL_B0Y8 XF27/28.36A12 hybridoma house mouse CVCL_B0Y8 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4052 151360146 CVCL_B0XZ XF11.1G8 hybridoma house mouse CVCL_B0XZ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3027 151360147 CVCL_B0XY XF11.1F8 hybridoma house mouse CVCL_B0XY CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3150 151360148 CVCL_B0Y1 XF11.4D10 hybridoma house mouse CVCL_B0Y1 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3026 151360149 CVCL_B0Y0 XF11.4C4 hybridoma house mouse CVCL_B0Y0 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3028 151360150 CVCL_B0Y3 XF22.3C9.6 hybridoma house mouse CVCL_B0Y3 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3702 151360151 CVCL_B0Y2 XF11.5H1 hybridoma house mouse CVCL_B0Y2 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3029 151360152 CVCL_B0XT Abcam HEK293T SIGMAR1 KO transformed cell line human CVCL_B0XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8157; SIGMAR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 151360153 CVCL_B0Y5 XF27/28.7D5 hybridoma house mouse CVCL_B0Y5 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4049 151360154 CVCL_B0Y4 XF22.9E6 hybridoma house mouse CVCL_B0Y4 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3859 151360155 CVCL_B0XV Abcam HeLa SORT1 KO cancer cell line human CVCL_B0XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11186; SORT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360156 CVCL_B0Y7 XF27/28.25G10 hybridoma house mouse CVCL_B0Y7 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4051 151360157 CVCL_B0XU HeLa SIGMAR1 KO cancer cell line human CVCL_B0XU From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8157; SIGMAR1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360158 CVCL_B0Y6 XF27/28.18B5 hybridoma house mouse CVCL_B0Y6 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4050 151360159 CVCL_B2CI Abcam HeLa PSME4 KO cancer cell line human CVCL_B2CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20635; PSME4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360160 CVCL_B2CH Abcam HeLa PSMD5 KO cancer cell line human CVCL_B2CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9563; PSMD5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360161 CVCL_B2CK Abcam HeLa PTBP1 KO cancer cell line human CVCL_B2CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9583; PTBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360162 CVCL_B2CJ Abcam HeLa PSRC1 KO cancer cell line human CVCL_B2CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24472; PSRC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360163 CVCL_B2CM Abcam HeLa PTGER3 KO cancer cell line human CVCL_B2CM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9595; PTGER3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360164 CVCL_B2CL Abcam HeLa PTEN KO cancer cell line human CVCL_B2CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360165 CVCL_B2D0 Abcam HeLa RAB20 KO cancer cell line human CVCL_B2D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18260; RAB20 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360166 CVCL_B2CN Abcam HeLa PTGFRN KO cancer cell line human CVCL_B2CN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9601; PTGFRN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360167 CVCL_B2CA Abcam HeLa PRSS23 KO cancer cell line human CVCL_B2CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14370; PRSS23 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360168 CVCL_B2CC Abcam HeLa PSCA KO cancer cell line human CVCL_B2CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9500; PSCA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360169 CVCL_B2CB Abcam HeLa PSAP KO cancer cell line human CVCL_B2CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9498; PSAP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360170 CVCL_B2CE Abcam HeLa PSKH1 KO cancer cell line human CVCL_B2CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9529; PSKH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360171 CVCL_B2CD Abcam HeLa PSENEN KO cancer cell line human CVCL_B2CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30100; PSENEN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265826; true Female 151360172 CVCL_B2CG Abcam HeLa PSMD10 KO cancer cell line human CVCL_B2CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9555; PSMD10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360173 CVCL_B2CF Abcam HeLa PSMB10 KO cancer cell line human CVCL_B2CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9538; PSMB10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360174 CVCL_B2BX Abcam HeLa PPP1R3C KO cancer cell line human CVCL_B2BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9293; PPP1R3C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360175 CVCL_B2C9 Abcam HeLa PRSS21 KO cancer cell line human CVCL_B2C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9485; PRSS21 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360176 CVCL_B2BW Abcam HeLa PPP1R26 KO cancer cell line human CVCL_B2BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29089; PPP1R26 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360177 CVCL_B2C8 Abcam HeLa PRRT2 KO cancer cell line human CVCL_B2C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30500; PRRT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360178 CVCL_B2BZ Abcam HeLa PPP3CA KO cancer cell line human CVCL_B2BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9314; PPP3CA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360179 CVCL_B2BY Abcam HeLa PPP2R5E KO cancer cell line human CVCL_B2BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9313; PPP2R5E Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360180 CVCL_B2BP Abcam HeLa PPID KO cancer cell line human CVCL_B2BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9257; PPID Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360181 CVCL_B2C1 Abcam HeLa PRAP1 KO cancer cell line human CVCL_B2C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23304; PRAP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360182 CVCL_B2C0 Abcam HeLa PPP4R3B KO cancer cell line human CVCL_B2C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29267; PPP4R3B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360183 CVCL_B2BR Abcam HeLa PPM1H KO cancer cell line human CVCL_B2BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18583; PPM1H Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360184 CVCL_B2C3 Abcam HeLa PRKAR1B KO cancer cell line human CVCL_B2C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9390; PRKAR1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360185 CVCL_B2BQ Abcam HeLa PPM1A KO cancer cell line human CVCL_B2BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9275; PPM1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360186 CVCL_B2C2 Abcam HeLa PRKACB KO cancer cell line human CVCL_B2C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9381; PRKACB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360187 CVCL_B2BT Abcam HeLa PPP1R13L KO cancer cell line human CVCL_B2BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18838; PPP1R13L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360188 CVCL_B2C5 Abcam HeLa PRKCD KO cancer cell line human CVCL_B2C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9399; PRKCD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360189 CVCL_B2BS Abcam HeLa PPP1CC KO cancer cell line human CVCL_B2BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9283; PPP1CC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360190 CVCL_B2C4 Abcam HeLa PRKAR2A KO cancer cell line human CVCL_B2C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9391; PRKAR2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360191 CVCL_B2BV Abcam HeLa PPP1R2 KO cancer cell line human CVCL_B2BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9288; PPP1R2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360192 CVCL_B2C7 Abcam HeLa PRKD3 KO cancer cell line human CVCL_B2C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9408; PRKD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360193 CVCL_B2BU Abcam HeLa PPP1R15B KO cancer cell line human CVCL_B2BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14951; PPP1R15B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360194 CVCL_B2C6 Abcam HeLa PRKCI KO cancer cell line human CVCL_B2C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9404; PRKCI Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360195 CVCL_B2DJ Abcam HeLa RBPMS KO cancer cell line human CVCL_B2DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19097; RBPMS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360196 CVCL_B2DI Abcam HeLa RBL1 KO cancer cell line human CVCL_B2DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9893; RBL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360197 CVCL_B2DL Abcam HeLa RELA KO cancer cell line human CVCL_B2DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360198 CVCL_B2DK Abcam HeLa RCHY1 KO cancer cell line human CVCL_B2DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17479; RCHY1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360199 CVCL_B2DN Abcam HeLa REXO4 KO cancer cell line human CVCL_B2DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12820; REXO4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360200 CVCL_B2DM Abcam HeLa RELB KO cancer cell line human CVCL_B2DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9956; RELB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360201 CVCL_B2DP Abcam HeLa RFWD3 KO cancer cell line human CVCL_B2DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25539; RFWD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360202 CVCL_B2E1 Abcam HeLa ROCK2 KO cancer cell line human CVCL_B2E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360203 CVCL_B2E0 Abcam HeLa RNF41 KO cancer cell line human CVCL_B2E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18401; RNF41 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360204 CVCL_B2DB Abcam HeLa RALBP1 KO cancer cell line human CVCL_B2DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9841; RALBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360205 CVCL_B2DA Abcam HeLa RALA KO cancer cell line human CVCL_B2DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9839; RALA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360206 CVCL_B2DD Abcam HeLa RANBP2 KO cancer cell line human CVCL_B2DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9848; RANBP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360207 CVCL_B2DC Abcam HeLa RANBP10 KO cancer cell line human CVCL_B2DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29285; RANBP10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360208 CVCL_B2DF Abcam HeLa RARA KO cancer cell line human CVCL_B2DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9864; RARA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360209 CVCL_B2DE Abcam HeLa RAP1GDS1 KO cancer cell line human CVCL_B2DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9859; RAP1GDS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360210 CVCL_B2DH Abcam HeLa RBBP7 KO cancer cell line human CVCL_B2DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9890; RBBP7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360211 CVCL_B2DG Abcam HeLa RAVER1 KO cancer cell line human CVCL_B2DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30296; RAVER1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360212 CVCL_B2CY Abcam HeLa QRICH1 KO cancer cell line human CVCL_B2CY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24713; QRICH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360213 CVCL_B2CX Abcam HeLa PXN KO cancer cell line human CVCL_B2CX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9718; PXN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360214 CVCL_B2D9 Abcam HeLa RAF1 KO cancer cell line human CVCL_B2D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360215 CVCL_B2CZ Abcam HeLa QTRT1 KO cancer cell line human CVCL_B2CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23797; QTRT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360216 CVCL_B2CQ Abcam HeLa PTGS2 KO cancer cell line human CVCL_B2CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9605; PTGS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360217 CVCL_B2D2 Abcam HeLa RAB31 KO cancer cell line human CVCL_B2D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9771; RAB31 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360218 CVCL_B2CP Abcam HeLa PTGR1 KO cancer cell line human CVCL_B2CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18429; PTGR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360219 CVCL_B2D1 Abcam HeLa RAB27A KO cancer cell line human CVCL_B2D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9766; RAB27A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360220 CVCL_B2CS Abcam HeLa PTPN13 KO cancer cell line human CVCL_B2CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9646; PTPN13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360221 CVCL_B2D4 Abcam HeLa RAB7A KO cancer cell line human CVCL_B2D4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9788; RAB7A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360222 CVCL_B2CR Abcam HeLa PTPN1 KO cancer cell line human CVCL_B2CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9642; PTPN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360223 CVCL_B2D3 Abcam HeLa RAB35 KO cancer cell line human CVCL_B2D3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9774; RAB35 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360224 CVCL_B2CU Abcam HeLa PTS KO cancer cell line human CVCL_B2CU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9689; PTS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360225 CVCL_B2D6 Abcam HeLa RAB9A KO cancer cell line human CVCL_B2D6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9792; RAB9A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360226 CVCL_B2CT Abcam HeLa PTPRS KO cancer cell line human CVCL_B2CT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9681; PTPRS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360227 CVCL_B2D5 Abcam HeLa RAB8A KO cancer cell line human CVCL_B2D5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360228 CVCL_B2CW Abcam HeLa PUS7 KO cancer cell line human CVCL_B2CW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26033; PUS7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360229 CVCL_B2D8 Abcam HeLa RAD1 KO cancer cell line human CVCL_B2D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9806; RAD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360230 CVCL_B2CV Abcam HeLa PUM1 KO cancer cell line human CVCL_B2CV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14957; PUM1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360231 CVCL_B2D7 Abcam HeLa RABAC1 KO cancer cell line human CVCL_B2D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9794; RABAC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360232 CVCL_B2AG Abcam HeLa PERP KO cancer cell line human CVCL_B2AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17637; PERP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360233 CVCL_B2AF Abcam HeLa PEG10 KO cancer cell line human CVCL_B2AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14005; PEG10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360234 CVCL_B2AI Abcam HeLa PGAM5 KO cancer cell line human CVCL_B2AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28763; PGAM5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360235 CVCL_B2AH Abcam HeLa PFKP KO cancer cell line human CVCL_B2AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8878; PFKP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360236 CVCL_B2AK Abcam HeLa PHF6 KO cancer cell line human CVCL_B2AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360237 CVCL_B2AJ Abcam HeLa PGR KO cancer cell line human CVCL_B2AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8910; PGR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360238 CVCL_B2AM Abcam HeLa PHLDA3 KO cancer cell line human CVCL_B2AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8934; PHLDA3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360239 CVCL_B2AL Abcam HeLa PHIP KO cancer cell line human CVCL_B2AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15673; PHIP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360240 CVCL_B2AA Abcam HeLa PDGFD KO cancer cell line human CVCL_B2AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30620; PDGFD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265304; true Female 151360241 CVCL_B2AC Abcam HeLa PDHA1 KO cancer cell line human CVCL_B2AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8806; PDHA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360242 CVCL_B2AB Abcam HeLa PDGFRA KO cancer cell line human CVCL_B2AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261827; true Female 151360243 CVCL_B2AE Abcam HeLa PDK4 KO cancer cell line human CVCL_B2AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8812; PDK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360244 CVCL_B2AD Abcam HeLa PDIA5 KO cancer cell line human CVCL_B2AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24811; PDIA5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360245 CVCL_B2A7 Abcam HeLa PDE3B KO cancer cell line human CVCL_B2A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8779; PDE3B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360246 CVCL_B2A6 Abcam HeLa PDCD4 KO cancer cell line human CVCL_B2A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8763; PDCD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360247 CVCL_B2A9 Abcam HeLa PDGFC KO cancer cell line human CVCL_B2A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8801; PDGFC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360248 CVCL_B2A8 Abcam HeLa PDE4B KO cancer cell line human CVCL_B2A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8781; PDE4B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360249 CVCL_B2A1 Abcam HeLa PATL1 KO cancer cell line human CVCL_B2A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26721; PATL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360250 CVCL_B2A0 Abcam HeLa PARP3 KO cancer cell line human CVCL_B2A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360251 CVCL_B2A3 Abcam HeLa PCOLCE2 KO cancer cell line human CVCL_B2A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8739; PCOLCE2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360252 CVCL_B2A2 Abcam HeLa PCNT KO cancer cell line human CVCL_B2A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16068; PCNT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360253 CVCL_B2A5 Abcam HeLa PDCD10 KO cancer cell line human CVCL_B2A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8761; PDCD10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360254 CVCL_B2A4 Abcam HeLa PDCD1 KO cancer cell line human CVCL_B2A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8760; PDCD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360255 CVCL_B2BH Abcam HeLa POLM KO cancer cell line human CVCL_B2BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9185; POLM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360256 CVCL_B2BG Abcam HeLa POLL KO cancer cell line human CVCL_B2BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9184; POLL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360257 CVCL_B2BJ Abcam HeLa PON2 KO cancer cell line human CVCL_B2BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9205; PON2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360258 CVCL_B2BI Abcam HeLa POLR1D KO cancer cell line human CVCL_B2BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20422; POLR1D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360259 CVCL_B2BL Abcam HeLa PORCN KO cancer cell line human CVCL_B2BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17652; PORCN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360260 CVCL_B2BK Abcam HeLa POR KO cancer cell line human CVCL_B2BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9208; POR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360261 CVCL_B2BN Abcam HeLa PPIB KO cancer cell line human CVCL_B2BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9255; PPIB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360262 CVCL_B2BM Abcam HeLa POSTN KO cancer cell line human CVCL_B2BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16953; POSTN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360263 CVCL_B2BB Abcam HeLa PODXL KO cancer cell line human CVCL_B2BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360264 CVCL_B2BA Abcam HeLa PNKD KO cancer cell line human CVCL_B2BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9153; PNKD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360265 CVCL_B2BD Abcam HeLa POLB KO cancer cell line human CVCL_B2BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9174; POLB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261748; true Female 151360266 CVCL_B2BC Abcam HeLa POGK KO cancer cell line human CVCL_B2BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18800; POGK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360267 CVCL_B2BF Abcam HeLa POLE4 KO cancer cell line human CVCL_B2BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18755; POLE4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360268 CVCL_B2BE Abcam HeLa POLDIP3 KO cancer cell line human CVCL_B2BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23782; POLDIP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360269 CVCL_B2AW Abcam HeLa PITPNB KO cancer cell line human CVCL_B2AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9002; PITPNB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360270 CVCL_B2B8 Abcam HeLa PML KO cancer cell line human CVCL_B2B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360271 CVCL_B2AV Abcam HeLa PIP5K1C KO cancer cell line human CVCL_B2AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8996; PIP5K1C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360272 CVCL_B2B7 Abcam HeLa PLK2 KO cancer cell line human CVCL_B2B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360273 CVCL_B2AY Abcam HeLa PKN2 KO cancer cell line human CVCL_B2AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9406; PKN2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360274 CVCL_B2AX Abcam HeLa PKDCC KO cancer cell line human CVCL_B2AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25123; PKDCC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360275 CVCL_B2B9 Abcam HeLa PMS2 KO cancer cell line human CVCL_B2B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9122; PMS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360276 CVCL_B2AZ Abcam HeLa PKP3 KO cancer cell line human CVCL_B2AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9025; PKP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360277 CVCL_B2B0 Abcam HeLa PLA2G12A KO cancer cell line human CVCL_B2B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18554; PLA2G12A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360278 CVCL_B2AN Abcam HeLa PI4K2A KO cancer cell line human CVCL_B2AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30031; PI4K2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360279 CVCL_B2AQ Abcam HeLa PICALM KO cancer cell line human CVCL_B2AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15514; PICALM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360280 CVCL_B2B2 Abcam HeLa PLA2G4A KO cancer cell line human CVCL_B2B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360281 CVCL_B2AP Abcam HeLa PI4K2B KO cancer cell line human CVCL_B2AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18215; PI4K2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360282 CVCL_B2B1 Abcam HeLa PLA2G15 KO cancer cell line human CVCL_B2B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17163; PLA2G15 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360283 CVCL_B2AS Abcam HeLa PIK3R1 KO cancer cell line human CVCL_B2AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360284 CVCL_B2B4 Abcam HeLa PLCB1 KO cancer cell line human CVCL_B2B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15917; PLCB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360285 CVCL_B2AR Abcam HeLa PIK3C2A KO cancer cell line human CVCL_B2AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8971; PIK3C2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360286 CVCL_B2B3 Abcam HeLa PLAA KO cancer cell line human CVCL_B2B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9043; PLAA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360287 CVCL_B2AU Abcam HeLa PIP4K2C KO cancer cell line human CVCL_B2AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23786; PIP4K2C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360288 CVCL_B2B6 Abcam HeLa PLD2 KO cancer cell line human CVCL_B2B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9068; PLD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360289 CVCL_B2AT Abcam HeLa PIP4K2A KO cancer cell line human CVCL_B2AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8997; PIP4K2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360290 CVCL_B2B5 Abcam HeLa PLCB3 KO cancer cell line human CVCL_B2B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360291 CVCL_B2KQ Abcam HeLa USP54 KO cancer cell line human CVCL_B2KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23513; USP54 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360292 CVCL_B2L2 Abcam HeLa VIM KO cancer cell line human CVCL_B2L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12692; VIM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360293 CVCL_B2KP Abcam HeLa USP42 KO cancer cell line human CVCL_B2KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20068; USP42 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360294 CVCL_B2L1 Abcam HeLa VEGFA KO cancer cell line human CVCL_B2L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12680; VEGFA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab255445; true Female 151360295 CVCL_B2KS Abcam HeLa USP9X KO cancer cell line human CVCL_B2KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12632; USP9X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360296 CVCL_B2L4 Abcam HeLa VOPP1 KO cancer cell line human CVCL_B2L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34518; VOPP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360297 CVCL_B2KR Abcam HeLa USP8 KO cancer cell line human CVCL_B2KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360298 CVCL_B2L3 Abcam HeLa VKORC1 KO cancer cell line human CVCL_B2L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23663; VKORC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360299 CVCL_B2KU Abcam HeLa VASP KO cancer cell line human CVCL_B2KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12652; VASP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360300 CVCL_B2L6 Abcam HeLa VRK3 KO cancer cell line human CVCL_B2L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18996; VRK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360301 CVCL_B2KT Abcam HeLa VAC14 KO cancer cell line human CVCL_B2KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25507; VAC14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360302 CVCL_B2L5 Abcam HeLa VRK2 KO cancer cell line human CVCL_B2L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12719; VRK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360303 CVCL_B2KW Abcam HeLa VAV2 KO cancer cell line human CVCL_B2KW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12658; VAV2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360304 CVCL_B2L8 Abcam HeLa WASF2 KO cancer cell line human CVCL_B2L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12733; WASF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360305 CVCL_B2KV Abcam HeLa VAV1 KO cancer cell line human CVCL_B2KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12657; VAV1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265196; true Female 151360306 CVCL_B2L7 Abcam HeLa VTI1B KO cancer cell line human CVCL_B2L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17793; VTI1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360307 CVCL_B2KI Abcam HeLa USP14 KO cancer cell line human CVCL_B2KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12612; USP14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360308 CVCL_B2KH Abcam HeLa USP1 KO cancer cell line human CVCL_B2KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12607; USP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360309 CVCL_B2KK Abcam HeLa USP22 KO cancer cell line human CVCL_B2KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12621; USP22 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360310 CVCL_B2KJ Abcam HeLa USP18 KO cancer cell line human CVCL_B2KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12616; USP18 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265458; true Female 151360311 CVCL_B2KM Abcam HeLa USP40 KO 1 cancer cell line human CVCL_B2KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20069; USP40 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360312 CVCL_B2KL Abcam HeLa USP34 KO cancer cell line human CVCL_B2KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20066; USP34 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360313 CVCL_B2L0 Abcam HeLa VDR KO cancer cell line human CVCL_B2L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12679; VDR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360314 CVCL_B2KN Abcam HeLa USP40 KO 2 cancer cell line human CVCL_B2KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20069; USP40 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360315 CVCL_B2KA Abcam HeLa UBE3B KO 2 cancer cell line human CVCL_B2KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13478; UBE3B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360316 CVCL_B2KC Abcam HeLa UBXN4 KO cancer cell line human CVCL_B2KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14860; UBXN4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360317 CVCL_B2KB Abcam HeLa UBQLN1 KO cancer cell line human CVCL_B2KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12508; UBQLN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360318 CVCL_B2KE Abcam HeLa UHMK1 KO cancer cell line human CVCL_B2KE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19683; UHMK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360319 CVCL_B2KD Abcam HeLa UGCG KO cancer cell line human CVCL_B2KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12524; UGCG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265916; true Female 151360320 CVCL_B2KG Abcam HeLa USB1 KO cancer cell line human CVCL_B2KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25792; USB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360321 CVCL_B2KF Abcam HeLa UNG KO cancer cell line human CVCL_B2KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12572; UNG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360322 CVCL_B2JX Abcam HeLa TTC3 KO cancer cell line human CVCL_B2JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12393; TTC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360323 CVCL_B2K9 Abcam HeLa UBE3B KO 1 cancer cell line human CVCL_B2K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13478; UBE3B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360324 CVCL_B2JW Abcam HeLa TSSK4 KO cancer cell line human CVCL_B2JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19825; TSSK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360325 CVCL_B2K8 Abcam HeLa UBE2O KO cancer cell line human CVCL_B2K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29554; UBE2O Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360326 CVCL_B2JZ Abcam HeLa TWF1 KO cancer cell line human CVCL_B2JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9620; TWF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360327 CVCL_B2JY Abcam HeLa TUBB3 KO cancer cell line human CVCL_B2JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20772; TUBB3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360328 CVCL_B2M3 Abcam A-549 APOL6 KO 1 cancer cell line human CVCL_B2M3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14870; APOL6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360329 CVCL_B2LR Abcam HeLa ZMAT3 KO cancer cell line human CVCL_B2LR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29983; ZMAT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360330 CVCL_B2M2 Abcam A-549 APOL2 KO 1 cancer cell line human CVCL_B2M2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 619; APOL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360331 CVCL_B2LQ Abcam HeLa ZDHHC7 KO cancer cell line human CVCL_B2LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18459; ZDHHC7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360332 CVCL_B2M5 Abcam A-549 ATM KO cancer cell line human CVCL_B2M5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360333 CVCL_B2LT Abcam HeLa ZMYM3 KO cancer cell line human CVCL_B2LT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13054; ZMYM3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360334 CVCL_B2M4 Abcam A-549 ARRDC3 KO cancer cell line human CVCL_B2M4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29263; ARRDC3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360335 CVCL_B2LS Abcam HeLa ZMPSTE24 KO cancer cell line human CVCL_B2LS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12877; ZMPSTE24 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360336 CVCL_B2M7 Abcam A-549 BATF2 KO 2 cancer cell line human CVCL_B2M7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25163; BATF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360337 CVCL_B2LV Abcam HeLa ZNF609 KO cancer cell line human CVCL_B2LV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29003; ZNF609 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360338 CVCL_B2M6 Abcam A-549 ATR KO cancer cell line human CVCL_B2M6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 882; ATR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360339 CVCL_B2LU Abcam HeLa ZNF326 KO cancer cell line human CVCL_B2LU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14104; ZNF326 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360340 CVCL_B2M9 Abcam A-549 CBR1 KO cancer cell line human CVCL_B2M9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1548; CBR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360341 CVCL_B2LX Abcam HeLa ZNF692 KO cancer cell line human CVCL_B2LX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26049; ZNF692 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360342 CVCL_B2M8 Abcam A-549 BSG KO cancer cell line human CVCL_B2M8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1116; BSG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360343 CVCL_B2LW Abcam HeLa ZNF622 KO cancer cell line human CVCL_B2LW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30958; ZNF622 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360344 CVCL_B2LJ Abcam HeLa WWC2 KO cancer cell line human CVCL_B2LJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24148; WWC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360345 CVCL_B2LI Abcam HeLa WSB2 KO cancer cell line human CVCL_B2LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19222; WSB2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360346 CVCL_B2LL Abcam HeLa YY1AP1 KO cancer cell line human CVCL_B2LL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30935; YY1AP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360347 CVCL_B2LK Abcam HeLa YES1 KO cancer cell line human CVCL_B2LK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12841; YES1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360348 CVCL_B2LN Abcam HeLa ZCCHC17 KO cancer cell line human CVCL_B2LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30246; ZCCHC17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360349 CVCL_B2LM Abcam HeLa ZAP70 KO cancer cell line human CVCL_B2LM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12858; ZAP70 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265522; true Female 151360350 CVCL_B2M1 Abcam A-549 ALDH1A1 KO cancer cell line human CVCL_B2M1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 402; ALDH1A1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360351 CVCL_B2LP Abcam HeLa ZDHHC6 KO cancer cell line human CVCL_B2LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19160; ZDHHC6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360352 CVCL_B2M0 Abcam A-549 ABCC2 KO cancer cell line human CVCL_B2M0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 53; ABCC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 151360353 CVCL_B2LB Abcam HeLa WDR4 KO cancer cell line human CVCL_B2LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12756; WDR4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360354 CVCL_B2LA Abcam HeLa WDR13 KO cancer cell line human CVCL_B2LA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14352; WDR13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360355 CVCL_B2LD Abcam HeLa WDR45 KO cancer cell line human CVCL_B2LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28912; WDR45 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360356 CVCL_B2LC Abcam HeLa WDR41 KO cancer cell line human CVCL_B2LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25601; WDR41 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360357 CVCL_B2LF Abcam HeLa WDR6 KO cancer cell line human CVCL_B2LF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12758; WDR6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360358 CVCL_B2LE Abcam HeLa WDR59 KO cancer cell line human CVCL_B2LE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25706; WDR59 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360359 CVCL_B2LH Abcam HeLa WRNIP1 KO cancer cell line human CVCL_B2LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20876; WRNIP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360360 CVCL_B2LG Abcam HeLa WNT5A KO cancer cell line human CVCL_B2LG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12784; WNT5A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360361 CVCL_B2KY Abcam HeLa VCL KO cancer cell line human CVCL_B2KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12665; VCL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360362 CVCL_B2KX Abcam HeLa VAV3 KO cancer cell line human CVCL_B2KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12659; VAV3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360363 CVCL_B2L9 Abcam HeLa WBP2 KO cancer cell line human CVCL_B2L9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12738; WBP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360364 CVCL_B2KZ Abcam HeLa VCPIP1 KO cancer cell line human CVCL_B2KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30897; VCPIP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360365 CVCL_B2J0 Abcam HeLa TNFAIP3 KO cancer cell line human CVCL_B2J0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11896; TNFAIP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360366 CVCL_B2IN Abcam HeLa TLK1 KO cancer cell line human CVCL_B2IN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11841; TLK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360367 CVCL_B2IQ Abcam HeLa TM9SF4 KO cancer cell line human CVCL_B2IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30797; TM9SF4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360368 CVCL_B2J2 Abcam HeLa TNFRSF10B KO cancer cell line human CVCL_B2J2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11905; TNFRSF10B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360369 CVCL_B2IP Abcam HeLa TM4SF1 KO cancer cell line human CVCL_B2IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11853; TM4SF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360370 CVCL_B2J1 Abcam HeLa TNFRSF10A KO cancer cell line human CVCL_B2J1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11904; TNFRSF10A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360371 CVCL_B2IS Abcam HeLa TMEM175 KO cancer cell line human CVCL_B2IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28709; TMEM175 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360372 CVCL_B2J4 Abcam HeLa TNFRSF8 KO cancer cell line human CVCL_B2J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11923; TNFRSF8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265460; true Female 151360373 CVCL_B2IR Abcam HeLa TMEM126A KO cancer cell line human CVCL_B2IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25382; TMEM126A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360374 CVCL_B2J3 Abcam HeLa TNFRSF1A KO cancer cell line human CVCL_B2J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11916; TNFRSF1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360375 CVCL_B2IU Abcam HeLa TMEM69 KO cancer cell line human CVCL_B2IU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28035; TMEM69 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360376 CVCL_B2J6 Abcam HeLa TNIP1 KO cancer cell line human CVCL_B2J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16903; TNIP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360377 CVCL_B2IT Abcam HeLa TMEM30A KO cancer cell line human CVCL_B2IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16667; TMEM30A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360378 CVCL_B2J5 Abcam HeLa TNFSF10 KO cancer cell line human CVCL_B2J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11925; TNFSF10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360379 CVCL_B2IG Abcam HeLa TGM2 KO cancer cell line human CVCL_B2IG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11778; TGM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360380 CVCL_B2IF Abcam HeLa TGFB1 KO cancer cell line human CVCL_B2IF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11766; TGFB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360381 CVCL_B2II Abcam HeLa THOC3 KO cancer cell line human CVCL_B2II CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19072; THOC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360382 CVCL_B2IH Abcam HeLa THAP7 KO cancer cell line human CVCL_B2IH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23190; THAP7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360383 CVCL_B2IK Abcam HeLa TIAL1 KO cancer cell line human CVCL_B2IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11804; TIAL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360384 CVCL_B2IJ Abcam HeLa THY1 KO cancer cell line human CVCL_B2IJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11801; THY1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360385 CVCL_B2IM Abcam HeLa TLE1 KO cancer cell line human CVCL_B2IM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360386 CVCL_B2IL Abcam HeLa TJP1 KO cancer cell line human CVCL_B2IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11827; TJP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360387 CVCL_B2IA Abcam HeLa TCF7 KO cancer cell line human CVCL_B2IA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11639; TCF7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360388 CVCL_B2IC Abcam HeLa TFAP2A KO cancer cell line human CVCL_B2IC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11742; TFAP2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360389 CVCL_B2IB Abcam HeLa TDP2 KO cancer cell line human CVCL_B2IB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17768; TDP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360390 CVCL_B2IE Abcam HeLa TFG KO cancer cell line human CVCL_B2IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11758; TFG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360391 CVCL_B2ID Abcam HeLa TFAP4 KO cancer cell line human CVCL_B2ID CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11745; TFAP4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360392 CVCL_B2HV Abcam HeLa SUGP2 KO cancer cell line human CVCL_B2HV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18641; SUGP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360393 CVCL_B2I7 Abcam HeLa TBC1D7 KO cancer cell line human CVCL_B2I7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21066; TBC1D7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360394 CVCL_B2HU Abcam HeLa STX17 KO cancer cell line human CVCL_B2HU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11432; STX17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360395 CVCL_B2I6 Abcam HeLa TAP2 KO cancer cell line human CVCL_B2I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 44; TAP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360396 CVCL_B2HX Abcam HeLa SURF6 KO cancer cell line human CVCL_B2HX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11478; SURF6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360397 CVCL_B2I9 Abcam HeLa TBL1X KO cancer cell line human CVCL_B2I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11585; TBL1X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264717; true Female 151360398 CVCL_B2HW Abcam HeLa SUGT1 KO cancer cell line human CVCL_B2HW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16987; SUGT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360399 CVCL_B2I8 Abcam HeLa TBKBP1 KO cancer cell line human CVCL_B2I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30140; TBKBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360400 CVCL_B2HZ Abcam HeLa SYNJ1 KO cancer cell line human CVCL_B2HZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11503; SYNJ1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360401 CVCL_B2HY Abcam HeLa SUZ12 KO cancer cell line human CVCL_B2HY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360402 CVCL_B2JP Abcam HeLa TRIM29 KO cancer cell line human CVCL_B2JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17274; TRIM29 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360403 CVCL_B2K1 Abcam HeLa TXNDC9 KO cancer cell line human CVCL_B2K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24110; TXNDC9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360404 CVCL_B2K0 Abcam HeLa TXLNA KO cancer cell line human CVCL_B2K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30685; TXLNA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360405 CVCL_B2JR Abcam HeLa TRMT2A KO cancer cell line human CVCL_B2JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360406 CVCL_B2K3 Abcam HeLa UBE2D4 KO cancer cell line human CVCL_B2K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21647; UBE2D4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360407 CVCL_B2JQ Abcam HeLa TRIM7 KO cancer cell line human CVCL_B2JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16278; TRIM7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360408 CVCL_B2K2 Abcam HeLa TYMP KO cancer cell line human CVCL_B2K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3148; TYMP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360409 CVCL_B2JT Abcam HeLa TSC22D4 KO cancer cell line human CVCL_B2JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21696; TSC22D4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360410 CVCL_B2K5 Abcam HeLa UBE2H KO cancer cell line human CVCL_B2K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12484; UBE2H Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360411 CVCL_B2JS Abcam HeLa TRPM7 KO cancer cell line human CVCL_B2JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17994; TRPM7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360412 CVCL_B2K4 Abcam HeLa UBE2F KO cancer cell line human CVCL_B2K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12480; UBE2F Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360413 CVCL_B2JV Abcam HeLa TSSK3 KO cancer cell line human CVCL_B2JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15473; TSSK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360414 CVCL_B2K7 Abcam HeLa UBE2K KO cancer cell line human CVCL_B2K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4914; UBE2K Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360415 CVCL_B2JU Abcam HeLa TSPO KO cancer cell line human CVCL_B2JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1158; TSPO Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360416 CVCL_B2K6 Abcam HeLa UBE2J1 KO cancer cell line human CVCL_B2K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17598; UBE2J1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360417 CVCL_B2JH Abcam HeLa TRAF5 KO cancer cell line human CVCL_B2JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12035; TRAF5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360418 CVCL_B2JG Abcam HeLa TRAF3 KO cancer cell line human CVCL_B2JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12033; TRAF3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265101; true Female 151360419 CVCL_B2JJ Abcam HeLa TRAF7 KO cancer cell line human CVCL_B2JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20456; TRAF7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264998; true Female 151360420 CVCL_B2JI Abcam HeLa TRAF6 KO cancer cell line human CVCL_B2JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12036; TRAF6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360421 CVCL_B2JL Abcam HeLa TRIB3 KO cancer cell line human CVCL_B2JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16228; TRIB3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360422 CVCL_B2JK Abcam HeLa TREX1 KO cancer cell line human CVCL_B2JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12269; TREX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360423 CVCL_B2JN Abcam HeLa TRIM24 KO cancer cell line human CVCL_B2JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11812; TRIM24 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360424 CVCL_B2JM Abcam HeLa TRIM16 KO cancer cell line human CVCL_B2JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17241; TRIM16 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360425 CVCL_B2JB Abcam HeLa TOMM70A KO cancer cell line human CVCL_B2JB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11985; TOMM70 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360426 CVCL_B2JA Abcam HeLa TOMM34 KO cancer cell line human CVCL_B2JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15746; TOMM34 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360427 CVCL_B2JD Abcam HeLa TP53I3 KO cancer cell line human CVCL_B2JD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19373; TP53I3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360428 CVCL_B2JC Abcam HeLa TOR3A KO cancer cell line human CVCL_B2JC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11997; TOR3A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360429 CVCL_B2JF Abcam HeLa TPGS2 KO cancer cell line human CVCL_B2JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24561; TPGS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360430 CVCL_B2JE Abcam HeLa TPD52L1 KO cancer cell line human CVCL_B2JE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12006; TPD52L1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360431 CVCL_B2IW Abcam HeLa TMPRSS6 KO cancer cell line human CVCL_B2IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16517; TMPRSS6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360432 CVCL_B2J8 Abcam HeLa TNKS1BP1 KO cancer cell line human CVCL_B2J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19081; TNKS1BP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360433 CVCL_B2IV Abcam HeLa TMOD3 KO cancer cell line human CVCL_B2IV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11873; TMOD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360434 CVCL_B2J7 Abcam HeLa TNK1 KO cancer cell line human CVCL_B2J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11940; TNK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360435 CVCL_B2IY Abcam HeLa TMUB1 partial KO cancer cell line human CVCL_B2IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21709; TMUB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360436 CVCL_B2IX Abcam HeLa TMUB1 KO cancer cell line human CVCL_B2IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21709; TMUB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360437 CVCL_B2J9 Abcam HeLa TOB1 KO cancer cell line human CVCL_B2J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11979; TOB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360438 CVCL_B2IZ Abcam HeLa TNC KO cancer cell line human CVCL_B2IZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5318; TNC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360439 CVCL_B2GM Abcam HeLa SMARCC1 KO cancer cell line human CVCL_B2GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360440 CVCL_B2GL Abcam HeLa SMARCA2 KO cancer cell line human CVCL_B2GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11098; SMARCA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360441 CVCL_B2H0 Abcam HeLa SOAT1 KO cancer cell line human CVCL_B2H0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11177; SOAT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360442 CVCL_B2GN Abcam HeLa SMC1B KO cancer cell line human CVCL_B2GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11112; SMC1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360443 CVCL_B2GQ Abcam HeLa SMURF2 KO cancer cell line human CVCL_B2GQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16809; SMURF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360444 CVCL_B2H2 Abcam HeLa SOX17 KO cancer cell line human CVCL_B2H2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18122; SOX17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360445 CVCL_B2GP Abcam HeLa SMIM4 KO cancer cell line human CVCL_B2GP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37257; SMIM4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360446 CVCL_B2H1 Abcam HeLa SOCS4 KO cancer cell line human CVCL_B2H1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19392; SOCS4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360447 CVCL_B2GS Abcam HeLa SNAP29 KO cancer cell line human CVCL_B2GS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11133; SNAP29 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360448 CVCL_B2H4 Abcam HeLa SP100 KO cancer cell line human CVCL_B2H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11206; SP100 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360449 CVCL_B2GR Abcam HeLa SNAI1 KO cancer cell line human CVCL_B2GR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11128; SNAI1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360450 CVCL_B2H3 Abcam HeLa SP1 KO cancer cell line human CVCL_B2H3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11205; SP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360451 CVCL_B2GE Abcam HeLa SLC9A3R1 KO cancer cell line human CVCL_B2GE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11075; SLC9A3R1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360452 CVCL_B2GD Abcam HeLa SLC7A6 KO cancer cell line human CVCL_B2GD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11064; SLC7A6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360453 CVCL_B2GG Abcam HeLa SLPI KO cancer cell line human CVCL_B2GG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11092; SLPI Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360454 CVCL_B2GF Abcam HeLa SLCO4A1 KO cancer cell line human CVCL_B2GF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10953; SLCO4A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360455 CVCL_B2GI Abcam HeLa SMAD2 KO cancer cell line human CVCL_B2GI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6768; SMAD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360456 CVCL_B2GH Abcam HeLa SMAD1 KO cancer cell line human CVCL_B2GH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6767; SMAD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360457 CVCL_B2GK Abcam HeLa SMAD7 KO cancer cell line human CVCL_B2GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6773; SMAD7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360458 CVCL_B2GJ Abcam HeLa SMAD3 KO cancer cell line human CVCL_B2GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6769; SMAD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360459 CVCL_B2GA Abcam HeLa SLC44A1 KO cancer cell line human CVCL_B2GA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18798; SLC44A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360460 CVCL_B2GC Abcam HeLa SLC52A2 KO cancer cell line human CVCL_B2GC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30224; SLC52A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360461 CVCL_B2GB Abcam HeLa SLC50A1 KO cancer cell line human CVCL_B2GB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30657; SLC50A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360462 CVCL_B2FT Abcam HeLa SLC2A4 KO cancer cell line human CVCL_B2FT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11009; SLC2A4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360463 CVCL_B2G5 Abcam HeLa SLC39A1 KO cancer cell line human CVCL_B2G5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12876; SLC39A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360464 CVCL_B2FS Abcam HeLa SLC25A5 KO cancer cell line human CVCL_B2FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10991; SLC25A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360465 CVCL_B2G4 Abcam HeLa SLC38A9 KO cancer cell line human CVCL_B2G4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26907; SLC38A9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360466 CVCL_B2FV Abcam HeLa SLC30A1 KO cancer cell line human CVCL_B2FV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11012; SLC30A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360467 CVCL_B2G7 Abcam HeLa SLC39A9 KO cancer cell line human CVCL_B2G7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20182; SLC39A9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360468 CVCL_B2FU Abcam HeLa SLC2A8 KO cancer cell line human CVCL_B2FU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13812; SLC2A8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360469 CVCL_B2G6 Abcam HeLa SLC39A8 KO cancer cell line human CVCL_B2G6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20862; SLC39A8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360470 CVCL_B2FX Abcam HeLa SLC35A1 KO cancer cell line human CVCL_B2FX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11021; SLC35A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360471 CVCL_B2G9 Abcam HeLa SLC43A3 KO cancer cell line human CVCL_B2G9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17466; SLC43A3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360472 CVCL_B2FW Abcam HeLa SLC30A7 KO cancer cell line human CVCL_B2FW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19306; SLC30A7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360473 CVCL_B2G8 Abcam HeLa SLC3A2 KO cancer cell line human CVCL_B2G8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11026; SLC3A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360474 CVCL_B2FZ Abcam HeLa SLC35A5 KO cancer cell line human CVCL_B2FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20792; SLC35A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360475 CVCL_B2FY Abcam HeLa SLC35A2 KO cancer cell line human CVCL_B2FY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11022; SLC35A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360476 CVCL_B2HN Abcam HeLa STK17A KO cancer cell line human CVCL_B2HN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11395; STK17A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360477 CVCL_B2HM Abcam HeLa STK10 KO cancer cell line human CVCL_B2HM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11388; STK10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360478 CVCL_B2HP Abcam HeLa STK3 KO cancer cell line human CVCL_B2HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11406; STK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360479 CVCL_B2I1 Abcam HeLa TACC2 KO cancer cell line human CVCL_B2I1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11523; TACC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360480 CVCL_B2I0 Abcam HeLa SYNJ2 KO cancer cell line human CVCL_B2I0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11504; SYNJ2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360481 CVCL_B2HR Abcam HeLa STK4 KO cancer cell line human CVCL_B2HR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360482 CVCL_B2I3 Abcam HeLa TAF12 KO cancer cell line human CVCL_B2I3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11545; TAF12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360483 CVCL_B2HQ Abcam HeLa STK38L KO cancer cell line human CVCL_B2HQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17848; STK38L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360484 CVCL_B2I2 Abcam HeLa TAF11 KO cancer cell line human CVCL_B2I2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11544; TAF11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360485 CVCL_B2HT Abcam HeLa STS KO cancer cell line human CVCL_B2HT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11425; STS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360486 CVCL_B2I5 Abcam HeLa TAOK3 KO cancer cell line human CVCL_B2I5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18133; TAOK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360487 CVCL_B2HS Abcam HeLa STK40 KO cancer cell line human CVCL_B2HS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21373; STK40 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360488 CVCL_B2I4 Abcam HeLa TANK KO cancer cell line human CVCL_B2I4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360489 CVCL_B2HF Abcam HeLa STAG2 KO cancer cell line human CVCL_B2HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360490 CVCL_B2HE Abcam HeLa SSBP3 KO cancer cell line human CVCL_B2HE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15674; SSBP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360491 CVCL_B2HH Abcam HeLa STAR KO cancer cell line human CVCL_B2HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11359; STAR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360492 CVCL_B2HG Abcam HeLa STAMBP KO cancer cell line human CVCL_B2HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16950; STAMBP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360493 CVCL_B2HJ Abcam HeLa STAT2 KO cancer cell line human CVCL_B2HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360494 CVCL_B2HI Abcam HeLa STAT1 KO cancer cell line human CVCL_B2HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360495 CVCL_B2HL Abcam HeLa STAT5B KO cancer cell line human CVCL_B2HL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11367; STAT5B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360496 CVCL_B2HK Abcam HeLa STAT3 KO cancer cell line human CVCL_B2HK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360497 CVCL_B2HB Abcam HeLa SRD5A1 KO cancer cell line human CVCL_B2HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11284; SRD5A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360498 CVCL_B2HA Abcam HeLa SQLE KO cancer cell line human CVCL_B2HA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11279; SQLE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360499 CVCL_B2HD Abcam HeLa SS18 KO cancer cell line human CVCL_B2HD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11340; SS18 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360500 CVCL_B2HC Abcam HeLa SRGN KO cancer cell line human CVCL_B2HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9361; SRGN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360501 CVCL_B2GU Abcam HeLa SNCG KO cancer cell line human CVCL_B2GU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11141; SNCG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360502 CVCL_B2H6 Abcam HeLa SPG11 KO cancer cell line human CVCL_B2H6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11226; SPG11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360503 CVCL_B2GT Abcam HeLa SNAPIN KO cancer cell line human CVCL_B2GT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17145; SNAPIN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360504 CVCL_B2H5 Abcam HeLa SPCS3 KO cancer cell line human CVCL_B2H5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26212; SPCS3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360505 CVCL_B2GW Abcam HeLa SNRPB2 KO cancer cell line human CVCL_B2GW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11155; SNRPB2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360506 CVCL_B2H8 Abcam HeLa SPP1 KO cancer cell line human CVCL_B2H8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab255435; true Female 151360507 CVCL_B2GV Abcam HeLa SNRK KO cancer cell line human CVCL_B2GV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30598; SNRK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360508 CVCL_B2H7 Abcam HeLa SPOP KO cancer cell line human CVCL_B2H7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11254; SPOP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360509 CVCL_B2GY Abcam HeLa SNX17 KO cancer cell line human CVCL_B2GY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14979; SNX17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360510 CVCL_B2GX Abcam HeLa SNX12 KO cancer cell line human CVCL_B2GX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14976; SNX12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360511 CVCL_B2H9 Abcam HeLa SPR KO cancer cell line human CVCL_B2H9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11257; SPR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360512 CVCL_B2GZ Abcam HeLa SNX2 KO cancer cell line human CVCL_B2GZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11173; SNX2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360513 CVCL_B2EK Abcam HeLa S1PR1 KO cancer cell line human CVCL_B2EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3165; S1PR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360514 CVCL_B2EJ Abcam HeLa S100P KO cancer cell line human CVCL_B2EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10504; S100P Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360515 CVCL_B2EM Abcam HeLa SCAMP1 KO cancer cell line human CVCL_B2EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10563; SCAMP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360516 CVCL_B2EL Abcam HeLa SCAF11 KO cancer cell line human CVCL_B2EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10784; SCAF11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360517 CVCL_B2F0 Abcam HeLa SENP5 KO cancer cell line human CVCL_B2F0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28407; SENP5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360518 CVCL_B2EN Abcam HeLa SCAND1 KO cancer cell line human CVCL_B2EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10566; SCAND1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360519 CVCL_B2EQ Abcam HeLa SCD5 KO cancer cell line human CVCL_B2EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21088; SCD5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360520 CVCL_B2F2 Abcam HeLa SERTAD3 KO cancer cell line human CVCL_B2F2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17931; SERTAD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360521 CVCL_B2EP Abcam HeLa SCD KO cancer cell line human CVCL_B2EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10571; SCD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360522 CVCL_B2F1 Abcam HeLa SERPINB5 KO cancer cell line human CVCL_B2F1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8949; SERPINB5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360523 CVCL_B2EC Abcam HeLa RTN4RL2 KO cancer cell line human CVCL_B2EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23053; RTN4RL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360524 CVCL_B2EB Abcam HeLa RRP36 KO cancer cell line human CVCL_B2EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21374; RRP36 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360525 CVCL_B2EE Abcam HeLa RYK KO cancer cell line human CVCL_B2EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10481; RYK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360526 CVCL_B2ED Abcam HeLa RUNX1 KO cancer cell line human CVCL_B2ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10471; RUNX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360527 CVCL_B2EG Abcam HeLa S100A16 KO cancer cell line human CVCL_B2EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20441; S100A16 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360528 CVCL_B2EF Abcam HeLa S100A11 KO cancer cell line human CVCL_B2EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10488; S100A11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360529 CVCL_B2EI Abcam HeLa S100A8 KO cancer cell line human CVCL_B2EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10498; S100A8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265632; true Female 151360530 CVCL_B2EH Abcam HeLa S100A4 KO cancer cell line human CVCL_B2EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10494; S100A4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360531 CVCL_B2DZ Abcam HeLa RNF4 KO cancer cell line human CVCL_B2DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10067; RNF4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360532 CVCL_B2DY Abcam HeLa RNF2 KO cancer cell line human CVCL_B2DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360533 CVCL_B2EA Abcam HeLa RRM2B KO cancer cell line human CVCL_B2EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17296; RRM2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360534 CVCL_B2DR Abcam HeLa RHOT2 KO cancer cell line human CVCL_B2DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21169; RHOT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360535 CVCL_B2E3 Abcam HeLa RPL36A KO cancer cell line human CVCL_B2E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10359; RPL36A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360536 CVCL_B2DQ Abcam HeLa RHOT1 KO cancer cell line human CVCL_B2DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21168; RHOT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360537 CVCL_B2E2 Abcam HeLa RORC KO cancer cell line human CVCL_B2E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10260; RORC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360538 CVCL_B2DT Abcam HeLa RIOK3 KO cancer cell line human CVCL_B2DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11451; RIOK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360539 CVCL_B2E5 Abcam HeLa RPS27L KO cancer cell line human CVCL_B2E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18476; RPS27L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360540 CVCL_B2DS Abcam HeLa RIN1 KO cancer cell line human CVCL_B2DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18749; RIN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360541 CVCL_B2E4 Abcam HeLa RPRM KO cancer cell line human CVCL_B2E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24201; RPRM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360542 CVCL_B2DV Abcam HeLa RIPOR1 KO cancer cell line human CVCL_B2DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25836; RIPOR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360543 CVCL_B2E7 Abcam HeLa RRAGC KO cancer cell line human CVCL_B2E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19902; RRAGC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360544 CVCL_B2DU Abcam HeLa RIPK2 KO cancer cell line human CVCL_B2DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10020; RIPK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360545 CVCL_B2E6 Abcam HeLa RRAGB KO cancer cell line human CVCL_B2E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19901; RRAGB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360546 CVCL_B2DX Abcam HeLa RNF149 KO cancer cell line human CVCL_B2DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23137; RNF149 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360547 CVCL_B2E9 Abcam HeLa RRBP1 KO cancer cell line human CVCL_B2E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10448; RRBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360548 CVCL_B2DW Abcam HeLa RMDN3 KO cancer cell line human CVCL_B2DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25550; RMDN3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360549 CVCL_B2E8 Abcam HeLa RRAS KO cancer cell line human CVCL_B2E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10447; RRAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265306; true Female 151360550 CVCL_B2FL Abcam HeLa SLC20A2 KO cancer cell line human CVCL_B2FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360551 CVCL_B2FK Abcam HeLa SLC1A4 KO cancer cell line human CVCL_B2FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10942; SLC1A4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360552 CVCL_B2FN Abcam HeLa SLC25A13 KO cancer cell line human CVCL_B2FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10983; SLC25A13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360553 CVCL_B2FM Abcam HeLa SLC22A5 KO cancer cell line human CVCL_B2FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10969; SLC22A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360554 CVCL_B2FP Abcam HeLa SLC25A20 KO cancer cell line human CVCL_B2FP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1421; SLC25A20 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360555 CVCL_B2G1 Abcam HeLa SLC35C1 KO cancer cell line human CVCL_B2G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20197; SLC35C1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360556 CVCL_B2G0 Abcam HeLa SLC35B2 KO cancer cell line human CVCL_B2G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16872; SLC35B2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360557 CVCL_B2FR Abcam HeLa SLC25A40 KO cancer cell line human CVCL_B2FR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29680; SLC25A40 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360558 CVCL_B2G3 Abcam HeLa SLC38A5 KO cancer cell line human CVCL_B2G3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18070; SLC38A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360559 CVCL_B2FQ Abcam HeLa SLC25A29 KO cancer cell line human CVCL_B2FQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20116; SLC25A29 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360560 CVCL_B2G2 Abcam HeLa SLC35E2B KO cancer cell line human CVCL_B2G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33941; SLC35E2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360561 CVCL_B2FD Abcam HeLa SIKE1 KO cancer cell line human CVCL_B2FD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26119; SIKE1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360562 CVCL_B2FC Abcam HeLa SIK1 KO cancer cell line human CVCL_B2FC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11142; SIK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360563 CVCL_B2FF Abcam HeLa SIRT5 KO cancer cell line human CVCL_B2FF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14933; SIRT5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265617; true Female 151360564 CVCL_B2FE Abcam HeLa SIPA1 KO cancer cell line human CVCL_B2FE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10885; SIPA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360565 CVCL_B2FH Abcam HeLa SLC11A2 KO cancer cell line human CVCL_B2FH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10908; SLC11A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360566 CVCL_B2FG Abcam HeLa SIRT6 KO cancer cell line human CVCL_B2FG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14934; SIRT6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360567 CVCL_B2FJ Abcam HeLa SLC17A5 KO cancer cell line human CVCL_B2FJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10933; SLC17A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360568 CVCL_B2FI Abcam HeLa SLC12A9 KO cancer cell line human CVCL_B2FI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17435; SLC12A9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360569 CVCL_B2EZ Abcam HeLa SELENOS KO cancer cell line human CVCL_B2EZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30396; SELENOS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360570 CVCL_B2FB Abcam HeLa SIAH1 KO cancer cell line human CVCL_B2FB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10857; SIAH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360571 CVCL_B2FA Abcam HeLa SHKBP1 KO cancer cell line human CVCL_B2FA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19214; SHKBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360572 CVCL_B2ES Abcam HeLa SCN1B KO cancer cell line human CVCL_B2ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10586; SCN1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360573 CVCL_B2F4 Abcam HeLa SETD7 KO cancer cell line human CVCL_B2F4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30412; SETD7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360574 CVCL_B2ER Abcam HeLa SCFD2 KO cancer cell line human CVCL_B2ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30676; SCFD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360575 CVCL_B2F3 Abcam HeLa SESN2 KO cancer cell line human CVCL_B2F3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20746; SESN2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360576 CVCL_B2EU Abcam HeLa SCRIB KO cancer cell line human CVCL_B2EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30377; SCRIB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360577 CVCL_B2F6 Abcam HeLa SH2D4A KO cancer cell line human CVCL_B2F6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26102; SH2D4A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360578 CVCL_B2ET Abcam HeLa SCNN1D KO cancer cell line human CVCL_B2ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10601; SCNN1D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360579 CVCL_B2F5 Abcam HeLa SFN KO cancer cell line human CVCL_B2F5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10773; SFN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360580 CVCL_B2EW Abcam HeLa SDHAF2 KO cancer cell line human CVCL_B2EW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26034; SDHAF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360581 CVCL_B2F8 Abcam HeLa SHC3 KO cancer cell line human CVCL_B2F8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18181; SHC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360582 CVCL_B2EV Abcam HeLa SCYL2 KO cancer cell line human CVCL_B2EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19286; SCYL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360583 CVCL_B2F7 Abcam HeLa SHC2 KO cancer cell line human CVCL_B2F7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29869; SHC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360584 CVCL_B2EY Abcam HeLa SELENBP1 KO cancer cell line human CVCL_B2EY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10719; SELENBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360585 CVCL_B2EX Abcam HeLa SEC16A KO cancer cell line human CVCL_B2EX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29006; SEC16A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360586 CVCL_B2F9 Abcam HeLa SHC4 KO cancer cell line human CVCL_B2F9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16743; SHC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360587 CVCL_B1QX Abcam HeLa EIF4EBP1 KO cancer cell line human CVCL_B1QX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3288; EIF4EBP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360588 CVCL_B1R9 Abcam HeLa ENG KO cancer cell line human CVCL_B1R9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3349; ENG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360589 CVCL_B1R8 Abcam HeLa ADGRE1 KO cancer cell line human CVCL_B1R8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3336; ADGRE1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360590 CVCL_B1QW Abcam HeLa EIF3H KO cancer cell line human CVCL_B1QW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3273; EIF3H Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360591 CVCL_B1QZ Abcam HeLa ELK1 KO cancer cell line human CVCL_B1QZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3321; ELK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360592 CVCL_B1QY Abcam HeLa EIPR1 KO cancer cell line human CVCL_B1QY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12383; EIPR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360593 CVCL_B1QP Abcam HeLa ECHDC1 KO cancer cell line human CVCL_B1QP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21489; ECHDC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360594 CVCL_B1R1 Abcam HeLa ELOVL5 KO cancer cell line human CVCL_B1R1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21308; ELOVL5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265942; true Female 151360595 CVCL_B1R0 Abcam HeLa ELL2 KO cancer cell line human CVCL_B1R0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17064; ELL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360596 CVCL_B1QR Abcam HeLa EFNA1 KO cancer cell line human CVCL_B1QR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3221; EFNA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265232; true Female 151360597 CVCL_B1R3 Abcam HeLa EMC2 KO cancer cell line human CVCL_B1R3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28963; EMC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360598 CVCL_B1QQ Abcam HeLa EEA1 KO cancer cell line human CVCL_B1QQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3185; EEA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360599 CVCL_B1R2 Abcam HeLa EMC10 KO cancer cell line human CVCL_B1R2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27609; EMC10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360600 CVCL_B1QT Abcam HeLa EGFR KO cancer cell line human CVCL_B1QT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3236; EGFR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360601 CVCL_B1R5 Abcam HeLa EMC8 KO cancer cell line human CVCL_B1R5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7864; EMC8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360602 CVCL_B1QS Abcam HeLa EGF KO cancer cell line human CVCL_B1QS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3229; EGF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360603 CVCL_B1R4 Abcam HeLa EMC6 KO cancer cell line human CVCL_B1R4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28430; EMC6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360604 CVCL_B1QV Abcam HeLa EIF2AK2 KO cancer cell line human CVCL_B1QV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9437; EIF2AK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360605 CVCL_B1R7 Abcam HeLa EMP1 KO cancer cell line human CVCL_B1R7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3333; EMP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360606 CVCL_B1QU Abcam HeLa EI24 KO cancer cell line human CVCL_B1QU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13276; EI24 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360607 CVCL_B1R6 Abcam HeLa EML4 KO cancer cell line human CVCL_B1R6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1316; EML4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360608 CVCL_B1QH Abcam HeLa DYNLL1 KO cancer cell line human CVCL_B1QH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15476; DYNLL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360609 CVCL_B1QG Abcam HeLa DTX3 KO cancer cell line human CVCL_B1QG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24457; DTX3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360610 CVCL_B1QJ Abcam HeLa DYRK3 KO cancer cell line human CVCL_B1QJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3094; DYRK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360611 CVCL_B1QI Abcam HeLa DYNLT3 KO cancer cell line human CVCL_B1QI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11694; DYNLT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360612 CVCL_B1QL Abcam HeLa DYSF KO cancer cell line human CVCL_B1QL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3097; DYSF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264764; true Female 151360613 CVCL_B1QK Abcam HeLa DYRK4 KO cancer cell line human CVCL_B1QK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3095; DYRK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360614 CVCL_B1QN Abcam HeLa ECE2 KO cancer cell line human CVCL_B1QN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13275; ECE2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360615 CVCL_B1QM Abcam HeLa E2F3 KO cancer cell line human CVCL_B1QM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3115; E2F3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360616 CVCL_B1QB Abcam HeLa DNMT3A KO cancer cell line human CVCL_B1QB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2978; DNMT3A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360617 CVCL_B1QA Abcam HeLa DNAJC14 KO cancer cell line human CVCL_B1QA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24581; DNAJC14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360618 CVCL_B1QD Abcam HeLa DPM2 KO cancer cell line human CVCL_B1QD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3006; DPM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360619 CVCL_B1QC Abcam HeLa DPH2 KO cancer cell line human CVCL_B1QC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3004; DPH2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360620 CVCL_B1QF Abcam HeLa DSTYK KO cancer cell line human CVCL_B1QF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29043; DSTYK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360621 CVCL_B1QE Abcam HeLa DSG2 KO cancer cell line human CVCL_B1QE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360622 CVCL_B1RY Abcam HeLa FAS KO cancer cell line human CVCL_B1RY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11920; FAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360623 CVCL_B1RX Abcam HeLa FANCD2 KO cancer cell line human CVCL_B1RX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360624 CVCL_B1S9 Abcam HeLa FOCAD KO cancer cell line human CVCL_B1S9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23377; FOCAD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360625 CVCL_B1RZ Abcam HeLa FASTK KO cancer cell line human CVCL_B1RZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24676; FASTK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360626 CVCL_B1RQ Abcam HeLa EXOSC1 KO cancer cell line human CVCL_B1RQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17286; EXOSC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265194; true Female 151360627 CVCL_B1S2 Abcam HeLa FER KO cancer cell line human CVCL_B1S2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3655; FER Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360628 CVCL_B1RP Abcam HeLa EXOC7 KO cancer cell line human CVCL_B1RP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23214; EXOC7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360629 CVCL_B1S1 Abcam HeLa FCER2 KO cancer cell line human CVCL_B1S1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3612; FCER2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab266040; true Female 151360630 CVCL_B1RS Abcam HeLa FABP5 KO cancer cell line human CVCL_B1RS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3560; FABP5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360631 CVCL_B1S4 Abcam HeLa FHL1 KO cancer cell line human CVCL_B1S4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3702; FHL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360632 CVCL_B1RR Abcam HeLa EZR KO cancer cell line human CVCL_B1RR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12691; EZR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264912; true Female 151360633 CVCL_B1S3 Abcam HeLa FERMT2 KO cancer cell line human CVCL_B1S3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15767; FERMT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360634 CVCL_B1RU Abcam HeLa FAM20B KO cancer cell line human CVCL_B1RU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23017; FAM20B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360635 CVCL_B1S6 Abcam HeLa FIBP KO cancer cell line human CVCL_B1S6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3705; FIBP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360636 CVCL_B1RT Abcam HeLa FADD KO cancer cell line human CVCL_B1RT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3573; FADD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360637 CVCL_B1S5 Abcam HeLa FHL2 KO cancer cell line human CVCL_B1S5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3703; FHL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360638 CVCL_B1RW Abcam HeLa FAM98A KO cancer cell line human CVCL_B1RW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24520; FAM98A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360639 CVCL_B1S8 Abcam HeLa FLYWCH1 KO cancer cell line human CVCL_B1S8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25404; FLYWCH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360640 CVCL_B1RV Abcam HeLa FAM3C KO cancer cell line human CVCL_B1RV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18664; FAM3C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360641 CVCL_B1S7 Abcam HeLa FLII KO cancer cell line human CVCL_B1S7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3750; FLII Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360642 CVCL_B1RI Abcam HeLa ERMP1 KO cancer cell line human CVCL_B1RI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23703; ERMP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360643 CVCL_B1RH Abcam HeLa ERI3 KO cancer cell line human CVCL_B1RH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17276; ERI3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360644 CVCL_B1RK Abcam HeLa ESRP2 KO cancer cell line human CVCL_B1RK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26152; ESRP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360645 CVCL_B1RJ Abcam HeLa ERN1 KO cancer cell line human CVCL_B1RJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3449; ERN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360646 CVCL_B1RM Abcam HeLa ETV5 KO cancer cell line human CVCL_B1RM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3494; ETV5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360647 CVCL_B1RL Abcam HeLa ETNK1 KO cancer cell line human CVCL_B1RL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24649; ETNK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360648 CVCL_B1S0 Abcam HeLa FBXO11 KO cancer cell line human CVCL_B1S0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13590; FBXO11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360649 CVCL_B1RN Abcam HeLa EXOC2 KO cancer cell line human CVCL_B1RN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24968; EXOC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360650 CVCL_B1RA Abcam HeLa ENPP2 KO cancer cell line human CVCL_B1RA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3357; ENPP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360651 CVCL_B1RC Abcam HeLa EPHA2 KO cancer cell line human CVCL_B1RC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3386; EPHA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360652 CVCL_B1RB Abcam HeLa EPHA1 KO cancer cell line human CVCL_B1RB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3385; EPHA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360653 CVCL_B1RE Abcam HeLa EPHB3 KO cancer cell line human CVCL_B1RE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3394; EPHB3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265529; true Female 151360654 CVCL_B1RD Abcam HeLa EPHA4 KO cancer cell line human CVCL_B1RD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3388; EPHA4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360655 CVCL_B1RG Abcam HeLa ERGIC2 KO cancer cell line human CVCL_B1RG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30208; ERGIC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360656 CVCL_B1RF Abcam HeLa EPS8L2 KO cancer cell line human CVCL_B1RF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21296; EPS8L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360657 CVCL_B1P7 Abcam HeLa CREB3L2 KO cancer cell line human CVCL_B1P7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23720; CREB3L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360658 CVCL_B1P6 Abcam HeLa CPT2 KO cancer cell line human CVCL_B1P6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2330; CPT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360659 CVCL_B1P9 Abcam HeLa CRK KO cancer cell line human CVCL_B1P9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2362; CRK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360660 CVCL_B1P8 Abcam HeLa CREB5 KO cancer cell line human CVCL_B1P8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16844; CREB5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360661 CVCL_B1P1 Abcam HeLa COL9A3 KO cancer cell line human CVCL_B1P1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2219; COL9A3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360662 CVCL_B1P0 Abcam HeLa COL5A1 KO cancer cell line human CVCL_B1P0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2209; COL5A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360663 CVCL_B1P3 Abcam HeLa COQ8B KO cancer cell line human CVCL_B1P3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19041; COQ8B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360664 CVCL_B1P2 Abcam HeLa COP1 KO cancer cell line human CVCL_B1P2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17440; COP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab266013; true Female 151360665 CVCL_B1P5 Abcam HeLa CPS1 KO cancer cell line human CVCL_B1P5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2323; CPS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360666 CVCL_B1P4 Abcam HeLa CPA4 KO cancer cell line human CVCL_B1P4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15740; CPA4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360667 CVCL_B1PW Abcam HeLa DDIT3 KO cancer cell line human CVCL_B1PW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2726; DDIT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360668 CVCL_B1Q8 Abcam HeLa DNAJC10 KO cancer cell line human CVCL_B1Q8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24637; DNAJC10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360669 CVCL_B1PV Abcam HeLa DDB2 KO cancer cell line human CVCL_B1PV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2718; DDB2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360670 CVCL_B1Q7 Abcam HeLa DNAJB4 KO cancer cell line human CVCL_B1Q7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14886; DNAJB4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360671 CVCL_B1PY Abcam HeLa DDR2 KO cancer cell line human CVCL_B1PY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264864; true Female 151360672 CVCL_B1PX Abcam HeLa DDR1 KO cancer cell line human CVCL_B1PX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2730; DDR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360673 CVCL_B1Q9 Abcam HeLa DNAJC13 KO cancer cell line human CVCL_B1Q9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30343; DNAJC13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360674 CVCL_B1PZ Abcam HeLa DENND4B KO cancer cell line human CVCL_B1PZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29044; DENND4B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360675 CVCL_B1Q0 Abcam HeLa DENND5A KO cancer cell line human CVCL_B1Q0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19344; DENND5A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360676 CVCL_B1PN Abcam HeLa CXCL1 KO cancer cell line human CVCL_B1PN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4602; CXCL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360677 CVCL_B1PQ Abcam HeLa CYRIB KO cancer cell line human CVCL_B1PQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25216; CYRIB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360678 CVCL_B1Q2 Abcam HeLa DGKD KO cancer cell line human CVCL_B1Q2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2851; DGKD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360679 CVCL_B1PP Abcam HeLa CXCR4 KO cancer cell line human CVCL_B1PP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2561; CXCR4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360680 CVCL_B1Q1 Abcam HeLa DENR KO cancer cell line human CVCL_B1Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2769; DENR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360681 CVCL_B1PS Abcam HeLa DAB2 KO cancer cell line human CVCL_B1PS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2662; DAB2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360682 CVCL_B1Q4 Abcam HeLa DHRS13 KO cancer cell line human CVCL_B1Q4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28326; DHRS13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360683 CVCL_B1PR Abcam HeLa CCN1 KO cancer cell line human CVCL_B1PR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2654; CCN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360684 CVCL_B1Q3 Abcam HeLa DHCR7 KO cancer cell line human CVCL_B1Q3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2860; DHCR7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360685 CVCL_B1PU Abcam HeLa DCAF12 KO cancer cell line human CVCL_B1PU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19911; DCAF12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360686 CVCL_B1Q6 Abcam HeLa DMAC2 KO cancer cell line human CVCL_B1Q6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25496; DMAC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360687 CVCL_B1PT Abcam HeLa DAXX KO cancer cell line human CVCL_B1PT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360688 CVCL_B1Q5 Abcam HeLa DLD KO cancer cell line human CVCL_B1Q5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2898; DLD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360689 CVCL_B1PG Abcam HeLa CSNK1G1 KO cancer cell line human CVCL_B1PG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2454; CSNK1G1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360690 CVCL_B1PF Abcam HeLa CSNK1E KO cancer cell line human CVCL_B1PF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2453; CSNK1E Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360691 CVCL_B1PI Abcam HeLa CSTF2 KO cancer cell line human CVCL_B1PI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2484; CSTF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360692 CVCL_B1PH Abcam HeLa CSRP1 KO cancer cell line human CVCL_B1PH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2469; CSRP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360693 CVCL_B1PK Abcam HeLa CTNNB1 KO cancer cell line human CVCL_B1PK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360694 CVCL_B1PJ Abcam HeLa CTDSPL KO cancer cell line human CVCL_B1PJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16890; CTDSPL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360695 CVCL_B1PM Abcam HeLa CUTC KO cancer cell line human CVCL_B1PM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24271; CUTC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360696 CVCL_B1PL Abcam HeLa CTSC KO cancer cell line human CVCL_B1PL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2528; CTSC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360697 CVCL_B1PA Abcam HeLa CRKL KO cancer cell line human CVCL_B1PA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2363; CRKL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360698 CVCL_B1PC Abcam HeLa CSAD KO cancer cell line human CVCL_B1PC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18966; CSAD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360699 CVCL_B1PB Abcam HeLa CRY1 KO cancer cell line human CVCL_B1PB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2384; CRY1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360700 CVCL_B1PE Abcam HeLa CSNK1D KO cancer cell line human CVCL_B1PE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2452; CSNK1D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360701 CVCL_B1PD Abcam HeLa CSF1R KO cancer cell line human CVCL_B1PD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2433; CSF1R Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360702 CVCL_B1MT Abcam HeLa CD70 KO cancer cell line human CVCL_B1MT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11937; CD70 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360703 CVCL_B1N5 Abcam HeLa CDK8 KO cancer cell line human CVCL_B1N5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1779; CDK8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360704 CVCL_B1MS Abcam HeLa CD58 KO cancer cell line human CVCL_B1MS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1688; CD58 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360705 CVCL_B1N4 Abcam HeLa CDK6 KO cancer cell line human CVCL_B1N4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1777; CDK6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360706 CVCL_B1MV Abcam HeLa CDC25C KO cancer cell line human CVCL_B1MV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1727; CDC25C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360707 CVCL_B1N7 Abcam HeLa CDKN1A KO cancer cell line human CVCL_B1N7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360708 CVCL_B1MU Abcam HeLa CD9 KO cancer cell line human CVCL_B1MU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1709; CD9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360709 CVCL_B1N6 Abcam HeLa CDKL1 KO cancer cell line human CVCL_B1N6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1781; CDKL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360710 CVCL_B1MX Abcam HeLa CDC42EP4 KO cancer cell line human CVCL_B1MX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17147; CDC42EP4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360711 CVCL_B1N9 Abcam HeLa CEBPB KO cancer cell line human CVCL_B1N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1834; CEBPB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360712 CVCL_B1MW Abcam HeLa CDC42BPA KO cancer cell line human CVCL_B1MW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1737; CDC42BPA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360713 CVCL_B1N8 Abcam HeLa CDKN2B KO cancer cell line human CVCL_B1N8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1788; CDKN2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360714 CVCL_B1MZ Abcam HeLa CDK12 KO cancer cell line human CVCL_B1MZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24224; CDK12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265209; true Female 151360715 CVCL_B1MY Abcam HeLa CDC42SE1 KO cancer cell line human CVCL_B1MY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17719; CDC42SE1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360716 CVCL_B1ML Abcam HeLa CCND1 KO 2 cancer cell line human CVCL_B1ML CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1582; CCND1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360717 CVCL_B1MK Abcam HeLa CCND1 KO 1 cancer cell line human CVCL_B1MK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1582; CCND1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360718 CVCL_B1MN Abcam HeLa CD276 KO cancer cell line human CVCL_B1MN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19137; CD276 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360719 CVCL_B1MM Abcam HeLa CD160 KO cancer cell line human CVCL_B1MM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17013; CD160 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265834; true Female 151360720 CVCL_B1MP Abcam HeLa CD28 KO cancer cell line human CVCL_B1MP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1653; CD28 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261739; true Female 151360721 CVCL_B1N1 Abcam HeLa CDK19 KO cancer cell line human CVCL_B1N1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19338; CDK19 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360722 CVCL_B1N0 Abcam HeLa CDK17 KO cancer cell line human CVCL_B1N0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8750; CDK17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360723 CVCL_B1MR Abcam HeLa CD44 KO cancer cell line human CVCL_B1MR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1681; CD44 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360724 CVCL_B1N3 Abcam HeLa CDK4 KO cancer cell line human CVCL_B1N3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1773; CDK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360725 CVCL_B1MQ Abcam HeLa CD38 KO cancer cell line human CVCL_B1MQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1667; CD38 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265951; true Female 151360726 CVCL_B1N2 Abcam HeLa CDK3 KO cancer cell line human CVCL_B1N2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1772; CDK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360727 CVCL_B1MD Abcam HeLa CBS KO cancer cell line human CVCL_B1MD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1550; CBS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360728 CVCL_B1MC Abcam HeLa CBLL1 KO cancer cell line human CVCL_B1MC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21225; CBLL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360729 CVCL_B1MF Abcam HeLa CCDC137 KO cancer cell line human CVCL_B1MF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33451; CCDC137 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360730 CVCL_B1ME Abcam HeLa CBX3 KO cancer cell line human CVCL_B1ME CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1553; CBX3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360731 CVCL_B1MH Abcam HeLa CCL2 KO cancer cell line human CVCL_B1MH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10618; CCL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360732 CVCL_B1MG Abcam HeLa CCDC6 KO cancer cell line human CVCL_B1MG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18782; CCDC6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360733 CVCL_B1MJ Abcam HeLa CCN2 KO cancer cell line human CVCL_B1MJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2500; CCN2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360734 CVCL_B1MI Abcam HeLa CCL20 KO cancer cell line human CVCL_B1MI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10619; CCL20 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360735 CVCL_B1LZ Abcam HeLa CALD1 KO cancer cell line human CVCL_B1LZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1441; CALD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360736 CVCL_B1MB Abcam HeLa CBLB KO cancer cell line human CVCL_B1MB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1542; CBLB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360737 CVCL_B1MA Abcam HeLa CAVIN1 KO cancer cell line human CVCL_B1MA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9688; CAVIN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360738 CVCL_B1NU Abcam HeLa COL4A1 KO cancer cell line human CVCL_B1NU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2202; COL4A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360739 CVCL_B1NT Abcam HeLa COIL KO cancer cell line human CVCL_B1NT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2184; COIL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360740 CVCL_B1NW Abcam HeLa COL4A3 KO cancer cell line human CVCL_B1NW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2204; COL4A3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360741 CVCL_B1NV Abcam HeLa COL4A2 KO cancer cell line human CVCL_B1NV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2203; COL4A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360742 CVCL_B1NY Abcam HeLa COL4A5 KO cancer cell line human CVCL_B1NY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2207; COL4A5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360743 CVCL_B1NX Abcam HeLa COL4A4 KO cancer cell line human CVCL_B1NX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2206; COL4A4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360744 CVCL_B1NZ Abcam HeLa COL4A6 KO cancer cell line human CVCL_B1NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2208; COL4A6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360745 CVCL_B1NM Abcam HeLa CLPX KO cancer cell line human CVCL_B1NM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2088; CLPX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360746 CVCL_B1NL Abcam HeLa CLOCK KO 2 cancer cell line human CVCL_B1NL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2082; CLOCK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360747 CVCL_B1NN Abcam HeLa CLTCL1 KO cancer cell line human CVCL_B1NN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2093; CLTCL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360748 CVCL_B1NQ Abcam HeLa CNOT7 KO cancer cell line human CVCL_B1NQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14101; CNOT7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360749 CVCL_B1NP Abcam HeLa CNN1 KO cancer cell line human CVCL_B1NP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2155; CNN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265620; true Female 151360750 CVCL_B1NS Abcam HeLa CNP KO cancer cell line human CVCL_B1NS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2158; CNP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360751 CVCL_B1NR Abcam HeLa CNOT9 KO cancer cell line human CVCL_B1NR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10445; CNOT9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360752 CVCL_B1NE Abcam HeLa CIC KO cancer cell line human CVCL_B1NE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14214; CIC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360753 CVCL_B1ND Abcam HeLa CHMP4A KO cancer cell line human CVCL_B1ND CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20274; CHMP4A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360754 CVCL_B1NG Abcam HeLa CLCN7 KO cancer cell line human CVCL_B1NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2025; CLCN7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360755 CVCL_B1NF Abcam HeLa CISD1 KO cancer cell line human CVCL_B1NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30880; CISD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360756 CVCL_B1NI Abcam HeLa CLK3 KO cancer cell line human CVCL_B1NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2071; CLK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360757 CVCL_B1NH Abcam HeLa CLK1 KO cancer cell line human CVCL_B1NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2068; CLK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360758 CVCL_B1NK Abcam HeLa CLOCK KO 1 cancer cell line human CVCL_B1NK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2082; CLOCK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360759 CVCL_B1NJ Abcam HeLa CLK4 KO cancer cell line human CVCL_B1NJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13659; CLK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360760 CVCL_B1NA Abcam HeLa CEP57 KO cancer cell line human CVCL_B1NA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30794; CEP57 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360761 CVCL_B1NC Abcam HeLa CHEK2 KO cancer cell line human CVCL_B1NC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16627; CHEK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360762 CVCL_B1NB Abcam HeLa CHAT KO cancer cell line human CVCL_B1NB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1912; CHAT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab266018; true Female 151360763 CVCL_B1KR Abcam HeLa ATP5F1E KO cancer cell line human CVCL_B1KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 838; ATP5F1E Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360764 CVCL_B1L3 Abcam HeLa BCAR3 KO cancer cell line human CVCL_B1L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 973; BCAR3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360765 CVCL_B1KQ Abcam HeLa ATP2B4 KO cancer cell line human CVCL_B1KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 817; ATP2B4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360766 CVCL_B1L2 Abcam HeLa BBC3 KO cancer cell line human CVCL_B1L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17868; BBC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360767 CVCL_B1KT Abcam HeLa AXL KO 2 cancer cell line human CVCL_B1KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 905; AXL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360768 CVCL_B1L5 Abcam HeLa BCL2L2 KO cancer cell line human CVCL_B1L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 995; BCL2L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360769 CVCL_B1KS Abcam HeLa AXL KO 1 cancer cell line human CVCL_B1KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 905; AXL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360770 CVCL_B1L4 Abcam HeLa BCL10 KO cancer cell line human CVCL_B1L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 989; BCL10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360771 CVCL_B1KV Abcam HeLa AZIN1 KO cancer cell line human CVCL_B1KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16432; AZIN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360772 CVCL_B1L7 Abcam HeLa BCOR KO cancer cell line human CVCL_B1L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20893; BCOR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360773 CVCL_B1KU Abcam HeLa AZI2 KO cancer cell line human CVCL_B1KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24002; AZI2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360774 CVCL_B1L6 Abcam HeLa BCL6 KO cancer cell line human CVCL_B1L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360775 CVCL_B1KX Abcam HeLa BAG2 KO cancer cell line human CVCL_B1KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 938; BAG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360776 CVCL_B1L9 Abcam HeLa BIRC2 KO cancer cell line human CVCL_B1L9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 590; BIRC2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360777 CVCL_B1KW Abcam HeLa B4GALT1 KO cancer cell line human CVCL_B1KW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 924; B4GALT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360778 CVCL_B1L8 Abcam HeLa BECN1 KO cancer cell line human CVCL_B1L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1034; BECN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360779 CVCL_B1KJ Abcam HeLa ATG2B KO cancer cell line human CVCL_B1KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20187; ATG2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360780 CVCL_B1KI Abcam HeLa ATG2A KO cancer cell line human CVCL_B1KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29028; ATG2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360781 CVCL_B1KL Abcam HeLa ATG4B KO cancer cell line human CVCL_B1KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20790; ATG4B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360782 CVCL_B1KK Abcam HeLa ATG4A KO cancer cell line human CVCL_B1KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16489; ATG4A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360783 CVCL_B1KN Abcam HeLa ATP13A3 KO cancer cell line human CVCL_B1KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24113; ATP13A3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360784 CVCL_B1KM Abcam HeLa ATG4D KO cancer cell line human CVCL_B1KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20789; ATG4D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360785 CVCL_B1KP Abcam HeLa ATP2B1 KO cancer cell line human CVCL_B1KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 814; ATP2B1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360786 CVCL_B1L1 Abcam HeLa BAZ1B KO cancer cell line human CVCL_B1L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 961; BAZ1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360787 CVCL_B1L0 Abcam HeLa BAZ1A KO cancer cell line human CVCL_B1L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 960; BAZ1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360788 CVCL_B1KB Abcam HeLa ATG10 KO cancer cell line human CVCL_B1KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20315; ATG10 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360789 CVCL_B1KA Abcam HeLa ATF6 KO cancer cell line human CVCL_B1KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360790 CVCL_B1KD Abcam HeLa ATG14 KO cancer cell line human CVCL_B1KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360791 CVCL_B1KC Abcam HeLa ATG101 KO cancer cell line human CVCL_B1KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25679; ATG101 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360792 CVCL_B1KF Abcam HeLa ATG16L1 KO 2 cancer cell line human CVCL_B1KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360793 CVCL_B1KE Abcam HeLa ATG16L1 KO 1 cancer cell line human CVCL_B1KE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360794 CVCL_B1KH Abcam HeLa ATG16L2 KO cancer cell line human CVCL_B1KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25464; ATG16L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360795 CVCL_B1KG Abcam HeLa ATG16L1 KO 3 cancer cell line human CVCL_B1KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360796 CVCL_B1JY Abcam HeLa ARID2 KO cancer cell line human CVCL_B1JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18037; ARID2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360797 CVCL_B1JX Abcam HeLa ARHGEF2 KO cancer cell line human CVCL_B1JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 682; ARHGEF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360798 CVCL_B1K9 Abcam HeLa ATF3 KO cancer cell line human CVCL_B1K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360799 CVCL_B1JZ Abcam HeLa ARL13B KO cancer cell line human CVCL_B1JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25419; ARL13B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360800 CVCL_B1LS Abcam HeLa C1orf131 KO cancer cell line human CVCL_B1LS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25332; C1orf131 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360801 CVCL_B1M4 Abcam HeLa CASP3 KO cancer cell line human CVCL_B1M4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1504; CASP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360802 CVCL_B1LR Abcam HeLa C1D KO cancer cell line human CVCL_B1LR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29911; C1D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab266023; true Female 151360803 CVCL_B1M3 Abcam HeLa CAPG KO cancer cell line human CVCL_B1M3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1474; CAPG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360804 CVCL_B1LU Abcam HeLa C6orf62 KO cancer cell line human CVCL_B1LU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20998; C6orf62 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360805 CVCL_B1M6 Abcam HeLa CASP8 KO cancer cell line human CVCL_B1M6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360806 CVCL_B1LT Abcam HeLa C5orf51 KO cancer cell line human CVCL_B1LT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27750; RIMOC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360807 CVCL_B1M5 Abcam HeLa CASP7 KO cancer cell line human CVCL_B1M5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1508; CASP7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360808 CVCL_B1LW Abcam HeLa C9orf78 KO cancer cell line human CVCL_B1LW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24932; C9orf78 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360809 CVCL_B1M8 Abcam HeLa CAT KO 2 cancer cell line human CVCL_B1M8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1516; CAT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360810 CVCL_B1LV Abcam HeLa C9orf69 KO cancer cell line human CVCL_B1LV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31009; TMEM250 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360811 CVCL_B1M7 Abcam HeLa CAT KO 1 cancer cell line human CVCL_B1M7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1516; CAT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360812 CVCL_B1LY Abcam HeLa CACNB3 KO cancer cell line human CVCL_B1LY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1403; CACNB3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360813 CVCL_B1LX Abcam HeLa CACNA2D1 KO cancer cell line human CVCL_B1LX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1399; CACNA2D1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360814 CVCL_B1M9 Abcam HeLa CAV1 KO cancer cell line human CVCL_B1M9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1527; CAV1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360815 CVCL_B1LK Abcam HeLa BRSK2 KO cancer cell line human CVCL_B1LK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11405; BRSK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360816 CVCL_B1LJ Abcam HeLa BRSK1 KO cancer cell line human CVCL_B1LJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18994; BRSK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360817 CVCL_B1LM Abcam HeLa BTN3A2 KO cancer cell line human CVCL_B1LM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1139; BTN3A2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360818 CVCL_B1LL Abcam HeLa BRWD1 KO cancer cell line human CVCL_B1LL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12760; BRWD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360819 CVCL_B1M0 Abcam HeLa CALM2 KO cancer cell line human CVCL_B1M0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1445; CALM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360820 CVCL_B1LN Abcam HeLa BUB1 KO cancer cell line human CVCL_B1LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1148; BUB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360821 CVCL_B1LQ Abcam HeLa C19orf33 KO cancer cell line human CVCL_B1LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16668; C19orf33 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360822 CVCL_B1M2 Abcam HeLa CAMKK1 KO cancer cell line human CVCL_B1M2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1469; CAMKK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360823 CVCL_B1LP Abcam HeLa C11orf58 KO cancer cell line human CVCL_B1LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16990; C11orf58 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360824 CVCL_B1M1 Abcam HeLa CAMK2G KO cancer cell line human CVCL_B1M1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1463; CAMK2G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360825 CVCL_B1LC Abcam HeLa BMP2 KO cancer cell line human CVCL_B1LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1069; BMP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360826 CVCL_B1LB Abcam HeLa BLOC1S1 KO cancer cell line human CVCL_B1LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4200; BLOC1S1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360827 CVCL_B1LE Abcam HeLa BMPR1A KO cancer cell line human CVCL_B1LE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360828 CVCL_B1LD Abcam HeLa BMP2K KO cancer cell line human CVCL_B1LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18041; BMP2K Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360829 CVCL_B1LG Abcam HeLa BRAF KO cancer cell line human CVCL_B1LG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360830 CVCL_B1LF Abcam HeLa BOD1 KO cancer cell line human CVCL_B1LF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25114; BOD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360831 CVCL_B1LI Abcam HeLa BRK1 KO cancer cell line human CVCL_B1LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23057; BRK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360832 CVCL_B1LH Abcam HeLa BRE KO cancer cell line human CVCL_B1LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1106; BABAM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360833 CVCL_B1KZ Abcam HeLa BAX KO cancer cell line human CVCL_B1KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360834 CVCL_B1KY Abcam HeLa BAK1 KO cancer cell line human CVCL_B1KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360835 CVCL_B1LA Abcam HeLa BLMH KO cancer cell line human CVCL_B1LA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1059; BLMH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360836 CVCL_B1ZA Abcam HeLa NTRK2 KO cancer cell line human CVCL_B1ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8032; NTRK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261808; true Female 151360837 CVCL_B1ZC Abcam HeLa NUDT3 KO cancer cell line human CVCL_B1ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8050; NUDT3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360838 CVCL_B1ZB Abcam HeLa NUDT2 KO cancer cell line human CVCL_B1ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8049; NUDT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360839 CVCL_B1ZE Abcam HeLa NUPR1 KO cancer cell line human CVCL_B1ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29990; NUPR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360840 CVCL_B1ZD Abcam HeLa NUP153 KO cancer cell line human CVCL_B1ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8062; NUP153 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360841 CVCL_B1ZG Abcam HeLa OBSCN KO cancer cell line human CVCL_B1ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15719; OBSCN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360842 CVCL_B1ZF Abcam HeLa OAS1 KO cancer cell line human CVCL_B1ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8086; OAS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360843 CVCL_B1YX Abcam HeLa NPTX1 KO cancer cell line human CVCL_B1YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7952; NPTX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360844 CVCL_B1Z9 Abcam HeLa NSD2 KO cancer cell line human CVCL_B1Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360845 CVCL_B1YW Abcam HeLa NPR1 KO cancer cell line human CVCL_B1YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7943; NPR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360846 CVCL_B1Z8 Abcam HeLa NRG4 KO cancer cell line human CVCL_B1Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29862; NRG4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360847 CVCL_B1YZ Abcam HeLa NR2F2 KO cancer cell line human CVCL_B1YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7976; NR2F2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab261829; true Female 151360848 CVCL_B1YY Abcam HeLa NPY4R KO cancer cell line human CVCL_B1YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9329; NPY4R Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360849 CVCL_B1YP Abcam HeLa NLRX1 KO cancer cell line human CVCL_B1YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29890; NLRX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360850 CVCL_B1Z1 Abcam HeLa NR3C2 KO cancer cell line human CVCL_B1Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360851 CVCL_B1Z0 Abcam HeLa NR3C1 KO cancer cell line human CVCL_B1Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7978; NR3C1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360852 CVCL_B1YR Abcam HeLa NOMO2 KO cancer cell line human CVCL_B1YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22652; NOMO2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360853 CVCL_B1Z3 Abcam HeLa NRAS KO 2 cancer cell line human CVCL_B1Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360854 CVCL_B1YQ Abcam HeLa NNMT KO cancer cell line human CVCL_B1YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7861; NNMT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360855 CVCL_B1Z2 Abcam HeLa NRAS KO 1 cancer cell line human CVCL_B1Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360856 CVCL_B1YT Abcam HeLa NOTCH1 KO cancer cell line human CVCL_B1YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360857 CVCL_B1Z5 Abcam HeLa NRBF2 KO cancer cell line human CVCL_B1Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19692; NRBF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360858 CVCL_B1YS Abcam HeLa NOS2 KO cancer cell line human CVCL_B1YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360859 CVCL_B1Z4 Abcam HeLa NRAS KO 3 cancer cell line human CVCL_B1Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab267225; true Female 151360860 CVCL_B1YV Abcam HeLa NPPB KO cancer cell line human CVCL_B1YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7940; NPPB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360861 CVCL_B1Z7 Abcam HeLa NRG2 KO cancer cell line human CVCL_B1Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7998; NRG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360862 CVCL_B1YU Abcam HeLa NPHS1 KO cancer cell line human CVCL_B1YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7908; NPHS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265099; true Female 151360863 CVCL_B1Z6 Abcam HeLa NRBP2 KO cancer cell line human CVCL_B1Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19339; NRBP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360864 CVCL_B1YH Abcam HeLa NEFH KO cancer cell line human CVCL_B1YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7737; NEFH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab255413; true Female 151360865 CVCL_B1YG Abcam HeLa NDUFB9 KO cancer cell line human CVCL_B1YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7704; NDUFB9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360866 CVCL_B1YJ Abcam HeLa NF1 KO cancer cell line human CVCL_B1YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360867 CVCL_B1YI Abcam HeLa NEK6 KO cancer cell line human CVCL_B1YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7749; NEK6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360868 CVCL_B1YL Abcam HeLa NFATC1 KO cancer cell line human CVCL_B1YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7775; NFATC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265199; true Female 151360869 CVCL_B1YK Abcam HeLa NF2 KO cancer cell line human CVCL_B1YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360870 CVCL_B1YN Abcam HeLa NLK KO cancer cell line human CVCL_B1YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29858; NLK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360871 CVCL_B1YM Abcam HeLa NLGN4X KO cancer cell line human CVCL_B1YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14287; NLGN4X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360872 CVCL_B1ZY Abcam HeLa PAQR5 KO cancer cell line human CVCL_B1ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29645; PAQR5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360873 CVCL_B1ZX Abcam HeLa PAQR4 KO cancer cell line human CVCL_B1ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26386; PAQR4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360874 CVCL_B1ZZ Abcam HeLa PARD6A KO cancer cell line human CVCL_B1ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15943; PARD6A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360875 CVCL_B1ZQ Abcam HeLa P2RX5 KO cancer cell line human CVCL_B1ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8536; P2RX5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360876 CVCL_B1ZP Abcam HeLa OXCT1 KO cancer cell line human CVCL_B1ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8527; OXCT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360877 CVCL_B1ZS Abcam HeLa PAK1 KO cancer cell line human CVCL_B1ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360878 CVCL_B1ZR Abcam HeLa PACSIN2 KO cancer cell line human CVCL_B1ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8571; PACSIN2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360879 CVCL_B1ZU Abcam HeLa PALM KO cancer cell line human CVCL_B1ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8594; PALM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360880 CVCL_B1ZT Abcam HeLa PAK2 KO cancer cell line human CVCL_B1ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360881 CVCL_B1ZW Abcam HeLa PAPSS2 KO cancer cell line human CVCL_B1ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8604; PAPSS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360882 CVCL_B1ZV Abcam HeLa PALS1 KO cancer cell line human CVCL_B1ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18669; PALS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360883 CVCL_B1ZI Abcam HeLa OGFR KO cancer cell line human CVCL_B1ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15768; OGFR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360884 CVCL_B1ZH Abcam HeLa OGA KO cancer cell line human CVCL_B1ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7056; OGA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360885 CVCL_B1ZK Abcam HeLa OSMR KO cancer cell line human CVCL_B1ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8507; OSMR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360886 CVCL_B1ZJ Abcam HeLa OSBPL5 KO cancer cell line human CVCL_B1ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16392; OSBPL5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360887 CVCL_B1ZM Abcam HeLa OTUD7B KO cancer cell line human CVCL_B1ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16683; OTUD7B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360888 CVCL_B1ZL Abcam HeLa OTUD4 KO cancer cell line human CVCL_B1ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24949; OTUD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360889 CVCL_B1ZN Abcam HeLa OTX2 KO cancer cell line human CVCL_B1ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8522; OTX2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265267; true Female 151360890 CVCL_B1XA Abcam HeLa MME KO cancer cell line human CVCL_B1XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7154; MME Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264794; true Female 151360891 CVCL_B1XC Abcam HeLa MMRN1 KO cancer cell line human CVCL_B1XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7178; MMRN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360892 CVCL_B1XB Abcam HeLa MMP24 KO cancer cell line human CVCL_B1XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7172; MMP24 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360893 CVCL_B1XE Abcam HeLa MPLKIP KO cancer cell line human CVCL_B1XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16002; MPLKIP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360894 CVCL_B1XD Abcam HeLa MOK KO cancer cell line human CVCL_B1XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9833; MOK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360895 CVCL_B1WV Abcam HeLa MC2R KO cancer cell line human CVCL_B1WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6930; MC2R Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360896 CVCL_B1X7 Abcam HeLa MLEC KO cancer cell line human CVCL_B1X7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28973; MLEC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360897 CVCL_B1WU Abcam HeLa MBD4 KO cancer cell line human CVCL_B1WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6919; MBD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360898 CVCL_B1X6 Abcam HeLa MKNK1 KO cancer cell line human CVCL_B1X6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7110; MKNK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360899 CVCL_B1WX Abcam HeLa MCFD2 KO cancer cell line human CVCL_B1WX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18451; MCFD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360900 CVCL_B1X9 Abcam HeLa MLKL KO cancer cell line human CVCL_B1X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26617; MLKL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360901 CVCL_B1WW Abcam HeLa MCAM KO cancer cell line human CVCL_B1WW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6934; MCAM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360902 CVCL_B1X8 Abcam HeLa MLH1 KO cancer cell line human CVCL_B1X8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360903 CVCL_B1WZ Abcam HeLa MERTK KO cancer cell line human CVCL_B1WZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264765; true Female 151360904 CVCL_B1WY Abcam HeLa MEOX1 KO cancer cell line human CVCL_B1WY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7013; MEOX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360905 CVCL_B1WN Abcam HeLa MAP4K3 KO cancer cell line human CVCL_B1WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6865; MAP4K3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360906 CVCL_B1WM Abcam HeLa MAP4 KO cancer cell line human CVCL_B1WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6862; MAP4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360907 CVCL_B1WP Abcam HeLa MAPK1 KO cancer cell line human CVCL_B1WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6871; MAPK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360908 CVCL_B1X1 Abcam HeLa METTL5 KO cancer cell line human CVCL_B1X1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25006; METTL5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360909 CVCL_B1X0 Abcam HeLa MET KO cancer cell line human CVCL_B1X0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7029; MET Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360910 CVCL_B1WR Abcam HeLa MAPK7 KO cancer cell line human CVCL_B1WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360911 CVCL_B1X3 Abcam HeLa MIOS KO cancer cell line human CVCL_B1X3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21905; MIOS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360912 CVCL_B1WQ Abcam HeLa MAPK6 KO cancer cell line human CVCL_B1WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6879; MAPK6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360913 CVCL_B1X2 Abcam HeLa MFSD1 KO cancer cell line human CVCL_B1X2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25874; MFSD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360914 CVCL_B1WT Abcam HeLa MBD1 KO cancer cell line human CVCL_B1WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360915 CVCL_B1X5 Abcam HeLa MKI67 KO cancer cell line human CVCL_B1X5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360916 CVCL_B1WS Abcam HeLa MAST2 KO cancer cell line human CVCL_B1WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19035; MAST2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360917 CVCL_B1X4 Abcam HeLa MISP KO cancer cell line human CVCL_B1X4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27000; MISP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360918 CVCL_B1WF Abcam HeLa MAN1C1 KO cancer cell line human CVCL_B1WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19080; MAN1C1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360919 CVCL_B1WE Abcam HeLa MALT1 KO cancer cell line human CVCL_B1WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6819; MALT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360920 CVCL_B1WH Abcam HeLa MAP3K11 KO cancer cell line human CVCL_B1WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360921 CVCL_B1WG Abcam HeLa MAP3K1 KO cancer cell line human CVCL_B1WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6848; MAP3K1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360922 CVCL_B1WJ Abcam HeLa MAP3K2 KO cancer cell line human CVCL_B1WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360923 CVCL_B1WI Abcam HeLa MAP3K12 KO cancer cell line human CVCL_B1WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6851; MAP3K12 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360924 CVCL_B1WL Abcam HeLa MAP3K8 KO cancer cell line human CVCL_B1WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6860; MAP3K8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360925 CVCL_B1WK Abcam HeLa MAP3K20 KO cancer cell line human CVCL_B1WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17797; MAP3K20 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360926 CVCL_B1YB Abcam HeLa NDC1 KO cancer cell line human CVCL_B1YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25525; NDC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360927 CVCL_B1YA Abcam HeLa NCL KO cancer cell line human CVCL_B1YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7667; NCL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360928 CVCL_B1YD Abcam HeLa NDUFA2 KO cancer cell line human CVCL_B1YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7685; NDUFA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360929 CVCL_B1YC Abcam HeLa NDUFA13 KO cancer cell line human CVCL_B1YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17194; NDUFA13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360930 CVCL_B1YF Abcam HeLa NDUFB5 KO cancer cell line human CVCL_B1YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7700; NDUFB5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360931 CVCL_B1YE Abcam HeLa NDUFA6 KO cancer cell line human CVCL_B1YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7690; NDUFA6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360932 CVCL_B1XW Abcam HeLa MTMR3 KO cancer cell line human CVCL_B1XW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7451; MTMR3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360933 CVCL_B1Y8 Abcam HeLa NCAPD3 KO cancer cell line human CVCL_B1Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28952; NCAPD3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360934 CVCL_B1XV Abcam HeLa MTMR2 KO cancer cell line human CVCL_B1XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7450; MTMR2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360935 CVCL_B1Y7 Abcam HeLa NCAM1 KO cancer cell line human CVCL_B1Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7656; NCAM1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265275; true Female 151360936 CVCL_B1XY Abcam HeLa MVB12A KO cancer cell line human CVCL_B1XY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25153; MVB12A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360937 CVCL_B1XX Abcam HeLa MUC1 KO cancer cell line human CVCL_B1XX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7508; MUC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360938 CVCL_B1Y9 Abcam HeLa NCK1 KO cancer cell line human CVCL_B1Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7664; NCK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360939 CVCL_B1XZ Abcam HeLa MVP KO cancer cell line human CVCL_B1XZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7531; MVP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360940 CVCL_B1Y0 Abcam HeLa MYG1 KO cancer cell line human CVCL_B1Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17590; MYG1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360941 CVCL_B1XN Abcam HeLa MSH6 KO cancer cell line human CVCL_B1XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360942 CVCL_B1XQ Abcam HeLa MT1X KO cancer cell line human CVCL_B1XQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7405; MT1X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360943 CVCL_B1Y2 Abcam HeLa MYOF KO cancer cell line human CVCL_B1Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3656; MYOF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360944 CVCL_B1XP Abcam HeLa MSL1 KO cancer cell line human CVCL_B1XP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27905; MSL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360945 CVCL_B1Y1 Abcam HeLa MYL9 KO cancer cell line human CVCL_B1Y1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15754; MYL9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360946 CVCL_B1XS Abcam HeLa MTCH1 KO cancer cell line human CVCL_B1XS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17586; MTCH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360947 CVCL_B1Y4 Abcam HeLa MZT1 KO cancer cell line human CVCL_B1Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33830; MZT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360948 CVCL_B1XR Abcam HeLa MTAP KO cancer cell line human CVCL_B1XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360949 CVCL_B1Y3 Abcam HeLa MYPN KO cancer cell line human CVCL_B1Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23246; MYPN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360950 CVCL_B1XU Abcam HeLa MTMR14 KO cancer cell line human CVCL_B1XU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26190; MTMR14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360951 CVCL_B1Y6 Abcam HeLa NARF KO cancer cell line human CVCL_B1Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29916; NARF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360952 CVCL_B1XT Abcam HeLa MTFP1 KO cancer cell line human CVCL_B1XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26945; MTFP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360953 CVCL_B1Y5 Abcam HeLa NAA60 KO cancer cell line human CVCL_B1Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25875; NAA60 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360954 CVCL_B1XG Abcam HeLa MPRIP KO cancer cell line human CVCL_B1XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30321; MPRIP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360955 CVCL_B1XF Abcam HeLa MPND KO cancer cell line human CVCL_B1XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25934; MPND Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360956 CVCL_B1XI Abcam HeLa MPZL1 KO cancer cell line human CVCL_B1XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7226; MPZL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360957 CVCL_B1XH Abcam HeLa MPV17 KO cancer cell line human CVCL_B1XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7224; MPV17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360958 CVCL_B1XK Abcam HeLa MRPL40 KO cancer cell line human CVCL_B1XK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14491; MRPL40 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360959 CVCL_B1XJ Abcam HeLa MRAS KO cancer cell line human CVCL_B1XJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7227; MRAS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360960 CVCL_B1XM Abcam HeLa MSH5 KO cancer cell line human CVCL_B1XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7328; MSH5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360961 CVCL_B1XL Abcam HeLa MRPS7 KO cancer cell line human CVCL_B1XL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14499; MRPS7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360962 CVCL_B1VA Abcam HeLa KIT KO cancer cell line human CVCL_B1VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab264768; true Female 151360963 CVCL_B1VC Abcam HeLa KMT2C KO cancer cell line human CVCL_B1VC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13726; KMT2C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360964 CVCL_B1VB Abcam HeLa KLC1 KO cancer cell line human CVCL_B1VB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6387; KLC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360965 CVCL_B1UT Abcam HeLa ITFG1 KO cancer cell line human CVCL_B1UT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30697; ITFG1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360966 CVCL_B1V5 Abcam HeLa KDM6A KO cancer cell line human CVCL_B1V5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360967 CVCL_B1US Abcam HeLa ITCH KO cancer cell line human CVCL_B1US CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13890; ITCH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360968 CVCL_B1V4 Abcam HeLa KDM1B KO cancer cell line human CVCL_B1V4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360969 CVCL_B1UV Abcam HeLa ITGA2 KO cancer cell line human CVCL_B1UV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360970 CVCL_B1V7 Abcam HeLa KIAA1191 KO cancer cell line human CVCL_B1V7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29209; KIAA1191 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360971 CVCL_B1UU Abcam HeLa ITGA11 KO cancer cell line human CVCL_B1UU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6136; ITGA11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360972 CVCL_B1V6 Abcam HeLa KHDC4 KO cancer cell line human CVCL_B1V6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29145; KHDC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360973 CVCL_B1UX Abcam HeLa IVNS1ABP KO cancer cell line human CVCL_B1UX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16951; IVNS1ABP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360974 CVCL_B1V9 Abcam HeLa KIFC3 KO cancer cell line human CVCL_B1V9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6326; KIFC3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360975 CVCL_B1UW Abcam HeLa ITGA6 KO cancer cell line human CVCL_B1UW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6142; ITGA6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360976 CVCL_B1V8 Abcam HeLa KIF7 KO cancer cell line human CVCL_B1V8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30497; KIF7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360977 CVCL_B1UZ Abcam HeLa JAG2 KO cancer cell line human CVCL_B1UZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6189; JAG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360978 CVCL_B1UY Abcam HeLa IWS1 KO cancer cell line human CVCL_B1UY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25467; IWS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360979 CVCL_B1UL Abcam HeLa IP6K2 KO cancer cell line human CVCL_B1UL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17313; IP6K2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360980 CVCL_B1UK Abcam HeLa INPP5K KO cancer cell line human CVCL_B1UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33882; INPP5K Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360981 CVCL_B1UN Abcam HeLa IRF1 KO cancer cell line human CVCL_B1UN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6116; IRF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360982 CVCL_B1UM Abcam HeLa IPO9 KO cancer cell line human CVCL_B1UM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19425; IPO9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360983 CVCL_B1V1 Abcam HeLa KCNJ11 KO cancer cell line human CVCL_B1V1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6257; KCNJ11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360984 CVCL_B1UP Abcam HeLa IRF3 KO cancer cell line human CVCL_B1UP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6118; IRF3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360985 CVCL_B1V0 Abcam HeLa JKAMP KO cancer cell line human CVCL_B1V0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20184; JKAMP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360986 CVCL_B1UR Abcam HeLa IRF9 KO cancer cell line human CVCL_B1UR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6131; IRF9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360987 CVCL_B1V3 Abcam HeLa KDM1A KO cancer cell line human CVCL_B1V3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360988 CVCL_B1UQ Abcam HeLa IRF7 KO cancer cell line human CVCL_B1UQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360989 CVCL_B1V2 Abcam HeLa KCNN4 KO cancer cell line human CVCL_B1V2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6293; KCNN4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360990 CVCL_B1UD Abcam HeLa IL13RA1 KO cancer cell line human CVCL_B1UD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5974; IL13RA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265998; true Female 151360991 CVCL_B1UC Abcam HeLa IKBKB KO cancer cell line human CVCL_B1UC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5960; IKBKB Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360992 CVCL_B1UF Abcam HeLa IL1RAP KO cancer cell line human CVCL_B1UF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5995; IL1RAP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360993 CVCL_B1UE Abcam HeLa IL18 KO cancer cell line human CVCL_B1UE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5986; IL18 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360994 CVCL_B1UH Abcam HeLa IL6ST KO cancer cell line human CVCL_B1UH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6021; IL6ST Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360995 CVCL_B1UG Abcam HeLa IL20 KO cancer cell line human CVCL_B1UG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6002; IL20 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360996 CVCL_B1UJ Abcam HeLa INF2 KO cancer cell line human CVCL_B1UJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23791; INF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360997 CVCL_B1UI Abcam HeLa INA KO cancer cell line human CVCL_B1UI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6057; INA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360998 CVCL_B1WB Abcam HeLa LYPLA2 KO cancer cell line human CVCL_B1WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6738; LYPLA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151360999 CVCL_B1WA Abcam HeLa LY6K KO cancer cell line human CVCL_B1WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24225; LY6K Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361000 CVCL_B1WD Abcam HeLa MAGT1 KO cancer cell line human CVCL_B1WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28880; MAGT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361001 CVCL_B1WC Abcam HeLa MAGEA6 KO cancer cell line human CVCL_B1WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6804; MAGEA6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361002 CVCL_B1VU Abcam HeLa LIN7C KO cancer cell line human CVCL_B1VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17789; LIN7C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361003 CVCL_B1W6 Abcam HeLa LRRK1 KO cancer cell line human CVCL_B1W6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18608; LRRK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361004 CVCL_B1VT Abcam HeLa LIMCH1 KO cancer cell line human CVCL_B1VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29191; LIMCH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361005 CVCL_B1W5 Abcam HeLa LRRC58 KO cancer cell line human CVCL_B1W5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26968; LRRC58 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361006 CVCL_B1VW Abcam HeLa LIX1L KO cancer cell line human CVCL_B1VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28715; LIX1L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361007 CVCL_B1W8 Abcam HeLa LTB4R2 KO cancer cell line human CVCL_B1W8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19260; LTB4R2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361008 CVCL_B1VV Abcam HeLa LITAF KO cancer cell line human CVCL_B1VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16841; LITAF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361009 CVCL_B1W7 Abcam HeLa LRWD1 KO cancer cell line human CVCL_B1W7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21769; LRWD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361010 CVCL_B1VY Abcam HeLa LMNA KO cancer cell line human CVCL_B1VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361011 CVCL_B1VX Abcam HeLa LMF2 KO cancer cell line human CVCL_B1VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25096; LMF2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361012 CVCL_B1W9 Abcam HeLa LXN KO cancer cell line human CVCL_B1W9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13347; LXN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361013 CVCL_B1VZ Abcam HeLa LMNB1 KO cancer cell line human CVCL_B1VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361014 CVCL_B1VM Abcam HeLa LAMTOR2 KO cancer cell line human CVCL_B1VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29796; LAMTOR2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361015 CVCL_B1VL Abcam HeLa LAMTOR1 KO cancer cell line human CVCL_B1VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26068; LAMTOR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361016 CVCL_B1W0 Abcam HeLa LOX KO cancer cell line human CVCL_B1W0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6664; LOX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361017 CVCL_B1VN Abcam HeLa LAMTOR3 KO cancer cell line human CVCL_B1VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15606; LAMTOR3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361018 CVCL_B1VQ Abcam HeLa LARP4B KO cancer cell line human CVCL_B1VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28987; LARP4B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361019 CVCL_B1W2 Abcam HeLa LPGAT1 KO cancer cell line human CVCL_B1W2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28985; LPGAT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361020 CVCL_B1VP Abcam HeLa LANCL1 KO cancer cell line human CVCL_B1VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6508; LANCL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361021 CVCL_B1W1 Abcam HeLa LOXL2 KO cancer cell line human CVCL_B1W1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6666; LOXL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361022 CVCL_B1VS Abcam HeLa LIF KO cancer cell line human CVCL_B1VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6596; LIF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361023 CVCL_B1W4 Abcam HeLa LRRC41 KO cancer cell line human CVCL_B1W4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16917; LRRC41 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361024 CVCL_B1VR Abcam HeLa LDB1 KO cancer cell line human CVCL_B1VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6532; LDB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361025 CVCL_B1W3 Abcam HeLa LPL KO cancer cell line human CVCL_B1W3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6677; LPL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361026 CVCL_B1VE Abcam HeLa L1CAM KO 1 cancer cell line human CVCL_B1VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6470; L1CAM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361027 CVCL_B1VD Abcam HeLa KRT8 KO cancer cell line human CVCL_B1VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6446; KRT8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361028 CVCL_B1VG Abcam HeLa L3MBTL2 KO cancer cell line human CVCL_B1VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18594; L3MBTL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361029 CVCL_B1VF Abcam HeLa L1CAM KO 2 cancer cell line human CVCL_B1VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6470; L1CAM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361030 CVCL_B1VI Abcam HeLa LAMB1 KO cancer cell line human CVCL_B1VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6486; LAMB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361031 CVCL_B1VH Abcam HeLa LAMA3 KO cancer cell line human CVCL_B1VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6483; LAMA3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361032 CVCL_B1VK Abcam HeLa LAMP3 KO cancer cell line human CVCL_B1VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14582; LAMP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361033 CVCL_B1VJ Abcam HeLa LAMP2 KO cancer cell line human CVCL_B1VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6501; LAMP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361034 CVCL_B1SZ Abcam HeLa GMNN KO cancer cell line human CVCL_B1SZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17493; GMNN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361035 CVCL_B1SY Abcam HeLa GLRX2 KO cancer cell line human CVCL_B1SY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16065; GLRX2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361036 CVCL_B1TA Abcam HeLa GSTM4 KO cancer cell line human CVCL_B1TA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4636; GSTM4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361037 CVCL_B1SR Abcam HeLa GDA KO cancer cell line human CVCL_B1SR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4212; GDA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361038 CVCL_B1T3 Abcam HeLa GNG11 KO cancer cell line human CVCL_B1T3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4403; GNG11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361039 CVCL_B1SQ Abcam HeLa GBA KO cancer cell line human CVCL_B1SQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361040 CVCL_B1T2 Abcam HeLa GNB4 KO cancer cell line human CVCL_B1T2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20731; GNB4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361041 CVCL_B1ST Abcam HeLa GEMIN6 KO cancer cell line human CVCL_B1ST CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20044; GEMIN6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361042 CVCL_B1T5 Abcam HeLa GNS KO cancer cell line human CVCL_B1T5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4422; GNS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361043 CVCL_B1SS Abcam HeLa GDE1 KO cancer cell line human CVCL_B1SS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29644; GDE1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361044 CVCL_B1T4 Abcam HeLa GNPAT KO cancer cell line human CVCL_B1T4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4416; GNPAT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361045 CVCL_B1SV Abcam HeLa GIT1 KO cancer cell line human CVCL_B1SV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4272; GIT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361046 CVCL_B1T7 Abcam HeLa GPSM2 KO cancer cell line human CVCL_B1T7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29501; GPSM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361047 CVCL_B1SU Abcam HeLa GGCX KO cancer cell line human CVCL_B1SU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4247; GGCX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361048 CVCL_B1T6 Abcam HeLa GOLM2 KO cancer cell line human CVCL_B1T6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24892; GOLM2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361049 CVCL_B1SX Abcam HeLa GLOD4 KO cancer cell line human CVCL_B1SX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14111; GLOD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361050 CVCL_B1T9 Abcam HeLa GRK4 KO cancer cell line human CVCL_B1T9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4543; GRK4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361051 CVCL_B1SW Abcam HeLa GLA KO cancer cell line human CVCL_B1SW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361052 CVCL_B1T8 Abcam HeLa GPX4 KO cancer cell line human CVCL_B1T8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4556; GPX4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361053 CVCL_B1SJ Abcam HeLa GABRE KO cancer cell line human CVCL_B1SJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4085; GABRE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361054 CVCL_B1SI Abcam HeLa FZD6 KO cancer cell line human CVCL_B1SI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4044; FZD6 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361055 CVCL_B1SL Abcam HeLa GAGE12J KO cancer cell line human CVCL_B1SL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17778; GAGE12J Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361056 CVCL_B1SK Abcam HeLa GADD45B KO cancer cell line human CVCL_B1SK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4096; GADD45B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361057 CVCL_B1SN Abcam HeLa GALK1 KO cancer cell line human CVCL_B1SN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4118; GALK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361058 CVCL_B1SM Abcam HeLa GAL KO cancer cell line human CVCL_B1SM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4114; GAL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361059 CVCL_B1SP Abcam HeLa GANC KO cancer cell line human CVCL_B1SP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4139; GANC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361060 CVCL_B1T1 Abcam HeLa GNB1 KO cancer cell line human CVCL_B1T1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4396; GNB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361061 CVCL_B1T0 Abcam HeLa GNA13 KO cancer cell line human CVCL_B1T0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4381; GNA13 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361062 CVCL_B1SB Abcam HeLa FOXA1 KO cancer cell line human CVCL_B1SB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5021; FOXA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361063 CVCL_B1SA Abcam HeLa FOLR1 KO cancer cell line human CVCL_B1SA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3791; FOLR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361064 CVCL_B1SD Abcam HeLa FTL KO 1 cancer cell line human CVCL_B1SD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361065 CVCL_B1SC Abcam HeLa FOXA2 KO cancer cell line human CVCL_B1SC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5022; FOXA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265862; true Female 151361066 CVCL_B1SF Abcam HeLa FXR1 KO cancer cell line human CVCL_B1SF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4023; FXR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361067 CVCL_B1SE Abcam HeLa FTL KO 2 cancer cell line human CVCL_B1SE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361068 CVCL_B1SH Abcam HeLa FZD2 KO cancer cell line human CVCL_B1SH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4040; FZD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361069 CVCL_B1SG Abcam HeLa FZD1 KO cancer cell line human CVCL_B1SG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4038; FZD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361070 CVCL_B1TZ Abcam HeLa HSPA8 KO cancer cell line human CVCL_B1TZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5241; HSPA8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361071 CVCL_B1UB Abcam HeLa IGF1R KO cancer cell line human CVCL_B1UB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5465; IGF1R Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361072 CVCL_B1UA Abcam HeLa IFNGR1 KO cancer cell line human CVCL_B1UA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361073 CVCL_B1TS Abcam HeLa HNRNPDL KO cancer cell line human CVCL_B1TS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5037; HNRNPDL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361074 CVCL_B1U4 Abcam HeLa IDE KO cancer cell line human CVCL_B1U4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5381; IDE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361075 CVCL_B1TR Abcam HeLa HMGN4 KO cancer cell line human CVCL_B1TR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4989; HMGN4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361076 CVCL_B1U3 Abcam HeLa ICAM1 KO cancer cell line human CVCL_B1U3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5344; ICAM1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361077 CVCL_B1TU Abcam HeLa HPDL KO cancer cell line human CVCL_B1TU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28242; HPDL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361078 CVCL_B1U6 Abcam HeLa IDS KO cancer cell line human CVCL_B1U6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5389; IDS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361079 CVCL_B1TT Abcam HeLa HPCAL1 KO cancer cell line human CVCL_B1TT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5145; HPCAL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361080 CVCL_B1U5 Abcam HeLa IDH1 KO cancer cell line human CVCL_B1U5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361081 CVCL_B1TW Abcam HeLa HPSE KO cancer cell line human CVCL_B1TW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5164; HPSE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361082 CVCL_B1U8 Abcam HeLa IFITM3 KO cancer cell line human CVCL_B1U8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361083 CVCL_B1TV Abcam HeLa HPS5 KO cancer cell line human CVCL_B1TV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17022; HPS5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361084 CVCL_B1U7 Abcam HeLa IER2 KO cancer cell line human CVCL_B1U7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28871; IER2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361085 CVCL_B1TY Abcam HeLa HSD3B7 KO cancer cell line human CVCL_B1TY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18324; HSD3B7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361086 CVCL_B1TX Abcam HeLa HR KO cancer cell line human CVCL_B1TX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5172; HR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361087 CVCL_B1U9 Abcam HeLa IFNE KO cancer cell line human CVCL_B1U9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18163; IFNE Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361088 CVCL_B1TK Abcam HeLa HES1 KO cancer cell line human CVCL_B1TK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5192; HES1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361089 CVCL_B1TJ Abcam HeLa HERC4 KO cancer cell line human CVCL_B1TJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24521; HERC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361090 CVCL_B1TM Abcam HeLa HIBADH KO cancer cell line human CVCL_B1TM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4907; HIBADH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361091 CVCL_B1TL Abcam HeLa HGF KO cancer cell line human CVCL_B1TL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4893; HGF Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Abcam; ab265221; true Female 151361092 CVCL_B1U0 Abcam HeLa HSPB1 KO cancer cell line human CVCL_B1U0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5246; HSPB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361093 CVCL_B1TN Abcam HeLa HINT1 KO cancer cell line human CVCL_B1TN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4912; HINT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361094 CVCL_B1TQ Abcam HeLa HMGB1 KO cancer cell line human CVCL_B1TQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4983; HMGB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361095 CVCL_B1U2 Abcam HeLa HTT KO cancer cell line human CVCL_B1U2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4851; HTT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361096 CVCL_B1TP Abcam HeLa HIPK3 KO cancer cell line human CVCL_B1TP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4915; HIPK3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361097 CVCL_B1U1 Abcam HeLa HSPB8 KO cancer cell line human CVCL_B1U1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30171; HSPB8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361098 CVCL_B1TC Abcam HeLa GTPBP2 KO cancer cell line human CVCL_B1TC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4670; GTPBP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361099 CVCL_B1TB Abcam HeLa GSTT2B KO cancer cell line human CVCL_B1TB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33437; GSTT2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361100 CVCL_B1TE Abcam HeLa H1-2 KO cancer cell line human CVCL_B1TE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4716; H1-2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361101 CVCL_B1TD Abcam HeLa GYS1 KO cancer cell line human CVCL_B1TD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4706; GYS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361102 CVCL_B1TG Abcam HeLa HAO1 KO cancer cell line human CVCL_B1TG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4809; HAO1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361103 CVCL_B1TF Abcam HeLa HAGH KO cancer cell line human CVCL_B1TF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4805; HAGH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361104 CVCL_B1TI Abcam HeLa HENMT1 KO cancer cell line human CVCL_B1TI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26400; HENMT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151361105 CVCL_B1TH Abcam HeLa HELLS KO cancer cell line human CVCL_B1TH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4861; HELLS Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151665932 CVCL_B5J3 HAP1 FASTKD2 (-) 2 cancer cell line human CVCL_B5J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29160; FASTKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665933 CVCL_B5J2 1B5 [Mouse myogenic] cancer cell line house mouse CVCL_B5J2 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99659; Ryr1; Transfected with: MGI; MGI:97275; Myod1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skeletal muscle Cell type=Fibroblast.; Breed/subspecies: 129SV ry1(53). Unspecified Characteristics: Can be induced to differentiate into noncontractile multinucleated myotubes (PubMed=9472036) Doubling time: ~18-24 hours (PubMed=9472036) 151665934 CVCL_B5JM HAP1 C17orf80 (-) 2 cancer cell line human CVCL_B5JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29601; C17orf80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665935 CVCL_B5JL HAP1 BCKDHA (-) 2 cancer cell line human CVCL_B5JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 986; BCKDHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665936 CVCL_B5K0 HAP1 DHTKD1 (-) 6 cancer cell line human CVCL_B5K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665937 CVCL_B5JN HAP1 C17orf80 (-) 3 cancer cell line human CVCL_B5JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29601; C17orf80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665938 CVCL_B5JQ HAP1 C17orf80 (-) 5 cancer cell line human CVCL_B5JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29601; C17orf80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665939 CVCL_B5K2 HAP1 ECHS1 (-) 3 cancer cell line human CVCL_B5K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3151; ECHS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665940 CVCL_B5JP HAP1 C17orf80 (-) 4 cancer cell line human CVCL_B5JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29601; C17orf80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665941 CVCL_B5K1 HAP1 ECHS1 (-) 2 cancer cell line human CVCL_B5K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3151; ECHS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665942 CVCL_B5JS HAP1 CCDC92 (-) 2 cancer cell line human CVCL_B5JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29563; CCDC92; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665943 CVCL_B5K4 HAP1 ECHS1 (-) 5 cancer cell line human CVCL_B5K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3151; ECHS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665944 CVCL_B5JR HAP1 C7orf55 (-) 2 cancer cell line human CVCL_B5JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26946; FMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665945 CVCL_B5K3 HAP1 ECHS1 (-) 4 cancer cell line human CVCL_B5K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3151; ECHS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665946 CVCL_B5JE END-1 cancer cell line human CVCL_B5JE CL:0000010 Female Characteristics: Established from an undifferentiated endometrial carcinoma serially transplanted into nude mice (PubMed=1176207) Doubling time: 14 hours (PubMed=1176207). 151665947 CVCL_B5JD alpha-Mel/37 hybridoma house mouse CVCL_B5JD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665948 CVCL_B5JG HAP1 ALOX5 (-) 2 cancer cell line human CVCL_B5JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 435; ALOX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665949 CVCL_B5JF HAP1 ACSL4 (-) 2 cancer cell line human CVCL_B5JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3571; ACSL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665950 CVCL_B5JI HAP1 ARRDC1 (-) 2 cancer cell line human CVCL_B5JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28633; ARRDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665951 CVCL_B5JH HAP1 ALOX5 (-) 3 cancer cell line human CVCL_B5JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 435; ALOX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665952 CVCL_B5JK HAP1 ATE1 (-) 2 cancer cell line human CVCL_B5JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 782; ATE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665953 CVCL_B5JJ HAP1 ARRDC1 (-) 3 cancer cell line human CVCL_B5JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28633; ARRDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665954 CVCL_B5JA alpha-Mel/12 hybridoma house mouse CVCL_B5JA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665955 CVCL_B5JC alpha-Mel/34 hybridoma house mouse CVCL_B5JC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665956 CVCL_B5JB alpha-Mel/14 hybridoma house mouse CVCL_B5JB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665957 CVCL_B5J5 HAP1 FASTKD2 (-) 4 cancer cell line human CVCL_B5J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29160; FASTKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665958 CVCL_B5J4 HAP1 FASTKD2 (-) 3 cancer cell line human CVCL_B5J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29160; FASTKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665959 CVCL_B5J7 alpha-Mel/5 hybridoma house mouse CVCL_B5J7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665960 CVCL_B5J6 HAP1 DHX30 (-) cancer cell line human CVCL_B5J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16716; DHX30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151665961 CVCL_B5J9 alpha-Mel/11 hybridoma house mouse CVCL_B5J9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665962 CVCL_B5J8 alpha-Mel/7 hybridoma house mouse CVCL_B5J8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cells. 151665963 CVCL_B5R5 CBiPS-E7C9 induced pluripotent stem cell human CVCL_B5R5 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665964 CVCL_B5QT GM02340 iPSC clone 1 induced pluripotent stem cell human CVCL_B5QT CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 151665965 CVCL_B5R4 CBiPS-E7C12 induced pluripotent stem cell human CVCL_B5R4 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665966 CVCL_B5QS ICNDXHi001-A induced pluripotent stem cell human CVCL_B5QS From: Innovation Center for Neurological Disorders, Xuanwu Hospital, National Clinical Research Center for Geriatric Diseases, Capital Medical University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Leu658Val (c.1972C>G) (p.Leu266Val, c.796C>G or p.Leu583Val, c.1747C>G); ClinVar=VCV000014266; Zygosity=Heterozygous (PubMed=34995843) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151665967 CVCL_B5QV iHUF3 induced pluripotent stem cell human CVCL_B5QV CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 151665968 CVCL_B5R7 LZ6+3 induced pluripotent stem cell human CVCL_B5R7 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 151665969 CVCL_B5QU GM02340 iPSC clone 6 induced pluripotent stem cell human CVCL_B5QU CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 151665970 CVCL_B5R6 LZ6+2 induced pluripotent stem cell human CVCL_B5R6 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 151665971 CVCL_B5QX CBiPS-E17C1 induced pluripotent stem cell human CVCL_B5QX CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665972 CVCL_B5R9 UMNi001-C induced pluripotent stem cell human CVCL_B5R9 CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665973 CVCL_B5QW CBiPS-E12C1 induced pluripotent stem cell human CVCL_B5QW CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665974 CVCL_B5R8 LZ6+10 induced pluripotent stem cell human CVCL_B5R8 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 151665975 CVCL_B5QZ CBiPS-E20C2 induced pluripotent stem cell human CVCL_B5QZ CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665976 CVCL_B5QY CBiPS-E17C6 induced pluripotent stem cell human CVCL_B5QY CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665977 CVCL_B5QL WAe009-A-80 embryonic stem cell human CVCL_B5QL From: QiqiHar Medical University; Qiqihar; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28956; GPD1L. Female 151665978 CVCL_B5QK WAe009-A-79 embryonic stem cell human CVCL_B5QK From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple_edited; p.Leu114Pro (c.341T>C); ClinVar=VCV000053036; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg). Female 151665979 CVCL_B5QN WAe009-A-82 embryonic stem cell human CVCL_B5QN From: Southern Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8507; OSMR; Simple_edited; p.Gly513Asp (c.1538G>A); ClinVar=VCV000802119; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=35714449). Female 151665980 CVCL_B5QM WAe009-A-81 embryonic stem cell human CVCL_B5QM From: Center for Stem Cell Biology and Tissue Engineering, Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7391; MSX1. Female 151665981 CVCL_B5R1 CBiPS-E5C3 induced pluripotent stem cell human CVCL_B5R1 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665982 CVCL_B5QP WAe001-A-76 embryonic stem cell human CVCL_B5QP From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1. Male 151665983 CVCL_B5R0 CBiPS-E24C2 induced pluripotent stem cell human CVCL_B5R0 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665984 CVCL_B5R3 CBiPS-E7C1 induced pluripotent stem cell human CVCL_B5R3 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665985 CVCL_B5QR CPGHi006-A induced pluripotent stem cell human CVCL_B5QR From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Unexplicit; Ex3-15del; Zygosity=Heterozygous (PubMed=35091308) Population: Chinese; Derived from sampling site: Peripheral blood. Female 151665986 CVCL_B5R2 CBiPS-E32C9 induced pluripotent stem cell human CVCL_B5R2 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 151665987 CVCL_B5QQ CPGHi005-A induced pluripotent stem cell human CVCL_B5QQ From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 11190; SOX10; Unexplicit; SVA-F retrotransposon insertion in intron 2; Zygosity=Heterozygous (PubMed=35691110) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151665988 CVCL_B5QD ITXi002-A induced pluripotent stem cell human CVCL_B5QD From: Institut du Thorax; Nantes; France CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 151665989 CVCL_B5QC ITXi011-A induced pluripotent stem cell human CVCL_B5QC From: Institut du Thorax; Nantes; France CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Arg4959Glu (c.14876G>A); Zygosity=Heterozygous (PubMed=35101670) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151665990 CVCL_B5QF ITXi002-A-2 induced pluripotent stem cell human CVCL_B5QF From: Institut du Thorax; Nantes; France CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14361; IRX5 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 151665991 CVCL_B5QE ITXi002-A-1 induced pluripotent stem cell human CVCL_B5QE From: Institut du Thorax; Nantes; France CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 14361; IRX5 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 151665992 CVCL_B5QH ITXi001-A-1 induced pluripotent stem cell human CVCL_B5QH From: Institut du Thorax; Nantes; France CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21718; GPR146 Population: Caucasian; Derived from sampling site: Urine. Female 151665993 CVCL_B5QG ITXi002-A-3 induced pluripotent stem cell human CVCL_B5QG From: Institut du Thorax; Nantes; France CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male Characteristics: Using CRISPR/Cas9 a HA tag was introduced at the C-termini of IRX5 (PubMed=34929443) 151665994 CVCL_B5QJ WAe009-A-78 embryonic stem cell human CVCL_B5QJ From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11595; TBX18. Female 151665995 CVCL_B5QI WAe009-A-76 embryonic stem cell human CVCL_B5QI From: Research Institute of Molecular Pathology; Vienna; Austria CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using TALEN a construct containing CAGGS:loxP-STOP-loxp_mCherrynls-T2A-Puro was introduced in the AAVS1 safe harbor locus (hPSCreg); Characteristics: Using CRISPR/Cas9 a construct containing T2A-H2BVenus-p2A-CreERT was introduced at the C-terminus of BEST1 (hPSCreg) 151665996 CVCL_B5PZ JWR-26c hybrid cell line CVCL_B5PZ CL:0000010 Group: Human/rodent somatic cell hybrid. 151665997 CVCL_B5QB ITXi010-A induced pluripotent stem cell human CVCL_B5QB From: Institut du Thorax; Nantes; France CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Tyr2476Asp (c.7426T>G); Zygosity=Heterozygous (PubMed=35101670) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151665998 CVCL_B5QA ITXi009-A induced pluripotent stem cell human CVCL_B5QA From: Institut du Thorax; Nantes; France CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Arg4959Glu (c.14876G>A); Zygosity=Heterozygous (PubMed=35101670) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151665999 CVCL_B5RU CSUASOi010-A induced pluripotent stem cell human CVCL_B5RU From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 151666000 CVCL_B5S6 PUMCHi018-A induced pluripotent stem cell human CVCL_B5S6 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 19977; RDH12; Simple; p.Arg62Ter (c.184C>T); ClinVar=VCV000002050; Zygosity=Heterozygous (PubMed=35016144); Sequence variation: Mutation; HGNC; 19977; RDH12; Simple; p.Val146Asp (c.437T>A); ClinVar=VCV000841398; Zygosity=Heterozygous (PubMed=35016144) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151666001 CVCL_B5S5 CRMi003-A-2 induced pluripotent stem cell human CVCL_B5S5 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Umbilical cord blood. Male Characteristics: Expresses a doxycycline inducible H2B-mTurquoise2 reporter Instrumental to track cells and to temporally assess cell divisions and apoptosis in iPSC-based differentiation and cell toxicity assays (PubMed=34775202).; Characteristics: Using CRISPR/Cas9 a T2A-PuroR-CAG-rTA3G-H2B-mTurquoise2-TRE3G construct was introduced in the AAVS1 safe harbor locus (PubMed=34775202) 151666002 CVCL_B5RT CSUASOi009-A induced pluripotent stem cell human CVCL_B5RT From: Central South University, Aier School of Ophthalmology; Changsha; China. CL:0000010 151666003 CVCL_B5RW BCHCNi001-A induced pluripotent stem cell human CVCL_B5RW From: Department of Neurology, Beijing Children's Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 25695; CARS2; Simple; p.Gly476Arg (c.1426G>A); Zygosity=Homozygous (PubMed=34953328) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151666004 CVCL_B5S8 PUMCHi007-A induced pluripotent stem cell human CVCL_B5S8 From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666005 CVCL_B5RV CSUASOi011-A induced pluripotent stem cell human CVCL_B5RV From: Central South University, Aier School of Ophthalmology; Changsha; China. CL:0000010 151666006 CVCL_B5S7 PUMCHi017-A induced pluripotent stem cell human CVCL_B5S7 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Unexplicit; Ex1-2del; Zygosity=Hemizygous (PubMed=35032821) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 151666007 CVCL_B5RY SKLRMe001-A embryonic stem cell human CVCL_B5RY From: State Key Laboratory of Reproductive Medicine, Nanjing Medical University; Nanjing; China. CL:0000010 Male 151666008 CVCL_B5S9 PUMCHi008-A induced pluripotent stem cell human CVCL_B5S9 From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666009 CVCL_B5RX UIi001-A induced pluripotent stem cell human CVCL_B5RX From: University of Iowa; Iowa City; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666010 CVCL_B5RZ KSCBi014-A induced pluripotent stem cell human CVCL_B5RZ From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Thr152Profs*14 (c.453delC); ClinVar=VCV000200598; Zygosity=Heterozygous (PubMed=34678663) Population: Korean; Derived from sampling site: Peripheral blood. Female 151666011 CVCL_B5RM CHA-NTK6 embryonic stem cell human CVCL_B5RM From: CHA University; Seongnam; South Korea CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Characteristics: Produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 52-year-old female patient with age-related macular degeneration 151666012 CVCL_B5RL UNIZARi001-A induced pluripotent stem cell human CVCL_B5RL From: University of Zaragoza; Zaragoza; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11831; TK2; Simple; p.Arg130Trp (c.388C>T); ClinVar=VCV000038988; Zygosity=Heterozygous (PubMed=34973561); Sequence variation: Mutation; HGNC; 11831; TK2; Simple; p.Lys202del (c.604_606delAAG); ClinVar=VCV000038995; Zygosity=Heterozygous (PubMed=34973561) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666013 CVCL_B5S0 KSCBi016-A induced pluripotent stem cell human CVCL_B5S0 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea. CL:0000010 151666014 CVCL_B5RN CHA-NTK7 embryonic stem cell human CVCL_B5RN From: CHA University; Seongnam; South Korea CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Characteristics: Produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 52-year-old female patient with age-related macular degeneration 151666015 CVCL_B5RQ CHAHESe001-A-1 embryonic stem cell human CVCL_B5RQ From: Konkuk University; Seoul; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M. Female Characteristics: The parent cell line was produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 59-year-old male patient with age-related macular degeneration 151666016 CVCL_B5S2 KICRi002-A-5 induced pluripotent stem cell human CVCL_B5S2 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9187; POLR2A Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 151666017 CVCL_B5RP CHA-NTK8 embryonic stem cell human CVCL_B5RP From: CHA University; Seongnam; South Korea CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Characteristics: Produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 59-year-old male patient with age-related macular degeneration 151666018 CVCL_B5S1 KICRi002-A-4 induced pluripotent stem cell human CVCL_B5S1 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 151666019 CVCL_B5S4 HVRDe008-A-2 embryonic stem cell human CVCL_B5S4 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using CRISPR/Cas9 a P2A-eSpCas9-IRES-PuroR-pA construct was introduced at the C-terminus of one allele of GAPDH (PubMed=34741877) 151666020 CVCL_B5RS SHCDNi006-A induced pluripotent stem cell human CVCL_B5RS From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 18865; KCNT1; Simple; p.Ala934Thr (c.2800G>A); ClinVar=VCV000039594; Zygosity=Heterozygous; Note=De novo mutation (PubMed=35537242) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 151666021 CVCL_B5RR CHA-NTK9 embryonic stem cell human CVCL_B5RR From: CHA University; Seongnam; South Korea CL:0000010 Male Characteristics: Produced by somatic cell nuclear transfer from a dermal fibroblast (hDF) cells donated from a 59-year-old male patient with age-related macular degeneration. 151666022 CVCL_B5S3 IRFMNi001-B-1 induced pluripotent stem cell human CVCL_B5S3 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA Population: Caucasian; Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 151666023 CVCL_B5RE SW4#SE induced pluripotent stem cell human CVCL_B5RE CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 151666024 CVCL_B5RD SW4#N1 induced pluripotent stem cell human CVCL_B5RD CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Female 151666025 CVCL_B5RG SW8#5P induced pluripotent stem cell human CVCL_B5RG CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 151666026 CVCL_B5RF SW8#20I induced pluripotent stem cell human CVCL_B5RF CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Female 151666027 CVCL_B5RI T1D HKSV#D induced pluripotent stem cell human CVCL_B5RI CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 151666028 CVCL_B5RH T1D HKLV#2 induced pluripotent stem cell human CVCL_B5RH CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 151666029 CVCL_B5RK T2D2 HKSV#i induced pluripotent stem cell human CVCL_B5RK CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 151666030 CVCL_B5RJ T2D1 HKSV#A induced pluripotent stem cell human CVCL_B5RJ CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Female 151666031 CVCL_B5RA SW10#20A induced pluripotent stem cell human CVCL_B5RA CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 151666032 CVCL_B5RC SW3#B induced pluripotent stem cell human CVCL_B5RC CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Female 151666033 CVCL_B5RB SW10#5P induced pluripotent stem cell human CVCL_B5RB CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 151666034 CVCL_B5P2 TF173B induced pluripotent stem cell human CVCL_B5P2 CL:0000010 Derived from sampling site: Peripheral blood. Female 151666035 CVCL_B5P5 SPF [Trachinotus] spontaneously immortalized cell line CVCL_B5P5 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 27 hours, at 55th passage (PubMed=34609743) Group: Fish cell line 151666036 CVCL_B5P4 SPE spontaneously immortalized cell line CVCL_B5P4 CL:0000010 Derived from sampling site: Eye. Unspecified Doubling time: 34 hours, at 72th passage (PubMed=34609743) Group: Fish cell line 151666037 CVCL_B5P7 SPH [Trachinotus] spontaneously immortalized cell line CVCL_B5P7 CL:0000010 Derived from sampling site: Heart. Unspecified Doubling time: 36 hours, at 61th passage (PubMed=34609743) Group: Fish cell line 151666038 CVCL_B5P6 SPG spontaneously immortalized cell line CVCL_B5P6 CL:0000010 Derived from sampling site: Gill. Unspecified Doubling time: 29 hours, at 45th passage (PubMed=34609743) Group: Fish cell line 151666039 CVCL_B5P9 WG1826 finite cell line human CVCL_B5P9 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666040 CVCL_B5P8 SPK spontaneously immortalized cell line CVCL_B5P8 CL:0000010 Derived from sampling site: Kidney. Unspecified Doubling time: 30 hours, at 66th passage (PubMed=34609743) Group: Fish cell line 151666041 CVCL_B5P1 88.6/D800-B spontaneously immortalized cell line house mouse CVCL_B5P1 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Sequence variation: Mutation; MGI; MGI:1347061; Abcg2; Simple; p.Arg482Ser (c.1446G>T); Zygosity=Homozygous (PubMed=11956086) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Cell type=Fibroblast. Unspecified 151666042 CVCL_B5P0 88.6/D800-A spontaneously immortalized cell line house mouse CVCL_B5P0 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Sequence variation: Mutation; MGI; MGI:1347061; Abcg2; Simple; p.Arg482Met (c.1445G>T); Zygosity=Homozygous (PubMed=11956086) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Cell type=Fibroblast. Unspecified 151666043 CVCL_B5NY 88.6/D200-A spontaneously immortalized cell line house mouse CVCL_B5NY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Cell type=Fibroblast. Unspecified 151666044 CVCL_B5NX 88.6 spontaneously immortalized cell line house mouse CVCL_B5NX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b Derived from sampling site: Cell type=Fibroblast. Unspecified 151666045 CVCL_B5NZ 88.6/D200-B spontaneously immortalized cell line house mouse CVCL_B5NZ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Cell type=Fibroblast. Unspecified 151666046 CVCL_B5PS AG27611 induced pluripotent stem cell human CVCL_B5PS CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 151666047 CVCL_B5Q4 ITXi005-A induced pluripotent stem cell human CVCL_B5Q4 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; French; Derived from sampling site: Peripheral blood. Male 151666048 CVCL_B5PR AG27609 induced pluripotent stem cell human CVCL_B5PR CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 151666049 CVCL_B5Q3 SCVIi041-A induced pluripotent stem cell human CVCL_B5Q3 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Gln (c.398G>A); ClinVar=VCV000200934; Zygosity=Heterozygous (PubMed=34999423) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666050 CVCL_B5PU AG27875 induced pluripotent stem cell human CVCL_B5PU CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 151666051 CVCL_B5Q6 ITXi007-A induced pluripotent stem cell human CVCL_B5Q6 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; French; Derived from sampling site: Urine. Female 151666052 CVCL_B5PT AG27703 induced pluripotent stem cell human CVCL_B5PT CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+21 (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666053 CVCL_B5Q5 ITXi006-A induced pluripotent stem cell human CVCL_B5Q5 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; French; Derived from sampling site: Peripheral blood. Male 151666054 CVCL_B5Q8 ITXi003-A induced pluripotent stem cell human CVCL_B5Q8 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 151666055 CVCL_B5PW TS-408 finite cell line human CVCL_B5PW CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. 151666056 CVCL_B5Q7 ITXi008-A induced pluripotent stem cell human CVCL_B5Q7 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; French; Derived from sampling site: Peripheral blood. Female 151666057 CVCL_B5PV NCC-DMM1-C1 cancer cell line human CVCL_B5PV CL:0000010 Population: Japanese; Derived from sampling site: Lung; pleura. Omics: SNP array analysis Male Doubling time: 25.9 hours (PubMed=35069873) 151666058 CVCL_B5PY JoVa finite cell line human CVCL_B5PY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 151666059 CVCL_B5Q9 ITXi004-A induced pluripotent stem cell human CVCL_B5Q9 From: Institut du Thorax; Nantes; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 151666060 CVCL_B5PX TS-495 finite cell line human CVCL_B5PX CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. 151666061 CVCL_B5PK AG28262 induced pluripotent stem cell human CVCL_B5PK CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 151666062 CVCL_B5PJ AG28205 induced pluripotent stem cell human CVCL_B5PJ CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666063 CVCL_B5PM AG28278 induced pluripotent stem cell human CVCL_B5PM CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 151666064 CVCL_B5PL AG28269 induced pluripotent stem cell human CVCL_B5PL CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666065 CVCL_B5Q0 JWR-5 hybrid cell line CVCL_B5Q0 CL:0000010 Group: Human/rodent somatic cell hybrid. 151666066 CVCL_B5PN AG28340 induced pluripotent stem cell human CVCL_B5PN CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell) Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 151666067 CVCL_B5PQ AG27608 induced pluripotent stem cell human CVCL_B5PQ CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666068 CVCL_B5Q2 SCVIi040-A induced pluripotent stem cell human CVCL_B5Q2 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Gln (c.398G>A); ClinVar=VCV000200934; Zygosity=Heterozygous (PubMed=34999423) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666069 CVCL_B5PP AG27606 induced pluripotent stem cell human CVCL_B5PP CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666070 CVCL_B5Q1 SCVIi039-A induced pluripotent stem cell human CVCL_B5Q1 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Gln (c.398G>A); ClinVar=VCV000200934; Zygosity=Heterozygous (PubMed=34999423) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666071 CVCL_B5PC WG1871 finite cell line human CVCL_B5PC From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg157Gln (c.470G>A); ClinVar=VCV000003519; Zygosity=Heterozygous (PubMed=8940272) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666072 CVCL_B5PB WG2073 finite cell line human CVCL_B5PB From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666073 CVCL_B5PE iMSC#3 telomerase immortalized cell line human CVCL_B5PE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Array-based CGH; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 151666074 CVCL_B5PD WG1872 finite cell line human CVCL_B5PD From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg567Ter (c.1699C>T); ClinVar=VCV000660609; Zygosity=Heterozygous (from familial inference of WG1779 and WG1871) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666075 CVCL_B5PG AG28041 induced pluripotent stem cell human CVCL_B5PG CL:0000010 Population: African American; Karyotypic information: 46,XX,inv(9)(pter->p11::q13->p11::q13->qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 151666076 CVCL_B5PF MCF7-FGFR1 cancer cell line human CVCL_B5PF CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3688; FGFR1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 151666077 CVCL_B5PI AG28057 induced pluripotent stem cell human CVCL_B5PI CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666078 CVCL_B5PH AG28049 induced pluripotent stem cell human CVCL_B5PH CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 151666079 CVCL_B5PA WG1951 finite cell line human CVCL_B5PA From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666080 CVCL_B5N1 RCM-25 hybridoma CVCL_B5N1 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04460; Rabbit MYH6. 151666081 CVCL_B5MP SCC15/R1 cancer cell line human CVCL_B5MP CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Oral cavity; tongue. Male Doubling time: 1.5-1.7 days (PubMed=6201865) 151666082 CVCL_B5N0 CCM-52 hybridoma house mouse CVCL_B5N0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P29616; Chicken MYH6 (Note=Also reacts with mouse). 151666083 CVCL_B5N3 1003-pK4 clone 8129 cancer cell line house mouse CVCL_B5N3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Unspecified 151666084 CVCL_B5MR SCC15/R3 cancer cell line human CVCL_B5MR CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Oral cavity; tongue. Male Doubling time: 1.5-1.7 days (PubMed=6201865) 151666085 CVCL_B5N2 RCM-37 hybridoma CVCL_B5N2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04460; Rabbit MYH6. 151666086 CVCL_B5MQ SCC15/R2 cancer cell line human CVCL_B5MQ CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Oral cavity; tongue. Male Doubling time: 1.5-1.7 days (PubMed=6201865) 151666087 CVCL_B5N5 120G8 hybridoma CVCL_B5N5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8R2Q8; Mouse Bst2/Cd317. 151666088 CVCL_B5MT F9K4b2 cancer cell line house mouse CVCL_B5MT CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: 129/Sv. Male 151666089 CVCL_B5N4 C1 [Mouse teratocarcinoma] cancer cell line house mouse CVCL_B5N4 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Unspecified Characteristics: Established from a tumor obtained by injection of parent cell line into irradiated syngeneic mice (PubMed=2153146); Characteristics: After injection into syngeneic mice, produce typical osteosarcomas 151666090 CVCL_B5MS SCC15/R4 cancer cell line human CVCL_B5MS CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Oral cavity; tongue. Male Doubling time: 1.5-1.7 days (PubMed=6201865) 151666091 CVCL_B5MV C17 [Mouse teratocarcinoma] cancer cell line house mouse CVCL_B5MV CL:0000010 Breed/subspecies: C3H. Unspecified 151666092 CVCL_B5N7 MFUM-BrTNBC-1 cancer cell line human CVCL_B5N7 CL:0000010 Sequence variation: Mutation; HGNC; 393; AKT3; Simple; p.Lys294Ter (c.880A>T); Zygosity=Heterozygous (PubMed=35011679); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Tyr2037Ter (c.6111C>G); Zygosity=Heterozygous (PubMed=35011679); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly32Arg (c.94G>C); ClinVar=VCV001690925; Zygosity=Heterozygous (PubMed=35011679); Sequence variation: Mutation; HGNC; 7993; NRBP1; Simple; p.Lys217Ter (c.649A>T); Zygosity=Heterozygous (PubMed=35011679); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=35011679); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gln829Ter (c.2485C>T); Zygosity=Heterozygous (PubMed=35011679) Population: Caucasian; Slovenian; Derived from sampling site: Breast. Female Characteristics: Shown by ICC and PCR to be ER-negative, PR-negative and ERBB2-negative (PubMed=35011679) Doubling time: 80 hours (PubMed=35011679) Group: Triple negative breast cancer (TNBC) cell line 151666093 CVCL_B5MU 1C11 [Mouse teratocarcinoma] cancer cell line house mouse CVCL_B5MU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: 129/Sv. Male Characteristics: Tumorigenic in syngeneic mice (PubMed=2155426); Characteristics: Presents two states: an immature phenotype (1C11 precursor) and a more differentiated state (1C11*) After induction by Bt2cAMP and cyclohexanecarboxylate, 1C11* cells extend neurites and express neural markers such as NCAM1, synaptophysin and [Met5]enkephalin in >95% of the clonal population (PubMed=2155426). Doubling time: 20 hours (PubMed=2155426) 151666094 CVCL_B5N6 927 hybridoma CVCL_B5N6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8R2Q8; Mouse Bst2/Cd317. 151666095 CVCL_B5MH 77RD40 finite cell line human CVCL_B5MH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666096 CVCL_B5MG 77RD224 finite cell line human CVCL_B5MG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666097 CVCL_B5MJ 79RD200 finite cell line human CVCL_B5MJ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666098 CVCL_B5MI 77RD6 finite cell line human CVCL_B5MI CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666099 CVCL_B5ML 79RD257 finite cell line human CVCL_B5ML CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666100 CVCL_B5MK 79RD220 finite cell line human CVCL_B5MK CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666101 CVCL_B5MN 81RD5 finite cell line human CVCL_B5MN CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666102 CVCL_B5MM 80RD143 finite cell line human CVCL_B5MM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666103 CVCL_B5MB AT8BI finite cell line human CVCL_B5MB CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Met1Thr (c.2T>C); ClinVar=VCV000187275; Zygosity=Unspecified (from autologous cell line AT8BI LCL) Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666104 CVCL_B5MA M-3405 finite cell line human CVCL_B5MA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666105 CVCL_B5MD AT4LA finite cell line human CVCL_B5MD CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666106 CVCL_B5MC AT5LA finite cell line human CVCL_B5MC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 151666107 CVCL_B5MF 77RD218 finite cell line human CVCL_B5MF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666108 CVCL_B5ME AT3LA finite cell line human CVCL_B5ME CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666109 CVCL_B5M8 alphaTN4-1-26 transformed cell line house mouse CVCL_B5M8 CL:0000010 Transfected with: RGD; 2279; Cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 151666110 CVCL_B5LW CS4MI finite cell line human CVCL_B5LW CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666111 CVCL_B5LV CS5MI finite cell line human CVCL_B5LV CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666112 CVCL_B5M7 N/N1003A-KL spontaneously immortalized cell line CVCL_B5M7 CL:0000010 Transfected with: RGD; 2279; Cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: New Zealand white. Female 151666113 CVCL_B5LY AP57P finite cell line human CVCL_B5LY CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33355142); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Trp322Ter (c.966delG); Zygosity=Homozygous (PubMed=33355142); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33355142) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666114 CVCL_B5LX CS1ATM finite cell line human CVCL_B5LX CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666115 CVCL_B5M9 SC [Human Marfan syndrome] finite cell line human CVCL_B5M9 From: Departement Scienze Biomediche e Biotecnologie, Universita degli Studi di Brescia; Brescia; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666116 CVCL_B5LZ AP57P(SVT) transformed cell line human CVCL_B5LZ CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Trp322Ter (c.966delG); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666117 CVCL_B5NQ PGPC3_87 induced pluripotent stem cell human CVCL_B5NQ CL:0000010 Sequence variation: Mutation; HGNC; 17993; TRPM4; Simple; p.Gly844Asp (c.2531G>A); ClinVar=VCV000035489; Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666118 CVCL_B5NP PGPC3_75 induced pluripotent stem cell human CVCL_B5NP CL:0000010 Sequence variation: Mutation; HGNC; 17993; TRPM4; Simple; p.Gly844Asp (c.2531G>A); ClinVar=VCV000035489; Zygosity=Heterozygous (PubMed=31813827); Sequence variation: Mutation; HGNC; 13077; ZNF283; Simple; p.Cys21Ter (c.63C>A); Zygosity=Heterozygous (PubMed=31813827) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151666119 CVCL_B5NR PGPC3_93 induced pluripotent stem cell human CVCL_B5NR CL:0000010 Sequence variation: Mutation; HGNC; 17993; TRPM4; Simple; p.Gly844Asp (c.2531G>A); ClinVar=VCV000035489; Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666120 CVCL_B5NU KOT52/D320 spontaneously immortalized cell line house mouse CVCL_B5NU CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1; Sequence variation: Mutation; MGI; MGI:1347061; Abcg2; Simple; p.Arg482Met (c.1445G>T); Zygosity=Heterozygous (PubMed=11956086) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ear Cell type=Fibroblast.. Unspecified 151666121 CVCL_B5NT KOT52 spontaneously immortalized cell line house mouse CVCL_B5NT CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1 Derived from sampling site: Ear Cell type=Fibroblast.. Unspecified 151666122 CVCL_B5NW KOT52/D800 spontaneously immortalized cell line house mouse CVCL_B5NW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1; Sequence variation: Mutation; MGI; MGI:1347061; Abcg2; Simple; p.Arg482Met (c.1445G>T); Zygosity=Heterozygous (PubMed=11956086) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ear Cell type=Fibroblast.. Unspecified 151666123 CVCL_B5NV KOT52/D80 spontaneously immortalized cell line house mouse CVCL_B5NV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ear Cell type=Fibroblast.. Unspecified 151666124 CVCL_B5NI PGPC17_142 induced pluripotent stem cell human CVCL_B5NI CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666125 CVCL_B5NH PGPC17_11_MYBPC3_KO induced pluripotent stem cell human CVCL_B5NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7551; MYBPC3 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 151666126 CVCL_B5NK PGPC17_45 induced pluripotent stem cell human CVCL_B5NK CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666127 CVCL_B5NJ PGPC17_4 induced pluripotent stem cell human CVCL_B5NJ CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666128 CVCL_B5NM PGPC3_23 induced pluripotent stem cell human CVCL_B5NM CL:0000010 Sequence variation: Mutation; HGNC; 17993; TRPM4; Simple; p.Gly844Asp (c.2531G>A); ClinVar=VCV000035489; Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666129 CVCL_B5NL PGPC17_80 induced pluripotent stem cell human CVCL_B5NL CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666130 CVCL_B5NN PGPC3_66 induced pluripotent stem cell human CVCL_B5NN CL:0000010 Sequence variation: Mutation; HGNC; 17993; TRPM4; Simple; p.Gly844Asp (c.2531G>A); ClinVar=VCV000035489; Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666131 CVCL_B5NA PGPC1_73 induced pluripotent stem cell human CVCL_B5NA CL:0000010 Sequence variation: Mutation; HGNC; 3581; BPTF; Simple; p.Lys1039Ter (c.3115A>T); Zygosity=Heterozygous (PubMed=31813827); Sequence variation: Mutation; HGNC; 3039; DSCAM; Simple; c.509-1G>A; dbSNP=rs1569089053; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31813827); Sequence variation: Mutation; HGNC; 4199; GCN1; Simple; p.Ser2475Profs*19 (c.7423delT); Zygosity=Heterozygous (PubMed=31813827) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151666132 CVCL_B5NC PGPC14_16 induced pluripotent stem cell human CVCL_B5NC CL:0000010 Sequence variation: Mutation; HGNC; 6242; KCNE2; Simple; p.Thr10Met (c.29C>T); Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666133 CVCL_B5NB PGPC1_96 induced pluripotent stem cell human CVCL_B5NB CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666134 CVCL_B5NE PGPC14_70 induced pluripotent stem cell human CVCL_B5NE CL:0000010 Sequence variation: Mutation; HGNC; 6242; KCNE2; Simple; p.Thr10Met (c.29C>T); Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666135 CVCL_B5ND PGPC14_26 induced pluripotent stem cell human CVCL_B5ND CL:0000010 Sequence variation: Mutation; HGNC; 25491; FRMD4A; Simple; c.563+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=31813827); Sequence variation: Mutation; HGNC; 6242; KCNE2; Simple; p.Thr10Met (c.29C>T); Zygosity=Heterozygous (from inference of genome of donor); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Heterozygous (PubMed=31813827); Sequence variation: Mutation; HGNC; 32669; TRIM71; Simple; p.Arg655Ter (c.1963C>T); Zygosity=Heterozygous (PubMed=31813827) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 151666136 CVCL_B5NG PGPC17_11 induced pluripotent stem cell human CVCL_B5NG CL:0000010 Sequence variation: Mutation; HGNC; 10250; ROBO2; Simple; p.Trp874Ter (c.2621G>A); Zygosity=Heterozygous (PubMed=31813827) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 151666137 CVCL_B5NF PGPC14_94 induced pluripotent stem cell human CVCL_B5NF CL:0000010 Sequence variation: Mutation; HGNC; 6242; KCNE2; Simple; p.Thr10Met (c.29C>T); Zygosity=Heterozygous (from inference of genome of donor) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666138 CVCL_B5MX C17-S1 clone 1003 cancer cell line house mouse CVCL_B5MX CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Unspecified 151666139 CVCL_B5N9 PGPC1_67 induced pluripotent stem cell human CVCL_B5N9 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666140 CVCL_B5MW C17-S1 cancer cell line house mouse CVCL_B5MW CL:0000010 Breed/subspecies: C3H. Unspecified 151666141 CVCL_B5N8 PGPC1_30 induced pluripotent stem cell human CVCL_B5N8 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666142 CVCL_B5MZ C17-S1-D-T984-15 cancer cell line house mouse CVCL_B5MZ CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Unspecified Characteristics: No longer differentiates in vitro into myogenic tissue (PubMed=7029000) 151666143 CVCL_B5MY C17-S1-D-T984 cancer cell line house mouse CVCL_B5MY CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Unspecified 151666144 CVCL_B5KN HAP1 PEX3 (-) 3 cancer cell line human CVCL_B5KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8858; PEX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666145 CVCL_B5KM HAP1 PEX3 (-) 2 cancer cell line human CVCL_B5KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8858; PEX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666146 CVCL_B5KP HAP1 PMS1 (-) 2 cancer cell line human CVCL_B5KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9121; PMS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666147 CVCL_B5L1 HAP1 TMEM189 (-) 2 cancer cell line human CVCL_B5L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16735; PEDS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666148 CVCL_B5L0 HAP1 TLR4 (-) 3 cancer cell line human CVCL_B5L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11850; TLR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666149 CVCL_B5KR HAP1 PPARGC1A (-) 3 cancer cell line human CVCL_B5KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9237; PPARGC1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666150 CVCL_B5L3 HAP1 TMEM39B (-) 2 cancer cell line human CVCL_B5L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25510; TMEM39B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666151 CVCL_B5KQ HAP1 PPARGC1A (-) 2 cancer cell line human CVCL_B5KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9237; PPARGC1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666152 CVCL_B5L2 HAP1 TMEM189 (-) 3 cancer cell line human CVCL_B5L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16735; PEDS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666153 CVCL_B5KT HAP1 RAB1A (-) 2 cancer cell line human CVCL_B5KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9758; RAB1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666154 CVCL_B5L5 HAP1 TMEM8A (-) 2 cancer cell line human CVCL_B5L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17205; PGAP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666155 CVCL_B5KS HAP1 PPARGC1A (-) 4 cancer cell line human CVCL_B5KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9237; PPARGC1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666156 CVCL_B5L4 HAP1 TMEM69 (-) 2 cancer cell line human CVCL_B5L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28035; TMEM69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666157 CVCL_B5KF HAP1 NDUFS3 (-) 2 cancer cell line human CVCL_B5KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7710; NDUFS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666158 CVCL_B5KE END-2 cancer cell line human CVCL_B5KE CL:0000010 Female Characteristics: Established from an undifferentiated endometrial carcinoma serially transplanted into nude mice (PubMed=1176207) Doubling time: 16 hours (PubMed=1176207). 151666159 CVCL_B5KH HAP1 NDUFS3 (-) 4 cancer cell line human CVCL_B5KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7710; NDUFS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666160 CVCL_B5KG HAP1 NDUFS3 (-) 3 cancer cell line human CVCL_B5KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7710; NDUFS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666161 CVCL_B5KJ HAP1 NR5A2 (-) 2 cancer cell line human CVCL_B5KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7984; NR5A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666162 CVCL_B5KI HAP1 NMRK1 (-) 2 cancer cell line human CVCL_B5KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26057; NMRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666163 CVCL_B5KL HAP1 PAN3 (-) 2 cancer cell line human CVCL_B5KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29991; PAN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666164 CVCL_B5KK HAP1 NUDT9 (-) 2 cancer cell line human CVCL_B5KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8056; NUDT9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666165 CVCL_B5KB HAP1 MDH2 (-) 2 cancer cell line human CVCL_B5KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6971; MDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666166 CVCL_B5KA HAP1 LPIN1 (-) 2 cancer cell line human CVCL_B5KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13345; LPIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666167 CVCL_B5KD HAP1 MYO18A (-) 3 cancer cell line human CVCL_B5KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31104; MYO18A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666168 CVCL_B5KC HAP1 MYO18A (-) 2 cancer cell line human CVCL_B5KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31104; MYO18A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666169 CVCL_B5JU HAP1 DGUOK (-) 2 cancer cell line human CVCL_B5JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2858; DGUOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666170 CVCL_B5K6 HAP1 GLB1 (-) 2 cancer cell line human CVCL_B5K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4298; GLB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666171 CVCL_B5JT HAP1 CCDC92 (-) 3 cancer cell line human CVCL_B5JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29563; CCDC92; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666172 CVCL_B5K5 HAP1 ESR1 (-) 2 cancer cell line human CVCL_B5K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3467; ESR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666173 CVCL_B5JW HAP1 DHTKD1 (-) 2 cancer cell line human CVCL_B5JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666174 CVCL_B5K8 HAP1 HECTD1 (-) 2 cancer cell line human CVCL_B5K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20157; HECTD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666175 CVCL_B5JV HAP1 DGUOK (-) 3 cancer cell line human CVCL_B5JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2858; DGUOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666176 CVCL_B5K7 HAP1 GSDMD (-) 2 cancer cell line human CVCL_B5K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25697; GSDMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666177 CVCL_B5JY HAP1 DHTKD1 (-) 4 cancer cell line human CVCL_B5JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666178 CVCL_B5JX HAP1 DHTKD1 (-) 3 cancer cell line human CVCL_B5JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666179 CVCL_B5K9 HAP1 HIF1AN (-) 2 cancer cell line human CVCL_B5K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17113; HIF1AN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666180 CVCL_B5JZ HAP1 DHTKD1 (-) 5 cancer cell line human CVCL_B5JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666181 CVCL_B5M0 FA50P finite cell line human CVCL_B5M0 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Trp322Ter (c.966delG); Zygosity=Homozygous (PubMed=33355142); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33355142) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666182 CVCL_B5LN GM02351 finite cell line human CVCL_B5LN CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM02351; probable Female 151666183 CVCL_B5M2 AP39P-iPSC#1 induced pluripotent stem cell human CVCL_B5M2 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33512438); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Ala278Pro (c.832G>C); ClinVar=VCV000995827; Zygosity=Heterozygous (PubMed=33512438); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33512438) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666184 CVCL_B5LQ N19OS finite cell line human CVCL_B5LQ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666185 CVCL_B5LP AG22791 finite cell line house mouse CVCL_B5LP CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 151666186 CVCL_B5M1 FA50P-iPSC#1 induced pluripotent stem cell human CVCL_B5M1 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Trp322Ter (c.966delG); Zygosity=Homozygous (PubMed=33512438); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33512438) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666187 CVCL_B5M4 AP39P-iPSC#2 induced pluripotent stem cell human CVCL_B5M4 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33512438); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Ala278Pro (c.832G>C); ClinVar=VCV000995827; Zygosity=Heterozygous (PubMed=33512438); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33512438) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666188 CVCL_B5LS CS1YO finite cell line human CVCL_B5LS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666189 CVCL_B5M3 FA50P-iPSC#2 induced pluripotent stem cell human CVCL_B5M3 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Trp322Ter (c.966delG); Zygosity=Homozygous (PubMed=33512438); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33512438) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666190 CVCL_B5LR N20OS finite cell line human CVCL_B5LR CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 151666191 CVCL_B5LU CS1YOM finite cell line human CVCL_B5LU CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666192 CVCL_B5M6 MK-40 finite cell line human CVCL_B5M6 CL:0000010 Population: Japanese; Karyotypic information: 46,XX,inv(9)(p13;q21)pat (JCRB); Derived from sampling site: Amniotic fluid. Unspecified 151666193 CVCL_B5LT CS1YOF finite cell line human CVCL_B5LT CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666194 CVCL_B5M5 MK-41 finite cell line human CVCL_B5M5 CL:0000010 Population: Japanese; Karyotypic information: 48,XY,+16,+22 (JCRB); Derived from sampling site: Chorionic villus. Female 151666195 CVCL_B5LG GM28283 finite cell line human CVCL_B5LG CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with inclusion myopathy but possess the mutation affecting his brother, mother and uncle; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666196 CVCL_B5LF GM28302 transformed cell line human CVCL_B5LF CL:0000010 Population: Jewish; Ashkenazi and Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151666197 CVCL_B5LI IGR-10 cancer cell line human CVCL_B5LI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Inguinal lymph node. Male 151666198 CVCL_B5LH IPC-167 cancer cell line human CVCL_B5LH CL:0000010 Derived from metastatic site: Inguinal lymph node. Female 151666199 CVCL_B5LK IPC-164 cancer cell line human CVCL_B5LK CL:0000010 Derived from sampling site: Skin. Female 151666200 CVCL_B5LJ IGR-5 finite cell line human CVCL_B5LJ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666201 CVCL_B5LM RCMGi007-A induced pluripotent stem cell human CVCL_B5LM From: Research Centre for Medical Genetics; Moscow; Russia. CL:0000010 151666202 CVCL_B5LL IMEDEAi001-F-1 induced pluripotent stem cell human CVCL_B5LL From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous; Note=By TALEN (PubMed=32373648) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 151666203 CVCL_B5LA BREC1 transformed cell line CVCL_B5LA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rumen Cell type=Epithelial cell.; Breed/subspecies: Angus. Omics: Transcriptome analysis by RNAseq Male 151666204 CVCL_B5LC GM28299 finite cell line human CVCL_B5LC CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly237Valfs*11 (c.710delG) (p.Gly249Valfs*11, c.746delG); ClinVar=VCV000011846; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi and Jewish; Moroccan; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 151666205 CVCL_B5LB GM28047 transformed cell line human CVCL_B5LB CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe107del (c.318CTT[1]) (c.321_323delCTT); ClinVar=VCV000021448; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 151666206 CVCL_B5LE GM28301 transformed cell line human CVCL_B5LE CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151666207 CVCL_B5LD GM28300 transformed cell line human CVCL_B5LD CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly237Valfs*11 (c.710delG) (p.Gly249Valfs*11, c.746delG); ClinVar=VCV000011846; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi and Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 151666208 CVCL_B5KV HAP1 SGSH (-) 2 cancer cell line human CVCL_B5KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10818; SGSH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666209 CVCL_B5L7 HAP1 YTHDF1 (-) 2 cancer cell line human CVCL_B5L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666210 CVCL_B5KU HAP1 SEC31B (-) 2 cancer cell line human CVCL_B5KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23197; SEC31B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666211 CVCL_B5L6 HAP1 WDR45 (-) 2 cancer cell line human CVCL_B5L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28912; WDR45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666212 CVCL_B5L9 8H5 [Mouse/rat hybridoma against human GABARAP] hybridoma CVCL_B5L9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O95166; Human GABARAP. 151666213 CVCL_B5KX HAP1 SHPRH (-) 2 cancer cell line human CVCL_B5KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19336; SHPRH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666214 CVCL_B5L8 HAP1 YTHDF1 (-) 3 cancer cell line human CVCL_B5L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666215 CVCL_B5KZ HAP1 TLR4 (-) 2 cancer cell line human CVCL_B5KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11850; TLR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666216 CVCL_B5KY HAP1 SHPRH (-) 3 cancer cell line human CVCL_B5KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19336; SHPRH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 151666217 CVCL_B6KM Mel Ch cancer cell line human CVCL_B6KM CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Right axillary lymph node. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 706D 151666218 CVCL_B6KL Mel Bgf cancer cell line human CVCL_B6KL CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Right thigh; hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 714D 151666219 CVCL_B6L0 Mel 263 cancer cell line human CVCL_B6L0 CL:0000010 151666220 CVCL_B6KN Mel Gi cancer cell line human CVCL_B6KN CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680). 151666221 CVCL_B6KQ Mel H cancer cell line human CVCL_B6KQ HLA typing: A*03,30; B*07,13 (Patent=RU2402604) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Inguinal lymph node. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 715D 151666222 CVCL_B6L2 Mel IG cancer cell line human CVCL_B6L2 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Hypodermis. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 700D 151666223 CVCL_B6L1 Mel 26G cancer cell line human CVCL_B6L1 CL:0000010 Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 701D 151666224 CVCL_B6KP Mel Gus cancer cell line human CVCL_B6KP CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Right thigh; hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 707D 151666225 CVCL_B6L4 Mel 31G cancer cell line human CVCL_B6L4 CL:0000010 Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 698D 151666226 CVCL_B6KS Mel Is cancer cell line human CVCL_B6KS CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680). 151666227 CVCL_B6L3 Mel 311 cancer cell line human CVCL_B6L3 CL:0000010 151666228 CVCL_B6KR Mel Hn cancer cell line human CVCL_B6KR CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680). 151666229 CVCL_B6KE Mel Z cancer cell line human CVCL_B6KE CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=28881731; PubMed=30551515) Derived from metastatic site: Interscapular region; hypodermis. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 711D 151666230 CVCL_B6KD Mel Il cancer cell line human CVCL_B6KD CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=28881731; PubMed=30551515) Derived from metastatic site: Chest; hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 686D 151666231 CVCL_B6KG Mel Mtp cancer cell line human CVCL_B6KG CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=30551515) Derived from metastatic site: Right axillary lymph node. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 705D 151666232 CVCL_B6KF Mel IL/R cancer cell line human CVCL_B6KF CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=30551515) Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Chest; hypodermis. 151666233 CVCL_B6KI NCC-UPS4-C1 cancer cell line human CVCL_B6KI CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Heterozygous (PubMed=35118583); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (PubMed=35118583) Population: Japanese; Derived from metastatic site: Right knee; hypodermis. Omics: SNP array analysis Female Doubling time: 76 hours (PubMed=35118583) Part of: NCC sarcoma cell line panel 151666234 CVCL_B6KH Mel Me cancer cell line human CVCL_B6KH HLA typing: A*02,31; B*56,58 (Patent=RU2402603) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=30551515) Derived from metastatic site: Back; skin. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 712D 151666235 CVCL_B6KK Mel Kor-TurboRFP cancer cell line human CVCL_B6KK CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain TurboRFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 730D 151666236 CVCL_B6KJ TSK-CHO1 cancer cell line human CVCL_B6KJ CL:0000010 Population: Japanese; Derived from sampling site: Bone; cranium; clivus. Female Doubling time: 47.8 hours (PubMed=35098443) 151666237 CVCL_B6KA Mel Rac cancer cell line human CVCL_B6KA HLA typing: A*23,26; B*08,39 (Patent=RU2402602) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (DOI=10.17650/1726-9784-2018-17-4-27-35; PubMed=28881731); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Right thigh; hypodermis. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 710D 151666238 CVCL_B6KC Mel Ibr subclone cancer cell line human CVCL_B6KC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Hypodermis. Female 151666239 CVCL_B6KB Mel Kor cancer cell line human CVCL_B6KB CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 687D 151666240 CVCL_B6K5 Mel min-16 cancer cell line human CVCL_B6K5 CL:0000010 151666241 CVCL_B6JT Mel min-5 cancer cell line human CVCL_B6JT CL:0000010 151666242 CVCL_B6K4 Mel min-15 cancer cell line human CVCL_B6K4 CL:0000010 151666243 CVCL_B6JS Mel min-4 cancer cell line human CVCL_B6JS CL:0000010 151666244 CVCL_B6K7 Mel min-18 cancer cell line human CVCL_B6K7 CL:0000010 151666245 CVCL_B6JV Mel min-7 cancer cell line human CVCL_B6JV CL:0000010 151666246 CVCL_B6K6 Mel min-17 cancer cell line human CVCL_B6K6 CL:0000010 151666247 CVCL_B6JU Mel min-6 cancer cell line human CVCL_B6JU CL:0000010 151666248 CVCL_B6K9 Mel Cher 5C cancer cell line human CVCL_B6K9 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Male 151666249 CVCL_B6JX U2OS CHMP2B KO cancer cell line human CVCL_B6JX From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24537; CHMP2B Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 151666250 CVCL_B6K8 Mel Cher cancer cell line human CVCL_B6K8 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680; DOI=10.17650/1726-9784-2018-17-4-27-35); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=28881731) Derived from metastatic site: Lymph node. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 704D 151666251 CVCL_B6JW Mel min-8 cancer cell line human CVCL_B6JW CL:0000010 151666252 CVCL_B6JZ Mel min-10 cancer cell line human CVCL_B6JZ CL:0000010 151666253 CVCL_B6JY Mel min-9 cancer cell line human CVCL_B6JY CL:0000010 151666254 CVCL_B6LN 7D8 hybridoma house mouse CVCL_B6LN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03040; Lake Victoria marburgvirus (strain Popp-67) matrix protein VP40. Group: Patented cell line 151666255 CVCL_B6LM 7C4 hybridoma house mouse CVCL_B6LM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q03040; Lake Victoria marburgvirus (strain Popp-67) matrix protein VP40. 151666256 CVCL_B6LP 7H10 [Mouse hybridoma against Marburg virus VP40] hybridoma house mouse CVCL_B6LP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03040; Lake Victoria marburgvirus (strain Popp-67) matrix protein VP40. Group: Patented cell line 151666257 CVCL_B6M1 Ea3.2 factor-dependent cell line house mouse CVCL_B6M1 CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 15-17 hours (PubMed=6201749) 151666258 CVCL_B6M0 Ea3.15 factor-dependent cell line house mouse CVCL_B6M0 CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 19 hours (PubMed=6201749) 151666259 CVCL_B6M3 8G3 hybridoma house mouse CVCL_B6M3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q03039; Lake Victoria marburgvirus (strain Popp-67) polymerase cofactor VP35. 151666260 CVCL_B6LR MPS VII iPSC induced pluripotent stem cell human CVCL_B6LR CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666261 CVCL_B6M2 9C7 hybridoma house mouse CVCL_B6M2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P35263; Lake Victoria marburgvirus (strain Popp-67) nucleoprotein (NP). 151666262 CVCL_B6LQ Mel KG cancer cell line human CVCL_B6LQ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 699D 151666263 CVCL_B6M5 9G6 [Mouse hybridoma against Lake Victoria marburvirus VP40] hybridoma house mouse CVCL_B6M5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q03040; Lake Victoria marburgvirus (strain Popp-67) matrix protein VP40. 151666264 CVCL_B6LT Anti-NG-R1 hybridoma house mouse CVCL_B6LT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:77149; Notoginsenoside R1. 151666265 CVCL_B6M4 9D8 [Mouse hybridoma against Marburg virus VP35] hybridoma house mouse CVCL_B6M4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q03039; Lake Victoria marburgvirus (strain Popp-67) polymerase cofactor VP35. 151666266 CVCL_B6LS 9F [Mouse hybridoma against ginkgolic acids] hybridoma house mouse CVCL_B6LS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:5354; Ginkgolic acids (Ginkgoic acid). 151666267 CVCL_B6LF 3F9 [Mouse hybridoma against Lake Victoria marburgvirus VP35] hybridoma house mouse CVCL_B6LF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03039; Lake Victoria marburgvirus (strain Popp-67) polymerase cofactor VP35. 151666268 CVCL_B6LE 1C1 [Mouse hybridoma against Ebola virus VP40] hybridoma house mouse CVCL_B6LE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q05128; Zaire ebolavirus (strain Mayinga-76) matrix protein VP40. Group: Patented cell line 151666269 CVCL_B6LH 5F1 hybridoma house mouse CVCL_B6LH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P35263; Lake Victoria marburgvirus (strain Popp-67) nucleoprotein (NP). 151666270 CVCL_B6LG 4A2 [Mouse hybridoma against Ebola virus VP40] hybridoma house mouse CVCL_B6LG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q05128; Zaire ebolavirus (strain Mayinga-76) matrix protein VP40. Group: Patented cell line 151666271 CVCL_B6LJ 1C6 [Mouse hybridoma against Ebola virus VP35] hybridoma house mouse CVCL_B6LJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q05127; Zaire ebolavirus (strain Mayinga-76) polymerase cofactor VP35. 151666272 CVCL_B6LI 5F10 hybridoma house mouse CVCL_B6LI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06725; Human cytomegalovirus (strain AD169) 65 kDa phosphoprotein (pp65). Group: Patented cell line 151666273 CVCL_B6LL 7B11 [Rat hybridoma against Ebola virus NP] hybridoma Norway rat CVCL_B6LL CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P18272; Zaire ebolavirus (strain Mayinga-76) nucleoprotein (NP). Group: Patented cell line 151666274 CVCL_B6LK 6F7 [Mouse hybridoma against Ebola virus VP35] hybridoma house mouse CVCL_B6LK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q05127; Zaire ebolavirus (strain Mayinga-76) polymerase cofactor VP35. 151666275 CVCL_B6LB Mel S cancer cell line human CVCL_B6LB CL:0000010 151666276 CVCL_B6LA Mel Kis cancer cell line human CVCL_B6LA CL:0000010 151666277 CVCL_B6LD 1B2 [Mouse hybridoma against Ebola virus NP] hybridoma house mouse CVCL_B6LD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18272; Zaire ebolavirus (strain Mayinga-76) nucleoprotein (NP). Group: Patented cell line 151666278 CVCL_B6LC Mel ILG cancer cell line human CVCL_B6LC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Chest; hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 697D 151666279 CVCL_B6L6 Mel 226 cancer cell line human CVCL_B6L6 CL:0000010 151666280 CVCL_B6KU Mel R cancer cell line human CVCL_B6KU CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680). 151666281 CVCL_B6KT Mel Ksen cancer cell line human CVCL_B6KT CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 713D 151666282 CVCL_B6L5 MEL-REO cancer cell line human CVCL_B6L5 CL:0000010 151666283 CVCL_B6L8 Mel 82 cancer cell line human CVCL_B6L8 CL:0000010 151666284 CVCL_B6KW RIM9 hybridoma house mouse CVCL_B6KW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07498; Human CASK (AA 57-134; lactapin). Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 722D 151666285 CVCL_B6L7 Mel 259 cancer cell line human CVCL_B6L7 CL:0000010 151666286 CVCL_B6KV Mel Si cancer cell line human CVCL_B6KV CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Gln (c.1790T>A); ClinVar=VCV000076687; Zygosity=Unspecified (CelloPub=CLPUB00680); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Back; skin. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 708D 151666287 CVCL_B6KY 1H8 [Mouse hybridoma against sheep IgG] hybridoma house mouse CVCL_B6KY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Sheep IgG. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 73 151666288 CVCL_B6KX A-4A7 hybridoma house mouse CVCL_B6KX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09466; Human PAEP. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 722D 151666289 CVCL_B6L9 Mel E cancer cell line human CVCL_B6L9 CL:0000010 151666290 CVCL_B6KZ Mel PG cancer cell line human CVCL_B6KZ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2434; CSF2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 702D 151666291 CVCL_B6IK NH50362 induced pluripotent stem cell human CVCL_B6IK CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666292 CVCL_B6IJ NH50361 induced pluripotent stem cell human CVCL_B6IJ CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666293 CVCL_B6IM mPAC-4.4 transformed cell line house mouse CVCL_B6IM CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666294 CVCL_B6IL mPAC-4.3 transformed cell line house mouse CVCL_B6IL CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666295 CVCL_B6J0 NIH/3T3-174 transformed cell line house mouse CVCL_B6J0 CL:0000010 Transfected with: MGI; MGI:98447; Surf6; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Overexpresses SURF6 in the presence of doxycycline; Characteristics: Transfected with two constructs: 1) pcDNA3.1(-)rtTA which contains a rtTA and a neo gene The reverse tetracycline-controlled transactivator (rtTA) is a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16. 2) pBI-mSURF6 that contains a bidirectorial tetracycline-responsible element (Tre) flanked by two minimal bi-directorial CMV promoters which govern co-expression of SURF6 and EGFP. Group: Patented cell line 151666296 CVCL_B6IN DZ-MAb hybridoma house mouse CVCL_B6IN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:42202; Daidzin (Daidzein 7-O-beta-D-glucoside); Monoclonal antibody target: ChEBI; CHEBI:27514; Genistin (Genistein 7-O-beta-D-glucoside). 151666297 CVCL_B6IQ 2H9 [Mouse hybridoma against trans-resveratrol] hybridoma house mouse CVCL_B6IQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:45713; Trans-resveratrol. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-121 151666298 CVCL_B6J2 mEER transformed cell line house mouse CVCL_B6J2 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Age/sex of donor from personal communication of Vermeer P.D Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Caution: Was originally said to be derived from tonsils, an anatomical structure that does not exist in mouse 151666299 CVCL_B6IP 1B1 hybridoma house mouse CVCL_B6IP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:45713; Trans-resveratrol. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-122 151666300 CVCL_B6J1 P56 hybridoma Norway rat CVCL_B6J1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12004; Human PCNA. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-107 151666301 CVCL_B6IC NH50353 induced pluripotent stem cell human CVCL_B6IC CL:0000010 Population: Caucasian. Female 151666302 CVCL_B6IB NH50352 induced pluripotent stem cell human CVCL_B6IB CL:0000010 Population: Caucasian. Female 151666303 CVCL_B6IE NH50355 induced pluripotent stem cell human CVCL_B6IE CL:0000010 Population: Asian. Male 151666304 CVCL_B6ID NH50354 induced pluripotent stem cell human CVCL_B6ID CL:0000010 Population: Asian. Male 151666305 CVCL_B6IG NH50357 induced pluripotent stem cell human CVCL_B6IG CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666306 CVCL_B6IF NH50356 induced pluripotent stem cell human CVCL_B6IF CL:0000010 Population: Asian. Male 151666307 CVCL_B6II NH50360 induced pluripotent stem cell human CVCL_B6II CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666308 CVCL_B6IH NH50358 induced pluripotent stem cell human CVCL_B6IH CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666309 CVCL_B6HZ NH50340 finite cell line human CVCL_B6HZ CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666310 CVCL_B6HY NH50339 induced pluripotent stem cell human CVCL_B6HY CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666311 CVCL_B6IA NH50351 induced pluripotent stem cell human CVCL_B6IA CL:0000010 Population: Caucasian. Female 151666312 CVCL_B6HR NH50332 induced pluripotent stem cell human CVCL_B6HR CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666313 CVCL_B6I3 NH50344 induced pluripotent stem cell human CVCL_B6I3 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666314 CVCL_B6HQ NH50331 induced pluripotent stem cell human CVCL_B6HQ CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666315 CVCL_B6I2 NH50343 induced pluripotent stem cell human CVCL_B6I2 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666316 CVCL_B6HT NH50334 induced pluripotent stem cell human CVCL_B6HT CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666317 CVCL_B6I5 NH50346 induced pluripotent stem cell human CVCL_B6I5 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666318 CVCL_B6HS NH50333 induced pluripotent stem cell human CVCL_B6HS CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666319 CVCL_B6I4 NH50345 induced pluripotent stem cell human CVCL_B6I4 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666320 CVCL_B6HV NH50336 induced pluripotent stem cell human CVCL_B6HV CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male Characteristics: Non-edited control for NH50337 (Cellosaurus=CVCL_B6HW) 151666321 CVCL_B6I7 NH50348 induced pluripotent stem cell human CVCL_B6I7 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (NHCDR). Population: Caucasian Female 151666322 CVCL_B6HU NH50335 induced pluripotent stem cell human CVCL_B6HU CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666323 CVCL_B6I6 NH50347 induced pluripotent stem cell human CVCL_B6I6 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (NHCDR). Population: Caucasian Male 151666324 CVCL_B6HX NH50338 induced pluripotent stem cell human CVCL_B6HX CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666325 CVCL_B6I9 NH50350 induced pluripotent stem cell human CVCL_B6I9 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (NHCDR). Population: Caucasian Female 151666326 CVCL_B6HW NH50337 induced pluripotent stem cell human CVCL_B6HW CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 151666327 CVCL_B6I8 NH50349 induced pluripotent stem cell human CVCL_B6I8 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (NHCDR). Population: Caucasian Female 151666328 CVCL_B6JK Mel Ibr cancer cell line human CVCL_B6JK CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680; PubMed=28881731) Derived from metastatic site: Hypodermis. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 689D 151666329 CVCL_B6JN PiGAS cancer cell line human CVCL_B6JN CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Hypodermis. Characteristics: Transfected with a construct pGL3-6xGAS-FFL-Neo that contains six gamma-interferon-activated sites (GAS) followed by a minimum SV40 promoter and the Luc gene Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-161 151666330 CVCL_B6JM Mel P cancer cell line human CVCL_B6JM CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00680) Derived from metastatic site: Hypodermis. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 688D 151666331 CVCL_B6JP Mel min-1 cancer cell line human CVCL_B6JP CL:0000010 151666332 CVCL_B6K1 Mel min-12 cancer cell line human CVCL_B6K1 CL:0000010 151666333 CVCL_B6K0 Mel min-11 cancer cell line human CVCL_B6K0 CL:0000010 151666334 CVCL_B6K3 Mel min-14 cancer cell line human CVCL_B6K3 CL:0000010 151666335 CVCL_B6JR Mel min-3 cancer cell line human CVCL_B6JR CL:0000010 151666336 CVCL_B6K2 Mel min-13 cancer cell line human CVCL_B6K2 CL:0000010 151666337 CVCL_B6JQ Mel min-2 cancer cell line human CVCL_B6JQ CL:0000010 151666338 CVCL_B6JD N52 hybridoma house mouse CVCL_B6JD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08833; Human IGFBP1 (Note=Indicated to recognizes PAMG-1 but it is not 100% clear if PAMG-1=IGFBP1). Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-92 151666339 CVCL_B6JC C-HAlb spontaneously immortalized cell line CVCL_B6JC CL:0000010 Transfected with: HGNC; 399; ALB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-179 151666340 CVCL_B6JF N42 hybridoma house mouse CVCL_B6JF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08833; Human IGFBP1 (Note=Indicated to recognizes PAMG-1 but it is not 100% clear if PAMG-1=IGFBP1). Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-94 151666341 CVCL_B6JE N271 hybridoma house mouse CVCL_B6JE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08833; Human IGFBP1 (Note=Indicated to recognizes PAMG-1 but it is not 100% clear if PAMG-1=IGFBP1). Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-93 151666342 CVCL_B6JH 4G1-D2 hybridoma house mouse CVCL_B6JH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DTW1; Human GAGE1. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-174 151666343 CVCL_B6JG MEL-P cancer cell line human CVCL_B6JG CL:0000010 Derived from sampling site: Neck; skin. Male Doubling time: 22-24 hours, at 50th passage (PubMed=8819123) 151666344 CVCL_B6JJ AMACR, clone G8 hybridoma house mouse CVCL_B6JJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UHK6; Human AMACR. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-166 151666345 CVCL_B6JI 6H9 [Mouse hybridoma against human AMACR] hybridoma house mouse CVCL_B6JI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9UHK6; Human AMACR. 151666346 CVCL_B6IZ 3A3 [Mouse hybridoma against plumbagin] hybridoma house mouse CVCL_B6IZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:8273; Plumbagin. 151666347 CVCL_B6JB mEERL95 transformed cell line house mouse CVCL_B6JB CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Characteristics: Established from a tumor in a C57BL/6JRj mouse which was implanted with the parent cell line (PubMed=29313973) 151666348 CVCL_B6JA MOSEC Trp53-/-;Pten-/- DKO clone 4 transformed cell line house mouse CVCL_B6JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:109583; Pten; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct epithelium; Breed/subspecies: C57BL/6. Female 151666349 CVCL_B6IS 4A3 hybridoma house mouse CVCL_B6IS CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:15948; Lycopene. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-171 151666350 CVCL_B6J4 MLM #1 transformed cell line house mouse CVCL_B6J4 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Characteristics: Established from lung tumors obtained after injection of the parent cell line into a mouse that was then treated with cisplatin/radiation therapy (CRT) (PubMed=27013584) 151666351 CVCL_B6IR 3B12 hybridoma house mouse CVCL_B6IR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:15948; Lycopene. 151666352 CVCL_B6J3 mEERL transformed cell line house mouse CVCL_B6J3 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Age/sex of donor from personal communication of Vermeer P.D Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Caution: Was originally said to be derived from tonsils, an anatomical structure that does not exist in mouse 151666353 CVCL_B6IU 6B9 [Mouse hybridoma against lycopene] hybridoma house mouse CVCL_B6IU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:15948; Lycopene. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-172 151666354 CVCL_B6J6 MLM #5 transformed cell line house mouse CVCL_B6J6 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Characteristics: Established from lung tumors obtained after injection of the parent cell line into a mouse that was then treated with cisplatin/radiation therapy (CRT) (PubMed=27013584) 151666355 CVCL_B6IT 4F10 [Mouse hybridoma against lycopene] hybridoma house mouse CVCL_B6IT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:15948; Lycopene. 151666356 CVCL_B6J5 MLM #3 transformed cell line house mouse CVCL_B6J5 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Characteristics: Established from lung tumors obtained after injection of the parent cell line into a mouse that was then treated with cisplatin/radiation therapy (CRT) (PubMed=27013584) 151666357 CVCL_B6IW 6C3 hybridoma house mouse CVCL_B6IW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:28838; Lutein. 151666359 CVCL_B6IV 2F3 [Mouse hybridoma against lutein and other carotenoids] hybridoma house mouse CVCL_B6IV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:40968; Astaxanthin; Monoclonal antibody target: ChEBI; CHEBI:17579; Beta-carotene; Monoclonal antibody target: ChEBI; CHEBI:28838; Lutein. 151666360 CVCL_B6J7 MLM #10 transformed cell line house mouse CVCL_B6J7 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; oropharynx Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Characteristics: Established from lung tumors obtained after injection of the parent cell line into a mouse that was then treated with cisplatin/radiation therapy (CRT) (PubMed=27013584) 151666361 CVCL_B6IY 1B3 [Mouse hybridoma against aconitine-type alkaloids] hybridoma house mouse CVCL_B6IY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:2430; Aconitine; Monoclonal antibody target: ChEBI; CHEBI:5831; Hypaconitine; Monoclonal antibody target: ChEBI; CHEBI:6089; Jesaconitine; Monoclonal antibody target: ChEBI; CHEBI:6773; Mesaconitine. 151666362 CVCL_B6IX 6H8 hybridoma house mouse CVCL_B6IX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:28838; Lutein. Group: Patented cell line; Registration: International Depositary Authority, Russian National Collection of Industrial Microorganisms; VKPM H-176 151666363 CVCL_B6J9 MOSEC Trp53-/-;Pten-/- DKO clone 2 transformed cell line house mouse CVCL_B6J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:109583; Pten; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct epithelium; Breed/subspecies: C57BL/6. Female 151666364 CVCL_B6GI 1C1 [Mouse hybridoma against artemisinin/artesunate] hybridoma house mouse CVCL_B6GI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:223316; (+)-artemisinin; Monoclonal antibody target: ChEBI; CHEBI:63918; Artesunate. 151666365 CVCL_B6GH 5F7 [Mouse hybridoma against thebaine] hybridoma house mouse CVCL_B6GH CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666366 CVCL_B6GK 5C6 hybridoma house mouse CVCL_B6GK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:34975; Sennoside B. 151666367 CVCL_B6GJ 9D6 hybridoma house mouse CVCL_B6GJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:2981; Baicalin. 151666368 CVCL_B6GM 7H12 hybridoma house mouse CVCL_B6GM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:34975; Sennoside B. 151666369 CVCL_B6GL 5C7 [Mouse hybridoma against sennoside B] hybridoma house mouse CVCL_B6GL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:34975; Sennoside B. 151666370 CVCL_B6H0 MC3T3-NM4 spontaneously immortalized cell line house mouse CVCL_B6H0 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Compared to the parent cell line, lost the ability for mineral deposition (PubMed=11136541) 151666371 CVCL_B6GN 4G6 hybridoma house mouse CVCL_B6GN CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:561823; Glycyrrhizin (Uralsaponin A); Monoclonal antibody target: ChEBI; CHEBI:189708; Glycyrrhetic acid 3-O-glucuronide. 151666372 CVCL_B6GA 1H5 hybridoma house mouse CVCL_B6GA CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666373 CVCL_B6GC 2G1 [Mouse hybridoma against thebaine] hybridoma house mouse CVCL_B6GC CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666374 CVCL_B6GB 2F3 [Mouse hybridoma against thebaine] hybridoma house mouse CVCL_B6GB CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666375 CVCL_B6GE 3A11 hybridoma house mouse CVCL_B6GE CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666376 CVCL_B6GD 2G4 hybridoma house mouse CVCL_B6GD CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666377 CVCL_B6GG 5B6 hybridoma house mouse CVCL_B6GG CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666378 CVCL_B6GF 4C7 hybridoma house mouse CVCL_B6GF CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9519; Thebaine. 151666379 CVCL_B6G9 6B9 [Mouse hybridoma against codeine] hybridoma house mouse CVCL_B6G9 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:16714; Codeine. 151666380 CVCL_B6FX 9D12 hybridoma house mouse CVCL_B6FX CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666381 CVCL_B6FW 4G12 [Mouse hybridoma against forskolin] hybridoma house mouse CVCL_B6FW CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666382 CVCL_B6G8 4H4 hybridoma house mouse CVCL_B6G8 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:16714; Codeine. 151666383 CVCL_B6FZ 1D5-3B-7 hybridoma house mouse CVCL_B6FZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16118; Berberine. 151666384 CVCL_B6FY 9E12 hybridoma house mouse CVCL_B6FY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666385 CVCL_B6G1 9G7 hybridoma house mouse CVCL_B6G1 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:67989; Ginsenoside Rb1. Group: Patented cell line 151666386 CVCL_B6FP SMG-BD9 hybridoma house mouse CVCL_B6FP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666387 CVCL_B6G0 1F4 hybridoma house mouse CVCL_B6G0 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:67987; Ginsenoside Rg1. Group: Patented cell line 151666388 CVCL_B6G3 anti-Rf hybridoma house mouse CVCL_B6G3 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:67986; Ginsenoside Rf. 151666389 CVCL_B6FR SMG-G9 hybridoma house mouse CVCL_B6FR CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666390 CVCL_B6G2 4G10 [Mouse hybridoma against ginsenoside Re] hybridoma house mouse CVCL_B6G2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:77148; Ginsenoside Re. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM AP-20188 151666391 CVCL_B6FQ SMG-G4 hybridoma house mouse CVCL_B6FQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666392 CVCL_B6FT 11A9 hybridoma house mouse CVCL_B6FT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666393 CVCL_B6G5 2A8 hybridoma house mouse CVCL_B6G5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8996; Saikosaponin A. 151666394 CVCL_B6G4 1G6 hybridoma house mouse CVCL_B6G4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8996; Saikosaponin A. 151666395 CVCL_B6FS SMG-G10 hybridoma house mouse CVCL_B6FS CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666396 CVCL_B6FV 1A9 [Mouse hybridoma against forskolin] hybridoma house mouse CVCL_B6FV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666397 CVCL_B6G7 4B9 [Mouse hybridoma against saikosaponins A/C] hybridoma house mouse CVCL_B6G7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8996; Saikosaponin A; Monoclonal antibody target: ChEBI; CHEBI:189704; Saikosaponin C. 151666398 CVCL_B6FU 122F9 hybridoma house mouse CVCL_B6FU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:42471; Forskolin. 151666399 CVCL_B6G6 3G10 hybridoma house mouse CVCL_B6G6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8996; Saikosaponin A; Monoclonal antibody target: ChEBI; CHEBI:183954; Saikosaponin B2. 151666400 CVCL_B6HJ NH50326 induced pluripotent stem cell human CVCL_B6HJ CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 151666401 CVCL_B6HI NH50325 induced pluripotent stem cell human CVCL_B6HI CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male Characteristics: Non-edited control for NH50326 (Cellosaurus=CVCL_B6HJ) 151666402 CVCL_B6HL NH50328 induced pluripotent stem cell human CVCL_B6HL CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ala9Asp (c.26C>A); ClinVar=VCV000016013; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female Characteristics: Non-edited control for NH50327 (Cellosaurus=CVCL_B6HK) 151666403 CVCL_B6HK NH50327 induced pluripotent stem cell human CVCL_B6HK CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple_corrected; p.Ala9Asp (c.26C>A); ClinVar=VCV000016013; Zygosity=Heterozygous; By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666404 CVCL_B6HN NH50359 induced pluripotent stem cell human CVCL_B6HN CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Non-edited control for NH50329 (Cellosaurus=CVCL_B6HM) 151666405 CVCL_B6HM NH50329 induced pluripotent stem cell human CVCL_B6HM CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion_corrected; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666406 CVCL_B6HP NH50330 induced pluripotent stem cell human CVCL_B6HP CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 151666407 CVCL_B6I1 NH50342 finite cell line human CVCL_B6I1 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666408 CVCL_B6I0 NH50341 finite cell line human CVCL_B6I0 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666409 CVCL_B6HB MRL28.8A stromal cell line house mouse CVCL_B6HB CL:0000010 Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: MRL/Mp-lpr/lpr. Unspecified 151666410 CVCL_B6HA MRL28 stromal cell line house mouse CVCL_B6HA CL:0000010 Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: MRL/Mp-lpr/lpr. Unspecified 151666411 CVCL_B6HD KKE transformed cell line house mouse CVCL_B6HD CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2k. Unspecified 151666412 CVCL_B6HC N3 transformed cell line house mouse CVCL_B6HC CL:0000010 Transformant: Recombinant retrovirus 3RV/VN-11; Derived from sampling site: Embryonic brain Cell type=Microglial cell.; Breed/subspecies: CD-1. Unspecified 151666413 CVCL_B6HF NH50322 induced pluripotent stem cell human CVCL_B6HF CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666414 CVCL_B6HE NRBB transformed cell line house mouse CVCL_B6HE CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2b. Unspecified 151666415 CVCL_B6HH NH50324 induced pluripotent stem cell human CVCL_B6HH CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666416 CVCL_B6HG NH50323 induced pluripotent stem cell human CVCL_B6HG CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male 151666417 CVCL_B6GY ROSE 199 spontaneously immortalized cell line Norway rat CVCL_B6GY CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Female 151666418 CVCL_B6GX A13/BACii transformed cell line CVCL_B6GX CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Joint articular cartilage Cell type=Chondrocyte.. Female 151666419 CVCL_B6H9 MRL104 stromal cell line house mouse CVCL_B6H9 CL:0000010 Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: MRL/Mp-lpr/lpr. Unspecified 151666420 CVCL_B6GZ ROSE 239 spontaneously immortalized cell line Norway rat CVCL_B6GZ CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Female 151666421 CVCL_B6GQ 5A8 [Mouse hybridoma against glycyrrhizin] hybridoma house mouse CVCL_B6GQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:561823; Glycyrrhizin (Uralsaponin A). 151666422 CVCL_B6H2 mPAC-4.1 transformed cell line house mouse CVCL_B6H2 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666423 CVCL_B6GP 5A5 [Mouse hybridoma against glycyrrhizin] hybridoma house mouse CVCL_B6GP CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:561823; Glycyrrhizin (Uralsaponin A); Monoclonal antibody target: ChEBI; CHEBI:189708; Glycyrrhetic acid 3-O-glucuronide. 151666424 CVCL_B6H1 mPAC-4 transformed cell line house mouse CVCL_B6H1 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666425 CVCL_B6GS 2C4 [Mouse hybridoma against 2,4-D/2,4-DP] hybridoma house mouse CVCL_B6GS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16738; 2,4-dichlorophenol (2,4-DP); Monoclonal antibody target: ChEBI; CHEBI:28854; 2,4-dichlorophenoxyacetic acid (2,4-D). Group: Patented cell line 151666426 CVCL_B6H4 mPAC-4.1.1.1 transformed cell line house mouse CVCL_B6H4 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666427 CVCL_B6GR 5B4 [Mouse hybridoma against glycyrrhizin] hybridoma house mouse CVCL_B6GR CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:561823; Glycyrrhizin (Uralsaponin A); Monoclonal antibody target: ChEBI; CHEBI:189708; Glycyrrhetic acid 3-O-glucuronide. 151666428 CVCL_B6H3 mPAC-4.1.1 transformed cell line house mouse CVCL_B6H3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666429 CVCL_B6GU HCS-TG cancer cell line human CVCL_B6GU CL:0000010 Population: Japanese; Derived from sampling site: Bone; ilium. Male Characteristics: Established from a tumor obtained by subcutaneous injection of cancer cell in athymic ICR nu/nu mice (PubMed=15118855) 151666430 CVCL_B6H6 mPAC-4.1.2.1 transformed cell line house mouse CVCL_B6H6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666431 CVCL_B6GT DDCS2 cancer cell line human CVCL_B6GT CL:0000010 Derived from sampling site: Bone; right distal femur. Male Doubling time: 60-72 hours (PubMed=34767468) 151666432 CVCL_B6H5 mPAC-4.1.2 transformed cell line house mouse CVCL_B6H5 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666433 CVCL_B6GW HCS-TG E2 cancer cell line human CVCL_B6GW CL:0000010 Population: Japanese; Derived from sampling site: Bone; ilium. Male Doubling time: 48 hours, in 20% FBS (PubMed=15118855) 151666434 CVCL_B6H8 mDCT15 transformed cell line house mouse CVCL_B6H8 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; distal convoluted tubule Cell type=Epithelial cell.. Unspecified 151666435 CVCL_B6GV HCS-TG C3 cancer cell line human CVCL_B6GV CL:0000010 Population: Japanese; Derived from sampling site: Bone; ilium. Male Doubling time: 68 hours, in 20% FBS (PubMed=15118855) 151666436 CVCL_B6H7 mPAC-4.1.2.2 transformed cell line house mouse CVCL_B6H7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: C3H. Unspecified 151666437 CVCL_B6EG SV40RH1 transformed cell line Norway rat CVCL_B6EG CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666438 CVCL_B6EF P9 transformed cell line Norway rat CVCL_B6EF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666439 CVCL_B6EI NPC2-hTERT telomerase immortalized cell line human CVCL_B6EI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Female 151666440 CVCL_B6EH Hc3716-hTERT telomerase immortalized cell line human CVCL_B6EH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified Doubling time: ~2.5 days (PubMed=20456367) 151666441 CVCL_B6EK OUMS-29/TK transformed cell line human CVCL_B6EK CL:0000010 Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Male Characteristics: The introduction of HSV-1 TK gene makes the cell line 100x as sensitive to ganciclovir (GCV) compared with unmodified cells This suicide gene can be used as a safeguard in the use of this cell line in hybrid artificial liver (PubMed=11575821). 151666442 CVCL_B6EJ HepLL transformed cell line human CVCL_B6EJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 151666443 CVCL_B6EM OUMS-29/H-14 transformed cell line human CVCL_B6EM CL:0000010 Transfected with: HGNC; 5024; HNF4A (isoform Alpha-2); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Male 151666444 CVCL_B6EL OUMS-29/H-11 transformed cell line human CVCL_B6EL CL:0000010 Transfected with: HGNC; 5024; HNF4A (isoform Alpha-2); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Male 151666445 CVCL_B6EA AFP-27-NP hybridoma house mouse CVCL_B6EA CL:0000010 Characteristics: Non-producing clone; Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02771; Human AFP. 151666446 CVCL_B6EC C3-II-B-2-3 transformed cell line Norway rat CVCL_B6EC CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666447 CVCL_B6EB TCL-598 cancer cell line human CVCL_B6EB CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Characteristics: Produces and secretes pro-urokinase (DOI=10.1038/nbt0784-628) 151666448 CVCL_B6EE C8-IV transformed cell line Norway rat CVCL_B6EE CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666449 CVCL_B6ED C4-1-B-2 transformed cell line Norway rat CVCL_B6ED CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666450 CVCL_B6E7 BRAD-5 transformed cell line human CVCL_B6E7 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 151666451 CVCL_B6DV HL3 transformed cell line CVCL_B6DV CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: FOS+HRAS; Derived from sampling site: Peripheral blood Cell type=Lymphocyte.. Unspecified Group: Fish cell line 151666452 CVCL_B6E6 BRAD-3 transformed cell line human CVCL_B6E6 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 151666453 CVCL_B6DU KB-26.5 hybridoma house mouse CVCL_B6DU CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:62485; Blood group A antigen type 1 (Alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc). 151666454 CVCL_B6E9 AFP-27 hybridoma house mouse CVCL_B6E9 From: Vessella R.L.; Department of Urologic Surgery at the University of Minnesota; Minneapolis; USA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02771; Human AFP. 151666455 CVCL_B6DX HL8 transformed cell line CVCL_B6DX CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: FOS+HRAS; Derived from sampling site: Peripheral blood Cell type=Lymphocyte.. Unspecified Group: Fish cell line 151666456 CVCL_B6E8 BTSN6 transformed cell line human CVCL_B6E8 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1 151666457 CVCL_B6DW HL7 transformed cell line CVCL_B6DW CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: FOS+HRAS; Derived from sampling site: Peripheral blood Cell type=Lymphocyte.. Unspecified Group: Fish cell line 151666458 CVCL_B6DZ PL51 transformed cell line CVCL_B6DZ CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: FOS+HRAS; Derived from sampling site: Peripheral blood Cell type=Lymphocyte.. Unspecified Group: Fish cell line 151666459 CVCL_B6DY HL9 transformed cell line CVCL_B6DY CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: FOS+HRAS; Derived from sampling site: Peripheral blood Cell type=Lymphocyte.. Unspecified Group: Fish cell line 151666460 CVCL_B6DN TMHepTG4912 10 cancer cell line house mouse CVCL_B6DN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x SJL transgenic TG4912. Characteristics: Established from a transgenic mice that contains a human SERPINA1 promoter driving the expression of SV40 T-antigen (PubMed=1369183) 151666461 CVCL_B6DM TMHepTG2984 2 cancer cell line house mouse CVCL_B6DM CL:0000010 Transfected with: HGNC; 8941; SERPINA1; Transfected with: MGI; MGI:97250; Myc Transformant: Myc; Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x SJL transgenic TG2984. Characteristics: Established from a transgenic mice that contains a human SERPINA1 promoter driving the expression of a mouse Myc as well as a second SERPINA1 promoter in front of a full copy of SERPINA1 (PubMed=1369183) 151666462 CVCL_B6E1 Caco-2-SF cancer cell line human CVCL_B6E1 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male Group: Serum/protein free medium cell line 151666463 CVCL_B6DP TMhep39 cancer cell line house mouse CVCL_B6DP CL:0000010 Transfected with: HGNC; 3551; F9; Transfected with: HGNC; 8941; SERPINA1; Transfected with: MGI; MGI:97250; Myc Transformant: Myc; Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x SJL transgenic TG3960 x TG2984 x TG4912. Characteristics: Established from a triple transgenic mice that contains 1) a human SERPINA1 promoter driving the expression of a mouse Myc as well as a second SERPINA1 promoter in front of a full copy of SERPINA1, 2) a human SERPINA1 promoter driving the expression of SV40 T-antigen and 3) a human F9 promoter driving the expression of F9 (PubMed=1369183) 151666464 CVCL_B6E0 PAT-206 spontaneously immortalized cell line human CVCL_B6E0 CL:0000010 Karyotypic information: Has a modal chromosome number of 61 (PubMed=21559682); Donor information: Established from a patient with breast cancer metastasized to the peritoneal cavity; Derived from sampling site: Ascites Cell type=Macrophage.. Female Doubling time: ~36 hours (PubMed=21559682; PubMed=22358691) 151666465 CVCL_B6DR HL-60 clone F8 cancer cell line human CVCL_B6DR CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:16134; Ammonia; Selected for resistance to: ChEBI; CHEBI:24996; Lactate; Derived from sampling site: Peripheral blood. Female 151666466 CVCL_B6E3 WTC-mEGFP-G3BP1-cl1 induced pluripotent stem cell human CVCL_B6E3 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 G3BP1 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 151666467 CVCL_B6E2 HD7/1A1.15.24 hybridoma human CVCL_B6E2 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q02161; Human RHD. Doubling time: ~24 hours (PubMed=3101287) 151666468 CVCL_B6DQ TMhep48 cancer cell line house mouse CVCL_B6DQ CL:0000010 Transfected with: HGNC; 8941; SERPINA1; Transfected with: HGNC; 3551; F9; Transfected with: MGI; MGI:97250; Myc Transformant: Myc; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x SJL transgenic TG3960 x TG2984 x TG4912. Characteristics: Established from a triple transgenic mice that contains 1) a human SERPINA1 promoter driving the expression of a mouse Myc as well as a second SERPINA1 promoter in front of a full copy of SERPINA1, 2) a human SERPINA1 promoter driving the expression of SV40 T-antigen and 3) a human F9 promoter driving the expression of F9 (PubMed=1369183) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-989 151666469 CVCL_B6E5 BTSN5 transformed cell line human CVCL_B6E5 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 151666470 CVCL_B6DT H1R8 hybridoma house mouse CVCL_B6DT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:62485; Blood group A antigen type 1 (Alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->3)-beta-D-GlcpNAc); Monoclonal antibody target: ChEBI; CHEBI:62486; Blood group A antigen type 2 (Alpha-D-GalpNAc-(1->3)-[alpha-L-Fucp-(1->2)]-beta-D-Galp-(1->4)-beta-D-GlcpNAc). 151666471 CVCL_B6E4 BTSN4 transformed cell line human CVCL_B6E4 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 151666472 CVCL_B6DS HL-60 clone H6 cancer cell line human CVCL_B6DS CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:16134; Ammonia; Selected for resistance to: ChEBI; CHEBI:24996; Lactate; Derived from sampling site: Peripheral blood. Female 151666473 CVCL_B6FH Veggie-CHO spontaneously immortalized cell line CVCL_B6FH CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 22.5 hours (PubMed=19003404) Group: Serum/protein free medium cell line 151666474 CVCL_B6FG F6D2 cancer cell line human CVCL_B6FG CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: The expression of the beta-galactosidase gene (lacZ) is under the control of a hypoxia-inducible EPO promoter (PubMed=22358881) Doubling time: 45 hours (PubMed=22358881) 151666475 CVCL_B6FJ MAb 12a hybridoma house mouse CVCL_B6FJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:79068; Crocin. 151666476 CVCL_B6FI Veggie-CHO:FLT-3L spontaneously immortalized cell line CVCL_B6FI CL:0000010 Transfected with: HGNC; 3766; FLT3LG Derived from sampling site: Ovary. Female Doubling time: 21.2 +- 2.9 hours (PubMed=19003404) Group: Serum/protein free medium cell line 151666477 CVCL_B6FL MAb 11h hybridoma house mouse CVCL_B6FL CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:79068; Crocin. 151666478 CVCL_B6FK MAb 1d hybridoma house mouse CVCL_B6FK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:79068; Crocin. 151666479 CVCL_B6FN SMG-F3 hybridoma house mouse CVCL_B6FN CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666480 CVCL_B6FM SMG-B3 hybridoma house mouse CVCL_B6FM CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:9185; Solamargine. 151666481 CVCL_B6FB WB6 conditionally immortalized cell line Norway rat CVCL_B6FB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Unspecified Characteristics: Proliferates at the permissive temperature (33 Celsius) Rapid decrease in cell proliferation at the restrictive temperature (39 Celsius). Doubling time: 28.7 hours (at 15th passage), 23.5 hours (at 50th passage) (PubMed=10762059) 151666482 CVCL_B6FA WA1 conditionally immortalized cell line Norway rat CVCL_B6FA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Unspecified Characteristics: Proliferates at the permissive temperature (33 Celsius) Rapid decrease in cell proliferation at the restrictive temperature (39 Celsius). Doubling time: 42.2 hours (at 15th passage), 30.8 hours (at 50th passage) (PubMed=10762059) 151666483 CVCL_B6FD RFM spontaneously immortalized cell line CVCL_B6FD CL:0000010 Derived from sampling site: Head kidney Cell type=Macrophage.. Unspecified Group: Fish cell line 151666484 CVCL_B6FC HepZ transformed cell line human CVCL_B6FC CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 3113; E2F1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Transfected with albumin-promoter regulated antisense constructs against RB1 and TP53 Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2302 151666485 CVCL_B6FF ADG undefined cell line type CVCL_B6FF CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to originate from an abalone but rather seem to either be from a a protist or a fungi living in the digestive gland of the abalone (PubMed=22358657).. 151666486 CVCL_B6FE RFF spontaneously immortalized cell line CVCL_B6FE CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Group: Fish cell line 151666487 CVCL_B6F8 BQ1 conditionally immortalized cell line Norway rat CVCL_B6F8 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Brown Norway. Unspecified Characteristics: Proliferates at the permissive temperature (33 Celsius) Rapid decrease in cell proliferation at the restrictive temperature (39 Celsius). Doubling time: 59.3 hours (at 15th passage), 23.7 hours (at 50th passage) (PubMed=10762059) 151666488 CVCL_B6EW RH 3 transformed cell line Norway rat CVCL_B6EW CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666489 CVCL_B6EV RH 2 transformed cell line Norway rat CVCL_B6EV CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666490 CVCL_B6F7 RH/Thy66A transformed cell line CVCL_B6F7 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Thymus Cell type=Thymocyte.; Breed/subspecies: New Zealand white. Unspecified 151666491 CVCL_B6EY RH 6 transformed cell line Norway rat CVCL_B6EY CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666492 CVCL_B6F9 BV1 conditionally immortalized cell line Norway rat CVCL_B6F9 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Brown Norway. Male Characteristics: Proliferates at the permissive temperature (33 Celsius) Rapid decrease in cell proliferation at the restrictive temperature (39 Celsius). Doubling time: 33.4 hours (at 15th passage), 17.8 hours (at 50th passage) (PubMed=10762059) 151666493 CVCL_B6EX RH 4 transformed cell line Norway rat CVCL_B6EX CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666494 CVCL_B6EZ RH 7 transformed cell line Norway rat CVCL_B6EZ CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666495 CVCL_B6F0 RH 8 transformed cell line Norway rat CVCL_B6F0 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666496 CVCL_B6EN TTNT-16 telomerase immortalized cell line human CVCL_B6EN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the SV40 T gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites 151666497 CVCL_B6F2 AdPX3 transformed cell line Norway rat CVCL_B6F2 CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Fischer 344. Male 151666498 CVCL_B6EQ TTNT-16-3 telomerase immortalized cell line human CVCL_B6EQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06956; Escherichia phage P1 cre; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Reversibly immortalized; exposure to tamoxifen induces the expression of the Cre gene that effects Cre/LoxP recombination and excise the TERT gene; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites and a plasmid pCAGMerCreMer/Puro that expresses Cre fused to 2 mutant estrogen-receptor ligand-binding domains (MerCreMer) under the control of the CAG promoter Doubling time: ~48 hours (PubMed=17434229) 151666499 CVCL_B6F1 RH 9 transformed cell line Norway rat CVCL_B6F1 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666500 CVCL_B6EP TPH1 transformed cell line human CVCL_B6EP CL:0000010 Transformant: Hepatitis C virus(NCBI-Taxonomy; 11103); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666501 CVCL_B6F4 C8-B transformed cell line Norway rat CVCL_B6F4 CL:0000010 Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Lewis. Male Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the SV40 T gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with the retroviral vector SSR#69 (MoMLV/LTR-LoxP-HygroR-HSV/TK-IRES-SV40T-LoxP-NeoR-MoMLV/LTR) expressing HygroR, HSV-1 TK and SV40 T-antigen flanked by two loxP sites 151666502 CVCL_B6ES SVHep B4 transformed cell line Norway rat CVCL_B6ES CL:0000010 Transformant: Simian virus 40 (SV40) [LP](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666503 CVCL_B6F3 AdPX4 transformed cell line Norway rat CVCL_B6F3 CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Fischer 344. Male 151666504 CVCL_B6ER YOCK-13 telomerase immortalized cell line human CVCL_B6ER CL:0000010 Transfected with: HGNC; 6081; INS (engineered variant); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06956; Escherichia phage P1 cre; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Expresses an insulin variant which is a single-chain modified insulin which is made of the signal sequence of albumin, the A chain followed by short turn-forming heptapeptide (GGGPGKR) and the B chain This construct does not require pancreas-specific enzymatic processing (PubMed=14693704).; Characteristics: Reversibly immortalized; exposure to tamoxifen induces the expression of the Cre gene that effects Cre/LoxP recombination and excise the TERT gene; Characteristics: Transduced with three constructs: 1) a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites, 2) a plasmid pCAGMerCreMer/Puro that expresses Cre fused to 2 mutant estrogen-receptor ligand-binding domains (MerCreMer) under the control of the CAG promoter and 3) a plasmid vector expressing modified insulin and zeocin resistance genes under the control of the rat L-PK promoter 151666505 CVCL_B6EU RH 10 transformed cell line Norway rat CVCL_B6EU CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666506 CVCL_B6F6 RH/Thy2 transformed cell line CVCL_B6F6 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Thymus Cell type=Thymocyte.; Breed/subspecies: New Zealand white. Unspecified 151666507 CVCL_B6F5 C8-B/Ras transformed cell line Norway rat CVCL_B6F5 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Lewis. Male Characteristics: Tumorigenic; Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the SV40 T gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with the retroviral vector SSR#69 (MoMLV/LTR-LoxP-HygroR-HSV/TK-IRES-SV40T-LoxP-NeoR-MoMLV/LTR) expressing HygroR, HSV-1 TK and SV40 T-antigen flanked by two loxP sites 151666508 CVCL_B6ET RH 1 transformed cell line Norway rat CVCL_B6ET CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male 151666509 CVCL_B6T6 Ab7 hybridoma house mouse CVCL_B6T6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666510 CVCL_B6SU TrJ5 hybridoma CVCL_B6SU CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*12=B*38/B*39). 151666511 CVCL_B6T5 Ab6 hybridoma house mouse CVCL_B6T5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666512 CVCL_B6ST UL/F11 hybridoma CVCL_B6ST CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P26663; Hepatitis C virus genotype 1b (isolate BK) genome polyprotein (AA 1-150; Core protein p21). 151666513 CVCL_B6T8 Ab9 hybridoma house mouse CVCL_B6T8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666514 CVCL_B6SW TrJ3 hybridoma CVCL_B6SW CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes alleles B*12=B*44/B*45). 151666515 CVCL_B6T7 Ab8 hybridoma house mouse CVCL_B6T7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666516 CVCL_B6SV UL/F14 hybridoma CVCL_B6SV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes alleles B*12=B*44/B*45). 151666517 CVCL_B6SY TrB12 hybridoma human CVCL_B6SY CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P01909; Human HLA-DQA1; Monoclonal antibody target: UniProtKB; P01920; Human HLA-DQB1. 151666518 CVCL_B6T9 Ab10 hybridoma house mouse CVCL_B6T9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q5NID3; Francisella tularensis (strain Schu 4) rplL. 151666519 CVCL_B6SX TrD3 hybridoma human CVCL_B6SX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes HLA-Bw6 epitope). 151666520 CVCL_B6SZ TrJ1 hybridoma CVCL_B6SZ CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P01909; Human HLA-DQA1 (Note=Recognizes allele DQA1*05); Monoclonal antibody target: UniProtKB; P01920; Human HLA-DQB1 (Note=Recognizes allele DQB1*02). 151666521 CVCL_B6SM BS 45 hybridoma house mouse CVCL_B6SM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23276; Human KEL/CD238. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-268 151666522 CVCL_B6SL BS 50 hybridoma house mouse CVCL_B6SL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P60568; Human IL2 (Note=Also regognizes IgG lambda). Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-313 151666523 CVCL_B6T0 TU165 hybridoma house mouse CVCL_B6T0 CL:0000010 Characteristics: Produces a mAb that acts in a T-cell receptor-like manner (PubMed=8449221); Characteristics: The produced mAb recognizes the nonapeptide LPPHDITPY from EBV EBNA6/EBNA3C when bound to HLAB*35:01 (PubMed=9878435); Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*35:01); Monoclonal antibody target: UniProtKB; P03204; Epstein-Barr virus nuclear antigen 6 (Note=Recognizes AA 98-106) Caution: TU165 has a U umlaut and should thus be transcribed as TUE165, but the umlaut is most often ommitted in online resources. 151666524 CVCL_B6SN BRIC 107 hybridoma house mouse CVCL_B6SN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P23276; Human KEL/CD238. 151666525 CVCL_B6T2 Ab3 hybridoma house mouse CVCL_B6T2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666526 CVCL_B6SQ BRIC 203 hybridoma house mouse CVCL_B6SQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P23276; Human KEL/CD238. 151666527 CVCL_B6T1 Ab2 hybridoma house mouse CVCL_B6T1 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666528 CVCL_B6SP BRIC 18 hybridoma house mouse CVCL_B6SP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P23276; Human KEL/CD238. 151666529 CVCL_B6T4 Ab5 hybridoma house mouse CVCL_B6T4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666530 CVCL_B6SS UL/F10 hybridoma CVCL_B6SS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26663; Hepatitis C virus genotype 1b (isolate BK) genome polyprotein (AA 1-150; Core protein p21) 151666531 CVCL_B6T3 Ab4 hybridoma house mouse CVCL_B6T3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Francisella tularensis (strain Schu 4) lipopolysaccharide O-antigen. 151666532 CVCL_B6SR BRIC 68 hybridoma house mouse CVCL_B6SR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P23276; Human KEL/CD238. 151666533 CVCL_B6SE HEK293 GFP-DUSP12 transformed cell line human CVCL_B6SE CL:0000010 Transfected with: HGNC; 3067; DUSP12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably overexpress a eGFP-DUSP12 fusion protein (PubMed=21556130) 151666534 CVCL_B6SD FC-2.15 hybridoma house mouse CVCL_B6SD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 151666535 CVCL_B6SG IST-1 [Mouse hybridoma against human FN] hybridoma house mouse CVCL_B6SG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 151666536 CVCL_B6SF HEK293 CHI3L1 transformed cell line human CVCL_B6SF CL:0000010 Transfected with: HGNC; 1932; CHI3L1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151666537 CVCL_B6SI IST-3 hybridoma house mouse CVCL_B6SI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 151666538 CVCL_B6SH IST-2 hybridoma house mouse CVCL_B6SH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 151666539 CVCL_B6SK IST-9 hybridoma house mouse CVCL_B6SK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02751; Human FN1 (Note=Recognizes the ED-A domain Also reacts with dog, mouse, pig and rat).. 151666540 CVCL_B6SJ IST-4 hybridoma house mouse CVCL_B6SJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1 (Note=Recognizes the 5th FNIII domain). 151666541 CVCL_B6SA ME510 hybridoma house mouse CVCL_B6SA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Unknown. 151666542 CVCL_B6SC FKH1 hybridoma house mouse CVCL_B6SC CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human melanoma 50/70 kDa antigen. 151666543 CVCL_B6SB ME515 hybridoma house mouse CVCL_B6SB CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Not specified ganglioside. 151666544 CVCL_B6TV NWR 5764 iPSC-c503 induced pluripotent stem cell CVCL_B6TV CL:0000010 Anecdotal: Established from a rhinoceros named Nadi that lived in San Diego Zoo Safari Park and died in 2007 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666545 CVCL_B6U7 UL-101/68 hybridoma house mouse CVCL_B6U7 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04439; Human HLA-A (Note=Recognizes allele A*03). 151666546 CVCL_B6TU NWR 5765 iPSC-c509 induced pluripotent stem cell CVCL_B6TU CL:0000010 Anecdotal: Established from a rhinoceros named Suni that lived in Dvur Kralove zoo and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666547 CVCL_B6U6 TU110 hybridoma house mouse CVCL_B6U6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*13) Caution: TU110 has a U umlaut, but the umlaut is most often ommitted in online resources. 151666548 CVCL_B6TX NWR 6571 iPSC-c505 induced pluripotent stem cell CVCL_B6TX CL:0000010 Anecdotal: Established from a rhinoceros named Dinka that lived in San Diego Zoo Safari Park and died in 1991 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666549 CVCL_B6U9 UL-39/24 hybridoma house mouse CVCL_B6U9 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04439; Human HLA-A (Note=Recognizes allele A*02/A*69). 151666550 CVCL_B6TW NWR 6571 iPSC-c502 induced pluripotent stem cell CVCL_B6TW CL:0000010 Anecdotal: Established from a rhinoceros named Dinka that lived in San Diego Zoo Safari Park and died in 1991 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666551 CVCL_B6U8 UL-39/10 hybridoma house mouse CVCL_B6U8 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*13). 151666552 CVCL_B6TZ NWR 8174 iPSC-c501 induced pluripotent stem cell CVCL_B6TZ CL:0000010 Anecdotal: Established from a rhinoceros named Nasima that lived in Dvur Kralove zoo and died in 1992 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666553 CVCL_B6TY NWR 8173 iPSC-c505 induced pluripotent stem cell CVCL_B6TY CL:0000010 Anecdotal: Established from Najin, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666554 CVCL_B6TN 5D6 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666555 CVCL_B6TM 5D4 hybridoma house mouse CVCL_B6TM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666556 CVCL_B6TP 1E1 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666557 CVCL_B6U1 SWR 21328 iPSC-c560 induced pluripotent stem cell CVCL_B6U1 CL:0000010 Anecdotal: Established from a rhinoceros named Amani that lives in San Diego Zoo Safari Park Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666558 CVCL_B6U0 NWR 9939 iPSC-c5101 induced pluripotent stem cell CVCL_B6U0 CL:0000010 Anecdotal: Established from a rhinoceros named Saut that lived in San Diego Zoo Safari Park and died in 1997 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666559 CVCL_B6TR 1E2 [CRISPR/Cas9 edited mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TR CL:0000010 Transfected with: UniProtKB; Q08101; Bovine herpesvirus 1 envelope glycoprotein E (gE); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Using CRISPR/Cas9, a bovine herpesvirus type 1 glycoprotein E (BoHV1gE)-GFP fusion was inserted in the C region of the Ig light chain V12.41/J4/C (PubMed=34171554); Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE) 151666560 CVCL_B6U3 SWR 21409 iPSC-c550 induced pluripotent stem cell CVCL_B6U3 CL:0000010 Anecdotal: Established from a rhinoceros named Wallis that lives in San Diego Zoo Safari Park Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666561 CVCL_B6TQ 1D11 hybridoma house mouse CVCL_B6TQ CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Using CRISPR/Cas9, GFP was inserted in the C region of the Ig light chain V12.41/J4/C (PubMed=34171554); Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE) 151666562 CVCL_B6U2 SWR 21409 iPSC-c5156 induced pluripotent stem cell CVCL_B6U2 CL:0000010 Anecdotal: Established from a rhinoceros named Wallis that lives in San Diego Zoo Safari Park Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151666563 CVCL_B6TT NWR 5765 iPSC-c508 induced pluripotent stem cell CVCL_B6TT CL:0000010 Anecdotal: Established from a rhinoceros named Suni that lived in Dvur Kralove zoo and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666564 CVCL_B6U5 TU101 hybridoma house mouse CVCL_B6U5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04439; Human HLA-A (Note=Recognizes allele A*02/A*28) Caution: TU101 has a U umlaut, but the umlaut is most often ommitted in online resources. 151666565 CVCL_B6TS NWR 5765 iPSC-c507 induced pluripotent stem cell CVCL_B6TS CL:0000010 Anecdotal: Established from a rhinoceros named Suni that lived in Dvur Kralove zoo and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666566 CVCL_B6U4 NWR 9947 iPSC-c5101 induced pluripotent stem cell CVCL_B6U4 CL:0000010 Anecdotal: Established from a rhinoceros named Angalifu that lived in San Diego Zoo Safari Park and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 151666567 CVCL_B6TF 1D4 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666568 CVCL_B6TE Ab31 hybridoma house mouse CVCL_B6TE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5NFG7; Francisella tularensis (strain Schu 4) dnaK. 151666569 CVCL_B6TH 2E12 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666570 CVCL_B6TG 2E11 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666571 CVCL_B6TJ 2E9 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666572 CVCL_B6TI 2E3 hybridoma house mouse CVCL_B6TI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666573 CVCL_B6TL 4G4 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666574 CVCL_B6TK 3G3 [Mouse hybridoma against influenza D virus HE] hybridoma house mouse CVCL_B6TK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A140AT86; Influenza D virus (D/swine/Italy/199724-3/2015) hemagglutinin-esterase-fusion protein (HE). 151666575 CVCL_B6TB Ab12 hybridoma house mouse CVCL_B6TB CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q5NEE1; Francisella tularensis (strain Schu 4) groEL. 151666576 CVCL_B6TA Ab11 hybridoma house mouse CVCL_B6TA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q5NE75; Francisella tularensis (strain Schu 4) membrane protein FTT_1778c. 151666577 CVCL_B6TD Ab17 hybridoma house mouse CVCL_B6TD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q5NI56; Francisella tularensis (strain Schu 4) yidC. 151666578 CVCL_B6TC Ab13 hybridoma house mouse CVCL_B6TC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5NFG7; Francisella tularensis (strain Schu 4) dnaK. 151666579 CVCL_B6R4 Akata deltaLMP2A cancer cell line human CVCL_B6R4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for LMP2A 151666580 CVCL_B6QS Lico D-23 spontaneously immortalized cell line human CVCL_B6QS CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Mixed Characteristics: Mixture of 23 cell lines Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8492 151666581 CVCL_B6QR 691-I-5Nu4B hybridoma house mouse CVCL_B6QR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma cell surface antigen. 151666582 CVCL_B6R3 Akata delta1 EBER2(+) cancer cell line human CVCL_B6R3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for EBER1 and EBER2 and which was knocked-in for EBER2 only 151666583 CVCL_B6R6 Akata ZKO cancer cell line human CVCL_B6R6 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for BZLF1 151666584 CVCL_B6QU HNSC.100 transformed cell line human CVCL_B6QU CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; diencephalon and fetal brain; telencephalon Cell type=Neural stem cell.. Unspecified Doubling time: 1.7 + 0.08 days (PubMed=10683274) 151666585 CVCL_B6QT IhNSCs transformed cell line human CVCL_B6QT CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: v-Myc; Derived from sampling site: Fetal brain; diencephalon and fetal brain; telencephalon Cell type=Neural stem cell.. Male Doubling time: 2-3 days (PubMed=17556596) 151666586 CVCL_B6R5 Yub2564c somatic stem cell human CVCL_B6R5 CL:0000010 Derived from sampling site: Foot; toe; cartilage. Female 151666587 CVCL_B6QW 1R [Rat embryo fibroblast] transformed cell line Norway rat CVCL_B6QW CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified 151666588 CVCL_B6R8 U-CH17PII cancer cell line human CVCL_B6R8 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous or homozygous (from autologous cell lines U-CH17M, U-CH17P and U-CH17S) Derived from sampling site: Bone; sacrum. Male Doubling time: 3-4 days (Chordoma_Foundation) 151666589 CVCL_B6QV 5R transformed cell line Norway rat CVCL_B6QV CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified 151666590 CVCL_B6R7 Akata deltagp85 cancer cell line human CVCL_B6R7 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome is KO for BXLF2/gp85 151666591 CVCL_B6QY RE 2 transformed cell line Norway rat CVCL_B6QY CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 2 [E1A](NCBI-Taxonomy; 10515); Derived from sampling site: Cell type=Fibroblast. Unspecified 151666592 CVCL_B6QX 2R transformed cell line Norway rat CVCL_B6QX CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified 151666593 CVCL_B6R9 U3-DT transformed cell line human CVCL_B6R9 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Transcriptome analysis by microarray Female Senescence: Long term culture of parent cell line (maximum PDL is 252); Doubling time: 22 hours (PubMed=25978455) 151666594 CVCL_B6QK 691-6-5 hybridoma house mouse CVCL_B6QK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666595 CVCL_B6QJ 691-6 hybridoma house mouse CVCL_B6QJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666596 CVCL_B6QM T21M transformed cell line Norway rat CVCL_B6QM CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Derived from sampling site: Thymus Cell type=Fibroblast.; Breed/subspecies: Osborne-Mendel. Unspecified 151666597 CVCL_B6QL SK 37-7 hybridoma house mouse CVCL_B6QL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human HLA-DR + HLA-DQ. 151666598 CVCL_B6R0 dl-884-3Y1-KO2 transformed cell line Norway rat CVCL_B6R0 CL:0000010 Transformant: Simian virus 40 (SV40) [dl-884](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 151666599 CVCL_B6QN T24M [Rat thymus] transformed cell line Norway rat CVCL_B6QN CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Derived from sampling site: Thymus; Breed/subspecies: Osborne-Mendel. Unspecified 151666600 CVCL_B6QQ 691-6-37 hybridoma house mouse CVCL_B6QQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666601 CVCL_B6R2 Yub2564a somatic stem cell human CVCL_B6R2 CL:0000010 Derived from sampling site: Foot; adipose tissue. Female 151666602 CVCL_B6QP 691-6-11 hybridoma house mouse CVCL_B6QP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666603 CVCL_B6R1 GM1 [Human GM1 gangliosidosis] finite cell line human CVCL_B6R1 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1986; probable Male 151666604 CVCL_B6QC 691-19-19 hybridoma house mouse CVCL_B6QC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666605 CVCL_B6QB 691-19 hybridoma house mouse CVCL_B6QB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666606 CVCL_B6QE 691-2-4 hybridoma house mouse CVCL_B6QE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666607 CVCL_B6QD 691-2 hybridoma house mouse CVCL_B6QD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666608 CVCL_B6QG 691-4-144 hybridoma house mouse CVCL_B6QG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666609 CVCL_B6QF 691-4 hybridoma house mouse CVCL_B6QF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666610 CVCL_B6QI 691-4-27 hybridoma house mouse CVCL_B6QI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666611 CVCL_B6QH 691-4-155 hybridoma house mouse CVCL_B6QH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666612 CVCL_B6PZ TJU-UM001-tdTomato cancer cell line human CVCL_B6PZ CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from metastatic site: Liver. Doubling time: ~72 hours (PubMed=26613897) 151666613 CVCL_B6PY TJU-UM004 cancer cell line human CVCL_B6PY CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Homozygous (PubMed=25952648) Derived from metastatic site: Eye socket. 151666614 CVCL_B6QA 691-13-17 hybridoma house mouse CVCL_B6QA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01911; Human HLA-DRB1. 151666615 CVCL_B6RT DMBi004-A induced pluripotent stem cell human CVCL_B6RT From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Synovium Cell type=Fibroblast.. Female 151666616 CVCL_B6S5 ME416 hybridoma house mouse CVCL_B6S5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Not specified ganglioside. 151666617 CVCL_B6RS DMBi003-A induced pluripotent stem cell human CVCL_B6RS From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666618 CVCL_B6S4 ME325 hybridoma house mouse CVCL_B6S4 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Unknown. 151666619 CVCL_B6RV FC-5.01 hybridoma house mouse CVCL_B6RV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151666620 CVCL_B6S7 ME491 hybridoma house mouse CVCL_B6S7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151666621 CVCL_B6RU HeLa VAPB KO cancer cell line human CVCL_B6RU From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12649; VAPB Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 151666622 CVCL_B6S6 ME425 hybridoma house mouse CVCL_B6S6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Unknown. 151666623 CVCL_B6RX 8E8 hybridoma house mouse CVCL_B6RX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00254; Human F2RL2 (Note=Recognizes AA 31-47). 151666624 CVCL_B6S9 ME493 hybridoma house mouse CVCL_B6S9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151666625 CVCL_B6RW JS-1 hybridoma house mouse CVCL_B6RW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 151666626 CVCL_B6S8 ME492 hybridoma house mouse CVCL_B6S8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151666627 CVCL_B6RZ 5C7 [Rat hybridoma against rat Chrna4] hybridoma house mouse CVCL_B6RZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P09483; Rat Chrna4 (Note=Recognizes AA 216-227). 151666628 CVCL_B6RY 1D6-3-8 hybridoma house mouse CVCL_B6RY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04757; Rat Chrna3 (Note=Recognizes AA 206-217). 151666629 CVCL_B6RL MHHi001-A-9 induced pluripotent stem cell human CVCL_B6RL From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: RCaMP1h, a red fluorescent calcium sensor; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female Characteristics: Using TALEN a CAG-promoter driven RCaMP1h and a pMYH6-NeoR-pPGK-HygroR construct were introduced in both alleles of the AAVS1 safe harbor locus (PubMed=35152180) 151666630 CVCL_B6RK MHHi001-A-8 induced pluripotent stem cell human CVCL_B6RK From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: GCaMP6f, a green fluorescent calcium sensor; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female Characteristics: Using TALEN a CAG-promoter driven GCamP6f and a pMYH6-NeoR-pPGK-HygroR construct were introduced in both alleles of the AAVS1 safe harbor locus (PubMed=35152180) 151666631 CVCL_B6RN ICGi039-B induced pluripotent stem cell human CVCL_B6RN From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 151666632 CVCL_B6RM ICGi039-A induced pluripotent stem cell human CVCL_B6RM From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 151666633 CVCL_B6RP ICGi039-C induced pluripotent stem cell human CVCL_B6RP From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 151666634 CVCL_B6S1 ME109 hybridoma house mouse CVCL_B6S1 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma 92 kDa antigen. 151666635 CVCL_B6S0 4BL spontaneously immortalized cell line human CVCL_B6S0 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 151666636 CVCL_B6RR KLRMMEi002-A induced pluripotent stem cell human CVCL_B6RR From: Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; c.8559-2A>G (p.Tyr2854_Arg2894del); ClinVar=VCV000048604; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=35152177) Population: Chinese; Derived from sampling site: Peripheral blood. Male 151666637 CVCL_B6S3 ME165 hybridoma house mouse CVCL_B6S3 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human melanoma 200 kDa antigen. 151666638 CVCL_B6RQ ICGi040-A induced pluripotent stem cell human CVCL_B6RQ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+mar [26]; 46,XY [4] (PubMed=35303600); Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666639 CVCL_B6S2 ME121 hybridoma house mouse CVCL_B6S2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma 80 kDa membrane antigen. 151666640 CVCL_B6RD iKLF1.7 induced pluripotent stem cell human CVCL_B6RD CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain with p.Gly400Val, p.Met543Ala and p.Leu544Ala = ET[T2]); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN a CAG-HA-KLF1-ERT2 construct has been inserted at the safe harbor locus (AAVS1) so as to allow temporally controlled activation during macrophage differentiation 151666641 CVCL_B6RC iKLF1.6 induced pluripotent stem cell human CVCL_B6RC CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain with p.Gly400Val, p.Met543Ala and p.Leu544Ala = ET[T2]); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN a CAG-HA-KLF1-ERT2 construct has been inserted at the safe harbor locus (AAVS1) so as to allow temporally controlled activation during macrophage differentiation 151666642 CVCL_B6RF KUIMSi012-A-1 induced pluripotent stem cell human CVCL_B6RF From: Kyoto University; Kyoto; Japan CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Using CRISPR/Cas9 a 2A-tdTomato construct was inserted at the C-terminal end of one allele of GAPDH (PubMed=35176664) 151666643 CVCL_B6RE iKLF1.12 induced pluripotent stem cell human CVCL_B6RE CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain with p.Gly400Val, p.Met543Ala and p.Leu544Ala = ET[T2]); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN a CAG-HA-KLF1-ERT2 construct has been inserted at the safe harbor locus (AAVS1) so as to allow temporally controlled activation during macrophage differentiation 151666644 CVCL_B6RH KUIMSi012-A-3 induced pluripotent stem cell human CVCL_B6RH From: Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Using CRISPR/Cas9 a 2A-tdTomato construct in combination with a PGK-hygroR-pA construct was inserted at the C-terminal end of both alleles of SOX10 (PubMed=35144211) 151666645 CVCL_B6RG KUIMSi012-A-2 induced pluripotent stem cell human CVCL_B6RG From: Kyoto University; Kyoto; Japan CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Using CRISPR/Cas9 a 2A-tdTomato construct was inserted at the C-terminal end of both alleles of GAPDH (PubMed=35176664) 151666646 CVCL_B6RJ ATCi002-A induced pluripotent stem cell human CVCL_B6RJ From: Aegicare (Shenzhen) Technology Co; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 4452; GPC4; Simple; c.877+1G>A; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=35168097) Population: Chinese; Derived from sampling site: Peripheral blood. Male 151666647 CVCL_B6RI YCMi006-A induced pluripotent stem cell human CVCL_B6RI From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Ile343Met (c.1029C>G); ClinVar=VCV001306956; Zygosity=Heterozygous (PubMed=35917599) Population: Korean; Derived from sampling site: Peripheral blood. Female 151666648 CVCL_B6QZ RE 6 transformed cell line Norway rat CVCL_B6QZ CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 2 [E1A](NCBI-Taxonomy; 10515); Derived from sampling site: Cell type=Fibroblast. Unspecified 151666649 CVCL_B6RB iKLF1.2 induced pluripotent stem cell human CVCL_B6RB CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain with p.Gly400Val, p.Met543Ala and p.Leu544Ala = ET[T2]); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN a CAG-HA-KLF1-ERT2 construct has been inserted at the safe harbor locus (AAVS1) so as to allow temporally controlled activation during macrophage differentiation 151666650 CVCL_B6RA iKLF1.1 induced pluripotent stem cell human CVCL_B6RA CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain with p.Gly400Val, p.Met543Ala and p.Leu544Ala = ET[T2]); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN a CAG-HA-KLF1-ERT2 construct has been inserted at the safe harbor locus (AAVS1) so as to allow temporally controlled activation during macrophage differentiation 151666651 CVCL_B6P2 TaA2 clone E3 transformed cell line CVCL_B6P2 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666652 CVCL_B6P1 TaA2 clone C9 transformed cell line CVCL_B6P1 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666653 CVCL_B6P4 TaA2 clone D7 transformed cell line CVCL_B6P4 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666654 CVCL_B6P3 TaA2 clone D3 transformed cell line CVCL_B6P3 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666655 CVCL_B6P6 1C7 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6P6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts. 151666656 CVCL_B6P5 TaA2 clone D7B12 transformed cell line CVCL_B6P5 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666657 CVCL_B6P8 4A4 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6P8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts. 151666658 CVCL_B6P7 2G2 hybridoma house mouse CVCL_B6P7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts. 151666659 CVCL_B6P0 TaA2 transformed cell line CVCL_B6P0 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 151666660 CVCL_B6NX EA2.31 hybridoma house mouse CVCL_B6NX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4380 151666661 CVCL_B6NW LK17 clone K9 hybrid cell line house mouse CVCL_B6NW CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.. Characteristics: Produces high level of testosterone; Characteristics: The parent cell line is an hybrid of 6-week-old BALB/c mice Leydig cells with a tioguanine resistant clone of MA-10 151666662 CVCL_B6NZ Eph101.530.241 hybridoma house mouse CVCL_B6NZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4724 151666663 CVCL_B6NY EA5.12 hybridoma house mouse CVCL_B6NY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4381 151666664 CVCL_B6PR Carousel cancer cell line human CVCL_B6PR CL:0000010 Population: Caucasian; Derived from sampling site: Ovary. Female 151666665 CVCL_B6Q3 DUR 4R hybrid cell line CVCL_B6Q3 CL:0000010 151666666 CVCL_B6Q2 DUV finite cell line human CVCL_B6Q2 CL:0000010 Karyotypic information: 46,X,t(X;15) (PubMed=69325); Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666667 CVCL_B6PQ MUi030-A induced pluripotent stem cell human CVCL_B6PQ From: Mahidol University; Bangkok; Thailand. CL:0000010 151666668 CVCL_B6Q5 DUR 10R hybrid cell line CVCL_B6Q5 CL:0000010 151666669 CVCL_B6PT Jacket cancer cell line human CVCL_B6PT CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Phe814Val (c.2440T>G); Zygosity=Hemizygous (Cellaria); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (Cellaria); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly477Ser (c.1429G>A); ClinVar=VCV000455136; Zygosity=Heterozygous (Cellaria); Sequence variation: Mutation; HGNC; 7527; MUTYH; Simple; p.Val493Met (c.1477G>A) (p.Val468Met, c.1402G>A); ClinVar=VCV000140942; Zygosity=Heterozygous (Cellaria); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Homozygous (Cellaria) Population: Caucasian; Derived from sampling site: Lung. Male 151666670 CVCL_B6Q4 DUR 5R hybrid cell line CVCL_B6Q4 CL:0000010 151666671 CVCL_B6PS Ferry cancer cell line human CVCL_B6PS CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Cys282Arg (c.844T>C) (p.Cys350Arg, c.1048T>C); Zygosity=Heterozygous (Cellaria) Population: Caucasian; Derived from sampling site: Colon. Female 151666672 CVCL_B6Q7 691-I-5Nu 4 hybridoma house mouse CVCL_B6Q7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human melanoma cell surface antigen. 151666673 CVCL_B6PV Wood cancer cell line human CVCL_B6PV CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu424Gln (c.1270G>C); ClinVar=VCV001352477; Zygosity=Heterozygous (Cellaria) Population: Caucasian; Derived from sampling site: Breast. Female 151666674 CVCL_B6Q6 BREN finite cell line human CVCL_B6Q6 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666675 CVCL_B6PU Powder cancer cell line human CVCL_B6PU CL:0000010 Sequence variation: Mutation; HGNC; 11119; SMO; Simple; p.Leu23dup (c.49CTG[8]); ClinVar=VCV000769335; Zygosity=Heterozygous (Cellaria) Population: Caucasian; Derived from sampling site: Ovary. Female 151666676 CVCL_B6Q9 691-13 hybridoma house mouse CVCL_B6Q9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen. 151666677 CVCL_B6PX TJU-UM003 cancer cell line human CVCL_B6PX CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=24354797; PubMed=25952648) Derived from metastatic site: Retroperitoneal space. 151666678 CVCL_B6Q8 691-I-5Nu-4-42 hybridoma house mouse CVCL_B6Q8 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma cell surface antigen. 151666679 CVCL_B6PW TJU-UM001 cancer cell line human CVCL_B6PW CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (PubMed=24354797; PubMed=25952648) Derived from metastatic site: Liver. 151666680 CVCL_B6PJ TC-1/E2 transformed cell line house mouse CVCL_B6PJ CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 151666681 CVCL_B6PI EL4-B7-1+B7-2 cancer cell line house mouse CVCL_B6PI CL:0000010 Transfected with: MGI; MGI:101775; Cd80; Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 151666682 CVCL_B6PL EL4B7-2 cancer cell line house mouse CVCL_B6PL CL:0000010 Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Caution: There are two EL4 Cd86 (B7-2) transfected cell lines: EL4B7-2 (Cellosaurus=CVCL_B6PL) and EL4-B7-2 (Cellosaurus=CVCL_B6PH) 151666683 CVCL_B6PK EL4/E2 cancer cell line house mouse CVCL_B6PK CL:0000010 Transfected with: HGNC; 3430; ERBB2 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 151666684 CVCL_B6PN MUi031-A induced pluripotent stem cell human CVCL_B6PN From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=35151019) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 151666685 CVCL_B6PM K1735-B7 cancer cell line house mouse CVCL_B6PM CL:0000010 Transfected with: MGI; MGI:101775; Cd80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: C3H/HeN. 151666686 CVCL_B6PP MUi029-A induced pluripotent stem cell human CVCL_B6PP From: Mahidol University; Bangkok; Thailand. CL:0000010 151666687 CVCL_B6Q1 WM164 VDR KO cancer cell line human CVCL_B6Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12679; VDR; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Arm; skin. Male 151666688 CVCL_B6Q0 WM164-Bch4 cancer cell line human CVCL_B6Q0 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Arm; skin. Male Characteristics: Highly invasive variant obtained from WM164 cells by four serial passages of these cells in the Boyden chamber assay (PubMed=2156614) 151666689 CVCL_B6PB 4F2 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6PB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts (Note=Also reacts with Theileria parva). 151666690 CVCL_B6PA 1C12 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6PA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts (Note=Also reacts with sporozoites). 151666691 CVCL_B6PD 2E4 hybridoma house mouse CVCL_B6PD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts (Note=Also reacts with sporozoites). 151666692 CVCL_B6PC 1E11 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6PC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts (Note=Also reacts with sporozoites). 151666693 CVCL_B6PF BoMac transformed cell line CVCL_B6PF CL:0000010 Transformant: Simian virus 40 (SV40) [776](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: Jersey. Female Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=29316971) Doubling time: 24 hours (PubMed=7676607) 151666694 CVCL_B6PE TM3-SF spontaneously immortalized cell line house mouse CVCL_B6PE CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/c. Male Doubling time: ~4-5 days (PubMed=16786125) Group: Serum/protein free medium cell line 151666695 CVCL_B6PH EL4-B7-2 cancer cell line house mouse CVCL_B6PH CL:0000010 Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Caution: There are two EL4 Cd86 (B7-2) transfected cell lines: EL4B7-2 (Cellosaurus=CVCL_B6PL) and EL4-B7-2 (Cellosaurus=CVCL_B6PH) 151666696 CVCL_B6PG EL4B7-1 cancer cell line house mouse CVCL_B6PG CL:0000010 Transfected with: MGI; MGI:101775; Cd80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 151666697 CVCL_B6P9 1F2 [Mouse hybridoma against T.annulata macroschizonts] hybridoma house mouse CVCL_B6P9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Theileria annulata macroschizonts (Note=Also reacts with Theileria parva). 151666698 CVCL_B6N0 3C6.4.2 hybridoma house mouse CVCL_B6N0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75888; Human TNFSF13/CD256. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1347 151666699 CVCL_B6MN HCEFi spontaneously immortalized cell line CVCL_B6MN CL:0000010 Derived from sampling site: Embryonic heart Cell type=Fibroblast.; Breed/subspecies: White Leghorn SPAFAS. Unspecified Group: Bird cell line 151666700 CVCL_B6N2 5E8.7.4 hybridoma house mouse CVCL_B6N2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75888; Human TNFSF13/CD256. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1344 151666701 CVCL_B6MQ VCEFi spontaneously immortalized cell line CVCL_B6MQ CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 151666702 CVCL_B6N1 5E11.1.2 hybridoma house mouse CVCL_B6N1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75888; Human TNFSF13/CD256. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1346 151666703 CVCL_B6MP SkCEFi spontaneously immortalized cell line CVCL_B6MP CL:0000010 Derived from sampling site: Embryonic skin Cell type=Fibroblast.; Breed/subspecies: White Leghorn SPAFAS. Unspecified Group: Bird cell line 151666704 CVCL_B6MS BoCEFi spontaneously immortalized cell line CVCL_B6MS CL:0000010 Derived from sampling site: Embryonic bone Cell type=Fibroblast.; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 151666705 CVCL_B6N4 TF8-11D12 hybridoma house mouse CVCL_B6N4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. 151666706 CVCL_B6N3 5G8.2.2 hybridoma house mouse CVCL_B6N3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75888; Human TNFSF13/CD256. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1345 151666707 CVCL_B6MR LF-1 spontaneously immortalized cell line CVCL_B6MR CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Compared to the parent cell line, has a 1.5 fold improvement in supporting the replication of Marek's disease virus (Patent=US20200179507) Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-123527 151666708 CVCL_B6N6 TF8-5G9 hybridoma house mouse CVCL_B6N6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9382 151666709 CVCL_B6MU Tp(Kilifi) transformed cell line CVCL_B6MU CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.. Female Characteristics: Infected by Theileria parva isolate Kilifi 151666710 CVCL_B6N5 TF8-5C4 hybridoma house mouse CVCL_B6N5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. 151666711 CVCL_B6MT TpM(588) transformed cell line CVCL_B6MT CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Infected by Theileria parva isolate Muguga 151666712 CVCL_B6MG TCL-Fuj3 transformed cell line human CVCL_B6MG CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 151666713 CVCL_B6MF 1E9 hybridoma house mouse CVCL_B6MF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:2622; Amarogentin. 151666714 CVCL_B6MI TCL-Sug2 transformed cell line human CVCL_B6MI CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 151666715 CVCL_B6MH TCL-Fuj4 transformed cell line human CVCL_B6MH CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 151666716 CVCL_B6MK AL/N-E spontaneously immortalized cell line house mouse CVCL_B6MK CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: AL/N. Unspecified 151666717 CVCL_B6MJ TCL-Tan transformed cell line human CVCL_B6MJ CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 151666718 CVCL_B6MM BCEFi spontaneously immortalized cell line CVCL_B6MM CL:0000010 Derived from sampling site: Embryonic breast Cell type=Fibroblast.; Breed/subspecies: White Leghorn SPAFAS. Unspecified Group: Bird cell line 151666719 CVCL_B6ML AL/N-F spontaneously immortalized cell line house mouse CVCL_B6ML CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AL/N. Unspecified 151666720 CVCL_B6MA 3H10-2F4 hybridoma house mouse CVCL_B6MA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:77148; Ginsenoside Re; Monoclonal antibody target: ChEBI; CHEBI:67987; Ginsenoside Rg1. 151666721 CVCL_B6MC 2D3B5 hybridoma house mouse CVCL_B6MC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8822; Retrorsine (Note=Also recognizes many other pyrrolizidine alkaloids). 151666722 CVCL_B6MB 2C3C5 hybridoma house mouse CVCL_B6MB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8822; Retrorsine (Note=Also recognizes many other pyrrolizidine alkaloids). 151666723 CVCL_B6ME 2B4 [Mouse hybridoma against asiaticoside] hybridoma house mouse CVCL_B6ME CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:79928; Asiaticoside. 151666724 CVCL_B6MD 5F2B1 hybridoma house mouse CVCL_B6MD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8822; Retrorsine (Note=Also recognizes many other pyrrolizidine alkaloids). 151666725 CVCL_B6LV 1A6 [Mouse hybridoma against mitragynine] hybridoma house mouse CVCL_B6LV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:6956; Mitragynine. 151666726 CVCL_B6M7 6A1 hybridoma house mouse CVCL_B6M7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; HHT). 151666727 CVCL_B6LU AA9 [Mouse hybridoma against puerarin] hybridoma house mouse CVCL_B6LU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:8633; Puerarin; Monoclonal antibody target: ChEBI; CHEBI:2979; Baicalein (Note=58% reactivity compared to puerarin). 151666728 CVCL_B6M6 E8 hybridoma house mouse CVCL_B6M6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:18418; (RS)-norcoclaurine (Higenamine). 151666729 CVCL_B6M9 Anti-PF hybridoma house mouse CVCL_B6M9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:7889; Paeoniflorin. 151666730 CVCL_B6LX Ea3.10 factor-dependent cell line house mouse CVCL_B6LX CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 20 hours (PubMed=6201749) 151666731 CVCL_B6M8 Anti-miroestrol hybridoma house mouse CVCL_B6M8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:6949; Miroestrol. 151666732 CVCL_B6LW RTS7c transformed cell line human CVCL_B6LW CL:0000010 Derived from sampling site: Hand; skin; epidermis Cell type=Keratinocyte.. Unspecified 151666733 CVCL_B6LZ Ea3.13 factor-dependent cell line house mouse CVCL_B6LZ CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 15-17 hours (PubMed=6201749) 151666734 CVCL_B6LY Ea3.11 factor-dependent cell line house mouse CVCL_B6LY CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 15-17 hours (PubMed=6201749) 151666735 CVCL_B6NP Eph099B-210.248 hybridoma house mouse CVCL_B6NP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4574 151666736 CVCL_B6NR Flow12000 finite cell line human CVCL_B6NR From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Nose; nasal cavity; olfactory mucosa. 151666737 CVCL_B6NQ Eph099B-233.152 hybridoma house mouse CVCL_B6NQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5194 151666738 CVCL_B6NT LIM6-TR cancer cell line human CVCL_B6NT CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: UniProtKB; P50591; Human TNFSF10/CD253; Derived from sampling site: Colon. Female Characteristics: Has high liver-metastasizing ability during cecal growth (from parent cell line) 151666739 CVCL_B6NS LS174T-LM12 cancer cell line human CVCL_B6NS CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Produces low amount of mucin in culture (PubMed=3664476) 151666740 CVCL_B6NV LK17 hybrid cell line house mouse CVCL_B6NV CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.. Characteristics: Hybrid of 6-week-old BALB/c mice Leydig cells with a tioguanine resistant clone of MA-10 151666741 CVCL_B6NU MA-10 mutant clone LK cancer cell line house mouse CVCL_B6NU CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: C57BL/6J. Male 151666742 CVCL_B6NH CHO-Flt-3 spontaneously immortalized cell line CVCL_B6NH CL:0000010 Transfected with: HGNC; 3765; FLT3 Derived from sampling site: Ovary. Female 151666743 CVCL_B6NG 8213 hybridoma house mouse CVCL_B6NG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TDQ0; Human HAVCR2/CD366. 151666744 CVCL_B6NJ Flt-3A20.9 hybridoma house mouse CVCL_B6NJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P36888; Human FLT3. 151666745 CVCL_B6NI P3XBcl-2-13 cancer cell line house mouse CVCL_B6NI CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Characteristics: Enhances the outgrowth of hybridomas following somatic fusion with immune lymphocytes isolated from pooled peripheral lymph nodes (PLN) 8-14 days after the initial immunization (PubMed=9309429) Group: Hybridoma fusion partner cell line 151666746 CVCL_B6NL Flt-3B7.5 hybridoma house mouse CVCL_B6NL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P36888; Human FLT3. 151666747 CVCL_B6NK Flt-3B3.33 hybridoma house mouse CVCL_B6NK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P36888; Human FLT3. 151666748 CVCL_B6NN Eph099B-208.261 hybridoma house mouse CVCL_B6NN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4573 151666749 CVCL_B6NM Eph099B-102.147 hybridoma house mouse CVCL_B6NM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P29317; Human EPHA2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4572 151666750 CVCL_B6NB TF9-6B4 hybridoma house mouse CVCL_B6NB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9381 151666751 CVCL_B6NA TF9-5B7 hybridoma house mouse CVCL_B6NA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. 151666752 CVCL_B6ND 644 hybridoma house mouse CVCL_B6ND CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized 'KM' mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG4; Monoclonal antibody target: UniProtKB; Q8TDQ0; Human HAVCR2/CD366 151666753 CVCL_B6NC 512 hybridoma house mouse CVCL_B6NC CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized 'KM' mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TDQ0; Human HAVCR2/CD366 151666754 CVCL_B6NF 4545 hybridoma house mouse CVCL_B6NF CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized 'KM' mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; Q8TDQ0; Human HAVCR2/CD366 151666755 CVCL_B6NE 4177 hybridoma house mouse CVCL_B6NE CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized 'KM' mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8TDQ0; Human HAVCR2/CD366 151666756 CVCL_B6MW hT-SerC telomerase immortalized cell line human CVCL_B6MW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Testis Cell type=Sertoli cell.. Omics: Transcriptome analysis by microarray Male 151666757 CVCL_B6N8 TF9-1B8 hybridoma house mouse CVCL_B6N8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. 151666758 CVCL_B6MV hS1 telomerase immortalized cell line human CVCL_B6MV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Chinese; Derived from sampling site: Testis Cell type=Sertoli cell.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.3 days (in 10% FBS), 1.03 days (in 15% FBS) (PubMed=28152522) 151666759 CVCL_B6N7 TF9-10H10 hybridoma house mouse CVCL_B6N7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9383 151666760 CVCL_B6MY 64M2 spontaneously immortalized cell line CVCL_B6MY CL:0000010 Miscellaneous: It is probable that what is termed '64M2' in PubMed=8799617 is termed 'cell culture 2' in PubMed=1499835 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Group: Fish cell line 151666761 CVCL_B6MX F13L-3 spontaneously immortalized cell line CVCL_B6MX CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Group: Fish cell line 151666762 CVCL_B6N9 TF9-2C4 hybridoma house mouse CVCL_B6N9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13726; Human F3/CD142. 151666763 CVCL_B6MZ 2H8 [Mouse hybridoma against phenylethanolamine A] hybridoma house mouse CVCL_B6MZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:144925; 1-(4-methoxyphenyl)-2-\{[4-(4-nitrophenyl)butan-2-yl]amino\}ethanol (Phenylethylamine A). 151666764 CVCL_B5ZA HE3-2 finite cell line CVCL_B5ZA CL:0000010 Derived from sampling site: Whole embryo. Female 151666765 CVCL_B5ZC MBEC2 transformed cell line house mouse CVCL_B5ZC CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 151666766 CVCL_B5ZB HE4-2 finite cell line CVCL_B5ZB CL:0000010 Derived from sampling site: Whole embryo. Female 151666767 CVCL_B5YT 2E1 [Mouse hybridoma against Seneca Valley virus VP1] hybridoma house mouse CVCL_B5YT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 674-937; Capsid protein VP1). 151666768 CVCL_B5Z5 4I16 hybridoma house mouse CVCL_B5Z5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL52; Sleeping disease virus (SDV) structural polyprotein (AA 355-792; Spike glycoprotein E2). 151666769 CVCL_B5YS 2A5 [Mouse hybridoma against Seneca Valley virus VP3] hybridoma house mouse CVCL_B5YS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 435-673; Capsid protein VP3). 151666770 CVCL_B5Z4 49K16 hybridoma house mouse CVCL_B5Z4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL52; Sleeping disease virus (SDV) structural polyprotein (AA 355-792; Spike glycoprotein E2). 151666771 CVCL_B5YV 3F2 [Mouse hybridoma against Seneca Valley virus VP2] hybridoma house mouse CVCL_B5YV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 151-434; Capsid protein VP2). 151666772 CVCL_B5Z7 71L2 hybridoma house mouse CVCL_B5Z7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL53; Sleeping disease virus (SDV) polyprotein P1234 (AA 1-561; mRNA-capping enzyme nsP1). 151666773 CVCL_B5YU 3E2 hybridoma house mouse CVCL_B5YU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 151-434; Capsid protein VP2). 151666774 CVCL_B5Z6 51B8 hybridoma house mouse CVCL_B5Z6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL52; Sleeping disease virus (SDV) structural polyprotein (AA 355-792; Spike glycoprotein E2). 151666775 CVCL_B5Z9 8A16 hybridoma house mouse CVCL_B5Z9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL53; Sleeping disease virus (SDV) polyprotein P1234 (AA 1-561; mRNA-capping enzyme nsP1). 151666776 CVCL_B5YX NCC-MFS5-C1 cancer cell line human CVCL_B5YX CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=35053323); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=35053323); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=35053323) Population: Japanese; Derived from sampling site: Right elbow; hypodermis. Omics: SNP array analysis Male Doubling time: 91.7 hours (PubMed=35053323) Part of: NCC sarcoma cell line panel 151666777 CVCL_B5YW 4B8 [Mouse hybridoma against Seneca Valley virus VP2] hybridoma house mouse CVCL_B5YW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 151-434; Capsid protein VP2). 151666778 CVCL_B5Z8 78K5 hybridoma house mouse CVCL_B5Z8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL52; Sleeping disease virus (SDV) structural polyprotein (AA 861-1322; Spike glycoprotein E1). 151666779 CVCL_B5YZ ASG-10 spontaneously immortalized cell line CVCL_B5YZ CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV), infectious pancreatic necrosis virus (IPNV), Pacific salmon paramyxovirus (PSPV), Atlantic salmon reovirus TS (TSRV) and viral hemorrhagic septicemia virus (VHSV) (PubMed=29444101) Group: Fish cell line 151666780 CVCL_B5YY LG-1 spontaneously immortalized cell line CVCL_B5YY CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by salmonid alphavirus 1 (SAV1) (PubMed=34572091) Doubling time: 14 days, at 20 Celsius (PubMed=34572091) Group: Fish cell line 151666781 CVCL_B5YL 1A3 [Mouse hybridoma against Seneca Valley virus VP2] hybridoma house mouse CVCL_B5YL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 151-434; Capsid protein VP2). 151666782 CVCL_B5YK 2G6 [Mouse hybridoma against Seneca Valley virus VP1] hybridoma house mouse CVCL_B5YK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 674-937; Capsid protein VP1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017226 151666783 CVCL_B5YN 1C12 [Mouse hybridoma against Seneca Valley virus VP2] hybridoma house mouse CVCL_B5YN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 151-434; Capsid protein VP2). 151666784 CVCL_B5YM 1A5 [Mouse hybridoma against Seneca Valley virus VP3] hybridoma house mouse CVCL_B5YM CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 435-673; Capsid protein VP3). 151666785 CVCL_B5Z1 17H23 hybridoma house mouse CVCL_B5Z1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL52; Sleeping disease virus (SDV) structural polyprotein (AA 355-792; Spike glycoprotein E2) (Note=Recognizes other salmonid alphavirus (SAV) E2). 151666786 CVCL_B5YP 1C2 hybridoma house mouse CVCL_B5YP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 674-937; Capsid protein VP1). 151666787 CVCL_B5Z0 ASG-13 spontaneously immortalized cell line CVCL_B5Z0 CL:0000010 Derived from sampling site: Gill Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV), infectious pancreatic necrosis virus (IPNV), Pacific salmon paramyxovirus (PSPV), Atlantic salmon reovirus TS (TSRV) and viral hemorrhagic septicemia virus (VHSV) (PubMed=29444101) Group: Fish cell line 151666788 CVCL_B5YR 1F5 [Mouse hybridoma against Seneca Valley virus VP1] hybridoma house mouse CVCL_B5YR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 674-937; Capsid protein VP1). 151666789 CVCL_B5Z3 3E17 hybridoma house mouse CVCL_B5Z3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL53; Sleeping disease virus (SDV) polyprotein P1234 (AA 1421-1984; Non-structural protein 3). 151666790 CVCL_B5Z2 19F3 hybridoma house mouse CVCL_B5Z2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QL53; Sleeping disease virus (SDV) polyprotein P1234 (AA 1-561; mRNA-capping enzyme nsP1). 151666791 CVCL_B5YQ 1E7 [Mouse hybridoma against Seneca Valley virus VP1] hybridoma house mouse CVCL_B5YQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q155Z9; Seneca Valley virus genome polyprotein (AA 674-937; Capsid protein VP1). 151666792 CVCL_B5YD A431-AC3 cancer cell line human CVCL_B5YD CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4056; G6PC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Skin; epidermis. Female 151666793 CVCL_B5YC Ho-15-D3 transformed cell line house mouse CVCL_B5YC CL:0000010 Knockout cell: Method=KO mouse; MGI:95607; G6pc; Transfected with: MGI; MGI:95607; G6pc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [A255](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666794 CVCL_B5YF SNE 2 transformed cell line human CVCL_B5YF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. 151666795 CVCL_B5YE SNE 1 transformed cell line human CVCL_B5YE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. 151666796 CVCL_B5YH SNE 3 transformed cell line human CVCL_B5YH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. 151666797 CVCL_B5YG Josh 5 transformed cell line human CVCL_B5YG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 151666798 CVCL_B5YJ PO-88 undefined cell line type CVCL_B5YJ CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line 151666799 CVCL_B5YI LCL22 transformed cell line human CVCL_B5YI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Expresses membrane IgM and IgD, together with lower levels of IgG and IgA, with expression of kappa and lambda light chains; both IgM kappa and lambda were present in the cytoplasm (PubMed=1326002) 151666800 CVCL_B5ZU C2BBe1 MDR1/BCRP KO cancer cell line human CVCL_B5ZU CL:0000010 Knockout cell: Method=ZFN; HGNC; 40; ABCB1; Knockout cell: Method=ZFN; HGNC; 74; ABCG2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666801 CVCL_B5ZT C2BBe1 MDR1 KO cancer cell line human CVCL_B5ZT CL:0000010 Knockout cell: Method=ZFN; HGNC; 40; ABCB1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666802 CVCL_B5ZW C2BBe1 MDR1/MRP2 KO cancer cell line human CVCL_B5ZW CL:0000010 Knockout cell: Method=ZFN; HGNC; 40; ABCB1; Knockout cell: Method=ZFN; HGNC; 53; ABCC2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666803 CVCL_B5ZV C2BBe1 MRP2 KO cancer cell line human CVCL_B5ZV CL:0000010 Knockout cell: Method=ZFN; HGNC; 53; ABCC2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666804 CVCL_B5ZY C2BBe1 MRP1 KO cancer cell line human CVCL_B5ZY CL:0000010 Knockout cell: Method=ZFN; HGNC; 51; ABCC1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666805 CVCL_B5ZX C2BBe1 MRP2/BCRP KO cancer cell line human CVCL_B5ZX CL:0000010 Knockout cell: Method=ZFN; HGNC; 53; ABCC2; Knockout cell: Method=ZFN; HGNC; 74; ABCG2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666806 CVCL_B5ZZ C2BBe1 MRP5 KO cancer cell line human CVCL_B5ZZ CL:0000010 Knockout cell: Method=ZFN; HGNC; 56; ABCC5; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666807 CVCL_B5ZM Spli-S spontaneously immortalized cell line CVCL_B5ZM CL:0000010 Unspecified Virology: Susceptible to infection by Spodoptera littoralis multicapsid nucleopolyhedrovirus (SpliMNPV) (CelloPub=CLPUB00678; CelloPub=CLPUB00679) Doubling time: 31 hours (at 19th passage), 27 hours (at 120th passage) (CelloPub=CLPUB00678; CelloPub=CLPUB00679). Group: Insect cell line 151666808 CVCL_B5ZL Spli-C spontaneously immortalized cell line CVCL_B5ZL CL:0000010 Unspecified Virology: Highly susceptible to infection by Spodoptera littoralis multicapsid nucleopolyhedrovirus (SpliMNPV) (CelloPub=CLPUB00678; CelloPub=CLPUB00679; PubMed=31069609) Doubling time: 30.5 hours (at 19th passage), 26 hours (at 120th passage) (CelloPub=CLPUB00678; CelloPub=CLPUB00679). Group: Insect cell line 151666809 CVCL_B5ZN PoCo83-3 transformed cell line pig CVCL_B5ZN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colon; proximal Cell type=Epithelial cell.. Male Doubling time: 20.3 hours (at 18th passage), 20.47 hours (at 34th passage) (PubMed=28052271) 151666810 CVCL_B5ZQ SA7K MDR1 KO transformed cell line human CVCL_B5ZQ CL:0000010 Knockout cell: Method=ZFN; HGNC; 40; ABCB1 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The parent cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151666811 CVCL_B5ZP SA7K transformed cell line human CVCL_B5ZP CL:0000010 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151666812 CVCL_B5ZS C2BBe1 BCRP KO cancer cell line human CVCL_B5ZS CL:0000010 Knockout cell: Method=ZFN; HGNC; 74; ABCG2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151666813 CVCL_B5ZR SA7K OCT2 KO transformed cell line human CVCL_B5ZR CL:0000010 Knockout cell: Method=ZFN; HGNC; 10966; SLC22A2 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The parent cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151666814 CVCL_B5ZE NK92-CD16 cancer cell line human CVCL_B5ZE CL:0000010 Transfected with: HGNC; 3619; FCGR3A Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male 151666815 CVCL_B5ZD MBEC0 transformed cell line house mouse CVCL_B5ZD CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 151666816 CVCL_B5ZG Hepa/HS cancer cell line house mouse CVCL_B5ZG CL:0000010 Transfected with: MGI; MGI:99480; Cebpa; Transfected with: MGI; MGI:88373; Cebpb; Transfected with: MGI; MGI:104982; Cebpg; Transfected with: MGI; MGI:1347476; Foxa2; Transfected with: MGI; MGI:98504; Hnf1a; Transfected with: MGI; MGI:98505; Hnf1b; Transfected with: MGI; MGI:109128; Hnf4a; Transfected with: MGI; MGI:1196423; Onecut1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Female Characteristics: When doxycycline-induced overexpresses 8 liver-enriched transcription factors (LETFs) (from parent cell line); Characteristics: The parent cell line was modified to enable switching between proliferation and expression of proteins for liver function in response to heat by introducing a new heat-inducible gene expression/amplification system (pHSP-tTA-TRE-tTA-pEF1a-Puro) which was transferred using a PiggyBac transposon vector (PubMed=34149171) 151666817 CVCL_B5ZF NK92-41BB cancer cell line human CVCL_B5ZF CL:0000010 Transfected with: HGNC; 3619; FCGR3A (extracellular domain) Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: Transfected with the CD16-CAR construct that consist of the signal peptide, the FCGR3/CD16A extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD247/CD3Z signaling domain 151666818 CVCL_B5ZI WA09 NRL+/eGFP embryonic stem cell human CVCL_B5ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 8002; NRL; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Valuable tool for studying human rod development and disease and testing therapeutic strategies for retinitis pigmentosa (PubMed=29402929); Characteristics: Using CRISPR/Cas9 a single allele of NRL was replaced with an eGFP reporter gene (PubMed=29402929) 151666819 CVCL_B5ZH HUC-5 finite cell line human CVCL_B5ZH CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 151666820 CVCL_B5ZK Spli-B spontaneously immortalized cell line CVCL_B5ZK CL:0000010 Unspecified Virology: Susceptible to infection by Spodoptera littoralis multicapsid nucleopolyhedrovirus (SpliMNPV) (CelloPub=CLPUB00678; CelloPub=CLPUB00679; PubMed=31069609) Doubling time: 44.5 hours (at 19th passage), 32 hours (at 120th passage) (CelloPub=CLPUB00678; CelloPub=CLPUB00679). Group: Insect cell line 151666821 CVCL_B5ZJ WA09 CRX+/tdTomato embryonic stem cell human CVCL_B5ZJ CL:0000010 Knockout cell: Method=BAC homologous recombination (1 of 2 alleles); HGNC; 2383; CRX; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using BAC homologous recombination a single allele of CRX was replaced with a tdTomato reporter gene (PubMed=29230913) 151666822 CVCL_B5WZ LS803 transformed cell line human CVCL_B5WZ CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666823 CVCL_B5WY LS802 transformed cell line human CVCL_B5WY CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666824 CVCL_B5XA HGF25 finite cell line human CVCL_B5XA CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666825 CVCL_B5X3 LS501 transformed cell line human CVCL_B5X3 CL:0000010 Transformant: Ad-SV40 hybrid virus; Donor information: Established from a patient suffering from acute nonlymphocytic leukemia; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666826 CVCL_B5WR MMH-D2 spontaneously immortalized cell line house mouse CVCL_B5WR CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 151666827 CVCL_B5WQ EqS01a cancer cell line CVCL_B5WQ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Virology: Infected by bovine papillomavirus-1 (BPV-1) Doubling time: 32.7 hours (PubMed=18191170) 151666828 CVCL_B5X2 LP101 transformed cell line human CVCL_B5X2 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Macrophage.. Unspecified 151666829 CVCL_B5X5 HGF3 finite cell line human CVCL_B5X5 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666830 CVCL_B5WT MMH-E14 spontaneously immortalized cell line house mouse CVCL_B5WT CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Embryonic liver Cell type=Hepatocyte.. Unspecified 151666831 CVCL_B5X4 HGF1 finite cell line human CVCL_B5X4 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666832 CVCL_B5WS MMH-D6 spontaneously immortalized cell line house mouse CVCL_B5WS CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Liver Cell type=Hepatocyte.. 151666833 CVCL_B5X7 HGF11 finite cell line human CVCL_B5X7 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666834 CVCL_B5WV MMH-E14 pal. spontaneously immortalized cell line house mouse CVCL_B5WV CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Embryonic liver Cell type=Hepatocyte.. Unspecified Characteristics: Clone that can spread with multiple projections (PubMed=9817765) 151666835 CVCL_B5X6 HGF10 finite cell line human CVCL_B5X6 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666836 CVCL_B5WU MMH-E14 ep. spontaneously immortalized cell line house mouse CVCL_B5WU CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Embryonic liver Cell type=Hepatocyte.. Unspecified 151666837 CVCL_B5X9 HGF22 finite cell line human CVCL_B5X9 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666838 CVCL_B5WX LS801 transformed cell line human CVCL_B5WX CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666839 CVCL_B5X8 HGF13 finite cell line human CVCL_B5X8 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666840 CVCL_B5WW IDIBGIi005-A induced pluripotent stem cell human CVCL_B5WW From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain. CL:0000010 Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 151666841 CVCL_B5WJ IM-HREC transformed cell line human CVCL_B5WJ CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Retinal endothelial cell.. 151666842 CVCL_B5WI IM-HBlSMC transformed cell line human CVCL_B5WI CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; smooth muscle. Caution: Indicated as P10951-IM in the online catalog but as P10561-IM in the technical sheet 151666843 CVCL_B5WL IM-HAEC transformed cell line human CVCL_B5WL CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.. 151666844 CVCL_B5WK IM-HCEpiC transformed cell line human CVCL_B5WK CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium. 151666845 CVCL_B5WN MDCK tGFP-APP spontaneously immortalized cell line dog CVCL_B5WN CL:0000010 Transfected with: HGNC; 620; APP; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Allows to perform assays to evaluate the endogenous secretase proteolytic process in living cells (Innoprot) 151666846 CVCL_B5WM U2OS tGFP-ADCYAP1R1 cancer cell line human CVCL_B5WM CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Has been designed to assay potential agonists/antagonists against ADCYAP1R1, modulating its activation and the following redistribution process inside the cells (Innoprot); Characteristics: Transfected with ADCYAP1R1 N-terminally tagged with turboGFP 151666847 CVCL_B5X1 HAS701 transformed cell line human CVCL_B5X1 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666848 CVCL_B5WP V79MZh1B1 spontaneously immortalized cell line CVCL_B5WP CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2597; CYP1B1; Transfected with: HGNC; 9208; POR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 151666849 CVCL_B5X0 AA101 transformed cell line human CVCL_B5X0 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 151666850 CVCL_B5WB TIEC1 telomerase immortalized cell line CVCL_B5WB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Small intestine Cell type=Epithelial cell.. Unspecified 151666851 CVCL_B5WA HTLC-7 transformed cell line human CVCL_B5WA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 14-20 days (PubMed=11370807) 151666852 CVCL_B5WD TIEC3 telomerase immortalized cell line CVCL_B5WD CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Small intestine Cell type=Epithelial cell.. Unspecified 151666853 CVCL_B5WC TIEC2 telomerase immortalized cell line CVCL_B5WC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Small intestine Cell type=Epithelial cell.. Unspecified 151666854 CVCL_B5WF IM-HCEC transformed cell line human CVCL_B5WF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; endothelium. 151666855 CVCL_B5WE iSEC transformed cell line human CVCL_B5WE CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Fetal liver Cell type=Sinusoidal endothelial cell.. Unspecified 151666856 CVCL_B5WH IM-HK transformed cell line human CVCL_B5WH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Eye; cornea Cell type=Keratocyte.. 151666857 CVCL_B5WG IM-HA transformed cell line human CVCL_B5WG CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.. 151666858 CVCL_B5XZ PDL 9 finite cell line human CVCL_B5XZ CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666859 CVCL_B5YB HGF16 finite cell line human CVCL_B5YB CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666860 CVCL_B5YA HGF15 finite cell line human CVCL_B5YA CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666861 CVCL_B5Y4 HGF4 finite cell line human CVCL_B5Y4 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666862 CVCL_B5XS PDL 2 finite cell line human CVCL_B5XS CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666863 CVCL_B5Y3 HGF2 finite cell line human CVCL_B5Y3 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666864 CVCL_B5XR PDL 1 finite cell line human CVCL_B5XR CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 151666865 CVCL_B5Y6 HGF6 finite cell line human CVCL_B5Y6 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666866 CVCL_B5XU PDL 4 finite cell line human CVCL_B5XU CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666867 CVCL_B5Y5 HGF5 finite cell line human CVCL_B5Y5 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666868 CVCL_B5XT PDL 3 finite cell line human CVCL_B5XT CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666869 CVCL_B5Y8 HGF9 finite cell line human CVCL_B5Y8 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666870 CVCL_B5XW PDL 6 finite cell line human CVCL_B5XW CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 151666871 CVCL_B5Y7 HGF7 finite cell line human CVCL_B5Y7 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666872 CVCL_B5XV PDL 5 finite cell line human CVCL_B5XV CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 151666873 CVCL_B5XY PDL 8 finite cell line human CVCL_B5XY CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 151666874 CVCL_B5Y9 HGF12 finite cell line human CVCL_B5Y9 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666875 CVCL_B5XX PDL 7 finite cell line human CVCL_B5XX CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666876 CVCL_B5XK HGF 8 finite cell line human CVCL_B5XK CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666877 CVCL_B5XJ HGF 7 finite cell line human CVCL_B5XJ CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666878 CVCL_B5XM HGF 10 finite cell line human CVCL_B5XM CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666879 CVCL_B5XL HGF 9 finite cell line human CVCL_B5XL CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 151666880 CVCL_B5Y0 PDL 10 finite cell line human CVCL_B5Y0 CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 151666881 CVCL_B5XN HGF 11 finite cell line human CVCL_B5XN CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 151666882 CVCL_B5XQ HGF 13 finite cell line human CVCL_B5XQ CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 151666883 CVCL_B5Y2 SKH1 [Mouse hybridoma against human 40 kDa cytokeratin] hybridoma house mouse CVCL_B5Y2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human 40 kDa cytokeratin. 151666884 CVCL_B5XP HGF 12 finite cell line human CVCL_B5XP CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666885 CVCL_B5Y1 PDL 11 finite cell line human CVCL_B5Y1 CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151666886 CVCL_B5XC HGF42 finite cell line human CVCL_B5XC CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666887 CVCL_B5XB HGF27 finite cell line human CVCL_B5XB CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 151666888 CVCL_B5XE HGF 2 finite cell line human CVCL_B5XE CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666889 CVCL_B5XD HGF 1 finite cell line human CVCL_B5XD CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666890 CVCL_B5XG HGF 4 finite cell line human CVCL_B5XG CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666891 CVCL_B5XF HGF 3 finite cell line human CVCL_B5XF CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 151666892 CVCL_B5XI HGF 6 finite cell line human CVCL_B5XI CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 151666893 CVCL_B5XH HGF 5 finite cell line human CVCL_B5XH CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 151666894 CVCL_B5V9 CET-IPF-FFCYSTFIB2-500 induced pluripotent stem cell human CVCL_B5V9 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (JP2MRI) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666895 CVCL_B5UX TRNDi022-D induced pluripotent stem cell human CVCL_B5UX From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666896 CVCL_B5V8 CET.IPS.FFALP1-500 induced pluripotent stem cell human CVCL_B5V8 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (JP2MRI) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666897 CVCL_B5UW TRNDi022-C induced pluripotent stem cell human CVCL_B5UW From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666898 CVCL_B5UZ TRNDi026-B induced pluripotent stem cell human CVCL_B5UZ From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666899 CVCL_B5UY TRNDi026-A induced pluripotent stem cell human CVCL_B5UY From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666900 CVCL_B5UP TRNDi020-A induced pluripotent stem cell human CVCL_B5UP From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666901 CVCL_B5V1 TRNDi027-A induced pluripotent stem cell human CVCL_B5V1 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (PubMed=29631617) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666902 CVCL_B5V0 TRNDi026-C induced pluripotent stem cell human CVCL_B5V0 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666903 CVCL_B5V3 TRNDi008-B induced pluripotent stem cell human CVCL_B5V3 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.His70Profs*29 (c.208dupC) (c.208insC); ClinVar=VCV000195037; Zygosity=Hemizygous (from parent cell line) Population: Caribbean; Haitian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151666904 CVCL_B5UR TRNDi020-C induced pluripotent stem cell human CVCL_B5UR From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666905 CVCL_B5UQ TRNDi020-B induced pluripotent stem cell human CVCL_B5UQ From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666906 CVCL_B5V2 TRNDi027-B induced pluripotent stem cell human CVCL_B5V2 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151666907 CVCL_B5V5 NCATS-CL6482 induced pluripotent stem cell human CVCL_B5V5 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 151666908 CVCL_B5UT TRNDi020-E induced pluripotent stem cell human CVCL_B5UT From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666909 CVCL_B5V4 NCATS-CL6481 induced pluripotent stem cell human CVCL_B5V4 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 151666910 CVCL_B5US TRNDi020-D induced pluripotent stem cell human CVCL_B5US From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666911 CVCL_B5V7 NCATS-CL6484 induced pluripotent stem cell human CVCL_B5V7 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151666912 CVCL_B5UV TRNDi022-B induced pluripotent stem cell human CVCL_B5UV From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666913 CVCL_B5V6 NCATS-CL6483 induced pluripotent stem cell human CVCL_B5V6 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151666914 CVCL_B5UU TRNDi022-A induced pluripotent stem cell human CVCL_B5UU From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666915 CVCL_B5UH TRNDi017-A induced pluripotent stem cell human CVCL_B5UH From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666916 CVCL_B5UG TRNDi016-B induced pluripotent stem cell human CVCL_B5UG From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666917 CVCL_B5UJ TRNDi019-A induced pluripotent stem cell human CVCL_B5UJ From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666918 CVCL_B5UI TRNDi017-B induced pluripotent stem cell human CVCL_B5UI From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666919 CVCL_B5UL TRNDi019-C induced pluripotent stem cell human CVCL_B5UL From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666920 CVCL_B5UK TRNDi019-B induced pluripotent stem cell human CVCL_B5UK From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666921 CVCL_B5UN TRNDi019-E induced pluripotent stem cell human CVCL_B5UN From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666922 CVCL_B5UM TRNDi019-D induced pluripotent stem cell human CVCL_B5UM From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666923 CVCL_B5UB TRNDi014-C induced pluripotent stem cell human CVCL_B5UB From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666924 CVCL_B5UA TRNDi014-B induced pluripotent stem cell human CVCL_B5UA From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666925 CVCL_B5UD TRNDi015-B induced pluripotent stem cell human CVCL_B5UD From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666926 CVCL_B5UC TRNDi015-A induced pluripotent stem cell human CVCL_B5UC From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666927 CVCL_B5UF TRNDi016-A induced pluripotent stem cell human CVCL_B5UF From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666928 CVCL_B5UE TRNDi015-C induced pluripotent stem cell human CVCL_B5UE From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666929 CVCL_B5VY Hepc/2B6.68 cancer cell line human CVCL_B5VY CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2615; CYP2B6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666930 CVCL_B5VX Hepc/2A6L.14 cancer cell line human CVCL_B5VX CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2610; CYP2A6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666931 CVCL_B5W9 HTLC-19 transformed cell line human CVCL_B5W9 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 14-20 days (PubMed=11370807) 151666932 CVCL_B5VZ Hepc/2C19.12 cancer cell line human CVCL_B5VZ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2621; CYP2C19; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666933 CVCL_B5W2 Hepc/2D6.39 cancer cell line human CVCL_B5W2 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2625; CYP2D6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666934 CVCL_B5VQ mKSA207-H transformed cell line house mouse CVCL_B5VQ CL:0000010 Transformant: Simian virus 40 (SV40) [tsA207](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified Characteristics: Heat-adapted, grows at 39.8 Celsius 151666935 CVCL_B5W1 Hepc/2C9.1 cancer cell line human CVCL_B5W1 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2623; CYP2C9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666936 CVCL_B5VP mKSA207-CH transformed cell line house mouse CVCL_B5VP CL:0000010 Transformant: Simian virus 40 (SV40) [tsA207](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified Characteristics: Heat-adapted, grows at 39.8 Celsius 151666937 CVCL_B5W4 Hepc/3A4.2-30 cancer cell line human CVCL_B5W4 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2637; CYP3A4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666938 CVCL_B5VS mKS(tsC) transformed cell line house mouse CVCL_B5VS CL:0000010 Transformant: Simian virus 40 (SV40) [tsC307](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified 151666939 CVCL_B5W3 Hepc/2E1.3-8 cancer cell line human CVCL_B5W3 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666940 CVCL_B5VR mKS(tsB) transformed cell line house mouse CVCL_B5VR CL:0000010 Transformant: Simian virus 40 (SV40) [tsB206](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified 151666941 CVCL_B5W6 HTLC-17 transformed cell line human CVCL_B5W6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 7-10 days (PubMed=11370807) 151666942 CVCL_B5VU mKS(wt)-H transformed cell line house mouse CVCL_B5VU CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified Characteristics: Heat-adapted, grows at 39.8 Celsius 151666943 CVCL_B5W5 HEK293-UGT2B9 transformed cell line human CVCL_B5W5 CL:0000010 Transfected with: UniProtKB; O02663; Macaca fascicularis UGT2B9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 151666944 CVCL_B5VT mKS(wt) transformed cell line house mouse CVCL_B5VT CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified 151666945 CVCL_B5VW Hepc/1A2.9 cancer cell line human CVCL_B5VW CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666946 CVCL_B5W8 HTLC-15 transformed cell line human CVCL_B5W8 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 14-20 days (PubMed=11370807) 151666947 CVCL_B5VV Hepc/1A1.4 cancer cell line human CVCL_B5VV CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666948 CVCL_B5W7 HTLC-11 transformed cell line human CVCL_B5W7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 14-20 days (PubMed=11370807) 151666949 CVCL_B5VI BALB/3T3 clone A31 THO2 transformed cell line house mouse CVCL_B5VI CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Deficient in hypoxanthine-guanine phosphoribosyltransferase (HGPRT) Doubling time: 30 hours (PubMed=1028169); 16 hours (in 10% FBS), 20.4 hours (in 1% FBS) (PubMed=701383) 151666950 CVCL_B5VH BALB/3T3 clone A31 NTG2 transformed cell line house mouse CVCL_B5VH CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 151666951 CVCL_B5VK BALB/3T3 clone A31 ts2-TGO transformed cell line house mouse CVCL_B5VK CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 151666952 CVCL_B5VJ BALB/3T3 clone A31 ts2-TG-31 transformed cell line house mouse CVCL_B5VJ CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 151666953 CVCL_B5VM mKSA207 conditionally immortalized cell line house mouse CVCL_B5VM CL:0000010 Transformant: Simian virus 40 (SV40) [tsA207](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified Characteristics: At temperatures above 39.5 Celsius fails to form colonies either in soft agar or on plastic and fails to sustain growth in monolayer culture (PubMed=204069) 151666954 CVCL_B5VL BALB/3T3 clone A31 H transformed cell line house mouse CVCL_B5VL CL:0000010 Transformant: Nitrosocarbaryl(ChEBI; CHEBI:189529); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 151666955 CVCL_B5W0 Hepc/2C8.46 cancer cell line human CVCL_B5W0 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2622; CYP2C8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 151666956 CVCL_B5VN mKSA207-C conditionally immortalized cell line house mouse CVCL_B5VN CL:0000010 Transformant: Simian virus 40 (SV40) [tsA207](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. Unspecified 151666957 CVCL_B5VA AD-2 spontaneously immortalized cell line house mouse CVCL_B5VA CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: SAMR1. Unspecified 151666958 CVCL_B5VC U-33/gamma-2 spontaneously immortalized cell line house mouse CVCL_B5VC CL:0000010 Transfected with: MGI; MGI:97747; Pparg (isoform 2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: SAMR1. Omics: Transcriptome analysis by microarray Unspecified 151666959 CVCL_B5VB U-33/c spontaneously immortalized cell line house mouse CVCL_B5VB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: SAMR1. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Control cell line for U-33/gamma-2 151666960 CVCL_B5VE BALB/3T3 clone A31 ts2 transformed cell line house mouse CVCL_B5VE CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Temperature sensitive At the non-permissive temperature of 38 Celsius cease to proliferate due to a defect in DNA synthesis (PubMed=182373). Doubling time: 35-40 hours, at 33 Celsius (PubMed=182373) 151666961 CVCL_B5VD BALB/3T3 clone A31 Ts-1 transformed cell line house mouse CVCL_B5VD CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Temperature sensitive At the non-permissive temperature (38-38.5 Celsius) cell division cease (PubMed=4798834). Doubling time: 30-32 hours (at 33 Celsius), 22-24 hours (at 38.5 Celsius) (PubMed=4798834) 151666962 CVCL_B5VG BALB/3T3 clone A31 ts22 transformed cell line house mouse CVCL_B5VG CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Temperature sensitive (PubMed=6933701) 151666963 CVCL_B5VF BALB/3T3 clone A31 ts2R transformed cell line house mouse CVCL_B5VF CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Revertant of parent cell line, no longer temperature sensitive (PubMed=6933701) 151666964 CVCL_B5SV HUVEC/TERT66 telomerase immortalized cell line human CVCL_B5SV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile and sex of donor from personal communication of Evercyte Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female Doubling time: ~ 72 hours (Evercyte) 151666965 CVCL_B5T7 SCTCi016-A induced pluripotent stem cell human CVCL_B5T7 From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10294; RPE65; Simple; c.11+5G>A; ClinVar=VCV000098825; Zygosity=Homozygous (PubMed=35121194) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666966 CVCL_B5T6 SCTCi017-A induced pluripotent stem cell human CVCL_B5T6 From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Derived from sampling site: Finger Cell type=Fibroblast.. Female 151666967 CVCL_B5SX RA-MSC/TERT308 telomerase immortalized cell line human CVCL_B5SX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile and sex of donor from personal communication of Evercyte Derived from sampling site: Amnion Cell type=Mesenchymal stem cell.. Female Doubling time: 28-34 hours (Evercyte) 151666968 CVCL_B5T9 SCTCi015-A induced pluripotent stem cell human CVCL_B5T9 From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 5394; CFI; Simple; p.Gly119Arg (c.355G>A); ClinVar=VCV000066014; Zygosity=Heterozygous (PubMed=35526389) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 151666969 CVCL_B5SW HDMVEC/TERT164-B telomerase immortalized cell line human CVCL_B5SW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Skin; microvascular endothelium Cell type=Dermis microvascular lymphatic vessel endothelial cell.. Female Doubling time: 72-96 hours (Evercyte) 151666970 CVCL_B5T8 SCTCi018-A induced pluripotent stem cell human CVCL_B5T8 From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Derived from sampling site: Finger Cell type=Fibroblast.. Female 151666971 CVCL_B5SZ WJ-MSC/TERT273 telomerase immortalized cell line human CVCL_B5SZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile and sex of donor from personal communication of Evercyte Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. Female Doubling time: 40-44 hours (Evercyte) 151666972 CVCL_B5SY P-MSC/TERT308 telomerase immortalized cell line human CVCL_B5SY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Female Doubling time: 30-36 hours (Evercyte) 151666973 CVCL_B5SN cen2 finite cell line human CVCL_B5SN CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151666974 CVCL_B5SM cen3 finite cell line human CVCL_B5SM CL:0000010 Karyotypic information: Gains an extra copy of chromosome 7, X and 18 during progression towards senescence (PubMed=10530795); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151666975 CVCL_B5T1 ASC/TERT300 telomerase immortalized cell line human CVCL_B5T1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile, sex and age of donor from personal communication of Evercyte Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female Doubling time: 30-36 hours (Evercyte) 151666976 CVCL_B5SP cen4 finite cell line human CVCL_B5SP CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151666977 CVCL_B5T0 BM-MSC/TERT292 telomerase immortalized cell line human CVCL_B5T0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile, sex and age of donor from personal communication of Evercyte Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female Doubling time: 34-38 hours (Evercyte) 151666978 CVCL_B5SR CYHI finite cell line human CVCL_B5SR CL:0000010 Derived from sampling site: Axilla; skin Cell type=Myoepithelial cell.. Female Senescence: Senesces at 45-60 PDL (PubMed=10341211) 151666979 CVCL_B5T3 RS-1C9 transformed cell line human CVCL_B5T3 CL:0000010 Transfected with: HGNC; 3415; EPO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male 151666980 CVCL_B5SQ cen1 finite cell line human CVCL_B5SQ CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 151666981 CVCL_B5T2 CP-MSC/TERT308 telomerase immortalized cell line human CVCL_B5T2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Placenta; chorionic plate Cell type=Mesenchymal stem cell.. Female Doubling time: 28-34 hours (Evercyte) 151666982 CVCL_B5ST PODO/SVTERT152 transformed cell line human CVCL_B5ST CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte.. Male Doubling time: 24-32 hours (Evercyte) 151666983 CVCL_B5SS HDF/TERT164 telomerase immortalized cell line human CVCL_B5SS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile and age of donor from personal communication of Evercyte Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Doubling time: 60-72 hours (Evercyte) 151666984 CVCL_B5SF PUMCHi019-A induced pluripotent stem cell human CVCL_B5SF From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Ser269Pro (c.805T>C); ClinVar=VCV001185094; Zygosity=Heterozygous; Note=De novo mutation (PubMed=35152176) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 151666985 CVCL_B5SE PUMCHi013-A induced pluripotent stem cell human CVCL_B5SE From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666986 CVCL_B5SH MUSIe002-A-1 embryonic stem cell human CVCL_B5SH From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1. Population: Southeast Asian; Thai Male 151666987 CVCL_B5SG MUSIe002-A embryonic stem cell human CVCL_B5SG From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai. Male 151666988 CVCL_B5SJ MUSIi017-A induced pluripotent stem cell human CVCL_B5SJ From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand. CL:0000010 151666989 CVCL_B5SI MUSIi016-A induced pluripotent stem cell human CVCL_B5SI From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 79; ABO; Simple; p.Thr88Profs*31 (c.261delG); ClinVar=VCV000017735; Zygosity=Homozygous; Note=Allele ABO*O.01 (PubMed=36603353) Derived from sampling site: Peripheral blood. Female 151666990 CVCL_B5SL CUIMCi004-A induced pluripotent stem cell human CVCL_B5SL From: Columbia University Irving Medical Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 8108; OCRL; Simple; p.Leu713Argfs*28 (c.2136_2139del+1insCT); Zygosity=Hemizygous (PubMed=35074682) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151666991 CVCL_B5SK DHMi005-A-1 induced pluripotent stem cell human CVCL_B5SK From: German Heart Center Munich; Munich; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11604; TBX5; Simple_edited; p.Pro85Thr (c.253C>A); ClinVar=VCV000626359; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35121196) Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male 151666992 CVCL_B5SB PUMCHi010-A induced pluripotent stem cell human CVCL_B5SB From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666993 CVCL_B5SA PUMCHi009-A induced pluripotent stem cell human CVCL_B5SA From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666994 CVCL_B5SD PUMCHi012-A induced pluripotent stem cell human CVCL_B5SD From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666995 CVCL_B5SC PUMCHi011-A induced pluripotent stem cell human CVCL_B5SC From: Peking Union Medical College Hospital; Beijing; China. CL:0000010 151666996 CVCL_B5U8 TRNDi013-F induced pluripotent stem cell human CVCL_B5U8 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666997 CVCL_B5TW TRNDi028-C induced pluripotent stem cell human CVCL_B5TW From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 151666998 CVCL_B5U7 TRNDi013-E induced pluripotent stem cell human CVCL_B5U7 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151666999 CVCL_B5TV TRNDi028-B induced pluripotent stem cell human CVCL_B5TV From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 151667000 CVCL_B5TY HT151A induced pluripotent stem cell human CVCL_B5TY From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp392Ter (c.1176G>A); ClinVar=VCV000003936; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (from parent cell line) Population: Jewish; Ashkenazi; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Female 151667001 CVCL_B5TX HT134A induced pluripotent stem cell human CVCL_B5TX From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151667002 CVCL_B5U9 TRNDi014-A induced pluripotent stem cell human CVCL_B5U9 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667003 CVCL_B5TZ HT151C induced pluripotent stem cell human CVCL_B5TZ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp392Ter (c.1176G>A); ClinVar=VCV000003936; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (from parent cell line) Population: Jewish; Ashkenazi; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Female 151667004 CVCL_B5U0 HT134E induced pluripotent stem cell human CVCL_B5U0 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151667005 CVCL_B5TN NCATS-CL7567 induced pluripotent stem cell human CVCL_B5TN From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Glu153Lys (c.457G>A); ClinVar=VCV001067431; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151667006 CVCL_B5TQ NCATS-CL7569 induced pluripotent stem cell human CVCL_B5TQ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg626Ter (c.1876C>T); ClinVar=VCV000001561; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151667007 CVCL_B5U2 TRNDi011-B induced pluripotent stem cell human CVCL_B5U2 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667008 CVCL_B5TP NCATS-CL7568 induced pluripotent stem cell human CVCL_B5TP From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Glu153Lys (c.457G>A); ClinVar=VCV001067431; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151667009 CVCL_B5U1 TRNDi011-A induced pluripotent stem cell human CVCL_B5U1 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667010 CVCL_B5TS NCATS-CL9316 induced pluripotent stem cell human CVCL_B5TS CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667011 CVCL_B5U4 TRNDi013-B induced pluripotent stem cell human CVCL_B5U4 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667012 CVCL_B5TR NCATS-CL7570 induced pluripotent stem cell human CVCL_B5TR From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg626Ter (c.1876C>T); ClinVar=VCV000001561; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 151667013 CVCL_B5U3 TRNDi013-A induced pluripotent stem cell human CVCL_B5U3 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667014 CVCL_B5U6 TRNDi013-D induced pluripotent stem cell human CVCL_B5U6 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667015 CVCL_B5TU TRNDi028-A induced pluripotent stem cell human CVCL_B5TU From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 151667016 CVCL_B5TT NCATS-CL9318 induced pluripotent stem cell human CVCL_B5TT CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667017 CVCL_B5U5 TRNDi013-C induced pluripotent stem cell human CVCL_B5U5 From: NIH-NCATS-TRND Branch; Rockville; USA. CL:0000010 151667018 CVCL_B5TG PODO/TERT252 telomerase immortalized cell line human CVCL_B5TG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line available upon request to Evercyte; Miscellaneous: Cell line information from personal communication of Evercyte Derived from sampling site: Urine Cell type=Podocyte.. Female 151667019 CVCL_B5TF DSM ACC2258 transformed cell line human CVCL_B5TF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colon Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2258 151667020 CVCL_B5TI LF/TERT309 telomerase immortalized cell line human CVCL_B5TI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex and age of donor from personal communication of Evercyte Derived from sampling site: Lung Cell type=Fibroblast.. Female Doubling time: ~36 hours (Evercyte) 151667021 CVCL_B5TH PODO/TERT255 telomerase immortalized cell line human CVCL_B5TH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line available upon request to Evercyte; Miscellaneous: Cell line information from personal communication of Evercyte Derived from sampling site: Kidney; glomerulus Cell type=Podocyte.. Male 151667022 CVCL_B5TK HT147D induced pluripotent stem cell human CVCL_B5TK From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667023 CVCL_B5TJ HT142C induced pluripotent stem cell human CVCL_B5TJ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; c.590-7G>A (IVS5AS-7G>A); ClinVar=VCV000222996; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667024 CVCL_B5TM HT148D induced pluripotent stem cell human CVCL_B5TM From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667025 CVCL_B5TL HT148A induced pluripotent stem cell human CVCL_B5TL From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667026 CVCL_B5TA SCTCi014-A induced pluripotent stem cell human CVCL_B5TA From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 5394; CFI; Simple; p.Gly119Arg (c.355G>A); ClinVar=VCV000066014; Zygosity=Heterozygous (PubMed=35526386) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 151667027 CVCL_B5TC IDIBGIi002-A induced pluripotent stem cell human CVCL_B5TC From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain. CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val1525Met (c.4573G>A) (p.Val1524Met, c.4570G>A); ClinVar=VCV000067910; Zygosity=Heterozygous (PubMed=35772296) Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 151667028 CVCL_B5TB IDIBGIi001-A induced pluripotent stem cell human CVCL_B5TB From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain. CL:0000010 Population: Caucasian; Derived from sampling site: Neck; skin Cell type=Fibroblast.. Male 151667029 CVCL_B5TE IDIBGIi004-A induced pluripotent stem cell human CVCL_B5TE From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain. CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val1525Met (c.4573G>A) (p.Val1524Met, c.4570G>A); ClinVar=VCV000067910; Zygosity=Heterozygous (PubMed=35772296) Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 151667030 CVCL_B5TD IDIBGIi003-A induced pluripotent stem cell human CVCL_B5TD From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain. CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val1525Met (c.4573G>A) (p.Val1524Met, c.4570G>A); ClinVar=VCV000067910; Zygosity=Heterozygous (PubMed=35772296) Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 151667031 CVCL_B6CE HF-4 hybridoma human CVCL_B6CE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: ssDNA, poly(A), poly(G) and poly(dC). 151667032 CVCL_B6CD HL-349 hybridoma human CVCL_B6CD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA; Monoclonal antibody target: ChEBI; CHEBI:33697; RNA. 151667033 CVCL_B6CG HB-7 hybridoma human CVCL_B6CG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: ssDNA, poly(A), poly(G) and poly(dC). 151667034 CVCL_B6CF HF-7 hybridoma human CVCL_B6CF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: ssDNA, poly(A), poly(G) and poly(dC). 151667035 CVCL_B6CI HB-5 hybridoma human CVCL_B6CI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:73300; Poly(deoxythymidylic acid) (poly(dT)). 151667036 CVCL_B6CH HL-259 hybridoma human CVCL_B6CH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: ssDNA, poly(A), poly(G) and poly(dC). 151667037 CVCL_B6CK EMK-F7 hybridoma human CVCL_B6CK CL:0000010 Anecdotal: The peripheral blood cells that were hybridized with the HO-323 cell line were obtained from Kotaro Koyama who injected himself with stomach cancer cell lines MKN-28 and MKN-45 (PubMed=2121682). Monoclonal antibody isotype: IgG; Monoclonal antibody target: Human stomach cancer cell lines 151667038 CVCL_B6CJ SH-9 [Human hybridoma against poly(dT)] hybridoma human CVCL_B6CJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:73300; Poly(deoxythymidylic acid) (poly(dT)). 151667039 CVCL_B6CA SH-9 [Mouse hybridoma against human MUC16] hybridoma house mouse CVCL_B6CA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. 151667040 CVCL_B6CC HL-321 hybridoma human CVCL_B6CC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: poly(dT), poly(I) and poly(dU). 151667041 CVCL_B6CB SU-1 hybridoma human CVCL_B6CB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Nucleic acids: dsDNA, ssDNA and RNA. 151667042 CVCL_B6BT MSC IGF-1#3 finite cell line house mouse CVCL_B6BT CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C57BL/6-EGFP transgenic. Male 151667043 CVCL_B6C5 Vero-EGFP-SBV-N spontaneously immortalized cell line green monkey CVCL_B6C5 CL:0000010 Transfected with: UniProtKB; H2AM13; Bovine Schmallenberg virus (SBV) nucleoprotein (N); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; epithelium. Female Characteristics: Transfected with a fusion eGFP-SBV-N protein Group: Non-human primate cell line 151667044 CVCL_B6C4 2H12 hybridoma house mouse CVCL_B6C4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37. 151667045 CVCL_B6BS MSC IGF-1#2 finite cell line house mouse CVCL_B6BS CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C57BL/6-EGFP transgenic. Male 151667046 CVCL_B6C7 E6 hybridoma house mouse CVCL_B6C7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Labeo rohita thymocyte 166.2 kDa protein. 151667047 CVCL_B6BV Sf9-GFP spontaneously immortalized cell line CVCL_B6BV CL:0000010 Transfected with: UniProtKB; P17501; Autographa californica nuclear polyhedrosis virus (AcMNPV) GP64; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female Characteristics: Expresses GFP at the cell surface Transfected with a vector containing a fused AcMNPV gp64-GFP construct (PubMed=28365799). Group: Insect cell line 151667048 CVCL_B6C6 2C8 hybridoma house mouse CVCL_B6C6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; H2AM13; Bovine Schmallenberg virus (SBV) nucleoprotein (N). 151667049 CVCL_B6BU hTBME telomerase immortalized cell line CVCL_B6BU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female Doubling time: ~54 hours (PubMed=28918563) 151667050 CVCL_B6BX 1C6 [Mouse hybridoma against human IL37] hybridoma house mouse CVCL_B6BX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37 (isoform B). 151667051 CVCL_B6C9 HO-323-3 transformed cell line human CVCL_B6C9 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line 151667052 CVCL_B6BW H5-GFP spontaneously immortalized cell line CVCL_B6BW CL:0000010 Transfected with: UniProtKB; P17501; Autographa californica nuclear polyhedrosis virus (AcMNPV) GP64; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Unspecified Characteristics: Expresses GFP at the cell surface Transfected with a vector containing a fused AcMNPV gp64-GFP construct (PubMed=28365799). Group: Insect cell line 151667053 CVCL_B6C8 MARC-145 PBD-1+EGFP clone 9/D6 spontaneously immortalized cell line CVCL_B6C8 CL:0000010 Transfected with: VGNC; 87240; Pig DEFB1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal kidney. Unspecified Characteristics: Transfected with a Neo-CMV-DEFB1-IRES-EGFP construct Group: Non-human primate cell line Problematic cell line: Misidentified Grand-parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 151667054 CVCL_B6BZ 1D4 [Mouse hybridoma against human IL37] hybridoma house mouse CVCL_B6BZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37. 151667055 CVCL_B6BY 1D10 hybridoma house mouse CVCL_B6BY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37. 151667056 CVCL_B6BL ELLU clone #136 transformed cell line human CVCL_B6BL CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667057 CVCL_B6BK ELLU clone #131 transformed cell line human CVCL_B6BK CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667058 CVCL_B6BN STPDLDS transformed cell line human CVCL_B6BN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Karyotypic information: Has a large number of abnormal chromosomes (PubMed=34590290); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151667059 CVCL_B6BM STPDL transformed cell line human CVCL_B6BM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 151667060 CVCL_B6C1 2D1 [Mouse hybridoma against human IL37] hybridoma house mouse CVCL_B6C1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37 (isoform B). 151667061 CVCL_B6BP MSC G-CSF#1 finite cell line house mouse CVCL_B6BP CL:0000010 Transfected with: HGNC; 2438; CSF3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C57BL/6-EGFP transgenic. Male 151667062 CVCL_B6C0 2A3 [Mouse hybridoma against human IL37] hybridoma house mouse CVCL_B6C0 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37. 151667063 CVCL_B6C3 2F5 hybridoma house mouse CVCL_B6C3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37 (isoform B). 151667064 CVCL_B6BR MSC IGF-1#1 finite cell line house mouse CVCL_B6BR CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C57BL/6-EGFP transgenic. Male 151667065 CVCL_B6C2 2E9 [Mouse hybridoma against human IL37] hybridoma house mouse CVCL_B6C2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NZH6; Human IL37 (isoform B). 151667066 CVCL_B6BQ MSC G-CSF#2 finite cell line house mouse CVCL_B6BQ CL:0000010 Transfected with: HGNC; 2438; CSF3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C57BL/6-EGFP transgenic. Male 151667067 CVCL_B6DF CG3/12/26 hybridoma house mouse CVCL_B6DF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667068 CVCL_B6DE CG53/2/4 hybridoma house mouse CVCL_B6DE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Chuzan virus isolate K-47 100 kDa antigen. 151667069 CVCL_B6DH CM1/33 hybridoma house mouse CVCL_B6DH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Chuzan virus isolate K-47 41 kDa antigen. 151667070 CVCL_B6DG CG14/3/1 hybridoma house mouse CVCL_B6DG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667071 CVCL_B6DJ CM5/57 hybridoma house mouse CVCL_B6DJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667072 CVCL_B6DI CM3/5/3 hybridoma house mouse CVCL_B6DI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667073 CVCL_B6DL CM23/24 hybridoma house mouse CVCL_B6DL CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667074 CVCL_B6DK CM11/33 hybridoma house mouse CVCL_B6DK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667075 CVCL_B6DB CG31 hybridoma house mouse CVCL_B6DB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667076 CVCL_B6DA CG13/14/2 hybridoma house mouse CVCL_B6DA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667077 CVCL_B6DD CG49 hybridoma house mouse CVCL_B6DD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa+lambda; Monoclonal antibody target: Chuzan virus isolate K-47. 151667078 CVCL_B6DC CG41/44/11 hybridoma house mouse CVCL_B6DC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667079 CVCL_B6CU 9P-13-4 hybridoma human CVCL_B6CU CL:0000010 Characteristics: Seems to secrete two different mAbs; Monoclonal antibody isotype: IgA+IgM. 151667080 CVCL_B6D6 CG1/1 hybridoma house mouse CVCL_B6D6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Chuzan virus isolate K-47 41 kDa antigen. 151667081 CVCL_B6CT 9L-27-9 hybridoma human CVCL_B6CT CL:0000010 Characteristics: Seems to secrete two different mAbs; Monoclonal antibody isotype: IgA+IgM. 151667082 CVCL_B6D5 F3(B6) hybridoma house mouse CVCL_B6D5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P47712; Human PLA2G4A. 151667083 CVCL_B6D8 CG12 hybridoma house mouse CVCL_B6D8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667084 CVCL_B6CW IM-9-P3 transformed cell line human CVCL_B6CW CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Produces prolactin Problematic cell line: Misclassified Grand-parent cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667085 CVCL_B6D7 CG2/2D hybridoma house mouse CVCL_B6D7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667086 CVCL_B6CV IM-9-P transformed cell line human CVCL_B6CV CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Produces prolactin But after approximately 7 months in culture the capacity to synthesize prolactin is greatly reduced (PubMed=1366653; PubMed=2836165). Problematic cell line: Misclassified Parent cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667087 CVCL_B6CY IM-9-P33 transformed cell line human CVCL_B6CY CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Produces high quantity of prolactin Problematic cell line: Misclassified Ancestral cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667088 CVCL_B6D9 CG7 hybridoma house mouse CVCL_B6D9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Chuzan virus isolate K-47. 151667089 CVCL_B6CX IM-9-P6 transformed cell line human CVCL_B6CX CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Compared to the parent cell line, has lost the ability to produces prolactin Problematic cell line: Misclassified Grand-parent cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667090 CVCL_B6CZ IM-9-P31 transformed cell line human CVCL_B6CZ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Produces low quantity of prolactin Problematic cell line: Misclassified Ancestral cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667091 CVCL_B6CM KMK-41 hybridoma human CVCL_B6CM CL:0000010 Monoclonal antibody isotype: Not specified. 151667092 CVCL_B6CL FMK-H3 hybridoma human CVCL_B6CL CL:0000010 Anecdotal: The peripheral blood cells that were hybridized with the HO-323 cell line were obtained from Kotaro Koyama who injected himself with stomach cancer cell lines MKN-28 and MKN-45 (PubMed=2121682). Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human stomach cancer cell lines 151667093 CVCL_B6D0 IM-9-P32 transformed cell line human CVCL_B6D0 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Produces medium quantity of prolactin Problematic cell line: Misclassified Ancestral cell line originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 151667094 CVCL_B6CN SH-75 hybridoma human CVCL_B6CN CL:0000010 Monoclonal antibody isotype: Not specified. 151667095 CVCL_B6D2 P7E9C7 hybridoma human CVCL_B6D2 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta). Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1810; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50139 151667096 CVCL_B6CQ SH-77 hybridoma human CVCL_B6CQ CL:0000010 Monoclonal antibody isotype: Not specified. 151667097 CVCL_B6D1 PEA7-1-6D transformed cell line human CVCL_B6D1 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a healthy donor infected with Pseudomonas aeruginosa; Derived from sampling site: Peripheral blood. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1809; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50138 151667098 CVCL_B6CP SH-76 hybridoma human CVCL_B6CP CL:0000010 Monoclonal antibody isotype: Not specified. 151667099 CVCL_B6D4 HH-1 hybridoma human CVCL_B6D4 CL:0000010 Characteristics: Tridoma obtained by the biological fusion of an hybridoma (AGC-78) with an EBV-transformed LCL cell line; Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: Human cancer cell line A431; Monoclonal antibody target: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1811; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50162 151667100 CVCL_B6CS SH-83 hybridoma human CVCL_B6CS CL:0000010 Monoclonal antibody isotype: Not specified. 151667101 CVCL_B6D3 AGC-78 hybridoma human CVCL_B6D3 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: Human cancer cell line A431. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1812; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50165 151667102 CVCL_B6CR SH-78 hybridoma human CVCL_B6CR CL:0000010 Monoclonal antibody isotype: Not specified. 151667103 CVCL_B6AC HepaRG FXR KO cancer cell line human CVCL_B6AC CL:0000010 Knockout cell: Method=ZFN; HGNC; 7967; NR1H4 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1031 Female 151667104 CVCL_B6AB HepaRG CYP3A4 KO cancer cell line human CVCL_B6AB CL:0000010 Knockout cell: Method=ZFN; HGNC; 2637; CYP3A4 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1026 Female 151667105 CVCL_B6AE HepaRG MDR1 KO cancer cell line human CVCL_B6AE CL:0000010 Knockout cell: Method=ZFN; HGNC; 40; ABCB1 Derived from sampling site: Liver. Female 151667106 CVCL_B6AD HepaRG MATE1 KO cancer cell line human CVCL_B6AD CL:0000010 Knockout cell: Method=ZFN; HGNC; 25588; SLC47A1 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1022 Female 151667107 CVCL_B6AG HepaRG MRP2 KO cancer cell line human CVCL_B6AG CL:0000010 Knockout cell: Method=ZFN; HGNC; 53; ABCC2 Derived from sampling site: Liver. Female 151667108 CVCL_B6AF HepaRG MDR3 KO cancer cell line human CVCL_B6AF CL:0000010 Knockout cell: Method=ZFN; HGNC; 45; ABCB4 Derived from sampling site: Liver. Female 151667109 CVCL_B6AI HepaRG MRP3 KO cancer cell line human CVCL_B6AI CL:0000010 Knockout cell: Method=ZFN; HGNC; 54; ABCC3 Derived from sampling site: Liver. Female 151667110 CVCL_B6AH HepaRG MRP2/MRP4 KO cancer cell line human CVCL_B6AH CL:0000010 Knockout cell: Method=ZFN; HGNC; 53; ABCC2; Knockout cell: Method=ZFN; HGNC; 55; ABCC4 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1103 Female 151667111 CVCL_B6AA HepaRG CAR KO cancer cell line human CVCL_B6AA CL:0000010 Knockout cell: Method=ZFN; HGNC; 7969; NR1I3 Derived from sampling site: Liver. Female 151667112 CVCL_B6A3 C2BBe1 MRP6 KO cancer cell line human CVCL_B6A3 CL:0000010 Knockout cell: Method=ZFN; HGNC; 57; ABCC6; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Discontinued: Sigma-Aldrich; Catalog number MTOX1096 Male 151667113 CVCL_B6A2 C2BBe1 MRP3 KO cancer cell line human CVCL_B6A2 CL:0000010 Knockout cell: Method=ZFN; HGNC; 54; ABCC3; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151667114 CVCL_B6A5 HUPEC 004 FSGS G1/G2 conditionally immortalized cell line human CVCL_B6A5 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte-like epithelial cell.. Male 151667115 CVCL_B6A4 C2BBe1 MRP3/MRP4 KO cancer cell line human CVCL_B6A4 CL:0000010 Knockout cell: Method=ZFN; HGNC; 54; ABCC3; Knockout cell: Method=ZFN; HGNC; 55; ABCC4; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Discontinued: Sigma-Aldrich; Catalog number MTOX1098 Male 151667116 CVCL_B6A7 HepaRG AHR KO cancer cell line human CVCL_B6A7 CL:0000010 Knockout cell: Method=ZFN; HGNC; 348; AHR Derived from sampling site: Liver. Female 151667117 CVCL_B6A6 HepaRG 5F cancer cell line human CVCL_B6A6 CL:0000010 Derived from sampling site: Liver. Female Characteristics: These cells were modified with the use of transfected mRNA encoding ZFNs targeting a specific site (Sigma-Aldrich) 151667118 CVCL_B6A9 HepaRG BSEP KO cancer cell line human CVCL_B6A9 CL:0000010 Knockout cell: Method=ZFN; HGNC; 42; ABCB11 Derived from sampling site: Liver. Female 151667119 CVCL_B6A8 HepaRG BCRP KO cancer cell line human CVCL_B6A8 CL:0000010 Knockout cell: Method=ZFN; HGNC; 74; ABCG2 Derived from sampling site: Liver. Female 151667120 CVCL_B6A1 C2BBe1 MRP4 KO cancer cell line human CVCL_B6A1 CL:0000010 Knockout cell: Method=ZFN; HGNC; 55; ABCC4; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151667121 CVCL_B6A0 C2BBe1 MRP7 KO cancer cell line human CVCL_B6A0 CL:0000010 Knockout cell: Method=ZFN; HGNC; 52; ABCC10; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 151667122 CVCL_B6BD ELLU clone #110 transformed cell line human CVCL_B6BD CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 This clone does not express BCL11A and thus expresses HBE1 and HBZ instead of adult beta globin. 151667123 CVCL_B6BC ELLU clone #104 transformed cell line human CVCL_B6BC CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 Also expresses HBB. 151667124 CVCL_B6BF ELLU clone #121 transformed cell line human CVCL_B6BF CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667125 CVCL_B6BE ELLU clone #116 transformed cell line human CVCL_B6BE CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 Also expresses HBB. 151667126 CVCL_B6BH ELLU clone #125 transformed cell line human CVCL_B6BH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667127 CVCL_B6BG ELLU clone #123 transformed cell line human CVCL_B6BG CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667128 CVCL_B6BJ ELLU clone #127 transformed cell line human CVCL_B6BJ CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667129 CVCL_B6BI ELLU clone #126 transformed cell line human CVCL_B6BI CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Erythroid progenitor cell.. Unspecified Characteristics: Expresses HBA1, HBA2 and HBG1 151667130 CVCL_B6AZ MuRTE21 spontaneously immortalized cell line house mouse CVCL_B6AZ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667131 CVCL_B6BB PTEN-KO BMSC finite cell line CVCL_B6BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G1SVU9; PTEN Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Unspecified 151667132 CVCL_B6BA MuRTE82 spontaneously immortalized cell line house mouse CVCL_B6BA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667133 CVCL_B6AS HepaRG PXR KO cancer cell line human CVCL_B6AS CL:0000010 Knockout cell: Method=ZFN; HGNC; 7968; NR1I2 Derived from sampling site: Liver. Female 151667134 CVCL_B6B4 MuRTE42 spontaneously immortalized cell line house mouse CVCL_B6B4 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667135 CVCL_B6AR HepaRG POR KO cancer cell line human CVCL_B6AR CL:0000010 Knockout cell: Method=ZFN; HGNC; 9208; POR Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1025 Female 151667136 CVCL_B6B3 MuRTE31 spontaneously immortalized cell line house mouse CVCL_B6B3 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667137 CVCL_B6AU HepaRG SOD2 KO cancer cell line human CVCL_B6AU CL:0000010 Knockout cell: Method=ZFN; HGNC; 11180; SOD2 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1027 Female 151667138 CVCL_B6B6 MuRTE61 spontaneously immortalized cell line house mouse CVCL_B6B6 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667139 CVCL_B6AT HepaRG PXR/CAR KO cancer cell line human CVCL_B6AT CL:0000010 Knockout cell: Method=ZFN; HGNC; 7968; NR1I2; Knockout cell: Method=ZFN; HGNC; 7969; NR1I3 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1014 Female 151667140 CVCL_B6B5 MuRTE52 spontaneously immortalized cell line house mouse CVCL_B6B5 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667141 CVCL_B6B8 MuRTE72 spontaneously immortalized cell line house mouse CVCL_B6B8 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667142 CVCL_B6AW SA7K MATE1/MATE2K KO transformed cell line human CVCL_B6AW CL:0000010 Knockout cell: Method=ZFN; HGNC; 25588; SLC47A1; Knockout cell: Method=ZFN; HGNC; 26439; SLC47A2 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The parent cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151667143 CVCL_B6B7 MuRTE71 spontaneously immortalized cell line house mouse CVCL_B6B7 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667144 CVCL_B6AV SA7K MATE1 KO transformed cell line human CVCL_B6AV CL:0000010 Knockout cell: Method=ZFN; HGNC; 25588; SLC47A1 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The parent cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151667145 CVCL_B6AY MuRTE15 spontaneously immortalized cell line house mouse CVCL_B6AY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667146 CVCL_B6B9 MuRTE73 spontaneously immortalized cell line house mouse CVCL_B6B9 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667147 CVCL_B6AX SA7K MATE2K KO transformed cell line human CVCL_B6AX CL:0000010 Knockout cell: Method=ZFN; HGNC; 26439; SLC47A2 Population: African American; Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Female Characteristics: The parent cell line was established by zinc finger nuclease-mediated knockout of a cell cycle protein (Sigma-Aldrich) 151667148 CVCL_B6AK HepaRG MRP6 KO cancer cell line human CVCL_B6AK CL:0000010 Knockout cell: Method=ZFN; HGNC; 57; ABCC6 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1104 Female 151667149 CVCL_B6AJ HepaRG MRP4 KO cancer cell line human CVCL_B6AJ CL:0000010 Knockout cell: Method=ZFN; HGNC; 55; ABCC4 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1106 Female 151667150 CVCL_B6AM HepaRG OATP1B1/OATP1B3 KO cancer cell line human CVCL_B6AM CL:0000010 Knockout cell: Method=ZFN; HGNC; 10959; SLCO1B1; Knockout cell: Method=ZFN; HGNC; 10961; SLCO1B3 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1017 Female 151667151 CVCL_B6AL HepaRG OATP1B1 KO cancer cell line human CVCL_B6AL CL:0000010 Knockout cell: Method=ZFN; HGNC; 10959; SLCO1B1 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1015 Female 151667152 CVCL_B6B0 MuRTE22 spontaneously immortalized cell line house mouse CVCL_B6B0 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667153 CVCL_B6AN HepaRG OATP1B3 KO cancer cell line human CVCL_B6AN CL:0000010 Knockout cell: Method=ZFN; HGNC; 10961; SLCO1B3 Derived from sampling site: Liver. Female 151667154 CVCL_B6AQ HepaRG PERK KO cancer cell line human CVCL_B6AQ CL:0000010 Knockout cell: Method=ZFN; HGNC; 3255; EIF2AK3 Derived from sampling site: Liver. Female 151667155 CVCL_B6B2 MuRTE24 spontaneously immortalized cell line house mouse CVCL_B6B2 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667156 CVCL_B6AP HepaRG P66SHC KO cancer cell line human CVCL_B6AP CL:0000010 Knockout cell: Method=ZFN; HGNC; 10840; SHC1 Derived from sampling site: Liver. Discontinued: Sigma-Aldrich; Catalog number MTOX1023 Female 151667157 CVCL_B6B1 MuRTE23 spontaneously immortalized cell line house mouse CVCL_B6B1 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Kidney; proximal tubule Cell type=Epithelial cell.. Male 151667158 CVCL_B6YZ UFERSA-PC1 finite cell line CVCL_B6YZ CL:0000010 Miscellaneous: Age/sex of donor and cell line name from personal communication of Pereira A.F Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 151667159 CVCL_B6ZB IMC-118 cancer cell line dog CVCL_B6ZB CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Female Characteristics: Luminal type B inflammatory and ERBB2+ (Patent=CN113980904A; PubMed=35429113) Doubling time: 50.31 hours (Patent=CN113980904A; PubMed=35429113) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021285 151667160 CVCL_B6ZA RNCEC/HL-032 finite cell line CVCL_B6ZA CL:0000010 Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.; Breed/subspecies: New Zealand white. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201677 151667161 CVCL_B6YS iTIME.219 telomerase immortalized cell line human CVCL_B6YS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Foreskin; skin; dermis; microvascular endothelium. Male Characteristics: rKSHV.219 includes a RFP-GFP-Puro construct that contains RFP under the control of the lytic PAN RNA promoter, GFP under the control of human EF-1 alpha promoter and PuroR expressed by the RSV promoter; Characteristics: Transduced with pRetroX-Tet-On that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 and with RetroX-Tight-Hyg-RTA; Virology: Maintains latent rKSHV.219 as indicated by expression of constitutively expressed (eGFP) but not a lytic phase (RFP) reporter gene When exposed to either sodium butyrate or doxycycline, the cells are activated to lytic replication and express RFP and KSHV lytic genes and release large quantities of infectious virus (PubMed=33937098).; Virology: Infected with a recombinant human herpesvirus 8 (HHV-8/KSHV) rKSHV.219 151667162 CVCL_B6Z4 MNUEC/HL-027 finite cell line house mouse CVCL_B6Z4 CL:0000010 Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015108 151667163 CVCL_B6Z3 AD [Mouse hybridoma against phenacetin] hybridoma house mouse CVCL_B6Z3 CL:0000010 Transformant: Phenacetin(ChEBI; CHEBI:8050). Monoclonal antibody isotype: IgG2b, kappa Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.19681 151667164 CVCL_B6YR TIME.219 telomerase immortalized cell line human CVCL_B6YR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin; dermis; microvascular endothelium. Male Characteristics: rKSHV.219 includes a RFP-GFP-Puro construct that contains RFP under the control of the lytic PAN RNA promoter, GFP under the control of human EF-1 alpha promoter and PuroR expressed by the RSV promoter; Virology: Infected with a recombinant human herpesvirus 8 (HHV-8/KSHV) rKSHV.219 151667165 CVCL_B6Z6 HNCEC/HL-043 finite cell line human CVCL_B6Z6 CL:0000010 Population: Chinese; Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201676 151667166 CVCL_B6YU iSLK cancer cell line human CVCL_B6YU CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Skin. Male Problematic cell line: Contaminated Shown to be a Caki-1 derivative (PubMed=22987579). The parent cell line was originally thought to originate from a 28 year old male patient with HIV-1 negative Kaposi sarcoma. 151667167 CVCL_B6Z5 MFC/HL-041 finite cell line house mouse CVCL_B6Z5 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201714 151667168 CVCL_B6YT ZYXY-T1 cancer cell line human CVCL_B6YT CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC 202143 151667169 CVCL_B6Z8 HNCEC/HL-008 finite cell line human CVCL_B6Z8 CL:0000010 Population: Chinese; Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201550 151667170 CVCL_B6YW NWR 17626 iPSC-c501 induced pluripotent stem cell CVCL_B6YW CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151667171 CVCL_B6Z7 HBCC/HL-004 cancer cell line human CVCL_B6Z7 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201535 151667172 CVCL_B6YV iSLK.219 cancer cell line human CVCL_B6YV CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Skin. Male Characteristics: rKSHV.219 includes a RFP-GFP-Puro construct that contains RFP under the control of the lytic PAN RNA promoter, GFP under the control of human EF-1 alpha promoter and PuroR expressed by the RSV promoter; Characteristics: Transduced with pRetroX-Tet-On that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 and with RetroX-Tight-Hyg-RTA; Virology: Maintains latent rKSHV.219 as indicated by expression of constitutively expressed (eGFP) but not a lytic phase (RFP) reporter gene When exposed to either sodium butyrate or doxycycline, the cells are activated to lytic replication and express RFP and KSHV lytic genes and release large quantities of infectious virus (PubMed=21419799).; Virology: Infected with a recombinant human herpesvirus 8 (HHV-8/KSHV) rKSHV.219 Problematic cell line: Contaminated Shown to be a Caki-1 derivative (PubMed=22987579). The grand-parent cell line was originally thought to originate from a 28 year old male patient with HIV-1 negative Kaposi sarcoma. 151667173 CVCL_B6YY NWR 17626 iPSC-c5103 induced pluripotent stem cell CVCL_B6YY CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151667174 CVCL_B6YX NWR 17626 iPSC-c5101 induced pluripotent stem cell CVCL_B6YX CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 151667175 CVCL_B6Z9 VvmAb1m1n7 hybridoma house mouse CVCL_B6Z9 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Vibrio vulnificus membrane protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016146 151667176 CVCL_B6YK HUVECs-hTERT telomerase immortalized cell line human CVCL_B6YK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. 151667177 CVCL_B6YJ FPKLPV-WBPH spontaneously immortalized cell line CVCL_B6YJ CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and the species. Unspecified Group: Insect cell line 151667178 CVCL_B6YM ZYXY-M2 cancer cell line human CVCL_B6YM CL:0000010 Population: Chinese; Karyotypic information: 47,XY,+12 [1]; 48,XY,+12,+9 [9] (DOI=10.1182/blood-2021-152639); Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Doubling time: 48-72 hours (DOI=10.1182/blood-2021-152639) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC 202145 151667179 CVCL_B6YL FPKLPV-BPH spontaneously immortalized cell line CVCL_B6YL CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and the species. Unspecified Group: Insect cell line 151667180 CVCL_B6Z0 UFERSA-PC2 finite cell line CVCL_B6Z0 CL:0000010 Miscellaneous: Age/sex of donor and cell line name from personal communication of Pereira A.F Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 151667181 CVCL_B6YN HaCaT-hGSTP1 ARE-SV40p-Luc2 spontaneously immortalized cell line human CVCL_B6YN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Expression of the luciferase reporter gene is under the control of the antioxidant response element (ARE) of GSTP1 (Patent=CN113265423B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021113 151667182 CVCL_B6Z2 UFERSA-PC4 finite cell line CVCL_B6Z2 CL:0000010 Miscellaneous: Age/sex of donor and cell line name from personal communication of Pereira A.F Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 151667183 CVCL_B6YQ ZYXY-M1 luc cancer cell line human CVCL_B6YQ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Chinese; Derived from sampling site: Peripheral blood. Male 151667184 CVCL_B6Z1 UFERSA-PC3 finite cell line CVCL_B6Z1 CL:0000010 Miscellaneous: Age/sex of donor and cell line name from personal communication of Pereira A.F Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 151667185 CVCL_B6YP ZYXY-M1 cancer cell line human CVCL_B6YP CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC 202144 151667186 CVCL_B6YC OFEC18-FGBC spontaneously immortalized cell line CVCL_B6YC CL:0000010 Unspecified Doubling time: 73.8 hours (PubMed=33110952). Group: Fish cell line 151667187 CVCL_B6YB alphaTC1-6 ins2:eGFP cancer cell line house mouse CVCL_B6YB CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Alpha cell.; Breed/subspecies: C57BL/6 x DBA/2. Characteristics: Transfected with a PuroR-ins2-eGFP construct where the expression of the eGFP gene is under the control of the mouse ins2 promoter (PubMed=34871457) 151667188 CVCL_B6YE HCD-57 SHP2-E76K cancer cell line house mouse CVCL_B6YE CL:0000010 Transfected with: HGNC; 9644; PTPN11 (with p.Glu76Lys); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: NIH Swiss. Characteristics: EPO independent (DOI=10.1182/blood-2021-150007) 151667189 CVCL_B6YD HCD-57 SHP2-D61Y cancer cell line house mouse CVCL_B6YD CL:0000010 Transfected with: HGNC; 9644; PTPN11 (with p.Asp61Tyr); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: NIH Swiss. Characteristics: EPO independent (DOI=10.1182/blood-2021-150007) 151667190 CVCL_B6YG 0840-FusionRed cancer cell line dog CVCL_B6YG CL:0000010 Transfected with: FusionRed, a bright red fluorescent protein derived from eqFP578; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Pitbull Terrier. Male 151667191 CVCL_B6YF EO-1 cancer cell line dog CVCL_B6YF CL:0000010 Derived from metastatic site: Lymph node Cell type=T-cell.; Breed/subspecies: English bulldog. Female Doubling time: 28.4 hours (PubMed=28668559) 151667192 CVCL_B6YI FPKLPV-SBPH spontaneously immortalized cell line CVCL_B6YI CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and the species. Unspecified Group: Insect cell line 151667193 CVCL_B6YH 0846-FusionRed cancer cell line dog CVCL_B6YH CL:0000010 Transfected with: FusionRed, a bright red fluorescent protein derived from eqFP578; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: German Rough-haired Pointer. Male 151667194 CVCL_B6ZT V/1Ki-Delta spontaneously immortalized cell line CVCL_B6ZT CL:0000010 Derived from sampling site: Kidney. Virology: Persistently infected by Swiss snake colony virus 1 (SwSCV-1) Group: Reptilian cell line 151667195 CVCL_B6ZS I/1Ki-Delta spontaneously immortalized cell line CVCL_B6ZS CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Virology: Persistently infected by Swiss snake colony virus 1 (SwSCV-1) Group: Reptilian cell line 151667196 CVCL_B6ZV V/5Lu-Delta spontaneously immortalized cell line CVCL_B6ZV CL:0000010 Derived from sampling site: Lung; smooth muscle Cell type=Vascular associated smooth muscle cell.. Virology: Persistently infected by Swiss snake colony virus 1 (SwSCV-1) Group: Reptilian cell line 151667197 CVCL_B6ZU V/2Hz-Delta spontaneously immortalized cell line CVCL_B6ZU CL:0000010 Derived from sampling site: Heart Cell type=Cardiomyocyte.. Virology: Persistently infected by Swiss snake colony virus 1 (SwSCV-1) Group: Reptilian cell line 151667198 CVCL_B6ZX I/1Ki-1.2xDelta spontaneously immortalized cell line CVCL_B6ZX CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Virology: Persistently infected by a '1.2 genome' Swiss snake colony virus 1 (SwSCV-1) This is a construct bearing two copies of the genomic and antigenomic ribozymes (PubMed=35062311). Group: Reptilian cell line 151667199 CVCL_B6ZW V/1Liv-Delta spontaneously immortalized cell line CVCL_B6ZW CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Virology: Persistently infected by Swiss snake colony virus 1 (SwSCV-1) Group: Reptilian cell line 151667200 CVCL_B6ZZ SCVIi035-A induced pluripotent stem cell human CVCL_B6ZZ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151667201 CVCL_B6ZY SCVIi036-A induced pluripotent stem cell human CVCL_B6ZY From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Ile154Leufs*5 (c.459delC); ClinVar=VCV000042755; Zygosity=Heterozygous (PubMed=35413566); Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Thr568Met (c.1703C>T); ClinVar=VCV000181464; Zygosity=Heterozygous (PubMed=35413566) Population: Southeast Asian; Derived from sampling site: Peripheral blood. Male 151667202 CVCL_B6ZL V/1Ki spontaneously immortalized cell line CVCL_B6ZL CL:0000010 Derived from sampling site: Kidney. Group: Reptilian cell line 151667203 CVCL_B6ZK I/1Ki spontaneously immortalized cell line CVCL_B6ZK CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Group: Reptilian cell line 151667204 CVCL_B6ZN V/2Hz spontaneously immortalized cell line CVCL_B6ZN CL:0000010 Derived from sampling site: Heart Cell type=Cardiomyocyte.. Group: Reptilian cell line 151667205 CVCL_B6ZM V/1Liv spontaneously immortalized cell line CVCL_B6ZM CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Group: Reptilian cell line 151667206 CVCL_B6ZP V/4Br spontaneously immortalized cell line CVCL_B6ZP CL:0000010 Derived from sampling site: Brain. Group: Reptilian cell line 151667207 CVCL_B6ZR V/5Lu spontaneously immortalized cell line CVCL_B6ZR CL:0000010 Derived from sampling site: Lung; smooth muscle Cell type=Vascular associated smooth muscle cell.. Group: Reptilian cell line 151667208 CVCL_B6ZQ V/4Lu spontaneously immortalized cell line CVCL_B6ZQ CL:0000010 Derived from sampling site: Lung. Group: Reptilian cell line 151667209 CVCL_B6ZD ZX2021H cancer cell line human CVCL_B6ZD CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp22Asn (c.64G>A); ClinVar=VCV000040335; Zygosity=Unspecified (PubMed=35297208); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Cys2134Tyrfs*8 (c.6401_6402del) (p.L2133fs, c.6398_6399del); ClinVar=VCV000818199; Zygosity=Unspecified (PubMed=35297208); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Unspecified (PubMed=35297208) Population: Chinese; Derived from metastatic site: Cervical lymph node. Male Doubling time: ~29.8 hours (PubMed=35297208) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021215 151667210 CVCL_B6ZC Res1-6 cancer cell line house mouse CVCL_B6ZC CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Resistant to antibodies against CD274/PD-L1 (Patent=CN114009399A) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021234 151667211 CVCL_B6ZF 6E4 hybridoma house mouse CVCL_B6ZF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Enzootic nasal tumour virus of goats (ENTV-2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202181 151667212 CVCL_B6ZE 6F3H hybridoma house mouse CVCL_B6ZE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O11424; Duck adenovirus 1 fiber protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021286 151667213 CVCL_B6ZH IgM-1 hybridoma house mouse CVCL_B6ZH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human IgM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201843 151667214 CVCL_B6ZG A5 hybridoma house mouse CVCL_B6ZG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:169037; Armillaric acid. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021127 151667215 CVCL_B6ZJ JHJ hybridoma house mouse CVCL_B6ZJ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:34692; Dicofol (Kelthane). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.22329 151667216 CVCL_B6ZI 3B8.10D9 hybridoma house mouse CVCL_B6ZI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:34692; Dicofol (Kelthane); Monoclonal antibody target: ChEBI; CHEBI:190399; 4,4'-dichlorobenzhydrol (DCBH). 151667217 CVCL_B6WY 9-1 hybridoma house mouse CVCL_B6WY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P09104; Human ENO2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015103 151667218 CVCL_B6WX 2-2 [Mouse hybridoma against human ENO2] hybridoma house mouse CVCL_B6WX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P09104; Human ENO2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015104 151667219 CVCL_B6X9 3-26-1 hybridoma house mouse CVCL_B6X9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201208 151667220 CVCL_B6WZ 1-10-1 hybridoma house mouse CVCL_B6WZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human high density lipoprotein (HDL). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201599 151667221 CVCL_B6X2 13-2 hybridoma house mouse CVCL_B6X2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08727; Human KRT19 (AA 301-400 = CYFRA21-1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201597 151667222 CVCL_B6WQ BS 59 hybridoma house mouse CVCL_B6WQ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667223 CVCL_B6X1 10-2 hybridoma house mouse CVCL_B6X1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08727; Human KRT19 (AA 301-400 = CYFRA21-1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201596 151667224 CVCL_B6WP BS 57 hybridoma house mouse CVCL_B6WP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). 151667225 CVCL_B6X4 27-1 hybridoma house mouse CVCL_B6X4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P19429; Human TNNI3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201592 151667226 CVCL_B6WS BS 75 hybridoma house mouse CVCL_B6WS CL:0000010 Monoclonal antibody isotype: Not determined; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667227 CVCL_B6X3 18-1 hybridoma house mouse CVCL_B6X3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P19429; Human TNNI3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201593 151667228 CVCL_B6WR BS 61 hybridoma house mouse CVCL_B6WR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667229 CVCL_B6X6 7-1 [Mouse hybridoma against human CKB/CKM] hybridoma house mouse CVCL_B6X6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12277; Human CKB; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201591 151667230 CVCL_B6WU LM 17/20 hybridoma house mouse CVCL_B6WU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (Note=Recognizes both M and N blood group antigens). 151667231 CVCL_B6X5 4-2 hybridoma house mouse CVCL_B6X5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12277; Human CKB; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201590 151667232 CVCL_B6WT LM 17/19 hybridoma house mouse CVCL_B6WT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (Note=Recognizes both M and N blood group antigens). 151667233 CVCL_B6X8 3-20-1 hybridoma house mouse CVCL_B6X8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201202 151667234 CVCL_B6WW 9-2 hybridoma house mouse CVCL_B6WW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02144; Human MB. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015102 151667235 CVCL_B6WV 49-2 hybridoma house mouse CVCL_B6WV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02144; Human MB. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015101 151667236 CVCL_B6X7 4D1 [Mouse hybridoma against SYNV P] hybridoma house mouse CVCL_B6X7 CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: UniProtKB; P21299; Sonchus yellow net virus (SYNV) phosphoprotein (P). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.9326 151667237 CVCL_B6WI BS 38 hybridoma house mouse CVCL_B6WI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). 151667238 CVCL_B6WH 8-1 hybridoma house mouse CVCL_B6WH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02649; Human APOE. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201595 151667239 CVCL_B6WK BS 40 hybridoma house mouse CVCL_B6WK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667240 CVCL_B6WJ BS 39 hybridoma house mouse CVCL_B6WJ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (Note=Recognizes both M and N blood group antigens). 151667241 CVCL_B6WM BS 42 hybridoma house mouse CVCL_B6WM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667242 CVCL_B6WL BS 41 hybridoma house mouse CVCL_B6WL CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667243 CVCL_B6X0 1-35-1 hybridoma house mouse CVCL_B6X0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human high density lipoprotein (HDL). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201598 151667244 CVCL_B6WN BS 44 hybridoma house mouse CVCL_B6WN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). 151667245 CVCL_B6WA 1E5 [Mouse hybridoma against amantadine] hybridoma house mouse CVCL_B6WA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:2618; Amantadine. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.10865 151667246 CVCL_B6WC G1-OA embryonic stem cell house mouse CVCL_B6WC CL:0000010 Breed/subspecies: BALB/c. Female Characteristics: Germ stem cell line 151667247 CVCL_B6WB anti-S6K2/B2 hybridoma house mouse CVCL_B6WB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9UBS0; Human RPS6KB2. 151667248 CVCL_B6WE D4 [Mouse hybridoma against human RICTOR] hybridoma house mouse CVCL_B6WE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6R327; Human RICTOR. 151667249 CVCL_B6WD G1-T embryonic stem cell house mouse CVCL_B6WD CL:0000010 Breed/subspecies: BALB/c. Female Characteristics: Germ stem cell line 151667250 CVCL_B6WG 23-1 hybridoma house mouse CVCL_B6WG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02649; Human APOE. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201594 151667251 CVCL_B6WF ZJED0-02 hybridoma house mouse CVCL_B6WF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; X5H5A9; Zaire ebolavirus (strain Makona) envelope glycoprotein (GP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201584 151667252 CVCL_B6XZ MDCK-79 spontaneously immortalized cell line dog CVCL_B6XZ CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Obtained from the parent cell line by limited dilution method so as to obtain a cell line with low ABCB1 expression (PubMed=36651516) 151667253 CVCL_B6XY NSC-19 hybrid cell line house mouse CVCL_B6XY CL:0000010 Characteristics: Produced by the fusion of motor neuron enriched, embryonic 12-14 days mouse spinal cord cells with N18TG2 (PubMed=1467557). 151667254 CVCL_B6YA R-7 transformed cell line CVCL_B6YA CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Vibrissa; skin; dermal papilla Cell type=Hair follicle dermal papilla cell.; Breed/subspecies: White Rex. Female 151667255 CVCL_B6XR BUTE1D transformed cell line CVCL_B6XR CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 151667256 CVCL_B6Y3 MSH spontaneously immortalized cell line CVCL_B6Y3 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 151667257 CVCL_B6XQ BUTE1C transformed cell line CVCL_B6XQ CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 151667258 CVCL_B6Y2 TrJ6 hybridoma CVCL_B6Y2 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P01920; Human HLA-DQB1. 151667259 CVCL_B6Y5 KTS spontaneously immortalized cell line CVCL_B6Y5 CL:0000010 Derived from sampling site: Fin. Unspecified Characteristics: Capable of growing from 23 to 30 Celsius, the optimal temperature is 27 Celsius (DOI=10.1016/j.aquaculture.2020.735534) Group: Fish cell line 151667260 CVCL_B6XT SYSUIMi001-A induced pluripotent stem cell human CVCL_B6XT From: Sun Yat-sen University Fifth Affiliated Hospital; Zhuhai; China CL:0000010 Sequence variation: Mutation; HGNC; 13266; DDX24; Simple; p.Glu271Lys (c.811G>A); Zygosity=Heterozygous (PubMed=35091306) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151667261 CVCL_B6Y4 ALF [Acanthopagrus latus] spontaneously immortalized cell line CVCL_B6Y4 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 151667262 CVCL_B6XS BUTE1E transformed cell line CVCL_B6XS CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 151667263 CVCL_B6Y7 Aag2INF spontaneously immortalized cell line CVCL_B6Y7 CL:0000010 Anecdotal: Was accidentally created by a student that was working with Aag-2 and also manipulating samples containing arboviruses Derived from sampling site: Whole embryo. Unspecified Virology: Persistently infected by Chikungunya virus and Mayaro virus (PubMed=34878970); Virology: The Chikungunya virus in this cell line has accumulated non-synonymous mutations and encodes a shorter nsP3 gene and has lost the capacity to infect mammalian cells (PubMed=34878970) Group: Insect cell line 151667264 CVCL_B6XV SYSUIMi003-A induced pluripotent stem cell human CVCL_B6XV From: Sun Yat-sen University Fifth Affiliated Hospital; Zhuhai; China CL:0000010 Sequence variation: Mutation; HGNC; 13266; DDX24; Simple; p.Glu271Lys (c.811G>A); Zygosity=Heterozygous (PubMed=35091306) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151667265 CVCL_B6Y6 SK-BR-3/nab-P cancer cell line human CVCL_B6Y6 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female 151667266 CVCL_B6XU SYSUIMi002-A induced pluripotent stem cell human CVCL_B6XU From: Sun Yat-sen University Fifth Affiliated Hospital; Zhuhai; China CL:0000010 Sequence variation: Mutation; HGNC; 13266; DDX24; Simple; p.Glu271Lys (c.811G>A); Zygosity=Heterozygous (PubMed=35091306) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 151667267 CVCL_B6Y9 mDPCET transformed cell line house mouse CVCL_B6Y9 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P06956; Escherichia phage P1 cre Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic tooth bud; dental papilla; molar Cell type=Mesenchymal cell.; Breed/subspecies: CD-1. Unspecified Characteristics: Reversibly immortalized; exposure to tamoxifen induces the expression of the Cre gene that effects Cre/LoxP recombination and excise the SV40 TAG gene; Characteristics: Transduced with a pHLox-CMV-TAg-IRES-TK lentiviral construct as well as a pCAG-ERT2-Cre-ERT2-neo construct 151667268 CVCL_B6XX N6HB426-20 hybridoma house mouse CVCL_B6XX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14973; Human SLC10A1. 151667269 CVCL_B6XW iEM transformed cell line human CVCL_B6XW CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; sweat gland Cell type=Myoepithelial cell.. Unspecified 151667270 CVCL_B6Y8 mDPC6T transformed cell line house mouse CVCL_B6Y8 CL:0000010 Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic tooth bud; dental papilla; molar Cell type=Mesenchymal cell.; Breed/subspecies: CD-1. Unspecified Characteristics: Transduced with a pHLox-CMV-TAg-IRES-TK lentiviral construct The TK gene allows selection using ganciclovir (GCV). 151667271 CVCL_B6XJ SFL [Kareius] spontaneously immortalized cell line CVCL_B6XJ CL:0000010 Derived from sampling site: Liver Cell type=Fibroblast.. Unspecified Characteristics: The optimal growth temperature is 22 Celsius (DOI=10.1111/j.1749-7345.2010.00445.x) Doubling time: 38.8 hours (DOI=10.1111/j.1749-7345.2010.00445.x) Group: Fish cell line 151667272 CVCL_B6XI PSD-LWHT transformed cell line CVCL_B6XI CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Back; skin; dermis Cell type=Fibroblast.. Female Doubling time: 68.9 hours (PubMed=30064049) Group: Cetacean cell line 151667273 CVCL_B6XL BFIB2 transformed cell line CVCL_B6XL CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Fibroblast.; Breed/subspecies: Holstein. Female Doubling time: 28.35 hours (PubMed=35064470) 151667274 CVCL_B6XK BFIB1 transformed cell line CVCL_B6XK CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 151667275 CVCL_B6XN BUTE1A transformed cell line CVCL_B6XN CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female Doubling time: 74.99 hours (PubMed=35064470) 151667276 CVCL_B6XM BFIB3 transformed cell line CVCL_B6XM CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 151667277 CVCL_B6XP BUTE1B transformed cell line CVCL_B6XP CL:0000010 Transformant: Simian virus 40 (SV40) [pW2](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 151667278 CVCL_B6Y1 GrB spontaneously immortalized cell line CVCL_B6Y1 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Can grow between 22 to 27 Celsius, with an optimal growth temperature of 27 Celsius (DOI=10.1111/are.15702); Virology: Susceptible to infection by tilapia lake virus 2017A (TiLV-2017A) (DOI=10.1111/are.15702) Group: Fish cell line 151667279 CVCL_B6Y0 SW620/Ad300-ABCB1ko cancer cell line human CVCL_B6Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 151667280 CVCL_B6XB G6 embryonic stem cell house mouse CVCL_B6XB CL:0000010 Breed/subspecies: BALB/c. Characteristics: Germ stem cell line 151667281 CVCL_B6XA G4 [Mouse germ stem cell] embryonic stem cell house mouse CVCL_B6XA CL:0000010 Breed/subspecies: BALB/c. Characteristics: Germ stem cell line 151667283 CVCL_B6XC G7 embryonic stem cell house mouse CVCL_B6XC CL:0000010 Breed/subspecies: BALB/c. Characteristics: Germ stem cell line 151667284 CVCL_B6XF ACRJ-PC28 cancer cell line human CVCL_B6XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: Age at sampling from personal communication of Badal-McCreath S.A.M Population: Caribbean; Jamaican; Derived from sampling site: Prostate. Omics: Transcriptome analysis by RNAseq Male Characteristics: Lack of expression of AR (DOI=10.1158/1538-7755.DISP21-PO-138) Doubling time: 45 hours (DOI=10.1158/1538-7755.DISP21-PO-138) 151667285 CVCL_B6XE C5 [Mouse hybridoma against V.anguillarum] hybridoma house mouse CVCL_B6XE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Vibrio anguillarum. 151667286 CVCL_B6XH HCF spontaneously immortalized cell line CVCL_B6XH CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 151667288 CVCL_B6UW BM9.1 cancer cell line human CVCL_B6UW CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667289 CVCL_B6V8 TrC5 hybridoma human CVCL_B6V8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01909; Human HLA-DQA1. 151667290 CVCL_B6UV BM8.5 cancer cell line human CVCL_B6UV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667291 CVCL_B6V7 TrB50 hybridoma human CVCL_B6V7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04440; Human HLA-DPB1. 151667292 CVCL_B6UY BM11.1 cancer cell line human CVCL_B6UY CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667293 CVCL_B6UX BM10.1 cancer cell line human CVCL_B6UX CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667294 CVCL_B6V9 TrE11 hybridoma human CVCL_B6V9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04440; Human HLA-DPB1. 151667295 CVCL_B6UZ BM12.1 cancer cell line human CVCL_B6UZ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667296 CVCL_B6V0 BM13.1 cancer cell line human CVCL_B6V0 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667297 CVCL_B6UN BM1.5 cancer cell line human CVCL_B6UN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667298 CVCL_B6V2 BM15.3 cancer cell line human CVCL_B6V2 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667299 CVCL_B6UQ BM3.1 cancer cell line human CVCL_B6UQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667300 CVCL_B6V1 BM14.1 cancer cell line human CVCL_B6V1 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667301 CVCL_B6UP BM2.2 cancer cell line human CVCL_B6UP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667302 CVCL_B6V4 BM2.2.3 cancer cell line human CVCL_B6V4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the grand-parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins 151667303 CVCL_B6US BM5.2 cancer cell line human CVCL_B6US CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667304 CVCL_B6V3 BM19 cancer cell line human CVCL_B6V3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667305 CVCL_B6UR BM4.1 cancer cell line human CVCL_B6UR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667306 CVCL_B6UU BM7.4 cancer cell line human CVCL_B6UU CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667307 CVCL_B6V6 UL-F6 hybridoma CVCL_B6V6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*27). 151667308 CVCL_B6UT BM6.3 cancer cell line human CVCL_B6UT CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Groin. Female Characteristics: Obtained from the parent cell line that was subjected to 3 Gy of gamma-irradiation and selected for cells having mutations of MHC class 1 and class 2 genes with mAb against MHC proteins (PubMed=3872842) 151667309 CVCL_B6V5 UL-4F11 hybridoma CVCL_B6V5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*27). 151667310 CVCL_B6UG M305 hybridoma house mouse CVCL_B6UG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667311 CVCL_B6UF M204 hybridoma house mouse CVCL_B6UF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667312 CVCL_B6UI M515 hybridoma house mouse CVCL_B6UI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667313 CVCL_B6UH M409 [Mouse hybridoma against human FCRLA] hybridoma house mouse CVCL_B6UH CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667314 CVCL_B6UK BJAB/HR1K cancer cell line human CVCL_B6UK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Groin. Female Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) 151667315 CVCL_B6UJ M616 hybridoma house mouse CVCL_B6UJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667316 CVCL_B6UM BJAB-B95.8.6 cancer cell line human CVCL_B6UM CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Karyotypic information: 45,XX,-8,3q+,7p+,8q+,10p+,11p+,inv(13) (PubMed=2995242); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Groin. Female Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=170210) 151667317 CVCL_B6UL II-WA-Ramos cancer cell line human CVCL_B6UL CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) 151667318 CVCL_B6UA UL-52 hybridoma house mouse CVCL_B6UA CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01903; Human HLA-DRA; Monoclonal antibody target: UniProtKB; P79483; Human HLA-DRB3. 151667319 CVCL_B6UC N/92 hybridoma house mouse CVCL_B6UC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667320 CVCL_B6UB N/61 hybridoma house mouse CVCL_B6UB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). 151667321 CVCL_B6UE M101 [Mouse hybridoma against human FCRLA] hybridoma house mouse CVCL_B6UE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7L513; Human FCRLA. 151667322 CVCL_B6UD 425/2B hybridoma house mouse CVCL_B6UD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). 151667323 CVCL_B6VX 13C2 hybridoma house mouse CVCL_B6VX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667324 CVCL_B6W9 1F10 hybridoma house mouse CVCL_B6W9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:15346; Coenzyme A. 151667325 CVCL_B6VW 12F11 hybridoma house mouse CVCL_B6VW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667326 CVCL_B6W8 G1 [Mouse germ stem cell] embryonic stem cell house mouse CVCL_B6W8 CL:0000010 Breed/subspecies: BALB/c. Female Characteristics: Germ stem cell line 151667327 CVCL_B6VZ 14C8 hybridoma house mouse CVCL_B6VZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667328 CVCL_B6VY 13G4 hybridoma house mouse CVCL_B6VY CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667329 CVCL_B6W1 21B7 hybridoma house mouse CVCL_B6W1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667330 CVCL_B6VP 296B11 hybridoma house mouse CVCL_B6VP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667331 CVCL_B6W0 17F9 hybridoma house mouse CVCL_B6W0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667332 CVCL_B6W3 21F4 hybridoma house mouse CVCL_B6W3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667333 CVCL_B6VR 296H8 hybridoma house mouse CVCL_B6VR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667334 CVCL_B6W2 21D7 hybridoma house mouse CVCL_B6W2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667335 CVCL_B6VQ 296G2 hybridoma house mouse CVCL_B6VQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667336 CVCL_B6VT 11B5 hybridoma house mouse CVCL_B6VT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667337 CVCL_B6W5 24H7 hybridoma house mouse CVCL_B6W5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667338 CVCL_B6W4 23B4 hybridoma house mouse CVCL_B6W4 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667339 CVCL_B6VS 296H9 hybridoma house mouse CVCL_B6VS CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667340 CVCL_B6VV 12C7 hybridoma house mouse CVCL_B6VV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667341 CVCL_B6W7 27C10 hybridoma house mouse CVCL_B6W7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667342 CVCL_B6VU 11G5 hybridoma house mouse CVCL_B6VU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667343 CVCL_B6W6 26B9 hybridoma house mouse CVCL_B6W6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. 151667344 CVCL_B6VH 293F4 hybridoma house mouse CVCL_B6VH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667345 CVCL_B6VG 293D2 hybridoma house mouse CVCL_B6VG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667346 CVCL_B6VJ 294F7 hybridoma house mouse CVCL_B6VJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667347 CVCL_B6VI 294F5 hybridoma house mouse CVCL_B6VI CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667348 CVCL_B6VL 295A5 hybridoma house mouse CVCL_B6VL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667349 CVCL_B6VK 294G2 hybridoma house mouse CVCL_B6VK CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667350 CVCL_B6VN 296A10 hybridoma house mouse CVCL_B6VN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667351 CVCL_B6VM 295D2 hybridoma house mouse CVCL_B6VM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667352 CVCL_B6VB TrH6 hybridoma human CVCL_B6VB CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P79483; Human HLA-DRB3. 151667353 CVCL_B6VA TrG6 hybridoma human CVCL_B6VA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01920; Human HLA-DQB1. 151667354 CVCL_B6VD 291C10 hybridoma house mouse CVCL_B6VD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667355 CVCL_B6VC 291B2 hybridoma house mouse CVCL_B6VC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667356 CVCL_B6VF 293C8 hybridoma house mouse CVCL_B6VF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667357 CVCL_B6VE 291F8 hybridoma house mouse CVCL_B6VE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16155; Chlamydia trachomatis major outer membrane porin (MOMP) serovar F (ompA). 151667358 CVCL_B7BK GM3498B-HV1 transformed cell line human CVCL_B7BK CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Gly (c.3163T>G); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; English and Jewish; Ashkenazi; Transformant: Harvey murine sarcoma virus (Ha-MSV)(NCBI-Taxonomy; 11807); Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667359 CVCL_B7BJ H5G11 hybridoma house mouse CVCL_B7BJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11279; Human LAMP1/CD107a. 151667360 CVCL_B7BL GM3498B-HV2 transformed cell line human CVCL_B7BL CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Gly (c.3163T>G); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; English and Jewish; Ashkenazi; Transformant: Harvey murine sarcoma virus (Ha-MSV)(NCBI-Taxonomy; 11807); Derived from sampling site: Skin Cell type=Fibroblast.. Male 151667361 CVCL_B7AB CCRF-CEM C7/H cancer cell line human CVCL_B7AB CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis; Characteristics: Cultured under hypoxia for 5 weeks (PubMed=31221196) 151667362 CVCL_B7AA CCRF-CEM C7-14 cancer cell line human CVCL_B7AA CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis 151667363 CVCL_B7AD CCRF-CEM C7/HDR-C2 cancer cell line human CVCL_B7AD CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Made glucocorticoid resistant by culturing the grand-parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196) 151667364 CVCL_B7AC CCRF-CEM C7/HDR cancer cell line human CVCL_B7AC CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Made glucocorticoid resistant by culturing the parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196) 151667365 CVCL_B7AF VII/2Liv spontaneously immortalized cell line CVCL_B7AF CL:0000010 Derived from sampling site: Fetal liver. Group: Reptilian cell line 151667366 CVCL_B7AH CCRF-CEM C7-SC14/H cancer cell line human CVCL_B7AH CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis; Characteristics: Cultured under hypoxia for 5 weeks (PubMed=31221196) 151667367 CVCL_B7AG CCRF-CEM C7-SC14 cancer cell line human CVCL_B7AG CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis 151667368 CVCL_B7A9 CCRF-CEM C1-15 cancer cell line human CVCL_B7A9 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Resistant to glucocorticoid-mediated lysis Doubling time: 25 +- 3 hours (PubMed=6134583) 151667369 CVCL_B7A2 SCVIi033-A induced pluripotent stem cell human CVCL_B7A2 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151667370 CVCL_B7A1 SCVIi037-A induced pluripotent stem cell human CVCL_B7A1 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Ile154Leufs*5 (c.459delC); ClinVar=VCV000042755; Zygosity=Heterozygous (PubMed=35413566); Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Thr568Met (c.1703C>T); ClinVar=VCV000181464; Zygosity=Heterozygous (PubMed=35413566) Population: Southeast Asian; Derived from sampling site: Peripheral blood. Male 151667371 CVCL_B7A4 CHO-K1 DeltaGMD spontaneously immortalized cell line CVCL_B7A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q8K3X3; Gmds Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 151667372 CVCL_B7A3 SCVIi032-A induced pluripotent stem cell human CVCL_B7A3 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151667373 CVCL_B7A6 PANDA cancer cell line human CVCL_B7A6 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=34818028); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=34818028) Karyotypic information: Complex hypertriploid karyotype (PubMed=34818028); Derived from sampling site: Pancreas. Omics: Metabolome analysis Male Doubling time: 36 hours (PubMed=34818028) 151667374 CVCL_B7A5 CHO-K1 DeltaGMDDeltaGFT spontaneously immortalized cell line CVCL_B7A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3HCE4; Fut8; Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q8K3X3; Gmds Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 151667375 CVCL_B7A8 CCRF-CEM C1 cancer cell line human CVCL_B7A8 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Resistant to glucocorticoid-mediated lysis Doubling time: 25 +- 3 hours (PubMed=6134583) 151667376 CVCL_B7A7 HXEX-ALL1/HDR cancer cell line human CVCL_B7A7 CL:0000010 Population: Chinese; Derived from sampling site: Bone marrow. Male Characteristics: Made glucocorticoid resistant by culturing the parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196) 151667377 CVCL_B7A0 SCVIi034-A induced pluripotent stem cell human CVCL_B7A0 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 151667378 CVCL_B7BC H4F8 hybridoma house mouse CVCL_B7BC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151667379 CVCL_B7BB H4C4 hybridoma house mouse CVCL_B7BB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 151667380 CVCL_B7BE H52 hybridoma house mouse CVCL_B7BE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 151667381 CVCL_B7BD H4H3 hybridoma house mouse CVCL_B7BD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11279; Human LAMP1/CD107a. 151667382 CVCL_B7BG H5C6 hybridoma house mouse CVCL_B7BG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151667383 CVCL_B7BF H5A4 hybridoma house mouse CVCL_B7BF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 151667384 CVCL_B7BI H5B9 hybridoma house mouse CVCL_B7BI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 151667385 CVCL_B7BH H5D2 hybridoma house mouse CVCL_B7BH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 151667386 CVCL_B7AZ HOMC-D4 transformed cell line human CVCL_B7AZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Karyotypic information: 45,XY,-13,-22,+mar [55%] (PubMed=34663305); Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Greater omentum mesothelium Cell type=Mesothelial cell.. Omics: Transcriptome analysis by microarray Male 151667387 CVCL_B7AY HOMC-B1 transformed cell line human CVCL_B7AY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Karyotypic information: 45,XY,-13 [80%] (PubMed=34663305); Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Greater omentum mesothelium Cell type=Mesothelial cell.. Omics: Transcriptome analysis by microarray Male 151667388 CVCL_B7BA H4B4 hybridoma house mouse CVCL_B7BA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13473; Human LAMP2/CD107b. 151667389 CVCL_B7AR Pell-1 cancer cell line human CVCL_B7AR CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 151667390 CVCL_B7B3 PMAC4 cancer cell line human CVCL_B7B3 CL:0000010 Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Glu1750Ter (c.5248G>T); Zygosity=Unspecified (PubMed=34663790) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Anal canal. Omics: Deep exome analysis Male Doubling time: 25 hours (PubMed=34663790) 151667391 CVCL_B7AQ LIXC127 cancer cell line human CVCL_B7AQ CL:0000010 Population: Chinese; Han; Derived from sampling site: Bile duct. Female Doubling time: 43.6 hours (Patent=CN107541494A) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201662 151667392 CVCL_B7B2 PMAC3 cancer cell line human CVCL_B7B2 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Pro (c.1637A>C); ClinVar=VCV000375898; Zygosity=Unspecified (PubMed=34663790) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Anal canal. Omics: Deep exome analysis Female Doubling time: 33 hours (PubMed=34663790) 151667393 CVCL_B7B5 CONACYT-CenVir-Brain spontaneously immortalized cell line CVCL_B7B5 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution, the species Latin name and the tissue Derived from sampling site: Brain. Unspecified Group: Fish cell line 151667394 CVCL_B7AT KU-Lu-MPPt3 CS cancer cell line human CVCL_B7AT CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 151667395 CVCL_B7AS KU-Lu-MPPt3 AD cancer cell line human CVCL_B7AS CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 151667396 CVCL_B7B4 PMAC5 cancer cell line human CVCL_B7B4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=34663790); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly279Trp (c.835G>T); Zygosity=Unspecified (PubMed=34663790) Derived from sampling site: Anal canal. Omics: Deep exome analysis Female Doubling time: 24 hours (PubMed=34663790) 151667397 CVCL_B7B7 MHM23 hybridoma house mouse CVCL_B7B7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 151667398 CVCL_B7AV wAflu1.tet spontaneously immortalized cell line CVCL_B7AV CL:0000010 Unspecified Characteristics: Cured of Wolbachia strain wFlu infection by tetracycline (PubMed=34584163). Group: Insect cell line 151667399 CVCL_B7B6 CONACYT-CenVir-Heart spontaneously immortalized cell line CVCL_B7B6 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution, the species Latin name and the tissue Derived from sampling site: Heart. Unspecified Group: Fish cell line 151667400 CVCL_B7AU wAflu1 spontaneously immortalized cell line CVCL_B7AU CL:0000010 Unspecified Characteristics: Infected by Wolbachia strain wFlu (PubMed=34584163). Group: Insect cell line 151667401 CVCL_B7B9 H4A3 hybridoma house mouse CVCL_B7B9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11279; Human LAMP1/CD107a (Note=Also reacts with rat and hamster). 151667402 CVCL_B7AX HOMC-A4 transformed cell line human CVCL_B7AX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Karyotypic information: 46,XY,-14,-20,+2mar [45%] (PubMed=34663305); Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Greater omentum mesothelium Cell type=Mesothelial cell.. Omics: Transcriptome analysis by microarray Male 151667403 CVCL_B7AW Aflu2 spontaneously immortalized cell line CVCL_B7AW CL:0000010 Unspecified Characteristics: Not infected by Wolbachia strain wFlu (PubMed=34584163). Group: Insect cell line 151667404 CVCL_B7B8 MHM24 hybridoma house mouse CVCL_B7B8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20701; Human ITGAL/CD11a. 151667405 CVCL_B7AJ CCRF-CEM-C7-SC2 cancer cell line human CVCL_B7AJ CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis 151667406 CVCL_B7AI CCRF-CEM C7-SC14/HDR cancer cell line human CVCL_B7AI CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Made glucocorticoid resistant by culturing the parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196) 151667407 CVCL_B7AL CCRF-CEM-C7-SC2/HDR cancer cell line human CVCL_B7AL CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Made glucocorticoid resistant by culturing the parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196) 151667408 CVCL_B7AK CCRF-CEM-C7-SC2/H cancer cell line human CVCL_B7AK CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis; Characteristics: Cultured under hypoxia for 5 weeks (PubMed=31221196) 151667409 CVCL_B7AN NALM-6/HDR cancer cell line human CVCL_B7AN CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Made glucocorticoid resistant by culturing the parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=31221196; PubMed=34823530) Doubling time: 19-22 hours (PubMed=34823530) 151667410 CVCL_B7AM NALM-6/H cancer cell line human CVCL_B7AM CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Cultured under hypoxia for 5 weeks (PubMed=34823530) 151667411 CVCL_B7AP NALM-6/HDR-C5 cancer cell line human CVCL_B7AP CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Made glucocorticoid resistant by culturing the grand-parent cell line under hypoxia for 5 weeks after a single dexamethasone (Dex) treatment (PubMed=34823530) 151667412 CVCL_B7B1 PMAC2 cancer cell line human CVCL_B7B1 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Glu458Ter (c.1372G>T); Zygosity=Unspecified (PubMed=34663790) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Anal canal. Omics: Deep exome analysis Female Doubling time: 41 hours (PubMed=34663790) 151667413 CVCL_B7B0 PMAC1 cancer cell line human CVCL_B7B0 CL:0000010 Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Gln88Ter (c.262C>T); Zygosity=Unspecified (PubMed=34663790); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu726Lys (c.2176G>A); ClinVar=VCV000376476; Zygosity=Unspecified (PubMed=34663790) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Anal canal. Omics: Deep exome analysis Male Doubling time: 47 hours (PubMed=34663790) 152995580 CVCL_B7MN FDOVL cancer cell line human CVCL_B7MN CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ile1432Thr (c.4295C>T); Zygosity=Homozygous (Direct_author_submission); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu252del (c.754_756delCTC); ClinVar=VCV000998484; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Age of donor and sequence variations by personal communication of Jiang W Population: Chinese; Derived from metastatic site: Pelvic lymph node. Female Doubling time: 87 hours (Patent=CN110835623A) Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.15484 152995581 CVCL_B7MM TS 065 cancer cell line human CVCL_B7MM From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 152995582 CVCL_B7MP LLC-PK1/NRa1 spontaneously immortalized cell line pig CVCL_B7MP CL:0000010 Selected for resistance to: ChEBI; CHEBI:7507; Neomycin; Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 152995583 CVCL_B7N1 STB6 Gill spontaneously immortalized cell line CVCL_B7N1 CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Unspecified Group: Fish cell line 152995584 CVCL_B7N0 STB5 Gill spontaneously immortalized cell line CVCL_B7N0 CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Unspecified Group: Fish cell line 152995585 CVCL_B7N3 HCC827-HGF2 cancer cell line human CVCL_B7N3 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Lung. Female 152995586 CVCL_B7MR VA10 transformed cell line human CVCL_B7MR CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Female 152995587 CVCL_B7N2 HCC827-HGF1 cancer cell line human CVCL_B7N2 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Lung. Female 152995588 CVCL_B7MQ LLC-PK1/NRa3 spontaneously immortalized cell line pig CVCL_B7MQ CL:0000010 Selected for resistance to: ChEBI; CHEBI:7507; Neomycin; Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 152995589 CVCL_B7N5 A549/TS1 cancer cell line human CVCL_B7N5 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Lung. Male 152995590 CVCL_B7MT SDM161 cancer cell line human CVCL_B7MT From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Cell line information from personal communication of Wipplinger M Population: Caucasian; Derived from sampling site: Lung; pleura. Female 152995591 CVCL_B7N4 MTA-13 cancer cell line house mouse CVCL_B7N4 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63616; Pemetrexed (Alimta; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 152995592 CVCL_B7MS SDM117 cancer cell line human CVCL_B7MS From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Cell line information from personal communication of Wipplinger M Population: Caucasian; Derived from sampling site: Lung; pleura. Male 152995593 CVCL_B7MF UWO23 cancer cell line human CVCL_B7MF CL:0000010 Transformant: Human papillomavirus type 33 (HPV33)(NCBI-Taxonomy; 10586); Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Male Doubling time: 50 +- 6 hours (PubMed=35317874) 152995594 CVCL_B7ME UWO17 cancer cell line human CVCL_B7ME CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Female Doubling time: 40 +- 4 hours (PubMed=35317874) 152995595 CVCL_B7MH UWO37 cancer cell line human CVCL_B7MH CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tonsil. Omics: Deep exome analysis Male Doubling time: 41 +- 4 hours (PubMed=35317874) 152995596 CVCL_B7MG UWO31 cancer cell line human CVCL_B7MG CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Female Doubling time: 62 +- 6 hours (PubMed=35317874) 152995597 CVCL_B7MJ CAL-85-2 cancer cell line human CVCL_B7MJ CL:0000010 Derived from metastatic site: Thorax. Female 152995598 CVCL_B7MI Col-GFP HSC transformed cell line house mouse CVCL_B7MI CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: Age/sex of donor from personal communication of Weiskirchen R Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: pCol9GFP-HS4,5 transgenic. Male 152995599 CVCL_B7ML TS 031 cancer cell line human CVCL_B7ML From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 152995600 CVCL_B7MK TS 0120 cancer cell line human CVCL_B7MK From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 152995601 CVCL_B7MB KEN transformed cell line human CVCL_B7MB CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Arg149Gln (c.446G>A); ClinVar=VCV000007648; Zygosity=Homozygous (from familial inference of Ker) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995602 CVCL_B7MA PAS [Human LCL] transformed cell line human CVCL_B7MA CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln51Metfs*32 (c.151_154delCAAG); Zygosity=Heterozygous (PubMed=10079298) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995603 CVCL_B7MD UJSi002-A induced pluripotent stem cell human CVCL_B7MD From: Jiangsu University; Jiangsu; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 152995604 CVCL_B7MC INMi005-A induced pluripotent stem cell human CVCL_B7MC From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys759Phe (c.2276G>T); ClinVar=VCV000002356; Zygosity=Heterozygous (PubMed=35248879); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Leu2451Pro (c.7352T>C); Zygosity=Heterozygous (PubMed=35248879) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152995605 CVCL_B7LU SaA LCL transformed cell line human CVCL_B7LU CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (PubMed=11466404) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995606 CVCL_B7M6 SSI transformed cell line human CVCL_B7M6 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln321Ter (c.961C>T); Zygosity=Homozygous (PubMed=10395672) Population: Caucasian; Dutch and Indonesian; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995607 CVCL_B7LT SaA fibroblast transformed cell line human CVCL_B7LT CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (from autologous cell line SaA LCL) Population: Caucasian; Greek; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 152995608 CVCL_B7M5 WSI transformed cell line human CVCL_B7M5 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln321Ter (c.961C>T); Zygosity=Heterozygous (PubMed=10395672) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 152995609 CVCL_B7M8 OSE transformed cell line human CVCL_B7M8 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln51Metfs*32 (c.151_154delCAAG); Zygosity=Homozygous (PubMed=10079298); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Turkish; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995610 CVCL_B7LW SaE LCL transformed cell line human CVCL_B7LW CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (PubMed=11466404) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995611 CVCL_B7M7 6.1.6 transformed cell line human CVCL_B7M7 HLA typing: A*01,02; B*08,27; C*01 (PubMed=6967232) CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Gly102Argfs*5 (c.302dupG) (1-BP INS, 413G); ClinVar=VCV000007649; Zygosity=Heterozygous (PubMed=9118943); Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser132Glnfs*43 (c.392dupG) (1-BP INS, 505G); ClinVar=VCV000007650; Zygosity=Heterozygous (PubMed=9118943) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Characteristics: Good model for bare lymphocyte syndorme 2 as it does not express MHC class II determinants due to mutations in the RFXAP gene 152995612 CVCL_B7LV SaE fibroblast transformed cell line human CVCL_B7LV CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (from autologous cell line SaE LCL) Population: Caucasian; Greek; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 152995613 CVCL_B7LY SaM LCL transformed cell line human CVCL_B7LY CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (PubMed=11466404) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995614 CVCL_B7M9 MAS transformed cell line human CVCL_B7M9 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln51Metfs*32 (c.151_154delCAAG); Zygosity=Heterozygous (PubMed=10079298) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995615 CVCL_B7LX SaM fibroblast transformed cell line human CVCL_B7LX CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu469Pro (c.1406T>C) (T1524C); Zygosity=Homozygous (from autologous cell line SaM LCL) Population: Caucasian; Greek; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 152995616 CVCL_B7LZ Fern transformed cell line human CVCL_B7LZ CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Phe962Ser (c.2885T>C) (F961S); Zygosity=Homozygous (PubMed=10501838) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152995617 CVCL_B7NN CT26-PD-L1 KO cancer cell line house mouse CVCL_B7NN CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1926446; Cd274; Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 152995618 CVCL_B7NQ MC38-Luc-RFP cancer cell line house mouse CVCL_B7NQ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152995619 CVCL_B7NP CT26-hPD-L1 cancer cell line house mouse CVCL_B7NP CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 152995620 CVCL_B7NS B16/F10-Luc-RFP cancer cell line house mouse CVCL_B7NS CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152995621 CVCL_B7NR A375-Luc-RFP cancer cell line human CVCL_B7NR CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152995622 CVCL_B7NU HCT116-Luc-GFP cancer cell line human CVCL_B7NU CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transduced with a CAG-Luc-PGK-GFP-T2A-Puro lentiviral reporter construct 152995623 CVCL_B7NT HeLa-Luc-RFP cancer cell line human CVCL_B7NT CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152995624 CVCL_B7NG KOL02C2TT induced pluripotent stem cell human CVCL_B7NG CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 152995625 CVCL_B7NF KOL01SB1CC induced pluripotent stem cell human CVCL_B7NF CL:0000010 Sequence variation: Mutation; HGNC; 5293; HTR2A; Simple; p.Ser34Ser (c.102T>C) (T102C) (rs6313); ClinVar=VCV000515935; Zygosity=Homozygous (PubMed=27916472; PubMed=34999422) Population: Japanese; Derived from sampling site: Peripheral blood. Female 152995626 CVCL_B7NI SB3 spontaneously immortalized cell line CVCL_B7NI CL:0000010 Derived from sampling site: Brain Cell type=Epithelial cell.. Unspecified Group: Fish cell line 152995627 CVCL_B7NH KOL02SB2CC induced pluripotent stem cell human CVCL_B7NH CL:0000010 Sequence variation: Mutation; HGNC; 5293; HTR2A; Simple; p.Ser34Ser (c.102T>C) (T102C) (rs6313); ClinVar=VCV000515935; Zygosity=Homozygous (PubMed=27916472; PubMed=34999422) Population: Japanese; Derived from sampling site: Peripheral blood. Female 152995628 CVCL_B7NK TI-3 hybridoma house mouse CVCL_B7NK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08057; Bovine TNNI3. 152995629 CVCL_B7NJ ZPR-1 hybridoma house mouse CVCL_B7NJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q6DH07; Danio rerio arr3a. 152995630 CVCL_B7NM MC38-PD-L1 KO cancer cell line house mouse CVCL_B7NM CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1926446; Cd274 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 152995631 CVCL_B7NL MC38-hPD-L1 cancer cell line house mouse CVCL_B7NL CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 152995632 CVCL_B7NA PC9/TS2 cancer cell line human CVCL_B7NA CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from metastatic site: Lymph node. Male 152995633 CVCL_B7NC CGRM03C3TT induced pluripotent stem cell human CVCL_B7NC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 152995634 CVCL_B7NB GarL spontaneously immortalized cell line CVCL_B7NB CL:0000010 Miscellaneous: Age at sampling from from personal communication of Bols N.C Derived from sampling site: Liver Cell type=Epithelial cell.. Unspecified Group: Fish cell line 152995635 CVCL_B7NE KOL01C1TT induced pluripotent stem cell human CVCL_B7NE CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 152995636 CVCL_B7ND CGRM03SB3CC induced pluripotent stem cell human CVCL_B7ND CL:0000010 Sequence variation: Mutation; HGNC; 5293; HTR2A; Simple; p.Ser34Ser (c.102T>C) (T102C) (rs6313); ClinVar=VCV000515935; Zygosity=Homozygous (PubMed=34999422) Population: Japanese; Derived from sampling site: Peripheral blood. Female 152995637 CVCL_B7N7 H1299/TS1 cancer cell line human CVCL_B7N7 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Lymph node. Male 152995638 CVCL_B7MV HeLa ITCH KO cancer cell line human CVCL_B7MV From: Ayoubi R.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13890; ITCH Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152995639 CVCL_B7N6 A549/TS2 cancer cell line human CVCL_B7N6 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Lung. Male 152995640 CVCL_B7MU JAR-Smad3/c cancer cell line human CVCL_B7MU CL:0000010 Transfected with: HGNC; 6769; SMAD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male 152995641 CVCL_B7MX ASCF spontaneously immortalized cell line CVCL_B7MX CL:0000010 Miscellaneous: Age at sampling from from personal communication of Pham P.H Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 152995642 CVCL_B7N9 PC9/TS1 cancer cell line human CVCL_B7N9 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from metastatic site: Lymph node. Male 152995643 CVCL_B7N8 H1299/TS2 cancer cell line human CVCL_B7N8 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12441; TYMS; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Lymph node. Male 152995644 CVCL_B7MW Mel Ku cancer cell line human CVCL_B7MW CL:0000010 Derived from sampling site: Skin. 152995645 CVCL_B7MZ STBH spontaneously immortalized cell line CVCL_B7MZ CL:0000010 Derived from sampling site: Heart Cell type=Epithelial cell.. Unspecified Group: Fish cell line 152995646 CVCL_B7MY HK13 spontaneously immortalized cell line CVCL_B7MY CL:0000010 Miscellaneous: Age at sampling from from personal communication of Pham P.H Derived from sampling site: Head kidney Cell type=Epithelial cell.. Unspecified Virology: Derived from a piscine orthoreovirus-1 (PRV-1) infected fish Group: Fish cell line 152995647 CVCL_B7KL BCH-RB31 cancer cell line human CVCL_B7KL CL:0000010 Female 152995648 CVCL_B7KK BCH-N-SL cancer cell line human CVCL_B7KK CL:0000010 Male 152995649 CVCL_B7KN BCH-RB33 cancer cell line human CVCL_B7KN CL:0000010 Male 152995650 CVCL_B7KM BCH-RB32 cancer cell line human CVCL_B7KM CL:0000010 Female 152995651 CVCL_B7KP BCH-RB34 cancer cell line human CVCL_B7KP CL:0000010 Male 152995652 CVCL_B7L1 BCH-RB46 cancer cell line human CVCL_B7L1 CL:0000010 Female 152995653 CVCL_B7L0 BCH-RB45 cancer cell line human CVCL_B7L0 CL:0000010 Female 152995654 CVCL_B7KR BCH-RB36 cancer cell line human CVCL_B7KR CL:0000010 Male 152995655 CVCL_B7L3 BCH-RB48 cancer cell line human CVCL_B7L3 CL:0000010 Male 152995656 CVCL_B7KQ BCH-RB35 cancer cell line human CVCL_B7KQ CL:0000010 Female 152995657 CVCL_B7L2 BCH-RB47 cancer cell line human CVCL_B7L2 CL:0000010 Female 152995658 CVCL_B7KD BCH-N-DW cancer cell line human CVCL_B7KD CL:0000010 Derived from metastatic site: Bone marrow. Male 152995659 CVCL_B7KC BCH-N-DR cancer cell line human CVCL_B7KC CL:0000010 Derived from metastatic site: Bone marrow. Male 152995660 CVCL_B7KF BCH-N-KB cancer cell line human CVCL_B7KF CL:0000010 Male 152995661 CVCL_B7KE BCH-N-JW cancer cell line human CVCL_B7KE CL:0000010 Derived from metastatic site: Bone marrow. Male 152995662 CVCL_B7KH BCH-N-LR cancer cell line human CVCL_B7KH CL:0000010 Male 152995663 CVCL_B7KG BCH-N-KE cancer cell line human CVCL_B7KG CL:0000010 Derived from metastatic site: Bone marrow. Male 152995664 CVCL_B7KJ BCH-N-NS cancer cell line human CVCL_B7KJ CL:0000010 Derived from metastatic site: Bone marrow. Male 152995665 CVCL_B7KI BCH-N-MS cancer cell line human CVCL_B7KI CL:0000010 Derived from metastatic site: Bone marrow. Male 152995666 CVCL_B7JZ MC-BR-BTY-0006 cancer cell line human CVCL_B7JZ CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Gln2829Leu (c.8486A>C); Zygosity=Homozygous (PubMed=34145270); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174His (c.521G>A); Zygosity=Homozygous (PubMed=34145270) Derived from sampling site: Breast. Omics: Deep exome analysis Female Characteristics: Established from a nude mouse xenograft Doubling time: 48-72 hours (PubMed=34145270) Group: Triple negative breast cancer (TNBC) cell line 152995667 CVCL_B7KB BCH-N-AD cancer cell line human CVCL_B7KB CL:0000010 Derived from metastatic site: Bone marrow. Male 152995668 CVCL_B7KA VIP2 transformed cell line human CVCL_B7KA CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser123Thrfs*15 (c.368delG) (484delG); ClinVar=VCV000007651; Zygosity=Homozygous (PubMed=20197681) Population: Caucasian; Austrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995669 CVCL_B7JS CHO/PA16-TROP2-RAP-MAP spontaneously immortalized cell line CVCL_B7JS CL:0000010 Transfected with: HGNC; 11530; TACSTD2 (with N-terminal GLEGGVAMPGAEDDVV = PA16-tag, C-terminal DMVNPGLEDRIE = RAP-tag and GDGMVPPGIEDK = MAP-tag) Derived from sampling site: Ovary. Female 152995670 CVCL_B7K4 FZA transformed cell line human CVCL_B7K4 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Simple; p.Leu195Pro (c.584T>C); ClinVar=VCV000827735; Zygosity=Homozygous (PubMed=10725724); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 152995671 CVCL_B7K3 EBA transformed cell line human CVCL_B7K3 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Simple; p.Glu102Ter (c.304G>T); Zygosity=Homozygous (PubMed=10725724); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 152995672 CVCL_B7JR TrMab-6 hybridoma house mouse CVCL_B7JR CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. 152995673 CVCL_B7JU Lec1/TROP2 spontaneously immortalized cell line CVCL_B7JU CL:0000010 Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Gln339Arg; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Lys401Arg; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11530; TACSTD2 (with C-terminal GVAMPGAEDDVV = PA-tag) Derived from sampling site: Ovary. Female 152995674 CVCL_B7K6 Nacera transformed cell line human CVCL_B7K6 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Simple; c.338-25_338del (752delG26bp) (752delG-25) (26-BP DEL, NT752) (I5E6-25_I5E6+1); ClinVar=VCV001435455; Zygosity=Homozygous (PubMed=9806546; PubMed=10072068) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995675 CVCL_B7K5 Bequit transformed cell line human CVCL_B7K5 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Simple; c.338-25_338del (752delG26bp) (752delG-25) (26-BP DEL, NT752) (I5E6-25_I5E6+1); ClinVar=VCV001435455; Zygosity=Homozygous (PubMed=9806546; PubMed=10072068) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995676 CVCL_B7JT CHO/TROP2-PA spontaneously immortalized cell line CVCL_B7JT CL:0000010 Transfected with: HGNC; 11530; TACSTD2 (with C-terminal GVAMPGAEDDVV = PA-tag) Derived from sampling site: Ovary. Female 152995677 CVCL_B7K8 BCH transformed cell line human CVCL_B7K8 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Glu381Ter (c.1141G>T) (G1256T); ClinVar=VCV000009541; Zygosity=Heterozygous (PubMed=9099848); Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; c.3317+1G>A (IVS18DS,G-A,+1) (del3349-3432); ClinVar=VCV000009542; Zygosity=Heterozygous (PubMed=9099848) Population: Caucasian; Austrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995678 CVCL_B7JW Lec8/TROP2 spontaneously immortalized cell line CVCL_B7JW CL:0000010 Transfected with: HGNC; 11530; TACSTD2 (with C-terminal GVAMPGAEDDVV = PA-tag) Derived from sampling site: Ovary. Female 152995679 CVCL_B7JV Lec2/TROP2 spontaneously immortalized cell line CVCL_B7JV CL:0000010 Transfected with: HGNC; 11530; TACSTD2 (with C-terminal GVAMPGAEDDVV = PA-tag) Derived from sampling site: Ovary. Female 152995680 CVCL_B7K7 Ramia transformed cell line human CVCL_B7K7 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Simple; c.338-25_338del (752delG26bp) (752delG-25) (26-BP DEL, NT752) (I5E6-25_I5E6+1); ClinVar=VCV001435455; Zygosity=Homozygous (PubMed=10725724) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995681 CVCL_B7JY CAB spontaneously immortalized cell line CVCL_B7JY CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Optimal growth rate at 26 Celsius Group: Fish cell line 152995682 CVCL_B7JX ciPEC conditionally immortalized cell line human CVCL_B7JX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Parietal epithelial cell.. Doubling time: 35 hours (PubMed=34181939) 152995683 CVCL_B7K9 VIP1 transformed cell line human CVCL_B7K9 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Glu381Ter (c.1141G>T) (G1256T); ClinVar=VCV000009541; Zygosity=Homozygous (PubMed=20197681) Population: Caucasian; Austrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995684 CVCL_B7LM ShA transformed cell line human CVCL_B7LM CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Pro12Argfs (c.35insGCGGGCG) (151ins7(GCGGGCG)fs329X); Zygosity=Homozygous (PubMed=9536093) Population: Druze; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995685 CVCL_B7LL AkO transformed cell line human CVCL_B7LL CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000007652; Zygosity=Homozygous (PubMed=9536093) Population: Turkish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995686 CVCL_B7M0 Ind transformed cell line human CVCL_B7M0 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 152995687 CVCL_B7LN ShG transformed cell line human CVCL_B7LN CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Pro12Argfs (c.35insGCGGGCG) (151ins7(GCGGGCG)fs329X); Zygosity=Homozygous (PubMed=9536093) Population: Druze; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995688 CVCL_B7M2 ETU transformed cell line human CVCL_B7M2 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu1051_Asp1078del (c.3153_3236del84); Zygosity=Heterozygous (PubMed=10663561) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152995689 CVCL_B7LQ Ss transformed cell line human CVCL_B7LQ CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser123Thrfs*15 (c.368delG) (484delG); ClinVar=VCV000007651; Zygosity=Homozygous (PubMed=9536093) Population: Algerian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995690 CVCL_B7M1 AST [Human LCL] transformed cell line human CVCL_B7M1 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu1051_Asp1078del (c.3153_3236del84); Zygosity=Heterozygous (PubMed=10663561) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995691 CVCL_B7LP KER transformed cell line human CVCL_B7LP CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Arg149Gln (c.446G>A); ClinVar=VCV000007648; Zygosity=Homozygous (PubMed=12368908) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995692 CVCL_B7M4 FSI transformed cell line human CVCL_B7M4 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Gln321Ter (c.961C>T); Zygosity=Heterozygous (PubMed=10395672) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 152995693 CVCL_B7LS UW-DS transformed cell line human CVCL_B7LS HLA typing: A*01,29; B*12,37 (PubMed=6967232) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 152995694 CVCL_B7M3 ATU transformed cell line human CVCL_B7M3 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; p.Leu1051_Asp1078del (c.3153_3236del84); Zygosity=Homozygous (PubMed=10663561) Population: Turkish; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995695 CVCL_B7LR G4B1 hybridoma house mouse CVCL_B7LR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08138; Human NGFR/CD271 (Note=Recognizes the glycosylated protein). 152995696 CVCL_B7LE BCH-RB59 cancer cell line human CVCL_B7LE CL:0000010 Male 152995697 CVCL_B7LD BCH-RB58 cancer cell line human CVCL_B7LD CL:0000010 Female 152995698 CVCL_B7LG ZM fibroblast transformed cell line human CVCL_B7LG CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser123Thrfs*14 (c.368delG) (484delG); ClinVar=VCV000007651; Zygosity=Homozygous (PubMed=9287230) Population: Moroccan; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 152995699 CVCL_B7LF BCH-P-SS cancer cell line human CVCL_B7LF CL:0000010 Derived from sampling site: Chest wall. Female 152995700 CVCL_B7LI DERM transformed cell line human CVCL_B7LI CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 152995701 CVCL_B7LH ZM LCL transformed cell line human CVCL_B7LH CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser123Thrfs*15 (c.368delG) (484delG); ClinVar=VCV000007651; Zygosity=Homozygous (PubMed=9287230) Population: Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152995702 CVCL_B7LK DA transformed cell line human CVCL_B7LK CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Ser123Thrfs*15 (c.368delG) (484delG); ClinVar=VCV000007651; Zygosity=Homozygous (PubMed=9118943; PubMed=9287230) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152995703 CVCL_B7LJ ABI transformed cell line human CVCL_B7LJ CL:0000010 Sequence variation: Mutation; HGNC; 9988; RFXAP; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000007652; Zygosity=Homozygous (PubMed=9287230) Population: Turkish; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Amnion Cell type=Fibroblast.. 152995704 CVCL_B7LA BCH-RB55 cancer cell line human CVCL_B7LA CL:0000010 Female 152995705 CVCL_B7LC BCH-RB57 cancer cell line human CVCL_B7LC CL:0000010 Male 152995706 CVCL_B7LB BCH-RB56 cancer cell line human CVCL_B7LB CL:0000010 Male 152995707 CVCL_B7KT BCH-RB38 cancer cell line human CVCL_B7KT CL:0000010 Male 152995708 CVCL_B7L5 BCH-RB50 cancer cell line human CVCL_B7L5 CL:0000010 Male 152995709 CVCL_B7KS BCH-RB37 cancer cell line human CVCL_B7KS CL:0000010 Male 152995710 CVCL_B7L4 BCH-RB49 cancer cell line human CVCL_B7L4 CL:0000010 Female 152995711 CVCL_B7KV BCH-RB40 cancer cell line human CVCL_B7KV CL:0000010 Male 152995712 CVCL_B7L7 BCH-RB52 cancer cell line human CVCL_B7L7 CL:0000010 Female 152995713 CVCL_B7KU BCH-RB39 cancer cell line human CVCL_B7KU CL:0000010 Male 152995714 CVCL_B7L6 BCH-RB51 cancer cell line human CVCL_B7L6 CL:0000010 Female 152995715 CVCL_B7KX BCH-RB42 cancer cell line human CVCL_B7KX CL:0000010 Male 152995716 CVCL_B7L9 BCH-RB54 cancer cell line human CVCL_B7L9 CL:0000010 Female 152995717 CVCL_B7KW BCH-RB41 cancer cell line human CVCL_B7KW CL:0000010 Female 152995718 CVCL_B7L8 BCH-RB53 cancer cell line human CVCL_B7L8 CL:0000010 Female 152995719 CVCL_B7KZ BCH-RB44 cancer cell line human CVCL_B7KZ CL:0000010 Male 152995720 CVCL_B7KY BCH-RB43 cancer cell line human CVCL_B7KY CL:0000010 Male 152995721 CVCL_B7IJ 94P0496 finite cell line human CVCL_B7IJ CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (PubMed=29445421) Population: Caucasian; Polish; Karyotypic information: Mosaic; 46,XY; 45,XY,der(6)(6pter->6q11.1::13q11->13q21.33::20q11.22->20qter),-13 (PubMed=29445421); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced Male 152995722 CVCL_B7II RB355 Eto-R cancer cell line human CVCL_B7II CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Eye; globe. Female Problematic cell line: Contaminated Parent cell line (RB355) has been shown to be a Y-79 derivative. 152995723 CVCL_B7IL MDBK527 spontaneously immortalized cell line CVCL_B7IL CL:0000010 Derived from sampling site: Kidney. Male Characteristics: Adapted to growth without serum in suspension; Virology: Can be used for the production of a bovine alphaherpesvirus-1 (BoHV-1) vaccine Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 152995724 CVCL_B7IK SCI13D finite cell line human CVCL_B7IK CL:0000010 Karyotypic information: 46,XY,+10 (PubMed=34572381); Derived from sampling site: Lung; bronchoalveolar fluid Cell type=Fibroblast.. Male 152995725 CVCL_B7IN IP4 finite cell line human CVCL_B7IN CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro772_His773insProTyrAsnPro (P772_H773insPYNP); Zygosity=Heterozygous (PubMed=34429452) Derived from sampling site: Nose; nasal cavity. Male Doubling time: 55 hours (PubMed=34429452) 152995726 CVCL_B7IM BC-PAK1 cancer cell line human CVCL_B7IM CL:0000010 Sequence variation: Mutation; HGNC; 14214; CIC; Simple; p.Ala1591Alafs*28 (c.4773T>TGC); Zygosity=Heterozygous (PubMed=34495459); Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Tyr987Ter (c.2961C>G); ClinVar=VCV000694634; Zygosity=Heterozygous (PubMed=34495459); Sequence variation: Mutation; HGNC; 8554; PABPC1; Simple; p.Lys333Lysfs*21 (c.999delT); Zygosity=Heterozygous (PubMed=34495459) Population: Pakistani; Derived from sampling site: Breast. Omics: Deep exome analysis Female Characteristics: ER-positive, PR-positive and ERBB2-negative 152995727 CVCL_B7J1 HindIIIG-1 transformed cell line Norway rat CVCL_B7J1 CL:0000010 Transfected with: UniProtKB; P03255; Adenovirus 5 E1A protein; Transfected with: UniProtKB; P03246; Adenovirus 5 E1B 19 kDa protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 152995728 CVCL_B7IP IP4/K4DT telomerase immortalized cell line human CVCL_B7IP CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro772_His773insProTyrAsnPro (P772_H773insPYNP); Zygosity=Heterozygous (PubMed=34429452); Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Karyotypic information: 46,XY [24/50]; 46,XY,add(8)(q24) [26/50] (PubMed=34429452); Derived from sampling site: Nose; nasal cavity. Male Doubling time: 51 hours (PubMed=34429452) 152995729 CVCL_B7J0 LYCT spontaneously immortalized cell line CVCL_B7J0 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 152995730 CVCL_B7IB AIK2 telomerase immortalized cell line human CVCL_B7IB CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 152995731 CVCL_B7IA AIK1 telomerase immortalized cell line human CVCL_B7IA CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 152995732 CVCL_B7ID WERI-Rb-1 Eto-R cancer cell line human CVCL_B7ID CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Eye; globe. Omics: Deep quantitative proteome analysis Female 152995733 CVCL_B7IC AIK3 telomerase immortalized cell line human CVCL_B7IC CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 152995734 CVCL_B7IF Y-79 CDDP-R cancer cell line human CVCL_B7IF CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Eye; globe. Female 152995735 CVCL_B7IE WERI-Rb-1 CDDP-R cancer cell line human CVCL_B7IE CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Eye; globe. Female 152995736 CVCL_B7IH RB355 CDDP-R cancer cell line human CVCL_B7IH CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Eye; globe. Female Problematic cell line: Contaminated Parent cell line (RB355) has been shown to be a Y-79 derivative. 152995737 CVCL_B7IG Y-79 Eto-R cancer cell line human CVCL_B7IG CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Eye; globe. Female 152995738 CVCL_B7HY KU-CAS3 cancer cell line human CVCL_B7HY CL:0000010 Population: Korean; Derived from sampling site: Scalp; skin. Male Doubling time: 34 hours (PubMed=34693591) 152995739 CVCL_B7I9 AIF3 telomerase immortalized cell line human CVCL_B7I9 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152995740 CVCL_B7HX NSG-70-WNT5A-GFP cancer cell line human CVCL_B7HX CL:0000010 Transfected with: HGNC; 12784; WNT5A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Group: Cancer stem cell line 152995741 CVCL_B7HZ KU-CAS5 cancer cell line human CVCL_B7HZ CL:0000010 Population: Korean; Derived from sampling site: Scalp; skin. Female Doubling time: 29 hours (PubMed=34693591) Problematic cell line: Possibly contaminated The STR profile on KU-CAS5 is identical to that of KU-CAS3 while it originates from another patient. As KU-CAS3 is supposed to be from a male patient and KU-CAS5 from a female patient and that the amelogenin marker is reported to be X,Y for both, it is KU-CAS5 which is problematic. We are currently investigating this issue. 152995742 CVCL_B7HQ MA11 cancer cell line human CVCL_B7HQ CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Female Group: Triple negative breast cancer (TNBC) cell line 152995743 CVCL_B7I2 PC-B-148CA cancer cell line human CVCL_B7I2 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Heterozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (PubMed=34651665) Population: Southeast Asian; Thai; Karyotypic information: 47-58 chromosomes with loss of both copies of chr X (PubMed=34651665); Derived from sampling site: Breast. Female Doubling time: 155.7 +- 5.2 hours (PubMed=34651665) Group: Triple negative breast cancer (TNBC) cell line 152995744 CVCL_B7HP 2BG2 hybridoma house mouse CVCL_B7HP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9RAJ4; Mycobacterium paratuberculosis 35 kDa major membrane protein (mmpI). 152995745 CVCL_B7I1 PC-B-142CA cancer cell line human CVCL_B7I1 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro871Leu (c.2612C>T); ClinVar=VCV000041812; Zygosity=Homozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser425Cys (c.1274C>G); Zygosity=Homozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.7806-14T>C; ClinVar=VCV000126158; Zygosity=Homozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Glu839Lys (c.2515G>A); ClinVar=VCV000013862; Zygosity=Heterozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln224Ter (c.670C>T); Zygosity=Homozygous (PubMed=34651665); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Thr (c.695T>C); ClinVar=VCV000141224; Zygosity=Homozygous (PubMed=34651665) Population: Southeast Asian; Thai; Karyotypic information: 38 chromosomes with a chr X monosomy (PubMed=34651665); Derived from sampling site: Breast. Female Characteristics: ER-negative, PR-negative, ERBB2-positive Doubling time: 45 +- 3 hours (PubMed=34651665) 152995746 CVCL_B7I4 AIA1 telomerase immortalized cell line human CVCL_B7I4 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; adipose tissue Cell type=Stromal cell.. Male 152995747 CVCL_B7HS mCCDcl1 Ed1 spontaneously immortalized cell line house mouse CVCL_B7HS CL:0000010 Derived from sampling site: Kidney; cortical collecting duct Cell type=Kidney collecting duct principal cell.. Omics: Transcriptome analysis by RNAseq Unspecified 152995748 CVCL_B7I3 ELHK spontaneously immortalized cell line CVCL_B7I3 CL:0000010 Derived from sampling site: Head kidney Cell type=Fibroblast.. Unspecified Characteristics: Can grow at temperatures ranging from 24 to 32 Celsius with an optimal growth temperature at 28 Celsius (DOI=10.1016/j.aqrep.2021.100899); Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) and red-spotted grouper nervous necrosis virus (RGNNV) (DOI=10.1016/j.aqrep.2021.100899) Group: Fish cell line 152995749 CVCL_B7HR mCCDcl1 spontaneously immortalized cell line house mouse CVCL_B7HR CL:0000010 Miscellaneous: Doubling time from personal communication of Rossier B.C Derived from sampling site: Kidney; cortical collecting duct Cell type=Kidney collecting duct principal cell.. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Expresses epithelial sodium channels (ENaC) as well as the necessary cellular machinery to enable their stimulation by physiological concentrations of aldosterone, including 11-betahydroxysteroid dehydrogenase (HSD11b2), mineralocorticoid and glucocorticoid receptors and have therefore been used as a model for the study of principal cells physiology (PubMed=15743993; PubMed=29357433) Doubling time: ~24 hours (Direct_author_submission) 152995750 CVCL_B7I6 AIA3 telomerase immortalized cell line human CVCL_B7I6 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; adipose tissue Cell type=Stromal cell.. Male 152995751 CVCL_B7HU mCCDcl1 Ed3 spontaneously immortalized cell line house mouse CVCL_B7HU CL:0000010 Derived from sampling site: Kidney; cortical collecting duct Cell type=Kidney collecting duct principal cell.. Omics: Transcriptome analysis by RNAseq Unspecified 152995752 CVCL_B7I5 AIA2 telomerase immortalized cell line human CVCL_B7I5 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; adipose tissue Cell type=Stromal cell.. Male 152995753 CVCL_B7HT mCCDcl1 Ed2 spontaneously immortalized cell line house mouse CVCL_B7HT CL:0000010 Derived from sampling site: Kidney; cortical collecting duct Cell type=Kidney collecting duct principal cell.. Omics: Transcriptome analysis by RNAseq Unspecified 152995754 CVCL_B7I8 AIF2 telomerase immortalized cell line human CVCL_B7I8 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152995755 CVCL_B7HW NSG-70-GFP cancer cell line human CVCL_B7HW CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Group: Cancer stem cell line 152995756 CVCL_B7I7 AIF1 telomerase immortalized cell line human CVCL_B7I7 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152995757 CVCL_B7HV NSG-70 cancer cell line human CVCL_B7HV CL:0000010 Male Doubling time: ~150 hours (PubMed=35430703). Group: Cancer stem cell line 152995758 CVCL_B7JK SCLC-J1 cancer cell line human CVCL_B7JK CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Gly1111Val (c.3332_3333delGGinsTT); Zygosity=Homozygous (PubMed=34381882); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu218Val (c.652T>G); ClinVar=VCV000572140; Zygosity=Homozygous (PubMed=34381882) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 64.5 hours (PubMed=34381882) 152995759 CVCL_B7JJ PEO4-iPSC-OSKM-05 induced pluripotent stem cell human CVCL_B7JJ CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg160Trp (c.478A>T); ClinVar=VCV000412204; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Female 152995760 CVCL_B7JM DF-1-AvBD9 spontaneously immortalized cell line CVCL_B7JM CL:0000010 Transfected with: UniProtKB; Q6QLR1; Chicken gallinacin-9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 152995761 CVCL_B7JL KDF finite cell line CVCL_B7JL CL:0000010 Anecdotal: Established from a rhinoceros named Puntung, the second last Sumatran rhinoceros to survive in captivity in Malaysia and died in 2017 of terminal cancer Derived from sampling site: Kidney Cell type=Fibroblast.. Female Doubling time: 20.45 hours (at 5th passage), 22.35 hours (at 10th and 15th passages) (DOI=10.46754/jssm.2021.06.008) Group: Endangered species/breed cell line 152995762 CVCL_B7K0 MC-BR-BTY-0019 cancer cell line human CVCL_B7K0 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34145270); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34145270); Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (PubMed=34145270); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Leu2088Profs*11 (c.6261_6262insC); Zygosity=Heterozygous (PubMed=34145270); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (PubMed=34145270) Derived from sampling site: Breast. Omics: Deep exome analysis Female Characteristics: Established from a nude mouse xenograft; Characteristics: ER-negative, PR-negative, ERBB2-positive Doubling time: 24-48 hours (PubMed=34145270) 152995763 CVCL_B7JN MCF10A BLV spontaneously immortalized cell line human CVCL_B7JN CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Virology: Infected with bovine leukemia virus from the peripheral blood of BLV-infected adult cows Does not release viral particles into the cell culture supernatant. 152995764 CVCL_B7K2 KAIMRC2 cancer cell line human CVCL_B7K2 CL:0000010 Population: Saudi Arabian; Derived from sampling site: Breast. Female Doubling time: ~16 hours (PubMed=34073849) Group: Triple negative breast cancer (TNBC) cell line 152995765 CVCL_B7JQ TrMab-29 hybridoma house mouse CVCL_B7JQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. 152995766 CVCL_B7K1 MCF-7 PRODH KO cancer cell line human CVCL_B7K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9453; PRODH; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152995767 CVCL_B7JP MCF7/TROP2-KO cancer cell line human CVCL_B7JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11530; TACSTD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152995768 CVCL_B7JC PC-R1 transformed cell line human CVCL_B7JC HLA typing: DRB1*02,04 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Male 152995769 CVCL_B7JB PC-H1 finite cell line human CVCL_B7JB HLA typing: DRB1*03,06 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Male Senescence: SV40-transformed but with a finite life span 152995770 CVCL_B7JE EPN spontaneously immortalized cell line human CVCL_B7JE CL:0000010 Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 152995771 CVCL_B7JD PC-S1 transformed cell line human CVCL_B7JD HLA typing: DRB1*04,12 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Male 152995772 CVCL_B7JG OUC-SebSc-Skm-1 spontaneously immortalized cell line CVCL_B7JG CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution, the species Latin name and the tissue Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Omics: Transcriptome analysis by RNAseq Female Group: Fish cell line 152995773 CVCL_B7JF EPN-PKM3 spontaneously immortalized cell line human CVCL_B7JF CL:0000010 Transfected with: HGNC; 9612; PTK2B (with p.Lys457Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 152995774 CVCL_B7JI PEO4-iPSC-OSKM-03 induced pluripotent stem cell human CVCL_B7JI CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg160Trp (c.478A>T); ClinVar=VCV000412204; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Female 152995775 CVCL_B7JH YG-PLL cancer cell line human CVCL_B7JH CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from metastatic site: Left inguinal lymph node Cell type=T-cell.. Male Characteristics: IL2 and IL4 dependent Doubling time: ~35 hours (PubMed=34334531) 152995776 CVCL_B7IZ LYCO spontaneously immortalized cell line CVCL_B7IZ CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 152995777 CVCL_B7IY hEM3 ARID1A-KO transformed cell line human CVCL_B7IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 152995778 CVCL_B7JA PC-E1 transformed cell line human CVCL_B7JA HLA typing: DRB1*04,07 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Male 152995779 CVCL_B7J3 HPr-1 transformed cell line human CVCL_B7J3 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Hispanic; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 152995780 CVCL_B7IR NP2/K4DT telomerase immortalized cell line human CVCL_B7IR CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Karyotypic information: 46,XY [21/50]; 46,XY,del(6)(q21;qter) [29/50] (PubMed=34429452); Derived from sampling site: Nose; nasal cavity; maxillary sinus (Note=From a polyp). Male Doubling time: 59 hours (PubMed=34429452) 152995781 CVCL_B7IQ NP2 [Human nose] finite cell line human CVCL_B7IQ CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus (Note=From a polyp). Male Doubling time: 62 hours (PubMed=34429452) 152995782 CVCL_B7J2 PC-346CF cancer cell line human CVCL_B7J2 CL:0000010 Derived from sampling site: Prostate. Male Characteristics: Established from tumors in male nude mice injected with the parent cell line; Characteristics: Androgen insensitive 152995783 CVCL_B7J5 BC-H1 transformed cell line human CVCL_B7J5 HLA typing: DRB1*07,11 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Female 152995784 CVCL_B7IT NP3/T telomerase immortalized cell line human CVCL_B7IT CL:0000010 Transfected with: HGNC; 11730; TERT Karyotypic information: 46,XY [5/50]; 47,XY,+4 [45/50] (PubMed=34429452); Transformant: Human papillomavirus type 58 (HPV58)(NCBI-Taxonomy; 10598); Derived from sampling site: Nose; nasal cavity; maxillary sinus (Note=From a polyp). Male Doubling time: 62 hours (PubMed=34429452) 152995785 CVCL_B7J4 HPr-1-AR transformed cell line human CVCL_B7J4 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Hispanic; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 152995786 CVCL_B7IS NP3 [Human nose] finite cell line human CVCL_B7IS CL:0000010 Transformant: Human papillomavirus type 58 (HPV58)(NCBI-Taxonomy; 10598); Derived from sampling site: Nose; nasal cavity; maxillary sinus (Note=From a polyp). Male Doubling time: 63 hours (PubMed=34429452) 152995787 CVCL_B7IV CAK [Cromileptes] spontaneously immortalized cell line CVCL_B7IV CL:0000010 Derived from sampling site: Kidney. Unspecified Characteristics: Optimal growth rate at 26 Celsius Group: Fish cell line 152995788 CVCL_B7J7 CC-B1 transformed cell line human CVCL_B7J7 HLA typing: DRB1*03,06 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Unspecified 152995789 CVCL_B7J6 BC-K1 finite cell line human CVCL_B7J6 HLA typing: DRB1*03,14 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Female Senescence: SV40-transformed but with a finite life span 152995790 CVCL_B7IU GBRS spontaneously immortalized cell line CVCL_B7IU CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 152995791 CVCL_B7IX hEM3 transformed cell line human CVCL_B7IX CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 152995792 CVCL_B7J9 LC-M1 transformed cell line human CVCL_B7J9 HLA typing: DRB1*09,11 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Unspecified 152995793 CVCL_B7J8 LC-D1 transformed cell line human CVCL_B7J8 HLA typing: DRB1*03,13 (PubMed=9892213) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Bone marrow Cell type=Epithelial cell.. Unspecified 152995794 CVCL_B7IW SPNE1 cancer cell line human CVCL_B7IW CL:0000010 Population: Chinese; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: ~140 hours (PubMed=35394261) 152995795 CVCL_B7GH CTCL-3 cancer cell line human CVCL_B7GH CL:0000010 Population: African American; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 152995796 CVCL_B7GG 603B-iNOS antisense transformed cell line house mouse CVCL_B7GG CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [U19tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c. Female Characteristics: Transfected with an antisense human INOS gene fragment (PubMed=14977638) 152995797 CVCL_B7GJ CHK-Q_SF spontaneously immortalized cell line CVCL_B7GJ CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female Group: Serum/protein free medium cell line 152995798 CVCL_B7GI CTCL-2 cancer cell line human CVCL_B7GI CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 independent Caution: Indicated as originating from a 60 year old in PubMed=6256763 and 64 year old in PubMed=6272125 152995799 CVCL_B7GL BERP35T1 transformed cell line human CVCL_B7GL CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Plutonium-238 alpha particle radiation(NCIt; C129642); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from tumors obtained from xenografts of the parent cell line implanted in BALB/C nude mice 152995800 CVCL_B7GK CHK-Q_SS spontaneously immortalized cell line CVCL_B7GK CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Adapted to both serum-free and suspension condition Group: Serum/protein free medium cell line 152995801 CVCL_B7GN ODM-2 transformed cell line human CVCL_B7GN CL:0000010 Transformant: Simian virus 40 (SV40) [8-4](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ciliary body; ciliary epithelium Cell type=Non-pigmented ciliary epithelial cell.. Male Doubling time: ~24 hours (PubMed=2553750) 152995802 CVCL_B7GM BERP35T4 transformed cell line human CVCL_B7GM CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Plutonium-238 alpha particle radiation(NCIt; C129642); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from tumors obtained from xenografts of the parent cell line implanted in BALB/C nude mice 152995803 CVCL_B7GB IBEC line A transformed cell line house mouse CVCL_B7GB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c/aNn. Female Doubling time: ~24-48 hours (PubMed=10421641) 152995804 CVCL_B7GA 3F12 [Mouse hybridoma against I.punctatus Ig light chains] hybridoma house mouse CVCL_B7GA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Ictalurus punctatus Ig light chains G-type. 152995805 CVCL_B7GD IBEC line C transformed cell line house mouse CVCL_B7GD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c/aNn. Female Doubling time: ~72-96 hours (PubMed=10421641) 152995806 CVCL_B7GC IBEC line B transformed cell line house mouse CVCL_B7GC CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c/aNn. Female Doubling time: ~168-192 hours (PubMed=10421641) 152995807 CVCL_B7GF 603B transformed cell line house mouse CVCL_B7GF CL:0000010 Transformant: Simian virus 40 (SV40) [U19tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c. Female 152995808 CVCL_B7GE IBEC line D transformed cell line house mouse CVCL_B7GE CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: BALB/c/aNn. Female Doubling time: ~24-48 hours (PubMed=10421641) 152995809 CVCL_B7FW alpha48T transformed cell line CVCL_B7FW CL:0000010 Transformant: Rous sarcoma virus [Bryan high titer(NCBI-Taxonomy; 11886); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 152995810 CVCL_B7G8 MCEC-1 conditionally immortalized cell line house mouse CVCL_B7G8 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Cardiac endothelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 152995811 CVCL_B7FV alpha40T transformed cell line CVCL_B7FV CL:0000010 Transformant: Rous sarcoma virus [Bryan high titer(NCBI-Taxonomy; 11886); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 152995812 CVCL_B7G7 MJ7/18 hybridoma CVCL_B7G7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q63961; Mouse Eng/Cd105. 152995813 CVCL_B7FY QOR1 CJ07-18/1/F6 transformed cell line CVCL_B7FY CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08020603 152995814 CVCL_B7G9 1G7 [Mouse hybridoma against I.punctatus Ig light chains] hybridoma house mouse CVCL_B7G9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Ictalurus punctatus Ig light chains F-type. 152995815 CVCL_B7FX QOR2-sf transformed cell line CVCL_B7FX CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08020602 152995816 CVCL_B7FZ COR CJ0780 transformed cell line CVCL_B7FZ CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 08020604 152995817 CVCL_B7G0 BLN-5 cancer cell line human CVCL_B7G0 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. 152995818 CVCL_B7FN DFSC somatic stem cell human CVCL_B7FN CL:0000010 Derived from sampling site: Dental follicle. Unspecified 152995819 CVCL_B7G2 BLN-2 cancer cell line human CVCL_B7G2 CL:0000010 Omics: Transcriptome analysis by RNAseq. 152995820 CVCL_B7FQ HROG17 T1 M1 cancer cell line human CVCL_B7FQ From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left parieto-occipital lobe. Male Characteristics: Established from a patient-derived xenograft 152995821 CVCL_B7G1 BLN-1 cancer cell line human CVCL_B7G1 CL:0000010 Omics: Transcriptome analysis by RNAseq. 152995822 CVCL_B7FP HROG06 T0 M2 cancer cell line human CVCL_B7FP From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left frontal lobe. Male Characteristics: Established from a patient-derived xenograft 152995823 CVCL_B7G4 BLN-6 cancer cell line human CVCL_B7G4 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. 152995824 CVCL_B7FS HK-CRISPR-mEGFP-Nup358 no.97 cancer cell line human CVCL_B7FS CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NUP358 has been endogenously tagged in both alleles at the N-terminus with mEGFP (CLS) 152995825 CVCL_B7G3 BLN-4 cancer cell line human CVCL_B7G3 CL:0000010 Omics: Transcriptome analysis by RNAseq. 152995826 CVCL_B7FR HROG12 T0 M1 cancer cell line human CVCL_B7FR From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; right fronto-parietal lobe. Male Characteristics: Established from a patient-derived xenograft 152995827 CVCL_B7FU 3T transformed cell line CVCL_B7FU CL:0000010 Transformant: Rous sarcoma virus [Bryan high titer(NCBI-Taxonomy; 11886); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 152995828 CVCL_B7G6 BLN-9 cancer cell line human CVCL_B7G6 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. 152995829 CVCL_B7G5 BLN-8 cancer cell line human CVCL_B7G5 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. 152995830 CVCL_B7FT HK-2xZFN-Smc4-mEGFP no.82-68 cancer cell line human CVCL_B7FT CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using ZFN SMC4 has been endogenously tagged in both alleles at the C-terminus with mEGFP 152995831 CVCL_B7HI 9CE5 hybridoma house mouse CVCL_B7HI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (IVRI isolate No 216).. 152995832 CVCL_B7HH 9BC6 hybridoma house mouse CVCL_B7HH CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Bovine herpesvirus 1 (IVRI isolate No 216).. 152995833 CVCL_B7HK 1AG2 hybridoma house mouse CVCL_B7HK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9RAJ4; Mycobacterium paratuberculosis 35 kDa major membrane protein (mmpI). 152995834 CVCL_B7HJ WCRC-25 cancer cell line human CVCL_B7HJ CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Heterozygous (CelloPub=CLPUB00696); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Gln706Ter (c.2116C>T); Zygosity=Heterozygous (CelloPub=CLPUB00696) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: ER-positive, PR-negative and ERBB2-negative Doubling time: ~5 days (CelloPub=CLPUB00696) 152995835 CVCL_B7HM 1DE8 hybridoma house mouse CVCL_B7HM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9RAJ4; Mycobacterium paratuberculosis 35 kDa major membrane protein (mmpI). 152995836 CVCL_B7HL 1AG8 hybridoma house mouse CVCL_B7HL CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9RAJ4; Mycobacterium paratuberculosis 35 kDa major membrane protein (mmpI). 152995837 CVCL_B7I0 3A3 [Mouse hybridoma against human NEK2] hybridoma house mouse CVCL_B7I0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51955; Human NEK2. 152995838 CVCL_B7HN 2BD2 hybridoma house mouse CVCL_B7HN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9RAJ4; Mycobacterium paratuberculosis 35 kDa major membrane protein (mmpI). 152995839 CVCL_B7HA UG-GlyPy-Hem-1 spontaneously immortalized cell line CVCL_B7HA CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution, the species Latin name and the tissue Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 152995840 CVCL_B7HC COS7 moRIII-gamma transformed cell line CVCL_B7HC CL:0000010 Transfected with: MGI; MGI:95496; Fcer1g; Transfected with: MGI; MGI:95500; Fcgr3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 152995841 CVCL_B7HB COS7-moRIII transformed cell line CVCL_B7HB CL:0000010 Transfected with: MGI; MGI:95500; Fcgr3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 152995842 CVCL_B7HE 3AC3 hybridoma house mouse CVCL_B7HE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (IVRI isolate No 216).. 152995843 CVCL_B7HD COS7-pc transformed cell line CVCL_B7HD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Control cell line for COS7-moRIII and COS7 moRIII-gamma Group: Non-human primate cell line 152995844 CVCL_B7HG 9AG3 hybridoma house mouse CVCL_B7HG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (IVRI isolate No 216).. 152995845 CVCL_B7HF 9AE3 hybridoma house mouse CVCL_B7HF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (IVRI isolate No 216).. 152995846 CVCL_B7H9 CMT-Star cancer cell line dog CVCL_B7H9 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Mammary gland. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: 24.4 +- 0.028 hours (DOI=10.1080/09712119.2022.2032719) 152995847 CVCL_B7GX MhCT08-E cancer cell line human CVCL_B7GX CL:0000010 Population: Indian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue Cell type=Epithelial cell.. Female Doubling time: 23.61 +- 1.32 hours (PubMed=35796014) 152995848 CVCL_B7GW CAE606 cancer cell line human CVCL_B7GW CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.329G>A); ClinVar=VCV000376304; Zygosity=Homozygous (PubMed=35349366); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu28Lysfs*16 (c.81delT); Zygosity=Homozygous (PubMed=35349366) Derived from sampling site: Ear; auditory canal. Male Doubling time: 25.8 hours (PubMed=35349366) 152995849 CVCL_B7H8 CMT-Stylo cancer cell line dog CVCL_B7H8 CL:0000010 Derived from sampling site: Mammary gland. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: 23.55 +- 1.8 hours (DOI=10.1080/09712119.2022.2032719) 152995850 CVCL_B7GZ MhCT12-E cancer cell line human CVCL_B7GZ CL:0000010 Population: Indian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue Cell type=Epithelial cell.. Female Doubling time: 25.54 +- 0.64 hours (PubMed=35796014) 152995851 CVCL_B7GY MhCT08-F cancer cell line human CVCL_B7GY CL:0000010 Population: Indian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue Cell type=Fibroblast.. Female Doubling time: 32.23 +- 0.91 hours (PubMed=35796014) 152995852 CVCL_B7GP 8-SVHCE transformed cell line human CVCL_B7GP CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ciliary body; ciliary epithelium Cell type=Non-pigmented ciliary epithelial cell.. Unspecified 152995853 CVCL_B7H1 PHG spontaneously immortalized cell line CVCL_B7H1 CL:0000010 Derived from sampling site: Gill Cell type=Fibroblast.. Unspecified Doubling time: ~42 hours, at 11th passage (PubMed=35169909) Group: Fish cell line 152995854 CVCL_B7H0 MhCT12-F cancer cell line human CVCL_B7H0 CL:0000010 Population: Indian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue Cell type=Fibroblast.. Female Doubling time: 39.73 +- 1.35 hours (PubMed=35796014) 152995855 CVCL_B7H3 AGS-PTX-R cancer cell line human CVCL_B7H3 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Stomach. Female Doubling time: 25.6-25.8 hours (PubMed=35122114) 152995856 CVCL_B7GR SV40-PE transformed cell line CVCL_B7GR CL:0000010 Transformant: Simian virus 40 (SV40) [8-4](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ciliary body; ciliary epithelium Cell type=Pigmented ciliary epithelial cell.. Unspecified 152995857 CVCL_B7H2 AGS-5FU-R cancer cell line human CVCL_B7H2 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Stomach. Female 152995858 CVCL_B7GQ SV40-NPE transformed cell line CVCL_B7GQ CL:0000010 Transformant: Simian virus 40 (SV40) [8-4](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ciliary body; ciliary epithelium Cell type=Non-pigmented ciliary epithelial cell.. Unspecified 152995859 CVCL_B7GT IBBISTi004-B induced pluripotent stem cell human CVCL_B7GT From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152995860 CVCL_B7H5 OATL9 cancer cell line human CVCL_B7H5 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 152995861 CVCL_B7H4 HCM-MEC010 cancer cell line human CVCL_B7H4 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2; Note=In frame CRTC1 exon 1 fused to MAML2 exon 2 (PubMed=35251626). Population: Japanese; Derived from sampling site: Oral cavity; hard palate. Omics: Transcriptome analysis by RNAseq Female 152995862 CVCL_B7GS IBBISTi004-A induced pluripotent stem cell human CVCL_B7GS From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152995863 CVCL_B7H7 HEp-2/VCR cancer cell line human CVCL_B7H7 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 152995864 CVCL_B7GV MPT-S1 cancer cell line human CVCL_B7GV CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; c.6079_6082delAATT; Zygosity=Heterozygous (PubMed=35365682); Sequence variation: Mutation; HGNC; 11957; MED12; Simple; p.Gly44Asp (c.131G>A); ClinVar=VCV000092220; Zygosity=Heterozygous (PubMed=35365682); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.1530_1531delAG; Zygosity=Heterozygous (PubMed=35365682); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.1588_1589delAA; Zygosity=Heterozygous (PubMed=35365682); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu252del (c.754_756delCTC); ClinVar=VCV000998484; Zygosity=Heterozygous (PubMed=35365682); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.750_754delinsA; Zygosity=Heterozygous (PubMed=35365682) Population: Chinese; Derived from sampling site: Breast. Omics: Deep exome analysis Female Characteristics: Established from a nude mouse xenograft Doubling time: 2-3 days (PubMed=35365682) 152995865 CVCL_B7GU IBBISTi004-C induced pluripotent stem cell human CVCL_B7GU From: Simao Jose Teixeira da Rocha; Porto Salvo; Portugal CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152995866 CVCL_B7H6 MELS cancer cell line human CVCL_B7H6 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Male 152995867 CVCL_B7V7 Abcam Hep-G2 SLC7A11 KO cancer cell line human CVCL_B7V7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11059; SLC7A11; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 152995868 CVCL_B7UV e-mHepC transformed cell line house mouse CVCL_B7UV CL:0000010 Transfected with: HGNC; 6348; KLF4 Derived from sampling site: Liver Cell type=Hepatocyte.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995869 CVCL_B7V6 Abcam Hep-G2 ARG1 KO cancer cell line human CVCL_B7V6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 663; ARG1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 152995870 CVCL_B7UU e-mHepB transformed cell line house mouse CVCL_B7UU CL:0000010 Transfected with: HGNC; 5362; ID3; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052); Characteristics: Tumorigenic 152995871 CVCL_B7UX 10-4A(BFP) transformed cell line Norway rat CVCL_B7UX CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:99187; Zfp42; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the BFP mTagBFP) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Alveolar type 2 fibroblast.; Breed/subspecies: Sprague Dawley. Male Characteristics: Using CRISPR/Cas9 a T2A-BFP-NLS construct was introduced at the C-terminus of Acta2 (PubMed=33162897); Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line 152995872 CVCL_B7V9 Abcam Jurkat CD247 KO cancer cell line human CVCL_B7V9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1677; CD247; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995873 CVCL_B7UW 10-4A transformed cell line Norway rat CVCL_B7UW CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:99187; Zfp42; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Alveolar type 2 fibroblast.; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by RNAseq Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line 152995874 CVCL_B7V8 Abcam Jurkat CD1A KO cancer cell line human CVCL_B7V8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1634; CD1A; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995875 CVCL_B7UZ 533 OOS cancer cell line human CVCL_B7UZ CL:0000010 Derived from sampling site: Ascites. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 742D 152995876 CVCL_B7UY 485 colo can cancer cell line human CVCL_B7UY CL:0000010 Derived from metastatic site: Abdominal wall. Male Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 740D 152995877 CVCL_B7UN e-hUVEC-6 transformed cell line human CVCL_B7UN CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995878 CVCL_B7UM e-hUVEC-5 transformed cell line human CVCL_B7UM CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5109; HOXA9; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 6348; KLF4; Transfected with: HGNC; 7553; MYC; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995879 CVCL_B7UP e-hUVEC-7 transformed cell line human CVCL_B7UP CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995880 CVCL_B7V1 TAM-1 cancer cell line human CVCL_B7V1 HLA typing: A*02; B*06,27 (PubMed=2939141) CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 152995881 CVCL_B7V0 716 SS MNV cancer cell line human CVCL_B7V0 CL:0000010 Derived from metastatic site: Colon. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 790D 152995882 CVCL_B7UR e-hUVEC-9 transformed cell line human CVCL_B7UR CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995883 CVCL_B7V3 IBMS-iPSC-069-05 induced pluripotent stem cell human CVCL_B7V3 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian. Male 152995884 CVCL_B7UQ e-hUVEC-8 transformed cell line human CVCL_B7UQ CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 7553; MYC Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995885 CVCL_B7V2 TAM-6 transformed cell line human CVCL_B7V2 HLA typing: A*02; B*06,27 (PubMed=2939141) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 152995886 CVCL_B7V5 Abcam Hep-G2 APOE KO cancer cell line human CVCL_B7V5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 152995887 CVCL_B7UT e-mHepA transformed cell line house mouse CVCL_B7UT CL:0000010 Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 6348; KLF4; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995888 CVCL_B7V4 Abcam A-375 NT5E KO cancer cell line human CVCL_B7V4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8021; NT5E; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 152995889 CVCL_B7US e-hUVEC-10 transformed cell line human CVCL_B7US CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Karyotypic information: 84-88<4n>XXXX,-3,-4,+9,i(21)(q10) (PubMed=29520052); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995890 CVCL_B7UF e-hStr-3 transformed cell line human CVCL_B7UF CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:102811; Lmo2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995891 CVCL_B7UE e-hStr-2 transformed cell line human CVCL_B7UE CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7545; MYB; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Karyotypic information: 44<2n>XY,der(5)t(5;14)(p12;q11),-13,-21 (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995892 CVCL_B7UH e-hStr-5 transformed cell line human CVCL_B7UH CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: MGI; MGI:102811; Lmo2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995893 CVCL_B7UG e-hStr-4 transformed cell line human CVCL_B7UG CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995894 CVCL_B7UJ e-hUVEC-2 transformed cell line human CVCL_B7UJ CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Karyotypic information: 46<2n>XY,+5,-13 (PubMed=29520052); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995895 CVCL_B7UI e-hUVEC-1 transformed cell line human CVCL_B7UI CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7545; MYB; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:99187; Zfp42; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995896 CVCL_B7UL e-hUVEC-4 transformed cell line human CVCL_B7UL CL:0000010 Transfected with: HGNC; 5363; ID4; Transfected with: HGNC; 17101; SUZ12; Transfected with: MGI; MGI:99187; Zfp42 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995897 CVCL_B7UK e-hUVEC-3 transformed cell line human CVCL_B7UK CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5362; ID3; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995898 CVCL_B7UB e-hOB-3 transformed cell line human CVCL_B7UB CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen Karyotypic information: 46<2n>XX,add(22)(q13) (at 21th passage); 46<2n>XX,ins(15)(q11),add(22)(q13) (at 66th passage) (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995899 CVCL_B7UA e-hOB-2 transformed cell line human CVCL_B7UA CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:88138; Bcl2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:99187; Zfp42; Transfected with: UniProtKB; P03070; SV40 large T antigen Karyotypic information: 40-47<2n>add(X)(q27),add(10)(p11),-13,add(14)(q32),+20,+21,+22 (PubMed=29520052); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995900 CVCL_B7UD e-hStr-1 transformed cell line human CVCL_B7UD CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:102811; Lmo2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Karyotypic information: 111<5n>XXXX,-X,del(X)(q25),del(1)(p22),i(21)(q10) (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995901 CVCL_B7UC e-hOB-4 transformed cell line human CVCL_B7UC CL:0000010 Transfected with: HGNC; 2514; CTNNB1; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995902 CVCL_B7VW Abcam Raji AIM2 KO cancer cell line human CVCL_B7VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 357; AIM2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995903 CVCL_B7W8 Abcam Raji BRD2 KO cancer cell line human CVCL_B7W8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995904 CVCL_B7VV Abcam Raji AHR KO cancer cell line human CVCL_B7VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 348; AHR; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995905 CVCL_B7W7 Abcam Raji BRD1 KO cancer cell line human CVCL_B7W7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995906 CVCL_B7VY Abcam Raji ALKBH1 KO cancer cell line human CVCL_B7VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17911; ALKBH1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995907 CVCL_B7VX Abcam Raji ALCAM KO cancer cell line human CVCL_B7VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 400; ALCAM; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995908 CVCL_B7W9 Abcam Raji BRD9 KO cancer cell line human CVCL_B7W9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995909 CVCL_B7VZ Abcam Raji ALYREF KO cancer cell line human CVCL_B7VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19071; ALYREF; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995910 CVCL_B7W0 Abcam Raji APOBEC3B KO cancer cell line human CVCL_B7W0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17352; APOBEC3B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995911 CVCL_B7VN Abcam SH-SY5Y EFNB2 KO cancer cell line human CVCL_B7VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3227; EFNB2; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 152995912 CVCL_B7W2 Abcam Raji ATF5 KO cancer cell line human CVCL_B7W2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995913 CVCL_B7VQ Abcam SH-SY5Y LMOD1 KO cancer cell line human CVCL_B7VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6647; LMOD1; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 152995914 CVCL_B7W1 Abcam Raji ASAH1 KO cancer cell line human CVCL_B7W1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 735; ASAH1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995915 CVCL_B7VP Abcam SH-SY5Y SNAP25 KO cancer cell line human CVCL_B7VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11132; SNAP25; Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 152995916 CVCL_B7VS Abcam Raji AATF KO cancer cell line human CVCL_B7VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19235; AATF; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995917 CVCL_B7W4 Abcam Raji ATG9A KO cancer cell line human CVCL_B7W4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995918 CVCL_B7VR Abcam K-562 EP300 KO cancer cell line human CVCL_B7VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 152995919 CVCL_B7W3 Abcam Raji ATG3 KO cancer cell line human CVCL_B7W3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20962; ATG3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995920 CVCL_B7VU Abcam Raji AGTR1 KO cancer cell line human CVCL_B7VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 336; AGTR1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995921 CVCL_B7W6 Abcam Raji BMPR2 KO cancer cell line human CVCL_B7W6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1078; BMPR2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995922 CVCL_B7VT Abcam Raji ABCB1 KO cancer cell line human CVCL_B7VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995923 CVCL_B7W5 Abcam Raji BAK1 KO cancer cell line human CVCL_B7W5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152995924 CVCL_B7VG Abcam RAW 264.7 Ccr2 KO cancer cell line house mouse CVCL_B7VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:106185; Ccr2 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 152995925 CVCL_B7VF Abcam Jurkat PVRIG KO cancer cell line human CVCL_B7VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32190; PVRIG; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995926 CVCL_B7VI Abcam RAW 264.7 Sirpa KO cancer cell line house mouse CVCL_B7VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:108563; Sirpa Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 152995927 CVCL_B7VH Abcam RAW 264.7 Cx3cr1 KO cancer cell line house mouse CVCL_B7VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1333815; Cx3cr1 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 152995928 CVCL_B7VK Abcam RAW 264.7 Cdkn1b KO cancer cell line house mouse CVCL_B7VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:104565; Cdkn1b Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 152995929 CVCL_B7VJ Abcam Neuro-2a Arc KO cancer cell line house mouse CVCL_B7VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:88067; Arc Breed/subspecies: A/J. Male 152995930 CVCL_B7VM Abcam HCT 116 XPO1 KO cancer cell line human CVCL_B7VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12825; XPO1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152995931 CVCL_B7VL Abcam A-549 XPO1 KO cancer cell line human CVCL_B7VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12825; XPO1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152995932 CVCL_B7VA Abcam Jurkat LCK KO cancer cell line human CVCL_B7VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6524; LCK; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995933 CVCL_B7VC Abcam Jurkat ZAP70 KO cancer cell line human CVCL_B7VC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12858; ZAP70; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995934 CVCL_B7VB Abcam Jurkat LEF1 KO cancer cell line human CVCL_B7VB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6551; LEF1; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995935 CVCL_B7VE Abcam Jurkat TP53 KO cancer cell line human CVCL_B7VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995936 CVCL_B7VD Abcam Jurkat IDH2 KO cancer cell line human CVCL_B7VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152995937 CVCL_B7ST NIHTVBi017-A induced pluripotent stem cell human CVCL_B7ST From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 9545; PSMB8; Simple; p.Thr75Met (c.224C>T); ClinVar=VCV000659832; Zygosity=Homozygous (PubMed=35660921) Derived from sampling site: Peripheral blood. Male 152995938 CVCL_B7T5 UCL-CTRL002 finite cell line human CVCL_B7T5 From: University College London; London; United Kingdom CL:0000010 Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 48 hours (Direct_author_submission) 152995939 CVCL_B7SS NIHTVBi016-A induced pluripotent stem cell human CVCL_B7SS From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 9545; PSMB8; Simple; p.Thr75Met (c.224C>T); ClinVar=VCV000659832; Zygosity=Homozygous (PubMed=35660921) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Female 152995940 CVCL_B7T4 UCL-CTRL001 finite cell line human CVCL_B7T4 From: University College London; London; United Kingdom CL:0000010 Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 48 hours (Direct_author_submission) 152995941 CVCL_B7SV NIHTVBi019-A induced pluripotent stem cell human CVCL_B7SV From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple; p.His69Pro (c.206A>C); Zygosity=Heterozygous (PubMed=36070637); Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple; p.Gly120Glu (c.359G>A); Zygosity=Heterozygous (PubMed=36070637) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152995942 CVCL_B7SU NIHTVBi018-A induced pluripotent stem cell human CVCL_B7SU From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 9545; PSMB8; Simple; p.Thr75Met (c.224C>T); ClinVar=VCV000659832; Zygosity=Homozygous (PubMed=35660921) Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Female 152995943 CVCL_B7T6 UCL-CTRL003 finite cell line human CVCL_B7T6 From: University College London; London; United Kingdom CL:0000010 Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 48 hours (Direct_author_submission) 152995944 CVCL_B7SX NIHTVBi020-A induced pluripotent stem cell human CVCL_B7SX From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple; p.His69Pro (c.206A>C); Zygosity=Heterozygous (PubMed=36070637) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152995945 CVCL_B7T9 UCL-E001K finite cell line human CVCL_B7T9 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 72 hours (Direct_author_submission) 152995946 CVCL_B7SW NIHTVBi019-A-1 induced pluripotent stem cell human CVCL_B7SW From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple_corrected; p.His69Pro (c.206A>C); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36070637); Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple_corrected; p.Gly120Glu (c.359G>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36070637) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152995947 CVCL_B7T8 UCL-YCTRL001 finite cell line human CVCL_B7T8 From: University College London; London; United Kingdom CL:0000010 Miscellaneous: Cell line information from personal communication of Koletsi S Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: ~2 days (Direct_author_submission) 152995948 CVCL_B7SZ NIHTVBi022-A induced pluripotent stem cell human CVCL_B7SZ From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple; p.Leu62Pro (c.185T>C); Zygosity=Homozygous (PubMed=36070637) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152995949 CVCL_B7SY NIHTVBi021-A induced pluripotent stem cell human CVCL_B7SY From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 4200; BLOC1S1; Simple; p.Gly120Glu (c.359G>A); Zygosity=Heterozygous (PubMed=36070637) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152995950 CVCL_B7SL SCVIi043-A induced pluripotent stem cell human CVCL_B7SL From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995951 CVCL_B7SK SCVIi042-A induced pluripotent stem cell human CVCL_B7SK From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995952 CVCL_B7SN SCVIi045-A induced pluripotent stem cell human CVCL_B7SN From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995953 CVCL_B7SM SCVIi044-A induced pluripotent stem cell human CVCL_B7SM From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995954 CVCL_B7SP SCVIi046-A induced pluripotent stem cell human CVCL_B7SP From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Female 152995955 CVCL_B7T1 ZZUNEUi026-A induced pluripotent stem cell human CVCL_B7T1 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12665; VCL; Simple; p.Met209Leu (c.625A>T); ClinVar=VCV000488174; Zygosity=Heterozygous (PubMed=35567849) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152995956 CVCL_B7T0 NIHTVBi023-A induced pluripotent stem cell human CVCL_B7T0 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA. CL:0000010 152995957 CVCL_B7SR SCVIi048-A induced pluripotent stem cell human CVCL_B7SR From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995958 CVCL_B7T3 ZZUNEUi028-A induced pluripotent stem cell human CVCL_B7T3 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Arg502Trp (c.1504C>T); ClinVar=VCV000042540; Zygosity=Heterozygous (PubMed=35772297) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152995959 CVCL_B7SQ SCVIi047-A induced pluripotent stem cell human CVCL_B7SQ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 152995960 CVCL_B7T2 ZZUNEUi027-A induced pluripotent stem cell human CVCL_B7T2 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr43Cys (c.128A>G); ClinVar=VCV000067182; Zygosity=Heterozygous (PubMed=35700634) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152995961 CVCL_B7SD Scid.adh.2C2 cancer cell line house mouse CVCL_B7SD CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Thymus Cell type=T-cell.; Breed/subspecies: C.B.-17-scid (CB17/Icr-Prkdcscid/IcrIcoCrl). Characteristics: Overexpresses PU.1 (Spi1) 152995962 CVCL_B7SC Scid.adh cancer cell line house mouse CVCL_B7SC CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Thymus Cell type=T-cell.; Breed/subspecies: C.B.-17-scid (CB17/Icr-Prkdcscid/IcrIcoCrl). 152995963 CVCL_B7SF Scid.adh.14B2 cancer cell line house mouse CVCL_B7SF CL:0000010 Derived from sampling site: Thymus Cell type=T-cell.. 152995964 CVCL_B7SE Scid.adh.6D4 cancer cell line house mouse CVCL_B7SE CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Thymus Cell type=T-cell.; Breed/subspecies: C.B.-17-scid (CB17/Icr-Prkdcscid/IcrIcoCrl). Characteristics: Overexpresses PU.1 (Spi1) 152995965 CVCL_B7SH CSSi014-A induced pluripotent stem cell human CVCL_B7SH From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Pro160Leu (c.479C>T); Zygosity=Hemizygous (PubMed=35759972) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152995966 CVCL_B7SG CSSi013-A induced pluripotent stem cell human CVCL_B7SG From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly376Asp (c.1127G>A); Zygosity=Heterozygous (PubMed=35714448) Population: Caucasian; Italian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152995967 CVCL_B7SJ SCVIi050-A induced pluripotent stem cell human CVCL_B7SJ From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35853412) Derived from sampling site: Peripheral blood. Male 152995968 CVCL_B7SI SCVIi049-A induced pluripotent stem cell human CVCL_B7SI From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg9Cys (c.25C>T); ClinVar=VCV000013636; Zygosity=Heterozygous (PubMed=35853412) Derived from sampling site: Skin Cell type=Fibroblast.. Male 152995969 CVCL_B7RZ SJSC cancer cell line human CVCL_B7RZ CL:0000010 Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Female 152995970 CVCL_B7SB HEK293-MRP7-C18 transformed cell line human CVCL_B7SB CL:0000010 Transfected with: HGNC; 52; ABCC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152995971 CVCL_B7SA HEK293-MRP7-C17 transformed cell line human CVCL_B7SA CL:0000010 Transfected with: HGNC; 52; ABCC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152995972 CVCL_B7TU e-hChon-1 transformed cell line human CVCL_B7TU CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 6348; KLF4; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:88174; Bmi1; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P03077; Murine polyomavirus (strain A2) middle T antigen (MPyV). Karyotypic information: 46<2n>XX,del(2)(q3?),-4,add(7)(p14),+21,add(22)(q13) (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Femoral head; cartilage Cell type=Chondrocyte.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995973 CVCL_B7U6 e-hMEC-1 transformed cell line human CVCL_B7U6 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 4317; GLI1; Transfected with: HGNC; 5109; HOXA9; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium Cell type=Microvascular endothelial cell.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995974 CVCL_B7U5 e-hLEC-2 transformed cell line human CVCL_B7U5 CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC Derived from sampling site: Skin; dermis Cell type=Lymphatic endothelial cell.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995975 CVCL_B7TT J.CaM1.7 cancer cell line human CVCL_B7TT CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Deficient for LCK activity due to a deletion of exon 7 Also lacks LAT expression. Can re-express LAT after protein kinase C (PKC) activation (PubMed=33562083). 152995976 CVCL_B7TW e-hChon-3 transformed cell line human CVCL_B7TW CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:88138; Bcl2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Femoral head; cartilage Cell type=Chondrocyte.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995977 CVCL_B7U8 e-hMEC-3 transformed cell line human CVCL_B7U8 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5109; HOXA9; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: MGI; MGI:1919200; Nanog Derived from sampling site: Skin; microvascular endothelium Cell type=Microvascular endothelial cell.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995978 CVCL_B7TV e-hChon-2 transformed cell line human CVCL_B7TV CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 6348; KLF4; Transfected with: HGNC; 11195; SOX2; Transfected with: MGI; MGI:102811; Lmo2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Femoral head; cartilage Cell type=Chondrocyte.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995979 CVCL_B7U7 e-hMEC-2 transformed cell line human CVCL_B7U7 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: MGI; MGI:88138; Bcl2 Derived from sampling site: Skin; microvascular endothelium Cell type=Microvascular endothelial cell.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995980 CVCL_B7TY e-hDFib1 transformed cell line human CVCL_B7TY CL:0000010 Transfected with: HGNC; 5109; HOXA9; Transfected with: HGNC; 7545; MYB; Transfected with: HGNC; 7553; MYC; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995981 CVCL_B7TX e-hChon-4 transformed cell line human CVCL_B7TX CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 3796; FOS; Transfected with: MGI; MGI:1919200; Nanog Derived from sampling site: Femoral head; cartilage Cell type=Chondrocyte.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995982 CVCL_B7U9 e-hOB-1 transformed cell line human CVCL_B7U9 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P03070; SV40 large T antigen Karyotypic information: 46<2n>XX (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Female Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995983 CVCL_B7TZ e-hDFib2 transformed cell line human CVCL_B7TZ CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Karyotypic information: 44<2n>XY,der(2)t(2;4)(p24;p11),-4,-13,add(14)(p11) (PubMed=29520052); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995984 CVCL_B7TM RIL-175-KC cancer cell line house mouse CVCL_B7TM CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: MGI; MGI:108068; Cxcl1 Breed/subspecies: C57BL/6. Caution: We are not certain that the Cxcl1 gene is from mouse or from human as the paper does not mention the source of the construct 152995985 CVCL_B7TL RIL-175-GM-CSF cancer cell line house mouse CVCL_B7TL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: MGI; MGI:1339752; Csf2 Breed/subspecies: C57BL/6. Caution: We are not certain that the Csf2 gene is from mouse or from human as the paper does not mention the source of the construct 152995986 CVCL_B7U0 e-hDFib3 transformed cell line human CVCL_B7U0 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995987 CVCL_B7TN RIL175-R cancer cell line house mouse CVCL_B7TN CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Breed/subspecies: C57BL/6. 152995988 CVCL_B7U2 e-hFib-2 transformed cell line human CVCL_B7U2 CL:0000010 Transfected with: MGI; MGI:1919200; Nanog Karyotypic information: 69<3n>XXYY,+X/Y,t(2;5)(p16;q13),+3,+5,-9,+11,-13,+16,+20,-21,-22 (PubMed=29520052); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995989 CVCL_B7TQ F3II-NM cancer cell line house mouse CVCL_B7TQ CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established through the following protocol: the parental cell line was inoculated in the subcutis of BALB/c mice, a pulmonary metastatic tumor was transplanted by surgery in another mouse The transplantation process was repeated twice and the cell line was established from primary culture of the resulting tumor (CelloPub=CLPUB00707). Doubling time: 31.71 hours (CelloPub=CLPUB00707) 152995990 CVCL_B7U1 e-hFib-1 transformed cell line human CVCL_B7U1 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 667; RHOA Karyotypic information: 78<3n>XXYY,+1,add(2)(p24),-3,+6,+7,+del(8)(q21),+9,add(9)(p2?),+10,der(10)t(5;10)(q15:p15),+11,+18,der(19)t(11;19)(q13;p13),+20,+21,+22,+2mar (PubMed=29520052); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995991 CVCL_B7TP J558L-CD40L cancer cell line house mouse CVCL_B7TP CL:0000010 Transfected with: MGI; MGI:88337; Cd40lg; Transfected with: UniProtKB; P06988; Escherichia coli hisD Derived from sampling site: Cell type=B-cell; Breed/subspecies: BALB/c. 152995992 CVCL_B7TS C6rho0 cancer cell line Norway rat CVCL_B7TS CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with ethidium bromide and 2',3'dideoxycytidine. 152995993 CVCL_B7U4 e-hLEC-1 transformed cell line human CVCL_B7U4 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 6348; KLF4; Transfected with: HGNC; 7553; MYC; Transfected with: Hepatitis C virus core protein Derived from sampling site: Skin; dermis Cell type=Lymphatic endothelial cell.. Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995994 CVCL_B7U3 e-hFib-3 transformed cell line human CVCL_B7U3 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: HGNC; 5360; ID1; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: MGI; MGI:103262; Yap1; Transfected with: MGI; MGI:99187; Zfp42; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line (PubMed=29520052) 152995995 CVCL_B7TR F3II-TP cancer cell line house mouse CVCL_B7TR CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established through the following protocol: the parental cell line was inoculated in the subcutis of BALB/c mice, the produced tumor was transplanted by surgery in another mouse The transplantation process was repeated twice and the cell line was established from primary culture of the resulting tumor (CelloPub=CLPUB00707). Doubling time: 25.52 hours (CelloPub=CLPUB00707) 152995996 CVCL_B7TE SK/IFN-gamma cancer cell line human CVCL_B7TE CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5438; IFNG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 152995997 CVCL_B7TD ACN/neo cancer cell line human CVCL_B7TD CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Caucasian Unspecified Problematic cell line: Probably contaminated Parent cell line (ACN) has been shown to probably be a melanoma cell line. 152995998 CVCL_B7TG Abcam THP-1 TYROBP KO cancer cell line human CVCL_B7TG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12449; TYROBP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152995999 CVCL_B7TF SK/neo cancer cell line human CVCL_B7TF CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 152996000 CVCL_B7TI HUH7-R cancer cell line human CVCL_B7TI CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 152996001 CVCL_B7TH BNL/R transformed cell line house mouse CVCL_B7TH CL:0000010 Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified 152996002 CVCL_B7TK RIL-175 cancer cell line house mouse CVCL_B7TK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Breed/subspecies: C57BL/6. 152996003 CVCL_B7TJ HUH7-R-LUC cancer cell line human CVCL_B7TJ CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 152996004 CVCL_B7TA UCL-N001S finite cell line human CVCL_B7TA From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 48 hours (Direct_author_submission) 152996005 CVCL_B7TC ACN/IFN-gamma cancer cell line human CVCL_B7TC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5438; IFNG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Caucasian Unspecified Problematic cell line: Probably contaminated Parent cell line (ACN) has been shown to probably be a melanoma cell line. 152996006 CVCL_B7TB UCL-N002S finite cell line human CVCL_B7TB From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Koletsi S Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 96 hours (Direct_author_submission) 152996007 CVCL_B7R3 M-T61 hybridoma house mouse CVCL_B7R3 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Human T-cells. 152996008 CVCL_B7QR MUC 2-63 hybridoma house mouse CVCL_B7QR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996009 CVCL_B7R2 M-T321 hybridoma house mouse CVCL_B7R2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 152996010 CVCL_B7QQ MUC 15-22 hybridoma house mouse CVCL_B7QQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996011 CVCL_B7R5 85HG-59 cancer cell line human CVCL_B7R5 CL:0000010 Unspecified 152996012 CVCL_B7QT MUC 8-22 hybridoma house mouse CVCL_B7QT CL:0000010 Monoclonal antibody isotype: IgG2a. 152996013 CVCL_B7R4 85HG-3 cancer cell line human CVCL_B7R4 CL:0000010 Unspecified 152996014 CVCL_B7QS MUC 7-22 hybridoma house mouse CVCL_B7QS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996015 CVCL_B7R7 85HG-64 cancer cell line human CVCL_B7R7 CL:0000010 Unspecified 152996016 CVCL_B7QV M-T811 hybridoma house mouse CVCL_B7QV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01732; Human CD8A; Monoclonal antibody target: UniProtKB; P10966; Human CD8B. 152996017 CVCL_B7R6 85HG-63 cancer cell line human CVCL_B7R6 CL:0000010 Unspecified 152996018 CVCL_B7QU M-T411 hybridoma house mouse CVCL_B7QU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 152996019 CVCL_B7R9 85HG-66 cancer cell line human CVCL_B7R9 CL:0000010 Unspecified 152996020 CVCL_B7QX M-M522 hybridoma house mouse CVCL_B7QX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 152996021 CVCL_B7R8 85HG-65 cancer cell line human CVCL_B7R8 CL:0000010 Unspecified 152996022 CVCL_B7QW M-G1120 hybridoma house mouse CVCL_B7QW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 152996023 CVCL_B7QJ TVI spontaneously immortalized cell line CVCL_B7QJ CL:0000010 Derived from sampling site: Dorsal eye; iris. Unspecified Doubling time: 84 hours (PubMed=1010157) Group: Amphibian cell line 152996024 CVCL_B7QI SCHL spontaneously immortalized cell line CVCL_B7QI CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 32.2 hours (PubMed=28691159) Group: Fish cell line 152996025 CVCL_B7QL 22/18 hybridoma house mouse CVCL_B7QL CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Notophthalmus viridescens blastemal cells specific antigen. 152996026 CVCL_B7QK 12/101 hybridoma house mouse CVCL_B7QK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Notophthalmus viridescens 102 kda protein in adult muscles. 152996027 CVCL_B7QN MUC 11-22 hybridoma house mouse CVCL_B7QN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996028 CVCL_B7QM MUC 10-22 hybridoma house mouse CVCL_B7QM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996029 CVCL_B7R1 M-T151 hybridoma house mouse CVCL_B7R1 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 152996030 CVCL_B7QP MUC 14-22 hybridoma house mouse CVCL_B7QP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen on gliomas, neuroblastomas and melanomas as well as embryonic and fetal cells. 152996031 CVCL_B7R0 M-T1020 hybridoma house mouse CVCL_B7R0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human T-cells. 152996032 CVCL_B7QB SJU-1 spontaneously immortalized cell line CVCL_B7QB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by infectious pancreatic necrosis virus (IPNV) (DOI=10.1111/j.1095-8649.1973.tb04461.x) Group: Fish cell line 152996033 CVCL_B7QA FtGL spontaneously immortalized cell line CVCL_B7QA CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fantail. Unspecified Virology: Susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=33556411) Doubling time: 63.43 hours (PubMed=33556411) Group: Fish cell line 152996034 CVCL_B7QD SSB spontaneously immortalized cell line CVCL_B7QD CL:0000010 Derived from sampling site: Embryonic brain. Unspecified Characteristics: Can grow at temperatures ranging from 20 to 37 Celsius with an optimum temperature of 29-30 Celsius (DOI=10.1007/BF02631047) Doubling time: 67 hours, at 30th passage (CelloPub=CLPUB00705; DOI=10.1007/BF02631047) Group: Fish cell line 152996035 CVCL_B7QC CrF spontaneously immortalized cell line CVCL_B7QC CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male Characteristics: Optimal growth temperature is from 26 to 32 Celsius (PubMed=7422670) Group: Fish cell line 152996036 CVCL_B7QF RBT-H spontaneously immortalized cell line CVCL_B7QF CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC075 152996037 CVCL_B7QE NSB spontaneously immortalized cell line CVCL_B7QE CL:0000010 Derived from sampling site: Brain. Unspecified Doubling time: 84 hours, at 6th passage (CelloPub=CLPUB00705) Group: Fish cell line 152996038 CVCL_B7QH TSB spontaneously immortalized cell line CVCL_B7QH CL:0000010 Derived from sampling site: Brain Cell type=Fibroblast.. Male Characteristics: Optimal growth at 28 Celsius (DOI=10.1111/j.1095-8649.1987.tb05322.x) Group: Fish cell line 152996039 CVCL_B7QG OCrF-1 spontaneously immortalized cell line CVCL_B7QG CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC077 152996040 CVCL_B7PY LM38-LP cancer cell line house mouse CVCL_B7PY CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established from the mouse M38 transplantable tumor M38 is a spontaneously arising well differentiated ductal papillary adenocarcinoma (PubMed=14979922). Doubling time: 18 +- 1.1 hours (PubMed=14979922) 152996041 CVCL_B7Q9 FtGG spontaneously immortalized cell line CVCL_B7Q9 CL:0000010 Derived from sampling site: Gill; Breed/subspecies: Fantail. Unspecified Virology: Highly susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=33556411) Doubling time: 41.47 hours (PubMed=33556411) Group: Fish cell line 152996042 CVCL_B7PX LM38-HP cancer cell line house mouse CVCL_B7PX CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established from the mouse M38 transplantable tumor M38 is a spontaneously arising well differentiated ductal papillary adenocarcinoma (PubMed=14979922). Doubling time: 1O +- 0.6 hours (PubMed=14979922) 152996043 CVCL_B7PZ LM38-D2 cancer cell line house mouse CVCL_B7PZ CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Doubling time: 33 +- 2.4 hours (PubMed=14979922) 152996044 CVCL_B7S4 1A9/CP10 cancer cell line human CVCL_B7S4 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996045 CVCL_B7RS K-3506 cancer cell line human CVCL_B7RS CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:06); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996046 CVCL_B7S3 A1847/CP6 cancer cell line human CVCL_B7S3 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996047 CVCL_B7RR K-3504 cancer cell line human CVCL_B7RR CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:04); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996048 CVCL_B7S6 A2780/C300 cancer cell line human CVCL_B7S6 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996049 CVCL_B7RU SZGT-31 spontaneously immortalized cell line CVCL_B7RU CL:0000010 Derived from sampling site: Testis Cell type=Fibroblast.. Male Characteristics: Optimal growth at 31 Celsius Doubling time: ~18 hours (DOI=10.1016/B978-0-12-427150-0.50040-1) Group: Fish cell line 152996050 CVCL_B7S5 A2780/C80 cancer cell line human CVCL_B7S5 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996051 CVCL_B7RT K-3508 cancer cell line human CVCL_B7RT CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:08); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996052 CVCL_B7S8 A2780/C50 cancer cell line human CVCL_B7S8 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996053 CVCL_B7RW NF-HFO-2 finite cell line human CVCL_B7RW CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 65 +- 10 PDL (PubMed=6785281) 152996054 CVCL_B7S7 A2780/C100 cancer cell line human CVCL_B7S7 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 152996055 CVCL_B7RV SZGT-37 spontaneously immortalized cell line CVCL_B7RV CL:0000010 Derived from sampling site: Testis Cell type=Fibroblast.. Male Characteristics: Adapted to growth at 37 Celsius Doubling time: ~18 hours (DOI=10.1016/B978-0-12-427150-0.50040-1) Group: Fish cell line 152996056 CVCL_B7RY FW-4 hybridoma house mouse CVCL_B7RY CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P60568; Human IL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8456 152996057 CVCL_B7S9 3AKRP spontaneously immortalized cell line CVCL_B7S9 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Amphibian cell line 152996058 CVCL_B7RX T-199 hybridoma house mouse CVCL_B7RX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen on the cell surface of neuroectodermally derived tumors. 152996059 CVCL_B7RK KE37/1 cancer cell line human CVCL_B7RK CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Male 152996060 CVCL_B7RJ B-187 transformed cell line human CVCL_B7RJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 152996061 CVCL_B7RM K562/A*0201 cancer cell line human CVCL_B7RM CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*02:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pleural effusion. Female 152996062 CVCL_B7RL A1 [Newt ankle] spontaneously immortalized cell line CVCL_B7RL CL:0000010 Derived from sampling site: Hindlimb; ankle; hypodermis. Unspecified Group: Amphibian cell line 152996063 CVCL_B7S0 FC-IBC-02 cancer cell line human CVCL_B7S0 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Group: Triple negative breast cancer (TNBC) cell line 152996064 CVCL_B7RN K-3501 cancer cell line human CVCL_B7RN CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:01); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996065 CVCL_B7S2 FC-muMCL1 cancer cell line house mouse CVCL_B7S2 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Derived from sampling site: Spleen; Breed/subspecies: C57BL/6 Em-cyclin D1 transgenic. Omics: Array-based CGH Male Doubling time: ~24 hours (PubMed=23271511) 152996066 CVCL_B7RQ K-3503 cancer cell line human CVCL_B7RQ CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:03); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996067 CVCL_B7S1 EMF-011 cancer cell line human CVCL_B7S1 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 152996068 CVCL_B7RP K-3502 cancer cell line human CVCL_B7RP CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*35:02); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: HLA class I peptidome analysis by proteomics Female 152996069 CVCL_B7RC TH4B spontaneously immortalized cell line CVCL_B7RC CL:0000010 Derived from sampling site: Hindlimb; thigh; hypodermis. Unspecified Group: Amphibian cell line 152996070 CVCL_B7RB BlH1 spontaneously immortalized cell line CVCL_B7RB CL:0000010 Derived from sampling site: Hindlimb; blastema. Unspecified Group: Amphibian cell line 152996071 CVCL_B7RE RPMI-8392 transformed cell line human CVCL_B7RE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 152996072 CVCL_B7RD RPMI-8382 transformed cell line human CVCL_B7RD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 152996073 CVCL_B7RG HUSP-3L transformed cell line human CVCL_B7RG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152996074 CVCL_B7RF ASPC-3L transformed cell line human CVCL_B7RF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152996075 CVCL_B7RI BES-1 transformed cell line human CVCL_B7RI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 152996076 CVCL_B7RH MANACA-2 cancer cell line human CVCL_B7RH CL:0000010 Male 152996077 CVCL_B7QZ M-N72 hybridoma house mouse CVCL_B7QZ CL:0000010 Monoclonal antibody isotype: IgM, kappa. 152996078 CVCL_B7QY M-M67 hybridoma house mouse CVCL_B7QY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human monocytes (CDw12). 152996079 CVCL_B7RA TH4-7-5 cancer cell line human CVCL_B7RA CL:0000010 Unspecified Virology: In vitro persistently infected by HIV-1 Produces substantial amounts of Nef (PubMed=1373627).. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-861 152996080 CVCL_B7P1 F6T cancer cell line human CVCL_B7P1 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 152996081 CVCL_B7P0 C8ID cancer cell line human CVCL_B7P0 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 152996082 CVCL_B7P3 Oh13T cancer cell line human CVCL_B7P3 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 152996083 CVCL_B7P2 K3T cancer cell line human CVCL_B7P2 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 152996084 CVCL_B7P5 Su9T01 cancer cell line human CVCL_B7P5 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Characteristics: IL2 dependent 152996085 CVCL_B7P4 S1T cancer cell line human CVCL_B7P4 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 152996086 CVCL_B7P7 MCF-7/PacR cancer cell line human CVCL_B7P7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Doubling time, ABCB1 status and STR profile from personal communication of Daniel P Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Omics: Mitochondrion proteome analysis by 2D-DE/MS Female Characteristics: Generated by step-increasing drug concentration to 300 nm of paclitaxel Overexpresses ABCB1 which is amplified and inserted in chromosome 3 (PubMed=27664577; Direct_author_submission). Doubling time: ~25-30 hours (Direct_author_submission) 152996087 CVCL_B7P6 OATL4 cancer cell line human CVCL_B7P6 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray 152996088 CVCL_B7NW HEK293-Luc-GFP transformed cell line human CVCL_B7NW CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a CAG-Luc-PGK-GFP-T2A-Puro lentiviral reporter construct 152996089 CVCL_B7NV HCT116-NanoLuc-RFP cancer cell line human CVCL_B7NV CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transduced with a CAG-NanoLuc-PGK-TdTomato-T2A-Puro lentiviral reporter construct 152996090 CVCL_B7NY HEK293-NanoLuc-RFP transformed cell line human CVCL_B7NY CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a CAG-NanoLuc-PGK-TdTomato-T2A-Puro lentiviral reporter construct 152996091 CVCL_B7NX HEK293-Luc-RFP transformed cell line human CVCL_B7NX CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152996092 CVCL_B7NZ Jurkat-Luc-RFP cancer cell line human CVCL_B7NZ CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a SFFV-Luc-PGK-tdTomato-T2A-Puro lentiviral reporter construct 152996093 CVCL_B7PQ Ei 151 transformed cell line human CVCL_B7PQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996094 CVCL_B7Q2 HEK293-TA-Lv-T7 R1D3 transformed cell line human CVCL_B7Q2 CL:0000010 Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996095 CVCL_B7Q1 Abcam A-549 ARID1A KO cancer cell line human CVCL_B7Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152996096 CVCL_B7PP Ei 81 transformed cell line human CVCL_B7PP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996097 CVCL_B7PS Abcam HCT 116 ARID1A KO cancer cell line human CVCL_B7PS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996098 CVCL_B7Q4 HEK293-TA-Lv-T7 R5B9 transformed cell line human CVCL_B7Q4 CL:0000010 Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996099 CVCL_B7Q3 HEK293-TA-Lv-T7 R1D8 transformed cell line human CVCL_B7Q3 CL:0000010 Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996100 CVCL_B7PR JcTaxWT-Neo7 cancer cell line human CVCL_B7PR CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03409; Human T-cell leukemia virus 1 (HTLV-1) Tax; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 152996101 CVCL_B7PU HCT116-A2 cancer cell line human CVCL_B7PU CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Leu617Ile (c.1849C>A); Zygosity=Homozygous (PubMed=21619602) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male Doubling time: 25.0 hours (PubMed=21619602) 152996102 CVCL_B7Q6 SW620-Lv-T7 R3C5 cancer cell line human CVCL_B7Q6 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996103 CVCL_B7PT HCT116-s cancer cell line human CVCL_B7PT CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg621His (c.1862G>A); Zygosity=Heterozygous (PubMed=21619602); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu710Gly (c.2129A>G); Zygosity=Heterozygous (PubMed=21619602) Derived from sampling site: Colon. Male Doubling time: 19.8 hours (PubMed=21619602) 152996104 CVCL_B7Q5 SW620-Lv-T7 R1C11 cancer cell line human CVCL_B7Q5 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996105 CVCL_B7Q8 FtGB spontaneously immortalized cell line CVCL_B7Q8 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: Fantail. Unspecified Virology: Susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=33556411) Doubling time: 79.79 hours (PubMed=33556411) Group: Fish cell line 152996106 CVCL_B7PW HCT116-G7 cancer cell line human CVCL_B7PW CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg621His (c.1862G>A); Zygosity=Heterozygous (PubMed=21619602); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu710Gly (c.2129A>G); Zygosity=Heterozygous (PubMed=21619602) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male Doubling time: 42.1 hours (PubMed=21619602) 152996107 CVCL_B7PV HCT116-C8 cancer cell line human CVCL_B7PV CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg621His (c.1862G>A); Zygosity=Heterozygous (PubMed=21619602); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu710Gly (c.2129A>G); Zygosity=Heterozygous (PubMed=21619602) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male Doubling time: 38.7 hours (PubMed=21619602) 152996108 CVCL_B7Q7 SW620-Lv-T7 R3E6 cancer cell line human CVCL_B7Q7 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: Transduced with a lentiviral vector pLv-T7 containing T7-RNAP gene, puroR and mCherry 152996109 CVCL_B7PI Se21 transformed cell line human CVCL_B7PI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996110 CVCL_B7PH NCC-ES2-C1 cancer cell line human CVCL_B7PH CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 7 fused to FLI1 exon 8 (PubMed=35441357) Population: Japanese; Derived from sampling site: Bone; right femur. Male Doubling time: ~159 hours (PubMed=35441357) Part of: NCC sarcoma cell line panel 152996111 CVCL_B7PK SeA2 transformed cell line human CVCL_B7PK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996112 CVCL_B7PJ SeA1 transformed cell line human CVCL_B7PJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996113 CVCL_B7PM Ei 26 transformed cell line human CVCL_B7PM CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996114 CVCL_B7PL SeD transformed cell line human CVCL_B7PL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Spleen. Female 152996115 CVCL_B7Q0 MC38-hPD-L1-LZ cancer cell line house mouse CVCL_B7Q0 CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 152996116 CVCL_B7PN Ei 39 transformed cell line human CVCL_B7PN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic lymphocytic leukemia; Derived from sampling site: Peripheral blood. Female 152996117 CVCL_B7PA SRD-14 transformed cell line CVCL_B7PA CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248) Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 152996118 CVCL_B7PC SRD-14/pInsig-2 transformed cell line CVCL_B7PC CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248); Transfected with: HGNC; 20452; INSIG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Transfected with INSIG2 followed by 6 tandem copies of the Myc epitope 152996119 CVCL_B7PB SRD-14/pInsig-1 transformed cell line CVCL_B7PB CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248); Transfected with: HGNC; 6083; INSIG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Transfected with INSIG1 followed by 6 tandem copies of the Myc epitope 152996120 CVCL_B7PE SRD-15/pInsig-1 transformed cell line CVCL_B7PE CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248); Sequence variation: Gene deletion; UniProtKB; Q8CFA5; Insig2; Zygosity=Heterozygous (PubMed=15866869); Transfected with: HGNC; 6083; INSIG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Selected for resistance to: ChEBI; CHEBI:42977; 25-hydroxycholesterol; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Transfected with INSIG1 followed by 6 tandem copies of the Myc epitope 152996121 CVCL_B7PD SRD-15 transformed cell line CVCL_B7PD CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248); Sequence variation: Gene deletion; UniProtKB; Q8CFA5; Insig2; Zygosity=Heterozygous (PubMed=15866869) Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Selected for resistance to: ChEBI; CHEBI:42977; 25-hydroxycholesterol; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 152996122 CVCL_B7PG SRD-5 transformed cell line CVCL_B7PG CL:0000010 Sequence variation: Mutation; UniProtKB; P97260; Scap; Simple; p.Leu315Phe (c.943C>T); Zygosity=Heterozygous (PubMed=12482938) Selected for resistance to: ChEBI; CHEBI:42977; 25-hydroxycholesterol; Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Ovary. Female 152996123 CVCL_B7PF SRD-15/pInsig-2 transformed cell line CVCL_B7PF CL:0000010 Sequence variation: Gene deletion; UniProtKB; Q8CFA6; Insig1; Zygosity=Heterozygous; Note=The 2nd allele has a loss of function (PubMed=15247248); Sequence variation: Gene deletion; UniProtKB; Q8CFA5; Insig2; Zygosity=Heterozygous (PubMed=15866869); Transfected with: HGNC; 20452; INSIG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:77317; 4-[2,2-bis(diethoxyphosphoryl)ethenyl]-2,6-ditert-butylphenol] (SR12813); Selected for resistance to: ChEBI; CHEBI:42977; 25-hydroxycholesterol; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Transfected with INSIG2 followed by 6 tandem copies of the Myc epitope 152996124 CVCL_B7P9 PC3PR cancer cell line human CVCL_B7P9 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone. Male 152996125 CVCL_B7P8 SK-BR-3/PacR cancer cell line human CVCL_B7P8 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Miscellaneous: Cell line no longer available (personal communication of Daniel P.) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female 152996126 CVCL_B7EF Mel JuSo ABCB5 KO clone HO1 cancer cell line human CVCL_B7EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 152996127 CVCL_B7EE NHKT finite cell line human CVCL_B7EE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 152996128 CVCL_B7EH Mel JuSo ABCB5 KO clone HO3 cancer cell line human CVCL_B7EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 152996129 CVCL_B7EG Mel JuSo ABCB5 KO clone HO2 cancer cell line human CVCL_B7EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 152996130 CVCL_B7EJ hTERT-DMECN telomerase immortalized cell line human CVCL_B7EJ CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; dermis; microvascular endothelium Cell type=Microvascular endothelial cell.. Male Doubling time: ~56 hours (ATCC=CRL-4060) 152996131 CVCL_B7EI Mel JuSo ABCB5 KO clone HO4 cancer cell line human CVCL_B7EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 152996132 CVCL_B7EL hTERT-NDM telomerase immortalized cell line human CVCL_B7EL CL:0000010 Transfected with: HGNC; 11730; TERT Population: Asian; Derived from sampling site: Skin; dermis Cell type=Melanocyte.. Male Doubling time: ~123 hours (ATCC=CRL-4064) 152996133 CVCL_B7EK hTERT-GF telomerase immortalized cell line human CVCL_B7EK CL:0000010 Transfected with: HGNC; 11730; TERT Karyotypic information: 46,XX,del(16)(q10) [17]; 46,XX [1] (ATCC); Derived from sampling site: Oral cavity; gingiva. Female Doubling time: 22-25 hours (ATCC=CRL-4061) 152996134 CVCL_B7EB SIAISi020-A induced pluripotent stem cell human CVCL_B7EB From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=35853414) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996135 CVCL_B7EA SIAISi019-A induced pluripotent stem cell human CVCL_B7EA From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=35853414) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996136 CVCL_B7ED A6/C1 spontaneously immortalized cell line African clawed frog CVCL_B7ED CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male Characteristics: Selected for its high transepithelial resistance and for its responsiveness to aldosterone and antidiuretic hormone (PubMed=8392584) Group: Amphibian cell line 152996137 CVCL_B7EC SJTUi003-A induced pluripotent stem cell human CVCL_B7EC From: Shanghai Jiao Tong University School of Medicine; Shanghai; China. CL:0000010 152996138 CVCL_B7DU HCEnC-21 finite cell line human CVCL_B7DU CL:0000010 Derived from sampling site: Eye; cornea; endothelium. Male 152996139 CVCL_B7E6 MUi021-A induced pluripotent stem cell human CVCL_B7E6 From: Mahidol University; Bangkok; Thailand. CL:0000010 152996140 CVCL_B7DT HeLa SMOC1 KO cancer cell line human CVCL_B7DT From: Durcan T.M.; Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20318; SMOC1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152996141 CVCL_B7E5 MUi020-A induced pluripotent stem cell human CVCL_B7E5 From: Mahidol University; Bangkok; Thailand. CL:0000010 152996142 CVCL_B7DW iPSC-hDPSC induced pluripotent stem cell human CVCL_B7DW CL:0000010 Population: Caucasian; Derived from sampling site: Tooth; molar; dental pulp. Unspecified 152996143 CVCL_B7E8 MUi034-A induced pluripotent stem cell human CVCL_B7E8 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Simple; p.Ter143Glnext*32 (c.427T>C); ClinVar=VCV000015624; Zygosity=Homozygous; Note=Hb Constant Spring (PubMed=36427475) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 152996144 CVCL_B7DV hTERT EP153T telomerase immortalized cell line human CVCL_B7DV CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 152996145 CVCL_B7E7 MUi033-A induced pluripotent stem cell human CVCL_B7E7 From: Mahidol University; Bangkok; Thailand. CL:0000010 152996146 CVCL_B7DY SCVIi031-A induced pluripotent stem cell human CVCL_B7DY From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35700631) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152996147 CVCL_B7E9 NYSCF-AG0002-01-MR induced pluripotent stem cell human CVCL_B7E9 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.His361Tyr (c.1081C>T); ClinVar=VCV000637315; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 152996148 CVCL_B7DX Vero-CDM spontaneously immortalized cell line green monkey CVCL_B7DX CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to the serum free, chemically-defined culture medium SciN4Vero (CLS) Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 152996149 CVCL_B7DZ SCVIi030-A induced pluripotent stem cell human CVCL_B7DZ From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35700631) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152996150 CVCL_B7DM CPGHi001-A-1 induced pluripotent stem cell human CVCL_B7DM From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 16513; TMC1; Simple_corrected; p.Met418Lys (c.1253T>A); ClinVar=VCV000183668; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35247837) Population: Chinese; Han; Derived from sampling site: Urine. Male 152996151 CVCL_B7DL CIBi011-A induced pluripotent stem cell human CVCL_B7DL From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female 152996152 CVCL_B7E0 BBANTWi008-A induced pluripotent stem cell human CVCL_B7E0 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Arg287Gln (c.860G>A); ClinVar=VCV000180524; Zygosity=Heterozygous (PubMed=36219981) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 152996153 CVCL_B7DN CPGHi007-A induced pluripotent stem cell human CVCL_B7DN From: Chinese PLA General Hospital; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996154 CVCL_B7DQ CAPF 1 finite cell line dog CVCL_B7DQ CL:0000010 Derived from sampling site: Prostate Cell type=Fibroblast.; Breed/subspecies: Mixed breed. Male 152996155 CVCL_B7E2 SMBCi014-A induced pluripotent stem cell human CVCL_B7E2 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Pro817Leufs*291 (c.2450delC); ClinVar=VCV000035912; Zygosity=Heterozygous (PubMed=35660813) Derived from sampling site: Urine. Female 152996156 CVCL_B7DP CPGHi008-A induced pluripotent stem cell human CVCL_B7DP From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Leu2665Pro (c.7994T>C); Zygosity=Homozygous (PubMed=35405383) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996157 CVCL_B7E1 FMUPDCi001-A induced pluripotent stem cell human CVCL_B7E1 From: Fetal Medicine unit and Prenatal Diagnosis Center, Shanghai 1st Maternity and Infant Hospital of Tongji University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 25151; ADAT3; Simple; p.Arg58Thrfs (c.171dupA) (p.Arg74Thrfs, c.219dupA); dbSNP=rs1267546394; Zygosity=Heterozygous (PubMed=35405382); Sequence variation: Mutation; HGNC; 25151; ADAT3; Simple; p.Ala180Val (c.539C>T) (p.Ala196Val, c.587C>T); Zygosity=Heterozygous (PubMed=35405382) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996158 CVCL_B7DS Kodiak2016 cancer cell line dog CVCL_B7DS CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Siberian Husky. Omics: Genome sequenced Male 152996159 CVCL_B7E4 MUi032-A induced pluripotent stem cell human CVCL_B7E4 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; CHM p.Arg293Ter (c.877C>T); ClinVar=VCV000011154; Zygosity=Hemizygous (PubMed=36395688) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Male 152996160 CVCL_B7DR CAPF 3 finite cell line dog CVCL_B7DR CL:0000010 Derived from sampling site: Prostate Cell type=Fibroblast.; Breed/subspecies: Mixed breed. Male 152996161 CVCL_B7E3 HEBHMUi012-A induced pluripotent stem cell human CVCL_B7E3 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=35717858) Derived from sampling site: Peripheral blood. Male 152996162 CVCL_B7FG B-LCL-HROC130 transformed cell line human CVCL_B7FG HLA typing: A*01:01:01,02:01:01; B*07:02:01; C*07:02:01; DPB1*04:01:01G,04:02:01G; DQB1*03:01:01,06:02:01; DRB1*12:01:01,15:01:01 (CLS=302032) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152996163 CVCL_B7FF B-LCL-HROC118 transformed cell line human CVCL_B7FF HLA typing: A*01:01:01,23:01:01; B*49:01:01,57:01:01; C*06:02:01,07:01:01; DPB1*02:01:02,03:01:01; DQB1*05:01:01,06:02:01; DRB1*01:01:01,15:01:01 (CLS=302025) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: CLS; 302025; true Female 152996164 CVCL_B7FI U-2 OS-CRISPR-NUP96-Halo clone no.252 cancer cell line human CVCL_B7FI CL:0000010 Transfected with: UniProtKB; P0A3G2; Rhodococcus rhodochrous dhaA (mutated = Halo-Tag) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Using CRISPR/Cas9D10A NUP96 has been endogenously tagged in both alleles at the C-terminus with a Halo-Tag (PubMed=31562488) 152996165 CVCL_B7FH B-LCL-PB16 transformed cell line human CVCL_B7FH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152996166 CVCL_B7FK U-2 OS-CRISPR-NUP96-mMaple clone no.16 cancer cell line human CVCL_B7FK CL:0000010 Transfected with: UniProtKB; Q9U6Y3; GFP-like fluorescent chromoprotein cFP484 (with many modification leading to the photoconvertible protein mMaple) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Using CRISPR/Cas9D10A NUP96 has been endogenously tagged in both alleles at the C-terminus with mMaple (PubMed=31562488) 152996167 CVCL_B7FJ U-2 OS-CRISPR-NUP96-mEGFP clone no.195 cancer cell line human CVCL_B7FJ CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Using CRISPR/Cas9D10A NUP96 has been endogenously tagged in both alleles at the C-terminus with mEGFP (PubMed=31562488) 152996168 CVCL_B7FM U-2 OS-ZFN-SNAP-Nup107 no.294 cancer cell line human CVCL_B7FM CL:0000010 Transfected with: HGNC; 7059; MGMT (with p.Gly180_Asn_207del and 19 mutations = SNAP-tag) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Using ZFN NUP107 has been endogenously tagged in both alleles at the N-terminus with a SNAP-tag (PubMed=29630062) 152996169 CVCL_B7FL U-2 OS-CRISPR-NUP96-SNAP clone #33 cancer cell line human CVCL_B7FL CL:0000010 Transfected with: HGNC; 7059; MGMT (with p.Gly180_Asn_207del and 19 mutations = SNAP-tag) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Using CRISPR/Cas9D10A NUP96 has been endogenously tagged in both alleles at the C-terminus with a SNAP-tag (PubMed=31562488) 152996170 CVCL_B7FA HVEM 18.10 hybridoma house mouse CVCL_B7FA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q92956; Human TNFRSF14/CD270. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4752 152996171 CVCL_B7FC B-LCL-HROC195 transformed cell line human CVCL_B7FC From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152996172 CVCL_B7FB HVEM 11.8 hybridoma house mouse CVCL_B7FB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q92956; Human TNFRSF14/CD270. 152996173 CVCL_B7FE B-LCL-HROC103 transformed cell line human CVCL_B7FE HLA typing: A*01:01:01,02:01:01; B*07:02:01,13:02:01; C*06:02:01,07:02:01; DPB1*04:01:01,13:01:01G; DQB1*02:02:01,06:02:01; DRB1*07:01:01,15:01:01 (CLS=302020) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152996174 CVCL_B7FD B-LCL-HROC06 transformed cell line human CVCL_B7FD From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152996175 CVCL_B7F7 MM.1S-luc cancer cell line human CVCL_B7F7 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression = effLuc) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgA lambda 152996176 CVCL_B7EV RP.0.03 finite cell line house mouse CVCL_B7EV CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6. Unspecified 152996177 CVCL_B7EU AMUFAHi003-A induced pluripotent stem cell human CVCL_B7EU From: The First Affiliated Hospital of Anhui Medical University; Anhui; China CL:0000010 Sequence variation: Mutation; HGNC; 33630; PATL2; Simple; c.223-14_223-2delCCCTCCTGTTCCA; ClinVar=VCV000444049; Zygosity=Heterozygous (PubMed=35397397) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996178 CVCL_B7F6 F3-effLuc transformed cell line human CVCL_B7F6 CL:0000010 Transfected with: MGI; MGI:98747; Thy1 (with p.Gln108Arg = Thy1.1); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression = effLuc) Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Female Characteristics: Transduced with a CMV promoter controlled effLuc-IRES-Thy1.1 construct (PubMed=25198726) 152996179 CVCL_B7F9 PD-L1.3 hybridoma house mouse CVCL_B7F9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZQ7; Human CD274. 152996180 CVCL_B7EX RP.0.10 finite cell line house mouse CVCL_B7EX CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6. Unspecified 152996181 CVCL_B7F8 PD-L2.1 hybridoma house mouse CVCL_B7F8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BQ51; Human PDCD1LG2/CD273. 152996182 CVCL_B7EW RP.0.07 finite cell line house mouse CVCL_B7EW CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6. Unspecified 152996183 CVCL_B7EZ UNIBSi017-A induced pluripotent stem cell human CVCL_B7EZ From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6859; MAP3K7; Simple; p.Asn245_Gly246insValVal (c.737-7A>G) (IVS7AS,A-G,-7); ClinVar=VCV000974910; Zygosity=Heterozygous (PubMed=35700636) Population: Caucasian; Karyotypic information: 45,XX,rob(13;14)(q10;q10) (PubMed=35700636); Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 152996184 CVCL_B7EY RP.0.16 finite cell line house mouse CVCL_B7EY CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6. Unspecified 152996185 CVCL_B7EN TFA1.4 induced pluripotent stem cell human CVCL_B7EN CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=28132834) Derived from sampling site: Cell type=Fibroblast. Female 152996186 CVCL_B7EM NCC-DDLPS5-C1 cancer cell line human CVCL_B7EM CL:0000010 Population: Japanese; Derived from sampling site: Inguinal fat pad. Omics: SNP array analysis Male Doubling time: 47 hours (PubMed=35292923) Part of: NCC sarcoma cell line panel 152996187 CVCL_B7F1 BTLA6.4 hybridoma house mouse CVCL_B7F1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA/CD272. 152996188 CVCL_B7EP TDA2.3 induced pluripotent stem cell human CVCL_B7EP CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=28132834) Derived from sampling site: Cell type=Fibroblast. Female 152996189 CVCL_B7F0 PD-1.6 hybridoma house mouse CVCL_B7F0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. 152996190 CVCL_B7F3 BTLA8.2 hybridoma house mouse CVCL_B7F3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA/CD272. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4123 152996191 CVCL_B7ER TDA3.1 induced pluripotent stem cell human CVCL_B7ER CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=28132834) Derived from sampling site: Cell type=Fibroblast. Female 152996192 CVCL_B7F2 BTLA7.1 hybridoma house mouse CVCL_B7F2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA/CD272. 152996193 CVCL_B7EQ TFA2 induced pluripotent stem cell human CVCL_B7EQ CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=28132834) Derived from sampling site: Cell type=Fibroblast. Female 152996194 CVCL_B7ET AMUFAHi002-A induced pluripotent stem cell human CVCL_B7ET From: The First Affiliated Hospital of Anhui Medical University; Anhui; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152996195 CVCL_B7F5 ANBL-6-luc cancer cell line human CVCL_B7F5 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression = effLuc) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 152996196 CVCL_B7ES BRCi021-A induced pluripotent stem cell human CVCL_B7ES CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Tyr267Ter (c.801T>A); Zygosity=Heterozygous (PubMed=35500377) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152996197 CVCL_B7F4 HVEM8.5 hybridoma house mouse CVCL_B7F4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92956; Human TNFRSF14/CD270. 152996198 CVCL_B7CD SG237S finite cell line human CVCL_B7CD CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Female Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 78 PDL (PubMed=1693627). 152996199 CVCL_B7CC SG237R finite cell line human CVCL_B7CC CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; duct. Female Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 38 PDL (PubMed=1693627). 152996200 CVCL_B7CF NP24(CF) finite cell line human CVCL_B7CF CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Nose; nasal cavity (Note=From a polyp) Cell type=Epithelial cell.. Male Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 16 PDL (PubMed=1693627). 152996201 CVCL_B7CE NP23(CF) finite cell line human CVCL_B7CE CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Nose; nasal cavity (Note=From a polyp) Cell type=Epithelial cell.. Male Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 20 PDL (PubMed=1693627). 152996202 CVCL_B7CH VRISGi002-A induced pluripotent stem cell human CVCL_B7CH From: Vinmec Research Insitute of Stem Cell and Gene Technology; Hanoi; Vietnam CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Peripheral blood. Female 152996203 CVCL_B7CG NP34 transformed cell line human CVCL_B7CG CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Nose; nasal cavity (Note=From a polyp) Cell type=Epithelial cell.. Male Senescence: May have a finite life span; not cultured over 48 PDL (PubMed=1693627) 152996204 CVCL_B7CJ 10B5.B4 hybridoma house mouse CVCL_B7CJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O24566; Maize 3-phosphoshikimate 1-carboxyvinyltransferase (with p.Thr102Ile and p.Pro106Ser). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8900 152996205 CVCL_B7CI UMi040-A induced pluripotent stem cell human CVCL_B7CI From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 28472; TMEM43; Simple; p.Arg372Ter (c.1114C>T); ClinVar=VCV000403555; Zygosity=Heterozygous (PubMed=35364395) Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152996206 CVCL_B7BZ EC23 clone 3 transformed cell line human CVCL_B7BZ CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996207 CVCL_B7CB SG224(CF)S transformed cell line human CVCL_B7CB CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Male Characteristics: Seems to be immortalized (PubMed=1693627) 152996208 CVCL_B7CA SG223(CF)S finite cell line human CVCL_B7CA CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Male Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 67 PDL (PubMed=1693627). 152996209 CVCL_B7C4 EC23 clone 9 transformed cell line human CVCL_B7C4 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996210 CVCL_B7BS HIHCNi006-A-2 induced pluripotent stem cell human CVCL_B7BS From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11233; SPAST Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 152996211 CVCL_B7C3 EC23 clone 8 transformed cell line human CVCL_B7C3 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996212 CVCL_B7BR HIHCNi006-A-1 induced pluripotent stem cell human CVCL_B7BR From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 allelles); HGNC; 11233; SPAST Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 152996213 CVCL_B7C6 SG141R finite cell line human CVCL_B7C6 CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; duct. Female Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 62 PDL (PubMed=1693627). 152996214 CVCL_B7BU SGDC-1D10 transformed cell line human CVCL_B7BU CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; eccrine sweat gland; duct. Unspecified Doubling time: 30-35 hours (PubMed=35262932) 152996215 CVCL_B7BT JLUe003-A embryonic stem cell human CVCL_B7BT From: Jilin University; Changchun; China CL:0000010 Male Characteristics: Using CRISPR/Cas9 two FLAG tags were introduced at the C-terminus of one allelle of GFI1 (PubMed=35248880). 152996216 CVCL_B7C5 SG87 finite cell line human CVCL_B7C5 CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland. Female Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 63 PDL (PubMed=1693627). 152996217 CVCL_B7BW EC23 transformed cell line human CVCL_B7BW CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996218 CVCL_B7C8 SG146S finite cell line human CVCL_B7C8 CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Female Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 74 PDL (PubMed=1693627). 152996219 CVCL_B7BV NCL-SG3 transformed cell line human CVCL_B7BV CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Male Doubling time: ~70 hours, in serum-free medium (PubMed=2777923) 152996220 CVCL_B7C7 SG143(CF)R finite cell line human CVCL_B7C7 CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; duct. Male Senescence: Ad-5-SV40 transformed but with a finite life span Senesces after 59 PDL (PubMed=1693627). 152996221 CVCL_B7BY EC23 clone 2 transformed cell line human CVCL_B7BY CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996222 CVCL_B7BX EC23 clone 1 transformed cell line human CVCL_B7BX CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996223 CVCL_B7C9 SG209(CF)S transformed cell line human CVCL_B7C9 CL:0000010 Transformant: Ad5-SV40 hybrid virus [1613 ori-]; Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Female Characteristics: Seems to be immortalized (PubMed=1693627) 152996224 CVCL_B7BM NCC-PMP1-C1 cancer cell line human CVCL_B7BM CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=35207746) Population: Japanese; Derived from metastatic site: Right thigh. Omics: SNP array analysis Male Doubling time: ~147 hours (PubMed=35207746) 152996225 CVCL_B7C0 EC23 clone 4 transformed cell line human CVCL_B7C0 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996226 CVCL_B7BN SuSa-CP cancer cell line human CVCL_B7BN CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Testis. Male Doubling time: 29.8 +- 0.8 hours (PubMed=2144165) 152996227 CVCL_B7C2 EC23 clone 7 transformed cell line human CVCL_B7C2 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996228 CVCL_B7BQ HIHCNi006-A induced pluripotent stem cell human CVCL_B7BQ From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 152996229 CVCL_B7C1 EC23 clone 5 transformed cell line human CVCL_B7C1 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; eccrine sweat gland; secretory coil. Unspecified 152996230 CVCL_B7BP RT112-CP cancer cell line human CVCL_B7BP CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female Doubling time: 21.5 +- 1.5 hours (PubMed=2144165) 152996231 CVCL_B7DE 1274A15 induced pluripotent stem cell human CVCL_B7DE From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996232 CVCL_B7DD PD17-7 induced pluripotent stem cell human CVCL_B7DD From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. 152996233 CVCL_B7DG 1275A2 induced pluripotent stem cell human CVCL_B7DG From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996234 CVCL_B7DF 1274A8 induced pluripotent stem cell human CVCL_B7DF From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996235 CVCL_B7DI 783E2 induced pluripotent stem cell human CVCL_B7DI From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996236 CVCL_B7DH 1275A3 induced pluripotent stem cell human CVCL_B7DH From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996237 CVCL_B7DK PD12-1 induced pluripotent stem cell human CVCL_B7DK From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152996238 CVCL_B7DJ N112-4 induced pluripotent stem cell human CVCL_B7DJ From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. 152996239 CVCL_B7DA N117-11 induced pluripotent stem cell human CVCL_B7DA From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152996240 CVCL_B7DC 1263A18 induced pluripotent stem cell human CVCL_B7DC From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 152996241 CVCL_B7DB N117-8 induced pluripotent stem cell human CVCL_B7DB From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152996242 CVCL_B7CT Panc.1.5C10.5D11 hybridoma house mouse CVCL_B7CT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4244 152996243 CVCL_B7CS BLA.3.3B6.3D4 hybridoma house mouse CVCL_B7CS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4218 152996244 CVCL_B7D4 DCR-2 hybridoma house mouse CVCL_B7D4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8TDQ1; Human CD300LF/CD300f. Group: Patented cell line; Registration: International Depositary Authority, Cell Bank Australia; CBA20160029 152996245 CVCL_B7CV GT512muMAB 55A hybridoma house mouse CVCL_B7CV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3089 152996246 CVCL_B7D7 HC-04.J7 cancer cell line human CVCL_B7D7 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Compared to the parent cell line, has an inscreased susceptibility to Plasmodium falciparum sporozoite invasion (PubMed=30891005) Problematic cell line: Possibly contaminated Parent cell line (HC-04) has been shown to have an STR profile identical to that of Hep-G2. 152996247 CVCL_B7D6 4Z-B-1 cancer cell line human CVCL_B7D6 CL:0000010 Population: Chinese; Karyotypic information: Nearly triploid (PubMed=34141711); Derived from metastatic site: Pleural effusion. Female Characteristics: ER-negative, PR-negative and ERBB2-positive (PubMed=34141711) Doubling time: 40 hours (PubMed=34141711) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202123 152996248 CVCL_B7CU Skin.2.6A2.1A8 hybridoma house mouse CVCL_B7CU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4245 152996249 CVCL_B7D9 1147F1 induced pluripotent stem cell human CVCL_B7D9 CL:0000010 Derived from sampling site: Peripheral blood. Male 152996250 CVCL_B7CX GT512muMAB 60A hybridoma house mouse CVCL_B7CX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3068 152996251 CVCL_B7CW GT512muMAB 59A hybridoma house mouse CVCL_B7CW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3067 152996252 CVCL_B7D8 NDC hybrid cell line CVCL_B7D8 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 152996253 CVCL_B7CZ GT512muMAB 64A hybridoma house mouse CVCL_B7CZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3070 152996254 CVCL_B7CY GT512muMAB 61D hybridoma house mouse CVCL_B7CY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3069 152996255 CVCL_B7CL 12H1.B1 hybridoma house mouse CVCL_B7CL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O24566; Maize 3-phosphoshikimate 1-carboxyvinyltransferase (with p.Thr102Ile and p.Pro106Ser). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8902 152996256 CVCL_B7CK 10B9.E8 hybridoma house mouse CVCL_B7CK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O24566; Maize 3-phosphoshikimate 1-carboxyvinyltransferase (with p.Thr102Ile and p.Pro106Ser). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8901 152996257 CVCL_B7CN 1C5 [Mouse hybridoma against Pseudomonas P.J. 874 hpd] hybridoma house mouse CVCL_B7CN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80064; Pseudomonas sp (strain P.J. 874) 4-hydroxyphenylpyruvate dioxygenase (hpd) (with p.Gly335Trp).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10312 152996258 CVCL_B7CM 5E11.E11 hybridoma house mouse CVCL_B7CM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O24566; Maize 3-phosphoshikimate 1-carboxyvinyltransferase (with p.Thr102Ile and p.Pro106Ser). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8903 152996259 CVCL_B7CP 2E6 [Mouse hybridoma against Pseudomonas P.J. 874 hpd] hybridoma house mouse CVCL_B7CP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80064; Pseudomonas sp (strain P.J. 874) 4-hydroxyphenylpyruvate dioxygenase (hpd) (with p.Gly335Trp).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10313 152996260 CVCL_B7D1 GT512muMAB 66B hybridoma house mouse CVCL_B7D1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3072 152996261 CVCL_B7D0 GT512muMAB 65A hybridoma house mouse CVCL_B7D0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3071 152996262 CVCL_B7CR CA130.1.4C3.1H4 hybridoma house mouse CVCL_B7CR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4217 152996263 CVCL_B7D3 GT512muMAB 89A hybridoma house mouse CVCL_B7D3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3090 152996264 CVCL_B7CQ 6H11 hybridoma house mouse CVCL_B7CQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80064; Pseudomonas sp (strain P.J. 874) 4-hydroxyphenylpyruvate dioxygenase (hpd) (with p.Gly335Trp).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10314 152996265 CVCL_B7D2 GT512muMAB 67A hybridoma house mouse CVCL_B7D2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P56747; Human CLDN6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3073 152996266 CVCL_B8P0 Abcam HCT 116 RSF1 KO cancer cell line human CVCL_B8P0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18118; RSF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996267 CVCL_B8P2 Abcam HCT 116 RUNX1 KO cancer cell line human CVCL_B8P2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10471; RUNX1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996268 CVCL_B8P1 Abcam HCT 116 RSPO2 KO cancer cell line human CVCL_B8P1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28583; RSPO2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996269 CVCL_B8P4 Abcam HCT 116 S100A8 KO cancer cell line human CVCL_B8P4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10498; S100A8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996270 CVCL_B8P3 Abcam HCT 116 RUNX3 KO cancer cell line human CVCL_B8P3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10473; RUNX3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996271 CVCL_B8P6 Abcam HCT 116 SEMA4D KO cancer cell line human CVCL_B8P6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10732; SEMA4D; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996272 CVCL_B8P5 Abcam HCT 116 SALL4 KO cancer cell line human CVCL_B8P5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15924; SALL4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996273 CVCL_B8NV Abcam HCT 116 RNF2 KO cancer cell line human CVCL_B8NV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996274 CVCL_B8NU Abcam HCT 116 RICTOR KO cancer cell line human CVCL_B8NU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28611; RICTOR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996275 CVCL_B8NX Abcam HCT 116 ROS1 KO cancer cell line human CVCL_B8NX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10261; ROS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996276 CVCL_B8NW Abcam HCT 116 RORC KO cancer cell line human CVCL_B8NW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10260; RORC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996277 CVCL_B8NZ Abcam HCT 116 RPS6KA3 KO cancer cell line human CVCL_B8NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10432; RPS6KA3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996278 CVCL_B8NY Abcam HCT 116 RPS6KA1 KO cancer cell line human CVCL_B8NY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10430; RPS6KA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996279 CVCL_B8PP Abcam HCT 116 SMARCA4 KO cancer cell line human CVCL_B8PP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996280 CVCL_B8Q1 Abcam HCT 116 SP1 KO cancer cell line human CVCL_B8Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11205; SP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996281 CVCL_B8Q0 Abcam HCT 116 SOX6 KO cancer cell line human CVCL_B8Q0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16421; SOX6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996282 CVCL_B8PR Abcam HCT 116 SMARCD3 KO cancer cell line human CVCL_B8PR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11108; SMARCD3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996283 CVCL_B8Q3 Abcam HCT 116 SPN KO cancer cell line human CVCL_B8Q3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11249; SPN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996284 CVCL_B8PQ Abcam HCT 116 SMARCC1 KO cancer cell line human CVCL_B8PQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996285 CVCL_B8Q2 Abcam HCT 116 SPI1 KO cancer cell line human CVCL_B8Q2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11241; SPI1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996286 CVCL_B8PT Abcam HCT 116 SNAI1 KO cancer cell line human CVCL_B8PT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11128; SNAI1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996287 CVCL_B8Q5 Abcam HCT 116 SRC KO cancer cell line human CVCL_B8Q5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996288 CVCL_B8PS Abcam HCT 116 SMO KO cancer cell line human CVCL_B8PS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996289 CVCL_B8Q4 Abcam HCT 116 SPP1 KO cancer cell line human CVCL_B8Q4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996290 CVCL_B8PV Abcam HCT 116 SOS1 KO cancer cell line human CVCL_B8PV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11187; SOS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996291 CVCL_B8Q7 Abcam HCT 116 SREBF2 KO cancer cell line human CVCL_B8Q7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996292 CVCL_B8PU Abcam HCT 116 SNAI2 KO cancer cell line human CVCL_B8PU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11094; SNAI2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996293 CVCL_B8Q6 Abcam HCT 116 SREBF1 KO cancer cell line human CVCL_B8Q6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11289; SREBF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996294 CVCL_B8PH Abcam HCT 116 SIRT7 KO cancer cell line human CVCL_B8PH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14935; SIRT7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996295 CVCL_B8PG Abcam HCT 116 SIRT6 KO cancer cell line human CVCL_B8PG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14934; SIRT6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996296 CVCL_B8PJ Abcam HCT 116 SMAD2 KO cancer cell line human CVCL_B8PJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6768; SMAD2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996297 CVCL_B8PI Abcam HCT 116 SLAMF1 KO cancer cell line human CVCL_B8PI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10903; SLAMF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996298 CVCL_B8PL Abcam HCT 116 SMAD4 KO cancer cell line human CVCL_B8PL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996299 CVCL_B8PK Abcam HCT 116 SMAD3 KO cancer cell line human CVCL_B8PK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6769; SMAD3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996300 CVCL_B8PN Abcam HCT 116 SMARCA1 KO cancer cell line human CVCL_B8PN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11097; SMARCA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996301 CVCL_B8PM Abcam HCT 116 SMAD7 KO cancer cell line human CVCL_B8PM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6773; SMAD7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996302 CVCL_B8PB Abcam HCT 116 SIRPA KO cancer cell line human CVCL_B8PB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9662; SIRPA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996303 CVCL_B8PA Abcam HCT 116 SETD7 KO cancer cell line human CVCL_B8PA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30412; SETD7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996304 CVCL_B8PD Abcam HCT 116 SIRT2 KO cancer cell line human CVCL_B8PD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10886; SIRT2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996305 CVCL_B8PC Abcam HCT 116 SIRT1 KO cancer cell line human CVCL_B8PC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996306 CVCL_B8PF Abcam HCT 116 SIRT4 KO cancer cell line human CVCL_B8PF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14932; SIRT4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996307 CVCL_B8PE Abcam HCT 116 SIRT3 KO cancer cell line human CVCL_B8PE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14931; SIRT3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996308 CVCL_B8P8 Abcam HCT 116 SENP1 KO cancer cell line human CVCL_B8P8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17927; SENP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996309 CVCL_B8P7 Abcam HCT 116 SEMA7A KO cancer cell line human CVCL_B8P7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10741; SEMA7A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996310 CVCL_B8P9 Abcam HCT 116 SERPINE1 KO cancer cell line human CVCL_B8P9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8583; SERPINE1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996311 CVCL_B8MM Abcam HCT 116 PIWIL4 KO cancer cell line human CVCL_B8MM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18444; PIWIL4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996312 CVCL_B8ML Abcam HCT 116 PIK3R2 KO cancer cell line human CVCL_B8ML CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996313 CVCL_B8N0 Abcam HCT 116 PRF1 KO cancer cell line human CVCL_B8N0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9360; PRF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996314 CVCL_B8MN Abcam HCT 116 PMEL KO cancer cell line human CVCL_B8MN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10880; PMEL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996315 CVCL_B8MQ Abcam HCT 116 PMS2 KO cancer cell line human CVCL_B8MQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9122; PMS2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996316 CVCL_B8N2 Abcam HCT 116 PRKAA2 KO cancer cell line human CVCL_B8N2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9377; PRKAA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996317 CVCL_B8MP Abcam HCT 116 PML KO cancer cell line human CVCL_B8MP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996318 CVCL_B8N1 Abcam HCT 116 PRKAA1 KO cancer cell line human CVCL_B8N1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9376; PRKAA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996319 CVCL_B8MS Abcam HCT 116 POLR2A KO cancer cell line human CVCL_B8MS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9187; POLR2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996320 CVCL_B8N4 Abcam HCT 116 PRKCA KO cancer cell line human CVCL_B8N4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9393; PRKCA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996321 CVCL_B8MR Abcam HCT 116 POLQ KO cancer cell line human CVCL_B8MR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9186; POLQ; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996322 CVCL_B8N3 Abcam HCT 116 PRKAR1A KO cancer cell line human CVCL_B8N3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9388; PRKAR1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996323 CVCL_B8ME Abcam HCT 116 PECAM1 KO cancer cell line human CVCL_B8ME CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8823; PECAM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996324 CVCL_B8MD Abcam HCT 116 PEBP1 KO cancer cell line human CVCL_B8MD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8630; PEBP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996325 CVCL_B8MG Abcam HCT 116 PGF KO cancer cell line human CVCL_B8MG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8893; PGF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996326 CVCL_B8MF Abcam HCT 116 PER1 KO cancer cell line human CVCL_B8MF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8845; PER1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996327 CVCL_B8MI Abcam HCT 116 PHF1 KO cancer cell line human CVCL_B8MI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8919; PHF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996328 CVCL_B8MH Abcam HCT 116 PGR KO cancer cell line human CVCL_B8MH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8910; PGR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996329 CVCL_B8MK Abcam HCT 116 PIK3R1 KO cancer cell line human CVCL_B8MK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996330 CVCL_B8MJ Abcam HCT 116 PHLPP1 KO cancer cell line human CVCL_B8MJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20610; PHLPP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996331 CVCL_B8MA Abcam HCT 116 PDGFRB KO cancer cell line human CVCL_B8MA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8804; PDGFRB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996332 CVCL_B8MC Abcam HCT 116 PDPN KO cancer cell line human CVCL_B8MC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996333 CVCL_B8MB Abcam HCT 116 PDPK1 KO cancer cell line human CVCL_B8MB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8816; PDPK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996334 CVCL_B8LT Abcam HCT 116 OLIG2 KO cancer cell line human CVCL_B8LT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9398; OLIG2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996335 CVCL_B8M5 Abcam HCT 116 PBK KO cancer cell line human CVCL_B8M5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996336 CVCL_B8LS Abcam HCT 116 NTRK3 KO cancer cell line human CVCL_B8LS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8033; NTRK3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996337 CVCL_B8M4 Abcam HCT 116 PAX8 KO cancer cell line human CVCL_B8M4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8622; PAX8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996338 CVCL_B8LV Abcam HCT 116 PADI4 KO cancer cell line human CVCL_B8LV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18368; PADI4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996339 CVCL_B8M7 Abcam HCT 116 PDCD1 KO cancer cell line human CVCL_B8M7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8760; PDCD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996340 CVCL_B8LU Abcam HCT 116 OPRM1 KO cancer cell line human CVCL_B8LU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8156; OPRM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996341 CVCL_B8M6 Abcam HCT 116 PBRM1 KO cancer cell line human CVCL_B8M6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996342 CVCL_B8LX Abcam HCT 116 PAK2 KO cancer cell line human CVCL_B8LX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996343 CVCL_B8M9 Abcam HCT 116 PDGFRA KO cancer cell line human CVCL_B8M9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996344 CVCL_B8LW Abcam HCT 116 PAK1 KO cancer cell line human CVCL_B8LW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996345 CVCL_B8M8 Abcam HCT 116 PDGFB KO cancer cell line human CVCL_B8M8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8800; PDGFB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996346 CVCL_B8LZ Abcam HCT 116 PALB2 KO cancer cell line human CVCL_B8LZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26144; PALB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996347 CVCL_B8LY Abcam HCT 116 PAK4 KO cancer cell line human CVCL_B8LY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996348 CVCL_B8NN Abcam HCT 116 RARB KO cancer cell line human CVCL_B8NN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9865; RARB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996349 CVCL_B8NM Abcam HCT 116 RAF1 KO cancer cell line human CVCL_B8NM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996350 CVCL_B8NP Abcam HCT 116 RB1 KO cancer cell line human CVCL_B8NP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996351 CVCL_B8NR Abcam HCT 116 RELA KO cancer cell line human CVCL_B8NR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996352 CVCL_B8NQ Abcam HCT 116 REL KO cancer cell line human CVCL_B8NQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9954; REL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996353 CVCL_B8NT Abcam HCT 116 RET KO cancer cell line human CVCL_B8NT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996354 CVCL_B8NS Abcam HCT 116 REST KO cancer cell line human CVCL_B8NS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996355 CVCL_B8NF Abcam HCT 116 PTPN1 KO cancer cell line human CVCL_B8NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9642; PTPN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996356 CVCL_B8NE Abcam HCT 116 PTN KO cancer cell line human CVCL_B8NE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9630; PTN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996357 CVCL_B8NH Abcam HCT 116 PTPN2 KO cancer cell line human CVCL_B8NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9650; PTPN2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996358 CVCL_B8NG Abcam HCT 116 PTPN11 KO cancer cell line human CVCL_B8NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9644; PTPN11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996359 CVCL_B8NJ Abcam HCT 116 RAD50 KO cancer cell line human CVCL_B8NJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9816; RAD50; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996360 CVCL_B8NI Abcam HCT 116 PTPN6 KO cancer cell line human CVCL_B8NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9658; PTPN6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996361 CVCL_B8NL Abcam HCT 116 RAET1E KO cancer cell line human CVCL_B8NL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16793; RAET1E; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996362 CVCL_B8NK Abcam HCT 116 RAD51D KO cancer cell line human CVCL_B8NK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996363 CVCL_B8NB Abcam HCT 116 PTEN KO cancer cell line human CVCL_B8NB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996364 CVCL_B8NA Abcam HCT 116 PTCH2 KO cancer cell line human CVCL_B8NA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9586; PTCH2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996365 CVCL_B8ND Abcam HCT 116 PTK6 KO cancer cell line human CVCL_B8ND CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9617; PTK6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996366 CVCL_B8NC Abcam HCT 116 PTGS1 KO cancer cell line human CVCL_B8NC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9604; PTGS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996367 CVCL_B8MU Abcam HCT 116 POU5F1 KO cancer cell line human CVCL_B8MU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9221; POU5F1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996368 CVCL_B8N6 Abcam HCT 116 PROCR KO cancer cell line human CVCL_B8N6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9452; PROCR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996369 CVCL_B8MT Abcam HCT 116 POU2F2 KO cancer cell line human CVCL_B8MT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9213; POU2F2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996370 CVCL_B8N5 Abcam HCT 116 PRKCB KO cancer cell line human CVCL_B8N5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9395; PRKCB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996371 CVCL_B8MW Abcam HCT 116 PPARD KO cancer cell line human CVCL_B8MW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9235; PPARD; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996372 CVCL_B8N8 Abcam HCT 116 PROX1 KO cancer cell line human CVCL_B8N8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9459; PROX1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996373 CVCL_B8MV Abcam HCT 116 PPARA KO cancer cell line human CVCL_B8MV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9232; PPARA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996374 CVCL_B8N7 Abcam HCT 116 PROM1 KO cancer cell line human CVCL_B8N7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9454; PROM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996375 CVCL_B8MY Abcam HCT 116 PRDM1 KO cancer cell line human CVCL_B8MY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9346; PRDM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996376 CVCL_B8MX Abcam HCT 116 PPARG KO cancer cell line human CVCL_B8MX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9236; PPARG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996377 CVCL_B8N9 Abcam HCT 116 PTCH1 KO cancer cell line human CVCL_B8N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996378 CVCL_B8MZ Abcam HCT 116 PRDM16 KO cancer cell line human CVCL_B8MZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14000; PRDM16; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996379 CVCL_B8KK Abcam HCT 116 MLH1 KO cancer cell line human CVCL_B8KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996380 CVCL_B8KJ Abcam HCT 116 MKI67 KO cancer cell line human CVCL_B8KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996381 CVCL_B8KM Abcam HCT 116 MMP12 KO cancer cell line human CVCL_B8KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7158; MMP12; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996382 CVCL_B8KL Abcam HCT 116 MMP1 KO cancer cell line human CVCL_B8KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7155; MMP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996383 CVCL_B8L0 Abcam HCT 116 MUC16 KO cancer cell line human CVCL_B8L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15582; MUC16; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996384 CVCL_B8KN Abcam HCT 116 MMP2 KO cancer cell line human CVCL_B8KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7166; MMP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996385 CVCL_B8KQ Abcam HCT 116 MPO KO cancer cell line human CVCL_B8KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7218; MPO; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996386 CVCL_B8L2 Abcam HCT 116 MYD88 KO cancer cell line human CVCL_B8L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7562; MYD88; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996387 CVCL_B8KP Abcam HCT 116 MMP9 KO cancer cell line human CVCL_B8KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7176; MMP9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996388 CVCL_B8L1 Abcam HCT 116 MYB KO cancer cell line human CVCL_B8L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7545; MYB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996389 CVCL_B8KC Abcam HCT 116 MEF2C KO cancer cell line human CVCL_B8KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6996; MEF2C; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996390 CVCL_B8KB Abcam HCT 116 MEF2A KO cancer cell line human CVCL_B8KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6993; MEF2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996391 CVCL_B8KE Abcam HCT 116 MET KO cancer cell line human CVCL_B8KE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7029; MET; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996392 CVCL_B8KD Abcam HCT 116 MEN1 KO cancer cell line human CVCL_B8KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996393 CVCL_B8KG Abcam HCT 116 MICA KO cancer cell line human CVCL_B8KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7090; MICA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996394 CVCL_B8KF Abcam HCT 116 MGMT KO cancer cell line human CVCL_B8KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996395 CVCL_B8KI Abcam HCT 116 MITF KO cancer cell line human CVCL_B8KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7105; MITF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996396 CVCL_B8KH Abcam HCT 116 MICB KO cancer cell line human CVCL_B8KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7091; MICB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996397 CVCL_B8JZ Abcam HCT 116 MAP2K1 KO cancer cell line human CVCL_B8JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6840; MAP2K1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996398 CVCL_B8JY Abcam HCT 116 MALT1 KO cancer cell line human CVCL_B8JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6819; MALT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996399 CVCL_B8KA Abcam HCT 116 MED12 KO cancer cell line human CVCL_B8KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11957; MED12; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996400 CVCL_B8JR Abcam HCT 116 LILRB1 KO cancer cell line human CVCL_B8JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6605; LILRB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996401 CVCL_B8K3 Abcam HCT 116 MAP3K7 KO cancer cell line human CVCL_B8K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6859; MAP3K7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996402 CVCL_B8JQ Abcam HCT 116 LGR5 KO cancer cell line human CVCL_B8JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4504; LGR5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996403 CVCL_B8K2 Abcam HCT 116 MAP3K11 KO cancer cell line human CVCL_B8K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996404 CVCL_B8JT Abcam HCT 116 LIN28B KO cancer cell line human CVCL_B8JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32207; LIN28B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996405 CVCL_B8K5 Abcam HCT 116 MAPK14 KO cancer cell line human CVCL_B8K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996406 CVCL_B8JS Abcam HCT 116 LIN28A KO cancer cell line human CVCL_B8JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15986; LIN28A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996407 CVCL_B8K4 Abcam HCT 116 MAPK1 KO cancer cell line human CVCL_B8K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6871; MAPK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996408 CVCL_B8JV Abcam HCT 116 LRP5 KO cancer cell line human CVCL_B8JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996409 CVCL_B8K7 Abcam HCT 116 MDC1 KO cancer cell line human CVCL_B8K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996410 CVCL_B8JU Abcam HCT 116 LMNA KO cancer cell line human CVCL_B8JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996411 CVCL_B8K6 Abcam HCT 116 MAPK3 KO cancer cell line human CVCL_B8K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6877; MAPK3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996412 CVCL_B8JX Abcam HCT 116 MAF KO cancer cell line human CVCL_B8JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6776; MAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996413 CVCL_B8K9 Abcam HCT 116 MECP2 KO cancer cell line human CVCL_B8K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6990; MECP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996414 CVCL_B8JW Abcam HCT 116 LYN KO cancer cell line human CVCL_B8JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6735; LYN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996415 CVCL_B8K8 Abcam HCT 116 MECOM KO cancer cell line human CVCL_B8K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3498; MECOM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996416 CVCL_B8LL Abcam HCT 116 NR1H3 KO cancer cell line human CVCL_B8LL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7966; NR1H3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996417 CVCL_B8LK Abcam HCT 116 NOTCH2 KO cancer cell line human CVCL_B8LK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7882; NOTCH2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996418 CVCL_B8LN Abcam HCT 116 NR4A3 KO cancer cell line human CVCL_B8LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7982; NR4A3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996419 CVCL_B8LM Abcam HCT 116 NR4A1 KO cancer cell line human CVCL_B8LM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996420 CVCL_B8LP Abcam HCT 116 NRAS KO cancer cell line human CVCL_B8LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996421 CVCL_B8M1 Abcam HCT 116 PAX5 KO cancer cell line human CVCL_B8M1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8619; PAX5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996422 CVCL_B8M0 Abcam HCT 116 PARP3 KO cancer cell line human CVCL_B8M0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996423 CVCL_B8LR Abcam HCT 116 NTRK2 KO cancer cell line human CVCL_B8LR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8032; NTRK2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996424 CVCL_B8M3 Abcam HCT 116 PAX7 KO cancer cell line human CVCL_B8M3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8621; PAX7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996425 CVCL_B8LQ Abcam HCT 116 NSD2 KO cancer cell line human CVCL_B8LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996426 CVCL_B8M2 Abcam HCT 116 PAX6 KO cancer cell line human CVCL_B8M2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8620; PAX6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996427 CVCL_B8LD Abcam HCT 116 NF1 KO cancer cell line human CVCL_B8LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996428 CVCL_B8LC Abcam HCT 116 NECTIN3 KO cancer cell line human CVCL_B8LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17664; NECTIN3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996429 CVCL_B8LF Abcam HCT 116 NFATC1 KO cancer cell line human CVCL_B8LF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7775; NFATC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996430 CVCL_B8LE Abcam HCT 116 NF2 KO cancer cell line human CVCL_B8LE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996431 CVCL_B8LH Abcam HCT 116 NFE2L2 KO cancer cell line human CVCL_B8LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7782; NFE2L2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996432 CVCL_B8LG Abcam HCT 116 NFATC2 KO cancer cell line human CVCL_B8LG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7776; NFATC2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996433 CVCL_B8LJ Abcam HCT 116 NOTCH1 KO cancer cell line human CVCL_B8LJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996434 CVCL_B8LI Abcam HCT 116 NOS2 KO cancer cell line human CVCL_B8LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996435 CVCL_B8KZ Abcam HCT 116 MUC1 KO cancer cell line human CVCL_B8KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7508; MUC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996436 CVCL_B8LB Abcam HCT 116 NECTIN2 KO cancer cell line human CVCL_B8LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9707; NECTIN2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996437 CVCL_B8LA Abcam HCT 116 NCR1 KO cancer cell line human CVCL_B8LA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6731; NCR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996438 CVCL_B8KS Abcam HCT 116 MRE11 KO cancer cell line human CVCL_B8KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7230; MRE11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996439 CVCL_B8L4 Abcam HCT 116 NANOG KO cancer cell line human CVCL_B8L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20857; NANOG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996440 CVCL_B8KR Abcam HCT 116 MRC1 KO cancer cell line human CVCL_B8KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7228; MRC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996441 CVCL_B8L3 Abcam HCT 116 MYOD1 KO cancer cell line human CVCL_B8L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7611; MYOD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996442 CVCL_B8KU Abcam HCT 116 MSH3 KO cancer cell line human CVCL_B8KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996443 CVCL_B8L6 Abcam HCT 116 NCAM1 KO cancer cell line human CVCL_B8L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7656; NCAM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996444 CVCL_B8KT Abcam HCT 116 MSH2 KO cancer cell line human CVCL_B8KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996445 CVCL_B8L5 Abcam HCT 116 NBN KO cancer cell line human CVCL_B8L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7652; NBN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996446 CVCL_B8KW Abcam HCT 116 MSLN KO cancer cell line human CVCL_B8KW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7371; MSLN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996447 CVCL_B8L8 Abcam HCT 116 NCF4 KO cancer cell line human CVCL_B8L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7662; NCF4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996448 CVCL_B8KV Abcam HCT 116 MSH6 KO cancer cell line human CVCL_B8KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996449 CVCL_B8L7 Abcam HCT 116 NCAM2 KO cancer cell line human CVCL_B8L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7657; NCAM2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996450 CVCL_B8KY Abcam HCT 116 MTA2 KO cancer cell line human CVCL_B8KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7411; MTA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996451 CVCL_B8KX Abcam HCT 116 MSR1 KO cancer cell line human CVCL_B8KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7376; MSR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996452 CVCL_B8L9 Abcam HCT 116 NCOA1 KO cancer cell line human CVCL_B8L9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7668; NCOA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996453 CVCL_B8II Abcam HCT 116 IL7R KO cancer cell line human CVCL_B8II CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6024; IL7R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996454 CVCL_B8IH Abcam HCT 116 IL6R KO cancer cell line human CVCL_B8IH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6019; IL6R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996455 CVCL_B8IK Abcam HCT 116 INPP5D KO cancer cell line human CVCL_B8IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6079; INPP5D; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996456 CVCL_B8IJ Abcam HCT 116 IL9 KO cancer cell line human CVCL_B8IJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6029; IL9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996457 CVCL_B8IM Abcam HCT 116 IRAK1 KO cancer cell line human CVCL_B8IM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6112; IRAK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996458 CVCL_B8IL Abcam HCT 116 IQGAP1 KO cancer cell line human CVCL_B8IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6110; IQGAP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996459 CVCL_B8J0 Abcam HCT 116 JARID2 KO cancer cell line human CVCL_B8J0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6196; JARID2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996460 CVCL_B8IN Abcam HCT 116 IRAK4 KO cancer cell line human CVCL_B8IN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17967; IRAK4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996461 CVCL_B8IA Abcam HCT 116 IL1A KO cancer cell line human CVCL_B8IA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5991; IL1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996462 CVCL_B8IC Abcam HCT 116 IL23A KO cancer cell line human CVCL_B8IC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15488; IL23A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996463 CVCL_B8IB Abcam HCT 116 IL1B KO cancer cell line human CVCL_B8IB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5992; IL1B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996464 CVCL_B8IE Abcam HCT 116 IL27 KO cancer cell line human CVCL_B8IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19157; IL27; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996465 CVCL_B8ID Abcam HCT 116 IL23R KO cancer cell line human CVCL_B8ID CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19100; IL23R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996466 CVCL_B8IG Abcam HCT 116 IL3RA KO cancer cell line human CVCL_B8IG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6012; IL3RA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996467 CVCL_B8IF Abcam HCT 116 IL2RB KO cancer cell line human CVCL_B8IF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6009; IL2RB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996468 CVCL_B8HX Abcam HCT 116 IFNGR1 KO cancer cell line human CVCL_B8HX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996469 CVCL_B8I9 Abcam HCT 116 IL18 KO cancer cell line human CVCL_B8I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5986; IL18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996470 CVCL_B8HW Abcam HCT 116 IFNB1 KO cancer cell line human CVCL_B8HW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5434; IFNB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996471 CVCL_B8I8 Abcam HCT 116 IL17A KO cancer cell line human CVCL_B8I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5981; IL17A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996472 CVCL_B8HZ Abcam HCT 116 IGF1 KO cancer cell line human CVCL_B8HZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5464; IGF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996473 CVCL_B8HY Abcam HCT 116 IFNGR2 KO cancer cell line human CVCL_B8HY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5440; IFNGR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996474 CVCL_B8HP Abcam HCT 116 ICAM1 KO cancer cell line human CVCL_B8HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5344; ICAM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996475 CVCL_B8I1 Abcam HCT 116 IGF2BP1 KO cancer cell line human CVCL_B8I1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28866; IGF2BP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996476 CVCL_B8I0 Abcam HCT 116 IGF1R KO cancer cell line human CVCL_B8I0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5465; IGF1R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996477 CVCL_B8HR Abcam HCT 116 ICOSLG KO cancer cell line human CVCL_B8HR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17087; ICOSLG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996478 CVCL_B8I3 Abcam HCT 116 IGF2BP3 KO cancer cell line human CVCL_B8I3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996479 CVCL_B8HQ Abcam HCT 116 ICOS KO cancer cell line human CVCL_B8HQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5351; ICOS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996480 CVCL_B8I2 Abcam HCT 116 IGF2BP2 KO cancer cell line human CVCL_B8I2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28867; IGF2BP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996481 CVCL_B8HT Abcam HCT 116 IDH2 KO cancer cell line human CVCL_B8HT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996482 CVCL_B8I5 Abcam HCT 116 IKBKE KO cancer cell line human CVCL_B8I5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14552; IKBKE; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996483 CVCL_B8HS Abcam HCT 116 IDH1 KO cancer cell line human CVCL_B8HS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996484 CVCL_B8I4 Abcam HCT 116 IHH KO cancer cell line human CVCL_B8I4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5956; IHH; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996485 CVCL_B8HV Abcam HCT 116 IFNAR1 KO cancer cell line human CVCL_B8HV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5432; IFNAR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996486 CVCL_B8I7 Abcam HCT 116 IL15 KO cancer cell line human CVCL_B8I7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5977; IL15; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996487 CVCL_B8HU Abcam HCT 116 IFITM1 KO cancer cell line human CVCL_B8HU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996488 CVCL_B8I6 Abcam HCT 116 IL12A KO cancer cell line human CVCL_B8I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5969; IL12A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996489 CVCL_B8JJ Abcam HCT 116 LAMP1 KO cancer cell line human CVCL_B8JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6499; LAMP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996490 CVCL_B8JI Abcam HCT 116 KRT1 KO cancer cell line human CVCL_B8JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6412; KRT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996491 CVCL_B8JL Abcam HCT 116 LATS2 KO cancer cell line human CVCL_B8JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6515; LATS2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996492 CVCL_B8JK Abcam HCT 116 LATS1 KO cancer cell line human CVCL_B8JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996493 CVCL_B8JN Abcam HCT 116 LGALS1 KO cancer cell line human CVCL_B8JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6561; LGALS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996494 CVCL_B8JM Abcam HCT 116 LCK KO cancer cell line human CVCL_B8JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6524; LCK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996495 CVCL_B8JP Abcam HCT 116 LGALS3 KO cancer cell line human CVCL_B8JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6563; LGALS3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996496 CVCL_B8K1 Abcam HCT 116 MAP2K4 KO cancer cell line human CVCL_B8K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996497 CVCL_B8K0 Abcam HCT 116 MAP2K2 KO cancer cell line human CVCL_B8K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996498 CVCL_B8JB Abcam HCT 116 KITLG KO cancer cell line human CVCL_B8JB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6343; KITLG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996499 CVCL_B8JA Abcam HCT 116 KIT KO cancer cell line human CVCL_B8JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996500 CVCL_B8JD Abcam HCT 116 KLRB1 KO cancer cell line human CVCL_B8JD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6373; KLRB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996501 CVCL_B8JC Abcam HCT 116 KLF4 KO cancer cell line human CVCL_B8JC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6348; KLF4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996502 CVCL_B8JF Abcam HCT 116 KMT2A KO cancer cell line human CVCL_B8JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7132; KMT2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996503 CVCL_B8JE Abcam HCT 116 KLRC1 KO cancer cell line human CVCL_B8JE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6374; KLRC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996504 CVCL_B8JH Abcam HCT 116 KMT5A KO cancer cell line human CVCL_B8JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29489; KMT5A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996505 CVCL_B8JG Abcam HCT 116 KMT2D KO cancer cell line human CVCL_B8JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996506 CVCL_B8IY Abcam HCT 116 JAK1 KO cancer cell line human CVCL_B8IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6190; JAK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996507 CVCL_B8IX Abcam HCT 116 ITPR1 KO cancer cell line human CVCL_B8IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996508 CVCL_B8J9 Abcam HCT 116 KEAP1 KO cancer cell line human CVCL_B8J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996509 CVCL_B8IZ Abcam HCT 116 JAK3 KO cancer cell line human CVCL_B8IZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6193; JAK3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996510 CVCL_B8IQ Abcam HCT 116 ITGA2 KO cancer cell line human CVCL_B8IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996511 CVCL_B8J2 Abcam HCT 116 KAT2B KO cancer cell line human CVCL_B8J2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8638; KAT2B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996512 CVCL_B8IP Abcam HCT 116 IRF4 KO cancer cell line human CVCL_B8IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6119; IRF4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996513 CVCL_B8J1 Abcam HCT 116 KAT2A KO cancer cell line human CVCL_B8J1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4201; KAT2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996514 CVCL_B8IS Abcam HCT 116 ITGAL KO cancer cell line human CVCL_B8IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6148; ITGAL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996515 CVCL_B8J4 Abcam HCT 116 KDM3A KO cancer cell line human CVCL_B8J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20815; KDM3A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996516 CVCL_B8IR Abcam HCT 116 ITGAE KO cancer cell line human CVCL_B8IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996517 CVCL_B8J3 Abcam HCT 116 KDM1A KO cancer cell line human CVCL_B8J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996518 CVCL_B8IU Abcam HCT 116 ITGAV KO cancer cell line human CVCL_B8IU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6150; ITGAV; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996519 CVCL_B8J6 Abcam HCT 116 KDM5B KO cancer cell line human CVCL_B8J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996520 CVCL_B8IT Abcam HCT 116 ITGAM KO cancer cell line human CVCL_B8IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6149; ITGAM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996521 CVCL_B8J5 Abcam HCT 116 KDM5A KO cancer cell line human CVCL_B8J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9886; KDM5A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996522 CVCL_B8IW Abcam HCT 116 ITK KO cancer cell line human CVCL_B8IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6171; ITK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996523 CVCL_B8J8 Abcam HCT 116 KDR KO cancer cell line human CVCL_B8J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6307; KDR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996524 CVCL_B8IV Abcam HCT 116 ITGAX KO cancer cell line human CVCL_B8IV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6152; ITGAX; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996525 CVCL_B8J7 Abcam HCT 116 KDM6A KO cancer cell line human CVCL_B8J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996526 CVCL_B8WW Abcam MCF-7 HNF1A KO cancer cell line human CVCL_B8WW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11621; HNF1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996527 CVCL_B8X8 Abcam MCF-7 IL12A KO cancer cell line human CVCL_B8X8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5969; IL12A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996528 CVCL_B8WV Abcam MCF-7 HMGA2 KO cancer cell line human CVCL_B8WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5009; HMGA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996529 CVCL_B8X7 Abcam MCF-7 IGF2BP2 KO cancer cell line human CVCL_B8X7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28867; IGF2BP2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996530 CVCL_B8WY Abcam MCF-7 HRAS KO cancer cell line human CVCL_B8WY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5173; HRAS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996531 CVCL_B8WX Abcam MCF-7 HOXA9 KO cancer cell line human CVCL_B8WX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5109; HOXA9; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996532 CVCL_B8X9 Abcam MCF-7 IL18 KO cancer cell line human CVCL_B8X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5986; IL18; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996533 CVCL_B8WZ Abcam MCF-7 ICOS KO cancer cell line human CVCL_B8WZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5351; ICOS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996534 CVCL_B8X0 Abcam MCF-7 IDH1 KO cancer cell line human CVCL_B8X0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996535 CVCL_B8WN Abcam MCF-7 HDAC6 KO cancer cell line human CVCL_B8WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996536 CVCL_B8WQ Abcam MCF-7 HELQ KO cancer cell line human CVCL_B8WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18536; HELQ; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996537 CVCL_B8X2 Abcam MCF-7 IFNB1 KO cancer cell line human CVCL_B8X2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5434; IFNB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996538 CVCL_B8WP Abcam MCF-7 HDAC7 KO cancer cell line human CVCL_B8WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14067; HDAC7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996539 CVCL_B8X1 Abcam MCF-7 IDH2 KO cancer cell line human CVCL_B8X1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996540 CVCL_B8WS Abcam MCF-7 HGF KO cancer cell line human CVCL_B8WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4893; HGF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996541 CVCL_B8X4 Abcam MCF-7 IFNGR2 KO cancer cell line human CVCL_B8X4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5440; IFNGR2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996542 CVCL_B8WR Abcam MCF-7 HEY1 KO cancer cell line human CVCL_B8WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4880; HEY1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996543 CVCL_B8X3 Abcam MCF-7 IFNGR1 KO cancer cell line human CVCL_B8X3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996544 CVCL_B8WU Abcam MCF-7 HLA-DRA KO cancer cell line human CVCL_B8WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4947; HLA-DRA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996545 CVCL_B8X6 Abcam MCF-7 IGF1R KO cancer cell line human CVCL_B8X6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5465; IGF1R; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996546 CVCL_B8WT Abcam MCF-7 HLA-A KO cancer cell line human CVCL_B8WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996547 CVCL_B8X5 Abcam MCF-7 IGF1 KO cancer cell line human CVCL_B8X5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5464; IGF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996548 CVCL_B8WG Abcam MCF-7 GSR KO cancer cell line human CVCL_B8WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4623; GSR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996549 CVCL_B8WF Abcam MCF-7 GSK3B KO cancer cell line human CVCL_B8WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4617; GSK3B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996550 CVCL_B8WI Abcam MCF-7 HCN1 KO cancer cell line human CVCL_B8WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4845; HCN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996551 CVCL_B8WH Abcam MCF-7 HAT1 KO cancer cell line human CVCL_B8WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4821; HAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996552 CVCL_B8WK Abcam MCF-7 HDAC2 KO cancer cell line human CVCL_B8WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996553 CVCL_B8WJ Abcam MCF-7 HDAC1 KO cancer cell line human CVCL_B8WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996554 CVCL_B8WM Abcam MCF-7 HDAC5 KO cancer cell line human CVCL_B8WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14068; HDAC5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996555 CVCL_B8WL Abcam MCF-7 HDAC4 KO cancer cell line human CVCL_B8WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14063; HDAC4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996556 CVCL_B8WA Abcam MCF-7 GLI1 KO cancer cell line human CVCL_B8WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4317; GLI1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996557 CVCL_B8WC Abcam MCF-7 GLS KO cancer cell line human CVCL_B8WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4331; GLS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996558 CVCL_B8WB Abcam MCF-7 GLI2 KO cancer cell line human CVCL_B8WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4318; GLI2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996559 CVCL_B8WE Abcam MCF-7 GPNMB KO cancer cell line human CVCL_B8WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4462; GPNMB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996560 CVCL_B8WD Abcam MCF-7 GP1BA KO cancer cell line human CVCL_B8WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4439; GP1BA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996561 CVCL_B8XX Abcam MCF-7 KDM1A KO cancer cell line human CVCL_B8XX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996562 CVCL_B8Y9 Abcam MCF-7 LATS2 KO cancer cell line human CVCL_B8Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6515; LATS2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996563 CVCL_B8XW Abcam MCF-7 KAT2B KO cancer cell line human CVCL_B8XW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8638; KAT2B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996564 CVCL_B8Y8 Abcam MCF-7 LATS1 KO cancer cell line human CVCL_B8Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996565 CVCL_B8XZ Abcam MCF-7 KDM5A KO cancer cell line human CVCL_B8XZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9886; KDM5A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996566 CVCL_B8XY Abcam MCF-7 KDM3A KO cancer cell line human CVCL_B8XY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20815; KDM3A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996567 CVCL_B8XP Abcam MCF-7 ITGAV KO cancer cell line human CVCL_B8XP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6150; ITGAV; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996568 CVCL_B8Y1 Abcam MCF-7 KDM6A KO cancer cell line human CVCL_B8Y1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996569 CVCL_B8Y0 Abcam MCF-7 KDM5B KO cancer cell line human CVCL_B8Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996570 CVCL_B8XR Abcam MCF-7 ITGB1 KO cancer cell line human CVCL_B8XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996571 CVCL_B8Y3 Abcam MCF-7 KEAP1 KO cancer cell line human CVCL_B8Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996572 CVCL_B8XQ Abcam MCF-7 ITGAX KO cancer cell line human CVCL_B8XQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6152; ITGAX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996573 CVCL_B8Y2 Abcam MCF-7 KDR KO cancer cell line human CVCL_B8Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6307; KDR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996574 CVCL_B8XT Abcam MCF-7 ITPR1 KO cancer cell line human CVCL_B8XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996575 CVCL_B8Y5 Abcam MCF-7 KLF4 KO cancer cell line human CVCL_B8Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6348; KLF4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996576 CVCL_B8XS Abcam MCF-7 ITK KO cancer cell line human CVCL_B8XS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6171; ITK; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996577 CVCL_B8Y4 Abcam MCF-7 KIT KO cancer cell line human CVCL_B8Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996578 CVCL_B8XV Abcam MCF-7 JAK3 KO cancer cell line human CVCL_B8XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6193; JAK3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996579 CVCL_B8Y7 Abcam MCF-7 KMT2D KO cancer cell line human CVCL_B8Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996580 CVCL_B8XU Abcam MCF-7 JAK1 KO cancer cell line human CVCL_B8XU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6190; JAK1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996581 CVCL_B8Y6 Abcam MCF-7 KMT2A KO cancer cell line human CVCL_B8Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7132; KMT2A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996582 CVCL_B8XH Abcam MCF-7 INPP5D KO cancer cell line human CVCL_B8XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6079; INPP5D; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996583 CVCL_B8XG Abcam MCF-7 IL7R KO cancer cell line human CVCL_B8XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6024; IL7R; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996584 CVCL_B8XJ Abcam MCF-7 IRF4 KO cancer cell line human CVCL_B8XJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6119; IRF4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996585 CVCL_B8XI Abcam MCF-7 IRAK4 KO cancer cell line human CVCL_B8XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17967; IRAK4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996586 CVCL_B8XL Abcam MCF-7 ITGAE KO cancer cell line human CVCL_B8XL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996587 CVCL_B8XK Abcam MCF-7 ITGA2 KO cancer cell line human CVCL_B8XK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996588 CVCL_B8XN Abcam MCF-7 ITGAM KO cancer cell line human CVCL_B8XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6149; ITGAM; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996589 CVCL_B8XM Abcam MCF-7 ITGAL KO cancer cell line human CVCL_B8XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6148; ITGAL; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996590 CVCL_B8XB Abcam MCF-7 IL1B KO cancer cell line human CVCL_B8XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5992; IL1B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996591 CVCL_B8XA Abcam MCF-7 IL1A KO cancer cell line human CVCL_B8XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5991; IL1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996592 CVCL_B8XD Abcam MCF-7 IL2RB KO cancer cell line human CVCL_B8XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6009; IL2RB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996593 CVCL_B8XC Abcam MCF-7 IL27 KO cancer cell line human CVCL_B8XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19157; IL27; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996594 CVCL_B8XF Abcam MCF-7 IL6R KO cancer cell line human CVCL_B8XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6019; IL6R; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996595 CVCL_B8XE Abcam MCF-7 IL3RA KO cancer cell line human CVCL_B8XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6012; IL3RA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996596 CVCL_B8UU Abcam MCF-7 DMC1 KO cancer cell line human CVCL_B8UU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2927; DMC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996597 CVCL_B8V6 Abcam MCF-7 EHMT1 KO cancer cell line human CVCL_B8V6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996598 CVCL_B8UT Abcam MCF-7 DGCR8 KO cancer cell line human CVCL_B8UT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2847; DGCR8; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996599 CVCL_B8V5 Abcam MCF-7 EGFR KO cancer cell line human CVCL_B8V5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3236; EGFR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996600 CVCL_B8UW Abcam MCF-7 DNMT1 KO cancer cell line human CVCL_B8UW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2976; DNMT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996601 CVCL_B8V8 Abcam MCF-7 EPC1 KO cancer cell line human CVCL_B8V8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19876; EPC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996602 CVCL_B8UV Abcam MCF-7 DNAJB1 KO cancer cell line human CVCL_B8UV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5270; DNAJB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996603 CVCL_B8V7 Abcam MCF-7 EP300 KO cancer cell line human CVCL_B8V7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996604 CVCL_B8UY Abcam MCF-7 DOT1L KO cancer cell line human CVCL_B8UY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24948; DOT1L; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996605 CVCL_B8UX Abcam MCF-7 DNMT3B KO cancer cell line human CVCL_B8UX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2979; DNMT3B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996606 CVCL_B8V9 Abcam MCF-7 EPHA3 KO cancer cell line human CVCL_B8V9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3387; EPHA3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996607 CVCL_B8UZ Abcam MCF-7 DROSHA KO cancer cell line human CVCL_B8UZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17904; DROSHA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996608 CVCL_B8UM Abcam MCF-7 DCC KO cancer cell line human CVCL_B8UM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2701; DCC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996609 CVCL_B8UL Abcam MCF-7 DAXX KO cancer cell line human CVCL_B8UL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996610 CVCL_B8V0 Abcam MCF-7 DUSP4 KO cancer cell line human CVCL_B8V0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3070; DUSP4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996611 CVCL_B8UN Abcam MCF-7 DDB2 KO cancer cell line human CVCL_B8UN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2718; DDB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996612 CVCL_B8UQ Abcam MCF-7 DDR2 KO cancer cell line human CVCL_B8UQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996613 CVCL_B8V2 Abcam MCF-7 EBF1 KO cancer cell line human CVCL_B8V2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3126; EBF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996614 CVCL_B8UP Abcam MCF-7 DDR1 KO cancer cell line human CVCL_B8UP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2730; DDR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996615 CVCL_B8V1 Abcam MCF-7 E2F1 KO cancer cell line human CVCL_B8V1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996616 CVCL_B8US Abcam MCF-7 DEPTOR KO cancer cell line human CVCL_B8US CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22953; DEPTOR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996617 CVCL_B8V4 Abcam MCF-7 EGF KO cancer cell line human CVCL_B8V4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3229; EGF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996618 CVCL_B8UR Abcam MCF-7 DDX5 KO cancer cell line human CVCL_B8UR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2746; DDX5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996619 CVCL_B8V3 Abcam MCF-7 EBI3 KO cancer cell line human CVCL_B8V3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3129; EBI3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996620 CVCL_B8UE Abcam MCF-7 CSF3R KO cancer cell line human CVCL_B8UE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2439; CSF3R; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996621 CVCL_B8UD Abcam MCF-7 CSF1R KO cancer cell line human CVCL_B8UD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2433; CSF1R; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996622 CVCL_B8UG Abcam MCF-7 CTNNB1 KO cancer cell line human CVCL_B8UG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996623 CVCL_B8UF Abcam MCF-7 CTLA4 KO cancer cell line human CVCL_B8UF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2505; CTLA4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996624 CVCL_B8UI Abcam MCF-7 CXCR4 KO cancer cell line human CVCL_B8UI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2561; CXCR4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996625 CVCL_B8UH Abcam MCF-7 CXCR1 KO cancer cell line human CVCL_B8UH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6026; CXCR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996626 CVCL_B8UK Abcam MCF-7 CYLD KO cancer cell line human CVCL_B8UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2584; CYLD; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996627 CVCL_B8UJ Abcam MCF-7 CYBB KO cancer cell line human CVCL_B8UJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2578; CYBB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996628 CVCL_B8UA Abcam MCF-7 CREB1 KO cancer cell line human CVCL_B8UA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2345; CREB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996629 CVCL_B8UC Abcam MCF-7 CRLF2 KO cancer cell line human CVCL_B8UC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14281; CRLF2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996630 CVCL_B8UB Abcam MCF-7 CREBBP KO cancer cell line human CVCL_B8UB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996631 CVCL_B8VV Abcam MCF-7 FGFR4 KO cancer cell line human CVCL_B8VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3691; FGFR4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996632 CVCL_B8W7 Abcam MCF-7 GABRG2 KO cancer cell line human CVCL_B8W7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4087; GABRG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996633 CVCL_B8VU Abcam MCF-7 FGFR2 KO cancer cell line human CVCL_B8VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3689; FGFR2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996634 CVCL_B8W6 Abcam MCF-7 GABRA1 KO cancer cell line human CVCL_B8W6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4075; GABRA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996635 CVCL_B8VX Abcam MCF-7 FLT1 KO cancer cell line human CVCL_B8VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3763; FLT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996636 CVCL_B8W9 Abcam MCF-7 GATA2 KO cancer cell line human CVCL_B8W9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996637 CVCL_B8VW Abcam MCF-7 FLI1 KO cancer cell line human CVCL_B8VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3749; FLI1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996638 CVCL_B8W8 Abcam MCF-7 GATA1 KO cancer cell line human CVCL_B8W8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4170; GATA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996639 CVCL_B8VZ Abcam MCF-7 FN1 KO cancer cell line human CVCL_B8VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3778; FN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996640 CVCL_B8VY Abcam MCF-7 FLT4 KO cancer cell line human CVCL_B8VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3767; FLT4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996641 CVCL_B8VN Abcam MCF-7 FBXO38 KO cancer cell line human CVCL_B8VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28844; FBXO38; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996642 CVCL_B8VM Abcam MCF-7 FAS KO cancer cell line human CVCL_B8VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11920; FAS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996643 CVCL_B8VP Abcam MCF-7 FCER2 KO cancer cell line human CVCL_B8VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3612; FCER2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996644 CVCL_B8W1 Abcam MCF-7 FOSL1 KO cancer cell line human CVCL_B8W1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13718; FOSL1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996645 CVCL_B8W0 Abcam MCF-7 FOS KO cancer cell line human CVCL_B8W0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996646 CVCL_B8VR Abcam MCF-7 FCGR2B KO cancer cell line human CVCL_B8VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3618; FCGR2B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996647 CVCL_B8W3 Abcam MCF-7 FOXO4 KO cancer cell line human CVCL_B8W3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7139; FOXO4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996648 CVCL_B8VQ Abcam MCF-7 FCGR2A KO cancer cell line human CVCL_B8VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3616; FCGR2A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996649 CVCL_B8W2 Abcam MCF-7 FOXM1 KO cancer cell line human CVCL_B8W2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3818; FOXM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996650 CVCL_B8VT Abcam MCF-7 FEN1 KO cancer cell line human CVCL_B8VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3650; FEN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996651 CVCL_B8W5 Abcam MCF-7 FTO KO cancer cell line human CVCL_B8W5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996652 CVCL_B8VS Abcam MCF-7 FCGR3A KO cancer cell line human CVCL_B8VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3619; FCGR3A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996653 CVCL_B8W4 Abcam MCF-7 FOXP1 KO cancer cell line human CVCL_B8W4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3823; FOXP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996654 CVCL_B8VF Abcam MCF-7 ERCC5 KO cancer cell line human CVCL_B8VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3437; ERCC5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996655 CVCL_B8VE Abcam MCF-7 ERCC4 KO cancer cell line human CVCL_B8VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3436; ERCC4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996656 CVCL_B8VH Abcam MCF-7 ETS1 KO cancer cell line human CVCL_B8VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3488; ETS1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996657 CVCL_B8VG Abcam MCF-7 ESR1 KO cancer cell line human CVCL_B8VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3467; ESR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996658 CVCL_B8VJ Abcam MCF-7 EZH1 KO cancer cell line human CVCL_B8VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3526; EZH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996659 CVCL_B8VI Abcam MCF-7 ETV6 KO cancer cell line human CVCL_B8VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996660 CVCL_B8VL Abcam MCF-7 FANCD2 KO cancer cell line human CVCL_B8VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996661 CVCL_B8VK Abcam MCF-7 FANCA KO cancer cell line human CVCL_B8VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996662 CVCL_B8VB Abcam MCF-7 ERBB2 KO cancer cell line human CVCL_B8VB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996663 CVCL_B8VA Abcam MCF-7 EPHB2 KO cancer cell line human CVCL_B8VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996664 CVCL_B8VD Abcam MCF-7 ERBB4 KO cancer cell line human CVCL_B8VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3432; ERBB4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996665 CVCL_B8VC Abcam MCF-7 ERBB3 KO cancer cell line human CVCL_B8VC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3431; ERBB3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996666 CVCL_B8SS Abcam MCF-7 BAX KO cancer cell line human CVCL_B8SS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996667 CVCL_B8T4 Abcam MCF-7 BRD3 KO cancer cell line human CVCL_B8T4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996668 CVCL_B8SR Abcam MCF-7 BARD1 KO cancer cell line human CVCL_B8SR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 952; BARD1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996669 CVCL_B8T3 Abcam MCF-7 BRCA2 KO cancer cell line human CVCL_B8T3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1101; BRCA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996670 CVCL_B8SU Abcam MCF-7 BCL11A KO cancer cell line human CVCL_B8SU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13221; BCL11A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996671 CVCL_B8T6 Abcam MCF-7 BRIP1 KO cancer cell line human CVCL_B8T6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20473; BRIP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996672 CVCL_B8ST Abcam MCF-7 BCL10 KO cancer cell line human CVCL_B8ST CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 989; BCL10; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996673 CVCL_B8T5 Abcam MCF-7 BRD7 KO cancer cell line human CVCL_B8T5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14310; BRD7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996674 CVCL_B8SW Abcam MCF-7 BCL2 KO cancer cell line human CVCL_B8SW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996675 CVCL_B8T8 Abcam MCF-7 CALR KO cancer cell line human CVCL_B8T8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996676 CVCL_B8SV Abcam MCF-7 BCL11B KO cancer cell line human CVCL_B8SV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13222; BCL11B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996677 CVCL_B8T7 Abcam MCF-7 CA9 KO cancer cell line human CVCL_B8T7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1383; CA9; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996678 CVCL_B8SY Abcam MCF-7 BCL6 KO cancer cell line human CVCL_B8SY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996679 CVCL_B8SX Abcam MCF-7 BCL3 KO cancer cell line human CVCL_B8SX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 998; BCL3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996680 CVCL_B8T9 Abcam MCF-7 CARD11 KO cancer cell line human CVCL_B8T9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16393; CARD11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996681 CVCL_B8SK Abcam MCF-7 ARID1B KO cancer cell line human CVCL_B8SK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18040; ARID1B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996682 CVCL_B8SJ Abcam MCF-7 ARID1A KO cancer cell line human CVCL_B8SJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996683 CVCL_B8SM Abcam MCF-7 ATF2 KO cancer cell line human CVCL_B8SM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 784; ATF2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996684 CVCL_B8SL Abcam MCF-7 ARNT KO cancer cell line human CVCL_B8SL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 700; ARNT; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996685 CVCL_B8T0 Abcam MCF-7 BMPR1A KO cancer cell line human CVCL_B8T0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996686 CVCL_B8SN Abcam MCF-7 ATRX KO cancer cell line human CVCL_B8SN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996687 CVCL_B8SQ Abcam MCF-7 B2M KO cancer cell line human CVCL_B8SQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996688 CVCL_B8T2 Abcam MCF-7 BRCA1 KO cancer cell line human CVCL_B8T2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1100; BRCA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996689 CVCL_B8SP Abcam MCF-7 AXIN1 KO cancer cell line human CVCL_B8SP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996690 CVCL_B8T1 Abcam MCF-7 BRAF KO cancer cell line human CVCL_B8T1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996691 CVCL_B8SC Abcam MCF-7 ALKBH5 KO cancer cell line human CVCL_B8SC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25996; ALKBH5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996692 CVCL_B8SB Abcam MCF-7 AKT3 KO cancer cell line human CVCL_B8SB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996693 CVCL_B8SE Abcam MCF-7 ANGPT2 KO cancer cell line human CVCL_B8SE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 485; ANGPT2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996694 CVCL_B8SD Abcam MCF-7 ANGPT1 KO cancer cell line human CVCL_B8SD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 484; ANGPT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996695 CVCL_B8SG Abcam MCF-7 AQP4 KO cancer cell line human CVCL_B8SG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 637; AQP4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996696 CVCL_B8SF Abcam MCF-7 ANXA1 KO cancer cell line human CVCL_B8SF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 533; ANXA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996697 CVCL_B8SI Abcam MCF-7 ARAF KO cancer cell line human CVCL_B8SI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996698 CVCL_B8SH Abcam MCF-7 AR KO cancer cell line human CVCL_B8SH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996699 CVCL_B8RZ Abcam HCT 116 ZBTB16 KO cancer cell line human CVCL_B8RZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12930; ZBTB16; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996700 CVCL_B8RY Abcam HCT 116 YWHAB KO cancer cell line human CVCL_B8RY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12849; YWHAB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996701 CVCL_B8SA Abcam MCF-7 AKT2 KO cancer cell line human CVCL_B8SA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 392; AKT2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996702 CVCL_B8TT Abcam MCF-7 CD86 KO cancer cell line human CVCL_B8TT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1705; CD86; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996703 CVCL_B8U5 Abcam MCF-7 CHD9 KO cancer cell line human CVCL_B8U5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25701; CHD9; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996704 CVCL_B8TS Abcam MCF-7 CD80 KO cancer cell line human CVCL_B8TS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1700; CD80; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996705 CVCL_B8U4 Abcam MCF-7 CHD5 KO cancer cell line human CVCL_B8U4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16816; CHD5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996706 CVCL_B8TV Abcam MCF-7 CDK2 KO cancer cell line human CVCL_B8TV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1771; CDK2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996707 CVCL_B8U7 Abcam MCF-7 CLOCK KO cancer cell line human CVCL_B8U7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2082; CLOCK; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996708 CVCL_B8TU Abcam MCF-7 CDH11 KO cancer cell line human CVCL_B8TU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1750; CDH11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996709 CVCL_B8U6 Abcam MCF-7 CHUK KO cancer cell line human CVCL_B8U6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1974; CHUK; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996710 CVCL_B8TX Abcam MCF-7 CDK6 KO cancer cell line human CVCL_B8TX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1777; CDK6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996711 CVCL_B8U9 Abcam MCF-7 COL1A1 KO cancer cell line human CVCL_B8U9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996712 CVCL_B8TW Abcam MCF-7 CDK5 KO cancer cell line human CVCL_B8TW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996713 CVCL_B8U8 Abcam MCF-7 CNTNAP2 KO cancer cell line human CVCL_B8U8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13830; CNTNAP2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996714 CVCL_B8TZ Abcam MCF-7 CDKN1A KO cancer cell line human CVCL_B8TZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996715 CVCL_B8TY Abcam MCF-7 CDK8 KO cancer cell line human CVCL_B8TY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1779; CDK8; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996716 CVCL_B8TL Abcam MCF-7 CD209 KO cancer cell line human CVCL_B8TL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1641; CD209; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996717 CVCL_B8TK Abcam MCF-7 CD19 KO cancer cell line human CVCL_B8TK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1633; CD19; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996718 CVCL_B8TN Abcam MCF-7 CD3E KO cancer cell line human CVCL_B8TN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1674; CD3E; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996719 CVCL_B8TM Abcam MCF-7 CD28 KO cancer cell line human CVCL_B8TM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1653; CD28; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996720 CVCL_B8TP Abcam MCF-7 CD4 KO cancer cell line human CVCL_B8TP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1678; CD4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996721 CVCL_B8U1 Abcam MCF-7 CDX2 KO cancer cell line human CVCL_B8U1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1806; CDX2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996722 CVCL_B8U0 Abcam MCF-7 CDKN1B KO cancer cell line human CVCL_B8U0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996723 CVCL_B8TR Abcam MCF-7 CD79A KO cancer cell line human CVCL_B8TR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1698; CD79A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996724 CVCL_B8U3 Abcam MCF-7 CEBPA KO cancer cell line human CVCL_B8U3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996725 CVCL_B8TQ Abcam MCF-7 CD74 KO cancer cell line human CVCL_B8TQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996726 CVCL_B8U2 Abcam MCF-7 CEACAM5 KO cancer cell line human CVCL_B8U2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1817; CEACAM5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996727 CVCL_B8TD Abcam MCF-7 CBLB KO cancer cell line human CVCL_B8TD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1542; CBLB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996728 CVCL_B8TC Abcam MCF-7 CBL KO cancer cell line human CVCL_B8TC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996729 CVCL_B8TF Abcam MCF-7 CCNE1 KO cancer cell line human CVCL_B8TF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1589; CCNE1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996730 CVCL_B8TE Abcam MCF-7 CCND2 KO cancer cell line human CVCL_B8TE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996731 CVCL_B8TH Abcam MCF-7 CCR6 KO cancer cell line human CVCL_B8TH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1607; CCR6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996732 CVCL_B8TG Abcam MCF-7 CCR4 KO cancer cell line human CVCL_B8TG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1605; CCR4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996733 CVCL_B8TJ Abcam MCF-7 CD14 KO cancer cell line human CVCL_B8TJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1628; CD14; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996734 CVCL_B8TI Abcam MCF-7 CCR7 KO cancer cell line human CVCL_B8TI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1608; CCR7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996735 CVCL_B8SZ Abcam MCF-7 BLM KO cancer cell line human CVCL_B8SZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1058; BLM; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996736 CVCL_B8TB Abcam MCF-7 CASP8 KO cancer cell line human CVCL_B8TB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996737 CVCL_B8TA Abcam MCF-7 CARM1 KO cancer cell line human CVCL_B8TA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996738 CVCL_B8QQ Abcam HCT 116 TFAP2A KO cancer cell line human CVCL_B8QQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11742; TFAP2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996739 CVCL_B8R2 Abcam HCT 116 TMEM173 KO cancer cell line human CVCL_B8R2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996740 CVCL_B8QP Abcam HCT 116 TET3 KO cancer cell line human CVCL_B8QP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28313; TET3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996741 CVCL_B8R1 Abcam HCT 116 TLR7 KO cancer cell line human CVCL_B8R1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15631; TLR7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996742 CVCL_B8QS Abcam HCT 116 TGFBR1 KO cancer cell line human CVCL_B8QS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11772; TGFBR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996743 CVCL_B8R4 Abcam HCT 116 TNFRSF18 KO cancer cell line human CVCL_B8R4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11914; TNFRSF18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996744 CVCL_B8QR Abcam HCT 116 TGFB1 KO cancer cell line human CVCL_B8QR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11766; TGFB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996745 CVCL_B8R3 Abcam HCT 116 TNFRSF17 KO cancer cell line human CVCL_B8R3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11913; TNFRSF17; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996746 CVCL_B8QU Abcam HCT 116 THBD KO cancer cell line human CVCL_B8QU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11784; THBD; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996747 CVCL_B8R6 Abcam HCT 116 TNFRSF8 KO cancer cell line human CVCL_B8R6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11923; TNFRSF8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996748 CVCL_B8QT Abcam HCT 116 TGFBR2 KO cancer cell line human CVCL_B8QT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996749 CVCL_B8R5 Abcam HCT 116 TNFRSF4 KO cancer cell line human CVCL_B8R5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11918; TNFRSF4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996750 CVCL_B8QW Abcam HCT 116 TLR1 KO cancer cell line human CVCL_B8QW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11847; TLR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996751 CVCL_B8R8 Abcam HCT 116 TNFSF11 KO cancer cell line human CVCL_B8R8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11926; TNFSF11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996752 CVCL_B8QV Abcam HCT 116 TIA1 KO cancer cell line human CVCL_B8QV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11802; TIA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996753 CVCL_B8R7 Abcam HCT 116 TNFRSF9 KO cancer cell line human CVCL_B8R7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11924; TNFRSF9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996754 CVCL_B8QI Abcam HCT 116 TBX21 KO cancer cell line human CVCL_B8QI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11599; TBX21; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996755 CVCL_B8QH Abcam HCT 116 TAFFAZIN KO cancer cell line human CVCL_B8QH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996756 CVCL_B8QK Abcam HCT 116 TEK KO cancer cell line human CVCL_B8QK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11724; TEK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996757 CVCL_B8QJ Abcam HCT 116 TDO2 KO cancer cell line human CVCL_B8QJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11708; TDO2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996758 CVCL_B8QM Abcam HCT 116 TET1 KO cancer cell line human CVCL_B8QM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29484; TET1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996759 CVCL_B8QL Abcam HCT 116 TERT KO cancer cell line human CVCL_B8QL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11730; TERT; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996760 CVCL_B8R0 Abcam HCT 116 TLR6 KO cancer cell line human CVCL_B8R0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16711; TLR6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996761 CVCL_B8QN Abcam HCT 116 TET2 KO cancer cell line human CVCL_B8QN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996762 CVCL_B8QA Abcam HCT 116 STAT3 KO cancer cell line human CVCL_B8QA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996763 CVCL_B8QC Abcam HCT 116 STAT6 KO cancer cell line human CVCL_B8QC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11368; STAT6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996764 CVCL_B8QB Abcam HCT 116 STAT5B KO cancer cell line human CVCL_B8QB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11367; STAT5B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996765 CVCL_B8QE Abcam HCT 116 SUFU KO cancer cell line human CVCL_B8QE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996766 CVCL_B8QD Abcam HCT 116 STK11 KO cancer cell line human CVCL_B8QD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996767 CVCL_B8QG Abcam HCT 116 TACSTD2 KO cancer cell line human CVCL_B8QG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11530; TACSTD2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996768 CVCL_B8QF Abcam HCT 116 SYK KO cancer cell line human CVCL_B8QF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11491; SYK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996769 CVCL_B8PX Abcam HCT 116 SOX11 KO cancer cell line human CVCL_B8PX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11191; SOX11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996770 CVCL_B8Q9 Abcam HCT 116 STAG2 KO cancer cell line human CVCL_B8Q9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996771 CVCL_B8PW Abcam HCT 116 SOX10 KO cancer cell line human CVCL_B8PW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11190; SOX10; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996772 CVCL_B8Q8 Abcam HCT 116 SS18 KO cancer cell line human CVCL_B8Q8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11340; SS18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996773 CVCL_B8PZ Abcam HCT 116 SOX2 KO cancer cell line human CVCL_B8PZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11195; SOX2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996774 CVCL_B8PY Abcam HCT 116 SOX17 KO cancer cell line human CVCL_B8PY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18122; SOX17; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996775 CVCL_B8RR Abcam HCT 116 VTCN1 KO cancer cell line human CVCL_B8RR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28873; VTCN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996776 CVCL_B8S3 Abcam MCF-7 ACKR3 KO cancer cell line human CVCL_B8S3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23692; ACKR3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996777 CVCL_B8RQ Abcam HCT 116 VSIR KO cancer cell line human CVCL_B8RQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30085; VSIR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996778 CVCL_B8S2 Abcam MCF-7 ABL2 KO cancer cell line human CVCL_B8S2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996779 CVCL_B8RT Abcam HCT 116 WWTR1 KO cancer cell line human CVCL_B8RT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996780 CVCL_B8S5 Abcam MCF-7 ACVR1B KO cancer cell line human CVCL_B8S5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 172; ACVR1B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996781 CVCL_B8RS Abcam HCT 116 WT1 KO cancer cell line human CVCL_B8RS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12796; WT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996782 CVCL_B8S4 Abcam MCF-7 ACTA2 KO cancer cell line human CVCL_B8S4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 130; ACTA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996783 CVCL_B8RV Abcam HCT 116 XIAP KO cancer cell line human CVCL_B8RV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 592; XIAP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996784 CVCL_B8S7 Abcam MCF-7 ADRB2 KO cancer cell line human CVCL_B8S7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 286; ADRB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996785 CVCL_B8RU Abcam HCT 116 WNT3A KO cancer cell line human CVCL_B8RU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15983; WNT3A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996786 CVCL_B8S6 Abcam MCF-7 ADAM10 KO cancer cell line human CVCL_B8S6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 188; ADAM10; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996787 CVCL_B8RX Abcam HCT 116 YTHDF2 KO cancer cell line human CVCL_B8RX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31675; YTHDF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996788 CVCL_B8S9 Abcam MCF-7 AKT1 KO cancer cell line human CVCL_B8S9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996789 CVCL_B8RW Abcam HCT 116 XPC KO cancer cell line human CVCL_B8RW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996790 CVCL_B8S8 Abcam MCF-7 AGO2 KO cancer cell line human CVCL_B8S8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3263; AGO2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996791 CVCL_B8RJ Abcam HCT 116 USP22 KO cancer cell line human CVCL_B8RJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12621; USP22; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996792 CVCL_B8RI Abcam HCT 116 UHRF1 KO cancer cell line human CVCL_B8RI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12556; UHRF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996793 CVCL_B8RL Abcam HCT 116 VDR KO cancer cell line human CVCL_B8RL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12679; VDR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996794 CVCL_B8RK Abcam HCT 116 USP8 KO cancer cell line human CVCL_B8RK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996795 CVCL_B8RN Abcam HCT 116 VEGFC KO cancer cell line human CVCL_B8RN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12682; VEGFC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996796 CVCL_B8RM Abcam HCT 116 VEGFA KO cancer cell line human CVCL_B8RM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12680; VEGFA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996797 CVCL_B8RP Abcam HCT 116 VIM KO cancer cell line human CVCL_B8RP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12692; VIM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996798 CVCL_B8S1 Abcam MCF-7 ABCC1 KO cancer cell line human CVCL_B8S1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152996799 CVCL_B8S0 Abcam HCT 116 ZEB1 KO cancer cell line human CVCL_B8S0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996800 CVCL_B8RB Abcam HCT 116 TRAF1 KO cancer cell line human CVCL_B8RB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12031; TRAF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996801 CVCL_B8RA Abcam HCT 116 TP63 KO cancer cell line human CVCL_B8RA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15979; TP63; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996802 CVCL_B8RD Abcam HCT 116 TRIM28 KO cancer cell line human CVCL_B8RD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16384; TRIM28; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996803 CVCL_B8RC Abcam HCT 116 TRIM24 KO cancer cell line human CVCL_B8RC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11812; TRIM24; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996804 CVCL_B8RF Abcam HCT 116 TSC1 KO cancer cell line human CVCL_B8RF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12362; TSC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996805 CVCL_B8RE Abcam HCT 116 TRIM33 KO cancer cell line human CVCL_B8RE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16290; TRIM33; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996806 CVCL_B8RH Abcam HCT 116 UBB KO cancer cell line human CVCL_B8RH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12463; UBB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996807 CVCL_B8RG Abcam HCT 116 TSC2 KO cancer cell line human CVCL_B8RG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12363; TSC2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996808 CVCL_B8QY Abcam HCT 116 TLR3 KO cancer cell line human CVCL_B8QY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11849; TLR3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996809 CVCL_B8QX Abcam HCT 116 TLR2 KO cancer cell line human CVCL_B8QX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996810 CVCL_B8R9 Abcam HCT 116 TP53BP1 KO cancer cell line human CVCL_B8R9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996811 CVCL_B8QZ Abcam HCT 116 TLR4 KO cancer cell line human CVCL_B8QZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11850; TLR4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996812 CVCL_B7YZ Abcam Raji PTGES2 KO cancer cell line human CVCL_B7YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17822; PTGES2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996813 CVCL_B7YY Abcam Raji PTGER4 KO cancer cell line human CVCL_B7YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9596; PTGER4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996814 CVCL_B7ZA Abcam Raji SDC4 KO cancer cell line human CVCL_B7ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10661; SDC4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996815 CVCL_B7YR Abcam Raji PIK3CD KO cancer cell line human CVCL_B7YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996816 CVCL_B7Z3 Abcam Raji PUS1 KO cancer cell line human CVCL_B7Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15508; PUS1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996817 CVCL_B7YQ Abcam Raji PIK3CA KO cancer cell line human CVCL_B7YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996818 CVCL_B7Z2 Abcam Raji PTPN12 KO cancer cell line human CVCL_B7Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9645; PTPN12; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996819 CVCL_B7YT Abcam Raji PLA2G4A KO cancer cell line human CVCL_B7YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996820 CVCL_B7Z5 Abcam Raji RING1 KO cancer cell line human CVCL_B7Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996821 CVCL_B7YS Abcam Raji PIK3R4 KO cancer cell line human CVCL_B7YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8982; PIK3R4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996822 CVCL_B7Z4 Abcam Raji RAC2 KO cancer cell line human CVCL_B7Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9802; RAC2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996823 CVCL_B7YV Abcam Raji PLCG1 KO cancer cell line human CVCL_B7YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996824 CVCL_B7Z7 Abcam Raji ROR2 KO cancer cell line human CVCL_B7Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10257; ROR2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996825 CVCL_B7YU Abcam Raji PLCB3 KO cancer cell line human CVCL_B7YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996826 CVCL_B7Z6 Abcam Raji ROCK2 KO cancer cell line human CVCL_B7Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996827 CVCL_B7YX Abcam Raji PSEN1 KO cancer cell line human CVCL_B7YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996828 CVCL_B7Z9 Abcam Raji SCARB1 KO cancer cell line human CVCL_B7Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996829 CVCL_B7YW Abcam Raji PRMT7 KO cancer cell line human CVCL_B7YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25557; PRMT7; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996830 CVCL_B7Z8 Abcam Raji RYBP KO cancer cell line human CVCL_B7Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10480; RYBP; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996831 CVCL_B7YJ Abcam Raji NOTCH3 KO cancer cell line human CVCL_B7YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7883; NOTCH3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996832 CVCL_B7YI Abcam Raji NLRC4 KO cancer cell line human CVCL_B7YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16412; NLRC4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996833 CVCL_B7YL Abcam Raji NR1H4 KO cancer cell line human CVCL_B7YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7967; NR1H4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996834 CVCL_B7YK Abcam Raji NOTCH4 KO cancer cell line human CVCL_B7YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7884; NOTCH4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996835 CVCL_B7YN Abcam Raji PDCD1LG2 KO cancer cell line human CVCL_B7YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996836 CVCL_B7YM Abcam Raji NR3C2 KO cancer cell line human CVCL_B7YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996837 CVCL_B7YP Abcam Raji PHF8 KO cancer cell line human CVCL_B7YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20672; PHF8; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996838 CVCL_B7Z1 Abcam Raji PTP4A3 KO cancer cell line human CVCL_B7Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9636; PTP4A3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996839 CVCL_B7Z0 Abcam Raji PTK2 KO cancer cell line human CVCL_B7Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9611; PTK2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996840 CVCL_B7YB Abcam Raji MMP8 KO cancer cell line human CVCL_B7YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7175; MMP8; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996841 CVCL_B7YA Abcam Raji MMP13 KO cancer cell line human CVCL_B7YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7159; MMP13; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996842 CVCL_B7YD Abcam Raji MTA3 KO cancer cell line human CVCL_B7YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23784; MTA3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996843 CVCL_B7YC Abcam Raji MS4A1 KO cancer cell line human CVCL_B7YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7315; MS4A1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996844 CVCL_B7YF Abcam Raji NCR3LG1 KO cancer cell line human CVCL_B7YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 42400; NCR3LG1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996845 CVCL_B7YE Abcam Raji NBR1 KO cancer cell line human CVCL_B7YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996846 CVCL_B7YH Abcam Raji NFKB1 KO cancer cell line human CVCL_B7YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7794; NFKB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996847 CVCL_B7YG Abcam Raji NFATC2 KO cancer cell line human CVCL_B7YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7776; NFATC2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996848 CVCL_B7ZZ Abcam Raji TNFRSF10B KO cancer cell line human CVCL_B7ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11905; TNFRSF10B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996849 CVCL_B7ZS Abcam Raji TAPBP KO cancer cell line human CVCL_B7ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11566; TAPBP; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996850 CVCL_B7ZR Abcam Raji SUZ12 KO cancer cell line human CVCL_B7ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996851 CVCL_B7ZU Abcam Raji TBP KO cancer cell line human CVCL_B7ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11588; TBP; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996852 CVCL_B7ZT Abcam Raji TBK1 KO cancer cell line human CVCL_B7ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996853 CVCL_B7ZW Abcam Raji TFDP1 KO cancer cell line human CVCL_B7ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11749; TFDP1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996854 CVCL_B7ZV Abcam Raji TCF7L2 KO cancer cell line human CVCL_B7ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11641; TCF7L2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996855 CVCL_B7ZY Abcam Raji TLN1 KO cancer cell line human CVCL_B7ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11845; TLN1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996856 CVCL_B7ZX Abcam Raji TIMP3 KO cancer cell line human CVCL_B7ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11822; TIMP3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996857 CVCL_B7ZK Abcam Raji SRF KO cancer cell line human CVCL_B7ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11291; SRF; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996858 CVCL_B7ZJ Abcam Raji SOCS3 KO cancer cell line human CVCL_B7ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996859 CVCL_B7ZM Abcam Raji STAT4 KO cancer cell line human CVCL_B7ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11365; STAT4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996860 CVCL_B7ZL Abcam Raji SRPK1 KO cancer cell line human CVCL_B7ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996861 CVCL_B7ZN Abcam Raji STAT5A KO cancer cell line human CVCL_B7ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11366; STAT5A; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996862 CVCL_B7ZQ Abcam Raji SUV39H1 KO cancer cell line human CVCL_B7ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996863 CVCL_B7ZP Abcam Raji STK4 KO cancer cell line human CVCL_B7ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996864 CVCL_B7ZC Abcam Raji SLFN11 KO cancer cell line human CVCL_B7ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996865 CVCL_B7ZB Abcam Raji SETD2 KO cancer cell line human CVCL_B7ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996866 CVCL_B7ZE Abcam Raji SMARCC2 KO cancer cell line human CVCL_B7ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11105; SMARCC2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996867 CVCL_B7ZD Abcam Raji SMARCAL1 KO cancer cell line human CVCL_B7ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11102; SMARCAL1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996868 CVCL_B7ZG Abcam Raji SMURF1 KO cancer cell line human CVCL_B7ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16807; SMURF1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996869 CVCL_B7ZF Abcam Raji SMARCE1 KO cancer cell line human CVCL_B7ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11109; SMARCE1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996870 CVCL_B7ZI Abcam Raji SMYD3 KO cancer cell line human CVCL_B7ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15513; SMYD3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996871 CVCL_B7ZH Abcam Raji SMYD2 KO cancer cell line human CVCL_B7ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20982; SMYD2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996872 CVCL_B7WX Abcam Raji CUL4B KO cancer cell line human CVCL_B7WX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2555; CUL4B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996873 CVCL_B7X9 Abcam Raji FABP4 KO cancer cell line human CVCL_B7X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3559; FABP4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996874 CVCL_B7WW Abcam Raji CUL3 KO cancer cell line human CVCL_B7WW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2553; CUL3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996875 CVCL_B7X8 Abcam Raji EXO1 KO cancer cell line human CVCL_B7X8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3511; EXO1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996876 CVCL_B7WZ Abcam Raji DCP2 KO cancer cell line human CVCL_B7WZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24452; DCP2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996877 CVCL_B7WY Abcam Raji CXXC1 KO cancer cell line human CVCL_B7WY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24343; CXXC1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996878 CVCL_B7WP Abcam Raji CLU KO cancer cell line human CVCL_B7WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2095; CLU; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996879 CVCL_B7X1 Abcam Raji DVL3 KO cancer cell line human CVCL_B7X1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3087; DVL3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996880 CVCL_B7X0 Abcam Raji DLL1 KO cancer cell line human CVCL_B7X0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2908; DLL1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996881 CVCL_B7WR Abcam Raji CMTM6 KO cancer cell line human CVCL_B7WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19177; CMTM6; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996882 CVCL_B7X3 Abcam Raji EHMT2 KO cancer cell line human CVCL_B7X3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996883 CVCL_B7WQ Abcam Raji CMKLR1 KO cancer cell line human CVCL_B7WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2121; CMKLR1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996884 CVCL_B7X2 Abcam Raji EGLN1 KO cancer cell line human CVCL_B7X2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1232; EGLN1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996885 CVCL_B7WT Abcam Raji CST3 KO cancer cell line human CVCL_B7WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2475; CST3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996886 CVCL_B7X5 Abcam Raji EPHB4 KO cancer cell line human CVCL_B7X5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996887 CVCL_B7WS Abcam Raji CNR2 KO cancer cell line human CVCL_B7WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2160; CNR2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996888 CVCL_B7X4 Abcam Raji EIF2AK4 KO cancer cell line human CVCL_B7X4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996889 CVCL_B7WV Abcam Raji CUL2 KO cancer cell line human CVCL_B7WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2552; CUL2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996890 CVCL_B7X7 Abcam Raji ETS2 KO cancer cell line human CVCL_B7X7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3489; ETS2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996891 CVCL_B7WU Abcam Raji CTSB KO cancer cell line human CVCL_B7WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996892 CVCL_B7X6 Abcam Raji ERAP1 KO cancer cell line human CVCL_B7X6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18173; ERAP1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996893 CVCL_B7WH Abcam Raji CD36 KO cancer cell line human CVCL_B7WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1663; CD36; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996894 CVCL_B7WG Abcam Raji CCL22 KO cancer cell line human CVCL_B7WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10621; CCL22; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996895 CVCL_B7WJ Abcam Raji CD58 KO cancer cell line human CVCL_B7WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1688; CD58; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996896 CVCL_B7WI Abcam Raji CD48 KO cancer cell line human CVCL_B7WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1683; CD48; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996897 CVCL_B7WL Abcam Raji CD81 KO cancer cell line human CVCL_B7WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996898 CVCL_B7WK Abcam Raji CD59 KO cancer cell line human CVCL_B7WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1689; CD59; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996899 CVCL_B7WN Abcam Raji CITED2 KO cancer cell line human CVCL_B7WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1987; CITED2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996900 CVCL_B7WM Abcam Raji CD83 KO cancer cell line human CVCL_B7WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1703; CD83; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996901 CVCL_B7WB Abcam Raji BTK KO cancer cell line human CVCL_B7WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1133; BTK; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996902 CVCL_B7WA Abcam Raji BTG1 KO cancer cell line human CVCL_B7WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1130; BTG1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996903 CVCL_B7WD Abcam Raji C3 KO cancer cell line human CVCL_B7WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1318; C3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996904 CVCL_B7WC Abcam Raji BTRC KO cancer cell line human CVCL_B7WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996905 CVCL_B7WF Abcam Raji CCRL2 KO cancer cell line human CVCL_B7WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1612; CCRL2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996906 CVCL_B7WE Abcam Raji CASP3 KO cancer cell line human CVCL_B7WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1504; CASP3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996907 CVCL_B7XY Abcam Raji LAMP2 KO cancer cell line human CVCL_B7XY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6501; LAMP2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996908 CVCL_B7XX Abcam Raji LAIR1 KO cancer cell line human CVCL_B7XX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6477; LAIR1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996909 CVCL_B7Y9 Abcam Raji MME KO cancer cell line human CVCL_B7Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7154; MME; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996910 CVCL_B7XZ Abcam Raji LDHA KO cancer cell line human CVCL_B7XZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6535; LDHA; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996911 CVCL_B7XQ Abcam Raji ITPR3 KO cancer cell line human CVCL_B7XQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996912 CVCL_B7Y2 Abcam Raji MACROH2A1 KO cancer cell line human CVCL_B7Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4740; MACROH2A1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996913 CVCL_B7XP Abcam Raji IL17RB KO cancer cell line human CVCL_B7XP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18015; IL17RB; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996914 CVCL_B7Y1 Abcam Raji LMNB1 KO cancer cell line human CVCL_B7Y1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996915 CVCL_B7XS Abcam Raji JMJD6 KO cancer cell line human CVCL_B7XS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19355; JMJD6; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996916 CVCL_B7Y4 Abcam Raji MAP2K3 KO cancer cell line human CVCL_B7Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6843; MAP2K3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996917 CVCL_B7XR Abcam Raji JAG1 KO cancer cell line human CVCL_B7XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996918 CVCL_B7Y3 Abcam Raji MAGEA3 KO cancer cell line human CVCL_B7Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6801; MAGEA3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996919 CVCL_B7XU Abcam Raji KDM1B KO cancer cell line human CVCL_B7XU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996920 CVCL_B7Y6 Abcam Raji MAPK7 KO cancer cell line human CVCL_B7Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996921 CVCL_B7XT Abcam Raji KAT7 KO cancer cell line human CVCL_B7XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996922 CVCL_B7Y5 Abcam Raji MAP3K3 KO cancer cell line human CVCL_B7Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6855; MAP3K3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996923 CVCL_B7XW Abcam Raji KPNA2 KO cancer cell line human CVCL_B7XW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6395; KPNA2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996924 CVCL_B7Y8 Abcam Raji MBD3 KO cancer cell line human CVCL_B7Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996925 CVCL_B7XV Abcam Raji KDM6B KO cancer cell line human CVCL_B7XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996926 CVCL_B7Y7 Abcam Raji MBD1 KO cancer cell line human CVCL_B7Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996927 CVCL_B7XI Abcam Raji GPR132 KO cancer cell line human CVCL_B7XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17482; GPR132; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996928 CVCL_B7XH Abcam Raji GLB1 KO cancer cell line human CVCL_B7XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4298; GLB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996929 CVCL_B7XK Abcam Raji HLA-B KO cancer cell line human CVCL_B7XK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996930 CVCL_B7XJ Abcam Raji GZMA KO cancer cell line human CVCL_B7XJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4708; GZMA; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996931 CVCL_B7XM Abcam Raji HSPG2 KO cancer cell line human CVCL_B7XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996932 CVCL_B7XL Abcam Raji HNF1B KO cancer cell line human CVCL_B7XL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11630; HNF1B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996933 CVCL_B7Y0 Abcam Raji LGR6 KO cancer cell line human CVCL_B7Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19719; LGR6; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996934 CVCL_B7XN Abcam Raji ID2 KO cancer cell line human CVCL_B7XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5361; ID2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996935 CVCL_B7XA Abcam Raji FKBP5 KO cancer cell line human CVCL_B7XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3721; FKBP5; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996936 CVCL_B7XC Abcam Raji FOXO3 KO cancer cell line human CVCL_B7XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3821; FOXO3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996937 CVCL_B7XB Abcam Raji FOXO1 KO cancer cell line human CVCL_B7XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996938 CVCL_B7XE Abcam Raji FTL KO cancer cell line human CVCL_B7XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996939 CVCL_B7XD Abcam Raji FST KO cancer cell line human CVCL_B7XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3971; FST; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996940 CVCL_B7XG Abcam Raji GAB1 KO cancer cell line human CVCL_B7XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4066; GAB1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996941 CVCL_B7XF Abcam Raji FZD7 KO cancer cell line human CVCL_B7XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4045; FZD7; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152996942 CVCL_B8GG Abcam HCT 116 FOXM1 KO cancer cell line human CVCL_B8GG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3818; FOXM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996943 CVCL_B8GF Abcam HCT 116 FOXG1 KO cancer cell line human CVCL_B8GF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3811; FOXG1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996944 CVCL_B8GI Abcam HCT 116 FOXP1 KO cancer cell line human CVCL_B8GI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3823; FOXP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996945 CVCL_B8GH Abcam HCT 116 FOXO4 KO cancer cell line human CVCL_B8GH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7139; FOXO4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996946 CVCL_B8GK Abcam HCT 116 FLT3LG KO cancer cell line human CVCL_B8GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3766; FLT3LG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996947 CVCL_B8GJ Abcam HCT 116 FOXP3 KO cancer cell line human CVCL_B8GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6106; FOXP3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996948 CVCL_B8GM Abcam HCT 116 GABRG2 KO cancer cell line human CVCL_B8GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4087; GABRG2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996949 CVCL_B8GL Abcam HCT 116 GABRA1 KO cancer cell line human CVCL_B8GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4075; GABRA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996950 CVCL_B8GA Abcam HCT 116 FOSL1 KO cancer cell line human CVCL_B8GA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13718; FOSL1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996951 CVCL_B8GC Abcam HCT 116 FOXA2 KO cancer cell line human CVCL_B8GC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5022; FOXA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996952 CVCL_B8GB Abcam HCT 116 FOXA1 KO cancer cell line human CVCL_B8GB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5021; FOXA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996953 CVCL_B8GE Abcam HCT 116 FOXC2 KO cancer cell line human CVCL_B8GE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3801; FOXC2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996954 CVCL_B8GD Abcam HCT 116 FOXC1 KO cancer cell line human CVCL_B8GD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3800; FOXC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996955 CVCL_B8FV Abcam HCT 116 FCER2 KO cancer cell line human CVCL_B8FV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3612; FCER2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996956 CVCL_B8G7 Abcam HCT 116 FOLH1 KO cancer cell line human CVCL_B8G7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3788; FOLH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996957 CVCL_B8FU Abcam HCT 116 FBXO38 KO cancer cell line human CVCL_B8FU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28844; FBXO38; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996958 CVCL_B8G6 Abcam HCT 116 FN1 KO cancer cell line human CVCL_B8G6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3778; FN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996959 CVCL_B8FX Abcam HCT 116 FCGR2B KO cancer cell line human CVCL_B8FX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3618; FCGR2B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996960 CVCL_B8G9 Abcam HCT 116 FOS KO cancer cell line human CVCL_B8G9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996961 CVCL_B8FW Abcam HCT 116 FCGR2A KO cancer cell line human CVCL_B8FW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3616; FCGR2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996962 CVCL_B8G8 Abcam HCT 116 FOLR1 KO cancer cell line human CVCL_B8G8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3791; FOLR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996963 CVCL_B8FZ Abcam HCT 116 FEN1 KO cancer cell line human CVCL_B8FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3650; FEN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996964 CVCL_B8FY Abcam HCT 116 FCGR3A KO cancer cell line human CVCL_B8FY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3619; FCGR3A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996965 CVCL_B8FN Abcam HCT 116 ETV6 KO cancer cell line human CVCL_B8FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996966 CVCL_B8FM Abcam HCT 116 ETS1 KO cancer cell line human CVCL_B8FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3488; ETS1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996967 CVCL_B8FP Abcam HCT 116 EZH1 KO cancer cell line human CVCL_B8FP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3526; EZH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996968 CVCL_B8G1 Abcam HCT 116 FGFR2 KO cancer cell line human CVCL_B8G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3689; FGFR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996969 CVCL_B8G0 Abcam HCT 116 FGF2 KO cancer cell line human CVCL_B8G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3676; FGF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996970 CVCL_B8FR Abcam HCT 116 FANCD2 KO cancer cell line human CVCL_B8FR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996971 CVCL_B8G3 Abcam HCT 116 FLT1 KO cancer cell line human CVCL_B8G3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3763; FLT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996972 CVCL_B8FQ Abcam HCT 116 FANCA KO cancer cell line human CVCL_B8FQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996973 CVCL_B8G2 Abcam HCT 116 FLI1 KO cancer cell line human CVCL_B8G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3749; FLI1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996974 CVCL_B8FT Abcam HCT 116 FAS KO cancer cell line human CVCL_B8FT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11920; FAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996975 CVCL_B8G5 Abcam HCT 116 FMR1 KO cancer cell line human CVCL_B8G5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996976 CVCL_B8FS Abcam HCT 116 FAP KO cancer cell line human CVCL_B8FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3590; FAP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996977 CVCL_B8G4 Abcam HCT 116 FLT4 KO cancer cell line human CVCL_B8G4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3767; FLT4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996978 CVCL_B8HH Abcam HCT 116 HLA-G KO cancer cell line human CVCL_B8HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4964; HLA-G; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996979 CVCL_B8HG Abcam HCT 116 HLA-DRA KO cancer cell line human CVCL_B8HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4947; HLA-DRA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996980 CVCL_B8HJ Abcam HCT 116 HNF1A KO cancer cell line human CVCL_B8HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11621; HNF1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996981 CVCL_B8HI Abcam HCT 116 HMGA2 KO cancer cell line human CVCL_B8HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5009; HMGA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996982 CVCL_B8HL Abcam HCT 116 HOXA9 KO cancer cell line human CVCL_B8HL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5109; HOXA9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996983 CVCL_B8HK Abcam HCT 116 HNF4A KO cancer cell line human CVCL_B8HK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5024; HNF4A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996984 CVCL_B8HN Abcam HCT 116 HRAS KO cancer cell line human CVCL_B8HN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5173; HRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996985 CVCL_B8HM Abcam HCT 116 HPSE KO cancer cell line human CVCL_B8HM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5164; HPSE; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996986 CVCL_B8HB Abcam HCT 116 HDAC7 KO cancer cell line human CVCL_B8HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14067; HDAC7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996987 CVCL_B8HA Abcam HCT 116 HDAC6 KO cancer cell line human CVCL_B8HA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996988 CVCL_B8HD Abcam HCT 116 HEY1 KO cancer cell line human CVCL_B8HD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4880; HEY1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996989 CVCL_B8HC Abcam HCT 116 HELQ KO cancer cell line human CVCL_B8HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18536; HELQ; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996990 CVCL_B8HF Abcam HCT 116 HLA-A KO cancer cell line human CVCL_B8HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996991 CVCL_B8HE Abcam HCT 116 HGF KO cancer cell line human CVCL_B8HE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4893; HGF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996992 CVCL_B8GW Abcam HCT 116 GLS KO cancer cell line human CVCL_B8GW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4331; GLS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996993 CVCL_B8H8 Abcam HCT 116 HDAC4 KO cancer cell line human CVCL_B8H8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14063; HDAC4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996994 CVCL_B8GV Abcam HCT 116 GLI3 KO cancer cell line human CVCL_B8GV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4319; GLI3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996995 CVCL_B8H7 Abcam HCT 116 HDAC2 KO cancer cell line human CVCL_B8H7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996996 CVCL_B8GY Abcam HCT 116 GPC1 KO cancer cell line human CVCL_B8GY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4449; GPC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996997 CVCL_B8GX Abcam HCT 116 GP1BA KO cancer cell line human CVCL_B8GX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4439; GP1BA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996998 CVCL_B8H9 Abcam HCT 116 HDAC5 KO cancer cell line human CVCL_B8H9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14068; HDAC5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152996999 CVCL_B8GZ Abcam HCT 116 GPER1 KO cancer cell line human CVCL_B8GZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4485; GPER1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997000 CVCL_B8H0 Abcam HCT 116 GPNMB KO cancer cell line human CVCL_B8H0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4462; GPNMB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997001 CVCL_B8GN Abcam HCT 116 GADD45B KO cancer cell line human CVCL_B8GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4096; GADD45B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997002 CVCL_B8GQ Abcam HCT 116 GATA2 KO cancer cell line human CVCL_B8GQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997003 CVCL_B8H2 Abcam HCT 116 GZMB KO cancer cell line human CVCL_B8H2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4709; GZMB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997004 CVCL_B8GP Abcam HCT 116 GATA1 KO cancer cell line human CVCL_B8GP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4170; GATA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997005 CVCL_B8H1 Abcam HCT 116 GSR KO cancer cell line human CVCL_B8H1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4623; GSR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997006 CVCL_B8GS Abcam HCT 116 GATA4 KO cancer cell line human CVCL_B8GS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4173; GATA4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997007 CVCL_B8H4 Abcam HCT 116 HAT1 KO cancer cell line human CVCL_B8H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4821; HAT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997008 CVCL_B8GR Abcam HCT 116 GATA3 KO cancer cell line human CVCL_B8GR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4172; GATA3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997009 CVCL_B8H3 Abcam HCT 116 H2BC21 KO cancer cell line human CVCL_B8H3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4760; H2BC21; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997010 CVCL_B8GU Abcam HCT 116 GLI2 KO cancer cell line human CVCL_B8GU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4318; GLI2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997011 CVCL_B8H6 Abcam HCT 116 HDAC1 KO cancer cell line human CVCL_B8H6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997012 CVCL_B8GT Abcam HCT 116 GATA6 KO cancer cell line human CVCL_B8GT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4174; GATA6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997013 CVCL_B8H5 Abcam HCT 116 HAVCR2 KO cancer cell line human CVCL_B8H5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18437; HAVCR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997014 CVCL_B8EE Abcam HCT 116 CXCR4 KO cancer cell line human CVCL_B8EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2561; CXCR4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997015 CVCL_B8ED Abcam HCT 116 CXCR3 KO cancer cell line human CVCL_B8ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4540; CXCR3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997016 CVCL_B8EG Abcam HCT 116 CYBB KO cancer cell line human CVCL_B8EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2578; CYBB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997017 CVCL_B8EF Abcam HCT 116 CXCR6 KO cancer cell line human CVCL_B8EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16647; CXCR6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997018 CVCL_B8EI Abcam HCT 116 DAXX KO cancer cell line human CVCL_B8EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997019 CVCL_B8EH Abcam HCT 116 CYLD KO cancer cell line human CVCL_B8EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2584; CYLD; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997020 CVCL_B8EK Abcam HCT 116 DDB2 KO cancer cell line human CVCL_B8EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2718; DDB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997021 CVCL_B8EJ Abcam HCT 116 DCC KO cancer cell line human CVCL_B8EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2701; DCC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997022 CVCL_B8EA Abcam HCT 116 CXCL11 KO cancer cell line human CVCL_B8EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10638; CXCL11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997023 CVCL_B8EC Abcam HCT 116 CXCR1 KO cancer cell line human CVCL_B8EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6026; CXCR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997024 CVCL_B8EB Abcam HCT 116 CXCL13 KO cancer cell line human CVCL_B8EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10639; CXCL13; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997025 CVCL_B8DT Abcam HCT 116 CISH KO cancer cell line human CVCL_B8DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1984; CISH; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997026 CVCL_B8E5 Abcam HCT 116 CSF1R KO cancer cell line human CVCL_B8E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2433; CSF1R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997027 CVCL_B8DS Abcam HCT 116 CIRBP KO cancer cell line human CVCL_B8DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1982; CIRBP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997028 CVCL_B8E4 Abcam HCT 116 CSF1 KO cancer cell line human CVCL_B8E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997029 CVCL_B8DV Abcam HCT 116 CLOCK KO cancer cell line human CVCL_B8DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2082; CLOCK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997030 CVCL_B8E7 Abcam HCT 116 CSPG4 KO cancer cell line human CVCL_B8E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2466; CSPG4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997031 CVCL_B8DU Abcam HCT 116 CLDN18 KO cancer cell line human CVCL_B8DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2039; CLDN18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997032 CVCL_B8E6 Abcam HCT 116 CSF3R KO cancer cell line human CVCL_B8E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2439; CSF3R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997033 CVCL_B8DX Abcam HCT 116 CNTNAP2 KO cancer cell line human CVCL_B8DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13830; CNTNAP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997034 CVCL_B8E9 Abcam HCT 116 CX3CL1 KO cancer cell line human CVCL_B8E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10647; CX3CL1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997035 CVCL_B8DW Abcam HCT 116 CNOT6 KO cancer cell line human CVCL_B8DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14099; CNOT6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997036 CVCL_B8E8 Abcam HCT 116 CTLA4 KO cancer cell line human CVCL_B8E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2505; CTLA4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997037 CVCL_B8DZ Abcam HCT 116 CR2 KO cancer cell line human CVCL_B8DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2336; CR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997038 CVCL_B8DY Abcam HCT 116 COL1A1 KO cancer cell line human CVCL_B8DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997039 CVCL_B8DL Abcam HCT 116 CEBPA KO cancer cell line human CVCL_B8DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997040 CVCL_B8DK Abcam HCT 116 CEACAM5 KO cancer cell line human CVCL_B8DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1817; CEACAM5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997041 CVCL_B8DN Abcam HCT 116 CHD7 KO cancer cell line human CVCL_B8DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20626; CHD7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997042 CVCL_B8DM Abcam HCT 116 CHD5 KO cancer cell line human CVCL_B8DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16816; CHD5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997043 CVCL_B8DP Abcam HCT 116 CHD8 KO cancer cell line human CVCL_B8DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20153; CHD8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997044 CVCL_B8E1 Abcam HCT 116 CREB1 KO cancer cell line human CVCL_B8E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2345; CREB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997045 CVCL_B8E0 Abcam HCT 116 CRBN KO cancer cell line human CVCL_B8E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30185; CRBN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997046 CVCL_B8DR Abcam HCT 116 CHUK KO cancer cell line human CVCL_B8DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1974; CHUK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997047 CVCL_B8E3 Abcam HCT 116 CRLF2 KO cancer cell line human CVCL_B8E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14281; CRLF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997048 CVCL_B8DQ Abcam HCT 116 CHD9 KO cancer cell line human CVCL_B8DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25701; CHD9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997049 CVCL_B8E2 Abcam HCT 116 CREBBP KO cancer cell line human CVCL_B8E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997050 CVCL_B8FF Abcam HCT 116 ERBB2 KO cancer cell line human CVCL_B8FF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997051 CVCL_B8FE Abcam HCT 116 EPHB2 KO cancer cell line human CVCL_B8FE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997052 CVCL_B8FH Abcam HCT 116 ERBB4 KO cancer cell line human CVCL_B8FH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3432; ERBB4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997053 CVCL_B8FG Abcam HCT 116 ERBB3 KO cancer cell line human CVCL_B8FG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3431; ERBB3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997054 CVCL_B8FJ Abcam HCT 116 ERCC5 KO cancer cell line human CVCL_B8FJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3437; ERCC5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997055 CVCL_B8FI Abcam HCT 116 ERCC4 KO cancer cell line human CVCL_B8FI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3436; ERCC4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997056 CVCL_B8FL Abcam HCT 116 ESRRA KO cancer cell line human CVCL_B8FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3471; ESRRA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997057 CVCL_B8FK Abcam HCT 116 ESR1 KO cancer cell line human CVCL_B8FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3467; ESR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997058 CVCL_B8FB Abcam HCT 116 EP300 KO cancer cell line human CVCL_B8FB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997059 CVCL_B8FA Abcam HCT 116 EOMES KO cancer cell line human CVCL_B8FA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3372; EOMES; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997060 CVCL_B8FD Abcam HCT 116 EPHA3 KO cancer cell line human CVCL_B8FD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3387; EPHA3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997061 CVCL_B8FC Abcam HCT 116 EPC1 KO cancer cell line human CVCL_B8FC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19876; EPC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997062 CVCL_B8EU Abcam HCT 116 DOT1L KO cancer cell line human CVCL_B8EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24948; DOT1L; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997063 CVCL_B8F6 Abcam HCT 116 EHMT1 KO cancer cell line human CVCL_B8F6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997064 CVCL_B8ET Abcam HCT 116 DNMT3B KO cancer cell line human CVCL_B8ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2979; DNMT3B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997065 CVCL_B8F5 Abcam HCT 116 EGR1 KO cancer cell line human CVCL_B8F5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3238; EGR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997066 CVCL_B8EW Abcam HCT 116 DROSHA KO cancer cell line human CVCL_B8EW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17904; DROSHA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997067 CVCL_B8F8 Abcam HCT 116 ELK1 KO cancer cell line human CVCL_B8F8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3321; ELK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997068 CVCL_B8EV Abcam HCT 116 DPP4 KO cancer cell line human CVCL_B8EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3009; DPP4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997069 CVCL_B8F7 Abcam HCT 116 EIF2AK3 KO cancer cell line human CVCL_B8F7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3255; EIF2AK3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997070 CVCL_B8EY Abcam HCT 116 E2F1 KO cancer cell line human CVCL_B8EY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997071 CVCL_B8EX Abcam HCT 116 DUSP4 KO cancer cell line human CVCL_B8EX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3070; DUSP4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997072 CVCL_B8F9 Abcam HCT 116 ENTPD1 KO cancer cell line human CVCL_B8F9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3363; ENTPD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997073 CVCL_B8EZ Abcam HCT 116 E2F2 KO cancer cell line human CVCL_B8EZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3114; E2F2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997074 CVCL_B8EM Abcam HCT 116 DDX4 KO cancer cell line human CVCL_B8EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18700; DDX4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997075 CVCL_B8EL Abcam HCT 116 DDR2 KO cancer cell line human CVCL_B8EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997076 CVCL_B8F0 Abcam HCT 116 EBF1 KO cancer cell line human CVCL_B8F0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3126; EBF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997077 CVCL_B8EN Abcam HCT 116 DGCR8 KO cancer cell line human CVCL_B8EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2847; DGCR8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997078 CVCL_B8EQ Abcam HCT 116 DMC1 KO cancer cell line human CVCL_B8EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2927; DMC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997079 CVCL_B8F2 Abcam HCT 116 EGF KO cancer cell line human CVCL_B8F2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3229; EGF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997080 CVCL_B8EP Abcam HCT 116 DLL3 KO cancer cell line human CVCL_B8EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2909; DLL3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997081 CVCL_B8F1 Abcam HCT 116 EBI3 KO cancer cell line human CVCL_B8F1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3129; EBI3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997082 CVCL_B8ES Abcam HCT 116 DNMT1 KO cancer cell line human CVCL_B8ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2976; DNMT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997083 CVCL_B8F4 Abcam HCT 116 EGLN3 KO cancer cell line human CVCL_B8F4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14661; EGLN3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997084 CVCL_B8ER Abcam HCT 116 DNAJB1 KO cancer cell line human CVCL_B8ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5270; DNAJB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997085 CVCL_B8F3 Abcam HCT 116 EGFR KO cancer cell line human CVCL_B8F3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997086 CVCL_B8CC Abcam HCT 116 CALR KO cancer cell line human CVCL_B8CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997087 CVCL_B8CB Abcam HCT 116 CACNA1D KO cancer cell line human CVCL_B8CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1391; CACNA1D; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997088 CVCL_B8CE Abcam HCT 116 CARD9 KO cancer cell line human CVCL_B8CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16391; CARD9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997089 CVCL_B8CD Abcam HCT 116 CARD11 KO cancer cell line human CVCL_B8CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16393; CARD11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997090 CVCL_B8CG Abcam HCT 116 CASP8 KO cancer cell line human CVCL_B8CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997091 CVCL_B8CF Abcam HCT 116 CARM1 KO cancer cell line human CVCL_B8CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997092 CVCL_B8CI Abcam HCT 116 CBLB KO cancer cell line human CVCL_B8CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1542; CBLB; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997093 CVCL_B8CH Abcam HCT 116 CBL KO cancer cell line human CVCL_B8CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997094 CVCL_B8BZ Abcam HCT 116 BCL6 KO cancer cell line human CVCL_B8BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997095 CVCL_B8BY Abcam HCT 116 BCL3 KO cancer cell line human CVCL_B8BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 998; BCL3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997096 CVCL_B8CA Abcam HCT 116 CA9 KO cancer cell line human CVCL_B8CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1383; CA9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997097 CVCL_B8BR Abcam HCT 116 BAD KO cancer cell line human CVCL_B8BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 936; BAD; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997098 CVCL_B8C3 Abcam HCT 116 BRAF KO cancer cell line human CVCL_B8C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997099 CVCL_B8BQ Abcam HCT 116 B2M KO cancer cell line human CVCL_B8BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997100 CVCL_B8C2 Abcam HCT 116 BMPR1A KO cancer cell line human CVCL_B8C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997101 CVCL_B8BT Abcam HCT 116 BCAR1 KO cancer cell line human CVCL_B8BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 971; BCAR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997102 CVCL_B8C5 Abcam HCT 116 BRD4 KO cancer cell line human CVCL_B8C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997103 CVCL_B8BS Abcam HCT 116 BAX KO cancer cell line human CVCL_B8BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997104 CVCL_B8C4 Abcam HCT 116 BRD3 KO cancer cell line human CVCL_B8C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997105 CVCL_B8BV Abcam HCT 116 BCL11A KO cancer cell line human CVCL_B8BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13221; BCL11A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997106 CVCL_B8C7 Abcam HCT 116 BRIP1 KO cancer cell line human CVCL_B8C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20473; BRIP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997107 CVCL_B8BU Abcam HCT 116 BCL10 KO cancer cell line human CVCL_B8BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 989; BCL10; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997108 CVCL_B8C6 Abcam HCT 116 BRD7 KO cancer cell line human CVCL_B8C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14310; BRD7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997109 CVCL_B8BX Abcam HCT 116 BCL2 KO cancer cell line human CVCL_B8BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997110 CVCL_B8C9 Abcam HCT 116 C5AR1 KO cancer cell line human CVCL_B8C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1338; C5AR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997111 CVCL_B8BW Abcam HCT 116 BCL11B KO cancer cell line human CVCL_B8BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13222; BCL11B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997112 CVCL_B8C8 Abcam HCT 116 C3AR1 KO cancer cell line human CVCL_B8C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1319; C3AR1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997113 CVCL_B8BJ Abcam HCT 116 ASH2L KO cancer cell line human CVCL_B8BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 744; ASH2L; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997114 CVCL_B8BI Abcam HCT 116 ARNTL KO cancer cell line human CVCL_B8BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 701; BMAL1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997115 CVCL_B8BL Abcam HCT 116 ATF6 KO cancer cell line human CVCL_B8BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997116 CVCL_B8BK Abcam HCT 116 ATF2 KO cancer cell line human CVCL_B8BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 784; ATF2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997117 CVCL_B8BN Abcam HCT 116 ATRX KO cancer cell line human CVCL_B8BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997118 CVCL_B8BM Abcam HCT 116 ATG14 KO cancer cell line human CVCL_B8BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997119 CVCL_B8BP Abcam HCT 116 AXIN1 KO cancer cell line human CVCL_B8BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997120 CVCL_B8C1 Abcam HCT 116 BLM KO cancer cell line human CVCL_B8C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1058; BLM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997121 CVCL_B8C0 Abcam HCT 116 BHLHE40 KO cancer cell line human CVCL_B8C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1046; BHLHE40; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997122 CVCL_B8DD Abcam HCT 116 CDK4 KO cancer cell line human CVCL_B8DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1773; CDK4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997123 CVCL_B8DC Abcam HCT 116 CDH11 KO cancer cell line human CVCL_B8DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1750; CDH11; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997124 CVCL_B8DF Abcam HCT 116 CDK6 KO cancer cell line human CVCL_B8DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1777; CDK6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997125 CVCL_B8DE Abcam HCT 116 CDK5 KO cancer cell line human CVCL_B8DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997126 CVCL_B8DH Abcam HCT 116 CDKN1B KO cancer cell line human CVCL_B8DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997127 CVCL_B8DG Abcam HCT 116 CDK8 KO cancer cell line human CVCL_B8DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1779; CDK8; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997128 CVCL_B8DJ Abcam HCT 116 CDX2 KO cancer cell line human CVCL_B8DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1806; CDX2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997129 CVCL_B8DI Abcam HCT 116 CDKN1C KO cancer cell line human CVCL_B8DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1786; CDKN1C; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997130 CVCL_B8CZ Abcam HCT 116 CD34 KO cancer cell line human CVCL_B8CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1662; CD34; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997131 CVCL_B8DB Abcam HCT 116 CD8A KO cancer cell line human CVCL_B8DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1706; CD8A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997132 CVCL_B8DA Abcam HCT 116 CD86 KO cancer cell line human CVCL_B8DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1705; CD86; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997133 CVCL_B8CS Abcam HCT 116 CCR9 KO cancer cell line human CVCL_B8CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1610; CCR9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997134 CVCL_B8D4 Abcam HCT 116 CD5 KO cancer cell line human CVCL_B8D4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1685; CD5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997135 CVCL_B8CR Abcam HCT 116 CCR7 KO cancer cell line human CVCL_B8CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1608; CCR7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997136 CVCL_B8D3 Abcam HCT 116 CD40LG KO cancer cell line human CVCL_B8D3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11935; CD40LG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997137 CVCL_B8CU Abcam HCT 116 CD163 KO cancer cell line human CVCL_B8CU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1631; CD163; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997138 CVCL_B8D6 Abcam HCT 116 CD7 KO cancer cell line human CVCL_B8D6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1695; CD7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997139 CVCL_B8CT Abcam HCT 116 CD14 KO cancer cell line human CVCL_B8CT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1628; CD14; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997140 CVCL_B8D5 Abcam HCT 116 CD69 KO cancer cell line human CVCL_B8D5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1694; CD69; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997141 CVCL_B8CW Abcam HCT 116 CD209 KO cancer cell line human CVCL_B8CW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1641; CD209; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997142 CVCL_B8D8 Abcam HCT 116 CD79A KO cancer cell line human CVCL_B8D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1698; CD79A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997143 CVCL_B8CV Abcam HCT 116 CD19 KO cancer cell line human CVCL_B8CV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1633; CD19; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997144 CVCL_B8D7 Abcam HCT 116 CD74 KO cancer cell line human CVCL_B8D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997145 CVCL_B8CY Abcam HCT 116 CD28 KO cancer cell line human CVCL_B8CY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1653; CD28; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997146 CVCL_B8CX Abcam HCT 116 CD226 KO cancer cell line human CVCL_B8CX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16961; CD226; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997147 CVCL_B8D9 Abcam HCT 116 CD80 KO cancer cell line human CVCL_B8D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1700; CD80; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997148 CVCL_B8CK Abcam HCT 116 CCND2 KO cancer cell line human CVCL_B8CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997149 CVCL_B8CJ Abcam HCT 116 CCL3 KO cancer cell line human CVCL_B8CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10627; CCL3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997150 CVCL_B8CM Abcam HCT 116 CCR3 KO cancer cell line human CVCL_B8CM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1604; CCR3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997151 CVCL_B8CL Abcam HCT 116 CCNE1 KO cancer cell line human CVCL_B8CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1589; CCNE1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997152 CVCL_B8D0 Abcam HCT 116 CD38 KO cancer cell line human CVCL_B8D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1667; CD38; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997153 CVCL_B8CN Abcam HCT 116 CCR4 KO cancer cell line human CVCL_B8CN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1605; CCR4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997154 CVCL_B8CQ Abcam HCT 116 CCR6 KO cancer cell line human CVCL_B8CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1607; CCR6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997155 CVCL_B8D2 Abcam HCT 116 CD4 KO cancer cell line human CVCL_B8D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1678; CD4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997156 CVCL_B8CP Abcam HCT 116 CCR5 KO cancer cell line human CVCL_B8CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1606; CCR5; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997157 CVCL_B8D1 Abcam HCT 116 CD3E KO cancer cell line human CVCL_B8D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1674; CD3E; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997158 CVCL_B8AA Abcam Raji UCHL5 KO cancer cell line human CVCL_B8AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19678; UCHL5; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997159 CVCL_B8AC Abcam Raji UVRAG KO cancer cell line human CVCL_B8AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12640; UVRAG; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997160 CVCL_B8AB Abcam Raji ULBP3 KO cancer cell line human CVCL_B8AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14895; ULBP3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997161 CVCL_B8AE Abcam Raji VCAN KO cancer cell line human CVCL_B8AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2464; VCAN; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997162 CVCL_B8AD Abcam Raji VAV1 KO cancer cell line human CVCL_B8AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12657; VAV1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997163 CVCL_B8AG Abcam Raji WNT11 KO cancer cell line human CVCL_B8AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12776; WNT11; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997164 CVCL_B8AF Abcam Raji WDR77 KO cancer cell line human CVCL_B8AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29652; WDR77; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997165 CVCL_B8A9 Abcam Raji UBE2D2 KO cancer cell line human CVCL_B8A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997166 CVCL_B8A8 Abcam Raji UBA1 KO cancer cell line human CVCL_B8A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12469; UBA1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997167 CVCL_B8A1 Abcam Raji TP73 KO cancer cell line human CVCL_B8A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997168 CVCL_B8A0 Abcam Raji TNFRSF1B KO cancer cell line human CVCL_B8A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11917; TNFRSF1B; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997169 CVCL_B8A3 Abcam Raji TRAF2 KO cancer cell line human CVCL_B8A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997170 CVCL_B8A2 Abcam Raji TRADD KO cancer cell line human CVCL_B8A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12030; TRADD; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997171 CVCL_B8A5 Abcam Raji TWIST1 KO cancer cell line human CVCL_B8A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12428; TWIST1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997172 CVCL_B8A4 Abcam Raji TRMT2A KO cancer cell line human CVCL_B8A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997173 CVCL_B8A7 Abcam Raji U2AF1 KO cancer cell line human CVCL_B8A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12453; U2AF1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997174 CVCL_B8A6 Abcam Raji TWIST2 KO cancer cell line human CVCL_B8A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20670; TWIST2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997175 CVCL_B8BB Abcam HCT 116 APC KO cancer cell line human CVCL_B8BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997176 CVCL_B8BA Abcam HCT 116 ANXA1 KO cancer cell line human CVCL_B8BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 533; ANXA1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997177 CVCL_B8BD Abcam HCT 116 AR KO cancer cell line human CVCL_B8BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997178 CVCL_B8BC Abcam HCT 116 AQP4 KO cancer cell line human CVCL_B8BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 637; AQP4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997179 CVCL_B8BF Abcam HCT 116 AREG KO cancer cell line human CVCL_B8BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 651; AREG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997180 CVCL_B8BE Abcam HCT 116 ARAF KO cancer cell line human CVCL_B8BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997181 CVCL_B8BH Abcam HCT 116 ARNT KO cancer cell line human CVCL_B8BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 700; ARNT; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997182 CVCL_B8BG Abcam HCT 116 ARID1B KO cancer cell line human CVCL_B8BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18040; ARID1B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997183 CVCL_B8AY Abcam HCT 116 ADK KO cancer cell line human CVCL_B8AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 257; ADK; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997184 CVCL_B8AX Abcam HCT 116 ADAR KO cancer cell line human CVCL_B8AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 225; ADAR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997185 CVCL_B8B9 Abcam HCT 116 ANGPT2 KO cancer cell line human CVCL_B8B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 485; ANGPT2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997186 CVCL_B8AZ Abcam HCT 116 ADORA2A KO cancer cell line human CVCL_B8AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 263; ADORA2A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997187 CVCL_B8AQ Abcam HCT 116 ABCC1 KO cancer cell line human CVCL_B8AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997188 CVCL_B8B2 Abcam HCT 116 AFP KO cancer cell line human CVCL_B8B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 317; AFP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997189 CVCL_B8B1 Abcam HCT 116 ADRB2 KO cancer cell line human CVCL_B8B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 286; ADRB2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997190 CVCL_B8AP Abcam HCT 116 FGFR4 KO 2 cancer cell line human CVCL_B8AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3691; FGFR4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997191 CVCL_B8AS Abcam HCT 116 ACKR3 KO cancer cell line human CVCL_B8AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23692; ACKR3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997192 CVCL_B8B4 Abcam HCT 116 AGO4 KO cancer cell line human CVCL_B8B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18424; AGO4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997193 CVCL_B8AR Abcam HCT 116 ABL2 KO cancer cell line human CVCL_B8AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997194 CVCL_B8B3 Abcam HCT 116 AGO2 KO cancer cell line human CVCL_B8B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3263; AGO2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997195 CVCL_B8AU Abcam HCT 116 ACVR1B KO cancer cell line human CVCL_B8AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 172; ACVR1B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997196 CVCL_B8B6 Abcam HCT 116 AKT2 KO cancer cell line human CVCL_B8B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 392; AKT2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997197 CVCL_B8AT Abcam HCT 116 ACTA2 KO cancer cell line human CVCL_B8AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 130; ACTA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997198 CVCL_B8B5 Abcam HCT 116 AKT1 KO cancer cell line human CVCL_B8B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997199 CVCL_B8AW Abcam HCT 116 ADAM10 KO cancer cell line human CVCL_B8AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 188; ADAM10; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997200 CVCL_B8B8 Abcam HCT 116 ANGPT1 KO cancer cell line human CVCL_B8B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 484; ANGPT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997201 CVCL_B8AV Abcam HCT 116 ADA KO cancer cell line human CVCL_B8AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 186; ADA; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997202 CVCL_B8B7 Abcam HCT 116 AKT3 KO cancer cell line human CVCL_B8B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997203 CVCL_B8AI Abcam Raji YTHDF1 KO cancer cell line human CVCL_B8AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997204 CVCL_B8AH Abcam Raji YTHDC2 KO cancer cell line human CVCL_B8AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24721; YTHDC2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997205 CVCL_B8AK Abcam Raji YY1 KO cancer cell line human CVCL_B8AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12856; YY1; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997206 CVCL_B8AJ Abcam Raji YTHDF3 KO cancer cell line human CVCL_B8AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26465; YTHDF3; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997207 CVCL_B8AM Abcam Raji CD79A KO cancer cell line human CVCL_B8AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1698; CD79A; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997208 CVCL_B8AL Abcam Raji ZEB2 KO cancer cell line human CVCL_B8AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152997209 CVCL_B8B0 Abcam HCT 116 ADRA2B KO cancer cell line human CVCL_B8B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 282; ADRA2B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997210 CVCL_B8AN Abcam HCT 116 CDKN1A KO 2 cancer cell line human CVCL_B8AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 152997211 CVCL_B9QP Abcam A-549 PTN KO cancer cell line human CVCL_B9QP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9630; PTN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997212 CVCL_B9R1 Abcam A-549 RB1CC1 KO cancer cell line human CVCL_B9R1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15574; RB1CC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997213 CVCL_B9R0 Abcam A-549 RB1 KO cancer cell line human CVCL_B9R0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997214 CVCL_B9QR Abcam A-549 PTPN11 KO cancer cell line human CVCL_B9QR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9644; PTPN11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997215 CVCL_B9R3 Abcam A-549 RELA KO cancer cell line human CVCL_B9R3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997216 CVCL_B9QQ Abcam A-549 PTPN1 KO cancer cell line human CVCL_B9QQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9642; PTPN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997217 CVCL_B9R2 Abcam A-549 REL KO cancer cell line human CVCL_B9R2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9954; REL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997218 CVCL_B9QT Abcam A-549 PTPN6 KO cancer cell line human CVCL_B9QT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9658; PTPN6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997219 CVCL_B9R5 Abcam A-549 RET KO cancer cell line human CVCL_B9R5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997220 CVCL_B9QS Abcam A-549 PTPN2 KO cancer cell line human CVCL_B9QS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9650; PTPN2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997221 CVCL_B9R4 Abcam A-549 REST KO cancer cell line human CVCL_B9R4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997222 CVCL_B9QV Abcam A-549 RAD50 KO cancer cell line human CVCL_B9QV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9816; RAD50; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997223 CVCL_B9R7 Abcam A-549 ROR1 KO cancer cell line human CVCL_B9R7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10256; ROR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997224 CVCL_B9QU Abcam A-549 RAB8 KO cancer cell line human CVCL_B9QU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997225 CVCL_B9R6 Abcam A-549 RNF2 KO cancer cell line human CVCL_B9R6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997226 CVCL_B9QH Abcam A-549 PROM1 KO cancer cell line human CVCL_B9QH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9454; PROM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997227 CVCL_B9QG Abcam A-549 PROCR KO cancer cell line human CVCL_B9QG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9452; PROCR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997228 CVCL_B9QJ Abcam A-549 PTCH1 KO cancer cell line human CVCL_B9QJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997229 CVCL_B9QI Abcam A-549 PROX1 KO cancer cell line human CVCL_B9QI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9459; PROX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997230 CVCL_B9QL Abcam A-549 PTEN KO cancer cell line human CVCL_B9QL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997231 CVCL_B9QK Abcam A-549 PTCH2 KO cancer cell line human CVCL_B9QK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9586; PTCH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997232 CVCL_B9QN Abcam A-549 PTK6 KO cancer cell line human CVCL_B9QN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9617; PTK6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997233 CVCL_B9QM Abcam A-549 PTGS1 KO cancer cell line human CVCL_B9QM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9604; PTGS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997234 CVCL_B9QB Abcam A-549 PRKAA2 KO cancer cell line human CVCL_B9QB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9377; PRKAA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997235 CVCL_B9QA Abcam A-549 PRKAA1 KO cancer cell line human CVCL_B9QA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9376; PRKAA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997236 CVCL_B9QD Abcam A-549 PRKCA KO cancer cell line human CVCL_B9QD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9393; PRKCA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997237 CVCL_B9QC Abcam A-549 PRKAR1A KO cancer cell line human CVCL_B9QC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9388; PRKAR1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997238 CVCL_B9QF Abcam A-549 PRKDC KO cancer cell line human CVCL_B9QF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9413; PRKDC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997239 CVCL_B9QE Abcam A-549 PRKCB KO cancer cell line human CVCL_B9QE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9395; PRKCB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997240 CVCL_B9PW Abcam A-549 PMEL KO cancer cell line human CVCL_B9PW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10880; PMEL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997241 CVCL_B9Q8 Abcam A-549 PRDM16 KO cancer cell line human CVCL_B9Q8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14000; PRDM16; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997242 CVCL_B9PV Abcam A-549 PIWIL4 KO cancer cell line human CVCL_B9PV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18444; PIWIL4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997243 CVCL_B9Q7 Abcam A-549 PRDM1 KO cancer cell line human CVCL_B9Q7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9346; PRDM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997244 CVCL_B9PY Abcam A-549 PML KO 2 cancer cell line human CVCL_B9PY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997245 CVCL_B9PX Abcam A-549 PML KO 1 cancer cell line human CVCL_B9PX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997246 CVCL_B9Q9 Abcam A-549 PRF1 KO cancer cell line human CVCL_B9Q9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9360; PRF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997247 CVCL_B9PZ Abcam A-549 PMS2 KO cancer cell line human CVCL_B9PZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9122; PMS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997248 CVCL_B9RQ Abcam A-549 SIRT1 KO cancer cell line human CVCL_B9RQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997249 CVCL_B9S2 Abcam A-549 SMAD7 KO cancer cell line human CVCL_B9S2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6773; SMAD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997250 CVCL_B9RP Abcam A-549 SIRPA KO cancer cell line human CVCL_B9RP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9662; SIRPA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997251 CVCL_B9S1 Abcam A-549 SMAD5 KO cancer cell line human CVCL_B9S1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6771; SMAD5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997252 CVCL_B9RS Abcam A-549 SIRT3 KO cancer cell line human CVCL_B9RS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14931; SIRT3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997253 CVCL_B9S4 Abcam A-549 SMARCA2 KO cancer cell line human CVCL_B9S4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11098; SMARCA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997254 CVCL_B9RR Abcam A-549 SIRT2 KO cancer cell line human CVCL_B9RR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10886; SIRT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997255 CVCL_B9S3 Abcam A-549 SMARCA1 KO cancer cell line human CVCL_B9S3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11097; SMARCA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997256 CVCL_B9RU Abcam A-549 SIRT5 KO cancer cell line human CVCL_B9RU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14933; SIRT5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997257 CVCL_B9S6 Abcam A-549 SMARCC1 KO cancer cell line human CVCL_B9S6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997258 CVCL_B9RT Abcam A-549 SIRT4 KO cancer cell line human CVCL_B9RT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14932; SIRT4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997259 CVCL_B9S5 Abcam A-549 SMARCA4 KO cancer cell line human CVCL_B9S5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997260 CVCL_B9RW Abcam A-549 SIRT7 KO cancer cell line human CVCL_B9RW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14935; SIRT7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997261 CVCL_B9S8 Abcam A-549 SMO KO cancer cell line human CVCL_B9S8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997262 CVCL_B9RV Abcam A-549 SIRT6 KO cancer cell line human CVCL_B9RV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14934; SIRT6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997263 CVCL_B9S7 Abcam A-549 SMARCD3 KO cancer cell line human CVCL_B9S7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11108; SMARCD3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997264 CVCL_B9RI Abcam A-549 SAV1 KO cancer cell line human CVCL_B9RI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17795; SAV1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997265 CVCL_B9RH Abcam A-549 SALL4 KO cancer cell line human CVCL_B9RH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15924; SALL4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997266 CVCL_B9RK Abcam A-549 SEMA7A KO cancer cell line human CVCL_B9RK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10741; SEMA7A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997267 CVCL_B9RJ Abcam A-549 SEMA4D KO cancer cell line human CVCL_B9RJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10732; SEMA4D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997268 CVCL_B9RM Abcam A-549 SERPINE1 KO cancer cell line human CVCL_B9RM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8583; SERPINE1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997269 CVCL_B9RL Abcam A-549 SENP1 KO cancer cell line human CVCL_B9RL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17927; SENP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997270 CVCL_B9S0 Abcam A-549 SMAD4 KO cancer cell line human CVCL_B9S0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997271 CVCL_B9RN Abcam A-549 SETD7 KO cancer cell line human CVCL_B9RN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30412; SETD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997272 CVCL_B9RA Abcam A-549 RPS6KA1 KO cancer cell line human CVCL_B9RA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10430; RPS6KA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997273 CVCL_B9RC Abcam A-549 RSF1 KO cancer cell line human CVCL_B9RC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18118; RSF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997274 CVCL_B9RB Abcam A-549 RPS6KA3 KO cancer cell line human CVCL_B9RB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10432; RPS6KA3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997275 CVCL_B9RE Abcam A-549 RUNX1 KO cancer cell line human CVCL_B9RE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10471; RUNX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997276 CVCL_B9RD Abcam A-549 RSPO2 KO cancer cell line human CVCL_B9RD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28583; RSPO2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997277 CVCL_B9RG Abcam A-549 S100A8 KO cancer cell line human CVCL_B9RG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10498; S100A8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997278 CVCL_B9RF Abcam A-549 RUNX3 KO cancer cell line human CVCL_B9RF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10473; RUNX3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997279 CVCL_B9QX Abcam A-549 RAET1E KO cancer cell line human CVCL_B9QX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16793; RAET1E; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997280 CVCL_B9R9 Abcam A-549 ROS1 KO cancer cell line human CVCL_B9R9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10261; ROS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997281 CVCL_B9QW Abcam A-549 RAD51D KO cancer cell line human CVCL_B9QW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997282 CVCL_B9R8 Abcam A-549 RORC KO cancer cell line human CVCL_B9R8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10260; RORC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997283 CVCL_B9QZ Abcam A-549 RARB KO cancer cell line human CVCL_B9QZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9865; RARB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997284 CVCL_B9QY Abcam A-549 RAF1 KO cancer cell line human CVCL_B9QY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997285 CVCL_B9P1 Abcam A-549 PADI4 KO cancer cell line human CVCL_B9P1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18368; PADI4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997286 CVCL_B9P0 Abcam A-549 OPRM1 KO cancer cell line human CVCL_B9P0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8156; OPRM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997287 CVCL_B9P3 Abcam A-549 PAK2 KO cancer cell line human CVCL_B9P3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997288 CVCL_B9P2 Abcam A-549 PAK1 KO cancer cell line human CVCL_B9P2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997289 CVCL_B9P5 Abcam A-549 PALB2 KO cancer cell line human CVCL_B9P5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26144; PALB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997290 CVCL_B9P4 Abcam A-549 PAK4 KO cancer cell line human CVCL_B9P4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997291 CVCL_B9NU Abcam A-549 NRAS KO cancer cell line human CVCL_B9NU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997292 CVCL_B9NT Abcam A-549 NR4A3 KO cancer cell line human CVCL_B9NT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7982; NR4A3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997293 CVCL_B9NW Abcam A-549 NTRK2 KO cancer cell line human CVCL_B9NW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8032; NTRK2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997294 CVCL_B9NV Abcam A-549 NSD2 KO cancer cell line human CVCL_B9NV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997295 CVCL_B9NY Abcam A-549 OGT KO cancer cell line human CVCL_B9NY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8127; OGT; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997296 CVCL_B9NX Abcam A-549 NTRK3 KO cancer cell line human CVCL_B9NX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8033; NTRK3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997297 CVCL_B9NZ Abcam A-549 OLIG2 KO cancer cell line human CVCL_B9NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9398; OLIG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997298 CVCL_B9Q0 Abcam A-549 POLQ KO cancer cell line human CVCL_B9Q0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9186; POLQ; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997299 CVCL_B9PN Abcam A-549 PGR KO cancer cell line human CVCL_B9PN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8910; PGR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997300 CVCL_B9PQ Abcam A-549 PHLPP1 KO cancer cell line human CVCL_B9PQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20610; PHLPP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997301 CVCL_B9Q2 Abcam A-549 POU2F2 KO cancer cell line human CVCL_B9Q2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9213; POU2F2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997302 CVCL_B9PP Abcam A-549 PHF1 KO cancer cell line human CVCL_B9PP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8919; PHF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997303 CVCL_B9Q1 Abcam A-549 POLR2A KO cancer cell line human CVCL_B9Q1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9187; POLR2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997304 CVCL_B9PS Abcam A-549 PIK3R1 KO cancer cell line human CVCL_B9PS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997305 CVCL_B9Q4 Abcam A-549 PPARA KO cancer cell line human CVCL_B9Q4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9232; PPARA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997306 CVCL_B9PR Abcam A-549 PIK3CA KO cancer cell line human CVCL_B9PR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997307 CVCL_B9Q3 Abcam A-549 POU5F1 KO cancer cell line human CVCL_B9Q3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9221; POU5F1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997308 CVCL_B9PU Abcam A-549 PINK1 KO cancer cell line human CVCL_B9PU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997309 CVCL_B9Q6 Abcam A-549 PPARG KO cancer cell line human CVCL_B9Q6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9236; PPARG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997310 CVCL_B9PT Abcam A-549 PIK3R2 KO cancer cell line human CVCL_B9PT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997311 CVCL_B9Q5 Abcam A-549 PPARD KO cancer cell line human CVCL_B9Q5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9235; PPARD; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997312 CVCL_B9PG Abcam A-549 PDGFRA KO cancer cell line human CVCL_B9PG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997313 CVCL_B9PF Abcam A-549 PDGFB KO cancer cell line human CVCL_B9PF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8800; PDGFB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997314 CVCL_B9PI Abcam A-549 PDPN KO cancer cell line human CVCL_B9PI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997315 CVCL_B9PH Abcam A-549 PDGFRB KO cancer cell line human CVCL_B9PH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8804; PDGFRB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997316 CVCL_B9PK Abcam A-549 PECAM1 KO cancer cell line human CVCL_B9PK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8823; PECAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997317 CVCL_B9PJ Abcam A-549 PEBP1 KO cancer cell line human CVCL_B9PJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8630; PEBP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997318 CVCL_B9PM Abcam A-549 PGF KO cancer cell line human CVCL_B9PM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8893; PGF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997319 CVCL_B9PL Abcam A-549 PER1 KO cancer cell line human CVCL_B9PL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8845; PER1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997320 CVCL_B9PA Abcam A-549 PAX7 KO cancer cell line human CVCL_B9PA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8621; PAX7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997321 CVCL_B9PC Abcam A-549 PBK KO cancer cell line human CVCL_B9PC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997322 CVCL_B9PB Abcam A-549 PAX8 KO cancer cell line human CVCL_B9PB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8622; PAX8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997323 CVCL_B9PE Abcam A-549 PDCD1 KO cancer cell line human CVCL_B9PE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8760; PDCD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997324 CVCL_B9PD Abcam A-549 PBRM1 KO cancer cell line human CVCL_B9PD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997325 CVCL_B9P7 Abcam A-549 PARP3 KO cancer cell line human CVCL_B9P7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997326 CVCL_B9P6 Abcam A-549 PARP1 KO cancer cell line human CVCL_B9P6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997327 CVCL_B9P9 Abcam A-549 PAX6 KO cancer cell line human CVCL_B9P9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8620; PAX6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997328 CVCL_B9P8 Abcam A-549 PAX5 KO cancer cell line human CVCL_B9P8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8619; PAX5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997329 CVCL_B9ML Abcam A-549 MEF2C KO cancer cell line human CVCL_B9ML CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6996; MEF2C; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997330 CVCL_B9MK Abcam A-549 MEF2A KO cancer cell line human CVCL_B9MK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6993; MEF2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997331 CVCL_B9MN Abcam A-549 MET KO cancer cell line human CVCL_B9MN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7029; MET; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997332 CVCL_B9MM Abcam A-549 MEN1 KO cancer cell line human CVCL_B9MM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997333 CVCL_B9MP Abcam A-549 MGMT KO cancer cell line human CVCL_B9MP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997334 CVCL_B9N1 Abcam A-549 MSH3 KO cancer cell line human CVCL_B9N1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997335 CVCL_B9N0 Abcam A-549 MSH2 KO cancer cell line human CVCL_B9N0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997336 CVCL_B9MR Abcam A-549 MICB KO cancer cell line human CVCL_B9MR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7091; MICB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997337 CVCL_B9N3 Abcam A-549 MSLN KO cancer cell line human CVCL_B9N3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7371; MSLN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997338 CVCL_B9MQ Abcam A-549 MICA KO cancer cell line human CVCL_B9MQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7090; MICA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997339 CVCL_B9N2 Abcam A-549 MSH6 KO cancer cell line human CVCL_B9N2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997340 CVCL_B9MD Abcam A-549 MAPK14 KO cancer cell line human CVCL_B9MD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997341 CVCL_B9MC Abcam A-549 MAPK1 KO cancer cell line human CVCL_B9MC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6871; MAPK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997342 CVCL_B9MF Abcam A-549 MAVS KO cancer cell line human CVCL_B9MF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29233; MAVS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997343 CVCL_B9ME Abcam A-549 MAPK3 KO cancer cell line human CVCL_B9ME CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6877; MAPK3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997344 CVCL_B9MH Abcam A-549 MECOM KO cancer cell line human CVCL_B9MH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3498; MECOM; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997345 CVCL_B9MG Abcam A-549 MDC1 KO cancer cell line human CVCL_B9MG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997346 CVCL_B9MJ Abcam A-549 MED12 KO cancer cell line human CVCL_B9MJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11957; MED12; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997347 CVCL_B9MI Abcam A-549 MECP2 KO cancer cell line human CVCL_B9MI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6990; MECP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997348 CVCL_B9LZ Abcam A-549 LGR5 KO cancer cell line human CVCL_B9LZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4504; LGR5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997349 CVCL_B9MB Abcam A-549 MAP3K7 KO cancer cell line human CVCL_B9MB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6859; MAP3K7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997350 CVCL_B9MA Abcam A-549 MAP2K4 KO cancer cell line human CVCL_B9MA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997351 CVCL_B9LS Abcam A-549 KRT1 KO cancer cell line human CVCL_B9LS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6412; KRT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997352 CVCL_B9M4 Abcam A-549 LRP5 KO cancer cell line human CVCL_B9M4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997353 CVCL_B9LR Abcam A-549 KMT2D KO cancer cell line human CVCL_B9LR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997354 CVCL_B9M3 Abcam A-549 LMNA KO cancer cell line human CVCL_B9M3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997355 CVCL_B9LU Abcam A-549 LATS1 KO cancer cell line human CVCL_B9LU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997356 CVCL_B9M6 Abcam A-549 MAF KO cancer cell line human CVCL_B9M6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6776; MAF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997357 CVCL_B9LT Abcam A-549 LAMP1 KO cancer cell line human CVCL_B9LT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6499; LAMP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997358 CVCL_B9M5 Abcam A-549 LYN KO cancer cell line human CVCL_B9M5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6735; LYN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997359 CVCL_B9LW Abcam A-549 LCK KO cancer cell line human CVCL_B9LW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6524; LCK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997360 CVCL_B9M8 Abcam A-549 MAP2K1 KO cancer cell line human CVCL_B9M8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6840; MAP2K1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997361 CVCL_B9LV Abcam A-549 LATS2 KO cancer cell line human CVCL_B9LV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6515; LATS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997362 CVCL_B9M7 Abcam A-549 MALT1 KO cancer cell line human CVCL_B9M7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6819; MALT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997363 CVCL_B9LY Abcam A-549 LGALS3 KO cancer cell line human CVCL_B9LY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6563; LGALS3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997364 CVCL_B9LX Abcam A-549 LGALS1 KO cancer cell line human CVCL_B9LX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6561; LGALS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997365 CVCL_B9M9 Abcam A-549 MAP2K2 KO cancer cell line human CVCL_B9M9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997366 CVCL_B9NM Abcam A-549 NFATC2 KO cancer cell line human CVCL_B9NM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7776; NFATC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997367 CVCL_B9NL Abcam A-549 NFATC1 KO cancer cell line human CVCL_B9NL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7775; NFATC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997368 CVCL_B9NN Abcam A-549 NOS2 KO cancer cell line human CVCL_B9NN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997369 CVCL_B9NQ Abcam A-549 NOTCH2 KO cancer cell line human CVCL_B9NQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7882; NOTCH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997370 CVCL_B9NP Abcam A-549 NOTCH1 KO cancer cell line human CVCL_B9NP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997371 CVCL_B9NS Abcam A-549 NR4A1 KO cancer cell line human CVCL_B9NS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997372 CVCL_B9NR Abcam A-549 NR1H3 KO cancer cell line human CVCL_B9NR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7966; NR1H3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997373 CVCL_B9NE Abcam A-549 NCF4 KO cancer cell line human CVCL_B9NE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7662; NCF4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997374 CVCL_B9ND Abcam A-549 NCAM2 KO cancer cell line human CVCL_B9ND CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7657; NCAM2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997375 CVCL_B9NG Abcam A-549 NCR1 KO cancer cell line human CVCL_B9NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6731; NCR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997376 CVCL_B9NF Abcam A-549 NCOA1 KO cancer cell line human CVCL_B9NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7668; NCOA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997377 CVCL_B9NI Abcam A-549 NECTIN3 KO cancer cell line human CVCL_B9NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17664; NECTIN3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997378 CVCL_B9NH Abcam A-549 NECTIN2 KO cancer cell line human CVCL_B9NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9707; NECTIN2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997379 CVCL_B9NK Abcam A-549 NF2 KO cancer cell line human CVCL_B9NK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997380 CVCL_B9NJ Abcam A-549 NF1 KO cancer cell line human CVCL_B9NJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997381 CVCL_B9NA Abcam A-549 MYOD1 KO cancer cell line human CVCL_B9NA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7611; MYOD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997382 CVCL_B9NC Abcam A-549 NCAM1 KO cancer cell line human CVCL_B9NC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7656; NCAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997383 CVCL_B9NB Abcam A-549 NANOG KO cancer cell line human CVCL_B9NB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20857; NANOG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997384 CVCL_B9MT Abcam A-549 MKI67 KO cancer cell line human CVCL_B9MT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997385 CVCL_B9N5 Abcam A-549 MTA2 KO cancer cell line human CVCL_B9N5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7411; MTA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997386 CVCL_B9MS Abcam A-549 MITF KO cancer cell line human CVCL_B9MS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7105; MITF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997387 CVCL_B9N4 Abcam A-549 MSR1 KO cancer cell line human CVCL_B9N4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7376; MSR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997388 CVCL_B9MV Abcam A-549 MMP12 KO cancer cell line human CVCL_B9MV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7158; MMP12; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997389 CVCL_B9N7 Abcam A-549 MUC16 KO cancer cell line human CVCL_B9N7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15582; MUC16; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997390 CVCL_B9MU Abcam A-549 MMP1 KO cancer cell line human CVCL_B9MU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7155; MMP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997391 CVCL_B9N6 Abcam A-549 MUC1 KO cancer cell line human CVCL_B9N6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7508; MUC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997392 CVCL_B9MX Abcam A-549 MMP9 KO cancer cell line human CVCL_B9MX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7176; MMP9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997393 CVCL_B9N9 Abcam A-549 MYD88 KO cancer cell line human CVCL_B9N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7562; MYD88; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997394 CVCL_B9MW Abcam A-549 MMP2 KO cancer cell line human CVCL_B9MW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7166; MMP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997395 CVCL_B9N8 Abcam A-549 MYB KO cancer cell line human CVCL_B9N8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7545; MYB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997396 CVCL_B9MZ Abcam A-549 MRC1 KO cancer cell line human CVCL_B9MZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7228; MRC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997397 CVCL_B9MY Abcam A-549 MPO KO cancer cell line human CVCL_B9MY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7218; MPO; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997398 CVCL_B9KJ Abcam A-549 IL1A KO cancer cell line human CVCL_B9KJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5991; IL1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997399 CVCL_B9KI Abcam A-549 IL18 KO cancer cell line human CVCL_B9KI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5986; IL18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997400 CVCL_B9KL Abcam A-549 IL23A KO cancer cell line human CVCL_B9KL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15488; IL23A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997401 CVCL_B9KK Abcam A-549 IL1B KO cancer cell line human CVCL_B9KK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5992; IL1B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997402 CVCL_B9KN Abcam A-549 IL27 KO cancer cell line human CVCL_B9KN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19157; IL27; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997403 CVCL_B9KM Abcam A-549 IL23R KO cancer cell line human CVCL_B9KM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19100; IL23R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997404 CVCL_B9KP Abcam A-549 IL2RB KO cancer cell line human CVCL_B9KP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6009; IL2RB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997405 CVCL_B9L1 Abcam A-549 ITGAE KO cancer cell line human CVCL_B9L1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997406 CVCL_B9L0 Abcam A-549 ITGA2 KO cancer cell line human CVCL_B9L0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997407 CVCL_B9KB Abcam A-549 IGF2BP2 KO cancer cell line human CVCL_B9KB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28867; IGF2BP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997408 CVCL_B9KA Abcam A-549 IGF2BP1 KO cancer cell line human CVCL_B9KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28866; IGF2BP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997409 CVCL_B9KD Abcam A-549 IHH KO cancer cell line human CVCL_B9KD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5956; IHH; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997410 CVCL_B9KC Abcam A-549 IGF2BP3 KO cancer cell line human CVCL_B9KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997411 CVCL_B9KF Abcam A-549 IL12A KO cancer cell line human CVCL_B9KF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5969; IL12A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997412 CVCL_B9KE Abcam A-549 IKBKE KO cancer cell line human CVCL_B9KE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14552; IKBKE; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997413 CVCL_B9KH Abcam A-549 IL17A KO cancer cell line human CVCL_B9KH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5981; IL17A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997414 CVCL_B9KG Abcam A-549 IL15 KO cancer cell line human CVCL_B9KG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5977; IL15; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997415 CVCL_B9JY Abcam A-549 HRAS KO cancer cell line human CVCL_B9JY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5173; HRAS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997416 CVCL_B9JX Abcam A-549 HPSE KO cancer cell line human CVCL_B9JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5164; HPSE; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997417 CVCL_B9K9 Abcam A-549 IGF1 KO cancer cell line human CVCL_B9K9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5464; IGF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997418 CVCL_B9JZ Abcam A-549 ICAM1 KO cancer cell line human CVCL_B9JZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5344; ICAM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997419 CVCL_B9JQ Abcam A-549 HLA-A KO cancer cell line human CVCL_B9JQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997420 CVCL_B9K2 Abcam A-549 IDH1 KO cancer cell line human CVCL_B9K2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997421 CVCL_B9JP Abcam A-549 HIF1A KO cancer cell line human CVCL_B9JP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4910; HIF1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997422 CVCL_B9K1 Abcam A-549 ICOSLG KO cancer cell line human CVCL_B9K1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17087; ICOSLG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997423 CVCL_B9JS Abcam A-549 HLA-G KO cancer cell line human CVCL_B9JS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4964; HLA-G; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997424 CVCL_B9K4 Abcam A-549 IFITM1 KO cancer cell line human CVCL_B9K4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997425 CVCL_B9JR Abcam A-549 HLA-DRA KO cancer cell line human CVCL_B9JR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4947; HLA-DRA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997426 CVCL_B9K3 Abcam A-549 IDH2 KO cancer cell line human CVCL_B9K3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997427 CVCL_B9JU Abcam A-549 HNF1A KO cancer cell line human CVCL_B9JU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11621; HNF1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997428 CVCL_B9K6 Abcam A-549 IFNB1 KO cancer cell line human CVCL_B9K6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5434; IFNB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997429 CVCL_B9JT Abcam A-549 HMGA2 KO cancer cell line human CVCL_B9JT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5009; HMGA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997430 CVCL_B9K5 Abcam A-549 IFNAR1 KO cancer cell line human CVCL_B9K5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5432; IFNAR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997431 CVCL_B9JW Abcam A-549 HOXA9 KO cancer cell line human CVCL_B9JW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5109; HOXA9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997432 CVCL_B9K8 Abcam A-549 IFNGR2 KO cancer cell line human CVCL_B9K8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5440; IFNGR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997433 CVCL_B9JV Abcam A-549 HNF4A KO cancer cell line human CVCL_B9JV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5024; HNF4A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997434 CVCL_B9K7 Abcam A-549 IFNGR1 KO cancer cell line human CVCL_B9K7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997435 CVCL_B9LK Abcam A-549 KIT KO cancer cell line human CVCL_B9LK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997436 CVCL_B9LJ Abcam A-549 KEAP1 KO cancer cell line human CVCL_B9LJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997437 CVCL_B9LM Abcam A-549 KLF4 KO cancer cell line human CVCL_B9LM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6348; KLF4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997438 CVCL_B9LL Abcam A-549 KITLG KO cancer cell line human CVCL_B9LL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6343; KITLG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997439 CVCL_B9M0 Abcam A-549 LILRB1 KO cancer cell line human CVCL_B9M0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6605; LILRB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997440 CVCL_B9LN Abcam A-549 KLRB1 KO cancer cell line human CVCL_B9LN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6373; KLRB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997441 CVCL_B9LQ Abcam A-549 KMT2A KO cancer cell line human CVCL_B9LQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7132; KMT2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997442 CVCL_B9M2 Abcam A-549 LIN28B KO cancer cell line human CVCL_B9M2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32207; LIN28B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997443 CVCL_B9LP Abcam A-549 KLRC1 KO cancer cell line human CVCL_B9LP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6374; KLRC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997444 CVCL_B9M1 Abcam A-549 LIN28A KO cancer cell line human CVCL_B9M1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15986; LIN28A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997445 CVCL_B9LC Abcam A-549 KAT2A KO cancer cell line human CVCL_B9LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4201; KAT2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997446 CVCL_B9LB Abcam A-549 JARID2 KO cancer cell line human CVCL_B9LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6196; JARID2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997447 CVCL_B9LE Abcam A-549 KDM1A KO cancer cell line human CVCL_B9LE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997448 CVCL_B9LD Abcam A-549 KAT2B KO cancer cell line human CVCL_B9LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8638; KAT2B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997449 CVCL_B9LG Abcam A-549 KDM5A KO cancer cell line human CVCL_B9LG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9886; KDM5A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997450 CVCL_B9LF Abcam A-549 KDM3A KO cancer cell line human CVCL_B9LF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20815; KDM3A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997451 CVCL_B9LI Abcam A-549 KDM6A KO cancer cell line human CVCL_B9LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997452 CVCL_B9LH Abcam A-549 KDM5B KO cancer cell line human CVCL_B9LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997453 CVCL_B9KZ Abcam A-549 IRF4 KO cancer cell line human CVCL_B9KZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6119; IRF4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997454 CVCL_B9KY Abcam A-549 IRAK4 KO cancer cell line human CVCL_B9KY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17967; IRAK4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997455 CVCL_B9LA Abcam A-549 JAK3 KO cancer cell line human CVCL_B9LA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6193; JAK3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997456 CVCL_B9KR Abcam A-549 IL6R KO cancer cell line human CVCL_B9KR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6019; IL6R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997457 CVCL_B9L3 Abcam A-549 ITGAM KO cancer cell line human CVCL_B9L3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6149; ITGAM; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997458 CVCL_B9KQ Abcam A-549 IL3RA KO cancer cell line human CVCL_B9KQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6012; IL3RA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997459 CVCL_B9L2 Abcam A-549 ITGAL KO cancer cell line human CVCL_B9L2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6148; ITGAL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997460 CVCL_B9KT Abcam A-549 IL9 KO cancer cell line human CVCL_B9KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6029; IL9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997461 CVCL_B9L5 Abcam A-549 ITGAX KO cancer cell line human CVCL_B9L5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6152; ITGAX; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997462 CVCL_B9KS Abcam A-549 IL7R KO cancer cell line human CVCL_B9KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6024; IL7R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997463 CVCL_B9L4 Abcam A-549 ITGAV KO cancer cell line human CVCL_B9L4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6150; ITGAV; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997464 CVCL_B9KV Abcam A-549 INPP5D KO cancer cell line human CVCL_B9KV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6079; INPP5D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997465 CVCL_B9L7 Abcam A-549 ITK KO cancer cell line human CVCL_B9L7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6171; ITK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997466 CVCL_B9KU Abcam A-549 INHBA KO cancer cell line human CVCL_B9KU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6066; INHBA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997467 CVCL_B9L6 Abcam A-549 ITGB1 KO cancer cell line human CVCL_B9L6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997468 CVCL_B9KX Abcam A-549 IRAK1 KO cancer cell line human CVCL_B9KX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6112; IRAK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997469 CVCL_B9L9 Abcam A-549 JAK1 KO cancer cell line human CVCL_B9L9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6190; JAK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997470 CVCL_B9KW Abcam A-549 IQGAP1 KO cancer cell line human CVCL_B9KW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6110; IQGAP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997471 CVCL_B9L8 Abcam A-549 ITPR1 KO cancer cell line human CVCL_B9L8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997472 CVCL_B9YX Abcam THP-1 MBD1 KO cancer cell line human CVCL_B9YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997473 CVCL_B9Z9 Abcam THP-1 NOTCH4 KO cancer cell line human CVCL_B9Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7884; NOTCH4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997474 CVCL_B9YW Abcam THP-1 MAPK7 KO cancer cell line human CVCL_B9YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997475 CVCL_B9Z8 Abcam THP-1 NOTCH3 KO cancer cell line human CVCL_B9Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7883; NOTCH3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997476 CVCL_B9YZ Abcam THP-1 MME KO cancer cell line human CVCL_B9YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7154; MME; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997477 CVCL_B9YY Abcam THP-1 MBD3 KO cancer cell line human CVCL_B9YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997478 CVCL_B9YP Abcam THP-1 LDHA KO cancer cell line human CVCL_B9YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6535; LDHA; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997479 CVCL_B9Z1 Abcam THP-1 MMP8 KO cancer cell line human CVCL_B9Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7175; MMP8; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997480 CVCL_B9Z0 Abcam THP-1 MMP13 KO cancer cell line human CVCL_B9Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7159; MMP13; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997481 CVCL_B9YR Abcam THP-1 LMNB1 KO cancer cell line human CVCL_B9YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997482 CVCL_B9Z3 Abcam THP-1 NBR1 KO cancer cell line human CVCL_B9Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997483 CVCL_B9YQ Abcam THP-1 LGR6 KO cancer cell line human CVCL_B9YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19719; LGR6; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997484 CVCL_B9Z2 Abcam THP-1 MTA3 KO cancer cell line human CVCL_B9Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23784; MTA3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997485 CVCL_B9YT Abcam THP-1 MAGEA3 KO cancer cell line human CVCL_B9YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6801; MAGEA3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997486 CVCL_B9Z5 Abcam THP-1 NFKB1 KO cancer cell line human CVCL_B9Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7794; NFKB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997487 CVCL_B9YS Abcam THP-1 MACROH2A1 KO cancer cell line human CVCL_B9YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4740; MACROH2A1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997488 CVCL_B9Z4 Abcam THP-1 NCR3LG1 KO cancer cell line human CVCL_B9Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 42400; NCR3LG1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997489 CVCL_B9YV Abcam THP-1 MAP3K3 KO cancer cell line human CVCL_B9YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6855; MAP3K3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997490 CVCL_B9Z7 Abcam THP-1 NLRP3 KO cancer cell line human CVCL_B9Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16400; NLRP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997491 CVCL_B9YU Abcam THP-1 MAP2K3 KO cancer cell line human CVCL_B9YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6843; MAP2K3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997492 CVCL_B9Z6 Abcam THP-1 NLRC4 KO cancer cell line human CVCL_B9Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16412; NLRC4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997493 CVCL_B9YH Abcam THP-1 JMJD6 KO cancer cell line human CVCL_B9YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19355; JMJD6; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997494 CVCL_B9YG Abcam THP-1 JAG1 KO cancer cell line human CVCL_B9YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997495 CVCL_B9YJ Abcam THP-1 KDM1B KO cancer cell line human CVCL_B9YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997496 CVCL_B9YI Abcam THP-1 KAT7 KO cancer cell line human CVCL_B9YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997497 CVCL_B9YL Abcam THP-1 KPNA2 KO cancer cell line human CVCL_B9YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6395; KPNA2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997498 CVCL_B9YK Abcam THP-1 KDM6B KO cancer cell line human CVCL_B9YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997499 CVCL_B9YN Abcam THP-1 LAMP2 KO cancer cell line human CVCL_B9YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6501; LAMP2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997500 CVCL_B9YM Abcam THP-1 LAIR1 KO cancer cell line human CVCL_B9YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6477; LAIR1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997501 CVCL_B9YB Abcam THP-1 HSPG2 KO cancer cell line human CVCL_B9YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997502 CVCL_B9YA Abcam THP-1 HNF1B KO cancer cell line human CVCL_B9YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11630; HNF1B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997503 CVCL_B9YD Abcam THP-1 IL17RB KO cancer cell line human CVCL_B9YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18015; IL17RB; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997504 CVCL_B9YC Abcam THP-1 ID2 KO cancer cell line human CVCL_B9YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5361; ID2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997505 CVCL_B9YF Abcam THP-1 ITPR3 KO cancer cell line human CVCL_B9YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997506 CVCL_B9YE Abcam THP-1 IRAK3 KO cancer cell line human CVCL_B9YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17020; IRAK3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997507 CVCL_B9ZY Abcam THP-1 ROR2 KO cancer cell line human CVCL_B9ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10257; ROR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997508 CVCL_B9ZX Abcam THP-1 ROCK2 KO cancer cell line human CVCL_B9ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997509 CVCL_B9ZZ Abcam THP-1 RUNX2 KO cancer cell line human CVCL_B9ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10472; RUNX2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997510 CVCL_B9ZQ Abcam THP-1 PTGES2 KO cancer cell line human CVCL_B9ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17822; PTGES2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997511 CVCL_B9ZP Abcam THP-1 PTGER4 KO cancer cell line human CVCL_B9ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9596; PTGER4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997512 CVCL_B9ZS Abcam THP-1 PTP4A3 KO cancer cell line human CVCL_B9ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9636; PTP4A3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997513 CVCL_B9ZR Abcam THP-1 PTK2 KO cancer cell line human CVCL_B9ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9611; PTK2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997514 CVCL_B9ZU Abcam THP-1 PUS1 KO cancer cell line human CVCL_B9ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15508; PUS1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997515 CVCL_B9ZT Abcam THP-1 PTPN12 KO cancer cell line human CVCL_B9ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9645; PTPN12; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997516 CVCL_B9ZW Abcam THP-1 RING1 KO cancer cell line human CVCL_B9ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997517 CVCL_B9ZV Abcam THP-1 RAC2 KO cancer cell line human CVCL_B9ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9802; RAC2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997518 CVCL_B9ZI Abcam THP-1 PLA2G4A KO cancer cell line human CVCL_B9ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997519 CVCL_B9ZH Abcam THP-1 PIK3R4 KO cancer cell line human CVCL_B9ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8982; PIK3R4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997520 CVCL_B9ZK Abcam THP-1 PLCB3 KO cancer cell line human CVCL_B9ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997521 CVCL_B9ZJ Abcam THP-1 PLAU KO cancer cell line human CVCL_B9ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9052; PLAU; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997522 CVCL_B9ZM Abcam THP-1 PRMT7 KO cancer cell line human CVCL_B9ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25557; PRMT7; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997523 CVCL_B9ZL Abcam THP-1 PLCG1 KO cancer cell line human CVCL_B9ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997524 CVCL_B9ZN Abcam THP-1 PSEN1 KO cancer cell line human CVCL_B9ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997525 CVCL_B9ZA Abcam THP-1 NQO1 KO cancer cell line human CVCL_B9ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2874; NQO1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997526 CVCL_B9ZC Abcam THP-1 NR3C2 KO cancer cell line human CVCL_B9ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997527 CVCL_B9ZB Abcam THP-1 NR1H4 KO cancer cell line human CVCL_B9ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7967; NR1H4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997528 CVCL_B9ZE Abcam THP-1 PHF8 KO cancer cell line human CVCL_B9ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20672; PHF8; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997529 CVCL_B9ZD Abcam THP-1 PDCD1LG2 KO cancer cell line human CVCL_B9ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997530 CVCL_B9ZG Abcam THP-1 PIK3CD KO cancer cell line human CVCL_B9ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997531 CVCL_B9ZF Abcam THP-1 PIK3CA KO cancer cell line human CVCL_B9ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997532 CVCL_B9WV Abcam THP-1 BTRC KO cancer cell line human CVCL_B9WV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997533 CVCL_B9X7 Abcam THP-1 CITED2 KO cancer cell line human CVCL_B9X7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1987; CITED2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997534 CVCL_B9WU Abcam THP-1 BTK KO cancer cell line human CVCL_B9WU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1133; BTK; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997535 CVCL_B9X6 Abcam THP-1 CD81 KO cancer cell line human CVCL_B9X6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997536 CVCL_B9WX Abcam THP-1 CASP3 KO cancer cell line human CVCL_B9WX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1504; CASP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997537 CVCL_B9X9 Abcam THP-1 CMKLR1 KO cancer cell line human CVCL_B9X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2121; CMKLR1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997538 CVCL_B9WW Abcam THP-1 C3 KO cancer cell line human CVCL_B9WW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1318; C3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997539 CVCL_B9X8 Abcam THP-1 CLU KO cancer cell line human CVCL_B9X8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2095; CLU; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997540 CVCL_B9WZ Abcam THP-1 CCR2 KO cancer cell line human CVCL_B9WZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1603; CCR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997541 CVCL_B9WY Abcam THP-1 CCL4 KO cancer cell line human CVCL_B9WY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10630; CCL4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997542 CVCL_B9WN Abcam THP-1 BAK1 KO cancer cell line human CVCL_B9WN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997543 CVCL_B9WM Abcam THP-1 ATG9A KO cancer cell line human CVCL_B9WM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997544 CVCL_B9WP Abcam THP-1 BMPR2 KO cancer cell line human CVCL_B9WP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1078; BMPR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997545 CVCL_B9X1 Abcam THP-1 CCL22 KO cancer cell line human CVCL_B9X1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10621; CCL22; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997546 CVCL_B9X0 Abcam THP-1 CCRL2 KO cancer cell line human CVCL_B9X0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1612; CCRL2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997547 CVCL_B9WR Abcam THP-1 BRD2 KO cancer cell line human CVCL_B9WR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997548 CVCL_B9X3 Abcam THP-1 CD48 KO cancer cell line human CVCL_B9X3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1683; CD48; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997549 CVCL_B9WQ Abcam THP-1 BRD1 KO cancer cell line human CVCL_B9WQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997550 CVCL_B9X2 Abcam THP-1 CD36 KO cancer cell line human CVCL_B9X2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1663; CD36; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997551 CVCL_B9WT Abcam THP-1 BTG1 KO cancer cell line human CVCL_B9WT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1130; BTG1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997552 CVCL_B9X5 Abcam THP-1 CD59 KO cancer cell line human CVCL_B9X5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1689; CD59; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997553 CVCL_B9WS Abcam THP-1 BRD9 KO cancer cell line human CVCL_B9WS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997554 CVCL_B9X4 Abcam THP-1 CD58 KO cancer cell line human CVCL_B9X4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1688; CD58; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997555 CVCL_B9WF Abcam THP-1 ALCAM KO cancer cell line human CVCL_B9WF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 400; ALCAM; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997556 CVCL_B9WE Abcam THP-1 AIM2 KO cancer cell line human CVCL_B9WE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 357; AIM2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997557 CVCL_B9WH Abcam THP-1 ALYREF KO cancer cell line human CVCL_B9WH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19071; ALYREF; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997558 CVCL_B9WG Abcam THP-1 ALKBH1 KO cancer cell line human CVCL_B9WG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17911; ALKBH1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997559 CVCL_B9WJ Abcam THP-1 ASAH1 KO cancer cell line human CVCL_B9WJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 735; ASAH1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997560 CVCL_B9WI Abcam THP-1 APOBEC3B KO cancer cell line human CVCL_B9WI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17352; APOBEC3B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997561 CVCL_B9WL Abcam THP-1 ATG3 KO cancer cell line human CVCL_B9WL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20962; ATG3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997562 CVCL_B9WK Abcam THP-1 ATF5 KO cancer cell line human CVCL_B9WK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997563 CVCL_B9WB Abcam THP-1 ADGRG1 KO cancer cell line human CVCL_B9WB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4512; ADGRG1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997564 CVCL_B9WA Abcam THP-1 ACVR1B KO cancer cell line human CVCL_B9WA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 172; ACVR1B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997565 CVCL_B9WD Abcam THP-1 AHR KO cancer cell line human CVCL_B9WD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 348; AHR; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997566 CVCL_B9WC Abcam THP-1 AGTR1 KO cancer cell line human CVCL_B9WC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 336; AGTR1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997567 CVCL_B9XW Abcam THP-1 FABP4 KO cancer cell line human CVCL_B9XW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3559; FABP4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997568 CVCL_B9Y8 Abcam THP-1 GZMA KO cancer cell line human CVCL_B9Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4708; GZMA; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997569 CVCL_B9XV Abcam THP-1 EXO1 KO cancer cell line human CVCL_B9XV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3511; EXO1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997570 CVCL_B9Y7 Abcam THP-1 GPR132 KO cancer cell line human CVCL_B9Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17482; GPR132; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997571 CVCL_B9XY Abcam THP-1 FGF23 KO cancer cell line human CVCL_B9XY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3680; FGF23; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997572 CVCL_B9XX Abcam THP-1 FCGR1A KO cancer cell line human CVCL_B9XX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3613; FCGR1A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997573 CVCL_B9Y9 Abcam THP-1 HLA-B KO cancer cell line human CVCL_B9Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997574 CVCL_B9XZ Abcam THP-1 FKBP5 KO cancer cell line human CVCL_B9XZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3721; FKBP5; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997575 CVCL_B9Y0 Abcam THP-1 FOXO1 KO cancer cell line human CVCL_B9Y0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997576 CVCL_B9XN Abcam THP-1 EGLN1 KO cancer cell line human CVCL_B9XN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1232; EGLN1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997577 CVCL_B9XQ Abcam THP-1 EIF2AK4 KO cancer cell line human CVCL_B9XQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997578 CVCL_B9Y2 Abcam THP-1 FST KO cancer cell line human CVCL_B9Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3971; FST; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997579 CVCL_B9XP Abcam THP-1 EHMT2 KO cancer cell line human CVCL_B9XP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997580 CVCL_B9Y1 Abcam THP-1 FOXO3 KO cancer cell line human CVCL_B9Y1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3821; FOXO3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997581 CVCL_B9XS Abcam THP-1 EPHB4 KO cancer cell line human CVCL_B9XS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997582 CVCL_B9Y4 Abcam THP-1 FZD7 KO cancer cell line human CVCL_B9Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4045; FZD7; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997583 CVCL_B9XR Abcam THP-1 ENG KO cancer cell line human CVCL_B9XR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3349; ENG; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997584 CVCL_B9Y3 Abcam THP-1 FTL KO cancer cell line human CVCL_B9Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997585 CVCL_B9XU Abcam THP-1 ETS2 KO cancer cell line human CVCL_B9XU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3489; ETS2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997586 CVCL_B9Y6 Abcam THP-1 GLB1 KO cancer cell line human CVCL_B9Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4298; GLB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997587 CVCL_B9XT Abcam THP-1 ERAP1 KO cancer cell line human CVCL_B9XT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18173; ERAP1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997588 CVCL_B9Y5 Abcam THP-1 GAB1 KO cancer cell line human CVCL_B9Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4066; GAB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997589 CVCL_B9XG Abcam THP-1 CUL3 KO cancer cell line human CVCL_B9XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2553; CUL3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997590 CVCL_B9XF Abcam THP-1 CUL2 KO cancer cell line human CVCL_B9XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2552; CUL2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997591 CVCL_B9XI Abcam THP-1 CX3CR1 KO cancer cell line human CVCL_B9XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2558; CX3CR1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997592 CVCL_B9XH Abcam THP-1 CUL4B KO cancer cell line human CVCL_B9XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2555; CUL4B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997593 CVCL_B9XK Abcam THP-1 DCP2 KO cancer cell line human CVCL_B9XK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24452; DCP2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997594 CVCL_B9XJ Abcam THP-1 CXXC1 KO cancer cell line human CVCL_B9XJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24343; CXXC1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997595 CVCL_B9XM Abcam THP-1 DVL3 KO cancer cell line human CVCL_B9XM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3087; DVL3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997596 CVCL_B9XL Abcam THP-1 DLL1 KO cancer cell line human CVCL_B9XL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2908; DLL1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997597 CVCL_B9XA Abcam THP-1 CMTM6 KO cancer cell line human CVCL_B9XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19177; CMTM6; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997598 CVCL_B9XC Abcam THP-1 CST3 KO cancer cell line human CVCL_B9XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2475; CST3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997599 CVCL_B9XB Abcam THP-1 CNR2 KO cancer cell line human CVCL_B9XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2160; CNR2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997600 CVCL_B9XE Abcam THP-1 CTSS KO cancer cell line human CVCL_B9XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2545; CTSS; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997601 CVCL_B9XD Abcam THP-1 CTSB KO cancer cell line human CVCL_B9XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997602 CVCL_B9V5 cNF98.4c finite cell line human CVCL_B9V5 CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997603 CVCL_B9UT MaNRAS1 cancer cell line house mouse CVCL_B9UT CL:0000010 Transfected with: HGNC; 7989; NRAS (with p.Gln61Lys) Breed/subspecies: ((C57BL/6J x DBA/2) Tg(Tyr-NRAS*Q61K)1Bee transgenic x C57BL/6J) F2. Male Characteristics: Established from a tumor engrafted into 2-month-old C57BL/6 mice and collected after growth (PubMed=31251472) 152997604 CVCL_B9US IBMS-iPSC-075-01 induced pluripotent stem cell human CVCL_B9US From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian. Male 152997605 CVCL_B9V4 icNF97.2b telomerase immortalized cell line human CVCL_B9V4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997606 CVCL_B9V7 icNF98.4c telomerase immortalized cell line human CVCL_B9V7 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997607 CVCL_B9UV McNRAS1 spontaneously immortalized cell line house mouse CVCL_B9UV CL:0000010 Transfected with: HGNC; 7989; NRAS (with p.Gln61Lys) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: ((C57BL/6J x DBA/2) Tg(Tyr-NRAS*Q61K)1Bee transgenic x C57BL/6J) F2. Omics: Transcriptome analysis by microarray Male 152997608 CVCL_B9V6 cNF98.4d finite cell line human CVCL_B9V6 CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997609 CVCL_B9UU MaNRAS2 cancer cell line house mouse CVCL_B9UU CL:0000010 Transfected with: HGNC; 7989; NRAS (with p.Gln61Lys) Breed/subspecies: ((C57BL/6J x DBA/2) Tg(Tyr-NRAS*Q61K)1Bee transgenic x C57BL/6J) F2. Female Characteristics: Established from a tumor engrafted into 2-month-old C57BL/6 mice and collected after growth (PubMed=31251472) 152997610 CVCL_B9V9 28cNF finite cell line human CVCL_B9V9 CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997611 CVCL_B9UX McWT1 spontaneously immortalized cell line house mouse CVCL_B9UX CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6J. Omics: Transcriptome analysis by microarray Male 152997612 CVCL_B9V8 icNF98.4d telomerase immortalized cell line human CVCL_B9V8 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997613 CVCL_B9UW McNRAS2 spontaneously immortalized cell line house mouse CVCL_B9UW CL:0000010 Transfected with: HGNC; 7989; NRAS (with p.Gln61Lys) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: ((C57BL/6J x DBA/2) Tg(Tyr-NRAS*Q61K)1Bee transgenic x C57BL/6J) F2. Omics: Transcriptome analysis by microarray Male 152997614 CVCL_B9UZ cNF00.10a finite cell line human CVCL_B9UZ CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: African American; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997615 CVCL_B9UY McWT2 spontaneously immortalized cell line house mouse CVCL_B9UY CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6J. Omics: Transcriptome analysis by microarray Female 152997616 CVCL_B9UL MC38/EGFP cancer cell line house mouse CVCL_B9UL CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 152997617 CVCL_B9UK Abcam A-549 ETV6 KO 3 cancer cell line human CVCL_B9UK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997618 CVCL_B9UN IBMS-iPSC-005-11 induced pluripotent stem cell human CVCL_B9UN From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 152997619 CVCL_B9UM Abcam A-549 CD3E KO cancer cell line human CVCL_B9UM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1674; CD3E; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997620 CVCL_B9V1 cNF97.2a finite cell line human CVCL_B9V1 CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997621 CVCL_B9UP IBMS-iPSC-006-02 induced pluripotent stem cell human CVCL_B9UP From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 152997622 CVCL_B9V0 icNF00.10a telomerase immortalized cell line human CVCL_B9V0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: African American; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997623 CVCL_B9UR IBMS-iPSC-011-05 induced pluripotent stem cell human CVCL_B9UR From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 152997624 CVCL_B9V3 icNF97.2a telomerase immortalized cell line human CVCL_B9V3 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997625 CVCL_B9V2 cNF97.2b finite cell line human CVCL_B9V2 CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997626 CVCL_B9UQ IBMS-iPSC-009-05 induced pluripotent stem cell human CVCL_B9UQ From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 152997627 CVCL_B9UD Abcam A-549 XIAP KO cancer cell line human CVCL_B9UD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 592; XIAP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997628 CVCL_B9UC Abcam A-549 WWTR1 KO cancer cell line human CVCL_B9UC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997629 CVCL_B9UF Abcam A-549 YTHDF2 KO cancer cell line human CVCL_B9UF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31675; YTHDF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997630 CVCL_B9UE Abcam A-549 XPC KO cancer cell line human CVCL_B9UE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997631 CVCL_B9UH Abcam A-549 YWHAQ KO cancer cell line human CVCL_B9UH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12854; YWHAQ; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997632 CVCL_B9UG Abcam A-549 YWHAB KO cancer cell line human CVCL_B9UG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12849; YWHAB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997633 CVCL_B9UJ Abcam A-549 ZEB1 KO cancer cell line human CVCL_B9UJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997634 CVCL_B9UI Abcam A-549 ZBTB16 KO cancer cell line human CVCL_B9UI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12930; ZBTB16; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997635 CVCL_B9TZ Abcam A-549 USP22 KO cancer cell line human CVCL_B9TZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12621; USP22; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997636 CVCL_B9UB Abcam A-549 WT1 KO cancer cell line human CVCL_B9UB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12796; WT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997637 CVCL_B9UA Abcam A-549 WRN KO cancer cell line human CVCL_B9UA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12791; WRN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997638 CVCL_B9VU Abcam HEK293 CBX4 KO transformed cell line human CVCL_B9VU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1554; CBX4 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152997639 CVCL_B9W6 Abcam HEK293T SYK KO transformed cell line human CVCL_B9W6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11491; SYK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997640 CVCL_B9W5 Abcam HEK293T SCARB1 KO transformed cell line human CVCL_B9W5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997641 CVCL_B9VT Abcam HeLa REST KO cancer cell line human CVCL_B9VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997642 CVCL_B9VW Abcam HeLa UBE2C KO cancer cell line human CVCL_B9VW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15937; UBE2C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997643 CVCL_B9W8 Abcam THP-1 ABCB1 KO cancer cell line human CVCL_B9W8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997644 CVCL_B9VV Abcam HeLa SETD2 KO cancer cell line human CVCL_B9VV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997645 CVCL_B9W7 Abcam THP-1 AATF KO cancer cell line human CVCL_B9W7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19235; AATF; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997646 CVCL_B9VY Abcam HEK293 FYN KO transformed cell line human CVCL_B9VY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4037; FYN Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152997647 CVCL_B9VX Abcam HeLa WWTR1 KO cancer cell line human CVCL_B9VX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997648 CVCL_B9W9 Abcam THP-1 ABL1 KO cancer cell line human CVCL_B9W9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 76; ABL1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152997649 CVCL_B9VZ Abcam HEK293 GAS6 KO transformed cell line human CVCL_B9VZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4168; GAS6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152997650 CVCL_B9VM Abcam HeLa MAD2L1BP KO cancer cell line human CVCL_B9VM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21059; MAD2L1BP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997651 CVCL_B9VL Abcam HeLa IFNAR1 KO cancer cell line human CVCL_B9VL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5432; IFNAR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997652 CVCL_B9W0 Abcam HEK293 PSENEN KO transformed cell line human CVCL_B9W0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30100; PSENEN Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152997653 CVCL_B9VN Abcam HeLa MSN KO cancer cell line human CVCL_B9VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7373; MSN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997654 CVCL_B9W2 Abcam HEK293T DNAJC9 KO transformed cell line human CVCL_B9W2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19123; DNAJC9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997655 CVCL_B9VQ Abcam HeLa NEK2 KO cancer cell line human CVCL_B9VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7745; NEK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997656 CVCL_B9W1 Abcam HEK293T ZYX KO 1 transformed cell line human CVCL_B9W1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13200; ZYX; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997657 CVCL_B9VP Abcam HeLa NBN KO cancer cell line human CVCL_B9VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7652; NBN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997658 CVCL_B9W4 Abcam HEK293T PTTG1 KO transformed cell line human CVCL_B9W4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9690; PTTG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997659 CVCL_B9VS Abcam HeLa NR4A1 KO cancer cell line human CVCL_B9VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997660 CVCL_B9W3 Abcam HEK293T MPI KO transformed cell line human CVCL_B9W3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7216; MPI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152997661 CVCL_B9VR Abcam HeLa NFE2L2 KO cancer cell line human CVCL_B9VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7782; NFE2L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997662 CVCL_B9VE Abcam HeLa ATG7 KO cancer cell line human CVCL_B9VE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16935; ATG7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997663 CVCL_B9VD Abcam HeLa ADORA2A KO cancer cell line human CVCL_B9VD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 263; ADORA2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997664 CVCL_B9VG Abcam HeLa EHMT2 KO cancer cell line human CVCL_B9VG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997665 CVCL_B9VF Abcam HeLa CDKN1C KO cancer cell line human CVCL_B9VF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1786; CDKN1C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997666 CVCL_B9VI Abcam HeLa FGF21 KO cancer cell line human CVCL_B9VI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3678; FGF21 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997667 CVCL_B9VH Abcam HeLa ERCC4 KO cancer cell line human CVCL_B9VH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3436; ERCC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997668 CVCL_B9VK Abcam HeLa GSN KO cancer cell line human CVCL_B9VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4620; GSN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997669 CVCL_B9VJ Abcam HeLa FLCN KO cancer cell line human CVCL_B9VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27310; FLCN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152997670 CVCL_B9VA i28cNF telomerase immortalized cell line human CVCL_B9VA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Male 152997671 CVCL_B9VC icNF04.9a telomerase immortalized cell line human CVCL_B9VC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997672 CVCL_B9VB cNF04.9a finite cell line human CVCL_B9VB CL:0000010 Miscellaneous: Cell line information from personal communication of Allaway R.J Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Schwann cell.. Female 152997673 CVCL_B9SR Abcam A-549 STAT3 KO cancer cell line human CVCL_B9SR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997674 CVCL_B9T3 Abcam A-549 TET1 KO cancer cell line human CVCL_B9T3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29484; TET1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997675 CVCL_B9SQ Abcam A-549 STAG2 KO cancer cell line human CVCL_B9SQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997676 CVCL_B9T2 Abcam A-549 TERT KO cancer cell line human CVCL_B9T2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11730; TERT; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997677 CVCL_B9ST Abcam A-549 STAT6 KO cancer cell line human CVCL_B9ST CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11368; STAT6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997678 CVCL_B9T5 Abcam A-549 TET3 KO cancer cell line human CVCL_B9T5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28313; TET3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997679 CVCL_B9SS Abcam A-549 STAT5B KO cancer cell line human CVCL_B9SS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11367; STAT5B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997680 CVCL_B9T4 Abcam A-549 TET2 KO cancer cell line human CVCL_B9T4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997681 CVCL_B9SV Abcam A-549 SUFU KO cancer cell line human CVCL_B9SV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997682 CVCL_B9T7 Abcam A-549 TGFBR3 KO cancer cell line human CVCL_B9T7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11774; TGFBR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997683 CVCL_B9SU Abcam A-549 STK11 KO cancer cell line human CVCL_B9SU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997684 CVCL_B9T6 Abcam A-549 TFAP2A KO cancer cell line human CVCL_B9T6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11742; TFAP2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997685 CVCL_B9SX Abcam A-549 TACSTD2 KO cancer cell line human CVCL_B9SX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11530; TACSTD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997686 CVCL_B9T9 Abcam A-549 TIA1 KO cancer cell line human CVCL_B9T9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11802; TIA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997687 CVCL_B9SW Abcam A-549 SYK KO cancer cell line human CVCL_B9SW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11491; SYK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997688 CVCL_B9T8 Abcam A-549 THBD KO cancer cell line human CVCL_B9T8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11784; THBD; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997689 CVCL_B9SJ Abcam A-549 SPN KO cancer cell line human CVCL_B9SJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11249; SPN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997690 CVCL_B9SI Abcam A-549 SPI1 KO cancer cell line human CVCL_B9SI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11241; SPI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997691 CVCL_B9SL Abcam A-549 SRC KO cancer cell line human CVCL_B9SL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997692 CVCL_B9SK Abcam A-549 SPP1 KO cancer cell line human CVCL_B9SK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997693 CVCL_B9SN Abcam A-549 SREBF2 KO cancer cell line human CVCL_B9SN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997694 CVCL_B9SM Abcam A-549 SREBF1 KO cancer cell line human CVCL_B9SM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11289; SREBF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997695 CVCL_B9SP Abcam A-549 SS18 KO cancer cell line human CVCL_B9SP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11340; SS18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997696 CVCL_B9T1 Abcam A-549 TEK KO cancer cell line human CVCL_B9T1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11724; TEK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997697 CVCL_B9T0 Abcam A-549 TDO2 KO cancer cell line human CVCL_B9T0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11708; TDO2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997698 CVCL_B9SB Abcam A-549 SOS1 KO cancer cell line human CVCL_B9SB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11187; SOS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997699 CVCL_B9SA Abcam A-549 SNAI2 KO cancer cell line human CVCL_B9SA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11094; SNAI2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997700 CVCL_B9SD Abcam A-549 SOX11 KO cancer cell line human CVCL_B9SD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11191; SOX11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997701 CVCL_B9SC Abcam A-549 SOX10 KO cancer cell line human CVCL_B9SC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11190; SOX10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997702 CVCL_B9SF Abcam A-549 SOX2 KO cancer cell line human CVCL_B9SF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11195; SOX2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997703 CVCL_B9SE Abcam A-549 SOX17 KO cancer cell line human CVCL_B9SE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18122; SOX17; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997704 CVCL_B9SH Abcam A-549 SP1 KO cancer cell line human CVCL_B9SH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11205; SP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997705 CVCL_B9SG Abcam A-549 SOX6 KO cancer cell line human CVCL_B9SG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16421; SOX6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997706 CVCL_B9RY Abcam A-549 SMAD1 KO cancer cell line human CVCL_B9RY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6767; SMAD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997707 CVCL_B9RX Abcam A-549 SLAMF1 KO cancer cell line human CVCL_B9RX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10903; SLAMF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997708 CVCL_B9S9 Abcam A-549 SNAI1 KO cancer cell line human CVCL_B9S9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11128; SNAI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997709 CVCL_B9RZ Abcam A-549 SMAD2 KO cancer cell line human CVCL_B9RZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6768; SMAD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997710 CVCL_B9TS Abcam A-549 TRIM28 KO cancer cell line human CVCL_B9TS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16384; TRIM28; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997711 CVCL_B9U4 Abcam A-549 VIM KO cancer cell line human CVCL_B9U4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12692; VIM; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997712 CVCL_B9TR Abcam A-549 TRIM24 KO cancer cell line human CVCL_B9TR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11812; TRIM24; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997713 CVCL_B9U3 Abcam A-549 VEGFC KO cancer cell line human CVCL_B9U3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12682; VEGFC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997714 CVCL_B9TU Abcam A-549 TSC1 KO cancer cell line human CVCL_B9TU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12362; TSC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997715 CVCL_B9U6 Abcam A-549 VTCN1 KO cancer cell line human CVCL_B9U6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28873; VTCN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997716 CVCL_B9TT Abcam A-549 TRIM33 KO cancer cell line human CVCL_B9TT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16290; TRIM33; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997717 CVCL_B9U5 Abcam A-549 VSIR KO cancer cell line human CVCL_B9U5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30085; VSIR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997718 CVCL_B9TW Abcam A-549 UBB KO cancer cell line human CVCL_B9TW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12463; UBB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997719 CVCL_B9U8 Abcam A-549 WNT3A KO cancer cell line human CVCL_B9U8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15983; WNT3A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997720 CVCL_B9TV Abcam A-549 TSC2 KO cancer cell line human CVCL_B9TV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12363; TSC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997721 CVCL_B9U7 Abcam A-549 WIF1 KO cancer cell line human CVCL_B9U7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18081; WIF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997722 CVCL_B9TY Abcam A-549 ULK1 KO cancer cell line human CVCL_B9TY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12558; ULK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997723 CVCL_B9TX Abcam A-549 UHRF1 KO cancer cell line human CVCL_B9TX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12556; UHRF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997724 CVCL_B9U9 Abcam A-549 WNT5A KO cancer cell line human CVCL_B9U9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12784; WNT5A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997725 CVCL_B9TK Abcam A-549 TNFRSF8 KO cancer cell line human CVCL_B9TK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11923; TNFRSF8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997726 CVCL_B9TJ Abcam A-549 TNFRSF4 KO cancer cell line human CVCL_B9TJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11918; TNFRSF4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997727 CVCL_B9TM Abcam A-549 TNFSF11 KO cancer cell line human CVCL_B9TM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11926; TNFSF11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997728 CVCL_B9TL Abcam A-549 TNFRSF9 KO cancer cell line human CVCL_B9TL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11924; TNFRSF9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997729 CVCL_B9U0 Abcam A-549 USP8 KO cancer cell line human CVCL_B9U0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997730 CVCL_B9TN Abcam A-549 TP53BP1 KO cancer cell line human CVCL_B9TN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997731 CVCL_B9TQ Abcam A-549 TRAF1 KO cancer cell line human CVCL_B9TQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12031; TRAF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997732 CVCL_B9U2 Abcam A-549 VEGFA KO cancer cell line human CVCL_B9U2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12680; VEGFA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997733 CVCL_B9TP Abcam A-549 TP63 KO cancer cell line human CVCL_B9TP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15979; TP63; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997734 CVCL_B9U1 Abcam A-549 VDR KO cancer cell line human CVCL_B9U1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12679; VDR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997735 CVCL_B9TC Abcam A-549 TLR3 KO cancer cell line human CVCL_B9TC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11849; TLR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997736 CVCL_B9TB Abcam A-549 TLR2 KO cancer cell line human CVCL_B9TB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997737 CVCL_B9TE Abcam A-549 TLR6 KO cancer cell line human CVCL_B9TE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16711; TLR6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997738 CVCL_B9TD Abcam A-549 TLR4 KO cancer cell line human CVCL_B9TD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11850; TLR4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997739 CVCL_B9TG Abcam A-549 TMEM173 KO cancer cell line human CVCL_B9TG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997740 CVCL_B9TF Abcam A-549 TLR7 KO cancer cell line human CVCL_B9TF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15631; TLR7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997741 CVCL_B9TI Abcam A-549 TNFRSF18 KO cancer cell line human CVCL_B9TI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11914; TNFRSF18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997742 CVCL_B9TH Abcam A-549 TNFRSF17 KO cancer cell line human CVCL_B9TH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11913; TNFRSF17; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997743 CVCL_B9SZ Abcam A-549 TBX21 KO cancer cell line human CVCL_B9SZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11599; TBX21; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997744 CVCL_B9SY Abcam A-549 TAFAZZIN KO cancer cell line human CVCL_B9SY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997745 CVCL_B9TA Abcam A-549 TLR1 KO cancer cell line human CVCL_B9TA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11847; TLR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997746 CVCL_B9AB Abcam MCF-7 PIK3R1 KO cancer cell line human CVCL_B9AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997747 CVCL_B9AA Abcam MCF-7 PHLPP1 KO cancer cell line human CVCL_B9AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20610; PHLPP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997748 CVCL_B9AD Abcam MCF-7 PML KO cancer cell line human CVCL_B9AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997749 CVCL_B9AC Abcam MCF-7 PIK3R2 KO cancer cell line human CVCL_B9AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997750 CVCL_B9AF Abcam MCF-7 POLQ KO cancer cell line human CVCL_B9AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9186; POLQ; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997751 CVCL_B9AE Abcam MCF-7 PMS2 KO cancer cell line human CVCL_B9AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9122; PMS2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997752 CVCL_B9A8 Abcam MCF-7 PGR KO cancer cell line human CVCL_B9A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8910; PGR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997753 CVCL_B9A7 Abcam MCF-7 PGF KO cancer cell line human CVCL_B9A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8893; PGF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997754 CVCL_B9A9 Abcam MCF-7 PHF1 KO cancer cell line human CVCL_B9A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8919; PHF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997755 CVCL_B9A0 Abcam MCF-7 PAX8 KO cancer cell line human CVCL_B9A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8622; PAX8; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997756 CVCL_B9A2 Abcam MCF-7 PDCD1 KO cancer cell line human CVCL_B9A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8760; PDCD1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997757 CVCL_B9A1 Abcam MCF-7 PBRM1 KO cancer cell line human CVCL_B9A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997758 CVCL_B9A4 Abcam MCF-7 PDGFRA KO cancer cell line human CVCL_B9A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997759 CVCL_B9A3 Abcam MCF-7 PDGFB KO cancer cell line human CVCL_B9A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8800; PDGFB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997760 CVCL_B9A6 Abcam MCF-7 PER1 KO cancer cell line human CVCL_B9A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8845; PER1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997761 CVCL_B9A5 Abcam MCF-7 PDGFRB KO cancer cell line human CVCL_B9A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8804; PDGFRB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997762 CVCL_B9BA Abcam MCF-7 RSF1 KO cancer cell line human CVCL_B9BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18118; RSF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997763 CVCL_B9BC Abcam MCF-7 RUNX1 KO cancer cell line human CVCL_B9BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10471; RUNX1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997764 CVCL_B9BB Abcam MCF-7 RSPO2 KO cancer cell line human CVCL_B9BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28583; RSPO2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997765 CVCL_B9BE Abcam MCF-7 SCARB2 KO cancer cell line human CVCL_B9BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1665; SCARB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997766 CVCL_B9BD Abcam MCF-7 SALL4 KO cancer cell line human CVCL_B9BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15924; SALL4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997767 CVCL_B9BG Abcam MCF-7 SIRPA KO cancer cell line human CVCL_B9BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9662; SIRPA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997768 CVCL_B9BF Abcam MCF-7 SETD7 KO cancer cell line human CVCL_B9BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30412; SETD7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997769 CVCL_B9AX Abcam MCF-7 RAD50 KO cancer cell line human CVCL_B9AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9816; RAD50; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997770 CVCL_B9B9 Abcam MCF-7 RPS6KA3 KO cancer cell line human CVCL_B9B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10432; RPS6KA3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997771 CVCL_B9AW Abcam MCF-7 PTPN6 KO cancer cell line human CVCL_B9AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9658; PTPN6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997772 CVCL_B9B8 Abcam MCF-7 ROS1 KO cancer cell line human CVCL_B9B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10261; ROS1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997773 CVCL_B9AZ Abcam MCF-7 RAF1 KO cancer cell line human CVCL_B9AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997774 CVCL_B9AY Abcam MCF-7 RAD51D KO cancer cell line human CVCL_B9AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997775 CVCL_B9AP Abcam MCF-7 PRKCA KO cancer cell line human CVCL_B9AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9393; PRKCA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997776 CVCL_B9B1 Abcam MCF-7 RB1 KO cancer cell line human CVCL_B9B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997777 CVCL_B9B0 Abcam MCF-7 RARB KO cancer cell line human CVCL_B9B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9865; RARB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997778 CVCL_B9AR Abcam MCF-7 PROCR KO cancer cell line human CVCL_B9AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9452; PROCR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997779 CVCL_B9B3 Abcam MCF-7 RELA KO cancer cell line human CVCL_B9B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997780 CVCL_B9AQ Abcam MCF-7 PRKCB KO cancer cell line human CVCL_B9AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9395; PRKCB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997781 CVCL_B9B2 Abcam MCF-7 REL KO cancer cell line human CVCL_B9B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9954; REL; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997782 CVCL_B9AT Abcam MCF-7 PTEN KO cancer cell line human CVCL_B9AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997783 CVCL_B9B5 Abcam MCF-7 RET KO cancer cell line human CVCL_B9B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997784 CVCL_B9AS Abcam MCF-7 PROX1 KO cancer cell line human CVCL_B9AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9459; PROX1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997785 CVCL_B9B4 Abcam MCF-7 REST KO cancer cell line human CVCL_B9B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997786 CVCL_B9AV Abcam MCF-7 PTPN2 KO cancer cell line human CVCL_B9AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9650; PTPN2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997787 CVCL_B9B7 Abcam MCF-7 RNF2 KO cancer cell line human CVCL_B9B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997788 CVCL_B9AU Abcam MCF-7 PTGS1 KO cancer cell line human CVCL_B9AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9604; PTGS1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997789 CVCL_B9B6 Abcam MCF-7 RICTOR KO cancer cell line human CVCL_B9B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28611; RICTOR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997790 CVCL_B9AH Abcam MCF-7 POU5F1 KO cancer cell line human CVCL_B9AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9221; POU5F1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997791 CVCL_B9AG Abcam MCF-7 POLR2A KO cancer cell line human CVCL_B9AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9187; POLR2A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997792 CVCL_B9AJ Abcam MCF-7 PRDM1 KO cancer cell line human CVCL_B9AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9346; PRDM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997793 CVCL_B9AI Abcam MCF-7 PPARG KO cancer cell line human CVCL_B9AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9236; PPARG; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997794 CVCL_B9AL Abcam MCF-7 PRF1 KO cancer cell line human CVCL_B9AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9360; PRF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997795 CVCL_B9AK Abcam MCF-7 PRDM16 KO cancer cell line human CVCL_B9AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14000; PRDM16; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997796 CVCL_B9AN Abcam MCF-7 PRKAA2 KO cancer cell line human CVCL_B9AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9377; PRKAA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997797 CVCL_B9AM Abcam MCF-7 PRKAA1 KO cancer cell line human CVCL_B9AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9376; PRKAA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997798 CVCL_B8YY Abcam MCF-7 MMP12 KO cancer cell line human CVCL_B8YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7158; MMP12; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997799 CVCL_B8YX Abcam MCF-7 MMP1 KO cancer cell line human CVCL_B8YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7155; MMP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997800 CVCL_B8Z9 Abcam MCF-7 MYD88 KO cancer cell line human CVCL_B8Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7562; MYD88; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997801 CVCL_B8YZ Abcam MCF-7 MMP2 KO cancer cell line human CVCL_B8YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7166; MMP2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997802 CVCL_B8YQ Abcam MCF-7 MECOM KO cancer cell line human CVCL_B8YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3498; MECOM; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997803 CVCL_B8Z2 Abcam MCF-7 MSH2 KO cancer cell line human CVCL_B8Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997804 CVCL_B8YP Abcam MCF-7 MDC1 KO cancer cell line human CVCL_B8YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21163; MDC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997805 CVCL_B8Z1 Abcam MCF-7 MRE11 KO cancer cell line human CVCL_B8Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7230; MRE11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997806 CVCL_B8YS Abcam MCF-7 MEN1 KO cancer cell line human CVCL_B8YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997807 CVCL_B8Z4 Abcam MCF-7 MSR1 KO cancer cell line human CVCL_B8Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7376; MSR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997808 CVCL_B8YR Abcam MCF-7 MED12 KO cancer cell line human CVCL_B8YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11957; MED12; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997809 CVCL_B8Z3 Abcam MCF-7 MSH6 KO cancer cell line human CVCL_B8Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997810 CVCL_B8YU Abcam MCF-7 MGMT KO cancer cell line human CVCL_B8YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997811 CVCL_B8Z6 Abcam MCF-7 MUC1 KO cancer cell line human CVCL_B8Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7508; MUC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997812 CVCL_B8YT Abcam MCF-7 MET KO cancer cell line human CVCL_B8YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7029; MET; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997813 CVCL_B8Z5 Abcam MCF-7 MTA2 KO cancer cell line human CVCL_B8Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7411; MTA2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997814 CVCL_B8YW Abcam MCF-7 MLH1 KO cancer cell line human CVCL_B8YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997815 CVCL_B8Z8 Abcam MCF-7 MYB KO cancer cell line human CVCL_B8Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7545; MYB; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997816 CVCL_B8YV Abcam MCF-7 MITF KO cancer cell line human CVCL_B8YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7105; MITF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997817 CVCL_B8Z7 Abcam MCF-7 MUC16 KO cancer cell line human CVCL_B8Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15582; MUC16; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997818 CVCL_B8YI Abcam MCF-7 MAP2K4 KO cancer cell line human CVCL_B8YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997819 CVCL_B8YH Abcam MCF-7 MAP2K2 KO cancer cell line human CVCL_B8YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997820 CVCL_B8YK Abcam MCF-7 MAP3K7 KO cancer cell line human CVCL_B8YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6859; MAP3K7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997821 CVCL_B8YJ Abcam MCF-7 MAP3K11 KO cancer cell line human CVCL_B8YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997822 CVCL_B8YM Abcam MCF-7 MAPK14 KO cancer cell line human CVCL_B8YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997823 CVCL_B8YL Abcam MCF-7 MAPK1 KO cancer cell line human CVCL_B8YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6871; MAPK1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997824 CVCL_B8Z0 Abcam MCF-7 MMP9 KO cancer cell line human CVCL_B8Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7176; MMP9; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997825 CVCL_B8YN Abcam MCF-7 MAPK3 KO cancer cell line human CVCL_B8YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6877; MAPK3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997826 CVCL_B8YA Abcam MCF-7 LCK KO cancer cell line human CVCL_B8YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6524; LCK; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997827 CVCL_B8YC Abcam MCF-7 LRP5 KO cancer cell line human CVCL_B8YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997828 CVCL_B8YB Abcam MCF-7 LMNA KO cancer cell line human CVCL_B8YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997829 CVCL_B8YE Abcam MCF-7 MAF KO cancer cell line human CVCL_B8YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6776; MAF; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997830 CVCL_B8YD Abcam MCF-7 LYN KO cancer cell line human CVCL_B8YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6735; LYN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997831 CVCL_B8YG Abcam MCF-7 MAP2K1 KO cancer cell line human CVCL_B8YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6840; MAP2K1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997832 CVCL_B8YF Abcam MCF-7 MALT1 KO cancer cell line human CVCL_B8YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6819; MALT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997833 CVCL_B8ZZ Abcam MCF-7 PAX7 KO cancer cell line human CVCL_B8ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8621; PAX7; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997834 CVCL_B8ZY Abcam MCF-7 PAX5 KO cancer cell line human CVCL_B8ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8619; PAX5; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997835 CVCL_B8ZR Abcam MCF-7 OLIG2 KO cancer cell line human CVCL_B8ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9398; OLIG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997836 CVCL_B8ZQ Abcam MCF-7 NTRK3 KO cancer cell line human CVCL_B8ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8033; NTRK3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997837 CVCL_B8ZT Abcam MCF-7 PAK1 KO cancer cell line human CVCL_B8ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997838 CVCL_B8ZS Abcam MCF-7 OPRM1 KO cancer cell line human CVCL_B8ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8156; OPRM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997839 CVCL_B8ZV Abcam MCF-7 PALB2 KO cancer cell line human CVCL_B8ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26144; PALB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997840 CVCL_B8ZU Abcam MCF-7 PAK2 KO cancer cell line human CVCL_B8ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997841 CVCL_B8ZX Abcam MCF-7 PARP3 KO cancer cell line human CVCL_B8ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997842 CVCL_B8ZW Abcam MCF-7 PARP1 KO cancer cell line human CVCL_B8ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997843 CVCL_B8ZJ Abcam MCF-7 NOTCH1 KO cancer cell line human CVCL_B8ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997844 CVCL_B8ZI Abcam MCF-7 NOS2 KO cancer cell line human CVCL_B8ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997845 CVCL_B8ZL Abcam MCF-7 NR4A1 KO cancer cell line human CVCL_B8ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997846 CVCL_B8ZK Abcam MCF-7 NOTCH2 KO cancer cell line human CVCL_B8ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7882; NOTCH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997847 CVCL_B8ZN Abcam MCF-7 NRAS KO cancer cell line human CVCL_B8ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7989; NRAS; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997848 CVCL_B8ZM Abcam MCF-7 NR4A3 KO cancer cell line human CVCL_B8ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7982; NR4A3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997849 CVCL_B8ZP Abcam MCF-7 NSD2 KO cancer cell line human CVCL_B8ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997850 CVCL_B8ZB Abcam MCF-7 NBN KO cancer cell line human CVCL_B8ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7652; NBN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997851 CVCL_B8ZA Abcam MCF-7 MYOD1 KO cancer cell line human CVCL_B8ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7611; MYOD1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997852 CVCL_B8ZD Abcam MCF-7 NCOA1 KO cancer cell line human CVCL_B8ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7668; NCOA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997853 CVCL_B8ZC Abcam MCF-7 NCAM1 KO cancer cell line human CVCL_B8ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7656; NCAM1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997854 CVCL_B8ZF Abcam MCF-7 NF2 KO cancer cell line human CVCL_B8ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997855 CVCL_B8ZE Abcam MCF-7 NF1 KO cancer cell line human CVCL_B8ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997856 CVCL_B8ZH Abcam MCF-7 NFE2L2 KO cancer cell line human CVCL_B8ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7782; NFE2L2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997857 CVCL_B8ZG Abcam MCF-7 NFATC2 KO cancer cell line human CVCL_B8ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7776; NFATC2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152997858 CVCL_B9IH Abcam A-549 FOLR1 KO cancer cell line human CVCL_B9IH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3791; FOLR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997859 CVCL_B9IG Abcam A-549 FOLH1 KO cancer cell line human CVCL_B9IG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3788; FOLH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997860 CVCL_B9IJ Abcam A-549 FOSL1 KO cancer cell line human CVCL_B9IJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13718; FOSL1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997861 CVCL_B9II Abcam A-549 FOS KO cancer cell line human CVCL_B9II CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997862 CVCL_B9IL Abcam A-549 FOXA2 KO cancer cell line human CVCL_B9IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5022; FOXA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997863 CVCL_B9IK Abcam A-549 FOXA1 KO cancer cell line human CVCL_B9IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5021; FOXA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997864 CVCL_B9IN Abcam A-549 FOXC2 KO cancer cell line human CVCL_B9IN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3801; FOXC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997865 CVCL_B9IM Abcam A-549 FOXC1 KO cancer cell line human CVCL_B9IM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3800; FOXC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997866 CVCL_B9IB Abcam A-549 FLT1 KO cancer cell line human CVCL_B9IB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3763; FLT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997867 CVCL_B9IA Abcam A-549 FLI1 KO cancer cell line human CVCL_B9IA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3749; FLI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997868 CVCL_B9ID Abcam A-549 FLT4 KO cancer cell line human CVCL_B9ID CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3767; FLT4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997869 CVCL_B9IC Abcam A-549 FLT3LG KO cancer cell line human CVCL_B9IC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3766; FLT3LG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997870 CVCL_B9IF Abcam A-549 FN1 KO cancer cell line human CVCL_B9IF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3778; FN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997871 CVCL_B9IE Abcam A-549 FMR1 KO cancer cell line human CVCL_B9IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997872 CVCL_B9HW Abcam A-549 EZH1 KO cancer cell line human CVCL_B9HW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3526; EZH1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997873 CVCL_B9I8 Abcam A-549 FGFR2 KO cancer cell line human CVCL_B9I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3689; FGFR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997874 CVCL_B9HV Abcam A-549 ETS1 KO cancer cell line human CVCL_B9HV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3488; ETS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997875 CVCL_B9I7 Abcam A-549 FGF2 KO cancer cell line human CVCL_B9I7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3676; FGF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997876 CVCL_B9HY Abcam A-549 FANCD2 KO cancer cell line human CVCL_B9HY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997877 CVCL_B9HX Abcam A-549 FANCA KO cancer cell line human CVCL_B9HX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997878 CVCL_B9I9 Abcam A-549 FGFR4 KO cancer cell line human CVCL_B9I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3691; FGFR4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997879 CVCL_B9HZ Abcam A-549 FAP KO cancer cell line human CVCL_B9HZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3590; FAP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997880 CVCL_B9I0 Abcam A-549 FAS KO cancer cell line human CVCL_B9I0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11920; FAS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997881 CVCL_B9HN Abcam A-549 ERBB2 KO cancer cell line human CVCL_B9HN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997882 CVCL_B9HQ Abcam A-549 ERBB4 KO cancer cell line human CVCL_B9HQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3432; ERBB4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997883 CVCL_B9I2 Abcam A-549 FCER2 KO cancer cell line human CVCL_B9I2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3612; FCER2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997884 CVCL_B9HP Abcam A-549 ERBB3 KO cancer cell line human CVCL_B9HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3431; ERBB3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997885 CVCL_B9I1 Abcam A-549 FBXO38 KO cancer cell line human CVCL_B9I1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28844; FBXO38; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997886 CVCL_B9HS Abcam A-549 ERCC5 KO cancer cell line human CVCL_B9HS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3437; ERCC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997887 CVCL_B9I4 Abcam A-549 FCGR2B KO cancer cell line human CVCL_B9I4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3618; FCGR2B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997888 CVCL_B9HR Abcam A-549 ERCC4 KO cancer cell line human CVCL_B9HR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3436; ERCC4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997889 CVCL_B9I3 Abcam A-549 FCGR2A KO cancer cell line human CVCL_B9I3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3616; FCGR2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997890 CVCL_B9HU Abcam A-549 ESRRA KO cancer cell line human CVCL_B9HU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3471; ESRRA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997891 CVCL_B9I6 Abcam A-549 FEN1 KO cancer cell line human CVCL_B9I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3650; FEN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997892 CVCL_B9HT Abcam A-549 ESR1 KO cancer cell line human CVCL_B9HT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3467; ESR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997893 CVCL_B9I5 Abcam A-549 FCGR3A KO cancer cell line human CVCL_B9I5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3619; FCGR3A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997894 CVCL_B9JI Abcam A-549 HDAC4 KO cancer cell line human CVCL_B9JI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14063; HDAC4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997895 CVCL_B9JH Abcam A-549 HDAC2 KO cancer cell line human CVCL_B9JH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997896 CVCL_B9JK Abcam A-549 HDAC6 KO cancer cell line human CVCL_B9JK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997897 CVCL_B9JJ Abcam A-549 HDAC5 KO cancer cell line human CVCL_B9JJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14068; HDAC5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997898 CVCL_B9JM Abcam A-549 HEY1 KO cancer cell line human CVCL_B9JM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4880; HEY1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997899 CVCL_B9JL Abcam A-549 HELQ KO cancer cell line human CVCL_B9JL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18536; HELQ; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997900 CVCL_B9K0 Abcam A-549 ICOS KO cancer cell line human CVCL_B9K0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5351; ICOS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997901 CVCL_B9JN Abcam A-549 HGF KO cancer cell line human CVCL_B9JN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4893; HGF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997902 CVCL_B9JA Abcam A-549 GSK3B KO cancer cell line human CVCL_B9JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4617; GSK3B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997903 CVCL_B9JC Abcam A-549 GZMB KO cancer cell line human CVCL_B9JC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4709; GZMB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997904 CVCL_B9JB Abcam A-549 GSR KO cancer cell line human CVCL_B9JB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4623; GSR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997905 CVCL_B9JE Abcam A-549 HAT1 KO cancer cell line human CVCL_B9JE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4821; HAT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997906 CVCL_B9JD Abcam A-549 H2BC21 KO cancer cell line human CVCL_B9JD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4760; H2BC21; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997907 CVCL_B9JG Abcam A-549 HDAC1 KO cancer cell line human CVCL_B9JG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997908 CVCL_B9JF Abcam A-549 HAVCR2 KO cancer cell line human CVCL_B9JF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18437; HAVCR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997909 CVCL_B9IX Abcam A-549 GATA1 KO cancer cell line human CVCL_B9IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4170; GATA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997910 CVCL_B9J9 Abcam A-549 GPNMB KO cancer cell line human CVCL_B9J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4462; GPNMB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997911 CVCL_B9IW Abcam A-549 GADD45B KO cancer cell line human CVCL_B9IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4096; GADD45B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997912 CVCL_B9J8 Abcam A-549 GPER1 KO cancer cell line human CVCL_B9J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4485; GPER1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997913 CVCL_B9IZ Abcam A-549 GATA3 KO cancer cell line human CVCL_B9IZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4172; GATA3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997914 CVCL_B9IY Abcam A-549 GATA2 KO cancer cell line human CVCL_B9IY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997915 CVCL_B9IP Abcam A-549 FOXG1 KO cancer cell line human CVCL_B9IP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3811; FOXG1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997916 CVCL_B9J1 Abcam A-549 GATA6 KO cancer cell line human CVCL_B9J1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4174; GATA6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997917 CVCL_B9J0 Abcam A-549 GATA4 KO cancer cell line human CVCL_B9J0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4173; GATA4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997918 CVCL_B9IR Abcam A-549 FOXO4 KO cancer cell line human CVCL_B9IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7139; FOXO4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997919 CVCL_B9J3 Abcam A-549 GLI2 KO cancer cell line human CVCL_B9J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4318; GLI2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997920 CVCL_B9IQ Abcam A-549 FOXM1 KO cancer cell line human CVCL_B9IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3818; FOXM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997921 CVCL_B9J2 Abcam A-549 GLI1 KO cancer cell line human CVCL_B9J2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4317; GLI1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997922 CVCL_B9IT Abcam A-549 FOXP3 KO cancer cell line human CVCL_B9IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6106; FOXP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997923 CVCL_B9J5 Abcam A-549 GLS KO cancer cell line human CVCL_B9J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4331; GLS; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997924 CVCL_B9IS Abcam A-549 FOXP1 KO cancer cell line human CVCL_B9IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3823; FOXP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997925 CVCL_B9J4 Abcam A-549 GLI3 KO cancer cell line human CVCL_B9J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4319; GLI3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997926 CVCL_B9IV Abcam A-549 GABRG2 KO cancer cell line human CVCL_B9IV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4087; GABRG2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997927 CVCL_B9J7 Abcam A-549 GPC1 KO cancer cell line human CVCL_B9J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4449; GPC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997928 CVCL_B9IU Abcam A-549 GABRA1 KO cancer cell line human CVCL_B9IU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4075; GABRA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997929 CVCL_B9J6 Abcam A-549 GP1BA KO cancer cell line human CVCL_B9J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4439; GP1BA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997930 CVCL_B9GF Abcam A-549 CSPG4 KO cancer cell line human CVCL_B9GF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2466; CSPG4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997931 CVCL_B9GE Abcam A-549 CSF3R KO cancer cell line human CVCL_B9GE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2439; CSF3R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997932 CVCL_B9GH Abcam A-549 CTNNB1 KO cancer cell line human CVCL_B9GH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997933 CVCL_B9GG Abcam A-549 CTLA4 KO cancer cell line human CVCL_B9GG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2505; CTLA4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997934 CVCL_B9GJ Abcam A-549 CXCL13 KO cancer cell line human CVCL_B9GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10639; CXCL13; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997935 CVCL_B9GI Abcam A-549 CX3CL1 KO cancer cell line human CVCL_B9GI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10647; CX3CL1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997936 CVCL_B9GL Abcam A-549 CXCR3 KO cancer cell line human CVCL_B9GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4540; CXCR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997937 CVCL_B9GK Abcam A-549 CXCR1 KO cancer cell line human CVCL_B9GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6026; CXCR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997938 CVCL_B9GB Abcam A-549 CRLF2 KO cancer cell line human CVCL_B9GB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14281; CRLF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997939 CVCL_B9GA Abcam A-549 CREBBP KO cancer cell line human CVCL_B9GA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997940 CVCL_B9GD Abcam A-549 CSF1R KO cancer cell line human CVCL_B9GD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2433; CSF1R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997941 CVCL_B9GC Abcam A-549 CSF1 KO cancer cell line human CVCL_B9GC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997942 CVCL_B9FU Abcam A-549 CEBPA KO cancer cell line human CVCL_B9FU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997943 CVCL_B9G6 Abcam A-549 COL1A1 KO cancer cell line human CVCL_B9G6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997944 CVCL_B9FT Abcam A-549 CEACAM5 KO cancer cell line human CVCL_B9FT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1817; CEACAM5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997945 CVCL_B9G5 Abcam A-549 CNTNAP2 KO cancer cell line human CVCL_B9G5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13830; CNTNAP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997946 CVCL_B9FW Abcam A-549 CHD7 KO cancer cell line human CVCL_B9FW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20626; CHD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997947 CVCL_B9G8 Abcam A-549 CRBN KO cancer cell line human CVCL_B9G8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30185; CRBN; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997948 CVCL_B9FV Abcam A-549 CHD5 KO cancer cell line human CVCL_B9FV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16816; CHD5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997949 CVCL_B9G7 Abcam A-549 CR2 KO cancer cell line human CVCL_B9G7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2336; CR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997950 CVCL_B9FY Abcam A-549 CHD9 KO cancer cell line human CVCL_B9FY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25701; CHD9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997951 CVCL_B9FX Abcam A-549 CHD8 KO cancer cell line human CVCL_B9FX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20153; CHD8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997952 CVCL_B9G9 Abcam A-549 CREB1 KO cancer cell line human CVCL_B9G9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2345; CREB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997953 CVCL_B9FZ Abcam A-549 CHUK KO cancer cell line human CVCL_B9FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1974; CHUK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997954 CVCL_B9FM Abcam A-549 CDK6 KO cancer cell line human CVCL_B9FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1777; CDK6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997955 CVCL_B9FL Abcam A-549 CDK5 KO cancer cell line human CVCL_B9FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997956 CVCL_B9G0 Abcam A-549 CIRBP KO cancer cell line human CVCL_B9G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1982; CIRBP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997957 CVCL_B9FN Abcam A-549 CDK8 KO cancer cell line human CVCL_B9FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1779; CDK8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997958 CVCL_B9FQ Abcam A-549 CDKN1B KO cancer cell line human CVCL_B9FQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997959 CVCL_B9G2 Abcam A-549 CLDN18 KO cancer cell line human CVCL_B9G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2039; CLDN18; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997960 CVCL_B9FP Abcam A-549 CDKN1A KO cancer cell line human CVCL_B9FP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997961 CVCL_B9G1 Abcam A-549 CISH KO cancer cell line human CVCL_B9G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1984; CISH; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997962 CVCL_B9FS Abcam A-549 CDX2 KO cancer cell line human CVCL_B9FS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1806; CDX2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997963 CVCL_B9G4 Abcam A-549 CNOT6 KO cancer cell line human CVCL_B9G4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14099; CNOT6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997964 CVCL_B9FR Abcam A-549 CDKN1C KO cancer cell line human CVCL_B9FR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1786; CDKN1C; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997965 CVCL_B9G3 Abcam A-549 CLOCK KO cancer cell line human CVCL_B9G3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2082; CLOCK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997966 CVCL_B9HG Abcam A-549 ELK1 KO cancer cell line human CVCL_B9HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3321; ELK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997967 CVCL_B9HF Abcam A-549 EIF2AK3 KO cancer cell line human CVCL_B9HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3255; EIF2AK3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997968 CVCL_B9HI Abcam A-549 EOMES KO cancer cell line human CVCL_B9HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3372; EOMES; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997969 CVCL_B9HH Abcam A-549 ENTPD1 KO cancer cell line human CVCL_B9HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3363; ENTPD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997970 CVCL_B9HK Abcam A-549 EPC1 KO cancer cell line human CVCL_B9HK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19876; EPC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997971 CVCL_B9HJ Abcam A-549 EP300 KO cancer cell line human CVCL_B9HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997972 CVCL_B9HM Abcam A-549 EPHB2 KO cancer cell line human CVCL_B9HM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997973 CVCL_B9HL Abcam A-549 EPHA3 KO cancer cell line human CVCL_B9HL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3387; EPHA3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997974 CVCL_B9HA Abcam A-549 EGF KO cancer cell line human CVCL_B9HA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3229; EGF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997975 CVCL_B9HC Abcam A-549 EGLN3 KO cancer cell line human CVCL_B9HC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14661; EGLN3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997976 CVCL_B9HB Abcam A-549 EGFR KO cancer cell line human CVCL_B9HB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997977 CVCL_B9HE Abcam A-549 EHMT1 KO cancer cell line human CVCL_B9HE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997978 CVCL_B9HD Abcam A-549 EGR1 KO cancer cell line human CVCL_B9HD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3238; EGR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997979 CVCL_B9GV Abcam A-549 DDX3X KO cancer cell line human CVCL_B9GV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2745; DDX3X; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997980 CVCL_B9H7 Abcam A-549 E2F2 KO cancer cell line human CVCL_B9H7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3114; E2F2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997981 CVCL_B9GU Abcam A-549 DDR2 KO cancer cell line human CVCL_B9GU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997982 CVCL_B9H6 Abcam A-549 E2F1 KO cancer cell line human CVCL_B9H6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997983 CVCL_B9GX Abcam A-549 DGCR8 KO cancer cell line human CVCL_B9GX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2847; DGCR8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997984 CVCL_B9H9 Abcam A-549 EBI3 KO cancer cell line human CVCL_B9H9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3129; EBI3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997985 CVCL_B9GW Abcam A-549 DDX4 KO cancer cell line human CVCL_B9GW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18700; DDX4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997986 CVCL_B9H8 Abcam A-549 EBF1 KO cancer cell line human CVCL_B9H8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3126; EBF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997987 CVCL_B9GZ Abcam A-549 DMC1 KO cancer cell line human CVCL_B9GZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2927; DMC1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997988 CVCL_B9GY Abcam A-549 DLL3 KO cancer cell line human CVCL_B9GY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2909; DLL3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997989 CVCL_B9GN Abcam A-549 CXCR6 KO cancer cell line human CVCL_B9GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16647; CXCR6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997990 CVCL_B9GM Abcam A-549 CXCR4 KO cancer cell line human CVCL_B9GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2561; CXCR4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997991 CVCL_B9GP Abcam A-549 CYBB KO cancer cell line human CVCL_B9GP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2578; CYBB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997992 CVCL_B9H1 Abcam A-549 DNMT3B KO cancer cell line human CVCL_B9H1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2979; DNMT3B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997993 CVCL_B9H0 Abcam A-549 DNAJB1 KO cancer cell line human CVCL_B9H0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5270; DNAJB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997994 CVCL_B9GR Abcam A-549 DAXX KO cancer cell line human CVCL_B9GR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997995 CVCL_B9H3 Abcam A-549 DPP4 KO cancer cell line human CVCL_B9H3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3009; DPP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997996 CVCL_B9GQ Abcam A-549 CYLD KO cancer cell line human CVCL_B9GQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2584; CYLD; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997997 CVCL_B9H2 Abcam A-549 DOT1L KO cancer cell line human CVCL_B9H2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24948; DOT1L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997998 CVCL_B9GT Abcam A-549 DDB2 KO cancer cell line human CVCL_B9GT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2718; DDB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152997999 CVCL_B9H5 Abcam A-549 DVL2 KO cancer cell line human CVCL_B9H5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3086; DVL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998000 CVCL_B9GS Abcam A-549 DCC KO cancer cell line human CVCL_B9GS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2701; DCC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998001 CVCL_B9H4 Abcam A-549 DROSHA KO cancer cell line human CVCL_B9H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17904; DROSHA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998002 CVCL_B9ED Abcam A-549 BRIP1 KO cancer cell line human CVCL_B9ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20473; BRIP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998003 CVCL_B9EC Abcam A-549 BRD7 KO cancer cell line human CVCL_B9EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14310; BRD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998004 CVCL_B9EF Abcam A-549 C5AR1 KO cancer cell line human CVCL_B9EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1338; C5AR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998005 CVCL_B9EE Abcam A-549 C3AR1 KO cancer cell line human CVCL_B9EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1319; C3AR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998006 CVCL_B9EH Abcam A-549 CACNA1D KO cancer cell line human CVCL_B9EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1391; CACNA1D; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998007 CVCL_B9EG Abcam A-549 CA9 KO cancer cell line human CVCL_B9EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1383; CA9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998008 CVCL_B9EJ Abcam A-549 CARD11 KO cancer cell line human CVCL_B9EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16393; CARD11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998009 CVCL_B9EI Abcam A-549 CALR KO cancer cell line human CVCL_B9EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998010 CVCL_B9DZ Abcam A-549 BCL11A KO cancer cell line human CVCL_B9DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13221; BCL11A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998011 CVCL_B9EB Abcam A-549 BRD4 KO cancer cell line human CVCL_B9EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998012 CVCL_B9EA Abcam A-549 BRD3 KO cancer cell line human CVCL_B9EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998013 CVCL_B9DS Abcam A-549 ATRX KO cancer cell line human CVCL_B9DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998014 CVCL_B9E4 Abcam A-549 BDNF KO cancer cell line human CVCL_B9E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1033; BDNF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998015 CVCL_B9DR Abcam A-549 ATF6 KO cancer cell line human CVCL_B9DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998016 CVCL_B9E3 Abcam A-549 BCL6 KO cancer cell line human CVCL_B9E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998017 CVCL_B9DU Abcam A-549 B2M KO cancer cell line human CVCL_B9DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998018 CVCL_B9E6 Abcam A-549 BLM KO cancer cell line human CVCL_B9E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1058; BLM; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998019 CVCL_B9DT Abcam A-549 AXIN1 KO cancer cell line human CVCL_B9DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998020 CVCL_B9E5 Abcam A-549 BHLHE40 KO cancer cell line human CVCL_B9E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1046; BHLHE40; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998021 CVCL_B9DW Abcam A-549 BAX KO cancer cell line human CVCL_B9DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998022 CVCL_B9E8 Abcam A-549 BMPR1A KO cancer cell line human CVCL_B9E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998023 CVCL_B9DV Abcam A-549 BAD KO cancer cell line human CVCL_B9DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 936; BAD; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998024 CVCL_B9E7 Abcam A-549 BMP4 KO cancer cell line human CVCL_B9E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1071; BMP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998025 CVCL_B9DY Abcam A-549 BCL10 KO cancer cell line human CVCL_B9DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 989; BCL10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998026 CVCL_B9DX Abcam A-549 BCAR1 KO cancer cell line human CVCL_B9DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 971; BCAR1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998027 CVCL_B9E9 Abcam A-549 BRAF KO cancer cell line human CVCL_B9E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998028 CVCL_B9DK Abcam A-549 ARNT KO cancer cell line human CVCL_B9DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 700; ARNT; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998029 CVCL_B9DJ Abcam A-549 ARID1B KO cancer cell line human CVCL_B9DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18040; ARID1B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998030 CVCL_B9DM Abcam A-549 ARRB1 KO cancer cell line human CVCL_B9DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 711; ARRB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998031 CVCL_B9DL Abcam A-549 ARNTL KO cancer cell line human CVCL_B9DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 701; BMAL1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998032 CVCL_B9E0 Abcam A-549 BCL11B KO cancer cell line human CVCL_B9E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13222; BCL11B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998033 CVCL_B9DN Abcam A-549 ARRB2 KO cancer cell line human CVCL_B9DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 712; ARRB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998034 CVCL_B9DQ Abcam A-549 ATF2 KO cancer cell line human CVCL_B9DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 784; ATF2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998035 CVCL_B9E2 Abcam A-549 BCL3 KO cancer cell line human CVCL_B9E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 998; BCL3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998036 CVCL_B9DP Abcam A-549 ASH2L KO cancer cell line human CVCL_B9DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 744; ASH2L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998037 CVCL_B9E1 Abcam A-549 BCL2 KO cancer cell line human CVCL_B9E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998038 CVCL_B9FE Abcam A-549 CD74 KO cancer cell line human CVCL_B9FE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998039 CVCL_B9FD Abcam A-549 CD7 KO cancer cell line human CVCL_B9FD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1695; CD7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998040 CVCL_B9FG Abcam A-549 CD80 KO cancer cell line human CVCL_B9FG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1700; CD80; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998041 CVCL_B9FF Abcam A-549 CD79A KO cancer cell line human CVCL_B9FF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1698; CD79A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998042 CVCL_B9FI Abcam A-549 CD8A KO cancer cell line human CVCL_B9FI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1706; CD8A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998043 CVCL_B9FH Abcam A-549 CD86 KO cancer cell line human CVCL_B9FH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1705; CD86; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998044 CVCL_B9FK Abcam A-549 CDK4 KO cancer cell line human CVCL_B9FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1773; CDK4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998045 CVCL_B9FJ Abcam A-549 CDH11 KO cancer cell line human CVCL_B9FJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1750; CDH11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998046 CVCL_B9FA Abcam A-549 CD40LG KO cancer cell line human CVCL_B9FA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11935; CD40LG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998047 CVCL_B9FC Abcam A-549 CD69 KO cancer cell line human CVCL_B9FC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1694; CD69; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998048 CVCL_B9FB Abcam A-549 CD5 KO cancer cell line human CVCL_B9FB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1685; CD5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998049 CVCL_B9ET Abcam A-549 CCND2 KO cancer cell line human CVCL_B9ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998050 CVCL_B9F5 Abcam A-549 CD226 KO cancer cell line human CVCL_B9F5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16961; CD226; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998051 CVCL_B9ES Abcam A-549 CCND1 KO cancer cell line human CVCL_B9ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1582; CCND1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998052 CVCL_B9F4 Abcam A-549 CD209 KO cancer cell line human CVCL_B9F4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1641; CD209; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998053 CVCL_B9EV Abcam A-549 CCR3 KO cancer cell line human CVCL_B9EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1604; CCR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998054 CVCL_B9F7 Abcam A-549 CD34 KO cancer cell line human CVCL_B9F7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1662; CD34; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998055 CVCL_B9EU Abcam A-549 CCNE1 KO cancer cell line human CVCL_B9EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1589; CCNE1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998056 CVCL_B9F6 Abcam A-549 CD28 KO cancer cell line human CVCL_B9F6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1653; CD28; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998057 CVCL_B9EX Abcam A-549 CCR5 KO cancer cell line human CVCL_B9EX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1606; CCR5; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998058 CVCL_B9F9 Abcam A-549 CD4 KO cancer cell line human CVCL_B9F9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1678; CD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998059 CVCL_B9EW Abcam A-549 CCR4 KO cancer cell line human CVCL_B9EW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1605; CCR4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998060 CVCL_B9F8 Abcam A-549 CD38 KO cancer cell line human CVCL_B9F8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1667; CD38; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998061 CVCL_B9EZ Abcam A-549 CCR7 KO cancer cell line human CVCL_B9EZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1608; CCR7; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998062 CVCL_B9EY Abcam A-549 CCR6 KO cancer cell line human CVCL_B9EY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1607; CCR6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998063 CVCL_B9EL Abcam A-549 CARM1 KO cancer cell line human CVCL_B9EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998064 CVCL_B9EK Abcam A-549 CARD9 KO cancer cell line human CVCL_B9EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16391; CARD9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998065 CVCL_B9EN Abcam A-549 CBL KO cancer cell line human CVCL_B9EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998066 CVCL_B9EM Abcam A-549 CASP8 KO cancer cell line human CVCL_B9EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998067 CVCL_B9EP Abcam A-549 CBLB KO cancer cell line human CVCL_B9EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1542; CBLB; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998068 CVCL_B9F1 Abcam A-549 CD14 KO cancer cell line human CVCL_B9F1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1628; CD14; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998069 CVCL_B9F0 Abcam A-549 CCR9 KO cancer cell line human CVCL_B9F0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1610; CCR9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998070 CVCL_B9ER Abcam A-549 CCNB1 KO cancer cell line human CVCL_B9ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1579; CCNB1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998071 CVCL_B9F3 Abcam A-549 CD19 KO cancer cell line human CVCL_B9F3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1633; CD19; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998072 CVCL_B9EQ Abcam A-549 CCL3 KO cancer cell line human CVCL_B9EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10627; CCL3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998073 CVCL_B9F2 Abcam A-549 CD163 KO cancer cell line human CVCL_B9F2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1631; CD163; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998074 CVCL_B9CB Abcam MCF-7 TP53 KO cancer cell line human CVCL_B9CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998075 CVCL_B9CA Abcam MCF-7 TNFSF11 KO cancer cell line human CVCL_B9CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11926; TNFSF11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998076 CVCL_B9CD Abcam MCF-7 TSC1 KO cancer cell line human CVCL_B9CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12362; TSC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998077 CVCL_B9CC Abcam MCF-7 TP63 KO cancer cell line human CVCL_B9CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15979; TP63; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998078 CVCL_B9CF Abcam MCF-7 USP8 KO cancer cell line human CVCL_B9CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998079 CVCL_B9CE Abcam MCF-7 TSC2 KO cancer cell line human CVCL_B9CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12363; TSC2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998080 CVCL_B9CH Abcam MCF-7 WWTR1 KO cancer cell line human CVCL_B9CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998081 CVCL_B9CG Abcam MCF-7 WRN KO cancer cell line human CVCL_B9CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12791; WRN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998082 CVCL_B9BY Abcam MCF-7 STAT1 KO cancer cell line human CVCL_B9BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998083 CVCL_B9BX Abcam MCF-7 STAG2 KO cancer cell line human CVCL_B9BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998084 CVCL_B9C9 Abcam MCF-7 TGFBR2 KO cancer cell line human CVCL_B9C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998085 CVCL_B9BZ Abcam MCF-7 STAT3 KO cancer cell line human CVCL_B9BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998086 CVCL_B9BQ Abcam MCF-7 SOS1 KO cancer cell line human CVCL_B9BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11187; SOS1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998087 CVCL_B9C2 Abcam MCF-7 STK11 KO cancer cell line human CVCL_B9C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998088 CVCL_B9BP Abcam MCF-7 SMARCD3 KO cancer cell line human CVCL_B9BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11108; SMARCD3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998089 CVCL_B9C1 Abcam MCF-7 STING1 KO cancer cell line human CVCL_B9C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998090 CVCL_B9BS Abcam MCF-7 SP1 KO cancer cell line human CVCL_B9BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11205; SP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998091 CVCL_B9C4 Abcam MCF-7 TACSTD2 KO cancer cell line human CVCL_B9C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11530; TACSTD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998092 CVCL_B9BR Abcam MCF-7 SOX2 KO cancer cell line human CVCL_B9BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11195; SOX2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998093 CVCL_B9C3 Abcam MCF-7 SUFU KO cancer cell line human CVCL_B9C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998094 CVCL_B9BU Abcam MCF-7 SPP1 KO cancer cell line human CVCL_B9BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998095 CVCL_B9C6 Abcam MCF-7 TET2 KO cancer cell line human CVCL_B9C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998096 CVCL_B9BT Abcam MCF-7 SPN KO cancer cell line human CVCL_B9BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11249; SPN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998097 CVCL_B9C5 Abcam MCF-7 TAFFAZIN KO cancer cell line human CVCL_B9C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998098 CVCL_B9BW Abcam MCF-7 SS18 KO cancer cell line human CVCL_B9BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11340; SS18; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998099 CVCL_B9C8 Abcam MCF-7 TGFB1 KO cancer cell line human CVCL_B9C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11766; TGFB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998100 CVCL_B9BV Abcam MCF-7 SRC KO cancer cell line human CVCL_B9BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998101 CVCL_B9C7 Abcam MCF-7 TFF3 KO cancer cell line human CVCL_B9C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11757; TFF3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998102 CVCL_B9BI Abcam MCF-7 SMAD2 KO cancer cell line human CVCL_B9BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6768; SMAD2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998103 CVCL_B9BH Abcam MCF-7 SIRT1 KO cancer cell line human CVCL_B9BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998104 CVCL_B9BK Abcam MCF-7 SMAD4 KO cancer cell line human CVCL_B9BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998105 CVCL_B9BJ Abcam MCF-7 SMAD3 KO cancer cell line human CVCL_B9BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6769; SMAD3; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998106 CVCL_B9BM Abcam MCF-7 SMARCA4 KO cancer cell line human CVCL_B9BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998107 CVCL_B9BL Abcam MCF-7 SMARCA1 KO cancer cell line human CVCL_B9BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11097; SMARCA1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998108 CVCL_B9C0 Abcam MCF-7 STAT6 KO cancer cell line human CVCL_B9C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11368; STAT6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998109 CVCL_B9BN Abcam MCF-7 SMARCC1 KO cancer cell line human CVCL_B9BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998110 CVCL_B9DC Abcam A-549 ANGPT2 KO cancer cell line human CVCL_B9DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 485; ANGPT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998111 CVCL_B9DB Abcam A-549 ANGPT1 KO cancer cell line human CVCL_B9DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 484; ANGPT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998112 CVCL_B9DE Abcam A-549 APEX1 KO cancer cell line human CVCL_B9DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 587; APEX1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998113 CVCL_B9DD Abcam A-549 ANXA1 KO cancer cell line human CVCL_B9DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 533; ANXA1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998114 CVCL_B9DG Abcam A-549 AR KO cancer cell line human CVCL_B9DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998115 CVCL_B9DF Abcam A-549 AQP4 KO cancer cell line human CVCL_B9DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 637; AQP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998116 CVCL_B9DI Abcam A-549 AREG KO cancer cell line human CVCL_B9DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 651; AREG; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998117 CVCL_B9DH Abcam A-549 ARAF KO cancer cell line human CVCL_B9DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998118 CVCL_B9CZ Abcam A-549 ADAR KO cancer cell line human CVCL_B9CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 225; ADAR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998119 CVCL_B9CY Abcam A-549 ADAM10 KO cancer cell line human CVCL_B9CY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 188; ADAM10; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998120 CVCL_B9DA Abcam A-549 ALK KO cancer cell line human CVCL_B9DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 427; ALK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998121 CVCL_B9D3 Abcam A-549 ADRB2 KO cancer cell line human CVCL_B9D3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 286; ADRB2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998122 CVCL_B9CR Abcam A-549 OAS1 KO 1 cancer cell line human CVCL_B9CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8086; OAS1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998123 CVCL_B9D2 Abcam A-549 ADRA2B KO cancer cell line human CVCL_B9D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 282; ADRA2B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998124 CVCL_B9CQ Abcam A-549 MAP3K11 KO 3 cancer cell line human CVCL_B9CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998125 CVCL_B9CT Abcam A-549 ABL2 KO cancer cell line human CVCL_B9CT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998126 CVCL_B9D5 Abcam A-549 AGO2 KO cancer cell line human CVCL_B9D5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3263; AGO2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998127 CVCL_B9D4 Abcam A-549 AFP KO cancer cell line human CVCL_B9D4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 317; AFP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998128 CVCL_B9CS Abcam A-549 TGFBR2 KO 2 cancer cell line human CVCL_B9CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998129 CVCL_B9CV Abcam A-549 ACTA2 KO cancer cell line human CVCL_B9CV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 130; ACTA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998130 CVCL_B9D7 Abcam A-549 AKT1 KO cancer cell line human CVCL_B9D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998131 CVCL_B9CU Abcam A-549 ACKR3 KO cancer cell line human CVCL_B9CU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23692; ACKR3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998132 CVCL_B9D6 Abcam A-549 AGO4 KO cancer cell line human CVCL_B9D6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18424; AGO4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998133 CVCL_B9CX Abcam A-549 ADA KO cancer cell line human CVCL_B9CX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 186; ADA; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998134 CVCL_B9D9 Abcam A-549 AKT3 KO cancer cell line human CVCL_B9D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998135 CVCL_B9CW Abcam A-549 ACVR1B KO cancer cell line human CVCL_B9CW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 172; ACVR1B; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998136 CVCL_B9D8 Abcam A-549 AKT2 KO cancer cell line human CVCL_B9D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 392; AKT2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998137 CVCL_B9CJ Abcam MCF-7 YAP1 KO cancer cell line human CVCL_B9CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998138 CVCL_B9CI Abcam MCF-7 XPC KO cancer cell line human CVCL_B9CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998139 CVCL_B9CL Abcam MCF-7 ZEB1 KO cancer cell line human CVCL_B9CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998140 CVCL_B9CK Abcam MCF-7 ZBTB16 KO cancer cell line human CVCL_B9CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12930; ZBTB16; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 152998141 CVCL_B9CN MC38Luc8 cancer cell line house mouse CVCL_B9CN CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Characteristics: Expression of luciferase is under the control of the CMV promoter 152998142 CVCL_B9CM MC38Luc4 cancer cell line house mouse CVCL_B9CM CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Characteristics: Expression of luciferase is under the control of the CMV promoter 152998143 CVCL_B9D1 Abcam A-549 ADORA2A KO cancer cell line human CVCL_B9D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 263; ADORA2A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998144 CVCL_B9CP Abcam A-549 CYP1B1 KO 2 cancer cell line human CVCL_B9CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2597; CYP1B1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998145 CVCL_B9D0 Abcam A-549 ADK KO cancer cell line human CVCL_B9D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 257; ADK; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998146 CVCL_C0DM HTR.C/B7-2 cancer cell line house mouse CVCL_C0DM CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998147 CVCL_C0DL HTR.C cancer cell line house mouse CVCL_C0DL CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998148 CVCL_C0E0 1-11A hybridoma house mouse CVCL_C0E0 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q6UY09; Human CEACAM20. 152998149 CVCL_C0DN HTR.C/C cancer cell line house mouse CVCL_C0DN CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998150 CVCL_C0E2 1H7-4B hybridoma house mouse CVCL_C0E2 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40199; Human CEACAM6/CD66c. 152998151 CVCL_C0DQ RMA.Trh4 Kb KO cancer cell line house mouse CVCL_C0DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:95904; H2-K1; Transfected with: MGI; MGI:1919199; Cers5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 152998152 CVCL_C0E1 11-1H hybridoma house mouse CVCL_C0E1 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13688; Human CEACAM1/CD66a. 152998153 CVCL_C0DP HTR.C/IL-12 cancer cell line house mouse CVCL_C0DP CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:96539; Il12a; Transfected with: MGI; MGI:96540; Il12b; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998154 CVCL_C0E4 308/3-3 hybridoma house mouse CVCL_C0E4 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40198; Human CEACAM3/CD66d; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 152998155 CVCL_C0DS THC-253.1 cancer cell line Norway rat CVCL_C0DS CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Derived from sampling site: Liver; Breed/subspecies: ACI. Male 152998156 CVCL_C0E3 3-7G hybridoma house mouse CVCL_C0E3 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q3KPI0; Human CEACAM21. 152998157 CVCL_C0DR THC-252.2 cancer cell line Norway rat CVCL_C0DR CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Derived from sampling site: Liver; Breed/subspecies: ACI. Male Characteristics: Substrate adherent 152998158 CVCL_C0DE RMA.Trh4 Db KO cancer cell line house mouse CVCL_C0DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:95896; H2-D1; Transfected with: MGI; MGI:1919199; Cers5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 152998159 CVCL_C0DD RMA-S.Trh4 cancer cell line house mouse CVCL_C0DD CL:0000010 Transfected with: MGI; MGI:1919199; Cers5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. Characteristics: This cell line provides a model to help to understand T-cell recognition through Cers5/Trh4 expression (Ximbio) 152998160 CVCL_C0DG HTR.B7-1 cancer cell line house mouse CVCL_C0DG CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101775; Cd80; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998161 CVCL_C0DF P815.Trh4 cancer cell line house mouse CVCL_C0DF CL:0000010 Transfected with: MGI; MGI:1919199; Cers5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998162 CVCL_C0DI HTR.B7-1/B7-2 cancer cell line house mouse CVCL_C0DI CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101775; Cd80; Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998163 CVCL_C0DH HTR.B7-1/C cancer cell line house mouse CVCL_C0DH CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101775; Cd80; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998164 CVCL_C0DK HTR.B7-2 cancer cell line house mouse CVCL_C0DK CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101773; Cd86; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998165 CVCL_C0DJ HTR.B7-1/IL-12 cancer cell line house mouse CVCL_C0DJ CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: MGI; MGI:101775; Cd80; Transfected with: MGI; MGI:96539; Il12a; Transfected with: MGI; MGI:96540; Il12b; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 152998166 CVCL_C0DA A2780 PTX(64) cancer cell line human CVCL_C0DA CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998167 CVCL_C0DC RMA.Trh4 cancer cell line house mouse CVCL_C0DC CL:0000010 Transfected with: MGI; MGI:1919199; Cers5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. Characteristics: This cell line provides a model to help to understand T-cell recognition through Cers5/Trh4 expression (Ximbio) 152998168 CVCL_C0DB A2780 PTX(128) cancer cell line human CVCL_C0DB CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998169 CVCL_C0D5 2C4 gamma2A/JAK2 cancer cell line human CVCL_C0D5 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1639; CD2; Transfected with: MGI; MGI:96629; Jak2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male 152998170 CVCL_C0CT UPPL1541 cancer cell line house mouse CVCL_C0CT CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 Upk3a-CreERT2; Trp53L/L; PtenL/L; Rosa26LSL-Luc transgenic. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Displays a similar expression profiles to luminal-like molecular subtype bladder cancers in humans (ABM) Doubling time: 24-36 hours (ABM) 152998171 CVCL_C0D4 2C4 gamma2A cancer cell line human CVCL_C0D4 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1639; CD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Retain a normal IFN-alpha/beta response but is completely defective in the IFN-gamma response (PubMed=9001223) 152998172 CVCL_C0CS BBN963 cancer cell line house mouse CVCL_C0CS CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 152998173 CVCL_C0D7 A2780 PTX(8) cancer cell line human CVCL_C0D7 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998174 CVCL_C0CV PSEN2-N141I-hiPSC induced pluripotent stem cell human CVCL_C0CV From: IxCells Biotechnologies, LLC; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=34634760) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 152998175 CVCL_C0D6 A2780 PTX(4) cancer cell line human CVCL_C0D6 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998176 CVCL_C0CU MCF-7/SB-T-0035R cancer cell line human CVCL_C0CU CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Doubling time, ABCB1 status and STR profile from personal communication of Daniel P Population: Caucasian; Selected for resistance to: SB-T-0035 (Stony-Brooke Taxane 35); Derived from metastatic site: Pleural effusion. Female Characteristics: Generated by step-increasing drug concentration to 300 nm of SB-T-0035 Overexpresses ABCB1 which is amplified and inserted in chromosome 19 (PubMed=29625142; Direct_author_submission). Doubling time: ~25-30 hours (Direct_author_submission) 152998177 CVCL_C0D9 A2780 PTX(32) cancer cell line human CVCL_C0D9 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998178 CVCL_C0CX FDCHDPe009-B embryonic stem cell human CVCL_C0CX From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6701; LRPAP1. Female 152998179 CVCL_C0D8 A2780 PTX(16) cancer cell line human CVCL_C0D8 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 152998180 CVCL_C0CW PSEN2-141 N-hiPSC induced pluripotent stem cell human CVCL_C0CW From: IxCells Biotechnologies, LLC; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple_corrected; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34634760) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 152998181 CVCL_C0CZ HEK293T SOD2 KO transformed cell line human CVCL_C0CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11180; SOD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 152998182 CVCL_C0CY IBKMOLi001-A induced pluripotent stem cell human CVCL_C0CY From: Institute for Molecular Biology, University of Innsbruck; Innsbruck; Austria CL:0000010 Transfected with: mScarlet, a red fluorescent protein Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9, MNX1 was C-terminally tagged on one allele with 2 x TY1 epitope tags together with a T2A-separated red fluorescent reporter mScarlet (PubMed=34509159) 152998183 CVCL_C0EN HEK293-ratCEACAM1-dN-Fc transformed cell line human CVCL_C0EN CL:0000010 Transfected with: RGD; 67396; Ceacam1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a rat Ceacam1 lacking the N-domain-human immunoglobulin G (IgG) Fc domain chimera protein 152998184 CVCL_C0EM HEK293-MacCEACAM1-Fc transformed cell line human CVCL_C0EM CL:0000010 Transfected with: UniProtKB; A0A1D5QNP0; Macaca mulatta CEACAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a Macaca mulatta CEACAM1-human immunoglobulin G (IgG) Fc domain chimera protein 152998185 CVCL_C0EP HEK293-ratCEACAM1-Fc transformed cell line human CVCL_C0EP CL:0000010 Transfected with: RGD; 67396; Ceacam1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a rat Ceacam1-human immunoglobulin G (IgG) Fc domain chimera protein 152998186 CVCL_C0F1 KRIBBi005-A induced pluripotent stem cell human CVCL_C0F1 From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Derived from sampling site: Umbilical cord blood. Female 152998187 CVCL_C0F0 GWCMCi005-A induced pluripotent stem cell human CVCL_C0F0 From: Guangzhou Women and Children's Medical Center; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 30212; TANC2; Simple; p.Gln1441Ter (c.4321C>T); Zygosity=Heterozygous; Note=De novo mutation (PubMed=35066241) Population: Chinese; Derived from sampling site: Peripheral blood. Male 152998188 CVCL_C0F3 KRIBBi008-A induced pluripotent stem cell human CVCL_C0F3 From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea. CL:0000010 152998189 CVCL_C0ER NCCDFWi001-A-1 induced pluripotent stem cell human CVCL_C0ER From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Pro228fs (c.684_736+4del); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3603; FBN1; Simple_corrected; p.Leu871Phe (c.2613A>C); ClinVar=VCV000667457; Zygosity=Heterozygous; Note=Using CRISPR/Cas9 (PubMed=34592602) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998190 CVCL_C0EQ iHAEC transformed cell line human CVCL_C0EQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Aorta Cell type=Aortic endothelial cell.. Unspecified 152998191 CVCL_C0F2 KRIBBi006-A induced pluripotent stem cell human CVCL_C0F2 From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 152998192 CVCL_C0F5 SXMUi002-A induced pluripotent stem cell human CVCL_C0F5 From: Shanxi Medical University; Taiyuan; China CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Simple; p.Arg814Ter (c.2440C>T); ClinVar=VCV000993607; Zygosity=Hemizygous (PubMed=35123343) Derived from sampling site: Urine. Male Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.23095 152998193 CVCL_C0ET UPITTi002-A induced pluripotent stem cell human CVCL_C0ET From: University of Pittsburgh; Pittsburgh; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 152998194 CVCL_C0F4 TVGHi008-A induced pluripotent stem cell human CVCL_C0F4 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser308Ter (c.923C>A); Zygosity=Homozygous (PubMed=35091309) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 152998195 CVCL_C0ES UPITTi001-A induced pluripotent stem cell human CVCL_C0ES From: University of Pittsburgh; Pittsburgh; USA. CL:0000010 152998196 CVCL_C0EF HEK293-CEACAM1-dN-Fc transformed cell line human CVCL_C0EF CL:0000010 Transfected with: HGNC; 1814; CEACAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM1 lacking the N-domain-human immunoglobulin G (IgG) Fc domain chimera protein 152998197 CVCL_C0EE P3-7B hybridoma house mouse CVCL_C0EE From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14002; Human CEACAM7. 152998198 CVCL_C0EH HEK293-CEACAM1-N-Fc transformed cell line human CVCL_C0EH CL:0000010 Transfected with: HGNC; 1814; CEACAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM1 N-domain-human immunoglobulin G (IgG) Fc domain chimera protein 152998199 CVCL_C0EG HEK293-CEACAM1-Fc transformed cell line human CVCL_C0EG CL:0000010 Transfected with: HGNC; 1814; CEACAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM1-human immunoglobulin G (IgG) Fc domain chimera protein 152998200 CVCL_C0EJ HEK293-CEACAM5-Fc transformed cell line human CVCL_C0EJ CL:0000010 Transfected with: HGNC; 1817; CEACAM5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM5-human immunoglobulin G (IgG) Fc domain chimera protein 152998201 CVCL_C0EI HEK293-CEACAM3-Fc transformed cell line human CVCL_C0EI CL:0000010 Transfected with: HGNC; 1815; CEACAM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM3-human immunoglobulin G (IgG) Fc domain chimera protein 152998202 CVCL_C0EL HEK293-CEACAM8-Fc transformed cell line human CVCL_C0EL CL:0000010 Transfected with: HGNC; 1820; CEACAM8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM8-human immunoglobulin G (IgG) Fc domain chimera protein 152998203 CVCL_C0EK HEK293-CEACAM6-Fc transformed cell line human CVCL_C0EK CL:0000010 Transfected with: HGNC; 1818; CEACAM6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Overexpresses a CEACAM6-human immunoglobulin G (IgG) Fc domain chimera protein 152998204 CVCL_C0EB D2-4H hybridoma house mouse CVCL_C0EB From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13688; Human CEACAM1/CD66a; Monoclonal antibody target: UniProtKB; P40198; Human CEACAM3/CD66d; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e; Monoclonal antibody target: UniProtKB; P40199; Human CEACAM6/CD66c. 152998205 CVCL_C0EA C5-1X hybridoma house mouse CVCL_C0EA From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13688; Human CEACAM1/CD66a. 152998206 CVCL_C0ED 7D-2/12 hybridoma house mouse CVCL_C0ED From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A1D5QNP0; Macaca mulatta CEACAM1. 152998207 CVCL_C0EC ivi4/27 hybridoma house mouse CVCL_C0EC From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e; Monoclonal antibody target: UniProtKB; P40199; Human CEACAM6/CD66c; Monoclonal antibody target: UniProtKB; P31997; Human CEACAM8/CD66b. 152998208 CVCL_C0E6 4H6-20 hybridoma house mouse CVCL_C0E6 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e; Monoclonal antibody target: UniProtKB; P40199; Human CEACAM6/CD66c; Monoclonal antibody target: UniProtKB; P31997; Human CEACAM8/CD66b. 152998209 CVCL_C0DU MAb 5.4 hybridoma house mouse CVCL_C0DU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16573; Rat Ceacam1/Cd66a. 152998210 CVCL_C0E5 3E10-3 hybridoma house mouse CVCL_C0E5 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 152998211 CVCL_C0DT MAb 362.50 hybridoma house mouse CVCL_C0DT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16573; Rat Ceacam1/Cd66a. 152998212 CVCL_C0E8 6/40c hybridoma house mouse CVCL_C0E8 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31997; Human CEACAM8/CD66b. 152998213 CVCL_C0DW HCT116/4008#13 rho-0 cancer cell line human CVCL_C0DW CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Cell line devoid of mitochondrial DNA (rho0) Produced by transient transfection with plasmid pMA4008 encoding HSV-1 UL12.5M185 protein, which damages mtDNA by an unknown mechanism. 152998214 CVCL_C0E7 5C8C4 hybridoma house mouse CVCL_C0E7 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 152998215 CVCL_C0DV A549 rho-0#1a cancer cell line human CVCL_C0DV CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with ethidium bromide. 152998216 CVCL_C0DY MS1/19dd#7 rho-0 transformed cell line house mouse CVCL_C0DY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with ethidium bromide and 2',3'dideoxycytidine. 152998217 CVCL_C0E9 B3-17 hybridoma house mouse CVCL_C0E9 From: Singer B.B., University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13688; Human CEACAM1/CD66a. 152998218 CVCL_C0DX HT-22 rho-0 transformed cell line house mouse CVCL_C0DX CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Cell line devoid of mitochondrial DNA (rho0) 152998219 CVCL_C0DZ A549-CEACAM1-4L cancer cell line human CVCL_C0DZ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1814; CEACAM1 (isoform 4L); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male 152998220 CVCL_C0BK Abcam HeLa PFN2 KO cancer cell line human CVCL_C0BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8882; PFN2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152998221 CVCL_C0BJ Abcam U-87MG SNCA KO cancer cell line human CVCL_C0BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA; Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male 152998222 CVCL_C0BM Abcam Caco-2 TMPRSS2 KO cancer cell line human CVCL_C0BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11876; TMPRSS2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 152998223 CVCL_C0BL Abcam Caco-2 BMP2 KO cancer cell line human CVCL_C0BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1069; BMP2; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 152998224 CVCL_C0C0 L95 hybridoma house mouse CVCL_C0C0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15151; Human PVR/CD155. 152998225 CVCL_C0BN Abcam U2OS COL1A1 KO cancer cell line human CVCL_C0BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 152998226 CVCL_C0BQ Abcam U2OS KDM4C KO cancer cell line human CVCL_C0BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17071; KDM4C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 152998227 CVCL_C0C2 M5A10 hybridoma house mouse CVCL_C0C2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15151; Human PVR/CD155. 152998228 CVCL_C0BP Abcam U2OS EZHIP KO cancer cell line human CVCL_C0BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33738; EZHIP Population: Caucasian; Derived from sampling site: Bone; tibia. Female 152998229 CVCL_C0C1 M2C24, hybridoma house mouse CVCL_C0C1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15151; Human PVR/CD155. 152998230 CVCL_C0BC Abcam THP-1 YTHDC2 KO cancer cell line human CVCL_C0BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24721; YTHDC2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998231 CVCL_C0BB Abcam THP-1 WNT11 KO cancer cell line human CVCL_C0BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12776; WNT11; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998232 CVCL_C0BE Abcam THP-1 YTHDF3 KO cancer cell line human CVCL_C0BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26465; YTHDF3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998233 CVCL_C0BD Abcam THP-1 YTHDF1 KO cancer cell line human CVCL_C0BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998234 CVCL_C0BG Abcam THP-1 ZEB2 KO cancer cell line human CVCL_C0BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998235 CVCL_C0BF Abcam THP-1 YY1 KO cancer cell line human CVCL_C0BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12856; YY1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998236 CVCL_C0BI Abcam LNCaP clone FGC TMPRSS2 KO cancer cell line human CVCL_C0BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11876; TMPRSS2; Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 152998237 CVCL_C0BH Abcam A-549 CXCL11 KO cancer cell line human CVCL_C0BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10638; CXCL11; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 152998238 CVCL_C0AZ Abcam THP-1 TWIST1 KO cancer cell line human CVCL_C0AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12428; TWIST1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998239 CVCL_C0AY Abcam THP-1 TRMT2A KO cancer cell line human CVCL_C0AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998240 CVCL_C0BA Abcam THP-1 WDR77 KO cancer cell line human CVCL_C0BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29652; WDR77; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998241 CVCL_C0AR Abcam THP-1 TIMP3 KO cancer cell line human CVCL_C0AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11822; TIMP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998242 CVCL_C0B3 Abcam THP-1 UBE2D2 KO cancer cell line human CVCL_C0B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998243 CVCL_C0AQ Abcam THP-1 THBS1 KO cancer cell line human CVCL_C0AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11785; THBS1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998244 CVCL_C0B2 Abcam THP-1 UBA1 KO cancer cell line human CVCL_C0B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12469; UBA1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998245 CVCL_C0AT Abcam THP-1 TNFRSF10B KO cancer cell line human CVCL_C0AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11905; TNFRSF10B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998246 CVCL_C0B5 Abcam THP-1 ULBP2 KO cancer cell line human CVCL_C0B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14894; ULBP2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998247 CVCL_C0AS Abcam THP-1 TLN1 KO cancer cell line human CVCL_C0AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11845; TLN1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998248 CVCL_C0B4 Abcam THP-1 UCHL5 KO cancer cell line human CVCL_C0B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19678; UCHL5; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998249 CVCL_C0AV Abcam THP-1 TP73 KO cancer cell line human CVCL_C0AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998250 CVCL_C0B7 Abcam THP-1 UVRAG KO cancer cell line human CVCL_C0B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12640; UVRAG; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998251 CVCL_C0AU Abcam THP-1 TNFRSF1B KO cancer cell line human CVCL_C0AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11917; TNFRSF1B; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998252 CVCL_C0B6 Abcam THP-1 ULBP3 KO cancer cell line human CVCL_C0B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14895; ULBP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998253 CVCL_C0AX Abcam THP-1 TRAF2 KO cancer cell line human CVCL_C0AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998254 CVCL_C0B9 Abcam THP-1 VCAN KO cancer cell line human CVCL_C0B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2464; VCAN; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998255 CVCL_C0AW Abcam THP-1 TRADD KO cancer cell line human CVCL_C0AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12030; TRADD; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998256 CVCL_C0B8 Abcam THP-1 VAV1 KO cancer cell line human CVCL_C0B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12657; VAV1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998257 CVCL_C0CL WCHi001-A induced pluripotent stem cell human CVCL_C0CL From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998258 CVCL_C0CK OGHFUi001-A-1 induced pluripotent stem cell human CVCL_C0CK From: Obstetrics and Gynecology Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 18060; ARX; Simple_corrected; p.Arg330Leu (c.989G>T); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=35121198) Derived from sampling site: Peripheral blood. Male 152998259 CVCL_C0CN ESIBIe003-A-10 embryonic stem cell human CVCL_C0CN From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Omics: SNP array analysis. Female Characteristics: Reporter cell line that expresses GFP and mCherry fluorescent proteins under the control of the endogenous insulin (INS) and glucagon (GCG) loci respectively Using homologous recombination an EGFP reporter gene was introduced in one allele of the INS locus. Using TALEN a mCherry reporter was introduced at the N-terminus in one allele of the GCG locus (PubMed=34619644). 152998260 CVCL_C0CM WCHi001-B induced pluripotent stem cell human CVCL_C0CM From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Discontinued: hPSCreg; WCHi001-B; true Female 152998261 CVCL_C0CP HECi001-A induced pluripotent stem cell human CVCL_C0CP From: Dongguan HEC Biopharmaceutical R&D Co Ltd; Chang'an Town; China. CL:0000010 Population: Chinese; Han; Derived from sampling site: Pancreas; islets of Langerhans. Male 152998262 CVCL_C0D1 HEL 92.1.7 SOD2 KO clone 13 cancer cell line human CVCL_C0D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11180; SOD2; Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Male 152998263 CVCL_C0D0 HEL 92.1.7 SOD2 KO clone 5 cancer cell line human CVCL_C0D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11180; SOD2; Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Male 152998264 CVCL_C0D3 2C4 gamma1A cancer cell line human CVCL_C0D3 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5440; IFNGR2; Simple; p.Thr299Aspfs*16 (c.897dupT); Zygosity=Homozygous (PubMed=9001223); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1639; CD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Retain a normal IFN-alpha/beta response but is completely defective in the IFN-gamma response (PubMed=9001223) 152998265 CVCL_C0CR KAIMRCi001-A induced pluripotent stem cell human CVCL_C0CR From: King Abdullah International Medical Research Center; Jeddah; Saudi Arabia CL:0000010 Population: Saudi Arabian; Derived from sampling site: Peripheral blood Cell type=Erythroid progenitor cell.. Male 152998266 CVCL_C0D2 HEK293 NDUSF2 KO transformed cell line human CVCL_C0D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7708; NDUFS2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line 152998267 CVCL_C0CQ TUSMi011-A induced pluripotent stem cell human CVCL_C0CQ From: Tongji University School of Medicine; Wuhan; China. CL:0000010 152998268 CVCL_C0CD WAe001-A-51 embryonic stem cell human CVCL_C0CD CL:0000010 Male Characteristics: Using CRISPR/Cas9, 3 FLAG tags were introduced at the C-terminus of both alleles of FMR1 (PubMed=32179589). 152998269 CVCL_C0CC WAe001-A-50 embryonic stem cell human CVCL_C0CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1. Male 152998270 CVCL_C0CF WAe013-A-2 embryonic stem cell human CVCL_C0CF CL:0000010 Male Characteristics: Using CRISPR/Cas9, 3 FLAG tags were introduced at the C-terminus of both alleles of FMR1 (PubMed=32179589). 152998271 CVCL_C0CE WAe013-A-1 embryonic stem cell human CVCL_C0CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1. Male 152998272 CVCL_C0CH NIMHi004-A induced pluripotent stem cell human CVCL_C0CH From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 152998273 CVCL_C0CG DPNJMUi001-A induced pluripotent stem cell human CVCL_C0CG From: Children's Hospital of Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 14880; GTPBP3; Simple; p.Gly182Glu (c.545G>A); Zygosity=Heterozygous (PubMed=35413567); Sequence variation: Mutation; HGNC; 14880; GTPBP3; Simple; p.Cys398Tyr (c.1193G>A) (p.Cys430Tyr, c.1289G>A); Zygosity=Heterozygous (PubMed=35413567) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 152998274 CVCL_C0CJ NIMHi006-A induced pluripotent stem cell human CVCL_C0CJ From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 152998275 CVCL_C0CI NIMHi005-A induced pluripotent stem cell human CVCL_C0CI From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 152998276 CVCL_C0BZ L14 [Mouse hybridoma against human NECTIN2] hybridoma house mouse CVCL_C0BZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92692; Human NECTIN2/CD112. 152998277 CVCL_C0CB WAe001-A-77 embryonic stem cell human CVCL_C0CB From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Male Characteristics: Using CRISPR/Cas9, a FLAG-HA tag followed by a PGK-Puro cassette were introduced at the C-terminus of both alleles of RYBP (PubMed=35537243). 152998278 CVCL_C0CA WAe001-A-78 embryonic stem cell human CVCL_C0CA From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4722; H1-10. Male 152998279 CVCL_C0BS 3S9 hybridoma CVCL_C0BS CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: UniProtKB; P26715; Human KLRC1/CD159a; Monoclonal antibody target: UniProtKB; P26717; Human KLRC2/CD159c; Monoclonal antibody target: UniProtKB; Q07444; Human KLRC3. Group: Patented cell line 152998280 CVCL_C0C4 CHCMUi001-A induced pluripotent stem cell human CVCL_C0C4 From: Children's hospital of Chongqing Medical University; Chongqing; China CL:0000010 Sequence variation: Mutation; HGNC; 8977; PIK3CD; Simple; p.Glu1021Lys (c.3061G>A); ClinVar=VCV000088675; Zygosity=Heterozygous (PubMed=35660815) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998281 CVCL_C0BR Abcam U2OS PARP2 KO cancer cell line human CVCL_C0BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 152998282 CVCL_C0C3 MA127 [Mouse hybridoma against human SLAMF6] hybridoma house mouse CVCL_C0C3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96DU3; Human SLAMF6/CD352. 152998283 CVCL_C0BU 3D11 [Mouse hybridoma against human HLA-F] hybridoma house mouse CVCL_C0BU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30511; Human HLA-F. 152998284 CVCL_C0C6 RCMGi005-B induced pluripotent stem cell human CVCL_C0C6 From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=36067639) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998285 CVCL_C0BT 4D12 [Mouse/rat hybridoma against mouse Klra3/Klra5] hybridoma CVCL_C0BT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q64329; Mouse Klra3/Ly49C; Monoclonal antibody target: UniProtKB; Q60652; Mouse Klra5/Ly49E. Group: Patented cell line 152998286 CVCL_C0C5 RCMGi008-A induced pluripotent stem cell human CVCL_C0C5 From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser18Argfs*16 (c.54-5940_273+10250del) (CFTRdele2,3); ClinVar=VCV000066105; Zygosity=Heterozygous (PubMed=35843019); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=35843019) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998287 CVCL_C0BW 5B14 hybridoma house mouse CVCL_C0BW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 152998288 CVCL_C0C8 BBANTWi010-A induced pluripotent stem cell human CVCL_C0C8 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11769; TGFB3; Simple; p.Asp263His (c.787G>C); ClinVar=VCV000203492; Zygosity=Heterozygous (PubMed=36356561) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 152998289 CVCL_C0BV 4D12 [Mouse hybridoma against human HLA-E] hybridoma house mouse CVCL_C0BV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13747; Human HLA-E. 152998290 CVCL_C0C7 BBANTWi009-A induced pluripotent stem cell human CVCL_C0C7 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1044; BGN; Simple; g.chrX:153502980_153530518del (27.5kb deletion); ClinVar=VCV000265797; Zygosity=Hemizygous (PubMed=36599284) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 152998291 CVCL_C0BY GL183 hybridoma house mouse CVCL_C0BY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43627; Human KIR2DL2/CD158b1; Monoclonal antibody target: UniProtKB; P43628; Human KIR2DL3/CD158b2. 152998292 CVCL_C0BX BAB281 hybridoma house mouse CVCL_C0BX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O76036; Human NCR1/CD335. 152998293 CVCL_C0C9 WAe001-A-79 embryonic stem cell human CVCL_C0C9 From: University of Houston; Houston; USA CL:0000010 Transfected with: mEos4b, a photoconvertible red fluorescent protein. Male Characteristics: Using CRISPR/Cas9, mEos4b followed by a FLAG tag was inserted 4 amino acids before the HCH domain of the cytoplasmic tail of CTR1 (PubMed=35728441) 152998294 CVCL_C0A0 Abcam THP-1 RYBP KO cancer cell line human CVCL_C0A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10480; RYBP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998295 CVCL_C0AJ Abcam THP-1 SUZ12 KO cancer cell line human CVCL_C0AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998296 CVCL_C0AI Abcam THP-1 SUV39H1 KO cancer cell line human CVCL_C0AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998297 CVCL_C0AL Abcam THP-1 TBK1 KO cancer cell line human CVCL_C0AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998298 CVCL_C0AK Abcam THP-1 TAPBP KO cancer cell line human CVCL_C0AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11566; TAPBP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998299 CVCL_C0AN Abcam THP-1 TCF7L2 KO cancer cell line human CVCL_C0AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11641; TCF7L2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998300 CVCL_C0AM Abcam THP-1 TBP KO cancer cell line human CVCL_C0AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11588; TBP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998301 CVCL_C0AP Abcam THP-1 TFDP1 KO cancer cell line human CVCL_C0AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11749; TFDP1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998302 CVCL_C0B1 Abcam THP-1 U2AF1 KO cancer cell line human CVCL_C0B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12453; U2AF1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998303 CVCL_C0B0 Abcam THP-1 TWIST2 KO cancer cell line human CVCL_C0B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20670; TWIST2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998304 CVCL_C0AB Abcam THP-1 SMYD3 KO cancer cell line human CVCL_C0AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15513; SMYD3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998305 CVCL_C0AA Abcam THP-1 SMYD2 KO cancer cell line human CVCL_C0AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20982; SMYD2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998306 CVCL_C0AD Abcam THP-1 SRF KO cancer cell line human CVCL_C0AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11291; SRF; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998307 CVCL_C0AC Abcam THP-1 SOCS3 KO cancer cell line human CVCL_C0AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998308 CVCL_C0AF Abcam THP-1 STAT4 KO cancer cell line human CVCL_C0AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11365; STAT4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998309 CVCL_C0AE Abcam THP-1 SRPK1 KO cancer cell line human CVCL_C0AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998310 CVCL_C0AH Abcam THP-1 STK4 KO cancer cell line human CVCL_C0AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998311 CVCL_C0AG Abcam THP-1 STAT5A KO cancer cell line human CVCL_C0AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11366; STAT5A; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998312 CVCL_C0A9 Abcam THP-1 SMURF1 KO cancer cell line human CVCL_C0A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16807; SMURF1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998313 CVCL_C0A2 Abcam THP-1 SCARB1 KO cancer cell line human CVCL_C0A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998314 CVCL_C0A1 Abcam THP-1 S100A8 KO cancer cell line human CVCL_C0A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10498; S100A8; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998315 CVCL_C0A4 Abcam THP-1 SETD2 KO cancer cell line human CVCL_C0A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998316 CVCL_C0A3 Abcam THP-1 SDC4 KO cancer cell line human CVCL_C0A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10661; SDC4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998317 CVCL_C0A6 Abcam THP-1 SMARCAL1 KO cancer cell line human CVCL_C0A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11102; SMARCAL1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998318 CVCL_C0A5 Abcam THP-1 SLFN11 KO cancer cell line human CVCL_C0A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998319 CVCL_C0A8 Abcam THP-1 SMARCE1 KO cancer cell line human CVCL_C0A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11109; SMARCE1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998320 CVCL_C0A7 Abcam THP-1 SMARCC2 KO cancer cell line human CVCL_C0A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11105; SMARCC2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998321 CVCL_C0VN B-LCL-CDG15 transformed cell line human CVCL_C0VN CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Leu32Arg (c.95_96delinsGC) (c.95TA>GC); ClinVar=VCV000092807; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe207Ser (c.620T>C); ClinVar=VCV000189141; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998322 CVCL_C0VQ B-LCL-CDG17 transformed cell line human CVCL_C0VQ CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg123Gln (c.368G>A); ClinVar=VCV000265255; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Cys241Ser (c.722G>C); ClinVar=VCV000007717; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998323 CVCL_C0VP B-LCL-CDG16 transformed cell line human CVCL_C0VP CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Leu32Arg (c.95_96delinsGC) (c.95TA>GC); ClinVar=VCV000092807; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe157Ser (c.470T>C); ClinVar=VCV000188763; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998324 CVCL_C0VS B-LCL-CDG19 transformed cell line human CVCL_C0VS CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Cys241Ser (c.722G>C); ClinVar=VCV000007717; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998325 CVCL_C0VR B-LCL-CDG18 transformed cell line human CVCL_C0VR CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Gly214Ser (c.640G>A); ClinVar=VCV000553503; Zygosity=Homozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998326 CVCL_C0VG ELO spontaneously immortalized cell line CVCL_C0VG CL:0000010 Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Group: Fish cell line 152998327 CVCL_C0VF B-LCL-CDG1 transformed cell line human CVCL_C0VF CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Val231Met (c.691G>A); ClinVar=VCV000007719; Zygosity=Heterozygous (PubMed=34420056) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998328 CVCL_C0VI B-LCL-CDG10 transformed cell line human CVCL_C0VI CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Gln33Ter (c.97C>T); ClinVar=VCV000803211; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Val44Ala (c.131T>C); ClinVar=VCV000007725; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998329 CVCL_C0VH FLT spontaneously immortalized cell line CVCL_C0VH CL:0000010 Derived from sampling site: Testis Cell type=Fibroblast.. Male Group: Fish cell line 152998330 CVCL_C0VK B-LCL-CDG12 transformed cell line human CVCL_C0VK CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Pro113Leu (c.338C>T); ClinVar=VCV000007723; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe207Ser (c.620T>C); ClinVar=VCV000189141; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998331 CVCL_C0VJ B-LCL-CDG11 transformed cell line human CVCL_C0VJ CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Tyr64Cys (c.191A>G); Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998332 CVCL_C0VM B-LCL-CDG14 transformed cell line human CVCL_C0VM CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe157Ser (c.470T>C); ClinVar=VCV000188763; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg162Trp (c.484C>T); ClinVar=VCV000007709; Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998333 CVCL_C0VL B-LCL-CDG13 transformed cell line human CVCL_C0VL CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Pro113Leu (c.338C>T); ClinVar=VCV000007723; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Thr118Ser (c.353C>T); Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Pro184Asp (c.550C>A); Zygosity=Heterozygous (PubMed=34420056) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998334 CVCL_C0LU GM28368 finite cell line human CVCL_C0LU CL:0000010 Sequence variation: Mutation; HGNC; 1349; SAMD9L; Simple; p.Arg986His (c.2957G>A); ClinVar=VCV001190635; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998335 CVCL_C0M6 GM28471 transformed cell line human CVCL_C0M6 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998336 CVCL_C0LT GM28366 transformed cell line human CVCL_C0LT CL:0000010 Population: Caucasian; English/Scottish; Derived from sampling site: Peripheral blood. Male 152998337 CVCL_C0M5 GM28469 transformed cell line human CVCL_C0M5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998338 CVCL_C0LW GM28386 finite cell line human CVCL_C0LW CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg576Ter (c.1726C>T) (p.Arg572Ter, c.1714C>T); ClinVar=VCV000488988; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Labioscrotal fold; skin Cell type=Fibroblast.. Male 152998339 CVCL_C0M8 GM28544 transformed cell line human CVCL_C0M8 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Val1392Met (c.4174G>A); ClinVar=VCV000195935; Zygosity=Mosaic (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998340 CVCL_C0LV GM28374 induced pluripotent stem cell human CVCL_C0LV CL:0000010 Population: Hispanic; Derived from sampling site: Lung Cell type=Fibroblast.. Female 152998341 CVCL_C0M7 GM28532 transformed cell line human CVCL_C0M7 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ile256Asn (c.767T>A); ClinVar=VCV000187883; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Trp583Ter (c.1748G>A); ClinVar=VCV000998376; Zygosity=Heterozygous (Coriell) Population: African American and Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998342 CVCL_C0LY GM28388 finite cell line human CVCL_C0LY CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998343 CVCL_C0LX GM28387 transformed cell line human CVCL_C0LX CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg576Ter (c.1726C>T) (p.Arg572Ter, c.1714C>T); ClinVar=VCV000488988; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998344 CVCL_C0M9 GM28545 transformed cell line human CVCL_C0M9 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Val1392Met (c.4174G>A); ClinVar=VCV000195935; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7470; MT-RNR1; Simple; m.963C>T; Zygosity=Homoplasmic (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998345 CVCL_C0LZ GM28389 transformed cell line human CVCL_C0LZ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998346 CVCL_C0LM GM28332 finite cell line human CVCL_C0LM CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Ala79Thr (c.235G>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Finnish/German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998347 CVCL_C0LL GM28467 transformed cell line human CVCL_C0LL CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Gly67Asp (c.200G>A); Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998348 CVCL_C0M0 GM28390 finite cell line human CVCL_C0M0 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998349 CVCL_C0LN GM28333 transformed cell line human CVCL_C0LN CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Ala79Thr (c.235G>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Finnish/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998350 CVCL_C0LQ GM28350 finite cell line human CVCL_C0LQ CL:0000010 Sequence variation: Mutation; HGNC; 17300; TAF8; Simple; p.Thr240Argfs*7 (c.719_720delAC); ClinVar=VCV001686246; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17300; TAF8; Simple; p.Asn269Thrfs*29 (c.806_809delACAC); ClinVar=VCV001686247; Zygosity=Heterozygous (Coriell) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998351 CVCL_C0M2 GM28392 transformed cell line human CVCL_C0M2 CL:0000010 Sequence variation: Mutation; HGNC; 886; ATRX; Simple; p.Arg2085Cys (c.6253C>T); ClinVar=VCV001180765; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998352 CVCL_C0LP GM28311 transformed cell line human CVCL_C0LP CL:0000010 Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Leu573Phe (c.1719A>T); ClinVar=VCV000811288; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2548; CUBN; Simple; p.Glu3077Lys (c.9229G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 19440; SBDS; Simple; p.Asn14Ser (c.41A>G); ClinVar=VCV000427147; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 19440; SBDS; Simple; c.258+2T>C (IVS2+2T>C); ClinVar=VCV000003196; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998353 CVCL_C0M1 GM28391 transformed cell line human CVCL_C0M1 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998354 CVCL_C0LS GM28365 transformed cell line human CVCL_C0LS CL:0000010 Population: Caucasian; Hungarian/Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998355 CVCL_C0M4 GM28404 induced pluripotent stem cell human CVCL_C0M4 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 152998356 CVCL_C0LR GM28364 transformed cell line human CVCL_C0LR CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Arg1666Pro (c.4997G>C); ClinVar=VCV000638582; Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 6831; MANBA; Simple; p.Asn578Ilefs*47 (c.1733delT); dbSNP=rs1404226085; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998357 CVCL_C0M3 GM28395 transformed cell line human CVCL_C0M3 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998358 CVCL_C0LE STAT6 KO (BalbC) transformed cell line house mouse CVCL_C0LE From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI:103034; Stat6 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/c. Unspecified 152998359 CVCL_C0LD STAT2 KO (129) transformed cell line house mouse CVCL_C0LD From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:103039; Stat2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: 129. Unspecified 152998360 CVCL_C0LG GM28076 transformed cell line human CVCL_C0LG CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998361 CVCL_C0LF GM28075 transformed cell line human CVCL_C0LF CL:0000010 Sequence variation: Mutation; HGNC; 18060; ARX; Simple; p.Ala151_Ala155dup (c.441_455dup15); ClinVar=VCV000818170; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Asn336del (c.1000AAC[2]) (c.1006_1008delAAC); ClinVar=VCV000265402; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 152998362 CVCL_C0LI GM28285 transformed cell line human CVCL_C0LI CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Gln18Ter (c.52C>T); ClinVar=VCV000620358; Zygosity=Heterozygous (Coriell) Population: Asian and Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998363 CVCL_C0LH GM28284 finite cell line human CVCL_C0LH CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Gly163Ter (c.487G>T); ClinVar=VCV000504345; Zygosity=Heterozygous (Coriell) Population: Caucasian; German/Irish; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 152998364 CVCL_C0LK GM28466 finite cell line human CVCL_C0LK CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Gly67Asp (c.200G>A); Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998365 CVCL_C0LJ GM28286 finite cell line human CVCL_C0LJ CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Gln18Ter (c.52C>T); ClinVar=VCV000620358; Zygosity=Heterozygous (Coriell) Population: Asian and Caucasian; Greek; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 152998366 CVCL_C0LA LAT/LAB KO (C57) transformed cell line house mouse CVCL_C0LA From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1342293; Lat; Knockout cell: Method=KO mouse; MGI; MGI:1926479; Lat2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998367 CVCL_C0LC STAT1 KO (129/SvEV) transformed cell line house mouse CVCL_C0LC From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:103063; Stat1 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: 129/SvEV. Unspecified 152998368 CVCL_C0LB PKR KO (C57) transformed cell line house mouse CVCL_C0LB From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1353449; Eif2ak2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998369 CVCL_C0MV Bone marrow macrophage immortalized C57BL/6 x 129P3 transformed cell line house mouse CVCL_C0MV From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6 x 129P3. Unspecified 152998370 CVCL_C0N7 XTN-12 spontaneously immortalized cell line tropical clawed frog CVCL_C0N7 CL:0000010 Karyotypic information: Diploid karyotype (PubMed=35857907); Derived from sampling site: Whole embryo; Breed/subspecies: Nigerian St.549. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 21.7 hours (PubMed=35857907) Group: Amphibian cell line 152998371 CVCL_C0MU Bone marrow macrophage immortalized C57BL/6 transformed cell line house mouse CVCL_C0MU From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998372 CVCL_C0N6 XTN-10 spontaneously immortalized cell line tropical clawed frog CVCL_C0N6 CL:0000010 Karyotypic information: Diploid karyotype (PubMed=35857907); Derived from sampling site: Whole embryo; Breed/subspecies: Nigerian St.549. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 23.6 hours (PubMed=35857907) Group: Amphibian cell line 152998373 CVCL_C0MX Bone marrow macrophage immortalized FVB/N transformed cell line house mouse CVCL_C0MX From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: FVB/N. Unspecified 152998374 CVCL_C0N9 XL177 lacZ clone 2.1 spontaneously immortalized cell line African clawed frog CVCL_C0N9 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Group: Amphibian cell line 152998375 CVCL_C0MW Bone marrow macrophage immortalized C57BL/6J transformed cell line house mouse CVCL_C0MW From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6j. Unspecified 152998376 CVCL_C0N8 XL177 lacZ clone 1.18 spontaneously immortalized cell line African clawed frog CVCL_C0N8 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Group: Amphibian cell line 152998377 CVCL_C0MZ 3B12F7 hybridoma house mouse CVCL_C0MZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q96SW2; Human CRBN (Note=Also reacts with other mammalian species). 152998378 CVCL_C0MY A20-Nluc-copGFP cancer cell line house mouse CVCL_C0MY CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (copGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Breed/subspecies: BALB/cAnN. Unspecified Characteristics: Transduced with a CMV-Nluc-P2A-copGFP-T2A-Puro construct 152998379 CVCL_C0MN Dog-OralMel-18333 cancer cell line dog CVCL_C0MN CL:0000010 Sequence variation: Gene deletion; VGNC; 109332; CDKN2A; Zygosity=Unspecified (CelloPub=CLPUB00708) Miscellaneous: Exact sampling site, sex, age and breed of donor from personal communication of Hedan B Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Poodle. Omics: Genome sequenced Female 152998380 CVCL_C0MM Dog-OralMel-18249 cancer cell line dog CVCL_C0MM CL:0000010 Miscellaneous: Sex, age and breed of donor from personal communication of Hedan B Derived from sampling site: Oral cavity; Breed/subspecies: Shih Tzu. Omics: Deep exome analysis Male 152998381 CVCL_C0N1 4E11E2 hybridoma house mouse CVCL_C0N1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96SW2; Human CRBN (Note=Also reacts with other mammalian species). 152998382 CVCL_C0MP Dog-OralMel-18395 cancer cell line dog CVCL_C0MP CL:0000010 Sequence variation: Gene deletion; VGNC; 109332; CDKN2A; Zygosity=Unspecified (CelloPub=CLPUB00708) Miscellaneous: Sex, age and breed of donor from personal communication of Hedan B Derived from sampling site: Oral cavity; Breed/subspecies: Rottweiler. Omics: Genome sequenced Male 152998383 CVCL_C0N0 4A7H6 hybridoma house mouse CVCL_C0N0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q96SW2; Human CRBN (Note=Also reacts with other mammalian species). 152998384 CVCL_C0MR Dog-OralMel-18848 cancer cell line dog CVCL_C0MR CL:0000010 Miscellaneous: Sex, age and breed of donor from personal communication of Hedan B Derived from sampling site: Oral cavity; Breed/subspecies: Yorkshire Terrier. Female 152998385 CVCL_C0N3 NOOC1 cancer cell line house mouse CVCL_C0N3 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: C57BL/6J. Omics: Deep exome analysis Male Characteristics: Tumorigenic 152998386 CVCL_C0MQ Dog-OralMel-18657 cancer cell line dog CVCL_C0MQ CL:0000010 Miscellaneous: Exact sampling site, sex, age and breed of donor from personal communication of Hedan B Derived from sampling site: Oral cavity; palate; Breed/subspecies: Golden Retriever. Female 152998387 CVCL_C0N2 HEK293-IRF3 transformed cell line human CVCL_C0N2 CL:0000010 Transfected with: HGNC; 6118; IRF3; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a VenusC1-IRF3 fusion protein 152998388 CVCL_C0MT Bone marrow macrophage immortalized C57BL/10SnJ transformed cell line house mouse CVCL_C0MT From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/10SnJ. Unspecified 152998389 CVCL_C0N5 XTN-8 spontaneously immortalized cell line tropical clawed frog CVCL_C0N5 CL:0000010 Karyotypic information: Diploid karyotype (PubMed=35857907); Derived from sampling site: Whole embryo; Breed/subspecies: Nigerian St.549. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 24.5 hours (PubMed=35857907) Group: Amphibian cell line 152998390 CVCL_C0MS Bone marrow macrophage immortalized BALB/c transformed cell line house mouse CVCL_C0MS From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/c. Unspecified 152998391 CVCL_C0N4 XTN-6 spontaneously immortalized cell line tropical clawed frog CVCL_C0N4 CL:0000010 Karyotypic information: Diploid [56]; diploid with trisomy of chromosome 8 [93]; tetraploid [28] (PubMed=35857907); Derived from sampling site: Whole embryo; Breed/subspecies: Nigerian St.549. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 24.0 hours (PubMed=35857907) Group: Amphibian cell line 152998392 CVCL_C0MF NH50375 induced pluripotent stem cell human CVCL_C0MF CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion_corrected; p.Gln18[44] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998393 CVCL_C0ME NH50374 finite cell line human CVCL_C0ME CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (nhcdr) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998394 CVCL_C0MH GREC spontaneously immortalized cell line CVCL_C0MH CL:0000010 Derived from sampling site: Embryonic eye; retina; retinal pigment epithelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021238 152998395 CVCL_C0MG MSBr spontaneously immortalized cell line CVCL_C0MG CL:0000010 Derived from sampling site: Brain. Unspecified Doubling time: 49.6 hours (Patent=CN113025574B) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202166 152998396 CVCL_C0MJ HNEEC/HL-015 finite cell line human CVCL_C0MJ CL:0000010 Population: Chinese; Derived from sampling site: Eye lid; skin Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015181 152998397 CVCL_C0MI HNEEC/HL-014 finite cell line human CVCL_C0MI CL:0000010 Population: Chinese; Derived from sampling site: Eye lid; skin Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015180 152998398 CVCL_C0ML HCINC/HL-017 cancer cell line human CVCL_C0ML CL:0000010 Population: Chinese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Vulva. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015124 152998399 CVCL_C0MK HNVEC/HL-016 finite cell line human CVCL_C0MK CL:0000010 Population: Chinese; Derived from sampling site: Vagina Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2015113 152998400 CVCL_C0MB NFKB p50 KO (C57/129) transformed cell line house mouse CVCL_C0MB From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97312; Nfkb1 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6 x 129. Unspecified 152998401 CVCL_C0MA GM28546 transformed cell line human CVCL_C0MA CL:0000010 Sequence variation: Mutation; HGNC; 7470; MT-RNR1; Simple; m.963C>T; Zygosity=Homoplasmic (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998402 CVCL_C0MD GM28259 induced pluripotent stem cell human CVCL_C0MD CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998403 CVCL_C0MC TNF Rec KO transformed cell line house mouse CVCL_C0MC From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1314884; Tnfrsf1a Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998404 CVCL_C0K4 MNZTASi004-A induced pluripotent stem cell human CVCL_C0K4 From: Menzies Institute for Medical Research, University of Tasmania; Hobart; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998405 CVCL_C0JS UCSCi002-A induced pluripotent stem cell human CVCL_C0JS From: Universita Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A Gemelli; Rome; Italy. CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ser332Asn (c.995G>A); ClinVar=VCV001448395; Zygosity=Heterozygous (PubMed=35667216) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 152998406 CVCL_C0JR DHMCi009-A induced pluripotent stem cell human CVCL_C0JR From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12412; TUBB2A; Simple; p.Ala248Val (c.743C>T); ClinVar=VCV000127101; Zygosity=Heterozygous (PubMed=35930870) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998407 CVCL_C0K3 MNZTASi003-A induced pluripotent stem cell human CVCL_C0K3 From: Menzies Institute for Medical Research, University of Tasmania; Hobart; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998408 CVCL_C0K6 CBIGi002-A induced pluripotent stem cell human CVCL_C0K6 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Trp417Gly (c.1249T>G) (W378G); ClinVar=VCV001211295; Zygosity=Heterozygous (PubMed=36130446) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998409 CVCL_C0JU CSUi002-A-3 induced pluripotent stem cell human CVCL_C0JU From: Louisiana State University Health Sciences Center in Shreveport; Shreveport; USA CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple_corrected; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35533513) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998410 CVCL_C0JT CSUi002-A-2 induced pluripotent stem cell human CVCL_C0JT From: Louisiana State University Health Sciences Center in Shreveport; Shreveport; USA CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple_corrected; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35533513) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998411 CVCL_C0K5 MNZTASi005-A induced pluripotent stem cell human CVCL_C0K5 From: Menzies Institute for Medical Research, University of Tasmania; Hobart; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998412 CVCL_C0K8 CBIGi003-A induced pluripotent stem cell human CVCL_C0K8 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=36130446) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998413 CVCL_C0JW SHCDCLi001-B induced pluripotent stem cell human CVCL_C0JW From: Department of Central Laboratory, Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 43532; MIR5004 Derived from sampling site: Peripheral blood. Male 152998414 CVCL_C0K7 CBIGi002-A-1 induced pluripotent stem cell human CVCL_C0K7 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple_corrected; p.Trp417Gly (c.1249T>G) (W378G); ClinVar=VCV001211295; Zygosity=Heterozygous; By CRISPR/Cas9 (PubMed=36130446) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998415 CVCL_C0JV GIBHe013-A embryonic stem cell human CVCL_C0JV From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1. Male 152998416 CVCL_C0JY CBIGi001-A induced pluripotent stem cell human CVCL_C0JY From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998417 CVCL_C0K9 CBIGi003-A-1 induced pluripotent stem cell human CVCL_C0K9 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple_corrected; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36130446) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998418 CVCL_C0JX SKLRMe002-A embryonic stem cell human CVCL_C0JX From: State Key Laboratory of Reproductive Medicine, Nanjing Medical University; Nanjing; China CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using CRISPR/Cas9 two different constructs were introduced in the two alleles of the AAVS1 safe harbor locus In one allele a doxycycline inducible PuroR-Cas9 cassette was introduced while in the other alleles a constitutive reverse tetracycline trans-activator (M2rtTA) expression cassette Neo-M2rtTA was introduced (PubMed=35617843). 152998419 CVCL_C0JK SMBCi018-A induced pluripotent stem cell human CVCL_C0JK From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 9004; PITX1; Simple; p.Gly299Ala (c.896G>C); ClinVar=VCV000286868; Zygosity=Unspecified; Note=De novo mutation (PubMed=35605480) Population: Chinese; Han; Derived from sampling site: Urine. Male Caution: Indicated in PubMed=35605480 both as being established from a 12 year old and a 29 year old patient 152998420 CVCL_C0JJ JSPHi002-A induced pluripotent stem cell human CVCL_C0JJ From: Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.His258Leu (c.773A>T); Zygosity=Heterozygous (PubMed=35580545) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998421 CVCL_C0JM SMBCi016-A induced pluripotent stem cell human CVCL_C0JM From: Shandong Medical Biotechnological Center; Jinan; China. CL:0000010 152998422 CVCL_C0JL SMBCi015-A induced pluripotent stem cell human CVCL_C0JL From: Shandong Medical Biotechnological Center; Jinan; China. CL:0000010 152998423 CVCL_C0K0 CBIGi001-A-2 induced pluripotent stem cell human CVCL_C0K0 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998424 CVCL_C0JN SMBCi017-A induced pluripotent stem cell human CVCL_C0JN From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 152998425 CVCL_C0JQ DHMCi008-A induced pluripotent stem cell human CVCL_C0JQ From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20766; TUBA1A; Simple; p.Ala174Val (c.521C>T); ClinVar=VCV000160159; Zygosity=Heterozygous; Note=De novo mutation (PubMed=35636247) Population: Turkish; Derived from sampling site: Peripheral blood. Female 152998426 CVCL_C0K2 MNZTASi002-A induced pluripotent stem cell human CVCL_C0K2 From: Menzies Institute for Medical Research, University of Tasmania; Hobart; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998427 CVCL_C0K1 CBIGi001-A-3 induced pluripotent stem cell human CVCL_C0K1 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998428 CVCL_C0JP SMBCi019-A induced pluripotent stem cell human CVCL_C0JP From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp203Ter (c.609G>A); ClinVar=VCV000030800; Zygosity=Heterozygous (PubMed=35660814) Derived from sampling site: Urine. Male 152998429 CVCL_C0JC INNDSUi001-A induced pluripotent stem cell human CVCL_C0JC From: Institute of Neuromuscular and Neurodegenerative Diseases, Shandong University; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998430 CVCL_C0JB INNDSUi003-A induced pluripotent stem cell human CVCL_C0JB From: Institute of Neuromuscular and Neurodegenerative Diseases, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.1483-2A>G; ClinVar=VCV001322654; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=35526387) Population: Chinese; Han; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 152998431 CVCL_C0JE WAe009-A-86 embryonic stem cell human CVCL_C0JE From: Shenzhen People's Hospital; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple_edited; p.Arg541Cys (c.1621 C>T); ClinVar=VCV000937094; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg). Female 152998432 CVCL_C0JD WAe009-A-88 embryonic stem cell human CVCL_C0JD From: Shenzhen People's Hospital; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple_edited; p.Met574Val (c.1720 A>G); ClinVar=VCV000067252; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35526388). Female 152998433 CVCL_C0JG KEIOi003-A induced pluripotent stem cell human CVCL_C0JG From: Keio University; Tokyo; Japan. CL:0000010 152998434 CVCL_C0JF KEIOi005-A induced pluripotent stem cell human CVCL_C0JF From: Keio University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 1052; BIN1; Simple; g.chr2:127894615A>G; dbSNP=rs744373; Zygosity=Heterozygous (PubMed=35537244); Sequence variation: Mutation; HGNC; 13375; MS4A6A; Simple; g.chr11:60171834T>G; dbSNP=rs610932; Zygosity=Homozygous (PubMed=35537244) Population: Japanese; Derived from sampling site: Urine. Male 152998435 CVCL_C0JI SHCDNi007-A induced pluripotent stem cell human CVCL_C0JI From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 8636; PC; Simple; p.Ile61Thr (c.182T>C); Zygosity=Heterozygous (PubMed=36508859); Sequence variation: Mutation; HGNC; 8636; PC; Simple; p.Val861Met (c.2581G>A); Zygosity=Heterozygous (PubMed=36508859) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998436 CVCL_C0JH KEIOi004-A induced pluripotent stem cell human CVCL_C0JH From: Keio University; Tokyo; Japan. CL:0000010 152998437 CVCL_C0IZ MRIi003-A-6 induced pluripotent stem cell human CVCL_C0IZ From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the bright RFP mRuby2) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 a CAG-promoter driven voltage-sensing fluorescent protein (VSFP) that consist of of a voltage-sensing transmembrane domain fused to a pair of fluorescent proteins: Clover and mRuby2 was inserted into both alleles of the AAVS1 safe harbor locus (PubMed=35421847) 152998438 CVCL_C0IY MRIi003-A-5 induced pluripotent stem cell human CVCL_C0IY From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the bright RFP mRuby2) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 a CAG-promoter driven voltage-sensing fluorescent protein (VSFP) that consist of of a voltage-sensing transmembrane domain fused to a pair of fluorescent proteins: Clover and mRuby2 was inserted into one allele of the AAVS1 safe harbor locus (PubMed=35421847) 152998439 CVCL_C0JA LCSBi008-A-1 induced pluripotent stem cell human CVCL_C0JA From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple_corrected; p.Pro158del (c.471_473delGCC); ClinVar=VCV000987356; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=35617842) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998440 CVCL_C0L5 IFN-gamma KO (C57) transformed cell line house mouse CVCL_C0L5 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:107656; Ifng Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998441 CVCL_C0KT TD02 induced pluripotent stem cell human CVCL_C0KT From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female 152998442 CVCL_C0L4 IFN-alpha/beta Rec KO (129) transformed cell line house mouse CVCL_C0L4 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:107658; Ifnar1 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: 129. Unspecified 152998443 CVCL_C0KS TD03 induced pluripotent stem cell human CVCL_C0KS From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998444 CVCL_C0L7 IGTP KO transformed cell line house mouse CVCL_C0L7 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:107729; Igtp Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.. Unspecified 152998445 CVCL_C0KV TD22 induced pluripotent stem cell human CVCL_C0KV From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998446 CVCL_C0L6 IFN-gamma Rec KO (129) transformed cell line house mouse CVCL_C0L6 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:107655; Ifngr1; Knockout cell: Method=KO mouse; MGI; MGI:107654; Ifngr2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: 129. Unspecified 152998447 CVCL_C0KU TD10 induced pluripotent stem cell human CVCL_C0KU From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female 152998448 CVCL_C0KX 3518 induced pluripotent stem cell human CVCL_C0KX From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female 152998449 CVCL_C0L9 LAB KO (C57) transformed cell line house mouse CVCL_C0L9 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1926479; Lat2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998450 CVCL_C0KW 3394 induced pluripotent stem cell human CVCL_C0KW From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998451 CVCL_C0L8 iNOS KO (C57) transformed cell line house mouse CVCL_C0L8 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97361; Nos2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998452 CVCL_C0KZ 3630 induced pluripotent stem cell human CVCL_C0KZ From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998453 CVCL_C0KY 3620 induced pluripotent stem cell human CVCL_C0KY From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female 152998454 CVCL_C0KL AIW002-02/USP19-KO induced pluripotent stem cell human CVCL_C0KL From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12617; USP19 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998455 CVCL_C0KK AIW002-02/SNCA-KO induced pluripotent stem cell human CVCL_C0KK From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998456 CVCL_C0KN AJG001-C4 induced pluripotent stem cell human CVCL_C0KN From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998457 CVCL_C0KM AJC001-5 induced pluripotent stem cell human CVCL_C0KM From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998458 CVCL_C0KP 3448 induced pluripotent stem cell human CVCL_C0KP From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998459 CVCL_C0L1 3750 induced pluripotent stem cell human CVCL_C0L1 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998460 CVCL_C0L0 3675 induced pluripotent stem cell human CVCL_C0L0 From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998461 CVCL_C0KR AJD002-3 induced pluripotent stem cell human CVCL_C0KR From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male 152998462 CVCL_C0L3 DAP12 KO (C57) transformed cell line house mouse CVCL_C0L3 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1277211; Tyrobp Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998463 CVCL_C0KQ 3450 induced pluripotent stem cell human CVCL_C0KQ From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Derived from sampling site: Peripheral blood. Female 152998464 CVCL_C0L2 BAX KO (C57) transformed cell line house mouse CVCL_C0L2 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99702; Bax Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 152998465 CVCL_C0KD AIW002-02/FUS-KO induced pluripotent stem cell human CVCL_C0KD From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998466 CVCL_C0KC AIW002-02/C9ORF72-KO induced pluripotent stem cell human CVCL_C0KC From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998467 CVCL_C0KF AIW002-02/GBA-KO induced pluripotent stem cell human CVCL_C0KF From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998468 CVCL_C0KE AIW002-02/GALC-KO induced pluripotent stem cell human CVCL_C0KE From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4115; GALC Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998469 CVCL_C0KH AIW002-02/MAPT-KO induced pluripotent stem cell human CVCL_C0KH From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6893; MAPT Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998470 CVCL_C0KG AIW002-02/LRRK2-KO induced pluripotent stem cell human CVCL_C0KG From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998471 CVCL_C0KJ AIW002-02/SMPD1-KO induced pluripotent stem cell human CVCL_C0KJ From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11120; SMPD1 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998472 CVCL_C0KI AIW002-02/OPTN-KO induced pluripotent stem cell human CVCL_C0KI From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17142; OPTN Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998473 CVCL_C0JZ CBIGi001-A-1 induced pluripotent stem cell human CVCL_C0JZ From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998474 CVCL_C0KB AIW002-02/ATXN3-KO induced pluripotent stem cell human CVCL_C0KB From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7106; ATXN3 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998475 CVCL_C0KA AIW002-02/ASAH1-KO induced pluripotent stem cell human CVCL_C0KA From: Clinical Biospecimen Imaging and Genetic (C-BIG) Repository, Montreal Neurological Institute, McGill University; Montreal; Canada CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 735; ASAH1 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998476 CVCL_C0I2 LMM3 FNwt10 cancer cell line house mouse CVCL_C0I2 CL:0000010 Transfected with: HGNC; 3778; FN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 152998477 CVCL_C0HQ SJHi001-A induced pluripotent stem cell human CVCL_C0HQ From: Shengjing Hospital of China Medical University; Shenyang; China CL:0000010 Sequence variation: Mutation; HGNC; 4192; GCGR; Simple; p.Trp83Ter (c.248G>A); Zygosity=Heterozygous (PubMed=35381520) Population: Chinese; Derived from sampling site: Peripheral blood. Female 152998478 CVCL_C0I1 LMM3 FNwt2 cancer cell line house mouse CVCL_C0I1 CL:0000010 Transfected with: HGNC; 3778; FN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 152998479 CVCL_C0HP NSI002-B induced pluripotent stem cell human CVCL_C0HP From: Stem Cell and Neurobiology Lab, National Centre for Cell Science; Pune; India CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Karyotypic information: Lost the third copy of chromosome 21 (from parent cell line); Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male Characteristics: Using ZFN a AAV-CAGGS-EGFP cassette was introduced in the AAVS1 safe harbor locus (PubMed=35961104) 152998480 CVCL_C0HS HMGUi003-A induced pluripotent stem cell human CVCL_C0HS From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 25686; PPCS; Simple; p.Pro107_Ala111del (c.320_334del); ClinVar=VCV000590784; Zygosity=Heterozygous (PubMed=35397396); Sequence variation: Mutation; HGNC; 25686; PPCS; Simple; p.Ala180Pro (c.538G>C); ClinVar=VCV000590783; Zygosity=Heterozygous (PubMed=35397396) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998481 CVCL_C0I4 LMM3 FN RGD/LGD cancer cell line house mouse CVCL_C0I4 CL:0000010 Transfected with: HGNC; 3778; FN1 (with p.Arg1615Leu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 152998482 CVCL_C0I3 LMM3 FN RGD/LAV cancer cell line house mouse CVCL_C0I3 CL:0000010 Transfected with: HGNC; 3778; FN1 (with p.Arg1615Leu, p.Gly1616Ala and p.Asp1617Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 152998483 CVCL_C0HR SJHi002-A induced pluripotent stem cell human CVCL_C0HR From: Shengjing Hospital of China Medical University; Shenyang; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 152998484 CVCL_C0I6 293L-APP-/- transformed cell line human CVCL_C0I6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9, TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope 152998485 CVCL_C0HU Raji/A cancer cell line human CVCL_C0HU CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 152998486 CVCL_C0I5 293L transformed cell line human CVCL_C0I5 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9, TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope 152998487 CVCL_C0HT K562/G cancer cell line human CVCL_C0HT CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 152998488 CVCL_C0I8 293EL-APP-/- transformed cell line human CVCL_C0I8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP; Transfected with: HGNC; 3185; EEA1 (with a N-terminal FLAG tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9, TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope 152998489 CVCL_C0HW Wh43 transformed cell line human CVCL_C0HW CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152998490 CVCL_C0I7 293EL transformed cell line human CVCL_C0I7 CL:0000010 Transfected with: HGNC; 3185; EEA1 (with a N-terminal FLAG tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9, TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope 152998491 CVCL_C0HV Wh3 transformed cell line human CVCL_C0HV CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152998492 CVCL_C0HI BRCi017-A induced pluripotent stem cell human CVCL_C0HI CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 152998494 CVCL_C0HK NSI001-A induced pluripotent stem cell human CVCL_C0HK From: Stem Cell and Neurobiology Lab, National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Karyotypic information: 46,XX,rob(14;21) (PubMed=35381521); Derived from sampling site: Peripheral blood. Female 152998495 CVCL_C0HJ BRCi018-A induced pluripotent stem cell human CVCL_C0HJ CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 152998496 CVCL_C0HM NSI001-C induced pluripotent stem cell human CVCL_C0HM From: Stem Cell and Neurobiology Lab, National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Karyotypic information: 46,XX,rob(14;21) (PubMed=35381521); Derived from sampling site: Peripheral blood. Female 152998497 CVCL_C0HL NSI001-B induced pluripotent stem cell human CVCL_C0HL From: Stem Cell and Neurobiology Lab, National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Karyotypic information: 46,XX,rob(14;21) (PubMed=35381521); Derived from sampling site: Peripheral blood. Female 152998498 CVCL_C0I0 MYD88 KO (C57/129) transformed cell line house mouse CVCL_C0I0 From: Young H.A.; National Cancer Institute, National Institutes of Health; Frederick; USA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6 x 129. Unspecified 152998499 CVCL_C0HN NSI002-A induced pluripotent stem cell human CVCL_C0HN From: Stem Cell and Neurobiology Lab, National Centre for Cell Science; Pune; India CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male Characteristics: Using ZFN a AAV-CAGGS-EGFP cassette was introduced in the AAVS1 safe harbor locus (PubMed=35961104) 152998500 CVCL_C0HA PUMCi003-A induced pluripotent stem cell human CVCL_C0HA From: Peking Union Medical College; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu363Gln (c.1087G>C); Zygosity=Heterozygous (PubMed=35421846) Population: Chinese; Han; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 152998501 CVCL_C0HC IBMS-iPSC-074-01 induced pluripotent stem cell human CVCL_C0HC From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Cys490Arg (c.1468T>C); Zygosity=Heterozygous (PubMed=36075118) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 152998502 CVCL_C0HB IBKMOLi002-A induced pluripotent stem cell human CVCL_C0HB From: Institute for Molecular Biology, University of Innsbruck; Innsbruck; Austria CL:0000010 Sequence variation: Mutation; HGNC; 1391; CACNA1D; Simple; p.Leu271His (c.812T>A); Zygosity=Heterozygous; Note=De novo mutation (PubMed=35453044) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998503 CVCL_C0HE MDCi008-A induced pluripotent stem cell human CVCL_C0HE From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Pro (m.8993T>C); ClinVar=VCV000009642; Zygosity=Homoplasmic (PubMed=35279592) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998504 CVCL_C0HD MDCi007-A induced pluripotent stem cell human CVCL_C0HD From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Homoplasmic (PubMed=35279592) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998505 CVCL_C0HG MDCi010-A induced pluripotent stem cell human CVCL_C0HG From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Homoplasmic (PubMed=35279592) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998506 CVCL_C0HF MDCi009-A induced pluripotent stem cell human CVCL_C0HF From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Homoplasmic (PubMed=35279592) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998507 CVCL_C0H9 KUMi006-A induced pluripotent stem cell human CVCL_C0H9 From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow. Male 152998508 CVCL_C0GX SUSMi005-A-3.2 induced pluripotent stem cell human CVCL_C0GX From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (2 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998509 CVCL_C0H8 KUMi005-A induced pluripotent stem cell human CVCL_C0H8 From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow. Female 152998510 CVCL_C0GW SUSMi005-A-3.1 induced pluripotent stem cell human CVCL_C0GW From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (2 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998511 CVCL_C0GZ SUSMi005-A-4.2 induced pluripotent stem cell human CVCL_C0GZ From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (3 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998512 CVCL_C0GY SUSMi005-A-4.1 induced pluripotent stem cell human CVCL_C0GY From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (3 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998513 CVCL_C0J3 JUCTCi019-B induced pluripotent stem cell human CVCL_C0J3 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Heterozygous (from autologous cell line JUCTCi019-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998514 CVCL_C0IR WCHi005-A induced pluripotent stem cell human CVCL_C0IR From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998515 CVCL_C0J2 JUCTCi019-A induced pluripotent stem cell human CVCL_C0J2 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Heterozygous (PubMed=35468369) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998516 CVCL_C0IQ WCHi004-A induced pluripotent stem cell human CVCL_C0IQ From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998517 CVCL_C0IT DHMi005-A-4 induced pluripotent stem cell human CVCL_C0IT From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a FLAG tag was introduced at the C-terminus of one allele of TBX5 (PubMed=36610218) 152998518 CVCL_C0J5 JUCTCi018-A induced pluripotent stem cell human CVCL_C0J5 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998519 CVCL_C0IS DHMi005-A-3 induced pluripotent stem cell human CVCL_C0IS From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a FLAG tag was introduced at the C-terminus of one allele of TBX5 (PubMed=36610218) 152998520 CVCL_C0J4 JUCTCi019-C induced pluripotent stem cell human CVCL_C0J4 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Heterozygous (from autologous cell line JUCTCi019-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998521 CVCL_C0J7 JUCTCi018-C induced pluripotent stem cell human CVCL_C0J7 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998522 CVCL_C0IV UCSFi001-A-60 induced pluripotent stem cell human CVCL_C0IV CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 1388; CACNA1A Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 152998523 CVCL_C0IU DHMi005-A-2 induced pluripotent stem cell human CVCL_C0IU From: German Heart Center Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a FLAG tag was introduced at the C-terminus of one allele of TBX5 (hPSCreg) 152998524 CVCL_C0J6 JUCTCi018-B induced pluripotent stem cell human CVCL_C0J6 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998525 CVCL_C0J9 LCSBi008-A induced pluripotent stem cell human CVCL_C0J9 From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple; p.Pro158del (c.471_473delGCC); ClinVar=VCV000987356; Zygosity=Homozygous (PubMed=35500378) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998526 CVCL_C0IX UCSFi001-A-62 induced pluripotent stem cell human CVCL_C0IX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1388; CACNA1A Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 152998527 CVCL_C0IW UCSFi001-A-61 induced pluripotent stem cell human CVCL_C0IW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1388; CACNA1A Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 152998528 CVCL_C0J8 WMUi032-A induced pluripotent stem cell human CVCL_C0J8 From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12496; UBE3A; Simple; p.Asp583Gly (c.1748A>G) (p.Asp563Gly, c.1688A>G); ClinVar=VCV000160209; Zygosity=Heterozygous (PubMed=35489268) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998529 CVCL_C0IJ ZJUi010-A induced pluripotent stem cell human CVCL_C0IJ From: Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr652Ter (c.1956C>A); Zygosity=Heterozygous (PubMed=35569348) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998530 CVCL_C0II CIPi002-A induced pluripotent stem cell human CVCL_C0II From: Children's Hospital of Capital Institute of Pediatrics; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 10596; SCN8A; Simple; p.Met367Val (c.1099A>G); ClinVar=VCV000207105; Zygosity=Heterozygous (PubMed=35853415) Population: Chinese; Derived from sampling site: Peripheral blood. Female 152998531 CVCL_C0IL ZJUi011-A induced pluripotent stem cell human CVCL_C0IL From: Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Glu1462Lys (c.4384G>A); ClinVar=VCV000918880; Zygosity=Heterozygous (PubMed=35944310) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998532 CVCL_C0IK ZJUi009-A induced pluripotent stem cell human CVCL_C0IK From: Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 152998533 CVCL_C0IN WCHi006-A induced pluripotent stem cell human CVCL_C0IN From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998534 CVCL_C0IM ZJUi012-A induced pluripotent stem cell human CVCL_C0IM From: Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Ala1255Asp (c.3764C>A); ClinVar=VCV000179227; Zygosity=Heterozygous (PubMed=36041398) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 152998535 CVCL_C0J1 SCIKFi001-A induced pluripotent stem cell human CVCL_C0J1 CL:0000010 Population: Asian; Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 152998536 CVCL_C0IP WCHi003-A induced pluripotent stem cell human CVCL_C0IP From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 152998537 CVCL_C0J0 SCVIi038-A induced pluripotent stem cell human CVCL_C0J0 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a doxycycline-inducible dCas9-KRAB-mCherry cassette was introduced in both alleles of the AAVS1 safe harbor locus (PubMed=35325819); Characteristics: Using CRISPR/Cas9 MYL7 has been endogenously tagged in one allele at the C-terminus with mEGFP 152998538 CVCL_C0IB GZHMCi009-A induced pluripotent stem cell human CVCL_C0IB From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=35421843) Population: Chinese; Derived from sampling site: Peripheral blood. Male 152998539 CVCL_C0IA HIE1 cancer cell line human CVCL_C0IA CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=11876951) Population: Chinese; Derived from sampling site: Peripheral blood. Male Doubling time: 22-24 hours (PubMed=11876951) 152998540 CVCL_C0ID UMILi027-A induced pluripotent stem cell human CVCL_C0ID From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9143; PHOX2B; Simple; p.Ala260(5_9) (c.765_779dup); ClinVar=VCV000006008; Zygosity=Heterozygous (PubMed=35421844) Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 152998541 CVCL_C0IC GZHMCi010-A induced pluripotent stem cell human CVCL_C0IC From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=35421843) Population: Chinese; Derived from sampling site: Peripheral blood. Female 152998542 CVCL_C0IF WYUi001-A induced pluripotent stem cell human CVCL_C0IF From: Wuyi University; Jiangmen; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15782; ARHGAP11B Derived from sampling site: Umbilical cord blood. Female Caution: The original paper (PubMed=35358830) was retracted (PubMed=36868040) and it is indicated that 'new information that has come to the attention of the authors regarding the extent of the editing in the generated iPSC line' They will submit a new paper that 'will include all corrected and updated details with respect to their edited iPSC line'. 152998543 CVCL_C0IE UMILi028-A induced pluripotent stem cell human CVCL_C0IE From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9143; PHOX2B; Simple; p.Ala260(5_9) (c.765_779dup); ClinVar=VCV000006008; Zygosity=Heterozygous (PubMed=35421844) Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 152998544 CVCL_C0IH ZZUi036-A induced pluripotent stem cell human CVCL_C0IH From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 53924; NOTCH2NLC; Simple; c.-164GGC[(66_517)]; ClinVar=VCV000691867; Zygosity=Heterozygous; Note=93 GGC repeats (PubMed=35772299) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998545 CVCL_C0IG LZUSHI001-A induced pluripotent stem cell human CVCL_C0IG From: Lanzhou University Second Hospital; Lanzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2853; DGKG; Simple; p.Arg681Gln (c.2042G>A); Zygosity=Heterozygous (PubMed=35421845) Population: Chinese/Asian ethnic group: Hui; Derived from sampling site: Peripheral blood. Male 152998546 CVCL_C0HY LCL1 transformed cell line human CVCL_C0HY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998547 CVCL_C0I9 293EL-APP* transformed cell line human CVCL_C0I9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP; Transfected with: HGNC; 620; APP (with p.Lys670Asn, p.Met671Leu, p.Thr719Asn = APPSw/T700N); Transfected with: HGNC; 3185; EEA1 (with a N-terminal FLAG tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9, TMEM192 was C-terminally tagged on both alleles with a 3xHA epitope 152998548 CVCL_C0HX Wh8 transformed cell line human CVCL_C0HX CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 152998549 CVCL_C0HZ LCL2 transformed cell line human CVCL_C0HZ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998550 CVCL_C0G0 ISMMSi045-A induced pluripotent stem cell human CVCL_C0G0 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35247838) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998551 CVCL_C0FN IDIBGIi010-A induced pluripotent stem cell human CVCL_C0FN From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain.. CL:0000010 152998552 CVCL_C0FQ FHUSTCi001-A induced pluripotent stem cell human CVCL_C0FQ From: The First Affiliated Hospital of USTC, Division of life Science and Medicine, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 3778; FN1; Simple; p.Val1868Met (c.5602G>A); ClinVar=VCV001051358; Zygosity=Heterozygous (PubMed=35395622) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998553 CVCL_C0G2 ISMMSi047-A induced pluripotent stem cell human CVCL_C0G2 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35247838) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998554 CVCL_C0FP FMCPGHi001-A induced pluripotent stem cell human CVCL_C0FP From: The First Medical Center of PLA General Hospital; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998555 CVCL_C0G1 ISMMSi046-A induced pluripotent stem cell human CVCL_C0G1 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35247838) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998556 CVCL_C0G4 ISMMSi049-A induced pluripotent stem cell human CVCL_C0G4 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998557 CVCL_C0FS SCTCi015-A-1 induced pluripotent stem cell human CVCL_C0FS From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 5394; CFI; Simple_corrected; p.Gly119Arg (c.355G>A); ClinVar=VCV000066014; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35526389) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998558 CVCL_C0FR FJMUNi001-A induced pluripotent stem cell human CVCL_C0FR From: Department of Neurology, Fujian Institute of Neurology, First Affiliated Hospital, Fujian Medical University; Fuzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.4518+512T>A; Zygosity=Hemizygous; Note=Induces a cryptic exon activation (PubMed=35247844) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: Indicated in PubMed=35247844 both as being established from a 8 year old and a 10 year old boy 152998559 CVCL_C0G3 ISMMSi048-A induced pluripotent stem cell human CVCL_C0G3 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35247838) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998560 CVCL_C0FU FMUFAHi001-A induced pluripotent stem cell human CVCL_C0FU From: The First Affiliated Hospital, Fujian Medical University; Fuzhou; China CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 2 repeats) (PubMed=35093715) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998561 CVCL_C0G6 ISMMSi051-A induced pluripotent stem cell human CVCL_C0G6 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998562 CVCL_C0G5 ISMMSi050-A induced pluripotent stem cell human CVCL_C0G5 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998563 CVCL_C0FT SCTCi014-A-1 induced pluripotent stem cell human CVCL_C0FT From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 5394; CFI; Simple_corrected; p.Gly119Arg (c.355G>A); ClinVar=VCV000066014; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=35526386) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998564 CVCL_C0FG MUSIi017-A-2 induced pluripotent stem cell human CVCL_C0FG From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand. CL:0000010 152998565 CVCL_C0FF MUSIi017-A-1 induced pluripotent stem cell human CVCL_C0FF From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand. CL:0000010 152998566 CVCL_C0FI MUSIi019-A induced pluripotent stem cell human CVCL_C0FI From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 11027; SLC4A1; Simple; p.Ala400_Ala408del (c.1199_1225del); ClinVar=VCV000017753; Zygosity=Heterozygous (PubMed=36791635); Sequence variation: Mutation; HGNC; 11027; SLC4A1; Simple; p.Thr444Asn (c.1331C>A); ClinVar=VCV001691099; Zygosity=Heterozygous (PubMed=36791635) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 152998567 CVCL_C0FH MUSIi018-A induced pluripotent stem cell human CVCL_C0FH From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Discontinued: hPSCreg; MUSIi018-A; true. 152998568 CVCL_C0FK IDIBGIi007-A induced pluripotent stem cell human CVCL_C0FK From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain.. CL:0000010 152998569 CVCL_C0FJ IDIBGIi006-A induced pluripotent stem cell human CVCL_C0FJ From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain.. CL:0000010 152998570 CVCL_C0FM IDIBGIi009-A induced pluripotent stem cell human CVCL_C0FM From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain.. CL:0000010 152998571 CVCL_C0FL IDIBGIi008-A induced pluripotent stem cell human CVCL_C0FL From: Institut d'Investigacio Biomedica de Girona Dr Josep Trueta; Salt; Spain.. CL:0000010 152998572 CVCL_C0FA EURACi014-A induced pluripotent stem cell human CVCL_C0FA From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=35189566) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998573 CVCL_C0FC EURACi011-A induced pluripotent stem cell human CVCL_C0FC From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998574 CVCL_C0FB EURACi010-A induced pluripotent stem cell human CVCL_C0FB From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex7del; Zygosity=Heterozygous (PubMed=35121197) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998575 CVCL_C0FE EURACi013-A induced pluripotent stem cell human CVCL_C0FE From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 152998576 CVCL_C0FD EURACi012-A induced pluripotent stem cell human CVCL_C0FD From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex7del; Zygosity=Heterozygous (PubMed=35121197) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998577 CVCL_C0F7 SJTUXHi002-A induced pluripotent stem cell human CVCL_C0F7 From: Shanghai Xinhua Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 4572; GRIA2; Simple; c.1998delT; Zygosity=Heterozygous (PubMed=35134694) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998578 CVCL_C0EV UPITTi003-A induced pluripotent stem cell human CVCL_C0EV From: University of Pittsburgh; Pittsburgh; USA. CL:0000010 152998579 CVCL_C0EU UPITTi002-A-1 induced pluripotent stem cell human CVCL_C0EU From: University of Pittsburgh; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple_edited; p.Arg9Cys (c.25C>T); ClinVar=VCV000013636; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34583280) Derived from sampling site: Peripheral blood. Male 152998580 CVCL_C0F6 ZSPHARi001-A induced pluripotent stem cell human CVCL_C0F6 From: Zhongshan Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; c.2992+2T>G; ClinVar=VCV001048002; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=35121199); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly2680Ser (c.8038G>A); ClinVar=VCV001075764; Zygosity=Heterozygous (PubMed=35121199) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998581 CVCL_C0F9 FDCHi008-A induced pluripotent stem cell human CVCL_C0F9 From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Derived from sampling site: Peripheral blood. Male 152998582 CVCL_C0EX SCVIi028-A-1 induced pluripotent stem cell human CVCL_C0EX From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (with p.His840Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P42212; GFP (with p.Tyr66His and p.Tyr145Phe = BFP) Derived from sampling site: Peripheral blood. Male Characteristics: Dox-inducible expression of the prime editor protein (PE2) which is a fusion between the S.pyogenes Cas9(H840A) and an engineered Moloney murine leukemia virus (MMLV) reverse transcriptase domain PE2 enables gene editing at potentially any locus in the genome by transfecting a pegRNA specific for the desired target locus (PubMed=34875545).; Characteristics: Using CRISPR/Cas9 a T2A-Neo-CAG-rRTA-BFP-P2A-PE2-TRE3G construct has been inserted at the safe harbor locus (AAVS1) (PubMed=34875545) 152998583 CVCL_C0EW SCVIi028-A induced pluripotent stem cell human CVCL_C0EW From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 152998584 CVCL_C0F8 SJTUXHi001-A induced pluripotent stem cell human CVCL_C0F8 From: Shanghai Xinhua Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 13315; HDAC8; Simple; p.Pro359Ser (c.1075C>T); Zygosity=Heterozygous (PubMed=35358829) Population: Chinese; Derived from sampling site: Peripheral blood. Female 152998585 CVCL_C0EZ KUMi004-A induced pluripotent stem cell human CVCL_C0EZ From: Korea University Medical School Hospital; Seoul; South Korea CL:0000010 Population: Korean; Karyotypic information: 46,XX,t(13;14)(q32;q11.2->q24.3) (PubMed=35066240); Derived from sampling site: Bone marrow. Female 152998586 CVCL_C0EY YUSEVi005-A-1 induced pluripotent stem cell human CVCL_C0EY From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple_corrected; p.Gly512Ser (c.1534G>A); ClinVar=VCV000585301; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=35042083) Population: Korean; Derived from sampling site: Cell type=Fibroblast. Male 152998587 CVCL_C0H1 SUSMi005-A-5.2 induced pluripotent stem cell human CVCL_C0H1 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (4 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998588 CVCL_C0GP UMGi158-A-1.2 induced pluripotent stem cell human CVCL_C0GP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10582; SCN10A Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998589 CVCL_C0H0 SUSMi005-A-5.1 induced pluripotent stem cell human CVCL_C0H0 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (4 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998590 CVCL_C0GR ESIBIe003-A-12 embryonic stem cell human CVCL_C0GR From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT. Female 152998591 CVCL_C0H3 UKWNLi006-A induced pluripotent stem cell human CVCL_C0H3 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Asp170Asn (c.508G>A); Zygosity=Hemizygous (PubMed=36640471) Population: Caucasian; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 152998592 CVCL_C0GQ ESIBIe003-A-11 embryonic stem cell human CVCL_C0GQ From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 6342; KIT. Female 152998593 CVCL_C0H2 ICGi041-A induced pluripotent stem cell human CVCL_C0H2 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia. CL:0000010 152998594 CVCL_C0H5 FUHSi001-A induced pluripotent stem cell human CVCL_C0H5 From: Huashan Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Pro620Ser (c.1858C>T); ClinVar=VCV000924443; Zygosity=Heterozygous (PubMed=35339882) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998595 CVCL_C0GT SUSMi005-A-1.2 induced pluripotent stem cell human CVCL_C0GT From: Stanford University School of Medicine; Stanford; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998596 CVCL_C0GS SUSMi005-A-1.1 induced pluripotent stem cell human CVCL_C0GS From: Stanford University School of Medicine; Stanford; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998597 CVCL_C0H4 UKWNLi007-A induced pluripotent stem cell human CVCL_C0H4 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Cys172Tyr (c.515G>A); ClinVar=VCV001323002; Zygosity=Hemizygous (PubMed=36640471) Population: Caucasian; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 152998598 CVCL_C0H7 LZUi002-A induced pluripotent stem cell human CVCL_C0H7 From: Lanzhou University Second Hospital; Lanzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11585; TBL1X; Simple; c.342_343insGCGGCG; Zygosity=Hemizygous (PubMed=35339883) Population: Chinese/Asian ethnic group: Uyghur; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998599 CVCL_C0GV SUSMi005-A-2.2 induced pluripotent stem cell human CVCL_C0GV From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998600 CVCL_C0H6 LZUi001-A induced pluripotent stem cell human CVCL_C0H6 From: Lanzhou University Second Hospital; Lanzhou; China. CL:0000010 152998601 CVCL_C0GU SUSMi005-A-2.1 induced pluripotent stem cell human CVCL_C0GU From: Stanford University School of Medicine; Stanford; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 4 alleles); HGNC; 11138; SNCA; Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998602 CVCL_C0GH JUCGRMi002-B induced pluripotent stem cell human CVCL_C0GH From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan. CL:0000010 152998603 CVCL_C0GG JUCGRMi002-A induced pluripotent stem cell human CVCL_C0GG From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan. CL:0000010 152998604 CVCL_C0GJ MWRIi001-A-3 induced pluripotent stem cell house mouse CVCL_C0GJ From: Magee-Womens Research Institute, University of Pittsburgh School of Medicine; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; MGI; MGI:1933237; Tex11; Simple; p.Asp421fs (c.1260insTT); Zygosity=Hemizygous; Note=By CRISPR/Cas9 In a mouse model of human TEX11_1258Ins(TT) (PubMed=35240466). Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: C57BL/6 Tex11PM/Y. Male 152998605 CVCL_C0GI JUCGRMi002-C induced pluripotent stem cell human CVCL_C0GI From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan. CL:0000010 152998606 CVCL_C0GL WAe009-A-83 embryonic stem cell human CVCL_C0GL From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple_edited; p.Gln290Ter (c.868C>T); ClinVar=VCV000037070; Zygosity=Heterozygous (PubMed=35247836). Female 152998607 CVCL_C0GK CuFi-8 transformed cell line human CVCL_C0GK CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=32337159); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Female Virology: Supports productive infection by human bocavirus 1 (HBoV1) (PubMed=22956907) 152998608 CVCL_C0GN UMGi158-A-1.1 induced pluripotent stem cell human CVCL_C0GN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10582; SCN10A Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998609 CVCL_C0GM UMGi158-A induced pluripotent stem cell human CVCL_C0GM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 152998610 CVCL_C0GB UQACi005-A induced pluripotent stem cell human CVCL_C0GB From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6416; KRT14; Simple; p.Ile412Phe (c.1234A>T); ClinVar=VCV000066317; Zygosity=Heterozygous (PubMed=35334406) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998611 CVCL_C0GA UQACi002-A induced pluripotent stem cell human CVCL_C0GA From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6416; KRT14; Simple; p.Ile377Thr (c.1130T>C); ClinVar=VCV000066303; Zygosity=Heterozygous (PubMed=35334406) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998612 CVCL_C0GD JUCGRMi001-A induced pluripotent stem cell human CVCL_C0GD From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 13487; VPS35; Simple; p.Asp620Asn (c.1858G>A); ClinVar=VCV000030196; Zygosity=Heterozygous (PubMed=35247840) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998613 CVCL_C0GC UQACi007-A induced pluripotent stem cell human CVCL_C0GC From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6416; KRT14; Simple; p.Ile377Thr (c.1130T>C); ClinVar=VCV000066303; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998614 CVCL_C0GF JUCGRMi001-C induced pluripotent stem cell human CVCL_C0GF From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 13487; VPS35; Simple; p.Asp620Asn (c.1858G>A); ClinVar=VCV000030196; Zygosity=Heterozygous (PubMed=35247840) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998615 CVCL_C0GE JUCGRMi001-B induced pluripotent stem cell human CVCL_C0GE From: Center for Genomic and Regenerative Medicine, Juntendo University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 13487; VPS35; Simple; p.Asp620Asn (c.1858G>A); ClinVar=VCV000030196; Zygosity=Heterozygous (PubMed=35247840) Population: Japanese; Derived from sampling site: Peripheral blood. Male 152998616 CVCL_C0FW CHUSJi001-A induced pluripotent stem cell human CVCL_C0FW From: CHU-Sainte Justine; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Val432Glufs*41 (c.1295_1296del); Zygosity=Heterozygous (PubMed=35193008) Derived from sampling site: Peripheral blood. Male 152998617 CVCL_C0G8 UQACi004-A induced pluripotent stem cell human CVCL_C0G8 From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Met327Thr (c.980T>C); ClinVar=VCV000014641; Zygosity=Heterozygous (PubMed=35247839) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998618 CVCL_C0FV FMUFAHi002-A induced pluripotent stem cell human CVCL_C0FV From: The First Affiliated Hospital, Fujian Medical University; Fuzhou; China CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 4 repeats) (PubMed=35093715) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998619 CVCL_C0G7 UQACi003-A induced pluripotent stem cell human CVCL_C0G7 From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Leu150Pro (c.449T>C); ClinVar=VCV000066241; Zygosity=Heterozygous (PubMed=35247839) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 152998620 CVCL_C0FY CHUSJi003-A induced pluripotent stem cell human CVCL_C0FY CL:0000010 Sequence variation: Mutation; HGNC; 24238; CEP350; Simple; p.Ser1571Phefs*3 (c.4711_4712del); Zygosity=Heterozygous (PubMed=35193008) Derived from sampling site: Peripheral blood. Male 152998621 CVCL_C0FX CHUSJi002-A induced pluripotent stem cell human CVCL_C0FX CL:0000010 Derived from sampling site: Peripheral blood. Male 152998622 CVCL_C0G9 UQACi006-A induced pluripotent stem cell human CVCL_C0G9 From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Leu203Pro (c.608T>C); Zygosity=Heterozygous (PubMed=35247839) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 152998623 CVCL_C0FZ ISMMSi044-A induced pluripotent stem cell human CVCL_C0FZ From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (PubMed=35247838) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998624 CVCL_C0UB HT22 TR/TO-mKlf13 transformed cell line house mouse CVCL_C0UB CL:0000010 Transfected with: MGI; MGI:1354948; Klf13; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Doxycycline induced expression of Klf13 Transfected with both pCDNA4:TO-Klf9 containing CMV-tetO2-Klf9 and the zeocin resistance gene (ble) and pCDNA6:TR containing tetR and the blasticidin resistance gene Bsr. 152998625 CVCL_C0UA HT22 TR/TO-rKlf9 clone 2.1 transformed cell line house mouse CVCL_C0UA CL:0000010 Transfected with: RGD; 70934; Klf9; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Doxycycline induced expression of Klf9 Transfected with both pCDNA4:TO-Klf9 containing CMV-tetO2-Klf9 and the zeocin resistance gene (ble) and pCDNA6:TR containing tetR and the blasticidin resistance gene Bsr. 152998626 CVCL_C0UD B-LCL-HROC18 transformed cell line human CVCL_C0UD From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998627 CVCL_C0UC KE37/1-IIIB cancer cell line human CVCL_C0UC CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Male Virology: Latently infected with HIV-1 isolate LAI 152998628 CVCL_C0U6 4T1/EPB cancer cell line house mouse CVCL_C0U6 CL:0000010 Selected for resistance to: ChEBI; CHEBI:47898; 4'-epidoxorubicin (Epirubicin); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 152998629 CVCL_C0TU ACTOne TSHR transformed cell line human CVCL_C0TU CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 12373; TSHR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998630 CVCL_C0U5 ACTOne cAMP-PDE4D spontaneously immortalized cell line CVCL_C0U5 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8783; PDE4D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998631 CVCL_C0TT ACTOne TGR5 transformed cell line human CVCL_C0TT CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 19680; GPBAR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998632 CVCL_C0TW ACTOne VIPR2 transformed cell line human CVCL_C0TW CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 12695; VIPR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998633 CVCL_C0U8 HT22-BLRP-hTRb/pSV40-BirAV5 transformed cell line house mouse CVCL_C0U8 CL:0000010 Transfected with: HGNC; 11799; THRB (with a N-terminal BLRP); Transfected with: UniProtKB; P06709; Escherichia coli birA (V5-tagged); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Expresses human THRB fused to a biotin ligase recognition peptide (BLRP); Characteristics: Expresses C-terminal V5-tagged birA under the control of the human EF-1 alpha promoter 152998634 CVCL_C0TV ACTOne VIPR1 transformed cell line human CVCL_C0TV CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 12694; VIPR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998635 CVCL_C0U7 HT22-pSV40-BirAV5 transformed cell line house mouse CVCL_C0U7 CL:0000010 Transfected with: UniProtKB; P06709; Escherichia coli birA (V5-tagged); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Expresses C-terminal V5-tagged birA under the control of the human EF-1 alpha promoter 152998636 CVCL_C0TY SiHa-APOA1 cancer cell line human CVCL_C0TY CL:0000010 Transfected with: HGNC; 600; APOA1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line) 152998637 CVCL_C0U9 HT22-FLBIO-rKLF9/SV40-BirAV5 transformed cell line house mouse CVCL_C0U9 CL:0000010 Transfected with: RGD; 70934; Klf9 (with a N-terminal FLBIO tag); Transfected with: UniProtKB; P06709; Escherichia coli birA (V5-tagged); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: Expresses C-terminal V5-tagged birA under the control of the human EF-1 alpha promoter 152998638 CVCL_C0TX JPR3 cancer cell line CVCL_C0TX CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Characteristics: Using homologous recombination a 3xFLAG-2xHis6 construct was inserted at the C-terminus of one allele of PIP4K2B (PubMed=17303380) Group: Bird cell line 152998639 CVCL_C0TZ HEK293 MUT-KO clone 2 transformed cell line human CVCL_C0TZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7526; MMUT; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Deep quantitative proteome analysis Female 152998640 CVCL_C0TM ACTOne PTGER4 transformed cell line human CVCL_C0TM CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9596; PTGER4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998641 CVCL_C0TL ACTOne PTGER2 transformed cell line human CVCL_C0TL CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9594; PTGER2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998642 CVCL_C0U0 SH-SY5Y-FLAG-NGB cancer cell line human CVCL_C0U0 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 14077; NGB (with a C-terminal 3xFLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Deep quantitative proteome analysis Female 152998643 CVCL_C0TN ACTOne PTGIR transformed cell line human CVCL_C0TN CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9602; PTGIR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998644 CVCL_C0U2 ACTOne cAMP-PDE4A spontaneously immortalized cell line CVCL_C0U2 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8780; PDE4A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998645 CVCL_C0TQ ACTOne PTHR2 transformed cell line human CVCL_C0TQ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9609; PTH2R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998646 CVCL_C0TP ACTOne PTHR1 transformed cell line human CVCL_C0TP CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9608; PTH1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998647 CVCL_C0U1 HEK293T ALKBH5/FTO DKO transformed cell line human CVCL_C0U1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25996; ALKBH5; Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by RNAseq Female 152998648 CVCL_C0U4 ACTOne cAMP-PDE4C spontaneously immortalized cell line CVCL_C0U4 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8782; PDE4C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Discontinued: Codex Biosolutions; Catalog number CL-02-PDE4C Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998649 CVCL_C0TS ACTOne SSTR5 transformed cell line human CVCL_C0TS CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 11334; SSTR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998650 CVCL_C0U3 ACTOne cAMP-PDE4B spontaneously immortalized cell line CVCL_C0U3 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8781; PDE4B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998651 CVCL_C0TR ACTOne SCTR transformed cell line human CVCL_C0TR CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 10608; SCTR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998652 CVCL_C0TE ACTOne OPRM1 transformed cell line human CVCL_C0TE CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8156; OPRM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998653 CVCL_C0TD ACTOne OPRL1 transformed cell line human CVCL_C0TD CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8155; OPRL1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998654 CVCL_C0TG ACTOne PDE1B transformed cell line human CVCL_C0TG CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8775; PDE1B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998655 CVCL_C0TF ACTOne PDE10A transformed cell line human CVCL_C0TF CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8772; PDE10A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998656 CVCL_C0TI ACTOne PDE2A transformed cell line human CVCL_C0TI CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8777; PDE2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998657 CVCL_C0TH ACTOne PDE1C transformed cell line human CVCL_C0TH CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8776; PDE1C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR 152998658 CVCL_C0TK ACTOne PTGDR2 transformed cell line human CVCL_C0TK CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4502; PTGDR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998659 CVCL_C0TJ ACTOne PPYR1 transformed cell line human CVCL_C0TJ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 9329; NPY4R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998660 CVCL_C0VA Pv11-Hsf1-/- spontaneously immortalized cell line CVCL_C0VA CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; E1AC50; Hsf1; Transfected with: UniProtKB; Q6YGZ0; Aequorea coerulescens GFP (AcGFP1); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Unspecified Characteristics: Using CRISPR/Cas9, Hsf1 was disrupted by insertion of a AcGFP1-P2A-ZeoR construct (PubMed=34071490) Group: Insect cell line 152998661 CVCL_C0VC B-LCL-CDG3 transformed cell line human CVCL_C0VC CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Asp188Gly (c.563A>G); ClinVar=VCV000007712; Zygosity=Heterozygous (PubMed=34420056) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998662 CVCL_C0VB Capan-26 cancer cell line human CVCL_C0VB CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Glu37_Asn86del; Zygosity=Heterozygous (PubMed=33788731); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val172Phe (c.514G>T); ClinVar=VCV000428909; Zygosity=Unspecified (PubMed=33788731) Population: Caucasian; Lithuanian; Derived from sampling site: Pancreas. Female Doubling time: 74 hours (PubMed=33788731) 152998663 CVCL_C0VE B-LCL-CDG6 transformed cell line human CVCL_C0VE CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998664 CVCL_C0VD B-LCL-CDG5 transformed cell line human CVCL_C0VD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998665 CVCL_C0V7 HepG2 PXR-CYP3A4 clone 1 cancer cell line human CVCL_C0V7 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2637; CYP3A4; Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hPXR and pGLuc-CYP3A4 152998666 CVCL_C0UV KUCaP13 cancer cell line human CVCL_C0UV CL:0000010 Sequence variation: Gene deletion; HGNC; 1915; CHD1; Zygosity=Homozygous (PubMed=33960594); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His61Arg (c.182A>G); ClinVar=VCV000189402; Zygosity=Unspecified (PubMed=33960594); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (PubMed=33960594) Population: Japanese; Derived from metastatic site: Penis. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established via a mouse xenograft 152998667 CVCL_C0UU HCT116tax cancer cell line human CVCL_C0UU CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Colon. Male 152998668 CVCL_C0V6 HepG2 CAR-CYP2B6 clone 10 cancer cell line human CVCL_C0V6 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2615; CYP2B6; Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hCAR and pGLuc-CYP2B6 152998669 CVCL_C0UX GBM8401/Luc2 cancer cell line human CVCL_C0UX CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Chinese; Derived from sampling site: Brain; right parietal lobe. Female 152998670 CVCL_C0V9 HepG2 PXR-CYP3A4 clone 8 cancer cell line human CVCL_C0V9 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2637; CYP3A4; Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hPXR and pGLuc-CYP3A4 152998671 CVCL_C0UW GBM8401/TMZR cancer cell line human CVCL_C0UW CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:72564; Temozolomide (TMZ); Derived from sampling site: Brain; right parietal lobe. Omics: Transcriptome analysis by RNAseq Female 152998672 CVCL_C0V8 HepG2 PXR-CYP3A4 clone 3 cancer cell line human CVCL_C0V8 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2637; CYP3A4; Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hPXR and pGLuc-CYP3A4 152998673 CVCL_C0UZ NOKT-1-XG cancer cell line human CVCL_C0UZ CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Characteristics: The parent cell line was transplanted subcutaneously into nude mice and a xenograft was formed from which this cell line was established 152998674 CVCL_C0UY NOKT-1 cancer cell line human CVCL_C0UY CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 27 hours (at 15th passage), 23 hours (at 30th passage) (DOI=10.2485/jhtb.30.97) 152998675 CVCL_C0UN HEK293 HLA-A*33:03 transformed cell line human CVCL_C0UN CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*33:03); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998676 CVCL_C0UM HEK293 HLA-A*31:01 transformed cell line human CVCL_C0UM CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*31:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998677 CVCL_C0V1 HepG2 AhR-CYP1A1 clone 4 cancer cell line human CVCL_C0V1 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 348; AHR; Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hAhR and pGLuc-CYP1A1 152998678 CVCL_C0UP HP-CD36 cancer cell line human CVCL_C0UP CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1663; CD36; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Biotechnology: Used in assay systems for the detection of CD36 antibodies (PubMed=19389219; PubMed=24387678) Female 152998679 CVCL_C0V0 DHSF-BR16 cancer cell line human CVCL_C0V0 CL:0000010 Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female Characteristics: ER-negative, PR-negative and ERBB2-positive (PubMed=33863935) Doubling time: 28 hours (PubMed=33863935) 152998680 CVCL_C0UR HEK293T HNA-3aa transformed cell line human CVCL_C0UR CL:0000010 Transfected with: HGNC; 17292; SLC44A2 (with p.Gln154Arg = HNA3a, with a C-terminal V5 tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Biotechnology: Used in an assay for the detection of alloantibodies against the human neutrophil alloantigen-3a Female 152998681 CVCL_C0V3 HepG2 AhR-CYP1A1 clone 10 cancer cell line human CVCL_C0V3 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 348; AHR; Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hAhR and pGLuc-CYP1A1 152998682 CVCL_C0V2 HepG2 AhR-CYP1A1 clone 9 cancer cell line human CVCL_C0V2 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 348; AHR; Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hAhR and pGLuc-CYP1A1 152998683 CVCL_C0UQ HP-mock cancer cell line human CVCL_C0UQ CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Control cell line for HP-CD36 (Cellosaurus=CVCL_C0UP) 152998684 CVCL_C0UT HCT116nut cancer cell line human CVCL_C0UT CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from sampling site: Colon. Male 152998685 CVCL_C0V5 HepG2 CAR-CYP2B6 clone 7 cancer cell line human CVCL_C0V5 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2615; CYP2B6; Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hCAR and pGLuc-CYP2B6 152998686 CVCL_C0US HEK293T HNA-3bb transformed cell line human CVCL_C0US CL:0000010 Transfected with: HGNC; 17292; SLC44A2 (with p.Gln154Gln = HNA3b, with a C-terminal V5 tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Biotechnology: Used in an assay for the detection of alloantibodies against the human neutrophil alloantigen-3a Female 152998687 CVCL_C0V4 HepG2 CAR-CYP2B6 clone 6 cancer cell line human CVCL_C0V4 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2615; CYP2B6; Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; Q9BLZ2; Gaussia princeps luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with both pcDNA3.1-hCAR and pGLuc-CYP2B6 152998688 CVCL_C0UF BP50 cancer cell line human CVCL_C0UF CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.264+2T>C; Zygosity=Unspecified; Note=Splice donor mutation, germline mutation (PubMed=34043754) Derived from sampling site: Eye; ocular adnexa. Omics: Deep exome analysis Female Doubling time: 52.3 hours (PubMed=34043754) 152998689 CVCL_C0UE hTERT-hNOF telomerase immortalized cell line human CVCL_C0UE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 152998690 CVCL_C0UH HEK293 HLA-A*02:01 transformed cell line human CVCL_C0UH CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*02:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998691 CVCL_C0UG HEK293 HLA-A*01:01 transformed cell line human CVCL_C0UG CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*01:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998692 CVCL_C0UJ HEK293 HLA-A*11:01 transformed cell line human CVCL_C0UJ CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*11:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998693 CVCL_C0UI HEK293 HLA-A*03:01 transformed cell line human CVCL_C0UI CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*03:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998694 CVCL_C0UL HEK293 HLA-A*26:02 transformed cell line human CVCL_C0UL CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*26:02); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998695 CVCL_C0UK HEK293 HLA-A*24:02 transformed cell line human CVCL_C0UK CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*24:02); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used in a modified immunocomplex capture fluorescence analysis (m-ICFA) assay to detect HLA antibodies Female 152998696 CVCL_C0RZ ACTOne ADCYAP1R1 transformed cell line human CVCL_C0RZ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998697 CVCL_C0SB ACTOne CB1 transformed cell line human CVCL_C0SB CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 2159; CNR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998698 CVCL_C0SA ACTOne CALCRL transformed cell line human CVCL_C0SA CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 16709; CALCRL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998699 CVCL_C0S4 ACTOne ADRB1 transformed cell line human CVCL_C0S4 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 285; ADRB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998700 CVCL_C0RS LNCaP-PDR2 cancer cell line human CVCL_C0RS CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:85993; Palbociclib (Ibrance); Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep quantitative phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Male 152998701 CVCL_C0S3 ACTOne ADORA3 transformed cell line human CVCL_C0S3 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 268; ADORA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998702 CVCL_C0RR LNCaP-PDR1 cancer cell line human CVCL_C0RR CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:85993; Palbociclib (Ibrance); Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep quantitative phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Male 152998703 CVCL_C0S6 ACTOne AGTRL1 transformed cell line human CVCL_C0S6 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 339; APLNR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998704 CVCL_C0RU HEK293-CNG transformed cell line human CVCL_C0RU CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Has Codex Biosolutions catalog number CB-81200-200/AG-10200-200, but not distributed separately from children cell lines Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Parent cell line for many ACTOne cell lines 152998705 CVCL_C0S5 ACTOne ADRB2 transformed cell line human CVCL_C0S5 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 286; ADRB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998706 CVCL_C0RT HEK293-hERG transformed cell line human CVCL_C0RT CL:0000010 Transfected with: HGNC; 6251; KCNH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152998707 CVCL_C0S8 ACTOne AVPR2 transformed cell line human CVCL_C0S8 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 897; AVPR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998708 CVCL_C0RW HEK293-CNG-Gs transformed cell line human CVCL_C0RW CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Has Codex Biosolutions catalog number CB-81200-100, but not distributed separately from children cell lines Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR Serves as a parent cell line for various ACTOne PDE cell lines. 152998709 CVCL_C0S7 ACTOne AMY3 transformed cell line human CVCL_C0S7 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9845; RAMP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998710 CVCL_C0RV CHO-K1-CNG-Gs spontaneously immortalized cell line CVCL_C0RV CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Has Codex Biosolutions catalog number CB-81300-100, but not distributed separately from children cell lines Derived from sampling site: Ovary. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Expresses a constitutively active over-expressed Gs-coupled GPCR Serves as a parent cell line for various ACTOne PDE cell lines. 152998711 CVCL_C0RY HEK293-ACE2-GFP transformed cell line human CVCL_C0RY CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a ACE2-GFP construct Group: SARS-CoV-2 research cell line 152998712 CVCL_C0S9 ACTOne CALCR transformed cell line human CVCL_C0S9 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 1440; CALCR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998713 CVCL_C0RX HEK293-CNG-Slc1a3 transformed cell line human CVCL_C0RX CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 10941; SLC1A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Has Codex Biosolutions catalog number CB-81200-238, but not distributed separately from children cell lines Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions).; Characteristics: Parental and control cell line for ACTOne GRM2, ACTOne GRM7 and ACTOne GRM8 152998714 CVCL_C0RK CAL-27 2B1 cancer cell line human CVCL_C0RK CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6156; ITGB3 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 152998715 CVCL_C0RJ KPB6 cancer cell line house mouse CVCL_C0RJ From: Quezada S.A., University College London; London; United Kingdom CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Heterozygous Derived from sampling site: Lung; Breed/subspecies: C57BL/6 KrasLSL-G12D/+; Trp53flox/flox (KP). 152998716 CVCL_C0RM Hu1703He/lacZ cancer cell line human CVCL_C0RM CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Karyotypic information: Near tetraploid karyotype (PubMed=16158950); Derived from sampling site: Urinary bladder; urothelium. Male Doubling time: 25 hours (PubMed=11848473) 152998717 CVCL_C0RL CAL-27 2B3 cancer cell line human CVCL_C0RL CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6156; ITGB3 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 152998718 CVCL_C0S0 ACTOne ADORA1 transformed cell line human CVCL_C0S0 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 262; ADORA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998719 CVCL_C0RN A375M1 cancer cell line human CVCL_C0RN CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Metastatic Established from pulmonary metastases obtained afer intravenous injection of the parent cell line into the tail veins of nude mice. 152998720 CVCL_C0S2 ACTOne ADORA2B transformed cell line human CVCL_C0S2 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 264; ADORA2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998721 CVCL_C0RQ LAPC4-PDR1 cancer cell line human CVCL_C0RQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:85993; Palbociclib (Ibrance); Derived from metastatic site: Lymph node. Omics: Deep quantitative phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 152998722 CVCL_C0RP A375M2 cancer cell line human CVCL_C0RP CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Metastatic Established from pulmonary metastases obtained afer intravenous injection of the parent cell line into the tail veins of nude mice. 152998723 CVCL_C0S1 ACTOne ADORA2A transformed cell line human CVCL_C0S1 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 263; ADORA2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998724 CVCL_C0RC Aag2 eGFP-Piwi4 spontaneously immortalized cell line CVCL_C0RC CL:0000010 Transfected with: UniProtKB; Q171B3; Aedes aegypti Piwi4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo. Unspecified Characteristics: Transfected with a PUb-GFP-V5-3F-Piwi4-2A-Puro construct Group: Insect cell line 152998725 CVCL_C0RB Aag2 eGFP-Ago3 spontaneously immortalized cell line CVCL_C0RB CL:0000010 Transfected with: UniProtKB; Q170R5; Aedes aegypti Ago3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo. Unspecified Characteristics: Transfected with a PUb-GFP-V5-3F-Ago3-2A-Puro construct Group: Insect cell line 152998726 CVCL_C0RE Aag2 eGFP-Piwi6 spontaneously immortalized cell line CVCL_C0RE CL:0000010 Transfected with: UniProtKB; Q16JS1; Aedes aegypti Piwi6; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo. Unspecified Characteristics: Transfected with a PUb-GFP-V5-3F-Piwi6-2A-Puro construct Group: Insect cell line 152998727 CVCL_C0RD Aag2 eGFP-Piwi5 spontaneously immortalized cell line CVCL_C0RD CL:0000010 Transfected with: UniProtKB; Q16JS2; Aedes aegypti Piwi5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo. Unspecified Characteristics: Transfected with a PUb-GFP-V5-3F-Piwi5-2A-Puro construct Group: Insect cell line 152998728 CVCL_C0RG HT1080 EWSR1-FLI1-EGFP cancer cell line human CVCL_C0RG CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3508; EWSR1 (EWSR1-FLI1 fusion); Transfected with: HGNC; 3749; FLI1 (EWSR1-FLI1 fusion); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Omics: Transcriptome analysis by RNAseq Male 152998729 CVCL_C0RF HT1080 EGFP cancer cell line human CVCL_C0RF CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Omics: Transcriptome analysis by RNAseq Male 152998730 CVCL_C0RI HeLa HNRNPD-/- cl4 cancer cell line human CVCL_C0RI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5036; HNRNPD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152998731 CVCL_C0RH HeLa HNRNPD-/- cl10 cancer cell line human CVCL_C0RH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5036; HNRNPD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 152998732 CVCL_C0TA ACTOne NPY5R transformed cell line human CVCL_C0TA CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 7958; NPY5R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998733 CVCL_C0TC ACTOne OPRD1 transformed cell line human CVCL_C0TC CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8153; OPRD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998734 CVCL_C0TB ACTOne OPRK1 transformed cell line human CVCL_C0TB CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 8154; OPRK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998735 CVCL_C0ST ACTOne GRM2 transformed cell line human CVCL_C0ST CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4594; GRM2; Transfected with: HGNC; 10941; SLC1A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998736 CVCL_C0T5 ACTOne MC4R transformed cell line human CVCL_C0T5 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 6932; MC4R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998737 CVCL_C0SS ACTOne GPR119 transformed cell line human CVCL_C0SS CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 19060; GPR119; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998738 CVCL_C0T4 ACTOne MC3R transformed cell line human CVCL_C0T4 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 6931; MC3R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998739 CVCL_C0SV ACTOne GRM7 transformed cell line human CVCL_C0SV CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4599; GRM7; Transfected with: HGNC; 10941; SLC1A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998740 CVCL_C0T7 ACTOne MCHR1 transformed cell line human CVCL_C0T7 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4479; MCHR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998741 CVCL_C0SU ACTOne GRM4 transformed cell line human CVCL_C0SU CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4596; GRM4; Transfected with: HGNC; 10941; SLC1A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998742 CVCL_C0T6 ACTOne MC5R transformed cell line human CVCL_C0T6 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 6933; MC5R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998743 CVCL_C0SX ACTOne HTR1A transformed cell line human CVCL_C0SX CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 5286; HTR1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998744 CVCL_C0T9 ACTOne NPY2R transformed cell line human CVCL_C0T9 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 7957; NPY2R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998745 CVCL_C0SW ACTOne GRM8 transformed cell line human CVCL_C0SW CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4600; GRM8; Transfected with: HGNC; 10941; SLC1A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998746 CVCL_C0T8 ACTOne NPY1R transformed cell line human CVCL_C0T8 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 7956; NPY1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998747 CVCL_C0SZ ACTOne HTR4 transformed cell line human CVCL_C0SZ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 5299; HTR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998748 CVCL_C0SY ACTOne HTR1F transformed cell line human CVCL_C0SY CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 5292; HTR1F; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998749 CVCL_C0SL ACTOne EDG1 transformed cell line human CVCL_C0SL CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 3165; S1PR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998750 CVCL_C0SK ACTOne DRD5 transformed cell line human CVCL_C0SK CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 3026; DRD5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998751 CVCL_C0SN ACTOne GCGR transformed cell line human CVCL_C0SN CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4192; GCGR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998752 CVCL_C0SM ACTOne FSHR transformed cell line human CVCL_C0SM CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 3969; FSHR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998753 CVCL_C0SP ACTOne GIPR transformed cell line human CVCL_C0SP CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4271; GIPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998754 CVCL_C0T1 ACTOne HTR7B transformed cell line human CVCL_C0T1 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 5302; HTR7 (isoform B); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998755 CVCL_C0T0 ACTOne HTR6 transformed cell line human CVCL_C0T0 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 5301; HTR6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998756 CVCL_C0SR ACTOne GLP2R transformed cell line human CVCL_C0SR CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4325; GLP2R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998757 CVCL_C0T3 ACTOne MC1R transformed cell line human CVCL_C0T3 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 6929; MC1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998758 CVCL_C0SQ ACTOne GLP1R transformed cell line human CVCL_C0SQ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 4324; GLP1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998759 CVCL_C0T2 ACTOne LHCGR transformed cell line human CVCL_C0T2 CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 6585; LHCGR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998760 CVCL_C0SD ACTOne CB2 transformed cell line human CVCL_C0SD CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 2160; CNR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998761 CVCL_C0SF ACTOne CRHR1 transformed cell line human CVCL_C0SF CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 2357; CRHR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998762 CVCL_C0SE ACTOne CCR5 transformed cell line human CVCL_C0SE CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998763 CVCL_C0SH ACTOne CXCR4 transformed cell line human CVCL_C0SH CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998764 CVCL_C0SG ACTOne CRHR2 transformed cell line human CVCL_C0SG CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 2358; CRHR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998765 CVCL_C0SJ ACTOne DRD2 transformed cell line human CVCL_C0SJ CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 3023; DRD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998766 CVCL_C0SI ACTOne DRD1 transformed cell line human CVCL_C0SI CL:0000010 Transfected with: RGD; 2367; Cnga2 (with p.Phe68Ala, p.Trp81Ala, p.Cys460Trp and p.Glu583Met = oCNG-NC); Transfected with: HGNC; 3020; DRD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a modified cyclic nucleotide gated (CNG) channel that opens in response to elevated intracellular cAMP levels and consequently result in ion flux and cell membrane depolarization Allows sensitive detection of signaling by Gs, Gi or Gq-coupled receptors (Codex BioSolutions). 152998767 CVCL_C0PY PC12 6c cancer cell line Norway rat CVCL_C0PY CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998768 CVCL_C0PX PC12-FR cancer cell line Norway rat CVCL_C0PX CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Established after 3 passages by subcutaneous injection of the parent cell line into Deaconess rats 152998769 CVCL_C0Q9 SK-N-AS RET overexpressing clone C1 cancer cell line human CVCL_C0Q9 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female Characteristics: Was engineered using CRISPR/Cas9 to be a RET KO cell line, but unexpectedly expresses a high level of RET due to a mutation in intron 1 of the RET gene (PubMed=33921066) 152998770 CVCL_C0PZ PC12 cA4 cancer cell line Norway rat CVCL_C0PZ CL:0000010 Transfected with: UniProtKB; P04625; Chicken THRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998771 CVCL_C0PQ PC12-1 cancer cell line Norway rat CVCL_C0PQ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998772 CVCL_C0Q2 XB691 spontaneously immortalized cell line CVCL_C0Q2 CL:0000010 Unspecified Group: Amphibian cell line. 152998773 CVCL_C0Q1 GL-40 cancer cell line dog CVCL_C0Q1 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: German Shepherd. Male 152998774 CVCL_C0PP PC12.4 cancer cell line Norway rat CVCL_C0PP CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Has high ethanol sensitivity Highly adhesive. Doubling time: 24 hours (PubMed=9886495) 152998775 CVCL_C0PS PC12-16A cancer cell line Norway rat CVCL_C0PS CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998776 CVCL_C0Q4 XB693T transformed cell line CVCL_C0Q4 CL:0000010 Karyotypic information: Hypotetraploid with a modal chromosome number of 62 (PubMed=6861277); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759). Unspecified Characteristics: Tumorigenic Group: Amphibian cell line 152998777 CVCL_C0PR PC12-15 cancer cell line Norway rat CVCL_C0PR CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998778 CVCL_C0Q3 XB693 spontaneously immortalized cell line CVCL_C0Q3 CL:0000010 Unspecified Group: Amphibian cell line. 152998779 CVCL_C0Q6 A375 PLX/AZD-resistant cancer cell line human CVCL_C0Q6 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from sampling site: Skin. Omics: Deep quantitative proteome analysis Female 152998780 CVCL_C0PU PC12-21 cancer cell line Norway rat CVCL_C0PU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998781 CVCL_C0Q5 A549-ACE2 cancer cell line human CVCL_C0Q5 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13557; ACE2 Population: Caucasian; Derived from sampling site: Lung. Omics: Transcriptome analysis by RNAseq Male Group: SARS-CoV-2 research cell line 152998782 CVCL_C0PT PC12-19 cancer cell line Norway rat CVCL_C0PT CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 152998783 CVCL_C0PW PC12-27 c7 cancer cell line Norway rat CVCL_C0PW CL:0000010 Transfected with: HGNC; 1930; CHGB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Neurosecretion incompetent (from parent cell line) 152998784 CVCL_C0Q8 U2OS-GFP-HK2 cancer cell line human CVCL_C0Q8 CL:0000010 Transfected with: HGNC; 4923; HK2; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Omics: Deep quantitative proteome analysis Female Characteristics: Transfected with a pCMV6-AC-HK2-GFP construct that contains HK2 c-terminally tagged with turbo-GFP 152998785 CVCL_C0Q7 143B-GFP-HK2 cancer cell line human CVCL_C0Q7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4923; HK2; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; right femur. Female Characteristics: Transfected with a pCMV6-AC-HK2-GFP construct that contains HK2 c-terminally tagged with turbo-GFP 152998786 CVCL_C0PV PC12-27 cancer cell line Norway rat CVCL_C0PV CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Fully incompetent for both branches of regulated secretion, those of dense granules and synaptic-like microvesicles, possibly because of the impairment of a general expression control system that appears to operate independently of neuroendocrine cell differentiation (PubMed=8900203) 152998787 CVCL_C0PI BALB/Edeltat transformed cell line house mouse CVCL_C0PI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pUKdeltat](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. Male Doubling time: ~27 hours (PubMed=1851133) 152998788 CVCL_C0PH BALB/42 transformed cell line house mouse CVCL_C0PH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pUK42](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. Male Doubling time: ~27 hours (PubMed=1851133) 152998789 CVCL_C0PK MN12 hybridoma house mouse CVCL_C0PK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9R3Q6; Neisseria meningitidis strain P1.16 major outer membrane protein P.IA (porA). 152998790 CVCL_C0PJ BALB/Eori- transformed cell line house mouse CVCL_C0PJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pUKEori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. Male Doubling time: 96 hours (at 27th passage), 48 hours (after 27th passage) (DOI=10.1016/B978-0-7506-0421-5.50008-8) 152998791 CVCL_C0PM ICGi033-B induced pluripotent stem cell human CVCL_C0PM From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[77] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line ICGi033-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998792 CVCL_C0PL 1D4 [Mouse hybridoma against human TG] hybridoma house mouse CVCL_C0PL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01266; Human TG Caution: Incorrectly indicated as producing an IgG1 mAb in KCL technology transfer data sheet. 152998793 CVCL_C0Q0 PC-DR-LUC cancer cell line Norway rat CVCL_C0Q0 CL:0000010 Transfected with: UniProtKB; P04625; Chicken THRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Biotechnology: Used in an assay that can be used to identify compounds that have thyromimetic or TH-antagonistic effects, and that could be useful for detecting thyroid-disrupting chemicals in environmental samples (PubMed=17532181) Male Characteristics: Expression of luciferase is under the control of a promoter containing two thyroid hormone response elements (TREs) separated by four nucleotides (DR4) followed by a SV40 promoter (PubMed=17532181) 152998794 CVCL_C0PN ICGi033-C induced pluripotent stem cell human CVCL_C0PN From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[77] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line ICGi033-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 152998795 CVCL_C0PA AK-5 clone BC-8 cancer cell line Norway rat CVCL_C0PA CL:0000010 Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998796 CVCL_C0PC AK-5 clone EC-2 cancer cell line Norway rat CVCL_C0PC CL:0000010 Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998797 CVCL_C0PB AK-5 clone BE-5 cancer cell line Norway rat CVCL_C0PB CL:0000010 Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998798 CVCL_C0PE BB [Human macrophage] transformed cell line human CVCL_C0PE CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral blood Cell type=Macrophage.. Unspecified 152998799 CVCL_C0PD AK-5 clone FB-11 cancer cell line Norway rat CVCL_C0PD CL:0000010 Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998800 CVCL_C0PG DM [Human macrophage] transformed cell line human CVCL_C0PG CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral blood Cell type=Macrophage.. Unspecified 152998801 CVCL_C0PF CS transformed cell line human CVCL_C0PF CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral blood Cell type=Macrophage.. Unspecified 152998802 CVCL_C0QZ HepaRG(VC) cancer cell line human CVCL_C0QZ CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver. Female 152998803 CVCL_C0QY THP1 ST-PEAK3 cancer cell line human CVCL_C0QY CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 24793; PEAK3 (with a N-terminal Strep tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a pSBbi-PuroR-ST-PEAK3 that contains a N-terminally Strep-tagged PEAK3 152998804 CVCL_C0RA C1R-A33 transformed cell line human CVCL_C0RA CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*33:03); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998805 CVCL_C0QR DU145-R cancer cell line human CVCL_C0QR CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Brain. Male 152998806 CVCL_C0R3 OKF6/TERT1-Shisha-4 month telomerase immortalized cell line human CVCL_C0R3 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Deep quantitative proteome analysis Male Characteristics: The parental cell line was chronically exposed with 0.5% shisha extract for 4 months 152998807 CVCL_C0R2 OKF6/TERT1-Shisha-2 month telomerase immortalized cell line human CVCL_C0R2 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Deep quantitative proteome analysis Male Characteristics: The parental cell line was chronically exposed with 0.5% shisha extract for 2 months 152998808 CVCL_C0QQ VCaP-R cancer cell line human CVCL_C0QQ CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone; vertebra. Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 152998809 CVCL_C0R5 OKF6/TERT1-Shisha-8 month telomerase immortalized cell line human CVCL_C0R5 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis Male Characteristics: The parental cell line was chronically exposed with 0.5% shisha extract for 8 months 152998810 CVCL_C0QT U2OS GFP-PEAK3 cancer cell line human CVCL_C0QT CL:0000010 Transfected with: HGNC; 24793; PEAK3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a pBABE-GFP-PEAK3 construct that contains a GFP-PEAK3 fusion 152998811 CVCL_C0R4 OKF6/TERT1-Shisha-6 month telomerase immortalized cell line human CVCL_C0R4 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Deep quantitative proteome analysis Male Characteristics: The parental cell line was chronically exposed with 0.5% shisha extract for 6 months 152998812 CVCL_C0QS PC-3-R cancer cell line human CVCL_C0QS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone. Male 152998813 CVCL_C0QV HeLa GFP-PEAK3 cancer cell line human CVCL_C0QV CL:0000010 Transfected with: HGNC; 24793; PEAK3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a pBABE-GFP-PEAK3 construct that contains a GFP-PEAK3 fusion 152998814 CVCL_C0R7 OKF6/TERT1-Smoke telomerase immortalized cell line human CVCL_C0R7 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis Male Characteristics: The parental cell line was chronically exposed to 0.1% cigarette smoke condensate (CSC) for a period of 12 months 152998815 CVCL_C0R6 3T3J2NHP spontaneously immortalized cell line house mouse CVCL_C0R6 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Characteristics: Used a feeder cells to support transduced keratinocyte populations during selection with one of G418, hygromycin or puromycin 152998816 CVCL_C0QU U2OS ST-PEAK3 cancer cell line human CVCL_C0QU CL:0000010 Transfected with: HGNC; 24793; PEAK3 (with a N-terminal Strep tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a pSBbi-PuroR-ST-PEAK3 that contains a N-terminally Strep-tagged PEAK3 152998817 CVCL_C0R9 C1R-A11 transformed cell line human CVCL_C0R9 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*11:01); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 152998818 CVCL_C0QX THP1 GFP-PEAK3 cancer cell line human CVCL_C0QX CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 24793; PEAK3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a pBABE-GFP-PEAK3 construct that contains a GFP-PEAK3 fusion 152998819 CVCL_C0R8 Caco-2 DUSP6 KO cancer cell line human CVCL_C0R8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3072; DUSP6; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Male 152998820 CVCL_C0QW HeLa ST-PEAK3 cancer cell line human CVCL_C0QW CL:0000010 Transfected with: HGNC; 24793; PEAK3 (with a N-terminal Strep tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a pSBbi-PuroR-ST-PEAK3 that contains a N-terminally Strep-tagged PEAK3 152998821 CVCL_C0QJ NTERA-2-R cancer cell line human CVCL_C0QJ CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lung. Omics: Deep quantitative proteome analysis Male 152998822 CVCL_C0QI S37P-hTERT telomerase immortalized cell line human CVCL_C0QI CL:0000010 Sequence variation: Mutation; HGNC; 18704; NAA10; Simple; p.Ser37Pro (c.109T>C); ClinVar=VCV000029927; Zygosity=Hemizygous (PubMed=25489052); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Acetylation analysis by proteomics Male 152998823 CVCL_C0QL NCCIT-R cancer cell line human CVCL_C0QL CL:0000010 Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Omics: Deep quantitative proteome analysis. Male 152998824 CVCL_C0QK 2102EP-R cancer cell line human CVCL_C0QK CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Testis. Omics: Deep quantitative proteome analysis Male 152998825 CVCL_C0QN HEK Flp-In T-REx-293-C22orf39-KO transformed cell line human CVCL_C0QN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27012; C22orf39; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152998826 CVCL_C0QM HUDEP2 HBB-KO transformed cell line human CVCL_C0QM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4827; HBB; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord blood Cell type=Erythroid progenitor cell.. Omics: ATAC-seq; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Unspecified 152998827 CVCL_C0QP HEK Flp-In T-REx-293-LYRM9-KO transformed cell line human CVCL_C0QP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27314; LYRM9; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152998828 CVCL_C0R1 HepaRG-POR#2 cancer cell line human CVCL_C0R1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9208; POR; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver. Female Characteristics: Not completely KO for POR, can be considered as a POR knockdown cell line (PubMed=33441761) 152998829 CVCL_C0R0 HepaRG-POR#1 cancer cell line human CVCL_C0R0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9208; POR; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver. Female Characteristics: Not completely KO for POR, can be considered as a POR knockdown cell line (PubMed=33441761) 152998830 CVCL_C0QB SK-N-AS RET KO clone C5 cancer cell line human CVCL_C0QB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 152998831 CVCL_C0QA SK-N-AS RET KO clone C2 cancer cell line human CVCL_C0QA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 152998832 CVCL_C0QD SK-N-AS RET KO clone C17 cancer cell line human CVCL_C0QD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 152998833 CVCL_C0QC SK-N-AS RET KO clone C9 cancer cell line human CVCL_C0QC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 152998834 CVCL_C0QF U2OS-PER2-BioID2 cancer cell line human CVCL_C0QF CL:0000010 Transfected with: HGNC; 8846; PER2; Transfected with: UniProtKB; O66837; Aquifex aeolicus biRA (with p.Arg40Gly = BioID2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a MCS-hPER2-13XLinker-BioID2-HA construct which express PER2 fused with the BioID2 protein so as to use proximity-dependent biotin labeling (PubMed=35122331) 152998835 CVCL_C0QE SK-N-AS RET KO clone C19 cancer cell line human CVCL_C0QE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 152998836 CVCL_C0QH HEK293 HA-RB1 transformed cell line human CVCL_C0QH CL:0000010 Transfected with: HGNC; 9884; RB1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152998837 CVCL_C0QG U2OS-BioID2 cancer cell line human CVCL_C0QG CL:0000010 Transfected with: UniProtKB; O66837; Aquifex aeolicus biRA (with p.Arg40Gly = BioID2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a Myc.BioID2.13xLinker construct Control cell line for U2OS-PER2-BioID2 (Cellosaurus=CVCL_C0QF). 152998838 CVCL_C0NW GM1-22-SV transformed cell line human CVCL_C0NW CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998839 CVCL_C0NV GM1-22 finite cell line human CVCL_C0NV CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998840 CVCL_C0NY GM1-1019-SV transformed cell line human CVCL_C0NY CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Doubling time: ~20 hours (PubMed=2990594) 152998841 CVCL_C0NX GM1-1019 finite cell line human CVCL_C0NX CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998842 CVCL_C0NZ GM1-1026 finite cell line human CVCL_C0NZ CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998843 CVCL_C0NN PZ-TR cancer cell line human CVCL_C0NN CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Used for as reporter cell line for the assessment of thyroid receptor (TR) transcriptional activity Triiodothyronine (T3) induced luciferase activity in a dose-dependent manner, and the sensitivity of assay allowed for the detection of nanomolar T3 concentrations (PubMed=26208032). Male Characteristics: Expression of luciferase is under the control of a promoter containing two thyroid hormone response elements (TREs) separated by four nucleotides (DR4) followed by a SV40 promoter (PubMed=26208032) 152998844 CVCL_C0NQ GA-15-SV transformed cell line human CVCL_C0NQ CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998845 CVCL_C0NP GA-15 finite cell line human CVCL_C0NP CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998846 CVCL_C0NS FA-1073-SV transformed cell line human CVCL_C0NS CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998847 CVCL_C0NR FA-1073 finite cell line human CVCL_C0NR CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998848 CVCL_C0NU SA-1077-SV transformed cell line human CVCL_C0NU CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Doubling time: ~20 hours (PubMed=2990594) 152998849 CVCL_C0NT SA-1077 finite cell line human CVCL_C0NT CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998850 CVCL_C0NG HT22 Klf9/Klf13 double KO transformed cell line house mouse CVCL_C0NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1333856; Klf9; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1354948; Klf13 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. 152998851 CVCL_C0NF HT22 Klf9 KO transformed cell line house mouse CVCL_C0NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1333856; Klf9 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. 152998852 CVCL_C0NI XTC-2 BirAV5-FLBIO-xKLF9 spontaneously immortalized cell line African clawed frog CVCL_C0NI CL:0000010 Transfected with: UniProtKB; Q91632; Xenopus laevis Klf9 (with a N-terminal FLBIO tag); Transfected with: UniProtKB; P06709; Escherichia coli birA (V5-tagged); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Expresses C-terminal V5-tagged birA under the control of the human EF-1 alpha promoter and a N-terminal FLBIO (FLAG tag and biotin ligase recognition peptide) Xenopus Klf9 fusion protein Group: Amphibian cell line 152998853 CVCL_C0NH XTC-2 BirAV5 spontaneously immortalized cell line African clawed frog CVCL_C0NH CL:0000010 Transfected with: UniProtKB; P06709; Escherichia coli birA (V5-tagged); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Expresses C-terminal V5-tagged birA under the control of the human EF-1 alpha promoter Group: Amphibian cell line 152998854 CVCL_C0NK SAPi001-A induced pluripotent stem cell human CVCL_C0NK From: Sapienza University of Rome; Rome; Italy. CL:0000010 152998855 CVCL_C0NJ BIHi001-A-2 induced pluripotent stem cell human CVCL_C0NJ From: Berlin Institute of Health; Berlin; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a Puro-CAG-eGFP construct was introduced in the AAVS1 safe harbor locus (PubMed=32384610) 152998856 CVCL_C0NM HEK293-KL transformed cell line human CVCL_C0NM CL:0000010 Transfected with: HGNC; 6344; KL (with a N-terminal mycHis6 tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 152998857 CVCL_C0NL WCHi002-A induced pluripotent stem cell human CVCL_C0NL From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Gly2948Ser (c.8842G>A); ClinVar=VCV000432055; Zygosity=Heterozygous (PubMed=35924034; PubMed=36535090) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 152998858 CVCL_C0NA XL177 lacZ clone 2.14 spontaneously immortalized cell line African clawed frog CVCL_C0NA CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Group: Amphibian cell line 152998859 CVCL_C0NC XL58 spontaneously immortalized cell line African clawed frog CVCL_C0NC CL:0000010 Unspecified Group: Amphibian cell line. 152998860 CVCL_C0NB XL177 lacZ clone 2.5 spontaneously immortalized cell line African clawed frog CVCL_C0NB CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Group: Amphibian cell line 152998861 CVCL_C0NE HT22 Klf13 KO transformed cell line house mouse CVCL_C0NE CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1354948; Klf13 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. 152998862 CVCL_C0ND XL58-TRE-Luc spontaneously immortalized cell line African clawed frog CVCL_C0ND CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Biotechnology: Used in a thyroid hormone (TH) inducible primary screening assay for the identification and assessment of chemicals that interfere with the TH-signalling pathway within target cells (PubMed=16179385) Unspecified Characteristics: Expression of luciferase is under the control of Xenopus T3-response elements (TREs) Expression of EGFP is under the control of the CMV promoter. Group: Amphibian cell line 152998863 CVCL_C0P9 AK-5 clone BC-7 cancer cell line Norway rat CVCL_C0P9 CL:0000010 Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998864 CVCL_C0P8 AK-5 cancer cell line Norway rat CVCL_C0P8 CL:0000010 Miscellaneous: This is not a cell line but a transplantable tumor that originally arose in a rats given an intraperitoneal injection with the cell-free ascitic fluid of a chemically induced, established ascites liver tumor ZAH (PubMed=3457975) Derived from sampling site: Cell type=Macrophage; Breed/subspecies: Wistar. Unspecified 152998865 CVCL_C0P1 NCBL1.c5 induced pluripotent stem cell human CVCL_C0P1 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998866 CVCL_C0P0 GM1-1026-SV transformed cell line human CVCL_C0P0 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 152998867 CVCL_C0P3 NCBL2.c46 induced pluripotent stem cell human CVCL_C0P3 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998868 CVCL_C0P2 NCBL2.c11 induced pluripotent stem cell human CVCL_C0P2 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998869 CVCL_C0P5 NCBL3.c6 induced pluripotent stem cell human CVCL_C0P5 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998870 CVCL_C0P4 NCBL3.c2 induced pluripotent stem cell human CVCL_C0P4 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 152998871 CVCL_C0P7 NCBL4.c33 induced pluripotent stem cell human CVCL_C0P7 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 152998872 CVCL_C0P6 NCBL4.c27 induced pluripotent stem cell human CVCL_C0P6 From: Neuronal Circuits and Behavior Lab, Center for Neuroscience and Cell Biology; Coimbra; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser301Cysfs*61 (c.900_901dupGT); Zygosity=Heterozygous (PubMed=36009452) Population: Caucasian; Portuguese; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 155260372 CVCL_C0ZZ MCF10A_EZH2_19 spontaneously immortalized cell line human CVCL_C0ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260373 CVCL_C0ZS MCF10A_CDKN2C_161 spontaneously immortalized cell line human CVCL_C0ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1789; CDKN2C; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260374 CVCL_C0ZR MCF10A_ATRX_734 spontaneously immortalized cell line human CVCL_C0ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260375 CVCL_C0ZU MCF10A_DAXX_703_SC1 spontaneously immortalized cell line human CVCL_C0ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260376 CVCL_C0ZT MCF10A_CDKN2C_163 spontaneously immortalized cell line human CVCL_C0ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1789; CDKN2C; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260377 CVCL_C0ZW MCF10A_DAXX_715 spontaneously immortalized cell line human CVCL_C0ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260378 CVCL_C0ZV MCF10A_DAXX_704 spontaneously immortalized cell line human CVCL_C0ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260379 CVCL_C0ZY MCF10A_EZH2_10B4 spontaneously immortalized cell line human CVCL_C0ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260380 CVCL_C0ZX MCF10A_EZH2_10A3 spontaneously immortalized cell line human CVCL_C0ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260381 CVCL_C0ZK MCF10A_APC_735 spontaneously immortalized cell line human CVCL_C0ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260382 CVCL_C0ZJ MCF10A_APC_7 spontaneously immortalized cell line human CVCL_C0ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260383 CVCL_C0ZM MCF10A_ARID1A_B4 spontaneously immortalized cell line human CVCL_C0ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260384 CVCL_C0ZL MCF10A_APC_753 spontaneously immortalized cell line human CVCL_C0ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260385 CVCL_C0ZN MCF10A_ARID1A_C11_SC1 spontaneously immortalized cell line human CVCL_C0ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260386 CVCL_C0ZQ MCF10A_ATRX_722 spontaneously immortalized cell line human CVCL_C0ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260387 CVCL_C0ZP MCF10A_ATRX_718 spontaneously immortalized cell line human CVCL_C0ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: Cancer Pathway Knockout Panel 155260388 CVCL_C0YB B'SYS CHO Nav1.5 Duo spontaneously immortalized cell line CVCL_C0YB CL:0000010 Transfected with: HGNC; 10593; SCN5A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: SCN5A was transfected twice 155260389 CVCL_C0YA B'SYS CHO Nav1.4 spontaneously immortalized cell line CVCL_C0YA CL:0000010 Transfected with: HGNC; 10591; SCN4A; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260390 CVCL_C0YD B'SYS CHO Nav1.8/beta3 spontaneously immortalized cell line CVCL_C0YD CL:0000010 Transfected with: HGNC; 10582; SCN10A; Transfected with: HGNC; 20665; SCN3B; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260391 CVCL_C0YC B'SYS CHO Nav1.7 spontaneously immortalized cell line CVCL_C0YC CL:0000010 Transfected with: HGNC; 10597; SCN9A Derived from sampling site: Ovary. Female 155260392 CVCL_C0YF B'SYS CHO P2X2 spontaneously immortalized cell line CVCL_C0YF CL:0000010 Transfected with: HGNC; 15459; P2RX2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260393 CVCL_C0YE B'SYS CHO P2X1 spontaneously immortalized cell line CVCL_C0YE CL:0000010 Transfected with: HGNC; 8533; P2RX1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260394 CVCL_C0YH B'SYS HEK 293 Cav3.2 transformed cell line human CVCL_C0YH CL:0000010 Transfected with: HGNC; 1395; CACNA1H; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260395 CVCL_C0YG B'SYS CHO P2X3 spontaneously immortalized cell line CVCL_C0YG CL:0000010 Transfected with: HGNC; 8534; P2RX3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260396 CVCL_C0XY B'SYS CHO Kv1.2 spontaneously immortalized cell line CVCL_C0XY CL:0000010 Transfected with: HGNC; 6220; KCNA2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260397 CVCL_C0XX B'SYS CHO Kv1.1 spontaneously immortalized cell line CVCL_C0XX CL:0000010 Transfected with: HGNC; 6218; KCNA1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260398 CVCL_C0Y9 B'SYS CHO Nav1.2 spontaneously immortalized cell line CVCL_C0Y9 CL:0000010 Transfected with: HGNC; 10588; SCN2A; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260399 CVCL_C0XZ B'SYS CHO Kv1.3 spontaneously immortalized cell line CVCL_C0XZ CL:0000010 Transfected with: HGNC; 6221; KCNA3; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260400 CVCL_C0XQ B'SYS CHO alpha1beta2gamma2 GABA(A) spontaneously immortalized cell line CVCL_C0XQ CL:0000010 Transfected with: HGNC; 4075; GABRA1; Transfected with: HGNC; 4082; GABRB2; Transfected with: HGNC; 4087; GABRG2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female 155260401 CVCL_C0Y2 B'SYS CHO Kv1.6 spontaneously immortalized cell line CVCL_C0Y2 CL:0000010 Transfected with: HGNC; 6225; KCNA6; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260402 CVCL_C0Y1 B'SYS CHO Kv1.5 spontaneously immortalized cell line CVCL_C0Y1 CL:0000010 Transfected with: HGNC; 6224; KCNA5; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260403 CVCL_C0XP Xela VS2 spontaneously immortalized cell line African clawed frog CVCL_C0XP CL:0000010 Derived from sampling site: Ventral; skin Cell type=Epithelial cell.. Female Group: Amphibian cell line 155260404 CVCL_C0XS B'SYS CHO ASIC1b spontaneously immortalized cell line CVCL_C0XS CL:0000010 Transfected with: HGNC; 100; ASIC1 (isoform 3/Asic1b); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260405 CVCL_C0Y4 B'SYS CHO Kv4.3 spontaneously immortalized cell line CVCL_C0Y4 CL:0000010 Transfected with: HGNC; 6239; KCND3; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260406 CVCL_C0XR B'SYS CHO ASIC1a spontaneously immortalized cell line CVCL_C0XR CL:0000010 Transfected with: HGNC; 100; ASIC1 (isoform 1/Asic1a); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155260407 CVCL_C0Y3 B'SYS CHO Kv2.1 spontaneously immortalized cell line CVCL_C0Y3 CL:0000010 Transfected with: HGNC; 6231; KCNB1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260408 CVCL_C0XU B'SYS CHO GlyRalpha3 spontaneously immortalized cell line CVCL_C0XU CL:0000010 Transfected with: HGNC; 4328; GLRA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155260409 CVCL_C0Y6 B'SYS CHO Kv7.2 spontaneously immortalized cell line CVCL_C0Y6 CL:0000010 Transfected with: HGNC; 6296; KCNQ2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260410 CVCL_C0XT B'SYS CHO ASIC3 spontaneously immortalized cell line CVCL_C0XT CL:0000010 Transfected with: HGNC; 101; ASIC3; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260411 CVCL_C0Y5 B'SYS CHO Kv4.3/KChiP2 spontaneously immortalized cell line CVCL_C0Y5 CL:0000010 Transfected with: HGNC; 6239; KCND3; Transfected with: HGNC; 15522; KCNIP2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260412 CVCL_C0XW B'SYS CHO Kir2.1 spontaneously immortalized cell line CVCL_C0XW CL:0000010 Transfected with: HGNC; 6263; KCNJ2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260413 CVCL_C0Y8 B'SYS CHO KvLQT1/minK spontaneously immortalized cell line CVCL_C0Y8 CL:0000010 Transfected with: HGNC; 6240; KCNE1; Transfected with: HGNC; 6294; KCNQ1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 155260414 CVCL_C0XV B'SYS CHO hERG-Duo spontaneously immortalized cell line CVCL_C0XV CL:0000010 Transfected with: HGNC; 6251; KCNH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: KCNH2 was transfected twice 155260415 CVCL_C0Y7 B'SYS CHO Kv7.2/3 spontaneously immortalized cell line CVCL_C0Y7 CL:0000010 Transfected with: HGNC; 6296; KCNQ2; Transfected with: HGNC; 6297; KCNQ3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female 155260416 CVCL_C0XI BEL-A 5x KO transformed cell line human CVCL_C0XI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4035; ACKR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 4012; FUT1; Knockout cell: Method=CRISPR/Cas9; HGNC; 4703; GYPB; Knockout cell: Method=CRISPR/Cas9; HGNC; 6308; KEL; Knockout cell: Method=CRISPR/Cas9; HGNC; 10006; RHAG; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Omics: Deep quantitative proteome analysis; Omics: Genome sequenced Unspecified Characteristics: Completely deficient in blood groups encoded by five different genes that encode antigens responsible for the most common transfusion incompatibilities 155260417 CVCL_C0XH BEL-A 4x KO transformed cell line human CVCL_C0XH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4035; ACKR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 4012; FUT1; Knockout cell: Method=CRISPR/Cas9; HGNC; 4703; GYPB; Knockout cell: Method=CRISPR/Cas9; HGNC; 6308; KEL; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260418 CVCL_C0XK GPF-1 transformed cell line CVCL_C0XK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~26 hours (PubMed=35362864) Group: Endangered species/breed cell line 155260419 CVCL_C0XJ ASE-14 spontaneously immortalized cell line CVCL_C0XJ CL:0000010 Unspecified Doubling time: 3-4 days (PubMed=35427959). Group: Tick cell line 155260420 CVCL_C0XM RG17 spontaneously immortalized cell line house mouse CVCL_C0XM CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: GLAST-CreERT; Rbfl/fl transgenic. Unspecified Doubling time: 58.47 hours (at 5th passage), 60.90 hours (at 20th passage) (PubMed=35377941) 155260421 CVCL_C0XL XG69 spontaneously immortalized cell line African clawed frog CVCL_C0XL CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Unspecified Doubling time: 60.59 hours (at 5th passage), 60.35 hours (at 20th passage) (PubMed=35377941) Group: Amphibian cell line 155260422 CVCL_C0Y0 B'SYS CHO Kv1.4 spontaneously immortalized cell line CVCL_C0Y0 CL:0000010 Transfected with: HGNC; 6222; KCNA4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 155260423 CVCL_C0XN Xela DS2 spontaneously immortalized cell line African clawed frog CVCL_C0XN CL:0000010 Derived from sampling site: Dorsal; skin Cell type=Epithelial cell.. Female Group: Amphibian cell line 155260424 CVCL_C0ZC PK-9 [Pig] spontaneously immortalized cell line pig CVCL_C0ZC CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163 (isoform CD163v1); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Unspecified 155260425 CVCL_C0ZB 5F12 hybridoma house mouse CVCL_C0ZB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F1SPC2; Pig CD69. 155260426 CVCL_C0ZE HPIi003-A induced pluripotent stem cell human CVCL_C0ZE From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Ala172Glu (c.515C>A); ClinVar=VCV000128261; Zygosity=Heterozygous (PubMed=35728439) Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155260427 CVCL_C0ZD U-2OS-Cas9-4 cancer cell line human CVCL_C0ZD CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with a Cas9-T2A-PuroR construct 155260428 CVCL_C0ZG HPIi004-B induced pluripotent stem cell human CVCL_C0ZG From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Arg39Ter (c.121C>T); Zygosity=Homozygous (PubMed=35728440) Population: Caucasian; Romani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155260429 CVCL_C0ZF HPIi004-A induced pluripotent stem cell human CVCL_C0ZF From: Harry Perkins Institute of Medical Research, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Arg39Ter (c.121C>T); Zygosity=Homozygous (PubMed=35728440) Population: Caucasian; Romani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155260430 CVCL_C0ZI UOMi008-A induced pluripotent stem cell human CVCL_C0ZI From: University of Manitoba; Winnipeg; Canada CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Glu191Lys (c.571G>A) (E174K); ClinVar=VCV000013670; Zygosity=Heterozygous (PubMed=35964540); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gly334Asp (c.1001G>A) (G317D, 1177A); ClinVar=VCV000013672; Zygosity=Heterozygous (PubMed=35964540) Derived from sampling site: Peripheral blood. Male 155260431 CVCL_C0ZH UOMi007-A induced pluripotent stem cell human CVCL_C0ZH From: University of Manitoba; Winnipeg; Canada CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Glu191Lys (c.571G>A) (E174K); ClinVar=VCV000013670; Zygosity=Heterozygous (PubMed=35700635); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gly334Asp (c.1001G>A) (G317D, 1177A); ClinVar=VCV000013672; Zygosity=Heterozygous (PubMed=35700635) Derived from sampling site: Peripheral blood. Male 155260432 CVCL_C0YZ UMi038-A-1 induced pluripotent stem cell human CVCL_C0YZ From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple_corrected; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260433 CVCL_C0YY UMi039-B induced pluripotent stem cell human CVCL_C0YY From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous (from autologous cell line UMi039-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260434 CVCL_C0ZA 2O2 hybridoma house mouse CVCL_C0ZA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A0A8I3MI11; Dog OSMR. 155260435 CVCL_C0YR MT-2CB1 transformed cell line human CVCL_C0YR CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46664; Chrysotile asbestos; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=Regulatory T-cell.. Male 155260436 CVCL_C0Z3 PK0809 spontaneously immortalized cell line pig CVCL_C0Z3 From: Draayer H.A.; Beecham Laboratories; Whitehall; USA CL:0000010 Miscellaneous: Identity of PK0809 with PK032495 and origin of cell line from personal commuincation of Calvert J.G Derived from sampling site: Kidney. Unspecified 155260437 CVCL_C0YQ THP-1-R cancer cell line human CVCL_C0YQ CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Cultured continuously for 26 months (PubMed=6949641) 155260438 CVCL_C0Z2 UMi037-A induced pluripotent stem cell human CVCL_C0Z2 From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 155260439 CVCL_C0Z5 NLFK spontaneously immortalized cell line CVCL_C0Z5 CL:0000010 Derived from sampling site: Kidney. 155260440 CVCL_C0YT THP-1-Cs5 cancer cell line human CVCL_C0YT CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260441 CVCL_C0YS MT-2CR1 transformed cell line human CVCL_C0YS CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46666; Crocidolite asbestos; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=Regulatory T-cell.. Male 155260442 CVCL_C0Z4 PK15CD163 spontaneously immortalized cell line pig CVCL_C0Z4 CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) (PubMed=24398227) 155260443 CVCL_C0Z7 FK-A6 spontaneously immortalized cell line CVCL_C0Z7 CL:0000010 Transfected with: HGNC; 1631; CD163; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. 155260444 CVCL_C0YV UMi038-A induced pluripotent stem cell human CVCL_C0YV From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous (PubMed=35671596) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260445 CVCL_C0Z6 FK-D4 spontaneously immortalized cell line CVCL_C0Z6 CL:0000010 Transfected with: UniProtKB; Q2VLG4; Chlorocebus aethiops CD163; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. 155260446 CVCL_C0YU WU-TSC-1 cancer cell line human CVCL_C0YU CL:0000010 Population: Chinese; Derived from sampling site: Oral cavity; tongue. Female Doubling time: 51.15 hours (DOI=10.13701/j.cnki.kqyxyj.2022.04.013) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021161 155260447 CVCL_C0Z9 JHU-LNCaP-SM cancer cell line human CVCL_C0Z9 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=26499105); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Forms subcutaneous tumors in male athymic nude mice and reliably metastasize to the lymph nodes (PubMed=26499105). 155260448 CVCL_C0YX UMi038-B induced pluripotent stem cell human CVCL_C0YX From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous (from autologous cell line UMi038-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260449 CVCL_C0Z8 IPO43 cancer cell line human CVCL_C0Z8 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=35501869); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val172Phe (c.514G>T); ClinVar=VCV000428909; Zygosity=Heterozygous (PubMed=35501869) Population: Caucasian; Derived from metastatic site: Ascites. Female Doubling time: 37.3 hours (PubMed=35501869) 155260450 CVCL_C0YW UMi039-A induced pluripotent stem cell human CVCL_C0YW From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous (PubMed=35671596) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260451 CVCL_C0YJ B'SYS HEK 293 K2P18.1 transformed cell line human CVCL_C0YJ CL:0000010 Transfected with: HGNC; 19439; KCNK18; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260452 CVCL_C0YI B'SYS HEK 293 hERG transformed cell line human CVCL_C0YI CL:0000010 Transfected with: HGNC; 6251; KCNH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260453 CVCL_C0YL B'SYS HEK 293 P2X4 transformed cell line human CVCL_C0YL CL:0000010 Transfected with: HGNC; 8535; P2RX4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260454 CVCL_C0YK B'SYS HEK 293 KvLQT1/minK transformed cell line human CVCL_C0YK CL:0000010 Transfected with: HGNC; 6240; KCNE1; Transfected with: HGNC; 6294; KCNQ1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260455 CVCL_C0YN A8 2k transformed cell line African clawed frog CVCL_C0YN CL:0000010 Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Liver. Female Group: Amphibian cell line 155260456 CVCL_C0YM B'SYS HEK 293 P2X7 transformed cell line human CVCL_C0YM CL:0000010 Transfected with: HGNC; 8537; P2RX7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155260457 CVCL_C0YP CHO-K1 GABA(A)R alpha1beta2gamma2L spontaneously immortalized cell line CVCL_C0YP CL:0000010 Transfected with: HGNC; 4075; GABRA1; Transfected with: HGNC; 4082; GABRB2; Transfected with: HGNC; 4087; GABRG2 (isoform 3); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female Characteristics: The expression of GABRA1 is induced by tetracycline while the expression of GABRB2 and GABRG2 is constitutive 155260458 CVCL_C0Z1 UMi036-A induced pluripotent stem cell human CVCL_C0Z1 From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 155260459 CVCL_C0Z0 UMi039-A-1 induced pluripotent stem cell human CVCL_C0Z0 From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11185; SORL1; Simple_corrected; p.Cys1431Trpfs*2 (c.4293delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155260460 CVCL_C0WB STPLF-fE transformed cell line human CVCL_C0WB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260461 CVCL_C0WA RIRI-GG3 spontaneously immortalized cell line CVCL_C0WA CL:0000010 Unspecified Group: Insect cell line. 155260462 CVCL_C0WD STPLF-mB transformed cell line human CVCL_C0WD CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Male 155260463 CVCL_C0WC STPLF-fF transformed cell line human CVCL_C0WC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260464 CVCL_C0WF 1-17 transformed cell line human CVCL_C0WF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260465 CVCL_C0WE 1-11 transformed cell line human CVCL_C0WE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female Characteristics: Derived from a progenitor/stem cell present in the periodontal ligament and may be very useful for studying the biology and regeneration of periodontium (PubMed=18181171) 155260466 CVCL_C0W8 RIRI-PX1-C31 spontaneously immortalized cell line CVCL_C0W8 CL:0000010 Unspecified Virology: Highly susceptible to infection by Autographa californica nuclear polyhedrosis virus (AcMNPV) (PubMed=35653076). Group: Insect cell line 155260467 CVCL_C0VW SFL [Astyanax] spontaneously immortalized cell line CVCL_C0VW CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Surface morph. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 1.5 days (PubMed=35710938) Group: Fish cell line 155260468 CVCL_C0VV CFL spontaneously immortalized cell line CVCL_C0VV CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Pachon cave morph. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 1.7 days (PubMed=35710938) Group: Fish cell line 155260469 CVCL_C0W7 RIRI-PX1-C24 spontaneously immortalized cell line CVCL_C0W7 CL:0000010 Unspecified Virology: Highly susceptible to infection by Autographa californica nuclear polyhedrosis virus (AcMNPV) (DOI=10.16380/j.kcxb.2019.03.004). Group: Insect cell line 155260470 CVCL_C0VY Shef6EOS embryonic stem cell human CVCL_C0VY CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Transduced with a EOS-C(3+)-GFP/puroR construct EOS (ETn, Oct-4 and Sox2) combines a highly active promoter from a mouse early transposon (ETn) that is specific for undifferentiated pluripotent stem cells and combined it with Oct-4 (Pou5f1) and Sox2-binding motifs. EOS regulates an enhanced green fluorescent protein (eGFP), an internal ribosome entry site (IRES) and a puromycin resistance gene to allow live-cell visualization and antibiotic selection simultaneously. 155260471 CVCL_C0VX H9EOS embryonic stem cell human CVCL_C0VX CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Transduced with a EOS-C(3+)-GFP/puroR construct EOS (ETn, Oct-4 and Sox2) combines a highly active promoter from a mouse early transposon (ETn) that is specific for undifferentiated pluripotent stem cells and combined it with Oct-4 (Pou5f1) and Sox2-binding motifs. EOS regulates an enhanced green fluorescent protein (eGFP), an internal ribosome entry site (IRES) and a puromycin resistance gene to allow live-cell visualization and antibiotic selection simultaneously. 155260472 CVCL_C0W9 RIRI-GG2 spontaneously immortalized cell line CVCL_C0W9 CL:0000010 Unspecified Group: Insect cell line. 155260473 CVCL_C0VZ cR-NCRM2 induced pluripotent stem cell human CVCL_C0VZ CL:0000010 Derived from sampling site: Umbilical cord blood. Female Characteristics: Epigenetically reset using a t2iLGo naive cell maintenance medium (PubMed=28765214) 155260474 CVCL_C0W0 AME-1 [Ameloblastoma] finite cell line human CVCL_C0W0 CL:0000010 Derived from sampling site: Bone; jaw; mandible Cell type=Ameloblast.. Female 155260475 CVCL_C0W2 AME-hTERT telomerase immortalized cell line human CVCL_C0W2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone; jaw; mandible Cell type=Ameloblast.. Omics: Transcriptome analysis by RNAseq Female 155260476 CVCL_C0W1 AME-HPV transformed cell line human CVCL_C0W1 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone; jaw; mandible Cell type=Ameloblast.. Omics: Transcriptome analysis by RNAseq Female 155260477 CVCL_C0W4 A549/DDP cancer cell line human CVCL_C0W4 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Male 155260478 CVCL_C0W3 GWH04 cancer cell line human CVCL_C0W3 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu1038Gly (c.3113A>G); ClinVar=VCV000041815; Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ser423Gly (c.1267A>G); ClinVar=VCV001398791; Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Val384Asp (c.1151T>A); ClinVar=VCV000041632; Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Ter640Argext (c.1918T>C); Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser478Pro (c.1432T>C); ClinVar=VCV000041794; Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr315Ter (c.945T>A); ClinVar=VCV000234509; Zygosity=Unspecified (PubMed=36169178); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=36169178); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=36169178) Population: Chinese; Derived from sampling site: Brain; right temporal lobe. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202163 155260479 CVCL_C0W6 B-LCL-HROC75 transformed cell line human CVCL_C0W6 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155260480 CVCL_C0VU BIONi010-C-NKX2.5-T2A-Nluc-73.59 induced pluripotent stem cell human CVCL_C0VU CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Biotechnology: Part of the PluriLum assay which is used for predicting developmental toxicity which relies on the formation of embryoid bodies (EBs) and the differentiation of these into cardiomyocytes (PubMed=33660062) Male Characteristics: Using CRISPR/Cas9 a T2A-Nluc construct was inserted at the C-terminus of both alleles of NKX2-5 (PubMed=33660062) 155260481 CVCL_C0VT BIONi010-C-NKX2.5-T2A-Nluc-44.37 induced pluripotent stem cell human CVCL_C0VT CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Biotechnology: Part of the PluriLum assay which is used for predicting developmental toxicity which relies on the formation of embryoid bodies (EBs) and the differentiation of these into cardiomyocytes (PubMed=33660062) Male Characteristics: Using CRISPR/Cas9 a T2A-Nluc construct was inserted at the C-terminus of both alleles of NKX2-5 (PubMed=33660062) 155260482 CVCL_C0W5 PIEC spontaneously immortalized cell line pig CVCL_C0W5 CL:0000010 Derived from sampling site: Iliac artery; endothelium. 155260483 CVCL_C0XA BEL-A BSG KO transformed cell line human CVCL_C0XA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1116; BSG; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260484 CVCL_C0XC BEL-A GPA KO transformed cell line human CVCL_C0XC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4702; GYPA; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260485 CVCL_C0XB BEL-A FUT1 KO transformed cell line human CVCL_C0XB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4012; FUT1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260486 CVCL_C0XE BEL-A KEL KO transformed cell line human CVCL_C0XE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6308; KEL; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260487 CVCL_C0XD BEL-A GPB KO transformed cell line human CVCL_C0XD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4703; GYPB; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260488 CVCL_C0XG BEL-A RHCE KO transformed cell line human CVCL_C0XG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10008; RHCE; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260489 CVCL_C0XF BEL-A RHAG KO transformed cell line human CVCL_C0XF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10006; RHAG; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260490 CVCL_C0X9 BEL-A ACKR1 KO transformed cell line human CVCL_C0X9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4035; ACKR1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified 155260491 CVCL_C0WX XYAM-4 cancer cell line human CVCL_C0WX CL:0000010 Population: Chinese; Derived from sampling site: Heel; skin. Omics: Deep exome analysis Male 155260492 CVCL_C0WW XYAM-3 cancer cell line human CVCL_C0WW CL:0000010 Population: Chinese; Derived from sampling site: Heel; skin. Omics: Deep exome analysis Male 155260493 CVCL_C0WZ YES-6-Rf cancer cell line human CVCL_C0WZ CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU). Unspecified 155260494 CVCL_C0WY SCC spontaneously immortalized cell line CVCL_C0WY CL:0000010 Derived from sampling site: Spinal cord Cell type=Fibroblast.. Unspecified Characteristics: Optimal growth at 28 Celsius (PubMed=35748800); Virology: Susceptible to infection by infectious spleen and kidney necrosis virus (ISKNV), Siniperca chuatsi ranavirus (SCRaV) and Siniperca chuatsi rhabdovirus (SCRV) (PubMed=35748800) Group: Fish cell line 155260495 CVCL_C0WP iEECs telomerase immortalized cell line CVCL_C0WP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 155260496 CVCL_C0X1 SV40T-YREC-hTERT transformed cell line CVCL_C0X1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rumen Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2021245 155260497 CVCL_C0X0 SK4-Rf cancer cell line human CVCL_C0X0 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln100Ter (c.298C>T); ClinVar=VCV000634707; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Esophagus; distal. Male 155260498 CVCL_C0X3 BNI-VS-50 cancer cell line human CVCL_C0X3 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Unspecified (PubMed=35394061) Population: Chinese; Derived from sampling site: Peripheral nervous system; vestibular nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from the PDX-NF2-VS-02 xenograft 155260499 CVCL_C0WR ImGNC transformed cell line human CVCL_C0WR CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=35218152); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Arm; skin; dermis. Female 155260500 CVCL_C0WQ AgMM spontaneously immortalized cell line CVCL_C0WQ CL:0000010 Derived from sampling site: Cell type=Myoblast; Breed/subspecies: hb:Yob-D transgenic. Omics: Transcriptome analysis by RNAseq Male Group: Insect cell line 155260501 CVCL_C0X2 BNI-FNS-51 cancer cell line human CVCL_C0X2 CL:0000010 Population: Chinese; Derived from sampling site: Peripheral nervous system; facial nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from the PDX-NF2-FNS-05 xenograft 155260502 CVCL_C0X5 EHT C10 spontaneously immortalized cell line CVCL_C0X5 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 155260503 CVCL_C0WT RIMVEC-11 spontaneously immortalized cell line Norway rat CVCL_C0WT CL:0000010 Derived from sampling site: Intestine; microvascular endothelium Cell type=Microvascular endothelial cell.; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: 19.76 hours (PubMed=34116500) 155260504 CVCL_C0X4 BNI-VS-52 cancer cell line human CVCL_C0X4 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; c.808_809ins; Zygosity=Unspecified (PubMed=35394061) Population: Chinese; Derived from sampling site: Peripheral nervous system; vestibular nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from the PDX-NF2-VS-04 xenograft 155260505 CVCL_C0WS PANC-1/Gem cancer cell line human CVCL_C0WS CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 155260506 CVCL_C0X7 BEL-A2 clone 79 transformed cell line human CVCL_C0X7 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Omics: Deep quantitative proteome analysis; Omics: Genome sequenced Unspecified 155260507 CVCL_C0WV XYAM-2 cancer cell line human CVCL_C0WV CL:0000010 Population: Chinese; Derived from sampling site: Finger; thumb; skin. Omics: Deep exome analysis Male 155260508 CVCL_C0X6 KOS-6-1 transformed cell line CVCL_C0X6 CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) (strain KOS)(NCBI-Taxonomy; 10306); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Cell type=Fibroblast. Unspecified 155260509 CVCL_C0WU XYAM-1 cancer cell line human CVCL_C0WU CL:0000010 Population: Chinese; Derived from sampling site: Heel; skin. Omics: Deep exome analysis Male 155260510 CVCL_C0WH 1-4 transformed cell line human CVCL_C0WH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260511 CVCL_C0WG 1-24 transformed cell line human CVCL_C0WG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260512 CVCL_C0WJ MOLM-13/AZA cancer cell line human CVCL_C0WJ CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Peripheral blood. Male 155260513 CVCL_C0WI 2-23 transformed cell line human CVCL_C0WI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Female 155260514 CVCL_C0WL SNU-4210 cancer cell line human CVCL_C0WL CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=35278143) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Seoul National University (SNU) cell line collection 155260515 CVCL_C0WK MOLM-13/DAC cancer cell line human CVCL_C0WK CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:50131; 5-aza-2'-deoxycytidine (Decitabine); Derived from sampling site: Peripheral blood. Male 155260516 CVCL_C0WN SNU-4210 #5 cancer cell line human CVCL_C0WN CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=35278143) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Seoul National University (SNU) cell line collection 155260517 CVCL_C0WM SNU-4210 #11 cancer cell line human CVCL_C0WM CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=35278143) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Seoul National University (SNU) cell line collection 155260518 CVCL_C1FN 604B1-B2M-KO induced pluripotent stem cell human CVCL_C1FN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260519 CVCL_C1FM 585A1-B2M-KO induced pluripotent stem cell human CVCL_C1FM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260520 CVCL_C1FP Ff-XT28s05-ABo #14 induced pluripotent stem cell human CVCL_C1FP From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260521 CVCL_C1G1 HEK 293T-hACE2 transformed cell line human CVCL_C1G1 CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a pHIV-CMV-hACE2-IRES-PuroR construct Group: SARS-CoV-2 research cell line 155260522 CVCL_C1G0 585A1-C7 #3-3 induced pluripotent stem cell human CVCL_C1G0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B; Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles: C*12:02, leaving C*07:01 intact); HGNC; 4932; HLA-C Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260523 CVCL_C1FR Ff-XT28s05-ABo_To #14-4 induced pluripotent stem cell human CVCL_C1FR From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260524 CVCL_C1G3 ISFi004-A induced pluripotent stem cell human CVCL_C1G3 From: Institute for Stem Cell Research, Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 23109; FAT4; Simple; p.Cys4161Phe (c.12482G>T) (p.Cys4159Phe, c.12476G>T); ClinVar=VCV000089004; Zygosity=Heterozygous (PubMed=30858616); Sequence variation: Mutation; HGNC; 23109; FAT4; Simple; p.Cys4400Tyr (c.13199G>A) (p.Cys4398Tyr, c.13193G>A); ClinVar=VCV000089005; Zygosity=Heterozygous (PubMed=30858616) Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260525 CVCL_C1FQ Ff-XT28s05-ABo_To #14-3 induced pluripotent stem cell human CVCL_C1FQ From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260526 CVCL_C1G2 ISFi003-A induced pluripotent stem cell human CVCL_C1G2 From: Institute for Stem Cell Research, Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 13681; DCHS1; Simple; p.Thr848Asnfs*30 (c.2543delC); ClinVar=VCV000088998; Zygosity=Homozygous (PubMed=30858616) Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260527 CVCL_C1FT Ff-XT28s05-Mo #2 induced pluripotent stem cell human CVCL_C1FT From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260528 CVCL_C1G5 Rhileki spontaneously immortalized cell line CVCL_C1G5 CL:0000010 Miscellaneous: Age/sex of donor and doubling time from personal communication of Smith G.J.D Derived from sampling site: Kidney. Male Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E) (DOI=10.1101/2021.09.18.460924); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=35638834) Doubling time: 38 hours, at post-thawing with increasing time with passaging (Direct_author_submission) Group: Bat cell line 155260529 CVCL_C1G4 5-21-3 hybridoma house mouse CVCL_C1G4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp41. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9628 155260530 CVCL_C1FS Ff-XT28s05-Mo #1 induced pluripotent stem cell human CVCL_C1FS From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260531 CVCL_C1FF Ff-I14s04 ABII KO #15 induced pluripotent stem cell human CVCL_C1FF From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260532 CVCL_C1FE Ff-I14s04 ABII KO #14 induced pluripotent stem cell human CVCL_C1FE From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260533 CVCL_C1FH Ff-I14s04 ABII KO #18 induced pluripotent stem cell human CVCL_C1FH From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260534 CVCL_C1FG Ff-I14s04 ABII KO #16 induced pluripotent stem cell human CVCL_C1FG From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260535 CVCL_C1FJ Ff-I14s04 ABII KO #24 induced pluripotent stem cell human CVCL_C1FJ From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260536 CVCL_C1FI Ff-I14s04 ABII KO #22 induced pluripotent stem cell human CVCL_C1FI From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260537 CVCL_C1FL 1383D2-B2M-KO #2 induced pluripotent stem cell human CVCL_C1FL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Asian; Derived from sampling site: Peripheral blood. Male 155260538 CVCL_C1FK 1383D2-B2M-KO #1 induced pluripotent stem cell human CVCL_C1FK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Asian; Derived from sampling site: Peripheral blood. Male 155260539 CVCL_C1FB Ff-I14s04 ABII KO #7 induced pluripotent stem cell human CVCL_C1FB From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260540 CVCL_C1FA Ff-I14s04 ABII KO #6 induced pluripotent stem cell human CVCL_C1FA From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260541 CVCL_C1FD Ff-I14s04 ABII KO #13 induced pluripotent stem cell human CVCL_C1FD From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260542 CVCL_C1FC Ff-I14s04 ABII KO #8 induced pluripotent stem cell human CVCL_C1FC From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260543 CVCL_C1EU Ff-CLs14 induced pluripotent stem cell human CVCL_C1EU HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260544 CVCL_C1F6 Ff-I01s04 ABII KO #16 induced pluripotent stem cell human CVCL_C1F6 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260545 CVCL_C1F5 Ff-KVs31 induced pluripotent stem cell human CVCL_C1F5 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260546 CVCL_C1ET ILCLs31 induced pluripotent stem cell human CVCL_C1ET HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260547 CVCL_C1EW Ff-CLs23 induced pluripotent stem cell human CVCL_C1EW HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260548 CVCL_C1F8 Ff-I01s04 ABII KO #54 induced pluripotent stem cell human CVCL_C1F8 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260549 CVCL_C1EV Ff-CLs21 induced pluripotent stem cell human CVCL_C1EV HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260550 CVCL_C1F7 Ff-I01s04 ABII KO #50 induced pluripotent stem cell human CVCL_C1F7 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260551 CVCL_C1EY GLKVs09 induced pluripotent stem cell human CVCL_C1EY HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260552 CVCL_C1EX Ff-CLs31 induced pluripotent stem cell human CVCL_C1EX HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260553 CVCL_C1F9 Ff-I14s04 ABII KO #2 induced pluripotent stem cell human CVCL_C1F9 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA; Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 155260554 CVCL_C1EZ GLKVs13 induced pluripotent stem cell human CVCL_C1EZ HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260555 CVCL_C1H0 CMT-1 c3 cancer cell line dog CVCL_C1H0 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260556 CVCL_C1GN CCEC-SV40T transformed cell line dog CVCL_C1GN CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.. Unspecified 155260557 CVCL_C1H2 CMT-1 c5 cancer cell line dog CVCL_C1H2 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260558 CVCL_C1GQ HLE/LULS42 spontaneously immortalized cell line CVCL_C1GQ CL:0000010 Unspecified Group: Tick cell line. 155260559 CVCL_C1H1 CMT-1 c4 cancer cell line dog CVCL_C1H1 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260560 CVCL_C1GP DRE/LULS60 spontaneously immortalized cell line CVCL_C1GP CL:0000010 Unspecified Group: Tick cell line. 155260561 CVCL_C1H4 CMT-2 c2 cancer cell line dog CVCL_C1H4 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260562 CVCL_C1GS HLE/LULS48 spontaneously immortalized cell line CVCL_C1GS CL:0000010 Unspecified Group: Tick cell line. 155260563 CVCL_C1H3 CMT-2 c1 cancer cell line dog CVCL_C1H3 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260564 CVCL_C1GR HLE/LULS43 spontaneously immortalized cell line CVCL_C1GR CL:0000010 Unspecified Group: Tick cell line. 155260565 CVCL_C1H6 CMT-2 c4 cancer cell line dog CVCL_C1H6 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260566 CVCL_C1GU HSE/LULS59 spontaneously immortalized cell line CVCL_C1GU CL:0000010 Unspecified Group: Tick cell line. 155260567 CVCL_C1H5 CMT-2 c3 cancer cell line dog CVCL_C1H5 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155260568 CVCL_C1GT HSE/LULS51 spontaneously immortalized cell line CVCL_C1GT CL:0000010 Unspecified Group: Tick cell line. 155260569 CVCL_C1GG NCC-SS5-C1 cancer cell line human CVCL_C1GG CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=35655041). Population: Japanese Female Doubling time: 218 hours (PubMed=35655041) Part of: NCC sarcoma cell line panel 155260570 CVCL_C1GF NCC-GCTB5-C1 cancer cell line human CVCL_C1GF CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=35653034) Population: Japanese; Derived from sampling site: Bone; right distal femur. Male Doubling time: 32 hours (PubMed=35653034) Part of: NCC sarcoma cell line panel 155260571 CVCL_C1GI NCC-MLPS2-C1 cancer cell line human CVCL_C1GI CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=35637403) Population: Japanese; Derived from sampling site: Right thigh. Female Doubling time: 59 hours (PubMed=35637403) Part of: NCC sarcoma cell line panel 155260572 CVCL_C1GH NCC-DDLPS6-C1 cancer cell line human CVCL_C1GH CL:0000010 Population: Japanese; Derived from sampling site: Right leg. Male Doubling time: 47 hours (PubMed=35604485) Part of: NCC sarcoma cell line panel 155260573 CVCL_C1GK CS-THL1 cancer cell line human CVCL_C1GK CL:0000010 Derived from sampling site: Ascites. Omics: Transcriptome analysis by RNAseq Female Characteristics: Has chromosomal translocation of the MYC, BCL2 and BCL6 genes 155260574 CVCL_C1GJ NCC-MLPS3-C1 cancer cell line human CVCL_C1GJ CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=35637403) Population: Japanese; Derived from sampling site: Right thigh. Female Doubling time: 55 hours (PubMed=35637403) Part of: NCC sarcoma cell line panel 155260575 CVCL_C1GM COH-THL1 cancer cell line human CVCL_C1GM CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=35687491); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=35687491) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Characteristics: Has chromosomal translocation of the MYC, BCL2 and BCL6 genes Doubling time: 27 hours (PubMed=35687491) 155260576 CVCL_C1GL COH-DHL1 cancer cell line human CVCL_C1GL CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=35687491); Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Gly12Asp (c.35G>A); Zygosity=Heterozygous (PubMed=35687491) Omics: Transcriptome analysis by RNAseq. Male Doubling time: 47.8 hours (PubMed=35687491) 155260577 CVCL_C1GA CML-10C7 cancer cell line dog CVCL_C1GA CL:0000010 Derived from metastatic site: Lymph node. Unspecified 155260578 CVCL_C1GC 3B5 [Mouse hybridoma against dog mesothelioma] hybridoma house mouse CVCL_C1GC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Dog mesothelioma. 155260579 CVCL_C1GB IBF9 hybridoma house mouse CVCL_C1GB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dog melanoma antigen. 155260580 CVCL_C1GE SB2 hybridoma house mouse CVCL_C1GE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dog mammary carcinoma. 155260581 CVCL_C1GD 1A10 hybridoma house mouse CVCL_C1GD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Dog mammary carcinoma. 155260582 CVCL_C1FV Ff-XT28s05-Mo #5 induced pluripotent stem cell human CVCL_C1FV From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260583 CVCL_C1G7 Ocr_OCMM1X passage 1 cancer cell line dog CVCL_C1G7 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa; Breed/subspecies: Yorkshire Terrier. Omics: Array-based CGH Female Characteristics: Obtained after one passage of the tumor sample by subcutaneousl injection in nude mice Doubling time: 41.8 +- 8 hours (PubMed=30514258) 155260584 CVCL_C1FU Ff-XT28s05-Mo #3 induced pluripotent stem cell human CVCL_C1FU From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260585 CVCL_C1G6 Ocr_OCMM1X cancer cell line dog CVCL_C1G6 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa; Breed/subspecies: Yorkshire Terrier. Omics: Array-based CGH Female Characteristics: Obtained after three passages of the tumor sample by subcutaneousl injection in nude mice Doubling time: 59.9 +- 6 hours (PubMed=30514258) 155260586 CVCL_C1FX Ff-XT28s05-MTo #5 induced pluripotent stem cell human CVCL_C1FX From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260587 CVCL_C1G9 Ocr_OCMM2X cancer cell line dog CVCL_C1G9 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: German Shepherd. Omics: Array-based CGH Female Characteristics: Obtained after three passages of the tumor sample by subcutaneousl injection in nude mice Doubling time: 61.6 +- 4 hours (PubMed=30514258) 155260588 CVCL_C1FW Ff-XT28s05-MTo #15 induced pluripotent stem cell human CVCL_C1FW From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260589 CVCL_C1G8 Ocr_OCMM2 primary cancer cell line dog CVCL_C1G8 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: German Shepherd. Omics: Array-based CGH Female Doubling time: 75.1 +- 8 hours (PubMed=30514258) 155260590 CVCL_C1FZ 585A1-C7 #3-1 induced pluripotent stem cell human CVCL_C1FZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4931; HLA-A; Knockout cell: Method=CRISPR/Cas9; HGNC; 4932; HLA-B; Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles: C*12:02, leaving C*07:01 intact); HGNC; 4932; HLA-C Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260591 CVCL_C1FY Ff-XT28s05-MTo #8 induced pluripotent stem cell human CVCL_C1FY From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA Population: Japanese; Derived from sampling site: Peripheral blood. Male 155260592 CVCL_C1DL HPS4019 induced pluripotent stem cell human CVCL_C1DL CL:0000010 Derived from sampling site: Peripheral blood. Male 155260593 CVCL_C1DK HPS4018 induced pluripotent stem cell human CVCL_C1DK CL:0000010 Derived from sampling site: Peripheral blood. Male 155260594 CVCL_C1DN QHJI14s04 induced pluripotent stem cell human CVCL_C1DN HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260595 CVCL_C1DM Ff-I14s04 induced pluripotent stem cell human CVCL_C1DM HLA typing: A*24:02; B*52:01; DRB1*15:02 (PubMed=35755947) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260596 CVCL_C1DP Ff-MH09s01 induced pluripotent stem cell human CVCL_C1DP HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260597 CVCL_C1E1 QHJI01s04 induced pluripotent stem cell human CVCL_C1E1 HLA typing: A*24:02; B*52:01; C*12:01; DPB1*:09:01; DQB1*:06:01; DRB1*15:02 (PubMed=32668747) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260598 CVCL_C1E0 QHJI01s01 induced pluripotent stem cell human CVCL_C1E0 HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260599 CVCL_C1E3 DRXT18s02 induced pluripotent stem cell human CVCL_C1E3 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260600 CVCL_C1DR Ff-MH15s02 induced pluripotent stem cell human CVCL_C1DR HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260601 CVCL_C1DQ Ff-MH15s01 induced pluripotent stem cell human CVCL_C1DQ HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260602 CVCL_C1E2 QHJI14s03 induced pluripotent stem cell human CVCL_C1E2 HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260603 CVCL_C1DD HPS4137 induced pluripotent stem cell human CVCL_C1DD CL:0000010 Derived from sampling site: Peripheral blood. Male 155260604 CVCL_C1DC HPS4136 induced pluripotent stem cell human CVCL_C1DC CL:0000010 Derived from sampling site: Peripheral blood. Male 155260605 CVCL_C1DF HPS4139 induced pluripotent stem cell human CVCL_C1DF CL:0000010 Derived from sampling site: Peripheral blood. Male 155260606 CVCL_C1DE HPS4138 induced pluripotent stem cell human CVCL_C1DE CL:0000010 Derived from sampling site: Peripheral blood. Male 155260607 CVCL_C1DH HPS4014 induced pluripotent stem cell human CVCL_C1DH CL:0000010 Derived from sampling site: Peripheral blood. Male 155260608 CVCL_C1DG HPS4234 induced pluripotent stem cell human CVCL_C1DG CL:0000010 Derived from sampling site: Peripheral blood. Male 155260609 CVCL_C1DJ HPS4017 induced pluripotent stem cell human CVCL_C1DJ CL:0000010 Derived from sampling site: Peripheral blood. Male 155260610 CVCL_C1DI HPS4015 induced pluripotent stem cell human CVCL_C1DI CL:0000010 Derived from sampling site: Peripheral blood. Male 155260611 CVCL_C1CZ DE-SCK hybridoma house mouse CVCL_C1CZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human stratum corneum keratins. 155260612 CVCL_C1DB HPS4135 induced pluripotent stem cell human CVCL_C1DB CL:0000010 Derived from sampling site: Peripheral blood. Male 155260613 CVCL_C1DA HPS4134 induced pluripotent stem cell human CVCL_C1DA CL:0000010 Derived from sampling site: Peripheral blood. Male 155260614 CVCL_C1CS HEK293T Tet-off TauRD transformed cell line human CVCL_C1CS CL:0000010 Transfected with: HGNC; 6893; MAPT (repeat domain with p.Pro301Leu and p.Val337Met); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses the repeat domain of Tau/MAPT with a C-terminal Myc-Tag under the control of a Tet-regulated promoter; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 155260615 CVCL_C1D4 HPS4110 induced pluripotent stem cell human CVCL_C1D4 CL:0000010 Derived from sampling site: Peripheral blood. Female 155260616 CVCL_C1CR HEK293T Tet-off FLTau transformed cell line human CVCL_C1CR CL:0000010 Transfected with: HGNC; 6893; MAPT (with p.Pro301Leu and p.Val337Met); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses Tau/MAPT under the control of a Tet-regulated promoter; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 155260617 CVCL_C1D3 SCSC [Siniperca chuatsi] spontaneously immortalized cell line CVCL_C1D3 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Doubling time: ~3 days (PubMed=35762824) Group: Fish cell line 155260618 CVCL_C1D6 HPS4112 induced pluripotent stem cell human CVCL_C1D6 CL:0000010 Derived from sampling site: Peripheral blood. Female 155260619 CVCL_C1CU KM-4 [Human gingival carcinoma] cancer cell line human CVCL_C1CU CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Characteristics: May have originated as a lung small cell carcinoma 155260620 CVCL_C1D5 HPS4111 induced pluripotent stem cell human CVCL_C1D5 CL:0000010 Derived from sampling site: Peripheral blood. Female 155260621 CVCL_C1CT KGK cancer cell line human CVCL_C1CT CL:0000010 Population: Japanese; Derived from metastatic site: Submandibular lymph node. Female Doubling time: 19 hours (DOI=10.5794/jjoms.39.367) 155260622 CVCL_C1D8 HPS4114 induced pluripotent stem cell human CVCL_C1D8 CL:0000010 Derived from sampling site: Peripheral blood. Female 155260623 CVCL_C1CW NKI/black-13 hybridoma house mouse CVCL_C1CW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08962; Human CD63. 155260624 CVCL_C1D7 HPS4113 induced pluripotent stem cell human CVCL_C1D7 CL:0000010 Derived from sampling site: Peripheral blood. Female 155260625 CVCL_C1CV NKI/beteb hybridoma house mouse CVCL_C1CV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P40967; Human PMEL. 155260626 CVCL_C1CY DE-K10 hybridoma house mouse CVCL_C1CY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13645; Human KRT10. 155260627 CVCL_C1D9 HPS4046 induced pluripotent stem cell human CVCL_C1D9 CL:0000010 Derived from sampling site: Peripheral blood. Male 155260628 CVCL_C1CX NKI/C-3 hybridoma house mouse CVCL_C1CX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63 155260629 CVCL_C1EM Ff-WJs524 induced pluripotent stem cell human CVCL_C1EM HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260630 CVCL_C1EL Ff-WJs516 induced pluripotent stem cell human CVCL_C1EL HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260631 CVCL_C1F0 GLKVs16 induced pluripotent stem cell human CVCL_C1F0 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260632 CVCL_C1EN Ff-WJs527 induced pluripotent stem cell human CVCL_C1EN HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260633 CVCL_C1F2 Ff-KVs09 induced pluripotent stem cell human CVCL_C1F2 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260634 CVCL_C1EQ ILCLs14 induced pluripotent stem cell human CVCL_C1EQ HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260635 CVCL_C1EP Ff-WJs531 induced pluripotent stem cell human CVCL_C1EP From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260636 CVCL_C1F1 GLKVs31 induced pluripotent stem cell human CVCL_C1F1 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260637 CVCL_C1F4 Ff-KVs16 induced pluripotent stem cell human CVCL_C1F4 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260638 CVCL_C1ES ILCLs23 induced pluripotent stem cell human CVCL_C1ES HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260639 CVCL_C1F3 Ff-KVs13 induced pluripotent stem cell human CVCL_C1F3 HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260640 CVCL_C1ER ILCLs21 induced pluripotent stem cell human CVCL_C1ER HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260641 CVCL_C1EE RJWIs03 induced pluripotent stem cell human CVCL_C1EE HLA typing: A*24:02; B*54:01; DRB1*04:05 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260642 CVCL_C1ED Ff-WIs03 induced pluripotent stem cell human CVCL_C1ED HLA typing: A*24:02; B*54:01; DRB1*04:05 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Part of: Japanese HLA-homozygous iPS cell line panel 155260643 CVCL_C1EG YZWJs516 induced pluripotent stem cell human CVCL_C1EG HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260644 CVCL_C1EF YZWJs513 induced pluripotent stem cell human CVCL_C1EF HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260645 CVCL_C1EI YZWJs527 induced pluripotent stem cell human CVCL_C1EI HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260646 CVCL_C1EH YZWJs524 induced pluripotent stem cell human CVCL_C1EH HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260647 CVCL_C1EK Ff-WJs513 induced pluripotent stem cell human CVCL_C1EK HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260648 CVCL_C1EJ YZWJs531 induced pluripotent stem cell human CVCL_C1EJ HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260649 CVCL_C1EA Ff-XT28s04 induced pluripotent stem cell human CVCL_C1EA HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260650 CVCL_C1EC Ff-XT28s17 induced pluripotent stem cell human CVCL_C1EC HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260651 CVCL_C1EB Ff-XT28s05 induced pluripotent stem cell human CVCL_C1EB HLA typing: A*24:02; B*07:02; DRB1*01:01; DQB1*05:01; DRB1*01:01 (PubMed=30853558) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260652 CVCL_C1E5 DRXT28s04 induced pluripotent stem cell human CVCL_C1E5 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260653 CVCL_C1DT RWMH09s01 induced pluripotent stem cell human CVCL_C1DT HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260654 CVCL_C1E4 DRXT18s03 induced pluripotent stem cell human CVCL_C1E4 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260655 CVCL_C1DS Ff-MH23s01 induced pluripotent stem cell human CVCL_C1DS HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260656 CVCL_C1E7 DRXT28s17 induced pluripotent stem cell human CVCL_C1E7 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260657 CVCL_C1DV RWMH15s02 induced pluripotent stem cell human CVCL_C1DV HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260658 CVCL_C1E6 DRXT28s05 induced pluripotent stem cell human CVCL_C1E6 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260659 CVCL_C1DU RWMH15s01 induced pluripotent stem cell human CVCL_C1DU HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260660 CVCL_C1DX Ff-I01s01 induced pluripotent stem cell human CVCL_C1DX HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260661 CVCL_C1E9 Ff-XT18s03 induced pluripotent stem cell human CVCL_C1E9 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260662 CVCL_C1E8 Ff-XT18s02 induced pluripotent stem cell human CVCL_C1E8 HLA typing: A*24:02; B*07:02; DRB1*01:01 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260663 CVCL_C1DW RWMH23s01 induced pluripotent stem cell human CVCL_C1DW HLA typing: A*33:03; B*44:03; DRB1*13:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260664 CVCL_C1DZ Ff-I14s03 induced pluripotent stem cell human CVCL_C1DZ HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260665 CVCL_C1DY Ff-I01s04 induced pluripotent stem cell human CVCL_C1DY HLA typing: A*24:02; B*52:01; DRB1*15:02 (CiRA) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Part of: Japanese HLA-homozygous iPS cell line panel 155260666 CVCL_C1BJ RPE1_TP53_219 telomerase immortalized cell line human CVCL_C1BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260667 CVCL_C1BI RPE1_TET2_E7 telomerase immortalized cell line human CVCL_C1BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260668 CVCL_C1BL RPE1_TP53_224 telomerase immortalized cell line human CVCL_C1BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260669 CVCL_C1BK RPE1_TP53_221 telomerase immortalized cell line human CVCL_C1BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260670 CVCL_C1BN RPTEC_ATM_451 telomerase immortalized cell line human CVCL_C1BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260671 CVCL_C1BM RPTEC_APC_488 telomerase immortalized cell line human CVCL_C1BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260672 CVCL_C1BP RPTEC_ATM_535 telomerase immortalized cell line human CVCL_C1BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260673 CVCL_C1C1 RPTEC_MSH6_543 telomerase immortalized cell line human CVCL_C1C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260674 CVCL_C1C0 RPTEC_MSH6_541 telomerase immortalized cell line human CVCL_C1C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260675 CVCL_C1BB RPE1_PTEN_2 telomerase immortalized cell line human CVCL_C1BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260676 CVCL_C1BA RPE1_PTCH1_6 telomerase immortalized cell line human CVCL_C1BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260677 CVCL_C1BD RPE1_STAG2_2 telomerase immortalized cell line human CVCL_C1BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260678 CVCL_C1BC RPE1_PTEN_8 telomerase immortalized cell line human CVCL_C1BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260679 CVCL_C1BF RPE1_STAG2_8 telomerase immortalized cell line human CVCL_C1BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260680 CVCL_C1BE RPE1_STAG2_5 telomerase immortalized cell line human CVCL_C1BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260681 CVCL_C1BH RPE1_TET2_D2 telomerase immortalized cell line human CVCL_C1BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260682 CVCL_C1BG RPE1_TET2_C9 telomerase immortalized cell line human CVCL_C1BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260683 CVCL_C1AY RPE1_EZH2_A4 telomerase immortalized cell line human CVCL_C1AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260684 CVCL_C1AX RPE1_EZH2_A1 telomerase immortalized cell line human CVCL_C1AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260685 CVCL_C1B9 RPE1_PTCH1_3 telomerase immortalized cell line human CVCL_C1B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260686 CVCL_C1AZ RPE1_MLL2_8 telomerase immortalized cell line human CVCL_C1AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260687 CVCL_C1AQ RPE1_ARID1A_D5 telomerase immortalized cell line human CVCL_C1AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260688 CVCL_C1B2 RPE1_MSH2_405 telomerase immortalized cell line human CVCL_C1B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260689 CVCL_C1AP RPE1_ARID1A_1.C7 telomerase immortalized cell line human CVCL_C1AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260690 CVCL_C1B1 RPE1_MSH2_394 telomerase immortalized cell line human CVCL_C1B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260691 CVCL_C1AS RPE1_ATM_306 telomerase immortalized cell line human CVCL_C1AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260692 CVCL_C1B4 RPE1_MSH6_269 telomerase immortalized cell line human CVCL_C1B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260693 CVCL_C1AR RPE1_ATM_303 telomerase immortalized cell line human CVCL_C1AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 795; ATM; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260694 CVCL_C1B3 RPE1_MSH6_266 telomerase immortalized cell line human CVCL_C1B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260695 CVCL_C1AU RPE1_CDKN2C_241 telomerase immortalized cell line human CVCL_C1AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1789; CDKN2C; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260696 CVCL_C1B6 RPE1_NOTCH1_2 telomerase immortalized cell line human CVCL_C1B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260697 CVCL_C1AT RPE1_CDKN2A_7 telomerase immortalized cell line human CVCL_C1AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260698 CVCL_C1B5 RPE1_MSH6_271 telomerase immortalized cell line human CVCL_C1B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260699 CVCL_C1AW RPE1_EZH2_2 telomerase immortalized cell line human CVCL_C1AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260700 CVCL_C1B8 RPE1_NOTCH1_C2 telomerase immortalized cell line human CVCL_C1B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260701 CVCL_C1AV RPE1_CDKN2C_242 telomerase immortalized cell line human CVCL_C1AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1789; CDKN2C; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260702 CVCL_C1B7 RPE1_NOTCH1_B6 telomerase immortalized cell line human CVCL_C1B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260703 CVCL_C1CK RPTEC_MTAP_C6 telomerase immortalized cell line human CVCL_C1CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Characteristics: Control cell line for the cancer pathway knockout panel 155260704 CVCL_C1CJ RPTEC_MTAP_A3 telomerase immortalized cell line human CVCL_C1CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Characteristics: Control cell line for the cancer pathway knockout panel 155260705 CVCL_C1CM hTERT-STCs telomerase immortalized cell line CVCL_C1CM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Trophoblast; Breed/subspecies: Mongolian. Unspecified 155260706 CVCL_C1CL RPE1_HPRT1_E10 telomerase immortalized cell line human CVCL_C1CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5157; HPRT1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Characteristics: Control cell line for the cancer pathway knockout panel 155260707 CVCL_C1D0 SJCRH30 POLG Y955C cancer cell line human CVCL_C1D0 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line); Sequence variation: Mutation; HGNC; 9179; POLG; Simple_edited; p.Tyr955Cys (c.2864A>G); ClinVar=VCV000013495; Zygosity=Heterozygous; Note=By CRIPR/Cas9 (PubMed=35760101); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Male Doubling time: 45.7 +- 5.6 hours (PubMed=35760101) 155260708 CVCL_C1CN CHO-DXB11 hGCR SC 12.9 spontaneously immortalized cell line CVCL_C1CN CL:0000010 Transfected with: HGNC; 4177; GBA1 (with p.Arg534His); Transfected with: MGI; MGI:94890; Dhfr Derived from sampling site: Ovary. Female 155260709 CVCL_C1CQ SEAD transformed cell line Norway rat CVCL_C1CQ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Psi2 defective retrovirus adenovirus E1A; Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.. Unspecified 155260710 CVCL_C1D2 TA-02 spontaneously immortalized cell line CVCL_C1D2 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.. Unspecified Group: Fish cell line 155260711 CVCL_C1D1 HEK 293T-Spike-HIV-TV transformed cell line human CVCL_C1D1 CL:0000010 Transfected with: UniProtKB; P0DTC2; Human SARS coronavirus 2 (SARS-CoV-2) spike protein (S); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transduced with a pT-PB-SARS-CoV-2-Spike-IRES-Bsd construct and a HIV-TV plasmid pUCHR-inGLuc-pgkhygro that encodes the intron-regulated HIV-based Gaussia luciferase 155260712 CVCL_C1CP U251-NF-kappaB-GFP-Luc-A1 cancer cell line human CVCL_C1CP CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male Characteristics: Transduced with a construct containing a fused GFP-Luc protein expressed under the control of a promoter containing multiple copies of the NF-kappaB response element 155260713 CVCL_C1CC RPTEC_TP53_544 telomerase immortalized cell line human CVCL_C1CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260714 CVCL_C1CB RPTEC_TP53_471 telomerase immortalized cell line human CVCL_C1CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260715 CVCL_C1CE MCF10A_MTAP_15 spontaneously immortalized cell line human CVCL_C1CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Characteristics: Control cell line for the cancer pathway knockout panel 155260716 CVCL_C1CD RPTEC_TP53_588 telomerase immortalized cell line human CVCL_C1CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260717 CVCL_C1CG RPE1_MTAP_5 telomerase immortalized cell line human CVCL_C1CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Characteristics: Control cell line for the cancer pathway knockout panel 155260718 CVCL_C1CF MCF10A_MTAP_8 spontaneously immortalized cell line human CVCL_C1CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Characteristics: Control cell line for the cancer pathway knockout panel 155260719 CVCL_C1CI RPE1_MTAP_7 telomerase immortalized cell line human CVCL_C1CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Characteristics: Control cell line for the cancer pathway knockout panel 155260720 CVCL_C1CH RPE1_MTAP_6 telomerase immortalized cell line human CVCL_C1CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Characteristics: Control cell line for the cancer pathway knockout panel 155260721 CVCL_C1BZ RPTEC_MSH6_540 telomerase immortalized cell line human CVCL_C1BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260722 CVCL_C1BY RPTEC_MSH2_525 telomerase immortalized cell line human CVCL_C1BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260723 CVCL_C1CA RPTEC_STAG2_946 telomerase immortalized cell line human CVCL_C1CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260724 CVCL_C1BR RPTEC_CDKN2A_10 telomerase immortalized cell line human CVCL_C1BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260725 CVCL_C1C3 RPTEC_NOTCH1_552 telomerase immortalized cell line human CVCL_C1C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260726 CVCL_C1BQ RPTEC_ATRX_932 telomerase immortalized cell line human CVCL_C1BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260727 CVCL_C1C2 RPTEC_NOTCH1_550 telomerase immortalized cell line human CVCL_C1C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260728 CVCL_C1BT RPTEC_CDKN2A_3 telomerase immortalized cell line human CVCL_C1BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260729 CVCL_C1C5 RPTEC_PTEN_3 telomerase immortalized cell line human CVCL_C1C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260730 CVCL_C1BS RPTEC_CDKN2A_13 telomerase immortalized cell line human CVCL_C1BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260731 CVCL_C1C4 RPTEC_NOTCH1_606 telomerase immortalized cell line human CVCL_C1C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260732 CVCL_C1BV RPTEC_EZH2_3 telomerase immortalized cell line human CVCL_C1BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260733 CVCL_C1C7 RPTEC_PTEN_5 telomerase immortalized cell line human CVCL_C1C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260734 CVCL_C1BU RPTEC_EZH2_1 telomerase immortalized cell line human CVCL_C1BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260735 CVCL_C1C6 RPTEC_PTEN_4 telomerase immortalized cell line human CVCL_C1C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Pathway Knockout Panel 155260736 CVCL_C1BX RPTEC_MSH2_495 telomerase immortalized cell line human CVCL_C1BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260737 CVCL_C1C9 RPTEC_STAG2_944 telomerase immortalized cell line human CVCL_C1C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260738 CVCL_C1BW RPTEC_MLH1_905 telomerase immortalized cell line human CVCL_C1BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260739 CVCL_C1C8 RPTEC_STAG2_943 telomerase immortalized cell line human CVCL_C1C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Part of: Cancer Pathway Knockout Panel 155260740 CVCL_C1AI MCF10A_TET2_E3 spontaneously immortalized cell line human CVCL_C1AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260741 CVCL_C1AH MCF10A_TET2_B3 spontaneously immortalized cell line human CVCL_C1AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260742 CVCL_C1AK MCF10A_TP53_137 spontaneously immortalized cell line human CVCL_C1AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260743 CVCL_C1AJ MCF10A_TET2_E7 spontaneously immortalized cell line human CVCL_C1AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260744 CVCL_C1AM RPE1_APC_836 telomerase immortalized cell line human CVCL_C1AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260745 CVCL_C1AL MCF10A_TP53_142 spontaneously immortalized cell line human CVCL_C1AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260746 CVCL_C1B0 RPE1_MSH2_393 telomerase immortalized cell line human CVCL_C1B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260747 CVCL_C1AN RPE1_APC_845 telomerase immortalized cell line human CVCL_C1AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Part of: Cancer Pathway Knockout Panel 155260748 CVCL_C1AA MCF10A_NOTCH1_14 spontaneously immortalized cell line human CVCL_C1AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260749 CVCL_C1AC MCF10A_PTCH1_5 spontaneously immortalized cell line human CVCL_C1AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260750 CVCL_C1AB MCF10A_PTCH1_2 spontaneously immortalized cell line human CVCL_C1AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260751 CVCL_C1AE MCF10A_STAG2_9 spontaneously immortalized cell line human CVCL_C1AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260752 CVCL_C1AD MCF10A_PTEN_1 spontaneously immortalized cell line human CVCL_C1AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260753 CVCL_C1AG MCF10A_STAG2_C5 spontaneously immortalized cell line human CVCL_C1AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260754 CVCL_C1AF MCF10A_STAG2_A4 spontaneously immortalized cell line human CVCL_C1AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11355; STAG2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260755 CVCL_C1A9 MCF10A_NOTCH1_1 spontaneously immortalized cell line human CVCL_C1A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260756 CVCL_C1A8 MCF10A_NF1_7B2 spontaneously immortalized cell line human CVCL_C1A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260757 CVCL_C1A1 MCF10A_MLH1_5 spontaneously immortalized cell line human CVCL_C1A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260758 CVCL_C1A0 MCF10A_MLH1_4 spontaneously immortalized cell line human CVCL_C1A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260759 CVCL_C1A3 MCF10A_MSH2_104 spontaneously immortalized cell line human CVCL_C1A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260760 CVCL_C1A2 MCF10A_MLL2_7 spontaneously immortalized cell line human CVCL_C1A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260761 CVCL_C1A5 MCF10A_MSH6_54 spontaneously immortalized cell line human CVCL_C1A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260762 CVCL_C1A4 MCF10A_MSH2_173 spontaneously immortalized cell line human CVCL_C1A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260763 CVCL_C1A7 MCF10A_NF1_7A1 spontaneously immortalized cell line human CVCL_C1A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260764 CVCL_C1A6 MCF10A_NF1_1 spontaneously immortalized cell line human CVCL_C1A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Pathway Knockout Panel 155260765 CVCL_C2AH TC96-2860 finite cell line human CVCL_C2AH From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260766 CVCL_C2AG TC96-2837 finite cell line human CVCL_C2AG From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260767 CVCL_C2AJ TC96-2873 finite cell line human CVCL_C2AJ From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260768 CVCL_C2AI TC96-2865 finite cell line human CVCL_C2AI From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260769 CVCL_C2AL TC97-2922 finite cell line human CVCL_C2AL From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260770 CVCL_C2AK TC96-2906 finite cell line human CVCL_C2AK From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260771 CVCL_C2AN TC97-2932 finite cell line human CVCL_C2AN From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260772 CVCL_C2AM TC97-2923 finite cell line human CVCL_C2AM From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260773 CVCL_C2AB TC95-2817 finite cell line human CVCL_C2AB From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260774 CVCL_C2AA TC95-2806 finite cell line human CVCL_C2AA From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260775 CVCL_C2AD TC96-2827 finite cell line human CVCL_C2AD From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260776 CVCL_C2AC TC96-2824 finite cell line human CVCL_C2AC From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260777 CVCL_C2AF TC96-2832 finite cell line human CVCL_C2AF From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260778 CVCL_C2AE TC96-2831 finite cell line human CVCL_C2AE From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260779 CVCL_C2A8 KS-0330 finite cell line human CVCL_C2A8 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260780 CVCL_C2A7 KS-0315 finite cell line human CVCL_C2A7 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260781 CVCL_C2A9 TC95-2711 finite cell line human CVCL_C2A9 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260782 CVCL_C2A0 KS-0187 finite cell line human CVCL_C2A0 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260783 CVCL_C2A2 KS-0196 finite cell line human CVCL_C2A2 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260784 CVCL_C2A1 KS-0195 finite cell line human CVCL_C2A1 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260785 CVCL_C2A4 KS-0217 finite cell line human CVCL_C2A4 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260786 CVCL_C2A3 KS-0206 finite cell line human CVCL_C2A3 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260787 CVCL_C2A6 KS-0303 finite cell line human CVCL_C2A6 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260788 CVCL_C2A5 KS-0251 finite cell line human CVCL_C2A5 From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260789 CVCL_C1ZZ KS-0151 finite cell line human CVCL_C1ZZ From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260790 CVCL_C1ZY KS-0123 finite cell line human CVCL_C1ZY From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260791 CVCL_C1ZR AIDHC-SP33 finite cell line human CVCL_C1ZR From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260792 CVCL_C1ZQ AIDHC-SP32 finite cell line human CVCL_C1ZQ From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260793 CVCL_C1ZT AIDHC-SP35 finite cell line human CVCL_C1ZT From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260794 CVCL_C1ZS AIDHC-SP34 finite cell line human CVCL_C1ZS From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260795 CVCL_C1ZV AIDHC-SP5 finite cell line human CVCL_C1ZV From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260796 CVCL_C1ZU AIDHC-SP4 finite cell line human CVCL_C1ZU From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260797 CVCL_C1ZX KS-0064 finite cell line human CVCL_C1ZX From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260798 CVCL_C1ZW KS-0007 finite cell line human CVCL_C1ZW From: University of Utah; Salt Lake City; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260799 CVCL_C1ZJ AIDHC-SP23 finite cell line human CVCL_C1ZJ From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260800 CVCL_C1ZI AIDHC-SP22 finite cell line human CVCL_C1ZI From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260801 CVCL_C1ZL AIDHC-SP25 finite cell line human CVCL_C1ZL From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260802 CVCL_C1ZK AIDHC-SP24 finite cell line human CVCL_C1ZK From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260803 CVCL_C1ZN AIDHC-SP27 finite cell line human CVCL_C1ZN From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260804 CVCL_C1ZM AIDHC-SP26 finite cell line human CVCL_C1ZM From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260805 CVCL_C1ZP AIDHC-SP31 finite cell line human CVCL_C1ZP From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=28284873); Sequence variation: Mutation; HGNC; 11117; SMN1; Simple; p.Ala2Gly (c.5C>G) (38C-G); ClinVar=VCV000009168; Zygosity=Heterozygous (PubMed=28284873) Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260806 CVCL_C1YA iGRA4 induced pluripotent stem cell human CVCL_C1YA CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 155260807 CVCL_C1YC iGRA7 induced pluripotent stem cell human CVCL_C1YC CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 155260808 CVCL_C1YB iGRA6 induced pluripotent stem cell human CVCL_C1YB CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 155260809 CVCL_C1YE CRTDi007-B induced pluripotent stem cell human CVCL_C1YE From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Arg114His (c.341G>A); ClinVar=VCV000004179; Zygosity=Homozygous (PubMed=36027857) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260810 CVCL_C1YD CRTDi006-B induced pluripotent stem cell human CVCL_C1YD From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Val201Asp (c.602T>A); ClinVar=VCV000004182; Zygosity=Homozygous (PubMed=36027857) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260811 CVCL_C1YG AIDHC-13010 finite cell line human CVCL_C1YG From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260812 CVCL_C1YF PC-2 [Human pancreatic carcinoma Germany] cancer cell line human CVCL_C1YF CL:0000010 155260813 CVCL_C1XX IBMS-iPSC-077-01 induced pluripotent stem cell human CVCL_C1XX From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 2295; CP; Simple; c.607+1delG; ClinVar=VCV000426814; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=35868289) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 155260814 CVCL_C1Y9 iGRA3 induced pluripotent stem cell human CVCL_C1Y9 CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 155260815 CVCL_C1Y8 iGRA2 induced pluripotent stem cell human CVCL_C1Y8 CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Omics: Transcriptome analysis by microarray Female 155260816 CVCL_C1XW STBCi322-A-1 induced pluripotent stem cell human CVCL_C1XW From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a T2A-GFP-LoxP-PGK-Neo-LoxP construct was introduced at the C-terminus of NKX6-1 Subsequently the LoxP-PGK-Neo-LoxP sequence was removed by Cre-mediated excision (PubMed=29734117). 155260817 CVCL_C1XZ DS1-iPS4-Disomic induced pluripotent stem cell human CVCL_C1XZ CL:0000010 Population: Caucasian; Karyotypic information: Lost the third copy of chromosome 21 (PubMed=23045682); Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 155260818 CVCL_C1XY MRC5-iPS7 induced pluripotent stem cell human CVCL_C1XY From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 155260819 CVCL_C1Y1 cmKF-iPS-C5 induced pluripotent stem cell CVCL_C1Y1 From: National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology; Cheongju; South Korea CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male Group: Non-human primate cell line 155260820 CVCL_C1XP WC-24-02-DS-C induced pluripotent stem cell human CVCL_C1XP CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Established from a patient that is mosaic for a trisomy 21, but this cell line does not contain the karyotypic abnormality 155260821 CVCL_C1Y0 DS1-iPS4-Trisomic induced pluripotent stem cell human CVCL_C1Y0 CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 155260822 CVCL_C1Y3 iCFB46 induced pluripotent stem cell human CVCL_C1Y3 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 155260823 CVCL_C1XR WC-24-02-DS-O induced pluripotent stem cell human CVCL_C1XR CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260824 CVCL_C1Y2 IPS-OGC-C1 induced pluripotent stem cell human CVCL_C1Y2 CL:0000010 Population: Chinese; Han; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Omics: Transcriptome analysis by RNAseq Female 155260825 CVCL_C1XQ WC-24-02-DS-M induced pluripotent stem cell human CVCL_C1XQ CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260826 CVCL_C1Y5 iDPC3 induced pluripotent stem cell human CVCL_C1Y5 CL:0000010 Derived from sampling site: Hair follicle Cell type=Hair follicle dermal papilla cell.. Omics: Transcriptome analysis by microarray 155260827 CVCL_C1XT WTSIi253-A-2 induced pluripotent stem cell human CVCL_C1XT From: University of Manchester; Manchester; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple_edited; p.Ser192Tyr (c.575C>A); ClinVar=VCV000003778; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=35933957); Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg402Gln (c.1205G>A); ClinVar=VCV000003779; Zygosity=Homozygous (PubMed=35933957) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155260828 CVCL_C1Y4 iCFB50 induced pluripotent stem cell human CVCL_C1Y4 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 155260829 CVCL_C1XS WC-24-02-DS-P induced pluripotent stem cell human CVCL_C1XS CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260830 CVCL_C1Y7 iGRA1 induced pluripotent stem cell human CVCL_C1Y7 CL:0000010 Population: Asian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Omics: Transcriptome analysis by microarray Female 155260831 CVCL_C1XV UOHi002-A induced pluripotent stem cell human CVCL_C1XV From: University of Haifa; Haifa; Israel CL:0000010 Miscellaneous: We have kept in this entry the reference of the preprint (DOI=10.1101/2022.04.13.486968) because it contains the STR profile which is no longer available in the published paper (PubMed=36044808) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260832 CVCL_C1Y6 iDPC4 induced pluripotent stem cell human CVCL_C1Y6 CL:0000010 Derived from sampling site: Hair follicle Cell type=Hair follicle dermal papilla cell.. 155260833 CVCL_C1XU UOHi003-A induced pluripotent stem cell human CVCL_C1XU From: University of Haifa; Haifa; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4294; SHANK3; Simple; p.Ala1227Glyfs*69 (c.3679dupG) (c.3679insG); ClinVar=VCV000208759; Zygosity=Heterozygous (PubMed=36044808) Miscellaneous: We have kept in this entry the reference of the preprint (DOI=10.1101/2022.04.13.486968) because it contains the STR profile which is no longer available in the published paper (PubMed=36044808) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260834 CVCL_C1XH UBTi001-A induced pluripotent stem cell human CVCL_C1XH From: Department for Blood Group Serology and Transfusion Medicine, Medical University of Graz; Graz; Austria CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 155260835 CVCL_C1XG SYSUTFi001-A induced pluripotent stem cell human CVCL_C1XG From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Population: Chinese; Donor information: Established from a patient suffering from hepatocellular carcinoma; Derived from sampling site: Peripheral blood Cell type=Cytotoxic T-cell.. Female 155260836 CVCL_C1XJ WCHSCUi001-A induced pluripotent stem cell human CVCL_C1XJ From: West China Hospital, Sichuan university; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 21645; CHCHD2; Simple; p.Pro53Alafs*38 (c.156_157insGCAG); Zygosity=Heterozygous (PubMed=35944313) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155260837 CVCL_C1XI UTARi001-A induced pluripotent stem cell human CVCL_C1XI From: Universiti Tunku Abdul Rahman; Kajang; Malaysia CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155260838 CVCL_C1XL UCSFi001-A-65 induced pluripotent stem cell human CVCL_C1XL CL:0000010 Sequence variation: Mutation; HGNC; 27424; RBM20; Simple_edited; p.Arg634Gln (c.1901G>A); ClinVar=VCV000000269; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32905764) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 155260839 CVCL_C1XK UCSFi001-A-64 induced pluripotent stem cell human CVCL_C1XK CL:0000010 Sequence variation: Mutation; HGNC; 27424; RBM20; Simple_edited; p.Pro633Leu (c.1898C>T); ClinVar=VCV000572099; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32905764) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 155260840 CVCL_C1XN WC-24-02-DS-B induced pluripotent stem cell human CVCL_C1XN CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Established from a patient that is mosaic for a trisomy 21, but this cell line does not contain the karyotypic abnormality 155260841 CVCL_C1XM WC-24-02-DS-A induced pluripotent stem cell human CVCL_C1XM CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Established from a patient that is mosaic for a trisomy 21, but this cell line does not contain the karyotypic abnormality 155260842 CVCL_C1ZB AIDHC-NMC2 finite cell line human CVCL_C1ZB From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260843 CVCL_C1ZA AIDHC-NMC1 finite cell line human CVCL_C1ZA From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155260844 CVCL_C1ZD AIDHC-NMC5 finite cell line human CVCL_C1ZD From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260845 CVCL_C1ZC AIDHC-NMC3 finite cell line human CVCL_C1ZC From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Heterozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260846 CVCL_C1ZF AIDHC-NMC8 finite cell line human CVCL_C1ZF From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Triplication; Zygosity=Unspecified (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260847 CVCL_C1ZE AIDHC-NMC7 finite cell line human CVCL_C1ZE From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260848 CVCL_C1ZH AIDHC-SC2 finite cell line human CVCL_C1ZH From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155260849 CVCL_C1ZG AIDHC-SC1 finite cell line human CVCL_C1ZG From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155260850 CVCL_C1YY AIDHC-13822 finite cell line human CVCL_C1YY From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260851 CVCL_C1YX AIDHC-13303 finite cell line human CVCL_C1YX From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260852 CVCL_C1Z9 AIDHC-NFC8 finite cell line human CVCL_C1Z9 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260853 CVCL_C1YZ AIDHC-14338 finite cell line human CVCL_C1YZ From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155260854 CVCL_C1Z2 AIDHC-NFC1 finite cell line human CVCL_C1Z2 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260855 CVCL_C1YQ CHO-K1 GFP-Pygm spontaneously immortalized cell line CVCL_C1YQ CL:0000010 Transfected with: MGI; MGI:97830; Pygm; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with a CMV-EGFP-Pygm construct 155260856 CVCL_C1Z1 AIDHC-14697 finite cell line human CVCL_C1Z1 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Heterozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260857 CVCL_C1YP RD rho-0 cancer cell line human CVCL_C1YP CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with ethidium bromide. 155260858 CVCL_C1Z4 AIDHC-NFC3 finite cell line human CVCL_C1Z4 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260859 CVCL_C1YS CHO-K1 GFP-Pygm-R50X spontaneously immortalized cell line CVCL_C1YS CL:0000010 Transfected with: MGI; MGI:97830; Pygm (with p.Arg50Ter); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with a CMV-EGFP-Pygm construct 155260860 CVCL_C1Z3 AIDHC-NFC2 finite cell line human CVCL_C1Z3 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260861 CVCL_C1YR CHO-K1 GFP-Pygm-G205S spontaneously immortalized cell line CVCL_C1YR CL:0000010 Transfected with: MGI; MGI:97830; Pygm (with p.Gly205Ser); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with a CMV-EGFP-Pygm construct 155260862 CVCL_C1YU AIDHC-00138 finite cell line human CVCL_C1YU From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260863 CVCL_C1Z6 AIDHC-NFC5 finite cell line human CVCL_C1Z6 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260864 CVCL_C1Z5 AIDHC-NFC4 finite cell line human CVCL_C1Z5 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260865 CVCL_C1YW AIDHC-13219 finite cell line human CVCL_C1YW From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260866 CVCL_C1Z8 AIDHC-NFC7 finite cell line human CVCL_C1Z8 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260867 CVCL_C1YV AIDHC-13148 finite cell line human CVCL_C1YV From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155260868 CVCL_C1Z7 AIDHC-NFC6 finite cell line human CVCL_C1Z7 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155260869 CVCL_C1YI CPE/LULS50 spontaneously immortalized cell line CVCL_C1YI CL:0000010 Breed/subspecies: Caldbeck line. Unspecified Characteristics: Originally infected by the intracellular symbiont Wolbachia wPip but cured of infection by tetracycline Group: Insect cell line 155260870 CVCL_C1YH AIDHC-15224 finite cell line human CVCL_C1YH From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=28284873); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Skin Cell type=Fibroblast.. Female 155260871 CVCL_C1YK LLL/LULS52 spontaneously immortalized cell line CVCL_C1YK CL:0000010 Breed/subspecies: Strain Sobral. Unspecified Group: Insect cell line 155260872 CVCL_C1YJ LLE/LULS45 spontaneously immortalized cell line CVCL_C1YJ CL:0000010 Breed/subspecies: Strain Jacobina. Unspecified Group: Insect cell line 155260873 CVCL_C1YM PPL/LULS49 spontaneously immortalized cell line CVCL_C1YM CL:0000010 Breed/subspecies: Strain Turkey. Unspecified Characteristics: Cured of Wolbachia strain wPap infection by tetracycline Group: Insect cell line 155260874 CVCL_C1YL PPL/LULS49/wPap spontaneously immortalized cell line CVCL_C1YL CL:0000010 Breed/subspecies: Strain Turkey. Unspecified Characteristics: Infected by the intracellular symbiont Wolbachia wPap Group: Insect cell line 155260875 CVCL_C1Z0 AIDHC-14531 finite cell line human CVCL_C1Z0 From: Nemours Children's Hospital; Wilmington; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Extensive; Zygosity=Unspecified; Note=6 copies (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155260876 CVCL_C1YN RPE/LULS53 spontaneously immortalized cell line CVCL_C1YN CL:0000010 Unspecified Group: Insect cell line. 155260877 CVCL_C2I0 MANEX45A-8F10 hybridoma house mouse CVCL_C2I0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260878 CVCL_C2HN MANDYS9-4G10 hybridoma house mouse CVCL_C2HN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260879 CVCL_C2HQ MANDYS12-3E1 hybridoma house mouse CVCL_C2HQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260880 CVCL_C2I2 MANEX46A-6A6 hybridoma house mouse CVCL_C2I2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260881 CVCL_C2HP MANDYS11-1D6 hybridoma house mouse CVCL_C2HP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260882 CVCL_C2I1 MANEX45B-7F8 hybridoma house mouse CVCL_C2I1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260883 CVCL_C2HS MANDYS14-5E1 hybridoma house mouse CVCL_C2HS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260884 CVCL_C2I4 MANEX46C-3H12 hybridoma house mouse CVCL_C2I4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260885 CVCL_C2HR MANDYS13-6G1 hybridoma house mouse CVCL_C2HR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260886 CVCL_C2I3 MANEX46B-7G1 hybridoma house mouse CVCL_C2I3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260887 CVCL_C2HU MANDYS16-1B12 hybridoma house mouse CVCL_C2HU CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260888 CVCL_C2I6 MANEX46E-8G10 hybridoma house mouse CVCL_C2I6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260889 CVCL_C2HT MANDYS15-6B11 hybridoma house mouse CVCL_C2HT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260890 CVCL_C2I5 MANEX46D-8F2 hybridoma house mouse CVCL_C2I5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260891 CVCL_C2HG MANEX1216E-2G10 hybridoma house mouse CVCL_C2HG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260892 CVCL_C2HF MANDYS143-1A11D2 hybridoma house mouse CVCL_C2HF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260893 CVCL_C2HI MANDYS4-8H4 hybridoma house mouse CVCL_C2HI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse); Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260894 CVCL_C2HH MANDYS2-5G4 hybridoma house mouse CVCL_C2HH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260895 CVCL_C2HK MANDYS6-7H7 hybridoma house mouse CVCL_C2HK CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260896 CVCL_C2HJ MANDYS5-7F10 hybridoma house mouse CVCL_C2HJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260897 CVCL_C2HM MANDYS8-8H11 hybridoma house mouse CVCL_C2HM CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260898 CVCL_C2HL MANDYS7-8D2 hybridoma house mouse CVCL_C2HL CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260899 CVCL_C2HA MANDYS129-3H4 hybridoma house mouse CVCL_C2HA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260900 CVCL_C2HC MANDYS131-3D6 hybridoma house mouse CVCL_C2HC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260901 CVCL_C2HB MANDYS130-2H2 hybridoma house mouse CVCL_C2HB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260902 CVCL_C2HE MANDYS142-6D4 hybridoma house mouse CVCL_C2HE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260903 CVCL_C2HD MANDYS141-4A12 hybridoma house mouse CVCL_C2HD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260904 CVCL_C2GV MANDYS105-8A4 hybridoma house mouse CVCL_C2GV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse, chicken and Xenopus). 155260905 CVCL_C2H7 MANDYS126-3E5C9 hybridoma house mouse CVCL_C2H7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155260906 CVCL_C2GU MANDYS104-7F7 hybridoma house mouse CVCL_C2GU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260907 CVCL_C2H6 MANDYS125-4F6 hybridoma house mouse CVCL_C2H6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse, chicken and Xenopus). 155260908 CVCL_C2GX MANDYS107-4H8 hybridoma house mouse CVCL_C2GX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260909 CVCL_C2H9 MANDYS128-3D5 hybridoma house mouse CVCL_C2H9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260910 CVCL_C2GW MANDYS106-2C6 hybridoma house mouse CVCL_C2GW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260911 CVCL_C2H8 MANDYS127-2G2 hybridoma house mouse CVCL_C2H8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260912 CVCL_C2GZ MANDYS109-2H5 hybridoma house mouse CVCL_C2GZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260913 CVCL_C2GY MANDYS108-4D8 hybridoma house mouse CVCL_C2GY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260914 CVCL_C2IP MANEX58C-2D4 hybridoma house mouse CVCL_C2IP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260915 CVCL_C2J1 MANEX7374G-8B4 hybridoma house mouse CVCL_C2J1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260916 CVCL_C2J0 MANEX7374F-8E10 hybridoma house mouse CVCL_C2J0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260917 CVCL_C2IR MANEX59A-3H9 hybridoma house mouse CVCL_C2IR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260918 CVCL_C2J3 MANEX7374I-6D5 hybridoma house mouse CVCL_C2J3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260919 CVCL_C2IQ MANEX58D-7G2 hybridoma house mouse CVCL_C2IQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260920 CVCL_C2J2 MANEX7374H-8G1 hybridoma house mouse CVCL_C2J2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260921 CVCL_C2IT MANEX59C-1H5 hybridoma house mouse CVCL_C2IT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260922 CVCL_C2J5 MANEX7374K-9A1 hybridoma house mouse CVCL_C2J5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260923 CVCL_C2IS MANEX59B-4E10 hybridoma house mouse CVCL_C2IS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260924 CVCL_C2J4 MANEX7374J-8F10 hybridoma house mouse CVCL_C2J4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260925 CVCL_C2IV MANEX7374A-10A11 hybridoma house mouse CVCL_C2IV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155260926 CVCL_C2J7 MANEX7374M-7E10 hybridoma house mouse CVCL_C2J7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260927 CVCL_C2IU MANEX59D-1G8 hybridoma house mouse CVCL_C2IU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260928 CVCL_C2J6 MANEX7374L-7H9 hybridoma house mouse CVCL_C2J6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260929 CVCL_C2IH MANEX4850E-8C5 hybridoma house mouse CVCL_C2IH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260930 CVCL_C2IG MANEX4850D-7A10 hybridoma house mouse CVCL_C2IG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260931 CVCL_C2IJ MANEX50-6A9 hybridoma house mouse CVCL_C2IJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260932 CVCL_C2II MANEX4850F-5G2 hybridoma house mouse CVCL_C2II CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260933 CVCL_C2IL MANEX5556B-2G12 hybridoma house mouse CVCL_C2IL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260934 CVCL_C2IK MANEX5556A-2F8 hybridoma house mouse CVCL_C2IK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260935 CVCL_C2IN MANEX58B-1A5 hybridoma house mouse CVCL_C2IN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260936 CVCL_C2IM MANEX58A-2D9 hybridoma house mouse CVCL_C2IM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260937 CVCL_C2IB MANEX4748C-5G11 hybridoma house mouse CVCL_C2IB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260938 CVCL_C2IA MANEX4748B-8E6 hybridoma house mouse CVCL_C2IA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260939 CVCL_C2ID MANEX4850A-5E3 hybridoma house mouse CVCL_C2ID CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260940 CVCL_C2IC MANEX4748D-7A5 hybridoma house mouse CVCL_C2IC CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260941 CVCL_C2IF MANEX4850C-7B8 hybridoma house mouse CVCL_C2IF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260942 CVCL_C2IE MANEX4850B-6A7 hybridoma house mouse CVCL_C2IE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260943 CVCL_C2HW MANDYS18-5H9 hybridoma house mouse CVCL_C2HW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260944 CVCL_C2I8 MANEX47-8B12 hybridoma house mouse CVCL_C2I8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260945 CVCL_C2HV MANDYS17-3B12 hybridoma house mouse CVCL_C2HV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155260946 CVCL_C2I7 MANEX46F-6G1 hybridoma house mouse CVCL_C2I7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260947 CVCL_C2HY MANEX44A-5B2 hybridoma house mouse CVCL_C2HY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse) Caution: Indicated as producing an IgG2b mAb in glennmorris.org.uk and an IgG1 mAb in DSHB. 155260948 CVCL_C2HX MANDYS19-8F6 hybridoma house mouse CVCL_C2HX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260949 CVCL_C2I9 MANEX4748A-8C1 hybridoma house mouse CVCL_C2I9 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260950 CVCL_C2HZ MANEX44B-10G5 hybridoma house mouse CVCL_C2HZ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260951 CVCL_C2FM MANNUT11-3B3 hybridoma house mouse CVCL_C2FM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260952 CVCL_C2FL MANNUT10-3C10 hybridoma house mouse CVCL_C2FL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260953 CVCL_C2G0 MANDRA3-3F4 hybridoma house mouse CVCL_C2G0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and fish); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260954 CVCL_C2FN MANNUT12-4B12 hybridoma house mouse CVCL_C2FN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260955 CVCL_C2G2 MANDRA5-2E2 hybridoma house mouse CVCL_C2G2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155260956 CVCL_C2FQ MANNUT14-8A3 hybridoma house mouse CVCL_C2FQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260957 CVCL_C2G1 MANDRA4-5H7 hybridoma house mouse CVCL_C2G1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155260958 CVCL_C2FP MANNUT13-2A5 hybridoma house mouse CVCL_C2FP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with dog). 155260959 CVCL_C2G4 MANDRA7-5A8 hybridoma house mouse CVCL_C2G4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155260960 CVCL_C2FS MANNUT16-4H12 hybridoma house mouse CVCL_C2FS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN 155260961 CVCL_C2G3 MANDRA6-8D11 hybridoma house mouse CVCL_C2G3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155260962 CVCL_C2FR MANNUT15-5E10 hybridoma house mouse CVCL_C2FR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with dog). 155260963 CVCL_C2FE MANNUT3-4E3 hybridoma house mouse CVCL_C2FE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with dog). 155260964 CVCL_C2FD MANNUT2-5C9 hybridoma house mouse CVCL_C2FD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with rat). 155260965 CVCL_C2FG MANNUT5-8C11 hybridoma house mouse CVCL_C2FG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with dog). 155260966 CVCL_C2FF MANNUT4-6H4 hybridoma house mouse CVCL_C2FF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with dog). 155260967 CVCL_C2FI MANNUT7-6A10 hybridoma house mouse CVCL_C2FI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260968 CVCL_C2FH MANNUT6-10D4 hybridoma house mouse CVCL_C2FH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260969 CVCL_C2FK MANNUT9-7C11 hybridoma house mouse CVCL_C2FK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155260970 CVCL_C2FJ MANNUT8-10A7 hybridoma house mouse CVCL_C2FJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with rat). 155260971 CVCL_C2FA N1G-9G5 hybridoma house mouse CVCL_C2FA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260972 CVCL_C2FC MANNUT1-3B6 hybridoma house mouse CVCL_C2FC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46939; Human UTRN (Note=Also reacts with rat). 155260973 CVCL_C2FB N1G-ex130 hybridoma house mouse CVCL_C2FB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260974 CVCL_C2ET 36C2 hybridoma house mouse CVCL_C2ET CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P48679; Rat Lmna. 155260975 CVCL_C2F5 N1G-6C9 hybridoma house mouse CVCL_C2F5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260976 CVCL_C2ES 34B6 hybridoma house mouse CVCL_C2ES CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P48679; Rat Lmna; Monoclonal antibody target: Rat lamin B (Note=Uncertain if it recognized both Lmnb1 and Lmnb2). 155260977 CVCL_C2F4 N1G-5A6 hybridoma house mouse CVCL_C2F4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260978 CVCL_C2EV 133A2 hybridoma house mouse CVCL_C2EV CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P02545; Human LMNA. 155260979 CVCL_C2F7 N1G-7C8 hybridoma house mouse CVCL_C2F7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260980 CVCL_C2EU 55B3 hybridoma house mouse CVCL_C2EU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P48679; Rat Lmna; Monoclonal antibody target: Rat lamin B (Note=Uncertain if it recognized both Lmnb1 and Lmnb2). 155260981 CVCL_C2F6 N1G-6F7 hybridoma house mouse CVCL_C2F6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260982 CVCL_C2EX MANLAC1-4A7 hybridoma house mouse CVCL_C2EX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02545; Human LMNA (Note=Also reacts with hamster, mouse and rabbit). 155260983 CVCL_C2F9 N1G-8C8 hybridoma house mouse CVCL_C2F9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260984 CVCL_C2EW 131C3 hybridoma house mouse CVCL_C2EW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02545; Human LMNA. 155260985 CVCL_C2F8 N1G-7D9 hybridoma house mouse CVCL_C2F8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155260986 CVCL_C2EZ MANLAC3-4C10 hybridoma house mouse CVCL_C2EZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02545; Human LMNA (Note=Also reacts with mouse and rabbit). 155260987 CVCL_C2EY MANLAC2-10F8 hybridoma house mouse CVCL_C2EY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02545; Human LMNA (Note=Also reacts with rabbit). 155260988 CVCL_C2GN MANEX1216B-6B11 hybridoma house mouse CVCL_C2GN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260989 CVCL_C2GM MANEX1216A-5A4 hybridoma house mouse CVCL_C2GM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260990 CVCL_C2H1 MANDYS111-4F12 hybridoma house mouse CVCL_C2H1 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260991 CVCL_C2GP MANEX1216C-8C8 hybridoma house mouse CVCL_C2GP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155260992 CVCL_C2H0 MANDYS110-3H10 hybridoma house mouse CVCL_C2H0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260993 CVCL_C2GR MANDYS101-7D12 hybridoma house mouse CVCL_C2GR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD. 155260994 CVCL_C2H3 MANDYS122-8D11 hybridoma house mouse CVCL_C2H3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260995 CVCL_C2H2 MANDYS121-8C9 hybridoma house mouse CVCL_C2H2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse, chicken, fish and Xenopus). 155260996 CVCL_C2GQ MANEX1216D-8D11 hybridoma house mouse CVCL_C2GQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD Caution: Indicated as producing an IgG1 mAb in PubMed=10835598 and an IgG2a mAb in DSHB. 155260997 CVCL_C2GT MANDYS103-8E11 hybridoma house mouse CVCL_C2GT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog). 155260998 CVCL_C2H5 MANDYS124-3H7 hybridoma house mouse CVCL_C2H5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155260999 CVCL_C2GS MANDYS102-7D2 hybridoma house mouse CVCL_C2GS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD Caution: Indicated as producing an IgG2a mAb in PubMed=1281410 and an IgG1 mAb in DSHB. 155261000 CVCL_C2H4 MANDYS123-4C3 hybridoma house mouse CVCL_C2H4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155261001 CVCL_C2GF MANDRA18-7H7 hybridoma house mouse CVCL_C2GF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155261002 CVCL_C2GE MANDRA17-5C3 hybridoma house mouse CVCL_C2GE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261003 CVCL_C2GH MANEX1011A-8A12 hybridoma house mouse CVCL_C2GH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155261004 CVCL_C2GG MANDRA19-5G6 hybridoma house mouse CVCL_C2GG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155261005 CVCL_C2GJ MANEX1011C-4F9 hybridoma house mouse CVCL_C2GJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155261006 CVCL_C2GI MANEX1011B-1C7 hybridoma house mouse CVCL_C2GI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155261007 CVCL_C2GL MANEX1011E-8H7 hybridoma house mouse CVCL_C2GL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261008 CVCL_C2GK MANEX1011D-7G5 hybridoma house mouse CVCL_C2GK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155261009 CVCL_C2GB MANDRA14-2F2 hybridoma house mouse CVCL_C2GB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155261010 CVCL_C2GA MANDRA13-7E4 hybridoma house mouse CVCL_C2GA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155261011 CVCL_C2GD MANDRA16-4B11 hybridoma house mouse CVCL_C2GD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and fish); Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261012 CVCL_C2GC MANDRA15-3G11 hybridoma house mouse CVCL_C2GC CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse, fish and Xenopus) Caution: Indicated as producing an IgG2b mAb in PubMed=1281410 and an IgG2a mAb in DSHB. 155261013 CVCL_C2G6 MANDRA9-4A2 hybridoma house mouse CVCL_C2G6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155261014 CVCL_C2FU MANNUT18-7C7 hybridoma house mouse CVCL_C2FU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261015 CVCL_C2G5 MANDRA8-6H6 hybridoma house mouse CVCL_C2G5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155261016 CVCL_C2FT MANNUT17-6H7 hybridoma house mouse CVCL_C2FT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261017 CVCL_C2FW MANCHO12-1H1 hybridoma house mouse CVCL_C2FW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261018 CVCL_C2G8 MANDRA11-8B11 hybridoma house mouse CVCL_C2G8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155261019 CVCL_C2G7 MANDRA10-8E8 hybridoma house mouse CVCL_C2G7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog and mouse). 155261020 CVCL_C2FV MANNUT19-8B5 hybridoma house mouse CVCL_C2FV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46939; Human UTRN. 155261021 CVCL_C2FY MANDRA1-7A10 hybridoma house mouse CVCL_C2FY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse, fish and Xenopus). 155261022 CVCL_C2FX DAG-3H9 hybridoma house mouse CVCL_C2FX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q14118; Human DAG1 (alpha-dystroglycan) (Note=Also reacts with mouse). 155261023 CVCL_C2G9 MANDRA12-5C5 hybridoma house mouse CVCL_C2G9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and fish). 155261024 CVCL_C2FZ MANDRA2-7G12 hybridoma house mouse CVCL_C2FZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with dog, mouse and Xenopus). 155261025 CVCL_C2DK GEM4F-2A2 hybridoma house mouse CVCL_C2DK CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with pig). 155261026 CVCL_C2DJ GEM4E-7B5 hybridoma house mouse CVCL_C2DJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with pig). 155261027 CVCL_C2DM GEM5B-1B1 hybridoma house mouse CVCL_C2DM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse). 155261028 CVCL_C2DL GEM5A-1A5 hybridoma house mouse CVCL_C2DL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261029 CVCL_C2E0 GEM5O-3E11 hybridoma house mouse CVCL_C2E0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse and pig). 155261030 CVCL_C2DN GEM5C-1C10 hybridoma house mouse CVCL_C2DN CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse and pig). 155261031 CVCL_C2DQ GEM5E-2B11 hybridoma house mouse CVCL_C2DQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261032 CVCL_C2E2 GEM5Q-4G7 hybridoma house mouse CVCL_C2E2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse and pig). 155261033 CVCL_C2DP GEM5D-2A12 hybridoma house mouse CVCL_C2DP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with pig). 155261034 CVCL_C2E1 GEM5P-3G2 hybridoma house mouse CVCL_C2E1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with pig). 155261035 CVCL_C2DC PF2A4-5A6 hybridoma house mouse CVCL_C2DC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261036 CVCL_C2DB PF2A3-6D10 hybridoma house mouse CVCL_C2DB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261037 CVCL_C2DE PF2A6-9G7 hybridoma house mouse CVCL_C2DE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261038 CVCL_C2DD PF2A5-6B3 hybridoma house mouse CVCL_C2DD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261039 CVCL_C2DG GEM4B-1G4 hybridoma house mouse CVCL_C2DG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with pig). 155261040 CVCL_C2DF GEM4A-1A8 hybridoma house mouse CVCL_C2DF CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with mouse and pig). 155261041 CVCL_C2DI GEM4D-2H8 hybridoma house mouse CVCL_C2DI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with pig). 155261042 CVCL_C2DH GEM4C-9E6 hybridoma house mouse CVCL_C2DH CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P57678; Human GEMIN4 (Note=Also reacts with mouse and pig). 155261043 CVCL_C2CZ MANSMA20-8C1 hybridoma house mouse CVCL_C2CZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261044 CVCL_C2CY MANSMA2-8F7 hybridoma house mouse CVCL_C2CY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261045 CVCL_C2DA PF2A2-6D1 hybridoma house mouse CVCL_C2DA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261046 CVCL_C2CR MANSMA13-5E3 hybridoma house mouse CVCL_C2CR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261047 CVCL_C2D3 MANSMA4-10A8 hybridoma house mouse CVCL_C2D3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261048 CVCL_C2CQ MANSMA12-2E6 hybridoma house mouse CVCL_C2CQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261049 CVCL_C2D2 MANSMA3-8E1 hybridoma house mouse CVCL_C2D2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261050 CVCL_C2CT MANSMA15-6G1 hybridoma house mouse CVCL_C2CT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261051 CVCL_C2D5 MANSMA6-4H2 hybridoma house mouse CVCL_C2D5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261052 CVCL_C2CS MANSMA14-6A6 hybridoma house mouse CVCL_C2CS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261053 CVCL_C2D4 MANSMA5-12G6 hybridoma house mouse CVCL_C2D4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261054 CVCL_C2CV MANSMA17-8B11 hybridoma house mouse CVCL_C2CV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261055 CVCL_C2D7 MANSMA8-6H3 hybridoma house mouse CVCL_C2D7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261056 CVCL_C2CU MANSMA16-8A6 hybridoma house mouse CVCL_C2CU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261057 CVCL_C2D6 MANSMA7-1B12 hybridoma house mouse CVCL_C2D6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261058 CVCL_C2CX MANSMA19-7G12 hybridoma house mouse CVCL_C2CX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261059 CVCL_C2D9 PF2A1-8F8 hybridoma house mouse CVCL_C2D9 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35080; Human PFN2 (Note=Also reacts with rat). 155261060 CVCL_C2CW MANSMA18-8B12 hybridoma house mouse CVCL_C2CW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261061 CVCL_C2D8 MANSMA9-9C7 hybridoma house mouse CVCL_C2D8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261062 CVCL_C2EL MB2b-6A10 hybridoma house mouse CVCL_C2EL CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5VZF2; Human MBNL2. 155261063 CVCL_C2EK MB2a-3B4 hybridoma house mouse CVCL_C2EK CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5VZF2; Human MBNL2 (Note=Also reacts with mouse). 155261064 CVCL_C2EN MB2d-9F11 hybridoma house mouse CVCL_C2EN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5VZF2; Human MBNL2. 155261065 CVCL_C2EM MB2c-8B1 hybridoma house mouse CVCL_C2EM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5VZF2; Human MBNL2. 155261066 CVCL_C2F1 MANLAC5-7F12 hybridoma house mouse CVCL_C2F1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02545; Human LMNA (Note=Also reacts with rabbit). 155261067 CVCL_C2EP MB3a-5A11 hybridoma house mouse CVCL_C2EP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NUK0; Human MBNL3 (Note=Also reacts with mouse). 155261068 CVCL_C2F0 MANLAC4-9G5 hybridoma house mouse CVCL_C2F0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02545; Human LMNA (Note=Also reacts with rabbit). 155261069 CVCL_C2ER 31B5 hybridoma house mouse CVCL_C2ER CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Rat lamin B (Note=Uncertain if it recognized both Lmnb1 and Lmnb2). 155261070 CVCL_C2F3 N1G-4C11 hybridoma house mouse CVCL_C2F3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155261071 CVCL_C2EQ MB3b-2F9 hybridoma house mouse CVCL_C2EQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NUK0; Human MBNL3. 155261072 CVCL_C2F2 N1alpha2-1H2 hybridoma house mouse CVCL_C2F2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (isoform alpha-2). 155261073 CVCL_C2ED GEM7C-6A9 hybridoma house mouse CVCL_C2ED CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261074 CVCL_C2EC GEM7B-6A2 hybridoma house mouse CVCL_C2EC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261075 CVCL_C2EF GEM7E-8D8 hybridoma house mouse CVCL_C2EF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261076 CVCL_C2EE GEM7D-7A12 hybridoma house mouse CVCL_C2EE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261077 CVCL_C2EH GEM7G-10C12 hybridoma house mouse CVCL_C2EH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261078 CVCL_C2EG GEM7F-8H1 hybridoma house mouse CVCL_C2EG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7 (Note=Also reacts with pig). 155261079 CVCL_C2EJ MB1b-5F9 hybridoma house mouse CVCL_C2EJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NR56; Human MBNL1 (Note=Also reacts with mouse). 155261080 CVCL_C2EI MB1a-4A8 hybridoma house mouse CVCL_C2EI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NR56; Human MBNL1 (Note=Also reacts with mouse). 155261081 CVCL_C2DZ GEM5N-2E6 hybridoma house mouse CVCL_C2DZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse and pig). 155261082 CVCL_C2EB GEM7A-2A11 hybridoma house mouse CVCL_C2EB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H840; Human GEMIN7. 155261083 CVCL_C2EA GEM6G-3F12 hybridoma house mouse CVCL_C2EA CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6. 155261084 CVCL_C2DS GEM5G-6C4 hybridoma house mouse CVCL_C2DS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261085 CVCL_C2E4 GEM6A-2C11 hybridoma house mouse CVCL_C2E4 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6. 155261086 CVCL_C2DR GEM5F-5C3 hybridoma house mouse CVCL_C2DR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse). 155261087 CVCL_C2E3 GEM5R-6G5 hybridoma house mouse CVCL_C2E3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with pig). 155261088 CVCL_C2DU GEM5I-7A1 hybridoma house mouse CVCL_C2DU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261089 CVCL_C2E6 GEM6C-5E9 hybridoma house mouse CVCL_C2E6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6. 155261090 CVCL_C2DT GEM5H-6E2 hybridoma house mouse CVCL_C2DT CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261091 CVCL_C2E5 GEM6B-4H6 hybridoma house mouse CVCL_C2E5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6 (Note=Also reacts with pig). 155261092 CVCL_C2DW GEM5K-8C7 hybridoma house mouse CVCL_C2DW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261093 CVCL_C2E8 GEM6E-8A9 hybridoma house mouse CVCL_C2E8 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6. 155261094 CVCL_C2DV GEM5J-7F1 hybridoma house mouse CVCL_C2DV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261095 CVCL_C2E7 GEM6D-6F5 hybridoma house mouse CVCL_C2E7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6 (Note=Also reacts with pig). 155261096 CVCL_C2DY GEM5M-1E12 hybridoma house mouse CVCL_C2DY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5 (Note=Also reacts with mouse and pig). 155261097 CVCL_C2DX GEM5L-8E7 hybridoma house mouse CVCL_C2DX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEQ6; Human GEMIN5. 155261098 CVCL_C2E9 GEM6F-8D8 hybridoma house mouse CVCL_C2E9 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXD5; Human GEMIN6 (Note=Also reacts with pig). 155261099 CVCL_C2BI MANEM10-1H9 hybridoma house mouse CVCL_C2BI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261100 CVCL_C2BH MANEM1-5D10 hybridoma house mouse CVCL_C2BH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD (Note=Also reacts with rabbit). 155261101 CVCL_C2BK MANEM12-5B11 hybridoma house mouse CVCL_C2BK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261102 CVCL_C2BJ MANEM11-7D9 hybridoma house mouse CVCL_C2BJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261103 CVCL_C2BM MANEM14-3C3 hybridoma house mouse CVCL_C2BM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261104 CVCL_C2BL MANEM13-2D6 hybridoma house mouse CVCL_C2BL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261105 CVCL_C2C0 MANNES1C-6C10 hybridoma house mouse CVCL_C2C0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (Note=Also reacts with mouse, rat and rabbit). 155261106 CVCL_C2BN MANEM15-8E1 hybridoma house mouse CVCL_C2BN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261107 CVCL_C2BA MANDOP22-3D9 hybridoma house mouse CVCL_C2BA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P14416; Human DRD2. 155261108 CVCL_C2BC MANDOP32-3F1 hybridoma house mouse CVCL_C2BC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35462; Human DRD3. 155261109 CVCL_C2BB MANDOP31-1D7 hybridoma house mouse CVCL_C2BB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35462; Human DRD3. 155261110 CVCL_C2BE MANDOP34-4D10 hybridoma house mouse CVCL_C2BE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35462; Human DRD3. 155261111 CVCL_C2BD MANDOP33-3B7 hybridoma house mouse CVCL_C2BD CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35462; Human DRD3. 155261112 CVCL_C2BG MANDOP41-2B9 hybridoma house mouse CVCL_C2BG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21917; Human DRD4. 155261113 CVCL_C2BF MANDOP35-9F4 hybridoma house mouse CVCL_C2BF CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35462; Human DRD3. 155261114 CVCL_C2AX MANDM5-5G12 hybridoma house mouse CVCL_C2AX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261115 CVCL_C2B9 MANDOP21-3B9 hybridoma house mouse CVCL_C2B9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14416; Human DRD2. 155261116 CVCL_C2B8 MANDM16-9A4 hybridoma house mouse CVCL_C2B8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261117 CVCL_C2AW MANDM4-9H9 hybridoma house mouse CVCL_C2AW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261118 CVCL_C2AZ MANDM7-12G5 hybridoma house mouse CVCL_C2AZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK (Note=Also reacts with rabbit). 155261119 CVCL_C2AY MANDM6-7E4B7 hybridoma house mouse CVCL_C2AY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261120 CVCL_C2B1 MANDM9-3D10 hybridoma house mouse CVCL_C2B1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261121 CVCL_C2AP TC97-2947 finite cell line human CVCL_C2AP From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155261122 CVCL_C2B0 MANDM8-7E7 hybridoma house mouse CVCL_C2B0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK (Note=Also reacts with rabbit). 155261123 CVCL_C2B3 MANDM11-6B6 hybridoma house mouse CVCL_C2B3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261124 CVCL_C2AR UMB-4648 finite cell line human CVCL_C2AR From: NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155261125 CVCL_C2B2 MANDM10-2H12 hybridoma house mouse CVCL_C2B2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261126 CVCL_C2AQ UMB-1897 finite cell line human CVCL_C2AQ From: NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Male 155261127 CVCL_C2AT MANDM1-6G8 hybridoma house mouse CVCL_C2AT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK (Note=Also reacts with mouse and rabbit). 155261128 CVCL_C2B5 MANDM13-12A4 hybridoma house mouse CVCL_C2B5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261129 CVCL_C2B4 MANDM12-7E4G2 hybridoma house mouse CVCL_C2B4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261130 CVCL_C2AS UMB-4994 finite cell line human CVCL_C2AS From: NICHD Brain and Tissue Bank for Developmental Disorders at the University of Maryland; Baltimore; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Derived from sampling site: Cell type=Fibroblast. Female 155261131 CVCL_C2B7 MANDM15-5C9 hybridoma house mouse CVCL_C2B7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261132 CVCL_C2AV MANDM3-8B5 hybridoma house mouse CVCL_C2AV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261133 CVCL_C2B6 MANDM14-7E6 hybridoma house mouse CVCL_C2B6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261134 CVCL_C2AU MANDM2-10A7 hybridoma house mouse CVCL_C2AU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09013; Human DMPK. 155261135 CVCL_C2CJ MANSIP1B-3F8 hybridoma house mouse CVCL_C2CJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14893; Human GEMIN2 (Note=Also reacts with mouse and rabbit) Caution: Indicated as producing an IgG1 mAb in glennmorris.org.uk and an IgG2b mAb in DSHB. 155261136 CVCL_C2CI MANSIP1A-1G9 hybridoma house mouse CVCL_C2CI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14893; Human GEMIN2 (Note=Also reacts with mouse and rabbit) Caution: Indicated as producing an IgG1 mAb in glennmorris.org.uk and an IgG2b mAb in DSHB. 155261137 CVCL_C2CL MANSIP1D-7C11 hybridoma house mouse CVCL_C2CL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14893; Human GEMIN2 (Note=Also reacts with mouse and rabbit) Caution: Indicated as producing an IgG1 mAb in glennmorris.org.uk and an IgG2b mAb in DSHB. 155261138 CVCL_C2CK MANSIP1C-6D1 hybridoma house mouse CVCL_C2CK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14893; Human GEMIN2 (Note=Also reacts with mouse and rabbit) Caution: Indicated as producing an IgG1 mAb in glennmorris.org.uk and an IgG2b mAb in DSHB. 155261139 CVCL_C2CN MANSMA10-8A10 hybridoma house mouse CVCL_C2CN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261140 CVCL_C2CM MANSMA1-11F3 hybridoma house mouse CVCL_C2CM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261141 CVCL_C2CP MANSMA11-6G9 hybridoma house mouse CVCL_C2CP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261142 CVCL_C2D1 MANSMA22-8B3 hybridoma house mouse CVCL_C2D1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2. 155261143 CVCL_C2D0 MANSMA21-1F1 hybridoma house mouse CVCL_C2D0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16637; Human SMN1/SMN2 (Note=Also reacts with mouse). 155261144 CVCL_C2CB MANNES2G-4B5 hybridoma house mouse CVCL_C2CB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261145 CVCL_C2CA MANNES2F-11C5 hybridoma house mouse CVCL_C2CA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261146 CVCL_C2CD MANNES2I-4A11 hybridoma house mouse CVCL_C2CD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261147 CVCL_C2CC MANNES2H-3C4 hybridoma house mouse CVCL_C2CC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261148 CVCL_C2CF MANNES2K-1A11 hybridoma house mouse CVCL_C2CF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261149 CVCL_C2CE MANNES2J-3H4 hybridoma house mouse CVCL_C2CE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261150 CVCL_C2CH MANNES2M-16H2 hybridoma house mouse CVCL_C2CH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261151 CVCL_C2CG MANNES2L-17F5 hybridoma house mouse CVCL_C2CG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261152 CVCL_C2BY MANNES1A-7A12 hybridoma house mouse CVCL_C2BY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (Note=Also reacts with mouse, rat and rabbit). 155261153 CVCL_C2BX MANEM9-9F8 hybridoma house mouse CVCL_C2BX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261154 CVCL_C2C9 MANNES2E-18F7 hybridoma house mouse CVCL_C2C9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261155 CVCL_C2BZ MANNES1B-7B2 hybridoma house mouse CVCL_C2BZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155261156 CVCL_C2BQ MANEM2-9B2 hybridoma house mouse CVCL_C2BQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD (Note=Also reacts with rabbit). 155261157 CVCL_C2C2 MANNES1E-8C3 hybridoma house mouse CVCL_C2C2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (Note=Also reacts with mouse and rat). 155261158 CVCL_C2BP MANEM16-7A6 hybridoma house mouse CVCL_C2BP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261159 CVCL_C2C1 MANNES1D-8B8 hybridoma house mouse CVCL_C2C1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1. 155261160 CVCL_C2BS MANEM4-6C4 hybridoma house mouse CVCL_C2BS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261161 CVCL_C2C4 MANNES1G-6G2 hybridoma house mouse CVCL_C2C4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (Note=Also reacts with mouse, rat and rabbit). 155261162 CVCL_C2BR MANEM3-6D2 hybridoma house mouse CVCL_C2BR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD (Note=Also reacts with rabbit). 155261163 CVCL_C2C3 MANNES1F-9G10 hybridoma house mouse CVCL_C2C3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1 (Note=Also reacts with mouse, rat and rabbit). 155261164 CVCL_C2BU MANEM6-8E9 hybridoma house mouse CVCL_C2BU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261165 CVCL_C2C6 MANNES2B-6A8 hybridoma house mouse CVCL_C2C6 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8NF91; Human SYNE1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2 Caution: Indicated as producing an IgG2a mAb in PubMed=20108321 and an IgG1 mAb in DSHB. 155261166 CVCL_C2BT MANEM5-8A1 hybridoma house mouse CVCL_C2BT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261167 CVCL_C2C5 MANNES2A-11A3 hybridoma house mouse CVCL_C2C5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2 Caution: Indicated as producing an IgG1 mAb in PubMed=20108321 and an IgG2a mAb in DSHB. 155261168 CVCL_C2BW MANEM8-7B9 hybridoma house mouse CVCL_C2BW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261169 CVCL_C2C8 MANNES2D-6H5 hybridoma house mouse CVCL_C2C8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2. 155261170 CVCL_C2BV MANEM7-7A9 hybridoma house mouse CVCL_C2BV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50402; Human EMD. 155261171 CVCL_C2C7 MANNES2C-12A5 hybridoma house mouse CVCL_C2C7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXH0; Human SYNE2 Caution: Indicated as producing an IgG1 mAb in PubMed=20108321 and an IgG2a mAb in DSHB. 155261172 CVCL_C1NV CHOPi008-B induced pluripotent stem cell human CVCL_C1NV From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 155261173 CVCL_C1NU CHOPi008-A induced pluripotent stem cell human CVCL_C1NU From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 155261174 CVCL_C1NX CHOPi009-A induced pluripotent stem cell human CVCL_C1NX From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 Male 155261175 CVCL_C1NW CHOPi008-C induced pluripotent stem cell human CVCL_C1NW From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 155261176 CVCL_C1NZ CHOPi011-A induced pluripotent stem cell human CVCL_C1NZ From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 Male 155261177 CVCL_C1NY CHOPi010-A induced pluripotent stem cell human CVCL_C1NY From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 Female 155261178 CVCL_C1NN NCHi001-A induced pluripotent stem cell human CVCL_C1NN From: Nationwide Children's Hospital; Columbus; USA CL:0000010 Sequence variation: Mutation; HGNC; 7775; NFATC1; Simple; chr18:g.7753998G>A; Zygosity=Homozygous; Note=Enhancer (PubMed=36343514) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155261179 CVCL_C1NM SJ-HGGX6c cancer cell line human CVCL_C1NM CL:0000010 Sequence variation: Mutation; HGNC; 886; ATRX; Simple; p.Thr1582fs (c.4745delA); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Arg (c.103G>A) (H3.3G34R); ClinVar=VCV000438766; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 25311; H3C13; Simple; p.Ser88Pro (c.262T>C); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asp583_Trp586del (c.1749_1760del); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=34215733); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Brain; cortex. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Derived from a patient-derived xenograft Doubling time: 5.6 days (PubMed=34215733) 155261180 CVCL_C1NP BGUi026-A induced pluripotent stem cell human CVCL_C1NP From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 Male 155261181 CVCL_C1NR BIHi250-B induced pluripotent stem cell human CVCL_C1NR From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261182 CVCL_C1NQ BGUi027-A induced pluripotent stem cell human CVCL_C1NQ From: Ben Gurion University of the Negev; Beer Sheva; Israel. CL:0000010 Male 155261183 CVCL_C1NT BIONi010-C-64 induced pluripotent stem cell human CVCL_C1NT From: Bioneer A/S; Horsholm; Denmark CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a T2A-Nluc construct was inserted at the C-terminus of one of the alleles of CYP3A4 (PubMed=35598806) 155261184 CVCL_C1NS BIOi003-A induced pluripotent stem cell human CVCL_C1NS From: Beijing Institute of Ophthalmology; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Arg408Ter (c.1222C>T); ClinVar=VCV000099035; Zygosity=Heterozygous (PubMed=35973334); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Phe973Leufs*3 (c.2919-884G>T); Zygosity=Heterozygous (PubMed=35973334) Population: Chinese; Derived from sampling site: Peripheral blood. Female 155261185 CVCL_C1NF SJ-DIPGX29c cancer cell line human CVCL_C1NF CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=34215733) Derived from sampling site: Brainstem; pons. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Derived from a patient-derived xenograft Doubling time: 9.0 days (PubMed=34215733) 155261186 CVCL_C1NE A2780veliR cancer cell line human CVCL_C1NE CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:62880; Veliparib; Derived from sampling site: Ovary. Female 155261187 CVCL_C1NH SJ-DIPGX7c cancer cell line human CVCL_C1NH CL:0000010 Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Thr200_Leu201fs (c.600_603delGCCA); Zygosity=Homozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Homozygous (PubMed=34215733) Derived from sampling site: Brainstem; pons. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Derived from a patient-derived xenograft Doubling time: 6.1 days (PubMed=34215733) 155261188 CVCL_C1NG SJ-DIPGX37c cancer cell line human CVCL_C1NG CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Homozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Tyr452_Asn453Tyr (c.1356_1358delTAA); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Leu513fs (c.1539dupT); Zygosity=Heterozygous (PubMed=34215733) Derived from sampling site: Brainstem; pons. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived from a patient-derived xenograft Doubling time: 9.0 days (PubMed=34215733) 155261189 CVCL_C1NJ SJ-HGGX2c cancer cell line human CVCL_C1NJ CL:0000010 Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asn659Lys (c.1977C>G); ClinVar=VCV000375902; Zygosity=Homozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Homozygous (PubMed=34215733) Derived from sampling site: Brain; cerebellum. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived from a patient-derived xenograft Doubling time: 8.2 days (PubMed=34215733) 155261190 CVCL_C1NI SJ-DIPGX9c cancer cell line human CVCL_C1NI CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Gly328Glu (c.983G>A); ClinVar=VCV000029595; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=34215733) Derived from sampling site: Brainstem; pons. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Derived from a patient-derived xenograft Doubling time: 9.1 days (PubMed=34215733) 155261191 CVCL_C1NL SJ-HGGX42c cancer cell line human CVCL_C1NL CL:0000010 Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Ser177fs (c.529_530delAG); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Arg (c.103G>A) (H3.3G34R); ClinVar=VCV000438766; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265del (c.792_794delTCT); Zygosity=Heterozygous (PubMed=34215733); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Brain; cortex. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived from a patient-derived xenograft Doubling time: 6.1 days (PubMed=34215733) 155261192 CVCL_C1NK SJ-HGGX39c cancer cell line human CVCL_C1NK CL:0000010 Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Gly1429_Thr1431fs (c.4286_4293delCCAGAGCG); Zygosity=Homozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Ser1045Phe (c.3134C>T); Zygosity=Heterozygous (PubMed=34215733); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=34215733) Derived from sampling site: Brain; cortex. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Derived from a patient-derived xenograft Doubling time: 3.7 days (PubMed=34215733) 155261193 CVCL_C1NB SNU-601 Ola-R cancer cell line human CVCL_C1NB CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 18884; TDP1; Simple; p.Ala520Asp; Zygosity=Unspecified (PubMed=32028591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:83766; Olaparib; Derived from metastatic site: Ascites. Male 155261194 CVCL_C1NA SNU-484 Ola-R cancer cell line human CVCL_C1NA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:83766; Olaparib; Derived from sampling site: Stomach. Male 155261195 CVCL_C1ND KATO III Ola-R cancer cell line human CVCL_C1ND CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:83766; Olaparib; Derived from metastatic site: Pleural effusion. Male 155261196 CVCL_C1NC SNU-668 Ola-R cancer cell line human CVCL_C1NC CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:83766; Olaparib; Derived from metastatic site: Ascites. Male 155261197 CVCL_C1P8 CRTDi011-A induced pluripotent stem cell human CVCL_C1P8 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany. CL:0000010 Female 155261198 CVCL_C1P7 CRTDi010-A induced pluripotent stem cell human CVCL_C1P7 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Arg164Ter (c.490C>T); ClinVar=VCV000004069; Zygosity=Homozygous (from autologous cell line CRTDi010-B) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261199 CVCL_C1P9 CRTDi011-B induced pluripotent stem cell human CVCL_C1P9 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany. CL:0000010 Female 155261200 CVCL_C1P0 CRICKi003-A induced pluripotent stem cell human CVCL_C1P0 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155261201 CVCL_C1P2 CRTDi006-A induced pluripotent stem cell human CVCL_C1P2 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Val201Asp (c.602T>A); ClinVar=VCV000004182; Zygosity=Homozygous (PubMed=36027857) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261202 CVCL_C1P1 CRMi003-A-3 induced pluripotent stem cell human CVCL_C1P1 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: mScarlet, a red fluorescent protein Derived from sampling site: Umbilical cord blood. Male Characteristics: Expresses a doxycycline inducible H2B-mTurquoise2 reporter Instrumental to track cells and to temporally assess cell divisions and apoptosis in iPSC-based differentiation and cell toxicity assays (hPSCreg).; Characteristics: Using CRISPR/Cas9 a T2A-PuroR-CAG-rTA3G-H2B-mTurquoise2-TRE3G construct was introduced in the AAVS1 safe harbor locus (PubMed=34775202); Characteristics: Using CRISPR/Cas9 a mScarletI-GMNN(1-110) construct was introduced in the AAVS1 safe harbor locus (hPSCreg) 155261203 CVCL_C1P4 CRTDi008-A induced pluripotent stem cell human CVCL_C1P4 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Arg290His (c.869G>A); Zygosity=Heterozygous (from autologous cell line CRTDi008-B); Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Gln548Ter (c.1642C>T); ClinVar=VCV000004071; Zygosity=Heterozygous (from autologous cell line CRTDi008-B) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261204 CVCL_C1P3 CRTDi007-A induced pluripotent stem cell human CVCL_C1P3 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Arg114His (c.341G>A); ClinVar=VCV000004179; Zygosity=Homozygous (PubMed=36027857) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261205 CVCL_C1P6 CRTDi009-B induced pluripotent stem cell human CVCL_C1P6 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.His167Tyr (c.499C>T); Zygosity=Homozygous (from autologous cell line CRTDi009-A) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261206 CVCL_C1P5 CRTDi009-A induced pluripotent stem cell human CVCL_C1P5 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.His167Tyr (c.499C>T); Zygosity=Homozygous (PubMed=36115319) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261207 CVCL_C1LT NCHi007-A induced pluripotent stem cell human CVCL_C1LT From: Nationwide Children's Hospital; Columbus; USA. CL:0000010 155261208 CVCL_C1M5 RA/1 spontaneously immortalized cell line CVCL_C1M5 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description and of a another rabbit cell line from the same group (Cellosaurus=CVCL_C1M6) Derived from sampling site: Dorsal aorta Cell type=Endothelial cell.. Unspecified 155261209 CVCL_C1M4 5G12 hybridoma house mouse CVCL_C1M4 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; V5XK21; Severe fever with thrombocytopenia virus (SFTV) nucleocapsid protein (N). 155261210 CVCL_C1LS NCHi006-A induced pluripotent stem cell human CVCL_C1LS From: Nationwide Children's Hospital; Columbus; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261211 CVCL_C1M7 IGROV(CDDP) cancer cell line human CVCL_C1M7 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female Doubling time: 26 hours (PubMed=9488600) 155261212 CVCL_C1LV PPAP-10 cancer cell line house mouse CVCL_C1LV CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Lung; Breed/subspecies: K5-HPV16-E6/E7-2303 transgenic. Unspecified 155261213 CVCL_C1LU NCHi008-A induced pluripotent stem cell human CVCL_C1LU From: Nationwide Children's Hospital; Columbus; USA. CL:0000010 155261214 CVCL_C1M6 RB/1 spontaneously immortalized cell line CVCL_C1M6 CL:0000010 Derived from sampling site: Brain. Unspecified 155261215 CVCL_C1LX Hepa1c1c7 BORIS C68 cancer cell line house mouse CVCL_C1LX CL:0000010 Transfected with: HGNC; 16234; CTCFL (isoform C68); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver; Breed/subspecies: C57L. Female 155261216 CVCL_C1M9 MEN cancer cell line human CVCL_C1M9 CL:0000010 Population: Chinese Male Doubling time: 37.6 hours (PubMed=13954855). 155261217 CVCL_C1M8 MEF cancer cell line human CVCL_C1M8 CL:0000010 Population: Chinese. Female 155261218 CVCL_C1LW PPAP-9 cancer cell line house mouse CVCL_C1LW CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Lung; Breed/subspecies: K5-HPV16-E6/E7-2303 transgenic. Unspecified 155261219 CVCL_C1LZ AXiAEC transformed cell line human CVCL_C1LZ CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 1 pneumocyte.. Unspecified Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line 155261220 CVCL_C1LY Hepa1c1c7 BORIS sf2 cancer cell line house mouse CVCL_C1LY CL:0000010 Transfected with: HGNC; 16234; CTCFL (isoform sf2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver; Breed/subspecies: C57L. Female 155261221 CVCL_C1LL KMUGMCi002-A induced pluripotent stem cell human CVCL_C1LL From: Kanazawa Medical University; Uchinada; Japan CL:0000010 Sequence variation: Mutation; HGNC; 28862; NIPBL; Simple; p.Lys2121del (c.6362_6364delAAA); ClinVar=VCV000159190; Zygosity=Heterozygous (PubMed=35834947) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155261222 CVCL_C1LK HL60-CDR cancer cell line human CVCL_C1LK CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Female Characteristics: Resistant to doxorubicin, cisplatin, etoposide and daunorubicin (PubMed=35822500) 155261223 CVCL_C1LN KMUGMCi004-A induced pluripotent stem cell human CVCL_C1LN From: Kanazawa Medical University; Uchinada; Japan CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly611Valfs*19 (c.1832delG); Zygosity=Heterozygous (PubMed=35868288) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155261224 CVCL_C1LM KMUGMCi003-A induced pluripotent stem cell human CVCL_C1LM From: Kanazawa Medical University; Uchinada; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg26Pro (c.77G>C); Zygosity=Heterozygous (PubMed=35944311); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly47Arg (c.139G>A); ClinVar=VCV001176084; Zygosity=Heterozygous (PubMed=35944311) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155261225 CVCL_C1M1 hAELVi.B transformed cell line human CVCL_C1M1 CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:88138; Bcl2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Lung; alveolus Cell type=Type 1 pneumocyte.. Unspecified Characteristics: Suitable to model the air-blood barrier of the peripheral lung Forms tight intercellular junctions, with high trans-epithelial electrical resistance (PubMed=26985677).; Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line 155261226 CVCL_C1LP NCHi003-A induced pluripotent stem cell human CVCL_C1LP From: Nationwide Children's Hospital; Columbus; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261227 CVCL_C1M0 hAELVi.A transformed cell line human CVCL_C1M0 CL:0000010 Transfected with: HGNC; 5361; ID2; Transfected with: HGNC; 5362; ID3; Transfected with: HGNC; 7553; MYC; Transfected with: MGI; MGI:88138; Bcl2; Transfected with: MGI; MGI:1919200; Nanog; Transfected with: Hepatitis C virus core protein; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Lung; alveolus Cell type=Type 1 pneumocyte.. Unspecified Characteristics: Suitable to model the air-blood barrier of the peripheral lung Forms tight intercellular junctions, with high trans-epithelial electrical resistance (PubMed=26985677).; Characteristics: Transduced with a lentiviral library consisting of 33 genes, some of which are retained in the immortalized cell line 155261228 CVCL_C1M3 4A10 [Mouse hybridoma against SFTV N] hybridoma house mouse CVCL_C1M3 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; V5XK21; Severe fever with thrombocytopenia virus (SFTV) nucleocapsid protein (N). 155261229 CVCL_C1LR NCHi005-A induced pluripotent stem cell human CVCL_C1LR From: Nationwide Children's Hospital; Columbus; USA. CL:0000010 155261230 CVCL_C1M2 1C3 [Mouse hybridoma against SFTV N] hybridoma house mouse CVCL_C1M2 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; V5XK21; Severe fever with thrombocytopenia virus (SFTV) nucleocapsid protein (N). 155261231 CVCL_C1LQ NCHi004-A induced pluripotent stem cell human CVCL_C1LQ From: Nationwide Children's Hospital; Columbus; USA. CL:0000010 155261232 CVCL_C1LD 50B11 clone E4 transformed cell line Norway rat CVCL_C1LD CL:0000010 Knockout cell: Method=CRISPR/Cas9; RGD 1589721; Gla; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.. Unspecified 155261233 CVCL_C1LC 50B11 clone D4W transformed cell line Norway rat CVCL_C1LC CL:0000010 Knockout cell: Method=CRISPR/Cas9; RGD 1589721; Gla; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.. Unspecified 155261234 CVCL_C1LF HB-2 transformed cell line human CVCL_C1LF CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Female Characteristics: Increased tumorigenicity compared to the parent cell line Established from a tumor obtained from inoculation of the parent cell line in nude mice (PubMed=20464641). 155261235 CVCL_C1LE HIOEC-B(a)P-56 transformed cell line human CVCL_C1LE CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Female 155261236 CVCL_C1LH HAP1 HTRA1 (-) 1 cancer cell line human CVCL_C1LH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9476; HTRA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155261237 CVCL_C1LG HIOEC-B(a)P-TPA transformed cell line human CVCL_C1LG CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Female 155261238 CVCL_C1LJ KUSTi001-A induced pluripotent stem cell human CVCL_C1LJ From: Khalifa University of Science and Technology (KUST); Abu Dhabi; United Arab Emirates CL:0000010 Population: Arab; Derived from sampling site: Peripheral blood. Female 155261239 CVCL_C1LI HAP1 HTRA1 (-) 2 cancer cell line human CVCL_C1LI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9476; HTRA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155261240 CVCL_C1KZ CHO-K1 HAY1C-L spontaneously immortalized cell line CVCL_C1KZ CL:0000010 Transfected with: RGD; 3198; Npy1r (with p.Cys337Ala and a HA tag) Derived from sampling site: Ovary. Female 155261241 CVCL_C1LB RZPBi001 induced pluripotent stem cell human CVCL_C1LB CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261242 CVCL_C1LA MA09-hRPE finite cell line human CVCL_C1LA From: Astellas Institute of Regenerative Medicine (AIRM); Marlborough; USA CL:0000010 Derived from sampling site: Fetal eye; retina; retinal pigment epithelium. Biotechnology: Used in clinical trials were it is sub-retinaly transplanted in patients with macular degeneration and Stargardt's macular dystrophy MA09-hRPE can rescue photoreceptors and prevent loss of vision.; Omics: Transcriptome analysis by microarray Female Characteristics: The MA09 hESC cell line was terminally differentiated into retinal pigment epithelial (RPE) cells 155261243 CVCL_C1MU HSJD-DIPG-007-TP53 KO cancer cell line human CVCL_C1MU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Brainstem; pons. Male 155261244 CVCL_C1N6 SU-DIPG-XXXVIII cancer cell line human CVCL_C1N6 CL:0000010 Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=33319914) Derived from sampling site: Brainstem; pons. 155261245 CVCL_C1MT HSJD-DIPG-007-NTC cancer cell line human CVCL_C1MT CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Brainstem; pons. Male Characteristics: Control cell line for HSJD-DIPG-007-TP53 KO (Cellosaurus=CVCL_C1MU) 155261246 CVCL_C1N5 SU-DIPG-XXXVI cancer cell line human CVCL_C1N5 CL:0000010 Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=33319914) Derived from sampling site: Brainstem; pons. 155261247 CVCL_C1MW SU-DIPG-XVII cancer cell line human CVCL_C1MW CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Male Doubling time: 5.8 days (PubMed=34215733) 155261248 CVCL_C1N8 SU-pGBM3 cancer cell line human CVCL_C1N8 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male 155261249 CVCL_C1MV SU-DIPG-XIX cancer cell line human CVCL_C1MV CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Male Doubling time: 4.6 days (PubMed=34215733) 155261250 CVCL_C1N7 SU-DIPG-XLVIII cancer cell line human CVCL_C1N7 CL:0000010 Derived from sampling site: Brainstem; pons. 155261251 CVCL_C1MY SU-DIPG-XXIV cancer cell line human CVCL_C1MY CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Female 155261252 CVCL_C1MX SU-DIPG-XXI cancer cell line human CVCL_C1MX CL:0000010 Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Male Doubling time: 4.6 days (PubMed=34215733) 155261253 CVCL_C1N9 SU-pSCG-1 cancer cell line human CVCL_C1N9 CL:0000010 Derived from sampling site: Spinal cord. Male 155261254 CVCL_C1MZ SU-DIPG-XXIX cancer cell line human CVCL_C1MZ CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Female 155261255 CVCL_C1MM TT10714 cancer cell line human CVCL_C1MM CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Cys478Ter (c.1434C>A); Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 37.1 +- 0.3 hours (PubMed=29100338) 155261256 CVCL_C1ML TT10630 cancer cell line human CVCL_C1ML CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Ser516Ter (c.1547C>G); Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 43.1 +- 1.6 hours (PubMed=29100338) 155261257 CVCL_C1N0 SU-DIPG-XXV cancer cell line human CVCL_C1N0 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Female 155261258 CVCL_C1MN TT10728 cancer cell line human CVCL_C1MN CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=29100338; PubMed=32229503; PubMed=34732238) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 46.8 +- 0.4 hours (PubMed=29100338) 155261259 CVCL_C1N2 HSJD-DIPG-008 cancer cell line human CVCL_C1N2 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=31439867); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Arg429fs; Zygosity=Unspecified (PubMed=31439867) Derived from sampling site: Brainstem; pons. 155261260 CVCL_C1MQ TT11111 cancer cell line human CVCL_C1MQ CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 49.0 +- 0.8 hours (PubMed=29100338) 155261261 CVCL_C1N1 SU-DIPG-XXVII cancer cell line human CVCL_C1N1 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=28823557) Derived from sampling site: Brainstem; pons. Male 155261262 CVCL_C1MP TT10902 cancer cell line human CVCL_C1MP CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=29100338); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 54.9 +- 0.1 hours (PubMed=29100338) 155261263 CVCL_C1N4 SU-DIPG-XXXIII cancer cell line human CVCL_C1N4 CL:0000010 Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=33319914) Derived from sampling site: Brainstem; pons. 155261264 CVCL_C1MS TT11201 cancer cell line human CVCL_C1MS CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Female Doubling time: 49.5 +- 0.2 hours (PubMed=29100338) 155261265 CVCL_C1N3 HSJD-DIPG-014b cancer cell line human CVCL_C1N3 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=31439867); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Leu484fs (c.1451dup); ClinVar=VCV000871469; Zygosity=Unspecified (PubMed=31439867) Derived from sampling site: Brainstem; pons. 155261266 CVCL_C1MR TT11118 cancer cell line human CVCL_C1MR CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Male Doubling time: 70.9 +- 4.7 hours (PubMed=29100338) 155261267 CVCL_C1ME ALL-VG cancer cell line human CVCL_C1ME CL:0000010 Sequence variation: Gene deletion; HGNC; 1785; CDKN1B; Zygosity=Unspecified (PubMed=18656692); Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=18656692); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (PubMed=18656692); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 3495; ETV6; Name(s)=ETV6-ABL1 (PubMed=18656692; PubMed=28650474) Karyotypic information: 45,XY,der(1)t(1;9),der(9)t(9;13),-13,der(16)t(16;22) (PubMed=18656692); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis Male 155261268 CVCL_C1MD H446/VP cancer cell line human CVCL_C1MD CL:0000010 Sequence variation: Gene fusion; HGNC; 6728; LY6H + HGNC; 9709; PVT1; Name(s)=PVT1-LY6H (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: 35.7 hours (CelloPub=CLPUB00716) 155261269 CVCL_C1MG J774.C3C cancer cell line house mouse CVCL_C1MG CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: BALB/c. Female Characteristics: Lacks the ability to produce O2- or H2O2 when stimulated by PMA or aggregated immunoglobulin (PubMed=6252274); Characteristics: Unable to restrict the growth of epimastigotes or trypomastigotes of Trypanosoma cruzi to a significant degree (PubMed=6350185) 155261270 CVCL_C1MF ALL-VG TKI-resistant cancer cell line human CVCL_C1MF CL:0000010 Sequence variation: Gene deletion; HGNC; 1785; CDKN1B; Zygosity=Unspecified (from parent cell line); Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (from parent cell line); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 3495; ETV6; Name(s)=ETV6-ABL1 (PubMed=28650474); Sequence variation: Mutation; HGNC; 4396; GNB1; Simple; p.Lys89Met (c.266A>T); ClinVar=VCV001360749; Zygosity=Heterozygous; Note=Involved in imatinib resistance (PubMed=28650474) Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis Male 155261271 CVCL_C1MI HSJD-DIPG-013 cancer cell line human CVCL_C1MI CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238) Derived from sampling site: Brainstem; pons. 155261272 CVCL_C1MH BCH869 cancer cell line human CVCL_C1MH CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=29674595); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=29674595); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu39Lys (c.115G>A); Zygosity=Unspecified (PubMed=29674595); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly1007Arg (c.3019G>C); Zygosity=Unspecified (PubMed=29674595); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Gln510fs (c.1529delA); Zygosity=Unspecified (PubMed=29674595) Derived from sampling site: Brainstem; pons. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 155261273 CVCL_C1MK TT10603 cancer cell line human CVCL_C1MK CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=29100338); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=29100338) Population: Chinese; Derived from sampling site: Brainstem; pons. Male Doubling time: 67.6 +- 4.2 hours (PubMed=29100338) 155261274 CVCL_C1MJ SU-DIPG-XXXV cancer cell line human CVCL_C1MJ CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=34732238); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Ser432Ter; Zygosity=Unspecified (PubMed=34732238) Derived from sampling site: Brainstem; pons. 155261275 CVCL_C1MA MEO cancer cell line human CVCL_C1MA CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male 155261276 CVCL_C1MC MEP cancer cell line human CVCL_C1MC CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male Doubling time: 37.7 hours (PubMed=13954855) 155261277 CVCL_C1MB MEO clone 515 cancer cell line human CVCL_C1MB CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male Doubling time: 38.7 hours (PubMed=13954855) 155261278 CVCL_C1K3 KB319 transformed cell line human CVCL_C1K3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062; PubMed=8423817) 155261279 CVCL_C1JR UKERi010-A induced pluripotent stem cell human CVCL_C1JR From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 155261280 CVCL_C1K2 UKERi004-B induced pluripotent stem cell human CVCL_C1K2 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261281 CVCL_C1JQ UKERi009-A induced pluripotent stem cell human CVCL_C1JQ From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 155261282 CVCL_C1K5 KB319 subclone E1 transformed cell line human CVCL_C1K5 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261283 CVCL_C1JT UKERi010-A-2 induced pluripotent stem cell human CVCL_C1JT From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 155261284 CVCL_C1K4 KB319 subclone E transformed cell line human CVCL_C1K4 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261285 CVCL_C1JS UKERi010-A-1 induced pluripotent stem cell human CVCL_C1JS From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 155261286 CVCL_C1JV betaG 11/3E9 cancer cell line Norway rat CVCL_C1JV CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with both a pCB6-INS-Neo and a pRIP7-INS-HygroR constructs Expresses 27 times more insulin than the grand-parent cell line (PubMed=9166666). 155261287 CVCL_C1K7 KB319 subclone E9 transformed cell line human CVCL_C1K7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261288 CVCL_C1JU betaG I/17 cancer cell line Norway rat CVCL_C1JU CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with a pCB6-INS-Neo construct Expresses 10 times more insulin than the parent cell line (PubMed=9166666). 155261289 CVCL_C1K6 KB319 subclone E8 transformed cell line human CVCL_C1K6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261290 CVCL_C1JX betaG 40/107 cancer cell line Norway rat CVCL_C1JX CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: RGD; 2670; Gck; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with both a pCB6-INS-Neo and a PCB7-GK-HygroR constructs (PubMed=9166666) 155261291 CVCL_C1K9 KB319 subclone E1-7 transformed cell line human CVCL_C1K9 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261292 CVCL_C1JW betaG 23/21 cancer cell line Norway rat CVCL_C1JW CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: RGD; 2670; Gck; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with both a pCB6-INS-Neo and a pCMV8-GK-IRES-GPT constructs (PubMed=9166666) 155261293 CVCL_C1K8 KB319 subclone E1-6 transformed cell line human CVCL_C1K8 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261294 CVCL_C1JJ BL-76 cancer cell line human CVCL_C1JJ CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. 155261295 CVCL_C1JI BL-75 cancer cell line human CVCL_C1JI CL:0000010 Population: Caucasian Virology: EBV-negative. 155261296 CVCL_C1JL betaG 111/228 cancer cell line Norway rat CVCL_C1JL CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with both a pCMV8-INS-IRES-Neo and a pCMV8-INS-IRES-PuroR constructs Expresses 60 times more insulin than the grand-parent cell line (PubMed=9166666). 155261297 CVCL_C1JK betaG 18/3E1 cancer cell line Norway rat CVCL_C1JK CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with a pCMV8-INS-IRES-Neo construct (PubMed=9166666) 155261298 CVCL_C1JN WAe009-A-91 embryonic stem cell human CVCL_C1JN From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN. Female 155261299 CVCL_C1JM WAe009-A-89 embryonic stem cell human CVCL_C1JM From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11822; TIMP3. Female 155261300 CVCL_C1JP TAUi008-A induced pluripotent stem cell human CVCL_C1JP From: University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155261301 CVCL_C1K1 UKERi003-B induced pluripotent stem cell human CVCL_C1K1 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261302 CVCL_C1K0 UKERi002-B induced pluripotent stem cell human CVCL_C1K0 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261303 CVCL_C1JB MAZ1 transformed cell line human CVCL_C1JB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155261304 CVCL_C1JA LAW2 transformed cell line human CVCL_C1JA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic myeloid leukemia; Derived from sampling site: Peripheral blood. Female 155261305 CVCL_C1JD ORI1 transformed cell line human CVCL_C1JD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155261306 CVCL_C1JC ODY1 transformed cell line human CVCL_C1JC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155261307 CVCL_C1JF SHA1 transformed cell line human CVCL_C1JF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic myeloid leukemia; Derived from sampling site: Peripheral blood. Female 155261308 CVCL_C1JE PRA1 transformed cell line human CVCL_C1JE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155261309 CVCL_C1JH ASCC transformed cell line CVCL_C1JH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Neck; skin Cell type=Stromal cell.. Female Virology: Susceptible to infection by bovine herpesvirus-1, bovine viral diarrhea virus and caprine herpesvirus-1 and the endocellular parasite Neospora caninum (PubMed=25140515) Doubling time: 28.21 hours (PubMed=25140515) 155261310 CVCL_C1JG SHA2 transformed cell line human CVCL_C1JG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic myeloid leukemia; Derived from sampling site: Peripheral blood. Female 155261311 CVCL_C1IY 804G.003A cancer cell line Norway rat CVCL_C1IY CL:0000010 Transformant: N-butyl-N-(3-carboxypropyl)nitrosamine (BCPN)(ChEBI; CHEBI:91112); Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: ACI. Male Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11555 155261312 CVCL_C1J9 LAW1 transformed cell line human CVCL_C1J9 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic myeloid leukemia; Derived from sampling site: Peripheral blood. Female 155261313 CVCL_C1IX T9 cancer cell line Norway rat CVCL_C1IX CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261314 CVCL_C1IZ mAb1 hybridoma house mouse CVCL_C1IZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC9; Human SARS coronavirus 2 (SARS-CoV-2) nucleoprotein (N) (Note=Also reacts with SARS-CoV N). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2020231 155261315 CVCL_C1KS HCA7 colony 1 C1Y1C-3 cancer cell line human CVCL_C1KS CL:0000010 Transfected with: RGD; 3198; Npy1r (with p.Cys337Ser); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Female 155261316 CVCL_C1L4 KKU-M055/46 cancer cell line human CVCL_C1L4 CL:0000010 Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver; intrahepatic bile duct. Male 155261317 CVCL_C1KR HCA7 colony 1 C1Y1-15 cancer cell line human CVCL_C1KR CL:0000010 Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Female 155261318 CVCL_C1L3 MT-CHC01R1.5 cancer cell line human CVCL_C1L3 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Italian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Female Doubling time: 49.1 hours (PubMed=30979003) 155261319 CVCL_C1KU CHO-K1 Y1 spontaneously immortalized cell line CVCL_C1KU CL:0000010 Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155261320 CVCL_C1L6 KKU-M214/246 cancer cell line human CVCL_C1L6 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver. Male Problematic cell line: Contaminated Parent cell line (KKU-213B) shown to be a KKU-M213 derivative. 155261321 CVCL_C1KT HCA7 colony 1 C1Y1C-5 cancer cell line human CVCL_C1KT CL:0000010 Transfected with: RGD; 3198; Npy1r (with p.Cys337Ser); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Female 155261322 CVCL_C1L5 KKU-M055/8 cancer cell line human CVCL_C1L5 CL:0000010 Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver; intrahepatic bile duct. Male 155261323 CVCL_C1KW CHO-K1 HAY1-H spontaneously immortalized cell line CVCL_C1KW CL:0000010 Transfected with: RGD; 3198; Npy1r (with a HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155261324 CVCL_C1L8 HubCCA-1 cancer cell line human CVCL_C1L8 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver; intrahepatic bile duct. 155261325 CVCL_C1KV CHO-K1 Y1C spontaneously immortalized cell line CVCL_C1KV CL:0000010 Transfected with: RGD; 3198; Npy1r (with p.Cys337Ser); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155261326 CVCL_C1L7 KKU-M214/9 cancer cell line human CVCL_C1L7 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver. Male Problematic cell line: Contaminated Parent cell line (KKU-213B) shown to be a KKU-M213 derivative. 155261327 CVCL_C1KY CHO-K1 HAY1C-H spontaneously immortalized cell line CVCL_C1KY CL:0000010 Transfected with: RGD; 3198; Npy1r (with p.Cys337Ala and a HA tag) Derived from sampling site: Ovary. Female 155261328 CVCL_C1KX CHO-K1 HAY1-L spontaneously immortalized cell line CVCL_C1KX CL:0000010 Transfected with: RGD; 3198; Npy1r (with a HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155261329 CVCL_C1L9 LCF [Labeo] spontaneously immortalized cell line CVCL_C1L9 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Grows well from 24 to 32 Celsius, the optimal growth temperature is 28 Celsius Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC063 155261330 CVCL_C1KK GuRt09 conditionally immortalized cell line human CVCL_C1KK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal eye; retina. Unspecified Characteristics: Proliferates at the permissive temperature of 33 Celsius Differentiates at the non-permissive temperature of 37 Celsius. 155261331 CVCL_C1KJ BBANTWi011-A induced pluripotent stem cell human CVCL_C1KJ From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 9853; IPO8; Simple; p.Arg474Ter (c.1420C>T); ClinVar=VCV001047908; Zygosity=Homozygous (PubMed=36905820) Population: African; Derived from sampling site: Peripheral blood. Male 155261332 CVCL_C1KM HCA7 colony 1 C1Y1-6 cancer cell line human CVCL_C1KM CL:0000010 Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Female 155261333 CVCL_C1KL GuRt05 conditionally immortalized cell line human CVCL_C1KL CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal eye; retina. Unspecified Characteristics: Proliferates at the permissive temperature of 33 Celsius Differentiates at the non-permissive temperature of 37 Celsius. 155261334 CVCL_C1L0 Rn33B-A68B2M conditionally immortalized cell line Norway rat CVCL_C1L0 CL:0000010 Transfected with: UniProtKB; C9K796; Horse ELA A68; Transfected with: VGNC; 15722; Horse B2M; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; medullary raphe nucleus; Breed/subspecies: Sprague Dawley. Unspecified Virology: Susceptible to infection by equine herpesvirus type 1 (EHV-1) (PubMed=31758567) 155261335 CVCL_C1KN HT-29 Y1-16 cancer cell line human CVCL_C1KN CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 155261336 CVCL_C1KQ HT-29 Y1-7 cancer cell line human CVCL_C1KQ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 155261337 CVCL_C1L2 SNU-1196/GR cancer cell line human CVCL_C1L2 CL:0000010 Population: Korean; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Common hepatic duct. Unspecified 155261338 CVCL_C1L1 HCM-SqCC010 cancer cell line human CVCL_C1L1 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 27.3 hours (PubMed=36299342) 155261339 CVCL_C1KP HT-29 Y1-4 cancer cell line human CVCL_C1KP CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: RGD; 3198; Npy1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 155261340 CVCL_C1KC KB319 subclone E9-2 transformed cell line human CVCL_C1KC CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261341 CVCL_C1KB KB319 subclone E8-4 transformed cell line human CVCL_C1KB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261342 CVCL_C1KE RIN 100/1 cancer cell line Norway rat CVCL_C1KE CL:0000010 Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with Slc2a2 at high (100) passage 155261343 CVCL_C1KD KB319 subclone E9-6 transformed cell line human CVCL_C1KD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261344 CVCL_C1KG RIN 100/6 cancer cell line Norway rat CVCL_C1KG CL:0000010 Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with Slc2a2 at high (100) passage 155261345 CVCL_C1KF RIN 100/2 cancer cell line Norway rat CVCL_C1KF CL:0000010 Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with Slc2a2 at high (100) passage 155261346 CVCL_C1KI RIN 30/7 cancer cell line Norway rat CVCL_C1KI CL:0000010 Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with Slc2a2 at intermediate (30) passage 155261347 CVCL_C1KH RIN 30/10 cancer cell line Norway rat CVCL_C1KH CL:0000010 Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with Slc2a2 at intermediate (30) passage 155261348 CVCL_C1JZ betaG 40/110 cancer cell line Norway rat CVCL_C1JZ CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: RGD; 2670; Gck; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with both a pCB6-INS-Neo and a PCB7-GK-HygroR constructs (PubMed=9166666) 155261349 CVCL_C1JY betaG 49/206 cancer cell line Norway rat CVCL_C1JY CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: RGD; 2670; Gck; Transfected with: RGD; 3705; Slc2a2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Transfected with a pCB6-INS-Neo, a pCMV8-GK-IRES-GPT and a pCB7-GLUT2-HygroR constructs (PubMed=9166666) 155261350 CVCL_C1KA KB319 subclone E8-2 transformed cell line human CVCL_C1KA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The transfected plasmid pMSTKneo DNA was integrated at the telomere of chromosome 13 (PubMed=7957062) 155261351 CVCL_C1I1 GTX-103 cancer cell line human CVCL_C1I1 CL:0000010 Population: Korean; Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Male Characteristics: Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice 155261352 CVCL_C1HP LFS-05F-24 spontaneously immortalized cell line human CVCL_C1HP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (PubMed=19935656) Senescence: Became immortalized at 48-50 PDL (PubMed=19935656) 155261353 CVCL_C1I0 GTX-087 cancer cell line human CVCL_C1I0 CL:0000010 Population: Korean; Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261354 CVCL_C1I3 GTX-139 cancer cell line human CVCL_C1I3 CL:0000010 Population: Korean; Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261355 CVCL_C1HR LA-N-6 MUT p53 cancer cell line human CVCL_C1HR CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=28636942); Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Asp1091Asn (c.3271G>A); ClinVar=VCV000218628; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Heterozygous; Note=Acquired spontaneously at 90 PDL (PubMed=28636942) Derived from metastatic site: Bone marrow. Male 155261356 CVCL_C1HQ DOS16 cancer cell line human CVCL_C1HQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (DOI=10.26190/unsworks/20387) Miscellaneous: STR profile from personal communication of MacKenzie K Karyotypic information: Near triploid karyotype (DOI=10.26190/unsworks/20387); Derived from metastatic site: Retroperitoneal space. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) Doubling time: 44 hours (DOI=10.26190/unsworks/20387) 155261357 CVCL_C1I2 GTX-116 cancer cell line human CVCL_C1I2 CL:0000010 Population: Korean; Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Female Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261358 CVCL_C1I5 CT306X1 cancer cell line human CVCL_C1I5 CL:0000010 Derived from metastatic site: Liver. Unspecified Characteristics: Established from a xenograft, XenoCT306, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261359 CVCL_C1HT LM216 transformed cell line human CVCL_C1HT CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261360 CVCL_C1I4 CT305X1 cancer cell line human CVCL_C1I4 CL:0000010 Derived from sampling site: Colon; proximal. Unspecified Characteristics: Established from a xenograft, XenoCT305, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261361 CVCL_C1HS LM205 transformed cell line human CVCL_C1HS CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261362 CVCL_C1I7 CT310X6 cancer cell line human CVCL_C1I7 CL:0000010 Derived from metastatic site: Liver. Unspecified Characteristics: Established from a xenograft, XenoCT310, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261363 CVCL_C1HV GIST-M cancer cell line human CVCL_C1HV CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Pro573_Thr574insSerPro (c.1720_1725insGCCCCA); Zygosity=Heterozygous (DOI=10.26190/unsworks/20387) Derived from sampling site: Small intestine; duodenum. Female 155261364 CVCL_C1I6 CT307X1 cancer cell line human CVCL_C1I6 CL:0000010 Derived from metastatic site: Ovary. Female Characteristics: Established from a xenograft, XenoCT307, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261365 CVCL_C1HU LM217 transformed cell line human CVCL_C1HU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLR309](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261366 CVCL_C1HH GM847/hTERT-6 subclone 11 transformed cell line human CVCL_C1HH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261367 CVCL_C1HG GM847/hTERT-3 subclone 9 transformed cell line human CVCL_C1HG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261368 CVCL_C1HJ AT4BINE1-3 transformed cell line human CVCL_C1HJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261369 CVCL_C1HI AT3BISV transformed cell line human CVCL_C1HI CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261370 CVCL_C1HL TAT2SF T4-B transformed cell line human CVCL_C1HL CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1774Lysfs*17 (c.5320_5326del) (c.5320del7); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2769Ter (c.8307G>A); ClinVar=VCV000189104; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transfected with a pSXneo-1.6-T2AG3 plasmid that contains 1.6 kb of telomeric repeat sequences (PubMed=9357546) 155261371 CVCL_C1HK TAT2SF T4 transformed cell line human CVCL_C1HK CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1774Lysfs*17 (c.5320_5326del) (c.5320del7); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2769Ter (c.8307G>A); ClinVar=VCV000189104; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transfected with a pSXneo-1.6-T2AG3 plasmid that contains 1.6 kb of telomeric repeat sequences (PubMed=9357546) 155261372 CVCL_C1HN AT1BR44neo transformed cell line human CVCL_C1HN CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 155261373 CVCL_C1HM TAT2SF T4-F transformed cell line human CVCL_C1HM CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1774Lysfs*17 (c.5320_5326del) (c.5320del7); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2769Ter (c.8307G>A); ClinVar=VCV000189104; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transfected with a pSXneo-1.6-T2AG3 plasmid that contains 1.6 kb of telomeric repeat sequences (PubMed=9357546) 155261374 CVCL_C1HB CMT-7 c3 cancer cell line dog CVCL_C1HB CL:0000010 Derived from sampling site: Mammary gland. Female 155261375 CVCL_C1HA CMT-7 c2 cancer cell line dog CVCL_C1HA CL:0000010 Derived from sampling site: Mammary gland. Female 155261376 CVCL_C1HD CMT-7 c5 cancer cell line dog CVCL_C1HD CL:0000010 Derived from sampling site: Mammary gland. Female 155261377 CVCL_C1HC CMT-7 c4 cancer cell line dog CVCL_C1HC CL:0000010 Derived from sampling site: Mammary gland. Female 155261378 CVCL_C1HF GM847/hTERT-6 transformed cell line human CVCL_C1HF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261379 CVCL_C1HE GM847/hTERT-3 transformed cell line human CVCL_C1HE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261380 CVCL_C1H8 CMT-7 cancer cell line dog CVCL_C1H8 CL:0000010 Derived from sampling site: Mammary gland. Female 155261381 CVCL_C1GW IRE/LULS55 spontaneously immortalized cell line CVCL_C1GW CL:0000010 Unspecified Group: Tick cell line. 155261382 CVCL_C1H7 CMT-2 c5 cancer cell line dog CVCL_C1H7 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261383 CVCL_C1GV IRE/LUAP46 spontaneously immortalized cell line CVCL_C1GV CL:0000010 Unspecified Group: Tick cell line. 155261384 CVCL_C1GY CMT-1 c1 cancer cell line dog CVCL_C1GY CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261385 CVCL_C1H9 CMT-7 c1 cancer cell line dog CVCL_C1H9 CL:0000010 Derived from sampling site: Mammary gland. Female 155261386 CVCL_C1GX RBE/LULS58 spontaneously immortalized cell line CVCL_C1GX CL:0000010 Unspecified Group: Tick cell line. 155261387 CVCL_C1GZ CMT-1 c2 cancer cell line dog CVCL_C1GZ CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261388 CVCL_C1J2 mAb5 hybridoma house mouse CVCL_C1J2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC9; Human SARS coronavirus 2 (SARS-CoV-2) nucleoprotein (N) (Note=Also reacts with SARS-CoV N). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2020235 155261389 CVCL_C1IQ T2 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IQ CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261390 CVCL_C1J1 mAb4 hybridoma house mouse CVCL_C1J1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC9; Human SARS coronavirus 2 (SARS-CoV-2) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2020234 155261391 CVCL_C1IP T13 cancer cell line Norway rat CVCL_C1IP CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261392 CVCL_C1J4 1-903-430 hybridoma house mouse CVCL_C1J4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P80188; Human LCN2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8026 155261393 CVCL_C1IS T4 cancer cell line Norway rat CVCL_C1IS CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261394 CVCL_C1J3 1-2322-455 hybridoma house mouse CVCL_C1J3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P80188; Human LCN2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8024 155261395 CVCL_C1IR T3 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IR CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261396 CVCL_C1J6 CHO NGAL rAg C87S spontaneously immortalized cell line CVCL_C1J6 CL:0000010 Transfected with: HGNC; 6526; LCN2 (with p.Cys107Ser) Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8168 155261397 CVCL_C1IU T6 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IU CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261398 CVCL_C1J5 CHO NGAL rAg 662 spontaneously immortalized cell line CVCL_C1J5 CL:0000010 Transfected with: HGNC; 6526; LCN2 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8020 155261399 CVCL_C1IT T5 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IT CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261400 CVCL_C1J8 ART1 transformed cell line human CVCL_C1J8 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from chronic myeloid leukemia; Derived from sampling site: Peripheral blood. Female 155261401 CVCL_C1IW T8 cancer cell line Norway rat CVCL_C1IW CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261402 CVCL_C1J7 F-89 transformed cell line human CVCL_C1J7 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Male 155261403 CVCL_C1IV T7 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IV CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261404 CVCL_C1II CMT-12CnB7-2Q2 cancer cell line dog CVCL_C1II CL:0000010 Transfected with: VGNC; 38979; Dog CD86; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261405 CVCL_C1IH CMT-12CnB7-1R26 cancer cell line dog CVCL_C1IH CL:0000010 Transfected with: VGNC; 38975; Dog CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261406 CVCL_C1IK T1 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IK CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261407 CVCL_C1IJ CMT-12HuB7-2C10 cancer cell line dog CVCL_C1IJ CL:0000010 Transfected with: HGNC; 1705; CD86; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261408 CVCL_C1IM T11 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IM CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261409 CVCL_C1IL T10 [Rat mesothelioma] cancer cell line Norway rat CVCL_C1IL CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261410 CVCL_C1J0 mAb2 hybridoma house mouse CVCL_C1J0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DTC9; Human SARS coronavirus 2 (SARS-CoV-2) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2020233 155261411 CVCL_C1IN T12 cancer cell line Norway rat CVCL_C1IN CL:0000010 Transformant: Erionite(ChEBI; CHEBI:82272); Derived from sampling site: Lung; Breed/subspecies: Fischer 344. Male 155261412 CVCL_C1IA CT320 cancer cell line human CVCL_C1IA CL:0000010 Derived from sampling site: Colon; distal. Male 155261413 CVCL_C1IC CT329 cancer cell line human CVCL_C1IC CL:0000010 Derived from sampling site: Colon; distal. Male 155261414 CVCL_C1IB CT320X6 cancer cell line human CVCL_C1IB CL:0000010 Derived from sampling site: Colon; distal. Male Characteristics: Established from a xenograft, XenoCT320, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261415 CVCL_C1IE CT339X cancer cell line human CVCL_C1IE CL:0000010 Derived from metastatic site: Liver. Unspecified Characteristics: Established from a xenograft, XenoCT339, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261416 CVCL_C1ID CT329X12 cancer cell line human CVCL_C1ID CL:0000010 Derived from sampling site: Colon; distal. Male Characteristics: Established from a xenograft, XenoCT329, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261417 CVCL_C1IG CMT-12CnB7-1R25 cancer cell line dog CVCL_C1IG CL:0000010 Transfected with: VGNC; 38975; Dog CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female 155261418 CVCL_C1IF CT343 cancer cell line human CVCL_C1IF CL:0000010 Derived from sampling site: Colon; distal. Unspecified 155261419 CVCL_C1I9 CT316X5 cancer cell line human CVCL_C1I9 CL:0000010 Derived from metastatic site: Liver. Unspecified Characteristics: Established from a xenograft, XenoCT316, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261420 CVCL_C1HX GTX-007 cancer cell line human CVCL_C1HX CL:0000010 Population: Korean; Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261421 CVCL_C1I8 CT314X6 cancer cell line human CVCL_C1I8 CL:0000010 Derived from sampling site: Colon; proximal. Unspecified Characteristics: Established from a xenograft, XenoCT314, obtained from subcutaneous grafting of the tumor in male Swiss nu/nu nude mice 155261422 CVCL_C1HW GTX-006 cancer cell line human CVCL_C1HW CL:0000010 Population: Korean; Derived from sampling site: Stomach; body. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261423 CVCL_C1HZ GTX-086 cancer cell line human CVCL_C1HZ CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Stomach; body. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261424 CVCL_C1HY GTX-085 cancer cell line human CVCL_C1HY CL:0000010 Population: Korean; Derived from sampling site: Stomach; cardia. Omics: Array-based CGH Male Characteristics: Highly tumorigenic Established from a xenograft after serial heterotransplantation of the original gastric tumor in nude mice. 155261425 CVCL_C1WA SMBCi020-A induced pluripotent stem cell human CVCL_C1WA From: Shandong Medical Biotechnological Center; Jinan; China. CL:0000010 155261426 CVCL_C1WC SPPHIi004-A induced pluripotent stem cell human CVCL_C1WC From: Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro215Ser (c.643C>T) (p.Pro140Ser, c.418C>T); ClinVar=VCV000706054; Zygosity=Heterozygous (PubMed=35933956) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261427 CVCL_C1WB SPPHIi003-A induced pluripotent stem cell human CVCL_C1WB From: Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asp252Val (c.755A>T) (p.Asp177Val, c.530A>T); Zygosity=Heterozygous (PubMed=35933956) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261428 CVCL_C1WE SDQLCHi045-A induced pluripotent stem cell human CVCL_C1WE From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Gln642Ter (c.1924C>T); Zygosity=Heterozygous (PubMed=36473251) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261429 CVCL_C1WD SDQLCHi044-A induced pluripotent stem cell human CVCL_C1WD From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 11497; SYNGAP1; Simple; p.Arg687Ter (c.2059C>T); ClinVar=VCV000411584; Zygosity=Heterozygous (PubMed=36183676) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261430 CVCL_C1VV QBRIi014-A induced pluripotent stem cell human CVCL_C1VV From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 15751; NAPB; Simple; c.354+2T>G; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=36272305) Population: Arab; Donor information: Established from monozygotic triplet of QBRIi015-A (Cellosaurus=CVCL_C1VW) and QBRIi016-A (Cellosaurus=CVCL_C1VX); Derived from sampling site: Peripheral blood. Male 155261431 CVCL_C1W7 SCTi003-A induced pluripotent stem cell human CVCL_C1W7 HLA typing: A*24:02:01,26:01:01; B*07:02:01; C*07:02:01; DPB1*02:01:02,04:01:01; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01 (STEMCELL_Technologies) From: STEMCELL Technologies, Inc.; Vancouver; Canada CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH; Omics: Deep exome analysis Female 155261432 CVCL_C1VU PMUi002-C induced pluripotent stem cell human CVCL_C1VU From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261433 CVCL_C1W6 SCSe001-A-4 embryonic stem cell human CVCL_C1W6 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18060; ARX; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: Using homologous recombination an EGFP reporter gene was introduced in the INS locus 155261434 CVCL_C1VX QBRIi016-A induced pluripotent stem cell human CVCL_C1VX From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 15751; NAPB; Simple; c.354+2T>G; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=36272305) Population: Arab; Donor information: Established from monozygotic triplet of QBRIi014-A (Cellosaurus=CVCL_C1VV) and QBRIi015-A (Cellosaurus=CVCL_C1VW); Derived from sampling site: Peripheral blood. Male 155261435 CVCL_C1W9 SIAISi021-A induced pluripotent stem cell human CVCL_C1W9 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=35843023) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261436 CVCL_C1VW QBRIi015-A induced pluripotent stem cell human CVCL_C1VW From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 15751; NAPB; Simple; c.354+2T>G; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=36272305) Population: Arab; Donor information: Established from monozygotic triplet of QBRIi014-A (Cellosaurus=CVCL_C1VV) and QBRIi016-A (Cellosaurus=CVCL_C1VX); Derived from sampling site: Peripheral blood. Male 155261437 CVCL_C1W8 SHCDCLi001-A induced pluripotent stem cell human CVCL_C1W8 From: Department of Central Laboratory, Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 43532; MIR5004 Derived from sampling site: Peripheral blood. Male 155261438 CVCL_C1VZ QBRIi018-A induced pluripotent stem cell human CVCL_C1VZ From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 15751; NAPB; Simple; c.354+2T>G; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=36272305) Population: Arab; Derived from sampling site: Peripheral blood. Male 155261439 CVCL_C1VY QBRIi017-A induced pluripotent stem cell human CVCL_C1VY From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 15751; NAPB; Simple; c.354+2T>G; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=36272305) Population: Arab; Derived from sampling site: Peripheral blood. Female 155261440 CVCL_C1VN PMUi001-D induced pluripotent stem cell human CVCL_C1VN From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 155261441 CVCL_C1VM PMUi001-C induced pluripotent stem cell human CVCL_C1VM From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 155261442 CVCL_C1VP PMUi002-A induced pluripotent stem cell human CVCL_C1VP From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261443 CVCL_C1W1 RIi002-A-1 induced pluripotent stem cell human CVCL_C1W1 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Unexplicit_edited; Ex2del; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261444 CVCL_C1W0 REGUi015-A induced pluripotent stem cell human CVCL_C1W0 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France. CL:0000010 155261445 CVCL_C1VR PMUi002-A-2 induced pluripotent stem cell human CVCL_C1VR From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2988; DOCK2 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261446 CVCL_C1W3 RUESe002-A-2 embryonic stem cell human CVCL_C1W3 From: Rockefeller University; New York; USA CL:0000010 Omics: Array-based CGH. Female 155261447 CVCL_C1VQ PMUi002-A-1 induced pluripotent stem cell human CVCL_C1VQ From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2988; DOCK2 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261448 CVCL_C1W2 RUESe002-A-1 embryonic stem cell human CVCL_C1W2 CL:0000010 Omics: Array-based CGH. Female 155261449 CVCL_C1VT PMUi002-B induced pluripotent stem cell human CVCL_C1VT From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261450 CVCL_C1W5 RUESe002-A-5 embryonic stem cell human CVCL_C1W5 From: Rockefeller University; New York; USA CL:0000010 Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP). Female Characteristics: Using CRISPR/Cas9 a Bsd-P2A-tagRFP construct was introduced at the N-terminal end of SMAD1 155261451 CVCL_C1VS PMUi002-A-3 induced pluripotent stem cell human CVCL_C1VS From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2988; DOCK2 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 155261452 CVCL_C1W4 RUESe002-A-4 embryonic stem cell human CVCL_C1W4 From: Rockefeller University; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using CRISPR/Cas9 a PuroR-P2A-mcitrine construct was introduced at the N-terminal end of SMAD2 155261453 CVCL_C1VF PNUi003-B induced pluripotent stem cell human CVCL_C1VF From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Sequence variation: Gene deletion; HGNC; 2183; VPS13B; Zygosity=Heterozygous (PubMed=35944312) Miscellaneous: Has also a 16p13.11 duplication Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261454 CVCL_C1VE PNUi003-A induced pluripotent stem cell human CVCL_C1VE From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Sequence variation: Gene deletion; HGNC; 2183; VPS13B; Zygosity=Heterozygous (PubMed=35944312) Miscellaneous: Has also a 16p13.11 duplication Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261455 CVCL_C1VH PNUSCRi001-A induced pluripotent stem cell human CVCL_C1VH From: Convergence Stem Cell Research Center, Pusan National University; Yangsan; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn227Ser (c.680A>G) (N188S); ClinVar=VCV000004314; Zygosity=Heterozygous (PubMed=36332465) Population: Korean; Derived from sampling site: Peripheral blood. Male 155261456 CVCL_C1VG PNUi003-C induced pluripotent stem cell human CVCL_C1VG From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Sequence variation: Gene deletion; HGNC; 2183; VPS13B; Zygosity=Heterozygous (PubMed=35944312) Miscellaneous: Has also a 16p13.11 duplication Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261457 CVCL_C1VJ PUFHi004-A induced pluripotent stem cell human CVCL_C1VJ From: Peking University First Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 25380; TMEM163; Simple; p.Leu76Pro (c.227T>C); Zygosity=Heterozygous (hPSCreg) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261458 CVCL_C1VI PNUSCRi002-A induced pluripotent stem cell human CVCL_C1VI From: Convergence Stem Cell Research Center, Pusan National University; Yangsan; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg159Trp (c.475C>T) (R120W); ClinVar=VCV000065570; Zygosity=Heterozygous (PubMed=36274270) Population: Korean; Derived from sampling site: Peripheral blood. Male 155261459 CVCL_C1VL PMUi001-B induced pluripotent stem cell human CVCL_C1VL From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 155261460 CVCL_C1VK PMUi001-A induced pluripotent stem cell human CVCL_C1VK From: Institute of Experimental and Clinical Cell Therapy, Paracelsus Medical University; Salzburg; Austria CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 155261461 CVCL_C1XB UGOTSAi006-A induced pluripotent stem cell human CVCL_C1XB From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Male 155261462 CVCL_C1XA UGOTSAi005-B induced pluripotent stem cell human CVCL_C1XA From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Female 155261463 CVCL_C1XD UKBi018-A induced pluripotent stem cell human CVCL_C1XD From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany. CL:0000010 Female 155261464 CVCL_C1XC SUTCMi001-A induced pluripotent stem cell human CVCL_C1XC From: Shandong University of Traditional Chinese Medicine; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261465 CVCL_C1XF iLB-C89bf induced pluripotent stem cell human CVCL_C1XF From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 155261466 CVCL_C1XE UKBi015-B induced pluripotent stem cell human CVCL_C1XE From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261467 CVCL_C1WW STBCi017-A-1 induced pluripotent stem cell human CVCL_C1WW From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple_corrected; p.Arg841Ter (c.2521C>T) (p.Arg830Ter, c.2488C>T); ClinVar=VCV000440257; Zygosity=Heterozygous; By CRISPR/Cas9 (hPSCreg); Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple_corrected; p.Glu1784Glyfs*14 (c.5351delA) (p.Glu1773Glyfs, c.5318delA); ClinVar=VCV000471143; Zygosity=Heterozygous; By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 155261468 CVCL_C1X8 UGOTSAi004-B induced pluripotent stem cell human CVCL_C1X8 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 155261469 CVCL_C1WV STBCi014-B-1 induced pluripotent stem cell human CVCL_C1WV From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple_corrected; c.338+1delG (p.Leu113_Ile114insThr) (int4del); ClinVar=VCV000098013; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261470 CVCL_C1X7 UGOTSAi004-A induced pluripotent stem cell human CVCL_C1X7 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 155261471 CVCL_C1WY UBi005-A induced pluripotent stem cell human CVCL_C1WY From: University of Barcelona; Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261472 CVCL_C1WX STBCi028-A-1 induced pluripotent stem cell human CVCL_C1WX From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple_corrected; p.Arg582Gln (c.1745G>A) (p.Arg583Gln, c.1748G>A); ClinVar=VCV000008505; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 155261473 CVCL_C1X9 UGOTSAi005-A induced pluripotent stem cell human CVCL_C1X9 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Female 155261474 CVCL_C1WZ UMCGi011-A induced pluripotent stem cell human CVCL_C1WZ From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155261475 CVCL_C1X0 UMCGi011-B induced pluripotent stem cell human CVCL_C1X0 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155261476 CVCL_C1WN SKLOi002-A induced pluripotent stem cell human CVCL_C1WN From: State Key Laboratory of Ophthalmology, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9454; PROM1; Simple; p.Glu207Ter (c.619G>T); Zygosity=Homozygous (PubMed=36191543) Population: Chinese; Han; Derived from sampling site: Urine. Male 155261477 CVCL_C1X2 UIOi002-A induced pluripotent stem cell human CVCL_C1X2 From: University of Oslo; Oslo; Norway CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 155261478 CVCL_C1WQ XACHi018-A induced pluripotent stem cell human CVCL_C1WQ From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 155261479 CVCL_C1WP SKLOi003-A induced pluripotent stem cell human CVCL_C1WP From: State Key Laboratory of Ophthalmology, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9454; PROM1; Simple; p.Glu207Ter (c.619G>T); Zygosity=Heterozygous (PubMed=36191543) Population: Chinese; Han; Derived from sampling site: Urine. Female 155261480 CVCL_C1X1 UMCGi011-C induced pluripotent stem cell human CVCL_C1X1 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155261481 CVCL_C1X4 UGOTSAi002-B induced pluripotent stem cell human CVCL_C1X4 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Male 155261482 CVCL_C1WS XACHi020-A induced pluripotent stem cell human CVCL_C1WS From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 155261483 CVCL_C1X3 UIOi006-A induced pluripotent stem cell human CVCL_C1X3 From: University of Oslo; Oslo; Norway CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 155261484 CVCL_C1WR XACHi019-A induced pluripotent stem cell human CVCL_C1WR From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 155261485 CVCL_C1WU SIPDi001-A induced pluripotent stem cell human CVCL_C1WU From: Shaanxi Institute of Pediatric Diseases; Xi'an; China. CL:0000010 Male 155261486 CVCL_C1X6 UGOTSAi003-B induced pluripotent stem cell human CVCL_C1X6 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Male 155261487 CVCL_C1X5 UGOTSAi003-A induced pluripotent stem cell human CVCL_C1X5 From: The Sahlgrenska Academy, University of Gothenburg; Gothenburg; Sweden. CL:0000010 Male 155261488 CVCL_C1WT XACHi021-A induced pluripotent stem cell human CVCL_C1WT From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 155261489 CVCL_C1WG SFMUi001-A induced pluripotent stem cell human CVCL_C1WG From: Shandong First Medical University; Jinan; China CL:0000010 Derived from sampling site: Peripheral blood. Male 155261490 CVCL_C1WF SDQLCHi046-A induced pluripotent stem cell human CVCL_C1WF From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 13315; HDAC8; Simple; p.Glu186Lys (c.556G>A); ClinVar=VCV000211142; Zygosity=Hemizygous (PubMed=36481505) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261491 CVCL_C1WI SHFDi002-A induced pluripotent stem cell human CVCL_C1WI From: Shanghai Stomatological Hospital, Fudan University; Shanghai; China. CL:0000010 155261492 CVCL_C1WH SHETi003-A induced pluripotent stem cell human CVCL_C1WH From: Department of Cardiology, Shanghai Children's Hospital, Shanghai Jiaotong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 27365; TECRL; Simple; p.Arg196Gln (c.587G>A); ClinVar=VCV000372284; Zygosity=Heterozygous (PubMed=35679758); Sequence variation: Mutation; HGNC; 27365; TECRL; Simple; c.918+3T>G; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=35679758) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261493 CVCL_C1WK SHTUi002-A induced pluripotent stem cell human CVCL_C1WK From: ShanghaiTech University; Shanghai; China. CL:0000010 155261494 CVCL_C1WJ SHTUi001-A induced pluripotent stem cell human CVCL_C1WJ From: ShanghaiTech University; Shanghai; China. CL:0000010 155261495 CVCL_C1WM SJHi003-A induced pluripotent stem cell human CVCL_C1WM From: Shengjing Hospital of China Medical University; Shenyang; China. CL:0000010 155261496 CVCL_C1WL SHUPLi002-A induced pluripotent stem cell human CVCL_C1WL From: Shanghai University of Political Science and Law; Shanghai; China. CL:0000010 155261497 CVCL_C1UA iPSC 285.1 induced pluripotent stem cell human CVCL_C1UA From: Cincinnati Children's Hospital Medical Center; Cincinnati; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261498 CVCL_C1UC LEIi019-A induced pluripotent stem cell human CVCL_C1UC From: Lions Eye Institute, University of Western Australia; Nedlands; Australia. CL:0000010 155261499 CVCL_C1UB iPSC 75.1 induced pluripotent stem cell human CVCL_C1UB From: Cincinnati Children's Hospital Medical Center; Cincinnati; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261500 CVCL_C1TT JSPHi003-A induced pluripotent stem cell human CVCL_C1TT From: Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Ser437Hisfs*2 (c.1304_1307dupGCAC); ClinVar=VCV000066803; Zygosity=Heterozygous (PubMed=36095892) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261501 CVCL_C1U5 SIGi001-A-21 induced pluripotent stem cell human CVCL_C1U5 From: KU Leuven; Leuven; Belgium CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female Characteristics: Using ZFN a FRT-Hyg-TK-FRT construct was introduced in the AAVS1 safe harbor locus 155261502 CVCL_C1TS IRFMNi001-B-2 induced pluripotent stem cell human CVCL_C1TS From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Knockout cell: Method=CRISPR/Cas9; HGNC; 7067; CIITA Population: Caucasian; Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 155261503 CVCL_C1U4 KthES16 embryonic stem cell human CVCL_C1U4 From: Kyoto University; Kyoto; Japan. CL:0000010 Female Group: Clinical grade hESC cell line 155261504 CVCL_C1TV KSCBi018-A-1 induced pluripotent stem cell human CVCL_C1TV From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 12010; TPM1; Simple_edited; p.Glu192Lys (c.574G>A); ClinVar=VCV000031882; Zygosity=Heterozygous; Note=By CRISPR/Cas9 The cell also contains c.576G>A which is a silent mutation (PubMed=35917600). Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155261505 CVCL_C1U7 KULi003-A induced pluripotent stem cell human CVCL_C1U7 From: KU Leuven; Leuven; Belgium CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261506 CVCL_C1TU KSCBi017-A induced pluripotent stem cell human CVCL_C1TU From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 155261507 CVCL_C1U6 SIGi001-A-20 induced pluripotent stem cell human CVCL_C1U6 From: KU Leuven; Leuven; Belgium CL:0000010 Transfected with: HGNC; 11204; SOX9; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female Characteristics: Using ZFN a cassette containing a Tet-ON SOX9 construct framed by FRT and FRT3 sites was introduced in the AAVS1 safe harbor locus (PubMed=33982246) 155261508 CVCL_C1U9 iPSC 115.1 induced pluripotent stem cell human CVCL_C1U9 From: Cincinnati Children's Hospital Medical Center; Cincinnati; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155261509 CVCL_C1TX KSCBi018-A-2 induced pluripotent stem cell human CVCL_C1TX From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155261510 CVCL_C1TW KSCBi002-A-2 induced pluripotent stem cell human CVCL_C1TW CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 155261511 CVCL_C1U8 LCHi003-A induced pluripotent stem cell human CVCL_C1U8 From: Lurie Children's Hospital of Chicago; Chicago; USA. CL:0000010 155261512 CVCL_C1TZ KSCBi018-A-4 induced pluripotent stem cell human CVCL_C1TZ From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12403; TTN Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155261513 CVCL_C1TY KSCBi018-A-3 induced pluripotent stem cell human CVCL_C1TY From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12403; TTN Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155261514 CVCL_C1TL WUMi003-A induced pluripotent stem cell human CVCL_C1TL From: Medical University of Warsaw; Warsaw; Poland. CL:0000010 Male 155261515 CVCL_C1TK WUMi002-A induced pluripotent stem cell human CVCL_C1TK From: Medical University of Warsaw; Warsaw; Poland. CL:0000010 Male 155261516 CVCL_C1TN ICGi042-A induced pluripotent stem cell human CVCL_C1TN From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Glu334Lys (c.1000G>A); ClinVar=VCV000039128; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile723Val (c.2167A>G); ClinVar=VCV000039146; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Asn521Thr (c.1562A>C); ClinVar=VCV000295006; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 155261517 CVCL_C1TM WUMi004-A induced pluripotent stem cell human CVCL_C1TM From: Medical University of Warsaw; Warsaw; Poland. CL:0000010 Male 155261518 CVCL_C1TP ICGi042-B induced pluripotent stem cell human CVCL_C1TP From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Glu334Lys (c.1000G>A); ClinVar=VCV000039128; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile723Val (c.2167A>G); ClinVar=VCV000039146; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Asn521Thr (c.1562A>C); ClinVar=VCV000295006; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 155261519 CVCL_C1U1 KUCFRi005-A induced pluripotent stem cell pig CVCL_C1U1 From: Korea University Cell Function Regulation Lab; Seoul; South Korea CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155261520 CVCL_C1U0 KSCBi018-A-5 induced pluripotent stem cell human CVCL_C1U0 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12403; TTN Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155261521 CVCL_C1TR IOBi001-A induced pluripotent stem cell human CVCL_C1TR From: Institute of Molecular and Clinical Ophthalmology Basel; Basel; Switzerland CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155261522 CVCL_C1U3 KthES15 embryonic stem cell human CVCL_C1U3 From: Kyoto University; Kyoto; Japan. CL:0000010 Male Group: Clinical grade hESC cell line 155261523 CVCL_C1TQ ICGi042-C induced pluripotent stem cell human CVCL_C1TQ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Glu334Lys (c.1000G>A); ClinVar=VCV000039128; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile723Val (c.2167A>G); ClinVar=VCV000039146; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Asn521Thr (c.1562A>C); ClinVar=VCV000295006; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 155261524 CVCL_C1U2 KUCFRi005-A-1 induced pluripotent stem cell pig CVCL_C1U2 From: Korea University Cell Function Regulation Lab; Seoul; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 86395; CD2 Derived from sampling site: Cell type=Fibroblast. Female 155261525 CVCL_C1TD HIHDNEi004-A induced pluripotent stem cell human CVCL_C1TD From: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18539; STX1B; Simple; p.Lys45delinsArgMetCysIleGlu (c.133_134insGGATGTGCATTG); ClinVar=VCV000162396; Zygosity=Heterozygous (PubMed=36652844); Sequence variation: Mutation; HGNC; 18539; STX1B; Simple; p.Leu46Met (c.135_136delinsGA) (c.135_136AC>GA); Zygosity=Heterozygous (PubMed=36652844) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261526 CVCL_C1TC HHUi006-B induced pluripotent stem cell human CVCL_C1TC From: Universitatsklinikum Dusseldorf, Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Heteroplasmic; Note=In about 4% of cells (PubMed=36137325) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261527 CVCL_C1TF HUJIi002-A induced pluripotent stem cell human CVCL_C1TF From: Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 12799; WWOX; Simple; c.517-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (hPSCreg) Population: Jewish; Yemenite; Derived from sampling site: Peripheral blood. Female 155261528 CVCL_C1TE HUJIi001-A induced pluripotent stem cell human CVCL_C1TE From: Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 12799; WWOX; Simple; c.517-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (hPSCreg) Population: Jewish; Yemenite; Derived from sampling site: Peripheral blood. Male 155261529 CVCL_C1TH VUB25_CMT1A embryonic stem cell human CVCL_C1TH From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 155261530 CVCL_C1TG HUJIi003-A induced pluripotent stem cell human CVCL_C1TG From: Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 12799; WWOX; Simple; c.517-2A>G; Zygosity=Homozygous; Note=Splice acceptor mutation (hPSCreg) Population: Jewish; Yemenite; Derived from sampling site: Peripheral blood. Male 155261531 CVCL_C1TJ WUMi001-A induced pluripotent stem cell human CVCL_C1TJ From: Medical University of Warsaw; Warsaw; Poland. CL:0000010 155261532 CVCL_C1TI YCMi007-A induced pluripotent stem cell human CVCL_C1TI From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Arg205Trp (c.613C>T); ClinVar=VCV000180554; Zygosity=Heterozygous (PubMed=36801602) Population: Korean; Derived from sampling site: Peripheral blood. Male 155261533 CVCL_C1VB NMIi012-D induced pluripotent stem cell human CVCL_C1VB From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261534 CVCL_C1VA NMIi012-C induced pluripotent stem cell human CVCL_C1VA From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Female 155261535 CVCL_C1VD NUIGi002-B induced pluripotent stem cell human CVCL_C1VD From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 155261536 CVCL_C1VC NMIi012-E induced pluripotent stem cell human CVCL_C1VC From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261537 CVCL_C1UU MUSIi020-A induced pluripotent stem cell human CVCL_C1UU From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155261538 CVCL_C1V6 NMIi011-C induced pluripotent stem cell human CVCL_C1V6 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261539 CVCL_C1UT MRIi027-A-1 induced pluripotent stem cell human CVCL_C1UT From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261540 CVCL_C1V5 NMIi011-B induced pluripotent stem cell human CVCL_C1V5 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261541 CVCL_C1UW NCBSi004-A induced pluripotent stem cell human CVCL_C1UW From: Tata Institute of Fundamental Research, National Centre for Biological Sciences; Bangalore; India. CL:0000010 155261542 CVCL_C1V8 NMIi012-A induced pluripotent stem cell human CVCL_C1V8 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Female 155261543 CVCL_C1UV NCBSi003-A induced pluripotent stem cell human CVCL_C1UV From: Tata Institute of Fundamental Research, National Centre for Biological Sciences; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Arg741Gln (c.2222G>A); ClinVar=VCV000006203; Zygosity=Unspecified (hPSCreg). 155261544 CVCL_C1V7 NMIi011-D induced pluripotent stem cell human CVCL_C1V7 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261545 CVCL_C1UY NEIi002-A induced pluripotent stem cell human CVCL_C1UY From: National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261546 CVCL_C1UX NEIi001-A induced pluripotent stem cell human CVCL_C1UX From: National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261547 CVCL_C1V9 NMIi012-B induced pluripotent stem cell human CVCL_C1V9 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261548 CVCL_C1UZ NEIi003-A induced pluripotent stem cell human CVCL_C1UZ From: National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261549 CVCL_C1UM LUMCi050-B induced pluripotent stem cell human CVCL_C1UM From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261550 CVCL_C1UL LUMCi050-A induced pluripotent stem cell human CVCL_C1UL From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261551 CVCL_C1V0 NEIi004-A induced pluripotent stem cell human CVCL_C1V0 From: National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261552 CVCL_C1UN LUMCi050-C induced pluripotent stem cell human CVCL_C1UN From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261553 CVCL_C1UQ LZUSHI002-A induced pluripotent stem cell human CVCL_C1UQ From: Lanzhou University Second Hospital; Lanzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3483; ETFDH; Simple; p.Ser457Pro (c.1369T>C); ClinVar=VCV001040865; Zygosity=Heterozygous (PubMed=36162333); Sequence variation: Mutation; HGNC; 3483; ETFDH; Simple; p.Met617Ile (c.1851G>A); Zygosity=Heterozygous (PubMed=36162333) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261554 CVCL_C1V2 NIHi003-A induced pluripotent stem cell human CVCL_C1V2 From: National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 155261555 CVCL_C1UP LVPEIi001-A induced pluripotent stem cell human CVCL_C1UP From: LV Prasad Eye Institute; Banjara Hills; India CL:0000010 Population: Indian; Derived from sampling site: Ear; skin; dermis Cell type=Fibroblast.. Female 155261556 CVCL_C1V1 NFHHMUi001-A induced pluripotent stem cell human CVCL_C1V1 From: Department of Neurosurgery, First Affiliated Hospital of Harbin Medical University; Harbin; China CL:0000010 Sequence variation: Mutation; HGNC; 1573; KRIT1; Simple; p.Thr545fs*6 (c.1635delA); Zygosity=Heterozygous (PubMed=35716468) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261557 CVCL_C1US MMCi002-A induced pluripotent stem cell human CVCL_C1US From: Mackay Medical College; New Taipei City; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 155261558 CVCL_C1V4 NMIi011-A induced pluripotent stem cell human CVCL_C1V4 From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Donor information: Established from a patient suffering from invasive lobular breast carcinoma; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 155261559 CVCL_C1UR MDCi234-A induced pluripotent stem cell human CVCL_C1UR From: Max Delbruck Center Berlin Buch; Berlin; Germany. CL:0000010 155261560 CVCL_C1V3 NIHi004-A induced pluripotent stem cell human CVCL_C1V3 From: National Institutes of Health; Bethesda; USA. CL:0000010 Female 155261561 CVCL_C1UE LEIi020-B induced pluripotent stem cell human CVCL_C1UE From: Lions Eye Institute, University of Western Australia; Nedlands; Australia. CL:0000010 155261562 CVCL_C1UD LEIi020-A induced pluripotent stem cell human CVCL_C1UD From: Lions Eye Institute, University of Western Australia; Nedlands; Australia. CL:0000010 155261563 CVCL_C1UG LUMCi048-B induced pluripotent stem cell human CVCL_C1UG From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261564 CVCL_C1UF LUMCi048-A induced pluripotent stem cell human CVCL_C1UF From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261565 CVCL_C1UI LUMCi049-A induced pluripotent stem cell human CVCL_C1UI From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 155261566 CVCL_C1UH LUMCi048-C induced pluripotent stem cell human CVCL_C1UH From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 155261567 CVCL_C1UK LUMCi049-C induced pluripotent stem cell human CVCL_C1UK From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 155261568 CVCL_C1UJ LUMCi049-B induced pluripotent stem cell human CVCL_C1UJ From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 155261569 CVCL_C1RZ SCVIi052-A induced pluripotent stem cell human CVCL_C1RZ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261570 CVCL_C1RY SCVIi051-A induced pluripotent stem cell human CVCL_C1RY From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261571 CVCL_C1SA SCVIi063-A induced pluripotent stem cell human CVCL_C1SA From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 16882; HCN4; Simple; p.Ala863Ser (c.2587G>T); ClinVar=VCV000573236; Zygosity=Heterozygous (PubMed=36332467) Derived from sampling site: Peripheral blood. Female 155261572 CVCL_C1RR PSYLMUi041-A induced pluripotent stem cell human CVCL_C1RR From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261573 CVCL_C1S3 SCVIi056-A induced pluripotent stem cell human CVCL_C1S3 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Female 155261574 CVCL_C1RQ PSYLMUi040-A induced pluripotent stem cell human CVCL_C1RQ From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261575 CVCL_C1S2 SCVIi055-A induced pluripotent stem cell human CVCL_C1S2 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Female 155261576 CVCL_C1RT PSYLMUi043-A induced pluripotent stem cell human CVCL_C1RT From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261577 CVCL_C1S5 SCVIi058-A induced pluripotent stem cell human CVCL_C1S5 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261578 CVCL_C1RS PSYLMUi042-A induced pluripotent stem cell human CVCL_C1RS From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261579 CVCL_C1S4 SCVIi057-A induced pluripotent stem cell human CVCL_C1S4 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 155261580 CVCL_C1RV PSYLMUi045-A induced pluripotent stem cell human CVCL_C1RV From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261581 CVCL_C1S7 SCVIi060-A induced pluripotent stem cell human CVCL_C1S7 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Simple; p.Asp1249Asn (c.3745G>A); ClinVar=VCV000539405; Zygosity=Heterozygous (PubMed=36194907) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261582 CVCL_C1RU PSYLMUi044-A induced pluripotent stem cell human CVCL_C1RU From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261583 CVCL_C1S6 SCVIi059-A induced pluripotent stem cell human CVCL_C1S6 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 3756; FLNC; Simple; p.Arg2230His (c.6689G>A); ClinVar=VCV000567146; Zygosity=Heterozygous (PubMed=36194907) Population: Asian; Derived from sampling site: Peripheral blood. Male 155261584 CVCL_C1RX PSYLMUi047-A induced pluripotent stem cell human CVCL_C1RX From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261585 CVCL_C1S9 SCVIi062-A induced pluripotent stem cell human CVCL_C1S9 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 11167; SNTA1; Simple; p.Glu363Ala (c.1088A>C); ClinVar=VCV000190918; Zygosity=Heterozygous (PubMed=36528013) Population: Asian; Derived from sampling site: Peripheral blood. Female 155261586 CVCL_C1RW PSYLMUi046-A induced pluripotent stem cell human CVCL_C1RW From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261587 CVCL_C1S8 SCVIi061-A induced pluripotent stem cell human CVCL_C1S8 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 11167; SNTA1; Simple; p.Glu363Ala (c.1088A>C); ClinVar=VCV000190918; Zygosity=Heterozygous (PubMed=36528013) Population: Asian; Derived from sampling site: Peripheral blood. Female 155261588 CVCL_C1RJ PSYLMUi034-A induced pluripotent stem cell human CVCL_C1RJ From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261589 CVCL_C1RI PSYLMUi033-A induced pluripotent stem cell human CVCL_C1RI From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261590 CVCL_C1RL PSYLMUi036-A induced pluripotent stem cell human CVCL_C1RL From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261591 CVCL_C1RK PSYLMUi035-A induced pluripotent stem cell human CVCL_C1RK From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261592 CVCL_C1RN PSYLMUi038-A induced pluripotent stem cell human CVCL_C1RN From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261593 CVCL_C1RM PSYLMUi037-A induced pluripotent stem cell human CVCL_C1RM From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261594 CVCL_C1RP PSYLMUi039-A induced pluripotent stem cell human CVCL_C1RP From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261595 CVCL_C1S1 SCVIi054-A induced pluripotent stem cell human CVCL_C1S1 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261596 CVCL_C1S0 SCVIi053-A induced pluripotent stem cell human CVCL_C1S0 From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261597 CVCL_C1RB PSYLMUi026-A induced pluripotent stem cell human CVCL_C1RB From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261598 CVCL_C1RA PSYLMUi025-A induced pluripotent stem cell human CVCL_C1RA From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261599 CVCL_C1RD PSYLMUi028-A induced pluripotent stem cell human CVCL_C1RD From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261600 CVCL_C1RC PSYLMUi027-A induced pluripotent stem cell human CVCL_C1RC From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261601 CVCL_C1RF PSYLMUi030-A induced pluripotent stem cell human CVCL_C1RF From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261602 CVCL_C1RE PSYLMUi029-A induced pluripotent stem cell human CVCL_C1RE From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261603 CVCL_C1RH PSYLMUi032-A induced pluripotent stem cell human CVCL_C1RH From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261604 CVCL_C1RG PSYLMUi031-A induced pluripotent stem cell human CVCL_C1RG From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261605 CVCL_C1SZ CUIMCi005-A induced pluripotent stem cell human CVCL_C1SZ From: Columbia University Irving Medical Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Glu1650Argfs*12 (c.4947delC); ClinVar=VCV000289420; Zygosity=Heterozygous (PubMed=36455383); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Gly1961Glu (c.5882G>A); ClinVar=VCV000007888; Zygosity=Heterozygous (PubMed=36455383) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261606 CVCL_C1TB HHUi006-A induced pluripotent stem cell human CVCL_C1TB From: Universitatsklinikum Dusseldorf, Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Heteroplasmic; Note=In about 4% of cells (PubMed=36137325) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261607 CVCL_C1TA HHUi003-C induced pluripotent stem cell human CVCL_C1TA From: Universitatsklinikum Dusseldorf, Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=36137325) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261608 CVCL_C1SS BJTTHi001-A-5 induced pluripotent stem cell human CVCL_C1SS From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 12362; TSC1 Population: Chinese; Derived from sampling site: Peripheral blood. Male 155261609 CVCL_C1T4 FHUSTCi002-A induced pluripotent stem cell human CVCL_C1T4 From: The First Affiliated Hospital of USTC, Division of life Science and Medicine, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 25538; DARS2; Simple; p.Arg76Serfs*5 (c.228-21_228-20delinsC); ClinVar=VCV000001057; Zygosity=Heterozygous (PubMed=35914483); Sequence variation: Mutation; HGNC; 25538; DARS2; Simple; p.Tyr173Cys (c.518A>G); Zygosity=Heterozygous (PubMed=35914483) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155261610 CVCL_C1SR BJTTHi001-A-4 induced pluripotent stem cell human CVCL_C1SR From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6251; KCNH2 Population: Chinese; Derived from sampling site: Peripheral blood. Male 155261611 CVCL_C1T3 FDHSi001-A induced pluripotent stem cell human CVCL_C1T3 From: Huashan Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 1226; GIPC1; Repeat_expansion; c.-211GGC(163); c.-211GGC[(73_?)]; ClinVar=VCV000972742; Zygosity=Heterozygous (PubMed=36055118) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155261612 CVCL_C1SU CBCHi001-A-1 induced pluripotent stem cell human CVCL_C1SU From: Beijing Chest Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 143; ACTC1; Simple_edited; p.Glu239Gln (c.715G>C); ClinVar=VCV000520471; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg). Female 155261613 CVCL_C1T6 GIBHi002-A-5 induced pluripotent stem cell human CVCL_C1T6 From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16963; RRAGA Population: Caucasian; Derived from sampling site: Urine. Female 155261614 CVCL_C1ST CBCHi001-A induced pluripotent stem cell human CVCL_C1ST From: Beijing Chest Hospital; Beijing; China. CL:0000010 Female 155261615 CVCL_C1T5 GBCi001-A induced pluripotent stem cell human CVCL_C1T5 From: Guangzhou Blood Centre; Guangzhou; China. CL:0000010 Female 155261616 CVCL_C1SW CMGANTi003-A induced pluripotent stem cell human CVCL_C1SW From: Center of Medical Genetics Antwerp; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1044; BGN; Simple; p.Gly259Val (c.776G>T); ClinVar=VCV000243091; Zygosity=Hemizygous (PubMed=36640472) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 155261617 CVCL_C1T8 HHUi003-A induced pluripotent stem cell human CVCL_C1T8 From: Universitatsklinikum Dusseldorf, Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (from autologous cell lines HHUi003-A and HHUi003-B) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261618 CVCL_C1SV CIPi003-A induced pluripotent stem cell human CVCL_C1SV From: Children's Hospital of Capital Institute of Pediatrics; Beijing; China. CL:0000010 155261619 CVCL_C1T7 GZHMUi002-A induced pluripotent stem cell human CVCL_C1T7 From: Guangzhou Medical University; Guangzhou; China. CL:0000010 155261620 CVCL_C1SY CUIMCi003-A-1 induced pluripotent stem cell human CVCL_C1SY From: Columbia University Irving Medical Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16876; ARNT2; Simple_corrected; p.Pro130Ala (c.388C>G); Zygosity=Heterozygous; Note=Using CRISPR/Cas9 (PubMed=35950852) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155261621 CVCL_C1SX CMGANTi004-A induced pluripotent stem cell human CVCL_C1SX From: Center of Medical Genetics Antwerp; Antwerp; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1044; BGN; Simple; p.Gly259Val (c.776G>T); ClinVar=VCV000243091; Zygosity=Hemizygous (PubMed=36640472) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 155261622 CVCL_C1T9 HHUi003-B induced pluripotent stem cell human CVCL_C1T9 From: Universitatsklinikum Dusseldorf, Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Homoplasmic (PubMed=36137325) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261623 CVCL_C1SK AIBNi015-A induced pluripotent stem cell human CVCL_C1SK From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Pro459Leu (c.1376C>T); ClinVar=VCV000571544; Zygosity=Heterozygous (PubMed=36166872); Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Arg488Trp (c.1462C>T); ClinVar=VCV000039504; Zygosity=Heterozygous (PubMed=36166872) Derived from sampling site: Cell type=Fibroblast. Female 155261624 CVCL_C1SJ AHMUi005-A induced pluripotent stem cell human CVCL_C1SJ From: Anhui Medical University; Anhui; China. CL:0000010 155261625 CVCL_C1SM AIBNi017-A induced pluripotent stem cell human CVCL_C1SM From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Ile158Serfs*2 (c.471delC); ClinVar=VCV000655971; Zygosity=Heterozygous (PubMed=36166872) Derived from sampling site: Peripheral blood. Female 155261626 CVCL_C1SL AIBNi016-A induced pluripotent stem cell human CVCL_C1SL From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Ile158Serfs*2 (c.471delC); ClinVar=VCV000655971; Zygosity=Heterozygous (PubMed=36166872); Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Leu362Pro (c.1085T>C); Zygosity=Heterozygous (PubMed=36166872) Derived from sampling site: Peripheral blood. Female 155261627 CVCL_C1T0 DMBi001-A-2 induced pluripotent stem cell human CVCL_C1T0 From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Knockout cell: Method=CRISPR/Cas9; 31543; MIR15A; Knockout cell: Method=CRISPR/Cas9; 31545; MIR16-1 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261628 CVCL_C1SN AIBNi018-A induced pluripotent stem cell human CVCL_C1SN From: Australian Institute for Bioengineering and Nanotechnology; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 20582; CYP2U1; Simple; p.Leu362Pro (c.1085T>C); Zygosity=Heterozygous (PubMed=36166872) Derived from sampling site: Peripheral blood. Male 155261629 CVCL_C1SQ BJTTHi001-A-3 induced pluripotent stem cell human CVCL_C1SQ From: Beijing Tiantan Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6220; KCNA2 Population: Chinese; Derived from sampling site: Peripheral blood. Male 155261630 CVCL_C1T2 FDEENTi005-A induced pluripotent stem cell human CVCL_C1T2 From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China. CL:0000010 155261631 CVCL_C1SP AKOSi010-A induced pluripotent stem cell human CVCL_C1SP From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 21197; FA2H; Simple; p.Gly45Arg (c.133G>A); ClinVar=VCV001344330; Zygosity=Heterozygous (PubMed=35843022); Sequence variation: Mutation; HGNC; 21197; FA2H; Simple; p.His319Arg (c.956A>G); ClinVar=VCV001344335; Zygosity=Heterozygous (PubMed=35843022) Derived from sampling site: Cell type=Fibroblast. Female 155261632 CVCL_C1T1 FDEENTi004-A induced pluripotent stem cell human CVCL_C1T1 From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China. CL:0000010 Male 155261633 CVCL_C1SC SCVIi065-A induced pluripotent stem cell human CVCL_C1SC From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 155261634 CVCL_C1SB SCVIi064-A induced pluripotent stem cell human CVCL_C1SB From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 16882; HCN4; Simple; p.Arg949Gln (c.2846G>A); ClinVar=VCV000933551; Zygosity=Heterozygous (PubMed=36332467) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261635 CVCL_C1SE SCVIi067-A induced pluripotent stem cell human CVCL_C1SE From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 Male 155261636 CVCL_C1SD SCVIi066-A induced pluripotent stem cell human CVCL_C1SD From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 Male 155261637 CVCL_C1SG AHMUi002-A induced pluripotent stem cell human CVCL_C1SG From: Anhui Medical University; Anhui; China. CL:0000010 155261638 CVCL_C1SF AHMUi001-A induced pluripotent stem cell human CVCL_C1SF From: Anhui Medical University; Anhui; China CL:0000010 Sequence variation: Mutation; HGNC; 7455; MT-ND1; Simple; p.Ser110Asn (m.3635G>A); ClinVar=VCV000065518; Zygosity=Homoplasmic (PubMed=35905669) Population: Chinese; Derived from sampling site: Peripheral blood. Male 155261639 CVCL_C1SI AHMUi004-A induced pluripotent stem cell human CVCL_C1SI From: Anhui Medical University; Anhui; China. CL:0000010 155261640 CVCL_C1SH AHMUi003-A induced pluripotent stem cell human CVCL_C1SH From: Anhui Medical University; Anhui; China. CL:0000010 155261641 CVCL_C1PX HMSCATi005-A induced pluripotent stem cell human CVCL_C1PX From: Stem Cell Application and Translation Laboratory, Hebei Medical University; Shijiazhuang; China. CL:0000010 155261642 CVCL_C1Q9 IMBAi002-A induced pluripotent stem cell human CVCL_C1Q9 From: Institute of Molecular Biotechnology; Vienna; Austria CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 155261643 CVCL_C1PW HMSCATi004-A induced pluripotent stem cell human CVCL_C1PW From: Stem Cell Application and Translation Laboratory, Hebei Medical University; Shijiazhuang; China. CL:0000010 Female 155261644 CVCL_C1Q8 IMBAi001-A induced pluripotent stem cell human CVCL_C1Q8 From: Institute of Molecular Biotechnology; Vienna; Austria CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 155261645 CVCL_C1PZ IBTCMi002-A induced pluripotent stem cell human CVCL_C1PZ From: Institute of Basic Theory for Chinese Medicine; Beijing; China CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 155261646 CVCL_C1PY HMUi002-A induced pluripotent stem cell human CVCL_C1PY From: Eye Hospital, Harbin Medical University; Harbin; China CL:0000010 Population: Chinese; Han. Male 155261647 CVCL_C1PP ESi087-A induced pluripotent stem cell human CVCL_C1PP From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155261648 CVCL_C1Q1 IBTCMi004-A induced pluripotent stem cell human CVCL_C1Q1 From: Institute of Basic Theory for Chinese Medicine; Beijing; China CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 155261649 CVCL_C1Q0 IBTCMi003-A induced pluripotent stem cell human CVCL_C1Q0 From: Institute of Basic Theory for Chinese Medicine; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (hPSCreg) Derived from sampling site: Urine Cell type=Epithelial cell.. Female 155261650 CVCL_C1PR ESi089-A induced pluripotent stem cell human CVCL_C1PR From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155261651 CVCL_C1Q3 IIMCBi003-A induced pluripotent stem cell human CVCL_C1Q3 From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155261652 CVCL_C1PQ ESi088-A induced pluripotent stem cell human CVCL_C1PQ From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155261653 CVCL_C1Q2 IBTCMi005-A induced pluripotent stem cell human CVCL_C1Q2 From: Institute of Basic Theory for Chinese Medicine; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (hPSCreg) Derived from sampling site: Urine Cell type=Epithelial cell.. Male 155261654 CVCL_C1PT ESi086-A-3 induced pluripotent stem cell human CVCL_C1PT From: Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1348; SAMD9; Simple_edited; p.Ile1567Met (c.4701A>G); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36087523) Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155261655 CVCL_C1Q5 IIMCBi005-A induced pluripotent stem cell human CVCL_C1Q5 From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[53] (c.52CAG(53)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36228511) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261656 CVCL_C1PS ESi090-A induced pluripotent stem cell human CVCL_C1PS From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Population: Caucasian. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155261657 CVCL_C1Q4 IIMCBi004-A induced pluripotent stem cell human CVCL_C1Q4 From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36228511) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261658 CVCL_C1PV HHUUKDi012-A induced pluripotent stem cell human CVCL_C1PV From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Urine. Female 155261659 CVCL_C1Q7 IMAGINi020-A induced pluripotent stem cell human CVCL_C1Q7 From: Imagine Institute; Paris; France. CL:0000010 Female 155261660 CVCL_C1PU HHUUKDi011-A induced pluripotent stem cell human CVCL_C1PU From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Urine. Male 155261661 CVCL_C1Q6 IIMCBi006-A induced pluripotent stem cell human CVCL_C1Q6 From: International Institute of Molecular and Cell Biology; Warsaw; Poland CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[47] (c.52CAG(47)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36228511) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155261662 CVCL_C1PH DRICUi011-A induced pluripotent stem cell human CVCL_C1PH From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 155261663 CVCL_C1PG DRICUi010-A induced pluripotent stem cell human CVCL_C1PG From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 155261664 CVCL_C1PJ DRICUi013-A induced pluripotent stem cell human CVCL_C1PJ From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Male 155261665 CVCL_C1PI DRICUi012-A induced pluripotent stem cell human CVCL_C1PI From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 155261666 CVCL_C1PL DRICUi015-A induced pluripotent stem cell human CVCL_C1PL From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 155261667 CVCL_C1PK DRICUi014-A induced pluripotent stem cell human CVCL_C1PK From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 Female 155261668 CVCL_C1PN EMCi238-A induced pluripotent stem cell human CVCL_C1PN From: Erasmus University Medical Center; Rotterdam; Netherlands. CL:0000010 155261669 CVCL_C1PM EMCi230-A induced pluripotent stem cell human CVCL_C1PM From: Erasmus University Medical Center; Rotterdam; Netherlands. CL:0000010 155261670 CVCL_C1PB CRTDi011-D induced pluripotent stem cell human CVCL_C1PB From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany. CL:0000010 Female 155261671 CVCL_C1PA CRTDi011-C induced pluripotent stem cell human CVCL_C1PA From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany. CL:0000010 Female 155261672 CVCL_C1PD CTEFe001-A embryonic stem cell human CVCL_C1PD From: Cell and Tissue Engineering Facility, St Anne's University Hospital Brno; Brno; Czech Republic.. CL:0000010 Female 155261673 CVCL_C1PC CSSi015-A induced pluripotent stem cell human CVCL_C1PC From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1514; CASR; Simple; p.Thr972Met (c.2915C>T); ClinVar=VCV000342802; Zygosity=Heterozygous (PubMed=36638628) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 155261674 CVCL_C1PF CTEFe003-A embryonic stem cell human CVCL_C1PF From: Cell and Tissue Engineering Facility, St Anne's University Hospital Brno; Brno; Czech Republic.. CL:0000010 Male 155261675 CVCL_C1PE CTEFe002-A embryonic stem cell human CVCL_C1PE From: Cell and Tissue Engineering Facility, St Anne's University Hospital Brno; Brno; Czech Republic.. CL:0000010 Female 155261676 CVCL_C1QY PSYLMUi013-A induced pluripotent stem cell human CVCL_C1QY From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261677 CVCL_C1QX PSYLMUi012-A induced pluripotent stem cell human CVCL_C1QX From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261678 CVCL_C1R9 PSYLMUi024-A induced pluripotent stem cell human CVCL_C1R9 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261679 CVCL_C1QZ PSYLMUi014-A induced pluripotent stem cell human CVCL_C1QZ From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261680 CVCL_C1QQ PSYLMUi005-A induced pluripotent stem cell human CVCL_C1QQ From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261681 CVCL_C1R2 PSYLMUi017-A induced pluripotent stem cell human CVCL_C1R2 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261682 CVCL_C1QP PSYLMUi004-A induced pluripotent stem cell human CVCL_C1QP From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261683 CVCL_C1R1 PSYLMUi016-A induced pluripotent stem cell human CVCL_C1R1 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261684 CVCL_C1QS PSYLMUi007-A induced pluripotent stem cell human CVCL_C1QS From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261685 CVCL_C1R4 PSYLMUi019-A induced pluripotent stem cell human CVCL_C1R4 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261686 CVCL_C1QR PSYLMUi006-A induced pluripotent stem cell human CVCL_C1QR From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261687 CVCL_C1R3 PSYLMUi018-A induced pluripotent stem cell human CVCL_C1R3 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261688 CVCL_C1QU PSYLMUi009-A induced pluripotent stem cell human CVCL_C1QU From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261689 CVCL_C1R6 PSYLMUi021-A induced pluripotent stem cell human CVCL_C1R6 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261690 CVCL_C1QT PSYLMUi008-A induced pluripotent stem cell human CVCL_C1QT From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261691 CVCL_C1R5 PSYLMUi020-A induced pluripotent stem cell human CVCL_C1R5 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261692 CVCL_C1QW PSYLMUi011-A induced pluripotent stem cell human CVCL_C1QW From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261693 CVCL_C1R8 PSYLMUi023-A induced pluripotent stem cell human CVCL_C1R8 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261694 CVCL_C1QV PSYLMUi010-A induced pluripotent stem cell human CVCL_C1QV From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261695 CVCL_C1R7 PSYLMUi022-A induced pluripotent stem cell human CVCL_C1R7 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261696 CVCL_C1QI MPIPi058-A induced pluripotent stem cell human CVCL_C1QI From: Max Planck Institute of Psychiatry; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155261697 CVCL_C1QH MPIPi057-A induced pluripotent stem cell human CVCL_C1QH From: Max Planck Institute of Psychiatry; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155261698 CVCL_C1QK UOCi002-A induced pluripotent stem cell human CVCL_C1QK From: University of Calgary; Calgary; Canada CL:0000010 Population: Southeast Asian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 155261699 CVCL_C1QJ UOCi001-A induced pluripotent stem cell human CVCL_C1QJ From: University of Calgary; Calgary; Canada CL:0000010 Population: Southeast Asian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 155261700 CVCL_C1QM PSYLMUi002-A induced pluripotent stem cell human CVCL_C1QM From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261701 CVCL_C1QL PSYLMUi001-A induced pluripotent stem cell human CVCL_C1QL From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261702 CVCL_C1R0 PSYLMUi015-A induced pluripotent stem cell human CVCL_C1R0 From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany. CL:0000010 155261703 CVCL_C1QN PSYLMUi003-A induced pluripotent stem cell human CVCL_C1QN From: Department of Psychiatry and Psychotherapy, University Hospital, Ludwig Maximilians University of Munich; Munich; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 155261704 CVCL_C1QA IMBAi003-A induced pluripotent stem cell human CVCL_C1QA From: Institute of Molecular Biotechnology; Vienna; Austria. CL:0000010 155261705 CVCL_C1QC IPi001-A induced pluripotent stem cell human CVCL_C1QC From: Institut Pasteur; Paris; France. CL:0000010 Male 155261706 CVCL_C1QB ORIONi002-A induced pluripotent stem cell human CVCL_C1QB From: Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University; Martin; Slovakia CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 155261707 CVCL_C1QE NIHTVBi025-A induced pluripotent stem cell human CVCL_C1QE From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 27962; STING1; Simple; p.Val147Leu (c.439G>C); ClinVar=VCV000143863; Zygosity=Heterozygous (PubMed=36399927) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155261708 CVCL_C1QD NIHTVBi024-A induced pluripotent stem cell human CVCL_C1QD From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 27962; STING1; Simple; p.Asn154Ser (c.461A>G); ClinVar=VCV000143861; Zygosity=Heterozygous (PubMed=36399927) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261709 CVCL_C1QG NIHTVBi027-A induced pluripotent stem cell human CVCL_C1QG From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 27962; STING1; Simple; p.Asn154Ser (c.461A>G); ClinVar=VCV000143861; Zygosity=Heterozygous (PubMed=36399927) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261710 CVCL_C1QF NIHTVBi026-A induced pluripotent stem cell human CVCL_C1QF From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 27962; STING1; Simple; p.Asn154Ser (c.461A>G); ClinVar=VCV000143861; Zygosity=Heterozygous (PubMed=36399927) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155261711 CVCL_C3BH LM10 hybridoma Norway rat CVCL_C3BH CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Xylan-4. 155261712 CVCL_C3BG LM1 [Rat hybridoma against arabinogalactan] hybridoma Norway rat CVCL_C3BG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261713 CVCL_C3BJ LM5 hybridoma Norway rat CVCL_C3BJ CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: ChEBI; CHEBI:62776; (1->4)-beta-D-galactan (Beta-1,4-galactan). 155261714 CVCL_C3BI LM11 hybridoma Norway rat CVCL_C3BI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155261715 CVCL_C3BL LM6 hybridoma Norway rat CVCL_C3BL CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Pectic polysaccharide, alpha-1,5-arabinan. 155261716 CVCL_C3BK LM9 hybridoma Norway rat CVCL_C3BK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Feruloylated beta-1,4-galactan. 155261717 CVCL_C3BN PN16.4B4 hybridoma house mouse CVCL_C3BN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261718 CVCL_C3BM PN16.1B3 hybridoma house mouse CVCL_C3BM CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155261719 CVCL_C3BB JIM3 [Rat hybridoma against rhamnogalacturonan] hybridoma Norway rat CVCL_C3BB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155261720 CVCL_C3BA JIM20 hybridoma Norway rat CVCL_C3BA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type I. 155261721 CVCL_C3BD JIM5 hybridoma Norway rat CVCL_C3BD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Pectin backbone. 155261722 CVCL_C3BC JIM4 hybridoma Norway rat CVCL_C3BC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261723 CVCL_C3BF JIM8 hybridoma Norway rat CVCL_C3BF CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261724 CVCL_C3BE JIM7 hybridoma Norway rat CVCL_C3BE CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Pectin backbone. 155261725 CVCL_C3AW CCRC-M92 hybridoma house mouse CVCL_C3AW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155261726 CVCL_C3B8 JIM16 hybridoma Norway rat CVCL_C3B8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261727 CVCL_C3AV CCRC-M91 hybridoma house mouse CVCL_C3AV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155261728 CVCL_C3B7 JIM15 hybridoma Norway rat CVCL_C3B7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261729 CVCL_C3AY CCRC-M94 hybridoma house mouse CVCL_C3AY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Physcomitrella pectin. 155261730 CVCL_C3AX CCRC-M93 hybridoma house mouse CVCL_C3AX CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261731 CVCL_C3B9 JIM17 hybridoma Norway rat CVCL_C3B9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261732 CVCL_C3AZ CCRC-M95 hybridoma house mouse CVCL_C3AZ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261733 CVCL_C3B0 CCRC-M96 hybridoma house mouse CVCL_C3B0 CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261734 CVCL_C3AN CCRC-M85 hybridoma house mouse CVCL_C3AN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261735 CVCL_C3AQ CCRC-M87 hybridoma house mouse CVCL_C3AQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261736 CVCL_C3B2 CCRC-M99 hybridoma house mouse CVCL_C3B2 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261737 CVCL_C3AP CCRC-M86 hybridoma house mouse CVCL_C3AP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261738 CVCL_C3B1 CCRC-M98 hybridoma house mouse CVCL_C3B1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Physcomitrella pectin. 155261739 CVCL_C3AS CCRC-M89 hybridoma house mouse CVCL_C3AS CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261740 CVCL_C3B4 JIM12 hybridoma Norway rat CVCL_C3B4 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type II. 155261741 CVCL_C3AR CCRC-M88 hybridoma house mouse CVCL_C3AR CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261742 CVCL_C3B3 JIM11 hybridoma Norway rat CVCL_C3B3 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Arabinogalactan type I. 155261743 CVCL_C3AU CCRC-M90 hybridoma house mouse CVCL_C3AU CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261744 CVCL_C3B6 JIM14 hybridoma Norway rat CVCL_C3B6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type II. 155261745 CVCL_C3AT CCRC-M9 hybridoma house mouse CVCL_C3AT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261746 CVCL_C3B5 JIM13 hybridoma Norway rat CVCL_C3B5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155261747 CVCL_C3CI A549 HLA-A*11:01 cancer cell line human CVCL_C3CI CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*11:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261748 CVCL_C3CH A549 HLA-A*03:01 cancer cell line human CVCL_C3CH CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*03:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261749 CVCL_C3CK A549 HLA-B*07:02 cancer cell line human CVCL_C3CK CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*07:02) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155261750 CVCL_C3CJ A549 HLA-A*24:02 cancer cell line human CVCL_C3CJ CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*24:02) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261751 CVCL_C3CM A549 HLA-B*15:10 cancer cell line human CVCL_C3CM CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*15:10) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155261752 CVCL_C3CL A549 HLA-B*08:01 cancer cell line human CVCL_C3CL CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*08:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155261753 CVCL_C3D0 Raji HLA-A*01:01 cancer cell line human CVCL_C3D0 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*01:01) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261754 CVCL_C3CN A549 HLA-B*35:01 cancer cell line human CVCL_C3CN CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*35:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155261755 CVCL_C3CA U2OS GFP-ACTB RFP-TUBA1B cancer cell line human CVCL_C3CA CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the ACTB locus to insert a TagGFP2 construct at the N-terminus of the gene and the TUBA1B locus to insert a TagRFP construct at the N-terminus of the gene 155261756 CVCL_C3CC A549 B2M KO cancer cell line human CVCL_C3CC CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 155261757 CVCL_C3CB U2OS BFP-LMNB1 RFP-ACTB cancer cell line human CVCL_C3CB CL:0000010 Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the BFP mTagBFP); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the LMNB1 locus to insert a TagBFP construct at the N-terminus of the gene and at the ACTB locus to insert a TagRFP construct at the N-terminus of the gene 155261758 CVCL_C3CE Jurkat B2M KO cancer cell line human CVCL_C3CE CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 155261759 CVCL_C3CD Raji B2M KO cancer cell line human CVCL_C3CD CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 155261760 CVCL_C3CG A549 HLA-A*02:01 cancer cell line human CVCL_C3CG CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*02:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261761 CVCL_C3CF A549 HLA-A*01:01 cancer cell line human CVCL_C3CF CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*01:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155261762 CVCL_C3BX CR-M2 cancer cell line human CVCL_C3BX CL:0000010 Population: African American; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 155261763 CVCL_C3C9 U2OS BFP-LMNB1 GFP-TUBA1B RFP-ACTB cancer cell line human CVCL_C3C9 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2); Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the BFP mTagBFP); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the LMNB1 locus to insert a TagBFP construct at the N-terminus of the gene, at the TUB1A1B locus to insert a TagGFP2 construct at the N-terminus of the gene and at the ACTB locus to insert a TagRFP construct at the N-terminus of the gene 155261764 CVCL_C3C8 A549 RFP-STAT3 cancer cell line human CVCL_C3C8 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Edited by ZFN at the STAT3 locus to insert a TagRFP construct at the N-terminus of the gene 155261765 CVCL_C3BW MC21C hybridoma house mouse CVCL_C3BW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:18296; Chondroitin 6'-sulfate (Chondroitin sulfate C). 155261766 CVCL_C3BZ Tor-3E5 hybridoma house mouse CVCL_C3BZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07692; Torpedo marmorata acetylcholinesterase (Ache). 155261767 CVCL_C3BY Tor-1A5 hybridoma house mouse CVCL_C3BY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07692; Torpedo marmorata acetylcholinesterase (Ache). 155261768 CVCL_C3BP NA-6 hybridoma house mouse CVCL_C3BP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:90151; Ganglioside GM1b. 155261769 CVCL_C3C1 SKOV3-GFP-STAT3 cancer cell line human CVCL_C3C1 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Edited by ZFN at the STAT3 locus to insert a TagGFP2 construct at the N-terminus of the gene 155261770 CVCL_C3C0 Tor-ME8 hybridoma house mouse CVCL_C3C0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07692; Torpedo marmorata acetylcholinesterase (Ache). 155261771 CVCL_C3BR AGM-2 hybridoma house mouse CVCL_C3BR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61048; Ganglioside GM1. 155261772 CVCL_C3C3 SKOV3-GFP-HER2 RFP-EGFR cancer cell line human CVCL_C3C3 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Edited by ZFN at the ERBB2 locus to insert a TagGFP2 construct at the C-terminus of the gene and at the EGFR locus to insert a TagRFP construct at the C-terminus of the gene 155261773 CVCL_C3BQ AGM-1 hybridoma house mouse CVCL_C3BQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61048; Ganglioside GM1. 155261774 CVCL_C3C2 SKOV3-GFP-HER2 cancer cell line human CVCL_C3C2 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Edited by ZFN at the ERBB2 locus to insert a TagGFP2 construct at the C-terminus of the gene 155261775 CVCL_C3BT 2G10 [Mouse hybridoma against human TYR] hybridoma house mouse CVCL_C3BT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14679; Human TYR. 155261776 CVCL_C3C5 A549 HIF1A -/-/- cancer cell line human CVCL_C3C5 CL:0000010 Knockout cell: Method=ZFN; HGNC; 4910; HIF1A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 155261777 CVCL_C3C4 A549 SMAD4 -/- cancer cell line human CVCL_C3C4 CL:0000010 Knockout cell: Method=ZFN; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from sampling site: Lung. Male 155261778 CVCL_C3BS AGM-3 hybridoma house mouse CVCL_C3BS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61048; Ganglioside GM1. 155261779 CVCL_C3C7 A549 GFP-CTNNB1 RFP-LMNB1 cancer cell line human CVCL_C3C7 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Edited by ZFN at the CTNNB1 locus to insert a 3xFLAG-TagGFP2 construct at the N-terminus of the gene and at the LMNB1 locus to insert a TagRFP construct at the N-terminus of the gene 155261780 CVCL_C3BV CS-56 hybridoma house mouse CVCL_C3BV CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:18250; Chondroitin 4'-sulfate (Chondroitin sulfate A); Monoclonal antibody target: ChEBI; CHEBI:18296; Chondroitin 6'-sulfate (Chondroitin sulfate C). 155261781 CVCL_C3BU 5C12 [Mouse hybridoma against human TYR] hybridoma house mouse CVCL_C3BU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14679; Human TYR. 155261782 CVCL_C3C6 A549 GFP-SMAD4 cancer cell line human CVCL_C3C6 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Edited by ZFN at the SMAD4 locus to insert a TagGFP2 construct at the C-terminus of the gene 155261783 CVCL_C3AG CCRC-M79 hybridoma house mouse CVCL_C3AG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261784 CVCL_C3AF CCRC-M78 hybridoma house mouse CVCL_C3AF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155261785 CVCL_C3AI CCRC-M80 hybridoma house mouse CVCL_C3AI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261786 CVCL_C3AH CCRC-M8 hybridoma house mouse CVCL_C3AH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261787 CVCL_C3AK CCRC-M82 hybridoma house mouse CVCL_C3AK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155261788 CVCL_C3AJ CCRC-M81 hybridoma house mouse CVCL_C3AJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155261789 CVCL_C3AM CCRC-M84 hybridoma house mouse CVCL_C3AM CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Fucosylated xyloglucans. 155261790 CVCL_C3AL CCRC-M83 hybridoma house mouse CVCL_C3AL CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155261791 CVCL_C3AA CCRC-M72 hybridoma house mouse CVCL_C3AA CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Pectin backbone. 155261792 CVCL_C3AC CCRC-M75 hybridoma house mouse CVCL_C3AC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 155261793 CVCL_C3AB CCRC-M74 hybridoma house mouse CVCL_C3AB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 155261794 CVCL_C3AE CCRC-M77 hybridoma house mouse CVCL_C3AE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261795 CVCL_C3AD CCRC-M76 hybridoma house mouse CVCL_C3AD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Undefined glycan. 155261796 CVCL_C3A7 CCRC-M69 hybridoma house mouse CVCL_C3A7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Pectin backbone. 155261797 CVCL_C3A6 CCRC-M61 hybridoma house mouse CVCL_C3A6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ic. 155261798 CVCL_C3A9 CCRC-M70 hybridoma house mouse CVCL_C3A9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27680; Galactomannan. 155261799 CVCL_C3A8 CCRC-M7 hybridoma house mouse CVCL_C3A8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Arabinogalactan type II. 155261800 CVCL_C3A1 CCRC-M55 hybridoma house mouse CVCL_C3A1 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261801 CVCL_C3A0 CCRC-M54 hybridoma house mouse CVCL_C3A0 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261802 CVCL_C3A3 CCRC-M57 hybridoma house mouse CVCL_C3A3 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261803 CVCL_C3A2 CCRC-M56 hybridoma house mouse CVCL_C3A2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155261804 CVCL_C3A5 CCRC-M60 hybridoma house mouse CVCL_C3A5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261805 CVCL_C3A4 CCRC-M58 hybridoma house mouse CVCL_C3A4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261806 CVCL_C2ZY CCRC-M52 hybridoma house mouse CVCL_C2ZY CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261807 CVCL_C2ZX CCRC-M51 hybridoma house mouse CVCL_C2ZX CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261808 CVCL_C2ZZ CCRC-M53 hybridoma house mouse CVCL_C2ZZ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261809 CVCL_C2ZQ CCRC-M42 hybridoma house mouse CVCL_C2ZQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261810 CVCL_C2ZP CCRC-M41 hybridoma house mouse CVCL_C2ZP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261811 CVCL_C2ZS CCRC-M47 hybridoma house mouse CVCL_C2ZS CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261812 CVCL_C2ZR CCRC-M44 hybridoma house mouse CVCL_C2ZR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261813 CVCL_C2ZU CCRC-M49 hybridoma house mouse CVCL_C2ZU CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261814 CVCL_C2ZT CCRC-M48 hybridoma house mouse CVCL_C2ZT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261815 CVCL_C2ZW CCRC-M50 hybridoma house mouse CVCL_C2ZW CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155261816 CVCL_C2ZV CCRC-M5 hybridoma house mouse CVCL_C2ZV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ia. 155261817 CVCL_C2ZI CCRC-M34 hybridoma house mouse CVCL_C2ZI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Pectin backbone. 155261818 CVCL_C2ZH CCRC-M33 hybridoma house mouse CVCL_C2ZH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155261819 CVCL_C2ZK CCRC-M36 hybridoma house mouse CVCL_C2ZK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Pectin backbone. 155261820 CVCL_C2ZJ CCRC-M35 hybridoma house mouse CVCL_C2ZJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Pectin backbone. 155261821 CVCL_C2ZM CCRC-M39 hybridoma house mouse CVCL_C2ZM CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Fucosylated xyloglucans. 155261822 CVCL_C2ZL CCRC-M38 hybridoma house mouse CVCL_C2ZL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Pectin backbone. 155261823 CVCL_C2ZN CCRC-M40 hybridoma house mouse CVCL_C2ZN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155261824 CVCL_C3K1 N/Tert-1 AKT1 telomerase immortalized cell line human CVCL_C3K1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 391; AKT1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261825 CVCL_C3JP N/Tert-1 HPV6b E6 telomerase immortalized cell line human CVCL_C3JP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06462; Human papillomavirus type 6b protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 155261826 CVCL_C3K0 N/Tert-1 ADRB2 telomerase immortalized cell line human CVCL_C3K0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 286; ADRB2 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261827 CVCL_C3K3 N/Tert-1 BAP1 telomerase immortalized cell line human CVCL_C3K3 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 950; BAP1 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261828 CVCL_C3JR N/Tert-1 HPV74 E7 telomerase immortalized cell line human CVCL_C3JR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q98005; Human papillomavirus type 74 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261829 CVCL_C3K2 N/Tert-1 AMPH telomerase immortalized cell line human CVCL_C3K2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 471; AMPH (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261830 CVCL_C3JQ N/Tert-1 HPV6b E7 telomerase immortalized cell line human CVCL_C3JQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06464; Human papillomavirus type 6b protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261831 CVCL_C3K5 N/Tert-1 CHEK2 telomerase immortalized cell line human CVCL_C3K5 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 16627; CHEK2 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261832 CVCL_C3JT N/Tert-1 HPV76 E7 telomerase immortalized cell line human CVCL_C3JT CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; O56941; Human papillomavirus type 76 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261833 CVCL_C3K4 N/Tert-1 CHAF1B telomerase immortalized cell line human CVCL_C3K4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 1911; CHAF1B (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261834 CVCL_C3JS N/Tert-1 HPV76 E6 telomerase immortalized cell line human CVCL_C3JS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; O56940; Human papillomavirus type 76 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261835 CVCL_C3K7 N/Tert-1 GARS telomerase immortalized cell line human CVCL_C3K7 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 4162; GARS1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261836 CVCL_C3JV N/Tert-1 HPV8 E7 telomerase immortalized cell line human CVCL_C3JV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06430; Human papillomavirus type 8 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261837 CVCL_C3K6 N/Tert-1 FOSL1 telomerase immortalized cell line human CVCL_C3K6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 13718; FOSL1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261838 CVCL_C3JU N/Tert-1 HPV8 E6 telomerase immortalized cell line human CVCL_C3JU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06428; Human papillomavirus type 8 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 155261839 CVCL_C3JH N/Tert-1 HPV38 E7 telomerase immortalized cell line human CVCL_C3JH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q80908; Human papillomavirus type 38 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261840 CVCL_C3JG N/Tert-1 HPV38 E6 telomerase immortalized cell line human CVCL_C3JG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q80907; Human papillomavirus type 38 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261841 CVCL_C3JJ N/Tert-1 HPV45 E7 telomerase immortalized cell line human CVCL_C3JJ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P21736; Human papillomavirus type 45 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261842 CVCL_C3JI N/Tert-1 HPV45 E6 telomerase immortalized cell line human CVCL_C3JI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P21735; Human papillomavirus type 45 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261843 CVCL_C3JL N/Tert-1 HPV55 E7 telomerase immortalized cell line human CVCL_C3JL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q80935; Human papillomavirus type 55 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261844 CVCL_C3JK N/Tert-1 HPV52 E6 telomerase immortalized cell line human CVCL_C3JK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P36814; Human papillomavirus type 52 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261845 CVCL_C3JN N/Tert-1 HPV57 E7 telomerase immortalized cell line human CVCL_C3JN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P22160; Human papillomavirus type 57 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261846 CVCL_C3JM N/Tert-1 HPV57 E6 telomerase immortalized cell line human CVCL_C3JM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P22158; Human papillomavirus type 57 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261847 CVCL_C3JB N/Tert-1 HPV2a E7 telomerase immortalized cell line human CVCL_C3JB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P25485; Human papillomavirus type 2a protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261848 CVCL_C3JA N/Tert-1 HPV2a E6 HA + E7 telomerase immortalized cell line human CVCL_C3JA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P25484; Human papillomavirus type 2a protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261849 CVCL_C3JD N/Tert-1 HPV33 E6 telomerase immortalized cell line human CVCL_C3JD CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06427; Human papillomavirus type 33 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261850 CVCL_C3JC N/Tert-1 HPV31 E7 telomerase immortalized cell line human CVCL_C3JC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17387; Human papillomavirus type 31 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261851 CVCL_C3JF N/Tert-1 HPV33 E7 telomerase immortalized cell line human CVCL_C3JF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06429; Human papillomavirus type 33 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261852 CVCL_C3JE N/Tert-1 HPV33 E6 HA + E7 telomerase immortalized cell line human CVCL_C3JE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06427; Human papillomavirus type 33 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P06429; Human papillomavirus type 33 protein E7; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261853 CVCL_C3IW N/Tert-1 HPV16 E6 Flag-HA 8S9A10T telomerase immortalized cell line human CVCL_C3IW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with p.Arg15Ser; p.Pro16Ala and p.Arg17Ser and a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261854 CVCL_C3J8 N/Tert-1 HPV25 E7 telomerase immortalized cell line human CVCL_C3J8 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P36823; Human papillomavirus type 25 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261855 CVCL_C3IV N/Tert-1 HPV16 E6 Flag-HA telomerase immortalized cell line human CVCL_C3IV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261856 CVCL_C3J7 N/Tert-1 HPV25 E6 telomerase immortalized cell line human CVCL_C3J7 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P28833; Human papillomavirus type 25 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261857 CVCL_C3IY N/Tert-1 HPV16 E6 Flag-HA I128T telomerase immortalized cell line human CVCL_C3IY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with p.Ile135Thr and a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261858 CVCL_C3IX N/Tert-1 HPV16 E6 Flag-HA Delta146-151 telomerase immortalized cell line human CVCL_C3IX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with p.Arg153_Leu158del and a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261859 CVCL_C3J9 N/Tert-1 HPV2a E6 telomerase immortalized cell line human CVCL_C3J9 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P25484; Human papillomavirus type 2a protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P25485; Human papillomavirus type 2a protein E7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261860 CVCL_C3IZ N/Tert-1 HPV16 E6 HA telomerase immortalized cell line human CVCL_C3IZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 155261861 CVCL_C3L2 MSHRIe001-A-SOX7 control 1 embryonic stem cell human CVCL_C3L2 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Transfected with a loxP-BetaGeo(lacZ-neo)-polyA-loxP-SOX7-IRES-PuroR-polyA construct This control cell line can be selected via neomycin resistance and does not overexpress SOX7 as this would require Cre-mediated excision of the loxP flanked betaGeo (PubMed=18682240). 155261862 CVCL_C3KQ N/Tert-1 UCHL3 telomerase immortalized cell line human CVCL_C3KQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12515; UCHL3 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261863 CVCL_C3KP N/Tert-1 UBOX5 telomerase immortalized cell line human CVCL_C3KP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 17777; UBOX5 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261864 CVCL_C3L1 N/Tert-1 WWP2 telomerase immortalized cell line human CVCL_C3L1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 16804; WWP2 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261865 CVCL_C3L4 MSHRIe001-A-SOX7 overexpressing 1 embryonic stem cell human CVCL_C3L4 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Using Cre the loxP-BetaGeo(lacZ-neo)-polyA-loxP section of the parent control cell line construct was excised leaving the SOX7-IRES-PuroR-polyA part This cell line overexpresses SOX7 and can be selected via puromycin resistance (PubMed=18682240). 155261866 CVCL_C3KS N/Tert-1 USP10 telomerase immortalized cell line human CVCL_C3KS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12608; USP10 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261867 CVCL_C3L3 MSHRIe001-A-SOX7 control 2 embryonic stem cell human CVCL_C3L3 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Transfected with a loxP-BetaGeo(lacZ-neo)-polyA-loxP-SOX7-IRES-PuroR-polyA construct This control cell line can be selected via neomycin resistance and does not overexpress SOX7 as this would require Cre-mediated excision of the loxP flanked betaGeo (PubMed=18682240). 155261868 CVCL_C3KR N/Tert-1 UCHL5 telomerase immortalized cell line human CVCL_C3KR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 19678; UCHL5 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261869 CVCL_C3L6 MSHRIe002-A-SOX17 control 1 embryonic stem cell human CVCL_C3L6 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Transfected with a loxP-BetaGeo(lacZ-neo)-polyA-loxP-SOX17-IRES-PuroR-polyA construct This control cell line can be selected via neomycin resistance and does not overexpress SOX17 as this would require Cre-mediated excision of the loxP flanked betaGeo (PubMed=18682240). 155261870 CVCL_C3KU N/Tert-1 USP13 telomerase immortalized cell line human CVCL_C3KU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12611; USP13 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261871 CVCL_C3L5 MSHRIe001-A-SOX7 overexpressing 2 embryonic stem cell human CVCL_C3L5 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Using Cre the loxP-BetaGeo(lacZ-neo)-polyA-loxP section of the parent control cell line construct was excised leaving the SOX7-IRES-PuroR-polyA part This cell line overexpresses SOX7 and can be selected via puromycin resistance (PubMed=18682240). 155261872 CVCL_C3KT N/Tert-1 USP12 telomerase immortalized cell line human CVCL_C3KT CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 20485; USP12 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261873 CVCL_C3L8 MSHRIe002-A-SOX17 overexpressing 1 embryonic stem cell human CVCL_C3L8 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Using Cre the loxP-BetaGeo(lacZ-neo)-polyA-loxP section of the parent control cell line construct was excised leaving the SOX17-IRES-PuroR-polyA part This cell line overexpresses SOX17 and can be selected via puromycin resistance (PubMed=18682240). 155261874 CVCL_C3KW N/Tert-1 USP28 telomerase immortalized cell line human CVCL_C3KW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12625; USP28 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261875 CVCL_C3L7 MSHRIe002-A-SOX17 control 2 embryonic stem cell human CVCL_C3L7 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Transfected with a loxP-BetaGeo(lacZ-neo)-polyA-loxP-SOX17-IRES-PuroR-polyA construct This control cell line can be selected via neomycin resistance and does not overexpress SOX17 as this would require Cre-mediated excision of the loxP flanked betaGeo (PubMed=18682240). 155261876 CVCL_C3KV N/Tert-1 USP21 telomerase immortalized cell line human CVCL_C3KV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12620; USP21 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261877 CVCL_C3KI N/Tert-1 SRC telomerase immortalized cell line human CVCL_C3KI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11283; SRC (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261878 CVCL_C3KH N/Tert-1 SNCG telomerase immortalized cell line human CVCL_C3KH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11141; SNCG (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261879 CVCL_C3KK N/Tert-1 TBPL1 telomerase immortalized cell line human CVCL_C3KK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11589; TBPL1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261880 CVCL_C3KJ N/Tert-1 STAT4 telomerase immortalized cell line human CVCL_C3KJ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11365; STAT4 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261881 CVCL_C3KM N/Tert-1 TIMP1 telomerase immortalized cell line human CVCL_C3KM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11820; TIMP1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261882 CVCL_C3KL N/Tert-1 TCTE1 telomerase immortalized cell line human CVCL_C3KL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11693; TCTE1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261883 CVCL_C3L0 N/Tert-1 WHSC2 telomerase immortalized cell line human CVCL_C3L0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12768; NELFA (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261884 CVCL_C3KN N/Tert-1 UBE3AI telomerase immortalized cell line human CVCL_C3KN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12496; UBE3A (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261885 CVCL_C3KA N/Tert-1 JUN telomerase immortalized cell line human CVCL_C3KA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 6204; JUN (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261886 CVCL_C3KC N/Tert-1 PP2CA telomerase immortalized cell line human CVCL_C3KC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 9299; PPP2CA (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261887 CVCL_C3KB N/Tert-1 NIPA1 telomerase immortalized cell line human CVCL_C3KB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 17043; NIPA1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261888 CVCL_C3KE N/Tert-1 PTPN18 telomerase immortalized cell line human CVCL_C3KE CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 9649; PTPN18 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261889 CVCL_C3KD N/Tert-1 PTENP1 telomerase immortalized cell line human CVCL_C3KD CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 9589; PTENP1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261890 CVCL_C3KG N/Tert-1 RBCK1 telomerase immortalized cell line human CVCL_C3KG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 15864; RBCK1 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261891 CVCL_C3KF N/Tert-1 PXMP3 telomerase immortalized cell line human CVCL_C3KF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 9717; PEX2 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261892 CVCL_C3K9 N/Tert-1 GPRC5B telomerase immortalized cell line human CVCL_C3K9 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 13308; GPRC5B (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261893 CVCL_C3JX N/Tert-1 HPV92 E7 telomerase immortalized cell line human CVCL_C3JX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q8B5B5; Human papillomavirus type 92 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261894 CVCL_C3K8 N/Tert-1 GLTSCR1 telomerase immortalized cell line human CVCL_C3K8 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 4332; BICRA (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261895 CVCL_C3JW N/Tert-1 HPV92 E6 telomerase immortalized cell line human CVCL_C3JW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q8B5B6; Human papillomavirus type 92 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male 155261896 CVCL_C3JZ N/Tert-1 HPV98 E7 telomerase immortalized cell line human CVCL_C3JZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; C4PUC1; Human papillomavirus type 98 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261897 CVCL_C3JY N/Tert-1 HPV98 E6 telomerase immortalized cell line human CVCL_C3JY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; C4PUC0; Human papillomavirus type 98 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261898 CVCL_C3HN RCC-26/CD80/IL-7 cancer cell line human CVCL_C3HN CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: HGNC; 6023; IL7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney Cell type=Epithelial cell.. 155261899 CVCL_C3HM RCC-26/CD80/IL-2 cancer cell line human CVCL_C3HM CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney Cell type=Epithelial cell.. 155261900 CVCL_C3I1 IMCE 28 transformed cell line dog CVCL_C3I1 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Doubling time: 18-20 hours (at 33 Celsius), 8-10 hours (at 37 Celsius) (PubMed=11574662) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2503 155261901 CVCL_C3HP LCL-26 transformed cell line human CVCL_C3HP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155261902 CVCL_C3I0 IMCE 20 transformed cell line dog CVCL_C3I0 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2502 155261903 CVCL_C3HR RCC-53 cancer cell line human CVCL_C3HR HLA typing: A*02:01,25:01; B*15:01,18:01; C*03:03,12:03 (PubMed=16045799) CL:0000010 Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray 155261904 CVCL_C3I3 RW-2982-NS cancer cell line human CVCL_C3I3 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Ter (c.3925G>T); ClinVar=VCV000824390; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Cys363Tyr (c.1088G>A); ClinVar=VCV000233663; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Omentum. Male Group: Serum/protein free medium cell line 155261905 CVCL_C3I2 IMCE 29 transformed cell line dog CVCL_C3I2 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2504 155261906 CVCL_C3HQ RCC-26/CD80 cancer cell line human CVCL_C3HQ CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney Cell type=Epithelial cell.. 155261907 CVCL_C3HT HVP transformed cell line human CVCL_C3HT CL:0000010 Transformant: Simian virus 40 (SV40) [pX8 ori-](NCBI-Taxonomy; 1891767); Donor information: Established from a fetus heterozygous carrier of an unknown paternal CFTR mutation; Derived from sampling site: Fetal vas deferens; epithelium. Male 155261908 CVCL_C3I5 U-251MG-GFP cancer cell line human CVCL_C3I5 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Omics: Transcriptome analysis by microarray Male 155261909 CVCL_C3HS CVP transformed cell line human CVCL_C3HS CL:0000010 Transformant: Simian virus 40 (SV40) [pX8 ori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal vas deferens; epithelium. Male 155261910 CVCL_C3I4 U-251MG-PARK2 cancer cell line human CVCL_C3I4 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Omics: Transcriptome analysis by microarray Male 155261911 CVCL_C3HF 39.4D5 hybridoma house mouse CVCL_C3HF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61374; Rat Isl1 (Note=Also reacts with many other species); Monoclonal antibody target: UniProtKB; P50480; Rat Isl2 (Note=Also reacts with many other species). 155261912 CVCL_C3HE 40.2D6 hybridoma house mouse CVCL_C3HE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61374; Rat Isl1 (Note=Also reacts with many other species). 155261913 CVCL_C3HH PC-3-AR cancer cell line human CVCL_C3HH CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by RNAseq Male 155261914 CVCL_C3HG MV-4-11B cancer cell line human CVCL_C3HG CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=29491412; PubMed=29454094) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: BRD4 ChIP-seq epigenome analysis; Omics: Pol2 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male 155261915 CVCL_C3HJ SVG-A CHMP1A null transformed cell line human CVCL_C3HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male 155261916 CVCL_C3HI IPS(IMR90)-4-CHMP1A KO induced pluripotent stem cell human CVCL_C3HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 155261917 CVCL_C3HL Panc 02.05-EYA2 cancer cell line human CVCL_C3HL CL:0000010 Transfected with: HGNC; 3520; EYA2; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Omics: Transcriptome analysis by microarray. Female 155261918 CVCL_C3HK Panc 3.014-EYA2 cancer cell line human CVCL_C3HK CL:0000010 Transfected with: HGNC; 3520; EYA2; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Omics: Transcriptome analysis by microarray. Male 155261919 CVCL_C3HB iOSE-C21 telomerase immortalized cell line human CVCL_C3HB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: ~56 hours (PubMed=17877616) 155261920 CVCL_C3HA iOSE-C10 telomerase immortalized cell line human CVCL_C3HA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: ~56 hours (PubMed=17877616) 155261921 CVCL_C3HD PLB-985 CYBB KO cancer cell line human CVCL_C3HD CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 2578; CYBB; Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Problematic cell line: Contaminated Parent cell line (PLB-985) was shown to be a HL-60 derivative. 155261922 CVCL_C3HC iOSE-C9 telomerase immortalized cell line human CVCL_C3HC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: ~56 hours (PubMed=17877616) 155261923 CVCL_C3H6 FTE05 finite cell line human CVCL_C3H6 CL:0000010 Karyotypic information: 46,XX,t(6;6)(p21;q21) (PubMed=24070420); Donor information: Established from a patient suffering from a complex hyperplasia with atypia; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 155261924 CVCL_C3GU iPSC982-18 WT induced pluripotent stem cell human CVCL_C3GU CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 155261925 CVCL_C3H5 FTE03 finite cell line human CVCL_C3H5 CL:0000010 Donor information: Established from a patient suffering from fibroid adenomyosis; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: Transcriptome analysis by microarray Female 155261926 CVCL_C3GT iPSC982-17 MUT induced pluripotent stem cell human CVCL_C3GT CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155261927 CVCL_C3H8 FTE284 finite cell line human CVCL_C3H8 CL:0000010 Donor information: Established from a patient with history of endometrial cancer; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 155261928 CVCL_C3GW SW780 FOXP3Delta3 cancer cell line human CVCL_C3GW CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6106; FOXP3 (isoform Delta3); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by RNAseq Female 155261929 CVCL_C3H7 FTE283 finite cell line human CVCL_C3H7 CL:0000010 Donor information: Established from a patient suffering from a grade 2-3 endometrial cancer; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: Transcriptome analysis by microarray Female 155261930 CVCL_C3GV SW780 FOXP3 cancer cell line human CVCL_C3GV CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by RNAseq Female 155261931 CVCL_C3GY T24 FOXP3Delta3 cancer cell line human CVCL_C3GY CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6106; FOXP3 (isoform Delta3); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female 155261932 CVCL_C3H9 NOSE21R finite cell line human CVCL_C3H9 CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 155261933 CVCL_C3GX T24 FOXP3 cancer cell line human CVCL_C3GX CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female 155261934 CVCL_C3GZ 293T FOXP3 transformed cell line human CVCL_C3GZ CL:0000010 Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 155261935 CVCL_C3J0 N/Tert-1 HPV16 E6 HA + E7 telomerase immortalized cell line human CVCL_C3J0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261936 CVCL_C3IN HeLa-TFEB cancer cell line human CVCL_C3IN CL:0000010 Transfected with: HGNC; 11753; TFEB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female 155261937 CVCL_C3IQ 1321N1 MRTFA KO cancer cell line human CVCL_C3IQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14334; MRTFA; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 155261938 CVCL_C3J2 N/Tert-1 HPV17a E6 telomerase immortalized cell line human CVCL_C3J2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P36805; Human papillomavirus type 17a protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261939 CVCL_C3IP HeLa-TFEB-3xFLAG cancer cell line human CVCL_C3IP CL:0000010 Transfected with: HGNC; 11753; TFEB (with a C-terminal 3xFLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female 155261940 CVCL_C3J1 N/Tert-1 HPV16 E7 telomerase immortalized cell line human CVCL_C3J1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261941 CVCL_C3IS 1321N1 YAP1 KO cancer cell line human CVCL_C3IS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 155261942 CVCL_C3J4 N/Tert-1 HPV18 E6 telomerase immortalized cell line human CVCL_C3J4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06463; Human papillomavirus type 18 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261943 CVCL_C3IR 1321N1 RHOA KO cancer cell line human CVCL_C3IR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 667; RHOA; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 155261944 CVCL_C3J3 N/Tert-1 HPV17a E7 telomerase immortalized cell line human CVCL_C3J3 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P36821; Human papillomavirus type 17a protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261945 CVCL_C3IU H14.s3 somatic stem cell human CVCL_C3IU CL:0000010 Omics: Transcriptome analysis by microarray. Male 155261946 CVCL_C3J6 N/Tert-1 HPV20 E6 telomerase immortalized cell line human CVCL_C3J6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P28831; Human papillomavirus type 20 protein E6 (with a N-terminal HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261947 CVCL_C3IT A549 MIR1343 KO cancer cell line human CVCL_C3IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 41902; MIR1343; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Omics: Transcriptome analysis by RNAseq Male 155261948 CVCL_C3J5 N/Tert-1 HPV18 E7 telomerase immortalized cell line human CVCL_C3J5 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06788; Human papillomavirus type 18 protein E7 (with a C-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155261949 CVCL_C3IG U-87MG-parkin clone 25 cancer cell line human CVCL_C3IG CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Transcriptome analysis by microarray. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155261950 CVCL_C3IF U-87MG-parkin clone 19 cancer cell line human CVCL_C3IF CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Transcriptome analysis by microarray. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155261951 CVCL_C3II SfTPS4-10 spontaneously immortalized cell line CVCL_C3II CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261952 CVCL_C3IH Sf9/TPS4 spontaneously immortalized cell line CVCL_C3IH CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261953 CVCL_C3IK SfTPS4-3 spontaneously immortalized cell line CVCL_C3IK CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261954 CVCL_C3IJ SfTPS4-2-1 spontaneously immortalized cell line CVCL_C3IJ CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261955 CVCL_C3IM SfTPS4-7 spontaneously immortalized cell line CVCL_C3IM CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261956 CVCL_C3IL SfTPS4-3A2 spontaneously immortalized cell line CVCL_C3IL CL:0000010 Transfected with: UniProtKB; Q6JD73; Maize 7-epi-sesquithujene synthase (TPS4) Derived from sampling site: Ovary. Female Group: Insect cell line 155261957 CVCL_C3IA SH-SY5Y-parkin p.T240R cancer cell line human CVCL_C3IA CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN (with p.Thr240Arg and a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 155261958 CVCL_C3IC MCF7-parkin clone 7 cancer cell line human CVCL_C3IC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 155261959 CVCL_C3IB MCF7-parkin clone 5 cancer cell line human CVCL_C3IB CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 155261960 CVCL_C3IE U-87MG-parkin clone 7 cancer cell line human CVCL_C3IE CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Transcriptome analysis by microarray. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155261961 CVCL_C3ID MCF7-parkin clone 11 cancer cell line human CVCL_C3ID CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 155261962 CVCL_C3HV RVP transformed cell line human CVCL_C3HV CL:0000010 Transformant: Simian virus 40 (SV40) [pX8 ori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal vas deferens; epithelium. Male 155261963 CVCL_C3I7 SH-SY5Y-parkin clone 2 cancer cell line human CVCL_C3I7 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 155261964 CVCL_C3HU REP transformed cell line human CVCL_C3HU CL:0000010 Transformant: Simian virus 40 (SV40) [pX8 ori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal testis; epididymis; epithelium. Omics: Transcriptome analysis by RNAseq Male 155261965 CVCL_C3I6 SH-SY5Y-parkin clone 1 cancer cell line human CVCL_C3I6 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 155261966 CVCL_C3HX IMCE 3 transformed cell line dog CVCL_C3HX CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2499 155261967 CVCL_C3I9 SH-SY5Y-parkin p.A82E cancer cell line human CVCL_C3I9 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN (with p.Ala82Glu and a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 155261968 CVCL_C3HW HEP transformed cell line human CVCL_C3HW CL:0000010 Transformant: Simian virus 40 (SV40) [pX8 ori-](NCBI-Taxonomy; 1891767); Donor information: Established from a fetus heterozygous carrier of an unknown paternal CFTR mutation; Derived from sampling site: Fetal testis; epididymis; epithelium. Male 155261969 CVCL_C3I8 SH-SY5Y-parkin clone 6 cancer cell line human CVCL_C3I8 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8607; PRKN (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 155261970 CVCL_C3HZ IMCE 12 transformed cell line dog CVCL_C3HZ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Doubling time: 28-30 hours (at 33 Celsius), 16-18 hours (at 37 Celsius) (PubMed=11574662) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2501 155261971 CVCL_C3HY IMCE 7 transformed cell line dog CVCL_C3HY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; Breed/subspecies: Mixed breed. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2500 155261972 CVCL_C3FL MM130626 cancer cell line human CVCL_C3FL From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Female 155261973 CVCL_C3FK M121008 cancer cell line human CVCL_C3FK From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lung. Omics: Transcriptome analysis by RNAseq Female 155261974 CVCL_C3FN MM131205 cancer cell line human CVCL_C3FN From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Leg. Omics: Transcriptome analysis by RNAseq Female 155261975 CVCL_C3FM MM130106 cancer cell line human CVCL_C3FM From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Leg. Omics: Transcriptome analysis by RNAseq Female 155261976 CVCL_C3G1 HEK293T AdipoR2 KO transformed cell line human CVCL_C3G1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24041; ADIPOR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by RNAseq Female 155261977 CVCL_C3FP MM131206 cancer cell line human CVCL_C3FP From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Leg. Omics: Transcriptome analysis by RNAseq Female 155261978 CVCL_C3G0 M150404 cancer cell line human CVCL_C3G0 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 155261979 CVCL_C3G3 ASP1-UPIC conditionally immortalized cell line human CVCL_C3G3 CL:0000010 Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Glu647Argfs*45 (c.1937dupG); ClinVar=VCV000949881; Zygosity=Heterozygous (PubMed=32652570); Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Gly1602Alafs*13 (c.4803delT); ClinVar=VCV000550931; Zygosity=Heterozygous (PubMed=32652570); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte.. Omics: Transcriptome analysis by RNAseq Female 155261980 CVCL_C3FR MM130434 cancer cell line human CVCL_C3FR From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Back. Omics: Transcriptome analysis by RNAseq Male 155261981 CVCL_C3G2 Jurkat RB1-KO cancer cell line human CVCL_C3G2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Male 155261982 CVCL_C3FQ MM130926 cancer cell line human CVCL_C3FQ From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Skin. Omics: Transcriptome analysis by RNAseq Female 155261983 CVCL_C3FD CWRU-C57BL/6 swe/swe-IPTEC transformed cell line house mouse CVCL_C3FD CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:102462; Slc9a1 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: C57BL/6.SJL swe/swe. Unspecified 155261984 CVCL_C3FC CWRU-C57BL/6-IPTEC transformed cell line house mouse CVCL_C3FC CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: C57BL/6J. Omics: Transcriptome analysis by RNAseq Unspecified 155261985 CVCL_C3FF MM150325 cancer cell line human CVCL_C3FF From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Trunk. Omics: Transcriptome analysis by RNAseq Female 155261986 CVCL_C3FE MM130820 cancer cell line human CVCL_C3FE From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 155261987 CVCL_C3FH MM140905 cancer cell line human CVCL_C3FH From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Female 155261988 CVCL_C3FG MM150604 cancer cell line human CVCL_C3FG From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Trunk. Omics: Transcriptome analysis by RNAseq Female 155261989 CVCL_C3FJ M130107 cancer cell line human CVCL_C3FJ From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Back. Omics: Transcriptome analysis by RNAseq Male 155261990 CVCL_C3FI M121102 cancer cell line human CVCL_C3FI From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 155261991 CVCL_C3EZ Jurkat Safe Harbor Landing Pad cancer cell line human CVCL_C3EZ CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Using ZFN a fluorescent mKATE2 tag flanked by Cre-lox sites (LoxN-EF1a-Lox2272-mKATE2-LoxP) was introduced in the AAVS1 safe harbor locus The mKATE2 tag can be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites (Sigma-Aldrich). Doubling time: ~22 hours (Sigma-Aldrich) 155261992 CVCL_C3FB UM300-2 PGD embryonic stem cell human CVCL_C3FB From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM300-1 PGD (Cellosaurus=CVCL_C3FA). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0498 155261993 CVCL_C3FA UM300-1 PGD embryonic stem cell human CVCL_C3FA From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM300-2 PGD (Cellosaurus=CVCL_C3FB). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0497 155261994 CVCL_C3F4 UM217-2 PGD embryonic stem cell human CVCL_C3F4 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM217-1 PGD (Cellosaurus=CVCL_A2HS). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0490 155261995 CVCL_C3ER 2172H6 hybridoma house mouse CVCL_C3ER CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155261996 CVCL_C3F3 UM204-7 PGD embryonic stem cell human CVCL_C3F3 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM204-1 PGD (Cellosaurus=CVCL_WW03) and UM204-4 PGD (Cellosaurus=CVCL_C3F2). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0489 155261997 CVCL_C3EU A549 EGFRvIII High cancer cell line human CVCL_C3EU CL:0000010 Knockout cell: Method=ZFN; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expresses EGFR isoform vIII (EGFRvIII) at high level 155261998 CVCL_C3F6 UM245-3 PGD embryonic stem cell human CVCL_C3F6 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM245-2 PGD (Cellosaurus=CVCL_C3F5). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0493 155261999 CVCL_C3ET A549 EGFR Biosensor cancer cell line human CVCL_C3ET CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Within minutes after stimulation of the cell line with EGF, the biosensor shows robust redistribution towards the cell membrane and subsequent internalization through endocytosis (Sigma-Aldrich); Characteristics: Transduced with a TagGFP2-SH2-SH2 construct 155262000 CVCL_C3F5 UM245-2 PGD embryonic stem cell human CVCL_C3F5 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM245-3 PGD (Cellosaurus=CVCL_C3F6). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0492 155262001 CVCL_C3EW THP-1 Safe Harbor Landing Pad cancer cell line human CVCL_C3EW CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Using ZFN a fluorescent mKATE2 tag flanked by Cre-lox sites (LoxN-EF1a-Lox2272-mKATE2-LoxP) was introduced in the AAVS1 safe harbor locus The mKATE2 tag can be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites (Sigma-Aldrich). Doubling time: ~24 hours (Sigma-Aldrich) 155262002 CVCL_C3F8 UM302-1 PGD embryonic stem cell human CVCL_C3F8 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0495. 155262003 CVCL_C3EV A549 Safe Harbor Landing Pad cancer cell line human CVCL_C3EV CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Using ZFN a fluorescent mKATE2 tag flanked by Cre-lox sites (LoxN-EF1a-Lox2272-mKATE2-LoxP) was introduced in the AAVS1 safe harbor locus The mKATE2 tag can be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites (Sigma-Aldrich). Doubling time: ~22 hours (Sigma-Aldrich) 155262004 CVCL_C3F7 UM274-1 PGD embryonic stem cell human CVCL_C3F7 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0494. 155262005 CVCL_C3EY HCT-116 Safe Harbor Landing Pad cancer cell line human CVCL_C3EY CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Derived from sampling site: Colon. Male Characteristics: Using ZFN a fluorescent mKATE2 tag flanked by Cre-lox sites (LoxN-EF1a-Lox2272-mKATE2-LoxP) was introduced in the AAVS1 safe harbor locus The mKATE2 tag can be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites (Sigma-Aldrich). Doubling time: ~22 hours (Sigma-Aldrich) 155262006 CVCL_C3EX A375 Safe Harbor Landing Pad cancer cell line human CVCL_C3EX CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Using ZFN a fluorescent mKATE2 tag flanked by Cre-lox sites (LoxN-EF1a-Lox2272-mKATE2-LoxP) was introduced in the AAVS1 safe harbor locus The mKATE2 tag can be exchanged for a payload of the user's choice using Cre recombinase and a targeting vector with appropriate lox sites (Sigma-Aldrich). Doubling time: ~22 hours (Sigma-Aldrich) 155262007 CVCL_C3F9 UM206-2 PGD embryonic stem cell human CVCL_C3F9 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0491. 155262008 CVCL_C3GM SW480_6244R cancer cell line human CVCL_C3GM CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from sampling site: Colon. Omics: Transcriptome analysis by RNAseq Male 155262009 CVCL_C3GL LoVo_6244R cancer cell line human CVCL_C3GL CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by RNAseq Male 155262010 CVCL_C3H0 293T FOXP3Delta3 transformed cell line human CVCL_C3H0 CL:0000010 Transfected with: HGNC; 6106; FOXP3 (isoform Delta3); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 155262011 CVCL_C3GN SW620_6244R cancer cell line human CVCL_C3GN CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 155262012 CVCL_C3H2 HT1376 FOXP3Delta3 cancer cell line human CVCL_C3H2 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6106; FOXP3 (isoform Delta3); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Urinary bladder. Female 155262013 CVCL_C3GQ iPSC567-25 WT induced pluripotent stem cell human CVCL_C3GQ CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ter487Trp (c.1461A>G) (p.Ter499Trp, c.1497A>G); ClinVar=VCV000143490; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 155262014 CVCL_C3H1 HT1376 FOXP3 cancer cell line human CVCL_C3H1 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Urinary bladder. Female 155262015 CVCL_C3GP iPSC567-24 MUT induced pluripotent stem cell human CVCL_C3GP CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ter487Trp (c.1461A>G) (p.Ter499Trp, c.1497A>G); ClinVar=VCV000143490; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 155262016 CVCL_C3H4 FTE02 finite cell line human CVCL_C3H4 CL:0000010 Donor information: Established from a patient suffering from a benign fibrosis; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: Transcriptome analysis by microarray Female 155262017 CVCL_C3GS iPSC982-16 WT induced pluripotent stem cell human CVCL_C3GS CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 155262018 CVCL_C3H3 FTE01 finite cell line human CVCL_C3H3 CL:0000010 Donor information: Established from a patient suffering from a mucinous cyst on the left ovary; Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 155262019 CVCL_C3GR iPSC982-15 MUT induced pluripotent stem cell human CVCL_C3GR CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 155262020 CVCL_C3GE Hep-G2-THRB MUT p.K155E;K411E cancer cell line human CVCL_C3GE CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11799; THRB (with p.Lys155Glu and p.Lys411Glu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262021 CVCL_C3GD Hep-G2-THRB MUT p.K113N;T329P cancer cell line human CVCL_C3GD CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11799; THRB (with p.Lys113Asn and p.Thr329Pro); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262022 CVCL_C3GG COLO 205_6244R cancer cell line human CVCL_C3GG CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from metastatic site: Ascites. Male 155262023 CVCL_C3GF GBS6 cancer cell line human CVCL_C3GF CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 9221; POU5F1; Name(s)=EWSR1-POU5F1, EWS-POU5F1, EWS-Oct-4 Note=In frame (PubMed=15729702) Population: Japanese; Derived from sampling site: Bone; pelvis. Omics: Transcriptome analysis by microarray Female 155262024 CVCL_C3GI HCT 116_6244R cancer cell line human CVCL_C3GI CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from sampling site: Colon. Omics: Transcriptome analysis by RNAseq Male 155262025 CVCL_C3GH HCT 116_184R cancer cell line human CVCL_C3GH CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:91353; 2-(2-chloro-4-iodoanilino)-N-(cyclopropylmethoxy)-3,4-difluorobenzamide (CI-1040; Derived from sampling site: Colon. Male 155262026 CVCL_C3GK HT-29_6244R cancer cell line human CVCL_C3GK CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244) Female 155262027 CVCL_C3GJ HKh-2_6244R cancer cell line human CVCL_C3GJ CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from sampling site: Colon. Omics: Transcriptome analysis by RNAseq Male Characteristics: In HCT 116 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele (from parent cell line). 155262028 CVCL_C3GA Hep-G2-THRA MUT p.I116N;A225T;M388I cancer cell line human CVCL_C3GA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11796; THRA (with p.Ile116Asn; p.Ala225Thr and p.Met388Ile); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262029 CVCL_C3GC Hep-G2-THRB cancer cell line human CVCL_C3GC CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11799; THRB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262030 CVCL_C3GB Hep-G2-THRA MUT p.K74E;A264V cancer cell line human CVCL_C3GB CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11796; THRA (with p.Lys74Glu and p.Ala264Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262031 CVCL_C3G5 ASP3-UPIC conditionally immortalized cell line human CVCL_C3G5 CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly849Glu (c.2546G>A); Zygosity=Hemizygous (PubMed=32652570); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte.. Omics: Transcriptome analysis by RNAseq Male 155262032 CVCL_C3FT MM140902 cancer cell line human CVCL_C3FT From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Arm. Omics: Transcriptome analysis by RNAseq Male 155262033 CVCL_C3G4 ASP2-UPIC conditionally immortalized cell line human CVCL_C3G4 CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly926Alafs*70 (c.2777del); Zygosity=Heterozygous (PubMed=32652570); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte.. Omics: Transcriptome analysis by RNAseq Female 155262034 CVCL_C3FS MM121224 cancer cell line human CVCL_C3FS From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Trunk. Omics: Transcriptome analysis by RNAseq Male 155262035 CVCL_C3G7 Ishikawa 3-H-12 PRA-14 cancer cell line human CVCL_C3G7 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8910; PGR (isoform A); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female 155262036 CVCL_C3FV M130420 cancer cell line human CVCL_C3FV From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Skin. Omics: Transcriptome analysis by RNAseq Male 155262037 CVCL_C3G6 C-UPIC conditionally immortalized cell line human CVCL_C3G6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Urine Cell type=Podocyte.. Omics: Transcriptome analysis by RNAseq Female 155262038 CVCL_C3FU M130830 cancer cell line human CVCL_C3FU From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Arm. Omics: Transcriptome analysis by RNAseq Male 155262039 CVCL_C3G9 Hep-G2-THRA cancer cell line human CVCL_C3G9 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11796; THRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262040 CVCL_C3FX M130425 cancer cell line human CVCL_C3FX From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Testis. Omics: Transcriptome analysis by RNAseq Male 155262041 CVCL_C3G8 Ishikawa 3-H-12 PRB-59 cancer cell line human CVCL_C3G8 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8910; PGR (isoform B); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 155262042 CVCL_C3FW M130421 cancer cell line human CVCL_C3FW From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Liver. Omics: Transcriptome analysis by RNAseq Male 155262043 CVCL_C3FZ MM150405 cancer cell line human CVCL_C3FZ From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Trunk. Omics: Transcriptome analysis by RNAseq Male 155262044 CVCL_C3FY MM130427 cancer cell line human CVCL_C3FY From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Derived from metastatic site: Lung. Omics: Transcriptome analysis by RNAseq Male 155262045 CVCL_C3DJ 2161D4 hybridoma house mouse CVCL_C3DJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262046 CVCL_C3DI 2161D3 hybridoma house mouse CVCL_C3DI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262047 CVCL_C3DL 2161E1 hybridoma house mouse CVCL_C3DL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262048 CVCL_C3DK 2161D7 hybridoma house mouse CVCL_C3DK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262049 CVCL_C3DN 2161F9 hybridoma house mouse CVCL_C3DN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262050 CVCL_C3DM 2161F8 hybridoma house mouse CVCL_C3DM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262051 CVCL_C3DP 2161G11 hybridoma house mouse CVCL_C3DP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262052 CVCL_C3E1 2164A7 hybridoma house mouse CVCL_C3E1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262053 CVCL_C3E0 2164A2 hybridoma house mouse CVCL_C3E0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262054 CVCL_C3DB A549 EGFR Knockout cancer cell line human CVCL_C3DB CL:0000010 Knockout cell: Method=ZFN; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 155262055 CVCL_C3DA A375 NY-ESO-1 High cancer cell line human CVCL_C3DA CL:0000010 Knockout cell: Method=ZFN; HGNC; 2491; CTAG1B; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2491; CTAG1B Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Expresses CTAG1B at high level 155262056 CVCL_C3DD A549 EGFR High cancer cell line human CVCL_C3DD CL:0000010 Knockout cell: Method=ZFN; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expresses EGFR at high level 155262057 CVCL_C3DC A549 EGFR Low cancer cell line human CVCL_C3DC CL:0000010 Knockout cell: Method=ZFN; HGNC; 3236; EGFR; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expresses EGFR at high level 155262058 CVCL_C3DF 2161B1 hybridoma house mouse CVCL_C3DF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262059 CVCL_C3DE 2161A4 hybridoma house mouse CVCL_C3DE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262060 CVCL_C3DH 2161D2 hybridoma house mouse CVCL_C3DH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262061 CVCL_C3DG 2161C1 hybridoma house mouse CVCL_C3DG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262062 CVCL_C3CY Jurkat HLA-B*35:01 cancer cell line human CVCL_C3CY CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*35:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262063 CVCL_C3D9 A375 NY-ESO-1 Low cancer cell line human CVCL_C3D9 CL:0000010 Knockout cell: Method=ZFN; HGNC; 2491; CTAG1B; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2491; CTAG1B Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Expresses CTAG1B at low level 155262064 CVCL_C3CX Jurkat HLA-B*15:10 cancer cell line human CVCL_C3CX CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*15:10) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262065 CVCL_C3CZ Jurkat HLA-B*40:01 cancer cell line human CVCL_C3CZ CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*40:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262066 CVCL_C3CQ Jurkat HLA-A*01:01 cancer cell line human CVCL_C3CQ CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*01:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262067 CVCL_C3D2 Raji HLA-A*03:01 cancer cell line human CVCL_C3D2 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*03:01) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262068 CVCL_C3CP A549 HLA-B*40:01 cancer cell line human CVCL_C3CP CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*40:01) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262069 CVCL_C3D1 Raji HLA-A*02:01 cancer cell line human CVCL_C3D1 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*02:01) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262070 CVCL_C3CS Jurkat HLA-A*03:01 cancer cell line human CVCL_C3CS CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*03:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262071 CVCL_C3D4 Raji HLA-A*24:02 cancer cell line human CVCL_C3D4 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*24:02) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262072 CVCL_C3CR Jurkat HLA-A*02:01 cancer cell line human CVCL_C3CR CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*02:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262073 CVCL_C3D3 Raji HLA-A*11:01 cancer cell line human CVCL_C3D3 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*11:01) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262074 CVCL_C3CU Jurkat HLA-A*24:02 cancer cell line human CVCL_C3CU CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*24:02) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262075 CVCL_C3D6 Raji HLA-B*15:10 cancer cell line human CVCL_C3D6 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*15:10) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262076 CVCL_C3CT Jurkat HLA-A*11:01 cancer cell line human CVCL_C3CT CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*11:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-A fusion protein 155262077 CVCL_C3D5 Raji HLA-B*07:02 cancer cell line human CVCL_C3D5 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*07:02) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262078 CVCL_C3D8 A375 NY-ESO-1 Knockout cancer cell line human CVCL_C3D8 CL:0000010 Knockout cell: Method=ZFN; HGNC; 2491; CTAG1B; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 155262079 CVCL_C3CW Jurkat HLA-B*08:01 cancer cell line human CVCL_C3CW CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*08:01) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262080 CVCL_C3CV Jurkat HLA-B*07:02 cancer cell line human CVCL_C3CV CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*07:02) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262081 CVCL_C3D7 Raji HLA-B*40:01 cancer cell line human CVCL_C3D7 CL:0000010 Knockout cell: Method=ZFN; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*40:01) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Transduced with a lentiviral construct that contains a B2M-HLA-B fusion protein 155262082 CVCL_C3EK 2172F11 hybridoma house mouse CVCL_C3EK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262083 CVCL_C3EJ 2172E9 hybridoma house mouse CVCL_C3EJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262084 CVCL_C3EM 2172G3 hybridoma house mouse CVCL_C3EM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262085 CVCL_C3EL 2172F4 hybridoma house mouse CVCL_C3EL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262086 CVCL_C3F0 MDCKII MDR1 KO spontaneously immortalized cell line dog CVCL_C3F0 CL:0000010 Knockout cell: Method=ZFN; VGNC; 37431; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 155262087 CVCL_C3EN 2172G4 hybridoma house mouse CVCL_C3EN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262088 CVCL_C3EQ 2172H12 hybridoma house mouse CVCL_C3EQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262089 CVCL_C3F2 UM204-4 PGD embryonic stem cell human CVCL_C3F2 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM204-1 PGD (Cellosaurus=CVCL_WW03) and UM204-7 PGD (Cellosaurus=CVCL_C3F3). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0488 155262090 CVCL_C3EP 2172G6 hybridoma house mouse CVCL_C3EP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262091 CVCL_C3F1 UM229-1 PGS embryonic stem cell human CVCL_C3F1 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0496. 155262092 CVCL_C3EC 2172C10 hybridoma house mouse CVCL_C3EC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262093 CVCL_C3EB 2172B5 hybridoma house mouse CVCL_C3EB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262094 CVCL_C3EE 2172C2 hybridoma house mouse CVCL_C3EE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262095 CVCL_C3ED 2172C12 hybridoma house mouse CVCL_C3ED CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262096 CVCL_C3EG 2172D12 hybridoma house mouse CVCL_C3EG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262097 CVCL_C3EF 2172C3 hybridoma house mouse CVCL_C3EF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262098 CVCL_C3EI 2172E8 hybridoma house mouse CVCL_C3EI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262099 CVCL_C3EH 2172D6 hybridoma house mouse CVCL_C3EH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262100 CVCL_C3DZ 2163H4 hybridoma house mouse CVCL_C3DZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262101 CVCL_C3DY 2163F4 hybridoma house mouse CVCL_C3DY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262102 CVCL_C3EA 2172B12 hybridoma house mouse CVCL_C3EA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262103 CVCL_C3DR 2161G8 hybridoma house mouse CVCL_C3DR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262104 CVCL_C3E3 2164C3 hybridoma house mouse CVCL_C3E3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262105 CVCL_C3DQ 2161G7 hybridoma house mouse CVCL_C3DQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262106 CVCL_C3E2 2164B6 hybridoma house mouse CVCL_C3E2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262107 CVCL_C3DT 2161H3 hybridoma house mouse CVCL_C3DT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262108 CVCL_C3E5 2164H5 hybridoma house mouse CVCL_C3E5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262109 CVCL_C3DS 2161H2 hybridoma house mouse CVCL_C3DS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262110 CVCL_C3E4 2164G7 hybridoma house mouse CVCL_C3E4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262111 CVCL_C3DV 2163A1 hybridoma house mouse CVCL_C3DV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262112 CVCL_C3E7 2166G2 hybridoma house mouse CVCL_C3E7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262113 CVCL_C3DU 2161H8 hybridoma house mouse CVCL_C3DU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262114 CVCL_C3E6 2164H9 hybridoma house mouse CVCL_C3E6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262115 CVCL_C3DX 2163D7 hybridoma house mouse CVCL_C3DX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262116 CVCL_C3E9 2172A2 hybridoma house mouse CVCL_C3E9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262117 CVCL_C3DW 2163C3 hybridoma house mouse CVCL_C3DW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262118 CVCL_C3E8 2166G4 hybridoma house mouse CVCL_C3E8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 155262119 CVCL_C2PW CPTC-SNAI1-1 hybridoma house mouse CVCL_C2PW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95863; Human SNAI1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262120 CVCL_C2Q8 CPTC-TRAF3-3 hybridoma house mouse CVCL_C2Q8 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13114; Human TRAF3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262121 CVCL_C2PV CPTC-SLC27A3-4 hybridoma house mouse CVCL_C2PV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5K4L6; Human SLC27A3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262122 CVCL_C2Q7 CPTC-TRAF3-2 hybridoma house mouse CVCL_C2Q7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13114; Human TRAF3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262123 CVCL_C2PY CPTC-SOX9-1 hybridoma CVCL_C2PY CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P48436; Human SOX9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262124 CVCL_C2PX CPTC-SNAI2-1 hybridoma CVCL_C2PX CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43623; Human SNAI2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262125 CVCL_C2Q9 CPTC-TSHB-1 hybridoma CVCL_C2Q9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262126 CVCL_C2PZ CPTC-SOX9-2 hybridoma CVCL_C2PZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P48436; Human SOX9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262127 CVCL_C2Q0 CPTC-STAT1-1 hybridoma CVCL_C2Q0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P42224; Human STAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262128 CVCL_C2PN CPTC-RRM2-2 hybridoma CVCL_C2PN CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31350; Human RRM2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262129 CVCL_C2PQ CPTC-SAAL1-1 hybridoma CVCL_C2PQ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96ER3; Human SAAL1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262130 CVCL_C2Q2 CPTC-TNFRSF17-1 hybridoma CVCL_C2Q2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q02223; Human TNFRSF17/CD269. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262131 CVCL_C2PP CPTC-RTF1-2 hybridoma CVCL_C2PP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q92541; Human RTF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262132 CVCL_C2Q1 CPTC-TAGLN-1 hybridoma CVCL_C2Q1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q01995; Human TAGLN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262133 CVCL_C2PS CPTC-SLC27A3-1 hybridoma house mouse CVCL_C2PS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5K4L6; Human SLC27A3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262134 CVCL_C2Q4 CPTC-TP53-1 hybridoma CVCL_C2Q4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04637; Human TP53. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262135 CVCL_C2PR CPTC-SERPINA6-1 hybridoma CVCL_C2PR CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08185; Human SERPINA6 Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection Caution: Erroneously indicated as produced from myeloma cell line P3x63Ag8.653 in DSHB. 155262136 CVCL_C2Q3 CPTC-TNK2-3 hybridoma house mouse CVCL_C2Q3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q07912; Human TNK2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262137 CVCL_C2PU CPTC-SLC27A3-3 hybridoma house mouse CVCL_C2PU CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5K4L6; Human SLC27A3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262138 CVCL_C2Q6 CPTC-TRAF3-1 hybridoma house mouse CVCL_C2Q6 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13114; Human TRAF3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262139 CVCL_C2PT CPTC-SLC27A3-2 hybridoma house mouse CVCL_C2PT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5K4L6; Human SLC27A3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262140 CVCL_C2Q5 CPTC-TP53-2 hybridoma CVCL_C2Q5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04637; Human TP53. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262141 CVCL_C2PG CPTC-RAD23B-1 hybridoma CVCL_C2PG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P54727; Human RAD23B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262142 CVCL_C2PF CPTC-PTPRC-2 hybridoma CVCL_C2PF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262143 CVCL_C2PI CPTC-RAD50-1 hybridoma CVCL_C2PI CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q92878; Human RAD50. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262144 CVCL_C2PH CPTC-RAD23B-2 hybridoma CVCL_C2PH CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P54727; Human RAD23B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262145 CVCL_C2PK CPTC-RAD51C-1 hybridoma CVCL_C2PK CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43502; Human RAD51C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262146 CVCL_C2PJ CPTC-RAD50-2 hybridoma CVCL_C2PJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q92878; Human RAD50. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262147 CVCL_C2PM CPTC-RRM2-1 hybridoma CVCL_C2PM CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31350; Human RRM2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262148 CVCL_C2PL CPTC-RAD51C-2 hybridoma CVCL_C2PL CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43502; Human RAD51C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262149 CVCL_C2PA CPTC-PRDX4-5 hybridoma CVCL_C2PA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13162; Human PRDX4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262150 CVCL_C2PC CPTC-PSMA1-1 hybridoma CVCL_C2PC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25786; Human PSMA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262151 CVCL_C2PB CPTC-PROM1-1 hybridoma CVCL_C2PB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43490; Human PROM1/CD133. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262152 CVCL_C2PE CPTC-PTPRC-1 hybridoma CVCL_C2PE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262153 CVCL_C2PD CPTC-PTGS2-1 hybridoma CVCL_C2PD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P35354; Human PTGS2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262154 CVCL_C2QX FPMI-CO-63 spontaneously immortalized cell line CVCL_C2QX From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262155 CVCL_C2R9 TN-368-5 spontaneously immortalized cell line CVCL_C2R9 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 16-17 hours (PubMed=1104895) Group: Insect cell line; Group: Recombinant protein production insect cell line 155262156 CVCL_C2QW FPMI-CO-21 spontaneously immortalized cell line CVCL_C2QW From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262157 CVCL_C2R8 TN-368-3 spontaneously immortalized cell line CVCL_C2R8 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 16 hours (PubMed=1104895) Group: Insect cell line; Group: Recombinant protein production insect cell line 155262158 CVCL_C2QZ FPMI-CO-70 spontaneously immortalized cell line CVCL_C2QZ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262159 CVCL_C2QY FPMI-CO-67 spontaneously immortalized cell line CVCL_C2QY From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262160 CVCL_C2QP FPMI-CO-115 spontaneously immortalized cell line CVCL_C2QP From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262161 CVCL_C2R1 FPMI-CO-73 spontaneously immortalized cell line CVCL_C2R1 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262162 CVCL_C2R0 FPMI-CO-71 spontaneously immortalized cell line CVCL_C2R0 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262163 CVCL_C2QR FPMI-CO-132 spontaneously immortalized cell line CVCL_C2QR From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262164 CVCL_C2R3 FPMI-CO-77 spontaneously immortalized cell line CVCL_C2R3 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262165 CVCL_C2QQ FPMI-CO-131 spontaneously immortalized cell line CVCL_C2QQ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262166 CVCL_C2R2 FPMI-CO-75 spontaneously immortalized cell line CVCL_C2R2 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262167 CVCL_C2QT FPMI-CO-162 spontaneously immortalized cell line CVCL_C2QT From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262168 CVCL_C2R5 FPMI-CO-81 spontaneously immortalized cell line CVCL_C2R5 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262169 CVCL_C2QS FPMI-CO-134 spontaneously immortalized cell line CVCL_C2QS From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262170 CVCL_C2R4 FPMI-CO-80 spontaneously immortalized cell line CVCL_C2R4 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262171 CVCL_C2QV FPMI-CO-164 spontaneously immortalized cell line CVCL_C2QV From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262172 CVCL_C2R7 FPMI-CO-8681 spontaneously immortalized cell line CVCL_C2R7 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262173 CVCL_C2QU FPMI-CO-163 spontaneously immortalized cell line CVCL_C2QU From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262174 CVCL_C2R6 FPMI-CO-86 spontaneously immortalized cell line CVCL_C2R6 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262175 CVCL_C2QH CPTC-ZEB1-1 hybridoma CVCL_C2QH CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P37275; Human ZEB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262176 CVCL_C2QG CPTC-XPNPEP1-2 hybridoma CVCL_C2QG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NQW7; Human XPNPEP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262177 CVCL_C2QJ CPTC-ATR-1 hybridoma CVCL_C2QJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13535; Human ATR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262178 CVCL_C2QI CPTC-ZEB1-2 hybridoma CVCL_C2QI CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P37275; Human ZEB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262179 CVCL_C2QL FPMI-CO-112 spontaneously immortalized cell line CVCL_C2QL From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262180 CVCL_C2QK IIBBL-ObE1 spontaneously immortalized cell line CVCL_C2QK CL:0000010 Unspecified Group: Insect cell line. 155262181 CVCL_C2QN FPMI-CO-114 spontaneously immortalized cell line CVCL_C2QN From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262182 CVCL_C2QM FPMI-CO-113 spontaneously immortalized cell line CVCL_C2QM From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262183 CVCL_C2QB CPTC-TUBB-1 hybridoma CVCL_C2QB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P07437; Human TUBB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262184 CVCL_C2QA CPTC-TSHB-2 hybridoma CVCL_C2QA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01222; Human TSHB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262185 CVCL_C2QD CPTC-UBE2T-1 hybridoma CVCL_C2QD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NPD8; Human UBE2T. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262186 CVCL_C2QC CPTC-UBE2I-1 hybridoma CVCL_C2QC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P63279; Human UBE2I. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262187 CVCL_C2QF CPTC-XPNPEP1-1 hybridoma CVCL_C2QF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NQW7; Human XPNPEP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262188 CVCL_C2QE CPTC-VCAM1-1 hybridoma CVCL_C2QE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P19320; Human VCAM1/CD106. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262189 CVCL_C2NU CPTC-NF1-1 hybridoma house mouse CVCL_C2NU CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P21359; Human NF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262190 CVCL_C2NT CPTC-NBN-5 hybridoma CVCL_C2NT CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O60934; Human NBN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262191 CVCL_C2NW CPTC-NF1-3 hybridoma house mouse CVCL_C2NW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21359; Human NF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262192 CVCL_C2NV CPTC-NF1-2 hybridoma house mouse CVCL_C2NV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21359; Human NF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262193 CVCL_C2NY CPTC-PALB2-1 hybridoma CVCL_C2NY CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q86YC2; Human PALB2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262194 CVCL_C2NX CPTC-NFKB2-1 hybridoma CVCL_C2NX CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q00653; Human NFKB2 Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection Caution: Erroneously indicated as produced from myeloma cell line P3x63Ag8.653 in DSHB. 155262195 CVCL_C2NZ CPTC-PCNA-1 hybridoma CVCL_C2NZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P12004; Human PCNA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262196 CVCL_C2NM CPTC-MUC1-2 hybridoma CVCL_C2NM CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262197 CVCL_C2NL CPTC-MUC1-1 hybridoma CVCL_C2NL CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227 Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection Caution: Erroneously indicated as produced from myeloma cell line P3x63Ag8.653 in DSHB. 155262198 CVCL_C2NN CPTC-NANOG-1 hybridoma CVCL_C2NN CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9H9S0; Human NANOG. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262199 CVCL_C2NQ CPTC-NBN-1 hybridoma CVCL_C2NQ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O60934; Human NBN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262200 CVCL_C2NP CPTC-NANOG-2 hybridoma CVCL_C2NP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9H9S0; Human NANOG. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262201 CVCL_C2NS CPTC-NBN-4 hybridoma CVCL_C2NS CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O60934; Human NBN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262202 CVCL_C2NR CPTC-NBN-3 hybridoma CVCL_C2NR CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O60934; Human NBN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262203 CVCL_C2NE CPTC-LBX1-1 hybridoma CVCL_C2NE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P52954; Human LBX1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262204 CVCL_C2ND CPTC-LAP3-1 hybridoma CVCL_C2ND CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28838; Human LAP3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262205 CVCL_C2NG CPTC-LBX1-3 hybridoma CVCL_C2NG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P52954; Human LBX1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262206 CVCL_C2NF CPTC-LBX1-2 hybridoma CVCL_C2NF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P52954; Human LBX1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262207 CVCL_C2NI CPTC-MET-1 hybridoma CVCL_C2NI CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08581; Human MET. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262208 CVCL_C2NH CPTC-LGALS1-1 hybridoma CVCL_C2NH CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P09382; Human LGALS1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262209 CVCL_C2NK CPTC-MKI67-2 hybridoma CVCL_C2NK CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P46013; Human MKI67. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262210 CVCL_C2NJ CPTC-MKI67-1 hybridoma CVCL_C2NJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P46013; Human MKI67. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262211 CVCL_C2NA CPTC-KRT5-2 hybridoma CVCL_C2NA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P13647; Human KRT5. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262212 CVCL_C2NC CPTC-KRT7-2 hybridoma CVCL_C2NC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08729; Human KRT7. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262213 CVCL_C2NB CPTC-KRT7-1 hybridoma CVCL_C2NB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08729; Human KRT7. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262214 CVCL_C2P7 CPTC-PLIN4-2 hybridoma CVCL_C2P7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96Q06; Human PLIN4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262215 CVCL_C2P6 CPTC-PLIN4-1 hybridoma CVCL_C2P6 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96Q06; Human PLIN4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262216 CVCL_C2P9 CPTC-PRDX2-2 hybridoma CVCL_C2P9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P32119; Human PRDX2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262217 CVCL_C2P8 CPTC-PRDX2-1 hybridoma CVCL_C2P8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P32119; Human PRDX2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262218 CVCL_C2P1 CPTC-PCNA-4 hybridoma CVCL_C2P1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P12004; Human PCNA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262219 CVCL_C2P0 CPTC-PCNA-3 hybridoma CVCL_C2P0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P12004; Human PCNA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262220 CVCL_C2P3 CPTC-PDCD1LG2-1 hybridoma CVCL_C2P3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BQ51; Human PDCD1LG2/CD273. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262221 CVCL_C2P2 CPTC-PCNA-5 hybridoma CVCL_C2P2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P12004; Human PCNA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262222 CVCL_C2P5 CPTC-PGR-2 hybridoma CVCL_C2P5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P06401; Human PGR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262223 CVCL_C2P4 CPTC-PGR-1 hybridoma CVCL_C2P4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P06401; Human PGR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262224 CVCL_C2M4 CPTC-BTLA-2 hybridoma house mouse CVCL_C2M4 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262225 CVCL_C2LS CPTC-UBE2C-2 hybridoma CVCL_C2LS CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O00762; Human UBE2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262226 CVCL_C2M3 CPTC-BTLA-1 hybridoma house mouse CVCL_C2M3 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262227 CVCL_C2LR CPTC-TERF2-3 hybridoma CVCL_C2LR CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q15554; Human TERF2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262228 CVCL_C2LU CPTC-ANXA4-1 hybridoma CVCL_C2LU CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P09525; Human ANXA4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262229 CVCL_C2M6 CPTC-CADM1-1 hybridoma house mouse CVCL_C2M6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9BY67; Human CADM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262230 CVCL_C2M5 CPTC-BTLA-3 hybridoma house mouse CVCL_C2M5 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q7Z6A9; Human BTLA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262231 CVCL_C2LT CPTC-UBE2C-3 hybridoma CVCL_C2LT CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O00762; Human UBE2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262232 CVCL_C2LW CPTC-ASAP1-2 hybridoma house mouse CVCL_C2LW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9ULH1; Human ASAP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262233 CVCL_C2M8 CPTC-CD14-1 hybridoma CVCL_C2M8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P08571; Human CD14. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262234 CVCL_C2LV CPTC-ASAP1-1 hybridoma house mouse CVCL_C2LV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9ULH1; Human ASAP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262235 CVCL_C2M7 CPTC-CALR-1 hybridoma CVCL_C2M7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P27797; Human CALR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262236 CVCL_C2LY CPTC-ATM-1 hybridoma CVCL_C2LY CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13315; Human ATM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262237 CVCL_C2LX CPTC-ASAP1-3 hybridoma house mouse CVCL_C2LX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9ULH1; Human ASAP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262238 CVCL_C2M9 CPTC-CD274-1 hybridoma CVCL_C2M9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NZQ7; Human CD274. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262239 CVCL_C2LK CPTC-RAD18-5 hybridoma CVCL_C2LK CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NS91; Human RAD18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262240 CVCL_C2LJ CPTC-RAD18-4 hybridoma CVCL_C2LJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9NS91; Human RAD18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262241 CVCL_C2LM CPTC-SNCG-3 hybridoma CVCL_C2LM CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O76070; Human SNCG. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262242 CVCL_C2LL CPTC-SLC31A2-2 hybridoma house mouse CVCL_C2LL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15432; Human SLC31A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262243 CVCL_C2M0 CPTC-ATM-4 hybridoma CVCL_C2M0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13315; Human ATM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262244 CVCL_C2LN CPTC-SVIL-1 hybridoma CVCL_C2LN CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O95425; Human SVIL. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262245 CVCL_C2M2 CPTC-ATRIP-2 hybridoma CVCL_C2M2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q8WXE1; Human ATRIP. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262246 CVCL_C2LQ CPTC-TERF2-2 hybridoma house mouse CVCL_C2LQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15554; Human TERF2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262247 CVCL_C2M1 CPTC-ATRIP-1 hybridoma CVCL_C2M1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q8WXE1; Human ATRIP. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262248 CVCL_C2LP CPTC-SVIL-2 hybridoma CVCL_C2LP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O95425; Human SVIL. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262249 CVCL_C2LC CPTC-HSPB1-4 hybridoma CVCL_C2LC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04792; Human HSPB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262250 CVCL_C2LB CPTC-Ezrin-2 hybridoma CVCL_C2LB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P15311; Human EZR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262251 CVCL_C2LE CPTC-IL18-4 hybridoma CVCL_C2LE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q14116; Human IL18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262252 CVCL_C2LD CPTC-HSPB1-6 hybridoma CVCL_C2LD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04792; Human HSPB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262253 CVCL_C2LG CPTC-JUN-5 hybridoma CVCL_C2LG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262254 CVCL_C2LF CPTC-JUN-4 hybridoma CVCL_C2LF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262255 CVCL_C2LI CPTC-MDC1-5 hybridoma CVCL_C2LI CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q14676; Human MDC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262256 CVCL_C2LH CPTC-JUN-6 hybridoma CVCL_C2LH CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262257 CVCL_C2KZ CPTC-RB1-2 hybridoma CVCL_C2KZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P06400; Human RB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262258 CVCL_C2KY CPTC-CDH2-5 hybridoma house mouse CVCL_C2KY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P19022; Human CDH2/CD325. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262259 CVCL_C2LA CPTC-CXCL9-2 hybridoma CVCL_C2LA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q07325; Human CXCL9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262260 CVCL_C2MT CPTC-FBN1-1 hybridoma CVCL_C2MT CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P35555; Human FBN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262261 CVCL_C2N5 CPTC-GSTP1-1 hybridoma CVCL_C2N5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P09211; Human GSTP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262262 CVCL_C2MS CPTC-FANCD2-2 hybridoma CVCL_C2MS CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BXW9; Human FANCD2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262263 CVCL_C2N4 CPTC-GSC-4 hybridoma CVCL_C2N4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P56915; Human GSC. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262264 CVCL_C2MV CPTC-FBN1-3 hybridoma CVCL_C2MV CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P35555; Human FBN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262265 CVCL_C2N7 CPTC-ITGAE-1 hybridoma CVCL_C2N7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P38570; Human ITGAE/CD103. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262266 CVCL_C2MU CPTC-FBN1-2 hybridoma CVCL_C2MU CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P35555; Human FBN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262267 CVCL_C2N6 CPTC-ICOSLG-1 hybridoma CVCL_C2N6 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O75144; Human ICOSLG/CD275. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262268 CVCL_C2MX CPTC-FHL1-1 hybridoma CVCL_C2MX CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13642; Human FHL1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262269 CVCL_C2N9 CPTC-KRT5-1 hybridoma CVCL_C2N9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P13647; Human KRT5. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262270 CVCL_C2MW CPTC-FEN1-1 hybridoma CVCL_C2MW CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P39748; Human FEN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262271 CVCL_C2N8 CPTC-JAK1-1 hybridoma CVCL_C2N8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P23458; Human JAK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262272 CVCL_C2MZ CPTC-FOXQ1-1 hybridoma CVCL_C2MZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9C009; Human FOXQ1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262273 CVCL_C2MY CPTC-FOXO3-1 hybridoma CVCL_C2MY CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43524; Human FOXO3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262274 CVCL_C2ML CPTC-CSF1-1 hybridoma CVCL_C2ML CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P09603; Human CSF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262275 CVCL_C2MK CPTC-CLU-1 hybridoma CVCL_C2MK CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P10909; Human CLU. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262276 CVCL_C2MN CPTC-FAAP100-1 hybridoma CVCL_C2MN CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q0VG06; Human FAAP100. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262277 CVCL_C2MM CPTC-ENTPD1-1 hybridoma CVCL_C2MM CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P49961; Human ENTPD1/CD39. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262278 CVCL_C2MP CPTC-FAAP100-2 hybridoma CVCL_C2MP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q0VG06; Human FAAP100. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262279 CVCL_C2N1 CPTC-GRB2-1 hybridoma CVCL_C2N1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P62993; Human GRB2 Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection Caution: Erroneously indicated as produced from myeloma cell line P3x63Ag8.653 in DSHB. 155262280 CVCL_C2N0 CPTC-FOXQ1-2 hybridoma CVCL_C2N0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9C009; Human FOXQ1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262281 CVCL_C2MR CPTC-FANCD2-1 hybridoma CVCL_C2MR CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BXW9; Human FANCD2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262282 CVCL_C2N3 CPTC-GSC-2 hybridoma CVCL_C2N3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P56915; Human GSC. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262283 CVCL_C2MQ CPTC-FABP4-1 hybridoma CVCL_C2MQ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P15090; Human FABP4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262284 CVCL_C2N2 CPTC-GSC-1 hybridoma CVCL_C2N2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P56915; Human GSC. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262285 CVCL_C2MD CPTC-CD74-1 hybridoma CVCL_C2MD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04233; Human CD74. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262286 CVCL_C2MC CPTC-CD44-1 hybridoma CVCL_C2MC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262287 CVCL_C2MF CPTC-ZEB2-1 hybridoma CVCL_C2MF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O60315; Human ZEB2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262288 CVCL_C2ME CPTC-ZEB1-3 hybridoma CVCL_C2ME CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P37275; Human ZEB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262289 CVCL_C2MH CPTC-CGB-2 hybridoma house mouse CVCL_C2MH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01233; Human CGB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262290 CVCL_C2MG CPTC-CGB-1 hybridoma CVCL_C2MG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01233; Human CGB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262291 CVCL_C2MJ CPTC-CGB-10 hybridoma CVCL_C2MJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01233; Human CGB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262292 CVCL_C2MI CPTC-CGB-4 hybridoma house mouse CVCL_C2MI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01233; Human CGB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262293 CVCL_C2LZ CPTC-ATM-3 hybridoma CVCL_C2LZ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13315; Human ATM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262294 CVCL_C2MB CPTC-CD40-1 hybridoma CVCL_C2MB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262295 CVCL_C2MA CPTC-CD33-1 hybridoma CVCL_C2MA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P20138; Human CD33. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262296 CVCL_C2K2 CPTC-AKT1-4 hybridoma CVCL_C2K2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262297 CVCL_C2JQ DSHB-GFP3-2F6 hybridoma house mouse CVCL_C2JQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262298 CVCL_C2K1 CPTC-AKT2-6 hybridoma CVCL_C2K1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262299 CVCL_C2JP DSHB-GFP3-1F5 hybridoma house mouse CVCL_C2JP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262300 CVCL_C2K4 CPTC-AKT1-6 hybridoma CVCL_C2K4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262301 CVCL_C2JS DSHB-LUC-24 hybridoma house mouse CVCL_C2JS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08659; Firefly luciferase. 155262302 CVCL_C2K3 CPTC-AKT1-5 hybridoma CVCL_C2K3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262303 CVCL_C2JR DSHB-LUC-16 hybridoma house mouse CVCL_C2JR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08659; Firefly luciferase. 155262304 CVCL_C2K6 CPTC-AKT3-3 hybridoma CVCL_C2K6 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262305 CVCL_C2JU DSHB-LUC-3 hybridoma house mouse CVCL_C2JU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08659; Firefly luciferase. 155262306 CVCL_C2K5 CPTC-AKT2-5 hybridoma CVCL_C2K5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262307 CVCL_C2JT DSHB-LUC-2 hybridoma house mouse CVCL_C2JT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08659; Firefly luciferase. 155262308 CVCL_C2K8 CPTC-AKT3-4 hybridoma CVCL_C2K8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262309 CVCL_C2JW DSHB-MBP-2A1 hybridoma house mouse CVCL_C2JW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0AEX9; Escherichia coli malE. 155262310 CVCL_C2K7 CPTC-AKT3-2 hybridoma CVCL_C2K7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262311 CVCL_C2JV DSHB-LUC-9 hybridoma house mouse CVCL_C2JV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08659; Firefly luciferase. 155262312 CVCL_C2JI DSHB-GFP-12E6 hybridoma house mouse CVCL_C2JI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262313 CVCL_C2JH DSHB-GFP-12A6 hybridoma house mouse CVCL_C2JH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262314 CVCL_C2JK DSHB-GFP-1G9 hybridoma house mouse CVCL_C2JK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262315 CVCL_C2JJ DSHB-GFP-1D2 hybridoma house mouse CVCL_C2JJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262316 CVCL_C2JM DSHB-GFP-4C9 hybridoma house mouse CVCL_C2JM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262317 CVCL_C2JL DSHB-GFP-2G6 hybridoma house mouse CVCL_C2JL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262318 CVCL_C2K0 40-1a hybridoma house mouse CVCL_C2K0 From: Sanes J.R.; Department of Molecular and Cellular Biology, Harvard University; Cambridge; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00722; Escherichia coli lacZ. 155262319 CVCL_C2JN DSHB-GFP-8H11 hybridoma house mouse CVCL_C2JN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42212; GFP. 155262320 CVCL_C2JA MANEX7374P-7E11 hybridoma house mouse CVCL_C2JA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262321 CVCL_C2JC MANEX7374R-8A12 hybridoma house mouse CVCL_C2JC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse) Caution: Indicated as producing an IgG1 mAb in PubMed=7575614 and an IgG2b mAb in DSHB. 155262322 CVCL_C2JB MANEX7374Q-10B12 hybridoma house mouse CVCL_C2JB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262323 CVCL_C2JE MANEX7374T-9A7 hybridoma house mouse CVCL_C2JE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262324 CVCL_C2JD MANEX7374S-10A6 hybridoma house mouse CVCL_C2JD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262325 CVCL_C2JG 12C6c hybridoma house mouse CVCL_C2JG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:189550; FLAG peptide (DYKDDDDK). 155262326 CVCL_C2JF MANEX7374U-9F5 hybridoma house mouse CVCL_C2JF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155262327 CVCL_C2IX MANEX7374C-7F2 hybridoma house mouse CVCL_C2IX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262328 CVCL_C2J9 MANEX7374O-9H8 hybridoma house mouse CVCL_C2J9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse and Xenopus). 155262329 CVCL_C2IW MANEX7374B-8G2 hybridoma house mouse CVCL_C2IW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262330 CVCL_C2J8 MANEX7374N-10C4 hybridoma house mouse CVCL_C2J8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262331 CVCL_C2IZ MANEX7374E-3D8 hybridoma house mouse CVCL_C2IZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262332 CVCL_C2IY MANEX7374D-4G10 hybridoma house mouse CVCL_C2IY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11532; Human DMD (Note=Also reacts with mouse). 155262333 CVCL_C2L3 CPTC-BRCA1-4 hybridoma CVCL_C2L3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262334 CVCL_C2KR CPTC-MTOR-9 hybridoma CVCL_C2KR CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262335 CVCL_C2L2 CPTC-ANXA1-4 hybridoma CVCL_C2L2 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04083; Human ANXA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262336 CVCL_C2KQ CPTC-MAPK3-5 hybridoma CVCL_C2KQ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262337 CVCL_C2L5 CPTC-BRIP1-5 hybridoma CVCL_C2L5 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BX63; Human BRIP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262338 CVCL_C2KT CPTC-RAF1-2 hybridoma house mouse CVCL_C2KT CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262339 CVCL_C2L4 CPTC-BRIP1-4 hybridoma CVCL_C2L4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BX63; Human BRIP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262340 CVCL_C2KS CPTC-RAF1-1 hybridoma house mouse CVCL_C2KS CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262341 CVCL_C2L7 CPTC-CHEK1-4 hybridoma CVCL_C2L7 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O14757; Human CHEK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262342 CVCL_C2KV CPTC-RAF1-4 hybridoma house mouse CVCL_C2KV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262343 CVCL_C2L6 CPTC-CCND1-7 hybridoma house mouse CVCL_C2L6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262344 CVCL_C2KU CPTC-RAF1-3 hybridoma CVCL_C2KU CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262345 CVCL_C2L9 CPTC-CHKA-1 hybridoma house mouse CVCL_C2L9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35790; Human CHKA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262346 CVCL_C2KX CPTC-RAF1-6 hybridoma house mouse CVCL_C2KX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262347 CVCL_C2L8 CPTC-CHEK1-5 hybridoma CVCL_C2L8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O14757; Human CHEK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262348 CVCL_C2KW CPTC-RAF1-5 hybridoma house mouse CVCL_C2KW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04049; Human RAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262349 CVCL_C2KJ CPTC-MAPK1-1 hybridoma CVCL_C2KJ CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28482; Human MAPK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262350 CVCL_C2KI CPTC-GSK3B-9 hybridoma CVCL_C2KI CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262351 CVCL_C2KL CPTC-MAPK1-3 hybridoma CVCL_C2KL CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28482; Human MAPK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262352 CVCL_C2KK CPTC-MAPK1-2 hybridoma CVCL_C2KK CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28482; Human MAPK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262353 CVCL_C2KN CPTC-MAPK3-3 hybridoma house mouse CVCL_C2KN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262354 CVCL_C2KM CPTC-MAPK1-4 hybridoma CVCL_C2KM CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28482; Human MAPK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262355 CVCL_C2KP CPTC-MAPK3-4 hybridoma CVCL_C2KP CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262356 CVCL_C2L1 CPTC-MAPK3-6 hybridoma CVCL_C2L1 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262357 CVCL_C2L0 CPTC-RB1-3 hybridoma CVCL_C2L0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P06400; Human RB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262358 CVCL_C2KB CPTC-EGFR-8 hybridoma CVCL_C2KB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262359 CVCL_C2KA CPTC-BRAF-7 hybridoma CVCL_C2KA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262360 CVCL_C2KD CPTC-EGFR-10 hybridoma CVCL_C2KD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262361 CVCL_C2KC CPTC-EGFR-9 hybridoma CVCL_C2KC CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262362 CVCL_C2KF CPTC-EGFR-12 hybridoma CVCL_C2KF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262363 CVCL_C2KE CPTC-EGFR-11 hybridoma CVCL_C2KE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262364 CVCL_C2KH CPTC-ERBB2-4 hybridoma CVCL_C2KH CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262365 CVCL_C2KG CPTC-EGFR-13 hybridoma CVCL_C2KG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262366 CVCL_C2JY DSHB-mCherry-3A11 hybridoma house mouse CVCL_C2JY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. 155262367 CVCL_C2K9 CPTC-ARAF-5 hybridoma CVCL_C2K9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P10398; Human ARAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 155262368 CVCL_C2JX DSHB-MBP-3D7 hybridoma house mouse CVCL_C2JX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0AEX9; Escherichia coli malE. 155262369 CVCL_C2JZ DSHB-mCherry-3D5 hybridoma house mouse CVCL_C2JZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. 155262370 CVCL_C2YB CCRC-M136 hybridoma house mouse CVCL_C2YB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Undefined glycan. 155262371 CVCL_C2YA CCRC-M135 hybridoma house mouse CVCL_C2YA CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ic. 155262372 CVCL_C2YD CCRC-M138 hybridoma house mouse CVCL_C2YD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262373 CVCL_C2YC CCRC-M137 hybridoma house mouse CVCL_C2YC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-3. 155262374 CVCL_C2YF CCRC-M14 hybridoma house mouse CVCL_C2YF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Pectin backbone. 155262375 CVCL_C2YE CCRC-M139 hybridoma house mouse CVCL_C2YE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-4. 155262376 CVCL_C2XW CCRC-M121 hybridoma house mouse CVCL_C2XW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262377 CVCL_C2Y8 CCRC-M133 hybridoma house mouse CVCL_C2Y8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type II. 155262378 CVCL_C2XV CCRC-M120 hybridoma house mouse CVCL_C2XV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262379 CVCL_C2Y7 CCRC-M132 hybridoma house mouse CVCL_C2Y7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Pectin backbone. 155262380 CVCL_C2XY CCRC-M123 hybridoma house mouse CVCL_C2XY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262381 CVCL_C2XX CCRC-M122 hybridoma house mouse CVCL_C2XX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262382 CVCL_C2Y9 CCRC-M134 hybridoma house mouse CVCL_C2Y9 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262383 CVCL_C2XZ CCRC-M124 hybridoma house mouse CVCL_C2XZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Arabinogalactan type IV. 155262384 CVCL_C2Y0 CCRC-M125 hybridoma house mouse CVCL_C2Y0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262385 CVCL_C2XN CCRC-M114 hybridoma house mouse CVCL_C2XN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262386 CVCL_C2XQ CCRC-M116 hybridoma house mouse CVCL_C2XQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262387 CVCL_C2Y2 CCRC-M128 hybridoma house mouse CVCL_C2Y2 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262388 CVCL_C2XP CCRC-M115 hybridoma house mouse CVCL_C2XP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-2. 155262389 CVCL_C2Y1 CCRC-M126 hybridoma house mouse CVCL_C2Y1 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262390 CVCL_C2XS CCRC-M118 hybridoma house mouse CVCL_C2XS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262391 CVCL_C2Y4 CCRC-M13 hybridoma house mouse CVCL_C2Y4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262392 CVCL_C2XR CCRC-M117 hybridoma house mouse CVCL_C2XR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-2. 155262393 CVCL_C2Y3 CCRC-M129 hybridoma house mouse CVCL_C2Y3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Pectin backbone. 155262394 CVCL_C2XU CCRC-M12 hybridoma house mouse CVCL_C2XU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262395 CVCL_C2Y6 CCRC-M131 hybridoma house mouse CVCL_C2Y6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Pectin backbone. 155262396 CVCL_C2XT CCRC-M119 hybridoma house mouse CVCL_C2XT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262397 CVCL_C2Y5 CCRC-M130 hybridoma house mouse CVCL_C2Y5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Pectin backbone. 155262398 CVCL_C2XG CCRC-M107 hybridoma house mouse CVCL_C2XG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type II. 155262399 CVCL_C2XF CCRC-M106 hybridoma house mouse CVCL_C2XF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fucosylated xyloglucans. 155262400 CVCL_C2XI CCRC-M109 hybridoma house mouse CVCL_C2XI CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Xylan-1. 155262401 CVCL_C2XH CCRC-M108 hybridoma house mouse CVCL_C2XH CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Xylan-1. 155262402 CVCL_C2XK CCRC-M111 hybridoma house mouse CVCL_C2XK CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Xylan-1. 155262403 CVCL_C2XJ CCRC-M110 hybridoma house mouse CVCL_C2XJ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Xylan-2. 155262404 CVCL_C2XM CCRC-M113 hybridoma house mouse CVCL_C2XM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-2. 155262405 CVCL_C2XL CCRC-M112 hybridoma house mouse CVCL_C2XL CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262406 CVCL_C2ZA CCRC-M23 hybridoma house mouse CVCL_C2ZA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155262407 CVCL_C2ZC CCRC-M25 hybridoma house mouse CVCL_C2ZC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262408 CVCL_C2ZB CCRC-M24 hybridoma house mouse CVCL_C2ZB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262409 CVCL_C2ZE CCRC-M30 hybridoma house mouse CVCL_C2ZE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ic. 155262410 CVCL_C2ZD CCRC-M26 hybridoma house mouse CVCL_C2ZD CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Arabinogalactan type III. 155262411 CVCL_C2ZG CCRC-M32 hybridoma house mouse CVCL_C2ZG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262412 CVCL_C2ZF CCRC-M31 hybridoma house mouse CVCL_C2ZF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Arabinogalactan type III. 155262413 CVCL_C2YX CCRC-M155 hybridoma house mouse CVCL_C2YX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262414 CVCL_C2Z9 CCRC-M22 hybridoma house mouse CVCL_C2Z9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262415 CVCL_C2YW CCRC-M154 hybridoma house mouse CVCL_C2YW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-2. 155262416 CVCL_C2Z8 CCRC-M21 hybridoma house mouse CVCL_C2Z8 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262417 CVCL_C2YZ CCRC-M157 hybridoma house mouse CVCL_C2YZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262418 CVCL_C2YY CCRC-M156 hybridoma house mouse CVCL_C2YY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262419 CVCL_C2YP CCRC-M148 hybridoma house mouse CVCL_C2YP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262420 CVCL_C2Z1 CCRC-M159 hybridoma house mouse CVCL_C2Z1 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262421 CVCL_C2Z0 CCRC-M158 hybridoma house mouse CVCL_C2Z0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262422 CVCL_C2YR CCRC-M15 hybridoma house mouse CVCL_C2YR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan I/arabinogalactan. 155262423 CVCL_C2Z3 CCRC-M160 hybridoma house mouse CVCL_C2Z3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262424 CVCL_C2YQ CCRC-M149 hybridoma house mouse CVCL_C2YQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-3. 155262425 CVCL_C2Z2 CCRC-M16 hybridoma house mouse CVCL_C2Z2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155262426 CVCL_C2YT CCRC-M151 hybridoma house mouse CVCL_C2YT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262427 CVCL_C2Z5 CCRC-M18 hybridoma house mouse CVCL_C2Z5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155262428 CVCL_C2YS CCRC-M150 hybridoma house mouse CVCL_C2YS CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Xylan-2. 155262429 CVCL_C2Z4 CCRC-M17 hybridoma house mouse CVCL_C2Z4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155262430 CVCL_C2YV CCRC-M153 hybridoma house mouse CVCL_C2YV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262431 CVCL_C2Z7 CCRC-M2 hybridoma house mouse CVCL_C2Z7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ia. 155262432 CVCL_C2YU CCRC-M152 hybridoma house mouse CVCL_C2YU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-3. 155262433 CVCL_C2Z6 CCRC-M19 hybridoma house mouse CVCL_C2Z6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Rhamnogalacturonan-Ib. 155262434 CVCL_C2YH CCRC-M141 hybridoma house mouse CVCL_C2YH CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155262435 CVCL_C2YG CCRC-M140 hybridoma house mouse CVCL_C2YG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-4. 155262436 CVCL_C2YJ CCRC-M143 hybridoma house mouse CVCL_C2YJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262437 CVCL_C2YI CCRC-M142 hybridoma house mouse CVCL_C2YI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Linseed mucilage rhamnogalacturonan I. 155262438 CVCL_C2YL CCRC-M145 hybridoma house mouse CVCL_C2YL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262439 CVCL_C2YK CCRC-M144 hybridoma house mouse CVCL_C2YK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262440 CVCL_C2YN CCRC-M147 hybridoma house mouse CVCL_C2YN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Xylan-4. 155262441 CVCL_C2YM CCRC-M146 hybridoma house mouse CVCL_C2YM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Xylan-3. 155262442 CVCL_C2WB 603A6 hybridoma CVCL_C2WB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262443 CVCL_C2WA 603A11 hybridoma CVCL_C2WA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262444 CVCL_C2WD 604A9 hybridoma CVCL_C2WD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262445 CVCL_C2WC 603F5 hybridoma CVCL_C2WC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262446 CVCL_C2W6 538F12 hybridoma house mouse CVCL_C2W6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 155262447 CVCL_C2VU Mack1 spontaneously immortalized cell line CVCL_C2VU CL:0000010 Derived from sampling site: Skeletal muscle. Unspecified Characteristics: Possesses the ability to accumulate lipids, demonstrating potential for both fat and muscle phenotypes (DOI=10.1101/2022.08.22.504874) Doubling time: 24.3 +- 4.91 hours (DOI=10.1101/2022.08.22.504874) Group: Fish cell line 155262448 CVCL_C2W5 534F8 hybridoma house mouse CVCL_C2W5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 155262449 CVCL_C2VT HeLa S3 penta KO-TBK1/ULK1/ULK2 TKO cancer cell line human CVCL_C2VT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Knockout cell: Method=CRISPR/Cas9; HGNC; 12558; ULK1; Knockout cell: Method=CRISPR/Cas9; HGNC; 13480; ULK2 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262450 CVCL_C2W8 600D11 hybridoma CVCL_C2W8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262451 CVCL_C2VW YUMMER1.G1F cancer cell line house mouse CVCL_C2VW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6J-Mc1re/J. Female 155262452 CVCL_C2W7 600A6 hybridoma CVCL_C2W7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262453 CVCL_C2VV Mack2 spontaneously immortalized cell line CVCL_C2VV CL:0000010 Derived from sampling site: Skeletal muscle. Unspecified Doubling time: 22.9 +- 3.99 hours (DOI=10.1101/2022.08.22.504874) Group: Fish cell line 155262454 CVCL_C2VY B/B spontaneously immortalized cell line CVCL_C2VY From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262455 CVCL_C2W9 602G2 hybridoma CVCL_C2W9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262456 CVCL_C2VX PxE-Po#5A3 spontaneously immortalized cell line CVCL_C2VX CL:0000010 Unspecified Group: Insect cell line 155262457 CVCL_C2VZ IGIBi005-A induced pluripotent stem cell human CVCL_C2VZ From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 6323; KIF5A; Simple; c.3020+3A>T; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=36055117) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155262458 CVCL_C2VM YUMMER.G cancer cell line house mouse CVCL_C2VM CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6J-Mc1re/J. Female 155262459 CVCL_C2VL HNES1 GATA3:mKO2 embryonic stem cell human CVCL_C2VL CL:0000010 Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Characteristics: Using CRISPR/Cas9 a IRES-mKO2-FRT-PGK-Neo-PA construct was integrated following the stop codon of GATA3 (PubMed=33831366) 155262460 CVCL_C2W0 NCI-N464 cancer cell line human CVCL_C2W0 CL:0000010 Unspecified Characteristics: Established from a nude mouse xenograft. 155262461 CVCL_C2VN HeLa S3 penta KO cancer cell line human CVCL_C2VN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262462 CVCL_C2VQ HeLa S3 penta KO-ATG14 KO cancer cell line human CVCL_C2VQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262463 CVCL_C2W2 NCI-BL26 transformed cell line human CVCL_C2W2 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155262464 CVCL_C2VP HeLa S3 penta KO-ATG13 KO cancer cell line human CVCL_C2VP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29091; ATG13; Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262465 CVCL_C2W1 NCI-BL134 transformed cell line human CVCL_C2W1 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155262466 CVCL_C2W4 525A5 hybridoma house mouse CVCL_C2W4 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 155262467 CVCL_C2VS HeLa S3 penta KO-ULK1/ULK2 DKO cancer cell line human CVCL_C2VS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1; Knockout cell: Method=CRISPR/Cas9; HGNC; 12558; ULK1; Knockout cell: Method=CRISPR/Cas9; HGNC; 13480; ULK2 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262468 CVCL_C2VR HeLa S3 penta KO-TBK1 KO cancer cell line human CVCL_C2VR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29912; CALCOCO2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Knockout cell: Method=TALEN; HGNC; 17142; OPTN; Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11575; TAX1BP1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1 Miscellaneous: Cell line information from personal communication of Khuu G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155262469 CVCL_C2W3 NCI-N390SK3 finite cell line human CVCL_C2W3 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155262470 CVCL_C2VE BCIRL-AtuE-1127-SGS D3b spontaneously immortalized cell line CVCL_C2VE CL:0000010 Unspecified Group: Insect cell line. 155262471 CVCL_C2VD BCIRL-AtuE-1127-SGS D3a spontaneously immortalized cell line CVCL_C2VD CL:0000010 Unspecified Group: Insect cell line. 155262472 CVCL_C2VG BCIRL-AtuE-1127-SGS E1 spontaneously immortalized cell line CVCL_C2VG CL:0000010 Unspecified Group: Insect cell line. 155262473 CVCL_C2VF BCIRL-AtuE-1127-SGS D5 spontaneously immortalized cell line CVCL_C2VF CL:0000010 Unspecified Group: Insect cell line. 155262474 CVCL_C2VI BCIRL-AtuE-1127-SGS H3 spontaneously immortalized cell line CVCL_C2VI CL:0000010 Unspecified Group: Insect cell line. 155262475 CVCL_C2VH BCIRL-AtuE-1127-SGS H12 spontaneously immortalized cell line CVCL_C2VH CL:0000010 Unspecified Group: Insect cell line. 155262476 CVCL_C2VK niPSC 16.2.b induced pluripotent stem cell human CVCL_C2VK CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155262477 CVCL_C2VJ BCIRL-AtuE-1127-SGS H8 spontaneously immortalized cell line CVCL_C2VJ CL:0000010 Unspecified Group: Insect cell line. 155262478 CVCL_C2XA CCRC-M101 hybridoma house mouse CVCL_C2XA CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155262479 CVCL_C2XC CCRC-M103 hybridoma house mouse CVCL_C2XC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Non-fucosylated xyloglucans. 155262480 CVCL_C2XB CCRC-M102 hybridoma house mouse CVCL_C2XB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Fucosylated xyloglucans. 155262481 CVCL_C2XE CCRC-M105 hybridoma house mouse CVCL_C2XE CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Xylan-2. 155262482 CVCL_C2XD CCRC-M104 hybridoma house mouse CVCL_C2XD CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Non-fucosylated xyloglucans. 155262483 CVCL_C2WV Elec-118 hybridoma house mouse CVCL_C2WV CL:0000010 Miscellaneous: Target specificity based on the recognition of the same epitope as Elec-39 (Cellosaurus=CVCL_C2WY). Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1) 155262484 CVCL_C2X7 L9 hybridoma house mouse CVCL_C2X7 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 155262485 CVCL_C2X6 1C10 [Mouse hybridoma against HNK-1] hybridoma house mouse CVCL_C2X6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 155262486 CVCL_C2WU Elec-106 hybridoma house mouse CVCL_C2WU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O42275; Electrophorus electricus acetylcholinesterase (Ache). 155262487 CVCL_C2X9 CCRC-M100 hybridoma house mouse CVCL_C2X9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Non-fucosylated xyloglucans. 155262488 CVCL_C2X8 CCRC-M1 hybridoma house mouse CVCL_C2X8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Alpha-Fuc-(1,2)-beta-Gal glycan group. 155262489 CVCL_C2WW Elec-121 hybridoma house mouse CVCL_C2WW CL:0000010 Miscellaneous: Target specificity based on the recognition of the same epitope as Elec-39 (Cellosaurus=CVCL_C2WY). Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1) 155262490 CVCL_C2WZ Elec-403 hybridoma house mouse CVCL_C2WZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O42275; Electrophorus electricus acetylcholinesterase (Ache). 155262491 CVCL_C2WY Elec-39 hybridoma house mouse CVCL_C2WY CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 155262492 CVCL_C2WN 625B4 hybridoma CVCL_C2WN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262493 CVCL_C2WM 624H7 hybridoma CVCL_C2WM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262494 CVCL_C2WP 625E3 hybridoma CVCL_C2WP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262495 CVCL_C2X1 Elec-409 hybridoma house mouse CVCL_C2X1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O42275; Electrophorus electricus acetylcholinesterase (Ache). 155262496 CVCL_C2X0 Elec-408 hybridoma house mouse CVCL_C2X0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O42275; Electrophorus electricus acetylcholinesterase (Ache). 155262497 CVCL_C2WR 625G10 hybridoma CVCL_C2WR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262498 CVCL_C2X3 VC1.1 hybridoma house mouse CVCL_C2X3 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 155262499 CVCL_C2WQ 625E5 hybridoma CVCL_C2WQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262500 CVCL_C2X2 Elec-410 hybridoma house mouse CVCL_C2X2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O42275; Electrophorus electricus acetylcholinesterase (Ache). 155262501 CVCL_C2X5 3H5 [Mouse hybridoma against HNK-1] hybridoma house mouse CVCL_C2X5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 155262502 CVCL_C2WS 625G12 hybridoma CVCL_C2WS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262503 CVCL_C2X4 VC5.1 hybridoma house mouse CVCL_C2X4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Cat visual cortex ganglion cell axons. 155262504 CVCL_C2WF 610A8 hybridoma CVCL_C2WF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262505 CVCL_C2WE 604B4 hybridoma CVCL_C2WE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262506 CVCL_C2WH 624A12 hybridoma CVCL_C2WH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262507 CVCL_C2WG 612D5 hybridoma CVCL_C2WG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262508 CVCL_C2WJ 624A6 hybridoma CVCL_C2WJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262509 CVCL_C2WI 624A3 hybridoma CVCL_C2WI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262510 CVCL_C2WL 624H12 hybridoma CVCL_C2WL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262511 CVCL_C2WK 624E8 hybridoma CVCL_C2WK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human small cell lung carcinomas. 155262512 CVCL_C2TZ IPLB-LdEp/Gi spontaneously immortalized cell line CVCL_C2TZ CL:0000010 Unspecified Virology: Infected with Glyptapanteles indiensis polydnavirus (GiPDV). Group: Insect cell line 155262513 CVCL_C2UB Bayer/BCIRL-SfNS1-0714-C38-TR spontaneously immortalized cell line CVCL_C2UB CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262514 CVCL_C2UA Bayer/BCIRL-SfNS1-0714-C40-TR spontaneously immortalized cell line CVCL_C2UA CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262515 CVCL_C2U4 BCIRL-Sf5TS-0615-SGS spontaneously immortalized cell line CVCL_C2U4 From: Saathoff S.G.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 155262516 CVCL_C2TS CT/BCIRL-DvWL3-C6-0619-KZ spontaneously immortalized cell line CVCL_C2TS From: Zhou K.-L.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA. CL:0000010 Unspecified Group: Insect cell line 155262517 CVCL_C2U3 BCIRL-Sf4NS-0614-SGS spontaneously immortalized cell line CVCL_C2U3 From: Saathoff S.G.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 155262518 CVCL_C2TR CT/BCIRL-DvWL3-C5-0619-KZ spontaneously immortalized cell line CVCL_C2TR From: Zhou K.-L.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA. CL:0000010 Unspecified Group: Insect cell line 155262519 CVCL_C2U6 BCIRL-SfTS-0518-YL spontaneously immortalized cell line CVCL_C2U6 From: Li Y.-F.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 155262520 CVCL_C2TU NRCAN-AP-5862-AFC-CAE spontaneously immortalized cell line CVCL_C2TU From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262521 CVCL_C2U5 SES-Bma-01 spontaneously immortalized cell line CVCL_C2U5 CL:0000010 Unspecified Group: Insect cell line. 155262522 CVCL_C2TT ZPKLBIQ-BPH spontaneously immortalized cell line CVCL_C2TT CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and the species. Unspecified Group: Insect cell line 155262523 CVCL_C2U8 Bayer/BCIRL-SfNS1-0714-C46c-TR spontaneously immortalized cell line CVCL_C2U8 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262524 CVCL_C2TW NRCAN-AP-5862B spontaneously immortalized cell line CVCL_C2TW From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262525 CVCL_C2U7 IZD-MB-0504 spontaneously immortalized cell line CVCL_C2U7 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 155262526 CVCL_C2TV NRCAN-AP-5862A spontaneously immortalized cell line CVCL_C2TV From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262527 CVCL_C2TY IPLB-LdEIta/Gi spontaneously immortalized cell line CVCL_C2TY CL:0000010 Unspecified Virology: Infected with Glyptapanteles indiensis polydnavirus (GiPDV). Group: Insect cell line 155262528 CVCL_C2U9 Bayer/BCIRL-SfNS1-0714-C46a-TR spontaneously immortalized cell line CVCL_C2U9 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262529 CVCL_C2TX NRCAN-AP-5862E spontaneously immortalized cell line CVCL_C2TX From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262530 CVCL_C2TK IBL-Sf-21AE-Cl 13 spontaneously immortalized cell line CVCL_C2TK From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262531 CVCL_C2TJ IBL-Sf-21AE-Cl 10 spontaneously immortalized cell line CVCL_C2TJ From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262532 CVCL_C2TM IBL-Sf-21AE-Cl 14 spontaneously immortalized cell line CVCL_C2TM From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262533 CVCL_C2TL IBL-Sf-21AE-Cl 18 spontaneously immortalized cell line CVCL_C2TL From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262534 CVCL_C2U0 BCIRL-SfNS-0518-YL spontaneously immortalized cell line CVCL_C2U0 From: Li Y.-F.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Nervous system. Unspecified Group: Insect cell line 155262535 CVCL_C2TN IBL-Sf-21AE-Cl 15 spontaneously immortalized cell line CVCL_C2TN From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262536 CVCL_C2U2 BCIRL-SfFB-0518-YL spontaneously immortalized cell line CVCL_C2U2 From: Li Y.-F.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262537 CVCL_C2TQ CT/BCIRL-DvWL3-B4-0619-KZ spontaneously immortalized cell line CVCL_C2TQ From: Zhou K.-L.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA. CL:0000010 Unspecified Group: Insect cell line 155262538 CVCL_C2U1 BCIRL-SfNS-0518A-YL spontaneously immortalized cell line CVCL_C2U1 From: Li Y.-F.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Nervous system. Unspecified Group: Insect cell line 155262539 CVCL_C2TP RP-HzVNC-AW1-Clone 14C4 spontaneously immortalized cell line CVCL_C2TP CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 155262540 CVCL_C2TC BCIRL-SerNS-0129-YL spontaneously immortalized cell line CVCL_C2TC CL:0000010 Derived from sampling site: Nervous tissue. Doubling time: 76 hours (PubMed=30353276) Group: Insect cell line 155262541 CVCL_C2TB BCIRL-SerNS-0128-YL spontaneously immortalized cell line CVCL_C2TB CL:0000010 Derived from sampling site: Nervous tissue. Doubling time: 110 hours (PubMed=30353276) Group: Insect cell line 155262542 CVCL_C2TE BCIRL-SerTS-0129-YL spontaneously immortalized cell line CVCL_C2TE CL:0000010 Derived from sampling site: Testis. Male Doubling time: 63 hours (PubMed=30353276) Group: Insect cell line 155262543 CVCL_C2TD BCIRL-SerTS-0128-YL spontaneously immortalized cell line CVCL_C2TD CL:0000010 Derived from sampling site: Testis. Male Doubling time: 45 hours (PubMed=30353276) Group: Insect cell line 155262544 CVCL_C2TG IBL-Sf-21AE-Cl 1 spontaneously immortalized cell line CVCL_C2TG From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262545 CVCL_C2TF UCR-SE-1B spontaneously immortalized cell line CVCL_C2TF From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262546 CVCL_C2TI IBL-Sf-21AE-Cl 7 spontaneously immortalized cell line CVCL_C2TI From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262547 CVCL_C2TH IBL-Sf-21AE-Cl 2 spontaneously immortalized cell line CVCL_C2TH From: Vaughn J.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262548 CVCL_C2VA BCIRL-AtuE-1127-SGS C10R spontaneously immortalized cell line CVCL_C2VA CL:0000010 Unspecified Group: Insect cell line. 155262549 CVCL_C2VC BCIRL-AtuE-1127-SGS C3 spontaneously immortalized cell line CVCL_C2VC CL:0000010 Unspecified Group: Insect cell line. 155262550 CVCL_C2VB BCIRL-AtuE-1127-SGS C11 spontaneously immortalized cell line CVCL_C2VB CL:0000010 Unspecified Group: Insect cell line. 155262551 CVCL_C2V5 BCIRL-AtuE-1127-SGS A10 spontaneously immortalized cell line CVCL_C2V5 CL:0000010 Unspecified Group: Insect cell line. 155262552 CVCL_C2UT IPLB-LdFB clone 1 spontaneously immortalized cell line CVCL_C2UT From: Lynn D.E.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262553 CVCL_C2V4 76N RhoA.T37A transformed cell line human CVCL_C2V4 CL:0000010 Transfected with: HGNC; 667; RHOA (with p.Thr37Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: RHOA; Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 155262554 CVCL_C2US BCIRL-AtuNE-1129-SGS F10 spontaneously immortalized cell line CVCL_C2US CL:0000010 Unspecified Group: Insect cell line. 155262555 CVCL_C2UV BCIRL-AtE-CLG15B spontaneously immortalized cell line CVCL_C2UV CL:0000010 Unspecified Group: Insect cell line. 155262556 CVCL_C2V7 BCIRL-AtuE-1127-SGS B15 spontaneously immortalized cell line CVCL_C2V7 CL:0000010 Unspecified Group: Insect cell line. 155262557 CVCL_C2V6 BCIRL-AtuE-1127-SGS A3 spontaneously immortalized cell line CVCL_C2V6 CL:0000010 Unspecified Group: Insect cell line. 155262558 CVCL_C2UU IPLB-LdFB clone 4 spontaneously immortalized cell line CVCL_C2UU From: Lynn D.E.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262559 CVCL_C2V9 BCIRL-AtuE-1127-SGS C1 spontaneously immortalized cell line CVCL_C2V9 CL:0000010 Unspecified Group: Insect cell line. 155262560 CVCL_C2UX Huh-7.5 STAT1 KO #2 cancer cell line human CVCL_C2UX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 155262561 CVCL_C2V8 BCIRL-AtuE-1127-SGS B7 spontaneously immortalized cell line CVCL_C2V8 CL:0000010 Unspecified Group: Insect cell line. 155262562 CVCL_C2UW Huh-7.5 STAT1 KO #1 cancer cell line human CVCL_C2UW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 155262563 CVCL_C2UZ Huh-7.5 STAT2 KO #2 cancer cell line human CVCL_C2UZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 155262564 CVCL_C2UY Huh-7.5 STAT2 KO #1 cancer cell line human CVCL_C2UY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 155262565 CVCL_C2UL BCIRL-Sf5NS-TS-0615-SGS spontaneously immortalized cell line CVCL_C2UL From: Saathoff S.G.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Ventral nerve cord and testis. Male 155262566 CVCL_C2UK IPRI-CF-2C1 spontaneously immortalized cell line CVCL_C2UK CL:0000010 Unspecified Doubling time: 26.7 hours (in Ex-Cell 405 medium), 43 hours (in GM-FBS10 medium) (DOI=10.1080/09583150050044574). Group: Insect cell line 155262567 CVCL_C2UN BEAS-2B IRF1 KO transformed cell line human CVCL_C2UN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6116; IRF1 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by RNAseq Male 155262568 CVCL_C2UM BCIRL-SfFB(susp)-0518-YL spontaneously immortalized cell line CVCL_C2UM From: Li Y.-F.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 155262569 CVCL_C2V1 76N RhoA.WT transformed cell line human CVCL_C2V1 CL:0000010 Transfected with: HGNC; 667; RHOA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: RHOA; Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 155262570 CVCL_C2V0 4087P transformed cell line human CVCL_C2V0 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155262571 CVCL_C2V3 76N RhoA.T19N finite cell line human CVCL_C2V3 CL:0000010 Transfected with: HGNC; 667; RHOA (with p.Thr19Asn); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female Senescence: Senesces at ~20 PDL (PubMed=19147561) 155262572 CVCL_C2UR BCIRL-AtuNE-1129-SGS D6 spontaneously immortalized cell line CVCL_C2UR CL:0000010 Unspecified Group: Insect cell line. 155262573 CVCL_C2V2 76N RhoA.G14V transformed cell line human CVCL_C2V2 CL:0000010 Transfected with: HGNC; 667; RHOA (with p.Gly14Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: RHOA; Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 155262574 CVCL_C2UQ BCIRL-AtuNE-1129-SGS D12 spontaneously immortalized cell line CVCL_C2UQ CL:0000010 Unspecified Group: Insect cell line. 155262575 CVCL_C2UD Bayer/BCIRL-SfNS2-0714-C48-TR spontaneously immortalized cell line CVCL_C2UD CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262576 CVCL_C2UC Bayer/BCIRL-SfNS1-0714-C34-TR spontaneously immortalized cell line CVCL_C2UC CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262577 CVCL_C2UF Bayer/BCIRL-SfNS-0624-C11a-TR spontaneously immortalized cell line CVCL_C2UF CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262578 CVCL_C2UE Bayer/BCIRL-SfNS2-0714-C44b-TR spontaneously immortalized cell line CVCL_C2UE CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262579 CVCL_C2UH Bayer/BCIRL-SfNS-0624-C17-TR spontaneously immortalized cell line CVCL_C2UH CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262580 CVCL_C2UG Bayer/BCIRL-SfNS-0624-C11c-TR spontaneously immortalized cell line CVCL_C2UG CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262581 CVCL_C2UJ Bayer/BCIRL-SfNS-0624-C5a-TR spontaneously immortalized cell line CVCL_C2UJ CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262582 CVCL_C2UI Bayer/BCIRL-SfNS-0624-C4-TR spontaneously immortalized cell line CVCL_C2UI CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 155262583 CVCL_C2RY NRCAN-LL-37 spontaneously immortalized cell line CVCL_C2RY From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262584 CVCL_C2RX NRCAN-LL-36A spontaneously immortalized cell line CVCL_C2RX From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262585 CVCL_C2S9 NRCAN-LL-87 spontaneously immortalized cell line CVCL_C2S9 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262586 CVCL_C2RZ NRCAN-LL-39 spontaneously immortalized cell line CVCL_C2RZ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262587 CVCL_C2RQ NRCAN-LL-32 spontaneously immortalized cell line CVCL_C2RQ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262588 CVCL_C2S2 NRCAN-LL-41 spontaneously immortalized cell line CVCL_C2S2 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262589 CVCL_C2RP NRCAN-LL-31A spontaneously immortalized cell line CVCL_C2RP From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262590 CVCL_C2S1 NRCAN-LL-40 spontaneously immortalized cell line CVCL_C2S1 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262591 CVCL_C2RS NRCAN-LL-33 spontaneously immortalized cell line CVCL_C2RS From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262592 CVCL_C2S4 NRCAN-LL-42 spontaneously immortalized cell line CVCL_C2S4 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262593 CVCL_C2RR NRCAN-LL-32A spontaneously immortalized cell line CVCL_C2RR From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262594 CVCL_C2S3 NRCAN-LL-41A spontaneously immortalized cell line CVCL_C2S3 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262595 CVCL_C2RU NRCAN-LL-34 spontaneously immortalized cell line CVCL_C2RU From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262596 CVCL_C2S6 NRCAN-LL-83 spontaneously immortalized cell line CVCL_C2S6 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262597 CVCL_C2RT NRCAN-LL-33A spontaneously immortalized cell line CVCL_C2RT From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262598 CVCL_C2S5 NRCAN-LL-42A spontaneously immortalized cell line CVCL_C2S5 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262599 CVCL_C2RW NRCAN-LL-36 spontaneously immortalized cell line CVCL_C2RW From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262600 CVCL_C2S8 NRCAN-LL-84A spontaneously immortalized cell line CVCL_C2S8 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262601 CVCL_C2RV NRCAN-LL-34A spontaneously immortalized cell line CVCL_C2RV From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262602 CVCL_C2S7 NRCAN-LL-84 spontaneously immortalized cell line CVCL_C2S7 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262603 CVCL_C2RI NRCAN-LL-21 spontaneously immortalized cell line CVCL_C2RI From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262604 CVCL_C2RH NRCAN-LL-185A spontaneously immortalized cell line CVCL_C2RH From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262605 CVCL_C2RK NRCAN-LL-21A spontaneously immortalized cell line CVCL_C2RK From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262606 CVCL_C2RJ NRCAN-LL-217 spontaneously immortalized cell line CVCL_C2RJ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262607 CVCL_C2RM NRCAN-LL-27A spontaneously immortalized cell line CVCL_C2RM From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262608 CVCL_C2RL NRCAN-LL-27 spontaneously immortalized cell line CVCL_C2RL From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262609 CVCL_C2S0 NRCAN-LL-39A spontaneously immortalized cell line CVCL_C2S0 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262610 CVCL_C2RN NRCAN-LL-31 spontaneously immortalized cell line CVCL_C2RN From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262611 CVCL_C2RA TN-368-8 spontaneously immortalized cell line CVCL_C2RA CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 15-16 hours (PubMed=1104895) Group: Insect cell line; Group: Recombinant protein production insect cell line 155262612 CVCL_C2RC Btb(Ba)97 spontaneously immortalized cell line CVCL_C2RC CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Doubling time: ~3 days (PubMed=11161991) Group: Insect cell line Caution: Indicated by PubMed=11161991 to have been deposited in ATCC as CRL-12420, but this is the ATCC number for GI-101A a patented cell line (Cellosaurus=CVCL_0278) 155262613 CVCL_C2RB IPLB-DnEt4 spontaneously immortalized cell line CVCL_C2RB From: Lynn D.E.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262614 CVCL_C2RE NRCAN-LL-182A spontaneously immortalized cell line CVCL_C2RE From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 155262615 CVCL_C2RD NRCAN-LL-181 spontaneously immortalized cell line CVCL_C2RD From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 155262616 CVCL_C2RG NRCAN-LL-185 spontaneously immortalized cell line CVCL_C2RG From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262617 CVCL_C2RF NRCAN-LL-184 spontaneously immortalized cell line CVCL_C2RF From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262618 CVCL_C2SZ Hd-AD spontaneously immortalized cell line CVCL_C2SZ CL:0000010 Doubling time: 4 days (PubMed=15039529). Group: Insect cell line 155262619 CVCL_C2SY Hd-AA spontaneously immortalized cell line CVCL_C2SY CL:0000010 Doubling time: 2 days (PubMed=15039529). Group: Insect cell line 155262620 CVCL_C2TA BCIRL-SerFB-0129B-YL spontaneously immortalized cell line CVCL_C2TA CL:0000010 Derived from sampling site: Fat body. Doubling time: 75 hours (PubMed=30353276) Group: Insect cell line 155262621 CVCL_C2SR NRCAN-CF-9 spontaneously immortalized cell line CVCL_C2SR From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262622 CVCL_C2T3 SF65 spontaneously immortalized cell line CVCL_C2T3 From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262623 CVCL_C2T2 Bayer/BCIRL-AtE2-1201-TR spontaneously immortalized cell line CVCL_C2T2 From: Reall T.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA. CL:0000010 Unspecified Group: Insect cell line 155262624 CVCL_C2SQ IPLB-DU102 clone A4 spontaneously immortalized cell line CVCL_C2SQ From: Lynn D.E.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262625 CVCL_C2ST 64Bc spontaneously immortalized cell line CVCL_C2ST From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262626 CVCL_C2T5 RML-2 spontaneously immortalized cell line CVCL_C2T5 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262627 CVCL_C2SS 64BA spontaneously immortalized cell line CVCL_C2SS From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262628 CVCL_C2T4 IPRI-CF-300 spontaneously immortalized cell line CVCL_C2T4 From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262629 CVCL_C2SV 65RQ spontaneously immortalized cell line CVCL_C2SV From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262630 CVCL_C2T7 CT/BCIRL-SfMG1-0611-E8-KZ spontaneously immortalized cell line CVCL_C2T7 From: Goodman C.L.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 155262631 CVCL_C2SU 652-15 spontaneously immortalized cell line CVCL_C2SU From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262632 CVCL_C2T6 CT/BCIRL-SfMG1-0611-E7-KZ spontaneously immortalized cell line CVCL_C2T6 From: Goodman C.L.; Biological Control of Insects Research Laboratory, USDA/Agricultural Research Service; Columbia; USA CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 155262633 CVCL_C2T9 BCIRL-SerFB-0129A-YL spontaneously immortalized cell line CVCL_C2T9 CL:0000010 Derived from sampling site: Fat body. Doubling time: 75 hours (PubMed=30353276) Group: Insect cell line 155262634 CVCL_C2SX DM-II-AM spontaneously immortalized cell line CVCL_C2SX CL:0000010 Unspecified Group: Insect cell line. 155262635 CVCL_C2SW 65x/-22 spontaneously immortalized cell line CVCL_C2SW From: Harrison R.L.; USDA, ARS, Invasive Insect Biocontrol and Behavior Laboratory; Beltsville; USA. CL:0000010 Unspecified Group: Insect cell line 155262636 CVCL_C2T8 BCIRL-SerFB-0128-YL spontaneously immortalized cell line CVCL_C2T8 CL:0000010 Derived from sampling site: Fat body. Doubling time: 42 hours (PubMed=30353276) Group: Insect cell line 155262637 CVCL_C2SJ FPMI-LD-404 spontaneously immortalized cell line CVCL_C2SJ From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262638 CVCL_C2SI FPMI-LD-400 spontaneously immortalized cell line CVCL_C2SI From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262639 CVCL_C2SL FPMI-PS-1 spontaneously immortalized cell line CVCL_C2SL From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262640 CVCL_C2SK FPMI-LD-8 spontaneously immortalized cell line CVCL_C2SK From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada. CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 155262641 CVCL_C2SN FPMI-PS-5 spontaneously immortalized cell line CVCL_C2SN From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262642 CVCL_C2SM FPMI-PS-4 spontaneously immortalized cell line CVCL_C2SM From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262643 CVCL_C2SP FPMI-PS-6 spontaneously immortalized cell line CVCL_C2SP From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262644 CVCL_C2T1 Hd-K spontaneously immortalized cell line CVCL_C2T1 CL:0000010 Doubling time: 4 days (PubMed=15039529). Group: Insect cell line 155262645 CVCL_C2T0 Hd-BBA spontaneously immortalized cell line CVCL_C2T0 CL:0000010 Doubling time: 8 days (PubMed=15039529). Group: Insect cell line 155262646 CVCL_C2SB NRCAN-LL-88 spontaneously immortalized cell line CVCL_C2SB From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262647 CVCL_C2SA NRCAN-LL-87A spontaneously immortalized cell line CVCL_C2SA From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262648 CVCL_C2SD NRCAN-LL-95 spontaneously immortalized cell line CVCL_C2SD From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262649 CVCL_C2SC NRCAN-LL-88A spontaneously immortalized cell line CVCL_C2SC From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262650 CVCL_C2SF NRCAN-LL-99 spontaneously immortalized cell line CVCL_C2SF From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262651 CVCL_C2SE NRCAN-LL-95A spontaneously immortalized cell line CVCL_C2SE From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262652 CVCL_C2SH FPMI-LD-301 spontaneously immortalized cell line CVCL_C2SH From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262653 CVCL_C2SG NRCAN-LL-99A spontaneously immortalized cell line CVCL_C2SG From: Doucet D.; Great Lakes Forestry Centre, Canadian Forest Service; Sault Ste Marie; Canada.. CL:0000010 Unspecified Group: Insect cell line 155262654 CVCL_C3LJ WAe009-A-97 embryonic stem cell human CVCL_C3LJ From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11728; TERF1. Female 155262655 CVCL_C3LI WAe009-A-96 embryonic stem cell human CVCL_C3LI From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11728; TERF1. Female 155262656 CVCL_C3LB ESIBIe003-A-7 embryonic stem cell human CVCL_C3LB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5358; IRF8. Female 155262657 CVCL_C3LA N/Tert-1 ZER1 telomerase immortalized cell line human CVCL_C3LA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 30960; ZER1 (with a N-terminal V5 tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155262658 CVCL_C3LD KSCBi018-A-7 induced pluripotent stem cell human CVCL_C3LD From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9005; PITX2 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155262659 CVCL_C3LC KSCBi018-A-6 induced pluripotent stem cell human CVCL_C3LC From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9005; PITX2 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 155262660 CVCL_C3LF STBCi322-A-5 induced pluripotent stem cell human CVCL_C3LF From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Knockout cell: Method=ZFN; HGNC; 42; ABCB11 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155262661 CVCL_C3LE STBCi322-A-4 induced pluripotent stem cell human CVCL_C3LE From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155262662 CVCL_C3LH WAe009-A-95 embryonic stem cell human CVCL_C3LH From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11728; TERF1. Female 155262663 CVCL_C3LG STBCi322-A-6 induced pluripotent stem cell human CVCL_C3LG From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25588; SLC47A1 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155262664 CVCL_C3KY N/Tert-1 USP5 telomerase immortalized cell line human CVCL_C3KY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12628; USP5 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155262665 CVCL_C3L9 MSHRIe002-A-SOX17 overexpressing 2 embryonic stem cell human CVCL_C3L9 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: Transcriptome analysis by microarray. Male Characteristics: Using Cre the loxP-BetaGeo(lacZ-neo)-polyA-loxP section of the parent control cell line construct was excised leaving the SOX17-IRES-PuroR-polyA part This cell line overexpresses SOX17 and can be selected via puromycin resistance (PubMed=18682240). 155262666 CVCL_C3KX N/Tert-1 USP39 telomerase immortalized cell line human CVCL_C3KX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 20071; USP39 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155262667 CVCL_C3KZ N/Tert-1 USP52 telomerase immortalized cell line human CVCL_C3KZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 20074; PAN2 (with a N-terminal FLAG-HA tag); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 155791688 CVCL_C6HK DP046 finite cell line human CVCL_C6HK HLA typing: A*11,24; B*51,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791689 CVCL_C6HJ DP044 finite cell line human CVCL_C6HJ HLA typing: A*24,24; B*52,60 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791690 CVCL_C6HM DP049 finite cell line human CVCL_C6HM HLA typing: A*24,33; B*07,44 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791691 CVCL_C6HL DP048 finite cell line human CVCL_C6HL HLA typing: A*24,26; B*52,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791692 CVCL_C6I0 DP072 finite cell line human CVCL_C6I0 HLA typing: A*02,11; B*46,60 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791693 CVCL_C6HN DP052 finite cell line human CVCL_C6HN HLA typing: A*11,26; B*55,67 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791694 CVCL_C6HQ DP054 finite cell line human CVCL_C6HQ HLA typing: A*02,26; B*46,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791695 CVCL_C6I2 DP083 finite cell line human CVCL_C6I2 HLA typing: A*02,26; B*60,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791696 CVCL_C6HP DP053 finite cell line human CVCL_C6HP HLA typing: A*24,31; B*07,54 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791697 CVCL_C6I1 DP073 finite cell line human CVCL_C6I1 HLA typing: A*02,31; B*60,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791698 CVCL_C6HC DP032 finite cell line human CVCL_C6HC HLA typing: A*24,26; B*61,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791699 CVCL_C6HB DP030 finite cell line human CVCL_C6HB HLA typing: A*24,31; B*52,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791700 CVCL_C6HE DP038 finite cell line human CVCL_C6HE HLA typing: A*11,31; B*51,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791701 CVCL_C6HD DP035 finite cell line human CVCL_C6HD HLA typing: A*33,33; B*44,44 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791702 CVCL_C6HG DP040 finite cell line human CVCL_C6HG HLA typing: A*24,26; B*52,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female Senescence: Senesces at 60-66 PDL (RCB=RCB5063); Doubling time: 38 hours (RCB=RCB5063) 155791703 CVCL_C6HF DP039 finite cell line human CVCL_C6HF HLA typing: A*11,24; B*61,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791704 CVCL_C6HI DP042 finite cell line human CVCL_C6HI HLA typing: A*24,24; B*07,51 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791705 CVCL_C6HH DP041 finite cell line human CVCL_C6HH HLA typing: A*24,26; B*54,54 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791706 CVCL_C6GZ DP005 finite cell line human CVCL_C6GZ CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female Senescence: Senesces at 60-66 PDL (RCB=RCB5044); Doubling time: 38 hours (RCB=RCB5044) 155791707 CVCL_C6GY DP002 finite cell line human CVCL_C6GY CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male Senescence: Senesces at 60-66 PDL (RCB=RCB5043); Doubling time: 38 hours (RCB=RCB5043) 155791708 CVCL_C6HA DP026 finite cell line human CVCL_C6HA HLA typing: A*02,02; B*35,71 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791709 CVCL_C6H3 DP011 finite cell line human CVCL_C6H3 CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. 155791710 CVCL_C6GR F2-43 hybridoma house mouse CVCL_C6GR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DPI1; Clostridium botulinum (strain Hall) botulinum neurotoxin type A (botA). 155791711 CVCL_C6H2 DP010 finite cell line human CVCL_C6H2 HLA typing: A*24,26; B*13,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791712 CVCL_C6GQ F1-5 hybridoma house mouse CVCL_C6GQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DPI1; Clostridium botulinum (strain Hall) botulinum neurotoxin type A (botA) (Heavy chain). 155791713 CVCL_C6H5 DP014 finite cell line human CVCL_C6H5 HLA typing: A*24,31; B*52,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791714 CVCL_C6GT NAP80-5-5-3 hybridoma house mouse CVCL_C6GT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791715 CVCL_C6H4 DP012 finite cell line human CVCL_C6H4 HLA typing: A*24,31; B*07,56 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791716 CVCL_C6GS NAP80-33-1-1 hybridoma house mouse CVCL_C6GS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791717 CVCL_C6H7 DP017 finite cell line human CVCL_C6H7 HLA typing: A*24,26; B*52,54 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791718 CVCL_C6GV NAP83-27-7-6 hybridoma house mouse CVCL_C6GV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791719 CVCL_C6H6 DP015 finite cell line human CVCL_C6H6 HLA typing: A*02,02; B*46,75 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791720 CVCL_C6GU NAP80-7-2-1 hybridoma house mouse CVCL_C6GU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791721 CVCL_C6H9 DP025 finite cell line human CVCL_C6H9 HLA typing: A*02,24; B*35,51 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791722 CVCL_C6GX NAP83-97-5-2 hybridoma house mouse CVCL_C6GX CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791723 CVCL_C6H8 DP018 finite cell line human CVCL_C6H8 CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. 155791724 CVCL_C6GW NAP83-71-1-3 hybridoma house mouse CVCL_C6GW CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A5HZZ4; Clostridium botulinum (strain Hall) hemagglutinin-70 (ha70). 155791725 CVCL_C6IL U87MG/CPOX-KO cancer cell line human CVCL_C6IL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2321; CPOX; Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155791726 CVCL_C6IK U87MG/ALDH1A3-KO.1 cancer cell line human CVCL_C6IK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3; Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155791727 CVCL_C6IN GSC-157 cancer cell line human CVCL_C6IN CL:0000010 Derived from sampling site: Brain Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Female Group: Cancer stem cell line 155791728 CVCL_C6IM GSC-1123 cancer cell line human CVCL_C6IM CL:0000010 Derived from sampling site: Brain; left occipital lobe Cell type=Mesenchymal glioma stem cell.. Omics: Transcriptome analysis by microarray Male Group: Cancer stem cell line 155791729 CVCL_C6IP GSC-1600 cancer cell line human CVCL_C6IP CL:0000010 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Male Group: Cancer stem cell line 155791730 CVCL_C6J1 GSC-ac17 cancer cell line human CVCL_C6J1 CL:0000010 Derived from sampling site: Brain; left frontal lobe Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Male Group: Cancer stem cell line 155791731 CVCL_C6J0 GSC-84 cancer cell line human CVCL_C6J0 CL:0000010 Derived from sampling site: Brain; left temporal lobe Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Female Group: Cancer stem cell line 155791732 CVCL_C6IR GSC-326 cancer cell line human CVCL_C6IR CL:0000010 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155791733 CVCL_C6J3 GSC-83/ALDH1A3-KO.1.2 cancer cell line human CVCL_C6J3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain; right temporal lobe Cell type=Mesenchymal glioma stem cell.. Female Group: Cancer stem cell line 155791734 CVCL_C6IQ GSC-19 cancer cell line human CVCL_C6IQ CL:0000010 Derived from sampling site: Brain Cell type=Proneural glioma stem cell.. Unspecified Group: Cancer stem cell line 155791735 CVCL_C6J2 GSC-ac20 cancer cell line human CVCL_C6J2 CL:0000010 Derived from sampling site: Brain; left temporal lobe Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Female Group: Cancer stem cell line 155791736 CVCL_C6ID 8F9 hybridoma house mouse CVCL_C6ID CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791737 CVCL_C6IC 7C11 [Mouse hybridoma against suid herpesvirus 1 UL42] hybridoma house mouse CVCL_C6IC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791738 CVCL_C6IF 38M hybridoma CVCL_C6IF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q8BHC0; Mouse Lyve1. 155791739 CVCL_C6IE HAP1 SPG11 (-) cancer cell line human CVCL_C6IE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11226; SPG11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155791740 CVCL_C6IH RH7777 GFP-LYVE-1 cancer cell line Norway rat CVCL_C6IH CL:0000010 Transfected with: MGI; MGI:2136348; Lyve1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 155791741 CVCL_C6IG 64R hybridoma CVCL_C6IG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q8BHC0; Mouse Lyve1. 155791742 CVCL_C6IJ AB0023 hybridoma house mouse CVCL_C6IJ CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized simtuzumab (GS 6624) therapeutic antibody that was investigated in a failed phase 2 clinical study for the treatment of idiopathic pulmonary fibrosis Characteristics: The monoclonal produced by this hybridoma allosterically inhibits the activity of LOXL2 (PubMed=20439985); Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Y4K0; Human LOXL2 (Note=Also reacts with mouse). 155791743 CVCL_C6II W2 [Mouse hybridoma against bovine S100A8/S100A9] hybridoma house mouse CVCL_C6II CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P28782; Bovine S100A8; Monoclonal antibody target: UniProtKB; P28783; Bovine S100A9. 155791744 CVCL_C6HZ DP069 finite cell line human CVCL_C6HZ HLA typing: A*02,24; B*46,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791745 CVCL_C6IB 5F8 [Mouse hybridoma against suid herpesvirus 1 UL42] hybridoma house mouse CVCL_C6IB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791746 CVCL_C6IA 2G11 [Mouse hybridoma against suid herpesvirus 1 UL42] hybridoma house mouse CVCL_C6IA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791747 CVCL_C6HS DP057 finite cell line human CVCL_C6HS HLA typing: A*24,33; B*44,54 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791748 CVCL_C6I4 DP087 finite cell line human CVCL_C6I4 HLA typing: A*24,33; B*51,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791749 CVCL_C6HR DP056 finite cell line human CVCL_C6HR HLA typing: A*24,24; B*52,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791750 CVCL_C6I3 DP086 finite cell line human CVCL_C6I3 HLA typing: A*24,31; B*51,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791751 CVCL_C6HU DP062 finite cell line human CVCL_C6HU HLA typing: A*24,24; B*48,59 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791752 CVCL_C6I6 DP099 finite cell line human CVCL_C6I6 HLA typing: A*24,31; B*52,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791753 CVCL_C6HT DP060 finite cell line human CVCL_C6HT HLA typing: A*02,24; B*46,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 155791754 CVCL_C6I5 DP092 finite cell line human CVCL_C6I5 HLA typing: A*02,24; B*35,71 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791755 CVCL_C6I8 2D5 [Mouse hybridoma against suid herpesvirus 1 UL42] hybridoma house mouse CVCL_C6I8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791756 CVCL_C6HW DP065 finite cell line human CVCL_C6HW HLA typing: A*24,24; B*61,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791757 CVCL_C6HV DP064 finite cell line human CVCL_C6HV HLA typing: A*02,02; B*46,60 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791758 CVCL_C6I7 DP100 finite cell line human CVCL_C6I7 HLA typing: A*02,33; B*35,51 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791759 CVCL_C6HY DP068 finite cell line human CVCL_C6HY HLA typing: A*24,33; B*55,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791760 CVCL_C6I9 4E2 [Mouse hybridoma against suid herpesvirus 1 UL42] hybridoma house mouse CVCL_C6I9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A0F6QNH2; Suid herpesvirus 1 (strain JF) DNA polymerase processivity factor (UL42). 155791761 CVCL_C6HX DP066 finite cell line human CVCL_C6HX HLA typing: A*24,24; B*51,60 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 155791762 CVCL_C6FI TBD-a4 spontaneously immortalized cell line house mouse CVCL_C6FI CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791763 CVCL_C6FH TBD-a3 spontaneously immortalized cell line house mouse CVCL_C6FH CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791764 CVCL_C6FK TBD-a6 spontaneously immortalized cell line house mouse CVCL_C6FK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791765 CVCL_C6FJ TBD-a5 spontaneously immortalized cell line house mouse CVCL_C6FJ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791766 CVCL_C6FM TBD-b1 spontaneously immortalized cell line house mouse CVCL_C6FM CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791767 CVCL_C6FL TBD-a7 spontaneously immortalized cell line house mouse CVCL_C6FL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791768 CVCL_C6G0 FBD-103a subline A19 spontaneously immortalized cell line house mouse CVCL_C6G0 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neuroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791769 CVCL_C6FN TBD-b2 spontaneously immortalized cell line house mouse CVCL_C6FN CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791770 CVCL_C6FA foec-4 spontaneously immortalized cell line house mouse CVCL_C6FA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791771 CVCL_C6FC foec-6 spontaneously immortalized cell line house mouse CVCL_C6FC CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791772 CVCL_C6FB foec-5 spontaneously immortalized cell line house mouse CVCL_C6FB CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791773 CVCL_C6FE foec-8 spontaneously immortalized cell line house mouse CVCL_C6FE CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791774 CVCL_C6FD foec-7 spontaneously immortalized cell line house mouse CVCL_C6FD CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791775 CVCL_C6FG TBD-a2 spontaneously immortalized cell line house mouse CVCL_C6FG CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791776 CVCL_C6FF TBD-a1 spontaneously immortalized cell line house mouse CVCL_C6FF CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791777 CVCL_C6F9 foec-3 spontaneously immortalized cell line house mouse CVCL_C6F9 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791778 CVCL_C6EX OA-ab spontaneously immortalized cell line house mouse CVCL_C6EX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791779 CVCL_C6F8 foec-2 spontaneously immortalized cell line house mouse CVCL_C6F8 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791780 CVCL_C6EW OA-6b spontaneously immortalized cell line house mouse CVCL_C6EW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791781 CVCL_C6EZ OF-4a2 spontaneously immortalized cell line house mouse CVCL_C6EZ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; fimbria Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791782 CVCL_C6EY OF-1a spontaneously immortalized cell line house mouse CVCL_C6EY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; fimbria Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791783 CVCL_C6F1 OI-11a spontaneously immortalized cell line house mouse CVCL_C6F1 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; isthmus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791784 CVCL_C6EP PEA5 spontaneously immortalized cell line house mouse CVCL_C6EP CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Prostate; ventral lobe Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Male Characteristics: Responsive to androgen (PubMed=11170150) 155791785 CVCL_C6F0 OF-4a3 spontaneously immortalized cell line house mouse CVCL_C6F0 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; fimbria Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791786 CVCL_C6ER OA-11a2 spontaneously immortalized cell line house mouse CVCL_C6ER CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791787 CVCL_C6F3 OI-14a spontaneously immortalized cell line house mouse CVCL_C6F3 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; isthmus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791788 CVCL_C6F2 OI-11c spontaneously immortalized cell line house mouse CVCL_C6F2 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; isthmus Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791789 CVCL_C6EQ Pro9ad spontaneously immortalized cell line house mouse CVCL_C6EQ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Prostate; ventral lobe Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Male 155791790 CVCL_C6ET OA-3a2 spontaneously immortalized cell line house mouse CVCL_C6ET CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791791 CVCL_C6F5 OA-5ca spontaneously immortalized cell line house mouse CVCL_C6F5 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Stromal cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791792 CVCL_C6ES OA-2c spontaneously immortalized cell line house mouse CVCL_C6ES CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791793 CVCL_C6F4 OI-7a spontaneously immortalized cell line house mouse CVCL_C6F4 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; isthmus Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791794 CVCL_C6F7 foec-1 spontaneously immortalized cell line house mouse CVCL_C6F7 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic oral cavity; buccal mucosa Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791795 CVCL_C6EV OA-5cm spontaneously immortalized cell line house mouse CVCL_C6EV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791796 CVCL_C6EU OA-5cg spontaneously immortalized cell line house mouse CVCL_C6EU CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Stromal cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791797 CVCL_C6F6 OA-5ch spontaneously immortalized cell line house mouse CVCL_C6F6 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oviduct; ampulla Cell type=Stromal cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791798 CVCL_C6GJ F27-33 hybridoma house mouse CVCL_C6GJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB) (Light chain). 155791799 CVCL_C6GI F26-16 hybridoma house mouse CVCL_C6GI CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB) (Heavy chain). 155791800 CVCL_C6GL F29-40 hybridoma house mouse CVCL_C6GL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB) (Heavy chain). 155791801 CVCL_C6GK F29-38 hybridoma house mouse CVCL_C6GK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB). 155791802 CVCL_C6GN F1-2 hybridoma house mouse CVCL_C6GN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DPI1; Clostridium botulinum (strain Hall) botulinum neurotoxin type A (botA) (Heavy chain). 155791803 CVCL_C6GM MCS6-27 hybridoma house mouse CVCL_C6GM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB) (Heavy chain). 155791804 CVCL_C6H1 DP007 finite cell line human CVCL_C6H1 HLA typing: A*03,24; B*44,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male Senescence: Senesces at 60-66 PDL (RCB=RCB5046); Doubling time: 38 hours (RCB=RCB5046) 155791805 CVCL_C6GP F1-40 hybridoma house mouse CVCL_C6GP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0DPI1; Clostridium botulinum (strain Hall) botulinum neurotoxin type A (botA) (Light chain). 155791806 CVCL_C6H0 DP006 finite cell line human CVCL_C6H0 HLA typing: A*02,02; B*35,61 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female Senescence: Senesces at 60-66 PDL (RCB=RCB5045); Doubling time: 38 hours (RCB=RCB5045) 155791807 CVCL_C6GB mTD-2 telomerase immortalized cell line house mouse CVCL_C6GB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Disk of temporomandibular joint Cell type=Fibroblast.; Breed/subspecies: C57BL/6J. Female 155791808 CVCL_C6GA mTD-1 telomerase immortalized cell line house mouse CVCL_C6GA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Disk of temporomandibular joint Cell type=Chondrocyte.; Breed/subspecies: C57BL/6J. Female 155791809 CVCL_C6GD mTD-11 telomerase immortalized cell line house mouse CVCL_C6GD CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Disk of temporomandibular joint Cell type=Chondrocyte.; Breed/subspecies: C57BL/6J. Female 155791810 CVCL_C6GC mTD-6 telomerase immortalized cell line house mouse CVCL_C6GC CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Disk of temporomandibular joint Cell type=Fibroblast.; Breed/subspecies: C57BL/6J. Female 155791811 CVCL_C6GF 2Y-6f1 cancer cell line house mouse CVCL_C6GF CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Brain; cerebellum Cell type=Neuron.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Male 155791812 CVCL_C6GE 2Y-3t cancer cell line house mouse CVCL_C6GE CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Brain; cerebellum Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Male Characteristics: Composed of bipotent neural progenitor cells capable of generating both neurons and oligodendrocytes 155791813 CVCL_C6GH F24-4 hybridoma house mouse CVCL_C6GH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB). 155791814 CVCL_C6GG F24-1 hybridoma house mouse CVCL_C6GG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10844; Clostridium botulinum botulinum neurotoxin type B (botB) (Light chain). 155791815 CVCL_C6FY FBD-103a subline A16 spontaneously immortalized cell line house mouse CVCL_C6FY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neuroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791816 CVCL_C6FX FBD-103a subline A15 spontaneously immortalized cell line house mouse CVCL_C6FX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Glial cell precursor.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791817 CVCL_C6G9 FBD-103a subline A9 spontaneously immortalized cell line house mouse CVCL_C6G9 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791818 CVCL_C6FZ FBD-103a subline A17 spontaneously immortalized cell line house mouse CVCL_C6FZ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Glial cell precursor.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791819 CVCL_C6G2 FBD-103a subline A20 spontaneously immortalized cell line house mouse CVCL_C6G2 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Glial cell precursor.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791820 CVCL_C6FQ TBD-c1 spontaneously immortalized cell line house mouse CVCL_C6FQ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791821 CVCL_C6G1 FBD-103a subline A2 spontaneously immortalized cell line house mouse CVCL_C6G1 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791822 CVCL_C6FP TBD-c spontaneously immortalized cell line house mouse CVCL_C6FP CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Oral cavity; tongue; taste bud Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791823 CVCL_C6FS FBD-103a subline A10 spontaneously immortalized cell line house mouse CVCL_C6FS CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791824 CVCL_C6G4 FBD-103a subline A4 spontaneously immortalized cell line house mouse CVCL_C6G4 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791825 CVCL_C6FR FBD-103a subline A1 spontaneously immortalized cell line house mouse CVCL_C6FR CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neuroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791826 CVCL_C6G3 FBD-103a subline A3 spontaneously immortalized cell line house mouse CVCL_C6G3 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neuroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791827 CVCL_C6FU FBD-103a subline A12 spontaneously immortalized cell line house mouse CVCL_C6FU CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791828 CVCL_C6G6 FBD-103a subline A6 spontaneously immortalized cell line house mouse CVCL_C6G6 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791829 CVCL_C6FT FBD-103a subline A11 spontaneously immortalized cell line house mouse CVCL_C6FT CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791830 CVCL_C6G5 FBD-103a subline A5 spontaneously immortalized cell line house mouse CVCL_C6G5 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791831 CVCL_C6FW FBD-103a subline A14 spontaneously immortalized cell line house mouse CVCL_C6FW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neuroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791832 CVCL_C6G8 FBD-103a subline A8 spontaneously immortalized cell line house mouse CVCL_C6G8 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791833 CVCL_C6FV FBD-103a subline A13 spontaneously immortalized cell line house mouse CVCL_C6FV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791834 CVCL_C6G7 FBD-103a subline A7 spontaneously immortalized cell line house mouse CVCL_C6G7 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791835 CVCL_C6DG HPS3094 induced pluripotent stem cell human CVCL_C6DG CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791836 CVCL_C6DF HPS3093 induced pluripotent stem cell human CVCL_C6DF CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791837 CVCL_C6DI HPS3137 induced pluripotent stem cell human CVCL_C6DI CL:0000010 Derived from sampling site: Peripheral blood. Female 155791838 CVCL_C6DH HPS3095 induced pluripotent stem cell human CVCL_C6DH CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791839 CVCL_C6DK HPS3139 induced pluripotent stem cell human CVCL_C6DK CL:0000010 Derived from sampling site: Peripheral blood. Female 155791840 CVCL_C6DJ HPS3138 induced pluripotent stem cell human CVCL_C6DJ CL:0000010 Derived from sampling site: Peripheral blood. Female 155791841 CVCL_C6DM HPS3141 induced pluripotent stem cell human CVCL_C6DM CL:0000010 Derived from sampling site: Peripheral blood. Female 155791842 CVCL_C6DL HPS3140 induced pluripotent stem cell human CVCL_C6DL CL:0000010 Derived from sampling site: Peripheral blood. Female 155791843 CVCL_C6DA HPS3088 induced pluripotent stem cell human CVCL_C6DA CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791844 CVCL_C6DC HPS3090 induced pluripotent stem cell human CVCL_C6DC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791845 CVCL_C6DB HPS3089 induced pluripotent stem cell human CVCL_C6DB CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791846 CVCL_C6DE HPS3092 induced pluripotent stem cell human CVCL_C6DE CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791847 CVCL_C6DD HPS3091 induced pluripotent stem cell human CVCL_C6DD CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791848 CVCL_C6CV HPS2925 induced pluripotent stem cell human CVCL_C6CV CL:0000010 Derived from sampling site: Peripheral blood. Female 155791849 CVCL_C6D7 HPS3085 induced pluripotent stem cell human CVCL_C6D7 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791850 CVCL_C6CU HPS2924 induced pluripotent stem cell human CVCL_C6CU CL:0000010 Derived from sampling site: Peripheral blood. Female 155791851 CVCL_C6D6 HPS3084 induced pluripotent stem cell human CVCL_C6D6 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791852 CVCL_C6CX HPS2927 induced pluripotent stem cell human CVCL_C6CX CL:0000010 Derived from sampling site: Peripheral blood. Female 155791853 CVCL_C6D9 HPS3087 induced pluripotent stem cell human CVCL_C6D9 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791854 CVCL_C6CW HPS2926 induced pluripotent stem cell human CVCL_C6CW CL:0000010 Derived from sampling site: Peripheral blood. Female 155791855 CVCL_C6D8 HPS3086 induced pluripotent stem cell human CVCL_C6D8 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791856 CVCL_C6CZ HPS2929 induced pluripotent stem cell human CVCL_C6CZ CL:0000010 Derived from sampling site: Peripheral blood. Female 155791857 CVCL_C6CY HPS2928 induced pluripotent stem cell human CVCL_C6CY CL:0000010 Derived from sampling site: Peripheral blood. Female 155791858 CVCL_C6CN HPS2592 induced pluripotent stem cell human CVCL_C6CN CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791859 CVCL_C6CM HPS2585 induced pluripotent stem cell human CVCL_C6CM CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791860 CVCL_C6CP HPS2593 induced pluripotent stem cell human CVCL_C6CP CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791861 CVCL_C6D1 HPS2973 induced pluripotent stem cell human CVCL_C6D1 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791862 CVCL_C6D0 HPS2972 induced pluripotent stem cell human CVCL_C6D0 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791863 CVCL_C6CR HPS2595 induced pluripotent stem cell human CVCL_C6CR CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791864 CVCL_C6D3 HPS2975 induced pluripotent stem cell human CVCL_C6D3 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791865 CVCL_C6CQ HPS2594 induced pluripotent stem cell human CVCL_C6CQ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791866 CVCL_C6D2 HPS2974 induced pluripotent stem cell human CVCL_C6D2 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791867 CVCL_C6CT HPS2597 induced pluripotent stem cell human CVCL_C6CT CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791868 CVCL_C6D5 HPS2971 induced pluripotent stem cell human CVCL_C6D5 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791869 CVCL_C6CS HPS2596 induced pluripotent stem cell human CVCL_C6CS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791870 CVCL_C6D4 HPS2976 induced pluripotent stem cell human CVCL_C6D4 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791871 CVCL_C6EH SV-4b4b2 spontaneously immortalized cell line house mouse CVCL_C6EH CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791872 CVCL_C6EG SV-2b2b5 spontaneously immortalized cell line house mouse CVCL_C6EG CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791873 CVCL_C6EJ SV-4b6b spontaneously immortalized cell line house mouse CVCL_C6EJ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female Doubling time: ~24 hours (PubMed=12762836) 155791874 CVCL_C6EI SV-4b6a spontaneously immortalized cell line house mouse CVCL_C6EI CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791875 CVCL_C6EL SV-6c4a1a spontaneously immortalized cell line house mouse CVCL_C6EL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791876 CVCL_C6EK SV-4e7a spontaneously immortalized cell line house mouse CVCL_C6EK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791877 CVCL_C6EN FBD-51 spontaneously immortalized cell line house mouse CVCL_C6EN CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Microglial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791878 CVCL_C6EM SV-6c4a1b spontaneously immortalized cell line house mouse CVCL_C6EM CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; lower part Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female Doubling time: ~24 hours (PubMed=12762836) 155791879 CVCL_C6EB MV-2b2a4h spontaneously immortalized cell line house mouse CVCL_C6EB CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791880 CVCL_C6EA MV-2a1b3 spontaneously immortalized cell line house mouse CVCL_C6EA CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791881 CVCL_C6ED MV-2b2b5b spontaneously immortalized cell line house mouse CVCL_C6ED CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791882 CVCL_C6EC MV-2b2b2d spontaneously immortalized cell line house mouse CVCL_C6EC CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791883 CVCL_C6EF MV-2g4h spontaneously immortalized cell line house mouse CVCL_C6EF CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791884 CVCL_C6EE MV-2g3b2 spontaneously immortalized cell line house mouse CVCL_C6EE CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791885 CVCL_C6DW FBD-103a spontaneously immortalized cell line house mouse CVCL_C6DW CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791886 CVCL_C6E8 MV-1i7d2c spontaneously immortalized cell line house mouse CVCL_C6E8 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791887 CVCL_C6DV FBD-102b spontaneously immortalized cell line house mouse CVCL_C6DV CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Oligodendrocyte precursor cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791888 CVCL_C6E7 MV-1i7c1a spontaneously immortalized cell line house mouse CVCL_C6E7 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791889 CVCL_C6DY MV-1a1b1 spontaneously immortalized cell line house mouse CVCL_C6DY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791890 CVCL_C6DX FBD-104 spontaneously immortalized cell line house mouse CVCL_C6DX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Fetal brain; cerebral cortex Cell type=Immature astrocyte.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Unspecified 155791891 CVCL_C6E9 MV-2a1b2 spontaneously immortalized cell line house mouse CVCL_C6E9 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791892 CVCL_C6DZ MV-1e3b spontaneously immortalized cell line house mouse CVCL_C6DZ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791893 CVCL_C6E0 MV-1e4b spontaneously immortalized cell line house mouse CVCL_C6E0 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791894 CVCL_C6DN HPS3142 induced pluripotent stem cell human CVCL_C6DN CL:0000010 Derived from sampling site: Peripheral blood. Female 155791895 CVCL_C6DQ HPS3216 induced pluripotent stem cell human CVCL_C6DQ CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 155791896 CVCL_C6E2 MV-1e6g1a spontaneously immortalized cell line house mouse CVCL_C6E2 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female Doubling time: ~24 hours (PubMed=12762836) 155791897 CVCL_C6DP HPS3215 induced pluripotent stem cell human CVCL_C6DP CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 155791898 CVCL_C6E1 MV-1e4f1a spontaneously immortalized cell line house mouse CVCL_C6E1 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female Doubling time: ~24 hours (PubMed=12762836) 155791899 CVCL_C6DS HPS0773 induced pluripotent stem cell human CVCL_C6DS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155791900 CVCL_C6E4 MV-1h1b1b spontaneously immortalized cell line house mouse CVCL_C6E4 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791901 CVCL_C6DR HPS3217 induced pluripotent stem cell human CVCL_C6DR CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 155791902 CVCL_C6E3 MV-1h1b1a spontaneously immortalized cell line house mouse CVCL_C6E3 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791903 CVCL_C6DU HPS0775 induced pluripotent stem cell human CVCL_C6DU CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155791904 CVCL_C6E6 MV-1i7b1 spontaneously immortalized cell line house mouse CVCL_C6E6 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791905 CVCL_C6DT HPS0774 induced pluripotent stem cell human CVCL_C6DT CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 155791906 CVCL_C6E5 MV-1i1b1 spontaneously immortalized cell line house mouse CVCL_C6E5 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Vagina; upper part Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155791907 CVCL_C6BE HPS1220 induced pluripotent stem cell human CVCL_C6BE CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791908 CVCL_C6BD HPS1219 induced pluripotent stem cell human CVCL_C6BD CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791909 CVCL_C6BG HPS1294 induced pluripotent stem cell human CVCL_C6BG CL:0000010 Derived from sampling site: Peripheral blood. Male 155791910 CVCL_C6BF HPS1221 induced pluripotent stem cell human CVCL_C6BF CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791911 CVCL_C6BI HPS1296 induced pluripotent stem cell human CVCL_C6BI CL:0000010 Derived from sampling site: Peripheral blood. Male 155791912 CVCL_C6BH HPS1295 induced pluripotent stem cell human CVCL_C6BH CL:0000010 Derived from sampling site: Peripheral blood. Male 155791913 CVCL_C6BK HPS1298 induced pluripotent stem cell human CVCL_C6BK CL:0000010 Derived from sampling site: Peripheral blood. Male 155791914 CVCL_C6BJ HPS1297 induced pluripotent stem cell human CVCL_C6BJ CL:0000010 Derived from sampling site: Peripheral blood. Male 155791915 CVCL_C6BA HPS1216 induced pluripotent stem cell human CVCL_C6BA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791916 CVCL_C6BC HPS1218 induced pluripotent stem cell human CVCL_C6BC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791917 CVCL_C6BB HPS1217 induced pluripotent stem cell human CVCL_C6BB CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791918 CVCL_C6AT HPS0844 induced pluripotent stem cell human CVCL_C6AT CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791919 CVCL_C6B5 HPS1199 induced pluripotent stem cell human CVCL_C6B5 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791920 CVCL_C6AS HPS0843 induced pluripotent stem cell human CVCL_C6AS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791921 CVCL_C6B4 HPS1198 induced pluripotent stem cell human CVCL_C6B4 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791922 CVCL_C6AV HPS0846 induced pluripotent stem cell human CVCL_C6AV CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791923 CVCL_C6B7 HPS1201 induced pluripotent stem cell human CVCL_C6B7 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791924 CVCL_C6AU HPS0845 induced pluripotent stem cell human CVCL_C6AU CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791925 CVCL_C6B6 HPS1200 induced pluripotent stem cell human CVCL_C6B6 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791926 CVCL_C6AX HPS0718 induced pluripotent stem cell human CVCL_C6AX CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791927 CVCL_C6B9 HPS1203 induced pluripotent stem cell human CVCL_C6B9 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791928 CVCL_C6AW HPS0847 induced pluripotent stem cell human CVCL_C6AW CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791929 CVCL_C6B8 HPS1202 induced pluripotent stem cell human CVCL_C6B8 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791930 CVCL_C6AZ HPS0720 induced pluripotent stem cell human CVCL_C6AZ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791931 CVCL_C6AY HPS0719 induced pluripotent stem cell human CVCL_C6AY CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791932 CVCL_C6AL HPS0801 induced pluripotent stem cell human CVCL_C6AL CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791933 CVCL_C6AK HPS0800 induced pluripotent stem cell human CVCL_C6AK CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791934 CVCL_C6AN HPS0803 induced pluripotent stem cell human CVCL_C6AN CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791935 CVCL_C6AM HPS0802 induced pluripotent stem cell human CVCL_C6AM CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791936 CVCL_C6B1 HPS0722 induced pluripotent stem cell human CVCL_C6B1 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791937 CVCL_C6AP HPS0804 induced pluripotent stem cell human CVCL_C6AP CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791938 CVCL_C6B0 HPS0721 induced pluripotent stem cell human CVCL_C6B0 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791939 CVCL_C6AR HPS0842 induced pluripotent stem cell human CVCL_C6AR CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791940 CVCL_C6B3 HPS1749 induced pluripotent stem cell human CVCL_C6B3 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791941 CVCL_C6B2 HPS0723 induced pluripotent stem cell human CVCL_C6B2 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791942 CVCL_C6AQ HPS0805 induced pluripotent stem cell human CVCL_C6AQ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155791943 CVCL_C6CF HPS2554 induced pluripotent stem cell human CVCL_C6CF CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791944 CVCL_C6CE HPS2553 induced pluripotent stem cell human CVCL_C6CE CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791945 CVCL_C6CH HPS2580 induced pluripotent stem cell human CVCL_C6CH CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791946 CVCL_C6CG HPS2555 induced pluripotent stem cell human CVCL_C6CG CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791947 CVCL_C6CJ HPS2582 induced pluripotent stem cell human CVCL_C6CJ CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791948 CVCL_C6CI HPS2581 induced pluripotent stem cell human CVCL_C6CI CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791949 CVCL_C6CL HPS2584 induced pluripotent stem cell human CVCL_C6CL CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791950 CVCL_C6CK HPS2583 induced pluripotent stem cell human CVCL_C6CK CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 155791951 CVCL_C6CB HPS2550 induced pluripotent stem cell human CVCL_C6CB CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791952 CVCL_C6CA HPS2352 induced pluripotent stem cell human CVCL_C6CA CL:0000010 Derived from sampling site: Peripheral blood. Male 155791953 CVCL_C6CD HPS2552 induced pluripotent stem cell human CVCL_C6CD CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791954 CVCL_C6CC HPS2551 induced pluripotent stem cell human CVCL_C6CC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155791955 CVCL_C6BU HPS1931 induced pluripotent stem cell human CVCL_C6BU CL:0000010 Derived from sampling site: Peripheral blood. Male 155791956 CVCL_C6C6 HPS2348 induced pluripotent stem cell human CVCL_C6C6 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791957 CVCL_C6BT HPS1930 induced pluripotent stem cell human CVCL_C6BT CL:0000010 Derived from sampling site: Peripheral blood. Male 155791958 CVCL_C6C5 HPS2347 induced pluripotent stem cell human CVCL_C6C5 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791959 CVCL_C6BW HPS1933 induced pluripotent stem cell human CVCL_C6BW CL:0000010 Derived from sampling site: Peripheral blood. Male 155791960 CVCL_C6C8 HPS2350 induced pluripotent stem cell human CVCL_C6C8 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791961 CVCL_C6BV HPS1932 induced pluripotent stem cell human CVCL_C6BV CL:0000010 Derived from sampling site: Peripheral blood. Male 155791962 CVCL_C6C7 HPS2349 induced pluripotent stem cell human CVCL_C6C7 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791963 CVCL_C6BY HPS1935 induced pluripotent stem cell human CVCL_C6BY CL:0000010 Derived from sampling site: Peripheral blood. Male 155791964 CVCL_C6BX HPS1934 induced pluripotent stem cell human CVCL_C6BX CL:0000010 Derived from sampling site: Peripheral blood. Male 155791965 CVCL_C6C9 HPS2351 induced pluripotent stem cell human CVCL_C6C9 CL:0000010 Derived from sampling site: Peripheral blood. Male 155791966 CVCL_C6BZ HPS2060 induced pluripotent stem cell human CVCL_C6BZ CL:0000010 Derived from sampling site: Peripheral blood. Female 155791967 CVCL_C6BM HPS1585 induced pluripotent stem cell human CVCL_C6BM CL:0000010 Derived from sampling site: Peripheral blood. Female 155791968 CVCL_C6BL HPS1299 induced pluripotent stem cell human CVCL_C6BL CL:0000010 Derived from sampling site: Peripheral blood. Male 155791969 CVCL_C6C0 HPS2061 induced pluripotent stem cell human CVCL_C6C0 CL:0000010 Derived from sampling site: Peripheral blood. Female 155791970 CVCL_C6BN HPS1586 induced pluripotent stem cell human CVCL_C6BN CL:0000010 Derived from sampling site: Peripheral blood. Female 155791971 CVCL_C6BQ HPS1588 induced pluripotent stem cell human CVCL_C6BQ CL:0000010 Derived from sampling site: Peripheral blood. Female 155791972 CVCL_C6C2 HPS2063 induced pluripotent stem cell human CVCL_C6C2 CL:0000010 Derived from sampling site: Peripheral blood. Female 155791973 CVCL_C6BP HPS1587 induced pluripotent stem cell human CVCL_C6BP CL:0000010 Derived from sampling site: Peripheral blood. Female 155791974 CVCL_C6C1 HPS2062 induced pluripotent stem cell human CVCL_C6C1 CL:0000010 Derived from sampling site: Peripheral blood. Female 155791975 CVCL_C6BS HPS1590 induced pluripotent stem cell human CVCL_C6BS CL:0000010 Derived from sampling site: Peripheral blood. Female 155791976 CVCL_C6C4 HPS2065 induced pluripotent stem cell human CVCL_C6C4 CL:0000010 Derived from sampling site: Peripheral blood. Female 155791977 CVCL_C6BR HPS1589 induced pluripotent stem cell human CVCL_C6BR CL:0000010 Derived from sampling site: Peripheral blood. Female 155791978 CVCL_C6C3 HPS2064 induced pluripotent stem cell human CVCL_C6C3 CL:0000010 Derived from sampling site: Peripheral blood. Female 155791979 CVCL_C6NI 93-22 hybridoma house mouse CVCL_C6NI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ULW2; Human FZD10. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10620 155791980 CVCL_C6NA LMB-S spontaneously immortalized cell line CVCL_C6NA CL:0000010 Donor information: Established from brains pooled from three individuals (PubMed=36028055); Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by Lateolabrax maculatus iridovirus (LMIV) (PubMed=36028055) Group: Fish cell line 155791981 CVCL_C6NC COG-LL-394h cancer cell line human CVCL_C6NC CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 16493; ZMIZ1; Name(s)=ABL1-ZMIZ1; ZMIZ1-ABL1 (PubMed=35354797) Derived from sampling site: Bone marrow. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 155791982 CVCL_C6NB 2E3-O hybridoma house mouse CVCL_C6NB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53067; 2,4,6-trinitrophenyl group (TNP). 155791983 CVCL_C6NE 39-2 hybridoma house mouse CVCL_C6NE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ULW2; Human FZD10. 155791984 CVCL_C6ND STC-1 pGIP/Neo cancer cell line house mouse CVCL_C6ND CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: Polyoma small T antigen (PyST); Derived from sampling site: Small intestine; duodenum; Breed/subspecies: C57BL/6J double transgenic RIP1Tag2/Rip2pyST1. Unspecified Characteristics: Expression of the neo gene is driven by a rat GIP promoter (PubMed=12124779); Characteristics: Compared to parent cell line secrete 3-6 times more GIP and substantially less CCK and PYY (PubMed=22768997) 155791985 CVCL_C6NG 92-13 hybridoma house mouse CVCL_C6NG CL:0000010 Biotechnology: When radiolabeled with Yttrium-90 the monoclonal antibody produced by this hybridoma can be used for the treatment of synovial sarcomas Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ULW2; Human FZD10. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10628 155791986 CVCL_C6NF 39-10 hybridoma house mouse CVCL_C6NF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ULW2; Human FZD10. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-08628 155791987 CVCL_C6N9 LMB-M spontaneously immortalized cell line CVCL_C6N9 CL:0000010 Donor information: Established from brains pooled from three individuals (PubMed=36028055); Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by Lateolabrax maculatus iridovirus (LMIV) (PubMed=36028055) Group: Fish cell line 155791988 CVCL_C6MX USZ20-EMC1 cancer cell line human CVCL_C6MX CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 7982; NR4A3; Name(s)=EWSR1-NR4A3; Note=EWSR1 exon 13 fused to NR4A3 exon 2 (PubMed=36316541) Derived from sampling site: Leg. Omics: DNA methylation analysis Female Characteristics: Maintained as a sarco-sphere Doubling time: 5.09 days (PubMed=36316541) 155791989 CVCL_C6MW 3B9 [Mouse hybridoma against morphine] hybridoma house mouse CVCL_C6MW CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155791990 CVCL_C6N8 LMB-L spontaneously immortalized cell line CVCL_C6N8 CL:0000010 Donor information: Established from brains pooled from three individuals (PubMed=36028055); Derived from sampling site: Brain Cell type=Astrocyte.. Unspecified Virology: Highly susceptible to infection by Lateolabrax maculatus iridovirus (LMIV) (PubMed=36028055) Group: Fish cell line 155791991 CVCL_C6MZ KKU-213L5 cancer cell line human CVCL_C6MZ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Derived from sampling site: Liver. Male Characteristics: Highly metastatic Established from the parent cell line passaged in a NOD/scid/Jak3 mice (NOJ mice). Doubling time: 20.3 hours (PubMed=27461717) 155791992 CVCL_C6MY USZ22-EMC2 cancer cell line human CVCL_C6MY CL:0000010 Sequence variation: Gene fusion; HGNC; 7982; NR4A3 + HGNC; 11547; TAF15; Name(s)=TAF15-NR4A3; Note=TAF15 exon 6 fused to NR4A3 exon 2 (PubMed=36316541); Sequence variation: Mutation; HGNC; 11114; KDM5C; Simple; c.1584-2A>T; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=36316541); Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Glu1689fs*28 (c.5065delG); Zygosity=Unspecified (PubMed=36316541) Derived from sampling site: Left thigh. Omics: DNA methylation analysis Male Characteristics: Maintained as a sarco-sphere Doubling time: 6.05 days (PubMed=36316541) 155791993 CVCL_C6M0 M03/01/01 hybridoma house mouse CVCL_C6M0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155791994 CVCL_C6LN ST91/MHT33 transformed cell line human CVCL_C6LN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Male 155791995 CVCL_C6M2 BAB2 transformed cell line human CVCL_C6M2 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; P15494; Betula pendula major pollen allergen Bet v 1-A Doubling time: ~16 hours (PubMed=8752951) 155791996 CVCL_C6LQ ST91/MHT35 transformed cell line human CVCL_C6LQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155791997 CVCL_C6M1 BAB1 transformed cell line human CVCL_C6M1 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15494; Betula pendula major pollen allergen Bet v 1-A Doubling time: ~16 hours (PubMed=8752951) 155791998 CVCL_C6LP ST91/MHT34 transformed cell line human CVCL_C6LP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155791999 CVCL_C6M4 BAB4 transformed cell line human CVCL_C6M4 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P15494; Betula pendula major pollen allergen Bet v 1-A Doubling time: ~16 hours (PubMed=8752951) 155792000 CVCL_C6LS PCNY1 cancer cell line human CVCL_C6LS CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=21565982); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gly (c.742C>G); ClinVar=VCV000376652; Zygosity=Heterozygous (PubMed=21565982; PubMed=32133047). 155792001 CVCL_C6M3 BAB3 transformed cell line human CVCL_C6M3 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG4, lambda; Monoclonal antibody target: UniProtKB; P15494; Betula pendula major pollen allergen Bet v 1-A Doubling time: ~16 hours (PubMed=8752951) 155792002 CVCL_C6LR ICR-SS-1 cancer cell line human CVCL_C6LR CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=35954262) Derived from sampling site: Hypodermis. Omics: Deep quantitative proteome analysis Male Characteristics: Established from the J000104314 xenograft maintained in NOD Scid gamma mice Doubling time: 93 hours (PubMed=35954262) 155792003 CVCL_C6M6 1F6C8 hybridoma house mouse CVCL_C6M6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O64255; Mycobacterium phage D29 Gp63 (AA 45-78 = PK34). 155792004 CVCL_C6LU M02/02/01 hybridoma house mouse CVCL_C6LU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792005 CVCL_C6M5 BAB5 transformed cell line human CVCL_C6M5 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; P15494; Betula pendula major pollen allergen Bet v 1-A Doubling time: ~16 hours (PubMed=8752951) 155792006 CVCL_C6LT M02/01/01 hybridoma house mouse CVCL_C6LT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792007 CVCL_C6LG ST91/MHT26 transformed cell line human CVCL_C6LG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792008 CVCL_C6LF ST90/MHT25 transformed cell line human CVCL_C6LF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Male 155792009 CVCL_C6LI ST91/MHT28 transformed cell line human CVCL_C6LI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792010 CVCL_C6LH ST91/MHT27 transformed cell line human CVCL_C6LH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792011 CVCL_C6LK ST91/MHT30 transformed cell line human CVCL_C6LK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792012 CVCL_C6LJ ST91/MHT29 transformed cell line human CVCL_C6LJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792013 CVCL_C6LM ST91/MHT32 transformed cell line human CVCL_C6LM CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792014 CVCL_C6LL ST91/MHT31 transformed cell line human CVCL_C6LL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Male 155792015 CVCL_C6LA ST90/MHT20 transformed cell line human CVCL_C6LA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792016 CVCL_C6LC ST90/MHT22 transformed cell line human CVCL_C6LC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792017 CVCL_C6LB ST90/MHT21 transformed cell line human CVCL_C6LB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792018 CVCL_C6LE ST90/MHT24 transformed cell line human CVCL_C6LE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792019 CVCL_C6LD ST90/MHT23 transformed cell line human CVCL_C6LD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792020 CVCL_C6KV ST89/MHT5 transformed cell line human CVCL_C6KV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792021 CVCL_C6L7 ST90/MHT17 transformed cell line human CVCL_C6L7 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792022 CVCL_C6KU ST89/MHT4 transformed cell line human CVCL_C6KU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792023 CVCL_C6L6 ST90/MHT16 transformed cell line human CVCL_C6L6 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792024 CVCL_C6KX ST90/MGH9 transformed cell line human CVCL_C6KX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792025 CVCL_C6L9 ST90/MHT19 transformed cell line human CVCL_C6L9 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792026 CVCL_C6KW ST89/MHT6 transformed cell line human CVCL_C6KW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792027 CVCL_C6L8 ST90/MHT18 transformed cell line human CVCL_C6L8 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792028 CVCL_C6KZ ST90/MGH11 transformed cell line human CVCL_C6KZ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792029 CVCL_C6KY ST90/MGH10 transformed cell line human CVCL_C6KY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792030 CVCL_C6N1 CL-2 cancer cell line human CVCL_C6N1 CL:0000010 Population: Southeast Asian; Thai. 155792031 CVCL_C6MP Si-TGCT-4 cancer cell line human CVCL_C6MP CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Knee; tendon sheath. Male Doubling time: 92.60 +- 1.80 hours (in 1% FBS), 45.34 +- 1.17 hours (in 10% FBS) (PubMed=36456782) 155792032 CVCL_C6N0 CL-19 [Human cholangiocarcinoma] cancer cell line human CVCL_C6N0 CL:0000010 Population: Southeast Asian; Thai. 155792033 CVCL_C6N3 ICC-1 cancer cell line human CVCL_C6N3 CL:0000010 Population: Chinese. 155792034 CVCL_C6MR NES-4G10G8 hybridoma house mouse CVCL_C6MR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48681; Human NES (Note=Also reacts with bovine and mouse). 155792035 CVCL_C6MQ 2F9-C9 hybridoma house mouse CVCL_C6MQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02792; Human FTL. 155792036 CVCL_C6N2 CL-6 cancer cell line human CVCL_C6N2 CL:0000010 Population: Southeast Asian; Thai. 155792037 CVCL_C6MT 10C3 hybridoma house mouse CVCL_C6MT CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792038 CVCL_C6N5 A673-SLFN11-KO cancer cell line human CVCL_C6N5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala119Glnfs*5 (c.353_354dupCA) (c.354_355insCA); Zygosity=Homozygous (from parent cell line). Female Problematic cell line: Misclassified Parent cell line (A-673) was originally thought to be a rhabdomyosarcoma cell line but is an Ewing sarcoma cell line. 155792039 CVCL_C6MS H107 hybridoma house mouse CVCL_C6MS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02794; Human FTH1. 155792040 CVCL_C6N4 ICC-2 cancer cell line human CVCL_C6N4 CL:0000010 Population: Chinese. 155792041 CVCL_C6MV 12D4 hybridoma house mouse CVCL_C6MV CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792042 CVCL_C6N7 JN-DSRCT-SLFN11-KO cancer cell line human CVCL_C6N7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex10-WT1 Ex8 fusion (from parent cell line); Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Arg1443Alafs*11; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Arg367Ter (c.1099C>T); ClinVar=VCV000016626; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg621Ser (c.1861C>A); ClinVar=VCV000135120; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Pleural effusion. Male 155792043 CVCL_C6MU 11C7 hybridoma house mouse CVCL_C6MU CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine 155792044 CVCL_C6N6 ES8-SLFN11-KO cancer cell line human CVCL_C6N6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line). Population: Caucasian Male 155792045 CVCL_C6MH ST8363 transformed cell line human CVCL_C6MH CL:0000010 Karyotypic information: Hypotetraploid (PubMed=6235882); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 155792046 CVCL_C6MG ST8252 transformed cell line human CVCL_C6MG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Unspecified 155792047 CVCL_C6MJ ST8368 transformed cell line human CVCL_C6MJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Unspecified 155792048 CVCL_C6MI ST8367 transformed cell line human CVCL_C6MI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Unspecified 155792049 CVCL_C6ML Si-TGCT-1 cancer cell line human CVCL_C6ML CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Knee; tendon sheath. Male Doubling time: 141.92 +- 0.85 hours (in 1% FBS), 78.87 +- 2.39 hours (in 10% FBS) (PubMed=36456782) 155792050 CVCL_C6MK CAtmus1PFR spontaneously immortalized cell line CVCL_C6MK CL:0000010 Derived from sampling site: Tail; skeletal muscle Cell type=Myofibroblast.. Unspecified Characteristics: Can grow well between 18 and 30 Celsius (PubMed=36378268) Group: Fish cell line 155792051 CVCL_C6MN Si-TGCT-3 cancer cell line human CVCL_C6MN CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Hip; tendon sheath. Female Doubling time: 136.87 +- 1.86 hours (in 1% FBS), 52.89 +- 1.13 hours (in 10% FBS) (PubMed=36456782) 155792052 CVCL_C6MM Si-TGCT-2 cancer cell line human CVCL_C6MM CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Ankle; tendon sheath. Male Doubling time: 271.38 +- 1.53 hours (in 1% FBS), 51.03 +- 3.52 hours (in 10% FBS) (PubMed=36456782) 155792053 CVCL_C6MB C822A transformed cell line human CVCL_C6MB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 155792054 CVCL_C6MA C821 transformed cell line human CVCL_C6MA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Unspecified 155792055 CVCL_C6MD ST821 transformed cell line human CVCL_C6MD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 155792056 CVCL_C6MC C822B transformed cell line human CVCL_C6MC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 155792057 CVCL_C6MF ST8251 transformed cell line human CVCL_C6MF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Female 155792058 CVCL_C6ME ST8241 transformed cell line human CVCL_C6ME CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Female 155792059 CVCL_C6M8 6E2F11 hybridoma house mouse CVCL_C6M8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O64255; Mycobacterium phage D29 Gp63 (AA 45-78 = PK34). 155792060 CVCL_C6LW M02/05/01 hybridoma house mouse CVCL_C6LW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792061 CVCL_C6M7 2B6H2 hybridoma house mouse CVCL_C6M7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O64255; Mycobacterium phage D29 Gp63 (AA 45-78 = PK34). 155792062 CVCL_C6LV M02/04/01 hybridoma house mouse CVCL_C6LV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792063 CVCL_C6LY M02/10/01 hybridoma house mouse CVCL_C6LY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792064 CVCL_C6M9 6E2B6 hybridoma house mouse CVCL_C6M9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O64255; Mycobacterium phage D29 Gp63 (AA 45-78 = PK34). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202226 155792065 CVCL_C6LX M02/09/01 hybridoma house mouse CVCL_C6LX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792066 CVCL_C6LZ M02/11/01 hybridoma house mouse CVCL_C6LZ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:63781; Traseolide (6-acetyl-1-isopropyl-2,3,3,5-tetramethylindane). 155792067 CVCL_C6JM FE25L transformed cell line human CVCL_C6JM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Characteristics: Tumorigenic 155792068 CVCL_C6JL FE25 transformed cell line human CVCL_C6JL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fallopian tube; fimbria Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.8 hours (PubMed=26363031) 155792069 CVCL_C6K0 HF-99/7 finite cell line human CVCL_C6K0 HLA typing: A*01:01,03:01; B*08:01,51:01; C*01:02,07:01 (DOI=10.15496/publikation-48348) From: Neumann-Haefelin D., Kapper-Falcone V.; Institute of Virology, Medical Center University of Freiburg; Freiburg; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155792070 CVCL_C6JN SarmaEmb spontaneously immortalized cell line CVCL_C6JN CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Unspecified Group: Insect cell line 155792071 CVCL_C6K2 2A1 [Mouse hybridoma against T.kirilowii trichosanthin] hybridoma house mouse CVCL_C6K2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09989; Trichosanthes kirilowii ribosome-inactivating protein alpha-trichosanthin. 155792072 CVCL_C6JQ NSC34-G93A hybrid cell line house mouse CVCL_C6JQ CL:0000010 Transfected with: HGNC; 11179; SOD1 (with p.Gly94Ala); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Transfected with a pcDNA3/mt-SOD1G93A-GFP construct (the \"mt\" stands for the mitochondrial targeting sequence of human COX8A) 155792073 CVCL_C6JP B-LSDM7 finite cell line human CVCL_C6JP CL:0000010 Derived from sampling site: Lung (Note=From a bronchoalveolar lavage) Cell type=Fibroblast.. Male 155792074 CVCL_C6K1 HF-99/5 finite cell line human CVCL_C6K1 HLA typing: A*11:01,24:02; B*08:01,52:01; C*07:01,12:02 (DOI=10.15496/publikation-48348) From: Neumann-Haefelin D., Kapper-Falcone V.; Institute of Virology, Medical Center University of Freiburg; Freiburg; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 155792075 CVCL_C6JS RLN-J-5-2 CL-1 spontaneously immortalized cell line Norway rat CVCL_C6JS CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 155792076 CVCL_C6K4 TE2 hybridoma house mouse CVCL_C6K4 CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: UniProtKB; P09989; Trichosanthes kirilowii ribosome-inactivating protein alpha-trichosanthin. 155792077 CVCL_C6JR hPheo1 KD-SDHB telomerase immortalized cell line human CVCL_C6JR CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 10681; SDHB; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Adrenal gland. Female 155792078 CVCL_C6K3 TE1 hybridoma house mouse CVCL_C6K3 CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: UniProtKB; P09989; Trichosanthes kirilowii ribosome-inactivating protein alpha-trichosanthin. 155792079 CVCL_C6JE MH161H hybridoma CVCL_C6JE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P00588; Corynephage beta diphtheria toxin. 155792080 CVCL_C6JD 53D11 hybridoma house mouse CVCL_C6JD CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00592; Human PODXL. 155792081 CVCL_C6JG MM9H-1 cancer cell line human CVCL_C6JG CL:0000010 Population: Chinese; Derived from sampling site: Oral cavity; gingiva. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~36 hours (PubMed=35666052) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202174 155792082 CVCL_C6JF HH28-3-1 hybridoma CVCL_C6JF CL:0000010 Characteristics: Tetradoma obtained by the biological fusion of two hybridomas; Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P00588; Corynephage beta diphtheria toxin; Monoclonal antibody target: UniProtKB; P0A3R9; Streptomyces carzinostaticus neocarzinostatin (ncsA). 155792083 CVCL_C6JI SFT-T1 cancer cell line human CVCL_C6JI CL:0000010 Sequence variation: Gene fusion; HGNC; 7627; NAB2 + HGNC; 11368; STAT6; Name(s)=NAB2-STAT6; Note=NAB2 exon 4 fused to STAT6 exon 2 (PubMed=36428694) Miscellaneous: STR profile from personal communication of Baier D Derived from sampling site: Lung; pleura. Male 155792084 CVCL_C6JH mEC25 cancer cell line house mouse CVCL_C6JH CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Esophagus; Breed/subspecies: C57BL/6. Female Doubling time: 26.8 hours (at 20th passage), 25.8 hours (at 50th passage) (PubMed=32510874) 155792085 CVCL_C6JK KCE spontaneously immortalized cell line CVCL_C6JK CL:0000010 Derived from sampling site: Eye; Breed/subspecies: Koi. Unspecified 155792086 CVCL_C6JJ SFT-T2 cancer cell line human CVCL_C6JJ CL:0000010 Sequence variation: Gene fusion; HGNC; 7627; NAB2 + HGNC; 11368; STAT6; Name(s)=NAB2-STAT6; Note=NAB2 exon 4 fused to STAT6 exon 2 (PubMed=36428694) Miscellaneous: STR profile from personal communication of Baier D Derived from sampling site: Lung; pleura. Female 155792087 CVCL_C6JA U-87MG ATCC ECE1 KO cancer cell line human CVCL_C6JA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3146; ECE1; Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Miscellaneous: Has been generated from a fee-for-service contract with Abcam Cell line information from personal communication of Laflamme C.. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 155792088 CVCL_C6JC CHO hPCLP1 clone 12C spontaneously immortalized cell line CVCL_C6JC CL:0000010 Transfected with: HGNC; HGNC; 9171; PODXL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155792089 CVCL_C6JB SupT1-CIITA cancer cell line human CVCL_C6JB HLA typing: DRB1*03:01,13:01; DRB3*01:01,02:02 (PubMed=31020640) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7067; CIITA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pleural effusion Cell type=T-cell.. Omics: HLA class II peptidome analysis by proteomics Male Virology: Has an enhanced susceptibility to infection by HIV-1 (PubMed=21041720); Virology: Susceptible to infection by herpesvirus 6B (HHV-6B) strain Z29 (PubMed=31020640) 155792090 CVCL_C6J5 GSC-326/ALDH1A3-KO.2.3 cancer cell line human CVCL_C6J5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792091 CVCL_C6IT GSC-347 cancer cell line human CVCL_C6IT CL:0000010 Derived from sampling site: Brain; right occipital lobe Cell type=Proneural glioma stem cell.. Male Group: Cancer stem cell line 155792092 CVCL_C6J4 GSC-326/ALDH1A3-KO.1.1 cancer cell line human CVCL_C6J4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792093 CVCL_C6IS GSC-345 cancer cell line human CVCL_C6IS CL:0000010 Derived from sampling site: Brain; right frontal lobe Cell type=Mesenchymal glioma stem cell.. Female Group: Cancer stem cell line 155792094 CVCL_C6J7 GSC-326/ALDH1A3-KO.3.1 cancer cell line human CVCL_C6J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792095 CVCL_C6IV GSC-528 cancer cell line human CVCL_C6IV CL:0000010 Derived from sampling site: Brain; left temporal lobe Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Male Group: Cancer stem cell line 155792096 CVCL_C6J6 GSC-326/ALDH1A3-KO.2.4 cancer cell line human CVCL_C6J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792097 CVCL_C6IU GSC-524 cancer cell line human CVCL_C6IU CL:0000010 Derived from sampling site: Brain; left temporal lobe Cell type=Mesenchymal glioma stem cell.. Male Group: Cancer stem cell line 155792098 CVCL_C6J9 GSC-326/ALDH1A3-KO.3.5 cancer cell line human CVCL_C6J9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792099 CVCL_C6IX GSC-718 cancer cell line human CVCL_C6IX CL:0000010 Derived from sampling site: Brain; right temporal lobe Cell type=Mesenchymal glioma stem cell.. Male Group: Cancer stem cell line 155792100 CVCL_C6J8 GSC-326/ALDH1A3-KO.3.4 cancer cell line human CVCL_C6J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 409; ALDH1A3 Derived from sampling site: Brain Cell type=Mesenchymal glioma stem cell.. Unspecified Group: Cancer stem cell line 155792101 CVCL_C6IW GSC-528rec cancer cell line human CVCL_C6IW CL:0000010 Derived from sampling site: Brain; left temporal lobe Cell type=Proneural glioma stem cell.. Male Group: Cancer stem cell line 155792102 CVCL_C6IZ GSC-83 cancer cell line human CVCL_C6IZ CL:0000010 Derived from sampling site: Brain; right temporal lobe Cell type=Mesenchymal glioma stem cell.. Omics: Transcriptome analysis by microarray Female Group: Cancer stem cell line 155792103 CVCL_C6IY GSC-816 cancer cell line human CVCL_C6IY CL:0000010 Derived from sampling site: Brain; left frontal lobe Cell type=Proneural glioma stem cell.. Omics: Transcriptome analysis by microarray Female Group: Cancer stem cell line 155792104 CVCL_C6KN M16 hybridoma house mouse CVCL_C6KN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792105 CVCL_C6KM 2IN16 hybridoma house mouse CVCL_C6KM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792106 CVCL_C6KP FE1 spontaneously immortalized cell line house mouse CVCL_C6KP CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: MutaMouse 40.6. Omics: Transcriptome analysis by microarray Male Characteristics: Can be employed for in vitro mutagenicity assessment Established from a MutaMouse that contains 40 copies of the lacZ reporter gene in a single locus on chromosome 3. Doubling time: 18.7 +- 1.2 hours (PubMed=14556224) 155792107 CVCL_C6L1 ST90/MGH13 transformed cell line human CVCL_C6L1 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792108 CVCL_C6L0 ST90/MGH12 transformed cell line human CVCL_C6L0 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792109 CVCL_C6KR ST87/MHT1 transformed cell line human CVCL_C6KR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792110 CVCL_C6L3 ST90/MHT8 transformed cell line human CVCL_C6L3 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792111 CVCL_C6KQ ST8246 transformed cell line human CVCL_C6KQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a traumatic rupture of the spleen; Derived from sampling site: Spleen. Male Characteristics: Produces extracellular, membrane-associated and cytoplasmic IgM (PubMed=1431313) 155792112 CVCL_C6L2 ST90/MHT7 transformed cell line human CVCL_C6L2 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792113 CVCL_C6KT ST89/MGH3 transformed cell line human CVCL_C6KT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792114 CVCL_C6L5 ST90/MHT15 transformed cell line human CVCL_C6L5 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792115 CVCL_C6KS ST88/MHT2 transformed cell line human CVCL_C6KS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792116 CVCL_C6L4 ST90/MHT14 transformed cell line human CVCL_C6L4 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Thymus Cell type=B-cell.. Female 155792117 CVCL_C6KF 2IN9 hybridoma house mouse CVCL_C6KF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792118 CVCL_C6KE 2IN8 hybridoma house mouse CVCL_C6KE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792119 CVCL_C6KH 2IN11 hybridoma house mouse CVCL_C6KH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792120 CVCL_C6KG 2IN10 hybridoma house mouse CVCL_C6KG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792121 CVCL_C6KJ 2IN13 hybridoma house mouse CVCL_C6KJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792122 CVCL_C6KI 2IN12 hybridoma house mouse CVCL_C6KI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792123 CVCL_C6KL 2IN15 hybridoma house mouse CVCL_C6KL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with pig). 155792124 CVCL_C6KK 2IN14 hybridoma house mouse CVCL_C6KK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792125 CVCL_C6KB 2IN5 hybridoma house mouse CVCL_C6KB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS. 155792126 CVCL_C6KA 2IN4 hybridoma house mouse CVCL_C6KA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792127 CVCL_C6KD 2IN7 hybridoma house mouse CVCL_C6KD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792128 CVCL_C6KC 2IN6 hybridoma house mouse CVCL_C6KC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with pig and rat). 155792129 CVCL_C6JU JAS-R cancer cell line human CVCL_C6JU CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: Secretes EPO 155792130 CVCL_C6K6 TE4 [Mouse hybridoma against T.kirilowii trichosanthin] hybridoma house mouse CVCL_C6K6 CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: UniProtKB; P09989; Trichosanthes kirilowii ribosome-inactivating protein alpha-trichosanthin. 155792131 CVCL_C6JT K/VP.5 cancer cell line human CVCL_C6JT CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Female Doubling time: 22 hours (PubMed=8142256) 155792132 CVCL_C6K5 TE3 [Mouse hybridoma against T.kirilowii trichosanthin] hybridoma house mouse CVCL_C6K5 CL:0000010 Monoclonal antibody isotype: IgE, kappa; Monoclonal antibody target: UniProtKB; P09989; Trichosanthes kirilowii ribosome-inactivating protein alpha-trichosanthin. 155792133 CVCL_C6K8 2IN2 hybridoma house mouse CVCL_C6K8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792134 CVCL_C6JW HROG02-CIITA cancer cell line human CVCL_C6JW CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 7067; CIITA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain; right parieto-occipital lobe. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Male 155792135 CVCL_C6K7 2IN1 hybridoma house mouse CVCL_C6K7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792136 CVCL_C6JV T68 cancer cell line human CVCL_C6JV CL:0000010 Population: Chinese; Derived from sampling site: Mediastinum. Male Characteristics: Tumorigenic Doubling time: 37 hours (DOI=10.21037/tcr.2018.12.12) 155792137 CVCL_C6JY RA cancer cell line human CVCL_C6JY HLA typing: A*02:01,24:02; B*35:03,51:01; C*04:01,14:02; DPA1*01:03,02:07; DPB1*04:01,19:01; DQA1*03:01,04:01; DQB1*03:02,04:02; DRB1*04:01,08:01; DRB4*01:03 (PubMed=33592498) CL:0000010 Derived from sampling site: Brain. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics 155792138 CVCL_C6K9 2IN3 hybridoma house mouse CVCL_C6K9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine, pig and rat). 155792139 CVCL_C6JX HROG17-CIITA cancer cell line human CVCL_C6JX CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 7067; CIITA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain; left parieto-occipital lobe. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Male 155792140 CVCL_C6JZ RA-CIITA cancer cell line human CVCL_C6JZ CL:0000010 Transfected with: HGNC; 7067; CIITA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain. Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics 155792141 CVCL_C5VZ GR [Human LCL] transformed cell line human CVCL_C5VZ HLA typing: A*01:01,03:01; B*07:02,27:05; C*02:02,07:02 (PubMed=34925382) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics Unspecified 155792142 CVCL_C5VY SC B-LCL transformed cell line human CVCL_C5VY HLA typing: A*02,02; B*27:05,27:05 (PubMed=10843661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792143 CVCL_C5WA MW162 hybridoma house mouse CVCL_C5WA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human high molecular weight mucin. 155792144 CVCL_C5VR CUTO22 cancer cell line human CVCL_C5VR CL:0000010 Sequence variation: Gene fusion; HGNC; 6324; KIF5B + HGNC; 9967; RET; Name(s)=KIF5B-RET; Note=KIF5B exon 23 fused to RET exon 12 (PubMed=33795352) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 155792145 CVCL_C5W3 MU78 hybridoma house mouse CVCL_C5W3 CL:0000010 Monoclonal antibody isotype: IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8877; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9752 155792146 CVCL_C5VQ 3E9 [Mouse hybridoma against P.vivax RBP2b] hybridoma house mouse CVCL_C5VQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A5K736; Plasmodium vivax (strain Salvador I) reticulocyte binding protein 2b (RBP2b). 155792147 CVCL_C5W2 MT334 hybridoma house mouse CVCL_C5W2 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8876; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9751 155792148 CVCL_C5VT CUTO42 cancer cell line human CVCL_C5VT CL:0000010 Sequence variation: Gene fusion; HGNC; 1316; EML4 + HGNC; 9967; RET; Name(s)=EML4-RET; Note=EML4 exon 9 fused to RET exon 12 (PubMed=33795352) Derived from sampling site: Lung. Omics: Transcriptome analysis by RNAseq Male 155792149 CVCL_C5W5 L2(20/3) hybridoma house mouse CVCL_C5W5 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792150 CVCL_C5VS CUTO32 cancer cell line human CVCL_C5VS CL:0000010 Sequence variation: Gene fusion; HGNC; 6324; KIF5B + HGNC; 9967; RET; Name(s)=KIF5B-RET; Note=KIF5B exon 15 fused to RET exon 12 (PubMed=33795352) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Male 155792151 CVCL_C5W4 L2(2/1) hybridoma house mouse CVCL_C5W4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792152 CVCL_C5VV KOR B-LCL transformed cell line human CVCL_C5VV HLA typing: A*24,28; B*27:02,44 (PubMed=10843661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792153 CVCL_C5W7 N-NaPi2b(15/1) hybridoma house mouse CVCL_C5W7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792154 CVCL_C5VU DH B-LCL transformed cell line human CVCL_C5VU HLA typing: A*02,11; B*27:04,40 (PubMed=10843661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792155 CVCL_C5W6 L3(28/1) hybridoma house mouse CVCL_C5W6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792156 CVCL_C5W9 MT179 hybridoma house mouse CVCL_C5W9 CL:0000010 Monoclonal antibody isotype: IgG1. 155792157 CVCL_C5VX RT B-LCL transformed cell line human CVCL_C5VX HLA typing: A*02,24; B*27:05,35 (PubMed=10843661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792158 CVCL_C5VW LY B-LCL transformed cell line human CVCL_C5VW HLA typing: A*01,24; B*27:02,35 (PubMed=10843661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792159 CVCL_C5W8 N-NaPi2b(18/1) hybridoma house mouse CVCL_C5W8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792160 CVCL_C5VJ LG2 DO-KO-1 transformed cell line human CVCL_C5VJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4937; HLA-DOB Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics Male 155792161 CVCL_C5VI LCL 6370 transformed cell line human CVCL_C5VI HLA typing: A*02,68; B*27:05,44; C*02,07 (PubMed=27110896) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155792162 CVCL_C5VL 10B12 hybridoma house mouse CVCL_C5VL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A5K736; Plasmodium vivax (strain Salvador I) reticulocyte binding protein 2b (RBP2b). 155792163 CVCL_C5VK LG2 DO-KO-2 transformed cell line human CVCL_C5VK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4937; HLA-DOB Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics Male 155792164 CVCL_C5VN 4F7 [Mouse hybridoma against P.vivax RBP2b] hybridoma house mouse CVCL_C5VN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A5K736; Plasmodium vivax (strain Salvador I) reticulocyte binding protein 2b (RBP2b). 155792165 CVCL_C5VM 8G7 hybridoma house mouse CVCL_C5VM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A5K736; Plasmodium vivax (strain Salvador I) reticulocyte binding protein 2b (RBP2b). 155792166 CVCL_C5VP 6H1 [Mouse hybridoma against P.vivax RBP2b] hybridoma house mouse CVCL_C5VP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A5K736; Plasmodium vivax (strain Salvador I) reticulocyte binding protein 2b (RBP2b). 155792167 CVCL_C5W1 MQ49 hybridoma house mouse CVCL_C5W1 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8874; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9750 155792168 CVCL_C5W0 MH99 hybridoma house mouse CVCL_C5W0 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8406 155792169 CVCL_C5VB Mouse-IMACS transformed cell line house mouse CVCL_C5VB CL:0000010 Miscellaneous: Cell line information from personal communication of Gamage A.M Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/c. Unspecified Characteristics: Readily divide in CSF-1 free-RPMI media and are to be passaged on non-tissue culture treated plastic ware (Direct_author_submission) 155792170 CVCL_C5VA LG2-MEL-220 cancer cell line human CVCL_C5VA CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (PubMed=12747754) Derived from metastatic site: Lymph node. Male Characteristics: Has lost the HLA-A*24, HLA-B*35 and HLA-C*4 alleles of the parent cell line (PubMed=12747754) Doubling time: 38 hours (PubMed=12747754) 155792171 CVCL_C5VD C1R-B*27:02 transformed cell line human CVCL_C5VD CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*27:02); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155792172 CVCL_C5VC MZ2-MEL.2.2 cancer cell line human CVCL_C5VC CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Abdomen. Unspecified 155792173 CVCL_C5VF P50 transformed cell line human CVCL_C5VF HLA typing: A*23,24; B*14,27:05; C*02,08 (PubMed=25469497) CL:0000010 Sequence variation: Mutation; HGNC; 29499; ERAP2; Simple; p.Lys392Asn (c.1176G>T); dbSNP=rs2549782; Zygosity=Heterozygous (PubMed=25469497) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155792174 CVCL_C5VE C1R-B*27:05 transformed cell line human CVCL_C5VE CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*27:05); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 155792175 CVCL_C5VH LCL 15510 transformed cell line human CVCL_C5VH HLA typing: A*01,11; B*27:05,37; C*01,06 (PubMed=27110896) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155792176 CVCL_C5VG LCL 10151 transformed cell line human CVCL_C5VG HLA typing: A*02,31; B*15,27:05; C*02,03 (PubMed=27110896) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 155792177 CVCL_C5WZ 175.2 hybridoma house mouse CVCL_C5WZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792178 CVCL_C5XB 2BBLC854.5 hybridoma house mouse CVCL_C5XB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792179 CVCL_C5XA 2BBLC817.4 hybridoma house mouse CVCL_C5XA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792180 CVCL_C5WS 1.1 hybridoma house mouse CVCL_C5WS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792181 CVCL_C5X4 20.1 [Mouse hybridoma against levan] hybridoma house mouse CVCL_C5X4 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792182 CVCL_C5X3 2.1 hybridoma house mouse CVCL_C5X3 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792183 CVCL_C5WR XA325.5 hybridoma house mouse CVCL_C5WR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792184 CVCL_C5WU 13.1 hybridoma house mouse CVCL_C5WU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792185 CVCL_C5X6 2677.1 hybridoma house mouse CVCL_C5X6 CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792186 CVCL_C5WT 10.1 hybridoma house mouse CVCL_C5WT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792187 CVCL_C5X5 2097.2 hybridoma house mouse CVCL_C5X5 CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792188 CVCL_C5WW 14.1 [Mouse hybridoma against levan] hybridoma house mouse CVCL_C5WW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792189 CVCL_C5X8 2BBLC803.1 hybridoma house mouse CVCL_C5X8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792190 CVCL_C5WV 134.6 hybridoma house mouse CVCL_C5WV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792191 CVCL_C5X7 2BBLC403.4 hybridoma house mouse CVCL_C5X7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792192 CVCL_C5WY 168.6 hybridoma house mouse CVCL_C5WY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792193 CVCL_C5WX 1471.1 [Mouse hybridoma against levan] hybridoma house mouse CVCL_C5WX CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792194 CVCL_C5X9 2BBLC811.2 hybridoma house mouse CVCL_C5X9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792195 CVCL_C5WK ID3-B9 hybridoma house mouse CVCL_C5WK CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9UJQ4; Human SALL4 (isoform SALL4A). 155792196 CVCL_C5WJ AU4 factor-dependent cell line house mouse CVCL_C5WJ CL:0000010 Derived from sampling site: Ear; skin; epidermis Cell type=Dendritic epidermal T-cell.; Breed/subspecies: C3H/HeN. Female Characteristics: IL2 dependent 155792197 CVCL_C5WM 3E12-E10 hybridoma house mouse CVCL_C5WM CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9UJQ4; Human SALL4 (isoform SALL4A). 155792198 CVCL_C5WL 2F12-F5 hybridoma house mouse CVCL_C5WL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9UJQ4; Human SALL4 (isoform SALL4A). 155792199 CVCL_C5X0 18.1 hybridoma house mouse CVCL_C5X0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792200 CVCL_C5WN GI-CO-T-9 cancer cell line human CVCL_C5WN CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2493fs*67 (c.7476_7477ins11); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion Cell type=T-cell.. Female 155792201 CVCL_C5X2 1904.2 hybridoma house mouse CVCL_C5X2 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792202 CVCL_C5WQ XA325.16 hybridoma house mouse CVCL_C5WQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792203 CVCL_C5X1 1802.2 hybridoma house mouse CVCL_C5X1 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792204 CVCL_C5WP JFSP spontaneously immortalized cell line CVCL_C5WP CL:0000010 Derived from sampling site: Spleen. Unspecified Characteristics: Grows well from 11 to 29 Celsius; Virology: Susceptible to infection by Bohle virus (BIV), viral hemorrhagic septicemia virus (VHSV), Hirame rhabdovirus (HIRRV), infectious hematopoietic necrosis virus (IHNV) and lymphocystis disease virus (LCDV) Group: Fish cell line 155792205 CVCL_C5WC MX35 hybridoma house mouse CVCL_C5WC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95436; Human SLC34A2. 155792206 CVCL_C5WB MW207 hybridoma house mouse CVCL_C5WB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 155792207 CVCL_C5WE FBP343 hybridoma house mouse CVCL_C5WE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 155792208 CVCL_C5WD FBP146 hybridoma house mouse CVCL_C5WD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 155792209 CVCL_C5WG FBP741 hybridoma house mouse CVCL_C5WG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 155792210 CVCL_C5WF FBP458 hybridoma house mouse CVCL_C5WF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 155792211 CVCL_C5WI AU16 factor-dependent cell line house mouse CVCL_C5WI CL:0000010 Derived from sampling site: Ear; skin; epidermis Cell type=Dendritic epidermal T-cell.; Breed/subspecies: C3H/HeN. Female Characteristics: IL2 dependent; Characteristics: Cytotoxic activity on melanoma cells (PubMed=7907126) 155792212 CVCL_C5WH ME-1477 cancer cell line human CVCL_C5WH CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 155792213 CVCL_C5U9 LG2-EBV transformed cell line human CVCL_C5U9 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155792214 CVCL_C5TX STSW-01 telomerase immortalized cell line human CVCL_C5TX CL:0000010 Sequence variation: Gene deletion; HGNC; 7773; NF2; Simple; Zygosity=Heterozygous (PubMed=35732500); Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Simple; Zygosity=Heterozygous (PubMed=35732500); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Trp60Cysfs*62 (c.180delG); Zygosity=Heterozygous; Note=Germline (PubMed=35732500); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Glu122Ter (c.364G>T); ClinVar=VCV001076272; Zygosity=Heterozygous; Note=Germline (PubMed=35732500); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Peripheral nervous system Cell type=Schwann cell.. Unspecified 155792215 CVCL_C5TW ASF spontaneously immortalized cell line CVCL_C5TW CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Grows well from 10 to 28 Celsius, the optimal growth temperature is 20 Celsius (DOI=10.1007/s11802-022-4875-8); Virology: Susceptible to infection by viral hemorrhagic septicemia virus (VHSV) and red-spotted grouper nervous necrosis virus (RGNNV) (DOI=10.1007/s11802-022-4875-8) Group: Fish cell line 155792216 CVCL_C5U8 LG2-MEL cancer cell line human CVCL_C5U8 CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Heterozygous (PubMed=12747754) Derived from metastatic site: Lymph node. Male 155792217 CVCL_C5TZ JC053 cancer cell line human CVCL_C5TZ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35724767) Population: Japanese; Derived from sampling site: Colon; transverse. Male 155792218 CVCL_C5TY STSW-01-LUC telomerase immortalized cell line human CVCL_C5TY CL:0000010 Sequence variation: Gene deletion; HGNC; 7773; NF2; Simple; Zygosity=Heterozygous (PubMed=35732500); Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Simple; Zygosity=Heterozygous (PubMed=35732500); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Trp60Cysfs*62 (c.180delG); Zygosity=Heterozygous; Note=Germline (PubMed=35732500); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Glu122Ter (c.364G>T); ClinVar=VCV001076272; Zygosity=Heterozygous; Note=Germline (PubMed=35732500); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Peripheral nervous system Cell type=Schwann cell.. Unspecified 155792219 CVCL_C5U1 JC053-DR2 cancer cell line human CVCL_C5U1 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35724767); Sequence variation: Mutation; HGNC; 1097; BRAF; Unexplicit; Ex3-8del; Zygosity=Heterozygous (PubMed=35724767); Sequence variation: Mutation; HGNC; 1097; BRAF; Unexplicit; Ex4-8del; Zygosity=Heterozygous (PubMed=35724767) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Colon; transverse. Male 155792220 CVCL_C5TP RK3E-ras transformed cell line Norway rat CVCL_C5TP CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus E1A; Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: Fischer. Unspecified Characteristics: Tumorigenic 155792221 CVCL_C5U0 JC053-DR1 cancer cell line human CVCL_C5U0 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35724767); Sequence variation: Mutation; HGNC; 1097; BRAF; Unexplicit; Ex2-8del; Zygosity=Unspecified (PubMed=35724767) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Colon; transverse. Male 155792222 CVCL_C5U3 L128 cancer cell line human CVCL_C5U3 CL:0000010 Omics: Transcriptome analysis by microarray. 155792223 CVCL_C5TR SNU-2535LR cancer cell line human CVCL_C5TR CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=35852680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Val (c.854A>T); ClinVar=VCV000012384; Zygosity=Homozygous (PubMed=35852680) Population: Korean; Selected for resistance to: ChEBI; CHEBI:143117; Lorlatinib (Lorbrena; Derived from metastatic site: Pleural effusion. Female Characteristics: Resistant to crizotinib (from parent cell line); Characteristics: Has lost the ALK p.Gly1269Ala mutation of the parent cell line (PubMed=35852680) 155792224 CVCL_C5U2 Arbo cancer cell line human CVCL_C5U2 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1853Asn (c.5557G>A); ClinVar=VCV000128458; Zygosity=Unspecified (PubMed=36467812); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asn1983Ser (c.5948A>G); Zygosity=Unspecified (PubMed=36467812); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Arg2400Ter (c.7198C>T); ClinVar=VCV000518450; Zygosity=Unspecified (DOI=10.1158/1538-7445.AM2022-3160; PubMed=36467812); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu206Ter (c.617T>A); Zygosity=Unspecified (PubMed=36467812) Miscellaneous: STR profile from personal communication of Safa F.M Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 48 hours (DOI=10.1158/1538-7445.AM2022-3160; PubMed=36467812) 155792225 CVCL_C5TQ FHO6T1-1 transformed cell line CVCL_C5TQ CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated HRAS; Derived from sampling site: Lung. Unspecified 155792226 CVCL_C5TT HEK293-SLC1A5 transformed cell line human CVCL_C5TT CL:0000010 Transfected with: HGNC; 10943; SLC1A5; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155792227 CVCL_C5U5 MZ2-EBV transformed cell line human CVCL_C5U5 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792228 CVCL_C5TS CnGSC spontaneously immortalized cell line CVCL_C5TS CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Endangered species/breed cell line; Group: Fish cell line 155792229 CVCL_C5U4 MZ2-MEL.3.0 cancer cell line human CVCL_C5U4 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Abdomen. Unspecified 155792230 CVCL_C5TV GABAA1-CHO spontaneously immortalized cell line CVCL_C5TV CL:0000010 Transfected with: HGNC; 4075; GABRA1; Transfected with: HGNC; 4082; GABRB2; Transfected with: HGNC; 4087; GABRG2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female 155792231 CVCL_C5U7 MZ2-MEL.3.1 cancer cell line human CVCL_C5U7 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Abdomen. Unspecified 155792232 CVCL_C5TU H9SNTA1KO embryonic stem cell human CVCL_C5TU From: Qiqihar Institute of Medical and Pharmaceutical Sciences, Qiqihar Medical University; Qiqihar; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11167; SNTA1 Female Caution: There seems to be two H9SNTA1KO cell line established in China, this one and CVCL_A5EP. 155792233 CVCL_C5U6 MZ2-MEL.43 cancer cell line human CVCL_C5U6 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Abdomen. Unspecified 155792234 CVCL_C5TH OS365 cancer cell line human CVCL_C5TH CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792235 CVCL_C5TG OS355 cancer cell line human CVCL_C5TG CL:0000010 Derived from sampling site: Bone. Omics: Deep proteome analysis 155792236 CVCL_C5TJ OS368 cancer cell line human CVCL_C5TJ CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792237 CVCL_C5TI OS366 cancer cell line human CVCL_C5TI CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792238 CVCL_C5TL OS377 cancer cell line human CVCL_C5TL CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792239 CVCL_C5TK OS373 cancer cell line human CVCL_C5TK CL:0000010 Derived from sampling site: Bone. 155792240 CVCL_C5TN OS396 cancer cell line human CVCL_C5TN CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792241 CVCL_C5TM OS379 cancer cell line human CVCL_C5TM CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792242 CVCL_C5TB OS337 cancer cell line human CVCL_C5TB CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792243 CVCL_C5TA OS322 cancer cell line human CVCL_C5TA CL:0000010 Derived from sampling site: Bone. Omics: Deep proteome analysis 155792244 CVCL_C5TD OS342 cancer cell line human CVCL_C5TD CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792245 CVCL_C5TC OS340 cancer cell line human CVCL_C5TC CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792246 CVCL_C5TF OS354 cancer cell line human CVCL_C5TF CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792247 CVCL_C5TE OS343 cancer cell line human CVCL_C5TE CL:0000010 Derived from sampling site: Bone. Omics: Deep proteome analysis 155792248 CVCL_C5UY AL2 hybridoma Norway rat CVCL_C5UY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155792249 CVCL_C5V9 EHRB-BL-41 cancer cell line human CVCL_C5V9 HLA typing: A*32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) (PubMed=3037521) 155792250 CVCL_C5UX NCL-CD10-270 hybridoma house mouse CVCL_C5UX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155792251 CVCL_C5UZ AL3 hybridoma Norway rat CVCL_C5UZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155792252 CVCL_C5V2 BL-41/95 cancer cell line human CVCL_C5V2 HLA typing: A*11,32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792253 CVCL_C5UQ LG2-MEL-5-32 cancer cell line human CVCL_C5UQ CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792254 CVCL_C5V1 AL5 hybridoma Norway rat CVCL_C5V1 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155792255 CVCL_C5UP LG2-MEL-5-31 cancer cell line human CVCL_C5UP CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792256 CVCL_C5V4 E95B-BL-28 cancer cell line human CVCL_C5V4 HLA typing: A*01; B*08,16 (PubMed=3037521) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792257 CVCL_C5US LG2-MEL-5-36 cancer cell line human CVCL_C5US CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792258 CVCL_C5V3 E95A-BL-28 cancer cell line human CVCL_C5V3 HLA typing: A*01; B*08,16 (PubMed=3037521) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792259 CVCL_C5UR LG2-MEL-5-35 cancer cell line human CVCL_C5UR CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792260 CVCL_C5V6 E95B-BL-41 cancer cell line human CVCL_C5V6 HLA typing: A*32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792261 CVCL_C5UU LG2-MEL-5-35isc3.1.1 cancer cell line human CVCL_C5UU CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male Characteristics: Obtained by in vitro immunoselection of the parent cell line with the anti-LG2-B CTL clones (PubMed=12747754) 155792262 CVCL_C5V5 E95A-BL-41 cancer cell line human CVCL_C5V5 HLA typing: A*32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792263 CVCL_C5UT LB14-EBV transformed cell line human CVCL_C5UT From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155792264 CVCL_C5V8 EHRA-BL-41 cancer cell line human CVCL_C5V8 HLA typing: A*32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) (PubMed=3037521) 155792265 CVCL_C5UW LG2 transformed cell line human CVCL_C5UW HLA typing: A*02; B*27:05; C*01 (PubMed=25469497); HLA typing: A*02; B*27:05:02; C*01; DPA1*01:01; DPB1*02:01; DQA1*01:01; DQB1*05:01; DRB1*01:01 (PubMed=12133989); HLA typing: B*02:01,27:05; DPA1*01:03:01:01; DQA1*01:01:01:01; DQB1*05:01:01:01; DRB1*01:01:01:01 (IPD-IMGT/HLA=10984) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics Male 155792266 CVCL_C5V7 E95C-BL-41 cancer cell line human CVCL_C5V7 HLA typing: A*32; B*35,49 (PubMed=3037521) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=3037521) 155792267 CVCL_C5UV LG2-MEL-28 cancer cell line human CVCL_C5UV CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male 155792268 CVCL_C5UI LB-MEL-5 cancer cell line human CVCL_C5UI From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792269 CVCL_C5UH LB-MEL-4 cancer cell line human CVCL_C5UH From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792270 CVCL_C5UK LG2-MEL-5-21 cancer cell line human CVCL_C5UK CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792271 CVCL_C5UJ LB-MEL-6 cancer cell line human CVCL_C5UJ From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792272 CVCL_C5UM LG2-MEL-5-23 cancer cell line human CVCL_C5UM CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792273 CVCL_C5UL LG2-MEL-5-22 cancer cell line human CVCL_C5UL CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792274 CVCL_C5V0 AL4 hybridoma Norway rat CVCL_C5V0 CL:0000010 Monoclonal antibody isotype: IgGM; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155792275 CVCL_C5UN LG2-MEL-5-30 cancer cell line human CVCL_C5UN CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (from parent cell line) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 155792276 CVCL_C5UA LG2-MEL-205 cancer cell line human CVCL_C5UA CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Homozygous (PubMed=12747754) Derived from metastatic site: Lymph node. Male Doubling time: 35 hours (PubMed=12747754) 155792277 CVCL_C5UC LG2-MEL-207 cancer cell line human CVCL_C5UC CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Heterozygous (PubMed=12747754) Derived from metastatic site: Lymph node. Male Doubling time: 40 hours (PubMed=12747754) 155792278 CVCL_C5UB LG2-MEL-206 cancer cell line human CVCL_C5UB CL:0000010 Sequence variation: Mutation; HGNC; 16994; OS9; Simple; p.Pro446Leu (c.1337C>T); Zygosity=Heterozygous (PubMed=12747754) Derived from metastatic site: Lymph node. Male Doubling time: 78 hours (PubMed=12747754) 155792279 CVCL_C5UE LB-MEL-1 cancer cell line human CVCL_C5UE From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792280 CVCL_C5UD SK-MEL-179 cancer cell line human CVCL_C5UD From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 155792281 CVCL_C5UG LB-MEL-3 cancer cell line human CVCL_C5UG From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792282 CVCL_C5UF LB-MEL-2 cancer cell line human CVCL_C5UF From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from sampling site: Skin. Unspecified 155792283 CVCL_C5S7 CHO Pro-3 MtxRII OuaR-5-3 transformed cell line CVCL_C5S7 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792284 CVCL_C5RV MCF-7:CFR cancer cell line human CVCL_C5RV CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 155792285 CVCL_C5S6 CHO Pro-3 MtxRI-6-3 transformed cell line CVCL_C5S6 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792286 CVCL_C5RU MCF-7/F cancer cell line human CVCL_C5RU CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 155792287 CVCL_C5S9 CHO Pro-3 MtxRII-7-5 transformed cell line CVCL_C5S9 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792288 CVCL_C5RX EMRK1184luc cancer cell line house mouse CVCL_C5RX CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Myc Omics: Transcriptome analysis by RNAseq. Characteristics: Established from a tumor resulting from the expression of Myc under the control of the IgH enhancer (PubMed=30069049) 155792289 CVCL_C5S8 CHO Pro-3 MtxRII-5-3 transformed cell line CVCL_C5S8 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Doubling time: 15 hours (PubMed=1028172) 155792290 CVCL_C5RW EMRK1184 cancer cell line house mouse CVCL_C5RW CL:0000010 Transformant: Myc. Characteristics: Established from a tumor resulting from the expression of Myc under the control of the IgH enhancer (PubMed=30069049) 155792291 CVCL_C5RZ A549/CisR cancer cell line human CVCL_C5RZ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Male 155792292 CVCL_C5RY CEM/VBL600 cancer cell line human CVCL_C5RY CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155792293 CVCL_C5RN HepG2-CD81 cancer cell line human CVCL_C5RN CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1701; CD81 Population: Caucasian; Derived from sampling site: Liver. Male 155792294 CVCL_C5RM MigA9 cancer cell line house mouse CVCL_C5RM CL:0000010 Transfected with: MGI; MGI:96180; Hoxa9 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray 155792295 CVCL_C5S1 H460/CisR cancer cell line human CVCL_C5S1 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 155792296 CVCL_C5RP HepG2/CD81++ cancer cell line human CVCL_C5RP CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1701; CD81 Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Expresses 4 times more CD81 than HepG2-CD81 (Cellosaurus=CVCL_C5RN) (PubMed=16819966) 155792297 CVCL_C5S0 A549/TR cancer cell line human CVCL_C5S0 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Lung. Male 155792298 CVCL_C5S3 CHO Pro-3 MtxRI-2-6 transformed cell line CVCL_C5S3 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792299 CVCL_C5RR CHO Pro-4 spontaneously immortalized cell line CVCL_C5RR CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Defective in purine biosynthesis 155792300 CVCL_C5S2 CHO Pro-3 MtxRI OuaR-3-6 transformed cell line CVCL_C5S2 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792301 CVCL_C5RQ MC/8 factor-dependent cell line house mouse CVCL_C5RQ CL:0000010 Derived from sampling site: Liver Cell type=Mast cell.; Breed/subspecies: C57BL/6 x A/J. Unspecified Characteristics: IL3 dependent 155792302 CVCL_C5RT A549/CDDP cancer cell line human CVCL_C5RT CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Male 155792303 CVCL_C5S5 CHO Pro-3 MtxRI-4-3 transformed cell line CVCL_C5S5 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792304 CVCL_C5S4 CHO Pro-3 MtxRI-3-3 transformed cell line CVCL_C5S4 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Doubling time: 14 hours (PubMed=1028172) 155792305 CVCL_C5RS MCF-7/PTX cancer cell line human CVCL_C5RS CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female 155792306 CVCL_C5RF N2a #34 cancer cell line house mouse CVCL_C5RF CL:0000010 Transfected with: MGI; MGI:97769; Prnp (with a 3F4 tag) Breed/subspecies: A/J. Male Characteristics: Prnp is tagged with an epitope recognized by the mAB 3F4 produced by hybridoma 263K 3F4 (Cellosaurus=CVCL_KR59) 155792307 CVCL_C5RE 28G7 hybridoma house mouse CVCL_C5RE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:7735; Olanzapine. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.45161 155792308 CVCL_C5RH N2a #58 F3 cancer cell line house mouse CVCL_C5RH CL:0000010 Transfected with: MGI; MGI:97769; Prnp Breed/subspecies: A/J. Male Characteristics: Infected with mouse Fukuoka-1 strain prions 155792309 CVCL_C5RG N2a #58 cancer cell line house mouse CVCL_C5RG CL:0000010 Transfected with: MGI; MGI:97769; Prnp Breed/subspecies: A/J. Male 155792310 CVCL_C5RJ CC531mdr+ cancer cell line Norway rat CVCL_C5RJ CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: WAG/Rij. Male Characteristics: Multidrug resistant, in addition to colchicine it also is resistant against actinomycin D, daunorubicin, doxorubicin and vinblastine (PubMed=7903965) 155792311 CVCL_C5RI GLC4/Sb30 cancer cell line human CVCL_C5RI CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:2761; Dipotassium bis[mu-tartrato(4-)]diantimonate(2-) trihydrate (Antimony potassium tartrate; Derived from metastatic site: Pleural effusion. Male 155792312 CVCL_C5RL HeLa-C3 cancer cell line human CVCL_C5RL CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Uterus; cervix. Female Characteristics: Obtained from the parent cell line that was subjected to 3 cycles of 10 Gy of Ce-137 irradiation (CelloPub=CLPUB00727; PubMed=9374378) Doubling time: 20.5-23 hours (PubMed=9374378) 155792313 CVCL_C5RK CC531rev cancer cell line Norway rat CVCL_C5RK CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: WAG/Rij. Male Characteristics: Revertant of parent cell line, no longer multidrug resistant 155792314 CVCL_C5RB CRCBT-06-007 hybridoma house mouse CVCL_C5RB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792315 CVCL_C5RA CRCBT-06-006 hybridoma house mouse CVCL_C5RA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792316 CVCL_C5RD 2F6 [Mouse hybridoma against M.synoviae] hybridoma house mouse CVCL_C5RD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycoplasma synoviae. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.45241 155792317 CVCL_C5RC 19.2.1 hybridoma house mouse CVCL_C5RC CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized enavatuzumab (PDL192) therapeutic antibody used in the treatment of solid tumors Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792318 CVCL_C5T8 OS301 cancer cell line human CVCL_C5T8 CL:0000010 Derived from sampling site: Bone. Omics: Deep proteome analysis 155792319 CVCL_C5SW R52.120 hybridoma CVCL_C5SW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26955; Mouse Csf2rb/Cd131. 155792320 CVCL_C5SV ED19Im-pre-TII transformed cell line Norway rat CVCL_C5SV CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Ad2-Ad5 hybrid E1A; Derived from sampling site: Embryonic lung; alveolus Cell type=Pre-type 2 pneumocyte.; Breed/subspecies: Sprague Dawley. Male Doubling time: ~53 hours (PubMed=1316350) 155792321 CVCL_C5T7 OS300 cancer cell line human CVCL_C5T7 CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792322 CVCL_C5SY SCP-HS undefined cell line type CVCL_C5SY CL:0000010 Unspecified Problematic cell line: Misidentified Originally thought to be a derivative of the sheep SCP cell line (Cellosaurus=CVCL_4298) but shown to originate from bovine (PubMed=34737324).. 155792323 CVCL_C5T9 OS308 cancer cell line human CVCL_C5T9 CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792324 CVCL_C5SX R52.625 hybridoma CVCL_C5SX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26955; Mouse Csf2rb/Cd131. 155792325 CVCL_C5SZ Sc10/01 spontaneously immortalized cell line CVCL_C5SZ CL:0000010 Miscellaneous: Cell line has been lost (PubMed=570703) Derived from sampling site: Ovary. Female Group: Marsupial cell line 155792326 CVCL_C5T0 CRICKi008-A induced pluripotent stem cell human CVCL_C5T0 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155792327 CVCL_C5SN NZB-S-M cancer cell line house mouse CVCL_C5SN CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZB/Scr. 155792328 CVCL_C5T2 CRICKi010-A induced pluripotent stem cell human CVCL_C5T2 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155792329 CVCL_C5SQ NZW-S1-M cancer cell line house mouse CVCL_C5SQ CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZW/Scr. 155792330 CVCL_C5T1 CRICKi009-A induced pluripotent stem cell human CVCL_C5T1 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155792331 CVCL_C5SP NZW-D-M cancer cell line house mouse CVCL_C5SP CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZW/Scr. 155792332 CVCL_C5SS BALB-G-M cancer cell line house mouse CVCL_C5SS CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: BALB/c. 155792333 CVCL_C5T4 CRICKi012-A induced pluripotent stem cell human CVCL_C5T4 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155792334 CVCL_C5T3 CRICKi011-A induced pluripotent stem cell human CVCL_C5T3 From: The Francis Crick Institute Limited; London; United Kingdom. CL:0000010 155792335 CVCL_C5SR NZW-S2-M cancer cell line house mouse CVCL_C5SR CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZW/Scr. 155792336 CVCL_C5SU ED18Im-pre-TII transformed cell line Norway rat CVCL_C5SU CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Ad2-Ad5 hybrid E1A; Derived from sampling site: Embryonic lung; alveolus Cell type=Pre-type 2 pneumocyte.; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: ~44 hours (PubMed=1316350) 155792337 CVCL_C5T6 OS255 cancer cell line human CVCL_C5T6 CL:0000010 Derived from sampling site: Bone. 155792338 CVCL_C5ST H460/TR cancer cell line human CVCL_C5ST CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Male 155792339 CVCL_C5T5 OS242 cancer cell line human CVCL_C5T5 CL:0000010 Derived from sampling site: Bone. Omics: Transcriptome analysis by RNAseq 155792340 CVCL_C5SG CHO Pro-4 MtxRII OuaR-2-4 transformed cell line CVCL_C5SG CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792341 CVCL_C5SF CHO Pro-4 MtxRI-3-4 transformed cell line CVCL_C5SF CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792342 CVCL_C5SI CHO Pro-4 MtxRII-4-5 transformed cell line CVCL_C5SI CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792343 CVCL_C5SH CHO Pro-4 MtxRII-2-1 transformed cell line CVCL_C5SH CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792344 CVCL_C5SK CHO Pro-4 OuaR-2-4 transformed cell line CVCL_C5SK CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792345 CVCL_C5SJ CHO Pro-4 MtxRIII OuaR-1-6 transformed cell line CVCL_C5SJ CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792346 CVCL_C5SM BW-L-M cancer cell line house mouse CVCL_C5SM CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZB x NZW. 155792347 CVCL_C5SL BW-J-M cancer cell line house mouse CVCL_C5SL CL:0000010 Derived from sampling site: Thymus Cell type=Macrophage.; Breed/subspecies: NZB x NZW. Virology: Venezuelan equine encephalomyelitis virus isolate TC-63 can bind to this cell line (PubMed=6337232) 155792348 CVCL_C5SA CHO Pro-3 MtxRIII OuaR-3-5 transformed cell line CVCL_C5SA CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792349 CVCL_C5SC CHO Pro-3 OuaR-1-2 transformed cell line CVCL_C5SC CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792350 CVCL_C5SB CHO Pro-3 MtxRIII-1-2 transformed cell line CVCL_C5SB CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Doubling time: 15 hours (PubMed=1028172) 155792351 CVCL_C5SE CHO Pro-4 MtxRI-1-2 transformed cell line CVCL_C5SE CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792352 CVCL_C5SD CHO Pro-4 MtxRI OuaR-6-3 transformed cell line CVCL_C5SD CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 155792353 CVCL_C5PT GCSK2 cancer cell line human CVCL_C5PT CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Female 155792354 CVCL_C5Q5 p2#51 hybridoma house mouse CVCL_C5Q5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792355 CVCL_C5PS GCS6K1 cancer cell line human CVCL_C5PS CL:0000010 Derived from sampling site: Brain. Female 155792356 CVCL_C5Q4 p2#21 hybridoma house mouse CVCL_C5Q4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792357 CVCL_C5PV 1-187-29 transformed cell line human CVCL_C5PV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P02708; Human CHRNA1 (Note=Also reacts with Torpedo) 155792358 CVCL_C5Q7 p2#66 hybridoma house mouse CVCL_C5Q7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792359 CVCL_C5PU 1-185-37 transformed cell line human CVCL_C5PU CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P02708; Human CHRNA1 (Note=Also reacts with Torpedo) 155792360 CVCL_C5Q6 p2#52 hybridoma house mouse CVCL_C5Q6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792361 CVCL_C5PX 2-115-58 transformed cell line human CVCL_C5PX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgG; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody TR63 155792362 CVCL_C5Q9 p6#32 hybridoma house mouse CVCL_C5Q9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792363 CVCL_C5PW 2-115-19 transformed cell line human CVCL_C5PW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P02708; Human CHRNA1 155792364 CVCL_C5Q8 p6#24 hybridoma house mouse CVCL_C5Q8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792365 CVCL_C5PZ EquiPSC Line B induced pluripotent stem cell CVCL_C5PZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792366 CVCL_C5PY TG180 cancer cell line house mouse CVCL_C5PY CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified Characteristics: Susceptible to infection by Toxoplasma gondii 155792367 CVCL_C5PL GCW29 cancer cell line human CVCL_C5PL CL:0000010 Derived from sampling site: Brain. Female 155792368 CVCL_C5PK GCW28 cancer cell line human CVCL_C5PK CL:0000010 Derived from sampling site: Brain. Male 155792369 CVCL_C5PN GCW31 cancer cell line human CVCL_C5PN CL:0000010 Derived from sampling site: Brain. Male 155792370 CVCL_C5PM GCW30 cancer cell line human CVCL_C5PM CL:0000010 Derived from sampling site: Brain. Male 155792371 CVCL_C5Q1 EquiPSC Line H induced pluripotent stem cell CVCL_C5Q1 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792372 CVCL_C5PP GCW33 cancer cell line human CVCL_C5PP CL:0000010 Derived from sampling site: Brain. Male 155792373 CVCL_C5Q0 EquiPSC Line E induced pluripotent stem cell CVCL_C5Q0 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792374 CVCL_C5PR GCS29K7 cancer cell line human CVCL_C5PR CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Female 155792375 CVCL_C5Q3 SV40imMyo transformed cell line CVCL_C5Q3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40) [pNIT-TAg](NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Thoroughbred. Male Characteristics: Capable of differentiation into multinucleated myotubes (PubMed=26111090) 155792376 CVCL_C5Q2 EquiPSC Line U induced pluripotent stem cell CVCL_C5Q2 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792377 CVCL_C5PQ GCS19K6 cancer cell line human CVCL_C5PQ CL:0000010 Derived from sampling site: Brain. Female 155792378 CVCL_C5PD GCW20 cancer cell line human CVCL_C5PD CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155792379 CVCL_C5PC GCW18 cancer cell line human CVCL_C5PC CL:0000010 Derived from sampling site: Brain. Female 155792380 CVCL_C5PF GCW22 cancer cell line human CVCL_C5PF CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Female 155792381 CVCL_C5PE GCW21 cancer cell line human CVCL_C5PE CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155792382 CVCL_C5PH GCW25 cancer cell line human CVCL_C5PH CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155792383 CVCL_C5PG GCW24 cancer cell line human CVCL_C5PG CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155792384 CVCL_C5PJ GCW27 cancer cell line human CVCL_C5PJ CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Female 155792385 CVCL_C5PI GCW26 cancer cell line human CVCL_C5PI CL:0000010 Derived from sampling site: Brain. Male 155792386 CVCL_C5PB GCW17 cancer cell line human CVCL_C5PB CL:0000010 Derived from sampling site: Brain. Male 155792387 CVCL_C5PA GCW11 cancer cell line human CVCL_C5PA CL:0000010 Derived from sampling site: Brain. Male 155792388 CVCL_C5QU ART-18 hybridoma house mouse CVCL_C5QU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26897; Rat Il2ra/Cd25. 155792389 CVCL_C5R6 CRCBT-06-002 hybridoma house mouse CVCL_C5R6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792390 CVCL_C5R5 CRCBT-06-001 hybridoma house mouse CVCL_C5R5 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792391 CVCL_C5QT Gli reporter-NIH3T3 spontaneously immortalized cell line house mouse CVCL_C5QT CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Expression of the luciferase reporter gene is under the control of Gli responsive elements 155792392 CVCL_C5QW 5A2-2-4 hybridoma CVCL_C5QW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. 155792393 CVCL_C5R8 CRCBT-06-004 hybridoma house mouse CVCL_C5R8 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792394 CVCL_C5QV AMT-13 hybridoma Norway rat CVCL_C5QV CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. 155792395 CVCL_C5R7 CRCBT-06-003 hybridoma house mouse CVCL_C5R7 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792396 CVCL_C5QY 135D5-1-12 hybridoma CVCL_C5QY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. 155792397 CVCL_C5QX 125A8-1-11 hybridoma CVCL_C5QX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. 155792398 CVCL_C5R9 CRCBT-06-005 hybridoma house mouse CVCL_C5R9 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9NP84; Human TNFRSF12A/CD266. 155792399 CVCL_C5QZ AI21 hybridoma house mouse CVCL_C5QZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Anti-idiotypic against human anti-acetylcholine receptor auto-antibodies. 155792400 CVCL_C5QM EpiSC 129Ba2 somatic stem cell house mouse CVCL_C5QM CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: 129S2/Sv x C57BL/6N. Female 155792401 CVCL_C5QL EpiSC 129Ba1 somatic stem cell house mouse CVCL_C5QL CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: 129S2/Sv x C57BL/6N. Male 155792402 CVCL_C5R0 3D10 factor-dependent cell line house mouse CVCL_C5R0 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C3H/HeN. Unspecified Characteristics: IL2 dependent; Characteristics: Produces IL3 and IFNG (PubMed=2580015) 155792403 CVCL_C5QN EpiSC B129a7 somatic stem cell house mouse CVCL_C5QN CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: 129S2/Sv x C57BL/6N. Male 155792404 CVCL_C5QQ EpiSC BNa1 somatic stem cell house mouse CVCL_C5QQ CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: C57BL/6N. Female 155792405 CVCL_C5R2 K23 factor-dependent cell line house mouse CVCL_C5R2 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: DBA/2. Unspecified Characteristics: IL2 dependent 155792406 CVCL_C5R1 5D2M factor-dependent cell line house mouse CVCL_C5R1 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: DBA/2. Unspecified Characteristics: IL2 dependent 155792407 CVCL_C5QP EpiSC B129b1 somatic stem cell house mouse CVCL_C5QP CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: 129S2/Sv x C57BL/6N. Female 155792408 CVCL_C5R4 CRCBT-02-001 hybridoma house mouse CVCL_C5R4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q6UXB8; Human PI16/CD364. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10685 155792409 CVCL_C5QS EpiSC BNa18 somatic stem cell house mouse CVCL_C5QS CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: C57BL/6N. Female 155792410 CVCL_C5QR EpiSC BNa17 somatic stem cell house mouse CVCL_C5QR CL:0000010 Derived from sampling site: Cell type=Epiblast; Breed/subspecies: C57BL/6N. Male 155792411 CVCL_C5R3 FMC63 hybridoma house mouse CVCL_C5R3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15391; Human CD19. 155792412 CVCL_C5QE 5G10 hybridoma house mouse CVCL_C5QE CL:0000010 Transformant: Ractopamine(ChEBI; CHEBI:82644). Monoclonal antibody isotype: IgG1, kappa 155792413 CVCL_C5QD 4B7 [Mouse hybridoma against ractopamine] hybridoma house mouse CVCL_C5QD CL:0000010 Transformant: Ractopamine(ChEBI; CHEBI:82644). Monoclonal antibody isotype: IgM, lambda 155792414 CVCL_C5QG MS1 hybridoma house mouse CVCL_C5QG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:63598; Levofloxacin ((S)-ofloxacin). 155792415 CVCL_C5QF 7D12 hybridoma house mouse CVCL_C5QF CL:0000010 Transformant: Ractopamine(ChEBI; CHEBI:82644). Monoclonal antibody isotype: IgG1, kappa 155792416 CVCL_C5QI MS1-hCD276 transformed cell line house mouse CVCL_C5QI CL:0000010 Transfected with: HGNC; 19137; CD276; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified 155792417 CVCL_C5QH WR1 hybridoma house mouse CVCL_C5QH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:46577; Dextrofloxacin ((R)-ofloxacin). 155792418 CVCL_C5QK E1SM finite cell line human CVCL_C5QK CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Unspecified 155792419 CVCL_C5QJ S-GAT mAb hybridoma house mouse CVCL_C5QJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53562; (S)-gatifloxacin (S-GAT). 155792420 CVCL_C5QA p6#41 hybridoma house mouse CVCL_C5QA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792421 CVCL_C5QC 13B7 hybridoma house mouse CVCL_C5QC CL:0000010 Transformant: Ractopamine(ChEBI; CHEBI:82644). Monoclonal antibody isotype: IgG1, kappa 155792422 CVCL_C5QB p6#42 hybridoma house mouse CVCL_C5QB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:81861; Forchlorfenuron. 155792423 CVCL_C6AD HPS0671 induced pluripotent stem cell human CVCL_C6AD CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792424 CVCL_C6AC HPS0670 induced pluripotent stem cell human CVCL_C6AC CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792425 CVCL_C6AF HPS0679 induced pluripotent stem cell human CVCL_C6AF CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792426 CVCL_C6AE HPS0678 induced pluripotent stem cell human CVCL_C6AE CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792427 CVCL_C6AH HPS0681 induced pluripotent stem cell human CVCL_C6AH CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792428 CVCL_C6AG HPS0680 induced pluripotent stem cell human CVCL_C6AG CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792429 CVCL_C6AJ HPS0683 induced pluripotent stem cell human CVCL_C6AJ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792430 CVCL_C6AI HPS0682 induced pluripotent stem cell human CVCL_C6AI CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792431 CVCL_C6AB HPS0669 induced pluripotent stem cell human CVCL_C6AB CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792432 CVCL_C6AA HPS0668 induced pluripotent stem cell human CVCL_C6AA CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792433 CVCL_C6A4 HPS0608 induced pluripotent stem cell human CVCL_C6A4 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792434 CVCL_C6A3 HPS0607 induced pluripotent stem cell human CVCL_C6A3 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792435 CVCL_C6A6 HPS0610 induced pluripotent stem cell human CVCL_C6A6 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792436 CVCL_C6A5 HPS0609 induced pluripotent stem cell human CVCL_C6A5 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792437 CVCL_C6A8 HPS0666 induced pluripotent stem cell human CVCL_C6A8 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792438 CVCL_C6A7 HPS0611 induced pluripotent stem cell human CVCL_C6A7 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792439 CVCL_C6A9 HPS0667 induced pluripotent stem cell human CVCL_C6A9 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155792440 CVCL_C6A0 HPS0604 induced pluripotent stem cell human CVCL_C6A0 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792441 CVCL_C6A2 HPS0606 induced pluripotent stem cell human CVCL_C6A2 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792442 CVCL_C6A1 HPS0605 induced pluripotent stem cell human CVCL_C6A1 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792443 CVCL_C5ZV HPS0599 induced pluripotent stem cell human CVCL_C5ZV CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792444 CVCL_C5ZU HPS0598 induced pluripotent stem cell human CVCL_C5ZU CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792445 CVCL_C5ZX HPS0601 induced pluripotent stem cell human CVCL_C5ZX CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792446 CVCL_C5ZW HPS0600 induced pluripotent stem cell human CVCL_C5ZW CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792447 CVCL_C5ZZ HPS0603 induced pluripotent stem cell human CVCL_C5ZZ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792448 CVCL_C5ZY HPS0602 induced pluripotent stem cell human CVCL_C5ZY CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792449 CVCL_C5ZN HPS0592 induced pluripotent stem cell human CVCL_C5ZN CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792450 CVCL_C5ZM HPS0591 induced pluripotent stem cell human CVCL_C5ZM CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792451 CVCL_C5ZP HPS0593 induced pluripotent stem cell human CVCL_C5ZP CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792452 CVCL_C5ZR HPS0595 induced pluripotent stem cell human CVCL_C5ZR CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792453 CVCL_C5ZQ HPS0594 induced pluripotent stem cell human CVCL_C5ZQ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792454 CVCL_C5ZT HPS0597 induced pluripotent stem cell human CVCL_C5ZT CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792455 CVCL_C5ZS HPS0596 induced pluripotent stem cell human CVCL_C5ZS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792456 CVCL_C5ZF HPS0584 induced pluripotent stem cell human CVCL_C5ZF CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792457 CVCL_C5ZE HPS0583 induced pluripotent stem cell human CVCL_C5ZE CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792458 CVCL_C5ZH HPS0586 induced pluripotent stem cell human CVCL_C5ZH CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792459 CVCL_C5ZG HPS0585 induced pluripotent stem cell human CVCL_C5ZG CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792460 CVCL_C5ZJ HPS0588 induced pluripotent stem cell human CVCL_C5ZJ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792461 CVCL_C5ZI HPS0587 induced pluripotent stem cell human CVCL_C5ZI CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792462 CVCL_C5ZL HPS0590 induced pluripotent stem cell human CVCL_C5ZL CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792463 CVCL_C5ZK HPS0589 induced pluripotent stem cell human CVCL_C5ZK CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 155792464 CVCL_C5YA CBLC302.2 hybridoma house mouse CVCL_C5YA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792465 CVCL_C5YC CBLC312.8 hybridoma house mouse CVCL_C5YC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792466 CVCL_C5YB CBLC308.7 hybridoma house mouse CVCL_C5YB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792467 CVCL_C5XT CBL175.1 hybridoma house mouse CVCL_C5XT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792468 CVCL_C5Y5 CBLC262.7 hybridoma house mouse CVCL_C5Y5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792469 CVCL_C5XS CBL166.10.28 hybridoma house mouse CVCL_C5XS CL:0000010 Monoclonal antibody isotype: IgM, kappa+lambda; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792470 CVCL_C5Y4 CBLC240.8 hybridoma house mouse CVCL_C5Y4 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792471 CVCL_C5XV CBL52.2 hybridoma house mouse CVCL_C5XV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792472 CVCL_C5Y7 CBLC264.7 hybridoma house mouse CVCL_C5Y7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792473 CVCL_C5XU CBL255.3 hybridoma house mouse CVCL_C5XU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792474 CVCL_C5Y6 CBLC263.3 hybridoma house mouse CVCL_C5Y6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792475 CVCL_C5XX CBLC212.5 hybridoma house mouse CVCL_C5XX CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792476 CVCL_C5Y9 CBLC276.3 hybridoma house mouse CVCL_C5Y9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792477 CVCL_C5XW CBL62.1 hybridoma house mouse CVCL_C5XW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792478 CVCL_C5Y8 CBLC270.1 hybridoma house mouse CVCL_C5Y8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792479 CVCL_C5XZ CBLC214.1 hybridoma house mouse CVCL_C5XZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792480 CVCL_C5XY CBLC213.7 hybridoma house mouse CVCL_C5XY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792481 CVCL_C5XL BBLC107.5 hybridoma house mouse CVCL_C5XL CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792482 CVCL_C5XK BBLC44.1 hybridoma house mouse CVCL_C5XK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792483 CVCL_C5XN BBLC310.2 hybridoma house mouse CVCL_C5XN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792484 CVCL_C5XM BBLC259.11 hybridoma house mouse CVCL_C5XM CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792485 CVCL_C5XP BBLC326.4 hybridoma house mouse CVCL_C5XP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792486 CVCL_C5Y1 CBLC229.14 hybridoma house mouse CVCL_C5Y1 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792487 CVCL_C5Y0 CBLC221.4 hybridoma house mouse CVCL_C5Y0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792488 CVCL_C5XR BBLC508.17 hybridoma house mouse CVCL_C5XR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792489 CVCL_C5Y3 CBLC237.2 hybridoma house mouse CVCL_C5Y3 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792490 CVCL_C5XQ BBLC434.22 hybridoma house mouse CVCL_C5XQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792491 CVCL_C5Y2 CBLC235.7 hybridoma house mouse CVCL_C5Y2 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792492 CVCL_C5XD 38.4 hybridoma house mouse CVCL_C5XD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792493 CVCL_C5XC 3660.5 hybridoma house mouse CVCL_C5XC CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792494 CVCL_C5XF 748.4 hybridoma house mouse CVCL_C5XF CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792495 CVCL_C5XE 703.2 hybridoma house mouse CVCL_C5XE CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792496 CVCL_C5XH 83.5 hybridoma house mouse CVCL_C5XH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792497 CVCL_C5XG 749.1 hybridoma house mouse CVCL_C5XG CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792498 CVCL_C5XJ BBLC1.1 hybridoma house mouse CVCL_C5XJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792499 CVCL_C5XI 98.3 hybridoma house mouse CVCL_C5XI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792500 CVCL_C5ZB K7701 hybridoma house mouse CVCL_C5ZB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. 155792501 CVCL_C5ZA XA325.10 hybridoma house mouse CVCL_C5ZA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792502 CVCL_C5ZD HPS0582 induced pluripotent stem cell human CVCL_C5ZD CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 155792503 CVCL_C5ZC K8450B hybridoma house mouse CVCL_C5ZC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P37231; Human PPARG (isoform 2). 155792504 CVCL_C5YU PFH spontaneously immortalized cell line CVCL_C5YU CL:0000010 Derived from sampling site: Heart. Unspecified Characteristics: Optimal growth at 28-32 Celsius (DOI=10.1016/j.aquaculture.2022.738711); Virology: Susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2022.738711) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC073 155792505 CVCL_C5Z6 XA325.1 hybridoma house mouse CVCL_C5Z6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792506 CVCL_C5YT PFB spontaneously immortalized cell line CVCL_C5YT CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Optimal growth at 32 Celsius (DOI=10.1016/j.aquaculture.2022.738711); Virology: Susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2022.738711) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC072 155792507 CVCL_C5Z5 XA325.6 hybridoma house mouse CVCL_C5Z5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792508 CVCL_C5YW OCF [Pseudetroplus] spontaneously immortalized cell line CVCL_C5YW CL:0000010 Derived from sampling site: Fin. Unspecified Virology: Not susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2021.737589) Group: Fish cell line 155792509 CVCL_C5Z8 XA325.4 hybridoma house mouse CVCL_C5Z8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792510 CVCL_C5YV PFS spontaneously immortalized cell line CVCL_C5YV CL:0000010 Derived from sampling site: Spleen. Unspecified Characteristics: Optimal growth at 28-32 Celsius (DOI=10.1016/j.aquaculture.2022.738711); Virology: Highly susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2022.738711) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC074 155792511 CVCL_C5Z7 XA325.2 hybridoma house mouse CVCL_C5Z7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792512 CVCL_C5YY YK136 transformed cell line human CVCL_C5YY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P0A3R9; Streptomyces carzinostaticus neocarzinostatin (ncsA) 155792513 CVCL_C5YX CPSF spontaneously immortalized cell line CVCL_C5YX CL:0000010 Derived from sampling site: Fin. Unspecified Virology: Not susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2021.737589) Group: Endangered species/breed cell line; Group: Fish cell line 155792514 CVCL_C5Z9 XA325.7 hybridoma house mouse CVCL_C5Z9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. 155792515 CVCL_C5YZ YK136H15-56-16 hybridoma CVCL_C5YZ CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P0A3R9; Streptomyces carzinostaticus neocarzinostatin (ncsA). 155792516 CVCL_C5YM UNAMi001-A induced pluripotent stem cell human CVCL_C5YM CL:0000010 Population: Mexican; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155792517 CVCL_C5YL RPMI-3026 cancer cell line human CVCL_C5YL CL:0000010 Unspecified 155792518 CVCL_C5Z0 YK136HNT56 hybridoma CVCL_C5Z0 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P0A3R9; Streptomyces carzinostaticus neocarzinostatin (ncsA) 155792519 CVCL_C5YN MUi035-A induced pluripotent stem cell human CVCL_C5YN From: Mahidol University; Bangkok; Thailand. CL:0000010 155792520 CVCL_C5YQ DDaF-1 spontaneously immortalized cell line CVCL_C5YQ CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC068 155792521 CVCL_C5Z2 NCC-PS-C1 cancer cell line human CVCL_C5Z2 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Cys72Ter (c.216C>A); Zygosity=Unspecified (PubMed=36103079); Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg1873Cys (c.5617C>T); ClinVar=VCV000932356; Zygosity=Unspecified (PubMed=36103079); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=36103079) Population: Japanese; Derived from sampling site: Popliteal fossa; hypodermis. Omics: SNP array analysis Female Doubling time: 39 hours (PubMed=36103079) Part of: NCC sarcoma cell line panel 155792522 CVCL_C5YP BBdF-1 spontaneously immortalized cell line CVCL_C5YP CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Optimal growth at 28 Celsius (DOI=10.2478/cjf-2021-0002) Doubling time: 68 hours (DOI=10.2478/cjf-2021-0002) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC061 155792523 CVCL_C5Z1 NCC-PLPS2-C1 cancer cell line human CVCL_C5Z1 CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Unspecified (PubMed=36436139); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Glu44Gly (c.131A>G); ClinVar=VCV000041768; Zygosity=Unspecified (PubMed=36436139); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>A); ClinVar=VCV001453627; Zygosity=Unspecified (PubMed=36436139) Population: Japanese; Derived from sampling site: Foot; hypodermis. Omics: SNP array analysis Male Doubling time: 24 hours (PubMed=36436139) Part of: NCC sarcoma cell line panel 155792524 CVCL_C5YS CyCKG spontaneously immortalized cell line CVCL_C5YS CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC064 155792525 CVCL_C5Z4 SETDB-1(Z4606) hybridoma house mouse CVCL_C5Z4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q15047; Human SETDB1. 155792526 CVCL_C5YR LRoF-1 spontaneously immortalized cell line CVCL_C5YR CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC070 155792527 CVCL_C5Z3 SETDB-1(Z4601) hybridoma house mouse CVCL_C5Z3 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q15047; Human SETDB1. 155792528 CVCL_C5YE CBLC333.4 hybridoma house mouse CVCL_C5YE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792529 CVCL_C5YD CBLC323.5 hybridoma house mouse CVCL_C5YD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792530 CVCL_C5YG CBLC482.4 hybridoma house mouse CVCL_C5YG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792531 CVCL_C5YF CBLC334.4 hybridoma house mouse CVCL_C5YF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792532 CVCL_C5YI CBLC551.8 hybridoma house mouse CVCL_C5YI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792533 CVCL_C5YH CBLC490.2 hybridoma house mouse CVCL_C5YH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792534 CVCL_C5YK CBLC687 hybridoma house mouse CVCL_C5YK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792535 CVCL_C5YJ CBLC650 hybridoma house mouse CVCL_C5YJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:16703; (2->6)-beta-D-fructan (Levan). 155792536 CVCL_C4DI AH6 hybridoma house mouse CVCL_C4DI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792537 CVCL_C4DH AD3 [Mouse hybridoma against MDI] hybridoma house mouse CVCL_C4DH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792538 CVCL_C4DK CE2 hybridoma house mouse CVCL_C4DK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792539 CVCL_C4DJ BC8 [Mouse hybridoma against MDI] hybridoma house mouse CVCL_C4DJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792540 CVCL_C4DM DD10 hybridoma house mouse CVCL_C4DM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792541 CVCL_C4DL DA5 hybridoma house mouse CVCL_C4DL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:53218; Diphenylmethane-4,4'-diisocyanate (Methylene diphenyl diisocyanate; MDI). 155792542 CVCL_C4E0 402-10 hybridoma house mouse CVCL_C4E0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792543 CVCL_C4DN Dig 40-120 hybridoma house mouse CVCL_C4DN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792544 CVCL_C4DA 8H9 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4DA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792545 CVCL_C4DC CTN-16A3-13 hybridoma house mouse CVCL_C4DC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:39178; Clothianidin; Monoclonal antibody target: ChEBI; CHEBI:39183; Dinotefuran. 155792546 CVCL_C4DB 9D5 hybridoma house mouse CVCL_C4DB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792547 CVCL_C4DE KCA226 hybridoma house mouse CVCL_C4DE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:3680; Chrysanthemic acid. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-15051 155792548 CVCL_C4DD KCA190 hybridoma house mouse CVCL_C4DD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:3680; Chrysanthemic acid. 155792549 CVCL_C4DG 3D11 [Mouse hybridoma against ciguatoxin CTX3C] hybridoma house mouse CVCL_C4DG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:61277; Ciguatoxin CTX3C. 155792550 CVCL_C4DF 10C9 [Mouse hybridoma against ciguatoxin CTX3C] hybridoma house mouse CVCL_C4DF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:61277; Ciguatoxin CTX3C. 155792551 CVCL_C4CX 4F12 [Mouse hybridoma against human PLPPR1] hybridoma house mouse CVCL_C4CX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TBJ4; Human PLPPR1. 155792552 CVCL_C4D9 8B10 hybridoma house mouse CVCL_C4D9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792553 CVCL_C4CW 4F11 hybridoma house mouse CVCL_C4CW CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TBJ4; Human PLPPR1. 155792554 CVCL_C4D8 7D5 hybridoma house mouse CVCL_C4D8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792555 CVCL_C4CZ 10A6 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4CZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792556 CVCL_C4CY 4F8 [Mouse hybridoma against human PLPPR1] hybridoma house mouse CVCL_C4CY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TBJ4; Human PLPPR1. 155792557 CVCL_C4D1 2E8 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792558 CVCL_C4CP Sp2/0-Ag14-K13 cancer cell line house mouse CVCL_C4CP CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 155792559 CVCL_C4D0 10B8 hybridoma house mouse CVCL_C4D0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792560 CVCL_C4D3 3E6 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792561 CVCL_C4CR AGA-3 hybridoma house mouse CVCL_C4CR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:30853; Glycyrrhetinic acid. 155792562 CVCL_C4D2 3D3 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792563 CVCL_C4CQ AGA-1 hybridoma house mouse CVCL_C4CQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:30853; Glycyrrhetinic acid. 155792564 CVCL_C4CT 4G9-12B hybridoma house mouse CVCL_C4CT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:28857; (Z)-hex-3-en-1-ol (Cis-3-Hexen-1-ol). 155792565 CVCL_C4D5 5D11 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792566 CVCL_C4D4 4B2 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792567 CVCL_C4CS AGA-6 hybridoma house mouse CVCL_C4CS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:30853; Glycyrrhetinic acid. 155792568 CVCL_C4CV 4F1 hybridoma house mouse CVCL_C4CV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TBJ4; Human PLPPR1. 155792569 CVCL_C4D7 6C8 hybridoma house mouse CVCL_C4D7 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792570 CVCL_C4D6 6C6 [Mouse hybridoma against MTPS] hybridoma house mouse CVCL_C4D6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:85377; 8-methoxypyrene-1,3,6-trisulfonic acid (MTPS). 155792571 CVCL_C4CU PRG-3/293T-Rex transformed cell line human CVCL_C4CU CL:0000010 Transfected with: HGNC; 25993; PLPPR1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155792572 CVCL_C4EJ V45-271-10 hybridoma house mouse CVCL_C4EJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792573 CVCL_C4EI V45-187-15 hybridoma house mouse CVCL_C4EI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792574 CVCL_C4EL H9 AAVS1-TRE3G-NGN2 ATG12-/- embryonic stem cell human CVCL_C4EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 588; ATG12; Transfected with: HGNC; 13805; NEUROG2. Female Characteristics: Using CRISPR/Cas9 a TRE3G promoter driven NEUROG2 construct was introduced in the AAVS1 safe harbor locus (from parent cell line) 155792575 CVCL_C4EK H9 AAVS1-TRE3G-NGN2 embryonic stem cell human CVCL_C4EK CL:0000010 Transfected with: HGNC; 13805; NEUROG2. Female Characteristics: Using CRISPR/Cas9 a TRE3G promoter driven NEUROG2 construct was introduced in the AAVS1 safe harbor locus (PubMed=34699746) 155792576 CVCL_C4EN H9 AAVS1-TRE3G-NGN2 FBXO7-/- embryonic stem cell human CVCL_C4EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13586; FBXO7; Transfected with: HGNC; 13805; NEUROG2 Miscellaneous: Cell line information from personal communication of Paoli J.C. Female Characteristics: Using CRISPR/Cas9 a TRE3G promoter driven NEUROG2 construct was introduced in the AAVS1 safe harbor locus (from parent cell line) 155792577 CVCL_C4EM H9 AAVS1-TRE3G-NGN2 PINK1-/- embryonic stem cell human CVCL_C4EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Transfected with: HGNC; 13805; NEUROG2. Female Characteristics: Using CRISPR/Cas9 a TRE3G promoter driven NEUROG2 construct was introduced in the AAVS1 safe harbor locus (from parent cell line) 155792578 CVCL_C4F1 18G8 hybridoma house mouse CVCL_C4F1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792579 CVCL_C4EP H9 PINK1-/- induced pluripotent stem cell human CVCL_C4EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1. Female 155792580 CVCL_C4F0 14F10 hybridoma house mouse CVCL_C4F0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792581 CVCL_C4EB R45-620-40 hybridoma house mouse CVCL_C4EB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792582 CVCL_C4EA R45-45-11 hybridoma house mouse CVCL_C4EA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792583 CVCL_C4ED V14-203 hybridoma house mouse CVCL_C4ED CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792584 CVCL_C4EC R45-83-40 hybridoma house mouse CVCL_C4EC CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792585 CVCL_C4EF V14-343 hybridoma house mouse CVCL_C4EF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792586 CVCL_C4EE V14-306 hybridoma house mouse CVCL_C4EE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792587 CVCL_C4EH V45-180-56 hybridoma house mouse CVCL_C4EH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792588 CVCL_C4EG V14-54-20 hybridoma house mouse CVCL_C4EG CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792589 CVCL_C4DY 368-13 hybridoma house mouse CVCL_C4DY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792590 CVCL_C4DX 368-11 hybridoma house mouse CVCL_C4DX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792591 CVCL_C4E9 R45-269-2 hybridoma house mouse CVCL_C4E9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792592 CVCL_C4DZ 368-21 hybridoma house mouse CVCL_C4DZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 155792593 CVCL_C4DQ Dig 40-160 hybridoma house mouse CVCL_C4DQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792594 CVCL_C4E2 R14-212-6 hybridoma house mouse CVCL_C4E2 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792595 CVCL_C4E1 78-299-4 hybridoma house mouse CVCL_C4E1 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792596 CVCL_C4DP Dig 40-140 hybridoma house mouse CVCL_C4DP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792597 CVCL_C4DS Dig 40-150 hybridoma house mouse CVCL_C4DS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792598 CVCL_C4E4 R14-85-1 hybridoma house mouse CVCL_C4E4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792599 CVCL_C4DR Dig 40-40 hybridoma house mouse CVCL_C4DR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792600 CVCL_C4E3 R14-7-20 hybridoma house mouse CVCL_C4E3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792601 CVCL_C4DU Dig 40-150 A2.4 P.10 hybridoma house mouse CVCL_C4DU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792602 CVCL_C4E6 R45-180-7 hybridoma house mouse CVCL_C4E6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792603 CVCL_C4DT Dig 40-150 A2.4 hybridoma house mouse CVCL_C4DT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792604 CVCL_C4E5 R45-109-22 hybridoma house mouse CVCL_C4E5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792605 CVCL_C4DW Dig 26-10 LL2 hybridoma house mouse CVCL_C4DW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792606 CVCL_C4E8 R45-246-2 hybridoma house mouse CVCL_C4E8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792607 CVCL_C4DV Dig 26-10 LB4 hybridoma house mouse CVCL_C4DV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 155792608 CVCL_C4E7 R45-200-7 hybridoma house mouse CVCL_C4E7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). 155792609 CVCL_C4BG 5G9A10E3 hybridoma house mouse CVCL_C4BG CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P19429; Human TNNI3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201059 155792610 CVCL_C4BF CCTCC-C201126 hybridoma house mouse CVCL_C4BF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P62937; Human PPIA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201126 155792611 CVCL_C4BI Ac22 hybridoma house mouse CVCL_C4BI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792612 CVCL_C4BH Ac17 hybridoma house mouse CVCL_C4BH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792613 CVCL_C4BK Ac38 hybridoma house mouse CVCL_C4BK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792614 CVCL_C4BJ Ac146 hybridoma house mouse CVCL_C4BJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792615 CVCL_C4BM Ac76 hybridoma house mouse CVCL_C4BM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792616 CVCL_C4BL Ac106 hybridoma house mouse CVCL_C4BL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B1-8. 155792617 CVCL_C4BA 211F3 hybridoma house mouse CVCL_C4BA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48509; Human CD151. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3918 155792618 CVCL_C4BC SFA1.2B4 hybridoma house mouse CVCL_C4BC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P48509; Human CD151. 155792619 CVCL_C4BB 214B2 hybridoma house mouse CVCL_C4BB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48509; Human CD151. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3919 155792620 CVCL_C4BE 14A2.H1 hybridoma house mouse CVCL_C4BE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48509; Human CD151. 155792621 CVCL_C4BD NIH 3T3/pL2neoSRalphaIIISFA-1 spontaneously immortalized cell line house mouse CVCL_C4BD CL:0000010 Transfected with: HGNC; 1630; CD151; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 155792622 CVCL_C4B7 4G10 [Mouse hybridoma against T.mossambica IgM] hybridoma house mouse CVCL_C4B7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Tilapia mossambica IgM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201645 155792623 CVCL_C4AV CGMCC-3240 hybridoma house mouse CVCL_C4AV CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P27824; Human CANX. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.3240 155792624 CVCL_C4B6 2C6 [Mouse hybridoma against T.mossambica IgM] hybridoma house mouse CVCL_C4B6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Tilapia mossambica IgM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201644 155792625 CVCL_C4AU KU-Lu-7 hybridoma house mouse CVCL_C4AU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HC84; Human MUC5B. 155792626 CVCL_C4B9 205H8 hybridoma house mouse CVCL_C4B9 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P48509; Human CD151. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3921 155792627 CVCL_C4AX A2E8 hybridoma house mouse CVCL_C4AX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75874; Human IDH1 (Note=Recongizes p.Arg132His). Group: Patented cell line 155792628 CVCL_C4B8 203B6 hybridoma house mouse CVCL_C4B8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48509; Human CD151. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3920 155792629 CVCL_C4AW A11B3 hybridoma house mouse CVCL_C4AW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75874; Human IDH1 (Note=Recongizes p.Arg132His). Group: Patented cell line 155792630 CVCL_C4AZ 1H9 hybridoma house mouse CVCL_C4AZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:48775; Cadmium(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201521 155792631 CVCL_C4AY D4C7 hybridoma house mouse CVCL_C4AY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75874; Human IDH1 (Note=Recongizes p.Arg132His). Group: Patented cell line 155792632 CVCL_C4AN CCAbrain spontaneously immortalized cell line CVCL_C4AN CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Highly susceptible to infection by common carp paramyxovirus (CCPV) (PubMed=35934930); Virology: Highly susceptible to infection by cyprinid herpesvirus 3 (CyHV-3) Taiwan isolate (KHV-T) (PubMed=35934930); Virology: Not susceptible to infection by carp edema virus (CEV) (PubMed=35934930) Group: Fish cell line 155792633 CVCL_C4AM LC-2/ad-cis cancer cell line human CVCL_C4AM CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Female 155792634 CVCL_C4B1 7G11 hybridoma house mouse CVCL_C4B1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:64983; Alternariol. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201703 155792635 CVCL_C4AP CCAcar spontaneously immortalized cell line CVCL_C4AP CL:0000010 Derived from sampling site: Heart. Unspecified Virology: Highly susceptible to infection by common carp paramyxovirus (CCPV) (PubMed=35934930); Virology: Highly susceptible to infection by cyprinid herpesvirus 3 (CyHV-3) Taiwan isolate (KHV-T) (PubMed=35934930); Virology: Not susceptible to infection by carp edema virus (CEV) (PubMed=35934930) Group: Fish cell line 155792636 CVCL_C4B0 4F4 hybridoma house mouse CVCL_C4B0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:9440; Tenuazonic acid (TeA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201702 155792637 CVCL_C4B3 3E9 [Mouse hybridoma against DHAV VP3] hybridoma house mouse CVCL_C4B3 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; A4KYM2; Duck hepatitis A virus (strain HP-1) (DHAV) genome polyprotein (AA 257-493; VP3). 155792638 CVCL_C4AR LCN2 cancer cell line human CVCL_C4AR CL:0000010 Population: Japanese. Unspecified 155792639 CVCL_C4B2 3B7 [Mouse hybridoma against DHAV VP3] hybridoma house mouse CVCL_C4B2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A4KYM2; Duck hepatitis A virus (strain HP-1) (DHAV) genome polyprotein (AA 257-493; VP3). 155792640 CVCL_C4AQ CCAgill spontaneously immortalized cell line CVCL_C4AQ CL:0000010 Derived from sampling site: Gill. Unspecified Virology: Moderately susceptible to infection by common carp paramyxovirus (CCPV) (PubMed=35934930); Virology: Moderately susceptible to infection by cyprinid herpesvirus 3 (CyHV-3) Taiwan isolate (KHV-T) (PubMed=35934930); Virology: Not susceptible to infection by carp edema virus (CEV) (PubMed=35934930) Group: Fish cell line 155792641 CVCL_C4B5 DHAV-MAb1 hybridoma house mouse CVCL_C4B5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Duck hepatitis A virus type 1 and type 3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201701 155792642 CVCL_C4AT KU-Lu-8 hybridoma house mouse CVCL_C4AT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792643 CVCL_C4B4 4F8 [Mouse hybridoma against DHAV VP3] hybridoma house mouse CVCL_C4B4 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; A4KYM2; Duck hepatitis A virus (strain HP-1) (DHAV) genome polyprotein (AA 257-493; VP3). 155792644 CVCL_C4AS KU-Lu-6 hybridoma house mouse CVCL_C4AS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P35579; Human MYH9. 155792645 CVCL_C4CH PAF-R14 hybridoma house mouse CVCL_C4CH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P25105; Human PTAFR. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4723 155792646 CVCL_C4CG M35A hybridoma house mouse CVCL_C4CG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q13797; Human ITGA9. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10831 155792647 CVCL_C4CJ JS20/27 hybridoma house mouse CVCL_C4CJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49884; Bovine ESR1. 155792648 CVCL_C4CI YM-PAFR hybridoma house mouse CVCL_C4CI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P25105; Human PTAFR. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4722 155792649 CVCL_C4CL JS30/1 hybridoma house mouse CVCL_C4CL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P49884; Bovine ESR1. 155792650 CVCL_C4CK JS28/32 hybridoma house mouse CVCL_C4CK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49884; Bovine ESR1. 155792651 CVCL_C4CN JS3/35 hybridoma house mouse CVCL_C4CN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49884; Bovine ESR1. 155792652 CVCL_C4CM JS34/32 hybridoma house mouse CVCL_C4CM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P49884; Bovine ESR1. 155792653 CVCL_C4CB r#101 hybridoma CVCL_C4CB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147 (Note=Also reacts with Macaca fascicularis). 155792654 CVCL_C4CA 2P10F2 hybridoma CVCL_C4CA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792655 CVCL_C4CD r#131 hybridoma CVCL_C4CD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147 (Note=Also reacts with Macaca fascicularis). 155792656 CVCL_C4CC r#110 hybridoma CVCL_C4CC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147 (Note=Also reacts with Macaca fascicularis). 155792657 CVCL_C4CF K33N hybridoma house mouse CVCL_C4CF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q13797; Human ITGA9. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10830 155792658 CVCL_C4CE r#84 hybridoma CVCL_C4CE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147 (Note=Also reacts with Macaca fascicularis). 155792659 CVCL_C4C8 2P2D10 hybridoma CVCL_C4C8 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792660 CVCL_C4BW S1F2 hybridoma house mouse CVCL_C4BW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792661 CVCL_C4C7 2P2D7 hybridoma CVCL_C4C7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792662 CVCL_C4BV N1G9 hybridoma house mouse CVCL_C4BV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792663 CVCL_C4BY S2D8 hybridoma house mouse CVCL_C4BY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792664 CVCL_C4C9 2P8C12 hybridoma CVCL_C4C9 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792665 CVCL_C4BX S1F12 hybridoma house mouse CVCL_C4BX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792666 CVCL_C4BZ S2E9 hybridoma house mouse CVCL_C4BZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792667 CVCL_C4C0 S2G7 hybridoma house mouse CVCL_C4C0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792668 CVCL_C4BN B1-8 hybridoma house mouse CVCL_C4BN CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792669 CVCL_C4BQ B1-48 hybridoma house mouse CVCL_C4BQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792670 CVCL_C4C2 LN22R8 hybridoma house mouse CVCL_C4C2 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792671 CVCL_C4BP B1-46 hybridoma house mouse CVCL_C4BP CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792672 CVCL_C4C1 S2H5 hybridoma house mouse CVCL_C4C1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792673 CVCL_C4C4 2P1B7 hybridoma CVCL_C4C4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792674 CVCL_C4BS B53-8 hybridoma house mouse CVCL_C4BS CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792675 CVCL_C4C3 2P1A6 hybridoma CVCL_C4C3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792676 CVCL_C4BR B1-52 hybridoma house mouse CVCL_C4BR CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792677 CVCL_C4C6 2P3G8 hybridoma CVCL_C4C6 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792678 CVCL_C4BU N1C12 hybridoma house mouse CVCL_C4BU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792679 CVCL_C4C5 2P2D6 hybridoma CVCL_C4C5 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 155792680 CVCL_C4BT B53-12 hybridoma house mouse CVCL_C4BT CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 155792681 CVCL_C4AF 6B8D11H12 hybridoma house mouse CVCL_C4AF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Fibrin D-dimer. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201060 155792682 CVCL_C4AE 6B9 [Mouse hybridoma against fibrin D-dimer] hybridoma house mouse CVCL_C4AE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts strongly with fibrinogen). 155792683 CVCL_C4AH KU-Lad-001 hybridoma house mouse CVCL_C4AH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27824; Human CANX. 155792684 CVCL_C4AG KU-Lu-5 hybridoma house mouse CVCL_C4AG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O43570; Human CA12. 155792685 CVCL_C4AJ KU-Lu-1 hybridoma house mouse CVCL_C4AJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q07065; Human CKAP4. 155792686 CVCL_C4AI LCN1 cancer cell line human CVCL_C4AI CL:0000010 Population: Japanese. Unspecified 155792687 CVCL_C4AL LCN1-cis cancer cell line human CVCL_C4AL CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Unspecified 155792688 CVCL_C4AK KU-Lu-3 hybridoma house mouse CVCL_C4AK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P63244; Human RACK1. 155792689 CVCL_C4AB 2F2 [Mouse hybridoma against fibrin D-dimer] hybridoma house mouse CVCL_C4AB CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts strongly with fibrinogen). 155792690 CVCL_C4AA 2B9 hybridoma house mouse CVCL_C4AA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer. 155792691 CVCL_C4AD 4G8 [Mouse hybridoma against fibrin D-dimer] hybridoma house mouse CVCL_C4AD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts weakly with fibrinogen). 155792692 CVCL_C4AC 3B3 [Mouse hybridoma against fibrin D-dimer] hybridoma house mouse CVCL_C4AC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts strongly with fibrinogen). 155792693 CVCL_C4A6 SC34.95 hybridoma house mouse CVCL_C4A6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792694 CVCL_C4A5 SC34.94 hybridoma house mouse CVCL_C4A5 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792695 CVCL_C4A8 1B4 [Mouse hybridoma against fibrin D-dimer] hybridoma house mouse CVCL_C4A8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts strongly with fibrinogen). 155792696 CVCL_C4A7 SC34.96 hybridoma house mouse CVCL_C4A7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792697 CVCL_C4A9 1H12 hybridoma house mouse CVCL_C4A9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Fibrin D-dimer (Note=Also reacts strongly with fibrinogen). 155792698 CVCL_C4A0 SC34.88 hybridoma house mouse CVCL_C4A0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792699 CVCL_C4A2 SC34.90 hybridoma house mouse CVCL_C4A2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792700 CVCL_C4A1 SC34.89 hybridoma house mouse CVCL_C4A1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792701 CVCL_C4A4 SC34.92 hybridoma house mouse CVCL_C4A4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792702 CVCL_C4A3 SC34.91 hybridoma house mouse CVCL_C4A3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155792703 CVCL_C4LQ 480CT5.4.3 hybridoma house mouse CVCL_C4LQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18827; Human SDC1/CD138. 155792704 CVCL_C4M2 WEHI-231-bcl-XL clone 69 cancer cell line house mouse CVCL_C4M2 CL:0000010 Transfected with: MGI; MGI:88139; Bcl2l1 (isoform Bcl-XL with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: BALB/c x NZB. Doubling time: 13.4 +- 2.1 hours (PubMed=7561089) 155792705 CVCL_C4M1 WEHI-231-bcl-XL clone 3 cancer cell line house mouse CVCL_C4M1 CL:0000010 Transfected with: MGI; MGI:88139; Bcl2l1 (isoform Bcl-XL with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: BALB/c x NZB. Doubling time: 14.6 +- 1.2 hours (PubMed=7561089) 155792706 CVCL_C4LS AKL3H6 hybridoma house mouse CVCL_C4LS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61930; N(6)-acetyl-L-lysine residue. 155792707 CVCL_C4M4 eCG 50.4 transformed cell line CVCL_C4M4 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792708 CVCL_C4LR 587CT7.3.6.5 hybridoma house mouse CVCL_C4LR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18827; Human SDC1/CD138. 155792709 CVCL_C4M3 eCG 50.1 transformed cell line CVCL_C4M3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792710 CVCL_C4LU AL11 hybridoma house mouse CVCL_C4LU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61930; N(6)-acetyl-L-lysine residue. 155792711 CVCL_C4M6 eCG 50.8 transformed cell line CVCL_C4M6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792712 CVCL_C4LT AKL5C1 hybridoma house mouse CVCL_C4LT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61930; N(6)-acetyl-L-lysine residue. 155792713 CVCL_C4M5 eCG 50.7 transformed cell line CVCL_C4M5 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792714 CVCL_C4M8 eCG 100.2 transformed cell line CVCL_C4M8 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792715 CVCL_C4LW MZ2861SVNN transformed cell line human CVCL_C4LW CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 155792716 CVCL_C4LV AL3D5 hybridoma house mouse CVCL_C4LV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61930; N(6)-acetyl-L-lysine residue. 155792717 CVCL_C4M7 eCG 50.9 transformed cell line CVCL_C4M7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 155792718 CVCL_C4LI S5C8 transformed cell line house mouse CVCL_C4LI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792719 CVCL_C4LH S5C7 transformed cell line house mouse CVCL_C4LH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792720 CVCL_C4LK S5C11 transformed cell line house mouse CVCL_C4LK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792721 CVCL_C4LJ S5C10 transformed cell line house mouse CVCL_C4LJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792722 CVCL_C4LM GMSM-K4.2 transformed cell line human CVCL_C4LM CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal oral cavity; mouth; labial vestibule Cell type=Keratinocyte.. Male Doubling time: ~38 hours (PubMed=10982956) 155792723 CVCL_C4LL GMSM-K4.1 transformed cell line human CVCL_C4LL CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal oral cavity; mouth; labial vestibule Cell type=Keratinocyte.. Male Doubling time: ~55 hours (PubMed=10982956) 155792724 CVCL_C4M0 WEHI-231-bcl-XL clone 18 cancer cell line house mouse CVCL_C4M0 CL:0000010 Transfected with: MGI; MGI:88139; Bcl2l1 (isoform Bcl-XL with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: BALB/c x NZB. Doubling time: 13.3 +- 2.2 hours (PubMed=7561089) 155792725 CVCL_C4LN LIV27 cancer cell line human CVCL_C4LN CL:0000010 Population: Caucasian; Derived from sampling site: Liver. Female Characteristics: Established from a nude mouse xenograft; Characteristics: Highly tumorigenic Doubling time: 57.8 hours, at 14th passage (PubMed=36291862) 155792726 CVCL_C4LA C3H10T1/2 myogenin-#1 spontaneously immortalized cell line house mouse CVCL_C4LA CL:0000010 Transfected with: RGD; 620432; Myog; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 155792727 CVCL_C4LC O5 hybridoma house mouse CVCL_C4LC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q63258; Rat Itga7. 155792728 CVCL_C4LB O26 hybridoma house mouse CVCL_C4LB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q63258; Rat Itga7. 155792729 CVCL_C4LE S5C1 transformed cell line house mouse CVCL_C4LE CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792730 CVCL_C4LD O14-1 hybridoma house mouse CVCL_C4LD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P49134; Rat Itgb1/Cd29. 155792731 CVCL_C4LG S5C4 transformed cell line house mouse CVCL_C4LG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified Doubling time: ~40 hours (PubMed=9870527) 155792732 CVCL_C4LF S5C3 transformed cell line house mouse CVCL_C4LF CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A 12S; Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: CD-1. Unspecified 155792733 CVCL_C4L9 C3H10T1/2 MyoD1-#8 spontaneously immortalized cell line house mouse CVCL_C4L9 CL:0000010 Transfected with: RGD; 631429; Myod1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 155792734 CVCL_C4KX L8 fu-5 spontaneously immortalized cell line Norway rat CVCL_C4KX CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570) Doubling time: 14.0 hours (in 10% serum), 18.8 hours (in 1% serum) (PubMed=6243570) 155792735 CVCL_C4L8 C3H10T1/2 MRF4-#7 spontaneously immortalized cell line house mouse CVCL_C4L8 CL:0000010 Transfected with: RGD; 3134; Myf6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 155792736 CVCL_C4KW L8 fu-4 spontaneously immortalized cell line Norway rat CVCL_C4KW CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 17.9 hours (in 10% serum), 21.9 hours (in 1% serum) (PubMed=6243570) 155792737 CVCL_C4KZ L8 fu-7 spontaneously immortalized cell line Norway rat CVCL_C4KZ CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 16.0 hours (in 10% serum), 18.8 hours (in 1% serum) (PubMed=6243570) 155792738 CVCL_C4KY L8 fu-6 spontaneously immortalized cell line Norway rat CVCL_C4KY CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 30.5 hours (in 10% serum), 71.3 hours (in 1% serum) (PubMed=6243570) 155792739 CVCL_C4N3 DO-m cancer cell line human CVCL_C4N3 CL:0000010 Derived from metastatic site: Ascites. Female 155792740 CVCL_C4MR RBL-hEIalpha-2B12 cancer cell line Norway rat CVCL_C4MR CL:0000010 Transfected with: HGNC; 3609; FCER1A Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. 155792741 CVCL_C4N2 iHGPINc transformed cell line human CVCL_C4N2 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Population: African American; Transformant: Human papillomavirus type 18 (HPV18) [pSHVPV-18m](NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 155792742 CVCL_C4MQ RBL-30/25 cancer cell line Norway rat CVCL_C4MQ CL:0000010 Transfected with: HGNC; 3609; FCER1A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. 155792743 CVCL_C4MT CxTr spontaneously immortalized cell line CVCL_C4MT CL:0000010 Unspecified Virology: Susceptible to infection by Japanese encephalitis virus (JEV), Mayaro virus, Rift Valley fever phlebovirus (RVFV) and Vesicular stomatitis virus (VSV) (PubMed=36260075) Doubling time: 2.2-2.5 days (PubMed=36260075). Group: Insect cell line 155792744 CVCL_C4N5 NT-18LM cancer cell line human CVCL_C4N5 CL:0000010 Sequence variation: Mutation; HGNC; 2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546) Derived from metastatic site: Liver. Male Doubling time: 6.35 days (PubMed=36269546) 155792745 CVCL_C4N4 SCVIi068-A induced pluripotent stem cell human CVCL_C4N4 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Arg31606Ter (c.94816C>T); ClinVar=VCV000404748; Zygosity=Heterozygous (PubMed=36270069) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 155792746 CVCL_C4MS WAe007-A-2 embryonic stem cell human CVCL_C4MS From: Institute for Cardiovascular Science of Soochow University; Suzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20869; BMP10. Female 155792747 CVCL_C4MV F1G-red spontaneously immortalized cell line green monkey CVCL_C4MV CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Kidney; epithelium. Female Characteristics: Transduced with a fluorescent reporter (F1G) which is a construct that contains the substrate of the nsp5 protease (SAVLQSGF) between a NLS-eGFP and a membrane anchor Thus GFP, upon cleavage of the nsp5 protease site by the SARS-CoV-2 main protease, re-localizes from the cytoplasm in non-infected cells to the nucleus in infected cells (PubMed=36246297).; Characteristics: Also transduced with a red fluorescent mCherry-NLS construct Thus SARS-CoV-2 infection can be scored automatically in living cells by comparing the patterns of green and red fluorescence signals (PubMed=36246297). Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 155792748 CVCL_C4N7 NT-36 cancer cell line human CVCL_C4N7 CL:0000010 Sequence variation: Mutation; HGNC; 2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 9816; RAD50; Simple; p.Glu723Glyfs*5 (c.2165dupA); ClinVar=VCV000141045; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546) Derived from sampling site: Pancreas. Male Doubling time: 7.09 days (PubMed=36269546) 155792749 CVCL_C4MU F1G spontaneously immortalized cell line green monkey CVCL_C4MU CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Kidney; epithelium. Female Characteristics: Transduced with a fluorescent reporter (F1G) which is a construct that contains the substrate of the nsp5 protease (SAVLQSGF) between a NLS-eGFP and a membrane anchor Thus GFP, upon cleavage of the nsp5 protease site by the SARS-CoV-2 main protease, re-localizes from the cytoplasm in non-infected cells to the nucleus in infected cells (PubMed=36246297). Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 155792750 CVCL_C4N6 NT-18P cancer cell line human CVCL_C4N6 CL:0000010 Sequence variation: Mutation; HGNC; 2681; DAXX; Simple; p.Cys629Leufs*29 (c.1884dupC); Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg29Ter (c.85C>T); ClinVar=VCV000200970; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 11633; TCF3; Simple; p.Lys101Arg (c.302A>G); ClinVar=VCV000810990; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; TP53 p.Arg158Ser (c.472C>A); ClinVar=VCV001067910; Zygosity=Unspecified (PubMed=36269546) Derived from sampling site: Pancreas. Male Doubling time: 4.64 days (PubMed=36269546) 155792751 CVCL_C4MX 4B5 hybridoma CVCL_C4MX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P09405; Mouse Ncl. 155792752 CVCL_C4N9 NT-38 cancer cell line human CVCL_C4N9 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1346Ter (c.4037C>A); Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser259Phe (c.776C>T); ClinVar=VCV000040603; Zygosity=Unspecified (PubMed=36269546) Derived from sampling site: Small intestine; duodenum. Female Doubling time: 5.21 days (PubMed=36269546) 155792753 CVCL_C4MW NCC-MRT1-C1 cancer cell line human CVCL_C4MW CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=35927606) Population: Japanese; Derived from sampling site: Left thigh; hypodermis. Omics: SNP array analysis Female Doubling time: 30 hours (PubMed=35927606) Part of: NCC sarcoma cell line panel 155792754 CVCL_C4N8 NT-32 cancer cell line human CVCL_C4N8 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asn486_Pro490del (c.1457_1471del); ClinVar=VCV000666267; Zygosity=Unspecified (PubMed=36269546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=36269546) Derived from sampling site: Pancreas. Female Doubling time: 5.35 days (PubMed=36269546) 155792755 CVCL_C4MJ 059-1.82.1 hybridoma house mouse CVCL_C4MJ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792756 CVCL_C4MI 059-1.51.2 hybridoma house mouse CVCL_C4MI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792757 CVCL_C4ML HpSV Cl1 transformed cell line Norway rat CVCL_C4ML CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Unspecified 155792758 CVCL_C4MK LT012 hybridoma house mouse CVCL_C4MK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018135 155792759 CVCL_C4MN LL1 hybridoma house mouse CVCL_C4MN CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized milatuzumab (hLL1; MEDI-115) therapeutic antibody used for the treatment of multiple myeloma, non-Hodgkin's lymphoma and chronic lymphocytic leukemia When conjugated with doxorubicin, milatuzumab is known as IMMU-110 (hLL1-Dox) and is used for the treatment of relapsed multiple myeloma. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04233; Human CD74. 155792760 CVCL_C4MM LL2 hybridoma house mouse CVCL_C4MM CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma when labelled with the radioactive isotope technetium-99m is known as bectumomab (LymphoScan) and is used to detect non-Hodgkin's lymphoma Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P20273; Human CD22. 155792761 CVCL_C4N1 HV65 transformed cell line human CVCL_C4N1 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient who underwent enucleation surgery for the treatment of choroidal tumour; Derived from sampling site: Eye; vitreous body. Male Senescence: Not immortalized (PubMed=19878119); Doubling time: 76 +- 5 hours (PubMed=19878119) 155792762 CVCL_C4MP RBL SX-38 cancer cell line Norway rat CVCL_C4MP CL:0000010 Transfected with: HGNC; 3609; FCER1A; Transfected with: HGNC; 7316; MS4A2; Transfected with: HGNC; 3611; FCER1G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. Biotechnology: Can be used in human allergy assays Because it expresses human Fc-epsilon RI, following sensitization with IgE from a subset of allergic donors, these cells can be triggered by exposure to anti-IgE or to very low concentrations of specific allergen. 155792763 CVCL_C4N0 HV64 transformed cell line human CVCL_C4N0 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient who underwent evisceration surgery for the treatment of neovascular glaucoma; Derived from sampling site: Eye; vitreous body. Female Senescence: Not immortalized (PubMed=19878119); Doubling time: 58 +- 2 hours (PubMed=19878119) 155792764 CVCL_C4MB RLC [Rat liver] spontaneously immortalized cell line Norway rat CVCL_C4MB CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Wistar. Male Doubling time: 2 days (in monolayer culture), 4 days (in suspension culture) (PubMed=4394388) 155792765 CVCL_C4MA T47D/XBP1 cancer cell line human CVCL_C4MA CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12801; XBP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Pleural effusion. Female 155792766 CVCL_C4MD 059-1.100.5 hybridoma house mouse CVCL_C4MD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792767 CVCL_C4MC AC-10 transformed cell line Norway rat CVCL_C4MC CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: ~24 hours (in the presence of 20 ng/ml FGF2), ~48 hours (without FGF2) (PubMed=9426306) 155792768 CVCL_C4MF 059-1.20.1 hybridoma house mouse CVCL_C4MF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792769 CVCL_C4ME 059-1.11.1 hybridoma house mouse CVCL_C4ME CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792770 CVCL_C4MH 059-1.43.1 hybridoma house mouse CVCL_C4MH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792771 CVCL_C4MG 059-1.30.1 hybridoma house mouse CVCL_C4MG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. 155792772 CVCL_C4LY FL5.12 Bcl-XL factor-dependent cell line house mouse CVCL_C4LY CL:0000010 Transfected with: MGI; MGI:88139; Bcl2l1 (isoform Bcl-XL with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Embryonic liver Cell type=Pro-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent (from parent cell line) 155792773 CVCL_C4M9 MCF-7(DOX/R) cancer cell line human CVCL_C4M9 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female 155792774 CVCL_C4LX MZ2858SVNN transformed cell line human CVCL_C4LX CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 155792775 CVCL_C4LZ WEHI-231-Neo cancer cell line house mouse CVCL_C4LZ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: BALB/c x NZB. Characteristics: Control cell line for the WEHI-231-bcl-XL cell lines Doubling time: 15.1 +- 0.7 hours (PubMed=7561089) 155792776 CVCL_C4K0 7G12 hybridoma house mouse CVCL_C4K0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P62937; Human PPIA. 155792777 CVCL_C4JN 6E11 [Mouse hybridoma against chicken CCL5] hybridoma house mouse CVCL_C4JN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792778 CVCL_C4JQ 14B1 hybridoma house mouse CVCL_C4JQ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792779 CVCL_C4K2 8H11 [Mouse hybridoma against chicken CCL5] hybridoma house mouse CVCL_C4K2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792780 CVCL_C4JP 13C9 hybridoma house mouse CVCL_C4JP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792781 CVCL_C4K1 6H1 [Mouse hybridoma against chicken CCL5] hybridoma house mouse CVCL_C4K1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792782 CVCL_C4K4 13D1 hybridoma house mouse CVCL_C4K4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792783 CVCL_C4JS 2A6 [Mouse hybridoma against chicken IL7R] hybridoma house mouse CVCL_C4JS CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792784 CVCL_C4K3 11G1 hybridoma house mouse CVCL_C4K3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792785 CVCL_C4JR 1G5 [Mouse hybridoma against chicken IL7R] hybridoma house mouse CVCL_C4JR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792786 CVCL_C4JU 9A8 hybridoma house mouse CVCL_C4JU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792787 CVCL_C4K6 SV-C3H-V4 transformed cell line house mouse CVCL_C4K6 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/He. Unspecified Characteristics: Weakly oncogenic Produced after 4 consecutive passages of the parent cell line through irradiated syngeneic recipients. 155792788 CVCL_C4JT 3B8 [Mouse hybridoma against chicken IL7R] hybridoma house mouse CVCL_C4JT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; A1EA95; Chicken IL7R/CD127. 155792789 CVCL_C4K5 SV-C3H transformed cell line house mouse CVCL_C4K5 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/He. Unspecified 155792790 CVCL_C4JG IxN/A6 transformed cell line house mouse CVCL_C4JG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. 155792791 CVCL_C4JF SKN [Human T-cell] transformed cell line human CVCL_C4JF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Contains an EBV genome in an episomal form (PubMed=8608235) 155792792 CVCL_C4JI 1B7 hybridoma house mouse CVCL_C4JI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q3C0R7; Chicken IL7. 155792793 CVCL_C4JH 10H3 hybridoma house mouse CVCL_C4JH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q3C0R7; Chicken IL7. 155792794 CVCL_C4JK 3D3 [Mouse hybridoma against chicken IL7] hybridoma house mouse CVCL_C4JK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q3C0R7; Chicken IL7. 155792795 CVCL_C4JJ 1H6 [Mouse hybridoma against chicken IL7] hybridoma house mouse CVCL_C4JJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q3C0R7; Chicken IL7. 155792796 CVCL_C4JM 13G3 hybridoma house mouse CVCL_C4JM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8QG57; Chicken CCL5. 155792797 CVCL_C4JL 4F12 [Mouse hybridoma against chicken IL7] hybridoma house mouse CVCL_C4JL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q3C0R7; Chicken IL7. 155792798 CVCL_C4JA SKOV3.ip1 PEA-15-DD cancer cell line human CVCL_C4JA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8822; PEA15 (with p.Ser104Asp and p.Ser116Asp and a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 155792799 CVCL_C4JC R118 hybridoma CVCL_C4JC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q96D31; Human ORAI1. 155792800 CVCL_C4JB SKOV3.ip1 PEA-15-WT cancer cell line human CVCL_C4JB CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8822; PEA15 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 155792801 CVCL_C4JE SIS transformed cell line human CVCL_C4JE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Contains an EBV genome in an episomal form (PubMed=8608235) 155792802 CVCL_C4JD R198 [Rat hybridoma against human ORAI1] hybridoma CVCL_C4JD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q96D31; Human ORAI1. 155792803 CVCL_C4J7 HAP1 PFN1 (-) 4 cancer cell line human CVCL_C4J7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8881; PFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155792804 CVCL_C4IV SC17.122 hybridoma house mouse CVCL_C4IV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792805 CVCL_C4J6 HAP1 PFN1 (-) 3 cancer cell line human CVCL_C4J6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8881; PFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155792806 CVCL_C4IU SC17.121 hybridoma house mouse CVCL_C4IU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792807 CVCL_C4IX SC17.151 hybridoma house mouse CVCL_C4IX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792808 CVCL_C4J9 SKOV3.ip1 PEA-15-AA cancer cell line human CVCL_C4J9 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8822; PEA15 (with p.Ser104Ala and p.Ser116Ala and a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 155792809 CVCL_C4J8 HAP1 PFN1 (-) 5 cancer cell line human CVCL_C4J8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8881; PFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 155792810 CVCL_C4IW SC17.140 hybridoma house mouse CVCL_C4IW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792811 CVCL_C4IZ SC17.161 hybridoma house mouse CVCL_C4IZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792812 CVCL_C4IY SC17.156 hybridoma house mouse CVCL_C4IY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792813 CVCL_C4KP L55-81 transformed cell line human CVCL_C4KP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from melanoma; Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2 155792814 CVCL_C4L1 L8 fu-9 spontaneously immortalized cell line Norway rat CVCL_C4L1 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 17.0 hours (in 10% serum), 26.0 hours (in 1% serum) (PubMed=6243570) 155792815 CVCL_C4L0 L8 fu-8 spontaneously immortalized cell line Norway rat CVCL_C4L0 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 22.8 hours (in 10% serum), 34.4 hours (in 1% serum) (PubMed=6243570) 155792816 CVCL_C4L3 L8 fu-14 spontaneously immortalized cell line Norway rat CVCL_C4L3 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 22.2 hours (in 10% serum), 79.8 hours (in 1% serum) (PubMed=6243570) 155792817 CVCL_C4KR TVBF-7 cancer cell line human CVCL_C4KR CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln247Ter (c.739C>T); ClinVar=VCV000827018; Zygosity=Unspecified (PubMed=35563746) Derived from metastatic site: Lymph node. Omics: Genome sequenced Male 155792818 CVCL_C4KQ 6B5 hybridoma house mouse CVCL_C4KQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:8058; Phencyclidine (PCP). 155792819 CVCL_C4L2 L8 fu-13 spontaneously immortalized cell line Norway rat CVCL_C4L2 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 30.4 hours (in 10% serum), 38.0 hours (in 1% serum) (PubMed=6243570) 155792820 CVCL_C4KT L8 fu-1 spontaneously immortalized cell line Norway rat CVCL_C4KT CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=269441); Virology: Expresses a C-type rat retrovirus (PubMed=269441; PubMed=6243570) Doubling time: 14.8 +- 1.2 hours (in 10% serum), 16.6 +- 2.0 hours (in 1% serum) (PubMed=269441) 155792821 CVCL_C4L5 L8 fu-16 spontaneously immortalized cell line Norway rat CVCL_C4L5 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570) Doubling time: 23.9 hours (in 10% serum), 30.0 hours (in 1% serum) (PubMed=6243570) 155792822 CVCL_C4KS alpha T2 line 4 transformed cell line house mouse CVCL_C4KS CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 155792823 CVCL_C4L4 L8 fu-15 spontaneously immortalized cell line Norway rat CVCL_C4L4 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 19.7 hours (in 10% serum), 29.4 hours (in 1% serum) (PubMed=6243570) 155792824 CVCL_C4L7 H36 [Mouse hybridoma against rat Itga7] hybridoma house mouse CVCL_C4L7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q63258; Rat Itga7. 155792825 CVCL_C4KV L8 fu-3 spontaneously immortalized cell line Norway rat CVCL_C4KV CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 14.5 hours (in 10% serum), 22.3 hours (in 1% serum) (PubMed=6243570) 155792826 CVCL_C4L6 BBEC-SV transformed cell line CVCL_C4L6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.. Unspecified 155792827 CVCL_C4KU L8 fu-2 spontaneously immortalized cell line Norway rat CVCL_C4KU CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified Characteristics: Non-fusing variant (PubMed=6243570); Virology: Expresses a C-type rat retrovirus (PubMed=6243570) Doubling time: 14.5 hours (in 10% serum), 18.9 hours (in 1% serum) (PubMed=6243570) 155792828 CVCL_C4KH UE1 spontaneously immortalized cell line house mouse CVCL_C4KH CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155792829 CVCL_C4KG MUC-1 cancer cell line human CVCL_C4KG CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Glufs*3 (c.1024delC); ClinVar=VCV000428885; Zygosity=Unspecified (PubMed=27764813) Derived from metastatic site: Neck; hypodermis. Omics: Genome sequenced Male Characteristics: Established from a patient-derived xenograft also called MUC-1 155792830 CVCL_C4KJ UE9 spontaneously immortalized cell line house mouse CVCL_C4KJ CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155792831 CVCL_C4KI UE2 spontaneously immortalized cell line house mouse CVCL_C4KI CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155792832 CVCL_C4KL UM10 spontaneously immortalized cell line house mouse CVCL_C4KL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155792833 CVCL_C4KK UM3 spontaneously immortalized cell line house mouse CVCL_C4KK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 155792834 CVCL_C4KN L72 transformed cell line human CVCL_C4KN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from melanoma; Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2 155792835 CVCL_C4KM L55 transformed cell line human CVCL_C4KM CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from melanoma; Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2 155792836 CVCL_C4KB SV-C3H-V5B transformed cell line house mouse CVCL_C4KB CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/He. Unspecified 155792837 CVCL_C4KA PS-SW transformed cell line house mouse CVCL_C4KA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen; Breed/subspecies: C3H/He. Male 155792838 CVCL_C4KD SV-COL transformed cell line house mouse CVCL_C4KD CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: C3H.OL. Unspecified 155792839 CVCL_C4KC SV-C3H-V6 transformed cell line house mouse CVCL_C4KC CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/He. Unspecified Characteristics: Derived by culturing cells from a growing SV-C3H-V5 tumor 14 days after inoculation (PubMed=2991384) 155792840 CVCL_C4KF SV-COL-F5 transformed cell line house mouse CVCL_C4KF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: C3H.OL. Unspecified 155792841 CVCL_C4KE SV-COL-E8 transformed cell line house mouse CVCL_C4KE CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: C3H.OL. Unspecified 155792842 CVCL_C4JW 14F8 hybridoma house mouse CVCL_C4JW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D8UWD9; Chicken CSF1. 155792843 CVCL_C4K8 SV-C3H-V5 transformed cell line house mouse CVCL_C4K8 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/He. Unspecified Characteristics: Highly oncogenic Produced after a passage of the parent cell line through irradiated syngeneic recipients. 155792844 CVCL_C4JV 12B2 hybridoma house mouse CVCL_C4JV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D8UWD9; Chicken CSF1. 155792845 CVCL_C4K7 SV-SW transformed cell line house mouse CVCL_C4K7 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H.SW/SnJ. Unspecified 155792846 CVCL_C4JY 1G4 [Mouse hybridoma against chicken CSF1] hybridoma house mouse CVCL_C4JY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D8UWD9; Chicken CSF1. 155792847 CVCL_C4JX 14H9 hybridoma house mouse CVCL_C4JX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D8UWD9; Chicken CSF1. 155792848 CVCL_C4K9 PS-C3H transformed cell line house mouse CVCL_C4K9 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen; Breed/subspecies: C3H.SW/SnJ. Male 155792849 CVCL_C4JZ 8A12 [Mouse hybridoma against chicken CSF1] hybridoma house mouse CVCL_C4JZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D8UWD9; Chicken CSF1. 155792850 CVCL_C4HM SC17.34 hybridoma house mouse CVCL_C4HM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792851 CVCL_C4HL SC17.32 hybridoma house mouse CVCL_C4HL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792852 CVCL_C4I0 SC17.53 hybridoma house mouse CVCL_C4I0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792853 CVCL_C4HN SC17.35 hybridoma house mouse CVCL_C4HN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792854 CVCL_C4HQ SC17.38 hybridoma house mouse CVCL_C4HQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792855 CVCL_C4I2 SC17.56 hybridoma house mouse CVCL_C4I2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792856 CVCL_C4HP SC17.36 hybridoma house mouse CVCL_C4HP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792857 CVCL_C4I1 SC17.54 hybridoma house mouse CVCL_C4I1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792858 CVCL_C4HS SC17.40 hybridoma house mouse CVCL_C4HS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792859 CVCL_C4I4 SC17.59 hybridoma house mouse CVCL_C4I4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792860 CVCL_C4HR SC17.39 hybridoma house mouse CVCL_C4HR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792861 CVCL_C4I3 SC17.57 hybridoma house mouse CVCL_C4I3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792862 CVCL_C4HE SC17.19 hybridoma house mouse CVCL_C4HE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792863 CVCL_C4HD SC17.18 hybridoma house mouse CVCL_C4HD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792864 CVCL_C4HG SC17.24 hybridoma house mouse CVCL_C4HG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792865 CVCL_C4HF SC17.22 hybridoma house mouse CVCL_C4HF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792866 CVCL_C4HI SC17.28 hybridoma house mouse CVCL_C4HI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792867 CVCL_C4HH SC17.27 hybridoma house mouse CVCL_C4HH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792868 CVCL_C4HK SC17.30 hybridoma house mouse CVCL_C4HK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792869 CVCL_C4HJ SC17.29 hybridoma house mouse CVCL_C4HJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792870 CVCL_C4HA SC17.15 hybridoma house mouse CVCL_C4HA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792871 CVCL_C4HC SC17.17 hybridoma house mouse CVCL_C4HC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792872 CVCL_C4HB SC17.16 hybridoma house mouse CVCL_C4HB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792873 CVCL_C4GT SC10.129 hybridoma house mouse CVCL_C4GT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792874 CVCL_C4H5 SC17.8 hybridoma house mouse CVCL_C4H5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792875 CVCL_C4GS SC10.128 hybridoma house mouse CVCL_C4GS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792876 CVCL_C4H4 SC17.4 hybridoma house mouse CVCL_C4H4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792877 CVCL_C4GV SC10.132 hybridoma house mouse CVCL_C4GV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792878 CVCL_C4H7 SC17.10 hybridoma house mouse CVCL_C4H7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792879 CVCL_C4GU SC10.130 hybridoma house mouse CVCL_C4GU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792880 CVCL_C4H6 SC17.9 hybridoma house mouse CVCL_C4H6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792881 CVCL_C4GX SC10.134 hybridoma house mouse CVCL_C4GX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792882 CVCL_C4H9 SC17.14 hybridoma house mouse CVCL_C4H9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792883 CVCL_C4GW SC10.133 hybridoma house mouse CVCL_C4GW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792884 CVCL_C4H8 SC17.11 hybridoma house mouse CVCL_C4H8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792885 CVCL_C4GZ SC10.168 hybridoma house mouse CVCL_C4GZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792886 CVCL_C4GY SC10.163 hybridoma house mouse CVCL_C4GY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792887 CVCL_C4IN SC17.97 hybridoma house mouse CVCL_C4IN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792888 CVCL_C4IM SC17.95 hybridoma house mouse CVCL_C4IM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792889 CVCL_C4J1 SC17.187 hybridoma house mouse CVCL_C4J1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792890 CVCL_C4IP SC17.99 hybridoma house mouse CVCL_C4IP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792891 CVCL_C4J0 SC17.166 hybridoma house mouse CVCL_C4J0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792892 CVCL_C4IR SC17.114 hybridoma house mouse CVCL_C4IR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792893 CVCL_C4J3 SC17.193 hybridoma house mouse CVCL_C4J3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792894 CVCL_C4IQ SC17.102 hybridoma house mouse CVCL_C4IQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792895 CVCL_C4J2 SC17.191 hybridoma house mouse CVCL_C4J2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792896 CVCL_C4IT SC17.120 hybridoma house mouse CVCL_C4IT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792897 CVCL_C4J5 SC17.200 hybridoma house mouse CVCL_C4J5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792898 CVCL_C4IS SC17.115 hybridoma house mouse CVCL_C4IS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792899 CVCL_C4J4 SC17.199 hybridoma house mouse CVCL_C4J4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792900 CVCL_C4IF SC17.84 hybridoma house mouse CVCL_C4IF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792901 CVCL_C4IE SC17.82 hybridoma house mouse CVCL_C4IE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792902 CVCL_C4IH SC17.87 hybridoma house mouse CVCL_C4IH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792903 CVCL_C4IG SC17.85 hybridoma house mouse CVCL_C4IG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792904 CVCL_C4IJ SC17.90 hybridoma house mouse CVCL_C4IJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792905 CVCL_C4II SC17.89 hybridoma house mouse CVCL_C4II CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792906 CVCL_C4IL SC17.93 hybridoma house mouse CVCL_C4IL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792907 CVCL_C4IK SC17.91 hybridoma house mouse CVCL_C4IK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792908 CVCL_C4IB SC17.77 hybridoma house mouse CVCL_C4IB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792909 CVCL_C4IA SC17.76 hybridoma house mouse CVCL_C4IA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792910 CVCL_C4ID SC17.81 hybridoma house mouse CVCL_C4ID CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792911 CVCL_C4IC SC17.79 hybridoma house mouse CVCL_C4IC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792912 CVCL_C4HU SC17.42 hybridoma house mouse CVCL_C4HU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792913 CVCL_C4I6 SC17.63 hybridoma house mouse CVCL_C4I6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792914 CVCL_C4HT SC17.41 hybridoma house mouse CVCL_C4HT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792915 CVCL_C4I5 SC17.61 hybridoma house mouse CVCL_C4I5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792916 CVCL_C4HW SC17.46 hybridoma house mouse CVCL_C4HW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792917 CVCL_C4I8 SC17.72 hybridoma house mouse CVCL_C4I8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792918 CVCL_C4HV SC17.45 hybridoma house mouse CVCL_C4HV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792919 CVCL_C4I7 SC17.71 hybridoma house mouse CVCL_C4I7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792920 CVCL_C4HY SC17.49 hybridoma house mouse CVCL_C4HY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792921 CVCL_C4HX SC17.47 hybridoma house mouse CVCL_C4HX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792922 CVCL_C4I9 SC17.74 hybridoma house mouse CVCL_C4I9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792923 CVCL_C4HZ SC17.50 hybridoma house mouse CVCL_C4HZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792924 CVCL_C4FK 19E11 hybridoma house mouse CVCL_C4FK CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792925 CVCL_C4FJ 17B6 hybridoma house mouse CVCL_C4FJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792926 CVCL_C4FM 3C5 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792927 CVCL_C4FL 1G7 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792928 CVCL_C4G0 CAL-19 hybridoma house mouse CVCL_C4G0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792929 CVCL_C4FN 5F9 hybridoma house mouse CVCL_C4FN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792930 CVCL_C4FQ 6F7 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FQ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792931 CVCL_C4G2 CAL-22 hybridoma house mouse CVCL_C4G2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792932 CVCL_C4FP 6B10 hybridoma house mouse CVCL_C4FP CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792933 CVCL_C4G1 CAL-21 hybridoma house mouse CVCL_C4G1 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792934 CVCL_C4FC 9G6 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792935 CVCL_C4FB 7B10 hybridoma house mouse CVCL_C4FB CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792936 CVCL_C4FE 10C11 hybridoma house mouse CVCL_C4FE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792937 CVCL_C4FD H26 hybridoma house mouse CVCL_C4FD CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792938 CVCL_C4FG 11G11 hybridoma house mouse CVCL_C4FG CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792939 CVCL_C4FF 10F7 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792940 CVCL_C4FI 16C3 hybridoma house mouse CVCL_C4FI CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792941 CVCL_C4FH 13G7 hybridoma house mouse CVCL_C4FH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792942 CVCL_C4EZ 14C7 hybridoma house mouse CVCL_C4EZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792943 CVCL_C4EY 13D4 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4EY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792944 CVCL_C4FA 6G11 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792945 CVCL_C4F3 2B2 hybridoma house mouse CVCL_C4F3 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792946 CVCL_C4ER HeLa HFT/TO-PRKN FBXO7-/- cancer cell line human CVCL_C4ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13586; FBXO7; Transfected with: HGNC; 8607; PRKN (with 3xFLAG and HA tags); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Miscellaneous: Cell line information from personal communication of Paoli J.C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155792947 CVCL_C4F2 20G9 hybridoma house mouse CVCL_C4F2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792948 CVCL_C4EQ HeLa HFT/TO-PRKN cancer cell line human CVCL_C4EQ CL:0000010 Transfected with: HGNC; 8607; PRKN (with 3xFLAG and HA tags); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155792949 CVCL_C4F5 3B6 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4F5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792950 CVCL_C4ET HeLa Flp-In T-REx cancer cell line human CVCL_C4ET CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155792951 CVCL_C4F4 2C7 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4F4 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792952 CVCL_C4ES HeLa HFT/TO-PRKN PINK1-/- cancer cell line human CVCL_C4ES CL:0000010 Knockout cell: Method=TALEN; HGNC; 14581; PINK1; Transfected with: HGNC; 8607; PRKN (with 3xFLAG and HA tags); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 155792953 CVCL_C4EV 11G3 hybridoma house mouse CVCL_C4EV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792954 CVCL_C4F7 3F2 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4F7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792955 CVCL_C4EU 10G10 hybridoma house mouse CVCL_C4EU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792956 CVCL_C4F6 3E3 hybridoma house mouse CVCL_C4F6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792957 CVCL_C4EX 12G10 hybridoma house mouse CVCL_C4EX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792958 CVCL_C4F9 5G11 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4F9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792959 CVCL_C4EW 12C4 hybridoma house mouse CVCL_C4EW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792960 CVCL_C4F8 5C3 hybridoma house mouse CVCL_C4F8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792961 CVCL_C4GL SC10.118 hybridoma house mouse CVCL_C4GL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792962 CVCL_C4GK SC10.115 hybridoma house mouse CVCL_C4GK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792963 CVCL_C4GN SC10.124 hybridoma house mouse CVCL_C4GN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792964 CVCL_C4GM SC10.123 hybridoma house mouse CVCL_C4GM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792965 CVCL_C4GP SC10.125 hybridoma house mouse CVCL_C4GP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792966 CVCL_C4H1 SC17.1 hybridoma house mouse CVCL_C4H1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792967 CVCL_C4H0 SC10.178 hybridoma house mouse CVCL_C4H0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792968 CVCL_C4GR SC10.127 hybridoma house mouse CVCL_C4GR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792969 CVCL_C4H3 SC17.3 hybridoma house mouse CVCL_C4H3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792970 CVCL_C4GQ SC10.126 hybridoma house mouse CVCL_C4GQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792971 CVCL_C4H2 SC17.2 hybridoma house mouse CVCL_C4H2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q53EL9; Human SEZ6. 155792972 CVCL_C4GD SC10.19 hybridoma house mouse CVCL_C4GD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792973 CVCL_C4GC SC10.17 hybridoma house mouse CVCL_C4GC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792974 CVCL_C4GF SC10.36 hybridoma house mouse CVCL_C4GF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792975 CVCL_C4GE SC10.35 hybridoma house mouse CVCL_C4GE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792976 CVCL_C4GH SC10.75 hybridoma house mouse CVCL_C4GH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792977 CVCL_C4GG SC10.38 hybridoma house mouse CVCL_C4GG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792978 CVCL_C4GJ SC10.112 hybridoma house mouse CVCL_C4GJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792979 CVCL_C4GI SC10.111 hybridoma house mouse CVCL_C4GI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792980 CVCL_C4FZ CAL-18 hybridoma house mouse CVCL_C4FZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792981 CVCL_C4GB SC10.15 hybridoma house mouse CVCL_C4GB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792982 CVCL_C4GA SC10.6 hybridoma house mouse CVCL_C4GA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. 155792983 CVCL_C4G4 CAL-27 [Mouse hybridoma against cardiolipin] hybridoma house mouse CVCL_C4G4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792984 CVCL_C4FS E18 hybridoma house mouse CVCL_C4FS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792985 CVCL_C4FR 8G6 [Mouse hybridoma against phOX] hybridoma house mouse CVCL_C4FR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792986 CVCL_C4G3 CAL-23 [Mouse hybridoma against cardiolipin] hybridoma house mouse CVCL_C4G3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792987 CVCL_C4FU CAL-11 hybridoma house mouse CVCL_C4FU CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792988 CVCL_C4G6 CAL-6 hybridoma house mouse CVCL_C4G6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792989 CVCL_C4G5 CAL-3 hybridoma house mouse CVCL_C4G5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792990 CVCL_C4FT H12 hybridoma house mouse CVCL_C4FT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155792991 CVCL_C4G8 2C4C2 hybridoma house mouse CVCL_C4G8 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792992 CVCL_C4FW CAL-15 hybridoma house mouse CVCL_C4FW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792993 CVCL_C4FV CAL-13 hybridoma house mouse CVCL_C4FV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792994 CVCL_C4G7 CAL-9 [Mouse hybridoma against cardiolipin] hybridoma house mouse CVCL_C4G7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792995 CVCL_C4FY CAL-17 hybridoma house mouse CVCL_C4FY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792996 CVCL_C4G9 2C4D1 hybridoma house mouse CVCL_C4G9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792997 CVCL_C4FX CAL-16 hybridoma house mouse CVCL_C4FX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28494; Cardiolipin. 155792998 CVCL_C3S9 UL-3A cancer cell line human CVCL_C3S9 CL:0000010 Donor information: Established during surgical debulking; Derived from metastatic site: Ascites. Female Doubling time: 36 hours (PubMed=9412727) 155792999 CVCL_C3S8 5.88.3 hybridoma house mouse CVCL_C3S8 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O15123; Human ANGPT2 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7259 155793000 CVCL_C3RZ HHF35 hybridoma house mouse CVCL_C3RZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P68133; Human ACTA1 (Note=Also reacts with many other mammalian species, with chicken and with zebrafish); Monoclonal antibody target: UniProtKB; P63267; Human ACTG2 (Note=Also reacts with many other mammalian species, with chicken and with zebrafish). 155793001 CVCL_C3S1 Aag2 (C) spontaneously immortalized cell line CVCL_C3S1 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Characteristics: Adapted to growth at 15 Celsius (PubMed=627872); Virology: Supports replication of Sindbis virus (PubMed=627872) Doubling time: ~10 days (PubMed=627872) Group: Insect cell line 155793002 CVCL_C3RP IAIi006-A induced pluripotent stem cell human CVCL_C3RP From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=36528014) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155793003 CVCL_C3S0 PDL-hTERT telomerase immortalized cell line human CVCL_C3S0 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.. Unspecified Doubling time: ~90 hours (PubMed=20473831) 155793004 CVCL_C3S3 CEM/GN150 cancer cell line human CVCL_C3S3 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28088; Genistein; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155793005 CVCL_C3RR IAIi008-A induced pluripotent stem cell human CVCL_C3RR From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=36528014) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155793006 CVCL_C3S2 CEM/GN50 cancer cell line human CVCL_C3S2 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28088; Genistein; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155793007 CVCL_C3RQ IAIi007-A induced pluripotent stem cell human CVCL_C3RQ From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=36528014) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155793008 CVCL_C3S5 HEK-Blue hACE2-TMPRSS2 transformed cell line human CVCL_C3S5 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites Group: SARS-CoV-2 research cell line 155793009 CVCL_C3RT IGIBi006-A induced pluripotent stem cell human CVCL_C3RT From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-48del; Zygosity=Hemizygous (PubMed=36191544) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155793010 CVCL_C3S4 CV-062020-PPB spontaneously immortalized cell line CVCL_C3S4 CL:0000010 Male Doubling time: 37.7 hours (PubMed=36164515). Group: Insect cell line 155793011 CVCL_C3RS IAIi009-A induced pluripotent stem cell human CVCL_C3RS From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155793012 CVCL_C3S7 3.3.2 hybridoma house mouse CVCL_C3S7 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O15123; Human ANGPT2 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7258 155793013 CVCL_C3RV IGIBi009-A induced pluripotent stem cell human CVCL_C3RV From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India. CL:0000010 155793014 CVCL_C3S6 3.19.3 hybridoma house mouse CVCL_C3S6 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from Xenomouse mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; O15123; Human ANGPT2 (Note=Also reacts with mouse) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7260 155793015 CVCL_C3RU IGIBi008-A induced pluripotent stem cell human CVCL_C3RU From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (PubMed=36191544) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 155793016 CVCL_C3RH HIHCNi007-A-2 induced pluripotent stem cell human CVCL_C3RH From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 2433; CSF1R. 155793017 CVCL_C3RG HIHCNi007-A-1 induced pluripotent stem cell human CVCL_C3RG From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2433; CSF1R. 155793018 CVCL_C3RJ HIHCNi008-A-1 induced pluripotent stem cell human CVCL_C3RJ From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 allelles); HGNC; 11233; SPAST. 155793019 CVCL_C3RI HIHCNi008-A induced pluripotent stem cell human CVCL_C3RI From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany. CL:0000010 155793020 CVCL_C3RL HIHCNi009-A induced pluripotent stem cell human CVCL_C3RL From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany. CL:0000010 155793021 CVCL_C3RK HIHCNi008-A-2 induced pluripotent stem cell human CVCL_C3RK From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11233; SPAST. 155793022 CVCL_C3RN IAIi005-A induced pluripotent stem cell human CVCL_C3RN From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=36528014) Population: Caucasian; Donor information: At sampling donor was asymptomatic for amyotrophic lateral sclerosis; Derived from sampling site: Cell type=Fibroblast. Male 155793023 CVCL_C3RM HIHCNi010-A induced pluripotent stem cell human CVCL_C3RM From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany. CL:0000010 155793024 CVCL_C3RB M4Be T9P76 cancer cell line human CVCL_C3RB CL:0000010 Derived from metastatic site: Lymph node. Male 155793025 CVCL_C3RA M4Be P4 cancer cell line human CVCL_C3RA CL:0000010 Derived from metastatic site: Lymph node. Male 155793026 CVCL_C3RD ESi091-A induced pluripotent stem cell human CVCL_C3RD HLA typing: A*29; B*44; C*16 (Spanish_Stem_Cell_Bank) From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 155793027 CVCL_C3RC CSSi016-A induced pluripotent stem cell human CVCL_C3RC From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 10542; SBF1; Simple; p.Arg763His (c.2288G>A); ClinVar=VCV001065826; Zygosity=Heterozygous (PubMed=36272304); Sequence variation: Mutation; HGNC; 10542; SBF1; Simple; p.Gly1064Glu (c.3191G>A); ClinVar=VCV001120019; Zygosity=Heterozygous (PubMed=36272304) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793028 CVCL_C3RF HIHCNi007-A induced pluripotent stem cell human CVCL_C3RF From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany. CL:0000010 155793029 CVCL_C3RE FDCHDPe012-A embryonic stem cell human CVCL_C3RE From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8547; P4HA2. Female 155793030 CVCL_C3SY 6E-12 hybridoma house mouse CVCL_C3SY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human herpesvirus 2 (HHV-2) 50-55 kDa protein. 155793031 CVCL_C3T9 1H4 hybridoma house mouse CVCL_C3T9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92934; Human BAD. 155793032 CVCL_C3SX 6A-6 hybridoma house mouse CVCL_C3SX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human herpesvirus 2 (HHV-2) 140 kDa protein. 155793033 CVCL_C3SZ 6H-11 hybridoma house mouse CVCL_C3SZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human herpesvirus 2 (HHV-2) 38 kDa protein. 155793034 CVCL_C3SQ RE7 transformed cell line Norway rat CVCL_C3SQ CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). 155793035 CVCL_C3T2 TG18 hybridoma house mouse CVCL_C3T2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P89452; Human herpesvirus 2 (HHV-2) major DNA-binding protein (DBP) (Note=Also reacts with HHV-1). 155793036 CVCL_C3SP RE2A transformed cell line Norway rat CVCL_C3SP CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) (strain HFEM)(NCBI-Taxonomy; 10303). 155793037 CVCL_C3T1 TG14 hybridoma house mouse CVCL_C3T1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P89452; Human herpesvirus 2 (HHV-2) major DNA-binding protein (DBP) (Note=Also reacts with HHV-1). 155793038 CVCL_C3SS REAsyn+C transformed cell line Norway rat CVCL_C3SS CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) (strain 17)(NCBI-Taxonomy; 10299). Female 155793039 CVCL_C3T4 TG5E hybridoma house mouse CVCL_C3T4 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P63018; Rat Hspa8. 155793040 CVCL_C3SR REalpha transformed cell line Norway rat CVCL_C3SR CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) (strain HFEM)(NCBI-Taxonomy; 10303). Female 155793041 CVCL_C3T3 TG512 hybridoma house mouse CVCL_C3T3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P89452; Human herpesvirus 2 (HHV-2) major DNA-binding protein (DBP) (Note=Also reacts with HHV-1). 155793042 CVCL_C3SU RT10 transformed cell line Norway rat CVCL_C3SU CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Female Characteristics: Produced from a tumor induced by the inoculation of the parent cell line 155793043 CVCL_C3T6 TI81 hybridoma house mouse CVCL_C3T6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04296; Human herpesvirus 1 (HHV-1) major DNA-binding protein (DBP). 155793044 CVCL_C3ST REI-S transformed cell line Norway rat CVCL_C3ST CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) (strain 17)(NCBI-Taxonomy; 10299). Female 155793045 CVCL_C3T5 TI56 hybridoma house mouse CVCL_C3T5 CL:0000010 Monoclonal antibody isotype: Not specified. 155793046 CVCL_C3SW 3G-11 hybridoma house mouse CVCL_C3SW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10228; Human herpesvirus 1 (HHV-1) glycoprotein C (gC). 155793047 CVCL_C3T8 E9F10 hybridoma house mouse CVCL_C3T8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P89452; Human herpesvirus 2 (HHV-2) major DNA-binding protein (DBP) (Note=Also reacts with HHV-1). 155793048 CVCL_C3T7 E3D7 hybridoma house mouse CVCL_C3T7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P89452; Human herpesvirus 2 (HHV-2) major DNA-binding protein (DBP) (Note=Also reacts with HHV-1). 155793049 CVCL_C3SV ICT1 transformed cell line Norway rat CVCL_C3SV CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Unspecified 155793050 CVCL_C3SI UL-B cancer cell line human CVCL_C3SI CL:0000010 Population: Caucasian. Female 155793051 CVCL_C3SH UL-8 cancer cell line human CVCL_C3SH CL:0000010 Female 155793052 CVCL_C3SK Bn3 transformed cell line Norway rat CVCL_C3SK CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Unspecified 155793053 CVCL_C3SJ UL-O cancer cell line human CVCL_C3SJ CL:0000010 Population: Caucasian. Female 155793054 CVCL_C3SM Bn5T transformed cell line Norway rat CVCL_C3SM CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Unspecified Characteristics: Produced from a tumor induced by the inoculation of the parent cell line 155793055 CVCL_C3SL Bn5 transformed cell line Norway rat CVCL_C3SL CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Unspecified 155793056 CVCL_C3T0 TG102 hybridoma house mouse CVCL_C3T0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08666; Human herpesvirus 2 (HHV-2) glycoprotein B (gB). 155793057 CVCL_C3SN RE1 transformed cell line Norway rat CVCL_C3SN CL:0000010 Transformant: Human herpesvirus 2 (HHV-2) (strain HG52)(NCBI-Taxonomy; 10315). Female 155793058 CVCL_C3SA UL-3B cancer cell line human CVCL_C3SA CL:0000010 Donor information: Established during chemotherapy; Derived from metastatic site: Ascites. Female Doubling time: 30 hours (PubMed=9412727) 155793059 CVCL_C3SC UL-1 [Human ovarian carcinoma] cancer cell line human CVCL_C3SC CL:0000010 Female 155793060 CVCL_C3SB UL-3C cancer cell line human CVCL_C3SB CL:0000010 Donor information: Established after clinical progression of the disease; Derived from metastatic site: Ascites. Female Doubling time: 20 hours (PubMed=9412727) 155793061 CVCL_C3SE UL-5 cancer cell line human CVCL_C3SE CL:0000010 Female 155793062 CVCL_C3SD UL-2 cancer cell line human CVCL_C3SD CL:0000010 Female 155793063 CVCL_C3SG UL-7 cancer cell line human CVCL_C3SG CL:0000010 Female 155793064 CVCL_C3SF UL-6 cancer cell line human CVCL_C3SF CL:0000010 Female 155793065 CVCL_C3Q7 CS1FABE LCL transformed cell line human CVCL_C3Q7 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM05325; probable Male 155793066 CVCL_C3PV M4Be T1C11 cancer cell line human CVCL_C3PV CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Intermediate metastatic potential 155793067 CVCL_C3Q6 CS1FABE finite cell line human CVCL_C3Q6 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05324; probable Male 155793068 CVCL_C3PU M4Be T1C6 cancer cell line human CVCL_C3PU CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Intermediate metastatic potential 155793069 CVCL_C3Q9 CSHM1FABE LCL transformed cell line human CVCL_C3Q9 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM05323; probable Male 155793070 CVCL_C3PX M4Be T1C3R cancer cell line human CVCL_C3PX CL:0000010 Derived from metastatic site: Lymph node. Male 155793071 CVCL_C3Q8 CSHM1FABE finite cell line human CVCL_C3Q8 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05322; probable Male 155793072 CVCL_C3PW M4Be Tw2 cancer cell line human CVCL_C3PW CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Highly metastatic 155793073 CVCL_C3PZ Nex2D cancer cell line house mouse CVCL_C3PZ CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: High metastatic potential 155793074 CVCL_C3PY Nex2B cancer cell line house mouse CVCL_C3PY CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Low metastatic potential 155793075 CVCL_C3PN M4Be 0PP20 cancer cell line human CVCL_C3PN CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Low metastatic potential Doubling time: 30 +- 0.5 hours (PubMed=8175891) 155793076 CVCL_C3PM M4Be T1C3 cancer cell line human CVCL_C3PM CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic Doubling time: 30 +- 0.5 hours (PubMed=8175891) 155793077 CVCL_C3Q1 B16-F10-Nex4 cancer cell line house mouse CVCL_C3Q1 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: The parent cell line was inoculated subcutaneously in C57BL/6 mice and the in vivo developing tumor cell were recultivated to produce this cell line (PubMed=12470474) 155793078 CVCL_C3PP M4Be 6PP177 cancer cell line human CVCL_C3PP CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic Doubling time: 30 +- 0.5 hours (PubMed=8175891) 155793079 CVCL_C3Q0 B16-F10-Nex3 cancer cell line house mouse CVCL_C3Q0 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Amelanotic 155793080 CVCL_C3Q3 7E7/A4 hybridoma house mouse CVCL_C3Q3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q91Y06; Mouse Pcdhb13. 155793081 CVCL_C3PR M4Be IC8 cancer cell line human CVCL_C3PR CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Low metastatic potential Doubling time: 30 +- 0.5 hours (PubMed=8175891) 155793082 CVCL_C3Q2 7E7/B11 hybridoma house mouse CVCL_C3Q2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse melanoma cell line B16 antigen. 155793083 CVCL_C3PQ M4Be 9PP257-262 cancer cell line human CVCL_C3PQ CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Low metastatic potential Was obtained after 10 successive subcutaneous passages of cells harvested from tumors of the parental cell line in immunodepressed newborn rats. Doubling time: 30 +- 0.5 hours (PubMed=8175891) 155793084 CVCL_C3Q5 HTZ-17 cancer cell line human CVCL_C3Q5 CL:0000010 Derived from sampling site: Brain. Unspecified 155793085 CVCL_C3PT M4Be G9 cancer cell line human CVCL_C3PT CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic 155793086 CVCL_C3Q4 HTZ-146 cancer cell line human CVCL_C3Q4 CL:0000010 Derived from sampling site: Brain. Unspecified 155793087 CVCL_C3PS M4Be G1 cancer cell line human CVCL_C3PS CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic 155793088 CVCL_C3PF HGADFN188 hTERT telomerase immortalized cell line human CVCL_C3PF CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793089 CVCL_C3PE HGADFN178 hTERT telomerase immortalized cell line human CVCL_C3PE CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793090 CVCL_C3PH TH-mOrange hiPSC induced pluripotent stem cell human CVCL_C3PH CL:0000010 Transfected with: mOrange, a bright orange fluorescent protein derived from mRFP1 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Characteristics: Using CRISPR/Cas9 P2A-mOrange construct was integrated after the stop codon of TH in both alleles (PubMed=31048719) 155793091 CVCL_C3PG PSADFN542 finite cell line human CVCL_C3PG CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg644Cys (c.1930C>T); ClinVar=VCV000014527; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 155793092 CVCL_C3PJ PoF7 hybridoma house mouse CVCL_C3PJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Phomopsis oblonga. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2022106 155793093 CVCL_C3PI 1A6 [Mouse hybridoma against PCV2 Cap] hybridoma house mouse CVCL_C3PI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O56129; Porcine circovirus type 2 (PCV2) caspid protein (Cap). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2022151 155793094 CVCL_C3PL MDCC-BO1(T) transformed cell line CVCL_C3PL CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Transformant: Meleagrid herpesvirus 1 (Herpes virus of turkey)(NCBI-Taxonomy; 37108); Derived from sampling site: Spleen Cell type=T-cell.. Female Virology: Was established from a chicken vaccinated with herpes virus of turkey (HVT) and naturally infected with Marek's disease virus (MDV) Contains 1.6 to 1.8 HVT genome equivalents/cell and 3.4 to 3.8 MDV genome equivalents/cell (PubMed=6268738). Doubling time: 18 hours (PubMed=6254498) Group: Bird cell line 155793095 CVCL_C3PK MDA-299-62A hybridoma house mouse CVCL_C3PK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9H999; Human PANK3. 155793096 CVCL_C3PB HGADFN003 hTERT telomerase immortalized cell line human CVCL_C3PB CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155793097 CVCL_C3PA HepDT transformed cell line pig CVCL_C3PA CL:0000010 Knockout cell: Method=KO pig; UniProtKB; P50127; GGTA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 27-32 hours (Patent=US20190345441) Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.15590 155793098 CVCL_C3PD HGADFN164 hTERT telomerase immortalized cell line human CVCL_C3PD CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793099 CVCL_C3PC HGADFN127 hTERT telomerase immortalized cell line human CVCL_C3PC CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793100 CVCL_C3QW CCMi009-A induced pluripotent stem cell human CVCL_C3QW From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Population: Caucasian; Donor information: Established from a COVID-19 patient who displayed increased levels of high-sensitivity Troponin (hsTnI) during the acute phase of infection; Derived from sampling site: Peripheral blood. Male 155793101 CVCL_C3R8 M4Be T1C3L cancer cell line human CVCL_C3R8 CL:0000010 Derived from metastatic site: Lymph node. Male 155793102 CVCL_C3QV CCMi008-A induced pluripotent stem cell human CVCL_C3QV From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Population: Caucasian; Donor information: Established from a COVID-19 patient who displayed increased levels of high-sensitivity Troponin (hsTnI) during the acute phase of infection Also developed severe myocarditis.; Derived from sampling site: Peripheral blood. Male 155793103 CVCL_C3R7 M4Be 4TP46 cancer cell line human CVCL_C3R7 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Was obtained after 5 successive subcutaneous passages of cells harvested from tumors of the parental cell line in immunodepressed newborn rats 155793104 CVCL_C3QY CMCi006-A-1 induced pluripotent stem cell human CVCL_C3QY From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18149; A4GALT; Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Leu324Trpfs*24 (c.969delC); ClinVar=VCV001050825; Zygosity=Hemizygous (from parent cell line) Population: Korean; Derived from sampling site: Peripheral blood. Male 155793105 CVCL_C3QX CCMi010-A induced pluripotent stem cell human CVCL_C3QX From: Centro Cardiologico Monzino; Milan; Italy. CL:0000010 155793106 CVCL_C3R9 M4Be 9GP217 cancer cell line human CVCL_C3R9 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Was obtained after 10 successive subcutaneous passages of cells harvested from tumors of the parental cell line in immunodepressed newborn rats 155793107 CVCL_C3QZ CRICKi004-A induced pluripotent stem cell human CVCL_C3QZ From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2961; DYNC1H1; Simple; p.Arg399Gly (c.1195A>G); ClinVar=VCV000637515; Zygosity=Homozygous (PubMed=36332468) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793108 CVCL_C3R0 CRICKi005-A induced pluripotent stem cell human CVCL_C3R0 From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2961; DYNC1H1; Simple; p.Arg399Gly (c.1195A>G); ClinVar=VCV000637515; Zygosity=Heterozygous (PubMed=36332468) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155793109 CVCL_C3QN HD5LO finite cell line human CVCL_C3QN CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 155793110 CVCL_C3R2 CRICKi007-A induced pluripotent stem cell human CVCL_C3R2 From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 17208; BICD2; Simple; p.Ile189Phe (c.565A>T); ClinVar=VCV000637065; Zygosity=Heterozygous (PubMed=36332468) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 155793111 CVCL_C3QQ RB16KY(SVT) transformed cell line human CVCL_C3QQ CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 155793112 CVCL_C3R1 CRICKi006-A induced pluripotent stem cell human CVCL_C3R1 From: The Francis Crick Institute Limited; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2961; DYNC1H1; Simple; p.Asp338Asn (c.1012G>A); ClinVar=VCV000637514; Zygosity=Heterozygous (PubMed=36332468) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155793113 CVCL_C3QP XP1JTO finite cell line human CVCL_C3QP CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155793114 CVCL_C3QS 7E7/A4M hybridoma house mouse CVCL_C3QS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q91Y06; Mouse Pcdhb13. 155793115 CVCL_C3R4 M4Be 9TP180 cancer cell line human CVCL_C3R4 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Was obtained after 10 successive subcutaneous passages of cells harvested from tumors of the parental cell line in immunodepressed newborn rats 155793116 CVCL_C3QR FPC1LO finite cell line human CVCL_C3QR CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 155793117 CVCL_C3R3 M4Be 4PP70 cancer cell line human CVCL_C3R3 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Was obtained after 5 successive subcutaneous passages of cells harvested from tumors of the parental cell line in immunodepressed newborn rats 155793118 CVCL_C3QU CCMi007-A induced pluripotent stem cell human CVCL_C3QU From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Population: Caucasian; Donor information: Established from a COVID-19 patient who displayed increased levels of high-sensitivity Troponin (hsTnI) during the acute phase of infection Also developed severe myocarditis.; Derived from sampling site: Peripheral blood. Male 155793119 CVCL_C3R6 M4Be 7GC21 cancer cell line human CVCL_C3R6 CL:0000010 Derived from metastatic site: Lymph node. Male 155793120 CVCL_C3QT KMUGMCi005-A induced pluripotent stem cell human CVCL_C3QT From: Kanazawa Medical University; Uchinada; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20474; TMC8; Simple; p.Gln51Profs*42 (c.298+1G>A); Zygosity=Homozygous; Note=Splice donor mutation (PubMed=36170758) Population: Japanese; Derived from sampling site: Peripheral blood. Female 155793121 CVCL_C3R5 M4Be 7GC6 cancer cell line human CVCL_C3R5 CL:0000010 Derived from metastatic site: Lymph node. Male 155793122 CVCL_C3QG 77LO finite cell line human CVCL_C3QG CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 54.1 hours (PubMed=6459055) 155793123 CVCL_C3QF 68LO finite cell line human CVCL_C3QF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 106.5 hours (PubMed=6459055) 155793124 CVCL_C3QI HD2BR finite cell line human CVCL_C3QI CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 40.7 hours (PubMed=6459055) 155793125 CVCL_C3QH HD1BR finite cell line human CVCL_C3QH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 77.0 hours (PubMed=6459055) 155793126 CVCL_C3QK HD2LO finite cell line human CVCL_C3QK CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female Doubling time: 38.0 hours (PubMed=6459055) 155793127 CVCL_C3QJ HD1LO finite cell line human CVCL_C3QJ CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 38.9 hours (PubMed=6459055) 155793128 CVCL_C3QM HD4LO finite cell line human CVCL_C3QM CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 32.4 hours (PubMed=6459055) 155793129 CVCL_C3QL HD3LO finite cell line human CVCL_C3QL CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female Doubling time: 48.8 hours (PubMed=6459055) 155793130 CVCL_C3QA Li106 finite cell line human CVCL_C3QA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 155793131 CVCL_C3QC 2974 finite cell line human CVCL_C3QC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155793132 CVCL_C3QB 2938 finite cell line human CVCL_C3QB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 155793133 CVCL_C3QE 66LO finite cell line human CVCL_C3QE CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 155793134 CVCL_C3QD 65LO finite cell line human CVCL_C3QD CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female Doubling time: 75.9 hours (PubMed=6459055) 155793135 CVCL_C3NT iKUF06 telomerase immortalized cell line pig CVCL_C3NT CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Landrace. Unspecified Characteristics: SLA gene typing is SLA-1:11:02,15:01,09:01; SLA-2:15:01,05:03; SLA-3:03:03,07:01:02; SLA-DQA:01:01,02:01; SLA-DQB1:02:01,06:01; SLA-DRB1:02:01,10:01 155793136 CVCL_C3NS iKUF05 telomerase immortalized cell line pig CVCL_C3NS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Landrace. Unspecified Characteristics: SLA gene typing is SLA-1:11:02,15:02; SLA-2:16:01,15:01; SLA-3:03:03,07:01:02; SLA-DQA:02:01,02:04; SLA-DQB1:02:01,03:03; SLA-DRB1:02:01,04:03 155793137 CVCL_C3NV iKUF08 telomerase immortalized cell line pig CVCL_C3NV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Yorkshire. Unspecified Characteristics: SLA gene typing is SLA-1:04:01,21:01,11:03; SLA-2:04:02:01,16:03; SLA-3:04:01,03:06; SLA-DQA:01:06,02:01; SLA-DQB1:02:01,07:01; SLA-DRB1:02:01,06:02 155793138 CVCL_C3NU iKUF07 telomerase immortalized cell line pig CVCL_C3NU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Landrace. Unspecified Characteristics: SLA gene typing is SLA-1:07:02,14:01; SLA-2:02:02,10:04; SLA-3:03:03,05:01; SLA-DQA:01:06; SLA-DQB1:07:01; SLA-DRB1:06:02 155793139 CVCL_C3NX iKUF10 telomerase immortalized cell line pig CVCL_C3NX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Seoul National University miniature pig. Unspecified Characteristics: SLA gene typing is SLA-1:02:01,07:01; SLA-2:03:01,21:01; SLA-3:03:01; SLA-DQA:01:02; SLA-DQB1:03:01; SLA-DRB1:03:01 155793140 CVCL_C3NW iKUF09 telomerase immortalized cell line pig CVCL_C3NW CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Landrace. Unspecified Characteristics: SLA gene typing is SLA-1:15:01,09:01; SLA-2:04:01,05:03; SLA-3:06:02,04:01; SLA-DQA:01:01,02:01; SLA-DQB1:04:01:01,06:01; SLA-DRB1:02:01,10:01 155793141 CVCL_C3NZ hTERT-PVEEC telomerase immortalized cell line pig CVCL_C3NZ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Heart; ventricle Cell type=Endothelial cell.. Unspecified Doubling time: 43 hours (in 5% FBS), 53 hours (in 10% FBS) (PubMed=17364895) 155793142 CVCL_C3NY CSC-1-5 spontaneously immortalized cell line CVCL_C3NY CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Rugao Yellow. Male Group: Bird cell line 155793143 CVCL_C3NL ICP1 telomerase immortalized cell line CVCL_C3NL CL:0000010 Transfected with: UniProtKB; Q537V4; Chicken TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Adipose tissue; hypodermis Cell type=Preadipocyte.; Breed/subspecies: Arbor Acres. Female Group: Bird cell line 155793144 CVCL_C3NK RKC2 transformed cell line Norway rat CVCL_C3NK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Kupffer cell.. Unspecified 155793145 CVCL_C3NN iKUF01 telomerase immortalized cell line pig CVCL_C3NN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: PWG Micropig. Unspecified Characteristics: SLA gene typing is SLA-1:13:01,11:04,12:03; SLA-2:04:02; SLA-3:04:01; SLA-DQA:02:04,05:01; SLA-DQB1:03:03,05:02; SLA-DRB1:04:03,07:01 155793146 CVCL_C3NM ICP2 telomerase immortalized cell line CVCL_C3NM CL:0000010 Transfected with: UniProtKB; Q537V4; Chicken TERT; Transfected with: Chicken telomerase RNA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Adipose tissue; hypodermis Cell type=Preadipocyte.; Breed/subspecies: Arbor Acres. Female Group: Bird cell line 155793147 CVCL_C3NP iKUF02 telomerase immortalized cell line pig CVCL_C3NP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Landrace. Unspecified Characteristics: SLA gene typing is SLA-1:16:01,08:10; SLA-2:12:01,10:09; SLA-3:06:01; SLA-DQA:01:01; SLA-DQB1:01:01,06:01; SLA-DRB1:01:01,10:01 155793148 CVCL_C3NR iKUF04 telomerase immortalized cell line pig CVCL_C3NR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: NIH miniature pig. Unspecified Characteristics: SLA gene typing is SLA-1:04:01; SLA-2:04:01; SLA-3:04:01; SLA-DQA:02:01; SLA-DQB1:04:01:01; SLA-DRB1:02:01 155793149 CVCL_C3NQ iKUF03 telomerase immortalized cell line pig CVCL_C3NQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: NIH miniature pig. Unspecified Characteristics: SLA gene typing is SLA-1:02:01,04:01,07:01; SLA-2:02:01,04:01; SLA-3:04:01,03:03; SLA-DQA:02:01; SLA-DQB1:02:01,04:01:01; SLA-DRB1:02:01 155793150 CVCL_C3ND rCHO(hBMP2)-C8 spontaneously immortalized cell line CVCL_C3ND CL:0000010 Transfected with: HGNC; 1069; BMP2; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155793151 CVCL_C3NC RAW-EGFP cancer cell line house mouse CVCL_C3NC CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Control cell line for RAW-E6 (Cellosaurus=CVCL_C3NB) 155793152 CVCL_C3NF A2780 LIN28B KO cancer cell line human CVCL_C3NF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32207; LIN28B; Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Ovary. Female 155793153 CVCL_C3NE AsPC-1 SPINK1 #10 cancer cell line human CVCL_C3NE CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11244; SPINK1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transduced with a lentiviral CMV-SPINK1-2A-eGFP construct 155793154 CVCL_C3NH HEK293 GOT2 KO clone A6 transformed cell line human CVCL_C3NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4433; GOT2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155793155 CVCL_C3NG HEK293 GOT2 KO clone A3 transformed cell line human CVCL_C3NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4433; GOT2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155793156 CVCL_C3NJ RKC1 spontaneously immortalized cell line Norway rat CVCL_C3NJ CL:0000010 Derived from sampling site: Liver Cell type=Kupffer cell.. Unspecified 155793157 CVCL_C3NI HEK293 GOT2 KO clone A7 transformed cell line human CVCL_C3NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4433; GOT2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155793158 CVCL_C3MZ 3G1-2B4 hybridoma house mouse CVCL_C3MZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793159 CVCL_C3NB RAW-E6 cancer cell line house mouse CVCL_C3NB CL:0000010 Transfected with: UniProtKB; P9WNK7; Mycobacterium tuberculosis ESAT-6 (esxA); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Expresses a EGFP-ESAT-6 fusion protein 155793160 CVCL_C3NA RSC96 L-periaxin KO spontaneously immortalized cell line Norway rat CVCL_C3NA CL:0000010 Knockout cell: Method=TALEN; RGD; 619960; Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Unspecified 155793161 CVCL_C3P6 BW6F2 hTERT clone 2-12 telomerase immortalized cell line CVCL_C3P6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793162 CVCL_C3P5 BW6F2 hTERT clone 2-8 telomerase immortalized cell line CVCL_C3P5 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793163 CVCL_C3P8 PSSCPi transformed cell line pig CVCL_C3P8 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatogonial stem cell.; Breed/subspecies: Landrace. Male 155793164 CVCL_C3P7 BW6F2 hTERT clone 2-13 telomerase immortalized cell line CVCL_C3P7 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793165 CVCL_C3P9 PSSCTi transformed cell line pig CVCL_C3P9 CL:0000010 Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatogonial stem cell.; Breed/subspecies: Landrace. Male 155793166 CVCL_C3P0 BW6F2 finite cell line CVCL_C3P0 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male Senescence: Senesces at 113 PDL (PubMed=12606403); Doubling time: 17-24 hours (PubMed=12606403) 155793167 CVCL_C3P2 BW6F2 hTERT clone 2-1 telomerase immortalized cell line CVCL_C3P2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793168 CVCL_C3P1 BW6F2 hTERT clone 1-1 telomerase immortalized cell line CVCL_C3P1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793169 CVCL_C3P4 BW6F2 hTERT clone 2-7 telomerase immortalized cell line CVCL_C3P4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793170 CVCL_C3P3 BW6F2 hTERT clone 2-5 telomerase immortalized cell line CVCL_C3P3 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Welsh. Male 155793171 CVCL_C3M3 HL-60/CDDP cancer cell line human CVCL_C3M3 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Peripheral blood. Female 155793172 CVCL_C3LR SK19-2E8 hybridoma house mouse CVCL_C3LR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14) 155793173 CVCL_C3M2 GIST-T1/IM-R cancer cell line human CVCL_C3M2 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=34738628); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Pro567Pro (c.1701A>G); ClinVar=VCV000259949; Zygosity=Unspecified (PubMed=34738628) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Female 155793174 CVCL_C3LQ SK19-1E10 hybridoma house mouse CVCL_C3LQ CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14) 155793175 CVCL_C3LT NUNK1 cancer cell line human CVCL_C3LT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male 155793176 CVCL_C3M5 PC3/DX cancer cell line human CVCL_C3M5 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone. Male 155793177 CVCL_C3M4 DRS [Xenopus] spontaneously immortalized cell line zebrafish CVCL_C3M4 CL:0000010 Derived from sampling site: Skin. Unspecified Doubling time: 31 hours, at 11th passage (DOI=10.21203/rs.3.rs-1890769/v1) Group: Fish cell line 155793178 CVCL_C3LS SK19-4G11 hybridoma house mouse CVCL_C3LS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14). 155793179 CVCL_C3M7 CEPI17-CL4 transformed cell line human CVCL_C3M7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIPSVU19](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1777 155793180 CVCL_C3LV WA14 GLA KO clone 01-56 embryonic stem cell human CVCL_C3LV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA. Male 155793181 CVCL_C3LU 409B2 HCN4-EGFP/SHOX2-mCherry induced pluripotent stem cell human CVCL_C3LU CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Dual reporter cell line Using homologous recombination EGFP was inserted at the N-terminus of HCN4 and using CRISPR/Cas9 mCherry was inserted at the N-terminus of SHOX2 (PubMed=36092505). 155793182 CVCL_C3M6 PC3/DX/AR+ cancer cell line human CVCL_C3M6 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 644; AR Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone. Male 155793183 CVCL_C3M9 iFTSEC283 telomerase immortalized cell line human CVCL_C3M9 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: STR profile from personal communication of Monteiro A.N.A Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: Transcriptome analysis by RNAseq Female 155793184 CVCL_C3LX IHM-2 telomerase immortalized cell line human CVCL_C3LX CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Miscellaneous: Cell line name and doubling time from personal communication of Lathuiliere A Derived from sampling site: Muscle; semitendinosus Cell type=Myoblast.. Female Doubling time: 34 hours (Direct_author_submission) Group: Patented cell line; Registration: International Depositary Authority, Culture Collection of Switzerland (CCOS); CCOS-1902 155793185 CVCL_C3M8 MVX-1 cancer cell line human CVCL_C3M8 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2434; CSF2 Population: Caucasian; Derived from sampling site: Pleural effusion. Biotechnology: Used in clinical trial of MVX-ONCO-1 a cancer immunotherapy method using cell encapsulation technology that contains dead tumor cells from the patient itself and MVX-1 cells that produce CSF2 Female Group: Patented cell line 155793186 CVCL_C3LW WA14 GLA KO clone 334-04 embryonic stem cell human CVCL_C3LW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA. Male 155793187 CVCL_C3LL 4A3-B1-E1 hybridoma house mouse CVCL_C3LL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01308; Human INS. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Guangdong Province Microorganism Culture Collection Center; GDMCC 61043 155793188 CVCL_C3LK NARO-Ac-314 spontaneously immortalized cell line CVCL_C3LK CL:0000010 Derived from sampling site: Fat body Cell type=Myoblast-like.. Unspecified Doubling time: 61.4 +- 10.1 hours (PubMed=35867318) Group: Insect cell line 155793189 CVCL_C3LN BG11 hybridoma house mouse CVCL_C3LN CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14). 155793190 CVCL_C3LM 4B2-E2-E7-C3 hybridoma house mouse CVCL_C3LM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01308; Human INS. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Guangdong Province Microorganism Culture Collection Center; GDMCC 61044 155793191 CVCL_C3M1 GC-4spc transformed cell line house mouse CVCL_C3M1 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; seminiferous tubule Cell type=Spermatocyte.; Breed/subspecies: TC transgenic. Male 155793192 CVCL_C3LP SK19-4C9 hybridoma house mouse CVCL_C3LP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14). 155793193 CVCL_C3M0 TE-1R cancer cell line human CVCL_C3M0 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Esophagus. Male Characteristics: Radioresistant Was irradiated at 1 Gy three times, at 2 Gy three times and and 4 Gy three times (PubMed=36090890). 155793194 CVCL_C3MS 1A12-2A4 hybridoma house mouse CVCL_C3MS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793195 CVCL_C3N4 5H10-2D1 hybridoma house mouse CVCL_C3N4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793196 CVCL_C3MR 1A1-1D7 hybridoma house mouse CVCL_C3MR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793197 CVCL_C3N3 5F7 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_C3N3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793198 CVCL_C3MU 1B11-2E3 hybridoma house mouse CVCL_C3MU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793199 CVCL_C3N6 WM115-MOCK cancer cell line human CVCL_C3N6 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Right anterior leg; skin. Female Characteristics: Control cell line for WM115-RAGE (Cellosaurus=CVCL_C3N7) Transfected with an empty pcDNA3 vector. 155793200 CVCL_C3MT 1B10-1D1 hybridoma house mouse CVCL_C3MT CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793201 CVCL_C3N5 5H9-2F1 hybridoma house mouse CVCL_C3N5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793202 CVCL_C3MW 1D12-1D5 hybridoma house mouse CVCL_C3MW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793203 CVCL_C3N8 NAU-BEMC spontaneously immortalized cell line CVCL_C3N8 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution and of the cell line description Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 155793204 CVCL_C3MV 1B12 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_C3MV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793205 CVCL_C3N7 WM115-RAGE cancer cell line human CVCL_C3N7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 320; AGER; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Right anterior leg; skin. Female 155793206 CVCL_C3MY 2E3-1D8 hybridoma house mouse CVCL_C3MY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793207 CVCL_C3MX 2B11-1F3 hybridoma house mouse CVCL_C3MX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793208 CVCL_C3N9 HCT116-TrxR1-KO cancer cell line human CVCL_C3N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12437; TXNRD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 155793209 CVCL_C3MK Hep-X1 cancer cell line human CVCL_C3MK CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Doubling time: ~60 hours (PubMed=36152230) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2022181 155793210 CVCL_C3MJ UOMi009-A induced pluripotent stem cell human CVCL_C3MJ From: University of Manitoba; Winnipeg; Canada CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Glu191Lys (c.571G>A) (E174K); ClinVar=VCV000013670; Zygosity=Heterozygous (PubMed=36152425); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gly334Asp (c.1001G>A) (G317D, 1177A); ClinVar=VCV000013672; Zygosity=Heterozygous (PubMed=36152425) Derived from sampling site: Peripheral blood. Male 155793211 CVCL_C3MM CHO-GPR81 spontaneously immortalized cell line CVCL_C3MM CL:0000010 Transfected with: HGNC; 4532; HCAR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 155793212 CVCL_C3ML G1 [Mouse hybridoma against imidacloprid] hybridoma house mouse CVCL_C3ML CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:5870; Imidacloprid. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202211 155793213 CVCL_C3N0 4B7-4D5 hybridoma house mouse CVCL_C3N0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793214 CVCL_C3MN HEK293 H5M2 transformed cell line human CVCL_C3MN CL:0000010 Transfected with: UniProtKB; Q5QF15; Influenza A virus isolate A/Thailand/5(KK-494)/2004(H5N1) matrix protein 2 (M2); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 155793215 CVCL_C3MQ 2G6/G12 hybridoma house mouse CVCL_C3MQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:5870; Imidacloprid. 155793216 CVCL_C3N2 5D3-1B5 hybridoma house mouse CVCL_C3N2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA) (Note=Recognizes AA 428-452). Group: Patented cell line 155793217 CVCL_C3MP 2F11/A9 hybridoma house mouse CVCL_C3MP CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:5870; Imidacloprid. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201047 155793218 CVCL_C3N1 4C8 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_C3N1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A2K8GIH5; Influenza A virus isolate A/chicken/Guangdong/GD15/2016(H7N9) hemagglutinin (HA). 155793219 CVCL_C3MC VL-001 transformed cell line CVCL_C3MC CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified Doubling time: 19.1-23.7 hours (Patent=WO2022178441A1) Group: Patented cell line 155793220 CVCL_C3MB IOSE11 p53R175H telomerase immortalized cell line human CVCL_C3MB CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11998; TP53 (with p.Arg175His); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 155793221 CVCL_C3ME SfSWT-5 spontaneously immortalized cell line CVCL_C3ME CL:0000010 Transfected with: HGNC; 7045; MGAT2; Transfected with: MGI; MGI:1337124; Cmas; Transfected with: MGI; MGI:2149820; Nans; Transfected with: MGI; MGI:1316659; St3gal3; Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Capable of producing terminally sialylated N-glycans under the transcriptional control of a doxycycline-inducible cytomegalovirus promoter (PubMed=22042767) Group: Insect cell line; Group: Recombinant protein production insect cell line 155793222 CVCL_C3MD SfSWT-4 spontaneously immortalized cell line CVCL_C3MD CL:0000010 Transfected with: HGNC; 7045; MGAT2; Transfected with: MGI; MGI:1337124; Cmas; Transfected with: MGI; MGI:2149820; Nans; Transfected with: MGI; MGI:1316659; St3gal3; Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Capable of producing terminally sialylated N-glycans when cultured in serum-free media supplemented with N-acetylmannosamine (PubMed=23065352) Group: Insect cell line; Group: Recombinant protein production insect cell line 155793223 CVCL_C3MG SfSWT-7 spontaneously immortalized cell line CVCL_C3MG CL:0000010 Transfected with: HGNC; 7045; MGAT2; Transfected with: MGI; MGI:1891160; Chst2; Transfected with: MGI; MGI:2685834; Gal3st2; Transfected with: VGNC; 26388; Bovine B4GALT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Can produce sulfated complex N-glycans The expression of the carbohydrate modidying enzymes is under the transcriptional control of baculovirus immediate early 1 (ie1) promoter and homologous region 5 (hr5) enhancer elements. Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line 155793224 CVCL_C3MF SfSWT-6 spontaneously immortalized cell line CVCL_C3MF CL:0000010 Transfected with: HGNC; 7045; MGAT2; Transfected with: HGNC; 11021; SLC35A1; Transfected with: MGI; MGI:1337124; Cmas; Transfected with: MGI; MGI:2149820; Nans; Transfected with: MGI; MGI:1316659; St3gal3; Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Capable of producing terminally sialylated N-glycans when cultured in serum-free media supplemented with N-acetylmannosamine (PubMed=23065352) Group: Insect cell line; Group: Recombinant protein production insect cell line 155793225 CVCL_C3MI ObSSC spontaneously immortalized cell line CVCL_C3MI CL:0000010 Derived from sampling site: Testis Cell type=Spermatogonial stem cell.. Male Characteristics: Can be induced to differentiate into sperm and other different types of somatic cells (PubMed=36101449) Group: Fish cell line 155793226 CVCL_C3MH GPG spontaneously immortalized cell line CVCL_C3MH CL:0000010 Derived from sampling site: Gill. Unspecified Characteristics: Optimal growth at 28 Celsius (PubMed=36373002) Group: Endangered species/breed cell line; Group: Fish cell line 155793227 CVCL_C3LZ KYSE-150R cancer cell line human CVCL_C3LZ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Esophagus. Female Characteristics: Radioresistant Was irradiated at 1 Gy three times, at 2 Gy three times and and 4 Gy three times (PubMed=36090890). 155793228 CVCL_C3LY MVX-2 telomerase immortalized cell line human CVCL_C3LY CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 2434; CSF2; Transfected with: HGNC; 11730; TERT Miscellaneous: Cell line name and doubling time from personal communication of Lathuiliere A Derived from sampling site: Muscle; semitendinosus Cell type=Myoblast.. Female Characteristics: Expression of CSF2 is under the control of a PGK promoter (PubMed=36092361) Doubling time: 37 hours (Direct_author_submission) Group: Patented cell line; Registration: International Depositary Authority, Culture Collection of Switzerland (CCOS); CCOS-1901 155793229 CVCL_C3MA iFTSEC283 p53R175H telomerase immortalized cell line human CVCL_C3MA CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11998; TP53 (with p.Arg175His); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 155793230 CVCL_C3ZX SC34.85 hybridoma house mouse CVCL_C3ZX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793231 CVCL_C3ZW SC34.84 hybridoma house mouse CVCL_C3ZW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793232 CVCL_C3ZZ SC34.87 hybridoma house mouse CVCL_C3ZZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793233 CVCL_C3ZY SC34.86 hybridoma house mouse CVCL_C3ZY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793234 CVCL_C3ZP SC34.75 hybridoma house mouse CVCL_C3ZP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793235 CVCL_C3ZR SC34.77 hybridoma house mouse CVCL_C3ZR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793236 CVCL_C3ZQ SC34.76 hybridoma house mouse CVCL_C3ZQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793237 CVCL_C3ZT SC34.80 hybridoma house mouse CVCL_C3ZT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793238 CVCL_C3ZS SC34.78 hybridoma house mouse CVCL_C3ZS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793239 CVCL_C3ZV SC34.83 hybridoma house mouse CVCL_C3ZV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with mouse). 155793240 CVCL_C3ZU SC34.81 hybridoma house mouse CVCL_C3ZU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793241 CVCL_C3ZH SC34.68 hybridoma house mouse CVCL_C3ZH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793242 CVCL_C3ZG SC34.67 hybridoma house mouse CVCL_C3ZG CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793243 CVCL_C3ZJ SC34.70 hybridoma house mouse CVCL_C3ZJ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with mouse and rat). 155793244 CVCL_C3ZI SC34.69 hybridoma house mouse CVCL_C3ZI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793245 CVCL_C3ZL SC34.72 hybridoma house mouse CVCL_C3ZL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793246 CVCL_C3ZK SC34.71 hybridoma house mouse CVCL_C3ZK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793247 CVCL_C3ZN SC34.74 hybridoma house mouse CVCL_C3ZN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793248 CVCL_C3ZM SC34.73 hybridoma house mouse CVCL_C3ZM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793249 CVCL_C3YA SC34.18 hybridoma house mouse CVCL_C3YA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793250 CVCL_C3YC SC34.20 hybridoma house mouse CVCL_C3YC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793251 CVCL_C3YB SC34.19 hybridoma house mouse CVCL_C3YB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793252 CVCL_C3YE SC34.24 hybridoma house mouse CVCL_C3YE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793253 CVCL_C3YD SC34.22 hybridoma house mouse CVCL_C3YD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793254 CVCL_C3XV C65B5 hybridoma house mouse CVCL_C3XV CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793255 CVCL_C3Y7 SC34.14 hybridoma house mouse CVCL_C3Y7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793256 CVCL_C3XU BC4B12 hybridoma house mouse CVCL_C3XU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793257 CVCL_C3Y6 SC34.13 hybridoma house mouse CVCL_C3Y6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793258 CVCL_C3Y9 SC34.16 hybridoma house mouse CVCL_C3Y9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793259 CVCL_C3XX SC34.3 hybridoma house mouse CVCL_C3XX CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793260 CVCL_C3Y8 SC34.15 hybridoma house mouse CVCL_C3Y8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793261 CVCL_C3XW SC34.2 hybridoma house mouse CVCL_C3XW CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793262 CVCL_C3XZ SC34.5 hybridoma house mouse CVCL_C3XZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793263 CVCL_C3XY SC34.4 hybridoma house mouse CVCL_C3XY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with rat). 155793264 CVCL_C3XN 40B11 hybridoma house mouse CVCL_C3XN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793265 CVCL_C3XM 39E1 hybridoma house mouse CVCL_C3XM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793266 CVCL_C3XP 7E11 [Mouse hybridoma against alprenolol] hybridoma house mouse CVCL_C3XP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793267 CVCL_C3Y1 SC34.7 hybridoma house mouse CVCL_C3Y1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793268 CVCL_C3Y0 SC34.6 hybridoma house mouse CVCL_C3Y0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793269 CVCL_C3XR A3A7 hybridoma house mouse CVCL_C3XR CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793270 CVCL_C3Y3 SC34.9 hybridoma house mouse CVCL_C3Y3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793271 CVCL_C3XQ A1E1 hybridoma house mouse CVCL_C3XQ CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793272 CVCL_C3Y2 SC34.8 hybridoma house mouse CVCL_C3Y2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793273 CVCL_C3XT BC3A1 hybridoma house mouse CVCL_C3XT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793274 CVCL_C3Y5 SC34.11 hybridoma house mouse CVCL_C3Y5 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793275 CVCL_C3XS A5B9 hybridoma house mouse CVCL_C3XS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793276 CVCL_C3Y4 SC34.10 hybridoma house mouse CVCL_C3Y4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793277 CVCL_C3XF 10E2 [Mouse hybridoma against alprenolol] hybridoma house mouse CVCL_C3XF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793278 CVCL_C3XE BRK-3 hybridoma house mouse CVCL_C3XE CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P08588; Human ADRB1; Monoclonal antibody target: UniProtKB; P07550; Human ADRB2. 155793279 CVCL_C3XH 17C1 hybridoma house mouse CVCL_C3XH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793280 CVCL_C3XG 14C3 hybridoma house mouse CVCL_C3XG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793281 CVCL_C3XJ 28B3 hybridoma house mouse CVCL_C3XJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793282 CVCL_C3XI 22C4 hybridoma house mouse CVCL_C3XI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793283 CVCL_C3XL 37A4 hybridoma house mouse CVCL_C3XL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793284 CVCL_C3XK 37A11 hybridoma house mouse CVCL_C3XK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:51211; Alprenolol. 155793285 CVCL_C3ZB SC34.60 hybridoma house mouse CVCL_C3ZB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793286 CVCL_C3ZA SC34.59 hybridoma house mouse CVCL_C3ZA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793287 CVCL_C3ZD SC34.63 hybridoma house mouse CVCL_C3ZD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793288 CVCL_C3ZC SC34.62 hybridoma house mouse CVCL_C3ZC CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with mouse and rat). 155793289 CVCL_C3ZF SC34.66 hybridoma house mouse CVCL_C3ZF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793290 CVCL_C3ZE SC34.65 hybridoma house mouse CVCL_C3ZE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793291 CVCL_C3YW SC34.44 hybridoma house mouse CVCL_C3YW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793292 CVCL_C3Z8 SC34.56 hybridoma house mouse CVCL_C3Z8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793293 CVCL_C3YV SC34.43 hybridoma house mouse CVCL_C3YV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793294 CVCL_C3Z7 SC34.55 hybridoma house mouse CVCL_C3Z7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793295 CVCL_C3YY SC34.46 hybridoma house mouse CVCL_C3YY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with mouse and rat). 155793296 CVCL_C3YX SC34.45 hybridoma house mouse CVCL_C3YX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793297 CVCL_C3Z9 SC34.58 hybridoma house mouse CVCL_C3Z9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793298 CVCL_C3YZ SC34.47 hybridoma house mouse CVCL_C3YZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793299 CVCL_C3Z0 SC34.48 hybridoma house mouse CVCL_C3Z0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793300 CVCL_C3YN SC34.35 hybridoma house mouse CVCL_C3YN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793301 CVCL_C3YQ SC34.37 hybridoma house mouse CVCL_C3YQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793302 CVCL_C3Z2 SC34.50 hybridoma house mouse CVCL_C3Z2 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793303 CVCL_C3YP SC34.36 hybridoma house mouse CVCL_C3YP CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793304 CVCL_C3Z1 SC34.49 hybridoma house mouse CVCL_C3Z1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793305 CVCL_C3YS SC34.39 hybridoma house mouse CVCL_C3YS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793306 CVCL_C3Z4 SC34.52 hybridoma house mouse CVCL_C3Z4 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4A9; Human DPEP2; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3 (Note=Also reacts with mouse). 155793307 CVCL_C3YR SC34.38 hybridoma house mouse CVCL_C3YR CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793308 CVCL_C3Z3 SC34.51 hybridoma house mouse CVCL_C3Z3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793309 CVCL_C3YU SC34.41 hybridoma house mouse CVCL_C3YU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793310 CVCL_C3Z6 SC34.54 hybridoma house mouse CVCL_C3Z6 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793311 CVCL_C3YT SC34.40 hybridoma house mouse CVCL_C3YT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793312 CVCL_C3Z5 SC34.53 hybridoma house mouse CVCL_C3Z5 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793313 CVCL_C3YG SC34.26 hybridoma house mouse CVCL_C3YG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793314 CVCL_C3YF SC34.25 hybridoma house mouse CVCL_C3YF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793315 CVCL_C3YI SC34.28 hybridoma house mouse CVCL_C3YI CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized antibody tamrintamab (hSC34.28) which when conjugated to a pyrrolobenzodiazepine dimer is known as tamrintamab pamozirine (SC-003) and is used in clinical trials for the treatment of ovarian carcinoma Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793316 CVCL_C3YH SC34.27 hybridoma house mouse CVCL_C3YH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793317 CVCL_C3YK SC34.32 hybridoma house mouse CVCL_C3YK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793318 CVCL_C3YJ SC34.29 hybridoma house mouse CVCL_C3YJ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793319 CVCL_C3YM SC34.34 hybridoma house mouse CVCL_C3YM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793320 CVCL_C3YL SC34.33 hybridoma house mouse CVCL_C3YL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H4B8; Human DPEP3. 155793321 CVCL_C3WA 20-6-3 hybridoma house mouse CVCL_C3WA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793322 CVCL_C3WC 3-13 hybridoma house mouse CVCL_C3WC CL:0000010 Monoclonal antibody isotype: IgG1, kappa (CelloPub=CLPUB00724; PubMed=6434941); IgM, kappa (PubMed=2104617); Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793323 CVCL_C3WB 3-12 hybridoma house mouse CVCL_C3WB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793324 CVCL_C3W5 2-9 hybridoma house mouse CVCL_C3W5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793325 CVCL_C3VT 3-C4F5 hybridoma house mouse CVCL_C3VT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:17347; Testosterone (Note=Also reacts with DHEAS). Group: Patented cell line 155793326 CVCL_C3W4 2-44 hybridoma house mouse CVCL_C3W4 CL:0000010 Monoclonal antibody isotype: IgG1+IgM, kappa+lambda; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793327 CVCL_C3VS SCP-9 telomerase immortalized cell line human CVCL_C3VS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 155793328 CVCL_C3VV 12C1 hybridoma house mouse CVCL_C3VV CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:193573; Isomiroestrol. 155793329 CVCL_C3W7 20-19-1 hybridoma house mouse CVCL_C3W7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793330 CVCL_C3W6 20-17-3 hybridoma house mouse CVCL_C3W6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793331 CVCL_C3VU FB5 hybridoma house mouse CVCL_C3VU CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized ontuxizumab (MORAb-004) therapeutic antibody which was used in clinical trials for the treatment of metastatic melanoma Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HCU0; Human CD248. 155793332 CVCL_C3VX 12-40 hybridoma house mouse CVCL_C3VX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793333 CVCL_C3W9 20-4-4 hybridoma house mouse CVCL_C3W9 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793334 CVCL_C3VW 10-25 hybridoma house mouse CVCL_C3VW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793335 CVCL_C3W8 20-20-3 hybridoma house mouse CVCL_C3W8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793336 CVCL_C3VZ 2-14 hybridoma house mouse CVCL_C3VZ CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793337 CVCL_C3VY 18-2-3 hybridoma house mouse CVCL_C3VY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793338 CVCL_C3VL 41D5 hybridoma house mouse CVCL_C3VL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A7LCJ3; Pig SIGLEC1/CD169. 155793339 CVCL_C3VK 41D3 hybridoma house mouse CVCL_C3VK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A7LCJ3; Pig SIGLEC1/CD169. 155793340 CVCL_C3VN PK15S1-CD163 spontaneously immortalized cell line pig CVCL_C3VN CL:0000010 Transfected with: VGNC; 108736; Pig SIGLEC1; Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome (PRRSV) 155793341 CVCL_C3VM PK15S1 spontaneously immortalized cell line pig CVCL_C3VM CL:0000010 Transfected with: VGNC; 108736; Pig SIGLEC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome (PRRSV) 155793342 CVCL_C3W1 2-27 hybridoma house mouse CVCL_C3W1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793343 CVCL_C3VP SCP-1 telomerase immortalized cell line human CVCL_C3VP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 155793344 CVCL_C3W0 2-21 hybridoma house mouse CVCL_C3W0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793345 CVCL_C3W3 2-40 hybridoma house mouse CVCL_C3W3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793346 CVCL_C3VR SCP-12 telomerase immortalized cell line human CVCL_C3VR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 155793347 CVCL_C3W2 2-3 hybridoma house mouse CVCL_C3W2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793348 CVCL_C3VQ SCP-11 telomerase immortalized cell line human CVCL_C3VQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 155793349 CVCL_C3VD HT-1080/hCLDN-7 cancer cell line human CVCL_C3VD CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2049; CLDN7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793350 CVCL_C3VC HT-1080/hCLDN-6 cancer cell line human CVCL_C3VC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2048; CLDN6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793351 CVCL_C3VF RK22 hybridoma house mouse CVCL_C3VF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14793; Human MSTN. Group: Patented cell line 155793352 CVCL_C3VE HT-1080/hCLDN-9 cancer cell line human CVCL_C3VE CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2051; CLDN9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793353 CVCL_C3VH 1G10 [Mouse hybridoma against pig SIGLEC10] hybridoma house mouse CVCL_C3VH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A068F110; Pig SIGLEC10. 155793354 CVCL_C3VG RK35 hybridoma house mouse CVCL_C3VG CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized domagrozumab (PF-06252616) therapeutic antibody which was used in clinical trials for the treatment of Duchenne muscular dystrophy Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14793; Human MSTN. Group: Patented cell line 155793355 CVCL_C3VJ PK15S10-CD163 spontaneously immortalized cell line pig CVCL_C3VJ CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; A0A068F110; Pig SIGLEC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome (PRRSV) 155793356 CVCL_C3VI PK15S10 spontaneously immortalized cell line pig CVCL_C3VI CL:0000010 Transfected with: UniProtKB; A0A068F110; Pig SIGLEC10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome (PRRSV) 155793357 CVCL_C3XB B120 hybridoma house mouse CVCL_C3XB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07700; Meleagris gallopavo ADRB1. 155793358 CVCL_C3XA HADMEC-5 transformed cell line human CVCL_C3XA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Perirenal fat Cell type=Adipose microvascular endothelial cell.. Unspecified 155793359 CVCL_C3XD BRK-2 hybridoma house mouse CVCL_C3XD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08588; Human ADRB1; Monoclonal antibody target: UniProtKB; P07550; Human ADRB2. 155793360 CVCL_C3XC BRK-1 hybridoma house mouse CVCL_C3XC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P07550; Human ADRB2. 155793361 CVCL_C3WU 9-40 hybridoma house mouse CVCL_C3WU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793362 CVCL_C3X6 mAbHpu24 hybridoma CVCL_C3X6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:21858; Hypusine (N6-[(2R)-4-amino-2-hydroxybutyl]-L-lysine). 155793363 CVCL_C3WT 6-19-1 hybridoma house mouse CVCL_C3WT CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793364 CVCL_C3X5 7G3 hybridoma house mouse CVCL_C3X5 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized talacotuzumab (CSL362) therapeutic antibody which was used in clinical trials for the treatment of acute myeloid leukemia Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26951; Human IL3RA/CD123. 155793365 CVCL_C3WW 7C11 [Mouse hybridoma against B.germanica Bla g 2] hybridoma house mouse CVCL_C3WW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54958; Blattella germanica aspartic protease Bla g 2. 155793366 CVCL_C3X8 mAbHpu98 hybridoma CVCL_C3X8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:21858; Hypusine (N6-[(2R)-4-amino-2-hydroxybutyl]-L-lysine). 155793367 CVCL_C3WV 4C3 [Mouse hybridoma against B.germanica Bla g 2] hybridoma house mouse CVCL_C3WV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54958; Blattella germanica aspartic protease Bla g 2. 155793368 CVCL_C3X7 mAbHpu91 hybridoma CVCL_C3X7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:21858; Hypusine (N6-[(2R)-4-amino-2-hydroxybutyl]-L-lysine). 155793369 CVCL_C3WY 1D4 [Mouse hybridoma against B.germanica Bla g 2] hybridoma house mouse CVCL_C3WY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54958; Blattella germanica aspartic protease Bla g 2. 155793370 CVCL_C3WX 10A6 [Mouse hybridoma against B.germanica Bla g 1] hybridoma house mouse CVCL_C3WX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UAM5; Blattella germanica allergen Bla g 1. 155793371 CVCL_C3X9 SV-BEC transformed cell line CVCL_C3X9 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.. Unspecified Doubling time: ~12 hours (PubMed=1683665) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1143 155793372 CVCL_C3WZ 3G12 [Mouse hybridoma against B.germanica unknown allergen] hybridoma house mouse CVCL_C3WZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Blattella germanica unknown allergen. 155793373 CVCL_C3WM 3-45 hybridoma house mouse CVCL_C3WM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793374 CVCL_C3WL 3-43 hybridoma house mouse CVCL_C3WL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793375 CVCL_C3X0 8F4 hybridoma house mouse CVCL_C3X0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54958; Blattella germanica aspartic protease Bla g 2. 155793376 CVCL_C3WN 4-4-20 hybridoma house mouse CVCL_C3WN CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793377 CVCL_C3WQ 5-14 hybridoma house mouse CVCL_C3WQ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793378 CVCL_C3X2 52R43 hybridoma house mouse CVCL_C3X2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46531; Human NOTCH1. Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9548 155793379 CVCL_C3WP 4-6-10 hybridoma house mouse CVCL_C3WP CL:0000010 Monoclonal antibody isotype: IgG1+IgG2, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793380 CVCL_C3X1 52M51 hybridoma house mouse CVCL_C3X1 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized brontictuzumab (OMP-52M51; 52M51H4L3) therapeutic antibody which was used in clinical trials for the treatment of lymphoid malignancies Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P46531; Human NOTCH1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9405 155793381 CVCL_C3WS 6-10-6 hybridoma house mouse CVCL_C3WS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793382 CVCL_C3X4 9F5 hybridoma house mouse CVCL_C3X4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26951; Human IL3RA/CD123. 155793383 CVCL_C3WR 5-27 hybridoma house mouse CVCL_C3WR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793384 CVCL_C3X3 6H6 [Mouse hybridoma against human IL3RA] hybridoma house mouse CVCL_C3X3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26951; Human IL3RA/CD123. 155793385 CVCL_C3WE 3-17 hybridoma house mouse CVCL_C3WE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793386 CVCL_C3WD 3-14 hybridoma house mouse CVCL_C3WD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793387 CVCL_C3WG 3-25 hybridoma house mouse CVCL_C3WG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793388 CVCL_C3WF 3-24 hybridoma house mouse CVCL_C3WF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793389 CVCL_C3WI 3-32 hybridoma house mouse CVCL_C3WI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793390 CVCL_C3WH 3-29 hybridoma house mouse CVCL_C3WH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793391 CVCL_C3WK 3-36 hybridoma house mouse CVCL_C3WK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793392 CVCL_C3WJ 3-35 hybridoma house mouse CVCL_C3WJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:172923; Fluorescein. 155793393 CVCL_C3TZ 10H2-C6 hybridoma house mouse CVCL_C3TZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793394 CVCL_C3TY 10B9-F6 hybridoma house mouse CVCL_C3TY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793395 CVCL_C3UA 5H8-C12 hybridoma house mouse CVCL_C3UA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793396 CVCL_C3U3 3E2-H12 hybridoma house mouse CVCL_C3U3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793397 CVCL_C3TR BABB75A4 hybridoma house mouse CVCL_C3TR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q17115; Babesia bovis 60 kDa merozoite surface protein rap-1 (Bv60) Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5171685 and PubMed=2473398 and to be P3X63Ag8.653 in PubMed=3410541. 155793398 CVCL_C3U2 3E2-E10 hybridoma house mouse CVCL_C3U2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793399 CVCL_C3TQ BABB35A4 hybridoma house mouse CVCL_C3TQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BN13; Babesia bovis merozoite surface antigen 1 (MSA-1) (Bo42) Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10115 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5171685 and PubMed=2473398 and to be P3X63Ag8.653 in PubMed=3410541. 155793400 CVCL_C3U5 4C1-B8 hybridoma house mouse CVCL_C3U5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1) (Note: Also reacts with Dermatophagoides pteronyssinus Der P 1). 155793401 CVCL_C3TT BABB93A1 hybridoma house mouse CVCL_C3TT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Babesia bovis merozoite 145 kDa surface antigen Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10112 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5171685 and to be P3X63Ag8.653 in PubMed=3410541. 155793402 CVCL_C3U4 3H8-G8 hybridoma house mouse CVCL_C3U4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793403 CVCL_C3TS BABB90C4 hybridoma house mouse CVCL_C3TS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Babesia bovis merozoite 85 kDa surface antigen Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10117 Caution: The myeloma fusion partner is indicated to be Sp2/0-Ag14 in Patent=US5171685 and to be P3X63Ag8.653 in PubMed=3410541. 155793404 CVCL_C3U7 5B1-C12 hybridoma house mouse CVCL_C3U7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793405 CVCL_C3TV CIIC2 hybridoma house mouse CVCL_C3TV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P02460; Chicken COL2A1. 155793406 CVCL_C3U6 4C1-C6 hybridoma house mouse CVCL_C3U6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1) (Note: Also reacts with Dermatophagoides pteronyssinus Der P 1). 155793407 CVCL_C3TU MBOC79B1 hybridoma house mouse CVCL_C3TU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q17115; Babesia bovis 60 kDa merozoite surface protein rap-1 (Bv60). 155793408 CVCL_C3TX 10B9-B6 hybridoma house mouse CVCL_C3TX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793409 CVCL_C3U9 5G5-A4 hybridoma house mouse CVCL_C3U9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793410 CVCL_C3U8 5B5-E6 hybridoma house mouse CVCL_C3U8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793411 CVCL_C3TW CC 29 hybridoma house mouse CVCL_C3TW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). 155793412 CVCL_C3TJ 23.28.57.108 hybridoma house mouse CVCL_C3TJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Babesia bovis merozoite 16 kDa surface antigen (Bo16). Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10116 155793413 CVCL_C3TI 23.10.36 hybridoma house mouse CVCL_C3TI CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BN13; Babesia bovis merozoite surface antigen 1 (MSA-1) (Bo42). 155793414 CVCL_C3TL 23.38.120.8 hybridoma house mouse CVCL_C3TL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q17115; Babesia bovis 60 kDa merozoite surface protein rap-1 (Bv60). Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10111 155793415 CVCL_C3TK 23.3.16 hybridoma house mouse CVCL_C3TK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BN13; Babesia bovis merozoite surface antigen 1 (MSA-1) (Bo42). 155793416 CVCL_C3TN 23.70.174.83 hybridoma house mouse CVCL_C3TN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Babesia bovis merozoite 44 kDa surface antigen (Bo44). Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10114 155793417 CVCL_C3TM 23.53.116 hybridoma house mouse CVCL_C3TM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q17115; Babesia bovis 60 kDa merozoite surface protein rap-1 (Bv60). 155793418 CVCL_C3TP 23.8.34.24 hybridoma house mouse CVCL_C3TP CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; A7ASX3; Babesia bovis spherical body protein 2 (SBP2) (Bo225). Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10113 155793419 CVCL_C3U1 3A6-A12 hybridoma house mouse CVCL_C3U1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793420 CVCL_C3U0 2G7-E8 hybridoma house mouse CVCL_C3U0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793421 CVCL_C3TB 5E11 hybridoma house mouse CVCL_C3TB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92934; Human BAD. 155793422 CVCL_C3TA 3E11 [Mouse hybridoma against human BAD] hybridoma house mouse CVCL_C3TA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92934; Human BAD. 155793423 CVCL_C3TD 6A11 hybridoma house mouse CVCL_C3TD CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92934; Human BAD. 155793424 CVCL_C3TC 5E6 hybridoma house mouse CVCL_C3TC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92934; Human BAD. 155793425 CVCL_C3TF 3H9 [Mouse hybridoma against human HBZ] hybridoma house mouse CVCL_C3TF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02008; Human HBZ. 155793426 CVCL_C3TE 1A12 hybridoma house mouse CVCL_C3TE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02008; Human HBZ. 155793427 CVCL_C3TH RP 215 hybridoma house mouse CVCL_C3TH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cells expressed IgH carbohydrate-associated epitope CA215/COX-1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10095 155793428 CVCL_C3TG 4D11 [Mouse hybridoma against human HBZ] hybridoma house mouse CVCL_C3TG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02008; Human HBZ. 155793429 CVCL_C3UZ CDN30 hybridoma house mouse CVCL_C3UZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793430 CVCL_C3VB HT-1080/hCLDN-5 cancer cell line human CVCL_C3VB CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2047; CLDN5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793431 CVCL_C3VA HT-1080/hCLDN-4 cancer cell line human CVCL_C3VA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2046; CLDN4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793432 CVCL_C3US CDN08 hybridoma house mouse CVCL_C3US CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793433 CVCL_C3V4 CDN36 hybridoma house mouse CVCL_C3V4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793434 CVCL_C3UR CDN07 hybridoma house mouse CVCL_C3UR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793435 CVCL_C3V3 CDN35 hybridoma house mouse CVCL_C3V3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3 (Note=Also reacts with mouse). 155793436 CVCL_C3UU CDN17 hybridoma house mouse CVCL_C3UU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793437 CVCL_C3V6 CDN38 hybridoma house mouse CVCL_C3V6 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793438 CVCL_C3UT CDN16 hybridoma house mouse CVCL_C3UT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3 (Note=Also reacts with mouse). 155793439 CVCL_C3V5 CDN37 hybridoma house mouse CVCL_C3V5 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793440 CVCL_C3UW CDN27 hybridoma house mouse CVCL_C3UW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793441 CVCL_C3V8 HT-1080/hCLDN-2 cancer cell line human CVCL_C3V8 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2041; CLDN2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793442 CVCL_C3UV CDN24 hybridoma house mouse CVCL_C3UV CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793443 CVCL_C3V7 HT-1080/hCLDN-1 cancer cell line human CVCL_C3V7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2032; CLDN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793444 CVCL_C3UY CDN29 hybridoma house mouse CVCL_C3UY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793445 CVCL_C3UX CDN28 hybridoma house mouse CVCL_C3UX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793446 CVCL_C3V9 HT-1080/hCLDN-3 cancer cell line human CVCL_C3V9 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2045; CLDN3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 155793447 CVCL_C3UK 5D12 [Rat hybridoma against human CLDN4] hybridoma CVCL_C3UK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4 (Note=Also reacts with mouse). 155793448 CVCL_C3UJ 5A5 [Rat hybridoma against human CLDN3 and CLDN4] hybridoma CVCL_C3UJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793449 CVCL_C3UM CDN02 hybridoma house mouse CVCL_C3UM CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793450 CVCL_C3UL CDN01 hybridoma house mouse CVCL_C3UL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793451 CVCL_C3V0 CDN31 hybridoma house mouse CVCL_C3V0 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793452 CVCL_C3UN CDN03 hybridoma house mouse CVCL_C3UN CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793453 CVCL_C3UQ CDN05 hybridoma house mouse CVCL_C3UQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3; Monoclonal antibody target: UniProtKB; O14493; Human CLDN4. 155793454 CVCL_C3V2 CDN33 hybridoma house mouse CVCL_C3V2 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793455 CVCL_C3UP CDN04 hybridoma house mouse CVCL_C3UP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793456 CVCL_C3V1 CDN32 hybridoma house mouse CVCL_C3V1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O15551; Human CLDN3. 155793457 CVCL_C3UC 6A8-B10 hybridoma house mouse CVCL_C3UC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793458 CVCL_C3UB 5H8-D8 hybridoma house mouse CVCL_C3UB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793459 CVCL_C3UE 6A9-D7 hybridoma house mouse CVCL_C3UE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793460 CVCL_C3UD 6A8-E8 hybridoma house mouse CVCL_C3UD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16311; Dermatophagoides farinae peptidase 1 (allergen Der f 1) (DERF1). 155793461 CVCL_C3UG 7E3-E8 hybridoma house mouse CVCL_C3UG CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793462 CVCL_C3UF 7E10-F6 hybridoma house mouse CVCL_C3UF CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08176; Dermatophagoides pteronyssinus peptidase 1 (allergen Der p 1) (DERP1). 155793463 CVCL_C3UI WH9 hybridoma house mouse CVCL_C3UI CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P49273; Dermatophagoides pteronyssinus allergen Der p 7 (DERP7) (Note=Also reacts with Dermatophagoides farinae Der f7). 155793464 CVCL_C3UH WH22 hybridoma house mouse CVCL_C3UH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49273; Dermatophagoides pteronyssinus allergen Der p 7 (DERP7) (Note=Also reacts with Dermatophagoides farinae Der f7). 155793465 CVCL_C5FJ 8G2 hybridoma house mouse CVCL_C5FJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793466 CVCL_C5FI 8G1 hybridoma house mouse CVCL_C5FI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793467 CVCL_C5FL 9B8 hybridoma house mouse CVCL_C5FL CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793468 CVCL_C5FK 9A10 hybridoma house mouse CVCL_C5FK CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793469 CVCL_C5FN P4G6a hybridoma house mouse CVCL_C5FN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Naja ashei three-finger toxins (3FTxs). Group: Animal toxin research hybridoma 155793470 CVCL_C5FM 9H4 hybridoma house mouse CVCL_C5FM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793471 CVCL_C5G1 BNTX4 hybridoma house mouse CVCL_C5G1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin). Group: Animal toxin research hybridoma 155793472 CVCL_C5FP P6D9a hybridoma house mouse CVCL_C5FP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Naja ashei three-finger toxins (3FTxs). Group: Animal toxin research hybridoma 155793473 CVCL_C5G0 4C4.1 hybridoma house mouse CVCL_C5G0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23631; Latrodectus tredecimguttatus alpha-latrotoxin-Lt1a. Group: Animal toxin research hybridoma 155793474 CVCL_C5FB 6D8 hybridoma house mouse CVCL_C5FB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793475 CVCL_C5FA 6C12 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5FA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793476 CVCL_C5FD 6G11 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5FD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793477 CVCL_C5FC 6E11 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5FC CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793478 CVCL_C5FF 8C7 hybridoma house mouse CVCL_C5FF CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793479 CVCL_C5FE 7A10 hybridoma house mouse CVCL_C5FE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793480 CVCL_C5FH 8E5 hybridoma house mouse CVCL_C5FH CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793481 CVCL_C5FG 8E12 hybridoma house mouse CVCL_C5FG CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793482 CVCL_C5EY Y11 hybridoma house mouse CVCL_C5EY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q61453; Rat Il17a Caution: The paper title of PubMed=21707364 mentions that the mAB is against mouse IL-17 but the text indicates it was raised against rat IL-17. 155793483 CVCL_C5EX 3F2 [Rat hybridoma against mouse Kpna7] hybridoma CVCL_C5EX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; C0LLJ0; Mouse Kpna7. 155793484 CVCL_C5F9 6B2 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5F9 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793485 CVCL_C5EZ 12C2 [Mouse hybridoma against T-2 mycotoxin] hybridoma house mouse CVCL_C5EZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:9381; T-2 mycotoxin. 155793486 CVCL_C5F2 1C11 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5F2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793487 CVCL_C5EQ 8F5 [Mouse hybridoma against T.tridentatus TP-1] hybridoma house mouse CVCL_C5EQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14213; Tachypleus tridentatus tachyplesin-1 (TP-1). 155793488 CVCL_C5EP 6B12 hybridoma house mouse CVCL_C5EP CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14213; Tachypleus tridentatus tachyplesin-1 (TP-1). 155793489 CVCL_C5F1 Li mAb(7) hybridoma house mouse CVCL_C5F1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0CE81; Loxosceles intermedia dermonecrotic toxin LiSicTox-alphaIA1bi. Group: Animal toxin research hybridoma 155793490 CVCL_C5F4 10E9 hybridoma house mouse CVCL_C5F4 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793491 CVCL_C5ES L929/CD83 spontaneously immortalized cell line house mouse CVCL_C5ES CL:0000010 Transfected with: HGNC; 1703; CD83; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 155793492 CVCL_C5F3 1C7 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5F3 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793493 CVCL_C5ER 3F8 [Rat hybridoma against human KPNA6] hybridoma CVCL_C5ER CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O60684; Human KPNA6 (Note=Also reacts with other mammalian species). 155793494 CVCL_C5F6 5E10 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5F6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793495 CVCL_C5EU 8B4 hybridoma house mouse CVCL_C5EU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01151; Human CD83. 155793496 CVCL_C5ET 1E11 [Mouse hybridoma against human CD83] hybridoma house mouse CVCL_C5ET CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01151; Human CD83. 155793497 CVCL_C5F5 5D6 [Mouse hybridoma against T.annularis PA2 inhibitor gamma A2] hybridoma house mouse CVCL_C5F5 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793498 CVCL_C5EW 4H7 [Mouse hybridoma against human CD276] hybridoma house mouse CVCL_C5EW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276 (isoform 2IgB7-H3). 155793499 CVCL_C5F8 5G1 hybridoma house mouse CVCL_C5F8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793500 CVCL_C5EV 21D4 hybridoma house mouse CVCL_C5EV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276 (isoform 2IgB7-H3). 155793501 CVCL_C5F7 5E9 hybridoma house mouse CVCL_C5F7 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0DQX3; Trimerodytes annularis phospholipase A2 inhibitor gamma A2 (Note=Also reacts with many other snake PA2 inhibitors). Group: Animal toxin research hybridoma 155793502 CVCL_C5GK 5B9 hybridoma house mouse CVCL_C5GK CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; E7BLC7; Androctonus crassicauda toxin Acra3. Group: Animal toxin research hybridoma 155793503 CVCL_C5GJ 3G8 [Mouse hybridoma against ciguatoxin CTX1B] hybridoma house mouse CVCL_C5GJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:36467; Ciguatoxin CTX1B. 155793504 CVCL_C5GM HU3R15 transformed cell line CVCL_C5GM CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 22.32 hours (PubMed=2793228) Group: Bird cell line 155793505 CVCL_C5GL RECC-HU3 transformed cell line CVCL_C5GL CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Derived from sampling site: Cell type=B-cell. Doubling time: 16.8 hours (PubMed=3273463); 18.34 hours (PubMed=2793228) Group: Bird cell line 155793506 CVCL_C5H0 R27H4 hybrid cell line CVCL_C5H0 CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Doubling time: 13.80 hours (PubMed=2045661) Group: Bird cell line; Group: Hybridoma fusion partner cell line 155793507 CVCL_C5GN HU3R22 transformed cell line CVCL_C5GN CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 18.01 hours (PubMed=2793228) Group: Bird cell line 155793508 CVCL_C5H2 HU/Ch-22-2 hybridoma CVCL_C5H2 CL:0000010 Monoclonal antibody isotype: IgG+IgM; Monoclonal antibody target: UniProtKB; Q10583; Megathura crenulata hemocyanin 1 (KLH1); Monoclonal antibody target: UniProtKB; Q10584; Megathura crenulata hemocyanin 2 (KLH2). Group: Bird cell line 155793509 CVCL_C5GQ HU3R24 transformed cell line CVCL_C5GQ CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 21.78 hours (PubMed=2793228) Group: Bird cell line 155793510 CVCL_C5H1 HU/Ch-22 hybridoma CVCL_C5H1 CL:0000010 Monoclonal antibody isotype: IgG+IgM; Monoclonal antibody target: UniProtKB; Q10583; Megathura crenulata hemocyanin 1 (KLH1); Monoclonal antibody target: UniProtKB; Q10584; Megathura crenulata hemocyanin 2 (KLH2). Group: Bird cell line 155793511 CVCL_C5GP HU3R23 transformed cell line CVCL_C5GP CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 28.01 hours (PubMed=2793228) Group: Bird cell line 155793512 CVCL_C5GC 6E2 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_C5GC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793513 CVCL_C5GB 6C1 hybridoma house mouse CVCL_C5GB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793514 CVCL_C5GE H305.G8G1 hybridoma house mouse CVCL_C5GE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20474; Bothrops asper basic phospholipase A2 myotoxin I. Group: Animal toxin research hybridoma 155793515 CVCL_C5GD 8H9 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_C5GD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793516 CVCL_C5GG Malpha2-3 hybridoma house mouse CVCL_C5GG CL:0000010 Characteristics: The mAb produced by this hybridoma partially mimicks the nicotinic AchR; Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01426; Naja pallida short neurotoxin 1 (Neurotoxin alpha) (Note=Reacts with short neurotoxins from many snake species). Group: Animal toxin research hybridoma 155793517 CVCL_C5GF H305.G9F4 hybridoma house mouse CVCL_C5GF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20474; Bothrops asper basic phospholipase A2 myotoxin I. Group: Animal toxin research hybridoma 155793518 CVCL_C5GI 8H4 hybridoma house mouse CVCL_C5GI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:36467; Ciguatoxin CTX1B; Monoclonal antibody target: ChEBI; CHEBI:61279; 51-hydroxy ciguatoxin CTX3C. 155793519 CVCL_C5GH Malpha1 hybridoma house mouse CVCL_C5GH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01426; Naja pallida short neurotoxin 1 (Neurotoxin alpha). Group: Animal toxin research hybridoma 155793520 CVCL_C5FZ LiD1mAb16 hybridoma house mouse CVCL_C5FZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0CE81; Loxosceles intermedia dermonecrotic toxin LiSicTox-alphaIA1bi (Note=Also reacts with other related toxins in both L.intermedia and other Loxosceles species). Group: Animal toxin research hybridoma 155793521 CVCL_C5FY 9H3 hybridoma house mouse CVCL_C5FY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P81694; Cupiennius salei toxin CSTX-1/CSTX-2. Group: Animal toxin research hybridoma 155793522 CVCL_C5GA 5B7 hybridoma house mouse CVCL_C5GA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793523 CVCL_C5FR BCF1 hybridoma house mouse CVCL_C5FR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2; Monoclonal antibody target: UniProtKB; P80076; Centruroides noxius toxin Cn3. Group: Animal toxin research hybridoma 155793524 CVCL_C5G3 BNTX14 hybridoma house mouse CVCL_C5G3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin). Group: Animal toxin research hybridoma 155793525 CVCL_C5G2 BNTX12 hybridoma house mouse CVCL_C5G2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin). Group: Animal toxin research hybridoma 155793526 CVCL_C5FQ P6D9b hybridoma house mouse CVCL_C5FQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Naja ashei three-finger toxins (3FTxs). Group: Animal toxin research hybridoma 155793527 CVCL_C5FT BCF3 hybridoma house mouse CVCL_C5FT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2. Group: Animal toxin research hybridoma 155793528 CVCL_C5G5 BNTX18 hybridoma house mouse CVCL_C5G5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin). Group: Animal toxin research hybridoma 155793529 CVCL_C5FS BCF2 hybridoma house mouse CVCL_C5FS CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2. Group: Animal toxin research hybridoma 155793530 CVCL_C5G4 BNTX16 hybridoma house mouse CVCL_C5G4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin) (Note=Also reacts with other Centruroides species). Group: Animal toxin research hybridoma 155793531 CVCL_C5G7 2A5 hybridoma house mouse CVCL_C5G7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793532 CVCL_C5FV BCF8 hybridoma house mouse CVCL_C5FV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2; Monoclonal antibody target: UniProtKB; P80076; Centruroides noxius toxin Cn3. Group: Animal toxin research hybridoma 155793533 CVCL_C5FU BCF7 hybridoma house mouse CVCL_C5FU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2. Group: Animal toxin research hybridoma 155793534 CVCL_C5G6 BNTX21 hybridoma house mouse CVCL_C5G6 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08815; Centruroides noxius potassium channel toxin alpha-KTx 2.1 (Noxiustoxin). Group: Animal toxin research hybridoma 155793535 CVCL_C5FX 10F8 hybridoma house mouse CVCL_C5FX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P58604; Cupiennius salei toxin CSTX-9/CSTX-7. Group: Animal toxin research hybridoma 155793536 CVCL_C5G9 4F10 [Mouse China hybridoma against human GRN] hybridoma house mouse CVCL_C5G9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793537 CVCL_C5G8 3E7 hybridoma house mouse CVCL_C5G8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28799; Human GRN. 155793538 CVCL_C5FW BCF9 hybridoma house mouse CVCL_C5FW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01495; Centruroides noxius toxin Cn2. Group: Animal toxin research hybridoma 155793539 CVCL_C5DH SC 3T3/W spontaneously immortalized cell line house mouse CVCL_C5DH CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: 19.5 hours (PubMed=1709732) 155793540 CVCL_C5DG 10F10-C1-B8 hybridoma house mouse CVCL_C5DG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P18507; Human GABRG2 (Note=Also reacts with mouse and rat). 155793541 CVCL_C5DJ sfBJAB cancer cell line human CVCL_C5DJ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative Group: Serum/protein free medium cell line 155793542 CVCL_C5DI SCSV-9 transformed cell line house mouse CVCL_C5DI CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: 27.1 hours (PubMed=1709732) 155793543 CVCL_C5DL sfRaji cancer cell line human CVCL_C5DL CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Group: Serum/protein free medium cell line 155793544 CVCL_C5DK sfJiyoye cancer cell line human CVCL_C5DK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Group: Serum/protein free medium cell line 155793545 CVCL_C5DN sfP3HR-1 cancer cell line human CVCL_C5DN CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Group: Serum/protein free medium cell line 155793546 CVCL_C5DM sfAWRamos cancer cell line human CVCL_C5DM CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (from parent cell line) Group: Serum/protein free medium cell line 155793547 CVCL_C5DB 34B2 hybridoma house mouse CVCL_C5DB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02548; Bovine NEFL. 155793548 CVCL_C5DA 2:1 hybridoma house mouse CVCL_C5DA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F7ED68; Macaca mulatta NEFL (Note=Also reacts with bovine). 155793549 CVCL_C5DD 45 hybridoma house mouse CVCL_C5DD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F7ED68; Macaca mulatta NEFL (Note=Also reacts with bovine). 155793550 CVCL_C5DC 43C2 hybridoma house mouse CVCL_C5DC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F7ED68; Macaca mulatta NEFL (Note=Also reacts with bovine). 155793551 CVCL_C5DF 5F3 hybridoma house mouse CVCL_C5DF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q10471; Human GALNT2. 155793552 CVCL_C5DE 47:3 hybridoma house mouse CVCL_C5DE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02548; Bovine NEFL. 155793553 CVCL_C5CW AM5 hybridoma house mouse CVCL_C5CW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793554 CVCL_C5D8 KLMab-1 hybridoma house mouse CVCL_C5D8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q96E93; Human KLRG1. 155793555 CVCL_C5CV AM4 hybridoma house mouse CVCL_C5CV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793556 CVCL_C5D7 CHO/PA-hKLRG1 spontaneously immortalized cell line CVCL_C5D7 CL:0000010 Transfected with: HGNC; 6380; KLRG1 (with a N-terminal PA tag); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Ovary. Female 155793557 CVCL_C5CY AM7 hybridoma house mouse CVCL_C5CY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793558 CVCL_C5D9 12C2 [Mouse hybridoma against bovine NEFL] hybridoma house mouse CVCL_C5D9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02548; Bovine NEFL. 155793559 CVCL_C5CX AM6 hybridoma house mouse CVCL_C5CX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793560 CVCL_C5CZ AM8 hybridoma house mouse CVCL_C5CZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793561 CVCL_C5D0 1B8 hybridoma house mouse CVCL_C5D0 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; D0EYG3; Chicken SELENOW. 155793562 CVCL_C5CN 2A2 [Mouse hybridoma against E.coli radA] hybridoma house mouse CVCL_C5CN CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P24554; Escherichia coli radA. 155793563 CVCL_C5D2 3F9 [Mouse hybridoma against human HSPA5] hybridoma house mouse CVCL_C5D2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11021; Human HSPA5. 155793564 CVCL_C5CQ 6F5 hybridoma house mouse CVCL_C5CQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24554; Escherichia coli radA. 155793565 CVCL_C5CP 3A10 [Mouse hybridoma against E.coli radA] hybridoma house mouse CVCL_C5CP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24554; Escherichia coli radA. 155793566 CVCL_C5D1 4H5 hybridoma house mouse CVCL_C5D1 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; D0EYG3; Chicken SELENOW. 155793567 CVCL_C5D4 1A6H14 hybridoma house mouse CVCL_C5D4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14907; Human TAX1BP3. 155793568 CVCL_C5CS AM1 hybridoma house mouse CVCL_C5CS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793569 CVCL_C5D3 2D6F9 hybridoma house mouse CVCL_C5D3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11021; Human HSPA5 Group: Patented cell line 155793570 CVCL_C5CR 7A11 [Mouse hybridoma against E.coli radA] hybridoma house mouse CVCL_C5CR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24554; Escherichia coli radA. 155793571 CVCL_C5D6 3A415 hybridoma house mouse CVCL_C5D6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14907; Human TAX1BP3. 155793572 CVCL_C5CU AM3 hybridoma house mouse CVCL_C5CU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793573 CVCL_C5D5 2C6F3 hybridoma house mouse CVCL_C5D5 CL:0000010 Biotechnology: When conjugated to a radioisotope, the monoclonal antibody produced by this hybridoma can be used as a radio-immunoconjugate for the treatment of lung cancer models in mice (PubMed=27270318) Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14907; Human TAX1BP3. Group: Patented cell line 155793574 CVCL_C5CT AM2 [Mouse hybridoma against bovine MPO] hybridoma house mouse CVCL_C5CT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6QPT4; Bovine MPO. 155793575 CVCL_C5EI 2D5 [Mouse hybridoma against human SKI] hybridoma house mouse CVCL_C5EI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12755; Human SKI. 155793576 CVCL_C5EH 24G5 hybridoma house mouse CVCL_C5EH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6NTJ3; Xenopus laevis greatwall (mastl). 155793577 CVCL_C5EK 4C9 [Mouse hybridoma against human SKI] hybridoma house mouse CVCL_C5EK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12755; Human SKI. 155793578 CVCL_C5EJ 3F7 [Mouse hybridoma against human SKI] hybridoma house mouse CVCL_C5EJ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P12755; Human SKI. 155793579 CVCL_C5EM 3B8 [Mouse hybridoma against T.tridentatus TP-1] hybridoma house mouse CVCL_C5EM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14213; Tachypleus tridentatus tachyplesin-1 (TP-1). 155793580 CVCL_C5EL 2D8 hybridoma house mouse CVCL_C5EL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14213; Tachypleus tridentatus tachyplesin-1 (TP-1). 155793581 CVCL_C5F0 15H6 hybridoma house mouse CVCL_C5F0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:9381; T-2 mycotoxin. 155793582 CVCL_C5EN 5H2 hybridoma house mouse CVCL_C5EN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14213; Tachypleus tridentatus tachyplesin-1 (TP-1). 155793583 CVCL_C5EA SZ-51 hybridoma house mouse CVCL_C5EA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P. 155793584 CVCL_C5EC Anti-FXYD6 hybridoma house mouse CVCL_C5EC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9H0Q3; Human FXYD6. 155793585 CVCL_C5EB MD3 hybridoma house mouse CVCL_C5EB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A8C0PTS8; Dog SELP/CD62P 155793586 CVCL_C5EE 19C5 hybridoma house mouse CVCL_C5EE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6NTJ3; Xenopus laevis greatwall (mastl). 155793587 CVCL_C5ED 11E4 hybridoma house mouse CVCL_C5ED CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6NTJ3; Xenopus laevis greatwall (mastl). 155793588 CVCL_C5EG 24B12 hybridoma house mouse CVCL_C5EG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6NTJ3; Xenopus laevis greatwall (mastl). 155793589 CVCL_C5EF 19G8 hybridoma house mouse CVCL_C5EF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6NTJ3; Xenopus laevis greatwall (mastl). 155793590 CVCL_C5DX S9E2 hybridoma house mouse CVCL_C5DX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Specific to bovine). 155793591 CVCL_C5E9 SZ-22 hybridoma house mouse CVCL_C5E9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08514; Human ITGA2B/CD41. 155793592 CVCL_C5DW S8D1 hybridoma house mouse CVCL_C5DW CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Also reacts with human, mouse, guinea-pig and pig). 155793593 CVCL_C5E8 SZ-21 hybridoma house mouse CVCL_C5E8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 155793594 CVCL_C5DZ ALB2 hybridoma house mouse CVCL_C5DZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155793595 CVCL_C5DY ALB1 hybridoma house mouse CVCL_C5DY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 155793596 CVCL_C5E1 ALB7 hybridoma house mouse CVCL_C5E1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 155793597 CVCL_C5DP LHN13 transformed cell line human CVCL_C5DP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155793598 CVCL_C5E0 ALB6 hybridoma house mouse CVCL_C5E0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21926; Human CD9. 155793599 CVCL_C5E3 ALB9 hybridoma house mouse CVCL_C5E3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 155793600 CVCL_C5DR LHN6 transformed cell line human CVCL_C5DR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155793601 CVCL_C5E2 ALB8 hybridoma house mouse CVCL_C5E2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 155793602 CVCL_C5DQ LHN17 transformed cell line human CVCL_C5DQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 155793603 CVCL_C5E5 1H11 [Mouse hybridoma against methyl-alpha-D-mannopyranoside] hybridoma house mouse CVCL_C5E5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:43943; Methyl alpha-D-mannoside (Methyl alpha-D-mannopyranoside). 155793604 CVCL_C5DT S6D8 hybridoma house mouse CVCL_C5DT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Also reacts with human, mouse, guinea-pig and pig). 155793605 CVCL_C5E4 N14 hybridoma house mouse CVCL_C5E4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P43652; Human AFAM. 155793606 CVCL_C5DS S2D2 hybridoma house mouse CVCL_C5DS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Also reacts with human). 155793607 CVCL_C5E7 2D10 [Mouse hybridoma against methyl-alpha-D-mannopyranoside] hybridoma house mouse CVCL_C5E7 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:43943; Methyl alpha-D-mannoside (Methyl alpha-D-mannopyranoside). 155793608 CVCL_C5DV S7D6 hybridoma house mouse CVCL_C5DV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Also reacts with human, mouse, guinea-pig and pig). 155793609 CVCL_C5E6 1H7 hybridoma house mouse CVCL_C5E6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:43943; Methyl alpha-D-mannoside (Methyl alpha-D-mannopyranoside). 155793610 CVCL_C5DU S6H8 hybridoma house mouse CVCL_C5DU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08168; Bovine SAG (Note=Also reacts with human, mouse, guinea-pig and pig). 155793611 CVCL_C5BF 2E11 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793612 CVCL_C5BE 1A1 hybridoma house mouse CVCL_C5BE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793613 CVCL_C5BH 4B8 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793614 CVCL_C5BG 4A8 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793615 CVCL_C5BJ 5D6 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793616 CVCL_C5BI 4E12 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793617 CVCL_C5BL 7D10 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793618 CVCL_C5BK 5G7 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793619 CVCL_C5BB IPAM 3C8 transformed cell line pig CVCL_C5BB CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Persistently infected with porcine circovirus type 1 (PCV1) (PubMed=34737324) Doubling time: 88 hours (PubMed=12088830) 155793620 CVCL_C5BA IPAM 3C10 transformed cell line pig CVCL_C5BA CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Persistently infected with porcine circovirus type 1 (PCV1) (PubMed=34737324) Doubling time: 68 hours (PubMed=12088830) 155793621 CVCL_C5BD IPAM 3F6 transformed cell line pig CVCL_C5BD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Persistently infected with porcine circovirus type 1 (PCV1) (PubMed=34737324) 155793622 CVCL_C5BC IPAM 3E8 transformed cell line pig CVCL_C5BC CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Persistently infected with porcine circovirus type 1 (PCV1) (PubMed=34737324) Doubling time: 70 hours (PubMed=12088830) 155793623 CVCL_C5AU 6B11 hybridoma house mouse CVCL_C5AU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793624 CVCL_C5B6 NL20T-B transformed cell line human CVCL_C5B6 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Female Characteristics: Tumorigenic Established from a subcutaneous tumor in an athymic nude mouse inoculated with the parent cell line (PubMed=8521416). 155793625 CVCL_C5AT 3G1 [Mouse hybridoma against G.vaginalis vaginolysin] hybridoma house mouse CVCL_C5AT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793626 CVCL_C5B5 NL20T transformed cell line human CVCL_C5B5 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Female Characteristics: Forms very slowly growing tumors in nude mice Established from a spontaneously occurring subcutaneous tumor in an athymic nude mouse inoculated with the parent cell line (PubMed=9216860). 155793627 CVCL_C5AW 4H7 [Mouse hybridoma against BPV12 VP7] hybridoma house mouse CVCL_C5AW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; R4J9J2; Bluetongue virus 12 VP7 (Note=Also reacts with all other BPV serotypes). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.5715 155793628 CVCL_C5B8 Efk1B transformed cell line CVCL_C5B8 CL:0000010 Transformant: Myotis polyomavirus large T-antigen (MyPVTag); Derived from sampling site: Kidney. Male Group: Bat cell line 155793629 CVCL_C5AV 9B4 hybridoma house mouse CVCL_C5AV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793630 CVCL_C5B7 ZZ-R MVV infected spontaneously immortalized cell line CVCL_C5B7 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Unspecified Virology: Persently infected by maedi visna virus (MVV) (PubMed=27795464) 155793631 CVCL_C5AY IVA4 hybridoma house mouse CVCL_C5AY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I7AFU8; Bluetongue virus 16 VP7 (Note=Also reacts with all other BPV serotypes). 155793632 CVCL_C5B9 Efk2F transformed cell line CVCL_C5B9 CL:0000010 Transformant: Myotis polyomavirus large T-antigen (MyPVTag); Derived from sampling site: Kidney. Male Group: Bat cell line 155793633 CVCL_C5AX IB7 hybridoma house mouse CVCL_C5AX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I7AFU8; Bluetongue virus 16 VP7 (Note=Also reacts with most other BPV serotypes except BTV7, BTV15 and BTV19). 155793634 CVCL_C5AZ NL20SV finite cell line human CVCL_C5AZ CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Female Senescence: SV40 transformed but with a finite life span Senesces after 22 passages (PubMed=21566947).; Doubling time: 36 hours (PubMed=21566947) 155793635 CVCL_C5AM 18B6 [Mouse hybridoma against G.vaginalis vaginolysin] hybridoma house mouse CVCL_C5AM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793636 CVCL_C5AL 12E1 hybridoma house mouse CVCL_C5AL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793637 CVCL_C5B0 NL11SV finite cell line human CVCL_C5B0 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Unspecified Senescence: SV40 transformed but with a finite life span Senesces after 22 passages (PubMed=21566947).; Doubling time: 44 hours (PubMed=21566947) 155793638 CVCL_C5AN 1E1 [Mouse hybridoma against G.vaginalis vaginolysin] hybridoma house mouse CVCL_C5AN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793639 CVCL_C5AQ 20E8 hybridoma house mouse CVCL_C5AQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793640 CVCL_C5B2 NL25 finite cell line human CVCL_C5B2 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Unspecified Senescence: SV40 transformed but with a finite life span Senesces after 21 passages (PubMed=21566947).; Doubling time: 32 hours (PubMed=21566947) 155793641 CVCL_C5AP 20E5 hybridoma house mouse CVCL_C5AP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793642 CVCL_C5B1 NL4SV finite cell line human CVCL_C5B1 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Unspecified Senescence: SV40 transformed but with a finite life span Senesces after 28 passages (PubMed=21566947).; Doubling time: 28 hours (PubMed=21566947) 155793643 CVCL_C5AS 23A2 hybridoma house mouse CVCL_C5AS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793644 CVCL_C5B4 NL30-O finite cell line human CVCL_C5B4 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Unspecified Senescence: SV40 transformed but with a finite life span Senesces after 19 passages (PubMed=21566947).; Doubling time: 28 hours (PubMed=21566947) 155793645 CVCL_C5AR 21A5 hybridoma house mouse CVCL_C5AR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793646 CVCL_C5B3 NL30-N finite cell line human CVCL_C5B3 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Unspecified Senescence: SV40 transformed but with a finite life span Senesces after 19 passages (PubMed=21566947).; Doubling time: 28 hours (PubMed=21566947) 155793647 CVCL_C5CG 3D9 [Mouse hybridoma against goose parvovirus NS1] hybridoma house mouse CVCL_C5CG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793648 CVCL_C5CF 2D4 [Mouse hybridoma against goose parvovirus NS1] hybridoma house mouse CVCL_C5CF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793649 CVCL_C5CI 3H8 hybridoma house mouse CVCL_C5CI CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793650 CVCL_C5CH 3F12 [Mouse hybridoma against goose parvovirus NS1] hybridoma house mouse CVCL_C5CH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793651 CVCL_C5CK G9G7 hybridoma house mouse CVCL_C5CK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a. 155793652 CVCL_C5CJ 4C6 [Mouse hybridoma against goose parvovirus NS1] hybridoma house mouse CVCL_C5CJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793653 CVCL_C5CM 4D2 [Mouse hybridoma against human CHI3L2] hybridoma house mouse CVCL_C5CM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q15782; Human CHI3L2. 155793654 CVCL_C5CL 2D3 [Mouse hybridoma against human CHI3L2] hybridoma house mouse CVCL_C5CL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q15782; Human CHI3L2. 155793655 CVCL_C5CA FMU-hBAP31.6 hybridoma house mouse CVCL_C5CA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793656 CVCL_C5CC FMU-ratBAP31 hybridoma house mouse CVCL_C5CC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q6AY58; Rat Bcap31. 155793657 CVCL_C5CB FMU-hBAP31.7 hybridoma house mouse CVCL_C5CB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793658 CVCL_C5CE 1B2 [Mouse hybridoma against goose parvovirus NS1] hybridoma house mouse CVCL_C5CE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I1VWH1; Goose parvovirus non-structural protein 1 (NS1). 155793659 CVCL_C5CD 1H5D7E3 hybridoma house mouse CVCL_C5CD CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P21554; Human CNR1. 155793660 CVCL_C5BV 6G11 [Mouse hybridoma against human ATP5F1B] hybridoma house mouse CVCL_C5BV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06576; Human ATP5F1B. 155793661 CVCL_C5C7 FMU-hBAP31.3 hybridoma house mouse CVCL_C5C7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793662 CVCL_C5BU 2F11-E10 hybridoma house mouse CVCL_C5BU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P41159; Human LEP. 155793663 CVCL_C5C6 FMU-hBAP31.2 hybridoma house mouse CVCL_C5C6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793664 CVCL_C5BX 2G8 hybridoma house mouse CVCL_C5BX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A3MYE8; Actinobacillus pleuropneumoniae tonB2. 155793665 CVCL_C5C9 FMU-hBAP31.5 hybridoma house mouse CVCL_C5C9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793666 CVCL_C5BW 2F2 [Mouse hybridoma against A.pleuropneumoniae tonB2] hybridoma house mouse CVCL_C5BW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A3MYE8; Actinobacillus pleuropneumoniae tonB2. 155793667 CVCL_C5C8 FMU-hBAP31.4 hybridoma house mouse CVCL_C5C8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793668 CVCL_C5BZ 6F10 hybridoma house mouse CVCL_C5BZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A3MYE8; Actinobacillus pleuropneumoniae tonB2. 155793669 CVCL_C5BY 3D2 [Mouse hybridoma against A.pleuropneumoniae tonB2] hybridoma house mouse CVCL_C5BY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A3MYE8; Actinobacillus pleuropneumoniae tonB2. 155793670 CVCL_C5BN 7H7 hybridoma house mouse CVCL_C5BN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793671 CVCL_C5BM 7D11 hybridoma house mouse CVCL_C5BM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793672 CVCL_C5BP 8B2 hybridoma house mouse CVCL_C5BP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793673 CVCL_C5C1 D2-31-18-11 hybridoma house mouse CVCL_C5C1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18031; Human PTPN1. 155793674 CVCL_C5C0 16F7 hybridoma house mouse CVCL_C5C0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P36952; Human SERPINB5. 155793675 CVCL_C5C3 395D2 hybridoma house mouse CVCL_C5C3 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: UniProtKB; Q9UMD9; Human COL17A1. 155793676 CVCL_C5BR 8G6 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_C5BR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793677 CVCL_C5C2 395A5 hybridoma house mouse CVCL_C5C2 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: UniProtKB; Q9UMD9; Human COL17A1. 155793678 CVCL_C5BQ 8F10 hybridoma house mouse CVCL_C5BQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 155793679 CVCL_C5C5 FMU-hBAP31.1 hybridoma house mouse CVCL_C5C5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51572; Human BCAP31. 155793680 CVCL_C5BT HBN8 hybridoma house mouse CVCL_C5BT CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08987; Streptococcus mutans glucosyltransferase B (gtfB) Caution: Isotype indicated as IgG2b in results section and IgG2a in abstract of PubMed=23244322. 155793681 CVCL_C5BS 7C3 hybridoma house mouse CVCL_C5BS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P14211; Mouse Calr. 155793682 CVCL_C5C4 FMU-PEX14 hybridoma house mouse CVCL_C5C4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O75381; Human PEX14. 155793683 CVCL_C5AE 4G12 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793684 CVCL_C5AD 4F3 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793685 CVCL_C5AG 5E7 hybridoma house mouse CVCL_C5AG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793686 CVCL_C5AF 5D12 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793687 CVCL_C5AI 10A6 [Mouse hybridoma against G.vaginalis vaginolysin] hybridoma house mouse CVCL_C5AI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793688 CVCL_C5AH 4C11 [Rat hybridoma against mouse Tnfsf14] hybridoma CVCL_C5AH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9QYH9; Mouse Tnfsf14. 155793689 CVCL_C5AK 10G5 hybridoma house mouse CVCL_C5AK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793690 CVCL_C5AJ 10B6 hybridoma house mouse CVCL_C5AJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B2ZUI2; Gardnerella vaginalis vaginolysin (vly). 155793691 CVCL_C5AA 2H9 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793692 CVCL_C5AC 4E11 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793693 CVCL_C5AB 4A4 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5AB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793694 CVCL_C5A5 34D03 hybridoma house mouse CVCL_C5A5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; C7G0W1; Dog IL31. 155793695 CVCL_C5A4 19D07 hybridoma house mouse CVCL_C5A4 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; C7G0W1; Dog IL31. 155793696 CVCL_C5A7 M4 [Mouse hybridoma against human CKLF] hybridoma house mouse CVCL_C5A7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UBR5; Human CKLF. 155793697 CVCL_C5A6 P10E1 hybridoma house mouse CVCL_C5A6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q3Y5Z3; Bovine ADIPOQ. 155793698 CVCL_C5A9 1E5 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5A9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793699 CVCL_C5A8 1D4 [Mouse hybridoma against parathion] hybridoma house mouse CVCL_C5A8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27928; Parathion. 155793700 CVCL_C5A1 3-3 hybridoma house mouse CVCL_C5A1 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9CQJ4; Mouse Rnf2 (Note=Also reacts with human). 155793701 CVCL_C5A0 1-10 [Mouse hybridoma against mouse Rnf2] hybridoma house mouse CVCL_C5A0 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9CQJ4; Mouse Rnf2. 155793702 CVCL_C5A3 11E12 hybridoma house mouse CVCL_C5A3 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b, kappa; Monoclonal antibody target: UniProtKB; C7G0W1; Dog IL31. 155793703 CVCL_C5A2 5-12 hybridoma house mouse CVCL_C5A2 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9CQJ4; Mouse Rnf2. 155793704 CVCL_C5NR 2D10 [Mouse hybridoma against zearalenone] hybridoma house mouse CVCL_C5NR CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 155793705 CVCL_C5NQ 1D9 [Mouse hybridoma against zearalenone] hybridoma house mouse CVCL_C5NQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 155793706 CVCL_C5NT 3C3 [Mouse hybridoma against zearalenone] hybridoma house mouse CVCL_C5NT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 155793707 CVCL_C5NS 2D3 [Mouse hybridoma against zearalenone] hybridoma house mouse CVCL_C5NS CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 155793708 CVCL_C5NV 4B3A4 hybridoma house mouse CVCL_C5NV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99572; Human P2RX7. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201927 155793709 CVCL_C5NU 5F7 [Mouse hybridoma against zearalenone] hybridoma house mouse CVCL_C5NU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 155793710 CVCL_C5NX 2C1 hybridoma house mouse CVCL_C5NX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:4388; Deltamethrin. 155793711 CVCL_C5NW 2B12 hybridoma house mouse CVCL_C5NW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:4388; Deltamethrin. 155793712 CVCL_C5NJ 2D9 [Mouse hybridoma against HAstV-8 VP25] hybridoma house mouse CVCL_C5NJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9IFX1; Human astrovirus-8 strain Yuc8 (HAstV-8) capsid protein VP90 (AA 424-648 = VP25). 155793713 CVCL_C5NI 40H6 hybridoma house mouse CVCL_C5NI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:17833; Gentamicin (Gentamycin). 155793714 CVCL_C5NL 3E8 [Mouse hybridoma against HAstV-8 VP25] hybridoma house mouse CVCL_C5NL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9IFX1; Human astrovirus-8 strain Yuc8 (HAstV-8) capsid protein VP90 (AA 424-648 = VP25). 155793715 CVCL_C5NK 3B4 [Mouse hybridoma against HAstV-1 VP25] hybridoma house mouse CVCL_C5NK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q82452; Human astrovirus-1 strain Oxford (HAstV-1) capsid protein VP90 (AA 424-648 = VP25). 155793716 CVCL_C5NN 4B6 [Mouse hybridoma against HAstV-2 VP25] hybridoma house mouse CVCL_C5NN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A0A3G6VE25; Human astrovirus-2 strain Oxford (HAstV-2) capsid protein VP90 (AA 423-651 = VP25). 155793717 CVCL_C5NM 3H4 [Mouse hybridoma against HAstV-1 VP25] hybridoma house mouse CVCL_C5NM CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; Q82452; Human astrovirus-1 strain Oxford (HAstV-1) capsid protein VP90 (AA 424-648 = VP25). 155793718 CVCL_C5NP 2C12 hybridoma house mouse CVCL_C5NP CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1). 155793719 CVCL_C5NB 68-1 hybridoma house mouse CVCL_C5NB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793720 CVCL_C5NA 46-9 hybridoma house mouse CVCL_C5NA CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793721 CVCL_C5ND 93-6 hybridoma house mouse CVCL_C5ND CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793722 CVCL_C5NC 69-4 hybridoma house mouse CVCL_C5NC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793723 CVCL_C5NF C6-C5 hybridoma house mouse CVCL_C5NF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793724 CVCL_C5NE B3-B5 hybridoma house mouse CVCL_C5NE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793725 CVCL_C5NH Odora conditionally immortalized cell line Norway rat CVCL_C5NH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; olfactory epithelium Cell type=Olfactory sensory neuron.. Unspecified 155793726 CVCL_C5NG D4-B6 hybridoma house mouse CVCL_C5NG CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793727 CVCL_C5MY H23D02 hybridoma house mouse CVCL_C5MY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793728 CVCL_C5N9 30-2 hybridoma house mouse CVCL_C5N9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793729 CVCL_C5MX H23B05 hybridoma house mouse CVCL_C5MX CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793730 CVCL_C5MZ H23F10 hybridoma house mouse CVCL_C5MZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793731 CVCL_C5P4 BF2 hybridoma house mouse CVCL_C5P4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793732 CVCL_C5P3 BF10 hybridoma house mouse CVCL_C5P3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793733 CVCL_C5P6 GCW04 cancer cell line human CVCL_C5P6 CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155793734 CVCL_C5P5 BF6 hybridoma house mouse CVCL_C5P5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793735 CVCL_C5P8 GCW08 cancer cell line human CVCL_C5P8 CL:0000010 Derived from sampling site: Brain. Male 155793736 CVCL_C5P7 GCW07 cancer cell line human CVCL_C5P7 CL:0000010 Derived from sampling site: Brain. Male 155793737 CVCL_C5P9 GCW10 cancer cell line human CVCL_C5P9 CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 155793738 CVCL_C5P0 AB2 [Mouse hybridoma against nisin] hybridoma house mouse CVCL_C5P0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793739 CVCL_C5P2 AD8 hybridoma house mouse CVCL_C5P2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793740 CVCL_C5P1 AD10 hybridoma house mouse CVCL_C5P1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13068; Lactococcus lactis subsp lactis nisin-A (nisA).; Monoclonal antibody target: UniProtKB; P29559; Lactococcus lactis subsp lactis nisin-Z (nisZ).. 155793741 CVCL_C5NZ 3D4 [Mouse hybridoma against deltamethrin] hybridoma house mouse CVCL_C5NZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:4388; Deltamethrin. 155793742 CVCL_C5NY 2F1 [Mouse hybridoma against deltamethrin] hybridoma house mouse CVCL_C5NY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:4388; Deltamethrin. 155793743 CVCL_C5LP L11-2E2 hybridoma house mouse CVCL_C5LP CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793744 CVCL_C5M1 T5-224 hybridoma house mouse CVCL_C5M1 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793745 CVCL_C5M0 T5-131 hybridoma house mouse CVCL_C5M0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793746 CVCL_C5LR L2-5D2 hybridoma house mouse CVCL_C5LR CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793747 CVCL_C5M3 T5-334 hybridoma house mouse CVCL_C5M3 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793748 CVCL_C5LQ L2-10C1 hybridoma house mouse CVCL_C5LQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793749 CVCL_C5M2 T5-314 hybridoma house mouse CVCL_C5M2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793750 CVCL_C5LT H220-19 hybridoma house mouse CVCL_C5LT CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793751 CVCL_C5M5 T5-626 hybridoma house mouse CVCL_C5M5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793752 CVCL_C5LS H152-43B2 hybridoma house mouse CVCL_C5LS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793753 CVCL_C5M4 T5-58 hybridoma house mouse CVCL_C5M4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793754 CVCL_C5LV T1-107 hybridoma house mouse CVCL_C5LV CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793755 CVCL_C5M7 T6-19 hybridoma house mouse CVCL_C5M7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793756 CVCL_C5LU H280-4 hybridoma house mouse CVCL_C5LU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793757 CVCL_C5M6 T6-112 hybridoma house mouse CVCL_C5M6 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793758 CVCL_C5LH H61-15 hybridoma house mouse CVCL_C5LH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793759 CVCL_C5LG H35-D1 hybridoma house mouse CVCL_C5LG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793760 CVCL_C5LJ IC5-2A6 hybridoma house mouse CVCL_C5LJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793761 CVCL_C5LI H8-2D1 hybridoma house mouse CVCL_C5LI CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793762 CVCL_C5LL IC5-4D1 hybridoma house mouse CVCL_C5LL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793763 CVCL_C5LK IC5-3A4 hybridoma house mouse CVCL_C5LK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793764 CVCL_C5LN L11-1A1 hybridoma house mouse CVCL_C5LN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793765 CVCL_C5LM IC5-4F8 hybridoma house mouse CVCL_C5LM CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793766 CVCL_C5LB H35-C10 hybridoma house mouse CVCL_C5LB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793767 CVCL_C5LA H3-4C5 hybridoma house mouse CVCL_C5LA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793768 CVCL_C5LD H35-C6 hybridoma house mouse CVCL_C5LD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793769 CVCL_C5LC H35-C4 hybridoma house mouse CVCL_C5LC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793770 CVCL_C5LF H35-C9 hybridoma house mouse CVCL_C5LF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793771 CVCL_C5LE H35-C7 hybridoma house mouse CVCL_C5LE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793772 CVCL_C5KW H220-22 hybridoma house mouse CVCL_C5KW CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793773 CVCL_C5L8 H280-10 hybridoma house mouse CVCL_C5L8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793774 CVCL_C5KV H220-20 hybridoma house mouse CVCL_C5KV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793775 CVCL_C5L7 H28-D14 hybridoma house mouse CVCL_C5L7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793776 CVCL_C5KY H220-25 hybridoma house mouse CVCL_C5KY CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793777 CVCL_C5KX H220-23 hybridoma house mouse CVCL_C5KX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793778 CVCL_C5L9 H280-15 hybridoma house mouse CVCL_C5L9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793779 CVCL_C5KZ H220-3 hybridoma house mouse CVCL_C5KZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793780 CVCL_C5MQ H19D03 hybridoma house mouse CVCL_C5MQ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793781 CVCL_C5N2 H26D02 hybridoma house mouse CVCL_C5N2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793782 CVCL_C5MP H19B10 hybridoma house mouse CVCL_C5MP CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793783 CVCL_C5N1 H26A09 hybridoma house mouse CVCL_C5N1 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127); Monoclonal antibody target: ChEBI; CHEBI:80171; HA tag. 155793784 CVCL_C5MS H20E03 hybridoma house mouse CVCL_C5MS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793785 CVCL_C5N4 H26F02 hybridoma house mouse CVCL_C5N4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793786 CVCL_C5MR H20C01 hybridoma house mouse CVCL_C5MR CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793787 CVCL_C5N3 H26D08 hybridoma house mouse CVCL_C5N3 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793788 CVCL_C5N6 169-3 hybridoma house mouse CVCL_C5N6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793789 CVCL_C5MU H21C08 hybridoma house mouse CVCL_C5MU CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793790 CVCL_C5N5 136-3 hybridoma house mouse CVCL_C5N5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793791 CVCL_C5MT H20F04 hybridoma house mouse CVCL_C5MT CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793792 CVCL_C5N8 179-2 hybridoma house mouse CVCL_C5N8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793793 CVCL_C5MW H22F05 hybridoma house mouse CVCL_C5MW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793794 CVCL_C5N7 172-3 hybridoma house mouse CVCL_C5N7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A879; Escherichia coli tryptophan synthase beta chain (trpB). 155793795 CVCL_C5MV H22F02 hybridoma house mouse CVCL_C5MV CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793796 CVCL_C5MI 338.18 hybridoma CVCL_C5MI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09237; Human MMP7 (Note=Also reacts with mouse, pig and gerbil). 155793797 CVCL_C5MH 2B8 [Mouse hybridoma against mouse Bub1] hybridoma house mouse CVCL_C5MH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O08901; Mouse Bub1. 155793798 CVCL_C5MK H16E07 hybridoma house mouse CVCL_C5MK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793799 CVCL_C5MJ H16C08 hybridoma house mouse CVCL_C5MJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793800 CVCL_C5MM H17D09 hybridoma house mouse CVCL_C5MM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127); Monoclonal antibody target: ChEBI; CHEBI:80171; HA tag. 155793801 CVCL_C5ML H17B11 hybridoma house mouse CVCL_C5ML CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793802 CVCL_C5N0 H24E07 hybridoma house mouse CVCL_C5N0 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793803 CVCL_C5MN H17D12 hybridoma house mouse CVCL_C5MN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; I6SHA6; Influenza A virus isolate X-47 hemagglutinin (HA) (AA 93-127). 155793804 CVCL_C5MA T6-626 hybridoma house mouse CVCL_C5MA CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793805 CVCL_C5MC T8-2 hybridoma house mouse CVCL_C5MC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793806 CVCL_C5MB T7-4 hybridoma house mouse CVCL_C5MB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793807 CVCL_C5ME T9-1 hybridoma house mouse CVCL_C5ME CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793808 CVCL_C5MD T8-3 hybridoma house mouse CVCL_C5MD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793809 CVCL_C5MG 17E9 hybridoma house mouse CVCL_C5MG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O08901; Mouse Bub1. 155793810 CVCL_C5MF 13G9 hybridoma house mouse CVCL_C5MF CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O08901; Mouse Bub1. 155793811 CVCL_C5LX T10-5 hybridoma house mouse CVCL_C5LX CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793812 CVCL_C5M9 T6-510 hybridoma house mouse CVCL_C5M9 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793813 CVCL_C5LW T10-1 hybridoma house mouse CVCL_C5LW CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793814 CVCL_C5M8 T6-416 hybridoma house mouse CVCL_C5M8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793815 CVCL_C5LZ T4-57 hybridoma house mouse CVCL_C5LZ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793816 CVCL_C5LY T2-150 hybridoma house mouse CVCL_C5LY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) (with p.Gly241Asp = PR8(Asp225)). 155793817 CVCL_C5JN H37-69 hybridoma house mouse CVCL_C5JN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793818 CVCL_C5JM H37-68 hybridoma house mouse CVCL_C5JM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793819 CVCL_C5JP H37-70 hybridoma house mouse CVCL_C5JP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793820 CVCL_C5K1 H37-87 hybridoma house mouse CVCL_C5K1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793821 CVCL_C5K0 H37-86 hybridoma house mouse CVCL_C5K0 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793822 CVCL_C5JR H37-76 hybridoma house mouse CVCL_C5JR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793823 CVCL_C5K3 H37-89 hybridoma house mouse CVCL_C5K3 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793824 CVCL_C5JQ H37-72 hybridoma house mouse CVCL_C5JQ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793825 CVCL_C5K2 H37-96 hybridoma house mouse CVCL_C5K2 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793826 CVCL_C5K5 H130-5 hybridoma house mouse CVCL_C5K5 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793827 CVCL_C5JT H37-78 hybridoma house mouse CVCL_C5JT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793828 CVCL_C5K4 H120-2 hybridoma house mouse CVCL_C5K4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793829 CVCL_C5JS H37-77 hybridoma house mouse CVCL_C5JS CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793830 CVCL_C5JF H37-60 hybridoma house mouse CVCL_C5JF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793831 CVCL_C5JE H37-90 hybridoma house mouse CVCL_C5JE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793832 CVCL_C5JH H37-62 hybridoma house mouse CVCL_C5JH CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793833 CVCL_C5JG H37-61 hybridoma house mouse CVCL_C5JG CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793834 CVCL_C5JJ H37-64 hybridoma house mouse CVCL_C5JJ CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793835 CVCL_C5JI H37-91 hybridoma house mouse CVCL_C5JI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793836 CVCL_C5JL H37-67 hybridoma house mouse CVCL_C5JL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793837 CVCL_C5JK H37-92 hybridoma house mouse CVCL_C5JK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793838 CVCL_C5JB H37-543 hybridoma house mouse CVCL_C5JB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793839 CVCL_C5JA H37-52 hybridoma house mouse CVCL_C5JA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793840 CVCL_C5JD H37-55 hybridoma house mouse CVCL_C5JD CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793841 CVCL_C5JC H37-545 hybridoma house mouse CVCL_C5JC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793842 CVCL_C5IU H37-23 hybridoma house mouse CVCL_C5IU CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793843 CVCL_C5J6 H37-42 hybridoma house mouse CVCL_C5J6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793844 CVCL_C5IT H37-112 hybridoma house mouse CVCL_C5IT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793845 CVCL_C5J5 H37-41 hybridoma house mouse CVCL_C5J5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793846 CVCL_C5IW C3RL4 spontaneously immortalized cell line house mouse CVCL_C5IW CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Biotechnology: Used in a bioassay to assess chemicals for the ability to interfere with retinol signaling Unspecified Characteristics: Expresses luciferase under the control of the retinoic acid response element (RARE) (PubMed=26820057) 155793847 CVCL_C5J8 H37-45 hybridoma house mouse CVCL_C5J8 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793848 CVCL_C5IV H37-24 hybridoma house mouse CVCL_C5IV CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793849 CVCL_C5J7 H37-43 hybridoma house mouse CVCL_C5J7 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793850 CVCL_C5IY H37-29 hybridoma house mouse CVCL_C5IY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793851 CVCL_C5IX H37-26 hybridoma house mouse CVCL_C5IX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793852 CVCL_C5J9 H37-50 hybridoma house mouse CVCL_C5J9 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793853 CVCL_C5IZ H37-311 hybridoma house mouse CVCL_C5IZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793854 CVCL_C5L0 H220-5 hybridoma house mouse CVCL_C5L0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793855 CVCL_C5KN H2-6C4 hybridoma house mouse CVCL_C5KN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793856 CVCL_C5KQ H210-56 hybridoma house mouse CVCL_C5KQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793857 CVCL_C5L2 H230-2 hybridoma house mouse CVCL_C5L2 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793858 CVCL_C5KP H20-A15 hybridoma house mouse CVCL_C5KP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793859 CVCL_C5L1 H220-7 hybridoma house mouse CVCL_C5L1 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793860 CVCL_C5KS H220-10 hybridoma house mouse CVCL_C5KS CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793861 CVCL_C5L4 H230-7 hybridoma house mouse CVCL_C5L4 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793862 CVCL_C5KR H220-1 hybridoma house mouse CVCL_C5KR CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793863 CVCL_C5L3 H230-5 hybridoma house mouse CVCL_C5L3 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793864 CVCL_C5KU H220-17 hybridoma house mouse CVCL_C5KU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793865 CVCL_C5L6 H28-A2 hybridoma house mouse CVCL_C5L6 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793866 CVCL_C5KT H220-11 hybridoma house mouse CVCL_C5KT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793867 CVCL_C5L5 H250-6 hybridoma house mouse CVCL_C5L5 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793868 CVCL_C5KG H158-89H4 hybridoma house mouse CVCL_C5KG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793869 CVCL_C5KF H153-70A12 hybridoma house mouse CVCL_C5KF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793870 CVCL_C5KI H163-130H9 hybridoma house mouse CVCL_C5KI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793871 CVCL_C5KH H163-130F2 hybridoma house mouse CVCL_C5KH CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793872 CVCL_C5KK H17-L10 hybridoma house mouse CVCL_C5KK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793873 CVCL_C5KJ H165-156A2 hybridoma house mouse CVCL_C5KJ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793874 CVCL_C5KM H17-L2 hybridoma house mouse CVCL_C5KM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793875 CVCL_C5KL H17-L19 hybridoma house mouse CVCL_C5KL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793876 CVCL_C5KA H144-17C5 hybridoma house mouse CVCL_C5KA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793877 CVCL_C5KC H146-24B3 hybridoma house mouse CVCL_C5KC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793878 CVCL_C5KB H146-24B1 hybridoma house mouse CVCL_C5KB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793879 CVCL_C5KE H147-25H1 hybridoma house mouse CVCL_C5KE CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793880 CVCL_C5KD H146-24E9 hybridoma house mouse CVCL_C5KD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793881 CVCL_C5K7 H140-1E6 hybridoma house mouse CVCL_C5K7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793882 CVCL_C5JV H37-93 hybridoma house mouse CVCL_C5JV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793883 CVCL_C5K6 H130-6 hybridoma house mouse CVCL_C5K6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793884 CVCL_C5JU H37-79 hybridoma house mouse CVCL_C5JU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793885 CVCL_C5K9 H144-17B7 hybridoma house mouse CVCL_C5K9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793886 CVCL_C5JX H37-83 hybridoma house mouse CVCL_C5JX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793887 CVCL_C5K8 H142-3H5 hybridoma house mouse CVCL_C5K8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793888 CVCL_C5JW H37-94 hybridoma house mouse CVCL_C5JW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793889 CVCL_C5JZ H37-85 hybridoma house mouse CVCL_C5JZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793890 CVCL_C5JY H37-84 hybridoma house mouse CVCL_C5JY CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793891 CVCL_C5HL HUNN2 hybridoma CVCL_C5HL CL:0000010 Monoclonal antibody isotype: IgY; Monoclonal antibody target: UniProtKB; P04925; Mouse PRNP (Note=Also reacts with bovine and sheep). Group: Bird cell line 155793892 CVCL_C5HK HUNN1 hybridoma CVCL_C5HK CL:0000010 Monoclonal antibody isotype: IgY; Monoclonal antibody target: UniProtKB; P04925; Mouse PRNP (Note=Also reacts with bovine and sheep). Group: Bird cell line 155793893 CVCL_C5HN Y1F2 hybridoma house mouse CVCL_C5HN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793894 CVCL_C5HM Y1A3 hybridoma house mouse CVCL_C5HM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793895 CVCL_C5I1 3e hybridoma house mouse CVCL_C5I1 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793896 CVCL_C5HP Y2H8 hybridoma house mouse CVCL_C5HP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793897 CVCL_C5I0 32b hybridoma house mouse CVCL_C5I0 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793898 CVCL_C5I3 7c hybridoma house mouse CVCL_C5I3 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793899 CVCL_C5HR Y3G3 hybridoma house mouse CVCL_C5HR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793900 CVCL_C5I2 40.d7 hybridoma house mouse CVCL_C5I2 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793901 CVCL_C5HQ Y3D7 hybridoma house mouse CVCL_C5HQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793902 CVCL_C5HD CHM4-HuIg4 hybridoma CVCL_C5HD CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793903 CVCL_C5HC CHM4-HuIg3 hybridoma CVCL_C5HC CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793904 CVCL_C5HF OA051-140 hybridoma CVCL_C5HF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Z1G4; Mouse Atp6v0a1. Group: Bird cell line 155793905 CVCL_C5HE HUC2-13 hybridoma CVCL_C5HE CL:0000010 Monoclonal antibody isotype: IgY; Monoclonal antibody target: UniProtKB; P04156; Human PRNP (Note=Recognizs AA 25-29). Group: Bird cell line 155793906 CVCL_C5HH 1-26-1 hybridoma CVCL_C5HH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15920; Mouse Atp6v0a2. Group: Bird cell line 155793907 CVCL_C5HG OA051-7 hybridoma CVCL_C5HG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Z1G4; Mouse Atp6v0a1. Group: Bird cell line 155793908 CVCL_C5HJ 1H11 [Mouse hybridoma against M.marinum 56 kDa antigen] hybridoma house mouse CVCL_C5HJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mycobacterium marinum 56 kDa antigen. 155793909 CVCL_C5HI 107E2 hybridoma CVCL_C5HI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9JL12; Mouse Tcirg1. Group: Bird cell line 155793910 CVCL_C5GZ R27H3 hybrid cell line CVCL_C5GZ CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Doubling time: 16.97 hours (PubMed=2045661) Group: Bird cell line 155793911 CVCL_C5HB CHM4-HuIg2 hybridoma CVCL_C5HB CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793912 CVCL_C5HA CHM4-HuIg1 hybridoma CVCL_C5HA CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793913 CVCL_C5GS HU3R26 transformed cell line CVCL_C5GS CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 21.06 hours (PubMed=2793228) Group: Bird cell line 155793914 CVCL_C5H4 MuH1 hybrid cell line CVCL_C5H4 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Characteristics: TK-deficient Synthesizes but does no secretes immunoglobulin mu chain (PubMed=8959651). Doubling time: 20.89 hours (PubMed=8959651) Group: Bird cell line; Group: Hybridoma fusion partner cell line 155793915 CVCL_C5H3 HU/Ch-22-6 hybridoma CVCL_C5H3 CL:0000010 Monoclonal antibody isotype: IgG+IgM; Monoclonal antibody target: UniProtKB; Q10583; Megathura crenulata hemocyanin 1 (KLH1); Monoclonal antibody target: UniProtKB; Q10584; Megathura crenulata hemocyanin 2 (KLH2). Group: Bird cell line 155793916 CVCL_C5GR HU3R25 transformed cell line CVCL_C5GR CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 18.41 hours (PubMed=2793228) Group: Bird cell line 155793917 CVCL_C5H6 CHM1-HuIg1 hybridoma CVCL_C5H6 CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793918 CVCL_C5GU HU3R28 transformed cell line CVCL_C5GU CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 18.67 hours (PubMed=2793228) Group: Bird cell line 155793919 CVCL_C5GT HU3R27 transformed cell line CVCL_C5GT CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 18.04 hours (PubMed=2793228) Group: Bird cell line; Group: Hybridoma fusion partner cell line 155793920 CVCL_C5H5 MuH4 hybrid cell line CVCL_C5H5 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Characteristics: TK-deficient Synthesizes immunoglobulin mu and L chain and secretes IgM (PubMed=8959651). Doubling time: 15.72 hours (PubMed=8959651) Group: Bird cell line; Group: Hybridoma fusion partner cell line 155793921 CVCL_C5H8 CHM1-HuIg3 hybridoma CVCL_C5H8 CL:0000010 Monoclonal antibody isotype: IgY; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793922 CVCL_C5GW HU3R27N hybrid cell line CVCL_C5GW CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Characteristics: Fusion between HU3R27 and spleen cells from a chicken immunized with Newcastle disease virus (NDV) (PubMed=2045661) Group: Bird cell line 155793923 CVCL_C5H7 CHM1-HuIg2 hybridoma CVCL_C5H7 CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793924 CVCL_C5GV HU3R29 transformed cell line CVCL_C5GV CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=B-cell. Doubling time: 19.35 hours (PubMed=2793228) Group: Bird cell line 155793925 CVCL_C5GY R27H2 hybrid cell line CVCL_C5GY CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Doubling time: 18.93 hours (PubMed=2045661) Group: Bird cell line 155793926 CVCL_C5H9 CHM1-HuIg4 hybridoma CVCL_C5H9 CL:0000010 Monoclonal antibody isotype: IgY+IgM; Monoclonal antibody target: Human IgG. Group: Bird cell line 155793927 CVCL_C5GX R27H1 hybrid cell line CVCL_C5GX CL:0000010 Selected for resistance to: ChEBI; CHEBI:75179; Trifluridine (Trifluorothymidine; Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Doubling time: 17.29 hours (PubMed=2045661) Group: Bird cell line; Group: Hybridoma fusion partner cell line 155793928 CVCL_C5IM H36-6 hybridoma house mouse CVCL_C5IM CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793929 CVCL_C5IL H36-5 hybridoma house mouse CVCL_C5IL CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793930 CVCL_C5J0 H37-312 hybridoma house mouse CVCL_C5J0 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793931 CVCL_C5IN H36-7 hybridoma house mouse CVCL_C5IN CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793932 CVCL_C5IQ H36-101 hybridoma house mouse CVCL_C5IQ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793933 CVCL_C5J2 H37-37 hybridoma house mouse CVCL_C5J2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793934 CVCL_C5IP H36-8 hybridoma house mouse CVCL_C5IP CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793935 CVCL_C5J1 H37-36 hybridoma house mouse CVCL_C5J1 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793936 CVCL_C5IS H37-109 hybridoma house mouse CVCL_C5IS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793937 CVCL_C5J4 H37-40 hybridoma house mouse CVCL_C5J4 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793938 CVCL_C5IR H37-104 hybridoma house mouse CVCL_C5IR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793939 CVCL_C5J3 H37-38 hybridoma house mouse CVCL_C5J3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793940 CVCL_C5IE H28-E23 hybridoma house mouse CVCL_C5IE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793941 CVCL_C5ID J14-16 hybridoma house mouse CVCL_C5ID CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P11597; Human CETP (Note=Also reacts with rabbit). 155793942 CVCL_C5IG H36-11 hybridoma house mouse CVCL_C5IG CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793943 CVCL_C5IF H36-1 hybridoma house mouse CVCL_C5IF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793944 CVCL_C5II H36-15 hybridoma house mouse CVCL_C5II CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793945 CVCL_C5IH H36-12 hybridoma house mouse CVCL_C5IH CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793946 CVCL_C5IK H36-18 hybridoma house mouse CVCL_C5IK CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793947 CVCL_C5IJ H36-17 hybridoma house mouse CVCL_C5IJ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA). 155793948 CVCL_C5IA F059-27.3 hybridoma house mouse CVCL_C5IA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP. 155793949 CVCL_C5IC ATM192 hybridoma house mouse CVCL_C5IC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11597; Human CETP (Note=Also reacts with rabbit). 155793950 CVCL_C5IB F062-4 hybridoma house mouse CVCL_C5IB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP (with p.Ala58Pro, p.Ser61Pro and p.Ser62Pro = pramlintide). 155793951 CVCL_C5HT 10d hybridoma house mouse CVCL_C5HT CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793952 CVCL_C5I5 F002-2.18 hybridoma house mouse CVCL_C5I5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP. 155793953 CVCL_C5I4 8a hybridoma house mouse CVCL_C5I4 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793954 CVCL_C5HS Y5D5 hybridoma house mouse CVCL_C5HS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. 155793955 CVCL_C5HV 19g hybridoma house mouse CVCL_C5HV CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793956 CVCL_C5I7 F025-27.4 hybridoma house mouse CVCL_C5I7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP (Note=Binds only to amidated amylin). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11045 155793957 CVCL_C5HU 17c hybridoma house mouse CVCL_C5HU CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793958 CVCL_C5I6 F024-4.4 hybridoma house mouse CVCL_C5I6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP. 155793959 CVCL_C5HX 21f hybridoma house mouse CVCL_C5HX CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793960 CVCL_C5I9 F058-5 hybridoma house mouse CVCL_C5I9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP (with p.Ala58Pro, p.Ser61Pro and p.Ser62Pro = pramlintide). 155793961 CVCL_C5HW 21a hybridoma house mouse CVCL_C5HW CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793962 CVCL_C5I8 F055-24 hybridoma house mouse CVCL_C5I8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10997; Human IAPP. 155793963 CVCL_C5HZ 27a hybridoma house mouse CVCL_C5HZ CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793964 CVCL_C5HY 24a hybridoma house mouse CVCL_C5HY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q01575; Paracoccidioides brasiliensis 43 kDa secreted glycoprotein (Gp43). 155793965 CVCL_C4TY FS7-20.3 hybridoma house mouse CVCL_C4TY CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA) (PubMed=6223094).. 155793966 CVCL_C4U9 258C4-5 hybridoma house mouse CVCL_C4U9 CL:0000010 Characteristics: T-cell hybridoma. 155793967 CVCL_C4TX FS7-20.22 hybridoma house mouse CVCL_C4TX CL:0000010 Characteristics: T-cell hybridoma Compared to the parent cell line, does not produce any detectable quantity of lymphokines (PubMed=6223094).. 155793968 CVCL_C4TZ FS7-20.5 hybridoma house mouse CVCL_C4TZ CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA). Compared to the parent cell line, produces relatively little IL2 (PubMed=6223094).. 155793969 CVCL_C4U2 DA-7 factor-dependent cell line house mouse CVCL_C4U2 CL:0000010 Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: AKR x DBA/2. Characteristics: IL2 dependent 155793970 CVCL_C4TQ L14-hCD80(5) transformed cell line pig CVCL_C4TQ CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 155793971 CVCL_C4TP 52.3 factor-dependent cell line house mouse CVCL_C4TP CL:0000010 Derived from sampling site: Lymph node Cell type=Helper T-cell.; Breed/subspecies: BALB/c x DBA/2. Characteristics: Recognizes the terpolymer Glu60-Ala30-Tyr10 (GAT); Characteristics: IL2 dependent 155793972 CVCL_C4U1 FS7-20.6.18 hybridoma house mouse CVCL_C4U1 CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA). Produces high level of IFNG (PubMed=6223094).. 155793973 CVCL_C4U4 DC10 hybridoma house mouse CVCL_C4U4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05783; Human KRT18. 155793974 CVCL_C4TS L14-hICAM1(10) transformed cell line pig CVCL_C4TS CL:0000010 Transfected with: HGNC; 5344; ICAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 155793975 CVCL_C4U3 DA7 hybridoma house mouse CVCL_C4U3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05783; Human KRT18. 155793976 CVCL_C4TR L14-hCD86(13) transformed cell line pig CVCL_C4TR CL:0000010 Transfected with: HGNC; 1705; CD86; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 155793977 CVCL_C4U6 267.C4.C4 hybridoma house mouse CVCL_C4U6 CL:0000010 Characteristics: T-cell hybridoma. 155793978 CVCL_C4TU Chem-5 CXCR6 undefined cell line type Norway rat CVCL_C4TU CL:0000010 Transfected with: HGNC; 16647; CXCR6. 155793979 CVCL_C4U5 267.A4.A1 hybridoma house mouse CVCL_C4U5 CL:0000010 Characteristics: T-cell hybridoma. 155793980 CVCL_C4TT Chem-4 CHRM4 undefined cell line type Norway rat CVCL_C4TT CL:0000010 Transfected with: HGNC; 1953; CHRM4. 155793981 CVCL_C4U8 258C4.4 hybridoma house mouse CVCL_C4U8 CL:0000010 Characteristics: T-cell hybridoma. 155793982 CVCL_C4TW FS7-20.12 hybridoma house mouse CVCL_C4TW CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA). Compared to the parent cell line, produces relatively high level of IL2 and undectable quantity of the four other lymphokines (PubMed=6223094).. 155793983 CVCL_C4U7 1780D2.6 hybridoma house mouse CVCL_C4U7 CL:0000010 Characteristics: T-cell hybridoma. 155793984 CVCL_C4TV FS7-20 hybridoma house mouse CVCL_C4TV CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA) (PubMed=6223094).. 155793985 CVCL_C4TI LTAg2B subclone cl.1D transformed cell line human CVCL_C4TI CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-TEX](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Male 155793986 CVCL_C4TH LD1 factor-dependent cell line house mouse CVCL_C4TH CL:0000010 Derived from sampling site: Cell type=Cytotoxic T-cell. Characteristics: IL4 dependent 155793987 CVCL_C4TK LTAg2B subclone cl.4C transformed cell line human CVCL_C4TK CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-TEX](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Male 155793988 CVCL_C4TJ LTAg2B subclone cl.2C transformed cell line human CVCL_C4TJ CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-TEX](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Male 155793989 CVCL_C4TM BDF1/56 factor-dependent cell line house mouse CVCL_C4TM CL:0000010 Derived from sampling site: Lymph node Cell type=Helper T-cell.; Breed/subspecies: BALB/c x DBA/2. Characteristics: Recognizes ovalbumin; Characteristics: IL2 dependent 155793990 CVCL_C4TL BDF1/52 factor-dependent cell line house mouse CVCL_C4TL CL:0000010 Derived from sampling site: Lymph node Cell type=Helper T-cell.; Breed/subspecies: BALB/c x DBA/2. Characteristics: Recognizes the terpolymer Glu60-Ala30-Tyr10 (GAT); Characteristics: IL2 dependent 155793991 CVCL_C4U0 FS7-20.6 hybridoma house mouse CVCL_C4U0 CL:0000010 Characteristics: T-cell hybridoma Produces IL2, IL10, IFNG, macrophage-activating factor (MAF) and Ia induction factor (IaIF) when stimulated by concanavalin A (ConA) (PubMed=6223094).. 155793992 CVCL_C4TN BDF1/E3 factor-dependent cell line house mouse CVCL_C4TN CL:0000010 Derived from sampling site: Spleen Cell type=Helper T-cell.; Breed/subspecies: BALB/c x DBA/2. Characteristics: Recognizes the terpolymer Glu60-Ala30-Tyr10 (GAT); Characteristics: IL2 dependent 155793993 CVCL_C4TA NC10.8 hybridoma house mouse CVCL_C4TA CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155793994 CVCL_C4TC NC10.11 hybridoma house mouse CVCL_C4TC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155793995 CVCL_C4TB NC10.10 hybridoma house mouse CVCL_C4TB CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155793996 CVCL_C4TE NC2.3 hybridoma house mouse CVCL_C4TE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155793997 CVCL_C4TD NC10.12 hybridoma house mouse CVCL_C4TD CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155793998 CVCL_C4TG Sl/Sl4-mSCF248 transformed cell line house mouse CVCL_C4TG CL:0000010 Transfected with: MGI; MGI:96974; Kitl (isoform SCF248); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: WBB6 F1 Sl/Sl(d). Unspecified 155793999 CVCL_C4TF NC6.7 hybridoma house mouse CVCL_C4TF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155794000 CVCL_C4UZ mAb1C3 hybridoma house mouse CVCL_C4UZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05067; Human APP. 155794001 CVCL_C4UY mAb158 hybridoma house mouse CVCL_C4UY CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized lecanemab (BAN2401) therapeutic antibody used for the treatmen of Alzheimer disease Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Selectively binds to large, soluble Abeta protofibrils, does not bind native APP). 155794002 CVCL_C4VA NQ10.2.12.8 hybridoma house mouse CVCL_C4VA CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794003 CVCL_C4UR K#2 (sc-) transformed cell line human CVCL_C4UR CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 155794004 CVCL_C4V3 NQ10.12.22 hybridoma house mouse CVCL_C4V3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794005 CVCL_C4UQ BD-2.118 factor-dependent cell line house mouse CVCL_C4UQ CL:0000010 Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6 x DBA/2. Characteristics: IL2 dependent 155794006 CVCL_C4V2 NQ10.11.1 hybridoma house mouse CVCL_C4V2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794007 CVCL_C4V5 NQ10.12.4.7 hybridoma house mouse CVCL_C4V5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794008 CVCL_C4UT PC12-P1F1 cancer cell line Norway rat CVCL_C4UT CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Hypersensitive for neuritogenesis to temperature-controlled repeated thermal stimulation (TRTS) (PubMed=33171774) 155794009 CVCL_C4V4 NQ10.12.4.6 hybridoma house mouse CVCL_C4V4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794010 CVCL_C4US PC12-P1D10 cancer cell line Norway rat CVCL_C4US CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Hyposensitive for neuritogenesis to temperature-controlled repeated thermal stimulation (TRTS) (PubMed=33171774) 155794011 CVCL_C4V7 NQ10.15.3 hybridoma house mouse CVCL_C4V7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794012 CVCL_C4UV SCCF3 cancer cell line CVCL_C4UV CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 30 +- 3 hours (PubMed=22265717) 155794013 CVCL_C4V6 NQ10.12.5 hybridoma house mouse CVCL_C4V6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794014 CVCL_C4UU SCCF2 cancer cell line CVCL_C4UU CL:0000010 Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 27 +- 3 hours (PubMed=22265717) 155794015 CVCL_C4V9 NQ10.2.12.4 hybridoma house mouse CVCL_C4V9 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794016 CVCL_C4UX SCCL-MT1 cancer cell line human CVCL_C4UX CL:0000010 Female 155794017 CVCL_C4V8 NQ10.15.9 hybridoma house mouse CVCL_C4V8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794018 CVCL_C4UW UM-HACC-2A cancer cell line human CVCL_C4UW CL:0000010 Sequence variation: Gene fusion; HGNC; 7545; MYB + HGNC; 7785; NFIB; Name(s)=MYB-NFIB (PubMed=30527239) Population: Caucasian; Derived from sampling site: Salivary gland; minor salivary gland. Female Doubling time: 3.47 days (at passages 0 to 4), 2.21 days (at passages 96-100) (PubMed=30527239) 155794019 CVCL_C4UJ 372D6.5 hybridoma house mouse CVCL_C4UJ CL:0000010 Characteristics: T-cell hybridoma. 155794020 CVCL_C4UI 372B3.5 hybridoma house mouse CVCL_C4UI CL:0000010 Characteristics: T-cell hybridoma. 155794021 CVCL_C4UL 632A1.1 hybridoma house mouse CVCL_C4UL CL:0000010 Characteristics: T-cell hybridoma. 155794022 CVCL_C4UK 395A4-4 hybridoma house mouse CVCL_C4UK CL:0000010 Characteristics: T-cell hybridoma. 155794023 CVCL_C4UN 762B3.1 hybridoma house mouse CVCL_C4UN CL:0000010 Characteristics: T-cell hybridoma. 155794024 CVCL_C4UM 633A1.4 hybridoma house mouse CVCL_C4UM CL:0000010 Characteristics: T-cell hybridoma. 155794025 CVCL_C4UP 14-1.6 factor-dependent cell line house mouse CVCL_C4UP CL:0000010 Derived from sampling site: Cell type=Helper T-cell; Breed/subspecies: C57BL/6. Characteristics: Recognizes the terpolymer Glu60-Ala30-Tyr10 (GAT); Characteristics: IL2 dependent 155794026 CVCL_C4V1 NQ10.1.12 hybridoma house mouse CVCL_C4V1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794027 CVCL_C4V0 NQ1.40.1 hybridoma house mouse CVCL_C4V0 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794028 CVCL_C4UB 342B1-11 hybridoma house mouse CVCL_C4UB CL:0000010 Characteristics: T-cell hybridoma. 155794029 CVCL_C4UA 266A4.5 hybridoma house mouse CVCL_C4UA CL:0000010 Characteristics: T-cell hybridoma. 155794030 CVCL_C4UD 365A1-1 hybridoma house mouse CVCL_C4UD CL:0000010 Characteristics: T-cell hybridoma. 155794031 CVCL_C4UC 359C1-12 hybridoma house mouse CVCL_C4UC CL:0000010 Characteristics: T-cell hybridoma. 155794032 CVCL_C4UF 366D3-2 hybridoma house mouse CVCL_C4UF CL:0000010 Characteristics: T-cell hybridoma. 155794033 CVCL_C4UE 365A2-4 hybridoma house mouse CVCL_C4UE CL:0000010 Characteristics: T-cell hybridoma. 155794034 CVCL_C4UH 368B1-5 hybridoma house mouse CVCL_C4UH CL:0000010 Characteristics: T-cell hybridoma. 155794035 CVCL_C4UG 367A5-2 hybridoma house mouse CVCL_C4UG CL:0000010 Characteristics: T-cell hybridoma. 155794036 CVCL_C4S8 BCHNEi002-A induced pluripotent stem cell human CVCL_C4S8 From: Department of Neurology, Beijing Children's Hospital; Beijing; China. CL:0000010 155794037 CVCL_C4RW DLD1-FX-R cancer cell line human CVCL_C4RW CL:0000010 Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Selected for resistance to: ChEBI; CHEBI:15640; 5-formyltetrahydrofolic acid (Folinic acid; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin). Male Characteristics: Resistant to FOLFOXIRI, the combination of 5-FU, folinic acic, oxaliplatin and SN-38 155794038 CVCL_C4S7 BCHNEi001-A induced pluripotent stem cell human CVCL_C4S7 From: Department of Neurology, Beijing Children's Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 1424; CAD; Simple; p.Tyr36Tyrfs*15 (c.108delC); Zygosity=Heterozygous (PubMed=36283272); Sequence variation: Mutation; HGNC; 1424; CAD; Simple; p.Val1259Met (c.3775G>A); Zygosity=Heterozygous (PubMed=36283272) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155794039 CVCL_C4RV WAe009-A-92 embryonic stem cell human CVCL_C4RV From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Transfected with: HGNC; 3491; ETV2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Expresses ETV2 induced by doxycyclin Transduced with a Tre-hETV2-mPGK-PuroR-rtTA-T2A-EF1a construct that contains the reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 (PubMed=36463633). 155794040 CVCL_C4RY LS174T-FX-R cancer cell line human CVCL_C4RY CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Selected for resistance to: ChEBI; CHEBI:15640; 5-formyltetrahydrofolic acid (Folinic acid; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Female Characteristics: Resistant to FOLFOXIRI, the combination of 5-FU, folinic acic, oxaliplatin and SN-38 155794041 CVCL_C4S9 CSUXHEi001-A induced pluripotent stem cell human CVCL_C4S9 From: Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Ser517Phefs*10 (c.1547dupC) (c.1545_1546insC); ClinVar=VCV000188759; Zygosity=Heterozygous (PubMed=36126472) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 155794042 CVCL_C4RX HCT116-FX-R cancer cell line human CVCL_C4RX CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Selected for resistance to: ChEBI; CHEBI:15640; 5-formyltetrahydrofolic acid (Folinic acid; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon; Derived from sampling site: Colon. Male Characteristics: Resistant to FOLFOXIRI, the combination of 5-FU, folinic acic, oxaliplatin and SN-38 155794043 CVCL_C4RZ SW620-FX-R cancer cell line human CVCL_C4RZ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Selected for resistance to: ChEBI; CHEBI:15640; 5-formyltetrahydrofolic acid (Folinic acid; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male Characteristics: Resistant to FOLFOXIRI, the combination of 5-FU, folinic acic, oxaliplatin and SN-38 155794044 CVCL_C4S0 N1E-115 GFP-ADNP cancer cell line house mouse CVCL_C4S0 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: A/J. Male Characteristics: Using CRISPR/Cas9, a GFP tag was inserted in the N-terminus of ADNP (PubMed=36230962) 155794045 CVCL_C4RN NIH-3T3 Tsc2 KO spontaneously immortalized cell line house mouse CVCL_C4RN CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:102548; Tsc2 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 155794046 CVCL_C4S2 N1E-115 GFP-ADNP p.Tyr718* cancer cell line house mouse CVCL_C4S2 CL:0000010 Sequence variation: Mutation; MGI; MGI:1338758; Adnp; Simple_edited; p.Tyr418Ter; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36230962); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: A/J. Male Characteristics: Using CRISPR/Cas9, a GFP tag was inserted in the N-terminus of ADNP (PubMed=36230962) 155794047 CVCL_C4RQ VeroE6-Pgp-KO spontaneously immortalized cell line green monkey CVCL_C4RQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9RIY5; ABCB1 Derived from sampling site: Kidney; epithelium. Female Virology: Can be used for in vitro virus infection system for SARS-CoV-2 and possibly other viruses to test antiviral therapies without a need to control the ABCB1/Pgp efflux transporter activity (PubMed=36208677) Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 155794048 CVCL_C4S1 N1E-115 GFP-ADNP p.Pro403* cancer cell line house mouse CVCL_C4S1 CL:0000010 Sequence variation: Mutation; MGI; MGI:1338758; Adnp; Simple_edited; p.Pro403Ter; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36230962); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: A/J. Male Characteristics: Using CRISPR/Cas9, a GFP tag was inserted in the N-terminus of ADNP (PubMed=36230962) 155794049 CVCL_C4RP WAe001-A-81 embryonic stem cell human CVCL_C4RP From: Sun Yat-sen University Seventh Affiliated Hospital; Shenzhen; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3619; FCGR3A. Male 155794050 CVCL_C4RS A375 XPA-mutated clone A9 cancer cell line human CVCL_C4RS CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12814; XPA; Simple_edited; p.Ala7Leufs*8 (c.19delG); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36232946); Sequence variation: Mutation; HGNC; 12814; XPA; Simple_edited; p.Ala7Glyfs*55 (c.19_20insG); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36232946) Population: Caucasian; Derived from sampling site: Skin. Female 155794051 CVCL_C4S4 WAZ-1 spontaneously immortalized cell line house mouse CVCL_C4S4 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 155794052 CVCL_C4RR A375 XPA-mutated clone A3 cancer cell line human CVCL_C4RR CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12814; XPA; Simple_edited; p.Ile69_Asp70delinsAsn (c.206_208delTTG); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36232946); Sequence variation: Mutation; HGNC; 12814; XPA; Simple_edited; p.Asp70Hisfs*31 (c.208_209delGA); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36232946) Population: Caucasian; Derived from sampling site: Skin. Female 155794053 CVCL_C4S3 T84SF cancer cell line human CVCL_C4S3 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu1488Phefs*19 (c.4464delA); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Lys340Asn (c.1020G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>T; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Caucasian; Derived from metastatic site: Lung. Male Characteristics: Metastatic Selected by repetitive plating on TNFA-activated human endothelial cells and subsequent selection for adherent cells (PubMed=15484219). 155794054 CVCL_C4S6 H-75 transformed cell line human CVCL_C4S6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.. Unspecified 155794055 CVCL_C4RU NIHTVBi028-A induced pluripotent stem cell human CVCL_C4RU From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 6735; LYN; Simple; p.Tyr508Ter (c.1524C>G); Zygosity=Homozygous (PubMed=36215934) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 155794056 CVCL_C4RT A375 XPA-mutated clone B1 cancer cell line human CVCL_C4RT CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12814; XPA; Simple_edited; p.Ala7Leufs*8 (c.19delG); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36232946) Population: Caucasian; Derived from sampling site: Skin. Female 155794057 CVCL_C4S5 H-59 [Human liver] transformed cell line human CVCL_C4S5 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.. Unspecified 155794058 CVCL_C4RG F71H10 hybridoma house mouse CVCL_C4RG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794059 CVCL_C4RF F71D7 hybridoma house mouse CVCL_C4RF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794060 CVCL_C4RI F81G2 hybridoma house mouse CVCL_C4RI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794061 CVCL_C4RH F71H9 hybridoma house mouse CVCL_C4RH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794062 CVCL_C4RK URi002-A induced pluripotent stem cell human CVCL_C4RK From: University of the Ryukyus; Okinawa; Japan CL:0000010 Population: Ryukyuan; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155794063 CVCL_C4RJ URi001-A induced pluripotent stem cell human CVCL_C4RJ From: University of the Ryukyus; Okinawa; Japan CL:0000010 Population: Ryukyuan; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155794064 CVCL_C4RM URi005-A induced pluripotent stem cell human CVCL_C4RM From: University of the Ryukyus; Okinawa; Japan CL:0000010 Population: Ryukyuan; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 155794065 CVCL_C4RL URi004-A induced pluripotent stem cell human CVCL_C4RL From: University of the Ryukyus; Okinawa; Japan CL:0000010 Population: Ryukyuan; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 155794066 CVCL_C4RA So-G3-1 hybridoma house mouse CVCL_C4RA CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794067 CVCL_C4RC So-G3-3 hybridoma house mouse CVCL_C4RC CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794068 CVCL_C4RB So-G3-2 hybridoma house mouse CVCL_C4RB CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794069 CVCL_C4RE F71B12 hybridoma house mouse CVCL_C4RE CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794070 CVCL_C4RD So-M-1 hybridoma house mouse CVCL_C4RD CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794071 CVCL_C4SX 2F1 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4SX CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794072 CVCL_C4T9 NC10.1 hybridoma house mouse CVCL_C4T9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155794073 CVCL_C4SW 1F3 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4SW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794074 CVCL_C4T8 NC10.14 hybridoma house mouse CVCL_C4T8 CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155794075 CVCL_C4SZ 4B10 hybridoma house mouse CVCL_C4SZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794076 CVCL_C4SY 2H3 hybridoma house mouse CVCL_C4SY CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794077 CVCL_C4T1 4F9 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4T1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794078 CVCL_C4SP Guo-2 hybridoma house mouse CVCL_C4SP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16750; Guanosine. 155794079 CVCL_C4T0 4E9 hybridoma house mouse CVCL_C4T0 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794080 CVCL_C4SR 5C hybridoma house mouse CVCL_C4SR CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794081 CVCL_C4T3 5D11 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4T3 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794082 CVCL_C4SQ 5A hybridoma house mouse CVCL_C4SQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794083 CVCL_C4T2 5C10 hybridoma house mouse CVCL_C4T2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794084 CVCL_C4T5 5F8 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4T5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794085 CVCL_C4ST 9D hybridoma house mouse CVCL_C4ST CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794086 CVCL_C4T4 5D3 [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4T4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794087 CVCL_C4SS 6C hybridoma house mouse CVCL_C4SS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794088 CVCL_C4SV 1D5 hybridoma house mouse CVCL_C4SV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794089 CVCL_C4T7 NC6.8 hybridoma house mouse CVCL_C4T7 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:385425; [N-(4-cyanophenyl)-N'-(diphenylmethyl)guanidine]acetic acid (NC174). 155794090 CVCL_C4T6 5H1 hybridoma house mouse CVCL_C4T6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794091 CVCL_C4SU 9F [Mouse hybridoma against human PTHLH] hybridoma house mouse CVCL_C4SU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH (AA 37-70 = PTHrP[1-34]). 155794092 CVCL_C4SH HyHEL-8 hybridoma house mouse CVCL_C4SH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794093 CVCL_C4SG HyHEL-7 hybridoma house mouse CVCL_C4SG CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794094 CVCL_C4SJ HyHEL-10 hybridoma house mouse CVCL_C4SJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794095 CVCL_C4SI HyHEL-9 hybridoma house mouse CVCL_C4SI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794096 CVCL_C4SL HyHEL-12 hybridoma house mouse CVCL_C4SL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794097 CVCL_C4SK HyHEL-11 hybridoma house mouse CVCL_C4SK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794098 CVCL_C4SN Guo-1 hybridoma house mouse CVCL_C4SN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16750; Guanosine. 155794099 CVCL_C4SM Cyd-1 hybridoma house mouse CVCL_C4SM CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:17562; Cytidine. 155794100 CVCL_C4SB CRTDi010-B induced pluripotent stem cell human CVCL_C4SB From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Arg164Ter (c.490C>T); ClinVar=VCV000004069; Zygosity=Homozygous (PubMed=36115319) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155794101 CVCL_C4SA CSUXHEi002-A induced pluripotent stem cell human CVCL_C4SA From: Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Lys440Ter (c.1318A>T); ClinVar=VCV000627478; Zygosity=Heterozygous (PubMed=36126472) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155794102 CVCL_C4SD CSUASOi004-A-1 induced pluripotent stem cell human CVCL_C4SD From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 15860; PRPF6; Simple_corrected; p.Arg900His (c.2699G>A); ClinVar=VCV000842292; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36103774) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 155794103 CVCL_C4SC CRTDi008-B induced pluripotent stem cell human CVCL_C4SC From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Arg290His (c.869G>A); Zygosity=Heterozygous (PubMed=36115319); Sequence variation: Mutation; HGNC; 15925; SAMHD1; Simple; p.Gln548Ter (c.1642C>T); ClinVar=VCV000004071; Zygosity=Heterozygous (PubMed=36115319) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 155794104 CVCL_C4SF HyHEL-5 hybridoma house mouse CVCL_C4SF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 155794105 CVCL_C4SE CCMB-Me-14-STGG-A1 embryonic stem cell house mouse CVCL_C4SE CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Using CRISPR/Cas9 a T2A-H2B-tdTomato construct was inserted at the C-terminus of one allele of Sox2 and a H2B-GFP-SV40-Bsd cassette was inserted at the C-terminus of one allele of Gata6 (PubMed=36063726) 155794106 CVCL_C4Q6 338.39.5 hybridoma house mouse CVCL_C4Q6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8432 155794107 CVCL_C4PU 6D/6F hybridoma house mouse CVCL_C4PU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Schistosoma mansoni soluble egg antigen (SEA). 155794108 CVCL_C4PT 2F/11F hybridoma house mouse CVCL_C4PT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Schistosoma haematobium soluble egg antigen (SEA). 155794109 CVCL_C4Q5 338.29.2 hybridoma house mouse CVCL_C4Q5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8433 155794110 CVCL_C4Q8 362.597.3.15 hybridoma house mouse CVCL_C4Q8 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8786 155794111 CVCL_C4PW 7F1/6B hybridoma house mouse CVCL_C4PW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Schistosoma mansoni soluble egg antigen (SEA). 155794112 CVCL_C4Q7 338.5.4 hybridoma house mouse CVCL_C4Q7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8317 155794113 CVCL_C4PV 7A/8F hybridoma house mouse CVCL_C4PV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Schistosoma mansoni soluble egg antigen (SEA). 155794114 CVCL_C4PY 338.11.5 hybridoma house mouse CVCL_C4PY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8314 155794115 CVCL_C4Q9 362.75.1.1 hybridoma house mouse CVCL_C4Q9 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8791 155794116 CVCL_C4PX UCH D4 transformed cell line human CVCL_C4PX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 155794117 CVCL_C4PZ 338.14.3 hybridoma house mouse CVCL_C4PZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8313 155794118 CVCL_C4PM TMOi001-A-5 induced pluripotent stem cell human CVCL_C4PM CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 2888; DISC1 Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 155794119 CVCL_C4PL MGN3-1 cancer cell line house mouse CVCL_C4PL CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: GP-Tag transgenic. Unspecified Characteristics: Secretes substantial amount of ghrelin 155794120 CVCL_C4Q0 338.15.5 hybridoma house mouse CVCL_C4Q0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8315 155794121 CVCL_C4PN TMOi001-A-6 induced pluripotent stem cell human CVCL_C4PN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2888; DISC1 Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 155794122 CVCL_C4Q2 338.24.5 hybridoma house mouse CVCL_C4Q2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8430 155794123 CVCL_C4PQ 92.1-B cancer cell line human CVCL_C4PQ CL:0000010 Derived from sampling site: Eye; uvea. Omics: Deep quantitative proteome analysis Female Characteristics: Established after transplantation of the parent cell line in the brain of inbred line nude mice 155794124 CVCL_C4Q1 338.17.3 hybridoma house mouse CVCL_C4Q1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8316 155794125 CVCL_C4PP 92.1-A cancer cell line human CVCL_C4PP CL:0000010 Derived from sampling site: Eye; uvea. Omics: Deep quantitative proteome analysis Female Characteristics: Established after transplantation of the parent cell line in the back of the eyeball of inbred line nude mice 155794126 CVCL_C4PS 2D/11C hybridoma house mouse CVCL_C4PS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Schistosoma haematobium soluble egg antigen (SEA). 155794127 CVCL_C4Q4 338.28.6 hybridoma house mouse CVCL_C4Q4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8434 155794128 CVCL_C4PR 10B/2C hybridoma house mouse CVCL_C4PR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Schistosoma haematobium soluble egg antigen (SEA). 155794129 CVCL_C4Q3 338.25.6 hybridoma house mouse CVCL_C4Q3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8431 155794130 CVCL_C4PE N6-KU70-2-DG cancer cell line human CVCL_C4PE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4055; XRCC6; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 155794131 CVCL_C4PD MHHi002-A-7 induced pluripotent stem cell human CVCL_C4PD From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1; Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous; Note=By TALEN (from parent cell line) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 155794132 CVCL_C4PG 4LP-B4 transformed cell line human CVCL_C4PG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX) 155794133 CVCL_C4PF 3GC-C2 transformed cell line human CVCL_C4PF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX) 155794134 CVCL_C4PI LP [Human LCL] transformed cell line human CVCL_C4PI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:194097; 3,5-dinitro-4-hydroxyphenylacetic acid (NNP) 155794135 CVCL_C4PH EP [Human LCL] transformed cell line human CVCL_C4PH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:194097; 3,5-dinitro-4-hydroxyphenylacetic acid (NNP) 155794136 CVCL_C4PK KS-RRP transformed cell line human CVCL_C4PK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q02161; Human RHD 155794137 CVCL_C4PJ SP transformed cell line human CVCL_C4PJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:194097; 3,5-dinitro-4-hydroxyphenylacetic acid (NNP) 155794138 CVCL_C4PA MHHi002-A-4 induced pluripotent stem cell human CVCL_C4PA From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1; Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 155794139 CVCL_C4PC MHHi002-A-6 induced pluripotent stem cell human CVCL_C4PC From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1; Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous; Note=By TALEN (from parent cell line) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 155794140 CVCL_C4PB MHHi002-A-5 induced pluripotent stem cell human CVCL_C4PB From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1; Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 155794141 CVCL_C4QV GZ-143 hybridoma house mouse CVCL_C4QV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794142 CVCL_C4R7 So-G2a-1 hybridoma house mouse CVCL_C4R7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794143 CVCL_C4QU GZ-13 hybridoma house mouse CVCL_C4QU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794144 CVCL_C4R6 So-G1-1 hybridoma house mouse CVCL_C4R6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794145 CVCL_C4QX GZ-413 hybridoma house mouse CVCL_C4QX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794146 CVCL_C4R9 So-G2b-1 hybridoma house mouse CVCL_C4R9 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794147 CVCL_C4QW GZ-3 hybridoma house mouse CVCL_C4QW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794148 CVCL_C4R8 So-G2a-2 hybridoma house mouse CVCL_C4R8 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794149 CVCL_C4QZ GZ-608 hybridoma house mouse CVCL_C4QZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794150 CVCL_C4QY GZ-507 hybridoma house mouse CVCL_C4QY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794151 CVCL_C4QN 3A3.C2 hybridoma house mouse CVCL_C4QN CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794152 CVCL_C4QM 2F8.C10 hybridoma house mouse CVCL_C4QM CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62898; Rat Cycs. 155794153 CVCL_C4QP 4A9.D6 hybridoma house mouse CVCL_C4QP CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794154 CVCL_C4R1 FA6-152 hybridoma house mouse CVCL_C4R1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16671; Human CD36. 155794155 CVCL_C4R0 GZ-70 hybridoma house mouse CVCL_C4R0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q08857; Mouse Cd36 (Note=Also reacts with human). 155794156 CVCL_C4QR 6A7.E5 hybridoma house mouse CVCL_C4QR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62898; Rat Cycs. 155794157 CVCL_C4R3 V58A4 hybridoma house mouse CVCL_C4R3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07996; Human THBS1. 155794158 CVCL_C4QQ 5F8.B7 hybridoma house mouse CVCL_C4QQ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794159 CVCL_C4R2 5G11 [Rat hybridoma against human THBS1] hybridoma Norway rat CVCL_C4R2 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07996; Human THBS1. 155794160 CVCL_C4QT 7D4.H4 hybridoma house mouse CVCL_C4QT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62894; Bovine CYCS. 155794161 CVCL_C4R5 CC1-IIA4 hybridoma house mouse CVCL_C4R5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794162 CVCL_C4QS 6H2.B4 hybridoma house mouse CVCL_C4QS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62898; Rat Cycs. 155794163 CVCL_C4R4 BE2-IA10 hybridoma house mouse CVCL_C4R4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9195; Soman. 155794164 CVCL_C4QF B/MT.4A.17.H5.A5 hybridoma house mouse CVCL_C4QF CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17347; Testosterone (Note=Also reacts with dihydrotestosterone). 155794165 CVCL_C4QE B/MF-2 hybrid cell line house mouse CVCL_C4QE CL:0000010 Group: Hybridoma fusion partner cell line. 155794166 CVCL_C4QH 1F5.D1 hybridoma house mouse CVCL_C4QH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794167 CVCL_C4QG 14D2.D6 hybridoma house mouse CVCL_C4QG CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62898; Rat Cycs. 155794168 CVCL_C4QJ 1G3.E3 hybridoma house mouse CVCL_C4QJ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P62894; Bovine CYCS. 155794169 CVCL_C4QI 1G1.E9 hybridoma house mouse CVCL_C4QI CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794170 CVCL_C4QL 2E5.G10 hybridoma house mouse CVCL_C4QL CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794171 CVCL_C4QK 2B5.F8 hybridoma house mouse CVCL_C4QK CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00004; Horse CYCS. 155794172 CVCL_C4QB 366.328.10.63 hybridoma house mouse CVCL_C4QB CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8789 155794173 CVCL_C4QA 362.78.1.44 hybridoma house mouse CVCL_C4QA CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8790 155794174 CVCL_C4QD 366.552.11.31 hybridoma house mouse CVCL_C4QD CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8787 155794175 CVCL_C4QC 366.345.6.11 hybridoma house mouse CVCL_C4QC CL:0000010 Miscellaneous: As the immunized splenic B-cells are from humanized transgenic mice the produced mAB is of human origin. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HBE4; Human IL21 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8788 155794176 CVCL_C4NS ODSBFC_31_8 embryonic stem cell CVCL_C4NS CL:0000010 Unspecified Group: Fish cell line. 155794177 CVCL_C4NR ODSBFC_31_7 embryonic stem cell CVCL_C4NR CL:0000010 Unspecified Group: Fish cell line. 155794178 CVCL_C4NU ODSBFC_31_12 embryonic stem cell CVCL_C4NU CL:0000010 Unspecified Group: Fish cell line. 155794179 CVCL_C4NT ODSBFC_31_9 embryonic stem cell CVCL_C4NT CL:0000010 Unspecified Group: Fish cell line. 155794180 CVCL_C4NW ODSBFC_31_14 embryonic stem cell CVCL_C4NW CL:0000010 Unspecified Group: Fish cell line. 155794181 CVCL_C4NV ODSBFC_31_13 embryonic stem cell CVCL_C4NV CL:0000010 Unspecified Group: Fish cell line. 155794182 CVCL_C4NY CIRA00150-22 induced pluripotent stem cell human CVCL_C4NY CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Val1316fs (c.3944dupC) (p.Thr1315fs*17) (c.3944_3945insC); ClinVar=VCV000180624; Zygosity=Heterozygous (PubMed=36259166) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 155794183 CVCL_C4NX CIRA00150-19 induced pluripotent stem cell human CVCL_C4NX CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Val1316fs (c.3944dupC) (p.Thr1315fs*17) (c.3944_3945insC); ClinVar=VCV000180624; Zygosity=Heterozygous (PubMed=36259166) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 155794184 CVCL_C4NK ODSBFC_31->28_13 embryonic stem cell CVCL_C4NK CL:0000010 Unspecified Group: Fish cell line. 155794185 CVCL_C4NJ ODSBFC_31->28_12 embryonic stem cell CVCL_C4NJ CL:0000010 Unspecified Group: Fish cell line. 155794186 CVCL_C4NM ODSBFC_31_1 embryonic stem cell CVCL_C4NM CL:0000010 Unspecified Group: Fish cell line. 155794187 CVCL_C4NL ODSBFC_31->28_14 embryonic stem cell CVCL_C4NL CL:0000010 Unspecified Group: Fish cell line. 155794188 CVCL_C4NN ODSBFC_31_2 embryonic stem cell CVCL_C4NN CL:0000010 Unspecified Group: Fish cell line. 155794189 CVCL_C4NQ ODSBFC_31_5 embryonic stem cell CVCL_C4NQ CL:0000010 Unspecified Group: Fish cell line. 155794190 CVCL_C4NP ODSBFC_31_3 embryonic stem cell CVCL_C4NP CL:0000010 Unspecified Group: Fish cell line. 155794191 CVCL_C4NC ODSBFC_28_8 embryonic stem cell CVCL_C4NC CL:0000010 Unspecified Group: Fish cell line. 155794192 CVCL_C4NB ODSBFC_28_7 embryonic stem cell CVCL_C4NB CL:0000010 Unspecified Group: Fish cell line. 155794193 CVCL_C4NE ODSBFC_28_13 embryonic stem cell CVCL_C4NE CL:0000010 Unspecified Group: Fish cell line. 155794194 CVCL_C4ND ODSBFC_28_10 embryonic stem cell CVCL_C4ND CL:0000010 Unspecified Group: Fish cell line. 155794195 CVCL_C4NG ODSBFC_31->28_2 embryonic stem cell CVCL_C4NG CL:0000010 Unspecified Group: Fish cell line. 155794196 CVCL_C4NF ODSBFC_31->28_1 embryonic stem cell CVCL_C4NF CL:0000010 Unspecified Group: Fish cell line. 155794197 CVCL_C4NI ODSBFC_31->28_7 embryonic stem cell CVCL_C4NI CL:0000010 Unspecified Group: Fish cell line. 155794198 CVCL_C4NH ODSBFC_31->28_5 embryonic stem cell CVCL_C4NH CL:0000010 Unspecified Group: Fish cell line. 155794199 CVCL_C4MZ 4C5A3 hybridoma CVCL_C4MZ CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Mouse ferroptotic cells (Note=Also reacts with human). 155794200 CVCL_C4MY 7E11 [Rat hybridoma against human IQGAP1] hybridoma CVCL_C4MY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P46940; Human IQGAP1. 155794201 CVCL_C4NA ODSBFC_28_4 embryonic stem cell CVCL_C4NA CL:0000010 Unspecified Group: Fish cell line. 155794202 CVCL_C4P5 J9F2 induced pluripotent stem cell CVCL_C4P5 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 155794203 CVCL_C4P4 J5F1 induced pluripotent stem cell CVCL_C4P4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 155794204 CVCL_C4P7 WAe009-A-94 embryonic stem cell human CVCL_C4P7 From: Lanzhou University School of Stomatology; Lanzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10500; S100B. Female 155794205 CVCL_C4P6 BAG50 cancer cell line human CVCL_C4P6 CL:0000010 Derived from sampling site: Stomach. Male Doubling time: ~30 hours (PubMed=36175578) Group: Cancer stem cell line 155794206 CVCL_C4P9 MHHi001-A-2 induced pluripotent stem cell human CVCL_C4P9 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female 155794207 CVCL_C4P8 MHHi001-A-1 induced pluripotent stem cell human CVCL_C4P8 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21625; ANO1 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female 155794208 CVCL_C4P1 UAZTi009-A induced pluripotent stem cell human CVCL_C4P1 From: University of Arizona; Tucson; USA CL:0000010 Sequence variation: Mutation; HGNC; 17944; EXOSC3; Simple; p.Asp132Ala (c.395A>C); ClinVar=VCV000031688; Zygosity=Heterozygous (PubMed=36257093) Derived from sampling site: Skin Cell type=Fibroblast.. Female 155794209 CVCL_C4P0 CIRA00153-9 induced pluripotent stem cell human CVCL_C4P0 CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Ala40Glyfs*24 (c.118dupG) (c.118_119insG); ClinVar=VCV000003810; Zygosity=Heterozygous (PubMed=36259166) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155794210 CVCL_C4P3 UAZTi011-A induced pluripotent stem cell human CVCL_C4P3 From: University of Arizona; Tucson; USA CL:0000010 Sequence variation: Mutation; HGNC; 17944; EXOSC3; Simple; p.Asp132Ala (c.395A>C); ClinVar=VCV000031688; Zygosity=Homozygous (PubMed=36257093) Derived from sampling site: Skin Cell type=Fibroblast.. Male 155794211 CVCL_C4P2 UAZTi010-A induced pluripotent stem cell human CVCL_C4P2 From: University of Arizona; Tucson; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 155794212 CVCL_C4NZ CIRA00153-18 induced pluripotent stem cell human CVCL_C4NZ CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Ala40Glyfs*24 (c.118dupG) (c.118_119insG); ClinVar=VCV000003810; Zygosity=Heterozygous (PubMed=36259166) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 155794213 CVCL_C4ZW 1E6H5 hybridoma house mouse CVCL_C4ZW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6LEG8; Soybean calmodulin (SCaM). 155794214 CVCL_C4ZV FMU7 hybridoma house mouse CVCL_C4ZV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794215 CVCL_C4ZY IM7 hybridoma house mouse CVCL_C4ZY CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02595; Patinopecten yessoensis calmodulin. 155794216 CVCL_C4ZX 2C8H3 hybridoma house mouse CVCL_C4ZX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6LEG8; Soybean calmodulin (SCaM). 155794217 CVCL_C4ZZ PBE2 hybridoma house mouse CVCL_C4ZZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04464; Wheat calmodulin. 155794218 CVCL_C4ZN #G65G hybridoma house mouse CVCL_C4ZN CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10683; Rat Gal. 155794219 CVCL_C4ZQ FMU2 hybridoma house mouse CVCL_C4ZQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794220 CVCL_C4ZP FMU1 hybridoma house mouse CVCL_C4ZP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794221 CVCL_C4ZS FMU4 hybridoma house mouse CVCL_C4ZS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794222 CVCL_C4ZR FMU3 hybridoma house mouse CVCL_C4ZR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794223 CVCL_C4ZU FMU6 hybridoma house mouse CVCL_C4ZU CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794224 CVCL_C4ZT FMU5 hybridoma house mouse CVCL_C4ZT CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15762; Human CD226. 155794225 CVCL_C4ZG D8 hybridoma house mouse CVCL_C4ZG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01008; Human SERPINC1. 155794226 CVCL_C4ZF C5 [Mouse hybridoma against human SERPINC1] hybridoma house mouse CVCL_C4ZF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01008; Human SERPINC1. 155794227 CVCL_C4ZI AlphaHT+N1 hybridoma house mouse CVCL_C4ZI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02787; Human TF. 155794228 CVCL_C4ZH 4A6 [Mouse hybridoma against chicken ATH] hybridoma house mouse CVCL_C4ZH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P19753; Chicken ATH. 155794229 CVCL_C4ZK AlphaHT+N3 hybridoma house mouse CVCL_C4ZK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02787; Human TF. 155794230 CVCL_C4ZJ AlphaHT+N2 hybridoma house mouse CVCL_C4ZJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02787; Human TF; Monoclonal antibody target: UniProtKB; P02787; Human TF. 155794231 CVCL_C4ZM MAM-6C-8 hybridoma house mouse CVCL_C4ZM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P06875; Escherichia coli penicillin G acylase (pac). 155794232 CVCL_C4ZL AlphaHT+N4 hybridoma house mouse CVCL_C4ZL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02787; Human TF. 155794233 CVCL_C4YB bfd03 hybridoma house mouse CVCL_C4YB CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=dsDNA>ssDNA). 155794234 CVCL_C4YA DNA 9 hybridoma house mouse CVCL_C4YA CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794235 CVCL_C4YD bfd37 hybridoma house mouse CVCL_C4YD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA. 155794236 CVCL_C4YC bfd05 hybridoma house mouse CVCL_C4YC CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:9160; Single-stranded DNA. 155794237 CVCL_C4Y6 DNA 5 hybridoma house mouse CVCL_C4Y6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794238 CVCL_C4XU NQ8.5.3 hybridoma house mouse CVCL_C4XU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794239 CVCL_C4Y5 DNA 4 hybridoma house mouse CVCL_C4Y5 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA. 155794240 CVCL_C4XT NQ7.7.1 hybridoma house mouse CVCL_C4XT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794241 CVCL_C4Y8 DNA 7 hybridoma house mouse CVCL_C4Y8 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=dsDNA>ssDNA). 155794242 CVCL_C4XW NQ8.9.2 hybridoma house mouse CVCL_C4XW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794243 CVCL_C4Y7 DNA 6 hybridoma house mouse CVCL_C4Y7 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=dsDNA>ssDNA). 155794244 CVCL_C4XV NQ8.16.2 hybridoma house mouse CVCL_C4XV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794245 CVCL_C4XY DNA 1 hybridoma house mouse CVCL_C4XY CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA. 155794246 CVCL_C4Y9 DNA 8 hybridoma house mouse CVCL_C4Y9 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794247 CVCL_C4XX WRL-LFBK-alphavbeta6 spontaneously immortalized cell line pig CVCL_C4XX CL:0000010 Transfected with: VGNC; 30323; Bovine ITGAV; Transfected with: VGNC; 30331; Bovine ITGB6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Virology: Treatment of the parent cell line with the aromatic cationic compound DB772 has cured the cell line from bovine viral diarrhea virus (BVDV) infection (PubMed=34458357) Problematic cell line: Misidentified Grand-parent cell line (LF-BK) was originally thought to be of bovine origin but originates from pig (PubMed=25617444). 155794248 CVCL_C4XZ DNA 10 hybridoma house mouse CVCL_C4XZ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA. 155794249 CVCL_C4XM NQ7.47.1 hybridoma house mouse CVCL_C4XM CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794250 CVCL_C4XL NQ7.41.3 hybridoma house mouse CVCL_C4XL CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794251 CVCL_C4Y0 DNA 11 hybridoma house mouse CVCL_C4Y0 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794252 CVCL_C4XN NQ7.5.3 hybridoma house mouse CVCL_C4XN CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794253 CVCL_C4Y2 DNA 13 hybridoma house mouse CVCL_C4Y2 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794254 CVCL_C4XQ NQ7.56.2 hybridoma house mouse CVCL_C4XQ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794255 CVCL_C4Y1 DNA 12 hybridoma house mouse CVCL_C4Y1 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794256 CVCL_C4XP NQ7.51.3 hybridoma house mouse CVCL_C4XP CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794257 CVCL_C4Y4 DNA 3 hybridoma house mouse CVCL_C4Y4 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794258 CVCL_C4XS NQ7.6.1.1 hybridoma house mouse CVCL_C4XS CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794259 CVCL_C4Y3 DNA 2 hybridoma house mouse CVCL_C4Y3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA (Note=ssDNA>dsDNA). 155794260 CVCL_C4XR NQ7.6.1 hybridoma house mouse CVCL_C4XR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794261 CVCL_C4XE NQ7.1.3 hybridoma house mouse CVCL_C4XE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794262 CVCL_C4XD NQ6.8.3.1 hybridoma house mouse CVCL_C4XD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794263 CVCL_C4XG NQ7.24.6 hybridoma house mouse CVCL_C4XG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794264 CVCL_C4XF NQ7.23.1 hybridoma house mouse CVCL_C4XF CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794265 CVCL_C4XI NQ7.3.3 hybridoma house mouse CVCL_C4XI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794266 CVCL_C4XH NQ7.28.1 hybridoma house mouse CVCL_C4XH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794267 CVCL_C4XK NQ7.40.1 hybridoma house mouse CVCL_C4XK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794268 CVCL_C4XJ NQ7.34.3 hybridoma house mouse CVCL_C4XJ CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794269 CVCL_C4ZA ior EGF/r3 hybridoma house mouse CVCL_C4ZA CL:0000010 Biotechnology: Widely used in the radioimmunodiagnosis of tumors of epithelial origin Labeled with 99mTc, its main application in Nuclear Medicine is the follow up, detection and evaluation of tumor recurrences. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. 155794270 CVCL_C4ZC TRP 7.4 hybridoma house mouse CVCL_C4ZC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00895; Escherichia coli trpE. 155794271 CVCL_C4ZB HT10 hybridoma house mouse CVCL_C4ZB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mesocricetus auratus 190 kDa airway mucin-associated protein. 155794272 CVCL_C4ZE B11 [Mouse hybridoma against human SERPINC1] hybridoma house mouse CVCL_C4ZE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01008; Human SERPINC1. 155794273 CVCL_C4ZD SubP14.36.1 hybridoma house mouse CVCL_C4ZD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20366; Human TAC1 (AA 58-68; substance P). 155794274 CVCL_C4Z7 12H9 hybridoma house mouse CVCL_C4Z7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8BN78; Mouse Zbtb33 (Note=Also reacts with human, dog, hamster, monkey and rat). 155794275 CVCL_C4YV H101.2 hybridoma house mouse CVCL_C4YV CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794276 CVCL_C4Z6 12G7 hybridoma house mouse CVCL_C4Z6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8BN78; Mouse Zbtb33 (Note=Also reacts with human, dog, hamster, monkey, rat and chicken). 155794277 CVCL_C4YU H101.1 hybridoma house mouse CVCL_C4YU CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794278 CVCL_C4Z9 6F8 hybridoma house mouse CVCL_C4Z9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8BN78; Mouse Zbtb33 (Note=Also reacts with human, dog, hamster, monkey, rat and chicken). 155794279 CVCL_C4YX H101.4 hybridoma house mouse CVCL_C4YX CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794280 CVCL_C4Z8 2G1 [Mouse hybridoma against mouse Zbtb33] hybridoma house mouse CVCL_C4Z8 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8BN78; Mouse Zbtb33 (Note=Also reacts with human, dog, hamster, and rat). 155794281 CVCL_C4YW H101.3 hybridoma house mouse CVCL_C4YW CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794282 CVCL_C4YZ H101.6 hybridoma house mouse CVCL_C4YZ CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794283 CVCL_C4YY H101.5 hybridoma house mouse CVCL_C4YY CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794284 CVCL_C4YN MSCC-Inv1a cancer cell line human CVCL_C4YN CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Characteristics: Highly invasive clone Lacks E-cadherin/CDH1 expression due to promoter hypermethylation (PubMed=22207358). 155794285 CVCL_C4YM MSCC-Inv2 cancer cell line human CVCL_C4YM CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Characteristics: Highly invasive clone 155794286 CVCL_C4YP KB N10 cancer cell line human CVCL_C4YP CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:22907; Bleomycin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Uterus; cervix. Female Characteristics: Radioresistant: 1.50 to 3.75-fold more resistant to X-irradiation than the parental cell line (PubMed=9659517) Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 155794287 CVCL_C4Z1 MVA-RCC-A36 hybridoma house mouse CVCL_C4Z1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human unknown antigen. 155794288 CVCL_C4Z0 H101.7 hybridoma house mouse CVCL_C4Z0 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q96T60; Human PNKP. 155794289 CVCL_C4YR A11 [Mouse hybridoma against human TERT] hybridoma house mouse CVCL_C4YR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14746; Human TERT. 155794290 CVCL_C4Z3 MVA-RCC-C5H hybridoma house mouse CVCL_C4Z3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8801 155794291 CVCL_C4YQ 6B4/3D2 hybridoma house mouse CVCL_C4YQ CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P11436; Pseudomonas aeruginosa alpha-amidase (amiE). 155794292 CVCL_C4Z2 MVA-RCC-A6H hybridoma house mouse CVCL_C4Z2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8803 155794293 CVCL_C4Z5 11D7 hybridoma house mouse CVCL_C4Z5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8BN78; Mouse Zbtb33 (Note=Also reacts with rat). 155794294 CVCL_C4YT H4 [Mouse hybridoma against human TERT] hybridoma house mouse CVCL_C4YT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O14746; Human TERT. 155794295 CVCL_C4YS G8 hybridoma house mouse CVCL_C4YS CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O14746; Human TERT. 155794296 CVCL_C4Z4 MVA-RCC-D5D hybridoma house mouse CVCL_C4Z4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human renal cell carcinoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8802 155794297 CVCL_C4YF bfd39 hybridoma house mouse CVCL_C4YF CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:9160; Single-stranded DNA. 155794298 CVCL_C4YE bfd38 hybridoma house mouse CVCL_C4YE CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:16991; DNA. 155794299 CVCL_C4YH LuNm01 hybridoma CVCL_C4YH CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q51228; Neisseria meningitidis class 5c outer membrane protein. 155794300 CVCL_C4YG bfd89 hybridoma house mouse CVCL_C4YG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:9160; Single-stranded DNA. 155794301 CVCL_C4YJ AR51A165.2 hybridoma house mouse CVCL_C4YJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human endometroid adenocarcinoma cells. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 180706-02 155794302 CVCL_C4YI LuNm03 hybridoma CVCL_C4YI CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q51228; Neisseria meningitidis class 5c outer membrane protein. 155794303 CVCL_C4YL MSCC-Inv1 cancer cell line human CVCL_C4YL CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Characteristics: Highly invasive clone Lacks E-cadherin/CDH1 expression due to promoter hypermethylation (PubMed=15328184). 155794304 CVCL_C4YK MSCC-1 cancer cell line human CVCL_C4YK CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male 155794305 CVCL_C4VZ NQ19.8.1 hybridoma house mouse CVCL_C4VZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794306 CVCL_C4WB NQ2.45.1 hybridoma house mouse CVCL_C4WB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794307 CVCL_C4WA NQ2.39.3 hybridoma house mouse CVCL_C4WA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794308 CVCL_C4VS NQ16.38.18 hybridoma house mouse CVCL_C4VS CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794309 CVCL_C4W4 NQ2.17.4.1 hybridoma house mouse CVCL_C4W4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794310 CVCL_C4VR NQ16.113.8 hybridoma house mouse CVCL_C4VR CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794311 CVCL_C4W3 NQ2.17.4 hybridoma house mouse CVCL_C4W3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794312 CVCL_C4VU NQ18.36.44 hybridoma house mouse CVCL_C4VU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794313 CVCL_C4W6 NQ2.20.5.3 hybridoma house mouse CVCL_C4W6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794314 CVCL_C4VT NQ17.10.24 hybridoma house mouse CVCL_C4VT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794315 CVCL_C4W5 NQ2.20.5 hybridoma house mouse CVCL_C4W5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794316 CVCL_C4VW NQ19.16.37 hybridoma house mouse CVCL_C4VW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794317 CVCL_C4W8 NQ2.24.1 hybridoma house mouse CVCL_C4W8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794318 CVCL_C4VV NQ19.1.1 hybridoma house mouse CVCL_C4VV CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794319 CVCL_C4W7 NQ2.21.2 hybridoma house mouse CVCL_C4W7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794320 CVCL_C4VY NQ19.22.21 hybridoma house mouse CVCL_C4VY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794321 CVCL_C4VX NQ19.2.4 hybridoma house mouse CVCL_C4VX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794322 CVCL_C4W9 NQ2.3.1 hybridoma house mouse CVCL_C4W9 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794323 CVCL_C4VK NQ11.14.5 hybridoma house mouse CVCL_C4VK CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794324 CVCL_C4VJ NQ11.1.18 hybridoma house mouse CVCL_C4VJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794325 CVCL_C4VM NQ11.7.12 hybridoma house mouse CVCL_C4VM CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794326 CVCL_C4VL NQ11.5.2 hybridoma house mouse CVCL_C4VL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794327 CVCL_C4W0 NQ2.12.4 hybridoma house mouse CVCL_C4W0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794328 CVCL_C4VN NQ11.7.22 hybridoma house mouse CVCL_C4VN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794329 CVCL_C4VQ NQ11.8.4 hybridoma house mouse CVCL_C4VQ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794330 CVCL_C4W2 NQ2.17.2 hybridoma house mouse CVCL_C4W2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794331 CVCL_C4VP NQ11.8.1 hybridoma house mouse CVCL_C4VP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794332 CVCL_C4W1 NQ2.16.2 hybridoma house mouse CVCL_C4W1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794333 CVCL_C4VC NQ10.2.22 hybridoma house mouse CVCL_C4VC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794334 CVCL_C4VB NQ10.2.2.5 hybridoma house mouse CVCL_C4VB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794335 CVCL_C4VE NQ10.3.8 hybridoma house mouse CVCL_C4VE CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794336 CVCL_C4VD NQ10.2.3 hybridoma house mouse CVCL_C4VD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794337 CVCL_C4VG NQ10.4.6.1 hybridoma house mouse CVCL_C4VG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794338 CVCL_C4VF NQ10.4.6 hybridoma house mouse CVCL_C4VF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794339 CVCL_C4VI NQ11.1.14 hybridoma house mouse CVCL_C4VI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794340 CVCL_C4VH NQ10.4.6.2 hybridoma house mouse CVCL_C4VH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794341 CVCL_C4XA NQ6.24.2.2 hybridoma house mouse CVCL_C4XA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794342 CVCL_C4XC NQ6.8.3 hybridoma house mouse CVCL_C4XC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794343 CVCL_C4XB NQ6.41.1 hybridoma house mouse CVCL_C4XB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794344 CVCL_C4WT NQ22.91.1 hybridoma house mouse CVCL_C4WT CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794345 CVCL_C4X5 NQ5.89.4 hybridoma house mouse CVCL_C4X5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794346 CVCL_C4WS NQ22.9.24 hybridoma house mouse CVCL_C4WS CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794347 CVCL_C4X4 NQ5.82.2 hybridoma house mouse CVCL_C4X4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794348 CVCL_C4WV NQ5.4.3 hybridoma house mouse CVCL_C4WV CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794349 CVCL_C4X7 NQ5.92.5 hybridoma house mouse CVCL_C4X7 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794350 CVCL_C4WU NQ5.3.3 hybridoma house mouse CVCL_C4WU CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794351 CVCL_C4X6 NQ5.91.1 hybridoma house mouse CVCL_C4X6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794352 CVCL_C4WX NQ5.48.2 hybridoma house mouse CVCL_C4WX CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794353 CVCL_C4X9 NQ6.24.2 hybridoma house mouse CVCL_C4X9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794354 CVCL_C4WW NQ5.4.3.1 hybridoma house mouse CVCL_C4WW CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794355 CVCL_C4X8 NQ5.96.2 hybridoma house mouse CVCL_C4X8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794356 CVCL_C4WZ NQ5.6.1 hybridoma house mouse CVCL_C4WZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794357 CVCL_C4WY NQ5.57.3 hybridoma house mouse CVCL_C4WY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794358 CVCL_C4WL NQ22.18.7 hybridoma house mouse CVCL_C4WL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794359 CVCL_C4WK NQ22.17.18 hybridoma house mouse CVCL_C4WK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794360 CVCL_C4WN NQ22.56.1 hybridoma house mouse CVCL_C4WN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794361 CVCL_C4WM NQ22.33.4 hybridoma house mouse CVCL_C4WM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794362 CVCL_C4WP NQ22.61.1 hybridoma house mouse CVCL_C4WP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794363 CVCL_C4X1 NQ5.61.1.2 hybridoma house mouse CVCL_C4X1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794364 CVCL_C4X0 NQ5.61.1 hybridoma house mouse CVCL_C4X0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794365 CVCL_C4WR NQ22.9.11 hybridoma house mouse CVCL_C4WR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794366 CVCL_C4X3 NQ5.78.2.6 hybridoma house mouse CVCL_C4X3 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794367 CVCL_C4WQ NQ22.87.1 hybridoma house mouse CVCL_C4WQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794368 CVCL_C4X2 NQ5.78.2 hybridoma house mouse CVCL_C4X2 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794369 CVCL_C4WD NQ2.46.2 hybridoma house mouse CVCL_C4WD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794370 CVCL_C4WC NQ2.45.10.4 hybridoma house mouse CVCL_C4WC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794371 CVCL_C4WF NQ2.48.2.2 hybridoma house mouse CVCL_C4WF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794372 CVCL_C4WE NQ2.48.2 hybridoma house mouse CVCL_C4WE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794373 CVCL_C4WH NQ22.10.17 hybridoma house mouse CVCL_C4WH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794374 CVCL_C4WG NQ2.6.1 hybridoma house mouse CVCL_C4WG CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794375 CVCL_C4WJ NQ22.16.4 hybridoma house mouse CVCL_C4WJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 155794376 CVCL_C4WI NQ22.15.18 hybridoma house mouse CVCL_C4WI CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:60296; 2-phenyloxazol-5(4H)-one (2-phenyloxazolone; phOX). 21083612 CVCL_6942 QBC939 cancer cell line human CVCL_6942 CL:0000010 Population: Chinese Male Doubling time: 23.6 hours (PubMed=20111907). 21083613 CVCL_6943 QG-56 cancer cell line human CVCL_6943 HLA typing: A*26:01; B*46:01; C*01:02 (PubMed=9023415) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=12794755). Population: Japanese Unspecified 21083614 CVCL_6944 QSG-7701 cancer cell line human CVCL_6944 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000200007) It was one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00553 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; PubMed=28807831). Originally thought to originate from an immortalized but non-transformed hepatocytes from a 35 year old female. 21083615 CVCL_6945 HCC94 cancer cell line human CVCL_6945 CL:0000010 Female Characteristics: Established from a xenograft (HCC-94V) obtained by subcutaneous injection in nude mice. 21083616 CVCL_6940 OMM-2 cancer cell line human CVCL_6940 CL:0000010 Derived from metastatic site: Hypodermis. Male 21083617 CVCL_6941 OMM-3 cancer cell line human CVCL_6941 CL:0000010 Derived from metastatic site: Hypodermis. Male 21083618 CVCL_6946 SUNE1 hybrid cell line human CVCL_6946 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00595. Problematic cell line: Contaminated On the basis of the STR profile (PubMed=26116706) it seems to be a hybrid of HeLa and of cell line of unknown origin. Originally thought to originate from a patient with a nasopharyngeal carcinoma. 21083619 CVCL_6947 SF17 cancer cell line human CVCL_6947 CL:0000010 Male 21083620 CVCL_6948 SF188 cancer cell line human CVCL_6948 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (PubMed=9614553; PubMed=10416987) Derived from sampling site: Brain; right frontal lobe. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 26 hours (PubMed=19365568) 21083621 CVCL_6949 SF763 cancer cell line human CVCL_6949 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Unspecified (PubMed=10416987). Female 21083622 CVCL_6953 SMG-C10 transformed cell line Norway rat CVCL_6953 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.; Breed/subspecies: Sprague Dawley. Male 21083623 CVCL_6954 SMG-C6 transformed cell line Norway rat CVCL_6954 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.; Breed/subspecies: Sprague Dawley. Male 21083624 CVCL_6955 SPC-A1 cancer cell line human CVCL_6955 CL:0000010 Miscellaneous: Formerly the CCRID database had 3 entries describing this cell line (3111C0001CCC000387, 3131C0001000700053, 3142C0001000000050) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00608 Problematic cell line: Contaminated Shown to be a HeLa derivative (CCRID; PubMed=26116706). Originally thought to be a lung adenocarcinoma. 21083625 CVCL_6956 SUNE2 hybrid cell line human CVCL_6956 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00598. Problematic cell line: Contaminated On the basis of the STR profile (PubMed=26116706) it seems to be a hybrid of HeLa and of cell line of unknown origin. Originally thought to originate from a 38 year old female patient with a nasopharyngeal carcinoma. 21083626 CVCL_6950 SF767 cancer cell line human CVCL_6950 Genome ancestry: African=1.45%; Native American=0.35%; East Asian, North=2.49%; East Asian, South=0%; South Asian=0%; European, North=61.71%; European, South=33.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000051) It was one of the sources for the STR profile of this entry. Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 29 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00452 Problematic cell line: Contaminated Shown to be a ME-180 derivative (PubMed=22570425). 21083627 CVCL_6951 HFT-8810 spontaneously immortalized cell line human CVCL_6951 CL:0000010 Population: Japanese; Derived from sampling site: Fetal thymus Cell type=Fetal thymocyte.. Unspecified 21083628 CVCL_6952 SK-ChA-1 cancer cell line human CVCL_6952 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: ~48 hours, at 55-60th passage (PubMed=4056357); 26 hours (PubMed=9824643) 21083629 CVCL_6957 MCF-7/TMX2-28 cancer cell line human CVCL_6957 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: DNA methylation analysis Female 21083630 CVCL_6958 Wien 133 cancer cell line human CVCL_6958 CL:0000010 Derived from sampling site: Bone marrow. Omics: Array-based CGH Male Virology: EBV-negative 21083631 CVCL_6959 YTMLC-90 cancer cell line human CVCL_6959 CL:0000010 Population: Chinese Male 21083632 CVCL_6920 HPC-YP cancer cell line human CVCL_6920 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Unspecified Doubling time: 34 hours (PubMed=2208167) 21083633 CVCL_6921 HPC-YS cancer cell line human CVCL_6921 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Unspecified Doubling time: 31 hours (PubMed=2208167) 21083634 CVCL_6922 JEG-3/VP16 cancer cell line human CVCL_6922 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000072) It was the sole source for the STR profile of this entry. Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Fetal brain. Male 21083635 CVCL_6923 JEG-3/VP16-IL-2 cancer cell line human CVCL_6923 CL:0000010 Transfected with: HGNC; 6001; IL2 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000073) It was the sole source of information for this entry. Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Fetal brain. Male 21083636 CVCL_6928 LTEP-a1 cancer cell line human CVCL_6928 CL:0000010 Population: Chinese. Female 21083637 CVCL_6929 LTEP-a2 cancer cell line human CVCL_6929 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700033) It was one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00576 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a 46 year old female patient with a lung adenocarcinoma. 21083638 CVCL_6924 JEG-3/VP16-TNFa cancer cell line human CVCL_6924 CL:0000010 Transfected with: HGNC; 11892; TNF Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000074) It was the sole source of information for this entry. Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Fetal brain. Male 21083639 CVCL_6925 Jurkat-77 cancer cell line human CVCL_6925 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21083640 CVCL_6926 L-02 cancer cell line human CVCL_6926 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00575 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a normal fetal liver. 21083641 CVCL_6927 LTEP-78 cancer cell line human CVCL_6927 CL:0000010 Population: Chinese Male Doubling time: 96 hours (PubMed=7297395). 21083642 CVCL_6931 LTEP-sm cancer cell line human CVCL_6931 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000286) It was the sole source for the STR profile of this entry.. Population: Chinese Male 21083643 CVCL_6932 Mz-ChA-1 cancer cell line human CVCL_6932 CL:0000010 Derived from metastatic site: Abdominal wall. Omics: Transcriptome analysis by RNAseq Female Doubling time: 3-5 days, at 10th passage (PubMed=4056357); 41 hours (PubMed=9824643) 21083644 CVCL_6933 Mz-ChA-2 cancer cell line human CVCL_6933 CL:0000010 Derived from metastatic site: Liver. Female Doubling time: 48-60 hours, at 10th passage (PubMed=4056357); 34 hours (PubMed=9824643) 21083645 CVCL_6934 OCM-1 cancer cell line human CVCL_6934 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22236444); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Omics: Transcriptome analysis by microarray Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00502 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=28940260). Originally thought to originate from a female patient with uveal melanoma. 21083646 CVCL_6930 LTEP-s cancer cell line human CVCL_6930 CL:0000010 Population: Chinese. Male 21083647 CVCL_6939 OMM-1 cancer cell line human CVCL_6939 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=22236444; PubMed=24994677) Derived from metastatic site: Hypodermis. Male Doubling time: 34 hours (PubMed=24994677) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21083648 CVCL_6935 OCM-1A cancer cell line human CVCL_6935 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000234) It was one of the sources for the STR profile of this entry. Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (OCM-1) has been shown to be a M14 derivative. 21083649 CVCL_6936 OCM-2 cancer cell line human CVCL_6936 CL:0000010 21083650 CVCL_6937 OCM-3 cancer cell line human CVCL_6937 From: Kan-Mitchell J.; Wayne State University; Detroit; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=22236444; PubMed=23851445); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434_435TG>GT); Zygosity=Homozygous (PubMed=23851445). Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00503 Problematic cell line: Contaminated Shown to be a SK-MEL-28 derivative (PubMed=22236444 and STR profile from PubMed=18689700). Originally thought to originate from an uveal melanoma. 21083651 CVCL_6938 OCM-8 cancer cell line human CVCL_6938 From: Kan-Mitchell J.; Wayne State University; Detroit; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=22236444); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line). Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00504 Problematic cell line: Contaminated Shown to be a SK-MEL-28 derivative (PubMed=22236444 and STR profile from PubMed=18689700). Originally thought to originate from an uveal melanoma. 21083652 CVCL_6900 EOM-29 cancer cell line human CVCL_6900 CL:0000010 Derived from sampling site: Eye; uvea. Male 21083653 CVCL_6901 EOM-3 cancer cell line human CVCL_6901 CL:0000010 Derived from sampling site: Eye; uvea. Male 21083654 CVCL_6906 HAC-84 cancer cell line human CVCL_6906 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00605 Problematic cell line: Contaminated Parent cell line (GLC-82) has been shown to be a HeLa derivative. 21083655 CVCL_6907 HB611 cancer cell line human CVCL_6907 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21083656 CVCL_6908 HCCC-9810 cancer cell line human CVCL_6908 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 20.4 hours (CCRID) 21083657 CVCL_6909 HCe-8693 cancer cell line human CVCL_6909 CL:0000010 Population: Chinese; Derived from metastatic site: Lymph node. Male Doubling time: 30.4 hours (PubMed=2634537) 21083658 CVCL_6902 FIP293 transformed cell line human CVCL_6902 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000138) It was the sole source of information for this entry. Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a RAB11-FIP protein but not indicated which one it is 21083659 CVCL_6903 GBC-SD cancer cell line human CVCL_6903 CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Male Doubling time: 21.4 hours (CelloPub=CLPUB00378); 33.5 hours (PubMed=31367188) 21083660 CVCL_6904 GLC-15 cancer cell line human CVCL_6904 CL:0000010 21083661 CVCL_6905 GM/SO cancer cell line human CVCL_6905 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=2198961; PubMed=10071072) Derived from sampling site: Bone marrow. Female Characteristics: CSF2 dependent 21083662 CVCL_6910 HEK293-A transformed cell line human CVCL_6910 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21083663 CVCL_6911 HEK293-FT transformed cell line human CVCL_6911 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: 21.7 hours (PubMed=34529719) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5077 21083664 CVCL_6912 HPC-Y0 cancer cell line human CVCL_6912 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (PubMed=7961102) Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 28 hours (PubMed=2208167) 21083665 CVCL_6917 HPC-Y25 cancer cell line human CVCL_6917 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7961102) Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 41 hours (PubMed=2208167) 21083666 CVCL_6918 HPC-Y5 cancer cell line human CVCL_6918 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7961102) Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 33 hours (PubMed=2208167) 21083667 CVCL_6919 HPC-Y9 cancer cell line human CVCL_6919 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Unspecified Doubling time: 35 hours (PubMed=2208167) 21083668 CVCL_6913 HPC-Y1 cancer cell line human CVCL_6913 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102) Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 48 hours (PubMed=2208167) 21083669 CVCL_6914 HPC-Y11 cancer cell line human CVCL_6914 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=7961102); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102) Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 36 hours (PubMed=2208167) 21083670 CVCL_6915 HPC-Y15 cancer cell line human CVCL_6915 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Unspecified Doubling time: 28 hours (PubMed=2208167) 21083671 CVCL_6916 HPC-Y19 cancer cell line human CVCL_6916 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (PubMed=7961102) Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 25 hours (PubMed=2208167) 21083672 CVCL_PE90 BayGenomics ES cell line TEA051 embryonic stem cell house mouse CVCL_PE90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083673 CVCL_PE91 BayGenomics ES cell line TEA052 embryonic stem cell house mouse CVCL_PE91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446143; Zfc3h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083674 CVCL_PE92 BayGenomics ES cell line TEA054 embryonic stem cell house mouse CVCL_PE92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083675 CVCL_PE93 BayGenomics ES cell line TEA055 embryonic stem cell house mouse CVCL_PE93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918667; Gpatch8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083676 CVCL_PE94 BayGenomics ES cell line TEA056 embryonic stem cell house mouse CVCL_PE94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196439; Cbx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083677 CVCL_PE95 BayGenomics ES cell line TEA057 embryonic stem cell house mouse CVCL_PE95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083678 CVCL_PE96 BayGenomics ES cell line TEA058 embryonic stem cell house mouse CVCL_PE96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083679 CVCL_PE97 BayGenomics ES cell line TEA059 embryonic stem cell house mouse CVCL_PE97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277119; Zfp105 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083680 CVCL_PE98 BayGenomics ES cell line TEA060 embryonic stem cell house mouse CVCL_PE98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922589; Mphosph8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083681 CVCL_PE99 BayGenomics ES cell line TEA061 embryonic stem cell house mouse CVCL_PE99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923749; Clasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083682 CVCL_GL08 ND14404 transformed cell line human CVCL_GL08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083683 CVCL_GL09 ND14405 transformed cell line human CVCL_GL09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083684 CVCL_GL04 ND14397 transformed cell line human CVCL_GL04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083685 CVCL_GL05 ND14400 transformed cell line human CVCL_GL05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083686 CVCL_GL06 ND14401 transformed cell line human CVCL_GL06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083687 CVCL_GL07 ND14403 transformed cell line human CVCL_GL07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083688 CVCL_GL00 ND14307 transformed cell line human CVCL_GL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083689 CVCL_GL01 ND14336 transformed cell line human CVCL_GL01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083690 CVCL_GL02 ND14380 transformed cell line human CVCL_GL02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083691 CVCL_GL03 ND14381 transformed cell line human CVCL_GL03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083692 CVCL_6990 MSK-QLL1 cancer cell line human CVCL_6990 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Unspecified (PubMed=7927946). Unspecified 21083693 CVCL_6991 MSK-QLL2 cancer cell line human CVCL_6991 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=7927946). Unspecified 21083694 CVCL_6992 Marimo cancer cell line human CVCL_6992 CL:0000010 Sequence variation: Mutation; HGNC; 1455; CALR; Simple; p.Leu367Metfs*43 (c.1099_1159del61); Zygosity=Heterozygous (PubMed=25249012; PubMed=30115971); Sequence variation: Mutation; HGNC; 7217; MPL; Simple; p.Ser505Asn (c.1514G>A); ClinVar=VCV000014163; Zygosity=Heterozygous (PubMed=30115971); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30115971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=30115971) Derived from sampling site: Bone marrow. Omics: Deep quantitative phosphoproteome analysis Female Characteristics: This cell line is independent of the CALR-MPL-JAK2-STAT5 pathway Doubling time: 25-28 hours (PubMed=9406575) 21083695 CVCL_6986 MDA-886 cancer cell line human CVCL_6986 CL:0000010 Male 21083696 CVCL_6987 MDA-886Ln cancer cell line human CVCL_6987 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21083697 CVCL_6988 MSK-921 cancer cell line human CVCL_6988 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Unspecified 21083698 CVCL_6989 MSK-922 cancer cell line human CVCL_6989 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21083699 CVCL_6982 MDA-1986 cancer cell line human CVCL_6982 CL:0000010 21083700 CVCL_6983 MDA-686 cancer cell line human CVCL_6983 CL:0000010 Male 21083701 CVCL_6984 MDA-686Ln cancer cell line human CVCL_6984 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=7927946) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00442 Problematic cell line: Partially contaminated Some stocks are contaminated by UM-SCC-1 (PubMed=21868764). 21083702 CVCL_6985 MDA-686Tu cancer cell line human CVCL_6985 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=7927946) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00443 Problematic cell line: Partially contaminated Some stocks are contaminated by T404/T406/Tu 1387Tu 158LN/Tu 159/Tu 182/Tu 212/Tu 212LN (PubMed=21868764). 21083703 CVCL_6997 FU-UR-1 cancer cell line human CVCL_6997 CL:0000010 Sequence variation: Gene fusion; HGNC; 13825; ASPSCR1 + HGNC; 11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3 (PubMed=15138551; PubMed=23288701) Population: Japanese; Derived from sampling site: Retroperitoneal space. Male Doubling time: 32 hours, at 51th passage (PubMed=15138551) 21083704 CVCL_6998 Sq-19 cancer cell line human CVCL_6998 CL:0000010 Population: Japanese. 21083705 CVCL_6999 IF6 cancer cell line human CVCL_6999 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21083706 CVCL_6993 WM1361B cancer cell line human CVCL_6993 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell line WM1361A); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from autologous cell line WM1361A) Derived from metastatic site: Skin. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21083707 CVCL_6994 WM1361C cancer cell line human CVCL_6994 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell line WM1361A); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from autologous cell line WM1361A) Derived from metastatic site: Skin. Male Part of: Wistar Institute melanoma cell line collection 21083708 CVCL_6995 WM51 cancer cell line human CVCL_6995 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00122; probable Male Part of: Wistar Institute melanoma cell line collection 21083709 CVCL_6996 HEK293-ET transformed cell line human CVCL_6996 CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21083710 CVCL_6970 E1C4 embryonic stem cell human CVCL_6970 From: University of New South Wales; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200628. 21083711 CVCL_6964 SK-MEL-15 cancer cell line human CVCL_6964 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Male 21083712 CVCL_6965 FS-133 finite cell line human CVCL_6965 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21083713 CVCL_6966 Endeavour-1 embryonic stem cell human CVCL_6966 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-14.; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200602. 21083714 CVCL_6967 E1C1 embryonic stem cell human CVCL_6967 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200626. 21083715 CVCL_6960 SK-MEL-8 cancer cell line human CVCL_6960 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21083716 CVCL_6961 SK-MEL-249 cancer cell line human CVCL_6961 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21083717 CVCL_6962 SK-MEL-250 cancer cell line human CVCL_6962 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21083718 CVCL_6963 SK-MEL-112 cancer cell line human CVCL_6963 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21083719 CVCL_6968 E1C2 embryonic stem cell human CVCL_6968 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200627. 21083720 CVCL_6969 E1C3 embryonic stem cell human CVCL_6969 From: Prince of Wales Hospital; Sidney; Australia. CL:0000010 Female 21083721 CVCL_6980 MDA-1483 cancer cell line human CVCL_6980 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~36 hours (PubMed=2452013) 21083722 CVCL_6981 MDA-1586 cancer cell line human CVCL_6981 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=7927946) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21083723 CVCL_6975 TJ905 cancer cell line human CVCL_6975 CL:0000010 Population: Chinese Omics: Proteome analysis by 2D-DE Male Doubling time: 41.03 hours (CCRID) 21083724 CVCL_6976 COLO 394 cancer cell line human CVCL_6976 CL:0000010 Unspecified 21083725 CVCL_6977 MDA-1186 cancer cell line human CVCL_6977 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Gly (c.773A>G); ClinVar=VCV000406590; Zygosity=Unspecified (PubMed=7927946) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21083726 CVCL_6978 MDA-183 cancer cell line human CVCL_6978 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~36 hours (PubMed=2452013) 21083727 CVCL_6971 FOX-NY cancer cell line house mouse CVCL_6971 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21083728 CVCL_6972 FO [Mouse myeloma] cancer cell line house mouse CVCL_6972 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21083729 CVCL_6973 IEC-CF7 finite cell line Norway rat CVCL_6973 CL:0000010 Transfected with: HGNC; 1884; CFTR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male 21083730 CVCL_6974 HEK293-EBNA transformed cell line human CVCL_6974 CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The use of recombinant protein expression vectors containing the EBV oriP in cell lines stably expressing EBV's EBNA1 protein significantly increases recombinant protein yield Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10852 21083731 CVCL_6979 MDA-1386 cancer cell line human CVCL_6979 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Pro (c.838_839AG>CC); Zygosity=Unspecified (PubMed=7927946); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=7927946). Male 21083732 CVCL_GK56 ND14129 transformed cell line human CVCL_GK56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083733 CVCL_GK57 ND14130 transformed cell line human CVCL_GK57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083734 CVCL_GK58 ND14131 transformed cell line human CVCL_GK58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083735 CVCL_GK59 ND14138 transformed cell line human CVCL_GK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083736 CVCL_PE00 BayGenomics ES cell line SYA226 embryonic stem cell house mouse CVCL_PE00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443298; Tet2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083737 CVCL_GK52 ND14118 transformed cell line human CVCL_GK52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083738 CVCL_PE01 BayGenomics ES cell line SYA228 embryonic stem cell house mouse CVCL_PE01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88266; Capns1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083739 CVCL_GK53 ND14120 transformed cell line human CVCL_GK53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083740 CVCL_PE02 BayGenomics ES cell line SYA242 embryonic stem cell house mouse CVCL_PE02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140359; Tmem64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083741 CVCL_GK54 ND14125 transformed cell line human CVCL_GK54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083742 CVCL_PE03 BayGenomics ES cell line SYA245 embryonic stem cell house mouse CVCL_PE03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145578; Slain1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083743 CVCL_GK55 ND14127 transformed cell line human CVCL_GK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083744 CVCL_PE04 BayGenomics ES cell line SYA247 embryonic stem cell house mouse CVCL_PE04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083745 CVCL_PE05 BayGenomics ES cell line SYA252 embryonic stem cell house mouse CVCL_PE05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027896; Ppp4r2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083746 CVCL_PE06 BayGenomics ES cell line SYA253 embryonic stem cell house mouse CVCL_PE06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083747 CVCL_GK50 ND14098 transformed cell line human CVCL_GK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083748 CVCL_PE07 BayGenomics ES cell line SYA254 embryonic stem cell house mouse CVCL_PE07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083749 CVCL_GK51 ND14116 transformed cell line human CVCL_GK51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083750 CVCL_GK67 ND14214 transformed cell line human CVCL_GK67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083751 CVCL_GK68 ND14215 transformed cell line human CVCL_GK68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083752 CVCL_GK69 ND14216 transformed cell line human CVCL_GK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083753 CVCL_GK63 ND14175 transformed cell line human CVCL_GK63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083754 CVCL_GK64 ND14184 transformed cell line human CVCL_GK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083755 CVCL_GK65 ND14189 transformed cell line human CVCL_GK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083756 CVCL_GK66 ND14213 transformed cell line human CVCL_GK66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083757 CVCL_GK60 ND14140 transformed cell line human CVCL_GK60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083758 CVCL_GK61 ND14150 transformed cell line human CVCL_GK61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083759 CVCL_GK62 ND14173 transformed cell line human CVCL_GK62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083760 CVCL_GK38 ND14053 transformed cell line human CVCL_GK38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083761 CVCL_GK39 ND14054 transformed cell line human CVCL_GK39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083762 CVCL_GK34 ND14037 transformed cell line human CVCL_GK34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083763 CVCL_GK35 ND14049 transformed cell line human CVCL_GK35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083764 CVCL_GK36 ND14051 transformed cell line human CVCL_GK36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083765 CVCL_GK37 ND14052 transformed cell line human CVCL_GK37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083766 CVCL_GK30 ND14027 transformed cell line human CVCL_GK30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083767 CVCL_GK31 ND14029 transformed cell line human CVCL_GK31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083768 CVCL_GK32 ND14035 transformed cell line human CVCL_GK32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083769 CVCL_GK33 ND14036 transformed cell line human CVCL_GK33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083770 CVCL_GK49 ND14097 transformed cell line human CVCL_GK49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083771 CVCL_GK45 ND14090 transformed cell line human CVCL_GK45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083772 CVCL_GK46 ND14094 transformed cell line human CVCL_GK46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083773 CVCL_GK47 ND14095 transformed cell line human CVCL_GK47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083774 CVCL_GK48 ND14096 transformed cell line human CVCL_GK48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083775 CVCL_GK41 ND14078 transformed cell line human CVCL_GK41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083776 CVCL_GK42 ND14079 transformed cell line human CVCL_GK42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083777 CVCL_GK43 ND14087 transformed cell line human CVCL_GK43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083778 CVCL_GK44 ND14089 transformed cell line human CVCL_GK44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083779 CVCL_GK40 ND14057 transformed cell line human CVCL_GK40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083780 CVCL_GK16 ND13958 transformed cell line human CVCL_GK16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083781 CVCL_GK17 ND13965 transformed cell line human CVCL_GK17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083782 CVCL_GK18 ND13969 transformed cell line human CVCL_GK18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083783 CVCL_GK19 ND14000 transformed cell line human CVCL_GK19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083784 CVCL_GK12 ND13936 transformed cell line human CVCL_GK12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083785 CVCL_GK13 ND13940 transformed cell line human CVCL_GK13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083786 CVCL_GK14 ND13941 transformed cell line human CVCL_GK14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083787 CVCL_GK15 ND13942 transformed cell line human CVCL_GK15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083788 CVCL_GK10 ND13927 transformed cell line human CVCL_GK10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083789 CVCL_GK11 ND13935 transformed cell line human CVCL_GK11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083790 CVCL_GK27 ND14022 transformed cell line human CVCL_GK27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083791 CVCL_GK28 ND14024 transformed cell line human CVCL_GK28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083792 CVCL_GK29 ND14025 transformed cell line human CVCL_GK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083793 CVCL_GK23 ND14017 transformed cell line human CVCL_GK23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083794 CVCL_GK24 ND14018 transformed cell line human CVCL_GK24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083795 CVCL_GK25 ND14019 transformed cell line human CVCL_GK25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083796 CVCL_GK26 ND14020 transformed cell line human CVCL_GK26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083797 CVCL_GK20 ND14001 transformed cell line human CVCL_GK20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083798 CVCL_GK21 ND14005 transformed cell line human CVCL_GK21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083799 CVCL_GK22 ND14006 transformed cell line human CVCL_GK22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083800 CVCL_GK09 ND13925 transformed cell line human CVCL_GK09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083801 CVCL_GK05 ND13921 transformed cell line human CVCL_GK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083802 CVCL_GK06 ND13922 transformed cell line human CVCL_GK06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083803 CVCL_GK07 ND13923 transformed cell line human CVCL_GK07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083804 CVCL_GK08 ND13924 transformed cell line human CVCL_GK08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083805 CVCL_GK01 ND13917 transformed cell line human CVCL_GK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083806 CVCL_GK02 ND13918 transformed cell line human CVCL_GK02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083807 CVCL_GK03 ND13919 transformed cell line human CVCL_GK03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083808 CVCL_GK04 ND13920 transformed cell line human CVCL_GK04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083809 CVCL_GK00 ND13915 transformed cell line human CVCL_GK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083810 CVCL_PE80 BayGenomics ES cell line TEA036 embryonic stem cell house mouse CVCL_PE80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894649; Ppfibp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083811 CVCL_PE81 BayGenomics ES cell line TEA037 embryonic stem cell house mouse CVCL_PE81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083812 CVCL_PE82 BayGenomics ES cell line TEA038 embryonic stem cell house mouse CVCL_PE82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083813 CVCL_PE83 BayGenomics ES cell line TEA041 embryonic stem cell house mouse CVCL_PE83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88548; Csnk2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083814 CVCL_PE84 BayGenomics ES cell line TEA043 embryonic stem cell house mouse CVCL_PE84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083815 CVCL_PE85 BayGenomics ES cell line TEA044 embryonic stem cell house mouse CVCL_PE85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083816 CVCL_PE86 BayGenomics ES cell line TEA045 embryonic stem cell house mouse CVCL_PE86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083817 CVCL_PE87 BayGenomics ES cell line TEA046 embryonic stem cell house mouse CVCL_PE87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083818 CVCL_PE88 BayGenomics ES cell line TEA047 embryonic stem cell house mouse CVCL_PE88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095419; Kdm6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083819 CVCL_PE89 BayGenomics ES cell line TEA050 embryonic stem cell house mouse CVCL_PE89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083820 CVCL_PE70 BayGenomics ES cell line TEA021 embryonic stem cell house mouse CVCL_PE70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96269; Ranbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083821 CVCL_PE71 BayGenomics ES cell line TEA022 embryonic stem cell house mouse CVCL_PE71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96269; Ranbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083822 CVCL_PE72 BayGenomics ES cell line TEA023 embryonic stem cell house mouse CVCL_PE72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96269; Ranbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083823 CVCL_PE73 BayGenomics ES cell line TEA025 embryonic stem cell house mouse CVCL_PE73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083824 CVCL_PE74 BayGenomics ES cell line TEA028 embryonic stem cell house mouse CVCL_PE74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083825 CVCL_PE75 BayGenomics ES cell line TEA030 embryonic stem cell house mouse CVCL_PE75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146808; Safb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083826 CVCL_PE76 BayGenomics ES cell line TEA031 embryonic stem cell house mouse CVCL_PE76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923998; Pbrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083827 CVCL_PE77 BayGenomics ES cell line TEA033 embryonic stem cell house mouse CVCL_PE77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342295; Celf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083828 CVCL_PE78 BayGenomics ES cell line TEA034 embryonic stem cell house mouse CVCL_PE78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342295; Celf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083829 CVCL_PE79 BayGenomics ES cell line TEA035 embryonic stem cell house mouse CVCL_PE79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083830 CVCL_PE60 BayGenomics ES cell line TEA005 embryonic stem cell house mouse CVCL_PE60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889002; Wdr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083831 CVCL_PE61 BayGenomics ES cell line TEA006 embryonic stem cell house mouse CVCL_PE61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083832 CVCL_PE62 BayGenomics ES cell line TEA007 embryonic stem cell house mouse CVCL_PE62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921565; Rnf145 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083833 CVCL_PE63 BayGenomics ES cell line TEA009 embryonic stem cell house mouse CVCL_PE63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915512; Agpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083834 CVCL_PE64 BayGenomics ES cell line TEA010 embryonic stem cell house mouse CVCL_PE64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347043; Orc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083835 CVCL_PE65 BayGenomics ES cell line TEA011 embryonic stem cell house mouse CVCL_PE65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353655; Usp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083836 CVCL_PE66 BayGenomics ES cell line TEA013 embryonic stem cell house mouse CVCL_PE66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138584; Gigyf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083837 CVCL_PE67 BayGenomics ES cell line TEA015 embryonic stem cell house mouse CVCL_PE67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107940; Ezh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083838 CVCL_PE68 BayGenomics ES cell line TEA017 embryonic stem cell house mouse CVCL_PE68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083839 CVCL_PE69 BayGenomics ES cell line TEA020 embryonic stem cell house mouse CVCL_PE69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355272; Csnk1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083840 CVCL_PE50 BayGenomics ES cell line SYA397 embryonic stem cell house mouse CVCL_PE50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083841 CVCL_PE51 BayGenomics ES cell line SYA398 embryonic stem cell house mouse CVCL_PE51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921356; Dcaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083842 CVCL_PE52 BayGenomics ES cell line SYA401 embryonic stem cell house mouse CVCL_PE52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446190; Nup188 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083843 CVCL_PE53 BayGenomics ES cell line SYA403 embryonic stem cell house mouse CVCL_PE53 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm3941 (MGI:3782115) which is no longer considered a gene by MGI 21083844 CVCL_PE54 BayGenomics ES cell line SYA405 embryonic stem cell house mouse CVCL_PE54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98444; Surf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083845 CVCL_PE55 BayGenomics ES cell line SYA410 embryonic stem cell house mouse CVCL_PE55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083846 CVCL_PE56 BayGenomics ES cell line SYA411 embryonic stem cell house mouse CVCL_PE56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103262; Yap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083847 CVCL_PE57 BayGenomics ES cell line SYA416 embryonic stem cell house mouse CVCL_PE57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083848 CVCL_PE58 BayGenomics ES cell line SYA418 embryonic stem cell house mouse CVCL_PE58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083849 CVCL_PE59 BayGenomics ES cell line TEA004 embryonic stem cell house mouse CVCL_PE59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083850 CVCL_PE40 BayGenomics ES cell line SYA364 embryonic stem cell house mouse CVCL_PE40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083851 CVCL_PE41 BayGenomics ES cell line SYA369 embryonic stem cell house mouse CVCL_PE41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351660; Csnk1e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083852 CVCL_PE42 BayGenomics ES cell line SYA372 embryonic stem cell house mouse CVCL_PE42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444720; Smcr8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083853 CVCL_PE43 BayGenomics ES cell line SYA376 embryonic stem cell house mouse CVCL_PE43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108025; Prkar2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083854 CVCL_PE44 BayGenomics ES cell line SYA377 embryonic stem cell house mouse CVCL_PE44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919822; Spats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083855 CVCL_GK96 ND14292 transformed cell line human CVCL_GK96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083856 CVCL_PE45 BayGenomics ES cell line SYA379 embryonic stem cell house mouse CVCL_PE45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685013; Cog7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083857 CVCL_GK97 ND08553 transformed cell line human CVCL_GK97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083858 CVCL_PE46 BayGenomics ES cell line SYA388 embryonic stem cell house mouse CVCL_PE46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083859 CVCL_GK98 ND14299 transformed cell line human CVCL_GK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083860 CVCL_PE47 BayGenomics ES cell line SYA390 embryonic stem cell house mouse CVCL_PE47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700012; Ostf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083861 CVCL_GK99 ND14302 transformed cell line human CVCL_GK99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083862 CVCL_PE48 BayGenomics ES cell line SYA393 embryonic stem cell house mouse CVCL_PE48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926143; Cnot10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083863 CVCL_GK92 ND14284 transformed cell line human CVCL_GK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083864 CVCL_PE49 BayGenomics ES cell line SYA394 embryonic stem cell house mouse CVCL_PE49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083865 CVCL_GK93 ND14285 transformed cell line human CVCL_GK93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083866 CVCL_GK94 ND14290 transformed cell line human CVCL_GK94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083867 CVCL_GK95 ND14291 transformed cell line human CVCL_GK95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083868 CVCL_PE30 BayGenomics ES cell line SYA334 embryonic stem cell house mouse CVCL_PE30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083869 CVCL_PE31 BayGenomics ES cell line SYA336 embryonic stem cell house mouse CVCL_PE31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107726; Supt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083870 CVCL_PE32 BayGenomics ES cell line SYA337 embryonic stem cell house mouse CVCL_PE32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109233; Kif22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083871 CVCL_PE33 BayGenomics ES cell line SYA338 embryonic stem cell house mouse CVCL_PE33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922989; Mpp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083872 CVCL_PE34 BayGenomics ES cell line SYA341 embryonic stem cell house mouse CVCL_PE34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915038; Sfr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083873 CVCL_PE35 BayGenomics ES cell line SYA352 embryonic stem cell house mouse CVCL_PE35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096572; Zfand3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083874 CVCL_PE36 BayGenomics ES cell line SYA356 embryonic stem cell house mouse CVCL_PE36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083875 CVCL_PE37 BayGenomics ES cell line SYA358 embryonic stem cell house mouse CVCL_PE37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083876 CVCL_PE38 BayGenomics ES cell line SYA359 embryonic stem cell house mouse CVCL_PE38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858232; Nudt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083877 CVCL_PE39 BayGenomics ES cell line SYA361 embryonic stem cell house mouse CVCL_PE39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924295; Bcl7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083878 CVCL_PE19 BayGenomics ES cell line SYA299 embryonic stem cell house mouse CVCL_PE19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97594; Prkacb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083879 CVCL_GK80 ND14240 transformed cell line human CVCL_GK80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083880 CVCL_GK78 ND14238 transformed cell line human CVCL_GK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083881 CVCL_GK79 ND14239 transformed cell line human CVCL_GK79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083882 CVCL_PE20 BayGenomics ES cell line SYA300 embryonic stem cell house mouse CVCL_PE20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97594; Prkacb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083883 CVCL_PE21 BayGenomics ES cell line SYA301 embryonic stem cell house mouse CVCL_PE21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083884 CVCL_PE22 BayGenomics ES cell line SYA303 embryonic stem cell house mouse CVCL_PE22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926162; Sp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083885 CVCL_GK74 ND14232 transformed cell line human CVCL_GK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083886 CVCL_PE23 BayGenomics ES cell line SYA309 embryonic stem cell house mouse CVCL_PE23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083887 CVCL_GK75 ND14233 transformed cell line human CVCL_GK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083888 CVCL_PE24 BayGenomics ES cell line SYA313 embryonic stem cell house mouse CVCL_PE24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083889 CVCL_GK76 ND14236 transformed cell line human CVCL_GK76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083890 CVCL_PE25 BayGenomics ES cell line SYA318 embryonic stem cell house mouse CVCL_PE25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083891 CVCL_GK77 ND14237 transformed cell line human CVCL_GK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083892 CVCL_PE26 BayGenomics ES cell line SYA319 embryonic stem cell house mouse CVCL_PE26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919891; Mob2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083893 CVCL_GK70 ND14217 transformed cell line human CVCL_GK70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083894 CVCL_PE27 BayGenomics ES cell line SYA320 embryonic stem cell house mouse CVCL_PE27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929183; Tsc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083895 CVCL_GK71 ND14218 transformed cell line human CVCL_GK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083896 CVCL_PE28 BayGenomics ES cell line SYA323 embryonic stem cell house mouse CVCL_PE28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687042; Ppp1r37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083897 CVCL_GK72 ND14230 transformed cell line human CVCL_GK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083898 CVCL_PE29 BayGenomics ES cell line SYA326 embryonic stem cell house mouse CVCL_PE29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104537; Brca1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083899 CVCL_GK73 ND14231 transformed cell line human CVCL_GK73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083900 CVCL_PE08 BayGenomics ES cell line SYA262 embryonic stem cell house mouse CVCL_PE08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441773; Pcmtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083901 CVCL_PE09 BayGenomics ES cell line SYA264 embryonic stem cell house mouse CVCL_PE09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083902 CVCL_GK90 ND14281 transformed cell line human CVCL_GK90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083903 CVCL_GK91 ND14282 transformed cell line human CVCL_GK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083904 CVCL_GK89 ND14275 transformed cell line human CVCL_GK89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083905 CVCL_PE10 BayGenomics ES cell line SYA268 embryonic stem cell house mouse CVCL_PE10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083906 CVCL_PE11 BayGenomics ES cell line SYA276 embryonic stem cell house mouse CVCL_PE11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3615624; Atg4a-ps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083907 CVCL_GK85 ND14266 transformed cell line human CVCL_GK85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083908 CVCL_PE12 BayGenomics ES cell line SYA278 embryonic stem cell house mouse CVCL_PE12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861607; Gbf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083909 CVCL_GK86 ND14269 transformed cell line human CVCL_GK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083910 CVCL_PE13 BayGenomics ES cell line SYA280 embryonic stem cell house mouse CVCL_PE13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083911 CVCL_GK87 ND14273 transformed cell line human CVCL_GK87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083912 CVCL_PE14 BayGenomics ES cell line SYA282 embryonic stem cell house mouse CVCL_PE14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083913 CVCL_GK88 ND14274 transformed cell line human CVCL_GK88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083914 CVCL_PE15 BayGenomics ES cell line SYA283 embryonic stem cell house mouse CVCL_PE15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083915 CVCL_GK81 ND14243 transformed cell line human CVCL_GK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083916 CVCL_PE16 BayGenomics ES cell line SYA285 embryonic stem cell house mouse CVCL_PE16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109529; Dpf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083917 CVCL_GK82 ND14244 transformed cell line human CVCL_GK82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083918 CVCL_PE17 BayGenomics ES cell line SYA297 embryonic stem cell house mouse CVCL_PE17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444354; Arid4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083919 CVCL_GK83 ND14245 transformed cell line human CVCL_GK83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21083920 CVCL_PE18 BayGenomics ES cell line SYA298 embryonic stem cell house mouse CVCL_PE18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913915; Msantd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21083921 CVCL_GK84 ND14259 transformed cell line human CVCL_GK84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21083922 CVCL_5Y63 GM15369 transformed cell line human CVCL_5Y63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083923 CVCL_5Y64 GM15370 transformed cell line human CVCL_5Y64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083924 CVCL_5Y65 GM15371 transformed cell line human CVCL_5Y65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083925 CVCL_5Y66 GM15372 transformed cell line human CVCL_5Y66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083926 CVCL_5Y60 GM15366 transformed cell line human CVCL_5Y60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083927 CVCL_5Y61 GM15367 transformed cell line human CVCL_5Y61 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083928 CVCL_5Y62 GM15368 transformed cell line human CVCL_5Y62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083929 CVCL_5Y67 GM15373 transformed cell line human CVCL_5Y67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083930 CVCL_5Y68 GM15374 transformed cell line human CVCL_5Y68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083931 CVCL_5Y69 GM15375 transformed cell line human CVCL_5Y69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083932 CVCL_5Y80 GM15389 transformed cell line human CVCL_5Y80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083933 CVCL_5Y74 GM15381 transformed cell line human CVCL_5Y74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083934 CVCL_5Y75 GM15382 transformed cell line human CVCL_5Y75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083935 CVCL_5Y76 GM15383 transformed cell line human CVCL_5Y76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083936 CVCL_5Y77 GM15385 transformed cell line human CVCL_5Y77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083937 CVCL_5Y70 GM15376 transformed cell line human CVCL_5Y70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083938 CVCL_5Y71 GM15377 transformed cell line human CVCL_5Y71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083939 CVCL_5Y72 GM15379 transformed cell line human CVCL_5Y72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083940 CVCL_5Y73 GM15380 transformed cell line human CVCL_5Y73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083941 CVCL_5Y78 GM15386 transformed cell line human CVCL_5Y78 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083942 CVCL_5Y79 GM15388 transformed cell line human CVCL_5Y79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083943 CVCL_5Y41 GM15342 transformed cell line human CVCL_5Y41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083944 CVCL_5Y42 GM15343 transformed cell line human CVCL_5Y42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083945 CVCL_5Y43 GM15344 transformed cell line human CVCL_5Y43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083946 CVCL_5Y44 GM15346 transformed cell line human CVCL_5Y44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083947 CVCL_5Y40 GM15341 transformed cell line human CVCL_5Y40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083948 CVCL_5Y49 GM15354 transformed cell line human CVCL_5Y49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083949 CVCL_5Y45 GM15348 transformed cell line human CVCL_5Y45 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083950 CVCL_5Y46 GM15349 transformed cell line human CVCL_5Y46 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083951 CVCL_5Y47 GM15351 transformed cell line human CVCL_5Y47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083952 CVCL_5Y48 GM15352 transformed cell line human CVCL_5Y48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083953 CVCL_5Y52 GM15357 transformed cell line human CVCL_5Y52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083954 CVCL_5Y53 GM15359 transformed cell line human CVCL_5Y53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083955 CVCL_5Y54 GM15360 transformed cell line human CVCL_5Y54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083956 CVCL_5Y55 GM15361 transformed cell line human CVCL_5Y55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083957 CVCL_5Y50 GM15355 transformed cell line human CVCL_5Y50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083958 CVCL_5Y51 GM15356 transformed cell line human CVCL_5Y51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083959 CVCL_5Y56 GM15362 transformed cell line human CVCL_5Y56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083960 CVCL_5Y57 GM15363 transformed cell line human CVCL_5Y57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083961 CVCL_5Y58 GM15364 transformed cell line human CVCL_5Y58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083962 CVCL_5Y59 GM15365 transformed cell line human CVCL_5Y59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083963 CVCL_5Y20 GM15319 transformed cell line human CVCL_5Y20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083964 CVCL_5Y21 GM15320 transformed cell line human CVCL_5Y21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083965 CVCL_5Y22 GM15321 transformed cell line human CVCL_5Y22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083966 CVCL_5Y27 GM15326 transformed cell line human CVCL_5Y27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083967 CVCL_5Y28 GM15327 transformed cell line human CVCL_5Y28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083968 CVCL_5Y29 GM15328 transformed cell line human CVCL_5Y29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083969 CVCL_5Y23 GM15322 transformed cell line human CVCL_5Y23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083970 CVCL_5Y24 GM15323 transformed cell line human CVCL_5Y24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083971 CVCL_5Y25 GM15324 transformed cell line human CVCL_5Y25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083972 CVCL_5Y26 GM15325 transformed cell line human CVCL_5Y26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083973 CVCL_5Y30 GM15330 transformed cell line human CVCL_5Y30 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083974 CVCL_5Y31 GM15331 transformed cell line human CVCL_5Y31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083975 CVCL_5Y32 GM15332 transformed cell line human CVCL_5Y32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083976 CVCL_5Y33 GM15333 transformed cell line human CVCL_5Y33 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083977 CVCL_5Y38 GM15339 transformed cell line human CVCL_5Y38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083978 CVCL_5Y39 GM15340 transformed cell line human CVCL_5Y39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083979 CVCL_5Y34 GM15334 transformed cell line human CVCL_5Y34 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083980 CVCL_5Y35 GM15335 transformed cell line human CVCL_5Y35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083981 CVCL_5Y36 GM15336 transformed cell line human CVCL_5Y36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083982 CVCL_5Y37 GM15337 transformed cell line human CVCL_5Y37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083983 CVCL_5Y09 GM15308 transformed cell line human CVCL_5Y09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083984 CVCL_5Y00 GM15282 transformed cell line human CVCL_5Y00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083985 CVCL_5Y05 GM15287 transformed cell line human CVCL_5Y05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083986 CVCL_5Y06 GM15288 transformed cell line human CVCL_5Y06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083987 CVCL_5Y07 GM15289 transformed cell line human CVCL_5Y07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083988 CVCL_5Y08 GM15307 transformed cell line human CVCL_5Y08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083989 CVCL_5Y01 GM15283 transformed cell line human CVCL_5Y01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083990 CVCL_5Y02 GM15284 transformed cell line human CVCL_5Y02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083991 CVCL_5Y03 GM15285 transformed cell line human CVCL_5Y03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083992 CVCL_5Y04 GM15286 transformed cell line human CVCL_5Y04 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083993 CVCL_5Y10 GM15309 transformed cell line human CVCL_5Y10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083994 CVCL_5Y11 GM15310 transformed cell line human CVCL_5Y11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083995 CVCL_5Y16 GM15315 transformed cell line human CVCL_5Y16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083996 CVCL_5Y17 GM15316 transformed cell line human CVCL_5Y17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083997 CVCL_5Y18 GM15317 transformed cell line human CVCL_5Y18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083998 CVCL_5Y19 GM15318 transformed cell line human CVCL_5Y19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21083999 CVCL_5Y12 GM15311 transformed cell line human CVCL_5Y12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084000 CVCL_5Y13 GM15312 transformed cell line human CVCL_5Y13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084001 CVCL_5Y14 GM15313 transformed cell line human CVCL_5Y14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084002 CVCL_5Y15 GM15314 transformed cell line human CVCL_5Y15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084003 CVCL_GM18 ND15746 transformed cell line human CVCL_GM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084004 CVCL_GM19 ND15753 transformed cell line human CVCL_GM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084005 CVCL_GM14 ND15632 transformed cell line human CVCL_GM14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084006 CVCL_GM15 ND15730 transformed cell line human CVCL_GM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084007 CVCL_GM16 ND15737 transformed cell line human CVCL_GM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084008 CVCL_GM17 ND15744 transformed cell line human CVCL_GM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084009 CVCL_GM10 ND15571 transformed cell line human CVCL_GM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084010 CVCL_GM11 ND15572 transformed cell line human CVCL_GM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084011 CVCL_GM12 ND15573 transformed cell line human CVCL_GM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084012 CVCL_GM13 ND15627 transformed cell line human CVCL_GM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084013 CVCL_GM29 ND15948 transformed cell line human CVCL_GM29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084014 CVCL_GM25 ND15896 transformed cell line human CVCL_GM25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084015 CVCL_GM26 ND15915 transformed cell line human CVCL_GM26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084016 CVCL_GM27 ND15919 transformed cell line human CVCL_GM27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084017 CVCL_GM28 ND15920 transformed cell line human CVCL_GM28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084018 CVCL_GM21 ND15820 transformed cell line human CVCL_GM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084019 CVCL_GM22 ND15843 transformed cell line human CVCL_GM22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084020 CVCL_GM23 ND15865 transformed cell line human CVCL_GM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084021 CVCL_GM24 ND15874 transformed cell line human CVCL_GM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084022 CVCL_GM20 ND15775 transformed cell line human CVCL_GM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084023 CVCL_GM07 ND15553 transformed cell line human CVCL_GM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084024 CVCL_GM08 ND15554 transformed cell line human CVCL_GM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084025 CVCL_GM09 ND15569 transformed cell line human CVCL_GM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084026 CVCL_GM03 ND15538 transformed cell line human CVCL_GM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084027 CVCL_GM04 ND15540 transformed cell line human CVCL_GM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084028 CVCL_GM05 ND15545 transformed cell line human CVCL_GM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084029 CVCL_GM06 ND15551 transformed cell line human CVCL_GM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084030 CVCL_GM00 ND15535 transformed cell line human CVCL_GM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084031 CVCL_GM01 ND15536 transformed cell line human CVCL_GM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084032 CVCL_GM02 ND15537 transformed cell line human CVCL_GM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084033 CVCL_5Y90 GM15402 transformed cell line human CVCL_5Y90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084034 CVCL_5Y91 GM15403 transformed cell line human CVCL_5Y91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084035 CVCL_5Y85 GM15397 transformed cell line human CVCL_5Y85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084036 CVCL_5Y86 GM15398 transformed cell line human CVCL_5Y86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084037 CVCL_5Y87 GM15399 transformed cell line human CVCL_5Y87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084038 CVCL_5Y88 GM15400 transformed cell line human CVCL_5Y88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084039 CVCL_5Y81 GM15391 transformed cell line human CVCL_5Y81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084040 CVCL_5Y82 GM15392 transformed cell line human CVCL_5Y82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084041 CVCL_5Y83 GM15393 transformed cell line human CVCL_5Y83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084042 CVCL_5Y84 GM15394 transformed cell line human CVCL_5Y84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084043 CVCL_5Y89 GM15401 transformed cell line human CVCL_5Y89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084044 CVCL_5Y96 GM15412 transformed cell line human CVCL_5Y96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084045 CVCL_5Y97 GM15414 transformed cell line human CVCL_5Y97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084046 CVCL_5Y98 GM15416 transformed cell line human CVCL_5Y98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084047 CVCL_5Y99 GM15417 transformed cell line human CVCL_5Y99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084048 CVCL_5Y92 GM15405 transformed cell line human CVCL_5Y92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084049 CVCL_5Y93 GM15406 transformed cell line human CVCL_5Y93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084050 CVCL_5Y94 GM15407 transformed cell line human CVCL_5Y94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084051 CVCL_5Y95 GM15409 transformed cell line human CVCL_5Y95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084052 CVCL_PF18 BayGenomics ES cell line TEA099 embryonic stem cell house mouse CVCL_PF18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084053 CVCL_PF19 BayGenomics ES cell line TEA101 embryonic stem cell house mouse CVCL_PF19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084054 CVCL_GL77 ND14958 transformed cell line human CVCL_GL77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084055 CVCL_GL78 ND14959 transformed cell line human CVCL_GL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084056 CVCL_GL79 ND14963 transformed cell line human CVCL_GL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084057 CVCL_PF20 BayGenomics ES cell line TEA104 embryonic stem cell house mouse CVCL_PF20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106913; Abi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084058 CVCL_PF21 BayGenomics ES cell line TEA105 embryonic stem cell house mouse CVCL_PF21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443446; Scfd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084059 CVCL_GL73 ND14950 transformed cell line human CVCL_GL73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084060 CVCL_PF22 BayGenomics ES cell line TEA106 embryonic stem cell house mouse CVCL_PF22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108247; Tdg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084061 CVCL_GL74 ND14951 transformed cell line human CVCL_GL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084062 CVCL_PF23 BayGenomics ES cell line TEA107 embryonic stem cell house mouse CVCL_PF23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084063 CVCL_GL75 ND14952 transformed cell line human CVCL_GL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084064 CVCL_PF24 BayGenomics ES cell line TEA112 embryonic stem cell house mouse CVCL_PF24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098583; Stag2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084065 CVCL_GL76 ND14953 transformed cell line human CVCL_GL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084066 CVCL_PF25 BayGenomics ES cell line TEA113 embryonic stem cell house mouse CVCL_PF25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084067 CVCL_PF26 BayGenomics ES cell line TEA120 embryonic stem cell house mouse CVCL_PF26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914309; Ola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084068 CVCL_GL70 ND14922 transformed cell line human CVCL_GL70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084069 CVCL_PF27 BayGenomics ES cell line TEA121 embryonic stem cell house mouse CVCL_PF27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914309; Ola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084070 CVCL_GL71 ND14939 transformed cell line human CVCL_GL71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084071 CVCL_PF28 BayGenomics ES cell line TEA124 embryonic stem cell house mouse CVCL_PF28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039562; Taf9b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084072 CVCL_GL72 ND14940 transformed cell line human CVCL_GL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084073 CVCL_PF07 BayGenomics ES cell line TEA078 embryonic stem cell house mouse CVCL_PF07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925905; Eif3j1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084074 CVCL_PF08 BayGenomics ES cell line TEA080 embryonic stem cell house mouse CVCL_PF08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084075 CVCL_PF09 BayGenomics ES cell line TEA082 embryonic stem cell house mouse CVCL_PF09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925905; Eif3j1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084076 CVCL_GL90 ND15291 transformed cell line human CVCL_GL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084077 CVCL_GL88 ND15267 transformed cell line human CVCL_GL88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084078 CVCL_GL89 ND15269 transformed cell line human CVCL_GL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084079 CVCL_PF10 BayGenomics ES cell line TEA084 embryonic stem cell house mouse CVCL_PF10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919908; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084080 CVCL_GL84 ND15127 transformed cell line human CVCL_GL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084081 CVCL_PF11 BayGenomics ES cell line TEA085 embryonic stem cell house mouse CVCL_PF11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084082 CVCL_GL85 ND15191 transformed cell line human CVCL_GL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084083 CVCL_PF12 BayGenomics ES cell line TEA088 embryonic stem cell house mouse CVCL_PF12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916471; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084084 CVCL_GL86 ND15247 transformed cell line human CVCL_GL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084085 CVCL_PF13 BayGenomics ES cell line TEA089 embryonic stem cell house mouse CVCL_PF13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084086 CVCL_GL87 ND15260 transformed cell line human CVCL_GL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084087 CVCL_PF14 BayGenomics ES cell line TEA090 embryonic stem cell house mouse CVCL_PF14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084088 CVCL_GL80 ND15000 transformed cell line human CVCL_GL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084089 CVCL_PF15 BayGenomics ES cell line TEA091 embryonic stem cell house mouse CVCL_PF15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99700; Cenpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084090 CVCL_GL81 ND15080 transformed cell line human CVCL_GL81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084091 CVCL_PF16 BayGenomics ES cell line TEA092 embryonic stem cell house mouse CVCL_PF16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444222; Tmem104 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084092 CVCL_GL82 ND15093 transformed cell line human CVCL_GL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084093 CVCL_PF17 BayGenomics ES cell line TEA097 embryonic stem cell house mouse CVCL_PF17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084094 CVCL_GL83 ND15125 transformed cell line human CVCL_GL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084095 CVCL_GL59 ND14899 transformed cell line human CVCL_GL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084096 CVCL_GL55 ND14835 transformed cell line human CVCL_GL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084097 CVCL_GL56 ND14861 transformed cell line human CVCL_GL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084098 CVCL_GL57 ND14872 transformed cell line human CVCL_GL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084099 CVCL_GL58 ND14873 transformed cell line human CVCL_GL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084100 CVCL_GL51 ND14798 transformed cell line human CVCL_GL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084101 CVCL_PF00 BayGenomics ES cell line TEA062 embryonic stem cell house mouse CVCL_PF00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448480; Fancd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084102 CVCL_GL52 ND14799 transformed cell line human CVCL_GL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084103 CVCL_PF01 BayGenomics ES cell line TEA063 embryonic stem cell house mouse CVCL_PF01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913732; Exoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084104 CVCL_GL53 ND14800 transformed cell line human CVCL_GL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084105 CVCL_PF02 BayGenomics ES cell line TEA065 embryonic stem cell house mouse CVCL_PF02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084106 CVCL_GL54 ND14817 transformed cell line human CVCL_GL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084107 CVCL_PF03 BayGenomics ES cell line TEA071 embryonic stem cell house mouse CVCL_PF03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084108 CVCL_PF04 BayGenomics ES cell line TEA073 embryonic stem cell house mouse CVCL_PF04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138584; Gigyf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084109 CVCL_PF05 BayGenomics ES cell line TEA074 embryonic stem cell house mouse CVCL_PF05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084110 CVCL_PF06 BayGenomics ES cell line TEA075 embryonic stem cell house mouse CVCL_PF06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084111 CVCL_GL50 ND14797 transformed cell line human CVCL_GL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084112 CVCL_GL66 ND14918 transformed cell line human CVCL_GL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084113 CVCL_GL67 ND14919 transformed cell line human CVCL_GL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084114 CVCL_GL68 ND14920 transformed cell line human CVCL_GL68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084115 CVCL_GL69 ND14921 transformed cell line human CVCL_GL69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084116 CVCL_GL62 ND14902 transformed cell line human CVCL_GL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084117 CVCL_GL63 ND14914 transformed cell line human CVCL_GL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084118 CVCL_GL64 ND14916 transformed cell line human CVCL_GL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084119 CVCL_GL65 ND14917 transformed cell line human CVCL_GL65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084120 CVCL_GL60 ND14900 transformed cell line human CVCL_GL60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084121 CVCL_GL61 ND14901 transformed cell line human CVCL_GL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084122 CVCL_GL37 ND14711 transformed cell line human CVCL_GL37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084123 CVCL_GL38 ND14725 transformed cell line human CVCL_GL38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084124 CVCL_GL39 ND14726 transformed cell line human CVCL_GL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084125 CVCL_GL33 ND14670 transformed cell line human CVCL_GL33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084126 CVCL_GL34 ND14671 transformed cell line human CVCL_GL34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084127 CVCL_GL35 ND14677 transformed cell line human CVCL_GL35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084128 CVCL_GL36 ND14678 transformed cell line human CVCL_GL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084129 CVCL_GL30 ND14650 transformed cell line human CVCL_GL30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084130 CVCL_GL31 ND14651 transformed cell line human CVCL_GL31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084131 CVCL_GL32 ND14666 transformed cell line human CVCL_GL32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084132 CVCL_GL48 ND14763 transformed cell line human CVCL_GL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084133 CVCL_GL49 ND14765 transformed cell line human CVCL_GL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084134 CVCL_GL44 ND14751 transformed cell line human CVCL_GL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084135 CVCL_GL45 ND14752 transformed cell line human CVCL_GL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084136 CVCL_GL46 ND14759 transformed cell line human CVCL_GL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084137 CVCL_GL47 ND14762 transformed cell line human CVCL_GL47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084138 CVCL_GL40 ND14740 transformed cell line human CVCL_GL40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084139 CVCL_GL41 ND14742 transformed cell line human CVCL_GL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084140 CVCL_GL42 ND14744 transformed cell line human CVCL_GL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084141 CVCL_GL43 ND14745 transformed cell line human CVCL_GL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084142 CVCL_GL19 ND14494 transformed cell line human CVCL_GL19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084143 CVCL_GL15 ND14433 transformed cell line human CVCL_GL15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084144 CVCL_GL16 ND14436 transformed cell line human CVCL_GL16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084145 CVCL_GL17 ND14437 transformed cell line human CVCL_GL17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084146 CVCL_GL18 ND14439 transformed cell line human CVCL_GL18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084147 CVCL_GL11 ND14411 transformed cell line human CVCL_GL11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084148 CVCL_GL12 ND14430 transformed cell line human CVCL_GL12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084149 CVCL_GL13 ND14431 transformed cell line human CVCL_GL13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084150 CVCL_GL14 ND14432 transformed cell line human CVCL_GL14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084151 CVCL_GL10 ND14406 transformed cell line human CVCL_GL10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084152 CVCL_GL26 ND14591 transformed cell line human CVCL_GL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084153 CVCL_GL27 ND14592 transformed cell line human CVCL_GL27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084154 CVCL_GL28 ND14593 transformed cell line human CVCL_GL28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084155 CVCL_GL29 ND14647 transformed cell line human CVCL_GL29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084156 CVCL_GL22 ND14526 transformed cell line human CVCL_GL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084157 CVCL_GL23 ND14533 transformed cell line human CVCL_GL23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084158 CVCL_GL24 ND14589 transformed cell line human CVCL_GL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084159 CVCL_GL25 ND14590 transformed cell line human CVCL_GL25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084160 CVCL_GL20 ND14522 transformed cell line human CVCL_GL20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084161 CVCL_GL21 ND14524 transformed cell line human CVCL_GL21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084162 CVCL_PF90 BayGenomics ES cell line XA045 embryonic stem cell house mouse CVCL_PF90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261758; Suz12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084163 CVCL_PF91 BayGenomics ES cell line XA051 embryonic stem cell house mouse CVCL_PF91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084164 CVCL_PF92 BayGenomics ES cell line XA052 embryonic stem cell house mouse CVCL_PF92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146423; Ccdc58 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084165 CVCL_PF93 BayGenomics ES cell line XA053 embryonic stem cell house mouse CVCL_PF93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88357; Cdk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084166 CVCL_PF94 BayGenomics ES cell line XA059 embryonic stem cell house mouse CVCL_PF94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109211; Pkn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084167 CVCL_PF95 BayGenomics ES cell line XA072 embryonic stem cell house mouse CVCL_PF95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084168 CVCL_PF96 BayGenomics ES cell line XA093 embryonic stem cell house mouse CVCL_PF96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925255; Rrn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084169 CVCL_PF97 BayGenomics ES cell line XA124 embryonic stem cell house mouse CVCL_PF97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913868; Snrnp27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084170 CVCL_PF98 BayGenomics ES cell line XA125 embryonic stem cell house mouse CVCL_PF98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913325; Chchd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084171 CVCL_PF99 BayGenomics ES cell line XA129 embryonic stem cell house mouse CVCL_PF99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104662; Pml Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084172 CVCL_PF80 BayGenomics ES cell line XA022 embryonic stem cell house mouse CVCL_PF80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446217; Phf13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084173 CVCL_PF81 BayGenomics ES cell line XA024 embryonic stem cell house mouse CVCL_PF81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197010; Sumo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084174 CVCL_PF82 BayGenomics ES cell line XA026 embryonic stem cell house mouse CVCL_PF82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890081; Foxo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084175 CVCL_PF83 BayGenomics ES cell line XA028 embryonic stem cell house mouse CVCL_PF83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084176 CVCL_PF84 BayGenomics ES cell line XA029 embryonic stem cell house mouse CVCL_PF84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446217; Phf13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084177 CVCL_PF85 BayGenomics ES cell line XA030 embryonic stem cell house mouse CVCL_PF85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107460; Cox6b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084178 CVCL_PF86 BayGenomics ES cell line XA031 embryonic stem cell house mouse CVCL_PF86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084179 CVCL_PF87 BayGenomics ES cell line XA033 embryonic stem cell house mouse CVCL_PF87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443069; Ppwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084180 CVCL_PF88 BayGenomics ES cell line XA034 embryonic stem cell house mouse CVCL_PF88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084181 CVCL_PF89 BayGenomics ES cell line XA037 embryonic stem cell house mouse CVCL_PF89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084182 CVCL_PF70 BayGenomics ES cell line TEA225 embryonic stem cell house mouse CVCL_PF70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084183 CVCL_PF71 BayGenomics ES cell line TEA231 embryonic stem cell house mouse CVCL_PF71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921500; Stimate Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084184 CVCL_PF72 BayGenomics ES cell line XA008 embryonic stem cell house mouse CVCL_PF72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919016; Raver1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084185 CVCL_PF73 BayGenomics ES cell line XA010 embryonic stem cell house mouse CVCL_PF73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084186 CVCL_PF74 BayGenomics ES cell line XA013 embryonic stem cell house mouse CVCL_PF74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933972; Tra2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084187 CVCL_PF75 BayGenomics ES cell line XA014 embryonic stem cell house mouse CVCL_PF75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084188 CVCL_PF76 BayGenomics ES cell line XA016 embryonic stem cell house mouse CVCL_PF76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084189 CVCL_PF77 BayGenomics ES cell line XA018 embryonic stem cell house mouse CVCL_PF77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88039; Apc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084190 CVCL_PF78 BayGenomics ES cell line XA020 embryonic stem cell house mouse CVCL_PF78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443882; Snx30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084191 CVCL_PF79 BayGenomics ES cell line XA021 embryonic stem cell house mouse CVCL_PF79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084192 CVCL_PF60 BayGenomics ES cell line TEA194 embryonic stem cell house mouse CVCL_PF60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917567; Arl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084193 CVCL_PF61 BayGenomics ES cell line TEA197 embryonic stem cell house mouse CVCL_PF61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107768; Zfp87 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084194 CVCL_PF62 BayGenomics ES cell line TEA200 embryonic stem cell house mouse CVCL_PF62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084195 CVCL_PF63 BayGenomics ES cell line TEA201 embryonic stem cell house mouse CVCL_PF63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084196 CVCL_PF64 BayGenomics ES cell line TEA202 embryonic stem cell house mouse CVCL_PF64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084197 CVCL_PF65 BayGenomics ES cell line TEA204 embryonic stem cell house mouse CVCL_PF65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918180; Nol8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084198 CVCL_PF66 BayGenomics ES cell line TEA205 embryonic stem cell house mouse CVCL_PF66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084199 CVCL_PF67 BayGenomics ES cell line TEA214 embryonic stem cell house mouse CVCL_PF67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918667; Gpatch8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084200 CVCL_PF68 BayGenomics ES cell line TEA217 embryonic stem cell house mouse CVCL_PF68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442483; Usp37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084201 CVCL_PF69 BayGenomics ES cell line TEA218 embryonic stem cell house mouse CVCL_PF69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2660884; Csnk1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084202 CVCL_PF50 BayGenomics ES cell line TEA172 embryonic stem cell house mouse CVCL_PF50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084203 CVCL_PF51 BayGenomics ES cell line TEA173 embryonic stem cell house mouse CVCL_PF51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109207; Eif4g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084204 CVCL_PF52 BayGenomics ES cell line TEA175 embryonic stem cell house mouse CVCL_PF52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109336; Etv6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084205 CVCL_PF53 BayGenomics ES cell line TEA178 embryonic stem cell house mouse CVCL_PF53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084206 CVCL_PF54 BayGenomics ES cell line TEA179 embryonic stem cell house mouse CVCL_PF54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084207 CVCL_PF55 BayGenomics ES cell line TEA183 embryonic stem cell house mouse CVCL_PF55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084208 CVCL_PF56 BayGenomics ES cell line TEA186 embryonic stem cell house mouse CVCL_PF56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333805; Srsf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084209 CVCL_PF57 BayGenomics ES cell line TEA188 embryonic stem cell house mouse CVCL_PF57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084210 CVCL_PF58 BayGenomics ES cell line TEA189 embryonic stem cell house mouse CVCL_PF58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084211 CVCL_PF59 BayGenomics ES cell line TEA190 embryonic stem cell house mouse CVCL_PF59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084212 CVCL_GL99 ND15533 transformed cell line human CVCL_GL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084213 CVCL_PF40 BayGenomics ES cell line TEA153 embryonic stem cell house mouse CVCL_PF40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084214 CVCL_PF41 BayGenomics ES cell line TEA154 embryonic stem cell house mouse CVCL_PF41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084215 CVCL_PF42 BayGenomics ES cell line TEA155 embryonic stem cell house mouse CVCL_PF42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084216 CVCL_PF43 BayGenomics ES cell line TEA160 embryonic stem cell house mouse CVCL_PF43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084217 CVCL_GL95 ND15474 transformed cell line human CVCL_GL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084218 CVCL_PF44 BayGenomics ES cell line TEA162 embryonic stem cell house mouse CVCL_PF44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341830; Eif2ak3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084219 CVCL_GL96 ND15489 transformed cell line human CVCL_GL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084220 CVCL_PF45 BayGenomics ES cell line TEA164 embryonic stem cell house mouse CVCL_PF45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914282; Snapc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084221 CVCL_GL97 ND15493 transformed cell line human CVCL_GL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084222 CVCL_PF46 BayGenomics ES cell line TEA167 embryonic stem cell house mouse CVCL_PF46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921867; Scpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084223 CVCL_GL98 ND15514 transformed cell line human CVCL_GL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084224 CVCL_PF47 BayGenomics ES cell line TEA168 embryonic stem cell house mouse CVCL_PF47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084225 CVCL_GL91 ND15346 transformed cell line human CVCL_GL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084226 CVCL_PF48 BayGenomics ES cell line TEA169 embryonic stem cell house mouse CVCL_PF48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084227 CVCL_GL92 ND15357 transformed cell line human CVCL_GL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084228 CVCL_PF49 BayGenomics ES cell line TEA171 embryonic stem cell house mouse CVCL_PF49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084229 CVCL_GL93 ND15415 transformed cell line human CVCL_GL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084230 CVCL_GL94 ND15465 transformed cell line human CVCL_GL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084231 CVCL_PF29 BayGenomics ES cell line TEA127 embryonic stem cell house mouse CVCL_PF29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289341; Sf3b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084232 CVCL_PF30 BayGenomics ES cell line TEA128 embryonic stem cell house mouse CVCL_PF30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104669; Man2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084233 CVCL_PF31 BayGenomics ES cell line TEA131 embryonic stem cell house mouse CVCL_PF31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084234 CVCL_PF32 BayGenomics ES cell line TEA132 embryonic stem cell house mouse CVCL_PF32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917029; Pphln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084235 CVCL_PF33 BayGenomics ES cell line TEA134 embryonic stem cell house mouse CVCL_PF33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084236 CVCL_PF34 BayGenomics ES cell line TEA138 embryonic stem cell house mouse CVCL_PF34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084237 CVCL_PF35 BayGenomics ES cell line TEA140 embryonic stem cell house mouse CVCL_PF35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084238 CVCL_PF36 BayGenomics ES cell line TEA141 embryonic stem cell house mouse CVCL_PF36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923749; Clasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084239 CVCL_PF37 BayGenomics ES cell line TEA146 embryonic stem cell house mouse CVCL_PF37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919840; Ppme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084240 CVCL_PF38 BayGenomics ES cell line TEA148 embryonic stem cell house mouse CVCL_PF38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919840; Ppme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084241 CVCL_PF39 BayGenomics ES cell line TEA150 embryonic stem cell house mouse CVCL_PF39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384874; Tmem51 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084242 CVCL_5Z90 GM15535 transformed cell line human CVCL_5Z90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084243 CVCL_5Z84 GM15528 transformed cell line human CVCL_5Z84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084244 CVCL_5Z85 GM15529 transformed cell line human CVCL_5Z85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084245 CVCL_5Z86 GM15530 transformed cell line human CVCL_5Z86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084246 CVCL_5Z87 GM15531 transformed cell line human CVCL_5Z87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084247 CVCL_5Z80 GM15524 transformed cell line human CVCL_5Z80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084248 CVCL_5Z81 GM15525 transformed cell line human CVCL_5Z81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084249 CVCL_5Z82 GM15526 transformed cell line human CVCL_5Z82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084250 CVCL_5Z83 GM15527 transformed cell line human CVCL_5Z83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084251 CVCL_5Z88 GM15533 transformed cell line human CVCL_5Z88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084252 CVCL_5Z89 GM15534 transformed cell line human CVCL_5Z89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084253 CVCL_5Z95 GM15540 transformed cell line human CVCL_5Z95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084254 CVCL_5Z96 GM15541 transformed cell line human CVCL_5Z96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084255 CVCL_5Z97 GM15548 transformed cell line human CVCL_5Z97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084256 CVCL_5Z98 GM15550 transformed cell line human CVCL_5Z98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084257 CVCL_5Z91 GM15536 transformed cell line human CVCL_5Z91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084258 CVCL_5Z92 GM15537 transformed cell line human CVCL_5Z92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084259 CVCL_5Z93 GM15538 transformed cell line human CVCL_5Z93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084260 CVCL_5Z94 GM15539 transformed cell line human CVCL_5Z94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084261 CVCL_5Z99 GM15551 transformed cell line human CVCL_5Z99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084262 CVCL_5Z62 GM15500 transformed cell line human CVCL_5Z62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084263 CVCL_5Z63 GM15501 transformed cell line human CVCL_5Z63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084264 CVCL_5Z64 GM15503 transformed cell line human CVCL_5Z64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084265 CVCL_5Z65 GM15504 transformed cell line human CVCL_5Z65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084266 CVCL_5Z60 GM15496 transformed cell line human CVCL_5Z60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084267 CVCL_5Z61 GM15499 transformed cell line human CVCL_5Z61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084268 CVCL_5Z66 GM15506 transformed cell line human CVCL_5Z66 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084269 CVCL_5Z67 GM15509 transformed cell line human CVCL_5Z67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084270 CVCL_5Z68 GM15512 transformed cell line human CVCL_5Z68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084271 CVCL_5Z69 GM15513 transformed cell line human CVCL_5Z69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084272 CVCL_5Z73 GM15517 transformed cell line human CVCL_5Z73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084273 CVCL_5Z74 GM15518 transformed cell line human CVCL_5Z74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084274 CVCL_5Z75 GM15519 transformed cell line human CVCL_5Z75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084275 CVCL_5Z76 GM15520 transformed cell line human CVCL_5Z76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084276 CVCL_5Z70 GM15514 transformed cell line human CVCL_5Z70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084277 CVCL_5Z71 GM15515 transformed cell line human CVCL_5Z71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084278 CVCL_5Z72 GM15516 transformed cell line human CVCL_5Z72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084279 CVCL_5Z77 GM15521 transformed cell line human CVCL_5Z77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084280 CVCL_5Z78 GM15522 transformed cell line human CVCL_5Z78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084281 CVCL_5Z79 GM15523 transformed cell line human CVCL_5Z79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084282 CVCL_YA92 12-120-94/6 hybridoma house mouse CVCL_YA92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084283 CVCL_YA93 123-353-1 hybridoma house mouse CVCL_YA93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084284 CVCL_YA94 20-121-1 hybridoma house mouse CVCL_YA94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084285 CVCL_YA95 20-53-1 hybridoma house mouse CVCL_YA95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084286 CVCL_YA90 SNB-44 cancer cell line human CVCL_YA90 CL:0000010 21084287 CVCL_YA91 169-477-5 hybridoma house mouse CVCL_YA91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0CE95; Dictyostelium discoideum talA. 21084288 CVCL_YA96 224-256-2 hybridoma house mouse CVCL_YA96 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54648; Dictyostelium discoideum vatC. 21084289 CVCL_YA97 24-210-2 hybridoma house mouse CVCL_YA97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084290 CVCL_YA98 29-55-4 hybridoma house mouse CVCL_YA98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08799; Dictyostelium discoideum mhcA. 21084291 CVCL_YA99 33-294-17 hybridoma house mouse CVCL_YA99 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 21084292 CVCL_5Z40 GM15472 transformed cell line human CVCL_5Z40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084293 CVCL_5Z41 GM15474 transformed cell line human CVCL_5Z41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084294 CVCL_5Z42 GM15475 transformed cell line human CVCL_5Z42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084295 CVCL_5Z43 GM15476 transformed cell line human CVCL_5Z43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084296 CVCL_5Z48 GM15482 transformed cell line human CVCL_5Z48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084297 CVCL_5Z49 GM15483 transformed cell line human CVCL_5Z49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084298 CVCL_5Z44 GM15477 transformed cell line human CVCL_5Z44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084299 CVCL_5Z45 GM15478 transformed cell line human CVCL_5Z45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084300 CVCL_5Z46 GM15479 transformed cell line human CVCL_5Z46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084301 CVCL_5Z47 GM15480 transformed cell line human CVCL_5Z47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084302 CVCL_YA81 IDG-HEK293T-TMC4-V5-OE transformed cell line human CVCL_YA81 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 22998; TMC4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses TMC4 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084303 CVCL_YA82 IDG-HEK293T-TMEM63A-V5-OE transformed cell line human CVCL_YA82 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 29118; TMEM63A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses TMEM63A with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084304 CVCL_YA83 IDG-HEK293T-TMEM63B-V5-OE transformed cell line human CVCL_YA83 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 17735; TMEM63B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses TMEM63B with a C-terminal V5 tag The V5 tag is expressed in very few cells. Part of: Illuminating the Druggable Genome consortium cell line panel 21084305 CVCL_YA84 IDG-HEK293T-TMEM63C-V5-OE transformed cell line human CVCL_YA84 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 23787; TMEM63C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses TMEM63C with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084306 CVCL_YA80 IDG-HEK293T-SCNN1D-V5-OE transformed cell line human CVCL_YA80 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 10601; SCNN1D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses SCNN1D with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084307 CVCL_YA89 MDA-MB-231T cancer cell line human CVCL_YA89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: Has metastatic potential Group: Triple negative breast cancer (TNBC) cell line 21084308 CVCL_YA85 IDG-HEK293T-TTYH2-V5-OE transformed cell line human CVCL_YA85 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 13877; TTYH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses TTYH2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084309 CVCL_YA86 HOP-27 cancer cell line human CVCL_YA86 CL:0000010 Unspecified 21084310 CVCL_YA87 A549/Asc-1 cancer cell line human CVCL_YA87 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male Characteristics: Established following following in vivo propagation of parent cell line as an ascites tumor (PubMed=3129183) 21084311 CVCL_YA88 HeLa-Luc cancer cell line human CVCL_YA88 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Caution: Probably not identical with HeLa-luc (lower case luc) (Cellosaurus=CVCL_5J41) from PerkinElmer/Caliper 21084312 CVCL_5Z51 GM15486 transformed cell line human CVCL_5Z51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084313 CVCL_5Z52 GM15487 transformed cell line human CVCL_5Z52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084314 CVCL_5Z53 GM15489 transformed cell line human CVCL_5Z53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084315 CVCL_5Z54 GM15490 transformed cell line human CVCL_5Z54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084316 CVCL_5Z50 GM15485 transformed cell line human CVCL_5Z50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084317 CVCL_5Z59 GM15495 transformed cell line human CVCL_5Z59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084318 CVCL_5Z55 GM15491 transformed cell line human CVCL_5Z55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084319 CVCL_5Z56 GM15492 transformed cell line human CVCL_5Z56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084320 CVCL_5Z57 GM15493 transformed cell line human CVCL_5Z57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084321 CVCL_5Z58 GM15494 transformed cell line human CVCL_5Z58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084322 CVCL_YA70 IDG-HEK293T-KCNS2-V5-OE transformed cell line human CVCL_YA70 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6301; KCNS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNS2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084323 CVCL_YA71 IDG-HEK293T-KCNS3-V5-OE transformed cell line human CVCL_YA71 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6302; KCNS3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNS3 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084324 CVCL_YA73 IDG-HEK293T-LRRC55-V5-OE transformed cell line human CVCL_YA73 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 32324; LRRC55; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses LRRC55 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084325 CVCL_YA78 IDG-HEK293T-SCN2B-V5-OE transformed cell line human CVCL_YA78 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 10589; SCN2B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses SCN2B with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084326 CVCL_YA79 IDG-HEK293T-SCNN1B-V5-OE transformed cell line human CVCL_YA79 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 10600; SCNN1B; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses SCNN1B with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084327 CVCL_YA74 IDG-HEK293T-PANX2-V5-OE transformed cell line human CVCL_YA74 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 8600; PANX2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses PANX2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084328 CVCL_YA75 IDG-HEK293T-PKD1L2-V5-OE transformed cell line human CVCL_YA75 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 21715; PKD1L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses PKD1L2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084329 CVCL_YA76 IDG-HEK293T-PKD2L2-V5-OE transformed cell line human CVCL_YA76 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 9012; PKD2L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses PKD2L2 with a C-terminal V5 tag The V5 tag is not detectable. Part of: Illuminating the Druggable Genome consortium cell line panel 21084330 CVCL_YA77 IDG-HEK293T-PLLP-V5-OE transformed cell line human CVCL_YA77 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 18553; PLLP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses PLLP with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084331 CVCL_5Z20 GM15441 transformed cell line human CVCL_5Z20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084332 CVCL_5Z21 GM15442 transformed cell line human CVCL_5Z21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084333 CVCL_5Z26 GM15455 transformed cell line human CVCL_5Z26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084334 CVCL_5Z27 GM15457 transformed cell line human CVCL_5Z27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084335 CVCL_5Z28 GM15458 transformed cell line human CVCL_5Z28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084336 CVCL_5Z29 GM15459 transformed cell line human CVCL_5Z29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084337 CVCL_5Z22 GM15443 transformed cell line human CVCL_5Z22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084338 CVCL_5Z23 GM15444 transformed cell line human CVCL_5Z23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084339 CVCL_5Z24 GM15445 transformed cell line human CVCL_5Z24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084340 CVCL_5Z25 GM15447 transformed cell line human CVCL_5Z25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084341 CVCL_YA60 IDG-HEK293T-KCNAB3-V5-OE transformed cell line human CVCL_YA60 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6230; KCNAB3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNAB3 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084342 CVCL_YA61 IDG-HEK293T-KCNG4-V5-OE transformed cell line human CVCL_YA61 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 19697; KCNG4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNG4 with a C-terminal V5 tag Very low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084343 CVCL_YA62 IDG-HEK293T-KCNIP1-V5-OE transformed cell line human CVCL_YA62 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 15521; KCNIP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNIP1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084344 CVCL_YA67 IDG-HEK293T-KCNK4-V5-OE transformed cell line human CVCL_YA67 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6279; KCNK4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNK4 with a C-terminal V5 tag Low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084345 CVCL_YA68 IDG-HEK293T-KCNK7-V5-OE transformed cell line human CVCL_YA68 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6282; KCNK7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNK7 with a C-terminal V5 tag Low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084346 CVCL_YA69 IDG-HEK293T-KCNS1-V5-OE transformed cell line human CVCL_YA69 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6300; KCNS1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNS1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084347 CVCL_YA63 IDG-HEK293T-KCNIP4-V5-OE transformed cell line human CVCL_YA63 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 30083; KCNIP4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNIP4 with a C-terminal V5 tag Low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084348 CVCL_YA64 IDG-HEK293T-KCNJ14-V5-OE transformed cell line human CVCL_YA64 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6260; KCNJ14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNJ14 with a C-terminal V5 tag The V5 tag is not detectable. Part of: Illuminating the Druggable Genome consortium cell line panel 21084349 CVCL_YA65 IDG-HEK293T-KCNJ15-V5-OE transformed cell line human CVCL_YA65 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6261; KCNJ15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNJ15 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084350 CVCL_YA66 IDG-HEK293T-KCNK12-V5-OE transformed cell line human CVCL_YA66 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6274; KCNK12; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNK12 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084351 CVCL_5Z30 GM15461 transformed cell line human CVCL_5Z30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084352 CVCL_5Z31 GM15463 transformed cell line human CVCL_5Z31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084353 CVCL_5Z32 GM15464 transformed cell line human CVCL_5Z32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084354 CVCL_5Z37 GM15469 transformed cell line human CVCL_5Z37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084355 CVCL_5Z38 GM15470 transformed cell line human CVCL_5Z38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084356 CVCL_5Z39 GM15471 transformed cell line human CVCL_5Z39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084357 CVCL_5Z33 GM15465 transformed cell line human CVCL_5Z33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084358 CVCL_5Z34 GM15466 transformed cell line human CVCL_5Z34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084359 CVCL_5Z35 GM15467 transformed cell line human CVCL_5Z35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084360 CVCL_5Z36 GM15468 transformed cell line human CVCL_5Z36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084361 CVCL_GN39 ND22865 transformed cell line human CVCL_GN39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084362 CVCL_GN35 ND22740 transformed cell line human CVCL_GN35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084363 CVCL_GN36 ND22775 transformed cell line human CVCL_GN36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084364 CVCL_GN37 ND22858 transformed cell line human CVCL_GN37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084365 CVCL_GN38 ND22864 transformed cell line human CVCL_GN38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084366 CVCL_GN31 ND22548 transformed cell line human CVCL_GN31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084367 CVCL_GN32 ND22576 transformed cell line human CVCL_GN32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084368 CVCL_GN33 ND22663 transformed cell line human CVCL_GN33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084369 CVCL_GN34 ND22729 transformed cell line human CVCL_GN34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084370 CVCL_GN30 ND22547 transformed cell line human CVCL_GN30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084371 CVCL_GN46 ND22901 transformed cell line human CVCL_GN46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084372 CVCL_GN47 ND22905 transformed cell line human CVCL_GN47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084373 CVCL_GN48 ND22911 transformed cell line human CVCL_GN48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084374 CVCL_GN49 ND22913 transformed cell line human CVCL_GN49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084375 CVCL_GN42 ND22884 transformed cell line human CVCL_GN42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084376 CVCL_GN43 ND22891 transformed cell line human CVCL_GN43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084377 CVCL_GN44 ND22897 transformed cell line human CVCL_GN44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084378 CVCL_GN45 ND22898 transformed cell line human CVCL_GN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084379 CVCL_GN40 ND22867 transformed cell line human CVCL_GN40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084380 CVCL_GN41 ND22882 transformed cell line human CVCL_GN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084381 CVCL_GN17 ND21003 transformed cell line human CVCL_GN17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084382 CVCL_GN18 ND21207 transformed cell line human CVCL_GN18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084383 CVCL_GN19 ND21233 transformed cell line human CVCL_GN19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084384 CVCL_GN13 ND20677 transformed cell line human CVCL_GN13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084385 CVCL_GN14 ND20727 transformed cell line human CVCL_GN14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084386 CVCL_GN15 ND20756 transformed cell line human CVCL_GN15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084387 CVCL_GN16 ND20920 transformed cell line human CVCL_GN16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084388 CVCL_GN10 ND20584 transformed cell line human CVCL_GN10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084389 CVCL_GN11 ND20585 transformed cell line human CVCL_GN11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084390 CVCL_GN12 ND20673 transformed cell line human CVCL_GN12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084391 CVCL_GN28 ND22544 transformed cell line human CVCL_GN28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084392 CVCL_GN29 ND22545 transformed cell line human CVCL_GN29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084393 CVCL_GN24 ND21698 transformed cell line human CVCL_GN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084394 CVCL_GN25 ND21902 transformed cell line human CVCL_GN25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084395 CVCL_GN26 ND22040 transformed cell line human CVCL_GN26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084396 CVCL_GN27 ND22106 transformed cell line human CVCL_GN27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084397 CVCL_GN20 ND21287 transformed cell line human CVCL_GN20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084398 CVCL_GN21 ND21520 transformed cell line human CVCL_GN21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084399 CVCL_GN22 ND21576 transformed cell line human CVCL_GN22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084400 CVCL_GN23 ND21618 transformed cell line human CVCL_GN23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084401 CVCL_GN06 ND20420 transformed cell line human CVCL_GN06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084402 CVCL_GN07 ND20433 transformed cell line human CVCL_GN07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084403 CVCL_GN08 ND20485 transformed cell line human CVCL_GN08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084404 CVCL_GN09 ND20518 transformed cell line human CVCL_GN09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084405 CVCL_GN02 ND20332 transformed cell line human CVCL_GN02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084406 CVCL_GN03 ND20334 transformed cell line human CVCL_GN03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084407 CVCL_GN04 ND20349 transformed cell line human CVCL_GN04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084408 CVCL_GN05 ND20358 transformed cell line human CVCL_GN05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084409 CVCL_GN00 ND20293 transformed cell line human CVCL_GN00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084410 CVCL_GN01 ND20304 transformed cell line human CVCL_GN01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084411 CVCL_PG39 BayGenomics ES cell line XA322 embryonic stem cell house mouse CVCL_PG39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1335094; Septin7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084412 CVCL_GM98 ND20274 transformed cell line human CVCL_GM98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084413 CVCL_GM99 ND20275 transformed cell line human CVCL_GM99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084414 CVCL_PG40 BayGenomics ES cell line XA360 embryonic stem cell house mouse CVCL_PG40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084415 CVCL_PG41 BayGenomics ES cell line XA425 embryonic stem cell house mouse CVCL_PG41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915142; Coa6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084416 CVCL_PG42 BayGenomics ES cell line XA436 embryonic stem cell house mouse CVCL_PG42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084417 CVCL_GM94 ND20156 transformed cell line human CVCL_GM94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084418 CVCL_PG43 BayGenomics ES cell line XA440 embryonic stem cell house mouse CVCL_PG43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084419 CVCL_GM95 ND20161 transformed cell line human CVCL_GM95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084420 CVCL_PG44 BayGenomics ES cell line XA449 embryonic stem cell house mouse CVCL_PG44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894293; Smad4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084421 CVCL_GM96 ND20219 transformed cell line human CVCL_GM96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084422 CVCL_PG45 BayGenomics ES cell line XA479 embryonic stem cell house mouse CVCL_PG45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343131; Timm17a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084423 CVCL_GM97 ND20238 transformed cell line human CVCL_GM97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084424 CVCL_PG46 BayGenomics ES cell line XA481 embryonic stem cell house mouse CVCL_PG46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084425 CVCL_GM90 ND20003 transformed cell line human CVCL_GM90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084426 CVCL_PG47 BayGenomics ES cell line XA487 embryonic stem cell house mouse CVCL_PG47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084427 CVCL_GM91 ND20091 transformed cell line human CVCL_GM91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084428 CVCL_PG48 BayGenomics ES cell line XA546 embryonic stem cell house mouse CVCL_PG48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919174; Tube1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084429 CVCL_GM92 ND08552 transformed cell line human CVCL_GM92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084430 CVCL_PG49 BayGenomics ES cell line XA571 embryonic stem cell house mouse CVCL_PG49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444520; Nhlrc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084431 CVCL_GM93 ND20136 transformed cell line human CVCL_GM93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084432 CVCL_PG28 BayGenomics ES cell line XA274 embryonic stem cell house mouse CVCL_PG28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917029; Pphln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084433 CVCL_PG29 BayGenomics ES cell line XA275 embryonic stem cell house mouse CVCL_PG29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137706; Actn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084434 CVCL_PG30 BayGenomics ES cell line XA278 embryonic stem cell house mouse CVCL_PG30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084435 CVCL_PG31 BayGenomics ES cell line XA287 embryonic stem cell house mouse CVCL_PG31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98809; Tpm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084436 CVCL_PG32 BayGenomics ES cell line XA295 embryonic stem cell house mouse CVCL_PG32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084437 CVCL_PG33 BayGenomics ES cell line XA298 embryonic stem cell house mouse CVCL_PG33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084438 CVCL_PG34 BayGenomics ES cell line XA305 embryonic stem cell house mouse CVCL_PG34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084439 CVCL_PG35 BayGenomics ES cell line XA307 embryonic stem cell house mouse CVCL_PG35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916176; Ubap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084440 CVCL_PG36 BayGenomics ES cell line XA308 embryonic stem cell house mouse CVCL_PG36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084441 CVCL_PG37 BayGenomics ES cell line XA311 embryonic stem cell house mouse CVCL_PG37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341788; Pdcd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084442 CVCL_PG38 BayGenomics ES cell line XA320 embryonic stem cell house mouse CVCL_PG38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107183; Cct8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084443 CVCL_PG17 BayGenomics ES cell line XA182 embryonic stem cell house mouse CVCL_PG17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444233; Ythdf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084444 CVCL_PG18 BayGenomics ES cell line XA189 embryonic stem cell house mouse CVCL_PG18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084445 CVCL_PG19 BayGenomics ES cell line XA206 embryonic stem cell house mouse CVCL_PG19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181182; Nup155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084446 CVCL_GM76 ND19576 transformed cell line human CVCL_GM76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084447 CVCL_GM77 ND19577 transformed cell line human CVCL_GM77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084448 CVCL_GM78 ND19584 transformed cell line human CVCL_GM78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084449 CVCL_GM79 ND19734 transformed cell line human CVCL_GM79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084450 CVCL_PG20 BayGenomics ES cell line XA208 embryonic stem cell house mouse CVCL_PG20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084451 CVCL_GM72 ND19356 transformed cell line human CVCL_GM72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084452 CVCL_PG21 BayGenomics ES cell line XA209 embryonic stem cell house mouse CVCL_PG21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084453 CVCL_GM73 ND19389 transformed cell line human CVCL_GM73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084454 CVCL_PG22 BayGenomics ES cell line XA217 embryonic stem cell house mouse CVCL_PG22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109634; Terf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084455 CVCL_GM74 ND19394 transformed cell line human CVCL_GM74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084456 CVCL_PG23 BayGenomics ES cell line XA232 embryonic stem cell house mouse CVCL_PG23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922928; Ippk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084457 CVCL_GM75 ND19493 transformed cell line human CVCL_GM75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084458 CVCL_PG24 BayGenomics ES cell line XA246 embryonic stem cell house mouse CVCL_PG24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084459 CVCL_PG25 BayGenomics ES cell line XA255 embryonic stem cell house mouse CVCL_PG25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2668828; H3c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084460 CVCL_PG26 BayGenomics ES cell line XA262 embryonic stem cell house mouse CVCL_PG26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891995; Mapre1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084461 CVCL_GM70 ND19309 transformed cell line human CVCL_GM70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084462 CVCL_PG27 BayGenomics ES cell line XA271 embryonic stem cell house mouse CVCL_PG27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084463 CVCL_GM71 ND19355 transformed cell line human CVCL_GM71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084464 CVCL_PG06 BayGenomics ES cell line XA140 embryonic stem cell house mouse CVCL_PG06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202384; Ddb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084465 CVCL_PG07 BayGenomics ES cell line XA142 embryonic stem cell house mouse CVCL_PG07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154441; Nop53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084466 CVCL_PG08 BayGenomics ES cell line XA143 embryonic stem cell house mouse CVCL_PG08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923164; Exoc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084467 CVCL_PG09 BayGenomics ES cell line XA144 embryonic stem cell house mouse CVCL_PG09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084468 CVCL_GM87 ND19925 transformed cell line human CVCL_GM87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084469 CVCL_GM88 ND19935 transformed cell line human CVCL_GM88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084470 CVCL_GM89 ND19979 transformed cell line human CVCL_GM89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084471 CVCL_GM83 ND19846 transformed cell line human CVCL_GM83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084472 CVCL_PG10 BayGenomics ES cell line XA146 embryonic stem cell house mouse CVCL_PG10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88071; Arnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084473 CVCL_GM84 ND19851 transformed cell line human CVCL_GM84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084474 CVCL_PG11 BayGenomics ES cell line XA147 embryonic stem cell house mouse CVCL_PG11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084475 CVCL_GM85 ND19852 transformed cell line human CVCL_GM85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084476 CVCL_PG12 BayGenomics ES cell line XA152 embryonic stem cell house mouse CVCL_PG12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96795; Lmnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084477 CVCL_GM86 ND19868 transformed cell line human CVCL_GM86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084478 CVCL_PG13 BayGenomics ES cell line XA153 embryonic stem cell house mouse CVCL_PG13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925212; Scaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084479 CVCL_PG14 BayGenomics ES cell line XA155 embryonic stem cell house mouse CVCL_PG14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916428; Snx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084480 CVCL_GM80 ND19735 transformed cell line human CVCL_GM80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084481 CVCL_PG15 BayGenomics ES cell line XA158 embryonic stem cell house mouse CVCL_PG15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100499; Vps4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084482 CVCL_GM81 ND19755 transformed cell line human CVCL_GM81 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084483 CVCL_PG16 BayGenomics ES cell line XA168 embryonic stem cell house mouse CVCL_PG16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084484 CVCL_GM82 ND19761 transformed cell line human CVCL_GM82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084485 CVCL_GM58 ND16620 transformed cell line human CVCL_GM58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084486 CVCL_GM59 ND16644 transformed cell line human CVCL_GM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084487 CVCL_GM54 ND16584 transformed cell line human CVCL_GM54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084488 CVCL_GM55 ND16585 transformed cell line human CVCL_GM55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084489 CVCL_GM56 ND16608 transformed cell line human CVCL_GM56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084490 CVCL_GM57 ND16614 transformed cell line human CVCL_GM57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084491 CVCL_GM50 ND16489 transformed cell line human CVCL_GM50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084492 CVCL_GM51 ND16505 transformed cell line human CVCL_GM51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084493 CVCL_PG00 BayGenomics ES cell line XA130 embryonic stem cell house mouse CVCL_PG00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96795; Lmnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084494 CVCL_GM52 ND16557 transformed cell line human CVCL_GM52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084495 CVCL_PG01 BayGenomics ES cell line XA131 embryonic stem cell house mouse CVCL_PG01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084496 CVCL_GM53 ND16579 transformed cell line human CVCL_GM53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084497 CVCL_PG02 BayGenomics ES cell line XA134 embryonic stem cell house mouse CVCL_PG02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084498 CVCL_PG03 BayGenomics ES cell line XA135 embryonic stem cell house mouse CVCL_PG03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298366; Atf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084499 CVCL_PG04 BayGenomics ES cell line XA136 embryonic stem cell house mouse CVCL_PG04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084500 CVCL_PG05 BayGenomics ES cell line XA139 embryonic stem cell house mouse CVCL_PG05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084501 CVCL_GM69 ND19259 transformed cell line human CVCL_GM69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084502 CVCL_GM65 ND19195 transformed cell line human CVCL_GM65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084503 CVCL_GM66 ND19199 transformed cell line human CVCL_GM66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084504 CVCL_GM67 ND19200 transformed cell line human CVCL_GM67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084505 CVCL_GM68 ND19217 transformed cell line human CVCL_GM68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084506 CVCL_GM61 ND16656 transformed cell line human CVCL_GM61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084507 CVCL_GM62 ND16705 transformed cell line human CVCL_GM62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084508 CVCL_GM63 ND16707 transformed cell line human CVCL_GM63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084509 CVCL_GM64 ND19191 transformed cell line human CVCL_GM64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084510 CVCL_GM60 ND16651 transformed cell line human CVCL_GM60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084511 CVCL_GM36 ND16176 transformed cell line human CVCL_GM36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084512 CVCL_GM37 ND16212 transformed cell line human CVCL_GM37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084513 CVCL_GM38 ND16266 transformed cell line human CVCL_GM38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084514 CVCL_GM39 ND16278 transformed cell line human CVCL_GM39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084515 CVCL_GM32 ND16066 transformed cell line human CVCL_GM32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084516 CVCL_GM33 ND16083 transformed cell line human CVCL_GM33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084517 CVCL_GM34 ND16112 transformed cell line human CVCL_GM34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084518 CVCL_GM35 ND16114 transformed cell line human CVCL_GM35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084519 CVCL_GM30 ND15955 transformed cell line human CVCL_GM30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084520 CVCL_GM31 ND16054 transformed cell line human CVCL_GM31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084521 CVCL_GM47 ND16467 transformed cell line human CVCL_GM47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084522 CVCL_GM48 ND16477 transformed cell line human CVCL_GM48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084523 CVCL_GM49 ND16481 transformed cell line human CVCL_GM49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084524 CVCL_GM43 ND16378 transformed cell line human CVCL_GM43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084525 CVCL_GM44 ND16385 transformed cell line human CVCL_GM44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084526 CVCL_GM45 ND16449 transformed cell line human CVCL_GM45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084527 CVCL_GM46 ND16457 transformed cell line human CVCL_GM46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084528 CVCL_GM40 ND16280 transformed cell line human CVCL_GM40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084529 CVCL_GM41 ND16327 transformed cell line human CVCL_GM41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084530 CVCL_GM42 ND16376 transformed cell line human CVCL_GM42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084531 CVCL_YA50 IDG-HEK293T-GABRR1-V5-OE transformed cell line human CVCL_YA50 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4090; GABRR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GABRR1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084532 CVCL_YA51 IDG-HEK293T-GLRA3-V5-OE transformed cell line human CVCL_YA51 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4328; GLRA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GLRA3 with a C-terminal V5 tag The V5 tag is expressed in few cells. Part of: Illuminating the Druggable Genome consortium cell line panel 21084533 CVCL_5Z08 GM15428 transformed cell line human CVCL_5Z08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084534 CVCL_5Z09 GM15429 transformed cell line human CVCL_5Z09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084535 CVCL_YA56 IDG-HEK293T-HTR3E-V5-OE transformed cell line human CVCL_YA56 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 24005; HTR3E; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses HTR3E with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084536 CVCL_YA57 IDG-HEK293T-KCNA6-V5-OE transformed cell line human CVCL_YA57 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6225; KCNA6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNA6 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084537 CVCL_YA58 IDG-HEK293T-KCNA7-V5-OE transformed cell line human CVCL_YA58 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6226; KCNA7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNA7 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084538 CVCL_YA59 IDG-HEK293T-KCNAB2-V5-OE transformed cell line human CVCL_YA59 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 6229; KCNAB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses KCNAB2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084539 CVCL_YA52 IDG-HEK293T-GRID1-isoform-1-V5-OE transformed cell line human CVCL_YA52 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4575; GRID1 (isoform 1); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GRID1 isoform 1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084540 CVCL_YA53 IDG-HEK293T-GRID1-isoform-2-V5-OE transformed cell line human CVCL_YA53 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4575; GRID1 (isoform 2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GRID1 isoform 2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084541 CVCL_YA54 IDG-HEK293T-HTR3C-V5-OE transformed cell line human CVCL_YA54 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 24003; HTR3C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses HTR3C with a C-terminal V5 tag Very low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084542 CVCL_YA55 IDG-HEK293T-HTR3D-V5-OE transformed cell line human CVCL_YA55 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 24004; HTR3D; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses HTR3D with a C-terminal V5 tag Low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084543 CVCL_5Z04 GM15422 transformed cell line human CVCL_5Z04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084544 CVCL_5Z05 GM15423 transformed cell line human CVCL_5Z05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084545 CVCL_5Z06 GM15426 transformed cell line human CVCL_5Z06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084546 CVCL_5Z07 GM15427 transformed cell line human CVCL_5Z07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084547 CVCL_5Z00 GM15418 transformed cell line human CVCL_5Z00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084548 CVCL_5Z01 GM15419 transformed cell line human CVCL_5Z01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084549 CVCL_5Z02 GM15420 transformed cell line human CVCL_5Z02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084550 CVCL_5Z03 GM15421 transformed cell line human CVCL_5Z03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084551 CVCL_YA40 IDG-HEK293T-CLCNKA-V5-OE transformed cell line human CVCL_YA40 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 2026; CLCNKA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CLCNKA with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084552 CVCL_5Z19 GM15440 transformed cell line human CVCL_5Z19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084553 CVCL_YA45 IDG-HEK293T-FXYD3-V5-OE transformed cell line human CVCL_YA45 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4027; FXYD3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses FXYD3 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084554 CVCL_YA46 IDG-HEK293T-FXYD7-V5-OE transformed cell line human CVCL_YA46 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4034; FXYD7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses FXYD7 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084555 CVCL_YA47 IDG-HEK293T-GABRA5-V5-OE transformed cell line human CVCL_YA47 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4079; GABRA5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GABRA5 with a C-terminal V5 tag The V5 tag is not detectable. Part of: Illuminating the Druggable Genome consortium cell line panel 21084556 CVCL_YA48 IDG-HEK293T-GABRG1-V5-OE transformed cell line human CVCL_YA48 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4086; GABRG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GABRG1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084557 CVCL_YA41 IDG-HEK293T-CLIC2-V5-OE transformed cell line human CVCL_YA41 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 2063; CLIC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CLIC2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084558 CVCL_YA42 IDG-HEK293T-CLIC5-V5-OE transformed cell line human CVCL_YA42 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 13517; CLIC5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CLIC5 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084559 CVCL_YA43 IDG-HEK293T-CNGA4-V5-OE transformed cell line human CVCL_YA43 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 2152; CNGA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CNGA4 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084560 CVCL_YA44 IDG-HEK293T-CALHM4-V5-OE transformed cell line human CVCL_YA44 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 21094; CALHM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CALHM4 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084561 CVCL_5Z10 GM15431 transformed cell line human CVCL_5Z10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084562 CVCL_YA49 IDG-HEK293T-GABRP-V5-OE transformed cell line human CVCL_YA49 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 4089; GABRP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses GABRP with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084563 CVCL_5Z15 GM15436 transformed cell line human CVCL_5Z15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084564 CVCL_5Z16 GM15437 transformed cell line human CVCL_5Z16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084565 CVCL_5Z17 GM15438 transformed cell line human CVCL_5Z17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084566 CVCL_5Z18 GM15439 transformed cell line human CVCL_5Z18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084567 CVCL_5Z11 GM15432 transformed cell line human CVCL_5Z11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084568 CVCL_5Z12 GM15433 transformed cell line human CVCL_5Z12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084569 CVCL_5Z13 GM15434 transformed cell line human CVCL_5Z13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084570 CVCL_5Z14 GM15435 transformed cell line human CVCL_5Z14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21084571 CVCL_YA34 IDG-HEK293T-CHRNA10-V5-OE transformed cell line human CVCL_YA34 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 13800; CHRNA10; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CHRNA10 with a C-terminal V5 tag Very low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084572 CVCL_YA35 IDG-HEK293T-CHRNA2-V5-OE transformed cell line human CVCL_YA35 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1956; CHRNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CHRNA2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084573 CVCL_YA36 IDG-HEK293T-CHRNB1-V5-OE transformed cell line human CVCL_YA36 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1961; CHRNB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CHRNB1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084574 CVCL_YA37 IDG-HEK293T-CHRND-V5-OE transformed cell line human CVCL_YA37 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1965; CHRND; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CHRND with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084575 CVCL_YA30 IDG-HEK293T-CACNG5-V5-OE transformed cell line human CVCL_YA30 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1409; CACNG5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNG5 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084576 CVCL_YA31 IDG-HEK293T-CACNG7-V5-OE transformed cell line human CVCL_YA31 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 13626; CACNG7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNG7 with a C-terminal V5 tag Very low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084577 CVCL_YA32 IDG-HEK293T-CACNG8-V5-OE transformed cell line human CVCL_YA32 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 13628; CACNG8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNG8 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084578 CVCL_YA33 IDG-HEK293T-CATSPER2-V5-OE transformed cell line human CVCL_YA33 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 18810; CATSPER2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CATSPER2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084579 CVCL_YA38 IDG-HEK293T-CLCA4-V5-OE transformed cell line human CVCL_YA38 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 2018; CLCA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CLCA4 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084580 CVCL_YA39 IDG-HEK293T-CLCN6-V5-OE transformed cell line human CVCL_YA39 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 2024; CLCN6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CLCN6 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084581 CVCL_YA23 SFE-HA-831 spontaneously immortalized cell line CVCL_YA23 CL:0000010 Derived from sampling site: Ovary. Female Virology: Susceptible to infection by Helicoverpa armigera cytoplasmic polyhedrosis virus (HaCPV) (DOI=10.1016/B978-0-12-470255-4.50027-4) Group: Insect cell line 21084582 CVCL_YA24 IDG-HEK293T-CACNA2D4-V5-OE transformed cell line human CVCL_YA24 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 20202; CACNA2D4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNA2D4 with a C-terminal V5 tag Very low expression of V5 tag. Part of: Illuminating the Druggable Genome consortium cell line panel 21084583 CVCL_YA25 IDG-HEK293T-CACNB1-V5-OE transformed cell line human CVCL_YA25 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1401; CACNB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNB1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084584 CVCL_YA26 IDG-HEK293T-CACNB2-V5-OE transformed cell line human CVCL_YA26 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1402; CACNB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNB2 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084585 CVCL_YA20 2A6 [Mouse hybridoma against human RBP4] hybridoma house mouse CVCL_YA20 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02753; Human RBP4. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200641 21084586 CVCL_YA21 BmIFV-4E12 hybridoma house mouse CVCL_YA21 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B5LPA0; Bombyx mori infectious flacherie virus polyprotein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200630 21084587 CVCL_YA22 HaE9 spontaneously immortalized cell line CVCL_YA22 CL:0000010 Unspecified Virology: Susceptible to infection by Helicoverpa armigera nucleopolyhedrovirus (HearNPV) (CelloPub=CLPUB00544) Doubling time: 3.63 days (at 1th passage), 4.75 days (at 5th passage) (CelloPub=CLPUB00544). Group: Insect cell line 21084588 CVCL_PG90 BayGenomics ES cell line XB173 embryonic stem cell house mouse CVCL_PG90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158400; Wdr18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084589 CVCL_PG91 BayGenomics ES cell line XB175 embryonic stem cell house mouse CVCL_PG91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342005; Mthfd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084590 CVCL_PG92 BayGenomics ES cell line XB193 embryonic stem cell house mouse CVCL_PG92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084591 CVCL_PG93 BayGenomics ES cell line XB200 embryonic stem cell house mouse CVCL_PG93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084592 CVCL_YA27 IDG-HEK293T-CACNB4-V5-OE transformed cell line human CVCL_YA27 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1404; CACNB4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNB4 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084593 CVCL_PG94 BayGenomics ES cell line XB204 embryonic stem cell house mouse CVCL_PG94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202384; Ddb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084594 CVCL_YA28 IDG-HEK293T-CACNG1-V5-OE transformed cell line human CVCL_YA28 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1405; CACNG1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNG1 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084595 CVCL_PG95 BayGenomics ES cell line XB206 embryonic stem cell house mouse CVCL_PG95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96795; Lmnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084596 CVCL_YA29 IDG-HEK293T-CACNG3-V5-OE transformed cell line human CVCL_YA29 From: UCSF Cell Core; San Fransisco; USA CL:0000010 Transfected with: HGNC; 1407; CACNG3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CACNG3 with a C-terminal V5 tag Part of: Illuminating the Druggable Genome consortium cell line panel 21084597 CVCL_PG96 BayGenomics ES cell line XB216 embryonic stem cell house mouse CVCL_PG96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336201; Sumo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084598 CVCL_PG97 BayGenomics ES cell line XB223 embryonic stem cell house mouse CVCL_PG97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97831; Ppa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084599 CVCL_PG98 BayGenomics ES cell line XB224 embryonic stem cell house mouse CVCL_PG98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084600 CVCL_PG99 BayGenomics ES cell line XB228 embryonic stem cell house mouse CVCL_PG99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150019; Spred2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084601 CVCL_YA12 221-64-1 hybridoma house mouse CVCL_YA12 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q86IA3; Dictyostelium discoideum pdi1. 21084602 CVCL_YA13 CHO-mPDPN spontaneously immortalized cell line CVCL_YA13 CL:0000010 Transfected with: MGI; MGI:103098; Pdpn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21084603 CVCL_YA14 HSC3-hPDPN cancer cell line human CVCL_YA14 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 29602; PDPN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21084604 CVCL_YA15 PMab-1 hybridoma CVCL_YA15 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q62011; Mouse Pdpn. 21084605 CVCL_YA10 221-342-5 hybridoma house mouse CVCL_YA10 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum common antigen 1 (CA1), a sulfated carbohydrate epitope. 21084606 CVCL_YA11 221-35-2 hybridoma house mouse CVCL_YA11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P54647; Dictyostelium discoideum vatA. 21084607 CVCL_PG80 BayGenomics ES cell line XB108 embryonic stem cell house mouse CVCL_PG80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894649; Ppfibp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084608 CVCL_PG81 BayGenomics ES cell line XB114 embryonic stem cell house mouse CVCL_PG81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914769; Dennd4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084609 CVCL_PG82 BayGenomics ES cell line XB120 embryonic stem cell house mouse CVCL_PG82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338068; Pdpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084610 CVCL_YA16 NZ-1.2 hybridoma CVCL_YA16 CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q86YL7; Human PDPN. 21084611 CVCL_PG83 BayGenomics ES cell line XB130 embryonic stem cell house mouse CVCL_PG83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915142; Coa6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084612 CVCL_YA17 S-115-8 hybridoma house mouse CVCL_YA17 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200620 21084613 CVCL_PG84 BayGenomics ES cell line XB134 embryonic stem cell house mouse CVCL_PG84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084614 CVCL_YA18 S-191-5 hybridoma house mouse CVCL_YA18 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200621 21084615 CVCL_PG85 BayGenomics ES cell line XB150 embryonic stem cell house mouse CVCL_PG85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919742; Smg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084616 CVCL_YA19 S-44-10 hybridoma house mouse CVCL_YA19 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200622 21084617 CVCL_PG86 BayGenomics ES cell line XB151 embryonic stem cell house mouse CVCL_PG86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084618 CVCL_PG87 BayGenomics ES cell line XB152 embryonic stem cell house mouse CVCL_PG87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108025; Prkar2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084619 CVCL_PG88 BayGenomics ES cell line XB154 embryonic stem cell house mouse CVCL_PG88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084620 CVCL_PG89 BayGenomics ES cell line XB155 embryonic stem cell house mouse CVCL_PG89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858496; Deaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084621 CVCL_YA01 KCB 200203 finite cell line CVCL_YA01 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21084622 CVCL_YA02 KCB 200250 finite cell line CVCL_YA02 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21084623 CVCL_YA03 KCB 200317 finite cell line CVCL_YA03 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21084624 CVCL_YA04 HUL-42 cancer cell line human CVCL_YA04 CL:0000010 21084625 CVCL_YA00 KCB 200208 finite cell line CVCL_YA00 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21084626 CVCL_YA09 221-1-1 hybridoma house mouse CVCL_YA09 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O15706; Dictyostelium discoideum vacA. 21084627 CVCL_PG70 BayGenomics ES cell line XB067A embryonic stem cell house mouse CVCL_PG70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913333; Setd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084628 CVCL_PG71 BayGenomics ES cell line XB076B embryonic stem cell house mouse CVCL_PG71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894649; Ppfibp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084629 CVCL_YA05 KCB 200547L finite cell line CVCL_YA05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21084630 CVCL_PG72 BayGenomics ES cell line XB078 embryonic stem cell house mouse CVCL_PG72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084631 CVCL_YA06 PMab-219 hybridoma house mouse CVCL_YA06 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; F6ZBL8; Horse PDPN. 21084632 CVCL_YA07 70-100-1 hybridoma house mouse CVCL_YA07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01501; Dictyostelium discoideum porA. 21084633 CVCL_PG73 BayGenomics ES cell line XB085 embryonic stem cell house mouse CVCL_PG73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923512; Pfdn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084634 CVCL_YA08 176-3-6 hybridoma house mouse CVCL_YA08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P27133; Dictyostelium discoideum corA. 21084635 CVCL_PG74 BayGenomics ES cell line XB089B embryonic stem cell house mouse CVCL_PG74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914617; Paxbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084636 CVCL_PG75 BayGenomics ES cell line XB091B embryonic stem cell house mouse CVCL_PG75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107943; Cct6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084637 CVCL_PG76 BayGenomics ES cell line XB093B embryonic stem cell house mouse CVCL_PG76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443957; Zfp516 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084638 CVCL_PG77 BayGenomics ES cell line XB097 embryonic stem cell house mouse CVCL_PG77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084639 CVCL_PG78 BayGenomics ES cell line XB098 embryonic stem cell house mouse CVCL_PG78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298366; Atf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084640 CVCL_PG79 BayGenomics ES cell line XB105 embryonic stem cell house mouse CVCL_PG79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352465; Nr2c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084641 CVCL_PG60 BayGenomics ES cell line XB039 embryonic stem cell house mouse CVCL_PG60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336201; Sumo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084642 CVCL_PG61 BayGenomics ES cell line XB040A embryonic stem cell house mouse CVCL_PG61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196624; Tcea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084643 CVCL_PG62 BayGenomics ES cell line XB042A embryonic stem cell house mouse CVCL_PG62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084644 CVCL_PG63 BayGenomics ES cell line XB044 embryonic stem cell house mouse CVCL_PG63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926228; Serinc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084645 CVCL_PG64 BayGenomics ES cell line XB045 embryonic stem cell house mouse CVCL_PG64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926228; Serinc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084646 CVCL_PG65 BayGenomics ES cell line XB050A embryonic stem cell house mouse CVCL_PG65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106014; Nudc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084647 CVCL_PG66 BayGenomics ES cell line XB051 embryonic stem cell house mouse CVCL_PG66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084648 CVCL_PG67 BayGenomics ES cell line XB063 embryonic stem cell house mouse CVCL_PG67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084649 CVCL_PG68 BayGenomics ES cell line XB065A embryonic stem cell house mouse CVCL_PG68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084650 CVCL_PG69 BayGenomics ES cell line XB066 embryonic stem cell house mouse CVCL_PG69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277103; Nudcd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084651 CVCL_PG50 BayGenomics ES cell line XA709 embryonic stem cell house mouse CVCL_PG50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084652 CVCL_PG51 BayGenomics ES cell line XA712 embryonic stem cell house mouse CVCL_PG51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084653 CVCL_PG52 BayGenomics ES cell line XA721 embryonic stem cell house mouse CVCL_PG52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084654 CVCL_PG53 BayGenomics ES cell line XB006BC3 embryonic stem cell house mouse CVCL_PG53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109211; Pkn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084655 CVCL_PG54 BayGenomics ES cell line XB010B embryonic stem cell house mouse CVCL_PG54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352754; Clic4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084656 CVCL_PG55 BayGenomics ES cell line XB011B embryonic stem cell house mouse CVCL_PG55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1195458; Abce1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084657 CVCL_PG56 BayGenomics ES cell line XB012 embryonic stem cell house mouse CVCL_PG56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104560; Nsf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084658 CVCL_PG57 BayGenomics ES cell line XB015 embryonic stem cell house mouse CVCL_PG57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927167; Morf4l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084659 CVCL_PG58 BayGenomics ES cell line XB022 embryonic stem cell house mouse CVCL_PG58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084660 CVCL_PG59 BayGenomics ES cell line XB025B embryonic stem cell house mouse CVCL_PG59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084661 CVCL_YB91 HPS3900 induced pluripotent stem cell human CVCL_YB91 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21084662 CVCL_YB92 CENSOi060-B induced pluripotent stem cell human CVCL_YB92 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21084663 CVCL_YB93 CIBi003-A induced pluripotent stem cell human CVCL_YB93 From: Cell Inspire Biotechnology; Shenzhen; China. CL:0000010 21084664 CVCL_YB94 CIBi004-A induced pluripotent stem cell human CVCL_YB94 From: Cell Inspire Biotechnology; Shenzhen; China. CL:0000010 21084665 CVCL_YB90 ZZUNEUi007-A induced pluripotent stem cell human CVCL_YB90 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg663His (c.1988G>A); ClinVar=VCV000042875; Zygosity=Heterozygous (PubMed=31931472) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084666 CVCL_YB99 ESi078-A induced pluripotent stem cell human CVCL_YB99 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21084667 CVCL_YB95 CIBi005-A induced pluripotent stem cell human CVCL_YB95 From: Cell Inspire Biotechnology; Shenzhen; China. CL:0000010 21084668 CVCL_YB96 CCMi004-A induced pluripotent stem cell human CVCL_YB96 From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.1705-8T>C; Zygosity=Hemizygous; Note=Splicing mutation (PubMed=32348941) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21084669 CVCL_YB97 ESi075-A induced pluripotent stem cell human CVCL_YB97 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21084670 CVCL_YB98 ESi076-A induced pluripotent stem cell human CVCL_YB98 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21084671 CVCL_YB80 ASGRCi006-A induced pluripotent stem cell human CVCL_YB80 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21084672 CVCL_YB81 AKOSi002-A induced pluripotent stem cell human CVCL_YB81 From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Glu1064Ala (c.3191A>C); ClinVar=VCV000370081; Zygosity=Heterozygous (PubMed=32028086); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (PubMed=32028086) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084673 CVCL_YB82 AKOSi003-A induced pluripotent stem cell human CVCL_YB82 From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Met769Val (c.2305A>G); ClinVar=VCV000035706; Zygosity=Homozygous (PubMed=32028086) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084674 CVCL_YB83 ZZUi016-A induced pluripotent stem cell human CVCL_YB83 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21084675 CVCL_YB88 ZZUNEUi005-A induced pluripotent stem cell human CVCL_YB88 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Pro992Leu (c.2975C>T); ClinVar=VCV000188831; Zygosity=Homozygous (PubMed=32745714) Population: Chinese; Han; Derived from sampling site: Urine. Male 21084676 CVCL_YB89 ZZUNEUi006-A induced pluripotent stem cell human CVCL_YB89 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 21084677 CVCL_YB84 ZZUi017-A induced pluripotent stem cell human CVCL_YB84 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[25] (c.6937CAG[25]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[13] (PubMed=32791484) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084678 CVCL_YB85 ZZUNEUi002-A induced pluripotent stem cell human CVCL_YB85 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[84]; Zygosity=Heterozygous (PubMed=32650241) Population: Chinese; Han; Derived from sampling site: Urine. Male 21084679 CVCL_YB86 ZZUNEUi003-A induced pluripotent stem cell human CVCL_YB86 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Arg778Leu (c.2333G>T); ClinVar=VCV000003852; Zygosity=Homozygous (PubMed=31783295) Population: Chinese; Han; Derived from sampling site: Urine. Female 21084680 CVCL_YB87 ZZUNEUi004-A induced pluripotent stem cell human CVCL_YB87 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Pro992Leu (c.2975C>T); ClinVar=VCV000188831; Zygosity=Homozygous (PubMed=32113134) Population: Chinese; Han; Derived from sampling site: Urine. Male 21084681 CVCL_H056 BY00547 transformed cell line human CVCL_H056 HLA typing: A*33:DWH,33:FDX; B*15:10,53:01; DRB1*08:04:01,11:86 (IPD-IMGT/HLA=19307) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084682 CVCL_H057 BY00548 transformed cell line human CVCL_H057 HLA typing: A*11:BTSH; B*13:VE,46:PU; DRB1*12:02:01,09:09 (IPD-IMGT/HLA=19305) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084683 CVCL_H058 BY00549 transformed cell line human CVCL_H058 HLA typing: A*02:11,68:AEBA; B*07:CUDU,15:YJR; DRB1*14:04,14:93 (IPD-IMGT/HLA=19304) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084684 CVCL_H059 BY00551 transformed cell line human CVCL_H059 HLA typing: A*01:DEPX,BLANK; B*07:JNC,08:DFAU; DRB1*11:85,13:01:01 (IPD-IMGT/HLA=19301) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084685 CVCL_H052 BY00542 transformed cell line human CVCL_H052 HLA typing: A*29:APBA,32:AE; B*15:ARAW,45:AC; DRB1*13:01:06,15:01:01:01/02 (IPD-IMGT/HLA=19312) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084686 CVCL_H053 BY00543 transformed cell line human CVCL_H053 HLA typing: A*02:ANNR,03:BG; B*35:CUPD,51:CUPF; DRB1*04:03:01,03:11:02 (IPD-IMGT/HLA=19311) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084687 CVCL_H054 BY00544 transformed cell line human CVCL_H054 HLA typing: A*01:DEPW,02:DERE; B*13:JG,44:BURE; DRB1*15:01:01:01/02,04:72 (IPD-IMGT/HLA=19310) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084688 CVCL_H055 BY00546 transformed cell line human CVCL_H055 HLA typing: A*01:YAG,02:ANGR; B*07:AWCA,18:04; DRB1*11:01:01/06/08,01:01:16 (IPD-IMGT/HLA=19308) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084689 CVCL_H050 BY00540 transformed cell line human CVCL_H050 HLA typing: A*11:DERS,31:FHK; B*15:BTMR,51:02; DRB1*04:01:01,14:94 (IPD-IMGT/HLA=19314) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084690 CVCL_H051 BY00541 transformed cell line human CVCL_H051 HLA typing: A*02:ANGN,03:ANGP; B*18:AERV,39:11; DRB1*04:17:02,11:04:01 (IPD-IMGT/HLA=19313) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084691 CVCL_PI00 BayGenomics ES cell line XB611 embryonic stem cell house mouse CVCL_PI00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103010; Epb41l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084692 CVCL_PI01 BayGenomics ES cell line XB612 embryonic stem cell house mouse CVCL_PI01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084693 CVCL_PI02 BayGenomics ES cell line XB613 embryonic stem cell house mouse CVCL_PI02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333873; Cog1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084694 CVCL_PI03 BayGenomics ES cell line XB614 embryonic stem cell house mouse CVCL_PI03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919936; Usp24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084695 CVCL_H067 BY00580 transformed cell line human CVCL_H067 HLA typing: A*30:02:05,36:01; B*07:AWCA,27:PEN; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=19562) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084696 CVCL_H068 BY00581 transformed cell line human CVCL_H068 HLA typing: A*32:21,02:20:01; B*07:DUEE,35:08; DRB1*04:AAHZ,11:01 (IPD-IMGT/HLA=19561) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084697 CVCL_H069 BY00583 transformed cell line human CVCL_H069 HLA typing: A*25:01,29:ANTJ; B*57:30,18:RRG; C*06:AJB,12:FT; DRB1*04:AMCV,15:FJH (IPD-IMGT/HLA=20549) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084698 CVCL_H063 BY00575 transformed cell line human CVCL_H063 HLA typing: A*01:FDYW,03:74; B*08:DGPV,15:CYGP; C*03:FXP,07:AJB; DRB1*01:EW,15:AK (IPD-IMGT/HLA=19567) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084699 CVCL_H064 BY00576 transformed cell line human CVCL_H064 HLA typing: A*02:171:02,33:FEAM; B*13:CJT,58:CWUS; C*03:02,03:GFW; DRB1*03:VHY,16:02 (IPD-IMGT/HLA=19566) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084700 CVCL_H065 BY00577 transformed cell line human CVCL_H065 HLA typing: A*24:CWFP,25:11; B*18:DUUV,41:AE; DRB1*07:01,15:01 (IPD-IMGT/HLA=19565) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084701 CVCL_H066 BY00578 transformed cell line human CVCL_H066 HLA typing: A*03:73,24:17; B*15:CCFP,40:DHRY; DRB1*10:01,12:02 (IPD-IMGT/HLA=19564) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084702 CVCL_H060 BY00564 transformed cell line human CVCL_H060 HLA typing: A*02:DFKP,30:34; B*51:WBA,57:03; C*15:BJ,18:02; DQB1*05:01,06:04; DRB1*13:01,13:02; DRB3*03:01 (IPD-IMGT/HLA=19583) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084703 CVCL_H061 BY00565 transformed cell line human CVCL_H061 HLA typing: A*02:01:43,24:CWFP; B*18:CNGW,52:AH; DRB1*11:ANTH,11:ARCT (IPD-IMGT/HLA=20027) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084704 CVCL_H062 BY00566 transformed cell line human CVCL_H062 HLA typing: A*03:70,23:ENWE; B*53:JV,53:JV; DRB1*01:02,11:APWP (IPD-IMGT/HLA=19531) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084705 CVCL_H038 BY00520 transformed cell line human CVCL_H038 HLA typing: A*01:ENWD,30:30; B*13:AFB,57:GW; DRB1*07:APA,15:AK (IPD-IMGT/HLA=17646) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084706 CVCL_H039 BY00521 transformed cell line human CVCL_H039 HLA typing: A*02:ANFV,31:AF; B*07:CZZS,27:59N; DRB1*08:02,11:APWP (IPD-IMGT/HLA=17674) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084707 CVCL_H034 BY00513 transformed cell line human CVCL_H034 HLA typing: A*02:CRFN,33:28; B*40:06,44:APAP; DRB1*09:01,13:02 (IPD-IMGT/HLA=17399) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084708 CVCL_H035 BY00514 transformed cell line human CVCL_H035 HLA typing: A*30:AUX,02:193; B*13:02,42:01; DRB1*03:02,07:APA (IPD-IMGT/HLA=17402) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084709 CVCL_H036 BY00515 transformed cell line human CVCL_H036 HLA typing: A*33:BEKE,01:43; B*07:CUCC,44:ABYZ; DRB1*14:HEM,15:FJH (IPD-IMGT/HLA=17403) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084710 CVCL_H037 BY00518 transformed cell line human CVCL_H037 HLA typing: A*29:02:01,11:52; B*44:APJW,55:XUB; DRB1*07:APA,08:FX (IPD-IMGT/HLA=17647) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084711 CVCL_H030 BY00500 transformed cell line human CVCL_H030 HLA typing: A*02:03,33; B*38:02,58; DRB1*13:02:01,04:06:03 (IPD-IMGT/HLA=16932) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084712 CVCL_H031 BY00501 transformed cell line human CVCL_H031 HLA typing: A*01:YAG,02:11; B*27:AETG,40:DG; DRB1*15:01,04:04:02 (IPD-IMGT/HLA=16933) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084713 CVCL_H032 BY00502 transformed cell line human CVCL_H032 HLA typing: A*02:CNDW; B*13:01,35:AWZB; DRB1*11:01:01,04:84 (IPD-IMGT/HLA=16934) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084714 CVCL_H033 BY00512 transformed cell line human CVCL_H033 HLA typing: A*11:ANRC,24:CNFM; B*27:AETG,51:AFHX; DRB1*15:02:01,13:03:03 (IPD-IMGT/HLA=17398) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084715 CVCL_H049 BY00539 transformed cell line human CVCL_H049 HLA typing: A*24:AZWY,32:MZ; B*40:PXF,51:02; DRB1*08:02:01,11:87 (IPD-IMGT/HLA=19315) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084716 CVCL_H045 BY00533 transformed cell line human CVCL_H045 HLA typing: A*30:01,02:ARDE; B*13:32,55:01:01/03; C*03:BPSK,06:02; DQB1*02:01,02:02; DRB1*03:VEW,07:FP; DRB3*02:UNW (IPD-IMGT/HLA=19320) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084717 CVCL_H046 BY00534 transformed cell line human CVCL_H046 HLA typing: A*02:AZGG,03:BTSC; B*15:25:01,15:185; DRB1*04:03,15:02 (IPD-IMGT/HLA=19319) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084718 CVCL_H047 BY00536 transformed cell line human CVCL_H047 HLA typing: A*02:EK,34:BD; B*07:CZZS,53:21; DRB1*11:02,15:03 (IPD-IMGT/HLA=19318) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084719 CVCL_H048 BY00538 transformed cell line human CVCL_H048 HLA typing: A*01:AGNS,24:AREE; B*40:06,50:01; DRB1*03:51,15:02:01 (IPD-IMGT/HLA=19316) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084720 CVCL_H041 BY00523 transformed cell line human CVCL_H041 HLA typing: A*24:AZWY,32:MZ; B*40:06:01:01/02,52:16; DRB1*04:BDJV,07:APA (IPD-IMGT/HLA=17672) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084721 CVCL_H042 BY00524 transformed cell line human CVCL_H042 HLA typing: A*02:ARSC,02:ARDB; B*40:AVGG,39:54; DRB1*08:AP (IPD-IMGT/HLA=17671) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084722 CVCL_H043 BY00526 transformed cell line human CVCL_H043 HLA typing: A*02:ANGN,03:ANGP; B*51:CVAE,37:19; DRB1*11:ARKC,13:ARCR (IPD-IMGT/HLA=17670) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084723 CVCL_H044 BY00531 transformed cell line human CVCL_H044 HLA typing: A*23:ASZA,30:UCB; B*14:02:05,15:17:01:01/02; DRB1*01:02,11:APWP (IPD-IMGT/HLA=19321) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084724 CVCL_H040 BY00522 transformed cell line human CVCL_H040 HLA typing: A*02:ANDC,11:XSH; B*51:CVAE,46:22; DRB1*09:01,16:02 (IPD-IMGT/HLA=17673) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084725 CVCL_H016 BY00483 transformed cell line human CVCL_H016 HLA typing: A*01:WUS,31:AF; B*08:XKT,44:76; DRB1*03:WHX,15:VYF (IPD-IMGT/HLA=16920) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084726 CVCL_H017 BY00486 transformed cell line human CVCL_H017 HLA typing: A*11:HGV,23:ANJU; B*44:ENWF,35:01:10; DRB1*01:EW,13:APWN (IPD-IMGT/HLA=17395) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084727 CVCL_H018 BY00488 transformed cell line human CVCL_H018 HLA typing: A*11:HGV,33:DWH; B*52:01:05,58:VE; DRB1*13:02,15:AAXP (IPD-IMGT/HLA=17396) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084728 CVCL_H019 BY00489 transformed cell line human CVCL_H019 HLA typing: A*30:YE,68:PNP; B*07:AWCA,14:12; DRB1*07:APA,13:02 (IPD-IMGT/HLA=16921) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084729 CVCL_H012 BY00478 transformed cell line human CVCL_H012 HLA typing: A*24:APEC,24:CNFP; B*38:01:01,15:18:03; DRB1*13:ARCM,14:VUU (IPD-IMGT/HLA=16916) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084730 CVCL_H013 BY00479 transformed cell line human CVCL_H013 HLA typing: A*02:BRHJ; B*35:DNXN,56:26; DRB1*01:01,15:01 (IPD-IMGT/HLA=16917) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084731 CVCL_H014 BY00480 transformed cell line human CVCL_H014 HLA typing: A*02:AZGG,02:BRHJ; B*07:CZZS,40:99; DRB1*04:07,08:01 (IPD-IMGT/HLA=19274) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084732 CVCL_H015 BY00482 transformed cell line human CVCL_H015 HLA typing: A*02:BRHJ,30:02; B*27,58:24; DRB1*11:01,13:03 (IPD-IMGT/HLA=16919) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084733 CVCL_H010 BY00467 transformed cell line human CVCL_H010 HLA typing: A*01:ECAD,11:44; B*52:AE,57:AG; DRB1*15:HW (IPD-IMGT/HLA=16454) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084734 CVCL_H011 BY00477 transformed cell line human CVCL_H011 HLA typing: A*11:ANRC,29:ANJP; B*35:DNXN,44:82; DRB1*03:BC,14:AFXK (IPD-IMGT/HLA=16915) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084735 CVCL_H027 BY00497 transformed cell line human CVCL_H027 HLA typing: A*02,11; B*40:BNBC,46; DRB1*11:01:01,04:05:08 (IPD-IMGT/HLA=16929) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084736 CVCL_H028 BY00498 transformed cell line human CVCL_H028 HLA typing: A*24:AZSP,31:AF; B*07:EH,27:PEN; DRB1*04:83,11:01:01 (IPD-IMGT/HLA=16930) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084737 CVCL_H029 BY00499 transformed cell line human CVCL_H029 HLA typing: A*02,23; B*07,39:10; DRB1*11:02:01,01:23 (IPD-IMGT/HLA=16931) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084738 CVCL_H023 BY00493 transformed cell line human CVCL_H023 HLA typing: A*11:FFF,66:AD; B*40:YZK,41:02; DRB1*13:01:01,13:94 (IPD-IMGT/HLA=16925) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084739 CVCL_H024 BY00494 transformed cell line human CVCL_H024 HLA typing: A*01:TUS,01:WCS; B*08:APTN,39:05; DRB1*11:83,04:07 (IPD-IMGT/HLA=16926) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084740 CVCL_H025 BY00495 transformed cell line human CVCL_H025 HLA typing: A*11,31; B*07,35; DRB1*15:01:07,10:01:01 (IPD-IMGT/HLA=16927) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084741 CVCL_H026 BY00496 transformed cell line human CVCL_H026 HLA typing: A*03,29; B*35,44; DRB1*04:02,11:84 (IPD-IMGT/HLA=16928) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084742 CVCL_H020 BY00490 transformed cell line human CVCL_H020 HLA typing: A*11:ANRC,24:CNFM; B*27:05:02,15:170; DRB1*04:08,12:02 (IPD-IMGT/HLA=16922) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084743 CVCL_H021 BY00491 transformed cell line human CVCL_H021 HLA typing: A*26:08,32; B*40:BUAG,51; DRB1*13:93,11:04:01 (IPD-IMGT/HLA=16923) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084744 CVCL_H022 BY00492 transformed cell line human CVCL_H022 HLA typing: A*02:02,29:BCHD; B*18:AETB,49:01; DRB1*11:02:01,11:01:11 (IPD-IMGT/HLA=16924) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084745 CVCL_H009 XLK2 finite cell line African clawed frog CVCL_H009 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Amphibian cell line 21084746 CVCL_H005 BY00525 transformed cell line human CVCL_H005 HLA typing: A*24:90N,33:01; B*42:01,55:01; DRB1*08:04,13:02:01 (IPD-IMGT/HLA=17578) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084747 CVCL_H006 BY00527 transformed cell line human CVCL_H006 HLA typing: A*02:ASAD,36:01; B*45:AC,53:01; DRB1*11:72,01:02:01 (IPD-IMGT/HLA=19325) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084748 CVCL_H007 BY00530 transformed cell line human CVCL_H007 HLA typing: A*02:ANFV,33:DWH; B*39:EDVK,18:33; DRB1*10:01,11:ARAP (IPD-IMGT/HLA=19322) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084749 CVCL_H008 BY00550 transformed cell line human CVCL_H008 HLA typing: A*03:ANPZ,11:ANRC; B*35:BJKC,56:01; DRB1*03:01:01:01/02,11:69 (IPD-IMGT/HLA=19303) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084750 CVCL_H001 BY00434 transformed cell line human CVCL_H001 HLA typing: A*24:07,24:APTB; B*35:97,48:AF; DRB1*11:01,15:01 (IPD-IMGT/HLA=16055) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084751 CVCL_H002 BY00459 transformed cell line human CVCL_H002 HLA typing: A*23:15,74:13; B*07:02/61/62/63/64,15:10; C*03:04/47,15:05; DQB1*04:02,05:01; DRB1*03:02,12:01/06/10/17; DRB3*01:01/12/13 (IPD-IMGT/HLA=16169) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084752 CVCL_H003 BY00503 transformed cell line human CVCL_H003 HLA typing: A*03:ANPZ,11:ANRC; B*40:XCG,50:01; DRB1*07:01:01:01/02,11:69 (IPD-IMGT/HLA=16908) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084753 CVCL_H004 BY00511 transformed cell line human CVCL_H004 HLA typing: A*32:01,33:03; B*58:VE,18:33; DRB1*03:01,11:04 (IPD-IMGT/HLA=16936) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084754 CVCL_H000 BY00433 transformed cell line human CVCL_H000 HLA typing: A*01:BMFN,31:01; B*42:10,35:DNXN; C*04:KBG,17:MN; DRB1*14:02,08:04 (IPD-IMGT/HLA=16057) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21084755 CVCL_PH60 BayGenomics ES cell line XB479 embryonic stem cell house mouse CVCL_PH60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924025; Slc10a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084756 CVCL_PH61 BayGenomics ES cell line XB481 embryonic stem cell house mouse CVCL_PH61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154441; Nop53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084757 CVCL_PH62 BayGenomics ES cell line XB482 embryonic stem cell house mouse CVCL_PH62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084758 CVCL_PH63 BayGenomics ES cell line XB484 embryonic stem cell house mouse CVCL_PH63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084759 CVCL_PH64 BayGenomics ES cell line XB485 embryonic stem cell house mouse CVCL_PH64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084760 CVCL_PH65 BayGenomics ES cell line XB486 embryonic stem cell house mouse CVCL_PH65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084761 CVCL_PH66 BayGenomics ES cell line XB487 embryonic stem cell house mouse CVCL_PH66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386741; Slc30a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084762 CVCL_PH67 BayGenomics ES cell line XB498 embryonic stem cell house mouse CVCL_PH67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97842; Rab1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084763 CVCL_PH68 BayGenomics ES cell line XB500 embryonic stem cell house mouse CVCL_PH68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929091; Sinhcaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084764 CVCL_PH69 BayGenomics ES cell line XB502 embryonic stem cell house mouse CVCL_PH69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385621; Nup153 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084765 CVCL_PH49 BayGenomics ES cell line XB462 embryonic stem cell house mouse CVCL_PH49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107689; Kif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084766 CVCL_PH50 BayGenomics ES cell line XB464 embryonic stem cell house mouse CVCL_PH50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298366; Atf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084767 CVCL_PH51 BayGenomics ES cell line XB465 embryonic stem cell house mouse CVCL_PH51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384313; Rrp9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084768 CVCL_PH52 BayGenomics ES cell line XB466 embryonic stem cell house mouse CVCL_PH52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918490; Osbpl7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084769 CVCL_PH53 BayGenomics ES cell line XB468 embryonic stem cell house mouse CVCL_PH53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084770 CVCL_PH54 BayGenomics ES cell line XB469 embryonic stem cell house mouse CVCL_PH54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084771 CVCL_PH55 BayGenomics ES cell line XB470 embryonic stem cell house mouse CVCL_PH55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084772 CVCL_PH56 BayGenomics ES cell line XB471 embryonic stem cell house mouse CVCL_PH56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084773 CVCL_PH57 BayGenomics ES cell line XB472 embryonic stem cell house mouse CVCL_PH57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890430; Paxip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084774 CVCL_PH58 BayGenomics ES cell line XB475 embryonic stem cell house mouse CVCL_PH58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084775 CVCL_PH59 BayGenomics ES cell line XB476 embryonic stem cell house mouse CVCL_PH59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918850; Ythdf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084776 CVCL_PH38 BayGenomics ES cell line XB432 embryonic stem cell house mouse CVCL_PH38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154263; Bicra Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084777 CVCL_PH39 BayGenomics ES cell line XB437 embryonic stem cell house mouse CVCL_PH39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344349; Rnf216 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084778 CVCL_GN97 ND23909 transformed cell line human CVCL_GN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084779 CVCL_GN98 ND23910 transformed cell line human CVCL_GN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084780 CVCL_GN99 ND23920 transformed cell line human CVCL_GN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084781 CVCL_PH40 BayGenomics ES cell line XB442 embryonic stem cell house mouse CVCL_PH40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278321; Epc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084782 CVCL_PH41 BayGenomics ES cell line XB443 embryonic stem cell house mouse CVCL_PH41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084783 CVCL_GN93 ND23851 transformed cell line human CVCL_GN93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084784 CVCL_PH42 BayGenomics ES cell line XB452 embryonic stem cell house mouse CVCL_PH42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084785 CVCL_GN94 ND23887 transformed cell line human CVCL_GN94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084786 CVCL_PH43 BayGenomics ES cell line XB453 embryonic stem cell house mouse CVCL_PH43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107760; Chka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084787 CVCL_GN95 ND23888 transformed cell line human CVCL_GN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084788 CVCL_PH44 BayGenomics ES cell line XB454 embryonic stem cell house mouse CVCL_PH44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914962; Slc25a37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084789 CVCL_GN96 ND23892 transformed cell line human CVCL_GN96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084790 CVCL_PH45 BayGenomics ES cell line XB455 embryonic stem cell house mouse CVCL_PH45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685992; Bclaf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084791 CVCL_PH46 BayGenomics ES cell line XB456 embryonic stem cell house mouse CVCL_PH46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084792 CVCL_GN90 ND23785 transformed cell line human CVCL_GN90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084793 CVCL_PH47 BayGenomics ES cell line XB457 embryonic stem cell house mouse CVCL_PH47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3028576; Dhx37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084794 CVCL_GN91 ND23787 transformed cell line human CVCL_GN91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084795 CVCL_PH48 BayGenomics ES cell line XB461 embryonic stem cell house mouse CVCL_PH48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346872; Map3k1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084796 CVCL_GN92 ND23788 transformed cell line human CVCL_GN92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084797 CVCL_PH27 BayGenomics ES cell line XB410 embryonic stem cell house mouse CVCL_PH27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97803; Ptma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084798 CVCL_PH28 BayGenomics ES cell line XB412 embryonic stem cell house mouse CVCL_PH28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353427; Eif2ak4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084799 CVCL_PH29 BayGenomics ES cell line XB417 embryonic stem cell house mouse CVCL_PH29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919221; Zswim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084800 CVCL_PH30 BayGenomics ES cell line XB418 embryonic stem cell house mouse CVCL_PH30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921662; Gle1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084801 CVCL_PH31 BayGenomics ES cell line XB419 embryonic stem cell house mouse CVCL_PH31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084802 CVCL_PH32 BayGenomics ES cell line XB421 embryonic stem cell house mouse CVCL_PH32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385206; Pabpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084803 CVCL_PH33 BayGenomics ES cell line XB424 embryonic stem cell house mouse CVCL_PH33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2677212; Bend3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084804 CVCL_PH34 BayGenomics ES cell line XB425 embryonic stem cell house mouse CVCL_PH34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298366; Atf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084805 CVCL_PH35 BayGenomics ES cell line XB428 embryonic stem cell house mouse CVCL_PH35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084806 CVCL_PH36 BayGenomics ES cell line XB429 embryonic stem cell house mouse CVCL_PH36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102724; Tpp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084807 CVCL_PH37 BayGenomics ES cell line XB430 embryonic stem cell house mouse CVCL_PH37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915943; Hnrnpul2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084808 CVCL_PH16 BayGenomics ES cell line XB323 embryonic stem cell house mouse CVCL_PH16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3041259; Mettl25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084809 CVCL_PH17 BayGenomics ES cell line XB338 embryonic stem cell house mouse CVCL_PH17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084810 CVCL_PH18 BayGenomics ES cell line XB339 embryonic stem cell house mouse CVCL_PH18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137706; Actn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084811 CVCL_PH19 BayGenomics ES cell line XB341 embryonic stem cell house mouse CVCL_PH19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084812 CVCL_GN79 ND23594 transformed cell line human CVCL_GN79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084813 CVCL_GN75 ND23350 transformed cell line human CVCL_GN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084814 CVCL_GN76 ND23420 transformed cell line human CVCL_GN76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084815 CVCL_GN77 ND23427 transformed cell line human CVCL_GN77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084816 CVCL_GN78 ND23532 transformed cell line human CVCL_GN78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084817 CVCL_GN71 ND23209 transformed cell line human CVCL_GN71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084818 CVCL_PH20 BayGenomics ES cell line XB358 embryonic stem cell house mouse CVCL_PH20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276125; Utf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084819 CVCL_GN72 ND23271 transformed cell line human CVCL_GN72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084820 CVCL_PH21 BayGenomics ES cell line XB359 embryonic stem cell house mouse CVCL_PH21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084821 CVCL_GN73 ND23294 transformed cell line human CVCL_GN73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084822 CVCL_PH22 BayGenomics ES cell line XB396 embryonic stem cell house mouse CVCL_PH22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387466; Pank4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084823 CVCL_GN74 ND23316 transformed cell line human CVCL_GN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084824 CVCL_PH23 BayGenomics ES cell line XB398 embryonic stem cell house mouse CVCL_PH23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084825 CVCL_PH24 BayGenomics ES cell line XB399 embryonic stem cell house mouse CVCL_PH24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084826 CVCL_PH25 BayGenomics ES cell line XB400 embryonic stem cell house mouse CVCL_PH25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084827 CVCL_PH26 BayGenomics ES cell line XB409 embryonic stem cell house mouse CVCL_PH26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084828 CVCL_GN70 ND08551 transformed cell line human CVCL_GN70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084829 CVCL_PH05 BayGenomics ES cell line XB276 embryonic stem cell house mouse CVCL_PH05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084830 CVCL_PH06 BayGenomics ES cell line XB278 embryonic stem cell house mouse CVCL_PH06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144726; Tmem11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084831 CVCL_PH07 BayGenomics ES cell line XB281 embryonic stem cell house mouse CVCL_PH07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384586; Armc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084832 CVCL_PH08 BayGenomics ES cell line XB282 embryonic stem cell house mouse CVCL_PH08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084833 CVCL_PH09 BayGenomics ES cell line XB289 embryonic stem cell house mouse CVCL_PH09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084834 CVCL_GN86 ND23687 transformed cell line human CVCL_GN86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084835 CVCL_GN87 ND23688 transformed cell line human CVCL_GN87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084836 CVCL_GN88 ND23717 transformed cell line human CVCL_GN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084837 CVCL_GN89 ND23718 transformed cell line human CVCL_GN89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084838 CVCL_GN82 ND23639 transformed cell line human CVCL_GN82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084839 CVCL_GN83 ND23640 transformed cell line human CVCL_GN83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084840 CVCL_PH10 BayGenomics ES cell line XB294 embryonic stem cell house mouse CVCL_PH10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084841 CVCL_GN84 ND23648 transformed cell line human CVCL_GN84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084842 CVCL_PH11 BayGenomics ES cell line XB295 embryonic stem cell house mouse CVCL_PH11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084843 CVCL_GN85 ND23649 transformed cell line human CVCL_GN85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084844 CVCL_PH12 BayGenomics ES cell line XB300 embryonic stem cell house mouse CVCL_PH12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929063; Copz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084845 CVCL_PH13 BayGenomics ES cell line XB308B embryonic stem cell house mouse CVCL_PH13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084846 CVCL_PH14 BayGenomics ES cell line XB315 embryonic stem cell house mouse CVCL_PH14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913892; Ctnnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084847 CVCL_GN80 ND23608 transformed cell line human CVCL_GN80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084848 CVCL_PH15 BayGenomics ES cell line XB322 embryonic stem cell house mouse CVCL_PH15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385923; Hexim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084849 CVCL_GN81 ND23613 transformed cell line human CVCL_GN81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084850 CVCL_GN57 ND23021 transformed cell line human CVCL_GN57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084851 CVCL_GN58 ND23049 transformed cell line human CVCL_GN58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084852 CVCL_GN59 ND23051 transformed cell line human CVCL_GN59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084853 CVCL_GN53 ND22929 transformed cell line human CVCL_GN53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084854 CVCL_GN54 ND22930 transformed cell line human CVCL_GN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084855 CVCL_GN55 ND22932 transformed cell line human CVCL_GN55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084856 CVCL_GN56 ND22934 transformed cell line human CVCL_GN56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084857 CVCL_GN50 ND22915 transformed cell line human CVCL_GN50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084858 CVCL_GN51 ND22919 transformed cell line human CVCL_GN51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084859 CVCL_PH00 BayGenomics ES cell line XB238 embryonic stem cell house mouse CVCL_PH00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084860 CVCL_GN52 ND22921 transformed cell line human CVCL_GN52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084861 CVCL_PH01 BayGenomics ES cell line XB250 embryonic stem cell house mouse CVCL_PH01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914820; Slc39a9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084862 CVCL_PH02 BayGenomics ES cell line XB261 embryonic stem cell house mouse CVCL_PH02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084863 CVCL_PH03 BayGenomics ES cell line XB264 embryonic stem cell house mouse CVCL_PH03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891832; Patz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084864 CVCL_PH04 BayGenomics ES cell line XB269 embryonic stem cell house mouse CVCL_PH04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098533; Ints9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084865 CVCL_GN68 ND23121 transformed cell line human CVCL_GN68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084866 CVCL_GN69 ND23179 transformed cell line human CVCL_GN69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084867 CVCL_GN64 ND23090 transformed cell line human CVCL_GN64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084868 CVCL_GN65 ND23092 transformed cell line human CVCL_GN65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084869 CVCL_GN66 ND23103 transformed cell line human CVCL_GN66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084870 CVCL_GN67 ND23109 transformed cell line human CVCL_GN67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084871 CVCL_GN60 ND23063 transformed cell line human CVCL_GN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084872 CVCL_GN61 ND23078 transformed cell line human CVCL_GN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21084873 CVCL_GN62 ND23082 transformed cell line human CVCL_GN62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084874 CVCL_GN63 ND23084 transformed cell line human CVCL_GN63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21084875 CVCL_YB70 RT-testis spontaneously immortalized cell line CVCL_YB70 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21084876 CVCL_YB71 Jurkat pNFAT-EGFP cancer cell line human CVCL_YB71 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expression of the eGFP reporter gene is under control of the NFAT response element 21084877 CVCL_YB72 QBRIi006-A induced pluripotent stem cell human CVCL_YB72 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21084878 CVCL_YB77 ASGRCi003-A induced pluripotent stem cell human CVCL_YB77 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21084879 CVCL_YB78 ASGRCi004-A induced pluripotent stem cell human CVCL_YB78 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21084880 CVCL_YB79 ASGRCi005-A induced pluripotent stem cell human CVCL_YB79 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21084881 CVCL_YB73 QBRIi006-B induced pluripotent stem cell human CVCL_YB73 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21084882 CVCL_YB74 QBRIi006-C induced pluripotent stem cell human CVCL_YB74 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21084883 CVCL_YB75 ASGRCi001-A induced pluripotent stem cell human CVCL_YB75 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21084884 CVCL_YB76 ASGRCi002-A induced pluripotent stem cell human CVCL_YB76 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21084885 CVCL_YB60 CCSN spontaneously immortalized cell line CVCL_YB60 CL:0000010 Group: Fish cell line. 21084886 CVCL_YB61 GCP spontaneously immortalized cell line CVCL_YB61 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21084887 CVCL_YB66 MUL spontaneously immortalized cell line CVCL_YB66 From: Callinan R.B.; Regional Veterinary Laboratory, North Coast Agricultural Institute; Wollongbar; Australia CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21084888 CVCL_YB67 SGP-2 spontaneously immortalized cell line CVCL_YB67 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21084889 CVCL_YB68 DMEPF-5 spontaneously immortalized cell line CVCL_YB68 CL:0000010 Derived from sampling site: Pectoral fin. Unspecified Virology: Infected with both marbled eel adomavirus (MEAdoV) and marbled eel aquareovirus (MERV) Group: Fish cell line 21084890 CVCL_YB69 RTO-2 spontaneously immortalized cell line CVCL_YB69 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21084891 CVCL_YB62 ONP spontaneously immortalized cell line CVCL_YB62 CL:0000010 Derived from sampling site: Caudal peduncle. Group: Fish cell line 21084892 CVCL_YB63 RSN spontaneously immortalized cell line CVCL_YB63 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21084893 CVCL_YB64 RSN-2 spontaneously immortalized cell line CVCL_YB64 CL:0000010 Unspecified Group: Fish cell line. 21084894 CVCL_YB65 ZFF spontaneously immortalized cell line zebrafish CVCL_YB65 CL:0000010 Unspecified Group: Fish cell line. 21084895 CVCL_YB50 UNIBSi007-C induced pluripotent stem cell human CVCL_YB50 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25671; RNASEH2B; Simple; p.Ala177Thr (c.529G>A); ClinVar=VCV000001262; Zygosity=Homozygous (PubMed=31678772) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084896 CVCL_YB55 UNIBSi009-B induced pluripotent stem cell human CVCL_YB55 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 18873; IFIH1; Simple; p.Arg824Lys (c.2471G>A); ClinVar=VCV000812536; Zygosity=Heterozygous (PubMed=31698194) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084897 CVCL_YB56 UNIBSi009-C induced pluripotent stem cell human CVCL_YB56 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 18873; IFIH1; Simple; p.Arg824Lys (c.2471G>A); ClinVar=VCV000812536; Zygosity=Heterozygous (PubMed=31698194) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084898 CVCL_YB57 UNIBSi010-A induced pluripotent stem cell human CVCL_YB57 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; p.Tyr512Ter (c.1536C>A); Zygosity=Heterozygous (PubMed=31794943); Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; c.2236+1G>A; ClinVar=VCV000558226; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=31794943) Derived from sampling site: Peripheral blood. Male 21084899 CVCL_YB58 UNIBSi010-B induced pluripotent stem cell human CVCL_YB58 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; p.Tyr512Ter (c.1536C>A); Zygosity=Heterozygous (PubMed=31794943); Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; c.2236+1G>A; ClinVar=VCV000558226; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=31794943) Derived from sampling site: Peripheral blood. Male 21084900 CVCL_YB51 UNIBSi008-A induced pluripotent stem cell human CVCL_YB51 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; g.108105741_108115748del (Ex5-7del); Zygosity=Heterozygous (PubMed=31669783) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21084901 CVCL_YB52 UNIBSi008-B induced pluripotent stem cell human CVCL_YB52 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; g.108105741_108115748del (Ex5-7del); Zygosity=Heterozygous (PubMed=31669783) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21084902 CVCL_YB53 UNIBSi008-C induced pluripotent stem cell human CVCL_YB53 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; g.108105741_108115748del (Ex5-7del); Zygosity=Heterozygous (PubMed=31669783) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21084903 CVCL_YB54 UNIBSi009-A induced pluripotent stem cell human CVCL_YB54 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 18873; IFIH1; Simple; p.Arg824Lys (c.2471G>A); ClinVar=VCV000812536; Zygosity=Heterozygous (PubMed=31698194) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084904 CVCL_YB59 UNIBSi010-C induced pluripotent stem cell human CVCL_YB59 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; p.Tyr512Ter (c.1536C>A); Zygosity=Heterozygous (PubMed=31794943); Sequence variation: Mutation; HGNC; 11647; TCIRG1; Simple; c.2236+1G>A; ClinVar=VCV000558226; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=31794943) Derived from sampling site: Peripheral blood. Male 21084905 CVCL_YB44 hSABCi-NS1.1 telomerase immortalized cell line human CVCL_YB44 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Useful for understanding the biology of small airway epithelium (SAE), the pathogenesis of SAE-related diseases and testing new pharmacologic agents (PubMed=31443657) Doubling time: 16 hours (PubMed=31443657) 21084906 CVCL_YB45 UNIBSi006-A induced pluripotent stem cell human CVCL_YB45 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Ser88fs*22 (c.260insAG); Zygosity=Heterozygous (PubMed=31644995); Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Arg97His (c.290G>A); ClinVar=VCV000225498; Zygosity=Heterozygous (PubMed=31644995) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084907 CVCL_YB46 UNIBSi006-B induced pluripotent stem cell human CVCL_YB46 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Ser88fs*22 (c.260insAG); Zygosity=Heterozygous (PubMed=31644995); Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Arg97His (c.290G>A); ClinVar=VCV000225498; Zygosity=Heterozygous (PubMed=31644995) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084908 CVCL_YB47 UNIBSi006-C induced pluripotent stem cell human CVCL_YB47 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Ser88fs*22 (c.260insAG); Zygosity=Heterozygous (PubMed=31644995); Sequence variation: Mutation; HGNC; 12269; TREX1; Simple; p.Arg97His (c.290G>A); ClinVar=VCV000225498; Zygosity=Heterozygous (PubMed=31644995) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21084909 CVCL_YB40 ACBA spontaneously immortalized cell line CVCL_YB40 CL:0000010 Derived from sampling site: Bulbus arteriosus Cell type=Fibroblast.. Female Characteristics: Capable of growing from 1 to 20 Celsius, the optimal temperature is 18-20 Celsius Doubling time: 21 days (at 4 Celsius), 84 days (at 1 Celsius) (PubMed=28261806) Group: Fish cell line 21084910 CVCL_YB41 OmB spontaneously immortalized cell line CVCL_YB41 CL:0000010 Derived from sampling site: Brain. Omics: Deep proteome analysis Male Doubling time: ~24 hours (ATCC=CRL-3481) Group: Fish cell line 21084911 CVCL_YB42 OmL spontaneously immortalized cell line CVCL_YB42 CL:0000010 Derived from sampling site: Oral cavity; lip. Omics: Deep proteome analysis Unspecified Group: Fish cell line 21084912 CVCL_YB43 SSN-2 spontaneously immortalized cell line CVCL_YB43 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21084913 CVCL_YB48 UNIBSi007-A induced pluripotent stem cell human CVCL_YB48 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25671; RNASEH2B; Simple; p.Ala177Thr (c.529G>A); ClinVar=VCV000001262; Zygosity=Homozygous (PubMed=31678772) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084914 CVCL_YB49 UNIBSi007-B induced pluripotent stem cell human CVCL_YB49 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25671; RNASEH2B; Simple; p.Ala177Thr (c.529G>A); ClinVar=VCV000001262; Zygosity=Homozygous (PubMed=31678772) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21084915 CVCL_YB33 EDi041-A induced pluripotent stem cell human CVCL_YB33 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084916 CVCL_YB34 EDi042-A induced pluripotent stem cell human CVCL_YB34 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084917 CVCL_YB35 EDi043-A induced pluripotent stem cell human CVCL_YB35 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084918 CVCL_YB36 EDi044-A induced pluripotent stem cell human CVCL_YB36 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084919 CVCL_YB30 EDi038-A induced pluripotent stem cell human CVCL_YB30 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084920 CVCL_YB31 EDi039-A induced pluripotent stem cell human CVCL_YB31 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084921 CVCL_YB32 EDi040-A induced pluripotent stem cell human CVCL_YB32 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084922 CVCL_YB37 EDi045-A induced pluripotent stem cell human CVCL_YB37 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084923 CVCL_YB38 BFTC-909 pBabeAR1 cancer cell line human CVCL_YB38 CL:0000010 Sequence variation: Gene fusion; HGNC; 2151; CNGB1 + HGNC; 6326; KIFC3; Name(s)=KIFC3-CNGB1 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Taiwan; Derived from sampling site: Kidney; renal pelvis. Male 21084924 CVCL_YB39 BFTC-909 pBabeAR2 cancer cell line human CVCL_YB39 CL:0000010 Sequence variation: Gene fusion; HGNC; 2151; CNGB1 + HGNC; 6326; KIFC3; Name(s)=KIFC3-CNGB1 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Taiwan; Derived from sampling site: Kidney; renal pelvis. Male 21084925 CVCL_YB22 EDi029-A induced pluripotent stem cell human CVCL_YB22 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084926 CVCL_YB23 EDi031-A induced pluripotent stem cell human CVCL_YB23 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084927 CVCL_YB24 EDi032-A induced pluripotent stem cell human CVCL_YB24 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084928 CVCL_YB25 EDi033-A induced pluripotent stem cell human CVCL_YB25 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084929 CVCL_YB20 EDi027-A induced pluripotent stem cell human CVCL_YB20 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084930 CVCL_YB21 EDi028-A induced pluripotent stem cell human CVCL_YB21 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084931 CVCL_PH90 BayGenomics ES cell line XB589 embryonic stem cell house mouse CVCL_PH90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106181; Mybbp1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084932 CVCL_PH91 BayGenomics ES cell line XB591 embryonic stem cell house mouse CVCL_PH91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925212; Scaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084933 CVCL_PH92 BayGenomics ES cell line XB592 embryonic stem cell house mouse CVCL_PH92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927155; Clptm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084934 CVCL_YB26 EDi034-A induced pluripotent stem cell human CVCL_YB26 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084935 CVCL_PH93 BayGenomics ES cell line XB593 embryonic stem cell house mouse CVCL_PH93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914418; Lpar6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084936 CVCL_YB27 EDi035-A induced pluripotent stem cell human CVCL_YB27 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084937 CVCL_PH94 BayGenomics ES cell line XB595 embryonic stem cell house mouse CVCL_PH94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084938 CVCL_YB28 EDi036-A induced pluripotent stem cell human CVCL_YB28 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084939 CVCL_PH95 BayGenomics ES cell line XB599 embryonic stem cell house mouse CVCL_PH95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923549; Erp44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084940 CVCL_YB29 EDi037-A induced pluripotent stem cell human CVCL_YB29 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084941 CVCL_PH96 BayGenomics ES cell line XB600 embryonic stem cell house mouse CVCL_PH96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105125; Eif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084942 CVCL_PH97 BayGenomics ES cell line XB604 embryonic stem cell house mouse CVCL_PH97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919240; Ddx54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084943 CVCL_PH98 BayGenomics ES cell line XB608 embryonic stem cell house mouse CVCL_PH98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084944 CVCL_PH99 BayGenomics ES cell line XB610 embryonic stem cell house mouse CVCL_PH99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919787; Cdca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084945 CVCL_YB11 RMA-SKb+ cancer cell line house mouse CVCL_YB11 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21084946 CVCL_YB12 RMA-SKb- cancer cell line house mouse CVCL_YB12 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21084947 CVCL_YB13 RMA-SKb- Ec7.1 cancer cell line house mouse CVCL_YB13 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. Characteristics: Lacks H-2D(B) and H2-K(B) expression 21084948 CVCL_YB14 PK-15S spontaneously immortalized cell line pig CVCL_YB14 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3307 21084949 CVCL_YB10 EndoC-betaH1 SLC30A8-KO transformed cell line human CVCL_YB10 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 20303; SLC30A8; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21084950 CVCL_YB19 EDi026-A induced pluripotent stem cell human CVCL_YB19 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21084951 CVCL_PH80 BayGenomics ES cell line XB556 embryonic stem cell house mouse CVCL_PH80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919936; Usp24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084952 CVCL_PH81 BayGenomics ES cell line XB557 embryonic stem cell house mouse CVCL_PH81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084953 CVCL_YB15 STS spontaneously immortalized cell line pig CVCL_YB15 CL:0000010 Derived from sampling site: Fetal testis. Male Group: Serum/protein free medium cell line; Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3308 21084954 CVCL_PH82 BayGenomics ES cell line XB563 embryonic stem cell house mouse CVCL_PH82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3527792; Zdhhc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084955 CVCL_YB16 EDi030-A induced pluripotent stem cell human CVCL_YB16 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21084956 CVCL_PH83 BayGenomics ES cell line XB566 embryonic stem cell house mouse CVCL_PH83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152895; Helb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084957 CVCL_YB17 pTr spontaneously immortalized cell line pig CVCL_YB17 CL:0000010 Derived from sampling site: Trophectoderm. Female 21084958 CVCL_PH84 BayGenomics ES cell line XB572 embryonic stem cell house mouse CVCL_PH84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084959 CVCL_YB18 pTr2 spontaneously immortalized cell line pig CVCL_YB18 CL:0000010 Derived from sampling site: Trophectoderm. Female Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus-2 (PRRSV-2) (PubMed=31670096) 21084960 CVCL_PH85 BayGenomics ES cell line XB577 embryonic stem cell house mouse CVCL_PH85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140843; Noc4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084961 CVCL_PH86 BayGenomics ES cell line XB580 embryonic stem cell house mouse CVCL_PH86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921452; Fblim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084962 CVCL_PH87 BayGenomics ES cell line XB582 embryonic stem cell house mouse CVCL_PH87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105072; Rab22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084963 CVCL_PH88 BayGenomics ES cell line XB583 embryonic stem cell house mouse CVCL_PH88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914393; Ikzf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084964 CVCL_PH89 BayGenomics ES cell line XB586 embryonic stem cell house mouse CVCL_PH89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136841; Morc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084965 CVCL_YB00 56-396-5 hybridoma house mouse CVCL_YB00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08799; Dictyostelium discoideum mhcA. 21084966 CVCL_YB01 H36 [Mouse hybridoma against D.discoideum cprG] hybridoma house mouse CVCL_YB01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q94504; Dictyostelium discoideum cprG. 21084967 CVCL_YB02 B4.2 hybridoma house mouse CVCL_YB02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O77257; Dictyostelium discoideum sctA. 21084968 CVCL_YB03 23-132-27 hybridoma house mouse CVCL_YB03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02599; Dictyostelium discoideum calA. 21084969 CVCL_YB08 EndoC-betaH1 NEUROD1-KO transformed cell line human CVCL_YB08 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 7762; NEUROD1; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21084970 CVCL_YB09 EndoC-betaH1 PAM-KO transformed cell line human CVCL_YB09 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 8596; PAM; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21084971 CVCL_YB04 80-52-13 hybridoma house mouse CVCL_YB04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dictyostelium discoideum discoidin 1. 21084972 CVCL_PH70 BayGenomics ES cell line XB503 embryonic stem cell house mouse CVCL_PH70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890357; Igf2bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084973 CVCL_YB05 224-236-1 hybridoma house mouse CVCL_YB05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07830; Dictyostelium discoideum act1. 21084974 CVCL_PH71 BayGenomics ES cell line XB514 embryonic stem cell house mouse CVCL_PH71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084975 CVCL_PH72 BayGenomics ES cell line XB515 embryonic stem cell house mouse CVCL_PH72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084976 CVCL_YB06 EndoC-betaH1 IDE-KO transformed cell line human CVCL_YB06 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 5381; IDE; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21084977 CVCL_PH73 BayGenomics ES cell line XB516 embryonic stem cell house mouse CVCL_PH73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915142; Coa6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084978 CVCL_YB07 EndoC-betaH1 INS-KO transformed cell line human CVCL_YB07 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 6081; INS; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21084979 CVCL_PH74 BayGenomics ES cell line XB518 embryonic stem cell house mouse CVCL_PH74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920026; Sass6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084980 CVCL_PH75 BayGenomics ES cell line XB522 embryonic stem cell house mouse CVCL_PH75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97838; Eprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084981 CVCL_PH76 BayGenomics ES cell line XB523 embryonic stem cell house mouse CVCL_PH76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084982 CVCL_PH77 BayGenomics ES cell line XB538 embryonic stem cell house mouse CVCL_PH77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354736; Kdm2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084983 CVCL_PH78 BayGenomics ES cell line XB539 embryonic stem cell house mouse CVCL_PH78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914195; Sdha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084984 CVCL_PH79 BayGenomics ES cell line XB551 embryonic stem cell house mouse CVCL_PH79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084985 CVCL_XZ10 Ba/F3 ETV6-NTRK3-G696A factor-dependent cell line house mouse CVCL_XZ10 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK3 fusion); Transfected with: HGNC; 8033; NTRK3 (ETV6-NTRK3 fusion; with p.Gly696Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084986 CVCL_XZ11 Ba/F3 FIP1L1-PDGFRA-D842V factor-dependent cell line house mouse CVCL_XZ11 CL:0000010 Transfected with: HGNC; 19124; FIP1L1 (FIP1L1-PDGFRA fusion); Transfected with: HGNC; 8803; PDGFRA (FIP1L1-PDGFRA fusion; with p.Asp842Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084987 CVCL_XZ12 Ba/F3 FLT3-ITD-A848P factor-dependent cell line house mouse CVCL_XZ12 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Ala848Pro); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084988 CVCL_XZ13 Ba/F3 FLT3-ITD-D835Del factor-dependent cell line house mouse CVCL_XZ13 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084989 CVCL_XZ18 Ba/F3 FLT3-ITD-F691I factor-dependent cell line house mouse CVCL_XZ18 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Phe691Ile); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084990 CVCL_XZ19 Ba/F3 FLT3-ITD-N767D factor-dependent cell line house mouse CVCL_XZ19 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asn767Asp); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084991 CVCL_XZ14 Ba/F3 FLT3-ITD-D835F factor-dependent cell line house mouse CVCL_XZ14 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835Phe); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084992 CVCL_PA80 BayGenomics ES cell line RST260 embryonic stem cell house mouse CVCL_PA80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084993 CVCL_XZ15 Ba/F3 FLT3-ITD-D835H factor-dependent cell line house mouse CVCL_XZ15 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835His); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084994 CVCL_PA81 BayGenomics ES cell line RST262 embryonic stem cell house mouse CVCL_PA81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084995 CVCL_XZ16 Ba/F3 FLT3-ITD-D835I factor-dependent cell line house mouse CVCL_XZ16 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835Ile); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084996 CVCL_PA82 BayGenomics ES cell line RST264 embryonic stem cell house mouse CVCL_PA82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915831; Tmed10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084997 CVCL_XZ17 Ba/F3 FLT3-ITD-D849G factor-dependent cell line house mouse CVCL_XZ17 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp849Gly); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21084998 CVCL_PA83 BayGenomics ES cell line RST265 embryonic stem cell house mouse CVCL_PA83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97748; Ctsa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21084999 CVCL_PA84 BayGenomics ES cell line RST267 embryonic stem cell house mouse CVCL_PA84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085000 CVCL_PA85 BayGenomics ES cell line RST268 embryonic stem cell house mouse CVCL_PA85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085001 CVCL_PA86 BayGenomics ES cell line RST271 embryonic stem cell house mouse CVCL_PA86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929282; Ptges3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085002 CVCL_PA87 BayGenomics ES cell line RST272 embryonic stem cell house mouse CVCL_PA87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085003 CVCL_PA88 BayGenomics ES cell line RST273 embryonic stem cell house mouse CVCL_PA88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039616; Znrf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085004 CVCL_PA89 BayGenomics ES cell line RST276 embryonic stem cell house mouse CVCL_PA89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085005 CVCL_XZ00 Ba/F3 c-Kit D816Y factor-dependent cell line house mouse CVCL_XZ00 CL:0000010 Transfected with: HGNC; 6342; KIT (with p.Asp816Tr); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085006 CVCL_XZ01 Ba/F3 c-Kit V560G factor-dependent cell line house mouse CVCL_XZ01 CL:0000010 Transfected with: HGNC; 6342; KIT (with p.Val560Gly); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085007 CVCL_XZ02 Ba/F3 EGFR-A763_Y764insFQEA factor-dependent cell line house mouse CVCL_XZ02 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val763_Tyr764insPheGlnGluAla); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085008 CVCL_XZ07 Ba/F3 EML4-ALK-G1269A factor-dependent cell line house mouse CVCL_XZ07 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Gly1269Ala); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085009 CVCL_XZ08 Ba/F3 ERBB2-L755P factor-dependent cell line house mouse CVCL_XZ08 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with p.Leu755Pro); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085010 CVCL_XZ09 Ba/F3 ERBB2-V777L factor-dependent cell line house mouse CVCL_XZ09 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with p.Val777Leu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085011 CVCL_XZ03 Ba/F3 EGFR-V769_D770insASV factor-dependent cell line house mouse CVCL_XZ03 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val769_Asp770insAlaSerVal); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085012 CVCL_XZ04 Ba/F3 EML4-ALK-D1203N-E1210K factor-dependent cell line house mouse CVCL_XZ04 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Asp1203Asn and p.Glu1210Lys); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085013 CVCL_PA70 BayGenomics ES cell line RST236 embryonic stem cell house mouse CVCL_PA70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085014 CVCL_XZ05 Ba/F3 EML4-ALK-F1174C-D1203N factor-dependent cell line house mouse CVCL_XZ05 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Phe1174Cys and p.Asp1203Asn); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085015 CVCL_PA71 BayGenomics ES cell line RST238 embryonic stem cell house mouse CVCL_PA71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085016 CVCL_XZ06 Ba/F3 EML4-ALK-G1202Del factor-dependent cell line house mouse CVCL_XZ06 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Gly1202del); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085017 CVCL_PA72 BayGenomics ES cell line RST240 embryonic stem cell house mouse CVCL_PA72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085018 CVCL_PA73 BayGenomics ES cell line RST244 embryonic stem cell house mouse CVCL_PA73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97748; Ctsa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085019 CVCL_PA74 BayGenomics ES cell line RST245 embryonic stem cell house mouse CVCL_PA74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085020 CVCL_PA75 BayGenomics ES cell line RST249 embryonic stem cell house mouse CVCL_PA75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085021 CVCL_PA76 BayGenomics ES cell line RST250 embryonic stem cell house mouse CVCL_PA76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085022 CVCL_PA77 BayGenomics ES cell line RST255 embryonic stem cell house mouse CVCL_PA77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085023 CVCL_PA78 BayGenomics ES cell line RST256 embryonic stem cell house mouse CVCL_PA78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108515; Cbx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085024 CVCL_PA79 BayGenomics ES cell line RST259 embryonic stem cell house mouse CVCL_PA79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345162; Adam23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085025 CVCL_PA60 BayGenomics ES cell line RST214 embryonic stem cell house mouse CVCL_PA60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444465; Frem2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085026 CVCL_PA61 BayGenomics ES cell line RST216 embryonic stem cell house mouse CVCL_PA61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929895; Clstn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085027 CVCL_PA62 BayGenomics ES cell line RST219 embryonic stem cell house mouse CVCL_PA62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88252; Calr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085028 CVCL_PA63 BayGenomics ES cell line RST220 embryonic stem cell house mouse CVCL_PA63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915358; Snhg17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085029 CVCL_PA64 BayGenomics ES cell line RST225 embryonic stem cell house mouse CVCL_PA64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085030 CVCL_PA65 BayGenomics ES cell line RST226 embryonic stem cell house mouse CVCL_PA65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98834; Trp53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085031 CVCL_PA66 BayGenomics ES cell line RST227 embryonic stem cell house mouse CVCL_PA66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1350921; Fkbp9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085032 CVCL_PA67 BayGenomics ES cell line RST228 embryonic stem cell house mouse CVCL_PA67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914195; Sdha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085033 CVCL_PA68 BayGenomics ES cell line RST229 embryonic stem cell house mouse CVCL_PA68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298229; Nid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085034 CVCL_PA69 BayGenomics ES cell line RST235 embryonic stem cell house mouse CVCL_PA69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107559; Sema4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085035 CVCL_PA50 BayGenomics ES cell line RST199 embryonic stem cell house mouse CVCL_PA50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914873; Tm7sf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085036 CVCL_PA51 BayGenomics ES cell line RST201 embryonic stem cell house mouse CVCL_PA51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085037 CVCL_PA52 BayGenomics ES cell line RST202 embryonic stem cell house mouse CVCL_PA52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927235; Mbtps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085038 CVCL_PA53 BayGenomics ES cell line RST203 embryonic stem cell house mouse CVCL_PA53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88356; Cdh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085039 CVCL_PA54 BayGenomics ES cell line RST204 embryonic stem cell house mouse CVCL_PA54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085040 CVCL_PA55 BayGenomics ES cell line RST205 embryonic stem cell house mouse CVCL_PA55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351651; Yme1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085041 CVCL_PA56 BayGenomics ES cell line RST207 embryonic stem cell house mouse CVCL_PA56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085042 CVCL_PA57 BayGenomics ES cell line RST208 embryonic stem cell house mouse CVCL_PA57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085043 CVCL_PA58 BayGenomics ES cell line RST209 embryonic stem cell house mouse CVCL_PA58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085044 CVCL_PA59 BayGenomics ES cell line RST211 embryonic stem cell house mouse CVCL_PA59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085045 CVCL_PA40 BayGenomics ES cell line RST170 embryonic stem cell house mouse CVCL_PA40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442146; Dnajc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085046 CVCL_PA41 BayGenomics ES cell line RST175 embryonic stem cell house mouse CVCL_PA41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927235; Mbtps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085047 CVCL_PA42 BayGenomics ES cell line RST176 embryonic stem cell house mouse CVCL_PA42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298229; Nid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085048 CVCL_PA43 BayGenomics ES cell line RST178 embryonic stem cell house mouse CVCL_PA43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443191; Nceh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085049 CVCL_PA44 BayGenomics ES cell line RST181 embryonic stem cell house mouse CVCL_PA44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085050 CVCL_PA45 BayGenomics ES cell line RST182 embryonic stem cell house mouse CVCL_PA45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927169; B4galt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085051 CVCL_PA46 BayGenomics ES cell line RST186 embryonic stem cell house mouse CVCL_PA46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085052 CVCL_PA47 BayGenomics ES cell line RST188 embryonic stem cell house mouse CVCL_PA47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97281; Ncam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085053 CVCL_PA48 BayGenomics ES cell line RST196 embryonic stem cell house mouse CVCL_PA48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351605; Rpl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085054 CVCL_PA49 BayGenomics ES cell line RST197 embryonic stem cell house mouse CVCL_PA49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88047; Aplp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085055 CVCL_GG96 ND11981 transformed cell line human CVCL_GG96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085056 CVCL_GG97 ND11982 transformed cell line human CVCL_GG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085057 CVCL_GG98 ND11983 transformed cell line human CVCL_GG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085058 CVCL_GG99 ND11984 transformed cell line human CVCL_GG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085059 CVCL_PA30 BayGenomics ES cell line RST153 embryonic stem cell house mouse CVCL_PA30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085060 CVCL_PA31 BayGenomics ES cell line RST154 embryonic stem cell house mouse CVCL_PA31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085061 CVCL_PA32 BayGenomics ES cell line RST155 embryonic stem cell house mouse CVCL_PA32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085062 CVCL_PA33 BayGenomics ES cell line RST157 embryonic stem cell house mouse CVCL_PA33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921867; Scpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085063 CVCL_PA34 BayGenomics ES cell line RST159 embryonic stem cell house mouse CVCL_PA34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085064 CVCL_PA35 BayGenomics ES cell line RST161 embryonic stem cell house mouse CVCL_PA35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085065 CVCL_PA36 BayGenomics ES cell line RST162 embryonic stem cell house mouse CVCL_PA36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343877; Rpl10a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085066 CVCL_PA37 BayGenomics ES cell line RST163 embryonic stem cell house mouse CVCL_PA37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085067 CVCL_PA38 BayGenomics ES cell line RST167 embryonic stem cell house mouse CVCL_PA38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085068 CVCL_PA39 BayGenomics ES cell line RST168 embryonic stem cell house mouse CVCL_PA39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914217; Edem3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085069 CVCL_GG81 ND11918 transformed cell line human CVCL_GG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085070 CVCL_GG82 ND11919 transformed cell line human CVCL_GG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085071 CVCL_GG83 ND11920 transformed cell line human CVCL_GG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085072 CVCL_GG84 ND11924 transformed cell line human CVCL_GG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085073 CVCL_GG80 ND11909 transformed cell line human CVCL_GG80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085074 CVCL_PA20 BayGenomics ES cell line RST125 embryonic stem cell house mouse CVCL_PA20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085075 CVCL_PA21 BayGenomics ES cell line RST129 embryonic stem cell house mouse CVCL_PA21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98085; Rpn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085076 CVCL_PA22 BayGenomics ES cell line RST130 embryonic stem cell house mouse CVCL_PA22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085077 CVCL_PA23 BayGenomics ES cell line RST132 embryonic stem cell house mouse CVCL_PA23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894652; Usp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085078 CVCL_PA24 BayGenomics ES cell line RST133 embryonic stem cell house mouse CVCL_PA24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085079 CVCL_PA25 BayGenomics ES cell line RST134 embryonic stem cell house mouse CVCL_PA25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345162; Adam23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085080 CVCL_PA26 BayGenomics ES cell line RST135 embryonic stem cell house mouse CVCL_PA26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085081 CVCL_GG78 ND11906 transformed cell line human CVCL_GG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085082 CVCL_PA27 BayGenomics ES cell line RST139 embryonic stem cell house mouse CVCL_PA27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97750; Ppib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085083 CVCL_GG79 ND11908 transformed cell line human CVCL_GG79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085084 CVCL_PA28 BayGenomics ES cell line RST142 embryonic stem cell house mouse CVCL_PA28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085085 CVCL_PA29 BayGenomics ES cell line RST146 embryonic stem cell house mouse CVCL_PA29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085086 CVCL_GG74 ND11893 transformed cell line human CVCL_GG74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085087 CVCL_GG75 ND11899 transformed cell line human CVCL_GG75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085088 CVCL_GG76 ND11904 transformed cell line human CVCL_GG76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085089 CVCL_GG77 ND11905 transformed cell line human CVCL_GG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085090 CVCL_GG92 ND11976 transformed cell line human CVCL_GG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085091 CVCL_GG93 ND11978 transformed cell line human CVCL_GG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085092 CVCL_GG94 ND11979 transformed cell line human CVCL_GG94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085093 CVCL_GG95 ND11980 transformed cell line human CVCL_GG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085094 CVCL_GG90 ND11973 transformed cell line human CVCL_GG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085095 CVCL_GG91 ND11975 transformed cell line human CVCL_GG91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085096 CVCL_PA10 BayGenomics ES cell line RST105 embryonic stem cell house mouse CVCL_PA10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085097 CVCL_PA11 BayGenomics ES cell line RST106 embryonic stem cell house mouse CVCL_PA11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347007; Plod2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085098 CVCL_PA12 BayGenomics ES cell line RST108 embryonic stem cell house mouse CVCL_PA12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085099 CVCL_PA13 BayGenomics ES cell line RST114 embryonic stem cell house mouse CVCL_PA13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085100 CVCL_PA14 BayGenomics ES cell line RST117 embryonic stem cell house mouse CVCL_PA14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085101 CVCL_PA15 BayGenomics ES cell line RST120 embryonic stem cell house mouse CVCL_PA15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085102 CVCL_GG89 ND11946 transformed cell line human CVCL_GG89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085103 CVCL_PA16 BayGenomics ES cell line RST121 embryonic stem cell house mouse CVCL_PA16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085104 CVCL_PA17 BayGenomics ES cell line RST122 embryonic stem cell house mouse CVCL_PA17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98085; Rpn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085105 CVCL_PA18 BayGenomics ES cell line RST123 embryonic stem cell house mouse CVCL_PA18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085106 CVCL_PA19 BayGenomics ES cell line RST124 embryonic stem cell house mouse CVCL_PA19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085107 CVCL_GG85 ND11928 transformed cell line human CVCL_GG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085108 CVCL_GG86 ND11929 transformed cell line human CVCL_GG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085109 CVCL_GG87 ND11944 transformed cell line human CVCL_GG87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085110 CVCL_GG88 ND11945 transformed cell line human CVCL_GG88 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085111 CVCL_XZ98 OAM-S1 finite cell line CVCL_XZ98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085113 CVCL_XZ94 YNH finite cell line CVCL_XZ94 CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21085114 CVCL_XZ95 KCB 89011 finite cell line CVCL_XZ95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: Indicated to be KCB 89010 in PubMed=14984103, but this corresponds to another cell line in the KCB collection 21085115 CVCL_XZ96 KCB 88002 finite cell line CVCL_XZ96 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085116 CVCL_XZ97 WG-S1 finite cell line CVCL_XZ97 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 21085117 CVCL_6550 C127 cancer cell line house mouse CVCL_6550 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21085118 CVCL_5T50 GM50147 transformed cell line human CVCL_5T50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085119 CVCL_6551 11P0-1 transformed cell line house mouse CVCL_6551 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/cAn. Unspecified 21085120 CVCL_5T51 GM50148 transformed cell line human CVCL_5T51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM50148; probable Female 21085121 CVCL_6552 15P-1 transformed cell line house mouse CVCL_6552 CL:0000010 Transfected with: UniProtKB; P03073; Murine polyomavirus (strain A2) large T antigen Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: C57BL/6 x DBA/2. Male 21085122 CVCL_5T52 GM50150 transformed cell line human CVCL_5T52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085123 CVCL_6546 4-1.10 cancer cell line human CVCL_6546 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Selected to be resistant to the anti proliferative effects of oncostatin 21085124 CVCL_5T46 GM50114 transformed cell line human CVCL_5T46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085125 CVCL_5T47 GM50115 transformed cell line human CVCL_5T47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085126 CVCL_6547 OV3121 cancer cell line house mouse CVCL_6547 CL:0000010 Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: C57BL/6N x C3H/He. Discontinued: JCRB; NIHS0255; true Female 21085127 CVCL_5T48 GM50136 transformed cell line human CVCL_5T48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085128 CVCL_6548 OV3121-ras4 cancer cell line house mouse CVCL_6548 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: C57BL/6N x C3H/He. Female 21085129 CVCL_5T49 GM50142 transformed cell line human CVCL_5T49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085130 CVCL_6549 OV3121-ras7 cancer cell line house mouse CVCL_6549 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: C57BL/6N x C3H/He. Female 21085131 CVCL_5T42 GM24587 finite cell line human CVCL_5T42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085132 CVCL_6542 T88-M factor-dependent cell line house mouse CVCL_6542 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: C3H/He. Female Characteristics: IL3 or IL5 dependent Caution: Not from strain DBA/2J as originally published but from strain C3H/He (DOI=10.4051/ibc.2010.2.4.0014) 21085133 CVCL_5T43 GM25313 induced pluripotent stem cell human CVCL_5T43 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085134 CVCL_6543 Ishikawa (Heraklio) 02 ER- cancer cell line human CVCL_6543 Genome ancestry: African=0%; Native American=0%; East Asian, North=80.66%; East Asian, South=19.33%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 98032302; probable Female Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21085135 CVCL_5T44 GM25541 induced pluripotent stem cell human CVCL_5T44 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex2-3dup; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21085136 CVCL_6544 WIL2 transformed cell line human CVCL_6544 HLA typing: A*01:01:01,02:01:01; B*53:38:02,57:01:01; C*06:02:01,14:02:01; DPB1*13:01:01G,16:01:01; DQA1*02:01:01; DQB1*02:02:01G,03:03:02; DRB1*07:01:01 (CLS=302011) CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from child cell lines TK6 and WIL2 NS) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 21085137 CVCL_5T45 GM25576 transformed cell line human CVCL_5T45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085138 CVCL_6545 NBT-2 cancer cell line human CVCL_6545 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male 21085139 CVCL_XZ87 RF-89s/t transformed cell line CVCL_XZ87 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21085140 CVCL_XZ88 U2OS-tetR cancer cell line human CVCL_XZ88 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Miscellaneous: Cell line information from personal communication of Nan X.-L Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21085141 CVCL_XZ89 U2OS-tetR-PAmCherry1-KRAS G12D cancer cell line human CVCL_XZ89 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Asp); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein (with p.Glu31Val, p.Ala62Thr, p.Lys75Asn, p.Leu88Phe, p.Asn103Lys, p.Ser151Leu, p.Ile166Val, p.Gln168Pro, p.Leu170Val and p.Ile202Arg = PAmCherry1) Miscellaneous: Cell line information from personal communication of Nan X.-L Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The PAmCherry1 fluorescent protein is fused to the N-terminal of KRAS with p.Val12Asp 21085142 CVCL_XZ83 YTM finite cell line CVCL_XZ83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21085143 CVCL_XZ84 Ghm finite cell line CVCL_XZ84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21085144 CVCL_XZ85 KCB 87020 finite cell line CVCL_XZ85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085145 CVCL_XZ86 RF-89s finite cell line CVCL_XZ86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21085146 CVCL_6560 9TR#1 embryonic stem cell house mouse CVCL_6560 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1314884; Tnfrsf1a Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11379 21085147 CVCL_5T60 GM50248 transformed cell line human CVCL_5T60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085148 CVCL_6561 A364 cancer cell line human CVCL_6561 From: De Greve J.; Oncologisch Centrum; Brussels; Belgium. CL:0000010 Female 21085149 CVCL_5T61 GM50275 transformed cell line human CVCL_5T61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085150 CVCL_6562 A547 cancer cell line human CVCL_6562 From: De Greve J.; Oncologisch Centrum; Brussels; Belgium. CL:0000010 Female 21085151 CVCL_5T62 GM50276 transformed cell line human CVCL_5T62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085152 CVCL_6563 Ainv15 embryonic stem cell house mouse CVCL_6563 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: 129P2/Ola. Discontinued: ATCC; SCRC-1029; true Male 21085153 CVCL_5T63 GM50284 transformed cell line human CVCL_5T63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085154 CVCL_5T57 GM50204 transformed cell line human CVCL_5T57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085155 CVCL_6557 KsOG transformed cell line Norway rat CVCL_6557 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Fischer. Female 21085156 CVCL_6558 7F2 spontaneously immortalized cell line house mouse CVCL_6558 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Bone marrow Cell type=Osteoblast.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12557 21085157 CVCL_5T58 GM50205 transformed cell line human CVCL_5T58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085158 CVCL_6559 91.1.F1 finite cell line tropical clawed frog CVCL_6559 CL:0000010 Derived from sampling site: Hindlimb. Unspecified Doubling time: ~90 hours (PubMed=22083648) Group: Amphibian cell line 21085159 CVCL_5T59 GM50215 transformed cell line human CVCL_5T59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085160 CVCL_6553 2018 transformed cell line house mouse CVCL_6553 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10907 21085161 CVCL_5T53 GM50159 transformed cell line human CVCL_5T53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085162 CVCL_6554 283TAg transformed cell line house mouse CVCL_6554 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97073; Mpg; Knockout cell: Method=KO mouse; MGI; MGI:97740; Polb Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21085163 CVCL_5T54 GM50166 transformed cell line human CVCL_5T54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085164 CVCL_6555 2E8 [Mouse bone marrow] factor-dependent cell line house mouse CVCL_6555 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: BALB/c.xid. Unspecified Characteristics: IL7 dependent Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085165 CVCL_5T55 GM50182 transformed cell line human CVCL_5T55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM50182; probable Female 21085166 CVCL_6556 2F-2B transformed cell line house mouse CVCL_6556 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male Characteristics: Derived from a SVEC4-10EE2 induced nodular cutaneous tumor (PubMed=8496612) 21085167 CVCL_5T56 GM50188 transformed cell line human CVCL_5T56 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085168 CVCL_XZ90 Msb finite cell line CVCL_XZ90 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085169 CVCL_XZ91 YBM finite cell line CVCL_XZ91 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085170 CVCL_XZ92 KCB 90004 finite cell line CVCL_XZ92 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085171 CVCL_XZ93 KCB 83003 finite cell line CVCL_XZ93 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21085172 CVCL_XZ76 KCB 200632 finite cell line CVCL_XZ76 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085173 CVCL_XZ77 KCB 200820 finite cell line CVCL_XZ77 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Group: Endangered species/breed cell line; Group: Cetacean cell line 21085174 CVCL_XZ78 KCB 200311S finite cell line CVCL_XZ78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085175 CVCL_XZ79 KCB 88023 finite cell line CVCL_XZ79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085176 CVCL_XZ72 MF-1 [Martes] finite cell line CVCL_XZ72 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085177 CVCL_XZ73 SIC finite cell line CVCL_XZ73 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21085178 CVCL_XZ74 KCB 200224 finite cell line CVCL_XZ74 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21085179 CVCL_XZ75 KCB 200405 finite cell line CVCL_XZ75 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21085180 CVCL_6530 23CLN spontaneously immortalized cell line pig CVCL_6530 CL:0000010 Discontinued: ECACC; 94042257; probable; Discontinued: RCB; RCB0179; true. Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of bovine origin but found to be a porcine cell line (see Riken web site). 21085181 CVCL_5T30 GM23900 transformed cell line human CVCL_5T30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085182 CVCL_5T24 GM23872 transformed cell line human CVCL_5T24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085183 CVCL_6524 S49.1TB.4 DEX R.63 cancer cell line house mouse CVCL_6524 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:41879; Dexamethasone; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085184 CVCL_5T25 GM23873 transformed cell line human CVCL_5T25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085185 CVCL_6525 Sl/Sl4 transformed cell line house mouse CVCL_6525 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: WBB6 F1 Sl/Sl(d). Unspecified 21085186 CVCL_5T26 GM23874 transformed cell line human CVCL_5T26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085187 CVCL_6526 Sl/Sl4 hSCF220 transformed cell line house mouse CVCL_6526 CL:0000010 Transfected with: HGNC; 6343; KITLG (isoform SCF220); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: WBB6 F1 Sl/Sl(d). Unspecified 21085188 CVCL_5T27 GM23877 transformed cell line human CVCL_5T27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085189 CVCL_6527 Sl/Sl4 hSCF248 transformed cell line house mouse CVCL_6527 CL:0000010 Transfected with: HGNC; 6343; KITLG (isoform SCF248); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: WBB6 F1 Sl/Sl(d). Unspecified 21085190 CVCL_5T20 GM23822 transformed cell line human CVCL_5T20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085191 CVCL_6520 S49.1G.3 cancer cell line house mouse CVCL_6520 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085192 CVCL_5T21 GM23830 transformed cell line human CVCL_5T21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085193 CVCL_6521 S49.1G.3 PHA.100/0 cancer cell line house mouse CVCL_6521 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085194 CVCL_5T22 GM23852 transformed cell line human CVCL_5T22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085195 CVCL_6522 S49.1H.1AG.6/2 cancer cell line house mouse CVCL_6522 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:17650; Cortisol; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085196 CVCL_5T23 GM23854 transformed cell line human CVCL_5T23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085197 CVCL_6523 S49.1TB.2 cancer cell line house mouse CVCL_6523 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085198 CVCL_XZ80 KCB 86005M finite cell line CVCL_XZ80 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21085199 CVCL_XZ81 KCB 88006L finite cell line CVCL_XZ81 CL:0000010 Derived from sampling site: Lung. 21085200 CVCL_XZ82 KCB 88006T finite cell line CVCL_XZ82 CL:0000010 21085201 CVCL_5T28 GM23878 transformed cell line human CVCL_5T28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085202 CVCL_6528 TK#1 embryonic stem cell house mouse CVCL_6528 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96591; Irf2 Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11383 21085203 CVCL_5T29 GM23881 transformed cell line human CVCL_5T29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085204 CVCL_6529 W-20-17 stromal cell line house mouse CVCL_6529 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: W++. 21085205 CVCL_XZ65 THP-1 NF-kb luciferase reporter cancer cell line human CVCL_XZ65 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: The luciferase reporter gene is under the control of the NF-kappaB response element Doubling time: ~48 hours (KYinno) 21085206 CVCL_XZ66 U87MG Human EGFR vIII cancer cell line human CVCL_XZ66 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Doubling time: ~30 hours (KYinno) Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21085207 CVCL_XZ67 GB-val4 cancer cell line human CVCL_XZ67 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=31388924); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305Arg (c.914A>G); Zygosity=Unspecified (PubMed=31388924) Derived from sampling site: Brain. Omics: Array-based CGH Male Doubling time: 22 hours (PubMed=31388924) 21085208 CVCL_XZ68 KCB 99002 transformed cell line CVCL_XZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 21085209 CVCL_XZ61 RS4;11 BCL2-F104L cancer cell line human CVCL_XZ61 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4; Note=In frame (from parent cell line); Transfected with: HGNC; 990; BCL2 (with p.Phe104Leu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow. Female 21085210 CVCL_XZ62 RS4;11 BCL2-G101V cancer cell line human CVCL_XZ62 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4; Note=In frame (from parent cell line); Transfected with: HGNC; 990; BCL2 (with p.Gly101Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow. Female 21085211 CVCL_XZ63 T47D HER2 cancer cell line human CVCL_XZ63 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Pleural effusion. Female Doubling time: ~30 hours (KYinno) 21085212 CVCL_XZ64 T47D P95HER2 cancer cell line human CVCL_XZ64 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (isoform CTF-611/P95HER2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Pleural effusion. Female Doubling time: ~30 hours (KYinno) 21085213 CVCL_5T40 GM24518 transformed cell line human CVCL_5T40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085214 CVCL_6540 R201C transformed cell line house mouse CVCL_6540 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88151; Glb1; Transfected with: HGNC; 4298; GLB1 (with p.Arg201Cys); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x CBA. Problematic cell line: Contaminated/misidentified Not from strain C57BL/6 as originally assigned but from a C57BL/6 x CBA cross (PubMed=27844419). 21085215 CVCL_5T41 GM24586 finite cell line human CVCL_5T41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21085216 CVCL_6541 Sq-1979 cancer cell line house mouse CVCL_6541 CL:0000010 Breed/subspecies: C3H. Doubling time: 10.1 +- 0.2 hours (PubMed=29435078) 21085217 CVCL_XZ69 MPC-L1 finite cell line CVCL_XZ69 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21085218 CVCL_6535 dRLa-74 Clone 2 transformed cell line Norway rat CVCL_6535 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21085219 CVCL_5T35 GM23908 transformed cell line human CVCL_5T35 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Gln252Argfs*12 (c.754delC); ClinVar=VCV000492852; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085220 CVCL_6536 dRLh-84 cancer cell line Norway rat CVCL_6536 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21085221 CVCL_5T36 GM23909 transformed cell line human CVCL_5T36 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Val115Trpfs*149 (c.343delG); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085222 CVCL_6537 dRLN-4 transformed cell line Norway rat CVCL_6537 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21085223 CVCL_5T37 GM23920 transformed cell line human CVCL_5T37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085224 CVCL_6538 dRLN-6 transformed cell line Norway rat CVCL_6538 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21085225 CVCL_5T38 GM23922 transformed cell line human CVCL_5T38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085226 CVCL_6531 305M finite cell line human CVCL_6531 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 47 PDL (RCB=RCB0156) 21085227 CVCL_5T31 GM23904 transformed cell line human CVCL_5T31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085228 CVCL_6532 9-15c somatic stem cell house mouse CVCL_6532 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: C3H/He. 21085229 CVCL_5T32 GM23905 transformed cell line human CVCL_5T32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085230 CVCL_6533 AU-BEK spontaneously immortalized cell line CVCL_6533 CL:0000010 Derived from sampling site: Fetal kidney. Mixed 21085231 CVCL_5T33 GM23906 transformed cell line human CVCL_5T33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM23906; probable Male 21085232 CVCL_6534 DBC1.2 spontaneously immortalized cell line house mouse CVCL_6534 CL:0000010 Derived from sampling site: Embryonic nose; nasal cavity; olfactory epithelium Cell type=Basal cell.; Breed/subspecies: C3H/He. Unspecified 21085233 CVCL_5T34 GM23907 transformed cell line human CVCL_5T34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085234 CVCL_XZ70 MPC-L2 finite cell line CVCL_XZ70 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21085235 CVCL_XZ71 EL-S1 finite cell line CVCL_XZ71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21085236 CVCL_6539 dRLN-9 transformed cell line Norway rat CVCL_6539 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21085237 CVCL_5T39 GM24465 transformed cell line human CVCL_5T39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085238 CVCL_XZ54 HT1080 human CD137 cancer cell line human CVCL_XZ54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11924; TNFRSF9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: ~48 hours (KYinno) 21085239 CVCL_XZ55 HT1080 human CD27 cancer cell line human CVCL_XZ55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11922; CD27; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: ~48 hours (KYinno) 21085240 CVCL_XZ56 HT1080 human CD40 cancer cell line human CVCL_XZ56 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11919; CD40; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: ~48 hours (KYinno) 21085241 CVCL_XZ57 Jurkat NF-kb luciferase reporter cancer cell line human CVCL_XZ57 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The luciferase reporter gene is under the control of the NF-kappaB response element Doubling time: ~48 hours (KYinno) 21085242 CVCL_XZ50 CT26.WT human CLDN18.2 cancer cell line house mouse CVCL_XZ50 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21085243 CVCL_XZ51 DLD-1 human PDL1 cancer cell line human CVCL_XZ51 CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Doubling time: ~30 hours (KYinno) 21085244 CVCL_XZ52 HEK293 human APP695 transformed cell line human CVCL_XZ52 CL:0000010 Transfected with: HGNC; 620; APP (isoform APP695); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085245 CVCL_XZ53 HEK293 human APP695 Swedish transformed cell line human CVCL_XZ53 CL:0000010 Transfected with: HGNC; 620; APP (isoform APP695; with p.Lys670_Met671delinsAsnLeu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085246 CVCL_XZ58 MC38 human PDL1 cancer cell line house mouse CVCL_XZ58 CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Doubling time: ~20 hours (KYinno) 21085247 CVCL_XZ59 NCI-N87 human CLDN18.2 cancer cell line human CVCL_XZ59 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2039; CLDN18 (isoform A2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Liver. Male Characteristics: Parent cell line established from a nude mouse xenograft Doubling time: ~30 hours (KYinno) 21085248 CVCL_5T02 GM23696 transformed cell line human CVCL_5T02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085249 CVCL_6502 Mile Sven 1 transformed cell line house mouse CVCL_6502 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified 21085250 CVCL_5T03 GM23697 transformed cell line human CVCL_5T03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085251 CVCL_6503 MS1 VEGF transformed cell line house mouse CVCL_6503 CL:0000010 Transfected with: HGNC; 12680; VEGFA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS0321; true Unspecified 21085252 CVCL_5T04 GM23698 transformed cell line human CVCL_5T04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085253 CVCL_6504 MTKP 97-12 spontaneously immortalized cell line house mouse CVCL_6504 CL:0000010 Transfected with: HGNC; 7037; MELTF Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8985 21085254 CVCL_5T05 GM23699 transformed cell line human CVCL_5T05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085255 CVCL_6505 PA317 containing JR-gal transformed cell line house mouse CVCL_6505 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9995 21085256 CVCL_5T00 GM23694 transformed cell line human CVCL_5T00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085257 CVCL_6500 MB19tsA clone 2B2 transformed cell line house mouse CVCL_6500 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Deficient in base excision repair due to homozygous deletion of the promoter and exon 1 of polB The deletion of polB is mediated by the Cre-loxP recombination. This deletion event is reversible and therefore this cell line is ideal for site-specific recombination using the Cre-lox system (ATCC). 21085258 CVCL_5T01 GM23695 transformed cell line human CVCL_5T01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085259 CVCL_6501 MBA C57.We finite cell line house mouse CVCL_6501 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Discontinued: ATCC; CRL-6370; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085260 CVCL_XZ60 NK-92MI human CD16a-V158 cancer cell line human CVCL_XZ60 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Peripheral blood. Male 21085261 CVCL_5T06 GM23700 transformed cell line human CVCL_5T06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085262 CVCL_6506 PA317 cyclin E-L transformed cell line house mouse CVCL_6506 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085263 CVCL_5T07 GM23701 transformed cell line human CVCL_5T07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085264 CVCL_6507 PA317 cyclin E-S transformed cell line house mouse CVCL_6507 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085265 CVCL_5T08 GM23702 transformed cell line human CVCL_5T08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085266 CVCL_6508 PA317 LXSN transformed cell line house mouse CVCL_6508 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085267 CVCL_5T09 GM23703 transformed cell line human CVCL_5T09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085268 CVCL_6509 PA317 LXSN 16E6 transformed cell line house mouse CVCL_6509 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085269 CVCL_XZ43 CHO-K1 human NTRK1 spontaneously immortalized cell line CVCL_XZ43 CL:0000010 Transfected with: HGNC; 8031; NTRK1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085270 CVCL_XZ44 CHO-K1 human TNFRSF1B spontaneously immortalized cell line CVCL_XZ44 CL:0000010 Transfected with: HGNC; 11917; TNFRSF1B; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085271 CVCL_XZ45 CHO-K1 mouse ICOS spontaneously immortalized cell line CVCL_XZ45 CL:0000010 Transfected with: MGI; MGI:1858745; Icos; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085272 CVCL_XZ46 CHO-K1 OS8 spontaneously immortalized cell line CVCL_XZ46 CL:0000010 Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains Doubling time: ~24 hours (KYinno) 21085273 CVCL_XZ40 CHO-K1 human CD70 spontaneously immortalized cell line CVCL_XZ40 CL:0000010 Transfected with: HGNC; 11937; CD70; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085274 CVCL_XZ41 CHO-K1 human CLDN18.1 spontaneously immortalized cell line CVCL_XZ41 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A1); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085275 CVCL_XZ42 CHO-K1 human CLDN18.2 spontaneously immortalized cell line CVCL_XZ42 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085276 CVCL_XZ47 CHO-K1 OS8-SIGLEC15 spontaneously immortalized cell line CVCL_XZ47 CL:0000010 Transfected with: HGNC; 27596; SIGLEC15; Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains Doubling time: ~24 hours (KYinno) 21085277 CVCL_XZ48 CHO-K1 rabbit CD47 spontaneously immortalized cell line CVCL_XZ48 CL:0000010 Transfected with: UniProtKB; G1TS80; Rabbit CD47; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085278 CVCL_XZ49 CHO-K1 rat CD47 spontaneously immortalized cell line CVCL_XZ49 CL:0000010 Transfected with: RGD; 2308; Cd47; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085279 CVCL_5T13 GM23712 transformed cell line human CVCL_5T13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085280 CVCL_6513 PA317 LXSN 6E7 transformed cell line house mouse CVCL_6513 CL:0000010 Transfected with: UniProtKB; P06464; Human papillomavirus type 6b protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 6b (HPV6b) [E7](NCBI-Taxonomy; 10600); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085281 CVCL_5T14 GM23713 transformed cell line human CVCL_5T14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085282 CVCL_6514 R1.1 cancer cell line house mouse CVCL_6514 CL:0000010 Breed/subspecies: C58/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085283 CVCL_5T15 GM23715 finite cell line human CVCL_5T15 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM23715; probable Male 21085284 CVCL_6515 R1.G1 cancer cell line house mouse CVCL_6515 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C58/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085285 CVCL_6516 ES-R1/E embryonic stem cell house mouse CVCL_6516 CL:0000010 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21085286 CVCL_5T16 GM23722 transformed cell line human CVCL_5T16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085287 CVCL_5T10 GM23704 transformed cell line human CVCL_5T10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085288 CVCL_6510 PA317 LXSN 16E6E7 transformed cell line house mouse CVCL_6510 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085289 CVCL_5T11 GM23708 transformed cell line human CVCL_5T11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085290 CVCL_6511 PA317 LXSN 16E7 transformed cell line house mouse CVCL_6511 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E7](NCBI-Taxonomy; 333760); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085291 CVCL_5T12 GM23711 transformed cell line human CVCL_5T12 CL:0000010 Sequence variation: Gene deletion; HGNC; 20444; MBD5; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085292 CVCL_6512 PA317 LXSN 6E6 transformed cell line house mouse CVCL_6512 CL:0000010 Transfected with: UniProtKB; P06462; Human papillomavirus type 6b protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 6b (HPV6b) [E6](NCBI-Taxonomy; 10600); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21085293 CVCL_5T17 GM23723 transformed cell line human CVCL_5T17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085294 CVCL_6517 RAW 264.7 gammaNO(-) cancer cell line house mouse CVCL_6517 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Unlike the parental cell line, does not produce nitric oxide upon treatment with interferon-gamma alone, but requires LPS for full activation (ATCC) 21085295 CVCL_5T18 GM23813 transformed cell line human CVCL_5T18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085296 CVCL_6518 S49 (Thy-1-a) cancer cell line house mouse CVCL_6518 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085297 CVCL_5T19 GM23818 transformed cell line human CVCL_5T19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085298 CVCL_6519 S49.1 cancer cell line house mouse CVCL_6519 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085299 CVCL_XZ32 CHO-K1 cyno ICOS spontaneously immortalized cell line CVCL_XZ32 CL:0000010 Transfected with: UniProtKB; A0A2K5TQU4; Macaca fascicularis ICOS; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085300 CVCL_XZ33 CHO-K1 cyno MSLN spontaneously immortalized cell line CVCL_XZ33 CL:0000010 Transfected with: UniProtKB; A0A2K5TW94; Macaca fascicularis MSLN; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085301 CVCL_XZ34 CHO-K1 cyno TNFRSF1B spontaneously immortalized cell line CVCL_XZ34 CL:0000010 Transfected with: UniProtKB; A0A2K5VET2; Macaca fascicularis TNFRSF1B; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085302 CVCL_XZ35 CHO-K1 cyno TPBG spontaneously immortalized cell line CVCL_XZ35 CL:0000010 Transfected with: UniProtKB; A0A2K5UEN3; Macaca fascicularis TPBG; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085303 CVCL_XZ30 Ba/F3 PIM1 factor-dependent cell line house mouse CVCL_XZ30 CL:0000010 Transfected with: HGNC; 8986; PIM1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085304 CVCL_XZ31 BxPC-3 human CLDN18.2 cancer cell line human CVCL_XZ31 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2039; CLDN18 (isoform A2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pancreas. Female Doubling time: ~30 hours (KYinno) 21085305 CVCL_XZ36 CHO-K1 dog CD47 spontaneously immortalized cell line CVCL_XZ36 CL:0000010 Transfected with: VGNC; 38960; Dog CD47; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085306 CVCL_XZ37 CHO-K1 human CD154(CD40L) spontaneously immortalized cell line CVCL_XZ37 CL:0000010 Transfected with: HGNC; 11935; CD40LG; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085307 CVCL_XZ38 CHO-K1 human CD16a-F158 spontaneously immortalized cell line CVCL_XZ38 CL:0000010 Transfected with: HGNC; 3619; FCGR3A; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085308 CVCL_XZ39 CHO-K1 human CD16a-V158 spontaneously immortalized cell line CVCL_XZ39 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21085309 CVCL_XZ21 Ba/F3 FLT3-ITD-Y842H factor-dependent cell line house mouse CVCL_XZ21 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Tyr842His); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085310 CVCL_XZ22 BaF3 HER2 factor-dependent cell line house mouse CVCL_XZ22 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085311 CVCL_XZ23 Ba/F3 KIF5B-RET-G810A factor-dependent cell line house mouse CVCL_XZ23 CL:0000010 Transfected with: HGNC; 6324; KIF5B (KIF5B-RET fusion); Transfected with: HGNC; 9967; RET (KIF5B-RET fusion; with p.Gly810Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085312 CVCL_XZ24 Ba/F3 KIF5B-RET-V804E factor-dependent cell line house mouse CVCL_XZ24 CL:0000010 Transfected with: HGNC; 6324; KIF5B (KIF5B-RET fusion); Transfected with: HGNC; 9967; RET (KIF5B-RET fusion; with p.Val804Glu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085313 CVCL_XZ20 Ba/F3 FLT3-ITD-Y842C factor-dependent cell line house mouse CVCL_XZ20 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Tyr842Cys); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085314 CVCL_XZ29 Ba/F3 PDGFRA-D842V factor-dependent cell line house mouse CVCL_XZ29 CL:0000010 Transfected with: HGNC; 8803; PDGFRA (with p.Asp842Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085315 CVCL_PA90 BayGenomics ES cell line RST278 embryonic stem cell house mouse CVCL_PA90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085316 CVCL_XZ25 Ba/F3 KIF5B-RET-V804L factor-dependent cell line house mouse CVCL_XZ25 CL:0000010 Transfected with: HGNC; 6324; KIF5B (KIF5B-RET fusion); Transfected with: HGNC; 9967; RET (KIF5B-RET fusion; with p.Val804Leu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085317 CVCL_PA91 BayGenomics ES cell line RST279 embryonic stem cell house mouse CVCL_PA91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95392; Eng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085318 CVCL_XZ26 Ba/F3 KIF5B-RET-V804M factor-dependent cell line house mouse CVCL_XZ26 CL:0000010 Transfected with: HGNC; 6324; KIF5B (KIF5B-RET fusion); Transfected with: HGNC; 9967; RET (KIF5B-RET fusion; with p.Val804Met); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085319 CVCL_PA92 BayGenomics ES cell line RST284 embryonic stem cell house mouse CVCL_PA92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88047; Aplp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085320 CVCL_XZ27 Ba/F3 LMNA-NTRK1-G667A factor-dependent cell line house mouse CVCL_XZ27 CL:0000010 Transfected with: HGNC; 6636; LMNA (LMNA-NTRK1 fusion); Transfected with: HGNC; 8031; NTRK1 (LMNA-NTRK1 fusion; with p.Gly667Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085321 CVCL_PA93 BayGenomics ES cell line RST286 embryonic stem cell house mouse CVCL_PA93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914873; Tm7sf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085322 CVCL_XZ28 Ba/F3 P95HER2 factor-dependent cell line house mouse CVCL_XZ28 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (isoform CTF-611/P95HER2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21085323 CVCL_PA94 BayGenomics ES cell line RST288 embryonic stem cell house mouse CVCL_PA94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085324 CVCL_PA95 BayGenomics ES cell line RST291 embryonic stem cell house mouse CVCL_PA95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085325 CVCL_PA96 BayGenomics ES cell line RST292 embryonic stem cell house mouse CVCL_PA96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085326 CVCL_PA97 BayGenomics ES cell line RST293 embryonic stem cell house mouse CVCL_PA97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889844; Sumf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085327 CVCL_PA98 BayGenomics ES cell line RST295 embryonic stem cell house mouse CVCL_PA98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442146; Dnajc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085328 CVCL_PA99 BayGenomics ES cell line RST296 embryonic stem cell house mouse CVCL_PA99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085329 CVCL_6494 022HU-NSO cancer cell line house mouse CVCL_6494 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-11177; probable Female 21085330 CVCL_5S94 GM23498 transformed cell line human CVCL_5S94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085331 CVCL_6495 D1 ORL UVA somatic stem cell house mouse CVCL_6495 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12424 21085332 CVCL_5S95 GM23504 transformed cell line human CVCL_5S95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085333 CVCL_6496 DBA A.Sp finite cell line house mouse CVCL_6496 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2J. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085334 CVCL_5S96 GM23616 transformed cell line human CVCL_5S96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085335 CVCL_6497 DBA C.Sp finite cell line house mouse CVCL_6497 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2J. Discontinued: ATCC; CRL-6342; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085336 CVCL_5S97 GM23675 transformed cell line human CVCL_5S97 CL:0000010 Sequence variation: Gene amplification; HGNC; 6990; MECP2; Duplication; Zygosity=Hemizygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21085337 CVCL_5S90 GM23488 transformed cell line human CVCL_5S90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085338 CVCL_6490 LBRM-33 clone 4A2 cancer cell line house mouse CVCL_6490 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: B10.BR. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085339 CVCL_5S91 GM23489 transformed cell line human CVCL_5S91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085340 CVCL_6491 M-7 cancer cell line house mouse CVCL_6491 CL:0000010 Breed/subspecies: C57BL/10. Male 21085341 CVCL_5S92 GM23492 transformed cell line human CVCL_5S92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085342 CVCL_6492 Src++ transformed cell line house mouse CVCL_6492 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21085343 CVCL_5S93 GM23493 transformed cell line human CVCL_5S93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085344 CVCL_6493 H19-7/IGF-IR transformed cell line Norway rat CVCL_6493 CL:0000010 Transfected with: HGNC; 5465; IGF1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Holtzman. Unspecified 21085345 CVCL_5S87 GM23302 transformed cell line human CVCL_5S87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085346 CVCL_6487 J26 spontaneously immortalized cell line house mouse CVCL_6487 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Omics: SNP array analysis Male 21085347 CVCL_5S88 GM23432 transformed cell line human CVCL_5S88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085348 CVCL_6488 J27-B7 spontaneously immortalized cell line house mouse CVCL_6488 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*07) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21085349 CVCL_5S89 GM23433 transformed cell line human CVCL_5S89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085350 CVCL_6489 J27-neo spontaneously immortalized cell line house mouse CVCL_6489 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21085351 CVCL_5S98 GM23676 transformed cell line human CVCL_5S98 CL:0000010 Sequence variation: Gene amplification; HGNC; 6990; MECP2; Duplication; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21085352 CVCL_6498 L-NGC-5HT2 L-cells spontaneously immortalized cell line house mouse CVCL_6498 CL:0000010 Transfected with: HGNC; 5293; HTR2A Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10287 21085353 CVCL_5S99 GM23693 transformed cell line human CVCL_5S99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085354 CVCL_6499 MB16tsA clone 1B5 transformed cell line house mouse CVCL_6499 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female Characteristics: The cell line is an isogenic, wild-type cell line to be used in concert with the base excision repair deficient cell line, MB19tsA, clone 2B2 (Cellosaurus=CVCL_6500) 21085355 CVCL_5S72 GM23095 transformed cell line human CVCL_5S72 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex35-43del; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085356 CVCL_6472 WM1552C cancer cell line human CVCL_6472 HLA typing: A*03:01,02:01; B*13:02,07:02; C*07:02,06:02; DPB1*04:01,04:02; DQB1*06:02,02:01; DRB1*15:01,ND (PubMed=15592718); Genome ancestry: African=0%; Native American=0.24%; East Asian, North=0%; East Asian, South=1.1%; South Asian=2.39%; European, North=72.29%; European, South=23.98% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Cosmic-CLP; DepMap; Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.634+5G>T; ClinVar=VCV001338631; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Cosmic-CLP; DepMap) Derived from sampling site: Hypodermis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2808; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D13S317 21085357 CVCL_5S73 GM23096 transformed cell line human CVCL_5S73 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex35-43del; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085358 CVCL_6473 WM278 cancer cell line human CVCL_6473 HLA typing: A*02:01,26:01; B*13:02,38:01; C*06:02,12:03; DPB1*02:01:02,01:01:02; DQB1*06:03,02:01; DRB1*13:01,07:01 (PubMed=15592718); Genome ancestry: African=0.85%; Native American=0%; East Asian, North=0.99%; East Asian, South=2.12%; South Asian=1.13%; European, North=64.04%; European, South=30.87% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=23851445; Cosmic-CLP; DepMap; Wistar) Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2809; true; Discontinued: Coriell; WC00054; probable Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Wistar Institute melanoma cell line collection 21085359 CVCL_5S74 GM23099 transformed cell line human CVCL_5S74 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex8-17dup; Zygosity=Heterozygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21085360 CVCL_6474 YS001 embryonic stem cell house mouse CVCL_6474 CL:0000010 Unspecified Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11776. 21085361 CVCL_5S75 GM23125 transformed cell line human CVCL_5S75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085362 CVCL_5S70 GM23087 transformed cell line human CVCL_5S70 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex2-30dup; Zygosity=Heterozygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21085363 CVCL_6470 UT-SCV-3 cancer cell line human CVCL_6470 CL:0000010 Derived from sampling site: Vulva. Female Doubling time: 13 hours (PubMed=15047230) 21085364 CVCL_5S71 GM23094 transformed cell line human CVCL_5S71 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex35-43del; Zygosity=Heterozygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21085365 CVCL_6471 VK2/E6E7 transformed cell line human CVCL_6471 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Vagina; mucosa Cell type=Epithelial cell.. Female Doubling time: ~24 hours (ATCC=CRL-2616) 21085366 CVCL_5S69 GM23086 transformed cell line human CVCL_5S69 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex2-30dup; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21085367 CVCL_6469 UT-SCV-2 cancer cell line human CVCL_6469 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 56 hours (PubMed=15047230) 21085368 CVCL_5S65 GM23053 transformed cell line human CVCL_5S65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085369 CVCL_6465 UC1BC3 spontaneously immortalized cell line house mouse CVCL_6465 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6462; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085370 CVCL_5S66 GM23054 transformed cell line human CVCL_5S66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085371 CVCL_6466 UC1BC4 spontaneously immortalized cell line house mouse CVCL_6466 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6463; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085372 CVCL_5S67 GM23055 transformed cell line human CVCL_5S67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085373 CVCL_6467 UC1BC5 spontaneously immortalized cell line house mouse CVCL_6467 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6464; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085374 CVCL_5S68 GM23081 transformed cell line human CVCL_5S68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085375 CVCL_6468 UT-SCV-1 cancer cell line human CVCL_6468 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9887230) Derived from metastatic site: Inguinal lymph node. Female Doubling time: 38 hours (PubMed=15047230) 21085376 CVCL_6483 Clone C conditionally immortalized cell line CVCL_6483 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; distal tubule Cell type=Renal intercalated cell.. Unspecified Characteristics: May be used to study terminal differentiation of intercalated cells (ATCC); Characteristics: Bicarbonate-secreting 21085377 CVCL_5S83 GM23255 transformed cell line human CVCL_5S83 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=33197628) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085378 CVCL_5S84 GM23263 transformed cell line human CVCL_5S84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085379 CVCL_5S85 GM23264 transformed cell line human CVCL_5S85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085380 CVCL_6485 IP-1B transformed cell line house mouse CVCL_6485 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male Characteristics: Derived from a SVEC4-10EHR1 induced ascite tumor (PubMed=8496612) 21085381 CVCL_5S86 GM23270 transformed cell line human CVCL_5S86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085382 CVCL_6486 IP2-E4 transformed cell line house mouse CVCL_6486 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male Characteristics: Derived from a SVEC4-10EHR1 induced ascite tumor (PubMed=8496612) 21085383 CVCL_6480 +/+ (B) finite cell line house mouse CVCL_6480 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6471; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085384 CVCL_5S80 GM23242 transformed cell line human CVCL_5S80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085385 CVCL_6481 10P12 transformed cell line house mouse CVCL_6481 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/cAn. Unspecified 21085386 CVCL_5S81 GM23243 transformed cell line human CVCL_5S81 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-44dup; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085387 CVCL_6482 10P2 transformed cell line house mouse CVCL_6482 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/cAn. Unspecified 21085388 CVCL_5S82 GM23244 transformed cell line human CVCL_5S82 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-44dup; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085389 CVCL_5S76 GM23159 transformed cell line human CVCL_5S76 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex17dup; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21085390 CVCL_6476 KTC-2 cancer cell line human CVCL_6476 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu490Ter (c.1468G>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 36 +- 3 hours (PubMed=12729473) 21085391 CVCL_5S77 GM23160 transformed cell line human CVCL_5S77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085392 CVCL_5S78 GM23161 transformed cell line human CVCL_5S78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085393 CVCL_6478 T235 cancer cell line human CVCL_6478 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21085394 CVCL_6479 +/+ (A) finite cell line house mouse CVCL_6479 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6470; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085395 CVCL_5S79 GM23235 transformed cell line human CVCL_5S79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085396 CVCL_XY99 A549 OS8 cancer cell line human CVCL_XY99 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains 21085397 CVCL_XY95 293T NF-kb luciferase reporter transformed cell line human CVCL_XY95 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: The luciferase reporter gene is under the control of the NF-kappaB response element Doubling time: ~30 hours (KYinno) 21085398 CVCL_XY96 293T rabbit CSF1R transformed cell line human CVCL_XY96 CL:0000010 Transfected with: UniProtKB; G1TTE0; Rabbit CSF1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085399 CVCL_XY97 293T rat CSF1R transformed cell line human CVCL_XY97 CL:0000010 Transfected with: RGD; 2425; Csf1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085400 CVCL_XY98 293T rat GITR transformed cell line human CVCL_XY98 CL:0000010 Transfected with: RGD; 1565872; Tnfrsf18; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085401 CVCL_5S50 GM22993 transformed cell line human CVCL_5S50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085402 CVCL_6450 Sp2/01-Ag cancer cell line house mouse CVCL_6450 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8006 21085403 CVCL_5S51 GM22994 transformed cell line human CVCL_5S51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085404 CVCL_6451 SQMK-FP spontaneously immortalized cell line CVCL_6451 CL:0000010 Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21085405 CVCL_5S52 GM22995 transformed cell line human CVCL_5S52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085406 CVCL_6452 Super Dome spontaneously immortalized cell line dog CVCL_6452 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Dome-forming clone of MDCK 21085407 CVCL_5S53 GM22996 transformed cell line human CVCL_5S53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085408 CVCL_6453 Super Tube spontaneously immortalized cell line dog CVCL_6453 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Tubule-forming clone of MDCK 21085409 CVCL_5S47 GM22979 transformed cell line human CVCL_5S47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085410 CVCL_6447 SOB-15 spontaneously immortalized cell line CVCL_6447 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Shasta. Unspecified Group: Fish cell line 21085411 CVCL_5S48 GM22991 transformed cell line human CVCL_5S48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085412 CVCL_6448 SODk1 transformed cell line human CVCL_6448 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12386 21085413 CVCL_5S49 GM22992 transformed cell line human CVCL_5S49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085414 CVCL_6449 Sol8 finite cell line house mouse CVCL_6449 CL:0000010 Derived from sampling site: Leg; skeletal muscle; soleus; Breed/subspecies: C3H. Unspecified Characteristics: Will differentiate into myotubes with serum deprivation (ATCC) 21085415 CVCL_5S43 GM22963 transformed cell line human CVCL_5S43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085416 CVCL_6443 SaI/N cancer cell line house mouse CVCL_6443 CL:0000010 Transformant: Dibenz[a,h]anthracene (DBA)(ChEBI; CHEBI:35299). 21085417 CVCL_5S44 GM22972 transformed cell line human CVCL_5S44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085418 CVCL_6444 SC [Human contaminated U-937] cancer cell line human CVCL_6444 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00525; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9855 Problematic cell line: Contaminated On the basis of the STR profile it seems to be a U-937 derivative. 21085419 CVCL_5S45 GM22976 transformed cell line human CVCL_5S45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085420 CVCL_6445 SCA-9 clone 15 cancer cell line house mouse CVCL_6445 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Salivary gland; submandibular gland; Breed/subspecies: Swiss Webster. Male 21085421 CVCL_5S46 GM22977 transformed cell line human CVCL_5S46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085422 CVCL_6446 SML, clone 4D8 transformed cell line CVCL_6446 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21085423 CVCL_XY88 293T human CD25 transformed cell line human CVCL_XY88 CL:0000010 Transfected with: HGNC; 6008; IL2RA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085424 CVCL_XY89 293T human CD47 transformed cell line human CVCL_XY89 CL:0000010 Transfected with: HGNC; 1682; CD47; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085425 CVCL_XY84 293T dog CSF1R transformed cell line human CVCL_XY84 CL:0000010 Transfected with: VGNC; 39653; Dog CSF1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085426 CVCL_XY85 293T dog GITR transformed cell line human CVCL_XY85 CL:0000010 Transfected with: VGNC; 47660; Dog TNFRSF18; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085427 CVCL_XY86 293T human CSF1R transformed cell line human CVCL_XY86 CL:0000010 Transfected with: HGNC; 2433; CSF1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085428 CVCL_XY87 293T human CD137L transformed cell line human CVCL_XY87 CL:0000010 Transfected with: HGNC; 11939; TNFSF9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085429 CVCL_5S61 GM23007 transformed cell line human CVCL_5S61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085430 CVCL_6461 SYF transformed cell line house mouse CVCL_6461 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95602; Fyn; Knockout cell: Method=KO mouse; MGI; MGI:98397; Src; Knockout cell: Method=KO mouse; MGI; MGI:99147; Yes1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21085431 CVCL_5S62 GM23008 transformed cell line human CVCL_5S62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085432 CVCL_6462 UC1B spontaneously immortalized cell line house mouse CVCL_6462 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6465; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085433 CVCL_5S63 GM23010 transformed cell line human CVCL_5S63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085434 CVCL_6463 UC1BC1 spontaneously immortalized cell line house mouse CVCL_6463 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6460; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085435 CVCL_5S64 GM23011 transformed cell line human CVCL_5S64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085436 CVCL_6464 UC1BC2 spontaneously immortalized cell line house mouse CVCL_6464 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6461; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085437 CVCL_5S60 GM23006 transformed cell line human CVCL_5S60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085438 CVCL_6460 SWR/J.We finite cell line house mouse CVCL_6460 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: SWR/J. Discontinued: ATCC; CRL-6458; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085439 CVCL_5S58 GM23004 transformed cell line human CVCL_5S58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085440 CVCL_6458 SW10 transformed cell line house mouse CVCL_6458 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.; Breed/subspecies: C57BL/6J. Omics: SNP array analysis Characteristics: At the permissive temperature (33 Celsius) proliferates Does not proliferate at the restrictive temperature (37 Celsius). 21085441 CVCL_5S59 GM23005 transformed cell line human CVCL_5S59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085442 CVCL_6459 Swiss SFME spontaneously immortalized cell line house mouse CVCL_6459 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Unspecified Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9391 21085443 CVCL_5S54 GM22998 transformed cell line human CVCL_5S54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085444 CVCL_6454 SV40LT-SMC Clone HEP-SA transformed cell line Norway rat CVCL_6454 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Sprague Dawley. Unspecified 21085445 CVCL_5S55 GM23001 transformed cell line human CVCL_5S55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085446 CVCL_6455 SVR transformed cell line house mouse CVCL_6455 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS0317; true Unspecified 21085447 CVCL_5S56 GM23002 transformed cell line human CVCL_5S56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085448 CVCL_6456 SVR A221a transformed cell line house mouse CVCL_6456 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (with p.Ser222Ala); Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS0316; true Unspecified 21085449 CVCL_5S57 GM23003 transformed cell line human CVCL_5S57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085450 CVCL_6457 SVR bag4 transformed cell line house mouse CVCL_6457 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified 21085451 CVCL_XY91 293T human CLDN18.2-M4 transformed cell line human CVCL_XY91 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A2; with p.Ala42Ser, p.Asn45Gln, p.Gln47Glu and p.Gln56Glu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085452 CVCL_XY92 293T human PVR transformed cell line human CVCL_XY92 CL:0000010 Transfected with: HGNC; 9705; PVR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085453 CVCL_XY93 293T mouse CSF1R transformed cell line human CVCL_XY93 CL:0000010 Transfected with: MGI; MGI:1339758; Csf1r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085454 CVCL_XY94 293T mouse GITR transformed cell line human CVCL_XY94 CL:0000010 Transfected with: MGI; MGI:894675; Tnfrsf18; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085455 CVCL_XY90 293T human CLDN18.1-Flag transformed cell line human CVCL_XY90 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A1; with a C-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21085456 CVCL_GG60 ND11840 transformed cell line human CVCL_GG60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085457 CVCL_GG61 ND11841 transformed cell line human CVCL_GG61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085458 CVCL_GG62 ND11842 transformed cell line human CVCL_GG62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085459 CVCL_PA00 BayGenomics ES cell line RST084 embryonic stem cell house mouse CVCL_PA00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085460 CVCL_PA01 BayGenomics ES cell line RST085 embryonic stem cell house mouse CVCL_PA01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913522; Cox16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085461 CVCL_PA02 BayGenomics ES cell line RST086 embryonic stem cell house mouse CVCL_PA02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96743; Lamb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085462 CVCL_PA03 BayGenomics ES cell line RST087 embryonic stem cell house mouse CVCL_PA03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924301; Os9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085463 CVCL_PA04 BayGenomics ES cell line RST092 embryonic stem cell house mouse CVCL_PA04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085464 CVCL_GG56 ND11804 transformed cell line human CVCL_GG56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085465 CVCL_PA05 BayGenomics ES cell line RST097 embryonic stem cell house mouse CVCL_PA05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443272; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085466 CVCL_GG57 ND11812 transformed cell line human CVCL_GG57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085467 CVCL_PA06 BayGenomics ES cell line RST098 embryonic stem cell house mouse CVCL_PA06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085468 CVCL_GG58 ND11816 transformed cell line human CVCL_GG58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085469 CVCL_PA07 BayGenomics ES cell line RST100 embryonic stem cell house mouse CVCL_PA07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99892; Lama1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085470 CVCL_GG59 ND11839 transformed cell line human CVCL_GG59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085471 CVCL_PA08 BayGenomics ES cell line RST101 embryonic stem cell house mouse CVCL_PA08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104652; Capzb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085472 CVCL_GG52 ND11800 transformed cell line human CVCL_GG52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085473 CVCL_PA09 BayGenomics ES cell line RST102 embryonic stem cell house mouse CVCL_PA09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085474 CVCL_GG53 ND11801 transformed cell line human CVCL_GG53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085475 CVCL_GG54 ND11802 transformed cell line human CVCL_GG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085476 CVCL_GG55 ND11803 transformed cell line human CVCL_GG55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085477 CVCL_GG70 ND11874 transformed cell line human CVCL_GG70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085478 CVCL_GG71 ND11876 transformed cell line human CVCL_GG71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085479 CVCL_GG72 ND11890 transformed cell line human CVCL_GG72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085480 CVCL_GG73 ND11892 transformed cell line human CVCL_GG73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085481 CVCL_GG67 ND11864 transformed cell line human CVCL_GG67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085482 CVCL_GG68 ND11868 transformed cell line human CVCL_GG68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085483 CVCL_GG69 ND11873 transformed cell line human CVCL_GG69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085484 CVCL_GG63 ND11843 transformed cell line human CVCL_GG63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085485 CVCL_GG64 ND11857 transformed cell line human CVCL_GG64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085486 CVCL_GG65 ND11860 transformed cell line human CVCL_GG65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085487 CVCL_GG66 ND11861 transformed cell line human CVCL_GG66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085488 CVCL_GG40 ND11723 transformed cell line human CVCL_GG40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085489 CVCL_GG38 ND11721 transformed cell line human CVCL_GG38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085490 CVCL_GG39 ND11722 transformed cell line human CVCL_GG39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085491 CVCL_GG34 ND11666 transformed cell line human CVCL_GG34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085492 CVCL_GG35 ND11691 transformed cell line human CVCL_GG35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085493 CVCL_GG36 ND11693 transformed cell line human CVCL_GG36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085494 CVCL_GG37 ND11696 transformed cell line human CVCL_GG37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085495 CVCL_GG30 ND11655 transformed cell line human CVCL_GG30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085496 CVCL_GG31 ND11656 transformed cell line human CVCL_GG31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085497 CVCL_GG32 ND11660 transformed cell line human CVCL_GG32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085498 CVCL_GG33 ND11661 transformed cell line human CVCL_GG33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085499 CVCL_GG50 ND11787 transformed cell line human CVCL_GG50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085500 CVCL_GG51 ND11788 transformed cell line human CVCL_GG51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085501 CVCL_GG49 ND11786 transformed cell line human CVCL_GG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085502 CVCL_GG45 ND11752 transformed cell line human CVCL_GG45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085503 CVCL_GG46 ND11769 transformed cell line human CVCL_GG46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085504 CVCL_GG47 ND11770 transformed cell line human CVCL_GG47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085505 CVCL_GG48 ND11771 transformed cell line human CVCL_GG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085506 CVCL_GG41 ND11725 transformed cell line human CVCL_GG41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085507 CVCL_GG42 ND11726 transformed cell line human CVCL_GG42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085508 CVCL_GG43 ND11731 transformed cell line human CVCL_GG43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085509 CVCL_GG44 ND11733 transformed cell line human CVCL_GG44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085510 CVCL_GG16 ND11551 transformed cell line human CVCL_GG16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085511 CVCL_GG17 ND11559 transformed cell line human CVCL_GG17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085512 CVCL_GG18 ND11572 transformed cell line human CVCL_GG18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085513 CVCL_GG19 ND11576 transformed cell line human CVCL_GG19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085514 CVCL_GG12 ND11537 transformed cell line human CVCL_GG12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085515 CVCL_GG13 ND11546 transformed cell line human CVCL_GG13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085516 CVCL_GG14 ND11547 transformed cell line human CVCL_GG14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085517 CVCL_GG15 ND11550 transformed cell line human CVCL_GG15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085518 CVCL_GG10 ND11525 transformed cell line human CVCL_GG10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085519 CVCL_GG11 ND11535 transformed cell line human CVCL_GG11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085520 CVCL_GG27 ND11615 transformed cell line human CVCL_GG27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085521 CVCL_GG28 ND11623 transformed cell line human CVCL_GG28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085522 CVCL_GG29 ND11635 transformed cell line human CVCL_GG29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085523 CVCL_GG23 ND11602 transformed cell line human CVCL_GG23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085524 CVCL_GG24 ND11605 transformed cell line human CVCL_GG24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085525 CVCL_GG25 ND11607 transformed cell line human CVCL_GG25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085526 CVCL_GG26 ND11614 transformed cell line human CVCL_GG26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085527 CVCL_GG20 ND11577 transformed cell line human CVCL_GG20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085528 CVCL_GG21 ND11584 transformed cell line human CVCL_GG21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085529 CVCL_GG22 ND11588 transformed cell line human CVCL_GG22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085530 CVCL_GG09 ND11508 transformed cell line human CVCL_GG09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085531 CVCL_GG05 ND11458 transformed cell line human CVCL_GG05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085532 CVCL_GG06 ND11462 transformed cell line human CVCL_GG06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085533 CVCL_GG07 ND11501 transformed cell line human CVCL_GG07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085534 CVCL_GG08 ND11504 transformed cell line human CVCL_GG08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085535 CVCL_GG01 ND11450 transformed cell line human CVCL_GG01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085536 CVCL_GG02 ND11452 transformed cell line human CVCL_GG02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085537 CVCL_GG03 ND11455 transformed cell line human CVCL_GG03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085538 CVCL_GG04 ND11456 transformed cell line human CVCL_GG04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085539 CVCL_GG00 ND11443 transformed cell line human CVCL_GG00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085540 CVCL_PB90 BayGenomics ES cell line RST495 embryonic stem cell house mouse CVCL_PB90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096335; Adam17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085541 CVCL_PB91 BayGenomics ES cell line RST498 embryonic stem cell house mouse CVCL_PB91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108079; Sdf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085542 CVCL_PB92 BayGenomics ES cell line RST499 embryonic stem cell house mouse CVCL_PB92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085543 CVCL_PB93 BayGenomics ES cell line RST501 embryonic stem cell house mouse CVCL_PB93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085544 CVCL_PB94 BayGenomics ES cell line RST502 embryonic stem cell house mouse CVCL_PB94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96392; Icam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085545 CVCL_PB95 BayGenomics ES cell line RST503 embryonic stem cell house mouse CVCL_PB95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085546 CVCL_PB96 BayGenomics ES cell line RST504 embryonic stem cell house mouse CVCL_PB96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085547 CVCL_PB97 BayGenomics ES cell line RST505 embryonic stem cell house mouse CVCL_PB97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085548 CVCL_PB98 BayGenomics ES cell line RST507 embryonic stem cell house mouse CVCL_PB98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443399; Tmem131l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085549 CVCL_PB99 BayGenomics ES cell line RST510 embryonic stem cell house mouse CVCL_PB99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085550 CVCL_PB80 BayGenomics ES cell line RST474 embryonic stem cell house mouse CVCL_PB80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085551 CVCL_PB81 BayGenomics ES cell line RST475 embryonic stem cell house mouse CVCL_PB81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085552 CVCL_PB82 BayGenomics ES cell line RST477 embryonic stem cell house mouse CVCL_PB82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97783; Psap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085553 CVCL_PB83 BayGenomics ES cell line RST478 embryonic stem cell house mouse CVCL_PB83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927947; Selenof Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085554 CVCL_PB84 BayGenomics ES cell line RST483 embryonic stem cell house mouse CVCL_PB84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085555 CVCL_PB85 BayGenomics ES cell line RST485 embryonic stem cell house mouse CVCL_PB85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338881; St14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085556 CVCL_PB86 BayGenomics ES cell line RST488 embryonic stem cell house mouse CVCL_PB86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085557 CVCL_PB87 BayGenomics ES cell line RST489 embryonic stem cell house mouse CVCL_PB87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085558 CVCL_PB88 BayGenomics ES cell line RST490 embryonic stem cell house mouse CVCL_PB88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194508; Ddost Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085559 CVCL_PB89 BayGenomics ES cell line RST491 embryonic stem cell house mouse CVCL_PB89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914111; Dnajc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085560 CVCL_PB70 BayGenomics ES cell line RST455 embryonic stem cell house mouse CVCL_PB70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085561 CVCL_PB71 BayGenomics ES cell line RST456 embryonic stem cell house mouse CVCL_PB71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95640; Gapdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085562 CVCL_PB72 BayGenomics ES cell line RST458 embryonic stem cell house mouse CVCL_PB72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085563 CVCL_PB73 BayGenomics ES cell line RST462 embryonic stem cell house mouse CVCL_PB73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932040; Sil1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085564 CVCL_PB74 BayGenomics ES cell line RST463 embryonic stem cell house mouse CVCL_PB74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3763743; Snhg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085565 CVCL_PB75 BayGenomics ES cell line RST464 embryonic stem cell house mouse CVCL_PB75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085566 CVCL_PB76 BayGenomics ES cell line RST465 embryonic stem cell house mouse CVCL_PB76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085567 CVCL_PB77 BayGenomics ES cell line RST467 embryonic stem cell house mouse CVCL_PB77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085568 CVCL_PB78 BayGenomics ES cell line RST470 embryonic stem cell house mouse CVCL_PB78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88108; Atp1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085569 CVCL_PB79 BayGenomics ES cell line RST471 embryonic stem cell house mouse CVCL_PB79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347007; Plod2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085570 CVCL_PB60 BayGenomics ES cell line RST436 embryonic stem cell house mouse CVCL_PB60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914325; Magt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085571 CVCL_PB61 BayGenomics ES cell line RST437 embryonic stem cell house mouse CVCL_PB61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085572 CVCL_PB62 BayGenomics ES cell line RST438 embryonic stem cell house mouse CVCL_PB62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914325; Magt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085573 CVCL_PB63 BayGenomics ES cell line RST440 embryonic stem cell house mouse CVCL_PB63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101357; Ece1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085574 CVCL_PB64 BayGenomics ES cell line RST442 embryonic stem cell house mouse CVCL_PB64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085575 CVCL_PB65 BayGenomics ES cell line RST445 embryonic stem cell house mouse CVCL_PB65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085576 CVCL_PB66 BayGenomics ES cell line RST448 embryonic stem cell house mouse CVCL_PB66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085577 CVCL_PB67 BayGenomics ES cell line RST450 embryonic stem cell house mouse CVCL_PB67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914705; Klhl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085578 CVCL_PB68 BayGenomics ES cell line RST453 embryonic stem cell house mouse CVCL_PB68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139220; Tm9sf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085579 CVCL_PB69 BayGenomics ES cell line RST454 embryonic stem cell house mouse CVCL_PB69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085580 CVCL_PB50 BayGenomics ES cell line RST423 embryonic stem cell house mouse CVCL_PB50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96522; Rbpj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085581 CVCL_PB51 BayGenomics ES cell line RST424 embryonic stem cell house mouse CVCL_PB51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085582 CVCL_PB52 BayGenomics ES cell line RST426 embryonic stem cell house mouse CVCL_PB52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921867; Scpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085583 CVCL_PB53 BayGenomics ES cell line RST428 embryonic stem cell house mouse CVCL_PB53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98084; Rpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085584 CVCL_PB54 BayGenomics ES cell line RST429 embryonic stem cell house mouse CVCL_PB54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104902; Gpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085585 CVCL_PB55 BayGenomics ES cell line RST430 embryonic stem cell house mouse CVCL_PB55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855698; Reck Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085586 CVCL_PB56 BayGenomics ES cell line RST431 embryonic stem cell house mouse CVCL_PB56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923549; Erp44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085587 CVCL_PB57 BayGenomics ES cell line RST433 embryonic stem cell house mouse CVCL_PB57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085588 CVCL_PB58 BayGenomics ES cell line RST434 embryonic stem cell house mouse CVCL_PB58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916863; Pofut2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085589 CVCL_PB59 BayGenomics ES cell line RST435 embryonic stem cell house mouse CVCL_PB59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085590 CVCL_PB40 BayGenomics ES cell line RST408 embryonic stem cell house mouse CVCL_PB40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96435; Igf2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085591 CVCL_PB41 BayGenomics ES cell line RST409 embryonic stem cell house mouse CVCL_PB41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085592 CVCL_PB42 BayGenomics ES cell line RST411 embryonic stem cell house mouse CVCL_PB42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918917; Tmem248 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085593 CVCL_PB43 BayGenomics ES cell line RST412 embryonic stem cell house mouse CVCL_PB43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106653; Epcam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085594 CVCL_PB44 BayGenomics ES cell line RST413 embryonic stem cell house mouse CVCL_PB44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106653; Epcam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085595 CVCL_PB45 BayGenomics ES cell line RST416 embryonic stem cell house mouse CVCL_PB45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085596 CVCL_PB46 BayGenomics ES cell line RST417 embryonic stem cell house mouse CVCL_PB46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309516; Tpst2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085597 CVCL_PB47 BayGenomics ES cell line RST418 embryonic stem cell house mouse CVCL_PB47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085598 CVCL_GH99 ND12612 transformed cell line human CVCL_GH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085599 CVCL_PB48 BayGenomics ES cell line RST421 embryonic stem cell house mouse CVCL_PB48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085600 CVCL_PB49 BayGenomics ES cell line RST422 embryonic stem cell house mouse CVCL_PB49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923549; Erp44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085601 CVCL_GH95 ND12593 transformed cell line human CVCL_GH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085602 CVCL_GH96 ND12601 transformed cell line human CVCL_GH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085603 CVCL_GH97 ND12603 transformed cell line human CVCL_GH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085604 CVCL_GH98 ND12604 transformed cell line human CVCL_GH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085605 CVCL_PB30 BayGenomics ES cell line RST390 embryonic stem cell house mouse CVCL_PB30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924015; Mlec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085606 CVCL_PB31 BayGenomics ES cell line RST395 embryonic stem cell house mouse CVCL_PB31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085607 CVCL_PB32 BayGenomics ES cell line RST396 embryonic stem cell house mouse CVCL_PB32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085608 CVCL_PB33 BayGenomics ES cell line RST397 embryonic stem cell house mouse CVCL_PB33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085609 CVCL_PB34 BayGenomics ES cell line RST398 embryonic stem cell house mouse CVCL_PB34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194891; Gpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085610 CVCL_PB35 BayGenomics ES cell line RST399 embryonic stem cell house mouse CVCL_PB35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890373; Cemip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085611 CVCL_PB36 BayGenomics ES cell line RST401 embryonic stem cell house mouse CVCL_PB36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96677; Kit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085612 CVCL_PB37 BayGenomics ES cell line RST403 embryonic stem cell house mouse CVCL_PB37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085613 CVCL_PB38 BayGenomics ES cell line RST406 embryonic stem cell house mouse CVCL_PB38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106906; Eif4a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085614 CVCL_PB39 BayGenomics ES cell line RST407 embryonic stem cell house mouse CVCL_PB39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085615 CVCL_6670 LS174T-HM7 cancer cell line human CVCL_6670 HLA typing: A*30:01,30:01; B*15:34,35:03; C*04:01,06:02; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces high amount of mucin in culture (PubMed=3664476) 21085616 CVCL_5U70 TR-BBB1 conditionally immortalized cell line Norway rat CVCL_5U70 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Capillary endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085617 CVCL_6671 MC/CAR-Z2 transformed cell line human CVCL_6671 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~20-24 hours (ATCC=CRL-8147) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8147 Problematic cell line: Misclassified Parent cell line (MC/CAR) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21085618 CVCL_5U71 TR-BBB5 conditionally immortalized cell line Norway rat CVCL_5U71 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Capillary endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085619 CVCL_6672 MCF-7M cancer cell line human CVCL_6672 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: 1.4 days (PubMed=9671407) 21085620 CVCL_5U72 TR-BBB6 conditionally immortalized cell line Norway rat CVCL_5U72 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Capillary endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085621 CVCL_6673 MCF-7N cancer cell line human CVCL_6673 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21085622 CVCL_5U73 TR-BBB11 conditionally immortalized cell line Norway rat CVCL_5U73 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Capillary endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085623 CVCL_6667 LAH2 spontaneously immortalized cell line CVCL_6667 CL:0000010 Derived from sampling site: Skin Cell type=Amelanotic melanocyte.; Breed/subspecies: KM stock. Discontinued: RCB; RCB1735; true Unspecified Doubling time: 7.7 days, at 39th passage (DOI=10.2108/zsj.18.483) Group: Amphibian cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00569 Problematic cell line: Misidentified/contaminated Originally thought to be of Pelophylax nigromaculatus origin but found to be from Pelophylax porosus brevipodus. LAH2 may be identical to LAH3 (Cellosaurus=CVCL_6668) (RCB). 21085624 CVCL_5U67 TR-iBRB6 conditionally immortalized cell line Norway rat CVCL_5U67 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085625 CVCL_6668 LAH3 spontaneously immortalized cell line CVCL_6668 CL:0000010 Derived from sampling site: Skin Cell type=Amelanotic melanocyte.; Breed/subspecies: BR stock. Unspecified Doubling time: 3.7 days, at 113th passage (DOI=10.2108/zsj.18.483) Group: Amphibian cell line 21085626 CVCL_5U68 TR-iBRB8 conditionally immortalized cell line Norway rat CVCL_5U68 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085627 CVCL_6669 DLM8 cancer cell line house mouse CVCL_6669 CL:0000010 Breed/subspecies: C3H/HeJ. Omics: Transcriptome analysis by microarray Female Characteristics: Highly metastatic to lung (PubMed=9579581) Doubling time: 13 hours (PubMed=9579581) 21085628 CVCL_5U69 TR-iBRB9 conditionally immortalized cell line Norway rat CVCL_5U69 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085629 CVCL_6663 KK-1 [Mouse granulosa] transformed cell line house mouse CVCL_6663 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Inha-promoter TAg transgenic. Female 21085630 CVCL_5U63 TR-BME clone 2 conditionally immortalized cell line Norway rat CVCL_5U63 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Female 21085631 CVCL_6664 KK-3 transformed cell line house mouse CVCL_6664 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; Breed/subspecies: Inha-promoter TAg transgenic. Female 21085632 CVCL_5U64 TR-BME clone 3 conditionally immortalized cell line Norway rat CVCL_5U64 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Female 21085633 CVCL_6665 L5178Y TK+/- (clone 3.7.2C) cancer cell line house mouse CVCL_6665 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Discontinued: JCRB; FDSC0053; true Female Doubling time: ~10 hours (lot 02052008) (JCRB) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9518 21085634 CVCL_5U65 TR-BME clone 8 conditionally immortalized cell line Norway rat CVCL_5U65 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Female 21085635 CVCL_6666 LAH1 spontaneously immortalized cell line CVCL_6666 CL:0000010 Derived from sampling site: Skin Cell type=Melanotic melanocyte.. Discontinued: RCB; RCB1733; true Unspecified Doubling time: 28.8 days, at 33th passage (DOI=10.2108/zsj.18.483) Group: Amphibian cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00568 Problematic cell line: Misidentified/contaminated Originally thought to be of Pelophylax nigromaculatus origin but found to be from Bufo japonicus formosus (RCB). 21085636 CVCL_5U66 TR-iBRB4 conditionally immortalized cell line Norway rat CVCL_5U66 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085637 CVCL_6681 MCF10CA1d.cl2 transformed cell line human CVCL_6681 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085638 CVCL_5U81 RMC1 cancer cell line Norway rat CVCL_5U81 CL:0000010 Breed/subspecies: Sprague Dawley. Female 21085639 CVCL_6682 MCF10CA1d.cl3 transformed cell line human CVCL_6682 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085640 CVCL_5U82 PCC4 [Mouse lung papillary tumor] cancer cell line house mouse CVCL_5U82 CL:0000010 Derived from sampling site: Lung Cell type=Club cell.; Breed/subspecies: BALB/cJ. 21085641 CVCL_5U83 C3H/HeN-emb finite cell line house mouse CVCL_5U83 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H/HeN Jcl. Unspecified 21085642 CVCL_6683 MCF10CA1h transformed cell line human CVCL_6683 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: CNV analysis; Omics: Deep proteome analysis Female 21085643 CVCL_5U84 C57BL/6J-emb finite cell line house mouse CVCL_5U84 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C57BL/6J. Unspecified 21085644 CVCL_6684 MDA-MB-435HGF cancer cell line human CVCL_6684 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Ancestral cell line (MDA-MB-435) has been shown to be a M14 derivative. 21085645 CVCL_6680 MCF10CA1d.cl1 transformed cell line human CVCL_6680 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085646 CVCL_5U80 TR-MUL4 conditionally immortalized cell line Norway rat CVCL_5U80 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085647 CVCL_6678 MCF10CA1c transformed cell line human CVCL_6678 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085648 CVCL_5U78 TR-MUL2 conditionally immortalized cell line Norway rat CVCL_5U78 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085649 CVCL_6679 MCF10CA1d transformed cell line human CVCL_6679 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085650 CVCL_5U79 TR-MUL3 conditionally immortalized cell line Norway rat CVCL_5U79 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085651 CVCL_6674 MCF-7TN-R cancer cell line human CVCL_6674 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21085652 CVCL_5U74 TR-BBB13 conditionally immortalized cell line Norway rat CVCL_5U74 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Capillary endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085653 CVCL_6675 MCF10CA1a transformed cell line human CVCL_6675 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: CNV analysis; Omics: Glycoproteome analysis by proteomics Female 21085654 CVCL_5U75 TR-rPCT2 conditionally immortalized cell line Norway rat CVCL_5U75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085655 CVCL_6676 MCF10CA1a.cl1 transformed cell line human CVCL_6676 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: Deep proteome analysis Female 21085656 CVCL_5U76 TR-rPCT5 conditionally immortalized cell line Norway rat CVCL_5U76 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085657 CVCL_6677 MCF10CA1b transformed cell line human CVCL_6677 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21085658 CVCL_5U77 TR-MUL1 conditionally immortalized cell line Norway rat CVCL_5U77 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21085659 CVCL_6650 HNS1A spontaneously immortalized cell line CVCL_6650 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 21085660 CVCL_5U50 RSC3-E2 cancer cell line Norway rat CVCL_5U50 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Fischer 344. Male 21085661 CVCL_6651 HNS2 spontaneously immortalized cell line CVCL_6651 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 21085662 CVCL_5U51 RSC3-LM cancer cell line Norway rat CVCL_5U51 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Fischer 344. Male 21085663 CVCL_6645 HGP53 transformed cell line human CVCL_6645 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: MGI; MGI:98834; Trp53 (with p.Ala132Val) Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085664 CVCL_5U45 RLT-3C cancer cell line Norway rat CVCL_5U45 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (PubMed=2872200) 21085665 CVCL_6646 HMB-2 cancer cell line human CVCL_6646 CL:0000010 Derived from metastatic site: Axillary lymph node. Female Doubling time: 36-49 hours (PubMed=3065655); 47.3 hours (PubMed=6819484) 21085666 CVCL_5U46 RLT-5G cancer cell line Norway rat CVCL_5U46 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Female Doubling time: 30 hours (PubMed=2872200) 21085667 CVCL_6647 HLaC-78 cancer cell line human CVCL_6647 CL:0000010 Derived from metastatic site: Neck. Male 21085668 CVCL_5U47 RLT-9F cancer cell line Norway rat CVCL_5U47 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Female Doubling time: 72 hours (PubMed=2872200) 21085669 CVCL_6648 HLaC-79 cancer cell line human CVCL_6648 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191) Derived from metastatic site: Cervical lymph node. Male 21085670 CVCL_5U48 Rca-B cancer cell line Norway rat CVCL_5U48 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Sprague Dawley. Male Doubling time: 26.34 hours (at 21th passage), 25.44 hours (at 65th passage) (Patent=CN101469320A; PubMed=18001591); 25.09 hours (PubMed=26605681) 21085671 CVCL_5U41 EGV-6T transformed cell line Norway rat CVCL_5U41 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Trachea; Breed/subspecies: Fischer 344. Male 21085672 CVCL_6641 PAGRS-28 transformed cell line Norway rat CVCL_6641 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085673 CVCL_5U42 C-1509 cancer cell line human CVCL_5U42 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 25-38 hours, at 25th passage (DOI=10.5795/jjscc.29.509) 21085674 CVCL_6642 HEK293-F transformed cell line human CVCL_6642 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21085675 CVCL_6643 HEK293-H transformed cell line human CVCL_6643 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21085676 CVCL_5U43 RLC-10 finite cell line Norway rat CVCL_5U43 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Female 21085677 CVCL_6644 HGL5 transformed cell line human CVCL_6644 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 96 hours, at 75th passage (PubMed=8126145) 21085678 CVCL_5U44 RLT-2M cancer cell line Norway rat CVCL_5U44 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Female Doubling time: 33 hours (PubMed=2872200) 21085679 CVCL_6649 HLaC-82 cancer cell line human CVCL_6649 CL:0000010 21085680 CVCL_5U49 UHG-RaC '93 cancer cell line Norway rat CVCL_5U49 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Wistar. Male Doubling time: 25 hours (PubMed=7586205) 21085681 CVCL_6660 JC-410 spontaneously immortalized cell line pig CVCL_6660 CL:0000010 Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 67 hours (PubMed=9584843) 21085682 CVCL_5U60 LCSC-6 cancer cell line Norway rat CVCL_5U60 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21085683 CVCL_6661 JHSK-rec cancer cell line human CVCL_6661 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Male 21085684 CVCL_5U61 RBL-01 finite cell line Norway rat CVCL_5U61 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Urothelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 1.033 +- 0.292 days (PubMed=2936252) 21085685 CVCL_6662 K:Molv NIH/3T3 transformed cell line house mouse CVCL_6662 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085686 CVCL_5U62 RLCNR cancer cell line Norway rat CVCL_5U62 CL:0000010 Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Lung; Breed/subspecies: Wistar. Male 21085687 CVCL_6656 HTOG cancer cell line human CVCL_6656 CL:0000010 Population: Japanese; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: Established from the granulosa cells of a granulosa-theca cell tumor Doubling time: 46.2 hours (at 5th passage), 28.4 hours (at 20th passage), 23.8 hours (at 40th passage) (PubMed=6323807); 25 hours (PubMed=10457904) 21085688 CVCL_5U56 LCSC-2 cancer cell line Norway rat CVCL_5U56 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21085689 CVCL_6657 HTOT cancer cell line human CVCL_6657 CL:0000010 Population: Japanese; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: Established from the theca cells of a granulosa-theca cell tumor Doubling time: 78 hours (PubMed=6323807) 21085690 CVCL_5U57 LCSC-3 cancer cell line Norway rat CVCL_5U57 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21085691 CVCL_6658 IA-5 cancer cell line human CVCL_6658 CL:0000010 Population: Japanese; Derived from metastatic site: Skin. Male 21085692 CVCL_5U58 LCSC-4 cancer cell line Norway rat CVCL_5U58 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21085693 CVCL_6659 11-18 cancer cell line human CVCL_6659 HLA typing: A*02:01,24:02; B*52:01,54:01; C*01:02,12:01 (PubMed=9023415) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Unspecified (PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Unspecified 21085694 CVCL_5U59 LCSC-5 cancer cell line Norway rat CVCL_5U59 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21085695 CVCL_6652 HNS3 spontaneously immortalized cell line CVCL_6652 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Amphibian cell line 21085696 CVCL_5U52 RSC3-E2R cancer cell line Norway rat CVCL_5U52 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Fischer 344. Male 21085697 CVCL_6653 HNS4 spontaneously immortalized cell line CVCL_6653 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 21085698 CVCL_5U53 HSM-1 cancer cell line human CVCL_5U53 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21085699 CVCL_5U54 CGCCA cancer cell line Norway rat CVCL_5U54 CL:0000010 Breed/subspecies: Sprague Dawley. Male 21085700 CVCL_6654 HNS5 spontaneously immortalized cell line CVCL_6654 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Amphibian cell line 21085701 CVCL_6655 HSOGT cancer cell line human CVCL_6655 CL:0000010 Population: Japanese; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 18.9 hours (PubMed=15005243) 21085702 CVCL_5U55 LCSC-1 cancer cell line Norway rat CVCL_5U55 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male Doubling time: 18 hours (CelloPub=CLPUB00282) 21085703 CVCL_6623 DM122 cancer cell line human CVCL_6623 HLA typing: A*03,33; B*07,18 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21085704 CVCL_5U23 GM09209 finite cell line human CVCL_5U23 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CNV analysis Male 21085705 CVCL_6624 DM281 cancer cell line human CVCL_6624 From: Duke University Medical Center; Durham; USA. CL:0000010 21085706 CVCL_5U24 GM09210 finite cell line human CVCL_5U24 CL:0000010 Derived from sampling site: Fetal testis Cell type=Fibroblast.. Male 21085707 CVCL_6625 DM319 cancer cell line human CVCL_6625 From: Duke University Medical Center; Durham; USA. CL:0000010 21085708 CVCL_5U25 GM12507 finite cell line human CVCL_5U25 CL:0000010 Discontinued: Coriell; GM12507; probable. Male 21085709 CVCL_6626 DM331 cancer cell line human CVCL_6626 HLA typing: A*01,02; B*15,62 (PubMed=10752474) From: Duke University Medical Center; Durham; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Right axillary lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray 21085710 CVCL_5U26 GM21261 transformed cell line human CVCL_5U26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085711 CVCL_6620 DC3 [Rat granulosa] transformed cell line Norway rat CVCL_6620 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Holtzman Sprague Dawley. Female 21085712 CVCL_5U20 GM06097 finite cell line human CVCL_5U20 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Female 21085713 CVCL_6621 DM13 cancer cell line human CVCL_6621 HLA typing: A*02,31; B*13,18 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray 21085714 CVCL_5U21 GM06248 finite cell line human CVCL_5U21 CL:0000010 Sequence variation: Mutation; HGNC; 399; ALB; Simple; c.714-2A>G (IVS6AS,A-G,-2); ClinVar=VCV000018210; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=3353369) Population: Native North American; Salish; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21085715 CVCL_6622 DM14 [Human melanoma] cancer cell line human CVCL_6622 HLA typing: A*11,68; B*05,08; C*02,04 (PubMed=10752474) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21085716 CVCL_5U22 GM09208 finite cell line human CVCL_5U22 CL:0000010 Derived from sampling site: Fetal diaphragm; skeletal muscle Cell type=Fibroblast.. Male 21085717 CVCL_6627 DM472 cancer cell line human CVCL_6627 From: Duke University Medical Center; Durham; USA. CL:0000010 21085718 CVCL_5U27 GM21496 transformed cell line human CVCL_5U27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085719 CVCL_6628 DM6 cancer cell line human CVCL_6628 HLA typing: A*02:01; B*12,13; C*01,02 (PubMed=10752474) From: Duke University Medical Center; Durham; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Characteristics: Pigmented Microsatellite instability: Stable (MSS) (PubMed=19147755) 21085720 CVCL_5U28 L.14 factor-dependent cell line house mouse CVCL_5U28 CL:0000010 Derived from sampling site: Cell type=Helper T-cell; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent; Characteristics: Recognizes the terpolymer Glu60-Ala30-Tyr10 (GAT) 21085721 CVCL_5U29 Ca761-86 cancer cell line house mouse CVCL_5U29 CL:0000010 Breed/subspecies: 615. Female 21085722 CVCL_6629 DM93 cancer cell line human CVCL_6629 HLA typing: A*02:01,33; B*08,49 (PubMed=10752474) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Characteristics: Pigmented 21085723 CVCL_5U40 EGV-5T transformed cell line Norway rat CVCL_5U40 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Trachea; Breed/subspecies: Fischer 344. Male 21085724 CVCL_6640 PAGRS-21 transformed cell line Norway rat CVCL_6640 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085725 CVCL_6634 GC48C hybrid cell line Norway rat CVCL_6634 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Holtzman Sprague Dawley. Female 21085726 CVCL_5U34 JB6 Cl 25 spontaneously immortalized cell line house mouse CVCL_5U34 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21085727 CVCL_6635 GFSHR-17 transformed cell line Norway rat CVCL_6635 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: RGD; 2632; Fshr Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085728 CVCL_5U35 NMuMG-ST transformed cell line house mouse CVCL_5U35 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female 21085729 CVCL_6636 GLHR-15 transformed cell line Norway rat CVCL_6636 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: RGD; 3007; Lhcgr Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085730 CVCL_5U36 HSDM1 cancer cell line house mouse CVCL_5U36 CL:0000010 Breed/subspecies: Swiss albino. 21085731 CVCL_6637 GRM01 transformed cell line house mouse CVCL_6637 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: NMRI. Female 21085732 CVCL_5U37 HSDM1C3 cancer cell line house mouse CVCL_5U37 CL:0000010 Breed/subspecies: Swiss albino. 21085733 CVCL_5U30 Ca761-P93 cancer cell line house mouse CVCL_5U30 CL:0000010 Breed/subspecies: 615. Female 21085734 CVCL_6630 G1SV1 transformed cell line CVCL_6630 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Group: Non-human primate cell line 21085735 CVCL_6631 Gbeta2AR13 transformed cell line Norway rat CVCL_6631 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 286; ADRB2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085736 CVCL_5U31 MCa3F transformed cell line house mouse CVCL_5U31 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. 21085737 CVCL_6632 GC1a transformed cell line human CVCL_6632 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21085738 CVCL_5U32 SN161 cancer cell line house mouse CVCL_5U32 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from metastatic site: Lymph node; Breed/subspecies: 129 x NIH Swiss. 21085739 CVCL_6633 GC-2spd(ts) conditionally immortalized cell line house mouse CVCL_6633 CL:0000010 Transfected with: MGI; MGI:98834; Trp53 (with p.Ala132Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatocyte.; Breed/subspecies: BALB/c. Male 21085740 CVCL_5U33 R681 transformed cell line house mouse CVCL_5U33 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21085741 CVCL_5U38 EGV-10T transformed cell line Norway rat CVCL_5U38 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Trachea; Breed/subspecies: Fischer 344. Male 21085742 CVCL_6638 GRM01L transformed cell line house mouse CVCL_6638 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: NMRI. Female 21085743 CVCL_5U39 EGV-3T transformed cell line Norway rat CVCL_5U39 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Trachea; Breed/subspecies: Fischer 344. Male 21085744 CVCL_6639 GRM02 transformed cell line house mouse CVCL_6639 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: NMRI. Female 21085745 CVCL_6601 CHLA-185 cancer cell line human CVCL_6601 CL:0000010 21085746 CVCL_5U01 UCW 181 spontaneously immortalized cell line CVCL_5U01 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21085747 CVCL_6602 CHLA-20 cancer cell line human CVCL_6602 CL:0000010 Female Doubling time: 28 hours (COG). 21085748 CVCL_5U02 UCW 282 transformed cell line CVCL_5U02 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female 21085749 CVCL_6603 CHLA-42 cancer cell line human CVCL_6603 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21085750 CVCL_5U03 UCW 296 transformed cell line CVCL_5U03 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female 21085751 CVCL_6604 CHLA-51 cancer cell line human CVCL_6604 CL:0000010 21085752 CVCL_5U04 HHW661 hybrid cell line human CVCL_5U04 CL:0000010 Miscellaneous: Indicated in PubMed=2945430 to be derived from UCW 56, but in PubMed=1663488 it is said to be derived from UCW 113 (Cellosaurus=CVCL_5T99). Characteristics: Hybrid for chromosome 4 mapping Group: Human/rodent somatic cell hybrid 21085753 CVCL_6600 CHLA-179 cancer cell line human CVCL_6600 CL:0000010 Male 21085754 CVCL_5U00 UCW 124 spontaneously immortalized cell line CVCL_5U00 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21085755 CVCL_6609 CHLA-8 cancer cell line human CVCL_6609 CL:0000010 21085756 CVCL_5U09 HHW878 hybrid cell line human CVCL_5U09 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085757 CVCL_6605 CHLA-52 cancer cell line human CVCL_6605 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 88 hours (COG) 21085758 CVCL_5U05 HHW693 hybrid cell line human CVCL_5U05 CL:0000010 Anecdotal: Was used to find the Huntington disease gene (HD). Characteristics: Hybrid for chromosome 4 mapping Group: Human/rodent somatic cell hybrid 21085759 CVCL_6606 CHLA-54 cancer cell line human CVCL_6606 CL:0000010 21085760 CVCL_5U06 HHW832 hybrid cell line human CVCL_5U06 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085761 CVCL_6607 CHLA-60 cancer cell line human CVCL_6607 CL:0000010 Male Doubling time: 96 hours (COG). 21085762 CVCL_5U07 HHW842 hybrid cell line human CVCL_5U07 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21085763 CVCL_6608 CHLA-79 cancer cell line human CVCL_6608 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071). Unspecified 21085764 CVCL_5U08 HHW847 hybrid cell line human CVCL_5U08 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21085765 CVCL_6612 CHLA-98 cancer cell line human CVCL_6612 CL:0000010 Male 21085766 CVCL_5U12 HHW892 hybrid cell line human CVCL_5U12 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21085767 CVCL_6613 CHP-901 cancer cell line human CVCL_6613 From: Ikegaki N.; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago; Chicago; USA CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH Male 21085768 CVCL_5U13 HHW1064 hybrid cell line human CVCL_5U13 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085769 CVCL_6614 CHP-902 cancer cell line human CVCL_6614 From: Kuroda H.; Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 Unspecified 21085770 CVCL_5U14 HHW1118 hybrid cell line human CVCL_5U14 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085771 CVCL_6615 CHP-902R cancer cell line human CVCL_6615 CL:0000010 Omics: Array-based CGH. Unspecified 21085772 CVCL_5U15 HHW1421 hybrid cell line human CVCL_5U15 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085773 CVCL_6610 CHLA-90 cancer cell line human CVCL_6610 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Unspecified (PubMed=11507071). Male Doubling time: 52 hours (PubMed=20922763); 59 hours (COG) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21085774 CVCL_5U10 HHW882 hybrid cell line human CVCL_5U10 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085775 CVCL_6611 CHLA-95 cancer cell line human CVCL_6611 CL:0000010 Female 21085776 CVCL_5U11 HHW886 hybrid cell line human CVCL_5U11 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21085777 CVCL_6616 CHP-903 cancer cell line human CVCL_6616 From: Ikegaki N.; Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago; Chicago; USA CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH Female 21085778 CVCL_5U16 HHW1499 hybrid cell line human CVCL_5U16 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085779 CVCL_6617 Co403 transformed cell line human CVCL_6617 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Coronary artery Cell type=Coronary artery smooth muscle cell.. 21085780 CVCL_5U17 HHW1600 hybrid cell line human CVCL_5U17 CL:0000010 Group: Human/rodent somatic cell hybrid. 21085781 CVCL_6618 CSMalphabeta1h cancer cell line house mouse CVCL_6618 CL:0000010 Transfected with: HGNC; 1885; CGA; Transfected with: HGNC; 1886; CGB3 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8401 21085782 CVCL_5U18 GM14213 transformed cell line human CVCL_5U18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085783 CVCL_6619 CSMalphabeta6C cancer cell line house mouse CVCL_6619 CL:0000010 Transfected with: HGNC; 1885; CGA; Transfected with: HGNC; 1886; CGB3 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8400 21085784 CVCL_5U19 GM06047 finite cell line human CVCL_5U19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21085785 CVCL_GH08 ND12067 transformed cell line human CVCL_GH08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085786 CVCL_GH09 ND12085 transformed cell line human CVCL_GH09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085787 CVCL_GH04 ND12016 transformed cell line human CVCL_GH04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085788 CVCL_GH05 ND12039 transformed cell line human CVCL_GH05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085789 CVCL_GH06 ND12040 transformed cell line human CVCL_GH06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085790 CVCL_GH07 ND12057 transformed cell line human CVCL_GH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085791 CVCL_GH00 ND11985 transformed cell line human CVCL_GH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085792 CVCL_GH01 ND12009 transformed cell line human CVCL_GH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085793 CVCL_GH02 ND12010 transformed cell line human CVCL_GH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085794 CVCL_GH03 ND12013 transformed cell line human CVCL_GH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085795 CVCL_6593 CHLA-143 cancer cell line human CVCL_6593 CL:0000010 21085796 CVCL_5T93 HT-1 [Human lymphoma] cancer cell line human CVCL_5T93 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Doubling time: ~51 hours (PubMed=1310890) 21085797 CVCL_5T94 C30.1 line 1 factor-dependent cell line house mouse CVCL_5T94 CL:0000010 Derived from sampling site: Cell type=Cytotoxic T-cell. Characteristics: IL2 or IL4 dependent 21085798 CVCL_6594 CHLA-15 cancer cell line human CVCL_6594 CL:0000010 Omics: Deep exome analysis. Female Doubling time: 21 hours (COG) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21085799 CVCL_6595 CHLA-152 cancer cell line human CVCL_6595 CL:0000010 21085800 CVCL_5T95 RME-5-3-1 spontaneously immortalized cell line house mouse CVCL_5T95 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: C3H/He. Unspecified 21085801 CVCL_6596 CHLA-153 cancer cell line human CVCL_6596 CL:0000010 21085802 CVCL_5T96 LRD cancer cell line house mouse CVCL_5T96 CL:0000010 Breed/subspecies: C3H/J. 21085803 CVCL_5T90 BFL-5 finite cell line CVCL_5T90 CL:0000010 Miscellaneous: Breed from personal communication of Talbot N.C Derived from sampling site: Fetal liver Cell type=Hepatocyte.; Breed/subspecies: Holstein. Unspecified Characteristics: Requires feeder cells 21085804 CVCL_6590 CHLA-136 cancer cell line human CVCL_6590 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071). Female Doubling time: 53 hours (PubMed=20922763); 44 hours (COG) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21085805 CVCL_5T91 BFL-7 finite cell line CVCL_5T91 CL:0000010 Miscellaneous: Breed from personal communication of Talbot N.C Derived from sampling site: Fetal liver Cell type=Hepatocyte.; Breed/subspecies: Holstein. Unspecified Characteristics: Requires feeder cells 21085806 CVCL_6591 CHLA-138 cancer cell line human CVCL_6591 CL:0000010 21085807 CVCL_6592 CHLA-140 cancer cell line human CVCL_6592 CL:0000010 Male 21085808 CVCL_5T92 HT-2 factor-dependent cell line house mouse CVCL_5T92 CL:0000010 Breed/subspecies: BALB/c. Characteristics: IL2 dependent 21085809 CVCL_6586 CHLA-108 cancer cell line human CVCL_6586 CL:0000010 21085810 CVCL_5T86 PCC1 cancer cell line house mouse CVCL_5T86 CL:0000010 Breed/subspecies: 129/Sv. Male 21085811 CVCL_6587 CHLA-124 cancer cell line human CVCL_6587 CL:0000010 21085812 CVCL_5T87 PCC2 cancer cell line house mouse CVCL_5T87 CL:0000010 Breed/subspecies: 129/Sv. Male 21085813 CVCL_6588 CHLA-132 cancer cell line human CVCL_6588 CL:0000010 21085814 CVCL_5T88 mKS-A TU-5 transformed cell line house mouse CVCL_5T88 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. 21085815 CVCL_6589 CHLA-134 cancer cell line human CVCL_6589 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071). 21085816 CVCL_5T89 UE8 spontaneously immortalized cell line house mouse CVCL_5T89 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Embryonic uterus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 x CBA Trp53-/-. Female 21085817 CVCL_6597 CHLA-171 cancer cell line human CVCL_6597 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071). Male 21085818 CVCL_5T97 ME [Mouse teratocarcinoma] cancer cell line house mouse CVCL_5T97 CL:0000010 Breed/subspecies: C3H/J. Unspecified 21085819 CVCL_6598 CHLA-174 cancer cell line human CVCL_6598 CL:0000010 21085820 CVCL_5T98 RBM1 [Human renal cell carcinoma] cancer cell line human CVCL_5T98 CL:0000010 Derived from metastatic site: Bone; left humerus. Male Doubling time: 32 hours (PubMed=12131367) 21085821 CVCL_6599 CHLA-178 cancer cell line human CVCL_6599 CL:0000010 21085822 CVCL_5T99 UCW 113 spontaneously immortalized cell line CVCL_5T99 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21085823 CVCL_6571 VM7Luc4E2 cancer cell line human CVCL_6571 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Biotechnology: Cell line developed for VM7Luc ER TA (VM7Luc Estrogen Receptor TransActivation) bioassay which was formerly known as BG1Luc ER TA (BG1Luc Estrogen Receptor TransActivation); Biotechnology: Used in the Organisation for Economic Co-operation and Development (OECD) detection of estrogenic/antiestrogenic chemicals test method 457 (DOI=10.1787/9789264185395-en) Female Characteristics: Emits measurable light in response to estrogen and estrogen-like substances Used for identifying estrogen receptor agonists and antagonists.; Characteristics: Acts through the activation of a luciferase reporter gene under the control of estrogen response elements (EREs) upstream of the mouse mammary tumor viral (MMTV) promoter Problematic cell line: Contaminated Shown to be a MCF-7 derivative (https://tsar.jrc.ec.europa.eu/test-method/tm2016-09). Originally thought to be a BG1 (Cellosaurus=CVCL_6570) derivative. 21085824 CVCL_5T71 BgV transformed cell line house mouse CVCL_5T71 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2b. Unspecified 21085825 CVCL_6572 BGC-1 spontaneously immortalized cell line CVCL_6572 CL:0000010 Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 23.5 hours (PubMed=2170405) 21085826 CVCL_5T72 KKA transformed cell line house mouse CVCL_5T72 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2k. Unspecified 21085827 CVCL_6573 BJ1-hTERT telomerase immortalized cell line human CVCL_6573 Genome ancestry: African=0.29%; Native American=0.6%; East Asian, North=1.01%; East Asian, South=0%; South Asian=0.05%; European, North=73.33%; European, South=24.72% (PubMed=30894373) CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Doubling time: 36 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21085828 CVCL_5T73 KgV transformed cell line house mouse CVCL_5T73 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2k. Unspecified 21085829 CVCL_6574 BJMC338 cancer cell line house mouse CVCL_6574 CL:0000010 Breed/subspecies: BALB/c. Female 21085830 CVCL_5T74 M5/CDDP cancer cell line house mouse CVCL_5T74 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: C57BL/6. Female 21085831 CVCL_6570 BG1 cancer cell line human CVCL_6570 CL:0000010 Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00456 Problematic cell line: Partially contaminated Some stocks are contaminated by MCF-7 (PubMed=22710073; PubMed=25321415). 21085832 CVCL_5T70 MDA-MB-435s-mKate2 cancer cell line human CVCL_5T70 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21085833 CVCL_6568 BEL-7404 cancer cell line human CVCL_6568 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700064) It was the sole source for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 26 hours (PubMed=6154311) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00550 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 69 year old male patient with a hepatocellular carcinoma. 21085834 CVCL_5T68 PICM-19H spontaneously immortalized cell line pig CVCL_5T68 CL:0000010 Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified Characteristics: Requires feeder cells 21085835 CVCL_6569 BEL-7405 cancer cell line human CVCL_6569 CL:0000010 Population: Chinese Omics: Transcriptome analysis by microarray. Female Doubling time: 23 hours (PubMed=6154311) 21085836 CVCL_5T69 PICM-19FF spontaneously immortalized cell line pig CVCL_5T69 CL:0000010 Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified Characteristics: Does not require feeder cells 21085837 CVCL_6564 AKR/JA.Sp finite cell line house mouse CVCL_6564 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: AKR/J. Discontinued: ATCC; CRL-6320; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21085838 CVCL_5T64 GM50324 transformed cell line human CVCL_5T64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085839 CVCL_6565 AKR1.G.1.OUAR.1.26 cancer cell line house mouse CVCL_6565 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085840 CVCL_5T65 GM10946 transformed cell line human CVCL_5T65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21085841 CVCL_6566 CGT-6 cancer cell line house mouse CVCL_6566 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: RGD; 3705; Slc2a2 Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11285 21085842 CVCL_5T66 GM20087 transformed cell line human CVCL_5T66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21085843 CVCL_6567 BC3A cancer cell line house mouse CVCL_6567 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085844 CVCL_5T67 PICM-19B spontaneously immortalized cell line pig CVCL_5T67 CL:0000010 Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified Characteristics: Requires feeder cells 21085845 CVCL_6582 C166-GFP spontaneously immortalized cell line house mouse CVCL_6582 CL:0000010 Transfected with: HGNC; 3657; FES; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Yolk sac; Breed/subspecies: NMRI/GSF x CD-1 transgenic. Unspecified 21085846 CVCL_5T82 MG20 transformed cell line house mouse CVCL_5T82 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: Tga20. Unspecified 21085847 CVCL_6583 CHLA-10 cancer cell line human CVCL_6583 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: scRNAseq analysis. Female Doubling time: 24 hours (PubMed=20922763); 32 hours (PubMed=24312454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21085848 CVCL_5T83 SIKR cancer cell line house mouse CVCL_5T83 CL:0000010 Breed/subspecies: 129/Sv-SlJ-CP. Male 21085849 CVCL_6584 CHLA-101 cancer cell line human CVCL_6584 CL:0000010 21085850 CVCL_5T84 SIKR-OSB cancer cell line house mouse CVCL_5T84 CL:0000010 Breed/subspecies: 129/Sv-SlJ-CP. Male 21085851 CVCL_6585 CHLA-103 cancer cell line human CVCL_6585 CL:0000010 21085852 CVCL_5T85 PCC3 cancer cell line house mouse CVCL_5T85 CL:0000010 Breed/subspecies: 129/Sv. Male 21085853 CVCL_6580 C127:LT cancer cell line house mouse CVCL_6580 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21085854 CVCL_5T80 RIN-5F-CrmA cancer cell line Norway rat CVCL_5T80 CL:0000010 Transfected with: UniProtKB; P07385; Cowpox virus crmA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 21085855 CVCL_6581 C166 spontaneously immortalized cell line house mouse CVCL_6581 CL:0000010 Transfected with: HGNC; 3657; FES Derived from sampling site: Yolk sac; Breed/subspecies: NMRI/GSF x CD-1 transgenic. Omics: SNP array analysis Unspecified 21085856 CVCL_5T81 UM-Chor2 cancer cell line human CVCL_5T81 CL:0000010 Derived from sampling site: Bone; spine. Male 21085857 CVCL_6579 C-8052 cancer cell line house mouse CVCL_6579 CL:0000010 Breed/subspecies: C3H/He. Male 21085858 CVCL_5T79 RIN-5F-Bcl-2 cancer cell line Norway rat CVCL_5T79 CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 21085859 CVCL_6575 BJMC3879 cancer cell line house mouse CVCL_6575 CL:0000010 Breed/subspecies: BALB/c. Female 21085860 CVCL_5T75 M5/CDDPc cancer cell line house mouse CVCL_5T75 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: C57BL/6. Female 21085861 CVCL_6576 BLK CL.4 spontaneously immortalized cell line house mouse CVCL_6576 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS) Discontinued: RCB; RCB2656; true; Discontinued: TKG; TKG 0472; probable Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085862 CVCL_5T76 MDA-MB-231/B02 cancer cell line human CVCL_5T76 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Cell surface proteome Female Group: Triple negative breast cancer (TNBC) cell line 21085863 CVCL_5T77 B02/GFP.2 cancer cell line human CVCL_5T77 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21085864 CVCL_6577 BLK SV HD.2 A.5R.1 A.3R.1 transformed cell line house mouse CVCL_6577 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21085865 CVCL_6578 C-8049 cancer cell line house mouse CVCL_6578 CL:0000010 Breed/subspecies: C3H/He. Male 21085866 CVCL_5T78 M12 [Human melanoma] cancer cell line human CVCL_5T78 CL:0000010 Male 21085867 CVCL_GH80 ND12512 transformed cell line human CVCL_GH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085868 CVCL_GH81 ND12513 transformed cell line human CVCL_GH81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085869 CVCL_GH82 ND12514 transformed cell line human CVCL_GH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085870 CVCL_GH83 ND12515 transformed cell line human CVCL_GH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085871 CVCL_PB20 BayGenomics ES cell line RST373 embryonic stem cell house mouse CVCL_PB20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085872 CVCL_PB21 BayGenomics ES cell line RST376 embryonic stem cell house mouse CVCL_PB21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085873 CVCL_PB22 BayGenomics ES cell line RST377 embryonic stem cell house mouse CVCL_PB22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97004; Mme Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085874 CVCL_PB23 BayGenomics ES cell line RST380 embryonic stem cell house mouse CVCL_PB23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106419; Itfg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085875 CVCL_PB24 BayGenomics ES cell line RST382 embryonic stem cell house mouse CVCL_PB24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085876 CVCL_PB25 BayGenomics ES cell line RST383 embryonic stem cell house mouse CVCL_PB25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926810; Tmeff1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085877 CVCL_GH77 ND12495 transformed cell line human CVCL_GH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085878 CVCL_PB26 BayGenomics ES cell line RST385 embryonic stem cell house mouse CVCL_PB26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085879 CVCL_GH78 ND12496 transformed cell line human CVCL_GH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085880 CVCL_PB27 BayGenomics ES cell line RST387 embryonic stem cell house mouse CVCL_PB27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085881 CVCL_GH79 ND12498 transformed cell line human CVCL_GH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085882 CVCL_PB28 BayGenomics ES cell line RST388 embryonic stem cell house mouse CVCL_PB28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085883 CVCL_PB29 BayGenomics ES cell line RST389 embryonic stem cell house mouse CVCL_PB29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108076; Frrs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085884 CVCL_GH73 ND12489 transformed cell line human CVCL_GH73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085885 CVCL_GH74 ND12490 transformed cell line human CVCL_GH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085886 CVCL_GH75 ND12493 transformed cell line human CVCL_GH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085887 CVCL_GH76 ND12494 transformed cell line human CVCL_GH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085888 CVCL_GH91 ND12568 transformed cell line human CVCL_GH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085889 CVCL_GH92 ND12571 transformed cell line human CVCL_GH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085890 CVCL_GH93 ND12574 transformed cell line human CVCL_GH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085891 CVCL_GH94 ND12585 transformed cell line human CVCL_GH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085892 CVCL_GH90 ND12567 transformed cell line human CVCL_GH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085893 CVCL_PB10 BayGenomics ES cell line RST325 embryonic stem cell house mouse CVCL_PB10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927235; Mbtps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085894 CVCL_PB11 BayGenomics ES cell line RST337 embryonic stem cell house mouse CVCL_PB11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923206; Srrm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085895 CVCL_PB12 BayGenomics ES cell line RST338 embryonic stem cell house mouse CVCL_PB12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860765; Extl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085896 CVCL_PB13 BayGenomics ES cell line RST339 embryonic stem cell house mouse CVCL_PB13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085897 CVCL_PB14 BayGenomics ES cell line RST341 embryonic stem cell house mouse CVCL_PB14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085898 CVCL_GH88 ND12559 transformed cell line human CVCL_GH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085899 CVCL_PB15 BayGenomics ES cell line RST343 embryonic stem cell house mouse CVCL_PB15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3603204; Piezo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085900 CVCL_GH89 ND12565 transformed cell line human CVCL_GH89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085901 CVCL_PB16 BayGenomics ES cell line RST350 embryonic stem cell house mouse CVCL_PB16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085902 CVCL_PB17 BayGenomics ES cell line RST353 embryonic stem cell house mouse CVCL_PB17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103268; Dnajc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085903 CVCL_PB18 BayGenomics ES cell line RST355 embryonic stem cell house mouse CVCL_PB18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3652219; Zfp345 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085904 CVCL_GH84 ND12516 transformed cell line human CVCL_GH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085905 CVCL_PB19 BayGenomics ES cell line RST357 embryonic stem cell house mouse CVCL_PB19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891468; Lgr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085906 CVCL_GH85 ND12519 transformed cell line human CVCL_GH85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085907 CVCL_GH86 ND12522 transformed cell line human CVCL_GH86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085908 CVCL_GH87 ND12532 transformed cell line human CVCL_GH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085909 CVCL_GH60 ND12362 transformed cell line human CVCL_GH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085910 CVCL_GH61 ND12371 transformed cell line human CVCL_GH61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085911 CVCL_GH59 ND12361 transformed cell line human CVCL_GH59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085912 CVCL_PB00 BayGenomics ES cell line RST297 embryonic stem cell house mouse CVCL_PB00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143702; Enpp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085913 CVCL_PB01 BayGenomics ES cell line RST302 embryonic stem cell house mouse CVCL_PB01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085914 CVCL_PB02 BayGenomics ES cell line RST303 embryonic stem cell house mouse CVCL_PB02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085915 CVCL_PB03 BayGenomics ES cell line RST308 embryonic stem cell house mouse CVCL_PB03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085916 CVCL_GH55 ND12324 transformed cell line human CVCL_GH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085917 CVCL_PB04 BayGenomics ES cell line RST313 embryonic stem cell house mouse CVCL_PB04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345162; Adam23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085918 CVCL_GH56 ND12346 transformed cell line human CVCL_GH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085919 CVCL_PB05 BayGenomics ES cell line RST316 embryonic stem cell house mouse CVCL_PB05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95797; Gpi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085920 CVCL_GH57 ND12356 transformed cell line human CVCL_GH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085921 CVCL_PB06 BayGenomics ES cell line RST317 embryonic stem cell house mouse CVCL_PB06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96435; Igf2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085922 CVCL_GH58 ND12359 transformed cell line human CVCL_GH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085923 CVCL_PB07 BayGenomics ES cell line RST319 embryonic stem cell house mouse CVCL_PB07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085924 CVCL_GH51 ND12297 transformed cell line human CVCL_GH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085925 CVCL_PB08 BayGenomics ES cell line RST321 embryonic stem cell house mouse CVCL_PB08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914217; Edem3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085926 CVCL_GH52 ND12313 transformed cell line human CVCL_GH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085927 CVCL_PB09 BayGenomics ES cell line RST323 embryonic stem cell house mouse CVCL_PB09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21085928 CVCL_GH53 ND12320 transformed cell line human CVCL_GH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085929 CVCL_GH54 ND12323 transformed cell line human CVCL_GH54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085930 CVCL_GH70 ND12454 transformed cell line human CVCL_GH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085931 CVCL_GH71 ND12458 transformed cell line human CVCL_GH71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085932 CVCL_GH72 ND12483 transformed cell line human CVCL_GH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085933 CVCL_GH66 ND12385 transformed cell line human CVCL_GH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085934 CVCL_GH67 ND12386 transformed cell line human CVCL_GH67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085935 CVCL_GH68 ND12395 transformed cell line human CVCL_GH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085936 CVCL_GH69 ND12424 transformed cell line human CVCL_GH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085937 CVCL_GH62 ND12372 transformed cell line human CVCL_GH62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085938 CVCL_GH63 ND12377 transformed cell line human CVCL_GH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085939 CVCL_GH64 ND12383 transformed cell line human CVCL_GH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085940 CVCL_GH65 ND12384 transformed cell line human CVCL_GH65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085941 CVCL_GH37 ND12235 transformed cell line human CVCL_GH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085942 CVCL_GH38 ND12240 transformed cell line human CVCL_GH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085943 CVCL_GH39 ND12241 transformed cell line human CVCL_GH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085944 CVCL_GH33 ND12201 transformed cell line human CVCL_GH33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085945 CVCL_GH34 ND12222 transformed cell line human CVCL_GH34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085946 CVCL_GH35 ND12224 transformed cell line human CVCL_GH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085947 CVCL_GH36 ND12225 transformed cell line human CVCL_GH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085948 CVCL_GH30 ND12183 transformed cell line human CVCL_GH30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085949 CVCL_GH31 ND12192 transformed cell line human CVCL_GH31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085950 CVCL_GH32 ND12193 transformed cell line human CVCL_GH32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085951 CVCL_GH50 ND12285 transformed cell line human CVCL_GH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085952 CVCL_GH48 ND12273 transformed cell line human CVCL_GH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085953 CVCL_GH49 ND12280 transformed cell line human CVCL_GH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085954 CVCL_GH44 ND12260 transformed cell line human CVCL_GH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085955 CVCL_GH45 ND12261 transformed cell line human CVCL_GH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085956 CVCL_GH46 ND12265 transformed cell line human CVCL_GH46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085957 CVCL_GH47 ND12271 transformed cell line human CVCL_GH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085958 CVCL_GH40 ND12242 transformed cell line human CVCL_GH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085959 CVCL_GH41 ND12250 transformed cell line human CVCL_GH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085960 CVCL_GH42 ND12251 transformed cell line human CVCL_GH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085961 CVCL_GH43 ND12253 transformed cell line human CVCL_GH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085962 CVCL_GH19 ND12143 transformed cell line human CVCL_GH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085963 CVCL_GH15 ND12129 transformed cell line human CVCL_GH15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085964 CVCL_GH16 ND12133 transformed cell line human CVCL_GH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085965 CVCL_GH17 ND12137 transformed cell line human CVCL_GH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085966 CVCL_GH18 ND12141 transformed cell line human CVCL_GH18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085967 CVCL_GH11 ND12091 transformed cell line human CVCL_GH11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085968 CVCL_GH12 ND12109 transformed cell line human CVCL_GH12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085969 CVCL_GH13 ND12118 transformed cell line human CVCL_GH13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085970 CVCL_GH14 ND12125 transformed cell line human CVCL_GH14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085971 CVCL_GH10 ND12087 transformed cell line human CVCL_GH10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085972 CVCL_GH26 ND12157 transformed cell line human CVCL_GH26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085973 CVCL_GH27 ND12160 transformed cell line human CVCL_GH27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085974 CVCL_GH28 ND12173 transformed cell line human CVCL_GH28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085975 CVCL_GH29 ND12181 transformed cell line human CVCL_GH29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085976 CVCL_GH22 ND12148 transformed cell line human CVCL_GH22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085977 CVCL_GH23 ND12149 transformed cell line human CVCL_GH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085978 CVCL_GH24 ND12151 transformed cell line human CVCL_GH24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085979 CVCL_GH25 ND12156 transformed cell line human CVCL_GH25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085980 CVCL_GH20 ND12145 transformed cell line human CVCL_GH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21085981 CVCL_GH21 ND12147 transformed cell line human CVCL_GH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21085982 CVCL_5V00 A5GR1 transformed cell line house mouse CVCL_5V00 CL:0000010 Transfected with: RGD; 2741; Nr3c1 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21085983 CVCL_6700 NR6W spontaneously immortalized cell line house mouse CVCL_6700 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21085984 CVCL_5V01 LM1 [Mouse lung adenoma] cancer cell line house mouse CVCL_5V01 CL:0000010 Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: A/J. 21085985 CVCL_6701 OCL-1 cancer cell line human CVCL_6701 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21085986 CVCL_5V02 LM2 cancer cell line house mouse CVCL_5V02 CL:0000010 Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: A/J. 21085987 CVCL_6702 OCL-3 cancer cell line human CVCL_6702 CL:0000010 Miscellaneous: Not listed anywhere else than in PubMed=19501511. Female 21085988 CVCL_5V03 Line 1 cancer cell line house mouse CVCL_5V03 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: BALB/c. Female 21085989 CVCL_6703 OSE10 sv transformed cell line human CVCL_6703 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 21.3 hours (PubMed=11277643) 21085990 CVCL_5V08 HAC50 cancer cell line human CVCL_5V08 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female 21085991 CVCL_6708 OSE6 sv transformed cell line human CVCL_6708 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 26.1 hours (PubMed=11277643) 21085992 CVCL_5V09 HAC13 cancer cell line human CVCL_5V09 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female 21085993 CVCL_6709 OSE7 sv transformed cell line human CVCL_6709 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 29.9 hours (PubMed=11277643) 21085994 CVCL_5V04 NAL1A clone C4SE9 transformed cell line house mouse CVCL_5V04 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Omics: Proteome analysis by 2D-DE/MS Female 21085995 CVCL_6704 OSE2a sv transformed cell line human CVCL_6704 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 33.1 hours (PubMed=11277643) 21085996 CVCL_5V05 EC9706 clone EC1 cancer cell line human CVCL_5V05 CL:0000010 Derived from sampling site: Esophagus. Male 21085997 CVCL_6705 OSE2b sv transformed cell line human CVCL_6705 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 26.1 hours (PubMed=11277643) 21085998 CVCL_5V06 EC9706 clone EC2 cancer cell line human CVCL_5V06 CL:0000010 Derived from sampling site: Esophagus. Male 21085999 CVCL_6706 OSE2b-2 sv transformed cell line human CVCL_6706 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21086000 CVCL_5V07 EC9706 clone EC3 cancer cell line human CVCL_5V07 CL:0000010 Derived from sampling site: Esophagus. Male 21086001 CVCL_6707 OSE4 sv transformed cell line human CVCL_6707 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-8-16](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 29.1 hours (PubMed=11277643) 21086002 CVCL_6711 PA-GRS1 transformed cell line Norway rat CVCL_6711 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21086003 CVCL_5V11 REN-2 cancer cell line Norway rat CVCL_5V11 CL:0000010 Breed/subspecies: Nb. Male 21086004 CVCL_6712 PCCL3 spontaneously immortalized cell line Norway rat CVCL_6712 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: BCRJ; 0204; probable Unspecified 21086005 CVCL_5V12 tsa-N11 transformed cell line Norway rat CVCL_5V12 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Pytsa](NCBI-Taxonomy; 1891730); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer. Unspecified 21086006 CVCL_5V13 CAL-23 [Human melanoma] cancer cell line human CVCL_5V13 CL:0000010 Unspecified Doubling time: 53 hours (PubMed=2145926). 21086007 CVCL_6713 PGC-2 spontaneously immortalized cell line pig CVCL_6713 CL:0000010 Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21086008 CVCL_5V14 CAL-24 cancer cell line human CVCL_5V14 CL:0000010 Unspecified Doubling time: 61 hours (PubMed=2145926). 21086009 CVCL_5V10 REN-1 cancer cell line Norway rat CVCL_5V10 CL:0000010 Breed/subspecies: Nb. Male 21086010 CVCL_5V19 GM14942 transformed cell line human CVCL_5V19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086011 CVCL_6719 RCSN-3 transformed cell line Norway rat CVCL_6719 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Brain; substantia nigra; Breed/subspecies: Fischer 344. Doubling time: 52 hours (PubMed=11299314) 21086012 CVCL_5V15 CAL-9 [Human ovarian carcinoma] cancer cell line human CVCL_5V15 CL:0000010 Female Doubling time: 54 hours (PubMed=2145926). 21086013 CVCL_6715 QGY-7703 cancer cell line human CVCL_6715 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700043) It was the sole source for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 20.5 hours (PubMed=6280941) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00552 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 35 year old female patient with hepatocellular carcinoma. 21086014 CVCL_5V16 CAL-41 cancer cell line human CVCL_5V16 CL:0000010 Unspecified Doubling time: 96 hours (PubMed=2145926). 21086015 CVCL_6716 Rao-gcl-29 transformed cell line Norway rat CVCL_6716 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Sprague Dawley. Female 21086016 CVCL_5V17 CAL-2 cancer cell line human CVCL_5V17 CL:0000010 Female Doubling time: 48 hours (PubMed=2145926). 21086017 CVCL_6717 RAW 264.7/LR5 cancer cell line house mouse CVCL_6717 CL:0000010 Transfected with: UniProtKB; P03023; Escherichia coli lacI Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21086018 CVCL_5V18 GM14940 transformed cell line human CVCL_5V18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086019 CVCL_6718 RC4 spontaneously immortalized cell line CVCL_6718 CL:0000010 Derived from sampling site: Eye; cornea. 21086020 CVCL_PC90 BayGenomics ES cell line RST732 embryonic stem cell house mouse CVCL_PC90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921867; Scpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086021 CVCL_PC91 BayGenomics ES cell line RST733 embryonic stem cell house mouse CVCL_PC91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086022 CVCL_PC92 BayGenomics ES cell line RST734 embryonic stem cell house mouse CVCL_PC92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086023 CVCL_PC93 BayGenomics ES cell line RST735 embryonic stem cell house mouse CVCL_PC93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086024 CVCL_PC94 BayGenomics ES cell line RST736 embryonic stem cell house mouse CVCL_PC94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086025 CVCL_PC95 BayGenomics ES cell line RST737 embryonic stem cell house mouse CVCL_PC95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086026 CVCL_PC96 BayGenomics ES cell line RST738 embryonic stem cell house mouse CVCL_PC96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109207; Eif4g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086027 CVCL_PC97 BayGenomics ES cell line RST743 embryonic stem cell house mouse CVCL_PC97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086028 CVCL_PC98 BayGenomics ES cell line RST744 embryonic stem cell house mouse CVCL_PC98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086029 CVCL_PC99 BayGenomics ES cell line RST749 embryonic stem cell house mouse CVCL_PC99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086030 CVCL_PC80 BayGenomics ES cell line RST691 embryonic stem cell house mouse CVCL_PC80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086031 CVCL_PC81 BayGenomics ES cell line RST693 embryonic stem cell house mouse CVCL_PC81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107804; Tuba1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086032 CVCL_PC82 BayGenomics ES cell line RST696 embryonic stem cell house mouse CVCL_PC82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086033 CVCL_PC83 BayGenomics ES cell line RST703 embryonic stem cell house mouse CVCL_PC83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086034 CVCL_PC84 BayGenomics ES cell line RST705 embryonic stem cell house mouse CVCL_PC84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086035 CVCL_PC85 BayGenomics ES cell line RST707 embryonic stem cell house mouse CVCL_PC85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086036 CVCL_PC86 BayGenomics ES cell line RST718 embryonic stem cell house mouse CVCL_PC86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086037 CVCL_PC87 BayGenomics ES cell line RST719 embryonic stem cell house mouse CVCL_PC87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086038 CVCL_PC88 BayGenomics ES cell line RST725 embryonic stem cell house mouse CVCL_PC88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086039 CVCL_PC89 BayGenomics ES cell line RST727 embryonic stem cell house mouse CVCL_PC89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341830; Eif2ak3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086040 CVCL_PC70 BayGenomics ES cell line RST669 embryonic stem cell house mouse CVCL_PC70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086041 CVCL_PC71 BayGenomics ES cell line RST670 embryonic stem cell house mouse CVCL_PC71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87904; Actb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086042 CVCL_PC72 BayGenomics ES cell line RST671 embryonic stem cell house mouse CVCL_PC72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87904; Actb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086043 CVCL_PC73 BayGenomics ES cell line RST672 embryonic stem cell house mouse CVCL_PC73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97388; Nucb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086044 CVCL_PC74 BayGenomics ES cell line RST673 embryonic stem cell house mouse CVCL_PC74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086045 CVCL_PC75 BayGenomics ES cell line RST676 embryonic stem cell house mouse CVCL_PC75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086046 CVCL_PC76 BayGenomics ES cell line RST677 embryonic stem cell house mouse CVCL_PC76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086047 CVCL_PC77 BayGenomics ES cell line RST681 embryonic stem cell house mouse CVCL_PC77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086048 CVCL_PC78 BayGenomics ES cell line RST688 embryonic stem cell house mouse CVCL_PC78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086049 CVCL_PC79 BayGenomics ES cell line RST689 embryonic stem cell house mouse CVCL_PC79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086050 CVCL_PC60 BayGenomics ES cell line RST653 embryonic stem cell house mouse CVCL_PC60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086051 CVCL_PC61 BayGenomics ES cell line RST654 embryonic stem cell house mouse CVCL_PC61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086052 CVCL_PC62 BayGenomics ES cell line RST655 embryonic stem cell house mouse CVCL_PC62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924059; Bri3bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086053 CVCL_PC63 BayGenomics ES cell line RST656 embryonic stem cell house mouse CVCL_PC63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443718; Lrig2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086054 CVCL_PC64 BayGenomics ES cell line RST657 embryonic stem cell house mouse CVCL_PC64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95298; Eif1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086055 CVCL_PC65 BayGenomics ES cell line RST658 embryonic stem cell house mouse CVCL_PC65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086056 CVCL_PC66 BayGenomics ES cell line RST659 embryonic stem cell house mouse CVCL_PC66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923159; Vmp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086057 CVCL_PC67 BayGenomics ES cell line RST664 embryonic stem cell house mouse CVCL_PC67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87904; Actb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086058 CVCL_PC68 BayGenomics ES cell line RST665 embryonic stem cell house mouse CVCL_PC68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385850; Nomo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086059 CVCL_PC69 BayGenomics ES cell line RST667 embryonic stem cell house mouse CVCL_PC69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139714; Adgrl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086060 CVCL_PC50 BayGenomics ES cell line RST639 embryonic stem cell house mouse CVCL_PC50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086061 CVCL_PC51 BayGenomics ES cell line RST640 embryonic stem cell house mouse CVCL_PC51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086062 CVCL_PC52 BayGenomics ES cell line RST641 embryonic stem cell house mouse CVCL_PC52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086063 CVCL_PC53 BayGenomics ES cell line RST642 embryonic stem cell house mouse CVCL_PC53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086064 CVCL_PC54 BayGenomics ES cell line RST643 embryonic stem cell house mouse CVCL_PC54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086065 CVCL_PC55 BayGenomics ES cell line RST646 embryonic stem cell house mouse CVCL_PC55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915096; Tmem39a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086066 CVCL_PC56 BayGenomics ES cell line RST647 embryonic stem cell house mouse CVCL_PC56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108050; Ext2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086067 CVCL_PC57 BayGenomics ES cell line RST648 embryonic stem cell house mouse CVCL_PC57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086068 CVCL_PC58 BayGenomics ES cell line RST651 embryonic stem cell house mouse CVCL_PC58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086069 CVCL_PC59 BayGenomics ES cell line RST652 embryonic stem cell house mouse CVCL_PC59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086070 CVCL_5V91 GM15106 transformed cell line human CVCL_5V91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086071 CVCL_6791 WM1617 cancer cell line human CVCL_6791 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell line WM278); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748) Derived from metastatic site: Right axillary lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00076; probable Female Part of: Wistar Institute melanoma cell line collection 21086072 CVCL_5V92 GM15118 transformed cell line human CVCL_5V92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086073 CVCL_6792 WM1789 cancer cell line human CVCL_6792 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Ser363Phe (c.1088C>T); Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Glu (c.1801A>G); ClinVar=VCV000013966; Zygosity=Homozygous (Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00080; probable Male Part of: Wistar Institute melanoma cell line collection 21086074 CVCL_5V93 GM15119 transformed cell line human CVCL_5V93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086075 CVCL_6793 WM1791C cancer cell line human CVCL_6793 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Thr50Ile (c.149_150delinsTT); Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Glu62Lys (c.184G>A); Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00086; probable Male Part of: Wistar Institute melanoma cell line collection 21086076 CVCL_5V94 GM15120 transformed cell line human CVCL_5V94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086077 CVCL_6794 WM1922 cancer cell line human CVCL_6794 CL:0000010 Discontinued: Coriell; WC00093; probable. Male Part of: Wistar Institute melanoma cell line collection 21086078 CVCL_5V90 GM15105 transformed cell line human CVCL_5V90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086079 CVCL_6790 WM1382 cancer cell line human CVCL_6790 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Unspecified (PubMed=24576830) Derived from metastatic site: Axillary lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00055; probable Female Part of: Wistar Institute melanoma cell line collection 21086080 CVCL_5V88 GM15103 transformed cell line human CVCL_5V88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086081 CVCL_6788 WM1361A cancer cell line human CVCL_6788 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445; Wistar) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00075; probable. Male Part of: Wistar Institute melanoma cell line collection 21086082 CVCL_5V89 GM15104 transformed cell line human CVCL_5V89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086083 CVCL_6789 WM1366 cancer cell line human CVCL_6789 HLA typing: A*32:01,32:01; B*41:01,41:01; C*17:01,17:01; DPB1*03:01,03:01; DQB1*02:01,02:01; DRB1*03:01:02,03:01:02 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro48Leu (c.143C>T); Zygosity=Unspecified (PubMed=17260012); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; PubMed=25645078; PubMed=25728708; Wistar); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from sampling site: Forearm; skin. Omics: Array-based CGH; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; WC00078; probable Male Part of: MD Anderson Cell Lines Project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21086084 CVCL_5V84 GM15098 transformed cell line human CVCL_5V84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086085 CVCL_6784 tsc2 ang1 cancer cell line house mouse CVCL_6784 CL:0000010 21086086 CVCL_5V85 GM15100 transformed cell line human CVCL_5V85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086087 CVCL_6785 WM1158 cancer cell line human CVCL_6785 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15009714; Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00046; probable Male Part of: Wistar Institute melanoma cell line collection 21086088 CVCL_5V86 GM15101 transformed cell line human CVCL_5V86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086089 CVCL_6786 WM1232 cancer cell line human CVCL_6786 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00084; probable. Female Part of: Wistar Institute melanoma cell line collection 21086090 CVCL_5V87 GM15102 transformed cell line human CVCL_5V87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086091 CVCL_6787 WM1341D cancer cell line human CVCL_6787 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Heterozygous (Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00096; probable Male Part of: Wistar Institute melanoma cell line collection 21086092 CVCL_5V99 GM15126 transformed cell line human CVCL_5V99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086093 CVCL_6799 WM3670 cancer cell line human CVCL_6799 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Glu (c.1406G>A) (p.Gly509Glu, c.1526G>A); ClinVar=VCV000013974; Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00119; probable Unspecified Part of: MD Anderson Cell Lines Project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21086094 CVCL_5V95 GM15121 transformed cell line human CVCL_5V95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086095 CVCL_6795 WM239A cancer cell line human CVCL_6795 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=15009714; Wistar) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00044; probable Female Part of: Wistar Institute melanoma cell line collection 21086096 CVCL_5V96 GM15122 transformed cell line human CVCL_5V96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086097 CVCL_6796 WM3060 cancer cell line human CVCL_6796 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=25056119; Wistar); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (PubMed=25056119) Derived from metastatic site: Left axillary lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00126; probable Male Part of: Wistar Institute melanoma cell line collection 21086098 CVCL_5V97 GM15123 transformed cell line human CVCL_5V97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086099 CVCL_6797 WM3211 cancer cell line human CVCL_6797 HLA typing: A*03:01,24:02; B*07:02; C*07:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gln50Ter (c.148C>T); ClinVar=VCV000220711; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Leu576Pro (c.1727T>C); ClinVar=VCV000375919; Zygosity=Unspecified (PubMed=23851445; PubMed=24576830; Wistar); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Gly (c.724T>G); ClinVar=VCV000376581; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00045; probable Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection 21086100 CVCL_5V98 GM15125 transformed cell line human CVCL_5V98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086101 CVCL_6798 WM3248 cancer cell line human CVCL_6798 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys144Ter (c.430A>T); ClinVar=VCV000379501; Zygosity=Homozygous (Wistar) Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00081; probable. Male Part of: Wistar Institute melanoma cell line collection 21086102 CVCL_6770 BAC1 transformed cell line house mouse CVCL_6770 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: BALB/c x A.CA. 21086103 CVCL_5V70 GM15082 transformed cell line human CVCL_5V70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086104 CVCL_6771 BAC1.2F5 transformed cell line house mouse CVCL_6771 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: BALB/c x A.CA. 21086105 CVCL_5V71 GM15083 transformed cell line human CVCL_5V71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086106 CVCL_6772 BAM [Mouse macrophage] transformed cell line house mouse CVCL_6772 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/c. 21086107 CVCL_5V72 GM15084 transformed cell line human CVCL_5V72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086108 CVCL_6766 6.12 hybridoma house mouse CVCL_6766 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P17948; Human FLT1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3344 21086109 CVCL_5V66 GM15078 transformed cell line human CVCL_5V66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086110 CVCL_6767 ES-R1/7AC5/EYFP embryonic stem cell house mouse CVCL_6767 CL:0000010 Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231) Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21086111 CVCL_5V67 GM15079 transformed cell line human CVCL_5V67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086112 CVCL_6768 88TAg transformed cell line house mouse CVCL_6768 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97740; Polb Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21086113 CVCL_5V68 GM15080 transformed cell line human CVCL_5V68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086114 CVCL_6769 AS-E2 cancer cell line human CVCL_6769 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: EPO dependent Doubling time: ~49 hours (PubMed=9369430) 21086115 CVCL_5V69 GM15081 transformed cell line human CVCL_5V69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086116 CVCL_6762 2H-11 transformed cell line house mouse CVCL_6762 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male Characteristics: Derived from a SVEC4-10EHR1 induced nodular spindle cell tumor (PubMed=8496612) 21086117 CVCL_5V62 GM15073 transformed cell line human CVCL_5V62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086118 CVCL_6763 308TAg transformed cell line house mouse CVCL_6763 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97073; Mpg Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21086119 CVCL_5V63 GM15075 transformed cell line human CVCL_5V63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086120 CVCL_6764 3197-3 transformed cell line house mouse CVCL_6764 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086121 CVCL_5V64 GM15076 transformed cell line human CVCL_5V64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086122 CVCL_6765 56B3 embryonic stem cell house mouse CVCL_6765 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96756; Lck Breed/subspecies: 129S2/SvPas. Discontinued: ATCC; CRL-2542; true Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11117 21086123 CVCL_5V65 GM15077 transformed cell line human CVCL_5V65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086124 CVCL_5V80 GM15094 transformed cell line human CVCL_5V80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086125 CVCL_6780 mh finite cell line house mouse CVCL_6780 CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21086126 CVCL_5V81 GM15095 transformed cell line human CVCL_5V81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086127 CVCL_6781 MRL104.8a stromal cell line house mouse CVCL_6781 CL:0000010 Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: MRL/Mp-lpr/lpr. Unspecified Characteristics: Produces CSF1 and IL6 (PubMed=2492055) 21086128 CVCL_5V82 GM15096 transformed cell line human CVCL_5V82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086129 CVCL_6782 OECM-1 cancer cell line human CVCL_6782 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (PubMed=14720193) Miscellaneous: STR profile mentioned but not shown in PubMed=24825747; obtained by personal communication of Yuan T-.C Population: Chinese; Taiwan; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 27 hours (PubMed=8083436) 21086130 CVCL_5V83 GM15097 transformed cell line human CVCL_5V83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086131 CVCL_6783 P493-6 transformed cell line human CVCL_6783 CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Cell surface proteome Unspecified Characteristics: The expression of the MYC gene is under the control of a tetracycline regulated promoter Doubling time: ~36 hours (DSMZ=ACC-915) 21086132 CVCL_5V77 GM15089 transformed cell line human CVCL_5V77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086133 CVCL_6777 HIVE-38 finite cell line human CVCL_6777 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2601; true; Discontinued: Coriell; WC00109; probable Male Part of: Wistar Institute Special Collection vascular cell lines 21086134 CVCL_5V78 GM15092 transformed cell line human CVCL_5V78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086135 CVCL_6778 MB352 spontaneously immortalized cell line house mouse CVCL_6778 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Cell type=Fibroblast. Unspecified 21086136 CVCL_5V79 GM15093 transformed cell line human CVCL_5V79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086137 CVCL_6779 MB355 spontaneously immortalized cell line house mouse CVCL_6779 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97740; Polb; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Cell type=Fibroblast. Unspecified 21086138 CVCL_6773 Cyt c-/- finite cell line house mouse CVCL_6773 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88578; Cycs Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified 21086139 CVCL_5V73 GM15085 transformed cell line human CVCL_5V73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086140 CVCL_6774 DOV13 cancer cell line human CVCL_6774 HLA typing: A*30:02,74:01; B*15:03,51:01; C*02:02,16:01 (PubMed=26589293); Genome ancestry: African=86.88%; Native American=0.11%; East Asian, North=5.26%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (DepMap) Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36.05 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21086141 CVCL_5V74 GM15086 transformed cell line human CVCL_5V74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086142 CVCL_5V75 GM15087 transformed cell line human CVCL_5V75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086143 CVCL_6775 HIAS-126 finite cell line human CVCL_6775 CL:0000010 Derived from sampling site: Iliac artery; smooth muscle. Discontinued: ATCC; CRL-2483; true; Discontinued: Coriell; WC00106; probable Female Part of: Wistar Institute Special Collection vascular cell lines 21086144 CVCL_5V76 GM15088 transformed cell line human CVCL_5V76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086145 CVCL_6776 HIVE-101 finite cell line human CVCL_6776 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2479; true; Discontinued: Coriell; WC00102; probable Female Part of: Wistar Institute Special Collection vascular cell lines 21086146 CVCL_6750 87-5 cancer cell line human CVCL_6750 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 1.8 days (CelloPub=CLPUB00161; PubMed=7817386) 21086147 CVCL_5V50 GM15054 transformed cell line human CVCL_5V50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086148 CVCL_5V44 GM15048 transformed cell line human CVCL_5V44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086149 CVCL_6744 XLT-15 spontaneously immortalized cell line African clawed frog CVCL_6744 CL:0000010 Derived from sampling site: Tail Cell type=Myoblast.. Unspecified Group: Amphibian cell line 21086150 CVCL_5V45 GM15049 transformed cell line human CVCL_5V45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086151 CVCL_6745 YSK undefined cell line type Norway rat CVCL_6745 CL:0000010 Discontinued: JCRB; JCRB0619; true. Unspecified 21086152 CVCL_5V46 GM15050 transformed cell line human CVCL_5V46 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086153 CVCL_6746 YTS-1 cancer cell line human CVCL_6746 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 20.2-22.5 hours (PubMed=3573461) 21086154 CVCL_5V47 GM15051 transformed cell line human CVCL_5V47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086155 CVCL_6747 WIL1 cancer cell line human CVCL_6747 CL:0000010 Population: Caucasian; Derived from sampling site: Lymph node. Male 21086156 CVCL_5V40 GM15041 transformed cell line human CVCL_5V40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086157 CVCL_6740 TNR-9 spontaneously immortalized cell line house mouse CVCL_6740 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086158 CVCL_5V41 GM15042 transformed cell line human CVCL_5V41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086159 CVCL_6741 WI-L2-729HF2 transformed cell line human CVCL_6741 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8062 21086160 CVCL_5V42 GM15043 transformed cell line human CVCL_5V42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086161 CVCL_6742 WTK-1 transformed cell line human CVCL_6742 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=11221843); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (PubMed=7744731; PubMed=11221843; PubMed=22525470) Anecdotal: Have been flown in space on the ISS in 2008-2009 to study the biological effects of space radiations, microgravity and the space environment on the expression of TP53-regulated genes (PubMed=20673130) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Omics: Transcriptome analysis by RNAseq Male Doubling time: 12.7 hours (PubMed=7744731) Group: Space-flown cell line (cellonaut) 21086162 CVCL_5V43 GM15047 transformed cell line human CVCL_5V43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086163 CVCL_6743 XL2 spontaneously immortalized cell line African clawed frog CVCL_6743 CL:0000010 Unspecified Doubling time: 39 hours (PubMed=7239540). Group: Amphibian cell line 21086164 CVCL_5V48 GM15052 transformed cell line human CVCL_5V48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086165 CVCL_6748 PK-45H cancer cell line human CVCL_6748 HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03; DQA1*01:02,01:02; DQB1*06:04,06:04; DRB1*03:01,13:02 (PubMed=26589293); Genome ancestry: African=1.31%; Native American=0.12%; East Asian, North=85.33%; East Asian, South=10.26%; South Asian=2.18%; European, North=0%; European, South=0.8% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21086166 CVCL_5V49 GM15053 transformed cell line human CVCL_5V49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086167 CVCL_6749 PK-45P cancer cell line human CVCL_6749 HLA typing: A*24:02,33:03; B*15:18,44:03; C*07:04,14:03; DQA1*01:02,03:02; DQB1*06:04,06:04; DRB1*04:01,13:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from autologous cell line PK-45H) Population: Japanese Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Unspecified 21086168 CVCL_6760 12-A-3 transformed cell line house mouse CVCL_6760 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6476; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21086169 CVCL_5V60 GM15070 transformed cell line human CVCL_5V60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086170 CVCL_6761 IxN/2b factor-dependent cell line house mouse CVCL_6761 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.. Characteristics: IL7 dependent 21086171 CVCL_5V61 GM15072 transformed cell line human CVCL_5V61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086172 CVCL_6755 EKOP spontaneously immortalized cell line house mouse CVCL_6755 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346865; Mapk14; Transfected with: HGNC; 6876; MAPK14 (isoform Exip); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast. Female 21086173 CVCL_5V55 GM15063 transformed cell line human CVCL_5V55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086174 CVCL_5V56 GM15064 transformed cell line human CVCL_5V56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086175 CVCL_6756 ZKOP spontaneously immortalized cell line house mouse CVCL_6756 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346865; Mapk14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast. Female 21086176 CVCL_6757 86-2 cancer cell line human CVCL_6757 HLA typing: A*11:01; B*51:01; C*04:01,15:02 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 1.5 days (CelloPub=CLPUB00161; PubMed=7817386) 21086177 CVCL_5V57 GM15065 transformed cell line human CVCL_5V57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086178 CVCL_5V58 GM15066 transformed cell line human CVCL_5V58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086179 CVCL_6758 Has undefined cell line type CVCL_6758 CL:0000010 21086180 CVCL_6751 103-LCL transformed cell line human CVCL_6751 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086181 CVCL_5V51 GM15055 transformed cell line human CVCL_5V51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086182 CVCL_6752 141-LCL transformed cell line human CVCL_6752 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086183 CVCL_5V52 GM15056 transformed cell line human CVCL_5V52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086184 CVCL_5V53 GM15061 transformed cell line human CVCL_5V53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086185 CVCL_6753 KOP spontaneously immortalized cell line house mouse CVCL_6753 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346865; Mapk14 Derived from sampling site: Cell type=Fibroblast. Female 21086186 CVCL_5V54 GM15062 transformed cell line human CVCL_5V54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086187 CVCL_6754 RKOP spontaneously immortalized cell line house mouse CVCL_6754 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1346865; Mapk14; Transfected with: HGNC; 6876; MAPK14; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast. Female 21086188 CVCL_6759 127TAg transformed cell line house mouse CVCL_6759 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104288; Pms2 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21086189 CVCL_5V59 GM15067 transformed cell line human CVCL_5V59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086190 CVCL_5V22 GM14945 transformed cell line human CVCL_5V22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086191 CVCL_6722 RI-T transformed cell line Norway rat CVCL_6722 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Discontinued: JCRB; NIHS0361; true Male 21086192 CVCL_5V23 GM15012 transformed cell line human CVCL_5V23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM15012; probable Male 21086193 CVCL_6723 RIE-1 spontaneously immortalized cell line Norway rat CVCL_6723 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Wistar. Female Doubling time: 40 hours (at 8th passage), 30 hours (at 17th passage) (PubMed=6204784) 21086194 CVCL_5V24 GM15233 finite cell line human CVCL_5V24 CL:0000010 Population: Caucasian; Northern European; Derived from sampling site: Cell type=Fibroblast. Female 21086195 CVCL_6724 ROG transformed cell line Norway rat CVCL_6724 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Sprague Dawley. Female 21086196 CVCL_5V25 GM15024 transformed cell line human CVCL_5V25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086197 CVCL_6725 RPH 67.205 spontaneously immortalized cell line CVCL_6725 CL:0000010 Unspecified Group: Amphibian cell line; Group: Haploid karyotype cell line. 21086198 CVCL_5V20 GM14943 transformed cell line human CVCL_5V20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21086199 CVCL_6720 RGA-1 transformed cell line Norway rat CVCL_6720 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: At the permissive temperature (33 Celsius) proliferates but reverts to a differentiated phenotype at the restrictive temperature (39 Celsius) 21086200 CVCL_5V21 GM14944 transformed cell line human CVCL_5V21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086201 CVCL_6721 RGA-41S conditionally immortalized cell line Norway rat CVCL_6721 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21086202 CVCL_5V26 GM15025 transformed cell line human CVCL_5V26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086203 CVCL_6726 SCC-131 cancer cell line Norway rat CVCL_6726 CL:0000010 Breed/subspecies: Fischer. 21086204 CVCL_5V27 GM15026 transformed cell line human CVCL_5V27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086205 CVCL_6727 SCC-158 cancer cell line Norway rat CVCL_6727 CL:0000010 Breed/subspecies: Fischer. 21086206 CVCL_5V28 GM15027 transformed cell line human CVCL_5V28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086207 CVCL_6728 SHG-44 cancer cell line human CVCL_6728 CL:0000010 Population: Chinese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female Doubling time: 26.67 hours (PubMed=25333456) 21086208 CVCL_5V29 GM15028 transformed cell line human CVCL_5V29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086209 CVCL_6729 SIGC spontaneously immortalized cell line Norway rat CVCL_6729 CL:0000010 Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: Berlin Duckrey (BD IV). Female 21086210 CVCL_5V33 GM15034 transformed cell line human CVCL_5V33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086211 CVCL_6733 THC-253 cancer cell line Norway rat CVCL_6733 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Derived from sampling site: Liver; Breed/subspecies: ACI. Male Characteristics: Established by subcutaneous transplantation of primary tumors 21086212 CVCL_5V34 GM15035 transformed cell line human CVCL_5V34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086213 CVCL_6734 H5D cancer cell line Norway rat CVCL_6734 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver. 21086214 CVCL_5V35 GM15036 transformed cell line human CVCL_5V35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified Part of: DNA polymorphism discovery resource collection 21086215 CVCL_6735 TM-31 cancer cell line human CVCL_6735 HLA typing: A*24:02,24:02; B*07:02,51:01; C*07:02,14:02 (PubMed=26589293); Genome ancestry: African=1.8%; Native American=0%; East Asian, North=80.56%; East Asian, South=14.37%; South Asian=0%; European, North=0%; European, South=3.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Gly (c.712T>G); ClinVar=VCV000376577; Zygosity=Homozygous (PubMed=11213969; DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 65 hours (at 50th passage), 62 hours (at 220th passage) (PubMed=11213969) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21086216 CVCL_5V36 GM15037 transformed cell line human CVCL_5V36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086217 CVCL_6736 TMCC-2 cancer cell line human CVCL_6736 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 24 hours (PubMed=1888705; PubMed=1890355) 21086218 CVCL_5V30 GM15029 transformed cell line human CVCL_5V30 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086219 CVCL_6730 Speedy spontaneously immortalized cell line tropical clawed frog CVCL_6730 CL:0000010 Karyotypic information: Diploid with a trisomy of chromosome 10 (PubMed=22083648); Derived from sampling site: Hindlimb Cell type=Fibroblast.. Unspecified Doubling time: ~24 hours (PubMed=22083648) Group: Amphibian cell line 21086220 CVCL_5V31 GM15030 transformed cell line human CVCL_5V31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086221 CVCL_6731 TEPC-1165 cancer cell line house mouse CVCL_6731 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Characteristics: IL6 dependent 21086222 CVCL_5V32 GM15031 transformed cell line human CVCL_5V32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086223 CVCL_6732 THC-252 cancer cell line Norway rat CVCL_6732 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Derived from sampling site: Liver; Breed/subspecies: ACI. Male Characteristics: Established by intraperitoneal transplantation of primary tumors 21086224 CVCL_5V37 GM15038 transformed cell line human CVCL_5V37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086225 CVCL_6737 TMCC-2.U cancer cell line human CVCL_6737 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 14 hours (PubMed=1888705) 21086226 CVCL_5V38 GM15039 transformed cell line human CVCL_5V38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086227 CVCL_6738 TN-1 cancer cell line human CVCL_6738 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male Doubling time: 36 hours (PubMed=2486611) 21086228 CVCL_5V39 GM15040 transformed cell line human CVCL_5V39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086229 CVCL_6739 TNR-2 spontaneously immortalized cell line house mouse CVCL_6739 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086230 CVCL_GI18 ND12724 transformed cell line human CVCL_GI18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086231 CVCL_GI19 ND12742 transformed cell line human CVCL_GI19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086232 CVCL_GI14 ND12696 transformed cell line human CVCL_GI14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086233 CVCL_GI15 ND12701 transformed cell line human CVCL_GI15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086234 CVCL_GI16 ND12707 transformed cell line human CVCL_GI16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086235 CVCL_GI17 ND12712 transformed cell line human CVCL_GI17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086236 CVCL_GI10 ND12675 transformed cell line human CVCL_GI10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086237 CVCL_GI11 ND12676 transformed cell line human CVCL_GI11 CL:0000010 Population: Uzbekistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086238 CVCL_GI12 ND12677 transformed cell line human CVCL_GI12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086239 CVCL_GI13 ND12679 transformed cell line human CVCL_GI13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086240 CVCL_GI29 ND12837 transformed cell line human CVCL_GI29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086241 CVCL_GI25 ND12798 transformed cell line human CVCL_GI25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086242 CVCL_GI26 ND12811 transformed cell line human CVCL_GI26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086243 CVCL_GI27 ND12813 transformed cell line human CVCL_GI27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086244 CVCL_GI28 ND12829 transformed cell line human CVCL_GI28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086245 CVCL_GI21 ND12766 transformed cell line human CVCL_GI21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086246 CVCL_GI22 ND12768 transformed cell line human CVCL_GI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086247 CVCL_GI23 ND12775 transformed cell line human CVCL_GI23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086248 CVCL_GI24 ND12786 transformed cell line human CVCL_GI24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086249 CVCL_GI20 ND12749 transformed cell line human CVCL_GI20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086250 CVCL_GI07 ND12639 transformed cell line human CVCL_GI07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086251 CVCL_GI08 ND12647 transformed cell line human CVCL_GI08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086252 CVCL_GI09 ND12660 transformed cell line human CVCL_GI09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086253 CVCL_GI03 ND12634 transformed cell line human CVCL_GI03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086254 CVCL_GI04 ND12635 transformed cell line human CVCL_GI04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086255 CVCL_GI05 ND12636 transformed cell line human CVCL_GI05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086256 CVCL_GI06 ND12638 transformed cell line human CVCL_GI06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086257 CVCL_GI00 ND12617 transformed cell line human CVCL_GI00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086258 CVCL_GI01 ND12627 transformed cell line human CVCL_GI01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086259 CVCL_GI02 ND12633 transformed cell line human CVCL_GI02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086260 CVCL_5U92 NAL1A clone C1C10 spontaneously immortalized cell line house mouse CVCL_5U92 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086261 CVCL_6692 NR-4 spontaneously immortalized cell line house mouse CVCL_6692 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086262 CVCL_5U93 NAL1A clone C1SA5 transformed cell line house mouse CVCL_5U93 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086263 CVCL_6693 NR-5 spontaneously immortalized cell line house mouse CVCL_6693 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086264 CVCL_5U94 HT29 LM1 cancer cell line human CVCL_5U94 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21086265 CVCL_6694 NR-6 spontaneously immortalized cell line house mouse CVCL_6694 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Characteristics: Does not express EGFR 21086266 CVCL_5U95 HT29 LM2 cancer cell line human CVCL_5U95 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21086267 CVCL_6695 NR-6-R spontaneously immortalized cell line house mouse CVCL_6695 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Characteristics: Can be employed in a wide variety of assays, such as soft agar assays and proliferation assays, to identify and measure FGF activity (UNeMed) 21086268 CVCL_5U90 NAL1A clone B5D3 spontaneously immortalized cell line house mouse CVCL_5U90 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086269 CVCL_6690 NR-2 spontaneously immortalized cell line house mouse CVCL_6690 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086270 CVCL_5U91 NAL1A clone B5SF11 transformed cell line house mouse CVCL_5U91 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086271 CVCL_6691 NR-3 spontaneously immortalized cell line house mouse CVCL_6691 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086272 CVCL_5U89 NAL1A clone C4 spontaneously immortalized cell line house mouse CVCL_5U89 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086273 CVCL_6689 NR-1 spontaneously immortalized cell line house mouse CVCL_6689 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086274 CVCL_6685 MDG2.1 transformed cell line pig CVCL_6685 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 24-36 hours (PubMed=8143903) 21086275 CVCL_5U85 NAL1AM transformed cell line house mouse CVCL_5U85 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086276 CVCL_6686 MM5.1 [Human myeloma] cancer cell line human CVCL_6686 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA kappa; Characteristics: Requires bone marrow stromal cells for growth 21086277 CVCL_5U86 NAL1AS spontaneously immortalized cell line house mouse CVCL_5U86 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086278 CVCL_6687 MM5.2 cancer cell line human CVCL_6687 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA kappa and IgG kappa; Characteristics: Does not require bone marrow stromal cells for growth 21086279 CVCL_5U87 NAL1A clone B5 spontaneously immortalized cell line house mouse CVCL_5U87 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086280 CVCL_5U88 NAL1A clone C1 spontaneously immortalized cell line house mouse CVCL_5U88 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female 21086281 CVCL_6688 NHOS cancer cell line house mouse CVCL_6688 CL:0000010 Breed/subspecies: BALB/c. Female 21086282 CVCL_5U96 HT29 LM3 cancer cell line human CVCL_5U96 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21086283 CVCL_6696 NR-7 spontaneously immortalized cell line house mouse CVCL_6696 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086284 CVCL_6697 NR-8 spontaneously immortalized cell line house mouse CVCL_6697 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086285 CVCL_5U97 NUL1 clone B3 cancer cell line house mouse CVCL_5U97 CL:0000010 Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: BALB/c. 21086286 CVCL_6698 NR6M spontaneously immortalized cell line house mouse CVCL_6698 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21086287 CVCL_5U98 NUL1 clone B5 cancer cell line house mouse CVCL_5U98 CL:0000010 Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: BALB/c. 21086288 CVCL_5U99 82-132 cancer cell line house mouse CVCL_5U99 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung; Breed/subspecies: Swiss Webster. Unspecified 21086289 CVCL_6699 NR6V spontaneously immortalized cell line house mouse CVCL_6699 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Characteristics: Control cell line for NR6M and NR6W 21086290 CVCL_PC40 BayGenomics ES cell line RST605 embryonic stem cell house mouse CVCL_PC40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086291 CVCL_PC41 BayGenomics ES cell line RST606 embryonic stem cell house mouse CVCL_PC41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086292 CVCL_PC42 BayGenomics ES cell line RST612 embryonic stem cell house mouse CVCL_PC42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891468; Lgr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086293 CVCL_PC43 BayGenomics ES cell line RST613 embryonic stem cell house mouse CVCL_PC43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95834; Pdia3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086294 CVCL_PC44 BayGenomics ES cell line RST620 embryonic stem cell house mouse CVCL_PC44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95286; Eed Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086295 CVCL_PC45 BayGenomics ES cell line RST624 embryonic stem cell house mouse CVCL_PC45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97464; P4hb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086296 CVCL_PC46 BayGenomics ES cell line RST626 embryonic stem cell house mouse CVCL_PC46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101864; Dag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086297 CVCL_GI98 ND13300 transformed cell line human CVCL_GI98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086298 CVCL_PC47 BayGenomics ES cell line RST630 embryonic stem cell house mouse CVCL_PC47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086299 CVCL_GI99 ND13301 transformed cell line human CVCL_GI99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086300 CVCL_PC48 BayGenomics ES cell line RST631 embryonic stem cell house mouse CVCL_PC48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298204; Ppt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086301 CVCL_PC49 BayGenomics ES cell line RST634 embryonic stem cell house mouse CVCL_PC49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915720; Bpnt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086302 CVCL_GI94 ND13289 transformed cell line human CVCL_GI94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086303 CVCL_GI95 ND13292 transformed cell line human CVCL_GI95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086304 CVCL_GI96 ND13294 transformed cell line human CVCL_GI96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086305 CVCL_GI97 ND13299 transformed cell line human CVCL_GI97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086306 CVCL_PC30 BayGenomics ES cell line RST575 embryonic stem cell house mouse CVCL_PC30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086307 CVCL_PC31 BayGenomics ES cell line RST579 embryonic stem cell house mouse CVCL_PC31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086308 CVCL_PC32 BayGenomics ES cell line RST586 embryonic stem cell house mouse CVCL_PC32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086309 CVCL_PC33 BayGenomics ES cell line RST587 embryonic stem cell house mouse CVCL_PC33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086310 CVCL_PC34 BayGenomics ES cell line RST590 embryonic stem cell house mouse CVCL_PC34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920014; Csnk1g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086311 CVCL_PC35 BayGenomics ES cell line RST592 embryonic stem cell house mouse CVCL_PC35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086312 CVCL_PC36 BayGenomics ES cell line RST596 embryonic stem cell house mouse CVCL_PC36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104669; Man2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086313 CVCL_PC37 BayGenomics ES cell line RST601 embryonic stem cell house mouse CVCL_PC37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086314 CVCL_PC38 BayGenomics ES cell line RST602 embryonic stem cell house mouse CVCL_PC38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914140; Lman2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086315 CVCL_PC39 BayGenomics ES cell line RST604 embryonic stem cell house mouse CVCL_PC39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086316 CVCL_GI80 ND13181 transformed cell line human CVCL_GI80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086317 CVCL_GI81 ND13186 transformed cell line human CVCL_GI81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086318 CVCL_GI82 ND13190 transformed cell line human CVCL_GI82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086319 CVCL_PC20 BayGenomics ES cell line RST554 embryonic stem cell house mouse CVCL_PC20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086320 CVCL_PC21 BayGenomics ES cell line RST556 embryonic stem cell house mouse CVCL_PC21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106653; Epcam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086321 CVCL_PC22 BayGenomics ES cell line RST557 embryonic stem cell house mouse CVCL_PC22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95705; B4galt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086322 CVCL_PC23 BayGenomics ES cell line RST560 embryonic stem cell house mouse CVCL_PC23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086323 CVCL_PC24 BayGenomics ES cell line RST561 embryonic stem cell house mouse CVCL_PC24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926157; Atf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086324 CVCL_GI76 ND13116 transformed cell line human CVCL_GI76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086325 CVCL_PC25 BayGenomics ES cell line RST562 embryonic stem cell house mouse CVCL_PC25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086326 CVCL_GI77 ND13117 transformed cell line human CVCL_GI77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086327 CVCL_PC26 BayGenomics ES cell line RST564 embryonic stem cell house mouse CVCL_PC26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929940; Bcam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086328 CVCL_GI78 ND13129 transformed cell line human CVCL_GI78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086329 CVCL_PC27 BayGenomics ES cell line RST570 embryonic stem cell house mouse CVCL_PC27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086330 CVCL_GI79 ND13130 transformed cell line human CVCL_GI79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086331 CVCL_PC28 BayGenomics ES cell line RST571 embryonic stem cell house mouse CVCL_PC28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086332 CVCL_GI72 ND13099 transformed cell line human CVCL_GI72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086333 CVCL_PC29 BayGenomics ES cell line RST573 embryonic stem cell house mouse CVCL_PC29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086334 CVCL_GI73 ND13100 transformed cell line human CVCL_GI73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086335 CVCL_GI74 ND13103 transformed cell line human CVCL_GI74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086336 CVCL_GI75 ND13115 transformed cell line human CVCL_GI75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086337 CVCL_GI90 ND13264 transformed cell line human CVCL_GI90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086338 CVCL_GI91 ND13286 transformed cell line human CVCL_GI91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086339 CVCL_GI92 ND13287 transformed cell line human CVCL_GI92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086340 CVCL_GI93 ND13288 transformed cell line human CVCL_GI93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086341 CVCL_PC10 BayGenomics ES cell line RST528 embryonic stem cell house mouse CVCL_PC10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3763743; Snhg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086342 CVCL_PC11 BayGenomics ES cell line RST529 embryonic stem cell house mouse CVCL_PC11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086343 CVCL_PC12 BayGenomics ES cell line RST538 embryonic stem cell house mouse CVCL_PC12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086344 CVCL_PC13 BayGenomics ES cell line RST539 embryonic stem cell house mouse CVCL_PC13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443162; Uggt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086345 CVCL_GI87 ND13214 transformed cell line human CVCL_GI87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086346 CVCL_PC14 BayGenomics ES cell line RST540 embryonic stem cell house mouse CVCL_PC14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107685; Plxna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086347 CVCL_GI88 ND13262 transformed cell line human CVCL_GI88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086348 CVCL_PC15 BayGenomics ES cell line RST543 embryonic stem cell house mouse CVCL_PC15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87961; Agrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086349 CVCL_GI89 ND13263 transformed cell line human CVCL_GI89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086350 CVCL_PC16 BayGenomics ES cell line RST544 embryonic stem cell house mouse CVCL_PC16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086351 CVCL_PC17 BayGenomics ES cell line RST546 embryonic stem cell house mouse CVCL_PC17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921819; Ttc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086352 CVCL_GI83 ND13191 transformed cell line human CVCL_GI83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086353 CVCL_PC18 BayGenomics ES cell line RST547 embryonic stem cell house mouse CVCL_PC18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87961; Agrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086354 CVCL_GI84 ND13198 transformed cell line human CVCL_GI84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086355 CVCL_PC19 BayGenomics ES cell line RST553 embryonic stem cell house mouse CVCL_PC19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914328; Pgp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086356 CVCL_GI85 ND13210 transformed cell line human CVCL_GI85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086357 CVCL_GI86 ND13213 transformed cell line human CVCL_GI86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086358 CVCL_GI60 ND13010 transformed cell line human CVCL_GI60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086359 CVCL_GI58 ND12984 transformed cell line human CVCL_GI58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086360 CVCL_GI59 ND13009 transformed cell line human CVCL_GI59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086361 CVCL_PC00 BayGenomics ES cell line RST512 embryonic stem cell house mouse CVCL_PC00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442146; Dnajc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086362 CVCL_PC01 BayGenomics ES cell line RST513 embryonic stem cell house mouse CVCL_PC01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086363 CVCL_PC02 BayGenomics ES cell line RST515 embryonic stem cell house mouse CVCL_PC02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933820; Jam2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086364 CVCL_GI54 ND12969 transformed cell line human CVCL_GI54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086365 CVCL_PC03 BayGenomics ES cell line RST516 embryonic stem cell house mouse CVCL_PC03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086366 CVCL_GI55 ND12971 transformed cell line human CVCL_GI55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086367 CVCL_PC04 BayGenomics ES cell line RST517 embryonic stem cell house mouse CVCL_PC04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086368 CVCL_GI56 ND12973 transformed cell line human CVCL_GI56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086369 CVCL_PC05 BayGenomics ES cell line RST521 embryonic stem cell house mouse CVCL_PC05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086370 CVCL_GI57 ND12981 transformed cell line human CVCL_GI57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086371 CVCL_PC06 BayGenomics ES cell line RST523 embryonic stem cell house mouse CVCL_PC06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086372 CVCL_GI50 ND12952 transformed cell line human CVCL_GI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086373 CVCL_PC07 BayGenomics ES cell line RST525 embryonic stem cell house mouse CVCL_PC07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443696; Emc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086374 CVCL_GI51 ND12954 transformed cell line human CVCL_GI51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086375 CVCL_PC08 BayGenomics ES cell line RST526 embryonic stem cell house mouse CVCL_PC08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780541; Lncenc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086376 CVCL_GI52 ND12955 transformed cell line human CVCL_GI52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086377 CVCL_PC09 BayGenomics ES cell line RST527 embryonic stem cell house mouse CVCL_PC09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086378 CVCL_GI53 ND12956 transformed cell line human CVCL_GI53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086379 CVCL_GI70 ND13086 transformed cell line human CVCL_GI70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086380 CVCL_GI71 ND13094 transformed cell line human CVCL_GI71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086381 CVCL_GI69 ND13085 transformed cell line human CVCL_GI69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086382 CVCL_GI65 ND13081 transformed cell line human CVCL_GI65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086383 CVCL_GI66 ND13082 transformed cell line human CVCL_GI66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086384 CVCL_GI67 ND13083 transformed cell line human CVCL_GI67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086385 CVCL_GI68 ND13084 transformed cell line human CVCL_GI68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086386 CVCL_GI61 ND13026 transformed cell line human CVCL_GI61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086387 CVCL_GI62 ND13059 transformed cell line human CVCL_GI62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086388 CVCL_GI63 ND13067 transformed cell line human CVCL_GI63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086389 CVCL_GI64 ND13077 transformed cell line human CVCL_GI64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086390 CVCL_GI36 ND12867 transformed cell line human CVCL_GI36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086391 CVCL_GI37 ND12870 transformed cell line human CVCL_GI37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086392 CVCL_GI38 ND12872 transformed cell line human CVCL_GI38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086393 CVCL_GI39 ND12884 transformed cell line human CVCL_GI39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086394 CVCL_GI32 ND12850 transformed cell line human CVCL_GI32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086395 CVCL_GI33 ND12859 transformed cell line human CVCL_GI33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086396 CVCL_GI34 ND12860 transformed cell line human CVCL_GI34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086397 CVCL_GI35 ND12866 transformed cell line human CVCL_GI35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086398 CVCL_GI30 ND12839 transformed cell line human CVCL_GI30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086399 CVCL_GI31 ND12844 transformed cell line human CVCL_GI31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086400 CVCL_GI47 ND12943 transformed cell line human CVCL_GI47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086401 CVCL_GI48 ND12944 transformed cell line human CVCL_GI48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086402 CVCL_GI49 ND12951 transformed cell line human CVCL_GI49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086403 CVCL_GI43 ND12907 transformed cell line human CVCL_GI43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086404 CVCL_GI44 ND12908 transformed cell line human CVCL_GI44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086405 CVCL_GI45 ND12920 transformed cell line human CVCL_GI45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086406 CVCL_GI46 ND12942 transformed cell line human CVCL_GI46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086407 CVCL_GI40 ND12887 transformed cell line human CVCL_GI40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086408 CVCL_GI41 ND12889 transformed cell line human CVCL_GI41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086409 CVCL_GI42 ND12906 transformed cell line human CVCL_GI42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086410 CVCL_6821 C-20/A4 transformed cell line human CVCL_6821 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.. Male 21086411 CVCL_5W21 GM15156 transformed cell line human CVCL_5W21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086412 CVCL_6822 C10/MJ-2 transformed cell line human CVCL_6822 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Virology: HTLV-1 producing cell line 21086413 CVCL_5W22 GM15158 transformed cell line human CVCL_5W22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086414 CVCL_6823 C2F3 spontaneously immortalized cell line house mouse CVCL_6823 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21086415 CVCL_5W23 GM15159 transformed cell line human CVCL_5W23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086416 CVCL_6824 C57MG spontaneously immortalized cell line house mouse CVCL_6824 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female Characteristics: Used to study Wnt signalling 21086417 CVCL_5W24 GM15160 transformed cell line human CVCL_5W24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086418 CVCL_6820 47.10 factor-dependent cell line house mouse CVCL_6820 CL:0000010 Transfected with: HGNC; 2433; CSF1R Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6 x DBA/2 transgenic. Male Characteristics: Produced in a transgenic mouse expressing human CSF1R; Characteristics: CSF1 or CSF2 or IL3 dependent 21086419 CVCL_5W20 GM15155 transformed cell line human CVCL_5W20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086420 CVCL_6829 CT.EV transformed cell line house mouse CVCL_6829 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21086421 CVCL_5W29 GM15165 transformed cell line human CVCL_5W29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086422 CVCL_6825 CCRF-CEM C7 cancer cell line human CVCL_6825 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Sensitive to glucocorticoid-mediated lysis Doubling time: 24 +- 3 hours (PubMed=6134583) 21086423 CVCL_5W25 GM15161 transformed cell line human CVCL_5W25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086424 CVCL_6826 CCRF-CEM C7A cancer cell line human CVCL_6826 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21086425 CVCL_5W26 GM15162 transformed cell line human CVCL_5W26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086426 CVCL_6827 CT.4R transformed cell line house mouse CVCL_6827 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: IL2 and IL4 dependent 21086427 CVCL_5W27 GM15163 transformed cell line human CVCL_5W27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086428 CVCL_6828 CT.4S transformed cell line house mouse CVCL_6828 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Discontinued: BCRJ; 0073; probable Characteristics: IL4 dependent 21086429 CVCL_5W28 GM15164 transformed cell line human CVCL_5W28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086430 CVCL_5W32 GM15176 transformed cell line human CVCL_5W32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086431 CVCL_6832 HCCLM3 cancer cell line human CVCL_6832 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male Characteristics: Established from pulmonary metastatic lesions produced in nude mice by 3 rounds of subcutaneous inoculation of parent cell line (PubMed=12133480) Doubling time: 34.9 hours (PubMed=12133480) 21086432 CVCL_5W33 GM15177 transformed cell line human CVCL_5W33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086433 CVCL_6833 HT-29-G cancer cell line human CVCL_6833 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21086434 CVCL_5W34 GM15178 transformed cell line human CVCL_5W34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086435 CVCL_6834 HT-29-MTX cancer cell line human CVCL_6834 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female 21086436 CVCL_5W35 GM15179 transformed cell line human CVCL_5W35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086437 CVCL_5W30 GM15166 transformed cell line human CVCL_5W30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086438 CVCL_5W31 GM15170 transformed cell line human CVCL_5W31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086439 CVCL_6831 NCI-H3255 cancer cell line human CVCL_6831 HLA typing: A*01:01,03:01; B*37:01,41:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=3.63%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=0%; European, North=59.85%; European, South=34.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep membrane proteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2882; true; Discontinued: DepMap; ACH-002137; true. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21086440 CVCL_5W36 GM15181 transformed cell line human CVCL_5W36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086441 CVCL_6836 KMB-17 finite cell line human CVCL_6836 CL:0000010 Population: Chinese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21086442 CVCL_5W37 GM15183 transformed cell line human CVCL_5W37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086443 CVCL_6837 L87/4 transformed cell line human CVCL_6837 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow. Male 21086444 CVCL_5W38 GM15184 transformed cell line human CVCL_5W38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086445 CVCL_6838 L88/5 transformed cell line human CVCL_6838 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow. Male 21086446 CVCL_5W39 GM15185 transformed cell line human CVCL_5W39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086447 CVCL_6839 LN-382T cancer cell line human CVCL_6839 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val197Leu (c.589G>T); ClinVar=VCV000216468; Zygosity=Homozygous (PubMed=10416987) Derived from sampling site: Brain; right fronto-parietal lobe. Male 21086448 CVCL_5W00 GM15127 transformed cell line human CVCL_5W00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086449 CVCL_6800 WM3734 cancer cell line human CVCL_6800 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Brain. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00090; probable Female Part of: Wistar Institute melanoma cell line collection 21086450 CVCL_5W01 GM15128 transformed cell line human CVCL_5W01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086451 CVCL_6801 WM3854 cancer cell line human CVCL_6801 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00125; probable Male Part of: Wistar Institute melanoma cell line collection 21086452 CVCL_5W02 GM15129 transformed cell line human CVCL_5W02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086453 CVCL_6802 WM3928 cancer cell line human CVCL_6802 CL:0000010 Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr177Ter (c.531T>G); ClinVar=VCV000235334; Zygosity=Unspecified (Wistar) Derived from metastatic site: Left inguinal lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00115; probable Male Part of: Wistar Institute melanoma cell line collection 21086454 CVCL_5W07 GM15134 transformed cell line human CVCL_5W07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086455 CVCL_6807 WM902B cancer cell line human CVCL_6807 HLA typing: A*01:01,29:01; B*07:02,08:01; C*07:01:01,15:05; DPB1*04:01,02:01:02; DQB1*03:01:01,04:02; DRB1*08:01,11:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; PubMed=21156289; PubMed=23851445; Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289; PubMed=23851445; Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00083; probable; Discontinued: ESTDAB; ESTDAB-085; probable Male Part of: Wistar Institute melanoma cell line collection 21086456 CVCL_5W08 GM15135 transformed cell line human CVCL_5W08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086457 CVCL_6808 WM983A cancer cell line human CVCL_6808 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; Wistar) Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00048; probable. Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21086458 CVCL_5W09 GM15136 transformed cell line human CVCL_5W09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086459 CVCL_6809 WM983B cancer cell line human CVCL_6809 HLA typing: A*01:01,29:02; B*14:02,37:01; C*06:02,08:02 (PubMed=26589293); Genome ancestry: African=2.75%; Native American=0%; East Asian, North=5.11%; East Asian, South=0%; South Asian=5.18%; European, North=22.68%; European, South=64.28% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; PubMed=21156289; DepMap; Wistar); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Phe (c.832_833CC>TT); Zygosity=Homozygous (DepMap) Derived from metastatic site: Inguinal lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; WC00066; probable Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: deletion of D18S51 21086460 CVCL_5W03 GM15130 transformed cell line human CVCL_5W03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086461 CVCL_6803 WM46 cancer cell line human CVCL_6803 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (Wistar) Derived from metastatic site: Abdomen; skin. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00069; probable Female Characteristics: Highly pigmented Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D13S317 21086462 CVCL_5W04 GM15131 transformed cell line human CVCL_5W04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086463 CVCL_6804 WM852 cancer cell line human CVCL_6804 HLA typing: A*03:01,02:01; B*15:01:01:01,07:02; C*03:04,07:02; DPB1*04:01; DQB1*06:02,03:02; DRB1*04:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Rockland, Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445; Wistar); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Abdomen; skin. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00065; probable Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21086464 CVCL_5W05 GM15132 transformed cell line human CVCL_5W05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086465 CVCL_6805 WM88 cancer cell line human CVCL_6805 HLA typing: A*11:01,23:01; B*35:01,44:03; C*04:01,04:01; DQA1*01:02,01:02; DQB1*05:01,06:02; DRB1*01:01,15:01 (PubMed=26589293); Genome ancestry: African=3.54%; Native American=0%; East Asian, North=3.99%; East Asian, South=0%; South Asian=0%; European, North=55.46%; European, South=37.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24576830; DepMap; Wistar) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; WC00123; probable Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21086466 CVCL_5W06 GM15133 transformed cell line human CVCL_5W06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086467 CVCL_6806 WM9 cancer cell line human CVCL_6806 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Left axillary lymph node. Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00056; probable Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D8S1179 21086468 CVCL_6810 77N1 transformed cell line Norway rat CVCL_6810 CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain Bratislava-77 (B77)](NCBI-Taxonomy; 11876); Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21086469 CVCL_5W10 GM15137 transformed cell line human CVCL_5W10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086470 CVCL_6811 BRIN-BD11 hybrid cell line Norway rat CVCL_6811 CL:0000010 Breed/subspecies: NEDH. Doubling time: ~20 hours (ECACC=10033003) 21086471 CVCL_5W11 GM15138 transformed cell line human CVCL_5W11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086472 CVCL_6812 C2 [Mouse myoblast] spontaneously immortalized cell line house mouse CVCL_6812 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21086473 CVCL_5W12 GM15140 transformed cell line human CVCL_5W12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086474 CVCL_6813 C8161 cancer cell line human CVCL_6813 CL:0000010 Derived from metastatic site: Abdominal wall. Female Doubling time: 5.8 +- 1.9 days (PubMed=1671030) 21086475 CVCL_5W13 GM15141 transformed cell line human CVCL_5W13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086476 CVCL_6818 CH12 cancer cell line house mouse CVCL_6818 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21086477 CVCL_5W18 GM15153 transformed cell line human CVCL_5W18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086478 CVCL_6819 10B10 cancer cell line human CVCL_6819 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: VGNC; 98476; Pig IL12RB2 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21086479 CVCL_5W19 GM15154 transformed cell line human CVCL_5W19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086480 CVCL_6814 C8161.9KFM cancer cell line human CVCL_6814 CL:0000010 Transfected with: HGNC; 6341; KISS1 Derived from metastatic site: Abdominal wall. Female 21086481 CVCL_5W14 GM15142 transformed cell line human CVCL_5W14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086482 CVCL_5W15 GM15144 transformed cell line human CVCL_5W15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086483 CVCL_6815 neo6/C8161.1 hybrid cell line CVCL_6815 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. 21086484 CVCL_5W16 GM15146 transformed cell line human CVCL_5W16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086485 CVCL_6816 neo6/C8161.2 hybrid cell line CVCL_6816 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. 21086486 CVCL_5W17 GM15151 transformed cell line human CVCL_5W17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086487 CVCL_6817 neo6/C8161.3 hybrid cell line CVCL_6817 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. 21086488 CVCL_PD90 BayGenomics ES cell line SYA196 embryonic stem cell house mouse CVCL_PD90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086489 CVCL_PD91 BayGenomics ES cell line SYA202 embryonic stem cell house mouse CVCL_PD91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894697; Rad54l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086490 CVCL_PD92 BayGenomics ES cell line SYA207 embryonic stem cell house mouse CVCL_PD92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086491 CVCL_PD93 BayGenomics ES cell line SYA208 embryonic stem cell house mouse CVCL_PD93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039623; Thada Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086492 CVCL_PD94 BayGenomics ES cell line SYA210 embryonic stem cell house mouse CVCL_PD94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086493 CVCL_PD95 BayGenomics ES cell line SYA212 embryonic stem cell house mouse CVCL_PD95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086494 CVCL_PD96 BayGenomics ES cell line SYA217 embryonic stem cell house mouse CVCL_PD96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086495 CVCL_PD97 BayGenomics ES cell line SYA222 embryonic stem cell house mouse CVCL_PD97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914923; Elob Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086496 CVCL_PD98 BayGenomics ES cell line SYA224 embryonic stem cell house mouse CVCL_PD98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086497 CVCL_PD99 BayGenomics ES cell line SYA225 embryonic stem cell house mouse CVCL_PD99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917433; Dzip3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086498 CVCL_PD80 BayGenomics ES cell line SYA153 embryonic stem cell house mouse CVCL_PD80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921700; Pank2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086499 CVCL_PD81 BayGenomics ES cell line SYA162 embryonic stem cell house mouse CVCL_PD81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918272; Ston2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086500 CVCL_PD82 BayGenomics ES cell line SYA169 embryonic stem cell house mouse CVCL_PD82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086501 CVCL_PD83 BayGenomics ES cell line SYA170 embryonic stem cell house mouse CVCL_PD83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086502 CVCL_PD84 BayGenomics ES cell line SYA173 embryonic stem cell house mouse CVCL_PD84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086503 CVCL_PD85 BayGenomics ES cell line SYA176 embryonic stem cell house mouse CVCL_PD85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921355; Gga2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086504 CVCL_PD86 BayGenomics ES cell line SYA183 embryonic stem cell house mouse CVCL_PD86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925771; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086505 CVCL_PD87 BayGenomics ES cell line SYA185 embryonic stem cell house mouse CVCL_PD87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88192; Smarca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086506 CVCL_PD88 BayGenomics ES cell line SYA187 embryonic stem cell house mouse CVCL_PD88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913466; Bsdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086507 CVCL_PD89 BayGenomics ES cell line SYA191 embryonic stem cell house mouse CVCL_PD89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918019; Nolc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086508 CVCL_PD70 BayGenomics ES cell line SYA132 embryonic stem cell house mouse CVCL_PD70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95286; Eed Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086509 CVCL_PD71 BayGenomics ES cell line SYA134 embryonic stem cell house mouse CVCL_PD71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914923; Elob Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086510 CVCL_PD72 BayGenomics ES cell line SYA135 embryonic stem cell house mouse CVCL_PD72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108451; Acaca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086511 CVCL_PD73 BayGenomics ES cell line SYA137 embryonic stem cell house mouse CVCL_PD73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384993; Paip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086512 CVCL_PD74 BayGenomics ES cell line SYA138 embryonic stem cell house mouse CVCL_PD74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203484; Zfp638 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086513 CVCL_PD75 BayGenomics ES cell line SYA140 embryonic stem cell house mouse CVCL_PD75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086514 CVCL_PD76 BayGenomics ES cell line SYA142 embryonic stem cell house mouse CVCL_PD76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086515 CVCL_PD77 BayGenomics ES cell line SYA144 embryonic stem cell house mouse CVCL_PD77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141847; Phrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086516 CVCL_PD78 BayGenomics ES cell line SYA146 embryonic stem cell house mouse CVCL_PD78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446249; Edc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086517 CVCL_PD79 BayGenomics ES cell line SYA147 embryonic stem cell house mouse CVCL_PD79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086518 CVCL_6890 CNE-2Z hybrid cell line human CVCL_6890 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000151) It was the sole source for the STR profile of this entry.. Problematic cell line: Probably contaminated Parent cell line (CNE-2) has been shown to be a hybrid of HeLa and of cell line of unknown origin. 21086519 CVCL_5W90 GM15271 transformed cell line human CVCL_5W90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086520 CVCL_6891 CoC1 cancer cell line human CVCL_6891 CL:0000010 Population: Chinese Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray. Female 21086521 CVCL_5W91 GM15272 transformed cell line human CVCL_5W91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086522 CVCL_6892 CoC1/DDP cancer cell line human CVCL_6892 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray. Female 21086523 CVCL_5W92 GM15273 transformed cell line human CVCL_5W92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086524 CVCL_6893 CRBM-1990 cancer cell line human CVCL_6893 CL:0000010 Derived from metastatic site: Bone; thoracic vertebra. Male 21086525 CVCL_5W93 GM15274 transformed cell line human CVCL_5W93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086526 CVCL_5W87 GM15268 transformed cell line human CVCL_5W87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086527 CVCL_6888 CNE-1 hybrid cell line human CVCL_6888 CL:0000010 Omics: Transcriptome analysis by RNAseq. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00473 Problematic cell line: Contaminated On the basis of the STR profile (PubMed=18196576) it is identical to CNE-2 and seems to be a hybrid of HeLa and of cell line of unknown origin. This is also confirmed by RNASeq data from PubMed=24991015. Originally thought to originate from a 58 year old female patient with a nasopharyngeal carcinoma. 21086528 CVCL_5W88 GM15269 transformed cell line human CVCL_5W88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086529 CVCL_6889 CNE-2 hybrid cell line human CVCL_6889 CL:0000010 Omics: Transcriptome analysis by RNAseq. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00474 Problematic cell line: Contaminated On the basis of the STR profile (PubMed=18196576) it is identical to CNE-1 and seems to be a hybrid of HeLa and of cell line of unknown origin. Originally thought to originate from a 68 year old male patient with a nasopharyngeal carcinoma. 21086530 CVCL_5W89 GM15270 transformed cell line human CVCL_5W89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086531 CVCL_6883 CAC2 undefined cell line type Norway rat CVCL_6883 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00362. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=19557180; PubMed=20143388). Originally thought to originate from salivary gland adenoid cystic carcinoma. 21086532 CVCL_5W83 GM15263 transformed cell line human CVCL_5W83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086533 CVCL_6884 CCC-ESF-1 finite cell line human CVCL_6884 CL:0000010 Derived from sampling site: Skin. Male 21086534 CVCL_5W84 GM15264 transformed cell line human CVCL_5W84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086535 CVCL_6885 CCC-HPF-1 finite cell line human CVCL_6885 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21086536 CVCL_5W85 GM15265 transformed cell line human CVCL_5W85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086537 CVCL_6886 CCC-HSF-1 finite cell line human CVCL_6886 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21086538 CVCL_5W86 GM15267 transformed cell line human CVCL_5W86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086539 CVCL_6898 Eca-109 cancer cell line human CVCL_6898 CL:0000010 Population: Chinese Female Doubling time: 28.57 +- 0.12 hours (PubMed=24002547). 21086540 CVCL_5W98 GM15280 transformed cell line human CVCL_5W98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086541 CVCL_6899 EH-GB2 cancer cell line human CVCL_6899 CL:0000010 Population: Chinese; Derived from metastatic site: Liver. Male Doubling time: ~48 hours (PubMed=22134783) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21086542 CVCL_5W99 GM15281 transformed cell line human CVCL_5W99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086543 CVCL_6894 DeH128 (M) cancer cell line human CVCL_6894 CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 30 hours (PubMed=1703129) 21086544 CVCL_5W94 GM15276 transformed cell line human CVCL_5W94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086545 CVCL_6895 DiFi cancer cell line human CVCL_6895 Genome ancestry: African=2.91%; Native American=0.44%; East Asian, North=1.85%; East Asian, South=0%; South Asian=0%; European, North=54.25%; European, South=40.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu443fs*16 (c.1328_1329delAA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1151Ter (c.3451G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (Cosmic-CLP; DepMap) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0002000000030) It was one of the sources for the STR profile of this entry. Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~40 hours (PubMed=8385096); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21086546 CVCL_5W95 GM15277 transformed cell line human CVCL_5W95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086547 CVCL_6896 DKC-8 transformed cell line house mouse CVCL_6896 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; distal convoluted tubule Cell type=Epithelial cell.. Unspecified 21086548 CVCL_5W96 GM15278 transformed cell line human CVCL_5W96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086549 CVCL_6897 EC109/CDDP cancer cell line human CVCL_6897 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female 21086550 CVCL_5W97 GM15279 transformed cell line human CVCL_5W97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086551 CVCL_6870 A7d factor-dependent cell line house mouse CVCL_6870 CL:0000010 Transfected with: HGNC; 6342; KIT Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000093) It was the sole source of information for this entry. Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21086552 CVCL_5W70 GM15244 transformed cell line human CVCL_5W70 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086553 CVCL_6871 AAV-293 transformed cell line human CVCL_6871 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Agilent Technologies/Stratagene; Catalog number: 240073 Female Caution: Not the same cell line as 293AAV from Cell Biolabs (Cellosaurus=CVCL_KA64) 21086554 CVCL_5W71 GM15245 transformed cell line human CVCL_5W71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086555 CVCL_5W65 GM15238 transformed cell line human CVCL_5W65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086556 CVCL_6865 KOCL-51 cancer cell line human CVCL_6865 CL:0000010 Population: Japanese. Male 21086557 CVCL_5W66 GM15239 transformed cell line human CVCL_5W66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086558 CVCL_6866 KOCL-50 cancer cell line human CVCL_6866 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Female 21086559 CVCL_5W67 GM15241 transformed cell line human CVCL_5W67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086560 CVCL_6867 KOCL-48 cancer cell line human CVCL_6867 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638). Population: Japanese Female 21086561 CVCL_5W68 GM15242 transformed cell line human CVCL_5W68 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086562 CVCL_6868 HO-8910 cancer cell line human CVCL_6868 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000280, 3131C0001000700024) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00606 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; CCRID). Originally thought to originate from the ascites of a 51 year old female patient with ovarian serous cystadenocarcinoma. 21086563 CVCL_6861 Caov-2 cancer cell line human CVCL_6861 CL:0000010 Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Discontinued: ATCC; HTB-74; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00458 Problematic cell line: Contaminated Shown to be a OVCAR-2 derivative (PubMed=22710073). 21086564 CVCL_5W61 GM15234 transformed cell line human CVCL_5W61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086565 CVCL_5W62 GM15235 transformed cell line human CVCL_5W62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086566 CVCL_6862 Lu-130 cancer cell line human CVCL_6862 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175) Population: Japanese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB0465; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00232 Problematic cell line: Contaminated Shown to be a Lu-134-A (or Lu-134-B) derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from a 61 year old male patient with small cell lung carcinoma. 21086567 CVCL_5W63 GM15236 transformed cell line human CVCL_5W63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086568 CVCL_6863 OV-MZ-19 cancer cell line human CVCL_6863 CL:0000010 Female 21086569 CVCL_5W64 GM15237 transformed cell line human CVCL_5W64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086570 CVCL_6864 Kasumi-5 cancer cell line human CVCL_6864 CL:0000010 Sequence variation: Gene fusion; HGNC; 8068; NUP98 + HGNC; 9859; RAP1GDS1; Name(s)=NUP98-RAP1GDS1 (PubMed=32180206) Population: Chinese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Male 21086571 CVCL_6869 6T-CEM cancer cell line human CVCL_6869 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8296 21086572 CVCL_5W69 GM15243 transformed cell line human CVCL_5W69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086573 CVCL_6880 B6Tert-1 telomerase immortalized cell line human CVCL_6880 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Trophoblast. Male 21086574 CVCL_5W80 GM15259 transformed cell line human CVCL_5W80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086575 CVCL_6881 BIU-87 undefined cell line type CVCL_6881 CL:0000010 Unspecified Doubling time: 34 hours (CCRID). Problematic cell line: Misidentified/contaminated Seems to be contaminated by non-human cells (PubMed=26116706). Originally thought to originate from a male patient with an urinary bladder carcinoma. 21086576 CVCL_5W81 GM15260 transformed cell line human CVCL_5W81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086577 CVCL_6882 BIU-87/ADMR undefined cell line type CVCL_6882 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Unspecified Problematic cell line: Misidentified/contaminated Parent cell line (BIU-87) seems to be contaminated by non-human cells. 21086578 CVCL_5W82 GM15261 transformed cell line human CVCL_5W82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086579 CVCL_6876 ACCS cancer cell line human CVCL_6876 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (DepMap) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00361 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=19557180; PubMed=20143388). Originally thought to originate from a 56 year old female patient with a salivary gland adenoid cystic carcinoma. 21086580 CVCL_5W76 GM15251 transformed cell line human CVCL_5W76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086581 CVCL_6877 ACCY cancer cell line human CVCL_6877 CL:0000010 Population: Japanese Male Doubling time: 130 hours (PubMed=2162254). 21086582 CVCL_5W77 GM15252 transformed cell line human CVCL_5W77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086583 CVCL_6878 AGZY83-a cancer cell line human CVCL_6878 CL:0000010 Population: Chinese. 21086584 CVCL_5W78 GM15256 transformed cell line human CVCL_5W78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086585 CVCL_6879 Anip-973 cancer cell line human CVCL_6879 CL:0000010 Population: Chinese. 21086586 CVCL_5W79 GM15257 transformed cell line human CVCL_5W79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086587 CVCL_6872 ACC-2 cancer cell line human CVCL_6872 CL:0000010 Miscellaneous: Formerly the CCRID database had 3 entries describing this cell line (3111C0001CCC000272, 3131C0001000700062, 3142C0001000000048) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00357 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=19557180; PubMed=20143388; PubMed=21868764; PubMed=26116706). Originally thought to originate from a 28 year old female patient with a salivary gland adenoid cystic carcinoma. 21086588 CVCL_5W72 GM15247 transformed cell line human CVCL_5W72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086589 CVCL_6873 ACC-3 cancer cell line human CVCL_6873 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00358 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=19557180; PubMed=20143388; PubMed=21868764). Originally thought to originate from a 49 year old male patient with a salivary gland adenoid cystic carcinoma. 21086590 CVCL_5W73 GM15248 transformed cell line human CVCL_5W73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086591 CVCL_6874 ACC-M cancer cell line human CVCL_6874 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00359 Problematic cell line: Contaminated Parent cell line (ACC-2) has been shown to be a HeLa derivative (PubMed=19557180; PubMed=20143388; PubMed=21868764; PubMed=26116706). 21086592 CVCL_5W74 GM15249 transformed cell line human CVCL_5W74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086593 CVCL_6875 ACCNS undefined cell line type house mouse CVCL_6875 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00360. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse (PubMed=19557180; PubMed=20143388). Originally thought to originate from a male patient with a salivary gland adenoid cystic carcinoma. 21086594 CVCL_5W75 GM15250 transformed cell line human CVCL_5W75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086595 CVCL_5W43 GM15193 transformed cell line human CVCL_5W43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086596 CVCL_6843 LN-827 cancer cell line human CVCL_6843 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; right frontal lobe. Female 21086597 CVCL_5W44 GM15194 transformed cell line human CVCL_5W44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086598 CVCL_6844 LN-859 cancer cell line human CVCL_6844 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; left temporo-parietal lobe. Male 21086599 CVCL_5W45 GM15212 transformed cell line human CVCL_5W45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086600 CVCL_6845 LN-992 cancer cell line human CVCL_6845 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; right temporal lobe. Male 21086601 CVCL_5W46 GM15213 transformed cell line human CVCL_5W46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086602 CVCL_6846 MACL-1 cancer cell line human CVCL_6846 CL:0000010 Miscellaneous: Age at sampling from personal communication of Goes A.M Population: Brazilian; Derived from sampling site: Breast. Omics: Array-based CGH Female Characteristics: Original tumor belongs to the luminal subtype A; ER+, PR+ and ERBB2-, but cell line is triple negative (PubMed=23404580) Doubling time: 29 hours (PubMed=19725227) 21086603 CVCL_5W40 GM15187 transformed cell line human CVCL_5W40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086604 CVCL_6840 LN-401 cancer cell line human CVCL_6840 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; right temporo-parietal lobe. Male 21086605 CVCL_5W41 GM15191 transformed cell line human CVCL_5W41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086606 CVCL_6841 LN-427 cancer cell line human CVCL_6841 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; left temporo-parietal lobe. Male 21086607 CVCL_5W42 GM15192 transformed cell line human CVCL_5W42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086608 CVCL_6842 LN-71 cancer cell line human CVCL_6842 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Unspecified (PubMed=10416987) Derived from sampling site: Brain; left temporo-parietal lobe. Male 21086609 CVCL_5W47 GM15215 transformed cell line human CVCL_5W47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086610 CVCL_6847 MGSO-3 cancer cell line human CVCL_6847 CL:0000010 Miscellaneous: Age at sampling from personal communication of Goes A.M Population: Brazilian; Derived from sampling site: Breast. Omics: Array-based CGH Female Characteristics: Original tumor is ER-negative, PR-negative and ERBB2-positive but cell line is triple negative (PubMed=23404580) Doubling time: 25 hours (PubMed=19725227) 21086611 CVCL_5W48 GM15216 transformed cell line human CVCL_5W48 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086612 CVCL_6848 REF52 spontaneously immortalized cell line Norway rat CVCL_6848 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Omics: Proteome analysis by 2D-DE Unspecified 21086613 CVCL_5W49 GM15217 transformed cell line human CVCL_5W49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086614 CVCL_6849 RNK-16 cancer cell line Norway rat CVCL_6849 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21086615 CVCL_5W60 GM15230 transformed cell line human CVCL_5W60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086616 CVCL_6860 MCF-7B cancer cell line human CVCL_6860 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21086617 CVCL_5W54 GM15224 transformed cell line human CVCL_5W54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086618 CVCL_6854 Tx3868 cancer cell line human CVCL_6854 CL:0000010 Derived from sampling site: Brain. Unspecified 21086619 CVCL_5W55 GM15225 transformed cell line human CVCL_5W55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086620 CVCL_6855 HMT-3522 spontaneously immortalized cell line human CVCL_6855 CL:0000010 Population: Caucasian; Donor information: Established from a nontumorigenic fibrocystic breast lesion; Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female Characteristics: EGF dependent 21086621 CVCL_5W56 GM15226 transformed cell line human CVCL_5W56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086622 CVCL_6856 HMT-3909S1 cancer cell line human CVCL_6856 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (PubMed=7786603). Female Characteristics: Non-tumorigenic Doubling time: 55 hours (PubMed=7786603) Group: Serum/protein free medium cell line; Group: Triple negative breast cancer (TNBC) cell line 21086623 CVCL_5W57 GM15227 transformed cell line human CVCL_5W57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086624 CVCL_6857 HMT-3909S8 cancer cell line human CVCL_6857 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (PubMed=7786603). Female Characteristics: Tumorigenic Doubling time: 38 hours (PubMed=7786603) Group: Serum/protein free medium cell line; Group: Triple negative breast cancer (TNBC) cell line 21086625 CVCL_5W50 GM15219 transformed cell line human CVCL_5W50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086626 CVCL_6850 T/C28a2 transformed cell line human CVCL_6850 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Female 21086627 CVCL_5W51 GM15221 transformed cell line human CVCL_5W51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086628 CVCL_6851 Tca8113 cancer cell line human CVCL_6851 CL:0000010 Miscellaneous: Formerly the CCRID database had 3 entries describing this cell line (3111C0001CCC000296, 3131C0001000700077, 3142C0001000000067) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00578 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; PubMed=28851942). Originally thought to originate from a female patient with a tongue squamous cell carcinoma. 21086629 CVCL_5W52 GM15222 transformed cell line human CVCL_5W52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086630 CVCL_6852 TCL-Na1 transformed cell line human CVCL_6852 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21086631 CVCL_5W53 GM15223 transformed cell line human CVCL_5W53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086632 CVCL_6853 Tx3095 cancer cell line human CVCL_6853 CL:0000010 Derived from sampling site: Brain. Unspecified 21086633 CVCL_5W58 GM15228 transformed cell line human CVCL_5W58 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086634 CVCL_6858 HMT-3909 cancer cell line human CVCL_6858 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (PubMed=7786603). Female Group: Triple negative breast cancer (TNBC) cell line 21086635 CVCL_5W59 GM15229 transformed cell line human CVCL_5W59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21086636 CVCL_6859 QGY-7701 cancer cell line human CVCL_6859 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700042) It was the sole source for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00551 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a hepatocellular carcinoma. 21086637 CVCL_GJ39 ND13521 transformed cell line human CVCL_GJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086638 CVCL_GJ35 ND13456 transformed cell line human CVCL_GJ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086639 CVCL_GJ36 ND13461 transformed cell line human CVCL_GJ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086640 CVCL_GJ37 ND13504 transformed cell line human CVCL_GJ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086641 CVCL_GJ38 ND13507 transformed cell line human CVCL_GJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086642 CVCL_GJ31 ND13393 transformed cell line human CVCL_GJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086643 CVCL_GJ32 ND13395 transformed cell line human CVCL_GJ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086644 CVCL_GJ33 ND13416 transformed cell line human CVCL_GJ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086645 CVCL_GJ34 ND13434 transformed cell line human CVCL_GJ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086646 CVCL_GJ30 ND13392 transformed cell line human CVCL_GJ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086647 CVCL_GJ46 ND13569 transformed cell line human CVCL_GJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086648 CVCL_GJ47 ND13572 transformed cell line human CVCL_GJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086649 CVCL_GJ48 ND13573 transformed cell line human CVCL_GJ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086650 CVCL_GJ49 ND13574 transformed cell line human CVCL_GJ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086651 CVCL_GJ42 ND13546 transformed cell line human CVCL_GJ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086652 CVCL_GJ43 ND13551 transformed cell line human CVCL_GJ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086653 CVCL_GJ44 ND13553 transformed cell line human CVCL_GJ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086654 CVCL_GJ45 ND13554 transformed cell line human CVCL_GJ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086655 CVCL_GJ40 ND13523 transformed cell line human CVCL_GJ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086656 CVCL_GJ41 ND13524 transformed cell line human CVCL_GJ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086657 CVCL_GJ17 ND13328 transformed cell line human CVCL_GJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086658 CVCL_GJ18 ND13330 transformed cell line human CVCL_GJ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086659 CVCL_GJ19 ND13334 transformed cell line human CVCL_GJ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086660 CVCL_GJ13 ND13324 transformed cell line human CVCL_GJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086661 CVCL_GJ14 ND13325 transformed cell line human CVCL_GJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086662 CVCL_GJ15 ND13326 transformed cell line human CVCL_GJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086663 CVCL_GJ16 ND13327 transformed cell line human CVCL_GJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086664 CVCL_GJ10 ND13320 transformed cell line human CVCL_GJ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086665 CVCL_GJ11 ND13321 transformed cell line human CVCL_GJ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086666 CVCL_GJ12 ND13323 transformed cell line human CVCL_GJ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086667 CVCL_GJ28 ND13375 transformed cell line human CVCL_GJ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086668 CVCL_GJ29 ND13376 transformed cell line human CVCL_GJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086669 CVCL_GJ24 ND13344 transformed cell line human CVCL_GJ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086670 CVCL_GJ25 ND13345 transformed cell line human CVCL_GJ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086671 CVCL_GJ26 ND13346 transformed cell line human CVCL_GJ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086672 CVCL_GJ27 ND13348 transformed cell line human CVCL_GJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086673 CVCL_GJ20 ND13335 transformed cell line human CVCL_GJ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086674 CVCL_GJ21 ND13337 transformed cell line human CVCL_GJ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086675 CVCL_GJ22 ND13342 transformed cell line human CVCL_GJ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086676 CVCL_GJ23 ND13343 transformed cell line human CVCL_GJ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086677 CVCL_GJ06 ND13314 transformed cell line human CVCL_GJ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086678 CVCL_GJ07 ND13315 transformed cell line human CVCL_GJ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086679 CVCL_GJ08 ND13318 transformed cell line human CVCL_GJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086680 CVCL_GJ09 ND13319 transformed cell line human CVCL_GJ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086681 CVCL_GJ02 ND13308 transformed cell line human CVCL_GJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086682 CVCL_GJ03 ND13309 transformed cell line human CVCL_GJ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086683 CVCL_GJ04 ND13311 transformed cell line human CVCL_GJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086684 CVCL_GJ05 ND13312 transformed cell line human CVCL_GJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086685 CVCL_GJ00 ND13302 transformed cell line human CVCL_GJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086686 CVCL_GJ01 ND13303 transformed cell line human CVCL_GJ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086687 CVCL_PD60 BayGenomics ES cell line SYA102 embryonic stem cell house mouse CVCL_PD60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086688 CVCL_PD61 BayGenomics ES cell line SYA108 embryonic stem cell house mouse CVCL_PD61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086689 CVCL_PD62 BayGenomics ES cell line SYA110 embryonic stem cell house mouse CVCL_PD62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921807; Ppp6r3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086690 CVCL_PD63 BayGenomics ES cell line SYA111 embryonic stem cell house mouse CVCL_PD63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354175; Txnrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086691 CVCL_PD64 BayGenomics ES cell line SYA112 embryonic stem cell house mouse CVCL_PD64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086692 CVCL_PD65 BayGenomics ES cell line SYA113 embryonic stem cell house mouse CVCL_PD65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086693 CVCL_PD66 BayGenomics ES cell line SYA117 embryonic stem cell house mouse CVCL_PD66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144224; Dnaaf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086694 CVCL_PD67 BayGenomics ES cell line SYA125 embryonic stem cell house mouse CVCL_PD67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87859; Abl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086695 CVCL_PD68 BayGenomics ES cell line SYA126 embryonic stem cell house mouse CVCL_PD68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914923; Elob Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086696 CVCL_PD69 BayGenomics ES cell line SYA128 embryonic stem cell house mouse CVCL_PD69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920832; Camkmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086697 CVCL_PD50 BayGenomics ES cell line SYA013 embryonic stem cell house mouse CVCL_PD50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086698 CVCL_PD51 BayGenomics ES cell line SYA043 embryonic stem cell house mouse CVCL_PD51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086699 CVCL_PD52 BayGenomics ES cell line SYA045 embryonic stem cell house mouse CVCL_PD52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3763743; Snhg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086700 CVCL_PD53 BayGenomics ES cell line SYA056 embryonic stem cell house mouse CVCL_PD53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086701 CVCL_PD54 BayGenomics ES cell line SYA061 embryonic stem cell house mouse CVCL_PD54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443590; Ddx11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086702 CVCL_PD55 BayGenomics ES cell line SYA072 embryonic stem cell house mouse CVCL_PD55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086703 CVCL_PD56 BayGenomics ES cell line SYA073 embryonic stem cell house mouse CVCL_PD56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086704 CVCL_PD57 BayGenomics ES cell line SYA074 embryonic stem cell house mouse CVCL_PD57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086705 CVCL_PD58 BayGenomics ES cell line SYA077 embryonic stem cell house mouse CVCL_PD58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153063; Parvb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086706 CVCL_PD59 BayGenomics ES cell line SYA089 embryonic stem cell house mouse CVCL_PD59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329034; Ccne2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086707 CVCL_PD40 BayGenomics ES cell line STA117 embryonic stem cell house mouse CVCL_PD40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101884; Ppard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086708 CVCL_PD41 BayGenomics ES cell line STB015 embryonic stem cell house mouse CVCL_PD41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086709 CVCL_PD42 BayGenomics ES cell line STB050 embryonic stem cell house mouse CVCL_PD42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915546; Smu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086710 CVCL_PD43 BayGenomics ES cell line STB080 embryonic stem cell house mouse CVCL_PD43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086711 CVCL_PD44 BayGenomics ES cell line STB129 embryonic stem cell house mouse CVCL_PD44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086712 CVCL_PD45 BayGenomics ES cell line STB249 embryonic stem cell house mouse CVCL_PD45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086713 CVCL_GJ97 ND13861 transformed cell line human CVCL_GJ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086714 CVCL_PD46 BayGenomics ES cell line STB609 embryonic stem cell house mouse CVCL_PD46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086715 CVCL_GJ98 ND13862 transformed cell line human CVCL_GJ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086716 CVCL_PD47 BayGenomics ES cell line SYA010 embryonic stem cell house mouse CVCL_PD47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086717 CVCL_GJ99 ND13914 transformed cell line human CVCL_GJ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086718 CVCL_PD48 BayGenomics ES cell line SYA011 embryonic stem cell house mouse CVCL_PD48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086719 CVCL_PD49 BayGenomics ES cell line SYA012 embryonic stem cell house mouse CVCL_PD49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086720 CVCL_GJ93 ND13840 transformed cell line human CVCL_GJ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086721 CVCL_GJ94 ND13841 transformed cell line human CVCL_GJ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086722 CVCL_GJ95 ND13843 transformed cell line human CVCL_GJ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086723 CVCL_GJ96 ND13860 transformed cell line human CVCL_GJ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086724 CVCL_PD30 BayGenomics ES cell line STA075 embryonic stem cell house mouse CVCL_PD30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:93830; Adipor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086725 CVCL_PD31 BayGenomics ES cell line STA078 embryonic stem cell house mouse CVCL_PD31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922066; Tpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086726 CVCL_PD32 BayGenomics ES cell line STA082 embryonic stem cell house mouse CVCL_PD32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914228; Luc7l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086727 CVCL_PD33 BayGenomics ES cell line STA084 embryonic stem cell house mouse CVCL_PD33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2175912; Arid5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086728 CVCL_PD34 BayGenomics ES cell line STA093 embryonic stem cell house mouse CVCL_PD34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086729 CVCL_PD35 BayGenomics ES cell line STA094 embryonic stem cell house mouse CVCL_PD35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086730 CVCL_PD36 BayGenomics ES cell line STA100 embryonic stem cell house mouse CVCL_PD36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442943; Zfp668 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086731 CVCL_PD37 BayGenomics ES cell line STA103 embryonic stem cell house mouse CVCL_PD37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925503; Map4k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086732 CVCL_PD38 BayGenomics ES cell line STA104 embryonic stem cell house mouse CVCL_PD38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915208; U2surp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086733 CVCL_PD39 BayGenomics ES cell line STA107 embryonic stem cell house mouse CVCL_PD39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914119; Zfp869 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086734 CVCL_GJ80 ND13734 transformed cell line human CVCL_GJ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086735 CVCL_GJ81 ND13735 transformed cell line human CVCL_GJ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086736 CVCL_GJ79 ND13733 transformed cell line human CVCL_GJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086737 CVCL_PD20 BayGenomics ES cell line STA027 embryonic stem cell house mouse CVCL_PD20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086738 CVCL_PD21 BayGenomics ES cell line STA028 embryonic stem cell house mouse CVCL_PD21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105968; Txlna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086739 CVCL_PD22 BayGenomics ES cell line STA029 embryonic stem cell house mouse CVCL_PD22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086740 CVCL_PD23 BayGenomics ES cell line STA031 embryonic stem cell house mouse CVCL_PD23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109349; Atf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086741 CVCL_GJ75 ND13728 transformed cell line human CVCL_GJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086742 CVCL_PD24 BayGenomics ES cell line STA034 embryonic stem cell house mouse CVCL_PD24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086743 CVCL_GJ76 ND13729 transformed cell line human CVCL_GJ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086744 CVCL_PD25 BayGenomics ES cell line STA054 embryonic stem cell house mouse CVCL_PD25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349767; Polk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086745 CVCL_GJ77 ND13730 transformed cell line human CVCL_GJ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086746 CVCL_PD26 BayGenomics ES cell line STA057 embryonic stem cell house mouse CVCL_PD26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927344; Gmnn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086747 CVCL_GJ78 ND13731 transformed cell line human CVCL_GJ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086748 CVCL_PD27 BayGenomics ES cell line STA066 embryonic stem cell house mouse CVCL_PD27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927167; Morf4l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086749 CVCL_GJ71 ND13678 transformed cell line human CVCL_GJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086750 CVCL_PD28 BayGenomics ES cell line STA067 embryonic stem cell house mouse CVCL_PD28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920247; Kantr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086751 CVCL_GJ72 ND13702 transformed cell line human CVCL_GJ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086752 CVCL_PD29 BayGenomics ES cell line STA072 embryonic stem cell house mouse CVCL_PD29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086753 CVCL_GJ73 ND13711 transformed cell line human CVCL_GJ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086754 CVCL_GJ74 ND13713 transformed cell line human CVCL_GJ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086755 CVCL_PD09 BayGenomics ES cell line ST519 embryonic stem cell house mouse CVCL_PD09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086756 CVCL_GJ90 ND13814 transformed cell line human CVCL_GJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086757 CVCL_GJ91 ND13838 transformed cell line human CVCL_GJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086758 CVCL_GJ92 ND13839 transformed cell line human CVCL_GJ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086759 CVCL_PD10 BayGenomics ES cell line ST531 embryonic stem cell house mouse CVCL_PD10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086760 CVCL_PD11 BayGenomics ES cell line ST567 embryonic stem cell house mouse CVCL_PD11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95321; Emb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086761 CVCL_PD12 BayGenomics ES cell line ST629 embryonic stem cell house mouse CVCL_PD12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105088; Ntn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086762 CVCL_GJ86 ND13764 transformed cell line human CVCL_GJ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086763 CVCL_PD13 BayGenomics ES cell line STA004 embryonic stem cell house mouse CVCL_PD13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443699; Fubp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086764 CVCL_GJ87 ND13767 transformed cell line human CVCL_GJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086765 CVCL_PD14 BayGenomics ES cell line STA005 embryonic stem cell house mouse CVCL_PD14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086766 CVCL_GJ88 ND13784 transformed cell line human CVCL_GJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086767 CVCL_PD15 BayGenomics ES cell line STA006 embryonic stem cell house mouse CVCL_PD15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086768 CVCL_GJ89 ND13812 transformed cell line human CVCL_GJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086769 CVCL_PD16 BayGenomics ES cell line STA011 embryonic stem cell house mouse CVCL_PD16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926252; Gipc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086770 CVCL_GJ82 ND13739 transformed cell line human CVCL_GJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086771 CVCL_PD17 BayGenomics ES cell line STA018 embryonic stem cell house mouse CVCL_PD17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm2050 (MGI:3780218) which is no longer considered a gene by MGI 21086772 CVCL_GJ83 ND13740 transformed cell line human CVCL_GJ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086773 CVCL_PD18 BayGenomics ES cell line STA020 embryonic stem cell house mouse CVCL_PD18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086774 CVCL_GJ84 ND13757 transformed cell line human CVCL_GJ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086775 CVCL_PD19 BayGenomics ES cell line STA021 embryonic stem cell house mouse CVCL_PD19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97838; Eprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086776 CVCL_GJ85 ND13760 transformed cell line human CVCL_GJ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086777 CVCL_GJ57 ND13592 transformed cell line human CVCL_GJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086778 CVCL_GJ58 ND13594 transformed cell line human CVCL_GJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086779 CVCL_GJ59 ND13609 transformed cell line human CVCL_GJ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086780 CVCL_PD00 BayGenomics ES cell line RST752 embryonic stem cell house mouse CVCL_PD00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333805; Srsf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086781 CVCL_PD01 BayGenomics ES cell line RST753 embryonic stem cell house mouse CVCL_PD01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914347; Rps10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086782 CVCL_GJ53 ND13582 transformed cell line human CVCL_GJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086783 CVCL_PD02 BayGenomics ES cell line RST760 embryonic stem cell house mouse CVCL_PD02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889844; Sumf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086784 CVCL_GJ54 ND13583 transformed cell line human CVCL_GJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086785 CVCL_PD03 BayGenomics ES cell line RST768 embryonic stem cell house mouse CVCL_PD03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086786 CVCL_GJ55 ND13584 transformed cell line human CVCL_GJ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086787 CVCL_PD04 BayGenomics ES cell line RST769 embryonic stem cell house mouse CVCL_PD04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086788 CVCL_GJ56 ND13585 transformed cell line human CVCL_GJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086789 CVCL_PD05 BayGenomics ES cell line RST770 embryonic stem cell house mouse CVCL_PD05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086790 CVCL_PD06 BayGenomics ES cell line ST484 embryonic stem cell house mouse CVCL_PD06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086791 CVCL_GJ50 ND13575 transformed cell line human CVCL_GJ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086792 CVCL_PD07 BayGenomics ES cell line ST497 embryonic stem cell house mouse CVCL_PD07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98277; Epha4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086793 CVCL_GJ51 ND13576 transformed cell line human CVCL_GJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086794 CVCL_PD08 BayGenomics ES cell line ST514 embryonic stem cell house mouse CVCL_PD08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105088; Ntn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086795 CVCL_GJ52 ND13579 transformed cell line human CVCL_GJ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086796 CVCL_GJ70 ND13676 transformed cell line human CVCL_GJ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086797 CVCL_GJ68 ND13671 transformed cell line human CVCL_GJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086798 CVCL_GJ69 ND13674 transformed cell line human CVCL_GJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086799 CVCL_GJ64 ND13660 transformed cell line human CVCL_GJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086800 CVCL_GJ65 ND13666 transformed cell line human CVCL_GJ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086801 CVCL_GJ66 ND13669 transformed cell line human CVCL_GJ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086802 CVCL_GJ67 ND13670 transformed cell line human CVCL_GJ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086803 CVCL_GJ60 ND13614 transformed cell line human CVCL_GJ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086804 CVCL_GJ61 ND13623 transformed cell line human CVCL_GJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086805 CVCL_GJ62 ND13627 transformed cell line human CVCL_GJ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086806 CVCL_GJ63 ND13630 transformed cell line human CVCL_GJ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086807 CVCL_PN10 BayGenomics ES cell line XE372 embryonic stem cell house mouse CVCL_PN10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086808 CVCL_PN11 BayGenomics ES cell line XE374 embryonic stem cell house mouse CVCL_PN11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086809 CVCL_PN12 BayGenomics ES cell line XE377 embryonic stem cell house mouse CVCL_PN12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086810 CVCL_PN13 BayGenomics ES cell line XE378 embryonic stem cell house mouse CVCL_PN13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109153; Ktn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086811 CVCL_PN14 BayGenomics ES cell line XE379 embryonic stem cell house mouse CVCL_PN14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914552; Zc3h13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086812 CVCL_PN15 BayGenomics ES cell line XE380 embryonic stem cell house mouse CVCL_PN15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086813 CVCL_PN16 BayGenomics ES cell line XE381 embryonic stem cell house mouse CVCL_PN16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289147; E2f7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086814 CVCL_PN17 BayGenomics ES cell line XE382 embryonic stem cell house mouse CVCL_PN17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914116; Nhlrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086815 CVCL_PN18 BayGenomics ES cell line XE383 embryonic stem cell house mouse CVCL_PN18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086816 CVCL_PN19 BayGenomics ES cell line XE387 embryonic stem cell house mouse CVCL_PN19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086817 CVCL_H577 Fer Ray finite cell line human CVCL_H577 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1156; true Male 21086818 CVCL_GT77 ND03385 transformed cell line human CVCL_GT77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086819 CVCL_H578 EH/A44 transformed cell line CVCL_H578 CL:0000010 Transformant: Human herpesvirus 1 (HHV-1)(NCBI-Taxonomy; 10298); Derived from sampling site: Cell type=Fibroblast. Unspecified 21086820 CVCL_GT78 ND03482 transformed cell line human CVCL_GT78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086821 CVCL_H579 Ketr-3 cancer cell line human CVCL_H579 CL:0000010 Population: Chinese. 21086822 CVCL_GT79 ND03483 transformed cell line human CVCL_GT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086823 CVCL_H573 GM14862 transformed cell line human CVCL_H573 HLA typing: A*33:01,74:AB; B*50:01,53:01; C*06:02,07:CVAG; DRB1*01:02,13:01 (IPD-IMGT/HLA=19248); HLA typing: A*33:01:01,74:01:01; B*50:01:01,53:01:01; C*06:02:01,07:18; DPA1*02:01:01,02:01:08; DPB1*01:01:01,11:01:01; DQA1*01:01:02,01:03:01; DQB1*05:01:01,06:03:01; DRB1*01:02:01,13:01:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21086824 CVCL_GT73 ND03335 transformed cell line human CVCL_GT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086825 CVCL_H574 GM14863 transformed cell line human CVCL_H574 HLA typing: A*01:01:01,02:01:01; B*08:01:01,14:02:01; C*07:01:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,04:01:01; DQB1*04:02:01,06:02:01; DRB1*08:01:01,15:03:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21086826 CVCL_GT74 ND03336 transformed cell line human CVCL_GT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086827 CVCL_H575 GM14864 transformed cell line human CVCL_H575 HLA typing: A*02:DFKP,03:DDKG; B*27:EKN,57:04; C*01:WG,18:AB; DRB1*01:03,07:01 (IPD-IMGT/HLA=16417) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086828 CVCL_GT75 ND03337 transformed cell line human CVCL_GT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086829 CVCL_H576 EHT spontaneously immortalized cell line CVCL_H576 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21086830 CVCL_GT76 ND03384 transformed cell line human CVCL_GT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086831 CVCL_H570 GM14826 transformed cell line human CVCL_H570 HLA typing: A*02:DFKP,30:AUX; B*42:01,45:AH; C*16:01,17:MN; DRB1*03:02,12:CVT (IPD-IMGT/HLA=15815) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086832 CVCL_GT70 ND03275 transformed cell line human CVCL_GT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086833 CVCL_H571 GM14837 transformed cell line human CVCL_H571 HLA typing: A*24:CWFP,29:03; B*37:01,53:01; C*06:02; DRB1*10:01,11:01 (IPD-IMGT/HLA=15336) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086834 CVCL_GT71 ND03277 transformed cell line human CVCL_GT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086835 CVCL_H572 GM14857 transformed cell line human CVCL_H572 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086836 CVCL_GT72 ND03278 transformed cell line human CVCL_GT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086837 CVCL_PN20 BayGenomics ES cell line XE388 embryonic stem cell house mouse CVCL_PN20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277166; Sp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086838 CVCL_PN00 BayGenomics ES cell line XE355 embryonic stem cell house mouse CVCL_PN00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086839 CVCL_PN01 BayGenomics ES cell line XE356 embryonic stem cell house mouse CVCL_PN01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:5141924; Pakap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086840 CVCL_PN02 BayGenomics ES cell line XE360 embryonic stem cell house mouse CVCL_PN02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920442; Xpot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086841 CVCL_PN03 BayGenomics ES cell line XE362 embryonic stem cell house mouse CVCL_PN03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086842 CVCL_PN04 BayGenomics ES cell line XE363 embryonic stem cell house mouse CVCL_PN04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086843 CVCL_PN05 BayGenomics ES cell line XE366 embryonic stem cell house mouse CVCL_PN05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913964; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086844 CVCL_PN06 BayGenomics ES cell line XE367 embryonic stem cell house mouse CVCL_PN06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99695; Cttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086845 CVCL_PN07 BayGenomics ES cell line XE368 embryonic stem cell house mouse CVCL_PN07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859866; Cdc20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086846 CVCL_PN08 BayGenomics ES cell line XE369 embryonic stem cell house mouse CVCL_PN08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922387; Rprd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086847 CVCL_PN09 BayGenomics ES cell line XE370 embryonic stem cell house mouse CVCL_PN09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086848 CVCL_GT88 ND09213 transformed cell line human CVCL_GT88 CL:0000010 Population: Caucasian; Norwegian/Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086849 CVCL_H588 W4 [Mouse lymphoma] cancer cell line house mouse CVCL_H588 CL:0000010 Transfected with: MGI; MGI:95484; Fas Breed/subspecies: BALB/c. Female 21086850 CVCL_GT89 ND09214 transformed cell line human CVCL_GT89 CL:0000010 Population: Caucasian; Belgian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086851 CVCL_H589 SACC-83 cancer cell line human CVCL_H589 CL:0000010 Population: Chinese; Derived from sampling site: Salivary gland; sublingual gland. Omics: Transcriptome analysis by microarray Female 21086852 CVCL_H584 BE-NQ5 cancer cell line human CVCL_H584 CL:0000010 Transfected with: HGNC; 2874; NQO1. Male 21086853 CVCL_GT84 ND09156 transformed cell line human CVCL_GT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086854 CVCL_H585 BE-NQ7 cancer cell line human CVCL_H585 CL:0000010 Transfected with: HGNC; 2874; NQO1. Male 21086855 CVCL_GT85 ND09184 transformed cell line human CVCL_GT85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086856 CVCL_H586 L2987 cancer cell line human CVCL_H586 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 21086857 CVCL_GT86 ND09186 transformed cell line human CVCL_GT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086858 CVCL_H587 MAC 15A cancer cell line house mouse CVCL_H587 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: NMRI. 21086859 CVCL_GT87 ND09187 transformed cell line human CVCL_GT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086860 CVCL_H580 BE [Human colon carcinoma] cancer cell line human CVCL_H580 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=12068308) Omics: Transcriptome analysis by microarray. Male Part of: KuDOS 95 cell line panel 21086861 CVCL_GT80 ND03486 transformed cell line human CVCL_GT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086862 CVCL_H581 BE-NQ2 cancer cell line human CVCL_H581 CL:0000010 Transfected with: HGNC; 2874; NQO1. Male 21086863 CVCL_GT81 ND03487 transformed cell line human CVCL_GT81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086864 CVCL_H582 BE-NQ3 cancer cell line human CVCL_H582 CL:0000010 Transfected with: HGNC; 2874; NQO1. Male 21086865 CVCL_GT82 ND03488 transformed cell line human CVCL_GT82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086866 CVCL_H583 BE-NQ4 cancer cell line human CVCL_H583 CL:0000010 Transfected with: HGNC; 2874; NQO1. Male 21086867 CVCL_GT83 ND09155 transformed cell line human CVCL_GT83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086868 CVCL_GT59 GM09919 finite cell line human CVCL_GT59 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21086869 CVCL_H559 GM14754 transformed cell line human CVCL_H559 HLA typing: A*02:DFKP,29:02; B*13:02,49:01; C*06:02,07:CVAG; DRB1*09:01,13:02 (IPD-IMGT/HLA=20685) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086870 CVCL_H555 GM00004 finite cell line human CVCL_H555 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21086871 CVCL_GT55 GM09849 transformed cell line human CVCL_GT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086872 CVCL_H556 GM00005 finite cell line human CVCL_H556 CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,der(14;22)(14qter->14q10::22q10->22qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21086873 CVCL_GT56 GM09850 transformed cell line human CVCL_GT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086874 CVCL_H557 GM00149 transformed cell line human CVCL_H557 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Lys285Asn (c.855G>T); ClinVar=VCV000003621; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086875 CVCL_GT57 GM09853 transformed cell line human CVCL_GT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086876 CVCL_GT58 GM09864 transformed cell line human CVCL_GT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086877 CVCL_H558 GM14753 transformed cell line human CVCL_H558 HLA typing: A*02:01:01,30:01:01; B*13:02:01,38:01:01; C*06:02:01,12:03:01; DPA1*01:03:01,02:01:01; DPB1*04:02:01,09:01:01; DQA1*02:01:01,05:05:01; DQB1*02:02:01,03:01:01; DRB1*07:01:01,11:04:01; DRB3*02:02:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21086878 CVCL_GT51 GM09589 transformed cell line human CVCL_GT51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086879 CVCL_H551 GM11576 finite cell line human CVCL_H551 CL:0000010 Sequence variation: Mutation; HGNC; 4976; HLCS; Simple; c.1519+5G>A (IVS10+5G>A); ClinVar=VCV000001912; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4976; HLCS; Simple; p.Leu514Pro; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Amniotic fluid. Female 21086880 CVCL_GT52 GM09667 finite cell line human CVCL_GT52 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21086881 CVCL_H552 GM11380 finite cell line human CVCL_H552 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21086882 CVCL_GT53 GM09822 transformed cell line human CVCL_GT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086883 CVCL_H553 GM11239 finite cell line human CVCL_H553 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1:16)(1pter->1q24::16q21->16qter;16pter->16q21::1q24->1qter) (Coriell); Derived from sampling site: Amniotic fluid. Female 21086884 CVCL_GT54 GM09832 transformed cell line human CVCL_GT54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086885 CVCL_H554 GM10015 transformed cell line human CVCL_H554 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086886 CVCL_GT50 GM04263 finite cell line human CVCL_GT50 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21086887 CVCL_H550 GM12452 finite cell line human CVCL_H550 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21086888 CVCL_GT66 GM13937 transformed cell line human CVCL_GT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086889 CVCL_H566 GM14788 transformed cell line human CVCL_H566 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086890 CVCL_H567 GM14807 transformed cell line human CVCL_H567 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086891 CVCL_GT67 ND03213 transformed cell line human CVCL_GT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086892 CVCL_H568 GM14817 transformed cell line human CVCL_H568 CL:0000010 Sequence variation: Mutation; HGNC; 9706; NECTIN1; Simple; p.Trp185Ter (c.554G>A); ClinVar=VCV000008969; Zygosity=Homozygous (Coriell) Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086893 CVCL_GT68 ND03214 transformed cell line human CVCL_GT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086894 CVCL_H569 GM14818 finite cell line human CVCL_H569 CL:0000010 Sequence variation: Mutation; HGNC; 9706; NECTIN1; Simple; p.Trp185Ter (c.554G>A); ClinVar=VCV000008969; Zygosity=Homozygous (Coriell) Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Male 21086895 CVCL_GT69 ND03274 transformed cell line human CVCL_GT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086896 CVCL_GT62 GM10474 finite cell line human CVCL_GT62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21086897 CVCL_H562 GM14772 transformed cell line human CVCL_H562 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21086898 CVCL_GT63 GM10507 finite cell line human CVCL_GT63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Unspecified 21086899 CVCL_H563 GM14779 transformed cell line human CVCL_H563 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086900 CVCL_GT64 GM10714 transformed cell line human CVCL_GT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with hereditary hemorrhagic telangiectasia but at risk for disease; Derived from sampling site: Peripheral blood. Female 21086901 CVCL_H564 GM14780 transformed cell line human CVCL_H564 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21086902 CVCL_GT65 GM13280 finite cell line human CVCL_GT65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21086903 CVCL_H565 GM14781 transformed cell line human CVCL_H565 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086904 CVCL_GT60 GM10232 transformed cell line human CVCL_GT60 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086905 CVCL_H560 GM14755 transformed cell line human CVCL_H560 HLA typing: A*01:02,33:03; B*18:RRG,49:01; C*05:AC,07:WTR (IPD-IMGT/HLA=15333) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086906 CVCL_GT61 GM10403 finite cell line human CVCL_GT61 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21086907 CVCL_H561 GM14771 transformed cell line human CVCL_H561 HLA typing: A*02:DFKP,31:CGAJ; B*35:BEZX,35:08; C*04:CVAF; DRB1*11:02,16:01 (IPD-IMGT/HLA=15820) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21086908 CVCL_GT37 OC-3-VGH cancer cell line human CVCL_GT37 CL:0000010 Population: Chinese; Derived from sampling site: Ovary. Female Doubling time: 48 hours (PubMed=3455323) 21086909 CVCL_H537 R5-28 clone C7 cancer cell line Norway rat CVCL_H537 CL:0000010 Breed/subspecies: Lewis. Female 21086910 CVCL_GT38 OC-7-NU cancer cell line human CVCL_GT38 CL:0000010 Derived from metastatic site: Ascites. Female 21086911 CVCL_H538 R5-28 clone D6 cancer cell line Norway rat CVCL_H538 CL:0000010 Breed/subspecies: Lewis. Female 21086912 CVCL_H539 MDA-8788-6 cancer cell line human CVCL_H539 CL:0000010 Female Doubling time: ~40 hours (PubMed=23032744). 21086913 CVCL_GT39 OC-89-VGH cancer cell line human CVCL_GT39 CL:0000010 Population: Chinese; Derived from sampling site: Ovary. Female Doubling time: 51 hours, at 20th passage (CelloPub=CLPUB00350) 21086914 CVCL_H533 BET-2A transformed cell line human CVCL_H533 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9443 21086915 CVCL_GT33 OC-109 cancer cell line human CVCL_GT33 CL:0000010 Derived from metastatic site: Ascites. Female 21086916 CVCL_H534 22D6 transformed cell line house mouse CVCL_H534 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21086917 CVCL_GT34 OC-109-VGH cancer cell line human CVCL_GT34 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Female 21086918 CVCL_GT35 OC-117-VGH cancer cell line human CVCL_GT35 CL:0000010 Population: Chinese; Derived from sampling site: Ovary. Female Characteristics: ER-alpha, ER-beta and PR-negative (PubMed=16138714) 21086919 CVCL_H535 R5-28 cancer cell line Norway rat CVCL_H535 CL:0000010 Breed/subspecies: Lewis. Female 21086920 CVCL_GT36 OC-238 cancer cell line human CVCL_GT36 CL:0000010 Derived from metastatic site: Ascites. Female 21086921 CVCL_H536 R5-28 clone C4 cancer cell line Norway rat CVCL_H536 CL:0000010 Breed/subspecies: Lewis. Female 21086922 CVCL_H530 GM17731 finite cell line human CVCL_H530 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Discontinued: Coriell; GM17731; probable Male Senescence: Capable of at least 32 PDL (Coriell=GM17731) 21086923 CVCL_GT30 NTUH-iPSC-002-02 induced pluripotent stem cell human CVCL_GT30 From: National Taiwan University; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21086924 CVCL_H531 MeT-4A transformed cell line human CVCL_H531 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21086925 CVCL_GT31 TVGH-iPSC-001-04 induced pluripotent stem cell human CVCL_GT31 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21086926 CVCL_H532 BES-1A1.6 transformed cell line human CVCL_H532 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9608 21086927 CVCL_GT32 TVGH-iPSC-002-07 induced pluripotent stem cell human CVCL_GT32 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21086928 CVCL_GT48 GM03418 finite cell line human CVCL_GT48 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21086929 CVCL_H548 GM13200 finite cell line human CVCL_H548 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21086930 CVCL_GT49 GM03419 finite cell line human CVCL_GT49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21086931 CVCL_H549 GM12519 finite cell line human CVCL_H549 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Female 21086932 CVCL_GT44 G cancer cell line dog CVCL_GT44 CL:0000010 Unspecified 21086933 CVCL_H544 GHR3 cancer cell line human CVCL_H544 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Characteristics: Derived from spontaneous HPRT- mutant of EJ30 Problematic cell line: Contaminated Ancestral cell line (Ej138) has been shown to be a T24 derivative. 21086934 CVCL_H545 GM14946 finite cell line human CVCL_H545 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Male 21086935 CVCL_GT45 NI-1 cancer cell line dog CVCL_GT45 CL:0000010 Miscellaneous: Sex of donor from personal communication of Willmann M Breed/subspecies: Mixed breed. Male 21086936 CVCL_GT46 GM02452 finite cell line human CVCL_GT46 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21086937 CVCL_H546 GM14758 finite cell line human CVCL_H546 CL:0000010 Derived from sampling site: Amnion. Female 21086938 CVCL_GT47 GM03015 finite cell line human CVCL_GT47 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21086939 CVCL_H547 GM14760 finite cell line human CVCL_H547 CL:0000010 Derived from sampling site: Chorionic villus. Female 21086940 CVCL_H540 MDA-8788-7 cancer cell line human CVCL_H540 CL:0000010 Female Doubling time: ~40 hours (PubMed=23032744). 21086941 CVCL_GT40 OCPC-2-VGH cancer cell line human CVCL_GT40 CL:0000010 Population: Chinese; Derived from sampling site: Ovary. Female Doubling time: 44.85 +- 4.02 hours (in 10% FCS), 46.69 +- 2.94 hours (in 2% FCS), 58.98 +- 2.05 hours (in 0% FCS) (CelloPub=CLPUB00351) 21086942 CVCL_H541 MDA-1386Ln cancer cell line human CVCL_H541 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21086943 CVCL_GT41 NTUH-iPSC-001-05 induced pluripotent stem cell human CVCL_GT41 From: National Taiwan University; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21086944 CVCL_GT42 BR cancer cell line dog CVCL_GT42 CL:0000010 Sequence variation: Mutation; VGNC; 42422; KIT; Simple; p.Leu575Pro (c.1724T>C); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 46054; SETD2; Simple; p.Arg526fs (c.1576delA); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ala193Asp (c.578C>A); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg263Cys (c.787C>T); Zygosity=Heterozygous (PubMed=31175136) Omics: Deep exome analysis. Unspecified Doubling time: 36 hours (PubMed=27257868) 21086945 CVCL_H542 MDA-1386Tu cancer cell line human CVCL_H542 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21086946 CVCL_GT43 CL1 [Dog mastocytoma] cancer cell line dog CVCL_GT43 CL:0000010 Derived from metastatic site: Ascites; Breed/subspecies: Labrador Retriever. Female 21086947 CVCL_H543 FDC-P3 factor-dependent cell line house mouse CVCL_H543 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6 x DBA/2. Characteristics: IL3 dependent 21086948 CVCL_H519 HEK293/hNav1.5 transformed cell line human CVCL_H519 CL:0000010 Transfected with: HGNC; 10593; SCN5A Miscellaneous: Cell line under development; catalog number M00293 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086949 CVCL_GT19 TO4 Y56A cancer cell line dog CVCL_GT19 CL:0000010 Discontinued: ATCC; CRL-6580; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21086950 CVCL_H515 HEK293/GCGR/Galpha15 transformed cell line human CVCL_H515 CL:0000010 Transfected with: HGNC; 4192; GCGR; Transfected with: HGNC; 4383; GNA15 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086951 CVCL_GT15 ND05195 transformed cell line human CVCL_GT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086952 CVCL_H516 HEK293/hERG transformed cell line human CVCL_H516 CL:0000010 Transfected with: HGNC; 6251; KCNH2 Miscellaneous: Cell line under development; catalog number M00282 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086953 CVCL_GT16 ND06808 transformed cell line human CVCL_GT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086954 CVCL_H517 HEK293/hKv1.5 transformed cell line human CVCL_H517 CL:0000010 Transfected with: HGNC; 6224; KCNA5 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086955 CVCL_GT17 ND06826 transformed cell line human CVCL_GT17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086956 CVCL_H518 HEK293/hKv4.2 transformed cell line human CVCL_H518 CL:0000010 Transfected with: HGNC; 6238; KCND2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086957 CVCL_GT18 ND07919 transformed cell line human CVCL_GT18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086958 CVCL_H511 CHO-K1/VPAC2/Galpha15 spontaneously immortalized cell line CVCL_H511 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 12695; VIPR2 Derived from sampling site: Ovary. Female 21086959 CVCL_GT11 ND02255 transformed cell line human CVCL_GT11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086960 CVCL_H512 CHO-K1/hERG spontaneously immortalized cell line CVCL_H512 CL:0000010 Transfected with: HGNC; 6251; KCNH2 Miscellaneous: Cell line under development; catalog number M00283 Derived from sampling site: Ovary. Female 21086961 CVCL_GT12 ND02557 transformed cell line human CVCL_GT12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21086962 CVCL_H513 HEK293/5-HT2C transformed cell line human CVCL_H513 CL:0000010 Transfected with: HGNC; 5295; HTR2C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086963 CVCL_GT13 ND02713 transformed cell line human CVCL_GT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086964 CVCL_H514 HEK293/AT1 transformed cell line human CVCL_H514 CL:0000010 Transfected with: HGNC; 336; AGTR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086965 CVCL_GT14 ND02796 transformed cell line human CVCL_GT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086966 CVCL_H510 CHO-K1/VPAC1/Galpha15 spontaneously immortalized cell line CVCL_H510 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 12694; VIPR1 Derived from sampling site: Ovary. Female 21086967 CVCL_GT10 ND02203 transformed cell line human CVCL_GT10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086968 CVCL_GT26 cbMSC-hTERT-RFP telomerase immortalized cell line human CVCL_GT26 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Female 21086969 CVCL_H526 ML-3 cancer cell line human CVCL_H526 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21086970 CVCL_H527 GM16560 transformed cell line human CVCL_H527 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086971 CVCL_GT27 IBMS-iPSC-001-02 induced pluripotent stem cell human CVCL_GT27 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21086972 CVCL_H528 GM16563 finite cell line human CVCL_H528 CL:0000010 Derived from sampling site: Skin Cell type=Keratinocyte.. Female 21086973 CVCL_GT28 IBMS-iPSC-002-07 induced pluripotent stem cell human CVCL_GT28 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21086974 CVCL_H529 GM19808 finite cell line human CVCL_H529 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21086975 CVCL_GT29 ND05437 transformed cell line human CVCL_GT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086976 CVCL_GT22 ALTS1C1-SDFkd transformed cell line house mouse CVCL_GT22 CL:0000010 Knockout cell: Method=siRNA knockdown; MGI; MGI:103556; Cxcl12 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J. Male 21086977 CVCL_H522 RH7777/EDG6 cancer cell line Norway rat CVCL_H522 CL:0000010 Transfected with: HGNC; 3170; S1PR4 Miscellaneous: Cell line under development; catalog number M00465 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21086978 CVCL_GT23 CC-135-VGH cancer cell line human CVCL_GT23 CL:0000010 Population: Chinese; Derived from sampling site: Uterus; cervix. Female Doubling time: ~44 hours (CelloPub=CLPUB00353) 21086979 CVCL_H523 RH7777/P2Y5 cancer cell line Norway rat CVCL_H523 CL:0000010 Transfected with: HGNC; 15520; LPAR6 Miscellaneous: Cell line under development; catalog number M00472 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21086980 CVCL_GT24 ESC 98B01 embryonic stem cell house mouse CVCL_GT24 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21086981 CVCL_H524 YT-nu cancer cell line human CVCL_H524 CL:0000010 Population: Japanese Unspecified Characteristics: Established from tissue heterotransplanted into nude mice. 21086982 CVCL_GT25 cbMSC-hTERT telomerase immortalized cell line human CVCL_GT25 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Female 21086983 CVCL_H525 ML-1 [Human thyroid carcinoma] cancer cell line human CVCL_H525 HLA typing: A*68:01,68:01; B*07:02,07:02; C*07:02,07:02; DQA1*03:02,03:02; DQB1*06:02,06:02; DRB1*13:26,15:01 (PubMed=26589293); Genome ancestry: African=0.17%; Native American=0.68%; East Asian, North=3.84%; East Asian, South=0%; South Asian=0%; European, North=57.01%; European, South=38.3% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: ~4-7 days (DSMZ=ACC-464); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21086984 CVCL_GT20 CG1476 finite cell line human CVCL_GT20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21086985 CVCL_H520 HEK293/hNav1.7 transformed cell line human CVCL_H520 CL:0000010 Transfected with: HGNC; 10597; SCN9A Miscellaneous: Cell line under development; catalog number M00509 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21086986 CVCL_GT21 CG1485 transformed cell line human CVCL_GT21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21086987 CVCL_H521 RH7777/EDG4 cancer cell line Norway rat CVCL_H521 CL:0000010 Transfected with: HGNC; 3168; LPAR2 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21086988 CVCL_PN98 BayGenomics ES cell line XE521 embryonic stem cell house mouse CVCL_PN98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086989 CVCL_PN99 BayGenomics ES cell line XE527 embryonic stem cell house mouse CVCL_PN99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21086990 CVCL_YH30 CPTC-NME1-2 hybridoma house mouse CVCL_YH30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15531; Human NME1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086991 CVCL_YH35 CPTC-NME2-2 hybridoma house mouse CVCL_YH35 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P22392; Human NME2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086992 CVCL_YH36 CPTC-NME2-3 hybridoma house mouse CVCL_YH36 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P22392; Human NME2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086993 CVCL_YH37 CPTC-ODC1-1 hybridoma house mouse CVCL_YH37 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11926; Human ODC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086994 CVCL_YH38 CPTC-ODC1-2 hybridoma house mouse CVCL_YH38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11926; Human ODC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086995 CVCL_YH31 CPTC-NME1-3 hybridoma house mouse CVCL_YH31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15531; Human NME1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086996 CVCL_YH32 CPTC-NME1-4 hybridoma house mouse CVCL_YH32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15531; Human NME1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086997 CVCL_YH33 CPTC-NME1-5 hybridoma house mouse CVCL_YH33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15531; Human NME1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086998 CVCL_YH34 CPTC-NME2-1 hybridoma house mouse CVCL_YH34 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P22392; Human NME2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21086999 CVCL_YH39 CPTC-ODC1-3 hybridoma house mouse CVCL_YH39 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11926; Human ODC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087000 CVCL_PN87 BayGenomics ES cell line XE501 embryonic stem cell house mouse CVCL_PN87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087001 CVCL_PN88 BayGenomics ES cell line XE502 embryonic stem cell house mouse CVCL_PN88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087002 CVCL_PN89 BayGenomics ES cell line XE504 embryonic stem cell house mouse CVCL_PN89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087003 CVCL_YH24 CPTC-NCOR1-1 hybridoma house mouse CVCL_YH24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75376; Human NCOR1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087004 CVCL_YH25 CPTC-NCOR1-2 hybridoma house mouse CVCL_YH25 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75376; Human NCOR1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087005 CVCL_YH26 CPTC-NEDD4-1 hybridoma house mouse CVCL_YH26 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P46934; Human NEDD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087006 CVCL_YH27 CPTC-NEDD4-2 hybridoma house mouse CVCL_YH27 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P46934; Human NEDD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087007 CVCL_YH20 CPTC-MTOR-8 hybridoma house mouse CVCL_YH20 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087008 CVCL_YH21 CPTC-MUC17 CRD1 L CRD2-1 hybridoma house mouse CVCL_YH21 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q685J3; Human MUC17. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087009 CVCL_YH22 CPTC-MUC17 CRD1 L CRD2-2 hybridoma house mouse CVCL_YH22 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q685J3; Human MUC17. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087010 CVCL_YH23 CPTC-MUC17 CRD1 L CRD2-3 hybridoma house mouse CVCL_YH23 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q685J3; Human MUC17. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087011 CVCL_PN90 BayGenomics ES cell line XE506 embryonic stem cell house mouse CVCL_PN90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926045; Armc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087012 CVCL_PN91 BayGenomics ES cell line XE508 embryonic stem cell house mouse CVCL_PN91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923402; Utp18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087013 CVCL_PN92 BayGenomics ES cell line XE509 embryonic stem cell house mouse CVCL_PN92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929608; Aatf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087014 CVCL_PN93 BayGenomics ES cell line XE515 embryonic stem cell house mouse CVCL_PN93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915392; Ino80 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087015 CVCL_PN94 BayGenomics ES cell line XE516 embryonic stem cell house mouse CVCL_PN94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926045; Armc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087016 CVCL_YH28 CPTC-NEDD4-3 hybridoma house mouse CVCL_YH28 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P46934; Human NEDD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087017 CVCL_PN95 BayGenomics ES cell line XE517 embryonic stem cell house mouse CVCL_PN95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923385; Prex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087018 CVCL_YH29 CPTC-NME1-1 hybridoma house mouse CVCL_YH29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15531; Human NME1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087019 CVCL_PN96 BayGenomics ES cell line XE518 embryonic stem cell house mouse CVCL_PN96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918817; Mcm9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087020 CVCL_PN97 BayGenomics ES cell line XE519 embryonic stem cell house mouse CVCL_PN97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087021 CVCL_PN76 BayGenomics ES cell line XE484 embryonic stem cell house mouse CVCL_PN76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087022 CVCL_PN77 BayGenomics ES cell line XE487 embryonic stem cell house mouse CVCL_PN77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925906; Brd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087023 CVCL_PN78 BayGenomics ES cell line XE489 embryonic stem cell house mouse CVCL_PN78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087024 CVCL_PN79 BayGenomics ES cell line XE491 embryonic stem cell house mouse CVCL_PN79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277212; Zfp644 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087025 CVCL_YH13 CPTC-MTOR-1 hybridoma house mouse CVCL_YH13 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087026 CVCL_YH14 CPTC-MTOR-2 hybridoma house mouse CVCL_YH14 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087027 CVCL_YH15 CPTC-MTOR-3 hybridoma house mouse CVCL_YH15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087028 CVCL_YH16 CPTC-MTOR-4 hybridoma house mouse CVCL_YH16 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087029 CVCL_YH10 CPTC-MSN-1 hybridoma house mouse CVCL_YH10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26038; Human MSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087030 CVCL_YH11 CPTC-MSN-2 hybridoma house mouse CVCL_YH11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26038; Human MSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087031 CVCL_YH12 CPTC-MSN-3 hybridoma house mouse CVCL_YH12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26038; Human MSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087032 CVCL_PN80 BayGenomics ES cell line XE492 embryonic stem cell house mouse CVCL_PN80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087033 CVCL_PN81 BayGenomics ES cell line XE493 embryonic stem cell house mouse CVCL_PN81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859646; Golga4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087034 CVCL_PN82 BayGenomics ES cell line XE494 embryonic stem cell house mouse CVCL_PN82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891704; Hbs1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087035 CVCL_PN83 BayGenomics ES cell line XE495 embryonic stem cell house mouse CVCL_PN83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104900; Nup88 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087036 CVCL_YH17 CPTC-MTOR-5 hybridoma house mouse CVCL_YH17 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087037 CVCL_PN84 BayGenomics ES cell line XE496 embryonic stem cell house mouse CVCL_PN84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309478; Baz1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087038 CVCL_YH18 CPTC-MTOR-6 hybridoma house mouse CVCL_YH18 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087039 CVCL_PN85 BayGenomics ES cell line XE498 embryonic stem cell house mouse CVCL_PN85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087040 CVCL_YH19 CPTC-MTOR-7 hybridoma house mouse CVCL_YH19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P42345; Human MTOR. Part of: gCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087041 CVCL_PN86 BayGenomics ES cell line XE499 embryonic stem cell house mouse CVCL_PN86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096572; Zfand3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087042 CVCL_PN65 BayGenomics ES cell line XE466 embryonic stem cell house mouse CVCL_PN65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924093; Dtl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087043 CVCL_PN66 BayGenomics ES cell line XE467 embryonic stem cell house mouse CVCL_PN66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087044 CVCL_PN67 BayGenomics ES cell line XE468 embryonic stem cell house mouse CVCL_PN67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087045 CVCL_PN68 BayGenomics ES cell line XE469 embryonic stem cell house mouse CVCL_PN68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087046 CVCL_PN69 BayGenomics ES cell line XE472 embryonic stem cell house mouse CVCL_PN69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087047 CVCL_YH02 CPTC-MDC1-3 hybridoma house mouse CVCL_YH02 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14676; Human MDC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087048 CVCL_YH03 CPTC-MDH1-1 hybridoma house mouse CVCL_YH03 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P40925; Human MDH1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087049 CVCL_YH04 CPTC-MDH1-2 hybridoma house mouse CVCL_YH04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40925; Human MDH1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087050 CVCL_YH05 CPTC-MDH1-3 hybridoma house mouse CVCL_YH05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40925; Human MDH1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087051 CVCL_YH00 CPTC-MDC1-1 hybridoma house mouse CVCL_YH00 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14676; Human MDC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087052 CVCL_YH01 CPTC-MDC1-2 hybridoma house mouse CVCL_YH01 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q14676; Human MDC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087053 CVCL_PN70 BayGenomics ES cell line XE473 embryonic stem cell house mouse CVCL_PN70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102774; Aimp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087054 CVCL_PN71 BayGenomics ES cell line XE475 embryonic stem cell house mouse CVCL_PN71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106330; Larp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087055 CVCL_PN72 BayGenomics ES cell line XE476 embryonic stem cell house mouse CVCL_PN72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137357; Trim33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087056 CVCL_YH06 CPTC-MEN1-1 hybridoma house mouse CVCL_YH06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00255; Human MEN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087057 CVCL_PN73 BayGenomics ES cell line XE478 embryonic stem cell house mouse CVCL_PN73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105098; Ube3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087058 CVCL_YH07 CPTC-MPO-1 hybridoma house mouse CVCL_YH07 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P05164; Human MPO. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087059 CVCL_PN74 BayGenomics ES cell line XE480 embryonic stem cell house mouse CVCL_PN74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3505790; Fcho2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087060 CVCL_YH08 CPTC-MPO-2 hybridoma house mouse CVCL_YH08 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P05164; Human MPO. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087061 CVCL_PN75 BayGenomics ES cell line XE482 embryonic stem cell house mouse CVCL_PN75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087062 CVCL_YH09 CPTC-MPO-3 hybridoma house mouse CVCL_YH09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05164; Human MPO. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087063 CVCL_PN54 BayGenomics ES cell line XE450 embryonic stem cell house mouse CVCL_PN54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087064 CVCL_PN55 BayGenomics ES cell line XE451 embryonic stem cell house mouse CVCL_PN55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3588234; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087065 CVCL_PN56 BayGenomics ES cell line XE453 embryonic stem cell house mouse CVCL_PN56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107207; Coq7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087066 CVCL_PN57 BayGenomics ES cell line XE454 embryonic stem cell house mouse CVCL_PN57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444593; Pptc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087067 CVCL_PN58 BayGenomics ES cell line XE455 embryonic stem cell house mouse CVCL_PN58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109198; Eif4ebp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087068 CVCL_PN59 BayGenomics ES cell line XE457 embryonic stem cell house mouse CVCL_PN59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891189; Ensa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087069 CVCL_PN60 BayGenomics ES cell line XE458 embryonic stem cell house mouse CVCL_PN60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109584; Prpf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087070 CVCL_PN61 BayGenomics ES cell line XE461 embryonic stem cell house mouse CVCL_PN61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915472; Tubb4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087071 CVCL_PN62 BayGenomics ES cell line XE462 embryonic stem cell house mouse CVCL_PN62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181074; Acbd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087072 CVCL_PN63 BayGenomics ES cell line XE464 embryonic stem cell house mouse CVCL_PN63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087073 CVCL_PN64 BayGenomics ES cell line XE465 embryonic stem cell house mouse CVCL_PN64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861942; Gtf2ird1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087074 CVCL_PN43 BayGenomics ES cell line XE423 embryonic stem cell house mouse CVCL_PN43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337096; Rnf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087075 CVCL_PN44 BayGenomics ES cell line XE426 embryonic stem cell house mouse CVCL_PN44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108025; Prkar2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087076 CVCL_PN45 BayGenomics ES cell line XE427 embryonic stem cell house mouse CVCL_PN45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087077 CVCL_PN46 BayGenomics ES cell line XE430 embryonic stem cell house mouse CVCL_PN46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920185; Ddx41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087078 CVCL_PN47 BayGenomics ES cell line XE433 embryonic stem cell house mouse CVCL_PN47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914751; Ccdc50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087079 CVCL_PN48 BayGenomics ES cell line XE434 embryonic stem cell house mouse CVCL_PN48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926227; Nup160 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087080 CVCL_PN49 BayGenomics ES cell line XE436 embryonic stem cell house mouse CVCL_PN49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924270; Atl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087081 CVCL_PN50 BayGenomics ES cell line XE439 embryonic stem cell house mouse CVCL_PN50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349399; Casp8ap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087082 CVCL_PN51 BayGenomics ES cell line XE440 embryonic stem cell house mouse CVCL_PN51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196337; Brms1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087083 CVCL_PN52 BayGenomics ES cell line XE444 embryonic stem cell house mouse CVCL_PN52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96250; Hsp90aa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087084 CVCL_PN53 BayGenomics ES cell line XE448 embryonic stem cell house mouse CVCL_PN53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087085 CVCL_PN32 BayGenomics ES cell line XE408 embryonic stem cell house mouse CVCL_PN32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385207; Gnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087086 CVCL_PN33 BayGenomics ES cell line XE409 embryonic stem cell house mouse CVCL_PN33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916066; Ppil1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087087 CVCL_PN34 BayGenomics ES cell line XE410 embryonic stem cell house mouse CVCL_PN34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933137; Cttnbp2nl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087088 CVCL_PN35 BayGenomics ES cell line XE411 embryonic stem cell house mouse CVCL_PN35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087089 CVCL_PN36 BayGenomics ES cell line XE413 embryonic stem cell house mouse CVCL_PN36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087090 CVCL_PN37 BayGenomics ES cell line XE414 embryonic stem cell house mouse CVCL_PN37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917678; Polr3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087091 CVCL_PN38 BayGenomics ES cell line XE417 embryonic stem cell house mouse CVCL_PN38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087092 CVCL_PN39 BayGenomics ES cell line XE419 embryonic stem cell house mouse CVCL_PN39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087093 CVCL_GT99 ND09994 transformed cell line human CVCL_GT99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087094 CVCL_GT95 ND09565 transformed cell line human CVCL_GT95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087095 CVCL_H595 TRAMP-C2G cancer cell line house mouse CVCL_H595 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087096 CVCL_GT96 ND09990 transformed cell line human CVCL_GT96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087097 CVCL_H596 TRAMP-C2D cancer cell line house mouse CVCL_H596 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087098 CVCL_GT97 ND09992 transformed cell line human CVCL_GT97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087099 CVCL_GT98 ND09993 transformed cell line human CVCL_GT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087100 CVCL_H598 PANC 430 cancer cell line human CVCL_H598 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 21087101 CVCL_GT91 ND09308 transformed cell line human CVCL_GT91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087102 CVCL_H591 TRAMP-C2H cancer cell line house mouse CVCL_H591 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087103 CVCL_GT92 ND09370 transformed cell line human CVCL_GT92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087104 CVCL_H592 TRAMP-C2N cancer cell line house mouse CVCL_H592 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087105 CVCL_GT93 ND09371 transformed cell line human CVCL_GT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087106 CVCL_H593 TRAMP-C1A cancer cell line house mouse CVCL_H593 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087107 CVCL_GT94 ND09372 transformed cell line human CVCL_GT94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087108 CVCL_H594 TRAMP-C1D cancer cell line house mouse CVCL_H594 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male 21087109 CVCL_GT90 ND09307 transformed cell line human CVCL_GT90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087110 CVCL_H590 SACC-LM cancer cell line human CVCL_H590 CL:0000010 Population: Chinese; Derived from sampling site: Salivary gland; sublingual gland. Omics: Transcriptome analysis by microarray Female Characteristics: Highly metastatic to lung 21087111 CVCL_PN40 BayGenomics ES cell line XE420 embryonic stem cell house mouse CVCL_PN40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087112 CVCL_PN41 BayGenomics ES cell line XE421 embryonic stem cell house mouse CVCL_PN41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087113 CVCL_PN42 BayGenomics ES cell line XE422 embryonic stem cell house mouse CVCL_PN42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087114 CVCL_PN21 BayGenomics ES cell line XE390 embryonic stem cell house mouse CVCL_PN21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921997; Ddit4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087115 CVCL_PN22 BayGenomics ES cell line XE393 embryonic stem cell house mouse CVCL_PN22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087116 CVCL_PN23 BayGenomics ES cell line XE394 embryonic stem cell house mouse CVCL_PN23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087117 CVCL_PN24 BayGenomics ES cell line XE395 embryonic stem cell house mouse CVCL_PN24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923714; Knl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087118 CVCL_PN25 BayGenomics ES cell line XE398 embryonic stem cell house mouse CVCL_PN25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087119 CVCL_PN26 BayGenomics ES cell line XE399 embryonic stem cell house mouse CVCL_PN26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087120 CVCL_PN27 BayGenomics ES cell line XE400 embryonic stem cell house mouse CVCL_PN27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102579; Nmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087121 CVCL_PN28 BayGenomics ES cell line XE402 embryonic stem cell house mouse CVCL_PN28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891763; Ppp4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087122 CVCL_PN29 BayGenomics ES cell line XE403 embryonic stem cell house mouse CVCL_PN29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891763; Ppp4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087123 CVCL_PN30 BayGenomics ES cell line XE404 embryonic stem cell house mouse CVCL_PN30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087124 CVCL_PN31 BayGenomics ES cell line XE405 embryonic stem cell house mouse CVCL_PN31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087125 CVCL_6A46 GM15633 transformed cell line human CVCL_6A46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087126 CVCL_6A47 GM15634 transformed cell line human CVCL_6A47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087127 CVCL_6A48 GM15636 transformed cell line human CVCL_6A48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087128 CVCL_6A49 GM15638 transformed cell line human CVCL_6A49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087129 CVCL_YG94 CPTC-MAPK14-3 hybridoma house mouse CVCL_YG94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16539; Human MAPK14. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087130 CVCL_YG95 CPTC-MAPK3-1 hybridoma house mouse CVCL_YG95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087131 CVCL_YG96 CPTC-MAPK3-2 hybridoma house mouse CVCL_YG96 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27361; Human MAPK3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087132 CVCL_YG97 CPTC-MBD1-1 hybridoma house mouse CVCL_YG97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UIS9; Human MBD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087133 CVCL_YG90 CPTC-MAP2K1-1 hybridoma house mouse CVCL_YG90 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q02750; Human MAP2K1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087134 CVCL_YG91 CPTC-MAP2K1-2 hybridoma house mouse CVCL_YG91 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q02750; Human MAP2K1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087135 CVCL_YG92 CPTC-MAPK14-1 hybridoma house mouse CVCL_YG92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16539; Human MAPK14. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087136 CVCL_YG93 CPTC-MAPK14-2 hybridoma house mouse CVCL_YG93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16539; Human MAPK14. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087137 CVCL_YG98 CPTC-MBD1-2 hybridoma house mouse CVCL_YG98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UIS9; Human MBD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087138 CVCL_YG99 CPTC-MBD1-3 hybridoma house mouse CVCL_YG99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UIS9; Human MBD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087139 CVCL_6A42 GM15624 transformed cell line human CVCL_6A42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087140 CVCL_6A43 GM15625 transformed cell line human CVCL_6A43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087141 CVCL_6A44 GM15626 transformed cell line human CVCL_6A44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087142 CVCL_6A45 GM15630 transformed cell line human CVCL_6A45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087143 CVCL_6A40 GM15622 transformed cell line human CVCL_6A40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087144 CVCL_6A41 GM15623 transformed cell line human CVCL_6A41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087145 CVCL_6A57 GM15666 transformed cell line human CVCL_6A57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087146 CVCL_6A58 GM15667 transformed cell line human CVCL_6A58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087147 CVCL_6A59 GM15679 transformed cell line human CVCL_6A59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087148 CVCL_YG83 CPTC-KRAS4B-2 hybridoma house mouse CVCL_YG83 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P01116; Human KRAS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087149 CVCL_YG84 CPTC-KRAS4B-3 hybridoma house mouse CVCL_YG84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01116; Human KRAS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087150 CVCL_YG85 CPTC-KRAS4B-4 hybridoma house mouse CVCL_YG85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01116; Human KRAS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087151 CVCL_YG86 CPTC-LIN28A-1 hybridoma house mouse CVCL_YG86 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H9Z2; Human LIN28A. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087152 CVCL_YG80 CPTC-KLHDC8A-1 hybridoma house mouse CVCL_YG80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IYD2; Human KLHDC8A. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087153 CVCL_YG81 CPTC-KLHDC8A-2 hybridoma house mouse CVCL_YG81 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8IYD2; Human KLHDC8A. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087154 CVCL_YG82 CPTC-KRAS4B-1 hybridoma house mouse CVCL_YG82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01116; Human KRAS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087155 CVCL_YG87 CPTC-MAGEA4-1 hybridoma house mouse CVCL_YG87 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P43358; Human MAGEA4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087156 CVCL_YG88 CPTC-MAGEA4-2 hybridoma house mouse CVCL_YG88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P43358; Human MAGEA4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087157 CVCL_YG89 CPTC-MAGEA4-3 hybridoma house mouse CVCL_YG89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43358; Human MAGEA4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087158 CVCL_6A53 GM15643 transformed cell line human CVCL_6A53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087159 CVCL_6A54 GM15644 transformed cell line human CVCL_6A54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087160 CVCL_6A55 GM15647 transformed cell line human CVCL_6A55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087161 CVCL_6A56 GM15664 transformed cell line human CVCL_6A56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087162 CVCL_6A50 GM15639 transformed cell line human CVCL_6A50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087163 CVCL_6A51 GM15640 transformed cell line human CVCL_6A51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087164 CVCL_6A52 GM15642 transformed cell line human CVCL_6A52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087165 CVCL_6A28 GM15595 transformed cell line human CVCL_6A28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087166 CVCL_6A29 GM15596 transformed cell line human CVCL_6A29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087167 CVCL_6A24 GM15590 transformed cell line human CVCL_6A24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087168 CVCL_6A25 GM15591 transformed cell line human CVCL_6A25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087169 CVCL_6A26 GM15593 transformed cell line human CVCL_6A26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087170 CVCL_6A27 GM15594 transformed cell line human CVCL_6A27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087171 CVCL_YG72 CPTC-JUN-1 hybridoma house mouse CVCL_YG72 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087172 CVCL_YG73 CPTC-JUN-2 hybridoma house mouse CVCL_YG73 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087173 CVCL_YG74 CPTC-JUN-3 hybridoma house mouse CVCL_YG74 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05412; Human JUN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087174 CVCL_YG75 CPTC-KIAA1967-1 hybridoma house mouse CVCL_YG75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N163; Human CCAR2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087175 CVCL_YG70 CPTC-ITCH-2 hybridoma house mouse CVCL_YG70 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q96J02; Human ITCH. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087176 CVCL_YG71 CPTC-ITCH-3 hybridoma house mouse CVCL_YG71 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q96J02; Human ITCH. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087177 CVCL_YG76 CPTC-KIAA1967-2 hybridoma house mouse CVCL_YG76 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N163; Human CCAR2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087178 CVCL_YG77 CPTC-KIF2C-1 hybridoma house mouse CVCL_YG77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99661; Human KIF2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087179 CVCL_YG78 CPTC-KIF2C-2 hybridoma house mouse CVCL_YG78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99661; Human KIF2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087180 CVCL_YG79 CPTC-KIF2C-3 hybridoma house mouse CVCL_YG79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99661; Human KIF2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087181 CVCL_6A20 GM15583 transformed cell line human CVCL_6A20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087182 CVCL_6A21 GM15584 transformed cell line human CVCL_6A21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087183 CVCL_6A22 GM15585 transformed cell line human CVCL_6A22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087184 CVCL_6A23 GM15589 transformed cell line human CVCL_6A23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087185 CVCL_6A39 GM15620 transformed cell line human CVCL_6A39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087186 CVCL_6A35 GM15616 transformed cell line human CVCL_6A35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087187 CVCL_6A36 GM15617 transformed cell line human CVCL_6A36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087188 CVCL_6A37 GM15618 transformed cell line human CVCL_6A37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087189 CVCL_6A38 GM15619 transformed cell line human CVCL_6A38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087190 CVCL_YG61 CPTC-IDO1-1 hybridoma house mouse CVCL_YG61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P14902; Human IDO1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087191 CVCL_YG62 CPTC-IDO1-2 hybridoma house mouse CVCL_YG62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P14902; Human IDO1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087192 CVCL_YG63 CPTC-IL18-1 hybridoma house mouse CVCL_YG63 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14116; Human IL18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087193 CVCL_YG64 CPTC-IL18-2 hybridoma house mouse CVCL_YG64 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14116; Human IL18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087194 CVCL_YG60 CPTC-HSPD1-3 hybridoma house mouse CVCL_YG60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10809; Human HSPD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087195 CVCL_YG69 CPTC-ITCH-1 hybridoma house mouse CVCL_YG69 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q96J02; Human ITCH. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087196 CVCL_YG65 CPTC-IL18-3 hybridoma house mouse CVCL_YG65 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q14116; Human IL18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087197 CVCL_YG66 CPTC-IL6-1 hybridoma house mouse CVCL_YG66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05231; Human IL6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087198 CVCL_YG67 CPTC-IL6-2 hybridoma house mouse CVCL_YG67 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05231; Human IL6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087199 CVCL_YG68 CPTC-IL6-3 hybridoma house mouse CVCL_YG68 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05231; Human IL6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087200 CVCL_6A31 GM15609 transformed cell line human CVCL_6A31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087201 CVCL_6A32 GM15610 transformed cell line human CVCL_6A32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087202 CVCL_6A33 GM15613 transformed cell line human CVCL_6A33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087203 CVCL_6A34 GM15614 transformed cell line human CVCL_6A34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087204 CVCL_6A30 GM15597 transformed cell line human CVCL_6A30 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087205 CVCL_6A06 GM15560 transformed cell line human CVCL_6A06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087206 CVCL_6A07 GM15562 transformed cell line human CVCL_6A07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087207 CVCL_6A08 GM15563 transformed cell line human CVCL_6A08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087208 CVCL_6A09 GM15564 transformed cell line human CVCL_6A09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087209 CVCL_6A02 GM15554 transformed cell line human CVCL_6A02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087210 CVCL_6A03 GM15556 transformed cell line human CVCL_6A03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087211 CVCL_6A04 GM15557 transformed cell line human CVCL_6A04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087212 CVCL_6A05 GM15558 transformed cell line human CVCL_6A05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087213 CVCL_YG50 CPTC-GSTMu2-2 hybridoma house mouse CVCL_YG50 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28161; Human GSTM2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087214 CVCL_YG51 CPTC-GSTMu2-3 hybridoma house mouse CVCL_YG51 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28161; Human GSTM2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087215 CVCL_YG52 CPTC-GSTMu3-1 hybridoma house mouse CVCL_YG52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P21266; Human GSTM3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087216 CVCL_YG53 CPTC-GSTMu3-2 hybridoma house mouse CVCL_YG53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21266; Human GSTM3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087217 CVCL_YG58 CPTC-HSPD1-1 hybridoma house mouse CVCL_YG58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10809; Human HSPD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087218 CVCL_YG59 CPTC-HSPD1-2 hybridoma house mouse CVCL_YG59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10809; Human HSPD1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087219 CVCL_YG54 CPTC-GSTMu3-3 hybridoma house mouse CVCL_YG54 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21266; Human GSTM3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087220 CVCL_YG55 CPTC-HSPB1-1 hybridoma house mouse CVCL_YG55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04792; Human HSPB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087221 CVCL_YG56 CPTC-HSPB1-2 hybridoma house mouse CVCL_YG56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04792; Human HSPB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087222 CVCL_YG57 CPTC-HSPB1-3 hybridoma house mouse CVCL_YG57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04792; Human HSPB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087223 CVCL_6A00 GM15552 transformed cell line human CVCL_6A00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087224 CVCL_6A01 GM15553 transformed cell line human CVCL_6A01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087225 CVCL_6A17 GM15579 transformed cell line human CVCL_6A17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087226 CVCL_6A18 GM15580 transformed cell line human CVCL_6A18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087227 CVCL_6A19 GM15581 transformed cell line human CVCL_6A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087228 CVCL_6A13 GM15573 transformed cell line human CVCL_6A13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087229 CVCL_6A14 GM15576 transformed cell line human CVCL_6A14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087230 CVCL_6A15 GM15577 transformed cell line human CVCL_6A15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087231 CVCL_6A16 GM15578 transformed cell line human CVCL_6A16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087232 CVCL_YG40 CPTC-GSK3B-7 hybridoma house mouse CVCL_YG40 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087233 CVCL_YG41 CPTC-GSK3B-8 hybridoma house mouse CVCL_YG41 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087234 CVCL_YG42 CPTC-GSTMu1-1 hybridoma house mouse CVCL_YG42 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087235 CVCL_YG47 CPTC-GSTMu1-6 hybridoma house mouse CVCL_YG47 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087236 CVCL_YG48 CPTC-GSTMu1-7 hybridoma house mouse CVCL_YG48 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087237 CVCL_YG49 CPTC-GSTMu2-1 hybridoma house mouse CVCL_YG49 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P28161; Human GSTM2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087238 CVCL_YG43 CPTC-GSTMu1-2 hybridoma house mouse CVCL_YG43 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087239 CVCL_YG44 CPTC-GSTMu1-3 hybridoma house mouse CVCL_YG44 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087240 CVCL_YG45 CPTC-GSTMu1-4 hybridoma house mouse CVCL_YG45 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087241 CVCL_YG46 CPTC-GSTMu1-5 hybridoma house mouse CVCL_YG46 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09488; Human GSTM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087242 CVCL_6A10 GM15566 transformed cell line human CVCL_6A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087243 CVCL_6A11 GM15567 transformed cell line human CVCL_6A11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087244 CVCL_6A12 GM15569 transformed cell line human CVCL_6A12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087245 CVCL_PM99 BayGenomics ES cell line XE354 embryonic stem cell house mouse CVCL_PM99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087246 CVCL_YG30 CPTC-GMNN-2 hybridoma house mouse CVCL_YG30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75496; Human GMNN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087247 CVCL_YG31 CPTC-GPI-1 hybridoma house mouse CVCL_YG31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06744; Human GPI. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087248 CVCL_YG36 CPTC-GSK3B-3 hybridoma house mouse CVCL_YG36 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087249 CVCL_YG37 CPTC-GSK3B-4 hybridoma house mouse CVCL_YG37 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087250 CVCL_YG38 CPTC-GSK3B-5 hybridoma house mouse CVCL_YG38 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087251 CVCL_YG39 CPTC-GSK3B-6 hybridoma house mouse CVCL_YG39 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087252 CVCL_YG32 CPTC-GPI-2 hybridoma house mouse CVCL_YG32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06744; Human GPI. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087253 CVCL_YG33 CPTC-GPI-3 hybridoma house mouse CVCL_YG33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06744; Human GPI. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087254 CVCL_YG34 CPTC-GSK3B-1 hybridoma house mouse CVCL_YG34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087255 CVCL_YG35 CPTC-GSK3B-2 hybridoma house mouse CVCL_YG35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49841; Human GSK3B. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087256 CVCL_PM88 BayGenomics ES cell line XE324 embryonic stem cell house mouse CVCL_PM88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087257 CVCL_PM89 BayGenomics ES cell line XE327 embryonic stem cell house mouse CVCL_PM89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087258 CVCL_YG20 CPTC-Gelsolin-2 hybridoma house mouse CVCL_YG20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06396; Human GSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087259 CVCL_YG25 CPTC-GI.1 Norovirus RDRP-3 hybridoma house mouse CVCL_YG25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q83883; Norovirus GI.1 genome polyprotein (AA 1282-1789; RNA-dependent RNA polymerase). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087260 CVCL_YG26 CPTC-GLO1-1 hybridoma house mouse CVCL_YG26 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q04760; Human GLO1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087261 CVCL_YG27 CPTC-GLO1-2 hybridoma house mouse CVCL_YG27 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q04760; Human GLO1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087262 CVCL_YG28 CPTC-GLO1-3 hybridoma house mouse CVCL_YG28 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q04760; Human GLO1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087263 CVCL_YG21 CPTC-Gelsolin-3 hybridoma house mouse CVCL_YG21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06396; Human GSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087264 CVCL_YG22 CPTC-Gelsolin-4 hybridoma house mouse CVCL_YG22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06396; Human GSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087265 CVCL_YG23 CPTC-GI.1 Norovirus RDRP-1 hybridoma house mouse CVCL_YG23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q83883; Norovirus GI.1 genome polyprotein (AA 1282-1789; RNA-dependent RNA polymerase). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087266 CVCL_PM90 BayGenomics ES cell line XE328 embryonic stem cell house mouse CVCL_PM90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087267 CVCL_YG24 CPTC-GI.1 Norovirus RDRP-2 hybridoma house mouse CVCL_YG24 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q83883; Norovirus GI.1 genome polyprotein (AA 1282-1789; RNA-dependent RNA polymerase). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087268 CVCL_PM91 BayGenomics ES cell line XE330 embryonic stem cell house mouse CVCL_PM91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929091; Sinhcaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087269 CVCL_PM92 BayGenomics ES cell line XE332 embryonic stem cell house mouse CVCL_PM92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087270 CVCL_PM93 BayGenomics ES cell line XE337 embryonic stem cell house mouse CVCL_PM93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157980; Vac14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087271 CVCL_PM94 BayGenomics ES cell line XE338 embryonic stem cell house mouse CVCL_PM94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087272 CVCL_PM95 BayGenomics ES cell line XE342 embryonic stem cell house mouse CVCL_PM95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087273 CVCL_YG29 CPTC-GMNN-1 hybridoma house mouse CVCL_YG29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75496; Human GMNN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087274 CVCL_PM96 BayGenomics ES cell line XE344 embryonic stem cell house mouse CVCL_PM96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446632; Ago2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087275 CVCL_PM97 BayGenomics ES cell line XE345 embryonic stem cell house mouse CVCL_PM97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087276 CVCL_PM98 BayGenomics ES cell line XE347 embryonic stem cell house mouse CVCL_PM98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087277 CVCL_H508 CHO-K1/V1B spontaneously immortalized cell line CVCL_H508 CL:0000010 Transfected with: HGNC; 896; AVPR1B Derived from sampling site: Ovary. Female 21087278 CVCL_GT08 ND02075 transformed cell line human CVCL_GT08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087279 CVCL_H509 CHO-K1/V2/Galpha15 spontaneously immortalized cell line CVCL_H509 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21087280 CVCL_GT09 ND02083 transformed cell line human CVCL_GT09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087281 CVCL_H504 CHO-K1/SUCNR1/Galpha15 spontaneously immortalized cell line CVCL_H504 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4542; SUCNR1 Miscellaneous: Cell line under development; catalog number M00471 Derived from sampling site: Ovary. Female 21087282 CVCL_GT04 GM25204 transformed cell line human CVCL_GT04 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly59Alafs*18 (c.176_191del16); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087283 CVCL_H505 CHO-K1/TRH1 spontaneously immortalized cell line CVCL_H505 CL:0000010 Transfected with: HGNC; 12299; TRHR Derived from sampling site: Ovary. Female 21087284 CVCL_GT05 ND02011 transformed cell line human CVCL_GT05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087285 CVCL_H506 CHO-K1/UT2/Galpha15 spontaneously immortalized cell line CVCL_H506 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4468; UTS2R Derived from sampling site: Ovary. Female 21087286 CVCL_GT06 ND02038 transformed cell line human CVCL_GT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087287 CVCL_H507 CHO-K1/V1A spontaneously immortalized cell line CVCL_H507 CL:0000010 Transfected with: HGNC; 895; AVPR1A Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00181 Female 21087288 CVCL_GT07 ND02039 transformed cell line human CVCL_GT07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087289 CVCL_H500 CHO-K1/SST2/Galpha15 spontaneously immortalized cell line CVCL_H500 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 11331; SSTR2 Derived from sampling site: Ovary. Female 21087290 CVCL_GT00 GM23665 transformed cell line human CVCL_GT00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087291 CVCL_H501 CHO-K1/SST3/Galpha15 spontaneously immortalized cell line CVCL_H501 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 11332; SSTR3 Derived from sampling site: Ovary. Female 21087292 CVCL_GT01 GM23731 transformed cell line human CVCL_GT01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087293 CVCL_H502 CHO-K1/SST4/Galpha15 spontaneously immortalized cell line CVCL_H502 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 11333; SSTR4 Derived from sampling site: Ovary. Female 21087294 CVCL_GT02 GM23835 transformed cell line human CVCL_GT02 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly12Valfs*2 (c.35delG); ClinVar=VCV000017004; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Met34Thr (c.101T>C); ClinVar=VCV000017000; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087295 CVCL_H503 CHO-K1/SST5/Galpha15 spontaneously immortalized cell line CVCL_H503 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 11334; SSTR5 Derived from sampling site: Ovary. Female 21087296 CVCL_GT03 GM23925 transformed cell line human CVCL_GT03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087297 CVCL_6A80 HC2S2 conditionally immortalized cell line Norway rat CVCL_6A80 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain; hippocampus; Breed/subspecies: Fischer. Unspecified 21087298 CVCL_6A81 Gie-No3B11 transformed cell line human CVCL_6A81 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line recommanded name and sex of donor from author direct submission Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Discontinued: ABM; T0049; probable Female 21087299 CVCL_6A86 TBR31-2 conditionally immortalized cell line house mouse CVCL_6A86 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087300 CVCL_6A87 883L transformed cell line human CVCL_6A87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21087301 CVCL_6A88 B84-15 transformed cell line CVCL_6A88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21087302 CVCL_6A89 LSCC-HD2 transformed cell line CVCL_6A89 CL:0000010 Breed/subspecies: White Leghorn SPAFAS. Female Group: Bird cell line 21087303 CVCL_6A82 GMSM-K transformed cell line human CVCL_6A82 CL:0000010 Karyotypic information: 46,XY [21%]; 89-92,XXYY [79%], hypotetraploid (PubMed=10982956); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal oral cavity; mouth; labial vestibule Cell type=Keratinocyte.. Male Doubling time: ~90 hours (PubMed=10982956) 21087304 CVCL_6A83 6R081Cl1 cancer cell line CVCL_6A83 CL:0000010 Derived from sampling site: Upper jaw; hypodermis. Female 21087305 CVCL_6A84 MGS transformed cell line CVCL_6A84 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; epithelium Cell type=Epithelial cell.. Unspecified 21087306 CVCL_6A85 BMA1 transformed cell line house mouse CVCL_6A85 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Bone marrow; Breed/subspecies: ddY. Male Characteristics: Produces CSF2 (PubMed=6603995) Doubling time: 21 hours, at 60th passage (PubMed=6603995) 21087307 CVCL_6A90 LSCC-HD4 transformed cell line CVCL_6A90 CL:0000010 Breed/subspecies: White Leghorn SPAFAS. Female Group: Bird cell line 21087308 CVCL_6A91 TBR-B conditionally immortalized cell line house mouse CVCL_6A91 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087309 CVCL_6A92 TBR52 conditionally immortalized cell line house mouse CVCL_6A92 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087310 CVCL_6A97 TM02-3 conditionally immortalized cell line house mouse CVCL_6A97 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087311 CVCL_6A98 Astro 1 conditionally immortalized cell line house mouse CVCL_6A98 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21087312 CVCL_6A99 Astro 2 conditionally immortalized cell line house mouse CVCL_6A99 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21087313 CVCL_6A93 SVS24 conditionally immortalized cell line house mouse CVCL_6A93 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; smooth muscle; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087314 CVCL_6A94 SVS30 conditionally immortalized cell line house mouse CVCL_6A94 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; smooth muscle; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087315 CVCL_6A95 TC6 conditionally immortalized cell line house mouse CVCL_6A95 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Joint articular cartilage Cell type=Chondrocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087316 CVCL_6A96 TM01 conditionally immortalized cell line house mouse CVCL_6A96 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087317 CVCL_6A68 GM15691 transformed cell line human CVCL_6A68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087318 CVCL_6A69 GM15692 transformed cell line human CVCL_6A69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087319 CVCL_6A64 GM15685 transformed cell line human CVCL_6A64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087320 CVCL_6A65 GM15686 transformed cell line human CVCL_6A65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087321 CVCL_6A66 GM15689 transformed cell line human CVCL_6A66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087322 CVCL_6A67 GM15690 transformed cell line human CVCL_6A67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087323 CVCL_6A60 GM15681 transformed cell line human CVCL_6A60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087324 CVCL_6A61 GM15682 transformed cell line human CVCL_6A61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087325 CVCL_6A62 GM15683 transformed cell line human CVCL_6A62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087326 CVCL_6A63 GM15684 transformed cell line human CVCL_6A63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087327 CVCL_6A79 PSI-1 spontaneously immortalized cell line pig CVCL_6A79 CL:0000010 Derived from sampling site: Small intestine. 21087328 CVCL_6A70 GM15740 transformed cell line human CVCL_6A70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087329 CVCL_6A75 Lovo-143X19 cancer cell line human CVCL_6A75 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Val143Ala) Derived from metastatic site: Left supraclavicular lymph node. Male 21087330 CVCL_6A76 Lovo-143X3 cancer cell line human CVCL_6A76 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Val143Ala) Derived from metastatic site: Left supraclavicular lymph node. Male 21087331 CVCL_6A77 CIEB spontaneously immortalized cell line CVCL_6A77 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Limousin. Unspecified 21087332 CVCL_6A78 CLAB spontaneously immortalized cell line pig CVCL_6A78 CL:0000010 Derived from sampling site: Intestine Cell type=Enterocyte.. 21087333 CVCL_6A71 GM15742 transformed cell line human CVCL_6A71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087334 CVCL_6A72 GM15747 transformed cell line human CVCL_6A72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: DNA polymorphism discovery resource collection 21087335 CVCL_6A73 A590 cancer cell line human CVCL_6A73 CL:0000010 21087336 CVCL_6A74 KST finite cell line CVCL_6A74 CL:0000010 Unspecified 21087337 CVCL_Q031 HG00700 transformed cell line human CVCL_Q031 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087338 CVCL_Q032 HG00701 transformed cell line human CVCL_Q032 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087339 CVCL_Q033 HG00702 transformed cell line human CVCL_Q033 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087340 CVCL_Q034 HG00703 transformed cell line human CVCL_Q034 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087341 CVCL_Q035 HG00704 transformed cell line human CVCL_Q035 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087342 CVCL_Q036 HG00705 transformed cell line human CVCL_Q036 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087343 CVCL_Q037 HG00706 transformed cell line human CVCL_Q037 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087344 CVCL_Q038 HG00707 transformed cell line human CVCL_Q038 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087345 CVCL_Q039 HG00708 transformed cell line human CVCL_Q039 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087346 CVCL_H698 AH371A-TC cancer cell line Norway rat CVCL_H698 CL:0000010 Breed/subspecies: Donryu. Male 21087347 CVCL_GU98 HG02545 transformed cell line human CVCL_GU98 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087348 CVCL_GU99 HG02546 transformed cell line human CVCL_GU99 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087349 CVCL_H699 L1210-6MP-R-TC cancer cell line house mouse CVCL_H699 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21087350 CVCL_GU94 HG02502 transformed cell line human CVCL_GU94 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087351 CVCL_H694 TGBC51TKB cancer cell line human CVCL_H694 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 96 hours (PubMed=9824643); 94 +- 0.1 hours (PubMed=15645130) 21087352 CVCL_GU95 HG02505 transformed cell line human CVCL_GU95 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087353 CVCL_H695 TGBC52TKB cancer cell line human CVCL_H695 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21087354 CVCL_GU96 HG02536 transformed cell line human CVCL_GU96 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087355 CVCL_H696 mos-3Y1-10 transformed cell line Norway rat CVCL_H696 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21087356 CVCL_GU97 HG02541 transformed cell line human CVCL_GU97 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087357 CVCL_H697 mos-3Y1-16 transformed cell line Norway rat CVCL_H697 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21087358 CVCL_GU90 HG02476 transformed cell line human CVCL_GU90 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087359 CVCL_H690 TPA30-4 transformed cell line human CVCL_H690 CL:0000010 Transformant: Simian virus 40 (SV40) [ts30](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. 21087360 CVCL_GU91 HG02477 transformed cell line human CVCL_GU91 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087361 CVCL_H691 MRHF finite cell line human CVCL_H691 From: BioWhittaker (now part of Lonza); Walkersville; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21087362 CVCL_GU92 HG02481 transformed cell line human CVCL_GU92 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087363 CVCL_GU93 HG02501 transformed cell line human CVCL_GU93 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087364 CVCL_H693 TGBC50TKB cancer cell line human CVCL_H693 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Omics: Deep proteome analysis Male 21087365 CVCL_Q040 HG00709 transformed cell line human CVCL_Q040 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087366 CVCL_Q041 HG00728 transformed cell line human CVCL_Q041 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087367 CVCL_Q020 HG00683 transformed cell line human CVCL_Q020 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087368 CVCL_Q021 HG00684 transformed cell line human CVCL_Q021 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087369 CVCL_Q022 HG00685 transformed cell line human CVCL_Q022 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087370 CVCL_Q023 HG00689 transformed cell line human CVCL_Q023 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087371 CVCL_Q024 HG00690 transformed cell line human CVCL_Q024 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087372 CVCL_Q025 HG00691 transformed cell line human CVCL_Q025 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087373 CVCL_Q026 HG00692 transformed cell line human CVCL_Q026 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087374 CVCL_Q027 HG00693 transformed cell line human CVCL_Q027 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087375 CVCL_Q028 HG00694 transformed cell line human CVCL_Q028 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087376 CVCL_Q029 HG00698 transformed cell line human CVCL_Q029 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087377 CVCL_Q030 HG00699 transformed cell line human CVCL_Q030 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087378 CVCL_Q010 HG00657 transformed cell line human CVCL_Q010 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087379 CVCL_Q011 HG00658 transformed cell line human CVCL_Q011 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087380 CVCL_Q012 HG00662 transformed cell line human CVCL_Q012 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087381 CVCL_Q013 HG00663 transformed cell line human CVCL_Q013 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087382 CVCL_Q014 HG00664 transformed cell line human CVCL_Q014 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087383 CVCL_Q015 HG00671 transformed cell line human CVCL_Q015 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087384 CVCL_Q016 HG00672 transformed cell line human CVCL_Q016 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087385 CVCL_Q017 HG00673 transformed cell line human CVCL_Q017 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087386 CVCL_Q018 HG00674 transformed cell line human CVCL_Q018 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087387 CVCL_Q019 HG00675 transformed cell line human CVCL_Q019 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087388 CVCL_GU76 HG02252 transformed cell line human CVCL_GU76 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087389 CVCL_H676 Meso35 cancer cell line human CVCL_H676 CL:0000010 Derived from sampling site: Pleural effusion. 21087390 CVCL_GU77 HG02253 transformed cell line human CVCL_GU77 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087391 CVCL_H677 Meso37 cancer cell line human CVCL_H677 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Glu54Ter (c.160G>T); Zygosity=Heterozygous (PubMed=21642991) Omics: SNP array analysis. 21087392 CVCL_GU78 HG02262 transformed cell line human CVCL_GU78 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087393 CVCL_H678 Meso4 cancer cell line human CVCL_H678 CL:0000010 Derived from sampling site: Pleural effusion. 21087394 CVCL_GU79 HG02265 transformed cell line human CVCL_GU79 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087395 CVCL_H679 Meso45 cancer cell line human CVCL_H679 CL:0000010 Derived from sampling site: Pleural effusion. 21087396 CVCL_GU72 HG02024 transformed cell line human CVCL_GU72 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087397 CVCL_H672 Meso13 cancer cell line human CVCL_H672 CL:0000010 Derived from sampling site: Pleural effusion. 21087398 CVCL_GU73 HG02102 transformed cell line human CVCL_GU73 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087399 CVCL_H673 Meso144 cancer cell line human CVCL_H673 CL:0000010 Derived from sampling site: Pleural effusion. 21087400 CVCL_GU74 HG02150 transformed cell line human CVCL_GU74 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087401 CVCL_H674 Meso148 cancer cell line human CVCL_H674 CL:0000010 Derived from sampling site: Pleural effusion. 21087402 CVCL_GU75 HG02219 transformed cell line human CVCL_GU75 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087403 CVCL_H675 Meso34 cancer cell line human CVCL_H675 CL:0000010 Derived from sampling site: Pleural effusion. 21087404 CVCL_GU70 HG01965 transformed cell line human CVCL_GU70 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087405 CVCL_H670 Meso11 cancer cell line human CVCL_H670 CL:0000010 Derived from sampling site: Pleural effusion. 21087406 CVCL_GU71 HG02006 transformed cell line human CVCL_GU71 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087407 CVCL_H671 Meso122 cancer cell line human CVCL_H671 CL:0000010 Derived from sampling site: Pleural effusion. 21087408 CVCL_Q000 HG00640 transformed cell line human CVCL_Q000 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087409 CVCL_Q001 HG00641 transformed cell line human CVCL_Q001 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087410 CVCL_Q002 HG00642 transformed cell line human CVCL_Q002 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087411 CVCL_Q003 HG00650 transformed cell line human CVCL_Q003 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087412 CVCL_Q004 HG00651 transformed cell line human CVCL_Q004 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087413 CVCL_Q005 HG00652 transformed cell line human CVCL_Q005 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087414 CVCL_Q006 HG00653 transformed cell line human CVCL_Q006 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087415 CVCL_Q007 HG00654 transformed cell line human CVCL_Q007 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087416 CVCL_Q008 HG00655 transformed cell line human CVCL_Q008 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087417 CVCL_Q009 HG00656 transformed cell line human CVCL_Q009 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087418 CVCL_GU87 HG02425 transformed cell line human CVCL_GU87 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087419 CVCL_H687 MDCC-LS1 cancer cell line CVCL_H687 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21087420 CVCL_GU88 HG02439 transformed cell line human CVCL_GU88 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087421 CVCL_H688 KBM-3/DOX cancer cell line human CVCL_H688 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Female 21087422 CVCL_GU89 HG02455 transformed cell line human CVCL_GU89 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087423 CVCL_H689 MIP-101 cancer cell line human CVCL_H689 HLA typing: A*24:02,02:01; B*35:08,35:08; C*07:01,04:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=7651727) Anecdotal: Have been flown in space on shuttle flights STS-70 and STS-85 to study growth in microgravity (PubMed=10949995) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 22 hours (PubMed=3442732); Microsatellite instability: Instable (MSI) (PubMed=23671654; PubMed=25926053) Group: Space-flown cell line (cellonaut) 21087424 CVCL_GU83 HG02304 transformed cell line human CVCL_GU83 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087425 CVCL_H683 Meso96 cancer cell line human CVCL_H683 CL:0000010 Derived from sampling site: Pleural effusion. 21087426 CVCL_GU84 HG02312 transformed cell line human CVCL_GU84 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087427 CVCL_H684 HKNM-2 finite cell line human CVCL_H684 From: Popper H.; University of Graz; Graz; Austria CL:0000010 Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Unspecified 21087428 CVCL_H685 XP1BE LCL transformed cell line human CVCL_H685 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys431Argfs*6 (c.1292_1293delAA) (1132_1133delAA); ClinVar=VCV000000256; Zygosity=Homozygous or hemizygous (from autologous cell line XP1BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087429 CVCL_GU85 HG02345 transformed cell line human CVCL_GU85 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087430 CVCL_H686 XP1BE finite cell line human CVCL_H686 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys431Argfs*6 (c.1292_1293delAA) (1132_1133delAA); ClinVar=VCV000000256; Zygosity=Homozygous or hemizygous (PubMed=26184184) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1170; true Female 21087431 CVCL_GU86 HG02348 transformed cell line human CVCL_GU86 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087432 CVCL_GU80 HG02266 transformed cell line human CVCL_GU80 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087433 CVCL_H680 Meso47 cancer cell line human CVCL_H680 CL:0000010 Derived from sampling site: Pleural effusion. 21087434 CVCL_GU81 HG02274 transformed cell line human CVCL_GU81 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087435 CVCL_H681 Meso56 cancer cell line human CVCL_H681 CL:0000010 Derived from sampling site: Pleural effusion. Omics: SNP array analysis 21087436 CVCL_GU82 HG02275 transformed cell line human CVCL_GU82 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087437 CVCL_H682 Meso62 cancer cell line human CVCL_H682 CL:0000010 Derived from sampling site: Pleural effusion. 21087438 CVCL_GU58 HG01474 transformed cell line human CVCL_GU58 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087439 CVCL_H658 Mes-9 cancer cell line human CVCL_H658 CL:0000010 21087440 CVCL_GU59 HG01479 transformed cell line human CVCL_GU59 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087441 CVCL_H659 Mes-8 cancer cell line human CVCL_H659 CL:0000010 21087442 CVCL_GU54 HG01435 transformed cell line human CVCL_GU54 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087443 CVCL_H654 Mes-49 cancer cell line human CVCL_H654 CL:0000010 21087444 CVCL_GU55 HG01447 transformed cell line human CVCL_GU55 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087445 CVCL_H655 Mes-50 cancer cell line human CVCL_H655 CL:0000010 21087446 CVCL_GU56 HG01459 transformed cell line human CVCL_GU56 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087447 CVCL_H656 Mes-19 cancer cell line human CVCL_H656 CL:0000010 21087448 CVCL_GU57 HG01468 transformed cell line human CVCL_GU57 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087449 CVCL_H657 Mes-10 cancer cell line human CVCL_H657 CL:0000010 21087450 CVCL_GU50 HG01405 transformed cell line human CVCL_GU50 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087451 CVCL_H650 Mes-30 cancer cell line human CVCL_H650 CL:0000010 21087452 CVCL_GU51 HG01412 transformed cell line human CVCL_GU51 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087453 CVCL_H651 Mes-29 cancer cell line human CVCL_H651 CL:0000010 21087454 CVCL_GU52 HG01413 transformed cell line human CVCL_GU52 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087455 CVCL_H652 Mes-36 cancer cell line human CVCL_H652 CL:0000010 21087456 CVCL_GU53 HG01414 transformed cell line human CVCL_GU53 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087457 CVCL_H653 Mes-45 cancer cell line human CVCL_H653 CL:0000010 21087458 CVCL_GU69 HG01961 transformed cell line human CVCL_GU69 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087459 CVCL_H669 Meso-9 cancer cell line human CVCL_H669 CL:0000010 Omics: SNP array analysis. 21087460 CVCL_GU65 HG01767 transformed cell line human CVCL_GU65 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087461 CVCL_H665 Mes-1 cancer cell line human CVCL_H665 CL:0000010 21087462 CVCL_GU66 HG01768 transformed cell line human CVCL_GU66 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087463 CVCL_H666 Mes-2 cancer cell line human CVCL_H666 CL:0000010 21087464 CVCL_GU67 HG01785 transformed cell line human CVCL_GU67 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087465 CVCL_H667 Mes-5 cancer cell line human CVCL_H667 CL:0000010 21087466 CVCL_GU68 HG01786 transformed cell line human CVCL_GU68 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087467 CVCL_H668 Meso-10 cancer cell line human CVCL_H668 CL:0000010 Omics: SNP array analysis. 21087468 CVCL_GU61 HG01486 transformed cell line human CVCL_GU61 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087469 CVCL_H661 Mes-11 cancer cell line human CVCL_H661 CL:0000010 21087470 CVCL_GU62 HG01556 transformed cell line human CVCL_GU62 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087471 CVCL_H662 Mes-15 cancer cell line human CVCL_H662 CL:0000010 21087472 CVCL_GU63 HG01765 transformed cell line human CVCL_GU63 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087473 CVCL_H663 Mes-20 cancer cell line human CVCL_H663 CL:0000010 21087474 CVCL_GU64 HG01766 transformed cell line human CVCL_GU64 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087475 CVCL_H664 Mes-54 cancer cell line human CVCL_H664 CL:0000010 21087476 CVCL_GU60 HG01485 transformed cell line human CVCL_GU60 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087477 CVCL_H660 Mes-7 cancer cell line human CVCL_H660 CL:0000010 21087478 CVCL_GU36 HG01311 transformed cell line human CVCL_GU36 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087479 CVCL_H636 PlyI cancer cell line human CVCL_H636 CL:0000010 Derived from sampling site: Pleural effusion. Male 21087480 CVCL_GU37 HG01312 transformed cell line human CVCL_GU37 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087481 CVCL_H637 Mac-2A cancer cell line human CVCL_H637 CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21087482 CVCL_GU38 HG01323 transformed cell line human CVCL_GU38 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087483 CVCL_H638 Mac-2B cancer cell line human CVCL_H638 CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma. Omics: Transcriptome analysis by RNAseq Male 21087484 CVCL_GU39 HG01325 transformed cell line human CVCL_GU39 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087485 CVCL_H639 MH-1 [Human lymphoma] cancer cell line human CVCL_H639 CL:0000010 Derived from sampling site: Bone marrow. Male 21087486 CVCL_GU32 HG01302 transformed cell line human CVCL_GU32 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087487 CVCL_H632 Mac-2 cancer cell line human CVCL_H632 CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma. Male 21087488 CVCL_GU33 HG01303 transformed cell line human CVCL_GU33 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087489 CVCL_H633 JB6 [Human anaplastic large cell lymphoma] cancer cell line human CVCL_H633 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=15356658) Derived from sampling site: Peripheral blood. Male Doubling time: 60 hours (CelloPub=CLPUB00058) 21087490 CVCL_GU34 HG01305 transformed cell line human CVCL_GU34 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087491 CVCL_H634 USP-91 cancer cell line human CVCL_H634 CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 26 hours (PubMed=8400235) 21087492 CVCL_GU35 HG01308 transformed cell line human CVCL_GU35 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087493 CVCL_H635 JK [Human anaplastic large cell lymphoma] cancer cell line human CVCL_H635 CL:0000010 Derived from sampling site: Cell type=T-cell. Male 21087494 CVCL_GU30 HG01284 transformed cell line human CVCL_GU30 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087495 CVCL_H630 HSC-M1 cancer cell line human CVCL_H630 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=15356658) Derived from sampling site: Bone marrow. Female 21087496 CVCL_GU31 HG01286 transformed cell line human CVCL_GU31 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087497 CVCL_H631 Mac-1 cancer cell line human CVCL_H631 CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Male 21087498 CVCL_GU47 HG01398 transformed cell line human CVCL_GU47 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087499 CVCL_H647 Mes-17 cancer cell line human CVCL_H647 CL:0000010 21087500 CVCL_GU48 HG01402 transformed cell line human CVCL_GU48 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087501 CVCL_H648 Mes-35 cancer cell line human CVCL_H648 CL:0000010 21087502 CVCL_GU49 HG01403 transformed cell line human CVCL_GU49 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087503 CVCL_H649 Mes-37 cancer cell line human CVCL_H649 CL:0000010 21087504 CVCL_GU43 HG01392 transformed cell line human CVCL_GU43 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087505 CVCL_H643 HOP-19 cancer cell line human CVCL_H643 CL:0000010 Unspecified 21087506 CVCL_H644 hESO-ST2 embryonic stem cell human CVCL_H644 CL:0000010 Female 21087507 CVCL_GU44 HG01393 transformed cell line human CVCL_GU44 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087508 CVCL_GU45 HG01395 transformed cell line human CVCL_GU45 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087509 CVCL_H645 TPWT-2 finite cell line human CVCL_H645 CL:0000010 Derived from sampling site: Placenta. Female 21087510 CVCL_GU46 HG01396 transformed cell line human CVCL_GU46 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087511 CVCL_H646 TPA30-6 transformed cell line human CVCL_H646 CL:0000010 Transformant: Simian virus 40 (SV40) [ts30](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21087512 CVCL_H640 A640-IS transformed cell line house mouse CVCL_H640 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: ICR. Male Characteristics: Grows actively at the permissive temperature (33 Celsius) At the repressive temperature (39 Celsius) the cells do not grow and differentiate into Ito cells. 21087513 CVCL_GU40 HG01326 transformed cell line human CVCL_GU40 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087514 CVCL_H641 3134 cancer cell line house mouse CVCL_H641 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female Characteristics: Contains 200 head to tail copies of a DNA sequence composed of a BPV transforming fragment and a MMTV promoter (LTR containing GR-binding sites) in front of the V-Ha-Ras gene Group: Patented cell line; Part of: ENCODE project mouse cell lines; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11998 21087515 CVCL_GU41 HG01369 transformed cell line human CVCL_GU41 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087516 CVCL_GU42 HG01372 transformed cell line human CVCL_GU42 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087517 CVCL_H642 HOP-18 cancer cell line human CVCL_H642 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21087518 CVCL_6C04 MGE511 conditionally immortalized cell line house mouse CVCL_6C04 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087519 CVCL_6C05 MGE727 conditionally immortalized cell line house mouse CVCL_6C05 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087520 CVCL_6C06 NE-MD conditionally immortalized cell line house mouse CVCL_6C06 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; macula densa; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. 21087521 CVCL_6C07 GH-1 spontaneously immortalized cell line CVCL_6C07 CL:0000010 Derived from sampling site: Heart. Male Group: Reptilian cell line 21087522 CVCL_6C00 MGE3-2 conditionally immortalized cell line house mouse CVCL_6C00 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087523 CVCL_6C01 MGE503 conditionally immortalized cell line house mouse CVCL_6C01 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087524 CVCL_6C02 MGE507 conditionally immortalized cell line house mouse CVCL_6C02 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087525 CVCL_6C03 MGE509 conditionally immortalized cell line house mouse CVCL_6C03 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087526 CVCL_YI50 CPTC-UBE2E2-3 hybridoma house mouse CVCL_YI50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96LR5; Human UBE2E2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087527 CVCL_YI51 CPTC-UBE2J1-1 hybridoma house mouse CVCL_YI51 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y385; Human UBE2J1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087528 CVCL_6C08 GH-2 spontaneously immortalized cell line CVCL_6C08 CL:0000010 Derived from sampling site: Heart. Male Group: Reptilian cell line 21087529 CVCL_6C09 TM-BBB1 conditionally immortalized cell line house mouse CVCL_6C09 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087530 CVCL_YI56 CPTC-XMRV P12-3 hybridoma house mouse CVCL_YI56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2F7J3; Xenotropic MuLV-related virus GAG-POL (AA 130-213: RNA-binding phosphoprotein p12). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087531 CVCL_YI57 CPTC-YWHAB-1 hybridoma house mouse CVCL_YI57 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P31946; Human YWHAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087532 CVCL_YI58 CPTC-YWHAB-2 hybridoma house mouse CVCL_YI58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31946; Human YWHAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087533 CVCL_YI59 CPTC-YWHAB-3 hybridoma house mouse CVCL_YI59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P31946; Human YWHAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087534 CVCL_YI52 CPTC-UBE2J1-2 hybridoma house mouse CVCL_YI52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y385; Human UBE2J1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087535 CVCL_YI53 CPTC-UBE2J1-3 hybridoma house mouse CVCL_YI53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y385; Human UBE2J1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087536 CVCL_YI54 CPTC-XMRV P12-1 hybridoma house mouse CVCL_YI54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2F7J3; Xenotropic MuLV-related virus GAG-POL (AA 130-213: RNA-binding phosphoprotein p12). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087537 CVCL_YI55 CPTC-XMRV P12-2 hybridoma house mouse CVCL_YI55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2F7J3; Xenotropic MuLV-related virus GAG-POL (AA 130-213: RNA-binding phosphoprotein p12). Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087538 CVCL_6C15 HUIEC spontaneously immortalized cell line human CVCL_6C15 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.. Unspecified 21087539 CVCL_6C16 TLT spontaneously immortalized cell line human CVCL_6C16 CL:0000010 Derived from sampling site: Peripheral blood. 21087540 CVCL_6C17 B1OXI undefined cell line type pig CVCL_6C17 CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of chicken origin but found to be a porcine cell line (PubMed=22193509). 21087541 CVCL_6C18 B6 [Contaminated chicken cell line] undefined cell line type pig CVCL_6C18 CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of chicken origin but found to be a porcine cell line (PubMed=22193509).. 21087542 CVCL_6C11 TM-BBB3 conditionally immortalized cell line house mouse CVCL_6C11 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087543 CVCL_6C12 TM-BBB4 conditionally immortalized cell line house mouse CVCL_6C12 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087544 CVCL_6C13 TM-BBB5 conditionally immortalized cell line house mouse CVCL_6C13 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087545 CVCL_6C14 SVDC conditionally immortalized cell line house mouse CVCL_6C14 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21087546 CVCL_YI40 CPTC-UBE2L6-2 hybridoma house mouse CVCL_YI40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14933; Human UBE2L6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087547 CVCL_6C19 H-4 spontaneously immortalized cell line human CVCL_6C19 CL:0000010 Derived from sampling site: Fetal small intestine Cell type=Enterocyte.. Male 21087548 CVCL_YI45 CPTC-UBE2E1-1 hybridoma house mouse CVCL_YI45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51965; Human UBE2E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087549 CVCL_YI46 CPTC-UBE2E1-2 hybridoma house mouse CVCL_YI46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51965; Human UBE2E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087550 CVCL_YI47 CPTC-UBE2E1-3 hybridoma house mouse CVCL_YI47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51965; Human UBE2E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087551 CVCL_YI48 CPTC-UBE2E2-1 hybridoma house mouse CVCL_YI48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96LR5; Human UBE2E2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087552 CVCL_YI41 CPTC-UBE2L6-3 hybridoma house mouse CVCL_YI41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14933; Human UBE2L6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087553 CVCL_YI42 CPTC-UBA1-2 hybridoma house mouse CVCL_YI42 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P22314; Human UBA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087554 CVCL_YI43 CPTC-UBA1-3 hybridoma house mouse CVCL_YI43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22314; Human UBA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087555 CVCL_YI44 CPTC-UBE2C-1 hybridoma house mouse CVCL_YI44 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O00762; Human UBE2C. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087556 CVCL_6C10 TM-BBB2 conditionally immortalized cell line house mouse CVCL_6C10 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087557 CVCL_YI49 CPTC-UBE2E2-2 hybridoma house mouse CVCL_YI49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96LR5; Human UBE2E2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087558 CVCL_Q097 HG01082 transformed cell line human CVCL_Q097 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087559 CVCL_Q098 HG01083 transformed cell line human CVCL_Q098 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087560 CVCL_Q099 HG01084 transformed cell line human CVCL_Q099 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087561 CVCL_YI34 CPTC-TOP1-2 hybridoma house mouse CVCL_YI34 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11387; Human TOP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087562 CVCL_YI35 CPTC-TOP1MT-1 hybridoma house mouse CVCL_YI35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q969P6; Human TOP1MT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087563 CVCL_YI36 CPTC-TOP1MT-2 hybridoma house mouse CVCL_YI36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q969P6; Human TOP1MT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087564 CVCL_YI37 CPTC-TOP1MT-3 hybridoma house mouse CVCL_YI37 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q969P6; Human TOP1MT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087565 CVCL_YI30 CPTC-TNFRSF9-1 hybridoma house mouse CVCL_YI30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q07011; Human TNFRSF9/CD137. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087566 CVCL_YI31 CPTC-TNFRSF9-2 hybridoma house mouse CVCL_YI31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q07011; Human TNFRSF9/CD137. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087567 CVCL_YI32 CPTC-TNFRSF9-3 hybridoma house mouse CVCL_YI32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q07011; Human TNFRSF9/CD137. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087568 CVCL_YI33 CPTC-TOP1-1 hybridoma house mouse CVCL_YI33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11387; Human TOP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087569 CVCL_YI38 CPTC-TTR-1 hybridoma house mouse CVCL_YI38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02766; Human TTR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087570 CVCL_YI39 CPTC-UBE2L6-1 hybridoma house mouse CVCL_YI39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14933; Human UBE2L6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087571 CVCL_Q086 HG01068 transformed cell line human CVCL_Q086 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087572 CVCL_Q087 HG01069 transformed cell line human CVCL_Q087 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087573 CVCL_Q088 HG01070 transformed cell line human CVCL_Q088 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087574 CVCL_Q089 HG01071 transformed cell line human CVCL_Q089 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087575 CVCL_YI23 CPTC-TACSTD2-3 hybridoma house mouse CVCL_YI23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087576 CVCL_YI24 CPTC-TAPBP-1 hybridoma house mouse CVCL_YI24 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: UniProtKB; O15533; Human TAPBP. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087577 CVCL_YI25 CPTC-TAPBP-2 hybridoma house mouse CVCL_YI25 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: UniProtKB; O15533; Human TAPBP. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087578 CVCL_YI26 CPTC-TDP2-1 hybridoma house mouse CVCL_YI26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95551; Human TDP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087579 CVCL_YI20 CPTC-SVIL-4 hybridoma house mouse CVCL_YI20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95425; Human SVIL. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087580 CVCL_YI21 CPTC-TACSTD2-1 hybridoma house mouse CVCL_YI21 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087581 CVCL_YI22 CPTC-TACSTD2-2 hybridoma house mouse CVCL_YI22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087582 CVCL_Q090 HG01072 transformed cell line human CVCL_Q090 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087583 CVCL_Q091 HG01073 transformed cell line human CVCL_Q091 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087584 CVCL_Q092 HG01074 transformed cell line human CVCL_Q092 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087585 CVCL_YI27 CPTC-TDP2-2 hybridoma house mouse CVCL_YI27 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95551; Human TDP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087586 CVCL_Q093 HG01075 transformed cell line human CVCL_Q093 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087587 CVCL_YI28 CPTC-TDP2-3 hybridoma house mouse CVCL_YI28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95551; Human TDP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087588 CVCL_Q094 HG01079 transformed cell line human CVCL_Q094 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087589 CVCL_YI29 CPTC-TERF2-1 hybridoma house mouse CVCL_YI29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15554; Human TERF2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087590 CVCL_Q095 HG01080 transformed cell line human CVCL_Q095 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087591 CVCL_Q096 HG01081 transformed cell line human CVCL_Q096 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087592 CVCL_Q075 HG01051 transformed cell line human CVCL_Q075 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087593 CVCL_Q076 HG01052 transformed cell line human CVCL_Q076 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087594 CVCL_Q077 HG01053 transformed cell line human CVCL_Q077 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087595 CVCL_Q078 HG01054 transformed cell line human CVCL_Q078 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087596 CVCL_Q079 HG01055 transformed cell line human CVCL_Q079 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087597 CVCL_YI12 CPTC-SLC31A2-1 hybridoma house mouse CVCL_YI12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15432; Human SLC31A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087598 CVCL_YI13 CPTC-SLC31A2-3 hybridoma house mouse CVCL_YI13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15432; Human SLC31A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087599 CVCL_YI14 CPTC-SNCG-1 hybridoma house mouse CVCL_YI14 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O76070; Human SNCG. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087600 CVCL_YI15 CPTC-SNCG-2 hybridoma house mouse CVCL_YI15 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O76070; Human SNCG. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087601 CVCL_YI10 CPTC-SFN-3 hybridoma house mouse CVCL_YI10 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31947; Human SFN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087602 CVCL_YI11 CPTC-SLC31A1-1 hybridoma house mouse CVCL_YI11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15431; Human SLC31A1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087603 CVCL_Q080 HG01056 transformed cell line human CVCL_Q080 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087604 CVCL_Q081 HG01060 transformed cell line human CVCL_Q081 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087605 CVCL_YI16 CPTC-SULT1E1-1 hybridoma house mouse CVCL_YI16 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P49888; Human SULT1E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087606 CVCL_Q082 HG01061 transformed cell line human CVCL_Q082 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087607 CVCL_YI17 CPTC-SULT1E1-2 hybridoma house mouse CVCL_YI17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49888; Human SULT1E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087608 CVCL_Q083 HG01062 transformed cell line human CVCL_Q083 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087609 CVCL_YI18 CPTC-SULT1E1-3 hybridoma house mouse CVCL_YI18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49888; Human SULT1E1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087610 CVCL_Q084 HG01066 transformed cell line human CVCL_Q084 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087611 CVCL_YI19 CPTC-SVIL-3 hybridoma house mouse CVCL_YI19 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O95425; Human SVIL Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection Caution: Indicated as producing an IgG2a mAb in PubMed=30332471 and an IgG2c mAb in DSHB. 21087612 CVCL_Q085 HG01067 transformed cell line human CVCL_Q085 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087613 CVCL_Q064 HG00978 transformed cell line human CVCL_Q064 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087614 CVCL_Q065 HG00982 transformed cell line human CVCL_Q065 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087615 CVCL_Q066 HG00983 transformed cell line human CVCL_Q066 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087616 CVCL_Q067 HG01028 transformed cell line human CVCL_Q067 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087617 CVCL_Q068 HG01029 transformed cell line human CVCL_Q068 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087618 CVCL_Q069 HG01031 transformed cell line human CVCL_Q069 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087619 CVCL_YI01 CPTC-SAT1-1 hybridoma house mouse CVCL_YI01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21673; Human SAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087620 CVCL_YI02 CPTC-SAT1-2 hybridoma house mouse CVCL_YI02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21673; Human SAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087621 CVCL_YI03 CPTC-SAT1-3 hybridoma house mouse CVCL_YI03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P21673; Human SAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087622 CVCL_YI04 CPTC-SERPINA1-1 hybridoma house mouse CVCL_YI04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01009; Human SERPINA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087623 CVCL_YI00 CPTC-S100A4-3 hybridoma house mouse CVCL_YI00 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: UniProtKB; P26447; Human S100A4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087624 CVCL_YI09 CPTC-SFN-2 hybridoma house mouse CVCL_YI09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31947; Human SFN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087625 CVCL_Q070 HG01046 transformed cell line human CVCL_Q070 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087626 CVCL_YI05 CPTC-SERPINB3-1 hybridoma house mouse CVCL_YI05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29508; Human SERPINB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087627 CVCL_Q071 HG01047 transformed cell line human CVCL_Q071 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087628 CVCL_YI06 CPTC-SERPINB3-2 hybridoma house mouse CVCL_YI06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29508; Human SERPINB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087629 CVCL_Q072 HG01048 transformed cell line human CVCL_Q072 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087630 CVCL_YI07 CPTC-SERPINB3-3 hybridoma house mouse CVCL_YI07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29508; Human SERPINB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087631 CVCL_Q073 HG01049 transformed cell line human CVCL_Q073 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087632 CVCL_YI08 CPTC-SFN-1 hybridoma house mouse CVCL_YI08 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31947; Human SFN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087633 CVCL_Q074 HG01050 transformed cell line human CVCL_Q074 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087634 CVCL_Q053 HG00741 transformed cell line human CVCL_Q053 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087635 CVCL_Q054 HG00759 transformed cell line human CVCL_Q054 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087636 CVCL_Q055 HG00766 transformed cell line human CVCL_Q055 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087637 CVCL_Q056 HG00844 transformed cell line human CVCL_Q056 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087638 CVCL_Q057 HG00851 transformed cell line human CVCL_Q057 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087639 CVCL_Q058 HG00864 transformed cell line human CVCL_Q058 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087640 CVCL_Q059 HG00866 transformed cell line human CVCL_Q059 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087641 CVCL_Q060 HG00867 transformed cell line human CVCL_Q060 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087642 CVCL_Q061 HG00879 transformed cell line human CVCL_Q061 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087643 CVCL_Q062 HG00881 transformed cell line human CVCL_Q062 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087644 CVCL_Q063 HG00956 transformed cell line human CVCL_Q063 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087645 CVCL_Q042 HG00729 transformed cell line human CVCL_Q042 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087646 CVCL_Q043 HG00731 transformed cell line human CVCL_Q043 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087647 CVCL_Q044 HG00732 transformed cell line human CVCL_Q044 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087648 CVCL_Q045 HG00733 transformed cell line human CVCL_Q045 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087649 CVCL_Q046 HG00734 transformed cell line human CVCL_Q046 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087650 CVCL_Q047 HG00735 transformed cell line human CVCL_Q047 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087651 CVCL_Q048 HG00736 transformed cell line human CVCL_Q048 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087652 CVCL_Q049 HG00737 transformed cell line human CVCL_Q049 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087653 CVCL_Q050 HG00738 transformed cell line human CVCL_Q050 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087654 CVCL_Q051 HG00739 transformed cell line human CVCL_Q051 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087655 CVCL_Q052 HG00740 transformed cell line human CVCL_Q052 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087656 CVCL_6B67 TRD-12 conditionally immortalized cell line Norway rat CVCL_6B67 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087657 CVCL_6B68 TRD-14 conditionally immortalized cell line Norway rat CVCL_6B68 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087658 CVCL_6B69 TRD-15 conditionally immortalized cell line Norway rat CVCL_6B69 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087659 CVCL_6B63 TRD-1 conditionally immortalized cell line Norway rat CVCL_6B63 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087660 CVCL_6B64 TRD-3 conditionally immortalized cell line Norway rat CVCL_6B64 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087661 CVCL_6B65 TRD-4 conditionally immortalized cell line Norway rat CVCL_6B65 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087662 CVCL_6B66 TRD-10 conditionally immortalized cell line Norway rat CVCL_6B66 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087663 CVCL_6B60 RGE1-21 conditionally immortalized cell line Norway rat CVCL_6B60 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087664 CVCL_6B61 RGE1-22 conditionally immortalized cell line Norway rat CVCL_6B61 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087665 CVCL_6B62 RGE2-01 conditionally immortalized cell line Norway rat CVCL_6B62 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087666 CVCL_6B78 TRD-35 conditionally immortalized cell line Norway rat CVCL_6B78 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087667 CVCL_6B79 TRD-38 conditionally immortalized cell line Norway rat CVCL_6B79 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087668 CVCL_6B74 TRD-27 conditionally immortalized cell line Norway rat CVCL_6B74 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087669 CVCL_6B75 TRD-29 conditionally immortalized cell line Norway rat CVCL_6B75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087670 CVCL_6B76 TRD-33 conditionally immortalized cell line Norway rat CVCL_6B76 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087671 CVCL_6B77 TRD-34 conditionally immortalized cell line Norway rat CVCL_6B77 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087672 CVCL_6B70 TRD-17 conditionally immortalized cell line Norway rat CVCL_6B70 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087673 CVCL_6B71 TRD-19 conditionally immortalized cell line Norway rat CVCL_6B71 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087674 CVCL_6B72 TRD-22 conditionally immortalized cell line Norway rat CVCL_6B72 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087675 CVCL_6B73 TRD-24 conditionally immortalized cell line Norway rat CVCL_6B73 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087676 CVCL_6B49 c-SST-2 clone 6 cancer cell line Norway rat CVCL_6B49 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Tumorigenic and highly metastatic to lung (PubMed=3121552) 21087677 CVCL_6B45 GM23097 transformed cell line human CVCL_6B45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087678 CVCL_6B46 c-SST-2 clone 4 cancer cell line Norway rat CVCL_6B46 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Tumorigenic and weakly metastatic to lung (PubMed=3121552) 21087679 CVCL_6B47 c-SST-2 clone 2 cancer cell line Norway rat CVCL_6B47 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Tumorigenic and highly metastatic to lung (PubMed=3121552) 21087680 CVCL_6B48 c-SST-2 clone 3 cancer cell line Norway rat CVCL_6B48 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Tumorigenic and highly metastatic to lung (PubMed=3121552) 21087681 CVCL_YH93 CPTC-RB1-1 hybridoma house mouse CVCL_YH93 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P06400; Human RB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087682 CVCL_YH94 CPTC-RPTOR-1 hybridoma house mouse CVCL_YH94 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q8N122; Human RPTOR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087683 CVCL_YH95 CPTC-S100A2-1 hybridoma house mouse CVCL_YH95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P29034; Human S100A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087684 CVCL_YH96 CPTC-S100A2-2 hybridoma house mouse CVCL_YH96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P29034; Human S100A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087685 CVCL_YH90 CPTC-RAD52-1 hybridoma house mouse CVCL_YH90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43351; Human RAD52. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087686 CVCL_YH91 CPTC-RAD52-2 hybridoma house mouse CVCL_YH91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P43351; Human RAD52. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087687 CVCL_YH92 CPTC-RAD52-3 hybridoma house mouse CVCL_YH92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43351; Human RAD52. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087688 CVCL_YH97 CPTC-S100A2-3 hybridoma house mouse CVCL_YH97 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P29034; Human S100A2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087689 CVCL_YH98 CPTC-S100A4-1 hybridoma house mouse CVCL_YH98 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: UniProtKB; P26447; Human S100A4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087690 CVCL_YH99 CPTC-S100A4-2 hybridoma house mouse CVCL_YH99 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: UniProtKB; P26447; Human S100A4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087691 CVCL_6B41 GM01017 transformed cell line human CVCL_6B41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087692 CVCL_6B42 GM02093 finite cell line human CVCL_6B42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21087693 CVCL_6B43 GM02331 finite cell line human CVCL_6B43 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21087694 CVCL_6B44 GM10199 finite cell line human CVCL_6B44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21087695 CVCL_6B40 GM01016 transformed cell line human CVCL_6B40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087696 CVCL_6B56 TR-PCT1 conditionally immortalized cell line Norway rat CVCL_6B56 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Female 21087697 CVCL_6B57 RGE1-01 conditionally immortalized cell line Norway rat CVCL_6B57 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087698 CVCL_6B58 RGE1-02 conditionally immortalized cell line Norway rat CVCL_6B58 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087699 CVCL_6B59 RGE1-03 conditionally immortalized cell line Norway rat CVCL_6B59 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087700 CVCL_YH82 CPTC-PTHrP-2 hybridoma house mouse CVCL_YH82 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087701 CVCL_YH83 CPTC-PTPN6-1 hybridoma house mouse CVCL_YH83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P29350; Human PTPN6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087702 CVCL_YH84 CPTC-PTPN6-2 hybridoma house mouse CVCL_YH84 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P29350; Human PTPN6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087703 CVCL_YH85 CPTC-PTPN6-3 hybridoma house mouse CVCL_YH85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P29350; Human PTPN6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087704 CVCL_YH80 CPTC-PTEN-8 hybridoma house mouse CVCL_YH80 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087705 CVCL_YH81 CPTC-PTHrP-1 hybridoma house mouse CVCL_YH81 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12272; Human PTHLH. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087706 CVCL_YH86 CPTC-RAC1-1 hybridoma house mouse CVCL_YH86 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P63000; Human RAC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087707 CVCL_YH87 CPTC-RAC1-2 hybridoma house mouse CVCL_YH87 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P63000; Human RAC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087708 CVCL_YH88 CPTC-RAD18-1 hybridoma house mouse CVCL_YH88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NS91; Human RAD18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087709 CVCL_YH89 CPTC-RAD18-2 hybridoma house mouse CVCL_YH89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NS91; Human RAD18. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087710 CVCL_6B52 TR-AST2 conditionally immortalized cell line Norway rat CVCL_6B52 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Astrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087711 CVCL_6B53 TR-AST3 conditionally immortalized cell line Norway rat CVCL_6B53 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Astrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087712 CVCL_6B54 TR-AST4 conditionally immortalized cell line Norway rat CVCL_6B54 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Astrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087713 CVCL_6B55 TR-AST5 conditionally immortalized cell line Norway rat CVCL_6B55 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Astrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087714 CVCL_6B50 c-SST-2 clone 2r cancer cell line Norway rat CVCL_6B50 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Tumorigenic and weakly metastatic to lung (PubMed=3121552) 21087715 CVCL_6B51 TR-AST1 conditionally immortalized cell line Norway rat CVCL_6B51 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebrum Cell type=Astrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087716 CVCL_6B27 FSHDCl17 telomerase immortalized cell line human CVCL_6B27 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 2 repeats) (PubMed=22040608); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Subscapularis muscle Cell type=Myoblast.. Unspecified 21087717 CVCL_6B28 LGMD2Cl11 telomerase immortalized cell line human CVCL_6B28 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.*107T>A; ClinVar=VCV000290170; Zygosity=Heterozygous; Note=3'UTR mutation (PubMed=22040608); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser483Ter (c.1448C>A) (p.Ser515Ter, c.1544C>A); ClinVar=VCV000554057; Zygosity=Heterozygous (PubMed=22040608); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Thigh; quadriceps skeletal muscle Cell type=Myoblast.. Unspecified 21087718 CVCL_6B29 OPMDCl2 telomerase immortalized cell line human CVCL_6B29 CL:0000010 Sequence variation: Mutation; HGNC; 8565; PABPN1; Simple; p.Ala11_Gly12insAlaAla (c.18_23dupGGCGGC) ((GCG)9); Zygosity=Heterozygous (PubMed=22040608); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cricopharyngeal muscle Cell type=Myoblast.. Unspecified 21087719 CVCL_6B23 GM00646 finite cell line human CVCL_6B23 CL:0000010 Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female Doubling time: 30.9 +- 1.2 hours (PubMed=1214005) 21087720 CVCL_6B24 KM155C25 telomerase immortalized cell line human CVCL_6B24 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Muscle; semitendinosus Cell type=Myoblast.. Unspecified 21087721 CVCL_6B25 CMDCl12 telomerase immortalized cell line human CVCL_6B25 CL:0000010 Sequence variation: Mutation; HGNC; 17089; SYNE1; Simple; c.2345G>T; Zygosity=Unspecified (PubMed=22040608); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Muscle; paravertebral Cell type=Myoblast.. Unspecified 21087722 CVCL_6B26 DMDCl2 telomerase immortalized cell line human CVCL_6B26 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex48-50del; Zygosity=Hemizygous (PubMed=22040608); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Thigh; quadriceps skeletal muscle Cell type=Myoblast.. Male 21087723 CVCL_YH71 CPTC-PSPHL-2 hybridoma house mouse CVCL_YH71 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15172; Human PSPHP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087724 CVCL_YH72 CPTC-PSPHL-3 hybridoma house mouse CVCL_YH72 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15172; Human PSPHP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087725 CVCL_YH73 CPTC-PTEN-1 hybridoma house mouse CVCL_YH73 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087726 CVCL_YH74 CPTC-PTEN-2 hybridoma house mouse CVCL_YH74 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087727 CVCL_YH70 CPTC-PSPHL-1 hybridoma house mouse CVCL_YH70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15172; Human PSPHP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087728 CVCL_YH79 CPTC-PTEN-7 hybridoma house mouse CVCL_YH79 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087729 CVCL_YH75 CPTC-PTEN-3 hybridoma house mouse CVCL_YH75 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087730 CVCL_YH76 CPTC-PTEN-4 hybridoma house mouse CVCL_YH76 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087731 CVCL_YH77 CPTC-PTEN-5 hybridoma house mouse CVCL_YH77 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087732 CVCL_YH78 CPTC-PTEN-6 hybridoma house mouse CVCL_YH78 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P60484; Human PTEN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087733 CVCL_6B20 tsAM5D conditionally immortalized cell line house mouse CVCL_6B20 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; medulla Cell type=Chromaffin cell.; Breed/subspecies: C57BL/6J SV40-tsA58 transgenic. Unspecified 21087734 CVCL_6B21 GM23707 transformed cell line human CVCL_6B21 CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Gln119Argfs*2 (c.356delA); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087735 CVCL_6B22 GM16864 transformed cell line human CVCL_6B22 CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Simple; p.Gln219Trpfs*20 (c.650_654dupTGGGC) (1712-1713insTGGGC); ClinVar=VCV000179133; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21087736 CVCL_6B38 GM00640 finite cell line human CVCL_6B38 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21087737 CVCL_6B39 GM00905 finite cell line human CVCL_6B39 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21087738 CVCL_6B34 GM00200 finite cell line human CVCL_6B34 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep quantitative phosphoproteome analysis Male 21087739 CVCL_6B35 GM00243 finite cell line human CVCL_6B35 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21087740 CVCL_6B36 GM00357 finite cell line human CVCL_6B36 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21087741 CVCL_6B37 c-SST-2 cancer cell line Norway rat CVCL_6B37 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female 21087742 CVCL_YH60 CPTC-PRDX4-1 hybridoma house mouse CVCL_YH60 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q13162; Human PRDX4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087743 CVCL_YH61 CPTC-PRDX4-2 hybridoma house mouse CVCL_YH61 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q13162; Human PRDX4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087744 CVCL_YH62 CPTC-PRDX4-3 hybridoma house mouse CVCL_YH62 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q13162; Human PRDX4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087745 CVCL_YH63 CPTC-PSAT1-1 hybridoma house mouse CVCL_YH63 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y617; Human PSAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087746 CVCL_YH68 CPTC-PSMD4-2 hybridoma house mouse CVCL_YH68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P55036; Human PSMD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087747 CVCL_YH69 CPTC-PSMD4-3 hybridoma house mouse CVCL_YH69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55036; Human PSMD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087748 CVCL_YH64 CPTC-PSAT1-2 hybridoma house mouse CVCL_YH64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y617; Human PSAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087749 CVCL_YH65 CPTC-PSAT1-3 hybridoma house mouse CVCL_YH65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y617; Human PSAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087750 CVCL_YH66 CPTC-PSAT1-4 hybridoma house mouse CVCL_YH66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y617; Human PSAT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087751 CVCL_YH67 CPTC-PSMD4-1 hybridoma house mouse CVCL_YH67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55036; Human PSMD4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087752 CVCL_6B30 GM00078 finite cell line human CVCL_6B30 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00078; probable Male 21087753 CVCL_6B31 GM00132 finite cell line human CVCL_6B31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21087754 CVCL_6B32 GM00196 finite cell line human CVCL_6B32 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21087755 CVCL_6B33 GM00197 finite cell line human CVCL_6B33 CL:0000010 Sequence variation: Mutation; HGNC; 713; ARSA; Simple; p.Thr393Ser (c.1178C>G) (p.Thr391Ser, c.1172C>G); ClinVar=VCV000021184; Zygosity=Heterozygous (PubMed=32950023) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21087756 CVCL_6B05 PC1 conditionally immortalized cell line house mouse CVCL_6B05 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; proximal caput; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087757 CVCL_6B06 SV40-tsA58 OMCD conditionally immortalized cell line house mouse CVCL_6B06 CL:0000010 Miscellaneous: As no cell line name was provided in the papers, we assigned the name based on the immortalization technique and the primary cell type name Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; outer medullary collecting duct; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087758 CVCL_6B07 SV40-tsA58 S1 conditionally immortalized cell line house mouse CVCL_6B07 CL:0000010 Miscellaneous: As no cell line name was provided in the papers, we assigned the name based on the immortalization technique and the primary cell type name Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal convolated tubule; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087759 CVCL_6B08 SV40-tsA58 S3 conditionally immortalized cell line house mouse CVCL_6B08 CL:0000010 Miscellaneous: As no cell line name was provided in the papers, we assigned the name based on the immortalization technique and the primary cell type name Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal straight tubule; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087760 CVCL_6B01 Astro 4 conditionally immortalized cell line house mouse CVCL_6B01 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21087761 CVCL_6B02 DC1 conditionally immortalized cell line house mouse CVCL_6B02 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; distal caput; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087762 CVCL_6B03 DC2 conditionally immortalized cell line house mouse CVCL_6B03 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; distal caput; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087763 CVCL_6B04 DC3 [Mouse epididymal] conditionally immortalized cell line house mouse CVCL_6B04 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; epididymis; distal caput; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087764 CVCL_YH50 CPTC-PLIN2-1 hybridoma house mouse CVCL_YH50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99541; Human PLIN2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087765 CVCL_YH51 CPTC-PLIN2-2 hybridoma house mouse CVCL_YH51 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99541; Human PLIN2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087766 CVCL_YH52 CPTC-PLIN2-3 hybridoma house mouse CVCL_YH52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99541; Human PLIN2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087767 CVCL_6B09 MCE301 conditionally immortalized cell line house mouse CVCL_6B09 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic colon; distal Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified 21087768 CVCL_YH57 CPTC-PP2A-2 hybridoma house mouse CVCL_YH57 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15257; Human PTPA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087769 CVCL_YH58 CPTC-PP2A-3 hybridoma house mouse CVCL_YH58 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15257; Human PTPA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087770 CVCL_YH59 CPTC-PP2A-4 hybridoma house mouse CVCL_YH59 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15257; Human PTPA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087771 CVCL_YH53 CPTC-PNMT-1 hybridoma house mouse CVCL_YH53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11086; Human PNMT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087772 CVCL_YH54 CPTC-PNMT-2 hybridoma house mouse CVCL_YH54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11086; Human PNMT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087773 CVCL_YH55 CPTC-PNMT-3 hybridoma house mouse CVCL_YH55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11086; Human PNMT. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087774 CVCL_YH56 CPTC-PP2A-1 hybridoma house mouse CVCL_YH56 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15257; Human PTPA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087775 CVCL_6B00 Astro 3 conditionally immortalized cell line house mouse CVCL_6B00 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21087776 CVCL_6B16 TR-TBT 18d-3 conditionally immortalized cell line Norway rat CVCL_6B16 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Syncytiotrophoblast; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087777 CVCL_6B17 TR-TBT 18d-4 conditionally immortalized cell line Norway rat CVCL_6B17 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Syncytiotrophoblast; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087778 CVCL_6B18 Kst-6 cancer cell line human CVCL_6B18 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21087779 CVCL_6B19 Kst-V100 cancer cell line human CVCL_6B19 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21087780 CVCL_6B12 MCC-35 conditionally immortalized cell line house mouse CVCL_6B12 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087781 CVCL_6B13 PDL-L2 conditionally immortalized cell line house mouse CVCL_6B13 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; periodontal ligament Cell type=Fibroblast.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified 21087782 CVCL_6B14 TR-TBT 18d-1 conditionally immortalized cell line Norway rat CVCL_6B14 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Syncytiotrophoblast; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087783 CVCL_6B15 TR-TBT 18d-2 conditionally immortalized cell line Norway rat CVCL_6B15 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Syncytiotrophoblast; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087784 CVCL_YH40 CPTC-OGG1-1 hybridoma house mouse CVCL_YH40 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O15527; Human OGG1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087785 CVCL_YH41 CPTC-OTUB1-1 hybridoma house mouse CVCL_YH41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96FW1; Human OTUB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087786 CVCL_YH46 CPTC-PDLIM1-1 hybridoma house mouse CVCL_YH46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00151; Human PDLIM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087787 CVCL_YH47 CPTC-PDLIM1-2 hybridoma house mouse CVCL_YH47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00151; Human PDLIM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087788 CVCL_YH48 CPTC-PDLIM1-3 hybridoma house mouse CVCL_YH48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00151; Human PDLIM1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087789 CVCL_YH49 CPTC-PEBP1-2 hybridoma house mouse CVCL_YH49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P30086; Human PEBP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087790 CVCL_YH42 CPTC-OTUB1-2 hybridoma house mouse CVCL_YH42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96FW1; Human OTUB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087791 CVCL_YH43 CPTC-OTUB1-3 hybridoma house mouse CVCL_YH43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96FW1; Human OTUB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087792 CVCL_YH44 CPTC-OTUB2-1 hybridoma house mouse CVCL_YH44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96DC9; Human OTUB2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087793 CVCL_YH45 CPTC-OTUB2-2 hybridoma house mouse CVCL_YH45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96DC9; Human OTUB2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21087794 CVCL_6B10 MCC-2 conditionally immortalized cell line house mouse CVCL_6B10 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087795 CVCL_6B11 MCC-5 conditionally immortalized cell line house mouse CVCL_6B11 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male 21087796 CVCL_GU18 HG01119 transformed cell line human CVCL_GU18 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087797 CVCL_H618 WLNA6 hybridoma human CVCL_H618 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgM, kappa 21087798 CVCL_H619 A2780-1A9 cancer cell line human CVCL_H619 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Ovary. Female 21087799 CVCL_GU19 HG01130 transformed cell line human CVCL_GU19 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087800 CVCL_H614 FE-PD cancer cell line human CVCL_H614 CL:0000010 Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Gly1097Val (c.3290_3291delinsTT); Zygosity=Unspecified (PubMed=28356514); Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Gly618Arg (c.1852G>C); ClinVar=VCV001192236; Zygosity=Unspecified (PubMed=28356514) Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 56 hours (PubMed=8035614) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21087801 CVCL_GU14 HG01077 transformed cell line human CVCL_GU14 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087802 CVCL_H615 GM1500-6TG-A11 transformed cell line human CVCL_H615 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgG2 kappa Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8032 Problematic cell line: Misclassified Parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21087803 CVCL_GU15 HG01088 transformed cell line human CVCL_GU15 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087804 CVCL_H616 GM1500-6TG-A12 transformed cell line human CVCL_H616 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgG2 kappa Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8038 Problematic cell line: Misclassified Parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21087805 CVCL_GU16 HG01089 transformed cell line human CVCL_GU16 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087806 CVCL_H617 GM1500-6TG-OUB transformed cell line human CVCL_H617 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgG2 kappa Group: Hybridoma fusion partner cell line Problematic cell line: Misclassified Grand-parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21087807 CVCL_GU17 HG01092 transformed cell line human CVCL_GU17 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087808 CVCL_H610 8701-BC cancer cell line human CVCL_H610 CL:0000010 Derived from sampling site: Breast. Omics: Proteome analysis by 2D-DE/MS Female Doubling time: ~29 hours (PubMed=2548558) 21087809 CVCL_GU10 HG00743 transformed cell line human CVCL_GU10 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087810 CVCL_GU11 HG01058 transformed cell line human CVCL_GU11 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087811 CVCL_H611 RIF-1 cancer cell line house mouse CVCL_H611 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H/Km. Male 21087812 CVCL_GU12 HG01063 transformed cell line human CVCL_GU12 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087813 CVCL_H612 RIF/Ptr1 cancer cell line house mouse CVCL_H612 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H/Km. Male 21087814 CVCL_H613 H22 cancer cell line house mouse CVCL_H613 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3HA. 21087815 CVCL_GU13 HG01064 transformed cell line human CVCL_GU13 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087816 CVCL_H629 AMS3 cancer cell line human CVCL_H629 CL:0000010 Population: Japanese Male Characteristics: Established from a patient-derived xenograft established in SCID mice. 21087817 CVCL_GU29 HG01281 transformed cell line human CVCL_GU29 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087818 CVCL_GU25 HG01169 transformed cell line human CVCL_GU25 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087819 CVCL_H625 NSCLC-N6 clone C65 cancer cell line human CVCL_H625 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 70 hours (PubMed=9568077) 21087820 CVCL_GU26 HG01200 transformed cell line human CVCL_GU26 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087821 CVCL_H626 NSCLC-N6 clone C92 cancer cell line human CVCL_H626 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 108 hours (PubMed=9568077) 21087822 CVCL_GU27 HG01269 transformed cell line human CVCL_GU27 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087823 CVCL_H627 NSCLC-N6 clone C98 cancer cell line human CVCL_H627 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 57 hours (PubMed=9568077) 21087824 CVCL_H628 CHO-M19 spontaneously immortalized cell line CVCL_H628 CL:0000010 Derived from sampling site: Ovary. Female 21087825 CVCL_GU28 HG01280 transformed cell line human CVCL_GU28 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087826 CVCL_H621 1A9PTX22 cancer cell line human CVCL_H621 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21087827 CVCL_GU21 HG01142 transformed cell line human CVCL_GU21 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087828 CVCL_H622 1A9PTX15 cancer cell line human CVCL_H622 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21087829 CVCL_GU22 HG01161 transformed cell line human CVCL_GU22 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087830 CVCL_GU23 HG01162 transformed cell line human CVCL_GU23 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087831 CVCL_H623 NSCLC-N6 cancer cell line human CVCL_H623 CL:0000010 Derived from sampling site: Lung. Male Doubling time: ~48 hours (PubMed=1776865) 21087832 CVCL_GU24 HG01164 transformed cell line human CVCL_GU24 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087833 CVCL_H624 NSCLC-N6 clone C15 cancer cell line human CVCL_H624 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 91 hours (PubMed=9568077) 21087834 CVCL_H620 1A9PTX10 cancer cell line human CVCL_H620 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21087835 CVCL_GU20 HG01131 transformed cell line human CVCL_GU20 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087836 CVCL_H607 D05 cancer cell line human CVCL_H607 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21087837 CVCL_GU07 HG00304 transformed cell line human CVCL_GU07 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087838 CVCL_H608 D08 cancer cell line human CVCL_H608 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21087839 CVCL_GU08 HG00717 transformed cell line human CVCL_GU08 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087840 CVCL_GU09 HG00742 transformed cell line human CVCL_GU09 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087841 CVCL_H603 H3677 cancer cell line human CVCL_H603 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21087842 CVCL_GU03 GEK spontaneously immortalized cell line CVCL_GU03 CL:0000010 Derived from sampling site: Fetal kidney; Breed/subspecies: Matou. Unspecified Doubling time: ~49.5 hours (CelloPub=CLPUB00354) Group: Vaccine production cell line 21087843 CVCL_GU04 CRI-G1-RS cancer cell line Norway rat CVCL_GU04 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Omics: Transcriptome analysis by microarray 21087844 CVCL_H604 D04 cancer cell line human CVCL_H604 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21087845 CVCL_H605 F-11 hybrid cell line CVCL_H605 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of rat embryonic day 13-14 dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=3858835) 21087846 CVCL_GU05 HG00288 transformed cell line human CVCL_GU05 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087847 CVCL_GU06 HG00290 transformed cell line human CVCL_GU06 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087848 CVCL_H606 NCB-20 hybrid cell line house mouse CVCL_H606 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21087849 CVCL_GU00 ND09997 transformed cell line human CVCL_GU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087850 CVCL_GU01 ND11267 transformed cell line human CVCL_GU01 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21087851 CVCL_GU02 JGG finite cell line CVCL_GU02 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Jining Grey. Mixed Doubling time: ~48 hours (DOI=10.3906/vet-1106-15) 21087852 CVCL_H602 M109 cancer cell line house mouse CVCL_H602 CL:0000010 Breed/subspecies: BALB/c. 21087853 CVCL_6B89 TRD-61 conditionally immortalized cell line Norway rat CVCL_6B89 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087854 CVCL_6B80 TRD-41 conditionally immortalized cell line Norway rat CVCL_6B80 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087855 CVCL_6B85 TRD-49 conditionally immortalized cell line Norway rat CVCL_6B85 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087856 CVCL_6B86 TRD-52 conditionally immortalized cell line Norway rat CVCL_6B86 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087857 CVCL_6B87 TRD-58 conditionally immortalized cell line Norway rat CVCL_6B87 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087858 CVCL_6B88 TRD-60 conditionally immortalized cell line Norway rat CVCL_6B88 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087859 CVCL_6B81 TRD-42 conditionally immortalized cell line Norway rat CVCL_6B81 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087860 CVCL_6B82 TRD-43 conditionally immortalized cell line Norway rat CVCL_6B82 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087861 CVCL_6B83 TRD-44 conditionally immortalized cell line Norway rat CVCL_6B83 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087862 CVCL_6B84 TRD-45 conditionally immortalized cell line Norway rat CVCL_6B84 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087863 CVCL_6B90 TRD-62 conditionally immortalized cell line Norway rat CVCL_6B90 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087864 CVCL_6B91 TRD-72 conditionally immortalized cell line Norway rat CVCL_6B91 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087865 CVCL_6B96 TT-E4 conditionally immortalized cell line house mouse CVCL_6B96 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Achilles tendon; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087866 CVCL_6B97 TT-G11 conditionally immortalized cell line house mouse CVCL_6B97 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Achilles tendon; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087867 CVCL_6B98 MGE02 conditionally immortalized cell line house mouse CVCL_6B98 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087868 CVCL_6B99 MGE12-1 conditionally immortalized cell line house mouse CVCL_6B99 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087869 CVCL_6B92 RPMC 21 conditionally immortalized cell line Norway rat CVCL_6B92 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087870 CVCL_6B93 RTEC11 conditionally immortalized cell line Norway rat CVCL_6B93 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087871 CVCL_6B94 RS182 conditionally immortalized cell line Norway rat CVCL_6B94 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; suprachiasmatic nucleus Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21087872 CVCL_6B95 TT-D6 conditionally immortalized cell line house mouse CVCL_6B95 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Achilles tendon; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21087873 CVCL_PP52 BayGenomics ES cell line XE738 embryonic stem cell house mouse CVCL_PP52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087874 CVCL_Q152 HG01182 transformed cell line human CVCL_Q152 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087875 CVCL_PP53 BayGenomics ES cell line XE743 embryonic stem cell house mouse CVCL_PP53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923035; Klhl24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087876 CVCL_Q153 HG01183 transformed cell line human CVCL_Q153 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087877 CVCL_PP54 BayGenomics ES cell line XE744 embryonic stem cell house mouse CVCL_PP54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109275; Trim24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087878 CVCL_Q154 HG01184 transformed cell line human CVCL_Q154 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087879 CVCL_PP55 BayGenomics ES cell line XE746 embryonic stem cell house mouse CVCL_PP55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087880 CVCL_Q155 HG01187 transformed cell line human CVCL_Q155 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087881 CVCL_PP56 BayGenomics ES cell line XE747 embryonic stem cell house mouse CVCL_PP56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97537; Pecam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087882 CVCL_Q156 HG01188 transformed cell line human CVCL_Q156 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087883 CVCL_PP57 BayGenomics ES cell line XE749 embryonic stem cell house mouse CVCL_PP57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918625; Foxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087884 CVCL_Q157 HG01189 transformed cell line human CVCL_Q157 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087885 CVCL_PP58 BayGenomics ES cell line XE751 embryonic stem cell house mouse CVCL_PP58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087886 CVCL_Q158 HG01190 transformed cell line human CVCL_Q158 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087887 CVCL_PP59 BayGenomics ES cell line XE752 embryonic stem cell house mouse CVCL_PP59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087888 CVCL_Q159 HG01191 transformed cell line human CVCL_Q159 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087889 CVCL_PP60 BayGenomics ES cell line XE754 embryonic stem cell house mouse CVCL_PP60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087890 CVCL_Q160 HG01192 transformed cell line human CVCL_Q160 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087891 CVCL_PP61 BayGenomics ES cell line XE755 embryonic stem cell house mouse CVCL_PP61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087892 CVCL_Q161 HG01197 transformed cell line human CVCL_Q161 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087893 CVCL_PP62 BayGenomics ES cell line XE756 embryonic stem cell house mouse CVCL_PP62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087894 CVCL_Q162 HG01198 transformed cell line human CVCL_Q162 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087895 CVCL_PP41 BayGenomics ES cell line XE686 embryonic stem cell house mouse CVCL_PP41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087896 CVCL_Q141 HG01167 transformed cell line human CVCL_Q141 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087897 CVCL_PP42 BayGenomics ES cell line XE690 embryonic stem cell house mouse CVCL_PP42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096881; Eef1a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087898 CVCL_Q142 HG01168 transformed cell line human CVCL_Q142 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087899 CVCL_PP43 BayGenomics ES cell line XE693 embryonic stem cell house mouse CVCL_PP43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108057; Rpl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087900 CVCL_Q143 HG01170 transformed cell line human CVCL_Q143 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087901 CVCL_PP44 BayGenomics ES cell line XE699 embryonic stem cell house mouse CVCL_PP44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96995; Kmt2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087902 CVCL_Q144 HG01171 transformed cell line human CVCL_Q144 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087903 CVCL_PP45 BayGenomics ES cell line XE701 embryonic stem cell house mouse CVCL_PP45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087904 CVCL_Q145 HG01172 transformed cell line human CVCL_Q145 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087905 CVCL_PP46 BayGenomics ES cell line XE704 embryonic stem cell house mouse CVCL_PP46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087906 CVCL_Q146 HG01173 transformed cell line human CVCL_Q146 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087907 CVCL_PP47 BayGenomics ES cell line XE705 embryonic stem cell house mouse CVCL_PP47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95476; Fabp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087908 CVCL_Q147 HG01174 transformed cell line human CVCL_Q147 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087909 CVCL_PP48 BayGenomics ES cell line XE707 embryonic stem cell house mouse CVCL_PP48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087910 CVCL_Q148 HG01175 transformed cell line human CVCL_Q148 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087911 CVCL_PP49 BayGenomics ES cell line XE726 embryonic stem cell house mouse CVCL_PP49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135637; Park7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087912 CVCL_Q149 HG01176 transformed cell line human CVCL_Q149 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087913 CVCL_PP50 BayGenomics ES cell line XE728 embryonic stem cell house mouse CVCL_PP50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928373; Dnajc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087914 CVCL_Q150 HG01177 transformed cell line human CVCL_Q150 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087915 CVCL_PP51 BayGenomics ES cell line XE732 embryonic stem cell house mouse CVCL_PP51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914176; Trmt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087916 CVCL_Q151 HG01178 transformed cell line human CVCL_Q151 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087917 CVCL_PP30 BayGenomics ES cell line XE664 embryonic stem cell house mouse CVCL_PP30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087918 CVCL_Q130 HG01134 transformed cell line human CVCL_Q130 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087919 CVCL_PP31 BayGenomics ES cell line XE666 embryonic stem cell house mouse CVCL_PP31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924270; Atl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087920 CVCL_Q131 HG01135 transformed cell line human CVCL_Q131 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087921 CVCL_PP32 BayGenomics ES cell line XE668 embryonic stem cell house mouse CVCL_PP32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087922 CVCL_Q132 HG01136 transformed cell line human CVCL_Q132 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087923 CVCL_PP33 BayGenomics ES cell line XE670 embryonic stem cell house mouse CVCL_PP33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087924 CVCL_Q133 HG01137 transformed cell line human CVCL_Q133 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087925 CVCL_PP34 BayGenomics ES cell line XE671 embryonic stem cell house mouse CVCL_PP34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087926 CVCL_Q134 HG01138 transformed cell line human CVCL_Q134 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087927 CVCL_PP35 BayGenomics ES cell line XE673 embryonic stem cell house mouse CVCL_PP35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087928 CVCL_Q135 HG01139 transformed cell line human CVCL_Q135 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087929 CVCL_PP36 BayGenomics ES cell line XE676 embryonic stem cell house mouse CVCL_PP36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087930 CVCL_Q136 HG01140 transformed cell line human CVCL_Q136 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087931 CVCL_PP37 BayGenomics ES cell line XE678 embryonic stem cell house mouse CVCL_PP37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919204; Suds3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087932 CVCL_Q137 HG01141 transformed cell line human CVCL_Q137 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087933 CVCL_PP38 BayGenomics ES cell line XE680 embryonic stem cell house mouse CVCL_PP38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444061; Ss18l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087934 CVCL_Q138 HG01148 transformed cell line human CVCL_Q138 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087935 CVCL_PP39 BayGenomics ES cell line XE681 embryonic stem cell house mouse CVCL_PP39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159210; Tiparp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087936 CVCL_Q139 HG01149 transformed cell line human CVCL_Q139 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087937 CVCL_H797 ES[MC1R(20):tetAscl2(21)] embryonic stem cell house mouse CVCL_H797 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21087938 CVCL_GV97 HG02856 transformed cell line human CVCL_GV97 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087939 CVCL_H798 ES[MC1R(20):tetAtf3(5)] embryonic stem cell house mouse CVCL_H798 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21087940 CVCL_GV98 HG02862 transformed cell line human CVCL_GV98 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087941 CVCL_H799 AG06846 finite cell line human CVCL_H799 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21087942 CVCL_GV99 HG02871 transformed cell line human CVCL_GV99 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087943 CVCL_H793 AG06840 finite cell line human CVCL_H793 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Coriell; PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21087944 CVCL_GV93 HG02821 transformed cell line human CVCL_GV93 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087945 CVCL_H794 AG06841 transformed cell line human CVCL_H794 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21087946 CVCL_GV94 HG02838 transformed cell line human CVCL_GV94 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087947 CVCL_H795 ES[MC1R(20):tetAes(24)] embryonic stem cell house mouse CVCL_H795 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21087948 CVCL_GV95 HG02841 transformed cell line human CVCL_GV95 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087949 CVCL_H796 ES[MC1R(20):tetAscl1(12)] embryonic stem cell house mouse CVCL_H796 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21087950 CVCL_GV96 HG02853 transformed cell line human CVCL_GV96 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087951 CVCL_H790 AG06241 finite cell line human CVCL_H790 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21087952 CVCL_GV90 HG02812 transformed cell line human CVCL_GV90 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087953 CVCL_H791 AG06838 finite cell line human CVCL_H791 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21087954 CVCL_GV91 HG02815 transformed cell line human CVCL_GV91 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087955 CVCL_H792 AG06839 transformed cell line human CVCL_H792 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21087956 CVCL_GV92 HG02818 transformed cell line human CVCL_GV92 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087957 CVCL_PP40 BayGenomics ES cell line XE685 embryonic stem cell house mouse CVCL_PP40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087958 CVCL_Q140 HG01150 transformed cell line human CVCL_Q140 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087959 CVCL_PP20 BayGenomics ES cell line XE595 embryonic stem cell house mouse CVCL_PP20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681840; Rsl24d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087960 CVCL_Q120 HG01111 transformed cell line human CVCL_Q120 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087961 CVCL_PP21 BayGenomics ES cell line XE596 embryonic stem cell house mouse CVCL_PP21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921407; Cmtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087962 CVCL_Q121 HG01112 transformed cell line human CVCL_Q121 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087963 CVCL_PP22 BayGenomics ES cell line XE617 embryonic stem cell house mouse CVCL_PP22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88190; Braf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087964 CVCL_Q122 HG01113 transformed cell line human CVCL_Q122 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087965 CVCL_PP23 BayGenomics ES cell line XE622 embryonic stem cell house mouse CVCL_PP23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087966 CVCL_Q123 HG01114 transformed cell line human CVCL_Q123 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087967 CVCL_PP24 BayGenomics ES cell line XE630 embryonic stem cell house mouse CVCL_PP24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919563; Fryl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087968 CVCL_Q124 HG01121 transformed cell line human CVCL_Q124 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087969 CVCL_PP25 BayGenomics ES cell line XE642 embryonic stem cell house mouse CVCL_PP25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98790; Top2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087970 CVCL_Q125 HG01122 transformed cell line human CVCL_Q125 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087971 CVCL_PP26 BayGenomics ES cell line XE643 embryonic stem cell house mouse CVCL_PP26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929212; Ap3m1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087972 CVCL_Q126 HG01124 transformed cell line human CVCL_Q126 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087973 CVCL_PP27 BayGenomics ES cell line XE644 embryonic stem cell house mouse CVCL_PP27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142651; Prmt9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087974 CVCL_Q127 HG01125 transformed cell line human CVCL_Q127 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087975 CVCL_PP28 BayGenomics ES cell line XE661 embryonic stem cell house mouse CVCL_PP28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106687; Pon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087976 CVCL_Q128 HG01126 transformed cell line human CVCL_Q128 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087977 CVCL_PP29 BayGenomics ES cell line XE663 embryonic stem cell house mouse CVCL_PP29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087978 CVCL_Q129 HG01133 transformed cell line human CVCL_Q129 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087979 CVCL_PP10 BayGenomics ES cell line XE550 embryonic stem cell house mouse CVCL_PP10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97887; Rdx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087980 CVCL_Q110 HG01101 transformed cell line human CVCL_Q110 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087981 CVCL_PP11 BayGenomics ES cell line XE565 embryonic stem cell house mouse CVCL_PP11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918972; Cic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087982 CVCL_Q111 HG01102 transformed cell line human CVCL_Q111 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087983 CVCL_PP12 BayGenomics ES cell line XE566 embryonic stem cell house mouse CVCL_PP12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087984 CVCL_Q112 HG01103 transformed cell line human CVCL_Q112 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087985 CVCL_PP13 BayGenomics ES cell line XE569 embryonic stem cell house mouse CVCL_PP13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138281; Lbr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087986 CVCL_Q113 HG01104 transformed cell line human CVCL_Q113 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087987 CVCL_PP14 BayGenomics ES cell line XE574 embryonic stem cell house mouse CVCL_PP14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087988 CVCL_Q114 HG01105 transformed cell line human CVCL_Q114 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087989 CVCL_PP15 BayGenomics ES cell line XE579 embryonic stem cell house mouse CVCL_PP15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098231; Kif11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087990 CVCL_Q115 HG01106 transformed cell line human CVCL_Q115 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087991 CVCL_H779 AG06264 finite cell line human CVCL_H779 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21087992 CVCL_PP16 BayGenomics ES cell line XE580 embryonic stem cell house mouse CVCL_PP16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921407; Cmtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087993 CVCL_Q116 HG01107 transformed cell line human CVCL_Q116 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087994 CVCL_GV79 HG02770 transformed cell line human CVCL_GV79 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087995 CVCL_PP17 BayGenomics ES cell line XE591 embryonic stem cell house mouse CVCL_PP17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087996 CVCL_Q117 HG01108 transformed cell line human CVCL_Q117 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087997 CVCL_PP18 BayGenomics ES cell line XE592 embryonic stem cell house mouse CVCL_PP18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685988; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21087998 CVCL_Q118 HG01109 transformed cell line human CVCL_Q118 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21087999 CVCL_PP19 BayGenomics ES cell line XE594 embryonic stem cell house mouse CVCL_PP19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088000 CVCL_Q119 HG01110 transformed cell line human CVCL_Q119 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088001 CVCL_H775 AG22719 finite cell line human CVCL_H775 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG22719) 21088002 CVCL_GV75 HG02738 transformed cell line human CVCL_GV75 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088003 CVCL_H776 AG22720 finite cell line human CVCL_H776 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 29 PDL (Coriell=AG22720) 21088004 CVCL_GV76 HG02758 transformed cell line human CVCL_GV76 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088005 CVCL_H777 AG06842 finite cell line human CVCL_H777 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21088006 CVCL_GV77 HG02761 transformed cell line human CVCL_GV77 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088007 CVCL_H778 AG06843 transformed cell line human CVCL_H778 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21088008 CVCL_GV78 HG02764 transformed cell line human CVCL_GV78 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088009 CVCL_H771 AG21839 finite cell line human CVCL_H771 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088010 CVCL_GV71 HG02723 transformed cell line human CVCL_GV71 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088011 CVCL_H772 AG22151 finite cell line human CVCL_H772 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21088012 CVCL_GV72 HG02726 transformed cell line human CVCL_GV72 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088013 CVCL_H773 AG22152 finite cell line human CVCL_H773 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21088014 CVCL_GV73 HG02729 transformed cell line human CVCL_GV73 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088015 CVCL_H774 AG22153 finite cell line human CVCL_H774 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at the 18th passage (PubMed=35628639) 21088016 CVCL_GV74 HG02735 transformed cell line human CVCL_GV74 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088017 CVCL_H770 AG21838 finite cell line human CVCL_H770 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21088018 CVCL_GV70 HG02717 transformed cell line human CVCL_GV70 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088019 CVCL_PP00 BayGenomics ES cell line XE529 embryonic stem cell house mouse CVCL_PP00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088020 CVCL_Q100 HG01085 transformed cell line human CVCL_Q100 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088021 CVCL_PP01 BayGenomics ES cell line XE532 embryonic stem cell house mouse CVCL_PP01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143340; Zfp445 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088022 CVCL_Q101 HG01086 transformed cell line human CVCL_Q101 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088023 CVCL_PP02 BayGenomics ES cell line XE534 embryonic stem cell house mouse CVCL_PP02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036240; Zfp939 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088024 CVCL_Q102 HG01087 transformed cell line human CVCL_Q102 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088025 CVCL_PP03 BayGenomics ES cell line XE537 embryonic stem cell house mouse CVCL_PP03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088026 CVCL_Q103 HG01094 transformed cell line human CVCL_Q103 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088027 CVCL_PP04 BayGenomics ES cell line XE538 embryonic stem cell house mouse CVCL_PP04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088028 CVCL_Q104 HG01095 transformed cell line human CVCL_Q104 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088029 CVCL_PP05 BayGenomics ES cell line XE541 embryonic stem cell house mouse CVCL_PP05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918708; Bcor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088030 CVCL_Q105 HG01096 transformed cell line human CVCL_Q105 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088031 CVCL_PP06 BayGenomics ES cell line XE542 embryonic stem cell house mouse CVCL_PP06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913744; Prelid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088032 CVCL_Q106 HG01097 transformed cell line human CVCL_Q106 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088033 CVCL_PP07 BayGenomics ES cell line XE543 embryonic stem cell house mouse CVCL_PP07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088034 CVCL_Q107 HG01098 transformed cell line human CVCL_Q107 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088035 CVCL_PP08 BayGenomics ES cell line XE544 embryonic stem cell house mouse CVCL_PP08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3645888; Gm6712 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088036 CVCL_Q108 HG01099 transformed cell line human CVCL_Q108 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088037 CVCL_H786 AG04400 finite cell line human CVCL_H786 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088038 CVCL_PP09 BayGenomics ES cell line XE545 embryonic stem cell house mouse CVCL_PP09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913993; Rnf220 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088039 CVCL_Q109 HG01100 transformed cell line human CVCL_Q109 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088040 CVCL_GV86 HG02794 transformed cell line human CVCL_GV86 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088041 CVCL_H787 AG04401 finite cell line human CVCL_H787 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088042 CVCL_GV87 HG02800 transformed cell line human CVCL_GV87 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088043 CVCL_H788 AG04402 finite cell line human CVCL_H788 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21088044 CVCL_GV88 HG02806 transformed cell line human CVCL_GV88 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088045 CVCL_H789 AG04560 finite cell line human CVCL_H789 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21088046 CVCL_GV89 HG02809 transformed cell line human CVCL_GV89 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088047 CVCL_H782 H19-5 transformed cell line Norway rat CVCL_H782 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [U19tsa](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Holtzman. Unspecified 21088048 CVCL_GV82 HG02779 transformed cell line human CVCL_GV82 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088049 CVCL_GV83 HG02785 transformed cell line human CVCL_GV83 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088050 CVCL_H783 WH19-4 transformed cell line Norway rat CVCL_H783 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [U19tsa](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus; Breed/subspecies: Wistar Kyoto. 21088051 CVCL_H784 H583-5 transformed cell line Norway rat CVCL_H784 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Holtzman. 21088052 CVCL_GV84 HG02788 transformed cell line human CVCL_GV84 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088053 CVCL_GV85 HG02791 transformed cell line human CVCL_GV85 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088054 CVCL_H780 AG06265 finite cell line human CVCL_H780 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21088055 CVCL_GV80 HG02773 transformed cell line human CVCL_GV80 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088056 CVCL_H781 H19-7 transformed cell line Norway rat CVCL_H781 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Holtzman. Unspecified Characteristics: Grows at the permissive temperature (34 Celsius) Differentiate to a neuronal phenotype at the nonpermissive temperature (39 Celsius) when induced by FGF2. 21088057 CVCL_GV81 HG02776 transformed cell line human CVCL_GV81 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088058 CVCL_H757 GM02150 transformed cell line human CVCL_H757 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Peripheral blood. Female 21088059 CVCL_GV57 HG02656 transformed cell line human CVCL_GV57 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088060 CVCL_H758 GM02151 finite cell line human CVCL_H758 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21088061 CVCL_GV58 HG02659 transformed cell line human CVCL_GV58 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088062 CVCL_H759 AG01522 finite cell line human CVCL_H759 CL:0000010 Anecdotal: Have been flown in space on the ISS to study growth in microgravity (PubMed=28248986) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Group: Space-flown cell line (cellonaut) 21088063 CVCL_GV59 HG02662 transformed cell line human CVCL_GV59 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088064 CVCL_H753 GM02148 transformed cell line human CVCL_H753 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21088065 CVCL_GV53 HG02644 transformed cell line human CVCL_GV53 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088066 CVCL_H754 GM02149 finite cell line human CVCL_H754 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21088067 CVCL_GV54 HG02647 transformed cell line human CVCL_GV54 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088068 CVCL_H755 GM02146 transformed cell line human CVCL_H755 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21088069 CVCL_GV55 HG02650 transformed cell line human CVCL_GV55 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088070 CVCL_H756 GM02147 finite cell line human CVCL_H756 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21088071 CVCL_GV56 HG02653 transformed cell line human CVCL_GV56 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088072 CVCL_H750 AG01520 finite cell line human CVCL_H750 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088073 CVCL_GV50 HG02625 transformed cell line human CVCL_GV50 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088074 CVCL_H751 AG01521 finite cell line human CVCL_H751 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088075 CVCL_GV51 HG02630 transformed cell line human CVCL_GV51 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088076 CVCL_H752 GM06419 finite cell line human CVCL_H752 CL:0000010 Population: Iranian; Persian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088077 CVCL_GV52 HG02636 transformed cell line human CVCL_GV52 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088078 CVCL_H768 AG21707 finite cell line human CVCL_H768 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21088079 CVCL_GV68 HG02701 transformed cell line human CVCL_GV68 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088080 CVCL_H769 AG21837 finite cell line human CVCL_H769 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21088081 CVCL_GV69 HG02704 transformed cell line human CVCL_GV69 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088082 CVCL_H764 AG01519 finite cell line human CVCL_H764 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088083 CVCL_GV64 HG02686 transformed cell line human CVCL_GV64 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088084 CVCL_H765 AG06297 finite cell line human CVCL_H765 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell; PubMed=12714972) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21088085 CVCL_GV65 HG02689 transformed cell line human CVCL_GV65 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088086 CVCL_H766 AG11498 finite cell line human CVCL_H766 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell; PubMed=12714972) Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21088087 CVCL_GV66 HG02692 transformed cell line human CVCL_GV66 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088088 CVCL_H767 AG21706 finite cell line human CVCL_H767 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21088089 CVCL_GV67 HG02698 transformed cell line human CVCL_GV67 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088090 CVCL_GV60 HG02668 transformed cell line human CVCL_GV60 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088091 CVCL_H760 HX138 cancer cell line human CVCL_H760 CL:0000010 Unspecified 21088092 CVCL_GV61 HG02677 transformed cell line human CVCL_GV61 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088093 CVCL_H761 HX142 cancer cell line human CVCL_H761 CL:0000010 21088094 CVCL_GV62 HG02680 transformed cell line human CVCL_GV62 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088095 CVCL_H762 HX118 cancer cell line human CVCL_H762 CL:0000010 Unspecified 21088096 CVCL_GV63 HG02683 transformed cell line human CVCL_GV63 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088097 CVCL_H763 Hx34 cancer cell line human CVCL_H763 CL:0000010 Unspecified 21088098 CVCL_6D25 TPM2-187 embryonic stem cell house mouse CVCL_6D25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1350933; Bcap31 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088099 CVCL_6D26 v17.2 embryonic stem cell house mouse CVCL_6D26 CL:0000010 Breed/subspecies: BALB/cTa x 129S4/SvJae. Male 21088100 CVCL_6D27 v18.6 embryonic stem cell house mouse CVCL_6D27 CL:0000010 Breed/subspecies: 129S4/SvJae. Male 21088101 CVCL_6D28 v26.2 embryonic stem cell house mouse CVCL_6D28 CL:0000010 Breed/subspecies: C57BL/6. Male 21088102 CVCL_6D21 33v1-051 embryonic stem cell house mouse CVCL_6D21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106354; Vps25 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088103 CVCL_6D22 36v-38 embryonic stem cell house mouse CVCL_6D22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147677; Lpxn Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088104 CVCL_6D23 37v-42 embryonic stem cell house mouse CVCL_6D23 CL:0000010 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088105 CVCL_6D24 38v-29 embryonic stem cell house mouse CVCL_6D24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107194; Shroom2 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088106 CVCL_YJ70 VAMPIRO SH-SY5Y cancer cell line human CVCL_YJ70 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21088107 CVCL_YJ71 VAMPIRO SK-BR-3 cancer cell line human CVCL_YJ71 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21088108 CVCL_YJ72 VAMPIRO U2OS cancer cell line human CVCL_YJ72 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088109 CVCL_6D29 v6.4 embryonic stem cell house mouse CVCL_6D29 CL:0000010 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088110 CVCL_YJ77 LINTERNA CHO-K1 spontaneously immortalized cell line CVCL_YJ77 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Derived from sampling site: Ovary. Female 21088111 CVCL_YJ78 LINTERNA COS-7 transformed cell line CVCL_YJ78 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21088112 CVCL_YJ79 LINTERNA CT-26 cancer cell line house mouse CVCL_YJ79 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21088113 CVCL_YJ73 MHHi006-A-4 induced pluripotent stem cell human CVCL_YJ73 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Umbilical cord blood. Male Characteristics: Using TALEN a P2A-eGFP-T2A-PGK-hph construct was integrated in front of the stop codon of NXK2-1 and a P2A-dTomato-nucmem-T2A-NeoR_PGKPuroR construct was integrated into exon 10 of TP63 21088114 CVCL_YJ74 LINTERNA A375 cancer cell line human CVCL_YJ74 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Skin. Female 21088115 CVCL_YJ75 LINTERNA A549 cancer cell line human CVCL_YJ75 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male 21088116 CVCL_YJ76 LINTERNA B16-F10 cancer cell line house mouse CVCL_YJ76 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21088117 CVCL_6D20 26v-023 embryonic stem cell house mouse CVCL_6D20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860486; Tdp2 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088118 CVCL_6D36 TPM6-360 embryonic stem cell house mouse CVCL_6D36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313312; Khdrbs3 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088119 CVCL_6D37 TpM(409) transformed cell line CVCL_6D37 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Infected by Theileria parva isolate Muguga 21088120 CVCL_6D38 Ta288 transformed cell line CVCL_6D38 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Infected by Theileria annulaza isolate Ankara 21088121 CVCL_6D39 Ta363 transformed cell line CVCL_6D39 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Infected by Theileria annulaza isolate Ankara 21088122 CVCL_6D32 v8.1 embryonic stem cell house mouse CVCL_6D32 CL:0000010 Breed/subspecies: 129S4/SvJae x FVB. Male 21088123 CVCL_6D33 2TP-084 embryonic stem cell house mouse CVCL_6D33 CL:0000010 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088124 CVCL_6D34 TPM5-123 embryonic stem cell house mouse CVCL_6D34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444748; Chd7 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088125 CVCL_6D35 TPM6-180 embryonic stem cell house mouse CVCL_6D35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142330; Ppm1n Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088126 CVCL_YJ60 DANi008-F induced pluripotent stem cell human CVCL_YJ60 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088127 CVCL_YJ61 SYSUi003-A induced pluripotent stem cell human CVCL_YJ61 From: Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 4585; GRIN2A; Simple; p.Leu611Gln (c.1832A>T); Zygosity=Heterozygous; Note=De novo mutation (PubMed=32036246) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21088128 CVCL_YJ66 VAMPIRO CHO-K1 spontaneously immortalized cell line CVCL_YJ66 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21088129 CVCL_YJ67 VAMPIRO HEK293 transformed cell line human CVCL_YJ67 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088130 CVCL_YJ68 VAMPIRO MDA-MB-231 cancer cell line human CVCL_YJ68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21088131 CVCL_YJ69 VAMPIRO PC-3 cancer cell line human CVCL_YJ69 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Bone. Male 21088132 CVCL_YJ62 46C-RYBP KO embryonic stem cell house mouse CVCL_YJ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1929059; Rybp; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Using CRISPR/Cas9 the last two exons of Rybp gene were replaced with PGK-Puro by homologous recombination; Characteristics: Expresses GFP under the control of the Sox1 promoter Caution: Named GIBHe001-A-1 which according to ESC nomenclature rules would imply being a derivative of the GIBHe001-A human ESC cell line, but this is not the case 21088133 CVCL_YJ63 HEBHMUi002-A induced pluripotent stem cell human CVCL_YJ63 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Female 21088134 CVCL_YJ64 VAMPIRO 3T3 spontaneously immortalized cell line house mouse CVCL_YJ64 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21088135 CVCL_YJ65 VAMPIRO B16-F10 cancer cell line house mouse CVCL_YJ65 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21088136 CVCL_6D30 v30.30 embryonic stem cell house mouse CVCL_6D30 CL:0000010 Breed/subspecies: C57BL/6J x BALB/c. Male 21088137 CVCL_6D31 v39.7 embryonic stem cell house mouse CVCL_6D31 CL:0000010 Breed/subspecies: BALB/c. Male 21088138 CVCL_6D03 HiPS-RIKEN-3E induced pluripotent stem cell human CVCL_6D03 CL:0000010 Population: Japanese. Female 21088139 CVCL_6D04 HiPS-RIKEN-4A induced pluripotent stem cell human CVCL_6D04 CL:0000010 Population: Japanese. Female 21088140 CVCL_6D05 HiPS-RIKEN-4B induced pluripotent stem cell human CVCL_6D05 CL:0000010 Population: Japanese. Female 21088141 CVCL_6D06 HiPS-RIKEN-4C induced pluripotent stem cell human CVCL_6D06 CL:0000010 Population: Japanese. Female 21088142 CVCL_6D00 HiPS-RIKEN-11B induced pluripotent stem cell human CVCL_6D00 CL:0000010 Population: Japanese; Derived from sampling site: Amniotic fluid. Male 21088143 CVCL_6D01 HiPS-RIKEN-3A induced pluripotent stem cell human CVCL_6D01 CL:0000010 Population: Japanese. Female 21088144 CVCL_6D02 HiPS-RIKEN-3D induced pluripotent stem cell human CVCL_6D02 CL:0000010 Population: Japanese. Female 21088145 CVCL_YJ50 DANi006-B induced pluripotent stem cell human CVCL_YJ50 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi006-F) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088146 CVCL_6D07 HiPS-RIKEN-4D induced pluripotent stem cell human CVCL_6D07 CL:0000010 Population: Japanese. Female 21088147 CVCL_6D08 HiPS-RIKEN-4E induced pluripotent stem cell human CVCL_6D08 CL:0000010 Population: Japanese. Female 21088148 CVCL_6D09 HiPS-RIKEN-4F induced pluripotent stem cell human CVCL_6D09 CL:0000010 Population: Japanese. Female 21088149 CVCL_YJ55 DANi008-A induced pluripotent stem cell human CVCL_YJ55 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from autologous cell line DANi008-F) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088150 CVCL_YJ56 DANi008-B induced pluripotent stem cell human CVCL_YJ56 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from autologous cell line DANi008-F) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088151 CVCL_YJ57 DANi008-C induced pluripotent stem cell human CVCL_YJ57 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from autologous cell line DANi008-F) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088152 CVCL_YJ58 DANi008-D induced pluripotent stem cell human CVCL_YJ58 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from autologous cell line DANi008-F) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088153 CVCL_YJ51 DANi006-C induced pluripotent stem cell human CVCL_YJ51 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi006-F) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088154 CVCL_YJ52 DANi006-D induced pluripotent stem cell human CVCL_YJ52 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi006-F) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088155 CVCL_YJ53 DANi006-E induced pluripotent stem cell human CVCL_YJ53 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi006-F) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088156 CVCL_YJ54 DANi006-F induced pluripotent stem cell human CVCL_YJ54 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088157 CVCL_YJ59 DANi008-E induced pluripotent stem cell human CVCL_YJ59 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from autologous cell line DANi008-F) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088158 CVCL_6D14 BJ hiPSC #5 induced pluripotent stem cell human CVCL_6D14 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088159 CVCL_6D15 BJ hiPSC #8 induced pluripotent stem cell human CVCL_6D15 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088160 CVCL_6D16 CALM KO MEF transformed cell line house mouse CVCL_6D16 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2385902; Picalm Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x CBA. Unspecified 21088161 CVCL_6D17 CALM WT MEF transformed cell line house mouse CVCL_6D17 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x CBA. Unspecified 21088162 CVCL_6D10 HiPS-RIKEN-4G induced pluripotent stem cell human CVCL_6D10 CL:0000010 Population: Japanese. Female 21088163 CVCL_6D11 HiPS-RIKEN-4H induced pluripotent stem cell human CVCL_6D11 CL:0000010 Population: Japanese. Female 21088164 CVCL_6D12 BJ hiPSC #11 induced pluripotent stem cell human CVCL_6D12 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088165 CVCL_6D13 BJ hiPSC #12 induced pluripotent stem cell human CVCL_6D13 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21088166 CVCL_6D18 26v-006 embryonic stem cell house mouse CVCL_6D18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088167 CVCL_6D19 26v-009 embryonic stem cell house mouse CVCL_6D19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99204; Zfp57 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21088168 CVCL_YJ44 IM-HM-tGFP transformed cell line human CVCL_YJ44 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. 21088169 CVCL_YJ45 NUE-1 cancer cell line human CVCL_YJ45 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 40 hours (PubMed=3819523) 21088170 CVCL_YJ46 HEC-1BE cancer cell line human CVCL_YJ46 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=15901131) Population: Japanese; Derived from sampling site: Endometrium. Female 21088171 CVCL_YJ47 FUB-1 hybridoma house mouse CVCL_YJ47 CL:0000010 Monoclonal antibody isotype: IgM. 21088172 CVCL_YJ40 IM-HDMEC-tGFP transformed cell line human CVCL_YJ40 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium. 21088173 CVCL_YJ41 IM-HHSEC transformed cell line human CVCL_YJ41 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. 21088174 CVCL_YJ42 IM-HM transformed cell line human CVCL_YJ42 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. 21088175 CVCL_YJ43 IM-HM-tFP602 transformed cell line human CVCL_YJ43 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (with p.Lys6Thr, p.Arg32Gly, p.Thr68Ala, p.Leu79Phe, p.Ile115Leu, p.Ser131Pro, p.Asn143Ser, p.Gly152Ser, p.Ser158Gly, p.Phe174Leu and p.Arg231Ser = TurboFP602) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. 21088176 CVCL_YJ48 hDMD/mdx ES embryonic stem cell house mouse CVCL_YJ48 CL:0000010 Sequence variation: Mutation; MGI; MGI:94909; Dmd; Simple; p.Gln995Ter (c.2983C>T); Zygosity=Hemizygous; Note=mdx mutation (PubMed=24057032); Transfected with: HGNC; 2928; DMD Breed/subspecies: B6.DBA2.129-hDMDtg/tg. Male 21088177 CVCL_YJ49 DANi006-A induced pluripotent stem cell human CVCL_YJ49 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi006-F) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088178 CVCL_PP96 BayGenomics ES cell line XE826 embryonic stem cell house mouse CVCL_PP96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088179 CVCL_Q196 HG01342 transformed cell line human CVCL_Q196 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088180 CVCL_PP97 BayGenomics ES cell line XE827 embryonic stem cell house mouse CVCL_PP97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088181 CVCL_Q197 HG01343 transformed cell line human CVCL_Q197 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088182 CVCL_PP98 BayGenomics ES cell line XE828 embryonic stem cell house mouse CVCL_PP98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088183 CVCL_Q198 HG01344 transformed cell line human CVCL_Q198 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088184 CVCL_PP99 BayGenomics ES cell line XE829 embryonic stem cell house mouse CVCL_PP99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088185 CVCL_Q199 HG01345 transformed cell line human CVCL_Q199 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088186 CVCL_YJ33 HEK293 rat P2rx2 transformed cell line human CVCL_YJ33 CL:0000010 Transfected with: RGD; 620251; P2rx2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Miscellaneous: Cell line information from personal communication of Sattler C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088187 CVCL_YJ34 HEK293 rat P2rx2 p.H319K transformed cell line human CVCL_YJ34 CL:0000010 Transfected with: RGD; 620251; P2rx2 (with p.His319Lys); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Miscellaneous: Cell line information from personal communication of Sattler C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088188 CVCL_YJ35 IM-HBMEC transformed cell line human CVCL_YJ35 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.. 21088189 CVCL_YJ36 IM-HBMEC-tGFP transformed cell line human CVCL_YJ36 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.. 21088190 CVCL_YJ31 SGA spontaneously immortalized cell line CVCL_YJ31 CL:0000010 Derived from sampling site: Skin. Unspecified Virology: Susceptible to infection by betanodaviruses Group: Fish cell line 21088191 CVCL_YJ32 A18GH hybridoma house mouse CVCL_YJ32 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; E3ULB7; Avian leukosis virus (ALV) subgroup A isolate SDAU09C1 protein gp85 (env). 21088192 CVCL_YJ37 IM-HCF transformed cell line human CVCL_YJ37 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Fibroblast.. 21088193 CVCL_YJ38 IM-HConEpiC transformed cell line human CVCL_YJ38 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.. Doubling time: 40.33 +- 5.67 hours (in collagen-coated flasks), 41.88 +- 4.97 hours (in collagen uncoated flasks) (PubMed=35985531) 21088194 CVCL_YJ39 IM-HDMEC transformed cell line human CVCL_YJ39 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium. 21088195 CVCL_PP85 BayGenomics ES cell line XE793 embryonic stem cell house mouse CVCL_PP85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088196 CVCL_Q185 HG01271 transformed cell line human CVCL_Q185 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088197 CVCL_PP86 BayGenomics ES cell line XE795 embryonic stem cell house mouse CVCL_PP86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088198 CVCL_Q186 HG01272 transformed cell line human CVCL_Q186 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088199 CVCL_PP87 BayGenomics ES cell line XE796 embryonic stem cell house mouse CVCL_PP87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088200 CVCL_Q187 HG01273 transformed cell line human CVCL_Q187 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088201 CVCL_PP88 BayGenomics ES cell line XE797 embryonic stem cell house mouse CVCL_PP88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088202 CVCL_Q188 HG01274 transformed cell line human CVCL_Q188 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088203 CVCL_PP89 BayGenomics ES cell line XE798 embryonic stem cell house mouse CVCL_PP89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088204 CVCL_Q189 HG01275 transformed cell line human CVCL_Q189 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088205 CVCL_YJ22 WAe009-A-21 embryonic stem cell human CVCL_YJ22 From: Department of Obstetrics, Central South University; Changsha; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6. Female 21088206 CVCL_YJ23 SDQLCHi013-A induced pluripotent stem cell human CVCL_YJ23 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Thr211Met (c.632C>T); ClinVar=VCV000093365; Zygosity=Heterozygous (PubMed=31775088); Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Leu427_Ala428delinsPro (c.1280_1282delTGG); ClinVar=VCV000557742; Zygosity=Heterozygous (PubMed=31775088) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21088207 CVCL_YJ24 FuB-1 spontaneously immortalized cell line CVCL_YJ24 CL:0000010 Miscellaneous: Age of donor from personal communication of Cuesta A Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by infectious pancreatic necrosis virus (IPNV) and spring viremia carp virus (SVCV) but not by nervous necrosis virus (NNV) (PubMed=31791770) Doubling time: 37.3 +- 2.81 hours (PubMed=31791770) Group: Fish cell line 21088208 CVCL_YJ25 MCF-7 shWDR12-4 cancer cell line human CVCL_YJ25 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: 16-18 hours (CelloPub=CLPUB00550) Group: Triple negative breast cancer (TNBC) cell line 21088209 CVCL_YJ20 YBT-5 cancer cell line human CVCL_YJ20 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=31701557) Population: Chinese; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male 21088210 CVCL_YJ21 HEK293-CB1 transformed cell line human CVCL_YJ21 CL:0000010 Transfected with: HGNC; 2159; CNR1 (with a N-terminal FLAG tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088211 CVCL_PP90 BayGenomics ES cell line XE799 embryonic stem cell house mouse CVCL_PP90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088212 CVCL_Q190 HG01276 transformed cell line human CVCL_Q190 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088213 CVCL_PP91 BayGenomics ES cell line XE800 embryonic stem cell house mouse CVCL_PP91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088214 CVCL_Q191 HG01277 transformed cell line human CVCL_Q191 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088215 CVCL_PP92 BayGenomics ES cell line XE802 embryonic stem cell house mouse CVCL_PP92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139883; Zbtb10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088216 CVCL_Q192 HG01278 transformed cell line human CVCL_Q192 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088217 CVCL_YJ26 MDA-MB-231 shWDR12-4 cancer cell line human CVCL_YJ26 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Miscellaneous: Corrections of STR profile from thesis manuscript (CelloPub=CLPUB00550) from personal communication of Al-Awar R Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: 20-27 hours (CelloPub=CLPUB00550) Group: Triple negative breast cancer (TNBC) cell line 21088218 CVCL_PP93 BayGenomics ES cell line XE804 embryonic stem cell house mouse CVCL_PP93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929455; Rpl23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088219 CVCL_Q193 HG01279 transformed cell line human CVCL_Q193 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088220 CVCL_YJ27 MDA-MB-468 shWDR12-4 cancer cell line human CVCL_YJ27 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Miscellaneous: Corrections of STR profile from thesis manuscript (CelloPub=CLPUB00550) from personal communication of Al-Awar R Population: African American; Derived from metastatic site: Pleural effusion. Female Doubling time: 24-31 hours (CelloPub=CLPUB00550) Group: Triple negative breast cancer (TNBC) cell line 21088221 CVCL_PP94 BayGenomics ES cell line XE819 embryonic stem cell house mouse CVCL_PP94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088222 CVCL_Q194 HG01334 transformed cell line human CVCL_Q194 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088223 CVCL_YJ28 SK-BR-3 shWDR12-4 cancer cell line human CVCL_YJ28 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12; Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: 36-39 hours (CelloPub=CLPUB00550) 21088224 CVCL_PP95 BayGenomics ES cell line XE820 embryonic stem cell house mouse CVCL_PP95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088225 CVCL_Q195 HG01341 transformed cell line human CVCL_Q195 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088226 CVCL_YJ29 ZR-75-1 shWDR12-4 cancer cell line human CVCL_YJ29 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 14098; WDR12; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Doubling time: 23-37 hours (CelloPub=CLPUB00550) 21088227 CVCL_PP74 BayGenomics ES cell line XE772 embryonic stem cell house mouse CVCL_PP74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931751; Pum2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088228 CVCL_Q174 HG01251 transformed cell line human CVCL_Q174 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088229 CVCL_PP75 BayGenomics ES cell line XE775 embryonic stem cell house mouse CVCL_PP75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088230 CVCL_Q175 HG01252 transformed cell line human CVCL_Q175 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088231 CVCL_PP76 BayGenomics ES cell line XE777 embryonic stem cell house mouse CVCL_PP76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333787; Inppl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088232 CVCL_Q176 HG01253 transformed cell line human CVCL_Q176 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088233 CVCL_PP77 BayGenomics ES cell line XE778 embryonic stem cell house mouse CVCL_PP77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088234 CVCL_Q177 HG01254 transformed cell line human CVCL_Q177 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088235 CVCL_PP78 BayGenomics ES cell line XE780 embryonic stem cell house mouse CVCL_PP78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922003; Trmo Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088236 CVCL_Q178 HG01255 transformed cell line human CVCL_Q178 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088237 CVCL_PP79 BayGenomics ES cell line XE782 embryonic stem cell house mouse CVCL_PP79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442782; Baz2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088238 CVCL_Q179 HG01256 transformed cell line human CVCL_Q179 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088239 CVCL_YJ11 CPP19 cancer cell line human CVCL_YJ11 CL:0000010 Derived from metastatic site: Liver. Male 21088240 CVCL_YJ12 CPP24 cancer cell line human CVCL_YJ12 CL:0000010 Male 21088241 CVCL_YJ13 CPP25 cancer cell line human CVCL_YJ13 CL:0000010 Male 21088242 CVCL_YJ14 CPP30 cancer cell line human CVCL_YJ14 CL:0000010 Derived from metastatic site: Liver. Male 21088243 CVCL_YJ10 HIE-18 spontaneously immortalized cell line CVCL_YJ10 CL:0000010 Unspecified Characteristics: Susceptible to infection by Wolbachia wAlbB native to mosquitoes and wMel and wMelPop native to Drosophila melanogaster; Characteristics: Optimal growth temperature is 30 Celsius (PubMed=32058670) Doubling time: ~67 hours (PubMed=32058670). Group: Insect cell line 21088244 CVCL_YJ19 CTC45 cancer cell line human CVCL_YJ19 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=27456153) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Group: Cancer stem cell line 21088245 CVCL_PP80 BayGenomics ES cell line XE786 embryonic stem cell house mouse CVCL_PP80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385292; Tnrc6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088246 CVCL_Q180 HG01257 transformed cell line human CVCL_Q180 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088247 CVCL_PP81 BayGenomics ES cell line XE788 embryonic stem cell house mouse CVCL_PP81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105072; Rab22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088248 CVCL_YJ15 CPP44 cancer cell line human CVCL_YJ15 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=27456153); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=27456153) Omics: Transcriptome analysis by RNAseq. Female 21088249 CVCL_Q181 HG01258 transformed cell line human CVCL_Q181 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088250 CVCL_PP82 BayGenomics ES cell line XE790 embryonic stem cell house mouse CVCL_PP82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088251 CVCL_YJ16 CPP45 cancer cell line human CVCL_YJ16 CL:0000010 Derived from metastatic site: Liver. Male 21088252 CVCL_Q182 HG01259 transformed cell line human CVCL_Q182 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088253 CVCL_PP83 BayGenomics ES cell line XE791 embryonic stem cell house mouse CVCL_PP83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088254 CVCL_YJ17 CTC41 cancer cell line human CVCL_YJ17 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Group: Cancer stem cell line 21088255 CVCL_Q183 HG01260 transformed cell line human CVCL_Q183 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088256 CVCL_PP84 BayGenomics ES cell line XE792 embryonic stem cell house mouse CVCL_PP84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098687; Aak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088257 CVCL_YJ18 CTC44 cancer cell line human CVCL_YJ18 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=27456153); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=27456153) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Group: Cancer stem cell line 21088258 CVCL_Q184 HG01261 transformed cell line human CVCL_Q184 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088259 CVCL_PP63 BayGenomics ES cell line XE757 embryonic stem cell house mouse CVCL_PP63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088260 CVCL_Q163 HG01199 transformed cell line human CVCL_Q163 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088261 CVCL_PP64 BayGenomics ES cell line XE758 embryonic stem cell house mouse CVCL_PP64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088262 CVCL_Q164 HG01204 transformed cell line human CVCL_Q164 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088263 CVCL_PP65 BayGenomics ES cell line XE759 embryonic stem cell house mouse CVCL_PP65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088264 CVCL_Q165 HG01205 transformed cell line human CVCL_Q165 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088265 CVCL_PP66 BayGenomics ES cell line XE760 embryonic stem cell house mouse CVCL_PP66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088266 CVCL_Q166 HG01206 transformed cell line human CVCL_Q166 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088267 CVCL_PP67 BayGenomics ES cell line XE761 embryonic stem cell house mouse CVCL_PP67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088268 CVCL_Q167 HG01241 transformed cell line human CVCL_Q167 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088269 CVCL_PP68 BayGenomics ES cell line XE762 embryonic stem cell house mouse CVCL_PP68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088270 CVCL_Q168 HG01242 transformed cell line human CVCL_Q168 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088271 CVCL_PP69 BayGenomics ES cell line XE763 embryonic stem cell house mouse CVCL_PP69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088272 CVCL_Q169 HG01243 transformed cell line human CVCL_Q169 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088273 CVCL_YJ00 mHypoA-BMAL1-WT/F3 transformed cell line house mouse CVCL_YJ00 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088274 CVCL_YJ01 mHypoA-BMAL1-WT/F4 transformed cell line house mouse CVCL_YJ01 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088275 CVCL_YJ02 mHypoA-BMAL1-WT/F5 transformed cell line house mouse CVCL_YJ02 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088276 CVCL_YJ03 mHypoA-BMAL1-WT/F6 transformed cell line house mouse CVCL_YJ03 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088277 CVCL_YJ08 mHypoA-BMAL1-KO/F3 transformed cell line house mouse CVCL_YJ08 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088278 CVCL_YJ09 mHypoA-BMAL1-KO/F4 transformed cell line house mouse CVCL_YJ09 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088279 CVCL_PP70 BayGenomics ES cell line XE764 embryonic stem cell house mouse CVCL_PP70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088280 CVCL_Q170 HG01247 transformed cell line human CVCL_Q170 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088281 CVCL_YJ04 mHypoA-BMAL1-WT/F7 transformed cell line house mouse CVCL_YJ04 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088282 CVCL_PP71 BayGenomics ES cell line XE765 embryonic stem cell house mouse CVCL_PP71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088283 CVCL_Q171 HG01248 transformed cell line human CVCL_Q171 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088284 CVCL_YJ05 mHypoA-BMAL1-WT/F8 transformed cell line house mouse CVCL_YJ05 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088285 CVCL_PP72 BayGenomics ES cell line XE767 embryonic stem cell house mouse CVCL_PP72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97286; Ncl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088286 CVCL_Q172 HG01249 transformed cell line human CVCL_Q172 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088287 CVCL_YJ06 mHypoA-BMAL1-KO/F1 transformed cell line house mouse CVCL_YJ06 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088288 CVCL_PP73 BayGenomics ES cell line XE769 embryonic stem cell house mouse CVCL_PP73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923799; Cecr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088289 CVCL_Q173 HG01250 transformed cell line human CVCL_Q173 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088290 CVCL_YJ07 mHypoA-BMAL1-KO/F2 transformed cell line house mouse CVCL_YJ07 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088291 CVCL_6C88 KUP5 transformed cell line house mouse CVCL_6C88 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Kupffer cell.; Breed/subspecies: C57BL/6. Male Doubling time: ~19 hours (PubMed=25379377) 21088292 CVCL_6C89 HiPS-RIKEN-1B induced pluripotent stem cell human CVCL_6C89 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21088293 CVCL_6C84 HPS0263 induced pluripotent stem cell human CVCL_6C84 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088294 CVCL_6C85 HPS0266 induced pluripotent stem cell human CVCL_6C85 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male 21088295 CVCL_6C86 HPS0312 induced pluripotent stem cell human CVCL_6C86 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (PubMed=28491099) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 21088296 CVCL_6C87 Ba/ER factor-dependent cell line house mouse CVCL_6C87 CL:0000010 Transfected with: MGI; MGI:95408; Epor Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: EPO or IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21088297 CVCL_6C80 HPS0249 induced pluripotent stem cell human CVCL_6C80 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088298 CVCL_6C81 HPS0254 induced pluripotent stem cell human CVCL_6C81 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088299 CVCL_6C82 HPS0255 induced pluripotent stem cell human CVCL_6C82 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088300 CVCL_6C83 HPS0256 induced pluripotent stem cell human CVCL_6C83 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088301 CVCL_6C99 HiPS-RIKEN-13B induced pluripotent stem cell human CVCL_6C99 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088302 CVCL_6C90 HiPS-RIKEN-1C induced pluripotent stem cell human CVCL_6C90 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21088303 CVCL_6C95 HiPS-RIKEN-2C induced pluripotent stem cell human CVCL_6C95 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088304 CVCL_6C96 HiPS-RIKEN-2D induced pluripotent stem cell human CVCL_6C96 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088305 CVCL_6C97 HiPS-RIKEN-2E induced pluripotent stem cell human CVCL_6C97 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088306 CVCL_6C98 HiPS-RIKEN-12B induced pluripotent stem cell human CVCL_6C98 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088307 CVCL_6C91 HiPS-RIKEN-1D induced pluripotent stem cell human CVCL_6C91 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21088308 CVCL_6C92 HiPS-RIKEN-1E induced pluripotent stem cell human CVCL_6C92 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21088309 CVCL_6C93 HiPS-RIKEN-1F induced pluripotent stem cell human CVCL_6C93 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21088310 CVCL_6C94 HiPS-RIKEN-2B induced pluripotent stem cell human CVCL_6C94 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21088311 CVCL_6C66 HPC-1P5 cancer cell line human CVCL_6C66 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female 21088312 CVCL_6C67 HPC-3 cancer cell line human CVCL_6C67 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~21 hours (DOI=10.15114/tr.21.9) 21088313 CVCL_6C68 HPC-3H4 cancer cell line human CVCL_6C68 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21088314 CVCL_6C69 HPC-3P4a cancer cell line human CVCL_6C69 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21088315 CVCL_6C62 RLA209-15 transformed cell line Norway rat CVCL_6C62 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver. Unspecified Doubling time: ~24 hours (PubMed=6166615) 21088316 CVCL_6C63 RLA255-4 transformed cell line Norway rat CVCL_6C63 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver. Unspecified Characteristics: At the permissive temperature (33 Celsius) expresses a transformed phenotype (rapid growth, high cell density, etc) and at the restrictive temperature (44 Celsius) expresses a non-transformed phenotype (slower growth, lower saturation density, etc) Doubling time: 15 hours (PubMed=6248862) 21088317 CVCL_6C64 HPC-1 cancer cell line human CVCL_6C64 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 26 hours (DOI=10.15114/tr.20.33) 21088318 CVCL_6C65 HPC-1H5 cancer cell line human CVCL_6C65 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female 21088319 CVCL_6C60 T4-PA transformed cell line house mouse CVCL_6C60 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Highly metastatic Produces widespread metastatic lesions throughout the bodies of nude NIH Swiss mice when injected intravenously. Obtained by injection of parent cell line (T3-HA) in the tail vein of nude NIH Swiss mice and selection of cells from a lung metastasis. 21088320 CVCL_6C61 SEWA/Rec4TC1 cancer cell line house mouse CVCL_6C61 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21088321 CVCL_6C77 HPS0185 induced pluripotent stem cell human CVCL_6C77 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088322 CVCL_6C78 HPS0247 induced pluripotent stem cell human CVCL_6C78 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088323 CVCL_6C79 HPS0248 induced pluripotent stem cell human CVCL_6C79 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088324 CVCL_6C73 YME4 transformed cell line Norway rat CVCL_6C73 CL:0000010 Transformant: Adenovirus 12 [E1A](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21088325 CVCL_6C74 HPS0059 induced pluripotent stem cell human CVCL_6C74 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088326 CVCL_6C75 HPS0060 induced pluripotent stem cell human CVCL_6C75 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088327 CVCL_6C76 HPS0180 induced pluripotent stem cell human CVCL_6C76 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088328 CVCL_6C70 HPC-4 cancer cell line human CVCL_6C70 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~24 hours (DOI=10.15114/tr.21.9) 21088329 CVCL_6C71 HPC-4H4 cancer cell line human CVCL_6C71 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21088330 CVCL_6C72 HPC-4P4a cancer cell line human CVCL_6C72 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21088331 CVCL_6C48 HT1080/DR4 cancer cell line human CVCL_6C48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; pelvis; acetabulum. Male 21088332 CVCL_6C49 LoVo/DR5 cancer cell line human CVCL_6C49 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Left supraclavicular lymph node. Male 21088333 CVCL_6C44 Yamato-SS cancer cell line human CVCL_6C44 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=20518020; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21088334 CVCL_6C45 FL-Y factor-dependent cell line house mouse CVCL_6C45 CL:0000010 Derived from metastatic site: Lymph node Cell type=Follicular dendritic cell.; Breed/subspecies: BALB/c. Male Characteristics: TNFA dependent 21088335 CVCL_6C46 FL-YB factor-dependent cell line house mouse CVCL_6C46 CL:0000010 Transfected with: MGI; MGI:1344376; Tnfsf13b; Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Lymph node Cell type=Follicular dendritic cell.; Breed/subspecies: BALB/c. Male Characteristics: TNFA dependent 21088336 CVCL_6C47 3A4Bla embryonic stem cell human CVCL_6C47 From: VistaGen Therapeutics, Inc.; South San Francisco; USA CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (humanized). Male Characteristics: The humanized beta-lactamase reporter gene is inserted in frame in the 3'-UTR region of the CYP3A4 gene 21088337 CVCL_YI92 HEK293-CB1-CRE-Luc transformed cell line human CVCL_YI92 CL:0000010 Transfected with: HGNC; 2159; CNR1 (with a N-terminal FLAG tag); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Cell line information from personal communication of Palomeros Canero B Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088338 CVCL_YI93 MPF spontaneously immortalized cell line CVCL_YI93 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Optimal growth temperature is 28 Celsius (PubMed=31755106) Group: Fish cell line 21088339 CVCL_YI94 mHypoA-BMAL1-WT/F transformed cell line house mouse CVCL_YI94 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088340 CVCL_YI95 mHypoA-BMAL1-WT/M transformed cell line house mouse CVCL_YI95 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Male 21088341 CVCL_YI90 MUSIi009-A-1 induced pluripotent stem cell human CVCL_YI90 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple_edited; p.Ala735Val (c.2204C>T); ClinVar=VCV000009391; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31677524) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21088342 CVCL_YI91 HEK293 CNR1 cAMP-Nomad transformed cell line human CVCL_YI91 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088343 CVCL_YI96 mHypoA-BMAL1-KO/F transformed cell line house mouse CVCL_YI96 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088344 CVCL_YI97 mHypoA-BMAL1-KO/M transformed cell line house mouse CVCL_YI97 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096381; Arntl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Male 21088345 CVCL_YI98 mHypoA-BMAL1-WT/F1 transformed cell line house mouse CVCL_YI98 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088346 CVCL_YI99 mHypoA-BMAL1-WT/F2 transformed cell line house mouse CVCL_YI99 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.129-Arntltm1Bra/J. Female 21088347 CVCL_6C40 RTS3-3 conditionally immortalized cell line Norway rat CVCL_6C40 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21088348 CVCL_6C41 IPEC-J2 MDR1 spontaneously immortalized cell line pig CVCL_6C41 CL:0000010 Transfected with: HGNC; 40; ABCB1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Unspecified Characteristics: Can be used to screen drug compounds for interactions with human efflux pump P-glycoprotein (P-gp) 21088349 CVCL_6C42 IPEC undefined cell line type CVCL_6C42 CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of pig origin but found to be a bovine cell line (PubMed=22193509).. 21088350 CVCL_6C43 Aska-SS cancer cell line human CVCL_6C43 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=20518020) Population: Japanese Omics: Transcriptome analysis by RNAseq. Male 21088351 CVCL_6C59 T3-HA transformed cell line house mouse CVCL_6C59 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Obtained by intravenous injection of parent cell line (T2-A) in the tail vein of nude NIH Swiss mice and selection of cells from a liver metastasis 21088352 CVCL_6C55 MCF-10A-neoN spontaneously immortalized cell line human CVCL_6C55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21088353 CVCL_6C56 MUCC cancer cell line house mouse CVCL_6C56 CL:0000010 Derived from metastatic site: Uterus; cervix; Breed/subspecies: Kunming. Female Doubling time: 27.8 hours (PubMed=3568983) 21088354 CVCL_6C57 T1-A transformed cell line house mouse CVCL_6C57 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Highly tumorigenic Obtained by subcutaneous hind quarter injection of parent cell line (GhrasT-NIH/3T3) in NIH Swiss mice and selection of cells from a hind quarter tumor. 21088355 CVCL_6C58 T2-A transformed cell line house mouse CVCL_6C58 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Obtained by intravenous injection of parent cell line (T1-A) in the tail vein of NIH Swiss mice and selection of cells from a local metastasis 21088356 CVCL_YI81 E006AA ZIC2-/- E5 cancer cell line human CVCL_YI81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12873; ZIC2; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Problematic cell line: Contaminated Parent cell line (E006AA) has been shown to be a 786-O derivative. 21088357 CVCL_YI82 E006AA ZIC2-/- G12 cancer cell line human CVCL_YI82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12873; ZIC2; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Problematic cell line: Contaminated Parent cell line (E006AA) has been shown to be a 786-O derivative. 21088358 CVCL_YI83 F11 hybridoma house mouse CVCL_YI83 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05187; Human ALPP. 21088359 CVCL_YI84 RTgutF spontaneously immortalized cell line CVCL_YI84 CL:0000010 Derived from sampling site: Intestine Cell type=Fibroblast.. Male Doubling time: 6.5 days (in 5% FBS), 5 days (in 10% FBS), 4.5 days (in 20% FBS) (PubMed=31256301) Group: Fish cell line 21088360 CVCL_YI80 CTC-3 cancer cell line human CVCL_YI80 CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201892 21088361 CVCL_YI89 SAPi004-A induced pluripotent stem cell human CVCL_YI89 From: Sapienza University of Rome; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Homozygous (PubMed=26035390; PubMed=27318155) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088362 CVCL_YI85 CHSE-GS2 spontaneously immortalized cell line CVCL_YI85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; stat2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (nuclear version; nCas9n) Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Characteristics: The parent cell line was transiently transfected with a mix of sgRNAs designed against stat2 and against mEGFP mEGFP-deficient cells were isolated. Group: Fish cell line 21088363 CVCL_YI86 HCC-DJ711 cancer cell line human CVCL_YI86 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201889 21088364 CVCL_YI87 SAPi002-A induced pluripotent stem cell human CVCL_YI87 From: Sapienza University of Rome; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg514Ser (c.1542G>T); Zygosity=Heterozygous (PubMed=26035390; PubMed=27318155) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21088365 CVCL_YI88 SAPi003-A induced pluripotent stem cell human CVCL_YI88 From: Sapienza University of Rome; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Cys (c.1561C>T); ClinVar=VCV000016224; Zygosity=Heterozygous (PubMed=26035390; PubMed=27318155) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21088366 CVCL_6C51 FK-91 spontaneously immortalized cell line CVCL_6C51 CL:0000010 Derived from sampling site: Kidney. Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 49 21088367 CVCL_6C52 F111 spontaneously immortalized cell line Norway rat CVCL_6C52 CL:0000010 Breed/subspecies: Fischer 344. Unspecified 21088368 CVCL_6C53 F1706 spontaneously immortalized cell line Norway rat CVCL_6C53 CL:0000010 Breed/subspecies: Fischer 344. Unspecified 21088369 CVCL_6C54 MCF-10A-neo spontaneously immortalized cell line human CVCL_6C54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21088370 CVCL_6C50 MCH262A1.D6 hybrid cell line CVCL_6C50 CL:0000010 21088371 CVCL_6C26 SVMC-c conditionally immortalized cell line house mouse CVCL_6C26 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088372 CVCL_6C27 SVMC-E conditionally immortalized cell line house mouse CVCL_6C27 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088373 CVCL_6C28 SVNK-1 conditionally immortalized cell line house mouse CVCL_6C28 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088374 CVCL_6C29 SVNK-2 conditionally immortalized cell line house mouse CVCL_6C29 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088375 CVCL_6C22 IPEC-J2-3 spontaneously immortalized cell line pig CVCL_6C22 CL:0000010 Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Unspecified 21088376 CVCL_6C23 IPEC-J2-9 spontaneously immortalized cell line pig CVCL_6C23 CL:0000010 Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Unspecified 21088377 CVCL_6C24 Pom2 finite cell line pig CVCL_6C24 CL:0000010 Derived from sampling site: Peripheral blood. 21088378 CVCL_6C25 SVMC-a conditionally immortalized cell line house mouse CVCL_6C25 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088379 CVCL_YI70 SNU-2466 cancer cell line human CVCL_YI70 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Thr18_Ala20del (c.51_59delCACGGCCGC); Zygosity=Homozygous (PubMed=31688591); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His168Arg (c.503A>G); ClinVar=VCV000428866; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 45 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088380 CVCL_YI71 SNU-2469 cancer cell line human CVCL_YI71 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe328fs (c.982_983insA); Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 48 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088381 CVCL_YI72 SNU-2485 cancer cell line human CVCL_YI72 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro70_Asn71del (c.208_213delCCCAAC); Zygosity=Homozygous (PubMed=31688591); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 45 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088382 CVCL_YI73 SNU-2491 cancer cell line human CVCL_YI73 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Male Doubling time: 29 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088383 CVCL_YI78 SNU-2608 cancer cell line human CVCL_YI78 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 48 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088384 CVCL_YI79 SNU-2617 cancer cell line human CVCL_YI79 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Male Doubling time: 17 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088385 CVCL_YI74 SNU-2543 cancer cell line human CVCL_YI74 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=31688591); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+2T>A (IVS9+2T>A); Zygosity=Unspecified; Note=Splice donor mutation (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 55 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088386 CVCL_YI75 SNU-2564 cancer cell line human CVCL_YI75 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 58 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088387 CVCL_YI76 SNU-2570 cancer cell line human CVCL_YI76 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 49 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088388 CVCL_YI77 SNU-2571 cancer cell line human CVCL_YI77 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=31688591) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Doubling time: 36 hours (PubMed=31688591) Part of: Seoul National University (SNU) cell line collection 21088389 CVCL_6C20 H4-1 [Human small intestinal epithelial] spontaneously immortalized cell line human CVCL_6C20 CL:0000010 Derived from sampling site: Fetal small intestine Cell type=Enterocyte.. Male 21088390 CVCL_6C21 HIEC-6 finite cell line human CVCL_6C21 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Epithelial cell.. Female Doubling time: 96 hours (ATCC=CRL-3266) 21088391 CVCL_6C37 TR-LE conditionally immortalized cell line Norway rat CVCL_6C37 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Thoracic duct Cell type=Lymphatic endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21088392 CVCL_6C38 TR-SIE1 conditionally immortalized cell line Norway rat CVCL_6C38 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21088393 CVCL_6C39 TR-SIE2 conditionally immortalized cell line Norway rat CVCL_6C39 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21088394 CVCL_6C33 SVNK-8 conditionally immortalized cell line house mouse CVCL_6C33 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088395 CVCL_6C34 SVNK-9 conditionally immortalized cell line house mouse CVCL_6C34 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088396 CVCL_6C35 SVNK-10 conditionally immortalized cell line house mouse CVCL_6C35 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088397 CVCL_6C36 TR-BE conditionally immortalized cell line Norway rat CVCL_6C36 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Inferior vena cava Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21088398 CVCL_YI60 CPTC-YWHAE-1 hybridoma house mouse CVCL_YI60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P62258; Human YWHAE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088399 CVCL_YI61 CPTC-YWHAE-2 hybridoma house mouse CVCL_YI61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P62258; Human YWHAE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088400 CVCL_YI62 CPTC-YWHAE-3 hybridoma house mouse CVCL_YI62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P62258; Human YWHAE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088401 CVCL_YI67 SDQLCHi014-A induced pluripotent stem cell human CVCL_YI67 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 4599; GRM7; Unexplicit; Ex3-7del; Zygosity=Heterozygous; Note=De novo mutation (PubMed=31707215) Derived from sampling site: Urine. Male 21088402 CVCL_YI68 MCF10A-KRAS spontaneously immortalized cell line human CVCL_YI68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6407; KRAS (with p.Gly12Val) Derived from sampling site: Breast; epithelium. Female 21088403 CVCL_YI69 Kitra-SRS cancer cell line human CVCL_YI69 CL:0000010 Sequence variation: Gene fusion; HGNC; 14214; CIC + HGNC; 50800; DUX4; Name(s)=CIC-DUX4 (PubMed=31676869). Population: Japanese Female Doubling time: ~43 hours (PubMed=31676869) 21088404 CVCL_YI63 CPTC-ZFAND6-1 hybridoma house mouse CVCL_YI63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6FIF0; Human ZFAND6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088405 CVCL_YI64 CPTC-ZFAND6-2 hybridoma house mouse CVCL_YI64 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q6FIF0; Human ZFAND6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088406 CVCL_YI65 CPTC-ZFAND6-3 hybridoma house mouse CVCL_YI65 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q6FIF0; Human ZFAND6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21088407 CVCL_YI66 LYCL spontaneously immortalized cell line CVCL_YI66 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013157 21088408 CVCL_6C30 SVNK-3 conditionally immortalized cell line house mouse CVCL_6C30 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088409 CVCL_6C31 SVNK-4 conditionally immortalized cell line house mouse CVCL_6C31 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088410 CVCL_6C32 SVNK-6 conditionally immortalized cell line house mouse CVCL_6C32 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21088411 CVCL_H739 DLKP-M cancer cell line human CVCL_H739 CL:0000010 Derived from metastatic site: Lymph node. Male 21088412 CVCL_GV39 HG02575 transformed cell line human CVCL_GV39 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088413 CVCL_GV35 HG02526 transformed cell line human CVCL_GV35 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088414 CVCL_H735 NFSa Y83 cancer cell line house mouse CVCL_H735 CL:0000010 Breed/subspecies: C3Hf/Bu. 21088415 CVCL_GV36 HG02563 transformed cell line human CVCL_GV36 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088416 CVCL_H736 SU-DHL-13 cancer cell line human CVCL_H736 CL:0000010 Female 21088417 CVCL_H737 DLKP cancer cell line human CVCL_H737 CL:0000010 Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE/MS Male 21088418 CVCL_GV37 HG02569 transformed cell line human CVCL_GV37 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088419 CVCL_H738 DLKP-I cancer cell line human CVCL_H738 CL:0000010 Derived from metastatic site: Lymph node. Male 21088420 CVCL_GV38 HG02572 transformed cell line human CVCL_GV38 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088421 CVCL_H731 A640-3Y1-1 transformed cell line Norway rat CVCL_H731 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21088422 CVCL_GV31 HG02514 transformed cell line human CVCL_GV31 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088423 CVCL_H732 FVTCT.fl cancer cell line house mouse CVCL_H732 CL:0000010 Breed/subspecies: BALB/c. Unspecified 21088424 CVCL_GV32 HG02523 transformed cell line human CVCL_GV32 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088425 CVCL_GV33 HG02524 transformed cell line human CVCL_GV33 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088426 CVCL_H733 HGRT finite cell line human CVCL_H733 CL:0000010 Population: Japanese; Derived from sampling site: Peritoneum. Female 21088427 CVCL_GV34 HG02525 transformed cell line human CVCL_GV34 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088428 CVCL_H734 JHTKI-col-L cancer cell line human CVCL_H734 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Male 21088429 CVCL_GV30 HG02495 transformed cell line human CVCL_GV30 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088430 CVCL_H730 PR310 cancer cell line human CVCL_H730 CL:0000010 21088431 CVCL_H746 CaOs-1 cancer cell line dog CVCL_H746 CL:0000010 Unspecified 21088432 CVCL_GV46 HG02605 transformed cell line human CVCL_GV46 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088433 CVCL_H747 FHDO-7 embryonic stem cell dog CVCL_H747 CL:0000010 Male 21088434 CVCL_GV47 HG02612 transformed cell line human CVCL_GV47 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088435 CVCL_GV48 HG02615 transformed cell line human CVCL_GV48 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088436 CVCL_H748 MRC-5 PDL40 finite cell line human CVCL_H748 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21088437 CVCL_GV49 HG02622 transformed cell line human CVCL_GV49 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088438 CVCL_H749 MRC-5 PDL27 finite cell line human CVCL_H749 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21088439 CVCL_H742 DLKP-A10 cancer cell line human CVCL_H742 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 21088440 CVCL_GV42 HG02590 transformed cell line human CVCL_GV42 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088441 CVCL_H743 DLKP-A5F cancer cell line human CVCL_H743 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 21088442 CVCL_GV43 HG02596 transformed cell line human CVCL_GV43 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088443 CVCL_H744 DLKP-A2B cancer cell line human CVCL_H744 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 21088444 CVCL_GV44 HG02599 transformed cell line human CVCL_GV44 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088445 CVCL_H745 A2780-cisR cancer cell line human CVCL_H745 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Omics: Metabolome analysis Female 21088446 CVCL_GV45 HG02602 transformed cell line human CVCL_GV45 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088447 CVCL_H740 DLKP-SQ cancer cell line human CVCL_H740 CL:0000010 Derived from metastatic site: Lymph node. Male 21088448 CVCL_GV40 HG02584 transformed cell line human CVCL_GV40 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088449 CVCL_H741 DLKP-A cancer cell line human CVCL_H741 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 21088450 CVCL_GV41 HG02587 transformed cell line human CVCL_GV41 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088451 CVCL_GV17 HG02071 transformed cell line human CVCL_GV17 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088452 CVCL_H717 Phoenix-Eco transformed cell line human CVCL_H717 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: ATCC; SD-3444; true Female Characteristics: Capable of delivering genes to dividing murine or rat cells Doubling time: ~16 hours (ATCC=CRL-3214) Group: Retrovirus packaging cell line 21088453 CVCL_GV18 HG02074 transformed cell line human CVCL_GV18 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088454 CVCL_H718 Phoenix-gp transformed cell line human CVCL_H718 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~16 hours (ATCC=CRL-3215) Group: Retrovirus packaging cell line 21088455 CVCL_GV19 HG02077 transformed cell line human CVCL_GV19 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088456 CVCL_H719 X5563 cancer cell line house mouse CVCL_H719 CL:0000010 Breed/subspecies: C3H/He. Male 21088457 CVCL_GV13 HG02030 transformed cell line human CVCL_GV13 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088458 CVCL_H713 MtT/S cancer cell line Norway rat CVCL_H713 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female 21088459 CVCL_GV14 HG02056 transformed cell line human CVCL_GV14 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088460 CVCL_H714 MtT/Se cancer cell line Norway rat CVCL_H714 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female 21088461 CVCL_GV15 HG02059 transformed cell line human CVCL_GV15 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088462 CVCL_H715 MtT/SM cancer cell line Norway rat CVCL_H715 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female 21088463 CVCL_GV16 HG02068 transformed cell line human CVCL_GV16 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088464 CVCL_H716 Phoenix-Ampho transformed cell line human CVCL_H716 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: ATCC; SD-3443; true Female Characteristics: Capable of delivering genes to dividing cells of most mammalian species, including human Doubling time: ~16 hours (ATCC=CRL-3213) Group: Retrovirus packaging cell line 21088465 CVCL_GV10 HG02015 transformed cell line human CVCL_GV10 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088466 CVCL_H710 TBCN-6 cancer cell line human CVCL_H710 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Unspecified Doubling time: 28 +- 0.2 hours (PubMed=15645130) 21088467 CVCL_H711 707.fl cancer cell line house mouse CVCL_H711 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21088468 CVCL_GV11 HG02018 transformed cell line human CVCL_GV11 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088469 CVCL_GV12 HG02027 transformed cell line human CVCL_GV12 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088470 CVCL_H712 MtT/E cancer cell line Norway rat CVCL_H712 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female 21088471 CVCL_GV28 HG02466 transformed cell line human CVCL_GV28 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088472 CVCL_H728 IOR/RCH cancer cell line human CVCL_H728 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=11891184) Omics: Array-based CGH. Unspecified 21088473 CVCL_GV29 HG02492 transformed cell line human CVCL_GV29 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088474 CVCL_H729 MMG3 cancer cell line human CVCL_H729 From: Department of Dermatology, Gifu University; Gifu; Japan CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15467732). Population: Japanese 21088475 CVCL_GV24 HG02129 transformed cell line human CVCL_GV24 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088476 CVCL_H724 IOR/BRZ cancer cell line human CVCL_H724 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=11891184) Omics: Array-based CGH. 21088477 CVCL_GV25 HG02132 transformed cell line human CVCL_GV25 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088478 CVCL_H725 IOR/CAR cancer cell line human CVCL_H725 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=18160777); Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=11891184) Omics: Array-based CGH. Unspecified 21088479 CVCL_GV26 HG02135 transformed cell line human CVCL_GV26 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088480 CVCL_H726 IOR/CLB cancer cell line human CVCL_H726 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=11891184) Omics: Array-based CGH. 21088481 CVCL_GV27 HG02463 transformed cell line human CVCL_GV27 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088482 CVCL_H727 IOR/NGR cancer cell line human CVCL_H727 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=11891184) Omics: Array-based CGH. 21088483 CVCL_H720 B16-C2M cancer cell line house mouse CVCL_H720 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21088484 CVCL_GV20 HG02080 transformed cell line human CVCL_GV20 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088485 CVCL_H721 B16-C2W cancer cell line house mouse CVCL_H721 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21088486 CVCL_GV21 HG02083 transformed cell line human CVCL_GV21 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088487 CVCL_H722 6647 cancer cell line human CVCL_H722 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=8040301; PubMed=11891184; PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=25010205) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Female 21088488 CVCL_GV22 HG02120 transformed cell line human CVCL_GV22 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088489 CVCL_GV23 HG02126 transformed cell line human CVCL_GV23 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088490 CVCL_H723 IOR/BER cancer cell line human CVCL_H723 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=11891184). Unspecified 21088491 CVCL_H706 GB-d2 cancer cell line human CVCL_H706 CL:0000010 Population: Japanese. Unspecified 21088492 CVCL_GV06 HG02580 transformed cell line human CVCL_GV06 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088493 CVCL_H707 GB-h3 cancer cell line human CVCL_H707 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21088494 CVCL_GV07 HG03948 transformed cell line human CVCL_GV07 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088495 CVCL_GV08 HG01433 transformed cell line human CVCL_GV08 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088496 CVCL_H708 Mz-ChA-3 cancer cell line human CVCL_H708 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=28765120). 21088497 CVCL_GV09 HG01594 transformed cell line human CVCL_GV09 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088498 CVCL_H709 TGBC-47 cancer cell line human CVCL_H709 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 38 +- 0.3 hours (PubMed=15645130) 21088499 CVCL_H702 AH173-TC cancer cell line Norway rat CVCL_H702 CL:0000010 Breed/subspecies: Donryu. Male 21088500 CVCL_GV02 HG02555 transformed cell line human CVCL_GV02 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088501 CVCL_H703 FU-GBC-1 cancer cell line human CVCL_H703 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 120 hours (PubMed=2680052) 21088502 CVCL_GV03 HG02557 transformed cell line human CVCL_GV03 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088503 CVCL_H704 FU-GBC-2 cancer cell line human CVCL_H704 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 43 hours, at 20th passage (PubMed=9211524) 21088504 CVCL_GV04 HG02558 transformed cell line human CVCL_GV04 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088505 CVCL_H705 GB-d1 cancer cell line human CVCL_H705 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male Doubling time: 23-25 hours, in 10% FBS (PubMed=7559084); 28 hours (PubMed=32293552) 21088506 CVCL_GV05 HG02577 transformed cell line human CVCL_GV05 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088507 CVCL_H700 AH311-TC cancer cell line Norway rat CVCL_H700 CL:0000010 Female 21088508 CVCL_GV00 HG02549 transformed cell line human CVCL_GV00 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088509 CVCL_H701 AH225A-TC cancer cell line Norway rat CVCL_H701 CL:0000010 Breed/subspecies: Donryu. Male 21088510 CVCL_GV01 HG02554 transformed cell line human CVCL_GV01 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088511 CVCL_PQ73 BayGenomics ES cell line XC580 embryonic stem cell house mouse CVCL_PQ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108064; Siah1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088512 CVCL_Q273 HG01507 transformed cell line human CVCL_Q273 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088513 CVCL_PQ74 BayGenomics ES cell line XC583 embryonic stem cell house mouse CVCL_PQ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923998; Pbrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088514 CVCL_Q274 HG01509 transformed cell line human CVCL_Q274 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088515 CVCL_PQ75 BayGenomics ES cell line XC586 embryonic stem cell house mouse CVCL_PQ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088516 CVCL_Q275 HG01510 transformed cell line human CVCL_Q275 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088517 CVCL_PQ76 BayGenomics ES cell line XC587 embryonic stem cell house mouse CVCL_PQ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384768; Hectd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088518 CVCL_Q276 HG01511 transformed cell line human CVCL_Q276 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088519 CVCL_PQ77 BayGenomics ES cell line XC588 embryonic stem cell house mouse CVCL_PQ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384768; Hectd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088520 CVCL_Q277 HG01512 transformed cell line human CVCL_Q277 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088521 CVCL_PQ78 BayGenomics ES cell line XC591 embryonic stem cell house mouse CVCL_PQ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088522 CVCL_Q278 HG01513 transformed cell line human CVCL_Q278 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088523 CVCL_PQ79 BayGenomics ES cell line XC593 embryonic stem cell house mouse CVCL_PQ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088524 CVCL_Q279 HG01514 transformed cell line human CVCL_Q279 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088525 CVCL_YK10 HEK293 CRHR2 HiTSeeker transformed cell line human CVCL_YK10 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088526 CVCL_YK11 HEK293 DRD1 cAMP-Nomad transformed cell line human CVCL_YK11 CL:0000010 Transfected with: HGNC; 3020; DRD1; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088527 CVCL_YK12 HEK293 DRD1 HiTSeeker transformed cell line human CVCL_YK12 CL:0000010 Transfected with: HGNC; 3020; DRD1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088528 CVCL_YK13 HEK293 DRD5 HiTSeeker transformed cell line human CVCL_YK13 CL:0000010 Transfected with: HGNC; 3026; DRD5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088529 CVCL_YK18 HEK293 MC4R HiTSeeker transformed cell line human CVCL_YK18 CL:0000010 Transfected with: HGNC; 6932; MC4R; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088530 CVCL_YK19 HEK293 PTGER2 HiTSeeker transformed cell line human CVCL_YK19 CL:0000010 Transfected with: HGNC; 9594; PTGER2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088531 CVCL_PQ80 BayGenomics ES cell line XC597 embryonic stem cell house mouse CVCL_PQ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088532 CVCL_YK14 HEK293 FSHR Fluo-HiTSeeker transformed cell line human CVCL_YK14 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088533 CVCL_Q280 HG01515 transformed cell line human CVCL_Q280 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088534 CVCL_PQ81 BayGenomics ES cell line XC598 embryonic stem cell house mouse CVCL_PQ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915149; Cmc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088535 CVCL_YK15 HEK293 FSHR HiTSeeker transformed cell line human CVCL_YK15 CL:0000010 Transfected with: HGNC; 3969; FSHR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088536 CVCL_Q281 HG01516 transformed cell line human CVCL_Q281 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088537 CVCL_PQ82 BayGenomics ES cell line XC603 embryonic stem cell house mouse CVCL_PQ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920336; Rps6ka5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088538 CVCL_YK16 HEK293 LHCGR Fluo-HiTSeeker transformed cell line human CVCL_YK16 CL:0000010 Transfected with: HGNC; 6585; LHCGR; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088539 CVCL_Q282 HG01517 transformed cell line human CVCL_Q282 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088540 CVCL_PQ83 BayGenomics ES cell line XC610 embryonic stem cell house mouse CVCL_PQ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926194; Tnip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088541 CVCL_YK17 HEK293 LHCGR HiTSeeker transformed cell line human CVCL_YK17 CL:0000010 Transfected with: HGNC; 6585; LHCGR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088542 CVCL_Q283 HG01518 transformed cell line human CVCL_Q283 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088543 CVCL_PQ62 BayGenomics ES cell line XC520 embryonic stem cell house mouse CVCL_PQ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088544 CVCL_Q262 HG01496 transformed cell line human CVCL_Q262 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088545 CVCL_PQ63 BayGenomics ES cell line XC521 embryonic stem cell house mouse CVCL_PQ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088546 CVCL_Q263 HG01497 transformed cell line human CVCL_Q263 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088547 CVCL_PQ64 BayGenomics ES cell line XC523 embryonic stem cell house mouse CVCL_PQ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088548 CVCL_Q264 HG01498 transformed cell line human CVCL_Q264 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088549 CVCL_PQ65 BayGenomics ES cell line XC532 embryonic stem cell house mouse CVCL_PQ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913750; Slc30a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088550 CVCL_Q265 HG01499 transformed cell line human CVCL_Q265 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088551 CVCL_PQ66 BayGenomics ES cell line XC533 embryonic stem cell house mouse CVCL_PQ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088552 CVCL_Q266 HG01500 transformed cell line human CVCL_Q266 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088553 CVCL_PQ67 BayGenomics ES cell line XC549 embryonic stem cell house mouse CVCL_PQ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088554 CVCL_Q267 HG01501 transformed cell line human CVCL_Q267 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088555 CVCL_PQ68 BayGenomics ES cell line XC553 embryonic stem cell house mouse CVCL_PQ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088556 CVCL_Q268 HG01502 transformed cell line human CVCL_Q268 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088557 CVCL_PQ69 BayGenomics ES cell line XC565 embryonic stem cell house mouse CVCL_PQ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932915; Ndel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088558 CVCL_Q269 HG01503 transformed cell line human CVCL_Q269 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088559 CVCL_YK00 HEK293 ADRB3 HiTSeeker transformed cell line human CVCL_YK00 CL:0000010 Transfected with: HGNC; 288; ADRB3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088560 CVCL_YK01 HEK293 AVPR1A HiTSeeker transformed cell line human CVCL_YK01 CL:0000010 Transfected with: HGNC; 895; AVPR1A; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088561 CVCL_YK02 HEK293 BDKRB1 HiTSeeker transformed cell line human CVCL_YK02 CL:0000010 Transfected with: HGNC; 1029; BDKRB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088562 CVCL_YK07 HEK293 CHRM1 HiTSeeker transformed cell line human CVCL_YK07 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088563 CVCL_YK08 HEK293 CNR1 HiTSeeker transformed cell line human CVCL_YK08 CL:0000010 Transfected with: HGNC; 2159; CNR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088564 CVCL_YK09 HEK293 CNR2 HiTSeeker transformed cell line human CVCL_YK09 CL:0000010 Transfected with: HGNC; 2160; CNR2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088565 CVCL_YK03 HEK293 BDKRB2 HiTSeeker transformed cell line human CVCL_YK03 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088566 CVCL_PQ70 BayGenomics ES cell line XC570 embryonic stem cell house mouse CVCL_PQ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924876; Smpd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088567 CVCL_YK04 HEK293 CALCR HiTSeeker transformed cell line human CVCL_YK04 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088568 CVCL_Q270 HG01504 transformed cell line human CVCL_Q270 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088569 CVCL_PQ71 BayGenomics ES cell line XC571 embryonic stem cell house mouse CVCL_PQ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97842; Rab1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088570 CVCL_YK05 HEK293 CCKBR arrestin-Nomad transformed cell line human CVCL_YK05 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: In basal conditions, the arrestin Biosensor shows a very low fluorescence intensity When an agonist binds to CCKBR, it is phosphorylated, promoting the recruitment of the arrestin-Nomad Biosensor and leading to a change in its structural folding and promoting an increase in fluorescence intensity. 21088571 CVCL_Q271 HG01505 transformed cell line human CVCL_Q271 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088572 CVCL_PQ72 BayGenomics ES cell line XC574 embryonic stem cell house mouse CVCL_PQ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088573 CVCL_YK06 HEK293 CCKBR calcium-Nomad transformed cell line human CVCL_YK06 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088574 CVCL_Q272 HG01506 transformed cell line human CVCL_Q272 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088575 CVCL_PQ51 BayGenomics ES cell line XC491 embryonic stem cell house mouse CVCL_PQ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153063; Parvb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088576 CVCL_Q251 HG01464 transformed cell line human CVCL_Q251 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088577 CVCL_PQ52 BayGenomics ES cell line XC493 embryonic stem cell house mouse CVCL_PQ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088578 CVCL_Q252 HG01465 transformed cell line human CVCL_Q252 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088579 CVCL_PQ53 BayGenomics ES cell line XC499 embryonic stem cell house mouse CVCL_PQ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088580 CVCL_Q253 HG01466 transformed cell line human CVCL_Q253 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088581 CVCL_PQ54 BayGenomics ES cell line XC500 embryonic stem cell house mouse CVCL_PQ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913989; Rcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088582 CVCL_Q254 HG01488 transformed cell line human CVCL_Q254 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088583 CVCL_PQ55 BayGenomics ES cell line XC502 embryonic stem cell house mouse CVCL_PQ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98166; Rps8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088584 CVCL_Q255 HG01489 transformed cell line human CVCL_Q255 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088585 CVCL_PQ56 BayGenomics ES cell line XC504 embryonic stem cell house mouse CVCL_PQ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442401; Ppp1r9a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088586 CVCL_Q256 HG01490 transformed cell line human CVCL_Q256 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088587 CVCL_PQ57 BayGenomics ES cell line XC505 embryonic stem cell house mouse CVCL_PQ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088588 CVCL_Q257 HG01491 transformed cell line human CVCL_Q257 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088589 CVCL_PQ58 BayGenomics ES cell line XC506 embryonic stem cell house mouse CVCL_PQ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088590 CVCL_Q258 HG01492 transformed cell line human CVCL_Q258 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088591 CVCL_PQ59 BayGenomics ES cell line XC510 embryonic stem cell house mouse CVCL_PQ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353655; Usp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088592 CVCL_Q259 HG01493 transformed cell line human CVCL_Q259 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088593 CVCL_PQ60 BayGenomics ES cell line XC512 embryonic stem cell house mouse CVCL_PQ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137092; Eefsec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088594 CVCL_Q260 HG01494 transformed cell line human CVCL_Q260 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088595 CVCL_PQ61 BayGenomics ES cell line XC514 embryonic stem cell house mouse CVCL_PQ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088596 CVCL_Q261 HG01495 transformed cell line human CVCL_Q261 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088597 CVCL_PQ40 BayGenomics ES cell line XC449 embryonic stem cell house mouse CVCL_PQ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088598 CVCL_Q240 HG01442 transformed cell line human CVCL_Q240 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088599 CVCL_PQ41 BayGenomics ES cell line XC452 embryonic stem cell house mouse CVCL_PQ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088600 CVCL_Q241 HG01443 transformed cell line human CVCL_Q241 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088601 CVCL_PQ42 BayGenomics ES cell line XC453 embryonic stem cell house mouse CVCL_PQ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088602 CVCL_Q242 HG01444 transformed cell line human CVCL_Q242 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088603 CVCL_PQ43 BayGenomics ES cell line XC455 embryonic stem cell house mouse CVCL_PQ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088604 CVCL_Q243 HG01452 transformed cell line human CVCL_Q243 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088605 CVCL_PQ44 BayGenomics ES cell line XC456 embryonic stem cell house mouse CVCL_PQ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109275; Trim24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088606 CVCL_Q244 HG01453 transformed cell line human CVCL_Q244 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088607 CVCL_PQ45 BayGenomics ES cell line XC471 embryonic stem cell house mouse CVCL_PQ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447670; Mgrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088608 CVCL_Q245 HG01455 transformed cell line human CVCL_Q245 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088609 CVCL_PQ46 BayGenomics ES cell line XC472 embryonic stem cell house mouse CVCL_PQ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920159; Chmp1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088610 CVCL_Q246 HG01456 transformed cell line human CVCL_Q246 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088611 CVCL_PQ47 BayGenomics ES cell line XC475 embryonic stem cell house mouse CVCL_PQ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316728; Gspt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088612 CVCL_Q247 HG01457 transformed cell line human CVCL_Q247 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088613 CVCL_PQ48 BayGenomics ES cell line XC484 embryonic stem cell house mouse CVCL_PQ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145901; Mfsd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088614 CVCL_Q248 HG01461 transformed cell line human CVCL_Q248 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088615 CVCL_PQ49 BayGenomics ES cell line XC485 embryonic stem cell house mouse CVCL_PQ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088616 CVCL_Q249 HG01462 transformed cell line human CVCL_Q249 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088617 CVCL_PQ50 BayGenomics ES cell line XC490 embryonic stem cell house mouse CVCL_PQ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088618 CVCL_Q250 HG01463 transformed cell line human CVCL_Q250 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088619 CVCL_PQ30 BayGenomics ES cell line XC426 embryonic stem cell house mouse CVCL_PQ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088620 CVCL_Q230 HG01389 transformed cell line human CVCL_Q230 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088621 CVCL_PQ31 BayGenomics ES cell line XC428 embryonic stem cell house mouse CVCL_PQ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088622 CVCL_Q231 HG01390 transformed cell line human CVCL_Q231 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088623 CVCL_PQ32 BayGenomics ES cell line XC431 embryonic stem cell house mouse CVCL_PQ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088624 CVCL_Q232 HG01391 transformed cell line human CVCL_Q232 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088625 CVCL_PQ33 BayGenomics ES cell line XC434 embryonic stem cell house mouse CVCL_PQ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921593; Crtc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088626 CVCL_Q233 HG01431 transformed cell line human CVCL_Q233 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088627 CVCL_PQ34 BayGenomics ES cell line XC436 embryonic stem cell house mouse CVCL_PQ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353653; Glrx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088628 CVCL_Q234 HG01432 transformed cell line human CVCL_Q234 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088629 CVCL_PQ35 BayGenomics ES cell line XC440 embryonic stem cell house mouse CVCL_PQ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442951; Zfp574 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088630 CVCL_Q235 HG01437 transformed cell line human CVCL_Q235 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088631 CVCL_PQ36 BayGenomics ES cell line XC444 embryonic stem cell house mouse CVCL_PQ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088632 CVCL_Q236 HG01438 transformed cell line human CVCL_Q236 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088633 CVCL_PQ37 BayGenomics ES cell line XC445 embryonic stem cell house mouse CVCL_PQ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108426; Kif1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088634 CVCL_Q237 HG01439 transformed cell line human CVCL_Q237 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088635 CVCL_PQ38 BayGenomics ES cell line XC446 embryonic stem cell house mouse CVCL_PQ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913540; Atp6v1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088636 CVCL_Q238 HG01440 transformed cell line human CVCL_Q238 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088637 CVCL_PQ39 BayGenomics ES cell line XC448 embryonic stem cell house mouse CVCL_PQ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088638 CVCL_Q239 HG01441 transformed cell line human CVCL_Q239 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088639 CVCL_H896 ES[MC1R(20):tetHsf2bp(10)] embryonic stem cell house mouse CVCL_H896 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088640 CVCL_GW96 HG03456 transformed cell line human CVCL_GW96 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088641 CVCL_H897 ES[MC1R(20):tetId3(18)] embryonic stem cell house mouse CVCL_H897 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088642 CVCL_GW97 HG03459 transformed cell line human CVCL_GW97 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088643 CVCL_H898 ES[MC1R(20):tetInppl1(21)] embryonic stem cell house mouse CVCL_H898 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088644 CVCL_GW98 HG03465 transformed cell line human CVCL_GW98 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088645 CVCL_H899 ES[MC1R(20):tetIrf2(7)] embryonic stem cell house mouse CVCL_H899 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088646 CVCL_GW99 HG03466 transformed cell line human CVCL_GW99 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088647 CVCL_H892 ES[MC1R(20):tetHmga2(18)] embryonic stem cell house mouse CVCL_H892 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088648 CVCL_GW92 HG03411 transformed cell line human CVCL_GW92 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088649 CVCL_H893 ES[MC1R(20):tetHnf4a(1)] embryonic stem cell house mouse CVCL_H893 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088650 CVCL_GW93 HG03438 transformed cell line human CVCL_GW93 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088651 CVCL_H894 ES[MC1R(20):tetHoxa2(12)] embryonic stem cell house mouse CVCL_H894 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088652 CVCL_GW94 HG03450 transformed cell line human CVCL_GW94 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088653 CVCL_H895 ES[MC1R(20):tetHoxa9(19)] embryonic stem cell house mouse CVCL_H895 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088654 CVCL_GW95 HG03453 transformed cell line human CVCL_GW95 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088655 CVCL_H890 ES[MC1R(20):tetGrhl2(22)] embryonic stem cell house mouse CVCL_H890 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088656 CVCL_GW90 HG03399 transformed cell line human CVCL_GW90 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088657 CVCL_H891 ES[MC1R(20):tetHesx1(8)] embryonic stem cell house mouse CVCL_H891 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088658 CVCL_GW91 HG03402 transformed cell line human CVCL_GW91 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088659 CVCL_PQ20 BayGenomics ES cell line XC402 embryonic stem cell house mouse CVCL_PQ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97583; Pik3r1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088660 CVCL_Q220 HG01367 transformed cell line human CVCL_Q220 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088661 CVCL_PQ21 BayGenomics ES cell line XC411 embryonic stem cell house mouse CVCL_PQ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919449; Mms19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088662 CVCL_Q221 HG01374 transformed cell line human CVCL_Q221 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088663 CVCL_PQ22 BayGenomics ES cell line XC416 embryonic stem cell house mouse CVCL_PQ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914416; Arl8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088664 CVCL_Q222 HG01375 transformed cell line human CVCL_Q222 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088665 CVCL_PQ23 BayGenomics ES cell line XC417 embryonic stem cell house mouse CVCL_PQ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027003; Ino80d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088666 CVCL_Q223 HG01376 transformed cell line human CVCL_Q223 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088667 CVCL_PQ24 BayGenomics ES cell line XC419 embryonic stem cell house mouse CVCL_PQ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916610; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088668 CVCL_Q224 HG01377 transformed cell line human CVCL_Q224 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088669 CVCL_PQ25 BayGenomics ES cell line XC420 embryonic stem cell house mouse CVCL_PQ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920442; Xpot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088670 CVCL_Q225 HG01378 transformed cell line human CVCL_Q225 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088671 CVCL_PQ26 BayGenomics ES cell line XC421 embryonic stem cell house mouse CVCL_PQ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914265; Ccdc91 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088672 CVCL_Q226 HG01379 transformed cell line human CVCL_Q226 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088673 CVCL_PQ27 BayGenomics ES cell line XC423 embryonic stem cell house mouse CVCL_PQ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088674 CVCL_Q227 HG01383 transformed cell line human CVCL_Q227 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088675 CVCL_PQ28 BayGenomics ES cell line XC424 embryonic stem cell house mouse CVCL_PQ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328306; Orc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088676 CVCL_Q228 HG01384 transformed cell line human CVCL_Q228 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088677 CVCL_PQ29 BayGenomics ES cell line XC425 embryonic stem cell house mouse CVCL_PQ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088678 CVCL_Q229 HG01385 transformed cell line human CVCL_Q229 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088679 CVCL_PQ10 BayGenomics ES cell line XC370 embryonic stem cell house mouse CVCL_PQ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088680 CVCL_Q210 HG01356 transformed cell line human CVCL_Q210 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088681 CVCL_PQ11 BayGenomics ES cell line XC372 embryonic stem cell house mouse CVCL_PQ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088682 CVCL_Q211 HG01357 transformed cell line human CVCL_Q211 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088683 CVCL_PQ12 BayGenomics ES cell line XC373 embryonic stem cell house mouse CVCL_PQ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088684 CVCL_Q212 HG01358 transformed cell line human CVCL_Q212 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088685 CVCL_PQ13 BayGenomics ES cell line XC376 embryonic stem cell house mouse CVCL_PQ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088686 CVCL_Q213 HG01359 transformed cell line human CVCL_Q213 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088687 CVCL_PQ14 BayGenomics ES cell line XC380 embryonic stem cell house mouse CVCL_PQ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99157; Zfp12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088688 CVCL_Q214 HG01360 transformed cell line human CVCL_Q214 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088689 CVCL_PQ15 BayGenomics ES cell line XC389 embryonic stem cell house mouse CVCL_PQ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088690 CVCL_H878 ES[MC1R(20):tetEtv5(24)] embryonic stem cell house mouse CVCL_H878 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088691 CVCL_Q215 HG01361 transformed cell line human CVCL_Q215 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088692 CVCL_GW78 HG03314 transformed cell line human CVCL_GW78 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088693 CVCL_PQ16 BayGenomics ES cell line XC390 embryonic stem cell house mouse CVCL_PQ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088694 CVCL_H879 ES[MC1R(20):tetFbxo15(14)] embryonic stem cell house mouse CVCL_H879 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088695 CVCL_Q216 HG01362 transformed cell line human CVCL_Q216 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088696 CVCL_GW79 HG03341 transformed cell line human CVCL_GW79 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088697 CVCL_PQ17 BayGenomics ES cell line XC392 embryonic stem cell house mouse CVCL_PQ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088698 CVCL_Q217 HG01363 transformed cell line human CVCL_Q217 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088699 CVCL_PQ18 BayGenomics ES cell line XC396 embryonic stem cell house mouse CVCL_PQ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106918; Hif1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088700 CVCL_Q218 HG01365 transformed cell line human CVCL_Q218 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088701 CVCL_PQ19 BayGenomics ES cell line XC398 embryonic stem cell house mouse CVCL_PQ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088702 CVCL_H874 ES[MC1R(20):tetElf5(18)] embryonic stem cell house mouse CVCL_H874 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088703 CVCL_Q219 HG01366 transformed cell line human CVCL_Q219 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088704 CVCL_GW74 HG03302 transformed cell line human CVCL_GW74 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088705 CVCL_H875 ES[MC1R(20):tetEll2(38)] embryonic stem cell house mouse CVCL_H875 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088706 CVCL_GW75 HG03305 transformed cell line human CVCL_GW75 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088707 CVCL_H876 ES[MC1R(20):tetEts1(6)] embryonic stem cell house mouse CVCL_H876 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088708 CVCL_GW76 HG03308 transformed cell line human CVCL_GW76 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088709 CVCL_H877 ES[MC1R(20):tetEtv1(15)] embryonic stem cell house mouse CVCL_H877 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088710 CVCL_GW77 HG03310 transformed cell line human CVCL_GW77 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088711 CVCL_H870 ES[MC1R(20):tetCtbp2(23)] embryonic stem cell house mouse CVCL_H870 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088712 CVCL_GW70 HG03272 transformed cell line human CVCL_GW70 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088713 CVCL_H871 ES[MC1R(20):tetDedd2(23)] embryonic stem cell house mouse CVCL_H871 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088714 CVCL_GW71 HG03293 transformed cell line human CVCL_GW71 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088715 CVCL_H872 ES[MC1R(20):tetDmrt1(21)] embryonic stem cell house mouse CVCL_H872 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088716 CVCL_GW72 HG03296 transformed cell line human CVCL_GW72 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088717 CVCL_H873 ES[MC1R(20):tetDppa3(7)] embryonic stem cell house mouse CVCL_H873 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088718 CVCL_GW73 HG03299 transformed cell line human CVCL_GW73 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088719 CVCL_PQ00 BayGenomics ES cell line XC347 embryonic stem cell house mouse CVCL_PQ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914149; Fip1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088720 CVCL_Q200 HG01346 transformed cell line human CVCL_Q200 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088721 CVCL_PQ01 BayGenomics ES cell line XC348 embryonic stem cell house mouse CVCL_PQ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088722 CVCL_Q201 HG01347 transformed cell line human CVCL_Q201 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088723 CVCL_PQ02 BayGenomics ES cell line XC350 embryonic stem cell house mouse CVCL_PQ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920336; Rps6ka5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088724 CVCL_Q202 HG01348 transformed cell line human CVCL_Q202 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088725 CVCL_PQ03 BayGenomics ES cell line XC351 embryonic stem cell house mouse CVCL_PQ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137357; Trim33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088726 CVCL_Q203 HG01349 transformed cell line human CVCL_Q203 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088727 CVCL_PQ04 BayGenomics ES cell line XC354 embryonic stem cell house mouse CVCL_PQ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107606; Srebf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088728 CVCL_H889 ES[MC1R(20):tetGbx2(8)] embryonic stem cell house mouse CVCL_H889 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088729 CVCL_Q204 HG01350 transformed cell line human CVCL_Q204 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088730 CVCL_GW89 HG03390 transformed cell line human CVCL_GW89 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088731 CVCL_PQ05 BayGenomics ES cell line XC356 embryonic stem cell house mouse CVCL_PQ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919404; Zfp157 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088732 CVCL_Q205 HG01351 transformed cell line human CVCL_Q205 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088733 CVCL_PQ06 BayGenomics ES cell line XC358 embryonic stem cell house mouse CVCL_PQ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088734 CVCL_Q206 HG01352 transformed cell line human CVCL_Q206 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088735 CVCL_PQ07 BayGenomics ES cell line XC361 embryonic stem cell house mouse CVCL_PQ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088736 CVCL_Q207 HG01353 transformed cell line human CVCL_Q207 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088737 CVCL_PQ08 BayGenomics ES cell line XC366 embryonic stem cell house mouse CVCL_PQ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088738 CVCL_H885 ES[MC1R(20):tetFoxg1(8)] embryonic stem cell house mouse CVCL_H885 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088739 CVCL_Q208 HG01354 transformed cell line human CVCL_Q208 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088740 CVCL_GW85 HG03371 transformed cell line human CVCL_GW85 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088741 CVCL_PQ09 BayGenomics ES cell line XC368 embryonic stem cell house mouse CVCL_PQ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088742 CVCL_H886 ES[MC1R(20):tetFoxl2(15)] embryonic stem cell house mouse CVCL_H886 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088743 CVCL_Q209 HG01355 transformed cell line human CVCL_Q209 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088744 CVCL_GW86 HG03374 transformed cell line human CVCL_GW86 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088745 CVCL_H887 ES[MC1R(20):tetFoxp3(12)] embryonic stem cell house mouse CVCL_H887 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088746 CVCL_GW87 HG03381 transformed cell line human CVCL_GW87 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088747 CVCL_H888 ES[MC1R(20):tetGata2(7)] embryonic stem cell house mouse CVCL_H888 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088748 CVCL_GW88 HG03384 transformed cell line human CVCL_GW88 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088749 CVCL_H881 ES[MC1R(20):tetFhl2(7)] embryonic stem cell house mouse CVCL_H881 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088750 CVCL_GW81 HG03350 transformed cell line human CVCL_GW81 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088751 CVCL_H882 ES[MC1R(20):tetFosl2(1)] embryonic stem cell house mouse CVCL_H882 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088752 CVCL_GW82 HG03362 transformed cell line human CVCL_GW82 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088753 CVCL_H883 ES[MC1R(20):tetFoxa1(36)] embryonic stem cell house mouse CVCL_H883 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088754 CVCL_GW83 HG03365 transformed cell line human CVCL_GW83 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088755 CVCL_H884 ES[MC1R(20):tetFoxc1(18)] embryonic stem cell house mouse CVCL_H884 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088756 CVCL_GW84 HG03368 transformed cell line human CVCL_GW84 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088757 CVCL_H880 ES[MC1R(20):tetFgfbp1(2)] embryonic stem cell house mouse CVCL_H880 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21088758 CVCL_GW80 HG03344 transformed cell line human CVCL_GW80 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088759 CVCL_6E46 mPEC conditionally immortalized cell line house mouse CVCL_6E46 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Parietal epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21088760 CVCL_6E47 HIO107C6 transformed cell line human CVCL_6E47 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21088761 CVCL_6E48 HIO118A5 transformed cell line human CVCL_6E48 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21088762 CVCL_6E49 HIO118D6 transformed cell line human CVCL_6E49 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21088763 CVCL_6E42 IHGK transformed cell line human CVCL_6E42 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Male 21088764 CVCL_6E43 HIOEC transformed cell line human CVCL_6E43 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Female 21088765 CVCL_6E44 HIOEC-B(a)P-96 transformed cell line human CVCL_6E44 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Female Characteristics: Tumorigenic (PubMed=18206853) 21088766 CVCL_6E45 SSO-2 spontaneously immortalized cell line CVCL_6E45 CL:0000010 Unspecified Group: Fish cell line. 21088767 CVCL_YK90 ICGi002-A induced pluripotent stem cell human CVCL_YK90 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.2950-1G>C; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=32777771) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21088768 CVCL_YK91 ICGi002-B induced pluripotent stem cell human CVCL_YK91 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.2950-1G>C; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=32777771) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21088769 CVCL_YK92 ICGi002-C induced pluripotent stem cell human CVCL_YK92 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.2950-1G>C; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=32777771) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21088770 CVCL_YK93 ICGi018-A induced pluripotent stem cell human CVCL_YK93 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (PubMed=32179492) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21088771 CVCL_YK98 SIAISi002-A induced pluripotent stem cell human CVCL_YK98 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=32339902) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21088772 CVCL_YK99 SIAISi001-A induced pluripotent stem cell human CVCL_YK99 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=32007762) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21088773 CVCL_YK94 ICGi018-B induced pluripotent stem cell human CVCL_YK94 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (from autologous cell line ICGi018-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21088774 CVCL_YK95 ICGi018-C induced pluripotent stem cell human CVCL_YK95 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (from autologous cell line ICGi018-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21088775 CVCL_YK96 ESi080-A induced pluripotent stem cell human CVCL_YK96 From: El Instituto de Investigacion Biomedica de A Coruna, University of Coruna; Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21088776 CVCL_YK97 AHQUi001-A induced pluripotent stem cell human CVCL_YK97 From: Affiliated Hospital of Qingdao University; Qingdao; China CL:0000010 Sequence variation: Mutation; HGNC; 6677; LPL; Simple; p.Cys310Arg (c.928T>C); ClinVar=VCV000226449; Zygosity=Heterozygous (PubMed=32353702) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21088777 CVCL_6E40 YAMC conditionally immortalized cell line house mouse CVCL_6E40 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Colon; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Omics: SNP array analysis 21088778 CVCL_6E41 WY084 transformed cell line human CVCL_6E41 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male Part of: Sonoda-Tajima cell collection 21088779 CVCL_6E57 MM-Sv/XS transformed cell line house mouse CVCL_6E57 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Xiphisternum cartilage Cell type=Chondrocyte.; Breed/subspecies: 129S9/SvEvH. Unspecified 21088780 CVCL_6E58 MM-Sv/XS-11 transformed cell line house mouse CVCL_6E58 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Xiphisternum cartilage Cell type=Chondrocyte.; Breed/subspecies: 129S9/SvEvH. Unspecified 21088781 CVCL_6E59 SVD-2 transformed cell line human CVCL_6E59 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Trunk; skin; epidermis Cell type=Keratinocyte.. Female Virology: Transfected with two copies of the genome of human papillomavirus type 1 (HPV1) 21088782 CVCL_6E53 CD-rA7 transformed cell line house mouse CVCL_6E53 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97171; Mt1; Knockout cell: Method=KO mouse; MGI; MGI:97172; Mt2 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified 21088783 CVCL_6E54 CD-rB5 transformed cell line house mouse CVCL_6E54 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97171; Mt1; Knockout cell: Method=KO mouse; MGI; MGI:97172; Mt2 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified 21088784 CVCL_6E55 59M13 cancer cell line human CVCL_6E55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Lysfs*49 (c.577_592delCATCTTATCCGAGTGG); Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Ascites. Female 21088785 CVCL_6E56 MM-ImJ/XS transformed cell line house mouse CVCL_6E56 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Xiphisternum cartilage Cell type=Chondrocyte.; Breed/subspecies: 129S1/SvImJ. Unspecified 21088786 CVCL_YK80 SDQLCHi019-A induced pluripotent stem cell human CVCL_YK80 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Discontinued: hPSCreg; SDQLCHi019-A; true. 21088787 CVCL_YK81 SDQLCHi020-A induced pluripotent stem cell human CVCL_YK81 From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 21088788 CVCL_YK82 SDQLCHi021-A induced pluripotent stem cell human CVCL_YK82 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Ile150Pro (c.448_449delinsCC); Zygosity=Heterozygous (PubMed=32058304); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000001425; Zygosity=Heterozygous (PubMed=32058304) Derived from sampling site: Peripheral blood. Male 21088789 CVCL_YK87 9C6-52-40 hybridoma house mouse CVCL_YK87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07944; Staphylococcus aureus beta-lactam-inducible penicillin-binding protein (PBP2a). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00203 21088790 CVCL_YK88 17A10-2-2 hybridoma house mouse CVCL_YK88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07944; Staphylococcus aureus beta-lactam-inducible penicillin-binding protein (PBP2a). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00204 21088791 CVCL_YK89 EB-1 hybridoma house mouse CVCL_YK89 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P16150; Human SPN/CD43. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00010 21088792 CVCL_YK83 SDQLCHi022-A induced pluripotent stem cell human CVCL_YK83 From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 21088793 CVCL_YK84 SAIT-MET-AbF24 hybridoma house mouse CVCL_YK84 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00219 21088794 CVCL_YK85 SAIT-MET-Stan34 hybridoma house mouse CVCL_YK85 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00223 21088795 CVCL_YK86 6G10-46-63 hybridoma house mouse CVCL_YK86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07944; Staphylococcus aureus beta-lactam-inducible penicillin-binding protein (PBP2a). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00202 21088796 CVCL_6E50 RT4-D6 cancer cell line Norway rat CVCL_6E50 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: BDIX. 21088797 CVCL_6E51 Nb2-SFJCD1 cancer cell line Norway rat CVCL_6E51 CL:0000010 Breed/subspecies: Nb. Male 21088798 CVCL_6E52 Mt1/Mt2 DKO SV40 transformed cell line house mouse CVCL_6E52 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97171; Mt1; Knockout cell: Method=KO mouse; MGI; MGI:97172; Mt2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified 21088799 CVCL_6E24 SAE spontaneously immortalized cell line CVCL_6E24 CL:0000010 Derived from sampling site: Whole embryo. Omics: Transcriptome analysis by ESTs sequencing Unspecified Doubling time: ~1 week (PubMed=16949345) Group: Fish cell line 21088800 CVCL_6E25 SBCP2 spontaneously immortalized cell line CVCL_6E25 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21088801 CVCL_6E26 HGF [Epinephelus] spontaneously immortalized cell line CVCL_6E26 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21088802 CVCL_6E27 CHP-1 cancer cell line dog CVCL_6E27 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Jack Russell Terrier. Male 21088803 CVCL_6E20 TS.32.5 spontaneously immortalized cell line CVCL_6E20 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21088804 CVCL_6E21 TS.75.2 spontaneously immortalized cell line CVCL_6E21 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21088805 CVCL_6E22 ZSSJ spontaneously immortalized cell line zebrafish CVCL_6E22 CL:0000010 Derived from sampling site: Spleen Cell type=Epithelial cell.. Unspecified Group: Fish cell line 21088806 CVCL_6E23 RTS34st(neo) spontaneously immortalized cell line CVCL_6E23 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21088807 CVCL_YK70 U2OS MPX-Nomad ETBR cancer cell line human CVCL_YK70 CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088808 CVCL_YK71 U2OS MPX-Nomad NK2R cancer cell line human CVCL_YK71 CL:0000010 Transfected with: HGNC; 11527; TACR2; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088809 CVCL_6E28 KKPS5 spontaneously immortalized cell line house mouse CVCL_6E28 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1328360; Arid3a Derived from sampling site: Kidney. Unspecified Characteristics: Arid3a deficient cells seem to be multipotent, developmentally plastic cells 21088810 CVCL_6E29 IHCE transformed cell line human CVCL_6E29 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Eye; cornea; endothelium. Male 21088811 CVCL_YK76 SDQLCHi015-A induced pluripotent stem cell human CVCL_YK76 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2555; CUL4B; Simple; p.Ile336Lysfs*2 (c.1007_1011delTTATA); ClinVar=VCV000426723; Zygosity=Hemizygous (PubMed=31678776) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21088812 CVCL_YK77 SDQLCHi016-A induced pluripotent stem cell human CVCL_YK77 From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 21088813 CVCL_YK78 SDQLCHi017-A induced pluripotent stem cell human CVCL_YK78 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.6915+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=32062132); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.14910+3G>C; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=32062132) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21088814 CVCL_YK79 SDQLCHi018-A induced pluripotent stem cell human CVCL_YK79 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 9863; RAPSN; Simple; c.532-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=33465529); Sequence variation: Mutation; HGNC; 9863; RAPSN; Simple; p.Asn88Lys (c.264C>A); ClinVar=VCV000008046; Zygosity=Heterozygous (PubMed=33465529) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21088815 CVCL_YK72 Well5 cancer cell line human CVCL_YK72 CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male Characteristics: Established from a xenograft produced in NOD/SCID mice Will develop spontaneous pulmonary metastases when orthotopically implanted. 21088816 CVCL_YK73 SDQLCHi009-A induced pluripotent stem cell human CVCL_YK73 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; c.663+2T>G; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=32014801) Derived from sampling site: Peripheral blood. Male 21088817 CVCL_YK74 SDQLCHi010-A induced pluripotent stem cell human CVCL_YK74 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 8620; PAX6; Simple; p.Ser74Gly (c.220A>G); Zygosity=Heterozygous (PubMed=31707209) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21088818 CVCL_YK75 SDQLCHi011-A induced pluripotent stem cell human CVCL_YK75 From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 21088819 CVCL_6E35 GM11432 transformed cell line human CVCL_6E35 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Female 21088820 CVCL_6E36 GM11433 transformed cell line human CVCL_6E36 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Female 21088821 CVCL_6E37 293Flp-In T-REx MAPPIT transformed cell line human CVCL_6E37 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Genome sequenced Female 21088822 CVCL_6E38 293SGlycoDelete transformed cell line human CVCL_6E38 CL:0000010 Transfected with: UniProtKB; C4RA89; H.jecorina endoT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Fetal kidney. Omics: Genome sequenced Female 21088823 CVCL_6E31 IHCK transformed cell line human CVCL_6E31 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Eye; cornea; epithelium Cell type=Keratinocyte.. Male 21088824 CVCL_6E32 RatCE transformed cell line Norway rat CVCL_6E32 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Eye; cornea; epithelium. Doubling time: 18.3 hours (PubMed=7513119) 21088825 CVCL_6E33 XP4PA(SV) transformed cell line human CVCL_6E33 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (PubMed=8298653) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Male 21088826 CVCL_6E34 GM11431 transformed cell line human CVCL_6E34 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Female 21088827 CVCL_YK60 U2OS TACR3 calcium-Nomad cancer cell line human CVCL_YK60 CL:0000010 Transfected with: HGNC; 11528; TACR3; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088828 CVCL_6E39 MSIE conditionally immortalized cell line house mouse CVCL_6E39 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21088829 CVCL_YK65 U2OS VIPR1 cAMP-Nomad cancer cell line human CVCL_YK65 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088830 CVCL_YK66 U2OS VIPR2 cAMP-Nomad cancer cell line human CVCL_YK66 CL:0000010 Transfected with: HGNC; 12695; VIPR2; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088831 CVCL_YK67 SH-SY5Y TagGFP2-SNCA cancer cell line human CVCL_YK67 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11138; SNCA Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21088832 CVCL_YK68 U2OS CHRM3 HiTSeeker cancer cell line human CVCL_YK68 CL:0000010 Transfected with: HGNC; 1952; CHRM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088833 CVCL_YK61 U2OS TACR3 HiTSeeker cancer cell line human CVCL_YK61 CL:0000010 Transfected with: HGNC; 11528; TACR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088834 CVCL_YK62 U2OS tGFP-PFN1 cancer cell line human CVCL_YK62 CL:0000010 Transfected with: HGNC; 8881; PFN1; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088835 CVCL_YK63 U2OS TRH1 HiTSeeker cancer cell line human CVCL_YK63 CL:0000010 Transfected with: HGNC; 12299; TRHR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088836 CVCL_YK64 U2OS UTS2R HiTSeeker cancer cell line human CVCL_YK64 CL:0000010 Transfected with: HGNC; 4468; UTS2R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088837 CVCL_6E30 IHCF transformed cell line human CVCL_6E30 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Eye; cornea Cell type=Fibroblast.. Male 21088838 CVCL_YK69 U2OS MPX-Nomad cancer cell line human CVCL_YK69 CL:0000010 Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088839 CVCL_6E02 EPCtiHSP70 spontaneously immortalized cell line CVCL_6E02 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Cell type=Epithelial cell. Unspecified Group: Fish cell line Problematic cell line: Misidentified Parent cell line (EPC) was originally deposited as a carp (Cyprinus carpio) cell line, is in fact a fathead minnow (Pimephales promelas) cell line. 21088840 CVCL_6E03 ABSa15 spontaneously immortalized cell line CVCL_6E03 CL:0000010 Derived from sampling site: Bone; branchial arch. Unspecified Group: Fish cell line 21088841 CVCL_6E04 JSa1 spontaneously immortalized cell line CVCL_6E04 CL:0000010 Derived from sampling site: Bone; jaw. Unspecified Group: Fish cell line 21088842 CVCL_6E05 SsJ1 spontaneously immortalized cell line CVCL_6E05 CL:0000010 Derived from sampling site: Bone; jaw. Unspecified Group: Fish cell line 21088843 CVCL_6E00 POBC spontaneously immortalized cell line CVCL_6E00 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21088844 CVCL_6E01 SPB spontaneously immortalized cell line CVCL_6E01 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by chum salmon virus (CSV), giant seaperch iridovirus (GSIV-K1) and red sea bream iridovirus (RSIV-Ku) Refractory to infection by grouper nervous necrosis virus (GNNV-K1) and eel herpesvirus (HVA) (PubMed=23305502). Group: Fish cell line 21088845 CVCL_6E06 SsV2 spontaneously immortalized cell line CVCL_6E06 CL:0000010 Derived from sampling site: Bone; vertebra. Unspecified Group: Fish cell line 21088846 CVCL_6E07 ESSA1 embryonic stem cell CVCL_6E07 CL:0000010 Unspecified Group: Fish cell line. 21088847 CVCL_6E08 ESSA2 embryonic stem cell CVCL_6E08 CL:0000010 Unspecified Group: Fish cell line. 21088848 CVCL_6E09 ZEB2 embryonic stem cell zebrafish CVCL_6E09 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Requires feeder cells Maintenance of ZEB2 depends on the presence of cell line RTS34st (Cellosaurus=CVCL_L016). Group: Fish cell line 21088849 CVCL_YK54 U2OS MC3R cAMP-Nomad cancer cell line human CVCL_YK54 CL:0000010 Transfected with: HGNC; 6931; MC3R; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088850 CVCL_YK55 U2OS NTSR1 HiTSeeker cancer cell line human CVCL_YK55 CL:0000010 Transfected with: HGNC; 8039; NTSR1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088851 CVCL_YK56 U2OS PTGER1 HiTSeeker cancer cell line human CVCL_YK56 CL:0000010 Transfected with: HGNC; 9593; PTGER1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088852 CVCL_YK57 U2OS PTGFR HiTSeeker cancer cell line human CVCL_YK57 CL:0000010 Transfected with: HGNC; 9600; PTGFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088853 CVCL_YK50 U2OS HTR2A HiTSeeker cancer cell line human CVCL_YK50 CL:0000010 Transfected with: HGNC; 5293; HTR2A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088854 CVCL_YK51 U2OS HTR2C HiTSeeker cancer cell line human CVCL_YK51 CL:0000010 Transfected with: HGNC; 5295; HTR2C; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088855 CVCL_YK52 U2OS LHCGR cAMP-Nomad cancer cell line human CVCL_YK52 CL:0000010 Transfected with: HGNC; 6585; LHCGR; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088856 CVCL_YK53 U2OS LPAR3 HiTSeeker cancer cell line human CVCL_YK53 CL:0000010 Transfected with: HGNC; 14298; LPAR3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088857 CVCL_YK58 U2OS TACR1 calcium-Nomad cancer cell line human CVCL_YK58 CL:0000010 Transfected with: HGNC; 11526; TACR1; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088858 CVCL_YK59 U2OS TACR2 HiTSeeker cancer cell line human CVCL_YK59 CL:0000010 Transfected with: HGNC; 11527; TACR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088859 CVCL_6E13 BAAn1F spontaneously immortalized cell line CVCL_6E13 CL:0000010 Derived from sampling site: Bone; branchial arch. Unspecified Group: Fish cell line 21088860 CVCL_6E14 VAn2H spontaneously immortalized cell line CVCL_6E14 CL:0000010 Derived from sampling site: Bone; vertebra. Unspecified Group: Fish cell line 21088861 CVCL_6E15 MDCC-3867K cancer cell line CVCL_6E15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b 47EGFP)(NCBI-Taxonomy; 33707); Derived from sampling site: Kidney. Group: Bird cell line 21088862 CVCL_6E16 TS.10.1 spontaneously immortalized cell line CVCL_6E16 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21088863 CVCL_6E10 ZEB2J spontaneously immortalized cell line zebrafish CVCL_6E10 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Does not require feeder cells Group: Fish cell line 21088864 CVCL_6E11 ZES1 embryonic stem cell zebrafish CVCL_6E11 CL:0000010 Unspecified Group: Fish cell line. 21088865 CVCL_6E12 ZFB1 spontaneously immortalized cell line zebrafish CVCL_6E12 CL:0000010 Derived from sampling site: Bone. Unspecified Group: Fish cell line 21088866 CVCL_6E17 TS.32.15 spontaneously immortalized cell line CVCL_6E17 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21088867 CVCL_6E18 TS.32.17 spontaneously immortalized cell line CVCL_6E18 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21088868 CVCL_6E19 TS.32.32 spontaneously immortalized cell line CVCL_6E19 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21088869 CVCL_YK43 U2OS EDNRA HiTSeeker cancer cell line human CVCL_YK43 CL:0000010 Transfected with: HGNC; 3179; EDNRA; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088870 CVCL_YK44 U2OS EDNRB HiTSeeker cancer cell line human CVCL_YK44 CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088871 CVCL_YK45 U2OS GLP1R cAMP-Nomad cancer cell line human CVCL_YK45 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088872 CVCL_YK46 U2OS GLP2R cAMP-Nomad cancer cell line human CVCL_YK46 CL:0000010 Transfected with: HGNC; 4325; GLP2R; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088873 CVCL_YK40 U2OS CHRM5 DAG-Nomad cancer cell line human CVCL_YK40 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of DAG, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells. 21088874 CVCL_YK41 U2OS CHRM5 HiTSeeker cancer cell line human CVCL_YK41 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088875 CVCL_YK42 U2OS CRHR2 cAMP-Nomad cancer cell line human CVCL_YK42 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088876 CVCL_YK47 U2OS GRPR calcium-Nomad cancer cell line human CVCL_YK47 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088877 CVCL_YK48 U2OS GRPR HiTSeeker cancer cell line human CVCL_YK48 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088878 CVCL_YK49 U2OS HRH1 HiTSeeker cancer cell line human CVCL_YK49 CL:0000010 Transfected with: HGNC; 5182; HRH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088879 CVCL_PQ95 BayGenomics ES cell line XC653 embryonic stem cell house mouse CVCL_PQ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181074; Acbd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088880 CVCL_Q295 HG01530 transformed cell line human CVCL_Q295 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088881 CVCL_PQ96 BayGenomics ES cell line XC656 embryonic stem cell house mouse CVCL_PQ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442859; Rnft2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088882 CVCL_Q296 HG01531 transformed cell line human CVCL_Q296 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088883 CVCL_PQ97 BayGenomics ES cell line XC657 embryonic stem cell house mouse CVCL_PQ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920037; Ndc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088884 CVCL_Q297 HG01532 transformed cell line human CVCL_Q297 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088885 CVCL_PQ98 BayGenomics ES cell line XC668 embryonic stem cell house mouse CVCL_PQ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088886 CVCL_Q298 HG01536 transformed cell line human CVCL_Q298 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088887 CVCL_PQ99 BayGenomics ES cell line XC671 embryonic stem cell house mouse CVCL_PQ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088888 CVCL_Q299 HG01537 transformed cell line human CVCL_Q299 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088889 CVCL_YK32 U2OS BDKRB2 HiTSeeker cancer cell line human CVCL_YK32 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088890 CVCL_YK33 U2OS CCKAR calcium-Nomad cancer cell line human CVCL_YK33 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088891 CVCL_YK34 U2OS CCKAR DAG-Nomad cancer cell line human CVCL_YK34 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of DAG, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells. 21088892 CVCL_YK35 U2OS CCKAR HiTSeeker cancer cell line human CVCL_YK35 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088893 CVCL_YK30 U2OS ADRB2 cAMP-Nomad cancer cell line human CVCL_YK30 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088894 CVCL_YK31 U2OS AVPR2 cAMP-Nomad cancer cell line human CVCL_YK31 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088895 CVCL_YK36 U2OS CCKBR HiTSeeker cancer cell line human CVCL_YK36 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088896 CVCL_YK37 U2OS CHRM1 HiTSeeker cancer cell line human CVCL_YK37 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088897 CVCL_YK38 U2OS CHRM4 PKA-Nomad cancer cell line human CVCL_YK38 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Before PKA activation, the fluorescent biosensor is localized in the cellular membrane After receptor activation, PKA is activated and this activated PKA leads to change in the structural folding of Nomad Biosensor that promotes its cellular relocation in the vesicular trafficking of the cells. 21088898 CVCL_YK39 U2OS CHRM5 calcium-Nomad cancer cell line human CVCL_YK39 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of calcium, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The green calcium-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboGFP fluorescent protein, a calmodulin-binding peptide fused to a KDEL signal 21088899 CVCL_PQ84 BayGenomics ES cell line XC614 embryonic stem cell house mouse CVCL_PQ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918963; Cdc40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088900 CVCL_Q284 HG01519 transformed cell line human CVCL_Q284 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088901 CVCL_PQ85 BayGenomics ES cell line XC620 embryonic stem cell house mouse CVCL_PQ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088902 CVCL_Q285 HG01520 transformed cell line human CVCL_Q285 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088903 CVCL_PQ86 BayGenomics ES cell line XC621 embryonic stem cell house mouse CVCL_PQ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088904 CVCL_Q286 HG01521 transformed cell line human CVCL_Q286 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088905 CVCL_PQ87 BayGenomics ES cell line XC629 embryonic stem cell house mouse CVCL_PQ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917498; Dazap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088906 CVCL_Q287 HG01522 transformed cell line human CVCL_Q287 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088907 CVCL_PQ88 BayGenomics ES cell line XC630 embryonic stem cell house mouse CVCL_PQ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088908 CVCL_Q288 HG01523 transformed cell line human CVCL_Q288 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088909 CVCL_PQ89 BayGenomics ES cell line XC631 embryonic stem cell house mouse CVCL_PQ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088910 CVCL_Q289 HG01524 transformed cell line human CVCL_Q289 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088911 CVCL_YK21 HEK293 TACR1 HiTSeeker transformed cell line human CVCL_YK21 CL:0000010 Transfected with: HGNC; 11526; TACR1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088912 CVCL_YK22 HEK293 tGFP-BACE1 transformed cell line human CVCL_YK22 CL:0000010 Transfected with: HGNC; 933; BACE1; Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with BACE1 N-terminally tagged with turboGFP 21088913 CVCL_YK23 HEK293 TSHR HiTSeeker transformed cell line human CVCL_YK23 CL:0000010 Transfected with: HGNC; 12373; TSHR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088914 CVCL_YK24 HEK293 VIPR1 HiTSeeker transformed cell line human CVCL_YK24 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088915 CVCL_YK20 HEK293 PTGER4 HiTSeeker transformed cell line human CVCL_YK20 CL:0000010 Transfected with: HGNC; 9596; PTGER4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088916 CVCL_YK29 U2OS ADRA1B HiTSeeker cancer cell line human CVCL_YK29 CL:0000010 Transfected with: HGNC; 278; ADRA1B; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088917 CVCL_PQ90 BayGenomics ES cell line XC632 embryonic stem cell house mouse CVCL_PQ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088918 CVCL_Q290 HG01525 transformed cell line human CVCL_Q290 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088919 CVCL_PQ91 BayGenomics ES cell line XC644 embryonic stem cell house mouse CVCL_PQ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088920 CVCL_Q291 HG01526 transformed cell line human CVCL_Q291 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088921 CVCL_YK25 U2OS ADCYAP1R1 cAMP-Nomad cancer cell line human CVCL_YK25 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of cAMP, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells.; Characteristics: The red cAMP-Nomad biosensor consists of a membrane localization peptide derived from interleukin-2 receptor alpha chain, a TurboFP650 fluorescent protein, a Ht31 peptide fused to a KDEL signal 21088922 CVCL_PQ92 BayGenomics ES cell line XC646 embryonic stem cell house mouse CVCL_PQ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088923 CVCL_Q292 HG01527 transformed cell line human CVCL_Q292 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088924 CVCL_YK26 U2OS ADRA1A DAG-Nomad cancer cell line human CVCL_YK26 CL:0000010 Transfected with: HGNC; 277; ADRA1A; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of DAG, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells. 21088925 CVCL_PQ93 BayGenomics ES cell line XC651 embryonic stem cell house mouse CVCL_PQ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918348; Cep170 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088926 CVCL_Q293 HG01528 transformed cell line human CVCL_Q293 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088927 CVCL_YK27 U2OS ADRA1A HiTSeeker cancer cell line human CVCL_YK27 CL:0000010 Transfected with: HGNC; 277; ADRA1A; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088928 CVCL_PQ94 BayGenomics ES cell line XC652 embryonic stem cell house mouse CVCL_PQ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21088929 CVCL_Q294 HG01529 transformed cell line human CVCL_Q294 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21088930 CVCL_YK28 U2OS ADRA1B DAG-Nomad cancer cell line human CVCL_YK28 CL:0000010 Transfected with: HGNC; 278; ADRA1B; Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: In absence of DAG, the fluorescent biosensor is localized in the cellular membrane An increase in this second messenger concentration leads to change in the structural folding of Nomad biosensor that promotes its cellular relocation in the vesicular trafficking of the cells. 21088931 CVCL_6D87 mBMS-B18 conditionally immortalized cell line house mouse CVCL_6D87 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic. Female 21088932 CVCL_6D88 mBMS-B21 conditionally immortalized cell line house mouse CVCL_6D88 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic. Female 21088933 CVCL_6D89 Raf1 KO SV40 MEF transformed cell line house mouse CVCL_6D89 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97847; Raf1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21088934 CVCL_6D83 HESS-1 CL.3 stromal cell line house mouse CVCL_6D83 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/HeN-Crj. 21088935 CVCL_6D84 mBMS-B1 conditionally immortalized cell line house mouse CVCL_6D84 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic. Female 21088936 CVCL_6D85 mBMS-B2 conditionally immortalized cell line house mouse CVCL_6D85 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic. Female 21088937 CVCL_6D86 mBMS-B14 conditionally immortalized cell line house mouse CVCL_6D86 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (C57BL/6 x DBA/2) F2-tsA58 transgenic. Female 21088938 CVCL_6D80 Kj-LCL transformed cell line human CVCL_6D80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21088939 CVCL_6D81 Pe-LCL transformed cell line human CVCL_6D81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21088940 CVCL_6D82 STA-WT-1 cancer cell line human CVCL_6D82 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gly317Aspfs*3 (c.950delG); Zygosity=Heterozygous (PubMed=9671307; PubMed=16945155) Derived from sampling site: Kidney. Male 21088941 CVCL_6D98 OLCAB-e21 spontaneously immortalized cell line CVCL_6D98 CL:0000010 Breed/subspecies: CAB. Unspecified Group: Fish cell line 21088942 CVCL_6D94 GFSe spontaneously immortalized cell line CVCL_6D94 CL:0000010 Derived from sampling site: Snout Cell type=Epithelial cell.. Unspecified Group: Fish cell line 21088943 CVCL_6D95 RTL-4 spontaneously immortalized cell line CVCL_6D95 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21088944 CVCL_6D96 CE spontaneously immortalized cell line CVCL_6D96 CL:0000010 Unspecified Group: Fish cell line. 21088945 CVCL_6D97 OLKaga-e1 spontaneously immortalized cell line CVCL_6D97 CL:0000010 Breed/subspecies: Kaga. Unspecified Group: Fish cell line 21088946 CVCL_6D90 Raf1 FF SV40 MEF transformed cell line house mouse CVCL_6D90 CL:0000010 Transfected with: MGI; MGI:97847; Raf1 (with p.Tyr340Phe and p.Tyr341Phe); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Female 21088947 CVCL_6D91 SE spontaneously immortalized cell line CVCL_6D91 CL:0000010 Unspecified Group: Fish cell line. 21088948 CVCL_6D92 BR-6 embryonic stem cell human CVCL_6D92 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Omics: SNP array analysis. Female 21088949 CVCL_6D93 GFKf spontaneously immortalized cell line CVCL_6D93 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified Group: Fish cell line 21088950 CVCL_6D69 K63 spontaneously immortalized cell line human CVCL_6D69 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Male 21088951 CVCL_6D65 RTC-8T3 transformed cell line Norway rat CVCL_6D65 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21088952 CVCL_6D66 RTC-8T6 transformed cell line Norway rat CVCL_6D66 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21088953 CVCL_6D67 PA-III cancer cell line Norway rat CVCL_6D67 CL:0000010 Breed/subspecies: Lobund-Wistar (L-W). Male 21088954 CVCL_6D68 K-22 [Rat liver] finite cell line Norway rat CVCL_6D68 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Male 21088955 CVCL_6D61 RSPC-2T transformed cell line Norway rat CVCL_6D61 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.; Breed/subspecies: Wistar. Male 21088956 CVCL_6D62 RTC-8C spontaneously immortalized cell line Norway rat CVCL_6D62 CL:0000010 Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21088957 CVCL_6D63 RTC-8T1 transformed cell line Norway rat CVCL_6D63 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21088958 CVCL_6D64 RTC-8T12 transformed cell line Norway rat CVCL_6D64 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21088959 CVCL_6D60 ASC-17D conditionally immortalized cell line Norway rat CVCL_6D60 CL:0000010 Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Sprague Dawley. Male 21088960 CVCL_6D76 HELP III spontaneously immortalized cell line house mouse CVCL_6D76 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Unspecified 21088961 CVCL_6D77 HELP IV spontaneously immortalized cell line house mouse CVCL_6D77 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Unspecified 21088962 CVCL_6D78 ATL-17-2 transformed cell line human CVCL_6D78 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21088963 CVCL_6D79 Ka-LCL transformed cell line human CVCL_6D79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21088964 CVCL_6D72 HEL-30 spontaneously immortalized cell line house mouse CVCL_6D72 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Female 21088965 CVCL_6D73 HEL-37 spontaneously immortalized cell line house mouse CVCL_6D73 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Female Characteristics: Adapted to growth at 37 Celsius 21088966 CVCL_6D74 HELP I spontaneously immortalized cell line house mouse CVCL_6D74 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Unspecified 21088967 CVCL_6D75 HELP II spontaneously immortalized cell line house mouse CVCL_6D75 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Unspecified 21088968 CVCL_6D70 H3L spontaneously immortalized cell line house mouse CVCL_6D70 CL:0000010 Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. Unspecified 21088969 CVCL_6D71 HD II cancer cell line house mouse CVCL_6D71 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. 21088970 CVCL_6D47 RLC [Rat lymphosarcoma] cancer cell line Norway rat CVCL_6D47 CL:0000010 Transformant: 3,3'-dichlorbenzedine(ChEBI; CHEBI:82315). 21088971 CVCL_6D48 EGFR-T17 spontaneously immortalized cell line house mouse CVCL_6D48 CL:0000010 Transfected with: HGNC; 3236; EGFR Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21088972 CVCL_6D49 STA-WT-3 cancer cell line human CVCL_6D49 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21088973 CVCL_6D43 DT40(v-myb)delta-pol-beta cancer cell line CVCL_6D43 CL:0000010 Knockout cell: Method=Targeted integration; POLB; Transfected with: UniProtKB; P01104; Avian myeloblastosis virus v-Myb Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088974 CVCL_6D44 DT40(v-myb)delta-pol-lambda cancer cell line CVCL_6D44 CL:0000010 Knockout cell: Method=Targeted integration; POLL; Transfected with: UniProtKB; P01104; Avian myeloblastosis virus v-Myb Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088975 CVCL_6D45 DT40(v-myb)delta-pol-beta-delta-pol-lambda cancer cell line CVCL_6D45 CL:0000010 Knockout cell: Method=Targeted integration; POLB, POLL; Transfected with: UniProtKB; P01104; Avian myeloblastosis virus v-Myb Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088976 CVCL_6D46 DT40 Cre1 cancer cell line CVCL_6D46 CL:0000010 Transfected with: UniProtKB; P01104; Avian myeloblastosis virus v-Myb Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088977 CVCL_YJ91 LINTERNA SH-SY5Y cancer cell line human CVCL_YJ91 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21088978 CVCL_YJ92 LINTERNA SK-BR-3 cancer cell line human CVCL_YJ92 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21088979 CVCL_YJ93 LINTERNA SK-LU-1 cancer cell line human CVCL_YJ93 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asn1253fs*16 (c.3753delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Female 21088980 CVCL_YJ94 LINTERNA SK-OV-3 cancer cell line human CVCL_YJ94 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 21088981 CVCL_YJ90 LINTERNA PC-3 cancer cell line human CVCL_YJ90 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone. Male 21088982 CVCL_YJ99 HEK293 ADRB2 HiTSeeker transformed cell line human CVCL_YJ99 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088983 CVCL_YJ95 LINTERNA U2OS cancer cell line human CVCL_YJ95 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21088984 CVCL_YJ96 HEK293 ADCYAP1R1 HiTSeeker transformed cell line human CVCL_YJ96 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088985 CVCL_YJ97 HEK293 ADORA2A HiTSeeker transformed cell line human CVCL_YJ97 CL:0000010 Transfected with: HGNC; 263; ADORA2A; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088986 CVCL_YJ98 HEK293 ADORA2B HiTSeeker transformed cell line human CVCL_YJ98 CL:0000010 Transfected with: HGNC; 264; ADORA2B; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088987 CVCL_6D40 SBL-H12578 cancer cell line CVCL_6D40 CL:0000010 Female 21088988 CVCL_6D41 DT40-RAD54B(-/-)-XRCC6(-/-) cancer cell line CVCL_6D41 CL:0000010 Knockout cell: Method=Targeted integration; RAD54B, XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088989 CVCL_6D42 DT40(v-myb)WT cancer cell line CVCL_6D42 CL:0000010 Transfected with: UniProtKB; P01104; Avian myeloblastosis virus v-Myb Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21088990 CVCL_6D58 LTC clone Rex cancer cell line Norway rat CVCL_6D58 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. 21088991 CVCL_6D59 93RS2 transformed cell line Norway rat CVCL_6D59 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male Characteristics: At the permissive temperature (32 Celsius) proliferates and has enhanced expression of a differentiated Sertoli cell phenotype at the restrictive temperature (40-41 Celsius) 21088992 CVCL_6D54 STA-OS-6 cancer cell line human CVCL_6D54 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from sampling site: Bone; femur. Male 21088993 CVCL_6D55 LTC 86 cancer cell line Norway rat CVCL_6D55 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. 21088994 CVCL_6D56 LTC 93 cancer cell line Norway rat CVCL_6D56 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. 21088995 CVCL_6D57 LTC clone Ng cancer cell line Norway rat CVCL_6D57 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. 21088996 CVCL_YJ80 LINTERNA HEK293 transformed cell line human CVCL_YJ80 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21088997 CVCL_YJ81 LINTERNA HeLa cancer cell line human CVCL_YJ81 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21088998 CVCL_YJ82 LINTERNA HEP-G2 cancer cell line human CVCL_YJ82 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Population: Caucasian; Derived from sampling site: Liver. Male 21088999 CVCL_YJ83 LINTERNA HT-29 cancer cell line human CVCL_YJ83 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21089000 CVCL_YJ88 LINTERNA 3T3 spontaneously immortalized cell line house mouse CVCL_YJ88 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21089001 CVCL_YJ89 LINTERNA PC-12 cancer cell line Norway rat CVCL_YJ89 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21089002 CVCL_YJ84 LINTERNA Jurkat cancer cell line human CVCL_YJ84 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21089003 CVCL_YJ85 LINTERNA LS 174 cancer cell line human CVCL_YJ85 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Female 21089004 CVCL_YJ86 LINTERNA MDA-MB-231 cancer cell line human CVCL_YJ86 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21089005 CVCL_YJ87 LINTERNA MDCK spontaneously immortalized cell line dog CVCL_YJ87 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21089006 CVCL_6D50 STA-OS-1 cancer cell line human CVCL_6D50 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from sampling site: Bone; humerus. Male 21089007 CVCL_6D51 STA-OS-2 cancer cell line human CVCL_6D51 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Female 21089008 CVCL_6D52 STA-OS-3 cancer cell line human CVCL_6D52 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21089009 CVCL_6D53 STA-OS-5 cancer cell line human CVCL_6D53 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from sampling site: Bone; femur. Female 21089010 CVCL_H856 ES[MC1R(20):tetWhsc2(18)] embryonic stem cell house mouse CVCL_H856 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089011 CVCL_GW56 HG03191 transformed cell line human CVCL_GW56 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089012 CVCL_H857 ES[MC1R(20):tetZfand3(6)] embryonic stem cell house mouse CVCL_H857 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089013 CVCL_GW57 HG03194 transformed cell line human CVCL_GW57 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089014 CVCL_H858 ES[MC1R(20):tetZscan4c(5)] embryonic stem cell house mouse CVCL_H858 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089015 CVCL_GW58 HG03197 transformed cell line human CVCL_GW58 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089016 CVCL_H859 ES[MC1R(20):tet4932441K18Rik(9)] embryonic stem cell house mouse CVCL_H859 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089017 CVCL_GW59 HG03200 transformed cell line human CVCL_GW59 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089018 CVCL_H852 ES[MC1R(20):tetTcea3(22)] embryonic stem cell house mouse CVCL_H852 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089019 CVCL_GW52 HG03167 transformed cell line human CVCL_GW52 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089020 CVCL_H853 ES[MC1R(20):tetTcf3(7)] embryonic stem cell house mouse CVCL_H853 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089021 CVCL_GW53 HG03170 transformed cell line human CVCL_GW53 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089022 CVCL_H854 ES[MC1R(20):tetTcf4(9)] embryonic stem cell house mouse CVCL_H854 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089023 CVCL_GW54 HG03173 transformed cell line human CVCL_GW54 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089024 CVCL_H855 ES[MC1R(20):tetTuba1a(12)] embryonic stem cell house mouse CVCL_H855 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089025 CVCL_GW55 HG03176 transformed cell line human CVCL_GW55 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089026 CVCL_H850 ES[MC1R(20):tetSuz12(9)] embryonic stem cell house mouse CVCL_H850 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089027 CVCL_GW50 HG03161 transformed cell line human CVCL_GW50 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089028 CVCL_H851 ES[MC1R(20):tetT(21)] embryonic stem cell house mouse CVCL_H851 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089029 CVCL_GW51 HG03164 transformed cell line human CVCL_GW51 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089030 CVCL_H867 ES[MC1R(20):tetCdyl(12)] embryonic stem cell house mouse CVCL_H867 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089031 CVCL_GW67 HG03260 transformed cell line human CVCL_GW67 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089032 CVCL_H868 ES[MC1R(20):tetCdyl2(24)] embryonic stem cell house mouse CVCL_H868 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089033 CVCL_GW68 HG03266 transformed cell line human CVCL_GW68 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089034 CVCL_H869 ES[MC1R(20):tetChes1(2)] embryonic stem cell house mouse CVCL_H869 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089035 CVCL_GW69 HG03269 transformed cell line human CVCL_GW69 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089036 CVCL_H863 ES[MC1R(20):tetAsh2l(6)] embryonic stem cell house mouse CVCL_H863 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089037 CVCL_GW63 HG03239 transformed cell line human CVCL_GW63 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089038 CVCL_H864 ES[MC1R(20):tetAtxn1(20)] embryonic stem cell house mouse CVCL_H864 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089039 CVCL_GW64 HG03242 transformed cell line human CVCL_GW64 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089040 CVCL_H865 ES[MC1R(20):tetBatf3(35)] embryonic stem cell house mouse CVCL_H865 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089041 CVCL_GW65 HG03248 transformed cell line human CVCL_GW65 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089042 CVCL_H866 ES[MC1R(20):tetBcl6(32)] embryonic stem cell house mouse CVCL_H866 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089043 CVCL_GW66 HG03251 transformed cell line human CVCL_GW66 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089044 CVCL_H860 ES[MC1R(20):tetAff1(9)] embryonic stem cell house mouse CVCL_H860 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089045 CVCL_GW60 HG03203 transformed cell line human CVCL_GW60 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089046 CVCL_H861 ES[MC1R(20):tetAnkrd22(9)] embryonic stem cell house mouse CVCL_H861 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089047 CVCL_GW61 HG03230 transformed cell line human CVCL_GW61 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089048 CVCL_H862 ES[MC1R(20):tetArnt2(26)] embryonic stem cell house mouse CVCL_H862 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089049 CVCL_GW62 HG03236 transformed cell line human CVCL_GW62 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089050 CVCL_H838 ES[MC1R(20):tetOtx2(15)] embryonic stem cell house mouse CVCL_H838 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089051 CVCL_GW38 HG03110 transformed cell line human CVCL_GW38 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089052 CVCL_H839 ES[MC1R(20):tetPou5f1(18)] embryonic stem cell house mouse CVCL_H839 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089053 CVCL_GW39 HG03113 transformed cell line human CVCL_GW39 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089054 CVCL_H834 ES[MC1R(20):tetNr0b1(15)] embryonic stem cell house mouse CVCL_H834 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089055 CVCL_GW34 HG03098 transformed cell line human CVCL_GW34 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089056 CVCL_H835 ES[MC1R(20):tetNr2f2(5)] embryonic stem cell house mouse CVCL_H835 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089057 CVCL_GW35 HG03101 transformed cell line human CVCL_GW35 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089058 CVCL_H836 ES[MC1R(20):tetNr5a2(7)] embryonic stem cell house mouse CVCL_H836 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089059 CVCL_GW36 HG03104 transformed cell line human CVCL_GW36 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089060 CVCL_H837 ES[MC1R(20):tetNrip1(20)] embryonic stem cell house mouse CVCL_H837 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089061 CVCL_GW37 HG03107 transformed cell line human CVCL_GW37 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089062 CVCL_H830 ES[MC1R(20):tetMyc(16)] embryonic stem cell house mouse CVCL_H830 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089063 CVCL_GW30 HG03059 transformed cell line human CVCL_GW30 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089064 CVCL_H831 ES[MC1R(20):tetMycn(44)] embryonic stem cell house mouse CVCL_H831 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089065 CVCL_GW31 HG03062 transformed cell line human CVCL_GW31 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089066 CVCL_H832 ES[MC1R(20):tetMyod1(14)] embryonic stem cell house mouse CVCL_H832 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089067 CVCL_GW32 HG03065 transformed cell line human CVCL_GW32 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089068 CVCL_H833 ES[MC1R(20):tetNanog(24)] embryonic stem cell house mouse CVCL_H833 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089069 CVCL_GW33 HG03080 transformed cell line human CVCL_GW33 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089070 CVCL_H849 ES[MC1R(20):tetStat3(15)] embryonic stem cell house mouse CVCL_H849 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089071 CVCL_GW49 HG03158 transformed cell line human CVCL_GW49 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089072 CVCL_H845 ES[MC1R(20):tetSmad4(14)] embryonic stem cell house mouse CVCL_H845 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089073 CVCL_GW45 HG03131 transformed cell line human CVCL_GW45 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089074 CVCL_H846 ES[MC1R(20):tetSmad7(3)] embryonic stem cell house mouse CVCL_H846 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089075 CVCL_GW46 HG03134 transformed cell line human CVCL_GW46 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089076 CVCL_H847 ES[MC1R(20):tetSox2(3)] embryonic stem cell house mouse CVCL_H847 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089077 CVCL_GW47 HG03137 transformed cell line human CVCL_GW47 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089078 CVCL_H848 ES[MC1R(20):tetSox9(13)] embryonic stem cell house mouse CVCL_H848 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089079 CVCL_GW48 HG03140 transformed cell line human CVCL_GW48 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089080 CVCL_H841 ES[MC1R(20):tetRxra(2)] embryonic stem cell house mouse CVCL_H841 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089081 CVCL_GW41 HG03119 transformed cell line human CVCL_GW41 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089082 CVCL_H842 ES[MC1R(20):tetSall4(17)] embryonic stem cell house mouse CVCL_H842 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089083 CVCL_GW42 HG03122 transformed cell line human CVCL_GW42 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089084 CVCL_H843 ES[MC1R(20):tetSfpi1(10)] embryonic stem cell house mouse CVCL_H843 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089085 CVCL_GW43 HG03125 transformed cell line human CVCL_GW43 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089086 CVCL_H844 ES[MC1R(20):tetSmad1(5)] embryonic stem cell house mouse CVCL_H844 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089087 CVCL_GW44 HG03128 transformed cell line human CVCL_GW44 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089088 CVCL_H840 ES[MC1R(20):tetRhox6(24)] embryonic stem cell house mouse CVCL_H840 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089089 CVCL_GW40 HG03116 transformed cell line human CVCL_GW40 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089090 CVCL_H816 ES[MC1R(20):tetEed(36)] embryonic stem cell house mouse CVCL_H816 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089091 CVCL_GW16 HG02978 transformed cell line human CVCL_GW16 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089092 CVCL_H817 ES[MC1R(20):tetElf1(21)] embryonic stem cell house mouse CVCL_H817 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089093 CVCL_GW17 HG02980 transformed cell line human CVCL_GW17 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089094 CVCL_H818 ES[MC1R(20):tetEomes(35)] embryonic stem cell house mouse CVCL_H818 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089095 CVCL_GW18 HG02984 transformed cell line human CVCL_GW18 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089096 CVCL_H819 ES[MC1R(20):tetEsx1(16)] embryonic stem cell house mouse CVCL_H819 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089097 CVCL_GW19 HG03008 transformed cell line human CVCL_GW19 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089098 CVCL_H812 ES[MC1R(20):tetCtnnb1(20)] embryonic stem cell house mouse CVCL_H812 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089099 CVCL_GW12 HG02966 transformed cell line human CVCL_GW12 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089100 CVCL_H813 ES[MC1R(20):tetDlx3(3)] embryonic stem cell house mouse CVCL_H813 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089101 CVCL_GW13 HG02969 transformed cell line human CVCL_GW13 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089102 CVCL_H814 ES[MC1R(20):tetDnmt3b(22)] embryonic stem cell house mouse CVCL_H814 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089103 CVCL_GW14 HG02972 transformed cell line human CVCL_GW14 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089104 CVCL_H815 ES[MC1R(20):tetDppa5(7)] embryonic stem cell house mouse CVCL_H815 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089105 CVCL_GW15 HG02975 transformed cell line human CVCL_GW15 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089106 CVCL_GW10 HG02948 transformed cell line human CVCL_GW10 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089107 CVCL_H810 MC1 embryonic stem cell house mouse CVCL_H810 From: Johns Hopkins University Transgenic Core Facility; Baltimore; USA CL:0000010 Breed/subspecies: 129S6/SvEvTac. Male 21089108 CVCL_H811 ES[MC1R(20):tetControl(13)] embryonic stem cell house mouse CVCL_H811 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089109 CVCL_GW11 HG02954 transformed cell line human CVCL_GW11 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089110 CVCL_H827 ES[MC1R(20):tetMef2c(5)] embryonic stem cell house mouse CVCL_H827 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089111 CVCL_GW27 HG03050 transformed cell line human CVCL_GW27 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089112 CVCL_H828 ES[MC1R(20):tetMsc(24)] embryonic stem cell house mouse CVCL_H828 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089113 CVCL_GW28 HG03053 transformed cell line human CVCL_GW28 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089114 CVCL_H829 ES[MC1R(20):tetMybl2(6)] embryonic stem cell house mouse CVCL_H829 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089115 CVCL_GW29 HG03056 transformed cell line human CVCL_GW29 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089116 CVCL_H823 ES[MC1R(20):tetGadd45a(6)] embryonic stem cell house mouse CVCL_H823 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089117 CVCL_GW23 HG03029 transformed cell line human CVCL_GW23 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089118 CVCL_H824 ES[MC1R(20):tetGata3(14)] embryonic stem cell house mouse CVCL_H824 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089119 CVCL_GW24 HG03035 transformed cell line human CVCL_GW24 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089120 CVCL_H825 ES[MC1R(20):tetId1(1)] embryonic stem cell house mouse CVCL_H825 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089121 CVCL_GW25 HG03041 transformed cell line human CVCL_GW25 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089122 CVCL_H826 ES[MC1R(20):tetKlf4(16)] embryonic stem cell house mouse CVCL_H826 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089123 CVCL_GW26 HG03047 transformed cell line human CVCL_GW26 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089124 CVCL_H820 ES[MC1R(20):tetEtv3(15)] embryonic stem cell house mouse CVCL_H820 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089125 CVCL_GW20 HG03017 transformed cell line human CVCL_GW20 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089126 CVCL_H821 ES[MC1R(20):tetFem1b(6)] embryonic stem cell house mouse CVCL_H821 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089127 CVCL_GW21 HG03023 transformed cell line human CVCL_GW21 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089128 CVCL_H822 ES[MC1R(20):tetFoxj2(6)] embryonic stem cell house mouse CVCL_H822 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089129 CVCL_GW22 HG03026 transformed cell line human CVCL_GW22 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089130 CVCL_H809 AG12589 finite cell line human CVCL_H809 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (Coriell=AG12589) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21089131 CVCL_GW09 HG02945 transformed cell line human CVCL_GW09 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089132 CVCL_H805 AG08169 transformed cell line human CVCL_H805 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG08170) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21089133 CVCL_GW05 HG02897 transformed cell line human CVCL_GW05 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089134 CVCL_H806 AG08170 finite cell line human CVCL_H806 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21089135 CVCL_GW06 HG02924 transformed cell line human CVCL_GW06 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089136 CVCL_H807 AG09553 finite cell line human CVCL_H807 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG09553) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21089137 CVCL_GW07 HG02939 transformed cell line human CVCL_GW07 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089138 CVCL_H808 AG09878 finite cell line human CVCL_H808 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (Coriell=AG09878) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21089139 CVCL_GW08 HG02942 transformed cell line human CVCL_GW08 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089140 CVCL_H801 ES[MC1R(20):tetCbx8(9)] embryonic stem cell house mouse CVCL_H801 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089141 CVCL_GW01 HG02883 transformed cell line human CVCL_GW01 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089142 CVCL_H802 ES[MC1R(20):tetCdx2(6)] embryonic stem cell house mouse CVCL_H802 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21089143 CVCL_GW02 HG02886 transformed cell line human CVCL_GW02 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089144 CVCL_H803 AG07377 finite cell line human CVCL_H803 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21089145 CVCL_GW03 HG02889 transformed cell line human CVCL_GW03 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089146 CVCL_H804 AG08044 finite cell line human CVCL_H804 CL:0000010 Population: African American; Karyotypic information: 46,XX,21s+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (Coriell=AG08044) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21089147 CVCL_GW04 HG02892 transformed cell line human CVCL_GW04 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089148 CVCL_H800 AG06847 transformed cell line human CVCL_H800 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21089149 CVCL_GW00 HG02880 transformed cell line human CVCL_GW00 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21089150 CVCL_H108 BY00087 transformed cell line human CVCL_H108 HLA typing: B*13:16,40:02:01 (IPD-IMGT/HLA=14349) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089151 CVCL_GP08 ND24060 transformed cell line human CVCL_GP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089152 CVCL_H109 BY00088 transformed cell line human CVCL_H109 HLA typing: B*13:02:01,55:21 (IPD-IMGT/HLA=14351) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089153 CVCL_GP09 ND24061 transformed cell line human CVCL_GP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089154 CVCL_H104 BY00647 transformed cell line human CVCL_H104 HLA typing: A*01:BTPU,33:DWH; B*14:BF,58:DFFP; DRB1*07:01:01:01/02,11:93 (IPD-IMGT/HLA=20116) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089155 CVCL_GP04 ND23990 transformed cell line human CVCL_GP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089156 CVCL_H105 BY00663 transformed cell line human CVCL_H105 HLA typing: A*01:DHUY,29:DHVF; B*44:ENWF,08:61; DRB1*03:01,13:01 (IPD-IMGT/HLA=20668) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089157 CVCL_GP05 ND23993 transformed cell line human CVCL_GP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089158 CVCL_H106 BY00083 transformed cell line human CVCL_H106 HLA typing: B*48:16,46:01 (IPD-IMGT/HLA=14350) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089159 CVCL_GP06 ND24006 transformed cell line human CVCL_GP06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089160 CVCL_H107 BY00086 transformed cell line human CVCL_H107 HLA typing: B*58:12,48:01 (IPD-IMGT/HLA=14342) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089161 CVCL_GP07 ND24022 transformed cell line human CVCL_GP07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089162 CVCL_H100 BY00641 transformed cell line human CVCL_H100 HLA typing: A*32:AJVG,33:FDX; B*15:17,44:ANNB; DRB1*13:98,15:02:01 (IPD-IMGT/HLA=20056) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089163 CVCL_GP00 ND23922 transformed cell line human CVCL_GP00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089164 CVCL_H101 BY00642 transformed cell line human CVCL_H101 HLA typing: A*01:DEPW,02:DERE; B*08:BMNN,44:BTNY; DRB1*08:04:05,04:01:01 (IPD-IMGT/HLA=20055) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089165 CVCL_GP01 ND23960 transformed cell line human CVCL_GP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089166 CVCL_H102 BY00645 transformed cell line human CVCL_H102 HLA typing: A*01:YAG,03:ANPZ; B*40:PXF,57:AG; DRB1*11:91,11:03 (IPD-IMGT/HLA=20049) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089167 CVCL_GP02 ND23969 transformed cell line human CVCL_GP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089168 CVCL_H103 BY00646 transformed cell line human CVCL_H103 HLA typing: A*02:ANDC,11:XSH; B*27:BFJA,55:CUDG; DRB1*15:01:01:01/02,01:01:18 (IPD-IMGT/HLA=20048) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089169 CVCL_GP03 ND23970 transformed cell line human CVCL_GP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089170 CVCL_PJ14 BayGenomics ES cell line XC149 embryonic stem cell house mouse CVCL_PJ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089171 CVCL_PJ15 BayGenomics ES cell line XC165 embryonic stem cell house mouse CVCL_PJ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276539; Ttc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089172 CVCL_PJ16 BayGenomics ES cell line XC166 embryonic stem cell house mouse CVCL_PJ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089173 CVCL_PJ17 BayGenomics ES cell line XC172 embryonic stem cell house mouse CVCL_PJ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925503; Map4k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089174 CVCL_PJ18 BayGenomics ES cell line XC181 embryonic stem cell house mouse CVCL_PJ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105968; Txlna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089175 CVCL_PJ19 BayGenomics ES cell line XC186 embryonic stem cell house mouse CVCL_PJ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089176 CVCL_GP77 CHO CERT spontaneously immortalized cell line CVCL_GP77 CL:0000010 Transfected with: HGNC; 2205; CERT1 (with p.Ser132Ala); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21089177 CVCL_H177 GM02055 finite cell line human CVCL_H177 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089178 CVCL_GP78 CHO XBP1s spontaneously immortalized cell line CVCL_GP78 CL:0000010 Transfected with: HGNC; 12801; XBP1 (isoform XBP1s) Derived from sampling site: Ovary. Female 21089179 CVCL_H178 GM02095 finite cell line human CVCL_H178 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089180 CVCL_GP79 EZQ-3 iPSC induced pluripotent stem cell human CVCL_GP79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089181 CVCL_H179 GM02214 finite cell line human CVCL_H179 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with metachromatic leukodystrophy but at risk for disease; Derived from sampling site: Amniotic fluid. Male 21089182 CVCL_GP73 BIOT-0726-LOAD induced pluripotent stem cell human CVCL_GP73 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Peripheral blood. Female 21089183 CVCL_H173 GM01741 finite cell line human CVCL_H173 CL:0000010 Sequence variation: Gene deletion; HGNC; 4135; GALT; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089184 CVCL_GP74 BIOT-0904-LOAD induced pluripotent stem cell human CVCL_GP74 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Peripheral blood. Female 21089185 CVCL_H174 GM01743 finite cell line human CVCL_H174 CL:0000010 Sequence variation: Gene deletion; HGNC; 4135; GALT; Zygosity=Heterozygous (from autologous cell line GM01741) Population: Caucasian; Derived from sampling site: Amniotic fluid. Male 21089186 CVCL_GP75 BIOT-4828-LOAD induced pluripotent stem cell human CVCL_GP75 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Peripheral blood. Female 21089187 CVCL_H175 GM00804 finite cell line human CVCL_H175 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21089188 CVCL_GP76 BIOTi001-A induced pluripotent stem cell human CVCL_GP76 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Val89Leu (c.265G>T); ClinVar=VCV000021027; Zygosity=Heterozygous (PubMed=27558604) Derived from sampling site: Peripheral blood. Female 21089189 CVCL_H176 GM00919 finite cell line human CVCL_H176 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089190 CVCL_GP70 ADHD-5 iPSC induced pluripotent stem cell human CVCL_GP70 From: D'Or Institute for Research and Education; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21089191 CVCL_H170 AFRC MAC 61 hybridoma Norway rat CVCL_H170 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: ChEBI; CHEBI:2365; (+)-abscisic acid. 21089192 CVCL_H171 AFRC MAC 79 hybridoma Norway rat CVCL_H171 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA. 21089193 CVCL_GP71 ASAN-PaCa cancer cell line human CVCL_GP71 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous; Note=1 of 3 alleles (PubMed=27518460); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=27518460) Population: Caucasian Omics: Deep exome analysis. Female Doubling time: 20 hours (PubMed=27518460) 21089194 CVCL_PJ20 BayGenomics ES cell line XC187 embryonic stem cell house mouse CVCL_PJ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135937; Sbk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089195 CVCL_GP72 BIOT-0630-LOAD induced pluripotent stem cell human CVCL_GP72 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Peripheral blood. Male 21089196 CVCL_H172 CDR2 hybridoma house mouse CVCL_H172 CL:0000010 Monoclonal antibody isotype: IgG2b. 21089197 CVCL_PJ21 BayGenomics ES cell line XC188 embryonic stem cell house mouse CVCL_PJ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135937; Sbk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089198 CVCL_PJ22 BayGenomics ES cell line XC190 embryonic stem cell house mouse CVCL_PJ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089199 CVCL_PJ23 BayGenomics ES cell line XC191 embryonic stem cell house mouse CVCL_PJ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178103; Arhgdia Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089200 CVCL_PJ24 BayGenomics ES cell line XC193 embryonic stem cell house mouse CVCL_PJ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089201 CVCL_PJ03 BayGenomics ES cell line XC050 embryonic stem cell house mouse CVCL_PJ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858943; Arl6ip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089202 CVCL_PJ04 BayGenomics ES cell line XC051 embryonic stem cell house mouse CVCL_PJ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089203 CVCL_PJ05 BayGenomics ES cell line XC054 embryonic stem cell house mouse CVCL_PJ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309465; Slc12a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089204 CVCL_PJ06 BayGenomics ES cell line XC055 embryonic stem cell house mouse CVCL_PJ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089205 CVCL_PJ07 BayGenomics ES cell line XC059 embryonic stem cell house mouse CVCL_PJ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915062; Ubxn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089206 CVCL_PJ08 BayGenomics ES cell line XC060 embryonic stem cell house mouse CVCL_PJ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089207 CVCL_PJ09 BayGenomics ES cell line XC067 embryonic stem cell house mouse CVCL_PJ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915127; Naa20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089208 CVCL_H188 GM03091 finite cell line human CVCL_H188 CL:0000010 Population: Caucasian; Karyotypic information: 47,XXY (Coriell); Derived from sampling site: Amniotic fluid. Male 21089209 CVCL_GP88 HHW980 hybrid cell line human CVCL_GP88 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089210 CVCL_H189 GM03102 finite cell line human CVCL_H189 CL:0000010 Population: Caucasian; Karyotypic information: 47,XXY (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089211 CVCL_GP89 HHW986 hybrid cell line human CVCL_GP89 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21089212 CVCL_H184 GM02529 finite cell line human CVCL_H184 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11013137); Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (PubMed=11013137) Population: Jewish; Ashkenazi; Derived from sampling site: Amniotic fluid. Female 21089213 CVCL_GP84 HHW786 hybrid cell line human CVCL_GP84 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089214 CVCL_H185 GM02587 finite cell line human CVCL_H185 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Male 21089215 CVCL_GP85 HHW950 hybrid cell line human CVCL_GP85 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089216 CVCL_H186 GM02662 finite cell line human CVCL_H186 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089217 CVCL_GP86 HHW962 hybrid cell line human CVCL_GP86 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089218 CVCL_H187 GM03090 finite cell line human CVCL_H187 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM03090; probable Female 21089219 CVCL_GP87 HHW965 hybrid cell line human CVCL_GP87 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089220 CVCL_GP80 EZQ-4 iPSC induced pluripotent stem cell human CVCL_GP80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089221 CVCL_H180 GM02269 finite cell line human CVCL_H180 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21089222 CVCL_GP81 EZQ-9 iPSC induced pluripotent stem cell human CVCL_GP81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089223 CVCL_H181 GM02380 finite cell line human CVCL_H181 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089224 CVCL_H182 GM02421 finite cell line human CVCL_H182 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089225 CVCL_GP82 H256 C6 CHMP2B IVS5AS GG-CC induced pluripotent stem cell human CVCL_GP82 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24537; CHMP2B Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089226 CVCL_H183 GM02422 finite cell line human CVCL_H183 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089227 CVCL_GP83 H256 C6 CHMP2B IVS5AS GG-GC induced pluripotent stem cell human CVCL_GP83 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 24537; CHMP2B Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089228 CVCL_PJ10 BayGenomics ES cell line XC100 embryonic stem cell house mouse CVCL_PJ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138811; Cdc123 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089229 CVCL_PJ11 BayGenomics ES cell line XC104 embryonic stem cell house mouse CVCL_PJ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089230 CVCL_PJ12 BayGenomics ES cell line XC113 embryonic stem cell house mouse CVCL_PJ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039600; Fbxl19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089231 CVCL_PJ13 BayGenomics ES cell line XC129 embryonic stem cell house mouse CVCL_PJ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089232 CVCL_H159 GM07548 finite cell line human CVCL_H159 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM07548; probable Female 21089233 CVCL_GP59 ND50033 induced pluripotent stem cell human CVCL_GP59 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089234 CVCL_H155 CIA-E-4.15 hybridoma house mouse CVCL_H155 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01854; Human immunoglobulin heavy chain epsilon. 21089235 CVCL_GP55 ND36040 transformed cell line human CVCL_GP55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089236 CVCL_H156 CIA-E-7.12 hybridoma house mouse CVCL_H156 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01854; Human immunoglobulin heavy chain epsilon. 21089237 CVCL_GP56 ND38782 transformed cell line human CVCL_GP56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089238 CVCL_H157 GM06314 transformed cell line human CVCL_H157 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1551+1G>C (IVS10+1G>C); ClinVar=VCV000554983; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21089239 CVCL_GP57 ND40268 transformed cell line human CVCL_GP57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089240 CVCL_H158 GM07510 transformed cell line human CVCL_H158 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089241 CVCL_GP58 ND50032 induced pluripotent stem cell human CVCL_GP58 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089242 CVCL_H151 GM03568 hybridoma CVCL_H151 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa. 21089243 CVCL_GP51 ND29309 transformed cell line human CVCL_GP51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089244 CVCL_H152 GM04279 hybridoma house mouse CVCL_H152 CL:0000010 Monoclonal antibody isotype: IgM. 21089245 CVCL_GP52 ND31016 transformed cell line human CVCL_GP52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089246 CVCL_H153 GM04280 hybridoma house mouse CVCL_H153 CL:0000010 Monoclonal antibody isotype: IgG2a. 21089247 CVCL_GP53 ND31058 transformed cell line human CVCL_GP53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089248 CVCL_H154 GM05426 cancer cell line house mouse CVCL_H154 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21089249 CVCL_GP54 ND31098 transformed cell line human CVCL_GP54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089250 CVCL_H150 GM03566 hybridoma CVCL_H150 CL:0000010 Monoclonal antibody isotype: IgM. 21089251 CVCL_GP50 ND28304 transformed cell line human CVCL_GP50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089252 CVCL_PJ00 BayGenomics ES cell line XB883 embryonic stem cell house mouse CVCL_PJ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98869; Tuba1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089253 CVCL_PJ01 BayGenomics ES cell line XC041 embryonic stem cell house mouse CVCL_PJ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183149; Nadk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089254 CVCL_PJ02 BayGenomics ES cell line XC048 embryonic stem cell house mouse CVCL_PJ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321159; Ppp2ca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089255 CVCL_H166 AFRC MAC 29 hybridoma Norway rat CVCL_H166 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21089256 CVCL_GP66 CHO-WBL spontaneously immortalized cell line CVCL_GP66 CL:0000010 Derived from sampling site: Ovary. Female 21089257 CVCL_H167 AFRC MAC 3 hybridoma Norway rat CVCL_H167 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21089258 CVCL_GP67 CHL/IU (IVGT) spontaneously immortalized cell line CVCL_GP67 CL:0000010 Derived from sampling site: Lung. Female Part of: In Vitro Genetic Toxicity (IVGT) cell line panel 21089259 CVCL_GP68 ADHD-10 iPSC induced pluripotent stem cell human CVCL_GP68 From: D'Or Institute for Research and Education; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21089260 CVCL_H168 AFRC MAC 5 hybridoma Norway rat CVCL_H168 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21089261 CVCL_GP69 ADHD-4 iPSC induced pluripotent stem cell human CVCL_GP69 From: D'Or Institute for Research and Education; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21089262 CVCL_H169 AFRC MAC 6 hybridoma Norway rat CVCL_H169 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21089263 CVCL_GP62 CLB-BARrec cancer cell line human CVCL_GP62 CL:0000010 Miscellaneous: Sex of donor from personal communication of Combaret V. Female 21089264 CVCL_H162 GM00636 finite cell line human CVCL_H162 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; c.1187delAAG; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Amniotic fluid. Male 21089265 CVCL_H163 GM00003 finite cell line human CVCL_H163 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089266 CVCL_GP63 U-87MG Uppsala cancer cell line human CVCL_GP63 CL:0000010 Female Caution: This is the original U-87MG cell line established in 1968 at the University of Uppsala The cell line distributed by most cell collections (including ATCC, CLS, ECACC, etc.) is a different cell line whose origin is not yet clear (PubMed=27582061). See U-87MG ATCC (Cellosaurus=CVCL_0022) for the cell line used by most research groups.. 21089267 CVCL_H164 AFRC MAC 27 hybridoma Norway rat CVCL_H164 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21089268 CVCL_GP64 S1-iPSC induced pluripotent stem cell human CVCL_GP64 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21089269 CVCL_H165 AFRC MAC 28 hybridoma Norway rat CVCL_H165 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21089270 CVCL_GP65 S2-iPSC induced pluripotent stem cell human CVCL_GP65 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21089271 CVCL_H160 GM17868 transformed cell line human CVCL_H160 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 5 repeats) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089272 CVCL_GP60 ND50034 induced pluripotent stem cell human CVCL_GP60 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089273 CVCL_H161 GM17869 finite cell line human CVCL_H161 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 5 repeats) (Coriell) Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Discontinued: Coriell; GM17869; probable Female 21089274 CVCL_GP61 ND50035 induced pluripotent stem cell human CVCL_GP61 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089275 CVCL_H137 GM00897 transformed cell line human CVCL_H137 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347Pro (c.1040G>C); ClinVar=VCV000007110; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089276 CVCL_GP37 ND26805 transformed cell line human CVCL_GP37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089277 CVCL_H138 GM00768 finite cell line human CVCL_H138 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347Pro (c.1040G>C); ClinVar=VCV000007110; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089278 CVCL_GP38 ND26816 transformed cell line human CVCL_GP38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089279 CVCL_H139 GM01063 transformed cell line human CVCL_H139 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21089280 CVCL_GP39 ND26818 transformed cell line human CVCL_GP39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089281 CVCL_H133 GM00604 transformed cell line human CVCL_H133 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089282 CVCL_GP33 ND26238 transformed cell line human CVCL_GP33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089283 CVCL_H134 AT7LA transformed cell line human CVCL_H134 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu522Ilefs (c.1564_1565delGA) (1563_1564delAG); Zygosity=Homozygous; Note=Produces no detectable ATM protein by conventional immunoblotting (PubMed=8808599; PubMed=18634022) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089284 CVCL_GP34 ND26243 transformed cell line human CVCL_GP34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089285 CVCL_H135 GM00718 transformed cell line human CVCL_H135 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089286 CVCL_GP35 ND26601 transformed cell line human CVCL_GP35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089287 CVCL_H136 GM00892 transformed cell line human CVCL_H136 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089288 CVCL_GP36 ND26656 transformed cell line human CVCL_GP36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089289 CVCL_H130 GM00474 finite cell line human CVCL_H130 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21089290 CVCL_GP30 ND25480 transformed cell line human CVCL_GP30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089291 CVCL_H131 GM00477 finite cell line human CVCL_H131 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21089292 CVCL_GP31 ND25754 transformed cell line human CVCL_GP31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089293 CVCL_H132 GM00608 transformed cell line human CVCL_H132 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089294 CVCL_GP32 ND26020 transformed cell line human CVCL_GP32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089295 CVCL_H148 GM03400 finite cell line human CVCL_H148 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089296 CVCL_GP48 ND27945 transformed cell line human CVCL_GP48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089297 CVCL_H149 GM03705 hybridoma CVCL_H149 CL:0000010 Monoclonal antibody isotype: IgM. 21089298 CVCL_GP49 ND28099 transformed cell line human CVCL_GP49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089299 CVCL_H144 XP19BE LCL transformed cell line human CVCL_H144 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Homozygous; Note=Also produces mis-splicing (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089300 CVCL_GP44 ND26993 transformed cell line human CVCL_GP44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089301 CVCL_H145 GM03239 transformed cell line human CVCL_H145 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089302 CVCL_GP45 ND26995 transformed cell line human CVCL_GP45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089303 CVCL_H146 GM03359 finite cell line human CVCL_H146 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089304 CVCL_GP46 ND27117 transformed cell line human CVCL_GP46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089305 CVCL_H147 GM03333 transformed cell line human CVCL_H147 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089306 CVCL_GP47 ND27461 transformed cell line human CVCL_GP47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089307 CVCL_H140 GM00972 finite cell line human CVCL_H140 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21089308 CVCL_GP40 ND26976 transformed cell line human CVCL_GP40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089309 CVCL_H141 GM01058 finite cell line human CVCL_H141 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089310 CVCL_GP41 ND26984 transformed cell line human CVCL_GP41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089311 CVCL_H142 GM01206 transformed cell line human CVCL_H142 HLA typing: A*02,11; B*12,15 (Coriell=GM01206) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089312 CVCL_GP42 ND26987 transformed cell line human CVCL_GP42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089313 CVCL_H143 XP19BE finite cell line human CVCL_H143 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Homozygous; Note=Also produces mis-splicing (Coriell; PubMed=9671271) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089314 CVCL_GP43 ND26988 transformed cell line human CVCL_GP43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089315 CVCL_H119 BY00018 transformed cell line human CVCL_H119 HLA typing: A*02; B*40:40,27:04; DRB1*12:KN,14:DJJ; DRB3*01:MS,02:CAY (IPD-IMGT/HLA=12664) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089316 CVCL_GP19 ND24312 transformed cell line human CVCL_GP19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089317 CVCL_H115 BY00099 transformed cell line human CVCL_H115 HLA typing: A*11:27 (IPD-IMGT/HLA=14370) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089318 CVCL_GP15 ND24220 transformed cell line human CVCL_GP15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089319 CVCL_H116 BY00101 transformed cell line human CVCL_H116 HLA typing: DRB1*09:01:02,04:58 (IPD-IMGT/HLA=14375) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089320 CVCL_GP16 ND24221 transformed cell line human CVCL_GP16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089321 CVCL_H117 BY00102 transformed cell line human CVCL_H117 HLA typing: DRB1*15:01:01,13:72 (IPD-IMGT/HLA=14376) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089322 CVCL_GP17 ND24284 transformed cell line human CVCL_GP17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089323 CVCL_H118 BY00118 transformed cell line human CVCL_H118 HLA typing: DRB1*15:01:01,14:62 (IPD-IMGT/HLA=14475) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089324 CVCL_GP18 ND24310 transformed cell line human CVCL_GP18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089325 CVCL_H111 BY00091 transformed cell line human CVCL_H111 HLA typing: B*27:36,51:01:01 (IPD-IMGT/HLA=14345) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089326 CVCL_GP11 ND24141 transformed cell line human CVCL_GP11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089327 CVCL_H112 BY00092 transformed cell line human CVCL_H112 HLA typing: B*58:12,51:01:01 (IPD-IMGT/HLA=14343) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089328 CVCL_GP12 ND24142 transformed cell line human CVCL_GP12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089329 CVCL_H113 BY00094 transformed cell line human CVCL_H113 HLA typing: A*02:05,02:99 (IPD-IMGT/HLA=14369) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089330 CVCL_GP13 ND24145 transformed cell line human CVCL_GP13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089331 CVCL_H114 BY00096 transformed cell line human CVCL_H114 HLA typing: A*01:CRY,03:23:01 (IPD-IMGT/HLA=14366) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089332 CVCL_GP14 ND24148 transformed cell line human CVCL_GP14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089333 CVCL_H110 BY00089 transformed cell line human CVCL_H110 HLA typing: B*27:36,57:01:01 (IPD-IMGT/HLA=14346) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089334 CVCL_GP10 ND24081 transformed cell line human CVCL_GP10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089335 CVCL_H126 BY00040 transformed cell line human CVCL_H126 HLA typing: A*02,30:02; B*40:43,27:05:02/27:05:04/27:13 (IPD-IMGT/HLA=12971) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089336 CVCL_GP26 ND24901 transformed cell line human CVCL_GP26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089337 CVCL_H127 BY00053 transformed cell line human CVCL_H127 HLA typing: A*01:10,02:01; B*07:05,13:02; C*06:02,15:05; DRB1*07:01:01 (IPD-IMGT/HLA=13314) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089338 CVCL_GP27 ND25126 transformed cell line human CVCL_GP27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089339 CVCL_H128 BY00103 transformed cell line human CVCL_H128 HLA typing: A*24:BZBD,11:15:02; B*35:BJGU,44:RDU; C*02:AFB,04:APNR; DRB1*01:EW,11:03 (IPD-IMGT/HLA=14374) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089340 CVCL_GP28 ND25209 transformed cell line human CVCL_GP28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089341 CVCL_H129 BY00128 transformed cell line human CVCL_H129 HLA typing: A*03:BUVE,32:13; B*14:02,40:JMM; C*03:GFW,08:BE (IPD-IMGT/HLA=14511) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089342 CVCL_GP29 ND25216 transformed cell line human CVCL_GP29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089343 CVCL_H122 BY00025 transformed cell line human CVCL_H122 HLA typing: A*02,03; B*27:05:02/27:05:04/27:13,40:40 (IPD-IMGT/HLA=12688) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089344 CVCL_GP22 ND24370 transformed cell line human CVCL_GP22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089345 CVCL_H123 BY00027 transformed cell line human CVCL_H123 HLA typing: A*30,23; B*15:16,42:04 (IPD-IMGT/HLA=12690) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089346 CVCL_GP23 ND24396 transformed cell line human CVCL_GP23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089347 CVCL_H124 BY00028 transformed cell line human CVCL_H124 HLA typing: A*24,26; B*55:10,40:02 (IPD-IMGT/HLA=12694) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089348 CVCL_GP24 ND24401 transformed cell line human CVCL_GP24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089349 CVCL_H125 BY00029 transformed cell line human CVCL_H125 HLA typing: A*30,03; B*57:03,07:29; DRB1*15:DEW,13:BMD; DRB3*02:CAN; DRB5*01:BMK (IPD-IMGT/HLA=12728) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089350 CVCL_GP25 ND24753 transformed cell line human CVCL_GP25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089351 CVCL_H120 BY00022 transformed cell line human CVCL_H120 HLA typing: A*11; B*27:04,40:40 (IPD-IMGT/HLA=12689) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089352 CVCL_GP20 ND24317 transformed cell line human CVCL_GP20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089353 CVCL_H121 BY00023 transformed cell line human CVCL_H121 HLA typing: A*02,33; B*40:02,53:09 (IPD-IMGT/HLA=12687) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089354 CVCL_GP21 ND24366 transformed cell line human CVCL_GP21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089355 CVCL_YC10 NCCSi005-C induced pluripotent stem cell human CVCL_YC10 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21089356 CVCL_YC11 NCCSi006-B induced pluripotent stem cell human CVCL_YC11 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21089357 CVCL_YC12 NCCSi006-C induced pluripotent stem cell human CVCL_YC12 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21089358 CVCL_YC13 NUIGi017-B induced pluripotent stem cell human CVCL_YC13 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21089359 CVCL_YC18 NUIGi028-A induced pluripotent stem cell human CVCL_YC18 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10294; RPE65; Simple; p.Asp477Gly (c.1430A>G); ClinVar=VCV000750796; Zygosity=Heterozygous (PubMed=31954326) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089360 CVCL_YC19 NUIGi029-A induced pluripotent stem cell human CVCL_YC19 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10294; RPE65; Simple; p.Asp477Gly (c.1430A>G); ClinVar=VCV000750796; Zygosity=Heterozygous (PubMed=31954326) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089361 CVCL_PI80 BayGenomics ES cell line XB829 embryonic stem cell house mouse CVCL_PI80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089362 CVCL_YC14 NUIGi017-C induced pluripotent stem cell human CVCL_YC14 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21089363 CVCL_PI81 BayGenomics ES cell line XB830 embryonic stem cell house mouse CVCL_PI81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343095; Emc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089364 CVCL_YC15 NUIGi021-B induced pluripotent stem cell human CVCL_YC15 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21089365 CVCL_PI82 BayGenomics ES cell line XB831 embryonic stem cell house mouse CVCL_PI82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98847; Kdm3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089366 CVCL_YC16 NUIGi021-C induced pluripotent stem cell human CVCL_YC16 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21089367 CVCL_PI83 BayGenomics ES cell line XB837 embryonic stem cell house mouse CVCL_PI83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915142; Coa6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089368 CVCL_YC17 NUIGi027-A induced pluripotent stem cell human CVCL_YC17 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10294; RPE65; Simple; p.Asp477Gly (c.1430A>G); ClinVar=VCV000750796; Zygosity=Heterozygous (PubMed=31954326) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089369 CVCL_PI84 BayGenomics ES cell line XB840 embryonic stem cell house mouse CVCL_PI84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107738; Dync1li2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089370 CVCL_PI85 BayGenomics ES cell line XB843 embryonic stem cell house mouse CVCL_PI85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151013; Erc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089371 CVCL_PI86 BayGenomics ES cell line XB844 embryonic stem cell house mouse CVCL_PI86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444576; Kif20b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089372 CVCL_PI87 BayGenomics ES cell line XB848 embryonic stem cell house mouse CVCL_PI87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923523; Ndfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089373 CVCL_PI88 BayGenomics ES cell line XB850 embryonic stem cell house mouse CVCL_PI88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089374 CVCL_PI89 BayGenomics ES cell line XB856 embryonic stem cell house mouse CVCL_PI89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089375 CVCL_YC00 ESi079-A induced pluripotent stem cell human CVCL_YC00 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21089376 CVCL_YC01 EURACi005-A induced pluripotent stem cell human CVCL_YC01 From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Homozygous (PubMed=31715428) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089377 CVCL_YC02 IBMS-iPSC-015-06 induced pluripotent stem cell human CVCL_YC02 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21089378 CVCL_YC07 IBMS-iPSC-023-03 induced pluripotent stem cell human CVCL_YC07 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Unspecified; Note=Allele ALDH2*2 (PubMed=34118567) Population: Asian; Derived from sampling site: Peripheral blood. Female 21089379 CVCL_YC08 IBMS-iPSC-048-05 induced pluripotent stem cell human CVCL_YC08 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=32151952) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21089380 CVCL_YC09 NCCSi005-B induced pluripotent stem cell human CVCL_YC09 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21089381 CVCL_YC03 IBMS-iPSC-016-06 induced pluripotent stem cell human CVCL_YC03 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21089382 CVCL_PI70 BayGenomics ES cell line XB794 embryonic stem cell house mouse CVCL_PI70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109275; Trim24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089383 CVCL_YC04 IBMS-iPSC-017-02 induced pluripotent stem cell human CVCL_YC04 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21089384 CVCL_PI71 BayGenomics ES cell line XB795 embryonic stem cell house mouse CVCL_PI71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3605986; Rad54b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089385 CVCL_YC05 IBMS-iPSC-021-04 induced pluripotent stem cell human CVCL_YC05 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Unspecified; Note=Allele ALDH2*2 (PubMed=34118567) Population: Asian; Derived from sampling site: Peripheral blood. Male 21089386 CVCL_PI72 BayGenomics ES cell line XB802 embryonic stem cell house mouse CVCL_PI72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089387 CVCL_YC06 IBMS-iPSC-022-01 induced pluripotent stem cell human CVCL_YC06 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Unspecified; Note=Allele ALDH2*2 (PubMed=34118567) Population: Asian; Derived from sampling site: Peripheral blood. Male 21089388 CVCL_PI73 BayGenomics ES cell line XB804 embryonic stem cell house mouse CVCL_PI73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089389 CVCL_PI74 BayGenomics ES cell line XB812 embryonic stem cell house mouse CVCL_PI74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894323; Ranbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089390 CVCL_PI75 BayGenomics ES cell line XB814 embryonic stem cell house mouse CVCL_PI75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448492; Kdm6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089391 CVCL_PI76 BayGenomics ES cell line XB818 embryonic stem cell house mouse CVCL_PI76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089392 CVCL_PI77 BayGenomics ES cell line XB820 embryonic stem cell house mouse CVCL_PI77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107846; Prmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089393 CVCL_PI78 BayGenomics ES cell line XB822 embryonic stem cell house mouse CVCL_PI78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916229; Nol11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089394 CVCL_PI79 BayGenomics ES cell line XB828 embryonic stem cell house mouse CVCL_PI79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351331; Chaf1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089395 CVCL_PI59 BayGenomics ES cell line XB769 embryonic stem cell house mouse CVCL_PI59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089396 CVCL_PI60 BayGenomics ES cell line XB770 embryonic stem cell house mouse CVCL_PI60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089397 CVCL_PI61 BayGenomics ES cell line XB774 embryonic stem cell house mouse CVCL_PI61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089398 CVCL_PI62 BayGenomics ES cell line XB776 embryonic stem cell house mouse CVCL_PI62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089399 CVCL_PI63 BayGenomics ES cell line XB777 embryonic stem cell house mouse CVCL_PI63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089400 CVCL_PI64 BayGenomics ES cell line XB780 embryonic stem cell house mouse CVCL_PI64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914404; Mtdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089401 CVCL_PI65 BayGenomics ES cell line XB784 embryonic stem cell house mouse CVCL_PI65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089402 CVCL_PI66 BayGenomics ES cell line XB786 embryonic stem cell house mouse CVCL_PI66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089403 CVCL_PI67 BayGenomics ES cell line XB787 embryonic stem cell house mouse CVCL_PI67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089404 CVCL_PI68 BayGenomics ES cell line XB789 embryonic stem cell house mouse CVCL_PI68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104689; Cct4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089405 CVCL_PI69 BayGenomics ES cell line XB793 embryonic stem cell house mouse CVCL_PI69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089406 CVCL_PI48 BayGenomics ES cell line XB737 embryonic stem cell house mouse CVCL_PI48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089407 CVCL_PI49 BayGenomics ES cell line XB742 embryonic stem cell house mouse CVCL_PI49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145541; H3c8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089408 CVCL_PI50 BayGenomics ES cell line XB743 embryonic stem cell house mouse CVCL_PI50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385865; Ice1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089409 CVCL_PI51 BayGenomics ES cell line XB744 embryonic stem cell house mouse CVCL_PI51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089410 CVCL_PI52 BayGenomics ES cell line XB745 embryonic stem cell house mouse CVCL_PI52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089411 CVCL_PI53 BayGenomics ES cell line XB748 embryonic stem cell house mouse CVCL_PI53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449057; Gars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089412 CVCL_PI54 BayGenomics ES cell line XB749 embryonic stem cell house mouse CVCL_PI54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2677212; Bend3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089413 CVCL_PI55 BayGenomics ES cell line XB751 embryonic stem cell house mouse CVCL_PI55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338056; Klf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089414 CVCL_PI56 BayGenomics ES cell line XB754 embryonic stem cell house mouse CVCL_PI56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089415 CVCL_PI57 BayGenomics ES cell line XB759 embryonic stem cell house mouse CVCL_PI57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089416 CVCL_PI58 BayGenomics ES cell line XB761 embryonic stem cell house mouse CVCL_PI58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039600; Fbxl19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089417 CVCL_PI37 BayGenomics ES cell line XB705 embryonic stem cell house mouse CVCL_PI37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684864; Pfas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089418 CVCL_PI38 BayGenomics ES cell line XB708 embryonic stem cell house mouse CVCL_PI38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089419 CVCL_PI39 BayGenomics ES cell line XB713 embryonic stem cell house mouse CVCL_PI39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341200; Pwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089420 CVCL_H096 BY00635 transformed cell line human CVCL_H096 HLA typing: A*01:YAG,02:ANGR; B*08:DHRE,55:DFXF; DRB1*09:01:02,03:01:09 (IPD-IMGT/HLA=20062) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089421 CVCL_H097 BY00637 transformed cell line human CVCL_H097 HLA typing: A*01:TUS,68:PNP; B*08:DGUB,14:02; DRB1*03:01:01:01/02,13:66:02 (IPD-IMGT/HLA=20059) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089422 CVCL_H098 BY00638 transformed cell line human CVCL_H098 HLA typing: A*01:BTPY,68:ADHW; B*35:AAJB,37:AUCE; DRB1*13:01:01,11:92 (IPD-IMGT/HLA=20058) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089423 CVCL_H099 BY00639 transformed cell line human CVCL_H099 HLA typing: A*02:CNDW,02:CNDW; B*40:DGRY,49:01; DRB1*14:97,04:05:01 (IPD-IMGT/HLA=20057) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089424 CVCL_PI40 BayGenomics ES cell line XB718 embryonic stem cell house mouse CVCL_PI40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089425 CVCL_H092 BY00629 transformed cell line human CVCL_H092 HLA typing: A*02:BANP,23:ANJU; B*18:DHPD,35:CWAD; C*07:CVAG,04:54; DRB1*07:APA,11:ARAP (IPD-IMGT/HLA=20072) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089426 CVCL_PI41 BayGenomics ES cell line XB720 embryonic stem cell house mouse CVCL_PI41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089427 CVCL_H093 BY00630 transformed cell line human CVCL_H093 HLA typing: A*01:YAG,02:ANGR; B*07:DGTG,51:DGTH; C*07:02/50/66/74,14:16; DRB1*03:WHX,15:VYF (IPD-IMGT/HLA=20071) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089428 CVCL_PI42 BayGenomics ES cell line XB723 embryonic stem cell house mouse CVCL_PI42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089429 CVCL_H094 BY00631 transformed cell line human CVCL_H094 HLA typing: A*02:BZNT,24:CNEX; B*35:DDPF,48:KG; C*15:27; DRB1*04:AFRE,08:02 (IPD-IMGT/HLA=20070) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089430 CVCL_PI43 BayGenomics ES cell line XB726 embryonic stem cell house mouse CVCL_PI43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97803; Ptma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089431 CVCL_H095 BY00632 transformed cell line human CVCL_H095 HLA typing: A*01:YAG,02:11; B*40:06:01:01/02,37:22; C*06:AJB,12:02; DRB1*10:01,15:AK (IPD-IMGT/HLA=20069) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089432 CVCL_PI44 BayGenomics ES cell line XB729 embryonic stem cell house mouse CVCL_PI44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915202; Tomm20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089433 CVCL_PI45 BayGenomics ES cell line XB730 embryonic stem cell house mouse CVCL_PI45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089434 CVCL_PI46 BayGenomics ES cell line XB732 embryonic stem cell house mouse CVCL_PI46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089435 CVCL_H090 BY00626 transformed cell line human CVCL_H090 HLA typing: A*02:ANXF,32:YH; B*37:JTB,50:01; C*06:02,06:30; DRB1*03:WKH,04:AFMT (IPD-IMGT/HLA=20079) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089436 CVCL_PI47 BayGenomics ES cell line XB733 embryonic stem cell house mouse CVCL_PI47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106014; Nudc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089437 CVCL_H091 BY00628 transformed cell line human CVCL_H091 HLA typing: A*01:TUS,01:WCS; B*35:DFWB,51:DFWU; C*14:02:01,04:55; DRB1*01:ANWV,04:AGCN (IPD-IMGT/HLA=20073) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089438 CVCL_PI26 BayGenomics ES cell line XB678 embryonic stem cell house mouse CVCL_PI26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108069; Ccna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089439 CVCL_PI27 BayGenomics ES cell line XB680 embryonic stem cell house mouse CVCL_PI27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933204; Rbm5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089440 CVCL_PI28 BayGenomics ES cell line XB683 embryonic stem cell house mouse CVCL_PI28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089441 CVCL_PI29 BayGenomics ES cell line XB686 embryonic stem cell house mouse CVCL_PI29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089442 CVCL_PI30 BayGenomics ES cell line XB691 embryonic stem cell house mouse CVCL_PI30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446217; Phf13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089443 CVCL_PI31 BayGenomics ES cell line XB695 embryonic stem cell house mouse CVCL_PI31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089444 CVCL_PI32 BayGenomics ES cell line XB696 embryonic stem cell house mouse CVCL_PI32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089445 CVCL_PI33 BayGenomics ES cell line XB697 embryonic stem cell house mouse CVCL_PI33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914449; Pfdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089446 CVCL_PI34 BayGenomics ES cell line XB699 embryonic stem cell house mouse CVCL_PI34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345643; Sufu Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089447 CVCL_PI35 BayGenomics ES cell line XB700 embryonic stem cell house mouse CVCL_PI35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913835; Snrnp40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089448 CVCL_PI36 BayGenomics ES cell line XB702 embryonic stem cell house mouse CVCL_PI36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914709; Nvl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089449 CVCL_PI15 BayGenomics ES cell line XB646 embryonic stem cell house mouse CVCL_PI15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927865; Zfp280b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089450 CVCL_PI16 BayGenomics ES cell line XB651 embryonic stem cell house mouse CVCL_PI16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089451 CVCL_PI17 BayGenomics ES cell line XB655 embryonic stem cell house mouse CVCL_PI17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089452 CVCL_PI18 BayGenomics ES cell line XB656 embryonic stem cell house mouse CVCL_PI18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109353; Ufd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089453 CVCL_PI19 BayGenomics ES cell line XB657 embryonic stem cell house mouse CVCL_PI19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089454 CVCL_H078 BY00603 transformed cell line human CVCL_H078 HLA typing: A*02:14,68:AEBA; B*27:EKN,53:22; C*02:AFB,04:APNR; DRB1*13:02,15:03 (IPD-IMGT/HLA=20106) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089455 CVCL_H079 BY00604 transformed cell line human CVCL_H079 HLA typing: A*03:APCS,68:APEB; B*07:CZZS,44:02:13; DRB1*01:EW,15:AK (IPD-IMGT/HLA=20107) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089456 CVCL_H074 BY00592 transformed cell line human CVCL_H074 HLA typing: A*03:DUDE,29:DHVF; B*53:01:01,08:55; DRB1*11:01,15:03 (IPD-IMGT/HLA=20556) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089457 CVCL_H075 BY00596 transformed cell line human CVCL_H075 HLA typing: A*03:ANKG,24:AZSA; B*47:06,15:DFRA; DRB1*13:AFWJ,13:APVH (IPD-IMGT/HLA=20101) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089458 CVCL_H076 BY00598 transformed cell line human CVCL_H076 HLA typing: A*02:DUEK,26:GAX; B*37:01:01,51:92; DRB1*04:AAHZ,10:01 (IPD-IMGT/HLA=20104) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089459 CVCL_H077 BY00600 transformed cell line human CVCL_H077 HLA typing: A*30:01,74:DWF; B*15:BKNX,78:07; C*02:TF,16:01; DRB1*13:AFWH,13:AFWK (IPD-IMGT/HLA=20105) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089460 CVCL_H070 BY00584 transformed cell line human CVCL_H070 HLA typing: A*30:YE,68:AEAV; B*18:RRG,51:90; C*05:ANJN,15:BC; DRB1*03:XEV,13:ASGS (IPD-IMGT/HLA=20550) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089461 CVCL_H071 BY00588 transformed cell line human CVCL_H071 HLA typing: A*03:ANGK,29:ANJP; B*44:03,51:91; C*07:BJ,16:01; DRB1*07:APA,08:APPA (IPD-IMGT/HLA=20553) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089462 CVCL_PI20 BayGenomics ES cell line XB659 embryonic stem cell house mouse CVCL_PI20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089463 CVCL_H072 BY00589 transformed cell line human CVCL_H072 HLA typing: A*11:HGV,23:ANJU; B*18:RRG,49:10; C*07:ANHC,07:ET; DRB1*11:APWP,12:02 (IPD-IMGT/HLA=20554) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089464 CVCL_PI21 BayGenomics ES cell line XB660 embryonic stem cell house mouse CVCL_PI21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089465 CVCL_H073 BY00590 transformed cell line human CVCL_H073 HLA typing: A*01:TUS,24:CNFN; B*37:01:01,51:01:17; C*01:BG,12:NP; DRB1*01:EW,04:07 (IPD-IMGT/HLA=20555) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089466 CVCL_PI22 BayGenomics ES cell line XB663 embryonic stem cell house mouse CVCL_PI22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101921; Ap2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089467 CVCL_PI23 BayGenomics ES cell line XB665 embryonic stem cell house mouse CVCL_PI23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089468 CVCL_PI24 BayGenomics ES cell line XB675 embryonic stem cell house mouse CVCL_PI24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089469 CVCL_PI25 BayGenomics ES cell line XB677 embryonic stem cell house mouse CVCL_PI25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089470 CVCL_PI04 BayGenomics ES cell line XB616 embryonic stem cell house mouse CVCL_PI04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915943; Hnrnpul2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089471 CVCL_PI05 BayGenomics ES cell line XB620 embryonic stem cell house mouse CVCL_PI05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089472 CVCL_PI06 BayGenomics ES cell line XB621 embryonic stem cell house mouse CVCL_PI06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147194; Rbm27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089473 CVCL_PI07 BayGenomics ES cell line XB623 embryonic stem cell house mouse CVCL_PI07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917834; Pak4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089474 CVCL_PI08 BayGenomics ES cell line XB626 embryonic stem cell house mouse CVCL_PI08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700006; Dbnl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089475 CVCL_PI09 BayGenomics ES cell line XB627 embryonic stem cell house mouse CVCL_PI09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089476 CVCL_H089 BY00623 transformed cell line human CVCL_H089 HLA typing: A*02:BANP,23:ANJU; B*35:08,52:01; C*04:FEAS,16:20; DRB1*04:BDJV,13:BMD (IPD-IMGT/HLA=20080) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089477 CVCL_H085 BY00615 transformed cell line human CVCL_H085 HLA typing: A*02:ASAD,36:01; B*15:CVZU,44:DGPW; C*05:36,12:03; DRB1*03:WHX,11:ARAP (IPD-IMGT/HLA=20088) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089478 CVCL_H086 BY00616 transformed cell line human CVCL_H086 HLA typing: A*02:ANGN,03:ANGP; B*44:DHNG,57:PXJ; C*05:AC,06:31; DRB1*07:APA,08:FX (IPD-IMGT/HLA=20087) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089479 CVCL_H087 BY00617 transformed cell line human CVCL_H087 HLA typing: A*03:ANKG,24:AZSA; B*08:CTZR,44:DGWR; C*07:CVAG,05:35; DRB1*03:WKH,04:AFMT (IPD-IMGT/HLA=20086) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089480 CVCL_H088 BY00618 transformed cell line human CVCL_H088 HLA typing: A*31:AF,68:AEBG; B*27:AETG,51:DREF; C*08:DJRU,02:26:02; DRB1*08:BJ,16:AB (IPD-IMGT/HLA=20085) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089481 CVCL_H081 BY00608 transformed cell line human CVCL_H081 HLA typing: A*02:ANJ,74:AB; B*46:DNXM,51:93; DRB1*04:05,14:04 (IPD-IMGT/HLA=20110) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089482 CVCL_H082 BY00610 transformed cell line human CVCL_H082 HLA typing: A*02:BDDA,02:CNDW; B*15:DFRA,54:20; DRB1*12:GW,15:VYF (IPD-IMGT/HLA=20114) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089483 CVCL_H083 BY00611 transformed cell line human CVCL_H083 HLA typing: A*01:TUS,25:01; B*18:RRG,08:56; DRB1*03:WHX,15:VYF (IPD-IMGT/HLA=20115) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089484 CVCL_PI10 BayGenomics ES cell line XB631 embryonic stem cell house mouse CVCL_PI10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089485 CVCL_H084 BY00614 transformed cell line human CVCL_H084 HLA typing: A*11:ANRC,24:CNFM; B*07:DGXD,40:DBEV; C*03:04,03:80; DRB1*03:WZB,04:ADTZ (IPD-IMGT/HLA=20089) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089486 CVCL_PI11 BayGenomics ES cell line XB632 embryonic stem cell house mouse CVCL_PI11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089487 CVCL_PI12 BayGenomics ES cell line XB634 embryonic stem cell house mouse CVCL_PI12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921367; Actr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089488 CVCL_PI13 BayGenomics ES cell line XB637 embryonic stem cell house mouse CVCL_PI13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089489 CVCL_PI14 BayGenomics ES cell line XB645 embryonic stem cell house mouse CVCL_PI14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278322; Epc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089490 CVCL_H080 BY00607 transformed cell line human CVCL_H080 HLA typing: A*02:ANJ,34:01; B*18:RRG,27:63; DRB1*12:02,15:02 (IPD-IMGT/HLA=20109) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21089491 CVCL_YC90 ZOCi001-A induced pluripotent stem cell human CVCL_YC90 From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Arg526Ter (c.1576C>T) (R457*); ClinVar=VCV000143167; Zygosity=Heterozygous (PubMed=32387899); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Thr745Met (c.2234C>T) (T676M); ClinVar=VCV000005733; Zygosity=Heterozygous (PubMed=32387899) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21089492 CVCL_YC91 CIMAi001-A induced pluripotent stem cell human CVCL_YC91 From: Centro de Investigacion Medica Aplicada (CIMA); Pamplona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Arg122Ter (c.364C>T); ClinVar=VCV000204097; Zygosity=Heterozygous (PubMed=31715429); Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Gly170Arg (c.508G>A); ClinVar=VCV000040166; Zygosity=Heterozygous (PubMed=31715429) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21089493 CVCL_YC92 UBCi001-A induced pluripotent stem cell human CVCL_YC92 From: University of British Columbia; Vancouver; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg418Ter (c.1252C>T); ClinVar=VCV000098177; Zygosity=Heterozygous (PubMed=31707213) Derived from sampling site: Peripheral blood. Female 21089494 CVCL_YC93 WAe001-A-29 embryonic stem cell human CVCL_YC93 From: Department of Chemistry, University of Houston; Houston; USA CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Male Characteristics: Using CRISPR/Cas9 mCherry was integrated in front of the start codon of ATOX1 in one allele (PubMed=31704540) 21089495 CVCL_YC98 SPB/pEGFP-B2 spontaneously immortalized cell line CVCL_YC98 CL:0000010 Transfected with: UniProtKB; L7Y5K1; Redspotted grouper nervous necrosis virus protein B2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain. Unspecified Characteristics: Transfected with GNNV-K1 protein B2-eGFP fusion transcript Group: Fish cell line 21089496 CVCL_YC99 TiB spontaneously immortalized cell line CVCL_YC99 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Capable of growing from 15 to 32 Celsius, the optimal growth temperature is 27 Celsius; Virology: Susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line 21089497 CVCL_YC94 6D10 hybridoma house mouse CVCL_YC94 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9QZH2; Rat Bard1. 21089498 CVCL_YC95 BMGB spontaneously immortalized cell line CVCL_YC95 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Optimal growth at 30 Celsius; Virology: Infected with redspotted grouper nervous necrosis virus (RGNNV); Virology: Susceptible to infection by chum salmon virus (CSV), grouper nervous necrosis virus (GNNV-K1), giant seaperch iridovirus (GSIV-K1) and red sea bream iridovirus (RSIV-Ku) Group: Fish cell line 21089499 CVCL_YC96 SPB/p35L-DsRed spontaneously immortalized cell line CVCL_YC96 CL:0000010 Transfected with: UniProtKB; L7YBE4; Giant seaperch iridovirus ORF35L; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain. Unspecified Characteristics: Transfected with GSIV ORF35L-RFP fusion transcript Group: Fish cell line 21089500 CVCL_YC97 SPB/pEGFP-B1 spontaneously immortalized cell line CVCL_YC97 CL:0000010 Transfected with: UniProtKB; L7YAM6; Redspotted grouper nervous necrosis virus protein B1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain. Unspecified Characteristics: Transfected with GNNV-K1 protein B1-eGFP fusion transcript Group: Fish cell line 21089501 CVCL_YC80 UMILi017-A induced pluripotent stem cell human CVCL_YC80 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089502 CVCL_YC81 UMILi018-A induced pluripotent stem cell human CVCL_YC81 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089503 CVCL_YC82 UMILi019-A induced pluripotent stem cell human CVCL_YC82 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089504 CVCL_YC87 UMILi024-A induced pluripotent stem cell human CVCL_YC87 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089505 CVCL_YC88 UMILi025-A induced pluripotent stem cell human CVCL_YC88 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089506 CVCL_YC89 UMILi026-A induced pluripotent stem cell human CVCL_YC89 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089507 CVCL_YC83 UMILi020-A induced pluripotent stem cell human CVCL_YC83 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089508 CVCL_YC84 UMILi021-A induced pluripotent stem cell human CVCL_YC84 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089509 CVCL_YC85 UMILi022-A induced pluripotent stem cell human CVCL_YC85 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089510 CVCL_YC86 UMILi023-A induced pluripotent stem cell human CVCL_YC86 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089511 CVCL_YC70 UMILi006-A induced pluripotent stem cell human CVCL_YC70 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089512 CVCL_YC71 UMILi007-A induced pluripotent stem cell human CVCL_YC71 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089513 CVCL_YC76 UMILi013-A induced pluripotent stem cell human CVCL_YC76 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Pro132Ser (c.394C>T); ClinVar=VCV000030200; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089514 CVCL_YC77 UMILi014-A induced pluripotent stem cell human CVCL_YC77 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3188; EED; Simple; p.His258Tyr (c.772C>T); ClinVar=VCV000430644; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21089515 CVCL_YC78 UMILi015-A induced pluripotent stem cell human CVCL_YC78 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Ala738Thr (c.2212G>A) (A733T); ClinVar=VCV001307224; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089516 CVCL_YC79 UMILi016-A induced pluripotent stem cell human CVCL_YC79 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089517 CVCL_YC72 UMILi008-A induced pluripotent stem cell human CVCL_YC72 From: University of Milan; Milan; Italy CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21089518 CVCL_YC73 UMILi010-A induced pluripotent stem cell human CVCL_YC73 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12856; YY1; Simple; p.Lys179Ter (c.535A>T); ClinVar=VCV000430621; Zygosity=Unspecified (hPSCreg) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089519 CVCL_YC74 UMILi011-A induced pluripotent stem cell human CVCL_YC74 From: University of Milan; Milan; Italy CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089520 CVCL_YC75 UMILi012-A induced pluripotent stem cell human CVCL_YC75 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Val626Met (c.1876G>A) (V621M); ClinVar=VCV000158579; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21089521 CVCL_YC60 UIOi001-A induced pluripotent stem cell human CVCL_YC60 From: University of Oslo; Oslo; Norway CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21089522 CVCL_YC65 UMILi001-A induced pluripotent stem cell human CVCL_YC65 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg2635Ter (c.7903C>T); ClinVar=VCV000196692; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089523 CVCL_YC66 UMILi002-A induced pluripotent stem cell human CVCL_YC66 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Cys197Alafs*11 (c.588del); Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21089524 CVCL_YC67 UMILi003-A induced pluripotent stem cell human CVCL_YC67 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Pro235Glnfs*26 (c.702delG); Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089525 CVCL_YC68 UMILi004-A induced pluripotent stem cell human CVCL_YC68 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg2635Ter (c.7903C>T); ClinVar=VCV000196692; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089526 CVCL_YC61 ULUNDi008-A induced pluripotent stem cell human CVCL_YC61 From: University of Lund; Lund; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=31954327) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089527 CVCL_YC62 UNIGEi001-A induced pluripotent stem cell human CVCL_YC62 From: University of Geneva; Geneva; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.His358_Thr364del (c.1073_1093del); ClinVar=VCV000557260; Zygosity=Heterozygous (PubMed=31678774); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (PubMed=31678774) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 21089528 CVCL_YC63 UQACi001-A induced pluripotent stem cell human CVCL_YC63 From: Universite du Quebec a Chicoutimi; Chicoutimi; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6416; KRT14; Simple; p.Arg125Ser (c.373C>A); ClinVar=VCV001338973; Zygosity=Heterozygous (PubMed=32179493) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089529 CVCL_YC64 VCCRIi001-A induced pluripotent stem cell human CVCL_YC64 From: Victor Chang Cardiac Research Institute; Sidney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 20990; PHACTR1; Simple; g.chr6:12903725A>G; dbSNP=rs9349379; Zygosity=Heterozygous (PubMed=31707208) Derived from sampling site: Peripheral blood. Female 21089530 CVCL_YC69 UMILi005-A induced pluripotent stem cell human CVCL_YC69 From: University of Milan; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg3321Ter (c.9961C>T); ClinVar=VCV000183371; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Female 21089531 CVCL_YC54 SMBCi002-A induced pluripotent stem cell human CVCL_YC54 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 5109; HOXA9; Simple; g.4868T>C; dbSNP=rs3801776; Zygosity=Homozygous (PubMed=31986484) Population: Chinese; Han; Derived from sampling site: Amniotic fluid. Female 21089532 CVCL_YC55 SMBCi003-A induced pluripotent stem cell human CVCL_YC55 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Val166Leufs*7 (c.496_497delGT); ClinVar=VCV000431562; Zygosity=Heterozygous (PubMed=32554297) Population: Chinese; Han; Derived from sampling site: Urine. Female 21089533 CVCL_YC56 SMBCi003-B induced pluripotent stem cell human CVCL_YC56 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Val166Leufs*7 (c.496_497delGT); ClinVar=VCV000431562; Zygosity=Heterozygous (PubMed=32554297) Population: Chinese; Han; Derived from sampling site: Urine. Female 21089534 CVCL_YC57 SMBCi003-C induced pluripotent stem cell human CVCL_YC57 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Val166Leufs*7 (c.496_497delGT); ClinVar=VCV000431562; Zygosity=Heterozygous (from autologous cell lines SMBCi003-A and SMBCi003-B) Population: Chinese; Han; Derived from sampling site: Urine. Female 21089535 CVCL_YC50 PEIi002-C induced pluripotent stem cell human CVCL_YC50 From: Paul Ehrlich Institute; Langen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Unexplicit; Ex14-15del; Zygosity=Homozygous (PubMed=32062129) Derived from sampling site: Peripheral blood. Male 21089536 CVCL_YC51 PEIi003-A induced pluripotent stem cell human CVCL_YC51 From: Paul Ehrlich Institute; Langen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 21089537 CVCL_YC52 PUMCHi001-A induced pluripotent stem cell human CVCL_YC52 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg349Trp (c.1045C>T); ClinVar=VCV000066762; Zygosity=Heterozygous (PubMed=31794942) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21089538 CVCL_YC53 RTIBDi001-A induced pluripotent stem cell human CVCL_YC53 From: National Institutes of Health, Regenerative therapies for inherited blood disorder; Bethesda; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21089539 CVCL_YC58 STBCi006-A-2 induced pluripotent stem cell human CVCL_YC58 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; STBCi006-A-2; true Female 21089540 CVCL_YC59 SYSUi002-A induced pluripotent stem cell human CVCL_YC59 From: Sun Yat-sen University; Guangzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089541 CVCL_YC43 NIDCRi002-A induced pluripotent stem cell human CVCL_YC43 From: National Institute of Dental and Craniofacial Research; Bethesda; USA. CL:0000010 21089542 CVCL_YC44 NIDCRi003-A induced pluripotent stem cell human CVCL_YC44 From: National Institute of Dental and Craniofacial Research; Bethesda; USA. CL:0000010 21089543 CVCL_YC45 NIDCRi004-A induced pluripotent stem cell human CVCL_YC45 From: National Institute of Dental and Craniofacial Research; Bethesda; USA. CL:0000010 21089544 CVCL_YC46 NYGCe001-A embryonic stem cell human CVCL_YC46 From: New York Genome Center; New York; USA CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: HGNC; 7764; NEUROG1; Transfected with: HGNC; 13805; NEUROG2. Female Characteristics: Using CRISPR/Cas9 MAP2 has been endogenously tagged at the C-terminus with a T2A-tdTomato construct 21089545 CVCL_YC40 LUEi011-A induced pluripotent stem cell human CVCL_YC40 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi010-A (Cellosaurus=CVCL_YC39); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089546 CVCL_YC41 NCAi001-A induced pluripotent stem cell human CVCL_YC41 From: Ncardia B.V.; Leiden; Netherlands. CL:0000010 Female 21089547 CVCL_YC42 NIDCRi001-A induced pluripotent stem cell human CVCL_YC42 From: National Institute of Dental and Craniofacial Research; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Pro250Arg (c.749C>G); ClinVar=VCV000016340; Zygosity=Heterozygous (PubMed=32505898) Derived from sampling site: Peripheral blood. Male 21089548 CVCL_YC47 PEIi001-A induced pluripotent stem cell human CVCL_YC47 From: Paul Ehrlich Institute; Langen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9330; PQBP1; Simple; p.Arg153Serfs*41 (c.451_452AG[4]) (c.459_462delAGAG); ClinVar=VCV000010980; Zygosity=Hemizygous (PubMed=31698189) Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 21089549 CVCL_YC48 PEIi002-A induced pluripotent stem cell human CVCL_YC48 From: Paul Ehrlich Institute; Langen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Unexplicit; Ex14-15del; Zygosity=Homozygous (PubMed=32062129) Derived from sampling site: Peripheral blood. Male 21089550 CVCL_YC49 PEIi002-B induced pluripotent stem cell human CVCL_YC49 From: Paul Ehrlich Institute; Langen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15925; SAMHD1; Unexplicit; Ex14-15del; Zygosity=Homozygous (PubMed=32062129) Derived from sampling site: Peripheral blood. Male 21089551 CVCL_YC32 KCi003-B induced pluripotent stem cell human CVCL_YC32 From: Kennedy Centret, Rigshospitalet; Glostrup; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 970; BBS5; Simple; p.Gly72Ser (c.214G>A); ClinVar=VCV000006161; Zygosity=Homozygous (PubMed=31760295) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089552 CVCL_YC33 KCi003-C induced pluripotent stem cell human CVCL_YC33 From: Kennedy Centret, Rigshospitalet; Glostrup; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 970; BBS5; Simple; p.Gly72Ser (c.214G>A); ClinVar=VCV000006161; Zygosity=Homozygous (PubMed=31760295) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089553 CVCL_YC34 HS1052 embryonic stem cell human CVCL_YC34 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 21089554 CVCL_YC35 LUEi006-A induced pluripotent stem cell human CVCL_YC35 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi007-A (Cellosaurus=CVCL_YC36); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089555 CVCL_YC30 INSAi002-A induced pluripotent stem cell human CVCL_YC30 From: Instituto Nacional de Saude Ricardo Jorge; Porto; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Trp287Ter (c.861G>A); ClinVar=VCV000010736; Zygosity=Hemizygous (PubMed=32388441) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089556 CVCL_YC31 KCi003-A induced pluripotent stem cell human CVCL_YC31 From: Kennedy Centret, Rigshospitalet; Glostrup; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 970; BBS5; Simple; p.Gly72Ser (c.214G>A); ClinVar=VCV000006161; Zygosity=Homozygous (PubMed=31760295) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089557 CVCL_YC36 LUEi007-A induced pluripotent stem cell human CVCL_YC36 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi006-A (Cellosaurus=CVCL_YC35); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089558 CVCL_YC37 LUEi008-A induced pluripotent stem cell human CVCL_YC37 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi009-A (Cellosaurus=CVCL_YC38); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089559 CVCL_YC38 LUEi009-A induced pluripotent stem cell human CVCL_YC38 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi008-A (Cellosaurus=CVCL_YC37); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089560 CVCL_YC39 LUEi010-A induced pluripotent stem cell human CVCL_YC39 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Donor information: Established from monozygotic twin of LUEi011-A (Cellosaurus=CVCL_YC40); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089561 CVCL_YC21 CENSOi041-D induced pluripotent stem cell human CVCL_YC21 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21089562 CVCL_YC22 CENSOi051-B induced pluripotent stem cell human CVCL_YC22 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21089563 CVCL_YC23 CENSOi054-B induced pluripotent stem cell human CVCL_YC23 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21089564 CVCL_YC24 CENSOi057-B induced pluripotent stem cell human CVCL_YC24 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21089565 CVCL_YC20 CENSOi041-C induced pluripotent stem cell human CVCL_YC20 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21089566 CVCL_YC29 INSAi001-A induced pluripotent stem cell human CVCL_YC29 From: Instituto Nacional de Saude Ricardo Jorge; Porto; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Phe252Ile (c.754T>A) (F213I); ClinVar=VCV000004301; Zygosity=Heterozygous (PubMed=31678773); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31678773) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089567 CVCL_PI90 BayGenomics ES cell line XB857 embryonic stem cell house mouse CVCL_PI90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442035; Atp5g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089568 CVCL_PI91 BayGenomics ES cell line XB864 embryonic stem cell house mouse CVCL_PI91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089569 CVCL_YC25 GIBHi002-A induced pluripotent stem cell human CVCL_YC25 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female 21089570 CVCL_PI92 BayGenomics ES cell line XB865 embryonic stem cell house mouse CVCL_PI92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337994; Bcl10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089571 CVCL_YC26 GIBHi003-A induced pluripotent stem cell human CVCL_YC26 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (PubMed=31778937) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21089572 CVCL_PI93 BayGenomics ES cell line XB867 embryonic stem cell house mouse CVCL_PI93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089573 CVCL_YC27 GIBHi002-A-1 induced pluripotent stem cell human CVCL_YC27 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=TALEN; HGNC; 8607; PRKN Population: Caucasian; Derived from sampling site: Urine. Female 21089574 CVCL_PI94 BayGenomics ES cell line XB873 embryonic stem cell house mouse CVCL_PI94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917672; Ints2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089575 CVCL_YC28 GIBHi002-A-2 induced pluripotent stem cell human CVCL_YC28 From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Urine. Female Characteristics: Using TALEN a construct containing eGFP and Pac was integrated in the first coding exon of NKX2-5 (PubMed=33352530) 21089576 CVCL_PI95 BayGenomics ES cell line XB877 embryonic stem cell house mouse CVCL_PI95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914449; Pfdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089577 CVCL_PI96 BayGenomics ES cell line XB878 embryonic stem cell house mouse CVCL_PI96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332234; Zfp148 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089578 CVCL_PI97 BayGenomics ES cell line XB879 embryonic stem cell house mouse CVCL_PI97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858417; Sec61a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089579 CVCL_PI98 BayGenomics ES cell line XB880 embryonic stem cell house mouse CVCL_PI98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089580 CVCL_PI99 BayGenomics ES cell line XB882 embryonic stem cell house mouse CVCL_PI99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089581 CVCL_H218 BRI-JM01 cancer cell line house mouse CVCL_H218 CL:0000010 Female 21089582 CVCL_GQ18 ND05793 transformed cell line human CVCL_GQ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089583 CVCL_H219 BRI-JM04 cancer cell line house mouse CVCL_H219 CL:0000010 Female 21089584 CVCL_GQ19 ND07600 transformed cell line human CVCL_GQ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089585 CVCL_H214 HepG2-GS cancer cell line human CVCL_H214 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 4341; GLUL Population: Caucasian; Derived from sampling site: Liver. Male 21089586 CVCL_GQ14 ND01547 transformed cell line human CVCL_GQ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089587 CVCL_H215 CHO-GS spontaneously immortalized cell line CVCL_H215 CL:0000010 Derived from sampling site: Ovary. Female 21089588 CVCL_GQ15 ND01564 transformed cell line human CVCL_GQ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089589 CVCL_H216 Jyg-MC(A) cancer cell line house mouse CVCL_H216 CL:0000010 Breed/subspecies: JYG. Female 21089590 CVCL_GQ16 ND01842 transformed cell line human CVCL_GQ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089591 CVCL_H217 Jyg-MC(B) cancer cell line house mouse CVCL_H217 CL:0000010 Breed/subspecies: JYG. Female 21089592 CVCL_GQ17 ND01932 transformed cell line human CVCL_GQ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089593 CVCL_H210 DEAU cancer cell line human CVCL_H210 CL:0000010 Derived from sampling site: Lymph node. Male 21089594 CVCL_GQ10 ND01453 transformed cell line human CVCL_GQ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089595 CVCL_GQ11 ND01499 transformed cell line human CVCL_GQ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089596 CVCL_H212 MEN1RGB finite cell line human CVCL_H212 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal cortex. Female 21089597 CVCL_GQ12 ND01509 transformed cell line human CVCL_GQ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089598 CVCL_H213 MEN2RGB finite cell line human CVCL_H213 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal cortex. Male 21089599 CVCL_GQ13 ND01512 transformed cell line human CVCL_GQ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089600 CVCL_GQ29 GM04946 transformed cell line human CVCL_GQ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089601 CVCL_H229 NG-3Y1-T6R transformed cell line Norway rat CVCL_H229 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089602 CVCL_GQ25 ND10251 transformed cell line human CVCL_GQ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089603 CVCL_H225 Py-3Y1-S2 transformed cell line Norway rat CVCL_H225 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089604 CVCL_H226 E1A-3Y1-1 transformed cell line Norway rat CVCL_H226 CL:0000010 Transformant: Adenovirus 12 [E1A](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089605 CVCL_GQ26 GM02790 finite cell line human CVCL_GQ26 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21089606 CVCL_GQ27 GM04931 finite cell line human CVCL_GQ27 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089607 CVCL_H227 NG-3Y1-T15L transformed cell line Norway rat CVCL_H227 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089608 CVCL_GQ28 GM04942 transformed cell line human CVCL_GQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089609 CVCL_H228 NG-3Y1-T308 transformed cell line Norway rat CVCL_H228 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089610 CVCL_H221 G12 cancer cell line human CVCL_H221 CL:0000010 Male Doubling time: 2.3 days (PubMed=10067924). 21089611 CVCL_GQ21 ND08166 transformed cell line human CVCL_GQ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089612 CVCL_H222 D3 [Human glioblastoma] cancer cell line human CVCL_H222 CL:0000010 Male Doubling time: 2.8 days (PubMed=10067924). 21089613 CVCL_GQ22 ND08727 transformed cell line human CVCL_GQ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089614 CVCL_H223 D19 cancer cell line human CVCL_H223 CL:0000010 Female Doubling time: 6.1 days (PubMed=10067924). 21089615 CVCL_GQ23 ND09165 transformed cell line human CVCL_GQ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089616 CVCL_H224 FM3A tsFT210 cancer cell line house mouse CVCL_H224 CL:0000010 Sequence variation: Mutation; MGI; MGI:88351; Cdk1; Simple; p.Pro272Ser (c.814C>T); Zygosity=Homozygous (PubMed=1903331; PubMed=2208288) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Stop growing at 39 Celsius. Cells are arrested at the G2 phase at 39 Celsius (PubMed=2428648). Doubling time: 16 hours (PubMed=2428648) Caution: An additional Cdk1 mutation p.Ile52Val (c.154A>G) was reported by PubMed=2208288 but was not found by PubMed=1903331 21089617 CVCL_GQ24 ND10167 transformed cell line human CVCL_GQ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089618 CVCL_H220 BRI-JM05 cancer cell line house mouse CVCL_H220 CL:0000010 Female 21089619 CVCL_GQ20 ND07830 transformed cell line human CVCL_GQ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089620 CVCL_H207 HLY-1 cancer cell line human CVCL_H207 From: Al Saati T.; Hopital de Purpan, Centre Hospitalier Universitaire de Toulouse; Toulouse; France CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Ser206Cys (c.617C>G) (p.Ser219Cys, c.656C>G) (S219C); Zygosity=Heterozygous (PubMed=21179087) Omics: Transcriptome analysis by microarray. Unspecified 21089621 CVCL_GQ07 WT-iPSC1 induced pluripotent stem cell human CVCL_GQ07 From: Department of Dermatology, Jikei University School of Medicine; Tokyo; Japan CL:0000010 Miscellaneous: Donor identity for WT-iPSC1, WT-iPSC2 and WT-iPSC4 by personal communication of Itoh M Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21089622 CVCL_H208 MIEU cancer cell line human CVCL_H208 From: Al Saati T.; Hopital de Purpan, Centre Hospitalier Universitaire de Toulouse; Toulouse; France. CL:0000010 Unspecified 21089623 CVCL_GQ08 WT-iPSC2 induced pluripotent stem cell human CVCL_GQ08 From: Department of Dermatology, Jikei University School of Medicine; Tokyo; Japan CL:0000010 Miscellaneous: Donor identity for WT-iPSC1, WT-iPSC2 and WT-iPSC4 by personal communication of Itoh M Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21089624 CVCL_H209 LIB cancer cell line human CVCL_H209 From: Al Saati T.; Hopital de Purpan, Centre Hospitalier Universitaire de Toulouse; Toulouse; France. CL:0000010 Unspecified 21089625 CVCL_GQ09 WT-iPSC4 induced pluripotent stem cell human CVCL_GQ09 From: Department of Dermatology, Jikei University School of Medicine; Tokyo; Japan CL:0000010 Miscellaneous: Donor identity for WT-iPSC1, WT-iPSC2 and WT-iPSC4 by personal communication of Itoh M Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21089626 CVCL_H203 Mel-2 cancer cell line human CVCL_H203 From: Institute for Advanced Medical Research, Keio University School of Medicine; Tokyo; Japan CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Omics: Deep exome analysis Male 21089627 CVCL_GQ03 RDEB-iPSC26 induced pluripotent stem cell human CVCL_GQ03 From: Department of Dermatology, Jikei University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Arg669Ter (c.2005C>T); ClinVar=VCV000374052; Zygosity=Heterozygous (PubMed=27558600); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Glu2857Ter (c.8569G>T); ClinVar=VCV001339053; Zygosity=Heterozygous (PubMed=27558600) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21089628 CVCL_GQ04 SKiPSc1 induced pluripotent stem cell human CVCL_GQ04 From: King Abdulaziz City for Science and Technology (KACST); Riyadh; Saudi Arabia CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21089629 CVCL_H204 TcHMC-1 finite cell line human CVCL_H204 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21089630 CVCL_H205 HMC-1.2 cancer cell line human CVCL_H205 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous (PubMed=12519307); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=12519307) Derived from sampling site: Peripheral blood Cell type=Mast cell.. Male 21089631 CVCL_GQ05 TOC-4 iPSC induced pluripotent stem cell human CVCL_GQ05 From: D'Or Institute for Research and Education; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21089632 CVCL_H206 HMC-1.1 cancer cell line human CVCL_H206 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous (PubMed=12519307) Derived from sampling site: Peripheral blood Cell type=Mast cell.. Male 21089633 CVCL_GQ06 WA09 MIXL1-2A-eGFP embryonic stem cell human CVCL_GQ06 CL:0000010 Female Characteristics: TALEN-engineered line where the stop codon of MIXL1 was replaced with a 2A-eGFP cassette, thus, creating a MIXL1-2A-eGFP allele. 21089634 CVCL_GQ00 mRPE spontaneously immortalized cell line house mouse CVCL_GQ00 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: NMRI. Female 21089635 CVCL_H200 SM2-1 cancer cell line human CVCL_H200 From: Department of Dermatology, Shinshu University; Matsumoto; Japan CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis (Note=In-transit between skin and lymph node). Omics: Deep exome analysis Male 21089636 CVCL_H201 Mel-18 cancer cell line human CVCL_H201 From: Institute for Advanced Medical Research, Keio University School of Medicine; Tokyo; Japan CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male 21089637 CVCL_GQ01 NOCC cancer cell line human CVCL_GQ01 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: ~29 hours (PubMed=27541369) 21089638 CVCL_GQ02 PB48 induced pluripotent stem cell human CVCL_GQ02 From: Universite Paris-Sud 11; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys634Tyr (c.1901G>A); ClinVar=VCV000013909; Zygosity=Heterozygous (PubMed=27558615) Derived from sampling site: Peripheral blood. Male 21089639 CVCL_H202 SM3 cancer cell line human CVCL_H202 From: Department of Dermatology, Shinshu University; Matsumoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Tyr (c.2458G>T); ClinVar=VCV000375928; Zygosity=Unspecified (PubMed=19035443). Population: Japanese Unspecified 21089640 CVCL_PK35 BayGenomics ES cell line XC758 embryonic stem cell house mouse CVCL_PK35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137357; Trim33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089641 CVCL_PK36 BayGenomics ES cell line XC762 embryonic stem cell house mouse CVCL_PK36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089642 CVCL_PK37 BayGenomics ES cell line XC763 embryonic stem cell house mouse CVCL_PK37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089643 CVCL_PK38 BayGenomics ES cell line XC765 embryonic stem cell house mouse CVCL_PK38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929996; Trpm7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089644 CVCL_PK39 BayGenomics ES cell line XC766 embryonic stem cell house mouse CVCL_PK39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920159; Chmp1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089645 CVCL_GQ98 GM07265 transformed cell line human CVCL_GQ98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089646 CVCL_H298 HGDP01371 transformed cell line human CVCL_H298 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089647 CVCL_GQ99 GM07266 finite cell line human CVCL_GQ99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089648 CVCL_H299 HGDP01372 transformed cell line human CVCL_H299 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089649 CVCL_GQ94 GM07261 transformed cell line human CVCL_GQ94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089650 CVCL_H294 HGDP01367 transformed cell line human CVCL_H294 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089651 CVCL_GQ95 GM07262 finite cell line human CVCL_GQ95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089652 CVCL_H295 HGDP01368 transformed cell line human CVCL_H295 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089653 CVCL_GQ96 GM07263 transformed cell line human CVCL_GQ96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089654 CVCL_H296 HGDP01369 transformed cell line human CVCL_H296 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089655 CVCL_GQ97 GM07264 finite cell line human CVCL_GQ97 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089656 CVCL_H297 HGDP01370 transformed cell line human CVCL_H297 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089657 CVCL_GQ90 GM07257 transformed cell line human CVCL_GQ90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089658 CVCL_H290 HGDP01363 transformed cell line human CVCL_H290 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089659 CVCL_GQ91 GM07258 finite cell line human CVCL_GQ91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089660 CVCL_H291 HGDP01364 transformed cell line human CVCL_H291 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089661 CVCL_PK40 BayGenomics ES cell line XC768 embryonic stem cell house mouse CVCL_PK40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089662 CVCL_GQ92 GM07259 transformed cell line human CVCL_GQ92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089663 CVCL_H292 HGDP01365 transformed cell line human CVCL_H292 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089664 CVCL_PK41 BayGenomics ES cell line XC769 embryonic stem cell house mouse CVCL_PK41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089665 CVCL_GQ93 GM07260 finite cell line human CVCL_GQ93 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089666 CVCL_H293 HGDP01366 transformed cell line human CVCL_H293 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089667 CVCL_PK42 BayGenomics ES cell line XC772 embryonic stem cell house mouse CVCL_PK42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089668 CVCL_PK43 BayGenomics ES cell line XC775 embryonic stem cell house mouse CVCL_PK43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926048; Eml4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089669 CVCL_PK44 BayGenomics ES cell line XC776 embryonic stem cell house mouse CVCL_PK44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089670 CVCL_PK45 BayGenomics ES cell line XC777 embryonic stem cell house mouse CVCL_PK45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089671 CVCL_PK24 BayGenomics ES cell line XC730 embryonic stem cell house mouse CVCL_PK24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089672 CVCL_PK25 BayGenomics ES cell line XC738 embryonic stem cell house mouse CVCL_PK25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089673 CVCL_PK26 BayGenomics ES cell line XC739 embryonic stem cell house mouse CVCL_PK26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089674 CVCL_PK27 BayGenomics ES cell line XC740 embryonic stem cell house mouse CVCL_PK27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089675 CVCL_PK28 BayGenomics ES cell line XC741 embryonic stem cell house mouse CVCL_PK28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089676 CVCL_PK29 BayGenomics ES cell line XC742 embryonic stem cell house mouse CVCL_PK29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089677 CVCL_PK30 BayGenomics ES cell line XC745 embryonic stem cell house mouse CVCL_PK30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089678 CVCL_PK31 BayGenomics ES cell line XC749 embryonic stem cell house mouse CVCL_PK31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146350; Scaf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089679 CVCL_PK32 BayGenomics ES cell line XC750 embryonic stem cell house mouse CVCL_PK32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915498; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089680 CVCL_PK33 BayGenomics ES cell line XC755 embryonic stem cell house mouse CVCL_PK33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089681 CVCL_PK34 BayGenomics ES cell line XC757 embryonic stem cell house mouse CVCL_PK34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089682 CVCL_PK13 BayGenomics ES cell line XC701 embryonic stem cell house mouse CVCL_PK13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089683 CVCL_PK14 BayGenomics ES cell line XC705 embryonic stem cell house mouse CVCL_PK14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446163; Fam120a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089684 CVCL_PK15 BayGenomics ES cell line XC706 embryonic stem cell house mouse CVCL_PK15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089685 CVCL_PK16 BayGenomics ES cell line XC709 embryonic stem cell house mouse CVCL_PK16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916906; Pir Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089686 CVCL_PK17 BayGenomics ES cell line XC710 embryonic stem cell house mouse CVCL_PK17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920336; Rps6ka5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089687 CVCL_PK18 BayGenomics ES cell line XC712 embryonic stem cell house mouse CVCL_PK18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447670; Mgrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089688 CVCL_PK19 BayGenomics ES cell line XC715 embryonic stem cell house mouse CVCL_PK19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089689 CVCL_GQ76 GM07201 transformed cell line human CVCL_GQ76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089690 CVCL_H276 HGDP01349 transformed cell line human CVCL_H276 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089691 CVCL_GQ77 GM07205 finite cell line human CVCL_GQ77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089692 CVCL_H277 HGDP01350 transformed cell line human CVCL_H277 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089693 CVCL_GQ78 GM07208 transformed cell line human CVCL_GQ78 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089694 CVCL_H278 HGDP01351 transformed cell line human CVCL_H278 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089695 CVCL_GQ79 GM07209 finite cell line human CVCL_GQ79 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21089696 CVCL_H279 HGDP01352 transformed cell line human CVCL_H279 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089697 CVCL_GQ72 GM07154 transformed cell line human CVCL_GQ72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089698 CVCL_H272 HGDP01345 transformed cell line human CVCL_H272 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089699 CVCL_GQ73 GM07155 finite cell line human CVCL_GQ73 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089700 CVCL_H273 HGDP01346 transformed cell line human CVCL_H273 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089701 CVCL_GQ74 GM07199 finite cell line human CVCL_GQ74 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21089702 CVCL_H274 HGDP01347 transformed cell line human CVCL_H274 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089703 CVCL_GQ75 GM07200 transformed cell line human CVCL_GQ75 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089704 CVCL_H275 HGDP01348 transformed cell line human CVCL_H275 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089705 CVCL_GQ70 GM07152 transformed cell line human CVCL_GQ70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089706 CVCL_GQ71 GM07153 finite cell line human CVCL_GQ71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089707 CVCL_H271 PAMC82 cancer cell line human CVCL_H271 CL:0000010 Population: Chinese Omics: Transcriptome analysis by microarray. 21089708 CVCL_PK20 BayGenomics ES cell line XC716 embryonic stem cell house mouse CVCL_PK20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089709 CVCL_PK21 BayGenomics ES cell line XC719 embryonic stem cell house mouse CVCL_PK21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915498; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089710 CVCL_PK22 BayGenomics ES cell line XC720 embryonic stem cell house mouse CVCL_PK22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99532; Mef2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089711 CVCL_PK23 BayGenomics ES cell line XC728 embryonic stem cell house mouse CVCL_PK23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349658; Cul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089712 CVCL_PK02 BayGenomics ES cell line XC677 embryonic stem cell house mouse CVCL_PK02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089713 CVCL_PK03 BayGenomics ES cell line XC678 embryonic stem cell house mouse CVCL_PK03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915498; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089714 CVCL_PK04 BayGenomics ES cell line XC681 embryonic stem cell house mouse CVCL_PK04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089715 CVCL_PK05 BayGenomics ES cell line XC683 embryonic stem cell house mouse CVCL_PK05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913099; Psrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089716 CVCL_PK06 BayGenomics ES cell line XC684 embryonic stem cell house mouse CVCL_PK06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089717 CVCL_PK07 BayGenomics ES cell line XC686 embryonic stem cell house mouse CVCL_PK07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914648; Srpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089718 CVCL_PK08 BayGenomics ES cell line XC687 embryonic stem cell house mouse CVCL_PK08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387123; Lnpep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089719 CVCL_PK09 BayGenomics ES cell line XC693 embryonic stem cell house mouse CVCL_PK09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346862; Mapk9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089720 CVCL_GQ87 GM07242 finite cell line human CVCL_GQ87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21089721 CVCL_H287 HGDP01360 transformed cell line human CVCL_H287 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089722 CVCL_GQ88 GM07245 transformed cell line human CVCL_GQ88 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089723 CVCL_H288 HGDP01361 transformed cell line human CVCL_H288 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089724 CVCL_GQ89 GM07246 finite cell line human CVCL_GQ89 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Male 21089725 CVCL_H289 HGDP01362 transformed cell line human CVCL_H289 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089726 CVCL_GQ83 GM07221 finite cell line human CVCL_GQ83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089727 CVCL_H283 HGDP01356 transformed cell line human CVCL_H283 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089728 CVCL_GQ84 GM07239 transformed cell line human CVCL_GQ84 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089729 CVCL_H284 HGDP01357 transformed cell line human CVCL_H284 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089730 CVCL_GQ85 GM07240 finite cell line human CVCL_GQ85 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Female 21089731 CVCL_H285 HGDP01358 transformed cell line human CVCL_H285 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089732 CVCL_GQ86 GM07241 transformed cell line human CVCL_GQ86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089733 CVCL_H286 HGDP01359 transformed cell line human CVCL_H286 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089734 CVCL_GQ80 GM07218 transformed cell line human CVCL_GQ80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089735 CVCL_H280 HGDP01353 transformed cell line human CVCL_H280 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089736 CVCL_GQ81 GM07219 finite cell line human CVCL_GQ81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089737 CVCL_H281 HGDP01354 transformed cell line human CVCL_H281 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089738 CVCL_GQ82 GM07220 transformed cell line human CVCL_GQ82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089739 CVCL_H282 HGDP01355 transformed cell line human CVCL_H282 CL:0000010 Population: Chinese/Asian ethnic group; Tu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21089740 CVCL_PK10 BayGenomics ES cell line XC694 embryonic stem cell house mouse CVCL_PK10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089741 CVCL_PK11 BayGenomics ES cell line XC697 embryonic stem cell house mouse CVCL_PK11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089742 CVCL_PK12 BayGenomics ES cell line XC699 embryonic stem cell house mouse CVCL_PK12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089743 CVCL_GQ58 GM06048 transformed cell line human CVCL_GQ58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089744 CVCL_H258 HE31 finite cell line human CVCL_H258 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21089745 CVCL_GQ59 GM06049 transformed cell line human CVCL_GQ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089746 CVCL_H259 HE40 finite cell line human CVCL_H259 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21089747 CVCL_GQ54 GM05239 transformed cell line human CVCL_GQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089748 CVCL_H254 HT-29 HD6 cancer cell line human CVCL_H254 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Clone of HT-29 established after treatment with hexamethylene bisacetamide (HMBA) 21089749 CVCL_GQ55 GM05240 transformed cell line human CVCL_GQ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089750 CVCL_H255 HT-29 HD8 cancer cell line human CVCL_H255 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Clone of HT-29 established after treatment with hexamethylene bisacetamide (HMBA) 21089751 CVCL_GQ56 GM05651 transformed cell line human CVCL_GQ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089752 CVCL_H256 LSCC-HD3 transformed cell line CVCL_H256 CL:0000010 Breed/subspecies: White Leghorn SPAFAS. Female Group: Bird cell line 21089753 CVCL_GQ57 GM05883 transformed cell line human CVCL_GQ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089754 CVCL_H257 HE23 finite cell line human CVCL_H257 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21089755 CVCL_GQ50 GM05226 finite cell line human CVCL_GQ50 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Discontinued: Coriell; GM05226; probable Female 21089756 CVCL_H250 TFA-11 cancer cell line house mouse CVCL_H250 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21089757 CVCL_GQ51 GM05227 finite cell line human CVCL_GQ51 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089758 CVCL_H251 TFP-10 cancer cell line house mouse CVCL_H251 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21089759 CVCL_GQ52 GM05228 finite cell line human CVCL_GQ52 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089760 CVCL_H252 HT-29 HD3 cancer cell line human CVCL_H252 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Clone of HT-29 established after treatment with hexamethylene bisacetamide (HMBA) 21089761 CVCL_GQ53 GM05236 transformed cell line human CVCL_GQ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089762 CVCL_H253 HT-29 HD4 cancer cell line human CVCL_H253 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Clone of HT-29 established after treatment with hexamethylene bisacetamide (HMBA) 21089763 CVCL_PK00 BayGenomics ES cell line XC674 embryonic stem cell house mouse CVCL_PK00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106918; Hif1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089764 CVCL_PK01 BayGenomics ES cell line XC676 embryonic stem cell house mouse CVCL_PK01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143340; Zfp445 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089765 CVCL_GQ69 GM07097 transformed cell line human CVCL_GQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089766 CVCL_H269 HT-29/CPT cancer cell line human CVCL_H269 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT) Female 21089767 CVCL_GQ65 GM06174 transformed cell line human CVCL_GQ65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089768 CVCL_H265 St-4 cancer cell line human CVCL_H265 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205del (c.613_615delTAT); Zygosity=Unspecified (PubMed=15900046) Population: Japanese Omics: Transcriptome analysis by microarray. Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel 21089769 CVCL_GQ66 GM06713 transformed cell line human CVCL_GQ66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089770 CVCL_H266 St-4/CPT cancer cell line human CVCL_H266 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT). 21089771 CVCL_GQ67 GM06876 transformed cell line human CVCL_GQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089772 CVCL_H267 ST-4 cancer cell line human CVCL_H267 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2493fs*67 (c.7476_7477ins11); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion Cell type=T-cell.. Female Problematic cell line: Contaminated Shown to be a PF-382 derivative. Originally thought to originate from the axillary lymph node biopsy of a 12 year old boy with a T-cell malignant lymphoma. 21089773 CVCL_H268 A549/CPT cancer cell line human CVCL_H268 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Derived from sampling site: Lung. Male 21089774 CVCL_GQ68 GM06974 transformed cell line human CVCL_GQ68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089775 CVCL_GQ61 GM06055 transformed cell line human CVCL_GQ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089776 CVCL_H261 hESO-ST4 embryonic stem cell human CVCL_H261 CL:0000010 Male 21089777 CVCL_GQ62 GM06107 transformed cell line human CVCL_GQ62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089778 CVCL_H262 hESO-ST5 embryonic stem cell human CVCL_H262 CL:0000010 Female 21089779 CVCL_GQ63 GM06128 transformed cell line human CVCL_GQ63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089780 CVCL_H263 hESO-ST6 embryonic stem cell human CVCL_H263 CL:0000010 Karyotypic information: Has a triploid karyotype. Female 21089781 CVCL_GQ64 GM06139 transformed cell line human CVCL_GQ64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089782 CVCL_H264 hESO-ST7 embryonic stem cell human CVCL_H264 CL:0000010 Male 21089783 CVCL_GQ60 GM06054 transformed cell line human CVCL_GQ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089784 CVCL_H260 hESO-ST3 embryonic stem cell human CVCL_H260 CL:0000010 Female 21089785 CVCL_GQ36 GM04986 transformed cell line human CVCL_GQ36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089786 CVCL_H236 NG-3Y1-D303 transformed cell line Norway rat CVCL_H236 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089787 CVCL_GQ37 GM04996 transformed cell line human CVCL_GQ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089788 CVCL_H237 NG-3Y1-T18D transformed cell line Norway rat CVCL_H237 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089789 CVCL_GQ38 GM05134 transformed cell line human CVCL_GQ38 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089790 CVCL_H238 HTAU transformed cell line house mouse CVCL_H238 CL:0000010 Transfected with: HGNC; 6893; MAPT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; cerebral cortex Cell type=Neuron.; Breed/subspecies: BALB/c. Unspecified 21089791 CVCL_GQ39 GM05135 transformed cell line human CVCL_GQ39 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089792 CVCL_H239 SV-JD transformed cell line human CVCL_H239 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 21089793 CVCL_H232 E1A-3Y1-3 transformed cell line Norway rat CVCL_H232 CL:0000010 Transformant: Adenovirus 12 [E1A](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089794 CVCL_GQ32 GM04952 transformed cell line human CVCL_GQ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089795 CVCL_H233 Ad12-3Y1-W5 transformed cell line Norway rat CVCL_H233 CL:0000010 Transformant: Adenovirus 12(NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089796 CVCL_GQ33 GM04972 transformed cell line human CVCL_GQ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089797 CVCL_H234 Ad12-3Y1-Z11 transformed cell line Norway rat CVCL_H234 CL:0000010 Transformant: Adenovirus 12(NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089798 CVCL_GQ34 GM04984 transformed cell line human CVCL_GQ34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089799 CVCL_H235 Ad12-3Y1-Z13 transformed cell line Norway rat CVCL_H235 CL:0000010 Transformant: Adenovirus 12(NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089800 CVCL_GQ35 GM04985 transformed cell line human CVCL_GQ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089801 CVCL_H230 3Y1-B clone 1-6-2 spontaneously immortalized cell line Norway rat CVCL_H230 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089802 CVCL_GQ30 GM04949 transformed cell line human CVCL_GQ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089803 CVCL_H231 E1A-3Y1-2 transformed cell line Norway rat CVCL_H231 CL:0000010 Transformant: Adenovirus 12 [E1A](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21089804 CVCL_GQ31 GM04950 transformed cell line human CVCL_GQ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089805 CVCL_H247 CMS-5 cancer cell line house mouse CVCL_H247 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. 21089806 CVCL_GQ47 GM05222 finite cell line human CVCL_GQ47 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Discontinued: Coriell; GM05222; probable Male 21089807 CVCL_H248 CMS cancer cell line human CVCL_H248 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 42 hours (DOI=10.1016/B978-0-12-221970-2.50457-5) 21089808 CVCL_GQ48 GM05224 finite cell line human CVCL_GQ48 CL:0000010 Population: Caucasian; Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089809 CVCL_GQ49 GM05225 finite cell line human CVCL_GQ49 CL:0000010 Population: Caucasian; Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089810 CVCL_GQ43 GM05218 finite cell line human CVCL_GQ43 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089811 CVCL_H243 HS-72 hybridoma house mouse CVCL_H243 CL:0000010 Monoclonal antibody isotype: IgM. 21089812 CVCL_GQ44 GM05219 finite cell line human CVCL_GQ44 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089813 CVCL_H244 RPMI-3460/CM1 cancer cell line CVCL_H244 CL:0000010 Male 21089814 CVCL_GQ45 GM05220 finite cell line human CVCL_GQ45 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089815 CVCL_H245 RPMI-3460/CS1 cancer cell line CVCL_H245 CL:0000010 Male 21089816 CVCL_H246 CM cancer cell line human CVCL_H246 CL:0000010 Derived from metastatic site: Ascites. Female 21089817 CVCL_GQ46 GM05221 finite cell line human CVCL_GQ46 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Male 21089818 CVCL_GQ40 GM05215 finite cell line human CVCL_GQ40 CL:0000010 Population: Caucasian; Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089819 CVCL_H240 SV6-1 Bam/HFK transformed cell line human CVCL_H240 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21089820 CVCL_GQ41 GM05216 finite cell line human CVCL_GQ41 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089821 CVCL_H241 MM-AN cancer cell line human CVCL_H241 CL:0000010 Derived from metastatic site: Inguinal lymph node. Unspecified 21089822 CVCL_GQ42 GM05217 finite cell line human CVCL_GQ42 CL:0000010 Derived from sampling site: Posterior iliac crest; skin Cell type=Fibroblast.. Female 21089823 CVCL_H242 MM-RU cancer cell line human CVCL_H242 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714) Derived from metastatic site: Cervical lymph node. Omics: Array-based CGH Male 21089824 CVCL_YD31 SNU-2627 cancer cell line human CVCL_YD31 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 40 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089825 CVCL_YD32 SNU-2637 cancer cell line human CVCL_YD32 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 30 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089826 CVCL_YD33 SNU-2641 cancer cell line human CVCL_YD33 CL:0000010 Sequence variation: Mutation; HGNC; 9668; PTPRD; Simple; p.Cys1668Ter (c.5004T>A); Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 44 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089827 CVCL_YD34 SNU-2643 cancer cell line human CVCL_YD34 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 27 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089828 CVCL_YD30 SNU-2612A cancer cell line human CVCL_YD30 CL:0000010 Sequence variation: Gene fusion; HGNC; 6324; KIF5B + HGNC; 9967; RET; Name(s)=KIF5B-RET (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 39 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089829 CVCL_YD39 SNU-2708.1 cancer cell line human CVCL_YD39 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Part of: Seoul National University (SNU) cell line collection 21089830 CVCL_YD35 SNU-2657 cancer cell line human CVCL_YD35 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 27 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089831 CVCL_YD36 SNU-2681 cancer cell line human CVCL_YD36 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (CelloPub=CLPUB00546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 34 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089832 CVCL_YD37 SNU-2689 cancer cell line human CVCL_YD37 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 25 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089833 CVCL_YD38 SNU-2693 cancer cell line human CVCL_YD38 CL:0000010 Sequence variation: Mutation; HGNC; 8592; PAK3; Simple; p.Glu480Ter (c.1438G>T); Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 34 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089834 CVCL_YD20 CHO-K1 Dd-B7/GLT-1 spontaneously immortalized cell line CVCL_YD20 CL:0000010 Transfected with: RGD; 3697; Slc1a2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Selected for resistance to: NCIt; C165595; Tritium beta radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21089835 CVCL_YD21 NCC-ESOS1-C1 cancer cell line human CVCL_YD21 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=31625124) Population: Japanese; Derived from metastatic site: Forearm; hypodermis. Female Characteristics: Exhibits invasion capability (PubMed=31625124) Doubling time: ~40 hours (PubMed=31625124); ~24 hours (DOI=10.2198/jelectroph.65.1) Part of: NCC sarcoma cell line panel 21089836 CVCL_YD22 SNU-2550 cancer cell line human CVCL_YD22 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 32 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089837 CVCL_YD23 SNU-2553 cancer cell line human CVCL_YD23 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 61 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089838 CVCL_YD28 SNU-2589 cancer cell line human CVCL_YD28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 33 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089839 CVCL_YD29 SNU-2606 cancer cell line human CVCL_YD29 CL:0000010 Sequence variation: Gene fusion; HGNC; 1697; CD74 + HGNC; 10261; ROS1; Name(s)=CD74-ROS1 (CelloPub=CLPUB00546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 28 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089840 CVCL_PJ90 BayGenomics ES cell line XC331 embryonic stem cell house mouse CVCL_PJ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107163; Ppp3cb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089841 CVCL_YD24 SNU-2556 cancer cell line human CVCL_YD24 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 35 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089842 CVCL_PJ91 BayGenomics ES cell line XC333 embryonic stem cell house mouse CVCL_PJ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914320; Lsm14a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089843 CVCL_YD25 SNU-2563 cancer cell line human CVCL_YD25 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 47 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089844 CVCL_PJ92 BayGenomics ES cell line XC334 embryonic stem cell house mouse CVCL_PJ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089845 CVCL_YD26 SNU-2585 cancer cell line human CVCL_YD26 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 31 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089846 CVCL_PJ93 BayGenomics ES cell line XC335 embryonic stem cell house mouse CVCL_PJ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089847 CVCL_YD27 SNU-2588 cancer cell line human CVCL_YD27 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 39 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21089848 CVCL_PJ94 BayGenomics ES cell line XC337 embryonic stem cell house mouse CVCL_PJ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99833; Rab23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089849 CVCL_PJ95 BayGenomics ES cell line XC338 embryonic stem cell house mouse CVCL_PJ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99532; Mef2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089850 CVCL_PJ96 BayGenomics ES cell line XC339 embryonic stem cell house mouse CVCL_PJ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142567; Arhgef18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089851 CVCL_PJ97 BayGenomics ES cell line XC341 embryonic stem cell house mouse CVCL_PJ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089852 CVCL_PJ98 BayGenomics ES cell line XC343 embryonic stem cell house mouse CVCL_PJ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442401; Ppp1r9a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089853 CVCL_PJ99 BayGenomics ES cell line XC345 embryonic stem cell house mouse CVCL_PJ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089854 CVCL_YD10 SSN-1 clone A-6 spontaneously immortalized cell line CVCL_YD10 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 20 and 25 Celsius; Virology: Highly susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Also susceptible but to a less extent to infection by barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). Group: Fish cell line 21089855 CVCL_YD11 SSN-1 clone B-7 spontaneously immortalized cell line CVCL_YD11 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 20 and 25 Celsius; Virology: Not susceptible to infection by barfin flounder nervous necrosis virus (BFNNV), redspotted grouper nervous necrosis virus (RGNNV), striped jack nervous necrosis virus (SJNNV) and tiger puffer nervous necrosis virus (TPNNV) Group: Fish cell line 21089856 CVCL_YD12 SSN-1 clone C-3 spontaneously immortalized cell line CVCL_YD12 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 25 Celsius but not at 20 Celsius; Virology: Highly susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Not susceptible to infection by barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). Group: Fish cell line 21089857 CVCL_YD17 CHO-K1 Dd-B7 spontaneously immortalized cell line CVCL_YD17 CL:0000010 Selected for resistance to: NCIt; C165595; Tritium beta radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Lacks Na+-dependent glutamate transport activity; Characteristics: Selection is effected by tritium suicide selection Mutagenized cells are bathed in tritiated D-aspartate and stored so as to allow time for cells that had taken up the D-aspartate to be killed by radiation damage. 21089858 CVCL_YD18 CHO-K1 Ed-A1 spontaneously immortalized cell line CVCL_YD18 CL:0000010 Selected for resistance to: NCIt; C165595; Tritium beta radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Has reduced Na+-dependent glutamate transport activity Have an increased permeability to small neutral molecules.; Characteristics: Selection is effected by tritium suicide selection Mutagenized cells are bathed in tritiated D-aspartate and stored so as to allow time for cells that had taken up the D-aspartate to be killed by radiation damage. 21089859 CVCL_YD19 CHO-K1 Ed-B8 spontaneously immortalized cell line CVCL_YD19 CL:0000010 Selected for resistance to: NCIt; C165595; Tritium beta radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Has reduced Na+-dependent glutamate transport activity Have an increased permeability to small neutral molecules.; Characteristics: Selection is effected by tritium suicide selection Mutagenized cells are bathed in tritiated D-aspartate and stored so as to allow time for cells that had taken up the D-aspartate to be killed by radiation damage. 21089861 CVCL_PJ80 BayGenomics ES cell line XC306 embryonic stem cell house mouse CVCL_PJ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089862 CVCL_YD14 SSN-1 clone E-2 spontaneously immortalized cell line CVCL_YD14 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 20 and 25 Celsius; Virology: Highly susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Also susceptible but to a less extent to infection by barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). Group: Fish cell line 21089863 CVCL_PJ81 BayGenomics ES cell line XC310 embryonic stem cell house mouse CVCL_PJ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089864 CVCL_YD15 SSN-1 clone E-9 spontaneously immortalized cell line CVCL_YD15 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 20 and 25 Celsius; Virology: Highly susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Also susceptible but to a less extent to infection by barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). Group: Fish cell line 21089865 CVCL_PJ82 BayGenomics ES cell line XC311 embryonic stem cell house mouse CVCL_PJ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089866 CVCL_YD16 CHO-K1 Dd-B6 spontaneously immortalized cell line CVCL_YD16 CL:0000010 Selected for resistance to: NCIt; C165595; Tritium beta radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Lacks Na+-dependent glutamate transport activity; Characteristics: Selection is effected by tritium suicide selection Mutagenized cells are bathed in tritiated D-aspartate and stored so as to allow time for cells that had taken up the D-aspartate to be killed by radiation damage. 21089867 CVCL_PJ83 BayGenomics ES cell line XC313 embryonic stem cell house mouse CVCL_PJ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143362; Zfp809 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089868 CVCL_PJ84 BayGenomics ES cell line XC314 embryonic stem cell house mouse CVCL_PJ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88494; Creb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089869 CVCL_PJ85 BayGenomics ES cell line XC316 embryonic stem cell house mouse CVCL_PJ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089870 CVCL_PJ86 BayGenomics ES cell line XC322 embryonic stem cell house mouse CVCL_PJ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:91860; Dcaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089871 CVCL_PJ87 BayGenomics ES cell line XC324 embryonic stem cell house mouse CVCL_PJ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089872 CVCL_PJ88 BayGenomics ES cell line XC326 embryonic stem cell house mouse CVCL_PJ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089873 CVCL_PJ89 BayGenomics ES cell line XC327 embryonic stem cell house mouse CVCL_PJ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089874 CVCL_PJ69 BayGenomics ES cell line XC294 embryonic stem cell house mouse CVCL_PJ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102774; Aimp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089875 CVCL_YD00 TiBC spontaneously immortalized cell line CVCL_YD00 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201829 21089876 CVCL_YD01 OreniImMac transformed cell line CVCL_YD01 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peritoneal effusion. Unspecified Group: Fish cell line 21089877 CVCL_YD06 TG spontaneously immortalized cell line CVCL_YD06 CL:0000010 Derived from sampling site: Gill. Unspecified Characteristics: Grows well from 25 to 32 Celsius, the optimal growth temperature is 28 Celsius; Virology: Highly susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line 21089878 CVCL_YD07 TH [Tilapia] spontaneously immortalized cell line CVCL_YD07 CL:0000010 Derived from sampling site: Heart. Unspecified Characteristics: Grows well from 25 to 32 Celsius, the optimal growth temperature is 28 Celsius; Virology: Highly susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line 21089879 CVCL_YD08 GB11 spontaneously immortalized cell line CVCL_YD08 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by megalocytivirus OSGIV-HN11, ranavirus-type grouper iridovirus GIV-R-SY1301 and red-spotted grouper nervous necrosis virus (RGNNV) Group: Fish cell line 21089880 CVCL_YD09 BEF-1 spontaneously immortalized cell line CVCL_YD09 CL:0000010 Unspecified Group: Fish cell line. 21089881 CVCL_YD02 MBCs spontaneously immortalized cell line CVCL_YD02 CL:0000010 Derived from sampling site: Bone. Unspecified Group: Fish cell line 21089882 CVCL_YD03 MFE spontaneously immortalized cell line CVCL_YD03 CL:0000010 Unspecified Group: Fish cell line. 21089883 CVCL_PJ70 BayGenomics ES cell line XC295 embryonic stem cell house mouse CVCL_PJ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089884 CVCL_YD04 CAMK spontaneously immortalized cell line CVCL_YD04 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201994 21089885 CVCL_PJ71 BayGenomics ES cell line XC296 embryonic stem cell house mouse CVCL_PJ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089886 CVCL_YD05 TE spontaneously immortalized cell line CVCL_YD05 CL:0000010 Derived from sampling site: Eye. Unspecified Characteristics: Grows well from 25 to 32 Celsius, the optimal growth temperature is 28 Celsius Group: Fish cell line 21089887 CVCL_PJ72 BayGenomics ES cell line XC297 embryonic stem cell house mouse CVCL_PJ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926162; Sp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089888 CVCL_PJ73 BayGenomics ES cell line XC298 embryonic stem cell house mouse CVCL_PJ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089889 CVCL_PJ74 BayGenomics ES cell line XC299 embryonic stem cell house mouse CVCL_PJ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917720; Rprd1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089890 CVCL_PJ75 BayGenomics ES cell line XC300 embryonic stem cell house mouse CVCL_PJ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928744; Vapb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089891 CVCL_PJ76 BayGenomics ES cell line XC302 embryonic stem cell house mouse CVCL_PJ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103232; Grb10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089892 CVCL_PJ77 BayGenomics ES cell line XC303 embryonic stem cell house mouse CVCL_PJ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089893 CVCL_PJ78 BayGenomics ES cell line XC304 embryonic stem cell house mouse CVCL_PJ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089894 CVCL_PJ79 BayGenomics ES cell line XC305 embryonic stem cell house mouse CVCL_PJ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089895 CVCL_PJ58 BayGenomics ES cell line XC272 embryonic stem cell house mouse CVCL_PJ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333803; Top3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089896 CVCL_PJ59 BayGenomics ES cell line XC277 embryonic stem cell house mouse CVCL_PJ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353418; Pmm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089897 CVCL_PJ60 BayGenomics ES cell line XC281 embryonic stem cell house mouse CVCL_PJ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183454; Rab40c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089898 CVCL_PJ61 BayGenomics ES cell line XC282 embryonic stem cell house mouse CVCL_PJ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103006; Epb41l5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089899 CVCL_PJ62 BayGenomics ES cell line XC283 embryonic stem cell house mouse CVCL_PJ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353418; Pmm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089900 CVCL_PJ63 BayGenomics ES cell line XC285 embryonic stem cell house mouse CVCL_PJ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089901 CVCL_PJ64 BayGenomics ES cell line XC288 embryonic stem cell house mouse CVCL_PJ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089902 CVCL_PJ65 BayGenomics ES cell line XC290 embryonic stem cell house mouse CVCL_PJ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894835; Rbbp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089903 CVCL_PJ66 BayGenomics ES cell line XC291 embryonic stem cell house mouse CVCL_PJ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2651932; Lcorl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089904 CVCL_PJ67 BayGenomics ES cell line XC292 embryonic stem cell house mouse CVCL_PJ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089905 CVCL_PJ68 BayGenomics ES cell line XC293 embryonic stem cell house mouse CVCL_PJ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137706; Actn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089906 CVCL_PJ47 BayGenomics ES cell line XC254 embryonic stem cell house mouse CVCL_PJ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104626; Strbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089907 CVCL_PJ48 BayGenomics ES cell line XC260 embryonic stem cell house mouse CVCL_PJ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141847; Phrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089908 CVCL_PJ49 BayGenomics ES cell line XC262 embryonic stem cell house mouse CVCL_PJ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860611; Pdlim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089909 CVCL_PJ50 BayGenomics ES cell line XC264 embryonic stem cell house mouse CVCL_PJ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089910 CVCL_PJ51 BayGenomics ES cell line XC265 embryonic stem cell house mouse CVCL_PJ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919224; Prmt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089911 CVCL_PJ52 BayGenomics ES cell line XC266 embryonic stem cell house mouse CVCL_PJ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384768; Hectd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089912 CVCL_PJ53 BayGenomics ES cell line XC267 embryonic stem cell house mouse CVCL_PJ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089913 CVCL_PJ54 BayGenomics ES cell line XC268 embryonic stem cell house mouse CVCL_PJ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107887; Gtf3c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089914 CVCL_PJ55 BayGenomics ES cell line XC269 embryonic stem cell house mouse CVCL_PJ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917822; Ipo5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089915 CVCL_PJ56 BayGenomics ES cell line XC270 embryonic stem cell house mouse CVCL_PJ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089916 CVCL_PJ57 BayGenomics ES cell line XC271 embryonic stem cell house mouse CVCL_PJ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108074; Sptlc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089917 CVCL_PJ36 BayGenomics ES cell line XC228 embryonic stem cell house mouse CVCL_PJ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328328; Map7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089918 CVCL_PJ37 BayGenomics ES cell line XC233 embryonic stem cell house mouse CVCL_PJ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089919 CVCL_PJ38 BayGenomics ES cell line XC239 embryonic stem cell house mouse CVCL_PJ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089920 CVCL_PJ39 BayGenomics ES cell line XC240 embryonic stem cell house mouse CVCL_PJ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98345; Snrpd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089921 CVCL_GP99 mpiNSC transformed cell line pig CVCL_GP99 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Neural stem cell.; Breed/subspecies: Miniature pig. Male 21089922 CVCL_H199 SMYM-PRGP cancer cell line human CVCL_H199 CL:0000010 Population: Japanese; Derived from sampling site: Sole; skin. Omics: Array-based CGH; Omics: Deep exome analysis Male Doubling time: 2-4 days (PubMed=17488338) 21089923 CVCL_GP95 HHW1452 hybrid cell line human CVCL_GP95 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089924 CVCL_H195 UTOS-1 cancer cell line human CVCL_H195 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; left humerus. Omics: Array-based CGH Male Doubling time: 40 hours (PubMed=19239720) 21089925 CVCL_GP96 HHW1796 transformed cell line human CVCL_GP96 CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089926 CVCL_GP97 HHW1798 transformed cell line human CVCL_GP97 CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089927 CVCL_H197 RJ002L cancer cell line human CVCL_H197 CL:0000010 21089928 CVCL_GP98 HHW1799 transformed cell line human CVCL_GP98 CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089929 CVCL_H198 MMG1 cancer cell line human CVCL_H198 From: Department of Dermatology, Gifu University; Gifu; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin. Omics: Deep exome analysis Male 21089930 CVCL_H191 GM03336 finite cell line human CVCL_H191 CL:0000010 Population: Caucasian; Derived from sampling site: Amniotic fluid. Female 21089931 CVCL_GP91 HHW1126 hybrid cell line human CVCL_GP91 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089932 CVCL_PJ40 BayGenomics ES cell line XC243 embryonic stem cell house mouse CVCL_PJ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089933 CVCL_H192 GM03502 finite cell line human CVCL_H192 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21089934 CVCL_GP92 HHW1185 hybrid cell line human CVCL_GP92 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089935 CVCL_PJ41 BayGenomics ES cell line XC245 embryonic stem cell house mouse CVCL_PJ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089936 CVCL_GP93 HHW1296 hybrid cell line human CVCL_GP93 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089937 CVCL_H193 YOS-B cancer cell line human CVCL_H193 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1486031; PubMed=10071072) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=1486031) 21089938 CVCL_PJ42 BayGenomics ES cell line XC246 embryonic stem cell house mouse CVCL_PJ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919806; Zfp566 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089939 CVCL_GP94 HHW1372 hybrid cell line human CVCL_GP94 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089940 CVCL_H194 YOS-M cancer cell line human CVCL_H194 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1486031; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 5-6 days (PubMed=1486031) 21089941 CVCL_PJ43 BayGenomics ES cell line XC247 embryonic stem cell house mouse CVCL_PJ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914852; Necap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089942 CVCL_PJ44 BayGenomics ES cell line XC248 embryonic stem cell house mouse CVCL_PJ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089943 CVCL_PJ45 BayGenomics ES cell line XC249 embryonic stem cell house mouse CVCL_PJ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446163; Fam120a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089944 CVCL_PJ46 BayGenomics ES cell line XC252 embryonic stem cell house mouse CVCL_PJ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089945 CVCL_H190 GM03100 finite cell line human CVCL_H190 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;17)(9qter->9p22::17p11->17pter;17qter->17p11::9p22->9pter)mat (Coriell); Derived from sampling site: Amniotic fluid. Female 21089946 CVCL_GP90 HHW996 hybrid cell line human CVCL_GP90 CL:0000010 Group: Human/rodent somatic cell hybrid. 21089947 CVCL_PJ25 BayGenomics ES cell line XC195 embryonic stem cell house mouse CVCL_PJ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101771; Sntb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089948 CVCL_PJ26 BayGenomics ES cell line XC196 embryonic stem cell house mouse CVCL_PJ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089949 CVCL_PJ27 BayGenomics ES cell line XC197 embryonic stem cell house mouse CVCL_PJ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089950 CVCL_PJ28 BayGenomics ES cell line XC201 embryonic stem cell house mouse CVCL_PJ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925212; Scaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089951 CVCL_PJ29 BayGenomics ES cell line XC204 embryonic stem cell house mouse CVCL_PJ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089952 CVCL_PJ30 BayGenomics ES cell line XC205 embryonic stem cell house mouse CVCL_PJ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387591; Arcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089953 CVCL_PJ31 BayGenomics ES cell line XC209 embryonic stem cell house mouse CVCL_PJ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089954 CVCL_PJ32 BayGenomics ES cell line XC210 embryonic stem cell house mouse CVCL_PJ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914162; Bzw2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089955 CVCL_PJ33 BayGenomics ES cell line XC211 embryonic stem cell house mouse CVCL_PJ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99146; Ybx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089956 CVCL_PJ34 BayGenomics ES cell line XC215 embryonic stem cell house mouse CVCL_PJ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182061; Usp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089957 CVCL_PJ35 BayGenomics ES cell line XC223 embryonic stem cell house mouse CVCL_PJ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138584; Gigyf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21089958 CVCL_YD90 NHLBIi001-A induced pluripotent stem cell human CVCL_YD90 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21089959 CVCL_YD91 NHLBIi001-B induced pluripotent stem cell human CVCL_YD91 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21089960 CVCL_YD92 TOB cancer cell line dog CVCL_YD92 CL:0000010 Derived from metastatic site: Bone; tibia; Breed/subspecies: Neapolitan Mastiff. Female Doubling time: 29.3 hours (PubMed=31640712) 21089961 CVCL_YD97 TNO finite cell line dog CVCL_YD97 CL:0000010 Derived from sampling site: Bone; radius; Breed/subspecies: Labrador Retriever. Female 21089962 CVCL_YD98 DEW1 transformed cell line human CVCL_YD98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089963 CVCL_YD99 BER1 transformed cell line human CVCL_YD99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089964 CVCL_YD93 TOK [Dog] cancer cell line dog CVCL_YD93 CL:0000010 Derived from sampling site: Bone; proximal humerus; Breed/subspecies: Golden Retriever. Male Doubling time: 32.07 hours (PubMed=31640712) 21089965 CVCL_YD94 TOL cancer cell line dog CVCL_YD94 CL:0000010 Derived from sampling site: Bone; distal radius; Breed/subspecies: Saint Bernard. Male Doubling time: 35.7 hours (PubMed=31640712) 21089966 CVCL_YD95 TOM cancer cell line dog CVCL_YD95 CL:0000010 Derived from sampling site: Bone; tibia; Breed/subspecies: Australian cattle dog. Female Doubling time: 34.85 hours (PubMed=31640712) 21089967 CVCL_YD96 TOT cancer cell line dog CVCL_YD96 CL:0000010 Derived from sampling site: Bone; proximal humerus; Breed/subspecies: Greyhound. Female Doubling time: 33.78 hours (PubMed=31640712) 21089968 CVCL_YD80 ABG7 spontaneously immortalized cell line CVCL_YD80 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21089969 CVCL_YD81 OrydaEmb1 spontaneously immortalized cell line CVCL_YD81 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Unspecified Doubling time: 29.84 hours (DOI=10.5657/FAS.2013.0177) Group: Fish cell line 21089970 CVCL_YD86 OrydaEmb1 subline-4 spontaneously immortalized cell line CVCL_YD86 CL:0000010 Unspecified Group: Fish cell line. 21089971 CVCL_YD87 OrydaEmb1 subline-5 spontaneously immortalized cell line CVCL_YD87 CL:0000010 Unspecified Group: Fish cell line. 21089972 CVCL_YD88 VCC1 cancer cell line human CVCL_YD88 CL:0000010 Derived from sampling site: Vulva. Female Doubling time: 18.90 +- 0.53 hours (PubMed=31654625) 21089973 CVCL_YD89 CAMB spontaneously immortalized cell line CVCL_YD89 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Grows well from 22 to 32 Celsius, the optimal growth temperature is 27 Celsius; Virology: Susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line 21089974 CVCL_YD82 OrydaEmb2 spontaneously immortalized cell line CVCL_YD82 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Unspecified Doubling time: 28.59 hours (DOI=10.5657/FAS.2013.0177) Group: Fish cell line 21089975 CVCL_YD83 OrydaEmb1 subline-1 spontaneously immortalized cell line CVCL_YD83 CL:0000010 Unspecified Group: Fish cell line. 21089976 CVCL_YD84 OrydaEmb1 subline-2 spontaneously immortalized cell line CVCL_YD84 CL:0000010 Unspecified Group: Fish cell line. 21089977 CVCL_YD85 OrydaEmb1 subline-3 spontaneously immortalized cell line CVCL_YD85 CL:0000010 Unspecified Group: Fish cell line. 21089978 CVCL_YD70 HEK293 RPS2 WT transformed cell line human CVCL_YD70 CL:0000010 Transfected with: MGI; MGI:105110; Rps2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Metabolome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfected with wildtype Rps2 linked to IRES-eGFP 21089979 CVCL_YD75 UD-SCC-7C cancer cell line human CVCL_YD75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=18487078). 21089980 CVCL_YD76 ABG1 spontaneously immortalized cell line CVCL_YD76 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21089981 CVCL_YD77 ABG3 spontaneously immortalized cell line CVCL_YD77 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21089982 CVCL_YD78 ABG5 spontaneously immortalized cell line CVCL_YD78 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21089983 CVCL_YD71 KHM1106 finite cell line human CVCL_YD71 CL:0000010 Miscellaneous: Age/sex of donor, disease and category of cell line from personal communication of Wittel U.A Derived from sampling site: Pancreas. Omics: Metabolome analysis Male 21089984 CVCL_YD72 endo-iPS 10 induced pluripotent stem cell human CVCL_YD72 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female 21089985 CVCL_YD73 endo-iPS 12 induced pluripotent stem cell human CVCL_YD73 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female 21089986 CVCL_YD74 UD-SCC-8 cancer cell line human CVCL_YD74 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (PubMed=18487078). 21089987 CVCL_YD79 ABG6 spontaneously immortalized cell line CVCL_YD79 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21089988 CVCL_YD64 LCSBi001-A induced pluripotent stem cell human CVCL_YD64 From: Luxembourg Centre for Systems Biomedicine; Belvaux; Luxembourg CL:0000010 Sequence variation: Mutation; HGNC; 13487; VPS35; Simple; p.Asp620Asn (c.1858G>A); ClinVar=VCV000030196; Zygosity=Heterozygous (CelloPub=CLPUB00553; PubMed=32387898) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21089989 CVCL_YD65 KICRi001-A induced pluripotent stem cell human CVCL_YD65 From: Department of Neuroscience, Karolinska Institutet; Stockholm; Sweden. CL:0000010 21089990 CVCL_YD66 FINCBi001-A induced pluripotent stem cell human CVCL_YD66 From: Fondazione IRCCS Istituto Neurologico C Besta; Milan; Italy. CL:0000010 Sequence variation: Mutation; HGNC; 7455; MT-ND1; Simple; p.Ala52Thr (m.3460G>A); ClinVar=VCV000009722; Zygosity=Homoplasmic (PubMed=32771908) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 21089991 CVCL_YD67 SVK-CR2 transformed cell line human CVCL_YD67 CL:0000010 Transfected with: HGNC; 2336; CR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21089992 CVCL_YD60 LUMCi013-A induced pluripotent stem cell human CVCL_YD60 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: While the patient is suffering from facioscapulohumeral muscular dystrophy 1 he is mosaic for the D4Z4 repeat contraction The fibroblast from which this iPSC was derived was normal. 21089993 CVCL_YD61 LUMCi014-A induced pluripotent stem cell human CVCL_YD61 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21089994 CVCL_YD62 LUMCi015-A induced pluripotent stem cell human CVCL_YD62 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of LUMCi016-A (Cellosaurus=CVCL_YD63); Derived from sampling site: Peripheral blood. Female 21089995 CVCL_YD63 LUMCi016-A induced pluripotent stem cell human CVCL_YD63 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of LUMCi015-A (Cellosaurus=CVCL_YD62); Derived from sampling site: Peripheral blood. Female 21089996 CVCL_YD68 SVK-Neo transformed cell line human CVCL_YD68 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21089997 CVCL_YD69 HEK293 RPS2 A226Y transformed cell line human CVCL_YD69 CL:0000010 Transfected with: MGI; MGI:105110; Rps2 (with p.Ala226Tyr); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Metabolome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfected with mutated Rps2 linked to IRES-eGFP 21089998 CVCL_YD53 B-LCL-HROC69 transformed cell line human CVCL_YD53 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21089999 CVCL_YD54 B-LCL-HROC277 transformed cell line human CVCL_YD54 HLA typing: A*02:01:01,32:01:01; B*15:17:01,35:03:01; C*04:01:01,07:01:02; DPB1*02:01:02,350:01; DQA1*01:02:01,05:05:01; DQB1*13:01:01,06:04:01; DRB1*11:01:06,13:02:01 (CLS=300867) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090000 CVCL_YD55 B-LCL-HROC32 transformed cell line human CVCL_YD55 HLA typing: A*01:01:01,02:01:01; B*08:01:01,51:01:01; C*07:01:01,14:02:01; DPB1*01:01:01,04:01:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,11:01:01 (CLS=300862) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090001 CVCL_YD56 B-LCL-HROC39 transformed cell line human CVCL_YD56 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090002 CVCL_YD50 SNU-2563CR cancer cell line human CVCL_YD50 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori); Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Seoul National University (SNU) cell line collection 21090003 CVCL_YD51 SS-2 cancer cell line human CVCL_YD51 CL:0000010 Population: Japanese; Derived from sampling site: Colon; ascending. Female 21090004 CVCL_YD52 B-LCL-HROC113 transformed cell line human CVCL_YD52 HLA typing: A*01:01:01:01,02:01:01:01; B*08:01:01:01,38:01:01:01; C*07:01:01:01,12:03:01:01; DPB1*04:01:01:02,04:01:01:05; DQA1*01:02:01:01,02:01:01:01; DQB1*02:02:01:01,06:02:01:01; DRB1*07:01:01:01,15:01:01:01 (CLS=300898) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090005 CVCL_YD57 B-LCL-HROC24 transformed cell line human CVCL_YD57 HLA typing: A*02:01:01,30:02:01; B*18:01:01,38:01:01; C*05:01:01,12:03:01; DPB1*02:02:01,03:01:01; DQA1*01:03:01,05:01:01; DQB1*02:01:01,06:03:01; DRB1*03:01:01,13:01:01 (CLS=300861) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090006 CVCL_YD58 CRL spontaneously immortalized cell line CVCL_YD58 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.. Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3930 21090007 CVCL_YD59 A110L-B35 cancer cell line human CVCL_YD59 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*35:01); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Lung. Male 21090008 CVCL_YD42 SNU-2749 cancer cell line human CVCL_YD42 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CelloPub=CLPUB00546); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 31 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090009 CVCL_YD43 SNU-2778 cancer cell line human CVCL_YD43 CL:0000010 Sequence variation: Gene fusion; HGNC; 6324; KIF5B + HGNC; 9967; RET; Name(s)=KIF5B-RET (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 35 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090010 CVCL_YD44 SNU-2832 cancer cell line human CVCL_YD44 CL:0000010 Sequence variation: Gene fusion; HGNC; 1697; CD74 + HGNC; 10261; ROS1; Name(s)=CD74-ROS1 (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 25 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090011 CVCL_YD45 SNU-2867 cancer cell line human CVCL_YD45 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Ser752del (c.2239_2256delTTAAGAGAAGCAACATCT); ClinVar=VCV000177647; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 87 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090012 CVCL_YD40 SNU-2727 cancer cell line human CVCL_YD40 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 102 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090013 CVCL_YD41 SNU-2741 cancer cell line human CVCL_YD41 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Thr751del (c.2240_2254delTAAGAGAAGCAACAT); ClinVar=VCV000177649; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 55 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090014 CVCL_YD46 SNU-2887 cancer cell line human CVCL_YD46 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 102 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090015 CVCL_YD47 SNU-2964 cancer cell line human CVCL_YD47 CL:0000010 Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 46 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090016 CVCL_YD48 SNU-3023 cancer cell line human CVCL_YD48 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (CelloPub=CLPUB00546) Population: Korean; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: 29 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21090017 CVCL_YD49 SNU-2550CR cancer cell line human CVCL_YD49 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546) Population: Korean; Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori); Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Seoul National University (SNU) cell line collection 21090018 CVCL_H339 HeLa-CD14 cancer cell line human CVCL_H339 CL:0000010 Transfected with: HGNC; 1628; CD14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21090019 CVCL_GR39 Mel-FC cancer cell line human CVCL_GR39 CL:0000010 Derived from metastatic site: Lymph node. 21090020 CVCL_H335 HGDP01418 transformed cell line human CVCL_H335 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090021 CVCL_GR35 Mel-DA cancer cell line human CVCL_GR35 CL:0000010 Derived from metastatic site: Hypodermis. 21090022 CVCL_H336 HGDP01419 transformed cell line human CVCL_H336 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090023 CVCL_GR36 Mel-BH cancer cell line human CVCL_GR36 CL:0000010 Derived from metastatic site: Hypodermis. 21090024 CVCL_H337 HGDP01026 transformed cell line human CVCL_H337 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090025 CVCL_GR37 Mel-BP cancer cell line human CVCL_GR37 CL:0000010 Derived from metastatic site: Hypodermis. 21090026 CVCL_H338 HGDP01410 transformed cell line human CVCL_H338 CL:0000010 Population: Nilote; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090027 CVCL_GR38 Mel-DH cancer cell line human CVCL_GR38 CL:0000010 Derived from metastatic site: Hypodermis. 21090028 CVCL_GR31 4T1.13 cancer cell line house mouse CVCL_GR31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: High propensity to metastasize spontaneously to bone, causing fractures and/or hindlimb paralysis (ATCC) 21090029 CVCL_H331 HGDP01414 transformed cell line human CVCL_H331 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090030 CVCL_GR32 4T1.2 cancer cell line house mouse CVCL_GR32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: High propensity to metastasize spontaneously to bone, causing fractures and/or hindlimb paralysis (ATCC) 21090031 CVCL_H332 HGDP01415 transformed cell line human CVCL_H332 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090032 CVCL_H333 HGDP01416 transformed cell line human CVCL_H333 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090033 CVCL_GR33 Mel-DP cancer cell line human CVCL_GR33 CL:0000010 Derived from metastatic site: Lymph node. 21090034 CVCL_H334 HGDP01417 transformed cell line human CVCL_H334 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090035 CVCL_GR34 Mel-WN cancer cell line human CVCL_GR34 CL:0000010 Derived from metastatic site: Lymph node. 21090036 CVCL_H330 HGDP01413 transformed cell line human CVCL_H330 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090037 CVCL_GR30 MM96 1 TgR cancer cell line human CVCL_GR30 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Lymph node. Female 21090038 CVCL_GR46 IGR-4 cancer cell line human CVCL_GR46 CL:0000010 Derived from sampling site: Skin. Male 21090039 CVCL_H346 MC615 4D5 transformed cell line house mouse CVCL_H346 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090040 CVCL_GR47 JD-MEL cancer cell line human CVCL_GR47 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female Doubling time: ~48 hours (at 7th passage), ~24 hours (at 41th passage) (PubMed=7453182) 21090041 CVCL_H347 MC615 4D7 transformed cell line house mouse CVCL_H347 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090042 CVCL_GR48 IPC-501 cancer cell line human CVCL_GR48 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Characteristics: Pigmented 21090043 CVCL_H348 MC615 4E3 transformed cell line house mouse CVCL_H348 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090044 CVCL_GR49 IPC-502 cancer cell line human CVCL_GR49 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21090045 CVCL_H349 MC615 4F6 transformed cell line house mouse CVCL_H349 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090046 CVCL_H342 MC615 4C1 transformed cell line house mouse CVCL_H342 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090047 CVCL_GR42 Mel-NG cancer cell line human CVCL_GR42 CL:0000010 Derived from metastatic site: Hypodermis. 21090049 CVCL_H343 MC615 4C3 transformed cell line house mouse CVCL_H343 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090050 CVCL_H344 MC615 4C6 transformed cell line house mouse CVCL_H344 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090051 CVCL_GR44 Mel-FHH cancer cell line human CVCL_GR44 CL:0000010 Derived from metastatic site: Lymph node. 21090052 CVCL_H345 MC615 4C9 transformed cell line house mouse CVCL_H345 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090053 CVCL_GR45 Mel-WD cancer cell line human CVCL_GR45 CL:0000010 Derived from metastatic site: Hypodermis. 21090054 CVCL_H340 CHO-A7 spontaneously immortalized cell line CVCL_H340 CL:0000010 Derived from sampling site: Ovary. Female 21090055 CVCL_GR40 Mel-JW cancer cell line human CVCL_GR40 CL:0000010 Derived from metastatic site: Hypodermis. 21090056 CVCL_H341 MC615 4B5 transformed cell line house mouse CVCL_H341 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090057 CVCL_GR41 Mel-JN cancer cell line human CVCL_GR41 CL:0000010 Derived from metastatic site: Lymph node. 21090058 CVCL_H317 HGDP01397 transformed cell line human CVCL_H317 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090059 CVCL_GR17 PB11 induced pluripotent stem cell human CVCL_GR17 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. 21090060 CVCL_H318 HGDP01398 transformed cell line human CVCL_H318 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090061 CVCL_GR18 PB17 induced pluripotent stem cell human CVCL_GR18 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood Cell type=Endothelial progenitor cell.. 21090062 CVCL_H319 HGDP01399 transformed cell line human CVCL_H319 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090063 CVCL_GR19 PB30 induced pluripotent stem cell human CVCL_GR19 From: Universite Paris-Sud 11; Paris; France. CL:0000010 21090064 CVCL_GR13 GM08196 transformed cell line human CVCL_GR13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090065 CVCL_H313 HGDP01386 transformed cell line human CVCL_H313 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090066 CVCL_GR14 GM08197 finite cell line human CVCL_GR14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090067 CVCL_H314 HGDP01387 transformed cell line human CVCL_H314 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090068 CVCL_GR15 GM11899 transformed cell line human CVCL_GR15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090069 CVCL_H315 HGDP01388 transformed cell line human CVCL_H315 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090070 CVCL_GR16 GM12127 transformed cell line human CVCL_GR16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090071 CVCL_H316 HGDP01396 transformed cell line human CVCL_H316 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090072 CVCL_GR10 GM07395 finite cell line human CVCL_GR10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090073 CVCL_H310 HGDP01383 transformed cell line human CVCL_H310 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090074 CVCL_GR11 GM07781 finite cell line human CVCL_GR11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090075 CVCL_H311 HGDP01384 transformed cell line human CVCL_H311 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090076 CVCL_GR12 GM07892 finite cell line human CVCL_GR12 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Unexplicit; Exon 41 acceptor site T>C substitution; Zygosity=Heterozygous (PubMed=25187577) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21090077 CVCL_H312 HGDP01385 transformed cell line human CVCL_H312 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090078 CVCL_H328 HGDP01411 transformed cell line human CVCL_H328 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090079 CVCL_GR28 MM339 cancer cell line human CVCL_GR28 CL:0000010 Derived from metastatic site: Not specified. Male 21090080 CVCL_H329 HGDP01412 transformed cell line human CVCL_H329 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090081 CVCL_GR29 MM344 cancer cell line human CVCL_GR29 CL:0000010 Derived from metastatic site: Not specified. Male 21090082 CVCL_H324 HGDP01404 transformed cell line human CVCL_H324 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090083 CVCL_GR24 PB32 induced pluripotent stem cell human CVCL_GR24 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21090084 CVCL_H325 HGDP01405 transformed cell line human CVCL_H325 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090085 CVCL_GR25 PB32-1 induced pluripotent stem cell human CVCL_GR25 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21090086 CVCL_H326 HGDP01406 transformed cell line human CVCL_H326 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090087 CVCL_GR26 PB32-4 induced pluripotent stem cell human CVCL_GR26 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21090088 CVCL_H327 HGDP01408 transformed cell line human CVCL_H327 CL:0000010 Population: African; Bantu N.E; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090089 CVCL_GR27 PB32-5 induced pluripotent stem cell human CVCL_GR27 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21090090 CVCL_H320 HGDP01400 transformed cell line human CVCL_H320 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090091 CVCL_GR20 PB33 induced pluripotent stem cell human CVCL_GR20 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Bone marrow. 21090092 CVCL_H321 HGDP01401 transformed cell line human CVCL_H321 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090093 CVCL_GR21 iPS-MSC-SA01 induced pluripotent stem cell human CVCL_GR21 From: Universite Paris-Sud 11; Paris; France. CL:0000010 Male 21090094 CVCL_H322 HGDP01402 transformed cell line human CVCL_H322 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090095 CVCL_GR22 iPS-MSC-H9 somatic stem cell human CVCL_GR22 From: Universite Paris-Sud 11; Paris; France. CL:0000010 Female 21090096 CVCL_GR23 EO771 cancer cell line house mouse CVCL_GR23 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6. Female Characteristics: Belongs to the luminal subtype B; ERalpha-, ERbeta+, PR+ and ErbB2+ (PubMed=32699527) 21090097 CVCL_H323 HGDP01403 transformed cell line human CVCL_H323 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090098 CVCL_GR06 GM07379 finite cell line human CVCL_GR06 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090099 CVCL_H306 HGDP01379 transformed cell line human CVCL_H306 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090100 CVCL_GR07 GM07392 transformed cell line human CVCL_GR07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090101 CVCL_H307 HGDP01380 transformed cell line human CVCL_H307 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090102 CVCL_GR08 GM07393 finite cell line human CVCL_GR08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090103 CVCL_H308 HGDP01381 transformed cell line human CVCL_H308 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090104 CVCL_GR09 GM07394 transformed cell line human CVCL_GR09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090105 CVCL_H309 HGDP01382 transformed cell line human CVCL_H309 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090106 CVCL_GR02 GM07320 finite cell line human CVCL_GR02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM07320; probable Female 21090107 CVCL_H302 HGDP01375 transformed cell line human CVCL_H302 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090108 CVCL_GR03 GM07324 transformed cell line human CVCL_GR03 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090109 CVCL_H303 HGDP01376 transformed cell line human CVCL_H303 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090110 CVCL_GR04 GM07325 finite cell line human CVCL_GR04 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21090111 CVCL_H304 HGDP01377 transformed cell line human CVCL_H304 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090112 CVCL_GR05 GM07378 transformed cell line human CVCL_GR05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090113 CVCL_H305 HGDP01378 transformed cell line human CVCL_H305 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090114 CVCL_GR00 GM07278 transformed cell line human CVCL_GR00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090115 CVCL_H300 HGDP01373 transformed cell line human CVCL_H300 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090116 CVCL_GR01 GM07279 finite cell line human CVCL_GR01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090117 CVCL_H301 HGDP01374 transformed cell line human CVCL_H301 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21090118 CVCL_PL56 BayGenomics ES cell line XD185 embryonic stem cell house mouse CVCL_PL56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090119 CVCL_PL57 BayGenomics ES cell line XD186 embryonic stem cell house mouse CVCL_PL57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922246; Usp47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090120 CVCL_PL58 BayGenomics ES cell line XD191 embryonic stem cell house mouse CVCL_PL58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916249; Anapc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090121 CVCL_PL59 BayGenomics ES cell line XD200 embryonic stem cell house mouse CVCL_PL59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919204; Suds3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090122 CVCL_PL60 BayGenomics ES cell line XE001 embryonic stem cell house mouse CVCL_PL60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277172; Ddx56 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090123 CVCL_PL61 BayGenomics ES cell line XE002 embryonic stem cell house mouse CVCL_PL61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090124 CVCL_PL62 BayGenomics ES cell line XE003 embryonic stem cell house mouse CVCL_PL62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090125 CVCL_PL63 BayGenomics ES cell line XE004 embryonic stem cell house mouse CVCL_PL63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090126 CVCL_PL64 BayGenomics ES cell line XE005 embryonic stem cell house mouse CVCL_PL64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923264; Zc3h18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090127 CVCL_PL65 BayGenomics ES cell line XE006 embryonic stem cell house mouse CVCL_PL65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351502; Nup50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090128 CVCL_PL66 BayGenomics ES cell line XE009 embryonic stem cell house mouse CVCL_PL66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090129 CVCL_PL45 BayGenomics ES cell line XD151 embryonic stem cell house mouse CVCL_PL45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090130 CVCL_PL46 BayGenomics ES cell line XD155 embryonic stem cell house mouse CVCL_PL46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090131 CVCL_PL47 BayGenomics ES cell line XD156 embryonic stem cell house mouse CVCL_PL47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914535; Cwc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090132 CVCL_PL48 BayGenomics ES cell line XD158 embryonic stem cell house mouse CVCL_PL48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442153; Gak Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090133 CVCL_PL49 BayGenomics ES cell line XD161 embryonic stem cell house mouse CVCL_PL49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090134 CVCL_PL50 BayGenomics ES cell line XD164 embryonic stem cell house mouse CVCL_PL50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090135 CVCL_PL51 BayGenomics ES cell line XD165 embryonic stem cell house mouse CVCL_PL51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916832; Plekhm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090136 CVCL_PL52 BayGenomics ES cell line XD170 embryonic stem cell house mouse CVCL_PL52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921443; Ccdc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090137 CVCL_PL53 BayGenomics ES cell line XD177 embryonic stem cell house mouse CVCL_PL53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915308; Chd1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090138 CVCL_PL54 BayGenomics ES cell line XD183 embryonic stem cell house mouse CVCL_PL54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343094; Kat2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090139 CVCL_PL55 BayGenomics ES cell line XD184 embryonic stem cell house mouse CVCL_PL55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918779; Kazn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090140 CVCL_PL34 BayGenomics ES cell line XD125 embryonic stem cell house mouse CVCL_PL34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919455; Eml2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090141 CVCL_PL35 BayGenomics ES cell line XD127 embryonic stem cell house mouse CVCL_PL35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448476; Smagp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090142 CVCL_PL36 BayGenomics ES cell line XD130 embryonic stem cell house mouse CVCL_PL36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090143 CVCL_PL37 BayGenomics ES cell line XD135 embryonic stem cell house mouse CVCL_PL37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915815; Mrps18a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090144 CVCL_PL38 BayGenomics ES cell line XD137 embryonic stem cell house mouse CVCL_PL38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915815; Mrps18a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090145 CVCL_PL39 BayGenomics ES cell line XD139 embryonic stem cell house mouse CVCL_PL39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090146 CVCL_H397 CHO-K1/AM2/Galpha15 spontaneously immortalized cell line CVCL_H397 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9845; RAMP3; Transfected with: HGNC; 4383; GNA15 Miscellaneous: Cell line under development; catalog number M00479 Derived from sampling site: Ovary. Female 21090147 CVCL_GR97 GM02440 finite cell line human CVCL_GR97 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Cell type=Fibroblast. Male 21090148 CVCL_H398 CHO-K1/AMY1/CRE-Luc spontaneously immortalized cell line CVCL_H398 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9843; RAMP1; Transfected with: UniProtKB; P08659; Firefly luciferase Miscellaneous: Cell line under development; catalog number M00350 Derived from sampling site: Ovary. Female 21090149 CVCL_GR98 GM02442 finite cell line human CVCL_GR98 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Cell type=Fibroblast. Female 21090150 CVCL_H399 CHO-K1/AMY1/Galpha15 spontaneously immortalized cell line CVCL_H399 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9843; RAMP1 Derived from sampling site: Ovary. Female 21090151 CVCL_GR99 GM02556 finite cell line human CVCL_GR99 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Cell type=Fibroblast. Female 21090152 CVCL_H393 CHO-K1/ADRB1/Galpha15 spontaneously immortalized cell line CVCL_H393 CL:0000010 Transfected with: HGNC; 285; ADRB1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090153 CVCL_GR93 GM01873 finite cell line human CVCL_GR93 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090154 CVCL_H394 CHO-K1/ADRB2/Galpha15 spontaneously immortalized cell line CVCL_H394 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00308 Female 21090155 CVCL_GR94 GM01905 transformed cell line human CVCL_GR94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090156 CVCL_H395 CHO-K1/AGTRL1/Galpha15 spontaneously immortalized cell line CVCL_H395 CL:0000010 Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090157 CVCL_GR95 GM01909 finite cell line human CVCL_GR95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090158 CVCL_H396 CHO-K1/AM1 spontaneously immortalized cell line CVCL_H396 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9844; RAMP2 Miscellaneous: Cell line under development; catalog number M00450 Derived from sampling site: Ovary. Female 21090159 CVCL_GR96 GM01911 finite cell line human CVCL_GR96 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090160 CVCL_GR90 AG09388 transformed cell line human CVCL_GR90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090161 CVCL_H390 CHO-K1/ADRA2A/Galpha15 spontaneously immortalized cell line CVCL_H390 CL:0000010 Transfected with: HGNC; 281; ADRA2A; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090162 CVCL_H391 CHO-K1/ADRA2B/Gqi5 spontaneously immortalized cell line CVCL_H391 CL:0000010 Transfected with: HGNC; 282; ADRA2B; Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1) Derived from sampling site: Ovary. Female 21090163 CVCL_GR91 GM00609 finite cell line human CVCL_GR91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090164 CVCL_PL40 BayGenomics ES cell line XD140 embryonic stem cell house mouse CVCL_PL40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090165 CVCL_H392 CHO-K1/ADRA2C/Galpha15 spontaneously immortalized cell line CVCL_H392 CL:0000010 Transfected with: HGNC; 283; ADRA2C; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090166 CVCL_GR92 GM01872 finite cell line human CVCL_GR92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090167 CVCL_PL41 BayGenomics ES cell line XD141 embryonic stem cell house mouse CVCL_PL41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913355; Ube2d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090168 CVCL_PL42 BayGenomics ES cell line XD143 embryonic stem cell house mouse CVCL_PL42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090169 CVCL_PL43 BayGenomics ES cell line XD148 embryonic stem cell house mouse CVCL_PL43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346040; Mpdu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090170 CVCL_PL44 BayGenomics ES cell line XD150 embryonic stem cell house mouse CVCL_PL44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929261; Mtch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090171 CVCL_PL23 BayGenomics ES cell line XD107 embryonic stem cell house mouse CVCL_PL23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915363; Cops8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090172 CVCL_PL24 BayGenomics ES cell line XD108 embryonic stem cell house mouse CVCL_PL24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090173 CVCL_PL25 BayGenomics ES cell line XD109 embryonic stem cell house mouse CVCL_PL25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859026; Cnot4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090174 CVCL_PL26 BayGenomics ES cell line XD111 embryonic stem cell house mouse CVCL_PL26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926953; Ctdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090175 CVCL_PL27 BayGenomics ES cell line XD114 embryonic stem cell house mouse CVCL_PL27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090176 CVCL_PL28 BayGenomics ES cell line XD117 embryonic stem cell house mouse CVCL_PL28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090177 CVCL_PL29 BayGenomics ES cell line XD118 embryonic stem cell house mouse CVCL_PL29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090178 CVCL_PL30 BayGenomics ES cell line XD120 embryonic stem cell house mouse CVCL_PL30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682313; Zfp335 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090179 CVCL_PL31 BayGenomics ES cell line XD121 embryonic stem cell house mouse CVCL_PL31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924483; Fam118b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090180 CVCL_PL32 BayGenomics ES cell line XD123 embryonic stem cell house mouse CVCL_PL32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104583; Eps15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090181 CVCL_PL33 BayGenomics ES cell line XD124 embryonic stem cell house mouse CVCL_PL33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445126; Tut4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090182 CVCL_PL12 BayGenomics ES cell line XD093 embryonic stem cell house mouse CVCL_PL12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107708; Ss18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090183 CVCL_PL13 BayGenomics ES cell line XD094 embryonic stem cell house mouse CVCL_PL13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87978; Ak2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090184 CVCL_PL14 BayGenomics ES cell line XD095 embryonic stem cell house mouse CVCL_PL14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919908; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090185 CVCL_PL15 BayGenomics ES cell line XD096 embryonic stem cell house mouse CVCL_PL15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298224; Pip5k1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090186 CVCL_PL16 BayGenomics ES cell line XD099 embryonic stem cell house mouse CVCL_PL16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914631; Med4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090187 CVCL_PL17 BayGenomics ES cell line XD100 embryonic stem cell house mouse CVCL_PL17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443390; Lrch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090188 CVCL_PL18 BayGenomics ES cell line XD102 embryonic stem cell house mouse CVCL_PL18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090189 CVCL_PL19 BayGenomics ES cell line XD103 embryonic stem cell house mouse CVCL_PL19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090190 CVCL_GR79 1174-mel cancer cell line human CVCL_GR79 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser31Ter (c.92C>G); Zygosity=Unspecified (PubMed=15661905) Derived from metastatic site: Hypodermis. Male 21090191 CVCL_H379 CHO-K1/5-HT2A spontaneously immortalized cell line CVCL_H379 CL:0000010 Transfected with: HGNC; 5293; HTR2A Derived from sampling site: Ovary. Female 21090192 CVCL_H375 293/TP transformed cell line human CVCL_H375 CL:0000010 Transfected with: HGNC; 11608; TBXA2R Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090193 CVCL_GR75 GD25T transformed cell line house mouse CVCL_GR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Breed/subspecies: 129S2/SvPas. Male 21090194 CVCL_H376 293T/AT1 transformed cell line human CVCL_H376 CL:0000010 Transfected with: HGNC; 336; AGTR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21090195 CVCL_GR76 586-EBV transformed cell line human CVCL_GR76 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090196 CVCL_GR77 1074-mel cancer cell line human CVCL_GR77 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000376368; Zygosity=Unspecified (PubMed=15661905) Derived from metastatic site: Lymph node. Female 21090197 CVCL_H377 293T/NMU2 transformed cell line human CVCL_H377 CL:0000010 Transfected with: HGNC; 16454; NMUR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21090198 CVCL_GR78 1106-mel cancer cell line human CVCL_GR78 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Unspecified (PubMed=15661905) Derived from metastatic site: Hypodermis. Male 21090199 CVCL_H378 CHO-K1/5-HT1A/Galpha15 spontaneously immortalized cell line CVCL_H378 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 5286; HTR1A Derived from sampling site: Ovary. Female 21090200 CVCL_H371 293/MC3/CRE-Luc transformed cell line human CVCL_H371 CL:0000010 Transfected with: HGNC; 6931; MC3R; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090201 CVCL_GR71 Ed149.BT cancer cell line human CVCL_GR71 CL:0000010 Male Characteristics: Early passage culture. 21090202 CVCL_GR72 18-8 transformed cell line house mouse CVCL_GR72 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21090203 CVCL_H372 293/MCH1 transformed cell line human CVCL_H372 CL:0000010 Transfected with: HGNC; 4479; MCHR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090204 CVCL_GR73 18-81 transformed cell line house mouse CVCL_GR73 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21090205 CVCL_H373 293/NPY1 transformed cell line human CVCL_H373 CL:0000010 Transfected with: HGNC; 7956; NPY1R Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00430 Female 21090206 CVCL_H374 293/PTH2/CRE-Luc transformed cell line human CVCL_H374 CL:0000010 Transfected with: HGNC; 9609; PTH2R; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090207 CVCL_GR74 Bine4.8 transformed cell line house mouse CVCL_GR74 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21090208 CVCL_H370 293/H1 transformed cell line human CVCL_H370 CL:0000010 Transfected with: HGNC; 5182; HRH1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090209 CVCL_GR70 Ed147.BT cancer cell line human CVCL_GR70 CL:0000010 Male Characteristics: Early passage culture. 21090210 CVCL_PL20 BayGenomics ES cell line XD104 embryonic stem cell house mouse CVCL_PL20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97549; Pfn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090211 CVCL_PL21 BayGenomics ES cell line XD105 embryonic stem cell house mouse CVCL_PL21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920036; Tdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090212 CVCL_PL22 BayGenomics ES cell line XD106 embryonic stem cell house mouse CVCL_PL22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444554; Mapkap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090213 CVCL_PL01 BayGenomics ES cell line XD077 embryonic stem cell house mouse CVCL_PL01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090214 CVCL_PL02 BayGenomics ES cell line XD079 embryonic stem cell house mouse CVCL_PL02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890165; Larp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090215 CVCL_PL03 BayGenomics ES cell line XD081 embryonic stem cell house mouse CVCL_PL03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109238; Sem1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090216 CVCL_PL04 BayGenomics ES cell line XD082 embryonic stem cell house mouse CVCL_PL04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090217 CVCL_PL05 BayGenomics ES cell line XD083 embryonic stem cell house mouse CVCL_PL05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090218 CVCL_PL06 BayGenomics ES cell line XD084 embryonic stem cell house mouse CVCL_PL06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928744; Vapb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090219 CVCL_PL07 BayGenomics ES cell line XD085 embryonic stem cell house mouse CVCL_PL07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923957; Clasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090220 CVCL_PL08 BayGenomics ES cell line XD088 embryonic stem cell house mouse CVCL_PL08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917606; St13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090221 CVCL_PL09 BayGenomics ES cell line XD089 embryonic stem cell house mouse CVCL_PL09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090222 CVCL_H386 CHO-K1/ADORA3/Galpha15 spontaneously immortalized cell line CVCL_H386 CL:0000010 Transfected with: HGNC; 268; ADORA3; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090223 CVCL_GR86 EUFA592 transformed cell line human CVCL_GR86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090224 CVCL_H387 CHO-K1/ADRA1A spontaneously immortalized cell line CVCL_H387 CL:0000010 Transfected with: HGNC; 277; ADRA1A Derived from sampling site: Ovary. Female 21090225 CVCL_GR87 EUFA696 transformed cell line human CVCL_GR87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090226 CVCL_H388 CHO-K1/ADRA1B spontaneously immortalized cell line CVCL_H388 CL:0000010 Transfected with: HGNC; 278; ADRA1B Derived from sampling site: Ovary. Female 21090227 CVCL_GR88 EUFA816 transformed cell line human CVCL_GR88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090228 CVCL_H389 CHO-K1/ADRA1D spontaneously immortalized cell line CVCL_H389 CL:0000010 Transfected with: HGNC; 280; ADRA1D Derived from sampling site: Ovary. Female 21090229 CVCL_GR89 EUFA961 transformed cell line human CVCL_GR89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090230 CVCL_GR82 AG0656 transformed cell line human CVCL_GR82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 04101820; true Part of: ECACC chromosomal abnormality collection 21090231 CVCL_H382 CHO-K1/5-HT4/Galpha15 spontaneously immortalized cell line CVCL_H382 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 5299; HTR4 Derived from sampling site: Ovary. Female 21090232 CVCL_GR83 BD0952 transformed cell line human CVCL_GR83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94031517; true Part of: ECACC chromosomal abnormality collection 21090233 CVCL_H383 CHO-K1/ADORA1/Galpha15 spontaneously immortalized cell line CVCL_H383 CL:0000010 Transfected with: HGNC; 262; ADORA1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090234 CVCL_H384 CHO-K1/ADORA2A/Galpha15 spontaneously immortalized cell line CVCL_H384 CL:0000010 Transfected with: HGNC; 263; ADORA2A; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090235 CVCL_GR84 EUFA1333 transformed cell line human CVCL_GR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090236 CVCL_H385 CHO-K1/ADORA2B/Galpha15 spontaneously immortalized cell line CVCL_H385 CL:0000010 Transfected with: HGNC; 264; ADORA2B; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090237 CVCL_GR85 EUFA543 transformed cell line human CVCL_GR85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21090238 CVCL_GR80 1180-mel cancer cell line human CVCL_GR80 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Unspecified (PubMed=15661905) Derived from metastatic site: Hypodermis. Female 21090239 CVCL_H380 CHO-K1/5-HT2B spontaneously immortalized cell line CVCL_H380 CL:0000010 Transfected with: HGNC; 5294; HTR2B Derived from sampling site: Ovary. Female 21090240 CVCL_GR81 1259-mel cancer cell line human CVCL_GR81 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Unspecified (PubMed=15661905) Derived from metastatic site: Hypodermis. Male 21090241 CVCL_H381 CHO-K1/5-HT2C spontaneously immortalized cell line CVCL_H381 CL:0000010 Transfected with: HGNC; 5295; HTR2C Derived from sampling site: Ovary. Female 21090242 CVCL_PL10 BayGenomics ES cell line XD091 embryonic stem cell house mouse CVCL_PL10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090243 CVCL_PL11 BayGenomics ES cell line XD092 embryonic stem cell house mouse CVCL_PL11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090244 CVCL_H357 1321N1/P2Y12/Galpha15 cancer cell line human CVCL_H357 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 18124; P2RY12 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090245 CVCL_GR57 WK-1 undefined cell line type CVCL_GR57 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line 21090246 CVCL_H358 1321N1/P2Y2 cancer cell line human CVCL_H358 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8541; P2RY2 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090247 CVCL_GR58 LCL-partial trisomy 12p13 transformed cell line human CVCL_GR58 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090248 CVCL_H359 1321N1/P2Y4 cancer cell line human CVCL_H359 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8542; P2RY4 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090249 CVCL_GR59 REF-4A transformed cell line Norway rat CVCL_GR59 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Unspecified 21090250 CVCL_H353 MC615 5F12 transformed cell line house mouse CVCL_H353 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090251 CVCL_GR53 U-1176MG cancer cell line human CVCL_GR53 CL:0000010 Miscellaneous: Sex of donor from personal communication of Westermark B. Male 21090252 CVCL_GR54 In-111-R1 cancer cell line CVCL_GR54 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Pancreas; islets of Langerhans. 21090253 CVCL_H354 MC615 5F9 transformed cell line house mouse CVCL_H354 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090254 CVCL_H355 1321N1/P2Y1 cancer cell line human CVCL_H355 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8539; P2RY1 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090255 CVCL_GR55 G355-5/fOX40 finite cell line CVCL_GR55 CL:0000010 Transfected with: VGNC; 66411; Cat TNFRSF4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 21090256 CVCL_H356 1321N1/P2Y11 cancer cell line human CVCL_H356 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8540; P2RY11 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090257 CVCL_GR56 G355 finite cell line CVCL_GR56 CL:0000010 Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 21090258 CVCL_GR50 IGR-31 cancer cell line human CVCL_GR50 CL:0000010 Derived from metastatic site: Axillary lymph node. Female 21090259 CVCL_H350 MC615 4G11 transformed cell line house mouse CVCL_H350 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090260 CVCL_GR51 IGRT-27 cancer cell line human CVCL_GR51 CL:0000010 Male 21090261 CVCL_H351 MC615 4H4 transformed cell line house mouse CVCL_H351 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090262 CVCL_H352 MC615 5A2 transformed cell line house mouse CVCL_H352 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21090263 CVCL_GR52 U-1073MG cancer cell line human CVCL_GR52 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21090264 CVCL_PL00 BayGenomics ES cell line XD076 embryonic stem cell house mouse CVCL_PL00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090265 CVCL_H368 293/FP/Galpha15 transformed cell line human CVCL_H368 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9600; PTGFR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090266 CVCL_GR68 HEK-293-Munc18b transformed cell line human CVCL_GR68 CL:0000010 Transfected with: HGNC; 11445; STXBP2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090267 CVCL_H369 293/GHRH/Galpha15 transformed cell line human CVCL_H369 CL:0000010 Transfected with: HGNC; 4266; GHRHR; Transfected with: HGNC; 4383; GNA15 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090268 CVCL_GR69 Ed141.MEL cancer cell line human CVCL_GR69 CL:0000010 Male Characteristics: Early passage culture. 21090269 CVCL_H364 293/CRE-Luc transformed cell line human CVCL_H364 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00188 Female 21090270 CVCL_GR64 XEMd-NH spontaneously immortalized cell line CVCL_GR64 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: RGD; 2459; Cyp1a2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21090271 CVCL_H365 293 c18/DRD4 transformed cell line human CVCL_H365 CL:0000010 Transfected with: HGNC; 3025; DRD4; Transfected with: UniProtKB; P03211; EBV EBNA1 Miscellaneous: Cell line under development; catalog number M00477 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090272 CVCL_GR65 DA01013 transformed cell line human CVCL_GR65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01013; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090273 CVCL_H366 293/EP1 transformed cell line human CVCL_H366 CL:0000010 Transfected with: HGNC; 9593; PTGER1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090274 CVCL_GR66 DA00971 transformed cell line human CVCL_GR66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00971; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090275 CVCL_H367 293 c18/EP4 transformed cell line human CVCL_H367 CL:0000010 Transfected with: HGNC; 9596; PTGER4; Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00485 Female 21090276 CVCL_GR67 HeLa-Munc18b cancer cell line human CVCL_GR67 CL:0000010 Transfected with: HGNC; 11445; STXBP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21090277 CVCL_H360 1321N1/P2Y6 cancer cell line human CVCL_H360 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8543; P2RY6 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21090278 CVCL_GR60 V79/SD1 spontaneously immortalized cell line CVCL_GR60 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: RGD; 2466; Cyp2b1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21090279 CVCL_H361 293/5-HT7/CRE-Luc transformed cell line human CVCL_H361 CL:0000010 Transfected with: HGNC; 5302; HTR7; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090280 CVCL_GR61 XEM1 spontaneously immortalized cell line CVCL_GR61 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: RGD; 2458; Cyp1a1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21090281 CVCL_H362 293/ADORA1/Galpha15 transformed cell line human CVCL_H362 CL:0000010 Transfected with: HGNC; 262; ADORA1; Transfected with: HGNC; 4383; GNA15 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090282 CVCL_GR62 XEM2 spontaneously immortalized cell line CVCL_GR62 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: RGD; 2458; Cyp1a1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21090283 CVCL_H363 293/ADRB3/CRE-Luc transformed cell line human CVCL_H363 CL:0000010 Transfected with: HGNC; 288; ADRB3; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21090284 CVCL_GR63 XEMd-MZ spontaneously immortalized cell line CVCL_GR63 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: RGD; 2459; Cyp1a2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21090285 CVCL_YE52 GM27464 induced pluripotent stem cell human CVCL_YE52 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Phe333Serfs*52 (c.996delC) (P330fs, 990delC); ClinVar=VCV000002990; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21090286 CVCL_YE53 GM27578 induced pluripotent stem cell human CVCL_YE53 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Phe299Cys (c.896T>G); ClinVar=VCV000000613; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg408Trp (c.1222C>T); ClinVar=VCV000000577; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21090287 CVCL_YE54 GM27461 finite cell line human CVCL_YE54 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Arg230Cys (c.688C>T); ClinVar=VCV000803013; Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 6111; IQGAP2; Simple; p.Gln953Ter (c.2857C>T); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21090288 CVCL_YE55 GM27452 transformed cell line human CVCL_YE55 CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple; p.Ser867Arg (c.2601C>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090289 CVCL_YE50 MUSIi012-A-1 induced pluripotent stem cell human CVCL_YE50 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21090290 CVCL_YE51 GM27462 finite cell line human CVCL_YE51 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Ser326Glufs*129 (c.974_975insA); Zygosity=Heterozygous (Coriell) Population: Caucasian; French; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21090291 CVCL_YE56 GM27453 finite cell line human CVCL_YE56 CL:0000010 Sequence variation: Mutation; HGNC; 15573; SETBP1; Simple; p.Ser867Arg (c.2601C>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21090292 CVCL_YE57 GM27448 finite cell line human CVCL_YE57 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Unexplicit; Ex10-11del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Romanian and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21090293 CVCL_YE58 GM27387 transformed cell line human CVCL_YE58 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Glu1979Ala (c.5936A>C); dbSNP=rs774657158; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11042; SLC6A1; Simple; p.Ser295Leu (c.884C>T); ClinVar=VCV000684489; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090294 CVCL_YE59 GM27388 finite cell line human CVCL_YE59 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Glu1979Ala (c.5936A>C); dbSNP=rs774657158; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11042; SLC6A1; Simple; p.Ser295Leu (c.884C>T); ClinVar=VCV000684489; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21090295 CVCL_YE41 HK7 s2 spontaneously immortalized cell line CVCL_YE41 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 38.4 +- 3.4 hours (PubMed=29532473) Group: Fish cell line 21090296 CVCL_YE42 HK7 s4 spontaneously immortalized cell line CVCL_YE42 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 47.0 +- 2.5 hours (PubMed=29532473) Group: Fish cell line 21090297 CVCL_YE43 HK7 s6 spontaneously immortalized cell line CVCL_YE43 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 38.9 +- 3.2 hours (PubMed=29532473) Group: Fish cell line 21090298 CVCL_YE44 HK7 s7 spontaneously immortalized cell line CVCL_YE44 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 32.2 +- 5.7 hours (PubMed=29532473) Group: Fish cell line 21090299 CVCL_YE40 HK7 s1 spontaneously immortalized cell line CVCL_YE40 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 34.5 +- 2.9 hours (PubMed=29532473) Group: Fish cell line 21090300 CVCL_YE49 MUSIi012-A induced pluripotent stem cell human CVCL_YE49 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21090301 CVCL_YE45 BUCREMi001-A induced pluripotent stem cell human CVCL_YE45 From: Boston University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 14934; SIRT6; Simple; p.Asp63His (c.187G>C); Zygosity=Homozygous (PubMed=29555651) Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Omics: Transcriptome analysis by RNAseq Female 21090302 CVCL_YE46 BUCREMi002-A induced pluripotent stem cell human CVCL_YE46 From: Boston University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 14934; SIRT6; Simple; p.Asp63His (c.187G>C); Zygosity=Homozygous (PubMed=29555651) Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Omics: Transcriptome analysis by RNAseq Male 21090303 CVCL_YE47 TVGHi007-A induced pluripotent stem cell human CVCL_YE47 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Homozygous (PubMed=32388442) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21090304 CVCL_YE48 ciPS induced pluripotent stem cell CVCL_YE48 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Taiwan black silkie. Unspecified Group: Bird cell line 21090305 CVCL_YE30 HK4 spontaneously immortalized cell line CVCL_YE30 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090306 CVCL_YE31 HK5 spontaneously immortalized cell line CVCL_YE31 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090307 CVCL_YE32 HK6 spontaneously immortalized cell line CVCL_YE32 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090308 CVCL_YE33 HK7 spontaneously immortalized cell line CVCL_YE33 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090309 CVCL_YE38 HK10 s8 spontaneously immortalized cell line CVCL_YE38 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 101.4 +- 6.9 hours (PubMed=29532473) Group: Fish cell line 21090310 CVCL_YE39 HK10 s10 spontaneously immortalized cell line CVCL_YE39 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 70.3 +- 15.9 hours (PubMed=29532473) Group: Fish cell line 21090311 CVCL_YE34 HK8 spontaneously immortalized cell line CVCL_YE34 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090312 CVCL_YE35 HK9 spontaneously immortalized cell line CVCL_YE35 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090313 CVCL_YE36 HK10 spontaneously immortalized cell line CVCL_YE36 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090314 CVCL_YE37 HK10 s7 spontaneously immortalized cell line CVCL_YE37 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 50.2 +- 8.2 hours (PubMed=29532473) Group: Fish cell line 21090315 CVCL_YE20 HOL spontaneously immortalized cell line CVCL_YE20 CL:0000010 Derived from sampling site: Snout. Unspecified Doubling time: 50.4 hours (DOI=10.3724/SP.J.1231.2013.38314) Group: Fish cell line 21090316 CVCL_YE21 SFB spontaneously immortalized cell line CVCL_YE21 CL:0000010 Derived from sampling site: Brain. Unspecified Doubling time: 43.048 hours, at 65th passage (DOI=10.3724/SP.J.1231.2013.38402) Group: Fish cell line 21090317 CVCL_YE22 mRTP1B spontaneously immortalized cell line CVCL_YE22 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 3.6 +- 0.7 days (PubMed=20093282) Group: Fish cell line 21090318 CVCL_YE27 HK1 spontaneously immortalized cell line CVCL_YE27 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090319 CVCL_YE28 HK2 spontaneously immortalized cell line CVCL_YE28 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090320 CVCL_YE29 HK3 spontaneously immortalized cell line CVCL_YE29 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21090321 CVCL_YE23 mRTP1E spontaneously immortalized cell line CVCL_YE23 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 2.8 +- 0.7 days (PubMed=20093282) Group: Fish cell line 21090322 CVCL_PK90 BayGenomics ES cell line XD045 embryonic stem cell house mouse CVCL_PK90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99212; Zfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090323 CVCL_YE24 mRTP1F spontaneously immortalized cell line CVCL_YE24 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 3.2 +- 0.8 days (PubMed=20093282) Group: Fish cell line 21090324 CVCL_PK91 BayGenomics ES cell line XD046 embryonic stem cell house mouse CVCL_PK91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108517; Denn2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090325 CVCL_YE25 mRTP1K spontaneously immortalized cell line CVCL_YE25 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 5.5 +- 0.6 days (PubMed=20093282) Group: Fish cell line 21090326 CVCL_PK92 BayGenomics ES cell line XD053 embryonic stem cell house mouse CVCL_PK92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090327 CVCL_YE26 mRTP2A spontaneously immortalized cell line CVCL_YE26 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 6.6 +- 0.6 days (PubMed=20093282) Group: Fish cell line 21090328 CVCL_PK93 BayGenomics ES cell line XD059 embryonic stem cell house mouse CVCL_PK93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919205; Ist1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090329 CVCL_PK94 BayGenomics ES cell line XD060 embryonic stem cell house mouse CVCL_PK94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107846; Prmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090330 CVCL_PK95 BayGenomics ES cell line XD061 embryonic stem cell house mouse CVCL_PK95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202875; Btf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090331 CVCL_PK96 BayGenomics ES cell line XD062 embryonic stem cell house mouse CVCL_PK96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919218; Wdr73 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090332 CVCL_PK97 BayGenomics ES cell line XD073 embryonic stem cell house mouse CVCL_PK97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914633; Carnmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090333 CVCL_PK98 BayGenomics ES cell line XD074 embryonic stem cell house mouse CVCL_PK98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342283; Slc12a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090334 CVCL_PK99 BayGenomics ES cell line XD075 embryonic stem cell house mouse CVCL_PK99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090335 CVCL_PK79 BayGenomics ES cell line XC904 embryonic stem cell house mouse CVCL_PK79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090336 CVCL_YE10 MON1 transformed cell line human CVCL_YE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090337 CVCL_YE11 SAD1 transformed cell line human CVCL_YE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090338 CVCL_YE16 LYCMS spontaneously immortalized cell line CVCL_YE16 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013158 21090339 CVCL_YE17 GGSK spontaneously immortalized cell line CVCL_YE17 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201515 21090340 CVCL_YE18 HOF spontaneously immortalized cell line CVCL_YE18 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 58.7 hours (DOI=10.3724/SP.J.1231.2013.38314) Group: Fish cell line 21090341 CVCL_YE19 HOK spontaneously immortalized cell line CVCL_YE19 CL:0000010 Derived from sampling site: Kidney. Unspecified Doubling time: 32.9 hours (DOI=10.3724/SP.J.1231.2013.38314) Group: Fish cell line 21090342 CVCL_YE12 SAN1 transformed cell line human CVCL_YE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090343 CVCL_YE13 LM-1-SF cancer cell line human CVCL_YE13 CL:0000010 Population: African American; Derived from sampling site: Bone; distal femur. Female Group: Serum/protein free medium cell line 21090344 CVCL_PK80 BayGenomics ES cell line XD005 embryonic stem cell house mouse CVCL_PK80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99212; Zfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090345 CVCL_YE14 TE-85-SF cancer cell line human CVCL_YE14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Group: Serum/protein free medium cell line 21090346 CVCL_YE15 1390G3 AGVT (XX) induced pluripotent stem cell human CVCL_YE15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Peripheral blood. Female Characteristics: Using TALEN a 2A-tdTomato construct was inserted at the C-terminal end of DDX4 (DDX4/hVH-tdTomato = VT) as well as a 2A-EGFP construct (TFAP2C-p2A-EGFP =AG) at the C-terminal end of TFAP2C 21090347 CVCL_PK81 BayGenomics ES cell line XD006 embryonic stem cell house mouse CVCL_PK81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090348 CVCL_PK82 BayGenomics ES cell line XD007 embryonic stem cell house mouse CVCL_PK82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917483; Cd2bp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090349 CVCL_PK83 BayGenomics ES cell line XD013 embryonic stem cell house mouse CVCL_PK83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289234; Rhpn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090350 CVCL_PK84 BayGenomics ES cell line XD015 embryonic stem cell house mouse CVCL_PK84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98884; U2af1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090351 CVCL_PK85 BayGenomics ES cell line XD019 embryonic stem cell house mouse CVCL_PK85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090352 CVCL_PK86 BayGenomics ES cell line XD024 embryonic stem cell house mouse CVCL_PK86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090353 CVCL_PK87 BayGenomics ES cell line XD028 embryonic stem cell house mouse CVCL_PK87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202875; Btf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090354 CVCL_PK88 BayGenomics ES cell line XD039 embryonic stem cell house mouse CVCL_PK88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97583; Pik3r1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090355 CVCL_PK89 BayGenomics ES cell line XD044 embryonic stem cell house mouse CVCL_PK89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99212; Zfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090356 CVCL_PK68 BayGenomics ES cell line XC832 embryonic stem cell house mouse CVCL_PK68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090357 CVCL_PK69 BayGenomics ES cell line XC840 embryonic stem cell house mouse CVCL_PK69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090358 CVCL_YE00 COA1 transformed cell line human CVCL_YE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090359 CVCL_YE05 GOL1 transformed cell line human CVCL_YE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090360 CVCL_YE06 HUN1 transformed cell line human CVCL_YE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090361 CVCL_YE07 KAT1 transformed cell line human CVCL_YE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090362 CVCL_YE08 LIZ1 transformed cell line human CVCL_YE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090363 CVCL_YE01 COA2 transformed cell line human CVCL_YE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090364 CVCL_YE02 DUN1 transformed cell line human CVCL_YE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090365 CVCL_YE03 FLE1 transformed cell line human CVCL_YE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090366 CVCL_PK70 BayGenomics ES cell line XC841 embryonic stem cell house mouse CVCL_PK70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090367 CVCL_YE04 G-S1 transformed cell line human CVCL_YE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090368 CVCL_PK71 BayGenomics ES cell line XC845 embryonic stem cell house mouse CVCL_PK71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919824; Zc3h14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090369 CVCL_PK72 BayGenomics ES cell line XC846 embryonic stem cell house mouse CVCL_PK72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090370 CVCL_PK73 BayGenomics ES cell line XC847 embryonic stem cell house mouse CVCL_PK73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090371 CVCL_PK74 BayGenomics ES cell line XC851 embryonic stem cell house mouse CVCL_PK74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915498; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090372 CVCL_PK75 BayGenomics ES cell line XC853 embryonic stem cell house mouse CVCL_PK75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917794; Tmem242 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090373 CVCL_YE09 MAR1 transformed cell line human CVCL_YE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090374 CVCL_PK76 BayGenomics ES cell line XC874 embryonic stem cell house mouse CVCL_PK76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108086; Hdac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090375 CVCL_PK77 BayGenomics ES cell line XC898 embryonic stem cell house mouse CVCL_PK77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915149; Cmc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090376 CVCL_PK78 BayGenomics ES cell line XC901 embryonic stem cell house mouse CVCL_PK78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917338; Meaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090377 CVCL_PK57 BayGenomics ES cell line XC797 embryonic stem cell house mouse CVCL_PK57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090378 CVCL_PK58 BayGenomics ES cell line XC798 embryonic stem cell house mouse CVCL_PK58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914116; Nhlrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090379 CVCL_PK59 BayGenomics ES cell line XC807 embryonic stem cell house mouse CVCL_PK59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914320; Lsm14a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090380 CVCL_PK60 BayGenomics ES cell line XC808 embryonic stem cell house mouse CVCL_PK60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914782; Mfap1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090381 CVCL_PK61 BayGenomics ES cell line XC809 embryonic stem cell house mouse CVCL_PK61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926048; Eml4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090382 CVCL_PK62 BayGenomics ES cell line XC815 embryonic stem cell house mouse CVCL_PK62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442951; Zfp574 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090383 CVCL_PK63 BayGenomics ES cell line XC819 embryonic stem cell house mouse CVCL_PK63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913989; Rcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090384 CVCL_PK64 BayGenomics ES cell line XC820 embryonic stem cell house mouse CVCL_PK64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090385 CVCL_PK65 BayGenomics ES cell line XC821 embryonic stem cell house mouse CVCL_PK65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090386 CVCL_PK66 BayGenomics ES cell line XC823 embryonic stem cell house mouse CVCL_PK66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95556; Flna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090387 CVCL_PK67 BayGenomics ES cell line XC827 embryonic stem cell house mouse CVCL_PK67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913750; Slc30a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090388 CVCL_PK46 BayGenomics ES cell line XC778 embryonic stem cell house mouse CVCL_PK46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090389 CVCL_PK47 BayGenomics ES cell line XC780 embryonic stem cell house mouse CVCL_PK47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090390 CVCL_PK48 BayGenomics ES cell line XC782 embryonic stem cell house mouse CVCL_PK48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098267; Ogdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090391 CVCL_PK49 BayGenomics ES cell line XC784 embryonic stem cell house mouse CVCL_PK49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090392 CVCL_PK50 BayGenomics ES cell line XC786 embryonic stem cell house mouse CVCL_PK50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090393 CVCL_PK51 BayGenomics ES cell line XC787 embryonic stem cell house mouse CVCL_PK51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090394 CVCL_PK52 BayGenomics ES cell line XC788 embryonic stem cell house mouse CVCL_PK52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090395 CVCL_PK53 BayGenomics ES cell line XC791 embryonic stem cell house mouse CVCL_PK53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917338; Meaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090396 CVCL_PK54 BayGenomics ES cell line XC792 embryonic stem cell house mouse CVCL_PK54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090397 CVCL_PK55 BayGenomics ES cell line XC793 embryonic stem cell house mouse CVCL_PK55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150037; Mta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090398 CVCL_PK56 BayGenomics ES cell line XC796 embryonic stem cell house mouse CVCL_PK56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090399 CVCL_YE90 CPTC-AKR1C2-3 hybridoma house mouse CVCL_YE90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P52895; Human AKR1C2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090400 CVCL_YE91 CPTC-AKT1-1 hybridoma house mouse CVCL_YE91 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090401 CVCL_YE96 CPTC-AKT2-3 hybridoma house mouse CVCL_YE96 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090402 CVCL_YE97 CPTC-AKT2-4 hybridoma house mouse CVCL_YE97 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090403 CVCL_YE98 CPTC-AKT3-1 hybridoma house mouse CVCL_YE98 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090404 CVCL_YE99 CPTC-AKT3-5 hybridoma house mouse CVCL_YE99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090405 CVCL_YE92 CPTC-AKT1-2 hybridoma house mouse CVCL_YE92 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090406 CVCL_YE93 CPTC-AKT1-3 hybridoma house mouse CVCL_YE93 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P31749; Human AKT1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090407 CVCL_YE94 CPTC-AKT2-1 hybridoma house mouse CVCL_YE94 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090408 CVCL_YE95 CPTC-AKT2-2 hybridoma house mouse CVCL_YE95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P31751; Human AKT2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090409 CVCL_YE80 PCRP-CARM1-1D9 hybridoma house mouse CVCL_YE80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86X55; Human CARM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21090410 CVCL_YE85 CPTC-AKR1B1-2 hybridoma house mouse CVCL_YE85 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15121; Human AKR1B1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090411 CVCL_YE86 CPTC-AKR1B1-3 hybridoma house mouse CVCL_YE86 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15121; Human AKR1B1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090412 CVCL_YE87 CPTC-AKR1C1-1 hybridoma house mouse CVCL_YE87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04828; Human AKR1C1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090413 CVCL_YE88 CPTC-AKR1C2-1 hybridoma house mouse CVCL_YE88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P52895; Human AKR1C2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090414 CVCL_YE81 PCRP-MED8-1B4 hybridoma house mouse CVCL_YE81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96G25; Human MED8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21090415 CVCL_YE82 PCRP-POU3F3-1G10 hybridoma house mouse CVCL_YE82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20264; Human POU3F3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21090416 CVCL_YE83 CPTC-ABCB1-2 hybridoma house mouse CVCL_YE83 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090417 CVCL_YE84 CPTC-AKR1B1-1 hybridoma house mouse CVCL_YE84 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15121; Human AKR1B1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090418 CVCL_YE89 CPTC-AKR1C2-2 hybridoma house mouse CVCL_YE89 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P52895; Human AKR1C2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090419 CVCL_YE74 ST-IOWA/PERV-C(5683) spontaneously immortalized cell line pig CVCL_YE74 CL:0000010 Derived from sampling site: Fetal testis. Male Virology: Infected with porcine endogenous retrovirus PERV-C(5683) 21090420 CVCL_YE75 PK15 PERV-inactivated clone 15 spontaneously immortalized cell line pig CVCL_YE75 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Using CRISPR/Cas9 all 62 copies of the PERV pol gene were inactivated (PubMed=26456528) 21090421 CVCL_YE76 PK15 PERV-inactivated clone 20 spontaneously immortalized cell line pig CVCL_YE76 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Using CRISPR/Cas9 all 62 copies of the PERV pol gene were inactivated (PubMed=26456528) 21090422 CVCL_YE77 PK15 PERV-inactivated clone 29 spontaneously immortalized cell line pig CVCL_YE77 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Using CRISPR/Cas9 all 62 copies of the PERV pol gene were inactivated (PubMed=26456528) 21090423 CVCL_YE70 UC XJY0903-iPS C1 induced pluripotent stem cell human CVCL_YE70 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090424 CVCL_YE71 UC ZGZ0816-iPS C1 induced pluripotent stem cell human CVCL_YE71 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090425 CVCL_YE72 UC ZQ0907-iPS C1 induced pluripotent stem cell human CVCL_YE72 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090426 CVCL_YE73 ST-IOWA/PERV-C(1312) spontaneously immortalized cell line pig CVCL_YE73 CL:0000010 Derived from sampling site: Fetal testis. Male Virology: Infected with porcine endogenous retrovirus PERV-C(1312) 21090427 CVCL_YE78 PK15 PERV-inactivated clone 38 spontaneously immortalized cell line pig CVCL_YE78 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Using CRISPR/Cas9 all 62 copies of the PERV pol gene were inactivated (PubMed=26456528) 21090428 CVCL_YE79 PCRP-BCL11A-1G10 hybridoma house mouse CVCL_YE79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H165; Human BCL11A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21090429 CVCL_YE63 UC LBJ0828-iPS C1 induced pluripotent stem cell human CVCL_YE63 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090430 CVCL_YE64 UC LXY0828-iPS C1 induced pluripotent stem cell human CVCL_YE64 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21090431 CVCL_YE65 UC LY0815-iPS C1 induced pluripotent stem cell human CVCL_YE65 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21090432 CVCL_YE66 UC NS0816-iPS C3 induced pluripotent stem cell human CVCL_YE66 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21090433 CVCL_YE60 UC C0406-iPS C4 induced pluripotent stem cell human CVCL_YE60 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21090434 CVCL_YE61 UC CGK0828-iPS C2 induced pluripotent stem cell human CVCL_YE61 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090435 CVCL_YE62 UC GM1020-iPS C1 induced pluripotent stem cell human CVCL_YE62 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21090437 CVCL_YE68 UC WXM0816-iPS C2 induced pluripotent stem cell human CVCL_YE68 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090438 CVCL_YE69 UC XB0722-iPS C2 induced pluripotent stem cell human CVCL_YE69 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21090439 CVCL_H456 CHO-K1/M3 spontaneously immortalized cell line CVCL_H456 CL:0000010 Transfected with: HGNC; 1952; CHRM3 Derived from sampling site: Ovary. Female 21090440 CVCL_GS56 GM02436 finite cell line human CVCL_GS56 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (PubMed=1346349; PubMed=1680289) Population: Caucasian; Swiss; Derived from sampling site: Cell type=Fibroblast. Female 21090441 CVCL_H457 CHO-K1/M4/Galpha15 spontaneously immortalized cell line CVCL_H457 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090442 CVCL_GS57 GM02445 finite cell line human CVCL_GS57 HLA typing: A*02,30; B*07,39 (Coriell=GM02445) CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.33+1G>C (IVS1DS,G-C,+1); ClinVar=VCV000001976; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg101Gln (c.302G>A); ClinVar=VCV000001956; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21090443 CVCL_H458 CHO-K1/M5 spontaneously immortalized cell line CVCL_H458 CL:0000010 Transfected with: HGNC; 1954; CHRM5 Derived from sampling site: Ovary. Female 21090444 CVCL_GS58 GM02471 transformed cell line human CVCL_GS58 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg156Cys (c.466C>T); ClinVar=VCV000001970; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu304Arg (c.911T>G); ClinVar=VCV000001958; Zygosity=Heterozygous (PubMed=1346349) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090445 CVCL_H459 CHO-K1/MC2/Galpha15 spontaneously immortalized cell line CVCL_H459 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 6930; MC2R Derived from sampling site: Ovary. Female 21090446 CVCL_GS59 GM02578 finite cell line human CVCL_GS59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090447 CVCL_H452 CHO-K1/KiSS1 spontaneously immortalized cell line CVCL_H452 CL:0000010 Transfected with: HGNC; 4510; KISS1R Derived from sampling site: Ovary. Female 21090448 CVCL_GS52 GM00732 finite cell line human CVCL_GS52 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090449 CVCL_H453 CHO-K1/LTB4/Galpha15 spontaneously immortalized cell line CVCL_H453 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 6713; LTB4R Derived from sampling site: Ovary. Female 21090450 CVCL_GS53 GM01082 finite cell line human CVCL_GS53 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090451 CVCL_H454 CHO-K1/M1 spontaneously immortalized cell line CVCL_H454 CL:0000010 Transfected with: HGNC; 1950; CHRM1 Derived from sampling site: Ovary. Female 21090452 CVCL_GS54 GM01715 transformed cell line human CVCL_GS54 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.33+1G>C (IVS1DS,G-C,+1); ClinVar=VCV000001976; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg101Gln (c.302G>A); ClinVar=VCV000001956; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090453 CVCL_H455 CHO-K1/M2/Galpha15 spontaneously immortalized cell line CVCL_H455 CL:0000010 Transfected with: HGNC; 1951; CHRM2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090454 CVCL_GS55 GM02434 finite cell line human CVCL_GS55 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg156Cys (c.466C>T); ClinVar=VCV000001970; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu304Arg (c.911T>G); ClinVar=VCV000001958; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090455 CVCL_H450 CHO-K1/H4/Galpha15 spontaneously immortalized cell line CVCL_H450 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 17383; HRH4 Derived from sampling site: Ovary. Female 21090456 CVCL_GS50 KU-MELTC-1 cancer cell line human CVCL_GS50 From: Ikeda H.; Keio University School of Medicine; Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 21090457 CVCL_H451 CHO-K1/IP1/Galpha15 spontaneously immortalized cell line CVCL_H451 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9602; PTGIR Derived from sampling site: Ovary. Female 21090458 CVCL_GS51 ENStem-A somatic stem cell human CVCL_GS51 CL:0000010 Discontinued: Millipore; SCC003; true. Female 21090459 CVCL_H467 CHO-K1/MT2/Galpha15 spontaneously immortalized cell line CVCL_H467 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 7464; MTNR1B Derived from sampling site: Ovary. Female 21090460 CVCL_GS67 GM05007 finite cell line human CVCL_GS67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090461 CVCL_H468 CHO-K1/MTLR/Galpha15 spontaneously immortalized cell line CVCL_H468 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4495; MLNR Derived from sampling site: Ovary. Female 21090462 CVCL_GS68 GM05008 finite cell line human CVCL_GS68 CL:0000010 Sequence variation: Mutation; HGNC; 3647; FECH; Simple; p.Phe417Ser (c.1250T>C); ClinVar=VCV000000551; Zygosity=Homozygous (PubMed=1376018) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090463 CVCL_H469 CHO-K1/NIACR1/Galpha15 spontaneously immortalized cell line CVCL_H469 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 24827; HCAR2 Derived from sampling site: Ovary. Female 21090464 CVCL_GS69 GM05816 transformed cell line human CVCL_GS69 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg76Trp (c.226C>T); ClinVar=VCV000001962; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Pro274Leu (c.821C>T); ClinVar=VCV000001964; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090465 CVCL_H463 CHO-K1/MCH2 spontaneously immortalized cell line CVCL_H463 CL:0000010 Transfected with: HGNC; 20867; MCHR2 Derived from sampling site: Ovary. Female 21090466 CVCL_GS63 GM04374 finite cell line human CVCL_GS63 CL:0000010 Population: Native North American; Derived from sampling site: Cell type=Fibroblast. Female 21090467 CVCL_H464 CHO-K1/MRGPRD/Galpha15 spontaneously immortalized cell line CVCL_H464 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 29626; MRGPRD Miscellaneous: Cell line under development; catalog number M00467 Derived from sampling site: Ovary. Female 21090468 CVCL_GS64 GM04395 finite cell line human CVCL_GS64 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu107Pro (c.320T>C); ClinVar=VCV000001965; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211Cys (c.631C>T); ClinVar=VCV000001966; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090469 CVCL_H465 CHO-K1/MRGPRX2 spontaneously immortalized cell line CVCL_H465 CL:0000010 Transfected with: HGNC; 17983; MRGPRX2 Derived from sampling site: Ovary. Female 21090470 CVCL_GS65 GM04396 transformed cell line human CVCL_GS65 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu107Pro (c.320T>C); ClinVar=VCV000001965; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211Cys (c.631C>T); ClinVar=VCV000001966; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090471 CVCL_H466 CHO-K1/MT1/Galpha15 spontaneously immortalized cell line CVCL_H466 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 7463; MTNR1A Derived from sampling site: Ovary. Female 21090472 CVCL_GS66 GM05005 finite cell line human CVCL_GS66 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090473 CVCL_H460 CHO-K1/MC3/Galpha15 spontaneously immortalized cell line CVCL_H460 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 6931; MC3R Derived from sampling site: Ovary. Female 21090474 CVCL_GS60 GM03136 finite cell line human CVCL_GS60 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu107Pro (c.320T>C); ClinVar=VCV000001965; Zygosity=Heterozygous (PubMed=1346349) Population: Jewish; Sephardic; Derived from sampling site: Cell type=Fibroblast. Female 21090475 CVCL_H461 CHO-K1/MC4/Galpha15 spontaneously immortalized cell line CVCL_H461 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 6932; MC4R Derived from sampling site: Ovary. Female 21090476 CVCL_GS61 GM03137 finite cell line human CVCL_GS61 CL:0000010 Karyotypic information: 46,XX,t(1;12)(1qter->1p36::12q15->12qter;12pter->12q15::1p36->1pter) [24]; 46,XX [26] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21090477 CVCL_H462 CHO-K1/MC5/Galpha15 spontaneously immortalized cell line CVCL_H462 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 6933; MC5R Derived from sampling site: Ovary. Female 21090478 CVCL_GS62 GM04258 transformed cell line human CVCL_GS62 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ser291Leu (c.872C>T); ClinVar=VCV000001971; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala329Val (c.986C>T); ClinVar=VCV000001959; Zygosity=Heterozygous (PubMed=1346349) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090479 CVCL_H438 CHO-K1/GLP1/Galpha15 spontaneously immortalized cell line CVCL_H438 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090480 CVCL_GS38 tST-14 transformed cell line pig CVCL_GS38 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis. Male 21090481 CVCL_H439 CHO-K1/GLP2/Galpha15 spontaneously immortalized cell line CVCL_H439 CL:0000010 Transfected with: HGNC; 4325; GLP2R; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090482 CVCL_GS39 tST-18 transformed cell line pig CVCL_GS39 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis. Male 21090483 CVCL_GS34 A3/MHV embryonic stem cell house mouse CVCL_GS34 CL:0000010 Breed/subspecies: 129X1/SvJ. Male Virology: Persistently infected by mouse hepatitis virus type-2 (MHV-2) 21090484 CVCL_H434 CHO-K1/GAL2 spontaneously immortalized cell line CVCL_H434 CL:0000010 Transfected with: HGNC; 4133; GALR2 Derived from sampling site: Ovary. Female 21090485 CVCL_GS35 CBL63 embryonic stem cell house mouse CVCL_GS35 CL:0000010 Unspecified 21090486 CVCL_H435 CHO-K1/GCGR/Galpha15 spontaneously immortalized cell line CVCL_H435 CL:0000010 Transfected with: HGNC; 4192; GCGR; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090487 CVCL_H436 CHO-K1/GHSR spontaneously immortalized cell line CVCL_H436 CL:0000010 Transfected with: HGNC; 4267; GHSR Derived from sampling site: Ovary. Female 21090488 CVCL_GS36 H200 embryonic stem cell house mouse CVCL_GS36 CL:0000010 Unspecified 21090489 CVCL_H437 CHO-K1/GIP/Galpha15 spontaneously immortalized cell line CVCL_H437 CL:0000010 Transfected with: HGNC; 4271; GIPR; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090490 CVCL_GS37 HD5 embryonic stem cell house mouse CVCL_GS37 CL:0000010 Unspecified 21090491 CVCL_H430 CHO-K1/FFA2/Galpha15 spontaneously immortalized cell line CVCL_H430 CL:0000010 Transfected with: HGNC; 4501; FFAR2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090492 CVCL_GS30 FE-8 transformed cell line Norway rat CVCL_GS30 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21090493 CVCL_H431 CHO-K1/FPR1/Galpha15 spontaneously immortalized cell line CVCL_H431 CL:0000010 Transfected with: HGNC; 3826; FPR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090494 CVCL_GS31 HFH-14 cancer cell line house mouse CVCL_GS31 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21090495 CVCL_H432 CHO-K1/FPRL1/Galpha15 spontaneously immortalized cell line CVCL_H432 CL:0000010 Transfected with: HGNC; 3827; FPR2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090496 CVCL_GS32 HFH-18 cancer cell line house mouse CVCL_GS32 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21090497 CVCL_GS33 A3-1 embryonic stem cell house mouse CVCL_GS33 CL:0000010 Breed/subspecies: 129X1/SvJ. Male 21090498 CVCL_H433 CHO-K1/GAL1/Galpha15 spontaneously immortalized cell line CVCL_H433 CL:0000010 Transfected with: HGNC; 4132; GALR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090499 CVCL_H449 CHO-K1/H3/Galpha15 spontaneously immortalized cell line CVCL_H449 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 5184; HRH3 Derived from sampling site: Ovary. Female 21090500 CVCL_GS49 TDMM1 cancer cell line human CVCL_GS49 From: Takahashi; Japanese Red Cross Medical Center; Tokyo; Japan CL:0000010 Population: Japanese. 21090501 CVCL_GS45 Chem-5 undefined cell line type Norway rat CVCL_GS45 CL:0000010 Discontinued: Millipore; HTSCHEM-5; true. 21090502 CVCL_H445 CHO-K1/GRM2/Galpha15 spontaneously immortalized cell line CVCL_H445 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4594; GRM2 Derived from sampling site: Ovary. Female 21090503 CVCL_GS46 Chem-10 undefined cell line type Norway rat CVCL_GS46 CL:0000010 Discontinued: Millipore; HTSCHEM-10; true. 21090504 CVCL_H446 CHO-K1/Galpha15 spontaneously immortalized cell line CVCL_H446 CL:0000010 Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090505 CVCL_H447 CHO-K1/Gqi5 spontaneously immortalized cell line CVCL_H447 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1) Derived from sampling site: Ovary. Female 21090506 CVCL_GS47 NCC-KT cancer cell line human CVCL_GS47 From: Hamanaka Y.; Yamaguchi University School of Medicine; Ube; Japan CL:0000010 Population: Japanese. 21090507 CVCL_H448 CHO-K1/H2/Galpha15 spontaneously immortalized cell line CVCL_H448 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 5183; HRH2 Derived from sampling site: Ovary. Female 21090508 CVCL_GS48 SMTK-1 cancer cell line human CVCL_GS48 From: Matsumoto; Shinsyu University School of Medicine; Matsumoto; Japan CL:0000010 Population: Japanese. Unspecified 21090509 CVCL_H441 CHO-K1/GPBAR1 spontaneously immortalized cell line CVCL_H441 CL:0000010 Transfected with: HGNC; 19680; GPBAR1 Derived from sampling site: Ovary. Female 21090510 CVCL_GS41 CMTI-1 embryonic stem cell house mouse CVCL_GS41 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Male 21090511 CVCL_H442 CHO-K1/GPR103/Galpha15 spontaneously immortalized cell line CVCL_H442 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 15565; QRFPR Derived from sampling site: Ovary. Female 21090512 CVCL_GS42 O9-1 spontaneously immortalized cell line house mouse CVCL_GS42 CL:0000010 Derived from sampling site: Neural crest; Breed/subspecies: Wnt1-Cre;R26R-GFP transgenic. Omics: Transcriptome analysis by microarray Characteristics: Capable of differentiating into four cell types: osteoblasts, chondrocytes, smooth muscle cells and glial cells 21090513 CVCL_H443 CHO-K1/GPR120/Galpha15 spontaneously immortalized cell line CVCL_H443 CL:0000010 Transfected with: HGNC; 19061; FFAR4; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00440 Female 21090514 CVCL_GS43 PluriStem NOD embryonic stem cell house mouse CVCL_GS43 CL:0000010 Breed/subspecies: NOD. Discontinued: Millipore; SCC051; true Unspecified 21090515 CVCL_GS44 Chem-4 undefined cell line type Norway rat CVCL_GS44 CL:0000010 Discontinued: Millipore; HTSCHEM-4; true. 21090516 CVCL_H444 CHO-K1/GPR68/Galpha15 spontaneously immortalized cell line CVCL_H444 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4519; GPR68 Derived from sampling site: Ovary. Female 21090517 CVCL_H440 CHO-K1/GNRHR/Galpha15 spontaneously immortalized cell line CVCL_H440 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4421; GNRHR Derived from sampling site: Ovary. Female 21090518 CVCL_GS40 tST-3 transformed cell line pig CVCL_GS40 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis. Male 21090519 CVCL_H416 CHO-K1/CRF2/Galpha15 spontaneously immortalized cell line CVCL_H416 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090520 CVCL_GS16 GM02868 finite cell line human CVCL_GS16 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090521 CVCL_H417 CHO-K1/CT/Galpha15 spontaneously immortalized cell line CVCL_H417 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090522 CVCL_GS17 GM02956 finite cell line human CVCL_GS17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090523 CVCL_H418 CHO-K1/CysLT1/Galpha15 spontaneously immortalized cell line CVCL_H418 CL:0000010 Transfected with: HGNC; 17451; CYSLTR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090524 CVCL_GS18 GM03027 transformed cell line human CVCL_GS18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090525 CVCL_H419 CHO-K1/CysLT2 spontaneously immortalized cell line CVCL_H419 CL:0000010 Transfected with: HGNC; 18274; CYSLTR2 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00449 Female 21090526 CVCL_GS19 SK-MG-5 cancer cell line human CVCL_GS19 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21090527 CVCL_H412 CHO-K1/CCKB spontaneously immortalized cell line CVCL_H412 CL:0000010 Transfected with: HGNC; 1571; CCKBR Derived from sampling site: Ovary. Female 21090528 CVCL_GS12 GM02763 transformed cell line human CVCL_GS12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090529 CVCL_H413 CHO-K1/CMKLR1/Galpha15 spontaneously immortalized cell line CVCL_H413 CL:0000010 Transfected with: HGNC; 2121; CMKLR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090530 CVCL_GS13 GM02764 transformed cell line human CVCL_GS13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090531 CVCL_H414 CHO-K1/CRE-Luc spontaneously immortalized cell line CVCL_H414 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Female 21090532 CVCL_GS14 GM02765 transformed cell line human CVCL_GS14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090533 CVCL_H415 CHO-K1/CRF1/Galpha15 spontaneously immortalized cell line CVCL_H415 CL:0000010 Transfected with: HGNC; 2357; CRHR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090534 CVCL_GS15 GM02793 transformed cell line human CVCL_GS15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090535 CVCL_H410 CHO-K1/CB2 spontaneously immortalized cell line CVCL_H410 CL:0000010 Transfected with: HGNC; 2160; CNR2 Derived from sampling site: Ovary. Female 21090536 CVCL_GS10 GM02713 transformed cell line human CVCL_GS10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090537 CVCL_H411 CHO-K1/CCKA/Galpha15 spontaneously immortalized cell line CVCL_H411 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090538 CVCL_GS11 GM02762 transformed cell line human CVCL_GS11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090539 CVCL_H427 CHO-K1/EDNRB spontaneously immortalized cell line CVCL_H427 CL:0000010 Transfected with: HGNC; 3180; EDNRB Derived from sampling site: Ovary. Female 21090540 CVCL_GS27 Lu-75(c) cancer cell line human CVCL_GS27 HLA typing: A*02; B*w35,w39 (PubMed=6956527) CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female 21090541 CVCL_H428 CHO-K1/EP2/Galpha15 spontaneously immortalized cell line CVCL_H428 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9594; PTGER2 Derived from sampling site: Ovary. Female 21090542 CVCL_GS28 SGBS finite cell line human CVCL_GS28 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Has a capacity for adipogenic differentiation Once differentiated, the cells function and behave as mature adipocytes. 21090543 CVCL_H429 CHO-K1/FFA1/Galpha15 spontaneously immortalized cell line CVCL_H429 CL:0000010 Transfected with: HGNC; 4498; FFAR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090544 CVCL_GS29 PAZ6 transformed cell line human CVCL_GS29 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brown adipose tissue Cell type=Preadipocyte.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1531 21090545 CVCL_H423 CHO-K1/D5/Galpha15 spontaneously immortalized cell line CVCL_H423 CL:0000010 Transfected with: HGNC; 3026; DRD5; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090546 CVCL_GS23 SK-LY-18 cancer cell line human CVCL_GS23 HLA typing: A*33; B*04,27 (PubMed=2939141). From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 21090547 CVCL_H424 CHO-K1/DP1/Galpha15 spontaneously immortalized cell line CVCL_H424 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9591; PTGDR Derived from sampling site: Ovary. Female 21090548 CVCL_GS24 SK-RC-16 cancer cell line human CVCL_GS24 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21090549 CVCL_H425 CHO-K1/DP2/Galpha15 spontaneously immortalized cell line CVCL_H425 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4502; PTGDR2 Derived from sampling site: Ovary. Female 21090550 CVCL_GS25 SK-CO-10 cancer cell line human CVCL_GS25 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21090551 CVCL_H426 CHO-K1/EDNRA spontaneously immortalized cell line CVCL_H426 CL:0000010 Transfected with: HGNC; 3179; EDNRA Derived from sampling site: Ovary. Female 21090552 CVCL_GS26 GCC-SV(c) cancer cell line human CVCL_GS26 HLA typing: A*02,w30; B*08,10 (PubMed=6956527). CL:0000010 Population: Caucasian Female 21090553 CVCL_H420 CHO-K1/D1 spontaneously immortalized cell line CVCL_H420 CL:0000010 Transfected with: HGNC; 3020; DRD1 Derived from sampling site: Ovary. Female 21090554 CVCL_GS20 SK-MG-6 cancer cell line human CVCL_GS20 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21090555 CVCL_H421 CHO-K1/D2/Galpha15 spontaneously immortalized cell line CVCL_H421 CL:0000010 Transfected with: HGNC; 3023; DRD2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090556 CVCL_GS21 SK-MG-14 cancer cell line human CVCL_GS21 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21090557 CVCL_H422 CHO-K1/D2s/Galpha15 spontaneously immortalized cell line CVCL_H422 CL:0000010 Transfected with: HGNC; 3023; DRD2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090558 CVCL_GS22 SK-LY-16 cancer cell line human CVCL_GS22 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21090559 CVCL_H409 CHO-K1/CB1/Galpha15 spontaneously immortalized cell line CVCL_H409 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090560 CVCL_GS09 GM02712 finite cell line human CVCL_GS09 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090561 CVCL_H405 CHO-K1/BB2 spontaneously immortalized cell line CVCL_H405 CL:0000010 Transfected with: HGNC; 4609; GRPR Derived from sampling site: Ovary. Female 21090562 CVCL_GS05 GM02638 finite cell line human CVCL_GS05 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090563 CVCL_H406 CHO-K1/BB3 spontaneously immortalized cell line CVCL_H406 CL:0000010 Transfected with: HGNC; 1113; BRS3 Derived from sampling site: Ovary. Female 21090564 CVCL_GS06 GM02676 transformed cell line human CVCL_GS06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090565 CVCL_H407 CHO-K1/C5a/Galpha15 spontaneously immortalized cell line CVCL_H407 CL:0000010 Transfected with: HGNC; 1338; C5AR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090566 CVCL_GS07 GM02677 transformed cell line human CVCL_GS07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090567 CVCL_H408 CHO-K1/CASR spontaneously immortalized cell line CVCL_H408 CL:0000010 Transfected with: HGNC; 1514; CASR Derived from sampling site: Ovary. Female 21090568 CVCL_GS08 GM02678 transformed cell line human CVCL_GS08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090569 CVCL_H401 CHO-K1/AMY3/Galpha15 spontaneously immortalized cell line CVCL_H401 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9845; RAMP3 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00481 Female 21090570 CVCL_GS01 GM02613 finite cell line human CVCL_GS01 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21090571 CVCL_H402 CHO-K1/B1/Galpha15 spontaneously immortalized cell line CVCL_H402 CL:0000010 Transfected with: HGNC; 1029; BDKRB1; Transfected with: HGNC; 4383; GNA15 Miscellaneous: Cell line under development; catalog number M00482 Derived from sampling site: Ovary. Female 21090572 CVCL_GS02 GM02614 finite cell line human CVCL_GS02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21090573 CVCL_H403 CHO-K1/B2/Galpha15 spontaneously immortalized cell line CVCL_H403 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090574 CVCL_GS03 GM02635 finite cell line human CVCL_GS03 HLA typing: A*01,02; B*08,15 (Coriell=GM02635) CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090575 CVCL_H404 CHO-K1/BB1 spontaneously immortalized cell line CVCL_H404 CL:0000010 Transfected with: HGNC; 7843; NMBR Derived from sampling site: Ovary. Female 21090576 CVCL_GS04 GM02637 finite cell line human CVCL_GS04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21090577 CVCL_H400 CHO-K1/AMY2/Galpha15 spontaneously immortalized cell line CVCL_H400 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9844; RAMP2 Miscellaneous: Cell line under development; catalog number M00400 Derived from sampling site: Ovary. Female 21090578 CVCL_GS00 GM02557 finite cell line human CVCL_GS00 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Cell type=Fibroblast. Female 21090579 CVCL_PM77 BayGenomics ES cell line XE268 embryonic stem cell house mouse CVCL_PM77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141101; Depdc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090580 CVCL_PM78 BayGenomics ES cell line XE269 embryonic stem cell house mouse CVCL_PM78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141101; Depdc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090581 CVCL_PM79 BayGenomics ES cell line XE279 embryonic stem cell house mouse CVCL_PM79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914144; Wwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090582 CVCL_YG14 CPTC-FOS-3 hybridoma house mouse CVCL_YG14 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01100; Human FOS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090583 CVCL_YG15 CPTC-FOS-4 hybridoma house mouse CVCL_YG15 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01100; Human FOS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090584 CVCL_YG16 CPTC-GCLM-1 hybridoma house mouse CVCL_YG16 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P48507; Human GCLM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090585 CVCL_YG17 CPTC-GCLM-2 hybridoma house mouse CVCL_YG17 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P48507; Human GCLM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090586 CVCL_YG10 CPTC-Fascin1-2 hybridoma house mouse CVCL_YG10 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q16658; Human FSCN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090587 CVCL_YG11 CPTC-Fascin1-3 hybridoma house mouse CVCL_YG11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16658; Human FSCN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090588 CVCL_YG12 CPTC-FOS-1 hybridoma house mouse CVCL_YG12 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01100; Human FOS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090589 CVCL_YG13 CPTC-FOS-2 hybridoma house mouse CVCL_YG13 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01100; Human FOS. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090590 CVCL_PM80 BayGenomics ES cell line XE282 embryonic stem cell house mouse CVCL_PM80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88190; Braf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090591 CVCL_PM81 BayGenomics ES cell line XE293 embryonic stem cell house mouse CVCL_PM81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090592 CVCL_PM82 BayGenomics ES cell line XE295 embryonic stem cell house mouse CVCL_PM82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928380; B4galt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090593 CVCL_PM83 BayGenomics ES cell line XE296 embryonic stem cell house mouse CVCL_PM83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090594 CVCL_PM84 BayGenomics ES cell line XE297 embryonic stem cell house mouse CVCL_PM84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090595 CVCL_YG18 CPTC-GCLM-3 hybridoma house mouse CVCL_YG18 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P48507; Human GCLM. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090596 CVCL_PM85 BayGenomics ES cell line XE307 embryonic stem cell house mouse CVCL_PM85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090597 CVCL_YG19 CPTC-Gelsolin-1 hybridoma house mouse CVCL_YG19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06396; Human GSN. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090598 CVCL_PM86 BayGenomics ES cell line XE315 embryonic stem cell house mouse CVCL_PM86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933162; Lrba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090599 CVCL_PM87 BayGenomics ES cell line XE323 embryonic stem cell house mouse CVCL_PM87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090600 CVCL_PM66 BayGenomics ES cell line XE237 embryonic stem cell house mouse CVCL_PM66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090601 CVCL_PM67 BayGenomics ES cell line XE239 embryonic stem cell house mouse CVCL_PM67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855693; Nap1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090602 CVCL_PM68 BayGenomics ES cell line XE242 embryonic stem cell house mouse CVCL_PM68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090603 CVCL_PM69 BayGenomics ES cell line XE243 embryonic stem cell house mouse CVCL_PM69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090604 CVCL_YG03 CPTC-FABP5-1 hybridoma house mouse CVCL_YG03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01469; Human FABP5. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090605 CVCL_YG04 CPTC-FABP5-2 hybridoma house mouse CVCL_YG04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01469; Human FABP5. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090606 CVCL_YG05 CPTC-FABP5-3 hybridoma house mouse CVCL_YG05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01469; Human FABP5. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090607 CVCL_YG06 CPTC-FAF1-1 hybridoma house mouse CVCL_YG06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UNN5; Human FAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090608 CVCL_YG00 CPTC-Ezrin-1 hybridoma house mouse CVCL_YG00 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P15311; Human EZR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090609 CVCL_YG01 CPTC-FABP2-1 hybridoma house mouse CVCL_YG01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12104; Human FABP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090610 CVCL_YG02 CPTC-FABP2-2 hybridoma house mouse CVCL_YG02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12104; Human FABP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090611 CVCL_PM70 BayGenomics ES cell line XE245 embryonic stem cell house mouse CVCL_PM70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090612 CVCL_PM71 BayGenomics ES cell line XE248 embryonic stem cell house mouse CVCL_PM71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090613 CVCL_PM72 BayGenomics ES cell line XE249 embryonic stem cell house mouse CVCL_PM72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090614 CVCL_PM73 BayGenomics ES cell line XE253 embryonic stem cell house mouse CVCL_PM73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090615 CVCL_YG07 CPTC-FAF1-2 hybridoma house mouse CVCL_YG07 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNN5; Human FAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090616 CVCL_PM74 BayGenomics ES cell line XE260 embryonic stem cell house mouse CVCL_PM74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387123; Lnpep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090617 CVCL_YG08 CPTC-FAF1-3 hybridoma house mouse CVCL_YG08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UNN5; Human FAF1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090618 CVCL_PM75 BayGenomics ES cell line XE262 embryonic stem cell house mouse CVCL_PM75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917623; Gpatch2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090619 CVCL_YG09 CPTC-Fascin1-1 hybridoma house mouse CVCL_YG09 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q16658; Human FSCN1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090620 CVCL_PM76 BayGenomics ES cell line XE266 embryonic stem cell house mouse CVCL_PM76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687042; Ppp1r37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090621 CVCL_PM55 BayGenomics ES cell line XE207 embryonic stem cell house mouse CVCL_PM55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141969; Efl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090622 CVCL_PM56 BayGenomics ES cell line XE208 embryonic stem cell house mouse CVCL_PM56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090623 CVCL_PM57 BayGenomics ES cell line XE209 embryonic stem cell house mouse CVCL_PM57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687042; Ppp1r37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090624 CVCL_PM58 BayGenomics ES cell line XE210 embryonic stem cell house mouse CVCL_PM58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109268; Vasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090625 CVCL_PM59 BayGenomics ES cell line XE220 embryonic stem cell house mouse CVCL_PM59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201787; Socs2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090626 CVCL_PM60 BayGenomics ES cell line XE222 embryonic stem cell house mouse CVCL_PM60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090627 CVCL_PM61 BayGenomics ES cell line XE223 embryonic stem cell house mouse CVCL_PM61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090628 CVCL_PM62 BayGenomics ES cell line XE227 embryonic stem cell house mouse CVCL_PM62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090629 CVCL_PM63 BayGenomics ES cell line XE228 embryonic stem cell house mouse CVCL_PM63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090630 CVCL_PM64 BayGenomics ES cell line XE229 embryonic stem cell house mouse CVCL_PM64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090631 CVCL_PM65 BayGenomics ES cell line XE234 embryonic stem cell house mouse CVCL_PM65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3649576; Gm14393 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090632 CVCL_PM44 BayGenomics ES cell line XE182 embryonic stem cell house mouse CVCL_PM44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924621; Sec24a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090633 CVCL_PM45 BayGenomics ES cell line XE184 embryonic stem cell house mouse CVCL_PM45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090634 CVCL_PM46 BayGenomics ES cell line XE187 embryonic stem cell house mouse CVCL_PM46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651014; Zfp268 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090635 CVCL_PM47 BayGenomics ES cell line XE188 embryonic stem cell house mouse CVCL_PM47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090636 CVCL_PM48 BayGenomics ES cell line XE192 embryonic stem cell house mouse CVCL_PM48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141101; Depdc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090637 CVCL_PM49 BayGenomics ES cell line XE193 embryonic stem cell house mouse CVCL_PM49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090638 CVCL_PM50 BayGenomics ES cell line XE196 embryonic stem cell house mouse CVCL_PM50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090639 CVCL_PM51 BayGenomics ES cell line XE198 embryonic stem cell house mouse CVCL_PM51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102467; Ptpn14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090640 CVCL_PM52 BayGenomics ES cell line XE199 embryonic stem cell house mouse CVCL_PM52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090641 CVCL_PM53 BayGenomics ES cell line XE201 embryonic stem cell house mouse CVCL_PM53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926879; Taf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090642 CVCL_PM54 BayGenomics ES cell line XE205 embryonic stem cell house mouse CVCL_PM54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687042; Ppp1r37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090643 CVCL_PM33 BayGenomics ES cell line XE148 embryonic stem cell house mouse CVCL_PM33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090644 CVCL_PM34 BayGenomics ES cell line XE149 embryonic stem cell house mouse CVCL_PM34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090645 CVCL_PM35 BayGenomics ES cell line XE150 embryonic stem cell house mouse CVCL_PM35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090646 CVCL_PM36 BayGenomics ES cell line XE151 embryonic stem cell house mouse CVCL_PM36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090647 CVCL_PM37 BayGenomics ES cell line XE152 embryonic stem cell house mouse CVCL_PM37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090648 CVCL_PM38 BayGenomics ES cell line XE153 embryonic stem cell house mouse CVCL_PM38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201685; Ctbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090649 CVCL_PM39 BayGenomics ES cell line XE154 embryonic stem cell house mouse CVCL_PM39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88110; Atp2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090650 CVCL_H496 CHO-K1/PTAFR spontaneously immortalized cell line CVCL_H496 CL:0000010 Transfected with: HGNC; 9582; PTAFR Derived from sampling site: Ovary. Female 21090651 CVCL_GS96 GM22595 transformed cell line human CVCL_GS96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090652 CVCL_H497 CHO-K1/PTH1/Galpha15 spontaneously immortalized cell line CVCL_H497 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9608; PTH1R Derived from sampling site: Ovary. Female 21090653 CVCL_GS97 GM23277 transformed cell line human CVCL_GS97 CL:0000010 Sequence variation: Mutation; HGNC; 14063; HDAC4; Simple; c.490+56_121del65; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090654 CVCL_H498 CHO-K1/SCTR/Galpha15 spontaneously immortalized cell line CVCL_H498 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 10608; SCTR Derived from sampling site: Ovary. Female 21090655 CVCL_GS98 GM23420 transformed cell line human CVCL_GS98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090656 CVCL_H499 CHO-K1/SST1/Gqi5 spontaneously immortalized cell line CVCL_H499 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: HGNC; 11330; SSTR1 Derived from sampling site: Ovary. Female 21090657 CVCL_GS99 GM23629 transformed cell line human CVCL_GS99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090658 CVCL_H492 CHO-K1/PAC1/Galpha15 spontaneously immortalized cell line CVCL_H492 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 12695; VIPR2 Derived from sampling site: Ovary. Female 21090659 CVCL_GS92 GM20189 transformed cell line human CVCL_GS92 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; p.Arg500Ter (c.1498C>T); ClinVar=VCV000001198; Zygosity=Homozygous (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090660 CVCL_H493 CHO-K1/PAR2/Galpha15 spontaneously immortalized cell line CVCL_H493 CL:0000010 Transfected with: HGNC; 3538; F2RL1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21090661 CVCL_GS93 GM20190 transformed cell line human CVCL_GS93 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1183-1G>A (IVS3-1G>A) (p.Cys395fs*396); ClinVar=VCV000001195; Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090662 CVCL_H494 CHO-K1/PAR4 spontaneously immortalized cell line CVCL_H494 CL:0000010 Transfected with: HGNC; 3540; F2RL3 Derived from sampling site: Ovary. Female 21090663 CVCL_GS94 GM20193 transformed cell line human CVCL_GS94 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+2T>C (IVS4+2T>C) (p.Cys395fs*403); ClinVar=VCV000001197; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090664 CVCL_H495 CHO-K1/PRLHR spontaneously immortalized cell line CVCL_H495 CL:0000010 Transfected with: HGNC; 4464; PRLHR Derived from sampling site: Ovary. Female 21090665 CVCL_GS95 GM20197 transformed cell line human CVCL_GS95 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+2T>C (IVS4+2T>C) (p.Cys395fs*403); ClinVar=VCV000001197; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090666 CVCL_H490 CHO-K1/OXGR1/Galpha15 spontaneously immortalized cell line CVCL_H490 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4531; OXGR1 Miscellaneous: Cell line under development; catalog number M00483 Derived from sampling site: Ovary. Female 21090667 CVCL_GS90 GM20182 transformed cell line human CVCL_GS90 CL:0000010 Sequence variation: Mutation; HGNC; 17009; TRIOBP; Simple; p.Arg1068Ter (c.3202C>T); ClinVar=VCV000001494; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090668 CVCL_H491 CHO-K1/OXTR spontaneously immortalized cell line CVCL_H491 CL:0000010 Transfected with: HGNC; 8529; OXTR Derived from sampling site: Ovary. Female 21090669 CVCL_GS91 GM20185 transformed cell line human CVCL_GS91 CL:0000010 Sequence variation: Mutation; HGNC; 17009; TRIOBP; Simple; p.Arg788Ter (c.2362C>T); ClinVar=VCV000001493; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090670 CVCL_PM40 BayGenomics ES cell line XE160 embryonic stem cell house mouse CVCL_PM40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95632; Gad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090671 CVCL_PM41 BayGenomics ES cell line XE163 embryonic stem cell house mouse CVCL_PM41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090672 CVCL_PM42 BayGenomics ES cell line XE164 embryonic stem cell house mouse CVCL_PM42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926879; Taf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090673 CVCL_PM43 BayGenomics ES cell line XE180 embryonic stem cell house mouse CVCL_PM43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925255; Rrn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090674 CVCL_PM22 BayGenomics ES cell line XE124 embryonic stem cell house mouse CVCL_PM22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917623; Gpatch2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090675 CVCL_PM23 BayGenomics ES cell line XE129 embryonic stem cell house mouse CVCL_PM23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339977; Agtrap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090676 CVCL_PM24 BayGenomics ES cell line XE133 embryonic stem cell house mouse CVCL_PM24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355333; Nckap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090677 CVCL_PM25 BayGenomics ES cell line XE134 embryonic stem cell house mouse CVCL_PM25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387464; Pank3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090678 CVCL_PM26 BayGenomics ES cell line XE136 embryonic stem cell house mouse CVCL_PM26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090679 CVCL_PM27 BayGenomics ES cell line XE140 embryonic stem cell house mouse CVCL_PM27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090680 CVCL_PM28 BayGenomics ES cell line XE141 embryonic stem cell house mouse CVCL_PM28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090681 CVCL_PM29 BayGenomics ES cell line XE143 embryonic stem cell house mouse CVCL_PM29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090682 CVCL_PM30 BayGenomics ES cell line XE145 embryonic stem cell house mouse CVCL_PM30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921747; Zfp710 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090683 CVCL_PM31 BayGenomics ES cell line XE146 embryonic stem cell house mouse CVCL_PM31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090684 CVCL_PM32 BayGenomics ES cell line XE147 embryonic stem cell house mouse CVCL_PM32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928380; B4galt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090685 CVCL_PM11 BayGenomics ES cell line XE089 embryonic stem cell house mouse CVCL_PM11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914144; Wwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090686 CVCL_PM12 BayGenomics ES cell line XE090 embryonic stem cell house mouse CVCL_PM12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090687 CVCL_PM13 BayGenomics ES cell line XE093 embryonic stem cell house mouse CVCL_PM13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090688 CVCL_PM14 BayGenomics ES cell line XE095 embryonic stem cell house mouse CVCL_PM14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182036; Gin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090689 CVCL_PM15 BayGenomics ES cell line XE101 embryonic stem cell house mouse CVCL_PM15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090690 CVCL_PM16 BayGenomics ES cell line XE107 embryonic stem cell house mouse CVCL_PM16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090691 CVCL_PM17 BayGenomics ES cell line XE115 embryonic stem cell house mouse CVCL_PM17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442757; Zfp667 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090692 CVCL_PM18 BayGenomics ES cell line XE117 embryonic stem cell house mouse CVCL_PM18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917338; Meaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090693 CVCL_PM19 BayGenomics ES cell line XE118 embryonic stem cell house mouse CVCL_PM19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917599; Copb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090694 CVCL_H478 CHO-K1/NPS1b/Galpha15 spontaneously immortalized cell line CVCL_H478 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 23631; NPSR1 Derived from sampling site: Ovary. Female 21090695 CVCL_GS78 GM11411 transformed cell line human CVCL_GS78 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Homozygous (PubMed=1346349; PubMed=1680289) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090696 CVCL_H479 CHO-K1/NPY1/Galpha15 spontaneously immortalized cell line CVCL_H479 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 7956; NPY1R Miscellaneous: Cell line under development; catalog number M00192 Derived from sampling site: Ovary. Female 21090697 CVCL_GS79 GM11813 transformed cell line human CVCL_GS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090698 CVCL_H474 CHO-K1/NPBW1/Galpha15 spontaneously immortalized cell line CVCL_H474 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4522; NPBWR1 Derived from sampling site: Ovary. Female 21090699 CVCL_GS74 GM08832 transformed cell line human CVCL_GS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090700 CVCL_H475 CHO-K1/NPFF1/Galpha15 spontaneously immortalized cell line CVCL_H475 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 17425; NPFFR1 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00431 Female 21090701 CVCL_GS75 GM09666 transformed cell line human CVCL_GS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090702 CVCL_H476 CHO-K1/NPFF2/Galpha15 spontaneously immortalized cell line CVCL_H476 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4525; NPFFR2 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00474 Female 21090703 CVCL_GS76 GM09670 transformed cell line human CVCL_GS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090704 CVCL_H477 CHO-K1/NPS1a/Galpha15 spontaneously immortalized cell line CVCL_H477 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 23631; NPSR1 Derived from sampling site: Ovary. Female 21090705 CVCL_GS77 GM09682 transformed cell line human CVCL_GS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090706 CVCL_H470 CHO-K1/NK1 spontaneously immortalized cell line CVCL_H470 CL:0000010 Transfected with: HGNC; 11526; TACR1 Derived from sampling site: Ovary. Female 21090707 CVCL_GS70 GM06142 transformed cell line human CVCL_GS70 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Pro297Gln (c.890C>A); ClinVar=VCV000001961; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090708 CVCL_H471 CHO-K1/NK2 spontaneously immortalized cell line CVCL_H471 CL:0000010 Transfected with: HGNC; 11527; TACR2 Derived from sampling site: Ovary. Female 21090709 CVCL_GS71 GM06143 transformed cell line human CVCL_GS71 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg149Gln (c.446G>A); ClinVar=VCV000001963; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Pro297Gln (c.890C>A); ClinVar=VCV000001961; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090710 CVCL_H472 CHO-K1/NK3 spontaneously immortalized cell line CVCL_H472 CL:0000010 Transfected with: HGNC; 11528; TACR3 Derived from sampling site: Ovary. Female 21090711 CVCL_GS72 GM06200 transformed cell line human CVCL_GS72 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg76Trp (c.226C>T); ClinVar=VCV000001962; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090712 CVCL_H473 CHO-K1/NMU1 spontaneously immortalized cell line CVCL_H473 CL:0000010 Transfected with: HGNC; 4518; NMUR1 Derived from sampling site: Ovary. Female 21090713 CVCL_GS73 GM06221 transformed cell line human CVCL_GS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090714 CVCL_PM20 BayGenomics ES cell line XE120 embryonic stem cell house mouse CVCL_PM20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090715 CVCL_PM21 BayGenomics ES cell line XE121 embryonic stem cell house mouse CVCL_PM21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316740; Morc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090716 CVCL_PM00 BayGenomics ES cell line XE067 embryonic stem cell house mouse CVCL_PM00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384993; Paip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090717 CVCL_PM01 BayGenomics ES cell line XE068 embryonic stem cell house mouse CVCL_PM01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355333; Nckap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090718 CVCL_PM02 BayGenomics ES cell line XE071 embryonic stem cell house mouse CVCL_PM02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090719 CVCL_PM03 BayGenomics ES cell line XE072 embryonic stem cell house mouse CVCL_PM03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202397; Ints6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090720 CVCL_PM04 BayGenomics ES cell line XE075 embryonic stem cell house mouse CVCL_PM04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108089; Erh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090721 CVCL_PM05 BayGenomics ES cell line XE077 embryonic stem cell house mouse CVCL_PM05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890613; Pes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090722 CVCL_PM06 BayGenomics ES cell line XE080 embryonic stem cell house mouse CVCL_PM06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090723 CVCL_PM07 BayGenomics ES cell line XE082 embryonic stem cell house mouse CVCL_PM07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354949; Dlc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090724 CVCL_PM08 BayGenomics ES cell line XE084 embryonic stem cell house mouse CVCL_PM08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090725 CVCL_PM09 BayGenomics ES cell line XE085 embryonic stem cell house mouse CVCL_PM09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354736; Kdm2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090726 CVCL_H489 CHO-K1/Galpha15/OXER1 spontaneously immortalized cell line CVCL_H489 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 24884; OXER1 Miscellaneous: Cell line under development; catalog number M00488 Derived from sampling site: Ovary. Female 21090727 CVCL_GS89 GM20172 transformed cell line human CVCL_GS89 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+4_1331+7delAGTG (IVS4+2delTGAG) (p.Lys445fs*461); ClinVar=VCV000001196; Zygosity=Homozygous (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090728 CVCL_H485 CHO-K1/OPRL1/Galpha15 spontaneously immortalized cell line CVCL_H485 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 8155; OPRL1 Derived from sampling site: Ovary. Female 21090729 CVCL_GS85 GM13343 transformed cell line human CVCL_GS85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090730 CVCL_H486 CHO-K1/OPRM1/Galpha15 spontaneously immortalized cell line CVCL_H486 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 8156; OPRM1 Derived from sampling site: Ovary. Female 21090731 CVCL_GS86 GM13344 transformed cell line human CVCL_GS86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090732 CVCL_H487 CHO-K1/OX1 spontaneously immortalized cell line CVCL_H487 CL:0000010 Transfected with: HGNC; 4848; HCRTR1 Derived from sampling site: Ovary. Female 21090733 CVCL_GS87 GM14952 transformed cell line human CVCL_GS87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from acute lymphocytic leukemia; Derived from sampling site: Peripheral blood. Male 21090734 CVCL_H488 CHO-K1/OX2 spontaneously immortalized cell line CVCL_H488 CL:0000010 Transfected with: HGNC; 4849; HCRTR2 Derived from sampling site: Ovary. Female 21090735 CVCL_GS88 GM17895 transformed cell line human CVCL_GS88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090736 CVCL_H481 CHO-K1/NPY4/Galpha15 spontaneously immortalized cell line CVCL_H481 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9329; NPY4R Derived from sampling site: Ovary. Female 21090737 CVCL_GS81 GM13078 finite cell line human CVCL_GS81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21090738 CVCL_H482 CHO-K1/NTS1 spontaneously immortalized cell line CVCL_H482 CL:0000010 Transfected with: HGNC; 8039; NTSR1 Derived from sampling site: Ovary. Female 21090739 CVCL_GS82 GM13241 finite cell line human CVCL_GS82 CL:0000010 Population: Caucasian; German; Derived from sampling site: Cell type=Fibroblast. Male 21090740 CVCL_H483 CHO-K1/OPRD1/Galpha15 spontaneously immortalized cell line CVCL_H483 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 8153; OPRD1 Derived from sampling site: Ovary. Female 21090741 CVCL_GS83 GM13278 transformed cell line human CVCL_GS83 CL:0000010 Sequence variation: Mutation; HGNC; 9155; PNLIP; Simple; p.Asn162Asn (c.486C>T) (486C/T); ClinVar=VCV000769789; Zygosity=Heterozygous (PubMed=11393534) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21090742 CVCL_H484 CHO-K1/OPRK1/Galpha15 spontaneously immortalized cell line CVCL_H484 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 8154; OPRK1 Derived from sampling site: Ovary. Female 21090743 CVCL_GS84 GM13322 transformed cell line human CVCL_GS84 CL:0000010 Sequence variation: Mutation; HGNC; 9155; PNLIP; Simple; p.Pro32Pro (c.96A>C) (96A/C); ClinVar=VCV000768391; Zygosity=Homozygous (PubMed=11393534); Sequence variation: Mutation; HGNC; 9155; PNLIP; Simple; p.Thr453Thr (c.1359C>T) (1359C/T); ClinVar=VCV000768392; Zygosity=Homozygous (PubMed=11393534) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090744 CVCL_H480 CHO-K1/NPY2/Gqi5 spontaneously immortalized cell line CVCL_H480 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: HGNC; 7957; NPY2R Derived from sampling site: Ovary. Female 21090745 CVCL_GS80 GM12126 transformed cell line human CVCL_GS80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21090746 CVCL_PM10 BayGenomics ES cell line XE087 embryonic stem cell house mouse CVCL_PM10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090747 CVCL_YF73 CPTC-CSTA-3 hybridoma house mouse CVCL_YF73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01040; Human CSTA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090748 CVCL_YF74 CPTC-CSTB-1 hybridoma house mouse CVCL_YF74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04080; Human CSTB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090749 CVCL_YF75 CPTC-CSTB-2 hybridoma house mouse CVCL_YF75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04080; Human CSTB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090750 CVCL_YF76 CPTC-CSTB-3 hybridoma house mouse CVCL_YF76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04080; Human CSTB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090751 CVCL_YF70 CPTC-CRYAB-3 hybridoma house mouse CVCL_YF70 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02511; Human CRYAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090752 CVCL_YF71 CPTC-CSTA-1 hybridoma house mouse CVCL_YF71 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01040; Human CSTA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090753 CVCL_YF72 CPTC-CSTA-2 hybridoma house mouse CVCL_YF72 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01040; Human CSTA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090754 CVCL_YF77 CPTC-CTNNBL1-1 hybridoma house mouse CVCL_YF77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WYA6; Human CTNNBL1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090755 CVCL_YF78 CPTC-CXCL9-1 hybridoma house mouse CVCL_YF78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q07325; Human CXCL9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090756 CVCL_YF79 CPTC-DDIT3-1 hybridoma house mouse CVCL_YF79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P35638; Human DDIT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090757 CVCL_YF62 CPTC-CKB-3 hybridoma house mouse CVCL_YF62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12277; Human CKB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090758 CVCL_YF63 CPTC-CLIC1-1 hybridoma house mouse CVCL_YF63 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; O00299; Human CLIC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090759 CVCL_YF64 CPTC-CLIC1-2 hybridoma house mouse CVCL_YF64 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O00299; Human CLIC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090760 CVCL_YF65 CPTC-CPE-1 hybridoma house mouse CVCL_YF65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16870; Human CPE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090761 CVCL_YF60 CPTC-CKB-1 hybridoma house mouse CVCL_YF60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12277; Human CKB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090762 CVCL_YF61 CPTC-CKB-2 hybridoma house mouse CVCL_YF61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12277; Human CKB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090763 CVCL_YF66 CPTC-CPE-2 hybridoma house mouse CVCL_YF66 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P16870; Human CPE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090764 CVCL_YF67 CPTC-CPE-3 hybridoma house mouse CVCL_YF67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16870; Human CPE. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090765 CVCL_YF68 CPTC-CRYAB-1 hybridoma house mouse CVCL_YF68 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02511; Human CRYAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090766 CVCL_YF69 CPTC-CRYAB-2 hybridoma house mouse CVCL_YF69 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02511; Human CRYAB. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090767 CVCL_YF51 CPTC-CHEK1-3 hybridoma house mouse CVCL_YF51 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O14757; Human CHEK1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090768 CVCL_YF52 CPTC-CHGA-1 hybridoma house mouse CVCL_YF52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10645; Human CHGA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090769 CVCL_YF53 CPTC-CHGA-2 hybridoma house mouse CVCL_YF53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10645; Human CHGA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090770 CVCL_YF54 CPTC-CHGA-3 hybridoma house mouse CVCL_YF54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10645; Human CHGA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090771 CVCL_YF50 CPTC-CDH2-4 hybridoma house mouse CVCL_YF50 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P19022; Human CDH2/CD325. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090772 CVCL_YF59 CPTC-CHP2-3 hybridoma house mouse CVCL_YF59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43745; Human CHP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090773 CVCL_YF55 CPTC-CHKA-2 hybridoma house mouse CVCL_YF55 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35790; Human CHKA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090774 CVCL_YF56 CPTC-CHKA-3 hybridoma house mouse CVCL_YF56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35790; Human CHKA. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090775 CVCL_YF57 CPTC-CHP2-1 hybridoma house mouse CVCL_YF57 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43745; Human CHP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090776 CVCL_YF58 CPTC-CHP2-2 hybridoma house mouse CVCL_YF58 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43745; Human CHP2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090777 CVCL_YF40 CPTC-CD47-2 hybridoma house mouse CVCL_YF40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090778 CVCL_YF41 CPTC-CD47-3 hybridoma house mouse CVCL_YF41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090779 CVCL_YF42 CPTC-CDC34-1 hybridoma house mouse CVCL_YF42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49427; Human CDC34. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090780 CVCL_YF43 CPTC-CDC34-2 hybridoma house mouse CVCL_YF43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49427; Human CDC34. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090781 CVCL_YF48 CPTC-CDH2-1 hybridoma house mouse CVCL_YF48 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P19022; Human CDH2/CD325. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090782 CVCL_YF49 CPTC-CDH2-2 hybridoma house mouse CVCL_YF49 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P19022; Human CDH2/CD325. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090783 CVCL_YF44 CPTC-CDH1-1 hybridoma house mouse CVCL_YF44 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090784 CVCL_YF45 CPTC-CDH1-2 hybridoma house mouse CVCL_YF45 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090785 CVCL_YF46 CPTC-CDH1-3 hybridoma house mouse CVCL_YF46 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090786 CVCL_YF47 CPTC-CDH1-4 hybridoma house mouse CVCL_YF47 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P12830; Human CDH1/CD324. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090787 CVCL_YF30 CPTC-CA8-2 hybridoma house mouse CVCL_YF30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35219; Human CA8. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090788 CVCL_YF31 CPTC-Calcyclin-1 hybridoma house mouse CVCL_YF31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06703; Human S100A6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090789 CVCL_YF32 CPTC-Calcyclin-3 hybridoma house mouse CVCL_YF32 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06703; Human S100A6. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090790 CVCL_YF37 CPTC-CCND1-5 hybridoma house mouse CVCL_YF37 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090791 CVCL_YF38 CPTC-CCND1-6 hybridoma house mouse CVCL_YF38 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090792 CVCL_YF39 CPTC-CD47-1 hybridoma house mouse CVCL_YF39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090793 CVCL_YF33 CPTC-CCND1-1 hybridoma house mouse CVCL_YF33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090794 CVCL_YF34 CPTC-CCND1-2 hybridoma house mouse CVCL_YF34 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090795 CVCL_YF35 CPTC-CCND1-3 hybridoma house mouse CVCL_YF35 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090796 CVCL_YF36 CPTC-CCND1-4 hybridoma house mouse CVCL_YF36 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P24385; Human CCND1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090797 CVCL_PL89 BayGenomics ES cell line XE043 embryonic stem cell house mouse CVCL_PL89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090798 CVCL_YF20 CPTC-BRAF-2 hybridoma house mouse CVCL_YF20 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090799 CVCL_YF21 CPTC-BRAF-3 hybridoma house mouse CVCL_YF21 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090800 CVCL_YF26 CPTC-BRCA1-2 hybridoma house mouse CVCL_YF26 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090801 CVCL_YF27 CPTC-BRIP1-1 hybridoma house mouse CVCL_YF27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BX63; Human BRIP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090802 CVCL_YF28 CPTC-BRIP1-2 hybridoma house mouse CVCL_YF28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BX63; Human BRIP1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090803 CVCL_YF29 CPTC-CA8-1 hybridoma house mouse CVCL_YF29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P35219; Human CA8. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090804 CVCL_YF22 CPTC-BRAF-4 hybridoma house mouse CVCL_YF22 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090805 CVCL_YF23 CPTC-BRAF-5 hybridoma house mouse CVCL_YF23 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090806 CVCL_PL90 BayGenomics ES cell line XE045 embryonic stem cell house mouse CVCL_PL90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090807 CVCL_YF24 CPTC-BRAF-6 hybridoma house mouse CVCL_YF24 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090808 CVCL_PL91 BayGenomics ES cell line XE047 embryonic stem cell house mouse CVCL_PL91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920037; Ndc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090809 CVCL_YF25 CPTC-BRCA1-1 hybridoma house mouse CVCL_YF25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090810 CVCL_PL92 BayGenomics ES cell line XE048 embryonic stem cell house mouse CVCL_PL92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090811 CVCL_PL93 BayGenomics ES cell line XE049 embryonic stem cell house mouse CVCL_PL93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443713; Ythdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090812 CVCL_PL94 BayGenomics ES cell line XE051 embryonic stem cell house mouse CVCL_PL94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090813 CVCL_PL95 BayGenomics ES cell line XE056 embryonic stem cell house mouse CVCL_PL95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929091; Sinhcaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090814 CVCL_PL96 BayGenomics ES cell line XE057 embryonic stem cell house mouse CVCL_PL96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090815 CVCL_PL97 BayGenomics ES cell line XE058 embryonic stem cell house mouse CVCL_PL97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090816 CVCL_PL98 BayGenomics ES cell line XE061 embryonic stem cell house mouse CVCL_PL98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916043; Rab3gap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090817 CVCL_PL99 BayGenomics ES cell line XE062 embryonic stem cell house mouse CVCL_PL99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855693; Nap1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090818 CVCL_PL78 BayGenomics ES cell line XE025 embryonic stem cell house mouse CVCL_PL78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354742; Synrg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090819 CVCL_PL79 BayGenomics ES cell line XE027 embryonic stem cell house mouse CVCL_PL79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090820 CVCL_YF10 CPTC-BAI1-1 hybridoma house mouse CVCL_YF10 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; O14514; Human ADGRB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090821 CVCL_YF15 CPTC-BCL2L1-3 hybridoma house mouse CVCL_YF15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q07817; Human BCL2L1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090822 CVCL_YF16 CPTC-BCL2L2-1 hybridoma house mouse CVCL_YF16 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q92843; Human BCL2L2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090823 CVCL_YF17 CPTC-BCL2L2-2 hybridoma house mouse CVCL_YF17 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q92843; Human BCL2L2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090824 CVCL_YF18 CPTC-BCL2L2-3 hybridoma house mouse CVCL_YF18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92843; Human BCL2L2. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090825 CVCL_YF11 CPTC-BAI1-2 hybridoma house mouse CVCL_YF11 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; O14514; Human ADGRB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090826 CVCL_YF12 CPTC-BAI1-3 hybridoma house mouse CVCL_YF12 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14514; Human ADGRB1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090827 CVCL_YF13 CPTC-BCL2L1-1 hybridoma house mouse CVCL_YF13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q07817; Human BCL2L1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090828 CVCL_PL80 BayGenomics ES cell line XE029 embryonic stem cell house mouse CVCL_PL80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090829 CVCL_YF14 CPTC-BCL2L1-2 hybridoma house mouse CVCL_YF14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q07817; Human BCL2L1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090830 CVCL_PL81 BayGenomics ES cell line XE030 embryonic stem cell house mouse CVCL_PL81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387464; Pank3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090831 CVCL_PL82 BayGenomics ES cell line XE031 embryonic stem cell house mouse CVCL_PL82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090832 CVCL_PL83 BayGenomics ES cell line XE033 embryonic stem cell house mouse CVCL_PL83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159614; Mia2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090833 CVCL_PL84 BayGenomics ES cell line XE034 embryonic stem cell house mouse CVCL_PL84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917029; Pphln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090834 CVCL_PL85 BayGenomics ES cell line XE036 embryonic stem cell house mouse CVCL_PL85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090835 CVCL_YF19 CPTC-BRAF-1 hybridoma house mouse CVCL_YF19 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15056; Human BRAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090836 CVCL_PL86 BayGenomics ES cell line XE039 embryonic stem cell house mouse CVCL_PL86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090837 CVCL_PL87 BayGenomics ES cell line XE041 embryonic stem cell house mouse CVCL_PL87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090838 CVCL_PL88 BayGenomics ES cell line XE042 embryonic stem cell house mouse CVCL_PL88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182061; Usp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090839 CVCL_PL67 BayGenomics ES cell line XE010 embryonic stem cell house mouse CVCL_PL67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444951; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090840 CVCL_PL68 BayGenomics ES cell line XE012 embryonic stem cell house mouse CVCL_PL68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929091; Sinhcaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090841 CVCL_PL69 BayGenomics ES cell line XE013 embryonic stem cell house mouse CVCL_PL69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917132; Ints14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090842 CVCL_YF04 CPTC-ANXA1-3 hybridoma house mouse CVCL_YF04 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04083; Human ANXA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090843 CVCL_YF05 CPTC-APEX1-2 hybridoma house mouse CVCL_YF05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27695; Human APEX1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090844 CVCL_YF06 CPTC-ARAF-1 hybridoma house mouse CVCL_YF06 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10398; Human ARAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090845 CVCL_YF07 CPTC-ARAF-2 hybridoma house mouse CVCL_YF07 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P10398; Human ARAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090846 CVCL_YF00 CPTC-AKT3-6 hybridoma house mouse CVCL_YF00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090847 CVCL_YF01 CPTC-AKT3-7 hybridoma house mouse CVCL_YF01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y243; Human AKT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090848 CVCL_YF02 CPTC-ANXA1-1 hybridoma house mouse CVCL_YF02 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04083; Human ANXA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090849 CVCL_YF03 CPTC-ANXA1-2 hybridoma house mouse CVCL_YF03 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04083; Human ANXA1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090850 CVCL_PL70 BayGenomics ES cell line XE014 embryonic stem cell house mouse CVCL_PL70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090851 CVCL_PL71 BayGenomics ES cell line XE016 embryonic stem cell house mouse CVCL_PL71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090852 CVCL_PL72 BayGenomics ES cell line XE017 embryonic stem cell house mouse CVCL_PL72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090853 CVCL_PL73 BayGenomics ES cell line XE018 embryonic stem cell house mouse CVCL_PL73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921414; Nfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090854 CVCL_PL74 BayGenomics ES cell line XE019 embryonic stem cell house mouse CVCL_PL74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387123; Lnpep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090855 CVCL_YF08 CPTC-ARAF-3 hybridoma house mouse CVCL_YF08 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10398; Human ARAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090856 CVCL_PL75 BayGenomics ES cell line XE021 embryonic stem cell house mouse CVCL_PL75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347070; Psma7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090857 CVCL_YF09 CPTC-ARAF-4 hybridoma house mouse CVCL_YF09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10398; Human ARAF. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090858 CVCL_PL76 BayGenomics ES cell line XE022 embryonic stem cell house mouse CVCL_PL76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090859 CVCL_PL77 BayGenomics ES cell line XE024 embryonic stem cell house mouse CVCL_PL77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21090860 CVCL_YF90 CPTC-EGFR-6 hybridoma house mouse CVCL_YF90 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090861 CVCL_YF95 CPTC-ERBB2-3 hybridoma house mouse CVCL_YF95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090862 CVCL_YF96 CPTC-ERBB3-1 hybridoma house mouse CVCL_YF96 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090863 CVCL_YF97 CPTC-ERBB3-2 hybridoma house mouse CVCL_YF97 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090864 CVCL_YF98 CPTC-ERBB3-3 hybridoma house mouse CVCL_YF98 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090865 CVCL_YF91 CPTC-EGFR-7 hybridoma house mouse CVCL_YF91 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090866 CVCL_YF92 CPTC-EPHB4-1 hybridoma house mouse CVCL_YF92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P54760; Human EPHB4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090867 CVCL_YF93 CPTC-EPHB4-2 hybridoma house mouse CVCL_YF93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54760; Human EPHB4. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090868 CVCL_YF94 CPTC-ERBB2-2 hybridoma house mouse CVCL_YF94 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090869 CVCL_YF99 CPTC-ERBB3-4 hybridoma house mouse CVCL_YF99 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090870 CVCL_YF84 CPTC-EBAG9-1 hybridoma house mouse CVCL_YF84 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O00559; Human EBAG9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090871 CVCL_YF85 CPTC-EBAG9-3 hybridoma house mouse CVCL_YF85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00559; Human EBAG9. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090872 CVCL_YF86 CPTC-EGFR-1 hybridoma house mouse CVCL_YF86 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090873 CVCL_YF87 CPTC-EGFR-2 hybridoma house mouse CVCL_YF87 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090874 CVCL_YF80 CPTC-DDIT3-2 hybridoma house mouse CVCL_YF80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P35638; Human DDIT3. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090875 CVCL_YF81 CPTC-DLC1-1 hybridoma house mouse CVCL_YF81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96QB1; Human DLC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090876 CVCL_YF82 CPTC-DLC1-2 hybridoma house mouse CVCL_YF82 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96QB1; Human DLC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090877 CVCL_YF83 CPTC-DLC1-3 hybridoma house mouse CVCL_YF83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96QB1; Human DLC1. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090878 CVCL_YF88 CPTC-EGFR-4 hybridoma house mouse CVCL_YF88 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090879 CVCL_YF89 CPTC-EGFR-5 hybridoma house mouse CVCL_YF89 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Part of: NCI Clinical Proteomics Technologies for Cancer (CPTC) hybridoma collection 21090880 CVCL_6J63 DA00275 transformed cell line human CVCL_6J63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090881 CVCL_6J64 DA00276 transformed cell line human CVCL_6J64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090882 CVCL_6J65 DA00277 transformed cell line human CVCL_6J65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090883 CVCL_6J66 DA00278 transformed cell line human CVCL_6J66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090884 CVCL_6J60 DA00272 transformed cell line human CVCL_6J60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090885 CVCL_6J61 DA00273 transformed cell line human CVCL_6J61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090886 CVCL_6J62 DA00274 transformed cell line human CVCL_6J62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090887 CVCL_6J67 DA00279 transformed cell line human CVCL_6J67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090888 CVCL_6J68 DA00280 transformed cell line human CVCL_6J68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090889 CVCL_6J69 DA00281 transformed cell line human CVCL_6J69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090890 CVCL_6J74 DA00286 transformed cell line human CVCL_6J74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090891 CVCL_6J75 DA00287 transformed cell line human CVCL_6J75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090892 CVCL_6J76 DA00288 transformed cell line human CVCL_6J76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090893 CVCL_6J77 DA00289 transformed cell line human CVCL_6J77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090894 CVCL_6J70 DA00282 transformed cell line human CVCL_6J70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090895 CVCL_6J71 DA00283 transformed cell line human CVCL_6J71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090896 CVCL_6J72 DA00284 transformed cell line human CVCL_6J72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090897 CVCL_6J73 DA00285 transformed cell line human CVCL_6J73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090898 CVCL_6J78 DA00290 transformed cell line human CVCL_6J78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090899 CVCL_6J79 DA00291 transformed cell line human CVCL_6J79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090900 CVCL_6J41 DA00253 transformed cell line human CVCL_6J41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090901 CVCL_6J42 DA00254 transformed cell line human CVCL_6J42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090902 CVCL_6J43 DA00255 transformed cell line human CVCL_6J43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090903 CVCL_6J44 DA00256 transformed cell line human CVCL_6J44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090904 CVCL_6J40 DA00252 transformed cell line human CVCL_6J40 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090905 CVCL_6J49 DA00261 transformed cell line human CVCL_6J49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090906 CVCL_6J45 DA00257 transformed cell line human CVCL_6J45 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090907 CVCL_6J46 DA00258 transformed cell line human CVCL_6J46 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090908 CVCL_6J47 DA00259 transformed cell line human CVCL_6J47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090909 CVCL_6J48 DA00260 transformed cell line human CVCL_6J48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090910 CVCL_Z193 CCE3 spontaneously immortalized cell line CVCL_Z193 CL:0000010 Female Group: Tick cell line. 21090911 CVCL_Z194 CCE5 spontaneously immortalized cell line CVCL_Z194 CL:0000010 Unspecified Group: Tick cell line. 21090912 CVCL_Z195 DAE100 spontaneously immortalized cell line CVCL_Z195 CL:0000010 Unspecified Group: Tick cell line. 21090913 CVCL_Z196 DAE100A spontaneously immortalized cell line CVCL_Z196 CL:0000010 Unspecified Group: Tick cell line. 21090914 CVCL_Z190 DVE1 spontaneously immortalized cell line CVCL_Z190 CL:0000010 Unspecified Group: Tick cell line. 21090915 CVCL_Z191 CCE1 spontaneously immortalized cell line CVCL_Z191 CL:0000010 Unspecified Group: Tick cell line. 21090916 CVCL_Z192 CCE2 spontaneously immortalized cell line CVCL_Z192 CL:0000010 Unspecified Group: Tick cell line. 21090917 CVCL_Z197 DAE100H spontaneously immortalized cell line CVCL_Z197 CL:0000010 Unspecified Group: Tick cell line. 21090918 CVCL_Z198 DAE15 spontaneously immortalized cell line CVCL_Z198 CL:0000010 Unspecified Group: Tick cell line. 21090919 CVCL_Z199 DAE3 spontaneously immortalized cell line CVCL_Z199 CL:0000010 Unspecified Group: Tick cell line. 21090920 CVCL_6J52 DA00264 transformed cell line human CVCL_6J52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090921 CVCL_6J53 DA00265 transformed cell line human CVCL_6J53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090922 CVCL_6J54 DA00266 transformed cell line human CVCL_6J54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090923 CVCL_6J55 DA00267 transformed cell line human CVCL_6J55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090924 CVCL_6J50 DA00262 transformed cell line human CVCL_6J50 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090925 CVCL_6J51 DA00263 transformed cell line human CVCL_6J51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090926 CVCL_6J56 DA00268 transformed cell line human CVCL_6J56 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090927 CVCL_6J57 DA00269 transformed cell line human CVCL_6J57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090928 CVCL_6J58 DA00270 transformed cell line human CVCL_6J58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090929 CVCL_6J59 DA00271 transformed cell line human CVCL_6J59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090930 CVCL_Z182 RML-RSE spontaneously immortalized cell line CVCL_Z182 CL:0000010 Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00583; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8052. Problematic cell line: Misidentified Originally thought to be of Dermacentor variabilis origin but found to be from Rhipicephalus sanguineus (PubMed=26210950). 21090931 CVCL_Z183 RML-16 spontaneously immortalized cell line CVCL_Z183 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Schwan T to Bell-Sakyi L.).. Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8053 21090932 CVCL_Z184 RML-17 spontaneously immortalized cell line CVCL_Z184 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Schwan T to Bell-Sakyi L.).. Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8054 21090933 CVCL_Z185 RML-18 spontaneously immortalized cell line CVCL_Z185 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Schwan T to Bell-Sakyi L.).. Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8055 21090934 CVCL_Z180 BME26-IVM spontaneously immortalized cell line CVCL_Z180 CL:0000010 Selected for resistance to: ChEBI; CHEBI:6078; Ivermectin. Male Group: Tick cell line 21090935 CVCL_Z181 RML-14 spontaneously immortalized cell line CVCL_Z181 CL:0000010 Miscellaneous: Cell line no longer exist As described in Patent=US4447537 it 'has accidentally been extinguished by toxic culture medium and bacterial contamination of frozen stocks'.. Unspecified Doubling time: ~70 hours (PubMed=592041) Group: Tick cell line 21090936 CVCL_Z186 RML-19 spontaneously immortalized cell line CVCL_Z186 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Schwan T to Bell-Sakyi L.).. Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8056 21090937 CVCL_Z187 RML-20 spontaneously immortalized cell line CVCL_Z187 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Schwan T to Bell-Sakyi L.).. Unspecified Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8057 21090938 CVCL_Z188 AAE12 spontaneously immortalized cell line CVCL_Z188 CL:0000010 Unspecified Group: Tick cell line. 21090939 CVCL_Z189 AAE2 spontaneously immortalized cell line CVCL_Z189 CL:0000010 Unspecified Group: Tick cell line. 21090940 CVCL_6J20 DA00230 transformed cell line human CVCL_6J20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090941 CVCL_6J21 DA00231 transformed cell line human CVCL_6J21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090942 CVCL_6J22 DA00234 transformed cell line human CVCL_6J22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090943 CVCL_6J27 DA00239 transformed cell line human CVCL_6J27 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090944 CVCL_6J28 DA00240 transformed cell line human CVCL_6J28 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090945 CVCL_6J29 DA00241 transformed cell line human CVCL_6J29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090946 CVCL_6J23 DA00235 transformed cell line human CVCL_6J23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090947 CVCL_6J24 DA00236 transformed cell line human CVCL_6J24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090948 CVCL_6J25 DA00237 transformed cell line human CVCL_6J25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090949 CVCL_6J26 DA00238 transformed cell line human CVCL_6J26 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090950 CVCL_Z171 DALBE3 spontaneously immortalized cell line CVCL_Z171 CL:0000010 Unspecified Group: Tick cell line. 21090951 CVCL_Z172 OME/CTVM21 spontaneously immortalized cell line CVCL_Z172 CL:0000010 Unspecified Group: Tick cell line. 21090952 CVCL_Z173 OME/CTVM22 spontaneously immortalized cell line CVCL_Z173 CL:0000010 Unspecified Group: Tick cell line. 21090953 CVCL_Z174 OME/CTVM24 spontaneously immortalized cell line CVCL_Z174 CL:0000010 Unspecified Group: Tick cell line. 21090954 CVCL_Z170 ISE6 spontaneously immortalized cell line CVCL_Z170 CL:0000010 Omics: Deep proteome analysis; Omics: Metabolome analysis; Omics: Transcriptome analysis by RNAseq. Unspecified Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11974 21090955 CVCL_Z179 BME26 spontaneously immortalized cell line CVCL_Z179 CL:0000010 Male Group: Tick cell line. 21090956 CVCL_Z175 OME/CTVM25 spontaneously immortalized cell line CVCL_Z175 CL:0000010 Unspecified Group: Tick cell line. 21090957 CVCL_Z176 OME/CTVM26 spontaneously immortalized cell line CVCL_Z176 CL:0000010 Unspecified Group: Tick cell line. 21090958 CVCL_Z177 OME/CTVM27 spontaneously immortalized cell line CVCL_Z177 CL:0000010 Unspecified Group: Tick cell line. 21090959 CVCL_Z178 ANE58 spontaneously immortalized cell line CVCL_Z178 CL:0000010 Miscellaneous: Called ANE 64 in the original publication (PubMed=6644089), but seems to have been called ANE58/ANE 58 since in all other publications from the same authors. Unspecified Group: Tick cell line 21090960 CVCL_6J30 DA00242 transformed cell line human CVCL_6J30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090961 CVCL_6J31 DA00243 transformed cell line human CVCL_6J31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090962 CVCL_6J32 DA00244 transformed cell line human CVCL_6J32 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090963 CVCL_6J33 DA00245 transformed cell line human CVCL_6J33 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090964 CVCL_6J38 DA00250 transformed cell line human CVCL_6J38 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090965 CVCL_6J39 DA00251 transformed cell line human CVCL_6J39 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090966 CVCL_6J34 DA00246 transformed cell line human CVCL_6J34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090967 CVCL_6J35 DA00247 transformed cell line human CVCL_6J35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090968 CVCL_6J36 DA00248 transformed cell line human CVCL_6J36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090969 CVCL_6J37 DA00249 transformed cell line human CVCL_6J37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090970 CVCL_Z160 RAN/CTVM3 spontaneously immortalized cell line CVCL_Z160 CL:0000010 Discontinued: ECACC; 94022806; probable. Unspecified Group: Tick cell line 21090971 CVCL_Z161 RAE25 spontaneously immortalized cell line CVCL_Z161 CL:0000010 Unspecified Group: Tick cell line. 21090972 CVCL_Z162 RSE13 spontaneously immortalized cell line CVCL_Z162 CL:0000010 Unspecified Group: Tick cell line. 21090973 CVCL_Z163 RSE8 spontaneously immortalized cell line CVCL_Z163 CL:0000010 Unspecified Group: Tick cell line. 21090974 CVCL_Z168 ISE18 spontaneously immortalized cell line CVCL_Z168 CL:0000010 Omics: Transcriptome analysis by RNAseq. Mixed Group: Tick cell line 21090975 CVCL_Z169 ISE5 spontaneously immortalized cell line CVCL_Z169 CL:0000010 Unspecified Group: Tick cell line 21090976 CVCL_Z164 IDE1 spontaneously immortalized cell line CVCL_Z164 CL:0000010 Unspecified Group: Tick cell line. 21090977 CVCL_Z165 IDE12 spontaneously immortalized cell line CVCL_Z165 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq. Mixed Group: Tick cell line 21090978 CVCL_Z166 IDE2 spontaneously immortalized cell line CVCL_Z166 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Group: Tick cell line 21090979 CVCL_Z167 IDE8 spontaneously immortalized cell line CVCL_Z167 CL:0000010 Omics: Transcriptome analysis by RNAseq. Mixed Group: Patented cell line; Group: Tick cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11973 21090980 CVCL_6J00 DA00210 transformed cell line human CVCL_6J00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090981 CVCL_6J05 DA00215 transformed cell line human CVCL_6J05 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090982 CVCL_6J06 DA00216 transformed cell line human CVCL_6J06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090983 CVCL_6J07 DA00217 transformed cell line human CVCL_6J07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090984 CVCL_6J08 DA00218 transformed cell line human CVCL_6J08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090985 CVCL_6J01 DA00211 transformed cell line human CVCL_6J01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090986 CVCL_6J02 DA00212 transformed cell line human CVCL_6J02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090987 CVCL_6J03 DA00213 transformed cell line human CVCL_6J03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090988 CVCL_6J04 DA00214 transformed cell line human CVCL_6J04 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21090989 CVCL_Z150 BME/CTVM6 spontaneously immortalized cell line CVCL_Z150 CL:0000010 Discontinued: ECACC; 94022803; probable. Unspecified Group: Tick cell line 21090990 CVCL_Z151 HAE/CTVM10 spontaneously immortalized cell line CVCL_Z151 CL:0000010 Unspecified Group: Tick cell line. 21090991 CVCL_Z152 HAE/CTVM11 spontaneously immortalized cell line CVCL_Z152 CL:0000010 Discontinued: ECACC; 94022801; probable. Unspecified Group: Tick cell line 21090992 CVCL_Z157 IRE/CTVM19 spontaneously immortalized cell line CVCL_Z157 CL:0000010 Unspecified Group: Tick cell line. 21090993 CVCL_Z158 IRE/CTVM20 spontaneously immortalized cell line CVCL_Z158 CL:0000010 Unspecified Group: Tick cell line. 21090994 CVCL_Z159 RAE/CTVM1 spontaneously immortalized cell line CVCL_Z159 CL:0000010 Discontinued: ECACC; 94022805; probable. Unspecified Group: Tick cell line 21090995 CVCL_Z153 HAE/CTVM7 spontaneously immortalized cell line CVCL_Z153 CL:0000010 Unspecified Group: Tick cell line. 21090996 CVCL_Z154 HAE/CTVM8 spontaneously immortalized cell line CVCL_Z154 CL:0000010 Discontinued: ECACC; 94022802; probable. Unspecified Group: Tick cell line 21090997 CVCL_Z155 HAE/CTVM9 spontaneously immortalized cell line CVCL_Z155 CL:0000010 Discontinued: ECACC; 94022809; probable. Unspecified Group: Tick cell line 21090998 CVCL_Z156 IRE/CTVM18 spontaneously immortalized cell line CVCL_Z156 CL:0000010 Miscellaneous: Cell line not distributed due to Mycoplasma contamination (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21090999 CVCL_6J10 DA00220 transformed cell line human CVCL_6J10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091000 CVCL_6J11 DA00221 transformed cell line human CVCL_6J11 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091001 CVCL_Z139 LSTM-BM-256 spontaneously immortalized cell line CVCL_Z139 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Pudney M to Bell-Sakyi L.).. Unspecified Group: Tick cell line 21091002 CVCL_6J16 DA00226 transformed cell line human CVCL_6J16 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091003 CVCL_6J17 DA00227 transformed cell line human CVCL_6J17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091004 CVCL_6J18 DA00228 transformed cell line human CVCL_6J18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091005 CVCL_6J19 DA00229 transformed cell line human CVCL_6J19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091006 CVCL_6J12 DA00222 transformed cell line human CVCL_6J12 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00222; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091007 CVCL_6J13 DA00223 transformed cell line human CVCL_6J13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091008 CVCL_6J14 DA00224 transformed cell line human CVCL_6J14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091009 CVCL_6J15 DA00225 transformed cell line human CVCL_6J15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091010 CVCL_Z140 AVL/CTVM13 spontaneously immortalized cell line CVCL_Z140 CL:0000010 Unspecified Group: Tick cell line. 21091011 CVCL_Z141 AVL/CTVM17 spontaneously immortalized cell line CVCL_Z141 CL:0000010 Discontinued: ECACC; 94022811; probable. Unspecified Group: Tick cell line 21091012 CVCL_6J09 DA00219 transformed cell line human CVCL_6J09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091013 CVCL_Z146 BME/CTVM23 spontaneously immortalized cell line CVCL_Z146 CL:0000010 Unspecified Group: Tick cell line. 21091014 CVCL_Z147 BME/CTVM30 spontaneously immortalized cell line CVCL_Z147 CL:0000010 Unspecified Group: Tick cell line. 21091015 CVCL_Z148 BME/CTVM4 spontaneously immortalized cell line CVCL_Z148 CL:0000010 Discontinued: ECACC; 94022804; probable. Unspecified Group: Tick cell line 21091016 CVCL_Z149 BME/CTVM5 spontaneously immortalized cell line CVCL_Z149 CL:0000010 Unspecified Group: Tick cell line. 21091017 CVCL_Z142 BDE/CTVM12 spontaneously immortalized cell line CVCL_Z142 CL:0000010 Unspecified Group: Tick cell line. 21091018 CVCL_Z143 BDE/CTVM14 spontaneously immortalized cell line CVCL_Z143 CL:0000010 Discontinued: ECACC; 94022808; probable. Unspecified Group: Tick cell line 21091019 CVCL_Z144 BDE/CTVM16 spontaneously immortalized cell line CVCL_Z144 CL:0000010 Unspecified Group: Tick cell line. 21091020 CVCL_Z145 BME/CTVM2 spontaneously immortalized cell line CVCL_Z145 CL:0000010 Unspecified Group: Tick cell line. 21091021 CVCL_6J85 DA00297 transformed cell line human CVCL_6J85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091022 CVCL_6J86 DA00299 transformed cell line human CVCL_6J86 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091023 CVCL_6J87 DA00300 transformed cell line human CVCL_6J87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091024 CVCL_6J88 DA00301 transformed cell line human CVCL_6J88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091025 CVCL_6J81 DA00293 transformed cell line human CVCL_6J81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091026 CVCL_6J82 DA00294 transformed cell line human CVCL_6J82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091027 CVCL_6J83 DA00295 transformed cell line human CVCL_6J83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091028 CVCL_6J84 DA00296 transformed cell line human CVCL_6J84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091029 CVCL_6J89 DA00302 transformed cell line human CVCL_6J89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091030 CVCL_6J80 DA00292 transformed cell line human CVCL_6J80 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091031 CVCL_6J96 DA00309 transformed cell line human CVCL_6J96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091032 CVCL_6J97 DA00310 transformed cell line human CVCL_6J97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091033 CVCL_6J98 DA00311 transformed cell line human CVCL_6J98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091034 CVCL_6J99 DA00312 transformed cell line human CVCL_6J99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091035 CVCL_6J92 DA00305 transformed cell line human CVCL_6J92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091036 CVCL_6J93 DA00306 transformed cell line human CVCL_6J93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091037 CVCL_6J94 DA00307 transformed cell line human CVCL_6J94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091038 CVCL_6J95 DA00308 transformed cell line human CVCL_6J95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091039 CVCL_6J90 DA00303 transformed cell line human CVCL_6J90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091040 CVCL_6J91 DA00304 transformed cell line human CVCL_6J91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091041 CVCL_PV10 BayGenomics ES cell line XG597 embryonic stem cell house mouse CVCL_PV10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091042 CVCL_Q710 HG02273 transformed cell line human CVCL_Q710 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091043 CVCL_PV11 BayGenomics ES cell line XG598 embryonic stem cell house mouse CVCL_PV11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091044 CVCL_Q711 HG02277 transformed cell line human CVCL_Q711 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091045 CVCL_PV12 BayGenomics ES cell line XG599 embryonic stem cell house mouse CVCL_PV12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153887; Eri3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091046 CVCL_Q712 HG02278 transformed cell line human CVCL_Q712 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091047 CVCL_PV13 BayGenomics ES cell line XG600 embryonic stem cell house mouse CVCL_PV13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914176; Trmt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091048 CVCL_Q713 HG02279 transformed cell line human CVCL_Q713 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091049 CVCL_PV14 BayGenomics ES cell line XG602 embryonic stem cell house mouse CVCL_PV14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091050 CVCL_Q714 HG02280 transformed cell line human CVCL_Q714 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091051 CVCL_PV15 BayGenomics ES cell line XG604 embryonic stem cell house mouse CVCL_PV15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914357; Ankrd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091052 CVCL_Q715 HG02281 transformed cell line human CVCL_Q715 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091053 CVCL_PV16 BayGenomics ES cell line XG606 embryonic stem cell house mouse CVCL_PV16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443306; Tom1l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091054 CVCL_Q716 HG02282 transformed cell line human CVCL_Q716 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091055 CVCL_PV17 BayGenomics ES cell line XG607 embryonic stem cell house mouse CVCL_PV17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091056 CVCL_Q717 HG02283 transformed cell line human CVCL_Q717 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091057 CVCL_PV18 BayGenomics ES cell line XG608 embryonic stem cell house mouse CVCL_PV18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916455; Zfp748 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091058 CVCL_Q718 HG02284 transformed cell line human CVCL_Q718 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091059 CVCL_PV19 BayGenomics ES cell line XG611 embryonic stem cell house mouse CVCL_PV19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95757; Slc2a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091060 CVCL_Q719 HG02285 transformed cell line human CVCL_Q719 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091061 CVCL_PV00 BayGenomics ES cell line XG567 embryonic stem cell house mouse CVCL_PV00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924281; Slc9a8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091062 CVCL_Q700 HG02250 transformed cell line human CVCL_Q700 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091063 CVCL_PV01 BayGenomics ES cell line XG571 embryonic stem cell house mouse CVCL_PV01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916218; Cdan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091064 CVCL_Q701 HG02255 transformed cell line human CVCL_Q701 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091065 CVCL_PV02 BayGenomics ES cell line XG578 embryonic stem cell house mouse CVCL_PV02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921382; Rnf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091066 CVCL_Q702 HG02256 transformed cell line human CVCL_Q702 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091067 CVCL_PV03 BayGenomics ES cell line XG586 embryonic stem cell house mouse CVCL_PV03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919847; Auts2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091068 CVCL_Q703 HG02257 transformed cell line human CVCL_Q703 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091069 CVCL_PV04 BayGenomics ES cell line XG587 embryonic stem cell house mouse CVCL_PV04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344380; Chd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091070 CVCL_Q704 HG02258 transformed cell line human CVCL_Q704 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091071 CVCL_PV05 BayGenomics ES cell line XG588 embryonic stem cell house mouse CVCL_PV05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091072 CVCL_Q705 HG02259 transformed cell line human CVCL_Q705 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091073 CVCL_PV06 BayGenomics ES cell line XG591 embryonic stem cell house mouse CVCL_PV06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091074 CVCL_Q706 HG02260 transformed cell line human CVCL_Q706 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091075 CVCL_PV07 BayGenomics ES cell line XG592 embryonic stem cell house mouse CVCL_PV07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091076 CVCL_Q707 HG02261 transformed cell line human CVCL_Q707 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091077 CVCL_PV08 BayGenomics ES cell line XG593 embryonic stem cell house mouse CVCL_PV08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106613; Dvl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091078 CVCL_Q708 HG02271 transformed cell line human CVCL_Q708 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091079 CVCL_PV09 BayGenomics ES cell line XG595 embryonic stem cell house mouse CVCL_PV09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890577; Srsf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091080 CVCL_Q709 HG02272 transformed cell line human CVCL_Q709 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091081 CVCL_PV90 BayGenomics ES cell line XG830 embryonic stem cell house mouse CVCL_PV90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99542; Usf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091082 CVCL_Q790 HG02410 transformed cell line human CVCL_Q790 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091083 CVCL_PV91 BayGenomics ES cell line XG831 embryonic stem cell house mouse CVCL_PV91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091084 CVCL_Q791 HG02419 transformed cell line human CVCL_Q791 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091085 CVCL_PV92 BayGenomics ES cell line XG833 embryonic stem cell house mouse CVCL_PV92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647701; Gm9222 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091086 CVCL_Q792 HG02420 transformed cell line human CVCL_Q792 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091087 CVCL_PV93 BayGenomics ES cell line XG836 embryonic stem cell house mouse CVCL_PV93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88353; Cdk11b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091088 CVCL_Q793 HG02427 transformed cell line human CVCL_Q793 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091089 CVCL_PV94 BayGenomics ES cell line XG839 embryonic stem cell house mouse CVCL_PV94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108515; Cbx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091090 CVCL_Q794 HG02429 transformed cell line human CVCL_Q794 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091091 CVCL_Z128 SES-MaBr-2 spontaneously immortalized cell line CVCL_Z128 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091092 CVCL_PV95 BayGenomics ES cell line XG841 embryonic stem cell house mouse CVCL_PV95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104557; Rps6ka3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091093 CVCL_Q795 HG02433 transformed cell line human CVCL_Q795 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091094 CVCL_Z129 SES-MaBr-3 spontaneously immortalized cell line CVCL_Z129 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091095 CVCL_PV96 BayGenomics ES cell line XG843 embryonic stem cell house mouse CVCL_PV96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091096 CVCL_Q796 HG02436 transformed cell line human CVCL_Q796 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091097 CVCL_PV97 BayGenomics ES cell line XG846 embryonic stem cell house mouse CVCL_PV97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091098 CVCL_Q797 HG02442 transformed cell line human CVCL_Q797 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091099 CVCL_PV98 BayGenomics ES cell line XG847 embryonic stem cell house mouse CVCL_PV98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107185; Cct5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091100 CVCL_Q798 HG02445 transformed cell line human CVCL_Q798 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091101 CVCL_PV99 BayGenomics ES cell line XG848 embryonic stem cell house mouse CVCL_PV99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933947; Rtn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091102 CVCL_Q799 HG02449 transformed cell line human CVCL_Q799 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091103 CVCL_Z130 SES-MaBr-4 spontaneously immortalized cell line CVCL_Z130 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091104 CVCL_Z135 LSTM-RA-219 spontaneously immortalized cell line CVCL_Z135 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1987 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21091105 CVCL_Z136 LSTM-RA-243 spontaneously immortalized cell line CVCL_Z136 CL:0000010 Unspecified Group: Tick cell line. 21091106 CVCL_Z137 LSTM-RA-257 spontaneously immortalized cell line CVCL_Z137 CL:0000010 Unspecified Group: Tick cell line. 21091107 CVCL_Z138 LSTM-BM-270 spontaneously immortalized cell line CVCL_Z138 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Pudney M to Bell-Sakyi L.).. Unspecified Group: Tick cell line 21091108 CVCL_Z131 SES-MaBr-5 spontaneously immortalized cell line CVCL_Z131 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091109 CVCL_Z132 NIAS-Px-58 spontaneously immortalized cell line CVCL_Z132 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091110 CVCL_Z133 FRI-SpIm-1229 spontaneously immortalized cell line CVCL_Z133 CL:0000010 Discontinued: RCB; RCB0281; true. Unspecified Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00566 Problematic cell line: Misidentified/contaminated Originally thought to be of Lemyra imparilis origin but found to be from Mamestra brassicae (RCB). 21091111 CVCL_Z134 NIAS-Px-64 spontaneously immortalized cell line CVCL_Z134 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091112 CVCL_PV80 BayGenomics ES cell line XG806 embryonic stem cell house mouse CVCL_PV80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99532; Mef2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091113 CVCL_Q780 HG02396 transformed cell line human CVCL_Q780 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091114 CVCL_PV81 BayGenomics ES cell line XG809 embryonic stem cell house mouse CVCL_PV81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344415; Dmtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091115 CVCL_Q781 HG02397 transformed cell line human CVCL_Q781 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091116 CVCL_PV82 BayGenomics ES cell line XG813 embryonic stem cell house mouse CVCL_PV82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091117 CVCL_Q782 HG02398 transformed cell line human CVCL_Q782 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091118 CVCL_PV83 BayGenomics ES cell line XG814 embryonic stem cell house mouse CVCL_PV83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920453; Zzz3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091119 CVCL_Z117 GaMe-LF1 spontaneously immortalized cell line CVCL_Z117 CL:0000010 Derived from sampling site: Fat body. Unspecified Characteristics: Grows at temperatures ranging from 15 to 35 Celsius Maximum growth rate at 25 Celsius (PubMed=16618204). Doubling time: 1.4-1.7 days (PubMed=16618204) Group: Insect cell line 21091120 CVCL_Q783 HG02399 transformed cell line human CVCL_Q783 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091121 CVCL_PV84 BayGenomics ES cell line XG815 embryonic stem cell house mouse CVCL_PV84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890393; Zfp277 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091122 CVCL_Q784 HG02401 transformed cell line human CVCL_Q784 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091123 CVCL_Z118 NIAS-PRC-819A spontaneously immortalized cell line CVCL_Z118 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091124 CVCL_PV85 BayGenomics ES cell line XG816 embryonic stem cell house mouse CVCL_PV85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923484; Magi3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091125 CVCL_Q785 HG02402 transformed cell line human CVCL_Q785 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091126 CVCL_Z119 NIAS-PRC-819B spontaneously immortalized cell line CVCL_Z119 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091127 CVCL_PV86 BayGenomics ES cell line XG817 embryonic stem cell house mouse CVCL_PV86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99542; Usf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091128 CVCL_Q786 HG02406 transformed cell line human CVCL_Q786 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091129 CVCL_PV87 BayGenomics ES cell line XG818 embryonic stem cell house mouse CVCL_PV87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091130 CVCL_Q787 HG02407 transformed cell line human CVCL_Q787 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091131 CVCL_PV88 BayGenomics ES cell line XG821 embryonic stem cell house mouse CVCL_PV88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091132 CVCL_Q788 HG02408 transformed cell line human CVCL_Q788 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091133 CVCL_PV89 BayGenomics ES cell line XG823 embryonic stem cell house mouse CVCL_PV89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102670; Ddx4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091134 CVCL_Q789 HG02409 transformed cell line human CVCL_Q789 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091135 CVCL_Z124 NIAS-MaBr-92 spontaneously immortalized cell line CVCL_Z124 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21091136 CVCL_Z125 NIAS-MaBr-93 spontaneously immortalized cell line CVCL_Z125 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21091137 CVCL_Z126 NIAS-MaBr-85 spontaneously immortalized cell line CVCL_Z126 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091138 CVCL_Z127 SES-MaBr-1 spontaneously immortalized cell line CVCL_Z127 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21091139 CVCL_Z120 NIAS-PRC-819C spontaneously immortalized cell line CVCL_Z120 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091140 CVCL_Z121 NIAS-Mb-19 spontaneously immortalized cell line CVCL_Z121 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091141 CVCL_Z122 NIAS-Mb-25 spontaneously immortalized cell line CVCL_Z122 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091142 CVCL_Z123 NIAS-Mb-32 spontaneously immortalized cell line CVCL_Z123 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091143 CVCL_PV70 BayGenomics ES cell line XG772 embryonic stem cell house mouse CVCL_PV70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091144 CVCL_Q770 HG02385 transformed cell line human CVCL_Q770 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091145 CVCL_PV71 BayGenomics ES cell line XG775 embryonic stem cell house mouse CVCL_PV71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443300; Cpped1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091146 CVCL_Q771 HG02386 transformed cell line human CVCL_Q771 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091147 CVCL_PV72 BayGenomics ES cell line XG778 embryonic stem cell house mouse CVCL_PV72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107726; Supt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091148 CVCL_Q772 HG02387 transformed cell line human CVCL_Q772 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091149 CVCL_Z106 SES-BoMo-J125 spontaneously immortalized cell line CVCL_Z106 CL:0000010 Breed/subspecies: J125. Unspecified Doubling time: 3.0 days (DOI=10.11416/kontyushigen1930.57.184) Group: Insect cell line 21091150 CVCL_PV73 BayGenomics ES cell line XG785 embryonic stem cell house mouse CVCL_PV73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091151 CVCL_Q773 HG02388 transformed cell line human CVCL_Q773 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091152 CVCL_Z107 NISES-Anya-0611 spontaneously immortalized cell line CVCL_Z107 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091153 CVCL_PV74 BayGenomics ES cell line XG788 embryonic stem cell house mouse CVCL_PV74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091154 CVCL_Q774 HG02389 transformed cell line human CVCL_Q774 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091155 CVCL_Z108 SES-BoMo-15A spontaneously immortalized cell line CVCL_Z108 CL:0000010 Breed/subspecies: Kuroko. Unspecified Doubling time: 3 days (CelloPub=CLPUB00372) Group: Insect cell line 21091156 CVCL_Z109 Ae spontaneously immortalized cell line CVCL_Z109 CL:0000010 Anecdotal: First arthropod cell line to be established Derived from sampling site: Ovary. Discontinued: ECACC; 90111908; probable Female Group: Insect cell line 21091157 CVCL_PV75 BayGenomics ES cell line XG792 embryonic stem cell house mouse CVCL_PV75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913565; Senp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091158 CVCL_Q775 HG02390 transformed cell line human CVCL_Q775 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091159 CVCL_PV76 BayGenomics ES cell line XG797 embryonic stem cell house mouse CVCL_PV76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091160 CVCL_Q776 HG02391 transformed cell line human CVCL_Q776 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091161 CVCL_PV77 BayGenomics ES cell line XG801 embryonic stem cell house mouse CVCL_PV77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894313; Rab6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091162 CVCL_Q777 HG02392 transformed cell line human CVCL_Q777 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091163 CVCL_PV78 BayGenomics ES cell line XG803 embryonic stem cell house mouse CVCL_PV78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091164 CVCL_Q778 HG02394 transformed cell line human CVCL_Q778 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091165 CVCL_PV79 BayGenomics ES cell line XG804 embryonic stem cell house mouse CVCL_PV79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913809; Metap1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091166 CVCL_Q779 HG02395 transformed cell line human CVCL_Q779 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091167 CVCL_Z113 IPLB-HvE6a spontaneously immortalized cell line CVCL_Z113 CL:0000010 Unspecified Group: Insect cell line. 21091168 CVCL_Z114 IPLB-HvE6a-lt spontaneously immortalized cell line CVCL_Z114 CL:0000010 Unspecified Group: Insect cell line. 21091169 CVCL_Z115 DZNU-Bm-12 spontaneously immortalized cell line CVCL_Z115 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: Kolar Gold. Female Group: Insect cell line 21091170 CVCL_Z116 DZNU-Bm-17 spontaneously immortalized cell line CVCL_Z116 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: Kolar Gold. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21091171 CVCL_Z110 IPLB-HvE1a spontaneously immortalized cell line CVCL_Z110 CL:0000010 Unspecified Group: Insect cell line. 21091172 CVCL_Z111 IPLB-HvE1a-lt spontaneously immortalized cell line CVCL_Z111 CL:0000010 Unspecified Group: Insect cell line. 21091173 CVCL_Z112 IPLB-HvE1s spontaneously immortalized cell line CVCL_Z112 CL:0000010 Unspecified Group: Insect cell line. 21091174 CVCL_PV60 BayGenomics ES cell line XG748 embryonic stem cell house mouse CVCL_PV60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99695; Cttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091175 CVCL_Q760 HG02373 transformed cell line human CVCL_Q760 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091176 CVCL_PV61 BayGenomics ES cell line XG752 embryonic stem cell house mouse CVCL_PV61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145578; Slain1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091177 CVCL_Q761 HG02374 transformed cell line human CVCL_Q761 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091178 CVCL_PV62 BayGenomics ES cell line XG753 embryonic stem cell house mouse CVCL_PV62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091179 CVCL_Q762 HG02375 transformed cell line human CVCL_Q762 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091180 CVCL_PV63 BayGenomics ES cell line XG754 embryonic stem cell house mouse CVCL_PV63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450166; Arhgap32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091181 CVCL_Q763 HG02377 transformed cell line human CVCL_Q763 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091182 CVCL_PV64 BayGenomics ES cell line XG755 embryonic stem cell house mouse CVCL_PV64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858202; Rab11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091183 CVCL_Q764 HG02379 transformed cell line human CVCL_Q764 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091184 CVCL_PV65 BayGenomics ES cell line XG756 embryonic stem cell house mouse CVCL_PV65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859646; Golga4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091185 CVCL_Q765 HG02380 transformed cell line human CVCL_Q765 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091186 CVCL_PV66 BayGenomics ES cell line XG757 embryonic stem cell house mouse CVCL_PV66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137336; Baiap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091187 CVCL_Q766 HG02381 transformed cell line human CVCL_Q766 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091188 CVCL_PV67 BayGenomics ES cell line XG759 embryonic stem cell house mouse CVCL_PV67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442211; Prrg4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091189 CVCL_Q767 HG02382 transformed cell line human CVCL_Q767 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091190 CVCL_PV68 BayGenomics ES cell line XG765 embryonic stem cell house mouse CVCL_PV68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929706; Ranbp17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091191 CVCL_Q768 HG02383 transformed cell line human CVCL_Q768 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091192 CVCL_PV69 BayGenomics ES cell line XG769 embryonic stem cell house mouse CVCL_PV69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338801; Cyfip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091193 CVCL_Q769 HG02384 transformed cell line human CVCL_Q769 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091194 CVCL_Z102 IPLB-LdEp spontaneously immortalized cell line CVCL_Z102 CL:0000010 Unspecified Group: Insect cell line. 21091195 CVCL_Z103 NISES-AnPe-426 spontaneously immortalized cell line CVCL_Z103 CL:0000010 Unspecified Group: Insect cell line. 21091196 CVCL_Z104 NISES-SaCy-12 spontaneously immortalized cell line CVCL_Z104 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 4 days (at 41th passage), 2.3 days (at 307th passage) (DOI=10.11416/kontyushigen1930.64.270) Group: Insect cell line 21091197 CVCL_Z105 SES-BoMo-C129 spontaneously immortalized cell line CVCL_Z105 CL:0000010 Breed/subspecies: C129. Unspecified Doubling time: 3.5 days (DOI=10.11416/kontyushigen1930.57.184) Group: Insect cell line 21091198 CVCL_Z100 IPLB-LdFB spontaneously immortalized cell line CVCL_Z100 CL:0000010 Derived from sampling site: Fat body. Unspecified Characteristics: Apoptosis can be easily induced through oxidative stress using the reducing sugar dRib or the NO donor sodium SNP (PubMed=18220824) Doubling time: 38 +- 1 hours (in static culture), 42 +- 4 hours (in suspension culture) (PubMed=10585188) Group: Insect cell line 21091199 CVCL_Z101 IPLB-HvT1 spontaneously immortalized cell line CVCL_Z101 CL:0000010 Derived from sampling site: Testicular sheath. Male Group: Insect cell line 21091200 CVCL_PV50 BayGenomics ES cell line XG716 embryonic stem cell house mouse CVCL_PV50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182472; Tpcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091201 CVCL_Q750 HG02351 transformed cell line human CVCL_Q750 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091202 CVCL_PV51 BayGenomics ES cell line XG718 embryonic stem cell house mouse CVCL_PV51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091203 CVCL_Q751 HG02353 transformed cell line human CVCL_Q751 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091204 CVCL_PV52 BayGenomics ES cell line XG725 embryonic stem cell house mouse CVCL_PV52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915120; Enoph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091205 CVCL_Q752 HG02355 transformed cell line human CVCL_Q752 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091206 CVCL_PV53 BayGenomics ES cell line XG732 embryonic stem cell house mouse CVCL_PV53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919055; Nup93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091207 CVCL_Q753 HG02356 transformed cell line human CVCL_Q753 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091208 CVCL_PV54 BayGenomics ES cell line XG733 embryonic stem cell house mouse CVCL_PV54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919055; Nup93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091209 CVCL_Q754 HG02360 transformed cell line human CVCL_Q754 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091210 CVCL_PV55 BayGenomics ES cell line XG734 embryonic stem cell house mouse CVCL_PV55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343489; Mpdz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091211 CVCL_Q755 HG02363 transformed cell line human CVCL_Q755 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091212 CVCL_PV56 BayGenomics ES cell line XG736 embryonic stem cell house mouse CVCL_PV56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091213 CVCL_Q756 HG02364 transformed cell line human CVCL_Q756 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091214 CVCL_PV57 BayGenomics ES cell line XG740 embryonic stem cell house mouse CVCL_PV57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3028576; Dhx37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091215 CVCL_Q757 HG02367 transformed cell line human CVCL_Q757 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091216 CVCL_PV58 BayGenomics ES cell line XG743 embryonic stem cell house mouse CVCL_PV58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918817; Mcm9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091217 CVCL_Q758 HG02371 transformed cell line human CVCL_Q758 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091218 CVCL_PV59 BayGenomics ES cell line XG745 embryonic stem cell house mouse CVCL_PV59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091219 CVCL_Q759 HG02372 transformed cell line human CVCL_Q759 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091220 CVCL_PV40 BayGenomics ES cell line XG670 embryonic stem cell house mouse CVCL_PV40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914185; Cir1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091221 CVCL_Q740 HG02321 transformed cell line human CVCL_Q740 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091222 CVCL_PV41 BayGenomics ES cell line XG677 embryonic stem cell house mouse CVCL_PV41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95390; En2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091223 CVCL_Q741 HG02322 transformed cell line human CVCL_Q741 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091224 CVCL_PV42 BayGenomics ES cell line XG682 embryonic stem cell house mouse CVCL_PV42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306795; Akap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091225 CVCL_Q742 HG02323 transformed cell line human CVCL_Q742 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091226 CVCL_PV43 BayGenomics ES cell line XG691 embryonic stem cell house mouse CVCL_PV43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894697; Rad54l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091227 CVCL_Q743 HG02325 transformed cell line human CVCL_Q743 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091228 CVCL_PV44 BayGenomics ES cell line XG694 embryonic stem cell house mouse CVCL_PV44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106913; Abi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091229 CVCL_Q744 HG02330 transformed cell line human CVCL_Q744 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091230 CVCL_PV45 BayGenomics ES cell line XG696 embryonic stem cell house mouse CVCL_PV45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091231 CVCL_Q745 HG02332 transformed cell line human CVCL_Q745 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091232 CVCL_PV46 BayGenomics ES cell line XG697 embryonic stem cell house mouse CVCL_PV46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153608; Ube2j2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091233 CVCL_Q746 HG02334 transformed cell line human CVCL_Q746 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091234 CVCL_PV47 BayGenomics ES cell line XG698 embryonic stem cell house mouse CVCL_PV47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99147; Yes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091235 CVCL_Q747 HG02337 transformed cell line human CVCL_Q747 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091236 CVCL_PV48 BayGenomics ES cell line XG702 embryonic stem cell house mouse CVCL_PV48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891748; Maea Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091237 CVCL_Q748 HG02339 transformed cell line human CVCL_Q748 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091238 CVCL_PV49 BayGenomics ES cell line XG708 embryonic stem cell house mouse CVCL_PV49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919224; Prmt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091239 CVCL_Q749 HG02343 transformed cell line human CVCL_Q749 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091240 CVCL_PV30 BayGenomics ES cell line XG653 embryonic stem cell house mouse CVCL_PV30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091241 CVCL_Q730 HG02303 transformed cell line human CVCL_Q730 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091242 CVCL_PV31 BayGenomics ES cell line XG654 embryonic stem cell house mouse CVCL_PV31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091243 CVCL_Q731 HG02307 transformed cell line human CVCL_Q731 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091244 CVCL_PV32 BayGenomics ES cell line XG655 embryonic stem cell house mouse CVCL_PV32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091245 CVCL_Q732 HG02308 transformed cell line human CVCL_Q732 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091246 CVCL_PV33 BayGenomics ES cell line XG656 embryonic stem cell house mouse CVCL_PV33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344415; Dmtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091247 CVCL_Q733 HG02309 transformed cell line human CVCL_Q733 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091248 CVCL_PV34 BayGenomics ES cell line XG661 embryonic stem cell house mouse CVCL_PV34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924049; Tmem234 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091249 CVCL_Q734 HG02314 transformed cell line human CVCL_Q734 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091250 CVCL_PV35 BayGenomics ES cell line XG664 embryonic stem cell house mouse CVCL_PV35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091251 CVCL_Q735 HG02315 transformed cell line human CVCL_Q735 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091252 CVCL_PV36 BayGenomics ES cell line XG665 embryonic stem cell house mouse CVCL_PV36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922083; Ciapin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091253 CVCL_Q736 HG02316 transformed cell line human CVCL_Q736 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091254 CVCL_PV37 BayGenomics ES cell line XG667 embryonic stem cell house mouse CVCL_PV37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921382; Rnf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091255 CVCL_Q737 HG02317 transformed cell line human CVCL_Q737 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091256 CVCL_PV38 BayGenomics ES cell line XG668 embryonic stem cell house mouse CVCL_PV38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103239; Tfap4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091257 CVCL_Q738 HG02318 transformed cell line human CVCL_Q738 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091258 CVCL_PV39 BayGenomics ES cell line XG669 embryonic stem cell house mouse CVCL_PV39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88071; Arnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091259 CVCL_Q739 HG02319 transformed cell line human CVCL_Q739 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21091260 CVCL_PV20 BayGenomics ES cell line XG614 embryonic stem cell house mouse CVCL_PV20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091261 CVCL_Q720 HG02286 transformed cell line human CVCL_Q720 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091262 CVCL_PV21 BayGenomics ES cell line XG616 embryonic stem cell house mouse CVCL_PV21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091263 CVCL_Q721 HG02287 transformed cell line human CVCL_Q721 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091264 CVCL_PV22 BayGenomics ES cell line XG621 embryonic stem cell house mouse CVCL_PV22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091265 CVCL_Q722 HG02291 transformed cell line human CVCL_Q722 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091266 CVCL_PV23 BayGenomics ES cell line XG623 embryonic stem cell house mouse CVCL_PV23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091267 CVCL_Q723 HG02292 transformed cell line human CVCL_Q723 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091268 CVCL_PV24 BayGenomics ES cell line XG637 embryonic stem cell house mouse CVCL_PV24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091269 CVCL_Q724 HG02293 transformed cell line human CVCL_Q724 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Unspecified Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091270 CVCL_PV25 BayGenomics ES cell line XG638 embryonic stem cell house mouse CVCL_PV25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921285; Nol9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091271 CVCL_Q725 HG02298 transformed cell line human CVCL_Q725 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091272 CVCL_PV26 BayGenomics ES cell line XG639 embryonic stem cell house mouse CVCL_PV26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091273 CVCL_Q726 HG02299 transformed cell line human CVCL_Q726 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091274 CVCL_PV27 BayGenomics ES cell line XG643 embryonic stem cell house mouse CVCL_PV27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091275 CVCL_Q727 HG02300 transformed cell line human CVCL_Q727 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091276 CVCL_PV28 BayGenomics ES cell line XG647 embryonic stem cell house mouse CVCL_PV28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091277 CVCL_Q728 HG02301 transformed cell line human CVCL_Q728 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091278 CVCL_PV29 BayGenomics ES cell line XG649 embryonic stem cell house mouse CVCL_PV29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091279 CVCL_Q729 HG02302 transformed cell line human CVCL_Q729 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091280 CVCL_6K84 DA00399 transformed cell line human CVCL_6K84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091281 CVCL_6K85 DA00400 transformed cell line human CVCL_6K85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091282 CVCL_6K86 DA00401 transformed cell line human CVCL_6K86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091283 CVCL_6K87 DA00402 transformed cell line human CVCL_6K87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091284 CVCL_6K80 DA00395 transformed cell line human CVCL_6K80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091285 CVCL_6K81 DA00396 transformed cell line human CVCL_6K81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091286 CVCL_6K82 DA00397 transformed cell line human CVCL_6K82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091287 CVCL_6K83 DA00398 transformed cell line human CVCL_6K83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091288 CVCL_6K88 DA00403 transformed cell line human CVCL_6K88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091289 CVCL_6K89 DA00404 transformed cell line human CVCL_6K89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091290 CVCL_6K95 DA00410 transformed cell line human CVCL_6K95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091291 CVCL_6K96 DA00411 transformed cell line human CVCL_6K96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091292 CVCL_6K97 DA00412 transformed cell line human CVCL_6K97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091293 CVCL_6K98 DA00413 transformed cell line human CVCL_6K98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091294 CVCL_6K91 DA00406 transformed cell line human CVCL_6K91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091295 CVCL_6K92 DA00407 transformed cell line human CVCL_6K92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091296 CVCL_6K93 DA00408 transformed cell line human CVCL_6K93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091297 CVCL_6K94 DA00409 transformed cell line human CVCL_6K94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091298 CVCL_6K99 DA00414 transformed cell line human CVCL_6K99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091299 CVCL_6K90 DA00405 transformed cell line human CVCL_6K90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091300 CVCL_6K62 DA00377 transformed cell line human CVCL_6K62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091301 CVCL_6K63 DA00378 transformed cell line human CVCL_6K63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091302 CVCL_6K64 DA00379 transformed cell line human CVCL_6K64 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091303 CVCL_6K65 DA00380 transformed cell line human CVCL_6K65 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091304 CVCL_6K60 DA00375 transformed cell line human CVCL_6K60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091305 CVCL_6K61 DA00376 transformed cell line human CVCL_6K61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091306 CVCL_6K66 DA00381 transformed cell line human CVCL_6K66 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091307 CVCL_6K67 DA00382 transformed cell line human CVCL_6K67 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091308 CVCL_6K68 DA00383 transformed cell line human CVCL_6K68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091309 CVCL_6K69 DA00384 transformed cell line human CVCL_6K69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091310 CVCL_6K73 DA00388 transformed cell line human CVCL_6K73 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091311 CVCL_6K74 DA00389 transformed cell line human CVCL_6K74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091312 CVCL_6K75 DA00390 transformed cell line human CVCL_6K75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091313 CVCL_6K76 DA00391 transformed cell line human CVCL_6K76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091314 CVCL_6K70 DA00385 transformed cell line human CVCL_6K70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091315 CVCL_6K71 DA00386 transformed cell line human CVCL_6K71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091316 CVCL_6K72 DA00387 transformed cell line human CVCL_6K72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091317 CVCL_6K77 DA00392 transformed cell line human CVCL_6K77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091318 CVCL_6K78 DA00393 transformed cell line human CVCL_6K78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091319 CVCL_6K79 DA00394 transformed cell line human CVCL_6K79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091320 CVCL_6K40 DA00355 transformed cell line human CVCL_6K40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091321 CVCL_6K41 DA00356 transformed cell line human CVCL_6K41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091322 CVCL_6K42 DA00357 transformed cell line human CVCL_6K42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091323 CVCL_6K43 DA00358 transformed cell line human CVCL_6K43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091324 CVCL_6K48 DA00363 transformed cell line human CVCL_6K48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091325 CVCL_6K49 DA00364 transformed cell line human CVCL_6K49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091326 CVCL_6K44 DA00359 transformed cell line human CVCL_6K44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091327 CVCL_6K45 DA00360 transformed cell line human CVCL_6K45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091328 CVCL_6K46 DA00361 transformed cell line human CVCL_6K46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091329 CVCL_6K47 DA00362 transformed cell line human CVCL_6K47 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091330 CVCL_Z292 USP-3 embryonic stem cell house mouse CVCL_Z292 CL:0000010 Breed/subspecies: 129/Sv. Male 21091331 CVCL_Z293 USP-4 embryonic stem cell house mouse CVCL_Z293 CL:0000010 Breed/subspecies: 129/Sv. Male 21091332 CVCL_Z294 FTRS-AoL1 spontaneously immortalized cell line CVCL_Z294 CL:0000010 Unspecified Doubling time: 24 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091333 CVCL_Z295 FTRS-AoL2 spontaneously immortalized cell line CVCL_Z295 CL:0000010 Unspecified Doubling time: 20 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091334 CVCL_Z290 USP-1 embryonic stem cell house mouse CVCL_Z290 CL:0000010 Breed/subspecies: 129/Sv. Male 21091335 CVCL_Z291 USP-2 embryonic stem cell house mouse CVCL_Z291 CL:0000010 Breed/subspecies: 129/Sv. Male 21091336 CVCL_Z296 FTRS-AfL spontaneously immortalized cell line CVCL_Z296 CL:0000010 Unspecified Doubling time: 26 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091337 CVCL_Z297 FTRS-PhL spontaneously immortalized cell line CVCL_Z297 CL:0000010 Unspecified Doubling time: 28 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091338 CVCL_Z298 FTRS-AbL81 spontaneously immortalized cell line CVCL_Z298 CL:0000010 Unspecified Doubling time: 30 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091339 CVCL_Z299 FTRS-HmL45 spontaneously immortalized cell line CVCL_Z299 CL:0000010 Unspecified Doubling time: 48 hours (CelloPub=CLPUB00170). Group: Insect cell line 21091340 CVCL_6K51 DA00366 transformed cell line human CVCL_6K51 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091341 CVCL_6K52 DA00367 transformed cell line human CVCL_6K52 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091342 CVCL_6K53 DA00368 transformed cell line human CVCL_6K53 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091343 CVCL_6K54 DA00369 transformed cell line human CVCL_6K54 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091344 CVCL_6K50 DA00365 transformed cell line human CVCL_6K50 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091345 CVCL_6K59 DA00374 transformed cell line human CVCL_6K59 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091346 CVCL_6K55 DA00370 transformed cell line human CVCL_6K55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091347 CVCL_6K56 DA00371 transformed cell line human CVCL_6K56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091348 CVCL_6K57 DA00372 transformed cell line human CVCL_6K57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091349 CVCL_6K58 DA00373 transformed cell line human CVCL_6K58 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091350 CVCL_Z281 Ciha-1 spontaneously immortalized cell line CVCL_Z281 CL:0000010 Unspecified Doubling time: ~2 days (PubMed=20019079). Group: Insect cell line 21091351 CVCL_Z282 CT 1 spontaneously immortalized cell line CVCL_Z282 CL:0000010 Unspecified Group: Insect cell line. 21091352 CVCL_Z283 NN-1 spontaneously immortalized cell line CVCL_Z283 CL:0000010 Unspecified Group: Insect cell line. 21091353 CVCL_Z284 NC-15 spontaneously immortalized cell line CVCL_Z284 CL:0000010 Unspecified Group: Insect cell line. 21091354 CVCL_Z280 79f7Dv3g spontaneously immortalized cell line CVCL_Z280 CL:0000010 Male Group: Insect cell line. 21091355 CVCL_Z289 NC-25 spontaneously immortalized cell line CVCL_Z289 CL:0000010 Unspecified Group: Insect cell line. 21091356 CVCL_Z285 NC-19 spontaneously immortalized cell line CVCL_Z285 CL:0000010 Unspecified Group: Insect cell line. 21091357 CVCL_Z286 NC-20 spontaneously immortalized cell line CVCL_Z286 CL:0000010 Unspecified Group: Insect cell line. 21091358 CVCL_Z287 NC-21 spontaneously immortalized cell line CVCL_Z287 CL:0000010 Unspecified Group: Insect cell line. 21091359 CVCL_Z288 NC-24 spontaneously immortalized cell line CVCL_Z288 CL:0000010 Unspecified Group: Insect cell line. 21091360 CVCL_6K20 DA00334 transformed cell line human CVCL_6K20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091361 CVCL_6K21 DA00336 transformed cell line human CVCL_6K21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091362 CVCL_6K26 DA00341 transformed cell line human CVCL_6K26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091363 CVCL_6K27 DA00342 transformed cell line human CVCL_6K27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091364 CVCL_6K28 DA00343 transformed cell line human CVCL_6K28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091365 CVCL_6K29 DA00344 transformed cell line human CVCL_6K29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091366 CVCL_6K22 DA00337 transformed cell line human CVCL_6K22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091367 CVCL_6K23 DA00338 transformed cell line human CVCL_6K23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091368 CVCL_6K24 DA00339 transformed cell line human CVCL_6K24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091369 CVCL_6K25 DA00340 transformed cell line human CVCL_6K25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091370 CVCL_Z270 FRI-AnCu-35 spontaneously immortalized cell line CVCL_Z270 CL:0000010 Unspecified Doubling time: ~4.5 days (PubMed=15117233). Group: Insect cell line 21091371 CVCL_Z271 XP-1 spontaneously immortalized cell line CVCL_Z271 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 5 days (PubMed=10614871) Group: Insect cell line 21091372 CVCL_Z272 APE1 spontaneously immortalized cell line CVCL_Z272 CL:0000010 Unspecified Group: Insect cell line. 21091373 CVCL_Z273 APHL1 spontaneously immortalized cell line CVCL_Z273 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21091374 CVCL_6K19 DA00333 transformed cell line human CVCL_6K19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091375 CVCL_Z278 PG100 cancer cell line human CVCL_Z278 CL:0000010 Population: Brazilian; Derived from sampling site: Stomach. Omics: Array-based CGH Male 21091376 CVCL_Z279 LSB-AA695BB spontaneously immortalized cell line CVCL_Z279 CL:0000010 Unspecified Doubling time: ~24 hours (PubMed=9302423). Group: Insect cell line 21091377 CVCL_Z274 PC-1 [Plagionotus] spontaneously immortalized cell line CVCL_Z274 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 3.79 days (PubMed=18946707) Group: Insect cell line 21091378 CVCL_Z275 ZJBIQ-Chsu-I spontaneously immortalized cell line CVCL_Z275 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: ~62 hours (PubMed=25381037) Group: Insect cell line 21091379 CVCL_Z276 BCIRL-TcA-CLG1 spontaneously immortalized cell line CVCL_Z276 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 155.2 hours (PubMed=22752637) Group: Insect cell line 21091380 CVCL_Z277 Tc81 spontaneously immortalized cell line CVCL_Z277 CL:0000010 Unspecified Group: Insect cell line. 21091381 CVCL_6K30 DA00345 transformed cell line human CVCL_6K30 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091382 CVCL_6K31 DA00346 transformed cell line human CVCL_6K31 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091383 CVCL_6K32 DA00347 transformed cell line human CVCL_6K32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091384 CVCL_6K37 DA00352 transformed cell line human CVCL_6K37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091385 CVCL_6K38 DA00353 transformed cell line human CVCL_6K38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091386 CVCL_6K39 DA00354 transformed cell line human CVCL_6K39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091387 CVCL_6K33 DA00348 transformed cell line human CVCL_6K33 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091388 CVCL_6K34 DA00349 transformed cell line human CVCL_6K34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091389 CVCL_6K35 DA00350 transformed cell line human CVCL_6K35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091390 CVCL_6K36 DA00351 transformed cell line human CVCL_6K36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091391 CVCL_Z260 L-2/M delta 2-3 spontaneously immortalized cell line fruit fly CVCL_Z260 CL:0000010 Transfected with: FlyBase_Gene; FBgn0013311; P\\T; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Breed/subspecies: Oregon-R. Male Group: Insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10191 21091392 CVCL_Z261 IAFEs-1 spontaneously immortalized cell line CVCL_Z261 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091393 CVCL_Z262 SPC-Ld-135 spontaneously immortalized cell line CVCL_Z262 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091394 CVCL_Z267 A.t. GRIP-3 spontaneously immortalized cell line CVCL_Z267 CL:0000010 Unspecified Doubling time: 60 hours (PubMed=8551501). Group: Insect cell line 21091395 CVCL_Z268 NIV-AA-706 spontaneously immortalized cell line CVCL_Z268 CL:0000010 Unspecified Doubling time: 102 hours (at 23th passage), 23 hours (at 52th passage) (PubMed=19533252). Group: Insect cell line 21091396 CVCL_Z269 FRI-AnCo-5B spontaneously immortalized cell line CVCL_Z269 CL:0000010 Unspecified Doubling time: ~4.5 days (DOI=10.11519/jjfs1953.71.12_491). Group: Insect cell line 21091397 CVCL_Z263 SPC-Sl-48 spontaneously immortalized cell line CVCL_Z263 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~72 hours (DOI=10.1007/BF02372123) Group: Insect cell line 21091398 CVCL_Z264 SPC-Sl-52 spontaneously immortalized cell line CVCL_Z264 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~48 hours (DOI=10.1007/BF02372123) Group: Insect cell line 21091399 CVCL_Z265 A.t. GRIP-1 spontaneously immortalized cell line CVCL_Z265 CL:0000010 Unspecified Doubling time: 30 hours (PubMed=8551501). Group: Insect cell line 21091400 CVCL_Z266 A.t. GRIP-2 spontaneously immortalized cell line CVCL_Z266 CL:0000010 Unspecified Doubling time: 60 hours (PubMed=8551501). Group: Insect cell line 21091401 CVCL_PW30 BayGenomics ES cell line XG936 embryonic stem cell house mouse CVCL_PW30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345144; Spry4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091402 CVCL_Q830 HG02570 transformed cell line human CVCL_Q830 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091403 CVCL_PW31 BayGenomics ES cell line XG941 embryonic stem cell house mouse CVCL_PW31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923799; Cecr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091404 CVCL_Q831 HG02571 transformed cell line human CVCL_Q831 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091405 CVCL_PW32 BayGenomics ES cell line XG944 embryonic stem cell house mouse CVCL_PW32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091406 CVCL_Q832 HG02573 transformed cell line human CVCL_Q832 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091407 CVCL_PW33 BayGenomics ES cell line XG945 embryonic stem cell house mouse CVCL_PW33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091408 CVCL_Q833 HG02574 transformed cell line human CVCL_Q833 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091409 CVCL_PW34 BayGenomics ES cell line XG947 embryonic stem cell house mouse CVCL_PW34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277214; Septin11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091410 CVCL_Q834 HG02582 transformed cell line human CVCL_Q834 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091411 CVCL_PW35 BayGenomics ES cell line XG948 embryonic stem cell house mouse CVCL_PW35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091412 CVCL_Q835 HG02583 transformed cell line human CVCL_Q835 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091413 CVCL_PW36 BayGenomics ES cell line XG951 embryonic stem cell house mouse CVCL_PW36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923455; Stard3nl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091414 CVCL_Q836 HG02585 transformed cell line human CVCL_Q836 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091415 CVCL_PW37 BayGenomics ES cell line XG955 embryonic stem cell house mouse CVCL_PW37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914556; Zc2hc1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091416 CVCL_Q837 HG02586 transformed cell line human CVCL_Q837 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091417 CVCL_PW38 BayGenomics ES cell line XG956 embryonic stem cell house mouse CVCL_PW38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919942; Hnrnpll Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091418 CVCL_Q838 HG02588 transformed cell line human CVCL_Q838 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091419 CVCL_PW39 BayGenomics ES cell line XG958 embryonic stem cell house mouse CVCL_PW39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091420 CVCL_Q839 HG02589 transformed cell line human CVCL_Q839 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091421 CVCL_PW20 BayGenomics ES cell line XG909 embryonic stem cell house mouse CVCL_PW20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443306; Tom1l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091422 CVCL_Q820 HG02511 transformed cell line human CVCL_Q820 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091423 CVCL_PW21 BayGenomics ES cell line XG914 embryonic stem cell house mouse CVCL_PW21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091424 CVCL_Q821 HG02512 transformed cell line human CVCL_Q821 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091425 CVCL_PW22 BayGenomics ES cell line XG918 embryonic stem cell house mouse CVCL_PW22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103560; Kpna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091426 CVCL_Q822 HG02513 transformed cell line human CVCL_Q822 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091427 CVCL_PW23 BayGenomics ES cell line XG920 embryonic stem cell house mouse CVCL_PW23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448542; Samd4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091428 CVCL_Q823 HG02521 transformed cell line human CVCL_Q823 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091429 CVCL_PW24 BayGenomics ES cell line XG924 embryonic stem cell house mouse CVCL_PW24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153608; Ube2j2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091430 CVCL_Q824 HG02522 transformed cell line human CVCL_Q824 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091431 CVCL_PW25 BayGenomics ES cell line XG925 embryonic stem cell house mouse CVCL_PW25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106426; Tmem170 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091432 CVCL_Q825 HG02537 transformed cell line human CVCL_Q825 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091433 CVCL_PW26 BayGenomics ES cell line XG926 embryonic stem cell house mouse CVCL_PW26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277958; Pcm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091434 CVCL_Q826 HG02561 transformed cell line human CVCL_Q826 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091435 CVCL_PW27 BayGenomics ES cell line XG930 embryonic stem cell house mouse CVCL_PW27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153608; Ube2j2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091436 CVCL_Q827 HG02562 transformed cell line human CVCL_Q827 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091437 CVCL_PW28 BayGenomics ES cell line XG931 embryonic stem cell house mouse CVCL_PW28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925212; Scaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091438 CVCL_Q828 HG02567 transformed cell line human CVCL_Q828 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091439 CVCL_PW29 BayGenomics ES cell line XG934 embryonic stem cell house mouse CVCL_PW29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091440 CVCL_Q829 HG02568 transformed cell line human CVCL_Q829 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091441 CVCL_PW10 BayGenomics ES cell line XG879 embryonic stem cell house mouse CVCL_PW10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091442 CVCL_Q810 HG02484 transformed cell line human CVCL_Q810 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091443 CVCL_PW11 BayGenomics ES cell line XG881 embryonic stem cell house mouse CVCL_PW11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96245; Hspa9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091444 CVCL_Q811 HG02485 transformed cell line human CVCL_Q811 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091445 CVCL_PW12 BayGenomics ES cell line XG883 embryonic stem cell house mouse CVCL_PW12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96245; Hspa9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091446 CVCL_Q812 HG02489 transformed cell line human CVCL_Q812 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091447 CVCL_PW13 BayGenomics ES cell line XG885 embryonic stem cell house mouse CVCL_PW13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145219; Iars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091448 CVCL_Q813 HG02490 transformed cell line human CVCL_Q813 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091449 CVCL_PW14 BayGenomics ES cell line XG888 embryonic stem cell house mouse CVCL_PW14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091450 CVCL_Q814 HG02491 transformed cell line human CVCL_Q814 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091451 CVCL_PW15 BayGenomics ES cell line XG889 embryonic stem cell house mouse CVCL_PW15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336880; Eftud2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091452 CVCL_Q815 HG02493 transformed cell line human CVCL_Q815 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091453 CVCL_PW16 BayGenomics ES cell line XG898 embryonic stem cell house mouse CVCL_PW16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153887; Eri3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091454 CVCL_Q816 HG02494 transformed cell line human CVCL_Q816 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091455 CVCL_PW17 BayGenomics ES cell line XG901 embryonic stem cell house mouse CVCL_PW17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923605; Tgds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091456 CVCL_Q817 HG02496 transformed cell line human CVCL_Q817 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091457 CVCL_PW18 BayGenomics ES cell line XG905 embryonic stem cell house mouse CVCL_PW18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091458 CVCL_Q818 HG02497 transformed cell line human CVCL_Q818 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091459 CVCL_PW19 BayGenomics ES cell line XG908 embryonic stem cell house mouse CVCL_PW19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146005; Mtbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091460 CVCL_Q819 HG02508 transformed cell line human CVCL_Q819 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091461 CVCL_PW00 BayGenomics ES cell line XG849 embryonic stem cell house mouse CVCL_PW00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091462 CVCL_Q800 HG02450 transformed cell line human CVCL_Q800 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091463 CVCL_PW01 BayGenomics ES cell line XG853 embryonic stem cell house mouse CVCL_PW01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091464 CVCL_Q801 HG02451 transformed cell line human CVCL_Q801 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091465 CVCL_PW02 BayGenomics ES cell line XG856 embryonic stem cell house mouse CVCL_PW02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202400; Supt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091466 CVCL_Q802 HG02461 transformed cell line human CVCL_Q802 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091467 CVCL_PW03 BayGenomics ES cell line XG862 embryonic stem cell house mouse CVCL_PW03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091468 CVCL_Q803 HG02462 transformed cell line human CVCL_Q803 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091469 CVCL_PW04 BayGenomics ES cell line XG866 embryonic stem cell house mouse CVCL_PW04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091470 CVCL_Q804 HG02464 transformed cell line human CVCL_Q804 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091471 CVCL_PW05 BayGenomics ES cell line XG868 embryonic stem cell house mouse CVCL_PW05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091472 CVCL_Q805 HG02465 transformed cell line human CVCL_Q805 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091473 CVCL_PW06 BayGenomics ES cell line XG870 embryonic stem cell house mouse CVCL_PW06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647701; Gm9222 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091474 CVCL_Q806 HG02470 transformed cell line human CVCL_Q806 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091475 CVCL_PW07 BayGenomics ES cell line XG873 embryonic stem cell house mouse CVCL_PW07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091476 CVCL_Q807 HG02471 transformed cell line human CVCL_Q807 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091477 CVCL_PW08 BayGenomics ES cell line XG876 embryonic stem cell house mouse CVCL_PW08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915342; Ncbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091478 CVCL_Q808 HG02478 transformed cell line human CVCL_Q808 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091479 CVCL_PW09 BayGenomics ES cell line XG877 embryonic stem cell house mouse CVCL_PW09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107605; Npat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091480 CVCL_Q809 HG02479 transformed cell line human CVCL_Q809 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091481 CVCL_Z249 LDA2 spontaneously immortalized cell line CVCL_Z249 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 64 hours (at 42th passage), 47 hours (at 45th passage) (PubMed=11928998) Group: Insect cell line 21091482 CVCL_6K04 DA00317 transformed cell line human CVCL_6K04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091483 CVCL_6K05 DA00318 transformed cell line human CVCL_6K05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091484 CVCL_6K06 DA00319 transformed cell line human CVCL_6K06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091485 CVCL_6K07 DA00320 transformed cell line human CVCL_6K07 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091486 CVCL_6K00 DA00313 transformed cell line human CVCL_6K00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091487 CVCL_6K01 DA00314 transformed cell line human CVCL_6K01 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091488 CVCL_6K02 DA00315 transformed cell line human CVCL_6K02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091489 CVCL_6K03 DA00316 transformed cell line human CVCL_6K03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091490 CVCL_Z250 LDE1 spontaneously immortalized cell line CVCL_Z250 CL:0000010 Unspecified Doubling time: 113.6 hours, at 112th passage (PubMed=11928998). Group: Insect cell line 21091491 CVCL_Z251 LDL1 spontaneously immortalized cell line CVCL_Z251 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 31 hours (at 29th passage), 40.2 hours (at 31th passage) (PubMed=11928998) Group: Insect cell line 21091492 CVCL_Z256 Ea.4 spontaneously immortalized cell line CVCL_Z256 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 36 hours (ECACC=96073116) Group: Insect cell line; Group: Recombinant protein production insect cell line 21091493 CVCL_Z257 TN-CL1 spontaneously immortalized cell line CVCL_Z257 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21091494 CVCL_Z258 BTI-Tn-AP2 spontaneously immortalized cell line CVCL_Z258 CL:0000010 Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line. 21091495 CVCL_Z259 RU-ASE-2A spontaneously immortalized cell line CVCL_Z259 CL:0000010 Unspecified Group: Insect cell line. 21091496 CVCL_Z252 BTI-Tnao38 spontaneously immortalized cell line CVCL_Z252 CL:0000010 Unspecified Doubling time: 20.2 hours (PubMed=20602790). Group: Insect cell line; Group: Recombinant protein production insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00510 Problematic cell line: Contaminated Originally thought to be from Ascalapha odorata. Shown to be a BTI-Tn-5B1-4 derivative (PubMed=22531032). 21091497 CVCL_Z253 BTI-EAA spontaneously immortalized cell line CVCL_Z253 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line 21091498 CVCL_Z254 BTI-EAH spontaneously immortalized cell line CVCL_Z254 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line 21091499 CVCL_Z255 BTI-Ea-88 spontaneously immortalized cell line CVCL_Z255 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line 21091500 CVCL_6K10 DA00323 transformed cell line human CVCL_6K10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091501 CVCL_Z238 RU-TAE-12V spontaneously immortalized cell line CVCL_Z238 CL:0000010 Unspecified Group: Insect cell line. 21091502 CVCL_Z239 RU-TAE-14 spontaneously immortalized cell line CVCL_Z239 CL:0000010 Unspecified Group: Insect cell line. 21091503 CVCL_6K15 DA00329 transformed cell line human CVCL_6K15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091504 CVCL_6K16 DA00330 transformed cell line human CVCL_6K16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091505 CVCL_6K17 DA00331 transformed cell line human CVCL_6K17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091506 CVCL_6K18 DA00332 transformed cell line human CVCL_6K18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091507 CVCL_6K11 DA00324 transformed cell line human CVCL_6K11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091508 CVCL_6K12 DA00325 transformed cell line human CVCL_6K12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091509 CVCL_6K13 DA00326 transformed cell line human CVCL_6K13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091510 CVCL_6K14 DA00328 transformed cell line human CVCL_6K14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091511 CVCL_Z240 LEM-CQ-01 spontaneously immortalized cell line CVCL_Z240 CL:0000010 Miscellaneous: Provisional name until main author of paper respond to request to assign a name to the cell line. Unspecified Group: Insect cell line 21091512 CVCL_6K08 DA00321 transformed cell line human CVCL_6K08 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091513 CVCL_6K09 DA00322 transformed cell line human CVCL_6K09 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091514 CVCL_Z245 ZIZ-LD-1-3 spontaneously immortalized cell line CVCL_Z245 CL:0000010 Unspecified Group: Insect cell line. 21091515 CVCL_Z246 ZIZ-LD-1-4 spontaneously immortalized cell line CVCL_Z246 CL:0000010 Unspecified Group: Insect cell line. 21091516 CVCL_Z247 BCIRL-Lepd-SL1 spontaneously immortalized cell line CVCL_Z247 CL:0000010 Female Doubling time: 3.4 days (at 56th passage), 2.3 days (at 111th passage) (DOI=10.1303/aez.2002.447). Group: Insect cell line 21091517 CVCL_Z248 LDA1 spontaneously immortalized cell line CVCL_Z248 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 81.1 hours (at 28th passage), 78.1 hours (at 67th passage) (PubMed=11928998) Group: Insect cell line 21091518 CVCL_Z241 Lulo spontaneously immortalized cell line CVCL_Z241 CL:0000010 Unspecified Characteristics: The promastigote form of species from the subgenera Leishmania and Viannia can adhere to Lulo cells (PubMed=22082050) Doubling time: 24.7 hours (PubMed=10656714). Group: Insect cell line 21091519 CVCL_Z242 PC-0199-BR spontaneously immortalized cell line CVCL_Z242 CL:0000010 Unspecified Doubling time: 26 hours (PubMed=11562717). Group: Insect cell line 21091520 CVCL_Z243 ZIZ-LD-1 spontaneously immortalized cell line CVCL_Z243 CL:0000010 Discontinued: ECACC; 93022523; probable. Unspecified Group: Insect cell line 21091521 CVCL_Z244 ZIZ-LD-1-15 spontaneously immortalized cell line CVCL_Z244 CL:0000010 Unspecified Group: Insect cell line. 21091522 CVCL_PW90 BayGenomics ES cell line XH084 embryonic stem cell house mouse CVCL_PW90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091523 CVCL_Q890 HG02699 transformed cell line human CVCL_Q890 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091524 CVCL_PW91 BayGenomics ES cell line XH085 embryonic stem cell house mouse CVCL_PW91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151114; Dgcr8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091525 CVCL_Q891 HG02700 transformed cell line human CVCL_Q891 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091526 CVCL_PW92 BayGenomics ES cell line XH090 embryonic stem cell house mouse CVCL_PW92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091527 CVCL_Q892 HG02702 transformed cell line human CVCL_Q892 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091528 CVCL_Z227 ATC-173 spontaneously immortalized cell line CVCL_Z227 CL:0000010 Unspecified Group: Insect cell line. 21091529 CVCL_PW93 BayGenomics ES cell line XH099 embryonic stem cell house mouse CVCL_PW93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091530 CVCL_Q893 HG02703 transformed cell line human CVCL_Q893 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091531 CVCL_Z228 ATC-176 spontaneously immortalized cell line CVCL_Z228 CL:0000010 Unspecified Group: Insect cell line. 21091532 CVCL_PW94 BayGenomics ES cell line XH102 embryonic stem cell house mouse CVCL_PW94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091533 CVCL_Q894 HG02715 transformed cell line human CVCL_Q894 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091534 CVCL_Z229 ATC-415 spontaneously immortalized cell line CVCL_Z229 CL:0000010 Unspecified Group: Insect cell line. 21091535 CVCL_PW95 BayGenomics ES cell line XH108 embryonic stem cell house mouse CVCL_PW95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091536 CVCL_Q895 HG02716 transformed cell line human CVCL_Q895 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091537 CVCL_PW96 BayGenomics ES cell line XH111 embryonic stem cell house mouse CVCL_PW96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091538 CVCL_Q896 HG02721 transformed cell line human CVCL_Q896 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091539 CVCL_PW97 BayGenomics ES cell line XH119 embryonic stem cell house mouse CVCL_PW97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921571; Tipin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091540 CVCL_Q897 HG02722 transformed cell line human CVCL_Q897 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091541 CVCL_PW98 BayGenomics ES cell line XH123 embryonic stem cell house mouse CVCL_PW98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104729; Akap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091542 CVCL_Q898 HG02724 transformed cell line human CVCL_Q898 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091543 CVCL_PW99 BayGenomics ES cell line XH125 embryonic stem cell house mouse CVCL_PW99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97286; Ncl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091544 CVCL_Q899 HG02725 transformed cell line human CVCL_Q899 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091545 CVCL_Z234 HAE/CTVM15 spontaneously immortalized cell line CVCL_Z234 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Bell-Sakyi L.) Discontinued: ECACC; 94022810; probable. Unspecified Group: Tick cell line 21091546 CVCL_Z235 TRA-171 spontaneously immortalized cell line CVCL_Z235 CL:0000010 Unspecified Group: Insect cell line. 21091547 CVCL_Z236 PRU-TA-42 spontaneously immortalized cell line CVCL_Z236 CL:0000010 Unspecified Group: Insect cell line. 21091548 CVCL_Z237 PRU-TA-9 spontaneously immortalized cell line CVCL_Z237 CL:0000010 Unspecified Group: Insect cell line. 21091549 CVCL_Z230 C6/36 spontaneously immortalized cell line CVCL_Z230 CL:0000010 Omics: Deep quantitative proteome analysis; Omics: Genome sequenced. Unspecified Virology: Used for detection, propagation and analysis of mosquito-borne viruses; Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Insect cell line 21091550 CVCL_Z231 Schneider 1 spontaneously immortalized cell line fruit fly CVCL_Z231 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 90070555; probable Male Doubling time: 32-35 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21091551 CVCL_Z232 Schneider 2 spontaneously immortalized cell line fruit fly CVCL_Z232 CL:0000010 Breed/subspecies: Oregon-R. Discontinued: ECACC; 90070554; probable Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: ~40 hours (DSMZ=ACC-130) Group: Insect cell line 21091552 CVCL_Z233 Schneider 3 spontaneously immortalized cell line fruit fly CVCL_Z233 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 90070548; probable Male Doubling time: 19-21 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21091553 CVCL_PW80 BayGenomics ES cell line XH070 embryonic stem cell house mouse CVCL_PW80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091554 CVCL_Q880 HG02682 transformed cell line human CVCL_Q880 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091555 CVCL_PW81 BayGenomics ES cell line XH071 embryonic stem cell house mouse CVCL_PW81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091556 CVCL_Q881 HG02684 transformed cell line human CVCL_Q881 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091557 CVCL_PW82 BayGenomics ES cell line XH073 embryonic stem cell house mouse CVCL_PW82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925349; Atrip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091558 CVCL_Q882 HG02685 transformed cell line human CVCL_Q882 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091559 CVCL_Z216 IPLB-HZ-1075/UND-K spontaneously immortalized cell line CVCL_Z216 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091560 CVCL_PW83 BayGenomics ES cell line XH074 embryonic stem cell house mouse CVCL_PW83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95610; Gabpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091561 CVCL_Q883 HG02687 transformed cell line human CVCL_Q883 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091562 CVCL_Z217 IPLB-HZ-1075/UND-L spontaneously immortalized cell line CVCL_Z217 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091563 CVCL_PW84 BayGenomics ES cell line XH076 embryonic stem cell house mouse CVCL_PW84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138584; Gigyf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091564 CVCL_Q884 HG02688 transformed cell line human CVCL_Q884 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091565 CVCL_Z218 IPLB-HZ-1075/UND-O spontaneously immortalized cell line CVCL_Z218 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091566 CVCL_PW85 BayGenomics ES cell line XH077 embryonic stem cell house mouse CVCL_PW85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091567 CVCL_Q885 HG02690 transformed cell line human CVCL_Q885 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091568 CVCL_Z219 IPLB-HZ-1075/UND-R spontaneously immortalized cell line CVCL_Z219 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091569 CVCL_PW86 BayGenomics ES cell line XH078 embryonic stem cell house mouse CVCL_PW86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261847; Vrk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091570 CVCL_Q886 HG02691 transformed cell line human CVCL_Q886 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091571 CVCL_PW87 BayGenomics ES cell line XH079 embryonic stem cell house mouse CVCL_PW87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913714; Taf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091572 CVCL_Q887 HG02694 transformed cell line human CVCL_Q887 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091573 CVCL_PW88 BayGenomics ES cell line XH081 embryonic stem cell house mouse CVCL_PW88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141847; Phrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091574 CVCL_Q888 HG02696 transformed cell line human CVCL_Q888 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091575 CVCL_PW89 BayGenomics ES cell line XH083 embryonic stem cell house mouse CVCL_PW89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913743; Mrpl51 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091576 CVCL_Q889 HG02697 transformed cell line human CVCL_Q889 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091577 CVCL_Z223 ATC-15 spontaneously immortalized cell line CVCL_Z223 CL:0000010 Unspecified Group: Insect cell line. 21091578 CVCL_Z224 ATC-121 spontaneously immortalized cell line CVCL_Z224 CL:0000010 Unspecified Virology: Susceptible to infection by Chikungunya virus, Japanese encephalitis virus (JEV), West Nile virus (WNV) and Chandipura virus (CelloPub=CLPUB00683). Group: Insect cell line 21091579 CVCL_Z225 ATC-136 spontaneously immortalized cell line CVCL_Z225 CL:0000010 Unspecified Group: Insect cell line. 21091580 CVCL_Z226 ATC-137 spontaneously immortalized cell line CVCL_Z226 CL:0000010 Unspecified Group: Insect cell line. 21091581 CVCL_Z220 IPLB-HZ-1075/UND-U spontaneously immortalized cell line CVCL_Z220 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091582 CVCL_Z221 IPLB-HZ-1075/UND-V spontaneously immortalized cell line CVCL_Z221 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091583 CVCL_Z222 ATC-10 spontaneously immortalized cell line CVCL_Z222 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Group: Insect cell line 21091584 CVCL_Z209 IPLB-HZ-1075 spontaneously immortalized cell line CVCL_Z209 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091585 CVCL_PW70 BayGenomics ES cell line XH058 embryonic stem cell house mouse CVCL_PW70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142567; Arhgef18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091586 CVCL_Q870 HG02658 transformed cell line human CVCL_Q870 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091587 CVCL_PW71 BayGenomics ES cell line XH060 embryonic stem cell house mouse CVCL_PW71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924315; Ints7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091588 CVCL_Z205 BmVIII-SCC-OPr-C54 spontaneously immortalized cell line CVCL_Z205 CL:0000010 Female Group: Tick cell line. 21091589 CVCL_Q871 HG02660 transformed cell line human CVCL_Q871 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091590 CVCL_PW72 BayGenomics ES cell line XH061 embryonic stem cell house mouse CVCL_PW72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091591 CVCL_Q872 HG02661 transformed cell line human CVCL_Q872 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091592 CVCL_Z206 REE/CTVM28 spontaneously immortalized cell line CVCL_Z206 CL:0000010 Unspecified Group: Tick cell line. 21091593 CVCL_PW73 BayGenomics ES cell line XH062 embryonic stem cell house mouse CVCL_PW73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914868; Aasdhppt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091594 CVCL_Q873 HG02666 transformed cell line human CVCL_Q873 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091595 CVCL_Z207 REE/CTVM29 spontaneously immortalized cell line CVCL_Z207 CL:0000010 Unspecified Group: Tick cell line. 21091596 CVCL_PW74 BayGenomics ES cell line XH063 embryonic stem cell house mouse CVCL_PW74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351657; Abcf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091597 CVCL_Q874 HG02667 transformed cell line human CVCL_Q874 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091598 CVCL_Z208 REE/CTVM31 spontaneously immortalized cell line CVCL_Z208 CL:0000010 Unspecified Group: Tick cell line. 21091599 CVCL_PW75 BayGenomics ES cell line XH064 embryonic stem cell house mouse CVCL_PW75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443114; Larp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091600 CVCL_Q875 HG02675 transformed cell line human CVCL_Q875 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091601 CVCL_PW76 BayGenomics ES cell line XH065 embryonic stem cell house mouse CVCL_PW76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443114; Larp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091602 CVCL_Q876 HG02676 transformed cell line human CVCL_Q876 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091603 CVCL_PW77 BayGenomics ES cell line XH066 embryonic stem cell house mouse CVCL_PW77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091604 CVCL_Q877 HG02678 transformed cell line human CVCL_Q877 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091605 CVCL_PW78 BayGenomics ES cell line XH068 embryonic stem cell house mouse CVCL_PW78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091606 CVCL_Q878 HG02679 transformed cell line human CVCL_Q878 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091607 CVCL_PW79 BayGenomics ES cell line XH069 embryonic stem cell house mouse CVCL_PW79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103067; Atrx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091608 CVCL_Q879 HG02681 transformed cell line human CVCL_Q879 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091609 CVCL_Z212 IPLB-HZ-1075/UND-F spontaneously immortalized cell line CVCL_Z212 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091610 CVCL_Z213 IPLB-HZ-1075/UND-G spontaneously immortalized cell line CVCL_Z213 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091611 CVCL_Z214 IPLB-HZ-1075/UND-H spontaneously immortalized cell line CVCL_Z214 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091612 CVCL_Z215 IPLB-HZ-1075/UND-I spontaneously immortalized cell line CVCL_Z215 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091613 CVCL_Z210 IPLB-HZ-1075/UND-B spontaneously immortalized cell line CVCL_Z210 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091614 CVCL_Z211 IPLB-HZ-1075/UND-C spontaneously immortalized cell line CVCL_Z211 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21091615 CVCL_PW60 BayGenomics ES cell line XH041 embryonic stem cell house mouse CVCL_PW60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091616 CVCL_Q860 HG02643 transformed cell line human CVCL_Q860 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091617 CVCL_PW61 BayGenomics ES cell line XH043 embryonic stem cell house mouse CVCL_PW61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091618 CVCL_Q861 HG02645 transformed cell line human CVCL_Q861 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091619 CVCL_PW62 BayGenomics ES cell line XH045 embryonic stem cell house mouse CVCL_PW62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091620 CVCL_Q862 HG02646 transformed cell line human CVCL_Q862 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091621 CVCL_PW63 BayGenomics ES cell line XH046 embryonic stem cell house mouse CVCL_PW63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914934; Luc7l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091622 CVCL_Q863 HG02648 transformed cell line human CVCL_Q863 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091623 CVCL_PW64 BayGenomics ES cell line XH051 embryonic stem cell house mouse CVCL_PW64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441787; Washc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091624 CVCL_Q864 HG02649 transformed cell line human CVCL_Q864 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091625 CVCL_PW65 BayGenomics ES cell line XH052 embryonic stem cell house mouse CVCL_PW65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091626 CVCL_Q865 HG02651 transformed cell line human CVCL_Q865 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091627 CVCL_PW66 BayGenomics ES cell line XH053 embryonic stem cell house mouse CVCL_PW66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091628 CVCL_Q866 HG02652 transformed cell line human CVCL_Q866 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091629 CVCL_PW67 BayGenomics ES cell line XH054 embryonic stem cell house mouse CVCL_PW67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860606; Akap8l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091630 CVCL_Q867 HG02654 transformed cell line human CVCL_Q867 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091631 CVCL_PW68 BayGenomics ES cell line XH056 embryonic stem cell house mouse CVCL_PW68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091632 CVCL_Q868 HG02655 transformed cell line human CVCL_Q868 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091633 CVCL_PW69 BayGenomics ES cell line XH057 embryonic stem cell house mouse CVCL_PW69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925212; Scaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091634 CVCL_Q869 HG02657 transformed cell line human CVCL_Q869 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091635 CVCL_Z201 BmIX spontaneously immortalized cell line CVCL_Z201 CL:0000010 Unspecified Group: Tick cell line. 21091636 CVCL_Z202 BmVIII-SCC spontaneously immortalized cell line CVCL_Z202 CL:0000010 Female Group: Tick cell line. 21091637 CVCL_Z203 BmVIII-SCC-OPr-C34 spontaneously immortalized cell line CVCL_Z203 CL:0000010 Female Group: Tick cell line. 21091638 CVCL_Z204 BmVIII-SCC-OPr-C44 spontaneously immortalized cell line CVCL_Z204 CL:0000010 Female Group: Tick cell line. 21091639 CVCL_Z200 IRE11 spontaneously immortalized cell line CVCL_Z200 CL:0000010 Unspecified Group: Tick cell line. 21091640 CVCL_PW50 BayGenomics ES cell line XH022 embryonic stem cell house mouse CVCL_PW50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919787; Cdca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091641 CVCL_Q850 HG02614 transformed cell line human CVCL_Q850 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091642 CVCL_PW51 BayGenomics ES cell line XH024 embryonic stem cell house mouse CVCL_PW51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091643 CVCL_Q851 HG02620 transformed cell line human CVCL_Q851 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091644 CVCL_PW52 BayGenomics ES cell line XH027 embryonic stem cell house mouse CVCL_PW52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091645 CVCL_Q852 HG02621 transformed cell line human CVCL_Q852 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091646 CVCL_PW53 BayGenomics ES cell line XH028 embryonic stem cell house mouse CVCL_PW53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091647 CVCL_Q853 HG02623 transformed cell line human CVCL_Q853 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091648 CVCL_PW54 BayGenomics ES cell line XH029 embryonic stem cell house mouse CVCL_PW54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091649 CVCL_Q854 HG02624 transformed cell line human CVCL_Q854 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091650 CVCL_PW55 BayGenomics ES cell line XH031 embryonic stem cell house mouse CVCL_PW55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091651 CVCL_Q855 HG02628 transformed cell line human CVCL_Q855 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091652 CVCL_PW56 BayGenomics ES cell line XH034 embryonic stem cell house mouse CVCL_PW56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139207; Sec16a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091653 CVCL_Q856 HG02629 transformed cell line human CVCL_Q856 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091654 CVCL_PW57 BayGenomics ES cell line XH037 embryonic stem cell house mouse CVCL_PW57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091655 CVCL_Q857 HG02634 transformed cell line human CVCL_Q857 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091656 CVCL_PW58 BayGenomics ES cell line XH038 embryonic stem cell house mouse CVCL_PW58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913808; Lars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091657 CVCL_Q858 HG02635 transformed cell line human CVCL_Q858 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091658 CVCL_PW59 BayGenomics ES cell line XH040 embryonic stem cell house mouse CVCL_PW59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386621; Cpne1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091659 CVCL_Q859 HG02642 transformed cell line human CVCL_Q859 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091660 CVCL_PW40 BayGenomics ES cell line XH001 embryonic stem cell house mouse CVCL_PW40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88110; Atp2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091661 CVCL_Q840 HG02594 transformed cell line human CVCL_Q840 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091662 CVCL_PW41 BayGenomics ES cell line XH003 embryonic stem cell house mouse CVCL_PW41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354736; Kdm2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091663 CVCL_Q841 HG02595 transformed cell line human CVCL_Q841 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091664 CVCL_PW42 BayGenomics ES cell line XH004 embryonic stem cell house mouse CVCL_PW42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182061; Usp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091665 CVCL_Q842 HG02597 transformed cell line human CVCL_Q842 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091666 CVCL_PW43 BayGenomics ES cell line XH005 embryonic stem cell house mouse CVCL_PW43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091667 CVCL_Q843 HG02600 transformed cell line human CVCL_Q843 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091668 CVCL_PW44 BayGenomics ES cell line XH007 embryonic stem cell house mouse CVCL_PW44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919002; Gtf3c2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091669 CVCL_Q844 HG02601 transformed cell line human CVCL_Q844 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091670 CVCL_PW45 BayGenomics ES cell line XH008 embryonic stem cell house mouse CVCL_PW45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091671 CVCL_Q845 HG02603 transformed cell line human CVCL_Q845 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091672 CVCL_PW46 BayGenomics ES cell line XH010 embryonic stem cell house mouse CVCL_PW46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915010; Slc38a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091673 CVCL_Q846 HG02604 transformed cell line human CVCL_Q846 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091674 CVCL_PW47 BayGenomics ES cell line XH014 embryonic stem cell house mouse CVCL_PW47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091675 CVCL_Q847 HG02610 transformed cell line human CVCL_Q847 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091676 CVCL_PW48 BayGenomics ES cell line XH017 embryonic stem cell house mouse CVCL_PW48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091677 CVCL_Q848 HG02611 transformed cell line human CVCL_Q848 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091678 CVCL_PW49 BayGenomics ES cell line XH020 embryonic stem cell house mouse CVCL_PW49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445220; Dcaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091679 CVCL_Q849 HG02613 transformed cell line human CVCL_Q849 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091680 CVCL_6L83 DA00499 transformed cell line human CVCL_6L83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091681 CVCL_6L84 DA00500 transformed cell line human CVCL_6L84 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091682 CVCL_6L85 DA00501 transformed cell line human CVCL_6L85 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091683 CVCL_6L86 DA00502 transformed cell line human CVCL_6L86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091684 CVCL_6L80 DA00496 transformed cell line human CVCL_6L80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091685 CVCL_6L81 DA00497 transformed cell line human CVCL_6L81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091686 CVCL_6L82 DA00498 transformed cell line human CVCL_6L82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091687 CVCL_6L87 DA00503 transformed cell line human CVCL_6L87 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091688 CVCL_6L88 DA00504 transformed cell line human CVCL_6L88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091689 CVCL_6L89 DA00505 transformed cell line human CVCL_6L89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091690 CVCL_6L94 DA00510 transformed cell line human CVCL_6L94 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091691 CVCL_6L95 DA00511 transformed cell line human CVCL_6L95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091692 CVCL_6L96 DA00512 transformed cell line human CVCL_6L96 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091693 CVCL_6L97 DA00513 transformed cell line human CVCL_6L97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091694 CVCL_6L90 DA00506 transformed cell line human CVCL_6L90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091695 CVCL_6L91 DA00507 transformed cell line human CVCL_6L91 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091696 CVCL_6L92 DA00508 transformed cell line human CVCL_6L92 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091697 CVCL_6L93 DA00509 transformed cell line human CVCL_6L93 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091698 CVCL_6L98 DA00514 transformed cell line human CVCL_6L98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091699 CVCL_6L99 DA00515 transformed cell line human CVCL_6L99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091700 CVCL_6L61 DA00477 transformed cell line human CVCL_6L61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091701 CVCL_6L62 DA00478 transformed cell line human CVCL_6L62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091702 CVCL_6L63 DA00479 transformed cell line human CVCL_6L63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091703 CVCL_6L64 DA00480 transformed cell line human CVCL_6L64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091704 CVCL_6L60 DA00476 transformed cell line human CVCL_6L60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091705 CVCL_6L69 DA00485 transformed cell line human CVCL_6L69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091706 CVCL_6L65 DA00481 transformed cell line human CVCL_6L65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091707 CVCL_6L66 DA00482 transformed cell line human CVCL_6L66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091708 CVCL_6L67 DA00483 transformed cell line human CVCL_6L67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091709 CVCL_6L68 DA00484 transformed cell line human CVCL_6L68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091710 CVCL_6L72 DA00488 transformed cell line human CVCL_6L72 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091711 CVCL_6L73 DA00489 transformed cell line human CVCL_6L73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091712 CVCL_6L74 DA00490 transformed cell line human CVCL_6L74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091713 CVCL_6L75 DA00491 transformed cell line human CVCL_6L75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091714 CVCL_6L70 DA00486 transformed cell line human CVCL_6L70 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091715 CVCL_6L71 DA00487 transformed cell line human CVCL_6L71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091716 CVCL_6L76 DA00492 transformed cell line human CVCL_6L76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091717 CVCL_6L77 DA00493 transformed cell line human CVCL_6L77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091718 CVCL_6L78 DA00494 transformed cell line human CVCL_6L78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091719 CVCL_6L79 DA00495 transformed cell line human CVCL_6L79 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091720 CVCL_6L40 DA00455 transformed cell line human CVCL_6L40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091721 CVCL_6L41 DA00456 transformed cell line human CVCL_6L41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091722 CVCL_6L42 DA00457 transformed cell line human CVCL_6L42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091723 CVCL_6L47 DA00462 transformed cell line human CVCL_6L47 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091724 CVCL_6L48 DA00463 transformed cell line human CVCL_6L48 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091725 CVCL_6L49 DA00464 transformed cell line human CVCL_6L49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091726 CVCL_6L43 DA00458 transformed cell line human CVCL_6L43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091727 CVCL_6L44 DA00459 transformed cell line human CVCL_6L44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091728 CVCL_6L45 DA00460 transformed cell line human CVCL_6L45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091729 CVCL_6L46 DA00461 transformed cell line human CVCL_6L46 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091730 CVCL_Z391 IAL-TND1 spontaneously immortalized cell line CVCL_Z391 CL:0000010 Derived from sampling site: Imaginal disc; wing. Unspecified Group: Insect cell line 21091731 CVCL_Z392 IAL-SFD1 spontaneously immortalized cell line CVCL_Z392 CL:0000010 Derived from sampling site: Imaginal disc; wing. Unspecified Group: Insect cell line 21091732 CVCL_Z393 IAL-PID2 spontaneously immortalized cell line CVCL_Z393 CL:0000010 Derived from sampling site: Imaginal disc; wing. Unspecified Group: Insect cell line 21091733 CVCL_Z394 UMN-PIE-1181 spontaneously immortalized cell line CVCL_Z394 CL:0000010 Unspecified Group: Insect cell line. 21091734 CVCL_Z390 MRRL-CH2 spontaneously immortalized cell line CVCL_Z390 CL:0000010 Unspecified Group: Insect cell line. 21091735 CVCL_Z399 BCIRL-HZ-AM1 spontaneously immortalized cell line CVCL_Z399 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 22 hours (PubMed=2022870) Group: Insect cell line 21091736 CVCL_Z395 BCIRL-AG-AM1 spontaneously immortalized cell line CVCL_Z395 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091737 CVCL_Z396 BCIRL-HS-AM1 spontaneously immortalized cell line CVCL_Z396 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line 21091738 CVCL_Z397 BCIRL-HV-AM1 spontaneously immortalized cell line CVCL_Z397 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091739 CVCL_Z398 BCIRL-HV-AM2 spontaneously immortalized cell line CVCL_Z398 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091740 CVCL_6L50 DA00465 transformed cell line human CVCL_6L50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091741 CVCL_6L51 DA00466 transformed cell line human CVCL_6L51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091742 CVCL_6L52 DA00467 transformed cell line human CVCL_6L52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091743 CVCL_6L53 DA00468 transformed cell line human CVCL_6L53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091744 CVCL_6L58 DA00474 transformed cell line human CVCL_6L58 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091745 CVCL_6L59 DA00475 transformed cell line human CVCL_6L59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091746 CVCL_6L54 DA00470 transformed cell line human CVCL_6L54 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091747 CVCL_6L55 DA00471 transformed cell line human CVCL_6L55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091748 CVCL_6L56 DA00472 transformed cell line human CVCL_6L56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091749 CVCL_6L57 DA00473 transformed cell line human CVCL_6L57 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091750 CVCL_Z380 IPLB-LD-652 spontaneously immortalized cell line CVCL_Z380 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091751 CVCL_Z381 IPLB-LD-652Y spontaneously immortalized cell line CVCL_Z381 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line Caution: IPLB-LD-652Y is not explicitely mentioned in PubMed=79542, but almost all authors cite this publication as the source PubMed=24986084 discuss the possibility that this is a typo for IPLB-LD-65Y, but this is not certain. 21091752 CVCL_Z382 IPLB-LD-65Y spontaneously immortalized cell line CVCL_Z382 CL:0000010 Derived from sampling site: Ovary. Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Insect cell line 21091753 CVCL_Z383 IPLB-LD-65Z spontaneously immortalized cell line CVCL_Z383 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091754 CVCL_Z388 KMITL-HA-E1 spontaneously immortalized cell line CVCL_Z388 CL:0000010 Unspecified Group: Insect cell line. 21091755 CVCL_Z389 MRRL-CH1 spontaneously immortalized cell line CVCL_Z389 CL:0000010 Unspecified Group: Insect cell line. 21091756 CVCL_Z384 IPLB-LD-66 spontaneously immortalized cell line CVCL_Z384 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091757 CVCL_Z385 IPLB-LD-67 spontaneously immortalized cell line CVCL_Z385 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091758 CVCL_Z386 KMITL-PX-E1 spontaneously immortalized cell line CVCL_Z386 CL:0000010 Unspecified Doubling time: 61.22 hours, at 18th passage (CelloPub=CLPUB00169). Group: Insect cell line 21091759 CVCL_Z387 PX-1187 spontaneously immortalized cell line CVCL_Z387 CL:0000010 Unspecified Doubling time: 27 hours, at 28 Celsius (DOI=10.1016/0022-2011(92)90029-4). Group: Insect cell line 21091760 CVCL_PX50 BayGenomics ES cell line XH227 embryonic stem cell house mouse CVCL_PX50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921451; Cep97 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091761 CVCL_Q950 HG02855 transformed cell line human CVCL_Q950 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091762 CVCL_PX51 BayGenomics ES cell line XH228 embryonic stem cell house mouse CVCL_PX51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099790; Plk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091763 CVCL_Q951 HG02860 transformed cell line human CVCL_Q951 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091764 CVCL_PX52 BayGenomics ES cell line XH230 embryonic stem cell house mouse CVCL_PX52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096573; Utp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091765 CVCL_Q952 HG02861 transformed cell line human CVCL_Q952 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091766 CVCL_PX53 BayGenomics ES cell line XH232 embryonic stem cell house mouse CVCL_PX53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343188; Ube2g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091767 CVCL_Q953 HG02869 transformed cell line human CVCL_Q953 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091768 CVCL_PX54 BayGenomics ES cell line XH236 embryonic stem cell house mouse CVCL_PX54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915545; Aar2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091769 CVCL_Q954 HG02870 transformed cell line human CVCL_Q954 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091770 CVCL_PX55 BayGenomics ES cell line XH237 embryonic stem cell house mouse CVCL_PX55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091771 CVCL_Q955 HG02878 transformed cell line human CVCL_Q955 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091772 CVCL_PX56 BayGenomics ES cell line XH239 embryonic stem cell house mouse CVCL_PX56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091773 CVCL_Q956 HG02879 transformed cell line human CVCL_Q956 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091774 CVCL_PX57 BayGenomics ES cell line XH241 embryonic stem cell house mouse CVCL_PX57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924295; Bcl7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091775 CVCL_Q957 HG02881 transformed cell line human CVCL_Q957 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091776 CVCL_PX58 BayGenomics ES cell line XH243 embryonic stem cell house mouse CVCL_PX58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923041; Fbxw8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091777 CVCL_Q958 HG02882 transformed cell line human CVCL_Q958 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091778 CVCL_PX59 BayGenomics ES cell line XH249 embryonic stem cell house mouse CVCL_PX59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924057; Phf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091779 CVCL_Q959 HG02884 transformed cell line human CVCL_Q959 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091780 CVCL_PX40 BayGenomics ES cell line XH212 embryonic stem cell house mouse CVCL_PX40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921831; Sbf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091781 CVCL_Q940 HG02817 transformed cell line human CVCL_Q940 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091782 CVCL_PX41 BayGenomics ES cell line XH213 embryonic stem cell house mouse CVCL_PX41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091783 CVCL_Q941 HG02819 transformed cell line human CVCL_Q941 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091784 CVCL_PX42 BayGenomics ES cell line XH214 embryonic stem cell house mouse CVCL_PX42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914487; Cul4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091785 CVCL_Q942 HG02820 transformed cell line human CVCL_Q942 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091786 CVCL_PX43 BayGenomics ES cell line XH215 embryonic stem cell house mouse CVCL_PX43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685179; Zfp407 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091787 CVCL_Q943 HG02836 transformed cell line human CVCL_Q943 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091788 CVCL_PX44 BayGenomics ES cell line XH216 embryonic stem cell house mouse CVCL_PX44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091789 CVCL_Q944 HG02837 transformed cell line human CVCL_Q944 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091790 CVCL_PX45 BayGenomics ES cell line XH218 embryonic stem cell house mouse CVCL_PX45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091791 CVCL_Q945 HG02839 transformed cell line human CVCL_Q945 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091792 CVCL_PX46 BayGenomics ES cell line XH221 embryonic stem cell house mouse CVCL_PX46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1315202; Slit3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091793 CVCL_Q946 HG02840 transformed cell line human CVCL_Q946 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091794 CVCL_PX47 BayGenomics ES cell line XH222 embryonic stem cell house mouse CVCL_PX47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091795 CVCL_Q947 HG02851 transformed cell line human CVCL_Q947 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091796 CVCL_PX48 BayGenomics ES cell line XH223 embryonic stem cell house mouse CVCL_PX48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920194; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091797 CVCL_Q948 HG02852 transformed cell line human CVCL_Q948 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091798 CVCL_PX49 BayGenomics ES cell line XH226 embryonic stem cell house mouse CVCL_PX49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091799 CVCL_Q949 HG02854 transformed cell line human CVCL_Q949 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091800 CVCL_PX30 BayGenomics ES cell line XH199 embryonic stem cell house mouse CVCL_PX30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927489; Pdlim5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091801 CVCL_Q930 HG02799 transformed cell line human CVCL_Q930 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091802 CVCL_PX31 BayGenomics ES cell line XH201 embryonic stem cell house mouse CVCL_PX31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091803 CVCL_Q931 HG02804 transformed cell line human CVCL_Q931 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091804 CVCL_PX32 BayGenomics ES cell line XH202 embryonic stem cell house mouse CVCL_PX32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919563; Fryl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091805 CVCL_Q932 HG02805 transformed cell line human CVCL_Q932 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091806 CVCL_PX33 BayGenomics ES cell line XH203 embryonic stem cell house mouse CVCL_PX33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091807 CVCL_Q933 HG02807 transformed cell line human CVCL_Q933 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091808 CVCL_PX34 BayGenomics ES cell line XH204 embryonic stem cell house mouse CVCL_PX34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920093; Prdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091809 CVCL_Q934 HG02808 transformed cell line human CVCL_Q934 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091810 CVCL_PX35 BayGenomics ES cell line XH205 embryonic stem cell house mouse CVCL_PX35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95480; Fancc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091811 CVCL_Q935 HG02810 transformed cell line human CVCL_Q935 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091812 CVCL_PX36 BayGenomics ES cell line XH206 embryonic stem cell house mouse CVCL_PX36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105926; Rab5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091813 CVCL_Q936 HG02811 transformed cell line human CVCL_Q936 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091814 CVCL_PX37 BayGenomics ES cell line XH207 embryonic stem cell house mouse CVCL_PX37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091815 CVCL_Q937 HG02813 transformed cell line human CVCL_Q937 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091816 CVCL_PX38 BayGenomics ES cell line XH209 embryonic stem cell house mouse CVCL_PX38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919933; Proser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091817 CVCL_Q938 HG02814 transformed cell line human CVCL_Q938 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091818 CVCL_PX39 BayGenomics ES cell line XH211 embryonic stem cell house mouse CVCL_PX39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933765; Btbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091819 CVCL_Q939 HG02816 transformed cell line human CVCL_Q939 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091820 CVCL_PX20 BayGenomics ES cell line XH183 embryonic stem cell house mouse CVCL_PX20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091821 CVCL_Q920 HG02781 transformed cell line human CVCL_Q920 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091822 CVCL_PX21 BayGenomics ES cell line XH184 embryonic stem cell house mouse CVCL_PX21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091823 CVCL_Q921 HG02783 transformed cell line human CVCL_Q921 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091824 CVCL_PX22 BayGenomics ES cell line XH185 embryonic stem cell house mouse CVCL_PX22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95610; Gabpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091825 CVCL_Q922 HG02784 transformed cell line human CVCL_Q922 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091826 CVCL_PX23 BayGenomics ES cell line XH186 embryonic stem cell house mouse CVCL_PX23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091827 CVCL_Q923 HG02786 transformed cell line human CVCL_Q923 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091828 CVCL_PX24 BayGenomics ES cell line XH188 embryonic stem cell house mouse CVCL_PX24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091829 CVCL_Q924 HG02787 transformed cell line human CVCL_Q924 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091830 CVCL_PX25 BayGenomics ES cell line XH189 embryonic stem cell house mouse CVCL_PX25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091831 CVCL_Q925 HG02789 transformed cell line human CVCL_Q925 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091832 CVCL_PX26 BayGenomics ES cell line XH191 embryonic stem cell house mouse CVCL_PX26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091833 CVCL_Q926 HG02790 transformed cell line human CVCL_Q926 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091834 CVCL_PX27 BayGenomics ES cell line XH192 embryonic stem cell house mouse CVCL_PX27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858965; Atf7ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091835 CVCL_Q927 HG02792 transformed cell line human CVCL_Q927 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091836 CVCL_PX28 BayGenomics ES cell line XH194 embryonic stem cell house mouse CVCL_PX28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109152; Lig3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091837 CVCL_Q928 HG02793 transformed cell line human CVCL_Q928 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091838 CVCL_PX29 BayGenomics ES cell line XH196 embryonic stem cell house mouse CVCL_PX29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860494; Ddx21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091839 CVCL_Q929 HG02798 transformed cell line human CVCL_Q929 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091840 CVCL_PX10 BayGenomics ES cell line XH152 embryonic stem cell house mouse CVCL_PX10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934606; Alms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091841 CVCL_Q910 HG02762 transformed cell line human CVCL_Q910 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091842 CVCL_PX11 BayGenomics ES cell line XH153 embryonic stem cell house mouse CVCL_PX11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97616; Plcg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091843 CVCL_Q911 HG02763 transformed cell line human CVCL_Q911 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091844 CVCL_PX12 BayGenomics ES cell line XH154 embryonic stem cell house mouse CVCL_PX12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091845 CVCL_Q912 HG02768 transformed cell line human CVCL_Q912 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091846 CVCL_PX13 BayGenomics ES cell line XH155 embryonic stem cell house mouse CVCL_PX13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140779; Sdad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091847 CVCL_Q913 HG02769 transformed cell line human CVCL_Q913 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091848 CVCL_PX14 BayGenomics ES cell line XH156 embryonic stem cell house mouse CVCL_PX14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091849 CVCL_Q914 HG02771 transformed cell line human CVCL_Q914 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091850 CVCL_PX15 BayGenomics ES cell line XH157 embryonic stem cell house mouse CVCL_PX15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151114; Dgcr8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091851 CVCL_Q915 HG02772 transformed cell line human CVCL_Q915 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091852 CVCL_PX16 BayGenomics ES cell line XH177 embryonic stem cell house mouse CVCL_PX16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914469; Med18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091853 CVCL_Q916 HG02774 transformed cell line human CVCL_Q916 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091854 CVCL_PX17 BayGenomics ES cell line XH178 embryonic stem cell house mouse CVCL_PX17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091855 CVCL_Q917 HG02775 transformed cell line human CVCL_Q917 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091856 CVCL_PX18 BayGenomics ES cell line XH180 embryonic stem cell house mouse CVCL_PX18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091857 CVCL_Q918 HG02778 transformed cell line human CVCL_Q918 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091858 CVCL_PX19 BayGenomics ES cell line XH182 embryonic stem cell house mouse CVCL_PX19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091859 CVCL_Q919 HG02780 transformed cell line human CVCL_Q919 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091860 CVCL_PX00 BayGenomics ES cell line XH127 embryonic stem cell house mouse CVCL_PX00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924057; Phf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091861 CVCL_Q900 HG02727 transformed cell line human CVCL_Q900 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091862 CVCL_PX01 BayGenomics ES cell line XH131 embryonic stem cell house mouse CVCL_PX01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313286; Eif2b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091863 CVCL_Q901 HG02728 transformed cell line human CVCL_Q901 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091864 CVCL_PX02 BayGenomics ES cell line XH133 embryonic stem cell house mouse CVCL_PX02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137379; Med15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091865 CVCL_Q902 HG02731 transformed cell line human CVCL_Q902 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091866 CVCL_PX03 BayGenomics ES cell line XH136 embryonic stem cell house mouse CVCL_PX03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926462; Hnrnph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091867 CVCL_Q903 HG02733 transformed cell line human CVCL_Q903 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091868 CVCL_PX04 BayGenomics ES cell line XH137 embryonic stem cell house mouse CVCL_PX04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95541; Fkbp1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091869 CVCL_Q904 HG02734 transformed cell line human CVCL_Q904 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091870 CVCL_PX05 BayGenomics ES cell line XH142 embryonic stem cell house mouse CVCL_PX05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918052; Pwwp2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091871 CVCL_Q905 HG02736 transformed cell line human CVCL_Q905 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091872 CVCL_PX06 BayGenomics ES cell line XH144 embryonic stem cell house mouse CVCL_PX06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96269; Ranbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091873 CVCL_Q906 HG02737 transformed cell line human CVCL_Q906 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091874 CVCL_PX07 BayGenomics ES cell line XH145 embryonic stem cell house mouse CVCL_PX07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091875 CVCL_Q907 HG02757 transformed cell line human CVCL_Q907 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091876 CVCL_PX08 BayGenomics ES cell line XH147 embryonic stem cell house mouse CVCL_PX08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88353; Cdk11b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091877 CVCL_Q908 HG02759 transformed cell line human CVCL_Q908 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091878 CVCL_PX09 BayGenomics ES cell line XH148 embryonic stem cell house mouse CVCL_PX09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88261; Canx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091879 CVCL_Q909 HG02760 transformed cell line human CVCL_Q909 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091880 CVCL_6L20 DA00435 transformed cell line human CVCL_6L20 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091881 CVCL_6L25 DA00440 transformed cell line human CVCL_6L25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091882 CVCL_6L26 DA00441 transformed cell line human CVCL_6L26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091883 CVCL_6L27 DA00442 transformed cell line human CVCL_6L27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091884 CVCL_6L28 DA00443 transformed cell line human CVCL_6L28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091885 CVCL_6L21 DA00436 transformed cell line human CVCL_6L21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091886 CVCL_6L22 DA00437 transformed cell line human CVCL_6L22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091887 CVCL_6L23 DA00438 transformed cell line human CVCL_6L23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091888 CVCL_6L24 DA00439 transformed cell line human CVCL_6L24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091889 CVCL_Z370 BTI-Pu-2 spontaneously immortalized cell line CVCL_Z370 CL:0000010 Unspecified Group: Insect cell line. 21091890 CVCL_Z371 BTI-Pu-A7 spontaneously immortalized cell line CVCL_Z371 CL:0000010 Unspecified Group: Insect cell line. 21091891 CVCL_Z372 BTI-Pu-A7S spontaneously immortalized cell line CVCL_Z372 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12285. 21091892 CVCL_6L18 DA00433 transformed cell line human CVCL_6L18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091893 CVCL_6L19 DA00434 transformed cell line human CVCL_6L19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091894 CVCL_Z377 IPLB-DU182E spontaneously immortalized cell line CVCL_Z377 CL:0000010 Unspecified Group: Insect cell line. 21091895 CVCL_Z378 IPLB-LD-64 spontaneously immortalized cell line CVCL_Z378 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091896 CVCL_Z379 IPLB-LD-65 spontaneously immortalized cell line CVCL_Z379 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091897 CVCL_Z373 BTI-Pu-B9 spontaneously immortalized cell line CVCL_Z373 CL:0000010 Unspecified Group: Insect cell line. 21091898 CVCL_Z374 BTI-Pu-M spontaneously immortalized cell line CVCL_Z374 CL:0000010 Unspecified Group: Insect cell line. 21091899 CVCL_Z375 BTI-Pu-M1B spontaneously immortalized cell line CVCL_Z375 CL:0000010 Unspecified Group: Insect cell line. 21091900 CVCL_Z376 IPLB-DU182A spontaneously immortalized cell line CVCL_Z376 CL:0000010 Unspecified Group: Insect cell line. 21091901 CVCL_6L30 DA00445 transformed cell line human CVCL_6L30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091902 CVCL_6L31 DA00446 transformed cell line human CVCL_6L31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091903 CVCL_Z359 LSTM-AS-46 spontaneously immortalized cell line CVCL_Z359 CL:0000010 Unspecified Group: Insect cell line. 21091904 CVCL_6L36 DA00451 transformed cell line human CVCL_6L36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091905 CVCL_6L37 DA00452 transformed cell line human CVCL_6L37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091906 CVCL_6L38 DA00453 transformed cell line human CVCL_6L38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091907 CVCL_6L39 DA00454 transformed cell line human CVCL_6L39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091908 CVCL_6L32 DA00447 transformed cell line human CVCL_6L32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091909 CVCL_6L33 DA00448 transformed cell line human CVCL_6L33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091910 CVCL_6L34 DA00449 transformed cell line human CVCL_6L34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091911 CVCL_6L35 DA00450 transformed cell line human CVCL_6L35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091912 CVCL_Z360 LSTM-AG-55 spontaneously immortalized cell line CVCL_Z360 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: ~6 hours (in MM/VP12 medium), ~18 hours (in L-15 medium) (DOI=10.17037/PUBS.04656048) Group: Insect cell line 21091913 CVCL_Z361 LSTM-AM-60 spontaneously immortalized cell line CVCL_Z361 CL:0000010 Unspecified Doubling time: ~36 hours (in MM/VP12 medium), ~32 hours (in L-15 medium) (DOI=10.17037/PUBS.04656048). Group: Insect cell line 21091914 CVCL_6L29 DA00444 transformed cell line human CVCL_6L29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091915 CVCL_Z366 SfSWT-1 spontaneously immortalized cell line CVCL_Z366 CL:0000010 Transfected with: HGNC; 7044; MGAT1; Transfected with: HGNC; 7045; MGAT2; Transfected with: MGI; MGI:1316743; St3gal4; Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1 Derived from sampling site: Ovary. Female Characteristics: Has been engineered to stably express a variety of mammalian glycosyltransferases thus allowing for production of biantennary, terminally sialyated N-glycans from insect cells Can be used to produce more mammalian-like proteins in both baculovirus and stable insect expression systems (ThermoFisher). Group: Insect cell line; Group: Recombinant protein production insect cell line 21091916 CVCL_Z367 SfSWT-3 spontaneously immortalized cell line CVCL_Z367 CL:0000010 Transfected with: HGNC; 7044; MGAT1; Transfected with: HGNC; 7045; MGAT2; Transfected with: MGI; MGI:1337124; Cmas; Transfected with: MGI; MGI:2149820; Nans; Transfected with: MGI; MGI:1316743; St3gal4; Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21091917 CVCL_Z368 NIAS-LeSe-11 spontaneously immortalized cell line CVCL_Z368 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: ~48 hours (DOI=10.1303/aez.18.533) Group: Insect cell line 21091918 CVCL_Z369 FRI-MntH-520A spontaneously immortalized cell line CVCL_Z369 CL:0000010 Unspecified Doubling time: 6.93 days (CelloPub=CLPUB00163). Group: Insect cell line 21091919 CVCL_Z362 LSTM-AP-61 spontaneously immortalized cell line CVCL_Z362 CL:0000010 Unspecified Doubling time: ~36 hours (in MM/VP12 medium), ~44 hours (in L-15 medium) (DOI=10.17037/PUBS.04656048). Group: Insect cell line 21091920 CVCL_Z363 LSTM-AA-63 spontaneously immortalized cell line CVCL_Z363 CL:0000010 Unspecified Group: Insect cell line. 21091921 CVCL_Z364 Sfbeta4GalT spontaneously immortalized cell line CVCL_Z364 CL:0000010 Transfected with: VGNC; 26388; Bovine B4GALT1 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21091922 CVCL_Z365 Sfbeta4GalT/ST6 spontaneously immortalized cell line CVCL_Z365 CL:0000010 Transfected with: RGD; 3676; St6gal1; Transfected with: VGNC; 26388; Bovine B4GALT1 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21091923 CVCL_Z348 NIV-CT-894 spontaneously immortalized cell line CVCL_Z348 CL:0000010 Unspecified Group: Insect cell line. 21091924 CVCL_Z349 NIV-PTM-1095 spontaneously immortalized cell line CVCL_Z349 CL:0000010 Unspecified Group: Insect cell line. 21091925 CVCL_6L03 DA00418 transformed cell line human CVCL_6L03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091926 CVCL_6L04 DA00419 transformed cell line human CVCL_6L04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091927 CVCL_6L05 DA00420 transformed cell line human CVCL_6L05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091928 CVCL_6L06 DA00421 transformed cell line human CVCL_6L06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091929 CVCL_6L00 DA00415 transformed cell line human CVCL_6L00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091930 CVCL_6L01 DA00416 transformed cell line human CVCL_6L01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091931 CVCL_6L02 DA00417 transformed cell line human CVCL_6L02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091932 CVCL_Z350 NIV-SU-893 spontaneously immortalized cell line CVCL_Z350 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091933 CVCL_Z355 LSTM-AA-29 spontaneously immortalized cell line CVCL_Z355 CL:0000010 Unspecified Group: Insect cell line. 21091934 CVCL_Z356 LSTM-AS-43 spontaneously immortalized cell line CVCL_Z356 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: ~15 hours (in MM/VP12 medium), ~15 hours (in L-15 medium) (DOI=10.17037/PUBS.04656048) Group: Insect cell line 21091935 CVCL_Z357 LSTM-AS-44 spontaneously immortalized cell line CVCL_Z357 CL:0000010 Unspecified Group: Insect cell line. 21091936 CVCL_Z358 LSTM-AS-45 spontaneously immortalized cell line CVCL_Z358 CL:0000010 Unspecified Group: Insect cell line. 21091937 CVCL_Z351 NIV-SU-992 spontaneously immortalized cell line CVCL_Z351 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21091938 CVCL_Z352 LSTM-TI-32 spontaneously immortalized cell line CVCL_Z352 CL:0000010 Unspecified Doubling time: 48 hours (PubMed=322623). Group: Insect cell line 21091939 CVCL_Z353 LSTM-AA-20 spontaneously immortalized cell line CVCL_Z353 CL:0000010 Unspecified Group: Insect cell line. 21091940 CVCL_Z354 LSTM-AA-20A spontaneously immortalized cell line CVCL_Z354 CL:0000010 Unspecified Doubling time: ~24 hours (in MM/VP12 medium), ~24 hours (in L-15 medium) (DOI=10.17037/PUBS.04656048). Group: Insect cell line 21091941 CVCL_Z337 BRL-AG-1 spontaneously immortalized cell line CVCL_Z337 CL:0000010 Unspecified Doubling time: 20-22 hours (DOI=10.1007/BF02877059). Group: Insect cell line 21091942 CVCL_Z338 BRL-AG-2 spontaneously immortalized cell line CVCL_Z338 CL:0000010 Unspecified Group: Insect cell line. 21091943 CVCL_Z339 BRL-AG-3A spontaneously immortalized cell line CVCL_Z339 CL:0000010 Unspecified Doubling time: 20-22 hours (DOI=10.1007/BF02877059). Group: Insect cell line 21091944 CVCL_6L14 DA00429 transformed cell line human CVCL_6L14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091945 CVCL_6L15 DA00430 transformed cell line human CVCL_6L15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091946 CVCL_6L16 DA00431 transformed cell line human CVCL_6L16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091947 CVCL_6L17 DA00432 transformed cell line human CVCL_6L17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091948 CVCL_6L10 DA00425 transformed cell line human CVCL_6L10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091949 CVCL_6L11 DA00426 transformed cell line human CVCL_6L11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091950 CVCL_6L12 DA00427 transformed cell line human CVCL_6L12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091951 CVCL_6L13 DA00428 transformed cell line human CVCL_6L13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091952 CVCL_6L07 DA00422 transformed cell line human CVCL_6L07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091953 CVCL_6L08 DA00423 transformed cell line human CVCL_6L08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091954 CVCL_6L09 DA00424 transformed cell line human CVCL_6L09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21091955 CVCL_Z344 TI-1 [Thysanoplusia] spontaneously immortalized cell line CVCL_Z344 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 36 hours (DOI=10.1303/aez.2000.245) Group: Insect cell line 21091956 CVCL_Z345 IBL-SLO-7A spontaneously immortalized cell line CVCL_Z345 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 21.4 hours (DOI=10.6660/TESFE.1995030) Group: Insect cell line 21091957 CVCL_Z346 IBL-SLO-1A spontaneously immortalized cell line CVCL_Z346 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 21.9 hours (PubMed=9028921) Group: Insect cell line 21091958 CVCL_Z347 NIV-AK-453 spontaneously immortalized cell line CVCL_Z347 CL:0000010 Unspecified Virology: Susceptible to infection by Chikungunya virus, Sindbis virus, Japanese encephalitis virus (JEV), West Nile virus (WNV), dengue virus types 1 to 4, vesicular stomatitis virus (VSV), Chandipura virus and African horse sickness virus (PubMed=1429352) Doubling time: 19 hours, at 83th passage (PubMed=1429352). Group: Insect cell line 21091959 CVCL_Z340 BRL-AG-3C spontaneously immortalized cell line CVCL_Z340 CL:0000010 Unspecified Doubling time: 20-22 hours (DOI=10.1007/BF02877059). Group: Insect cell line 21091960 CVCL_Z341 BRL-AG-4 spontaneously immortalized cell line CVCL_Z341 CL:0000010 Unspecified Doubling time: 20-22 hours (DOI=10.1007/BF02877059). Group: Insect cell line 21091961 CVCL_Z342 CP-1268 spontaneously immortalized cell line CVCL_Z342 CL:0000010 Unspecified Group: Insect cell line. 21091962 CVCL_Z343 CP-169 spontaneously immortalized cell line CVCL_Z343 CL:0000010 Unspecified Group: Insect cell line. 21091963 CVCL_PX90 BayGenomics ES cell line XH331 embryonic stem cell house mouse CVCL_PX90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091964 CVCL_Q990 HG03006 transformed cell line human CVCL_Q990 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091965 CVCL_PX91 BayGenomics ES cell line XH332 embryonic stem cell house mouse CVCL_PX91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917034; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091966 CVCL_Q991 HG03007 transformed cell line human CVCL_Q991 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091967 CVCL_PX92 BayGenomics ES cell line XH334 embryonic stem cell house mouse CVCL_PX92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920159; Chmp1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091968 CVCL_Q992 HG03009 transformed cell line human CVCL_Q992 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091969 CVCL_Z326 SPC-Gl-13 spontaneously immortalized cell line CVCL_Z326 CL:0000010 Unspecified Group: Insect cell line 21091970 CVCL_PX93 BayGenomics ES cell line XH337 embryonic stem cell house mouse CVCL_PX93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682334; Smg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091971 CVCL_Q993 HG03012 transformed cell line human CVCL_Q993 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091972 CVCL_Z327 SPC-BM-36 spontaneously immortalized cell line CVCL_Z327 CL:0000010 Discontinued: DSMZ; ACC-186; true. Doubling time: 72-80 hours (CelloPub=CLPUB00496); ~50-100 hours (DSMZ=ACC-186) Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00584 Problematic cell line: Misidentified/contaminated Originally thought to be from a Bombyx mori chrysalid but found to be from Spodoptera frugiperda (DSMZ). 21091973 CVCL_PX94 BayGenomics ES cell line XH339 embryonic stem cell house mouse CVCL_PX94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99260; Prkci Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091974 CVCL_Q994 HG03015 transformed cell line human CVCL_Q994 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091975 CVCL_Z328 NTU-Pn-HH spontaneously immortalized cell line CVCL_Z328 CL:0000010 Female Doubling time: 86 hours (in TNM-FH + 10% FBS), 54 hours (in TNM-FH + 20% FBS) (PubMed=8812599). Group: Insect cell line 21091976 CVCL_PX95 BayGenomics ES cell line XH340 embryonic stem cell house mouse CVCL_PX95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091977 CVCL_Q995 HG03016 transformed cell line human CVCL_Q995 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091978 CVCL_Z329 NTU-Pn-HF spontaneously immortalized cell line CVCL_Z329 CL:0000010 Female Virology: Persistently infected by Perina nuda picorna-like virus (PnPV) Doubling time: 52 hours, in TNM-FH + 8% FCS (DOI=10.1303/aez.2002.171). Group: Insect cell line 21091979 CVCL_PX96 BayGenomics ES cell line XH346 embryonic stem cell house mouse CVCL_PX96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892979; Chm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091980 CVCL_Q996 HG03018 transformed cell line human CVCL_Q996 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091981 CVCL_PX97 BayGenomics ES cell line XH348 embryonic stem cell house mouse CVCL_PX97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091982 CVCL_Q997 HG03019 transformed cell line human CVCL_Q997 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091983 CVCL_PX98 BayGenomics ES cell line XH359 embryonic stem cell house mouse CVCL_PX98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091984 CVCL_Q998 HG03021 transformed cell line human CVCL_Q998 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091985 CVCL_PX99 BayGenomics ES cell line XH368 embryonic stem cell house mouse CVCL_PX99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091986 CVCL_Q999 HG03022 transformed cell line human CVCL_Q999 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091987 CVCL_Z333 UM-BGE-2 spontaneously immortalized cell line CVCL_Z333 CL:0000010 Unspecified Virology: Susceptible to infection by Blattella germanica densovirus (BgDNV) (PubMed=16690920). Group: Insect cell line 21091988 CVCL_Z334 UM-BGE-4 spontaneously immortalized cell line CVCL_Z334 CL:0000010 Unspecified Group: Insect cell line. 21091989 CVCL_Z335 UM-BGE-5 alpha spontaneously immortalized cell line CVCL_Z335 CL:0000010 Unspecified Group: Insect cell line. 21091990 CVCL_Z336 UM-BGE-5 beta spontaneously immortalized cell line CVCL_Z336 CL:0000010 Unspecified Group: Insect cell line. 21091991 CVCL_Z330 DSIR-HA-1179 spontaneously immortalized cell line CVCL_Z330 CL:0000010 Unspecified Virology: Susceptible to infection by Oryctes rhinoceros nudivirus (OrNV) Doubling time: 6 days (DOI=10.1007/BF02796321). Group: Insect cell line 21091992 CVCL_Z331 RIRI-BR1 spontaneously immortalized cell line CVCL_Z331 CL:0000010 Unspecified Doubling time: 79.5 hours (PubMed=25278088). Group: Insect cell line 21091993 CVCL_Z332 UM-BGE-1 spontaneously immortalized cell line CVCL_Z332 CL:0000010 Unspecified Doubling time: 4.8 days (PubMed=192663). Group: Insect cell line 21091994 CVCL_Z319 MB-03 spontaneously immortalized cell line CVCL_Z319 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21091995 CVCL_PX80 BayGenomics ES cell line XH307 embryonic stem cell house mouse CVCL_PX80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346036; Pin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091996 CVCL_Q980 HG02970 transformed cell line human CVCL_Q980 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091997 CVCL_PX81 BayGenomics ES cell line XH309 embryonic stem cell house mouse CVCL_PX81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21091998 CVCL_Q981 HG02971 transformed cell line human CVCL_Q981 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21091999 CVCL_Z315 MB-L11 spontaneously immortalized cell line CVCL_Z315 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21092000 CVCL_PX82 BayGenomics ES cell line XH312 embryonic stem cell house mouse CVCL_PX82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858304; Ctps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092001 CVCL_Q982 HG02973 transformed cell line human CVCL_Q982 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092002 CVCL_Z316 MB-L2 spontaneously immortalized cell line CVCL_Z316 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21092003 CVCL_PX83 BayGenomics ES cell line XH314 embryonic stem cell house mouse CVCL_PX83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092004 CVCL_Q983 HG02974 transformed cell line human CVCL_Q983 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092005 CVCL_Z317 MB-020 spontaneously immortalized cell line CVCL_Z317 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21092006 CVCL_PX84 BayGenomics ES cell line XH316 embryonic stem cell house mouse CVCL_PX84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092007 CVCL_Q984 HG02976 transformed cell line human CVCL_Q984 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092008 CVCL_Z318 MB-021 spontaneously immortalized cell line CVCL_Z318 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21092009 CVCL_PX85 BayGenomics ES cell line XH320 embryonic stem cell house mouse CVCL_PX85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914803; Gstcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092010 CVCL_Q985 HG02977 transformed cell line human CVCL_Q985 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092011 CVCL_PX86 BayGenomics ES cell line XH324 embryonic stem cell house mouse CVCL_PX86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922387; Rprd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092012 CVCL_Q986 HG02979 transformed cell line human CVCL_Q986 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092013 CVCL_PX87 BayGenomics ES cell line XH325 embryonic stem cell house mouse CVCL_PX87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1335094; Septin7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092014 CVCL_Q987 HG02981 transformed cell line human CVCL_Q987 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092015 CVCL_PX88 BayGenomics ES cell line XH327 embryonic stem cell house mouse CVCL_PX88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092016 CVCL_Q988 HG02982 transformed cell line human CVCL_Q988 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092017 CVCL_PX89 BayGenomics ES cell line XH329 embryonic stem cell house mouse CVCL_PX89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914694; Ilkap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092018 CVCL_Q989 HG02983 transformed cell line human CVCL_Q989 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092019 CVCL_Z322 LPC-Aa98-19 spontaneously immortalized cell line CVCL_Z322 CL:0000010 Unspecified Group: Insect cell line. 21092020 CVCL_Z323 LPC-Aa98-20 spontaneously immortalized cell line CVCL_Z323 CL:0000010 Unspecified Group: Insect cell line. 21092021 CVCL_Z324 SPC-PL-40 spontaneously immortalized cell line CVCL_Z324 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092022 CVCL_Z325 SPC-PL-65 spontaneously immortalized cell line CVCL_Z325 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21092023 CVCL_Z320 MB-04 spontaneously immortalized cell line CVCL_Z320 CL:0000010 Unspecified Group: Insect cell line Caution: We are not certain that this cell line is derived from MB-H 260 The DSMZ web site points to the original publication of MB-H 260 (DOI=10.1080/03235408909438893) as the reference for the establishment of this cell line.. 21092024 CVCL_Z321 SL-ZSU-1 spontaneously immortalized cell line CVCL_Z321 CL:0000010 Unspecified Doubling time: 100-144 hours (CelloPub=CLPUB00174). Group: Insect cell line 21092025 CVCL_Z308 NIV-HA-1195 spontaneously immortalized cell line CVCL_Z308 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 96 hours (at 8th passage), 60 hours (at 43th passage) (PubMed=12561972) Group: Insect cell line 21092026 CVCL_Z309 NIV-BM-1296 spontaneously immortalized cell line CVCL_Z309 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~60 hours (PubMed=12362558) Group: Insect cell line 21092027 CVCL_PX70 BayGenomics ES cell line XH271 embryonic stem cell house mouse CVCL_PX70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916862; Kansl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092028 CVCL_Z304 DZNU-Bm-16 spontaneously immortalized cell line CVCL_Z304 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092029 CVCL_Q970 HG02941 transformed cell line human CVCL_Q970 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092030 CVCL_PX71 BayGenomics ES cell line XH279 embryonic stem cell house mouse CVCL_PX71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092031 CVCL_Q971 HG02943 transformed cell line human CVCL_Q971 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092032 CVCL_PX72 BayGenomics ES cell line XH282 embryonic stem cell house mouse CVCL_PX72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092033 CVCL_Q972 HG02944 transformed cell line human CVCL_Q972 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092034 CVCL_Z306 NIV-SU-1095 spontaneously immortalized cell line CVCL_Z306 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21092035 CVCL_PX73 BayGenomics ES cell line XH285 embryonic stem cell house mouse CVCL_PX73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092036 CVCL_Q973 HG02946 transformed cell line human CVCL_Q973 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092037 CVCL_Z307 NIV-HA-197 spontaneously immortalized cell line CVCL_Z307 CL:0000010 Unspecified Doubling time: ~60 hours (PubMed=12418922). Group: Insect cell line 21092038 CVCL_PX74 BayGenomics ES cell line XH287 embryonic stem cell house mouse CVCL_PX74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920460; Nup54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092039 CVCL_Q974 HG02947 transformed cell line human CVCL_Q974 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092040 CVCL_PX75 BayGenomics ES cell line XH290 embryonic stem cell house mouse CVCL_PX75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913392; Cox7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092041 CVCL_Q975 HG02952 transformed cell line human CVCL_Q975 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092042 CVCL_PX76 BayGenomics ES cell line XH291 embryonic stem cell house mouse CVCL_PX76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109299; Polr2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092043 CVCL_Q976 HG02953 transformed cell line human CVCL_Q976 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092044 CVCL_PX77 BayGenomics ES cell line XH296 embryonic stem cell house mouse CVCL_PX77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092045 CVCL_Q977 HG02964 transformed cell line human CVCL_Q977 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092046 CVCL_PX78 BayGenomics ES cell line XH297 embryonic stem cell house mouse CVCL_PX78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442306; Fancm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092047 CVCL_Q978 HG02965 transformed cell line human CVCL_Q978 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092048 CVCL_PX79 BayGenomics ES cell line XH303 embryonic stem cell house mouse CVCL_PX79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913941; Gapvd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092049 CVCL_Q979 HG02968 transformed cell line human CVCL_Q979 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092050 CVCL_Z311 UCR-SE-1 spontaneously immortalized cell line CVCL_Z311 CL:0000010 Unspecified Doubling time: 56 hours (DOI=10.1016/0022-2011(86)90124-2). Group: Insect cell line 21092051 CVCL_Z312 UCR-SE-1a spontaneously immortalized cell line CVCL_Z312 CL:0000010 Unspecified Group: Insect cell line. 21092052 CVCL_Z313 UCR-SE-1C spontaneously immortalized cell line CVCL_Z313 CL:0000010 Unspecified Group: Insect cell line. 21092053 CVCL_Z314 MB-H 260 spontaneously immortalized cell line CVCL_Z314 CL:0000010 Unspecified Group: Insect cell line. 21092054 CVCL_Z310 NIV-BM-197 spontaneously immortalized cell line CVCL_Z310 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~60 hours (PubMed=12362558) Group: Insect cell line 21092055 CVCL_PX60 BayGenomics ES cell line XH251 embryonic stem cell house mouse CVCL_PX60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092056 CVCL_Q960 HG02885 transformed cell line human CVCL_Q960 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092057 CVCL_PX61 BayGenomics ES cell line XH252 embryonic stem cell house mouse CVCL_PX61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107760; Chka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092058 CVCL_Q961 HG02887 transformed cell line human CVCL_Q961 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092059 CVCL_PX62 BayGenomics ES cell line XH253 embryonic stem cell house mouse CVCL_PX62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136459; Cdc42bpb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092060 CVCL_Q962 HG02888 transformed cell line human CVCL_Q962 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092061 CVCL_PX63 BayGenomics ES cell line XH256 embryonic stem cell house mouse CVCL_PX63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092062 CVCL_Q963 HG02890 transformed cell line human CVCL_Q963 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092063 CVCL_PX64 BayGenomics ES cell line XH261 embryonic stem cell house mouse CVCL_PX64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916401; Lzic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092064 CVCL_Q964 HG02891 transformed cell line human CVCL_Q964 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092065 CVCL_PX65 BayGenomics ES cell line XH264 embryonic stem cell house mouse CVCL_PX65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102718; Vav2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092066 CVCL_Q965 HG02895 transformed cell line human CVCL_Q965 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092067 CVCL_PX66 BayGenomics ES cell line XH265 embryonic stem cell house mouse CVCL_PX66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924203; Emsy Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092068 CVCL_Q966 HG02896 transformed cell line human CVCL_Q966 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092069 CVCL_PX67 BayGenomics ES cell line XH266 embryonic stem cell house mouse CVCL_PX67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092070 CVCL_Q967 HG02922 transformed cell line human CVCL_Q967 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092071 CVCL_PX68 BayGenomics ES cell line XH267 embryonic stem cell house mouse CVCL_PX68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092072 CVCL_Q968 HG02923 transformed cell line human CVCL_Q968 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092073 CVCL_PX69 BayGenomics ES cell line XH268 embryonic stem cell house mouse CVCL_PX69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092074 CVCL_Q969 HG02938 transformed cell line human CVCL_Q969 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092075 CVCL_Z300 FTRS-HlL1 spontaneously immortalized cell line CVCL_Z300 CL:0000010 Unspecified Doubling time: 32 hours (CelloPub=CLPUB00170) Group: Insect cell line 21092076 CVCL_Z301 FTRS-HlL2 spontaneously immortalized cell line CVCL_Z301 CL:0000010 Unspecified Doubling time: 36 hours (CelloPub=CLPUB00170) Group: Insect cell line 21092077 CVCL_Z302 IOZCAS-Osfu-1 transformed cell line CVCL_Z302 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Group: Insect cell line 21092078 CVCL_Z303 IOZCAS-Ha-1 spontaneously immortalized cell line CVCL_Z303 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 65.2 hours (CelloPub=CLPUB00225; Patent=CN101070533B) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.1690 21092079 CVCL_HA00 K562 eGFP-ZNF175 cancer cell line human CVCL_HA00 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12964; ZNF175; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092080 CVCL_HA01 K562 eGFP-ZNF197 cancer cell line human CVCL_HA01 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12988; ZNF197; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092081 CVCL_HA02 K562 eGFP-ZNF395 cancer cell line human CVCL_HA02 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 18737; ZNF395; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092082 CVCL_HA03 K562 eGFP-ZNF512 cancer cell line human CVCL_HA03 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 29380; ZNF512; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092083 CVCL_6M82 DA00602 transformed cell line human CVCL_6M82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092084 CVCL_6M83 DA00603 transformed cell line human CVCL_6M83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092085 CVCL_6M84 DA00604 transformed cell line human CVCL_6M84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092086 CVCL_6M85 DA00605 transformed cell line human CVCL_6M85 CL:0000010 Population: Caucasian and Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092087 CVCL_6M80 DA00600 transformed cell line human CVCL_6M80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092088 CVCL_6M81 DA00601 transformed cell line human CVCL_6M81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092089 CVCL_6M86 DA00606 transformed cell line human CVCL_6M86 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092090 CVCL_6M87 DA00607 transformed cell line human CVCL_6M87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092091 CVCL_6M88 DA00608 transformed cell line human CVCL_6M88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092092 CVCL_6M89 DA00609 transformed cell line human CVCL_6M89 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092093 CVCL_6M93 DA00613 transformed cell line human CVCL_6M93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092094 CVCL_6M94 DA00614 transformed cell line human CVCL_6M94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092095 CVCL_6M95 DA00615 transformed cell line human CVCL_6M95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092096 CVCL_6M96 DA00616 transformed cell line human CVCL_6M96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092097 CVCL_6M90 DA00610 transformed cell line human CVCL_6M90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092098 CVCL_6M91 DA00611 transformed cell line human CVCL_6M91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092099 CVCL_6M92 DA00612 transformed cell line human CVCL_6M92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092100 CVCL_6M97 DA00617 transformed cell line human CVCL_6M97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092101 CVCL_6M98 DA00618 transformed cell line human CVCL_6M98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092102 CVCL_6M99 DA00619 transformed cell line human CVCL_6M99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092103 CVCL_6M60 DA00578 transformed cell line human CVCL_6M60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092104 CVCL_6M61 DA00579 transformed cell line human CVCL_6M61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092105 CVCL_6M62 DA00580 transformed cell line human CVCL_6M62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092106 CVCL_6M63 DA00581 transformed cell line human CVCL_6M63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092107 CVCL_6M68 DA00586 transformed cell line human CVCL_6M68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092108 CVCL_6M69 DA00588 transformed cell line human CVCL_6M69 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092109 CVCL_6M64 DA00582 transformed cell line human CVCL_6M64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092110 CVCL_6M65 DA00583 transformed cell line human CVCL_6M65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092111 CVCL_6M66 DA00584 transformed cell line human CVCL_6M66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092112 CVCL_6M67 DA00585 transformed cell line human CVCL_6M67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092113 CVCL_6M71 DA00590 transformed cell line human CVCL_6M71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092114 CVCL_6M72 DA00591 transformed cell line human CVCL_6M72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092115 CVCL_6M73 DA00592 transformed cell line human CVCL_6M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092116 CVCL_6M74 DA00593 transformed cell line human CVCL_6M74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092117 CVCL_6M70 DA00589 transformed cell line human CVCL_6M70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092118 CVCL_6M79 DA00599 transformed cell line human CVCL_6M79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092119 CVCL_6M75 DA00595 transformed cell line human CVCL_6M75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092120 CVCL_6M76 DA00596 transformed cell line human CVCL_6M76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092121 CVCL_6M77 DA00597 transformed cell line human CVCL_6M77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092122 CVCL_6M78 DA00598 transformed cell line human CVCL_6M78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092123 CVCL_HA77 7SA transformed cell line house mouse CVCL_HA77 CL:0000010 Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21092124 CVCL_HA78 BW5147RicR.3 cancer cell line house mouse CVCL_HA78 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21092125 CVCL_HA79 CF/T43 transformed cell line human CVCL_HA79 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIPneoSV(X)1/SV40T](NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified 21092126 CVCL_HA73 BER-40 spontaneously immortalized cell line green monkey CVCL_HA73 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A0D9QZH2; GBF1; Simple; p.Ala796Glu (c.2387C>A) (A795E); Zygosity=Heterozygous; Note=Responsible for BFA resistance (PubMed=19023417) Selected for resistance to: ChEBI; CHEBI:48080; Brefeldin A (BFA); Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21092127 CVCL_HA74 BL8 spontaneously immortalized cell line Norway rat CVCL_HA74 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21092128 CVCL_HA75 JB1 [Rat hepatocellular carcinoma] cancer cell line Norway rat CVCL_HA75 CL:0000010 Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344. Male 21092129 CVCL_HA76 AFB-1 cancer cell line Norway rat CVCL_HA76 CL:0000010 Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Breed/subspecies: Fischer 344/JCI. Male 21092130 CVCL_HA70 MARC-Nsp11 spontaneously immortalized cell line CVCL_HA70 CL:0000010 Transfected with: UniProtKB; Q6QDR0; Porcine reproductive and respiratory syndrome virus strain NVSL 97-7895 nsp11 (AA 1088-1310) Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by microarray Unspecified Group: Non-human primate cell line Problematic cell line: Misidentified Grand-parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21092131 CVCL_HA71 HEK293T(DMT1) transformed cell line human CVCL_HA71 CL:0000010 Transfected with: MGI; MGI:1345279; Slc11a2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Useful to screen for potential iron transport inhibitors (Kerafast) 21092132 CVCL_HA72 RPT-I8 transformed cell line CVCL_HA72 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: New Zealand white. Male 21092133 CVCL_PZ10 BayGenomics ES cell line XH775 embryonic stem cell house mouse CVCL_PZ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923957; Clasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092134 CVCL_PZ11 BayGenomics ES cell line XH779 embryonic stem cell house mouse CVCL_PZ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092135 CVCL_PZ12 BayGenomics ES cell line XH782 embryonic stem cell house mouse CVCL_PZ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346006; Ptpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092136 CVCL_PZ13 BayGenomics ES cell line XH786 embryonic stem cell house mouse CVCL_PZ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092137 CVCL_PZ14 BayGenomics ES cell line XH789 embryonic stem cell house mouse CVCL_PZ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914398; Ramac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092138 CVCL_PZ15 BayGenomics ES cell line XH798 embryonic stem cell house mouse CVCL_PZ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88473; Cox4i1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092139 CVCL_PZ16 BayGenomics ES cell line XH801 embryonic stem cell house mouse CVCL_PZ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092140 CVCL_PZ17 BayGenomics ES cell line XH802 embryonic stem cell house mouse CVCL_PZ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092141 CVCL_PZ18 BayGenomics ES cell line XH803 embryonic stem cell house mouse CVCL_PZ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913224; Hs1bp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092142 CVCL_PZ19 BayGenomics ES cell line XH804 embryonic stem cell house mouse CVCL_PZ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092143 CVCL_HA88 RicR7 spontaneously immortalized cell line CVCL_HA88 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092144 CVCL_HA89 GEM-MIA PaCa-2 cancer cell line human CVCL_HA89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 21092145 CVCL_HA84 RicR15 spontaneously immortalized cell line CVCL_HA84 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092146 CVCL_HA85 RicR17 spontaneously immortalized cell line CVCL_HA85 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092147 CVCL_HA86 RicR19 spontaneously immortalized cell line CVCL_HA86 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092148 CVCL_HA87 RicR21 spontaneously immortalized cell line CVCL_HA87 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092149 CVCL_HA80 NL/T4 transformed cell line human CVCL_HA80 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIPneoSV(X)1/SV40T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified 21092150 CVCL_HA81 CHOR 3-4 spontaneously immortalized cell line CVCL_HA81 CL:0000010 Selected for resistance to: UniProtKB; P11140; Abrus precatorius abrin; Derived from sampling site: Ovary. Female 21092151 CVCL_HA82 Caco-2-RCAr clone 2 cancer cell line human CVCL_HA82 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Colon. Male 21092152 CVCL_HA83 RicR14 spontaneously immortalized cell line CVCL_HA83 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Kidney. Male 21092153 CVCL_PZ00 BayGenomics ES cell line XH737 embryonic stem cell house mouse CVCL_PZ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919742; Smg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092154 CVCL_PZ01 BayGenomics ES cell line XH740 embryonic stem cell house mouse CVCL_PZ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092155 CVCL_PZ02 BayGenomics ES cell line XH741 embryonic stem cell house mouse CVCL_PZ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092156 CVCL_PZ03 BayGenomics ES cell line XH743 embryonic stem cell house mouse CVCL_PZ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106613; Dvl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092157 CVCL_PZ04 BayGenomics ES cell line XH746 embryonic stem cell house mouse CVCL_PZ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040693; Zmiz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092158 CVCL_PZ05 BayGenomics ES cell line XH751 embryonic stem cell house mouse CVCL_PZ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344347; Synj2bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092159 CVCL_PZ06 BayGenomics ES cell line XH752 embryonic stem cell house mouse CVCL_PZ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092160 CVCL_PZ07 BayGenomics ES cell line XH754 embryonic stem cell house mouse CVCL_PZ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915171; Ube2f Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092161 CVCL_PZ08 BayGenomics ES cell line XH755 embryonic stem cell house mouse CVCL_PZ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96952; Mdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092162 CVCL_PZ09 BayGenomics ES cell line XH759 embryonic stem cell house mouse CVCL_PZ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107891; Nop2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092163 CVCL_HA55 Hutt45 induced pluripotent stem cell human CVCL_HA55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21092164 CVCL_HA56 Hutt60 induced pluripotent stem cell human CVCL_HA56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21092165 CVCL_HA57 BHK-PPI-C16 spontaneously immortalized cell line CVCL_HA57 CL:0000010 Transfected with: HGNC; 6081; INS Derived from sampling site: Kidney. Male Characteristics: Releases unprocessed proinsulin 21092166 CVCL_HA58 BHK-PPI-C16-GCK spontaneously immortalized cell line CVCL_HA58 CL:0000010 Transfected with: HGNC; 4195; GCK; Transfected with: HGNC; 6081; INS Derived from sampling site: Kidney. Male 21092167 CVCL_HA51 H19101 induced pluripotent stem cell human CVCL_HA51 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21092168 CVCL_HA52 H19114 induced pluripotent stem cell human CVCL_HA52 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21092169 CVCL_HA53 H20961 induced pluripotent stem cell human CVCL_HA53 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21092170 CVCL_HA54 H28834 induced pluripotent stem cell human CVCL_HA54 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21092171 CVCL_HA50 H18489 induced pluripotent stem cell human CVCL_HA50 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21092172 CVCL_HA48 IMR-90/GFPdeltaRaf-1[YY]:ER finite cell line human CVCL_HA48 CL:0000010 Transfected with: HGNC; 9829; RAF1 (catalytic domain with D-340 and D-341); Transfected with: HGNC; 3467; ESR1 (hormone-binding domain); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Characteristics: Transfected with a construct that is composed of EGFP at the N-terminus, the catalytic domain of RAF1 (with 340-DD-341) in the middle and the hormone-binding domain of ESR1 at the C-terminus Protein kinase activity is activated by estrogen or analogs such as 4-hydroxy-tamoxifen. 21092173 CVCL_HA49 JLS-V9R spontaneously immortalized cell line house mouse CVCL_HA49 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Unspecified Virology: In vitro infected by R-MuLV 21092174 CVCL_HA66 HAB-40 transformed cell line human CVCL_HA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL4 dependent 21092175 CVCL_HA67 IOMM-Lee-LucNeo cancer cell line human CVCL_HA67 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Brain. Male 21092176 CVCL_HA68 CH-157MN-LucNeo cancer cell line human CVCL_HA68 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21092177 CVCL_HA69 AC transformed cell line human CVCL_HA69 HLA typing: A*02; B*08,35; C*02,07 (ICLC=HTL14005) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092178 CVCL_HA62 HUH7-ins cancer cell line human CVCL_HA62 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6081; INS Population: Japanese; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male Characteristics: Secretes insulin in a regulated manner in response to glucose, calcium and theophylline 21092179 CVCL_HA63 Melligen cancer cell line human CVCL_HA63 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4195; GCK; Transfected with: HGNC; 6081; INS Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Produces insulin in response to extracellular glucose levels that are equivalent to physiological glucose levels; Characteristics: When transplanted into diabetic immunoincompetent mice, Melligen cells restore normoglycemia Group: Patented cell line 21092180 CVCL_HA64 PGLC-33h transformed cell line human CVCL_HA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092181 CVCL_HA65 HATAK cancer cell line human CVCL_HA65 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: ~48 hours (CelloPub=CLPUB00359) 21092182 CVCL_HA60 HEP G2ins cancer cell line human CVCL_HA60 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6081; INS Population: Caucasian; Derived from sampling site: Liver. Male Group: Patented cell line 21092183 CVCL_HA61 HEP G2ins/g cancer cell line human CVCL_HA61 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6081; INS; Transfected with: HGNC; 11006; SLC2A2 Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Synthesizes, stores and secretes insulin in a regulated manner when exposed to glucose in tissue culture Group: Patented cell line 21092184 CVCL_HA59 BHK-PPI-C16-GCK-GLUT spontaneously immortalized cell line CVCL_HA59 CL:0000010 Transfected with: HGNC; 4195; GCK; Transfected with: HGNC; 6081; INS; Transfected with: HGNC; 11006; SLC2A2 Derived from sampling site: Kidney. Male 21092185 CVCL_HA33 BHK-JC-19 spontaneously immortalized cell line CVCL_HA33 CL:0000010 Derived from sampling site: Kidney. Discontinued: BCRJ; 0053; probable Male 21092186 CVCL_HA34 CF [Rat heart fibroblast] finite cell line Norway rat CVCL_HA34 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Discontinued: BCRJ; 0065; probable 21092187 CVCL_HA35 NCF finite cell line Norway rat CVCL_HA35 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: BCRJ; 0183; probable 21092188 CVCL_HA36 IOR-CEA1 hybridoma house mouse CVCL_HA36 CL:0000010 Discontinued: BCRJ; 0119; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e 21092189 CVCL_HA30 ROT68/C1 cancer cell line Norway rat CVCL_HA30 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Ovary; Breed/subspecies: Sprague Dawley. Female 21092190 CVCL_HA31 ROT68/C1 Cis-Ptr cancer cell line Norway rat CVCL_HA31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Ovary; Breed/subspecies: Sprague Dawley. Female 21092191 CVCL_HA32 rBHK spontaneously immortalized cell line CVCL_HA32 CL:0000010 Derived from sampling site: Kidney. Omics: Transcriptome analysis by RNAseq Male 21092192 CVCL_HA26 J774.G8 cancer cell line house mouse CVCL_HA26 CL:0000010 Breed/subspecies: BALB/c. Female 21092193 CVCL_HA27 OFCOL II finite cell line house mouse CVCL_HA27 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: BALB/c. 21092194 CVCL_HA28 NuTu-19 cancer cell line Norway rat CVCL_HA28 CL:0000010 Breed/subspecies: Fischer 344. Female 21092195 CVCL_HA29 ROT58/C3 cancer cell line Norway rat CVCL_HA29 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Ovary; Breed/subspecies: Sprague Dawley. Female 21092196 CVCL_HA44 WT-126 C8 induced pluripotent stem cell human CVCL_HA44 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21092197 CVCL_HA45 WT-33 C1 induced pluripotent stem cell human CVCL_HA45 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21092198 CVCL_HA46 WT-9 induced pluripotent stem cell human CVCL_HA46 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21092199 CVCL_HA47 LTEP-a3 cancer cell line human CVCL_HA47 CL:0000010 Population: Chinese. Male 21092200 CVCL_HA40 JMA finite cell line human CVCL_HA40 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Female 21092201 CVCL_HA41 hPOB-tert transformed cell line human CVCL_HA41 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; femur; periosteum Cell type=Osteoblast.. 21092202 CVCL_HA42 NCI-H134 cancer cell line human CVCL_HA42 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21092203 CVCL_HA43 WT-ADRC-40 induced pluripotent stem cell human CVCL_HA43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21092204 CVCL_HA37 Saka-tert transformed cell line human CVCL_HA37 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Unspecified 21092205 CVCL_HA38 HHY-B spontaneously immortalized cell line human CVCL_HA38 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 4981CB 21092206 CVCL_HA39 19KW finite cell line human CVCL_HA39 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21092207 CVCL_HA11 MCF-7 eGFP-CEBPG cancer cell line human CVCL_HA11 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1837; CEBPG; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21092208 CVCL_HA12 MCF-7 eGFP-E2F4 cancer cell line human CVCL_HA12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3118; E2F4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092209 CVCL_HA13 MCF-7 eGFP-ELF1 cancer cell line human CVCL_HA13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3316; ELF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092210 CVCL_HA14 MCF-7 eGFP-GABPA cancer cell line human CVCL_HA14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4071; GABPA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092211 CVCL_HA10 K562 eGFP-ZNF83 cancer cell line human CVCL_HA10 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13158; ZNF83; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092212 CVCL_HA08 K562 eGFP-ZNF740 cancer cell line human CVCL_HA08 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 27465; ZNF740; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092213 CVCL_HA09 K562 eGFP-ZNF766 cancer cell line human CVCL_HA09 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 28063; ZNF766; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092214 CVCL_HA04 K562 eGFP-ZNF584 cancer cell line human CVCL_HA04 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 27318; ZNF584; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092215 CVCL_HA05 K562 eGFP-ZNF589 cancer cell line human CVCL_HA05 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 16747; ZNF589; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092216 CVCL_HA06 K562 eGFP-ZNF639 cancer cell line human CVCL_HA06 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 30950; ZNF639; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092217 CVCL_HA07 K562 eGFP-ZNF644 cancer cell line human CVCL_HA07 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 29222; ZNF644; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21092218 CVCL_HA22 XGC-2 cancer cell line human CVCL_HA22 CL:0000010 Population: Chinese; Derived from sampling site: Stomach; cardia. Male Doubling time: ~60 hours (PubMed=27633271) 21092219 CVCL_HA23 F C3H finite cell line house mouse CVCL_HA23 CL:0000010 Derived from sampling site: Liver Cell type=Fibroblast.; Breed/subspecies: C3H/HeJ. Unspecified 21092220 CVCL_HA24 J774.16 cancer cell line house mouse CVCL_HA24 CL:0000010 Breed/subspecies: BALB/c. Female Characteristics: Has a marked increase in the ability to reduce nitroblue tetrazolium (NBT) after stimulation with PMA (PubMed=6252274) 21092221 CVCL_HA25 GR [Mouse liver] finite cell line house mouse CVCL_HA25 CL:0000010 Derived from sampling site: Liver (Note=From a granulomatous inflammation) Cell type=Fibroblast.; Breed/subspecies: C3H/HeN. Unspecified Characteristics: Established from fibrotic granulomas induced in C3H/HeN mice liver by experimental infection with Schistosoma mansoni (PubMed=2126187) 21092222 CVCL_HA20 MCF-7/E2F1 cancer cell line human CVCL_HA20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3113; E2F1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with E2F1 fused at the N-terminus to an HA tag and the estrogen receptor ligand binding domain 21092223 CVCL_HA21 46-6B5 hybridoma Norway rat CVCL_HA21 CL:0000010 Monoclonal antibody isotype: IgM. 21092224 CVCL_HA19 MCF-7 eGFP-ZNF148 cancer cell line human CVCL_HA19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12933; ZNF148; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092225 CVCL_HA15 MCF-7 eGFP-GTF2E2 cancer cell line human CVCL_HA15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4651; GTF2E2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092226 CVCL_HA16 MCF-7 eGFP-HBP1 cancer cell line human CVCL_HA16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 23200; HBP1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092227 CVCL_HA17 MCF-7 eGFP-KLF4 cancer cell line human CVCL_HA17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6348; KLF4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092228 CVCL_HA18 MCF-7 eGFP-KLF9 cancer cell line human CVCL_HA18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1123; KLF9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092229 CVCL_Z407 IPLB-LdEIt spontaneously immortalized cell line CVCL_Z407 CL:0000010 Unspecified Group: Insect cell line. 21092230 CVCL_Z408 BTI-Tn-4B1 spontaneously immortalized cell line CVCL_Z408 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21092231 CVCL_Z409 BTI-Tn-5B1 spontaneously immortalized cell line CVCL_Z409 CL:0000010 Unspecified Group: Insect cell line. 21092232 CVCL_Z403 BCIRL-DP-AM/JG spontaneously immortalized cell line CVCL_Z403 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 32 hours (DOI=10.1303/aez.2009.331) Group: Insect cell line 21092233 CVCL_PY70 BayGenomics ES cell line XH658 embryonic stem cell house mouse CVCL_PY70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092234 CVCL_Z404 DpN1 spontaneously immortalized cell line CVCL_Z404 CL:0000010 Female Group: Insect cell line; Group: Recombinant protein production insect cell line. 21092235 CVCL_PY71 BayGenomics ES cell line XH662 embryonic stem cell house mouse CVCL_PY71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3033336; Szt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092236 CVCL_Z405 IPLB-LdEG spontaneously immortalized cell line CVCL_Z405 CL:0000010 Unspecified Group: Insect cell line. 21092237 CVCL_PY72 BayGenomics ES cell line XH664 embryonic stem cell house mouse CVCL_PY72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138982; Znfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092238 CVCL_Z406 IPLB-LdEI spontaneously immortalized cell line CVCL_Z406 CL:0000010 Unspecified Group: Insect cell line. 21092239 CVCL_PY73 BayGenomics ES cell line XH666 embryonic stem cell house mouse CVCL_PY73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092240 CVCL_PY74 BayGenomics ES cell line XH670 embryonic stem cell house mouse CVCL_PY74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100520; Twf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092241 CVCL_PY75 BayGenomics ES cell line XH675 embryonic stem cell house mouse CVCL_PY75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092242 CVCL_PY76 BayGenomics ES cell line XH676 embryonic stem cell house mouse CVCL_PY76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092243 CVCL_PY77 BayGenomics ES cell line XH677 embryonic stem cell house mouse CVCL_PY77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092244 CVCL_PY78 BayGenomics ES cell line XH679 embryonic stem cell house mouse CVCL_PY78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106381; Nopchap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092245 CVCL_PY79 BayGenomics ES cell line XH683 embryonic stem cell house mouse CVCL_PY79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092246 CVCL_Z410 BTI-Tn-5B1-28 spontaneously immortalized cell line CVCL_Z410 CL:0000010 Unspecified Group: Insect cell line. 21092247 CVCL_Z411 BTI-Tn-5C1 spontaneously immortalized cell line CVCL_Z411 CL:0000010 Unspecified Group: Insect cell line. 21092248 CVCL_Z412 BTI-Tn-5F2 spontaneously immortalized cell line CVCL_Z412 CL:0000010 Unspecified Group: Insect cell line. 21092249 CVCL_Z413 BTI-Tn-5F2P spontaneously immortalized cell line CVCL_Z413 CL:0000010 Unspecified Group: Insect cell line. 21092250 CVCL_PY60 BayGenomics ES cell line XH626 embryonic stem cell house mouse CVCL_PY60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643401; Gm8935 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092251 CVCL_PY61 BayGenomics ES cell line XH627 embryonic stem cell house mouse CVCL_PY61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346006; Ptpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092252 CVCL_PY62 BayGenomics ES cell line XH629 embryonic stem cell house mouse CVCL_PY62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913758; Lamtor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092253 CVCL_PY63 BayGenomics ES cell line XH636 embryonic stem cell house mouse CVCL_PY63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921802; Nipal3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092254 CVCL_PY64 BayGenomics ES cell line XH641 embryonic stem cell house mouse CVCL_PY64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092255 CVCL_PY65 BayGenomics ES cell line XH649 embryonic stem cell house mouse CVCL_PY65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092256 CVCL_PY66 BayGenomics ES cell line XH651 embryonic stem cell house mouse CVCL_PY66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97615; Plcg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092257 CVCL_PY67 BayGenomics ES cell line XH654 embryonic stem cell house mouse CVCL_PY67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98294; Shb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092258 CVCL_PY68 BayGenomics ES cell line XH655 embryonic stem cell house mouse CVCL_PY68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040674; Zfp708 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092259 CVCL_PY69 BayGenomics ES cell line XH657 embryonic stem cell house mouse CVCL_PY69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183453; Dlgap5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092260 CVCL_Z400 BCIRL-HZ-AM2 spontaneously immortalized cell line CVCL_Z400 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092261 CVCL_Z401 BCIRL-HZ-AM3 spontaneously immortalized cell line CVCL_Z401 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092262 CVCL_Z402 BCIRL-HA-AM1 spontaneously immortalized cell line CVCL_Z402 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092263 CVCL_PY50 BayGenomics ES cell line XH607 embryonic stem cell house mouse CVCL_PY50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092264 CVCL_PY51 BayGenomics ES cell line XH608 embryonic stem cell house mouse CVCL_PY51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092265 CVCL_PY52 BayGenomics ES cell line XH609 embryonic stem cell house mouse CVCL_PY52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092266 CVCL_PY53 BayGenomics ES cell line XH610 embryonic stem cell house mouse CVCL_PY53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141920; Wtip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092267 CVCL_PY54 BayGenomics ES cell line XH615 embryonic stem cell house mouse CVCL_PY54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316740; Morc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092268 CVCL_PY55 BayGenomics ES cell line XH616 embryonic stem cell house mouse CVCL_PY55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092269 CVCL_PY56 BayGenomics ES cell line XH617 embryonic stem cell house mouse CVCL_PY56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141920; Wtip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092270 CVCL_PY57 BayGenomics ES cell line XH618 embryonic stem cell house mouse CVCL_PY57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95817; Grik4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092271 CVCL_PY58 BayGenomics ES cell line XH621 embryonic stem cell house mouse CVCL_PY58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916199; Zfas1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092272 CVCL_PY59 BayGenomics ES cell line XH623 embryonic stem cell house mouse CVCL_PY59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97583; Pik3r1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092273 CVCL_PY40 BayGenomics ES cell line XH542 embryonic stem cell house mouse CVCL_PY40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092274 CVCL_PY41 BayGenomics ES cell line XH543 embryonic stem cell house mouse CVCL_PY41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913666; Ndufa7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092275 CVCL_PY42 BayGenomics ES cell line XH580 embryonic stem cell house mouse CVCL_PY42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144243; Clint1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092276 CVCL_PY43 BayGenomics ES cell line XH583 embryonic stem cell house mouse CVCL_PY43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092277 CVCL_PY44 BayGenomics ES cell line XH584 embryonic stem cell house mouse CVCL_PY44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316687; Nap1l4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092278 CVCL_PY45 BayGenomics ES cell line XH585 embryonic stem cell house mouse CVCL_PY45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092279 CVCL_PY46 BayGenomics ES cell line XH587 embryonic stem cell house mouse CVCL_PY46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138811; Cdc123 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092280 CVCL_PY47 BayGenomics ES cell line XH594 embryonic stem cell house mouse CVCL_PY47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916507; Elf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092281 CVCL_PY48 BayGenomics ES cell line XH604 embryonic stem cell house mouse CVCL_PY48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092282 CVCL_PY49 BayGenomics ES cell line XH606 embryonic stem cell house mouse CVCL_PY49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443807; Osbpl8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092283 CVCL_PY30 BayGenomics ES cell line XH521 embryonic stem cell house mouse CVCL_PY30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96433; Igf1r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092284 CVCL_PY31 BayGenomics ES cell line XH522 embryonic stem cell house mouse CVCL_PY31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925503; Map4k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092285 CVCL_PY32 BayGenomics ES cell line XH524 embryonic stem cell house mouse CVCL_PY32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141969; Efl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092286 CVCL_PY33 BayGenomics ES cell line XH527 embryonic stem cell house mouse CVCL_PY33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926879; Taf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092287 CVCL_PY34 BayGenomics ES cell line XH528 embryonic stem cell house mouse CVCL_PY34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924093; Dtl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092288 CVCL_PY35 BayGenomics ES cell line XH531 embryonic stem cell house mouse CVCL_PY35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346006; Ptpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092289 CVCL_PY36 BayGenomics ES cell line XH534 embryonic stem cell house mouse CVCL_PY36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092290 CVCL_PY37 BayGenomics ES cell line XH537 embryonic stem cell house mouse CVCL_PY37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443967; Dpp9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092291 CVCL_PY38 BayGenomics ES cell line XH538 embryonic stem cell house mouse CVCL_PY38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092292 CVCL_PY39 BayGenomics ES cell line XH540 embryonic stem cell house mouse CVCL_PY39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092293 CVCL_PY20 BayGenomics ES cell line XH474 embryonic stem cell house mouse CVCL_PY20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103250; Calm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092294 CVCL_PY21 BayGenomics ES cell line XH482 embryonic stem cell house mouse CVCL_PY21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092295 CVCL_PY22 BayGenomics ES cell line XH485 embryonic stem cell house mouse CVCL_PY22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3648690; Zfp975 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092296 CVCL_PY23 BayGenomics ES cell line XH505 embryonic stem cell house mouse CVCL_PY23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108411; Prkag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092297 CVCL_PY24 BayGenomics ES cell line XH507 embryonic stem cell house mouse CVCL_PY24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352762; Scmh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092298 CVCL_PY25 BayGenomics ES cell line XH508 embryonic stem cell house mouse CVCL_PY25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092299 CVCL_PY26 BayGenomics ES cell line XH511 embryonic stem cell house mouse CVCL_PY26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97312; Nfkb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092300 CVCL_PY27 BayGenomics ES cell line XH512 embryonic stem cell house mouse CVCL_PY27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092301 CVCL_PY28 BayGenomics ES cell line XH513 embryonic stem cell house mouse CVCL_PY28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928373; Dnajc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092302 CVCL_PY29 BayGenomics ES cell line XH517 embryonic stem cell house mouse CVCL_PY29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919861; Zfp655 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092303 CVCL_PY10 BayGenomics ES cell line XH445 embryonic stem cell house mouse CVCL_PY10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092304 CVCL_PY11 BayGenomics ES cell line XH457 embryonic stem cell house mouse CVCL_PY11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932395; Rrbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092305 CVCL_PY12 BayGenomics ES cell line XH462 embryonic stem cell house mouse CVCL_PY12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914163; Kdelr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092306 CVCL_PY13 BayGenomics ES cell line XH464 embryonic stem cell house mouse CVCL_PY13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092307 CVCL_PY14 BayGenomics ES cell line XH465 embryonic stem cell house mouse CVCL_PY14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925055; Esco1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092308 CVCL_PY15 BayGenomics ES cell line XH466 embryonic stem cell house mouse CVCL_PY15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092309 CVCL_PY16 BayGenomics ES cell line XH470 embryonic stem cell house mouse CVCL_PY16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95909; Slc39a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092310 CVCL_PY17 BayGenomics ES cell line XH471 embryonic stem cell house mouse CVCL_PY17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092311 CVCL_PY18 BayGenomics ES cell line XH472 embryonic stem cell house mouse CVCL_PY18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914707; Frmd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092312 CVCL_PY19 BayGenomics ES cell line XH473 embryonic stem cell house mouse CVCL_PY19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092313 CVCL_PY00 BayGenomics ES cell line XH374 embryonic stem cell house mouse CVCL_PY00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092314 CVCL_PY01 BayGenomics ES cell line XH392 embryonic stem cell house mouse CVCL_PY01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092315 CVCL_PY02 BayGenomics ES cell line XH400 embryonic stem cell house mouse CVCL_PY02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092316 CVCL_PY03 BayGenomics ES cell line XH403 embryonic stem cell house mouse CVCL_PY03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092317 CVCL_PY04 BayGenomics ES cell line XH413 embryonic stem cell house mouse CVCL_PY04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914454; Eif2s2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092318 CVCL_PY05 BayGenomics ES cell line XH421 embryonic stem cell house mouse CVCL_PY05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092319 CVCL_PY06 BayGenomics ES cell line XH429 embryonic stem cell house mouse CVCL_PY06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930708; Zfp386 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092320 CVCL_PY07 BayGenomics ES cell line XH430 embryonic stem cell house mouse CVCL_PY07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917829; Zc3h11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092321 CVCL_PY08 BayGenomics ES cell line XH431 embryonic stem cell house mouse CVCL_PY08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923998; Pbrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092322 CVCL_PY09 BayGenomics ES cell line XH442 embryonic stem cell house mouse CVCL_PY09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100494; Ercc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092323 CVCL_6M40 DA00558 transformed cell line human CVCL_6M40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092324 CVCL_6M41 DA00559 transformed cell line human CVCL_6M41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092325 CVCL_6M46 DA00564 transformed cell line human CVCL_6M46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092326 CVCL_6M47 DA00565 transformed cell line human CVCL_6M47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092327 CVCL_6M48 DA00566 transformed cell line human CVCL_6M48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092328 CVCL_6M49 DA00567 transformed cell line human CVCL_6M49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092329 CVCL_6M42 DA00560 transformed cell line human CVCL_6M42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092330 CVCL_6M43 DA00561 transformed cell line human CVCL_6M43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092331 CVCL_6M44 DA00562 transformed cell line human CVCL_6M44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092332 CVCL_6M45 DA00563 transformed cell line human CVCL_6M45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092333 CVCL_Z490 IPRI-OL-7 spontaneously immortalized cell line CVCL_Z490 CL:0000010 Unspecified Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00511. Problematic cell line: Contaminated Shown to probably be a IPRI-CF-124 derivative. Originate from Choristoneura fumiferana and not from Orgyia leucostigma (CelloPub=CLPUB00491; DOI=10.1139/z85-337). 21092334 CVCL_Z491 FPMI-NL-10 spontaneously immortalized cell line CVCL_Z491 CL:0000010 Unspecified Group: Insect cell line. 21092335 CVCL_Z492 FPMI-NL-18 spontaneously immortalized cell line CVCL_Z492 CL:0000010 Unspecified Group: Insect cell line. 21092336 CVCL_Z493 FPMI-NL-2 spontaneously immortalized cell line CVCL_Z493 CL:0000010 Unspecified Group: Insect cell line. 21092337 CVCL_6M39 DA00557 transformed cell line human CVCL_6M39 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092338 CVCL_Z498 FPMI-NL-4 spontaneously immortalized cell line CVCL_Z498 CL:0000010 Unspecified Group: Insect cell line. 21092339 CVCL_Z499 AS-H 1 spontaneously immortalized cell line CVCL_Z499 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 2.2 days (DOI=10.1080/03235409009438961) Group: Insect cell line 21092340 CVCL_Z494 FPMI-NL-21 spontaneously immortalized cell line CVCL_Z494 CL:0000010 Unspecified Group: Insect cell line. 21092341 CVCL_Z495 FPMI-NL-22 spontaneously immortalized cell line CVCL_Z495 CL:0000010 Unspecified Group: Insect cell line. 21092342 CVCL_Z496 FPMI-NL-28 spontaneously immortalized cell line CVCL_Z496 CL:0000010 Unspecified Group: Insect cell line. 21092343 CVCL_Z497 FPMI-NL-32 spontaneously immortalized cell line CVCL_Z497 CL:0000010 Unspecified Group: Insect cell line. 21092344 CVCL_6M50 DA00568 transformed cell line human CVCL_6M50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092345 CVCL_6M51 DA00569 transformed cell line human CVCL_6M51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092346 CVCL_6M52 DA00570 transformed cell line human CVCL_6M52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092347 CVCL_6M57 DA00575 transformed cell line human CVCL_6M57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092348 CVCL_6M58 DA00576 transformed cell line human CVCL_6M58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092349 CVCL_6M59 DA00577 transformed cell line human CVCL_6M59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092350 CVCL_6M53 DA00571 transformed cell line human CVCL_6M53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092351 CVCL_6M54 DA00572 transformed cell line human CVCL_6M54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092352 CVCL_6M55 DA00573 transformed cell line human CVCL_6M55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092353 CVCL_6M56 DA00574 transformed cell line human CVCL_6M56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092354 CVCL_Z480 IPRI-CF-124 spontaneously immortalized cell line CVCL_Z480 CL:0000010 Unspecified Doubling time: 31 hours (PubMed=903169). Group: Insect cell line 21092355 CVCL_Z481 IPRI-CF-124T spontaneously immortalized cell line CVCL_Z481 CL:0000010 Unspecified Characteristics: Has increased attachment adherence compared to the parent cell line Doubling time: 25 hours (PubMed=903169). Group: Insect cell line 21092356 CVCL_Z482 IPRI-MD-108 spontaneously immortalized cell line CVCL_Z482 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21092357 CVCL_Z487 IPRI-OL-4 spontaneously immortalized cell line CVCL_Z487 CL:0000010 Unspecified Group: Insect cell line. 21092358 CVCL_Z488 IPRI-OL-9 spontaneously immortalized cell line CVCL_Z488 CL:0000010 Unspecified Group: Insect cell line. 21092359 CVCL_Z489 IPRI-OL-11 spontaneously immortalized cell line CVCL_Z489 CL:0000010 Unspecified Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00512. Problematic cell line: Contaminated Shown to probably be a IPRI-CF-124 derivative. Originate from Choristoneura fumiferana and not from Orgyia leucostigma (CelloPub=CLPUB00491; DOI=10.1139/z85-337). 21092360 CVCL_Z483 IPRI-MD-109 spontaneously immortalized cell line CVCL_Z483 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092361 CVCL_Z484 IPRI-MD-63 spontaneously immortalized cell line CVCL_Z484 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092362 CVCL_Z485 IPRI-OL-12 spontaneously immortalized cell line CVCL_Z485 CL:0000010 Unspecified Group: Insect cell line. 21092363 CVCL_Z486 IPRI-OL-13 spontaneously immortalized cell line CVCL_Z486 CL:0000010 Unspecified Group: Insect cell line. 21092364 CVCL_Z469 FPMI-CF-203 spontaneously immortalized cell line CVCL_Z469 CL:0000010 Derived from sampling site: Midgut. Unspecified Doubling time: 47.3 hours (PubMed=33276037) Group: Insect cell line 21092365 CVCL_6M24 DA00540 transformed cell line human CVCL_6M24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092366 CVCL_6M25 DA00541 transformed cell line human CVCL_6M25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092367 CVCL_6M26 DA00542 transformed cell line human CVCL_6M26 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092368 CVCL_6M27 DA00543 transformed cell line human CVCL_6M27 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092369 CVCL_6M20 DA00536 transformed cell line human CVCL_6M20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092370 CVCL_6M21 DA00537 transformed cell line human CVCL_6M21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092371 CVCL_6M22 DA00538 transformed cell line human CVCL_6M22 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092372 CVCL_6M23 DA00539 transformed cell line human CVCL_6M23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092373 CVCL_Z470 FPMI-CF-50 spontaneously immortalized cell line CVCL_Z470 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092374 CVCL_Z471 FPMI-CF-60 spontaneously immortalized cell line CVCL_Z471 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092375 CVCL_6M17 DA00533 transformed cell line human CVCL_6M17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092376 CVCL_6M18 DA00534 transformed cell line human CVCL_6M18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092377 CVCL_6M19 DA00535 transformed cell line human CVCL_6M19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092378 CVCL_Z476 IPRI-CF-16 spontaneously immortalized cell line CVCL_Z476 CL:0000010 Unspecified Group: Insect cell line. 21092379 CVCL_Z477 IPRI-CF-5 spontaneously immortalized cell line CVCL_Z477 CL:0000010 Male Group: Insect cell line. 21092380 CVCL_Z478 IPRI-CF-6 spontaneously immortalized cell line CVCL_Z478 CL:0000010 Male Group: Insect cell line. 21092381 CVCL_Z479 IPRI-CF-8 spontaneously immortalized cell line CVCL_Z479 CL:0000010 Unspecified Group: Insect cell line. 21092382 CVCL_Z472 FPMI-CF-70 spontaneously immortalized cell line CVCL_Z472 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21092383 CVCL_Z473 IPRI-CF-1 spontaneously immortalized cell line CVCL_Z473 CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 21092384 CVCL_Z474 IPRI-CF-10 spontaneously immortalized cell line CVCL_Z474 CL:0000010 Unspecified Group: Insect cell line. 21092385 CVCL_Z475 IPRI-CF-12 spontaneously immortalized cell line CVCL_Z475 CL:0000010 Unspecified Group: Insect cell line. 21092386 CVCL_6M30 DA00546 transformed cell line human CVCL_6M30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092387 CVCL_Z458 Sf9-P35AcV5-3 spontaneously immortalized cell line CVCL_Z458 CL:0000010 Transfected with: UniProtKB; P08160; AcMNPV p35 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3100 21092388 CVCL_Z459 Sf9S spontaneously immortalized cell line CVCL_Z459 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4047 21092389 CVCL_6M35 DA00551 transformed cell line human CVCL_6M35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092390 CVCL_6M36 DA00552 transformed cell line human CVCL_6M36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092391 CVCL_6M37 DA00553 transformed cell line human CVCL_6M37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092392 CVCL_6M38 DA00554 transformed cell line human CVCL_6M38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092393 CVCL_6M31 DA00547 transformed cell line human CVCL_6M31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092394 CVCL_6M32 DA00548 transformed cell line human CVCL_6M32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092395 CVCL_6M33 DA00549 transformed cell line human CVCL_6M33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092396 CVCL_6M34 DA00550 transformed cell line human CVCL_6M34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092397 CVCL_Z460 ORS-Pop-93 spontaneously immortalized cell line CVCL_Z460 CL:0000010 Unspecified Doubling time: 40 hours, at 50th passage (PubMed=8826086). Group: Insect cell line 21092398 CVCL_6M28 DA00544 transformed cell line human CVCL_6M28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092399 CVCL_6M29 DA00545 transformed cell line human CVCL_6M29 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092400 CVCL_Z465 ORS-Pop-93 Pop cl 2B spontaneously immortalized cell line CVCL_Z465 CL:0000010 Unspecified Group: Insect cell line. 21092401 CVCL_Z466 ORS-Pop-94A spontaneously immortalized cell line CVCL_Z466 CL:0000010 Unspecified Group: Insect cell line. 21092402 CVCL_Z467 ORS-Pop-94B spontaneously immortalized cell line CVCL_Z467 CL:0000010 Unspecified Group: Insect cell line. 21092403 CVCL_Z468 ORS-Pop-95 spontaneously immortalized cell line CVCL_Z468 CL:0000010 Unspecified Group: Insect cell line. 21092404 CVCL_Z461 ORS-Pop-93 Pop 2 spontaneously immortalized cell line CVCL_Z461 CL:0000010 Unspecified Group: Insect cell line. 21092405 CVCL_Z462 ORS-Pop-93 Pop 3 spontaneously immortalized cell line CVCL_Z462 CL:0000010 Unspecified Group: Insect cell line. 21092406 CVCL_Z463 ORS-Pop-93 Pop 4 spontaneously immortalized cell line CVCL_Z463 CL:0000010 Unspecified Group: Insect cell line. 21092407 CVCL_Z464 ORS-Pop-93 Pop cl 1A spontaneously immortalized cell line CVCL_Z464 CL:0000010 Unspecified Group: Insect cell line. 21092408 CVCL_Z447 Cpp-512 spontaneously immortalized cell line CVCL_Z447 CL:0000010 Unspecified Doubling time: 21 hours (CelloPub=CLPUB00192). Group: Insect cell line 21092409 CVCL_Z448 FPMI-MS-4 spontaneously immortalized cell line CVCL_Z448 CL:0000010 Unspecified Group: Insect cell line. 21092410 CVCL_Z449 FPMI-MS-5 spontaneously immortalized cell line CVCL_Z449 CL:0000010 Unspecified Group: Insect cell line. 21092411 CVCL_6M02 DA00518 transformed cell line human CVCL_6M02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092412 CVCL_6M03 DA00519 transformed cell line human CVCL_6M03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092413 CVCL_6M04 DA00520 transformed cell line human CVCL_6M04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092414 CVCL_6M05 DA00521 transformed cell line human CVCL_6M05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092415 CVCL_6M00 DA00516 transformed cell line human CVCL_6M00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092416 CVCL_6M01 DA00517 transformed cell line human CVCL_6M01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092417 CVCL_Z454 VE-CL-01 spontaneously immortalized cell line CVCL_Z454 CL:0000010 Transfected with: UniProtKB; Q56IA8; Campoletis sonorensis ichnovirus P-vankyrin-1 Derived from sampling site: Ovary. Female Doubling time: 37.6 hours (Oxford_Expression_Technology) Group: Insect cell line; Group: Recombinant protein production insect cell line 21092418 CVCL_Z455 VE-CL-02 spontaneously immortalized cell line CVCL_Z455 CL:0000010 Transfected with: UniProtKB; Q56IA8; Campoletis sonorensis ichnovirus P-vankyrin-1 Derived from sampling site: Ovary. Female Doubling time: 29.7 hours (Oxford_Expression_Technology) Group: Insect cell line; Group: Recombinant protein production insect cell line 21092419 CVCL_Z456 VE-CL-03 spontaneously immortalized cell line CVCL_Z456 CL:0000010 Transfected with: UniProtKB; Q56IA8; Campoletis sonorensis ichnovirus P-vankyrin-1 Derived from sampling site: Ovary. Female Doubling time: 43.6 hours (Oxford_Expression_Technology) Group: Insect cell line; Group: Recombinant protein production insect cell line 21092420 CVCL_Z457 Sf9-P35AcV5-1 spontaneously immortalized cell line CVCL_Z457 CL:0000010 Transfected with: UniProtKB; P08160; AcMNPV p35 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3099 21092421 CVCL_Z450 FPMI-MS-7 spontaneously immortalized cell line CVCL_Z450 CL:0000010 Unspecified Group: Insect cell line. 21092422 CVCL_Z451 IBL-Sf-21AE-Cl 3 spontaneously immortalized cell line CVCL_Z451 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2207 21092423 CVCL_Z452 IBL-Sf-21AE-Cl 5 spontaneously immortalized cell line CVCL_Z452 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2206 21092424 CVCL_Z453 IBL-Sf-21AE-Cl 9 spontaneously immortalized cell line CVCL_Z453 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2205 21092425 CVCL_Z436 FM516SV transformed cell line human CVCL_Z436 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21092426 CVCL_Z437 IPRI-MD-66 spontaneously immortalized cell line CVCL_Z437 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21092427 CVCL_Z438 NCI-N857 cancer cell line human CVCL_Z438 CL:0000010 Miscellaneous: The existence of a line with this name is not clear: it is not mentioned in any NCI publications, only in some papers from Japanese groups. Characteristics: Established from a nude mouse xenograft 21092428 CVCL_Z439 IPLB-SF-1254 spontaneously immortalized cell line CVCL_Z439 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 36 hours (PubMed=68913) Group: Insect cell line 21092429 CVCL_6M13 DA00529 transformed cell line human CVCL_6M13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092430 CVCL_6M14 DA00530 transformed cell line human CVCL_6M14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092431 CVCL_6M15 DA00531 transformed cell line human CVCL_6M15 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092432 CVCL_6M16 DA00532 transformed cell line human CVCL_6M16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092433 CVCL_6M10 DA00526 transformed cell line human CVCL_6M10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092434 CVCL_6M11 DA00527 transformed cell line human CVCL_6M11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092435 CVCL_6M12 DA00528 transformed cell line human CVCL_6M12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092436 CVCL_6M06 DA00522 transformed cell line human CVCL_6M06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092437 CVCL_6M07 DA00523 transformed cell line human CVCL_6M07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092438 CVCL_6M08 DA00524 transformed cell line human CVCL_6M08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092439 CVCL_6M09 DA00525 transformed cell line human CVCL_6M09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21092440 CVCL_Z443 IPLB-AiEd6T spontaneously immortalized cell line CVCL_Z443 CL:0000010 Unspecified Group: Insect cell line. 21092441 CVCL_Z444 IPLB-DnEa3 spontaneously immortalized cell line CVCL_Z444 CL:0000010 Unspecified Group: Insect cell line 21092442 CVCL_Z445 IPLB-DnEs1 spontaneously immortalized cell line CVCL_Z445 CL:0000010 Unspecified Group: Insect cell line 21092443 CVCL_Z446 FPMI-MS-12 spontaneously immortalized cell line CVCL_Z446 CL:0000010 Unspecified Group: Insect cell line. 21092444 CVCL_Z440 UFL-AG-286 spontaneously immortalized cell line CVCL_Z440 CL:0000010 Unspecified Doubling time: 5.9 days (when seeded at 2x10^5 cells ml), 6.7 days (when seeded at 3X10^5 cells/ml) (DOI=10.1007/BF02623546). Group: Insect cell line 21092445 CVCL_Z441 IPLB-AiE1611S spontaneously immortalized cell line CVCL_Z441 CL:0000010 Unspecified Group: Insect cell line. 21092446 CVCL_Z442 IPLB-AiE1611T spontaneously immortalized cell line CVCL_Z442 CL:0000010 Unspecified Group: Insect cell line. 21092447 CVCL_Z429 QAU-Ho-E-4 spontaneously immortalized cell line CVCL_Z429 CL:0000010 Unspecified Doubling time: 105.2 hours (PubMed=24464351). Group: Insect cell line 21092448 CVCL_PY90 BayGenomics ES cell line XH711 embryonic stem cell house mouse CVCL_PY90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917882; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092449 CVCL_Z425 67j25D spontaneously immortalized cell line fruit fly CVCL_Z425 CL:0000010 Breed/subspecies: Oregon R-C. Female Doubling time: 48.3 hours (DGRC) Group: Insect cell line 21092450 CVCL_PY91 BayGenomics ES cell line XH715 embryonic stem cell house mouse CVCL_PY91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092451 CVCL_Z426 67j25D-G spontaneously immortalized cell line fruit fly CVCL_Z426 CL:0000010 Breed/subspecies: Oregon R-C. Female Group: Insect cell line 21092452 CVCL_PY92 BayGenomics ES cell line XH718 embryonic stem cell house mouse CVCL_PY92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860078; Txnl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092453 CVCL_Z427 67j25D-P spontaneously immortalized cell line fruit fly CVCL_Z427 CL:0000010 Breed/subspecies: Oregon R-C. Female Group: Insect cell line 21092454 CVCL_PY93 BayGenomics ES cell line XH719 embryonic stem cell house mouse CVCL_PY93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092455 CVCL_PY94 BayGenomics ES cell line XH723 embryonic stem cell house mouse CVCL_PY94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138865; Dlgap4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092456 CVCL_Z428 QAU-Ho-E-3 spontaneously immortalized cell line CVCL_Z428 CL:0000010 Unspecified Doubling time: 101.1 hours (PubMed=24464351). Group: Insect cell line 21092457 CVCL_PY95 BayGenomics ES cell line XH724 embryonic stem cell house mouse CVCL_PY95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092458 CVCL_PY96 BayGenomics ES cell line XH725 embryonic stem cell house mouse CVCL_PY96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092459 CVCL_PY97 BayGenomics ES cell line XH726 embryonic stem cell house mouse CVCL_PY97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913894; Uba6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092460 CVCL_PY98 BayGenomics ES cell line XH732 embryonic stem cell house mouse CVCL_PY98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914295; Riok2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092461 CVCL_PY99 BayGenomics ES cell line XH734 embryonic stem cell house mouse CVCL_PY99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092462 CVCL_Z432 Tn-4s spontaneously immortalized cell line CVCL_Z432 CL:0000010 Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line. 21092463 CVCL_Z433 AGE spontaneously immortalized cell line CVCL_Z433 CL:0000010 Breed/subspecies: Ebony. Unspecified Group: Insect cell line 21092464 CVCL_Z434 AGF2 spontaneously immortalized cell line CVCL_Z434 CL:0000010 Breed/subspecies: Ebony. Unspecified Group: Insect cell line 21092465 CVCL_Z435 IPLB-CPB2 spontaneously immortalized cell line CVCL_Z435 CL:0000010 Unspecified Group: Insect cell line. 21092466 CVCL_Z430 QAU-Ho-E-6 spontaneously immortalized cell line CVCL_Z430 CL:0000010 Unspecified Doubling time: 83.6 hours (PubMed=24464351). Group: Insect cell line 21092467 CVCL_Z431 Tn-4h spontaneously immortalized cell line CVCL_Z431 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2355. 21092468 CVCL_Z418 BTI-Tn-5G33 spontaneously immortalized cell line CVCL_Z418 CL:0000010 Unspecified Group: Insect cell line. 21092469 CVCL_Z419 SES-BoMo-15AII spontaneously immortalized cell line CVCL_Z419 CL:0000010 Breed/subspecies: Kuroko. Unspecified Group: Insect cell line 21092470 CVCL_PY80 BayGenomics ES cell line XH684 embryonic stem cell house mouse CVCL_PY80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860197; Wdr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092471 CVCL_Z414 BTI-Tn-5F2A spontaneously immortalized cell line CVCL_Z414 CL:0000010 Unspecified Group: Insect cell line. 21092472 CVCL_PY81 BayGenomics ES cell line XH685 embryonic stem cell house mouse CVCL_PY81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106264; Trim36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092473 CVCL_Z415 BTI-Tn-5G2A1 spontaneously immortalized cell line CVCL_Z415 CL:0000010 Unspecified Group: Insect cell line. 21092474 CVCL_PY82 BayGenomics ES cell line XH687 embryonic stem cell house mouse CVCL_PY82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092475 CVCL_Z416 BTI-Tn-5G2A1P spontaneously immortalized cell line CVCL_Z416 CL:0000010 Unspecified Group: Insect cell line. 21092476 CVCL_PY83 BayGenomics ES cell line XH688 embryonic stem cell house mouse CVCL_PY83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443306; Tom1l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092477 CVCL_Z417 BTI-Tn-5G3 spontaneously immortalized cell line CVCL_Z417 CL:0000010 Unspecified Group: Insect cell line. 21092478 CVCL_PY84 BayGenomics ES cell line XH690 embryonic stem cell house mouse CVCL_PY84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092479 CVCL_PY85 BayGenomics ES cell line XH693 embryonic stem cell house mouse CVCL_PY85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092480 CVCL_PY86 BayGenomics ES cell line XH694 embryonic stem cell house mouse CVCL_PY86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99260; Prkci Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092481 CVCL_PY87 BayGenomics ES cell line XH698 embryonic stem cell house mouse CVCL_PY87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141989; Grwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092482 CVCL_PY88 BayGenomics ES cell line XH706 embryonic stem cell house mouse CVCL_PY88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918272; Ston2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092483 CVCL_PY89 BayGenomics ES cell line XH708 embryonic stem cell house mouse CVCL_PY89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147437; Rrp12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092484 CVCL_Z421 BCIRL-Cc-AM spontaneously immortalized cell line CVCL_Z421 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 176.6 hours (with daily medium change), 204.3 hours (with weekly medium change) (PubMed=22580906) Group: Insect cell line 21092485 CVCL_Z422 BCIRL-Cc-JG spontaneously immortalized cell line CVCL_Z422 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 192.6 hours (with daily medium change), 112 hours (with weekly medium change) (PubMed=22580906) Group: Insect cell line 21092486 CVCL_Z423 UMC-DgE spontaneously immortalized cell line CVCL_Z423 CL:0000010 Unspecified Group: Insect cell line. 21092487 CVCL_Z424 UMC-OnE spontaneously immortalized cell line CVCL_Z424 CL:0000010 Unspecified Doubling time: 56 hours (at 17th passage), 36 hours (at 79th passage) (PubMed=10950000). Group: Insect cell line 21092488 CVCL_Z420 NISES-BoMo-15AIIc spontaneously immortalized cell line CVCL_Z420 CL:0000010 Breed/subspecies: Kuroko. Unspecified Group: Insect cell line 21092489 CVCL_PR94 BayGenomics ES cell line XF421 embryonic stem cell house mouse CVCL_PR94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349216; Abcd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092490 CVCL_Q394 HG01710 transformed cell line human CVCL_Q394 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092491 CVCL_PR95 BayGenomics ES cell line XF423 embryonic stem cell house mouse CVCL_PR95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891693; Mtmr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092492 CVCL_Q395 HG01711 transformed cell line human CVCL_Q395 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092493 CVCL_PR96 BayGenomics ES cell line XF425 embryonic stem cell house mouse CVCL_PR96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092494 CVCL_Q396 HG01746 transformed cell line human CVCL_Q396 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092495 CVCL_PR97 BayGenomics ES cell line XF430 embryonic stem cell house mouse CVCL_PR97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933162; Lrba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092496 CVCL_Q397 HG01747 transformed cell line human CVCL_Q397 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092497 CVCL_PR98 BayGenomics ES cell line XF445 embryonic stem cell house mouse CVCL_PR98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888697; Taf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092498 CVCL_Q398 HG01748 transformed cell line human CVCL_Q398 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092499 CVCL_PR99 BayGenomics ES cell line XF452 embryonic stem cell house mouse CVCL_PR99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442675; Rfx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092500 CVCL_Q399 HG01755 transformed cell line human CVCL_Q399 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092501 CVCL_YL31 SZ-Fanconi C embryonic stem cell human CVCL_YL31 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Unspecified; Note=Splice donor mutation (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0476 21092502 CVCL_YL34 SZ-FX11 embryonic stem cell human CVCL_YL34 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[80]; ClinVar=VCV000009972; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0447 21092503 CVCL_YL30 SZ-ED5 embryonic stem cell human CVCL_YL30 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3331; EMD; Unexplicit; 4bp deletion within exon 6; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0481 21092504 CVCL_YL39 SZ-FX17 embryonic stem cell human CVCL_YL39 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0453 21092505 CVCL_YL35 SZ-FX12 embryonic stem cell human CVCL_YL35 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[150-300]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=27690107). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0448 21092506 CVCL_YL36 SZ-FX13 embryonic stem cell human CVCL_YL36 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75]; ClinVar=VCV000009972; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0449 21092507 CVCL_YL37 SZ-FX14 embryonic stem cell human CVCL_YL37 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[290-600]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27690107). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0450 21092508 CVCL_YL38 SZ-FX16 embryonic stem cell human CVCL_YL38 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[180]; ClinVar=VCV000009972; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0452 21092509 CVCL_PR83 BayGenomics ES cell line XF326 embryonic stem cell house mouse CVCL_PR83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092510 CVCL_Q383 HG01699 transformed cell line human CVCL_Q383 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092511 CVCL_PR84 BayGenomics ES cell line XF338 embryonic stem cell house mouse CVCL_PR84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092512 CVCL_Q384 HG01700 transformed cell line human CVCL_Q384 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092513 CVCL_PR85 BayGenomics ES cell line XF344 embryonic stem cell house mouse CVCL_PR85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97306; Nf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092514 CVCL_Q385 HG01701 transformed cell line human CVCL_Q385 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092515 CVCL_PR86 BayGenomics ES cell line XF345 embryonic stem cell house mouse CVCL_PR86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092516 CVCL_Q386 HG01702 transformed cell line human CVCL_Q386 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092517 CVCL_PR87 BayGenomics ES cell line XF353 embryonic stem cell house mouse CVCL_PR87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97542; Pepd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092518 CVCL_Q387 HG01703 transformed cell line human CVCL_Q387 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092519 CVCL_PR88 BayGenomics ES cell line XF357 embryonic stem cell house mouse CVCL_PR88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092520 CVCL_Q388 HG01704 transformed cell line human CVCL_Q388 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092521 CVCL_PR89 BayGenomics ES cell line XF360 embryonic stem cell house mouse CVCL_PR89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092522 CVCL_Q389 HG01705 transformed cell line human CVCL_Q389 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092523 CVCL_YL20 SZ-DM16 embryonic stem cell human CVCL_YL20 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0433. 21092524 CVCL_YL22 SZ-DM20 embryonic stem cell human CVCL_YL22 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~300] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0425 21092525 CVCL_YL23 SZ-DM21 embryonic stem cell human CVCL_YL23 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0426. 21092526 CVCL_YL28 SZ-DM9 embryonic stem cell human CVCL_YL28 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~180] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0428 21092527 CVCL_YL29 SZ-DMD2 embryonic stem cell human CVCL_YL29 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex8dup; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0475 21092528 CVCL_PR90 BayGenomics ES cell line XF368 embryonic stem cell house mouse CVCL_PR90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917029; Pphln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092529 CVCL_Q390 HG01706 transformed cell line human CVCL_Q390 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092530 CVCL_PR91 BayGenomics ES cell line XF405 embryonic stem cell house mouse CVCL_PR91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092531 CVCL_Q391 HG01707 transformed cell line human CVCL_Q391 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092532 CVCL_YL25 SZ-DM6 embryonic stem cell human CVCL_YL25 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1060] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0427 21092533 CVCL_PR92 BayGenomics ES cell line XF409 embryonic stem cell house mouse CVCL_PR92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914449; Pfdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092534 CVCL_Q392 HG01708 transformed cell line human CVCL_Q392 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092535 CVCL_PR93 BayGenomics ES cell line XF410 embryonic stem cell house mouse CVCL_PR93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347043; Orc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092536 CVCL_Q393 HG01709 transformed cell line human CVCL_Q393 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092537 CVCL_YL27 SZ-DM8 embryonic stem cell human CVCL_YL27 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~400-2000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0424 21092538 CVCL_PR72 BayGenomics ES cell line XF270 embryonic stem cell house mouse CVCL_PR72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136957; Clmn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092539 CVCL_Q372 HG01682 transformed cell line human CVCL_Q372 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092540 CVCL_PR73 BayGenomics ES cell line XF287 embryonic stem cell house mouse CVCL_PR73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092541 CVCL_Q373 HG01683 transformed cell line human CVCL_Q373 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092542 CVCL_PR74 BayGenomics ES cell line XF288 embryonic stem cell house mouse CVCL_PR74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158400; Wdr18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092543 CVCL_Q374 HG01684 transformed cell line human CVCL_Q374 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092544 CVCL_PR75 BayGenomics ES cell line XF292 embryonic stem cell house mouse CVCL_PR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351485; Phlda3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092545 CVCL_Q375 HG01685 transformed cell line human CVCL_Q375 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092546 CVCL_PR76 BayGenomics ES cell line XF301 embryonic stem cell house mouse CVCL_PR76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95305; Eif4e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092547 CVCL_Q376 HG01686 transformed cell line human CVCL_Q376 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092548 CVCL_PR77 BayGenomics ES cell line XF302 embryonic stem cell house mouse CVCL_PR77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914880; Samd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092549 CVCL_Q377 HG01687 transformed cell line human CVCL_Q377 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092550 CVCL_PR78 BayGenomics ES cell line XF310 embryonic stem cell house mouse CVCL_PR78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151013; Erc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092551 CVCL_Q378 HG01694 transformed cell line human CVCL_Q378 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092552 CVCL_PR79 BayGenomics ES cell line XF311 embryonic stem cell house mouse CVCL_PR79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092553 CVCL_Q379 HG01695 transformed cell line human CVCL_Q379 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092554 CVCL_YL11 SZ-CMT embryonic stem cell human CVCL_YL11 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Arg75Trp (c.223C>T); ClinVar=VCV000021082; Zygosity=Unspecified Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0461 21092555 CVCL_YL12 SZ-DC10 embryonic stem cell human CVCL_YL12 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Arg631Gln (c.1892G>A); ClinVar=VCV000029899; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0480 21092556 CVCL_YL17 SZ-DM12 embryonic stem cell human CVCL_YL17 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~630] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0430 21092557 CVCL_YL18 SZ-DM14 embryonic stem cell human CVCL_YL18 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~2000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0431 21092558 CVCL_YL19 SZ-DM15 embryonic stem cell human CVCL_YL19 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0432. 21092559 CVCL_YL13 SZ-DC2 embryonic stem cell human CVCL_YL13 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Arg631Gln (c.1892G>A); ClinVar=VCV000029899; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0478 21092560 CVCL_PR80 BayGenomics ES cell line XF315 embryonic stem cell house mouse CVCL_PR80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092561 CVCL_Q380 HG01696 transformed cell line human CVCL_Q380 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092562 CVCL_YL14 SZ-DC3 embryonic stem cell human CVCL_YL14 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; p.Arg631Gln (c.1892G>A); ClinVar=VCV000029899; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0479 21092563 CVCL_PR81 BayGenomics ES cell line XF320 embryonic stem cell house mouse CVCL_PR81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95757; Slc2a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092564 CVCL_Q381 HG01697 transformed cell line human CVCL_Q381 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092565 CVCL_PR82 BayGenomics ES cell line XF325 embryonic stem cell house mouse CVCL_PR82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092566 CVCL_Q382 HG01698 transformed cell line human CVCL_Q382 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092567 CVCL_YL16 SZ-DM11 embryonic stem cell human CVCL_YL16 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0429 21092568 CVCL_PR61 BayGenomics ES cell line XF204 embryonic stem cell house mouse CVCL_PR61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916471; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092569 CVCL_Q361 HG01671 transformed cell line human CVCL_Q361 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092570 CVCL_PR62 BayGenomics ES cell line XF207 embryonic stem cell house mouse CVCL_PR62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092571 CVCL_Q362 HG01672 transformed cell line human CVCL_Q362 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092572 CVCL_PR63 BayGenomics ES cell line XF209 embryonic stem cell house mouse CVCL_PR63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925868; Acap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092573 CVCL_Q363 HG01673 transformed cell line human CVCL_Q363 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092574 CVCL_PR64 BayGenomics ES cell line XF210 embryonic stem cell house mouse CVCL_PR64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092575 CVCL_Q364 HG01674 transformed cell line human CVCL_Q364 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092576 CVCL_PR65 BayGenomics ES cell line XF217 embryonic stem cell house mouse CVCL_PR65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092577 CVCL_Q365 HG01675 transformed cell line human CVCL_Q365 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092578 CVCL_PR66 BayGenomics ES cell line XF224 embryonic stem cell house mouse CVCL_PR66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918677; Ibtk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092579 CVCL_Q366 HG01676 transformed cell line human CVCL_Q366 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092580 CVCL_PR67 BayGenomics ES cell line XF225 embryonic stem cell house mouse CVCL_PR67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2672032; Fmr1nb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092581 CVCL_Q367 HG01677 transformed cell line human CVCL_Q367 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092582 CVCL_PR68 BayGenomics ES cell line XF226 embryonic stem cell house mouse CVCL_PR68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092583 CVCL_Q368 HG01678 transformed cell line human CVCL_Q368 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092584 CVCL_PR69 BayGenomics ES cell line XF231 embryonic stem cell house mouse CVCL_PR69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092585 CVCL_Q369 HG01679 transformed cell line human CVCL_Q369 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092586 CVCL_YL00 SZ-ALS1 embryonic stem cell human CVCL_YL00 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=27773700). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0483 21092587 CVCL_YL01 SZ-ALS3 embryonic stem cell human CVCL_YL01 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=27773700). Ambiguous Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0484 21092588 CVCL_YL06 SZ-BRCA1-1 embryonic stem cell human CVCL_YL06 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0456 21092589 CVCL_YL07 SZ-BRCA2-1 embryonic stem cell human CVCL_YL07 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Unspecified. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0470 21092590 CVCL_YL08 SZ-BRCA2-6 embryonic stem cell human CVCL_YL08 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Unspecified Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0469 21092591 CVCL_YL09 SZ-CF12 embryonic stem cell human CVCL_YL09 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Homozygous Miscellaneous: Sex of donor from personal communication of Eiges R. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0466 21092592 CVCL_YL02 SZ-beta-thal8 embryonic stem cell human CVCL_YL02 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Trp38Ter (c.114G>A) (W37*); ClinVar=VCV000015405; Zygosity=Homozygous. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0462 21092593 CVCL_YL03 SZ-DM3 embryonic stem cell human CVCL_YL03 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~2000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Unspecified 21092594 CVCL_PR70 BayGenomics ES cell line XF241 embryonic stem cell house mouse CVCL_PR70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684913; Nol10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092595 CVCL_Q370 HG01680 transformed cell line human CVCL_Q370 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092596 CVCL_YL04 SZ-BOR2 embryonic stem cell human CVCL_YL04 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3519; EYA1; Simple; c.433delG; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0437 21092597 CVCL_PR71 BayGenomics ES cell line XF255 embryonic stem cell house mouse CVCL_PR71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092598 CVCL_Q371 HG01681 transformed cell line human CVCL_Q371 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092599 CVCL_YL05 MU2F cancer cell line human CVCL_YL05 CL:0000010 Characteristics: Established from a xenograft produced by implantation of parent cell line in BALB/cByJ nude mice Doubling time: 18 hours (PubMed=16034303). 21092600 CVCL_PR50 BayGenomics ES cell line XF168 embryonic stem cell house mouse CVCL_PR50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101785; Mybl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092601 CVCL_Q350 HG01627 transformed cell line human CVCL_Q350 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092602 CVCL_PR51 BayGenomics ES cell line XF172 embryonic stem cell house mouse CVCL_PR51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889001; Nub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092603 CVCL_Q351 HG01628 transformed cell line human CVCL_Q351 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092604 CVCL_PR52 BayGenomics ES cell line XF174 embryonic stem cell house mouse CVCL_PR52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923802; Plekha5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092605 CVCL_Q352 HG01629 transformed cell line human CVCL_Q352 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092606 CVCL_PR53 BayGenomics ES cell line XF175 embryonic stem cell house mouse CVCL_PR53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919906; Ints8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092607 CVCL_Q353 HG01630 transformed cell line human CVCL_Q353 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092608 CVCL_PR54 BayGenomics ES cell line XF176 embryonic stem cell house mouse CVCL_PR54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092609 CVCL_Q354 HG01631 transformed cell line human CVCL_Q354 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092610 CVCL_PR55 BayGenomics ES cell line XF185 embryonic stem cell house mouse CVCL_PR55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347044; Orc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092611 CVCL_Q355 HG01632 transformed cell line human CVCL_Q355 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092612 CVCL_PR56 BayGenomics ES cell line XF186 embryonic stem cell house mouse CVCL_PR56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092613 CVCL_Q356 HG01633 transformed cell line human CVCL_Q356 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092614 CVCL_PR57 BayGenomics ES cell line XF191 embryonic stem cell house mouse CVCL_PR57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101786; Mtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092615 CVCL_Q357 HG01667 transformed cell line human CVCL_Q357 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092616 CVCL_PR58 BayGenomics ES cell line XF196 embryonic stem cell house mouse CVCL_PR58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092617 CVCL_Q358 HG01668 transformed cell line human CVCL_Q358 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092618 CVCL_PR59 BayGenomics ES cell line XF202 embryonic stem cell house mouse CVCL_PR59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444855; Klhl20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092619 CVCL_Q359 HG01669 transformed cell line human CVCL_Q359 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092620 CVCL_PR60 BayGenomics ES cell line XF203 embryonic stem cell house mouse CVCL_PR60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351658; Abcf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092621 CVCL_Q360 HG01670 transformed cell line human CVCL_Q360 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092622 CVCL_PR40 BayGenomics ES cell line XF104 embryonic stem cell house mouse CVCL_PR40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387203; Ppat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092623 CVCL_Q340 HG01617 transformed cell line human CVCL_Q340 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092624 CVCL_PR41 BayGenomics ES cell line XF122 embryonic stem cell house mouse CVCL_PR41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092625 CVCL_Q341 HG01618 transformed cell line human CVCL_Q341 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092626 CVCL_PR42 BayGenomics ES cell line XF124 embryonic stem cell house mouse CVCL_PR42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137738; Prcc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092627 CVCL_Q342 HG01619 transformed cell line human CVCL_Q342 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092628 CVCL_PR43 BayGenomics ES cell line XF125 embryonic stem cell house mouse CVCL_PR43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99257; Eif3e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092629 CVCL_Q343 HG01620 transformed cell line human CVCL_Q343 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092630 CVCL_PR44 BayGenomics ES cell line XF127 embryonic stem cell house mouse CVCL_PR44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092631 CVCL_Q344 HG01621 transformed cell line human CVCL_Q344 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092632 CVCL_PR45 BayGenomics ES cell line XF155 embryonic stem cell house mouse CVCL_PR45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137512; Arid4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092633 CVCL_Q345 HG01622 transformed cell line human CVCL_Q345 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092634 CVCL_PR46 BayGenomics ES cell line XF162 embryonic stem cell house mouse CVCL_PR46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443584; L3mbtl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092635 CVCL_Q346 HG01623 transformed cell line human CVCL_Q346 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092636 CVCL_PR47 BayGenomics ES cell line XF164 embryonic stem cell house mouse CVCL_PR47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092637 CVCL_Q347 HG01624 transformed cell line human CVCL_Q347 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092638 CVCL_PR48 BayGenomics ES cell line XF165 embryonic stem cell house mouse CVCL_PR48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092639 CVCL_Q348 HG01625 transformed cell line human CVCL_Q348 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092640 CVCL_PR49 BayGenomics ES cell line XF166 embryonic stem cell house mouse CVCL_PR49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092641 CVCL_Q349 HG01626 transformed cell line human CVCL_Q349 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092642 CVCL_PR30 BayGenomics ES cell line XF031 embryonic stem cell house mouse CVCL_PR30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98658; Tdgf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092643 CVCL_Q330 HG01607 transformed cell line human CVCL_Q330 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092644 CVCL_PR31 BayGenomics ES cell line XF042 embryonic stem cell house mouse CVCL_PR31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449307; Upf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092645 CVCL_Q331 HG01608 transformed cell line human CVCL_Q331 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092646 CVCL_PR32 BayGenomics ES cell line XF043 embryonic stem cell house mouse CVCL_PR32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104633; Tle4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092647 CVCL_Q332 HG01609 transformed cell line human CVCL_Q332 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092648 CVCL_PR33 BayGenomics ES cell line XF048 embryonic stem cell house mouse CVCL_PR33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924261; Ticrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092649 CVCL_Q333 HG01610 transformed cell line human CVCL_Q333 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092650 CVCL_PR34 BayGenomics ES cell line XF054 embryonic stem cell house mouse CVCL_PR34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137512; Arid4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092651 CVCL_Q334 HG01611 transformed cell line human CVCL_Q334 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092652 CVCL_PR35 BayGenomics ES cell line XF060 embryonic stem cell house mouse CVCL_PR35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933549; Slmap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092653 CVCL_Q335 HG01612 transformed cell line human CVCL_Q335 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092654 CVCL_H999 1A3.3.13 hybridoma house mouse CVCL_H999 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11894 21092655 CVCL_PR36 BayGenomics ES cell line XF062 embryonic stem cell house mouse CVCL_PR36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092656 CVCL_Q336 HG01613 transformed cell line human CVCL_Q336 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092657 CVCL_GX99 MCF-7/C4-12 cancer cell line human CVCL_GX99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21092658 CVCL_PR37 BayGenomics ES cell line XF065 embryonic stem cell house mouse CVCL_PR37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102706; Fdft1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092659 CVCL_Q337 HG01614 transformed cell line human CVCL_Q337 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092660 CVCL_PR38 BayGenomics ES cell line XF099 embryonic stem cell house mouse CVCL_PR38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934950; Csnk1a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092661 CVCL_Q338 HG01615 transformed cell line human CVCL_Q338 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092662 CVCL_PR39 BayGenomics ES cell line XF102 embryonic stem cell house mouse CVCL_PR39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092663 CVCL_Q339 HG01616 transformed cell line human CVCL_Q339 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092664 CVCL_H995 GM50336 finite cell line human CVCL_H995 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092665 CVCL_GX95 HG01434 transformed cell line human CVCL_GX95 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21092666 CVCL_H996 GM50334 finite cell line human CVCL_H996 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092667 CVCL_GX96 HG02045 transformed cell line human CVCL_GX96 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092668 CVCL_H997 10C4.1.3 hybridoma house mouse CVCL_H997 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11029 21092669 CVCL_GX97 CH7C17 cancer cell line human CVCL_GX97 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12155; TRB (from HA1.7) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21092670 CVCL_H998 10H2.12.1 hybridoma house mouse CVCL_H998 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P25025; Human CXCR2/IL8RB/CD182. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11494 21092671 CVCL_GX98 CHO 22H11 spontaneously immortalized cell line CVCL_GX98 CL:0000010 Transfected with: Glutamine synthetase (GS) expression system carrying a gene for human-mouse chimeric antibody cB72.3 Derived from sampling site: Ovary. Female 21092672 CVCL_H991 GM21808 finite cell line human CVCL_H991 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21092673 CVCL_GX91 HG04208 transformed cell line human CVCL_GX91 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092674 CVCL_H992 GM21810 finite cell line human CVCL_H992 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 25 PDL (Coriell=GM21810) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21092675 CVCL_GX92 HG04215 transformed cell line human CVCL_GX92 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092676 CVCL_H993 GM50345 finite cell line human CVCL_H993 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092677 CVCL_GX93 HG04217 transformed cell line human CVCL_GX93 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092678 CVCL_H994 GM50346 finite cell line human CVCL_H994 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092679 CVCL_GX94 HG04228 transformed cell line human CVCL_GX94 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092680 CVCL_H990 GM21806 finite cell line human CVCL_H990 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 18 PDL (Coriell=GM21806) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21092681 CVCL_GX90 HG04204 transformed cell line human CVCL_GX90 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092682 CVCL_PR20 BayGenomics ES cell line XF002 embryonic stem cell house mouse CVCL_PR20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270126; Ulk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092683 CVCL_Q320 HG01597 transformed cell line human CVCL_Q320 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092684 CVCL_PR21 BayGenomics ES cell line XF003 embryonic stem cell house mouse CVCL_PR21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442153; Gak Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092685 CVCL_Q321 HG01598 transformed cell line human CVCL_Q321 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092686 CVCL_PR22 BayGenomics ES cell line XF013 embryonic stem cell house mouse CVCL_PR22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092687 CVCL_Q322 HG01599 transformed cell line human CVCL_Q322 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092688 CVCL_PR23 BayGenomics ES cell line XF014 embryonic stem cell house mouse CVCL_PR23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917394; Lrch3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092689 CVCL_Q323 HG01600 transformed cell line human CVCL_Q323 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092690 CVCL_PR24 BayGenomics ES cell line XF015 embryonic stem cell house mouse CVCL_PR24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092691 CVCL_Q324 HG01601 transformed cell line human CVCL_Q324 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092692 CVCL_PR25 BayGenomics ES cell line XF016 embryonic stem cell house mouse CVCL_PR25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94912; Dnmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092693 CVCL_Q325 HG01602 transformed cell line human CVCL_Q325 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092694 CVCL_PR26 BayGenomics ES cell line XF020 embryonic stem cell house mouse CVCL_PR26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95481; Ptk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092695 CVCL_Q326 HG01603 transformed cell line human CVCL_Q326 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092696 CVCL_PR27 BayGenomics ES cell line XF021 embryonic stem cell house mouse CVCL_PR27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933527; Srrt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092697 CVCL_Q327 HG01604 transformed cell line human CVCL_Q327 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092698 CVCL_PR28 BayGenomics ES cell line XF022 embryonic stem cell house mouse CVCL_PR28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109582; Polr2j Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092699 CVCL_Q328 HG01605 transformed cell line human CVCL_Q328 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092700 CVCL_PR29 BayGenomics ES cell line XF028 embryonic stem cell house mouse CVCL_PR29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140248; Zbtb48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092701 CVCL_Q329 HG01606 transformed cell line human CVCL_Q329 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092702 CVCL_6F67 BWK finite cell line CVCL_6F67 CL:0000010 Derived from sampling site: Kidney. Male Group: Cetacean cell line 21092703 CVCL_6F68 AS [Salmo] spontaneously immortalized cell line CVCL_6F68 CL:0000010 Unspecified Doubling time: 19.5 hours (DOI=10.1139/f73-152). Group: Fish cell line 21092704 CVCL_6F69 CB [Cobia] spontaneously immortalized cell line CVCL_6F69 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21092705 CVCL_6F63 Jari transformed cell line CVCL_6F63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21092706 CVCL_6F64 Kasey transformed cell line CVCL_6F64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21092707 CVCL_6F65 BB132-EBV transformed cell line human CVCL_6F65 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21092708 CVCL_6F66 BB65-EBV transformed cell line human CVCL_6F66 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21092709 CVCL_6F60 OLF10.1.8 transformed cell line house mouse CVCL_6F60 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21092710 CVCL_6F61 SC3a-MSC somatic stem cell human CVCL_6F61 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Derived from sampling site: Cell type=Mesenchymal stem cell. Female Doubling time: 38.8 +- 1.0 hours (PubMed=22567895) 21092711 CVCL_6F62 SC5-MSC somatic stem cell human CVCL_6F62 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Derived from sampling site: Cell type=Mesenchymal stem cell. Female Doubling time: 25.5 +- 0.1 hours (PubMed=22567895) 21092712 CVCL_6F78 CP spontaneously immortalized cell line CVCL_6F78 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21092713 CVCL_6F79 DLEC spontaneously immortalized cell line CVCL_6F79 CL:0000010 Unspecified Group: Fish cell line. 21092714 CVCL_6F74 CFS [Clarias] spontaneously immortalized cell line CVCL_6F74 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21092715 CVCL_6F75 CFS [Carassius] spontaneously immortalized cell line CVCL_6F75 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21092716 CVCL_6F76 CFSa1 spontaneously immortalized cell line CVCL_6F76 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21092717 CVCL_6F77 CLF spontaneously immortalized cell line CVCL_6F77 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Fin. Unspecified Doubling time: 108 hours (DOI=10.1139/f77-017) Group: Fish cell line 21092718 CVCL_6F70 CF [Cobia] spontaneously immortalized cell line CVCL_6F70 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21092719 CVCL_6F71 CFG spontaneously immortalized cell line CVCL_6F71 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21092720 CVCL_6F72 CFH spontaneously immortalized cell line CVCL_6F72 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21092721 CVCL_6F73 CFK spontaneously immortalized cell line CVCL_6F73 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21092722 CVCL_6F45 PFC telomerase immortalized cell line pig CVCL_6F45 CL:0000010 Transfected with: VGNC; 93883; Pig TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: Jangquhai. Unspecified Doubling time: 40.2 hours (at 10th passage), 37.0 hours (at 20th passage), 35.5 hours (at 30th passage), 35.7 hours (at 40th passage) (PubMed=26341227) 21092723 CVCL_6F46 F4374 finite cell line CVCL_6F46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092724 CVCL_6F47 F4869 finite cell line CVCL_6F47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092725 CVCL_6F48 F4869 hTERT telomerase immortalized cell line CVCL_6F48 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092726 CVCL_6F41 AY33 cancer cell line Norway rat CVCL_6F41 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male 21092727 CVCL_6F42 AY34 cancer cell line Norway rat CVCL_6F42 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male 21092728 CVCL_6F43 Ymnu transformed cell line house mouse CVCL_6F43 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: NMRI. Male 21092729 CVCL_6F44 DB-1 [Mouse macrophage] spontaneously immortalized cell line house mouse CVCL_6F44 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/KsJ-db/db. Male 21092730 CVCL_6F49 OF4374 finite cell line CVCL_6F49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092731 CVCL_6F40 AY32 cancer cell line Norway rat CVCL_6F40 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male 21092732 CVCL_6F56 Colin transformed cell line CVCL_6F56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21092733 CVCL_6F57 Ericka transformed cell line CVCL_6F57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21092734 CVCL_6F58 Harv transformed cell line CVCL_6F58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21092735 CVCL_6F59 Kampong transformed cell line CVCL_6F59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21092736 CVCL_6F52 BHK21-InVitrus spontaneously immortalized cell line CVCL_6F52 CL:0000010 Derived from sampling site: Kidney. Male Group: Serum/protein free medium cell line 21092737 CVCL_6F53 GM09694 transformed cell line human CVCL_6F53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092738 CVCL_6F54 JPKO transformed cell line human CVCL_6F54 HLA typing: A*33:03; B*44:03; DRB1*13:02 (IPD-IMGT/HLA=15828) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21092739 CVCL_6F55 Bosondjo transformed cell line bonobo/pygmy chimpanzee CVCL_6F55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21092740 CVCL_6F50 F4374 hTERT telomerase immortalized cell line CVCL_6F50 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092741 CVCL_6F51 FRSN somatic stem cell human CVCL_6F51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Mesenchymal stem cell.. Male 21092742 CVCL_6F23 SC4 [Human ESC] embryonic stem cell human CVCL_6F23 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Unspecified Doubling time: 37.5 +- 4.2 hours (PubMed=19764648). 21092743 CVCL_6F24 SC5 embryonic stem cell human CVCL_6F24 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia.. CL:0000010 Female 21092744 CVCL_6F25 SC6 embryonic stem cell human CVCL_6F25 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia.. CL:0000010 Female 21092745 CVCL_6F26 SC7 embryonic stem cell human CVCL_6F26 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia.. CL:0000010 Male 21092746 CVCL_6F20 SC2 embryonic stem cell human CVCL_6F20 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Unspecified Doubling time: 48.0 +- 6.9 hours (PubMed=19764648). 21092747 CVCL_6F21 SC3 embryonic stem cell human CVCL_6F21 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Unspecified Doubling time: 28.5 +- 2.5 hours (PubMed=19764648). 21092748 CVCL_6F22 SC3a embryonic stem cell human CVCL_6F22 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia.. CL:0000010 Female 21092749 CVCL_6F27 FetMSC somatic stem cell human CVCL_6F27 CL:0000010 Derived from sampling site: Fetal bone marrow Cell type=Mesenchymal stem cell.. Male Doubling time: 33.0 +- 1.4 hours (PubMed=25697001) 21092750 CVCL_6F28 M-FetMSC somatic stem cell human CVCL_6F28 CL:0000010 Derived from sampling site: Fetal limb; muscle Cell type=Mesenchymal stem cell.. Male Doubling time: 25.0 +- 0.1 hours (PubMed=25697001) 21092751 CVCL_6F29 HAdpc-27-TERT finite cell line human CVCL_6F29 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21092752 CVCL_6F34 gamma2-11.1 hybridoma house mouse CVCL_6F34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8699; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-242 21092753 CVCL_6F35 130-80-2 hybridoma house mouse CVCL_6F35 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P21837; Dictyostelium discoideum cryS. 21092754 CVCL_6F36 176-2-5 hybridoma house mouse CVCL_6F36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27133; Dictyostelium discoideum corA. 21092755 CVCL_6F37 BCPb8 telomerase immortalized cell line CVCL_6F37 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Dental follicle. 21092756 CVCL_6F30 HAdpc-23-E6E7 transformed cell line human CVCL_6F30 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21092757 CVCL_6F31 HAdpc-24-Bmi-1 finite cell line human CVCL_6F31 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21092758 CVCL_6F32 H4-1 [Human bone marrow] finite cell line human CVCL_6F32 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21092759 CVCL_6F33 UBE6T-8 telomerase immortalized cell line human CVCL_6F33 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21092760 CVCL_6F38 UBT-10 telomerase immortalized cell line human CVCL_6F38 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21092761 CVCL_6F39 BSN spontaneously immortalized cell line CVCL_6F39 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Virology: Infected by blotched snakehead virus (BSNV) Group: Fish cell line 21092762 CVCL_YL64 MU7 cancer cell line human CVCL_YL64 CL:0000010 Population: African. Male 21092763 CVCL_YL65 MU8 [Human uveal melanoma] cancer cell line human CVCL_YL65 CL:0000010 Doubling time: 20 days (PubMed=16034303). 21092764 CVCL_YL66 SZ-Rb4 embryonic stem cell human CVCL_YL66 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ala525Lysfs*7 (c.1572insAA); Zygosity=Unspecified. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0419 21092765 CVCL_YL67 SZ-SMA5 embryonic stem cell human CVCL_YL67 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=26473610). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0467 21092766 CVCL_YL60 SZ-OI8 embryonic stem cell human CVCL_YL60 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Arg361Ter (c.1081C>T); ClinVar=VCV000425593; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0460 21092767 CVCL_YL61 SZ-PKD1 embryonic stem cell human CVCL_YL61 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; c.8433_8438delinsGCCC; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0473 21092768 CVCL_YL62 SZ-Pompe4 embryonic stem cell human CVCL_YL62 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg819Pro (c.2456G>C); ClinVar=VCV001693550; Zygosity=Unspecified Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0474 21092769 CVCL_YL63 MU2 cancer cell line human CVCL_YL63 CL:0000010 Doubling time: 20 hours (PubMed=16034303). 21092770 CVCL_YL68 SZ-SMA6 embryonic stem cell human CVCL_YL68 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7del; Zygosity=Homozygous Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0468 21092771 CVCL_YL69 SZ-VHL1 embryonic stem cell human CVCL_YL69 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Arg64Pro (c.191G>C); ClinVar=VCV000002226; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0482 21092772 CVCL_6F01 TLNC-4 transformed cell line Norway rat CVCL_6F01 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lymph node; Breed/subspecies: Sprague Dawley. Unspecified 21092773 CVCL_6F02 BJ-610 transformed cell line CVCL_6F02 CL:0000010 Transformant: Alcelaphine herpesvirus 1(NCBI-Taxonomy; 35252); Derived from sampling site: Lymph node Cell type=Natural killer cell.; Breed/subspecies: New Zealand white. Female 21092774 CVCL_6F03 TRK-36 transformed cell line CVCL_6F03 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea Cell type=Keratocyte.. Unspecified 21092775 CVCL_6F04 HCK transformed cell line human CVCL_6F04 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea Cell type=Keratocyte.. Unspecified Doubling time: 34 hours (PubMed=15813699) 21092776 CVCL_6F00 TLNC-1 transformed cell line Norway rat CVCL_6F00 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lymph node; Breed/subspecies: Sprague Dawley. Unspecified 21092777 CVCL_6F09 BET-3A transformed cell line human CVCL_6F09 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. 21092778 CVCL_6F05 Calg-ARLC spontaneously immortalized cell line CVCL_6F05 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: New Zealand white. Female Doubling time: 12 hours (PubMed=4817948) 21092779 CVCL_6F06 B/C.Li finite cell line house mouse CVCL_6F06 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6328; true; Discontinued: ATCC; CRL-6330; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21092780 CVCL_6F07 B/C.Ov finite cell line house mouse CVCL_6F07 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: BALB/c. Female 21092781 CVCL_6F08 RCHO cancer cell line Norway rat CVCL_6F08 CL:0000010 Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Male 21092782 CVCL_YL53 SZ-HTT3 embryonic stem cell human CVCL_YL53 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[32] (c.52CAG(32)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0471 21092783 CVCL_YL56 SZ-Marfan7 embryonic stem cell human CVCL_YL56 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Gln1813Ter (c.5437C>T); ClinVar=VCV000042383; Zygosity=Unspecified. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0458 21092784 CVCL_YL51 SZ-HNPCC3 embryonic stem cell human CVCL_YL51 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0477. 21092785 CVCL_YL52 SZ-HTT210 embryonic stem cell human CVCL_YL52 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0472 21092786 CVCL_YL57 SZ-NF1 embryonic stem cell human CVCL_YL57 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; c.4269+1G>C; Zygosity=Unspecified; Note=Splice donor mutation (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0463 21092787 CVCL_YL58 SZ-NF2 embryonic stem cell human CVCL_YL58 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; c.4269+1G>C; Zygosity=Unspecified; Note=Splice donor mutation (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0464 21092788 CVCL_YL59 SZ-NF4 embryonic stem cell human CVCL_YL59 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; c.4269+1G>C; Zygosity=Unspecified; Note=Splice donor mutation (Direct_author_submission) Miscellaneous: Sequence variation from personal communication of Eiges R. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0465 21092789 CVCL_6F12 IIICF-T/B1 transformed cell line human CVCL_6F12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; stroma. Female 21092790 CVCL_6F13 IIICF-T/C3 transformed cell line human CVCL_6F13 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; stroma. Female 21092791 CVCL_6F14 MT [Muntjac] finite cell line CVCL_6F14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092792 CVCL_6F15 MTD finite cell line CVCL_6F15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092793 CVCL_6F10 BET-3B transformed cell line human CVCL_6F10 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. 21092794 CVCL_6F11 BET-3M transformed cell line human CVCL_6F11 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21092795 CVCL_6F16 CHO-K1v spontaneously immortalized cell line CVCL_6F16 CL:0000010 Derived from sampling site: Ovary. Female 21092796 CVCL_6F17 YDK-04 spontaneously immortalized cell line CVCL_6F17 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 63 21092797 CVCL_6F18 L6J1 transformed cell line Norway rat CVCL_6F18 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21092798 CVCL_6F19 SC1 embryonic stem cell human CVCL_6F19 From: Institute of Cytology, Russian Academy of Sciences; St Petersburg; Russia. CL:0000010 Unspecified Doubling time: 47.0 +- 6.3 hours (PubMed=19764648). 21092799 CVCL_YL43 SZ-FX4 embryonic stem cell human CVCL_YL43 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75]; ClinVar=VCV000009972; Zygosity=Hemizygous (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0444 21092800 CVCL_YL40 SZ-FX18 embryonic stem cell human CVCL_YL40 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Miscellaneous: Sex of donor from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0454 21092801 CVCL_YL41 SZ-FX22 embryonic stem cell human CVCL_YL41 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[74]; ClinVar=VCV000009972; Zygosity=Hemizygous (Direct_author_submission) Miscellaneous: Sex of donor and sequence variation from personal communication of Eiges R. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0451 21092802 CVCL_YL46 SZ-FX7 embryonic stem cell human CVCL_YL46 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[200-300]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=27690107). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0445 21092803 CVCL_YL47 SZ-FX8 embryonic stem cell human CVCL_YL47 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[200-600]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27690107). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0446 21092804 CVCL_YL48 SZ-Gaucher4 embryonic stem cell human CVCL_YL48 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu29Alafs*18 (c.84dupG) (c.84_85insG) (84GG); ClinVar=VCV000004311; Zygosity=Heterozygous; Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg535His (c.1604G>A) (R496H); ClinVar=VCV000004311; Zygosity=Heterozygous. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0457 21092805 CVCL_YL49 SZ-HED11 embryonic stem cell human CVCL_YL49 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Asp50Asn (c.148G>A); ClinVar=VCV000017020; Zygosity=Unspecified. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0435 21092806 CVCL_H908 ES[MC1R(20):tetMbd3(12)] embryonic stem cell house mouse CVCL_H908 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092807 CVCL_GX08 HG03510 transformed cell line human CVCL_GX08 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092808 CVCL_H909 ES[MC1R(20):tetMeis2(40)] embryonic stem cell house mouse CVCL_H909 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092809 CVCL_GX09 HG03513 transformed cell line human CVCL_GX09 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092810 CVCL_H904 ES[MC1R(20):tetKlf3(11)] embryonic stem cell house mouse CVCL_H904 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092811 CVCL_GX04 HG03480 transformed cell line human CVCL_GX04 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092812 CVCL_H905 ES[MC1R(20):tetKlf9(23)] embryonic stem cell house mouse CVCL_H905 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092813 CVCL_GX05 HG03486 transformed cell line human CVCL_GX05 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092814 CVCL_H906 ES[MC1R(20):tetLass2(12)] embryonic stem cell house mouse CVCL_H906 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092815 CVCL_GX06 HG03489 transformed cell line human CVCL_GX06 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092816 CVCL_H907 ES[MC1R(20):tetLhx2(13)] embryonic stem cell house mouse CVCL_H907 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092817 CVCL_GX07 HG03492 transformed cell line human CVCL_GX07 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092818 CVCL_H900 ES[MC1R(20):tetJarid1a(21)] embryonic stem cell house mouse CVCL_H900 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092819 CVCL_GX00 HG03468 transformed cell line human CVCL_GX00 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092820 CVCL_H901 ES[MC1R(20):tetJarid2(37)] embryonic stem cell house mouse CVCL_H901 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092821 CVCL_GX01 HG03471 transformed cell line human CVCL_GX01 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092822 CVCL_H902 ES[MC1R(20):tetJmjd2c(14)] embryonic stem cell house mouse CVCL_H902 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092823 CVCL_GX02 HG03474 transformed cell line human CVCL_GX02 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092824 CVCL_H903 ES[MC1R(20):tetJun(4)] embryonic stem cell house mouse CVCL_H903 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092825 CVCL_GX03 HG03477 transformed cell line human CVCL_GX03 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092826 CVCL_6E86 HE-SV transformed cell line human CVCL_6E86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21092827 CVCL_6E87 PC-3/MA2 cancer cell line human CVCL_6E87 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21092828 CVCL_6E88 PC-3 MC cancer cell line human CVCL_6E88 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21092829 CVCL_6E89 PC-3 MK cancer cell line human CVCL_6E89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21092830 CVCL_6E82 HMOS-A cancer cell line human CVCL_6E82 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; left ilium. Female 21092831 CVCL_6E83 HMOS-P cancer cell line human CVCL_6E83 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; humerus. Female 21092832 CVCL_6E84 Nagai cancer cell line human CVCL_6E84 CL:0000010 Population: Japanese Male Doubling time: 130 hours, at 17th passage (PubMed=233287). 21092833 CVCL_6E85 HE-209 transformed cell line human CVCL_6E85 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Has a different growth rate at the permissive temperature (33 Celsius) than at the restrictive temperature (40 Celsius) 21092834 CVCL_6E80 BEP2D R15H20 transformed cell line human CVCL_6E80 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Plutonium-238 alpha particle radiation(NCIt; C129642); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male 21092835 CVCL_6E81 BEP2D R15H35 transformed cell line human CVCL_6E81 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Plutonium-238 alpha particle radiation(NCIt; C129642); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male 21092836 CVCL_6E97 SR-3Y1-3 transformed cell line Norway rat CVCL_6E97 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21092837 CVCL_6E98 TLNC-2 transformed cell line Norway rat CVCL_6E98 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lymph node; Breed/subspecies: Sprague Dawley. Unspecified 21092838 CVCL_6E99 TLNC-3 transformed cell line Norway rat CVCL_6E99 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lymph node; Breed/subspecies: Sprague Dawley. Unspecified 21092839 CVCL_6E93 LNCaP C4-2Pr cancer cell line human CVCL_6E93 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21092840 CVCL_6E94 RCCT-28A transformed cell line CVCL_6E94 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: New Zealand white. Unspecified 21092841 CVCL_6E95 RCCT-28A(P+) transformed cell line CVCL_6E95 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: New Zealand white. Unspecified 21092842 CVCL_6E96 HR-3Y1-3 transformed cell line Norway rat CVCL_6E96 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21092843 CVCL_6E90 PC-3 ML cancer cell line human CVCL_6E90 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21092844 CVCL_6E91 PC-3 MR cancer cell line human CVCL_6E91 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21092845 CVCL_6E92 LNCaP C4-2Ln cancer cell line human CVCL_6E92 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21092846 CVCL_6E68 900-2K-34 transformed cell line house mouse CVCL_6E68 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA900](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Unspecified 21092847 CVCL_6E69 W-2K-11 transformed cell line house mouse CVCL_6E69 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Unspecified 21092848 CVCL_6E64 XF spontaneously immortalized cell line African clawed frog CVCL_6E64 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Amphibian cell line 21092849 CVCL_6E65 C3H2K spontaneously immortalized cell line house mouse CVCL_6E65 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Unspecified Doubling time: ~70 hours (PubMed=4168505) 21092850 CVCL_6E66 C3H2K-C4 spontaneously immortalized cell line house mouse CVCL_6E66 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Unspecified 21092851 CVCL_6E67 MSV512 transformed cell line house mouse CVCL_6E67 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Unspecified 21092852 CVCL_6E60 Xl1 spontaneously immortalized cell line African clawed frog CVCL_6E60 CL:0000010 Derived from sampling site: Bone. Unspecified Characteristics: Can mineralize their extracellular matrix upon addition of an inorganic phosphate donor and vitamin C (PubMed=23054192) Doubling time: 3-4 days (PubMed=23054192) Group: Amphibian cell line 21092853 CVCL_6E61 SS1C spontaneously immortalized cell line CVCL_6E61 CL:0000010 Derived from sampling site: Bone; vertebra. Unspecified Group: Fish cell line 21092854 CVCL_6E62 HeLa(tTA)1 cancer cell line human CVCL_6E62 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Expresses the tetracycline-controlled transactivator (tTA) 21092855 CVCL_6E63 B3.2(tTA)1 spontaneously immortalized cell line African clawed frog CVCL_6E63 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Unspecified Characteristics: Expresses the tetracycline-controlled transactivator (tTA) Group: Amphibian cell line 21092856 CVCL_6E79 BEP2D R15H transformed cell line human CVCL_6E79 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Plutonium-238 alpha particle radiation(NCIt; C129642); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Proteome analysis by 2D-DE/MS Male 21092857 CVCL_6E75 SMA-540 cancer cell line house mouse CVCL_6E75 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: VM/Dk. 21092858 CVCL_6E76 SMA-497 cancer cell line house mouse CVCL_6E76 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: VM/Dk. 21092859 CVCL_6E77 BEP2D transformed cell line human CVCL_6E77 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Doubling time: 35 hours (PubMed=8118924) 21092860 CVCL_6E78 BEP3D transformed cell line human CVCL_6E78 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Male 21092861 CVCL_6E71 W-3Y-23 transformed cell line Norway rat CVCL_6E71 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21092862 CVCL_6E72 SHCE transformed cell line human CVCL_6E72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium. 21092863 CVCL_6E73 OV176 cancer cell line human CVCL_6E73 CL:0000010 Female 21092864 CVCL_6E74 Ogg1 KO MEF spontaneously immortalized cell line house mouse CVCL_6E74 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1097693; Ogg1 Derived from sampling site: Cell type=Fibroblast. Female 21092865 CVCL_6E70 900-3Y-11 transformed cell line Norway rat CVCL_6E70 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA900](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21092866 CVCL_PR10 BayGenomics ES cell line XE856 embryonic stem cell house mouse CVCL_PR10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092867 CVCL_Q310 HG01577 transformed cell line human CVCL_Q310 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092868 CVCL_PR11 BayGenomics ES cell line XE858 embryonic stem cell house mouse CVCL_PR11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092869 CVCL_Q311 HG01578 transformed cell line human CVCL_Q311 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092870 CVCL_PR12 BayGenomics ES cell line XE859 embryonic stem cell house mouse CVCL_PR12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97887; Rdx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092871 CVCL_Q312 HG01579 transformed cell line human CVCL_Q312 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092872 CVCL_PR13 BayGenomics ES cell line XE861 embryonic stem cell house mouse CVCL_PR13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351320; Trp53bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092873 CVCL_Q313 HG01583 transformed cell line human CVCL_Q313 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092874 CVCL_H977 AG07454 finite cell line dog CVCL_H977 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21092875 CVCL_PR14 BayGenomics ES cell line XE862 embryonic stem cell house mouse CVCL_PR14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351320; Trp53bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092876 CVCL_Q314 HG01586 transformed cell line human CVCL_Q314 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092877 CVCL_GX77 HG04136 transformed cell line human CVCL_GX77 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092878 CVCL_H978 AG07455 finite cell line dog CVCL_H978 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Female 21092879 CVCL_PR15 BayGenomics ES cell line XE863 embryonic stem cell house mouse CVCL_PR15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098687; Aak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092880 CVCL_Q315 HG01589 transformed cell line human CVCL_Q315 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092881 CVCL_GX78 HG04142 transformed cell line human CVCL_GX78 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092882 CVCL_H979 AG08116 finite cell line pig CVCL_H979 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Duroc. Female 21092883 CVCL_PR16 BayGenomics ES cell line XE868 embryonic stem cell house mouse CVCL_PR16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092884 CVCL_Q316 HG01590 transformed cell line human CVCL_Q316 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092885 CVCL_GX79 HG04148 transformed cell line human CVCL_GX79 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092886 CVCL_PR17 BayGenomics ES cell line XE871 embryonic stem cell house mouse CVCL_PR17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092887 CVCL_Q317 HG01593 transformed cell line human CVCL_Q317 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092888 CVCL_PR18 BayGenomics ES cell line XE876 embryonic stem cell house mouse CVCL_PR18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139369; Rtel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092889 CVCL_H973 GM01486 finite cell line human CVCL_H973 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21092890 CVCL_Q318 HG01595 transformed cell line human CVCL_Q318 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092891 CVCL_GX73 HG04067 transformed cell line human CVCL_GX73 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092892 CVCL_PR19 BayGenomics ES cell line XE878 embryonic stem cell house mouse CVCL_PR19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092893 CVCL_H974 GM01482 finite cell line human CVCL_H974 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21092894 CVCL_Q319 HG01596 transformed cell line human CVCL_Q319 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092895 CVCL_GX74 HG04115 transformed cell line human CVCL_GX74 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092896 CVCL_H975 AG07429 finite cell line dog CVCL_H975 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21092897 CVCL_GX75 HG04122 transformed cell line human CVCL_GX75 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092898 CVCL_H976 AG07430 finite cell line dog CVCL_H976 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Female 21092899 CVCL_GX76 HG04133 transformed cell line human CVCL_GX76 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092900 CVCL_H970 GM01122 finite cell line human CVCL_H970 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21092901 CVCL_GX70 HG03992 transformed cell line human CVCL_GX70 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092902 CVCL_H971 GM01240 transformed cell line human CVCL_H971 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092903 CVCL_GX71 HG04036 transformed cell line human CVCL_GX71 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092904 CVCL_H972 GM01241 transformed cell line human CVCL_H972 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21092905 CVCL_GX72 HG04040 transformed cell line human CVCL_GX72 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092906 CVCL_PR00 BayGenomics ES cell line XE830 embryonic stem cell house mouse CVCL_PR00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092907 CVCL_Q300 HG01538 transformed cell line human CVCL_Q300 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092908 CVCL_PR01 BayGenomics ES cell line XE831 embryonic stem cell house mouse CVCL_PR01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092909 CVCL_Q301 HG01550 transformed cell line human CVCL_Q301 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092910 CVCL_PR02 BayGenomics ES cell line XE832 embryonic stem cell house mouse CVCL_PR02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092911 CVCL_Q302 HG01551 transformed cell line human CVCL_Q302 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092912 CVCL_PR03 BayGenomics ES cell line XE835 embryonic stem cell house mouse CVCL_PR03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921173; Tmco1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092913 CVCL_H988 GM21807 finite cell line human CVCL_H988 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 29 PDL (Coriell=GM21807) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21092914 CVCL_Q303 HG01552 transformed cell line human CVCL_Q303 CL:0000010 Population: Colombian from Medellin (CLM); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092915 CVCL_GX88 HG04197 transformed cell line human CVCL_GX88 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092916 CVCL_PR04 BayGenomics ES cell line XE839 embryonic stem cell house mouse CVCL_PR04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351320; Trp53bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092917 CVCL_H989 GM21811 finite cell line human CVCL_H989 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=GM21811) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21092918 CVCL_Q304 HG01565 transformed cell line human CVCL_Q304 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092919 CVCL_GX89 HG04199 transformed cell line human CVCL_GX89 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092920 CVCL_PR05 BayGenomics ES cell line XE841 embryonic stem cell house mouse CVCL_PR05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921407; Cmtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092921 CVCL_Q305 HG01566 transformed cell line human CVCL_Q305 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092922 CVCL_PR06 BayGenomics ES cell line XE842 embryonic stem cell house mouse CVCL_PR06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351320; Trp53bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092923 CVCL_Q306 HG01567 transformed cell line human CVCL_Q306 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092924 CVCL_H984 AG08132 finite cell line CVCL_H984 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Female 21092925 CVCL_PR07 BayGenomics ES cell line XE848 embryonic stem cell house mouse CVCL_PR07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092926 CVCL_Q307 HG01571 transformed cell line human CVCL_Q307 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092927 CVCL_GX84 HG04181 transformed cell line human CVCL_GX84 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092928 CVCL_H985 AG08133 finite cell line CVCL_H985 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Holstein. Female 21092929 CVCL_PR08 BayGenomics ES cell line XE850 embryonic stem cell house mouse CVCL_PR08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092930 CVCL_Q308 HG01572 transformed cell line human CVCL_Q308 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092931 CVCL_GX85 HG04184 transformed cell line human CVCL_GX85 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092932 CVCL_H986 AG08316 finite cell line CVCL_H986 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21092933 CVCL_PR09 BayGenomics ES cell line XE853 embryonic stem cell house mouse CVCL_PR09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351320; Trp53bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21092934 CVCL_Q309 HG01573 transformed cell line human CVCL_Q309 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092935 CVCL_GX86 HG04187 transformed cell line human CVCL_GX86 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092936 CVCL_H987 AG08318 finite cell line CVCL_H987 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle. Female Group: Non-human primate cell line 21092937 CVCL_GX87 HG04193 transformed cell line human CVCL_GX87 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092938 CVCL_H980 AG08113 finite cell line pig CVCL_H980 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Duroc. Female 21092939 CVCL_GX80 HG04151 transformed cell line human CVCL_GX80 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092940 CVCL_H981 AG08114 finite cell line pig CVCL_H981 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Duroc. Female 21092941 CVCL_GX81 HG04157 transformed cell line human CVCL_GX81 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092942 CVCL_H982 AG08130 finite cell line CVCL_H982 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21092943 CVCL_GX82 HG04160 transformed cell line human CVCL_GX82 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092944 CVCL_H983 AG08131 finite cell line CVCL_H983 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21092945 CVCL_GX83 HG04175 transformed cell line human CVCL_GX83 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092946 CVCL_H959 GM00090 finite cell line human CVCL_H959 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CNV analysis Male 21092947 CVCL_GX59 HG03876 transformed cell line human CVCL_GX59 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092948 CVCL_H955 GM00073 finite cell line human CVCL_H955 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;14)(q13;q32) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21092949 CVCL_GX55 HG03831 transformed cell line human CVCL_GX55 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092950 CVCL_H956 GM10073 transformed cell line human CVCL_H956 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21092951 CVCL_GX56 HG03834 transformed cell line human CVCL_GX56 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092952 CVCL_H957 GM00074 finite cell line human CVCL_H957 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21092953 CVCL_GX57 HG03835 transformed cell line human CVCL_GX57 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092954 CVCL_H958 GM10074 transformed cell line human CVCL_H958 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21092955 CVCL_GX58 HG03840 transformed cell line human CVCL_GX58 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092956 CVCL_H951 GM00083 finite cell line human CVCL_H951 CL:0000010 Population: Caucasian; Derived from sampling site: Gonad Cell type=Fibroblast.. Ambiguous 21092957 CVCL_GX51 HG03813 transformed cell line human CVCL_GX51 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092958 CVCL_H952 GM00048 finite cell line human CVCL_H952 CL:0000010 Population: Caucasian; Derived from sampling site: Gonad Cell type=Fibroblast.. Ambiguous 21092959 CVCL_GX52 HG03816 transformed cell line human CVCL_GX52 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092960 CVCL_H953 GM00044 finite cell line human CVCL_H953 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(7)(7qter->7p21.2::10q11.21->10qter),der(10)(10pter->10q11.21::7p22.1->7pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21092961 CVCL_GX53 HG03822 transformed cell line human CVCL_GX53 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092962 CVCL_H954 GM00633 transformed cell line human CVCL_H954 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21092963 CVCL_GX54 HG03825 transformed cell line human CVCL_GX54 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092964 CVCL_H950 GM00085 finite cell line human CVCL_H950 CL:0000010 Population: African American; Karyotypic information: 46,XY,t(13;13)(13qter->13q10::13q10->13qter),+13 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21092965 CVCL_GX50 HG03807 transformed cell line human CVCL_GX50 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092966 CVCL_H966 GM01246 transformed cell line human CVCL_H966 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21092967 CVCL_GX66 HG03927 transformed cell line human CVCL_GX66 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092968 CVCL_H967 GM01219 finite cell line human CVCL_H967 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21092969 CVCL_GX67 HG03930 transformed cell line human CVCL_GX67 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092970 CVCL_H968 GM01247 transformed cell line human CVCL_H968 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21092971 CVCL_GX68 HG03939 transformed cell line human CVCL_GX68 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092972 CVCL_H969 GM01237 finite cell line human CVCL_H969 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21092973 CVCL_GX69 HG03942 transformed cell line human CVCL_GX69 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092974 CVCL_H962 GM02899 finite cell line human CVCL_H962 CL:0000010 Population: Caucasian; Finnish; Karyotypic information: 46,X,t(X;3)(Xpter->Xq28::3q21->3qter;3pter->3q21::Xq28->Xqter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21092975 CVCL_GX62 HG03906 transformed cell line human CVCL_GX62 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092976 CVCL_H963 GM00220 finite cell line human CVCL_H963 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092977 CVCL_GX63 HG03909 transformed cell line human CVCL_GX63 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092978 CVCL_H964 GM01057 finite cell line human CVCL_H964 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21092979 CVCL_GX64 HG03915 transformed cell line human CVCL_GX64 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092980 CVCL_H965 GM01245 transformed cell line human CVCL_H965 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21092981 CVCL_GX65 HG03924 transformed cell line human CVCL_GX65 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092982 CVCL_H960 GM00304 finite cell line human CVCL_H960 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00091; true Male 21092983 CVCL_GX60 HG03879 transformed cell line human CVCL_GX60 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092984 CVCL_H961 GM00194 finite cell line human CVCL_H961 CL:0000010 Population: Caucasian; Finnish; Karyotypic information: 46,X,t(X;3)(q28;q21) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21092985 CVCL_GX61 HG03903 transformed cell line human CVCL_GX61 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092986 CVCL_H937 ES[MC1R(20):tetTgm2(14)] embryonic stem cell house mouse CVCL_H937 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092987 CVCL_GX37 HG03704 transformed cell line human CVCL_GX37 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092988 CVCL_H938 ES[MC1R(20):tetTrpv2(9)] embryonic stem cell house mouse CVCL_H938 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092989 CVCL_GX38 HG03707 transformed cell line human CVCL_GX38 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092990 CVCL_H939 ES[MC1R(20):tetUgp2(20)] embryonic stem cell house mouse CVCL_H939 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092991 CVCL_GX39 HG03710 transformed cell line human CVCL_GX39 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092992 CVCL_H933 ES[MC1R(20):tetTcfap2c(18)] embryonic stem cell house mouse CVCL_H933 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092993 CVCL_GX33 HG03669 transformed cell line human CVCL_GX33 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092994 CVCL_H934 ES[MC1R(20):tetTcfcp2l1(6)] embryonic stem cell house mouse CVCL_H934 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092995 CVCL_GX34 HG03683 transformed cell line human CVCL_GX34 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092996 CVCL_H935 ES[MC1R(20):tetTcl1(6)] embryonic stem cell house mouse CVCL_H935 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092997 CVCL_GX35 HG03688 transformed cell line human CVCL_GX35 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21092998 CVCL_H936 ES[MC1R(20):tetTgif1(8)] embryonic stem cell house mouse CVCL_H936 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21092999 CVCL_GX36 HG03701 transformed cell line human CVCL_GX36 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093000 CVCL_H930 ES[MC1R(20):tetSub1(12)] embryonic stem cell house mouse CVCL_H930 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093001 CVCL_GX30 HG03651 transformed cell line human CVCL_GX30 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093002 CVCL_H931 ES[MC1R(20):tetTbx3(15)] embryonic stem cell house mouse CVCL_H931 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093003 CVCL_GX31 HG03654 transformed cell line human CVCL_GX31 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093004 CVCL_H932 ES[MC1R(20):tetTbx5(2)] embryonic stem cell house mouse CVCL_H932 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093005 CVCL_GX32 HG03657 transformed cell line human CVCL_GX32 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093006 CVCL_GX48 HG03801 transformed cell line human CVCL_GX48 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093007 CVCL_H948 LLTC cancer cell line house mouse CVCL_H948 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90239; Tiazofurine; Derived from sampling site: Lung; Breed/subspecies: C57BL/6. 21093008 CVCL_GX49 HG03804 transformed cell line human CVCL_GX49 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093009 CVCL_H949 LLAK cancer cell line house mouse CVCL_H949 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. 21093010 CVCL_H944 D14 cancer cell line human CVCL_H944 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21093011 CVCL_GX44 HG03769 transformed cell line human CVCL_GX44 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093012 CVCL_H945 D10 cancer cell line human CVCL_H945 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21093013 CVCL_GX45 HG03783 transformed cell line human CVCL_GX45 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093014 CVCL_H946 D11 cancer cell line human CVCL_H946 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21093015 CVCL_GX46 HG03795 transformed cell line human CVCL_GX46 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093016 CVCL_GX47 HG03798 transformed cell line human CVCL_GX47 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093017 CVCL_H947 SIHN-006 cancer cell line human CVCL_H947 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 35.1 +- 1.7 hours (PubMed=11497283) 21093018 CVCL_H940 ES[MC1R(20):tetZfp57(22)] embryonic stem cell house mouse CVCL_H940 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093019 CVCL_GX40 HG03719 transformed cell line human CVCL_GX40 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093020 CVCL_H941 ES[MC1R(20):tetZic1(6)] embryonic stem cell house mouse CVCL_H941 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093021 CVCL_GX41 HG03732 transformed cell line human CVCL_GX41 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093022 CVCL_H942 ES[MC1R(20):tetZmat4(15)] embryonic stem cell house mouse CVCL_H942 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093023 CVCL_GX42 HG03763 transformed cell line human CVCL_GX42 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093024 CVCL_H943 D17 cancer cell line human CVCL_H943 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21093025 CVCL_GX43 HG03766 transformed cell line human CVCL_GX43 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093026 CVCL_H919 ES[MC1R(20):tetPrickle1(11)] embryonic stem cell house mouse CVCL_H919 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093027 CVCL_GX19 HG03590 transformed cell line human CVCL_GX19 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093028 CVCL_H915 ES[MC1R(20):tetNupr1(17)] embryonic stem cell house mouse CVCL_H915 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093029 CVCL_GX15 HG03576 transformed cell line human CVCL_GX15 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093030 CVCL_H916 ES[MC1R(20):tetOstf1(15)] embryonic stem cell house mouse CVCL_H916 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093031 CVCL_GX16 HG03579 transformed cell line human CVCL_GX16 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093032 CVCL_H917 ES[MC1R(20):tetOtx1(6)] embryonic stem cell house mouse CVCL_H917 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093033 CVCL_GX17 HG03584 transformed cell line human CVCL_GX17 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093034 CVCL_H918 ES[MC1R(20):tetPdlim1(15)] embryonic stem cell house mouse CVCL_H918 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093035 CVCL_GX18 HG03587 transformed cell line human CVCL_GX18 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093036 CVCL_H911 ES[MC1R(20):tetMkrn1(15)] embryonic stem cell house mouse CVCL_H911 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093037 CVCL_GX11 HG03519 transformed cell line human CVCL_GX11 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093038 CVCL_H912 ES[MC1R(20):tetNkx2-5(12)] embryonic stem cell house mouse CVCL_H912 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093039 CVCL_GX12 HG03522 transformed cell line human CVCL_GX12 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093040 CVCL_H913 ES[MC1R(20):tetNr2f1(14)] embryonic stem cell house mouse CVCL_H913 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093041 CVCL_GX13 HG03540 transformed cell line human CVCL_GX13 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093042 CVCL_H914 ES[MC1R(20):tetNsbp1(6)] embryonic stem cell house mouse CVCL_H914 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093043 CVCL_GX14 HG03564 transformed cell line human CVCL_GX14 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093044 CVCL_H910 ES[MC1R(20):tetMettl5(15)] embryonic stem cell house mouse CVCL_H910 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093045 CVCL_GX10 HG03516 transformed cell line human CVCL_GX10 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093046 CVCL_H926 ES[MC1R(20):tetSox11(2)] embryonic stem cell house mouse CVCL_H926 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093047 CVCL_GX26 HG03626 transformed cell line human CVCL_GX26 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093048 CVCL_H927 ES[MC1R(20):tetSox15(10)] embryonic stem cell house mouse CVCL_H927 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093049 CVCL_GX27 HG03635 transformed cell line human CVCL_GX27 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093050 CVCL_H928 ES[MC1R(20):tetSox7(32)] embryonic stem cell house mouse CVCL_H928 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093051 CVCL_GX28 HG03638 transformed cell line human CVCL_GX28 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093052 CVCL_H929 ES[MC1R(20):tetStra13(12)] embryonic stem cell house mouse CVCL_H929 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093053 CVCL_GX29 HG03641 transformed cell line human CVCL_GX29 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093054 CVCL_H922 ES[MC1R(20):tetSfrs6(2)] embryonic stem cell house mouse CVCL_H922 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093055 CVCL_GX22 HG03602 transformed cell line human CVCL_GX22 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093056 CVCL_H923 ES[MC1R(20):tetSirt3(19)] embryonic stem cell house mouse CVCL_H923 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093057 CVCL_GX23 HG03605 transformed cell line human CVCL_GX23 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093058 CVCL_H924 ES[MC1R(20):tetSix1(15)] embryonic stem cell house mouse CVCL_H924 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093059 CVCL_GX24 HG03617 transformed cell line human CVCL_GX24 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093060 CVCL_H925 ES[MC1R(20):tetSmad6(9)] embryonic stem cell house mouse CVCL_H925 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093061 CVCL_GX25 HG03620 transformed cell line human CVCL_GX25 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093062 CVCL_H920 ES[MC1R(20):tetRest(19)] embryonic stem cell house mouse CVCL_H920 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093063 CVCL_GX20 HG03596 transformed cell line human CVCL_GX20 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093064 CVCL_H921 ES[MC1R(20):tetSap30(12)] embryonic stem cell house mouse CVCL_H921 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: Transcriptome analysis by microarray Male 21093065 CVCL_GX21 HG03599 transformed cell line human CVCL_GX21 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093066 CVCL_6G00 ZF13 spontaneously immortalized cell line zebrafish CVCL_6G00 CL:0000010 Unspecified Group: Fish cell line. 21093067 CVCL_6G01 ZF29 spontaneously immortalized cell line zebrafish CVCL_6G01 CL:0000010 Unspecified Group: Fish cell line. 21093068 CVCL_6G02 BTF22 finite cell line CVCL_6G02 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Doubling time: ~28 hours (PubMed=20687455) Group: Endangered species/breed cell line 21093069 CVCL_6G03 SPA255-22 transformed cell line human CVCL_6G03 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093070 CVCL_6G08 SPA255-27 transformed cell line human CVCL_6G08 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093071 CVCL_6G09 SPA255-28 transformed cell line human CVCL_6G09 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093072 CVCL_6G04 SPA255-23 transformed cell line human CVCL_6G04 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093073 CVCL_6G05 SPA255-24 transformed cell line human CVCL_6G05 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093074 CVCL_6G06 SPA255-25 transformed cell line human CVCL_6G06 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093075 CVCL_6G07 SPA255-26 transformed cell line human CVCL_6G07 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21093076 CVCL_6G11 HP-A2 conditionally immortalized cell line human CVCL_6G11 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Unspecified 21093077 CVCL_6G12 HP-W transformed cell line human CVCL_6G12 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Placenta. Unspecified 21093078 CVCL_6G13 SV40 OFPAE transformed cell line CVCL_6G13 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta; arterial endothelium Cell type=Endothelial cell.. Unspecified 21093079 CVCL_6G14 HOFPAEC transformed cell line CVCL_6G14 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the transformation method, the species of origin and the primary cell type name Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal lung; artery; endothelium. Unspecified 21093080 CVCL_6G10 HP-A1 conditionally immortalized cell line human CVCL_6G10 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Unspecified 21093081 CVCL_6G19 ETCC006 telomerase immortalized cell line human CVCL_6G19 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Singaporian; Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Doubling time: 19.2 hours (PubMed=25264427); 30.7 hours (PubMed=34238275); ~2-4 days (DSMZ=ACC-790) 21093082 CVCL_6G15 ASE [Salmo] spontaneously immortalized cell line CVCL_6G15 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Group: Fish cell line 21093083 CVCL_6G16 IOWA-1T cancer cell line human CVCL_6G16 CL:0000010 Female Characteristics: Derived from IOWA-1 (a xenograft) after a single passage in nude mice. 21093084 CVCL_6G17 BS-SHI-4 transformed cell line human CVCL_6G17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Could be identical to EBV-BS4-1 (Cellosaurus=CVCL_WX65) 21093085 CVCL_6G18 ETCC001 finite cell line human CVCL_6G18 CL:0000010 Population: Chinese; Singaporian; Derived from sampling site: Breast. Female Doubling time: 18.4 hours (PubMed=25264427) 21093086 CVCL_PS93 BayGenomics ES cell line XG123 embryonic stem cell house mouse CVCL_PS93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093087 CVCL_Q493 HG01893 transformed cell line human CVCL_Q493 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093088 CVCL_PS94 BayGenomics ES cell line XG125 embryonic stem cell house mouse CVCL_PS94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093089 CVCL_Q494 HG01894 transformed cell line human CVCL_Q494 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093090 CVCL_PS95 BayGenomics ES cell line XG126 embryonic stem cell house mouse CVCL_PS95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349409; Cops3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093091 CVCL_Q495 HG01895 transformed cell line human CVCL_Q495 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093092 CVCL_PS96 BayGenomics ES cell line XG127 embryonic stem cell house mouse CVCL_PS96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093093 CVCL_Q496 HG01896 transformed cell line human CVCL_Q496 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093094 CVCL_PS97 BayGenomics ES cell line XG128 embryonic stem cell house mouse CVCL_PS97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918722; Usp19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093095 CVCL_Q497 HG01897 transformed cell line human CVCL_Q497 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093096 CVCL_PS98 BayGenomics ES cell line XG129 embryonic stem cell house mouse CVCL_PS98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913482; Znrd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093097 CVCL_Q498 HG01898 transformed cell line human CVCL_Q498 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093098 CVCL_PS99 BayGenomics ES cell line XG130 embryonic stem cell house mouse CVCL_PS99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093099 CVCL_Q499 HG01912 transformed cell line human CVCL_Q499 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093100 CVCL_PS82 BayGenomics ES cell line XG100 embryonic stem cell house mouse CVCL_PS82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093101 CVCL_Q482 HG01882 transformed cell line human CVCL_Q482 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093102 CVCL_PS83 BayGenomics ES cell line XG103 embryonic stem cell house mouse CVCL_PS83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093103 CVCL_Q483 HG01883 transformed cell line human CVCL_Q483 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093104 CVCL_PS84 BayGenomics ES cell line XG105 embryonic stem cell house mouse CVCL_PS84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100494; Ercc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093105 CVCL_Q484 HG01884 transformed cell line human CVCL_Q484 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093106 CVCL_PS85 BayGenomics ES cell line XG106 embryonic stem cell house mouse CVCL_PS85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093107 CVCL_Q485 HG01885 transformed cell line human CVCL_Q485 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093108 CVCL_PS86 BayGenomics ES cell line XG107 embryonic stem cell house mouse CVCL_PS86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093109 CVCL_Q486 HG01886 transformed cell line human CVCL_Q486 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093110 CVCL_PS87 BayGenomics ES cell line XG108 embryonic stem cell house mouse CVCL_PS87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093111 CVCL_Q487 HG01887 transformed cell line human CVCL_Q487 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093112 CVCL_PS88 BayGenomics ES cell line XG112 embryonic stem cell house mouse CVCL_PS88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917689; Taf15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093113 CVCL_Q488 HG01888 transformed cell line human CVCL_Q488 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093114 CVCL_PS89 BayGenomics ES cell line XG115 embryonic stem cell house mouse CVCL_PS89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1195458; Abce1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093115 CVCL_Q489 HG01889 transformed cell line human CVCL_Q489 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093116 CVCL_PS90 BayGenomics ES cell line XG116 embryonic stem cell house mouse CVCL_PS90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923257; Zmym2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093117 CVCL_Q490 HG01890 transformed cell line human CVCL_Q490 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093118 CVCL_PS91 BayGenomics ES cell line XG121 embryonic stem cell house mouse CVCL_PS91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093119 CVCL_Q491 HG01891 transformed cell line human CVCL_Q491 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093120 CVCL_PS92 BayGenomics ES cell line XG122 embryonic stem cell house mouse CVCL_PS92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261758; Suz12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093121 CVCL_Q492 HG01892 transformed cell line human CVCL_Q492 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093122 CVCL_PS71 BayGenomics ES cell line XG082 embryonic stem cell house mouse CVCL_PS71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98927; Vcl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093123 CVCL_Q471 HG01868 transformed cell line human CVCL_Q471 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093124 CVCL_PS72 BayGenomics ES cell line XG084 embryonic stem cell house mouse CVCL_PS72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093125 CVCL_Q472 HG01869 transformed cell line human CVCL_Q472 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093126 CVCL_PS73 BayGenomics ES cell line XG087 embryonic stem cell house mouse CVCL_PS73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093127 CVCL_Q473 HG01870 transformed cell line human CVCL_Q473 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093128 CVCL_PS74 BayGenomics ES cell line XG090 embryonic stem cell house mouse CVCL_PS74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093129 CVCL_Q474 HG01871 transformed cell line human CVCL_Q474 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093130 CVCL_PS75 BayGenomics ES cell line XG091 embryonic stem cell house mouse CVCL_PS75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093131 CVCL_Q475 HG01872 transformed cell line human CVCL_Q475 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093132 CVCL_PS76 BayGenomics ES cell line XG093 embryonic stem cell house mouse CVCL_PS76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093133 CVCL_Q476 HG01873 transformed cell line human CVCL_Q476 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093134 CVCL_PS77 BayGenomics ES cell line XG094 embryonic stem cell house mouse CVCL_PS77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093135 CVCL_Q477 HG01874 transformed cell line human CVCL_Q477 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093136 CVCL_PS78 BayGenomics ES cell line XG095 embryonic stem cell house mouse CVCL_PS78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093137 CVCL_Q478 HG01878 transformed cell line human CVCL_Q478 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093138 CVCL_PS79 BayGenomics ES cell line XG096 embryonic stem cell house mouse CVCL_PS79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682937; Zfp341 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093139 CVCL_Q479 HG01879 transformed cell line human CVCL_Q479 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093140 CVCL_PS80 BayGenomics ES cell line XG098 embryonic stem cell house mouse CVCL_PS80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915955; Gtf2f2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093141 CVCL_Q480 HG01880 transformed cell line human CVCL_Q480 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093142 CVCL_PS81 BayGenomics ES cell line XG099 embryonic stem cell house mouse CVCL_PS81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387179; Tut7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093143 CVCL_Q481 HG01881 transformed cell line human CVCL_Q481 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093144 CVCL_PS60 BayGenomics ES cell line XG068 embryonic stem cell house mouse CVCL_PS60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928488; Akap8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093145 CVCL_Q460 HG01857 transformed cell line human CVCL_Q460 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093146 CVCL_PS61 BayGenomics ES cell line XG069 embryonic stem cell house mouse CVCL_PS61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093147 CVCL_Q461 HG01858 transformed cell line human CVCL_Q461 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093148 CVCL_PS62 BayGenomics ES cell line XG070 embryonic stem cell house mouse CVCL_PS62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093149 CVCL_Q462 HG01859 transformed cell line human CVCL_Q462 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093150 CVCL_PS63 BayGenomics ES cell line XG071 embryonic stem cell house mouse CVCL_PS63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093151 CVCL_Q463 HG01860 transformed cell line human CVCL_Q463 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093152 CVCL_PS64 BayGenomics ES cell line XG072 embryonic stem cell house mouse CVCL_PS64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889364; Akirin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093153 CVCL_Q464 HG01861 transformed cell line human CVCL_Q464 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093154 CVCL_PS65 BayGenomics ES cell line XG073 embryonic stem cell house mouse CVCL_PS65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093155 CVCL_Q465 HG01862 transformed cell line human CVCL_Q465 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093156 CVCL_PS66 BayGenomics ES cell line XG075 embryonic stem cell house mouse CVCL_PS66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443812; Phf21b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093157 CVCL_Q466 HG01863 transformed cell line human CVCL_Q466 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093158 CVCL_PS67 BayGenomics ES cell line XG077 embryonic stem cell house mouse CVCL_PS67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093159 CVCL_Q467 HG01864 transformed cell line human CVCL_Q467 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093160 CVCL_PS68 BayGenomics ES cell line XG078 embryonic stem cell house mouse CVCL_PS68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917900; Zcchc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093161 CVCL_Q468 HG01865 transformed cell line human CVCL_Q468 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093162 CVCL_PS69 BayGenomics ES cell line XG079 embryonic stem cell house mouse CVCL_PS69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922670; Secisbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093163 CVCL_Q469 HG01866 transformed cell line human CVCL_Q469 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093164 CVCL_PS70 BayGenomics ES cell line XG080 embryonic stem cell house mouse CVCL_PS70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093165 CVCL_Q470 HG01867 transformed cell line human CVCL_Q470 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093166 CVCL_PS50 BayGenomics ES cell line XG055 embryonic stem cell house mouse CVCL_PS50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925771; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093167 CVCL_Q450 HG01845 transformed cell line human CVCL_Q450 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093168 CVCL_PS51 BayGenomics ES cell line XG056 embryonic stem cell house mouse CVCL_PS51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108086; Hdac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093169 CVCL_Q451 HG01846 transformed cell line human CVCL_Q451 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093170 CVCL_PS52 BayGenomics ES cell line XG057 embryonic stem cell house mouse CVCL_PS52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093171 CVCL_Q452 HG01847 transformed cell line human CVCL_Q452 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093172 CVCL_PS53 BayGenomics ES cell line XG058 embryonic stem cell house mouse CVCL_PS53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151114; Dgcr8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093173 CVCL_Q453 HG01848 transformed cell line human CVCL_Q453 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093174 CVCL_PS54 BayGenomics ES cell line XG059 embryonic stem cell house mouse CVCL_PS54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093175 CVCL_Q454 HG01849 transformed cell line human CVCL_Q454 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093176 CVCL_PS55 BayGenomics ES cell line XG060 embryonic stem cell house mouse CVCL_PS55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298375; Cabin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093177 CVCL_Q455 HG01850 transformed cell line human CVCL_Q455 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093178 CVCL_PS56 BayGenomics ES cell line XG061 embryonic stem cell house mouse CVCL_PS56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093179 CVCL_Q456 HG01851 transformed cell line human CVCL_Q456 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093180 CVCL_PS57 BayGenomics ES cell line XG063 embryonic stem cell house mouse CVCL_PS57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298398; Mcm7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093181 CVCL_Q457 HG01852 transformed cell line human CVCL_Q457 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093182 CVCL_PS58 BayGenomics ES cell line XG064 embryonic stem cell house mouse CVCL_PS58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448506; Pi4ka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093183 CVCL_Q458 HG01853 transformed cell line human CVCL_Q458 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093184 CVCL_PS59 BayGenomics ES cell line XG066 embryonic stem cell house mouse CVCL_PS59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093185 CVCL_Q459 HG01855 transformed cell line human CVCL_Q459 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093186 CVCL_PS40 BayGenomics ES cell line XG040 embryonic stem cell house mouse CVCL_PS40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344381; Dnajb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093187 CVCL_Q440 HG01812 transformed cell line human CVCL_Q440 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093188 CVCL_PS41 BayGenomics ES cell line XG042 embryonic stem cell house mouse CVCL_PS41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441773; Pcmtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093189 CVCL_Q441 HG01813 transformed cell line human CVCL_Q441 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093190 CVCL_PS42 BayGenomics ES cell line XG045 embryonic stem cell house mouse CVCL_PS42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95728; Gli2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093191 CVCL_Q442 HG01815 transformed cell line human CVCL_Q442 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093192 CVCL_PS43 BayGenomics ES cell line XG046 embryonic stem cell house mouse CVCL_PS43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922083; Ciapin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093193 CVCL_Q443 HG01816 transformed cell line human CVCL_Q443 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093194 CVCL_PS44 BayGenomics ES cell line XG047 embryonic stem cell house mouse CVCL_PS44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093195 CVCL_Q444 HG01817 transformed cell line human CVCL_Q444 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093196 CVCL_PS45 BayGenomics ES cell line XG048 embryonic stem cell house mouse CVCL_PS45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108086; Hdac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093197 CVCL_Q445 HG01840 transformed cell line human CVCL_Q445 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093198 CVCL_PS46 BayGenomics ES cell line XG049 embryonic stem cell house mouse CVCL_PS46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3505790; Fcho2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093199 CVCL_Q446 HG01841 transformed cell line human CVCL_Q446 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093200 CVCL_PS47 BayGenomics ES cell line XG051 embryonic stem cell house mouse CVCL_PS47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093201 CVCL_Q447 HG01842 transformed cell line human CVCL_Q447 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093202 CVCL_PS48 BayGenomics ES cell line XG052 embryonic stem cell house mouse CVCL_PS48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106264; Trim36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093203 CVCL_Q448 HG01843 transformed cell line human CVCL_Q448 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093204 CVCL_PS49 BayGenomics ES cell line XG054 embryonic stem cell house mouse CVCL_PS49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353561; Vapa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093205 CVCL_Q449 HG01844 transformed cell line human CVCL_Q449 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093206 CVCL_6G88 AG06086 finite cell line human CVCL_6G88 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093207 CVCL_6G89 AG06961 finite cell line human CVCL_6G89 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21093208 CVCL_6G84 AG06064 finite cell line human CVCL_6G84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093209 CVCL_6G85 AG06083 finite cell line human CVCL_6G85 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093210 CVCL_6G86 AG06084 finite cell line human CVCL_6G86 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093211 CVCL_6G87 AG06085 finite cell line human CVCL_6G87 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093212 CVCL_6G80 GM18366 finite cell line human CVCL_6G80 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly674Gly (c.2022A>G) (2101A>G); ClinVar=VCV000008307; Zygosity=Homozygous; Note=Silent mutation that causes increased levels of skipping exon 9 and activation of two cryptic splicing events from sites in exon 9 leading to termination in exon 10 (PubMed=12640452) Population: Pakistani; Derived from sampling site: Cell type=Fibroblast. Omics: Deep quantitative phosphoproteome analysis Male 21093213 CVCL_6G81 GM18367 transformed cell line human CVCL_6G81 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly674Gly (c.2022A>G) (2101A>G); ClinVar=VCV000008307; Zygosity=Homozygous; Note=Silent mutation that causes increased levels of skipping exon 9 and activation of two cryptic splicing events from sites in exon 9 leading to termination in exon 10 (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM18367; probable Male Caution: Could be identical to DK0064 (Cellosaurus=CVCL_R778) 21093214 CVCL_6G82 ID00017 transformed cell line human CVCL_6G82 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg156His (c.467G>A); ClinVar=VCV000001984; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21093215 CVCL_6G83 AG06063 finite cell line human CVCL_6G83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093216 CVCL_6G99 GM12324 transformed cell line human CVCL_6G99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093217 CVCL_6G95 GM09922 finite cell line human CVCL_6G95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21093218 CVCL_6G96 GM09946 transformed cell line human CVCL_6G96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093219 CVCL_6G97 GM10722 finite cell line human CVCL_6G97 CL:0000010 Karyotypic information: 46,XY,del(4)(qter->p15.2) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21093220 CVCL_6G98 GM12160 finite cell line human CVCL_6G98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)(qter->p15.1) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21093221 CVCL_6G91 GM08092 finite cell line human CVCL_6G91 CL:0000010 Population: Cuban; Derived from sampling site: Cell type=Fibroblast. Female 21093222 CVCL_6G92 GM08145 transformed cell line human CVCL_6G92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093223 CVCL_6G93 GM08148 finite cell line human CVCL_6G93 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21093224 CVCL_6G94 GM09562 transformed cell line human CVCL_6G94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093225 CVCL_6G90 GM07267 finite cell line human CVCL_6G90 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(4)(pter->q31.3) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21093226 CVCL_6G66 E487 transformed cell line human CVCL_6G66 HLA typing: A*03:01:01,30:01; B*44:27,13:02 (IPD-IMGT/HLA=12602) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093227 CVCL_6G67 GN00350 transformed cell line human CVCL_6G67 HLA typing: A*24,26; B*44:02:02,55:01; DRB1*15/16,13 (IPD-IMGT/HLA=12148) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21093228 CVCL_6G68 H156H2 transformed cell line human CVCL_6G68 HLA typing: B*27,37:04; DRB1*15/16,11; DRB3*02; DRB5*01 (IPD-IMGT/HLA=12649) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21093229 CVCL_6G69 HC030101,F.G. transformed cell line human CVCL_6G69 HLA typing: A*36:03,68:02; B*42:01,53:01; C*04:01,17; DPB1*01:01; DQA1*04:01; DQB1*04:02; DRB1*03:02; DRB3*01:01 (IPD-IMGT/HLA=12648) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093230 CVCL_6G62 10063349 transformed cell line human CVCL_6G62 HLA typing: A*03:MT,68:01:01; B*07:BD,40:JV; DQB1*06:04,03:BG; DRB1*04:04,13:02 (IPD-IMGT/HLA=12650) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21093231 CVCL_6G63 FHKW transformed cell line human CVCL_6G63 HLA typing: A*02:01,02:05; B*39:25N,50:01; C*06:02,12:03; DRB1*04:01,11:01 (IPD-IMGT/HLA=12644); HLA typing: A*02:01:01:01,02:05:01; B*39:25N,50:01:01; C*06:02:01:02,12:03:01:01; DPA1*01:03:01:03,01:03:01:02; DPB1*03:01:01(124:01),04:01:01:01(350:01); DQA1*03:03:01:01,05:05:01; DQB1*03:01:01:01,03:01:01:03; DRB1*04:01:01,11:01:01:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21093232 CVCL_6G64 BHCP transformed cell line human CVCL_6G64 HLA typing: A*02,11; B*51:01:01,15:69; C*02:BC,12:CF; DQB1*06:02,04:02; DRB1*15:01,08:04; DRB5*01 (IPD-IMGT/HLA=12645) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093233 CVCL_6G65 BUMC-40v transformed cell line human CVCL_6G65 HLA typing: A*01,03; B*07,40:39; C*07; DQB1*03:01,06:02; DRB1*12:01,15:01; DRB3*02:02; DRB5*01/02 (IPD-IMGT/HLA=12646) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21093234 CVCL_6G60 HOK-16B-MSEE transformed cell line human CVCL_6G60 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21093235 CVCL_6G61 07-S-0025#0100 transformed cell line human CVCL_6G61 HLA typing: A*02,24:32; B*38:01,58:01; DQB1*04:02,06:09; DRB1*13,08:01 (IPD-IMGT/HLA=12636) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093236 CVCL_6G77 HPLA-A3 cancer cell line human CVCL_6G77 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Male 21093237 CVCL_6G78 GM09703 transformed cell line human CVCL_6G78 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093238 CVCL_6G79 GM09812 finite cell line human CVCL_6G79 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21093239 CVCL_6G73 VTIS45561 transformed cell line human CVCL_6G73 HLA typing: B*07:02:01,56:07 (IPD-IMGT/HLA=12638) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21093240 CVCL_6G74 VTIS46155 transformed cell line human CVCL_6G74 HLA typing: A*31:01; B*15:07,39:03; C*01:02,07:02; DRB1*04 (IPD-IMGT/HLA=12643) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21093241 CVCL_6G75 IA1-7 spontaneously immortalized cell line CVCL_6G75 CL:0000010 Transfected with: HGNC; 2438; CSF3 Derived from sampling site: Ovary. Female 21093242 CVCL_6G76 BEVA-FBS cancer cell line human CVCL_6G76 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Adapted to growth in FBS Doubling time: ~96 hours (PubMed=9293903) 21093243 CVCL_6G70 T110 [Human B-cell IHW] transformed cell line human CVCL_6G70 HLA typing: A*01:09,23:01; B*44:15,81:01; C*04:07,18:AB (IPD-IMGT/HLA=12647) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093244 CVCL_6G71 VTIS39243 transformed cell line human CVCL_6G71 HLA typing: B*07:02:01,40:38; DRB1*04:04,15:01:01 (IPD-IMGT/HLA=12637) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21093245 CVCL_6G72 VTIS43878 transformed cell line human CVCL_6G72 HLA typing: A*32:01,68:BG; B*35:19,40:01:01/40:01:02; C*03,08; DRB1*04 (IPD-IMGT/HLA=12642) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21093246 CVCL_6G44 MELBA cancer cell line human CVCL_6G44 CL:0000010 Derived from metastatic site: Urinary bladder. Male Doubling time: 28 hours (PubMed=3761468) 21093247 CVCL_6G45 BLCA-8 hybridoma house mouse CVCL_6G45 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10406 21093248 CVCL_6G46 BLCA-30 hybridoma house mouse CVCL_6G46 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11784 21093249 CVCL_6G47 BLCA-38 hybridoma house mouse CVCL_6G47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35052; Human GPC1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11785 21093250 CVCL_6G40 SW1318 cancer cell line human CVCL_6G40 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from metastatic site: Brain. Male 21093251 CVCL_6G41 SW1370 cancer cell line human CVCL_6G41 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21093252 CVCL_6G42 6005 cancer cell line human CVCL_6G42 CL:0000010 21093253 CVCL_6G43 A1 [Human leukemia] cancer cell line human CVCL_6G43 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=1531243) 21093254 CVCL_6G48 PHEC1 transformed cell line human CVCL_6G48 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified Doubling time: 24 hours (PubMed=8835314) 21093255 CVCL_6G49 PE-1 [Pig] transformed cell line pig CVCL_6G49 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Doubling time: ~48 hours (PubMed=1280756) 21093256 CVCL_6G55 GEM-81 clone P15 cancer cell line CVCL_6G55 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Wakin. Unspecified Group: Fish cell line 21093257 CVCL_6G56 GEM-81 clone P15D cancer cell line CVCL_6G56 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Wakin. Unspecified Group: Fish cell line 21093258 CVCL_6G57 GEM-81 clone P15DI cancer cell line CVCL_6G57 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Wakin. Unspecified Group: Fish cell line 21093259 CVCL_6G58 HOK-16A-BaP transformed cell line human CVCL_6G58 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21093260 CVCL_6G51 GGD transformed cell line house mouse CVCL_6G51 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Embryonic liver; Breed/subspecies: C57BL/6-Ly-5a. Unspecified 21093261 CVCL_6G52 OC10B spontaneously immortalized cell line house mouse CVCL_6G52 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Bone marrow; stroma. Male 21093262 CVCL_6G53 Ro cl 3-1 factor-dependent cell line house mouse CVCL_6G53 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CD-1. Characteristics: IL3 dependent 21093263 CVCL_6G54 32Dcl23 factor-dependent cell line house mouse CVCL_6G54 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent 21093264 CVCL_6G59 HOK-16A-MSEE transformed cell line human CVCL_6G59 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21093265 CVCL_6G50 DA-1ER cancer cell line house mouse CVCL_6G50 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: BALB/c. Characteristics: CSF2, EPO and IL3 dependent 21093266 CVCL_6G22 ETCC010 telomerase immortalized cell line human CVCL_6G22 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Singaporian; Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Doubling time: 19.8 hours (PubMed=25264427); 29.7 hours (PubMed=34238275); ~30 hours (DSMZ=ACC-793) 21093267 CVCL_6G23 ETCC011 telomerase immortalized cell line human CVCL_6G23 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Singaporian; Derived from sampling site: Breast. Female Doubling time: 12.8 hours (PubMed=25264427); ~2-4 days (DSMZ=ACC-797) 21093268 CVCL_6G24 BLN-3 cancer cell line human CVCL_6G24 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. Female Doubling time: ~2-4 days (DSMZ=ACC-787) 21093269 CVCL_6G25 BLN-7 cancer cell line human CVCL_6G25 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28148826) Omics: Transcriptome analysis by RNAseq. Female Doubling time: ~3-5 days (DSMZ=ACC-789) 21093270 CVCL_6G20 ETCC007 telomerase immortalized cell line human CVCL_6G20 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Singaporian; Derived from sampling site: Breast. Female Doubling time: 21.7 hours (PubMed=25264427); ~40 hours (DSMZ=ACC-791) 21093271 CVCL_6G21 ETCC008 telomerase immortalized cell line human CVCL_6G21 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Singaporian; Derived from sampling site: Breast. Female Doubling time: 9.4 hours (PubMed=25264427); ~24 hours (DSMZ=ACC-792) 21093272 CVCL_6G26 MSF32 finite cell line CVCL_6G26 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Inner Mongolian. Female Doubling time: ~28.2 hours (PubMed=21729198) Group: Endangered species/breed cell line 21093273 CVCL_6G27 AY31 cancer cell line Norway rat CVCL_6G27 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male 21093274 CVCL_6G28 AY-11 cancer cell line Norway rat CVCL_6G28 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male 21093275 CVCL_6G29 Fang-8 cancer cell line human CVCL_6G29 CL:0000010 Anecdotal: Cell line name is derived from the name of the researcher that derived this cell line Population: African American; Derived from metastatic site: Intra-abdominal. Male Doubling time: ~24 hours (PubMed=265551) 21093276 CVCL_6G33 P-SC(1) spontaneously immortalized cell line pig CVCL_6G33 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Characteristics: Secretes a whole monomeric IgA and a mu chain (PubMed=3879567) 21093277 CVCL_6G34 253J-Lung-IV cancer cell line human CVCL_6G34 CL:0000010 Population: Caucasian; Derived from metastatic site: Retroperitoneal lymph node. Male Doubling time: 41 +- 4 hours (PubMed=7658585) 21093278 CVCL_6G35 1016T cancer cell line human CVCL_6G35 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified Doubling time: 44 hours (PubMed=748774) 21093279 CVCL_6G36 GKA cancer cell line human CVCL_6G36 CL:0000010 Female Doubling time: 48-72 hours (PubMed=6825111). 21093280 CVCL_6G30 292W cancer cell line human CVCL_6G30 CL:0000010 Derived from sampling site: Kidney; renal pelvis. Unspecified 21093281 CVCL_6G31 A4 [Pig peripheral blood] spontaneously immortalized cell line pig CVCL_6G31 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Duroc. Unspecified 21093282 CVCL_6G32 P-16(2) spontaneously immortalized cell line pig CVCL_6G32 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Characteristics: Secretes a whole monomeric IgA and a mu chain (PubMed=3879567) 21093283 CVCL_6G37 DU5873 cancer cell line human CVCL_6G37 CL:0000010 Unspecified 21093284 CVCL_6G38 1072F cancer cell line human CVCL_6G38 CL:0000010 Derived from metastatic site: Bone. Unspecified 21093285 CVCL_6G39 CCRF-6 cancer cell line human CVCL_6G39 CL:0000010 21093286 CVCL_GY18 GM01781 transformed cell line human CVCL_GY18 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr67Ile (c.200C>T); ClinVar=VCV000002939; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Gln240Glu (c.718C>G); ClinVar=VCV000002940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093287 CVCL_GY19 GM03851 transformed cell line human CVCL_GY19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093288 CVCL_GY14 UCDK9B5 cancer cell line human CVCL_GY14 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Samples were supplied to ICLAC for STR profiling by Kent M (UCSD) and tested by Hall E. (Genetica DNA laboratories). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00544 Problematic cell line: Contaminated Shown to be a Jurkat derivative (DOI=10.1016/j.leukres.2012.09.007, ICLAC). Originally thought to be of dog origin and to originate from a lymphoma from a male Greyhound. 21093289 CVCL_GY15 GM01368 finite cell line human CVCL_GY15 CL:0000010 Sequence variation: Gene deletion; HGNC; 4827; HBB; Zygosity=Homozygous (Coriell); Sequence variation: Gene deletion; HGNC; 4829; HBD; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21093290 CVCL_GY16 GM01454 transformed cell line human CVCL_GY16 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Leu262Thrfs*21 (c.784_785delCT) (940_941delCT); dbSNP=rs748374528; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093291 CVCL_GY17 GM01566 transformed cell line human CVCL_GY17 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr67Ile (c.200C>T); ClinVar=VCV000002939; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr355Ilefs (c.1220delC); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093292 CVCL_GY10 UCDK9B1 cancer cell line human CVCL_GY10 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Samples were supplied to ICLAC for STR profiling by Kent M (UCSD) and tested by Hall E. (Genetica DNA laboratories). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00540 Problematic cell line: Contaminated Shown to be a Jurkat derivative (DOI=10.1016/j.leukres.2012.09.007, ICLAC). Originally thought to be of dog origin and to originate from a female Bullmastiff with a lymphoma. 21093293 CVCL_GY11 UCDK9B2 cancer cell line human CVCL_GY11 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Samples were supplied to ICLAC for STR profiling by Kent M (UCSD) and tested by Hall E. (Genetica DNA laboratories). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00541 Problematic cell line: Contaminated Shown to be a Jurkat derivative (DOI=10.1016/j.leukres.2012.09.007, ICLAC). Originally thought to be of dog origin and to originate from a male German Shorthaired Pointer with a lymphoma. 21093294 CVCL_GY12 UCDK9B3 cancer cell line human CVCL_GY12 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Samples were supplied to ICLAC for STR profiling by Kent M (UCSD) and tested by Hall E. (Genetica DNA laboratories). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00542 Problematic cell line: Contaminated Shown to be a Jurkat derivative (DOI=10.1016/j.leukres.2012.09.007, ICLAC). Originally thought to be of dog origin and to originate from a lymphoma from a male Labrador Retriever. 21093295 CVCL_GY13 UCDK9B4 cancer cell line human CVCL_GY13 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Samples were supplied to ICLAC for STR profiling by Kent M (UCSD) and tested by Hall E. (Genetica DNA laboratories). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00543 Problematic cell line: Contaminated Shown to be a Jurkat derivative (DOI=10.1016/j.leukres.2012.09.007, ICLAC). Originally thought to be of dog origin and to originate from a lymphoma from a male Basset Hound. 21093296 CVCL_GY29 GM17494 finite cell line human CVCL_GY29 CL:0000010 Sequence variation: Mutation; HGNC; 5320; HYAL1; Simple; p.Val251Phefs*20 (c.751_787delinsTTCCGTGTGGCCCG) (1361del37ins14); ClinVar=VCV000003531; Zygosity=Heterozygous (PubMed=10339581); Sequence variation: Mutation; HGNC; 5320; HYAL1; Simple; p.Glu268Lys (c.802G>A); ClinVar=VCV000003530; Zygosity=Heterozygous (PubMed=10339581) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093297 CVCL_GY25 GM04598 finite cell line human CVCL_GY25 CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093298 CVCL_GY26 GM05300 finite cell line human CVCL_GY26 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21093299 CVCL_GY27 GM05301 transformed cell line human CVCL_GY27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093300 CVCL_GY28 GM11328 finite cell line human CVCL_GY28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21093301 CVCL_GY21 GM04594 finite cell line human CVCL_GY21 CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093302 CVCL_GY22 GM04595 finite cell line human CVCL_GY22 CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093303 CVCL_GY23 GM04596 finite cell line human CVCL_GY23 CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093304 CVCL_GY24 GM04597 finite cell line human CVCL_GY24 CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093305 CVCL_GY20 GM03852 finite cell line human CVCL_GY20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21093306 CVCL_GY07 LAZ-248 transformed cell line human CVCL_GY07 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093307 CVCL_GY08 LAZ-67 transformed cell line human CVCL_GY08 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21093308 CVCL_GY09 JT1 spontaneously immortalized cell line human CVCL_GY09 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 21093309 CVCL_GY03 T47D:C4:2 cancer cell line human CVCL_GY03 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21093310 CVCL_GY04 LAZ-388 transformed cell line human CVCL_GY04 HLA typing: A*01,24; B*22,35 (PubMed=2939141) From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21093311 CVCL_GY05 LAZ-166 transformed cell line human CVCL_GY05 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093312 CVCL_GY06 LAZ-187 transformed cell line human CVCL_GY06 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093313 CVCL_GY00 S3-1 spontaneously immortalized cell line African clawed frog CVCL_GY00 CL:0000010 Unspecified Group: Amphibian cell line. 21093314 CVCL_GY01 T47D:A18 cancer cell line human CVCL_GY01 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21093315 CVCL_GY02 T47D:C4 cancer cell line human CVCL_GY02 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21093316 CVCL_6F89 SHF-1 spontaneously immortalized cell line CVCL_6F89 CL:0000010 Derived from sampling site: Fin. Male Group: Fish cell line 21093317 CVCL_6F85 OLES1 embryonic stem cell CVCL_6F85 CL:0000010 Breed/subspecies: HNI. Unspecified Group: Fish cell line 21093318 CVCL_6F86 Omaka cells spontaneously immortalized cell line CVCL_6F86 CL:0000010 Unspecified Group: Fish cell line. 21093319 CVCL_6F87 SBK-2 spontaneously immortalized cell line CVCL_6F87 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21093320 CVCL_6F88 SGP spontaneously immortalized cell line CVCL_6F88 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21093321 CVCL_6F81 GSE spontaneously immortalized cell line CVCL_6F81 CL:0000010 Unspecified Group: Fish cell line. 21093322 CVCL_6F82 KRE-2 spontaneously immortalized cell line CVCL_6F82 CL:0000010 Breed/subspecies: Epinephelus moara x Epinephelus akaara hybrid. Unspecified Group: Fish cell line 21093323 CVCL_6F83 KRE-3 spontaneously immortalized cell line CVCL_6F83 CL:0000010 Breed/subspecies: Epinephelus moara x Epinephelus akaara hybrid. Unspecified Group: Fish cell line 21093324 CVCL_6F84 LEE-1 spontaneously immortalized cell line CVCL_6F84 CL:0000010 Derived from sampling site: Whole embryo. Omics: Transcriptome analysis by ESTs sequencing Unspecified Doubling time: ~10 days (PubMed=18407792) Group: Fish cell line 21093325 CVCL_6F80 GMCL spontaneously immortalized cell line CVCL_6F80 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21093326 CVCL_6F96 Ul-F spontaneously immortalized cell line CVCL_6F96 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21093327 CVCL_6F97 Ul-H spontaneously immortalized cell line CVCL_6F97 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21093328 CVCL_6F98 YO-K spontaneously immortalized cell line CVCL_6F98 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21093329 CVCL_6F99 YTF spontaneously immortalized cell line CVCL_6F99 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21093330 CVCL_6F92 SHK [Channa] spontaneously immortalized cell line CVCL_6F92 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21093331 CVCL_6F93 SHL spontaneously immortalized cell line CVCL_6F93 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21093332 CVCL_6F94 SHS spontaneously immortalized cell line CVCL_6F94 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21093333 CVCL_6F95 TmB spontaneously immortalized cell line CVCL_6F95 CL:0000010 Derived from sampling site: Bulbus arteriosus. Unspecified Group: Fish cell line 21093334 CVCL_6F90 SHG [Channa] spontaneously immortalized cell line CVCL_6F90 CL:0000010 Derived from sampling site: Gonad. Unspecified Group: Fish cell line 21093335 CVCL_6F91 SHH [Snakehead heart Philippine] spontaneously immortalized cell line CVCL_6F91 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21093336 CVCL_PS30 BayGenomics ES cell line XG019 embryonic stem cell house mouse CVCL_PS30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093337 CVCL_Q430 HG01801 transformed cell line human CVCL_Q430 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093338 CVCL_PS31 BayGenomics ES cell line XG021 embryonic stem cell house mouse CVCL_PS31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929510; Zfand6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093339 CVCL_Q431 HG01802 transformed cell line human CVCL_Q431 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093340 CVCL_PS32 BayGenomics ES cell line XG022 embryonic stem cell house mouse CVCL_PS32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093341 CVCL_Q432 HG01804 transformed cell line human CVCL_Q432 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093342 CVCL_PS33 BayGenomics ES cell line XG023 embryonic stem cell house mouse CVCL_PS33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093343 CVCL_Q433 HG01805 transformed cell line human CVCL_Q433 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093344 CVCL_PS34 BayGenomics ES cell line XG026 embryonic stem cell house mouse CVCL_PS34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093345 CVCL_Q434 HG01806 transformed cell line human CVCL_Q434 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093346 CVCL_GY98 A431/CDDP2 cancer cell line human CVCL_GY98 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Skin; epidermis. Female 21093347 CVCL_PS35 BayGenomics ES cell line XG029 embryonic stem cell house mouse CVCL_PS35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102666; Ppp5c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093348 CVCL_Q435 HG01807 transformed cell line human CVCL_Q435 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093349 CVCL_PS36 BayGenomics ES cell line XG031 embryonic stem cell house mouse CVCL_PS36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093350 CVCL_GY99 CAL-27 TPFR cancer cell line human CVCL_GY99 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Oral cavity; tongue. Male 21093351 CVCL_Q436 HG01808 transformed cell line human CVCL_Q436 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093352 CVCL_PS37 BayGenomics ES cell line XG034 embryonic stem cell house mouse CVCL_PS37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093353 CVCL_Q437 HG01809 transformed cell line human CVCL_Q437 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093354 CVCL_PS38 BayGenomics ES cell line XG038 embryonic stem cell house mouse CVCL_PS38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093355 CVCL_Q438 HG01810 transformed cell line human CVCL_Q438 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093356 CVCL_PS39 BayGenomics ES cell line XG039 embryonic stem cell house mouse CVCL_PS39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914099; Ppp1r2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093357 CVCL_Q439 HG01811 transformed cell line human CVCL_Q439 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093358 CVCL_GY94 LAZ-177 transformed cell line human CVCL_GY94 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 4827; HBB; Zygosity=Homozygous (PubMed=6196781); Sequence variation: Gene deletion; HGNC; 4829; HBD; Zygosity=Homozygous (PubMed=6196781) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21093359 CVCL_GY95 Luc9.1 spontaneously immortalized cell line dog CVCL_GY95 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Reporter cell line for rapid isolation and detection of replicating influenza A virus 21093360 CVCL_GY96 SH [Dog hemangiosarcoma] cancer cell line dog CVCL_GY96 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: German Shepherd. Omics: Transcriptome analysis by microarray Female 21093361 CVCL_GY97 A431/CDDP1 cancer cell line human CVCL_GY97 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Skin; epidermis. Female 21093362 CVCL_GY90 KOS-002 cancer cell line dog CVCL_GY90 CL:0000010 Breed/subspecies: Irish Setter. Female Doubling time: 24.7 hours (PubMed=21848623) 21093363 CVCL_GY91 KOS-003 cancer cell line dog CVCL_GY91 CL:0000010 Breed/subspecies: Labrador Retriever mix. Unspecified Doubling time: 16.0 hours (PubMed=21848623) 21093364 CVCL_GY92 KOS-004 cancer cell line dog CVCL_GY92 CL:0000010 Breed/subspecies: Mixed breed. Unspecified Doubling time: 12.1 hours (PubMed=21848623) 21093365 CVCL_GY93 KTOSA5 cancer cell line dog CVCL_GY93 CL:0000010 Derived from sampling site: Bone; right hindlimb; Breed/subspecies: Rottweiler. Omics: Transcriptome analysis by microarray Female 21093366 CVCL_PS20 BayGenomics ES cell line XG005 embryonic stem cell house mouse CVCL_PS20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093367 CVCL_Q420 HG01789 transformed cell line human CVCL_Q420 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093368 CVCL_PS21 BayGenomics ES cell line XG006 embryonic stem cell house mouse CVCL_PS21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093369 CVCL_Q421 HG01790 transformed cell line human CVCL_Q421 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093370 CVCL_PS22 BayGenomics ES cell line XG007 embryonic stem cell house mouse CVCL_PS22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137357; Trim33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093371 CVCL_Q422 HG01791 transformed cell line human CVCL_Q422 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093372 CVCL_PS23 BayGenomics ES cell line XG012 embryonic stem cell house mouse CVCL_PS23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093373 CVCL_Q423 HG01794 transformed cell line human CVCL_Q423 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093374 CVCL_PS24 BayGenomics ES cell line XG013 embryonic stem cell house mouse CVCL_PS24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922662; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093375 CVCL_Q424 HG01795 transformed cell line human CVCL_Q424 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093376 CVCL_PS25 BayGenomics ES cell line XG014 embryonic stem cell house mouse CVCL_PS25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915147; Rnmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093377 CVCL_Q425 HG01796 transformed cell line human CVCL_Q425 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093378 CVCL_PS26 BayGenomics ES cell line XG015 embryonic stem cell house mouse CVCL_PS26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093379 CVCL_Q426 HG01797 transformed cell line human CVCL_Q426 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093380 CVCL_PS27 BayGenomics ES cell line XG016 embryonic stem cell house mouse CVCL_PS27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093381 CVCL_Q427 HG01798 transformed cell line human CVCL_Q427 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093382 CVCL_PS28 BayGenomics ES cell line XG017 embryonic stem cell house mouse CVCL_PS28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107738; Dync1li2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093383 CVCL_Q428 HG01799 transformed cell line human CVCL_Q428 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093384 CVCL_PS29 BayGenomics ES cell line XG018 embryonic stem cell house mouse CVCL_PS29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093385 CVCL_Q429 HG01800 transformed cell line human CVCL_Q429 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093386 CVCL_PS10 BayGenomics ES cell line XF572 embryonic stem cell house mouse CVCL_PS10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913443; Pithd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093387 CVCL_Q410 HG01775 transformed cell line human CVCL_Q410 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093388 CVCL_PS11 BayGenomics ES cell line XF574 embryonic stem cell house mouse CVCL_PS11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093389 CVCL_Q411 HG01776 transformed cell line human CVCL_Q411 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093390 CVCL_PS12 BayGenomics ES cell line XF575 embryonic stem cell house mouse CVCL_PS12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96952; Mdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093391 CVCL_Q412 HG01777 transformed cell line human CVCL_Q412 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093392 CVCL_PS13 BayGenomics ES cell line XF579 embryonic stem cell house mouse CVCL_PS13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918625; Foxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093393 CVCL_Q413 HG01778 transformed cell line human CVCL_Q413 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093394 CVCL_GY76 ND02859 transformed cell line human CVCL_GY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093395 CVCL_PS14 BayGenomics ES cell line XF580 embryonic stem cell house mouse CVCL_PS14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920196; Lrrc47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093396 CVCL_Q414 HG01779 transformed cell line human CVCL_Q414 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093397 CVCL_GY77 ND02860 transformed cell line human CVCL_GY77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093398 CVCL_PS15 BayGenomics ES cell line XF586 embryonic stem cell house mouse CVCL_PS15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093399 CVCL_Q415 HG01780 transformed cell line human CVCL_Q415 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093400 CVCL_GY78 ND02868 transformed cell line human CVCL_GY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093401 CVCL_PS16 BayGenomics ES cell line XF590 embryonic stem cell house mouse CVCL_PS16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093402 CVCL_Q416 HG01781 transformed cell line human CVCL_Q416 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093403 CVCL_GY79 ND02869 transformed cell line human CVCL_GY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093404 CVCL_PS17 BayGenomics ES cell line XF596 embryonic stem cell house mouse CVCL_PS17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347488; Foxk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093405 CVCL_Q417 HG01782 transformed cell line human CVCL_Q417 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093406 CVCL_GY72 ND02837 transformed cell line human CVCL_GY72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093407 CVCL_PS18 BayGenomics ES cell line XG001 embryonic stem cell house mouse CVCL_PS18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445054; Senp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093408 CVCL_Q418 HG01783 transformed cell line human CVCL_Q418 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093409 CVCL_GY73 ND02838 transformed cell line human CVCL_GY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093410 CVCL_PS19 BayGenomics ES cell line XG003 embryonic stem cell house mouse CVCL_PS19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093411 CVCL_Q419 HG01784 transformed cell line human CVCL_Q419 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093412 CVCL_GY74 ND02840 transformed cell line human CVCL_GY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093413 CVCL_GY75 ND02857 transformed cell line human CVCL_GY75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093414 CVCL_GY70 ND02812 transformed cell line human CVCL_GY70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093415 CVCL_GY71 ND02836 transformed cell line human CVCL_GY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093416 CVCL_PS00 BayGenomics ES cell line XF485 embryonic stem cell house mouse CVCL_PS00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093417 CVCL_Q400 HG01756 transformed cell line human CVCL_Q400 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093418 CVCL_PS01 BayGenomics ES cell line XF488 embryonic stem cell house mouse CVCL_PS01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915848; Dnajc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093419 CVCL_Q401 HG01757 transformed cell line human CVCL_Q401 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093420 CVCL_PS02 BayGenomics ES cell line XF501 embryonic stem cell house mouse CVCL_PS02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093421 CVCL_Q402 HG01761 transformed cell line human CVCL_Q402 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093422 CVCL_GY87 ND07172 transformed cell line human CVCL_GY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093423 CVCL_PS03 BayGenomics ES cell line XF502 embryonic stem cell house mouse CVCL_PS03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342295; Celf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093424 CVCL_Q403 HG01762 transformed cell line human CVCL_Q403 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093425 CVCL_GY88 ND07256 transformed cell line human CVCL_GY88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093426 CVCL_PS04 BayGenomics ES cell line XF503 embryonic stem cell house mouse CVCL_PS04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96522; Rbpj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093427 CVCL_Q404 HG01763 transformed cell line human CVCL_Q404 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093428 CVCL_GY89 KOS-001 cancer cell line dog CVCL_GY89 CL:0000010 Breed/subspecies: Border Collie. Unspecified Doubling time: 16.8 hours (PubMed=21848623); 17.02 hours (PubMed=31640712) 21093429 CVCL_PS05 BayGenomics ES cell line XF516 embryonic stem cell house mouse CVCL_PS05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891693; Mtmr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093430 CVCL_Q405 HG01770 transformed cell line human CVCL_Q405 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093431 CVCL_PS06 BayGenomics ES cell line XF518 embryonic stem cell house mouse CVCL_PS06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093432 CVCL_Q406 HG01771 transformed cell line human CVCL_Q406 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093433 CVCL_GY83 ND03586 transformed cell line human CVCL_GY83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093434 CVCL_PS07 BayGenomics ES cell line XF521 embryonic stem cell house mouse CVCL_PS07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349393; Polr2f Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093435 CVCL_Q407 HG01772 transformed cell line human CVCL_Q407 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093436 CVCL_GY84 ND03707 transformed cell line human CVCL_GY84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093437 CVCL_PS08 BayGenomics ES cell line XF522 embryonic stem cell house mouse CVCL_PS08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093438 CVCL_Q408 HG01773 transformed cell line human CVCL_Q408 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=33197628) Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093439 CVCL_GY85 ND03828 transformed cell line human CVCL_GY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093440 CVCL_PS09 BayGenomics ES cell line XF523 embryonic stem cell house mouse CVCL_PS09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093441 CVCL_Q409 HG01774 transformed cell line human CVCL_Q409 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093442 CVCL_GY86 ND04888 transformed cell line human CVCL_GY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093443 CVCL_GY80 ND02921 transformed cell line human CVCL_GY80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093444 CVCL_GY81 ND02924 transformed cell line human CVCL_GY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093445 CVCL_GY82 ND02959 transformed cell line human CVCL_GY82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093446 CVCL_GY58 ND02474 transformed cell line human CVCL_GY58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093447 CVCL_GY59 ND02505 transformed cell line human CVCL_GY59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093448 CVCL_GY54 ND02420 transformed cell line human CVCL_GY54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093449 CVCL_GY55 ND02424 transformed cell line human CVCL_GY55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093450 CVCL_GY56 ND02433 transformed cell line human CVCL_GY56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093451 CVCL_GY57 ND02473 transformed cell line human CVCL_GY57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093452 CVCL_GY50 ND02397 transformed cell line human CVCL_GY50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093453 CVCL_GY51 ND02398 transformed cell line human CVCL_GY51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093454 CVCL_GY52 ND02417 transformed cell line human CVCL_GY52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093455 CVCL_GY53 ND02419 transformed cell line human CVCL_GY53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093456 CVCL_GY69 ND02743 transformed cell line human CVCL_GY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093457 CVCL_GY65 ND02572 transformed cell line human CVCL_GY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093458 CVCL_GY66 ND02627 transformed cell line human CVCL_GY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093459 CVCL_GY67 ND02628 transformed cell line human CVCL_GY67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093460 CVCL_GY68 ND02688 transformed cell line human CVCL_GY68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093461 CVCL_GY61 ND02538 transformed cell line human CVCL_GY61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093462 CVCL_GY62 ND02539 transformed cell line human CVCL_GY62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093463 CVCL_GY63 ND02540 transformed cell line human CVCL_GY63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093464 CVCL_GY64 ND02571 transformed cell line human CVCL_GY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093465 CVCL_GY60 ND02523 transformed cell line human CVCL_GY60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093466 CVCL_GY36 ND02257 transformed cell line human CVCL_GY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093467 CVCL_GY37 ND02262 transformed cell line human CVCL_GY37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093468 CVCL_GY38 ND02264 transformed cell line human CVCL_GY38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093469 CVCL_GY39 ND02265 transformed cell line human CVCL_GY39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093470 CVCL_GY32 GM23883 transformed cell line human CVCL_GY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093471 CVCL_GY33 GM23884 transformed cell line human CVCL_GY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093472 CVCL_GY34 GM23885 transformed cell line human CVCL_GY34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093473 CVCL_GY35 GM23886 transformed cell line human CVCL_GY35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093474 CVCL_GY30 GM20415 finite cell line human CVCL_GY30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093475 CVCL_GY31 GM20936 transformed cell line human CVCL_GY31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093476 CVCL_GY47 ND02324 transformed cell line human CVCL_GY47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093477 CVCL_GY48 ND02325 transformed cell line human CVCL_GY48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093478 CVCL_GY49 ND02384 transformed cell line human CVCL_GY49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093479 CVCL_GY43 ND02293 transformed cell line human CVCL_GY43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093480 CVCL_GY44 ND02294 transformed cell line human CVCL_GY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093481 CVCL_GY45 ND02319 transformed cell line human CVCL_GY45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093482 CVCL_GY46 ND02321 transformed cell line human CVCL_GY46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093483 CVCL_GY40 ND02268 transformed cell line human CVCL_GY40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093484 CVCL_GY41 ND02287 transformed cell line human CVCL_GY41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093485 CVCL_GY42 ND02291 transformed cell line human CVCL_GY42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093486 CVCL_6H21 DA00023 transformed cell line human CVCL_6H21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093487 CVCL_6H22 DA00024 transformed cell line human CVCL_6H22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093488 CVCL_6H23 DA00025 transformed cell line human CVCL_6H23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093489 CVCL_6H24 DA00026 transformed cell line human CVCL_6H24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093490 CVCL_6H20 DA00021 transformed cell line human CVCL_6H20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093491 CVCL_6H29 DA00031 transformed cell line human CVCL_6H29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093492 CVCL_6H25 DA00027 transformed cell line human CVCL_6H25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093493 CVCL_6H26 DA00028 transformed cell line human CVCL_6H26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093494 CVCL_6H27 DA00029 transformed cell line human CVCL_6H27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093495 CVCL_6H28 DA00030 transformed cell line human CVCL_6H28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093496 CVCL_6H32 DA00034 transformed cell line human CVCL_6H32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093497 CVCL_6H33 DA00036 transformed cell line human CVCL_6H33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093498 CVCL_6H34 DA00037 transformed cell line human CVCL_6H34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093499 CVCL_6H35 DA00038 transformed cell line human CVCL_6H35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093500 CVCL_6H30 DA00032 transformed cell line human CVCL_6H30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093501 CVCL_6H31 DA00033 transformed cell line human CVCL_6H31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093502 CVCL_6H36 DA00039 transformed cell line human CVCL_6H36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093503 CVCL_6H37 DA00040 transformed cell line human CVCL_6H37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093504 CVCL_6H38 DA00041 transformed cell line human CVCL_6H38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093505 CVCL_6H39 DA00042 transformed cell line human CVCL_6H39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093506 CVCL_6H00 DA00001 transformed cell line human CVCL_6H00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093507 CVCL_6H01 DA00002 transformed cell line human CVCL_6H01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093508 CVCL_6H02 DA00003 transformed cell line human CVCL_6H02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093509 CVCL_6H07 DA00008 transformed cell line human CVCL_6H07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093510 CVCL_6H08 DA00009 transformed cell line human CVCL_6H08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093511 CVCL_6H09 DA00010 transformed cell line human CVCL_6H09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093512 CVCL_6H03 DA00004 transformed cell line human CVCL_6H03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093513 CVCL_6H04 DA00005 transformed cell line human CVCL_6H04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093514 CVCL_6H05 DA00006 transformed cell line human CVCL_6H05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093515 CVCL_6H06 DA00007 transformed cell line human CVCL_6H06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093516 CVCL_6H10 DA00011 transformed cell line human CVCL_6H10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093517 CVCL_6H11 DA00012 transformed cell line human CVCL_6H11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093518 CVCL_6H12 DA00013 transformed cell line human CVCL_6H12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093519 CVCL_6H13 DA00014 transformed cell line human CVCL_6H13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093520 CVCL_6H18 DA00019 transformed cell line human CVCL_6H18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093521 CVCL_6H19 DA00020 transformed cell line human CVCL_6H19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093522 CVCL_6H14 DA00015 transformed cell line human CVCL_6H14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093523 CVCL_6H15 DA00016 transformed cell line human CVCL_6H15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093524 CVCL_6H16 DA00017 transformed cell line human CVCL_6H16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093525 CVCL_6H17 DA00018 transformed cell line human CVCL_6H17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093526 CVCL_PT92 BayGenomics ES cell line XG303 embryonic stem cell house mouse CVCL_PT92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093527 CVCL_Q592 HG02032 transformed cell line human CVCL_Q592 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093528 CVCL_PT93 BayGenomics ES cell line XG304 embryonic stem cell house mouse CVCL_PT93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093529 CVCL_Q593 HG02035 transformed cell line human CVCL_Q593 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093530 CVCL_PT94 BayGenomics ES cell line XG307 embryonic stem cell house mouse CVCL_PT94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919837; Pan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093531 CVCL_Q594 HG02040 transformed cell line human CVCL_Q594 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093532 CVCL_PT95 BayGenomics ES cell line XG309 embryonic stem cell house mouse CVCL_PT95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687042; Ppp1r37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093533 CVCL_Q595 HG02046 transformed cell line human CVCL_Q595 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093534 CVCL_PT96 BayGenomics ES cell line XG310 embryonic stem cell house mouse CVCL_PT96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681840; Rsl24d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093535 CVCL_Q596 HG02047 transformed cell line human CVCL_Q596 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093536 CVCL_PT97 BayGenomics ES cell line XG311 embryonic stem cell house mouse CVCL_PT97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093537 CVCL_Q597 HG02048 transformed cell line human CVCL_Q597 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093538 CVCL_PT98 BayGenomics ES cell line XG312 embryonic stem cell house mouse CVCL_PT98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093539 CVCL_Q598 HG02049 transformed cell line human CVCL_Q598 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093540 CVCL_PT99 BayGenomics ES cell line XG315 embryonic stem cell house mouse CVCL_PT99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448487; Fam168b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093541 CVCL_Q599 HG02050 transformed cell line human CVCL_Q599 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093542 CVCL_PT81 BayGenomics ES cell line XG280 embryonic stem cell house mouse CVCL_PT81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921414; Nfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093543 CVCL_Q581 HG02014 transformed cell line human CVCL_Q581 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093544 CVCL_PT82 BayGenomics ES cell line XG281 embryonic stem cell house mouse CVCL_PT82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093545 CVCL_Q582 HG02016 transformed cell line human CVCL_Q582 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093546 CVCL_PT83 BayGenomics ES cell line XG282 embryonic stem cell house mouse CVCL_PT83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093547 CVCL_Q583 HG02017 transformed cell line human CVCL_Q583 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093548 CVCL_PT84 BayGenomics ES cell line XG286 embryonic stem cell house mouse CVCL_PT84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093549 CVCL_Q584 HG02019 transformed cell line human CVCL_Q584 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093550 CVCL_PT85 BayGenomics ES cell line XG289 embryonic stem cell house mouse CVCL_PT85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920538; Vps50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093551 CVCL_Q585 HG02020 transformed cell line human CVCL_Q585 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093552 CVCL_PT86 BayGenomics ES cell line XG292 embryonic stem cell house mouse CVCL_PT86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104819; Hnrnpa2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093553 CVCL_Q586 HG02023 transformed cell line human CVCL_Q586 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093554 CVCL_PT87 BayGenomics ES cell line XG293 embryonic stem cell house mouse CVCL_PT87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104819; Hnrnpa2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093555 CVCL_Q587 HG02025 transformed cell line human CVCL_Q587 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093556 CVCL_PT88 BayGenomics ES cell line XG294 embryonic stem cell house mouse CVCL_PT88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093557 CVCL_Q588 HG02026 transformed cell line human CVCL_Q588 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093558 CVCL_PT89 BayGenomics ES cell line XG298 embryonic stem cell house mouse CVCL_PT89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859646; Golga4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093559 CVCL_Q589 HG02028 transformed cell line human CVCL_Q589 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093560 CVCL_PT90 BayGenomics ES cell line XG299 embryonic stem cell house mouse CVCL_PT90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102581; Rdh11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093561 CVCL_Q590 HG02029 transformed cell line human CVCL_Q590 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093562 CVCL_PT91 BayGenomics ES cell line XG302 embryonic stem cell house mouse CVCL_PT91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093563 CVCL_Q591 HG02031 transformed cell line human CVCL_Q591 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093564 CVCL_PT70 BayGenomics ES cell line XG264 embryonic stem cell house mouse CVCL_PT70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277166; Sp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093565 CVCL_Q570 HG01997 transformed cell line human CVCL_Q570 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093566 CVCL_PT71 BayGenomics ES cell line XG265 embryonic stem cell house mouse CVCL_PT71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913411; Pop4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093567 CVCL_Q571 HG01998 transformed cell line human CVCL_Q571 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093568 CVCL_PT72 BayGenomics ES cell line XG266 embryonic stem cell house mouse CVCL_PT72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915120; Enoph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093569 CVCL_Q572 HG02002 transformed cell line human CVCL_Q572 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093570 CVCL_PT73 BayGenomics ES cell line XG268 embryonic stem cell house mouse CVCL_PT73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924261; Ticrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093571 CVCL_Q573 HG02003 transformed cell line human CVCL_Q573 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093572 CVCL_PT74 BayGenomics ES cell line XG269 embryonic stem cell house mouse CVCL_PT74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915120; Enoph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093573 CVCL_Q574 HG02004 transformed cell line human CVCL_Q574 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093574 CVCL_PT75 BayGenomics ES cell line XG270 embryonic stem cell house mouse CVCL_PT75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135606; Pard6g Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093575 CVCL_Q575 HG02008 transformed cell line human CVCL_Q575 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093576 CVCL_PT76 BayGenomics ES cell line XG271 embryonic stem cell house mouse CVCL_PT76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093577 CVCL_Q576 HG02009 transformed cell line human CVCL_Q576 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093578 CVCL_PT77 BayGenomics ES cell line XG273 embryonic stem cell house mouse CVCL_PT77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093579 CVCL_Q577 HG02010 transformed cell line human CVCL_Q577 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093580 CVCL_PT78 BayGenomics ES cell line XG274 embryonic stem cell house mouse CVCL_PT78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915047; Snrnp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093581 CVCL_Q578 HG02011 transformed cell line human CVCL_Q578 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093582 CVCL_PT79 BayGenomics ES cell line XG278 embryonic stem cell house mouse CVCL_PT79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915986; Tyw5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093583 CVCL_Q579 HG02012 transformed cell line human CVCL_Q579 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093584 CVCL_PT80 BayGenomics ES cell line XG279 embryonic stem cell house mouse CVCL_PT80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450166; Arhgap32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093585 CVCL_Q580 HG02013 transformed cell line human CVCL_Q580 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093586 CVCL_PT60 BayGenomics ES cell line XG240 embryonic stem cell house mouse CVCL_PT60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093587 CVCL_Q560 HG01984 transformed cell line human CVCL_Q560 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093588 CVCL_PT61 BayGenomics ES cell line XG241 embryonic stem cell house mouse CVCL_PT61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682313; Zfp335 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093589 CVCL_Q561 HG01985 transformed cell line human CVCL_Q561 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093590 CVCL_PT62 BayGenomics ES cell line XG243 embryonic stem cell house mouse CVCL_PT62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093591 CVCL_Q562 HG01986 transformed cell line human CVCL_Q562 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093592 CVCL_PT63 BayGenomics ES cell line XG248 embryonic stem cell house mouse CVCL_PT63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093593 CVCL_Q563 HG01987 transformed cell line human CVCL_Q563 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093594 CVCL_PT64 BayGenomics ES cell line XG252 embryonic stem cell house mouse CVCL_PT64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915127; Naa20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093595 CVCL_Q564 HG01988 transformed cell line human CVCL_Q564 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093596 CVCL_PT65 BayGenomics ES cell line XG253 embryonic stem cell house mouse CVCL_PT65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97578; Phkb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093597 CVCL_Q565 HG01989 transformed cell line human CVCL_Q565 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093598 CVCL_PT66 BayGenomics ES cell line XG255 embryonic stem cell house mouse CVCL_PT66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093599 CVCL_Q566 HG01990 transformed cell line human CVCL_Q566 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093600 CVCL_PT67 BayGenomics ES cell line XG257 embryonic stem cell house mouse CVCL_PT67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093601 CVCL_Q567 HG01991 transformed cell line human CVCL_Q567 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093602 CVCL_PT68 BayGenomics ES cell line XG260 embryonic stem cell house mouse CVCL_PT68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093603 CVCL_Q568 HG01992 transformed cell line human CVCL_Q568 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093604 CVCL_PT69 BayGenomics ES cell line XG262 embryonic stem cell house mouse CVCL_PT69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093605 CVCL_Q569 HG01993 transformed cell line human CVCL_Q569 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093606 CVCL_6H87 DA00092 transformed cell line human CVCL_6H87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00092; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093607 CVCL_6H88 DA00093 transformed cell line human CVCL_6H88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093608 CVCL_6H89 DA00094 transformed cell line human CVCL_6H89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093609 CVCL_6H83 DA00088 transformed cell line human CVCL_6H83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093610 CVCL_6H84 DA00089 transformed cell line human CVCL_6H84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093611 CVCL_6H85 DA00090 transformed cell line human CVCL_6H85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093612 CVCL_6H86 DA00091 transformed cell line human CVCL_6H86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093613 CVCL_6H80 DA00084 transformed cell line human CVCL_6H80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093614 CVCL_6H81 DA00085 transformed cell line human CVCL_6H81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093615 CVCL_6H82 DA00086 transformed cell line human CVCL_6H82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093616 CVCL_6H98 DA00103 transformed cell line human CVCL_6H98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093617 CVCL_6H99 DA00104 transformed cell line human CVCL_6H99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093618 CVCL_6H94 DA00099 transformed cell line human CVCL_6H94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093619 CVCL_6H95 DA00100 transformed cell line human CVCL_6H95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093620 CVCL_6H96 DA00101 transformed cell line human CVCL_6H96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093621 CVCL_6H97 DA00102 transformed cell line human CVCL_6H97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093622 CVCL_6H90 DA00095 transformed cell line human CVCL_6H90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093623 CVCL_6H91 DA00096 transformed cell line human CVCL_6H91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093624 CVCL_6H92 DA00097 transformed cell line human CVCL_6H92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093625 CVCL_6H93 DA00098 transformed cell line human CVCL_6H93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093626 CVCL_6H65 DA00069 transformed cell line human CVCL_6H65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093627 CVCL_6H66 DA00070 transformed cell line human CVCL_6H66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093628 CVCL_6H67 DA00071 transformed cell line human CVCL_6H67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093629 CVCL_6H68 DA00072 transformed cell line human CVCL_6H68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093630 CVCL_6H61 DA00065 transformed cell line human CVCL_6H61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093631 CVCL_6H62 DA00066 transformed cell line human CVCL_6H62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093632 CVCL_6H63 DA00067 transformed cell line human CVCL_6H63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093633 CVCL_6H64 DA00068 transformed cell line human CVCL_6H64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093634 CVCL_6H69 DA00073 transformed cell line human CVCL_6H69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093635 CVCL_6H60 DA00064 transformed cell line human CVCL_6H60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093636 CVCL_6H76 DA00080 transformed cell line human CVCL_6H76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093637 CVCL_6H77 DA00081 transformed cell line human CVCL_6H77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093638 CVCL_6H78 DA00082 transformed cell line human CVCL_6H78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093639 CVCL_6H79 DA00083 transformed cell line human CVCL_6H79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093640 CVCL_6H72 DA00076 transformed cell line human CVCL_6H72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093641 CVCL_6H73 DA00077 transformed cell line human CVCL_6H73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093642 CVCL_6H74 DA00078 transformed cell line human CVCL_6H74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093643 CVCL_6H75 DA00079 transformed cell line human CVCL_6H75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093644 CVCL_6H70 DA00074 transformed cell line human CVCL_6H70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093645 CVCL_6H71 DA00075 transformed cell line human CVCL_6H71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093646 CVCL_6H43 DA00046 transformed cell line human CVCL_6H43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093647 CVCL_6H44 DA00047 transformed cell line human CVCL_6H44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093648 CVCL_6H45 DA00048 transformed cell line human CVCL_6H45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093649 CVCL_6H46 DA00050 transformed cell line human CVCL_6H46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093650 CVCL_6H40 DA00043 transformed cell line human CVCL_6H40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093651 CVCL_6H41 DA00044 transformed cell line human CVCL_6H41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093652 CVCL_6H42 DA00045 transformed cell line human CVCL_6H42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093653 CVCL_6H47 DA00051 transformed cell line human CVCL_6H47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093654 CVCL_6H48 DA00052 transformed cell line human CVCL_6H48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093655 CVCL_6H49 DA00053 transformed cell line human CVCL_6H49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093656 CVCL_6H54 DA00058 transformed cell line human CVCL_6H54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093657 CVCL_6H55 DA00059 transformed cell line human CVCL_6H55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093658 CVCL_6H56 DA00060 transformed cell line human CVCL_6H56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093659 CVCL_6H57 DA00061 transformed cell line human CVCL_6H57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093660 CVCL_6H50 DA00054 transformed cell line human CVCL_6H50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093661 CVCL_6H51 DA00055 transformed cell line human CVCL_6H51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093662 CVCL_6H52 DA00056 transformed cell line human CVCL_6H52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093663 CVCL_6H53 DA00057 transformed cell line human CVCL_6H53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093664 CVCL_6H58 DA00062 transformed cell line human CVCL_6H58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093665 CVCL_6H59 DA00063 transformed cell line human CVCL_6H59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093666 CVCL_GZ39 GM02241 finite cell line human CVCL_GZ39 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Simple; c.293-13A/C>G (IVS2-13A/C>G); Zygosity=Unspecified; Note=Aberrant splice site activation (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21093667 CVCL_GZ35 AtT-20/D16-16 cancer cell line house mouse CVCL_GZ35 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 21093668 CVCL_GZ36 Beta-HC13 cancer cell line house mouse CVCL_GZ36 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIP1Tag2. 21093669 CVCL_GZ37 Beta-HC8 transformed cell line house mouse CVCL_GZ37 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIP1Tag2. 21093670 CVCL_GZ38 FO1-12 cancer cell line human CVCL_GZ38 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Gamma radiation(NCIt; C44386); Derived from metastatic site: Iliac lymph node. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12177 21093671 CVCL_GZ31 CH12F3 (Lig4-/-) cancer cell line house mouse CVCL_GZ31 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1335098; Lig4 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093672 CVCL_GZ32 T-289/DPP3 cancer cell line human CVCL_GZ32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Unspecified 21093673 CVCL_GZ33 T-289/TAM6 cancer cell line human CVCL_GZ33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen. Unspecified 21093674 CVCL_GZ34 Efk3B transformed cell line CVCL_GZ34 CL:0000010 Transformant: Myotis polyomavirus large T-antigen (MyPVTag); Derived from sampling site: Kidney. Male Virology: Can be used to cultivate viruses from the Coronaviridae, Filoviridae, Herpesviridae, Paramyxoviridae and Rhabdoviridae; Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32511316) Doubling time: 24 hours (Kerafast) Group: Bat cell line 21093675 CVCL_GZ30 CH12F3 (Lig4+/-) cancer cell line house mouse CVCL_GZ30 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:1335098; Lig4 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093676 CVCL_GZ46 GM13242 transformed cell line human CVCL_GZ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093677 CVCL_GZ47 GM13276 transformed cell line human CVCL_GZ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093678 CVCL_GZ48 GM13350 transformed cell line human CVCL_GZ48 CL:0000010 Population: Saudi Arabian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093679 CVCL_GZ49 GM13365 finite cell line human CVCL_GZ49 CL:0000010 Population: Saudi Arabian; Derived from sampling site: Cell type=Fibroblast. Male 21093680 CVCL_GZ42 GM11781 transformed cell line human CVCL_GZ42 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Simple; c.293-13A/C>G (IVS2-13A/C>G); Zygosity=Homozygous; Note=Aberrant splice site activation (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093681 CVCL_GZ43 GM12217 transformed cell line human CVCL_GZ43 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Simple; p.Ile173Asn (c.518T>A) (p.Ile172Asn, c.515T>A); ClinVar=VCV000012150; Zygosity=Homozygous (PubMed=27896104); Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-3 30kb del (CH-3 type CYP21A1P/CYP21A2 chimer); Zygosity=Homozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093682 CVCL_GZ44 GM12690 transformed cell line human CVCL_GZ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093683 CVCL_GZ45 GM12895 transformed cell line human CVCL_GZ45 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093684 CVCL_GZ40 GM02242 transformed cell line human CVCL_GZ40 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Simple; c.293-13A/C>G (IVS2-13A/C>G); Zygosity=Unspecified; Note=Aberrant splice site activation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093685 CVCL_GZ41 GM06172 finite cell line human CVCL_GZ41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21093686 CVCL_GZ17 BO0292 transformed cell line human CVCL_GZ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91091002; probable Female Part of: ECACC chromosomal abnormality collection 21093687 CVCL_GZ18 BO0306 transformed cell line human CVCL_GZ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91111305; probable Female Part of: ECACC chromosomal abnormality collection 21093688 CVCL_GZ19 BO0283 transformed cell line human CVCL_GZ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91072912; probable Female Part of: ECACC chromosomal abnormality collection 21093689 CVCL_GZ13 HRL9 cancer cell line human CVCL_GZ13 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21093690 CVCL_GZ14 GM15266 transformed cell line human CVCL_GZ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM15266; probable Unspecified Part of: DNA polymorphism discovery resource collection 21093691 CVCL_GZ15 BK0013 transformed cell line human CVCL_GZ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98100924; probable Male Part of: ECACC chromosomal abnormality collection 21093692 CVCL_GZ16 BO2173 transformed cell line human CVCL_GZ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97032603; probable Female Part of: ECACC chromosomal abnormality collection 21093693 CVCL_GZ10 ARAC-8D cancer cell line human CVCL_GZ10 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21093694 CVCL_GZ11 TUB-4D cancer cell line human CVCL_GZ11 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:48267; Tubercidin (7-deazaadenosine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21093695 CVCL_GZ12 MDCKts.src spontaneously immortalized cell line dog CVCL_GZ12 CL:0000010 Transfected with: UniProtKB; P00524; Avian leukosis virus RSA v-Src Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21093696 CVCL_GZ28 CH12F3 (Lig1-/-) cancer cell line house mouse CVCL_GZ28 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:101789; Lig1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093697 CVCL_GZ29 CH12F3 (Lig1-/-Lig4-/-) cancer cell line house mouse CVCL_GZ29 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:101789; Lig1; Knockout cell: Method=Homologous recombination; MGI; MGI:1335098; Lig4 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093698 CVCL_GZ24 CH12F3 (CTNNBL1+/-) cancer cell line house mouse CVCL_GZ24 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:1913892; Ctnnbl1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093699 CVCL_GZ25 CH12F3 (CTNNBL1-/-) cancer cell line house mouse CVCL_GZ25 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1913892; Ctnnbl1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093700 CVCL_GZ26 CH12F3 (Lig1+/-) cancer cell line house mouse CVCL_GZ26 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:101789; Lig1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093701 CVCL_GZ27 CH12F3 (Lig1+/-Lig4-/-) cancer cell line house mouse CVCL_GZ27 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:101789; Lig1; Knockout cell: Method=Homologous recombination; MGI; MGI:1335098; Lig4 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093702 CVCL_GZ20 CH12F3 (AID+/-) cancer cell line house mouse CVCL_GZ20 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:1342279; Aicda Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093703 CVCL_GZ21 CH12F3 (AID-/-) cancer cell line house mouse CVCL_GZ21 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1342279; Aicda Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093704 CVCL_GZ22 CH12F3 (APE1-/-/-APE2-) cancer cell line house mouse CVCL_GZ22 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:88042; Apex1; Knockout cell: Method=Homologous recombination; MGI; MGI:1924872; Apex2 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093705 CVCL_GZ23 CH12F3 (APE2-) cancer cell line house mouse CVCL_GZ23 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1924872; Apex2 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21093706 CVCL_GZ06 H-1R cancer cell line human CVCL_GZ06 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by microarray Male 21093707 CVCL_GZ07 DC3F/ADII spontaneously immortalized cell line CVCL_GZ07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21093708 CVCL_GZ08 DC3F/ADIV spontaneously immortalized cell line CVCL_GZ08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21093709 CVCL_GZ09 ARAC-8C cancer cell line human CVCL_GZ09 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21093710 CVCL_GZ02 NT-1 [Human tongue SCC] cancer cell line human CVCL_GZ02 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 26.8 hours (DOI=10.3353/omp.9.133) 21093711 CVCL_GZ03 NT-2 cancer cell line human CVCL_GZ03 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 42.4 hours (DOI=10.3353/omp.9.133) 21093712 CVCL_GZ04 SCSC [Human gingival carcinoma] cancer cell line human CVCL_GZ04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=16918599) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male 21093713 CVCL_GZ05 TW2.6 cancer cell line human CVCL_GZ05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=17070096). Population: Chinese; Taiwan Male Doubling time: 24 hours (PubMed=17070096) 21093714 CVCL_GZ00 Hep-2 TPFR cancer cell line human CVCL_GZ00 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 21093715 CVCL_GZ01 NB-1 cancer cell line human CVCL_GZ01 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; buccal mucosa. Male Doubling time: 25.2 hours (DOI=10.3353/omp.9.133) 21093716 CVCL_PT50 BayGenomics ES cell line XG218 embryonic stem cell house mouse CVCL_PT50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093717 CVCL_Q550 HG01974 transformed cell line human CVCL_Q550 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093718 CVCL_PT51 BayGenomics ES cell line XG219 embryonic stem cell house mouse CVCL_PT51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929494; Arhgap35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093719 CVCL_Q551 HG01975 transformed cell line human CVCL_Q551 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093720 CVCL_PT52 BayGenomics ES cell line XG221 embryonic stem cell house mouse CVCL_PT52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859320; Cyhr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093721 CVCL_Q552 HG01976 transformed cell line human CVCL_Q552 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093722 CVCL_PT53 BayGenomics ES cell line XG226 embryonic stem cell house mouse CVCL_PT53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443816; Snx8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093723 CVCL_Q553 HG01977 transformed cell line human CVCL_Q553 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093724 CVCL_PT54 BayGenomics ES cell line XG232 embryonic stem cell house mouse CVCL_PT54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933765; Btbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093725 CVCL_Q554 HG01978 transformed cell line human CVCL_Q554 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093726 CVCL_PT55 BayGenomics ES cell line XG233 embryonic stem cell house mouse CVCL_PT55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916962; Prpf38a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093727 CVCL_Q555 HG01979 transformed cell line human CVCL_Q555 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093728 CVCL_PT56 BayGenomics ES cell line XG235 embryonic stem cell house mouse CVCL_PT56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093729 CVCL_Q556 HG01980 transformed cell line human CVCL_Q556 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093730 CVCL_PT57 BayGenomics ES cell line XG236 embryonic stem cell house mouse CVCL_PT57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685055; Dusp27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093731 CVCL_Q557 HG01981 transformed cell line human CVCL_Q557 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093732 CVCL_PT58 BayGenomics ES cell line XG237 embryonic stem cell house mouse CVCL_PT58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093733 CVCL_Q558 HG01982 transformed cell line human CVCL_Q558 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093734 CVCL_PT59 BayGenomics ES cell line XG239 embryonic stem cell house mouse CVCL_PT59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093735 CVCL_Q559 HG01983 transformed cell line human CVCL_Q559 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093736 CVCL_PT40 BayGenomics ES cell line XG198 embryonic stem cell house mouse CVCL_PT40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913411; Pop4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093737 CVCL_Q540 HG01958 transformed cell line human CVCL_Q540 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093738 CVCL_PT41 BayGenomics ES cell line XG199 embryonic stem cell house mouse CVCL_PT41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093739 CVCL_Q541 HG01959 transformed cell line human CVCL_Q541 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093740 CVCL_PT42 BayGenomics ES cell line XG203 embryonic stem cell house mouse CVCL_PT42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919865; Anks3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093741 CVCL_Q542 HG01960 transformed cell line human CVCL_Q542 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093742 CVCL_PT43 BayGenomics ES cell line XG204 embryonic stem cell house mouse CVCL_PT43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914176; Trmt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093743 CVCL_Q543 HG01967 transformed cell line human CVCL_Q543 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093744 CVCL_PT44 BayGenomics ES cell line XG205 embryonic stem cell house mouse CVCL_PT44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093745 CVCL_Q544 HG01968 transformed cell line human CVCL_Q544 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093746 CVCL_PT45 BayGenomics ES cell line XG207 embryonic stem cell house mouse CVCL_PT45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98809; Tpm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093747 CVCL_Q545 HG01969 transformed cell line human CVCL_Q545 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093748 CVCL_PT46 BayGenomics ES cell line XG213 embryonic stem cell house mouse CVCL_PT46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093749 CVCL_Q546 HG01970 transformed cell line human CVCL_Q546 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093750 CVCL_PT47 BayGenomics ES cell line XG214 embryonic stem cell house mouse CVCL_PT47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104810; Plaa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093751 CVCL_Q547 HG01971 transformed cell line human CVCL_Q547 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093752 CVCL_PT48 BayGenomics ES cell line XG215 embryonic stem cell house mouse CVCL_PT48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093753 CVCL_Q548 HG01972 transformed cell line human CVCL_Q548 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093754 CVCL_PT49 BayGenomics ES cell line XG216 embryonic stem cell house mouse CVCL_PT49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093755 CVCL_Q549 HG01973 transformed cell line human CVCL_Q549 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093756 CVCL_PT30 BayGenomics ES cell line XG183 embryonic stem cell house mouse CVCL_PT30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138271; Gorab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093757 CVCL_Q530 HG01947 transformed cell line human CVCL_Q530 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093758 CVCL_PT31 BayGenomics ES cell line XG186 embryonic stem cell house mouse CVCL_PT31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096867; Etv5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093759 CVCL_Q531 HG01948 transformed cell line human CVCL_Q531 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093760 CVCL_PT32 BayGenomics ES cell line XG188 embryonic stem cell house mouse CVCL_PT32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093761 CVCL_Q532 HG01949 transformed cell line human CVCL_Q532 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093762 CVCL_PT33 BayGenomics ES cell line XG189 embryonic stem cell house mouse CVCL_PT33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093763 CVCL_Q533 HG01950 transformed cell line human CVCL_Q533 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093764 CVCL_PT34 BayGenomics ES cell line XG190 embryonic stem cell house mouse CVCL_PT34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329014; Stam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093765 CVCL_Q534 HG01951 transformed cell line human CVCL_Q534 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093766 CVCL_GZ97 K562 eGFP-ZFX cancer cell line human CVCL_GZ97 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12869; ZFX; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093767 CVCL_PT35 BayGenomics ES cell line XG191 embryonic stem cell house mouse CVCL_PT35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920955; Mark4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093768 CVCL_Q535 HG01952 transformed cell line human CVCL_Q535 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093769 CVCL_GZ98 K562 eGFP-ZKSCAN8 cancer cell line human CVCL_GZ98 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12983; ZKSCAN8; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093770 CVCL_PT36 BayGenomics ES cell line XG193 embryonic stem cell house mouse CVCL_PT36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093771 CVCL_Q536 HG01953 transformed cell line human CVCL_Q536 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093772 CVCL_GZ99 K562 eGFP-ZNF148 cancer cell line human CVCL_GZ99 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12933; ZNF148; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093773 CVCL_PT37 BayGenomics ES cell line XG194 embryonic stem cell house mouse CVCL_PT37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141969; Efl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093774 CVCL_Q537 HG01954 transformed cell line human CVCL_Q537 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093775 CVCL_PT38 BayGenomics ES cell line XG195 embryonic stem cell house mouse CVCL_PT38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921456; Sipa1l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093776 CVCL_Q538 HG01955 transformed cell line human CVCL_Q538 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093777 CVCL_GZ93 K562 eGFP-POLR2H cancer cell line human CVCL_GZ93 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9195; POLR2H; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093778 CVCL_PT39 BayGenomics ES cell line XG196 embryonic stem cell house mouse CVCL_PT39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345144; Spry4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093779 CVCL_Q539 HG01956 transformed cell line human CVCL_Q539 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093780 CVCL_GZ94 K562 eGFP-TFDP1 cancer cell line human CVCL_GZ94 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11749; TFDP1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093781 CVCL_GZ95 K562 eGFP-USF2 cancer cell line human CVCL_GZ95 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12594; USF2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093782 CVCL_GZ96 K562 eGFP-ZBTB11 cancer cell line human CVCL_GZ96 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 16740; ZBTB11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093783 CVCL_GZ90 K562 eGFP-NFE2 cancer cell line human CVCL_GZ90 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7780; NFE2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093784 CVCL_GZ91 K562 eGFP-NR2C2 cancer cell line human CVCL_GZ91 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7972; NR2C2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093785 CVCL_GZ92 K562 eGFP-PBX2 cancer cell line human CVCL_GZ92 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8633; PBX2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093786 CVCL_PT20 BayGenomics ES cell line XG167 embryonic stem cell house mouse CVCL_PT20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093787 CVCL_Q520 HG01937 transformed cell line human CVCL_Q520 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093788 CVCL_PT21 BayGenomics ES cell line XG169 embryonic stem cell house mouse CVCL_PT21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913275; Rcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093789 CVCL_Q521 HG01938 transformed cell line human CVCL_Q521 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093790 CVCL_PT22 BayGenomics ES cell line XG171 embryonic stem cell house mouse CVCL_PT22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860197; Wdr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093791 CVCL_Q522 HG01939 transformed cell line human CVCL_Q522 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093792 CVCL_PT23 BayGenomics ES cell line XG173 embryonic stem cell house mouse CVCL_PT23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95791; Got1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093793 CVCL_Q523 HG01940 transformed cell line human CVCL_Q523 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093794 CVCL_PT24 BayGenomics ES cell line XG175 embryonic stem cell house mouse CVCL_PT24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913466; Bsdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093795 CVCL_Q524 HG01941 transformed cell line human CVCL_Q524 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093796 CVCL_PT25 BayGenomics ES cell line XG177 embryonic stem cell house mouse CVCL_PT25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182465; Vrk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093797 CVCL_Q525 HG01942 transformed cell line human CVCL_Q525 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093798 CVCL_PT26 BayGenomics ES cell line XG178 embryonic stem cell house mouse CVCL_PT26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107185; Cct5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093799 CVCL_Q526 HG01943 transformed cell line human CVCL_Q526 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093800 CVCL_PT27 BayGenomics ES cell line XG179 embryonic stem cell house mouse CVCL_PT27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99147; Yes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093801 CVCL_Q527 HG01944 transformed cell line human CVCL_Q527 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093802 CVCL_PT28 BayGenomics ES cell line XG181 embryonic stem cell house mouse CVCL_PT28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093803 CVCL_Q528 HG01945 transformed cell line human CVCL_Q528 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093804 CVCL_PT29 BayGenomics ES cell line XG182 embryonic stem cell house mouse CVCL_PT29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891840; Ncbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093805 CVCL_Q529 HG01946 transformed cell line human CVCL_Q529 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093806 CVCL_GZ79 K562 eGFP-E2F4 cancer cell line human CVCL_GZ79 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3118; E2F4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093807 CVCL_PT10 BayGenomics ES cell line XG145 embryonic stem cell house mouse CVCL_PT10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858202; Rab11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093808 CVCL_Q510 HG01924 transformed cell line human CVCL_Q510 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093809 CVCL_PT11 BayGenomics ES cell line XG146 embryonic stem cell house mouse CVCL_PT11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277166; Sp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093810 CVCL_Q511 HG01925 transformed cell line human CVCL_Q511 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093811 CVCL_PT12 BayGenomics ES cell line XG147 embryonic stem cell house mouse CVCL_PT12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98299; Shmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093812 CVCL_Q512 HG01926 transformed cell line human CVCL_Q512 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093813 CVCL_GZ75 K562 eGFP-ADNP cancer cell line human CVCL_GZ75 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 15766; ADNP; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21093814 CVCL_PT13 BayGenomics ES cell line XG149 embryonic stem cell house mouse CVCL_PT13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913482; Znrd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093815 CVCL_Q513 HG01927 transformed cell line human CVCL_Q513 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093816 CVCL_GZ76 K562 eGFP-ATF3 cancer cell line human CVCL_GZ76 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 785; ATF3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21093817 CVCL_PT14 BayGenomics ES cell line XG150 embryonic stem cell house mouse CVCL_PT14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093818 CVCL_Q514 HG01928 transformed cell line human CVCL_Q514 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093819 CVCL_GZ77 K562 eGFP-CEBPG cancer cell line human CVCL_GZ77 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1837; CEBPG; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21093820 CVCL_PT15 BayGenomics ES cell line XG155 embryonic stem cell house mouse CVCL_PT15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093821 CVCL_Q515 HG01932 transformed cell line human CVCL_Q515 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093822 CVCL_GZ78 K562 eGFP-CUX1 cancer cell line human CVCL_GZ78 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2557; CUX1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093823 CVCL_PT16 BayGenomics ES cell line XG157 embryonic stem cell house mouse CVCL_PT16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093824 CVCL_Q516 HG01933 transformed cell line human CVCL_Q516 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093825 CVCL_GZ71 KM3/DDP cancer cell line human CVCL_GZ71 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). 21093826 CVCL_PT17 BayGenomics ES cell line XG161 embryonic stem cell house mouse CVCL_PT17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443807; Osbpl8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093827 CVCL_Q517 HG01934 transformed cell line human CVCL_Q517 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093828 CVCL_GZ72 U266/ADM cancer cell line human CVCL_GZ72 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21093829 CVCL_PT18 BayGenomics ES cell line XG163 embryonic stem cell house mouse CVCL_PT18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443926; Dmxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093830 CVCL_GZ73 fHDF/TERT166 telomerase immortalized cell line human CVCL_GZ73 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male Doubling time: ~48 hours (Evercyte) 21093831 CVCL_Q518 HG01935 transformed cell line human CVCL_Q518 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093832 CVCL_PT19 BayGenomics ES cell line XG164 embryonic stem cell house mouse CVCL_PT19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442191; Dusp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093833 CVCL_GZ74 BMWi19851992 embryonic stem cell human CVCL_GZ74 CL:0000010 Unspecified 21093834 CVCL_Q519 HG01936 transformed cell line human CVCL_Q519 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093835 CVCL_GZ70 FPMI-NL-31 spontaneously immortalized cell line CVCL_GZ70 CL:0000010 Unspecified Group: Insect cell line. 21093836 CVCL_PT00 BayGenomics ES cell line XG131 embryonic stem cell house mouse CVCL_PT00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144243; Clint1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093837 CVCL_Q500 HG01914 transformed cell line human CVCL_Q500 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093838 CVCL_PT01 BayGenomics ES cell line XG134 embryonic stem cell house mouse CVCL_PT01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093839 CVCL_Q501 HG01915 transformed cell line human CVCL_Q501 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093840 CVCL_GZ86 K562 eGFP-GABPA cancer cell line human CVCL_GZ86 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4071; GABPA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093841 CVCL_PT02 BayGenomics ES cell line XG136 embryonic stem cell house mouse CVCL_PT02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913128; Bet1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093842 CVCL_Q502 HG01916 transformed cell line human CVCL_Q502 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093843 CVCL_GZ87 K562 eGFP-GTF2A2 cancer cell line human CVCL_GZ87 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4647; GTF2A2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093844 CVCL_PT03 BayGenomics ES cell line XG137 embryonic stem cell house mouse CVCL_PT03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923799; Cecr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093845 CVCL_Q503 HG01917 transformed cell line human CVCL_Q503 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093846 CVCL_GZ88 K562 eGFP-GTF2E2 cancer cell line human CVCL_GZ88 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4651; GTF2E2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093847 CVCL_PT04 BayGenomics ES cell line XG138 embryonic stem cell house mouse CVCL_PT04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917747; Arhgap17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093848 CVCL_Q504 HG01918 transformed cell line human CVCL_Q504 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093849 CVCL_GZ89 K562 eGFP-MEF2D cancer cell line human CVCL_GZ89 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6997; MEF2D; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093850 CVCL_PT05 BayGenomics ES cell line XG139 embryonic stem cell house mouse CVCL_PT05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096566; Pias2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093851 CVCL_Q505 HG01919 transformed cell line human CVCL_Q505 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093852 CVCL_GZ82 K562 eGFP-ELK1 cancer cell line human CVCL_GZ82 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3321; ELK1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093853 CVCL_PT06 BayGenomics ES cell line XG140 embryonic stem cell house mouse CVCL_PT06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103264; Arhgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093854 CVCL_Q506 HG01920 transformed cell line human CVCL_Q506 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093855 CVCL_GZ83 K562 eGFP-ETS2 cancer cell line human CVCL_GZ83 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3489; ETS2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093856 CVCL_PT07 BayGenomics ES cell line XG142 embryonic stem cell house mouse CVCL_PT07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093857 CVCL_Q507 HG01921 transformed cell line human CVCL_Q507 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093858 CVCL_GZ84 K562 eGFP-FOSL1 cancer cell line human CVCL_GZ84 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13718; FOSL1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093859 CVCL_PT08 BayGenomics ES cell line XG143 embryonic stem cell house mouse CVCL_PT08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919824; Zc3h14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093860 CVCL_Q508 HG01922 transformed cell line human CVCL_Q508 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093861 CVCL_GZ85 K562 eGFP-FOXJ2 cancer cell line human CVCL_GZ85 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 24818; FOXJ2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093862 CVCL_PT09 BayGenomics ES cell line XG144 embryonic stem cell house mouse CVCL_PT09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921605; Smchd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21093863 CVCL_Q509 HG01923 transformed cell line human CVCL_Q509 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21093864 CVCL_GZ80 K562 eGFP-E2F5 cancer cell line human CVCL_GZ80 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3119; E2F5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093865 CVCL_GZ81 K562 eGFP-ELF1 cancer cell line human CVCL_GZ81 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3316; ELF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21093866 CVCL_GZ57 hBRIE 380 hybrid cell line Norway rat CVCL_GZ57 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: Sprague Dawley. Characteristics: Fusion of the BRI 291 cell line with a freshly dispersed small intestinal mucosa epithelial cell (PubMed=1711225) 21093867 CVCL_GZ58 hBRIE 380i hybrid cell line Norway rat CVCL_GZ58 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: Sprague Dawley. Characteristics: Selected specifically for FABP2 (I-FABP) expression without FABP1 (L-FABP) expression (PubMed=7943338) 21093868 CVCL_GZ59 hBRIE 380i-neg hybrid cell line Norway rat CVCL_GZ59 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: Sprague Dawley. Characteristics: Does not express FABP2 (I-FABP) (PubMed=9487140) 21093869 CVCL_GZ53 GM23896 transformed cell line human CVCL_GZ53 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Ser153Glnfs*111 (c.457delT); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093870 CVCL_GZ54 GM25502 finite cell line human CVCL_GZ54 CL:0000010 Sequence variation: Mutation; HGNC; 18127; TUBGCP6; Simple; p.Ter1820Glyext*16 (c.5458T>G); ClinVar=VCV000030809; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21093871 CVCL_GZ55 BRIE 139 spontaneously immortalized cell line Norway rat CVCL_GZ55 CL:0000010 Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Unspecified 21093872 CVCL_GZ56 BRIE 291 spontaneously immortalized cell line Norway rat CVCL_GZ56 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Unspecified 21093873 CVCL_GZ50 GM14734 transformed cell line human CVCL_GZ50 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; Ex1-8del; Zygosity=Heterozygous (PubMed=27896104); Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-5 30kb del (CH-5 type CYP21A1P/CYP21A2 chimer); Zygosity=Heterozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21093874 CVCL_GZ51 GM22519 transformed cell line human CVCL_GZ51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093875 CVCL_GZ52 GM23858 transformed cell line human CVCL_GZ52 CL:0000010 Sequence variation: Mutation; HGNC; 17996; NAGS; Simple; c.-3063C>A; Zygosity=Unspecified; Note=In enhancer region (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21093876 CVCL_GZ68 FPMI-NL-1 spontaneously immortalized cell line CVCL_GZ68 CL:0000010 Unspecified Group: Insect cell line. 21093877 CVCL_GZ69 FPMI-NL-27 spontaneously immortalized cell line CVCL_GZ69 CL:0000010 Unspecified Group: Insect cell line. 21093878 CVCL_GZ64 MHM-8 cancer cell line human CVCL_GZ64 CL:0000010 21093879 CVCL_GZ65 KM3 [Human myeloma] cancer cell line human CVCL_GZ65 From: Hou J.; Second Military Medical University; Shanghai; China CL:0000010 Population: Chinese. 21093880 CVCL_GZ66 KM3/BTZ cancer cell line human CVCL_GZ66 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade). 21093881 CVCL_GZ67 TAB1 cancer cell line human CVCL_GZ67 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Requires bone marrow stromal cells for growth. Doubling time: ~72 hours (PubMed=12579318) 21093882 CVCL_GZ60 GM25503 finite cell line human CVCL_GZ60 CL:0000010 Sequence variation: Mutation; HGNC; 18127; TUBGCP6; Simple; p.Ter1820Glyext*16 (c.5458T>G); ClinVar=VCV000030809; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21093883 CVCL_GZ61 CHA59 cancer cell line human CVCL_GZ61 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21093884 CVCL_GZ62 MDA-ACC-01(hTERT) telomerase immortalized cell line human CVCL_GZ62 CL:0000010 Transfected with: HGNC; 11730; TERT. Male Doubling time: 60 hours (PubMed=25086988) 21093885 CVCL_GZ63 MHM-25 cancer cell line human CVCL_GZ63 CL:0000010 21093886 CVCL_6I42 DA00150 transformed cell line human CVCL_6I42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093887 CVCL_6I43 DA00151 transformed cell line human CVCL_6I43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093888 CVCL_6I44 DA00152 transformed cell line human CVCL_6I44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093889 CVCL_6I45 DA00153 transformed cell line human CVCL_6I45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093890 CVCL_6I40 DA00148 transformed cell line human CVCL_6I40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093891 CVCL_6I41 DA00149 transformed cell line human CVCL_6I41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093892 CVCL_6I46 DA00154 transformed cell line human CVCL_6I46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093893 CVCL_6I47 DA00155 transformed cell line human CVCL_6I47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093894 CVCL_6I48 DA00156 transformed cell line human CVCL_6I48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093895 CVCL_6I49 DA00158 transformed cell line human CVCL_6I49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093896 CVCL_Z094 H5CL-B spontaneously immortalized cell line CVCL_Z094 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5635. 21093897 CVCL_Z095 H5CL-F spontaneously immortalized cell line CVCL_Z095 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5636. 21093898 CVCL_Z096 IPLB-TN-R2 spontaneously immortalized cell line CVCL_Z096 CL:0000010 Unspecified Group: Insect cell line. 21093899 CVCL_Z097 IPLB-Ek-x4T spontaneously immortalized cell line CVCL_Z097 CL:0000010 Unspecified Group: Insect cell line. 21093900 CVCL_Z090 BmN4-IR spontaneously immortalized cell line CVCL_Z090 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Ovary. Female Group: Insect cell line 21093901 CVCL_Z091 BmN4-SID1 spontaneously immortalized cell line CVCL_Z091 CL:0000010 Transfected with: UniProtKB; Q0GZC8; Caenorhabditis elegans sid-1 Derived from sampling site: Ovary. Female Group: Insect cell line 21093902 CVCL_Z092 NIAS-Boma-529b spontaneously immortalized cell line CVCL_Z092 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21093903 CVCL_Z093 BTI-Tn-MG1 spontaneously immortalized cell line CVCL_Z093 CL:0000010 Derived from sampling site: Midgut. Unspecified Doubling time: 20 hours (PubMed=21667340) Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10860 21093904 CVCL_Z098 IPLB-Ek-x4S spontaneously immortalized cell line CVCL_Z098 CL:0000010 Unspecified Group: Insect cell line Caution: This cell line was originally called IPLB-Ek-x4V because it grew as vesicles (thus the \"V\") but subsequently changed their morphology to grow as small aggregates or chains of cells growing in suspension (thus the \"S\"). 21093905 CVCL_Z099 IPLB-LdEIta spontaneously immortalized cell line CVCL_Z099 CL:0000010 Unspecified Group: Insect cell line. 21093906 CVCL_6I53 DA00162 transformed cell line human CVCL_6I53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093907 CVCL_6I54 DA00163 transformed cell line human CVCL_6I54 CL:0000010 Population: Caribbean; Jamaican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093908 CVCL_6I55 DA00164 transformed cell line human CVCL_6I55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093909 CVCL_6I56 DA00165 transformed cell line human CVCL_6I56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093910 CVCL_6I50 DA00159 transformed cell line human CVCL_6I50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093911 CVCL_6I51 DA00160 transformed cell line human CVCL_6I51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093912 CVCL_6I52 DA00161 transformed cell line human CVCL_6I52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093913 CVCL_6I57 DA00166 transformed cell line human CVCL_6I57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093914 CVCL_6I58 DA00167 transformed cell line human CVCL_6I58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093915 CVCL_6I59 DA00168 transformed cell line human CVCL_6I59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093916 CVCL_Z083 TUAT-BME-11 spontaneously immortalized cell line CVCL_Z083 CL:0000010 Breed/subspecies: Kuroko. Unspecified Group: Insect cell line 21093917 CVCL_Z084 TUAT-BME-15 spontaneously immortalized cell line CVCL_Z084 CL:0000010 Breed/subspecies: Kuroko. Unspecified Group: Insect cell line 21093918 CVCL_Z085 BmE-SWU1 spontaneously immortalized cell line CVCL_Z085 CL:0000010 Breed/subspecies: Xiafang x Qiubai. Unspecified Doubling time: 58.7 hours (PubMed=17570024) Group: Insect cell line 21093919 CVCL_Z086 BmE-SWU2 spontaneously immortalized cell line CVCL_Z086 CL:0000010 Breed/subspecies: 12-010 x p98. Unspecified Doubling time: 51.8 hours (CelloPub=CLPUB00220); 46.6 hours (PubMed=17570024) Group: Insect cell line 21093920 CVCL_Z080 OAD2 cancer cell line human CVCL_Z080 CL:0000010 Population: Japanese. Unspecified 21093921 CVCL_Z081 OSQ1 cancer cell line human CVCL_Z081 CL:0000010 Population: Japanese. Unspecified 21093922 CVCL_Z082 DZNU-Bm-1 spontaneously immortalized cell line CVCL_Z082 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: Swarnandhra. Female Group: Insect cell line 21093923 CVCL_Z087 Bme21 spontaneously immortalized cell line CVCL_Z087 CL:0000010 Breed/subspecies: e21. Unspecified Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-20852 21093924 CVCL_Z088 BmN-SWU1 spontaneously immortalized cell line CVCL_Z088 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: 21-872nlw. Female Doubling time: ~57.7 hours, at 45th passage (PubMed=19665160) Group: Insect cell line 21093925 CVCL_Z089 BmN4-DR spontaneously immortalized cell line CVCL_Z089 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Ovary. Female Group: Insect cell line 21093926 CVCL_6I20 DA00126 transformed cell line human CVCL_6I20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093927 CVCL_6I21 DA00127 transformed cell line human CVCL_6I21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093928 CVCL_6I22 DA00128 transformed cell line human CVCL_6I22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093929 CVCL_6I23 DA00129 transformed cell line human CVCL_6I23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093930 CVCL_6I28 DA00134 transformed cell line human CVCL_6I28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093931 CVCL_6I29 DA00135 transformed cell line human CVCL_6I29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093932 CVCL_6I24 DA00130 transformed cell line human CVCL_6I24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093933 CVCL_6I25 DA00131 transformed cell line human CVCL_6I25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093934 CVCL_6I26 DA00132 transformed cell line human CVCL_6I26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093935 CVCL_6I27 DA00133 transformed cell line human CVCL_6I27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093936 CVCL_Z072 VLN1F9 hybridoma human CVCL_Z072 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8635 21093937 CVCL_Z073 VLN3F10 hybridoma human CVCL_Z073 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG3, kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8632 21093938 CVCL_Z074 VLN5C7 hybridoma human CVCL_Z074 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8634 21093939 CVCL_Z075 UM90-14 PGD embryonic stem cell human CVCL_Z075 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM90-12 PGD (Cellosaurus=CVCL_X364). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0306 21093940 CVCL_Z070 PAI-0 cancer cell line house mouse CVCL_Z070 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21093941 CVCL_Z071 SHEFP-1 transformed cell line human CVCL_Z071 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line 21093942 CVCL_Z076 UM25-2 embryonic stem cell human CVCL_Z076 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0305. 21093943 CVCL_Z077 UM112-2 PGD embryonic stem cell human CVCL_Z077 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM112-1 PGD (Cellosaurus=CVCL_X369). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0307 21093944 CVCL_Z078 TN-368-10 spontaneously immortalized cell line CVCL_Z078 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 14-17 hours (PubMed=1104895) Group: Insect cell line; Group: Recombinant protein production insect cell line 21093945 CVCL_Z079 TN-368-13 spontaneously immortalized cell line CVCL_Z079 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 14-15 hours (PubMed=1104895) Group: Insect cell line; Group: Recombinant protein production insect cell line 21093946 CVCL_6I31 DA00137 transformed cell line human CVCL_6I31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093947 CVCL_6I32 DA00138 transformed cell line human CVCL_6I32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093948 CVCL_6I33 DA00139 transformed cell line human CVCL_6I33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093949 CVCL_6I34 DA00140 transformed cell line human CVCL_6I34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093950 CVCL_6I30 DA00136 transformed cell line human CVCL_6I30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093951 CVCL_6I39 DA00147 transformed cell line human CVCL_6I39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093952 CVCL_6I35 DA00141 transformed cell line human CVCL_6I35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093953 CVCL_6I36 DA00142 transformed cell line human CVCL_6I36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093954 CVCL_6I37 DA00143 transformed cell line human CVCL_6I37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093955 CVCL_6I38 DA00145 transformed cell line human CVCL_6I38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093956 CVCL_Z061 CADO-LC24 cancer cell line human CVCL_Z061 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093957 CVCL_Z062 CADO-LC26 cancer cell line human CVCL_Z062 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093958 CVCL_Z063 CADO-LC41 cancer cell line human CVCL_Z063 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093959 CVCL_Z064 NFkappaB-TIME telomerase immortalized cell line human CVCL_Z064 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris Derived from sampling site: Foreskin; skin; dermis; microvascular endothelium. Male Characteristics: The NanoLuc reporter gene is under the control of multiple copies of the NF-kappaB response element (ATCC); Characteristics: When cells are exposed to inflammatory cytokines such as TNFalpha, activation of the NF-kappaB signaling pathway occurs resulting in increased luciferase activity (ATCC) 21093960 CVCL_Z060 CADO-LC22 cancer cell line human CVCL_Z060 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21093961 CVCL_Z069 240E-W2 cancer cell line CVCL_Z069 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line 21093962 CVCL_Z065 TeloHAEC telomerase immortalized cell line human CVCL_Z065 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.. Female 21093963 CVCL_Z066 TeloHAEC-GFP telomerase immortalized cell line human CVCL_Z066 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP) Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.. Female Characteristics: Stably expresses emerald GFP (emGFP) under the control of the EF-1 alpha promoter 21093964 CVCL_Z067 Sp2ab cancer cell line house mouse CVCL_Z067 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21093965 CVCL_Z068 240E-W cancer cell line CVCL_Z068 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 21093966 CVCL_6I00 DA00105 transformed cell line human CVCL_6I00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093967 CVCL_6I01 DA00106 transformed cell line human CVCL_6I01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093968 CVCL_6I06 DA00111 transformed cell line human CVCL_6I06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093969 CVCL_6I07 DA00112 transformed cell line human CVCL_6I07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093970 CVCL_6I08 DA00113 transformed cell line human CVCL_6I08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093971 CVCL_6I09 DA00114 transformed cell line human CVCL_6I09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093972 CVCL_6I02 DA00107 transformed cell line human CVCL_6I02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093973 CVCL_6I03 DA00108 transformed cell line human CVCL_6I03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093974 CVCL_6I04 DA00109 transformed cell line human CVCL_6I04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093975 CVCL_6I05 DA00110 transformed cell line human CVCL_6I05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093976 CVCL_Z050 CADO-LC6 cancer cell line human CVCL_Z050 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093977 CVCL_Z051 CADO-LC7 cancer cell line human CVCL_Z051 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093978 CVCL_Z052 CADO-LC8 cancer cell line human CVCL_Z052 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Unspecified 21093979 CVCL_Z053 CADO-LC9 cancer cell line human CVCL_Z053 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093980 CVCL_Z058 CADO-LC20 cancer cell line human CVCL_Z058 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093981 CVCL_Z059 CADO-LC21 cancer cell line human CVCL_Z059 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093982 CVCL_Z054 CADO-LC10 cancer cell line human CVCL_Z054 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093983 CVCL_Z055 CADO-LC11 cancer cell line human CVCL_Z055 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21093984 CVCL_Z056 CADO-LC15 cancer cell line human CVCL_Z056 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 60 hours (PubMed=7934063) 21093985 CVCL_Z057 CADO-LC17 cancer cell line human CVCL_Z057 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified Caution: Erroneously indicated in Table 1 of PubMed=7690355 as being a SCLC cell line 21093986 CVCL_6I10 DA00115 transformed cell line human CVCL_6I10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093987 CVCL_6I11 DA00116 transformed cell line human CVCL_6I11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093988 CVCL_6I12 DA00117 transformed cell line human CVCL_6I12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093989 CVCL_6I17 DA00122 transformed cell line human CVCL_6I17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093990 CVCL_6I18 DA00123 transformed cell line human CVCL_6I18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093991 CVCL_6I19 DA00125 transformed cell line human CVCL_6I19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093992 CVCL_6I13 DA00118 transformed cell line human CVCL_6I13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093993 CVCL_6I14 DA00119 transformed cell line human CVCL_6I14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093994 CVCL_6I15 DA00120 transformed cell line human CVCL_6I15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093995 CVCL_6I16 DA00121 transformed cell line human CVCL_6I16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21093996 CVCL_Z040 DMS 149 cancer cell line human CVCL_Z040 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 28-35 days (PubMed=6266631; PubMed=2986244) 21093997 CVCL_Z041 DMS 187 cancer cell line human CVCL_Z041 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified Doubling time: 8 days (PubMed=6266631); 4.1 days (PubMed=2986244) 21093998 CVCL_Z042 DMS 217 cancer cell line human CVCL_Z042 CL:0000010 Derived from metastatic site: Pericardial mass. Unspecified Doubling time: 28 days (PubMed=6266631; PubMed=2986244) 21093999 CVCL_Z047 CADO-LC1 cancer cell line human CVCL_Z047 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 29 hours (PubMed=7934063) 21094000 CVCL_Z048 CADO-LC3 cancer cell line human CVCL_Z048 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21094001 CVCL_Z049 CADO-LC5 cancer cell line human CVCL_Z049 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21094002 CVCL_Z043 DMS 235 cancer cell line human CVCL_Z043 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified Doubling time: 8.5 days (PubMed=6266631); 4.6 days (PubMed=2986244) 21094003 CVCL_Z044 TAW-925 transformed cell line human CVCL_Z044 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Institute for Fermentation, Osaka; IFO50095 21094004 CVCL_Z045 HO-323 transformed cell line human CVCL_Z045 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line 21094005 CVCL_Z046 AC-33 transformed cell line human CVCL_Z046 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Discontinued: JCRB; IFO50155; true Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2143 21094006 CVCL_PU91 BayGenomics ES cell line XG550 embryonic stem cell house mouse CVCL_PU91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384761; Rapgef6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094007 CVCL_Q691 HG02232 transformed cell line human CVCL_Q691 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094008 CVCL_PU92 BayGenomics ES cell line XG552 embryonic stem cell house mouse CVCL_PU92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894652; Usp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094009 CVCL_Q692 HG02233 transformed cell line human CVCL_Q692 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094010 CVCL_PU93 BayGenomics ES cell line XG556 embryonic stem cell house mouse CVCL_PU93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094011 CVCL_Q693 HG02234 transformed cell line human CVCL_Q693 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094012 CVCL_PU94 BayGenomics ES cell line XG557 embryonic stem cell house mouse CVCL_PU94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384909; Micu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094013 CVCL_Q694 HG02235 transformed cell line human CVCL_Q694 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094014 CVCL_PU95 BayGenomics ES cell line XG558 embryonic stem cell house mouse CVCL_PU95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917275; Acot7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094015 CVCL_Q695 HG02236 transformed cell line human CVCL_Q695 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094016 CVCL_Z029 SK-JHRCC-12 cancer cell line human CVCL_Z029 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Bone. Male Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK-JHRCC-12 21094017 CVCL_PU96 BayGenomics ES cell line XG561 embryonic stem cell house mouse CVCL_PU96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094018 CVCL_Q696 HG02237 transformed cell line human CVCL_Q696 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094019 CVCL_PU97 BayGenomics ES cell line XG563 embryonic stem cell house mouse CVCL_PU97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924281; Slc9a8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094020 CVCL_Q697 HG02238 transformed cell line human CVCL_Q697 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094021 CVCL_PU98 BayGenomics ES cell line XG564 embryonic stem cell house mouse CVCL_PU98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920362; Abracl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094022 CVCL_Q698 HG02239 transformed cell line human CVCL_Q698 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094023 CVCL_PU99 BayGenomics ES cell line XG565 embryonic stem cell house mouse CVCL_PU99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094024 CVCL_Q699 HG02240 transformed cell line human CVCL_Q699 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094025 CVCL_Z030 SK-JHRCC-120 cancer cell line human CVCL_Z030 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK-JHRCC-120 21094026 CVCL_Z031 SK-JHRCC-3 cancer cell line human CVCL_Z031 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK-JHRCC-3 21094027 CVCL_Z036 DMS 55 cancer cell line human CVCL_Z036 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified Doubling time: 6 days (PubMed=6266631); 4.8 days (PubMed=2986244) 21094028 CVCL_Z037 DMS 106 cancer cell line human CVCL_Z037 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21094029 CVCL_Z038 DMS 139 cancer cell line human CVCL_Z038 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified Doubling time: 35 days (PubMed=6266631; PubMed=2986244) 21094030 CVCL_Z039 DMS 148 cancer cell line human CVCL_Z039 CL:0000010 Derived from metastatic site: Liver. Unspecified Doubling time: 28-35 days (PubMed=6266631; PubMed=2986244) 21094031 CVCL_Z032 SK-JHRCC-92 cancer cell line human CVCL_Z032 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Bone. Male Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK-JHRCC-92 21094032 CVCL_Z033 DMS 154 cancer cell line human CVCL_Z033 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 35 days (PubMed=6266631; PubMed=2986244) 21094033 CVCL_Z034 DMS 44 cancer cell line human CVCL_Z034 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 2 weeks (PubMed=6266631) 21094034 CVCL_Z035 DMS 47 cancer cell line human CVCL_Z035 CL:0000010 Derived from metastatic site: Liver. Unspecified Doubling time: 28 days (PubMed=6266631; PubMed=2986244) 21094035 CVCL_PU80 BayGenomics ES cell line XG515 embryonic stem cell house mouse CVCL_PU80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860493; Arhgef7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094036 CVCL_Q680 HG02190 transformed cell line human CVCL_Q680 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094037 CVCL_PU81 BayGenomics ES cell line XG518 embryonic stem cell house mouse CVCL_PU81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347053; Git2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094038 CVCL_Q681 HG02215 transformed cell line human CVCL_Q681 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094039 CVCL_PU82 BayGenomics ES cell line XG519 embryonic stem cell house mouse CVCL_PU82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913993; Rnf220 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094040 CVCL_Q682 HG02220 transformed cell line human CVCL_Q682 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094041 CVCL_PU83 BayGenomics ES cell line XG520 embryonic stem cell house mouse CVCL_PU83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094042 CVCL_Q683 HG02221 transformed cell line human CVCL_Q683 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094043 CVCL_PU84 BayGenomics ES cell line XG521 embryonic stem cell house mouse CVCL_PU84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138982; Znfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094044 CVCL_Q684 HG02222 transformed cell line human CVCL_Q684 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094045 CVCL_Z018 hMSC-TERT20 telomerase immortalized cell line human CVCL_Z018 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow; stroma. Omics: Plasma membrane phosphoproteome analysis Male 21094046 CVCL_Z019 1335-mel cancer cell line human CVCL_Z019 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21094047 CVCL_PU85 BayGenomics ES cell line XG523 embryonic stem cell house mouse CVCL_PU85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892979; Chm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094048 CVCL_Q685 HG02223 transformed cell line human CVCL_Q685 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094049 CVCL_PU86 BayGenomics ES cell line XG525 embryonic stem cell house mouse CVCL_PU86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441773; Pcmtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094050 CVCL_Q686 HG02224 transformed cell line human CVCL_Q686 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094051 CVCL_PU87 BayGenomics ES cell line XG527 embryonic stem cell house mouse CVCL_PU87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107595; Sp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094052 CVCL_Q687 HG02225 transformed cell line human CVCL_Q687 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094053 CVCL_PU88 BayGenomics ES cell line XG533 embryonic stem cell house mouse CVCL_PU88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094054 CVCL_Q688 HG02229 transformed cell line human CVCL_Q688 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094055 CVCL_PU89 BayGenomics ES cell line XG537 embryonic stem cell house mouse CVCL_PU89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443272; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094056 CVCL_Q689 HG02230 transformed cell line human CVCL_Q689 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094057 CVCL_Z020 1352-mel cancer cell line human CVCL_Z020 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21094058 CVCL_Z025 ACC-LC-97 cancer cell line human CVCL_Z025 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21094059 CVCL_Z026 ACC-LC-175 cancer cell line human CVCL_Z026 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21094060 CVCL_Z027 ACC-LC-78 cancer cell line human CVCL_Z027 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21094061 CVCL_Z028 ACC-LC-66 cancer cell line human CVCL_Z028 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Unspecified 21094062 CVCL_Z021 586-mel cancer cell line human CVCL_Z021 HLA typing: A*29,31; B*44,68 (PubMed=8027550) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Female 21094063 CVCL_Z022 76-2 cancer cell line human CVCL_Z022 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 0.9 day (PubMed=7817386) 21094064 CVCL_Z023 77-4 cancer cell line human CVCL_Z023 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female Doubling time: 1.9 days (PubMed=7817386) 21094065 CVCL_Z024 ACC-LC-35D cancer cell line human CVCL_Z024 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary lymph node. Male 21094066 CVCL_PU90 BayGenomics ES cell line XG543 embryonic stem cell house mouse CVCL_PU90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344313; Zeb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094067 CVCL_Q690 HG02231 transformed cell line human CVCL_Q690 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094068 CVCL_6I86 DA00195 transformed cell line human CVCL_6I86 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094069 CVCL_6I87 DA00196 transformed cell line human CVCL_6I87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094070 CVCL_6I88 DA00197 transformed cell line human CVCL_6I88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094071 CVCL_6I89 DA00198 transformed cell line human CVCL_6I89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094072 CVCL_6I82 DA00191 transformed cell line human CVCL_6I82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094073 CVCL_6I83 DA00192 transformed cell line human CVCL_6I83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094074 CVCL_6I84 DA00193 transformed cell line human CVCL_6I84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094075 CVCL_6I85 DA00194 transformed cell line human CVCL_6I85 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094076 CVCL_6I80 DA00189 transformed cell line human CVCL_6I80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094077 CVCL_6I81 DA00190 transformed cell line human CVCL_6I81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094078 CVCL_6I97 DA00207 transformed cell line human CVCL_6I97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094079 CVCL_6I98 DA00208 transformed cell line human CVCL_6I98 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094080 CVCL_6I99 DA00209 transformed cell line human CVCL_6I99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094081 CVCL_6I93 DA00202 transformed cell line human CVCL_6I93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094082 CVCL_6I94 DA00204 transformed cell line human CVCL_6I94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094083 CVCL_6I95 DA00205 transformed cell line human CVCL_6I95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094084 CVCL_6I96 DA00206 transformed cell line human CVCL_6I96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094085 CVCL_6I90 DA00199 transformed cell line human CVCL_6I90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094086 CVCL_6I91 DA00200 transformed cell line human CVCL_6I91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094087 CVCL_6I92 DA00201 transformed cell line human CVCL_6I92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094088 CVCL_6I64 DA00173 transformed cell line human CVCL_6I64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094089 CVCL_6I65 DA00174 transformed cell line human CVCL_6I65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094090 CVCL_6I66 DA00175 transformed cell line human CVCL_6I66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094091 CVCL_6I67 DA00176 transformed cell line human CVCL_6I67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094092 CVCL_6I60 DA00169 transformed cell line human CVCL_6I60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094093 CVCL_6I61 DA00170 transformed cell line human CVCL_6I61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094094 CVCL_6I62 DA00171 transformed cell line human CVCL_6I62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094095 CVCL_6I63 DA00172 transformed cell line human CVCL_6I63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094096 CVCL_6I68 DA00177 transformed cell line human CVCL_6I68 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094097 CVCL_6I69 DA00178 transformed cell line human CVCL_6I69 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094098 CVCL_6I75 DA00184 transformed cell line human CVCL_6I75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094099 CVCL_6I76 DA00185 transformed cell line human CVCL_6I76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094100 CVCL_6I77 DA00186 transformed cell line human CVCL_6I77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094101 CVCL_6I78 DA00187 transformed cell line human CVCL_6I78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094102 CVCL_6I71 DA00180 transformed cell line human CVCL_6I71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094103 CVCL_6I72 DA00181 transformed cell line human CVCL_6I72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094104 CVCL_6I73 DA00182 transformed cell line human CVCL_6I73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094105 CVCL_6I74 DA00183 transformed cell line human CVCL_6I74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094106 CVCL_6I79 DA00188 transformed cell line human CVCL_6I79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094107 CVCL_6I70 DA00179 transformed cell line human CVCL_6I70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094108 CVCL_PU70 BayGenomics ES cell line XG496 embryonic stem cell house mouse CVCL_PU70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196373; Reps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094109 CVCL_Q670 HG02179 transformed cell line human CVCL_Q670 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094110 CVCL_PU71 BayGenomics ES cell line XG499 embryonic stem cell house mouse CVCL_PU71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139764; Sec24b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094111 CVCL_Q671 HG02180 transformed cell line human CVCL_Q671 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094112 CVCL_PU72 BayGenomics ES cell line XG500 embryonic stem cell house mouse CVCL_PU72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103007; Epb41l4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094113 CVCL_Q672 HG02181 transformed cell line human CVCL_Q672 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094114 CVCL_PU73 BayGenomics ES cell line XG501 embryonic stem cell house mouse CVCL_PU73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926950; Zfp236 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094115 CVCL_Z007 CHA-hES41 embryonic stem cell human CVCL_Z007 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012013. 21094116 CVCL_Q673 HG02182 transformed cell line human CVCL_Q673 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094117 CVCL_PU74 BayGenomics ES cell line XG502 embryonic stem cell house mouse CVCL_PU74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99542; Usf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094118 CVCL_Z008 CHA-hES42 embryonic stem cell human CVCL_Z008 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012014. 21094119 CVCL_Q674 HG02184 transformed cell line human CVCL_Q674 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094120 CVCL_PU75 BayGenomics ES cell line XG506 embryonic stem cell house mouse CVCL_PU75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094121 CVCL_Z009 CHA-hES43 embryonic stem cell human CVCL_Z009 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013001. 21094122 CVCL_Q675 HG02185 transformed cell line human CVCL_Q675 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094123 CVCL_PU76 BayGenomics ES cell line XG507 embryonic stem cell house mouse CVCL_PU76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924049; Tmem234 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094124 CVCL_Q676 HG02186 transformed cell line human CVCL_Q676 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094125 CVCL_PU77 BayGenomics ES cell line XG510 embryonic stem cell house mouse CVCL_PU77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347053; Git2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094126 CVCL_Q677 HG02187 transformed cell line human CVCL_Q677 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094127 CVCL_PU78 BayGenomics ES cell line XG512 embryonic stem cell house mouse CVCL_PU78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094128 CVCL_Q678 HG02188 transformed cell line human CVCL_Q678 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094129 CVCL_PU79 BayGenomics ES cell line XG514 embryonic stem cell house mouse CVCL_PU79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917497; Psmd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094130 CVCL_Q679 HG02189 transformed cell line human CVCL_Q679 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094131 CVCL_Z014 CHA-hES48 embryonic stem cell human CVCL_Z014 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013006. 21094132 CVCL_Z015 hMSC-TERT telomerase immortalized cell line human CVCL_Z015 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow; stroma. Male 21094133 CVCL_Z016 hMSC-TERT2 telomerase immortalized cell line human CVCL_Z016 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow; stroma. Male 21094134 CVCL_Z017 hMSC-TERT4 telomerase immortalized cell line human CVCL_Z017 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow; stroma. Male 21094135 CVCL_Z010 CHA-hES44 embryonic stem cell human CVCL_Z010 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013002. 21094136 CVCL_Z011 CHA-hES45 embryonic stem cell human CVCL_Z011 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013003. 21094137 CVCL_Z012 CHA-hES46 embryonic stem cell human CVCL_Z012 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013004. 21094138 CVCL_Z013 CHA-hES47 embryonic stem cell human CVCL_Z013 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12013005. 21094139 CVCL_PU60 BayGenomics ES cell line XG471 embryonic stem cell house mouse CVCL_PU60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094140 CVCL_Q660 HG02151 transformed cell line human CVCL_Q660 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094141 CVCL_PU61 BayGenomics ES cell line XG476 embryonic stem cell house mouse CVCL_PU61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928375; Arpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094142 CVCL_Q661 HG02152 transformed cell line human CVCL_Q661 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094143 CVCL_PU62 BayGenomics ES cell line XG478 embryonic stem cell house mouse CVCL_PU62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094144 CVCL_Q662 HG02153 transformed cell line human CVCL_Q662 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094145 CVCL_PU63 BayGenomics ES cell line XG481 embryonic stem cell house mouse CVCL_PU63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094146 CVCL_Q663 HG02154 transformed cell line human CVCL_Q663 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094147 CVCL_PU64 BayGenomics ES cell line XG485 embryonic stem cell house mouse CVCL_PU64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88407; Ckb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094148 CVCL_Q664 HG02155 transformed cell line human CVCL_Q664 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094149 CVCL_PU65 BayGenomics ES cell line XG488 embryonic stem cell house mouse CVCL_PU65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354713; Acsl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094150 CVCL_Q665 HG02156 transformed cell line human CVCL_Q665 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094151 CVCL_PU66 BayGenomics ES cell line XG492 embryonic stem cell house mouse CVCL_PU66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921453; Eif4enif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094152 CVCL_Q666 HG02164 transformed cell line human CVCL_Q666 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094153 CVCL_PU67 BayGenomics ES cell line XG493 embryonic stem cell house mouse CVCL_PU67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029414; Brwd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094154 CVCL_Q667 HG02165 transformed cell line human CVCL_Q667 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094155 CVCL_PU68 BayGenomics ES cell line XG494 embryonic stem cell house mouse CVCL_PU68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094156 CVCL_Q668 HG02166 transformed cell line human CVCL_Q668 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094157 CVCL_PU69 BayGenomics ES cell line XG495 embryonic stem cell house mouse CVCL_PU69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914394; Lrrc40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094158 CVCL_Q669 HG02178 transformed cell line human CVCL_Q669 CL:0000010 Population: Chinese/Asian ethnic group: Dai in Xishuangbanna, China (CDX); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094159 CVCL_Z003 CHA-hES37 embryonic stem cell human CVCL_Z003 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012008. 21094160 CVCL_Z004 CHA-hES38 embryonic stem cell human CVCL_Z004 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012010. 21094161 CVCL_Z005 CHA-hES39 embryonic stem cell human CVCL_Z005 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012011. 21094162 CVCL_Z006 CHA-hES40 embryonic stem cell human CVCL_Z006 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012012. 21094163 CVCL_Z000 CHA-hES34 embryonic stem cell human CVCL_Z000 From: CHA University; Seongnam; South Korea CL:0000010 Unspecified Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012005. 21094164 CVCL_Z001 CHA-hES35 embryonic stem cell human CVCL_Z001 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012006. 21094165 CVCL_Z002 CHA-hES36 embryonic stem cell human CVCL_Z002 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012007. 21094166 CVCL_PU50 BayGenomics ES cell line XG454 embryonic stem cell house mouse CVCL_PU50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094167 CVCL_Q650 HG02139 transformed cell line human CVCL_Q650 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094168 CVCL_PU51 BayGenomics ES cell line XG456 embryonic stem cell house mouse CVCL_PU51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094169 CVCL_Q651 HG02140 transformed cell line human CVCL_Q651 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094170 CVCL_PU52 BayGenomics ES cell line XG458 embryonic stem cell house mouse CVCL_PU52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094171 CVCL_Q652 HG02141 transformed cell line human CVCL_Q652 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094172 CVCL_PU53 BayGenomics ES cell line XG460 embryonic stem cell house mouse CVCL_PU53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109584; Prpf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094173 CVCL_Q653 HG02142 transformed cell line human CVCL_Q653 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094174 CVCL_PU54 BayGenomics ES cell line XG461 embryonic stem cell house mouse CVCL_PU54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094175 CVCL_Q654 HG02143 transformed cell line human CVCL_Q654 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094176 CVCL_PU55 BayGenomics ES cell line XG464 embryonic stem cell house mouse CVCL_PU55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094177 CVCL_Q655 HG02144 transformed cell line human CVCL_Q655 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094178 CVCL_PU56 BayGenomics ES cell line XG466 embryonic stem cell house mouse CVCL_PU56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094179 CVCL_Q656 HG02145 transformed cell line human CVCL_Q656 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094180 CVCL_PU57 BayGenomics ES cell line XG468 embryonic stem cell house mouse CVCL_PU57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094181 CVCL_Q657 HG02146 transformed cell line human CVCL_Q657 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094182 CVCL_PU58 BayGenomics ES cell line XG469 embryonic stem cell house mouse CVCL_PU58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094183 CVCL_Q658 HG02147 transformed cell line human CVCL_Q658 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094184 CVCL_PU59 BayGenomics ES cell line XG470 embryonic stem cell house mouse CVCL_PU59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913915; Msantd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094185 CVCL_Q659 HG02148 transformed cell line human CVCL_Q659 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094186 CVCL_PU40 BayGenomics ES cell line XG431 embryonic stem cell house mouse CVCL_PU40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094187 CVCL_Q640 HG02122 transformed cell line human CVCL_Q640 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094188 CVCL_PU41 BayGenomics ES cell line XG434 embryonic stem cell house mouse CVCL_PU41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094189 CVCL_Q641 HG02127 transformed cell line human CVCL_Q641 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094190 CVCL_PU42 BayGenomics ES cell line XG435 embryonic stem cell house mouse CVCL_PU42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094191 CVCL_Q642 HG02128 transformed cell line human CVCL_Q642 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094192 CVCL_PU43 BayGenomics ES cell line XG438 embryonic stem cell house mouse CVCL_PU43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106594; Gk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094193 CVCL_Q643 HG02130 transformed cell line human CVCL_Q643 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094194 CVCL_PU44 BayGenomics ES cell line XG442 embryonic stem cell house mouse CVCL_PU44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444343; Nbeal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094195 CVCL_Q644 HG02131 transformed cell line human CVCL_Q644 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094196 CVCL_PU45 BayGenomics ES cell line XG445 embryonic stem cell house mouse CVCL_PU45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96245; Hspa9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094197 CVCL_Q645 HG02133 transformed cell line human CVCL_Q645 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094198 CVCL_PU46 BayGenomics ES cell line XG446 embryonic stem cell house mouse CVCL_PU46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929494; Arhgap35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094199 CVCL_Q646 HG02134 transformed cell line human CVCL_Q646 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094200 CVCL_PU47 BayGenomics ES cell line XG447 embryonic stem cell house mouse CVCL_PU47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926048; Eml4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094201 CVCL_Q647 HG02136 transformed cell line human CVCL_Q647 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094202 CVCL_PU48 BayGenomics ES cell line XG451 embryonic stem cell house mouse CVCL_PU48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107726; Supt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094203 CVCL_Q648 HG02137 transformed cell line human CVCL_Q648 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094204 CVCL_PU49 BayGenomics ES cell line XG453 embryonic stem cell house mouse CVCL_PU49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100510; Bub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094205 CVCL_Q649 HG02138 transformed cell line human CVCL_Q649 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094206 CVCL_PU30 BayGenomics ES cell line XG381 embryonic stem cell house mouse CVCL_PU30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915589; Ccdc88c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094207 CVCL_Q630 HG02104 transformed cell line human CVCL_Q630 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094208 CVCL_PU31 BayGenomics ES cell line XG383 embryonic stem cell house mouse CVCL_PU31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449313; Gemin4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094209 CVCL_Q631 HG02105 transformed cell line human CVCL_Q631 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094210 CVCL_PU32 BayGenomics ES cell line XG385 embryonic stem cell house mouse CVCL_PU32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145578; Slain1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094211 CVCL_Q632 HG02106 transformed cell line human CVCL_Q632 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094212 CVCL_PU33 BayGenomics ES cell line XG386 embryonic stem cell house mouse CVCL_PU33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183691; Nav2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094213 CVCL_Q633 HG02107 transformed cell line human CVCL_Q633 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094214 CVCL_PU34 BayGenomics ES cell line XG389 embryonic stem cell house mouse CVCL_PU34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933185; Ctps2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094215 CVCL_Q634 HG02108 transformed cell line human CVCL_Q634 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094216 CVCL_PU35 BayGenomics ES cell line XG390 embryonic stem cell house mouse CVCL_PU35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918413; Zfp626 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094217 CVCL_Q635 HG02109 transformed cell line human CVCL_Q635 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094218 CVCL_PU36 BayGenomics ES cell line XG391 embryonic stem cell house mouse CVCL_PU36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924315; Ints7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094219 CVCL_Q636 HG02111 transformed cell line human CVCL_Q636 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094220 CVCL_PU37 BayGenomics ES cell line XG418 embryonic stem cell house mouse CVCL_PU37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95728; Gli2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094221 CVCL_Q637 HG02113 transformed cell line human CVCL_Q637 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094222 CVCL_PU38 BayGenomics ES cell line XG426 embryonic stem cell house mouse CVCL_PU38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094223 CVCL_Q638 HG02116 transformed cell line human CVCL_Q638 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094224 CVCL_PU39 BayGenomics ES cell line XG429 embryonic stem cell house mouse CVCL_PU39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928469; Trip4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094225 CVCL_Q639 HG02121 transformed cell line human CVCL_Q639 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094226 CVCL_PU20 BayGenomics ES cell line XG369 embryonic stem cell house mouse CVCL_PU20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107403; Clk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094227 CVCL_Q620 HG02082 transformed cell line human CVCL_Q620 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094228 CVCL_PU21 BayGenomics ES cell line XG370 embryonic stem cell house mouse CVCL_PU21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107307; Ing4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094229 CVCL_Q621 HG02084 transformed cell line human CVCL_Q621 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094230 CVCL_PU22 BayGenomics ES cell line XG371 embryonic stem cell house mouse CVCL_PU22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444804; Bod1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094231 CVCL_Q622 HG02085 transformed cell line human CVCL_Q622 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094232 CVCL_PU23 BayGenomics ES cell line XG372 embryonic stem cell house mouse CVCL_PU23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094233 CVCL_Q623 HG02086 transformed cell line human CVCL_Q623 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094234 CVCL_PU24 BayGenomics ES cell line XG373 embryonic stem cell house mouse CVCL_PU24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094235 CVCL_Q624 HG02087 transformed cell line human CVCL_Q624 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094236 CVCL_PU25 BayGenomics ES cell line XG374 embryonic stem cell house mouse CVCL_PU25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094237 CVCL_Q625 HG02088 transformed cell line human CVCL_Q625 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094238 CVCL_PU26 BayGenomics ES cell line XG375 embryonic stem cell house mouse CVCL_PU26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040703; Zfp874a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094239 CVCL_Q626 HG02089 transformed cell line human CVCL_Q626 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094240 CVCL_PU27 BayGenomics ES cell line XG376 embryonic stem cell house mouse CVCL_PU27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040703; Zfp874a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094241 CVCL_Q627 HG02090 transformed cell line human CVCL_Q627 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094242 CVCL_PU28 BayGenomics ES cell line XG378 embryonic stem cell house mouse CVCL_PU28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927347; Smarce1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094243 CVCL_Q628 HG02091 transformed cell line human CVCL_Q628 CL:0000010 Population: Peruvian in Lima (PEL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094244 CVCL_PU29 BayGenomics ES cell line XG379 embryonic stem cell house mouse CVCL_PU29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094245 CVCL_Q629 HG02095 transformed cell line human CVCL_Q629 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094246 CVCL_PU10 BayGenomics ES cell line XG339 embryonic stem cell house mouse CVCL_PU10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914869; Nob1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094247 CVCL_Q610 HG02067 transformed cell line human CVCL_Q610 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094248 CVCL_PU11 BayGenomics ES cell line XG349 embryonic stem cell house mouse CVCL_PU11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139746; Ankrd13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094249 CVCL_Q611 HG02069 transformed cell line human CVCL_Q611 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094250 CVCL_PU12 BayGenomics ES cell line XG352 embryonic stem cell house mouse CVCL_PU12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094251 CVCL_Q612 HG02070 transformed cell line human CVCL_Q612 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094252 CVCL_PU13 BayGenomics ES cell line XG355 embryonic stem cell house mouse CVCL_PU13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918047; Ankib1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094253 CVCL_Q613 HG02072 transformed cell line human CVCL_Q613 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094254 CVCL_PU14 BayGenomics ES cell line XG358 embryonic stem cell house mouse CVCL_PU14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142808; Cog4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094255 CVCL_Q614 HG02073 transformed cell line human CVCL_Q614 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094256 CVCL_PU15 BayGenomics ES cell line XG362 embryonic stem cell house mouse CVCL_PU15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351663; Skp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094257 CVCL_Q615 HG02075 transformed cell line human CVCL_Q615 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094258 CVCL_PU16 BayGenomics ES cell line XG364 embryonic stem cell house mouse CVCL_PU16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101884; Ppard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094259 CVCL_Q616 HG02076 transformed cell line human CVCL_Q616 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094260 CVCL_PU17 BayGenomics ES cell line XG365 embryonic stem cell house mouse CVCL_PU17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094261 CVCL_Q617 HG02078 transformed cell line human CVCL_Q617 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094262 CVCL_PU18 BayGenomics ES cell line XG366 embryonic stem cell house mouse CVCL_PU18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094263 CVCL_Q618 HG02079 transformed cell line human CVCL_Q618 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094264 CVCL_PU19 BayGenomics ES cell line XG368 embryonic stem cell house mouse CVCL_PU19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094265 CVCL_Q619 HG02081 transformed cell line human CVCL_Q619 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094266 CVCL_PU00 BayGenomics ES cell line XG316 embryonic stem cell house mouse CVCL_PU00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140050; Ints3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094267 CVCL_Q600 HG02051 transformed cell line human CVCL_Q600 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094268 CVCL_PU01 BayGenomics ES cell line XG320 embryonic stem cell house mouse CVCL_PU01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780541; Lncenc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094269 CVCL_Q601 HG02052 transformed cell line human CVCL_Q601 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094270 CVCL_PU02 BayGenomics ES cell line XG322 embryonic stem cell house mouse CVCL_PU02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094271 CVCL_Q602 HG02053 transformed cell line human CVCL_Q602 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094272 CVCL_PU03 BayGenomics ES cell line XG323 embryonic stem cell house mouse CVCL_PU03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094273 CVCL_Q603 HG02054 transformed cell line human CVCL_Q603 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094274 CVCL_PU04 BayGenomics ES cell line XG324 embryonic stem cell house mouse CVCL_PU04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094275 CVCL_Q604 HG02055 transformed cell line human CVCL_Q604 CL:0000010 Population: African Caribbean in Barbados (ACB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094276 CVCL_PU05 BayGenomics ES cell line XG326 embryonic stem cell house mouse CVCL_PU05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919369; Tpx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094277 CVCL_Q605 HG02057 transformed cell line human CVCL_Q605 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094278 CVCL_PU06 BayGenomics ES cell line XG329 embryonic stem cell house mouse CVCL_PU06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094279 CVCL_Q606 HG02058 transformed cell line human CVCL_Q606 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094280 CVCL_PU07 BayGenomics ES cell line XG334 embryonic stem cell house mouse CVCL_PU07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891037; Mtrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094281 CVCL_Q607 HG02060 transformed cell line human CVCL_Q607 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094282 CVCL_PU08 BayGenomics ES cell line XG335 embryonic stem cell house mouse CVCL_PU08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913721; Anp32e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094283 CVCL_Q608 HG02061 transformed cell line human CVCL_Q608 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094284 CVCL_PU09 BayGenomics ES cell line XG337 embryonic stem cell house mouse CVCL_PU09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921694; Tasor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094285 CVCL_Q609 HG02064 transformed cell line human CVCL_Q609 CL:0000010 Population: Southeast Asian; Kinh in Ho Chi Minh City, Vietnam (KHV); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21094286 CVCL_HF94 OSC-4 cancer cell line human CVCL_HF94 CL:0000010 Population: Japanese; Derived from metastatic site: Submandibular lymph node. Male Doubling time: 21.2 hours (PubMed=7703799) 21094287 CVCL_HF95 OSC-5 cancer cell line human CVCL_HF95 CL:0000010 Population: Japanese; Derived from metastatic site: Submandibular lymph node. Female Doubling time: 32.5 hours (PubMed=7703799) 21094288 CVCL_HF96 OSC-6 cancer cell line human CVCL_HF96 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 39.4 hours (PubMed=7703799) 21094289 CVCL_HF97 OSC-7 cancer cell line human CVCL_HF97 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 54.7 hours (PubMed=7703799) 21094290 CVCL_HF90 KK-p cancer cell line human CVCL_HF90 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue. Virology: HPV16 in only detected in early passages Doubling time: 14-48 hours (CelloPub=CLPUB00362) 21094291 CVCL_HF91 OSC-1 [Human tongue SCC] cancer cell line human CVCL_HF91 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 38.6 hours (PubMed=7703799) 21094292 CVCL_HF92 OSC-2 [Human gingival squamous cell carcinoma] cancer cell line human CVCL_HF92 CL:0000010 Population: Japanese; Derived from metastatic site: Submandibular lymph node. Female Doubling time: 22.9 hours (PubMed=7703799) 21094293 CVCL_HF93 OSC-3 cancer cell line human CVCL_HF93 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 31.3 hours (PubMed=7703799) 21094294 CVCL_HF87 HeLa/PTX cancer cell line human CVCL_HF87 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 32.5 +- 2.21 hours (PubMed=25015454) 21094295 CVCL_HF88 J53Z1 cancer cell line house mouse CVCL_HF88 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Breed/subspecies: C57BL/6 JAK2V617F/Trp53-/- transgenic. Doubling time: ~18 hours (PubMed=25036984) 21094296 CVCL_HF89 KK-m cancer cell line human CVCL_HF89 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Doubling time: 20-79 hours (CelloPub=CLPUB00362) 21094297 CVCL_HF98 D34 cancer cell line human CVCL_HF98 CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 21094298 CVCL_HF99 D38 [Human leukoplakia] cancer cell line human CVCL_HF99 CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 21094299 CVCL_HF72 HS916 embryonic stem cell human CVCL_HF72 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: SNP array analysis. Male 21094300 CVCL_HF73 HS999 embryonic stem cell human CVCL_HF73 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: SNP array analysis. Female 21094301 CVCL_HF74 HS1001 embryonic stem cell human CVCL_HF74 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: SNP array analysis. Male 21094302 CVCL_HF75 UM103-1 PGD embryonic stem cell human CVCL_HF75 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0383. 21094303 CVCL_HF70 Tet2 cancer cell line human CVCL_HF70 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Female 21094304 CVCL_HF71 HS983a embryonic stem cell human CVCL_HF71 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: SNP array analysis. Male 21094305 CVCL_HF69 SKOV3/TR cancer cell line human CVCL_HF69 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21094306 CVCL_HF65 PT-r 2 spontaneously immortalized cell line Norway rat CVCL_HF65 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Doubling time: 17 hours (PubMed=1700579) 21094307 CVCL_HF66 PT-r 3 spontaneously immortalized cell line Norway rat CVCL_HF66 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Doubling time: 21 hours (PubMed=1700579) 21094308 CVCL_HF67 PT-r 4 spontaneously immortalized cell line Norway rat CVCL_HF67 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Doubling time: 12 hours (PubMed=1700579) 21094309 CVCL_HF68 SHG-44/ADM cancer cell line human CVCL_HF68 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Female Doubling time: 32.22 hours (PubMed=25333456) 21094310 CVCL_HF83 WK2 cancer cell line human CVCL_HF83 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 32 hours (PubMed=24627082) 21094311 CVCL_HF84 WK3F cancer cell line human CVCL_HF84 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 24 hours (PubMed=24627082) 21094312 CVCL_HF85 AP-1 cancer cell line human CVCL_HF85 CL:0000010 Derived from sampling site: Salivary gland. Male Doubling time: 3.342 days (PubMed=25137137) 21094313 CVCL_HF86 BSC-OF cancer cell line human CVCL_HF86 CL:0000010 Male Doubling time: 18.2 +- 5.4 hours (PubMed=9379426). 21094314 CVCL_HF80 MO-N-1 cancer cell line human CVCL_HF80 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Unspecified Doubling time: 46.5 hours (DOI=10.5794/jjoms.43.789) 21094315 CVCL_HF81 MO-N-2 cancer cell line human CVCL_HF81 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Unspecified Doubling time: 36 hours (DOI=10.5794/jjoms.43.789) 21094316 CVCL_HF82 MO-T cancer cell line human CVCL_HF82 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Unspecified Doubling time: 48 hours (DOI=10.5794/jjoms.43.789) 21094317 CVCL_HF76 UM150-1 PGD embryonic stem cell human CVCL_HF76 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM150-3 PGD (Cellosaurus=CVCL_IS75) and UM150-4 PGD (Cellosaurus=CVCL_QY88). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0384 21094318 CVCL_HF77 UM57-3 PGD embryonic stem cell human CVCL_HF77 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM57-2 PGD (Cellosaurus=CVCL_E088). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0380 21094319 CVCL_HF78 UM66-3 PGD embryonic stem cell human CVCL_HF78 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0381. 21094320 CVCL_HF79 UM89-5 PGD embryonic stem cell human CVCL_HF79 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM89-1 PGD (Cellosaurus=CVCL_N809), UM89-2 PGD (Cellosaurus=CVCL_5H69), UM89-3 PGD (Cellosaurus=CVCL_5H70) and UM89-4 PGD (Cellosaurus=CVCL_5H71). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0382 21094321 CVCL_HF50 CGLK-2 embryonic stem cell human CVCL_HF50 From: Chang Gung Memorial Hospital, Lin-Kou Medical Centre, Chang Gung University; Tao-Yuan; Taiwan. CL:0000010 Female 21094322 CVCL_HF51 GCSR1 cancer cell line human CVCL_HF51 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=25892440) Population: Chinese; Derived from sampling site: Stomach. Male Doubling time: ~67.65 hours (PubMed=25892440) 21094323 CVCL_HF52 HNU-Ha-MG1 spontaneously immortalized cell line CVCL_HF52 CL:0000010 Derived from sampling site: Midgut. Unspecified Doubling time: 58.6 +- 7 hours (PubMed=25678461) Group: Insect cell line 21094324 CVCL_HF53 I-10/DDPi cancer cell line house mouse CVCL_HF53 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/cJ. Male 21094325 CVCL_HF47 T14c transformed cell line Norway rat CVCL_HF47 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cheek pouch (Note=From a granulomatous inflammation) Cell type=Fibroblast.. Unspecified Doubling time: ~24 hours (PubMed=2583278) 21094326 CVCL_HF48 THY28 cancer cell line human CVCL_HF48 CL:0000010 Population: Chinese; Derived from metastatic site: Bone; spine. Male Doubling time: 56 hours (PubMed=27811013) 21094327 CVCL_HF49 CGLK-1 embryonic stem cell human CVCL_HF49 From: Chang Gung Memorial Hospital, Lin-Kou Medical Centre, Chang Gung University; Tao-Yuan; Taiwan. CL:0000010 Female 21094328 CVCL_HF43 Hp-E-1 spontaneously immortalized cell line CVCL_HF43 CL:0000010 Unspecified Doubling time: 136.7 hours (PubMed=27083164). Group: Insect cell line 21094329 CVCL_HF44 Jurkat-FADD-/- cancer cell line human CVCL_HF44 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21094330 CVCL_HF45 MASE spontaneously immortalized cell line CVCL_HF45 CL:0000010 Derived from sampling site: Skin. Unspecified Doubling time: 53.3 hours (PubMed=27288257) Group: Fish cell line 21094331 CVCL_HF46 NAP cancer cell line human CVCL_HF46 CL:0000010 Derived from metastatic site: Bone marrow. Female 21094332 CVCL_HF61 NIAS-SL64 spontaneously immortalized cell line CVCL_HF61 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 24 hours (PubMed=25172011) Group: Insect cell line 21094333 CVCL_HF62 PTH-C1 spontaneously immortalized cell line Norway rat CVCL_HF62 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Characteristics: Produces parathyroid hormone and expresses the calcium sensing receptor (Casr) gene and other genes known to be involved in parathyroid function (PubMed=24627164) Doubling time: ~15 hours (PubMed=24627164) 21094334 CVCL_HF63 PT-r spontaneously immortalized cell line Norway rat CVCL_HF63 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Doubling time: ~20 hours (PubMed=3472208) 21094335 CVCL_HF64 PT-r 1 spontaneously immortalized cell line Norway rat CVCL_HF64 CL:0000010 Derived from sampling site: Parathyroid gland; Breed/subspecies: Sprague Dawley. Male Doubling time: 20 hours (PubMed=1700579) 21094336 CVCL_HF60 NCI-H1975/GR/XR cancer cell line human CVCL_HF60 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Transformant: X-Ray(NCIt; C17262). Female Doubling time: 46.68 +- 2.68 hours (PubMed=25008024) 21094337 CVCL_HF58 KKU-M214/GEM cancer cell line human CVCL_HF58 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Liver. Male Doubling time: 25.21 +- 1.88 hours (PubMed=25998688) Problematic cell line: Contaminated Parent cell line (KKU-213B) shown to be a KKU-M213 derivative. 21094338 CVCL_HF59 NCI-H1975/GR cancer cell line human CVCL_HF59 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839 Female Doubling time: 47.73 +- 3.50 hours (PubMed=25008024); 46.535 +- 0.428 hours (PubMed=25483995) 21094339 CVCL_HF54 I-10/DDPh cancer cell line house mouse CVCL_HF54 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/cJ. Male 21094340 CVCL_HF55 ImKC cancer cell line house mouse CVCL_HF55 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Discontinued: ABM; T0062; probable; Discontinued: Millipore; SCC119; true Male Doubling time: ~24 hours (PubMed=25138015); 19-29 hours (ABM) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00620 Problematic cell line: Contaminated Shown to be a RAW 264.7 derivative (Millipore; ICLAC). This is based on the STR profile. Originally thought to be a SV40 immortalized liver kupffer cell from a (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21094341 CVCL_HF56 JEKO-1 R cancer cell line human CVCL_HF56 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro58Glnfs*65 (c.173delC); Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:91385; PF-00477736; Derived from sampling site: Peripheral blood. Female Doubling time: 20.5 +- 1.2 hours (PubMed=26439697) 21094342 CVCL_HF57 KKU-M139/GEM cancer cell line human CVCL_HF57 CL:0000010 Population: Southeast Asian; Thai; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar). Doubling time: 20.32 +- 2.79 hours (PubMed=25998688) 21094343 CVCL_HF30 GM01133 finite cell line human CVCL_HF30 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01133; probable 21094344 CVCL_HF31 RB267 cancer cell line human CVCL_HF31 CL:0000010 Male 21094345 CVCL_HF29 AG03326 finite cell line human CVCL_HF29 CL:0000010 Derived from sampling site: Scalp; skin Cell type=Fibroblast.. Discontinued: Coriell; AG03326; probable Female 21094346 CVCL_HF25 OCUU-5 cancer cell line human CVCL_HF25 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21094347 CVCL_HF26 Am II spontaneously immortalized cell line pig CVCL_HF26 CL:0000010 Derived from sampling site: Kidney. Unspecified 21094348 CVCL_HF27 67BR finite cell line human CVCL_HF27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094349 CVCL_HF28 AG03139 finite cell line human CVCL_HF28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03139; probable Male 21094350 CVCL_HF21 OCUU-1 cancer cell line human CVCL_HF21 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21094351 CVCL_HF22 OCUU-2 cancer cell line human CVCL_HF22 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21094352 CVCL_HF23 OCUU-3 cancer cell line human CVCL_HF23 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21094353 CVCL_HF24 OCUU-4 cancer cell line human CVCL_HF24 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21094354 CVCL_HF40 HaLCCA-1.1 cancer cell line CVCL_HF40 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis viverrini(NCBI-Taxonomy; 6198). Unspecified Characteristics: Obtained by both Opisthorchis viverrini infection and N-nitrosodimethylamine treatment (PubMed=8629051) Doubling time: 31 hours (PubMed=8629051) 21094355 CVCL_HF41 HaLCCA-2 cancer cell line CVCL_HF41 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis viverrini(NCBI-Taxonomy; 6198). Unspecified 21094356 CVCL_HF42 HaTCCA-1.1 cancer cell line CVCL_HF42 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis viverrini(NCBI-Taxonomy; 6198). Unspecified Characteristics: Obtained by both Opisthorchis viverrini infection and N-nitrosodimethylamine treatment (PubMed=8629051) Doubling time: 26 hours (PubMed=8629051) 21094357 CVCL_HF36 HuCC-A1Nu cancer cell line human CVCL_HF36 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Male 21094358 CVCL_HF37 IAR 27 spontaneously immortalized cell line Norway rat CVCL_HF37 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21094359 CVCL_HF38 CEM-R6 cancer cell line human CVCL_HF38 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7978; NR3C1; Simple; p.Leu753Phe (c.2259A>T); ClinVar=VCV000016149; Zygosity=Heterozygous (PubMed=7812967); Sequence variation: Mutation; HGNC; 7978; NR3C1; Unexplicit; A>G mutation in the 3'-splice junction of intron G; Zygosity=Heterozygous (PubMed=7812967); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Glucocorticoids resistant 21094360 CVCL_HF39 BA3 induced pluripotent stem cell CVCL_HF39 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Black Australorp. Unspecified Doubling time: 21 hours (PubMed=26586283); 24-36 hours (Kerafast) Group: Bird cell line; Group: Vaccine production cell line 21094361 CVCL_HF32 RB429 cancer cell line human CVCL_HF32 CL:0000010 Female 21094362 CVCL_HF33 Beta-TC-2 transformed cell line house mouse CVCL_HF33 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIRTag2. 21094363 CVCL_HF34 S5 [Mouse hybridoma against human DRw13/DR2] hybridoma house mouse CVCL_HF34 CL:0000010 Discontinued: ECACC; 99061827; probable. Monoclonal antibody isotype: IgM 21094364 CVCL_HF35 RaBE (Slow Growth) spontaneously immortalized cell line Norway rat CVCL_HF35 CL:0000010 Derived from sampling site: Bronchus; epithelium; Breed/subspecies: Wistar. Male 21094365 CVCL_6S10 DA01050 transformed cell line human CVCL_6S10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094366 CVCL_7410 GM04503 finite cell line human CVCL_7410 CL:0000010 Donor information: Established from monozygotic twin of GM04504 (Cellosaurus=CVCL_7411); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3 21094367 CVCL_6S04 DA01044 transformed cell line human CVCL_6S04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094368 CVCL_7404 GM03987 finite cell line human CVCL_7404 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21094369 CVCL_6S05 DA01045 transformed cell line human CVCL_6S05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094370 CVCL_7405 GM04033 finite cell line human CVCL_7405 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21094371 CVCL_6S06 DA01046 transformed cell line human CVCL_6S06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094372 CVCL_7406 GM04260 finite cell line human CVCL_7406 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; AG04260; probable Male 21094373 CVCL_6S07 DA01047 transformed cell line human CVCL_6S07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094374 CVCL_7407 GM04390 finite cell line human CVCL_7407 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21094375 CVCL_6S00 DA01037 transformed cell line human CVCL_6S00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094376 CVCL_7400 GM03714 transformed cell line human CVCL_7400 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21094377 CVCL_6S01 DA01039 transformed cell line human CVCL_6S01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094378 CVCL_7401 GM03715 transformed cell line human CVCL_7401 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094379 CVCL_6S02 DA01040 transformed cell line human CVCL_6S02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094380 CVCL_7402 GM03797 transformed cell line human CVCL_7402 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094381 CVCL_6S03 DA01043 transformed cell line human CVCL_6S03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094382 CVCL_7403 GM03798 transformed cell line human CVCL_7403 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094383 CVCL_6S08 DA01048 transformed cell line human CVCL_6S08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094384 CVCL_7408 GM04408 transformed cell line human CVCL_7408 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Gly (c.3163T>G); Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; English and Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 87(AlFra) (BSR87); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples Caution: Coriell has p.Cys1055fs*23 (c.3159delT) (3233delT) as the second mutation for this cell line 21094385 CVCL_6S09 DA01049 transformed cell line human CVCL_6S09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01049; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094386 CVCL_7409 GM04501 finite cell line human CVCL_7409 CL:0000010 Donor information: Established from monozygotic twin of GM04502 (Cellosaurus=CVCL_F135); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: Transcriptome analysis by RNAseq Male 21094387 CVCL_6R63 DA00998 transformed cell line human CVCL_6R63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094388 CVCL_7363 GM02781 transformed cell line human CVCL_7363 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21094389 CVCL_6R64 DA00999 transformed cell line human CVCL_6R64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094390 CVCL_7364 GM02783 transformed cell line human CVCL_7364 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094391 CVCL_6R65 DA01000 transformed cell line human CVCL_6R65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094392 CVCL_7365 GM02824 finite cell line human CVCL_7365 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala329Val (c.986C>T); ClinVar=VCV000001959; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.219-2A>G (IVS3-2A>G); ClinVar=VCV000001969; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21094393 CVCL_6R66 DA01001 transformed cell line human CVCL_6R66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01001; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094394 CVCL_7366 GM02848 finite cell line human CVCL_7366 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(2)(qter->q33::p25->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21094395 CVCL_6R60 DA00995 transformed cell line human CVCL_6R60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094396 CVCL_7360 GM02605 finite cell line human CVCL_7360 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg101Trp (c.301C>T); ClinVar=VCV000001955; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211His (c.632G>A); ClinVar=VCV000001957; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21094397 CVCL_6R61 DA00996 transformed cell line human CVCL_6R61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094398 CVCL_7361 GM02673 finite cell line human CVCL_7361 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094399 CVCL_6R62 DA00997 transformed cell line human CVCL_6R62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094400 CVCL_7362 GM02707 transformed cell line human CVCL_7362 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094401 CVCL_6R56 DA00990 transformed cell line human CVCL_6R56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00990; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094402 CVCL_7356 GM02290 finite cell line human CVCL_7356 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094403 CVCL_6R57 DA00991 transformed cell line human CVCL_6R57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094404 CVCL_7357 GM02291 finite cell line human CVCL_7357 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21094405 CVCL_6R58 DA00992 transformed cell line human CVCL_6R58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094406 CVCL_7358 XP115LO 2 finite cell line human CVCL_7358 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln373Ter (c.1117C>T); ClinVar=VCV000005890; Zygosity=Homozygous (PubMed=10398605; PubMed=26884178) Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (PubMed=6492896) 21094407 CVCL_6R59 DA00994 transformed cell line human CVCL_6R59 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094408 CVCL_7359 XP7BE LCL transformed cell line human CVCL_7359 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094409 CVCL_Z997 P2 spontaneously immortalized cell line fruit fly CVCL_Z997 CL:0000010 Discontinued: ECACC; 90070558; probable. Unspecified Group: Insect cell line 21094410 CVCL_Z998 P4 spontaneously immortalized cell line fruit fly CVCL_Z998 CL:0000010 Discontinued: ECACC; 90070557; probable. Unspecified Group: Insect cell line 21094411 CVCL_Z999 Bm-Em-1 spontaneously immortalized cell line CVCL_Z999 CL:0000010 Breed/subspecies: Dazao. Unspecified Doubling time: 82.2 hours (DOI=10.16380/j.kcxb.2011.12.013) Group: Insect cell line 21094412 CVCL_6R74 DA01009 transformed cell line human CVCL_6R74 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01009; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094413 CVCL_7374 GM03123 finite cell line human CVCL_7374 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094414 CVCL_6R75 DA01010 transformed cell line human CVCL_6R75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094415 CVCL_7375 GM03124 transformed cell line human CVCL_7375 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094416 CVCL_6R76 DA01011 transformed cell line human CVCL_6R76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094417 CVCL_7376 GM03132 finite cell line human CVCL_7376 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21094418 CVCL_6R77 DA01012 transformed cell line human CVCL_6R77 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094419 CVCL_7377 AT4BE LCL transformed cell line human CVCL_7377 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser381Argfs*27 (c.1139_1142dupACAG) (c.1141_1142ins4); ClinVar=VCV000280044; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys2756Ter (c.8266A>T); ClinVar=VCV000135780; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21094420 CVCL_6R70 DA01005 transformed cell line human CVCL_6R70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094421 CVCL_7370 GM02987 finite cell line human CVCL_7370 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [43]; 46,XY,t(7;9)(7pter->7q36::9q12->9qter;9pter->9q12::7q36->qter) [7] (Coriell); Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) 21094422 CVCL_6R71 DA01006 transformed cell line human CVCL_6R71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094423 CVCL_7371 GM03044 finite cell line human CVCL_7371 CL:0000010 Population: Caucasian; Karyotypic information: 45,XY,der(13;14)(13qter->13q10::14q10->14qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21094424 CVCL_6R72 DA01007 transformed cell line human CVCL_6R72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01007; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094425 CVCL_7372 XP1CH [XP-V Cherevan] finite cell line human CVCL_7372 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Val125Ter (c.376C>T); Zygosity=Homozygous (PubMed=10398605) Population: Caucasian; Russian Armenian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094426 CVCL_6R73 DA01008 transformed cell line human CVCL_6R73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094427 CVCL_7373 GM03111 finite cell line human CVCL_7373 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gln298Gln (c.894G>A); ClinVar=VCV000203361; Zygosity=Heterozygous; Note=Affects splicing (Coriell); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ser323Leufs*44 (c.967_968delAG); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094428 CVCL_6R67 DA01002 transformed cell line human CVCL_6R67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094429 CVCL_7367 GM02912 finite cell line human CVCL_7367 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094430 CVCL_6R68 DA01003 transformed cell line human CVCL_6R68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01003; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094431 CVCL_7368 GM02936 finite cell line human CVCL_7368 CL:0000010 Population: Mexican; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Part of: Human variation panel 21094432 CVCL_6R69 DA01004 transformed cell line human CVCL_6R69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094433 CVCL_7369 GM02937 finite cell line human CVCL_7369 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094434 CVCL_Z986 TRA-284 spontaneously immortalized cell line CVCL_Z986 CL:0000010 Unspecified Virology: Infected by Toxorhynchites amboinensis densonucleosis virus (TaDNV) (PubMed=7636489) Group: Insect cell line 21094435 CVCL_Z987 TRA-284-SF spontaneously immortalized cell line CVCL_Z987 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line 21094436 CVCL_Z988 G01-874 spontaneously immortalized cell line CVCL_Z988 CL:0000010 Unspecified Doubling time: 48 hours (CelloPub=CLPUB00206). Group: Insect cell line 21094437 CVCL_Z989 MAb E9 hybridoma house mouse CVCL_Z989 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07900; Human HSP90AA1. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.2903 21094438 CVCL_6R41 DA00975 transformed cell line human CVCL_6R41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094439 CVCL_7341 GM01863 finite cell line human CVCL_7341 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [70%]; 46,XY,t(4;7)(4pter->4q21::7q36->7qter;7pter->7q36::4q21->4qter) [30%] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094440 CVCL_6R42 DA00976 transformed cell line human CVCL_6R42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094441 CVCL_7342 GM01864 finite cell line human CVCL_7342 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094442 CVCL_6R43 DA00977 transformed cell line human CVCL_6R43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094443 CVCL_7343 GM01891 finite cell line human CVCL_7343 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094444 CVCL_6R44 DA00978 transformed cell line human CVCL_6R44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00978; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094445 CVCL_7344 GM01953 transformed cell line human CVCL_7344 HLA typing: A*01:01:01,03:01:01; B*08:01:01,35:01:01; C*04:01:01,07:01:01; DPA1*01:03:01,02:06; DPB1*04:02:01,05:01:01; DQA1*01:01:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*01:01:01,03:01:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01079; true Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094446 CVCL_6R40 DA00974 transformed cell line human CVCL_6R40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094447 CVCL_7340 GM01815 transformed cell line human CVCL_7340 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01075; true Male Part of: Human variation panel 21094448 CVCL_6R38 DA00972 transformed cell line human CVCL_6R38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094449 CVCL_7338 GM01806 transformed cell line human CVCL_7338 HLA typing: A*01:01:01,02:05:01; B*37:01:01,58:01:01; C*06:02:01,07:18; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,01:05:01; DQB1*05:01:01,06:02:01; DRB1*10:01:01,15:01:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01074; true Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094450 CVCL_6R39 DA00973 transformed cell line human CVCL_6R39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094451 CVCL_7339 GM01814 transformed cell line human CVCL_7339 HLA typing: A*01:01:01,02:01:01; B*08:01:01,40:01:02; C*03:04:01,07:01:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,04:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:04:01; DRB1*03:01:01,13:02:01; DRB3*01:01:02,03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01072; true Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094452 CVCL_6R34 DA00967 transformed cell line human CVCL_6R34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00967; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094453 CVCL_7334 GM01706 finite cell line human CVCL_7334 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM00237; true Female 21094454 CVCL_6R35 DA00968 transformed cell line human CVCL_6R35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094455 CVCL_7335 GM01717 finite cell line human CVCL_7335 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094456 CVCL_6R36 DA00969 transformed cell line human CVCL_6R36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00969; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094457 CVCL_7336 GM01774 finite cell line human CVCL_7336 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094458 CVCL_6R37 DA00970 transformed cell line human CVCL_6R37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094459 CVCL_7337 GM01805 transformed cell line human CVCL_7337 HLA typing: A*02:01:01,24:02:01; B*27:05:02,51:01:01; C*01:02:01,15:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,03:01:01; DQA1*01:01:01,03:01:01; DQB1*03:02:01,05:01:01; DRB1*01:01:01,04:04:01; DRB4*01:03:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01073; true Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094460 CVCL_Z993 S2-Mt-Dl spontaneously immortalized cell line fruit fly CVCL_Z993 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000463; Dl Breed/subspecies: Oregon-R. Male Characteristics: Expresses Delta (Dl) from a copper-inducible metallothionein promoter Doubling time: 64 hours (DGRC) Group: Insect cell line 21094461 CVCL_Z994 311 spontaneously immortalized cell line fruit fly CVCL_Z994 CL:0000010 Unspecified Group: Insect cell line. 21094462 CVCL_Z995 Neopu spontaneously immortalized cell line fruit fly CVCL_Z995 CL:0000010 Unspecified Group: Insect cell line. 21094463 CVCL_Z996 P1 spontaneously immortalized cell line fruit fly CVCL_Z996 CL:0000010 Discontinued: ECACC; 90070556; probable. Unspecified Group: Insect cell line 21094464 CVCL_Z990 MAb D10 hybridoma house mouse CVCL_Z990 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07900; Human HSP90AA1. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.2904 21094465 CVCL_Z991 NTU-MV spontaneously immortalized cell line CVCL_Z991 CL:0000010 Unspecified Doubling time: 46.53 hours (in 0% FBS), 33.29 hours (in 4% FBS), 27.76 hours (in 8% FBS), 27.24 hours (in 16% FBS), 37.47 hours (in Sf-900 medium) (PubMed=17521666). Group: Insect cell line 21094466 CVCL_Z992 S2-DRSC spontaneously immortalized cell line fruit fly CVCL_Z992 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 46-93 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21094467 CVCL_Z979 CSIRO-BCIRL-HA2 spontaneously immortalized cell line CVCL_Z979 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094468 CVCL_Z975 ABAD-CuVa-1087-8 spontaneously immortalized cell line CVCL_Z975 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094469 CVCL_Z976 WU-CcE-1 spontaneously immortalized cell line CVCL_Z976 CL:0000010 Unspecified Group: Insect cell line. 21094470 CVCL_Z977 BCIRL-HZ-AM1-A11 spontaneously immortalized cell line CVCL_Z977 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 36 hours (PubMed=2022870) Group: Insect cell line 21094471 CVCL_Z978 CSIRO-BCIRL-HA1 spontaneously immortalized cell line CVCL_Z978 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094472 CVCL_6R52 DA00986 transformed cell line human CVCL_6R52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094473 CVCL_6R53 DA00987 transformed cell line human CVCL_6R53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094474 CVCL_6R54 DA00988 transformed cell line human CVCL_6R54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094475 CVCL_7354 GM02185 finite cell line human CVCL_7354 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling Male 21094476 CVCL_6R55 DA00989 transformed cell line human CVCL_6R55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094477 CVCL_7355 GM02254 transformed cell line human CVCL_7355 HLA typing: A*23:01:01,24:02:01; B*35:02:01,49:01:01; C*04:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRB1*11:04:01,11:04:01; DRB3*02:02:01,02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094478 CVCL_6R50 DA00984 transformed cell line human CVCL_6R50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094479 CVCL_7350 GM02052 finite cell line human CVCL_7350 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg35Ter (c.103C>T); ClinVar=VCV000003025; Zygosity=Homozygous (Coriell) Population: Jewish; Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094480 CVCL_6R51 DA00985 transformed cell line human CVCL_6R51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094481 CVCL_7351 XP1MI 2 finite cell line human CVCL_7351 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro334His (c.1001C>A); ClinVar=VCV000000253; Zygosity=Homozygous (PubMed=18809580) Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Female Senescence: Senesces at 24 PDL (PubMed=3003928; PubMed=6492896) 21094482 CVCL_6R49 DA00983 transformed cell line human CVCL_6R49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00983; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094483 CVCL_7349 GM02037 finite cell line human CVCL_7349 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [45]; 46,XY,t(4;16)(4qter->4p14::16q24->16qter;16pter->16q24::4p14->4pter) [5] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094484 CVCL_6R45 DA00979 transformed cell line human CVCL_6R45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094485 CVCL_7345 GM01954 transformed cell line human CVCL_7345 HLA typing: A*02:01:01,34:02:01; B*08:01:01,35:01:01; C*07:01:01,15:02:01; DPA1*01:03:01,02:02:02; DPB1*01:01:01,04:02:01; DQA1*01:01:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*01:03:01,03:01:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01080; true Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094486 CVCL_6R46 DA00980 transformed cell line human CVCL_6R46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094487 CVCL_7346 GM01989 transformed cell line human CVCL_7346 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01076; true Male Part of: Human variation panel 21094488 CVCL_6R47 DA00981 transformed cell line human CVCL_6R47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00981; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094489 CVCL_7347 GM01990 transformed cell line human CVCL_7347 HLA typing: A*01:01:01,01:01:01; B*07:02:01,08:01:01; C*07:01:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM01077; true Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094490 CVCL_6R48 DA00982 transformed cell line human CVCL_6R48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00982; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094491 CVCL_7348 GM02036 finite cell line human CVCL_7348 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094492 CVCL_Z982 CSIRO-BCIRL-HP2 spontaneously immortalized cell line CVCL_Z982 CL:0000010 Unspecified Group: Insect cell line. 21094493 CVCL_Z983 CSIRO-BCIRL-HP3 spontaneously immortalized cell line CVCL_Z983 CL:0000010 Unspecified Group: Insect cell line. 21094494 CVCL_Z984 CSIRO-BCIRL-HP4 spontaneously immortalized cell line CVCL_Z984 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094495 CVCL_Z985 CSIRO-BCIRL-HP5 spontaneously immortalized cell line CVCL_Z985 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094496 CVCL_Z980 CSIRO-BCIRL-HA3 spontaneously immortalized cell line CVCL_Z980 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094497 CVCL_Z981 CSIRO-BCIRL-HP1 spontaneously immortalized cell line CVCL_Z981 CL:0000010 Unspecified Group: Insect cell line. 21094498 CVCL_Z968 ABAD-CuVa-1087-1 spontaneously immortalized cell line CVCL_Z968 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Doubling time: 24 hours, at 15th passage (PubMed=2553822) Group: Insect cell line 21094499 CVCL_Z969 ABAD-CuVa-1087-2 spontaneously immortalized cell line CVCL_Z969 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094500 CVCL_Z964 NTU-LY-1 spontaneously immortalized cell line CVCL_Z964 CL:0000010 Unspecified Doubling time: 177 hours (PubMed=16989856). Group: Insect cell line 21094501 CVCL_Z965 NTU-LY-2 spontaneously immortalized cell line CVCL_Z965 CL:0000010 Unspecified Doubling time: 74 hours (PubMed=16989856). Group: Insect cell line 21094502 CVCL_Z966 NTU-LY-3 spontaneously immortalized cell line CVCL_Z966 CL:0000010 Unspecified Doubling time: 105 hours (PubMed=16989856). Group: Insect cell line 21094503 CVCL_Z967 NTU-LY-4 spontaneously immortalized cell line CVCL_Z967 CL:0000010 Unspecified Doubling time: 66 hours (PubMed=16989856). Group: Insect cell line 21094504 CVCL_6R20 DA00953 transformed cell line human CVCL_6R20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00953; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094505 CVCL_7320 GM01492 finite cell line human CVCL_7320 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 44(AbRu) (BSR44); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21094506 CVCL_6R21 DA00954 transformed cell line human CVCL_6R21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094507 CVCL_7321 AT2BI LCL transformed cell line human CVCL_7321 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2136Ter (c.6404_6405insTT) (p.Leu2135_Arg2136insTer) (6404insTT); ClinVar=VCV000220763; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094508 CVCL_6R22 DA00955 transformed cell line human CVCL_6R22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094509 CVCL_7322 AT8BI LCL transformed cell line human CVCL_7322 HLA typing: A*09,10; B*w17,13(w40) (Coriell=GM01526) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Met1Thr (c.2T>C); ClinVar=VCV000187275; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB3012; probable Female 21094510 CVCL_6R16 DA00949 transformed cell line human CVCL_6R16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00949; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094511 CVCL_7316 GM01310 transformed cell line human CVCL_7316 HLA typing: A*02:05:01,11:01:01; B*27:02:01,52:01:01; C*02:02:02,12:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*01:02:01,01:02:02; DQB1*05:02:01,06:09:01; DRB1*13:02:01,16:01:01; DRB3*03:01:01; DRB5*02:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094512 CVCL_6R17 DA00950 transformed cell line human CVCL_6R17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094513 CVCL_7317 GM01379 finite cell line human CVCL_7317 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21094514 CVCL_6R18 DA00951 transformed cell line human CVCL_6R18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00951; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094515 CVCL_7318 GM01380 finite cell line human CVCL_7318 CL:0000010 Population: Puerto Rican; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21094516 CVCL_6R19 DA00952 transformed cell line human CVCL_6R19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00952; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094517 CVCL_7319 GM01381 finite cell line human CVCL_7319 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094518 CVCL_6R12 DA00944 transformed cell line human CVCL_6R12 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094519 CVCL_7312 GM00970 finite cell line human CVCL_7312 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094520 CVCL_6R13 DA00945 transformed cell line human CVCL_6R13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094521 CVCL_7313 GM01078 transformed cell line human CVCL_7313 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094522 CVCL_6R14 DA00946 transformed cell line human CVCL_6R14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094523 CVCL_7314 CS2BE finite cell line human CVCL_7314 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Ser222Tyrfs*25 (c.665_723del59) (Ex10del); Zygosity=Heterozygous (PubMed=9443879); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Tyr1179Ilefs*22 (c.3535delT); Zygosity=Heterozygous (PubMed=9443879) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094524 CVCL_6R15 DA00948 transformed cell line human CVCL_6R15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094525 CVCL_7315 GM01229 finite cell line human CVCL_7315 CL:0000010 Population: Cuban; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Human variation panel 21094526 CVCL_Z971 ABAD-CuVa-1087-4 spontaneously immortalized cell line CVCL_Z971 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Doubling time: 72 hours, at 20th passage (PubMed=2553822) Group: Insect cell line 21094527 CVCL_Z972 ABAD-CuVa-1087-5 spontaneously immortalized cell line CVCL_Z972 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094528 CVCL_Z973 ABAD-CuVa-1087-6 spontaneously immortalized cell line CVCL_Z973 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094529 CVCL_Z974 ABAD-CuVa-1087-7 spontaneously immortalized cell line CVCL_Z974 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094530 CVCL_Z970 ABAD-CuVa-1087-3 spontaneously immortalized cell line CVCL_Z970 CL:0000010 Breed/subspecies: AA laboratory colony. Unspecified Group: Insect cell line 21094531 CVCL_Z957 BTI-Pr-10B spontaneously immortalized cell line CVCL_Z957 CL:0000010 Unspecified Group: Insect cell line. 21094532 CVCL_Z958 BTI-Pr-8A1 spontaneously immortalized cell line CVCL_Z958 CL:0000010 Unspecified Group: Insect cell line. 21094533 CVCL_Z959 BTI-Pr-8A2 spontaneously immortalized cell line CVCL_Z959 CL:0000010 Unspecified Group: Insect cell line. 21094534 CVCL_Z953 WVB-Pcr-02 spontaneously immortalized cell line CVCL_Z953 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 60-64 hours (DOI=10.14188/j.1671-8836.1997.02.019) Group: Insect cell line 21094535 CVCL_Z954 SIE-Ha-798 spontaneously immortalized cell line CVCL_Z954 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094536 CVCL_Z955 SIE-Ha-806 spontaneously immortalized cell line CVCL_Z955 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21094537 CVCL_Z956 NTU-YB spontaneously immortalized cell line CVCL_Z956 CL:0000010 Unspecified Doubling time: 38.85 hours (in 0% TNM-FH), 31.27 hours (in 5% TNM-FH), 26.87 hours (in 8% TNM-FH), 31.3 hours (in 16% TNM-FH) (PubMed=19761771). Group: Insect cell line 21094538 CVCL_6R30 DA00963 transformed cell line human CVCL_6R30 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094539 CVCL_7330 GM01652 finite cell line human CVCL_7330 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21094540 CVCL_6R31 DA00964 transformed cell line human CVCL_6R31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094541 CVCL_7331 GM01653 finite cell line human CVCL_7331 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21094542 CVCL_6R32 DA00965 transformed cell line human CVCL_6R32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00965; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094543 CVCL_7332 GM01680 finite cell line human CVCL_7332 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094544 CVCL_6R33 DA00966 transformed cell line human CVCL_6R33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094545 CVCL_7333 GM01681 finite cell line human CVCL_7333 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094546 CVCL_6R27 DA00960 transformed cell line human CVCL_6R27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094547 CVCL_7327 GM01646 transformed cell line human CVCL_7327 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Asn349del (c.1045_1047del); Zygosity=Heterozygous (from autologous cell line GM01389); Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Leu350Pro (c.1049T>C); Zygosity=Heterozygous (from autologous cell line GM01389) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094548 CVCL_6R28 DA00961 transformed cell line human CVCL_6R28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094549 CVCL_7328 GM01650 finite cell line human CVCL_7328 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21094550 CVCL_6R29 DA00962 transformed cell line human CVCL_6R29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094551 CVCL_7329 GM01651 finite cell line human CVCL_7329 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21094552 CVCL_6R23 DA00956 transformed cell line human CVCL_6R23 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094553 CVCL_7323 GM01582 finite cell line human CVCL_7323 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM00240; true; Discontinued: Coriell; GM01582; probable Female 21094554 CVCL_6R24 DA00957 transformed cell line human CVCL_6R24 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094555 CVCL_7324 GM01603 finite cell line human CVCL_7324 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094556 CVCL_6R25 DA00958 transformed cell line human CVCL_6R25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094557 CVCL_7325 GM01604 finite cell line human CVCL_7325 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21094558 CVCL_6R26 DA00959 transformed cell line human CVCL_6R26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094559 CVCL_7326 GM01607 finite cell line human CVCL_7326 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=19815695; PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Val433Leu (c.1297G>T) (V394L); ClinVar=VCV000004292; Zygosity=Heterozygous (PubMed=19815695; PubMed=30497978) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21094560 CVCL_Z960 BTI-Pr-9A spontaneously immortalized cell line CVCL_Z960 CL:0000010 Unspecified Group: Insect cell line. 21094561 CVCL_Z961 NYAES-PR4A spontaneously immortalized cell line CVCL_Z961 CL:0000010 Unspecified Group: Insect cell line. 21094562 CVCL_Z962 RIRI-PX1 spontaneously immortalized cell line CVCL_Z962 CL:0000010 Unspecified Virology: Susceptible to infection by Autographa californica nuclear polyhedrosis virus (AcMNPV) (DOI=10.16380/j.kcxb.2019.03.004) Doubling time: 42.5 hours (at 50th passage), 42.1 hours (at 60th passage) (PubMed=22386749). Group: Insect cell line 21094563 CVCL_Z963 NTU-SE spontaneously immortalized cell line CVCL_Z963 CL:0000010 Unspecified Virology: Highly susceptible to infection by Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV) and Autographa californica multiple nucleopolyhedrovirus (AcMNPV) Doubling time: 35.5 hours (PubMed=22867846). Group: Insect cell line 21094564 CVCL_Z946 PLS20 cancer cell line Norway rat CVCL_Z946 CL:0000010 Breed/subspecies: Fischer 344. Male 21094565 CVCL_Z947 PLS30 cancer cell line Norway rat CVCL_Z947 CL:0000010 Breed/subspecies: Fischer 344. Male 21094566 CVCL_Z948 Pr-111 transformed cell line house mouse CVCL_Z948 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Donor information: Established from a mouse suffering from a prostatic intraepithelial neoplasia (PIN) lesion; Derived from sampling site: Prostate; Breed/subspecies: FVB/N. Male 21094567 CVCL_Z949 Pr-117 transformed cell line house mouse CVCL_Z949 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Donor information: Established from a mouse suffering from a prostatic intraepithelial neoplasia (PIN) lesion; Derived from sampling site: Prostate; Breed/subspecies: FVB/N. Male 21094568 CVCL_Z942 MKN45R0.08 cancer cell line human CVCL_Z942 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Liver. Female 21094569 CVCL_Z943 RUCA-I cancer cell line Norway rat CVCL_Z943 CL:0000010 Derived from sampling site: Endometrium; Breed/subspecies: DA/Han. Female Doubling time: 16.6 +- 0.7 hours (PubMed=1459735) 21094570 CVCL_Z944 RUCA-II cancer cell line Norway rat CVCL_Z944 CL:0000010 Derived from sampling site: Endometrium; Breed/subspecies: BDII/Han. Female Doubling time: 24.4 +- 7.9 hours (PubMed=1459735) 21094571 CVCL_Z945 PLS10 cancer cell line Norway rat CVCL_Z945 CL:0000010 Breed/subspecies: Fischer 344. Male 21094572 CVCL_6R00 DA00932 transformed cell line human CVCL_6R00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094573 CVCL_7300 GM00719 transformed cell line human CVCL_7300 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094574 CVCL_Z950 Pr-14 transformed cell line house mouse CVCL_Z950 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: FVB/N. Male 21094575 CVCL_Z951 Pr-14C1 transformed cell line house mouse CVCL_Z951 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: FVB/N. Male 21094576 CVCL_Z952 Pr-14C2 transformed cell line house mouse CVCL_Z952 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: FVB/N. Male 21094577 CVCL_Z935 COS-7-InVitrus transformed cell line CVCL_Z935 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21094578 CVCL_Z936 MDCK-SIAT1 spontaneously immortalized cell line dog CVCL_Z936 CL:0000010 Transfected with: HGNC; 10860; ST6GAL1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21094579 CVCL_Z937 P3X63Ag8.653-Turbodoma cancer cell line house mouse CVCL_Z937 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21094580 CVCL_Z938 HL-60/ara-C [USA 1984] cancer cell line human CVCL_Z938 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Female 21094581 CVCL_Z931 H13a hybridoma house mouse CVCL_Z931 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Gray seal IgM. 21094582 CVCL_Z932 IC-04 hybridoma house mouse CVCL_Z932 CL:0000010 Discontinued: ECACC; 93042002; probable. Monoclonal antibody isotype: IgM 21094583 CVCL_Z933 904.13 cancer cell line house mouse CVCL_Z933 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21094584 CVCL_Z934 COS-1-InVitrus transformed cell line CVCL_Z934 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21094585 CVCL_6R10 DA00942 transformed cell line human CVCL_6R10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094586 CVCL_7310 GM00967 finite cell line human CVCL_7310 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094587 CVCL_6R11 DA00943 transformed cell line human CVCL_6R11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094588 CVCL_7311 GM00969 finite cell line human CVCL_7311 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21094589 CVCL_Z939 KY-ADR1 cancer cell line human CVCL_Z939 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Brain; meninges. Male 21094590 CVCL_6R05 DA00937 transformed cell line human CVCL_6R05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094591 CVCL_7305 GM00881 finite cell line human CVCL_7305 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Hemizygous (PubMed=29982630) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21094592 CVCL_6R06 DA00938 transformed cell line human CVCL_6R06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094593 CVCL_7306 GM00893 transformed cell line human CVCL_7306 HLA typing: A*01:01:01,30:01:01; B*08:01:01,13:02:01; C*06:02:01,07:01:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,17:01:01; DQA1*02:01:01,05:01:01; DQB1*02:01:01,02:02:01; DRB1*03:01:01,07:01:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094594 CVCL_6R07 DA00939 transformed cell line human CVCL_6R07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094595 CVCL_7307 GM00922 transformed cell line human CVCL_7307 HLA typing: A*02:01:01,26:01:01; B*07:02:01,14:01:01; C*07:02:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:02:01; DRB1*07:01:01,15:01:01; DRB4*01:01:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094596 CVCL_6R08 DA00940 transformed cell line human CVCL_6R08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094597 CVCL_7308 GM00946 transformed cell line human CVCL_7308 HLA typing: A*26:01:01,66:01:01; B*38:01:01,38:01:01; C*12:03:01,12:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRB1*04:02:01,11:01:01; DRB3*02:02:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; c.506-1G>A (IVSDS3,G-A,+1); ClinVar=VCV000016889; Zygosity=Heterozygous; Note=Splice acceptor mutation CYP2D6*4 allele (Coriell). Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094598 CVCL_6R01 DA00933 transformed cell line human CVCL_6R01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094599 CVCL_7301 GM00731 finite cell line human CVCL_7301 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094600 CVCL_6R02 DA00934 transformed cell line human CVCL_6R02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094601 CVCL_7302 GM00850 finite cell line human CVCL_7302 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094602 CVCL_6R03 DA00935 transformed cell line human CVCL_6R03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094603 CVCL_7303 GM00863 finite cell line human CVCL_7303 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Thr97Arg (c.290C>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly118Asp (c.353G>A); Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21094604 CVCL_6R04 DA00936 transformed cell line human CVCL_6R04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094605 CVCL_7304 GM00865 finite cell line human CVCL_7304 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21094606 CVCL_Z940 KY-ADR2 cancer cell line human CVCL_Z940 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Brain; meninges. Male 21094607 CVCL_Z941 MKN45R0.05 cancer cell line human CVCL_Z941 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Liver. Female 21094608 CVCL_6R09 DA00941 transformed cell line human CVCL_6R09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094609 CVCL_7309 GM00957 finite cell line human CVCL_7309 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21094610 CVCL_HF07 Me18656 cancer cell line human CVCL_HF07 CL:0000010 Derived from metastatic site: Lymph node. 21094611 CVCL_HF08 Me18816 cancer cell line human CVCL_HF08 CL:0000010 Derived from metastatic site: Lymph node. 21094612 CVCL_HF09 Me19410 cancer cell line human CVCL_HF09 CL:0000010 Derived from metastatic site: Lymph node. 21094613 CVCL_HF03 Me14362 cancer cell line human CVCL_HF03 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DOI=10.13130/grazia-giulia_phd2016-02-18) Derived from metastatic site: Lymph node. 21094614 CVCL_HF04 Me14464 cancer cell line human CVCL_HF04 CL:0000010 Derived from metastatic site: Lymph node. 21094615 CVCL_HF05 Me15094 cancer cell line human CVCL_HF05 CL:0000010 Derived from metastatic site: Soft tissue. 21094616 CVCL_HF06 Me15479 cancer cell line human CVCL_HF06 CL:0000010 21094617 CVCL_HF00 8016 cancer cell line house mouse CVCL_HF00 From: Yoshida K.; National Institute of Radiological Sciences; Chiba-shi; Japan CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H. 21094618 CVCL_HF01 Me10258 cancer cell line human CVCL_HF01 CL:0000010 21094619 CVCL_HF02 Me1274 cancer cell line human CVCL_HF02 CL:0000010 Derived from metastatic site: Lymph node. 21094620 CVCL_HF20 HEK293-EBNA1-6E transformed cell line human CVCL_HF20 CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 (with del 101-324 = EBNA1t) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The use of recombinant protein expression vectors containing the EBV oriP in cell lines stably expressing EBV's EBNA1 protein significantly increases recombinant protein yield; Characteristics: This cell line is transfected with EBNA1t, a truncated version of EBV EBNA1 lacking the Gly-Gly-Ala repeats region It has an enhanced ability to produce recombinant protein compared to HEK293-EBNA (Cellosaurus=CVCL_6974). Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 150305-01 21094621 CVCL_HF18 Me6824 cancer cell line human CVCL_HF18 CL:0000010 Derived from metastatic site: Hypodermis. 21094622 CVCL_HF19 Me879 cancer cell line human CVCL_HF19 CL:0000010 Derived from metastatic site: Lymph node. 21094623 CVCL_HF14 Me29318 cancer cell line human CVCL_HF14 CL:0000010 Derived from metastatic site: Lymph node. 21094624 CVCL_HF15 Me3044 cancer cell line human CVCL_HF15 CL:0000010 Derived from metastatic site: Soft tissue. 21094625 CVCL_HF16 Me32562 cancer cell line human CVCL_HF16 CL:0000010 Derived from metastatic site: Lymph node. 21094626 CVCL_HF17 Me32669 cancer cell line human CVCL_HF17 CL:0000010 Derived from metastatic site: Hypodermis. 21094627 CVCL_HF10 Me2211 cancer cell line human CVCL_HF10 CL:0000010 Derived from metastatic site: Lymph node. 21094628 CVCL_HF11 Me23526 cancer cell line human CVCL_HF11 CL:0000010 Derived from metastatic site: Lymph node. 21094629 CVCL_HF12 Me23682 cancer cell line human CVCL_HF12 CL:0000010 Derived from metastatic site: Lymph node. 21094630 CVCL_HF13 Me26635 cancer cell line human CVCL_HF13 CL:0000010 21094631 CVCL_6R80 DA01017 transformed cell line human CVCL_6R80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094632 CVCL_7380 GM03299 transformed cell line human CVCL_7380 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21094633 CVCL_6R85 DA01022 transformed cell line human CVCL_6R85 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094634 CVCL_7385 GM03395 finite cell line human CVCL_7385 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094635 CVCL_6R86 DA01023 transformed cell line human CVCL_6R86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01023; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094636 CVCL_7386 GM03396 finite cell line human CVCL_7386 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094637 CVCL_6R87 DA01024 transformed cell line human CVCL_6R87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01024; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094638 CVCL_7387 GM03397 finite cell line human CVCL_7387 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094639 CVCL_6R88 DA01025 transformed cell line human CVCL_6R88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01025; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094640 CVCL_7388 GM03440 finite cell line human CVCL_7388 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21094641 CVCL_6R81 DA01018 transformed cell line human CVCL_6R81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094642 CVCL_7381 GM03332 transformed cell line human CVCL_7381 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Homozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21094643 CVCL_6R82 DA01019 transformed cell line human CVCL_6R82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094644 CVCL_7382 GM03348 finite cell line human CVCL_7382 CL:0000010 Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM03348; probable Male Part of: ENCODE project common cell types; tier 3 21094645 CVCL_6R83 DA01020 transformed cell line human CVCL_6R83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094646 CVCL_7383 GM03349 finite cell line human CVCL_7383 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094647 CVCL_6R84 DA01021 transformed cell line human CVCL_6R84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01021; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094648 CVCL_7384 GM03377 finite cell line human CVCL_7384 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21094649 CVCL_6R78 DA01014 transformed cell line human CVCL_6R78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094650 CVCL_7378 GM03201 transformed cell line human CVCL_7378 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094651 CVCL_6R79 DA01015 transformed cell line human CVCL_6R79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094652 CVCL_7379 GM03252 finite cell line human CVCL_7379 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Heterozygous (PubMed=19815695) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21094653 CVCL_6R90 DA01027 transformed cell line human CVCL_6R90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01027; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094654 CVCL_7390 GM03469 transformed cell line human CVCL_7390 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg170His (c.509G>A); ClinVar=VCV000053983; Zygosity=Heterozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21094655 CVCL_6R91 DA01028 transformed cell line human CVCL_6R91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094656 CVCL_7391 GM03523 finite cell line human CVCL_7391 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [35]; 46,XY,t(3;11)(3pter->3q24::11p15->11pter;11qter->11p15::3q24->3qter) [15] (Coriell); Derived from sampling site: Neck; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094657 CVCL_6R96 DA01033 transformed cell line human CVCL_6R96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01033; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094658 CVCL_7396 GM03651 finite cell line human CVCL_7396 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; AG03651; probable Female 21094659 CVCL_6R97 DA01034 transformed cell line human CVCL_6R97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094660 CVCL_7397 GM03652 finite cell line human CVCL_7397 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094661 CVCL_6R98 DA01035 transformed cell line human CVCL_6R98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094662 CVCL_7398 GM03657 transformed cell line human CVCL_7398 HLA typing: A*02:01:01,68:01:02; B*40:01:02,44:02:01; C*03:04:01,05:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:01:01G; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:04:01; DRB1*13:02:01,14:54:01; DRB3*02:02:01,03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094663 CVCL_6R99 DA01036 transformed cell line human CVCL_6R99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094664 CVCL_7399 GM03658 finite cell line human CVCL_7399 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094665 CVCL_6R92 DA01029 transformed cell line human CVCL_6R92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01029; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094666 CVCL_7392 GM03524 finite cell line human CVCL_7392 CL:0000010 Population: African American; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094667 CVCL_6R93 DA01030 transformed cell line human CVCL_6R93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01030; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094668 CVCL_7393 GM03525 finite cell line human CVCL_7393 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094669 CVCL_6R94 DA01031 transformed cell line human CVCL_6R94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094670 CVCL_7394 GM03529 finite cell line human CVCL_7394 CL:0000010 Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094671 CVCL_6R95 DA01032 transformed cell line human CVCL_6R95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094672 CVCL_7395 XP30RO finite cell line human CVCL_7395 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ala35fs (c.104_116del); Zygosity=Homozygous (PubMed=10385124; PubMed=10398605) Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094673 CVCL_6R89 DA01026 transformed cell line human CVCL_6R89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094674 CVCL_7389 GM03468 finite cell line human CVCL_7389 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21094675 CVCL_QA50 BayGenomics ES cell line XK098 embryonic stem cell house mouse CVCL_QA50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916471; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094676 CVCL_QA51 BayGenomics ES cell line XK101 embryonic stem cell house mouse CVCL_QA51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094677 CVCL_QA52 BayGenomics ES cell line XK103 embryonic stem cell house mouse CVCL_QA52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925868; Acap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094678 CVCL_QA53 BayGenomics ES cell line XK104 embryonic stem cell house mouse CVCL_QA53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094679 CVCL_QA54 BayGenomics ES cell line XK109 embryonic stem cell house mouse CVCL_QA54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094680 CVCL_QA55 BayGenomics ES cell line XK113 embryonic stem cell house mouse CVCL_QA55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094681 CVCL_QA56 BayGenomics ES cell line XK115 embryonic stem cell house mouse CVCL_QA56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2674092; Zfp609 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094682 CVCL_QA57 BayGenomics ES cell line XK121 embryonic stem cell house mouse CVCL_QA57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094683 CVCL_QA58 BayGenomics ES cell line XK122 embryonic stem cell house mouse CVCL_QA58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99400; Atp7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094684 CVCL_QA59 BayGenomics ES cell line XK123 embryonic stem cell house mouse CVCL_QA59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094685 CVCL_QA40 BayGenomics ES cell line XK082 embryonic stem cell house mouse CVCL_QA40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094686 CVCL_QA41 BayGenomics ES cell line XK084 embryonic stem cell house mouse CVCL_QA41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101785; Mybl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094687 CVCL_QA42 BayGenomics ES cell line XK088 embryonic stem cell house mouse CVCL_QA42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094688 CVCL_QA43 BayGenomics ES cell line XK089 embryonic stem cell house mouse CVCL_QA43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913606; Knop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094689 CVCL_QA44 BayGenomics ES cell line XK090 embryonic stem cell house mouse CVCL_QA44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919369; Tpx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094690 CVCL_QA45 BayGenomics ES cell line XK091 embryonic stem cell house mouse CVCL_QA45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920196; Lrrc47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094691 CVCL_QA46 BayGenomics ES cell line XK093 embryonic stem cell house mouse CVCL_QA46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158813; Sumo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094692 CVCL_QA47 BayGenomics ES cell line XK094 embryonic stem cell house mouse CVCL_QA47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094693 CVCL_QA48 BayGenomics ES cell line XK096 embryonic stem cell house mouse CVCL_QA48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917887; Ankrd26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094694 CVCL_QA49 BayGenomics ES cell line XK097 embryonic stem cell house mouse CVCL_QA49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351658; Abcf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094695 CVCL_HG93 CW10201 induced pluripotent stem cell human CVCL_HG93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10201; true Male 21094696 CVCL_HG94 CW10203 induced pluripotent stem cell human CVCL_HG94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10203; true Male 21094697 CVCL_HG95 CW10205 induced pluripotent stem cell human CVCL_HG95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10205; true Female 21094698 CVCL_HG96 CW20004 induced pluripotent stem cell human CVCL_HG96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20004; true Female 21094699 CVCL_HG90 CW10189 induced pluripotent stem cell human CVCL_HG90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10189; true Male 21094700 CVCL_HG91 CW10191 induced pluripotent stem cell human CVCL_HG91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10191; true Female 21094701 CVCL_HG92 CW10192 induced pluripotent stem cell human CVCL_HG92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10192; true Female 21094702 CVCL_QA30 BayGenomics ES cell line XK068 embryonic stem cell house mouse CVCL_QA30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919592; Lsm12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094703 CVCL_QA31 BayGenomics ES cell line XK069 embryonic stem cell house mouse CVCL_QA31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094704 CVCL_QA32 BayGenomics ES cell line XK070 embryonic stem cell house mouse CVCL_QA32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094705 CVCL_QA33 BayGenomics ES cell line XK071 embryonic stem cell house mouse CVCL_QA33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98388; Sptbn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094706 CVCL_QA34 BayGenomics ES cell line XK072 embryonic stem cell house mouse CVCL_QA34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920538; Vps50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094707 CVCL_QA35 BayGenomics ES cell line XK073 embryonic stem cell house mouse CVCL_QA35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914489; Rpf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094708 CVCL_QA36 BayGenomics ES cell line XK074 embryonic stem cell house mouse CVCL_QA36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094709 CVCL_QA37 BayGenomics ES cell line XK078 embryonic stem cell house mouse CVCL_QA37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443584; L3mbtl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094710 CVCL_QA38 BayGenomics ES cell line XK080 embryonic stem cell house mouse CVCL_QA38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094711 CVCL_QA39 BayGenomics ES cell line XK081 embryonic stem cell house mouse CVCL_QA39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094712 CVCL_HG86 CW10184 induced pluripotent stem cell human CVCL_HG86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10184; true Female 21094713 CVCL_HG87 CW10185 induced pluripotent stem cell human CVCL_HG87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10185; true Female 21094714 CVCL_HG88 CW10187 induced pluripotent stem cell human CVCL_HG88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10187; true Female 21094715 CVCL_HG89 CW10188 induced pluripotent stem cell human CVCL_HG89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10188; true Female 21094716 CVCL_QA20 BayGenomics ES cell line XK051 embryonic stem cell house mouse CVCL_QA20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930197; Ncapg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094717 CVCL_QA21 BayGenomics ES cell line XK052 embryonic stem cell house mouse CVCL_QA21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97805; Ptpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094718 CVCL_QA22 BayGenomics ES cell line XK053 embryonic stem cell house mouse CVCL_QA22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351331; Chaf1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094719 CVCL_QA23 BayGenomics ES cell line XK055 embryonic stem cell house mouse CVCL_QA23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094720 CVCL_QA24 BayGenomics ES cell line XK056 embryonic stem cell house mouse CVCL_QA24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88302; Ccnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094721 CVCL_QA25 BayGenomics ES cell line XK057 embryonic stem cell house mouse CVCL_QA25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917349; Smc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094722 CVCL_QA26 BayGenomics ES cell line XK059 embryonic stem cell house mouse CVCL_QA26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88547; Csnk2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094723 CVCL_QA27 BayGenomics ES cell line XK062 embryonic stem cell house mouse CVCL_QA27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094724 CVCL_QA28 BayGenomics ES cell line XK065 embryonic stem cell house mouse CVCL_QA28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094725 CVCL_QA29 BayGenomics ES cell line XK066 embryonic stem cell house mouse CVCL_QA29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094726 CVCL_HG97 CW20009 induced pluripotent stem cell human CVCL_HG97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20009; true Female 21094727 CVCL_HG98 CW20015 induced pluripotent stem cell human CVCL_HG98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20015; true Male 21094728 CVCL_HG99 CW20021 induced pluripotent stem cell human CVCL_HG99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW20021; true. Female 21094729 CVCL_HG71 CW10146 induced pluripotent stem cell human CVCL_HG71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10146; true Male 21094730 CVCL_HG72 CW10153 induced pluripotent stem cell human CVCL_HG72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10153; true Male 21094731 CVCL_HG73 CW10155 induced pluripotent stem cell human CVCL_HG73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10155; true Female 21094732 CVCL_HG74 CW10157 induced pluripotent stem cell human CVCL_HG74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10157; true Male 21094733 CVCL_HG70 CW10143 induced pluripotent stem cell human CVCL_HG70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10143; true Male 21094734 CVCL_QA10 BayGenomics ES cell line XJ201 embryonic stem cell house mouse CVCL_QA10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931751; Pum2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094735 CVCL_QA11 BayGenomics ES cell line XJ205 embryonic stem cell house mouse CVCL_QA11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346098; Nelfa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094736 CVCL_QA12 BayGenomics ES cell line XJ208 embryonic stem cell house mouse CVCL_QA12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926185; Saal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094737 CVCL_QA13 BayGenomics ES cell line XK001 embryonic stem cell house mouse CVCL_QA13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094738 CVCL_QA14 BayGenomics ES cell line XK007 embryonic stem cell house mouse CVCL_QA14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914322; Cdc37l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094739 CVCL_QA15 BayGenomics ES cell line XK018 embryonic stem cell house mouse CVCL_QA15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858964; Actr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094740 CVCL_QA16 BayGenomics ES cell line XK021 embryonic stem cell house mouse CVCL_QA16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094741 CVCL_HG68 CW10139 induced pluripotent stem cell human CVCL_HG68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10139; true Female 21094742 CVCL_QA17 BayGenomics ES cell line XK022 embryonic stem cell house mouse CVCL_QA17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106621; Myo1e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094743 CVCL_HG69 CW10141 induced pluripotent stem cell human CVCL_HG69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10141; true Male 21094744 CVCL_QA18 BayGenomics ES cell line XK049 embryonic stem cell house mouse CVCL_QA18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915527; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094745 CVCL_QA19 BayGenomics ES cell line XK050 embryonic stem cell house mouse CVCL_QA19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094746 CVCL_HG64 CW10127 induced pluripotent stem cell human CVCL_HG64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10127; true Male 21094747 CVCL_HG65 CW10131 induced pluripotent stem cell human CVCL_HG65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10131; true Male 21094748 CVCL_HG66 CW10135 induced pluripotent stem cell human CVCL_HG66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10135; true Male 21094749 CVCL_HG67 CW10136 induced pluripotent stem cell human CVCL_HG67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10136; true Female 21094750 CVCL_HG82 CW10176 induced pluripotent stem cell human CVCL_HG82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10176; true Female 21094751 CVCL_HG83 CW10177 induced pluripotent stem cell human CVCL_HG83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10177; true Male 21094752 CVCL_HG84 CW10182 induced pluripotent stem cell human CVCL_HG84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10182; true Male 21094753 CVCL_HG85 CW10183 induced pluripotent stem cell human CVCL_HG85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10183; true Female 21094754 CVCL_HG80 CW10172 induced pluripotent stem cell human CVCL_HG80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10172; true Female 21094755 CVCL_HG81 CW10173 induced pluripotent stem cell human CVCL_HG81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10173; true Female 21094756 CVCL_QA00 BayGenomics ES cell line XJ144 embryonic stem cell house mouse CVCL_QA00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094757 CVCL_QA01 BayGenomics ES cell line XJ154 embryonic stem cell house mouse CVCL_QA01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094758 CVCL_QA02 BayGenomics ES cell line XJ178 embryonic stem cell house mouse CVCL_QA02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094759 CVCL_QA03 BayGenomics ES cell line XJ183 embryonic stem cell house mouse CVCL_QA03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140103; Nmd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094760 CVCL_QA04 BayGenomics ES cell line XJ191 embryonic stem cell house mouse CVCL_QA04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445220; Dcaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094761 CVCL_QA05 BayGenomics ES cell line XJ195 embryonic stem cell house mouse CVCL_QA05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861099; Ubr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094762 CVCL_HG79 CW10169 induced pluripotent stem cell human CVCL_HG79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10169; true Female 21094763 CVCL_QA06 BayGenomics ES cell line XJ196 embryonic stem cell house mouse CVCL_QA06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919583; Palld Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094764 CVCL_QA07 BayGenomics ES cell line XJ197 embryonic stem cell house mouse CVCL_QA07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858304; Ctps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094765 CVCL_QA08 BayGenomics ES cell line XJ198 embryonic stem cell house mouse CVCL_QA08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094766 CVCL_QA09 BayGenomics ES cell line XJ199 embryonic stem cell house mouse CVCL_QA09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094767 CVCL_HG75 CW10160 induced pluripotent stem cell human CVCL_HG75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10160; true Male 21094768 CVCL_HG76 CW10163 induced pluripotent stem cell human CVCL_HG76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10163; true Male 21094769 CVCL_HG77 CW10166 induced pluripotent stem cell human CVCL_HG77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10166; true Male 21094770 CVCL_HG78 CW10168 induced pluripotent stem cell human CVCL_HG78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10168; true Female 21094771 CVCL_HG50 CW10069 induced pluripotent stem cell human CVCL_HG50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10069; true Male 21094772 CVCL_HG51 CW10079 induced pluripotent stem cell human CVCL_HG51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10079; true Female 21094773 CVCL_HG52 CW10084 induced pluripotent stem cell human CVCL_HG52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10084; true Male 21094774 CVCL_HG46 CW10061 induced pluripotent stem cell human CVCL_HG46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10061; true Female 21094775 CVCL_HG47 CW10062 induced pluripotent stem cell human CVCL_HG47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10062; true Female 21094776 CVCL_HG48 CW10064 induced pluripotent stem cell human CVCL_HG48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10064; true Female 21094777 CVCL_HG49 CW10066 induced pluripotent stem cell human CVCL_HG49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10066; true Female 21094778 CVCL_HG42 BME-UV2 transformed cell line CVCL_HG42 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female 21094779 CVCL_HG43 CW10013 induced pluripotent stem cell human CVCL_HG43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10013; true Male 21094780 CVCL_HG44 CW10025 induced pluripotent stem cell human CVCL_HG44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10025; true Female 21094781 CVCL_HG45 CW10033 induced pluripotent stem cell human CVCL_HG45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10033; true. Female 21094782 CVCL_HG60 CW10109 induced pluripotent stem cell human CVCL_HG60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10109; true Female 21094783 CVCL_HG61 CW10111 induced pluripotent stem cell human CVCL_HG61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10111; true Female 21094784 CVCL_HG62 CW10116 induced pluripotent stem cell human CVCL_HG62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10116; true Male 21094785 CVCL_HG63 CW10120 induced pluripotent stem cell human CVCL_HG63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10120; true Female 21094786 CVCL_HG57 CW10097 induced pluripotent stem cell human CVCL_HG57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10097; true Male 21094787 CVCL_HG58 CW10103 induced pluripotent stem cell human CVCL_HG58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10103; true Male 21094788 CVCL_HG59 CW10104 induced pluripotent stem cell human CVCL_HG59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10104; true Female 21094789 CVCL_HG53 CW10085 induced pluripotent stem cell human CVCL_HG53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10085; true Female 21094790 CVCL_HG54 CW10087 induced pluripotent stem cell human CVCL_HG54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10087; true Female 21094791 CVCL_HG55 CW10088 induced pluripotent stem cell human CVCL_HG55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10088; true Female 21094792 CVCL_HG56 CW10091 induced pluripotent stem cell human CVCL_HG56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10091; true Male 21094793 CVCL_6T20 DA01170 transformed cell line human CVCL_6T20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094794 CVCL_7520 GM12057 transformed cell line human CVCL_7520 HLA typing: A*01:01,02:01; B*08:01,15:01; C*04:01,07:01; DPA1*01:03; DPB1*04:01,04:02; DQA1*01:03,02:01; DQB1*03:03:02,06:03; DRB1*07:01,13:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25862) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134413 21094795 CVCL_6T14 DA01163 transformed cell line human CVCL_6T14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094796 CVCL_7514 GM11973 transformed cell line human CVCL_7514 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094797 CVCL_6T15 DA01164 transformed cell line human CVCL_6T15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094798 CVCL_7515 GM11992 transformed cell line human CVCL_7515 HLA typing: A*01:01,02:01; B*35:01,08:01; C*04:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:02; DQA1*01:01,05:01; DQB1*02:01,05:01:01; DRB1*01:01,03:01 (IPD-IMGT/HLA=25931) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136213 21094799 CVCL_6T16 DA01166 transformed cell line human CVCL_6T16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094800 CVCL_7516 GM11993 transformed cell line human CVCL_7516 HLA typing: A*26:01,29:02; B*44:02,44:03; C*16:01,05:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01; DQA1*01:01,01:02; DQB1*05:01,06:02; DRB1*01:01,15:01 (IPD-IMGT/HLA=25930) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136214 21094801 CVCL_6T17 DA01167 transformed cell line human CVCL_6T17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094802 CVCL_7517 GM11994 transformed cell line human CVCL_7517 HLA typing: A*01:01,11:01; B*07:02,51:01; C*07:02,15:02; DPA1*01:03,01:03; DPB1*04:01,15:01; DQA1*03:01,03:01; DQB1*03:02,03:02:01; DRB1*04:02,04:04 (IPD-IMGT/HLA=25933) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136215 21094803 CVCL_6T10 DA01159 transformed cell line human CVCL_6T10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094804 CVCL_7510 GM11840 transformed cell line human CVCL_7510 HLA typing: A*02:01,02:01; B*27:03,57:01; C*02:02:02,06:02; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25915) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134914 21094805 CVCL_6T11 DA01160 transformed cell line human CVCL_6T11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094806 CVCL_7511 GM11854 transformed cell line human CVCL_7511 HLA typing: A*26:01:01,30:02:01; B*35:01:01,44:02:01; C*04:01:01,16:04:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,05:05:01; DQB1*03:01:01,06:09:01; DRB1*11:04:01,13:02:01; DRB3*02:02:01,03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094807 CVCL_6T12 DA01161 transformed cell line human CVCL_6T12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094808 CVCL_7512 GM11882 transformed cell line human CVCL_7512 HLA typing: A*01:01,29:02; B*15:01,44:03; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*03:01,04:02; DQA1*01:02,03:01; DQB1*03:02,06:02; DRB1*04:01,15:01; DRB4*01; DRB5*01 (IPD-IMGT/HLA=25893) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134715 21094809 CVCL_6T13 DA01162 transformed cell line human CVCL_6T13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094810 CVCL_7513 GM11883 transformed cell line human CVCL_7513 HLA typing: A*01:01,68:01:02; B*15:01,44:04; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:02; DRB1*04:01,11:01; DRB3*02; DRB4*01 (IPD-IMGT/HLA=25891) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134716 21094811 CVCL_6T18 DA01168 transformed cell line human CVCL_6T18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094812 CVCL_7518 GM12006 transformed cell line human CVCL_7518 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142012/147713 21094813 CVCL_6T19 DA01169 transformed cell line human CVCL_6T19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094814 CVCL_7519 GM12056 transformed cell line human CVCL_7519 HLA typing: A*01:01,24:02; B*15:01,40:01; C*03:03,03:04:01; DPA1*01:03; DPB1*02:01:02,03:01; DQA1*01:02,03:01; DQB1*03:02:01,06:02; DRB1*04:04,15:01; DRB4*01; DRB5*01 (IPD-IMGT/HLA=25863) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134412 21094815 CVCL_6T30 DA01182 transformed cell line human CVCL_6T30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094816 CVCL_7530 GM13079 transformed cell line human CVCL_7530 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094817 CVCL_6T31 DA01183 transformed cell line human CVCL_6T31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094818 CVCL_7531 GM13335 finite cell line human CVCL_7531 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094819 CVCL_6T25 DA01175 transformed cell line human CVCL_6T25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094820 CVCL_7525 GM12751 transformed cell line human CVCL_7525 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144414 21094821 CVCL_6T26 DA01176 transformed cell line human CVCL_6T26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01176; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094822 CVCL_7526 GM12878 transformed cell line human CVCL_7526 HLA typing: A*01,11; B*08,56; C*01,07; DPA1*01:03:01,02:01:01; DPB1*04:01:01,14:01; DQA1*01,05; DQB1*02,05; DRB1*01,03:01 (PubMed=27792722) CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 1; Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Genome in a Bottle (GIAB) consortium samples; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146302; Registration: National Institute of Standards and Technology, Standard Reference Materials; HG001 21094823 CVCL_6T27 DA01178 transformed cell line human CVCL_6T27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094824 CVCL_7527 GM13068 transformed cell line human CVCL_7527 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21094825 CVCL_6T28 DA01180 transformed cell line human CVCL_6T28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094826 CVCL_7528 GM13069 transformed cell line human CVCL_7528 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21094827 CVCL_6T21 DA01171 transformed cell line human CVCL_6T21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094828 CVCL_7521 GM12145 transformed cell line human CVCL_7521 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133411 21094829 CVCL_6T22 DA01172 transformed cell line human CVCL_6T22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094830 CVCL_7522 GM12155 transformed cell line human CVCL_7522 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01; DQA1*03:01,05:01; DQB1*02:01,03:01; DRB1*03:01,04:01 (IPD-IMGT/HLA=25942) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140812 21094831 CVCL_6T23 DA01173 transformed cell line human CVCL_6T23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094832 CVCL_7523 GM12497 transformed cell line human CVCL_7523 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094833 CVCL_6T24 DA01174 transformed cell line human CVCL_6T24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094834 CVCL_7524 GM12593 transformed cell line human CVCL_7524 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21094835 CVCL_6T29 DA01181 transformed cell line human CVCL_6T29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094836 CVCL_7529 GM13072 transformed cell line human CVCL_7529 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094837 CVCL_6T03 DA01152 transformed cell line human CVCL_6T03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094838 CVCL_7503 GM10860 transformed cell line human CVCL_7503 HLA typing: A*02:01,29:02; B*35:01,44:03; C*04:01,16:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,01:01; DQB1*05:01,05:01:01; DRB1*01:01,01:01 (IPD-IMGT/HLA=25921) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136201 21094839 CVCL_6T04 DA01153 transformed cell line human CVCL_6T04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094840 CVCL_7504 GM10902 transformed cell line human CVCL_7504 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094841 CVCL_6T05 DA01154 transformed cell line human CVCL_6T05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094842 CVCL_7505 GM10923 transformed cell line human CVCL_7505 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21094843 CVCL_6T06 DA01155 transformed cell line human CVCL_6T06 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094844 CVCL_7506 GM10924 transformed cell line human CVCL_7506 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094845 CVCL_6T00 DA01149 transformed cell line human CVCL_6T00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094846 CVCL_7500 GM09923 transformed cell line human CVCL_7500 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094847 CVCL_6T01 DA01150 transformed cell line human CVCL_6T01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094848 CVCL_7501 GM10492 transformed cell line human CVCL_7501 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21094849 CVCL_6T02 DA01151 transformed cell line human CVCL_6T02 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094850 CVCL_7502 GM10540 transformed cell line human CVCL_7502 CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21094851 CVCL_6T07 DA01156 transformed cell line human CVCL_6T07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094852 CVCL_7507 GM11522 transformed cell line human CVCL_7507 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21094853 CVCL_6T08 DA01157 transformed cell line human CVCL_6T08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094854 CVCL_7508 GM11829 transformed cell line human CVCL_7508 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135010 21094855 CVCL_6T09 DA01158 transformed cell line human CVCL_6T09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094856 CVCL_7509 GM11839 transformed cell line human CVCL_7509 HLA typing: A*02:01,25:01; B*44:02:01:01,07:02; C*05:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*01:02,03:01; DQB1*03:01,06:02; DRB1*04:01,15:01; DRB4*01; DRB5*01:01 (IPD-IMGT/HLA=25916) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134913 21094857 CVCL_QA90 BayGenomics ES cell line XK182 embryonic stem cell house mouse CVCL_QA90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094858 CVCL_QA91 BayGenomics ES cell line XK185 embryonic stem cell house mouse CVCL_QA91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919349; Elp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094859 CVCL_QA92 BayGenomics ES cell line XK187 embryonic stem cell house mouse CVCL_QA92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103575; Skp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094860 CVCL_QA93 BayGenomics ES cell line XK191 embryonic stem cell house mouse CVCL_QA93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094861 CVCL_QA94 BayGenomics ES cell line XK192 embryonic stem cell house mouse CVCL_QA94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094862 CVCL_QA95 BayGenomics ES cell line XK195 embryonic stem cell house mouse CVCL_QA95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094863 CVCL_QA96 BayGenomics ES cell line XK197 embryonic stem cell house mouse CVCL_QA96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094864 CVCL_QA97 BayGenomics ES cell line XK198 embryonic stem cell house mouse CVCL_QA97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448526; Gmps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094865 CVCL_QA98 BayGenomics ES cell line XK199 embryonic stem cell house mouse CVCL_QA98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094866 CVCL_QA99 BayGenomics ES cell line XK202 embryonic stem cell house mouse CVCL_QA99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891691; Arpp19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094867 CVCL_QA80 BayGenomics ES cell line XK165 embryonic stem cell house mouse CVCL_QA80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094868 CVCL_QA81 BayGenomics ES cell line XK166 embryonic stem cell house mouse CVCL_QA81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094869 CVCL_QA82 BayGenomics ES cell line XK167 embryonic stem cell house mouse CVCL_QA82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105976; Myo5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094870 CVCL_QA83 BayGenomics ES cell line XK168 embryonic stem cell house mouse CVCL_QA83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108426; Kif1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094871 CVCL_QA84 BayGenomics ES cell line XK169 embryonic stem cell house mouse CVCL_QA84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094872 CVCL_QA85 BayGenomics ES cell line XK171 embryonic stem cell house mouse CVCL_QA85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446190; Nup188 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094873 CVCL_QA86 BayGenomics ES cell line XK172 embryonic stem cell house mouse CVCL_QA86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094874 CVCL_QA87 BayGenomics ES cell line XK176 embryonic stem cell house mouse CVCL_QA87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98086; Polr2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094875 CVCL_QA88 BayGenomics ES cell line XK177 embryonic stem cell house mouse CVCL_QA88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106035; Mki67 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094876 CVCL_QA89 BayGenomics ES cell line XK181 embryonic stem cell house mouse CVCL_QA89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094877 CVCL_QA70 BayGenomics ES cell line XK148 embryonic stem cell house mouse CVCL_QA70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88547; Csnk2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094878 CVCL_QA71 BayGenomics ES cell line XK150 embryonic stem cell house mouse CVCL_QA71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094879 CVCL_QA72 BayGenomics ES cell line XK151 embryonic stem cell house mouse CVCL_QA72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094880 CVCL_QA73 BayGenomics ES cell line XK152 embryonic stem cell house mouse CVCL_QA73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094881 CVCL_QA74 BayGenomics ES cell line XK153 embryonic stem cell house mouse CVCL_QA74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094882 CVCL_QA75 BayGenomics ES cell line XK155 embryonic stem cell house mouse CVCL_QA75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094883 CVCL_QA76 BayGenomics ES cell line XK156 embryonic stem cell house mouse CVCL_QA76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094884 CVCL_QA77 BayGenomics ES cell line XK157 embryonic stem cell house mouse CVCL_QA77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094885 CVCL_QA78 BayGenomics ES cell line XK163 embryonic stem cell house mouse CVCL_QA78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094886 CVCL_QA79 BayGenomics ES cell line XK164 embryonic stem cell house mouse CVCL_QA79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094887 CVCL_QA60 BayGenomics ES cell line XK127 embryonic stem cell house mouse CVCL_QA60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277958; Pcm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094888 CVCL_QA61 BayGenomics ES cell line XK131 embryonic stem cell house mouse CVCL_QA61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094889 CVCL_QA62 BayGenomics ES cell line XK134 embryonic stem cell house mouse CVCL_QA62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196391; Pole Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094890 CVCL_QA63 BayGenomics ES cell line XK135 embryonic stem cell house mouse CVCL_QA63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443205; Rbm15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094891 CVCL_QA64 BayGenomics ES cell line XK136 embryonic stem cell house mouse CVCL_QA64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913355; Ube2d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094892 CVCL_QA65 BayGenomics ES cell line XK138 embryonic stem cell house mouse CVCL_QA65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094893 CVCL_QA66 BayGenomics ES cell line XK142 embryonic stem cell house mouse CVCL_QA66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443732; Dna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094894 CVCL_QA67 BayGenomics ES cell line XK143 embryonic stem cell house mouse CVCL_QA67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094895 CVCL_QA68 BayGenomics ES cell line XK146 embryonic stem cell house mouse CVCL_QA68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106906; Eif4a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094896 CVCL_QA69 BayGenomics ES cell line XK147 embryonic stem cell house mouse CVCL_QA69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102724; Tpp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21094897 CVCL_6S84 DA01133 transformed cell line human CVCL_6S84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094898 CVCL_7484 GM08401 finite cell line human CVCL_7484 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094899 CVCL_6S85 DA01134 transformed cell line human CVCL_6S85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094900 CVCL_7485 GM08402 finite cell line human CVCL_7485 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21094901 CVCL_6S86 DA01135 transformed cell line human CVCL_6S86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094902 CVCL_7486 GM08429 finite cell line human CVCL_7486 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 21094903 CVCL_6S87 DA01136 transformed cell line human CVCL_6S87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094904 CVCL_7487 GM08447 finite cell line human CVCL_7487 CL:0000010 Population: Caucasian; Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 21094905 CVCL_6S80 DA01129 transformed cell line human CVCL_6S80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094906 CVCL_7480 GM08390 transformed cell line human CVCL_7480 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094907 CVCL_6S81 DA01130 transformed cell line human CVCL_6S81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094908 CVCL_7481 GM08398 finite cell line human CVCL_7481 CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21094909 CVCL_6S82 DA01131 transformed cell line human CVCL_6S82 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094910 CVCL_7482 GM08399 finite cell line human CVCL_7482 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094911 CVCL_6S83 DA01132 transformed cell line human CVCL_6S83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094912 CVCL_7483 GM08400 finite cell line human CVCL_7483 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21094913 CVCL_6S77 DA01126 transformed cell line human CVCL_6S77 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094914 CVCL_7477 GM08333 finite cell line human CVCL_7477 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21094915 CVCL_6S78 DA01127 transformed cell line human CVCL_6S78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094916 CVCL_7478 GM08387 finite cell line human CVCL_7478 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21094917 CVCL_6S79 DA01128 transformed cell line human CVCL_6S79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094918 CVCL_7479 GM08388 transformed cell line human CVCL_7479 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094919 CVCL_6S90 DA01139 transformed cell line human CVCL_6S90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094920 CVCL_7490 GM08925 transformed cell line human CVCL_7490 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094921 CVCL_6S95 DA01144 transformed cell line human CVCL_6S95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094922 CVCL_7495 GM09732 transformed cell line human CVCL_7495 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21094923 CVCL_6S96 DA01145 transformed cell line human CVCL_6S96 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094924 CVCL_7496 GM09741 transformed cell line human CVCL_7496 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21094925 CVCL_6S97 DA01146 transformed cell line human CVCL_6S97 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094926 CVCL_7497 GM09820 transformed cell line human CVCL_7497 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21094927 CVCL_6S98 DA01147 transformed cell line human CVCL_6S98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094928 CVCL_7498 GM09869 transformed cell line human CVCL_7498 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21094929 CVCL_6S91 DA01140 transformed cell line human CVCL_6S91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094930 CVCL_7491 GM08928 transformed cell line human CVCL_7491 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094931 CVCL_6S92 DA01141 transformed cell line human CVCL_6S92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094932 CVCL_7492 GM09503 finite cell line human CVCL_7492 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+20 [2]; 46,XY [48] (Coriell); Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 21094933 CVCL_6S93 DA01142 transformed cell line human CVCL_6S93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094934 CVCL_7493 GM09545 transformed cell line human CVCL_7493 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (Coriell) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21094935 CVCL_6S94 DA01143 transformed cell line human CVCL_6S94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094936 CVCL_7494 GM09582 transformed cell line human CVCL_7494 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21094937 CVCL_6S88 DA01137 transformed cell line human CVCL_6S88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094938 CVCL_7488 GM08505 transformed cell line human CVCL_7488 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=7585968; PubMed=10521302; PubMed=17407155; Coriell) Population: Jewish; Ashkenazi; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Donor information: From Bloom Syndrome Registry patient 42(RaFr) (BSR42); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094939 CVCL_6S89 DA01138 transformed cell line human CVCL_6S89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094940 CVCL_7489 GM08680 finite cell line human CVCL_7489 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21094941 CVCL_6S62 DA01111 transformed cell line human CVCL_6S62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094942 CVCL_7462 GM07029 transformed cell line human CVCL_7462 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134001 21094943 CVCL_6S63 DA01112 transformed cell line human CVCL_6S63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094944 CVCL_7463 GM07055 transformed cell line human CVCL_7463 HLA typing: A*02:01,68:01:02; B*07:02,07:02; C*07:02,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01; DQA1*01:01,01:02; DQB1*05:03,06:02; DRB1*14:01,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=25859) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134112 21094945 CVCL_6S64 DA01113 transformed cell line human CVCL_6S64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094946 CVCL_7464 GM07166 finite cell line human CVCL_7464 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21094947 CVCL_6S65 DA01114 transformed cell line human CVCL_6S65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094948 CVCL_7465 GM07348 transformed cell line human CVCL_7465 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 134502 21094949 CVCL_6S60 DA01109 transformed cell line human CVCL_6S60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094950 CVCL_7460 GM06875 transformed cell line human CVCL_7460 HLA typing: A*01:01:01,02:01:01; B*15:01:01,52:01:01; C*03:03:01,12:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:03:01,02:01:01; DQB1*03:03:02,06:01:01; DRB1*07:01:01,15:02:01G; DRB4*01:03:01:02N; DRB5*01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094951 CVCL_6S61 DA01110 transformed cell line human CVCL_6S61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094952 CVCL_7461 GM07019 transformed cell line human CVCL_7461 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134002 21094953 CVCL_6S59 DA01108 transformed cell line human CVCL_6S59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094954 CVCL_7459 GM06862 transformed cell line human CVCL_7459 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21094955 CVCL_6S55 DA01104 transformed cell line human CVCL_6S55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094956 CVCL_7455 GM06167 finite cell line human CVCL_7455 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21094957 CVCL_6S56 DA01105 transformed cell line human CVCL_6S56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094958 CVCL_7456 GM06170 finite cell line human CVCL_7456 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094959 CVCL_6S57 DA01106 transformed cell line human CVCL_6S57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094960 CVCL_7457 GM06315 transformed cell line human CVCL_7457 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21094961 CVCL_6S58 DA01107 transformed cell line human CVCL_6S58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094962 CVCL_7458 GM06861 transformed cell line human CVCL_7458 HLA typing: A*01:01:01,34:02:01; B*08:01:01,44:02:01; C*05:01:01,07:01:01; DPA1*01:03:01,02:01:01; DPB1*05:01:01,15:01:01; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:04:01; DRB1*07:01:01,13:02:01; DRB3*03:01:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094963 CVCL_6S73 DA01122 transformed cell line human CVCL_6S73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094964 CVCL_7473 GM07544 transformed cell line human CVCL_7473 HLA typing: A*24:02:01,31:01:02; B*27:05:02,56:01:01; C*01:02:01,02:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*04:01:01,05:05:01; DQB1*03:01:01,04:02:01; DRB1*08:01:01,11:01:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094965 CVCL_6S74 DA01123 transformed cell line human CVCL_6S74 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01123; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094966 CVCL_7474 GM07752 transformed cell line human CVCL_7474 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21094967 CVCL_6S75 DA01124 transformed cell line human CVCL_6S75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094968 CVCL_7475 GM07753 finite cell line human CVCL_7475 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (from autologous cell line GM07752) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094969 CVCL_6S76 DA01125 transformed cell line human CVCL_6S76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094970 CVCL_7476 GM08271 transformed cell line human CVCL_7476 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21094971 CVCL_6S70 DA01119 transformed cell line human CVCL_6S70 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094972 CVCL_7470 GM07525 finite cell line human CVCL_7470 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21094973 CVCL_6S71 DA01120 transformed cell line human CVCL_6S71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094974 CVCL_7471 GM07532 finite cell line human CVCL_7471 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21094975 CVCL_6S72 DA01121 transformed cell line human CVCL_6S72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094976 CVCL_7472 GM07535 transformed cell line human CVCL_7472 HLA typing: A*01:01:01,29:02:01; B*08:01:01,44:03:01; C*07:01:01,16:01:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094977 CVCL_6S66 DA01115 transformed cell line human CVCL_6S66 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094978 CVCL_7466 GM07441 transformed cell line human CVCL_7466 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.2988+1G>A (3120+1G>A); ClinVar=VCV000007224; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094979 CVCL_6S67 DA01116 transformed cell line human CVCL_6S67 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094980 CVCL_7467 GM07492 finite cell line human CVCL_7467 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM07492; probable Male 21094981 CVCL_6S68 DA01117 transformed cell line human CVCL_6S68 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094982 CVCL_7468 GM07521 transformed cell line human CVCL_7468 HLA typing: A*02:05:01,26:01:01; B*38:01:01,58:01:01; C*07:18,12:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*03:01:01,03:01:01; DQB1*03:02:01,03:02:01; DRB1*04:02:01,04:02:01; DRB4*01:03:01,01:03:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Arg296Cys (c.886C>T); ClinVar=VCV000242771; Zygosity=Heterozygous; Note=CYP2D6*2 allele (Coriell); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Ser486Thr (c.1457G>C); ClinVar=VCV000242701; Zygosity=Heterozygous; Note=CYP2D6*2 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094983 CVCL_6S69 DA01118 transformed cell line human CVCL_6S69 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094984 CVCL_7469 GM07524 transformed cell line human CVCL_7469 HLA typing: A*02:01:01,29:02:01; B*13:02:01,44:03:01; C*06:02:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*02:01:01,02:01:01; DQB1*02:02:01,02:02:01; DRB1*07:01:01,07:01:01; DRB4*01:01:01,01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21094985 CVCL_6S40 DA01082 transformed cell line human CVCL_6S40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094986 CVCL_7440 GM05789 transformed cell line human CVCL_7440 CL:0000010 Sequence variation: Mutation; HGNC; 2860; DHCR7; Simple; p.Gly138Val (c.413G>T); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2860; DHCR7; Simple; p.His405Tyr (c.1213C>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21094987 CVCL_7441 AT5BI finite cell line human CVCL_7441 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2427_Arg2428del (c.7278_7283delCCTTAG); ClinVar=VCV000003020; Zygosity=Heterozygous (PubMed=7792600; PubMed=8845835) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094988 CVCL_6S41 DA01083 transformed cell line human CVCL_6S41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094989 CVCL_7442 AT5BIVA transformed cell line human CVCL_7442 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2427_Arg2428del (c.7278_7283delCCTTAG); ClinVar=VCV000003020; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21094990 CVCL_6S42 DA01084 transformed cell line human CVCL_6S42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094991 CVCL_6S43 DA01085 transformed cell line human CVCL_6S43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094992 CVCL_7443 GM05870 finite cell line human CVCL_7443 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21094993 CVCL_6S37 DA01079 transformed cell line human CVCL_6S37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094994 CVCL_7437 GM05757 finite cell line human CVCL_7437 CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21094995 CVCL_6S38 DA01080 transformed cell line human CVCL_6S38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094996 CVCL_7438 GM05758 finite cell line human CVCL_7438 CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 21094997 CVCL_6S39 DA01081 transformed cell line human CVCL_6S39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21094998 CVCL_7439 GM05788 finite cell line human CVCL_7439 CL:0000010 Sequence variation: Mutation; HGNC; 2860; DHCR7; Simple; p.Gly138Val (c.413G>T); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2860; DHCR7; Simple; p.His405Tyr (c.1213C>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21094999 CVCL_6S33 DA01075 transformed cell line human CVCL_6S33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095000 CVCL_7433 GM05658 finite cell line human CVCL_7433 CL:0000010 Population: African American; Derived from sampling site: Umbilical area; skin Cell type=Fibroblast.. Male 21095001 CVCL_6S34 DA01076 transformed cell line human CVCL_6S34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095002 CVCL_7434 GM05659 finite cell line human CVCL_7434 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (PubMed=30497978) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095003 CVCL_6S35 DA01077 transformed cell line human CVCL_6S35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095004 CVCL_7435 GM05752 finite cell line human CVCL_7435 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21095005 CVCL_6S36 DA01078 transformed cell line human CVCL_6S36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095006 CVCL_7436 GM05756 finite cell line human CVCL_7436 CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 21095007 CVCL_6S51 DA01098 transformed cell line human CVCL_6S51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095008 CVCL_7451 GM06151 finite cell line human CVCL_7451 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 24 repeats (Coriell) Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Male 21095009 CVCL_6S52 DA01099 transformed cell line human CVCL_6S52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095010 CVCL_7452 GM06153 finite cell line human CVCL_7452 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[71]; Zygosity=Heterozygous; Note=The other allele has 23 repeats (Coriell) Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Male 21095011 CVCL_6S53 DA01100 transformed cell line human CVCL_6S53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095012 CVCL_7453 GM06160 transformed cell line human CVCL_7453 HLA typing: A*01:01:01,24:02:01; B*08:01:01,35:01:01; C*04:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,06:01:01; DQA1*01:01:01,03:01:01; DQB1*03:02:01,05:01:01; DRB1*01:03:01,04:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095013 CVCL_6S54 DA01103 transformed cell line human CVCL_6S54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095014 CVCL_7454 GM06166 finite cell line human CVCL_7454 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095015 CVCL_6S50 DA01097 transformed cell line human CVCL_6S50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095016 CVCL_7450 GM06127 finite cell line human CVCL_7450 CL:0000010 Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; c.1078_1182del105 (c.1182+1G>A); Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21095017 CVCL_6S48 DA01093 transformed cell line human CVCL_6S48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095018 CVCL_7448 GM06112 finite cell line human CVCL_7448 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21095019 CVCL_6S49 DA01095 transformed cell line human CVCL_6S49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095020 CVCL_7449 GM06114 finite cell line human CVCL_7449 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CNV analysis Male 21095021 CVCL_6S44 DA01086 transformed cell line human CVCL_6S44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095022 CVCL_7444 GM05879 finite cell line human CVCL_7444 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21095023 CVCL_6S45 DA01087 transformed cell line human CVCL_6S45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095024 CVCL_7445 GM05920 transformed cell line human CVCL_7445 HLA typing: A*02:01:01,02:01:01; B*15:01:01,15:01:01; C*03:04:01,03:04:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:01:01G; DQA1*03:01:01,03:01:01; DQB1*03:02:01,03:02:01; DRB1*04:01:01,04:01:01; DRB4*01:03:01,01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095025 CVCL_6S46 DA01088 transformed cell line human CVCL_6S46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095026 CVCL_7446 GM06051 transformed cell line human CVCL_7446 HLA typing: A*02:01:01,02:05:01; B*44:02:01,53:01:01; C*05:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,13:01:01G; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:04:01; DRB1*07:01:01,13:02:01; DRB3*03:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095027 CVCL_6S47 DA01092 transformed cell line human CVCL_6S47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095028 CVCL_7447 GM06111 finite cell line human CVCL_7447 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21095029 CVCL_6S20 DA01060 transformed cell line human CVCL_6S20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095030 CVCL_7420 GM05386 finite cell line human CVCL_7420 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095031 CVCL_6S21 DA01062 transformed cell line human CVCL_6S21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095032 CVCL_7421 GM05387 finite cell line human CVCL_7421 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21095033 CVCL_6S15 DA01055 transformed cell line human CVCL_6S15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095034 CVCL_7415 GM04663 finite cell line human CVCL_7415 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Tyr (c.693C>T); ClinVar=VCV000197621; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21095035 CVCL_6S16 DA01056 transformed cell line human CVCL_6S16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095036 CVCL_7416 GM05048 transformed cell line human CVCL_7416 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21095037 CVCL_6S17 DA01057 transformed cell line human CVCL_6S17 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095038 CVCL_7417 GM05377 transformed cell line human CVCL_7417 HLA typing: A*01:01:01,30:01:01; B*13:02:01,40:01:02; C*03:04:01,06:02:01; DPA1*01:03:01,02:01:01; DPB1*02:01:02,17:01:01; DQA1*02:01:01,03:01:01; DQB1*02:02:01,03:02:01; DRB1*04:01:01,07:01:01; DRB4*01:03:01,01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095039 CVCL_6S18 DA01058 transformed cell line human CVCL_6S18 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095040 CVCL_7418 GM05380 transformed cell line human CVCL_7418 HLA typing: A*01:01:01,11:01:01; B*07:02:01,15:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:01:01G; DQA1*02:01:01,05:05:01; DQB1*03:01:01,03:03:02; DRB1*07:01:01,11:01:01; DRB3*02:02:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095041 CVCL_6S11 DA01051 transformed cell line human CVCL_6S11 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095042 CVCL_7411 GM04504 finite cell line human CVCL_7411 CL:0000010 Donor information: Established from monozygotic twin of GM04503 (Cellosaurus=CVCL_7410); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3 21095043 CVCL_6S12 DA01052 transformed cell line human CVCL_6S12 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095044 CVCL_7412 GM04505 finite cell line human CVCL_7412 CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of GM04506 (Cellosaurus=CVCL_7413); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21095045 CVCL_6S13 DA01053 transformed cell line human CVCL_6S13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095046 CVCL_7413 GM04506 finite cell line human CVCL_7413 CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of GM04505 (Cellosaurus=CVCL_7412); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21095047 CVCL_6S14 DA01054 transformed cell line human CVCL_6S14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01054; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095048 CVCL_7414 GM04522 finite cell line human CVCL_7414 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female 21095049 CVCL_6S19 DA01059 transformed cell line human CVCL_6S19 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095050 CVCL_7419 GM05381 finite cell line human CVCL_7419 CL:0000010 Population: African American; Derived from sampling site: Umbilical area; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21095051 CVCL_6S30 DA01072 transformed cell line human CVCL_6S30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095052 CVCL_7430 GM05422 transformed cell line human CVCL_7430 HLA typing: A*01:01:01,03:01:01; B*35:08:01,44:02:01; C*04:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:02,03:03:01; DQB1*03:01:01,05:02:01; DRB1*04:01:01,16:07; DRB4*01:03:01; DRB5*02:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095053 CVCL_6S31 DA01073 transformed cell line human CVCL_6S31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095054 CVCL_7431 GM05423 transformed cell line human CVCL_7431 HLA typing: A*02:01:01,11:01:01; B*27:05:02,39:01:01; C*02:02:02,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*03:01:01,04:01:01; DQB1*03:02:01,04:02:01; DRB1*04:04:01,08:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095055 CVCL_6S32 DA01074 transformed cell line human CVCL_6S32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095056 CVCL_7432 GM05565 finite cell line human CVCL_7432 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21095057 CVCL_6S26 DA01067 transformed cell line human CVCL_6S26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095058 CVCL_7426 GM05400 finite cell line human CVCL_7426 CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21095059 CVCL_6S27 DA01068 transformed cell line human CVCL_6S27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095060 CVCL_7427 GM05408 transformed cell line human CVCL_7427 HLA typing: A*01:01:01,29:02:01; B*08:01:01,44:03:01; C*07:01:01,16:01:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,02:01:02; DQA1*02:01:01,05:01:01; DQB1*02:01:01,02:02:01; DRB1*03:01:01,07:01:01; DRB3*01:01:02; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095061 CVCL_6S28 DA01070 transformed cell line human CVCL_6S28 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095062 CVCL_7428 GM05420 finite cell line human CVCL_7428 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal eye; conjunctiva Cell type=Fibroblast.. Male 21095063 CVCL_6S29 DA01071 transformed cell line human CVCL_6S29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095064 CVCL_7429 GM05421 finite cell line human CVCL_7429 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal eye; conjunctiva Cell type=Fibroblast.. Male 21095065 CVCL_6S22 DA01063 transformed cell line human CVCL_6S22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095066 CVCL_7422 GM05388 finite cell line human CVCL_7422 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095067 CVCL_6S23 DA01064 transformed cell line human CVCL_6S23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095068 CVCL_7423 GM05389 finite cell line human CVCL_7423 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21095069 CVCL_6S24 DA01065 transformed cell line human CVCL_6S24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095070 CVCL_7424 GM05398 transformed cell line human CVCL_7424 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21095071 CVCL_6S25 DA01066 transformed cell line human CVCL_6S25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095072 CVCL_7425 GM05399 finite cell line human CVCL_7425 CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 21095073 CVCL_HG30 HCT 116 EP300(-) rescued cancer cell line human CVCL_HG30 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3373; EP300 Derived from sampling site: Colon. Male Characteristics: HCT 116 is hemizygous for EP300 This cell line is KO for the single allele and is rescued by transfection of a wild-type copy of EP300. 21095074 CVCL_HG28 HCT 116 EP300(-) clone F2 cancer cell line human CVCL_HG28 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: HCT 116 is hemizygous for EP300 This cell line is KO for the single allele. 21095075 CVCL_HG29 HCT 116 EP300(-) clone F5 cancer cell line human CVCL_HG29 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: HCT 116 is hemizygous for EP300 This cell line is KO for the single allele. 21095076 CVCL_HG24 VEGFWT fibrosarcoma cancer cell line house mouse CVCL_HG24 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Control cell line for the Vegfa isoform-specific cell lines 21095077 CVCL_HG25 VEGFWT fibrosarcoma Luc2/mStrawberry cancer cell line house mouse CVCL_HG25 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: mStrawberry, a bright red fluorescent protein derived from mRFP1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Control cell line for the Vegfa isoform-specific cell lines 21095078 CVCL_HG26 HCT 116 EP300 WT cancer cell line human CVCL_HG26 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: HCT 116 is hemizygous for EP300 This cell line is a normal derivative of HCT 116 from which a number of clones KO for the EP300 single allele were established. 21095079 CVCL_HG27 HCT 116 EP300(-) clone D10 cancer cell line human CVCL_HG27 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3373; EP300; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: HCT 116 is hemizygous for EP300 This cell line is KO for the single allele. 21095080 CVCL_HG20 VEGF164 fibrosarcoma cancer cell line house mouse CVCL_HG20 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF164 21095081 CVCL_HG21 VEGF164 fibrosarcoma Luc2/mStrawberry cancer cell line house mouse CVCL_HG21 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: mStrawberry, a bright red fluorescent protein derived from mRFP1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF164 21095082 CVCL_HG22 VEGF188 fibrosarcoma cancer cell line house mouse CVCL_HG22 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF188 21095083 CVCL_HG23 VEGF188 fibrosarcoma Luc2/mStrawberry cancer cell line house mouse CVCL_HG23 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: mStrawberry, a bright red fluorescent protein derived from mRFP1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF188 21095084 CVCL_HG40 HH2a spontaneously immortalized cell line CVCL_HG40 CL:0000010 Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female 21095085 CVCL_HG41 MD-IGF-I transformed cell line CVCL_HG41 CL:0000010 Transfected with: UniProtKB; P10763; Sheep IGF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female 21095086 CVCL_HG39 L-1 [Bovine mammary gland] spontaneously immortalized cell line CVCL_HG39 CL:0000010 Derived from sampling site: Mammary gland; udder; Breed/subspecies: Holstein Friesian. Female 21095087 CVCL_HG35 BMEC-CH spontaneously immortalized cell line CVCL_HG35 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Chinese Holstein. Female 21095088 CVCL_HG36 BMGE-H spontaneously immortalized cell line CVCL_HG36 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21095089 CVCL_HG37 BMGE+H spontaneously immortalized cell line CVCL_HG37 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21095090 CVCL_HG38 H-7 spontaneously immortalized cell line CVCL_HG38 CL:0000010 Derived from sampling site: Mammary gland; udder; Breed/subspecies: Holstein Friesian. Female 21095091 CVCL_HG31 DLB-1 transformed cell line CVCL_HG31 CL:0000010 Transformant: Snakehead retrovirus(NCBI-Taxonomy; 40270); Derived from sampling site: Brain. Unspecified Doubling time: 22.41 +- 4.5 hours (PubMed=27746373) Group: Fish cell line 21095092 CVCL_HG32 Ho-15 transformed cell line house mouse CVCL_HG32 CL:0000010 Knockout cell: Method=KO mouse; MGI:95607; G6pc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [A255](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 21095093 CVCL_HG33 WSU-1 cancer cell line human CVCL_HG33 CL:0000010 Omics: Transcriptome analysis by microarray. 21095094 CVCL_HG34 BB [Lates] spontaneously immortalized cell line CVCL_HG34 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21095095 CVCL_HG06 HCT 116-I6 cancer cell line human CVCL_HG06 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Demonstrates a 4x and 20x increase in migration and invasion rate respectively compared to HCT 116 21095096 CVCL_HG07 N_M5R1 cancer cell line human CVCL_HG07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:134602; MI-63; Derived from metastatic site: Lung. Male 21095097 CVCL_HG08 N_N20R1 cancer cell line human CVCL_HG08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from metastatic site: Lung. Male 21095098 CVCL_HG09 S_M6R1 cancer cell line human CVCL_HG09 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: African American; Selected for resistance to: ChEBI; CHEBI:134602; MI-63; Derived from sampling site: Bone; femur. Male 21095099 CVCL_HG02 FH-/- CL 19 transformed cell line house mouse CVCL_HG02 CL:0000010 Knockout cell: Method=Cre/loxP; MGI; MGI:95530; Fh1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095100 CVCL_HG03 HCT 116 ADAM17 cancer cell line human CVCL_HG03 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:1096335; Adam17 Derived from sampling site: Colon. Male 21095101 CVCL_HG04 HCT 116 AXL KO Tet-inducible cancer cell line human CVCL_HG04 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 905; AXL; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21095102 CVCL_HG05 HCT 116 EphA2 KO Tet-inducible cancer cell line human CVCL_HG05 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 3386; EPHA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21095103 CVCL_HG00 FH fl/fl transformed cell line house mouse CVCL_HG00 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095104 CVCL_HG01 FH-/- CL 1 transformed cell line house mouse CVCL_HG01 CL:0000010 Knockout cell: Method=Cre/loxP; MGI; MGI:95530; Fh1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095105 CVCL_HG17 T47D-ST3-STn cancer cell line human CVCL_HG17 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 10862; ST3GAL1; Transfected with: HGNC; 23614; ST6GALNAC1 Derived from metastatic site: Pleural effusion. Female 21095106 CVCL_HG18 VEGF120 fibrosarcoma cancer cell line house mouse CVCL_HG18 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF120 21095107 CVCL_HG19 VEGF120 fibrosarcoma Luc2/mStrawberry cancer cell line house mouse CVCL_HG19 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: mStrawberry, a bright red fluorescent protein derived from mRFP1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Characteristics: Derived from a transgenic mouse strain expressing only a single isoform of Vegfa, VEGF120 21095108 CVCL_HG13 Sdhb-/- CL 7 transformed cell line house mouse CVCL_HG13 CL:0000010 Knockout cell: Method=Cre/loxP; MGI; MGI:1914930; Sdhb Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095109 CVCL_HG14 T47D-E2J cancer cell line human CVCL_HG14 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4203; GCNT1 Derived from metastatic site: Pleural effusion. Female 21095110 CVCL_HG15 T47D-ST3 cancer cell line human CVCL_HG15 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 10862; ST3GAL1 Derived from metastatic site: Pleural effusion. Female 21095111 CVCL_HG16 T47D-StN cancer cell line human CVCL_HG16 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4203; GCNT1; Transfected with: HGNC; 23614; ST6GALNAC1 Derived from metastatic site: Pleural effusion. Female 21095112 CVCL_HG10 S_N40R2 cancer cell line human CVCL_HG10 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: African American; Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from sampling site: Bone; femur. Male 21095113 CVCL_HG11 Sdhb fl/fl transformed cell line house mouse CVCL_HG11 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095114 CVCL_HG12 Sdhb-/- CL 5 transformed cell line house mouse CVCL_HG12 CL:0000010 Knockout cell: Method=Cre/loxP; MGI; MGI:1914930; Sdhb Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21095115 CVCL_6S99 DA01148 transformed cell line human CVCL_6S99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095116 CVCL_7499 GM09918 finite cell line human CVCL_7499 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21095117 CVCL_QB70 BayGenomics ES cell line XK411 embryonic stem cell house mouse CVCL_QB70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916249; Anapc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095118 CVCL_QB71 BayGenomics ES cell line XK413 embryonic stem cell house mouse CVCL_QB71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921493; Slx4ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095119 CVCL_QB72 BayGenomics ES cell line XK417 embryonic stem cell house mouse CVCL_QB72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442980; Dennd6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095120 CVCL_QB73 BayGenomics ES cell line XK421 embryonic stem cell house mouse CVCL_QB73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095121 CVCL_QB74 BayGenomics ES cell line XK423 embryonic stem cell house mouse CVCL_QB74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919398; Tdrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095122 CVCL_QB75 BayGenomics ES cell line XK427 embryonic stem cell house mouse CVCL_QB75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095123 CVCL_QB76 BayGenomics ES cell line XK429 embryonic stem cell house mouse CVCL_QB76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095124 CVCL_QB77 BayGenomics ES cell line XK430 embryonic stem cell house mouse CVCL_QB77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919736; Obi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095125 CVCL_QB78 BayGenomics ES cell line XK440 embryonic stem cell house mouse CVCL_QB78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99832; Sec13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095126 CVCL_QB79 BayGenomics ES cell line XK442 embryonic stem cell house mouse CVCL_QB79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313261; Sptbn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095127 CVCL_QB60 BayGenomics ES cell line XK381 embryonic stem cell house mouse CVCL_QB60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861774; Rbms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095128 CVCL_QB61 BayGenomics ES cell line XK383 embryonic stem cell house mouse CVCL_QB61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915309; Tm9sf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095129 CVCL_QB62 BayGenomics ES cell line XK388 embryonic stem cell house mouse CVCL_QB62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154263; Bicra Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095130 CVCL_QB63 BayGenomics ES cell line XK392 embryonic stem cell house mouse CVCL_QB63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88261; Canx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095131 CVCL_QB64 BayGenomics ES cell line XK393 embryonic stem cell house mouse CVCL_QB64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917818; Cpne3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095132 CVCL_QB65 BayGenomics ES cell line XK394 embryonic stem cell house mouse CVCL_QB65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095133 CVCL_QB66 BayGenomics ES cell line XK403 embryonic stem cell house mouse CVCL_QB66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444748; Chd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095134 CVCL_QB67 BayGenomics ES cell line XK405 embryonic stem cell house mouse CVCL_QB67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095135 CVCL_QB68 BayGenomics ES cell line XK406 embryonic stem cell house mouse CVCL_QB68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095136 CVCL_QB69 BayGenomics ES cell line XK409 embryonic stem cell house mouse CVCL_QB69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3708729; Rnps1-ps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095137 CVCL_QB50 BayGenomics ES cell line Xk351 embryonic stem cell house mouse CVCL_QB50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343094; Kat2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095138 CVCL_QB51 BayGenomics ES cell line XK355 embryonic stem cell house mouse CVCL_QB51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351625; Nbn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095139 CVCL_QB52 BayGenomics ES cell line XK358 embryonic stem cell house mouse CVCL_QB52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894652; Usp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095140 CVCL_QB53 BayGenomics ES cell line XK359 embryonic stem cell house mouse CVCL_QB53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095141 CVCL_QB54 BayGenomics ES cell line XK366 embryonic stem cell house mouse CVCL_QB54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095142 CVCL_QB55 BayGenomics ES cell line XK367 embryonic stem cell house mouse CVCL_QB55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923294; Ncapg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095143 CVCL_QB56 BayGenomics ES cell line XK373 embryonic stem cell house mouse CVCL_QB56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675669; Nusap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095144 CVCL_QB57 BayGenomics ES cell line XK376 embryonic stem cell house mouse CVCL_QB57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927170; Spata5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095145 CVCL_QB58 BayGenomics ES cell line XK377 embryonic stem cell house mouse CVCL_QB58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095146 CVCL_QB59 BayGenomics ES cell line XK378 embryonic stem cell house mouse CVCL_QB59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137512; Arid4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095147 CVCL_QB40 BayGenomics ES cell line XK328 embryonic stem cell house mouse CVCL_QB40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921393; Opa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095148 CVCL_QB41 BayGenomics ES cell line XK329 embryonic stem cell house mouse CVCL_QB41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095149 CVCL_QB42 BayGenomics ES cell line XK330 embryonic stem cell house mouse CVCL_QB42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140592; Slc44a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095150 CVCL_QB43 BayGenomics ES cell line XK333 embryonic stem cell house mouse CVCL_QB43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095151 CVCL_QB44 BayGenomics ES cell line XK334 embryonic stem cell house mouse CVCL_QB44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095152 CVCL_QB45 BayGenomics ES cell line XK335 embryonic stem cell house mouse CVCL_QB45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095153 CVCL_QB46 BayGenomics ES cell line XK338 embryonic stem cell house mouse CVCL_QB46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914782; Mfap1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095154 CVCL_QB47 BayGenomics ES cell line Xk343 embryonic stem cell house mouse CVCL_QB47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144865; Tecpr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095155 CVCL_QB48 BayGenomics ES cell line Xk346 embryonic stem cell house mouse CVCL_QB48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095156 CVCL_QB49 BayGenomics ES cell line Xk348 embryonic stem cell house mouse CVCL_QB49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442366; Peak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095157 CVCL_HH92 CW30417 induced pluripotent stem cell human CVCL_HH92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30417; true Male 21095158 CVCL_HH93 CW30418 induced pluripotent stem cell human CVCL_HH93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30418; true Female 21095159 CVCL_HH94 CW30420 induced pluripotent stem cell human CVCL_HH94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30420; true Male 21095160 CVCL_HH95 CW30421 induced pluripotent stem cell human CVCL_HH95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30421; true Female 21095161 CVCL_HH90 CW30400 induced pluripotent stem cell human CVCL_HH90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30400; true Male 21095162 CVCL_HH91 CW30403 induced pluripotent stem cell human CVCL_HH91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30403; true Male 21095163 CVCL_QB30 BayGenomics ES cell line XK308 embryonic stem cell house mouse CVCL_QB30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918079; Ccdc93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095164 CVCL_QB31 BayGenomics ES cell line XK309 embryonic stem cell house mouse CVCL_QB31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925868; Acap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095165 CVCL_QB32 BayGenomics ES cell line Xk314 embryonic stem cell house mouse CVCL_QB32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914447; Zcrb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095166 CVCL_QB33 BayGenomics ES cell line Xk316 embryonic stem cell house mouse CVCL_QB33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095167 CVCL_QB34 BayGenomics ES cell line Xk318 embryonic stem cell house mouse CVCL_QB34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919433; Snx6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095168 CVCL_QB35 BayGenomics ES cell line Xk320 embryonic stem cell house mouse CVCL_QB35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144865; Tecpr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095169 CVCL_QB36 BayGenomics ES cell line Xk321 embryonic stem cell house mouse CVCL_QB36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914081; Cab39l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095170 CVCL_QB37 BayGenomics ES cell line Xk324 embryonic stem cell house mouse CVCL_QB37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095171 CVCL_HH89 CW30399 induced pluripotent stem cell human CVCL_HH89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30399; true Male 21095172 CVCL_QB38 BayGenomics ES cell line Xk325 embryonic stem cell house mouse CVCL_QB38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095173 CVCL_QB39 BayGenomics ES cell line XK326 embryonic stem cell house mouse CVCL_QB39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095174 CVCL_HH85 CW30391 induced pluripotent stem cell human CVCL_HH85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30391; true Female 21095175 CVCL_HH86 CW30394 induced pluripotent stem cell human CVCL_HH86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30394; true Male 21095176 CVCL_HH87 CW30395 induced pluripotent stem cell human CVCL_HH87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30395; true Male 21095177 CVCL_HH88 CW30398 induced pluripotent stem cell human CVCL_HH88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30398; true Male 21095178 CVCL_QB20 BayGenomics ES cell line XK277 embryonic stem cell house mouse CVCL_QB20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095179 CVCL_QB21 BayGenomics ES cell line XK280 embryonic stem cell house mouse CVCL_QB21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914429; Ccdc25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095180 CVCL_QB22 BayGenomics ES cell line XK283 embryonic stem cell house mouse CVCL_QB22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095181 CVCL_QB23 BayGenomics ES cell line XK284 embryonic stem cell house mouse CVCL_QB23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277218; Rpap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095182 CVCL_QB24 BayGenomics ES cell line XK286 embryonic stem cell house mouse CVCL_QB24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929658; Tbk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095183 CVCL_QB25 BayGenomics ES cell line XK287 embryonic stem cell house mouse CVCL_QB25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920907; Fbrsl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095184 CVCL_QB26 BayGenomics ES cell line XK293 embryonic stem cell house mouse CVCL_QB26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095185 CVCL_QB27 BayGenomics ES cell line XK294 embryonic stem cell house mouse CVCL_QB27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095186 CVCL_QB28 BayGenomics ES cell line XK301 embryonic stem cell house mouse CVCL_QB28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095187 CVCL_QB29 BayGenomics ES cell line Xk303 embryonic stem cell house mouse CVCL_QB29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917933; Utp20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095188 CVCL_HH96 CW30438 induced pluripotent stem cell human CVCL_HH96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30438; true Female 21095189 CVCL_HH97 CW30439 induced pluripotent stem cell human CVCL_HH97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30439; true Male 21095190 CVCL_HH98 CW30443 induced pluripotent stem cell human CVCL_HH98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30443; true Female 21095191 CVCL_HH99 CW30445 induced pluripotent stem cell human CVCL_HH99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30445; true Male 21095192 CVCL_HH70 CW30346 induced pluripotent stem cell human CVCL_HH70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: East Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30346; true Female 21095193 CVCL_HH71 CW30349 induced pluripotent stem cell human CVCL_HH71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30349; true Female 21095194 CVCL_HH72 CW30350 induced pluripotent stem cell human CVCL_HH72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30350; true Female 21095195 CVCL_HH73 CW30353 induced pluripotent stem cell human CVCL_HH73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30353; true Male 21095196 CVCL_QB10 BayGenomics ES cell line XK226 embryonic stem cell house mouse CVCL_QB10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095197 CVCL_QB11 BayGenomics ES cell line XK227 embryonic stem cell house mouse CVCL_QB11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925939; Naa35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095198 CVCL_QB12 BayGenomics ES cell line XK228 embryonic stem cell house mouse CVCL_QB12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99511; Ptpn11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095199 CVCL_QB13 BayGenomics ES cell line XK231 embryonic stem cell house mouse CVCL_QB13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352466; Nr2c2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095200 CVCL_QB14 BayGenomics ES cell line XK232 embryonic stem cell house mouse CVCL_QB14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095201 CVCL_QB15 BayGenomics ES cell line XK242 embryonic stem cell house mouse CVCL_QB15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095202 CVCL_HH67 CW30332 induced pluripotent stem cell human CVCL_HH67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30332; true Male 21095203 CVCL_QB16 BayGenomics ES cell line XK248 embryonic stem cell house mouse CVCL_QB16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447876; Sec22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095204 CVCL_HH68 CW30337 induced pluripotent stem cell human CVCL_HH68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30337; true Male 21095205 CVCL_QB17 BayGenomics ES cell line XK249 embryonic stem cell house mouse CVCL_QB17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095206 CVCL_HH69 CW30343 induced pluripotent stem cell human CVCL_HH69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30343; true Female 21095207 CVCL_QB18 BayGenomics ES cell line XK257 embryonic stem cell house mouse CVCL_QB18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095208 CVCL_QB19 BayGenomics ES cell line XK258 embryonic stem cell house mouse CVCL_QB19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927165; Mettl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095209 CVCL_HH63 CW30293 induced pluripotent stem cell human CVCL_HH63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30293; true Male 21095210 CVCL_HH64 CW30298 induced pluripotent stem cell human CVCL_HH64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30298; true Male 21095211 CVCL_HH65 CW30321 induced pluripotent stem cell human CVCL_HH65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30321; true Male 21095212 CVCL_HH66 CW30324 induced pluripotent stem cell human CVCL_HH66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30324; true Male 21095213 CVCL_HH81 CW30364 induced pluripotent stem cell human CVCL_HH81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30364; true Male 21095214 CVCL_HH82 CW30376 induced pluripotent stem cell human CVCL_HH82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30376; true Female 21095215 CVCL_HH83 CW30386 induced pluripotent stem cell human CVCL_HH83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30386; true Male 21095216 CVCL_HH84 CW30390 induced pluripotent stem cell human CVCL_HH84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30390; true Male 21095217 CVCL_HH80 CW30363 induced pluripotent stem cell human CVCL_HH80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30363; true Male 21095218 CVCL_QB00 BayGenomics ES cell line XK203 embryonic stem cell house mouse CVCL_QB00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97451; Otx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095219 CVCL_QB01 BayGenomics ES cell line XK204 embryonic stem cell house mouse CVCL_QB01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095220 CVCL_QB02 BayGenomics ES cell line XK206 embryonic stem cell house mouse CVCL_QB02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095221 CVCL_QB03 BayGenomics ES cell line XK207 embryonic stem cell house mouse CVCL_QB03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095222 CVCL_QB04 BayGenomics ES cell line XK210 embryonic stem cell house mouse CVCL_QB04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095223 CVCL_HH78 CW30361 induced pluripotent stem cell human CVCL_HH78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30361; true Female 21095224 CVCL_QB05 BayGenomics ES cell line XK211 embryonic stem cell house mouse CVCL_QB05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349394; Map4k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095225 CVCL_HH79 CW30362 induced pluripotent stem cell human CVCL_HH79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30362; true Female 21095226 CVCL_QB06 BayGenomics ES cell line XK216 embryonic stem cell house mouse CVCL_QB06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590554; BC055324 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095227 CVCL_QB07 BayGenomics ES cell line XK217 embryonic stem cell house mouse CVCL_QB07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923356; Kdm3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095228 CVCL_QB08 BayGenomics ES cell line XK218 embryonic stem cell house mouse CVCL_QB08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095229 CVCL_HH74 CW30355 induced pluripotent stem cell human CVCL_HH74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30355; true Male 21095230 CVCL_QB09 BayGenomics ES cell line XK223 embryonic stem cell house mouse CVCL_QB09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443028; Taf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095231 CVCL_HH75 CW30356 induced pluripotent stem cell human CVCL_HH75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30356; true Male 21095232 CVCL_HH76 CW30357 induced pluripotent stem cell human CVCL_HH76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30357; true Male 21095233 CVCL_HH77 CW30360 induced pluripotent stem cell human CVCL_HH77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30360; true Male 21095234 CVCL_6U40 DA01298 transformed cell line human CVCL_6U40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095235 CVCL_7640 GM15807 transformed cell line human CVCL_7640 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095236 CVCL_6U41 DA01299 transformed cell line human CVCL_6U41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095237 CVCL_7641 GM15808 transformed cell line human CVCL_7641 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM15808; probable Male 21095238 CVCL_6U35 DA01292 transformed cell line human CVCL_6U35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095239 CVCL_7635 GM14819 transformed cell line human CVCL_7635 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095240 CVCL_6U36 DA01293 transformed cell line human CVCL_6U36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095241 CVCL_7636 GM14820 transformed cell line human CVCL_7636 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095242 CVCL_6U37 DA01294 transformed cell line human CVCL_6U37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095243 CVCL_7637 GM14907 transformed cell line human CVCL_7637 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095244 CVCL_6U38 DA01295 transformed cell line human CVCL_6U38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01295; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095245 CVCL_7638 GM14926 transformed cell line human CVCL_7638 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095246 CVCL_6U31 DA01287 transformed cell line human CVCL_6U31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095247 CVCL_7631 GM14782 transformed cell line human CVCL_7631 HLA typing: A*01:01:01,32:01:01; B*08:01:01,44:02:01; C*05:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*01:03:01,05:01:01; DQB1*02:01:01,06:03:01; DRB1*03:01:01,13:01:01; DRB3*01:01:02,01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095248 CVCL_6U32 DA01289 transformed cell line human CVCL_6U32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095249 CVCL_7632 GM14783 transformed cell line human CVCL_7632 HLA typing: A*26:GAX,68:AKR; B*08:XKT,44:WRJ; C*03:04,07:ET; DRB1*04:07,13:04 (IPD-IMGT/HLA=16416) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095250 CVCL_6U33 DA01290 transformed cell line human CVCL_6U33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095251 CVCL_7633 GM14805 transformed cell line human CVCL_7633 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095252 CVCL_6U34 DA01291 transformed cell line human CVCL_6U34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01291; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095253 CVCL_7634 GM14811 transformed cell line human CVCL_7634 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095254 CVCL_6U39 DA01297 transformed cell line human CVCL_6U39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095255 CVCL_7639 GM15453 transformed cell line human CVCL_7639 CL:0000010 Population: Cuban; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095256 CVCL_6U50 DA01308 transformed cell line human CVCL_6U50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095257 CVCL_7650 GM16119 transformed cell line human CVCL_7650 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095258 CVCL_6U51 DA01309 transformed cell line human CVCL_6U51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095259 CVCL_7651 GM16375 transformed cell line human CVCL_7651 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser595Ter (c.1784C>A); ClinVar=VCV000820081; Zygosity=Homozygous (PubMed=10521302; Coriell) Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 81(MaGrou) (BSR81); Derived from sampling site: Peripheral blood. Male 21095260 CVCL_6U52 DA01310 transformed cell line human CVCL_6U52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095261 CVCL_7652 XP12TA finite cell line human CVCL_7652 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Homozygous (PubMed=11121128) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095262 CVCL_6U46 DA01304 transformed cell line human CVCL_6U46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095263 CVCL_7646 GM16113 transformed cell line human CVCL_7646 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095264 CVCL_6U47 DA01305 transformed cell line human CVCL_6U47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095265 CVCL_7647 GM16115 transformed cell line human CVCL_7647 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095266 CVCL_6U48 DA01306 transformed cell line human CVCL_6U48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01306; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095267 CVCL_7648 GM16117 transformed cell line human CVCL_7648 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095268 CVCL_6U49 DA01307 transformed cell line human CVCL_6U49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01307; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095269 CVCL_7649 GM16118 transformed cell line human CVCL_7649 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095270 CVCL_6U42 DA01300 transformed cell line human CVCL_6U42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095271 CVCL_7642 GM15809 transformed cell line human CVCL_7642 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM15809; probable Female 21095272 CVCL_6U43 DA01301 transformed cell line human CVCL_6U43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095273 CVCL_6U44 DA01302 transformed cell line human CVCL_6U44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095274 CVCL_6U45 DA01303 transformed cell line human CVCL_6U45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095275 CVCL_7645 GM16111 transformed cell line human CVCL_7645 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095276 CVCL_6U13 DA01269 transformed cell line human CVCL_6U13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01269; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095277 CVCL_7613 GM14662 transformed cell line human CVCL_7613 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095278 CVCL_6U14 DA01270 transformed cell line human CVCL_6U14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095279 CVCL_7614 GM14663 transformed cell line human CVCL_7614 HLA typing: A*23:DFKR,74:AB; B*07:CZZS,45:AH; C*06:02,07:WCP; DRB1*13:02,15:03 (IPD-IMGT/HLA=19249) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095280 CVCL_6U15 DA01271 transformed cell line human CVCL_6U15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095281 CVCL_7615 GM14664 transformed cell line human CVCL_7615 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095282 CVCL_6U16 DA01272 transformed cell line human CVCL_6U16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095283 CVCL_7616 GM14665 transformed cell line human CVCL_7616 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095284 CVCL_6U10 DA01266 transformed cell line human CVCL_6U10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095285 CVCL_7610 GM14649 transformed cell line human CVCL_7610 HLA typing: A*24:CWFP,66:02; B*13:02,58:VE; C*06:02,07:CVAG; DRB1*15:01,15:03 (IPD-IMGT/HLA=15811) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095286 CVCL_6U11 DA01267 transformed cell line human CVCL_6U11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095287 CVCL_7611 GM14660 transformed cell line human CVCL_7611 HLA typing: A*23:DFKR,34:02; B*49:01,53:01; C*06:02,07:CVAG; DRB1*12:CVT,15:03 (IPD-IMGT/HLA=19230) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Thr107Ile (c.320C>T); ClinVar=VCV000039379; Zygosity=Heterozygous; Note=CYP2D6*17 allele (Coriell); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Arg296Cys (c.886C>T); ClinVar=VCV000242771; Zygosity=Heterozygous; Note=CYP2D6*17 allele (Coriell); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Ser486Thr (c.1457G>C); ClinVar=VCV000242701; Zygosity=Heterozygous; Note=CYP2D6*17 allele (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095288 CVCL_6U12 DA01268 transformed cell line human CVCL_6U12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095289 CVCL_7612 GM14661 transformed cell line human CVCL_7612 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095290 CVCL_6U17 DA01273 transformed cell line human CVCL_6U17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01273; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095291 CVCL_7617 GM14666 transformed cell line human CVCL_7617 HLA typing: A*23:06,33:01; B*42:01,57:03; C*07:CVAG,17:MN; DRB1*03:02 (IPD-IMGT/HLA=20682) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095292 CVCL_6U18 DA01274 transformed cell line human CVCL_6U18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095293 CVCL_7618 GM14667 transformed cell line human CVCL_7618 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095294 CVCL_6U19 DA01275 transformed cell line human CVCL_6U19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095295 CVCL_7619 GM14672 transformed cell line human CVCL_7619 HLA typing: A*23:06 (IPD-IMGT/HLA=12108) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095296 CVCL_6U30 DA01286 transformed cell line human CVCL_6U30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095297 CVCL_7630 GM14746 transformed cell line human CVCL_7630 HLA typing: A*30:02,32:01; B*35:BEZX,44:03; C*16:01,16:01; DRB1*01:02,07:01 (IPD-IMGT/HLA=23052) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095298 CVCL_6U24 DA01280 transformed cell line human CVCL_6U24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095299 CVCL_7624 GM14683 transformed cell line human CVCL_7624 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095300 CVCL_6U25 DA01281 transformed cell line human CVCL_6U25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095301 CVCL_7625 GM14687 transformed cell line human CVCL_7625 HLA typing: A*01:CNJK,03:CVAB; B*07:CZZS,08:XKT; C*07:CVAG,07:WCP; DRB1*03:01,13:02 (IPD-IMGT/HLA=20690) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21095302 CVCL_6U26 DA01282 transformed cell line human CVCL_6U26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095303 CVCL_7626 GM14698 transformed cell line human CVCL_7626 HLA typing: A*30:AUX,31:CGAJ; B*35:08,42:02; C*04:CVAF,17:MN; DRB1*04:03,08:04 (IPD-IMGT/HLA=20683); HLA typing: A*30:01:01,31:01:02; B*35:08:01,42:02:01; C*04:01:01,17:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:04,03:02:01; DRB1*04:03:01,08:04:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095304 CVCL_6U27 DA01283 transformed cell line human CVCL_6U27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01283; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095305 CVCL_7627 GM14700 transformed cell line human CVCL_7627 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095306 CVCL_6U20 DA01276 transformed cell line human CVCL_6U20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095307 CVCL_7620 GM14679 transformed cell line human CVCL_7620 HLA typing: A*02:DFKP,23:DFKR; B*18:RRG,57:03; C*02:02,07:CVAG; DRB1*07:01,13:02 (IPD-IMGT/HLA=19226) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095308 CVCL_6U21 DA01277 transformed cell line human CVCL_6U21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095309 CVCL_7621 GM14680 transformed cell line human CVCL_7621 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095310 CVCL_6U22 DA01278 transformed cell line human CVCL_6U22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095311 CVCL_7622 GM14681 transformed cell line human CVCL_7622 HLA typing: A*01:CNJK,32:01; B*08:XKT,27:09; C*01:02,07:CVAG; DRB1*03:01,11:01 (IPD-IMGT/HLA=19241) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095312 CVCL_6U23 DA01279 transformed cell line human CVCL_6U23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095313 CVCL_7623 GM14682 transformed cell line human CVCL_7623 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095314 CVCL_6U28 DA01284 transformed cell line human CVCL_6U28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01284; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095315 CVCL_7628 GM14704 transformed cell line human CVCL_7628 HLA typing: A*30:AUX,68:01; B*35:BEZX,42:02; C*04:CVAF,17:MN; DRB1*03:02,13:02 (IPD-IMGT/HLA=15812) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095316 CVCL_6U29 DA01285 transformed cell line human CVCL_6U29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095317 CVCL_7629 GM14720 transformed cell line human CVCL_7629 HLA typing: A*30:AUX,30:02; B*07:CZZS,44:03; C*04:CVAF,17:MN; DRB1*03:02,08:04 (IPD-IMGT/HLA=15819) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095318 CVCL_6U02 DA01258 transformed cell line human CVCL_6U02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01258; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095319 CVCL_7602 GM14592 transformed cell line human CVCL_7602 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14593 (Cellosaurus=CVCL_7603); Derived from sampling site: Peripheral blood. Male 21095320 CVCL_6U03 DA01259 transformed cell line human CVCL_6U03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01259; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095321 CVCL_7603 GM14593 transformed cell line human CVCL_7603 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14592 (Cellosaurus=CVCL_7602); Derived from sampling site: Peripheral blood. Male 21095322 CVCL_6U04 DA01260 transformed cell line human CVCL_6U04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01260; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095323 CVCL_7604 GM14611 transformed cell line human CVCL_7604 CL:0000010 Population: Indo Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095324 CVCL_6U05 DA01261 transformed cell line human CVCL_6U05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01261; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095325 CVCL_7605 GM14622 transformed cell line human CVCL_7605 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Leu2092Profs*7 (c.6275_6276delTT); ClinVar=VCV000009318; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095326 CVCL_6U00 DA01256 transformed cell line human CVCL_6U00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095327 CVCL_7600 GM14583 transformed cell line human CVCL_7600 HLA typing: A*30:02,68:02; B*15:10,57:03; C*03:04,08:02 (IPD-IMGT/HLA=15814); HLA typing: A*30:02:01,68:02:01; B*15:10:01,57:03:01; C*03:04:02,08:02:01; DPA1*01:03:01,03:NEW-1; DPB1*02:01:19,584:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:04; DRB1*08:04:01,13:03:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14584 (Cellosaurus=CVCL_7601); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095328 CVCL_6U01 DA01257 transformed cell line human CVCL_6U01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095329 CVCL_7601 GM14584 transformed cell line human CVCL_7601 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14583 (Cellosaurus=CVCL_7600); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21095330 CVCL_6U06 DA01262 transformed cell line human CVCL_6U06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095331 CVCL_7606 GM14632 transformed cell line human CVCL_7606 HLA typing: A*03:CVAB,36:03; B*35:BEZX,53:01; C*04:CVAF,04:CVAF; DRB1*03:02,12:CVT (IPD-IMGT/HLA=23059) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14633 (Cellosaurus=CVCL_7607); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095332 CVCL_6U07 DA01263 transformed cell line human CVCL_6U07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095333 CVCL_7607 GM14633 transformed cell line human CVCL_7607 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14632 (Cellosaurus=CVCL_7606); Derived from sampling site: Peripheral blood. Female 21095334 CVCL_6U08 DA01264 transformed cell line human CVCL_6U08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01264; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095335 CVCL_7608 GM14643 transformed cell line human CVCL_7608 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM18065; probable Male Part of: Human variation panel 21095336 CVCL_6U09 DA01265 transformed cell line human CVCL_6U09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095337 CVCL_7609 GM14648 transformed cell line human CVCL_7609 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21095338 CVCL_QB90 BayGenomics ES cell line XK499 embryonic stem cell house mouse CVCL_QB90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095339 CVCL_QB91 BayGenomics ES cell line XK500 embryonic stem cell house mouse CVCL_QB91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925868; Acap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095340 CVCL_QB92 BayGenomics ES cell line XK506 embryonic stem cell house mouse CVCL_QB92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095341 CVCL_QB93 BayGenomics ES cell line XK507 embryonic stem cell house mouse CVCL_QB93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919257; Fndc3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095342 CVCL_QB94 BayGenomics ES cell line XK510 embryonic stem cell house mouse CVCL_QB94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095343 CVCL_QB95 BayGenomics ES cell line XK512 embryonic stem cell house mouse CVCL_QB95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095344 CVCL_QB96 BayGenomics ES cell line XK514 embryonic stem cell house mouse CVCL_QB96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146430; Cblb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095345 CVCL_QB97 BayGenomics ES cell line XK515 embryonic stem cell house mouse CVCL_QB97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351611; Exoc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095346 CVCL_QB98 BayGenomics ES cell line XK516 embryonic stem cell house mouse CVCL_QB98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095347 CVCL_QB99 BayGenomics ES cell line XK517 embryonic stem cell house mouse CVCL_QB99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095348 CVCL_QB80 BayGenomics ES cell line XK445 embryonic stem cell house mouse CVCL_QB80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921690; Cmip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095349 CVCL_QB81 BayGenomics ES cell line XK448 embryonic stem cell house mouse CVCL_QB81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095350 CVCL_QB82 BayGenomics ES cell line XK451 embryonic stem cell house mouse CVCL_QB82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095351 CVCL_QB83 BayGenomics ES cell line XK452 embryonic stem cell house mouse CVCL_QB83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444575; Soga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095352 CVCL_QB84 BayGenomics ES cell line XK460 embryonic stem cell house mouse CVCL_QB84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095353 CVCL_QB85 BayGenomics ES cell line XK463 embryonic stem cell house mouse CVCL_QB85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095354 CVCL_QB86 BayGenomics ES cell line XK464 embryonic stem cell house mouse CVCL_QB86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928484; Nudt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095355 CVCL_QB87 BayGenomics ES cell line XK491 embryonic stem cell house mouse CVCL_QB87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095356 CVCL_QB88 BayGenomics ES cell line XK492 embryonic stem cell house mouse CVCL_QB88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095357 CVCL_QB89 BayGenomics ES cell line XK495 embryonic stem cell house mouse CVCL_QB89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095358 CVCL_6T98 DA01254 transformed cell line human CVCL_6T98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095359 CVCL_7598 GM14581 transformed cell line human CVCL_7598 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14582 (Cellosaurus=CVCL_7599); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095360 CVCL_6T99 DA01255 transformed cell line human CVCL_6T99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095361 CVCL_7599 GM14582 transformed cell line human CVCL_7599 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14581 (Cellosaurus=CVCL_7598); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095362 CVCL_6T83 DA01237 transformed cell line human CVCL_6T83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095363 CVCL_7583 GM14529 transformed cell line human CVCL_7583 HLA typing: A*24:CWFP,29:02; B*07:CZZS,44:03; C*07:WCP,16:01; DRB1*07:01,15:01 (IPD-IMGT/HLA=16402) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14530 (Cellosaurus=CVCL_7584); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095364 CVCL_6T84 DA01238 transformed cell line human CVCL_6T84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095365 CVCL_7584 GM14530 transformed cell line human CVCL_7584 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14529 (Cellosaurus=CVCL_7583); Derived from sampling site: Peripheral blood. Female 21095366 CVCL_6T85 DA01240 transformed cell line human CVCL_6T85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01240; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095367 CVCL_7585 GM14532 transformed cell line human CVCL_7585 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14533 (Cellosaurus=CVCL_7586); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095368 CVCL_6T86 DA01241 transformed cell line human CVCL_6T86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01241; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095369 CVCL_7586 GM14533 transformed cell line human CVCL_7586 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14532 (Cellosaurus=CVCL_7585); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095370 CVCL_6T80 DA01234 transformed cell line human CVCL_6T80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095371 CVCL_7580 GM14517 transformed cell line human CVCL_7580 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21095372 CVCL_6T81 DA01235 transformed cell line human CVCL_6T81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095373 CVCL_7581 GM14520 transformed cell line human CVCL_7581 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14521 (Cellosaurus=CVCL_7582); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Human variation panel 21095374 CVCL_6T82 DA01236 transformed cell line human CVCL_6T82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095375 CVCL_7582 GM14521 transformed cell line human CVCL_7582 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14520 (Cellosaurus=CVCL_7581); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095376 CVCL_6T76 DA01230 transformed cell line human CVCL_6T76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01230; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095377 CVCL_7576 GM14508 transformed cell line human CVCL_7576 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14509 (Cellosaurus=CVCL_7577); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095378 CVCL_6T77 DA01231 transformed cell line human CVCL_6T77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095379 CVCL_7577 GM14509 transformed cell line human CVCL_7577 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14508 (Cellosaurus=CVCL_7576); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095380 CVCL_6T78 DA01232 transformed cell line human CVCL_6T78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095381 CVCL_7578 GM14511 transformed cell line human CVCL_7578 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14512 (Cellosaurus=CVCL_7579); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21095382 CVCL_6T79 DA01233 transformed cell line human CVCL_6T79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095383 CVCL_7579 GM14512 transformed cell line human CVCL_7579 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14511 (Cellosaurus=CVCL_7578); Derived from sampling site: Peripheral blood. Female 21095384 CVCL_6T94 DA01250 transformed cell line human CVCL_6T94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095385 CVCL_7594 GM14568 transformed cell line human CVCL_7594 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14569 (Cellosaurus=CVCL_7595); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095386 CVCL_6T95 DA01251 transformed cell line human CVCL_6T95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095387 CVCL_7595 GM14569 transformed cell line human CVCL_7595 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14568 (Cellosaurus=CVCL_7594); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095388 CVCL_6T96 DA01252 transformed cell line human CVCL_6T96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095389 CVCL_6T97 DA01253 transformed cell line human CVCL_6T97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01253; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095390 CVCL_6T90 DA01246 transformed cell line human CVCL_6T90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095391 CVCL_7590 GM14538 transformed cell line human CVCL_7590 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14537 (Cellosaurus=CVCL_7589); Derived from sampling site: Peripheral blood. Male 21095392 CVCL_6T91 DA01247 transformed cell line human CVCL_6T91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01247; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095393 CVCL_7591 GM14547 transformed cell line human CVCL_7591 HLA typing: A*02:01:01,30:02:01; B*13:02:01,51:01:01; C*06:02:01,14:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,01:03:01; DQB1*06:02:01,06:03:01; DRB1*13:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095394 CVCL_6T92 DA01248 transformed cell line human CVCL_6T92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01248; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095395 CVCL_7592 GM14548 transformed cell line human CVCL_7592 HLA typing: A*02:05:01,68:02:01; B*44:02:01,53:01:01; C*04:01:01,16:04:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:02,05:05:01; DQB1*03:01:01,05:01:01; DRB1*01:02:01,11:04:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14549 (Cellosaurus=CVCL_7593); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095396 CVCL_6T93 DA01249 transformed cell line human CVCL_6T93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095397 CVCL_7593 GM14549 transformed cell line human CVCL_7593 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14548 (Cellosaurus=CVCL_7592); Derived from sampling site: Peripheral blood. Female 21095398 CVCL_6T87 DA01242 transformed cell line human CVCL_6T87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095399 CVCL_7587 GM14535 transformed cell line human CVCL_7587 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14536 (Cellosaurus=CVCL_7588); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095400 CVCL_6T88 DA01243 transformed cell line human CVCL_6T88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095401 CVCL_7588 GM14536 transformed cell line human CVCL_7588 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14535 (Cellosaurus=CVCL_7587); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095402 CVCL_6T89 DA01244 transformed cell line human CVCL_6T89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095403 CVCL_7589 GM14537 transformed cell line human CVCL_7589 HLA typing: A*02:02,11:BDFZ; B*15:17; C*05:AC,07:WTR (IPD-IMGT/HLA=15332); HLA typing: A*02:02:01,11:01:01; B*15:17:01,15:17:01; C*05:01:01,07:01:02; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:19:01; DRB1*03:01:01,11:02:01; DRB3*02:02:01,02:02:01 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14538 (Cellosaurus=CVCL_7590); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095404 CVCL_6T61 DA01214 transformed cell line human CVCL_6T61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01214; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095405 CVCL_7561 GM14474 transformed cell line human CVCL_7561 HLA typing: A*02:DFKP,03:DBVX; B*07:CZZS,57:01; C*06:02,07:WCP; DRB1*07:01,15:01 (IPD-IMGT/HLA=23058) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14475 (Cellosaurus=CVCL_7562); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095406 CVCL_6T62 DA01215 transformed cell line human CVCL_6T62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01215; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095407 CVCL_7562 GM14475 transformed cell line human CVCL_7562 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14474 (Cellosaurus=CVCL_7561); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095408 CVCL_6T63 DA01216 transformed cell line human CVCL_6T63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095409 CVCL_7563 GM14476 transformed cell line human CVCL_7563 HLA typing: A*03:CVAB,33:BEKE; B*42:02,44:03; C*17:MN,18:AB; DRB1*11:01,15:03 (IPD-IMGT/HLA=17384) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14477 (Cellosaurus=CVCL_7564); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095410 CVCL_6T64 DA01217 transformed cell line human CVCL_6T64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095411 CVCL_7564 GM14477 transformed cell line human CVCL_7564 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14476 (Cellosaurus=CVCL_7563); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095412 CVCL_6T60 DA01213 transformed cell line human CVCL_6T60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095413 CVCL_7560 GM14468 transformed cell line human CVCL_7560 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14467 (Cellosaurus=CVCL_7559); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095414 CVCL_6T58 DA01211 transformed cell line human CVCL_6T58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01211; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095415 CVCL_7558 GM14465 transformed cell line human CVCL_7558 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14464 (Cellosaurus=CVCL_7557); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095416 CVCL_6T59 DA01212 transformed cell line human CVCL_6T59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01212; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095417 CVCL_7559 GM14467 transformed cell line human CVCL_7559 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14468 (Cellosaurus=CVCL_7560); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Human variation panel 21095418 CVCL_6T54 DA01207 transformed cell line human CVCL_6T54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01207; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095419 CVCL_7554 GM14452 transformed cell line human CVCL_7554 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14453 (Cellosaurus=CVCL_7555); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Human variation panel 21095420 CVCL_6T55 DA01208 transformed cell line human CVCL_6T55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01208; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095421 CVCL_7555 GM14453 transformed cell line human CVCL_7555 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14452 (Cellosaurus=CVCL_7554); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095422 CVCL_6T56 DA01209 transformed cell line human CVCL_6T56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095423 CVCL_7556 GM14454 transformed cell line human CVCL_7556 HLA typing: A*24:CWFP,24:CWFP; B*18:RRG,27:EKN; C*02:02,05:AC; DRB1*04:05,15:01 (IPD-IMGT/HLA=20679) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14455 (Cellosaurus=CVCL_F218); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095424 CVCL_6T57 DA01210 transformed cell line human CVCL_6T57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095425 CVCL_7557 GM14464 transformed cell line human CVCL_7557 HLA typing: A*23:01,33:03; B*08:XKT,49:01; C*07:CVAG,07:WTR; DRB1*01:02,10:01 (IPD-IMGT/HLA=15330) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14465 (Cellosaurus=CVCL_7558); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095426 CVCL_6T72 DA01226 transformed cell line human CVCL_6T72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01226; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095427 CVCL_7572 GM14503 transformed cell line human CVCL_7572 HLA typing: A*02:DFKP,33:BEKE; B*07:CZZS,37:01; C*02:10,07:WCP; DRB1*03:01,07:01 (IPD-IMGT/HLA=15807) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14504 (Cellosaurus=CVCL_7573); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095428 CVCL_6T73 DA01227 transformed cell line human CVCL_6T73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095429 CVCL_7573 GM14504 transformed cell line human CVCL_7573 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14503 (Cellosaurus=CVCL_7572); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095430 CVCL_6T74 DA01228 transformed cell line human CVCL_6T74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095431 CVCL_7574 GM14506 transformed cell line human CVCL_7574 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14507 (Cellosaurus=CVCL_7575); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Human variation panel 21095432 CVCL_6T75 DA01229 transformed cell line human CVCL_6T75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095433 CVCL_7575 GM14507 transformed cell line human CVCL_7575 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14506 (Cellosaurus=CVCL_7574); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095434 CVCL_6T70 DA01224 transformed cell line human CVCL_6T70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095435 CVCL_7570 GM14496 transformed cell line human CVCL_7570 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14495 (Cellosaurus=CVCL_7569); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female 21095436 CVCL_6T71 DA01225 transformed cell line human CVCL_6T71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095437 CVCL_7571 GM14501 transformed cell line human CVCL_7571 HLA typing: A*02:DFKP,02:02; B*15:10,35:BEZX; C*08:04,16:01; DRB1*03:02,11:04 (IPD-IMGT/HLA=20681) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14502 (Cellosaurus=CVCL_7572); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095438 CVCL_6T69 DA01223 transformed cell line human CVCL_6T69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095439 CVCL_7569 GM14495 transformed cell line human CVCL_7569 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14496 (Cellosaurus=CVCL_7570); Derived from sampling site: Peripheral blood. Female 21095440 CVCL_6T65 DA01219 transformed cell line human CVCL_6T65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095441 CVCL_7565 GM14478 transformed cell line human CVCL_7565 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14479 (Cellosaurus=CVCL_7566); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095442 CVCL_6T66 DA01220 transformed cell line human CVCL_6T66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095443 CVCL_7566 GM14479 transformed cell line human CVCL_7566 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14478 (Cellosaurus=CVCL_7565); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095444 CVCL_6T67 DA01221 transformed cell line human CVCL_6T67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095445 CVCL_7567 GM14480 transformed cell line human CVCL_7567 HLA typing: A*11:BDFZ,74:AB; B*45:AH,52:01; C*16:01; DRB1*13:01,03:01 (IPD-IMGT/HLA=17386) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14481 (Cellosaurus=CVCL_7568); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095446 CVCL_6T68 DA01222 transformed cell line human CVCL_6T68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095447 CVCL_7568 GM14481 transformed cell line human CVCL_7568 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14480 (Cellosaurus=CVCL_7567); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095448 CVCL_6T40 DA01192 transformed cell line human CVCL_6T40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095449 CVCL_7540 GM14170 transformed cell line human CVCL_7540 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21095450 CVCL_6T41 DA01193 transformed cell line human CVCL_6T41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095451 CVCL_7541 GM14381 transformed cell line human CVCL_7541 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14382 (Cellosaurus=CVCL_7542); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095452 CVCL_6T42 DA01194 transformed cell line human CVCL_6T42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095453 CVCL_7542 GM14382 transformed cell line human CVCL_7542 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14381 (Cellosaurus=CVCL_7541); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095454 CVCL_6T36 DA01188 transformed cell line human CVCL_6T36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095455 CVCL_7536 GM13708 transformed cell line human CVCL_7536 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Tyr1563Ter (c.4689C>G); ClinVar=VCV000037607; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095456 CVCL_6T37 DA01189 transformed cell line human CVCL_6T37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095457 CVCL_7537 GM13709 transformed cell line human CVCL_7537 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Arg691Aspfs*10 (c.2071delA); ClinVar=VCV000037444; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095458 CVCL_6T38 DA01190 transformed cell line human CVCL_6T38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01190; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095459 CVCL_7538 GM13712 transformed cell line human CVCL_7538 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu720Argfs (c.2157dupA); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095460 CVCL_6T39 DA01191 transformed cell line human CVCL_6T39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095461 CVCL_7539 GM14090 transformed cell line human CVCL_7539 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21095462 CVCL_6T32 DA01184 transformed cell line human CVCL_6T32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095463 CVCL_7532 GM13336 transformed cell line human CVCL_7532 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21095464 CVCL_6T33 DA01185 transformed cell line human CVCL_6T33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095465 CVCL_7533 GM13591 transformed cell line human CVCL_7533 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg117His (c.350G>A); ClinVar=VCV000007109; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095466 CVCL_6T34 DA01186 transformed cell line human CVCL_6T34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095467 CVCL_7534 GM13672 finite cell line human CVCL_7534 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; c.1948_1949insAAGAT (ataagAT>ataagATAAGAT junction 2091/2092); Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095468 CVCL_6T35 DA01187 transformed cell line human CVCL_6T35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095469 CVCL_7535 GM13705 transformed cell line human CVCL_7535 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ser1253Argfs*10 (c.3752_3755GTCT[1]) (c.3756_3759delGTCT); ClinVar=VCV000017673; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21095470 CVCL_6T50 DA01203 transformed cell line human CVCL_6T50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095471 CVCL_7550 GM14433 transformed cell line human CVCL_7550 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14432 (Cellosaurus=CVCL_7549); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095472 CVCL_6T51 DA01204 transformed cell line human CVCL_6T51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095473 CVCL_7551 GM14439 transformed cell line human CVCL_7551 HLA typing: A*02:DFKP,30:02; B*15:10,35:BEZX; C*03:04,16:01; DRB1*13:03,14:01 (IPD-IMGT/HLA=20689) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14440 (Cellosaurus=CVCL_7552); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21095474 CVCL_6T52 DA01205 transformed cell line human CVCL_6T52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095475 CVCL_7552 GM14440 transformed cell line human CVCL_7552 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14439 (Cellosaurus=CVCL_7551); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095476 CVCL_6T53 DA01206 transformed cell line human CVCL_6T53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095477 CVCL_7553 GM14448 transformed cell line human CVCL_7553 HLA typing: A*02:01:01,32:01:01; B*35:01:01,40:01:02; C*03:04:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01; DRB3*03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14447 (Cellosaurus=CVCL_F161); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21095478 CVCL_6T47 DA01200 transformed cell line human CVCL_6T47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01200; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095479 CVCL_7547 GM14414 transformed cell line human CVCL_7547 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14417 (Cellosaurus=CVCL_7548); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21095480 CVCL_6T48 DA01201 transformed cell line human CVCL_6T48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095481 CVCL_7548 GM14417 transformed cell line human CVCL_7548 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14414 (Cellosaurus=CVCL_7547); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21095482 CVCL_6T49 DA01202 transformed cell line human CVCL_6T49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01202; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095483 CVCL_7549 GM14432 transformed cell line human CVCL_7549 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14433 (Cellosaurus=CVCL_7550); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21095484 CVCL_6T43 DA01195 transformed cell line human CVCL_6T43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095485 CVCL_7543 GM14405 transformed cell line human CVCL_7543 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14406 (Cellosaurus=CVCL_7544); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095486 CVCL_6T44 DA01196 transformed cell line human CVCL_6T44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01196; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095487 CVCL_7544 GM14406 transformed cell line human CVCL_7544 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14405 (Cellosaurus=CVCL_7543); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21095488 CVCL_6T45 DA01198 transformed cell line human CVCL_6T45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095489 CVCL_7545 GM14408 transformed cell line human CVCL_7545 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14409 (Cellosaurus=CVCL_7546); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095490 CVCL_6T46 DA01199 transformed cell line human CVCL_6T46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095491 CVCL_7546 GM14409 transformed cell line human CVCL_7546 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14408 (Cellosaurus=CVCL_7545); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21095492 CVCL_HH50 CW30092 induced pluripotent stem cell human CVCL_HH50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30092; true Female 21095493 CVCL_HH51 CW30115 induced pluripotent stem cell human CVCL_HH51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30115; true Female 21095494 CVCL_HH49 CW30084 induced pluripotent stem cell human CVCL_HH49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30084; true Female 21095495 CVCL_HH45 CW30050 induced pluripotent stem cell human CVCL_HH45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30050; true Female 21095496 CVCL_HH46 CW30053 induced pluripotent stem cell human CVCL_HH46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30053; true Male 21095497 CVCL_HH47 CW30055 induced pluripotent stem cell human CVCL_HH47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30055; true Female 21095498 CVCL_HH48 CW30081 induced pluripotent stem cell human CVCL_HH48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30081; true Male 21095499 CVCL_HH41 CW30037 induced pluripotent stem cell human CVCL_HH41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American Discontinued: Coriell; CW30037; true. Male 21095500 CVCL_HH42 CW30045 induced pluripotent stem cell human CVCL_HH42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30045; true Female 21095501 CVCL_HH43 CW30048 induced pluripotent stem cell human CVCL_HH43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30048; true Male 21095502 CVCL_HH44 CW30049 induced pluripotent stem cell human CVCL_HH44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30049; true Male 21095503 CVCL_HH60 CW30266 induced pluripotent stem cell human CVCL_HH60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30266; true Male 21095504 CVCL_HH61 CW30267 induced pluripotent stem cell human CVCL_HH61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30267; true Female 21095505 CVCL_HH62 CW30270 induced pluripotent stem cell human CVCL_HH62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30270; true Male 21095506 CVCL_HH56 CW30233 induced pluripotent stem cell human CVCL_HH56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30233; true Male 21095507 CVCL_HH57 CW30261 induced pluripotent stem cell human CVCL_HH57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30261; true Male 21095508 CVCL_HH58 CW30262 induced pluripotent stem cell human CVCL_HH58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30262; true Male 21095509 CVCL_HH59 CW30263 induced pluripotent stem cell human CVCL_HH59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30263; true Female 21095510 CVCL_HH52 CW30151 induced pluripotent stem cell human CVCL_HH52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30151; true Male 21095511 CVCL_HH53 CW30195 induced pluripotent stem cell human CVCL_HH53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30195; true Female 21095512 CVCL_HH54 CW30202 induced pluripotent stem cell human CVCL_HH54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30202; true Male 21095513 CVCL_HH55 CW30209 induced pluripotent stem cell human CVCL_HH55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30209; true Female 21095514 CVCL_HH27 CW20210 induced pluripotent stem cell human CVCL_HH27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20210; true Male 21095515 CVCL_HH28 CW20213 induced pluripotent stem cell human CVCL_HH28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20213; true Female 21095516 CVCL_HH29 CW20214 induced pluripotent stem cell human CVCL_HH29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20214; true Female 21095517 CVCL_HH23 CW20201 induced pluripotent stem cell human CVCL_HH23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20201; true Male 21095518 CVCL_HH24 CW20203 induced pluripotent stem cell human CVCL_HH24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20203; true Male 21095519 CVCL_HH25 CW20204 induced pluripotent stem cell human CVCL_HH25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20204; true Male 21095520 CVCL_HH26 CW20206 induced pluripotent stem cell human CVCL_HH26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20206; true Male 21095521 CVCL_HH20 CW20183 induced pluripotent stem cell human CVCL_HH20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20183; true Male 21095522 CVCL_HH21 CW20184 induced pluripotent stem cell human CVCL_HH21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20184; true Male 21095523 CVCL_HH22 CW20192 induced pluripotent stem cell human CVCL_HH22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20192; true Male 21095524 CVCL_HH40 CW30036 induced pluripotent stem cell human CVCL_HH40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30036; true. Female 21095525 CVCL_HH38 CW30008 induced pluripotent stem cell human CVCL_HH38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW30008; true. Male 21095526 CVCL_HH39 CW30015 induced pluripotent stem cell human CVCL_HH39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30015; true. Male 21095527 CVCL_HH34 CW20239 induced pluripotent stem cell human CVCL_HH34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20239; true Female 21095528 CVCL_HH35 CW20242 induced pluripotent stem cell human CVCL_HH35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20242; true Male 21095529 CVCL_HH36 CW20249 induced pluripotent stem cell human CVCL_HH36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20249; true Male 21095530 CVCL_HH37 CW30004 induced pluripotent stem cell human CVCL_HH37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30004; true. Male 21095531 CVCL_HH30 CW20222 induced pluripotent stem cell human CVCL_HH30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20222; true Female 21095532 CVCL_HH31 CW20225 induced pluripotent stem cell human CVCL_HH31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20225; true Male 21095533 CVCL_HH32 CW20226 induced pluripotent stem cell human CVCL_HH32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20226; true Female 21095534 CVCL_HH33 CW20231 induced pluripotent stem cell human CVCL_HH33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20231; true Male 21095535 CVCL_HH09 CW20111 induced pluripotent stem cell human CVCL_HH09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20111; true Male 21095536 CVCL_HH05 CW20069 induced pluripotent stem cell human CVCL_HH05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20069; true Male 21095537 CVCL_HH06 CW20087 induced pluripotent stem cell human CVCL_HH06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20087; true Male 21095538 CVCL_HH07 CW20103 induced pluripotent stem cell human CVCL_HH07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20103; true Female 21095539 CVCL_HH08 CW20105 induced pluripotent stem cell human CVCL_HH08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20105; true Male 21095540 CVCL_HH01 CW20039 induced pluripotent stem cell human CVCL_HH01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20039; true Male 21095541 CVCL_HH02 CW20041 induced pluripotent stem cell human CVCL_HH02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20041; true Female 21095542 CVCL_HH03 CW20053 induced pluripotent stem cell human CVCL_HH03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20053; true Male 21095543 CVCL_HH04 CW20054 induced pluripotent stem cell human CVCL_HH04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20054; true Female 21095544 CVCL_HH00 CW20029 induced pluripotent stem cell human CVCL_HH00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW20029; true. Female 21095545 CVCL_HH16 CW20140 induced pluripotent stem cell human CVCL_HH16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20140; true Male 21095546 CVCL_HH17 CW20141 induced pluripotent stem cell human CVCL_HH17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20141; true Male 21095547 CVCL_HH18 CW20152 induced pluripotent stem cell human CVCL_HH18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20152; true Female 21095548 CVCL_HH19 CW20153 induced pluripotent stem cell human CVCL_HH19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20153; true Male 21095549 CVCL_HH12 CW20129 induced pluripotent stem cell human CVCL_HH12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20129; true Female 21095550 CVCL_HH13 CW20131 induced pluripotent stem cell human CVCL_HH13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian Discontinued: Coriell; CW20131; true. Female 21095551 CVCL_HH14 CW20133 induced pluripotent stem cell human CVCL_HH14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20133; true Male 21095552 CVCL_HH15 CW20136 induced pluripotent stem cell human CVCL_HH15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Nepali; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20136; true Male 21095553 CVCL_HH10 CW20124 induced pluripotent stem cell human CVCL_HH10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20124; true Male 21095554 CVCL_HH11 CW20126 induced pluripotent stem cell human CVCL_HH11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20126; true Male 21095555 CVCL_QC90 BayGenomics ES cell line XL052 embryonic stem cell house mouse CVCL_QC90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107752; Myo1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095556 CVCL_QC91 BayGenomics ES cell line XL055 embryonic stem cell house mouse CVCL_QC91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96677; Kit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095557 CVCL_QC92 BayGenomics ES cell line XL056 embryonic stem cell house mouse CVCL_QC92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88547; Csnk2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095558 CVCL_QC93 BayGenomics ES cell line XL057 embryonic stem cell house mouse CVCL_QC93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095559 CVCL_QC94 BayGenomics ES cell line XL058 embryonic stem cell house mouse CVCL_QC94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146156; Espl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095560 CVCL_QC95 BayGenomics ES cell line XL060 embryonic stem cell house mouse CVCL_QC95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136773; Cwc22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095561 CVCL_QC96 BayGenomics ES cell line XL061 embryonic stem cell house mouse CVCL_QC96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98927; Vcl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095562 CVCL_QC97 BayGenomics ES cell line XL062 embryonic stem cell house mouse CVCL_QC97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858317; Timm23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095563 CVCL_QC98 BayGenomics ES cell line XL063 embryonic stem cell house mouse CVCL_QC98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142347; Zfp568 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095564 CVCL_QC99 BayGenomics ES cell line XL064 embryonic stem cell house mouse CVCL_QC99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197519; Bcl2l11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095565 CVCL_QC80 BayGenomics ES cell line XL036 embryonic stem cell house mouse CVCL_QC80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095566 CVCL_QC81 BayGenomics ES cell line XL037 embryonic stem cell house mouse CVCL_QC81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915264; Zwilch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095567 CVCL_QC82 BayGenomics ES cell line XL040 embryonic stem cell house mouse CVCL_QC82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197519; Bcl2l11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095568 CVCL_QC83 BayGenomics ES cell line XL041 embryonic stem cell house mouse CVCL_QC83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095569 CVCL_QC84 BayGenomics ES cell line XL042 embryonic stem cell house mouse CVCL_QC84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923356; Kdm3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095570 CVCL_QC85 BayGenomics ES cell line XL045 embryonic stem cell house mouse CVCL_QC85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095571 CVCL_QC86 BayGenomics ES cell line XL046 embryonic stem cell house mouse CVCL_QC86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98931; Ezr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095572 CVCL_QC87 BayGenomics ES cell line XL047 embryonic stem cell house mouse CVCL_QC87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095573 CVCL_QC88 BayGenomics ES cell line XL049 embryonic stem cell house mouse CVCL_QC88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920026; Sass6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095574 CVCL_QC89 BayGenomics ES cell line XL051 embryonic stem cell house mouse CVCL_QC89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095575 CVCL_QC70 BayGenomics ES cell line XL023 embryonic stem cell house mouse CVCL_QC70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347043; Orc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095576 CVCL_QC71 BayGenomics ES cell line XL025 embryonic stem cell house mouse CVCL_QC71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107716; Myo10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095577 CVCL_QC72 BayGenomics ES cell line XL026 embryonic stem cell house mouse CVCL_QC72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914869; Nob1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095578 CVCL_QC73 BayGenomics ES cell line XL027 embryonic stem cell house mouse CVCL_QC73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095579 CVCL_QC74 BayGenomics ES cell line XL028 embryonic stem cell house mouse CVCL_QC74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095580 CVCL_QC75 BayGenomics ES cell line XL030 embryonic stem cell house mouse CVCL_QC75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095581 CVCL_QC76 BayGenomics ES cell line XL031 embryonic stem cell house mouse CVCL_QC76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914302; Ndc80 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095582 CVCL_QC77 BayGenomics ES cell line XL033 embryonic stem cell house mouse CVCL_QC77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095583 CVCL_QC78 BayGenomics ES cell line XL034 embryonic stem cell house mouse CVCL_QC78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924288; Arfgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095584 CVCL_QC79 BayGenomics ES cell line XL035 embryonic stem cell house mouse CVCL_QC79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095585 CVCL_QC60 BayGenomics ES cell line XL004 embryonic stem cell house mouse CVCL_QC60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339639; Ogt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095586 CVCL_QC61 BayGenomics ES cell line XL005 embryonic stem cell house mouse CVCL_QC61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915389; Tox4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095587 CVCL_QC62 BayGenomics ES cell line XL006 embryonic stem cell house mouse CVCL_QC62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095588 CVCL_QC63 BayGenomics ES cell line XL009 embryonic stem cell house mouse CVCL_QC63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890357; Igf2bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095589 CVCL_QC64 BayGenomics ES cell line XL011 embryonic stem cell house mouse CVCL_QC64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355322; Exosc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095590 CVCL_QC65 BayGenomics ES cell line XL013 embryonic stem cell house mouse CVCL_QC65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893577; Stx4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095591 CVCL_QC66 BayGenomics ES cell line XL015 embryonic stem cell house mouse CVCL_QC66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109656; Lasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095592 CVCL_QC67 BayGenomics ES cell line XL017 embryonic stem cell house mouse CVCL_QC67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106478; Eif3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095593 CVCL_QC68 BayGenomics ES cell line XL018 embryonic stem cell house mouse CVCL_QC68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095594 CVCL_QC69 BayGenomics ES cell line XL021 embryonic stem cell house mouse CVCL_QC69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095595 CVCL_QC50 BayGenomics ES cell line XK731 embryonic stem cell house mouse CVCL_QC50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095596 CVCL_QC51 BayGenomics ES cell line XK732 embryonic stem cell house mouse CVCL_QC51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099804; Hip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095597 CVCL_QC52 BayGenomics ES cell line XK733 embryonic stem cell house mouse CVCL_QC52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916658; Dnajc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095598 CVCL_QC53 BayGenomics ES cell line XK737 embryonic stem cell house mouse CVCL_QC53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339984; Pak2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095599 CVCL_QC54 BayGenomics ES cell line XK742 embryonic stem cell house mouse CVCL_QC54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926788; Apip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095600 CVCL_QC55 BayGenomics ES cell line XK744 embryonic stem cell house mouse CVCL_QC55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443008; Trappc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095601 CVCL_QC56 BayGenomics ES cell line XK751 embryonic stem cell house mouse CVCL_QC56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095602 CVCL_QC57 BayGenomics ES cell line XK752 embryonic stem cell house mouse CVCL_QC57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106484; Rufy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095603 CVCL_QC58 BayGenomics ES cell line XK758 embryonic stem cell house mouse CVCL_QC58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443008; Trappc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095604 CVCL_QC59 BayGenomics ES cell line XL002 embryonic stem cell house mouse CVCL_QC59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095605 CVCL_QC40 BayGenomics ES cell line XK596 embryonic stem cell house mouse CVCL_QC40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095606 CVCL_QC41 BayGenomics ES cell line XK597 embryonic stem cell house mouse CVCL_QC41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924363; Klhl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095607 CVCL_QC42 BayGenomics ES cell line XK603 embryonic stem cell house mouse CVCL_QC42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101783; Plk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095608 CVCL_QC43 BayGenomics ES cell line XK681 embryonic stem cell house mouse CVCL_QC43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102706; Fdft1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095609 CVCL_QC44 BayGenomics ES cell line XK682 embryonic stem cell house mouse CVCL_QC44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913872; Ubr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095610 CVCL_QC45 BayGenomics ES cell line XK683 embryonic stem cell house mouse CVCL_QC45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096566; Pias2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095611 CVCL_QC46 BayGenomics ES cell line XK687 embryonic stem cell house mouse CVCL_QC46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444098; Heatr5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095612 CVCL_QC47 BayGenomics ES cell line XK712 embryonic stem cell house mouse CVCL_QC47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336993; Ap4e1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095613 CVCL_QC48 BayGenomics ES cell line XK714 embryonic stem cell house mouse CVCL_QC48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095614 CVCL_QC49 BayGenomics ES cell line XK730 embryonic stem cell house mouse CVCL_QC49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351511; Psmd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095615 CVCL_HI91 CW50134 induced pluripotent stem cell human CVCL_HI91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50134; true Female 21095616 CVCL_HI92 CW50138 induced pluripotent stem cell human CVCL_HI92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50138; true Male 21095617 CVCL_HI93 CW50139 induced pluripotent stem cell human CVCL_HI93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50139; true Female 21095618 CVCL_HI94 CW50141 induced pluripotent stem cell human CVCL_HI94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50141; true Male 21095619 CVCL_HI90 CW50133 induced pluripotent stem cell human CVCL_HI90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50133; true Female 21095620 CVCL_QC30 BayGenomics ES cell line XK582 embryonic stem cell house mouse CVCL_QC30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894652; Usp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095621 CVCL_QC31 BayGenomics ES cell line XK583 embryonic stem cell house mouse CVCL_QC31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095622 CVCL_QC32 BayGenomics ES cell line XK584 embryonic stem cell house mouse CVCL_QC32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095623 CVCL_QC33 BayGenomics ES cell line XK586 embryonic stem cell house mouse CVCL_QC33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333813; Mbd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095624 CVCL_QC34 BayGenomics ES cell line XK588 embryonic stem cell house mouse CVCL_QC34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095625 CVCL_QC35 BayGenomics ES cell line XK589 embryonic stem cell house mouse CVCL_QC35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095626 CVCL_QC36 BayGenomics ES cell line XK590 embryonic stem cell house mouse CVCL_QC36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095627 CVCL_HI88 CW50131 induced pluripotent stem cell human CVCL_HI88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50131; true Male 21095628 CVCL_QC37 BayGenomics ES cell line XK593 embryonic stem cell house mouse CVCL_QC37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930140; Wdr6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095629 CVCL_HI89 CW50132 induced pluripotent stem cell human CVCL_HI89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50132; true Female 21095630 CVCL_QC38 BayGenomics ES cell line XK594 embryonic stem cell house mouse CVCL_QC38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104913; Abi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095631 CVCL_QC39 BayGenomics ES cell line XK595 embryonic stem cell house mouse CVCL_QC39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095632 CVCL_HI84 CW50115 induced pluripotent stem cell human CVCL_HI84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50115; true Female 21095633 CVCL_HI85 CW50117 induced pluripotent stem cell human CVCL_HI85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50117; true Male 21095634 CVCL_HI86 CW50128 induced pluripotent stem cell human CVCL_HI86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50128; true Female 21095635 CVCL_HI87 CW50129 induced pluripotent stem cell human CVCL_HI87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50129; true Female 21095636 CVCL_QC20 BayGenomics ES cell line XK567 embryonic stem cell house mouse CVCL_QC20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922033; Fbf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095637 CVCL_QC21 BayGenomics ES cell line XK569 embryonic stem cell house mouse CVCL_QC21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916885; Dapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095638 CVCL_QC22 BayGenomics ES cell line XK570 embryonic stem cell house mouse CVCL_QC22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095639 CVCL_QC23 BayGenomics ES cell line XK571 embryonic stem cell house mouse CVCL_QC23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860206; Ammecr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095640 CVCL_QC24 BayGenomics ES cell line XK574 embryonic stem cell house mouse CVCL_QC24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919369; Tpx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095641 CVCL_QC25 BayGenomics ES cell line XK575 embryonic stem cell house mouse CVCL_QC25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196316; R3hcc1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095642 CVCL_HI99 CW50147 induced pluripotent stem cell human CVCL_HI99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50147; true Male 21095643 CVCL_QC26 BayGenomics ES cell line XK578 embryonic stem cell house mouse CVCL_QC26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106330; Larp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095644 CVCL_QC27 BayGenomics ES cell line XK579 embryonic stem cell house mouse CVCL_QC27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926188; Fbxo34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095645 CVCL_QC28 BayGenomics ES cell line XK580 embryonic stem cell house mouse CVCL_QC28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3694236; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095646 CVCL_QC29 BayGenomics ES cell line XK581 embryonic stem cell house mouse CVCL_QC29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095647 CVCL_HI95 CW50142 induced pluripotent stem cell human CVCL_HI95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50142; true Female 21095648 CVCL_HI96 CW50143 induced pluripotent stem cell human CVCL_HI96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50143; true Male 21095649 CVCL_HI97 CW50144 induced pluripotent stem cell human CVCL_HI97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50144; true Male 21095650 CVCL_HI98 CW50145 induced pluripotent stem cell human CVCL_HI98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50145; true Male 21095651 CVCL_6V60 DA01431 transformed cell line human CVCL_6V60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095652 CVCL_7760 UM-SCC-48 cancer cell line human CVCL_7760 CL:0000010 Male 21095653 CVCL_6V61 DA01432 transformed cell line human CVCL_6V61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01432; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095654 CVCL_7761 UM-SCC-49 cancer cell line human CVCL_7761 CL:0000010 Derived from sampling site: Oral cavity; tongue; lateral border. Omics: CNV analysis Male 21095655 CVCL_6V62 DA01433 transformed cell line human CVCL_6V62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095656 CVCL_7762 UM-SCC-5 cancer cell line human CVCL_7762 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Heterozygous (PubMed=12884349) Derived from sampling site: Larynx; supraglottis. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21095657 CVCL_6V56 DA01426 transformed cell line human CVCL_6V56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095658 CVCL_7756 UM-SCC-44 cancer cell line human CVCL_7756 CL:0000010 Male 21095659 CVCL_6V57 DA01427 transformed cell line human CVCL_6V57 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095660 CVCL_7757 UM-SCC-45 cancer cell line human CVCL_7757 CL:0000010 Female 21095661 CVCL_6V58 DA01428 transformed cell line human CVCL_6V58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095662 CVCL_7758 UM-SCC-46 cancer cell line human CVCL_7758 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Unspecified (PubMed=12884349; PubMed=18006756) Derived from sampling site: Larynx. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21095663 CVCL_6V59 DA01429 transformed cell line human CVCL_6V59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095664 CVCL_7759 UM-SCC-47 cancer cell line human CVCL_7759 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly192Ter (c.574G>T); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue; lateral border. Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Virology: Contains from 21 to 47 copies of the HPV16 genome (PubMed=24201445) Doubling time: 2.2 days (PubMed=29156801) Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21095665 CVCL_6V52 DA01418 transformed cell line human CVCL_6V52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01418; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095666 CVCL_7752 UM-SCC-40 cancer cell line human CVCL_7752 CL:0000010 Male 21095667 CVCL_6V53 DA01419 transformed cell line human CVCL_6V53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095668 CVCL_7753 UM-SCC-41 cancer cell line human CVCL_7753 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis. Male 21095669 CVCL_6V54 DA01420 transformed cell line human CVCL_6V54 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095670 CVCL_7754 UM-SCC-42 cancer cell line human CVCL_7754 CL:0000010 Male 21095671 CVCL_6V55 DA01424 transformed cell line human CVCL_6V55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095672 CVCL_7755 UM-SCC-43 cancer cell line human CVCL_7755 CL:0000010 Omics: CNV analysis. Male 21095673 CVCL_6V70 DA01441 transformed cell line human CVCL_6V70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095674 CVCL_7770 UM-SCC-57 cancer cell line human CVCL_7770 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=12884349) Omics: CNV analysis; Omics: Deep exome analysis. Male 21095675 CVCL_6V71 DA01442 transformed cell line human CVCL_6V71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095676 CVCL_7771 UM-SCC-58 cancer cell line human CVCL_7771 CL:0000010 Female 21095677 CVCL_6V72 DA01443 transformed cell line human CVCL_6V72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095678 CVCL_7772 UM-SCC-59 cancer cell line human CVCL_7772 CL:0000010 Derived from sampling site: Oral cavity; tongue; lateral border. Omics: CNV analysis Female 21095679 CVCL_6V73 DA01444 transformed cell line human CVCL_6V73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095680 CVCL_7773 UM-SCC-6 cancer cell line human CVCL_7773 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349; PubMed=18006756; PubMed=23613873) Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project Caution: Indicated as originating from a 32 year old patient in PubMed=3855324 and from a 37 year old in PubMed=18006756 and PubMed=33802339. 21095681 CVCL_6V67 DA01438 transformed cell line human CVCL_6V67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095682 CVCL_7767 UM-SCC-54 cancer cell line human CVCL_7767 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349). Male 21095683 CVCL_6V68 DA01439 transformed cell line human CVCL_6V68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095684 CVCL_7768 UM-SCC-55 cancer cell line human CVCL_7768 CL:0000010 Omics: CNV analysis. Male 21095685 CVCL_6V69 DA01440 transformed cell line human CVCL_6V69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01440; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095686 CVCL_7769 UM-SCC-56 cancer cell line human CVCL_7769 CL:0000010 21095687 CVCL_6V63 DA01434 transformed cell line human CVCL_6V63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095688 CVCL_7763 UM-SCC-50 cancer cell line human CVCL_7763 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male 21095689 CVCL_6V64 DA01435 transformed cell line human CVCL_6V64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095690 CVCL_7764 UM-SCC-51 cancer cell line human CVCL_7764 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male 21095691 CVCL_6V65 DA01436 transformed cell line human CVCL_6V65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095692 CVCL_7765 UM-SCC-52 cancer cell line human CVCL_7765 CL:0000010 Female 21095693 CVCL_6V66 DA01437 transformed cell line human CVCL_6V66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095694 CVCL_7766 UM-SCC-53 cancer cell line human CVCL_7766 CL:0000010 Male 21095695 CVCL_6V40 DA01406 transformed cell line human CVCL_6V40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095696 CVCL_7740 UM-SCC-3 cancer cell line human CVCL_7740 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=16203773) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female 21095697 CVCL_6V34 DA01398 transformed cell line human CVCL_6V34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095698 CVCL_7734 UM-SCC-24 cancer cell line human CVCL_7734 CL:0000010 Derived from sampling site: Larynx; vocal fold. Male 21095699 CVCL_6V35 DA01399 transformed cell line human CVCL_6V35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095700 CVCL_7735 UM-SCC-25 cancer cell line human CVCL_7735 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21095701 CVCL_6V36 DA01400 transformed cell line human CVCL_6V36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095702 CVCL_7736 UM-SCC-26 cancer cell line human CVCL_7736 CL:0000010 Male 21095703 CVCL_6V37 DA01401 transformed cell line human CVCL_6V37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095704 CVCL_7737 UM-SCC-27 cancer cell line human CVCL_7737 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=16203773) Derived from metastatic site: Lymph node. Male 21095705 CVCL_6V30 DA01394 transformed cell line human CVCL_6V30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095706 CVCL_7730 UM-SCC-21A cancer cell line human CVCL_7730 CL:0000010 Male 21095707 CVCL_6V31 DA01395 transformed cell line human CVCL_6V31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095708 CVCL_7731 UM-SCC-22A cancer cell line human CVCL_7731 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu341Gln (c.1021G>C); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Leu1935Val (c.5803C>G); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1679Ter (c.5035G>T); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (PubMed=18006756; PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=18006756; PubMed=23613873; PubMed=31541927) Derived from sampling site: Pharynx; hypopharynx. Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 31 +- 4 hours (PubMed=9139877) Part of: MD Anderson Cell Lines Project 21095709 CVCL_6V32 DA01396 transformed cell line human CVCL_6V32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095710 CVCL_7732 UM-SCC-22B cancer cell line human CVCL_7732 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1679Ter (c.5035G>T); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=15287027; PubMed=16203773; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=15287027; PubMed=16203773; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=31541927) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34 +- 2 hours (PubMed=9139877) Part of: MD Anderson Cell Lines Project Problematic cell line: Partially contaminated At least one lab used a stock contaminated by T24 (Cellosaurus=CVCL_0554) (PubMed=29873307). 21095711 CVCL_6V33 DA01397 transformed cell line human CVCL_6V33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095712 CVCL_7733 UM-SCC-23 cancer cell line human CVCL_7733 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=1394225; PubMed=12884349) Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585); Derived from sampling site: Larynx. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21095713 CVCL_6V38 DA01402 transformed cell line human CVCL_6V38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095714 CVCL_7738 UM-SCC-28 cancer cell line human CVCL_7738 CL:0000010 Derived from sampling site: Larynx; vocal fold. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21095715 CVCL_6V39 DA01405 transformed cell line human CVCL_6V39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095716 CVCL_7739 UM-SCC-29 cancer cell line human CVCL_7739 CL:0000010 Omics: CNV analysis. Male 21095717 CVCL_6V50 DA01416 transformed cell line human CVCL_6V50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095718 CVCL_7750 UM-SCC-39 cancer cell line human CVCL_7750 CL:0000010 Male 21095719 CVCL_6V51 DA01417 transformed cell line human CVCL_6V51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095720 CVCL_7751 UM-SCC-4 cancer cell line human CVCL_7751 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Unspecified (PubMed=25275298); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=16203773) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Female Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21095721 CVCL_6V45 DA01411 transformed cell line human CVCL_6V45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095722 CVCL_7745 UM-SCC-34 cancer cell line human CVCL_7745 CL:0000010 Male 21095723 CVCL_6V46 DA01412 transformed cell line human CVCL_6V46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095724 CVCL_7746 UM-SCC-35 cancer cell line human CVCL_7746 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Val584Met (c.1750G>A); ClinVar=VCV001303523; Zygosity=Unspecified (PubMed=31541927); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Pro2559Leu (c.7676C>T); Zygosity=Unspecified (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=31541927) Omics: Genome sequenced (low read coverage). Male Doubling time: 38 +- 2 hours (PubMed=9139877) 21095725 CVCL_6V47 DA01413 transformed cell line human CVCL_6V47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095726 CVCL_7747 UM-SCC-36 cancer cell line human CVCL_7747 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Pro (c.473G>C); ClinVar=VCV000246118; Zygosity=Unspecified (PubMed=12884349). Male 21095727 CVCL_6V48 DA01414 transformed cell line human CVCL_6V48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095728 CVCL_7748 UM-SCC-37 cancer cell line human CVCL_7748 CL:0000010 Male 21095729 CVCL_6V41 DA01407 transformed cell line human CVCL_6V41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095730 CVCL_7741 UM-SCC-30 cancer cell line human CVCL_7741 CL:0000010 Female 21095731 CVCL_6V42 DA01408 transformed cell line human CVCL_6V42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095732 CVCL_7742 UM-SCC-31 cancer cell line human CVCL_7742 CL:0000010 Male 21095733 CVCL_6V43 DA01409 transformed cell line human CVCL_6V43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095734 CVCL_7743 UM-SCC-32 cancer cell line human CVCL_7743 CL:0000010 Male 21095735 CVCL_6V44 DA01410 transformed cell line human CVCL_6V44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095736 CVCL_7744 UM-SCC-33 cancer cell line human CVCL_7744 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Female 21095737 CVCL_6V49 DA01415 transformed cell line human CVCL_6V49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095738 CVCL_7749 UM-SCC-38 cancer cell line human CVCL_7749 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Met3586Thr (c.10757T>C); ClinVar=VCV000785111; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (PubMed=18006756; PubMed=23613873; PubMed=31541927) Derived from sampling site: Tonsillar fossa. Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21095739 CVCL_6V12 DA01375 transformed cell line human CVCL_6V12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095740 CVCL_7712 UM-SCC-104 cancer cell line human CVCL_7712 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Ile1829Val (c.5485A>G); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Ala12Val (c.35C>T); ClinVar=VCV001494610; Zygosity=Homozygous (PubMed=31541927) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 48 hours (PubMed=22162267); 2.6 days (PubMed=29156801) 21095741 CVCL_6V13 DA01376 transformed cell line human CVCL_6V13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095742 CVCL_7713 UM-SCC-10A cancer cell line human CVCL_7713 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=1394225; PubMed=15287027; PubMed=18487078) Derived from sampling site: Larynx; vocal fold. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21095743 CVCL_6V14 DA01377 transformed cell line human CVCL_6V14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095744 CVCL_7714 UM-SCC-10B cancer cell line human CVCL_7714 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Heterozygous (PubMed=1394225; PubMed=12884349; PubMed=15287027; PubMed=16020667; PubMed=18487078) Derived from metastatic site: Submental lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21095745 CVCL_6V15 DA01378 transformed cell line human CVCL_6V15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095746 CVCL_7715 UM-SCC-11A cancer cell line human CVCL_7715 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18006756) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male 21095747 CVCL_6V10 DA01373 transformed cell line human CVCL_6V10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095748 CVCL_7710 UM-SCC-101B cancer cell line human CVCL_7710 CL:0000010 Derived from metastatic site: Cervical lymph node. Female 21095749 CVCL_6V11 DA01374 transformed cell line human CVCL_6V11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095750 CVCL_7711 UM-SCC-103 cancer cell line human CVCL_7711 CL:0000010 Omics: CNV analysis. 21095751 CVCL_6V16 DA01379 transformed cell line human CVCL_6V16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095752 CVCL_7716 UM-SCC-11B cancer cell line human CVCL_7716 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078; PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly2569Ser (c.7705G>A); ClinVar=VCV000134697; Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Leu4069Phe (c.12205C>T); ClinVar=VCV001412971; Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg912Trp (c.2734C>T); ClinVar=VCV000134921; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Homozygous (PubMed=12884349; PubMed=15287027; PubMed=18006756; PubMed=18487078; PubMed=23613873; PubMed=25275298; PubMed=31541927) Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 31 +- 3 hours (PubMed=9139877) Part of: OPC-22 oral and pharyngeal cancer cell line panel 21095753 CVCL_6V17 DA01381 transformed cell line human CVCL_6V17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095754 CVCL_7717 UM-SCC-12 cancer cell line human CVCL_7717 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Unspecified (PubMed=12884349) Derived from sampling site: Larynx. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21095755 CVCL_6V18 DA01382 transformed cell line human CVCL_6V18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095756 CVCL_7718 UM-SCC-13 cancer cell line human CVCL_7718 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Unspecified (PubMed=12884349) Derived from metastatic site: Esophagus. Omics: Deep exome analysis Male 21095757 CVCL_6V19 DA01383 transformed cell line human CVCL_6V19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095758 CVCL_7719 UM-SCC-14A cancer cell line human CVCL_7719 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18487078; PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1324Thr (c.3971G>C); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277_Glu286del (c.829_858del30); Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=12884349; PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=12884349; PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female 21095759 CVCL_6V23 DA01387 transformed cell line human CVCL_6V23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095760 CVCL_7723 UM-SCC-16 cancer cell line human CVCL_7723 CL:0000010 Female 21095761 CVCL_6V24 DA01388 transformed cell line human CVCL_6V24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095762 CVCL_7724 UM-SCC-17A cancer cell line human CVCL_7724 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078) Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Part of: MD Anderson Cell Lines Project 21095763 CVCL_6V25 DA01389 transformed cell line human CVCL_6V25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095764 CVCL_7725 UM-SCC-17B cancer cell line human CVCL_7725 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349) Derived from metastatic site: Cervical lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Part of: OPC-22 oral and pharyngeal cancer cell line panel 21095765 CVCL_6V26 DA01390 transformed cell line human CVCL_6V26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095766 CVCL_7726 UM-SCC-18 cancer cell line human CVCL_7726 CL:0000010 Male 21095767 CVCL_6V20 DA01384 transformed cell line human CVCL_6V20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095768 CVCL_7720 UM-SCC-14B cancer cell line human CVCL_7720 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1324Thr (c.3971G>C); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Phe977Tyr (c.2930T>A); Zygosity=Unspecified (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277_Glu286del (c.829_858del30); Zygosity=Heterozygous (PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Part of: MD Anderson Cell Lines Project 21095769 CVCL_6V21 DA01385 transformed cell line human CVCL_6V21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095770 CVCL_7721 UM-SCC-14C cancer cell line human CVCL_7721 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078; PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1324Thr (c.3971G>C); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277_Glu286del (c.829_858del30); Zygosity=Heterozygous (PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (PubMed=15287027; PubMed=18487078; PubMed=23613873; PubMed=31541927) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Omics: Genome sequenced (low read coverage) Discontinued: CLS; 300370; true Female Doubling time: 27 +- 4 hours (PubMed=9139877) 21095771 CVCL_6V22 DA01386 transformed cell line human CVCL_6V22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095772 CVCL_7722 UM-SCC-15 cancer cell line human CVCL_7722 CL:0000010 Derived from sampling site: Pharynx; hypopharynx. Male 21095773 CVCL_6V27 DA01391 transformed cell line human CVCL_6V27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095774 CVCL_7727 UM-SCC-19 cancer cell line human CVCL_7727 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21095775 CVCL_6V28 DA01392 transformed cell line human CVCL_6V28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095776 CVCL_7728 UM-SCC-2 cancer cell line human CVCL_7728 CL:0000010 Omics: Deep exome analysis. Female Part of: OPC-22 oral and pharyngeal cancer cell line panel 21095777 CVCL_6V29 DA01393 transformed cell line human CVCL_6V29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095778 CVCL_7729 UM-SCC-20 cancer cell line human CVCL_7729 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro71_Pro72del (c.211_216del6); Zygosity=Unspecified (PubMed=12884349) Derived from metastatic site: Neck. Male 21095779 CVCL_6V01 DA01364 transformed cell line human CVCL_6V01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095780 CVCL_7701 SH3 [Mouse hybridoma] hybridoma house mouse CVCL_7701 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human marrow-derived mesenchymal cells surface antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10744 21095781 CVCL_6V02 DA01365 transformed cell line human CVCL_6V02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095782 CVCL_7702 SH4 hybridoma house mouse CVCL_7702 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human marrow-derived mesenchymal cells surface antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10745 21095783 CVCL_6V03 DA01366 transformed cell line human CVCL_6V03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095784 CVCL_7703 tGM24 telomerase immortalized cell line human CVCL_7703 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21095785 CVCL_6V04 DA01367 transformed cell line human CVCL_6V04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095786 CVCL_7704 TWERC transformed cell line Norway rat CVCL_7704 CL:0000010 Transformant: Rous sarcoma virus (strain Prague C)(NCBI-Taxonomy; 11888); Derived from sampling site: Whole embryo; Breed/subspecies: Wistar. Unspecified 21095787 CVCL_6V00 DA01363 transformed cell line human CVCL_6V00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095788 CVCL_7700 SH2 [Mouse hybridoma] hybridoma house mouse CVCL_7700 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human marrow-derived mesenchymal cells surface antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10743 21095789 CVCL_6V09 DA01372 transformed cell line human CVCL_6V09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095790 CVCL_7709 UM-SCC-101A cancer cell line human CVCL_7709 CL:0000010 Female 21095791 CVCL_6V05 DA01368 transformed cell line human CVCL_6V05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095792 CVCL_7705 Karpas-230 cancer cell line human CVCL_7705 CL:0000010 Derived from sampling site: Bone marrow. Male 21095793 CVCL_6V06 DA01369 transformed cell line human CVCL_6V06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095794 CVCL_7706 Karpas-241 cancer cell line human CVCL_7706 CL:0000010 Derived from sampling site: Peripheral blood. Male 21095795 CVCL_6V07 DA01370 transformed cell line human CVCL_6V07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095796 CVCL_7707 UM-SCC-1 cancer cell line human CVCL_7707 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8725545; PubMed=8782485; PubMed=12884349; PubMed=18006756) Derived from sampling site: Oral cavity; floor of mouth. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project Caution: Indicated as originating from a 60 year old patient in PubMed=3855324 and from a 72 year old in PubMed=1851275 and PubMed=18006756 21095797 CVCL_6V08 DA01371 transformed cell line human CVCL_6V08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095798 CVCL_7708 UM-SCC-100 cancer cell line human CVCL_7708 CL:0000010 Female 21095799 CVCL_6U97 DA01358 transformed cell line human CVCL_6U97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095800 CVCL_7697 Psi2 BAG alpha transformed cell line house mouse CVCL_7697 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9560 21095801 CVCL_6U98 DA01359 transformed cell line human CVCL_6U98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095802 CVCL_7698 PSM-B cancer cell line house mouse CVCL_7698 CL:0000010 Breed/subspecies: SIM. Discontinued: ECACC; 85061802; probable 21095803 CVCL_6U99 DA01360 transformed cell line human CVCL_6U99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095804 CVCL_7699 SAKRTLS 12.1 cancer cell line house mouse CVCL_7699 CL:0000010 Breed/subspecies: AKR. 21095805 CVCL_6U82 DA01342 transformed cell line human CVCL_6U82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095806 CVCL_6U83 DA01344 transformed cell line human CVCL_6U83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095807 CVCL_7683 M3/38.1.2.8 HL.2 hybridoma CVCL_7683 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P16110; Mouse Lgals3. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21095808 CVCL_6U84 DA01345 transformed cell line human CVCL_6U84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095809 CVCL_7684 MZ1973/10-4 cancer cell line human CVCL_7684 CL:0000010 Derived from sampling site: Kidney. Unspecified 21095810 CVCL_6U85 DA01346 transformed cell line human CVCL_6U85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095811 CVCL_7685 MZ-CO-1 cancer cell line human CVCL_7685 CL:0000010 21095812 CVCL_6U80 DA01340 transformed cell line human CVCL_6U80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01340; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095813 CVCL_7680 HCCLM6 cancer cell line human CVCL_7680 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Established from pulmonary metastatic lesions produced in nude mice by 6 rounds of subcutaneous inoculation of parent cell line Doubling time: 32 hours (PubMed=15146329) 21095814 CVCL_6U81 DA01341 transformed cell line human CVCL_6U81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095815 CVCL_7681 M18/2.a.12.7 hybridoma CVCL_7681 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21095816 CVCL_6U79 DA01339 transformed cell line human CVCL_6U79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095817 CVCL_6U75 DA01334 transformed cell line human CVCL_6U75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095818 CVCL_7675 IR983F cancer cell line Norway rat CVCL_7675 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: LOU/C. Male Group: Hybridoma fusion partner cell line 21095819 CVCL_6U76 DA01335 transformed cell line human CVCL_6U76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095820 CVCL_7676 IT-26R21 spontaneously immortalized cell line Norway rat CVCL_7676 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: Wistar. Female 21095821 CVCL_6U77 DA01337 transformed cell line human CVCL_6U77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095822 CVCL_7677 IT-45R1 spontaneously immortalized cell line Norway rat CVCL_7677 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: Wistar. Unspecified Doubling time: 60 hours (DOI=10.2220/biomedres.2.11) Caution: Erroneously indicated as originating from mouse in BCRJ=0282 21095823 CVCL_6U78 DA01338 transformed cell line human CVCL_6U78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095824 CVCL_7678 IT-45R91 spontaneously immortalized cell line Norway rat CVCL_7678 CL:0000010 Derived from sampling site: Thymus Cell type=Fibroblast.; Breed/subspecies: Wistar. 21095825 CVCL_6U93 DA01354 transformed cell line human CVCL_6U93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095826 CVCL_7693 P1Bb1.1 (DBA/2) cancer cell line house mouse CVCL_7693 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 21095827 CVCL_6U94 DA01355 transformed cell line human CVCL_6U94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095828 CVCL_7694 Pam 212 cancer cell line house mouse CVCL_7694 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Male 21095829 CVCL_6U95 DA01356 transformed cell line human CVCL_6U95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095830 CVCL_7695 PK136 hybridoma house mouse CVCL_7695 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P27814; Mouse Klrb1c/Cd161c. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 787 21095831 CVCL_6U96 DA01357 transformed cell line human CVCL_6U96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095832 CVCL_7696 PR-GTL-16 cancer cell line human CVCL_7696 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:90197; PHA-665752; Derived from metastatic site: Liver. Female 21095833 CVCL_6U90 DA01351 transformed cell line human CVCL_6U90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095834 CVCL_7690 MZ-MEL-6 cancer cell line human CVCL_7690 CL:0000010 Unspecified 21095835 CVCL_6U91 DA01352 transformed cell line human CVCL_6U91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095836 CVCL_7691 NF2S-1 cancer cell line house mouse CVCL_7691 CL:0000010 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.; Breed/subspecies: NIH Swiss. Unspecified Doubling time: 24 hours (PubMed=17304235) 21095837 CVCL_6U92 DA01353 transformed cell line human CVCL_6U92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095838 CVCL_7692 NGUK-1 cancer cell line Norway rat CVCL_7692 CL:0000010 Derived from sampling site: Peripheral nervous system; gasserian ganglion Cell type=Schwann cell.. 21095839 CVCL_6U86 DA01347 transformed cell line human CVCL_6U86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095840 CVCL_7686 MZ-LC-1 cancer cell line human CVCL_7686 CL:0000010 Unspecified 21095841 CVCL_6U87 DA01348 transformed cell line human CVCL_6U87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095842 CVCL_7687 MZ-MEL-11 cancer cell line human CVCL_7687 CL:0000010 Unspecified 21095843 CVCL_6U88 DA01349 transformed cell line human CVCL_6U88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095844 CVCL_7688 MZ-MEL-18 cancer cell line human CVCL_7688 CL:0000010 Unspecified 21095845 CVCL_6U89 DA01350 transformed cell line human CVCL_6U89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095846 CVCL_7689 MZ-MEL-3.1 cancer cell line human CVCL_7689 HLA typing: A*26:01,26:01; B*18:01,18:01; C*07:01:01,07:01:01; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*11:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Female 21095847 CVCL_6U60 DA01318 transformed cell line human CVCL_6U60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01318; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095848 CVCL_7660 GM20466 transformed cell line human CVCL_7660 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Gln202Ter (c.604C>T); ClinVar=VCV000001740; Zygosity=Heterozygous (PubMed=16380922); Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Lys253fs*12 (c.752delA); Zygosity=Heterozygous (PubMed=16380922) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG04344; true Female 21095849 CVCL_6U61 DA01319 transformed cell line human CVCL_6U61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01319; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095850 CVCL_7661 GM20467 finite cell line human CVCL_7661 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Gln202Ter (c.604C>T); ClinVar=VCV000001740; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Lys253fs*12 (c.752delA); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03970; true Female 21095851 CVCL_6U62 DA01320 transformed cell line human CVCL_6U62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095852 CVCL_7662 GM21833 transformed cell line human CVCL_7662 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21095853 CVCL_6U63 DA01322 transformed cell line human CVCL_6U63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095854 CVCL_7663 GM21872 finite cell line human CVCL_7663 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Lys103Glufs*2 (c.307_311delAAAGA) (I102fs*1); ClinVar=VCV000021243; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21095855 CVCL_6U57 DA01315 transformed cell line human CVCL_6U57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095856 CVCL_7657 GM17507 finite cell line human CVCL_7657 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21095857 CVCL_6U58 DA01316 transformed cell line human CVCL_6U58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095858 CVCL_7658 GM17508 transformed cell line human CVCL_7658 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM17508; probable Male 21095859 CVCL_6U59 DA01317 transformed cell line human CVCL_6U59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095860 CVCL_7659 GM20431 transformed cell line human CVCL_7659 CL:0000010 Anecdotal: Established from George Church blood Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21095861 CVCL_6U53 DA01311 transformed cell line human CVCL_6U53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095862 CVCL_6U54 DA01312 transformed cell line human CVCL_6U54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095863 CVCL_7654 GM03725 transformed cell line human CVCL_7654 HLA typing: A*24:CRAC,74:AB; B*08:XKT,81:MN; C*07:27,08:04; DRB1*04:05,12:CVT (IPD-IMGT/HLA=15335) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21095864 CVCL_6U55 DA01313 transformed cell line human CVCL_6U55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095865 CVCL_6U56 DA01314 transformed cell line human CVCL_6U56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095866 CVCL_6U71 DA01330 transformed cell line human CVCL_6U71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095867 CVCL_7671 HOSE 11-12 transformed cell line human CVCL_7671 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21095868 CVCL_6U72 DA01331 transformed cell line human CVCL_6U72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095869 CVCL_7672 HOSE 17-1 transformed cell line human CVCL_7672 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21095870 CVCL_6U73 DA01332 transformed cell line human CVCL_6U73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095871 CVCL_7673 HOSE 6-3 transformed cell line human CVCL_7673 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21095872 CVCL_6U74 DA01333 transformed cell line human CVCL_6U74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095873 CVCL_7674 HSQ-89 cancer cell line human CVCL_7674 HLA typing: A*02:01,24:02 (PubMed=10741724) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (PubMed=10741724; DepMap) Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21095874 CVCL_6U70 DA01329 transformed cell line human CVCL_6U70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095875 CVCL_7670 HEI193 transformed cell line human CVCL_7670 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; c.1575-1G>A; ClinVar=VCV001285395; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=11836557); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Peripheral nervous system; vestibular nerve Cell type=Schwann cell.. Male Doubling time: 12 hours (PubMed=17304235) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4544 21095876 CVCL_6U68 DA01327 transformed cell line human CVCL_6U68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095877 CVCL_7668 GTL-16 cancer cell line human CVCL_7668 HLA typing: A*24:02,24:02; B*52:01,67:02; C*12:02,12:02; DRB1*14:01,14:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: MET is amplified and overexpressed in this cell line 21095878 CVCL_6U69 DA01328 transformed cell line human CVCL_6U69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095879 CVCL_7669 H-494 cancer cell line human CVCL_7669 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00051 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6244232; PubMed=20143388). Originally thought to originate from a prostate carcinoma. 21095880 CVCL_6U64 DA01323 transformed cell line human CVCL_6U64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095881 CVCL_7664 Panc 04.21 cancer cell line human CVCL_7664 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Discontinued: ATCC; CRL-2556; true. Doubling time: 36.0 hours (PubMed=9612602) Problematic cell line: Contaminated Panc 01.28, Panc 04.21 and Panc 06.03 have been shown to be identical (on the basis of STR profile). 21095882 CVCL_6U65 DA01324 transformed cell line human CVCL_6U65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095883 CVCL_7665 Panc 06.03 cancer cell line human CVCL_7665 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (ATCC) Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2550; true. Doubling time: 34.0 hours (PubMed=9612602) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00521 Problematic cell line: Contaminated Panc 01.28, Panc 04.21 and Panc 06.03 have been shown to be identical (on the basis of STR profile). 21095884 CVCL_6U66 DA01325 transformed cell line human CVCL_6U66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095885 CVCL_7666 Panc 01.28 cancer cell line human CVCL_7666 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Discontinued: ATCC; CRL-2548; true. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00519 Problematic cell line: Contaminated Panc 01.28, Panc 04.21 and Panc 06.03 have been shown to be identical (on the basis of STR profile). 21095886 CVCL_6U67 DA01326 transformed cell line human CVCL_6U67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21095887 CVCL_7667 GREF-X undefined cell line type Norway rat CVCL_7667 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00123. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=10508494; PubMed=20143388). 21095888 CVCL_HI70 CW40229 induced pluripotent stem cell human CVCL_HI70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40229; true Male 21095889 CVCL_HI71 CW40230 induced pluripotent stem cell human CVCL_HI71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40230; true Male 21095890 CVCL_HI72 CW40234 induced pluripotent stem cell human CVCL_HI72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40234; true Male 21095891 CVCL_QC10 BayGenomics ES cell line XK535 embryonic stem cell house mouse CVCL_QC10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095892 CVCL_QC11 BayGenomics ES cell line XK536 embryonic stem cell house mouse CVCL_QC11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095893 CVCL_QC12 BayGenomics ES cell line XK538 embryonic stem cell house mouse CVCL_QC12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095894 CVCL_QC13 BayGenomics ES cell line XK542 embryonic stem cell house mouse CVCL_QC13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97054; Mov10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095895 CVCL_QC14 BayGenomics ES cell line XK546 embryonic stem cell house mouse CVCL_QC14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098264; Kif13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095896 CVCL_HI66 CW40211 induced pluripotent stem cell human CVCL_HI66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40211; true Male 21095897 CVCL_QC15 BayGenomics ES cell line XK550 embryonic stem cell house mouse CVCL_QC15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095898 CVCL_HI67 CW40214 induced pluripotent stem cell human CVCL_HI67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40214; true Male 21095899 CVCL_QC16 BayGenomics ES cell line XK551 embryonic stem cell house mouse CVCL_QC16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444023; Tdrd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095900 CVCL_HI68 CW40218 induced pluripotent stem cell human CVCL_HI68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40218; true Male 21095901 CVCL_QC17 BayGenomics ES cell line XK552 embryonic stem cell house mouse CVCL_QC17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923334; Ptbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095902 CVCL_HI69 CW40228 induced pluripotent stem cell human CVCL_HI69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40228; true Male 21095903 CVCL_QC18 BayGenomics ES cell line XK553 embryonic stem cell house mouse CVCL_QC18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095904 CVCL_HI62 CW40167 induced pluripotent stem cell human CVCL_HI62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40167; true Male 21095905 CVCL_QC19 BayGenomics ES cell line XK554 embryonic stem cell house mouse CVCL_QC19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347045; Psmb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095906 CVCL_HI63 CW40185 induced pluripotent stem cell human CVCL_HI63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40185; true Male 21095907 CVCL_HI64 CW40206 induced pluripotent stem cell human CVCL_HI64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40206; true Male 21095908 CVCL_HI65 CW40209 induced pluripotent stem cell human CVCL_HI65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40209; true Female 21095909 CVCL_HI80 CW50075 induced pluripotent stem cell human CVCL_HI80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50075; true Male 21095910 CVCL_HI81 CW50101 induced pluripotent stem cell human CVCL_HI81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50101; true Female 21095911 CVCL_HI82 CW50108 induced pluripotent stem cell human CVCL_HI82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50108; true Female 21095912 CVCL_HI83 CW50113 induced pluripotent stem cell human CVCL_HI83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50113; true Male 21095913 CVCL_QC00 BayGenomics ES cell line XK518 embryonic stem cell house mouse CVCL_QC00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095914 CVCL_QC01 BayGenomics ES cell line XK521 embryonic stem cell house mouse CVCL_QC01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330299; Dyrk1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095915 CVCL_QC02 BayGenomics ES cell line XK522 embryonic stem cell house mouse CVCL_QC02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142523; Crtc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095916 CVCL_QC03 BayGenomics ES cell line XK523 embryonic stem cell house mouse CVCL_QC03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99400; Atp7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095917 CVCL_HI77 CW50068 induced pluripotent stem cell human CVCL_HI77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50068; true Female 21095918 CVCL_QC04 BayGenomics ES cell line XK524 embryonic stem cell house mouse CVCL_QC04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095919 CVCL_HI78 CW50073 induced pluripotent stem cell human CVCL_HI78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50073; true Female 21095920 CVCL_QC05 BayGenomics ES cell line XK525 embryonic stem cell house mouse CVCL_QC05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917887; Ankrd26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095921 CVCL_HI79 CW50074 induced pluripotent stem cell human CVCL_HI79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50074; true Female 21095922 CVCL_QC06 BayGenomics ES cell line XK527 embryonic stem cell house mouse CVCL_QC06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347045; Psmb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095923 CVCL_QC07 BayGenomics ES cell line XK529 embryonic stem cell house mouse CVCL_QC07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860486; Tdp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095924 CVCL_HI73 CW40235 induced pluripotent stem cell human CVCL_HI73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40235; true Male 21095925 CVCL_QC08 BayGenomics ES cell line XK530 embryonic stem cell house mouse CVCL_QC08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918006; Dock4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095926 CVCL_HI74 CW40243 induced pluripotent stem cell human CVCL_HI74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40243; true Male 21095927 CVCL_QC09 BayGenomics ES cell line XK531 embryonic stem cell house mouse CVCL_QC09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918006; Dock4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21095928 CVCL_HI75 CW50021 induced pluripotent stem cell human CVCL_HI75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50021; true Female 21095929 CVCL_HI76 CW50040 induced pluripotent stem cell human CVCL_HI76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50040; true Male 21095930 CVCL_HI50 CW40038 induced pluripotent stem cell human CVCL_HI50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40038; true. Male 21095931 CVCL_HI48 CW40018 induced pluripotent stem cell human CVCL_HI48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40018; true. Male 21095932 CVCL_HI49 CW40020 induced pluripotent stem cell human CVCL_HI49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40020; true. Male 21095933 CVCL_HI44 CW30508 induced pluripotent stem cell human CVCL_HI44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30508; true Female 21095934 CVCL_HI45 CW30509 induced pluripotent stem cell human CVCL_HI45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30509; true Male 21095935 CVCL_HI46 CW30510 induced pluripotent stem cell human CVCL_HI46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30510; true Male 21095936 CVCL_HI47 CW40017 induced pluripotent stem cell human CVCL_HI47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40017; true. Male 21095937 CVCL_HI40 CW30500 induced pluripotent stem cell human CVCL_HI40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30500; true Male 21095938 CVCL_HI41 CW30501 induced pluripotent stem cell human CVCL_HI41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30501; true Female 21095939 CVCL_HI42 CW30505 induced pluripotent stem cell human CVCL_HI42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30505; true Female 21095940 CVCL_HI43 CW30506 induced pluripotent stem cell human CVCL_HI43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30506; true Female 21095941 CVCL_HI60 CW40144 induced pluripotent stem cell human CVCL_HI60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40144; true Male 21095942 CVCL_HI61 CW40152 induced pluripotent stem cell human CVCL_HI61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40152; true Male 21095943 CVCL_HI59 CW40127 induced pluripotent stem cell human CVCL_HI59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40127; true Male 21095944 CVCL_HI55 CW40079 induced pluripotent stem cell human CVCL_HI55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40079; true. Female 21095945 CVCL_HI56 CW40081 induced pluripotent stem cell human CVCL_HI56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40081; true. Female 21095946 CVCL_HI57 CW40092 induced pluripotent stem cell human CVCL_HI57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40092; true Male 21095947 CVCL_HI58 CW40100 induced pluripotent stem cell human CVCL_HI58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40100; true Male 21095948 CVCL_HI51 CW40042 induced pluripotent stem cell human CVCL_HI51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40042; true. Male 21095949 CVCL_HI52 CW40046 induced pluripotent stem cell human CVCL_HI52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW40046; true. Male 21095950 CVCL_HI53 CW40047 induced pluripotent stem cell human CVCL_HI53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40047; true. Male 21095951 CVCL_HI54 CW40054 induced pluripotent stem cell human CVCL_HI54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40054; true Male 21095952 CVCL_HI26 CW30480 induced pluripotent stem cell human CVCL_HI26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30480; true Male 21095953 CVCL_HI27 CW30481 induced pluripotent stem cell human CVCL_HI27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30481; true Male 21095954 CVCL_HI28 CW30484 induced pluripotent stem cell human CVCL_HI28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30484; true Female 21095955 CVCL_HI29 CW30485 induced pluripotent stem cell human CVCL_HI29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30485; true Male 21095956 CVCL_HI22 CW30476 induced pluripotent stem cell human CVCL_HI22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30476; true Male 21095957 CVCL_HI23 CW30477 induced pluripotent stem cell human CVCL_HI23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30477; true Male 21095958 CVCL_HI24 CW30478 induced pluripotent stem cell human CVCL_HI24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30478; true Female 21095959 CVCL_HI25 CW30479 induced pluripotent stem cell human CVCL_HI25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30479; true Male 21095960 CVCL_HI20 CW30472 induced pluripotent stem cell human CVCL_HI20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30472; true Female 21095961 CVCL_HI21 CW30473 induced pluripotent stem cell human CVCL_HI21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30473; true Male 21095962 CVCL_HI37 CW30496 induced pluripotent stem cell human CVCL_HI37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30496; true Male 21095963 CVCL_HI38 CW30497 induced pluripotent stem cell human CVCL_HI38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30497; true Female 21095964 CVCL_HI39 CW30499 induced pluripotent stem cell human CVCL_HI39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30499; true Male 21095965 CVCL_HI33 CW30490 induced pluripotent stem cell human CVCL_HI33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30490; true Male 21095966 CVCL_HI34 CW30491 induced pluripotent stem cell human CVCL_HI34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30491; true Male 21095967 CVCL_HI35 CW30492 induced pluripotent stem cell human CVCL_HI35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30492; true Female 21095968 CVCL_HI36 CW30495 induced pluripotent stem cell human CVCL_HI36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30495; true Male 21095969 CVCL_HI30 CW30486 induced pluripotent stem cell human CVCL_HI30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30486; true Male 21095970 CVCL_HI31 CW30488 induced pluripotent stem cell human CVCL_HI31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30488; true Male 21095971 CVCL_HI32 CW30489 induced pluripotent stem cell human CVCL_HI32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30489; true Male 21095972 CVCL_HI08 CW30457 induced pluripotent stem cell human CVCL_HI08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30457; true Female 21095973 CVCL_HI09 CW30459 induced pluripotent stem cell human CVCL_HI09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30459; true Female 21095974 CVCL_HI04 CW30453 induced pluripotent stem cell human CVCL_HI04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30453; true Male 21095975 CVCL_HI05 CW30454 induced pluripotent stem cell human CVCL_HI05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30454; true Male 21095976 CVCL_HI06 CW30455 induced pluripotent stem cell human CVCL_HI06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30455; true Female 21095977 CVCL_HI07 CW30456 induced pluripotent stem cell human CVCL_HI07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30456; true Male 21095978 CVCL_HI00 CW30447 induced pluripotent stem cell human CVCL_HI00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30447; true Female 21095979 CVCL_HI01 CW30448 induced pluripotent stem cell human CVCL_HI01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30448; true Female 21095980 CVCL_HI02 CW30449 induced pluripotent stem cell human CVCL_HI02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30449; true Male 21095981 CVCL_HI03 CW30450 induced pluripotent stem cell human CVCL_HI03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30450; true Male 21095982 CVCL_HI19 CW30471 induced pluripotent stem cell human CVCL_HI19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30471; true Male 21095983 CVCL_HI15 CW30466 induced pluripotent stem cell human CVCL_HI15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30466; true Female 21095984 CVCL_HI16 CW30467 induced pluripotent stem cell human CVCL_HI16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30467; true Female 21095985 CVCL_HI17 CW30468 induced pluripotent stem cell human CVCL_HI17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30468; true Female 21095986 CVCL_HI18 CW30470 induced pluripotent stem cell human CVCL_HI18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30470; true Male 21095987 CVCL_HI11 CW30461 induced pluripotent stem cell human CVCL_HI11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30461; true Male 21095988 CVCL_HI12 CW30463 induced pluripotent stem cell human CVCL_HI12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30463; true Male 21095989 CVCL_HI13 CW30464 induced pluripotent stem cell human CVCL_HI13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30464; true Female 21095990 CVCL_HI14 CW30465 induced pluripotent stem cell human CVCL_HI14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30465; true Female 21095991 CVCL_HI10 CW30460 induced pluripotent stem cell human CVCL_HI10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30460; true Male 21095992 CVCL_HB10 ZP113 transformed cell line CVCL_HB10 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095993 CVCL_HB11 ZP114 transformed cell line CVCL_HB11 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095994 CVCL_HB12 ZP115 transformed cell line CVCL_HB12 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095995 CVCL_HB13 ZP116 transformed cell line CVCL_HB13 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095996 CVCL_HB07 ZP110 transformed cell line CVCL_HB07 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095997 CVCL_HB08 ZP111 transformed cell line CVCL_HB08 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095998 CVCL_HB09 ZP112 transformed cell line CVCL_HB09 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21095999 CVCL_HB03 ZP106 transformed cell line CVCL_HB03 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096000 CVCL_HB04 ZP107 transformed cell line CVCL_HB04 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096001 CVCL_HB05 ZP108 transformed cell line CVCL_HB05 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096002 CVCL_HB06 ZP109 transformed cell line CVCL_HB06 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096003 CVCL_HB21 ZP151 transformed cell line CVCL_HB21 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096004 CVCL_HB22 ZP158 transformed cell line CVCL_HB22 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096005 CVCL_HB23 ZP159 transformed cell line CVCL_HB23 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096006 CVCL_HB24 ZP160 transformed cell line CVCL_HB24 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096007 CVCL_HB20 ZP150 transformed cell line CVCL_HB20 CL:0000010 Sequence variation: Mutation; UniProtKB; Q9QYL1; Pex13; Simple; p.Asp265_Lys306del (c.793_918del126); Zygosity=Heterozygous (PubMed=10441330); Sequence variation: Mutation; UniProtKB; Q9QYL1; Pex13; Simple; p.Ser319Asn (c.956G>A); Zygosity=Heterozygous (PubMed=10441330); Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096008 CVCL_HB18 ZP128 transformed cell line CVCL_HB18 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096009 CVCL_HB19 ZP139 transformed cell line CVCL_HB19 CL:0000010 Sequence variation: Mutation; UniProtKB; Q920N5; Pex5; Simple; p.Gly530Glu (c.1589G>A) (G480E); Zygosity=Homozygous (PubMed=9418886); Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096010 CVCL_HB14 ZP117 transformed cell line CVCL_HB14 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096011 CVCL_HB15 ZP118 transformed cell line CVCL_HB15 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096012 CVCL_HB16 ZP119 transformed cell line CVCL_HB16 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096013 CVCL_HB17 ZP120 transformed cell line CVCL_HB17 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096014 CVCL_HB00 ZP103 transformed cell line CVCL_HB00 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096015 CVCL_HB01 ZP104 transformed cell line CVCL_HB01 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096016 CVCL_HB02 ZP105 transformed cell line CVCL_HB02 CL:0000010 Sequence variation: Mutation; UniProtKB; Q920N5; Pex5; Simple; p.Gly343Glu (c.1028G>A) (G298E); Zygosity=Homozygous (PubMed=9418886); Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096017 CVCL_6N81 DA00703 transformed cell line human CVCL_6N81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096018 CVCL_6N82 DA00704 transformed cell line human CVCL_6N82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096019 CVCL_6N83 DA00705 transformed cell line human CVCL_6N83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096020 CVCL_6N84 DA00706 transformed cell line human CVCL_6N84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096021 CVCL_6N80 DA00702 transformed cell line human CVCL_6N80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096022 CVCL_6N89 DA00711 transformed cell line human CVCL_6N89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096023 CVCL_6N85 DA00707 transformed cell line human CVCL_6N85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096024 CVCL_6N86 DA00708 transformed cell line human CVCL_6N86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096025 CVCL_6N87 DA00709 transformed cell line human CVCL_6N87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096026 CVCL_6N88 DA00710 transformed cell line human CVCL_6N88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096027 CVCL_6N92 DA00714 transformed cell line human CVCL_6N92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096028 CVCL_6N93 DA00715 transformed cell line human CVCL_6N93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096029 CVCL_6N94 DA00716 transformed cell line human CVCL_6N94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096030 CVCL_6N95 DA00717 transformed cell line human CVCL_6N95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096031 CVCL_6N90 DA00712 transformed cell line human CVCL_6N90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096032 CVCL_6N91 DA00713 transformed cell line human CVCL_6N91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096033 CVCL_6N96 DA00718 transformed cell line human CVCL_6N96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096034 CVCL_6N97 DA00720 transformed cell line human CVCL_6N97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096035 CVCL_6N98 DA00721 transformed cell line human CVCL_6N98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096036 CVCL_6N99 DA00722 transformed cell line human CVCL_6N99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096037 CVCL_HB98 NoCa9 transformed cell line human CVCL_HB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096038 CVCL_HB99 NoCa10 transformed cell line human CVCL_HB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096039 CVCL_HB94 NoCa5 transformed cell line human CVCL_HB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096040 CVCL_HB95 NoCa6 transformed cell line human CVCL_HB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096041 CVCL_HB96 NoCa7 transformed cell line human CVCL_HB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096042 CVCL_HB97 NoCa8 transformed cell line human CVCL_HB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096043 CVCL_HB90 NoCa1 transformed cell line human CVCL_HB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096044 CVCL_HB91 NoCa2 transformed cell line human CVCL_HB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096045 CVCL_HB92 NoCa3 transformed cell line human CVCL_HB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096046 CVCL_HB93 NoCa4 transformed cell line human CVCL_HB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096047 CVCL_HB76 ZPG209 spontaneously immortalized cell line CVCL_HB76 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096048 CVCL_HB77 ZPG210 spontaneously immortalized cell line CVCL_HB77 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096049 CVCL_HB78 BHK-21/WI-2 spontaneously immortalized cell line CVCL_HB78 CL:0000010 Derived from sampling site: Kidney. Male 21096050 CVCL_HB79 BHK-MP1 spontaneously immortalized cell line CVCL_HB79 CL:0000010 Derived from sampling site: Kidney. Male Virology: In vitro persistently infected by rubella virus strain M33 21096051 CVCL_HB72 ZPG205 spontaneously immortalized cell line CVCL_HB72 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096052 CVCL_HB73 ZPG206 spontaneously immortalized cell line CVCL_HB73 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096053 CVCL_HB74 ZPG207 spontaneously immortalized cell line CVCL_HB74 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096054 CVCL_HB75 ZPG208 spontaneously immortalized cell line CVCL_HB75 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096055 CVCL_HB70 ZPG118 spontaneously immortalized cell line CVCL_HB70 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096056 CVCL_HB71 ZPG203 spontaneously immortalized cell line CVCL_HB71 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096057 CVCL_HB69 ZPG117 spontaneously immortalized cell line CVCL_HB69 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096058 CVCL_HB87 HEKR3 transformed cell line human CVCL_HB87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096059 CVCL_HB88 HEKR3R1 transformed cell line human CVCL_HB88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096060 CVCL_HB89 Z65 transformed cell line CVCL_HB89 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21096061 CVCL_HB83 HEKR1 transformed cell line human CVCL_HB83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096062 CVCL_HB84 HEKR2 transformed cell line human CVCL_HB84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096063 CVCL_HB85 HEKR2R1 transformed cell line human CVCL_HB85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096064 CVCL_HB86 HEKR2R3 transformed cell line human CVCL_HB86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096065 CVCL_HB80 BHK-MP2 spontaneously immortalized cell line CVCL_HB80 CL:0000010 Derived from sampling site: Kidney. Male Virology: In vitro persistently infected by rubella virus strain M33 21096066 CVCL_HB81 Cb-E1A transformed cell line Norway rat CVCL_HB81 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5 [E1A(NCBI-Taxonomy; 28285); Derived from sampling site: Brain Cell type=Cerebellar granule cell.. Unspecified Characteristics: Can be used as a model system for differentiated cerebellar granule neurons Doubling time: 24 hours (Kerafast) 21096067 CVCL_HB82 HEK-3KO transformed cell line human CVCL_HB82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096068 CVCL_HB54 ZPEG240 transformed cell line CVCL_HB54 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096069 CVCL_HB55 ZPEG241 transformed cell line CVCL_HB55 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096070 CVCL_HB56 ZPEG242 transformed cell line CVCL_HB56 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096071 CVCL_HB57 ZPEG243 transformed cell line CVCL_HB57 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096072 CVCL_HB50 ZPEG236 transformed cell line CVCL_HB50 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096073 CVCL_HB51 ZPEG237 transformed cell line CVCL_HB51 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096074 CVCL_HB52 ZPEG238 transformed cell line CVCL_HB52 CL:0000010 Sequence variation: Mutation; UniProtKB; Q9JJK3; Pex3; Simple; p.Asn7Glufs*32 (c.18dupG); Zygosity=Homozygous (PubMed=18543353); Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096075 CVCL_HB53 ZPEG239 transformed cell line CVCL_HB53 CL:0000010 Sequence variation: Mutation; UniProtKB; Q06438; Pex2; Simple; p.Glu201Ter (c.601G>T); Zygosity=Homozygous (PubMed=18543353); Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096076 CVCL_HB47 ZPEG233 transformed cell line CVCL_HB47 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096077 CVCL_HB48 ZPEG234 transformed cell line CVCL_HB48 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096078 CVCL_HB49 ZPEG235 transformed cell line CVCL_HB49 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096079 CVCL_HB65 ZPG102 spontaneously immortalized cell line CVCL_HB65 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096080 CVCL_HB66 ZPG103 spontaneously immortalized cell line CVCL_HB66 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096081 CVCL_HB67 ZPG113 spontaneously immortalized cell line CVCL_HB67 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096082 CVCL_HB68 ZPG115 spontaneously immortalized cell line CVCL_HB68 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096083 CVCL_HB61 ZPEG247 transformed cell line CVCL_HB61 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096084 CVCL_HB62 CHOTKaG1 spontaneously immortalized cell line CVCL_HB62 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Female Characteristics: Contains a PTS1-fused GFP 21096085 CVCL_HB63 CHOTKaG2 spontaneously immortalized cell line CVCL_HB63 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Female Characteristics: Contains a PTS2-fused GFP 21096086 CVCL_HB64 ZPG101 spontaneously immortalized cell line CVCL_HB64 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096087 CVCL_HB60 ZPEG246 transformed cell line CVCL_HB60 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096088 CVCL_HB58 ZPEG244 transformed cell line CVCL_HB58 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096089 CVCL_HB59 ZPEG245 transformed cell line CVCL_HB59 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096090 CVCL_HB32 ZP92 transformed cell line CVCL_HB32 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096091 CVCL_HB33 ZP125 transformed cell line CVCL_HB33 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096092 CVCL_HB34 CHOTKa spontaneously immortalized cell line CVCL_HB34 CL:0000010 Transfected with: RGD; 61814; Pex2 Derived from sampling site: Ovary. Female 21096093 CVCL_HB35 Z24 transformed cell line CVCL_HB35 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21096094 CVCL_HB30 ZP166 transformed cell line CVCL_HB30 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096095 CVCL_HB31 ZP167 transformed cell line CVCL_HB31 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096096 CVCL_HB29 ZP165 transformed cell line CVCL_HB29 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096097 CVCL_HB25 ZP161 transformed cell line CVCL_HB25 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096098 CVCL_HB26 ZP162 transformed cell line CVCL_HB26 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096099 CVCL_HB27 ZP163 transformed cell line CVCL_HB27 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096100 CVCL_HB28 ZP164 transformed cell line CVCL_HB28 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096101 CVCL_HB43 ZPEG229 transformed cell line CVCL_HB43 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096102 CVCL_HB44 ZPEG230 transformed cell line CVCL_HB44 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096103 CVCL_HB45 ZPEG231 transformed cell line CVCL_HB45 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Does not express Pex7 mRNA 21096104 CVCL_HB46 ZPEG232 transformed cell line CVCL_HB46 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096105 CVCL_HB40 ZPEG224 transformed cell line CVCL_HB40 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096106 CVCL_HB41 ZPEG227 transformed cell line CVCL_HB41 CL:0000010 Sequence variation: Mutation; UniProtKB; Q8R537; Pex7; Simple; p.Trp158Ter (c.474G>A); Zygosity=Unspecified (PubMed=12054588); Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096107 CVCL_HB42 ZPEG228 transformed cell line CVCL_HB42 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096108 CVCL_HB36 CHOTKaEG1 spontaneously immortalized cell line CVCL_HB36 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Ovary. Female Characteristics: Contains a PTS1-fused EGFP 21096109 CVCL_HB37 CHOTKaEG2 spontaneously immortalized cell line CVCL_HB37 CL:0000010 Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Ovary. Female Characteristics: Contains a PTS2-fused EGFP 21096110 CVCL_HB38 ZPEG101 transformed cell line CVCL_HB38 CL:0000010 Sequence variation: Mutation; UniProtKB; Q920N5; Pex5; Simple; p.Leu74Profs*14 (c.147dupC); Zygosity=Homozygous (PubMed=23009329); Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096111 CVCL_HB39 ZPEG252 transformed cell line CVCL_HB39 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A061IQK5; Pex1; Simple; p.Gly569Glu (c.1706G>A) (Gly606Glu; G1817A); Zygosity=Homozygous (PubMed=16723118); Transfected with: RGD; 61814; Pex2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21096112 CVCL_Z528 SES-BoMo-J125K5 spontaneously immortalized cell line CVCL_Z528 CL:0000010 Breed/subspecies: J125. Unspecified Doubling time: 4.12 days (CelloPub=CLPUB00193) Group: Insect cell line 21096113 CVCL_Z529 SES-BoMo-J125K6 spontaneously immortalized cell line CVCL_Z529 CL:0000010 Breed/subspecies: J125. Unspecified Doubling time: 5.41 days (CelloPub=CLPUB00193) Group: Insect cell line 21096114 CVCL_PZ90 BayGenomics ES cell line XJ059 embryonic stem cell house mouse CVCL_PZ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096115 CVCL_Z524 Se6FHA spontaneously immortalized cell line CVCL_Z524 CL:0000010 Unspecified Doubling time: 19.35 +- 2.78 hours (PubMed=8167910). Group: Insect cell line 21096116 CVCL_PZ91 BayGenomics ES cell line XJ075 embryonic stem cell house mouse CVCL_PZ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096117 CVCL_Z525 Se6FHB spontaneously immortalized cell line CVCL_Z525 CL:0000010 Unspecified Doubling time: 23.0 +- 4.7 hours (PubMed=8167910). Group: Insect cell line 21096118 CVCL_PZ92 BayGenomics ES cell line XJ080 embryonic stem cell house mouse CVCL_PZ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104729; Akap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096119 CVCL_Z526 SES-BoMo-J125K1 spontaneously immortalized cell line CVCL_Z526 CL:0000010 Breed/subspecies: J125. Unspecified Doubling time: 5.41 days (CelloPub=CLPUB00193) Group: Insect cell line 21096120 CVCL_PZ93 BayGenomics ES cell line XJ101 embryonic stem cell house mouse CVCL_PZ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096121 CVCL_Z527 SES-BoMo-J125K2 spontaneously immortalized cell line CVCL_Z527 CL:0000010 Breed/subspecies: J125. Unspecified Doubling time: 1.96 days (CelloPub=CLPUB00193) Group: Insect cell line; Group: Recombinant protein production insect cell line 21096122 CVCL_PZ94 BayGenomics ES cell line XJ116 embryonic stem cell house mouse CVCL_PZ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925201; Cyp20a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096123 CVCL_PZ95 BayGenomics ES cell line XJ119 embryonic stem cell house mouse CVCL_PZ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858683; Copg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096124 CVCL_PZ96 BayGenomics ES cell line XJ130 embryonic stem cell house mouse CVCL_PZ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924514; Zfp142 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096125 CVCL_PZ97 BayGenomics ES cell line XJ132 embryonic stem cell house mouse CVCL_PZ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096398; Cd81 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096126 CVCL_PZ98 BayGenomics ES cell line XJ135 embryonic stem cell house mouse CVCL_PZ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096127 CVCL_PZ99 BayGenomics ES cell line XJ139 embryonic stem cell house mouse CVCL_PZ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109299; Polr2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096128 CVCL_Z531 KUN-DH-15 spontaneously immortalized cell line CVCL_Z531 CL:0000010 Unspecified Group: Insect cell line. 21096129 CVCL_Z532 KUN-DH-33 spontaneously immortalized cell line CVCL_Z532 CL:0000010 Male Doubling time: 22-24 hours, depending on growth medium (DGRC). Group: Insect cell line 21096130 CVCL_Z533 KUN-DH-47 spontaneously immortalized cell line CVCL_Z533 CL:0000010 Unspecified Group: Insect cell line. 21096131 CVCL_Z534 Ana-104 spontaneously immortalized cell line CVCL_Z534 CL:0000010 Unspecified Group: Insect cell line. 21096132 CVCL_Z530 KUN-DH-14 spontaneously immortalized cell line CVCL_Z530 CL:0000010 Unspecified Group: Insect cell line. 21096133 CVCL_Z517 LWSK spontaneously immortalized cell line CVCL_Z517 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 21096134 CVCL_Z518 PSCF spontaneously immortalized cell line CVCL_Z518 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21096135 CVCL_Z519 TUAT-SpLi-221 spontaneously immortalized cell line CVCL_Z519 CL:0000010 Discontinued: RCB; RCB0406; probable. Female Group: Insect cell line 21096136 CVCL_Z513 LJL spontaneously immortalized cell line CVCL_Z513 CL:0000010 Derived from sampling site: Liver. Unspecified Doubling time: 57 hours (DOI=10.1111/j.1095-8649.2006.01155.x) Group: Fish cell line 21096137 CVCL_PZ80 BayGenomics ES cell line XI459 embryonic stem cell house mouse CVCL_PZ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917829; Zc3h11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096138 CVCL_Z514 LJS spontaneously immortalized cell line CVCL_Z514 CL:0000010 Derived from sampling site: Spleen. Unspecified Doubling time: 52.7 hours (DOI=10.1111/j.1095-8649.2006.01155.x) Group: Fish cell line 21096139 CVCL_PZ81 BayGenomics ES cell line XI469 embryonic stem cell house mouse CVCL_PZ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444576; Kif20b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096140 CVCL_Z515 CPB spontaneously immortalized cell line CVCL_Z515 CL:0000010 Derived from sampling site: Brain Cell type=Fibroblast.. Unspecified Group: Fish cell line 21096141 CVCL_PZ82 BayGenomics ES cell line XI470 embryonic stem cell house mouse CVCL_PZ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919742; Smg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096142 CVCL_Z516 LWFN spontaneously immortalized cell line CVCL_Z516 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21096143 CVCL_PZ83 BayGenomics ES cell line XI473 embryonic stem cell house mouse CVCL_PZ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914120; Serbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096144 CVCL_PZ84 BayGenomics ES cell line XI478 embryonic stem cell house mouse CVCL_PZ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919742; Smg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096145 CVCL_PZ85 BayGenomics ES cell line XI486 embryonic stem cell house mouse CVCL_PZ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889272; Cadm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096146 CVCL_PZ86 BayGenomics ES cell line XJ018 embryonic stem cell house mouse CVCL_PZ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096147 CVCL_PZ87 BayGenomics ES cell line XJ022 embryonic stem cell house mouse CVCL_PZ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918367; Rbbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096148 CVCL_PZ88 BayGenomics ES cell line XJ023 embryonic stem cell house mouse CVCL_PZ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925349; Atrip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096149 CVCL_PZ89 BayGenomics ES cell line XJ042 embryonic stem cell house mouse CVCL_PZ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029632; Med13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096150 CVCL_Z520 Se301 spontaneously immortalized cell line CVCL_Z520 CL:0000010 Unspecified Group: Insect cell line. 21096151 CVCL_Z521 Se3FH spontaneously immortalized cell line CVCL_Z521 CL:0000010 Unspecified Doubling time: 30.09 +- 4.97 hours (PubMed=8167910). Group: Insect cell line 21096152 CVCL_Z522 Se4FH spontaneously immortalized cell line CVCL_Z522 CL:0000010 Unspecified Doubling time: 37.48 +- 6.15 hours (PubMed=8167910). Group: Insect cell line 21096153 CVCL_Z523 Se5FH spontaneously immortalized cell line CVCL_Z523 CL:0000010 Unspecified Doubling time: 21.75 +- 6.69 hours (PubMed=8167910). Group: Insect cell line 21096154 CVCL_Z506 TTCF spontaneously immortalized cell line CVCL_Z506 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Endangered species/breed cell line; Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC003 21096155 CVCL_Z507 KF-101 spontaneously immortalized cell line CVCL_Z507 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Koi. Unspecified Doubling time: ~41 hours (PubMed=23731143) Group: Fish cell line 21096156 CVCL_Z508 MES1 embryonic stem cell CVCL_Z508 CL:0000010 Unspecified Group: Fish cell line. 21096157 CVCL_Z509 CCES embryonic stem cell CVCL_Z509 CL:0000010 Unspecified Group: Fish cell line. 21096158 CVCL_Z502 MB-03C5-688 spontaneously immortalized cell line CVCL_Z502 CL:0000010 Unspecified Group: Insect cell line. 21096159 CVCL_Z503 IPLB-Tex2 spontaneously immortalized cell line CVCL_Z503 CL:0000010 Unspecified Doubling time: 50 hours (PubMed=1799679) Group: Insect cell line 21096160 CVCL_PZ70 BayGenomics ES cell line XI374 embryonic stem cell house mouse CVCL_PZ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096161 CVCL_Z504 IPLB-Tcon1 spontaneously immortalized cell line CVCL_Z504 CL:0000010 Unspecified Doubling time: 29 hours (PubMed=1799679). Group: Insect cell line 21096162 CVCL_PZ71 BayGenomics ES cell line XI401 embryonic stem cell house mouse CVCL_PZ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096163 CVCL_Z505 KSG spontaneously immortalized cell line CVCL_Z505 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: 40 hours (PubMed=24399253) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM AP-21161 21096164 CVCL_PZ72 BayGenomics ES cell line XI402 embryonic stem cell house mouse CVCL_PZ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278322; Epc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096165 CVCL_PZ73 BayGenomics ES cell line XI426 embryonic stem cell house mouse CVCL_PZ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109349; Atf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096166 CVCL_PZ74 BayGenomics ES cell line XI444 embryonic stem cell house mouse CVCL_PZ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913906; Eef1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096167 CVCL_PZ75 BayGenomics ES cell line XI445 embryonic stem cell house mouse CVCL_PZ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913906; Eef1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096168 CVCL_PZ76 BayGenomics ES cell line XI446 embryonic stem cell house mouse CVCL_PZ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96622; Itpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096169 CVCL_PZ77 BayGenomics ES cell line XI447 embryonic stem cell house mouse CVCL_PZ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928380; B4galt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096170 CVCL_PZ78 BayGenomics ES cell line XI452 embryonic stem cell house mouse CVCL_PZ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096171 CVCL_PZ79 BayGenomics ES cell line XI456 embryonic stem cell house mouse CVCL_PZ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096172 CVCL_Z510 LJH-1 spontaneously immortalized cell line CVCL_Z510 CL:0000010 Derived from sampling site: Heart. Unspecified Doubling time: 54.9 hours (DOI=10.1111/j.1095-8649.2006.01155.x) Group: Fish cell line 21096173 CVCL_Z511 LJH-2 spontaneously immortalized cell line CVCL_Z511 CL:0000010 Derived from sampling site: Heart. Unspecified Doubling time: 58.7 hours (DOI=10.1111/j.1095-8649.2006.01155.x) Group: Fish cell line 21096174 CVCL_Z512 LJHK spontaneously immortalized cell line CVCL_Z512 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 66 hours (DOI=10.1111/j.1095-8649.2006.01155.x) Group: Fish cell line 21096175 CVCL_PZ60 BayGenomics ES cell line XH952 embryonic stem cell house mouse CVCL_PZ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924234; Katnal2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096176 CVCL_PZ61 BayGenomics ES cell line XH984 embryonic stem cell house mouse CVCL_PZ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096177 CVCL_PZ62 BayGenomics ES cell line XI223 embryonic stem cell house mouse CVCL_PZ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913666; Ndufa7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096178 CVCL_PZ63 BayGenomics ES cell line XI250 embryonic stem cell house mouse CVCL_PZ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889023; Banp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096179 CVCL_PZ64 BayGenomics ES cell line XI253 embryonic stem cell house mouse CVCL_PZ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913906; Eef1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096180 CVCL_PZ65 BayGenomics ES cell line XI335 embryonic stem cell house mouse CVCL_PZ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443241; Ndufs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096181 CVCL_PZ66 BayGenomics ES cell line XI339 embryonic stem cell house mouse CVCL_PZ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914120; Serbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096182 CVCL_PZ67 BayGenomics ES cell line XI340 embryonic stem cell house mouse CVCL_PZ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313286; Eif2b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096183 CVCL_PZ68 BayGenomics ES cell line XI346 embryonic stem cell house mouse CVCL_PZ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096184 CVCL_PZ69 BayGenomics ES cell line XI369 embryonic stem cell house mouse CVCL_PZ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919849; Pdia5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096185 CVCL_Z500 AS-H 4 spontaneously immortalized cell line CVCL_Z500 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 2.5 days (DOI=10.1080/03235409009438961) Group: Insect cell line 21096186 CVCL_Z501 MB-03C4 spontaneously immortalized cell line CVCL_Z501 CL:0000010 Unspecified Group: Insect cell line. 21096187 CVCL_PZ50 BayGenomics ES cell line XH895 embryonic stem cell house mouse CVCL_PZ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137355; Trim11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096188 CVCL_PZ51 BayGenomics ES cell line XH897 embryonic stem cell house mouse CVCL_PZ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673965; Tmem60 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096189 CVCL_PZ52 BayGenomics ES cell line XH901 embryonic stem cell house mouse CVCL_PZ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921461; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096190 CVCL_PZ53 BayGenomics ES cell line XH905 embryonic stem cell house mouse CVCL_PZ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181182; Nup155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096191 CVCL_PZ54 BayGenomics ES cell line XH908 embryonic stem cell house mouse CVCL_PZ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096192 CVCL_PZ55 BayGenomics ES cell line XH920 embryonic stem cell house mouse CVCL_PZ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096193 CVCL_PZ56 BayGenomics ES cell line XH922 embryonic stem cell house mouse CVCL_PZ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443876; Zbtb11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096194 CVCL_PZ57 BayGenomics ES cell line XH923 embryonic stem cell house mouse CVCL_PZ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924057; Phf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096195 CVCL_PZ58 BayGenomics ES cell line XH925 embryonic stem cell house mouse CVCL_PZ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338068; Pdpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096196 CVCL_PZ59 BayGenomics ES cell line XH930 embryonic stem cell house mouse CVCL_PZ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096197 CVCL_PZ40 BayGenomics ES cell line XH857 embryonic stem cell house mouse CVCL_PZ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914632; Brd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096198 CVCL_PZ41 BayGenomics ES cell line XH859 embryonic stem cell house mouse CVCL_PZ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917167; Nabp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096199 CVCL_PZ42 BayGenomics ES cell line XH862 embryonic stem cell house mouse CVCL_PZ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95485; Fasn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096200 CVCL_PZ43 BayGenomics ES cell line XH863 embryonic stem cell house mouse CVCL_PZ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88071; Arnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096201 CVCL_PZ44 BayGenomics ES cell line XH865 embryonic stem cell house mouse CVCL_PZ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096202 CVCL_PZ45 BayGenomics ES cell line XH866 embryonic stem cell house mouse CVCL_PZ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104652; Capzb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096203 CVCL_PZ46 BayGenomics ES cell line XH881 embryonic stem cell house mouse CVCL_PZ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096204 CVCL_PZ47 BayGenomics ES cell line XH886 embryonic stem cell house mouse CVCL_PZ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096205 CVCL_PZ48 BayGenomics ES cell line XH891 embryonic stem cell house mouse CVCL_PZ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921285; Nol9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096206 CVCL_PZ49 BayGenomics ES cell line XH892 embryonic stem cell house mouse CVCL_PZ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700012; Ostf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096207 CVCL_HA99 ZP102 transformed cell line CVCL_HA99 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096208 CVCL_HA95 ZP122 transformed cell line CVCL_HA95 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096209 CVCL_HA96 ZP123 transformed cell line CVCL_HA96 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096210 CVCL_HA97 ZP137 transformed cell line CVCL_HA97 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096211 CVCL_HA98 ZP101 transformed cell line CVCL_HA98 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21096212 CVCL_HA91 KB/BF-2 cancer cell line human CVCL_HA91 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:48080; Brefeldin A (BFA); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21096213 CVCL_HA92 FEMX-V cancer cell line human CVCL_HA92 CL:0000010 Derived from metastatic site: Lymph node. Female Characteristics: Established from a fifth generation nude mouse xenograft of the original tumor; Characteristics: Cell line with no metastatic potential 21096214 CVCL_PZ30 BayGenomics ES cell line XH845 embryonic stem cell house mouse CVCL_PZ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102944; Ube2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096215 CVCL_HA93 FEMX-I/SUPERctr cancer cell line human CVCL_HA93 CL:0000010 Derived from metastatic site: Lymph node. Female Characteristics: Control cell line for FEMX-I/SUPER733 (Cellosaurus=CVCL_HA94) 21096216 CVCL_PZ31 BayGenomics ES cell line XH846 embryonic stem cell house mouse CVCL_PZ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096217 CVCL_HA94 FEMX-I/SUPER733 cancer cell line human CVCL_HA94 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 9454; PROM1 Derived from metastatic site: Lymph node. Female 21096218 CVCL_PZ32 BayGenomics ES cell line XH847 embryonic stem cell house mouse CVCL_PZ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096219 CVCL_PZ33 BayGenomics ES cell line XH848 embryonic stem cell house mouse CVCL_PZ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109452; Smad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096220 CVCL_PZ34 BayGenomics ES cell line XH849 embryonic stem cell house mouse CVCL_PZ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858419; Bysl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096221 CVCL_PZ35 BayGenomics ES cell line XH850 embryonic stem cell house mouse CVCL_PZ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913687; Fis1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096222 CVCL_HA90 KB/BF-1 cancer cell line human CVCL_HA90 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:48080; Brefeldin A (BFA); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21096223 CVCL_PZ36 BayGenomics ES cell line XH852 embryonic stem cell house mouse CVCL_PZ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096224 CVCL_PZ37 BayGenomics ES cell line XH853 embryonic stem cell house mouse CVCL_PZ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096225 CVCL_PZ38 BayGenomics ES cell line XH855 embryonic stem cell house mouse CVCL_PZ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145578; Slain1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096226 CVCL_PZ39 BayGenomics ES cell line XH856 embryonic stem cell house mouse CVCL_PZ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96239; Hsf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096227 CVCL_PZ20 BayGenomics ES cell line XH805 embryonic stem cell house mouse CVCL_PZ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096228 CVCL_PZ21 BayGenomics ES cell line XH809 embryonic stem cell house mouse CVCL_PZ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144013; Xpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096229 CVCL_PZ22 BayGenomics ES cell line XH811 embryonic stem cell house mouse CVCL_PZ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352755; Gtse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096230 CVCL_PZ23 BayGenomics ES cell line XH812 embryonic stem cell house mouse CVCL_PZ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096231 CVCL_PZ24 BayGenomics ES cell line XH814 embryonic stem cell house mouse CVCL_PZ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109519; Msh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096232 CVCL_PZ25 BayGenomics ES cell line XH815 embryonic stem cell house mouse CVCL_PZ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889642; Elp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096233 CVCL_PZ26 BayGenomics ES cell line XH816 embryonic stem cell house mouse CVCL_PZ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103040; Rsu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096234 CVCL_PZ27 BayGenomics ES cell line XH817 embryonic stem cell house mouse CVCL_PZ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103040; Rsu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096235 CVCL_PZ28 BayGenomics ES cell line XH819 embryonic stem cell house mouse CVCL_PZ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95770; Gna15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096236 CVCL_PZ29 BayGenomics ES cell line XH820 embryonic stem cell house mouse CVCL_PZ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98285; Srsf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21096237 CVCL_6N60 DA00682 transformed cell line human CVCL_6N60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096238 CVCL_6N61 DA00683 transformed cell line human CVCL_6N61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096239 CVCL_6N62 DA00684 transformed cell line human CVCL_6N62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096240 CVCL_6N67 DA00689 transformed cell line human CVCL_6N67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096241 CVCL_6N68 DA00690 transformed cell line human CVCL_6N68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096242 CVCL_6N69 DA00691 transformed cell line human CVCL_6N69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096243 CVCL_6N63 DA00685 transformed cell line human CVCL_6N63 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096244 CVCL_6N64 DA00686 transformed cell line human CVCL_6N64 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096245 CVCL_6N65 DA00687 transformed cell line human CVCL_6N65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096246 CVCL_6N66 DA00688 transformed cell line human CVCL_6N66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096247 CVCL_6N70 DA00692 transformed cell line human CVCL_6N70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096248 CVCL_6N71 DA00693 transformed cell line human CVCL_6N71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096249 CVCL_6N72 DA00694 transformed cell line human CVCL_6N72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096250 CVCL_6N73 DA00695 transformed cell line human CVCL_6N73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096251 CVCL_6N78 DA00700 transformed cell line human CVCL_6N78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096252 CVCL_6N79 DA00701 transformed cell line human CVCL_6N79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096253 CVCL_6N74 DA00696 transformed cell line human CVCL_6N74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096254 CVCL_6N75 DA00697 transformed cell line human CVCL_6N75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096255 CVCL_6N76 DA00698 transformed cell line human CVCL_6N76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096256 CVCL_6N77 DA00699 transformed cell line human CVCL_6N77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096257 CVCL_6N40 DA00662 transformed cell line human CVCL_6N40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096258 CVCL_6N45 DA00667 transformed cell line human CVCL_6N45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096259 CVCL_6N46 DA00668 transformed cell line human CVCL_6N46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096260 CVCL_6N47 DA00669 transformed cell line human CVCL_6N47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096261 CVCL_6N48 DA00670 transformed cell line human CVCL_6N48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096262 CVCL_6N41 DA00663 transformed cell line human CVCL_6N41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096263 CVCL_6N42 DA00664 transformed cell line human CVCL_6N42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096264 CVCL_6N43 DA00665 transformed cell line human CVCL_6N43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096265 CVCL_6N44 DA00666 transformed cell line human CVCL_6N44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096266 CVCL_Z590 MPN3 transformed cell line pig CVCL_Z590 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium; Breed/subspecies: Minnesota miniature pig. Unspecified Doubling time: 17.6 +- 3.8 hours (PubMed=15950500) 21096267 CVCL_Z591 MYP30 spontaneously immortalized cell line pig CVCL_Z591 CL:0000010 Derived from sampling site: Aorta; endothelium. Unspecified 21096268 CVCL_Z592 Pam LU-1 cancer cell line house mouse CVCL_Z592 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Male Characteristics: Established from the lung tumor of athymic nude BALB/c mice inoculated with the parent cell line (PubMed=9247255) 21096269 CVCL_6N38 DA00660 transformed cell line human CVCL_6N38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096270 CVCL_6N39 DA00661 transformed cell line human CVCL_6N39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096271 CVCL_Z597 AO2V4 cancer cell line human CVCL_Z597 CL:0000010 Male 21096272 CVCL_Z598 GJC cancer cell line human CVCL_Z598 CL:0000010 Derived from sampling site: Brain. Male 21096273 CVCL_Z599 GJR cancer cell line human CVCL_Z599 CL:0000010 Derived from sampling site: Brain. Male 21096274 CVCL_Z593 Pam LY-1 cancer cell line house mouse CVCL_Z593 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Male Characteristics: Established from the lymph node of athymic nude BALB/c mice inoculated with the parent cell line (PubMed=9247255) 21096275 CVCL_Z594 Pam LY-2 cancer cell line house mouse CVCL_Z594 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Male Characteristics: Established from the lymph node of athymic nude BALB/c mice inoculated with the parent cell line (PubMed=9247255) 21096276 CVCL_Z595 SK-astrocyte-IDH1 telomerase immortalized cell line human CVCL_Z595 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transfected with: HGNC; 5382; IDH1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain Cell type=Astrocyte.. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2012-113 21096277 CVCL_Z596 SK-astrocyte-IDH1-R132H telomerase immortalized cell line human CVCL_Z596 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transfected with: HGNC; 5382; IDH1 (with p.Arg132His); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain Cell type=Astrocyte.. Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2012-113 21096278 CVCL_6N50 DA00672 transformed cell line human CVCL_6N50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096279 CVCL_6N51 DA00673 transformed cell line human CVCL_6N51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096280 CVCL_Z579 Caco-2/PD-10 cancer cell line human CVCL_Z579 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096281 CVCL_6N56 DA00678 transformed cell line human CVCL_6N56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096282 CVCL_6N57 DA00679 transformed cell line human CVCL_6N57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096283 CVCL_6N58 DA00680 transformed cell line human CVCL_6N58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096284 CVCL_6N59 DA00681 transformed cell line human CVCL_6N59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096285 CVCL_6N52 DA00674 transformed cell line human CVCL_6N52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096286 CVCL_6N53 DA00675 transformed cell line human CVCL_6N53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096287 CVCL_6N54 DA00676 transformed cell line human CVCL_6N54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096288 CVCL_6N55 DA00677 transformed cell line human CVCL_6N55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096289 CVCL_Z580 Caco-2/PD-7 cancer cell line human CVCL_Z580 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096290 CVCL_Z581 Caco-2/PF-11 cancer cell line human CVCL_Z581 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096291 CVCL_6N49 DA00671 transformed cell line human CVCL_6N49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096292 CVCL_Z586 SKE-hTERT telomerase immortalized cell line pig CVCL_Z586 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium; Breed/subspecies: Large White. Unspecified 21096293 CVCL_Z587 SKE-Spon spontaneously immortalized cell line pig CVCL_Z587 CL:0000010 Derived from sampling site: Kidney; epithelium; Breed/subspecies: Large White. Unspecified 21096294 CVCL_Z588 SKE-SV40LT transformed cell line pig CVCL_Z588 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; epithelium; Breed/subspecies: Large White. Unspecified 21096295 CVCL_Z589 HaEpi spontaneously immortalized cell line CVCL_Z589 CL:0000010 Unspecified Doubling time: 64 hours (PubMed=18769621). Group: Insect cell line 21096296 CVCL_Z582 C2BBe2 cancer cell line human CVCL_Z582 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096297 CVCL_Z583 COGA-1A cancer cell line human CVCL_Z583 CL:0000010 Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=25926053) 21096298 CVCL_Z584 COGA-13 cancer cell line human CVCL_Z584 CL:0000010 Unspecified 21096299 CVCL_Z585 Caco-2/AQ cancer cell line human CVCL_Z585 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096300 CVCL_Z568 BCIRL-SO4-HNU4 spontaneously immortalized cell line CVCL_Z568 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 54 +- 5.07 hours (CelloPub=CLPUB00166) Group: Insect cell line 21096301 CVCL_Z569 BM-21E-HNU5 spontaneously immortalized cell line CVCL_Z569 CL:0000010 Breed/subspecies: Huahe 671 Dongfei. Unspecified Doubling time: 48 hours (CelloPub=CLPUB00535) Group: Insect cell line 21096302 CVCL_6N23 DA00644 transformed cell line human CVCL_6N23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096303 CVCL_6N24 DA00645 transformed cell line human CVCL_6N24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096304 CVCL_6N25 DA00646 transformed cell line human CVCL_6N25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096305 CVCL_6N26 DA00647 transformed cell line human CVCL_6N26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096306 CVCL_6N20 DA00641 transformed cell line human CVCL_6N20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096307 CVCL_6N21 DA00642 transformed cell line human CVCL_6N21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096308 CVCL_6N22 DA00643 transformed cell line human CVCL_6N22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096309 CVCL_Z570 BCIRL-PX2-HNU3 spontaneously immortalized cell line CVCL_Z570 CL:0000010 Unspecified Doubling time: 30 +- 2.06 hours (CelloPub=CLPUB00165). Group: Insect cell line 21096310 CVCL_6N16 DA00637 transformed cell line human CVCL_6N16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096311 CVCL_6N17 DA00638 transformed cell line human CVCL_6N17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096312 CVCL_6N18 DA00639 transformed cell line human CVCL_6N18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096313 CVCL_6N19 DA00640 transformed cell line human CVCL_6N19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096314 CVCL_Z575 IPLB-PxE1 spontaneously immortalized cell line CVCL_Z575 CL:0000010 Unspecified Group: Insect cell line. 21096315 CVCL_Z576 IPLB-PxE2 spontaneously immortalized cell line CVCL_Z576 CL:0000010 Unspecified Group: Insect cell line. 21096316 CVCL_Z577 AC20 spontaneously immortalized cell line CVCL_Z577 CL:0000010 Unspecified Group: Insect cell line. 21096317 CVCL_Z578 Caco-2/3 cancer cell line human CVCL_Z578 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21096318 CVCL_Z571 Pa-E-HNU6 spontaneously immortalized cell line CVCL_Z571 CL:0000010 Unspecified Group: Insect cell line. 21096319 CVCL_Z572 Le-H-HNU7 spontaneously immortalized cell line CVCL_Z572 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21096320 CVCL_Z573 Pr-E-HNU9 spontaneously immortalized cell line CVCL_Z573 CL:0000010 Unspecified Group: Insect cell line. 21096321 CVCL_Z574 IPLB-HvE6s spontaneously immortalized cell line CVCL_Z574 CL:0000010 Unspecified Group: Insect cell line. 21096322 CVCL_Z557 NISES-BoMo-E3 spontaneously immortalized cell line CVCL_Z557 CL:0000010 Breed/subspecies: N137 x C146. Unspecified Group: Insect cell line 21096323 CVCL_Z558 NISES-BoMo-E4 spontaneously immortalized cell line CVCL_Z558 CL:0000010 Breed/subspecies: N137 x C146. Unspecified Group: Insect cell line 21096324 CVCL_Z559 NIAS-Bm-aff3 spontaneously immortalized cell line CVCL_Z559 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21096325 CVCL_6N34 DA00656 transformed cell line human CVCL_6N34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096326 CVCL_6N35 DA00657 transformed cell line human CVCL_6N35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096327 CVCL_6N36 DA00658 transformed cell line human CVCL_6N36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096328 CVCL_6N37 DA00659 transformed cell line human CVCL_6N37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096329 CVCL_6N30 DA00652 transformed cell line human CVCL_6N30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096330 CVCL_6N31 DA00653 transformed cell line human CVCL_6N31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096331 CVCL_6N32 DA00654 transformed cell line human CVCL_6N32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096332 CVCL_6N33 DA00655 transformed cell line human CVCL_6N33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096333 CVCL_6N27 DA00648 transformed cell line human CVCL_6N27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096334 CVCL_6N28 DA00649 transformed cell line human CVCL_6N28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096335 CVCL_6N29 DA00650 transformed cell line human CVCL_6N29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096336 CVCL_Z564 NIAS-Bm-Oyanagi 2 spontaneously immortalized cell line CVCL_Z564 CL:0000010 Breed/subspecies: N137 x C146. Unspecified Group: Insect cell line 21096337 CVCL_Z565 NIAS-Bm-SLBEM-1228 spontaneously immortalized cell line CVCL_Z565 CL:0000010 Breed/subspecies: Sex limited black egg. Unspecified Group: Insect cell line 21096338 CVCL_Z566 NIAS-Bm-SLBEM-1230 spontaneously immortalized cell line CVCL_Z566 CL:0000010 Breed/subspecies: Sex limited black egg. Unspecified Group: Insect cell line 21096339 CVCL_Z567 BCIRL-SO3-HNU1 spontaneously immortalized cell line CVCL_Z567 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 47 +- 3.2 hours (CelloPub=CLPUB00166) Group: Insect cell line 21096340 CVCL_Z560 NIAS-Bm-ao1 spontaneously immortalized cell line CVCL_Z560 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096341 CVCL_Z561 NIAS-Bm-Ke1 spontaneously immortalized cell line CVCL_Z561 CL:0000010 Unspecified Group: Insect cell line. 21096342 CVCL_Z562 NIAS-Bm-Ke17 spontaneously immortalized cell line CVCL_Z562 CL:0000010 Unspecified Doubling time: 83.67 +- 5.22 hours (PubMed=22302376). Group: Insect cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-21809 21096343 CVCL_Z563 NIAS-Bm-Oyanagi 1 spontaneously immortalized cell line CVCL_Z563 CL:0000010 Breed/subspecies: N137 x C146. Unspecified Group: Insect cell line 21096344 CVCL_Z546 FFPRI-SpIm-2AM spontaneously immortalized cell line CVCL_Z546 CL:0000010 Unspecified Doubling time: ~3.5 days (CelloPub=CLPUB00196). Group: Insect cell line 21096345 CVCL_Z547 FFPRI-SpIm-2AM-IPL spontaneously immortalized cell line CVCL_Z547 CL:0000010 Unspecified Group: Insect cell line. 21096346 CVCL_Z548 FFPRI-SpIm-2AM-SF spontaneously immortalized cell line CVCL_Z548 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21096347 CVCL_Z549 NIAS-AeAl-2 spontaneously immortalized cell line CVCL_Z549 CL:0000010 Discontinued: RCB; RCB0277; true. Unspecified Doubling time: ~30 hours (DOI=10.2220/biomedres.2.599) Group: Insect cell line 21096348 CVCL_6N01 DA00621 transformed cell line human CVCL_6N01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096349 CVCL_6N02 DA00622 transformed cell line human CVCL_6N02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096350 CVCL_6N03 DA00623 transformed cell line human CVCL_6N03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096351 CVCL_6N04 DA00624 transformed cell line human CVCL_6N04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096352 CVCL_6N00 DA00620 transformed cell line human CVCL_6N00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096353 CVCL_Z553 NISES-BoMo-KG spontaneously immortalized cell line CVCL_Z553 CL:0000010 Breed/subspecies: Kokuga. Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-17390 21096354 CVCL_Z554 NISES-BoMo-MK spontaneously immortalized cell line CVCL_Z554 CL:0000010 Breed/subspecies: Murasaki kaiko. Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-17391 21096355 CVCL_Z555 NISES-BoMo-OH spontaneously immortalized cell line CVCL_Z555 CL:0000010 Breed/subspecies: Ohha. Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-17392 21096356 CVCL_Z556 NISES-BoMo-E2 spontaneously immortalized cell line CVCL_Z556 CL:0000010 Breed/subspecies: J147 x C145. Unspecified Group: Insect cell line 21096357 CVCL_Z550 NIH-SaPe-4 spontaneously immortalized cell line CVCL_Z550 CL:0000010 Discontinued: RCB; RCB0280; true. Unspecified Group: Insect cell line 21096358 CVCL_Z551 R05R transformed cell line CVCL_Z551 CL:0000010 Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285). Unspecified Doubling time: ~6 days (PubMed=19540275) Group: Bat cell line 21096359 CVCL_Z552 NISES-BoMo-DZ spontaneously immortalized cell line CVCL_Z552 CL:0000010 Breed/subspecies: Daizo. Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-17389 21096360 CVCL_Z539 MBL-3 embryonic stem cell house mouse CVCL_Z539 CL:0000010 Breed/subspecies: 129/Sv He. Female 21096361 CVCL_Z535 Aalb-105 spontaneously immortalized cell line CVCL_Z535 CL:0000010 Unspecified Group: Insect cell line. 21096362 CVCL_Z536 Anso-242 spontaneously immortalized cell line CVCL_Z536 CL:0000010 Female Group: Insect cell line. 21096363 CVCL_Z537 MBL-1 embryonic stem cell house mouse CVCL_Z537 CL:0000010 Breed/subspecies: 129/Sv He. Male 21096364 CVCL_Z538 MBL-2 [Mouse ESC] embryonic stem cell house mouse CVCL_Z538 CL:0000010 Breed/subspecies: 129/Sv He. Male 21096365 CVCL_6N12 DA00633 transformed cell line human CVCL_6N12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096366 CVCL_6N13 DA00634 transformed cell line human CVCL_6N13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096367 CVCL_6N14 DA00635 transformed cell line human CVCL_6N14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096368 CVCL_6N15 DA00636 transformed cell line human CVCL_6N15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096369 CVCL_6N10 DA00631 transformed cell line human CVCL_6N10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096370 CVCL_6N11 DA00632 transformed cell line human CVCL_6N11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096371 CVCL_6N09 DA00630 transformed cell line human CVCL_6N09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096372 CVCL_6N05 DA00626 transformed cell line human CVCL_6N05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096373 CVCL_6N06 DA00627 transformed cell line human CVCL_6N06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096374 CVCL_6N07 DA00628 transformed cell line human CVCL_6N07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096375 CVCL_6N08 DA00629 transformed cell line human CVCL_6N08 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096376 CVCL_Z542 MbL-3 spontaneously immortalized cell line CVCL_Z542 CL:0000010 Unspecified Doubling time: 33 hours (PubMed=8578995). Group: Insect cell line 21096377 CVCL_Z543 CLS-79 spontaneously immortalized cell line CVCL_Z543 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9373. 21096378 CVCL_Z544 CLS-79-C7 spontaneously immortalized cell line CVCL_Z544 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2723. 21096379 CVCL_Z545 NIAS-SpSe-1 spontaneously immortalized cell line CVCL_Z545 CL:0000010 Derived from sampling site: Fat body. Male Doubling time: ~3 days (CelloPub=CLPUB00195) Group: Insect cell line 21096380 CVCL_Z540 MBL-4 embryonic stem cell house mouse CVCL_Z540 CL:0000010 Breed/subspecies: 129/Sv He. Female 21096381 CVCL_Z541 MBL-5 embryonic stem cell house mouse CVCL_Z541 CL:0000010 Breed/subspecies: 129/Sv He. Male 21096382 CVCL_HC31 RadC12 transformed cell line human CVCL_HC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096383 CVCL_HC32 RadC13 transformed cell line human CVCL_HC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096384 CVCL_HC33 RadS1 transformed cell line human CVCL_HC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive breast cancer patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096385 CVCL_HC34 RadS2 transformed cell line human CVCL_HC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive low grade lymphoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096386 CVCL_HC30 RadC11 transformed cell line human CVCL_HC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a tongue carcinoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096387 CVCL_HC28 RadC9 transformed cell line human CVCL_HC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096388 CVCL_HC29 RadC10 transformed cell line human CVCL_HC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a tonsil carcinoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096389 CVCL_HC24 RadC5 transformed cell line human CVCL_HC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a salivary gland carcinoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096390 CVCL_HC25 RadC6 transformed cell line human CVCL_HC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from an oropharynx carcinoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096391 CVCL_HC26 RadC7 transformed cell line human CVCL_HC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096392 CVCL_HC27 RadC8 transformed cell line human CVCL_HC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096393 CVCL_HC42 RadS10 transformed cell line human CVCL_HC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive Hodgkin lymphoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096394 CVCL_HC43 RadS11 transformed cell line human CVCL_HC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive brain stem arteriovenous malformation patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096395 CVCL_HC44 RadS12 transformed cell line human CVCL_HC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive breast cancer patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096396 CVCL_HC45 RadS13 transformed cell line human CVCL_HC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive endometrial cancer patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096397 CVCL_HC40 RadS8 transformed cell line human CVCL_HC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive Hodgkin lymphoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096398 CVCL_HC41 RadS9 transformed cell line human CVCL_HC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive salivary gland carcinoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096399 CVCL_HC39 RadS7 transformed cell line human CVCL_HC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive low grade lymphoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096400 CVCL_HC35 RadS3 transformed cell line human CVCL_HC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive tongue carcinoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096401 CVCL_HC36 RadS4 transformed cell line human CVCL_HC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive breast cancer patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096402 CVCL_HC37 RadS5 transformed cell line human CVCL_HC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive orbital pseudotumor patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096403 CVCL_HC38 RadS6 transformed cell line human CVCL_HC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive Hodgkin lymphoma patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096404 CVCL_HC10 SkCa6 transformed cell line human CVCL_HC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096405 CVCL_HC11 SkCa7 transformed cell line human CVCL_HC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096406 CVCL_HC12 SkCa8 transformed cell line human CVCL_HC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096407 CVCL_HC06 SkCa2 transformed cell line human CVCL_HC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096408 CVCL_HC07 SkCa3 transformed cell line human CVCL_HC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096409 CVCL_HC08 SkCa4 transformed cell line human CVCL_HC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096410 CVCL_HC09 SkCa5 transformed cell line human CVCL_HC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096411 CVCL_HC02 NoCa13 transformed cell line human CVCL_HC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096412 CVCL_HC03 NoCa14 transformed cell line human CVCL_HC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096413 CVCL_HC04 NoCa15 transformed cell line human CVCL_HC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096414 CVCL_HC05 SkCa1 transformed cell line human CVCL_HC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096415 CVCL_HC20 RadC1 transformed cell line human CVCL_HC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a Hodgkin lymphoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096416 CVCL_HC21 RadC2 transformed cell line human CVCL_HC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a mixed cell lymphoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096417 CVCL_HC22 RadC3 transformed cell line human CVCL_HC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a large cell lymphoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21096418 CVCL_HC23 RadC4 transformed cell line human CVCL_HC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a Hodgkin lymphoma patient with limited toxicity to radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096419 CVCL_HC17 SkCa13 transformed cell line human CVCL_HC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096420 CVCL_HC18 SkCa14 transformed cell line human CVCL_HC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096421 CVCL_HC19 SkCa15 transformed cell line human CVCL_HC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096422 CVCL_HC13 SkCa9 transformed cell line human CVCL_HC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096423 CVCL_HC14 SkCa10 transformed cell line human CVCL_HC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096424 CVCL_HC15 SkCa11 transformed cell line human CVCL_HC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096425 CVCL_HC16 SkCa12 transformed cell line human CVCL_HC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096426 CVCL_HC00 NoCa11 transformed cell line human CVCL_HC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096427 CVCL_HC01 NoCa12 transformed cell line human CVCL_HC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 21096428 CVCL_HC97 HEK293 eGFP-WT1 transformed cell line human CVCL_HC97 CL:0000010 Transfected with: HGNC; 12796; WT1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096429 CVCL_HC98 HEK293 eGFP-ZBTB1 transformed cell line human CVCL_HC98 CL:0000010 Transfected with: HGNC; 20259; ZBTB1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096430 CVCL_HC99 HEK293 eGFP-ZBTB11 transformed cell line human CVCL_HC99 CL:0000010 Transfected with: HGNC; 16740; ZBTB11; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096431 CVCL_HC93 HEK293 eGFP-SP2 transformed cell line human CVCL_HC93 CL:0000010 Transfected with: HGNC; 11207; SP2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096432 CVCL_HC94 HEK293 eGFP-SP3 transformed cell line human CVCL_HC94 CL:0000010 Transfected with: HGNC; 11208; SP3; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096433 CVCL_HC95 HEK293 eGFP-SP7 transformed cell line human CVCL_HC95 CL:0000010 Transfected with: HGNC; 17321; SP7; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096434 CVCL_HC96 HEK293 eGFP-TSHZ1 transformed cell line human CVCL_HC96 CL:0000010 Transfected with: HGNC; 10669; TSHZ1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096435 CVCL_HC90 HEK293 eGFP-PRDM12 transformed cell line human CVCL_HC90 CL:0000010 Transfected with: HGNC; 13997; PRDM12; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096436 CVCL_HC91 HEK293 eGFP-REST transformed cell line human CVCL_HC91 CL:0000010 Transfected with: HGNC; 9966; REST; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096437 CVCL_HC92 HEK293 eGFP-SALL4 transformed cell line human CVCL_HC92 CL:0000010 Transfected with: HGNC; 15924; SALL4; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096438 CVCL_HC75 HEK293 eGFP-GLI4 transformed cell line human CVCL_HC75 CL:0000010 Transfected with: HGNC; 4320; GLI4; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096439 CVCL_HC76 HEK293 eGFP-GLIS1 transformed cell line human CVCL_HC76 CL:0000010 Transfected with: HGNC; 29525; GLIS1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096440 CVCL_HC77 HEK293 eGFP-GLIS2 transformed cell line human CVCL_HC77 CL:0000010 Transfected with: HGNC; 29450; GLIS2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096441 CVCL_HC78 HEK293 eGFP-INSM2 transformed cell line human CVCL_HC78 CL:0000010 Transfected with: HGNC; 17539; INSM2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096442 CVCL_HC71 HEK293 eGFP-BCL11B transformed cell line human CVCL_HC71 CL:0000010 Transfected with: HGNC; 13222; BCL11B; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21096443 CVCL_HC72 HEK293 eGFP-CTCF transformed cell line human CVCL_HC72 CL:0000010 Transfected with: HGNC; 13723; CTCF; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21096444 CVCL_HC73 HEK293 eGFP-EGR2 transformed cell line human CVCL_HC73 CL:0000010 Transfected with: HGNC; 3239; EGR2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096445 CVCL_HC74 HEK293 eGFP-GFI1B transformed cell line human CVCL_HC74 CL:0000010 Transfected with: HGNC; 4238; GFI1B; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096446 CVCL_HC70 HEK293 eGFP-ATF2 transformed cell line human CVCL_HC70 CL:0000010 Transfected with: HGNC; 784; ATF2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21096447 CVCL_HC68 PIE spontaneously immortalized cell line pig CVCL_HC68 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Landrace x Large White x Duroc (LWD). Omics: Transcriptome analysis by microarray Unspecified 21096448 CVCL_HC69 HEK293 eGFP-AEBP2 transformed cell line human CVCL_HC69 CL:0000010 Transfected with: HGNC; 24051; AEBP2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21096449 CVCL_HC86 HEK293 eGFP-OSR2 transformed cell line human CVCL_HC86 CL:0000010 Transfected with: HGNC; 15830; OSR2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096450 CVCL_HC87 HEK293 eGFP-OVOL3 transformed cell line human CVCL_HC87 CL:0000010 Transfected with: HGNC; 14186; OVOL3; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096451 CVCL_HC88 HEK293 eGFP-PRDM1 transformed cell line human CVCL_HC88 CL:0000010 Transfected with: HGNC; 9346; PRDM1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096452 CVCL_HC89 HEK293 eGFP-PRDM10 transformed cell line human CVCL_HC89 CL:0000010 Transfected with: HGNC; 13995; PRDM10; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096453 CVCL_HC82 HEK293 eGFP-KLF8 transformed cell line human CVCL_HC82 CL:0000010 Transfected with: HGNC; 6351; KLF8; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096454 CVCL_HC83 HEK293 eGFP-KLF9 transformed cell line human CVCL_HC83 CL:0000010 Transfected with: HGNC; 1123; KLF9; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096455 CVCL_HC84 HEK293 eGFP-MAZ transformed cell line human CVCL_HC84 CL:0000010 Transfected with: HGNC; 6914; MAZ; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096456 CVCL_HC85 HEK293 eGFP-MYNN transformed cell line human CVCL_HC85 CL:0000010 Transfected with: HGNC; 14955; MYNN; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096457 CVCL_HC80 HEK293 eGFP-KLF17 transformed cell line human CVCL_HC80 CL:0000010 Transfected with: HGNC; 18830; KLF17; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21096458 CVCL_HC81 HEK293 eGFP-KLF7 transformed cell line human CVCL_HC81 CL:0000010 Transfected with: HGNC; 6350; KLF7; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096459 CVCL_HC79 HEK293 eGFP-KLF1 transformed cell line human CVCL_HC79 CL:0000010 Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096460 CVCL_HC53 mRG1 spontaneously immortalized cell line CVCL_HC53 CL:0000010 Transfected with: MGI; MGI:95498; Fcgr1 Derived from sampling site: Ovary. Female 21096461 CVCL_HC54 CHO/Kcnk3 spontaneously immortalized cell line CVCL_HC54 CL:0000010 Transfected with: RGD; 621451; Kcnk9 Derived from sampling site: Ovary. Female 21096462 CVCL_HC55 CHO/Kcnk3/Kcnk9 spontaneously immortalized cell line CVCL_HC55 CL:0000010 Transfected with: RGD; 61997; Kcnk3; Transfected with: RGD; 621451; Kcnk9 Derived from sampling site: Ovary. Female 21096463 CVCL_HC56 CHO/Kcnk9 spontaneously immortalized cell line CVCL_HC56 CL:0000010 Transfected with: RGD; 61997; Kcnk3 Derived from sampling site: Ovary. Female 21096464 CVCL_HC50 NIH 3T3 Duo Parental spontaneously immortalized cell line house mouse CVCL_HC50 CL:0000010 Transfected with: UniProtKB; P03023; Escherichia coli lacI; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Cell developed for the induction and visualization of double-strand breaks chromosomal damage at specific sites of the mammalian genome Sytem based on the stable integration of endonuclease ISceI recognition sites flanked by LacO/TetO operator arrays, coupled with retroviral-mediated integration of their fluorescent repressors (LacR/TetR) to visualize the LacO/TetO sites.; Characteristics: Integrates one copy of a LacO-ISceI construct (256 copies of LacO) and two copies of a TetO-ISceI-TetO construct (96 copies of TetO) 21096465 CVCL_HC51 NIH 3T3 Duo spontaneously immortalized cell line house mouse CVCL_HC51 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P03023; Escherichia coli lacI; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Cell developed for the induction and visualization of double-strand breaks chromosomal damage at specific sites of the mammalian genome Sytem based on the stable integration of endonuclease ISceI recognition sites flanked by LacO/TetO operator arrays, coupled with retroviral-mediated integration of their fluorescent repressors (LacR/TetR) to visualize the LacO/TetO sites.; Characteristics: Integrates one copy of a LacO-ISceI construct (256 copies of LacO), two copies of a TetO-ISceI-TetO construct (96 copies of TetO) as well as a LacR-GFP and a TetR-mCherry constructs 21096466 CVCL_HC52 NIH 3T3 Duo-BFP53BP1 spontaneously immortalized cell line house mouse CVCL_HC52 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the BFP mTagBFP); Transfected with: UniProtKB; P03023; Escherichia coli lacI; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: MGI; MGI:1351320; Trp53bp1 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Cell developed for the induction and visualization of double-strand breaks chromosomal damage at specific sites of the mammalian genome Sytem based on the stable integration of endonuclease ISceI recognition sites flanked by LacO/TetO operator arrays, coupled with retroviral-mediated integration of their fluorescent repressors (LacR/TetR) to visualize the LacO/TetO sites.; Characteristics: Integrates one copy of a LacO-ISceI construct (256 copies of LacO), two copies of a TetO-ISceI-TetO construct (96 copies of TetO) as well as a LacR-GFP and a TetR-mCherry constructs 21096467 CVCL_HC46 RadS14 transformed cell line human CVCL_HC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a radiation-sensitive breast cancer patient that suffered from acute toxicity of radiation therapy; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21096468 CVCL_HC47 MDA-IBC-3 cancer cell line human CVCL_HC47 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: ER-negative, PR-negative and ERBB2-positive 21096469 CVCL_HC48 AVS transformed cell line CVCL_HC48 CL:0000010 Transformant: Cottontail rabbit papillomavirus (Kappapapillomavirus 2)(NCBI-Taxonomy; 10623); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: New Zealand white. Unspecified 21096470 CVCL_HC49 IMG transformed cell line house mouse CVCL_HC49 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Unspecified 21096471 CVCL_HC64 HEK293 Cav3.3 transformed cell line human CVCL_HC64 CL:0000010 Transfected with: HGNC; 1396; CACNA1I Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096472 CVCL_HC65 CHO 7WD10 spontaneously immortalized cell line CVCL_HC65 CL:0000010 Transfected with: HGNC; 620; APP (isoform APP751) Derived from sampling site: Ovary. Female 21096473 CVCL_HC66 CHO 7PA2 spontaneously immortalized cell line CVCL_HC66 CL:0000010 Transfected with: HGNC; 620; APP (isoform APP751; with p.Val717Phe) Derived from sampling site: Ovary. Female 21096474 CVCL_HC67 BIE transformed cell line CVCL_HC67 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: Japanese black. Male Doubling time: 36.7 hours (PubMed=19830445) 21096475 CVCL_HC60 Bcl-x-KO MEF transformed cell line house mouse CVCL_HC60 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88139; Bcl2l1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: 24 hours (Kerafast) 21096476 CVCL_HC61 Bcl-x-KO MEF Bcl-XL expressing transformed cell line house mouse CVCL_HC61 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88139; Bcl2l1; Transfected with: HGNC; 992; BCL2L1 (isoform Bcl-xL) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: 24 hours (Kerafast) 21096477 CVCL_HC62 HEK293 Cav3.1 transformed cell line human CVCL_HC62 CL:0000010 Transfected with: HGNC; 1394; CACNA1G Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096478 CVCL_HC63 HEK293 Cav3.2 transformed cell line human CVCL_HC63 CL:0000010 Transfected with: HGNC; 1395; CACNA1H Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096479 CVCL_HC57 OP-9S stromal cell line house mouse CVCL_HC57 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Unspecified Characteristics: Slow-growing derivative of OP9; Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene Doubling time: 58-72 hours (PubMed=15650053) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10785 21096480 CVCL_HC58 OP-9S/LMJSN stromal cell line house mouse CVCL_HC58 CL:0000010 Transfected with: MGI; MGI:1098270; Jag2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Unspecified Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene Doubling time: 58-72 hours (PubMed=15650053) 21096481 CVCL_HC59 KIL factor-dependent cell line house mouse CVCL_HC59 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6. Characteristics: Established from co-cultures of post-5-fluorouracil bone marrow mononuclear cells and OP-9S/LMJSN (Cellosaurus=CVCL_HC58); Characteristics: IL7 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6651 21096482 CVCL_Z649 BCIRL/RP-HvE-HN3 spontaneously immortalized cell line CVCL_Z649 CL:0000010 Unspecified Group: Insect cell line. 21096483 CVCL_Z645 BCIRL/RP-HvE-HN12 spontaneously immortalized cell line CVCL_Z645 CL:0000010 Unspecified Group: Insect cell line. 21096484 CVCL_Z646 BCIRL/RP-HvE-HN14 spontaneously immortalized cell line CVCL_Z646 CL:0000010 Unspecified Group: Insect cell line. 21096485 CVCL_Z647 BCIRL/RP-HvE-HN16 spontaneously immortalized cell line CVCL_Z647 CL:0000010 Unspecified Group: Insect cell line. 21096486 CVCL_Z648 BCIRL/RP-HvE-HN2 spontaneously immortalized cell line CVCL_Z648 CL:0000010 Unspecified Group: Insect cell line. 21096487 CVCL_7000 8029 NA cancer cell line human CVCL_7000 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21096488 CVCL_7001 8029 DDP4 cancer cell line human CVCL_7001 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Cervical lymph node. Male 21096489 CVCL_7002 A-1235 cancer cell line human CVCL_7002 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; c.(2062_3114)ins?; Zygosity=Unspecified (PubMed=10698499). Unspecified 21096490 CVCL_7003 ACC-LC-170 cancer cell line human CVCL_7003 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096491 CVCL_Z652 BCIRL/RP-HvVNC-WG3 spontaneously immortalized cell line CVCL_Z652 CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 21096492 CVCL_Z653 RP-HzGUT-AW1 spontaneously immortalized cell line CVCL_Z653 CL:0000010 Derived from sampling site: Midgut. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 58.2 hours (PubMed=33276037) Group: Insect cell line 21096493 CVCL_Z654 RP-HzOV-AW2 spontaneously immortalized cell line CVCL_Z654 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096494 CVCL_Z655 RP-HzVNC-AW1 spontaneously immortalized cell line CVCL_Z655 CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 21096495 CVCL_Z650 BCIRL/RP-HvVNC-WG1 spontaneously immortalized cell line CVCL_Z650 CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 21096496 CVCL_Z651 BCIRL/RP-HvVNC-WG2 spontaneously immortalized cell line CVCL_Z651 CL:0000010 Derived from sampling site: Ventral nerve cord. Unspecified Group: Insect cell line 21096497 CVCL_Z638 BCIRL-HV-AM-CL7 spontaneously immortalized cell line CVCL_Z638 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096498 CVCL_Z639 BCIRL/RP-HvE-CLG1 spontaneously immortalized cell line CVCL_Z639 CL:0000010 Unspecified Group: Insect cell line. 21096499 CVCL_Z634 BmN4 spontaneously immortalized cell line CVCL_Z634 CL:0000010 Derived from sampling site: Ovary. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female Virology: Infected by Bombyx mori macula-like latent virus (BmMLV) Doubling time: 73.3 hours (PubMed=24934233); 58 +- 6 hours (in static culture), 72 +- 2 hours (in suspension culture) (PubMed=10585188) Group: Insect cell line 21096500 CVCL_Z635 BmN-SFM spontaneously immortalized cell line CVCL_Z635 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 112.8 hours (PubMed=24934233) Group: Insect cell line; Group: Serum/protein free medium cell line 21096501 CVCL_Z636 BCIRL-HV-AM-CL3 spontaneously immortalized cell line CVCL_Z636 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096502 CVCL_Z637 BCIRL-HV-AM-CL5 spontaneously immortalized cell line CVCL_Z637 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096503 CVCL_7011 ACC-LC-314 cancer cell line human CVCL_7011 CL:0000010 Population: Japanese. Unspecified 21096504 CVCL_7012 ACC-LC-319 cancer cell line human CVCL_7012 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (PubMed=12794755); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro71fs (c.211delC); Zygosity=Unspecified (PubMed=12794755). Population: Japanese Unspecified 21096505 CVCL_7013 ACC-LC-321 cancer cell line human CVCL_7013 CL:0000010 Population: Japanese. Unspecified 21096506 CVCL_7014 ACC-LC-323 cancer cell line human CVCL_7014 CL:0000010 Population: Japanese. Unspecified 21096507 CVCL_7010 ACC-LC-178 cancer cell line human CVCL_7010 CL:0000010 Population: Japanese. Unspecified 21096508 CVCL_7008 ACC-LC-176 cancer cell line human CVCL_7008 CL:0000010 Population: Japanese. Unspecified 21096509 CVCL_7009 ACC-LC-177 cancer cell line human CVCL_7009 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096510 CVCL_7004 ACC-LC-171 cancer cell line human CVCL_7004 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096511 CVCL_7005 ACC-LC-172 cancer cell line human CVCL_7005 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (PubMed=12794755) Population: Japanese; Derived from metastatic site: Pericardial effusion. Male 21096512 CVCL_7006 ACC-LC-173 cancer cell line human CVCL_7006 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096513 CVCL_7007 ACC-LC-174 cancer cell line human CVCL_7007 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096514 CVCL_Z641 BCIRL/RP-HvE-CLG5 spontaneously immortalized cell line CVCL_Z641 CL:0000010 Unspecified Group: Insect cell line. 21096515 CVCL_Z642 BCIRL/RP-HvE-CLG6 spontaneously immortalized cell line CVCL_Z642 CL:0000010 Unspecified Group: Insect cell line. 21096516 CVCL_Z643 BCIRL/RP-HvE-CLG7 spontaneously immortalized cell line CVCL_Z643 CL:0000010 Unspecified Group: Insect cell line. 21096517 CVCL_Z644 BCIRL/RP-HvE-HN11 spontaneously immortalized cell line CVCL_Z644 CL:0000010 Unspecified Group: Insect cell line. 21096518 CVCL_Z640 BCIRL/RP-HvE-CLG4 spontaneously immortalized cell line CVCL_Z640 CL:0000010 Unspecified Group: Insect cell line. 21096519 CVCL_Z627 Sua1B spontaneously immortalized cell line CVCL_Z627 CL:0000010 Breed/subspecies: Suakoko 2La. Unspecified Group: Insect cell line 21096520 CVCL_Z628 SuaE.1 spontaneously immortalized cell line CVCL_Z628 CL:0000010 Breed/subspecies: Suakoko 2La. Omics: Transcriptome analysis by RNAseq Unspecified Group: Insect cell line 21096521 CVCL_Z629 Sua4.0 spontaneously immortalized cell line CVCL_Z629 CL:0000010 Breed/subspecies: Suakoko 2La. Omics: Transcriptome analysis by RNAseq Unspecified Group: Insect cell line 21096522 CVCL_Z623 4a-3B spontaneously immortalized cell line CVCL_Z623 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.; Breed/subspecies: 4a r/r. Omics: Transcriptome analysis by RNAseq Unspecified Group: Insect cell line 21096523 CVCL_Z624 L3-5 spontaneously immortalized cell line CVCL_Z624 CL:0000010 Breed/subspecies: L3-5. Omics: Transcriptome analysis by RNAseq Discontinued: BEI_Resources; MRA-920; probable Unspecified Group: Insect cell line 21096524 CVCL_Z625 L3-5-3 spontaneously immortalized cell line CVCL_Z625 CL:0000010 Breed/subspecies: L3-5. Unspecified Group: Insect cell line 21096525 CVCL_Z626 Sua1.1 spontaneously immortalized cell line CVCL_Z626 CL:0000010 Breed/subspecies: Suakoko 2La. Unspecified Group: Insect cell line 21096526 CVCL_Z630 Sua5.1* spontaneously immortalized cell line CVCL_Z630 CL:0000010 Breed/subspecies: Suakoko 2La. Omics: Transcriptome analysis by RNAseq Discontinued: BEI_Resources; MRA-922; probable Female Group: Insect cell line 21096527 CVCL_Z631 HC-04 cancer cell line human CVCL_Z631 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~24 hours (PubMed=17590308) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3441 Problematic cell line: Possibly contaminated Indicated (PubMed=24532842) to have a near genetic identity with Hep-G2 cells. But they are functionally different from Hep-G2 cells since they support sporozoite invasion and liver stage exoerythrocytic development of Plasmodium falciparum and Plasmodium vivax. But STR profile from BEI Resources is identical to that of Hep-G2. Originally thought to originate from the spontaneous immortalization of a normal liver tissue of an hepatoma patient. 21096528 CVCL_Z632 BmN-SWU2 spontaneously immortalized cell line CVCL_Z632 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: 21-872nlw. Female Doubling time: ~96 hours (PubMed=25221982) Group: Insect cell line 21096529 CVCL_Z633 BM-N spontaneously immortalized cell line CVCL_Z633 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used for the production of the VirBac Virbagen Omega, a recombinant cat alpha-inteferon used in veterinary medicine to treat cats infected with feline leukemia virus (FeLV) and/or feline immunodeficiency virus (FIV) infections; Omics: Deep proteome analysis Female Virology: Infected by Bombyx mori macula-like latent virus (BmMLV) Group: Insect cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8910 21096530 CVCL_Z616 MN-1112 cancer cell line human CVCL_Z616 CL:0000010 Population: Japanese; Derived from metastatic site: Right subclavius; hypodermis. Male Doubling time: 72 hours (PubMed=8598320) 21096531 CVCL_Z617 Aag-2 spontaneously immortalized cell line CVCL_Z617 CL:0000010 Derived from sampling site: Whole embryo. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: ~24 hours (PubMed=627872) Group: Insect cell line 21096532 CVCL_Z618 LT C-7 spontaneously immortalized cell line CVCL_Z618 CL:0000010 Unspecified Group: Insect cell line. 21096533 CVCL_Z619 C7-10 spontaneously immortalized cell line CVCL_Z619 CL:0000010 Unspecified Group: Insect cell line. 21096534 CVCL_Z612 OS15 cancer cell line human CVCL_Z612 CL:0000010 Population: Japanese. Unspecified 21096535 CVCL_Z613 OS17 cancer cell line human CVCL_Z613 CL:0000010 Population: Japanese. Unspecified 21096536 CVCL_Z614 OS18A cancer cell line human CVCL_Z614 CL:0000010 Population: Japanese. Unspecified 21096537 CVCL_Z615 KK0206 cancer cell line human CVCL_Z615 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Gly (c.466C>G); ClinVar=VCV001517870; Zygosity=Unspecified (PubMed=17374419) Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 72 hours (PubMed=17374419) 21096538 CVCL_Z620 4a-2 spontaneously immortalized cell line CVCL_Z620 CL:0000010 Breed/subspecies: 4a r/r. Omics: Transcriptome analysis by RNAseq Unspecified Group: Insect cell line 21096539 CVCL_Z621 4a-2s4 spontaneously immortalized cell line CVCL_Z621 CL:0000010 Breed/subspecies: 4a r/r. Unspecified Group: Insect cell line 21096540 CVCL_Z622 4a-3A spontaneously immortalized cell line CVCL_Z622 CL:0000010 Breed/subspecies: 4a r/r. Omics: Transcriptome analysis by RNAseq Discontinued: BEI_Resources; MRA-918; probable Unspecified Group: Insect cell line 21096541 CVCL_Z605 OS3 [Human lung carcinoma] cancer cell line human CVCL_Z605 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21096542 CVCL_Z606 OS3-R5 cancer cell line human CVCL_Z606 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21096543 CVCL_Z607 OS4 cancer cell line human CVCL_Z607 CL:0000010 Population: Japanese. Unspecified 21096544 CVCL_Z608 OS5 cancer cell line human CVCL_Z608 CL:0000010 Population: Japanese. Unspecified 21096545 CVCL_Z601 NNR cancer cell line human CVCL_Z601 CL:0000010 Derived from sampling site: Brain. Female 21096546 CVCL_Z602 OS1 [Human lung carcinoma] cancer cell line human CVCL_Z602 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21096547 CVCL_Z603 OS2 [Human lung carcinoma] cancer cell line human CVCL_Z603 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female 21096548 CVCL_Z604 OS2-RA cancer cell line human CVCL_Z604 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female 21096549 CVCL_Z609 OS6 cancer cell line human CVCL_Z609 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096550 CVCL_Z610 OS7 cancer cell line human CVCL_Z610 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21096551 CVCL_Z611 OS10 cancer cell line human CVCL_Z611 CL:0000010 Population: Japanese. Unspecified 21096552 CVCL_Z600 NN [Human glioblastoma Arizona] cancer cell line human CVCL_Z600 CL:0000010 Derived from sampling site: Brain. Female 21096553 CVCL_7080 MKT-BR cancer cell line human CVCL_7080 CL:0000010 Omics: Transcriptome analysis by microarray. 21096554 CVCL_7081 MR-Mel cancer cell line human CVCL_7081 CL:0000010 21096555 CVCL_7082 NA cancer cell line human CVCL_7082 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220His (c.658T>C); ClinVar=VCV000376687; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from sampling site: Oral cavity; tongue. Female Doubling time: ~21.6 hours (DOI=10.5794/jjoms.36.868) 21096556 CVCL_7083 NE-18 cancer cell line human CVCL_7083 CL:0000010 Female 21096557 CVCL_7088 PC-10 cancer cell line human CVCL_7088 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=10536175; PubMed=12794755; PubMed=20557307). Population: Japanese Female 21096558 CVCL_7084 NPC/HK1 cancer cell line human CVCL_7084 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male Virology: EBV-negative Doubling time: 28 +- 2 hours (PubMed=6259064) 21096559 CVCL_7085 Nu6-1 cancer cell line human CVCL_7085 CL:0000010 Female 21096560 CVCL_7086 Nu61 cancer cell line human CVCL_7086 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (from parent cell line) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Oral cavity; tongue. Male Characteristics: Established after 8 serial cycles of passage of the parental cell line in athymic nude mice and in vivo irradiation 21096561 CVCL_7087 PaCa-44 cancer cell line human CVCL_7087 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Unspecified (PubMed=11787853) Derived from sampling site: Pancreas. Male 21096562 CVCL_7091 PC6 cancer cell line Norway rat CVCL_7091 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096563 CVCL_7092 PC6-1 cancer cell line Norway rat CVCL_7092 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096564 CVCL_7093 PC6-10 cancer cell line Norway rat CVCL_7093 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096565 CVCL_7094 PC6-11 cancer cell line Norway rat CVCL_7094 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096566 CVCL_7090 PC4 cancer cell line Norway rat CVCL_7090 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096567 CVCL_7099 PC6-16 cancer cell line Norway rat CVCL_7099 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096568 CVCL_7095 PC6-12 cancer cell line Norway rat CVCL_7095 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096569 CVCL_7096 PC6-13 cancer cell line Norway rat CVCL_7096 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096570 CVCL_7097 PC6-14 cancer cell line Norway rat CVCL_7097 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096571 CVCL_7098 PC6-15 cancer cell line Norway rat CVCL_7098 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096572 CVCL_7060 Ma-2 cancer cell line human CVCL_7060 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 22.8 hours (PubMed=1650680) 21096573 CVCL_7061 Ma-10 cancer cell line human CVCL_7061 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 75.0 hours (PubMed=1650680) 21096574 CVCL_7066 Ma-26 cancer cell line human CVCL_7066 CL:0000010 Sequence variation: Mutation; HGNC; 2701; DCC; Simple; p.Asp832Asn (c.2494G>A); Zygosity=Heterozygous (PubMed=11005564); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=10536175; PubMed=20557307). Population: Japanese Male 21096575 CVCL_7067 Ma-29 cancer cell line human CVCL_7067 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser121fs (c.361delT); Zygosity=Unspecified (PubMed=10536175; PubMed=20557307). Population: Japanese Male 21096576 CVCL_7068 Ma-3 cancer cell line human CVCL_7068 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=10536175) Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 31.6 hours (PubMed=1650680) 21096577 CVCL_7069 Ma-31 cancer cell line human CVCL_7069 CL:0000010 Population: Japanese. Male 21096578 CVCL_7062 Ma-12 cancer cell line human CVCL_7062 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 23.0 hours (PubMed=1650680) 21096579 CVCL_7063 Ma-17 cancer cell line human CVCL_7063 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (PubMed=20557307) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 63.4 hours (PubMed=1650680) 21096580 CVCL_7064 Ma-24 cancer cell line human CVCL_7064 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307). Population: Japanese Male 21096581 CVCL_7065 Ma-25 cancer cell line human CVCL_7065 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307). Population: Japanese Male 21096582 CVCL_7059 Ma-1 cancer cell line human CVCL_7059 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Unspecified (PubMed=17332333); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=10536175) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 25.9 hours (PubMed=1650680) 21096583 CVCL_7070 Ma-34 cancer cell line human CVCL_7070 CL:0000010 Population: Japanese. Unspecified 21096584 CVCL_7071 Ma-44 cancer cell line human CVCL_7071 CL:0000010 Population: Japanese Characteristics: Highly tumorigenic. 21096585 CVCL_7072 Ma-45 cancer cell line human CVCL_7072 CL:0000010 Population: Japanese. Unspecified 21096586 CVCL_7077 Me665/2 cancer cell line human CVCL_7077 CL:0000010 Derived from metastatic site: Hypodermis. Female 21096587 CVCL_7078 Me665/2/21 cancer cell line human CVCL_7078 CL:0000010 Derived from metastatic site: Hypodermis. Female 21096588 CVCL_7079 Me665/2/60 cancer cell line human CVCL_7079 CL:0000010 Derived from metastatic site: Hypodermis. Female 21096589 CVCL_7073 Ma-46 cancer cell line human CVCL_7073 CL:0000010 Population: Japanese. Male 21096590 CVCL_7074 Ma-53 cancer cell line human CVCL_7074 CL:0000010 Population: Japanese. Unspecified 21096591 CVCL_7075 MB-02 cancer cell line human CVCL_7075 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098) Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 dependent Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00165 Problematic cell line: Partially contaminated Some stocks were contaminated by HU-3 (PubMed=10516762). 21096592 CVCL_7076 MB49 cancer cell line house mouse CVCL_7076 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=22559978); Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Urinary bladder; Breed/subspecies: C57BL/ICRF-a(t). Male 21096593 CVCL_Z689 BCIRL/AMCY-TnE-CLG3 spontaneously immortalized cell line CVCL_Z689 CL:0000010 Unspecified Group: Insect cell line. 21096594 CVCL_7044 GIST882 cancer cell line human CVCL_7044 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys642Glu (c.1924A>G); ClinVar=VCV000013866; Zygosity=Homozygous (PubMed=11526490; PubMed=16077968) Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. 21096595 CVCL_7045 GR-Mel cancer cell line human CVCL_7045 CL:0000010 Derived from sampling site: Skin. Microsatellite instability: Stable (MSS) (PubMed=11851879) 21096596 CVCL_7046 HA22T/VGH cancer cell line human CVCL_7046 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg22Glyfs*14 (c.63_85del23); Zygosity=Unspecified (PubMed=7972006) Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Mitochondrial genome sequenced Male 21096597 CVCL_7047 HK-1 cancer cell line human CVCL_7047 CL:0000010 Population: Mongolian; Derived from metastatic site: Cervical lymph node. Male Doubling time: ~24 hours (PubMed=1851672) 21096598 CVCL_7040 GIST430 cancer cell line human CVCL_7040 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Leu576del (c.1678_1728del); ClinVar=VCV000523644; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758; PubMed=25239608); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val654Ala (c.1961T>C); ClinVar=VCV000375921; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758; PubMed=25239608) Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. 21096599 CVCL_7041 GIST48 cancer cell line human CVCL_7041 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Ala (c.2459A>C); ClinVar=VCV000953798; Zygosity=Heterozygous (PubMed=16954519; PubMed=16982758); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Asp (c.1679T>A); ClinVar=VCV000375914; Zygosity=Homozygous (PubMed=16954519; PubMed=16982758) Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. 21096600 CVCL_7042 GIST522 cancer cell line human CVCL_7042 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Glu554_Lys558del (c.1661_1675del); Zygosity=Heterozygous (PubMed=19706776). 21096601 CVCL_7043 GIST62 cancer cell line human CVCL_7043 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Unexplicit; Ex11del; Zygosity=Unspecified (PubMed=16982758; PubMed=19706776). 21096602 CVCL_Z690 BCIRL/AMCY-TnTS-GES1 spontaneously immortalized cell line CVCL_Z690 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21096603 CVCL_Z691 BCIRL/AMCY-TnTS-GES3 spontaneously immortalized cell line CVCL_Z691 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21096604 CVCL_7037 CN-Mel cancer cell line human CVCL_7037 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (PubMed=11851879) 21096605 CVCL_7038 CR-Mel cancer cell line human CVCL_7038 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (PubMed=11851879) 21096606 CVCL_7039 EJ [Human endometrial adenocarcinoma] cancer cell line human CVCL_7039 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 16 hours (PubMed=12889855) 21096607 CVCL_Z696 SES-Bm-1 30A spontaneously immortalized cell line CVCL_Z696 CL:0000010 Breed/subspecies: 1 30(pM, Ze, L, q). Unspecified Group: Insect cell line 21096608 CVCL_Z697 SES-Bm-1 30R spontaneously immortalized cell line CVCL_Z697 CL:0000010 Breed/subspecies: 1 30(pM, Ze, L, q). Unspecified Group: Insect cell line 21096609 CVCL_Z698 SES-Bm-e 21A spontaneously immortalized cell line CVCL_Z698 CL:0000010 Breed/subspecies: e21. Unspecified Group: Insect cell line 21096610 CVCL_Z699 SES-Bm-e 21B spontaneously immortalized cell line CVCL_Z699 CL:0000010 Breed/subspecies: e21. Unspecified Group: Insect cell line 21096611 CVCL_Z692 HCRL-ATO10 spontaneously immortalized cell line CVCL_Z692 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 34 hours (DOI=10.1016/0022-2011(90)90038-8) Group: Insect cell line 21096612 CVCL_Z693 HCRL-ATO20 spontaneously immortalized cell line CVCL_Z693 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 35 hours (DOI=10.1016/0022-2011(90)90038-8) Group: Insect cell line 21096613 CVCL_Z694 SES-Bma-01A spontaneously immortalized cell line CVCL_Z694 CL:0000010 Unspecified Group: Insect cell line. 21096614 CVCL_Z695 SES-Bma-01R spontaneously immortalized cell line CVCL_Z695 CL:0000010 Unspecified Group: Insect cell line. 21096615 CVCL_7050 KP-MRT-NS cancer cell line human CVCL_7050 CL:0000010 Population: Japanese; Karyotypic information: 46,XX,add(10)(q26) [17]; 46,XX,add(10)(q26),dic(1;2)(p22;q31) [3] (PubMed=10417765); Derived from metastatic site: Ascites. Female Doubling time: 72 hours (PubMed=10417765) 21096616 CVCL_Z678 BCIRL/AMCY-OnFB-GES3 spontaneously immortalized cell line CVCL_Z678 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21096617 CVCL_Z679 BCIRL/AMCY-PxE-CLG spontaneously immortalized cell line CVCL_Z679 CL:0000010 Unspecified Group: Insect cell line. 21096618 CVCL_7055 KT-2 cancer cell line human CVCL_7055 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=17332333). Population: Japanese Male 21096619 CVCL_7056 KT-4 cancer cell line human CVCL_7056 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=17332333). Population: Japanese Male 21096620 CVCL_7057 MA 2 cancer cell line human CVCL_7057 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 70 hours (PubMed=9131270) 21096621 CVCL_7058 MA 3 cancer cell line human CVCL_7058 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 78 hours (PubMed=9131270) 21096622 CVCL_7051 KP-MRT-RY cancer cell line human CVCL_7051 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21096623 CVCL_7052 KP-MRT-YM cancer cell line human CVCL_7052 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=15378398) Population: Japanese; Derived from sampling site: Chest wall. Male 21096624 CVCL_7053 LCP-Mel cancer cell line human CVCL_7053 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from sampling site: Skin. Unspecified 21096625 CVCL_7054 Lec15.1 spontaneously immortalized cell line CVCL_7054 CL:0000010 Sequence variation: Mutation; UniProtKB; Q9Z1P1; Dpm2; Simple; p.Gly10Glu (c.29G>A); Zygosity=Unspecified (PubMed=14680801) Derived from sampling site: Ovary. Female 21096626 CVCL_Z680 BCIRL/AMCY-PxLP-CLG spontaneously immortalized cell line CVCL_Z680 CL:0000010 Unspecified Group: Insect cell line. 21096627 CVCL_7048 HK-2 [Human lung carcinoma] cancer cell line human CVCL_7048 CL:0000010 Population: Mongolian; Derived from metastatic site: Cervical lymph node. Male Characteristics: Established from a rat xenograft of the HK-1 cell line 21096628 CVCL_7049 MP-MRT-AN cancer cell line human CVCL_7049 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21096629 CVCL_Z685 BCIRL/AMCY-TnE-CLG1 spontaneously immortalized cell line CVCL_Z685 CL:0000010 Unspecified Group: Insect cell line. 21096630 CVCL_Z686 BCIRL/AMCY-TnE-CLG1MK spontaneously immortalized cell line CVCL_Z686 CL:0000010 Unspecified Group: Insect cell line. 21096631 CVCL_Z687 BCIRL/AMCY-TnE-CLG2 spontaneously immortalized cell line CVCL_Z687 CL:0000010 Unspecified Group: Insect cell line. 21096632 CVCL_Z688 BCIRL/AMCY-TnE-CLG2MK spontaneously immortalized cell line CVCL_Z688 CL:0000010 Unspecified Group: Insect cell line. 21096633 CVCL_Z681 BCIRL/AMCY-SeE-CLG1 spontaneously immortalized cell line CVCL_Z681 CL:0000010 Unspecified Group: Insect cell line. 21096634 CVCL_Z682 BCIRL/AMCY-SeE-CLG4 spontaneously immortalized cell line CVCL_Z682 CL:0000010 Unspecified Group: Insect cell line. 21096635 CVCL_Z683 BCIRL/AMCY-SeE-CLG5 spontaneously immortalized cell line CVCL_Z683 CL:0000010 Unspecified Group: Insect cell line. 21096636 CVCL_Z684 BCIRL/AMCY-SfTS-GES spontaneously immortalized cell line CVCL_Z684 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21096637 CVCL_Z667 BCIRL/AMCY-HvOV-CLG spontaneously immortalized cell line CVCL_Z667 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096638 CVCL_Z668 BCIRL/AMCY-HvTS-GES spontaneously immortalized cell line CVCL_Z668 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21096639 CVCL_Z669 BCIRL/AMCY-HzE-CLG1 spontaneously immortalized cell line CVCL_Z669 CL:0000010 Unspecified Group: Insect cell line. 21096640 CVCL_7022 ACC-LC-60 cancer cell line human CVCL_7022 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096641 CVCL_7023 ACC-LC-61 cancer cell line human CVCL_7023 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096642 CVCL_7024 ACC-LC-67 cancer cell line human CVCL_7024 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096643 CVCL_7025 ACC-LC-71 cancer cell line human CVCL_7025 CL:0000010 Population: Japanese. Unspecified 21096644 CVCL_7020 ACC-LC-5 cancer cell line human CVCL_7020 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21096645 CVCL_7021 ACC-LC-52 cancer cell line human CVCL_7021 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Unspecified 21096646 CVCL_7019 ACC-LC-49 cancer cell line human CVCL_7019 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Valfs*13 (c.328delC); ClinVar=VCV000127807; Zygosity=Unspecified (PubMed=12794755) Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21096647 CVCL_7015 ACC-LC-33 cancer cell line human CVCL_7015 CL:0000010 Population: Japanese. Unspecified 21096648 CVCL_7016 ACC-LC-35 cancer cell line human CVCL_7016 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary lymph node. Male 21096649 CVCL_7017 ACC-LC-36 cancer cell line human CVCL_7017 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary lymph node. Male 21096650 CVCL_7018 ACC-LC-48 cancer cell line human CVCL_7018 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=12794755) Population: Japanese; Derived from metastatic site: Pericardial effusion. Unspecified 21096651 CVCL_Z674 BCIRL/AMCY-HzE-CLG7 spontaneously immortalized cell line CVCL_Z674 CL:0000010 Unspecified Group: Insect cell line. 21096652 CVCL_Z675 BCIRL/AMCY-HzE-CLG8 spontaneously immortalized cell line CVCL_Z675 CL:0000010 Unspecified Group: Insect cell line. 21096653 CVCL_Z676 BCIRL/AMCY-HzE-CLG9 spontaneously immortalized cell line CVCL_Z676 CL:0000010 Unspecified Group: Insect cell line. 21096654 CVCL_Z677 BCIRL/AMCY-OnFB-GES1 spontaneously immortalized cell line CVCL_Z677 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21096655 CVCL_Z670 BCIRL/AMCY-HzE-CLG2 spontaneously immortalized cell line CVCL_Z670 CL:0000010 Unspecified Group: Insect cell line. 21096656 CVCL_Z671 BCIRL/AMCY-HzE-CLG3 spontaneously immortalized cell line CVCL_Z671 CL:0000010 Unspecified Group: Insect cell line. 21096657 CVCL_Z672 BCIRL/AMCY-HzE-CLG5 spontaneously immortalized cell line CVCL_Z672 CL:0000010 Unspecified Group: Insect cell line. 21096658 CVCL_Z673 BCIRL/AMCY-HzE-CLG6 spontaneously immortalized cell line CVCL_Z673 CL:0000010 Unspecified Group: Insect cell line. 21096659 CVCL_Z656 BCIRL/AMCY-AfOV-CLG spontaneously immortalized cell line CVCL_Z656 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21096660 CVCL_Z657 BCIRL/AMCY-AfTS-CLG spontaneously immortalized cell line CVCL_Z657 CL:0000010 Derived from sampling site: Testis and fat body. Male Group: Insect cell line 21096661 CVCL_Z658 BCIRL/AMCY-AgE-CLG spontaneously immortalized cell line CVCL_Z658 CL:0000010 Unspecified Group: Insect cell line. 21096662 CVCL_Z659 BCIRL/AMCY-AgOV-CLG1 spontaneously immortalized cell line CVCL_Z659 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21096663 CVCL_7033 ACC-LC-96 cancer cell line human CVCL_7033 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096664 CVCL_7034 BL-60 cancer cell line human CVCL_7034 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=1945409); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=2052620) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw. Female Virology: Contains an integrated EBV genome (PubMed=8382295) 21096665 CVCL_7035 BLM cancer cell line human CVCL_7035 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=25728708) Population: Caucasian; Derived from sampling site: Shoulder; skin. Omics: Transcriptome analysis by RNAseq Male Characteristics: Obtained by injection of parent cell line in nude mice and selection of cells from lung metastases 21096666 CVCL_7036 BRO cancer cell line human CVCL_7036 CL:0000010 Population: Caucasian; Derived from sampling site: Shoulder; skin. Male 21096667 CVCL_7030 ACC-LC-91 cancer cell line human CVCL_7030 CL:0000010 Population: Japanese. Unspecified 21096668 CVCL_7031 ACC-LC-93 cancer cell line human CVCL_7031 CL:0000010 Population: Japanese. Unspecified 21096669 CVCL_7032 ACC-LC-94 cancer cell line human CVCL_7032 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=12794755); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Unspecified (PubMed=12794755) Population: Japanese; Derived from metastatic site: Cervical lymph node. Unspecified 21096670 CVCL_7026 ACC-LC-73 cancer cell line human CVCL_7026 CL:0000010 Population: Japanese. Unspecified 21096671 CVCL_7027 ACC-LC-76 cancer cell line human CVCL_7027 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096672 CVCL_7028 ACC-LC-80 cancer cell line human CVCL_7028 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Unspecified (PubMed=12794755) Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21096673 CVCL_7029 ACC-LC-87 cancer cell line human CVCL_7029 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21096674 CVCL_Z663 BCIRL/AMCY-AiTS-CLG spontaneously immortalized cell line CVCL_Z663 CL:0000010 Derived from sampling site: Testis and fat body. Male Group: Insect cell line 21096675 CVCL_Z664 BCIRL/AMCY-HvE-CLG1 spontaneously immortalized cell line CVCL_Z664 CL:0000010 Unspecified Group: Insect cell line. 21096676 CVCL_Z665 BCIRL/AMCY-HvE-CLG2 spontaneously immortalized cell line CVCL_Z665 CL:0000010 Unspecified Group: Insect cell line. 21096677 CVCL_Z666 BCIRL/AMCY-HvE-CLG3 spontaneously immortalized cell line CVCL_Z666 CL:0000010 Unspecified Group: Insect cell line. 21096678 CVCL_Z660 BCIRL/AMCY-AgOV-CLG2 spontaneously immortalized cell line CVCL_Z660 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21096679 CVCL_Z661 BCIRL/AMCY-AgOV-CLG3 spontaneously immortalized cell line CVCL_Z661 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21096680 CVCL_Z662 BCIRL/AMCY-AiOV-CLG spontaneously immortalized cell line CVCL_Z662 CL:0000010 Derived from sampling site: Ovary and fat body. Female Group: Insect cell line 21096681 CVCL_HD52 DLD-1 AKT1(-/-) cancer cell line human CVCL_HD52 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 391; AKT1. Male 21096682 CVCL_HD53 DLD-1 AKT2(-/-) cancer cell line human CVCL_HD53 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 392; AKT2. Male 21096683 CVCL_HD54 DLD-1 ATG7(+/-) cancer cell line human CVCL_HD54 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 16935; ATG7. Male 21096684 CVCL_HD55 DLD-1 BBC3(-/-) cancer cell line human CVCL_HD55 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17868; BBC3. Male 21096685 CVCL_HD50 HEK293 eGFP-ZSCAN5A transformed cell line human CVCL_HD50 CL:0000010 Transfected with: HGNC; 23710; ZSCAN5A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096686 CVCL_HD51 HEK293 eGFP-ZXDB transformed cell line human CVCL_HD51 CL:0000010 Transfected with: HGNC; 13199; ZXDB; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096687 CVCL_HD49 HEK293 eGFP-ZSCAN4 transformed cell line human CVCL_HD49 CL:0000010 Transfected with: HGNC; 23709; ZSCAN4; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096688 CVCL_HD45 HEK293 eGFP-ZNF800 transformed cell line human CVCL_HD45 CL:0000010 Transfected with: HGNC; 27267; ZNF800; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096689 CVCL_HD46 HEK293 eGFP-ZNF837 transformed cell line human CVCL_HD46 CL:0000010 Transfected with: HGNC; 25164; ZNF837; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096690 CVCL_HD47 HEK293 eGFP-ZSCAN16 transformed cell line human CVCL_HD47 CL:0000010 Transfected with: HGNC; 20813; ZSCAN16; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096691 CVCL_HD48 HEK293 eGFP-ZSCAN23 transformed cell line human CVCL_HD48 CL:0000010 Transfected with: HGNC; 21193; ZSCAN23; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096692 CVCL_HD63 DLD-1 SLC2A1(-/-) cancer cell line human CVCL_HD63 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 11005; SLC2A1. Male 21096693 CVCL_HD64 DLD-1 USP7(-/-) cancer cell line human CVCL_HD64 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 12630; USP7. Male 21096694 CVCL_HD65 HaCaT BHLHE40 (-/-) spontaneously immortalized cell line human CVCL_HD65 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1046; BHLHE40; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 21096695 CVCL_HD66 HCT 116 AKT1(-/-) cancer cell line human CVCL_HD66 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 391; AKT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096696 CVCL_HD60 DLD-1 FBXW7(+/-) cancer cell line human CVCL_HD60 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 16712; FBXW7. Male 21096697 CVCL_HD61 DLD-1 FBXW7(-/-) cancer cell line human CVCL_HD61 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 16712; FBXW7. Male 21096698 CVCL_HD62 DLD-1 KRAS(+/-) 1 cancer cell line human CVCL_HD62 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS Miscellaneous: Horizon distributes two DLD-1 KRAS(+/-) cell lines, one developed internally (Cellosaurus=CVCL_HE28) and one originating from the group of Volgenstein (Cellosaurus=CVCL_HD62). Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21096699 CVCL_HD56 DLD-1 BRCA2(+/-) cancer cell line human CVCL_HD56 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 1101; BRCA2. Male 21096700 CVCL_HD57 DLD-1 BRCA2(-/-) cancer cell line human CVCL_HD57 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1101; BRCA2. Male 21096701 CVCL_HD58 DLD-1 CDKN1A(-/-) cancer cell line human CVCL_HD58 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1784; CDKN1A. Male 21096702 CVCL_HD59 DLD-1 DICER1(-/-) cancer cell line human CVCL_HD59 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17098; DICER1. Male 21096703 CVCL_HD30 HEK293 eGFP-ZNF580 transformed cell line human CVCL_HD30 CL:0000010 Transfected with: HGNC; 29473; ZNF580; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096704 CVCL_HD31 HEK293 eGFP-ZNF585B transformed cell line human CVCL_HD31 CL:0000010 Transfected with: HGNC; 30948; ZNF585B; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096705 CVCL_HD32 HEK293 eGFP-ZNF600 transformed cell line human CVCL_HD32 CL:0000010 Transfected with: HGNC; 30951; ZNF600; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096706 CVCL_HD33 HEK293 eGFP-ZNF610 transformed cell line human CVCL_HD33 CL:0000010 Transfected with: HGNC; 26687; ZNF610; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096707 CVCL_HD27 HEK293 eGFP-ZNF547 transformed cell line human CVCL_HD27 CL:0000010 Transfected with: HGNC; 26432; ZNF547; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096708 CVCL_HD28 HEK293 eGFP-ZNF558 transformed cell line human CVCL_HD28 CL:0000010 Transfected with: HGNC; 26422; ZNF558; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096709 CVCL_HD29 HEK293 eGFP-ZNF572 transformed cell line human CVCL_HD29 CL:0000010 Transfected with: HGNC; 26758; ZNF572; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096710 CVCL_HD23 HEK293 eGFP-ZNF354C transformed cell line human CVCL_HD23 CL:0000010 Transfected with: HGNC; 16736; ZNF354C; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096711 CVCL_HD24 HEK293 eGFP-ZNF391 transformed cell line human CVCL_HD24 CL:0000010 Transfected with: HGNC; 18779; ZNF391; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096712 CVCL_HD25 HEK293 eGFP-ZNF423 transformed cell line human CVCL_HD25 CL:0000010 Transfected with: HGNC; 16762; ZNF423; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096713 CVCL_HD26 HEK293 eGFP-ZNF488 transformed cell line human CVCL_HD26 CL:0000010 Transfected with: HGNC; 23535; ZNF488; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096714 CVCL_HD41 HEK293 eGFP-ZNF707 transformed cell line human CVCL_HD41 CL:0000010 Transfected with: HGNC; 27815; ZNF707; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096715 CVCL_HD42 HEK293 eGFP-ZNF76 transformed cell line human CVCL_HD42 CL:0000010 Transfected with: HGNC; 13149; ZNF76; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096716 CVCL_HD43 HEK293 eGFP-ZNF781 transformed cell line human CVCL_HD43 CL:0000010 Transfected with: HGNC; 26745; ZNF781; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096717 CVCL_HD44 HEK293 eGFP-ZNF8 transformed cell line human CVCL_HD44 CL:0000010 Transfected with: HGNC; 13154; ZNF8; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096718 CVCL_HD40 HEK293 eGFP-ZNF697 transformed cell line human CVCL_HD40 CL:0000010 Transfected with: HGNC; 32034; ZNF697; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096719 CVCL_HD38 HEK293 eGFP-ZNF664 transformed cell line human CVCL_HD38 CL:0000010 Transfected with: HGNC; 25406; ZNF664; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096720 CVCL_HD39 HEK293 eGFP-ZNF680 transformed cell line human CVCL_HD39 CL:0000010 Transfected with: HGNC; 26897; ZNF680; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096721 CVCL_HD34 HEK293 eGFP-ZNF623 transformed cell line human CVCL_HD34 CL:0000010 Transfected with: HGNC; 29084; ZNF623; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096722 CVCL_HD35 HEK293 eGFP-ZNF639 transformed cell line human CVCL_HD35 CL:0000010 Transfected with: HGNC; 30950; ZNF639; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096723 CVCL_HD36 HEK293 eGFP-ZNF654 transformed cell line human CVCL_HD36 CL:0000010 Transfected with: HGNC; 25612; ZNF654; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096724 CVCL_HD37 HEK293 eGFP-ZNF655 transformed cell line human CVCL_HD37 CL:0000010 Transfected with: HGNC; 30899; ZNF655; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096725 CVCL_HD10 HEK293 eGFP-ZNF146 transformed cell line human CVCL_HD10 CL:0000010 Transfected with: HGNC; 12931; ZNF146; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096726 CVCL_HD11 HEK293 eGFP-ZNF16 transformed cell line human CVCL_HD11 CL:0000010 Transfected with: HGNC; 12947; ZNF16; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096727 CVCL_HD09 HEK293 eGFP-ZNF138 transformed cell line human CVCL_HD09 CL:0000010 Transfected with: HGNC; 12922; ZNF138; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096728 CVCL_HD05 HEK293 eGFP-ZFP3 transformed cell line human CVCL_HD05 CL:0000010 Transfected with: HGNC; 12861; ZFP3; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096729 CVCL_HD06 HEK293 eGFP-ZFP41 transformed cell line human CVCL_HD06 CL:0000010 Transfected with: HGNC; 26786; ZFP41; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096730 CVCL_HD07 HEK293 eGFP-ZFP62 transformed cell line human CVCL_HD07 CL:0000010 Transfected with: HGNC; 23241; ZFP62; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096731 CVCL_HD08 HEK293 eGFP-ZFP64 transformed cell line human CVCL_HD08 CL:0000010 Transfected with: HGNC; 15940; ZFP64; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096732 CVCL_HD01 HEK293 eGFP-ZBTB7A transformed cell line human CVCL_HD01 CL:0000010 Transfected with: HGNC; 18078; ZBTB7A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096733 CVCL_HD02 HEK293 eGFP-ZBTB8A transformed cell line human CVCL_HD02 CL:0000010 Transfected with: HGNC; 24172; ZBTB8A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096734 CVCL_HD03 HEK293 eGFP-ZEB1 transformed cell line human CVCL_HD03 CL:0000010 Transfected with: HGNC; 11642; ZEB1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096735 CVCL_HD04 HEK293 eGFP-ZEB2 transformed cell line human CVCL_HD04 CL:0000010 Transfected with: HGNC; 14881; ZEB2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096736 CVCL_HD20 HEK293 eGFP-ZNF324 transformed cell line human CVCL_HD20 CL:0000010 Transfected with: HGNC; 14096; ZNF324; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096737 CVCL_HD21 HEK293 eGFP-ZNF335 transformed cell line human CVCL_HD21 CL:0000010 Transfected with: HGNC; 15807; ZNF335; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096738 CVCL_HD22 HEK293 eGFP-ZNF341 transformed cell line human CVCL_HD22 CL:0000010 Transfected with: HGNC; 15992; ZNF341; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096739 CVCL_HD16 HEK293 eGFP-ZNF24 transformed cell line human CVCL_HD16 CL:0000010 Transfected with: HGNC; 13032; ZNF24; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096740 CVCL_HD17 HEK293 eGFP-ZNF264 transformed cell line human CVCL_HD17 CL:0000010 Transfected with: HGNC; 13057; ZNF264; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096741 CVCL_HD18 HEK293 eGFP-ZNF292 transformed cell line human CVCL_HD18 CL:0000010 Transfected with: HGNC; 18410; ZNF292; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096742 CVCL_HD19 HEK293 eGFP-ZNF32 transformed cell line human CVCL_HD19 CL:0000010 Transfected with: HGNC; 13095; ZNF32; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096743 CVCL_HD12 HEK293 eGFP-ZNF165 transformed cell line human CVCL_HD12 CL:0000010 Transfected with: HGNC; 12953; ZNF165; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096744 CVCL_HD13 HEK293 eGFP-ZNF175 transformed cell line human CVCL_HD13 CL:0000010 Transfected with: HGNC; 12964; ZNF175; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096745 CVCL_HD14 HEK293 eGFP-ZNF18 transformed cell line human CVCL_HD14 CL:0000010 Transfected with: HGNC; 12969; ZNF18; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096746 CVCL_HD15 HEK293 eGFP-ZNF239 transformed cell line human CVCL_HD15 CL:0000010 Transfected with: HGNC; 13031; ZNF239; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096747 CVCL_HD00 HEK293 eGFP-ZBTB49 transformed cell line human CVCL_HD00 CL:0000010 Transfected with: HGNC; 19883; ZBTB49; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21096748 CVCL_Z803 ML83-1b spontaneously immortalized cell line CVCL_Z803 CL:0000010 Unspecified Doubling time: 66-74 hours, depending on growth medium (DGRC). Group: Insect cell line 21096749 CVCL_Z804 ML83-26 spontaneously immortalized cell line fruit fly CVCL_Z804 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Doubling time: 30-42 hours, depending on growth medium (DGRC) Group: Insect cell line 21096750 CVCL_Z805 ML83-33 spontaneously immortalized cell line CVCL_Z805 CL:0000010 Unspecified Doubling time: 1 week (DGRC). Group: Insect cell line 21096751 CVCL_Z806 ML83-62 spontaneously immortalized cell line fruit fly CVCL_Z806 CL:0000010 Unspecified Doubling time: 101 hours (DGRC). Group: Insect cell line 21096752 CVCL_Z800 MCW23 spontaneously immortalized cell line fruit fly CVCL_Z800 CL:0000010 Discontinued: DGRC; 161; probable. Unspecified Group: Insect cell line 21096753 CVCL_Z801 ML81-18 spontaneously immortalized cell line fruit fly CVCL_Z801 CL:0000010 Unspecified Doubling time: 22-24 hours, depending on growth medium (DGRC). Group: Insect cell line 21096754 CVCL_Z802 ML82-19a spontaneously immortalized cell line CVCL_Z802 CL:0000010 Unspecified Group: Insect cell line. 21096755 CVCL_Z807 ML83-63 spontaneously immortalized cell line CVCL_Z807 CL:0000010 Unspecified Doubling time: 56 hours (DGRC). Group: Insect cell line 21096756 CVCL_Z808 ML83-68 spontaneously immortalized cell line CVCL_Z808 CL:0000010 Unspecified Doubling time: 34-47 hours, depending on growth medium (DGRC). Group: Insect cell line 21096757 CVCL_Z809 ML84-1 spontaneously immortalized cell line fruit fly CVCL_Z809 CL:0000010 Unspecified Doubling time: 120 hours (DGRC). Group: Insect cell line 21096758 CVCL_HD96 HCT 116 TP53(+/-) cancer cell line human CVCL_HD96 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096759 CVCL_HD97 HCT 116 TP53(-/-) cancer cell line human CVCL_HD97 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male 21096760 CVCL_HD98 HCT 116 USP7(+/-) cancer cell line human CVCL_HD98 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12630; USP7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096761 CVCL_HD99 HCT 116 USP7(-/-) cancer cell line human CVCL_HD99 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 12630; USP7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096762 CVCL_HD92 HCT 116 PTEN(-/-) cancer cell line human CVCL_HD92 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9588; PTEN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096763 CVCL_HD93 HCT 116 PTTG1(-/-) cancer cell line human CVCL_HD93 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9690; PTTG1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096764 CVCL_HD94 HCT 116 SFN(-/-) cancer cell line human CVCL_HD94 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 10773; SFN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096765 CVCL_HD95 HCT 116 SMAD4(-/-) cancer cell line human CVCL_HD95 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096766 CVCL_HD90 HCT 116 PRKDC(-/-) cancer cell line human CVCL_HD90 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9413; PRKDC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096767 CVCL_HD91 HCT 116 PTEN(+/-) cancer cell line human CVCL_HD91 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9588; PTEN; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096768 CVCL_HD89 HCT 116 PRKDC(+/-) cancer cell line human CVCL_HD89 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9413; PRKDC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096769 CVCL_HD74 HCT 116 CTNNB1(+/-) cancer cell line human CVCL_HD74 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 2514; CTNNB1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: In HCT 116 one of the two CTNNB1 alleles has a 3-bp deletion that eliminates S-45 This cell line is KO for the mutant allele. 21096770 CVCL_HD75 HCT 116 DIABLO(-/-) cancer cell line human CVCL_HD75 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 21528; DIABLO; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096771 CVCL_HD76 HCT 116 DICER1(-/-) cancer cell line human CVCL_HD76 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17098; DICER1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096772 CVCL_HD77 HCT 116 DNMT3B(-/-) cancer cell line human CVCL_HD77 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 2979; DNMT3B; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096773 CVCL_HD70 HCT 116 BBC3(-/-) cancer cell line human CVCL_HD70 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17868; BBC3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096774 CVCL_HD71 HCT 116 BLM(-/-) cancer cell line human CVCL_HD71 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1058; BLM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096775 CVCL_HD72 HCT 116 CDK2(-/-) cancer cell line human CVCL_HD72 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1771; CDK2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096776 CVCL_HD73 HCT 116 CDKN1A(-/-) cancer cell line human CVCL_HD73 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1784; CDKN1A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096777 CVCL_HD67 HCT 116 AKT2(-/-) cancer cell line human CVCL_HD67 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 392; AKT2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096778 CVCL_HD68 HCT 116 APOC1(-/-) cancer cell line human CVCL_HD68 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 607; APOC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096779 CVCL_HD69 HCT 116 BAX(-/-) cancer cell line human CVCL_HD69 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 959; BAX; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096780 CVCL_HD85 HCT 116 NHEJ1(+/-) cancer cell line human CVCL_HD85 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 25737; NHEJ1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096781 CVCL_HD86 HCT 116 NHEJ1(-/-) cancer cell line human CVCL_HD86 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 25737; NHEJ1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096782 CVCL_HD87 HCT 116 PDPK1(+/-) cancer cell line human CVCL_HD87 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 8816; PDPK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096783 CVCL_HD88 HCT 116 PPARD(-/-) cancer cell line human CVCL_HD88 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9235; PPARD; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096784 CVCL_HD81 HCT 116 KRAS(+/-) cancer cell line human CVCL_HD81 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096785 CVCL_HD82 HCT 116 LIG4(+/-) cancer cell line human CVCL_HD82 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6601; LIG4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096786 CVCL_HD83 HCT 116 LIG4(-/-) cancer cell line human CVCL_HD83 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 6601; LIG4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096787 CVCL_HD84 HCT 116 MLH1(+/-) cancer cell line human CVCL_HD84 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 7127; MLH1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: HCT 116 has a point mutation C755A in exon 9 of MLH1 This cell line is knockin by homologous recombination of the wild-type MLH1 in 1 of the 2 alleles. 21096788 CVCL_HD80 HCT 116 KDM5A(-/-) cancer cell line human CVCL_HD80 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9886; KDM5A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096789 CVCL_HD78 HCT 116 FBXW7(-/-) cancer cell line human CVCL_HD78 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 16712; FBXW7; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096790 CVCL_HD79 HCT 116 KDM5A(+/-) cancer cell line human CVCL_HD79 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9886; KDM5A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21096791 CVCL_Z766 ML-DmD16-c3 spontaneously immortalized cell line fruit fly CVCL_Z766 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~80 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096792 CVCL_Z767 ML-DmD16-c4 spontaneously immortalized cell line fruit fly CVCL_Z767 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Group: Insect cell line 21096793 CVCL_Z768 ML-DmD16-c6 spontaneously immortalized cell line fruit fly CVCL_Z768 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Doubling time: 74 hours (DGRC) Group: Insect cell line 21096794 CVCL_Z769 ML-DmD16-c7 spontaneously immortalized cell line fruit fly CVCL_Z769 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Doubling time: ~1 week (DGRC) Group: Insect cell line 21096795 CVCL_6P21 DA00744 transformed cell line human CVCL_6P21 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096796 CVCL_7121 SCC-73 cancer cell line human CVCL_7121 CL:0000010 Derived from sampling site: Oral cavity; retromolar trigone. Unspecified 21096797 CVCL_6P22 DA00745 transformed cell line human CVCL_6P22 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096798 CVCL_7122 SCC-76 cancer cell line human CVCL_7122 CL:0000010 Unspecified 21096799 CVCL_6P23 DA00746 transformed cell line human CVCL_6P23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096800 CVCL_7123 SCMC-ES1 cancer cell line human CVCL_7123 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=7591257); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Tyr (c.422G>A); ClinVar=VCV000140801; Zygosity=Unspecified (PubMed=8221663) Population: Japanese Discontinued: JCRB; NIHS0048; true. Female 21096801 CVCL_6P24 DA00747 transformed cell line human CVCL_6P24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096802 CVCL_7124 SCMC-ES2 cancer cell line human CVCL_7124 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=7591257); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=8221663) Population: Japanese Discontinued: JCRB; NIHS0049; true. Male 21096803 CVCL_6P20 DA00743 transformed cell line human CVCL_6P20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096804 CVCL_7120 SCC-71 cancer cell line human CVCL_7120 CL:0000010 Male 21096805 CVCL_6P18 DA00741 transformed cell line human CVCL_6P18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096806 CVCL_7118 SCC-61 cancer cell line human CVCL_7118 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=17848307) Derived from sampling site: Oral cavity; tongue; anterior part. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Characteristics: Good model for studying radiation resistance in squamous cell carcinoma (Millipore); Characteristics: Sensitive to radiation (PubMed=2004949) Part of: MD Anderson Cell Lines Project 21096807 CVCL_6P19 DA00742 transformed cell line human CVCL_6P19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096808 CVCL_7119 SCC-66 cancer cell line human CVCL_7119 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male 21096809 CVCL_6P14 DA00737 transformed cell line human CVCL_6P14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096810 CVCL_7114 RH-SLC-L11 cancer cell line human CVCL_7114 CL:0000010 Female Doubling time: ~30-40 hours (PubMed=6089998). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 85061403 21096811 CVCL_6P15 DA00738 transformed cell line human CVCL_6P15 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096812 CVCL_7115 SCC-35 cancer cell line human CVCL_7115 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=1423286). Unspecified 21096813 CVCL_6P16 DA00739 transformed cell line human CVCL_6P16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096814 CVCL_7116 SCC-49 cancer cell line human CVCL_7116 CL:0000010 Derived from sampling site: Oral cavity; tonsil. Unspecified 21096815 CVCL_6P17 DA00740 transformed cell line human CVCL_6P17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096816 CVCL_7117 SCC-50 cancer cell line human CVCL_7117 CL:0000010 Unspecified 21096817 CVCL_Z773 ML-DmD20-c1 spontaneously immortalized cell line fruit fly CVCL_Z773 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Male Group: Insect cell line 21096818 CVCL_Z774 ML-DmD20-c2 spontaneously immortalized cell line fruit fly CVCL_Z774 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Omics: Transcriptome analysis by RNAseq Male Doubling time: 68 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096819 CVCL_Z775 ML-DmD20-c4 spontaneously immortalized cell line fruit fly CVCL_Z775 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Male Doubling time: 69 hours (DGRC) Group: Insect cell line 21096820 CVCL_Z776 ML-DmD20-c5 spontaneously immortalized cell line fruit fly CVCL_Z776 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096821 CVCL_Z770 ML-DmD16-c8 spontaneously immortalized cell line fruit fly CVCL_Z770 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Doubling time: ~72 hours (DGRC) Group: Insect cell line 21096822 CVCL_Z771 ML-DmD16-c9 spontaneously immortalized cell line fruit fly CVCL_Z771 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Doubling time: 94 hours (DGRC) Group: Insect cell line 21096823 CVCL_Z772 ML-DmD17-c3 spontaneously immortalized cell line fruit fly CVCL_Z772 CL:0000010 Derived from sampling site: Imaginal disc; haltere. Omics: Transcriptome analysis by RNAseq Female Doubling time: 70-94 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096824 CVCL_Z759 ML-DmD1-c6 spontaneously immortalized cell line fruit fly CVCL_Z759 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Group: Insect cell line 21096825 CVCL_Z755 ML-DmD9 spontaneously immortalized cell line fruit fly CVCL_Z755 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 54-67 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096826 CVCL_Z756 ML-DmD1-c3 spontaneously immortalized cell line fruit fly CVCL_Z756 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 58 hours (DGRC) Group: Insect cell line 21096827 CVCL_Z757 ML-DmD1-c4 spontaneously immortalized cell line fruit fly CVCL_Z757 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Male Doubling time: 73-78 hours, depending on growth medium (DGRC) Group: Insect cell line 21096828 CVCL_Z758 ML-DmD1-c5 spontaneously immortalized cell line fruit fly CVCL_Z758 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 37 hours (DGRC) Group: Insect cell line 21096829 CVCL_6P32 DA00755 transformed cell line human CVCL_6P32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096830 CVCL_7132 SMS-KANR cancer cell line human CVCL_7132 CL:0000010 Derived from metastatic site: Bone marrow. Female Doubling time: ~69 hours (PubMed=3456456) 21096831 CVCL_6P33 DA00756 transformed cell line human CVCL_6P33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096832 CVCL_7133 SMS-KCN cancer cell line human CVCL_7133 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep tyrosine phosphoproteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray. Male Characteristics: Substrate-adherent type (S-type) (PubMed=15720811) Doubling time: ~109 hours (PubMed=3456456) 21096833 CVCL_6P34 DA00757 transformed cell line human CVCL_6P34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096834 CVCL_7134 SMS-KCNR cancer cell line human CVCL_7134 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18923523) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: ~72 hours (PubMed=3456456) 21096835 CVCL_6P35 DA00758 transformed cell line human CVCL_6P35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096836 CVCL_7135 SMS-MSN cancer cell line human CVCL_7135 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH Male Doubling time: ~85 hours (PubMed=3456456) 21096837 CVCL_6P30 DA00753 transformed cell line human CVCL_6P30 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096838 CVCL_7130 SCMC-L9 cancer cell line human CVCL_7130 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Cys (c.523C>T); ClinVar=VCV000245851; Zygosity=Unspecified (PubMed=7727782); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=7727782); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu358Lys (c.1072G>A); ClinVar=VCV000142105; Zygosity=Unspecified (PubMed=7727782). Population: Japanese Unspecified 21096839 CVCL_6P31 DA00754 transformed cell line human CVCL_6P31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096840 CVCL_7131 SMS-KAN cancer cell line human CVCL_7131 CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Characteristics: Neuroblastic type (N-type) (PubMed=15720811) Doubling time: ~95 hours (PubMed=3456456) 21096841 CVCL_6P29 DA00752 transformed cell line human CVCL_6P29 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096842 CVCL_7129 SCMC-L20 cancer cell line human CVCL_7129 CL:0000010 Population: Japanese. 21096843 CVCL_6P25 DA00748 transformed cell line human CVCL_6P25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096844 CVCL_7125 SCMC-L1 cancer cell line human CVCL_7125 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638). Population: Japanese Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21096845 CVCL_6P26 DA00749 transformed cell line human CVCL_6P26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096846 CVCL_7126 SCMC-L10 cancer cell line human CVCL_7126 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.627_632AAACAC>CCCACACGCA; Zygosity=Unspecified (PubMed=7727782). Population: Japanese Unspecified 21096847 CVCL_6P27 DA00750 transformed cell line human CVCL_6P27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096848 CVCL_7127 SCMC-L11 cancer cell line human CVCL_7127 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser240Cys (c.718A>T); Zygosity=Unspecified (PubMed=7727782). Population: Japanese Female 21096849 CVCL_6P28 DA00751 transformed cell line human CVCL_6P28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096850 CVCL_7128 SCMC-L2 cancer cell line human CVCL_7128 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072). Population: Japanese Male 21096851 CVCL_Z762 ML-DmD11-c1 spontaneously immortalized cell line fruit fly CVCL_Z762 CL:0000010 Derived from sampling site: Imaginal disc; eye-antenna. Male Doubling time: 66 hours (DGRC) Group: Insect cell line 21096852 CVCL_Z763 ML-DmD11-c2 spontaneously immortalized cell line fruit fly CVCL_Z763 CL:0000010 Derived from sampling site: Imaginal disc; eye-antenna. Male Doubling time: 70 hours (DGRC) Group: Insect cell line 21096853 CVCL_Z764 ML-DmD11-c3 spontaneously immortalized cell line fruit fly CVCL_Z764 CL:0000010 Derived from sampling site: Imaginal disc; eye-antenna. Male Doubling time: 99 hours (DGRC) Group: Insect cell line 21096854 CVCL_Z765 ML-DmD16-c1 spontaneously immortalized cell line fruit fly CVCL_Z765 CL:0000010 Derived from sampling site: Imaginal disc; wing. Female Doubling time: 130 hours (DGRC) Group: Insect cell line 21096855 CVCL_Z760 ML-DmD1-c7 spontaneously immortalized cell line fruit fly CVCL_Z760 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 55 hours (DGRC) Group: Insect cell line 21096856 CVCL_Z761 ML-DmD1-c8 spontaneously immortalized cell line fruit fly CVCL_Z761 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 45 hours (DGRC) Group: Insect cell line 21096857 CVCL_Z748 ML-DmD31 spontaneously immortalized cell line fruit fly CVCL_Z748 CL:0000010 Unspecified Group: Insect cell line. 21096858 CVCL_Z749 ML-DmD32 spontaneously immortalized cell line fruit fly CVCL_Z749 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Unspecified Group: Insect cell line; Part of: modENCODE project cell lines 21096859 CVCL_Z744 ML-DmD21 spontaneously immortalized cell line fruit fly CVCL_Z744 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Male Doubling time: 27 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096860 CVCL_Z745 ML-DmD23 spontaneously immortalized cell line fruit fly CVCL_Z745 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 45 hours (DGRC) Group: Insect cell line 21096861 CVCL_Z746 ML-DmD25 spontaneously immortalized cell line fruit fly CVCL_Z746 CL:0000010 Derived from sampling site: Imaginal disc; wing. Discontinued: DGRC; 187; probable Unspecified Group: Insect cell line 21096862 CVCL_Z747 ML-DmD3 spontaneously immortalized cell line fruit fly CVCL_Z747 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Doubling time: 29 hours (DGRC) Group: Insect cell line 21096863 CVCL_6P00 DA00723 transformed cell line human CVCL_6P00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096864 CVCL_7100 PC6-2 cancer cell line Norway rat CVCL_7100 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096865 CVCL_6P01 DA00724 transformed cell line human CVCL_6P01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096866 CVCL_7101 PC6-3 cancer cell line Norway rat CVCL_7101 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096867 CVCL_6P02 DA00725 transformed cell line human CVCL_6P02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096868 CVCL_7102 PC6-4 cancer cell line Norway rat CVCL_7102 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096869 CVCL_Z751 ML-DmD5 spontaneously immortalized cell line fruit fly CVCL_Z751 CL:0000010 Derived from sampling site: Imaginal disc; wing. Unspecified Group: Insect cell line 21096870 CVCL_Z752 ML-DmD6 spontaneously immortalized cell line fruit fly CVCL_Z752 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21096871 CVCL_Z753 ML-DmD7 spontaneously immortalized cell line fruit fly CVCL_Z753 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21096872 CVCL_Z754 ML-DmD8 spontaneously immortalized cell line fruit fly CVCL_Z754 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Female Doubling time: 66 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096873 CVCL_Z750 ML-DmD4 spontaneously immortalized cell line fruit fly CVCL_Z750 CL:0000010 Derived from sampling site: Imaginal disc. Discontinued: DGRC; 186; probable Male Group: Insect cell line 21096874 CVCL_Z737 ML-DmD10 spontaneously immortalized cell line fruit fly CVCL_Z737 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Unspecified Group: Insect cell line 21096875 CVCL_Z738 ML-DmD11 spontaneously immortalized cell line fruit fly CVCL_Z738 CL:0000010 Derived from sampling site: Imaginal disc; eye-antenna. Omics: Transcriptome analysis by RNAseq Male Doubling time: ~84 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096876 CVCL_Z739 ML-DmD15 spontaneously immortalized cell line fruit fly CVCL_Z739 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21096877 CVCL_Z733 K562-CdA cancer cell line human CVCL_Z733 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:567361; Cladribine (2-chlorodeoxyadenosine; Derived from sampling site: Pleural effusion. Female 21096878 CVCL_Z734 K562-FLUD cancer cell line human CVCL_Z734 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63599; Fludarabine phosphate; Derived from sampling site: Pleural effusion. Female 21096879 CVCL_Z735 K562-GEM cancer cell line human CVCL_Z735 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pleural effusion. Female 21096880 CVCL_Z736 ML-DmD1 spontaneously immortalized cell line fruit fly CVCL_Z736 CL:0000010 Derived from sampling site: Imaginal disc; wing. Discontinued: DGRC; 79; probable Male Group: Insect cell line 21096881 CVCL_6P10 DA00733 transformed cell line human CVCL_6P10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096882 CVCL_7110 PLA-801D cancer cell line human CVCL_7110 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Omics: Deep proteome analysis Male 21096883 CVCL_6P11 DA00734 transformed cell line human CVCL_6P11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096884 CVCL_7111 POGRS-1 transformed cell line Norway rat CVCL_7111 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21096885 CVCL_6P12 DA00735 transformed cell line human CVCL_6P12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096886 CVCL_7112 POGS-5 transformed cell line Norway rat CVCL_7112 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21096887 CVCL_6P13 DA00736 transformed cell line human CVCL_6P13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096888 CVCL_7113 PR-Mel cancer cell line human CVCL_7113 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from metastatic site: Skin. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=11851879) 21096889 CVCL_6P07 DA00730 transformed cell line human CVCL_6P07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096890 CVCL_7107 PC6-9 cancer cell line Norway rat CVCL_7107 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096891 CVCL_6P08 DA00731 transformed cell line human CVCL_6P08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096892 CVCL_7108 PLA-801 cancer cell line human CVCL_7108 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male Doubling time: 29 hours (PubMed=6676078) 21096893 CVCL_6P09 DA00732 transformed cell line human CVCL_6P09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096894 CVCL_7109 PLA-801C cancer cell line human CVCL_7109 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Omics: Deep proteome analysis Male 21096895 CVCL_6P03 DA00726 transformed cell line human CVCL_6P03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096896 CVCL_7103 PC6-5 cancer cell line Norway rat CVCL_7103 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096897 CVCL_6P04 DA00727 transformed cell line human CVCL_6P04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096898 CVCL_7104 PC6-6 cancer cell line Norway rat CVCL_7104 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096899 CVCL_6P05 DA00728 transformed cell line human CVCL_6P05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096900 CVCL_7105 PC6-7 cancer cell line Norway rat CVCL_7105 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096901 CVCL_6P06 DA00729 transformed cell line human CVCL_6P06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096902 CVCL_7106 PC6-8 cancer cell line Norway rat CVCL_7106 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21096903 CVCL_Z740 ML-DmD16 spontaneously immortalized cell line fruit fly CVCL_Z740 CL:0000010 Derived from sampling site: Imaginal disc; wing. Discontinued: DGRC; 183; probable Female Group: Insect cell line 21096904 CVCL_Z741 ML-DmD17 spontaneously immortalized cell line fruit fly CVCL_Z741 CL:0000010 Derived from sampling site: Imaginal disc; haltere. Discontinued: DGRC; 184; probable Female Group: Insect cell line 21096905 CVCL_Z742 ML-DmD2 spontaneously immortalized cell line fruit fly CVCL_Z742 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21096906 CVCL_Z743 ML-DmD20 spontaneously immortalized cell line fruit fly CVCL_Z743 CL:0000010 Derived from sampling site: Imaginal disc; antenna. Omics: Transcriptome analysis by RNAseq Discontinued: DGRC; 185; probable Male Group: Insect cell line 21096907 CVCL_Z726 ML-DmBG2-c9 spontaneously immortalized cell line fruit fly CVCL_Z726 CL:0000010 Male Group: Insect cell line. 21096908 CVCL_Z727 ML-DmBG3-c1 spontaneously immortalized cell line fruit fly CVCL_Z727 CL:0000010 Male Doubling time: 56 hours (DGRC). Group: Insect cell line 21096909 CVCL_Z728 ML-DmBG3-c2 spontaneously immortalized cell line fruit fly CVCL_Z728 CL:0000010 Omics: Transcriptome analysis by RNAseq Male Doubling time: 48-127 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096910 CVCL_Z729 ML-DmBG3-c3 spontaneously immortalized cell line fruit fly CVCL_Z729 CL:0000010 Male Doubling time: 51 hours (DGRC). Group: Insect cell line 21096911 CVCL_Z722 ML-DmBG2-c5 spontaneously immortalized cell line fruit fly CVCL_Z722 CL:0000010 Male Doubling time: 98 hours (DGRC). Group: Insect cell line 21096912 CVCL_Z723 ML-DmBG2-c6 spontaneously immortalized cell line fruit fly CVCL_Z723 CL:0000010 Male Doubling time: 29 hours (DGRC). Group: Insect cell line 21096913 CVCL_Z724 ML-DmBG2-c7 spontaneously immortalized cell line fruit fly CVCL_Z724 CL:0000010 Male Group: Insect cell line. 21096914 CVCL_Z725 ML-DmBG2-c8 spontaneously immortalized cell line fruit fly CVCL_Z725 CL:0000010 Male Doubling time: 63 hours (DGRC). Group: Insect cell line 21096915 CVCL_Z730 ML-DmBG3-c4 spontaneously immortalized cell line fruit fly CVCL_Z730 CL:0000010 Male Group: Insect cell line. 21096916 CVCL_Z731 ML-DmBG3-c5 spontaneously immortalized cell line fruit fly CVCL_Z731 CL:0000010 Male Group: Insect cell line. 21096917 CVCL_Z732 K562-ARA-C cancer cell line human CVCL_Z732 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Pleural effusion. Female 21096918 CVCL_Z715 ML-DmBG7 spontaneously immortalized cell line fruit fly CVCL_Z715 CL:0000010 Unspecified Group: Insect cell line. 21096919 CVCL_Z716 ML-DmBG8 spontaneously immortalized cell line fruit fly CVCL_Z716 CL:0000010 Unspecified Group: Insect cell line. 21096920 CVCL_Z717 ML-DmBG2-c1 spontaneously immortalized cell line fruit fly CVCL_Z717 CL:0000010 Male Group: Insect cell line. 21096921 CVCL_Z718 ML-DmBG2-c10 spontaneously immortalized cell line fruit fly CVCL_Z718 CL:0000010 Male Doubling time: 76 hours (DGRC). Group: Insect cell line 21096922 CVCL_Z711 ML-DmBG3 spontaneously immortalized cell line fruit fly CVCL_Z711 CL:0000010 Male Group: Insect cell line. 21096923 CVCL_Z712 ML-DmBG4 spontaneously immortalized cell line fruit fly CVCL_Z712 CL:0000010 Unspecified Group: Insect cell line. 21096924 CVCL_Z713 ML-DmBG5 spontaneously immortalized cell line fruit fly CVCL_Z713 CL:0000010 Unspecified Group: Insect cell line. 21096925 CVCL_Z714 ML-DmBG6 spontaneously immortalized cell line fruit fly CVCL_Z714 CL:0000010 Unspecified Group: Insect cell line. 21096926 CVCL_Z719 ML-DmBG2-c2 spontaneously immortalized cell line fruit fly CVCL_Z719 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 104 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096927 CVCL_Z720 ML-DmBG2-c3 spontaneously immortalized cell line fruit fly CVCL_Z720 CL:0000010 Male Group: Insect cell line. 21096928 CVCL_Z721 ML-DmBG2-c4 spontaneously immortalized cell line fruit fly CVCL_Z721 CL:0000010 Male Doubling time: 78 hours (DGRC). Group: Insect cell line 21096929 CVCL_Z704 MCF-7/MDD2 cancer cell line human CVCL_Z704 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21096930 CVCL_Z705 MCF-7/MN1 cancer cell line human CVCL_Z705 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21096931 CVCL_Z706 mbn-2 spontaneously immortalized cell line fruit fly CVCL_Z706 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 54 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096932 CVCL_Z707 Sg4 spontaneously immortalized cell line fruit fly CVCL_Z707 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21096933 CVCL_Z700 SES-Bm-e 21R spontaneously immortalized cell line CVCL_Z700 CL:0000010 Breed/subspecies: e21. Unspecified Group: Insect cell line 21096934 CVCL_Z701 WIV-BS-481 spontaneously immortalized cell line CVCL_Z701 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21096935 CVCL_Z702 WIV-BS-484 spontaneously immortalized cell line CVCL_Z702 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21096936 CVCL_Z703 WIV-BS-02 spontaneously immortalized cell line CVCL_Z703 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21096937 CVCL_Z708 1182-4H spontaneously immortalized cell line fruit fly CVCL_Z708 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Characteristics: Constitutively lacks centrioles (CelloPub=CLPUB00568; PubMed=2515901; PubMed=32456186) Group: Insect cell line; Group: Haploid karyotype cell line; Part of: modENCODE project cell lines 21096938 CVCL_Z709 ML-DmBG1 spontaneously immortalized cell line fruit fly CVCL_Z709 CL:0000010 Unspecified Doubling time: 57 hours (DGRC). Group: Insect cell line 21096939 CVCL_Z710 ML-DmBG2 spontaneously immortalized cell line fruit fly CVCL_Z710 CL:0000010 Male Group: Insect cell line. 21096940 CVCL_7180 CHO-DG44 spontaneously immortalized cell line CVCL_7180 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Omics: Deep proteome analysis; Omics: Genome sequenced Female Characteristics: Lacks both copies of the Dhfr gene 21096941 CVCL_6P80 DA00808 transformed cell line human CVCL_6P80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096942 CVCL_7181 CHO-MG spontaneously immortalized cell line CVCL_7181 CL:0000010 Derived from sampling site: Ovary. Female 21096943 CVCL_6P81 DA00809 transformed cell line human CVCL_6P81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096944 CVCL_7182 CHO Pro-3 spontaneously immortalized cell line CVCL_7182 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Defective in purine biosynthesis Doubling time: 14 hours (PubMed=1028172) 21096945 CVCL_6P82 DA00810 transformed cell line human CVCL_6P82 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096946 CVCL_6P87 DA00815 transformed cell line human CVCL_6P87 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096947 CVCL_7187 DEV [Human lymphoma] cancer cell line human CVCL_7187 CL:0000010 Derived from sampling site: Pleural effusion. Omics: SNP array analysis Male Doubling time: ~3 days (PubMed=3881158) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be from a nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). 21096948 CVCL_6P88 DA00816 transformed cell line human CVCL_6P88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096949 CVCL_7188 DPK cancer cell line house mouse CVCL_7188 CL:0000010 Breed/subspecies: AND-TCR transgenic. Unspecified 21096950 CVCL_6P89 DA00817 transformed cell line human CVCL_6P89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096951 CVCL_7189 eCAS cancer cell line house mouse CVCL_7189 CL:0000010 Miscellaneous: Conversion of STR profile from fragment lengths to alleles value by personal communication of Wigger G (Microsynth). Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Doubling time: 9.7 hours (PubMed=14700538) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00601 Problematic cell line: Misidentified/contaminated Originally thought to be of horse origin but found to be a mouse RAW 264.7 derivative (PubMed=29844485). Originally thought to be established by telomerase transfection of bone marrow cells from two 10 year old horses. 21096952 CVCL_7183 CHO-S spontaneously immortalized cell line CVCL_7183 CL:0000010 Derived from sampling site: Ovary. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling Female 21096953 CVCL_6P83 DA00811 transformed cell line human CVCL_6P83 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096954 CVCL_7184 D1F4 factor-dependent cell line house mouse CVCL_7184 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Thymus Cell type=Thymocyte.. Unspecified Characteristics: IL7 dependent; Characteristics: Does not express CD4 and CD8 (from parent cell line) 21096955 CVCL_6P84 DA00812 transformed cell line human CVCL_6P84 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096956 CVCL_7185 D54 [Human glioblastoma] cancer cell line human CVCL_7185 CL:0000010 Female Part of: ENCODE project common cell types; tier 3. 21096957 CVCL_6P85 DA00813 transformed cell line human CVCL_6P85 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096958 CVCL_6P86 DA00814 transformed cell line human CVCL_6P86 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096959 CVCL_7186 Dante cancer cell line human CVCL_7186 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21096960 CVCL_6P90 DA00818 transformed cell line human CVCL_6P90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096961 CVCL_7190 EML-3C spontaneously immortalized cell line CVCL_7190 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Macrophage.; Breed/subspecies: Portuguese Garrano. Discontinued: ATCC; CRL-2996; true Male 21096962 CVCL_6P91 DA00819 transformed cell line human CVCL_6P91 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096963 CVCL_7191 EqT8888 cancer cell line CVCL_7191 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Arabian. Female 21096964 CVCL_6P92 DA00820 transformed cell line human CVCL_6P92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096965 CVCL_7192 Ezem-BL cancer cell line human CVCL_7192 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096966 CVCL_6P93 DA00821 transformed cell line human CVCL_6P93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096967 CVCL_7193 FHK-Tcl3.1 transformed cell line CVCL_7193 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Virology: Supports the growth of equine herpesvirus type 1 (EHV-1), equine herpesvirus type 2 (EHV-2), equine herpesvirus type 3 (EHV-3) and equine herpesvirus type 4 (EHV-4) (PubMed=23594411; PubMed=24833964) 21096968 CVCL_6P98 DA00828 transformed cell line human CVCL_6P98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096969 CVCL_7198 Kan-BL cancer cell line human CVCL_7198 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096970 CVCL_6P99 DA00829 transformed cell line human CVCL_6P99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096971 CVCL_7199 Kem-BL cancer cell line human CVCL_7199 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096972 CVCL_6P94 DA00822 transformed cell line human CVCL_6P94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096973 CVCL_7194 Gan-BL cancer cell line human CVCL_7194 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096974 CVCL_6P95 DA00824 transformed cell line human CVCL_6P95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096975 CVCL_7195 GBL-HU12 cancer cell line human CVCL_7195 CL:0000010 Derived from sampling site: Brain. Male Doubling time: 34 hours (PubMed=1320358) 21096976 CVCL_6P96 DA00825 transformed cell line human CVCL_6P96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096977 CVCL_7196 Glor-BL cancer cell line human CVCL_7196 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096978 CVCL_6P97 DA00826 transformed cell line human CVCL_6P97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096979 CVCL_7197 Jada-BL cancer cell line human CVCL_7197 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21096980 CVCL_6P60 DA00785 transformed cell line human CVCL_6P60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096981 CVCL_7160 hES 3.2 embryonic stem cell human CVCL_7160 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200624. 21096982 CVCL_6P65 DA00790 transformed cell line human CVCL_6P65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096983 CVCL_7165 MPanc-96 cancer cell line human CVCL_7165 CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=15367885); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (PubMed=15367885) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Proteome analysis by 2D-DE/MS Discontinued: ATCC; CRL-2380; true Female Doubling time: 27 hours (PubMed=9185703) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00329 Problematic cell line: Contaminated Shown to be a AsPC-1 derivative (PubMed=20143388). Originally thought to originate from a 67 year old male patient with a poorly differentiated primary pancreatic adenocarcinoma. 21096984 CVCL_7166 CHP-100 cancer cell line human CVCL_7166 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=26428435; PubMed=33460449); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; spine; epidural space. Discontinued: ECACC; 06122001; true Female Doubling time: 45.8 hours (PubMed=10079); ~36 hours (DSMZ=ACC-830) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00382 Problematic cell line: Misclassified Originally thought to originate from a neuroblastoma but shown to be from an Ewing sarcoma (PubMed=33460449). Was also partially contaminated as some stocks where shown to be IMR-32 derivatives. 21096985 CVCL_6P66 DA00791 transformed cell line human CVCL_6P66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096986 CVCL_6P67 DA00793 transformed cell line human CVCL_6P67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096987 CVCL_7167 TEC61 cancer cell line human CVCL_7167 CL:0000010 Derived from metastatic site: Fetal brain. Discontinued: ECACC; 06031505; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00364 Problematic cell line: Contaminated Shown to be a JEG-3 derivative (PubMed=20143388). Originally thought to be a thyroid endothelial cell.; Caution: PubMed=19625678 is a retractation of PubMed=12388152 21096988 CVCL_6P68 DA00794 transformed cell line human CVCL_6P68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096989 CVCL_7168 IPTP/98 undefined cell line type Norway rat CVCL_7168 CL:0000010 Discontinued: ECACC; 99050528; probable. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00321 Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=20143388). 21096990 CVCL_6P61 DA00786 transformed cell line human CVCL_6P61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096991 CVCL_7161 hES 3.3 embryonic stem cell human CVCL_7161 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200625. 21096992 CVCL_6P62 DA00787 transformed cell line human CVCL_6P62 CL:0000010 Population: Caucasian and Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096993 CVCL_7162 HTR-8/SVneo transformed cell line human CVCL_7162 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Karyotypic information: Near triploid karyotype (PubMed=33096371); Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast. Omics: DNA methylation analysis Unspecified Characteristics: Useful to study trophoblast and placental biology (ATCC); Characteristics: Contains both epithelial and mesenchymal-like cell populations (PubMed=28161053) Part of: ENCODE project common cell types; tier 3 21096994 CVCL_6P63 DA00788 transformed cell line human CVCL_6P63 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096995 CVCL_7163 SHZ-88 cancer cell line Norway rat CVCL_7163 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032). Female 21096996 CVCL_6P64 DA00789 transformed cell line human CVCL_6P64 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096997 CVCL_7164 SW1045 cancer cell line human CVCL_7164 From: Scott and White Clinic; Temple; USA. CL:0000010 Male 21096998 CVCL_6P58 DA00783 transformed cell line human CVCL_6P58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21096999 CVCL_7158 HES-3 embryonic stem cell human CVCL_7158 HLA typing: A*11:33; B*40,55; C*01,07; DQB1*06; DRB1*12,12; DRB3*01 (PubMed=16919167) From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Registration: Swiss research registry; BAG-hES-IMP-0055; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21097000 CVCL_6P59 DA00784 transformed cell line human CVCL_6P59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097001 CVCL_7159 hES 3.1 embryonic stem cell human CVCL_7159 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200601. 21097002 CVCL_6P70 DA00796 transformed cell line human CVCL_6P70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097003 CVCL_7170 L-41 cancer cell line human CVCL_7170 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00327 Problematic cell line: Contaminated Parent cell line (J-96) has been shown to be a HeLa derivative (PubMed=20143388). 21097004 CVCL_6P71 DA00797 transformed cell line human CVCL_6P71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097005 CVCL_7171 OVK18#102 cancer cell line human CVCL_7171 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Leu437fs*1 (c.1305delT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Gly (c.176C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Tyr366fs*17 (c.1096delT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Pro109fs*194 (c.322delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Female 21097006 CVCL_Z799 MCW12 spontaneously immortalized cell line fruit fly CVCL_Z799 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Doubling time: 70.4 hours (DGRC) Group: Insect cell line 21097007 CVCL_7176 CBRH-7919 cancer cell line Norway rat CVCL_7176 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar. 21097008 CVCL_6P76 DA00804 transformed cell line human CVCL_6P76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00804; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097009 CVCL_7177 CH27 [Human lung carcinoma] cancer cell line human CVCL_7177 CL:0000010 21097010 CVCL_6P77 DA00805 transformed cell line human CVCL_6P77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097011 CVCL_7178 CH27 [Mouse lymphoma] cancer cell line house mouse CVCL_7178 CL:0000010 Breed/subspecies: B10.H-2aH-4bp/Wts. 21097012 CVCL_6P78 DA00806 transformed cell line human CVCL_6P78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097013 CVCL_7179 CHM 2100 transformed cell line human CVCL_7179 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21097014 CVCL_6P79 DA00807 transformed cell line human CVCL_6P79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097015 CVCL_7172 Ali-BL cancer cell line human CVCL_7172 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097016 CVCL_6P72 DA00798 transformed cell line human CVCL_6P72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097017 CVCL_7173 Angu-BL cancer cell line human CVCL_7173 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097018 CVCL_6P73 DA00799 transformed cell line human CVCL_6P73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097019 CVCL_7174 Ava-BL cancer cell line human CVCL_7174 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097020 CVCL_6P74 DA00800 transformed cell line human CVCL_6P74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097021 CVCL_7175 CB-3512 transformed cell line human CVCL_7175 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. 21097022 CVCL_6P75 DA00803 transformed cell line human CVCL_6P75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097023 CVCL_6P69 DA00795 transformed cell line human CVCL_6P69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097024 CVCL_7169 IPDDC-A2 undefined cell line type Norway rat CVCL_7169 CL:0000010 Discontinued: ECACC; 99050529; probable. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00320 Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=20143388). 21097025 CVCL_Z788 CME L2 spontaneously immortalized cell line fruit fly CVCL_Z788 CL:0000010 Derived from sampling site: Imaginal disc; prothoracic leg; Breed/subspecies: Oregon-R. Unspecified Doubling time: 57 hours (DGRC) Group: Insect cell line 21097026 CVCL_Z789 CME W1 spontaneously immortalized cell line fruit fly CVCL_Z789 CL:0000010 Derived from sampling site: Imaginal disc; wing; Breed/subspecies: Oregon-R. Male Doubling time: 57 hours (DGRC) Group: Insect cell line 21097027 CVCL_6P43 DA00766 transformed cell line human CVCL_6P43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097028 CVCL_7143 SQ-43 cancer cell line human CVCL_7143 CL:0000010 Unspecified 21097029 CVCL_6P44 DA00767 transformed cell line human CVCL_6P44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097030 CVCL_7144 SQ-9G cancer cell line human CVCL_7144 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Argfs*110 (c.811delG); Zygosity=Unspecified (PubMed=1423286; PubMed=8339273). Unspecified 21097031 CVCL_6P45 DA00768 transformed cell line human CVCL_6P45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097032 CVCL_7145 ST-Mel cancer cell line human CVCL_7145 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Glu (c.1397G>A); ClinVar=VCV000376073; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from sampling site: Skin. 21097033 CVCL_6P46 DA00769 transformed cell line human CVCL_6P46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097034 CVCL_7146 SYO-1 cancer cell line human CVCL_7146 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=14744540; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Groin. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 28 hours (PubMed=14744540) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21097035 CVCL_6P40 DA00763 transformed cell line human CVCL_6P40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097036 CVCL_7140 SQ-31 cancer cell line human CVCL_7140 CL:0000010 Unspecified 21097037 CVCL_6P41 DA00764 transformed cell line human CVCL_6P41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097038 CVCL_7141 SQ-38 cancer cell line human CVCL_7141 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=1423286) Derived from sampling site: Oral cavity; retromolar trigone. Unspecified 21097039 CVCL_6P42 DA00765 transformed cell line human CVCL_6P42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097040 CVCL_7142 SQ-39 cancer cell line human CVCL_7142 CL:0000010 Derived from sampling site: Oral cavity; retromolar trigone. Unspecified 21097041 CVCL_Z790 CME W1 cl.8+ spontaneously immortalized cell line fruit fly CVCL_Z790 CL:0000010 Derived from sampling site: Imaginal disc; wing; Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 46 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097042 CVCL_6P36 DA00759 transformed cell line human CVCL_6P36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097043 CVCL_7136 SMS-SAN cancer cell line human CVCL_7136 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro252fs*144 (c.753_763del11); Zygosity=Unspecified (PubMed=23202128) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~71 hours (PubMed=3456456) 21097044 CVCL_6P37 DA00760 transformed cell line human CVCL_6P37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097045 CVCL_7137 SN-Mel cancer cell line human CVCL_7137 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from metastatic site: Hypodermis. Microsatellite instability: Stable (MSS) (PubMed=11851879) 21097046 CVCL_6P38 DA00761 transformed cell line human CVCL_6P38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097047 CVCL_7138 SQ-20B cancer cell line human CVCL_7138 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8339273) Derived from sampling site: Larynx. Omics: Transcriptome analysis by microarray Male 21097048 CVCL_6P39 DA00762 transformed cell line human CVCL_6P39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097049 CVCL_7139 SQ-29 cancer cell line human CVCL_7139 CL:0000010 Derived from sampling site: Oral cavity; retromolar trigone. Unspecified 21097050 CVCL_Z795 GM2 spontaneously immortalized cell line fruit fly CVCL_Z795 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 72 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097051 CVCL_Z796 GM3 spontaneously immortalized cell line fruit fly CVCL_Z796 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 25-28 hours, depending on growth medium (DGRC) Group: Insect cell line 21097052 CVCL_Z797 ML-DmBG2-c11 spontaneously immortalized cell line fruit fly CVCL_Z797 CL:0000010 Male Doubling time: 42 hours (DGRC). Group: Insect cell line 21097053 CVCL_Z798 ML-DmBG2-c12 spontaneously immortalized cell line fruit fly CVCL_Z798 CL:0000010 Male Group: Insect cell line. 21097054 CVCL_Z791 CME W2 spontaneously immortalized cell line fruit fly CVCL_Z791 CL:0000010 Derived from sampling site: Imaginal disc; wing; Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 55 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097055 CVCL_Z792 G1 [Drosophila] spontaneously immortalized cell line fruit fly CVCL_Z792 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 28-50 hours, depending on growth medium (DGRC) Group: Insect cell line 21097056 CVCL_Z793 G2 [Drosophila] spontaneously immortalized cell line fruit fly CVCL_Z793 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 25-43 hours, depending on growth medium (DGRC) Group: Insect cell line 21097057 CVCL_Z794 GM1 [Drosophila] spontaneously immortalized cell line fruit fly CVCL_Z794 CL:0000010 Male Group: Insect cell line. 21097058 CVCL_Z777 ML-DmD23-c1 spontaneously immortalized cell line fruit fly CVCL_Z777 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 34 hours (DGRC) Group: Insect cell line 21097059 CVCL_Z778 ML-DmD23-c2 spontaneously immortalized cell line fruit fly CVCL_Z778 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 130 hours (DGRC) Group: Insect cell line 21097060 CVCL_Z779 ML-DmD23-c3 spontaneously immortalized cell line fruit fly CVCL_Z779 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 49-117 hours, depending on growth medium (DGRC) Group: Insect cell line 21097061 CVCL_6P54 DA00778 transformed cell line human CVCL_6P54 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097062 CVCL_7154 U-1285dox cancer cell line human CVCL_7154 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male 21097063 CVCL_6P55 DA00779 transformed cell line human CVCL_6P55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097064 CVCL_7155 U-1568 cancer cell line human CVCL_7155 CL:0000010 Male 21097065 CVCL_6P56 DA00780 transformed cell line human CVCL_6P56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097066 CVCL_7156 WM75 cancer cell line human CVCL_7156 HLA typing: A*02:01,29:02; B*44:03:01; C*16:01; DPB1*04:01,03:01:01; DQB1*03:02,02:01; DRB1*04:05:01,01:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23851445; Wistar); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.261_262GG>AA) (p.Gly102Lys, c.304_305GG>AA); Zygosity=Unspecified (PubMed=23851445) Omics: Transcriptome analysis by microarray. Male Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection 21097067 CVCL_6P57 DA00781 transformed cell line human CVCL_6P57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097068 CVCL_7157 SRA01/04 transformed cell line human CVCL_7157 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000206) It was one of the sources for the STR profile of this entry. Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5454 21097069 CVCL_6P50 DA00773 transformed cell line human CVCL_6P50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097070 CVCL_7150 TC-253 cancer cell line human CVCL_7150 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Asn842fs; Zygosity=Unspecified (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Male 21097071 CVCL_6P51 DA00774 transformed cell line human CVCL_6P51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097072 CVCL_7151 TC-32 cancer cell line human CVCL_7151 Genome ancestry: African=0.13%; Native American=0.3%; East Asian, North=1.12%; East Asian, South=0%; South Asian=0.2%; European, North=67.6%; European, South=30.65% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=8040301; PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Tyr636fs; Zygosity=Unspecified (PubMed=25010205; DepMap) Derived from sampling site: Bone; left ilium. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=24312454); 36 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21097073 CVCL_6P52 DA00776 transformed cell line human CVCL_6P52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097074 CVCL_7152 TTC-547 cancer cell line human CVCL_7152 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205) Derived from sampling site: Pelvis. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Part of: MD Anderson Cell Lines Project 21097075 CVCL_6P53 DA00777 transformed cell line human CVCL_6P53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097076 CVCL_7153 U-1285 cancer cell line human CVCL_7153 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=12820372) Derived from metastatic site: Pleural effusion. Male Doubling time: 80-84 hours (PubMed=6285665) 21097077 CVCL_6P47 DA00770 transformed cell line human CVCL_6P47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097078 CVCL_7147 TC-131 cancer cell line human CVCL_7147 CL:0000010 Male 21097079 CVCL_6P48 DA00771 transformed cell line human CVCL_6P48 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097080 CVCL_7148 TC-174 cancer cell line human CVCL_7148 CL:0000010 Female 21097081 CVCL_6P49 DA00772 transformed cell line human CVCL_6P49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097082 CVCL_7149 TC-206 cancer cell line human CVCL_7149 CL:0000010 Male 21097083 CVCL_Z784 ML-DmD4-c1 spontaneously immortalized cell line fruit fly CVCL_Z784 CL:0000010 Derived from sampling site: Imaginal disc. Omics: Transcriptome analysis by RNAseq Male Doubling time: 33 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097084 CVCL_Z785 Jupiter spontaneously immortalized cell line fruit fly CVCL_Z785 CL:0000010 Transfected with: UniProtKB; P42212; GFP Omics: Transcriptome analysis by RNAseq. Male Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 103 hours (DGRC) Group: Insect cell line 21097085 CVCL_Z786 CME L1 spontaneously immortalized cell line fruit fly CVCL_Z786 CL:0000010 Derived from sampling site: Imaginal disc; prothoracic leg; Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 47 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097086 CVCL_Z787 CME L1A spontaneously immortalized cell line fruit fly CVCL_Z787 CL:0000010 Derived from sampling site: Imaginal disc; prothoracic leg; Breed/subspecies: Oregon-R. Male Doubling time: 38 hours (DGRC) Group: Insect cell line 21097087 CVCL_Z780 ML-DmD23-c4 spontaneously immortalized cell line fruit fly CVCL_Z780 CL:0000010 Derived from sampling site: Imaginal disc; wing. Omics: Transcriptome analysis by RNAseq Male Doubling time: 64 hours (DGRC) Group: Insect cell line 21097088 CVCL_Z781 ML-DmD23-c5 spontaneously immortalized cell line fruit fly CVCL_Z781 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 58 hours (DGRC) Group: Insect cell line 21097089 CVCL_Z782 ML-DmD23-c6 spontaneously immortalized cell line fruit fly CVCL_Z782 CL:0000010 Derived from sampling site: Imaginal disc; wing. Male Doubling time: 68 hours (DGRC) Group: Insect cell line 21097090 CVCL_Z783 ML-DmD25-c2 spontaneously immortalized cell line fruit fly CVCL_Z783 CL:0000010 Derived from sampling site: Imaginal disc; wing. Unspecified Doubling time: 45 hours (DGRC) Group: Insect cell line 21097091 CVCL_HE73 ImST conditionally immortalized cell line house mouse CVCL_HE73 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; epithelium Cell type=Epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21097092 CVCL_HE74 NF2C conditionally immortalized cell line Norway rat CVCL_HE74 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Neuron.; Breed/subspecies: Sprague Dawley SV40-tsA58 transgenic. Male Characteristics: Proliferates at the permissive temperature (33 Celsius) Dies at the restrictive temperature (39 Celsius). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 96092754 21097093 CVCL_HE75 TM10 spontaneously immortalized cell line house mouse CVCL_HE75 CL:0000010 Derived from sampling site: Back; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6J. Unspecified Doubling time: 17.7 hours (PubMed=4084981) 21097094 CVCL_HE76 SUHC-1 cancer cell line human CVCL_HE76 CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y. Male Characteristics: Although established from a patient suffering from persistent HCC infection, HCV-RNA is not detected Doubling time: ~24 hours (PubMed=1328123) 21097095 CVCL_HE70 FL5.12 Bax CL16 factor-dependent cell line house mouse CVCL_HE70 CL:0000010 Transfected with: MGI; MGI:99702; Bax Derived from sampling site: Embryonic liver Cell type=Pro-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent 21097096 CVCL_HE71 B2LT1 conditionally immortalized cell line Norway rat CVCL_HE71 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley SV40-tsA58 transgenic. Female Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 97032720 21097097 CVCL_HE72 D10S factor-dependent cell line house mouse CVCL_HE72 CL:0000010 Breed/subspecies: AKR/J. Male Characteristics: IL1A or IL1B dependent 21097098 CVCL_HE66 Ea3 factor-dependent cell line house mouse CVCL_HE66 CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 16 hours (PubMed=6422470); 15-17 hours (PubMed=6201749) 21097099 CVCL_HE67 Ea3.123 factor-dependent cell line house mouse CVCL_HE67 CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent 21097101 CVCL_HE69 SF-CMTI-2 embryonic stem cell house mouse CVCL_HE69 CL:0000010 Breed/subspecies: C57BL/6.Cg-Thy1. Male Characteristics: Pre-adapted to serum-free and feeder-free cell culture conditions and is intended for use with the ESGRO cell culture system Group: Serum/protein free medium cell line 21097102 CVCL_HE84 sHCC63 cancer cell line human CVCL_HE84 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). 21097103 CVCL_HE85 sHCC74 cancer cell line human CVCL_HE85 CL:0000010 Population: Chinese. 21097104 CVCL_HE86 GM15009 transformed cell line human CVCL_HE86 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21097105 CVCL_HE87 GM15010 transformed cell line human CVCL_HE87 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097106 CVCL_HE80 Hep10 cancer cell line human CVCL_HE80 CL:0000010 Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver; left lateral lobe. Male Virology: Contains at least 5 copies of integrated hepatitis B virus (HBV) genomes 21097107 CVCL_HE81 SAR-HCV cancer cell line human CVCL_HE81 CL:0000010 Population: Chinese; Taiwan; Karyotypic information: Near triploid karyotype; Derived from sampling site: Liver. Male Doubling time: 33.2 hours (PubMed=21273590) 21097108 CVCL_HE82 SH-J1 cancer cell line human CVCL_HE82 CL:0000010 Population: Korean; Karyotypic information: Has lost chromosome Y. Male 21097109 CVCL_HE83 sHCC29 cancer cell line human CVCL_HE83 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). 21097110 CVCL_HE77 HepG2T14 cancer cell line human CVCL_HE77 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Virology: Transfected with a circular hepatitis B virus (HBV) 21097111 CVCL_HE78 HepG2T14.1 cancer cell line human CVCL_HE78 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Virology: Transfected with a circular hepatitis B virus (HBV) 21097112 CVCL_HE79 H4-M cancer cell line human CVCL_HE79 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Portal vein. Male 21097113 CVCL_HE51 CAK-B3 spontaneously immortalized cell line house mouse CVCL_HE51 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AKR/J x C57BL/6J. Female 21097114 CVCL_HE52 CAK-B3-Toyr13 spontaneously immortalized cell line house mouse CVCL_HE52 CL:0000010 Selected for resistance to: ChEBI; CHEBI:134606; Toyocamycin; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AKR/J x C57BL/6J. Female 21097115 CVCL_HE53 CAK-TK- spontaneously immortalized cell line house mouse CVCL_HE53 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AKR/J x C57BL/6J. Female 21097116 CVCL_HE54 Jurkat clone 77-6.8 cancer cell line human CVCL_HE54 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21097117 CVCL_HE50 CAK-A32-G11 spontaneously immortalized cell line house mouse CVCL_HE50 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AKR/J x C57BL/6J. Female 21097118 CVCL_HE48 COS-3 transformed cell line CVCL_HE48 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21097119 CVCL_HE49 CAK [Mouse] spontaneously immortalized cell line house mouse CVCL_HE49 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: AKR/J x C57BL/6J. Female Doubling time: ~18 hours (PubMed=4138999) 21097120 CVCL_HE44 Me8530 cancer cell line human CVCL_HE44 CL:0000010 21097121 CVCL_HE45 INT-MEL-10 cancer cell line human CVCL_HE45 CL:0000010 Derived from metastatic site: Lymph node. Female 21097122 CVCL_HE46 TU-OC-2 cancer cell line human CVCL_HE46 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Characteristics: Does not express ARID1A Doubling time: 37.5 +- 3.3 hours (PubMed=26960408) 21097123 CVCL_HE47 4T1-S cancer cell line house mouse CVCL_HE47 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Omics: Transcriptome analysis by microarray Female Characteristics: Compared to the parent cell line, it is much more immunogenic When it is subcutaneously injected, striking enlargement of draining lymph nodes and increase of activated T cells are observed. 21097124 CVCL_HE62 MIP/CIS cancer cell line human CVCL_HE62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Liver. Male 21097125 CVCL_HE63 MIP/CPT cancer cell line human CVCL_HE63 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Liver. Male 21097126 CVCL_HE64 MIP/ETO cancer cell line human CVCL_HE64 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Liver. Male 21097127 CVCL_HE65 HU-01 cancer cell line human CVCL_HE65 CL:0000010 Male Characteristics: CSF2 dependent. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10249 21097128 CVCL_HE60 hTERT-RBS telomerase immortalized cell line human CVCL_HE60 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; French Canadian; Derived from sampling site: Cell type=Fibroblast. Male 21097129 CVCL_HE61 MIP/5FU cancer cell line human CVCL_HE61 HLA typing: A*24:02,02:01; B*35:08,35:08; C*07:01,04:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Liver. Omics: Transcriptome analysis by RNAseq Male 21097130 CVCL_HE59 RL(MSV) transformed cell line Norway rat CVCL_HE59 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Embryonic liver; Breed/subspecies: Sprague Dawley. Unspecified 21097131 CVCL_HE55 J31.13 cancer cell line human CVCL_HE55 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Does not express CD3 21097132 CVCL_HE56 LXKC40 hybrid cell line CVCL_HE56 CL:0000010 Transformant: X-Ray(NCIt; C17262). Group: Human/rodent somatic cell hybrid 21097133 CVCL_HE57 LXKC50 hybrid cell line CVCL_HE57 CL:0000010 Transformant: X-Ray(NCIt; C17262). Group: Human/rodent somatic cell hybrid 21097134 CVCL_HE58 LXKC56 hybrid cell line CVCL_HE58 CL:0000010 Transformant: X-Ray(NCIt; C17262). Group: Human/rodent somatic cell hybrid 21097135 CVCL_HE30 C23 cancer cell line human CVCL_HE30 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1408Ter (c.4222G>T); Zygosity=Unspecified (PubMed=9482574). Unspecified 21097136 CVCL_HE31 C6 [Human colon adenocarcinoma] cancer cell line human CVCL_HE31 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Aspfs*4 (c.3927_3931delAAAAG); Zygosity=Unspecified (PubMed=9482574). Unspecified 21097137 CVCL_HE32 TCO cancer cell line human CVCL_HE32 CL:0000010 Population: Japanese; Derived from metastatic site: Not specified. 21097138 CVCL_HE26 SW48 TP53(+/-) cancer cell line human CVCL_HE26 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female 21097139 CVCL_HE27 SW48 TP53(-/-) cancer cell line human CVCL_HE27 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female 21097140 CVCL_HE28 DLD-1 KRAS(+/-) 2 cancer cell line human CVCL_HE28 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS Miscellaneous: Horizon distributes two DLD-1 KRAS(+/-) cell lines, one developed internally (Cellosaurus=CVCL_HE28) and one originating from the group of Volgenstein (Cellosaurus=CVCL_HD62). Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21097141 CVCL_HE29 C14 cancer cell line human CVCL_HE29 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1335Lysfs*9 (c.3997_4003dup); Zygosity=Unspecified (PubMed=9482574). Unspecified 21097142 CVCL_HE22 RKO FANCG(-/-) cancer cell line human CVCL_HE22 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3588; FANCG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097143 CVCL_HE23 RKO MIR21(-/-) cancer cell line human CVCL_HE23 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 31586; MIR21; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097144 CVCL_HE24 RKO SLC2A1(-/-) cancer cell line human CVCL_HE24 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 11005; SLC2A1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097145 CVCL_HE25 RKO TP53(-/-) cancer cell line human CVCL_HE25 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097146 CVCL_HE40 INT-MEL-43 cancer cell line human CVCL_HE40 CL:0000010 Derived from metastatic site: Hypodermis. Male 21097147 CVCL_HE41 Me665/3 cancer cell line human CVCL_HE41 CL:0000010 Derived from metastatic site: Hypodermis. Female 21097148 CVCL_HE42 INT-MEL-8 cancer cell line human CVCL_HE42 CL:0000010 Derived from metastatic site: Hypodermis. Male 21097149 CVCL_HE43 INT-MEL-50 cancer cell line human CVCL_HE43 CL:0000010 Derived from metastatic site: Lymph node. Female 21097150 CVCL_HE37 INT-MEL-16/2 cancer cell line human CVCL_HE37 HLA typing: A*02; B*41,50; C*w02,06 (PubMed=9637706) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp79fs*6 (c.235_248del14); Zygosity=Homozygous (PubMed=9637706); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr86Ter (c.258C>G); Zygosity=Homozygous (PubMed=9637706) Derived from metastatic site: Lymph node. Female 21097151 CVCL_HE38 Me9229/18 cancer cell line human CVCL_HE38 CL:0000010 Derived from metastatic site: Lymph node. Male 21097152 CVCL_HE39 Me28 cancer cell line human CVCL_HE39 CL:0000010 Derived from metastatic site: Lymph node. 21097153 CVCL_HE33 INT-MEL-4 cancer cell line human CVCL_HE33 CL:0000010 Derived from metastatic site: Lymph node. Male 21097154 CVCL_HE34 LCL15392 transformed cell line human CVCL_HE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21097155 CVCL_HE35 INT-MEL-9 cancer cell line human CVCL_HE35 CL:0000010 Derived from metastatic site: Omentum. Female 21097156 CVCL_HE36 INT-MEL-11 cancer cell line human CVCL_HE36 CL:0000010 Derived from metastatic site: Lymph node. Female 21097157 CVCL_HE10 NALM-6 TOP2B(-/-) cancer cell line human CVCL_HE10 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 11990; TOP2B; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097158 CVCL_HE08 NALM-6 RAD54L(-/-) cancer cell line human CVCL_HE08 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9826; RAD54L; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097159 CVCL_HE09 NALM-6 TOP1(+/-) cancer cell line human CVCL_HE09 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11986; TOP1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097160 CVCL_HE04 NALM-6 DCLRE1C(-/-) cancer cell line human CVCL_HE04 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17642; DCLRE1C; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097161 CVCL_HE05 NALM-6 LIG4(-/-) cancer cell line human CVCL_HE05 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 6601; LIG4; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097162 CVCL_HE06 NALM-6 MUS81(-/-) cancer cell line human CVCL_HE06 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 29814; MUS81; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097163 CVCL_HE07 NALM-6 PRKDC(+/-) cancer cell line human CVCL_HE07 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9413; PRKDC; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097164 CVCL_HE00 HCT 116 XRCC4(-/-) cancer cell line human CVCL_HE00 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 12831: XRCC4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21097165 CVCL_HE01 HCT 116 XRCC6(+/-) cancer cell line human CVCL_HE01 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 4055; XRCC6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21097166 CVCL_HE02 KMS-11 WHSC1(+/-) cancer cell line human CVCL_HE02 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12766; NSD2; Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa; Characteristics: In KMS-11 one of the two WHSC1 alleles is translocated This cell line is KO for the translocated allele. 21097167 CVCL_HE03 KMS-11 WHSC1(trans/-) cancer cell line human CVCL_HE03 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12766; NSD2; Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa; Characteristics: In KMS-11 one of the two WHSC1 alleles is translocated This cell line is KO for the non-translocated allele. 21097168 CVCL_HE20 RKO FANCC(-/-/-) cancer cell line human CVCL_HE20 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 3584; FANCC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: RKO carries a stable triplication of the FANCC gene 21097169 CVCL_HE21 RKO FANCG(+/-) cancer cell line human CVCL_HE21 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 3588; FANCG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097170 CVCL_HE19 RKO FANCC(+/-/-) cancer cell line human CVCL_HE19 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 3 alleles); HGNC; 3584; FANCC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: RKO carries a stable triplication of the FANCC gene 21097171 CVCL_HE15 RKO BRAF(+/-/-) cancer cell line human CVCL_HE15 CL:0000010 Knockout cell: Method=Homologous recombination (2 of 3 alleles); HGNC; 1097; BRAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: RKO carries a stable triplication of the BRAF gene with one wild-type (V-600) and two mutant alleles (E-600) This KO cell line carries the wild-type allele. 21097172 CVCL_HE16 RKO BRAF(V600E/+/-) cancer cell line human CVCL_HE16 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 3 alleles); HGNC; 1097; BRAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: RKO carries a stable triplication of the BRAF gene with one wild-type (V-600) and two mutant alleles (E-600) This KO cell line carries both the wild-type and mutant alleles. 21097173 CVCL_HE17 RKO BRAF(V600E/-/-) cancer cell line human CVCL_HE17 CL:0000010 Knockout cell: Method=Homologous recombination (2 of 3 alleles); HGNC; 1097; BRAF; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: RKO carries a stable triplication of the BRAF gene with one wild-type (V-600) and two mutant alleles (E-600) This KO cell line carries only the mutant allele. 21097174 CVCL_HE18 RKO DICER1(-/-) cancer cell line human CVCL_HE18 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17098; DICER1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 21097175 CVCL_HE11 NALM-6 TP53(+/-) cancer cell line human CVCL_HE11 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097176 CVCL_HE12 NALM-6 TP53(-/-) cancer cell line human CVCL_HE12 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097177 CVCL_HE13 NALM-6 XRCC5(+/-) cancer cell line human CVCL_HE13 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12833; XRCC5; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21097178 CVCL_HE14 Panc 04.03 MAP2K4(-/-) cancer cell line human CVCL_HE14 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 6844; MAP2K4; Sequence variation: Gene fusion; HGNC; 16935; ATG7 + HGNC; 9829; RAF1; Name(s)=ATG7-RAF1 (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556fs*3 (c.4660_4661insA) (E1554fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (from parent cell line). Male 21097179 CVCL_Z924 UCD-Dm-mus103-1 spontaneously immortalized cell line fruit fly CVCL_Z924 CL:0000010 Unspecified Group: Insect cell line. 21097180 CVCL_Z925 UCD-Dm-mus104-1 spontaneously immortalized cell line fruit fly CVCL_Z925 CL:0000010 Unspecified Group: Insect cell line. 21097181 CVCL_Z926 75j23pe34 spontaneously immortalized cell line fruit fly CVCL_Z926 CL:0000010 Unspecified Group: Insect cell line. 21097182 CVCL_Z927 75e7vg1 spontaneously immortalized cell line fruit fly CVCL_Z927 CL:0000010 Unspecified Group: Insect cell line. 21097183 CVCL_Z920 UCD-Dm-mei-218-1 spontaneously immortalized cell line fruit fly CVCL_Z920 CL:0000010 Unspecified Group: Insect cell line. 21097184 CVCL_Z921 UCD-Dm-mei-41-1 spontaneously immortalized cell line fruit fly CVCL_Z921 CL:0000010 Unspecified Group: Insect cell line. 21097185 CVCL_Z922 UCD-Dm-mei-9-1 spontaneously immortalized cell line fruit fly CVCL_Z922 CL:0000010 Unspecified Group: Insect cell line. 21097186 CVCL_Z923 UCD-Dm-mei-9-2 spontaneously immortalized cell line fruit fly CVCL_Z923 CL:0000010 Discontinued: ECACC; 90070553; probable. Unspecified Group: Insect cell line Caution: It is uncertain whether ECACC Mei9a is UCD-Dm-mei-9-2 or UCD-Dm-mei-9-1 We believe it is the first one based on its use by many investigators. 21097187 CVCL_Z928 75e7vg3 spontaneously immortalized cell line fruit fly CVCL_Z928 CL:0000010 Unspecified Group: Insect cell line. 21097188 CVCL_Z929 75e7vg4 spontaneously immortalized cell line fruit fly CVCL_Z929 CL:0000010 Unspecified Group: Insect cell line. 21097189 CVCL_Z930 75e7vg6 spontaneously immortalized cell line fruit fly CVCL_Z930 CL:0000010 Unspecified Group: Insect cell line. 21097190 CVCL_Z913 ATC-307 spontaneously immortalized cell line CVCL_Z913 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097191 CVCL_Z914 ATC-308 spontaneously immortalized cell line CVCL_Z914 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097192 CVCL_Z915 ATC-309 spontaneously immortalized cell line CVCL_Z915 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097193 CVCL_Z916 ATC-311 spontaneously immortalized cell line CVCL_Z916 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097194 CVCL_Z910 PR9 spontaneously immortalized cell line fruit fly CVCL_Z910 CL:0000010 Discontinued: DGRC; 205; probable. Unspecified Group: Insect cell line 21097195 CVCL_Z911 ATC-281/282 spontaneously immortalized cell line CVCL_Z911 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097196 CVCL_Z912 ATC-304 spontaneously immortalized cell line CVCL_Z912 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21097197 CVCL_Z917 75e7vg2 spontaneously immortalized cell line fruit fly CVCL_Z917 CL:0000010 Unspecified Group: Insect cell line. 21097198 CVCL_Z918 75e7vg5 spontaneously immortalized cell line fruit fly CVCL_Z918 CL:0000010 Female Group: Insect cell line. 21097199 CVCL_Z919 75e7vg7 spontaneously immortalized cell line fruit fly CVCL_Z919 CL:0000010 Male Group: Insect cell line. 21097200 CVCL_Z902 E-E12[ts] mal[1] spontaneously immortalized cell line fruit fly CVCL_Z902 CL:0000010 Unspecified Group: Insect cell line. 21097201 CVCL_Z903 E-FM1 spontaneously immortalized cell line fruit fly CVCL_Z903 CL:0000010 Breed/subspecies: Df(1)N8(Notch)/FM1. Unspecified Doubling time: 42 hours (DGRC) Group: Insect cell line 21097202 CVCL_Z904 E-mal[1] spontaneously immortalized cell line fruit fly CVCL_Z904 CL:0000010 Female Doubling time: 36-51 hours, depending on growth medium (DGRC). Group: Insect cell line 21097203 CVCL_Z905 E-mal[F3] spontaneously immortalized cell line fruit fly CVCL_Z905 CL:0000010 Male Group: Insect cell line. 21097204 CVCL_Z900 Kc23 spontaneously immortalized cell line fruit fly CVCL_Z900 CL:0000010 Female Group: Insect cell line. 21097205 CVCL_Z901 E-Adh-n1 spontaneously immortalized cell line fruit fly CVCL_Z901 CL:0000010 Female Doubling time: 27-35 hours, depending on growth medium (DGRC). Group: Insect cell line 21097206 CVCL_Z906 E-r[1] spontaneously immortalized cell line fruit fly CVCL_Z906 CL:0000010 Unspecified Doubling time: 159 hours (DGRC). Group: Insect cell line 21097207 CVCL_Z907 E-r[36] spontaneously immortalized cell line fruit fly CVCL_Z907 CL:0000010 Male Doubling time: 200 hours (DGRC). Group: Insect cell line 21097208 CVCL_Z908 L57-3-11 spontaneously immortalized cell line fruit fly CVCL_Z908 CL:0000010 Female Doubling time: 31 hours (DGRC). Group: Insect cell line 21097209 CVCL_Z909 PR8 spontaneously immortalized cell line fruit fly CVCL_Z909 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 45 hours (DGRC) Group: Insect cell line 21097210 CVCL_HE95 Me21158 cancer cell line human CVCL_HE95 CL:0000010 Derived from metastatic site: Lymph node. 21097211 CVCL_HE96 Me2934 cancer cell line human CVCL_HE96 CL:0000010 Derived from metastatic site: Lymph node. 21097212 CVCL_HE97 Me3700 cancer cell line human CVCL_HE97 CL:0000010 Derived from metastatic site: Lymph node. 21097213 CVCL_HE98 Me4473 cancer cell line human CVCL_HE98 CL:0000010 Derived from metastatic site: Lymph node. 21097214 CVCL_HE91 ND04897 transformed cell line human CVCL_HE91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097215 CVCL_HE92 Me20842M1 cancer cell line human CVCL_HE92 CL:0000010 Derived from metastatic site: Lymph node. 21097216 CVCL_HE93 Me20842M2 cancer cell line human CVCL_HE93 CL:0000010 Derived from metastatic site: Hypodermis. 21097217 CVCL_HE94 Me13923 cancer cell line human CVCL_HE94 CL:0000010 Derived from metastatic site: Lymph node. 21097218 CVCL_HE90 GM15845 transformed cell line human CVCL_HE90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097219 CVCL_HE88 ND00196 transformed cell line human CVCL_HE88 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21097220 CVCL_HE89 ND00195 transformed cell line human CVCL_HE89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097221 CVCL_HE99 Me4686 cancer cell line human CVCL_HE99 CL:0000010 Derived from metastatic site: Lymph node. 21097222 CVCL_Z887 NIVI-CH-445 spontaneously immortalized cell line CVCL_Z887 CL:0000010 Unspecified Group: Insect cell line. 21097223 CVCL_Z888 GWSS-G3 spontaneously immortalized cell line CVCL_Z888 CL:0000010 Unspecified Doubling time: 100.3 +- 6.8 hours (PubMed=16153147). Group: Insect cell line 21097224 CVCL_Z889 GWSS-LH spontaneously immortalized cell line CVCL_Z889 CL:0000010 Unspecified Doubling time: 60.2 +- 4.9 hours (PubMed=16153147). Group: Insect cell line 21097225 CVCL_7242 9.0.4.C43 spontaneously immortalized cell line house mouse CVCL_7242 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21097226 CVCL_6Q42 DA00873 transformed cell line human CVCL_6Q42 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097227 CVCL_6Q43 DA00874 transformed cell line human CVCL_6Q43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097228 CVCL_7244 B/C.Sk finite cell line house mouse CVCL_7244 CL:0000010 Derived from sampling site: Ear; skin; Breed/subspecies: BALB/cCRGL. Discontinued: ATCC; CRL-6329; true; Discontinued: ECACC; 86111901; probable Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21097229 CVCL_6Q44 DA00875 transformed cell line human CVCL_6Q44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097230 CVCL_7245 BB7.1 hybridoma house mouse CVCL_7245 CL:0000010 Monoclonal antibody isotype: IgG1. 21097231 CVCL_6Q45 DA00876 transformed cell line human CVCL_6Q45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097232 CVCL_7240 51.1 hybridoma house mouse CVCL_7240 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human CD8. 21097233 CVCL_6Q40 DA00871 transformed cell line human CVCL_6Q40 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097234 CVCL_7241 58967 NRK transformed cell line Norway rat CVCL_7241 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21097235 CVCL_6Q41 DA00872 transformed cell line human CVCL_6Q41 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097236 CVCL_7239 35.1 hybridoma house mouse CVCL_7239 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06729; Human CD2. 21097237 CVCL_6Q39 DA00870 transformed cell line human CVCL_6Q39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097238 CVCL_7235 2.43 hybridoma CVCL_7235 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21097239 CVCL_6Q35 DA00866 transformed cell line human CVCL_6Q35 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097240 CVCL_7236 2C4 [Mouse hybridoma against rabbit RLA-DQ] hybridoma house mouse CVCL_7236 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rabbit RLA-DQ. 21097241 CVCL_6Q36 DA00867 transformed cell line human CVCL_6Q36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097242 CVCL_7237 3.334 SC5/8 hybrid cell line CVCL_7237 CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain Bratislava-77 (B77)](NCBI-Taxonomy; 11876). 21097243 CVCL_6Q37 DA00868 transformed cell line human CVCL_6Q37 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097244 CVCL_7238 31E9 hybridoma human CVCL_7238 CL:0000010 Characteristics: T-cell hybridoma Produces MIF.; Monoclonal antibody target: Japanese cedar pollen antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11052 21097245 CVCL_6Q38 DA00869 transformed cell line human CVCL_6Q38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097246 CVCL_Z894 E-OR spontaneously immortalized cell line fruit fly CVCL_Z894 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 109 hours (DGRC) Group: Insect cell line 21097247 CVCL_Z895 1182-1 spontaneously immortalized cell line fruit fly CVCL_Z895 CL:0000010 Female Group: Insect cell line. 21097248 CVCL_Z896 1182-5 spontaneously immortalized cell line fruit fly CVCL_Z896 CL:0000010 Female Group: Insect cell line. 21097249 CVCL_Z897 1182-6 spontaneously immortalized cell line fruit fly CVCL_Z897 CL:0000010 Female Group: Insect cell line. 21097250 CVCL_Z890 GWSS-Z10 spontaneously immortalized cell line CVCL_Z890 CL:0000010 Unspecified Doubling time: 46.2 +- 1.6 hours (PubMed=16153147). Group: Insect cell line 21097251 CVCL_Z891 GWSS-Z15 spontaneously immortalized cell line CVCL_Z891 CL:0000010 Unspecified Doubling time: 90.9 +- 14.0 hours (PubMed=16153147). Group: Insect cell line 21097252 CVCL_Z892 CME W1 Cl.8R spontaneously immortalized cell line fruit fly CVCL_Z892 CL:0000010 Derived from sampling site: Imaginal disc; wing; Breed/subspecies: Oregon-R. Male Doubling time: 41 hours (DGRC) Group: Insect cell line 21097253 CVCL_Z893 E-CS spontaneously immortalized cell line fruit fly CVCL_Z893 CL:0000010 Breed/subspecies: Canton-S. Omics: Transcriptome analysis by RNAseq Female Doubling time: 51-86 hours, depending on growth medium (DGRC) Group: Insect cell line 21097254 CVCL_Z876 HPa 34 spontaneously immortalized cell line CVCL_Z876 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Female Group: Insect cell line 21097255 CVCL_Z877 NHIK 3016 cancer cell line human CVCL_Z877 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21097256 CVCL_Z878 NHIK 3017 cancer cell line human CVCL_Z878 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21097257 CVCL_Z879 NHIK 3043 cancer cell line human CVCL_Z879 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21097258 CVCL_7253 CPN4B spontaneously immortalized cell line CVCL_7253 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Amphibian cell line 21097259 CVCL_6Q53 DA00884 transformed cell line human CVCL_6Q53 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097260 CVCL_7254 CT26 cancer cell line house mouse CVCL_7254 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from child cell line CT26.WT); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from child cell line CT26.WT) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21097261 CVCL_6Q54 DA00885 transformed cell line human CVCL_6Q54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097262 CVCL_7255 CT26.CL25 cancer cell line house mouse CVCL_7255 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21097263 CVCL_6Q55 DA00886 transformed cell line human CVCL_6Q55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097264 CVCL_7256 CT26.WT cancer cell line house mouse CVCL_7256 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=24621249); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (PubMed=24621249) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21097265 CVCL_6Q56 DA00887 transformed cell line human CVCL_6Q56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097266 CVCL_7250 BF-11 hybridoma CVCL_7250 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01588; Human EPO. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8164 21097267 CVCL_6Q50 DA00881 transformed cell line human CVCL_6Q50 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097268 CVCL_7251 CGM1 transformed cell line human CVCL_7251 HLA typing: A*03:01:01:01,29:02; B*08:01:01,14:02:01; C*08:02,07:01:01; DPB1*04:01 (IPD-IMGT/HLA=10407) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21097269 CVCL_6Q51 DA00882 transformed cell line human CVCL_6Q51 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097270 CVCL_7252 CL 21 hybrid cell line CVCL_7252 CL:0000010 Group: Human/rodent somatic cell hybrid. 21097271 CVCL_6Q52 DA00883 transformed cell line human CVCL_6Q52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097272 CVCL_7246 BB7.2 hybridoma house mouse CVCL_7246 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04439; Human HLA-A (Note=Recognizes allele A*02). 21097273 CVCL_6Q46 DA00877 transformed cell line human CVCL_6Q46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097274 CVCL_7247 BB7.5 hybridoma house mouse CVCL_7247 CL:0000010 Monoclonal antibody isotype: IgG1. 21097275 CVCL_6Q47 DA00878 transformed cell line human CVCL_6Q47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097276 CVCL_7248 BB7.6 hybridoma house mouse CVCL_7248 CL:0000010 Monoclonal antibody isotype: IgG1. 21097277 CVCL_6Q48 DA00879 transformed cell line human CVCL_6Q48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097278 CVCL_7249 BB7.7 hybridoma house mouse CVCL_7249 CL:0000010 Monoclonal antibody isotype: IgG2b. 21097279 CVCL_6Q49 DA00880 transformed cell line human CVCL_6Q49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097280 CVCL_Z883 CEC CC 128 spontaneously immortalized cell line CVCL_Z883 CL:0000010 Breed/subspecies: J.R.C Ispra.. Unspecified Doubling time: 22 hours (PubMed=7280302) Group: Insect cell line 21097281 CVCL_Z884 CEC CC 130 spontaneously immortalized cell line CVCL_Z884 CL:0000010 Breed/subspecies: J.R.C Ispra.. Unspecified Virology: Infected by Drosophila X virus (DXV) (DOI=10.1016/S0769-2617(81)80057-3) Doubling time: 22 hours (PubMed=7280302) Group: Insect cell line 21097282 CVCL_Z885 NIVI-CH-440 spontaneously immortalized cell line CVCL_Z885 CL:0000010 Unspecified Group: Insect cell line. 21097283 CVCL_Z886 NIVI-CH-442 spontaneously immortalized cell line CVCL_Z886 CL:0000010 Unspecified Group: Insect cell line. 21097284 CVCL_Z880 WT:CS3 spontaneously immortalized cell line fruit fly CVCL_Z880 CL:0000010 Unspecified Group: Insect cell line. 21097285 CVCL_Z881 WT:CS5 spontaneously immortalized cell line fruit fly CVCL_Z881 CL:0000010 Unspecified Group: Insect cell line. 21097286 CVCL_Z882 WT:LM6 spontaneously immortalized cell line fruit fly CVCL_Z882 CL:0000010 Unspecified Group: Insect cell line. 21097287 CVCL_Z869 Jup-GFP, DSas-4 line 69 spontaneously immortalized cell line fruit fly CVCL_Z869 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 440 hours (DGRC) Group: Insect cell line 21097288 CVCL_Z865 EH34A3 spontaneously immortalized cell line fruit fly CVCL_Z865 CL:0000010 Unspecified Doubling time: 26-58 hours, depending on growth medium (DGRC). Group: Insect cell line 21097289 CVCL_Z866 ML82-8 spontaneously immortalized cell line fruit fly CVCL_Z866 CL:0000010 Breed/subspecies: mus201D1. Unspecified Group: Insect cell line 21097290 CVCL_Z867 Jup-GFP, DSas-4 line 127 spontaneously immortalized cell line fruit fly CVCL_Z867 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 60 hours (DGRC) Group: Insect cell line 21097291 CVCL_Z868 Jup-GFP, DSas-4 line 131 spontaneously immortalized cell line fruit fly CVCL_Z868 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 28 hours (DGRC) Group: Insect cell line 21097292 CVCL_6Q20 DA00851 transformed cell line human CVCL_6Q20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097293 CVCL_7220 NIH-3T3 clone 5611 spontaneously immortalized cell line house mouse CVCL_7220 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21097294 CVCL_6Q21 DA00852 transformed cell line human CVCL_6Q21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097295 CVCL_7221 PSA1-NG2 cancer cell line house mouse CVCL_7221 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: 129/Sv-SlJ-CP. Discontinued: ECACC; 85011404; probable Male 21097296 CVCL_6Q22 DA00853 transformed cell line human CVCL_6Q22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097297 CVCL_7222 P388 cancer cell line house mouse CVCL_7222 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21097298 CVCL_6Q23 DA00854 transformed cell line human CVCL_6Q23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097299 CVCL_7223 FRhK-4/R spontaneously immortalized cell line CVCL_7223 CL:0000010 Derived from sampling site: Fetal kidney. Female Group: Non-human primate cell line 21097300 CVCL_6Q17 DA00847 transformed cell line human CVCL_6Q17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097301 CVCL_7217 HTC (BUdR) cancer cell line Norway rat CVCL_7217 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from metastatic site: Ascites; Breed/subspecies: Buffalo. Male 21097302 CVCL_6Q18 DA00848 transformed cell line human CVCL_6Q18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097303 CVCL_7218 NIH-3T3D4 spontaneously immortalized cell line house mouse CVCL_7218 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21097304 CVCL_6Q19 DA00850 transformed cell line human CVCL_6Q19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097305 CVCL_7219 NIH-3T3 4-2 spontaneously immortalized cell line house mouse CVCL_7219 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21097306 CVCL_6Q13 DA00843 transformed cell line human CVCL_6Q13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097307 CVCL_7213 HBZY-1 undefined cell line type Norway rat CVCL_7213 CL:0000010 Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.. 21097308 CVCL_6Q14 DA00844 transformed cell line human CVCL_6Q14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097309 CVCL_7214 FHK-Tcl3 transformed cell line CVCL_7214 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified 21097310 CVCL_7215 COR-L283R cancer cell line human CVCL_7215 CL:0000010 Discontinued: ECACC; 96020723; probable. Unspecified 21097311 CVCL_6Q15 DA00845 transformed cell line human CVCL_6Q15 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097312 CVCL_7216 Clone 81 transformed cell line CVCL_7216 CL:0000010 Derived from sampling site: Kidney. Female 21097313 CVCL_6Q16 DA00846 transformed cell line human CVCL_6Q16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097314 CVCL_Z872 Jup-GFP, DSas-4 line 96 spontaneously immortalized cell line fruit fly CVCL_Z872 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 48 hours (DGRC) Group: Insect cell line 21097315 CVCL_Z873 UCD-Dm-w-1 spontaneously immortalized cell line fruit fly CVCL_Z873 CL:0000010 Unspecified Group: Insect cell line. 21097316 CVCL_Z874 EPa spontaneously immortalized cell line CVCL_Z874 CL:0000010 Unspecified Group: Insect cell line. 21097317 CVCL_Z875 HPa 33 spontaneously immortalized cell line CVCL_Z875 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Male Group: Insect cell line 21097318 CVCL_Z870 Jup-GFP, DSas-4 line 70 spontaneously immortalized cell line fruit fly CVCL_Z870 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 100 hours (DGRC) Group: Insect cell line 21097319 CVCL_Z871 Jup-GFP, DSas-4 line 84 spontaneously immortalized cell line fruit fly CVCL_Z871 CL:0000010 Knockout cell: Method=Null mutation; FlyBase_Gene; FBgn0011020; Sas-4; Transfected with: UniProtKB; P42212; GFP. Unspecified Characteristics: Constitutively lacks centrioles (PubMed=23519377); Characteristics: Expresses a Jupiter-GFP fusion protein Doubling time: 6 days (DGRC) Group: Insect cell line 21097320 CVCL_Z858 BCIRL-HV-AM-CL2 spontaneously immortalized cell line CVCL_Z858 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21097321 CVCL_Z859 BL6T cancer cell line house mouse CVCL_Z859 CL:0000010 Transfected with: RGD; 67383; Prkcd Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21097322 CVCL_Z854 S2-Mt-GFP spontaneously immortalized cell line fruit fly CVCL_Z854 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21097323 CVCL_Z855 S2-Mt-GFP-Act5C spontaneously immortalized cell line fruit fly CVCL_Z855 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000042; Act5C; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Characteristics: Expresses a GFP-Act5C fusion under the control of a metallothionein promoter Doubling time: 2 days (DGRC) Group: Insect cell line 21097324 CVCL_Z856 S2-Mt-GFP-alphaTub84B spontaneously immortalized cell line fruit fly CVCL_Z856 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Characteristics: Expresses a GFP-alphaTub84B fusion under the control of a metallothionein promoter Group: Insect cell line 21097325 CVCL_Z857 ML-DmBG1-c1 spontaneously immortalized cell line fruit fly CVCL_Z857 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 44 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097326 CVCL_6Q31 DA00862 transformed cell line human CVCL_6Q31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA00862; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097327 CVCL_7231 V79 HRC spontaneously immortalized cell line CVCL_7231 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21097328 CVCL_6Q32 DA00863 transformed cell line human CVCL_6Q32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097329 CVCL_7232 V79/B7 spontaneously immortalized cell line CVCL_7232 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male Characteristics: Thymidine kinase-deficient 21097330 CVCL_7233 1116NS-3d hybridoma house mouse CVCL_7233 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8019 21097331 CVCL_6Q33 DA00864 transformed cell line human CVCL_6Q33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097332 CVCL_7234 145-2C11 hybridoma house mouse CVCL_7234 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P22646; Mouse Cd3e. 21097333 CVCL_6Q34 DA00865 transformed cell line human CVCL_6Q34 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097334 CVCL_6Q30 DA00861 transformed cell line human CVCL_6Q30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097335 CVCL_7230 V79 clone S spontaneously immortalized cell line CVCL_7230 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21097336 CVCL_6Q28 DA00859 transformed cell line human CVCL_6Q28 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097337 CVCL_7228 XTK0 transformed cell line CVCL_7228 CL:0000010 Transformant: Human herpesvirus 2 (HHV-2)(NCBI-Taxonomy; 10310); Derived from sampling site: Skin. 21097338 CVCL_6Q29 DA00860 transformed cell line human CVCL_6Q29 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097339 CVCL_7229 XCp cancer cell line Norway rat CVCL_7229 CL:0000010 Breed/subspecies: White-Weston. 21097340 CVCL_7224 A2780/100 cancer cell line human CVCL_7224 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28830; Chlorambucil (CBL; Derived from sampling site: Ovary. Female 21097341 CVCL_6Q24 DA00855 transformed cell line human CVCL_6Q24 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097342 CVCL_7225 A2780-DX3 cancer cell line human CVCL_7225 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21097343 CVCL_6Q25 DA00856 transformed cell line human CVCL_6Q25 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097344 CVCL_6Q26 DA00857 transformed cell line human CVCL_6Q26 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097345 CVCL_7226 INS-1 832/13 cancer cell line Norway rat CVCL_7226 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Shows robust glucose-stimulated insulin secretion (GSIS) (Millipore) 21097346 CVCL_6Q27 DA00858 transformed cell line human CVCL_6Q27 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097347 CVCL_7227 F-36E cancer cell line human CVCL_7227 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: EPO dependent 21097348 CVCL_Z861 Line C spontaneously immortalized cell line fruit fly CVCL_Z861 CL:0000010 Male Group: Insect cell line. 21097349 CVCL_Z862 D2 [Drosophila] spontaneously immortalized cell line fruit fly CVCL_Z862 CL:0000010 Breed/subspecies: Oregon-S. Discontinued: ECACC; 90070546; probable Unspecified Group: Insect cell line 21097350 CVCL_Z863 D1 [Drosophila] spontaneously immortalized cell line fruit fly CVCL_Z863 CL:0000010 Breed/subspecies: Oregon-S. Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 90070552; probable Male Doubling time: 23-34 hours, depending on growth medium (DGRC) Group: Insect cell line 21097351 CVCL_Z864 S2-act-GFP-alphaTub84B spontaneously immortalized cell line fruit fly CVCL_Z864 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Doubling time: 49 hours (DGRC) Group: Insect cell line 21097352 CVCL_Z860 S2-GFP-SKL spontaneously immortalized cell line fruit fly CVCL_Z860 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Characteristics: Expresses GFP tagged with a peroxisome-targeting signal under the control of an Actin5C promoter Doubling time: 46 hours (DGRC) Group: Insect cell line 21097353 CVCL_Z847 C8-MEF transformed cell line house mouse CVCL_Z847 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03255; Adenovirus 5 E1A protein; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified 21097354 CVCL_Z848 C9-MEF transformed cell line house mouse CVCL_Z848 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21097355 CVCL_Z849 AGY-502 spontaneously immortalized cell line CVCL_Z849 CL:0000010 Unspecified Group: Insect cell line. 21097356 CVCL_Z843 PP-9 spontaneously immortalized cell line CVCL_Z843 CL:0000010 Omics: Deep proteome analysis. Unspecified Group: Insect cell line 21097357 CVCL_Z844 NISES-BoMo-Cam1 spontaneously immortalized cell line CVCL_Z844 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: Cambodge. Female Group: Insect cell line 21097358 CVCL_Z845 Bmc140 spontaneously immortalized cell line CVCL_Z845 CL:0000010 Breed/subspecies: C140. Female Group: Insect cell line 21097359 CVCL_Z846 BCIRL-HV-AM-CL1 spontaneously immortalized cell line CVCL_Z846 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21097360 CVCL_6Q00 DA00830 transformed cell line human CVCL_6Q00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097361 CVCL_7200 Mais-BL cancer cell line human CVCL_7200 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097362 CVCL_6Q01 DA00831 transformed cell line human CVCL_6Q01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097363 CVCL_7201 MH60.BSF2 hybridoma house mouse CVCL_7201 CL:0000010 Characteristics: IL6 dependent; Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P05231; Human IL6. 21097364 CVCL_Z850 AGY-109 spontaneously immortalized cell line CVCL_Z850 CL:0000010 Unspecified Group: Insect cell line. 21097365 CVCL_Z851 AGY-104 spontaneously immortalized cell line CVCL_Z851 CL:0000010 Unspecified Group: Insect cell line. 21097366 CVCL_Z852 AGY-101 spontaneously immortalized cell line CVCL_Z852 CL:0000010 Unspecified Group: Insect cell line. 21097367 CVCL_Z853 ML-DmBG3-c2-Mt-GFP-Act5C spontaneously immortalized cell line fruit fly CVCL_Z853 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000042; Act5C; Transfected with: UniProtKB; P42212; GFP. Male Doubling time: 84 hours (DGRC) Group: Insect cell line 21097368 CVCL_Z836 MDR3 spontaneously immortalized cell line fruit fly CVCL_Z836 CL:0000010 Female Doubling time: 25 hours (DGRC). Group: Insect cell line 21097369 CVCL_Z837 Kc-H spontaneously immortalized cell line fruit fly CVCL_Z837 CL:0000010 Female Group: Insect cell line. 21097370 CVCL_Z838 Kc-HP spontaneously immortalized cell line fruit fly CVCL_Z838 CL:0000010 Female Group: Insect cell line Caution: We are not certain that Kc-HP and KcAlo are the same cell line. 21097371 CVCL_Z839 Ca spontaneously immortalized cell line fruit fly CVCL_Z839 CL:0000010 Male Group: Insect cell line. 21097372 CVCL_Z832 Line K spontaneously immortalized cell line fruit fly CVCL_Z832 CL:0000010 Female Group: Insect cell line. 21097373 CVCL_Z833 Kc spontaneously immortalized cell line fruit fly CVCL_Z833 CL:0000010 Female Group: Insect cell line. 21097374 CVCL_Z834 Kc167 spontaneously immortalized cell line fruit fly CVCL_Z834 CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 22-24 hours, depending on growth medium (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097375 CVCL_Z835 Kc7E10 spontaneously immortalized cell line fruit fly CVCL_Z835 CL:0000010 Female Doubling time: 4 days (DGRC). Group: Insect cell line 21097376 CVCL_6Q10 DA00840 transformed cell line human CVCL_6Q10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097377 CVCL_7210 Sav-BL cancer cell line human CVCL_7210 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21097378 CVCL_6Q11 DA00841 transformed cell line human CVCL_6Q11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097379 CVCL_6Q12 DA00842 transformed cell line human CVCL_6Q12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097380 CVCL_7212 Yak-BL cancer cell line human CVCL_7212 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097381 CVCL_6Q06 DA00836 transformed cell line human CVCL_6Q06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097382 CVCL_7206 Oku-BL cancer cell line human CVCL_7206 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21097383 CVCL_6Q07 DA00837 transformed cell line human CVCL_6Q07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097384 CVCL_7207 PRT-HU2 cancer cell line human CVCL_7207 CL:0000010 Derived from sampling site: Brain. Unspecified Doubling time: 48 hours (PubMed=1320358) 21097385 CVCL_6Q08 DA00838 transformed cell line human CVCL_6Q08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097386 CVCL_7208 Rael cancer cell line human CVCL_7208 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21097387 CVCL_6Q09 DA00839 transformed cell line human CVCL_6Q09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097388 CVCL_7209 Sal-BL cancer cell line human CVCL_7209 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21097389 CVCL_6Q02 DA00832 transformed cell line human CVCL_6Q02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097390 CVCL_7202 Mutu-1 cancer cell line human CVCL_7202 CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Asn (c.218C>A); Zygosity=Unspecified (PubMed=8108117) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: Contains a complete EBV genome (strain Mutu) which has been sequenced (PubMed=23152513; PubMed=25787276) 21097391 CVCL_6Q03 DA00833 transformed cell line human CVCL_6Q03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097392 CVCL_7203 Mutu-3 cancer cell line human CVCL_7203 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Male 21097393 CVCL_6Q04 DA00834 transformed cell line human CVCL_6Q04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097394 CVCL_7204 MV-522 cancer cell line human CVCL_7204 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Discontinued: ATCC; CRL-2519; true. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00409 Problematic cell line: Contaminated Shown to be a HT-29 derivative. Originally thought to originate from a 53 year old male patient with a lung squamous cell carcinoma. It was thought to be a metastatic derivative of UCLA-P3 (Cellosaurus=CVCL_N513). 21097395 CVCL_6Q05 DA00835 transformed cell line human CVCL_6Q05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097396 CVCL_7205 Mwika cancer cell line human CVCL_7205 CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro72Ser (c.214C>T); ClinVar=VCV000012574; Zygosity=Unspecified (PubMed=8108117) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21097397 CVCL_Z840 Kc0 spontaneously immortalized cell line fruit fly CVCL_Z840 CL:0000010 Female Group: Insect cell line. 21097398 CVCL_Z841 GML-HE-12 spontaneously immortalized cell line CVCL_Z841 CL:0000010 Unspecified Virology: Susceptible to infection by a variety of arboviruses (PubMed=6143720); Virology: Infected by Haemagogus equinus densovirus (HeDNV) (PubMed=7636489). Group: Insect cell line 21097399 CVCL_Z842 LL-5 spontaneously immortalized cell line CVCL_Z842 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Insect cell line 21097400 CVCL_Z825 UM-AVE1 spontaneously immortalized cell line CVCL_Z825 CL:0000010 Unspecified Group: Insect cell line. 21097401 CVCL_Z826 AP-64 spontaneously immortalized cell line CVCL_Z826 CL:0000010 Unspecified Group: Insect cell line. 21097402 CVCL_Z827 NIID-CTR spontaneously immortalized cell line CVCL_Z827 CL:0000010 Unspecified Doubling time: 20 hours (at 30th passage in the presence of 12% FBS), 46 hours (at 60th passage in 5% FBS), 76 hours (at 60th passage in the absence of FBS) (PubMed=22706601). Group: Insect cell line 21097403 CVCL_Z828 UOFS-CT-1 spontaneously immortalized cell line CVCL_Z828 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Unspecified Group: Insect cell line 21097404 CVCL_Z821 CCa spontaneously immortalized cell line fruit fly CVCL_Z821 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 1 week (DGRC) Group: Insect cell line 21097405 CVCL_Z822 DX spontaneously immortalized cell line fruit fly CVCL_Z822 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Doubling time: 103 hours (DGRC) Group: Insect cell line 21097406 CVCL_Z823 W20C6 spontaneously immortalized cell line fruit fly CVCL_Z823 CL:0000010 Unspecified Doubling time: 102 hours (DGRC). Group: Insect cell line 21097407 CVCL_Z824 L127D6 spontaneously immortalized cell line fruit fly CVCL_Z824 CL:0000010 Unspecified Group: Insect cell line. 21097408 CVCL_Z829 RML-12 spontaneously immortalized cell line CVCL_Z829 CL:0000010 Unspecified Group: Insect cell line Problematic cell line: Misidentified Originally thought to be of Aedes aegypti origin but found to be from Aedes albopictus (PubMed=19951376; PubMed=29973702).. 21097409 CVCL_Z830 GM02784 finite cell line human CVCL_Z830 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21097410 CVCL_Z831 S2R+ spontaneously immortalized cell line fruit fly CVCL_Z831 CL:0000010 Breed/subspecies: Oregon-R. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 39 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21097411 CVCL_Z814 WR Di-1 spontaneously immortalized cell line CVCL_Z814 CL:0000010 Unspecified Doubling time: ~2 days (DGRC). Group: Insect cell line 21097412 CVCL_Z815 WR Dv-1 spontaneously immortalized cell line CVCL_Z815 CL:0000010 Unspecified Doubling time: 26-32 hours, depending on growth medium (DGRC). Group: Insect cell line 21097413 CVCL_Z816 Dm2008Wb1 spontaneously immortalized cell line fruit fly CVCL_Z816 CL:0000010 Breed/subspecies: Chernomorka x F12. Male Characteristics: Infected by the intracellular symbiont Wolbachia pipientis Group: Insect cell line 21097414 CVCL_Z817 Aa23 spontaneously immortalized cell line CVCL_Z817 CL:0000010 Unspecified Characteristics: Infected by the intracellular symbiont Wolbachia pipientis; Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257). Group: Insect cell line 21097415 CVCL_Z810 ML84-27b spontaneously immortalized cell line fruit fly CVCL_Z810 CL:0000010 Unspecified Doubling time: 79-111 hours, depending on growth medium (DGRC). Group: Insect cell line 21097416 CVCL_Z811 ML84-29 spontaneously immortalized cell line fruit fly CVCL_Z811 CL:0000010 Unspecified Doubling time: 66 hours (DGRC). Group: Insect cell line 21097417 CVCL_Z812 ML85-5 spontaneously immortalized cell line CVCL_Z812 CL:0000010 Unspecified Doubling time: 51 hours (DGRC). Group: Insect cell line 21097418 CVCL_Z813 ML89-1 spontaneously immortalized cell line CVCL_Z813 CL:0000010 Unspecified Doubling time: 29-35 hours, depending on growth medium (DGRC). Group: Insect cell line 21097419 CVCL_Z818 C7-10B spontaneously immortalized cell line CVCL_Z818 CL:0000010 Unspecified Characteristics: In vitro infected by the intracellular symbiont Wolbachia pipientis strain wAlbB. Group: Insect cell line 21097420 CVCL_Z819 C7-10R spontaneously immortalized cell line CVCL_Z819 CL:0000010 Unspecified Characteristics: In vitro infected by the intracellular symbiont Wolbachia pipientis strain wRi. Group: Insect cell line 21097421 CVCL_Z820 U4.4 spontaneously immortalized cell line CVCL_Z820 CL:0000010 Unspecified Group: Insect cell line. 21097422 CVCL_6Q80 DA00911 transformed cell line human CVCL_6Q80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097423 CVCL_7280 GM00323 finite cell line human CVCL_7280 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21097424 CVCL_6Q81 DA00912 transformed cell line human CVCL_6Q81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097425 CVCL_7281 GM00333 transformed cell line human CVCL_7281 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21097426 CVCL_6Q86 DA00917 transformed cell line human CVCL_6Q86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097427 CVCL_7286 GM00472 finite cell line human CVCL_7286 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21097428 CVCL_6Q87 DA00919 transformed cell line human CVCL_6Q87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097429 CVCL_7287 GM00473 finite cell line human CVCL_7287 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21097430 CVCL_6Q88 DA00920 transformed cell line human CVCL_6Q88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097431 CVCL_7288 GM00483 finite cell line human CVCL_7288 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys667Tyr (c.2000G>A) (C646Y); ClinVar=VCV000003689; Zygosity=Heterozygous (Coriell) Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21097432 CVCL_6Q89 DA00921 transformed cell line human CVCL_6Q89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097433 CVCL_7289 GM00495 finite cell line human CVCL_7289 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM00104; true Male 21097434 CVCL_6Q82 DA00913 transformed cell line human CVCL_6Q82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097435 CVCL_7282 GM00409 finite cell line human CVCL_7282 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21097436 CVCL_6Q83 DA00914 transformed cell line human CVCL_6Q83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097437 CVCL_7283 GM00425 finite cell line human CVCL_7283 CL:0000010 Karyotypic information: 47,XY,+8,inv(9)(pter->p11::q21->p11::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21097438 CVCL_6Q84 DA00915 transformed cell line human CVCL_6Q84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097439 CVCL_7284 GM00468 finite cell line human CVCL_7284 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21097440 CVCL_6Q85 DA00916 transformed cell line human CVCL_6Q85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097441 CVCL_7285 GM00469 finite cell line human CVCL_7285 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21097442 CVCL_6Q79 DA00910 transformed cell line human CVCL_6Q79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097443 CVCL_7279 GM00321 finite cell line human CVCL_7279 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21097444 CVCL_6Q90 DA00922 transformed cell line human CVCL_6Q90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097445 CVCL_7290 GM00498 finite cell line human CVCL_7290 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21097446 CVCL_6Q91 DA00923 transformed cell line human CVCL_6Q91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097447 CVCL_7291 GM00499 finite cell line human CVCL_7291 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by RNAseq Male Doubling time: Slow growth (Coriell) 21097448 CVCL_6Q92 DA00924 transformed cell line human CVCL_6Q92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097449 CVCL_7292 GM00500 finite cell line human CVCL_7292 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21097450 CVCL_6Q97 DA00929 transformed cell line human CVCL_6Q97 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097451 CVCL_7297 GM00637 transformed cell line human CVCL_7297 HLA typing: A*02:01:01:01,26:01:01; C*15:02:01,16:01:01 (IPD-IMGT/HLA=10615) CL:0000010 Population: Puerto Rican; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21097452 CVCL_6Q98 DA00930 transformed cell line human CVCL_6Q98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097453 CVCL_7298 GM00638 transformed cell line human CVCL_7298 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Val44Met (c.130G>A); ClinVar=VCV000003611; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Met142Lys (c.425T>A); ClinVar=VCV000003609; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21097454 CVCL_6Q99 DA00931 transformed cell line human CVCL_6Q99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097455 CVCL_7299 GM00639 transformed cell line human CVCL_7299 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Ser135Leu (c.404C>T); ClinVar=VCV000003618; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Phe171Ser (c.512T>C); ClinVar=VCV000003616; Zygosity=Heterozygous (from parent cell line) Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00639; true Male 21097456 CVCL_6Q93 DA00925 transformed cell line human CVCL_6Q93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097457 CVCL_7293 GM00536 transformed cell line human CVCL_7293 HLA typing: A*24:02:01,26:01:01; B*14:01:01,35:01:01; C*04:01:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,16:01:01; DQA1*01:04:01,02:01:01; DQB1*02:02:01,05:03:01; DRB1*07:01:01,14:54:01; DRB3*02:02:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21097458 CVCL_6Q94 DA00926 transformed cell line human CVCL_6Q94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097459 CVCL_7294 GM00558 transformed cell line human CVCL_7294 HLA typing: A*03,11; B*w15,w22 (Coriell=GM00558); HLA typing: A*03:01:01,11:01:01; B*15:01:01,56:01:01; C*01:02:01,03:03:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,26:01:02; DQA1*01:03:01,02:01:01; DQB1*02:02:01,06:01:01; DRB1*07:01:01,15:02:02; DRB4*01:03:01; DRB5*01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21097460 CVCL_6Q95 DA00927 transformed cell line human CVCL_6Q95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097461 CVCL_7295 GM00607 transformed cell line human CVCL_7295 HLA typing: A*02:01:01,03:01:01; B*07:02:01,18:01:01; C*07:01:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02G,04:02:01G; DQA1*01:02:01,01:03:01; DQB1*06:02:01,06:03:01; DRB1*13:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21097462 CVCL_6Q96 DA00928 transformed cell line human CVCL_6Q96 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097463 CVCL_7296 GM00621 transformed cell line human CVCL_7296 HLA typing: A*03:01:01,68:01:02; B*35:01:01,44:03:01; C*04:01:01,14:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02G,04:02:01G; DQA1*01:01:01,02:01:01; DQB1*02:02:01,05:01:01; DRB1*01:01:01,07:01:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21097464 CVCL_6Q64 DA00895 transformed cell line human CVCL_6Q64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097465 CVCL_7264 GD25 transformed cell line house mouse CVCL_7264 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Breed/subspecies: 129S2/SvPas. Male 21097466 CVCL_6Q65 DA00896 transformed cell line human CVCL_6Q65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097467 CVCL_7265 GK-5 transformed cell line human CVCL_7265 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgG2 kappa Group: Hybridoma fusion partner cell line Problematic cell line: Misclassified Grand-parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21097468 CVCL_6Q66 DA00897 transformed cell line human CVCL_6Q66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097469 CVCL_7266 GM00010 finite cell line human CVCL_7266 CL:0000010 Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL 21097470 CVCL_6Q67 DA00898 transformed cell line human CVCL_6Q67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097471 CVCL_7267 GM00011 finite cell line human CVCL_7267 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21097472 CVCL_6Q60 DA00891 transformed cell line human CVCL_6Q60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097473 CVCL_7260 ECC-1 cancer cell line human CVCL_7260 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Omics: Array-based CGH; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2923; true Female Part of: ENCODE project common cell types; tier 3; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00460 Problematic cell line: Contaminated Shown to be a Ishikawa 3-H-12 derivative (PubMed=22710073). 21097474 CVCL_6Q61 DA00892 transformed cell line human CVCL_6Q61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097475 CVCL_7261 EcR-293 transformed cell line human CVCL_7261 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000546; EcR; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21097476 CVCL_6Q62 DA00893 transformed cell line human CVCL_6Q62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097477 CVCL_7262 EUE cancer cell line human CVCL_7262 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00044 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). Originally thought to originate from the skin and muscle explant of an embryo. 21097478 CVCL_6Q63 DA00894 transformed cell line human CVCL_6Q63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097479 CVCL_7263 F4/80 hybridoma CVCL_7263 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q61549; Mouse Adgre1. 21097480 CVCL_7257 D12/DM cancer cell line house mouse CVCL_7257 CL:0000010 Breed/subspecies: AKR. Discontinued: ECACC; 94031007; probable 21097481 CVCL_6Q57 DA00888 transformed cell line human CVCL_6Q57 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097482 CVCL_6Q58 DA00889 transformed cell line human CVCL_6Q58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097483 CVCL_7259 86HG39 cancer cell line human CVCL_7259 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male 21097484 CVCL_6Q59 DA00890 transformed cell line human CVCL_6Q59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097485 CVCL_6Q70 DA00901 transformed cell line human CVCL_6Q70 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097486 CVCL_7270 GM00037 finite cell line human CVCL_7270 CL:0000010 Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21097487 CVCL_Z898 1182-7b spontaneously immortalized cell line fruit fly CVCL_Z898 CL:0000010 Unspecified Group: Insect cell line. 21097488 CVCL_Z899 Cd R200 spontaneously immortalized cell line fruit fly CVCL_Z899 CL:0000010 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+). Female Group: Insect cell line 21097489 CVCL_6Q75 DA00906 transformed cell line human CVCL_6Q75 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097490 CVCL_7275 GM00131 transformed cell line human CVCL_7275 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21097491 CVCL_6Q76 DA00907 transformed cell line human CVCL_6Q76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097492 CVCL_7276 GM00254 finite cell line human CVCL_7276 CL:0000010 Population: African American; Karyotypic information: 47,XXX [48]; 46,XX [2] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21097493 CVCL_6Q77 DA00908 transformed cell line human CVCL_6Q77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097494 CVCL_7277 GM00302 finite cell line human CVCL_7277 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00075; true Male 21097495 CVCL_6Q78 DA00909 transformed cell line human CVCL_6Q78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097496 CVCL_7278 GM00316 finite cell line human CVCL_7278 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM00316; probable Male Senescence: Senesces at 22 PDL (PubMed=6492896) 21097497 CVCL_6Q71 DA00902 transformed cell line human CVCL_6Q71 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097498 CVCL_7271 GM00038 finite cell line human CVCL_7271 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21097499 CVCL_6Q72 DA00903 transformed cell line human CVCL_6Q72 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097500 CVCL_7272 GM00041 finite cell line human CVCL_7272 CL:0000010 Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21097501 CVCL_6Q73 DA00904 transformed cell line human CVCL_6Q73 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097502 CVCL_7273 GM00043 finite cell line human CVCL_7273 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21097503 CVCL_6Q74 DA00905 transformed cell line human CVCL_6Q74 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097504 CVCL_7274 GM00130 transformed cell line human CVCL_7274 HLA typing: A*01:01:01,02:01:01; B*35:08:01,39:01:01; C*04:01:01,17:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*01:05:01,05:05:01; DQB1*03:01:01,05:01:01; DRB1*10:01:01,11:04:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.4243-35delT (4375-36delT); ClinVar=VCV000035885; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21097505 CVCL_6Q68 DA00899 transformed cell line human CVCL_6Q68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097506 CVCL_7268 GM00023 finite cell line human CVCL_7268 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21097507 CVCL_6Q69 DA00900 transformed cell line human CVCL_6Q69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21097508 CVCL_7269 GM00024 finite cell line human CVCL_7269 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21097509 CVCL_I028 HGDP01014 transformed cell line human CVCL_I028 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097510 CVCL_I029 HGDP00029 transformed cell line human CVCL_I029 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097511 CVCL_I024 HGDP01012 transformed cell line human CVCL_I024 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097512 CVCL_I025 HGDP00025 transformed cell line human CVCL_I025 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097513 CVCL_I026 HGDP01013 transformed cell line human CVCL_I026 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097514 CVCL_I027 HGDP00027 transformed cell line human CVCL_I027 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097515 CVCL_I020 HGDP01010 transformed cell line human CVCL_I020 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097516 CVCL_I021 HGDP00021 transformed cell line human CVCL_I021 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097517 CVCL_I022 HGDP01011 transformed cell line human CVCL_I022 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097518 CVCL_I023 HGDP00023 transformed cell line human CVCL_I023 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097519 CVCL_I039 HGDP00039 transformed cell line human CVCL_I039 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097520 CVCL_I035 HGDP00035 transformed cell line human CVCL_I035 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097521 CVCL_I036 HGDP01018 transformed cell line human CVCL_I036 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097522 CVCL_I037 HGDP00037 transformed cell line human CVCL_I037 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097523 CVCL_I038 HGDP01019 transformed cell line human CVCL_I038 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097524 CVCL_I031 HGDP00031 transformed cell line human CVCL_I031 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097525 CVCL_I032 HGDP01016 transformed cell line human CVCL_I032 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097526 CVCL_I033 HGDP00033 transformed cell line human CVCL_I033 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097527 CVCL_I034 HGDP01017 transformed cell line human CVCL_I034 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097528 CVCL_I030 HGDP01015 transformed cell line human CVCL_I030 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097529 CVCL_I006 HGDP01003 transformed cell line human CVCL_I006 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097530 CVCL_I007 HGDP00007 transformed cell line human CVCL_I007 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097531 CVCL_I008 HGDP01004 transformed cell line human CVCL_I008 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097532 CVCL_I009 HGDP00009 transformed cell line human CVCL_I009 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097533 CVCL_I002 HGDP01000 transformed cell line human CVCL_I002 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097534 CVCL_I003 HGDP00003 transformed cell line human CVCL_I003 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097535 CVCL_I004 HGDP01001 transformed cell line human CVCL_I004 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097536 CVCL_I005 HGDP00005 transformed cell line human CVCL_I005 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097537 CVCL_I000 GM86.fl cancer cell line house mouse CVCL_I000 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21097538 CVCL_I001 HGDP00001 transformed cell line human CVCL_I001 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097539 CVCL_I017 HGDP00017 transformed cell line human CVCL_I017 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097540 CVCL_I018 HGDP01009 transformed cell line human CVCL_I018 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097541 CVCL_I019 HGDP00019 transformed cell line human CVCL_I019 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097542 CVCL_I013 HGDP00013 transformed cell line human CVCL_I013 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097543 CVCL_I014 HGDP01007 transformed cell line human CVCL_I014 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097544 CVCL_I015 HGDP00015 transformed cell line human CVCL_I015 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097545 CVCL_I016 HGDP01008 transformed cell line human CVCL_I016 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097546 CVCL_I010 HGDP01005 transformed cell line human CVCL_I010 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097547 CVCL_I011 HGDP00011 transformed cell line human CVCL_I011 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097548 CVCL_I012 HGDP01006 transformed cell line human CVCL_I012 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097549 CVCL_QH28 BayGenomics ES cell line YHA307 embryonic stem cell house mouse CVCL_QH28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097550 CVCL_QH29 BayGenomics ES cell line YHA315 embryonic stem cell house mouse CVCL_QH29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097551 CVCL_HN87 GM21034 transformed cell line human CVCL_HN87 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097552 CVCL_HN88 GM21035 transformed cell line human CVCL_HN88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097553 CVCL_HN89 GM21037 transformed cell line human CVCL_HN89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097554 CVCL_QH30 BayGenomics ES cell line YHA318 embryonic stem cell house mouse CVCL_QH30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097555 CVCL_QH31 BayGenomics ES cell line YHA328 embryonic stem cell house mouse CVCL_QH31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097556 CVCL_HN83 GM21030 transformed cell line human CVCL_HN83 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097557 CVCL_QH32 BayGenomics ES cell line YHA339 embryonic stem cell house mouse CVCL_QH32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448542; Samd4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097558 CVCL_HN84 GM21031 transformed cell line human CVCL_HN84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097559 CVCL_QH33 BayGenomics ES cell line YHA352 embryonic stem cell house mouse CVCL_QH33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140998; Ube3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097560 CVCL_HN85 GM21032 transformed cell line human CVCL_HN85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097561 CVCL_QH34 BayGenomics ES cell line YHA365 embryonic stem cell house mouse CVCL_QH34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353633; Fus Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097562 CVCL_HN86 GM21033 transformed cell line human CVCL_HN86 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097563 CVCL_QH35 BayGenomics ES cell line YHA367 embryonic stem cell house mouse CVCL_QH35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097564 CVCL_QH36 BayGenomics ES cell line YHA368 embryonic stem cell house mouse CVCL_QH36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276116; Ep300 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097565 CVCL_HN80 GM21027 transformed cell line human CVCL_HN80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097566 CVCL_QH37 BayGenomics ES cell line YHA398 embryonic stem cell house mouse CVCL_QH37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097567 CVCL_HN81 GM21028 transformed cell line human CVCL_HN81 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097568 CVCL_QH38 BayGenomics ES cell line YHA404 embryonic stem cell house mouse CVCL_QH38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097569 CVCL_HN82 GM21029 transformed cell line human CVCL_HN82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097570 CVCL_QH17 BayGenomics ES cell line YHA278 embryonic stem cell house mouse CVCL_QH17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097571 CVCL_QH18 BayGenomics ES cell line YHA279 embryonic stem cell house mouse CVCL_QH18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446634; Ago3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097572 CVCL_QH19 BayGenomics ES cell line YHA284 embryonic stem cell house mouse CVCL_QH19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913964; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097573 CVCL_HN98 GM21046 transformed cell line human CVCL_HN98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097574 CVCL_HN99 GM21048 transformed cell line human CVCL_HN99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097575 CVCL_QH20 BayGenomics ES cell line YHA285 embryonic stem cell house mouse CVCL_QH20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276116; Ep300 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097576 CVCL_HN94 GM21042 transformed cell line human CVCL_HN94 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097577 CVCL_QH21 BayGenomics ES cell line YHA286 embryonic stem cell house mouse CVCL_QH21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097578 CVCL_HN95 GM21043 transformed cell line human CVCL_HN95 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097579 CVCL_QH22 BayGenomics ES cell line YHA287 embryonic stem cell house mouse CVCL_QH22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097580 CVCL_HN96 GM21044 transformed cell line human CVCL_HN96 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097581 CVCL_QH23 BayGenomics ES cell line YHA289 embryonic stem cell house mouse CVCL_QH23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097582 CVCL_HN97 GM21045 transformed cell line human CVCL_HN97 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097583 CVCL_QH24 BayGenomics ES cell line YHA292 embryonic stem cell house mouse CVCL_QH24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097584 CVCL_HN90 GM21038 transformed cell line human CVCL_HN90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097585 CVCL_QH25 BayGenomics ES cell line YHA293 embryonic stem cell house mouse CVCL_QH25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104860; Fxr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097586 CVCL_HN91 GM21039 transformed cell line human CVCL_HN91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097587 CVCL_QH26 BayGenomics ES cell line YHA296 embryonic stem cell house mouse CVCL_QH26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097588 CVCL_HN92 GM21040 transformed cell line human CVCL_HN92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097589 CVCL_QH27 BayGenomics ES cell line YHA299 embryonic stem cell house mouse CVCL_QH27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922863; Med25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097590 CVCL_HN93 GM21041 transformed cell line human CVCL_HN93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097591 CVCL_QH06 BayGenomics ES cell line YHA237 embryonic stem cell house mouse CVCL_QH06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097592 CVCL_QH07 BayGenomics ES cell line YHA239 embryonic stem cell house mouse CVCL_QH07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95390; En2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097593 CVCL_QH08 BayGenomics ES cell line YHA242 embryonic stem cell house mouse CVCL_QH08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097594 CVCL_QH09 BayGenomics ES cell line YHA243 embryonic stem cell house mouse CVCL_QH09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097595 CVCL_HN69 GM21016 transformed cell line human CVCL_HN69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097596 CVCL_HN65 GM21012 transformed cell line human CVCL_HN65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097597 CVCL_HN66 GM21013 transformed cell line human CVCL_HN66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097598 CVCL_HN67 GM21014 transformed cell line human CVCL_HN67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097599 CVCL_HN68 GM21015 transformed cell line human CVCL_HN68 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097600 CVCL_HN61 GM21007 transformed cell line human CVCL_HN61 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097601 CVCL_QH10 BayGenomics ES cell line YHA247 embryonic stem cell house mouse CVCL_QH10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097602 CVCL_HN62 GM21008 transformed cell line human CVCL_HN62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097603 CVCL_QH11 BayGenomics ES cell line YHA252 embryonic stem cell house mouse CVCL_QH11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097604 CVCL_HN63 GM21010 transformed cell line human CVCL_HN63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097605 CVCL_QH12 BayGenomics ES cell line YHA254 embryonic stem cell house mouse CVCL_QH12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101917; Bcap29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097606 CVCL_HN64 GM21011 transformed cell line human CVCL_HN64 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097607 CVCL_QH13 BayGenomics ES cell line YHA266 embryonic stem cell house mouse CVCL_QH13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855692; Nono Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097608 CVCL_QH14 BayGenomics ES cell line YHA268 embryonic stem cell house mouse CVCL_QH14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097609 CVCL_QH15 BayGenomics ES cell line YHA275 embryonic stem cell house mouse CVCL_QH15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097610 CVCL_QH16 BayGenomics ES cell line YHA277 embryonic stem cell house mouse CVCL_QH16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108051; Smad2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097611 CVCL_HN60 GM21006 transformed cell line human CVCL_HN60 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097612 CVCL_HN76 GM21023 transformed cell line human CVCL_HN76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097613 CVCL_HN77 GM21024 transformed cell line human CVCL_HN77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097614 CVCL_HN78 GM21025 transformed cell line human CVCL_HN78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097615 CVCL_HN79 GM21026 transformed cell line human CVCL_HN79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097616 CVCL_HN72 GM21019 transformed cell line human CVCL_HN72 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097617 CVCL_HN73 GM21020 transformed cell line human CVCL_HN73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097618 CVCL_QH00 BayGenomics ES cell line YHA201 embryonic stem cell house mouse CVCL_QH00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139714; Adgrl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097619 CVCL_HN74 GM21021 transformed cell line human CVCL_HN74 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097620 CVCL_QH01 BayGenomics ES cell line YHA210 embryonic stem cell house mouse CVCL_QH01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097621 CVCL_HN75 GM21022 transformed cell line human CVCL_HN75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097622 CVCL_QH02 BayGenomics ES cell line YHA213 embryonic stem cell house mouse CVCL_QH02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097623 CVCL_QH03 BayGenomics ES cell line YHA216 embryonic stem cell house mouse CVCL_QH03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107410; Zbtb17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097624 CVCL_QH04 BayGenomics ES cell line YHA230 embryonic stem cell house mouse CVCL_QH04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097625 CVCL_HN70 GM21017 transformed cell line human CVCL_HN70 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097626 CVCL_QH05 BayGenomics ES cell line YHA234 embryonic stem cell house mouse CVCL_QH05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95486; Fbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097627 CVCL_HN71 GM21018 transformed cell line human CVCL_HN71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097628 CVCL_HN47 GM20993 transformed cell line human CVCL_HN47 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097629 CVCL_HN48 GM20994 transformed cell line human CVCL_HN48 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097630 CVCL_HN49 GM20995 transformed cell line human CVCL_HN49 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097631 CVCL_HN43 GM20989 transformed cell line human CVCL_HN43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097632 CVCL_HN44 ND05845 transformed cell line human CVCL_HN44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097633 CVCL_HN45 ND05926 transformed cell line human CVCL_HN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097634 CVCL_HN46 GM20992 transformed cell line human CVCL_HN46 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097635 CVCL_HN40 GM20986 transformed cell line human CVCL_HN40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097636 CVCL_HN41 ND05722 transformed cell line human CVCL_HN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097637 CVCL_HN42 ND05723 transformed cell line human CVCL_HN42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21097638 CVCL_HN58 GM21004 transformed cell line human CVCL_HN58 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097639 CVCL_HN59 GM21005 transformed cell line human CVCL_HN59 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097640 CVCL_HN54 GM21000 transformed cell line human CVCL_HN54 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097641 CVCL_HN55 GM21001 transformed cell line human CVCL_HN55 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097642 CVCL_HN56 GM21002 transformed cell line human CVCL_HN56 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097643 CVCL_HN57 GM21003 transformed cell line human CVCL_HN57 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097644 CVCL_HN50 GM20996 transformed cell line human CVCL_HN50 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097645 CVCL_HN51 GM20997 transformed cell line human CVCL_HN51 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097646 CVCL_HN52 GM20998 transformed cell line human CVCL_HN52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097647 CVCL_HN53 GM20999 transformed cell line human CVCL_HN53 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097648 CVCL_HN29 GM20973 transformed cell line human CVCL_HN29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097649 CVCL_HN25 GM20969 transformed cell line human CVCL_HN25 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097650 CVCL_HN26 GM20970 transformed cell line human CVCL_HN26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097651 CVCL_HN27 GM20971 transformed cell line human CVCL_HN27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097652 CVCL_HN28 GM20972 transformed cell line human CVCL_HN28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097653 CVCL_HN21 GM20694 transformed cell line human CVCL_HN21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097654 CVCL_HN22 GM20695 transformed cell line human CVCL_HN22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097655 CVCL_HN23 GM20696 transformed cell line human CVCL_HN23 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097656 CVCL_HN24 GM20697 transformed cell line human CVCL_HN24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097657 CVCL_HN20 GM20691 transformed cell line human CVCL_HN20 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097658 CVCL_HN36 GM20982 transformed cell line human CVCL_HN36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097659 CVCL_HN37 GM20983 transformed cell line human CVCL_HN37 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097660 CVCL_HN38 GM20984 transformed cell line human CVCL_HN38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097661 CVCL_HN39 GM20985 transformed cell line human CVCL_HN39 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097662 CVCL_HN32 GM20978 transformed cell line human CVCL_HN32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097663 CVCL_HN33 GM20979 transformed cell line human CVCL_HN33 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097664 CVCL_HN34 GM20980 transformed cell line human CVCL_HN34 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097665 CVCL_HN35 GM20981 transformed cell line human CVCL_HN35 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097666 CVCL_HN30 GM20974 transformed cell line human CVCL_HN30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097667 CVCL_HN31 GM20977 transformed cell line human CVCL_HN31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097668 CVCL_QH90 BayGenomics ES cell line YHB056 embryonic stem cell house mouse CVCL_QH90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097669 CVCL_QH91 BayGenomics ES cell line YHB057 embryonic stem cell house mouse CVCL_QH91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097670 CVCL_QH92 BayGenomics ES cell line YHB060 embryonic stem cell house mouse CVCL_QH92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097671 CVCL_QH93 BayGenomics ES cell line YHB062 embryonic stem cell house mouse CVCL_QH93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924093; Dtl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097672 CVCL_QH94 BayGenomics ES cell line YHB063 embryonic stem cell house mouse CVCL_QH94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443658; Prr14l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097673 CVCL_QH95 BayGenomics ES cell line YHB064 embryonic stem cell house mouse CVCL_QH95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913466; Bsdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097674 CVCL_QH96 BayGenomics ES cell line YHB065 embryonic stem cell house mouse CVCL_QH96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097675 CVCL_QH97 BayGenomics ES cell line YHB067 embryonic stem cell house mouse CVCL_QH97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914535; Cwc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097676 CVCL_QH98 BayGenomics ES cell line YHB068 embryonic stem cell house mouse CVCL_QH98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097677 CVCL_QH99 BayGenomics ES cell line YHB069 embryonic stem cell house mouse CVCL_QH99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916428; Snx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097678 CVCL_QH80 BayGenomics ES cell line YHB040 embryonic stem cell house mouse CVCL_QH80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097679 CVCL_QH81 BayGenomics ES cell line YHB042 embryonic stem cell house mouse CVCL_QH81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923041; Fbxw8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097680 CVCL_QH82 BayGenomics ES cell line YHB044 embryonic stem cell house mouse CVCL_QH82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097681 CVCL_QH83 BayGenomics ES cell line YHB047 embryonic stem cell house mouse CVCL_QH83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88353; Cdk11b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097682 CVCL_QH84 BayGenomics ES cell line YHB049 embryonic stem cell house mouse CVCL_QH84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915122; Nsmce4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097683 CVCL_QH85 BayGenomics ES cell line YHB050 embryonic stem cell house mouse CVCL_QH85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387367; Rbm45 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097684 CVCL_QH86 BayGenomics ES cell line YHB052 embryonic stem cell house mouse CVCL_QH86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097685 CVCL_QH87 BayGenomics ES cell line YHB053 embryonic stem cell house mouse CVCL_QH87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097686 CVCL_QH88 BayGenomics ES cell line YHB054 embryonic stem cell house mouse CVCL_QH88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097687 CVCL_QH89 BayGenomics ES cell line YHB055 embryonic stem cell house mouse CVCL_QH89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097688 CVCL_QH70 BayGenomics ES cell line YHB023 embryonic stem cell house mouse CVCL_QH70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097689 CVCL_QH71 BayGenomics ES cell line YHB024 embryonic stem cell house mouse CVCL_QH71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097690 CVCL_QH72 BayGenomics ES cell line YHB028 embryonic stem cell house mouse CVCL_QH72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916139; Ubac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097691 CVCL_QH73 BayGenomics ES cell line YHB030 embryonic stem cell house mouse CVCL_QH73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922865; Zfp933 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097692 CVCL_QH74 BayGenomics ES cell line YHB033 embryonic stem cell house mouse CVCL_QH74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929282; Ptges3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097693 CVCL_QH75 BayGenomics ES cell line YHB035 embryonic stem cell house mouse CVCL_QH75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097694 CVCL_QH76 BayGenomics ES cell line YHB036 embryonic stem cell house mouse CVCL_QH76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097695 CVCL_QH77 BayGenomics ES cell line YHB037 embryonic stem cell house mouse CVCL_QH77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918017; Prpf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097696 CVCL_QH78 BayGenomics ES cell line YHB038 embryonic stem cell house mouse CVCL_QH78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097697 CVCL_QH79 BayGenomics ES cell line YHB039 embryonic stem cell house mouse CVCL_QH79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097698 CVCL_QH60 BayGenomics ES cell line YHB006 embryonic stem cell house mouse CVCL_QH60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097699 CVCL_QH61 BayGenomics ES cell line YHB007 embryonic stem cell house mouse CVCL_QH61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97447; Osbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097700 CVCL_QH62 BayGenomics ES cell line YHB008 embryonic stem cell house mouse CVCL_QH62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097701 CVCL_QH63 BayGenomics ES cell line YHB009 embryonic stem cell house mouse CVCL_QH63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097702 CVCL_QH64 BayGenomics ES cell line YHB010 embryonic stem cell house mouse CVCL_QH64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097703 CVCL_QH65 BayGenomics ES cell line YHB011 embryonic stem cell house mouse CVCL_QH65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097704 CVCL_QH66 BayGenomics ES cell line YHB012 embryonic stem cell house mouse CVCL_QH66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107628; Prdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097705 CVCL_QH67 BayGenomics ES cell line YHB013 embryonic stem cell house mouse CVCL_QH67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097706 CVCL_QH68 BayGenomics ES cell line YHB017 embryonic stem cell house mouse CVCL_QH68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923356; Kdm3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097707 CVCL_QH69 BayGenomics ES cell line YHB022 embryonic stem cell house mouse CVCL_QH69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919421; Shq1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097708 CVCL_QH50 BayGenomics ES cell line YHA437 embryonic stem cell house mouse CVCL_QH50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99462; Pigf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097709 CVCL_QH51 BayGenomics ES cell line YHA448 embryonic stem cell house mouse CVCL_QH51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346873; Map3k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097710 CVCL_QH52 BayGenomics ES cell line YHA449 embryonic stem cell house mouse CVCL_QH52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354708; Fbxo31 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097711 CVCL_QH53 BayGenomics ES cell line YHA461 embryonic stem cell house mouse CVCL_QH53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097712 CVCL_QH54 BayGenomics ES cell line YHA462 embryonic stem cell house mouse CVCL_QH54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917875; Med26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097713 CVCL_QH55 BayGenomics ES cell line YHB001 embryonic stem cell house mouse CVCL_QH55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097714 CVCL_QH56 BayGenomics ES cell line YHB002 embryonic stem cell house mouse CVCL_QH56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196439; Cbx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097715 CVCL_QH57 BayGenomics ES cell line YHB003 embryonic stem cell house mouse CVCL_QH57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860513; Fnbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097716 CVCL_QH58 BayGenomics ES cell line YHB004 embryonic stem cell house mouse CVCL_QH58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88090; Ass1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097717 CVCL_QH59 BayGenomics ES cell line YHB005 embryonic stem cell house mouse CVCL_QH59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917498; Dazap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097718 CVCL_QH39 BayGenomics ES cell line YHA405 embryonic stem cell house mouse CVCL_QH39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443455; Dse Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097719 CVCL_QH40 BayGenomics ES cell line YHA406 embryonic stem cell house mouse CVCL_QH40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143755; AU041133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097720 CVCL_QH41 BayGenomics ES cell line YHA407 embryonic stem cell house mouse CVCL_QH41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143755; AU041133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097721 CVCL_QH42 BayGenomics ES cell line YHA408 embryonic stem cell house mouse CVCL_QH42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097722 CVCL_QH43 BayGenomics ES cell line YHA415 embryonic stem cell house mouse CVCL_QH43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921456; Sipa1l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097723 CVCL_QH44 BayGenomics ES cell line YHA421 embryonic stem cell house mouse CVCL_QH44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142347; Zfp568 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097724 CVCL_QH45 BayGenomics ES cell line YHA424 embryonic stem cell house mouse CVCL_QH45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097725 CVCL_QH46 BayGenomics ES cell line YHA427 embryonic stem cell house mouse CVCL_QH46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097726 CVCL_QH47 BayGenomics ES cell line YHA428 embryonic stem cell house mouse CVCL_QH47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097727 CVCL_QH48 BayGenomics ES cell line YHA429 embryonic stem cell house mouse CVCL_QH48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097728 CVCL_QH49 BayGenomics ES cell line YHA436 embryonic stem cell house mouse CVCL_QH49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097729 CVCL_HP49 GM21221 transformed cell line human CVCL_HP49 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097730 CVCL_I149 HGDP00149 transformed cell line human CVCL_I149 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097731 CVCL_HP45 GM21217 transformed cell line human CVCL_HP45 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097732 CVCL_I145 HGDP00145 transformed cell line human CVCL_I145 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097733 CVCL_HP46 GM21218 transformed cell line human CVCL_HP46 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097734 CVCL_I146 HGDP00146 transformed cell line human CVCL_I146 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097735 CVCL_HP47 GM21219 transformed cell line human CVCL_HP47 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097736 CVCL_I147 HGDP01060 transformed cell line human CVCL_I147 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097737 CVCL_I148 HGDP00148 transformed cell line human CVCL_I148 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097738 CVCL_HP48 ND05927 transformed cell line human CVCL_HP48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21097739 CVCL_HP41 GM21186 transformed cell line human CVCL_HP41 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097740 CVCL_I141 HGDP00141 transformed cell line human CVCL_I141 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097741 CVCL_HP42 GM21187 transformed cell line human CVCL_HP42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097742 CVCL_I142 HGDP01059 transformed cell line human CVCL_I142 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097743 CVCL_HP43 GM21215 transformed cell line human CVCL_HP43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097744 CVCL_I143 HGDP00143 transformed cell line human CVCL_I143 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097745 CVCL_HP44 GM21216 transformed cell line human CVCL_HP44 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097746 CVCL_I144 HGDP00144 transformed cell line human CVCL_I144 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097747 CVCL_HP40 GM21185 transformed cell line human CVCL_HP40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097748 CVCL_I140 HGDP00140 transformed cell line human CVCL_I140 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097749 CVCL_HP56 GM21256 transformed cell line human CVCL_HP56 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097750 CVCL_I156 HGDP01062 transformed cell line human CVCL_I156 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097751 CVCL_HP57 GM21257 transformed cell line human CVCL_HP57 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097752 CVCL_I157 HGDP00157 transformed cell line human CVCL_I157 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097753 CVCL_HP58 GM21258 transformed cell line human CVCL_HP58 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097754 CVCL_I158 HGDP00158 transformed cell line human CVCL_I158 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097755 CVCL_HP59 GM21259 transformed cell line human CVCL_HP59 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097756 CVCL_I159 HGDP01063 transformed cell line human CVCL_I159 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097757 CVCL_HP52 GM21252 transformed cell line human CVCL_HP52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097758 CVCL_I152 HGDP01061 transformed cell line human CVCL_I152 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097759 CVCL_HP53 GM21253 transformed cell line human CVCL_HP53 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097760 CVCL_I153 HGDP00153 transformed cell line human CVCL_I153 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097761 CVCL_HP54 GM21254 transformed cell line human CVCL_HP54 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097762 CVCL_I154 HGDP00154 transformed cell line human CVCL_I154 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097763 CVCL_HP55 GM21255 transformed cell line human CVCL_HP55 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097764 CVCL_I155 HGDP00155 transformed cell line human CVCL_I155 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097765 CVCL_HP50 GM21250 transformed cell line human CVCL_HP50 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097766 CVCL_I150 HGDP00150 transformed cell line human CVCL_I150 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097767 CVCL_HP51 GM21251 transformed cell line human CVCL_HP51 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097768 CVCL_I151 HGDP00151 transformed cell line human CVCL_I151 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097769 CVCL_HP27 GM21169 transformed cell line human CVCL_HP27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097770 CVCL_I127 HGDP00127 transformed cell line human CVCL_I127 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097771 CVCL_HP28 GM21170 transformed cell line human CVCL_HP28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097772 CVCL_I128 HGDP00128 transformed cell line human CVCL_I128 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097773 CVCL_HP29 GM21171 transformed cell line human CVCL_HP29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097774 CVCL_I129 HGDP00129 transformed cell line human CVCL_I129 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097775 CVCL_HP23 GM21165 transformed cell line human CVCL_HP23 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097776 CVCL_I123 HGDP01055 transformed cell line human CVCL_I123 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097777 CVCL_HP24 GM21166 transformed cell line human CVCL_HP24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097778 CVCL_I124 HGDP00124 transformed cell line human CVCL_I124 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097779 CVCL_HP25 GM21167 transformed cell line human CVCL_HP25 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097780 CVCL_I125 HGDP00125 transformed cell line human CVCL_I125 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097781 CVCL_HP26 GM21168 transformed cell line human CVCL_HP26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097782 CVCL_I126 HGDP01056 transformed cell line human CVCL_I126 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097783 CVCL_HP20 GM21162 transformed cell line human CVCL_HP20 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097784 CVCL_I120 HGDP00120 transformed cell line human CVCL_I120 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097785 CVCL_HP21 GM21163 transformed cell line human CVCL_HP21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097786 CVCL_I121 HGDP00121 transformed cell line human CVCL_I121 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097787 CVCL_HP22 GM21164 transformed cell line human CVCL_HP22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097788 CVCL_I122 HGDP00122 transformed cell line human CVCL_I122 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097789 CVCL_HP38 GM21183 transformed cell line human CVCL_HP38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097790 CVCL_I138 HGDP01058 transformed cell line human CVCL_I138 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097791 CVCL_HP39 GM21184 transformed cell line human CVCL_HP39 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097792 CVCL_I139 HGDP00139 transformed cell line human CVCL_I139 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097793 CVCL_HP34 GM21179 transformed cell line human CVCL_HP34 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097794 CVCL_I134 HGDP00134 transformed cell line human CVCL_I134 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097795 CVCL_HP35 GM21180 transformed cell line human CVCL_HP35 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097796 CVCL_I135 HGDP00135 transformed cell line human CVCL_I135 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097797 CVCL_HP36 GM21181 transformed cell line human CVCL_HP36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097798 CVCL_I136 HGDP00136 transformed cell line human CVCL_I136 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097799 CVCL_HP37 GM21182 transformed cell line human CVCL_HP37 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097800 CVCL_I137 HGDP00137 transformed cell line human CVCL_I137 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097801 CVCL_HP30 GM21172 transformed cell line human CVCL_HP30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097802 CVCL_I130 HGDP00130 transformed cell line human CVCL_I130 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097803 CVCL_HP31 GM21173 transformed cell line human CVCL_HP31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097804 CVCL_I131 HGDP00131 transformed cell line human CVCL_I131 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097805 CVCL_HP32 GM21174 transformed cell line human CVCL_HP32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097806 CVCL_I132 HGDP01057 transformed cell line human CVCL_I132 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097807 CVCL_HP33 GM21175 transformed cell line human CVCL_HP33 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097808 CVCL_I133 HGDP00133 transformed cell line human CVCL_I133 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097809 CVCL_HP09 GM21059 transformed cell line human CVCL_HP09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097810 CVCL_I109 HGDP00109 transformed cell line human CVCL_I109 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097811 CVCL_HP05 GM21055 transformed cell line human CVCL_HP05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097812 CVCL_I105 HGDP00105 transformed cell line human CVCL_I105 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097813 CVCL_HP06 GM21056 transformed cell line human CVCL_HP06 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097814 CVCL_I106 HGDP00106 transformed cell line human CVCL_I106 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097815 CVCL_HP07 GM21057 transformed cell line human CVCL_HP07 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097816 CVCL_I107 HGDP01052 transformed cell line human CVCL_I107 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097817 CVCL_HP08 GM21058 transformed cell line human CVCL_HP08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097818 CVCL_I108 HGDP00108 transformed cell line human CVCL_I108 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097819 CVCL_HP01 GM21051 transformed cell line human CVCL_HP01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097820 CVCL_I101 HGDP01051 transformed cell line human CVCL_I101 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097821 CVCL_HP02 GM21052 transformed cell line human CVCL_HP02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097822 CVCL_I102 HGDP00102 transformed cell line human CVCL_I102 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097823 CVCL_HP03 GM21053 transformed cell line human CVCL_HP03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097824 CVCL_I103 HGDP00103 transformed cell line human CVCL_I103 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097825 CVCL_HP04 GM21054 transformed cell line human CVCL_HP04 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097826 CVCL_I104 HGDP00104 transformed cell line human CVCL_I104 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097827 CVCL_HP00 GM21050 transformed cell line human CVCL_HP00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097828 CVCL_I100 HGDP00100 transformed cell line human CVCL_I100 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097829 CVCL_HP16 GM21066 transformed cell line human CVCL_HP16 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097830 CVCL_I116 HGDP00116 transformed cell line human CVCL_I116 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097831 CVCL_HP17 GM21067 transformed cell line human CVCL_HP17 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097832 CVCL_I117 HGDP01054 transformed cell line human CVCL_I117 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097833 CVCL_HP18 GM21160 transformed cell line human CVCL_HP18 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097834 CVCL_I118 HGDP00118 transformed cell line human CVCL_I118 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097835 CVCL_HP19 GM21161 transformed cell line human CVCL_HP19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097836 CVCL_I119 HGDP00119 transformed cell line human CVCL_I119 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097837 CVCL_HP12 GM21062 transformed cell line human CVCL_HP12 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097838 CVCL_I112 HGDP00112 transformed cell line human CVCL_I112 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097839 CVCL_HP13 GM21063 transformed cell line human CVCL_HP13 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097840 CVCL_I113 HGDP00113 transformed cell line human CVCL_I113 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097841 CVCL_HP14 GM21064 transformed cell line human CVCL_HP14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097842 CVCL_I114 HGDP01053 transformed cell line human CVCL_I114 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097843 CVCL_HP15 GM21065 transformed cell line human CVCL_HP15 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097844 CVCL_I115 HGDP00115 transformed cell line human CVCL_I115 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097845 CVCL_HP10 GM21060 transformed cell line human CVCL_HP10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21097846 CVCL_I110 HGDP00110 transformed cell line human CVCL_I110 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097847 CVCL_HP11 GM21061 transformed cell line human CVCL_HP11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21097848 CVCL_I111 HGDP00111 transformed cell line human CVCL_I111 CL:0000010 Population: Hazara (but could be Pathan); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097849 CVCL_QI49 BayGenomics ES cell line YHB178 embryonic stem cell house mouse CVCL_QI49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890496; Elac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097850 CVCL_QI50 BayGenomics ES cell line YHB179 embryonic stem cell house mouse CVCL_QI50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097851 CVCL_QI51 BayGenomics ES cell line YHB182 embryonic stem cell house mouse CVCL_QI51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919837; Pan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097852 CVCL_QI52 BayGenomics ES cell line YHB184 embryonic stem cell house mouse CVCL_QI52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097853 CVCL_QI53 BayGenomics ES cell line YHB185 embryonic stem cell house mouse CVCL_QI53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449121; Nme7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097854 CVCL_QI54 BayGenomics ES cell line YHB189 embryonic stem cell house mouse CVCL_QI54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109130; Stip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097855 CVCL_QI55 BayGenomics ES cell line YHB191 embryonic stem cell house mouse CVCL_QI55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916963; Pin4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097856 CVCL_QI56 BayGenomics ES cell line YHB193 embryonic stem cell house mouse CVCL_QI56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914713; Poc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097857 CVCL_QI57 BayGenomics ES cell line YHB201 embryonic stem cell house mouse CVCL_QI57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444133; Heatr5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097858 CVCL_QI58 BayGenomics ES cell line YHB205 embryonic stem cell house mouse CVCL_QI58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107572; Xiap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097859 CVCL_QI59 BayGenomics ES cell line YHB207 embryonic stem cell house mouse CVCL_QI59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261775; Atg14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097860 CVCL_QI38 BayGenomics ES cell line YHB147 embryonic stem cell house mouse CVCL_QI38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924767; Zfyve26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097861 CVCL_QI39 BayGenomics ES cell line YHB149 embryonic stem cell house mouse CVCL_QI39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95401; Epb41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097862 CVCL_QI40 BayGenomics ES cell line YHB151 embryonic stem cell house mouse CVCL_QI40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097863 CVCL_QI41 BayGenomics ES cell line YHB156 embryonic stem cell house mouse CVCL_QI41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644008; Ccdc85c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097864 CVCL_QI42 BayGenomics ES cell line YHB164 embryonic stem cell house mouse CVCL_QI42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931053; Marchf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097865 CVCL_QI43 BayGenomics ES cell line YHB165 embryonic stem cell house mouse CVCL_QI43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2652885; Tbc1d2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097866 CVCL_QI44 BayGenomics ES cell line YHB166 embryonic stem cell house mouse CVCL_QI44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338944; Acvr1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097867 CVCL_QI45 BayGenomics ES cell line YHB169 embryonic stem cell house mouse CVCL_QI45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097868 CVCL_QI46 BayGenomics ES cell line YHB170 embryonic stem cell house mouse CVCL_QI46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097869 CVCL_QI47 BayGenomics ES cell line YHB171 embryonic stem cell house mouse CVCL_QI47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107186; Cct2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097870 CVCL_QI48 BayGenomics ES cell line YHB175 embryonic stem cell house mouse CVCL_QI48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097871 CVCL_QI27 BayGenomics ES cell line YHB117 embryonic stem cell house mouse CVCL_QI27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920538; Vps50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097872 CVCL_QI28 BayGenomics ES cell line YHB119 embryonic stem cell house mouse CVCL_QI28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097873 CVCL_QI29 BayGenomics ES cell line YHB121 embryonic stem cell house mouse CVCL_QI29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109337; Brca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097874 CVCL_I086 HGDP00086 transformed cell line human CVCL_I086 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097875 CVCL_I087 HGDP01045 transformed cell line human CVCL_I087 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097876 CVCL_I088 HGDP00088 transformed cell line human CVCL_I088 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097877 CVCL_I089 HGDP01046 transformed cell line human CVCL_I089 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097878 CVCL_QI30 BayGenomics ES cell line YHB122 embryonic stem cell house mouse CVCL_QI30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387123; Lnpep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097879 CVCL_I082 HGDP00082 transformed cell line human CVCL_I082 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097880 CVCL_QI31 BayGenomics ES cell line YHB123 embryonic stem cell house mouse CVCL_QI31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097881 CVCL_I083 HGDP01043 transformed cell line human CVCL_I083 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097882 CVCL_QI32 BayGenomics ES cell line YHB127 embryonic stem cell house mouse CVCL_QI32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183752; Tubgcp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097883 CVCL_I084 HGDP00084 transformed cell line human CVCL_I084 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097884 CVCL_QI33 BayGenomics ES cell line YHB130 embryonic stem cell house mouse CVCL_QI33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144837; Ptpn23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097885 CVCL_I085 HGDP01044 transformed cell line human CVCL_I085 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097886 CVCL_QI34 BayGenomics ES cell line YHB132 embryonic stem cell house mouse CVCL_QI34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097887 CVCL_QI35 BayGenomics ES cell line YHB135 embryonic stem cell house mouse CVCL_QI35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097888 CVCL_QI36 BayGenomics ES cell line YHB138 embryonic stem cell house mouse CVCL_QI36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097889 CVCL_I080 HGDP00080 transformed cell line human CVCL_I080 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097890 CVCL_QI37 BayGenomics ES cell line YHB146 embryonic stem cell house mouse CVCL_QI37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097891 CVCL_I081 HGDP01042 transformed cell line human CVCL_I081 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097892 CVCL_QI16 BayGenomics ES cell line YHB101 embryonic stem cell house mouse CVCL_QI16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097893 CVCL_QI17 BayGenomics ES cell line YHB102 embryonic stem cell house mouse CVCL_QI17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097894 CVCL_QI18 BayGenomics ES cell line YHB103 embryonic stem cell house mouse CVCL_QI18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183446; Agap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097895 CVCL_QI19 BayGenomics ES cell line YHB104 embryonic stem cell house mouse CVCL_QI19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097896 CVCL_I097 HGDP01050 transformed cell line human CVCL_I097 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097897 CVCL_I098 HGDP00098 transformed cell line human CVCL_I098 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097898 CVCL_I099 HGDP00099 transformed cell line human CVCL_I099 CL:0000010 Population: Hazara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097899 CVCL_I093 HGDP01048 transformed cell line human CVCL_I093 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097900 CVCL_QI20 BayGenomics ES cell line YHB105 embryonic stem cell house mouse CVCL_QI20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097901 CVCL_I094 HGDP00094 transformed cell line human CVCL_I094 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097902 CVCL_QI21 BayGenomics ES cell line YHB106 embryonic stem cell house mouse CVCL_QI21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387629; Tardbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097903 CVCL_I095 HGDP01049 transformed cell line human CVCL_I095 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097904 CVCL_QI22 BayGenomics ES cell line YHB109 embryonic stem cell house mouse CVCL_QI22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915122; Nsmce4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097905 CVCL_I096 HGDP00096 transformed cell line human CVCL_I096 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097906 CVCL_QI23 BayGenomics ES cell line YHB110 embryonic stem cell house mouse CVCL_QI23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346865; Mapk14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097907 CVCL_QI24 BayGenomics ES cell line YHB112 embryonic stem cell house mouse CVCL_QI24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097908 CVCL_I090 HGDP00090 transformed cell line human CVCL_I090 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097909 CVCL_QI25 BayGenomics ES cell line YHB114 embryonic stem cell house mouse CVCL_QI25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097910 CVCL_I091 HGDP01047 transformed cell line human CVCL_I091 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097911 CVCL_QI26 BayGenomics ES cell line YHB116 embryonic stem cell house mouse CVCL_QI26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924223; Fbxo21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097912 CVCL_I092 HGDP00092 transformed cell line human CVCL_I092 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097913 CVCL_QI05 BayGenomics ES cell line YHB082 embryonic stem cell house mouse CVCL_QI05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675669; Nusap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097914 CVCL_QI06 BayGenomics ES cell line YHB083 embryonic stem cell house mouse CVCL_QI06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097915 CVCL_QI07 BayGenomics ES cell line YHB084 embryonic stem cell house mouse CVCL_QI07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097916 CVCL_QI08 BayGenomics ES cell line YHB085 embryonic stem cell house mouse CVCL_QI08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352502; Limd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097917 CVCL_QI09 BayGenomics ES cell line YHB091 embryonic stem cell house mouse CVCL_QI09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097918 CVCL_I068 HGDP00068 transformed cell line human CVCL_I068 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097919 CVCL_I069 HGDP01036 transformed cell line human CVCL_I069 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097920 CVCL_I064 HGDP00064 transformed cell line human CVCL_I064 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097921 CVCL_I065 HGDP01034 transformed cell line human CVCL_I065 CL:0000010 Population: African; Bantu S.E Tswana.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097922 CVCL_I066 HGDP00066 transformed cell line human CVCL_I066 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097923 CVCL_I067 HGDP01035 transformed cell line human CVCL_I067 CL:0000010 Population: African; Bantu S.W Herero.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097924 CVCL_I060 HGDP00060 transformed cell line human CVCL_I060 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097925 CVCL_I061 HGDP01032 transformed cell line human CVCL_I061 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097926 CVCL_QI10 BayGenomics ES cell line YHB094 embryonic stem cell house mouse CVCL_QI10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097927 CVCL_I062 HGDP00062 transformed cell line human CVCL_I062 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097928 CVCL_QI11 BayGenomics ES cell line YHB095 embryonic stem cell house mouse CVCL_QI11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891037; Mtrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097929 CVCL_I063 HGDP01033 transformed cell line human CVCL_I063 CL:0000010 Population: African; Bantu S.E Zulu.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097930 CVCL_QI12 BayGenomics ES cell line YHB097 embryonic stem cell house mouse CVCL_QI12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097931 CVCL_QI13 BayGenomics ES cell line YHB098 embryonic stem cell house mouse CVCL_QI13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178836; Tubgcp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097932 CVCL_QI14 BayGenomics ES cell line YHB099 embryonic stem cell house mouse CVCL_QI14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097933 CVCL_QI15 BayGenomics ES cell line YHB100 embryonic stem cell house mouse CVCL_QI15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919228; Ppp2r2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097934 CVCL_I079 HGDP01041 transformed cell line human CVCL_I079 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097935 CVCL_I075 HGDP01039 transformed cell line human CVCL_I075 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097936 CVCL_I076 HGDP00076 transformed cell line human CVCL_I076 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097937 CVCL_I077 HGDP01040 transformed cell line human CVCL_I077 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097938 CVCL_I078 HGDP00078 transformed cell line human CVCL_I078 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097939 CVCL_I071 HGDP01037 transformed cell line human CVCL_I071 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097940 CVCL_I072 HGDP00072 transformed cell line human CVCL_I072 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097941 CVCL_I073 HGDP01038 transformed cell line human CVCL_I073 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097942 CVCL_QI00 BayGenomics ES cell line YHB073 embryonic stem cell house mouse CVCL_QI00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445193; Utp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097943 CVCL_I074 HGDP00074 transformed cell line human CVCL_I074 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097944 CVCL_QI01 BayGenomics ES cell line YHB075 embryonic stem cell house mouse CVCL_QI01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097945 CVCL_QI02 BayGenomics ES cell line YHB076 embryonic stem cell house mouse CVCL_QI02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097946 CVCL_QI03 BayGenomics ES cell line YHB080 embryonic stem cell house mouse CVCL_QI03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99211; Zfx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097947 CVCL_QI04 BayGenomics ES cell line YHB081 embryonic stem cell house mouse CVCL_QI04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107891; Nop2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097948 CVCL_I070 HGDP00070 transformed cell line human CVCL_I070 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097949 CVCL_I046 HGDP01024 transformed cell line human CVCL_I046 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097950 CVCL_I047 HGDP00047 transformed cell line human CVCL_I047 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097951 CVCL_I048 HGDP01025 transformed cell line human CVCL_I048 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097952 CVCL_I049 HGDP00049 transformed cell line human CVCL_I049 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097953 CVCL_I042 HGDP01022 transformed cell line human CVCL_I042 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097954 CVCL_I043 HGDP00043 transformed cell line human CVCL_I043 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097955 CVCL_I044 HGDP01023 transformed cell line human CVCL_I044 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097956 CVCL_I045 HGDP00045 transformed cell line human CVCL_I045 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097957 CVCL_I040 HGDP01021 transformed cell line human CVCL_I040 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097958 CVCL_I041 HGDP00041 transformed cell line human CVCL_I041 CL:0000010 Population: Brahui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097959 CVCL_I057 HGDP00057 transformed cell line human CVCL_I057 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097960 CVCL_I058 HGDP00058 transformed cell line human CVCL_I058 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097961 CVCL_I059 HGDP01031 transformed cell line human CVCL_I059 CL:0000010 Population: African; Bantu S.W Ovambo.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097962 CVCL_I053 HGDP01029 transformed cell line human CVCL_I053 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced (low read coverage) Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097963 CVCL_I054 HGDP00054 transformed cell line human CVCL_I054 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097964 CVCL_I055 HGDP01030 transformed cell line human CVCL_I055 CL:0000010 Population: African; Bantu S.E Tswana.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097965 CVCL_I056 HGDP00056 transformed cell line human CVCL_I056 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097966 CVCL_I050 HGDP01027 transformed cell line human CVCL_I050 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097967 CVCL_I051 HGDP01028 transformed cell line human CVCL_I051 CL:0000010 Population: African; Bantu S.W Herero.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097968 CVCL_I052 HGDP00052 transformed cell line human CVCL_I052 CL:0000010 Population: Balochi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21097969 CVCL_QI90 BayGenomics ES cell line YHB289 embryonic stem cell house mouse CVCL_QI90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097970 CVCL_QI91 BayGenomics ES cell line YHB290 embryonic stem cell house mouse CVCL_QI91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443658; Prr14l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097971 CVCL_QI92 BayGenomics ES cell line YHB291 embryonic stem cell house mouse CVCL_QI92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931751; Pum2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097972 CVCL_QI93 BayGenomics ES cell line YHB295 embryonic stem cell house mouse CVCL_QI93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097973 CVCL_QI94 BayGenomics ES cell line YHB300 embryonic stem cell house mouse CVCL_QI94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097974 CVCL_QI95 BayGenomics ES cell line YHB304 embryonic stem cell house mouse CVCL_QI95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924223; Fbxo21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097975 CVCL_QI96 BayGenomics ES cell line YHB305 embryonic stem cell house mouse CVCL_QI96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103075; Wee1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097976 CVCL_QI97 BayGenomics ES cell line YHB306 embryonic stem cell house mouse CVCL_QI97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097977 CVCL_QI98 BayGenomics ES cell line YHB307 embryonic stem cell house mouse CVCL_QI98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097978 CVCL_QI99 BayGenomics ES cell line YHB308 embryonic stem cell house mouse CVCL_QI99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097979 CVCL_QI80 BayGenomics ES cell line YHB253 embryonic stem cell house mouse CVCL_QI80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097980 CVCL_QI81 BayGenomics ES cell line YHB257 embryonic stem cell house mouse CVCL_QI81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446979; Kif18b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097981 CVCL_QI82 BayGenomics ES cell line YHB259 embryonic stem cell house mouse CVCL_QI82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137357; Trim33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097982 CVCL_QI83 BayGenomics ES cell line YHB262 embryonic stem cell house mouse CVCL_QI83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147627; Yars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097983 CVCL_QI84 BayGenomics ES cell line YHB267 embryonic stem cell house mouse CVCL_QI84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097984 CVCL_QI85 BayGenomics ES cell line YHB273 embryonic stem cell house mouse CVCL_QI85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924281; Slc9a8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097985 CVCL_QI86 BayGenomics ES cell line YHB279 embryonic stem cell house mouse CVCL_QI86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921358; Parn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097986 CVCL_QI87 BayGenomics ES cell line YHB280 embryonic stem cell house mouse CVCL_QI87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027896; Ppp4r2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097987 CVCL_QI88 BayGenomics ES cell line YHB286 embryonic stem cell house mouse CVCL_QI88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444959; Kmt2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097988 CVCL_QI89 BayGenomics ES cell line YHB287 embryonic stem cell house mouse CVCL_QI89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097989 CVCL_QI70 BayGenomics ES cell line YHB232 embryonic stem cell house mouse CVCL_QI70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443265; Tnrc6c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097990 CVCL_QI71 BayGenomics ES cell line YHB233 embryonic stem cell house mouse CVCL_QI71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097991 CVCL_QI72 BayGenomics ES cell line YHB234 embryonic stem cell house mouse CVCL_QI72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097992 CVCL_QI73 BayGenomics ES cell line YHB235 embryonic stem cell house mouse CVCL_QI73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097993 CVCL_QI74 BayGenomics ES cell line YHB238 embryonic stem cell house mouse CVCL_QI74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097994 CVCL_QI75 BayGenomics ES cell line YHB239 embryonic stem cell house mouse CVCL_QI75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106581; Tsg101 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097995 CVCL_QI76 BayGenomics ES cell line YHB244 embryonic stem cell house mouse CVCL_QI76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921450; Khdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097996 CVCL_QI77 BayGenomics ES cell line YHB247 embryonic stem cell house mouse CVCL_QI77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097997 CVCL_QI78 BayGenomics ES cell line YHB248 embryonic stem cell house mouse CVCL_QI78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097998 CVCL_QI79 BayGenomics ES cell line YHB251 embryonic stem cell house mouse CVCL_QI79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21097999 CVCL_QI60 BayGenomics ES cell line YHB208 embryonic stem cell house mouse CVCL_QI60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918625; Foxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098000 CVCL_QI61 BayGenomics ES cell line YHB209 embryonic stem cell house mouse CVCL_QI61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100836; Kpna6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098001 CVCL_QI62 BayGenomics ES cell line YHB218 embryonic stem cell house mouse CVCL_QI62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924270; Atl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098002 CVCL_QI63 BayGenomics ES cell line YHB219 embryonic stem cell house mouse CVCL_QI63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136959; Bcl2l13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098003 CVCL_QI64 BayGenomics ES cell line YHB220 embryonic stem cell house mouse CVCL_QI64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098004 CVCL_QI65 BayGenomics ES cell line YHB224 embryonic stem cell house mouse CVCL_QI65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921570; Wdr33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098005 CVCL_QI66 BayGenomics ES cell line YHB226 embryonic stem cell house mouse CVCL_QI66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349410; Triobp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098006 CVCL_QI67 BayGenomics ES cell line YHB227 embryonic stem cell house mouse CVCL_QI67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109602; Gphn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098007 CVCL_QI68 BayGenomics ES cell line YHB228 embryonic stem cell house mouse CVCL_QI68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95659; Gas5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098008 CVCL_QI69 BayGenomics ES cell line YHB229 embryonic stem cell house mouse CVCL_QI69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098009 CVCL_QK03 BayGenomics ES cell line YHC106 embryonic stem cell house mouse CVCL_QK03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858259; Tomm40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098010 CVCL_QK04 BayGenomics ES cell line YHC111 embryonic stem cell house mouse CVCL_QK04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914189; Aagab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098011 CVCL_QK05 BayGenomics ES cell line YHC112 embryonic stem cell house mouse CVCL_QK05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098012 CVCL_QK06 BayGenomics ES cell line YHC116 embryonic stem cell house mouse CVCL_QK06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446296; Sik3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098013 CVCL_QK07 BayGenomics ES cell line YHC117 embryonic stem cell house mouse CVCL_QK07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098014 CVCL_QK08 BayGenomics ES cell line YHC118 embryonic stem cell house mouse CVCL_QK08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098015 CVCL_QK09 BayGenomics ES cell line YHC119 embryonic stem cell house mouse CVCL_QK09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919420; Chchd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098016 CVCL_HQ66 GM05051 transformed cell line human CVCL_HQ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098017 CVCL_I266 HGDP01169 transformed cell line human CVCL_I266 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098018 CVCL_I267 HGDP00267 transformed cell line human CVCL_I267 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098019 CVCL_HQ67 ND03085 transformed cell line human CVCL_HQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098020 CVCL_I268 HGDP01171 transformed cell line human CVCL_I268 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098021 CVCL_HQ68 ND03178 transformed cell line human CVCL_HQ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098022 CVCL_I269 HGDP01172 transformed cell line human CVCL_I269 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098023 CVCL_HQ69 ND03195 transformed cell line human CVCL_HQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098024 CVCL_HQ62 GM03219 finite cell line human CVCL_HQ62 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21098025 CVCL_I262 HGDP00262 transformed cell line human CVCL_I262 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098026 CVCL_HQ63 GM03220 finite cell line human CVCL_HQ63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21098027 CVCL_I263 HGDP01167 transformed cell line human CVCL_I263 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098028 CVCL_HQ64 GM03222 finite cell line human CVCL_HQ64 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21098029 CVCL_I264 HGDP00264 transformed cell line human CVCL_I264 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098030 CVCL_HQ65 GM05050 transformed cell line human CVCL_HQ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098031 CVCL_I265 HGDP01168 transformed cell line human CVCL_I265 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098032 CVCL_HQ60 GM03216 finite cell line human CVCL_HQ60 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21098033 CVCL_I260 HGDP01164 transformed cell line human CVCL_I260 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098034 CVCL_HQ61 GM03217 finite cell line human CVCL_HQ61 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21098035 CVCL_I261 HGDP01166 transformed cell line human CVCL_I261 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098036 CVCL_QK10 BayGenomics ES cell line YHC120 embryonic stem cell house mouse CVCL_QK10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098037 CVCL_QK11 BayGenomics ES cell line YHC127 embryonic stem cell house mouse CVCL_QK11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921294; Ttf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098038 CVCL_QK12 BayGenomics ES cell line YHC128 embryonic stem cell house mouse CVCL_QK12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101921; Ap2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098039 CVCL_QK13 BayGenomics ES cell line YHC129 embryonic stem cell house mouse CVCL_QK13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858195; Hnrnpu Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098040 CVCL_I277 HGDP00277 transformed cell line human CVCL_I277 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098041 CVCL_HQ77 ND04745 transformed cell line human CVCL_HQ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098042 CVCL_I278 HGDP01182 transformed cell line human CVCL_I278 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098043 CVCL_HQ78 ND04748 transformed cell line human CVCL_HQ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098044 CVCL_I279 HGDP00279 transformed cell line human CVCL_I279 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098045 CVCL_HQ79 ND04793 transformed cell line human CVCL_HQ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098046 CVCL_I273 HGDP01179 transformed cell line human CVCL_I273 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098047 CVCL_HQ73 ND04025 transformed cell line human CVCL_HQ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098048 CVCL_I274 HGDP00274 transformed cell line human CVCL_I274 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098049 CVCL_HQ74 ND04094 transformed cell line human CVCL_HQ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098050 CVCL_I275 HGDP01180 transformed cell line human CVCL_I275 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098051 CVCL_HQ75 ND04436 transformed cell line human CVCL_HQ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098052 CVCL_I276 HGDP01181 transformed cell line human CVCL_I276 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098053 CVCL_HQ76 ND04580 transformed cell line human CVCL_HQ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098054 CVCL_I270 HGDP01173 transformed cell line human CVCL_I270 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098055 CVCL_HQ70 ND03453 transformed cell line human CVCL_HQ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098056 CVCL_I271 HGDP01174 transformed cell line human CVCL_I271 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098057 CVCL_HQ71 ND03762 transformed cell line human CVCL_HQ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098058 CVCL_I272 HGDP01177 transformed cell line human CVCL_I272 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098059 CVCL_HQ72 ND03846 transformed cell line human CVCL_HQ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098060 CVCL_QK00 BayGenomics ES cell line YHC094 embryonic stem cell house mouse CVCL_QK00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96995; Kmt2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098061 CVCL_QK01 BayGenomics ES cell line YHC102 embryonic stem cell house mouse CVCL_QK01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098062 CVCL_QK02 BayGenomics ES cell line YHC103 embryonic stem cell house mouse CVCL_QK02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3782666; Gm4482 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098063 CVCL_HQ48 GM25494 transformed cell line human CVCL_HQ48 CL:0000010 Sequence variation: Mutation; HGNC; 30372; KLHL40; Simple; p.Arg547His (c.1640G>A); ClinVar=VCV000566161; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098064 CVCL_I248 HGDP00248 transformed cell line human CVCL_I248 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098065 CVCL_HQ49 GM25515 finite cell line human CVCL_HQ49 CL:0000010 Sequence variation: Mutation; HGNC; 29427; SH3TC2; Simple; p.Arg954Ter (c.2860C>T); ClinVar=VCV000002482; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 10994; SLC26A2; Simple; p.Arg279Trp (c.835C>T); ClinVar=VCV000004089; Zygosity=Unspecified (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21098066 CVCL_I249 HGDP01154 transformed cell line human CVCL_I249 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098067 CVCL_HQ44 GM25482 transformed cell line human CVCL_HQ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098068 CVCL_I244 HGDP00244 transformed cell line human CVCL_I244 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098069 CVCL_HQ45 GM25483 transformed cell line human CVCL_HQ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098070 CVCL_I245 HGDP01152 transformed cell line human CVCL_I245 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098071 CVCL_HQ46 GM25484 transformed cell line human CVCL_HQ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098072 CVCL_I246 HGDP01153 transformed cell line human CVCL_I246 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098073 CVCL_HQ47 GM25485 transformed cell line human CVCL_HQ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098074 CVCL_I247 HGDP00247 transformed cell line human CVCL_I247 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098075 CVCL_HQ40 GM25451 transformed cell line human CVCL_HQ40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098076 CVCL_I240 HGDP01149 transformed cell line human CVCL_I240 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098077 CVCL_HQ41 GM25452 transformed cell line human CVCL_HQ41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098078 CVCL_I241 HGDP00241 transformed cell line human CVCL_I241 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098079 CVCL_HQ42 GM25453 transformed cell line human CVCL_HQ42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098080 CVCL_I242 HGDP01151 transformed cell line human CVCL_I242 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098081 CVCL_HQ43 GM25454 transformed cell line human CVCL_HQ43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098082 CVCL_I243 HGDP00243 transformed cell line human CVCL_I243 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098083 CVCL_HQ59 GM03215 finite cell line human CVCL_HQ59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21098084 CVCL_I259 HGDP00259 transformed cell line human CVCL_I259 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098085 CVCL_HQ55 GM03209 finite cell line human CVCL_HQ55 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21098086 CVCL_I255 HGDP01161 transformed cell line human CVCL_I255 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098087 CVCL_HQ56 GM03210 finite cell line human CVCL_HQ56 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21098088 CVCL_I256 HGDP01162 transformed cell line human CVCL_I256 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098089 CVCL_HQ57 GM03213 finite cell line human CVCL_HQ57 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21098090 CVCL_I257 HGDP01163 transformed cell line human CVCL_I257 CL:0000010 Population: Caucasian; Tuscan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098091 CVCL_HQ58 GM03214 finite cell line human CVCL_HQ58 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21098092 CVCL_I258 HGDP00258 transformed cell line human CVCL_I258 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098093 CVCL_HQ51 GM25987 transformed cell line human CVCL_HQ51 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg580Trp (c.1738C>T) (p.Arg576Trp, c.1726C>T); ClinVar=VCV000007370; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098094 CVCL_I251 HGDP00251 transformed cell line human CVCL_I251 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098095 CVCL_HQ52 GM26037 transformed cell line human CVCL_HQ52 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg174Ter (c.520C>T); ClinVar=VCV000235853; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098096 CVCL_I252 HGDP01156 transformed cell line human CVCL_I252 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098097 CVCL_HQ53 GM26038 finite cell line human CVCL_HQ53 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg174Ter (c.520C>T); ClinVar=VCV000235853; Zygosity=Heterozygous (Coriell) Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21098098 CVCL_I253 HGDP01157 transformed cell line human CVCL_I253 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098099 CVCL_HQ54 GM23831 transformed cell line human CVCL_HQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098100 CVCL_I254 HGDP00254 transformed cell line human CVCL_I254 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098101 CVCL_HQ50 GM25544 transformed cell line human CVCL_HQ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098102 CVCL_I250 HGDP01155 transformed cell line human CVCL_I250 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098103 CVCL_HQ26 GM25413 transformed cell line human CVCL_HQ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098104 CVCL_I226 HGDP00226 transformed cell line human CVCL_I226 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098105 CVCL_HQ27 GM25415 transformed cell line human CVCL_HQ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098106 CVCL_I227 HGDP01099 transformed cell line human CVCL_I227 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098107 CVCL_HQ28 GM25416 transformed cell line human CVCL_HQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098108 CVCL_I228 HGDP00228 transformed cell line human CVCL_I228 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098109 CVCL_HQ29 GM25417 transformed cell line human CVCL_HQ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098110 CVCL_I229 HGDP01100 transformed cell line human CVCL_I229 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098111 CVCL_HQ22 GM25406 transformed cell line human CVCL_HQ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098112 CVCL_I222 HGDP00222 transformed cell line human CVCL_I222 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098113 CVCL_HQ23 GM25407 transformed cell line human CVCL_HQ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098114 CVCL_I223 HGDP01097 transformed cell line human CVCL_I223 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098115 CVCL_HQ24 GM25410 transformed cell line human CVCL_HQ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098116 CVCL_I224 HGDP00224 transformed cell line human CVCL_I224 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098117 CVCL_HQ25 GM25411 transformed cell line human CVCL_HQ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098118 CVCL_I225 HGDP01098 transformed cell line human CVCL_I225 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098119 CVCL_HQ20 GM25403 transformed cell line human CVCL_HQ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098120 CVCL_I220 HGDP00220 transformed cell line human CVCL_I220 CL:0000010 Population: Hazara (but could be Pathan); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098121 CVCL_HQ21 GM25405 transformed cell line human CVCL_HQ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098122 CVCL_I221 HGDP01096 transformed cell line human CVCL_I221 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098123 CVCL_HQ37 GM25448 transformed cell line human CVCL_HQ37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098124 CVCL_I237 HGDP00237 transformed cell line human CVCL_I237 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098125 CVCL_HQ38 GM25449 transformed cell line human CVCL_HQ38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098126 CVCL_I238 HGDP01147 transformed cell line human CVCL_I238 CL:0000010 Population: Caucasian; North Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098127 CVCL_HQ39 GM25450 transformed cell line human CVCL_HQ39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098128 CVCL_I239 HGDP00239 transformed cell line human CVCL_I239 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098129 CVCL_HQ33 GM25434 transformed cell line human CVCL_HQ33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098130 CVCL_I233 HGDP01102 transformed cell line human CVCL_I233 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098131 CVCL_HQ34 GM25435 transformed cell line human CVCL_HQ34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098132 CVCL_I234 HGDP00234 transformed cell line human CVCL_I234 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098133 CVCL_HQ35 GM25436 transformed cell line human CVCL_HQ35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098134 CVCL_I235 HGDP01103 transformed cell line human CVCL_I235 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098135 CVCL_HQ36 GM25437 transformed cell line human CVCL_HQ36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098136 CVCL_I236 HGDP01104 transformed cell line human CVCL_I236 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098137 CVCL_HQ30 GM25418 transformed cell line human CVCL_HQ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098138 CVCL_I230 HGDP00230 transformed cell line human CVCL_I230 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098139 CVCL_HQ31 GM25419 transformed cell line human CVCL_HQ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098140 CVCL_I231 HGDP01101 transformed cell line human CVCL_I231 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098141 CVCL_HQ32 GM25433 transformed cell line human CVCL_HQ32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098142 CVCL_I232 HGDP00232 transformed cell line human CVCL_I232 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098143 CVCL_HQ08 GM17724 transformed cell line human CVCL_HQ08 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 6 repeats) (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098144 CVCL_I208 HGDP00208 transformed cell line human CVCL_I208 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098145 CVCL_HQ09 GM17898 transformed cell line human CVCL_HQ09 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 4 repeats) (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098146 CVCL_I209 HGDP01090 transformed cell line human CVCL_I209 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098147 CVCL_HQ04 GM10642 finite cell line human CVCL_HQ04 CL:0000010 Sequence variation: Mutation; HGNC; 403; ALDH3A2; Simple; p.Glu433Argfs*3 (c.1293_1294GA[2]) (c.1297_1298delGA); ClinVar=VCV000001641; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21098148 CVCL_I204 HGDP01088 transformed cell line human CVCL_I204 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098149 CVCL_HQ05 GM14427 transformed cell line human CVCL_HQ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098150 CVCL_I205 HGDP00205 transformed cell line human CVCL_I205 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098151 CVCL_HQ06 GM16348 transformed cell line human CVCL_HQ06 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 4 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098152 CVCL_I206 HGDP00206 transformed cell line human CVCL_I206 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098153 CVCL_HQ07 GM16351 transformed cell line human CVCL_HQ07 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 4 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098154 CVCL_I207 HGDP01089 transformed cell line human CVCL_I207 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098155 CVCL_I200 HGDP01086 transformed cell line human CVCL_I200 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098156 CVCL_HQ00 ND04693 transformed cell line human CVCL_HQ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098157 CVCL_HQ01 GM01351 finite cell line human CVCL_HQ01 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21098158 CVCL_I201 HGDP00201 transformed cell line human CVCL_I201 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098159 CVCL_HQ02 GM01352 finite cell line human CVCL_HQ02 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female 21098160 CVCL_I202 HGDP01087 transformed cell line human CVCL_I202 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098161 CVCL_HQ03 GM10640 finite cell line human CVCL_HQ03 CL:0000010 Sequence variation: Mutation; HGNC; 403; ALDH3A2; Simple; p.Glu433Argfs*3 (c.1293_1294GA[2]) (c.1297_1298delGA); ClinVar=VCV000001641; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 403; ALDH3A2; Simple; p.Leu438Thrfs (c.1307_1311dupACAAA); ClinVar=VCV000001642; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21098162 CVCL_I203 HGDP00203 transformed cell line human CVCL_I203 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098163 CVCL_HQ19 GM25402 transformed cell line human CVCL_HQ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098164 CVCL_I219 HGDP01095 transformed cell line human CVCL_I219 CL:0000010 Population: Chinese/Asian ethnic group; Tujia; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098165 CVCL_HQ15 GM21995 finite cell line human CVCL_HQ15 CL:0000010 Sequence variation: Mutation; HGNC; 3604; FBN2; Simple; p.Asp1115His (c.3343G>C) (D1114H, 3340G>C); ClinVar=VCV000000525; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21098166 CVCL_I215 HGDP01093 transformed cell line human CVCL_I215 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098167 CVCL_HQ16 GM25291 transformed cell line human CVCL_HQ16 CL:0000010 Sequence variation: Mutation; HGNC; 11049; SLC6A3; Simple; p.Tyr470Ser (c.1408_1409delinsAG); ClinVar=VCV001404765; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098168 CVCL_I216 HGDP00216 transformed cell line human CVCL_I216 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098169 CVCL_HQ17 GM25335 transformed cell line human CVCL_HQ17 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Gly253Asp (c.758G>A); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098170 CVCL_I217 HGDP01094 transformed cell line human CVCL_I217 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098171 CVCL_HQ18 GM25336 finite cell line human CVCL_HQ18 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Gly253Asp (c.758G>A); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21098172 CVCL_I218 HGDP00218 transformed cell line human CVCL_I218 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098173 CVCL_HQ11 GM20171 transformed cell line human CVCL_HQ11 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098174 CVCL_I211 HGDP01091 transformed cell line human CVCL_I211 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098175 CVCL_HQ12 GM20175 transformed cell line human CVCL_HQ12 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098176 CVCL_I212 HGDP01092 transformed cell line human CVCL_I212 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098177 CVCL_HQ13 GM20198 transformed cell line human CVCL_HQ13 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098178 CVCL_I213 HGDP00213 transformed cell line human CVCL_I213 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098179 CVCL_HQ14 GM21902 transformed cell line human CVCL_HQ14 CL:0000010 Sequence variation: Mutation; HGNC; 4263; GHR; Simple; p.Val230fs*4 (c.689_690delTA) (fs234Ter); Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098180 CVCL_I214 HGDP00214 transformed cell line human CVCL_I214 CL:0000010 Population: Pashtun; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098181 CVCL_HQ10 GM18207 transformed cell line human CVCL_HQ10 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 3 repeats) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098182 CVCL_I210 HGDP00210 transformed cell line human CVCL_I210 CL:0000010 Sequence variation: Gene deletion; HGNC; 3620; FCGR3B; Zygosity=Homozygous (PubMed=27995740) Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098183 CVCL_QJ70 BayGenomics ES cell line YHC040 embryonic stem cell house mouse CVCL_QJ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914182; Rexo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098184 CVCL_QJ71 BayGenomics ES cell line YHC042 embryonic stem cell house mouse CVCL_QJ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925255; Rrn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098185 CVCL_QJ72 BayGenomics ES cell line YHC043 embryonic stem cell house mouse CVCL_QJ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202880; Traf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098186 CVCL_QJ73 BayGenomics ES cell line YHC044 embryonic stem cell house mouse CVCL_QJ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88141; Bcr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098187 CVCL_QJ74 BayGenomics ES cell line YHC046 embryonic stem cell house mouse CVCL_QJ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098188 CVCL_QJ75 BayGenomics ES cell line YHC048 embryonic stem cell house mouse CVCL_QJ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098189 CVCL_QJ76 BayGenomics ES cell line YHC049 embryonic stem cell house mouse CVCL_QJ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891704; Hbs1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098190 CVCL_QJ77 BayGenomics ES cell line YHC051 embryonic stem cell house mouse CVCL_QJ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925255; Rrn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098191 CVCL_QJ78 BayGenomics ES cell line YHC053 embryonic stem cell house mouse CVCL_QJ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098192 CVCL_QJ79 BayGenomics ES cell line YHC056 embryonic stem cell house mouse CVCL_QJ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915080; Rer1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098193 CVCL_QJ59 BayGenomics ES cell line YHC017 embryonic stem cell house mouse CVCL_QJ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098194 CVCL_QJ60 BayGenomics ES cell line YHC018 embryonic stem cell house mouse CVCL_QJ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385001; Fermt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098195 CVCL_QJ61 BayGenomics ES cell line YHC020 embryonic stem cell house mouse CVCL_QJ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100851; Elavl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098196 CVCL_QJ62 BayGenomics ES cell line YHC022 embryonic stem cell house mouse CVCL_QJ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914324; Mon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098197 CVCL_QJ63 BayGenomics ES cell line YHC023 embryonic stem cell house mouse CVCL_QJ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098198 CVCL_QJ64 BayGenomics ES cell line YHC024 embryonic stem cell house mouse CVCL_QJ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098199 CVCL_QJ65 BayGenomics ES cell line YHC028 embryonic stem cell house mouse CVCL_QJ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098200 CVCL_QJ66 BayGenomics ES cell line YHC029 embryonic stem cell house mouse CVCL_QJ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098201 CVCL_QJ67 BayGenomics ES cell line YHC032 embryonic stem cell house mouse CVCL_QJ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99695; Cttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098202 CVCL_QJ68 BayGenomics ES cell line YHC036 embryonic stem cell house mouse CVCL_QJ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098203 CVCL_QJ69 BayGenomics ES cell line YHC037 embryonic stem cell house mouse CVCL_QJ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917887; Ankrd26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098204 CVCL_QJ48 BayGenomics ES cell line YHB436 embryonic stem cell house mouse CVCL_QJ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098205 CVCL_QJ49 BayGenomics ES cell line YHB437 embryonic stem cell house mouse CVCL_QJ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098206 CVCL_QJ50 BayGenomics ES cell line YHB438 embryonic stem cell house mouse CVCL_QJ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098207 CVCL_QJ51 BayGenomics ES cell line YHB439 embryonic stem cell house mouse CVCL_QJ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098208 CVCL_QJ52 BayGenomics ES cell line YHB440 embryonic stem cell house mouse CVCL_QJ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098209 CVCL_QJ53 BayGenomics ES cell line YHC001 embryonic stem cell house mouse CVCL_QJ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914149; Fip1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098210 CVCL_QJ54 BayGenomics ES cell line YHC007 embryonic stem cell house mouse CVCL_QJ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353499; Baz1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098211 CVCL_QJ55 BayGenomics ES cell line YHC008 embryonic stem cell house mouse CVCL_QJ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098212 CVCL_QJ56 BayGenomics ES cell line YHC013 embryonic stem cell house mouse CVCL_QJ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098213 CVCL_QJ57 BayGenomics ES cell line YHC014 embryonic stem cell house mouse CVCL_QJ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098214 CVCL_QJ58 BayGenomics ES cell line YHC015 embryonic stem cell house mouse CVCL_QJ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923119; Arl5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098215 CVCL_QJ37 BayGenomics ES cell line YHB403 embryonic stem cell house mouse CVCL_QJ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107606; Srebf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098216 CVCL_QJ38 BayGenomics ES cell line YHB404 embryonic stem cell house mouse CVCL_QJ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098217 CVCL_QJ39 BayGenomics ES cell line YHB407 embryonic stem cell house mouse CVCL_QJ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100836; Kpna6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098218 CVCL_QJ40 BayGenomics ES cell line YHB409 embryonic stem cell house mouse CVCL_QJ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924223; Fbxo21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098219 CVCL_QJ41 BayGenomics ES cell line YHB416 embryonic stem cell house mouse CVCL_QJ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098220 CVCL_QJ42 BayGenomics ES cell line YHB417 embryonic stem cell house mouse CVCL_QJ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924223; Fbxo21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098221 CVCL_QJ43 BayGenomics ES cell line YHB424 embryonic stem cell house mouse CVCL_QJ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098222 CVCL_QJ44 BayGenomics ES cell line YHB426 embryonic stem cell house mouse CVCL_QJ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098223 CVCL_QJ45 BayGenomics ES cell line YHB427 embryonic stem cell house mouse CVCL_QJ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098224 CVCL_QJ46 BayGenomics ES cell line YHB431 embryonic stem cell house mouse CVCL_QJ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277961; Plec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098225 CVCL_QJ47 BayGenomics ES cell line YHB433 embryonic stem cell house mouse CVCL_QJ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098226 CVCL_QJ26 BayGenomics ES cell line YHB380 embryonic stem cell house mouse CVCL_QJ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098227 CVCL_QJ27 BayGenomics ES cell line YHB381 embryonic stem cell house mouse CVCL_QJ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914789; Dock6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098228 CVCL_QJ28 BayGenomics ES cell line YHB383 embryonic stem cell house mouse CVCL_QJ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914633; Carnmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098229 CVCL_QJ29 BayGenomics ES cell line YHB384 embryonic stem cell house mouse CVCL_QJ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098230 CVCL_I189 HGDP00189 transformed cell line human CVCL_I189 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098231 CVCL_HP89 OPC1 transformed cell line human CVCL_HP89 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pMx-1-SV40T](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal bone Cell type=Osteoblast.. Unspecified Doubling time: 1.8 days (PubMed=10491220) 21098232 CVCL_HP85 GM21795 transformed cell line human CVCL_HP85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098233 CVCL_I185 HGDP00185 transformed cell line human CVCL_I185 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098234 CVCL_HP86 HeLa S3 EGFP-alpha-tubulin/H2B-mCherry cancer cell line human CVCL_HP86 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21098235 CVCL_I186 HGDP01076 transformed cell line human CVCL_I186 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098236 CVCL_HP87 HeLa S3 EGFP-H2B cancer cell line human CVCL_HP87 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21098237 CVCL_I187 HGDP00187 transformed cell line human CVCL_I187 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098238 CVCL_HP88 GM21049 transformed cell line human CVCL_HP88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098239 CVCL_I188 HGDP01077 transformed cell line human CVCL_I188 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098240 CVCL_I181 HGDP00181 transformed cell line human CVCL_I181 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098241 CVCL_HP81 ND06088 transformed cell line human CVCL_HP81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098242 CVCL_QJ30 BayGenomics ES cell line YHB386 embryonic stem cell house mouse CVCL_QJ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096368; Ap1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098243 CVCL_HP82 GM21792 transformed cell line human CVCL_HP82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098244 CVCL_I182 HGDP01074 transformed cell line human CVCL_I182 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098245 CVCL_QJ31 BayGenomics ES cell line YHB390 embryonic stem cell house mouse CVCL_QJ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921487; Tubgcp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098246 CVCL_I183 HGDP00183 transformed cell line human CVCL_I183 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098247 CVCL_HP83 ND06601 transformed cell line human CVCL_HP83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098248 CVCL_QJ32 BayGenomics ES cell line YHB391 embryonic stem cell house mouse CVCL_QJ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098249 CVCL_I184 HGDP01075 transformed cell line human CVCL_I184 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098250 CVCL_HP84 ND07675 transformed cell line human CVCL_HP84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098251 CVCL_QJ33 BayGenomics ES cell line YHB392 embryonic stem cell house mouse CVCL_QJ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098252 CVCL_QJ34 BayGenomics ES cell line YHB395 embryonic stem cell house mouse CVCL_QJ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858907; Blcap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098253 CVCL_QJ35 BayGenomics ES cell line YHB396 embryonic stem cell house mouse CVCL_QJ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914134; Appbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098254 CVCL_QJ36 BayGenomics ES cell line YHB397 embryonic stem cell house mouse CVCL_QJ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098255 CVCL_HP80 GM21790 transformed cell line human CVCL_HP80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098256 CVCL_I180 HGDP01073 transformed cell line human CVCL_I180 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098257 CVCL_QJ15 BayGenomics ES cell line YHB347 embryonic stem cell house mouse CVCL_QJ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098258 CVCL_QJ16 BayGenomics ES cell line YHB348 embryonic stem cell house mouse CVCL_QJ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098259 CVCL_QJ17 BayGenomics ES cell line YHB353 embryonic stem cell house mouse CVCL_QJ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027896; Ppp4r2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098260 CVCL_QJ18 BayGenomics ES cell line YHB356 embryonic stem cell house mouse CVCL_QJ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098261 CVCL_QJ19 BayGenomics ES cell line YHB357 embryonic stem cell house mouse CVCL_QJ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098262 CVCL_I196 HGDP01084 transformed cell line human CVCL_I196 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098263 CVCL_HP96 ND04522 transformed cell line human CVCL_HP96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098264 CVCL_I197 HGDP00197 transformed cell line human CVCL_I197 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098265 CVCL_HP97 ND04616 transformed cell line human CVCL_HP97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098266 CVCL_I198 HGDP01085 transformed cell line human CVCL_I198 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098267 CVCL_HP98 ND04634 transformed cell line human CVCL_HP98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098268 CVCL_I199 HGDP00199 transformed cell line human CVCL_I199 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098269 CVCL_HP99 ND04635 transformed cell line human CVCL_HP99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098270 CVCL_I192 HGDP00192 transformed cell line human CVCL_I192 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098271 CVCL_HP92 STOSE spontaneously immortalized cell line house mouse CVCL_HP92 CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: FVB/N. Omics: Transcriptome analysis by microarray Female Doubling time: 13 hours (PubMed=24672774) 21098272 CVCL_I193 HGDP01079 transformed cell line human CVCL_I193 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098273 CVCL_HP93 ND04354 transformed cell line human CVCL_HP93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098274 CVCL_QJ20 BayGenomics ES cell line YHB362 embryonic stem cell house mouse CVCL_QJ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917900; Zcchc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098275 CVCL_I194 HGDP01081 transformed cell line human CVCL_I194 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098276 CVCL_HP94 ND04441 transformed cell line human CVCL_HP94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098277 CVCL_QJ21 BayGenomics ES cell line YHB367 embryonic stem cell house mouse CVCL_QJ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921452; Fblim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098278 CVCL_I195 HGDP00195 transformed cell line human CVCL_I195 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098279 CVCL_HP95 ND04521 transformed cell line human CVCL_HP95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098280 CVCL_QJ22 BayGenomics ES cell line YHB369 embryonic stem cell house mouse CVCL_QJ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183747; Fgd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098281 CVCL_QJ23 BayGenomics ES cell line YHB374 embryonic stem cell house mouse CVCL_QJ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921452; Fblim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098282 CVCL_QJ24 BayGenomics ES cell line YHB376 embryonic stem cell house mouse CVCL_QJ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098283 CVCL_I190 HGDP01078 transformed cell line human CVCL_I190 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098284 CVCL_HP90 LYCK spontaneously immortalized cell line CVCL_HP90 CL:0000010 Derived from sampling site: Head kidney. Unspecified Doubling time: 29.5 hours (PubMed=24773544) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013113 21098285 CVCL_QJ25 BayGenomics ES cell line YHB379 embryonic stem cell house mouse CVCL_QJ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919445; Supt7l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098286 CVCL_I191 HGDP00191 transformed cell line human CVCL_I191 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098287 CVCL_HP91 M0505 finite cell line house mouse CVCL_HP91 CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: FVB/N. Omics: Transcriptome analysis by microarray Female Doubling time: 48 hours (PubMed=24672774) 21098288 CVCL_QJ04 BayGenomics ES cell line YHB317 embryonic stem cell house mouse CVCL_QJ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99948; Zfhx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098289 CVCL_QJ05 BayGenomics ES cell line YHB322 embryonic stem cell house mouse CVCL_QJ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183446; Agap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098290 CVCL_QJ06 BayGenomics ES cell line YHB323 embryonic stem cell house mouse CVCL_QJ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096566; Pias2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098291 CVCL_QJ07 BayGenomics ES cell line YHB324 embryonic stem cell house mouse CVCL_QJ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098292 CVCL_QJ08 BayGenomics ES cell line YHB325 embryonic stem cell house mouse CVCL_QJ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098293 CVCL_QJ09 BayGenomics ES cell line YHB326 embryonic stem cell house mouse CVCL_QJ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098294 CVCL_HP67 GM21347 transformed cell line human CVCL_HP67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098295 CVCL_I167 HGDP00167 transformed cell line human CVCL_I167 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098296 CVCL_HP68 GM21348 transformed cell line human CVCL_HP68 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098297 CVCL_I168 HGDP01067 transformed cell line human CVCL_I168 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098298 CVCL_HP69 GM21349 transformed cell line human CVCL_HP69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098299 CVCL_I169 HGDP00169 transformed cell line human CVCL_I169 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098300 CVCL_HP63 GM21324 transformed cell line human CVCL_HP63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098301 CVCL_I163 HGDP00163 transformed cell line human CVCL_I163 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098302 CVCL_HP64 GM21325 transformed cell line human CVCL_HP64 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098303 CVCL_I164 HGDP01065 transformed cell line human CVCL_I164 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098304 CVCL_HP65 GM21345 transformed cell line human CVCL_HP65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098305 CVCL_I165 HGDP00165 transformed cell line human CVCL_I165 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098306 CVCL_HP66 GM21346 transformed cell line human CVCL_HP66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098307 CVCL_I166 HGDP01066 transformed cell line human CVCL_I166 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098308 CVCL_HP60 GM21260 transformed cell line human CVCL_HP60 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098309 CVCL_I160 HGDP00160 transformed cell line human CVCL_I160 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098310 CVCL_HP61 GM21322 transformed cell line human CVCL_HP61 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098311 CVCL_I161 HGDP00161 transformed cell line human CVCL_I161 CL:0000010 Population: Makrani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098312 CVCL_QJ10 BayGenomics ES cell line YHB327 embryonic stem cell house mouse CVCL_QJ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673709; Kntc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098313 CVCL_HP62 GM21323 transformed cell line human CVCL_HP62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098314 CVCL_I162 HGDP01064 transformed cell line human CVCL_I162 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098315 CVCL_QJ11 BayGenomics ES cell line YHB328 embryonic stem cell house mouse CVCL_QJ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098316 CVCL_QJ12 BayGenomics ES cell line YHB331 embryonic stem cell house mouse CVCL_QJ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098317 CVCL_QJ13 BayGenomics ES cell line YHB333 embryonic stem cell house mouse CVCL_QJ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147679; Patl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098318 CVCL_QJ14 BayGenomics ES cell line YHB336 embryonic stem cell house mouse CVCL_QJ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921452; Fblim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098319 CVCL_HP78 GM21464 transformed cell line human CVCL_HP78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098320 CVCL_I178 HGDP01072 transformed cell line human CVCL_I178 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098321 CVCL_HP79 GM21465 transformed cell line human CVCL_HP79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098322 CVCL_I179 HGDP00179 transformed cell line human CVCL_I179 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098323 CVCL_HP74 GM21377 transformed cell line human CVCL_HP74 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098324 CVCL_I174 HGDP01070 transformed cell line human CVCL_I174 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098325 CVCL_HP75 GM21461 transformed cell line human CVCL_HP75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098326 CVCL_I175 HGDP00175 transformed cell line human CVCL_I175 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098327 CVCL_HP76 GM21462 transformed cell line human CVCL_HP76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098328 CVCL_I176 HGDP01071 transformed cell line human CVCL_I176 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098329 CVCL_HP77 GM21463 transformed cell line human CVCL_HP77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098330 CVCL_I177 HGDP00177 transformed cell line human CVCL_I177 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098331 CVCL_HP70 GM21350 transformed cell line human CVCL_HP70 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098332 CVCL_I170 HGDP01068 transformed cell line human CVCL_I170 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098333 CVCL_HP71 GM21374 transformed cell line human CVCL_HP71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098334 CVCL_I171 HGDP00171 transformed cell line human CVCL_I171 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098335 CVCL_HP72 GM21375 transformed cell line human CVCL_HP72 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21098336 CVCL_I172 HGDP01069 transformed cell line human CVCL_I172 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098337 CVCL_HP73 GM21376 transformed cell line human CVCL_HP73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21098338 CVCL_I173 HGDP00173 transformed cell line human CVCL_I173 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098339 CVCL_QJ00 BayGenomics ES cell line YHB310 embryonic stem cell house mouse CVCL_QJ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098340 CVCL_QJ01 BayGenomics ES cell line YHB312 embryonic stem cell house mouse CVCL_QJ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916083; Pdcl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098341 CVCL_QJ02 BayGenomics ES cell line YHB313 embryonic stem cell house mouse CVCL_QJ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347070; Psma7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098342 CVCL_QJ03 BayGenomics ES cell line YHB315 embryonic stem cell house mouse CVCL_QJ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140796; Slc15a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098343 CVCL_QJ90 BayGenomics ES cell line YHC077 embryonic stem cell house mouse CVCL_QJ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917866; Sugp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098344 CVCL_QJ91 BayGenomics ES cell line YHC078 embryonic stem cell house mouse CVCL_QJ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923517; Fads1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098345 CVCL_QJ92 BayGenomics ES cell line YHC080 embryonic stem cell house mouse CVCL_QJ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344381; Dnajb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098346 CVCL_QJ93 BayGenomics ES cell line YHC081 embryonic stem cell house mouse CVCL_QJ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889505; B3gnt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098347 CVCL_QJ94 BayGenomics ES cell line YHC082 embryonic stem cell house mouse CVCL_QJ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098348 CVCL_QJ95 BayGenomics ES cell line YHC083 embryonic stem cell house mouse CVCL_QJ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098349 CVCL_QJ96 BayGenomics ES cell line YHC084 embryonic stem cell house mouse CVCL_QJ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913392; Cox7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098350 CVCL_QJ97 BayGenomics ES cell line YHC086 embryonic stem cell house mouse CVCL_QJ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098351 CVCL_QJ98 BayGenomics ES cell line YHC090 embryonic stem cell house mouse CVCL_QJ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861453; Actl6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098352 CVCL_QJ99 BayGenomics ES cell line YHC091 embryonic stem cell house mouse CVCL_QJ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098353 CVCL_QJ80 BayGenomics ES cell line YHC063 embryonic stem cell house mouse CVCL_QJ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858259; Tomm40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098354 CVCL_QJ81 BayGenomics ES cell line YHC064 embryonic stem cell house mouse CVCL_QJ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100865; Rbm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098355 CVCL_QJ82 BayGenomics ES cell line YHC065 embryonic stem cell house mouse CVCL_QJ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098356 CVCL_QJ83 BayGenomics ES cell line YHC069 embryonic stem cell house mouse CVCL_QJ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098357 CVCL_QJ84 BayGenomics ES cell line YHC070 embryonic stem cell house mouse CVCL_QJ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921638; Dpp8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098358 CVCL_QJ85 BayGenomics ES cell line YHC071 embryonic stem cell house mouse CVCL_QJ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913392; Cox7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098359 CVCL_QJ86 BayGenomics ES cell line YHC072 embryonic stem cell house mouse CVCL_QJ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913392; Cox7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098360 CVCL_QJ87 BayGenomics ES cell line YHC074 embryonic stem cell house mouse CVCL_QJ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333780; Rps19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098361 CVCL_QJ88 BayGenomics ES cell line YHC075 embryonic stem cell house mouse CVCL_QJ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446193; Tnks1bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098362 CVCL_QJ89 BayGenomics ES cell line YHC076 embryonic stem cell house mouse CVCL_QJ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858259; Tomm40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098363 CVCL_I307 HGDP00307 transformed cell line human CVCL_I307 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098364 CVCL_HR07 ND07721 transformed cell line human CVCL_HR07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098365 CVCL_I308 HGDP01201 transformed cell line human CVCL_I308 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098366 CVCL_HR08 ND07722 transformed cell line human CVCL_HR08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098367 CVCL_I309 HGDP00309 transformed cell line human CVCL_I309 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098368 CVCL_HR09 ND07724 transformed cell line human CVCL_HR09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098369 CVCL_I303 HGDP01198 transformed cell line human CVCL_I303 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098370 CVCL_HR03 ND07612 transformed cell line human CVCL_HR03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098371 CVCL_I304 HGDP00304 transformed cell line human CVCL_I304 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098372 CVCL_HR04 ND07613 transformed cell line human CVCL_HR04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098373 CVCL_I305 HGDP01199 transformed cell line human CVCL_I305 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098374 CVCL_HR05 ND07629 transformed cell line human CVCL_HR05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098375 CVCL_I306 HGDP01200 transformed cell line human CVCL_I306 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098376 CVCL_HR06 ND07693 transformed cell line human CVCL_HR06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098377 CVCL_I300 HGDP01196 transformed cell line human CVCL_I300 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098378 CVCL_HR00 ND07447 transformed cell line human CVCL_HR00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098379 CVCL_I301 HGDP01197 transformed cell line human CVCL_I301 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098380 CVCL_HR01 ND07580 transformed cell line human CVCL_HR01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098381 CVCL_I302 HGDP00302 transformed cell line human CVCL_I302 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098382 CVCL_HR02 ND07581 transformed cell line human CVCL_HR02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098383 CVCL_I318 HGDP01207 transformed cell line human CVCL_I318 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098384 CVCL_HR18 ND07969 transformed cell line human CVCL_HR18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098385 CVCL_I319 HGDP00319 transformed cell line human CVCL_I319 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098386 CVCL_HR19 ND08022 transformed cell line human CVCL_HR19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098387 CVCL_I314 HGDP01204 transformed cell line human CVCL_I314 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098388 CVCL_HR14 ND07732 transformed cell line human CVCL_HR14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098389 CVCL_I315 HGDP00315 transformed cell line human CVCL_I315 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098390 CVCL_HR15 ND07733 transformed cell line human CVCL_HR15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098391 CVCL_I316 HGDP01205 transformed cell line human CVCL_I316 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098392 CVCL_HR16 ND07736 transformed cell line human CVCL_HR16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098393 CVCL_I317 HGDP01206 transformed cell line human CVCL_I317 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098394 CVCL_HR17 ND07737 transformed cell line human CVCL_HR17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098395 CVCL_I310 HGDP01202 transformed cell line human CVCL_I310 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098396 CVCL_HR10 ND07725 transformed cell line human CVCL_HR10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098397 CVCL_I311 HGDP00311 transformed cell line human CVCL_I311 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098398 CVCL_HR11 ND07726 transformed cell line human CVCL_HR11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098399 CVCL_I312 HGDP01203 transformed cell line human CVCL_I312 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098400 CVCL_HR12 ND07727 transformed cell line human CVCL_HR12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098401 CVCL_I313 HGDP00313 transformed cell line human CVCL_I313 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098402 CVCL_HR13 ND07731 transformed cell line human CVCL_HR13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098403 CVCL_QL24 BayGenomics ES cell line YHC382 embryonic stem cell house mouse CVCL_QL24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098404 CVCL_QL25 BayGenomics ES cell line YHC383 embryonic stem cell house mouse CVCL_QL25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147611; Spindoc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098405 CVCL_QL26 BayGenomics ES cell line YHC388 embryonic stem cell house mouse CVCL_QL26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101841; Ppm1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098406 CVCL_QL27 BayGenomics ES cell line YHC395 embryonic stem cell house mouse CVCL_QL27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098407 CVCL_QL28 BayGenomics ES cell line YHC401 embryonic stem cell house mouse CVCL_QL28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139746; Ankrd13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098408 CVCL_QL29 BayGenomics ES cell line YHC405 embryonic stem cell house mouse CVCL_QL29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347046; Cop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098409 CVCL_I387 HGDP01258 transformed cell line human CVCL_I387 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098410 CVCL_HR87 ND14796 transformed cell line human CVCL_HR87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098411 CVCL_I388 HGDP00388 transformed cell line human CVCL_I388 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098412 CVCL_HR88 ND29985 transformed cell line human CVCL_HR88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098413 CVCL_I389 HGDP01259 transformed cell line human CVCL_I389 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098414 CVCL_HR89 ND30846 transformed cell line human CVCL_HR89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098415 CVCL_I383 HGDP01254 transformed cell line human CVCL_I383 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098416 CVCL_HR83 ND14174 transformed cell line human CVCL_HR83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098417 CVCL_I384 HGDP01255 transformed cell line human CVCL_I384 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098418 CVCL_HR84 ND14180 transformed cell line human CVCL_HR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098419 CVCL_I385 HGDP01256 transformed cell line human CVCL_I385 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098420 CVCL_HR85 ND14181 transformed cell line human CVCL_HR85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098421 CVCL_I386 HGDP01257 transformed cell line human CVCL_I386 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098422 CVCL_HR86 ND14570 transformed cell line human CVCL_HR86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098423 CVCL_I380 HGDP01251 transformed cell line human CVCL_I380 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098424 CVCL_HR80 ND13106 transformed cell line human CVCL_HR80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098425 CVCL_I381 HGDP01253 transformed cell line human CVCL_I381 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098426 CVCL_HR81 ND13821 transformed cell line human CVCL_HR81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098427 CVCL_QL30 BayGenomics ES cell line YHC407 embryonic stem cell house mouse CVCL_QL30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027003; Ino80d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098428 CVCL_I382 HGDP00382 transformed cell line human CVCL_I382 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098429 CVCL_HR82 ND14055 transformed cell line human CVCL_HR82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098430 CVCL_QL31 BayGenomics ES cell line YHC409 embryonic stem cell house mouse CVCL_QL31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924085; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098431 CVCL_QL32 BayGenomics ES cell line YHC410 embryonic stem cell house mouse CVCL_QL32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289147; E2f7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098432 CVCL_QL33 BayGenomics ES cell line YHC415 embryonic stem cell house mouse CVCL_QL33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914803; Gstcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098433 CVCL_QL34 BayGenomics ES cell line YHC417 embryonic stem cell house mouse CVCL_QL34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88431; Cnbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098434 CVCL_QL13 BayGenomics ES cell line YHC355 embryonic stem cell house mouse CVCL_QL13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098435 CVCL_QL14 BayGenomics ES cell line YHC357 embryonic stem cell house mouse CVCL_QL14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921437; Katnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098436 CVCL_QL15 BayGenomics ES cell line YHC360 embryonic stem cell house mouse CVCL_QL15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349473; Ppp2r5e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098437 CVCL_QL16 BayGenomics ES cell line YHC361 embryonic stem cell house mouse CVCL_QL16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920428; Wasl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098438 CVCL_QL17 BayGenomics ES cell line YHC362 embryonic stem cell house mouse CVCL_QL17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928679; Dpys Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098439 CVCL_QL18 BayGenomics ES cell line YHC367 embryonic stem cell house mouse CVCL_QL18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140494; Ppp1r8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098440 CVCL_QL19 BayGenomics ES cell line YHC369 embryonic stem cell house mouse CVCL_QL19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918052; Pwwp2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098441 CVCL_I398 HGDP01266 transformed cell line human CVCL_I398 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098442 CVCL_HR98 ND34761 transformed cell line human CVCL_HR98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098443 CVCL_I399 HGDP01267 transformed cell line human CVCL_I399 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098444 CVCL_HR99 ND35821 transformed cell line human CVCL_HR99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21098445 CVCL_I394 HGDP01263 transformed cell line human CVCL_I394 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098446 CVCL_HR94 ND34171 transformed cell line human CVCL_HR94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098447 CVCL_I395 HGDP01264 transformed cell line human CVCL_I395 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098448 CVCL_HR95 ND34172 transformed cell line human CVCL_HR95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098449 CVCL_I396 HGDP01265 transformed cell line human CVCL_I396 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098450 CVCL_HR96 ND34691 transformed cell line human CVCL_HR96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098451 CVCL_I397 HGDP00397 transformed cell line human CVCL_I397 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098452 CVCL_HR97 ND34693 transformed cell line human CVCL_HR97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098453 CVCL_I390 HGDP01260 transformed cell line human CVCL_I390 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098454 CVCL_HR90 ND30922 transformed cell line human CVCL_HR90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098455 CVCL_I391 HGDP01261 transformed cell line human CVCL_I391 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098456 CVCL_HR91 ND33780 transformed cell line human CVCL_HR91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098457 CVCL_I392 HGDP00392 transformed cell line human CVCL_I392 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098458 CVCL_HR92 ND33797 transformed cell line human CVCL_HR92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098459 CVCL_I393 HGDP01262 transformed cell line human CVCL_I393 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098460 CVCL_HR93 ND34088 transformed cell line human CVCL_HR93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098461 CVCL_QL20 BayGenomics ES cell line YHC370 embryonic stem cell house mouse CVCL_QL20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098462 CVCL_QL21 BayGenomics ES cell line YHC374 embryonic stem cell house mouse CVCL_QL21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347046; Cop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098463 CVCL_QL22 BayGenomics ES cell line YHC375 embryonic stem cell house mouse CVCL_QL22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917866; Sugp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098464 CVCL_QL23 BayGenomics ES cell line YHC376 embryonic stem cell house mouse CVCL_QL23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098465 CVCL_QL02 BayGenomics ES cell line YHC339 embryonic stem cell house mouse CVCL_QL02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109211; Pkn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098466 CVCL_QL03 BayGenomics ES cell line YHC341 embryonic stem cell house mouse CVCL_QL03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98397; Src Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098467 CVCL_QL04 BayGenomics ES cell line YHC342 embryonic stem cell house mouse CVCL_QL04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913687; Fis1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098468 CVCL_QL05 BayGenomics ES cell line YHC344 embryonic stem cell house mouse CVCL_QL05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913915; Msantd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098469 CVCL_QL06 BayGenomics ES cell line YHC345 embryonic stem cell house mouse CVCL_QL06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444812; Camkk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098470 CVCL_QL07 BayGenomics ES cell line YHC349 embryonic stem cell house mouse CVCL_QL07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098471 CVCL_QL08 BayGenomics ES cell line YHC350 embryonic stem cell house mouse CVCL_QL08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098472 CVCL_QL09 BayGenomics ES cell line YHC351 embryonic stem cell house mouse CVCL_QL09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860493; Arhgef7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098473 CVCL_I369 HGDP01243 transformed cell line human CVCL_I369 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098474 CVCL_HR69 ND10460 transformed cell line human CVCL_HR69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098475 CVCL_I365 HGDP01239 transformed cell line human CVCL_I365 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098476 CVCL_HR65 ND10250 transformed cell line human CVCL_HR65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098477 CVCL_I366 HGDP01240 transformed cell line human CVCL_I366 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098478 CVCL_HR66 ND10290 transformed cell line human CVCL_HR66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098479 CVCL_I367 HGDP01241 transformed cell line human CVCL_I367 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098480 CVCL_HR67 ND10291 transformed cell line human CVCL_HR67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098481 CVCL_I368 HGDP01242 transformed cell line human CVCL_I368 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098482 CVCL_HR68 ND10376 transformed cell line human CVCL_HR68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098483 CVCL_I361 HGDP01236 transformed cell line human CVCL_I361 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098484 CVCL_HR61 ND10032 transformed cell line human CVCL_HR61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098485 CVCL_I362 HGDP01237 transformed cell line human CVCL_I362 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098486 CVCL_HR62 ND10163 transformed cell line human CVCL_HR62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098487 CVCL_I363 HGDP01238 transformed cell line human CVCL_I363 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098488 CVCL_HR63 ND10164 transformed cell line human CVCL_HR63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098489 CVCL_I364 HGDP00364 transformed cell line human CVCL_I364 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098490 CVCL_HR64 ND10166 transformed cell line human CVCL_HR64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098491 CVCL_I360 HGDP01235 transformed cell line human CVCL_I360 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098492 CVCL_HR60 ND09511 transformed cell line human CVCL_HR60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098493 CVCL_QL10 BayGenomics ES cell line YHC352 embryonic stem cell house mouse CVCL_QL10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098494 CVCL_QL11 BayGenomics ES cell line YHC353 embryonic stem cell house mouse CVCL_QL11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098495 CVCL_QL12 BayGenomics ES cell line YHC354 embryonic stem cell house mouse CVCL_QL12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922670; Secisbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098496 CVCL_I376 HGDP00376 transformed cell line human CVCL_I376 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098497 CVCL_HR76 ND12348 transformed cell line human CVCL_HR76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098498 CVCL_I377 HGDP01248 transformed cell line human CVCL_I377 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098499 CVCL_HR77 ND12349 transformed cell line human CVCL_HR77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098500 CVCL_I378 HGDP01249 transformed cell line human CVCL_I378 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098501 CVCL_HR78 ND12819 transformed cell line human CVCL_HR78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098502 CVCL_I379 HGDP01250 transformed cell line human CVCL_I379 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098503 CVCL_HR79 ND12931 transformed cell line human CVCL_HR79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098504 CVCL_I372 HGDP00372 transformed cell line human CVCL_I372 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098505 CVCL_HR72 ND11101 transformed cell line human CVCL_HR72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098506 CVCL_I373 HGDP01245 transformed cell line human CVCL_I373 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098507 CVCL_HR73 ND11268 transformed cell line human CVCL_HR73 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Peripheral blood. Female 21098508 CVCL_I374 HGDP01246 transformed cell line human CVCL_I374 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098509 CVCL_HR74 ND11269 transformed cell line human CVCL_HR74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098510 CVCL_I375 HGDP01247 transformed cell line human CVCL_I375 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098511 CVCL_HR75 ND11831 transformed cell line human CVCL_HR75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098512 CVCL_I370 HGDP01244 transformed cell line human CVCL_I370 CL:0000010 Population: Chinese/Asian ethnic group; Xibo; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098513 CVCL_HR70 ND10762 transformed cell line human CVCL_HR70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098514 CVCL_I371 HGDP00371 transformed cell line human CVCL_I371 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098515 CVCL_HR71 ND10999 transformed cell line human CVCL_HR71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098516 CVCL_QL00 BayGenomics ES cell line YHC334 embryonic stem cell house mouse CVCL_QL00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104897; Rest Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098517 CVCL_QL01 BayGenomics ES cell line YHC336 embryonic stem cell house mouse CVCL_QL01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098518 CVCL_I347 HGDP01225 transformed cell line human CVCL_I347 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098519 CVCL_HR47 ND08586 transformed cell line human CVCL_HR47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098520 CVCL_I348 HGDP01226 transformed cell line human CVCL_I348 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098521 CVCL_HR48 ND08587 transformed cell line human CVCL_HR48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098522 CVCL_I349 HGDP01227 transformed cell line human CVCL_I349 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098523 CVCL_HR49 ND08726 transformed cell line human CVCL_HR49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098524 CVCL_I343 HGDP01222 transformed cell line human CVCL_I343 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098525 CVCL_HR43 ND08561 transformed cell line human CVCL_HR43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098526 CVCL_I344 HGDP01223 transformed cell line human CVCL_I344 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098527 CVCL_HR44 ND08562 transformed cell line human CVCL_HR44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098528 CVCL_I345 HGDP01224 transformed cell line human CVCL_I345 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098529 CVCL_HR45 ND08563 transformed cell line human CVCL_HR45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098530 CVCL_I346 HGDP00346 transformed cell line human CVCL_I346 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098531 CVCL_HR46 ND08584 transformed cell line human CVCL_HR46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098532 CVCL_I340 HGDP01220 transformed cell line human CVCL_I340 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098533 CVCL_HR40 ND08550 transformed cell line human CVCL_HR40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098534 CVCL_I341 HGDP00341 transformed cell line human CVCL_I341 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098535 CVCL_HR41 ND08557 transformed cell line human CVCL_HR41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098536 CVCL_I342 HGDP01221 transformed cell line human CVCL_I342 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098537 CVCL_HR42 ND08558 transformed cell line human CVCL_HR42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098538 CVCL_I358 HGDP01234 transformed cell line human CVCL_I358 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098539 CVCL_HR58 ND09313 transformed cell line human CVCL_HR58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098540 CVCL_I359 HGDP00359 transformed cell line human CVCL_I359 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098541 CVCL_HR59 ND09510 transformed cell line human CVCL_HR59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098542 CVCL_I354 HGDP01231 transformed cell line human CVCL_I354 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098543 CVCL_HR54 ND08829 transformed cell line human CVCL_HR54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098544 CVCL_I355 HGDP01232 transformed cell line human CVCL_I355 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098545 CVCL_HR55 ND08872 transformed cell line human CVCL_HR55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098546 CVCL_I356 HGDP00356 transformed cell line human CVCL_I356 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098547 CVCL_HR56 ND08873 transformed cell line human CVCL_HR56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098548 CVCL_I357 HGDP01233 transformed cell line human CVCL_I357 CL:0000010 Population: Chinese/Asian ethnic group; Hezhen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098549 CVCL_HR57 ND09215 transformed cell line human CVCL_HR57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098550 CVCL_I350 HGDP01228 transformed cell line human CVCL_I350 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098551 CVCL_HR50 ND08735 transformed cell line human CVCL_HR50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098552 CVCL_I351 HGDP00351 transformed cell line human CVCL_I351 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098553 CVCL_HR51 ND08736 transformed cell line human CVCL_HR51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098554 CVCL_I352 HGDP01229 transformed cell line human CVCL_I352 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098555 CVCL_HR52 ND08769 transformed cell line human CVCL_HR52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098556 CVCL_I353 HGDP01230 transformed cell line human CVCL_I353 CL:0000010 Population: Mongolian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098557 CVCL_HR53 ND08770 transformed cell line human CVCL_HR53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098558 CVCL_I329 HGDP01213 transformed cell line human CVCL_I329 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098559 CVCL_HR29 ND08536 transformed cell line human CVCL_HR29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098560 CVCL_I325 HGDP01211 transformed cell line human CVCL_I325 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098561 CVCL_HR25 ND08323 transformed cell line human CVCL_HR25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098562 CVCL_I326 HGDP00326 transformed cell line human CVCL_I326 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098563 CVCL_HR26 ND08407 transformed cell line human CVCL_HR26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098564 CVCL_I327 HGDP01212 transformed cell line human CVCL_I327 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098565 CVCL_HR27 ND08477 transformed cell line human CVCL_HR27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098566 CVCL_I328 HGDP00328 transformed cell line human CVCL_I328 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098567 CVCL_HR28 ND08507 transformed cell line human CVCL_HR28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098568 CVCL_I321 HGDP00321 transformed cell line human CVCL_I321 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098569 CVCL_HR21 ND08057 transformed cell line human CVCL_HR21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098570 CVCL_I322 HGDP01209 transformed cell line human CVCL_I322 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098571 CVCL_HR22 ND08274 transformed cell line human CVCL_HR22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098572 CVCL_I323 HGDP00323 transformed cell line human CVCL_I323 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098573 CVCL_HR23 ND08275 transformed cell line human CVCL_HR23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098574 CVCL_I324 HGDP01210 transformed cell line human CVCL_I324 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098575 CVCL_HR24 ND08322 transformed cell line human CVCL_HR24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098576 CVCL_I320 HGDP01208 transformed cell line human CVCL_I320 CL:0000010 Population: Chinese/Asian ethnic group; Oroqen; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098577 CVCL_HR20 ND08023 transformed cell line human CVCL_HR20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098578 CVCL_I336 HGDP00336 transformed cell line human CVCL_I336 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098579 CVCL_HR36 ND08546 transformed cell line human CVCL_HR36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098580 CVCL_I337 HGDP01218 transformed cell line human CVCL_I337 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098581 CVCL_HR37 ND08547 transformed cell line human CVCL_HR37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098582 CVCL_I338 HGDP00338 transformed cell line human CVCL_I338 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098583 CVCL_HR38 ND08548 transformed cell line human CVCL_HR38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098584 CVCL_I339 HGDP01219 transformed cell line human CVCL_I339 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098585 CVCL_HR39 ND08549 transformed cell line human CVCL_HR39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098586 CVCL_I332 HGDP01215 transformed cell line human CVCL_I332 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098587 CVCL_HR32 ND08541 transformed cell line human CVCL_HR32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098588 CVCL_I333 HGDP00333 transformed cell line human CVCL_I333 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098589 CVCL_HR33 ND08542 transformed cell line human CVCL_HR33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098590 CVCL_I334 HGDP01216 transformed cell line human CVCL_I334 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098591 CVCL_HR34 ND08544 transformed cell line human CVCL_HR34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098592 CVCL_I335 HGDP01217 transformed cell line human CVCL_I335 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098593 CVCL_HR35 ND08545 transformed cell line human CVCL_HR35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098594 CVCL_I330 HGDP00330 transformed cell line human CVCL_I330 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098595 CVCL_HR30 ND08537 transformed cell line human CVCL_HR30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098596 CVCL_I331 HGDP01214 transformed cell line human CVCL_I331 CL:0000010 Population: Chinese/Asian ethnic group; Daur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098597 CVCL_HR31 ND08540 transformed cell line human CVCL_HR31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098598 CVCL_QK90 BayGenomics ES cell line YHC313 embryonic stem cell house mouse CVCL_QK90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928739; Dnajb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098599 CVCL_QK91 BayGenomics ES cell line YHC314 embryonic stem cell house mouse CVCL_QK91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927551; Osbpl1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098600 CVCL_QK92 BayGenomics ES cell line YHC315 embryonic stem cell house mouse CVCL_QK92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098601 CVCL_QK93 BayGenomics ES cell line YHC316 embryonic stem cell house mouse CVCL_QK93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929701; Metap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098602 CVCL_QK94 BayGenomics ES cell line YHC319 embryonic stem cell house mouse CVCL_QK94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443679; Sipa1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098603 CVCL_QK95 BayGenomics ES cell line YHC321 embryonic stem cell house mouse CVCL_QK95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098604 CVCL_QK96 BayGenomics ES cell line YHC325 embryonic stem cell house mouse CVCL_QK96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88026; Ank3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098605 CVCL_QK97 BayGenomics ES cell line YHC328 embryonic stem cell house mouse CVCL_QK97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289280; Zfp410 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098606 CVCL_QK98 BayGenomics ES cell line YHC332 embryonic stem cell house mouse CVCL_QK98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201691; Rnf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098607 CVCL_QK99 BayGenomics ES cell line YHC333 embryonic stem cell house mouse CVCL_QK99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139714; Adgrl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098608 CVCL_QK80 BayGenomics ES cell line YHC280 embryonic stem cell house mouse CVCL_QK80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444155; Nmnat2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098609 CVCL_QK81 BayGenomics ES cell line YHC281 embryonic stem cell house mouse CVCL_QK81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700009; Sh3gl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098610 CVCL_QK82 BayGenomics ES cell line YHC285 embryonic stem cell house mouse CVCL_QK82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104982; Cebpg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098611 CVCL_QK83 BayGenomics ES cell line YHC286 embryonic stem cell house mouse CVCL_QK83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098612 CVCL_QK84 BayGenomics ES cell line YHC288 embryonic stem cell house mouse CVCL_QK84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098613 CVCL_QK85 BayGenomics ES cell line YHC292 embryonic stem cell house mouse CVCL_QK85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889341; Hacd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098614 CVCL_QK86 BayGenomics ES cell line YHC299 embryonic stem cell house mouse CVCL_QK86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109153; Ktn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098615 CVCL_QK87 BayGenomics ES cell line YHC305 embryonic stem cell house mouse CVCL_QK87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098616 CVCL_QK88 BayGenomics ES cell line YHC307 embryonic stem cell house mouse CVCL_QK88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098617 CVCL_QK89 BayGenomics ES cell line YHC312 embryonic stem cell house mouse CVCL_QK89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098618 CVCL_QK69 BayGenomics ES cell line YHC257 embryonic stem cell house mouse CVCL_QK69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098808; Pex5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098619 CVCL_QK70 BayGenomics ES cell line YHC260 embryonic stem cell house mouse CVCL_QK70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921197; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098620 CVCL_QK71 BayGenomics ES cell line YHC262 embryonic stem cell house mouse CVCL_QK71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921197; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098621 CVCL_QK72 BayGenomics ES cell line YHC264 embryonic stem cell house mouse CVCL_QK72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098622 CVCL_QK73 BayGenomics ES cell line YHC268 embryonic stem cell house mouse CVCL_QK73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339984; Pak2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098623 CVCL_QK74 BayGenomics ES cell line YHC271 embryonic stem cell house mouse CVCL_QK74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444453; Arhgef10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098624 CVCL_QK75 BayGenomics ES cell line YHC272 embryonic stem cell house mouse CVCL_QK75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098625 CVCL_QK76 BayGenomics ES cell line YHC273 embryonic stem cell house mouse CVCL_QK76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098626 CVCL_QK77 BayGenomics ES cell line YHC274 embryonic stem cell house mouse CVCL_QK77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098627 CVCL_QK78 BayGenomics ES cell line YHC276 embryonic stem cell house mouse CVCL_QK78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098628 CVCL_QK79 BayGenomics ES cell line YHC279 embryonic stem cell house mouse CVCL_QK79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98105; Rps12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098629 CVCL_QK58 BayGenomics ES cell line YHC236 embryonic stem cell house mouse CVCL_QK58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098630 CVCL_QK59 BayGenomics ES cell line YHC237 embryonic stem cell house mouse CVCL_QK59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098631 CVCL_QK60 BayGenomics ES cell line YHC239 embryonic stem cell house mouse CVCL_QK60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098632 CVCL_QK61 BayGenomics ES cell line YHC240 embryonic stem cell house mouse CVCL_QK61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858230; Sart3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098633 CVCL_QK62 BayGenomics ES cell line YHC243 embryonic stem cell house mouse CVCL_QK62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443502; Cep95 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098634 CVCL_QK63 BayGenomics ES cell line YHC246 embryonic stem cell house mouse CVCL_QK63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194912; Rbbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098635 CVCL_QK64 BayGenomics ES cell line YHC247 embryonic stem cell house mouse CVCL_QK64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95804; Gsr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098636 CVCL_QK65 BayGenomics ES cell line YHC248 embryonic stem cell house mouse CVCL_QK65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178103; Arhgdia Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098637 CVCL_QK66 BayGenomics ES cell line YHC251 embryonic stem cell house mouse CVCL_QK66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913617; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098638 CVCL_QK67 BayGenomics ES cell line YHC253 embryonic stem cell house mouse CVCL_QK67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098639 CVCL_QK68 BayGenomics ES cell line YHC256 embryonic stem cell house mouse CVCL_QK68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289280; Zfp410 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098640 CVCL_QK47 BayGenomics ES cell line YHC209 embryonic stem cell house mouse CVCL_QK47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891693; Mtmr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098641 CVCL_QK48 BayGenomics ES cell line YHC213 embryonic stem cell house mouse CVCL_QK48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276539; Ttc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098642 CVCL_QK49 BayGenomics ES cell line YHC214 embryonic stem cell house mouse CVCL_QK49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098643 CVCL_QK50 BayGenomics ES cell line YHC215 embryonic stem cell house mouse CVCL_QK50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098644 CVCL_QK51 BayGenomics ES cell line YHC217 embryonic stem cell house mouse CVCL_QK51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098645 CVCL_QK52 BayGenomics ES cell line YHC218 embryonic stem cell house mouse CVCL_QK52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927551; Osbpl1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098646 CVCL_QK53 BayGenomics ES cell line YHC219 embryonic stem cell house mouse CVCL_QK53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917498; Dazap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098647 CVCL_QK54 BayGenomics ES cell line YHC220 embryonic stem cell house mouse CVCL_QK54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098648 CVCL_QK55 BayGenomics ES cell line YHC222 embryonic stem cell house mouse CVCL_QK55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914189; Aagab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098649 CVCL_QK56 BayGenomics ES cell line YHC225 embryonic stem cell house mouse CVCL_QK56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924367; Zfp934 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098650 CVCL_QK57 BayGenomics ES cell line YHC234 embryonic stem cell house mouse CVCL_QK57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098651 CVCL_QK36 BayGenomics ES cell line YHC170 embryonic stem cell house mouse CVCL_QK36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183446; Agap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098652 CVCL_QK37 BayGenomics ES cell line YHC177 embryonic stem cell house mouse CVCL_QK37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142347; Zfp568 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098653 CVCL_QK38 BayGenomics ES cell line YHC179 embryonic stem cell house mouse CVCL_QK38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098654 CVCL_QK39 BayGenomics ES cell line YHC181 embryonic stem cell house mouse CVCL_QK39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098655 CVCL_QK40 BayGenomics ES cell line YHC182 embryonic stem cell house mouse CVCL_QK40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098656 CVCL_QK41 BayGenomics ES cell line YHC194 embryonic stem cell house mouse CVCL_QK41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925112; Thyn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098657 CVCL_QK42 BayGenomics ES cell line YHC200 embryonic stem cell house mouse CVCL_QK42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924367; Zfp934 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098658 CVCL_QK43 BayGenomics ES cell line YHC201 embryonic stem cell house mouse CVCL_QK43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098659 CVCL_QK44 BayGenomics ES cell line YHC202 embryonic stem cell house mouse CVCL_QK44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95769; Gna14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098660 CVCL_QK45 BayGenomics ES cell line YHC203 embryonic stem cell house mouse CVCL_QK45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917193; Lrch4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098661 CVCL_QK46 BayGenomics ES cell line YHC206 embryonic stem cell house mouse CVCL_QK46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098662 CVCL_QK25 BayGenomics ES cell line YHC152 embryonic stem cell house mouse CVCL_QK25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446159; Itpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098663 CVCL_QK26 BayGenomics ES cell line YHC154 embryonic stem cell house mouse CVCL_QK26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351455; Rpl13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098664 CVCL_QK27 BayGenomics ES cell line YHC157 embryonic stem cell house mouse CVCL_QK27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349423; Racgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098665 CVCL_QK28 BayGenomics ES cell line YHC158 embryonic stem cell house mouse CVCL_QK28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1195276; Bloc1s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098666 CVCL_QK29 BayGenomics ES cell line YHC159 embryonic stem cell house mouse CVCL_QK29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098667 CVCL_I288 HGDP00288 transformed cell line human CVCL_I288 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098668 CVCL_HQ88 ND06445 transformed cell line human CVCL_HQ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098669 CVCL_I289 HGDP01188 transformed cell line human CVCL_I289 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098670 CVCL_HQ89 ND06865 transformed cell line human CVCL_HQ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098671 CVCL_I284 HGDP01186 transformed cell line human CVCL_I284 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098672 CVCL_HQ84 ND06299 transformed cell line human CVCL_HQ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098673 CVCL_I285 HGDP00285 transformed cell line human CVCL_I285 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098674 CVCL_HQ85 ND06339 transformed cell line human CVCL_HQ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098675 CVCL_I286 HGDP00286 transformed cell line human CVCL_I286 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098676 CVCL_HQ86 ND06340 transformed cell line human CVCL_HQ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098677 CVCL_I287 HGDP01187 transformed cell line human CVCL_I287 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098678 CVCL_HQ87 ND06443 transformed cell line human CVCL_HQ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098679 CVCL_I280 HGDP01183 transformed cell line human CVCL_I280 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098680 CVCL_HQ80 ND05091 transformed cell line human CVCL_HQ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098681 CVCL_I281 HGDP00281 transformed cell line human CVCL_I281 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098682 CVCL_HQ81 ND05341 transformed cell line human CVCL_HQ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098683 CVCL_QK30 BayGenomics ES cell line YHC160 embryonic stem cell house mouse CVCL_QK30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915020; Caap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098684 CVCL_I282 HGDP01184 transformed cell line human CVCL_I282 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098685 CVCL_HQ82 ND05403 transformed cell line human CVCL_HQ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098686 CVCL_QK31 BayGenomics ES cell line YHC161 embryonic stem cell house mouse CVCL_QK31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106356; D11Wsu47e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098687 CVCL_I283 HGDP01185 transformed cell line human CVCL_I283 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098688 CVCL_HQ83 ND06298 transformed cell line human CVCL_HQ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098689 CVCL_QK32 BayGenomics ES cell line YHC162 embryonic stem cell house mouse CVCL_QK32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919318; Cnot2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098690 CVCL_QK33 BayGenomics ES cell line YHC163 embryonic stem cell house mouse CVCL_QK33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098691 CVCL_QK34 BayGenomics ES cell line YHC167 embryonic stem cell house mouse CVCL_QK34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109486; Prdx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098692 CVCL_QK35 BayGenomics ES cell line YHC168 embryonic stem cell house mouse CVCL_QK35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098693 CVCL_QK14 BayGenomics ES cell line YHC131 embryonic stem cell house mouse CVCL_QK14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918667; Gpatch8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098694 CVCL_QK15 BayGenomics ES cell line YHC136 embryonic stem cell house mouse CVCL_QK15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098695 CVCL_QK16 BayGenomics ES cell line YHC137 embryonic stem cell house mouse CVCL_QK16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107801; Atp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098696 CVCL_QK17 BayGenomics ES cell line YHC138 embryonic stem cell house mouse CVCL_QK17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926078; Rhot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098697 CVCL_QK18 BayGenomics ES cell line YHC139 embryonic stem cell house mouse CVCL_QK18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922570; Etnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098698 CVCL_QK19 BayGenomics ES cell line YHC140 embryonic stem cell house mouse CVCL_QK19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098699 CVCL_I299 HGDP01195 transformed cell line human CVCL_I299 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098700 CVCL_HQ99 ND07274 transformed cell line human CVCL_HQ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098701 CVCL_I295 HGDP01192 transformed cell line human CVCL_I295 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098702 CVCL_HQ95 ND07267 transformed cell line human CVCL_HQ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098703 CVCL_I296 HGDP01193 transformed cell line human CVCL_I296 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098704 CVCL_HQ96 ND07268 transformed cell line human CVCL_HQ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098705 CVCL_I297 HGDP01194 transformed cell line human CVCL_I297 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098706 CVCL_HQ97 ND07269 transformed cell line human CVCL_HQ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098707 CVCL_I298 HGDP00298 transformed cell line human CVCL_I298 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098708 CVCL_HQ98 ND07273 transformed cell line human CVCL_HQ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098709 CVCL_I291 HGDP01189 transformed cell line human CVCL_I291 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098710 CVCL_HQ91 ND07117 transformed cell line human CVCL_HQ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098711 CVCL_I292 HGDP00292 transformed cell line human CVCL_I292 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098712 CVCL_HQ92 ND07189 transformed cell line human CVCL_HQ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098713 CVCL_I293 HGDP01190 transformed cell line human CVCL_I293 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098714 CVCL_HQ93 ND07191 transformed cell line human CVCL_HQ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098715 CVCL_QK20 BayGenomics ES cell line YHC144 embryonic stem cell house mouse CVCL_QK20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2177308; Znrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098716 CVCL_I294 HGDP01191 transformed cell line human CVCL_I294 CL:0000010 Population: Chinese/Asian ethnic group; Miaozu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098717 CVCL_HQ94 ND07266 transformed cell line human CVCL_HQ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21098718 CVCL_QK21 BayGenomics ES cell line YHC145 embryonic stem cell house mouse CVCL_QK21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917689; Taf15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098719 CVCL_QK22 BayGenomics ES cell line YHC146 embryonic stem cell house mouse CVCL_QK22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098720 CVCL_QK23 BayGenomics ES cell line YHC149 embryonic stem cell house mouse CVCL_QK23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098721 CVCL_QK24 BayGenomics ES cell line YHC151 embryonic stem cell house mouse CVCL_QK24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098722 CVCL_I290 HGDP00290 transformed cell line human CVCL_I290 CL:0000010 Population: Kalash; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21098723 CVCL_HQ90 ND06866 transformed cell line human CVCL_HQ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21098724 CVCL_6W00 DA01471 transformed cell line human CVCL_6W00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098725 CVCL_7800 UM-SCC-96 cancer cell line human CVCL_7800 CL:0000010 Female 21098726 CVCL_6W01 DA01472 transformed cell line human CVCL_6W01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01472; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098727 CVCL_7801 UM-SCC-97 cancer cell line human CVCL_7801 CL:0000010 Omics: CNV analysis. Female 21098728 CVCL_6W02 DA01473 transformed cell line human CVCL_6W02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098729 CVCL_7802 UM-SCC-98 cancer cell line human CVCL_7802 CL:0000010 Male 21098730 CVCL_6W03 DA01474 transformed cell line human CVCL_6W03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098731 CVCL_7803 UM-SCC-99 cancer cell line human CVCL_7803 CL:0000010 Male 21098732 CVCL_6W08 DA01479 transformed cell line human CVCL_6W08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098733 CVCL_7808 UT-SCC-12B cancer cell line human CVCL_7808 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=8782485) Derived from metastatic site: Not specified. Female 21098734 CVCL_6W09 DA01480 transformed cell line human CVCL_6W09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01480; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098735 CVCL_7809 UT-SCC-13 cancer cell line human CVCL_7809 CL:0000010 Male 21098736 CVCL_6W04 DA01475 transformed cell line human CVCL_6W04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098737 CVCL_7804 UT-SCC-10 cancer cell line human CVCL_7804 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=29970484); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485; PubMed=11799138) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098738 CVCL_6W05 DA01476 transformed cell line human CVCL_6W05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098739 CVCL_7805 UT-SCC-11 cancer cell line human CVCL_7805 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly187_Arg196del (c.560_589del); Zygosity=Unspecified (PubMed=33802339) Derived from sampling site: Larynx; glottis. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21098740 CVCL_6W06 DA01477 transformed cell line human CVCL_6W06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098741 CVCL_7806 UT-SCC-118 cancer cell line human CVCL_7806 CL:0000010 Derived from sampling site: Face; skin. 21098742 CVCL_6W07 DA01478 transformed cell line human CVCL_6W07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098743 CVCL_7807 UT-SCC-12A cancer cell line human CVCL_7807 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=8782485) Derived from sampling site: Nose; skin. Female 21098744 CVCL_QD90 BayGenomics ES cell line XL964 embryonic stem cell house mouse CVCL_QD90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108405; Apbb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098745 CVCL_QD91 BayGenomics ES cell line XL965 embryonic stem cell house mouse CVCL_QD91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143333; Exog Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098746 CVCL_QD92 BayGenomics ES cell line XL978 embryonic stem cell house mouse CVCL_QD92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99137; Xrcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098747 CVCL_QD93 BayGenomics ES cell line XL988 embryonic stem cell house mouse CVCL_QD93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923164; Exoc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098748 CVCL_QD94 BayGenomics ES cell line XL989 embryonic stem cell house mouse CVCL_QD94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105982; Rfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098749 CVCL_QD95 BayGenomics ES cell line XM047 embryonic stem cell house mouse CVCL_QD95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96677; Kit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098750 CVCL_QD96 BayGenomics ES cell line XM051 embryonic stem cell house mouse CVCL_QD96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098751 CVCL_QD97 BayGenomics ES cell line XM052 embryonic stem cell house mouse CVCL_QD97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919000; R3hdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098752 CVCL_QD98 BayGenomics ES cell line XM060 embryonic stem cell house mouse CVCL_QD98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442675; Rfx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098753 CVCL_QD99 BayGenomics ES cell line XM062 embryonic stem cell house mouse CVCL_QD99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098754 CVCL_QD80 BayGenomics ES cell line XL924 embryonic stem cell house mouse CVCL_QD80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098755 CVCL_QD81 BayGenomics ES cell line XL931 embryonic stem cell house mouse CVCL_QD81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098756 CVCL_QD82 BayGenomics ES cell line XL933 embryonic stem cell house mouse CVCL_QD82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929492; Atl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098757 CVCL_QD83 BayGenomics ES cell line XL934 embryonic stem cell house mouse CVCL_QD83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917140; Zfp219 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098758 CVCL_QD84 BayGenomics ES cell line XL945 embryonic stem cell house mouse CVCL_QD84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443138; Mphosph9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098759 CVCL_QD85 BayGenomics ES cell line XL952 embryonic stem cell house mouse CVCL_QD85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916192; Chmp2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098760 CVCL_QD86 BayGenomics ES cell line XL954 embryonic stem cell house mouse CVCL_QD86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098761 CVCL_QD87 BayGenomics ES cell line XL958 embryonic stem cell house mouse CVCL_QD87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99526; Ddx19a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098762 CVCL_QD88 BayGenomics ES cell line XL960 embryonic stem cell house mouse CVCL_QD88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202879; Tcf7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098763 CVCL_QD89 BayGenomics ES cell line XL961 embryonic stem cell house mouse CVCL_QD89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098764 CVCL_QD70 BayGenomics ES cell line XL826 embryonic stem cell house mouse CVCL_QD70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387217; Ift52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098765 CVCL_QD71 BayGenomics ES cell line XL909 embryonic stem cell house mouse CVCL_QD71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347044; Orc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098766 CVCL_QD72 BayGenomics ES cell line XL911 embryonic stem cell house mouse CVCL_QD72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098767 CVCL_QD73 BayGenomics ES cell line XL913 embryonic stem cell house mouse CVCL_QD73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443432; Foxj3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098768 CVCL_QD74 BayGenomics ES cell line XL914 embryonic stem cell house mouse CVCL_QD74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443432; Foxj3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098769 CVCL_QD75 BayGenomics ES cell line XL916 embryonic stem cell house mouse CVCL_QD75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104878; Prkar1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098770 CVCL_QD76 BayGenomics ES cell line XL919 embryonic stem cell house mouse CVCL_QD76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922566; Taf1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098771 CVCL_QD77 BayGenomics ES cell line XL920 embryonic stem cell house mouse CVCL_QD77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917933; Utp20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098772 CVCL_QD78 BayGenomics ES cell line XL922 embryonic stem cell house mouse CVCL_QD78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925542; Orai1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098773 CVCL_QD79 BayGenomics ES cell line XL923 embryonic stem cell house mouse CVCL_QD79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098774 CVCL_QD60 BayGenomics ES cell line XL795 embryonic stem cell house mouse CVCL_QD60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098775 CVCL_QD61 BayGenomics ES cell line XL796 embryonic stem cell house mouse CVCL_QD61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098776 CVCL_QD62 BayGenomics ES cell line XL797 embryonic stem cell house mouse CVCL_QD62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919151; Fam219a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098777 CVCL_QD63 BayGenomics ES cell line XL798 embryonic stem cell house mouse CVCL_QD63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861728; Wwp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098778 CVCL_QD64 BayGenomics ES cell line XL799 embryonic stem cell house mouse CVCL_QD64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99638; Mark2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098779 CVCL_QD65 BayGenomics ES cell line XL802 embryonic stem cell house mouse CVCL_QD65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159344; Vangl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098780 CVCL_QD66 BayGenomics ES cell line XL817 embryonic stem cell house mouse CVCL_QD66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889023; Banp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098781 CVCL_QD67 BayGenomics ES cell line XL818 embryonic stem cell house mouse CVCL_QD67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921527; Chic2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098782 CVCL_QD68 BayGenomics ES cell line XL821 embryonic stem cell house mouse CVCL_QD68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098783 CVCL_QD69 BayGenomics ES cell line XL823 embryonic stem cell house mouse CVCL_QD69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446526; Cpt1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098784 CVCL_QD50 BayGenomics ES cell line XL643 embryonic stem cell house mouse CVCL_QD50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098785 CVCL_QD51 BayGenomics ES cell line XL738 embryonic stem cell house mouse CVCL_QD51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861728; Wwp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098786 CVCL_QD52 BayGenomics ES cell line XL742 embryonic stem cell house mouse CVCL_QD52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098787 CVCL_QD53 BayGenomics ES cell line XL772 embryonic stem cell house mouse CVCL_QD53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918667; Gpatch8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098788 CVCL_QD54 BayGenomics ES cell line XL783 embryonic stem cell house mouse CVCL_QD54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918457; Nudt4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098789 CVCL_QD55 BayGenomics ES cell line XL784 embryonic stem cell house mouse CVCL_QD55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147870; Lrch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098790 CVCL_QD56 BayGenomics ES cell line XL785 embryonic stem cell house mouse CVCL_QD56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098791 CVCL_QD57 BayGenomics ES cell line XL788 embryonic stem cell house mouse CVCL_QD57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098792 CVCL_QD58 BayGenomics ES cell line XL791 embryonic stem cell house mouse CVCL_QD58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925976; Scaper Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098793 CVCL_QD59 BayGenomics ES cell line XL794 embryonic stem cell house mouse CVCL_QD59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915963; Ifitm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098794 CVCL_QD40 BayGenomics ES cell line XL543 embryonic stem cell house mouse CVCL_QD40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145099; Mis18bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098795 CVCL_QD41 BayGenomics ES cell line XL544 embryonic stem cell house mouse CVCL_QD41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098796 CVCL_QD42 BayGenomics ES cell line XL545 embryonic stem cell house mouse CVCL_QD42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316717; Ifrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098797 CVCL_QD43 BayGenomics ES cell line XL571 embryonic stem cell house mouse CVCL_QD43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141867; Inpp5f Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098798 CVCL_QD44 BayGenomics ES cell line XL573 embryonic stem cell house mouse CVCL_QD44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891840; Ncbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098799 CVCL_QD45 BayGenomics ES cell line XL575 embryonic stem cell house mouse CVCL_QD45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446526; Cpt1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098800 CVCL_QD46 BayGenomics ES cell line XL577 embryonic stem cell house mouse CVCL_QD46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923497; Inka2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098801 CVCL_QD47 BayGenomics ES cell line XL629 embryonic stem cell house mouse CVCL_QD47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098802 CVCL_QD48 BayGenomics ES cell line XL635 embryonic stem cell house mouse CVCL_QD48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098803 CVCL_QD49 BayGenomics ES cell line XL637 embryonic stem cell house mouse CVCL_QD49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919283; Tsc22d2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21098804 CVCL_6W80 DA01564 transformed cell line human CVCL_6W80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098805 CVCL_7880 WEGLI-9 hybrid cell line CVCL_7880 CL:0000010 21098806 CVCL_6W81 DA01565 transformed cell line human CVCL_6W81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098807 CVCL_7881 WERC spontaneously immortalized cell line Norway rat CVCL_7881 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: Wistar. Unspecified 21098808 CVCL_6W82 DA01566 transformed cell line human CVCL_6W82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098809 CVCL_7882 LX830 cancer cell line house mouse CVCL_7882 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21098810 CVCL_6W83 DA01567 transformed cell line human CVCL_6W83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098811 CVCL_7883 NCC-BD1 cancer cell line human CVCL_7883 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (PubMed=20088962); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Ser (c.457C>T); ClinVar=VCV000422563; Zygosity=Unspecified (PubMed=20088962); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Unspecified (PubMed=20088962); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Unspecified (PubMed=20088962) Population: Japanese; Derived from sampling site: Bile duct. Female 21098812 CVCL_6W77 DA01561 transformed cell line human CVCL_6W77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098813 CVCL_7877 WEGLI-20 hybrid cell line CVCL_7877 CL:0000010 21098814 CVCL_6W78 DA01562 transformed cell line human CVCL_6W78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098815 CVCL_7878 WEGLI-22 hybrid cell line CVCL_7878 CL:0000010 21098816 CVCL_6W79 DA01563 transformed cell line human CVCL_6W79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098817 CVCL_7879 WEGLI-3 hybrid cell line CVCL_7879 CL:0000010 21098818 CVCL_6W73 DA01554 transformed cell line human CVCL_6W73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098819 CVCL_7873 WEGLI-11 hybrid cell line CVCL_7873 CL:0000010 21098820 CVCL_6W74 DA01555 transformed cell line human CVCL_6W74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098821 CVCL_7874 WEGLI-13 hybrid cell line CVCL_7874 CL:0000010 21098822 CVCL_6W75 DA01556 transformed cell line human CVCL_6W75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098823 CVCL_7875 WEGLI-16 hybrid cell line CVCL_7875 CL:0000010 21098824 CVCL_6W76 DA01559 transformed cell line human CVCL_6W76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098825 CVCL_7876 WEGLI-18 hybrid cell line CVCL_7876 CL:0000010 21098826 CVCL_6W91 DA01577 transformed cell line human CVCL_6W91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098827 CVCL_7891 S180-NCC-TC cancer cell line house mouse CVCL_7891 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21098828 CVCL_7892 2D9 [Human glioblastoma] cancer cell line human CVCL_7892 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male 21098829 CVCL_6W92 DA01578 transformed cell line human CVCL_6W92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098830 CVCL_6W93 DA01579 transformed cell line human CVCL_6W93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01579; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098831 CVCL_7893 DS1 [Tursiops] finite cell line CVCL_7893 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21098832 CVCL_6W94 DA01580 transformed cell line human CVCL_6W94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01580; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098833 CVCL_7894 DS2 finite cell line CVCL_7894 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21098834 CVCL_6W90 DA01575 transformed cell line human CVCL_6W90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098835 CVCL_7890 S180-Meiji-TC cancer cell line house mouse CVCL_7890 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21098836 CVCL_6W88 DA01573 transformed cell line human CVCL_6W88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098837 CVCL_7888 NCC-CC4-1 cancer cell line human CVCL_7888 CL:0000010 Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Male 21098838 CVCL_6W89 DA01574 transformed cell line human CVCL_6W89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098839 CVCL_7889 S180-Kumamoto-TC cancer cell line house mouse CVCL_7889 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21098840 CVCL_6W84 DA01568 transformed cell line human CVCL_6W84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098841 CVCL_7884 NCC-BD2 cancer cell line human CVCL_7884 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=20088962) Population: Japanese; Derived from sampling site: Bile duct. Female 21098842 CVCL_6W85 DA01569 transformed cell line human CVCL_6W85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098843 CVCL_7885 NCC-CC1 cancer cell line human CVCL_7885 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=20088962); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=20088962) Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Female 21098844 CVCL_6W86 DA01570 transformed cell line human CVCL_6W86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098845 CVCL_7886 NCC-CC3-1 cancer cell line human CVCL_7886 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20088962). Population: Japanese Female 21098846 CVCL_6W87 DA01571 transformed cell line human CVCL_6W87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098847 CVCL_7887 NCC-CC3-2 cancer cell line human CVCL_7887 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20088962) Population: Japanese; Derived from sampling site: Liver; intrahepatic bile duct. Female 21098848 CVCL_6W60 DA01537 transformed cell line human CVCL_6W60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098849 CVCL_7860 UT-SCC-51 cancer cell line human CVCL_7860 CL:0000010 Male 21098850 CVCL_6W61 DA01538 transformed cell line human CVCL_6W61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01538; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098851 CVCL_7861 UT-SCC-52 cancer cell line human CVCL_7861 CL:0000010 Male 21098852 CVCL_6W55 DA01530 transformed cell line human CVCL_6W55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01530; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098853 CVCL_7855 UT-SCC-47 cancer cell line human CVCL_7855 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Gly (c.653T>G); ClinVar=VCV000528249; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Oral cavity; floor of mouth. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098854 CVCL_6W56 DA01531 transformed cell line human CVCL_6W56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098855 CVCL_7856 UT-SCC-48 cancer cell line human CVCL_7856 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Male 21098856 CVCL_6W57 DA01532 transformed cell line human CVCL_6W57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098857 CVCL_7857 UT-SCC-49 cancer cell line human CVCL_7857 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Homozygous (PubMed=29970484; PubMed=33802339) Derived from sampling site: Larynx. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098858 CVCL_6W58 DA01533 transformed cell line human CVCL_6W58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098859 CVCL_7858 UT-SCC-5 cancer cell line human CVCL_7858 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly111Leufs*28 (c.331_352del); Zygosity=Unspecified (PubMed=33802339); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=33802339) Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by microarray Male 21098860 CVCL_6W51 DA01526 transformed cell line human CVCL_6W51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01526; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098861 CVCL_7851 UT-SCC-44 cancer cell line human CVCL_7851 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21098862 CVCL_6W52 DA01527 transformed cell line human CVCL_6W52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098863 CVCL_7852 UT-SCC-45 cancer cell line human CVCL_7852 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly72Arg (c.214G>A); Zygosity=Homozygous (PubMed=31541927) Transformant: Human papillomavirus type 33 (HPV33)(NCBI-Taxonomy; 10586); Derived from sampling site: Oral cavity; floor of mouth. Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Doubling time: 1.3 days (PubMed=29156801) 21098864 CVCL_6W53 DA01528 transformed cell line human CVCL_6W53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01528; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098865 CVCL_7853 UT-SCC-46A cancer cell line human CVCL_7853 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis Male 21098866 CVCL_6W54 DA01529 transformed cell line human CVCL_6W54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01529; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098867 CVCL_7854 UT-SCC-46B cancer cell line human CVCL_7854 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Male 21098868 CVCL_6W59 DA01536 transformed cell line human CVCL_6W59 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098869 CVCL_7859 UT-SCC-50 cancer cell line human CVCL_7859 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920del73; Zygosity=Unspecified (PubMed=18487078) Omics: miRNA expression profiling. Male 21098870 CVCL_6W70 DA01550 transformed cell line human CVCL_6W70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01550; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098871 CVCL_7870 UT-SCC-9 cancer cell line human CVCL_7870 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=8782485; PubMed=33802339) Derived from sampling site: Larynx; glottis. Omics: miRNA expression profiling Male 21098872 CVCL_6W71 DA01551 transformed cell line human CVCL_6W71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098873 CVCL_7871 UTHs transformed cell line human CVCL_7871 CL:0000010 Population: Caucasian; Swedish; Transformant: Human herpesvirus 1 (HHV-1)(NCBI-Taxonomy; 10298); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21098874 CVCL_6W72 DA01552 transformed cell line human CVCL_6W72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098875 CVCL_7872 W6/32 hybridoma house mouse CVCL_7872 CL:0000010 Omics: HLA class I peptidome analysis by proteomics. Monoclonal antibody isotype: IgG2a 21098876 CVCL_6W66 DA01546 transformed cell line human CVCL_6W66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098877 CVCL_7866 UT-SCC-6A cancer cell line human CVCL_7866 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (PubMed=29970484); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (PubMed=29970484) Derived from sampling site: Larynx; supraglottis. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21098878 CVCL_6W67 DA01547 transformed cell line human CVCL_6W67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01547; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098879 CVCL_7867 UT-SCC-6B cancer cell line human CVCL_7867 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8782485) Derived from metastatic site: Cervical lymph node. Female 21098880 CVCL_6W68 DA01548 transformed cell line human CVCL_6W68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01548; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098881 CVCL_7868 UT-SCC-7 cancer cell line human CVCL_7868 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (PubMed=8782485) Derived from metastatic site: Temple; skin. Male 21098882 CVCL_6W69 DA01549 transformed cell line human CVCL_6W69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098883 CVCL_7869 UT-SCC-8 cancer cell line human CVCL_7869 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Phe (c.763A>T); ClinVar=VCV000376621; Zygosity=Unspecified (PubMed=8782485; PubMed=33802339) Derived from sampling site: Larynx; supraglottis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098884 CVCL_6W62 DA01542 transformed cell line human CVCL_6W62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01542; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098885 CVCL_7862 UT-SCC-53 cancer cell line human CVCL_7862 CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098886 CVCL_6W63 DA01543 transformed cell line human CVCL_6W63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098887 CVCL_7863 UT-SCC-54A cancer cell line human CVCL_7863 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=15287027) Derived from sampling site: Oral cavity; buccal mucosa. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Caution: UT-SCC-54A, UT-SCC-54B and UT-SCC-54C are supposed to originate from the same patient but the STR profile of UT-SCC-54C is totally different from that of the two other cell lines 21098888 CVCL_6W64 DA01544 transformed cell line human CVCL_6W64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098889 CVCL_7864 UT-SCC-54B cancer cell line human CVCL_7864 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=15287027) Derived from sampling site: Oral cavity; buccal mucosa. Omics: Deep exome analysis Female Caution: UT-SCC-54A, UT-SCC-54B and UT-SCC-54C are supposed to originate from the same patient but the STR profile of UT-SCC-54C is totally different from that of the two other cell lines 21098890 CVCL_6W65 DA01545 transformed cell line human CVCL_6W65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098891 CVCL_7865 UT-SCC-55 cancer cell line human CVCL_7865 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098892 CVCL_6W33 DA01506 transformed cell line human CVCL_6W33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098893 CVCL_7833 UT-SCC-29 cancer cell line human CVCL_7833 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (PubMed=29970484; PubMed=33802339) Derived from sampling site: Larynx; glottis. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21098894 CVCL_6W34 DA01507 transformed cell line human CVCL_6W34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098895 CVCL_7834 UT-SCC-30 cancer cell line human CVCL_7834 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Pro (c.845G>C); ClinVar=VCV000376659; Zygosity=Homozygous (PubMed=8725545; PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21098896 CVCL_6W35 DA01508 transformed cell line human CVCL_6W35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098897 CVCL_7835 UT-SCC-31 cancer cell line human CVCL_7835 CL:0000010 Male 21098898 CVCL_6W36 DA01509 transformed cell line human CVCL_6W36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098899 CVCL_7836 UT-SCC-32 cancer cell line human CVCL_7836 CL:0000010 Male 21098900 CVCL_6W30 DA01501 transformed cell line human CVCL_6W30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098901 CVCL_7830 UT-SCC-26B cancer cell line human CVCL_7830 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21098902 CVCL_6W31 DA01503 transformed cell line human CVCL_6W31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098903 CVCL_7831 UT-SCC-27 cancer cell line human CVCL_7831 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098904 CVCL_6W32 DA01504 transformed cell line human CVCL_6W32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098905 CVCL_7832 UT-SCC-28 cancer cell line human CVCL_7832 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21098906 CVCL_6W37 DA01510 transformed cell line human CVCL_6W37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098907 CVCL_7837 UT-SCC-33 cancer cell line human CVCL_7837 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=11799138; PubMed=18487078). Female 21098908 CVCL_6W38 DA01511 transformed cell line human CVCL_6W38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098909 CVCL_7838 UT-SCC-34 cancer cell line human CVCL_7838 CL:0000010 Derived from sampling site: Larynx. Omics: Array-based CGH; Omics: miRNA expression profiling Male 21098910 CVCL_6W39 DA01512 transformed cell line human CVCL_6W39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098911 CVCL_7839 UT-SCC-35 cancer cell line human CVCL_7839 CL:0000010 Male 21098912 CVCL_6W50 DA01525 transformed cell line human CVCL_6W50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01525; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098913 CVCL_7850 UT-SCC-43B cancer cell line human CVCL_7850 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=15287027) Derived from sampling site: Oral cavity; gingiva. Female 21098914 CVCL_6W44 DA01518 transformed cell line human CVCL_6W44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098915 CVCL_7844 UT-SCC-4 cancer cell line human CVCL_7844 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248_Pro250del (c.742_750del9); Zygosity=Unspecified (PubMed=8782485) Derived from sampling site: Larynx. Omics: miRNA expression profiling Female 21098916 CVCL_6W45 DA01519 transformed cell line human CVCL_6W45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01519; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098917 CVCL_7845 UT-SCC-40 cancer cell line human CVCL_7845 CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098918 CVCL_6W46 DA01520 transformed cell line human CVCL_6W46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098919 CVCL_7846 UT-SCC-41 cancer cell line human CVCL_7846 CL:0000010 Male 21098920 CVCL_6W47 DA01522 transformed cell line human CVCL_6W47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098921 CVCL_7847 UT-SCC-42A cancer cell line human CVCL_7847 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (PubMed=15287027; PubMed=29970484) Derived from sampling site: Larynx; supraglottis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21098922 CVCL_6W40 DA01513 transformed cell line human CVCL_6W40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098923 CVCL_7840 UT-SCC-36 cancer cell line human CVCL_7840 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Oral cavity; floor of mouth. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098924 CVCL_6W41 DA01514 transformed cell line human CVCL_6W41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098925 CVCL_7841 UT-SCC-37 cancer cell line human CVCL_7841 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Argfs (c.216_217insCCCC); Zygosity=Heterozygous (PubMed=29970484) Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21098926 CVCL_6W42 DA01515 transformed cell line human CVCL_6W42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098927 CVCL_7842 UT-SCC-38 cancer cell line human CVCL_7842 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=33802339); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+5G>A; ClinVar=VCV000481015; Zygosity=Unspecified (PubMed=33802339) Derived from sampling site: Larynx; glottis. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21098928 CVCL_6W43 DA01516 transformed cell line human CVCL_6W43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098929 CVCL_7843 UT-SCC-39 cancer cell line human CVCL_7843 CL:0000010 Male 21098930 CVCL_6W48 DA01523 transformed cell line human CVCL_6W48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098931 CVCL_7848 UT-SCC-42B cancer cell line human CVCL_7848 CL:0000010 Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis Male 21098932 CVCL_6W49 DA01524 transformed cell line human CVCL_6W49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098933 CVCL_7849 UT-SCC-43A cancer cell line human CVCL_7849 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21098934 CVCL_6W11 DA01482 transformed cell line human CVCL_6W11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098935 CVCL_7811 UT-SCC-15 cancer cell line human CVCL_7811 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=33802339) Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by microarray Male 21098936 CVCL_6W12 DA01483 transformed cell line human CVCL_6W12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098937 CVCL_7812 UT-SCC-16A cancer cell line human CVCL_7812 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (PubMed=8725545; PubMed=8782485; PubMed=11799138; PubMed=15287027; PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Caution: UT-SCC-16A and UT-SCC-16B are supposed to originate from the same patient but have totally different STR profiles 21098938 CVCL_6W13 DA01484 transformed cell line human CVCL_6W13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098939 CVCL_7813 UT-SCC-16B cancer cell line human CVCL_7813 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485; PubMed=15287027); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485; PubMed=15287027) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis Female Caution: UT-SCC-16A and UT-SCC-16B are supposed to originate from the same patient but have totally different STR profiles 21098940 CVCL_6W14 DA01485 transformed cell line human CVCL_6W14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01485; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098941 CVCL_7814 UT-SCC-17 cancer cell line human CVCL_7814 CL:0000010 Omics: miRNA expression profiling. Male 21098942 CVCL_6W10 DA01481 transformed cell line human CVCL_6W10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01481; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098943 CVCL_7810 UT-SCC-14 cancer cell line human CVCL_7810 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Val (c.157A>G) (p.Asp67Gly, c.200A>G); ClinVar=VCV001467708; Zygosity=Homozygous (PubMed=18487078; PubMed=29970484); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>C (IVS8+1G>C); ClinVar=VCV000428905; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29970484) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098944 CVCL_6W19 DA01490 transformed cell line human CVCL_6W19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098945 CVCL_7819 UT-SCC-1B cancer cell line human CVCL_7819 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485) Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis Female 21098946 CVCL_6W15 DA01486 transformed cell line human CVCL_6W15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098947 CVCL_7815 UT-SCC-18 cancer cell line human CVCL_7815 CL:0000010 Male 21098948 CVCL_6W16 DA01487 transformed cell line human CVCL_6W16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098949 CVCL_7816 UT-SCC-19A cancer cell line human CVCL_7816 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=8782485; PubMed=15287027; PubMed=33802339) Derived from sampling site: Larynx; glottis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21098950 CVCL_6W17 DA01488 transformed cell line human CVCL_6W17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098951 CVCL_7817 UT-SCC-19B cancer cell line human CVCL_7817 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=8782485; PubMed=15287027) Derived from sampling site: Larynx; glottis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling Male 21098952 CVCL_6W18 DA01489 transformed cell line human CVCL_6W18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098953 CVCL_7818 UT-SCC-1A cancer cell line human CVCL_7818 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=8725545; PubMed=8782485) Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis Female 21098954 CVCL_6W22 DA01493 transformed cell line human CVCL_6W22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098955 CVCL_7822 UT-SCC-20B cancer cell line human CVCL_7822 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8725545; PubMed=15287027) Derived from sampling site: Oral cavity; floor of mouth. Female 21098956 CVCL_6W23 DA01494 transformed cell line human CVCL_6W23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098957 CVCL_7823 UT-SCC-21 cancer cell line human CVCL_7823 CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098958 CVCL_6W24 DA01495 transformed cell line human CVCL_6W24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098959 CVCL_7824 UT-SCC-22 cancer cell line human CVCL_7824 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Phe (c.713G>T); ClinVar=VCV000376574; Zygosity=Unspecified (PubMed=18487078) Omics: miRNA expression profiling. Male 21098960 CVCL_6W25 DA01496 transformed cell line human CVCL_6W25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098961 CVCL_7825 UT-SCC-23 cancer cell line human CVCL_7825 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078) Omics: miRNA expression profiling. Male 21098962 CVCL_6W20 DA01491 transformed cell line human CVCL_6W20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098963 CVCL_7820 UT-SCC-2 cancer cell line human CVCL_7820 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Homozygous (PubMed=8725545; PubMed=8782485; PubMed=29970484) Derived from sampling site: Oral cavity; floor of mouth. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21098964 CVCL_6W21 DA01492 transformed cell line human CVCL_6W21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098965 CVCL_7821 UT-SCC-20A cancer cell line human CVCL_7821 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8725545; PubMed=15287027) Derived from sampling site: Oral cavity; floor of mouth. Female 21098966 CVCL_6W26 DA01497 transformed cell line human CVCL_6W26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098967 CVCL_7826 UT-SCC-24A cancer cell line human CVCL_7826 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16203773; PubMed=29970484; PubMed=33802339) Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21098968 CVCL_6W27 DA01498 transformed cell line human CVCL_6W27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01498; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098969 CVCL_7827 UT-SCC-24B cancer cell line human CVCL_7827 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=11799138) Derived from metastatic site: Cervical lymph node. Male 21098970 CVCL_6W28 DA01499 transformed cell line human CVCL_6W28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098971 CVCL_7828 UT-SCC-25 cancer cell line human CVCL_7828 CL:0000010 Male 21098972 CVCL_6W29 DA01500 transformed cell line human CVCL_6W29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098973 CVCL_7829 UT-SCC-26A cancer cell line human CVCL_7829 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Unspecified (PubMed=16203773) Derived from metastatic site: Cervical lymph node. Male 21098974 CVCL_HJ07 CW60027 induced pluripotent stem cell human CVCL_HJ07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60027; true Male 21098975 CVCL_HJ08 CW60104 induced pluripotent stem cell human CVCL_HJ08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60104; true Male 21098976 CVCL_HJ09 CW60125 induced pluripotent stem cell human CVCL_HJ09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60125; true Female 21098977 CVCL_HJ03 CW50152 induced pluripotent stem cell human CVCL_HJ03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50152; true Male 21098978 CVCL_HJ04 CW50153 induced pluripotent stem cell human CVCL_HJ04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50153; true Female 21098979 CVCL_HJ05 CW50158 induced pluripotent stem cell human CVCL_HJ05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50158; true Male 21098980 CVCL_HJ06 CW60015 induced pluripotent stem cell human CVCL_HJ06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60015; true Female 21098981 CVCL_HJ00 CW50148 induced pluripotent stem cell human CVCL_HJ00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50148; true Female 21098982 CVCL_HJ01 CW50149 induced pluripotent stem cell human CVCL_HJ01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50149; true Male 21098983 CVCL_HJ02 CW50150 induced pluripotent stem cell human CVCL_HJ02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50150; true Female 21098984 CVCL_HJ18 CW60320 induced pluripotent stem cell human CVCL_HJ18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60320; true Male 21098985 CVCL_HJ19 CW60383 induced pluripotent stem cell human CVCL_HJ19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60383; true Female 21098986 CVCL_HJ14 CW60172 induced pluripotent stem cell human CVCL_HJ14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60172; true Male 21098987 CVCL_HJ15 CW60201 induced pluripotent stem cell human CVCL_HJ15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60201; true Female 21098988 CVCL_HJ16 CW60210 induced pluripotent stem cell human CVCL_HJ16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60210; true Male 21098989 CVCL_HJ17 CW60223 induced pluripotent stem cell human CVCL_HJ17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60223; true Male 21098990 CVCL_HJ10 CW60131 induced pluripotent stem cell human CVCL_HJ10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60131; true Male 21098991 CVCL_HJ11 CW60138 induced pluripotent stem cell human CVCL_HJ11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60138; true Female 21098992 CVCL_HJ12 CW60155 induced pluripotent stem cell human CVCL_HJ12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60155; true Female 21098993 CVCL_HJ13 CW60159 induced pluripotent stem cell human CVCL_HJ13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60159; true Male 21098994 CVCL_6V96 DA01467 transformed cell line human CVCL_6V96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098995 CVCL_7796 UM-SCC-92 cancer cell line human CVCL_7796 CL:0000010 Omics: CNV analysis. Female 21098996 CVCL_6V97 DA01468 transformed cell line human CVCL_6V97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098997 CVCL_7797 UM-SCC-93 cancer cell line human CVCL_7797 CL:0000010 Female 21098998 CVCL_6V98 DA01469 transformed cell line human CVCL_6V98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21098999 CVCL_7798 UM-SCC-94 cancer cell line human CVCL_7798 CL:0000010 Male 21099000 CVCL_6V99 DA01470 transformed cell line human CVCL_6V99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099001 CVCL_7799 UM-SCC-95 cancer cell line human CVCL_7799 CL:0000010 Male 21099002 CVCL_6V81 DA01452 transformed cell line human CVCL_6V81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099003 CVCL_7781 UM-SCC-8 cancer cell line human CVCL_7781 CL:0000010 Omics: CNV analysis; Omics: Protein expression by reverse-phase protein arrays. Female Part of: MD Anderson Cell Lines Project 21099004 CVCL_6V82 DA01453 transformed cell line human CVCL_6V82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099005 CVCL_7782 UM-SCC-80 cancer cell line human CVCL_7782 CL:0000010 Male 21099006 CVCL_6V83 DA01454 transformed cell line human CVCL_6V83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099007 CVCL_7783 UM-SCC-81A cancer cell line human CVCL_7783 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21099008 CVCL_6V84 DA01455 transformed cell line human CVCL_6V84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099009 CVCL_7784 UM-SCC-81B cancer cell line human CVCL_7784 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=12884349; PubMed=15287027) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21099010 CVCL_6V80 DA01451 transformed cell line human CVCL_6V80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099011 CVCL_7780 UM-SCC-74B cancer cell line human CVCL_7780 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349). Male 21099012 CVCL_6V78 DA01449 transformed cell line human CVCL_6V78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099013 CVCL_7778 UM-SCC-73B cancer cell line human CVCL_7778 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21099014 CVCL_6V79 DA01450 transformed cell line human CVCL_6V79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099015 CVCL_7779 UM-SCC-74A cancer cell line human CVCL_7779 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349) Omics: Protein expression by reverse-phase protein arrays. Male Part of: MD Anderson Cell Lines Project 21099016 CVCL_6V74 DA01445 transformed cell line human CVCL_6V74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099017 CVCL_7774 UM-SCC-60 cancer cell line human CVCL_7774 CL:0000010 Derived from sampling site: Pharynx; hypopharynx. Male 21099018 CVCL_6V75 DA01446 transformed cell line human CVCL_6V75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099019 CVCL_7775 UM-SCC-69 cancer cell line human CVCL_7775 CL:0000010 Omics: CNV analysis. Male 21099020 CVCL_6V76 DA01447 transformed cell line human CVCL_6V76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099021 CVCL_7776 UM-SCC-7 cancer cell line human CVCL_7776 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Male Part of: MD Anderson Cell Lines Project 21099022 CVCL_6V77 DA01448 transformed cell line human CVCL_6V77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099023 CVCL_7777 UM-SCC-70 cancer cell line human CVCL_7777 CL:0000010 Male 21099024 CVCL_6V92 DA01463 transformed cell line human CVCL_6V92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099025 CVCL_7792 UM-SCC-89 cancer cell line human CVCL_7792 CL:0000010 Male 21099026 CVCL_6V93 DA01464 transformed cell line human CVCL_6V93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01464; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099027 CVCL_7793 UM-SCC-9 cancer cell line human CVCL_7793 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18006756) Derived from metastatic site: Lymph node. Female Caution: Indicated as originating from a 74 year old patient in PubMed=3855324 and from a 72 year old in PubMed=18006756 21099028 CVCL_6V94 DA01465 transformed cell line human CVCL_6V94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099029 CVCL_7794 UM-SCC-90 cancer cell line human CVCL_7794 CL:0000010 Male 21099030 CVCL_6V95 DA01466 transformed cell line human CVCL_6V95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099031 CVCL_7795 UM-SCC-91 cancer cell line human CVCL_7795 CL:0000010 Male 21099032 CVCL_6V90 DA01461 transformed cell line human CVCL_6V90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099033 CVCL_7790 UM-SCC-87 cancer cell line human CVCL_7790 CL:0000010 Male 21099034 CVCL_6V91 DA01462 transformed cell line human CVCL_6V91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01462; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099035 CVCL_7791 UM-SCC-88 cancer cell line human CVCL_7791 CL:0000010 Female 21099036 CVCL_6V89 DA01460 transformed cell line human CVCL_6V89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099037 CVCL_7789 UM-SCC-86 cancer cell line human CVCL_7789 CL:0000010 Female 21099038 CVCL_6V85 DA01456 transformed cell line human CVCL_6V85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01456; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099039 CVCL_7785 UM-SCC-83A cancer cell line human CVCL_7785 CL:0000010 Male 21099040 CVCL_6V86 DA01457 transformed cell line human CVCL_6V86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099041 CVCL_7786 UM-SCC-83B cancer cell line human CVCL_7786 CL:0000010 Male 21099042 CVCL_6V87 DA01458 transformed cell line human CVCL_6V87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099043 CVCL_7787 UM-SCC-84 cancer cell line human CVCL_7787 CL:0000010 Male 21099044 CVCL_6V88 DA01459 transformed cell line human CVCL_6V88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099045 CVCL_7788 UM-SCC-85 cancer cell line human CVCL_7788 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male 21099046 CVCL_HJ90 GM16649 transformed cell line human CVCL_HJ90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099047 CVCL_HJ91 GM16650 finite cell line human CVCL_HJ91 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099048 CVCL_HJ92 GM16651 transformed cell line human CVCL_HJ92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099049 CVCL_HJ93 GM16652 finite cell line human CVCL_HJ93 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099050 CVCL_QD30 BayGenomics ES cell line XL512 embryonic stem cell house mouse CVCL_QD30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351500; Nup62 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099051 CVCL_QD31 BayGenomics ES cell line XL515 embryonic stem cell house mouse CVCL_QD31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2674092; Zfp609 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099052 CVCL_QD32 BayGenomics ES cell line XL516 embryonic stem cell house mouse CVCL_QD32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099053 CVCL_QD33 BayGenomics ES cell line XL525 embryonic stem cell house mouse CVCL_QD33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101919; Ap1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099054 CVCL_QD34 BayGenomics ES cell line XL526 embryonic stem cell house mouse CVCL_QD34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099055 CVCL_QD35 BayGenomics ES cell line XL528 embryonic stem cell house mouse CVCL_QD35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099056 CVCL_HJ87 GM16646 transformed cell line human CVCL_HJ87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099057 CVCL_QD36 BayGenomics ES cell line XL529 embryonic stem cell house mouse CVCL_QD36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919449; Mms19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099058 CVCL_HJ88 GM16647 transformed cell line human CVCL_HJ88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099059 CVCL_QD37 BayGenomics ES cell line XL530 embryonic stem cell house mouse CVCL_QD37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444266; Ube2o Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099060 CVCL_HJ89 GM16648 finite cell line human CVCL_HJ89 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099061 CVCL_QD38 BayGenomics ES cell line XL531 embryonic stem cell house mouse CVCL_QD38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099062 CVCL_QD39 BayGenomics ES cell line XL541 embryonic stem cell house mouse CVCL_QD39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429770; Nle1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099063 CVCL_HJ83 GM17429 transformed cell line human CVCL_HJ83 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099064 CVCL_HJ84 GM17464 transformed cell line human CVCL_HJ84 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21099065 CVCL_HJ85 GM17468 transformed cell line human CVCL_HJ85 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21099066 CVCL_HJ86 GM16645 transformed cell line human CVCL_HJ86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099067 CVCL_QD20 BayGenomics ES cell line XL166 embryonic stem cell house mouse CVCL_QD20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95481; Ptk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099068 CVCL_QD21 BayGenomics ES cell line XL167 embryonic stem cell house mouse CVCL_QD21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099069 CVCL_QD22 BayGenomics ES cell line XL169 embryonic stem cell house mouse CVCL_QD22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098824; Odf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099070 CVCL_QD23 BayGenomics ES cell line XL179 embryonic stem cell house mouse CVCL_QD23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443816; Snx8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099071 CVCL_QD24 BayGenomics ES cell line XL236 embryonic stem cell house mouse CVCL_QD24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137738; Prcc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099072 CVCL_HJ98 GM17784 transformed cell line human CVCL_HJ98 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21099073 CVCL_QD25 BayGenomics ES cell line XL240 embryonic stem cell house mouse CVCL_QD25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919451; Otud6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099074 CVCL_HJ99 GM18787 transformed cell line human CVCL_HJ99 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099075 CVCL_QD26 BayGenomics ES cell line XL241 embryonic stem cell house mouse CVCL_QD26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099076 CVCL_QD27 BayGenomics ES cell line XL243 embryonic stem cell house mouse CVCL_QD27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099077 CVCL_QD28 BayGenomics ES cell line XL244 embryonic stem cell house mouse CVCL_QD28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917275; Acot7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099078 CVCL_HJ94 GM17652 transformed cell line human CVCL_HJ94 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21099079 CVCL_QD29 BayGenomics ES cell line XL275 embryonic stem cell house mouse CVCL_QD29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108109; Ywhag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099080 CVCL_HJ95 GM17675 transformed cell line human CVCL_HJ95 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21099081 CVCL_HJ96 GM17694 transformed cell line human CVCL_HJ96 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21099082 CVCL_HJ97 GM17714 transformed cell line human CVCL_HJ97 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21099083 CVCL_HJ70 AG21236 somatic stem cell Norway rat CVCL_HJ70 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099084 CVCL_HJ71 AG21240 somatic stem cell Norway rat CVCL_HJ71 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099085 CVCL_HJ69 AG21232 somatic stem cell Norway rat CVCL_HJ69 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099086 CVCL_QD10 BayGenomics ES cell line XL080 embryonic stem cell house mouse CVCL_QD10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099087 CVCL_QD11 BayGenomics ES cell line XL083 embryonic stem cell house mouse CVCL_QD11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346035; Farsb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099088 CVCL_QD12 BayGenomics ES cell line XL087 embryonic stem cell house mouse CVCL_QD12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309528; Ppp1r12a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099089 CVCL_HJ65 AG21200 somatic stem cell Norway rat CVCL_HJ65 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099090 CVCL_QD13 BayGenomics ES cell line XL088 embryonic stem cell house mouse CVCL_QD13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309528; Ppp1r12a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099091 CVCL_HJ66 AG21204 somatic stem cell Norway rat CVCL_HJ66 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099092 CVCL_QD14 BayGenomics ES cell line XL140 embryonic stem cell house mouse CVCL_QD14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915560; Zmym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099093 CVCL_HJ67 AG21208 somatic stem cell Norway rat CVCL_HJ67 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099094 CVCL_QD15 BayGenomics ES cell line XL142 embryonic stem cell house mouse CVCL_QD15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929472; Uqcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099095 CVCL_HJ68 AG21212 somatic stem cell Norway rat CVCL_HJ68 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099096 CVCL_QD16 BayGenomics ES cell line XL144 embryonic stem cell house mouse CVCL_QD16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918667; Gpatch8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099097 CVCL_HJ61 AG23140 somatic stem cell house mouse CVCL_HJ61 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21099098 CVCL_QD17 BayGenomics ES cell line XL154 embryonic stem cell house mouse CVCL_QD17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099099 CVCL_HJ62 AG23144 somatic stem cell house mouse CVCL_HJ62 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21099100 CVCL_QD18 BayGenomics ES cell line XL162 embryonic stem cell house mouse CVCL_QD18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105089; Hsd17b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099101 CVCL_HJ63 AG22292 somatic stem cell house mouse CVCL_HJ63 CL:0000010 Derived from sampling site: Omentum; skin; adipose tissue Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Male Senescence: Senesces at 14 PDL (Coriell=AG22292) 21099102 CVCL_QD19 BayGenomics ES cell line XL165 embryonic stem cell house mouse CVCL_QD19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917129; Golph3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099103 CVCL_HJ64 AG21196 somatic stem cell Norway rat CVCL_HJ64 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099104 CVCL_HJ80 GM13304 transformed cell line human CVCL_HJ80 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp516Ter (c.1548G>A); ClinVar=VCV000189025; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099105 CVCL_HJ81 GM13891 transformed cell line human CVCL_HJ81 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099106 CVCL_HJ82 XPH298BE LCL transformed cell line human CVCL_HJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099107 CVCL_QD00 BayGenomics ES cell line XL065 embryonic stem cell house mouse CVCL_QD00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099108 CVCL_QD01 BayGenomics ES cell line XL066 embryonic stem cell house mouse CVCL_QD01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914750; Ccar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099109 CVCL_QD02 BayGenomics ES cell line XL067 embryonic stem cell house mouse CVCL_QD02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306778; Map1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099110 CVCL_HJ76 GM08878 transformed cell line human CVCL_HJ76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099111 CVCL_QD03 BayGenomics ES cell line XL068 embryonic stem cell house mouse CVCL_QD03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099112 CVCL_HJ77 GM10508 transformed cell line human CVCL_HJ77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099113 CVCL_QD04 BayGenomics ES cell line XL069 embryonic stem cell house mouse CVCL_QD04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780541; Lncenc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099114 CVCL_HJ78 GM10702 transformed cell line human CVCL_HJ78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099115 CVCL_QD05 BayGenomics ES cell line XL073 embryonic stem cell house mouse CVCL_QD05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099116 CVCL_HJ79 GM11052 transformed cell line human CVCL_HJ79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099117 CVCL_HJ72 AG21244 somatic stem cell Norway rat CVCL_HJ72 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099118 CVCL_QD06 BayGenomics ES cell line XL074 embryonic stem cell house mouse CVCL_QD06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099119 CVCL_HJ73 AG21271 somatic stem cell Norway rat CVCL_HJ73 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Fischer 344. Male 21099120 CVCL_QD07 BayGenomics ES cell line XL075 embryonic stem cell house mouse CVCL_QD07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917606; St13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099121 CVCL_QD08 BayGenomics ES cell line XL078 embryonic stem cell house mouse CVCL_QD08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099122 CVCL_HJ74 GM11776 transformed cell line human CVCL_HJ74 CL:0000010 Anecdotal: Part of a set of 5 cell lines that were established from blood samples of members of the Huaorani (Waorani) indigenous people These samples were allegedly taken without the Ecuadorian government's permission during the early 1990s. Population: Native South American; Huaorani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11776; true Male 21099123 CVCL_QD09 BayGenomics ES cell line XL079 embryonic stem cell house mouse CVCL_QD09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099124 CVCL_HJ75 GM04726 transformed cell line human CVCL_HJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21099125 CVCL_HJ47 CW70086 induced pluripotent stem cell human CVCL_HJ47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70086; true Male 21099126 CVCL_HJ48 S033665 finite cell line CVCL_HJ48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S033665; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21099127 CVCL_HJ49 AG22349 somatic stem cell CVCL_HJ49 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Subgriseus; stock PO. Female 21099128 CVCL_HJ43 CW70370 induced pluripotent stem cell human CVCL_HJ43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70370; true Male 21099129 CVCL_HJ44 9HTEo-/Dx transformed cell line human CVCL_HJ44 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Male 21099130 CVCL_HJ45 9HTEo-/S transformed cell line human CVCL_HJ45 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Male 21099131 CVCL_HJ46 CW40110 induced pluripotent stem cell human CVCL_HJ46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40110; true Male 21099132 CVCL_HJ40 CW70364 induced pluripotent stem cell human CVCL_HJ40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70364; true Female 21099133 CVCL_HJ41 CW70368 induced pluripotent stem cell human CVCL_HJ41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70368; true Male 21099134 CVCL_HJ42 CW70369 induced pluripotent stem cell human CVCL_HJ42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70369; true Male 21099135 CVCL_HJ60 AG23124 somatic stem cell house mouse CVCL_HJ60 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21099136 CVCL_HJ58 AG21152 somatic stem cell human CVCL_HJ58 CL:0000010 Derived from sampling site: Thigh; skin; adipose tissue Cell type=Stromal cell.. Female 21099137 CVCL_HJ59 AG23078 somatic stem cell house mouse CVCL_HJ59 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21099138 CVCL_HJ54 AG20468 somatic stem cell human CVCL_HJ54 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.. Female 21099139 CVCL_HJ55 AG20469 somatic stem cell human CVCL_HJ55 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.. Female 21099140 CVCL_HJ56 AG20472 somatic stem cell human CVCL_HJ56 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.. Female 21099141 CVCL_HJ57 AG20788 somatic stem cell human CVCL_HJ57 CL:0000010 Derived from sampling site: Arm; adipose tissue Cell type=Stromal cell.. Female 21099142 CVCL_HJ50 AG22362 somatic stem cell CVCL_HJ50 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.; Breed/subspecies: Bairdii; stock BW. Female 21099143 CVCL_HJ51 AG20716 finite cell line CVCL_HJ51 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: Bairdii; stock BW. Male 21099144 CVCL_HJ52 AG18380 somatic stem cell human CVCL_HJ52 CL:0000010 Derived from sampling site: Hip; skin; adipose tissue Cell type=Stromal cell.. Female 21099145 CVCL_HJ53 AG19820 somatic stem cell human CVCL_HJ53 CL:0000010 Karyotypic information: 47,XX,+18 [2]; 46,XX [48] (Coriell); Derived from sampling site: Breast; adipose tissue Cell type=Stromal cell.. Female 21099146 CVCL_HJ29 CW70255 induced pluripotent stem cell human CVCL_HJ29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70255; true Male 21099147 CVCL_HJ25 CW70224 induced pluripotent stem cell human CVCL_HJ25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70224; true Male 21099148 CVCL_HJ26 CW70232 induced pluripotent stem cell human CVCL_HJ26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70232; true Male 21099149 CVCL_HJ27 CW70233 induced pluripotent stem cell human CVCL_HJ27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70233; true Female 21099150 CVCL_HJ28 CW70248 induced pluripotent stem cell human CVCL_HJ28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70248; true Female 21099151 CVCL_HJ21 CW70101 induced pluripotent stem cell human CVCL_HJ21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70101; true Female 21099152 CVCL_HJ22 CW70120 induced pluripotent stem cell human CVCL_HJ22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70120; true Female 21099153 CVCL_HJ23 CW70132 induced pluripotent stem cell human CVCL_HJ23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70132; true Female 21099154 CVCL_HJ24 CW70140 induced pluripotent stem cell human CVCL_HJ24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70140; true Female 21099155 CVCL_HJ20 CW60384 induced pluripotent stem cell human CVCL_HJ20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60384; true Female 21099156 CVCL_HJ36 CW70351 induced pluripotent stem cell human CVCL_HJ36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70351; true Female 21099157 CVCL_HJ37 CW70353 induced pluripotent stem cell human CVCL_HJ37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70353; true Male 21099158 CVCL_HJ38 CW70354 induced pluripotent stem cell human CVCL_HJ38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Cuban; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70354; true Female 21099159 CVCL_HJ39 CW70363 induced pluripotent stem cell human CVCL_HJ39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70363; true Female 21099160 CVCL_HJ32 CW70327 induced pluripotent stem cell human CVCL_HJ32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70327; true Male 21099161 CVCL_HJ33 CW70337 induced pluripotent stem cell human CVCL_HJ33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70337; true Female 21099162 CVCL_HJ34 CW70348 induced pluripotent stem cell human CVCL_HJ34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70348; true Female 21099163 CVCL_HJ35 CW70350 induced pluripotent stem cell human CVCL_HJ35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70350; true Female 21099164 CVCL_HJ30 CW70283 induced pluripotent stem cell human CVCL_HJ30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70283; true Male 21099165 CVCL_HJ31 CW70314 induced pluripotent stem cell human CVCL_HJ31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70314; true Male 21099166 CVCL_6X10 DA01602 transformed cell line human CVCL_6X10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099167 CVCL_7910 KP-N-SI(LA) cancer cell line human CVCL_7910 CL:0000010 Population: Japanese; Derived from metastatic site: Left axillary lymph node. Male 21099168 CVCL_6X11 DA01603 transformed cell line human CVCL_6X11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099169 CVCL_7911 KP-N-SI4n cancer cell line human CVCL_7911 CL:0000010 Population: Japanese; Derived from metastatic site: Left axillary lymph node. Male Characteristics: Neuroblastic type (N-type) (PubMed=2019470) 21099170 CVCL_6X12 DA01604 transformed cell line human CVCL_6X12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099171 CVCL_7912 KP-N-SI8s cancer cell line human CVCL_7912 CL:0000010 Population: Japanese; Derived from metastatic site: Left axillary lymph node. Male Characteristics: Substrate-adherent type (S-type) (PubMed=2019470) 21099172 CVCL_6X13 DA01605 transformed cell line human CVCL_6X13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099173 CVCL_7913 KP-N-YN1s cancer cell line human CVCL_7913 CL:0000010 Population: Japanese; Derived from metastatic site: Right pararenal lymph node. Male Characteristics: Substrate-adherent type (S-type) (PubMed=2019470) 21099174 CVCL_6X18 DA01610 transformed cell line human CVCL_6X18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099175 CVCL_7918 MOLM-8 cancer cell line human CVCL_7918 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21099176 CVCL_6X19 DA01611 transformed cell line human CVCL_6X19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099177 CVCL_7919 MOLM-9 cancer cell line human CVCL_7919 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21099178 CVCL_6X14 DA01606 transformed cell line human CVCL_6X14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01606; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099179 CVCL_7914 KP-N-YN2n cancer cell line human CVCL_7914 CL:0000010 Population: Japanese; Derived from metastatic site: Right pararenal lymph node. Male Characteristics: Neuroblastic type (N-type) (PubMed=2019470) 21099180 CVCL_6X15 DA01607 transformed cell line human CVCL_6X15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01607; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099181 CVCL_7915 KP-N-YN3s cancer cell line human CVCL_7915 CL:0000010 Population: Japanese; Derived from metastatic site: Right pararenal lymph node. Male Characteristics: Substrate-adherent type (S-type) (PubMed=2019470) 21099182 CVCL_6X16 DA01608 transformed cell line human CVCL_6X16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099183 CVCL_7916 MOLM-14 cancer cell line human CVCL_7916 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=9305600); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep quantitative phosphoproteome analysis; Omics: H3K79me1 ChIP-seq epigenome analysis Male Doubling time: 3-4 days (PubMed=9305600); ~50 hours (DSMZ=ACC-777) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21099184 CVCL_6X17 DA01609 transformed cell line human CVCL_6X17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099185 CVCL_7917 MOLM-7 cancer cell line human CVCL_7917 CL:0000010 Sequence variation: Mutation; HGNC; 2468; SMC3; Simple; p.Arg661Pro (c.1982G>C); ClinVar=VCV001310284; Zygosity=Unspecified (PubMed=23955599) Population: Japanese; Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21099186 CVCL_6X21 DA01613 transformed cell line human CVCL_6X21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099187 CVCL_7921 MOLM-11 cancer cell line human CVCL_7921 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21099188 CVCL_6X22 DA01614 transformed cell line human CVCL_6X22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099189 CVCL_7922 MOLM-17 cancer cell line human CVCL_7922 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21099190 CVCL_6X23 DA01615 transformed cell line human CVCL_6X23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099191 CVCL_7923 MOLM-18 cancer cell line human CVCL_7923 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21099192 CVCL_6X24 DA01616 transformed cell line human CVCL_6X24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099193 CVCL_7924 MOLT-10 cancer cell line human CVCL_7924 CL:0000010 Female 21099194 CVCL_6X20 DA01612 transformed cell line human CVCL_6X20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099195 CVCL_7920 MOLM-10 cancer cell line human CVCL_7920 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21099196 CVCL_6X29 DA01623 transformed cell line human CVCL_6X29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099197 CVCL_7929 NT2-N cancer cell line human CVCL_7929 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male 21099198 CVCL_6X25 DA01617 transformed cell line human CVCL_6X25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099199 CVCL_7925 KYN-1 cancer cell line human CVCL_7925 HLA typing: A*24:02,24; B*54:01; C*01:02; DQA1*03:01; DQB1*04:01; DRB1*04:05 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 10-11 days, at 17th passage (PubMed=2430933) 21099200 CVCL_6X26 DA01618 transformed cell line human CVCL_6X26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099201 CVCL_7926 KYN-3 cancer cell line human CVCL_7926 HLA typing: A*11:01,24:02; B*52:01,54:01; C*01:02,12:02; DQA1*01:03,03:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~56 hours (CelloPub=CLPUB00070) 21099202 CVCL_6X27 DA01620 transformed cell line human CVCL_6X27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099203 CVCL_7927 Huh-7.5 cancer cell line human CVCL_7927 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Homozygous (PubMed=15708988); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Virology: Highly permissive for HCV replication; Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Part of: ENCODE project common cell types; tier 3 21099204 CVCL_6X28 DA01621 transformed cell line human CVCL_6X28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099205 CVCL_7928 WM164 cancer cell line human CVCL_7928 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15009714; PubMed=18632627; Wistar) Derived from metastatic site: Arm; skin. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 48 hours (PubMed=2253310) Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21099206 CVCL_7900 D581 Med cancer cell line human CVCL_7900 CL:0000010 Male 21099207 CVCL_6X00 DA01589 transformed cell line human CVCL_6X00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099208 CVCL_7901 D721 Med cancer cell line human CVCL_7901 CL:0000010 Male Part of: ENCODE project common cell types; tier 3. 21099209 CVCL_6X01 DA01590 transformed cell line human CVCL_6X01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099210 CVCL_7902 D487 Med cancer cell line human CVCL_7902 CL:0000010 Male 21099211 CVCL_6X02 DA01591 transformed cell line human CVCL_6X02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099212 CVCL_6X07 DA01599 transformed cell line human CVCL_6X07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099213 CVCL_7907 Tca8113-P60 cancer cell line human CVCL_7907 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21099214 CVCL_6X08 DA01600 transformed cell line human CVCL_6X08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099215 CVCL_7908 GM00847 transformed cell line human CVCL_7908 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21099216 CVCL_6X09 DA01601 transformed cell line human CVCL_6X09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099218 CVCL_6X03 DA01592 transformed cell line human CVCL_6X03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099219 CVCL_6X04 DA01593 transformed cell line human CVCL_6X04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099220 CVCL_7904 T1 hybrid cell line human CVCL_7904 CL:0000010 21099221 CVCL_7905 CEMR.3 cancer cell line human CVCL_7905 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21099222 CVCL_6X05 DA01595 transformed cell line human CVCL_6X05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099223 CVCL_6X06 DA01598 transformed cell line human CVCL_6X06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099224 CVCL_7906 Tca8113-P160 cancer cell line human CVCL_7906 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21099225 CVCL_QE90 BayGenomics ES cell line XN217 embryonic stem cell house mouse CVCL_QE90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107995; Upf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099226 CVCL_QE91 BayGenomics ES cell line XN237 embryonic stem cell house mouse CVCL_QE91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107502; H1f3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099227 CVCL_QE92 BayGenomics ES cell line XN242 embryonic stem cell house mouse CVCL_QE92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915261; Snrpg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099228 CVCL_QE93 BayGenomics ES cell line XN245 embryonic stem cell house mouse CVCL_QE93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446190; Nup188 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099229 CVCL_QE94 BayGenomics ES cell line XN246 embryonic stem cell house mouse CVCL_QE94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158736; Senp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099230 CVCL_QE95 BayGenomics ES cell line XN248 embryonic stem cell house mouse CVCL_QE95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099231 CVCL_QE96 BayGenomics ES cell line XN253 embryonic stem cell house mouse CVCL_QE96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098658; Stag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099232 CVCL_QE97 BayGenomics ES cell line XN254 embryonic stem cell house mouse CVCL_QE97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099233 CVCL_QE98 BayGenomics ES cell line XN256 embryonic stem cell house mouse CVCL_QE98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858313; Uba2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099234 CVCL_QE99 BayGenomics ES cell line XN258 embryonic stem cell house mouse CVCL_QE99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183683; Nav1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099235 CVCL_QE80 BayGenomics ES cell line XN156 embryonic stem cell house mouse CVCL_QE80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88115; Atp5a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099236 CVCL_QE81 BayGenomics ES cell line XN157 embryonic stem cell house mouse CVCL_QE81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106330; Larp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099237 CVCL_QE82 BayGenomics ES cell line XN161 embryonic stem cell house mouse CVCL_QE82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109433; Oaz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099238 CVCL_QE83 BayGenomics ES cell line XN165 embryonic stem cell house mouse CVCL_QE83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333856; Klf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099239 CVCL_QE84 BayGenomics ES cell line XN187 embryonic stem cell house mouse CVCL_QE84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858260; Gosr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099240 CVCL_QE85 BayGenomics ES cell line XN188 embryonic stem cell house mouse CVCL_QE85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914472; Srfbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099241 CVCL_QE86 BayGenomics ES cell line XN191 embryonic stem cell house mouse CVCL_QE86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924050; Usp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099242 CVCL_QE87 BayGenomics ES cell line XN195 embryonic stem cell house mouse CVCL_QE87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919885; Lins1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099243 CVCL_QE88 BayGenomics ES cell line XN196 embryonic stem cell house mouse CVCL_QE88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919421; Shq1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099244 CVCL_QE89 BayGenomics ES cell line XN199 embryonic stem cell house mouse CVCL_QE89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277166; Sp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099245 CVCL_QE70 BayGenomics ES cell line XN017 embryonic stem cell house mouse CVCL_QE70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096397; Polr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099246 CVCL_QE71 BayGenomics ES cell line XN019 embryonic stem cell house mouse CVCL_QE71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099247 CVCL_QE72 BayGenomics ES cell line XN022 embryonic stem cell house mouse CVCL_QE72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103067; Atrx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099248 CVCL_QE73 BayGenomics ES cell line XN029 embryonic stem cell house mouse CVCL_QE73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338068; Pdpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099249 CVCL_QE74 BayGenomics ES cell line XN033 embryonic stem cell house mouse CVCL_QE74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932610; Noc3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099250 CVCL_QE75 BayGenomics ES cell line XN124 embryonic stem cell house mouse CVCL_QE75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88190; Braf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099251 CVCL_QE76 BayGenomics ES cell line XN126 embryonic stem cell house mouse CVCL_QE76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97245; Mxi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099252 CVCL_QE77 BayGenomics ES cell line XN128 embryonic stem cell house mouse CVCL_QE77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099253 CVCL_QE78 BayGenomics ES cell line XN152 embryonic stem cell house mouse CVCL_QE78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929658; Tbk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099254 CVCL_QE79 BayGenomics ES cell line XN155 embryonic stem cell house mouse CVCL_QE79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925764; Arhgap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099255 CVCL_QE60 BayGenomics ES cell line XM261 embryonic stem cell house mouse CVCL_QE60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099256 CVCL_QE61 BayGenomics ES cell line XM263 embryonic stem cell house mouse CVCL_QE61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646700; Amt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099257 CVCL_QE62 BayGenomics ES cell line XM265 embryonic stem cell house mouse CVCL_QE62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099258 CVCL_QE63 BayGenomics ES cell line XM266 embryonic stem cell house mouse CVCL_QE63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890222; Midn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099259 CVCL_QE64 BayGenomics ES cell line XM268 embryonic stem cell house mouse CVCL_QE64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919433; Snx6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099260 CVCL_QE65 BayGenomics ES cell line XM269 embryonic stem cell house mouse CVCL_QE65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277178; Fam91a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099261 CVCL_QE66 BayGenomics ES cell line XM270 embryonic stem cell house mouse CVCL_QE66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099262 CVCL_QE67 BayGenomics ES cell line XM274 embryonic stem cell house mouse CVCL_QE67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105037; Ddx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099263 CVCL_QE68 BayGenomics ES cell line XN010 embryonic stem cell house mouse CVCL_QE68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261758; Suz12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099264 CVCL_QE69 BayGenomics ES cell line XN014 embryonic stem cell house mouse CVCL_QE69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099265 CVCL_6X98 DA01700 transformed cell line human CVCL_6X98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099266 CVCL_7998 STAV-AB cancer cell line human CVCL_7998 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Grows with an epithelial phenotype in the presence of the AB medium (PubMed=2790824) Doubling time: 45 hours (PubMed=23840376) 21099267 CVCL_6X99 DA01701 transformed cell line human CVCL_6X99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099268 CVCL_7999 STAV-FCS cancer cell line human CVCL_7999 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Grows with a fibroblast-like morphology in the presence of the FCS medium (PubMed=2790824) Doubling time: 90 hours (PubMed=23840376) 21099269 CVCL_6X94 DA01696 transformed cell line human CVCL_6X94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099270 CVCL_7994 NK3.3 factor-dependent cell line human CVCL_7994 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: IL2 dependent 21099271 CVCL_6X95 DA01697 transformed cell line human CVCL_6X95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099272 CVCL_7995 PAV-1 spontaneously immortalized cell line Norway rat CVCL_7995 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21099273 CVCL_6X96 DA01698 transformed cell line human CVCL_6X96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099274 CVCL_7996 Rcho-1 cancer cell line Norway rat CVCL_7996 CL:0000010 Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Male 21099275 CVCL_6X97 DA01699 transformed cell line human CVCL_6X97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099276 CVCL_7997 SP-6.5 cancer cell line human CVCL_7997 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22236444) Derived from sampling site: Eye; uvea. Omics: Transcriptome analysis by microarray Female 21099277 CVCL_6X80 DA01678 transformed cell line human CVCL_6X80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099278 CVCL_7980 KOPN-67 cancer cell line human CVCL_7980 CL:0000010 Population: Japanese. 21099279 CVCL_6X81 DA01679 transformed cell line human CVCL_6X81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099280 CVCL_7981 KOPN-72bi cancer cell line human CVCL_7981 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=12506034). Population: Japanese Unspecified 21099281 CVCL_6X82 DA01681 transformed cell line human CVCL_6X82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099282 CVCL_7982 KP-EW-MS cancer cell line human CVCL_7982 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=7591257) Population: Japanese; Derived from metastatic site: Bone marrow. Female 21099283 CVCL_6X76 DA01674 transformed cell line human CVCL_6X76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099284 CVCL_7976 KOPN-30bi cancer cell line human CVCL_7976 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=12506034) Population: Japanese; Derived from sampling site: Bone marrow. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21099285 CVCL_6X77 DA01675 transformed cell line human CVCL_6X77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099286 CVCL_7977 KOPN-55bi cancer cell line human CVCL_7977 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=12506034). Population: Japanese Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21099287 CVCL_6X78 DA01676 transformed cell line human CVCL_6X78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01676; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099288 CVCL_7978 KOPN-57bi cancer cell line human CVCL_7978 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=12506034) Population: Japanese; Derived from sampling site: Bone marrow. Male 21099289 CVCL_6X79 DA01677 transformed cell line human CVCL_6X79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01677; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099290 CVCL_7979 KOPN-66bi cancer cell line human CVCL_7979 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=12506034). Population: Japanese Unspecified 21099291 CVCL_6X72 DA01670 transformed cell line human CVCL_6X72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01670; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099292 CVCL_7972 KOPB-26 cancer cell line human CVCL_7972 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=14671638); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=20575032); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283fs (c.849_861delCACAGAGGAAGAG); Zygosity=Unspecified (PubMed=20575032) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21099293 CVCL_6X73 DA01671 transformed cell line human CVCL_6X73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099294 CVCL_7973 KOPM-28 cancer cell line human CVCL_7973 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=12506034) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21099295 CVCL_6X74 DA01672 transformed cell line human CVCL_6X74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01672; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099296 CVCL_7974 KOPM-30 cancer cell line human CVCL_7974 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=12506034); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Hemizygous (PubMed=8289498) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21099297 CVCL_6X75 DA01673 transformed cell line human CVCL_6X75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099298 CVCL_7975 KOPM-53 cancer cell line human CVCL_7975 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=12506034). Population: Japanese 21099299 CVCL_6X90 DA01690 transformed cell line human CVCL_6X90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099300 CVCL_7990 MHH-MED-3 cancer cell line human CVCL_7990 CL:0000010 Derived from sampling site: Brain; cerebellum. Female 21099301 CVCL_6X91 DA01691 transformed cell line human CVCL_6X91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099302 CVCL_7991 MHH-MED-4 cancer cell line human CVCL_7991 CL:0000010 Derived from sampling site: Brain; cerebellum. Male Doubling time: 61 +- 15.3 hours (PubMed=8205550) 21099303 CVCL_6X92 DA01692 transformed cell line human CVCL_6X92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01692; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099304 CVCL_7992 MHH-PNET-5 cancer cell line human CVCL_7992 CL:0000010 Female Doubling time: 96 +- 6.8 hours (PubMed=8205550). 21099305 CVCL_6X93 DA01695 transformed cell line human CVCL_6X93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099306 CVCL_7993 MP-ASKIN-SA cancer cell line human CVCL_7993 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=14553943) Population: Japanese; Derived from sampling site: Thoracic cavity. Male Doubling time: 19 hours (PubMed=14553943) 21099307 CVCL_6X87 DA01687 transformed cell line human CVCL_6X87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099308 CVCL_7987 LiLa-1 cancer cell line human CVCL_7987 CL:0000010 Derived from sampling site: Peripheral blood. Female 21099309 CVCL_6X88 DA01688 transformed cell line human CVCL_6X88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099310 CVCL_7988 MHH-MED-1 cancer cell line human CVCL_7988 CL:0000010 Derived from metastatic site: Cerebrospinal fluid. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 72 +- 9.8 hours (PubMed=8205550) 21099311 CVCL_6X89 DA01689 transformed cell line human CVCL_6X89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099312 CVCL_7989 MHH-MED-2 cancer cell line human CVCL_7989 CL:0000010 Derived from sampling site: Brain; cerebellum. Female Doubling time: 119 +- 26.3 hours (PubMed=8205550) 21099313 CVCL_6X83 DA01682 transformed cell line human CVCL_6X83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099314 CVCL_7983 KP-EW-YI cancer cell line human CVCL_7983 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=7591257) Population: Japanese; Derived from sampling site: Bone; pelvis. Male 21099315 CVCL_6X84 DA01684 transformed cell line human CVCL_6X84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01684; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099316 CVCL_7984 KP-L-RY cancer cell line human CVCL_7984 CL:0000010 Sequence variation: Gene fusion; HGNC; 17869; AFF4 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF4, MLL-AF5Q31 (PubMed=12399976; PubMed=14671638) Population: Japanese; Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21099317 CVCL_6X85 DA01685 transformed cell line human CVCL_6X85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099318 CVCL_7985 KP-MO-TS cancer cell line human CVCL_7985 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (CelloPub=CLPUB00413) 21099319 CVCL_6X86 DA01686 transformed cell line human CVCL_6X86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099320 CVCL_7986 LK63 [Melbourne] cancer cell line human CVCL_7986 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 13 hours (PubMed=1378917) 21099321 CVCL_6X60 DA01655 transformed cell line human CVCL_6X60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099322 CVCL_7960 HPB-Null cancer cell line human CVCL_7960 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21099323 CVCL_6X54 DA01649 transformed cell line human CVCL_6X54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099324 CVCL_7954 ETN-1 cancer cell line human CVCL_7954 CL:0000010 Derived from metastatic site: Skin. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 72 hours (PubMed=2732002) Part of: MD Anderson Cell Lines Project 21099325 CVCL_6X55 DA01650 transformed cell line human CVCL_6X55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099326 CVCL_7955 FOCUS cancer cell line human CVCL_7955 CL:0000010 Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Doubling time: 42-48 hours (PubMed=6086498) 21099327 CVCL_6X56 DA01651 transformed cell line human CVCL_6X56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099328 CVCL_7956 GAY2911 cancer cell line human CVCL_7956 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Arg57fs*15 (c.170delG); Zygosity=Heterozygous (PubMed=21642991) Omics: Secretome proteome analysis; Omics: SNP array analysis. Male 21099329 CVCL_6X57 DA01652 transformed cell line human CVCL_6X57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099330 CVCL_7957 HAK-1A cancer cell line human CVCL_7957 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=8393423) Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 27 hours, at 8th passage (PubMed=8393423) 21099331 CVCL_7950 CUMC-3 cancer cell line human CVCL_7950 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Doubling time: ~48 hours (PubMed=7705700) 21099332 CVCL_6X50 DA01645 transformed cell line human CVCL_6X50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099333 CVCL_7951 CUMC-6 cancer cell line human CVCL_7951 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~36 hours (PubMed=8751555) 21099334 CVCL_6X51 DA01646 transformed cell line human CVCL_6X51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099335 CVCL_7952 CW12 cancer cell line human CVCL_7952 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086). Unspecified 21099336 CVCL_6X52 DA01647 transformed cell line human CVCL_6X52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099337 CVCL_6X53 DA01648 transformed cell line human CVCL_6X53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01648; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099338 CVCL_7953 DV68F hybrid cell line CVCL_7953 CL:0000010 Discontinued: ATCC; CRL-6345; true. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21099339 CVCL_6X58 DA01653 transformed cell line human CVCL_6X58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099340 CVCL_7958 HAK-1B cancer cell line human CVCL_7958 HLA typing: A*02:01,33:02; B*44:03:01,54:01; C*01:02,14:03; DQA1*01:01,01:02; DQB1*06:02,06:04; DRB1*13:02,15:01 (PubMed=9178645) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=8393423) Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 11 hours, at 19th passage (PubMed=8393423) 21099341 CVCL_6X59 DA01654 transformed cell line human CVCL_6X59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099342 CVCL_7959 HPB-MLT cancer cell line human CVCL_7959 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: RCB; RCB1937; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00212 Problematic cell line: Contaminated Shown to be a HPB-ALL derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 62 year old female patient with a T-cell lymphoid malignancy. 21099343 CVCL_6X70 DA01668 transformed cell line human CVCL_6X70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01668; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099344 CVCL_7970 KMCH-1 cancer cell line human CVCL_7970 HLA typing: A*11:01,31:01; B*51:01; C*14:02; DRB1*08:02 (PubMed=9178645) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr346Cys (c.1037A>G); ClinVar=VCV000480380; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~39 hours (PubMed=3032760) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21099345 CVCL_6X71 DA01669 transformed cell line human CVCL_6X71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099346 CVCL_7971 KMCH-2 cancer cell line human CVCL_7971 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: ~44 hours (at 20th passage), ~32 hours (at 55th passage) (PubMed=8738727) 21099347 CVCL_6X65 DA01660 transformed cell line human CVCL_6X65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099348 CVCL_7965 KCC-T873 cancer cell line human CVCL_7965 HLA typing: A*11:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Doubling time: 13.95 hours (PubMed=21362583) 21099349 CVCL_6X66 DA01662 transformed cell line human CVCL_6X66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099350 CVCL_7966 KCC-TCM901 cancer cell line human CVCL_7966 HLA typing: A*68:02 (Direct_author_submission) CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 12.59 hours (PubMed=21362583) Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26780976; PubMed=26781072). Originally thought to originate from a lung metastasis of a tongue squamous cell carcinoma. 21099351 CVCL_6X67 DA01663 transformed cell line human CVCL_6X67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01663; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099352 CVCL_7967 KCC-TCM902 cancer cell line human CVCL_7967 HLA typing: A*11:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D Population: Japanese; Derived from metastatic site: Lung. Doubling time: 12.05 hours (PubMed=21362583) 21099353 CVCL_6X68 DA01664 transformed cell line human CVCL_6X68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099354 CVCL_7968 KCC-TCM903 cancer cell line human CVCL_7968 HLA typing: A*11:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D Population: Japanese; Derived from metastatic site: Lung. Doubling time: 21.39 hours (PubMed=21362583) 21099355 CVCL_6X61 DA01656 transformed cell line human CVCL_6X61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099356 CVCL_7961 KCC-L871 cancer cell line human CVCL_7961 HLA typing: A*24:02,31:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Male Doubling time: 23.14 hours (PubMed=21362583) 21099357 CVCL_6X62 DA01657 transformed cell line human CVCL_6X62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099358 CVCL_7962 KCC-M871 cancer cell line human CVCL_7962 HLA typing: A*24:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Omics: Transcriptome analysis by microarray Male Doubling time: 23.67 hours (PubMed=21362583) 21099359 CVCL_6X63 DA01658 transformed cell line human CVCL_6X63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01658; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099360 CVCL_7963 KCC-MS871 cancer cell line human CVCL_7963 HLA typing: A*68:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 27.17 hours (PubMed=21362583) Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26780976; PubMed=26781072). Originally thought to originate from a maxillary sinus squamous cell carcinoma. 21099361 CVCL_6X64 DA01659 transformed cell line human CVCL_6X64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099362 CVCL_7964 KCC-T871 cancer cell line human CVCL_7964 HLA typing: A*02:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Omics: Transcriptome analysis by microarray Male Doubling time: 23.49 hours (PubMed=21362583) 21099363 CVCL_6X69 DA01667 transformed cell line human CVCL_6X69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099364 CVCL_7969 KIM-1 cancer cell line human CVCL_7969 HLA typing: A*11:01,26:03; B*15:01,67:01; C*03:03,07:02; DQA1*01:02,03:01; DQB1*04:01,05:02; DRB1*04:05,16:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male 21099365 CVCL_7932 21MT-2 cancer cell line human CVCL_7932 HLA typing: A*26:01,31:01; B*35:02,38:01; C*04:01,12:03; DRB1*04:03,04:03 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system Doubling time: 42.0 +- 2.5 hours (in alpha H&E medium), 42.3 +- 4.7 hours (in D medium) (PubMed=8482634) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21099366 CVCL_6X32 DA01626 transformed cell line human CVCL_6X32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099367 CVCL_7933 21NT cancer cell line human CVCL_7933 HLA typing: A*26:01,31:01; B*35:02,38:01; C*04:01,12:03; DRB1*04:03,04:03 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system Doubling time: 31.4 +- 2.6 hours (in alpha H&E medium), 38.6 +- 2.9 hours (in D medium) (PubMed=8482634); 46.38 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21099368 CVCL_6X33 DA01627 transformed cell line human CVCL_6X33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099369 CVCL_7934 21PT cancer cell line human CVCL_7934 HLA typing: A*31:01,26:01; B*35:02,38:01; C*04:01,12:03; DRB1*04:03,04:03 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system Doubling time: 35.5 +- 1.1 hours (in alpha H&E medium), 42.3 +- 4.7 hours (in D medium) (PubMed=8482634); 35.70 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel 21099370 CVCL_6X34 DA01628 transformed cell line human CVCL_6X34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099371 CVCL_7935 253J cancer cell line human CVCL_7935 HLA typing: A*01:01,03:01; B*08:01,51:01; C*07:01,12:03 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Retroperitoneal lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-108; true Male Doubling time: 36 hours (PubMed=66978; PubMed=748774); 46 +- 3 hours (PubMed=7658585); 28 hours (PubMed=3708594); Microsatellite instability: Stable (MSS) (PubMed=31068700) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21099372 CVCL_6X35 DA01629 transformed cell line human CVCL_6X35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099373 CVCL_7930 192B cancer cell line human CVCL_7930 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified Doubling time: 20 hours (PubMed=66978; PubMed=748774) 21099374 CVCL_6X30 DA01624 transformed cell line human CVCL_6X30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099375 CVCL_7931 21MT-1 cancer cell line human CVCL_7931 HLA typing: A*31:01,26:01; B*38:01,35:02; C*04:01,12:03; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*04:02,04:02 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser33Phefs*9 (c.96_97insT); Zygosity=Unspecified (PubMed=7923592) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: 21PT is non-tumorigenic whereas 21NT and 21MT-1/21-MT-2 cause tumors in the nude mice system Doubling time: 36.8 +- 0.6 hours (in alpha H&E medium), 42.3 +- 4.7 hours (in D medium) (PubMed=8482634); 44.91 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21099376 CVCL_6X31 DA01625 transformed cell line human CVCL_6X31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099377 CVCL_7936 253J laval cancer cell line human CVCL_7936 CL:0000010 Population: Caucasian; Derived from metastatic site: Retroperitoneal lymph node. Male Part of: BLA-40 bladder carcinoma cell line panel 21099378 CVCL_6X36 DA01630 transformed cell line human CVCL_6X36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099379 CVCL_7937 253J-BV cancer cell line human CVCL_7937 HLA typing: A*01:01,03:01; B*08:01,51:01; C*07:06,12:03 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Retroperitoneal lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Metastatic phenotype Obtained after 5 serial passages of the parent cell line in the bladder of nude mice. Doubling time: 49 +- 5 hours (PubMed=7658585); Microsatellite instability: Stable (MSS) (PubMed=31068700) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21099380 CVCL_6X37 DA01631 transformed cell line human CVCL_6X37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099381 CVCL_6X38 DA01632 transformed cell line human CVCL_6X38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099382 CVCL_7939 3D5 [Human B-cell] transformed cell line human CVCL_7939 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Characteristics: IL4 dependent 21099383 CVCL_6X39 DA01633 transformed cell line human CVCL_6X39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099384 CVCL_7943 1290-mel cancer cell line human CVCL_7943 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Uterus. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21099385 CVCL_6X43 DA01637 transformed cell line human CVCL_6X43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099386 CVCL_7944 743E cancer cell line human CVCL_7944 CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Male Doubling time: 40 hours (PubMed=66978; PubMed=748774) 21099387 CVCL_6X44 DA01638 transformed cell line human CVCL_6X44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099388 CVCL_7945 751G cancer cell line human CVCL_7945 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Male Doubling time: 56 hours (PubMed=66978; PubMed=748774) 21099389 CVCL_6X45 DA01639 transformed cell line human CVCL_6X45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099390 CVCL_7946 A2B5 clone 105 hybridoma house mouse CVCL_7946 CL:0000010 Discontinued: ATCC; HB-29; true. Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:28892; Ganglioside 21099391 CVCL_6X46 DA01640 transformed cell line human CVCL_6X46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099392 CVCL_7940 486P cancer cell line human CVCL_7940 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Discontinued: ATCC; HTB-7; true Male Doubling time: 35 hours (PubMed=66978; PubMed=748774) 21099393 CVCL_6X40 DA01634 transformed cell line human CVCL_6X40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099394 CVCL_7941 575A cancer cell line human CVCL_7941 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; HTB-8; true Male Doubling time: 50 hours (PubMed=66978; PubMed=748774) Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21099395 CVCL_6X41 DA01635 transformed cell line human CVCL_6X41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01635; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099396 CVCL_7942 1011-mel cancer cell line human CVCL_7942 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Unspecified 21099397 CVCL_6X42 DA01636 transformed cell line human CVCL_6X42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099398 CVCL_7947 GM847/ATRkd transformed cell line human CVCL_7947 CL:0000010 Transfected with: HGNC; 882; ATR (with p.Asp2494Glu = ATRkd); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099399 CVCL_6X47 DA01641 transformed cell line human CVCL_6X47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099400 CVCL_7948 BOY-12E cancer cell line human CVCL_7948 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 14.4-25.6 hours (CelloPub=CLPUB00345) 21099401 CVCL_6X48 DA01643 transformed cell line human CVCL_6X48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099402 CVCL_7949 C666-1 cancer cell line human CVCL_7949 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by RNAseq. Male Virology: Contains a complete EBV genome (strain C666-1) which has been sequenced (PubMed=23915735; PubMed=25787276) Doubling time: 3.5 days (PubMed=10449618) 21099403 CVCL_6X49 DA01644 transformed cell line human CVCL_6X49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099404 CVCL_HK28 GM21953 finite cell line human CVCL_HK28 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2170Phe (c.6509G>T); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099405 CVCL_HK29 GM21954 finite cell line human CVCL_HK29 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys637Arg (c.1909T>C); ClinVar=VCV000222601; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099406 CVCL_HK24 GM21948 finite cell line human CVCL_HK24 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1039Tyr (c.3116G>A); ClinVar=VCV001069719; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099407 CVCL_HK25 GM21950 finite cell line human CVCL_HK25 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1171Arg (c.3511T>C); ClinVar=VCV001069718; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099408 CVCL_HK26 GM21951 finite cell line human CVCL_HK26 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2221Arg (c.6661T>C); ClinVar=VCV000439708; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099409 CVCL_HK27 GM21952 finite cell line human CVCL_HK27 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2111Arg (c.6331T>C); ClinVar=VCV000549340; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099410 CVCL_HK20 GM21944 finite cell line human CVCL_HK20 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1326Arg (c.3976T>C); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099411 CVCL_HK21 GM21945 finite cell line human CVCL_HK21 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2017Arg (c.6049T>C); ClinVar=VCV000457240; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099412 CVCL_HK22 GM21946 finite cell line human CVCL_HK22 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2686Phe (c.8057G>T); ClinVar=VCV001071312; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099413 CVCL_HK23 GM21947 finite cell line human CVCL_HK23 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys499Arg (c.1495T>C); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099414 CVCL_HK39 GM21971 finite cell line human CVCL_HK39 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Met717Ter (c.1888delAAinsC); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099415 CVCL_HK35 GM21967 finite cell line human CVCL_HK35 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Asn264Ter (755del8); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099416 CVCL_HK36 GM21968 finite cell line human CVCL_HK36 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Tyr434Ter (c.1302T>G); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099417 CVCL_HK37 GM21969 finite cell line human CVCL_HK37 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Ile578Ter (c.1642del3ins20); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099418 CVCL_HK38 GM21970 finite cell line human CVCL_HK38 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys628Ter (c.1884C>A); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099419 CVCL_HK31 GM21957 finite cell line human CVCL_HK31 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys832Tyr (c.2495G>A); ClinVar=VCV000042311; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099420 CVCL_HK32 GM21958 finite cell line human CVCL_HK32 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys570Arg (c.1708T>C); ClinVar=VCV000956400; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099421 CVCL_HK33 GM21960 finite cell line human CVCL_HK33 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1361Tyr (c.4082G>A); ClinVar=VCV000519726; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099422 CVCL_HK34 GM21966 finite cell line human CVCL_HK34 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu249Ter (c.745G>T); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099423 CVCL_HK30 GM21956 finite cell line human CVCL_HK30 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1672Phe (c.5015G>T); ClinVar=VCV000640108; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099424 CVCL_HK06 GM21498 transformed cell line human CVCL_HK06 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Asn28Ser (c.83A>G); ClinVar=VCV000036130; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099425 CVCL_HK07 GM21499 finite cell line human CVCL_HK07 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Asn28Ser (c.83A>G); ClinVar=VCV000036130; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099426 CVCL_HK08 GM21931 finite cell line human CVCL_HK08 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3464del17; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099427 CVCL_HK09 GM21932 finite cell line human CVCL_HK09 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1589Phe (c.4766G>T); ClinVar=VCV000549246; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099428 CVCL_HK02 GM21879 finite cell line human CVCL_HK02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099429 CVCL_HK03 GM21880 finite cell line human CVCL_HK03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099430 CVCL_HK04 GM21881 finite cell line human CVCL_HK04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099431 CVCL_HK05 GM24265 transformed cell line human CVCL_HK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099432 CVCL_HK00 GM20574 transformed cell line human CVCL_HK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099433 CVCL_HK01 GM21076 transformed cell line human CVCL_HK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099434 CVCL_HK17 GM21941 finite cell line human CVCL_HK17 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Ile2118Ile (c.6354C>T); ClinVar=VCV000016449; Zygosity=Unspecified; Note=Causes an in-frame skipping of exon 51 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099435 CVCL_HK18 GM21942 finite cell line human CVCL_HK18 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1153Tyr (c.3458G>A); ClinVar=VCV000457194; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099436 CVCL_HK19 GM21943 finite cell line human CVCL_HK19 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1242Tyr (c.3725G>A); ClinVar=VCV000016429; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099437 CVCL_HK13 GM21937 finite cell line human CVCL_HK13 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.7205-2A>G (IVS57-2A>G) (Ex58del); ClinVar=VCV000982349; Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099438 CVCL_HK14 GM21938 finite cell line human CVCL_HK14 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Gly1127Ser (c.3379G>A); ClinVar=VCV000016443; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099439 CVCL_HK15 GM21939 finite cell line human CVCL_HK15 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Unexplicit; Ex42-43del; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099440 CVCL_HK16 GM21940 finite cell line human CVCL_HK16 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Unexplicit; Ex44-46del; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099441 CVCL_HK10 GM21934 finite cell line human CVCL_HK10 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.5788+5G>A (IVS46+5G-A) (Ex46del); ClinVar=VCV000042394; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099442 CVCL_HK11 GM21935 finite cell line human CVCL_HK11 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.6163+2del6 (IVS49+2del6) (Ex49del); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099443 CVCL_HK12 GM21936 finite cell line human CVCL_HK12 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.3839-1G>A (IVS30-1G>A) (Ex31del); Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099444 CVCL_6W99 DA01588 transformed cell line human CVCL_6W99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099445 CVCL_7899 DKN1 transformed cell line CVCL_7899 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Female Group: Cetacean cell line 21099446 CVCL_6W95 DA01581 transformed cell line human CVCL_6W95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099447 CVCL_7895 DS3 finite cell line CVCL_7895 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21099448 CVCL_6W96 DA01583 transformed cell line human CVCL_6W96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01583; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099449 CVCL_7896 DS4 finite cell line CVCL_7896 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21099450 CVCL_6W97 DA01584 transformed cell line human CVCL_6W97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099451 CVCL_7897 DS5 finite cell line CVCL_7897 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21099452 CVCL_6W98 DA01587 transformed cell line human CVCL_6W98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099453 CVCL_7898 DS6 finite cell line CVCL_7898 CL:0000010 Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21099454 CVCL_QE50 BayGenomics ES cell line XM235 embryonic stem cell house mouse CVCL_QE50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099455 CVCL_QE51 BayGenomics ES cell line XM238 embryonic stem cell house mouse CVCL_QE51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921456; Sipa1l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099456 CVCL_QE52 BayGenomics ES cell line XM243 embryonic stem cell house mouse CVCL_QE52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099457 CVCL_QE53 BayGenomics ES cell line XM244 embryonic stem cell house mouse CVCL_QE53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099458 CVCL_QE54 BayGenomics ES cell line XM248 embryonic stem cell house mouse CVCL_QE54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099459 CVCL_QE55 BayGenomics ES cell line XM250 embryonic stem cell house mouse CVCL_QE55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099460 CVCL_QE56 BayGenomics ES cell line XM255 embryonic stem cell house mouse CVCL_QE56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099461 CVCL_QE57 BayGenomics ES cell line XM256 embryonic stem cell house mouse CVCL_QE57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449057; Gars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099462 CVCL_QE58 BayGenomics ES cell line XM258 embryonic stem cell house mouse CVCL_QE58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099463 CVCL_QE59 BayGenomics ES cell line XM260 embryonic stem cell house mouse CVCL_QE59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099464 CVCL_QE40 BayGenomics ES cell line XM220 embryonic stem cell house mouse CVCL_QE40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261827; Dnmt3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099465 CVCL_QE41 BayGenomics ES cell line XM221 embryonic stem cell house mouse CVCL_QE41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099466 CVCL_QE42 BayGenomics ES cell line XM222 embryonic stem cell house mouse CVCL_QE42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099467 CVCL_QE43 BayGenomics ES cell line XM223 embryonic stem cell house mouse CVCL_QE43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919933; Proser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099468 CVCL_QE44 BayGenomics ES cell line XM225 embryonic stem cell house mouse CVCL_QE44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442153; Gak Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099469 CVCL_QE45 BayGenomics ES cell line XM230 embryonic stem cell house mouse CVCL_QE45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109656; Lasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099470 CVCL_QE46 BayGenomics ES cell line XM231 embryonic stem cell house mouse CVCL_QE46 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm2393 (MGI:3780561) which is no longer considered a gene by MGI 21099471 CVCL_QE47 BayGenomics ES cell line XM232 embryonic stem cell house mouse CVCL_QE47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099472 CVCL_QE48 BayGenomics ES cell line XM233 embryonic stem cell house mouse CVCL_QE48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109367; Impdh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099473 CVCL_QE49 BayGenomics ES cell line XM234 embryonic stem cell house mouse CVCL_QE49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099474 CVCL_HK90 GM21507 transformed cell line human CVCL_HK90 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly252Val (c.755G>T); ClinVar=VCV000101156; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099475 CVCL_HK91 GM21508 finite cell line human CVCL_HK91 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly252Val (c.755G>T); ClinVar=VCV000101156; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099476 CVCL_HK92 GM21554 transformed cell line human CVCL_HK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099477 CVCL_QE30 BayGenomics ES cell line XM183 embryonic stem cell house mouse CVCL_QE30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890222; Midn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099478 CVCL_QE31 BayGenomics ES cell line XM184 embryonic stem cell house mouse CVCL_QE31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338881; St14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099479 CVCL_QE32 BayGenomics ES cell line XM188 embryonic stem cell house mouse CVCL_QE32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261820; Cand1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099480 CVCL_QE33 BayGenomics ES cell line XM190 embryonic stem cell house mouse CVCL_QE33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm2393 (MGI:3780561) which is no longer considered a gene by MGI 21099481 CVCL_QE34 BayGenomics ES cell line XM192 embryonic stem cell house mouse CVCL_QE34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923272; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099482 CVCL_HK86 GM21483 transformed cell line human CVCL_HK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099483 CVCL_QE35 BayGenomics ES cell line XM194 embryonic stem cell house mouse CVCL_QE35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915913; Slc25a25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099484 CVCL_HK87 GM21484 finite cell line human CVCL_HK87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099485 CVCL_QE36 BayGenomics ES cell line XM195 embryonic stem cell house mouse CVCL_QE36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099486 CVCL_HK88 GM21500 transformed cell line human CVCL_HK88 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.997-2A>G (IVS15-2A>G) (p.Gly333_Lys350del+); ClinVar=VCV000101317; Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099487 CVCL_QE37 BayGenomics ES cell line XM209 embryonic stem cell house mouse CVCL_QE37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099488 CVCL_HK89 GM21501 finite cell line human CVCL_HK89 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.997-2A>G (IVS15-2A>G) (p.Gly333_Lys350del+); ClinVar=VCV000101317; Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099489 CVCL_QE38 BayGenomics ES cell line XM215 embryonic stem cell house mouse CVCL_QE38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919933; Proser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099490 CVCL_HK82 GM23637 transformed cell line human CVCL_HK82 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with OTC deficiency but at risk for disease; Derived from sampling site: Peripheral blood. Female 21099491 CVCL_QE39 BayGenomics ES cell line XM219 embryonic stem cell house mouse CVCL_QE39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685106; Mideas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099492 CVCL_HK83 GM25936 finite cell line human CVCL_HK83 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly12Valfs*2 (c.35delG); ClinVar=VCV000017004; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Met34Thr (c.101T>C); ClinVar=VCV000017000; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Val10952Leu (c.32854G>C) (p.Val13520Leu, c.40558G>C); ClinVar=VCV000130666; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; c.39893-1G>A (IVS192-1G>A) (c.37112-1G>A, IVS191-1G>A); ClinVar=VCV000202368; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21099493 CVCL_HK84 GM21430 transformed cell line human CVCL_HK84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099494 CVCL_HK85 GM21459 transformed cell line human CVCL_HK85 CL:0000010 Sequence variation: Mutation; HGNC; 2209; COL5A1; Simple; p.Gly721Argfs*5 (c.2159dupC) (c.2160insC); ClinVar=VCV000213029; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099495 CVCL_QE20 BayGenomics ES cell line XM157 embryonic stem cell house mouse CVCL_QE20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099496 CVCL_QE21 BayGenomics ES cell line XM162 embryonic stem cell house mouse CVCL_QE21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099497 CVCL_QE22 BayGenomics ES cell line XM163 embryonic stem cell house mouse CVCL_QE22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099498 CVCL_QE23 BayGenomics ES cell line XM165 embryonic stem cell house mouse CVCL_QE23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98927; Vcl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099499 CVCL_HK97 GM21569 transformed cell line human CVCL_HK97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099500 CVCL_QE24 BayGenomics ES cell line XM167 embryonic stem cell house mouse CVCL_QE24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916944; Tatdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099501 CVCL_HK98 GM21570 transformed cell line human CVCL_HK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099502 CVCL_QE25 BayGenomics ES cell line XM172 embryonic stem cell house mouse CVCL_QE25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446296; Sik3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099503 CVCL_HK99 GM21590 transformed cell line human CVCL_HK99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099504 CVCL_QE26 BayGenomics ES cell line XM173 embryonic stem cell house mouse CVCL_QE26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099505 CVCL_QE27 BayGenomics ES cell line XM177 embryonic stem cell house mouse CVCL_QE27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913892; Ctnnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099506 CVCL_HK93 GM21555 finite cell line human CVCL_HK93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099507 CVCL_QE28 BayGenomics ES cell line XM179 embryonic stem cell house mouse CVCL_QE28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444959; Kmt2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099508 CVCL_HK94 GM21556 transformed cell line human CVCL_HK94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099509 CVCL_QE29 BayGenomics ES cell line XM182 embryonic stem cell house mouse CVCL_QE29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890222; Midn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099510 CVCL_HK95 GM21558 transformed cell line human CVCL_HK95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099511 CVCL_HK96 GM21560 transformed cell line human CVCL_HK96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099512 CVCL_QE09 BayGenomics ES cell line XM091 embryonic stem cell house mouse CVCL_QE09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928750; Rab2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099513 CVCL_HK70 GM25495 transformed cell line human CVCL_HK70 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Unexplicit; Ex6-8del; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099514 CVCL_HK68 GM25394 transformed cell line human CVCL_HK68 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg293Ter (c.877C>T); ClinVar=VCV000011154; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099515 CVCL_HK69 GM25422 transformed cell line human CVCL_HK69 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Glu177Lysfs*6 (c.525_526delAG); ClinVar=VCV000279773; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099516 CVCL_QE10 BayGenomics ES cell line XM102 embryonic stem cell house mouse CVCL_QE10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099517 CVCL_QE11 BayGenomics ES cell line XM103 embryonic stem cell house mouse CVCL_QE11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096573; Utp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099518 CVCL_QE12 BayGenomics ES cell line XM104 embryonic stem cell house mouse CVCL_QE12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099519 CVCL_HK64 GM25497 transformed cell line human CVCL_HK64 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Leu8168Phefs*13 (c.24502_24503dupAA) (p.Leu6277Phefs*13, c.18829_18830dupAA); ClinVar=VCV000855559; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099520 CVCL_QE13 BayGenomics ES cell line XM106 embryonic stem cell house mouse CVCL_QE13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918971; Fam13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099521 CVCL_HK65 GM25498 transformed cell line human CVCL_HK65 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Leu8168Phefs*13 (c.24502_24503dupAA) (p.Leu6277Phefs*13, c.18829_18830dupAA); ClinVar=VCV000855559; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099522 CVCL_QE14 BayGenomics ES cell line XM109 embryonic stem cell house mouse CVCL_QE14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099523 CVCL_HK66 GM25853 transformed cell line human CVCL_HK66 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.1152+1G>A; ClinVar=VCV000095104; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.17013+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099524 CVCL_QE15 BayGenomics ES cell line XM110 embryonic stem cell house mouse CVCL_QE15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102579; Nmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099525 CVCL_HK67 GM25854 finite cell line human CVCL_HK67 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.1152+1G>A; ClinVar=VCV000095104; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.17013+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099526 CVCL_QE16 BayGenomics ES cell line XM140 embryonic stem cell house mouse CVCL_QE16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917483; Cd2bp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099527 CVCL_HK60 GM25173 transformed cell line human CVCL_HK60 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.3255+1G>A; ClinVar=VCV000449502; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Arg8218Serfs*9 (c.24650_24651AG[2]) (c.24654_24655delAG) (p.Arg6327Serfs*9, c.18977_18978AG[2]); ClinVar=VCV000552108; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099528 CVCL_QE17 BayGenomics ES cell line XM150 embryonic stem cell house mouse CVCL_QE17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915560; Zmym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099529 CVCL_HK61 GM25250 transformed cell line human CVCL_HK61 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Arg2809Ter (c.8425C>T); ClinVar=VCV001213189; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Leu8106Ter (c.24317T>A); ClinVar=VCV000551889; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099530 CVCL_QE18 BayGenomics ES cell line XM151 embryonic stem cell house mouse CVCL_QE18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99256; Hdlbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099531 CVCL_HK62 GM25251 finite cell line human CVCL_HK62 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Arg2809Ter (c.8425C>T); ClinVar=VCV001213189; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Leu8106Ter (c.24317T>A); ClinVar=VCV000551889; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099532 CVCL_QE19 BayGenomics ES cell line XM155 embryonic stem cell house mouse CVCL_QE19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099533 CVCL_HK63 GM25308 finite cell line human CVCL_HK63 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Gln7398Ter (c.22192C>T) (p.Gln5662Ter, c.16984C>T); ClinVar=VCV000556628; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Leu8414Ter (c.25241T>G) (p.Leu6523Ter, c.19568T>G); ClinVar=VCV000633334; Zygosity=Heterozygous (Coriell) Derived from sampling site: Oral cavity; tonsil Cell type=Fibroblast.. Male 21099534 CVCL_HK80 GM25262 transformed cell line human CVCL_HK80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099535 CVCL_HK81 GM23597 transformed cell line human CVCL_HK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099536 CVCL_HK79 GM25243 transformed cell line human CVCL_HK79 CL:0000010 Population: Southeast Asian; Vietnamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099537 CVCL_QE00 BayGenomics ES cell line XM063 embryonic stem cell house mouse CVCL_QE00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289164; Ncaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099538 CVCL_QE01 BayGenomics ES cell line XM067 embryonic stem cell house mouse CVCL_QE01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95481; Ptk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099539 CVCL_HK75 GM23356 transformed cell line human CVCL_HK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21099540 CVCL_QE02 BayGenomics ES cell line XM071 embryonic stem cell house mouse CVCL_QE02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140729; Zfand2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099541 CVCL_HK76 GM24319 transformed cell line human CVCL_HK76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099542 CVCL_QE03 BayGenomics ES cell line XM073 embryonic stem cell house mouse CVCL_QE03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920243; Appl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099543 CVCL_HK77 GM24342 transformed cell line human CVCL_HK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099544 CVCL_QE04 BayGenomics ES cell line XM074 embryonic stem cell house mouse CVCL_QE04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442860; Eda2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099545 CVCL_HK78 GM24352 transformed cell line human CVCL_HK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099546 CVCL_QE05 BayGenomics ES cell line XM081 embryonic stem cell house mouse CVCL_QE05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443472; Atf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099547 CVCL_HK71 GM25496 transformed cell line human CVCL_HK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099548 CVCL_QE06 BayGenomics ES cell line XM083 embryonic stem cell house mouse CVCL_QE06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444959; Kmt2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099549 CVCL_HK72 GM25517 transformed cell line human CVCL_HK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099550 CVCL_QE07 BayGenomics ES cell line XM084 embryonic stem cell house mouse CVCL_QE07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137738; Prcc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099551 CVCL_HK73 GM26036 transformed cell line human CVCL_HK73 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg253Ter (c.757C>T); ClinVar=VCV000279774; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099552 CVCL_QE08 BayGenomics ES cell line XM087 embryonic stem cell house mouse CVCL_QE08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099553 CVCL_HK74 GM23354 transformed cell line human CVCL_HK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21099554 CVCL_HK46 GM21983 finite cell line human CVCL_HK46 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Arg1644Ter (c.4930C>T); ClinVar=VCV000200186; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099555 CVCL_HK47 GM21984 finite cell line human CVCL_HK47 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Ile1892Ter (c.5240insACACT); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099556 CVCL_HK48 GM21987 finite cell line human CVCL_HK48 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Arg2057Ter (c.6169C>T); ClinVar=VCV000200076; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099557 CVCL_HK49 GM21988 finite cell line human CVCL_HK49 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Tyr2062Ter (c.6185dupA) (c.6185insA); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099558 CVCL_HK42 GM21976 finite cell line human CVCL_HK42 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu1158Ter (c.3474insC); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099559 CVCL_HK43 GM21978 finite cell line human CVCL_HK43 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Met1275Ter (c.3823delA); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099560 CVCL_HK44 GM21979 finite cell line human CVCL_HK44 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu1260Ter (c.3778G>T); ClinVar=VCV000527164; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099561 CVCL_HK45 GM21982 finite cell line human CVCL_HK45 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Arg1523Ter (c.4567C>T); ClinVar=VCV000042365; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099562 CVCL_HK40 GM21972 finite cell line human CVCL_HK40 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Leu802Ter (c.2399delC); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099563 CVCL_HK41 GM21974 finite cell line human CVCL_HK41 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Arg861Ter (c.2581C>T); ClinVar=VCV000265401; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099564 CVCL_HK57 GM25160 transformed cell line human CVCL_HK57 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Ser8073Ter (c.24218C>A); ClinVar=VCV000496134; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099565 CVCL_HK58 GM25161 transformed cell line human CVCL_HK58 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Ser8073Ter (c.24218C>A); ClinVar=VCV000496134; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.13059+5G>A; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099566 CVCL_HK59 GM25172 transformed cell line human CVCL_HK59 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.9619-2A>G; ClinVar=VCV000379231; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.His8159Glnfs*8 (c.24473_24476dupAACA); Zygosity=Heterozygous (Coriell) Population: Chinese and Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099567 CVCL_HK53 GM21994 finite cell line human CVCL_HK53 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; c.8051+1G>A (IVS63+1G>A); ClinVar=VCV000042394; Zygosity=Unspecified; Note=Splice donor mutation (p.Val2751Ter) (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099568 CVCL_HK54 GM24523 transformed cell line human CVCL_HK54 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.12018+1G>A; ClinVar=VCV000265494; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Met8154Ilefs*13 (c.24458_24461dupAGAT); ClinVar=VCV000551882; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099569 CVCL_HK55 GM25146 transformed cell line human CVCL_HK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099570 CVCL_HK56 GM25151 transformed cell line human CVCL_HK56 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.3252_3255+3delTGACGTA; ClinVar=VCV000632922; Zygosity=Heterozygous; Note=Splicing mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099571 CVCL_HK50 GM21989 finite cell line human CVCL_HK50 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Asp2104Ter (c.6309dupC) (c.6283insC); ClinVar=VCV001426876; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099572 CVCL_HK51 GM21990 finite cell line human CVCL_HK51 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Leu2159Ter (c.6423delG); Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099573 CVCL_HK52 GM21992 finite cell line human CVCL_HK52 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Arg2414Ter (c.7240C>T); ClinVar=VCV000519729; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099574 CVCL_6Y31 DA01734 transformed cell line human CVCL_6Y31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099575 CVCL_6Y32 DA01735 transformed cell line human CVCL_6Y32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099576 CVCL_6Y33 DA01736 transformed cell line human CVCL_6Y33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099577 CVCL_6Y34 DA01738 transformed cell line human CVCL_6Y34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099578 CVCL_6Y30 DA01733 transformed cell line human CVCL_6Y30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099579 CVCL_6Y39 DA01743 transformed cell line human CVCL_6Y39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099580 CVCL_6Y35 DA01739 transformed cell line human CVCL_6Y35 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099581 CVCL_6Y36 DA01740 transformed cell line human CVCL_6Y36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099582 CVCL_6Y37 DA01741 transformed cell line human CVCL_6Y37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099583 CVCL_6Y38 DA01742 transformed cell line human CVCL_6Y38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099584 CVCL_6Y42 DA01746 transformed cell line human CVCL_6Y42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099585 CVCL_6Y43 DA01747 transformed cell line human CVCL_6Y43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099586 CVCL_6Y44 DA01748 transformed cell line human CVCL_6Y44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099587 CVCL_6Y45 DA01749 transformed cell line human CVCL_6Y45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01749; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099588 CVCL_6Y40 DA01744 transformed cell line human CVCL_6Y40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099589 CVCL_6Y41 DA01745 transformed cell line human CVCL_6Y41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01745; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099590 CVCL_6Y46 DA01750 transformed cell line human CVCL_6Y46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099591 CVCL_6Y47 DA01751 transformed cell line human CVCL_6Y47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099592 CVCL_6Y48 DA01752 transformed cell line human CVCL_6Y48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099593 CVCL_6Y49 DA01753 transformed cell line human CVCL_6Y49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099594 CVCL_6Y10 DA01713 transformed cell line human CVCL_6Y10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099595 CVCL_6Y11 DA01714 transformed cell line human CVCL_6Y11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099596 CVCL_6Y12 DA01715 transformed cell line human CVCL_6Y12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099597 CVCL_6Y17 DA01720 transformed cell line human CVCL_6Y17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099598 CVCL_6Y18 DA01721 transformed cell line human CVCL_6Y18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099599 CVCL_6Y19 DA01722 transformed cell line human CVCL_6Y19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099600 CVCL_6Y13 DA01716 transformed cell line human CVCL_6Y13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099601 CVCL_6Y14 DA01717 transformed cell line human CVCL_6Y14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099602 CVCL_6Y15 DA01718 transformed cell line human CVCL_6Y15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099603 CVCL_6Y16 DA01719 transformed cell line human CVCL_6Y16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099604 CVCL_6Y20 DA01723 transformed cell line human CVCL_6Y20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099605 CVCL_6Y21 DA01724 transformed cell line human CVCL_6Y21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099606 CVCL_6Y22 DA01725 transformed cell line human CVCL_6Y22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099607 CVCL_6Y23 DA01726 transformed cell line human CVCL_6Y23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099608 CVCL_6Y28 DA01731 transformed cell line human CVCL_6Y28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099609 CVCL_6Y29 DA01732 transformed cell line human CVCL_6Y29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099610 CVCL_6Y24 DA01727 transformed cell line human CVCL_6Y24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099611 CVCL_6Y25 DA01728 transformed cell line human CVCL_6Y25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099612 CVCL_6Y26 DA01729 transformed cell line human CVCL_6Y26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099613 CVCL_6Y27 DA01730 transformed cell line human CVCL_6Y27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099614 CVCL_6Y00 DA01702 transformed cell line human CVCL_6Y00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099615 CVCL_6Y01 DA01703 transformed cell line human CVCL_6Y01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099616 CVCL_6Y06 DA01709 transformed cell line human CVCL_6Y06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099617 CVCL_6Y07 DA01710 transformed cell line human CVCL_6Y07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099618 CVCL_6Y08 DA01711 transformed cell line human CVCL_6Y08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01711; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099619 CVCL_6Y09 DA01712 transformed cell line human CVCL_6Y09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099620 CVCL_6Y02 DA01704 transformed cell line human CVCL_6Y02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099621 CVCL_6Y03 DA01706 transformed cell line human CVCL_6Y03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099622 CVCL_6Y04 DA01707 transformed cell line human CVCL_6Y04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099623 CVCL_6Y05 DA01708 transformed cell line human CVCL_6Y05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099624 CVCL_QF90 BayGenomics ES cell line XST038 embryonic stem cell house mouse CVCL_QF90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099625 CVCL_QF91 BayGenomics ES cell line XST040 embryonic stem cell house mouse CVCL_QF91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196466; Dsg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099626 CVCL_QF92 BayGenomics ES cell line XST043 embryonic stem cell house mouse CVCL_QF92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913936; Dcbld1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099627 CVCL_QF93 BayGenomics ES cell line XST047 embryonic stem cell house mouse CVCL_QF93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099628 CVCL_QF94 BayGenomics ES cell line XST050 embryonic stem cell house mouse CVCL_QF94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099629 CVCL_QF95 BayGenomics ES cell line XST052 embryonic stem cell house mouse CVCL_QF95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099630 CVCL_QF96 BayGenomics ES cell line XST053 embryonic stem cell house mouse CVCL_QF96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96604; Itga5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099631 CVCL_QF97 BayGenomics ES cell line XST057 embryonic stem cell house mouse CVCL_QF97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2148019; Jade3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099632 CVCL_QF98 BayGenomics ES cell line XST060 embryonic stem cell house mouse CVCL_QF98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104902; Gpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099633 CVCL_QF99 BayGenomics ES cell line XST061 embryonic stem cell house mouse CVCL_QF99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309463; Hspa13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099634 CVCL_QF80 BayGenomics ES cell line XST020 embryonic stem cell house mouse CVCL_QF80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104860; Fxr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099635 CVCL_QF81 BayGenomics ES cell line XST022 embryonic stem cell house mouse CVCL_QF81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099636 CVCL_QF82 BayGenomics ES cell line XST027 embryonic stem cell house mouse CVCL_QF82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099637 CVCL_QF83 BayGenomics ES cell line XST028 embryonic stem cell house mouse CVCL_QF83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099638 CVCL_QF84 BayGenomics ES cell line XST029 embryonic stem cell house mouse CVCL_QF84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099639 CVCL_QF85 BayGenomics ES cell line XST030 embryonic stem cell house mouse CVCL_QF85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099640 CVCL_QF86 BayGenomics ES cell line XST032 embryonic stem cell house mouse CVCL_QF86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099641 CVCL_QF87 BayGenomics ES cell line XST033 embryonic stem cell house mouse CVCL_QF87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099642 CVCL_QF88 BayGenomics ES cell line XST034 embryonic stem cell house mouse CVCL_QF88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099643 CVCL_QF89 BayGenomics ES cell line XST035 embryonic stem cell house mouse CVCL_QF89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099644 CVCL_6Y97 DA01808 transformed cell line human CVCL_6Y97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099645 CVCL_6Y98 DA01809 transformed cell line human CVCL_6Y98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099646 CVCL_6Y99 DA01810 transformed cell line human CVCL_6Y99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099647 CVCL_6Y93 DA01804 transformed cell line human CVCL_6Y93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099648 CVCL_6Y94 DA01805 transformed cell line human CVCL_6Y94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099649 CVCL_6Y95 DA01806 transformed cell line human CVCL_6Y95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01806; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099650 CVCL_6Y96 DA01807 transformed cell line human CVCL_6Y96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01807; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099651 CVCL_6Y80 DA01788 transformed cell line human CVCL_6Y80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01788; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099652 CVCL_6Y81 DA01789 transformed cell line human CVCL_6Y81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099653 CVCL_6Y75 DA01782 transformed cell line human CVCL_6Y75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099654 CVCL_6Y76 DA01783 transformed cell line human CVCL_6Y76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01783; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099655 CVCL_6Y77 DA01784 transformed cell line human CVCL_6Y77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099656 CVCL_6Y78 DA01785 transformed cell line human CVCL_6Y78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099657 CVCL_6Y71 DA01777 transformed cell line human CVCL_6Y71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099658 CVCL_6Y72 DA01778 transformed cell line human CVCL_6Y72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099659 CVCL_6Y73 DA01779 transformed cell line human CVCL_6Y73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099660 CVCL_6Y74 DA01780 transformed cell line human CVCL_6Y74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099661 CVCL_6Y79 DA01786 transformed cell line human CVCL_6Y79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01786; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099662 CVCL_6Y90 DA01799 transformed cell line human CVCL_6Y90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099663 CVCL_6Y91 DA01801 transformed cell line human CVCL_6Y91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099664 CVCL_6Y92 DA01803 transformed cell line human CVCL_6Y92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099665 CVCL_6Y86 DA01794 transformed cell line human CVCL_6Y86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099666 CVCL_6Y87 DA01795 transformed cell line human CVCL_6Y87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099667 CVCL_6Y88 DA01796 transformed cell line human CVCL_6Y88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01796; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099668 CVCL_6Y89 DA01797 transformed cell line human CVCL_6Y89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01797; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099669 CVCL_6Y82 DA01790 transformed cell line human CVCL_6Y82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01790; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099670 CVCL_6Y83 DA01791 transformed cell line human CVCL_6Y83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099671 CVCL_6Y84 DA01792 transformed cell line human CVCL_6Y84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099672 CVCL_6Y85 DA01793 transformed cell line human CVCL_6Y85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099673 CVCL_6Y53 DA01758 transformed cell line human CVCL_6Y53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099674 CVCL_6Y54 DA01759 transformed cell line human CVCL_6Y54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099675 CVCL_6Y55 DA01760 transformed cell line human CVCL_6Y55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099676 CVCL_6Y56 DA01761 transformed cell line human CVCL_6Y56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099677 CVCL_6Y50 DA01755 transformed cell line human CVCL_6Y50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01755; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099678 CVCL_6Y51 DA01756 transformed cell line human CVCL_6Y51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099679 CVCL_6Y52 DA01757 transformed cell line human CVCL_6Y52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099680 CVCL_6Y57 DA01762 transformed cell line human CVCL_6Y57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099681 CVCL_6Y58 DA01763 transformed cell line human CVCL_6Y58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099682 CVCL_6Y59 DA01764 transformed cell line human CVCL_6Y59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099683 CVCL_6Y70 DA01776 transformed cell line human CVCL_6Y70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099684 CVCL_6Y64 DA01770 transformed cell line human CVCL_6Y64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099685 CVCL_6Y65 DA01771 transformed cell line human CVCL_6Y65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01771; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099686 CVCL_6Y66 DA01772 transformed cell line human CVCL_6Y66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01772; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099687 CVCL_6Y67 DA01773 transformed cell line human CVCL_6Y67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099688 CVCL_6Y60 DA01765 transformed cell line human CVCL_6Y60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099689 CVCL_6Y61 DA01766 transformed cell line human CVCL_6Y61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099690 CVCL_6Y62 DA01767 transformed cell line human CVCL_6Y62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099691 CVCL_6Y63 DA01769 transformed cell line human CVCL_6Y63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01769; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099692 CVCL_6Y68 DA01774 transformed cell line human CVCL_6Y68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099693 CVCL_6Y69 DA01775 transformed cell line human CVCL_6Y69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01775; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099694 CVCL_HL49 GM21482 finite cell line human CVCL_HL49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099695 CVCL_HL45 GM21467 finite cell line human CVCL_HL45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099696 CVCL_HL46 GM21468 transformed cell line human CVCL_HL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099697 CVCL_HL47 GM21469 finite cell line human CVCL_HL47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099698 CVCL_HL48 GM21481 transformed cell line human CVCL_HL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099699 CVCL_HL41 GM21428 transformed cell line human CVCL_HL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099700 CVCL_HL42 GM21431 transformed cell line human CVCL_HL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099701 CVCL_HL43 GM21432 finite cell line human CVCL_HL43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099702 CVCL_HL44 GM21466 transformed cell line human CVCL_HL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099703 CVCL_HL40 GM21394 finite cell line human CVCL_HL40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099704 CVCL_HL56 GM21561 transformed cell line human CVCL_HL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099705 CVCL_HL57 GM21627 transformed cell line human CVCL_HL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099706 CVCL_HL58 GM21629 transformed cell line human CVCL_HL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099707 CVCL_HL59 GM21637 transformed cell line human CVCL_HL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099708 CVCL_HL52 GM21505 transformed cell line human CVCL_HL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099709 CVCL_HL53 GM21506 finite cell line human CVCL_HL53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099710 CVCL_HL54 GM21548 transformed cell line human CVCL_HL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099711 CVCL_HL55 GM21549 finite cell line human CVCL_HL55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099712 CVCL_HL50 GM21503 transformed cell line human CVCL_HL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099713 CVCL_HL51 GM21504 finite cell line human CVCL_HL51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099714 CVCL_HL27 GM25948 transformed cell line human CVCL_HL27 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly12Valfs*2 (c.35delG); ClinVar=VCV000017004; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Val10952Leu (c.32854G>C) (p.Val13520Leu, c.40558G>C); ClinVar=VCV000130666; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099715 CVCL_HL28 GM25951 transformed cell line human CVCL_HL28 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Met34Thr (c.101T>C); ClinVar=VCV000017000; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; c.39893-1G>A (IVS192-1G>A) (c.37112-1G>A, IVS191-1G>A); ClinVar=VCV000202368; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099716 CVCL_HL29 GM25993 transformed cell line human CVCL_HL29 CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; c.39893-1G>A (IVS192-1G>A) (c.37112-1G>A, IVS191-1G>A); ClinVar=VCV000202368; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099717 CVCL_HL23 GM22768 transformed cell line human CVCL_HL23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099718 CVCL_HL24 GM24592 transformed cell line human CVCL_HL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099719 CVCL_HL25 GM25184 transformed cell line human CVCL_HL25 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099720 CVCL_HL26 GM25186 transformed cell line human CVCL_HL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099721 CVCL_HL20 GM22692 transformed cell line human CVCL_HL20 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr1885fs (c.5653delA); Zygosity=Homozygous (PubMed=17632790) Population: Caucasian; Circassian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099722 CVCL_HL21 GM22693 transformed cell line human CVCL_HL21 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr1885fs (c.5653delA); Zygosity=Homozygous (PubMed=17632790) Population: Caucasian; Circassian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099723 CVCL_HL22 GM22745 transformed cell line human CVCL_HL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099724 CVCL_HL38 GM25234 transformed cell line human CVCL_HL38 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Asn294Asp (c.880A>G) (p.Asn288Asp, c.862A>G); ClinVar=VCV000010948; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099725 CVCL_HL39 GM21393 transformed cell line human CVCL_HL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099726 CVCL_HL34 GM22749 transformed cell line human CVCL_HL34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099727 CVCL_HL35 GM25162 transformed cell line human CVCL_HL35 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Gln444Arg (c.1313A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099728 CVCL_HL36 GM25163 transformed cell line human CVCL_HL36 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Trp52Tyrfs*29 (c.259+1G>A) (IVS3+1G>A) (Ex3del); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099729 CVCL_HL37 GM25169 transformed cell line human CVCL_HL37 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Unexplicit; IVS7-2A>G (Ex8del); Zygosity=Hemizygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099730 CVCL_HL30 GM21751 transformed cell line human CVCL_HL30 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099731 CVCL_HL31 GM21752 finite cell line human CVCL_HL31 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21099732 CVCL_HL32 GM21867 transformed cell line human CVCL_HL32 CL:0000010 Sequence variation: Mutation; HGNC; 12731; WAS; Simple; c.449+5G>A (IVS6+5G>A); Zygosity=Unspecified; Note=Activates a cryptic splice site (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099733 CVCL_HL33 GM21868 transformed cell line human CVCL_HL33 CL:0000010 Sequence variation: Mutation; HGNC; 12731; WAS; Simple; p.Val75Met (c.223G>A); ClinVar=VCV000265289; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099734 CVCL_HL09 GM21672 transformed cell line human CVCL_HL09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099735 CVCL_HL05 GM21658 transformed cell line human CVCL_HL05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099736 CVCL_HL06 GM21659 finite cell line human CVCL_HL06 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21099737 CVCL_HL07 GM21662 transformed cell line human CVCL_HL07 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly540Arg (c.1618G>A); ClinVar=VCV000101297; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099738 CVCL_HL08 GM21663 finite cell line human CVCL_HL08 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly540Arg (c.1618G>A); ClinVar=VCV000101297; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21099739 CVCL_HL01 GM21595 finite cell line human CVCL_HL01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099740 CVCL_HL02 GM21603 transformed cell line human CVCL_HL02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099741 CVCL_HL03 GM21604 finite cell line human CVCL_HL03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099742 CVCL_HL04 GM21605 transformed cell line human CVCL_HL04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099743 CVCL_HL00 GM21594 transformed cell line human CVCL_HL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099744 CVCL_HL16 GM21847 transformed cell line human CVCL_HL16 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099745 CVCL_HL17 GM21894 finite cell line human CVCL_HL17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21099746 CVCL_HL18 GM22690 finite cell line human CVCL_HL18 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr1885fs (c.5653delA); Zygosity=Homozygous (PubMed=17632790) Population: Caucasian; Circassian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099747 CVCL_HL19 GM22691 finite cell line human CVCL_HL19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr1885fs (c.5653delA); Zygosity=Homozygous (PubMed=17632790) Population: Caucasian; Circassian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099748 CVCL_HL12 GM21675 finite cell line human CVCL_HL12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099749 CVCL_HL13 GM21814 transformed cell line human CVCL_HL13 CL:0000010 Sequence variation: Mutation; HGNC; 2209; COL5A1; Simple; p.Gly530Ser (c.1588G>A); ClinVar=VCV000038863; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099750 CVCL_HL14 GM21815 finite cell line human CVCL_HL14 CL:0000010 Sequence variation: Mutation; HGNC; 2209; COL5A1; Simple; p.Gly530Ser (c.1588G>A); ClinVar=VCV000038863; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21099751 CVCL_HL15 GM21819 finite cell line human CVCL_HL15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099752 CVCL_HL10 GM21673 finite cell line human CVCL_HL10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099753 CVCL_HL11 GM21674 transformed cell line human CVCL_HL11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099754 CVCL_QF70 BayGenomics ES cell line XST006 embryonic stem cell house mouse CVCL_QF70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099755 CVCL_QF71 BayGenomics ES cell line XST007 embryonic stem cell house mouse CVCL_QF71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915309; Tm9sf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099756 CVCL_QF72 BayGenomics ES cell line XST008 embryonic stem cell house mouse CVCL_QF72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917611; Lman1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099757 CVCL_QF73 BayGenomics ES cell line XST009 embryonic stem cell house mouse CVCL_QF73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914199; Trim59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099758 CVCL_QF74 BayGenomics ES cell line XST010 embryonic stem cell house mouse CVCL_QF74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917611; Lman1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099759 CVCL_QF75 BayGenomics ES cell line XST013 embryonic stem cell house mouse CVCL_QF75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099760 CVCL_QF76 BayGenomics ES cell line XST015 embryonic stem cell house mouse CVCL_QF76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328318; Atp6v0e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099761 CVCL_QF77 BayGenomics ES cell line XST016 embryonic stem cell house mouse CVCL_QF77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099762 CVCL_QF78 BayGenomics ES cell line XST018 embryonic stem cell house mouse CVCL_QF78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328318; Atp6v0e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099763 CVCL_QF79 BayGenomics ES cell line XST019 embryonic stem cell house mouse CVCL_QF79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099764 CVCL_QF60 BayGenomics ES cell line XN750 embryonic stem cell house mouse CVCL_QF60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108403; Polr1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099765 CVCL_QF61 BayGenomics ES cell line XN763 embryonic stem cell house mouse CVCL_QF61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099766 CVCL_QF62 BayGenomics ES cell line XN858 embryonic stem cell house mouse CVCL_QF62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918040; Ubr5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099767 CVCL_QF63 BayGenomics ES cell line XN864 embryonic stem cell house mouse CVCL_QF63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103287; Zrsr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099768 CVCL_QF64 BayGenomics ES cell line XN869 embryonic stem cell house mouse CVCL_QF64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099769 CVCL_QF65 BayGenomics ES cell line XN874 embryonic stem cell house mouse CVCL_QF65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913843; Diablo Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099770 CVCL_QF66 BayGenomics ES cell line XN886 embryonic stem cell house mouse CVCL_QF66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099771 CVCL_QF67 BayGenomics ES cell line XST002 embryonic stem cell house mouse CVCL_QF67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95834; Pdia3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099772 CVCL_QF68 BayGenomics ES cell line XST003 embryonic stem cell house mouse CVCL_QF68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328318; Atp6v0e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099773 CVCL_QF69 BayGenomics ES cell line XST004 embryonic stem cell house mouse CVCL_QF69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099774 CVCL_QF50 BayGenomics ES cell line XN685 embryonic stem cell house mouse CVCL_QF50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915549; Vps53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099775 CVCL_QF51 BayGenomics ES cell line XN687 embryonic stem cell house mouse CVCL_QF51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670178; Med13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099776 CVCL_QF52 BayGenomics ES cell line XN695 embryonic stem cell house mouse CVCL_QF52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099777 CVCL_QF53 BayGenomics ES cell line XN700 embryonic stem cell house mouse CVCL_QF53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918398; Mier1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099778 CVCL_QF54 BayGenomics ES cell line XN711 embryonic stem cell house mouse CVCL_QF54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099779 CVCL_QF55 BayGenomics ES cell line XN712 embryonic stem cell house mouse CVCL_QF55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914216; Trit1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099780 CVCL_QF56 BayGenomics ES cell line XN713 embryonic stem cell house mouse CVCL_QF56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97744; Por Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099781 CVCL_QF57 BayGenomics ES cell line XN716 embryonic stem cell house mouse CVCL_QF57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347478; Foxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099782 CVCL_QF58 BayGenomics ES cell line XN727 embryonic stem cell house mouse CVCL_QF58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682314; Zc3h4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099783 CVCL_QF59 BayGenomics ES cell line XN734 embryonic stem cell house mouse CVCL_QF59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099784 CVCL_QF40 BayGenomics ES cell line XN567 embryonic stem cell house mouse CVCL_QF40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97744; Por Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099785 CVCL_QF41 BayGenomics ES cell line XN572 embryonic stem cell house mouse CVCL_QF41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099786 CVCL_QF42 BayGenomics ES cell line XN573 embryonic stem cell house mouse CVCL_QF42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099787 CVCL_QF43 BayGenomics ES cell line XN606 embryonic stem cell house mouse CVCL_QF43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099788 CVCL_QF44 BayGenomics ES cell line XN619 embryonic stem cell house mouse CVCL_QF44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201387; Nlk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099789 CVCL_QF45 BayGenomics ES cell line XN628 embryonic stem cell house mouse CVCL_QF45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920977; Mcmbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099790 CVCL_QF46 BayGenomics ES cell line XN632 embryonic stem cell house mouse CVCL_QF46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102749; Trim25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099791 CVCL_QF47 BayGenomics ES cell line XN639 embryonic stem cell house mouse CVCL_QF47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3027003; Ino80d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099792 CVCL_QF48 BayGenomics ES cell line XN660 embryonic stem cell house mouse CVCL_QF48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137336; Baiap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099793 CVCL_QF49 BayGenomics ES cell line XN675 embryonic stem cell house mouse CVCL_QF49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915527; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099794 CVCL_HL90 GM13886 transformed cell line human CVCL_HL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099795 CVCL_HL91 GM13887 transformed cell line human CVCL_HL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099796 CVCL_HL89 GM25988 transformed cell line human CVCL_HL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099797 CVCL_QF30 BayGenomics ES cell line XN464 embryonic stem cell house mouse CVCL_QF30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448490; Sbno2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099798 CVCL_QF31 BayGenomics ES cell line XN475 embryonic stem cell house mouse CVCL_QF31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96522; Rbpj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099799 CVCL_QF32 BayGenomics ES cell line XN477 embryonic stem cell house mouse CVCL_QF32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099800 CVCL_QF33 BayGenomics ES cell line XN479 embryonic stem cell house mouse CVCL_QF33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099801 CVCL_HL85 GM25409 transformed cell line human CVCL_HL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099802 CVCL_QF34 BayGenomics ES cell line XN487 embryonic stem cell house mouse CVCL_QF34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098815; Cdc23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099803 CVCL_HL86 GM25412 transformed cell line human CVCL_HL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099804 CVCL_QF35 BayGenomics ES cell line XN495 embryonic stem cell house mouse CVCL_QF35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099805 CVCL_HL87 GM25427 transformed cell line human CVCL_HL87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099806 CVCL_QF36 BayGenomics ES cell line XN528 embryonic stem cell house mouse CVCL_QF36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858965; Atf7ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099807 CVCL_HL88 GM25953 finite cell line human CVCL_HL88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099808 CVCL_QF37 BayGenomics ES cell line XN536 embryonic stem cell house mouse CVCL_QF37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445220; Dcaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099809 CVCL_HL81 GM20174 transformed cell line human CVCL_HL81 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099810 CVCL_QF38 BayGenomics ES cell line XN537 embryonic stem cell house mouse CVCL_QF38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87860; Abl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099811 CVCL_HL82 GM20199 transformed cell line human CVCL_HL82 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099812 CVCL_QF39 BayGenomics ES cell line XN551 embryonic stem cell house mouse CVCL_QF39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106214; Jrk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099813 CVCL_HL83 GM25404 transformed cell line human CVCL_HL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099814 CVCL_HL84 GM25408 transformed cell line human CVCL_HL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099815 CVCL_QF19 BayGenomics ES cell line XN389 embryonic stem cell house mouse CVCL_QF19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925270; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099816 CVCL_QF20 BayGenomics ES cell line XN390 embryonic stem cell house mouse CVCL_QF20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922847; Ndufaf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099817 CVCL_QF21 BayGenomics ES cell line XN392 embryonic stem cell house mouse CVCL_QF21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107440; Cep131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099818 CVCL_QF22 BayGenomics ES cell line XN413 embryonic stem cell house mouse CVCL_QF22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925828; Cnih4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099819 CVCL_HL96 CCE1.1 transformed cell line human CVCL_HL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE1.2 (Cellosaurus=CVCL_HL97); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21099820 CVCL_QF23 BayGenomics ES cell line XN432 embryonic stem cell house mouse CVCL_QF23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099821 CVCL_HL97 CCE1.2 transformed cell line human CVCL_HL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE1.1 (Cellosaurus=CVCL_HL96); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21099822 CVCL_QF24 BayGenomics ES cell line XN436 embryonic stem cell house mouse CVCL_QF24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099823 CVCL_HL98 CCE2.1 transformed cell line human CVCL_HL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE2.2 (Cellosaurus=CVCL_HL99); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21099824 CVCL_QF25 BayGenomics ES cell line XN441 embryonic stem cell house mouse CVCL_QF25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919924; Adipor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099825 CVCL_HL99 CCE2.2 transformed cell line human CVCL_HL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE2.1 (Cellosaurus=CVCL_HL98); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21099826 CVCL_QF26 BayGenomics ES cell line XN443 embryonic stem cell house mouse CVCL_QF26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138271; Gorab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099827 CVCL_HL92 KRC-7 [Human RCC] cancer cell line human CVCL_HL92 CL:0000010 Derived from sampling site: Kidney. Unspecified 21099828 CVCL_QF27 BayGenomics ES cell line XN444 embryonic stem cell house mouse CVCL_QF27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099829 CVCL_HL93 CFBE41o- transformed cell line human CVCL_HL93 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Omics: Proteome analysis by 2D-DE/MS Unspecified 21099830 CVCL_QF28 BayGenomics ES cell line XN450 embryonic stem cell house mouse CVCL_QF28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933111; Apobec3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099831 CVCL_HL94 CMEC-UCONN spontaneously immortalized cell line CVCL_HL94 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Anglo-Nubian. Female Doubling time: 28 hours (PubMed=10691038) 21099832 CVCL_QF29 BayGenomics ES cell line XN462 embryonic stem cell house mouse CVCL_QF29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337100; Wdr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099833 CVCL_HL95 mitoLUHMES conditionally immortalized cell line human CVCL_HL95 CL:0000010 Transfected with: DsRed2, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon. Female 21099834 CVCL_QF08 BayGenomics ES cell line XN291 embryonic stem cell house mouse CVCL_QF08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099835 CVCL_QF09 BayGenomics ES cell line XN293 embryonic stem cell house mouse CVCL_QF09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95485; Fasn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099836 CVCL_HL67 GM21750 finite cell line human CVCL_HL67 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21099837 CVCL_HL68 GM25288 transformed cell line human CVCL_HL68 CL:0000010 Sequence variation: Mutation; HGNC; 18127; TUBGCP6; Simple; p.Ter1820Glyext*16 (c.5458T>G); ClinVar=VCV000030809; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099838 CVCL_HL69 GM26074 finite cell line human CVCL_HL69 CL:0000010 Population: Caucasian; Mennonite; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 21099839 CVCL_QF10 BayGenomics ES cell line XN297 embryonic stem cell house mouse CVCL_QF10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97847; Raf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099840 CVCL_QF11 BayGenomics ES cell line XN359 embryonic stem cell house mouse CVCL_QF11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334460; Bop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099841 CVCL_HL63 GM21669 finite cell line human CVCL_HL63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21099842 CVCL_QF12 BayGenomics ES cell line XN360 embryonic stem cell house mouse CVCL_QF12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917895; Oip5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099843 CVCL_HL64 GM21670 transformed cell line human CVCL_HL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099844 CVCL_QF13 BayGenomics ES cell line XN369 embryonic stem cell house mouse CVCL_QF13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859293; Atxn10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099845 CVCL_HL65 GM21671 finite cell line human CVCL_HL65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21099846 CVCL_QF14 BayGenomics ES cell line XN374 embryonic stem cell house mouse CVCL_QF14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96977; Mgmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099847 CVCL_HL66 GM21749 transformed cell line human CVCL_HL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099848 CVCL_QF15 BayGenomics ES cell line XN377 embryonic stem cell house mouse CVCL_QF15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344403; Cfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099849 CVCL_QF16 BayGenomics ES cell line XN380 embryonic stem cell house mouse CVCL_QF16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103300; Rbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099850 CVCL_HL60 GM21664 transformed cell line human CVCL_HL60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099851 CVCL_QF17 BayGenomics ES cell line XN383 embryonic stem cell house mouse CVCL_QF17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442637; Thrap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099852 CVCL_HL61 GM21665 finite cell line human CVCL_HL61 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21099853 CVCL_QF18 BayGenomics ES cell line XN384 embryonic stem cell house mouse CVCL_QF18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101857; Usp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099854 CVCL_HL62 GM21668 transformed cell line human CVCL_HL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099855 CVCL_HL80 GM20170 transformed cell line human CVCL_HL80 CL:0000010 Sequence variation: Mutation; HGNC; 4893; HGF; Simple; c.482+1986_1988delTGA; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099856 CVCL_HL78 GM21816 transformed cell line human CVCL_HL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099857 CVCL_HL79 GM13885 transformed cell line human CVCL_HL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099858 CVCL_QF00 BayGenomics ES cell line XN259 embryonic stem cell house mouse CVCL_QF00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919654; Wdr44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099859 CVCL_HL74 GM20838 transformed cell line human CVCL_HL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099860 CVCL_QF01 BayGenomics ES cell line XN260 embryonic stem cell house mouse CVCL_QF01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099861 CVCL_HL75 GM20913 transformed cell line human CVCL_HL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099862 CVCL_QF02 BayGenomics ES cell line XN263 embryonic stem cell house mouse CVCL_QF02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099863 CVCL_HL76 GM20914 transformed cell line human CVCL_HL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099864 CVCL_QF03 BayGenomics ES cell line XN265 embryonic stem cell house mouse CVCL_QF03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95659; Gas5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099865 CVCL_HL77 GM20920 transformed cell line human CVCL_HL77 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Unspecified (from child cell line WISC012i-SCA) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099866 CVCL_QF04 BayGenomics ES cell line XN269 embryonic stem cell house mouse CVCL_QF04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913506; Ssr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099867 CVCL_HL70 GM25185 transformed cell line human CVCL_HL70 CL:0000010 Sequence variation: Gene deletion; HGNC; 4827; HBB; Zygosity=Unspecified (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21099868 CVCL_QF05 BayGenomics ES cell line XN275 embryonic stem cell house mouse CVCL_QF05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917716; Ckap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099869 CVCL_HL71 GM20729 transformed cell line human CVCL_HL71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099870 CVCL_QF06 BayGenomics ES cell line XN277 embryonic stem cell house mouse CVCL_QF06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099871 CVCL_HL72 GM20736 transformed cell line human CVCL_HL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099872 CVCL_QF07 BayGenomics ES cell line XN286 embryonic stem cell house mouse CVCL_QF07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97860; Rasa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099873 CVCL_HL73 GM20748 transformed cell line human CVCL_HL73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21099874 CVCL_6Z52 DA01869 transformed cell line human CVCL_6Z52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099875 CVCL_6Z53 DA01870 transformed cell line human CVCL_6Z53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099876 CVCL_6Z54 DA01871 transformed cell line human CVCL_6Z54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099877 CVCL_6Z55 DA01872 transformed cell line human CVCL_6Z55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099878 CVCL_6Z50 DA01866 transformed cell line human CVCL_6Z50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099879 CVCL_6Z51 DA01868 transformed cell line human CVCL_6Z51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099880 CVCL_6Z56 DA01873 transformed cell line human CVCL_6Z56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099881 CVCL_6Z57 DA01874 transformed cell line human CVCL_6Z57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099882 CVCL_6Z58 DA01875 transformed cell line human CVCL_6Z58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099883 CVCL_6Z59 DA01876 transformed cell line human CVCL_6Z59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099884 CVCL_6Z63 DA01880 transformed cell line human CVCL_6Z63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099885 CVCL_6Z64 DA01881 transformed cell line human CVCL_6Z64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099886 CVCL_6Z65 DA01882 transformed cell line human CVCL_6Z65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01882; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099887 CVCL_6Z66 DA01883 transformed cell line human CVCL_6Z66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099888 CVCL_6Z60 DA01877 transformed cell line human CVCL_6Z60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099889 CVCL_6Z61 DA01878 transformed cell line human CVCL_6Z61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099890 CVCL_6Z62 DA01879 transformed cell line human CVCL_6Z62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01879; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099891 CVCL_6Z67 DA01884 transformed cell line human CVCL_6Z67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01884; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099892 CVCL_6Z68 DA01885 transformed cell line human CVCL_6Z68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099893 CVCL_6Z69 DA01886 transformed cell line human CVCL_6Z69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099894 CVCL_6Z30 DA01845 transformed cell line human CVCL_6Z30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099895 CVCL_6Z31 DA01846 transformed cell line human CVCL_6Z31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099896 CVCL_6Z32 DA01847 transformed cell line human CVCL_6Z32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099897 CVCL_6Z33 DA01848 transformed cell line human CVCL_6Z33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099898 CVCL_6Z38 DA01853 transformed cell line human CVCL_6Z38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099899 CVCL_6Z39 DA01854 transformed cell line human CVCL_6Z39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099900 CVCL_6Z34 DA01849 transformed cell line human CVCL_6Z34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099901 CVCL_6Z35 DA01850 transformed cell line human CVCL_6Z35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099902 CVCL_6Z36 DA01851 transformed cell line human CVCL_6Z36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099903 CVCL_6Z37 DA01852 transformed cell line human CVCL_6Z37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099904 CVCL_6Z41 DA01856 transformed cell line human CVCL_6Z41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01856; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099905 CVCL_6Z42 DA01857 transformed cell line human CVCL_6Z42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099906 CVCL_6Z43 DA01858 transformed cell line human CVCL_6Z43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099907 CVCL_6Z44 DA01859 transformed cell line human CVCL_6Z44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099908 CVCL_6Z40 DA01855 transformed cell line human CVCL_6Z40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099909 CVCL_6Z49 DA01865 transformed cell line human CVCL_6Z49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099910 CVCL_6Z45 DA01860 transformed cell line human CVCL_6Z45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099911 CVCL_6Z46 DA01861 transformed cell line human CVCL_6Z46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099912 CVCL_6Z47 DA01862 transformed cell line human CVCL_6Z47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099913 CVCL_6Z48 DA01863 transformed cell line human CVCL_6Z48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099914 CVCL_6Z10 DA01821 transformed cell line human CVCL_6Z10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099915 CVCL_6Z11 DA01822 transformed cell line human CVCL_6Z11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099916 CVCL_6Z16 DA01828 transformed cell line human CVCL_6Z16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099917 CVCL_6Z17 DA01829 transformed cell line human CVCL_6Z17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01829; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099918 CVCL_6Z18 DA01830 transformed cell line human CVCL_6Z18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099919 CVCL_6Z19 DA01831 transformed cell line human CVCL_6Z19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099920 CVCL_6Z12 DA01823 transformed cell line human CVCL_6Z12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099921 CVCL_6Z13 DA01825 transformed cell line human CVCL_6Z13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099922 CVCL_6Z14 DA01826 transformed cell line human CVCL_6Z14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099923 CVCL_6Z15 DA01827 transformed cell line human CVCL_6Z15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099924 CVCL_6Z20 DA01833 transformed cell line human CVCL_6Z20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099925 CVCL_6Z21 DA01834 transformed cell line human CVCL_6Z21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099926 CVCL_6Z22 DA01835 transformed cell line human CVCL_6Z22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01835; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099927 CVCL_6Z27 DA01842 transformed cell line human CVCL_6Z27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099928 CVCL_6Z28 DA01843 transformed cell line human CVCL_6Z28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099929 CVCL_6Z29 DA01844 transformed cell line human CVCL_6Z29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099930 CVCL_6Z23 DA01836 transformed cell line human CVCL_6Z23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099931 CVCL_6Z24 DA01837 transformed cell line human CVCL_6Z24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099932 CVCL_6Z25 DA01838 transformed cell line human CVCL_6Z25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099933 CVCL_6Z26 DA01839 transformed cell line human CVCL_6Z26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01839; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099934 CVCL_6Z09 DA01820 transformed cell line human CVCL_6Z09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01820; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099935 CVCL_6Z00 DA01811 transformed cell line human CVCL_6Z00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099936 CVCL_6Z05 DA01816 transformed cell line human CVCL_6Z05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099937 CVCL_6Z06 DA01817 transformed cell line human CVCL_6Z06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099938 CVCL_6Z07 DA01818 transformed cell line human CVCL_6Z07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01818; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099939 CVCL_6Z08 DA01819 transformed cell line human CVCL_6Z08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099940 CVCL_6Z01 DA01812 transformed cell line human CVCL_6Z01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01812; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099941 CVCL_6Z02 DA01813 transformed cell line human CVCL_6Z02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099942 CVCL_6Z03 DA01814 transformed cell line human CVCL_6Z03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099943 CVCL_6Z04 DA01815 transformed cell line human CVCL_6Z04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099944 CVCL_HN07 GM20678 transformed cell line human CVCL_HN07 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099945 CVCL_HN08 GM20679 transformed cell line human CVCL_HN08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099946 CVCL_HN09 GM20680 transformed cell line human CVCL_HN09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099947 CVCL_HN03 GM20673 transformed cell line human CVCL_HN03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099948 CVCL_HN04 GM20674 transformed cell line human CVCL_HN04 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099949 CVCL_HN05 GM20675 transformed cell line human CVCL_HN05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099950 CVCL_HN06 GM20677 transformed cell line human CVCL_HN06 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099951 CVCL_HN00 GM20670 transformed cell line human CVCL_HN00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099952 CVCL_HN01 GM20671 transformed cell line human CVCL_HN01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099953 CVCL_HN02 GM20672 transformed cell line human CVCL_HN02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099954 CVCL_HN18 GM20689 transformed cell line human CVCL_HN18 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099955 CVCL_HN19 GM20690 transformed cell line human CVCL_HN19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099956 CVCL_HN14 GM20685 transformed cell line human CVCL_HN14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099957 CVCL_HN15 GM20686 transformed cell line human CVCL_HN15 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099958 CVCL_HN16 GM20687 transformed cell line human CVCL_HN16 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099959 CVCL_HN17 GM20688 transformed cell line human CVCL_HN17 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099960 CVCL_HN10 GM20681 transformed cell line human CVCL_HN10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099961 CVCL_HN11 GM20682 transformed cell line human CVCL_HN11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099962 CVCL_HN12 GM20683 transformed cell line human CVCL_HN12 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099963 CVCL_HN13 GM20684 transformed cell line human CVCL_HN13 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21099964 CVCL_6Z96 DA01913 transformed cell line human CVCL_6Z96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099965 CVCL_6Z97 DA01914 transformed cell line human CVCL_6Z97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099966 CVCL_6Z98 DA01915 transformed cell line human CVCL_6Z98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01915; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099967 CVCL_6Z99 DA01916 transformed cell line human CVCL_6Z99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01916; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099968 CVCL_6Z92 DA01909 transformed cell line human CVCL_6Z92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099969 CVCL_6Z93 DA01910 transformed cell line human CVCL_6Z93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01910; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099970 CVCL_6Z94 DA01911 transformed cell line human CVCL_6Z94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099971 CVCL_6Z95 DA01912 transformed cell line human CVCL_6Z95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099972 CVCL_6Z80 DA01897 transformed cell line human CVCL_6Z80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099973 CVCL_6Z74 DA01891 transformed cell line human CVCL_6Z74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099974 CVCL_6Z75 DA01892 transformed cell line human CVCL_6Z75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099975 CVCL_6Z76 DA01893 transformed cell line human CVCL_6Z76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099976 CVCL_6Z77 DA01894 transformed cell line human CVCL_6Z77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099977 CVCL_6Z70 DA01887 transformed cell line human CVCL_6Z70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099978 CVCL_6Z71 DA01888 transformed cell line human CVCL_6Z71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01888; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099979 CVCL_6Z72 DA01889 transformed cell line human CVCL_6Z72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099980 CVCL_6Z73 DA01890 transformed cell line human CVCL_6Z73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01890; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099981 CVCL_6Z78 DA01895 transformed cell line human CVCL_6Z78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099982 CVCL_6Z79 DA01896 transformed cell line human CVCL_6Z79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099983 CVCL_6Z90 DA01907 transformed cell line human CVCL_6Z90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099984 CVCL_6Z91 DA01908 transformed cell line human CVCL_6Z91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099985 CVCL_6Z85 DA01902 transformed cell line human CVCL_6Z85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01902; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099986 CVCL_6Z86 DA01903 transformed cell line human CVCL_6Z86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099987 CVCL_6Z87 DA01904 transformed cell line human CVCL_6Z87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099988 CVCL_6Z88 DA01905 transformed cell line human CVCL_6Z88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099989 CVCL_6Z81 DA01898 transformed cell line human CVCL_6Z81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099990 CVCL_6Z82 DA01899 transformed cell line human CVCL_6Z82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01899; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099991 CVCL_6Z83 DA01900 transformed cell line human CVCL_6Z83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099992 CVCL_6Z84 DA01901 transformed cell line human CVCL_6Z84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01901; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099993 CVCL_6Z89 DA01906 transformed cell line human CVCL_6Z89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21099994 CVCL_QG07 BayGenomics ES cell line XST078 embryonic stem cell house mouse CVCL_QG07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099995 CVCL_QG08 BayGenomics ES cell line XST079 embryonic stem cell house mouse CVCL_QG08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107405; Lefty1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099996 CVCL_QG09 BayGenomics ES cell line XST081 embryonic stem cell house mouse CVCL_QG09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21099997 CVCL_HM66 GM20633 transformed cell line human CVCL_HM66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099998 CVCL_HM67 GM20634 transformed cell line human CVCL_HM67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21099999 CVCL_HM68 GM20635 transformed cell line human CVCL_HM68 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100000 CVCL_HM69 GM20636 transformed cell line human CVCL_HM69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100001 CVCL_QG10 BayGenomics ES cell line XST085 embryonic stem cell house mouse CVCL_QG10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100002 CVCL_HM62 V79/380-6 spontaneously immortalized cell line CVCL_HM62 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21100003 CVCL_QG11 BayGenomics ES cell line XST087 embryonic stem cell house mouse CVCL_QG11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918711; Ptk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100004 CVCL_HM63 GM20630 transformed cell line human CVCL_HM63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100005 CVCL_QG12 BayGenomics ES cell line XST088 embryonic stem cell house mouse CVCL_QG12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100006 CVCL_HM64 GM20631 transformed cell line human CVCL_HM64 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100007 CVCL_QG13 BayGenomics ES cell line XST092 embryonic stem cell house mouse CVCL_QG13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100008 CVCL_HM65 GM20632 transformed cell line human CVCL_HM65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100009 CVCL_QG14 BayGenomics ES cell line XST094 embryonic stem cell house mouse CVCL_QG14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100010 CVCL_QG15 BayGenomics ES cell line XST097 embryonic stem cell house mouse CVCL_QG15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100011 CVCL_QG16 BayGenomics ES cell line XST100 embryonic stem cell house mouse CVCL_QG16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345162; Adam23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100012 CVCL_HM60 XR-V9B spontaneously immortalized cell line CVCL_HM60 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; Q60449; Xrcc5; Simple; p.Ile267_Gln350del84 (c.799_1050del252); Zygosity=Unspecified (PubMed=8657125) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21100013 CVCL_QG17 BayGenomics ES cell line XST101 embryonic stem cell house mouse CVCL_QG17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100014 CVCL_HM61 V79/380 spontaneously immortalized cell line CVCL_HM61 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21100015 CVCL_HM77 GM20644 transformed cell line human CVCL_HM77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100016 CVCL_HM78 GM20645 transformed cell line human CVCL_HM78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100017 CVCL_HM79 GM20646 transformed cell line human CVCL_HM79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100018 CVCL_HM73 GM20640 transformed cell line human CVCL_HM73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100019 CVCL_QG00 BayGenomics ES cell line XST064 embryonic stem cell house mouse CVCL_QG00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100020 CVCL_HM74 GM20641 transformed cell line human CVCL_HM74 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100021 CVCL_QG01 BayGenomics ES cell line XST067 embryonic stem cell house mouse CVCL_QG01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100022 CVCL_HM75 GM20642 transformed cell line human CVCL_HM75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100023 CVCL_QG02 BayGenomics ES cell line XST069 embryonic stem cell house mouse CVCL_QG02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95321; Emb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100024 CVCL_HM76 GM20643 transformed cell line human CVCL_HM76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100025 CVCL_QG03 BayGenomics ES cell line XST071 embryonic stem cell house mouse CVCL_QG03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100026 CVCL_QG04 BayGenomics ES cell line XST074 embryonic stem cell house mouse CVCL_QG04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96748; Lamp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100027 CVCL_HM70 GM20637 transformed cell line human CVCL_HM70 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100028 CVCL_QG05 BayGenomics ES cell line XST075 embryonic stem cell house mouse CVCL_QG05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100029 CVCL_HM71 GM20638 transformed cell line human CVCL_HM71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100030 CVCL_QG06 BayGenomics ES cell line XST077 embryonic stem cell house mouse CVCL_QG06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97464; P4hb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100031 CVCL_HM72 GM20639 transformed cell line human CVCL_HM72 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100032 CVCL_HM48 GM20461 transformed cell line human CVCL_HM48 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100033 CVCL_HM49 GM20462 transformed cell line human CVCL_HM49 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100034 CVCL_HM44 RED-2 cancer cell line house mouse CVCL_HM44 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: DBA/2. Male 21100035 CVCL_HM45 GM20458 transformed cell line human CVCL_HM45 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100036 CVCL_HM46 GM20459 transformed cell line human CVCL_HM46 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100037 CVCL_HM47 GM20460 transformed cell line human CVCL_HM47 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100038 CVCL_HM40 GM20926 finite cell line human CVCL_HM40 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Lithuanian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21100039 CVCL_HM41 Ca9-22SF cancer cell line human CVCL_HM41 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 18 hours (DOI=10.5794/jjoms.31.264) Group: Serum/protein free medium cell line 21100040 CVCL_HM42 Ca9-22PF cancer cell line human CVCL_HM42 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Group: Serum/protein free medium cell line 21100041 CVCL_HM43 CL-52 transformed cell line Norway rat CVCL_HM43 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 21100042 CVCL_HM59 GM20917 transformed cell line human CVCL_HM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100043 CVCL_HM55 GM20919 transformed cell line human CVCL_HM55 CL:0000010 Population: Caucasian; Greek/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100044 CVCL_HM56 GM21081 transformed cell line human CVCL_HM56 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu27Lys (c.79G>A) (E26K); ClinVar=VCV000015161; Zygosity=Unspecified; Note=Hb E (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100045 CVCL_HM57 GM21082 transformed cell line human CVCL_HM57 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu27Lys (c.79G>A) (E26K); ClinVar=VCV000015161; Zygosity=Unspecified; Note=Hb E (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100046 CVCL_HM58 GM21154 transformed cell line human CVCL_HM58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100047 CVCL_HM51 GM20498 transformed cell line human CVCL_HM51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100048 CVCL_HM52 GM20577 transformed cell line human CVCL_HM52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100049 CVCL_HM53 GM20744 transformed cell line human CVCL_HM53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100050 CVCL_HM54 GM20839 transformed cell line human CVCL_HM54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100051 CVCL_HM50 GM20463 transformed cell line human CVCL_HM50 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Lys83Asn (c.249G>Y); ClinVar=VCV000015319; Zygosity=Unspecified; Note=Hb Providence (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100052 CVCL_HM26 ND03002 transformed cell line human CVCL_HM26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100053 CVCL_HM27 ND03053 transformed cell line human CVCL_HM27 CL:0000010 Population: Caucasian; Welsh; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100054 CVCL_HM28 ND03091 transformed cell line human CVCL_HM28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100055 CVCL_HM29 ND03146 transformed cell line human CVCL_HM29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100056 CVCL_HM22 CCN5.1 transformed cell line human CVCL_HM22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN5.2 (Cellosaurus=CVCL_HM23); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100057 CVCL_HM23 CCN5.2 transformed cell line human CVCL_HM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN5.1 (Cellosaurus=CVCL_HM22); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100058 CVCL_HM24 ND02216 transformed cell line human CVCL_HM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100059 CVCL_HM25 ND02218 transformed cell line human CVCL_HM25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100060 CVCL_HM20 CCN4.1 transformed cell line human CVCL_HM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN4.2 (Cellosaurus=CVCL_HM21); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100061 CVCL_HM21 CCN4.2 transformed cell line human CVCL_HM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN4.1 (Cellosaurus=CVCL_HM20); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100062 CVCL_HM37 GM20421 transformed cell line human CVCL_HM37 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100063 CVCL_HM38 GM20432 transformed cell line human CVCL_HM38 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100064 CVCL_HM39 GM20747 transformed cell line human CVCL_HM39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100065 CVCL_HM33 ND04023 transformed cell line human CVCL_HM33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100066 CVCL_HM34 ND14871 transformed cell line human CVCL_HM34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100067 CVCL_HM35 GM02568 transformed cell line human CVCL_HM35 CL:0000010 Sequence variation: Gene fusion; HGNC; 4827; HBB + HGNC; 4829; HBD; Name(s)=HBD-HBB, Hb Lepore (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100068 CVCL_HM36 GM11779 hybrid cell line human CVCL_HM36 CL:0000010 Group: Human/rodent somatic cell hybrid. 21100069 CVCL_HM30 ND03148 transformed cell line human CVCL_HM30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100070 CVCL_HM31 ND03988 transformed cell line human CVCL_HM31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100071 CVCL_HM32 ND04022 transformed cell line human CVCL_HM32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100072 CVCL_HM08 DCE3.1 transformed cell line human CVCL_HM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE3.2 (Cellosaurus=CVCL_HM09); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100073 CVCL_HM09 DCE3.2 transformed cell line human CVCL_HM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE3.1 (Cellosaurus=CVCL_HM08); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100074 CVCL_HM04 DCE1.1 transformed cell line human CVCL_HM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE1.2 (Cellosaurus=CVCL_HM05); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100075 CVCL_HM05 DCE1.2 transformed cell line human CVCL_HM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE1.1 (Cellosaurus=CVCL_HM04); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100076 CVCL_HM06 DCE2.1 transformed cell line human CVCL_HM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE2.2 (Cellosaurus=CVCL_HM07); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100077 CVCL_HM07 DCE2.2 transformed cell line human CVCL_HM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE2.1 (Cellosaurus=CVCL_HM06); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100078 CVCL_HM00 CCE3.1 transformed cell line human CVCL_HM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE3.2 (Cellosaurus=CVCL_HM01); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100079 CVCL_HM01 CCE3.2 transformed cell line human CVCL_HM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE3.1 (Cellosaurus=CVCL_HM00); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100080 CVCL_HM02 CCE4.1 transformed cell line human CVCL_HM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE4.2 (Cellosaurus=CVCL_HM03); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100081 CVCL_HM03 CCE4.2 transformed cell line human CVCL_HM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCE4.1 (Cellosaurus=CVCL_HM02); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100082 CVCL_HM19 CCN3.2 transformed cell line human CVCL_HM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN3.1 (Cellosaurus=CVCL_HM18); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100083 CVCL_HM15 CCN1.2 transformed cell line human CVCL_HM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN1.1 (Cellosaurus=CVCL_HM14); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100084 CVCL_HM16 CCN2.1 transformed cell line human CVCL_HM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN2.2 (Cellosaurus=CVCL_HM17); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100085 CVCL_HM17 CCN2.2 transformed cell line human CVCL_HM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN2.1 (Cellosaurus=CVCL_HM16); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100086 CVCL_HM18 CCN3.1 transformed cell line human CVCL_HM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN3.2 (Cellosaurus=CVCL_HM19); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100087 CVCL_HM11 DCE4.2 transformed cell line human CVCL_HM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE4.1 (Cellosaurus=CVCL_HM10); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100088 CVCL_HM12 DCE5.1 transformed cell line human CVCL_HM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE5.2 (Cellosaurus=CVCL_HM13); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100089 CVCL_HM13 DCE5.2 transformed cell line human CVCL_HM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE5.1 (Cellosaurus=CVCL_HM12); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21100090 CVCL_HM14 CCN1.1 transformed cell line human CVCL_HM14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of CCN1.2 (Cellosaurus=CVCL_HM15); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100091 CVCL_HM10 DCE4.1 transformed cell line human CVCL_HM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of DCE4.2 (Cellosaurus=CVCL_HM11); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21100092 CVCL_QG90 BayGenomics ES cell line YHA183 embryonic stem cell house mouse CVCL_QG90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860197; Wdr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100093 CVCL_QG91 BayGenomics ES cell line YHA184 embryonic stem cell house mouse CVCL_QG91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860513; Fnbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100094 CVCL_QG92 BayGenomics ES cell line YHA186 embryonic stem cell house mouse CVCL_QG92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98847; Kdm3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100095 CVCL_QG93 BayGenomics ES cell line YHA189 embryonic stem cell house mouse CVCL_QG93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685869; Dpy19l4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100096 CVCL_QG94 BayGenomics ES cell line YHA190 embryonic stem cell house mouse CVCL_QG94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100097 CVCL_QG95 BayGenomics ES cell line YHA194 embryonic stem cell house mouse CVCL_QG95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914872; Mxra7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100098 CVCL_QG96 BayGenomics ES cell line YHA195 embryonic stem cell house mouse CVCL_QG96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100099 CVCL_QG97 BayGenomics ES cell line YHA196 embryonic stem cell house mouse CVCL_QG97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138986; Qser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100100 CVCL_QG98 BayGenomics ES cell line YHA197 embryonic stem cell house mouse CVCL_QG98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95486; Fbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100101 CVCL_QG99 BayGenomics ES cell line YHA199 embryonic stem cell house mouse CVCL_QG99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100102 CVCL_QG80 BayGenomics ES cell line YHA151 embryonic stem cell house mouse CVCL_QG80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924223; Fbxo21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100103 CVCL_QG81 BayGenomics ES cell line YHA153 embryonic stem cell house mouse CVCL_QG81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106478; Eif3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100104 CVCL_QG82 BayGenomics ES cell line YHA157 embryonic stem cell house mouse CVCL_QG82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100105 CVCL_QG83 BayGenomics ES cell line YHA161 embryonic stem cell house mouse CVCL_QG83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925678; Pym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100106 CVCL_QG84 BayGenomics ES cell line YHA164 embryonic stem cell house mouse CVCL_QG84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100107 CVCL_QG85 BayGenomics ES cell line YHA168 embryonic stem cell house mouse CVCL_QG85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914504; Bmerb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100108 CVCL_QG86 BayGenomics ES cell line YHA169 embryonic stem cell house mouse CVCL_QG86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100109 CVCL_QG87 BayGenomics ES cell line YHA171 embryonic stem cell house mouse CVCL_QG87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328361; Bard1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100110 CVCL_QG88 BayGenomics ES cell line YHA178 embryonic stem cell house mouse CVCL_QG88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100111 CVCL_QG89 BayGenomics ES cell line YHA182 embryonic stem cell house mouse CVCL_QG89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100112 CVCL_QG70 BayGenomics ES cell line YHA006 embryonic stem cell house mouse CVCL_QG70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100113 CVCL_QG71 BayGenomics ES cell line YHA007 embryonic stem cell house mouse CVCL_QG71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100114 CVCL_QG72 BayGenomics ES cell line YHA061 embryonic stem cell house mouse CVCL_QG72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100115 CVCL_QG73 BayGenomics ES cell line YHA095 embryonic stem cell house mouse CVCL_QG73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917171; Hnrnpa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100116 CVCL_QG74 BayGenomics ES cell line YHA109 embryonic stem cell house mouse CVCL_QG74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100117 CVCL_QG75 BayGenomics ES cell line YHA114 embryonic stem cell house mouse CVCL_QG75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95486; Fbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100118 CVCL_QG76 BayGenomics ES cell line YHA122 embryonic stem cell house mouse CVCL_QG76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97842; Rab1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100119 CVCL_QG77 BayGenomics ES cell line YHA129 embryonic stem cell house mouse CVCL_QG77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100120 CVCL_QG78 BayGenomics ES cell line YHA144 embryonic stem cell house mouse CVCL_QG78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441931; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100121 CVCL_QG79 BayGenomics ES cell line YHA146 embryonic stem cell house mouse CVCL_QG79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100122 CVCL_QG60 BayGenomics ES cell line XST187 embryonic stem cell house mouse CVCL_QG60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100123 CVCL_QG61 BayGenomics ES cell line XST189 embryonic stem cell house mouse CVCL_QG61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100124 CVCL_QG62 BayGenomics ES cell line XST190 embryonic stem cell house mouse CVCL_QG62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100125 CVCL_QG63 BayGenomics ES cell line XST192 embryonic stem cell house mouse CVCL_QG63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100126 CVCL_QG64 BayGenomics ES cell line XST193 embryonic stem cell house mouse CVCL_QG64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100127 CVCL_QG65 BayGenomics ES cell line XST197 embryonic stem cell house mouse CVCL_QG65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96435; Igf2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100128 CVCL_QG66 BayGenomics ES cell line XST200 embryonic stem cell house mouse CVCL_QG66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100129 CVCL_QG67 BayGenomics ES cell line XST205 embryonic stem cell house mouse CVCL_QG67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100130 CVCL_QG68 BayGenomics ES cell line XST206 embryonic stem cell house mouse CVCL_QG68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100131 CVCL_QG69 BayGenomics ES cell line XST208 embryonic stem cell house mouse CVCL_QG69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100132 CVCL_QG50 BayGenomics ES cell line XST170 embryonic stem cell house mouse CVCL_QG50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100133 CVCL_QG51 BayGenomics ES cell line XST171 embryonic stem cell house mouse CVCL_QG51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354385; Ero1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100134 CVCL_QG52 BayGenomics ES cell line XST172 embryonic stem cell house mouse CVCL_QG52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100135 CVCL_QG53 BayGenomics ES cell line XST173 embryonic stem cell house mouse CVCL_QG53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100136 CVCL_QG54 BayGenomics ES cell line XST176 embryonic stem cell house mouse CVCL_QG54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914217; Edem3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100137 CVCL_QG55 BayGenomics ES cell line XST180 embryonic stem cell house mouse CVCL_QG55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100138 CVCL_QG56 BayGenomics ES cell line XST181 embryonic stem cell house mouse CVCL_QG56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100139 CVCL_QG57 BayGenomics ES cell line XST184 embryonic stem cell house mouse CVCL_QG57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109177; Cd59a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100140 CVCL_QG58 BayGenomics ES cell line XST185 embryonic stem cell house mouse CVCL_QG58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927947; Selenof Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100141 CVCL_QG59 BayGenomics ES cell line XST186 embryonic stem cell house mouse CVCL_QG59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100142 CVCL_QG40 BayGenomics ES cell line XST141 embryonic stem cell house mouse CVCL_QG40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100143 CVCL_QG41 BayGenomics ES cell line XST142 embryonic stem cell house mouse CVCL_QG41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354385; Ero1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100144 CVCL_QG42 BayGenomics ES cell line XST143 embryonic stem cell house mouse CVCL_QG42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860139; Gabbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100145 CVCL_QG43 BayGenomics ES cell line XST161 embryonic stem cell house mouse CVCL_QG43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924059; Bri3bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100146 CVCL_QG44 BayGenomics ES cell line XST163 embryonic stem cell house mouse CVCL_QG44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159727; Il17rd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100147 CVCL_QG45 BayGenomics ES cell line XST164 embryonic stem cell house mouse CVCL_QG45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100148 CVCL_QG46 BayGenomics ES cell line XST165 embryonic stem cell house mouse CVCL_QG46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100149 CVCL_QG47 BayGenomics ES cell line XST167 embryonic stem cell house mouse CVCL_QG47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3580376; Lemd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100150 CVCL_QG48 BayGenomics ES cell line XST168 embryonic stem cell house mouse CVCL_QG48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919727; Tmem87b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100151 CVCL_QG49 BayGenomics ES cell line XST169 embryonic stem cell house mouse CVCL_QG49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443162; Uggt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100152 CVCL_QG29 BayGenomics ES cell line XST121 embryonic stem cell house mouse CVCL_QG29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106419; Itfg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100153 CVCL_HM90 GM20657 transformed cell line human CVCL_HM90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100154 CVCL_HM88 GM20655 transformed cell line human CVCL_HM88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100155 CVCL_HM89 GM20656 transformed cell line human CVCL_HM89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100156 CVCL_QG30 BayGenomics ES cell line XST124 embryonic stem cell house mouse CVCL_QG30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100157 CVCL_QG31 BayGenomics ES cell line XST127 embryonic stem cell house mouse CVCL_QG31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100158 CVCL_QG32 BayGenomics ES cell line XST128 embryonic stem cell house mouse CVCL_QG32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100159 CVCL_HM84 GM20651 transformed cell line human CVCL_HM84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100160 CVCL_QG33 BayGenomics ES cell line XST129 embryonic stem cell house mouse CVCL_QG33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100161 CVCL_HM85 GM20652 transformed cell line human CVCL_HM85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100162 CVCL_QG34 BayGenomics ES cell line XST130 embryonic stem cell house mouse CVCL_QG34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100163 CVCL_HM86 GM20653 transformed cell line human CVCL_HM86 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100164 CVCL_QG35 BayGenomics ES cell line XST131 embryonic stem cell house mouse CVCL_QG35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100165 CVCL_HM87 GM20654 transformed cell line human CVCL_HM87 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100166 CVCL_QG36 BayGenomics ES cell line XST132 embryonic stem cell house mouse CVCL_QG36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100167 CVCL_HM80 GM20647 transformed cell line human CVCL_HM80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100168 CVCL_QG37 BayGenomics ES cell line XST133 embryonic stem cell house mouse CVCL_QG37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139714; Adgrl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100169 CVCL_HM81 GM20648 transformed cell line human CVCL_HM81 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100170 CVCL_QG38 BayGenomics ES cell line XST137 embryonic stem cell house mouse CVCL_QG38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99894; Hnrnpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100171 CVCL_HM82 GM20649 transformed cell line human CVCL_HM82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100172 CVCL_QG39 BayGenomics ES cell line XST139 embryonic stem cell house mouse CVCL_QG39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100173 CVCL_HM83 GM20650 transformed cell line human CVCL_HM83 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100174 CVCL_QG18 BayGenomics ES cell line XST102 embryonic stem cell house mouse CVCL_QG18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96392; Icam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100175 CVCL_QG19 BayGenomics ES cell line XST103 embryonic stem cell house mouse CVCL_QG19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96955; Slc3a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100176 CVCL_HM99 GM20669 transformed cell line human CVCL_HM99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100177 CVCL_QG20 BayGenomics ES cell line XST104 embryonic stem cell house mouse CVCL_QG20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100178 CVCL_QG21 BayGenomics ES cell line XST106 embryonic stem cell house mouse CVCL_QG21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97750; Ppib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100179 CVCL_HM95 GM20662 transformed cell line human CVCL_HM95 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100180 CVCL_QG22 BayGenomics ES cell line XST108 embryonic stem cell house mouse CVCL_QG22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100181 CVCL_HM96 GM20664 transformed cell line human CVCL_HM96 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100182 CVCL_QG23 BayGenomics ES cell line XST111 embryonic stem cell house mouse CVCL_QG23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100183 CVCL_HM97 GM20666 transformed cell line human CVCL_HM97 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100184 CVCL_QG24 BayGenomics ES cell line XST113 embryonic stem cell house mouse CVCL_QG24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96788; Lifr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100185 CVCL_HM98 GM20668 transformed cell line human CVCL_HM98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100186 CVCL_QG25 BayGenomics ES cell line XST114 embryonic stem cell house mouse CVCL_QG25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924042; Spring1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100187 CVCL_HM91 GM20658 transformed cell line human CVCL_HM91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21100188 CVCL_QG26 BayGenomics ES cell line XST117 embryonic stem cell house mouse CVCL_QG26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100189 CVCL_HM92 GM20659 transformed cell line human CVCL_HM92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100190 CVCL_QG27 BayGenomics ES cell line XST119 embryonic stem cell house mouse CVCL_QG27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095418; Tfpi Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100191 CVCL_HM93 GM20660 transformed cell line human CVCL_HM93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100192 CVCL_QG28 BayGenomics ES cell line XST120 embryonic stem cell house mouse CVCL_QG28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100193 CVCL_HM94 GM20661 transformed cell line human CVCL_HM94 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21100194 CVCL_QQ41 BayGenomics ES cell line YTA293 embryonic stem cell house mouse CVCL_QQ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349722; Pabpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100195 CVCL_R241 HG03629 transformed cell line human CVCL_R241 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100196 CVCL_QQ42 BayGenomics ES cell line YTA296 embryonic stem cell house mouse CVCL_QQ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147437; Rrp12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100197 CVCL_R242 HG03631 transformed cell line human CVCL_R242 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100198 CVCL_QQ43 BayGenomics ES cell line YTA297 embryonic stem cell house mouse CVCL_QQ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144224; Dnaaf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100199 CVCL_R243 HG03633 transformed cell line human CVCL_R243 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100200 CVCL_QQ44 BayGenomics ES cell line YTA299 embryonic stem cell house mouse CVCL_QQ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100201 CVCL_R244 HG03634 transformed cell line human CVCL_R244 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100202 CVCL_QQ45 BayGenomics ES cell line YTA302 embryonic stem cell house mouse CVCL_QQ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100203 CVCL_R245 HG03636 transformed cell line human CVCL_R245 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100204 CVCL_QQ46 BayGenomics ES cell line YTA303 embryonic stem cell house mouse CVCL_QQ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100205 CVCL_R246 HG03639 transformed cell line human CVCL_R246 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100206 CVCL_QQ47 BayGenomics ES cell line YTA304 embryonic stem cell house mouse CVCL_QQ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103296; Nfatc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100207 CVCL_R247 HG03640 transformed cell line human CVCL_R247 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100208 CVCL_QQ48 BayGenomics ES cell line YTA308 embryonic stem cell house mouse CVCL_QQ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100836; Kpna6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100209 CVCL_R248 HG03642 transformed cell line human CVCL_R248 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100210 CVCL_QQ49 BayGenomics ES cell line YTA309 embryonic stem cell house mouse CVCL_QQ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100211 CVCL_R249 HG03643 transformed cell line human CVCL_R249 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100212 CVCL_QQ50 BayGenomics ES cell line YTA310 embryonic stem cell house mouse CVCL_QQ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915467; Prrc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100213 CVCL_R250 HG03644 transformed cell line human CVCL_R250 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100214 CVCL_QQ51 BayGenomics ES cell line YTA311 embryonic stem cell house mouse CVCL_QQ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100215 CVCL_R251 HG03645 transformed cell line human CVCL_R251 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100216 CVCL_QQ30 BayGenomics ES cell line YTA274 embryonic stem cell house mouse CVCL_QQ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100217 CVCL_R230 HG03604 transformed cell line human CVCL_R230 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100218 CVCL_QQ31 BayGenomics ES cell line YTA276 embryonic stem cell house mouse CVCL_QQ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100219 CVCL_R231 HG03606 transformed cell line human CVCL_R231 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100220 CVCL_QQ32 BayGenomics ES cell line YTA279 embryonic stem cell house mouse CVCL_QQ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100221 CVCL_R232 HG03607 transformed cell line human CVCL_R232 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100222 CVCL_QQ33 BayGenomics ES cell line YTA280 embryonic stem cell house mouse CVCL_QQ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931520; Dbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100223 CVCL_R233 HG03611 transformed cell line human CVCL_R233 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100224 CVCL_QQ34 BayGenomics ES cell line YTA282 embryonic stem cell house mouse CVCL_QQ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144243; Clint1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100225 CVCL_R234 HG03615 transformed cell line human CVCL_R234 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100226 CVCL_QQ35 BayGenomics ES cell line YTA284 embryonic stem cell house mouse CVCL_QQ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443764; Iqcb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100227 CVCL_R235 HG03616 transformed cell line human CVCL_R235 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100228 CVCL_QQ36 BayGenomics ES cell line YTA285 embryonic stem cell house mouse CVCL_QQ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298398; Mcm7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100229 CVCL_R236 HG03618 transformed cell line human CVCL_R236 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100230 CVCL_QQ37 BayGenomics ES cell line YTA287 embryonic stem cell house mouse CVCL_QQ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298398; Mcm7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100231 CVCL_R237 HG03619 transformed cell line human CVCL_R237 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100232 CVCL_QQ38 BayGenomics ES cell line YTA290 embryonic stem cell house mouse CVCL_QQ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329037; Strap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100233 CVCL_R238 HG03621 transformed cell line human CVCL_R238 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100234 CVCL_QQ39 BayGenomics ES cell line YTA291 embryonic stem cell house mouse CVCL_QQ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100235 CVCL_R239 HG03624 transformed cell line human CVCL_R239 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100236 CVCL_QQ40 BayGenomics ES cell line YTA292 embryonic stem cell house mouse CVCL_QQ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100237 CVCL_R240 HG03625 transformed cell line human CVCL_R240 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Quadruplication; Zygosity=Unspecified (PubMed=33197628) Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100238 CVCL_QQ20 BayGenomics ES cell line YTA256 embryonic stem cell house mouse CVCL_QQ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442524; Heatr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100239 CVCL_R220 HG03582 transformed cell line human CVCL_R220 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100240 CVCL_QQ21 BayGenomics ES cell line YTA257 embryonic stem cell house mouse CVCL_QQ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100241 CVCL_R221 HG03583 transformed cell line human CVCL_R221 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100242 CVCL_QQ22 BayGenomics ES cell line YTA258 embryonic stem cell house mouse CVCL_QQ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100243 CVCL_R222 HG03585 transformed cell line human CVCL_R222 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100244 CVCL_QQ23 BayGenomics ES cell line YTA259 embryonic stem cell house mouse CVCL_QQ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100846; Med1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100245 CVCL_R223 HG03589 transformed cell line human CVCL_R223 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100246 CVCL_QQ24 BayGenomics ES cell line YTA261 embryonic stem cell house mouse CVCL_QQ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924113; Dcun1d5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100247 CVCL_R224 HG03593 transformed cell line human CVCL_R224 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100248 CVCL_QQ25 BayGenomics ES cell line YTA263 embryonic stem cell house mouse CVCL_QQ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100249 CVCL_R225 HG03594 transformed cell line human CVCL_R225 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100250 CVCL_QQ26 BayGenomics ES cell line YTA264 embryonic stem cell house mouse CVCL_QQ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926139; Wsb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100251 CVCL_R226 HG03595 transformed cell line human CVCL_R226 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100252 CVCL_QQ27 BayGenomics ES cell line YTA267 embryonic stem cell house mouse CVCL_QQ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926139; Wsb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100253 CVCL_R227 HG03598 transformed cell line human CVCL_R227 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100254 CVCL_QQ28 BayGenomics ES cell line YTA270 embryonic stem cell house mouse CVCL_QQ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328363; Ccnt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100255 CVCL_R228 HG03600 transformed cell line human CVCL_R228 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100256 CVCL_QQ29 BayGenomics ES cell line YTA273 embryonic stem cell house mouse CVCL_QQ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316728; Gspt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100257 CVCL_R229 HG03603 transformed cell line human CVCL_R229 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100258 CVCL_I886 HGDP00886 transformed cell line human CVCL_I886 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100259 CVCL_HW86 ND36505 transformed cell line human CVCL_HW86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100260 CVCL_I887 HGDP00887 transformed cell line human CVCL_I887 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100261 CVCL_HW87 ND36750 transformed cell line human CVCL_HW87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100262 CVCL_I888 HGDP00888 transformed cell line human CVCL_I888 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100263 CVCL_HW88 ND05022 transformed cell line human CVCL_HW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100264 CVCL_I889 HGDP00889 transformed cell line human CVCL_I889 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100265 CVCL_HW89 ND05024 transformed cell line human CVCL_HW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100266 CVCL_I882 HGDP00882 transformed cell line human CVCL_I882 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100267 CVCL_HW82 ND35934 transformed cell line human CVCL_HW82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100268 CVCL_I883 HGDP00883 transformed cell line human CVCL_I883 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100269 CVCL_HW83 ND35935 transformed cell line human CVCL_HW83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100270 CVCL_I884 HGDP00884 transformed cell line human CVCL_I884 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100271 CVCL_HW84 ND36127 transformed cell line human CVCL_HW84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100272 CVCL_I885 HGDP00885 transformed cell line human CVCL_I885 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100273 CVCL_HW85 ND36152 transformed cell line human CVCL_HW85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100274 CVCL_I880 HGDP00880 transformed cell line human CVCL_I880 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100275 CVCL_HW80 ND34896 transformed cell line human CVCL_HW80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100276 CVCL_I881 HGDP00881 transformed cell line human CVCL_I881 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100277 CVCL_HW81 ND35838 transformed cell line human CVCL_HW81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100278 CVCL_QQ10 BayGenomics ES cell line YTA238 embryonic stem cell house mouse CVCL_QQ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930948; Gar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100279 CVCL_R210 HG03565 transformed cell line human CVCL_R210 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100280 CVCL_QQ11 BayGenomics ES cell line YTA242 embryonic stem cell house mouse CVCL_QQ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100281 CVCL_R211 HG03566 transformed cell line human CVCL_R211 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100282 CVCL_QQ12 BayGenomics ES cell line YTA243 embryonic stem cell house mouse CVCL_QQ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100283 CVCL_R212 HG03567 transformed cell line human CVCL_R212 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100284 CVCL_QQ13 BayGenomics ES cell line YTA244 embryonic stem cell house mouse CVCL_QQ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100285 CVCL_R213 HG03569 transformed cell line human CVCL_R213 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100286 CVCL_QQ14 BayGenomics ES cell line YTA247 embryonic stem cell house mouse CVCL_QQ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100287 CVCL_R214 HG03571 transformed cell line human CVCL_R214 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100288 CVCL_QQ15 BayGenomics ES cell line YTA250 embryonic stem cell house mouse CVCL_QQ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100289 CVCL_R215 HG03572 transformed cell line human CVCL_R215 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100290 CVCL_QQ16 BayGenomics ES cell line YTA251 embryonic stem cell house mouse CVCL_QQ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919667; Zfta Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100291 CVCL_R216 HG03574 transformed cell line human CVCL_R216 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100292 CVCL_QQ17 BayGenomics ES cell line YTA252 embryonic stem cell house mouse CVCL_QQ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096573; Utp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100293 CVCL_R217 HG03575 transformed cell line human CVCL_R217 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100294 CVCL_QQ18 BayGenomics ES cell line YTA254 embryonic stem cell house mouse CVCL_QQ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100295 CVCL_R218 HG03577 transformed cell line human CVCL_R218 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100296 CVCL_QQ19 BayGenomics ES cell line YTA255 embryonic stem cell house mouse CVCL_QQ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100297 CVCL_R219 HG03578 transformed cell line human CVCL_R219 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100298 CVCL_I897 HGDP00897 transformed cell line human CVCL_I897 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100299 CVCL_HW97 ND05408 transformed cell line human CVCL_HW97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100300 CVCL_I898 HGDP00898 transformed cell line human CVCL_I898 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100301 CVCL_HW98 ND05419 transformed cell line human CVCL_HW98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100302 CVCL_I899 HGDP00899 transformed cell line human CVCL_I899 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100303 CVCL_HW99 ND05420 transformed cell line human CVCL_HW99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100304 CVCL_I893 HGDP00893 transformed cell line human CVCL_I893 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100305 CVCL_HW93 ND05137 transformed cell line human CVCL_HW93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100306 CVCL_I894 HGDP00894 transformed cell line human CVCL_I894 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100307 CVCL_HW94 ND05261 transformed cell line human CVCL_HW94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100308 CVCL_I895 HGDP00895 transformed cell line human CVCL_I895 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100309 CVCL_HW95 ND05262 transformed cell line human CVCL_HW95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100310 CVCL_I896 HGDP00896 transformed cell line human CVCL_I896 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100311 CVCL_HW96 ND05407 transformed cell line human CVCL_HW96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100312 CVCL_I890 HGDP00890 transformed cell line human CVCL_I890 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100313 CVCL_HW90 ND05074 transformed cell line human CVCL_HW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100314 CVCL_I891 HGDP00891 transformed cell line human CVCL_I891 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100315 CVCL_HW91 ND05075 transformed cell line human CVCL_HW91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100316 CVCL_I892 HGDP00892 transformed cell line human CVCL_I892 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100317 CVCL_HW92 ND05136 transformed cell line human CVCL_HW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100318 CVCL_QQ00 BayGenomics ES cell line YTA214 embryonic stem cell house mouse CVCL_QQ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100319 CVCL_R200 HG03538 transformed cell line human CVCL_R200 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100320 CVCL_QQ01 BayGenomics ES cell line YTA215 embryonic stem cell house mouse CVCL_QQ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889206; Skap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100321 CVCL_R201 HG03539 transformed cell line human CVCL_R201 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100322 CVCL_QQ02 BayGenomics ES cell line YTA221 embryonic stem cell house mouse CVCL_QQ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100323 CVCL_R202 HG03547 transformed cell line human CVCL_R202 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100324 CVCL_QQ03 BayGenomics ES cell line YTA222 embryonic stem cell house mouse CVCL_QQ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932339; Sf3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100325 CVCL_R203 HG03548 transformed cell line human CVCL_R203 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100326 CVCL_QQ04 BayGenomics ES cell line YTA224 embryonic stem cell house mouse CVCL_QQ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98354; Sos1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100327 CVCL_R204 HG03549 transformed cell line human CVCL_R204 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100328 CVCL_QQ05 BayGenomics ES cell line YTA225 embryonic stem cell house mouse CVCL_QQ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98858; Psmd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100329 CVCL_R205 HG03556 transformed cell line human CVCL_R205 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100330 CVCL_I868 HGDP00868 transformed cell line human CVCL_I868 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100331 CVCL_HW68 ND28829 transformed cell line human CVCL_HW68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100332 CVCL_QQ06 BayGenomics ES cell line YTA226 embryonic stem cell house mouse CVCL_QQ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141847; Phrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100333 CVCL_R206 HG03557 transformed cell line human CVCL_R206 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100334 CVCL_I869 HGDP00869 transformed cell line human CVCL_I869 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100335 CVCL_HW69 ND28886 transformed cell line human CVCL_HW69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100336 CVCL_QQ07 BayGenomics ES cell line YTA227 embryonic stem cell house mouse CVCL_QQ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100337 CVCL_R207 HG03558 transformed cell line human CVCL_R207 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100338 CVCL_QQ08 BayGenomics ES cell line YTA231 embryonic stem cell house mouse CVCL_QQ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102666; Ppp5c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100339 CVCL_R208 HG03559 transformed cell line human CVCL_R208 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100340 CVCL_QQ09 BayGenomics ES cell line YTA237 embryonic stem cell house mouse CVCL_QQ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100341 CVCL_R209 HG03563 transformed cell line human CVCL_R209 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100342 CVCL_I864 HGDP00864 transformed cell line human CVCL_I864 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100343 CVCL_HW64 ND26773 transformed cell line human CVCL_HW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100344 CVCL_I865 HGDP00865 transformed cell line human CVCL_I865 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100345 CVCL_HW65 ND27104 transformed cell line human CVCL_HW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100346 CVCL_I866 HGDP00866 transformed cell line human CVCL_I866 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100347 CVCL_HW66 ND27325 transformed cell line human CVCL_HW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100348 CVCL_I867 HGDP00867 transformed cell line human CVCL_I867 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100349 CVCL_HW67 ND27895 transformed cell line human CVCL_HW67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100350 CVCL_I860 HGDP00860 transformed cell line human CVCL_I860 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100351 CVCL_HW60 ND22448 transformed cell line human CVCL_HW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100352 CVCL_I861 HGDP00861 transformed cell line human CVCL_I861 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100353 CVCL_HW61 ND22451 transformed cell line human CVCL_HW61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100354 CVCL_I862 HGDP00862 transformed cell line human CVCL_I862 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100355 CVCL_HW62 ND22458 transformed cell line human CVCL_HW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100356 CVCL_I863 HGDP00863 transformed cell line human CVCL_I863 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100357 CVCL_HW63 ND22465 transformed cell line human CVCL_HW63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100358 CVCL_I879 HGDP00879 transformed cell line human CVCL_I879 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100359 CVCL_HW79 ND34184 transformed cell line human CVCL_HW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100360 CVCL_I875 HGDP00875 transformed cell line human CVCL_I875 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100361 CVCL_HW75 ND31400 transformed cell line human CVCL_HW75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100362 CVCL_I876 HGDP00876 transformed cell line human CVCL_I876 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100363 CVCL_HW76 ND31646 transformed cell line human CVCL_HW76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100364 CVCL_I877 HGDP00877 transformed cell line human CVCL_I877 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100365 CVCL_HW77 ND33113 transformed cell line human CVCL_HW77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100366 CVCL_I878 HGDP00878 transformed cell line human CVCL_I878 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100367 CVCL_HW78 ND33641 transformed cell line human CVCL_HW78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100368 CVCL_I871 HGDP00871 transformed cell line human CVCL_I871 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100369 CVCL_HW71 ND29874 transformed cell line human CVCL_HW71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100370 CVCL_I872 HGDP00872 transformed cell line human CVCL_I872 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100371 CVCL_HW72 ND30067 transformed cell line human CVCL_HW72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100372 CVCL_I873 HGDP00873 transformed cell line human CVCL_I873 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100373 CVCL_HW73 ND30188 transformed cell line human CVCL_HW73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100374 CVCL_I874 HGDP00874 transformed cell line human CVCL_I874 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100375 CVCL_HW74 ND30602 transformed cell line human CVCL_HW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100376 CVCL_I870 HGDP00870 transformed cell line human CVCL_I870 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100377 CVCL_HW70 ND29535 transformed cell line human CVCL_HW70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100378 CVCL_I846 HGDP00846 transformed cell line human CVCL_I846 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100379 CVCL_HW46 ND22369 transformed cell line human CVCL_HW46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100380 CVCL_I847 HGDP00847 transformed cell line human CVCL_I847 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100381 CVCL_HW47 ND22376 transformed cell line human CVCL_HW47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100382 CVCL_I848 HGDP00848 transformed cell line human CVCL_I848 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100383 CVCL_HW48 ND22379 transformed cell line human CVCL_HW48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100384 CVCL_I849 HGDP00849 transformed cell line human CVCL_I849 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100385 CVCL_HW49 ND22382 transformed cell line human CVCL_HW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100386 CVCL_I842 HGDP00842 transformed cell line human CVCL_I842 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100387 CVCL_HW42 ND22349 transformed cell line human CVCL_HW42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100388 CVCL_I843 HGDP00843 transformed cell line human CVCL_I843 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100389 CVCL_HW43 ND22359 transformed cell line human CVCL_HW43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100390 CVCL_I844 HGDP00844 transformed cell line human CVCL_I844 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100391 CVCL_HW44 ND22360 transformed cell line human CVCL_HW44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100392 CVCL_I845 HGDP00845 transformed cell line human CVCL_I845 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100393 CVCL_HW45 ND22367 transformed cell line human CVCL_HW45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100394 CVCL_I840 HGDP00840 transformed cell line human CVCL_I840 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100395 CVCL_HW40 ND22339 transformed cell line human CVCL_HW40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100396 CVCL_I841 HGDP00841 transformed cell line human CVCL_I841 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100397 CVCL_HW41 ND22347 transformed cell line human CVCL_HW41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100398 CVCL_I857 HGDP00857 transformed cell line human CVCL_I857 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100399 CVCL_HW57 ND22405 transformed cell line human CVCL_HW57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100400 CVCL_I858 HGDP00858 transformed cell line human CVCL_I858 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100401 CVCL_HW58 ND22414 transformed cell line human CVCL_HW58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100402 CVCL_I859 HGDP00859 transformed cell line human CVCL_I859 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100403 CVCL_HW59 ND22434 transformed cell line human CVCL_HW59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100404 CVCL_I853 HGDP01342 transformed cell line human CVCL_I853 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100405 CVCL_HW53 ND22389 transformed cell line human CVCL_HW53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100406 CVCL_I854 HGDP00854 transformed cell line human CVCL_I854 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100407 CVCL_HW54 ND22392 transformed cell line human CVCL_HW54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100408 CVCL_I855 HGDP00855 transformed cell line human CVCL_I855 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100409 CVCL_HW55 ND22395 transformed cell line human CVCL_HW55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100410 CVCL_I856 HGDP00856 transformed cell line human CVCL_I856 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100411 CVCL_HW56 ND22402 transformed cell line human CVCL_HW56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100412 CVCL_I850 HGDP00850 transformed cell line human CVCL_I850 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100413 CVCL_HW50 ND22383 transformed cell line human CVCL_HW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100414 CVCL_I851 HGDP00851 transformed cell line human CVCL_I851 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100415 CVCL_HW51 ND22386 transformed cell line human CVCL_HW51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100416 CVCL_I852 HGDP00852 transformed cell line human CVCL_I852 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100417 CVCL_HW52 ND22388 transformed cell line human CVCL_HW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100418 CVCL_7E14 DA02417 transformed cell line human CVCL_7E14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02417; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100419 CVCL_7E15 DA02418 transformed cell line human CVCL_7E15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100420 CVCL_7E16 DA02419 transformed cell line human CVCL_7E16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02419; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100421 CVCL_7E17 DA02421 transformed cell line human CVCL_7E17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02421; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100422 CVCL_7E10 DA02413 transformed cell line human CVCL_7E10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02413; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100423 CVCL_7E11 DA02414 transformed cell line human CVCL_7E11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02414; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100424 CVCL_7E12 DA02415 transformed cell line human CVCL_7E12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02415; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100425 CVCL_7E13 DA02416 transformed cell line human CVCL_7E13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02416; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100426 CVCL_7E18 DA02422 transformed cell line human CVCL_7E18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100427 CVCL_7E19 DA02424 transformed cell line human CVCL_7E19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100428 CVCL_7E25 DA02430 transformed cell line human CVCL_7E25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100429 CVCL_7E26 DA02431 transformed cell line human CVCL_7E26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02431; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100430 CVCL_7E27 DA02432 transformed cell line human CVCL_7E27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02432; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100431 CVCL_7E28 DA02433 transformed cell line human CVCL_7E28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100432 CVCL_7E21 DA02426 transformed cell line human CVCL_7E21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02426; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100433 CVCL_7E22 DA02427 transformed cell line human CVCL_7E22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100434 CVCL_7E23 DA02428 transformed cell line human CVCL_7E23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100435 CVCL_7E24 DA02429 transformed cell line human CVCL_7E24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100436 CVCL_7E29 DA02434 transformed cell line human CVCL_7E29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100437 CVCL_7E20 DA02425 transformed cell line human CVCL_7E20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100438 CVCL_QQ96 BayGenomics ES cell line YTA400 embryonic stem cell house mouse CVCL_QQ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3042141; Traf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100439 CVCL_7E03 DA02406 transformed cell line human CVCL_7E03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100440 CVCL_R296 HG03718 transformed cell line human CVCL_R296 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100441 CVCL_QQ97 BayGenomics ES cell line YTA401 embryonic stem cell house mouse CVCL_QQ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855693; Nap1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100442 CVCL_7E04 DA02407 transformed cell line human CVCL_7E04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100443 CVCL_R297 HG03720 transformed cell line human CVCL_R297 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100444 CVCL_QQ98 BayGenomics ES cell line YTA403 embryonic stem cell house mouse CVCL_QQ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100445 CVCL_7E05 DA02408 transformed cell line human CVCL_7E05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100446 CVCL_R298 HG03721 transformed cell line human CVCL_R298 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100447 CVCL_QQ99 BayGenomics ES cell line YTA404 embryonic stem cell house mouse CVCL_QQ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100448 CVCL_7E06 DA02409 transformed cell line human CVCL_7E06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02409; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100449 CVCL_R299 HG03722 transformed cell line human CVCL_R299 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100450 CVCL_7E00 DA02403 transformed cell line human CVCL_7E00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100451 CVCL_7E01 DA02404 transformed cell line human CVCL_7E01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100452 CVCL_7E02 DA02405 transformed cell line human CVCL_7E02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100453 CVCL_7E07 DA02410 transformed cell line human CVCL_7E07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02410; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100454 CVCL_7E08 DA02411 transformed cell line human CVCL_7E08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02411; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100455 CVCL_7E09 DA02412 transformed cell line human CVCL_7E09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02412; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100456 CVCL_QQ85 BayGenomics ES cell line YTA378 embryonic stem cell house mouse CVCL_QQ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914513; Zswim6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100457 CVCL_R285 HG03703 transformed cell line human CVCL_R285 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100458 CVCL_QQ86 BayGenomics ES cell line YTA379 embryonic stem cell house mouse CVCL_QQ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99778; Gpd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100459 CVCL_R286 HG03705 transformed cell line human CVCL_R286 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100460 CVCL_QQ87 BayGenomics ES cell line YTA380 embryonic stem cell house mouse CVCL_QQ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109637; Erf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100461 CVCL_R287 HG03706 transformed cell line human CVCL_R287 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100462 CVCL_QQ88 BayGenomics ES cell line YTA385 embryonic stem cell house mouse CVCL_QQ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181074; Acbd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100463 CVCL_R288 HG03708 transformed cell line human CVCL_R288 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100464 CVCL_QQ89 BayGenomics ES cell line YTA387 embryonic stem cell house mouse CVCL_QQ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915206; Kmt5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100465 CVCL_R289 HG03709 transformed cell line human CVCL_R289 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100466 CVCL_QQ90 BayGenomics ES cell line YTA389 embryonic stem cell house mouse CVCL_QQ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385066; Rprd1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100467 CVCL_R290 HG03711 transformed cell line human CVCL_R290 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100468 CVCL_QQ91 BayGenomics ES cell line YTA390 embryonic stem cell house mouse CVCL_QQ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98342; Snrpb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100469 CVCL_R291 HG03713 transformed cell line human CVCL_R291 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100470 CVCL_QQ92 BayGenomics ES cell line YTA392 embryonic stem cell house mouse CVCL_QQ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443008; Trappc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100471 CVCL_R292 HG03714 transformed cell line human CVCL_R292 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100472 CVCL_QQ93 BayGenomics ES cell line YTA393 embryonic stem cell house mouse CVCL_QQ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914371; Mastl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100473 CVCL_R293 HG03715 transformed cell line human CVCL_R293 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100474 CVCL_QQ94 BayGenomics ES cell line YTA398 embryonic stem cell house mouse CVCL_QQ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351660; Csnk1e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100475 CVCL_R294 HG03716 transformed cell line human CVCL_R294 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100476 CVCL_QQ95 BayGenomics ES cell line YTA399 embryonic stem cell house mouse CVCL_QQ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100477 CVCL_R295 HG03717 transformed cell line human CVCL_R295 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100478 CVCL_QQ74 BayGenomics ES cell line YTA359 embryonic stem cell house mouse CVCL_QQ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100479 CVCL_R274 HG03691 transformed cell line human CVCL_R274 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100480 CVCL_QQ75 BayGenomics ES cell line YTA360 embryonic stem cell house mouse CVCL_QQ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103250; Calm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100481 CVCL_R275 HG03692 transformed cell line human CVCL_R275 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100482 CVCL_QQ76 BayGenomics ES cell line YTA363 embryonic stem cell house mouse CVCL_QQ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107637; Psmb7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100483 CVCL_R276 HG03693 transformed cell line human CVCL_R276 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100484 CVCL_QQ77 BayGenomics ES cell line YTA364 embryonic stem cell house mouse CVCL_QQ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100485 CVCL_R277 HG03694 transformed cell line human CVCL_R277 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100486 CVCL_QQ78 BayGenomics ES cell line YTA365 embryonic stem cell house mouse CVCL_QQ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100487 CVCL_R278 HG03695 transformed cell line human CVCL_R278 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100488 CVCL_QQ79 BayGenomics ES cell line YTA367 embryonic stem cell house mouse CVCL_QQ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347352; Hunk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100489 CVCL_R279 HG03696 transformed cell line human CVCL_R279 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100490 CVCL_QQ80 BayGenomics ES cell line YTA369 embryonic stem cell house mouse CVCL_QQ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100491 CVCL_R280 HG03697 transformed cell line human CVCL_R280 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100492 CVCL_QQ81 BayGenomics ES cell line YTA370 embryonic stem cell house mouse CVCL_QQ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929608; Aatf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100493 CVCL_R281 HG03698 transformed cell line human CVCL_R281 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100494 CVCL_QQ82 BayGenomics ES cell line YTA371 embryonic stem cell house mouse CVCL_QQ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858304; Ctps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100495 CVCL_R282 HG03699 transformed cell line human CVCL_R282 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100496 CVCL_QQ83 BayGenomics ES cell line YTA374 embryonic stem cell house mouse CVCL_QQ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921793; Zfp871 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100497 CVCL_R283 HG03700 transformed cell line human CVCL_R283 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100498 CVCL_QQ84 BayGenomics ES cell line YTA375 embryonic stem cell house mouse CVCL_QQ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920924; Wdr75 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100499 CVCL_R284 HG03702 transformed cell line human CVCL_R284 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100500 CVCL_QQ63 BayGenomics ES cell line YTA341 embryonic stem cell house mouse CVCL_QQ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100501 CVCL_R263 HG03673 transformed cell line human CVCL_R263 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100502 CVCL_QQ64 BayGenomics ES cell line YTA342 embryonic stem cell house mouse CVCL_QQ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100503 CVCL_R264 HG03679 transformed cell line human CVCL_R264 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100504 CVCL_QQ65 BayGenomics ES cell line YTA343 embryonic stem cell house mouse CVCL_QQ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100505 CVCL_R265 HG03680 transformed cell line human CVCL_R265 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100506 CVCL_QQ66 BayGenomics ES cell line YTA344 embryonic stem cell house mouse CVCL_QQ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100507 CVCL_R266 HG03681 transformed cell line human CVCL_R266 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100508 CVCL_QQ67 BayGenomics ES cell line YTA345 embryonic stem cell house mouse CVCL_QQ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106478; Eif3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100509 CVCL_R267 HG03682 transformed cell line human CVCL_R267 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100510 CVCL_QQ68 BayGenomics ES cell line YTA349 embryonic stem cell house mouse CVCL_QQ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029414; Brwd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100511 CVCL_R268 HG03684 transformed cell line human CVCL_R268 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100512 CVCL_QQ69 BayGenomics ES cell line YTA350 embryonic stem cell house mouse CVCL_QQ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100513 CVCL_R269 HG03685 transformed cell line human CVCL_R269 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100514 CVCL_QQ70 BayGenomics ES cell line YTA353 embryonic stem cell house mouse CVCL_QQ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100515 CVCL_R270 HG03686 transformed cell line human CVCL_R270 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100516 CVCL_QQ71 BayGenomics ES cell line YTA355 embryonic stem cell house mouse CVCL_QQ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890396; Suv39h2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100517 CVCL_R271 HG03687 transformed cell line human CVCL_R271 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100518 CVCL_QQ72 BayGenomics ES cell line YTA357 embryonic stem cell house mouse CVCL_QQ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87989; Alas1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100519 CVCL_R272 HG03689 transformed cell line human CVCL_R272 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100520 CVCL_QQ73 BayGenomics ES cell line YTA358 embryonic stem cell house mouse CVCL_QQ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100521 CVCL_R273 HG03690 transformed cell line human CVCL_R273 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100522 CVCL_QQ52 BayGenomics ES cell line YTA312 embryonic stem cell house mouse CVCL_QQ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97960; Rnps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100523 CVCL_R252 HG03646 transformed cell line human CVCL_R252 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100524 CVCL_QQ53 BayGenomics ES cell line YTA317 embryonic stem cell house mouse CVCL_QQ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921700; Pank2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100525 CVCL_R253 HG03649 transformed cell line human CVCL_R253 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100526 CVCL_QQ54 BayGenomics ES cell line YTA321 embryonic stem cell house mouse CVCL_QQ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918023; Cwf19l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100527 CVCL_R254 HG03650 transformed cell line human CVCL_R254 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100528 CVCL_QQ55 BayGenomics ES cell line YTA326 embryonic stem cell house mouse CVCL_QQ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914324; Mon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100529 CVCL_R255 HG03652 transformed cell line human CVCL_R255 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100530 CVCL_QQ56 BayGenomics ES cell line YTA327 embryonic stem cell house mouse CVCL_QQ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858961; Prc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100531 CVCL_R256 HG03653 transformed cell line human CVCL_R256 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100532 CVCL_QQ57 BayGenomics ES cell line YTA330 embryonic stem cell house mouse CVCL_QQ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109584; Prpf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100533 CVCL_R257 HG03656 transformed cell line human CVCL_R257 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100534 CVCL_QQ58 BayGenomics ES cell line YTA331 embryonic stem cell house mouse CVCL_QQ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100535 CVCL_R258 HG03660 transformed cell line human CVCL_R258 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100536 CVCL_QQ59 BayGenomics ES cell line YTA332 embryonic stem cell house mouse CVCL_QQ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930134; Ern1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100537 CVCL_R259 HG03663 transformed cell line human CVCL_R259 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100538 CVCL_QQ60 BayGenomics ES cell line YTA334 embryonic stem cell house mouse CVCL_QQ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100539 CVCL_R260 HG03667 transformed cell line human CVCL_R260 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100540 CVCL_QQ61 BayGenomics ES cell line YTA337 embryonic stem cell house mouse CVCL_QQ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100541 CVCL_R261 HG03668 transformed cell line human CVCL_R261 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100542 CVCL_QQ62 BayGenomics ES cell line YTA340 embryonic stem cell house mouse CVCL_QQ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145245; Srek1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100543 CVCL_R262 HG03672 transformed cell line human CVCL_R262 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100544 CVCL_7D77 DA02368 transformed cell line human CVCL_7D77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02368; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100545 CVCL_7D78 DA02372 transformed cell line human CVCL_7D78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02372; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100546 CVCL_7D79 DA02375 transformed cell line human CVCL_7D79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100547 CVCL_7D73 DA02363 transformed cell line human CVCL_7D73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02363; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100548 CVCL_7D74 DA02364 transformed cell line human CVCL_7D74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02364; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100549 CVCL_7D75 DA02365 transformed cell line human CVCL_7D75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100550 CVCL_7D76 DA02366 transformed cell line human CVCL_7D76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02366; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100551 CVCL_7D70 DA02360 transformed cell line human CVCL_7D70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02360; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100552 CVCL_7D71 DA02361 transformed cell line human CVCL_7D71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100553 CVCL_7D72 DA02362 transformed cell line human CVCL_7D72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02362; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100554 CVCL_7D88 DA02390 transformed cell line human CVCL_7D88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100555 CVCL_7D89 DA02391 transformed cell line human CVCL_7D89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02391; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100556 CVCL_7D84 DA02384 transformed cell line human CVCL_7D84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02384; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100557 CVCL_7D85 DA02385 transformed cell line human CVCL_7D85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02385; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100558 CVCL_7D86 DA02387 transformed cell line human CVCL_7D86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02387; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100559 CVCL_7D87 DA02388 transformed cell line human CVCL_7D87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02388; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100560 CVCL_7D80 DA02376 transformed cell line human CVCL_7D80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100561 CVCL_7D81 DA02379 transformed cell line human CVCL_7D81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02379; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100562 CVCL_7D82 DA02380 transformed cell line human CVCL_7D82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02380; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100563 CVCL_7D83 DA02383 transformed cell line human CVCL_7D83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100564 CVCL_7D59 DA02344 transformed cell line human CVCL_7D59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02344; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100565 CVCL_7D55 DA02340 transformed cell line human CVCL_7D55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100566 CVCL_7D56 DA02341 transformed cell line human CVCL_7D56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100567 CVCL_7D57 DA02342 transformed cell line human CVCL_7D57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100568 CVCL_7D58 DA02343 transformed cell line human CVCL_7D58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02343; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100569 CVCL_7D51 DA02335 transformed cell line human CVCL_7D51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02335; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100570 CVCL_7D52 DA02337 transformed cell line human CVCL_7D52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02337; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100571 CVCL_7D53 DA02338 transformed cell line human CVCL_7D53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100572 CVCL_7D54 DA02339 transformed cell line human CVCL_7D54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100573 CVCL_7D50 DA02334 transformed cell line human CVCL_7D50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02334; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100574 CVCL_7D66 DA02353 transformed cell line human CVCL_7D66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02353; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100575 CVCL_7D67 DA02357 transformed cell line human CVCL_7D67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100576 CVCL_7D68 DA02358 transformed cell line human CVCL_7D68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100577 CVCL_7D69 DA02359 transformed cell line human CVCL_7D69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02359; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100578 CVCL_7D62 DA02347 transformed cell line human CVCL_7D62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100579 CVCL_7D63 DA02349 transformed cell line human CVCL_7D63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02349; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100580 CVCL_7D64 DA02350 transformed cell line human CVCL_7D64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02350; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100581 CVCL_7D65 DA02352 transformed cell line human CVCL_7D65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02352; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100582 CVCL_7D60 DA02345 transformed cell line human CVCL_7D60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100583 CVCL_7D61 DA02346 transformed cell line human CVCL_7D61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100584 CVCL_7D37 DA02317 transformed cell line human CVCL_7D37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100585 CVCL_7D38 DA02318 transformed cell line human CVCL_7D38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100586 CVCL_7D39 DA02319 transformed cell line human CVCL_7D39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100587 CVCL_7D33 DA02313 transformed cell line human CVCL_7D33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100588 CVCL_7D34 DA02314 transformed cell line human CVCL_7D34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100589 CVCL_7D35 DA02315 transformed cell line human CVCL_7D35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02315; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100590 CVCL_7D36 DA02316 transformed cell line human CVCL_7D36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100591 CVCL_7D30 DA02310 transformed cell line human CVCL_7D30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02310; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100592 CVCL_7D31 DA02311 transformed cell line human CVCL_7D31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02311; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100593 CVCL_7D32 DA02312 transformed cell line human CVCL_7D32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02312; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100594 CVCL_7D48 DA02330 transformed cell line human CVCL_7D48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02330; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100595 CVCL_7D49 DA02332 transformed cell line human CVCL_7D49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02332; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100596 CVCL_7D44 DA02326 transformed cell line human CVCL_7D44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02326; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100597 CVCL_7D45 DA02327 transformed cell line human CVCL_7D45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02327; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100598 CVCL_7D46 DA02328 transformed cell line human CVCL_7D46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02328; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100599 CVCL_7D47 DA02329 transformed cell line human CVCL_7D47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02329; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100600 CVCL_7D40 DA02320 transformed cell line human CVCL_7D40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02320; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100601 CVCL_7D41 DA02321 transformed cell line human CVCL_7D41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02321; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100602 CVCL_7D42 DA02323 transformed cell line human CVCL_7D42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02323; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100603 CVCL_7D43 DA02325 transformed cell line human CVCL_7D43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02325; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100604 CVCL_7D15 DA02291 transformed cell line human CVCL_7D15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02291; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100605 CVCL_7D16 DA02292 transformed cell line human CVCL_7D16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02292; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100606 CVCL_7D17 DA02293 transformed cell line human CVCL_7D17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02293; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100607 CVCL_7D18 DA02294 transformed cell line human CVCL_7D18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100608 CVCL_7D11 DA02285 transformed cell line human CVCL_7D11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02285; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100609 CVCL_7D12 DA02286 transformed cell line human CVCL_7D12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02286; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100610 CVCL_7D13 DA02287 transformed cell line human CVCL_7D13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02287; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100611 CVCL_7D14 DA02290 transformed cell line human CVCL_7D14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02290; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100612 CVCL_7D19 DA02295 transformed cell line human CVCL_7D19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100613 CVCL_7D10 DA02283 transformed cell line human CVCL_7D10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02283; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100614 CVCL_7D26 DA02305 transformed cell line human CVCL_7D26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100615 CVCL_7D27 DA02306 transformed cell line human CVCL_7D27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100616 CVCL_7D28 DA02307 transformed cell line human CVCL_7D28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100617 CVCL_7D29 DA02309 transformed cell line human CVCL_7D29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100618 CVCL_7D22 DA02300 transformed cell line human CVCL_7D22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100619 CVCL_7D23 DA02302 transformed cell line human CVCL_7D23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100620 CVCL_7D24 DA02303 transformed cell line human CVCL_7D24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100621 CVCL_7D25 DA02304 transformed cell line human CVCL_7D25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100622 CVCL_7D20 DA02296 transformed cell line human CVCL_7D20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100623 CVCL_7D21 DA02297 transformed cell line human CVCL_7D21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100624 CVCL_I828 HGDP00828 transformed cell line human CVCL_I828 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100625 CVCL_HW28 ND22285 transformed cell line human CVCL_HW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100626 CVCL_I829 HGDP01339 transformed cell line human CVCL_I829 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100627 CVCL_HW29 ND22286 transformed cell line human CVCL_HW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100628 CVCL_I824 HGDP00824 transformed cell line human CVCL_I824 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100629 CVCL_HW24 ND19266 transformed cell line human CVCL_HW24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100630 CVCL_I825 HGDP00825 transformed cell line human CVCL_I825 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100631 CVCL_HW25 ND22262 transformed cell line human CVCL_HW25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100632 CVCL_I826 HGDP00826 transformed cell line human CVCL_I826 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100633 CVCL_HW26 ND22265 transformed cell line human CVCL_HW26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100634 CVCL_I827 HGDP00827 transformed cell line human CVCL_I827 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100635 CVCL_HW27 ND22283 transformed cell line human CVCL_HW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100636 CVCL_I820 HGDP00820 transformed cell line human CVCL_I820 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100637 CVCL_HW20 ND15893 transformed cell line human CVCL_HW20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100638 CVCL_I821 HGDP00821 transformed cell line human CVCL_I821 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100639 CVCL_HW21 ND16024 transformed cell line human CVCL_HW21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100640 CVCL_I822 HGDP00822 transformed cell line human CVCL_I822 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100641 CVCL_HW22 ND16261 transformed cell line human CVCL_HW22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100642 CVCL_I823 HGDP00823 transformed cell line human CVCL_I823 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100643 CVCL_HW23 ND19187 transformed cell line human CVCL_HW23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100644 CVCL_I839 HGDP00839 transformed cell line human CVCL_I839 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100645 CVCL_HW39 ND22337 transformed cell line human CVCL_HW39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100646 CVCL_I835 HGDP00835 transformed cell line human CVCL_I835 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100647 CVCL_HW35 ND22325 transformed cell line human CVCL_HW35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100648 CVCL_I836 HGDP01341 transformed cell line human CVCL_I836 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100649 CVCL_HW36 ND22328 transformed cell line human CVCL_HW36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100650 CVCL_I837 HGDP00837 transformed cell line human CVCL_I837 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100651 CVCL_HW37 ND22331 transformed cell line human CVCL_HW37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100652 CVCL_I838 HGDP00838 transformed cell line human CVCL_I838 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100653 CVCL_HW38 ND22336 transformed cell line human CVCL_HW38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100654 CVCL_I831 HGDP01340 transformed cell line human CVCL_I831 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100655 CVCL_HW31 ND22297 transformed cell line human CVCL_HW31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100656 CVCL_I832 HGDP00832 transformed cell line human CVCL_I832 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100657 CVCL_HW32 ND22298 transformed cell line human CVCL_HW32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100658 CVCL_I833 HGDP00833 transformed cell line human CVCL_I833 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100659 CVCL_HW33 ND22299 transformed cell line human CVCL_HW33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100660 CVCL_I834 HGDP00834 transformed cell line human CVCL_I834 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100661 CVCL_HW34 ND22316 transformed cell line human CVCL_HW34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100662 CVCL_I830 HGDP00830 transformed cell line human CVCL_I830 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100663 CVCL_HW30 ND22289 transformed cell line human CVCL_HW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100664 CVCL_I806 HGDP00806 transformed cell line human CVCL_I806 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100665 CVCL_HW06 ND14467 transformed cell line human CVCL_HW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100666 CVCL_I807 HGDP00807 transformed cell line human CVCL_I807 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100667 CVCL_HW07 ND14658 transformed cell line human CVCL_HW07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100668 CVCL_I808 HGDP00808 transformed cell line human CVCL_I808 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100669 CVCL_HW08 ND14775 transformed cell line human CVCL_HW08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100670 CVCL_I809 HGDP01337 transformed cell line human CVCL_I809 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100671 CVCL_HW09 ND14787 transformed cell line human CVCL_HW09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100672 CVCL_I802 HGDP00802 transformed cell line human CVCL_I802 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100673 CVCL_HW02 ND13745 transformed cell line human CVCL_HW02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100674 CVCL_I803 HGDP00803 transformed cell line human CVCL_I803 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100675 CVCL_HW03 ND14165 transformed cell line human CVCL_HW03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100676 CVCL_I804 HGDP00804 transformed cell line human CVCL_I804 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100677 CVCL_HW04 ND14203 transformed cell line human CVCL_HW04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100678 CVCL_I805 HGDP00805 transformed cell line human CVCL_I805 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100679 CVCL_HW05 ND14369 transformed cell line human CVCL_HW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100680 CVCL_I800 HGDP00800 transformed cell line human CVCL_I800 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100681 CVCL_HW00 ND13428 transformed cell line human CVCL_HW00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100682 CVCL_I801 HGDP00801 transformed cell line human CVCL_I801 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100683 CVCL_HW01 ND13744 transformed cell line human CVCL_HW01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100684 CVCL_I817 HGDP00817 transformed cell line human CVCL_I817 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100685 CVCL_HW17 ND15760 transformed cell line human CVCL_HW17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100686 CVCL_I818 HGDP00818 transformed cell line human CVCL_I818 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100687 CVCL_HW18 ND15854 transformed cell line human CVCL_HW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100688 CVCL_I819 HGDP00819 transformed cell line human CVCL_I819 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100689 CVCL_HW19 ND15892 transformed cell line human CVCL_HW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100690 CVCL_I813 HGDP00813 transformed cell line human CVCL_I813 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100691 CVCL_HW13 ND15458 transformed cell line human CVCL_HW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100692 CVCL_I814 HGDP00814 transformed cell line human CVCL_I814 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100693 CVCL_HW14 ND15597 transformed cell line human CVCL_HW14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100694 CVCL_I815 HGDP00815 transformed cell line human CVCL_I815 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100695 CVCL_HW15 ND15656 transformed cell line human CVCL_HW15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100696 CVCL_I816 HGDP01338 transformed cell line human CVCL_I816 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100697 CVCL_HW16 ND15731 transformed cell line human CVCL_HW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100698 CVCL_I810 HGDP00810 transformed cell line human CVCL_I810 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100699 CVCL_HW10 ND14803 transformed cell line human CVCL_HW10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100700 CVCL_I811 HGDP00811 transformed cell line human CVCL_I811 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100701 CVCL_HW11 ND15047 transformed cell line human CVCL_HW11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100702 CVCL_I812 HGDP00812 transformed cell line human CVCL_I812 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100703 CVCL_HW12 ND15195 transformed cell line human CVCL_HW12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100704 CVCL_7D99 DA02402 transformed cell line human CVCL_7D99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100705 CVCL_7D90 DA02393 transformed cell line human CVCL_7D90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02393; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100706 CVCL_7D95 DA02398 transformed cell line human CVCL_7D95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100707 CVCL_7D96 DA02399 transformed cell line human CVCL_7D96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100708 CVCL_7D97 DA02400 transformed cell line human CVCL_7D97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100709 CVCL_7D98 DA02401 transformed cell line human CVCL_7D98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100710 CVCL_7D91 DA02394 transformed cell line human CVCL_7D91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100711 CVCL_7D92 DA02395 transformed cell line human CVCL_7D92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100712 CVCL_7D93 DA02396 transformed cell line human CVCL_7D93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100713 CVCL_7D94 DA02397 transformed cell line human CVCL_7D94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02397; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100714 CVCL_QR62 BayGenomics ES cell line YTA565 embryonic stem cell house mouse CVCL_QR62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100715 CVCL_R362 HG03814 transformed cell line human CVCL_R362 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100716 CVCL_QR63 BayGenomics ES cell line YTA566 embryonic stem cell house mouse CVCL_QR63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197010; Sumo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100717 CVCL_R363 HG03815 transformed cell line human CVCL_R363 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100718 CVCL_QR64 BayGenomics ES cell line YTA568 embryonic stem cell house mouse CVCL_QR64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339970; Rtn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100719 CVCL_R364 HG03817 transformed cell line human CVCL_R364 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100720 CVCL_QR65 BayGenomics ES cell line YTA569 embryonic stem cell house mouse CVCL_QR65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289341; Sf3b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100721 CVCL_R365 HG03821 transformed cell line human CVCL_R365 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100722 CVCL_QR66 BayGenomics ES cell line YTA570 embryonic stem cell house mouse CVCL_QR66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913125; Pias1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100723 CVCL_R366 HG03823 transformed cell line human CVCL_R366 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100724 CVCL_QR67 BayGenomics ES cell line YTA572 embryonic stem cell house mouse CVCL_QR67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97621; Plk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100725 CVCL_R367 HG03824 transformed cell line human CVCL_R367 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100726 CVCL_QR68 BayGenomics ES cell line YTA574 embryonic stem cell house mouse CVCL_QR68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354949; Dlc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100727 CVCL_R368 HG03826 transformed cell line human CVCL_R368 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100728 CVCL_QR69 BayGenomics ES cell line YTA575 embryonic stem cell house mouse CVCL_QR69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354949; Dlc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100729 CVCL_R369 HG03829 transformed cell line human CVCL_R369 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100730 CVCL_QR70 BayGenomics ES cell line YTA578 embryonic stem cell house mouse CVCL_QR70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100731 CVCL_R370 HG03830 transformed cell line human CVCL_R370 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100732 CVCL_QR71 BayGenomics ES cell line YTA579 embryonic stem cell house mouse CVCL_QR71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100733 CVCL_R371 HG03832 transformed cell line human CVCL_R371 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100734 CVCL_QR72 BayGenomics ES cell line YTA581 embryonic stem cell house mouse CVCL_QR72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101757; Cfl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100735 CVCL_R372 HG03833 transformed cell line human CVCL_R372 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100736 CVCL_QR51 BayGenomics ES cell line YTA535 embryonic stem cell house mouse CVCL_QR51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201408; Srpk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100737 CVCL_R351 HG03797 transformed cell line human CVCL_R351 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100738 CVCL_QR52 BayGenomics ES cell line YTA540 embryonic stem cell house mouse CVCL_QR52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88108; Atp1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100739 CVCL_R352 HG03799 transformed cell line human CVCL_R352 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100740 CVCL_QR53 BayGenomics ES cell line YTA541 embryonic stem cell house mouse CVCL_QR53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309489; Cask Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100741 CVCL_R353 HG03800 transformed cell line human CVCL_R353 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100742 CVCL_QR54 BayGenomics ES cell line YTA542 embryonic stem cell house mouse CVCL_QR54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98510; Tcf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100743 CVCL_R354 HG03802 transformed cell line human CVCL_R354 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100744 CVCL_QR55 BayGenomics ES cell line YTA543 embryonic stem cell house mouse CVCL_QR55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333856; Klf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100745 CVCL_R355 HG03803 transformed cell line human CVCL_R355 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100746 CVCL_QR56 BayGenomics ES cell line YTA544 embryonic stem cell house mouse CVCL_QR56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1206040; Vps26c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100747 CVCL_R356 HG03805 transformed cell line human CVCL_R356 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100748 CVCL_QR57 BayGenomics ES cell line YTA546 embryonic stem cell house mouse CVCL_QR57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100749 CVCL_R357 HG03806 transformed cell line human CVCL_R357 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100750 CVCL_QR58 BayGenomics ES cell line YTA553 embryonic stem cell house mouse CVCL_QR58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309489; Cask Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100751 CVCL_R358 HG03808 transformed cell line human CVCL_R358 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100752 CVCL_QR59 BayGenomics ES cell line YTA554 embryonic stem cell house mouse CVCL_QR59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98510; Tcf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100753 CVCL_R359 HG03809 transformed cell line human CVCL_R359 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100754 CVCL_QR60 BayGenomics ES cell line YTA555 embryonic stem cell house mouse CVCL_QR60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333856; Klf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100755 CVCL_R360 HG03811 transformed cell line human CVCL_R360 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100756 CVCL_QR61 BayGenomics ES cell line YTA556 embryonic stem cell house mouse CVCL_QR61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1206040; Vps26c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100757 CVCL_R361 HG03812 transformed cell line human CVCL_R361 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100758 CVCL_QR40 BayGenomics ES cell line YTA499 embryonic stem cell house mouse CVCL_QR40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100759 CVCL_R340 HG03784 transformed cell line human CVCL_R340 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100760 CVCL_QR41 BayGenomics ES cell line YTA502 embryonic stem cell house mouse CVCL_QR41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100761 CVCL_R341 HG03785 transformed cell line human CVCL_R341 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100762 CVCL_QR42 BayGenomics ES cell line YTA503 embryonic stem cell house mouse CVCL_QR42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100763 CVCL_R342 HG03786 transformed cell line human CVCL_R342 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100764 CVCL_QR43 BayGenomics ES cell line YTA504 embryonic stem cell house mouse CVCL_QR43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100765 CVCL_R343 HG03787 transformed cell line human CVCL_R343 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100766 CVCL_QR44 BayGenomics ES cell line YTA506 embryonic stem cell house mouse CVCL_QR44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104872; Ppp1cc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100767 CVCL_R344 HG03788 transformed cell line human CVCL_R344 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100768 CVCL_QR45 BayGenomics ES cell line YTA509 embryonic stem cell house mouse CVCL_QR45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100769 CVCL_R345 HG03789 transformed cell line human CVCL_R345 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100770 CVCL_QR46 BayGenomics ES cell line YTA516 embryonic stem cell house mouse CVCL_QR46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890222; Midn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100771 CVCL_R346 HG03790 transformed cell line human CVCL_R346 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100772 CVCL_QR47 BayGenomics ES cell line YTA523 embryonic stem cell house mouse CVCL_QR47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100773 CVCL_R347 HG03792 transformed cell line human CVCL_R347 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100774 CVCL_QR48 BayGenomics ES cell line YTA524 embryonic stem cell house mouse CVCL_QR48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100775 CVCL_R348 HG03793 transformed cell line human CVCL_R348 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100776 CVCL_QR49 BayGenomics ES cell line YTA528 embryonic stem cell house mouse CVCL_QR49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923264; Zc3h18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100777 CVCL_R349 HG03794 transformed cell line human CVCL_R349 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100778 CVCL_QR50 BayGenomics ES cell line YTA529 embryonic stem cell house mouse CVCL_QR50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97451; Otx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100779 CVCL_R350 HG03796 transformed cell line human CVCL_R350 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100780 CVCL_QR30 BayGenomics ES cell line YTA473 embryonic stem cell house mouse CVCL_QR30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100781 CVCL_R330 HG03772 transformed cell line human CVCL_R330 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100782 CVCL_QR31 BayGenomics ES cell line YTA474 embryonic stem cell house mouse CVCL_QR31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1314653; Afdn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100783 CVCL_R331 HG03773 transformed cell line human CVCL_R331 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100784 CVCL_QR32 BayGenomics ES cell line YTA475 embryonic stem cell house mouse CVCL_QR32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100785 CVCL_R332 HG03774 transformed cell line human CVCL_R332 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100786 CVCL_QR33 BayGenomics ES cell line YTA476 embryonic stem cell house mouse CVCL_QR33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100787 CVCL_R333 HG03775 transformed cell line human CVCL_R333 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100788 CVCL_QR34 BayGenomics ES cell line YTA477 embryonic stem cell house mouse CVCL_QR34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915309; Tm9sf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100789 CVCL_R334 HG03777 transformed cell line human CVCL_R334 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100790 CVCL_QR35 BayGenomics ES cell line YTA478 embryonic stem cell house mouse CVCL_QR35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921700; Pank2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100791 CVCL_R335 HG03778 transformed cell line human CVCL_R335 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100792 CVCL_QR36 BayGenomics ES cell line YTA479 embryonic stem cell house mouse CVCL_QR36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100793 CVCL_R336 HG03779 transformed cell line human CVCL_R336 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100794 CVCL_QR37 BayGenomics ES cell line YTA487 embryonic stem cell house mouse CVCL_QR37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925177; Ccdc88a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100795 CVCL_R337 HG03780 transformed cell line human CVCL_R337 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100796 CVCL_QR38 BayGenomics ES cell line YTA490 embryonic stem cell house mouse CVCL_QR38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100797 CVCL_R338 HG03781 transformed cell line human CVCL_R338 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100798 CVCL_QR39 BayGenomics ES cell line YTA497 embryonic stem cell house mouse CVCL_QR39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923038; Smurf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100799 CVCL_R339 HG03782 transformed cell line human CVCL_R339 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100800 CVCL_QR20 BayGenomics ES cell line YTA448 embryonic stem cell house mouse CVCL_QR20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102944; Ube2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100801 CVCL_R320 HG03755 transformed cell line human CVCL_R320 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100802 CVCL_QR21 BayGenomics ES cell line YTA449 embryonic stem cell house mouse CVCL_QR21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679002; Prr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100803 CVCL_R321 HG03756 transformed cell line human CVCL_R321 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100804 CVCL_QR22 BayGenomics ES cell line YTA451 embryonic stem cell house mouse CVCL_QR22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100805 CVCL_R322 HG03757 transformed cell line human CVCL_R322 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100806 CVCL_QR23 BayGenomics ES cell line YTA455 embryonic stem cell house mouse CVCL_QR23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99150; Yy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100807 CVCL_R323 HG03760 transformed cell line human CVCL_R323 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100808 CVCL_QR24 BayGenomics ES cell line YTA456 embryonic stem cell house mouse CVCL_QR24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100809 CVCL_R324 HG03761 transformed cell line human CVCL_R324 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100810 CVCL_QR25 BayGenomics ES cell line YTA465 embryonic stem cell house mouse CVCL_QR25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919367; Naa50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100811 CVCL_R325 HG03762 transformed cell line human CVCL_R325 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100812 CVCL_QR26 BayGenomics ES cell line YTA466 embryonic stem cell house mouse CVCL_QR26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100813 CVCL_R326 HG03765 transformed cell line human CVCL_R326 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100814 CVCL_I989 HGDP01343 transformed cell line human CVCL_I989 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100815 CVCL_HX89 ND01174 transformed cell line human CVCL_HX89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100816 CVCL_QR27 BayGenomics ES cell line YTA467 embryonic stem cell house mouse CVCL_QR27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143362; Zfp809 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100817 CVCL_R327 HG03767 transformed cell line human CVCL_R327 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100818 CVCL_QR28 BayGenomics ES cell line YTA470 embryonic stem cell house mouse CVCL_QR28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109637; Erf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100819 CVCL_R328 HG03770 transformed cell line human CVCL_R328 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100820 CVCL_QR29 BayGenomics ES cell line YTA472 embryonic stem cell house mouse CVCL_QR29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100821 CVCL_R329 HG03771 transformed cell line human CVCL_R329 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100822 CVCL_I985 HGDP00985 transformed cell line human CVCL_I985 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100823 CVCL_HX85 ND01138 transformed cell line human CVCL_HX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100824 CVCL_I986 HGDP00986 transformed cell line human CVCL_I986 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100825 CVCL_HX86 ND01139 transformed cell line human CVCL_HX86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100826 CVCL_I987 HGDP00987 transformed cell line human CVCL_I987 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100827 CVCL_HX87 ND01142 transformed cell line human CVCL_HX87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100828 CVCL_I988 HGDP00988 transformed cell line human CVCL_I988 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100829 CVCL_HX88 ND01172 transformed cell line human CVCL_HX88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100830 CVCL_I981 HGDP00981 transformed cell line human CVCL_I981 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100831 CVCL_HX81 ND01043 transformed cell line human CVCL_HX81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100832 CVCL_I982 HGDP00982 transformed cell line human CVCL_I982 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100833 CVCL_HX82 ND00093 transformed cell line human CVCL_HX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100834 CVCL_I983 HGDP00983 transformed cell line human CVCL_I983 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100835 CVCL_HX83 ND01061 transformed cell line human CVCL_HX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100836 CVCL_I984 HGDP00984 transformed cell line human CVCL_I984 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100837 CVCL_HX84 ND01098 transformed cell line human CVCL_HX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100838 CVCL_I980 HGDP00980 transformed cell line human CVCL_I980 CL:0000010 Population: Eurasian (was originally classified as Biaka pygmies); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100839 CVCL_HX80 ND00834 transformed cell line human CVCL_HX80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100840 CVCL_QR10 BayGenomics ES cell line YTA429 embryonic stem cell house mouse CVCL_QR10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890695; Rab9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100841 CVCL_R310 HG03741 transformed cell line human CVCL_R310 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100842 CVCL_QR11 BayGenomics ES cell line YTA432 embryonic stem cell house mouse CVCL_QR11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445179; Tmem184b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100843 CVCL_R311 HG03742 transformed cell line human CVCL_R311 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100844 CVCL_QR12 BayGenomics ES cell line YTA434 embryonic stem cell house mouse CVCL_QR12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100845 CVCL_R312 HG03743 transformed cell line human CVCL_R312 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100846 CVCL_QR13 BayGenomics ES cell line YTA435 embryonic stem cell house mouse CVCL_QR13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103251; Acly Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100847 CVCL_R313 HG03744 transformed cell line human CVCL_R313 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100848 CVCL_QR14 BayGenomics ES cell line YTA438 embryonic stem cell house mouse CVCL_QR14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100849 CVCL_R314 HG03745 transformed cell line human CVCL_R314 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100850 CVCL_QR15 BayGenomics ES cell line YTA441 embryonic stem cell house mouse CVCL_QR15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99256; Hdlbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100851 CVCL_R315 HG03746 transformed cell line human CVCL_R315 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100852 CVCL_QR16 BayGenomics ES cell line YTA442 embryonic stem cell house mouse CVCL_QR16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151055; Cnnm3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100853 CVCL_R316 HG03750 transformed cell line human CVCL_R316 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100854 CVCL_QR17 BayGenomics ES cell line YTA444 embryonic stem cell house mouse CVCL_QR17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921487; Tubgcp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100855 CVCL_R317 HG03752 transformed cell line human CVCL_R317 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100856 CVCL_QR18 BayGenomics ES cell line YTA445 embryonic stem cell house mouse CVCL_QR18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97552; Pgam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100857 CVCL_R318 HG03753 transformed cell line human CVCL_R318 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100858 CVCL_QR19 BayGenomics ES cell line YTA447 embryonic stem cell house mouse CVCL_QR19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346040; Mpdu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100859 CVCL_R319 HG03754 transformed cell line human CVCL_R319 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100860 CVCL_I996 HGDP00996 transformed cell line human CVCL_I996 CL:0000010 Sequence variation: Gene deletion; HGNC; 3620; FCGR3B; Zygosity=Homozygous (PubMed=27995740) Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100861 CVCL_HX96 ND01285 transformed cell line human CVCL_HX96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100862 CVCL_I997 HGDP00997 transformed cell line human CVCL_I997 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100863 CVCL_HX97 ND01287 transformed cell line human CVCL_HX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100864 CVCL_I998 HGDP00998 transformed cell line human CVCL_I998 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100865 CVCL_HX98 ND01288 transformed cell line human CVCL_HX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100866 CVCL_I999 HGDP00999 transformed cell line human CVCL_I999 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100867 CVCL_HX99 ND01289 transformed cell line human CVCL_HX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100868 CVCL_I992 HGDP00992 transformed cell line human CVCL_I992 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100869 CVCL_HX92 ND01185 transformed cell line human CVCL_HX92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100870 CVCL_I993 HGDP00993 transformed cell line human CVCL_I993 CL:0000010 Population: African; Bantu S.E Pedi.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100871 CVCL_HX93 ND01200 transformed cell line human CVCL_HX93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100872 CVCL_I994 HGDP00994 transformed cell line human CVCL_I994 CL:0000010 Population: African; Bantu S.E S.Sotho.; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100873 CVCL_HX94 ND01210 transformed cell line human CVCL_HX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100874 CVCL_I995 HGDP00995 transformed cell line human CVCL_I995 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100875 CVCL_HX95 ND01214 transformed cell line human CVCL_HX95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100876 CVCL_I990 HGDP01344 transformed cell line human CVCL_I990 CL:0000010 Population: Chinese/Asian ethnic group; Naxi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100877 CVCL_HX90 ND01176 transformed cell line human CVCL_HX90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100878 CVCL_I991 HGDP00991 transformed cell line human CVCL_I991 CL:0000010 Population: African; San; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100879 CVCL_HX91 ND01178 transformed cell line human CVCL_HX91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100880 CVCL_QR00 BayGenomics ES cell line YTA406 embryonic stem cell house mouse CVCL_QR00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923957; Clasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100881 CVCL_R300 HG03723 transformed cell line human CVCL_R300 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100882 CVCL_QR01 BayGenomics ES cell line YTA407 embryonic stem cell house mouse CVCL_QR01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203520; Dapk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100883 CVCL_R301 HG03725 transformed cell line human CVCL_R301 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100884 CVCL_QR02 BayGenomics ES cell line YTA408 embryonic stem cell house mouse CVCL_QR02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894652; Usp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100885 CVCL_R302 HG03727 transformed cell line human CVCL_R302 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100886 CVCL_QR03 BayGenomics ES cell line YTA410 embryonic stem cell house mouse CVCL_QR03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924177; Tsacc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100887 CVCL_R303 HG03729 transformed cell line human CVCL_R303 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100888 CVCL_QR04 BayGenomics ES cell line YTA411 embryonic stem cell house mouse CVCL_QR04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385089; Cbwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100889 CVCL_R304 HG03730 transformed cell line human CVCL_R304 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100890 CVCL_I967 HGDP00967 transformed cell line human CVCL_I967 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100891 CVCL_HX67 ND00670 transformed cell line human CVCL_HX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100892 CVCL_QR05 BayGenomics ES cell line YTA415 embryonic stem cell house mouse CVCL_QR05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3588201; Erich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100893 CVCL_R305 HG03731 transformed cell line human CVCL_R305 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100894 CVCL_I968 HGDP00968 transformed cell line human CVCL_I968 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100895 CVCL_HX68 ND00676 transformed cell line human CVCL_HX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100896 CVCL_QR06 BayGenomics ES cell line YTA416 embryonic stem cell house mouse CVCL_QR06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100897 CVCL_R306 HG03733 transformed cell line human CVCL_R306 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100898 CVCL_I969 HGDP00969 transformed cell line human CVCL_I969 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100899 CVCL_HX69 ND00681 transformed cell line human CVCL_HX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100900 CVCL_QR07 BayGenomics ES cell line YTA422 embryonic stem cell house mouse CVCL_QR07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100901 CVCL_R307 HG03736 transformed cell line human CVCL_R307 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100902 CVCL_QR08 BayGenomics ES cell line YTA425 embryonic stem cell house mouse CVCL_QR08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100903 CVCL_R308 HG03738 transformed cell line human CVCL_R308 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100904 CVCL_I963 HGDP00963 transformed cell line human CVCL_I963 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100905 CVCL_HX63 ND00613 transformed cell line human CVCL_HX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100906 CVCL_QR09 BayGenomics ES cell line YTA428 embryonic stem cell house mouse CVCL_QR09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99778; Gpd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100907 CVCL_R309 HG03740 transformed cell line human CVCL_R309 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100908 CVCL_I964 HGDP00964 transformed cell line human CVCL_I964 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100909 CVCL_HX64 ND00614 transformed cell line human CVCL_HX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100910 CVCL_I965 HGDP00965 transformed cell line human CVCL_I965 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100911 CVCL_HX65 ND00615 transformed cell line human CVCL_HX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100912 CVCL_I966 HGDP00966 transformed cell line human CVCL_I966 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100913 CVCL_HX66 ND00631 transformed cell line human CVCL_HX66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100914 CVCL_I960 HGDP00960 transformed cell line human CVCL_I960 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100915 CVCL_HX60 ND00411 transformed cell line human CVCL_HX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100916 CVCL_I961 HGDP00961 transformed cell line human CVCL_I961 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100917 CVCL_HX61 ND00448 transformed cell line human CVCL_HX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100918 CVCL_I962 HGDP00962 transformed cell line human CVCL_I962 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100919 CVCL_HX62 ND00474 transformed cell line human CVCL_HX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100920 CVCL_I978 HGDP00978 transformed cell line human CVCL_I978 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100921 CVCL_HX78 ND00739 transformed cell line human CVCL_HX78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100922 CVCL_I979 HGDP00979 transformed cell line human CVCL_I979 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100923 CVCL_HX79 ND00742 transformed cell line human CVCL_HX79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100924 CVCL_I974 HGDP00974 transformed cell line human CVCL_I974 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100925 CVCL_HX74 ND00719 transformed cell line human CVCL_HX74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100926 CVCL_I975 HGDP00975 transformed cell line human CVCL_I975 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100927 CVCL_HX75 ND00722 transformed cell line human CVCL_HX75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100928 CVCL_I976 HGDP00976 transformed cell line human CVCL_I976 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100929 CVCL_HX76 ND00725 transformed cell line human CVCL_HX76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100930 CVCL_I977 HGDP00977 transformed cell line human CVCL_I977 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100931 CVCL_HX77 ND00733 transformed cell line human CVCL_HX77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100932 CVCL_I970 HGDP00970 transformed cell line human CVCL_I970 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100933 CVCL_HX70 ND00682 transformed cell line human CVCL_HX70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100934 CVCL_I971 HGDP00971 transformed cell line human CVCL_I971 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100935 CVCL_HX71 ND00684 transformed cell line human CVCL_HX71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21100936 CVCL_I972 HGDP00972 transformed cell line human CVCL_I972 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100937 CVCL_HX72 ND00696 transformed cell line human CVCL_HX72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100938 CVCL_I973 HGDP00973 transformed cell line human CVCL_I973 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21100939 CVCL_HX73 ND00697 transformed cell line human CVCL_HX73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21100940 CVCL_7F35 DA02558 transformed cell line human CVCL_7F35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100941 CVCL_7F36 DA02559 transformed cell line human CVCL_7F36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100942 CVCL_7F37 DA02560 transformed cell line human CVCL_7F37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02560; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100943 CVCL_7F38 DA02561 transformed cell line human CVCL_7F38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100944 CVCL_7F31 DA02554 transformed cell line human CVCL_7F31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02554; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100945 CVCL_7F32 DA02555 transformed cell line human CVCL_7F32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02555; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100946 CVCL_7F33 DA02556 transformed cell line human CVCL_7F33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100947 CVCL_7F34 DA02557 transformed cell line human CVCL_7F34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100948 CVCL_7F39 DA02562 transformed cell line human CVCL_7F39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100949 CVCL_7F30 DA02553 transformed cell line human CVCL_7F30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02553; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100950 CVCL_7F46 DA02569 transformed cell line human CVCL_7F46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100951 CVCL_7F47 DA02570 transformed cell line human CVCL_7F47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02570; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100952 CVCL_7F48 DA02571 transformed cell line human CVCL_7F48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02571; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100953 CVCL_7F49 DA02572 transformed cell line human CVCL_7F49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100954 CVCL_7F42 DA02565 transformed cell line human CVCL_7F42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100955 CVCL_7F43 DA02566 transformed cell line human CVCL_7F43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100956 CVCL_7F44 DA02567 transformed cell line human CVCL_7F44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100957 CVCL_7F45 DA02568 transformed cell line human CVCL_7F45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100958 CVCL_7F40 DA02563 transformed cell line human CVCL_7F40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100959 CVCL_7F41 DA02564 transformed cell line human CVCL_7F41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100960 CVCL_7F13 DA02534 transformed cell line human CVCL_7F13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02534; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100961 CVCL_7F14 DA02535 transformed cell line human CVCL_7F14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100962 CVCL_7F15 DA02536 transformed cell line human CVCL_7F15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100963 CVCL_7F16 DA02537 transformed cell line human CVCL_7F16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100964 CVCL_7F10 DA02530 transformed cell line human CVCL_7F10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02530; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100965 CVCL_7F11 DA02532 transformed cell line human CVCL_7F11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02532; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100966 CVCL_7F12 DA02533 transformed cell line human CVCL_7F12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02533; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100967 CVCL_7F17 DA02538 transformed cell line human CVCL_7F17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02538; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100968 CVCL_7F18 DA02539 transformed cell line human CVCL_7F18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02539; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100969 CVCL_7F19 DA02540 transformed cell line human CVCL_7F19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02540; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100970 CVCL_7F24 DA02545 transformed cell line human CVCL_7F24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100971 CVCL_7F25 DA02546 transformed cell line human CVCL_7F25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100972 CVCL_7F26 DA02548 transformed cell line human CVCL_7F26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02548; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100973 CVCL_7F27 DA02549 transformed cell line human CVCL_7F27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02549; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100974 CVCL_7F20 DA02541 transformed cell line human CVCL_7F20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02541; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100975 CVCL_7F21 DA02542 transformed cell line human CVCL_7F21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02542; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100976 CVCL_7F22 DA02543 transformed cell line human CVCL_7F22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100977 CVCL_7F23 DA02544 transformed cell line human CVCL_7F23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100978 CVCL_7F28 DA02550 transformed cell line human CVCL_7F28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02550; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100979 CVCL_7F29 DA02552 transformed cell line human CVCL_7F29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02552; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100980 CVCL_QR95 BayGenomics ES cell line YTB032 embryonic stem cell house mouse CVCL_QR95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913452; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100981 CVCL_7F02 DA02522 transformed cell line human CVCL_7F02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100982 CVCL_R395 HG03868 transformed cell line human CVCL_R395 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100983 CVCL_QR96 BayGenomics ES cell line YTB034 embryonic stem cell house mouse CVCL_QR96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890156; Stx8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100984 CVCL_7F03 DA02523 transformed cell line human CVCL_7F03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100985 CVCL_R396 HG03869 transformed cell line human CVCL_R396 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100986 CVCL_QR97 BayGenomics ES cell line YTB036 embryonic stem cell house mouse CVCL_QR97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100987 CVCL_7F04 DA02524 transformed cell line human CVCL_7F04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100988 CVCL_R397 HG03870 transformed cell line human CVCL_R397 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100989 CVCL_QR98 BayGenomics ES cell line YTB037 embryonic stem cell house mouse CVCL_QR98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100990 CVCL_7F05 DA02525 transformed cell line human CVCL_7F05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100991 CVCL_R398 HG03871 transformed cell line human CVCL_R398 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100992 CVCL_QR99 BayGenomics ES cell line YTB038 embryonic stem cell house mouse CVCL_QR99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21100993 CVCL_R399 HG03872 transformed cell line human CVCL_R399 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21100994 CVCL_7F00 DA02520 transformed cell line human CVCL_7F00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02520; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100995 CVCL_7F01 DA02521 transformed cell line human CVCL_7F01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02521; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100996 CVCL_7F06 DA02526 transformed cell line human CVCL_7F06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100997 CVCL_7F07 DA02527 transformed cell line human CVCL_7F07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02527; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100998 CVCL_7F08 DA02528 transformed cell line human CVCL_7F08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02528; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21100999 CVCL_7F09 DA02529 transformed cell line human CVCL_7F09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02529; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101000 CVCL_QR84 BayGenomics ES cell line YTB011 embryonic stem cell house mouse CVCL_QR84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101001 CVCL_R384 HG03851 transformed cell line human CVCL_R384 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101002 CVCL_QR85 BayGenomics ES cell line YTB012 embryonic stem cell house mouse CVCL_QR85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101003 CVCL_R385 HG03854 transformed cell line human CVCL_R385 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101004 CVCL_QR86 BayGenomics ES cell line YTB013 embryonic stem cell house mouse CVCL_QR86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101005 CVCL_R386 HG03856 transformed cell line human CVCL_R386 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101006 CVCL_QR87 BayGenomics ES cell line YTB014 embryonic stem cell house mouse CVCL_QR87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931053; Marchf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101007 CVCL_R387 HG03857 transformed cell line human CVCL_R387 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101008 CVCL_QR88 BayGenomics ES cell line YTB019 embryonic stem cell house mouse CVCL_QR88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442117; Pogz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101009 CVCL_R388 HG03858 transformed cell line human CVCL_R388 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101010 CVCL_QR89 BayGenomics ES cell line YTB020 embryonic stem cell house mouse CVCL_QR89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101011 CVCL_R389 HG03861 transformed cell line human CVCL_R389 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101012 CVCL_QR90 BayGenomics ES cell line YTB023 embryonic stem cell house mouse CVCL_QR90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915821; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101013 CVCL_R390 HG03862 transformed cell line human CVCL_R390 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101014 CVCL_QR91 BayGenomics ES cell line YTB024 embryonic stem cell house mouse CVCL_QR91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109152; Lig3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101015 CVCL_R391 HG03863 transformed cell line human CVCL_R391 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101016 CVCL_QR92 BayGenomics ES cell line YTB025 embryonic stem cell house mouse CVCL_QR92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341788; Pdcd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101017 CVCL_R392 HG03864 transformed cell line human CVCL_R392 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101018 CVCL_QR93 BayGenomics ES cell line YTB026 embryonic stem cell house mouse CVCL_QR93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101019 CVCL_R393 HG03866 transformed cell line human CVCL_R393 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101020 CVCL_QR94 BayGenomics ES cell line YTB029 embryonic stem cell house mouse CVCL_QR94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101021 CVCL_R394 HG03867 transformed cell line human CVCL_R394 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101022 CVCL_QR73 BayGenomics ES cell line YTA585 embryonic stem cell house mouse CVCL_QR73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101023 CVCL_R373 HG03836 transformed cell line human CVCL_R373 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101024 CVCL_QR74 BayGenomics ES cell line YTA586 embryonic stem cell house mouse CVCL_QR74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923792; Hibch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101025 CVCL_R374 HG03837 transformed cell line human CVCL_R374 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101026 CVCL_QR75 BayGenomics ES cell line YTA589 embryonic stem cell house mouse CVCL_QR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99211; Zfx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101027 CVCL_R375 HG03838 transformed cell line human CVCL_R375 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101028 CVCL_QR76 BayGenomics ES cell line YTA594 embryonic stem cell house mouse CVCL_QR76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922471; Dpp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101029 CVCL_R376 HG03842 transformed cell line human CVCL_R376 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101030 CVCL_QR77 BayGenomics ES cell line YTA596 embryonic stem cell house mouse CVCL_QR77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101031 CVCL_R377 HG03844 transformed cell line human CVCL_R377 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101032 CVCL_QR78 BayGenomics ES cell line YTB002 embryonic stem cell house mouse CVCL_QR78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918398; Mier1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101033 CVCL_R378 HG03845 transformed cell line human CVCL_R378 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101034 CVCL_QR79 BayGenomics ES cell line YTB003 embryonic stem cell house mouse CVCL_QR79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108074; Sptlc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101035 CVCL_R379 HG03846 transformed cell line human CVCL_R379 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101036 CVCL_QR80 BayGenomics ES cell line YTB004 embryonic stem cell house mouse CVCL_QR80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98354; Sos1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101037 CVCL_R380 HG03847 transformed cell line human CVCL_R380 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101038 CVCL_QR81 BayGenomics ES cell line YTB006 embryonic stem cell house mouse CVCL_QR81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929274; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101039 CVCL_R381 HG03848 transformed cell line human CVCL_R381 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101040 CVCL_QR82 BayGenomics ES cell line YTB007 embryonic stem cell house mouse CVCL_QR82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913099; Psrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101041 CVCL_R382 HG03849 transformed cell line human CVCL_R382 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101042 CVCL_QR83 BayGenomics ES cell line YTB009 embryonic stem cell house mouse CVCL_QR83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101043 CVCL_R383 HG03850 transformed cell line human CVCL_R383 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101044 CVCL_7E98 DA02518 transformed cell line human CVCL_7E98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101045 CVCL_7E99 DA02519 transformed cell line human CVCL_7E99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101046 CVCL_7E94 DA02513 transformed cell line human CVCL_7E94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101047 CVCL_7E95 DA02515 transformed cell line human CVCL_7E95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02515; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101048 CVCL_7E96 DA02516 transformed cell line human CVCL_7E96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101049 CVCL_7E97 DA02517 transformed cell line human CVCL_7E97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02517; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101050 CVCL_7E90 DA02507 transformed cell line human CVCL_7E90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02507; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101051 CVCL_7E91 DA02510 transformed cell line human CVCL_7E91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02510; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101052 CVCL_7E92 DA02511 transformed cell line human CVCL_7E92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02511; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101053 CVCL_7E93 DA02512 transformed cell line human CVCL_7E93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101054 CVCL_7E76 DA02490 transformed cell line human CVCL_7E76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02490; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101055 CVCL_7E77 DA02491 transformed cell line human CVCL_7E77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02491; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101056 CVCL_7E78 DA02492 transformed cell line human CVCL_7E78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02492; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101057 CVCL_7E79 DA02494 transformed cell line human CVCL_7E79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101058 CVCL_7E72 DA02482 transformed cell line human CVCL_7E72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101059 CVCL_7E73 DA02487 transformed cell line human CVCL_7E73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02487; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101060 CVCL_7E74 DA02488 transformed cell line human CVCL_7E74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02488; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101061 CVCL_7E75 DA02489 transformed cell line human CVCL_7E75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02489; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101062 CVCL_7E70 DA02480 transformed cell line human CVCL_7E70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02480; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101063 CVCL_7E71 DA02481 transformed cell line human CVCL_7E71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101064 CVCL_7E87 DA02504 transformed cell line human CVCL_7E87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02504; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101065 CVCL_7E88 DA02505 transformed cell line human CVCL_7E88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02505; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101066 CVCL_7E89 DA02506 transformed cell line human CVCL_7E89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101067 CVCL_7E83 DA02498 transformed cell line human CVCL_7E83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101068 CVCL_7E84 DA02499 transformed cell line human CVCL_7E84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101069 CVCL_7E85 DA02500 transformed cell line human CVCL_7E85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02500; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101070 CVCL_7E86 DA02501 transformed cell line human CVCL_7E86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101071 CVCL_7E80 DA02495 transformed cell line human CVCL_7E80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101072 CVCL_7E81 DA02496 transformed cell line human CVCL_7E81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101073 CVCL_7E82 DA02497 transformed cell line human CVCL_7E82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101074 CVCL_7E58 DA02465 transformed cell line human CVCL_7E58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101075 CVCL_7E59 DA02466 transformed cell line human CVCL_7E59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101076 CVCL_7E54 DA02459 transformed cell line human CVCL_7E54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02459; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101077 CVCL_7E55 DA02460 transformed cell line human CVCL_7E55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02460; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101078 CVCL_7E56 DA02461 transformed cell line human CVCL_7E56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02461; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101079 CVCL_7E57 DA02463 transformed cell line human CVCL_7E57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101080 CVCL_7E50 DA02455 transformed cell line human CVCL_7E50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02455; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101081 CVCL_7E51 DA02456 transformed cell line human CVCL_7E51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02456; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101082 CVCL_7E52 DA02457 transformed cell line human CVCL_7E52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02457; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101083 CVCL_7E53 DA02458 transformed cell line human CVCL_7E53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02458; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101084 CVCL_7E69 DA02479 transformed cell line human CVCL_7E69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02479; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101085 CVCL_7E65 DA02473 transformed cell line human CVCL_7E65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101086 CVCL_7E66 DA02474 transformed cell line human CVCL_7E66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101087 CVCL_7E67 DA02475 transformed cell line human CVCL_7E67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101088 CVCL_7E68 DA02476 transformed cell line human CVCL_7E68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101089 CVCL_7E61 DA02468 transformed cell line human CVCL_7E61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101090 CVCL_7E62 DA02469 transformed cell line human CVCL_7E62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02469; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101091 CVCL_7E63 DA02470 transformed cell line human CVCL_7E63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02470; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101092 CVCL_7E64 DA02471 transformed cell line human CVCL_7E64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02471; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101093 CVCL_7E60 DA02467 transformed cell line human CVCL_7E60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101094 CVCL_7E36 DA02441 transformed cell line human CVCL_7E36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02441; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101095 CVCL_7E37 DA02442 transformed cell line human CVCL_7E37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02442; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101096 CVCL_7E38 DA02443 transformed cell line human CVCL_7E38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101097 CVCL_7E39 DA02444 transformed cell line human CVCL_7E39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101098 CVCL_7E32 DA02437 transformed cell line human CVCL_7E32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101099 CVCL_7E33 DA02438 transformed cell line human CVCL_7E33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101100 CVCL_7E34 DA02439 transformed cell line human CVCL_7E34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02439; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101101 CVCL_7E35 DA02440 transformed cell line human CVCL_7E35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02440; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101102 CVCL_7E30 DA02435 transformed cell line human CVCL_7E30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02435; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101103 CVCL_7E31 DA02436 transformed cell line human CVCL_7E31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02436; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101104 CVCL_7E47 DA02452 transformed cell line human CVCL_7E47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02452; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101105 CVCL_7E48 DA02453 transformed cell line human CVCL_7E48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02453; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101106 CVCL_7E49 DA02454 transformed cell line human CVCL_7E49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02454; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101107 CVCL_7E43 DA02448 transformed cell line human CVCL_7E43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02448; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101108 CVCL_7E44 DA02449 transformed cell line human CVCL_7E44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02449; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101109 CVCL_7E45 DA02450 transformed cell line human CVCL_7E45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101110 CVCL_7E46 DA02451 transformed cell line human CVCL_7E46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02451; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101111 CVCL_7E40 DA02445 transformed cell line human CVCL_7E40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02445; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101112 CVCL_7E41 DA02446 transformed cell line human CVCL_7E41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02446; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101113 CVCL_7E42 DA02447 transformed cell line human CVCL_7E42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02447; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101114 CVCL_I949 HGDP00949 transformed cell line human CVCL_I949 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101115 CVCL_HX49 ND00281 transformed cell line human CVCL_HX49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101116 CVCL_I945 HGDP00945 transformed cell line human CVCL_I945 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101117 CVCL_HX45 ND00224 transformed cell line human CVCL_HX45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101118 CVCL_I946 HGDP00946 transformed cell line human CVCL_I946 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101119 CVCL_HX46 ND00226 transformed cell line human CVCL_HX46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101120 CVCL_I947 HGDP00947 transformed cell line human CVCL_I947 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101121 CVCL_HX47 ND00278 transformed cell line human CVCL_HX47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101122 CVCL_I948 HGDP00948 transformed cell line human CVCL_I948 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101123 CVCL_HX48 ND00232 transformed cell line human CVCL_HX48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101124 CVCL_I941 HGDP00941 transformed cell line human CVCL_I941 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101125 CVCL_HX41 ND00217 transformed cell line human CVCL_HX41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101126 CVCL_I942 HGDP00942 transformed cell line human CVCL_I942 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101127 CVCL_HX42 ND00218 transformed cell line human CVCL_HX42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101128 CVCL_I943 HGDP00943 transformed cell line human CVCL_I943 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101129 CVCL_HX43 ND00219 transformed cell line human CVCL_HX43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101130 CVCL_I944 HGDP00944 transformed cell line human CVCL_I944 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101131 CVCL_HX44 ND00220 transformed cell line human CVCL_HX44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101132 CVCL_I940 HGDP00940 transformed cell line human CVCL_I940 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101133 CVCL_HX40 ND00202 transformed cell line human CVCL_HX40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101134 CVCL_I956 HGDP00956 transformed cell line human CVCL_I956 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101135 CVCL_HX56 ND00375 transformed cell line human CVCL_HX56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101136 CVCL_I957 HGDP00957 transformed cell line human CVCL_I957 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101137 CVCL_HX57 ND00385 transformed cell line human CVCL_HX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101138 CVCL_I958 HGDP00958 transformed cell line human CVCL_I958 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101139 CVCL_HX58 ND00391 transformed cell line human CVCL_HX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101140 CVCL_I959 HGDP00959 transformed cell line human CVCL_I959 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101141 CVCL_HX59 ND00400 transformed cell line human CVCL_HX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101142 CVCL_I952 HGDP00952 transformed cell line human CVCL_I952 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101143 CVCL_HX52 ND00364 transformed cell line human CVCL_HX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101144 CVCL_I953 HGDP00953 transformed cell line human CVCL_I953 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101145 CVCL_HX53 ND00371 transformed cell line human CVCL_HX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101146 CVCL_I954 HGDP00954 transformed cell line human CVCL_I954 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101147 CVCL_HX54 ND00372 transformed cell line human CVCL_HX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101148 CVCL_I955 HGDP00955 transformed cell line human CVCL_I955 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101149 CVCL_HX55 ND00374 transformed cell line human CVCL_HX55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101150 CVCL_I950 HGDP00950 transformed cell line human CVCL_I950 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101151 CVCL_HX50 ND00326 transformed cell line human CVCL_HX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101152 CVCL_I951 HGDP00951 transformed cell line human CVCL_I951 CL:0000010 Population: Yakut; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101153 CVCL_HX51 ND00345 transformed cell line human CVCL_HX51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101154 CVCL_HX27 7265PDA cancer cell line house mouse CVCL_HX27 CL:0000010 21101155 CVCL_I927 HGDP00927 transformed cell line human CVCL_I927 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced (low read coverage) Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101156 CVCL_I928 HGDP00928 transformed cell line human CVCL_I928 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101157 CVCL_HX28 UM-SCVa-1 cancer cell line human CVCL_HX28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9887230) Derived from sampling site: Vagina. Female 21101158 CVCL_I929 HGDP00929 transformed cell line human CVCL_I929 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101159 CVCL_HX29 KDH-8 cancer cell line Norway rat CVCL_HX29 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). 21101160 CVCL_I923 HGDP00923 transformed cell line human CVCL_I923 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101161 CVCL_HX23 LT2 [Human vulvar squamous cell carcinoma] cancer cell line human CVCL_HX23 CL:0000010 Derived from metastatic site: Right inguinal lymph node. Female Doubling time: ~32 hours (PubMed=686047) 21101162 CVCL_I924 HGDP00924 transformed cell line human CVCL_I924 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101163 CVCL_HX24 UM-SCV-5 cancer cell line human CVCL_HX24 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Ile (c.464C>T); ClinVar=VCV001005876; Zygosity=Unspecified (PubMed=7503188) Derived from sampling site: Vulva. Female 21101164 CVCL_I925 HGDP00925 transformed cell line human CVCL_I925 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101165 CVCL_HX25 UM-GCC-1 cancer cell line human CVCL_HX25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female 21101166 CVCL_HX26 6606PDA cancer cell line house mouse CVCL_HX26 CL:0000010 Breed/subspecies: C57BL/6 Mist1KrasG12D transgenic. 21101167 CVCL_I926 HGDP00926 transformed cell line human CVCL_I926 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101168 CVCL_I920 HGDP00920 transformed cell line human CVCL_I920 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101169 CVCL_HX20 XG-24 cancer cell line human CVCL_HX20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgA lambda; Characteristics: IL6 dependent 21101170 CVCL_I921 HGDP00921 transformed cell line human CVCL_I921 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101171 CVCL_HX21 XG-3E cancer cell line human CVCL_HX21 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Pleural effusion. Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21101172 CVCL_I922 HGDP00922 transformed cell line human CVCL_I922 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101173 CVCL_HX22 UHKT-893a cancer cell line human CVCL_HX22 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa; Characteristics: In contrast to the parent cell line it is no longer IL6 dependent Doubling time: 4.2-5.4 days (PubMed=23290585) 21101174 CVCL_I938 HGDP00938 transformed cell line human CVCL_I938 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101175 CVCL_HX38 ND00144 transformed cell line human CVCL_HX38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101176 CVCL_I939 HGDP00939 transformed cell line human CVCL_I939 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101177 CVCL_HX39 ND00145 transformed cell line human CVCL_HX39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101178 CVCL_I934 HGDP00934 transformed cell line human CVCL_I934 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101179 CVCL_HX34 ND01414 transformed cell line human CVCL_HX34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101180 CVCL_I935 HGDP00935 transformed cell line human CVCL_I935 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101181 CVCL_HX35 ND00135 transformed cell line human CVCL_HX35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101182 CVCL_I936 HGDP00936 transformed cell line human CVCL_I936 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101183 CVCL_HX36 ND00137 transformed cell line human CVCL_HX36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101184 CVCL_I937 HGDP00937 transformed cell line human CVCL_I937 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101185 CVCL_HX37 ND00140 transformed cell line human CVCL_HX37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101186 CVCL_I930 HGDP00930 transformed cell line human CVCL_I930 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101187 CVCL_HX30 KT-1 [Mouse tongue] spontaneously immortalized cell line house mouse CVCL_HX30 CL:0000010 Derived from sampling site: Oral cavity; tongue Cell type=Epithelial cell.; Breed/subspecies: C57BL/6J. Male Doubling time: 4 days (PubMed=12513125) Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8347 21101188 CVCL_I931 HGDP00931 transformed cell line human CVCL_I931 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101189 CVCL_HX31 ND00252 transformed cell line human CVCL_HX31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101190 CVCL_I932 HGDP00932 transformed cell line human CVCL_I932 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101191 CVCL_HX32 ND00718 transformed cell line human CVCL_HX32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101192 CVCL_I933 HGDP00933 transformed cell line human CVCL_I933 CL:0000010 Population: African; Yoruba; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101193 CVCL_HX33 ND01037 transformed cell line human CVCL_HX33 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex4del; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101194 CVCL_I909 HGDP00909 transformed cell line human CVCL_I909 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101195 CVCL_HX09 NAN-6 cancer cell line human CVCL_HX09 HLA typing: A*03,30; B*07,51; C*07,12 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex7-9del; Zygosity=Unspecified (PubMed=21173094) Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21101196 CVCL_I905 HGDP00905 transformed cell line human CVCL_I905 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101197 CVCL_HX05 ND14510 transformed cell line human CVCL_HX05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101198 CVCL_HX06 BCN cancer cell line human CVCL_HX06 HLA typing: A*11,26; B*13,27; C*02:02,06:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21101199 CVCL_I906 HGDP00906 transformed cell line human CVCL_I906 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101200 CVCL_I907 HGDP00907 transformed cell line human CVCL_I907 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101201 CVCL_HX07 MDN cancer cell line human CVCL_HX07 HLA typing: A*01,02:09; B*44,51; C*04,14 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Unspecified (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Characteristics: IL6 dependent 21101202 CVCL_I908 HGDP00908 transformed cell line human CVCL_I908 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101203 CVCL_HX08 NAN-2 cancer cell line human CVCL_HX08 CL:0000010 Miscellaneous: Cell line has been lost (from personal communication of Pellat-Deceunynck C.) Derived from sampling site: Peripheral blood. Unspecified Characteristics: Produces IgG lambda; Characteristics: IL6 dependent 21101204 CVCL_I901 HGDP00901 transformed cell line human CVCL_I901 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101205 CVCL_HX01 ND05588 transformed cell line human CVCL_HX01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101206 CVCL_I902 HGDP00902 transformed cell line human CVCL_I902 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101207 CVCL_HX02 ND06864 transformed cell line human CVCL_HX02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND06864; probable Male 21101208 CVCL_I903 HGDP00903 transformed cell line human CVCL_I903 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101209 CVCL_HX03 ND14508 transformed cell line human CVCL_HX03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101210 CVCL_I904 HGDP00904 transformed cell line human CVCL_I904 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101211 CVCL_HX04 ND14509 transformed cell line human CVCL_HX04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101212 CVCL_I900 HGDP00900 transformed cell line human CVCL_I900 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101213 CVCL_HX00 ND05587 transformed cell line human CVCL_HX00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101214 CVCL_I916 HGDP00916 transformed cell line human CVCL_I916 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101215 CVCL_HX16 XG-16 cancer cell line human CVCL_HX16 HLA typing: A*02,29; B*40,49; C*02,07 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces Ig kappa; Characteristics: IL6 dependent 21101216 CVCL_I917 HGDP00917 transformed cell line human CVCL_I917 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101217 CVCL_HX17 XG-19 cancer cell line human CVCL_HX17 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgA lambda; Characteristics: IL6 dependent 21101218 CVCL_I918 HGDP00918 transformed cell line human CVCL_I918 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101219 CVCL_HX18 XG-20 cancer cell line human CVCL_HX18 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21101220 CVCL_I919 HGDP00919 transformed cell line human CVCL_I919 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101221 CVCL_HX19 XG-21 cancer cell line human CVCL_HX19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21101222 CVCL_I912 HGDP00912 transformed cell line human CVCL_I912 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101223 CVCL_HX12 XG-11 cancer cell line human CVCL_HX12 HLA typing: A*02,26; B*18,38; C*07,12 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Unspecified (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21101224 CVCL_I913 HGDP00913 transformed cell line human CVCL_I913 CL:0000010 Sequence variation: Gene deletion; HGNC; 3620; FCGR3B; Zygosity=Homozygous (PubMed=27995740) Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101225 CVCL_HX13 XG-12 cancer cell line human CVCL_HX13 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21101226 CVCL_I914 HGDP00914 transformed cell line human CVCL_I914 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101227 CVCL_HX14 XG-13 cancer cell line human CVCL_HX14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG lambda; Characteristics: IL6 dependent 21101228 CVCL_I915 HGDP00915 transformed cell line human CVCL_I915 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101229 CVCL_HX15 XG-14 cancer cell line human CVCL_HX15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: Produces Ig kappa; Characteristics: IL6 dependent 21101230 CVCL_I910 HGDP00910 transformed cell line human CVCL_I910 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101231 CVCL_HX10 SBN cancer cell line human CVCL_HX10 HLA typing: A*02:01,32:01; B*14:02,57; C*06:02,08:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Characteristics: IL6 dependent 21101232 CVCL_I911 HGDP00911 transformed cell line human CVCL_I911 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21101233 CVCL_HX11 XG-10 cancer cell line human CVCL_HX11 HLA typing: A*01,24; B*14,51; C*08,14 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: IL6 dependent 21101234 CVCL_QS83 BayGenomics ES cell line YTC121 embryonic stem cell house mouse CVCL_QS83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913948; Cpsf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101235 CVCL_R483 HG04022 transformed cell line human CVCL_R483 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101236 CVCL_QS84 BayGenomics ES cell line YTC125 embryonic stem cell house mouse CVCL_QS84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101237 CVCL_R484 HG04023 transformed cell line human CVCL_R484 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101238 CVCL_QS85 BayGenomics ES cell line YTC126 embryonic stem cell house mouse CVCL_QS85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138080; Utp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101239 CVCL_R485 HG04024 transformed cell line human CVCL_R485 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101240 CVCL_QS86 BayGenomics ES cell line YTC130 embryonic stem cell house mouse CVCL_QS86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443699; Fubp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101241 CVCL_R486 HG04025 transformed cell line human CVCL_R486 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101242 CVCL_QS87 BayGenomics ES cell line YTC131 embryonic stem cell house mouse CVCL_QS87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146808; Safb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101243 CVCL_R487 HG04026 transformed cell line human CVCL_R487 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101244 CVCL_QS88 BayGenomics ES cell line YTC132 embryonic stem cell house mouse CVCL_QS88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917274; Mcm10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101245 CVCL_R488 HG04029 transformed cell line human CVCL_R488 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101246 CVCL_QS89 BayGenomics ES cell line YTC134 embryonic stem cell house mouse CVCL_QS89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096875; Wdfy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101247 CVCL_R489 HG04033 transformed cell line human CVCL_R489 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101248 CVCL_QS90 BayGenomics ES cell line YTC137 embryonic stem cell house mouse CVCL_QS90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914473; Rrp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101249 CVCL_R490 HG04035 transformed cell line human CVCL_R490 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101250 CVCL_QS91 BayGenomics ES cell line YTC138 embryonic stem cell house mouse CVCL_QS91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918367; Rbbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101251 CVCL_R491 HG04037 transformed cell line human CVCL_R491 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101252 CVCL_QS92 BayGenomics ES cell line YTC141 embryonic stem cell house mouse CVCL_QS92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927344; Gmnn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101253 CVCL_R492 HG04038 transformed cell line human CVCL_R492 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101254 CVCL_QS93 BayGenomics ES cell line YTC142 embryonic stem cell house mouse CVCL_QS93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97887; Rdx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101255 CVCL_R493 HG04039 transformed cell line human CVCL_R493 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101256 CVCL_QS72 BayGenomics ES cell line YTC103 embryonic stem cell house mouse CVCL_QS72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097691; Hdac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101257 CVCL_R472 HG03999 transformed cell line human CVCL_R472 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101258 CVCL_QS73 BayGenomics ES cell line YTC106 embryonic stem cell house mouse CVCL_QS73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101259 CVCL_R473 HG04001 transformed cell line human CVCL_R473 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101260 CVCL_QS74 BayGenomics ES cell line YTC107 embryonic stem cell house mouse CVCL_QS74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145955; Prkaa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101261 CVCL_R474 HG04002 transformed cell line human CVCL_R474 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101262 CVCL_QS75 BayGenomics ES cell line YTC108 embryonic stem cell house mouse CVCL_QS75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890773; Actn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101263 CVCL_R475 HG04003 transformed cell line human CVCL_R475 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101264 CVCL_QS76 BayGenomics ES cell line YTC109 embryonic stem cell house mouse CVCL_QS76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101265 CVCL_R476 HG04006 transformed cell line human CVCL_R476 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101266 CVCL_QS77 BayGenomics ES cell line YTC112 embryonic stem cell house mouse CVCL_QS77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919449; Mms19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101267 CVCL_R477 HG04014 transformed cell line human CVCL_R477 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101268 CVCL_QS78 BayGenomics ES cell line YTC113 embryonic stem cell house mouse CVCL_QS78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930089; Mcm3ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101269 CVCL_R478 HG04015 transformed cell line human CVCL_R478 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101270 CVCL_QS79 BayGenomics ES cell line YTC116 embryonic stem cell house mouse CVCL_QS79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894293; Smad4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101271 CVCL_R479 HG04017 transformed cell line human CVCL_R479 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101272 CVCL_QS80 BayGenomics ES cell line YTC117 embryonic stem cell house mouse CVCL_QS80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919686; Tbcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101273 CVCL_R480 HG04018 transformed cell line human CVCL_R480 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101274 CVCL_QS81 BayGenomics ES cell line YTC118 embryonic stem cell house mouse CVCL_QS81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104819; Hnrnpa2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101275 CVCL_R481 HG04019 transformed cell line human CVCL_R481 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101276 CVCL_QS82 BayGenomics ES cell line YTC119 embryonic stem cell house mouse CVCL_QS82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101277 CVCL_R482 HG04020 transformed cell line human CVCL_R482 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101278 CVCL_QS61 BayGenomics ES cell line YTC085 embryonic stem cell house mouse CVCL_QS61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932139; Oga Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101279 CVCL_R461 HG03977 transformed cell line human CVCL_R461 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101280 CVCL_QS62 BayGenomics ES cell line YTC087 embryonic stem cell house mouse CVCL_QS62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442040; G3bp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101281 CVCL_R462 HG03978 transformed cell line human CVCL_R462 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101282 CVCL_QS63 BayGenomics ES cell line YTC088 embryonic stem cell house mouse CVCL_QS63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147679; Patl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101283 CVCL_R463 HG03982 transformed cell line human CVCL_R463 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101284 CVCL_QS64 BayGenomics ES cell line YTC090 embryonic stem cell house mouse CVCL_QS64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445220; Dcaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101285 CVCL_R464 HG03985 transformed cell line human CVCL_R464 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101286 CVCL_QS65 BayGenomics ES cell line YTC091 embryonic stem cell house mouse CVCL_QS65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921407; Cmtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101287 CVCL_R465 HG03986 transformed cell line human CVCL_R465 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101288 CVCL_QS66 BayGenomics ES cell line YTC095 embryonic stem cell house mouse CVCL_QS66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860606; Akap8l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101289 CVCL_R466 HG03988 transformed cell line human CVCL_R466 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101290 CVCL_QS67 BayGenomics ES cell line YTC096 embryonic stem cell house mouse CVCL_QS67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919228; Ppp2r2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101291 CVCL_R467 HG03989 transformed cell line human CVCL_R467 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101292 CVCL_QS68 BayGenomics ES cell line YTC098 embryonic stem cell house mouse CVCL_QS68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101293 CVCL_R468 HG03990 transformed cell line human CVCL_R468 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101294 CVCL_QS69 BayGenomics ES cell line YTC100 embryonic stem cell house mouse CVCL_QS69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101295 CVCL_R469 HG03991 transformed cell line human CVCL_R469 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101296 CVCL_QS70 BayGenomics ES cell line YTC101 embryonic stem cell house mouse CVCL_QS70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097691; Hdac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101297 CVCL_R470 HG03995 transformed cell line human CVCL_R470 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101298 CVCL_QS71 BayGenomics ES cell line YTC102 embryonic stem cell house mouse CVCL_QS71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101299 CVCL_R471 HG03998 transformed cell line human CVCL_R471 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101300 CVCL_QS50 BayGenomics ES cell line YTC065 embryonic stem cell house mouse CVCL_QS50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101301 CVCL_R450 HG03960 transformed cell line human CVCL_R450 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101302 CVCL_QS51 BayGenomics ES cell line YTC066 embryonic stem cell house mouse CVCL_QS51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101303 CVCL_R451 HG03963 transformed cell line human CVCL_R451 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101304 CVCL_QS52 BayGenomics ES cell line YTC068 embryonic stem cell house mouse CVCL_QS52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101305 CVCL_R452 HG03965 transformed cell line human CVCL_R452 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101306 CVCL_QS53 BayGenomics ES cell line YTC071 embryonic stem cell house mouse CVCL_QS53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101307 CVCL_R453 HG03967 transformed cell line human CVCL_R453 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101308 CVCL_QS54 BayGenomics ES cell line YTC072 embryonic stem cell house mouse CVCL_QS54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101309 CVCL_R454 HG03968 transformed cell line human CVCL_R454 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101310 CVCL_QS55 BayGenomics ES cell line YTC075 embryonic stem cell house mouse CVCL_QS55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101311 CVCL_R455 HG03969 transformed cell line human CVCL_R455 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101312 CVCL_QS56 BayGenomics ES cell line YTC076 embryonic stem cell house mouse CVCL_QS56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101313 CVCL_R456 HG03971 transformed cell line human CVCL_R456 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101314 CVCL_QS57 BayGenomics ES cell line YTC079 embryonic stem cell house mouse CVCL_QS57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914552; Zc3h13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101315 CVCL_R457 HG03972 transformed cell line human CVCL_R457 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101316 CVCL_QS58 BayGenomics ES cell line YTC080 embryonic stem cell house mouse CVCL_QS58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101317 CVCL_R458 HG03973 transformed cell line human CVCL_R458 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101318 CVCL_QS59 BayGenomics ES cell line YTC081 embryonic stem cell house mouse CVCL_QS59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101319 CVCL_R459 HG03974 transformed cell line human CVCL_R459 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101320 CVCL_QS60 BayGenomics ES cell line YTC082 embryonic stem cell house mouse CVCL_QS60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101321 CVCL_R460 HG03976 transformed cell line human CVCL_R460 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101322 CVCL_QS40 BayGenomics ES cell line YTC047 embryonic stem cell house mouse CVCL_QS40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141070; Ccz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101323 CVCL_R440 HG03941 transformed cell line human CVCL_R440 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101324 CVCL_QS41 BayGenomics ES cell line YTC049 embryonic stem cell house mouse CVCL_QS41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349409; Cops3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101325 CVCL_R441 HG03943 transformed cell line human CVCL_R441 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101326 CVCL_QS42 BayGenomics ES cell line YTC051 embryonic stem cell house mouse CVCL_QS42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270126; Ulk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101327 CVCL_R442 HG03944 transformed cell line human CVCL_R442 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101328 CVCL_QS43 BayGenomics ES cell line YTC055 embryonic stem cell house mouse CVCL_QS43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101329 CVCL_R443 HG03945 transformed cell line human CVCL_R443 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101330 CVCL_QS44 BayGenomics ES cell line YTC057 embryonic stem cell house mouse CVCL_QS44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101331 CVCL_R444 HG03947 transformed cell line human CVCL_R444 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101332 CVCL_QS45 BayGenomics ES cell line YTC059 embryonic stem cell house mouse CVCL_QS45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101333 CVCL_R445 HG03949 transformed cell line human CVCL_R445 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101334 CVCL_QS46 BayGenomics ES cell line YTC060 embryonic stem cell house mouse CVCL_QS46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894313; Rab6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101335 CVCL_R446 HG03950 transformed cell line human CVCL_R446 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101336 CVCL_QS47 BayGenomics ES cell line YTC061 embryonic stem cell house mouse CVCL_QS47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924621; Sec24a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101337 CVCL_R447 HG03951 transformed cell line human CVCL_R447 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101338 CVCL_QS48 BayGenomics ES cell line YTC062 embryonic stem cell house mouse CVCL_QS48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101339 CVCL_R448 HG03953 transformed cell line human CVCL_R448 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101340 CVCL_QS49 BayGenomics ES cell line YTC063 embryonic stem cell house mouse CVCL_QS49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332234; Zfp148 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101341 CVCL_R449 HG03955 transformed cell line human CVCL_R449 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101342 CVCL_QS30 BayGenomics ES cell line YTC034 embryonic stem cell house mouse CVCL_QS30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101343 CVCL_R430 HG03920 transformed cell line human CVCL_R430 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101344 CVCL_QS31 BayGenomics ES cell line YTC035 embryonic stem cell house mouse CVCL_QS31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922816; Ing5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101345 CVCL_R431 HG03922 transformed cell line human CVCL_R431 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101346 CVCL_QS32 BayGenomics ES cell line YTC037 embryonic stem cell house mouse CVCL_QS32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918305; Nemf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101347 CVCL_R432 HG03925 transformed cell line human CVCL_R432 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101348 CVCL_QS33 BayGenomics ES cell line YTC038 embryonic stem cell house mouse CVCL_QS33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923666; Polr1has Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101349 CVCL_R433 HG03926 transformed cell line human CVCL_R433 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101350 CVCL_QS34 BayGenomics ES cell line YTC040 embryonic stem cell house mouse CVCL_QS34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101351 CVCL_R434 HG03928 transformed cell line human CVCL_R434 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101352 CVCL_QS35 BayGenomics ES cell line YTC041 embryonic stem cell house mouse CVCL_QS35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137624; Pom121 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101353 CVCL_R435 HG03929 transformed cell line human CVCL_R435 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101354 CVCL_QS36 BayGenomics ES cell line YTC042 embryonic stem cell house mouse CVCL_QS36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040701; Zfp459 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101355 CVCL_R436 HG03931 transformed cell line human CVCL_R436 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101356 CVCL_QS37 BayGenomics ES cell line YTC043 embryonic stem cell house mouse CVCL_QS37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101357 CVCL_R437 HG03934 transformed cell line human CVCL_R437 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101358 CVCL_QS38 BayGenomics ES cell line YTC045 embryonic stem cell house mouse CVCL_QS38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100887; Elavl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101359 CVCL_R438 HG03937 transformed cell line human CVCL_R438 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101360 CVCL_QS39 BayGenomics ES cell line YTC046 embryonic stem cell house mouse CVCL_QS39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097711; Degs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101361 CVCL_R439 HG03940 transformed cell line human CVCL_R439 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101362 CVCL_QS20 BayGenomics ES cell line YTC015 embryonic stem cell house mouse CVCL_QS20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916889; Exosc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101363 CVCL_R420 HG03905 transformed cell line human CVCL_R420 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101364 CVCL_QS21 BayGenomics ES cell line YTC016 embryonic stem cell house mouse CVCL_QS21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101365 CVCL_R421 HG03907 transformed cell line human CVCL_R421 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101366 CVCL_QS22 BayGenomics ES cell line YTC017 embryonic stem cell house mouse CVCL_QS22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919570; Kifbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101367 CVCL_R422 HG03908 transformed cell line human CVCL_R422 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101368 CVCL_QS23 BayGenomics ES cell line YTC019 embryonic stem cell house mouse CVCL_QS23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444593; Pptc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101369 CVCL_R423 HG03910 transformed cell line human CVCL_R423 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101370 CVCL_QS24 BayGenomics ES cell line YTC020 embryonic stem cell house mouse CVCL_QS24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101371 CVCL_R424 HG03911 transformed cell line human CVCL_R424 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101372 CVCL_QS25 BayGenomics ES cell line YTC023 embryonic stem cell house mouse CVCL_QS25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101373 CVCL_R425 HG03913 transformed cell line human CVCL_R425 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101374 CVCL_HY88 ND01443 transformed cell line human CVCL_HY88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101375 CVCL_QS26 BayGenomics ES cell line YTC024 embryonic stem cell house mouse CVCL_QS26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921605; Smchd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101376 CVCL_R426 HG03914 transformed cell line human CVCL_R426 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101377 CVCL_HY89 ND01456 transformed cell line human CVCL_HY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101378 CVCL_QS27 BayGenomics ES cell line YTC029 embryonic stem cell house mouse CVCL_QS27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338041; Tfg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101379 CVCL_R427 HG03916 transformed cell line human CVCL_R427 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101380 CVCL_QS28 BayGenomics ES cell line YTC032 embryonic stem cell house mouse CVCL_QS28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107380; Spag7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101381 CVCL_R428 HG03917 transformed cell line human CVCL_R428 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101382 CVCL_QS29 BayGenomics ES cell line YTC033 embryonic stem cell house mouse CVCL_QS29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101383 CVCL_R429 HG03919 transformed cell line human CVCL_R429 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101384 CVCL_HY84 ND01419 transformed cell line human CVCL_HY84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101385 CVCL_HY85 ND01437 transformed cell line human CVCL_HY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101386 CVCL_HY86 ND01439 transformed cell line human CVCL_HY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101387 CVCL_HY87 ND01442 transformed cell line human CVCL_HY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101388 CVCL_HY80 ND01410 transformed cell line human CVCL_HY80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101389 CVCL_HY81 ND01415 transformed cell line human CVCL_HY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101390 CVCL_HY82 ND01416 transformed cell line human CVCL_HY82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101391 CVCL_HY83 ND01417 transformed cell line human CVCL_HY83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101392 CVCL_QS10 BayGenomics ES cell line YTC001 embryonic stem cell house mouse CVCL_QS10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346872; Map3k1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101393 CVCL_R410 HG03894 transformed cell line human CVCL_R410 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101394 CVCL_QS11 BayGenomics ES cell line YTC004 embryonic stem cell house mouse CVCL_QS11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101395 CVCL_R411 HG03895 transformed cell line human CVCL_R411 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101396 CVCL_QS12 BayGenomics ES cell line YTC005 embryonic stem cell house mouse CVCL_QS12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101397 CVCL_R412 HG03896 transformed cell line human CVCL_R412 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101398 CVCL_QS13 BayGenomics ES cell line YTC007 embryonic stem cell house mouse CVCL_QS13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201691; Rnf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101399 CVCL_R413 HG03897 transformed cell line human CVCL_R413 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101400 CVCL_QS14 BayGenomics ES cell line YTC008 embryonic stem cell house mouse CVCL_QS14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101401 CVCL_R414 HG03898 transformed cell line human CVCL_R414 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101402 CVCL_HY99 ND01586 transformed cell line human CVCL_HY99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101403 CVCL_QS15 BayGenomics ES cell line YTC009 embryonic stem cell house mouse CVCL_QS15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95610; Gabpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101404 CVCL_R415 HG03899 transformed cell line human CVCL_R415 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101405 CVCL_QS16 BayGenomics ES cell line YTC010 embryonic stem cell house mouse CVCL_QS16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101406 CVCL_R416 HG03900 transformed cell line human CVCL_R416 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101407 CVCL_QS17 BayGenomics ES cell line YTC011 embryonic stem cell house mouse CVCL_QS17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139764; Sec24b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101408 CVCL_R417 HG03901 transformed cell line human CVCL_R417 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101409 CVCL_QS18 BayGenomics ES cell line YTC012 embryonic stem cell house mouse CVCL_QS18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332659; Bnip3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101410 CVCL_R418 HG03902 transformed cell line human CVCL_R418 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101411 CVCL_HY95 ND01540 transformed cell line human CVCL_HY95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101412 CVCL_QS19 BayGenomics ES cell line YTC013 embryonic stem cell house mouse CVCL_QS19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101413 CVCL_R419 HG03904 transformed cell line human CVCL_R419 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101414 CVCL_HY96 ND01549 transformed cell line human CVCL_HY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101415 CVCL_HY97 ND01571 transformed cell line human CVCL_HY97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101416 CVCL_HY98 ND01579 transformed cell line human CVCL_HY98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101417 CVCL_HY91 ND01458 transformed cell line human CVCL_HY91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101418 CVCL_HY92 ND01461 transformed cell line human CVCL_HY92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101419 CVCL_HY93 ND01538 transformed cell line human CVCL_HY93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101420 CVCL_HY94 ND01539 transformed cell line human CVCL_HY94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101421 CVCL_HY90 ND01457 transformed cell line human CVCL_HY90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101422 CVCL_7G56 DA02695 transformed cell line human CVCL_7G56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02695; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101423 CVCL_7G57 DA02696 transformed cell line human CVCL_7G57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02696; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101424 CVCL_7G58 DA02697 transformed cell line human CVCL_7G58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02697; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101425 CVCL_7G59 DA02698 transformed cell line human CVCL_7G59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02698; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101426 CVCL_7G52 DA02690 transformed cell line human CVCL_7G52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101427 CVCL_7G53 DA02691 transformed cell line human CVCL_7G53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101428 CVCL_7G54 DA02692 transformed cell line human CVCL_7G54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02692; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101429 CVCL_7G55 DA02694 transformed cell line human CVCL_7G55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02694; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101430 CVCL_7G50 DA02688 transformed cell line human CVCL_7G50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02688; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101431 CVCL_7G51 DA02689 transformed cell line human CVCL_7G51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02689; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101432 CVCL_7G67 DA02707 transformed cell line human CVCL_7G67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101433 CVCL_7G68 DA02708 transformed cell line human CVCL_7G68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101434 CVCL_7G69 DA02709 transformed cell line human CVCL_7G69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101435 CVCL_7G63 DA02703 transformed cell line human CVCL_7G63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101436 CVCL_7G64 DA02704 transformed cell line human CVCL_7G64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02704; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101437 CVCL_7G65 DA02705 transformed cell line human CVCL_7G65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02705; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101438 CVCL_7G66 DA02706 transformed cell line human CVCL_7G66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101439 CVCL_7G60 DA02699 transformed cell line human CVCL_7G60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02699; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101440 CVCL_7G61 DA02700 transformed cell line human CVCL_7G61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101441 CVCL_7G62 DA02701 transformed cell line human CVCL_7G62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101442 CVCL_7G34 DA02669 transformed cell line human CVCL_7G34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101443 CVCL_7G35 DA02671 transformed cell line human CVCL_7G35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02671; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101444 CVCL_7G36 DA02672 transformed cell line human CVCL_7G36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101445 CVCL_7G37 DA02675 transformed cell line human CVCL_7G37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02675; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101446 CVCL_7G30 DA02663 transformed cell line human CVCL_7G30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101447 CVCL_7G31 DA02664 transformed cell line human CVCL_7G31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101448 CVCL_7G32 DA02665 transformed cell line human CVCL_7G32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101449 CVCL_7G33 DA02666 transformed cell line human CVCL_7G33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101450 CVCL_7G38 DA02676 transformed cell line human CVCL_7G38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02676; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101451 CVCL_7G39 DA02677 transformed cell line human CVCL_7G39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02677; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101452 CVCL_7G45 DA02683 transformed cell line human CVCL_7G45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101453 CVCL_7G46 DA02684 transformed cell line human CVCL_7G46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02684; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101454 CVCL_7G47 DA02685 transformed cell line human CVCL_7G47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02685; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101455 CVCL_7G48 DA02686 transformed cell line human CVCL_7G48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101456 CVCL_7G41 DA02679 transformed cell line human CVCL_7G41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02679; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101457 CVCL_7G42 DA02680 transformed cell line human CVCL_7G42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02680; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101458 CVCL_7G43 DA02681 transformed cell line human CVCL_7G43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02681; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101459 CVCL_7G44 DA02682 transformed cell line human CVCL_7G44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101460 CVCL_7G49 DA02687 transformed cell line human CVCL_7G49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02687; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101461 CVCL_7G40 DA02678 transformed cell line human CVCL_7G40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02678; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101462 CVCL_7G12 DA02644 transformed cell line human CVCL_7G12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02644; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101463 CVCL_7G13 DA02645 transformed cell line human CVCL_7G13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02645; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101464 CVCL_7G14 DA02646 transformed cell line human CVCL_7G14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02646; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101465 CVCL_7G15 DA02647 transformed cell line human CVCL_7G15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02647; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101466 CVCL_7G10 DA02642 transformed cell line human CVCL_7G10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02642; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101467 CVCL_7G11 DA02643 transformed cell line human CVCL_7G11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02643; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101468 CVCL_7G16 DA02648 transformed cell line human CVCL_7G16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101469 CVCL_7G17 DA02649 transformed cell line human CVCL_7G17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101470 CVCL_7G18 DA02650 transformed cell line human CVCL_7G18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101471 CVCL_7G19 DA02651 transformed cell line human CVCL_7G19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02651; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101472 CVCL_7G23 DA02656 transformed cell line human CVCL_7G23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101473 CVCL_7G24 DA02657 transformed cell line human CVCL_7G24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101474 CVCL_7G25 DA02658 transformed cell line human CVCL_7G25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02658; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101475 CVCL_7G26 DA02659 transformed cell line human CVCL_7G26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02659; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101476 CVCL_7G20 DA02653 transformed cell line human CVCL_7G20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02653; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101477 CVCL_7G21 DA02654 transformed cell line human CVCL_7G21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02654; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101478 CVCL_7G22 DA02655 transformed cell line human CVCL_7G22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101479 CVCL_7G27 DA02660 transformed cell line human CVCL_7G27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02660; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101480 CVCL_7G28 DA02661 transformed cell line human CVCL_7G28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02661; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101481 CVCL_7G29 DA02662 transformed cell line human CVCL_7G29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02662; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101482 CVCL_QS94 BayGenomics ES cell line YTC143 embryonic stem cell house mouse CVCL_QS94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913355; Ube2d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101483 CVCL_7G01 DA02632 transformed cell line human CVCL_7G01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101484 CVCL_R494 HG04042 transformed cell line human CVCL_R494 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101485 CVCL_QS95 BayGenomics ES cell line YTC144 embryonic stem cell house mouse CVCL_QS95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924621; Sec24a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101486 CVCL_7G02 DA02633 transformed cell line human CVCL_7G02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02633; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101487 CVCL_R495 HG04047 transformed cell line human CVCL_R495 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101488 CVCL_QS96 BayGenomics ES cell line YTC145 embryonic stem cell house mouse CVCL_QS96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442040; G3bp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101489 CVCL_7G03 DA02635 transformed cell line human CVCL_7G03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02635; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101490 CVCL_R496 HG04050 transformed cell line human CVCL_R496 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101491 CVCL_QS97 BayGenomics ES cell line YTC146 embryonic stem cell house mouse CVCL_QS97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644000; Gm9008 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101492 CVCL_7G04 DA02636 transformed cell line human CVCL_7G04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02636; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101493 CVCL_R497 HG04053 transformed cell line human CVCL_R497 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101494 CVCL_QS98 BayGenomics ES cell line YTC147 embryonic stem cell house mouse CVCL_QS98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101495 CVCL_R498 HG04054 transformed cell line human CVCL_R498 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101496 CVCL_QS99 BayGenomics ES cell line YTC150 embryonic stem cell house mouse CVCL_QS99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921605; Smchd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101497 CVCL_R499 HG04055 transformed cell line human CVCL_R499 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101498 CVCL_7G00 DA02630 transformed cell line human CVCL_7G00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02630; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101499 CVCL_7G09 DA02641 transformed cell line human CVCL_7G09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101500 CVCL_7G05 DA02637 transformed cell line human CVCL_7G05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101501 CVCL_7G06 DA02638 transformed cell line human CVCL_7G06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101502 CVCL_7G07 DA02639 transformed cell line human CVCL_7G07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02639; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101503 CVCL_7G08 DA02640 transformed cell line human CVCL_7G08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02640; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101504 CVCL_7F97 DA02627 transformed cell line human CVCL_7F97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101505 CVCL_7F98 DA02628 transformed cell line human CVCL_7F98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02628; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101506 CVCL_7F99 DA02629 transformed cell line human CVCL_7F99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101507 CVCL_7F93 DA02622 transformed cell line human CVCL_7F93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02622; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101508 CVCL_7F94 DA02623 transformed cell line human CVCL_7F94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02623; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101509 CVCL_7F95 DA02624 transformed cell line human CVCL_7F95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02624; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101510 CVCL_7F96 DA02625 transformed cell line human CVCL_7F96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02625; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101511 CVCL_7F90 DA02619 transformed cell line human CVCL_7F90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101512 CVCL_7F91 DA02620 transformed cell line human CVCL_7F91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101513 CVCL_7F92 DA02621 transformed cell line human CVCL_7F92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101514 CVCL_7F79 DA02606 transformed cell line human CVCL_7F79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02606; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101515 CVCL_7F75 DA02602 transformed cell line human CVCL_7F75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02602; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101516 CVCL_7F76 DA02603 transformed cell line human CVCL_7F76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02603; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101517 CVCL_7F77 DA02604 transformed cell line human CVCL_7F77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02604; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101518 CVCL_7F78 DA02605 transformed cell line human CVCL_7F78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101519 CVCL_7F71 DA02597 transformed cell line human CVCL_7F71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101520 CVCL_7F72 DA02599 transformed cell line human CVCL_7F72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02599; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101521 CVCL_7F73 DA02600 transformed cell line human CVCL_7F73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101522 CVCL_7F74 DA02601 transformed cell line human CVCL_7F74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101523 CVCL_7F70 DA02596 transformed cell line human CVCL_7F70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101524 CVCL_7F86 DA02614 transformed cell line human CVCL_7F86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02614; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101525 CVCL_7F87 DA02615 transformed cell line human CVCL_7F87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02615; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101526 CVCL_7F88 DA02616 transformed cell line human CVCL_7F88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02616; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101527 CVCL_7F89 DA02617 transformed cell line human CVCL_7F89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101528 CVCL_7F82 DA02610 transformed cell line human CVCL_7F82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101529 CVCL_7F83 DA02611 transformed cell line human CVCL_7F83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02611; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101530 CVCL_7F84 DA02612 transformed cell line human CVCL_7F84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02612; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101531 CVCL_7F85 DA02613 transformed cell line human CVCL_7F85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02613; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101532 CVCL_7F80 DA02607 transformed cell line human CVCL_7F80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02607; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101533 CVCL_7F81 DA02609 transformed cell line human CVCL_7F81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02609; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101534 CVCL_7F57 DA02582 transformed cell line human CVCL_7F57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101535 CVCL_7F58 DA02583 transformed cell line human CVCL_7F58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101536 CVCL_7F59 DA02584 transformed cell line human CVCL_7F59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02584; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101537 CVCL_7F53 DA02578 transformed cell line human CVCL_7F53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101538 CVCL_7F54 DA02579 transformed cell line human CVCL_7F54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101539 CVCL_7F55 DA02580 transformed cell line human CVCL_7F55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101540 CVCL_7F56 DA02581 transformed cell line human CVCL_7F56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101541 CVCL_7F50 DA02573 transformed cell line human CVCL_7F50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02573; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101542 CVCL_7F51 DA02576 transformed cell line human CVCL_7F51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02576; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101543 CVCL_7F52 DA02577 transformed cell line human CVCL_7F52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101544 CVCL_7F68 DA02593 transformed cell line human CVCL_7F68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101545 CVCL_7F69 DA02595 transformed cell line human CVCL_7F69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02595; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101546 CVCL_7F64 DA02589 transformed cell line human CVCL_7F64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02589; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101547 CVCL_7F65 DA02590 transformed cell line human CVCL_7F65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02590; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101548 CVCL_7F66 DA02591 transformed cell line human CVCL_7F66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02591; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101549 CVCL_7F67 DA02592 transformed cell line human CVCL_7F67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02592; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101550 CVCL_7F60 DA02585 transformed cell line human CVCL_7F60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02585; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101551 CVCL_7F61 DA02586 transformed cell line human CVCL_7F61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02586; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101552 CVCL_7F62 DA02587 transformed cell line human CVCL_7F62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02587; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101553 CVCL_7F63 DA02588 transformed cell line human CVCL_7F63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02588; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101554 CVCL_QS00 BayGenomics ES cell line YTB039 embryonic stem cell house mouse CVCL_QS00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918398; Mier1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101555 CVCL_R400 HG03873 transformed cell line human CVCL_R400 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101556 CVCL_QS01 BayGenomics ES cell line YTB043 embryonic stem cell house mouse CVCL_QS01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101557 CVCL_R401 HG03874 transformed cell line human CVCL_R401 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101558 CVCL_QS02 BayGenomics ES cell line YTB045 embryonic stem cell house mouse CVCL_QS02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921256; Dnm1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101559 CVCL_R402 HG03875 transformed cell line human CVCL_R402 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101560 CVCL_QS03 BayGenomics ES cell line YTB047 embryonic stem cell house mouse CVCL_QS03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448487; Fam168b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101561 CVCL_R403 HG03882 transformed cell line human CVCL_R403 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101562 CVCL_HY66 ND09059 transformed cell line human CVCL_HY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101563 CVCL_QS04 BayGenomics ES cell line YTB048 embryonic stem cell house mouse CVCL_QS04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106281; Ilrun Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101564 CVCL_R404 HG03884 transformed cell line human CVCL_R404 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101565 CVCL_HY67 ND09060 transformed cell line human CVCL_HY67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101566 CVCL_QS05 BayGenomics ES cell line YTB050 embryonic stem cell house mouse CVCL_QS05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891751; Gps2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101567 CVCL_R405 HG03885 transformed cell line human CVCL_R405 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101568 CVCL_HY68 ND09365 transformed cell line human CVCL_HY68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101569 CVCL_QS06 BayGenomics ES cell line YTB051 embryonic stem cell house mouse CVCL_QS06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385189; Rap1gds1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101570 CVCL_R406 HG03886 transformed cell line human CVCL_R406 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101571 CVCL_HY69 ND09742 transformed cell line human CVCL_HY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101572 CVCL_QS07 BayGenomics ES cell line YTB055 embryonic stem cell house mouse CVCL_QS07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890393; Zfp277 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101573 CVCL_R407 HG03887 transformed cell line human CVCL_R407 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101574 CVCL_HY62 ND07039 transformed cell line human CVCL_HY62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101575 CVCL_QS08 BayGenomics ES cell line YTB057 embryonic stem cell house mouse CVCL_QS08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101576 CVCL_R408 HG03888 transformed cell line human CVCL_R408 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101577 CVCL_HY63 ND07040 transformed cell line human CVCL_HY63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101578 CVCL_QS09 BayGenomics ES cell line YTB059 embryonic stem cell house mouse CVCL_QS09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444748; Chd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101579 CVCL_R409 HG03890 transformed cell line human CVCL_R409 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101580 CVCL_HY64 ND08504 transformed cell line human CVCL_HY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101581 CVCL_HY65 ND08506 transformed cell line human CVCL_HY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101582 CVCL_HY60 ND06973 transformed cell line human CVCL_HY60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101583 CVCL_HY61 ND06974 transformed cell line human CVCL_HY61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101584 CVCL_HY77 ND01346 transformed cell line human CVCL_HY77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101585 CVCL_HY78 ND01360 transformed cell line human CVCL_HY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101586 CVCL_HY79 ND01377 transformed cell line human CVCL_HY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101587 CVCL_HY73 ND01319 transformed cell line human CVCL_HY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101588 CVCL_HY74 ND01321 transformed cell line human CVCL_HY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101589 CVCL_HY75 ND01330 transformed cell line human CVCL_HY75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101590 CVCL_HY76 ND01331 transformed cell line human CVCL_HY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101591 CVCL_HY70 ND09828 transformed cell line human CVCL_HY70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101592 CVCL_HY71 ND01291 transformed cell line human CVCL_HY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101593 CVCL_HY72 ND01316 transformed cell line human CVCL_HY72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101594 CVCL_HY48 ND01040 transformed cell line human CVCL_HY48 CL:0000010 Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Peripheral blood. Female 21101595 CVCL_HY49 ND01048 transformed cell line human CVCL_HY49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101596 CVCL_HY44 ND01027 transformed cell line human CVCL_HY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101597 CVCL_HY45 ND01028 transformed cell line human CVCL_HY45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101598 CVCL_HY46 ND01034 transformed cell line human CVCL_HY46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101599 CVCL_HY47 ND01038 transformed cell line human CVCL_HY47 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex4del; Zygosity=Unspecified (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Peripheral blood. Male 21101600 CVCL_HY40 ND00974 transformed cell line human CVCL_HY40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101601 CVCL_HY41 ND01000 transformed cell line human CVCL_HY41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101602 CVCL_HY42 ND01001 transformed cell line human CVCL_HY42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101603 CVCL_HY43 ND01004 transformed cell line human CVCL_HY43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101604 CVCL_HY59 ND06862 transformed cell line human CVCL_HY59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101605 CVCL_HY55 ND06168 transformed cell line human CVCL_HY55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101606 CVCL_HY56 ND06169 transformed cell line human CVCL_HY56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101607 CVCL_HY57 ND06666 transformed cell line human CVCL_HY57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101608 CVCL_HY58 ND06667 transformed cell line human CVCL_HY58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101609 CVCL_HY51 ND04995 transformed cell line human CVCL_HY51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101610 CVCL_HY52 ND04997 transformed cell line human CVCL_HY52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101611 CVCL_HY53 ND06050 transformed cell line human CVCL_HY53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101612 CVCL_HY54 ND06051 transformed cell line human CVCL_HY54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101613 CVCL_HY50 ND04994 transformed cell line human CVCL_HY50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101614 CVCL_HY26 ND02111 transformed cell line human CVCL_HY26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101615 CVCL_HY27 ND02112 transformed cell line human CVCL_HY27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101616 CVCL_HY28 ND02181 transformed cell line human CVCL_HY28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101617 CVCL_HY29 ND02182 transformed cell line human CVCL_HY29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101618 CVCL_HY22 ND01977 transformed cell line human CVCL_HY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101619 CVCL_HY23 ND01978 transformed cell line human CVCL_HY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101620 CVCL_HY24 ND02007 transformed cell line human CVCL_HY24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101621 CVCL_HY25 ND02008 transformed cell line human CVCL_HY25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101622 CVCL_HY20 ND01975 transformed cell line human CVCL_HY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101623 CVCL_HY21 ND01976 transformed cell line human CVCL_HY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101624 CVCL_HY37 ND03826 transformed cell line human CVCL_HY37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101625 CVCL_HY38 ND03827 transformed cell line human CVCL_HY38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101626 CVCL_HY39 ND04061 transformed cell line human CVCL_HY39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101627 CVCL_HY33 ND03553 transformed cell line human CVCL_HY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101628 CVCL_HY34 ND03554 transformed cell line human CVCL_HY34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101629 CVCL_HY35 ND03700 transformed cell line human CVCL_HY35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101630 CVCL_HY36 ND03701 transformed cell line human CVCL_HY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101631 CVCL_HY30 ND02997 transformed cell line human CVCL_HY30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101632 CVCL_HY31 ND03242 transformed cell line human CVCL_HY31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101633 CVCL_HY32 ND03243 transformed cell line human CVCL_HY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101634 CVCL_HY08 ND00789 transformed cell line human CVCL_HY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101635 CVCL_HY09 ND00790 transformed cell line human CVCL_HY09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101636 CVCL_HY04 ND00721 transformed cell line human CVCL_HY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101637 CVCL_HY05 ND00747 transformed cell line human CVCL_HY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101638 CVCL_HY06 ND00777 transformed cell line human CVCL_HY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101639 CVCL_HY07 ND00778 transformed cell line human CVCL_HY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101640 CVCL_HY00 ND00656 transformed cell line human CVCL_HY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101641 CVCL_HY01 ND00658 transformed cell line human CVCL_HY01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101642 CVCL_HY02 ND00698 transformed cell line human CVCL_HY02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101643 CVCL_HY03 ND00704 transformed cell line human CVCL_HY03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101644 CVCL_HY19 ND01926 transformed cell line human CVCL_HY19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101645 CVCL_HY15 ND01859 transformed cell line human CVCL_HY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101646 CVCL_HY16 ND01872 transformed cell line human CVCL_HY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101647 CVCL_HY17 ND01873 transformed cell line human CVCL_HY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101648 CVCL_HY18 ND01925 transformed cell line human CVCL_HY18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101649 CVCL_HY11 ND01805 transformed cell line human CVCL_HY11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101650 CVCL_HY12 ND01806 transformed cell line human CVCL_HY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101651 CVCL_HY13 ND01807 transformed cell line human CVCL_HY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101652 CVCL_HY14 ND01858 transformed cell line human CVCL_HY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101653 CVCL_HY10 ND01590 transformed cell line human CVCL_HY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101654 CVCL_QT93 BayGenomics ES cell line YTC319 embryonic stem cell house mouse CVCL_QT93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101655 CVCL_7H00 DA02744 transformed cell line human CVCL_7H00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101656 CVCL_R593 GM10830 transformed cell line human CVCL_R593 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,12:01; DRB3*01 (IPD-IMGT/HLA=13837) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140801 21101657 CVCL_QT94 BayGenomics ES cell line YTC321 embryonic stem cell house mouse CVCL_QT94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101658 CVCL_7H01 DA02745 transformed cell line human CVCL_7H01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02745; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101659 CVCL_R594 GM10831 transformed cell line human CVCL_R594 HLA typing: A*01:01,01:01; B*08:01,51:01; C*07:01,15:02; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*03:01,05:01; DQB1*02:01,03:01; DRB1*03:01,04:07; DRB3*01; DRB4*01 (IPD-IMGT/HLA=13830) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140802 21101660 CVCL_QT95 BayGenomics ES cell line YTC322 embryonic stem cell house mouse CVCL_QT95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103067; Atrx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101661 CVCL_7H02 DA02746 transformed cell line human CVCL_7H02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101662 CVCL_R595 GM10835 transformed cell line human CVCL_R595 HLA typing: A*02:01,23:01; B*40:01,41:01; C*03:04:01,17:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:02,02:01; DQB1*02:01,06:04; DRB1*07:01,13:02; DRB3*01; DRB4*01 (IPD-IMGT/HLA=13839) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141601 21101663 CVCL_QT96 BayGenomics ES cell line YTC324 embryonic stem cell house mouse CVCL_QT96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101664 CVCL_7H03 DA02749 transformed cell line human CVCL_7H03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02749; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101665 CVCL_R596 GM10836 transformed cell line human CVCL_R596 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141802 21101666 CVCL_QT97 BayGenomics ES cell line YTC328 embryonic stem cell house mouse CVCL_QT97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101667 CVCL_R597 GM10837 transformed cell line human CVCL_R597 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141801 21101668 CVCL_QT98 BayGenomics ES cell line YTC331 embryonic stem cell house mouse CVCL_QT98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915396; Arl13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101669 CVCL_R598 GM10838 transformed cell line human CVCL_R598 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142001 21101670 CVCL_QT99 BayGenomics ES cell line YTC333 embryonic stem cell house mouse CVCL_QT99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343463; Bub3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101671 CVCL_R599 GM10839 transformed cell line human CVCL_R599 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142002 21101672 CVCL_7H08 DA02754 transformed cell line human CVCL_7H08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02754; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101673 CVCL_7H09 DA02755 transformed cell line human CVCL_7H09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02755; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101674 CVCL_7H04 DA02750 transformed cell line human CVCL_7H04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101675 CVCL_7H05 DA02751 transformed cell line human CVCL_7H05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101676 CVCL_7H06 DA02752 transformed cell line human CVCL_7H06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101677 CVCL_7H07 DA02753 transformed cell line human CVCL_7H07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02753; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101678 CVCL_QT82 BayGenomics ES cell line YTC295 embryonic stem cell house mouse CVCL_QT82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101679 CVCL_R582 GM06997 transformed cell line human CVCL_R582 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329102 21101680 CVCL_QT83 BayGenomics ES cell line YTC298 embryonic stem cell house mouse CVCL_QT83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101681 CVCL_R583 GM07014 transformed cell line human CVCL_R583 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329202 21101682 CVCL_QT84 BayGenomics ES cell line YTC299 embryonic stem cell house mouse CVCL_QT84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914356; Zbtb8os Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101683 CVCL_R584 GM07031 transformed cell line human CVCL_R584 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329213/1329410 21101684 CVCL_QT85 BayGenomics ES cell line YTC301 embryonic stem cell house mouse CVCL_QT85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916023; Zc3hc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101685 CVCL_R585 GM07037 transformed cell line human CVCL_R585 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329111/1329211/1329311/1329412 21101686 CVCL_QT86 BayGenomics ES cell line YTC302 embryonic stem cell house mouse CVCL_QT86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916023; Zc3hc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101687 CVCL_R586 GM07045 transformed cell line human CVCL_R586 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329113 21101688 CVCL_QT87 BayGenomics ES cell line YTC306 embryonic stem cell house mouse CVCL_QT87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101689 CVCL_R587 GM07048 transformed cell line human CVCL_R587 HLA typing: A*02:01,02:01; B*07:02,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01; DRB4*01 (IPD-IMGT/HLA=25854) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134101 21101690 CVCL_QT88 BayGenomics ES cell line YTC307 embryonic stem cell house mouse CVCL_QT88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928744; Vapb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101691 CVCL_R588 GM07051 transformed cell line human CVCL_R588 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329212/1329409 21101692 CVCL_QT89 BayGenomics ES cell line YTC309 embryonic stem cell house mouse CVCL_QT89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384495; Mrtfa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101693 CVCL_R589 GM07346 transformed cell line human CVCL_R589 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 134511 21101694 CVCL_QT90 BayGenomics ES cell line YTC310 embryonic stem cell house mouse CVCL_QT90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917171; Hnrnpa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101695 CVCL_R590 GM07347 transformed cell line human CVCL_R590 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 134510 21101696 CVCL_QT91 BayGenomics ES cell line YTC317 embryonic stem cell house mouse CVCL_QT91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916139; Ubac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101697 CVCL_R591 GM07349 transformed cell line human CVCL_R591 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 134501 21101698 CVCL_QT92 BayGenomics ES cell line YTC318 embryonic stem cell house mouse CVCL_QT92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101699 CVCL_R592 GM07435 transformed cell line human CVCL_R592 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 1329110/1329210/1329310/1329411 21101700 CVCL_QT71 BayGenomics ES cell line YTC273 embryonic stem cell house mouse CVCL_QT71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444798; Atad2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101701 CVCL_R571 HG04222 transformed cell line human CVCL_R571 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101702 CVCL_QT72 BayGenomics ES cell line YTC276 embryonic stem cell house mouse CVCL_QT72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918843; Llgl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101703 CVCL_R572 HG04225 transformed cell line human CVCL_R572 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101704 CVCL_QT73 BayGenomics ES cell line YTC277 embryonic stem cell house mouse CVCL_QT73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101705 CVCL_R573 HG04227 transformed cell line human CVCL_R573 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101706 CVCL_QT74 BayGenomics ES cell line YTC278 embryonic stem cell house mouse CVCL_QT74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101707 CVCL_R574 HG04229 transformed cell line human CVCL_R574 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101708 CVCL_QT75 BayGenomics ES cell line YTC280 embryonic stem cell house mouse CVCL_QT75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104580; Rapgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101709 CVCL_R575 HG04235 transformed cell line human CVCL_R575 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101710 CVCL_QT76 BayGenomics ES cell line YTC281 embryonic stem cell house mouse CVCL_QT76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104872; Ppp1cc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101711 CVCL_R576 HG04238 transformed cell line human CVCL_R576 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101712 CVCL_QT77 BayGenomics ES cell line YTC282 embryonic stem cell house mouse CVCL_QT77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444098; Heatr5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101713 CVCL_R577 HG04239 transformed cell line human CVCL_R577 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101714 CVCL_QT78 BayGenomics ES cell line YTC284 embryonic stem cell house mouse CVCL_QT78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98388; Sptbn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101715 CVCL_R578 GM06986 transformed cell line human CVCL_R578 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329112 21101716 CVCL_QT79 BayGenomics ES cell line YTC289 embryonic stem cell house mouse CVCL_QT79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101717 CVCL_R579 GM06989 transformed cell line human CVCL_R579 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132802/1328109/1329313 21101718 CVCL_QT80 BayGenomics ES cell line YTC290 embryonic stem cell house mouse CVCL_QT80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916023; Zc3hc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101719 CVCL_R580 GM06991 transformed cell line human CVCL_R580 HLA typing: A*02:01,03:01; B*07:02,07:02:01; C*07:02,07:02; DPA1*01:03,01:04; DPB1*04:01,15:01; DQA1*01:02,03:01; DQB1*03:02:01,06:02; DRB1*04:04,15:01; DRB4*01 (IPD-IMGT/HLA=25851) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134102 21101720 CVCL_QT81 BayGenomics ES cell line YTC293 embryonic stem cell house mouse CVCL_QT81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96522; Rbpj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101721 CVCL_R581 GM06995 transformed cell line human CVCL_R581 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329101 21101722 CVCL_QT60 BayGenomics ES cell line YTC259 embryonic stem cell house mouse CVCL_QT60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101723 CVCL_R560 HG04198 transformed cell line human CVCL_R560 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101724 CVCL_QT61 BayGenomics ES cell line YTC260 embryonic stem cell house mouse CVCL_QT61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99690; Pola2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101725 CVCL_R561 HG04200 transformed cell line human CVCL_R561 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101726 CVCL_QT62 BayGenomics ES cell line YTC262 embryonic stem cell house mouse CVCL_QT62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644000; Gm9008 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101727 CVCL_R562 HG04202 transformed cell line human CVCL_R562 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101728 CVCL_QT63 BayGenomics ES cell line YTC263 embryonic stem cell house mouse CVCL_QT63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644000; Gm9008 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101729 CVCL_R563 HG04206 transformed cell line human CVCL_R563 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101730 CVCL_QT64 BayGenomics ES cell line YTC264 embryonic stem cell house mouse CVCL_QT64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101731 CVCL_R564 HG04209 transformed cell line human CVCL_R564 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101732 CVCL_QT65 BayGenomics ES cell line YTC266 embryonic stem cell house mouse CVCL_QT65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101733 CVCL_R565 HG04210 transformed cell line human CVCL_R565 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101734 CVCL_QT66 BayGenomics ES cell line YTC267 embryonic stem cell house mouse CVCL_QT66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929059; Rybp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101735 CVCL_R566 HG04211 transformed cell line human CVCL_R566 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101736 CVCL_QT67 BayGenomics ES cell line YTC268 embryonic stem cell house mouse CVCL_QT67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333803; Top3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101737 CVCL_R567 HG04212 transformed cell line human CVCL_R567 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101738 CVCL_QT68 BayGenomics ES cell line YTC269 embryonic stem cell house mouse CVCL_QT68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101739 CVCL_R568 HG04214 transformed cell line human CVCL_R568 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101740 CVCL_QT69 BayGenomics ES cell line YTC270 embryonic stem cell house mouse CVCL_QT69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101741 CVCL_R569 HG04216 transformed cell line human CVCL_R569 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101742 CVCL_QT70 BayGenomics ES cell line YTC271 embryonic stem cell house mouse CVCL_QT70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919064; Mrps27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101743 CVCL_R570 HG04219 transformed cell line human CVCL_R570 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101744 CVCL_QT50 BayGenomics ES cell line YTC243 embryonic stem cell house mouse CVCL_QT50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101745 CVCL_R550 HG04182 transformed cell line human CVCL_R550 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101746 CVCL_QT51 BayGenomics ES cell line YTC245 embryonic stem cell house mouse CVCL_QT51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444748; Chd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101747 CVCL_R551 HG04183 transformed cell line human CVCL_R551 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101748 CVCL_QT52 BayGenomics ES cell line YTC246 embryonic stem cell house mouse CVCL_QT52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105037; Ddx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101749 CVCL_R552 HG04185 transformed cell line human CVCL_R552 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101750 CVCL_QT53 BayGenomics ES cell line YTC247 embryonic stem cell house mouse CVCL_QT53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196274; Cdca8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101751 CVCL_R553 HG04186 transformed cell line human CVCL_R553 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101752 CVCL_QT54 BayGenomics ES cell line YTC248 embryonic stem cell house mouse CVCL_QT54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916176; Ubap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101753 CVCL_R554 HG04188 transformed cell line human CVCL_R554 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101754 CVCL_QT55 BayGenomics ES cell line YTC249 embryonic stem cell house mouse CVCL_QT55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917274; Mcm10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101755 CVCL_R555 HG04189 transformed cell line human CVCL_R555 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101756 CVCL_QT56 BayGenomics ES cell line YTC250 embryonic stem cell house mouse CVCL_QT56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101757 CVCL_R556 HG04191 transformed cell line human CVCL_R556 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101758 CVCL_QT57 BayGenomics ES cell line YTC251 embryonic stem cell house mouse CVCL_QT57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138986; Qser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101759 CVCL_R557 HG04192 transformed cell line human CVCL_R557 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101760 CVCL_QT58 BayGenomics ES cell line YTC256 embryonic stem cell house mouse CVCL_QT58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101761 CVCL_R558 HG04194 transformed cell line human CVCL_R558 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101762 CVCL_QT59 BayGenomics ES cell line YTC257 embryonic stem cell house mouse CVCL_QT59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101763 CVCL_R559 HG04195 transformed cell line human CVCL_R559 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101764 CVCL_QT40 BayGenomics ES cell line YTC227 embryonic stem cell house mouse CVCL_QT40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930768; Arid3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101765 CVCL_R540 HG04159 transformed cell line human CVCL_R540 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101766 CVCL_QT41 BayGenomics ES cell line YTC230 embryonic stem cell house mouse CVCL_QT41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929706; Ranbp17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101767 CVCL_R541 HG04161 transformed cell line human CVCL_R541 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101768 CVCL_QT42 BayGenomics ES cell line YTC231 embryonic stem cell house mouse CVCL_QT42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353499; Baz1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101769 CVCL_R542 HG04162 transformed cell line human CVCL_R542 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101770 CVCL_QT43 BayGenomics ES cell line YTC232 embryonic stem cell house mouse CVCL_QT43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916996; Znhit6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101771 CVCL_R543 HG04164 transformed cell line human CVCL_R543 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101772 CVCL_QT44 BayGenomics ES cell line YTC233 embryonic stem cell house mouse CVCL_QT44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101773 CVCL_R544 HG04171 transformed cell line human CVCL_R544 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101774 CVCL_QT45 BayGenomics ES cell line YTC235 embryonic stem cell house mouse CVCL_QT45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196274; Cdca8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101775 CVCL_R545 HG04173 transformed cell line human CVCL_R545 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101776 CVCL_QT46 BayGenomics ES cell line YTC236 embryonic stem cell house mouse CVCL_QT46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276116; Ep300 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101777 CVCL_R546 HG04174 transformed cell line human CVCL_R546 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101778 CVCL_QT47 BayGenomics ES cell line YTC238 embryonic stem cell house mouse CVCL_QT47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914729; Tmem183a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101779 CVCL_R547 HG04176 transformed cell line human CVCL_R547 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101780 CVCL_QT48 BayGenomics ES cell line YTC240 embryonic stem cell house mouse CVCL_QT48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201408; Srpk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101781 CVCL_R548 HG04177 transformed cell line human CVCL_R548 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101782 CVCL_QT49 BayGenomics ES cell line YTC242 embryonic stem cell house mouse CVCL_QT49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921134; Zdbf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101783 CVCL_R549 HG04180 transformed cell line human CVCL_R549 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101784 CVCL_QT30 BayGenomics ES cell line YTC205 embryonic stem cell house mouse CVCL_QT30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97577; Phka2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101785 CVCL_R530 HG04144 transformed cell line human CVCL_R530 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101786 CVCL_QT31 BayGenomics ES cell line YTC206 embryonic stem cell house mouse CVCL_QT31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913809; Metap1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101787 CVCL_R531 HG04146 transformed cell line human CVCL_R531 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101788 CVCL_QT32 BayGenomics ES cell line YTC207 embryonic stem cell house mouse CVCL_QT32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333856; Klf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101789 CVCL_R532 HG04147 transformed cell line human CVCL_R532 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101790 CVCL_QT33 BayGenomics ES cell line YTC209 embryonic stem cell house mouse CVCL_QT33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385096; Pprc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101791 CVCL_R533 HG04149 transformed cell line human CVCL_R533 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101792 CVCL_QT34 BayGenomics ES cell line YTC210 embryonic stem cell house mouse CVCL_QT34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104708; Cct3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101793 CVCL_R534 HG04150 transformed cell line human CVCL_R534 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101794 CVCL_QT35 BayGenomics ES cell line YTC212 embryonic stem cell house mouse CVCL_QT35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101795 CVCL_R535 HG04152 transformed cell line human CVCL_R535 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101796 CVCL_QT36 BayGenomics ES cell line YTC217 embryonic stem cell house mouse CVCL_QT36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923038; Smurf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101797 CVCL_R536 HG04153 transformed cell line human CVCL_R536 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101798 CVCL_QT37 BayGenomics ES cell line YTC218 embryonic stem cell house mouse CVCL_QT37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923038; Smurf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101799 CVCL_R537 HG04155 transformed cell line human CVCL_R537 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101800 CVCL_QT38 BayGenomics ES cell line YTC222 embryonic stem cell house mouse CVCL_QT38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98927; Vcl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101801 CVCL_R538 HG04156 transformed cell line human CVCL_R538 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101802 CVCL_QT39 BayGenomics ES cell line YTC226 embryonic stem cell house mouse CVCL_QT39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143977; Mbtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101803 CVCL_R539 HG04158 transformed cell line human CVCL_R539 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101804 CVCL_7H77 DA02831 transformed cell line human CVCL_7H77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101805 CVCL_7H78 DA02832 transformed cell line human CVCL_7H78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101806 CVCL_7H79 DA02833 transformed cell line human CVCL_7H79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101807 CVCL_7H73 DA02827 transformed cell line human CVCL_7H73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101808 CVCL_7H74 DA02828 transformed cell line human CVCL_7H74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101809 CVCL_7H75 DA02829 transformed cell line human CVCL_7H75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101810 CVCL_7H76 DA02830 transformed cell line human CVCL_7H76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101811 CVCL_7H70 DA02823 transformed cell line human CVCL_7H70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101812 CVCL_7H71 DA02824 transformed cell line human CVCL_7H71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101813 CVCL_7H72 DA02826 transformed cell line human CVCL_7H72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101814 CVCL_7H88 DA02843 transformed cell line human CVCL_7H88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101815 CVCL_7H89 DA02844 transformed cell line human CVCL_7H89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101816 CVCL_7H84 DA02839 transformed cell line human CVCL_7H84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101817 CVCL_7H85 DA02840 transformed cell line human CVCL_7H85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101818 CVCL_7H86 DA02841 transformed cell line human CVCL_7H86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101819 CVCL_7H87 DA02842 transformed cell line human CVCL_7H87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101820 CVCL_7H80 DA02835 transformed cell line human CVCL_7H80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101821 CVCL_7H81 DA02836 transformed cell line human CVCL_7H81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101822 CVCL_7H82 DA02837 transformed cell line human CVCL_7H82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101823 CVCL_7H83 DA02838 transformed cell line human CVCL_7H83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101824 CVCL_7H55 DA02808 transformed cell line human CVCL_7H55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101825 CVCL_7H56 DA02809 transformed cell line human CVCL_7H56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101826 CVCL_7H57 DA02810 transformed cell line human CVCL_7H57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101827 CVCL_7H58 DA02811 transformed cell line human CVCL_7H58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101828 CVCL_7H51 DA02804 transformed cell line human CVCL_7H51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101829 CVCL_7H52 DA02805 transformed cell line human CVCL_7H52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101830 CVCL_7H53 DA02806 transformed cell line human CVCL_7H53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101831 CVCL_7H54 DA02807 transformed cell line human CVCL_7H54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101832 CVCL_7H59 DA02812 transformed cell line human CVCL_7H59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101833 CVCL_7H50 DA02803 transformed cell line human CVCL_7H50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101834 CVCL_7H66 DA02819 transformed cell line human CVCL_7H66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101835 CVCL_7H67 DA02820 transformed cell line human CVCL_7H67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101836 CVCL_7H68 DA02821 transformed cell line human CVCL_7H68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101837 CVCL_7H69 DA02822 transformed cell line human CVCL_7H69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101838 CVCL_7H62 DA02815 transformed cell line human CVCL_7H62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02815; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101839 CVCL_7H63 DA02816 transformed cell line human CVCL_7H63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101840 CVCL_7H64 DA02817 transformed cell line human CVCL_7H64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101841 CVCL_7H65 DA02818 transformed cell line human CVCL_7H65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101842 CVCL_7H60 DA02813 transformed cell line human CVCL_7H60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101843 CVCL_7H61 DA02814 transformed cell line human CVCL_7H61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101844 CVCL_7H33 DA02782 transformed cell line human CVCL_7H33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101845 CVCL_7H34 DA02783 transformed cell line human CVCL_7H34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101846 CVCL_7H35 DA02784 transformed cell line human CVCL_7H35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101847 CVCL_7H36 DA02785 transformed cell line human CVCL_7H36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02785; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101848 CVCL_7H30 DA02777 transformed cell line human CVCL_7H30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101849 CVCL_7H31 DA02780 transformed cell line human CVCL_7H31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101850 CVCL_7H32 DA02781 transformed cell line human CVCL_7H32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101851 CVCL_7H37 DA02786 transformed cell line human CVCL_7H37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101852 CVCL_7H38 DA02787 transformed cell line human CVCL_7H38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101853 CVCL_7H39 DA02789 transformed cell line human CVCL_7H39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101854 CVCL_7H44 DA02795 transformed cell line human CVCL_7H44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101855 CVCL_7H45 DA02797 transformed cell line human CVCL_7H45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101856 CVCL_7H46 DA02798 transformed cell line human CVCL_7H46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101857 CVCL_7H47 DA02799 transformed cell line human CVCL_7H47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101858 CVCL_7H40 DA02791 transformed cell line human CVCL_7H40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02791; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101859 CVCL_7H41 DA02792 transformed cell line human CVCL_7H41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101860 CVCL_7H42 DA02793 transformed cell line human CVCL_7H42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101861 CVCL_7H43 DA02794 transformed cell line human CVCL_7H43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101862 CVCL_7H48 DA02800 transformed cell line human CVCL_7H48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02800; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101863 CVCL_7H49 DA02801 transformed cell line human CVCL_7H49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02801; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101864 CVCL_7H11 DA02757 transformed cell line human CVCL_7H11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101865 CVCL_7H12 DA02758 transformed cell line human CVCL_7H12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101866 CVCL_7H13 DA02759 transformed cell line human CVCL_7H13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101867 CVCL_7H14 DA02760 transformed cell line human CVCL_7H14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101868 CVCL_7H10 DA02756 transformed cell line human CVCL_7H10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101869 CVCL_7H19 DA02766 transformed cell line human CVCL_7H19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101870 CVCL_7H15 DA02761 transformed cell line human CVCL_7H15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02761; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101871 CVCL_7H16 DA02763 transformed cell line human CVCL_7H16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101872 CVCL_7H17 DA02764 transformed cell line human CVCL_7H17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02764; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101873 CVCL_7H18 DA02765 transformed cell line human CVCL_7H18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02765; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101874 CVCL_7H22 DA02769 transformed cell line human CVCL_7H22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02769; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101875 CVCL_7H23 DA02770 transformed cell line human CVCL_7H23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02770; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101876 CVCL_7H24 DA02771 transformed cell line human CVCL_7H24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02771; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101877 CVCL_7H25 DA02772 transformed cell line human CVCL_7H25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101878 CVCL_7H20 DA02767 transformed cell line human CVCL_7H20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02767; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101879 CVCL_7H21 DA02768 transformed cell line human CVCL_7H21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02768; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101880 CVCL_7H26 DA02773 transformed cell line human CVCL_7H26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02773; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101881 CVCL_7H27 DA02774 transformed cell line human CVCL_7H27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101882 CVCL_7H28 DA02775 transformed cell line human CVCL_7H28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101883 CVCL_7H29 DA02776 transformed cell line human CVCL_7H29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101884 CVCL_HZ07 ND01661 transformed cell line human CVCL_HZ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101885 CVCL_HZ08 ND01662 transformed cell line human CVCL_HZ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101886 CVCL_HZ09 ND01664 transformed cell line human CVCL_HZ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101887 CVCL_HZ03 ND01631 transformed cell line human CVCL_HZ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101888 CVCL_HZ04 ND01648 transformed cell line human CVCL_HZ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101889 CVCL_HZ05 ND01653 transformed cell line human CVCL_HZ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101890 CVCL_HZ06 ND01654 transformed cell line human CVCL_HZ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101891 CVCL_HZ00 ND01587 transformed cell line human CVCL_HZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101892 CVCL_HZ01 ND01603 transformed cell line human CVCL_HZ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101893 CVCL_HZ02 ND01608 transformed cell line human CVCL_HZ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101894 CVCL_HZ18 ND01774 transformed cell line human CVCL_HZ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101895 CVCL_HZ19 ND01775 transformed cell line human CVCL_HZ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101896 CVCL_HZ14 ND01745 transformed cell line human CVCL_HZ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101897 CVCL_HZ15 ND01746 transformed cell line human CVCL_HZ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101898 CVCL_HZ16 ND01747 transformed cell line human CVCL_HZ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101899 CVCL_HZ17 ND01765 transformed cell line human CVCL_HZ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101900 CVCL_HZ10 ND01673 transformed cell line human CVCL_HZ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101901 CVCL_HZ11 ND01685 transformed cell line human CVCL_HZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101902 CVCL_HZ12 ND01741 transformed cell line human CVCL_HZ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101903 CVCL_HZ13 ND01743 transformed cell line human CVCL_HZ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101904 CVCL_7G96 DA02740 transformed cell line human CVCL_7G96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101905 CVCL_7G97 DA02741 transformed cell line human CVCL_7G97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101906 CVCL_7G98 DA02742 transformed cell line human CVCL_7G98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101907 CVCL_7G99 DA02743 transformed cell line human CVCL_7G99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02743; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101908 CVCL_7G92 DA02735 transformed cell line human CVCL_7G92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02735; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101909 CVCL_7G93 DA02737 transformed cell line human CVCL_7G93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101910 CVCL_7G94 DA02738 transformed cell line human CVCL_7G94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101911 CVCL_7G95 DA02739 transformed cell line human CVCL_7G95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101912 CVCL_7G90 DA02733 transformed cell line human CVCL_7G90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02733; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101913 CVCL_7G91 DA02734 transformed cell line human CVCL_7G91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101914 CVCL_7G78 DA02718 transformed cell line human CVCL_7G78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02718; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101915 CVCL_7G79 DA02719 transformed cell line human CVCL_7G79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101916 CVCL_7G74 DA02714 transformed cell line human CVCL_7G74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02714; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101917 CVCL_7G75 DA02715 transformed cell line human CVCL_7G75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02715; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101918 CVCL_7G76 DA02716 transformed cell line human CVCL_7G76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101919 CVCL_7G77 DA02717 transformed cell line human CVCL_7G77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02717; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101920 CVCL_7G70 DA02710 transformed cell line human CVCL_7G70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101921 CVCL_7G71 DA02711 transformed cell line human CVCL_7G71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101922 CVCL_7G72 DA02712 transformed cell line human CVCL_7G72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101923 CVCL_7G73 DA02713 transformed cell line human CVCL_7G73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101924 CVCL_7G89 DA02732 transformed cell line human CVCL_7G89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02732; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101925 CVCL_7G85 DA02727 transformed cell line human CVCL_7G85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02727; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101926 CVCL_7G86 DA02728 transformed cell line human CVCL_7G86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101927 CVCL_7G87 DA02729 transformed cell line human CVCL_7G87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101928 CVCL_7G88 DA02730 transformed cell line human CVCL_7G88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101929 CVCL_7G81 DA02721 transformed cell line human CVCL_7G81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02721; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101930 CVCL_7G82 DA02722 transformed cell line human CVCL_7G82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02722; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101931 CVCL_7G83 DA02725 transformed cell line human CVCL_7G83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02725; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101932 CVCL_7G84 DA02726 transformed cell line human CVCL_7G84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02726; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101933 CVCL_7G80 DA02720 transformed cell line human CVCL_7G80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21101934 CVCL_QT20 BayGenomics ES cell line YTC190 embryonic stem cell house mouse CVCL_QT20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921605; Smchd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101935 CVCL_R520 HG04114 transformed cell line human CVCL_R520 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101936 CVCL_QT21 BayGenomics ES cell line YTC191 embryonic stem cell house mouse CVCL_QT21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101937 CVCL_R521 HG04118 transformed cell line human CVCL_R521 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101938 CVCL_QT22 BayGenomics ES cell line YTC192 embryonic stem cell house mouse CVCL_QT22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107892; Fam3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101939 CVCL_R522 HG04127 transformed cell line human CVCL_R522 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101940 CVCL_QT23 BayGenomics ES cell line YTC193 embryonic stem cell house mouse CVCL_QT23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101941 CVCL_R523 HG04128 transformed cell line human CVCL_R523 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101942 CVCL_QT24 BayGenomics ES cell line YTC197 embryonic stem cell house mouse CVCL_QT24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920336; Rps6ka5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101943 CVCL_R524 HG04131 transformed cell line human CVCL_R524 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101944 CVCL_HZ87 ND02334 transformed cell line human CVCL_HZ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101945 CVCL_QT25 BayGenomics ES cell line YTC198 embryonic stem cell house mouse CVCL_QT25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101946 CVCL_R525 HG04132 transformed cell line human CVCL_R525 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101947 CVCL_HZ88 ND02338 transformed cell line human CVCL_HZ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101948 CVCL_QT26 BayGenomics ES cell line YTC199 embryonic stem cell house mouse CVCL_QT26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101949 CVCL_R526 HG04134 transformed cell line human CVCL_R526 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101950 CVCL_HZ89 ND02370 transformed cell line human CVCL_HZ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101951 CVCL_QT27 BayGenomics ES cell line YTC201 embryonic stem cell house mouse CVCL_QT27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99690; Pola2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101952 CVCL_R527 HG04135 transformed cell line human CVCL_R527 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101953 CVCL_QT28 BayGenomics ES cell line YTC203 embryonic stem cell house mouse CVCL_QT28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101954 CVCL_R528 HG04140 transformed cell line human CVCL_R528 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101955 CVCL_HZ83 ND02279 transformed cell line human CVCL_HZ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101956 CVCL_QT29 BayGenomics ES cell line YTC204 embryonic stem cell house mouse CVCL_QT29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3042141; Traf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101957 CVCL_R529 HG04141 transformed cell line human CVCL_R529 CL:0000010 Population: Bengali in Bangladesh (BEB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101958 CVCL_HZ84 ND02282 transformed cell line human CVCL_HZ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101959 CVCL_HZ85 ND02284 transformed cell line human CVCL_HZ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101960 CVCL_HZ86 ND02285 transformed cell line human CVCL_HZ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101961 CVCL_HZ80 ND02228 transformed cell line human CVCL_HZ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101962 CVCL_HZ81 ND02231 transformed cell line human CVCL_HZ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101963 CVCL_HZ82 ND02275 transformed cell line human CVCL_HZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101964 CVCL_QT10 BayGenomics ES cell line YTC166 embryonic stem cell house mouse CVCL_QT10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921570; Wdr33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101965 CVCL_R510 HG04080 transformed cell line human CVCL_R510 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101966 CVCL_QT11 BayGenomics ES cell line YTC167 embryonic stem cell house mouse CVCL_QT11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890948; Supt16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101967 CVCL_R511 HG04090 transformed cell line human CVCL_R511 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101968 CVCL_QT12 BayGenomics ES cell line YTC169 embryonic stem cell house mouse CVCL_QT12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101969 CVCL_R512 HG04093 transformed cell line human CVCL_R512 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101970 CVCL_QT13 BayGenomics ES cell line YTC173 embryonic stem cell house mouse CVCL_QT13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108074; Sptlc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101971 CVCL_R513 HG04094 transformed cell line human CVCL_R513 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101972 CVCL_HZ98 ND02430 transformed cell line human CVCL_HZ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101973 CVCL_QT14 BayGenomics ES cell line YTC176 embryonic stem cell house mouse CVCL_QT14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2177308; Znrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101974 CVCL_R514 HG04096 transformed cell line human CVCL_R514 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101975 CVCL_HZ99 ND02437 transformed cell line human CVCL_HZ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101976 CVCL_QT15 BayGenomics ES cell line YTC179 embryonic stem cell house mouse CVCL_QT15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101977 CVCL_R515 HG04098 transformed cell line human CVCL_R515 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101978 CVCL_QT16 BayGenomics ES cell line YTC180 embryonic stem cell house mouse CVCL_QT16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101979 CVCL_R516 HG04099 transformed cell line human CVCL_R516 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101980 CVCL_QT17 BayGenomics ES cell line YTC182 embryonic stem cell house mouse CVCL_QT17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919936; Usp24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101981 CVCL_R517 HG04100 transformed cell line human CVCL_R517 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101982 CVCL_HZ94 ND02393 transformed cell line human CVCL_HZ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101983 CVCL_QT18 BayGenomics ES cell line YTC186 embryonic stem cell house mouse CVCL_QT18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915161; Zfp169 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101984 CVCL_R518 HG04106 transformed cell line human CVCL_R518 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101985 CVCL_HZ95 ND02394 transformed cell line human CVCL_HZ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101986 CVCL_QT19 BayGenomics ES cell line YTC189 embryonic stem cell house mouse CVCL_QT19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915438; Sympk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101987 CVCL_R519 HG04107 transformed cell line human CVCL_R519 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101988 CVCL_HZ96 ND02410 transformed cell line human CVCL_HZ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21101989 CVCL_HZ97 ND02412 transformed cell line human CVCL_HZ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101990 CVCL_HZ90 ND02374 transformed cell line human CVCL_HZ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101991 CVCL_HZ91 ND02390 transformed cell line human CVCL_HZ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101992 CVCL_HZ92 ND02391 transformed cell line human CVCL_HZ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101993 CVCL_HZ93 ND02392 transformed cell line human CVCL_HZ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101994 CVCL_HZ69 ND02158 transformed cell line human CVCL_HZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21101995 CVCL_QT00 BayGenomics ES cell line YTC151 embryonic stem cell house mouse CVCL_QT00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101996 CVCL_R500 HG04056 transformed cell line human CVCL_R500 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101997 CVCL_QT01 BayGenomics ES cell line YTC152 embryonic stem cell house mouse CVCL_QT01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21101998 CVCL_R501 HG04058 transformed cell line human CVCL_R501 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21101999 CVCL_QT02 BayGenomics ES cell line YTC153 embryonic stem cell house mouse CVCL_QT02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102000 CVCL_R502 HG04059 transformed cell line human CVCL_R502 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102001 CVCL_HZ65 ND02116 transformed cell line human CVCL_HZ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102002 CVCL_QT03 BayGenomics ES cell line YTC154 embryonic stem cell house mouse CVCL_QT03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443480; Setx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102003 CVCL_R503 HG04060 transformed cell line human CVCL_R503 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102004 CVCL_HZ66 ND02129 transformed cell line human CVCL_HZ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102005 CVCL_QT04 BayGenomics ES cell line YTC155 embryonic stem cell house mouse CVCL_QT04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107889; Exosc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102006 CVCL_R504 HG04061 transformed cell line human CVCL_R504 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102007 CVCL_HZ67 ND02149 transformed cell line human CVCL_HZ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102008 CVCL_QT05 BayGenomics ES cell line YTC158 embryonic stem cell house mouse CVCL_QT05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102009 CVCL_R505 HG04062 transformed cell line human CVCL_R505 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102010 CVCL_HZ68 ND02152 transformed cell line human CVCL_HZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102011 CVCL_QT06 BayGenomics ES cell line YTC161 embryonic stem cell house mouse CVCL_QT06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890165; Larp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102012 CVCL_R506 HG04063 transformed cell line human CVCL_R506 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102013 CVCL_HZ61 ND02076 transformed cell line human CVCL_HZ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102014 CVCL_QT07 BayGenomics ES cell line YTC162 embryonic stem cell house mouse CVCL_QT07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98790; Top2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102015 CVCL_R507 HG04070 transformed cell line human CVCL_R507 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102016 CVCL_HZ62 ND02078 transformed cell line human CVCL_HZ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102017 CVCL_QT08 BayGenomics ES cell line YTC163 embryonic stem cell house mouse CVCL_QT08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102018 CVCL_R508 HG04075 transformed cell line human CVCL_R508 CL:0000010 Population: Sri Lankan Tamil in the UK (STU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102019 CVCL_HZ63 ND02085 transformed cell line human CVCL_HZ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102020 CVCL_QT09 BayGenomics ES cell line YTC165 embryonic stem cell house mouse CVCL_QT09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102021 CVCL_R509 HG04076 transformed cell line human CVCL_R509 CL:0000010 Population: Indian; Telugu in the UK (ITU); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102022 CVCL_HZ64 ND02113 transformed cell line human CVCL_HZ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102023 CVCL_HZ60 ND02071 transformed cell line human CVCL_HZ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102024 CVCL_HZ76 ND02194 transformed cell line human CVCL_HZ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102025 CVCL_HZ77 ND02195 transformed cell line human CVCL_HZ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102026 CVCL_HZ78 ND02197 transformed cell line human CVCL_HZ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102027 CVCL_HZ79 ND02202 transformed cell line human CVCL_HZ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102028 CVCL_HZ72 ND02176 transformed cell line human CVCL_HZ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102029 CVCL_HZ73 ND02178 transformed cell line human CVCL_HZ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102030 CVCL_HZ74 ND02192 transformed cell line human CVCL_HZ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102031 CVCL_HZ75 ND02193 transformed cell line human CVCL_HZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102032 CVCL_HZ70 ND02164 transformed cell line human CVCL_HZ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102033 CVCL_HZ71 ND02170 transformed cell line human CVCL_HZ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102034 CVCL_HZ47 ND02000 transformed cell line human CVCL_HZ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102035 CVCL_HZ48 ND02001 transformed cell line human CVCL_HZ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102036 CVCL_HZ49 ND02002 transformed cell line human CVCL_HZ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102037 CVCL_HZ43 ND01992 transformed cell line human CVCL_HZ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102038 CVCL_HZ44 ND01994 transformed cell line human CVCL_HZ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102039 CVCL_HZ45 ND01997 transformed cell line human CVCL_HZ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102040 CVCL_HZ46 ND01999 transformed cell line human CVCL_HZ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102041 CVCL_HZ40 ND01969 transformed cell line human CVCL_HZ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102042 CVCL_HZ41 ND01986 transformed cell line human CVCL_HZ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102043 CVCL_HZ42 ND01989 transformed cell line human CVCL_HZ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102044 CVCL_HZ58 ND02053 transformed cell line human CVCL_HZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102045 CVCL_HZ59 ND02070 transformed cell line human CVCL_HZ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102046 CVCL_HZ54 ND02036 transformed cell line human CVCL_HZ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102047 CVCL_HZ55 ND02040 transformed cell line human CVCL_HZ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102048 CVCL_HZ56 ND02049 transformed cell line human CVCL_HZ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102049 CVCL_HZ57 ND02050 transformed cell line human CVCL_HZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102050 CVCL_HZ50 ND02005 transformed cell line human CVCL_HZ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102051 CVCL_HZ51 ND02017 transformed cell line human CVCL_HZ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102052 CVCL_HZ52 ND02022 transformed cell line human CVCL_HZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102053 CVCL_HZ53 ND02035 transformed cell line human CVCL_HZ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102054 CVCL_HZ29 ND01814 transformed cell line human CVCL_HZ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102055 CVCL_HZ25 ND01800 transformed cell line human CVCL_HZ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102056 CVCL_HZ26 ND01802 transformed cell line human CVCL_HZ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102057 CVCL_HZ27 ND01810 transformed cell line human CVCL_HZ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102058 CVCL_HZ28 ND01812 transformed cell line human CVCL_HZ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102059 CVCL_HZ21 ND01787 transformed cell line human CVCL_HZ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102060 CVCL_HZ22 ND01791 transformed cell line human CVCL_HZ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102061 CVCL_HZ23 ND01794 transformed cell line human CVCL_HZ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102062 CVCL_HZ24 ND01798 transformed cell line human CVCL_HZ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102063 CVCL_HZ20 ND01776 transformed cell line human CVCL_HZ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102064 CVCL_HZ36 ND01888 transformed cell line human CVCL_HZ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102065 CVCL_HZ37 ND01892 transformed cell line human CVCL_HZ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102066 CVCL_HZ38 ND01919 transformed cell line human CVCL_HZ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102067 CVCL_HZ39 ND01922 transformed cell line human CVCL_HZ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102068 CVCL_HZ32 ND01854 transformed cell line human CVCL_HZ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102069 CVCL_HZ33 ND01875 transformed cell line human CVCL_HZ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102070 CVCL_HZ34 ND01879 transformed cell line human CVCL_HZ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102071 CVCL_HZ35 ND01882 transformed cell line human CVCL_HZ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102072 CVCL_HZ30 ND01846 transformed cell line human CVCL_HZ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102073 CVCL_HZ31 ND01848 transformed cell line human CVCL_HZ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102074 CVCL_I428 HGDP00428 transformed cell line human CVCL_I428 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102075 CVCL_HS28 ND00791 transformed cell line human CVCL_HS28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102076 CVCL_I429 HGDP01291 transformed cell line human CVCL_I429 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102077 CVCL_HS29 ND00812 transformed cell line human CVCL_HS29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102078 CVCL_I424 HGDP01287 transformed cell line human CVCL_I424 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102079 CVCL_HS24 ND00645 transformed cell line human CVCL_HS24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102080 CVCL_I425 HGDP01288 transformed cell line human CVCL_I425 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102081 CVCL_HS25 ND00650 transformed cell line human CVCL_HS25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102082 CVCL_I426 HGDP01289 transformed cell line human CVCL_I426 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102083 CVCL_HS26 ND00651 transformed cell line human CVCL_HS26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102084 CVCL_I427 HGDP01290 transformed cell line human CVCL_I427 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102085 CVCL_HS27 ND00657 transformed cell line human CVCL_HS27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102086 CVCL_I420 HGDP01284 transformed cell line human CVCL_I420 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102087 CVCL_HS20 ND00619 transformed cell line human CVCL_HS20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102088 CVCL_I421 HGDP01285 transformed cell line human CVCL_I421 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102089 CVCL_HS21 ND00640 transformed cell line human CVCL_HS21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102090 CVCL_I422 HGDP01286 transformed cell line human CVCL_I422 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102091 CVCL_HS22 ND00643 transformed cell line human CVCL_HS22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102092 CVCL_I423 HGDP00423 transformed cell line human CVCL_I423 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102093 CVCL_HS23 ND00644 transformed cell line human CVCL_HS23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102094 CVCL_I439 HGDP01299 transformed cell line human CVCL_I439 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102095 CVCL_HS39 ND01049 transformed cell line human CVCL_HS39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102096 CVCL_I435 HGDP01296 transformed cell line human CVCL_I435 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102097 CVCL_HS35 ND00949 transformed cell line human CVCL_HS35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102098 CVCL_I436 HGDP01297 transformed cell line human CVCL_I436 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102099 CVCL_HS36 ND00979 transformed cell line human CVCL_HS36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102100 CVCL_I437 HGDP01298 transformed cell line human CVCL_I437 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102101 CVCL_HS37 ND01002 transformed cell line human CVCL_HS37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102102 CVCL_I438 HGDP00438 transformed cell line human CVCL_I438 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102103 CVCL_HS38 ND01046 transformed cell line human CVCL_HS38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102104 CVCL_I431 HGDP01293 transformed cell line human CVCL_I431 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102105 CVCL_HS31 ND00878 transformed cell line human CVCL_HS31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102106 CVCL_I432 HGDP01294 transformed cell line human CVCL_I432 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102107 CVCL_HS32 ND00892 transformed cell line human CVCL_HS32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102108 CVCL_I433 HGDP00433 transformed cell line human CVCL_I433 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102109 CVCL_HS33 ND00947 transformed cell line human CVCL_HS33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102110 CVCL_I434 HGDP01295 transformed cell line human CVCL_I434 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102111 CVCL_HS34 ND00948 transformed cell line human CVCL_HS34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102112 CVCL_I430 HGDP01292 transformed cell line human CVCL_I430 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102113 CVCL_HS30 ND00835 transformed cell line human CVCL_HS30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102114 CVCL_I406 HGDP01273 transformed cell line human CVCL_I406 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102115 CVCL_HS06 ND36531 transformed cell line human CVCL_HS06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102116 CVCL_I407 HGDP00407 transformed cell line human CVCL_I407 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102117 CVCL_HS07 ND36642 transformed cell line human CVCL_HS07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102118 CVCL_I408 HGDP01274 transformed cell line human CVCL_I408 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102119 CVCL_HS08 ND37179 transformed cell line human CVCL_HS08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102120 CVCL_I409 HGDP01275 transformed cell line human CVCL_I409 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102121 CVCL_HS09 ND37710 transformed cell line human CVCL_HS09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102122 CVCL_I402 HGDP00402 transformed cell line human CVCL_I402 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102123 CVCL_HS02 ND35991 transformed cell line human CVCL_HS02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102124 CVCL_I403 HGDP01270 transformed cell line human CVCL_I403 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102125 CVCL_HS03 ND35992 transformed cell line human CVCL_HS03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102126 CVCL_I404 HGDP01271 transformed cell line human CVCL_I404 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102127 CVCL_HS04 ND35993 transformed cell line human CVCL_HS04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102128 CVCL_I405 HGDP01272 transformed cell line human CVCL_I405 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102129 CVCL_HS05 ND36353 transformed cell line human CVCL_HS05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102130 CVCL_I400 HGDP01268 transformed cell line human CVCL_I400 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102131 CVCL_HS00 ND35894 transformed cell line human CVCL_HS00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102132 CVCL_I401 HGDP01269 transformed cell line human CVCL_I401 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102133 CVCL_HS01 ND35945 transformed cell line human CVCL_HS01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102134 CVCL_I417 HGDP00417 transformed cell line human CVCL_I417 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102135 CVCL_HS17 ND00594 transformed cell line human CVCL_HS17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102136 CVCL_I418 HGDP01282 transformed cell line human CVCL_I418 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102137 CVCL_HS18 ND00611 transformed cell line human CVCL_HS18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102138 CVCL_I419 HGDP01283 transformed cell line human CVCL_I419 CL:0000010 Population: African; Mandenka; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102139 CVCL_HS19 ND00617 transformed cell line human CVCL_HS19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102140 CVCL_I413 HGDP01278 transformed cell line human CVCL_I413 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102141 CVCL_HS13 ND38689 transformed cell line human CVCL_HS13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102142 CVCL_I414 HGDP01279 transformed cell line human CVCL_I414 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102143 CVCL_HS14 ND40985 transformed cell line human CVCL_HS14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102144 CVCL_I415 HGDP01280 transformed cell line human CVCL_I415 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102145 CVCL_HS15 ND41375 transformed cell line human CVCL_HS15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102146 CVCL_I416 HGDP01281 transformed cell line human CVCL_I416 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102147 CVCL_HS16 ND00593 transformed cell line human CVCL_HS16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102148 CVCL_I410 HGDP01276 transformed cell line human CVCL_I410 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102149 CVCL_HS10 ND38155 transformed cell line human CVCL_HS10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102150 CVCL_I411 HGDP01277 transformed cell line human CVCL_I411 CL:0000010 Population: Mozabite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102151 CVCL_HS11 ND38170 transformed cell line human CVCL_HS11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102152 CVCL_I412 HGDP00412 transformed cell line human CVCL_I412 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102153 CVCL_HS12 ND38181 transformed cell line human CVCL_HS12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102154 CVCL_QM45 BayGenomics ES cell line YHD168 embryonic stem cell house mouse CVCL_QM45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102155 CVCL_QM46 BayGenomics ES cell line YHD171 embryonic stem cell house mouse CVCL_QM46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2651932; Lcorl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102156 CVCL_QM47 BayGenomics ES cell line YHD172 embryonic stem cell house mouse CVCL_QM47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2651932; Lcorl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102157 CVCL_QM48 BayGenomics ES cell line YHD174 embryonic stem cell house mouse CVCL_QM48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97537; Pecam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102158 CVCL_QM49 BayGenomics ES cell line YHD176 embryonic stem cell house mouse CVCL_QM49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109326; Bnip3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102159 CVCL_QM50 BayGenomics ES cell line YHD179 embryonic stem cell house mouse CVCL_QM50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102160 CVCL_QM51 BayGenomics ES cell line YHD180 embryonic stem cell house mouse CVCL_QM51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102161 CVCL_QM52 BayGenomics ES cell line YHD181 embryonic stem cell house mouse CVCL_QM52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919669; Fam72a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102162 CVCL_QM53 BayGenomics ES cell line YHD182 embryonic stem cell house mouse CVCL_QM53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104819; Hnrnpa2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102163 CVCL_QM54 BayGenomics ES cell line YHD183 embryonic stem cell house mouse CVCL_QM54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934606; Alms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102164 CVCL_QM55 BayGenomics ES cell line YHD185 embryonic stem cell house mouse CVCL_QM55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446132; Bms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102165 CVCL_QM34 BayGenomics ES cell line YHD152 embryonic stem cell house mouse CVCL_QM34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102166 CVCL_QM35 BayGenomics ES cell line YHD154 embryonic stem cell house mouse CVCL_QM35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102167 CVCL_QM36 BayGenomics ES cell line YHD155 embryonic stem cell house mouse CVCL_QM36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102168 CVCL_QM37 BayGenomics ES cell line YHD156 embryonic stem cell house mouse CVCL_QM37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925055; Esco1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102169 CVCL_QM38 BayGenomics ES cell line YHD157 embryonic stem cell house mouse CVCL_QM38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352755; Gtse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102170 CVCL_QM39 BayGenomics ES cell line YHD158 embryonic stem cell house mouse CVCL_QM39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104872; Ppp1cc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102171 CVCL_QM40 BayGenomics ES cell line YHD159 embryonic stem cell house mouse CVCL_QM40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102172 CVCL_QM41 BayGenomics ES cell line YHD160 embryonic stem cell house mouse CVCL_QM41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449313; Gemin4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102173 CVCL_QM42 BayGenomics ES cell line YHD164 embryonic stem cell house mouse CVCL_QM42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921414; Nfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102174 CVCL_QM43 BayGenomics ES cell line YHD165 embryonic stem cell house mouse CVCL_QM43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102175 CVCL_QM44 BayGenomics ES cell line YHD167 embryonic stem cell house mouse CVCL_QM44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109580; Sf3b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102176 CVCL_QM23 BayGenomics ES cell line YHD133 embryonic stem cell house mouse CVCL_QM23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387629; Tardbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102177 CVCL_QM24 BayGenomics ES cell line YHD136 embryonic stem cell house mouse CVCL_QM24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102178 CVCL_QM25 BayGenomics ES cell line YHD137 embryonic stem cell house mouse CVCL_QM25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353423; Zfp292 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102179 CVCL_QM26 BayGenomics ES cell line YHD139 embryonic stem cell house mouse CVCL_QM26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102180 CVCL_QM27 BayGenomics ES cell line YHD140 embryonic stem cell house mouse CVCL_QM27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099832; Tln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102181 CVCL_QM28 BayGenomics ES cell line YHD141 embryonic stem cell house mouse CVCL_QM28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102182 CVCL_QM29 BayGenomics ES cell line YHD145 embryonic stem cell house mouse CVCL_QM29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102183 CVCL_I486 HGDP01312 transformed cell line human CVCL_I486 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102184 CVCL_HS86 ND02045 transformed cell line human CVCL_HS86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102185 CVCL_I487 HGDP01313 transformed cell line human CVCL_I487 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102186 CVCL_HS87 ND02046 transformed cell line human CVCL_HS87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102187 CVCL_I488 HGDP01314 transformed cell line human CVCL_I488 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102188 CVCL_HS88 ND02088 transformed cell line human CVCL_HS88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102189 CVCL_I489 HGDP01315 transformed cell line human CVCL_I489 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102190 CVCL_HS89 ND02117 transformed cell line human CVCL_HS89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102191 CVCL_I482 HGDP01308 transformed cell line human CVCL_I482 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102192 CVCL_HS82 ND01998 transformed cell line human CVCL_HS82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102193 CVCL_I483 HGDP01309 transformed cell line human CVCL_I483 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102194 CVCL_HS83 ND02023 transformed cell line human CVCL_HS83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102195 CVCL_I484 HGDP01310 transformed cell line human CVCL_I484 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102196 CVCL_HS84 ND02041 transformed cell line human CVCL_HS84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102197 CVCL_I485 HGDP01311 transformed cell line human CVCL_I485 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102198 CVCL_HS85 ND02042 transformed cell line human CVCL_HS85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102199 CVCL_I480 HGDP01306 transformed cell line human CVCL_I480 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102200 CVCL_HS80 ND01991 transformed cell line human CVCL_HS80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102201 CVCL_I481 HGDP01307 transformed cell line human CVCL_I481 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102202 CVCL_HS81 ND01996 transformed cell line human CVCL_HS81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102203 CVCL_QM30 BayGenomics ES cell line YHD146 embryonic stem cell house mouse CVCL_QM30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915455; Urm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102204 CVCL_QM31 BayGenomics ES cell line YHD147 embryonic stem cell house mouse CVCL_QM31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353499; Baz1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102205 CVCL_QM32 BayGenomics ES cell line YHD148 embryonic stem cell house mouse CVCL_QM32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151152; Baz2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102206 CVCL_QM33 BayGenomics ES cell line YHD149 embryonic stem cell house mouse CVCL_QM33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102207 CVCL_QM12 BayGenomics ES cell line YHD118 embryonic stem cell house mouse CVCL_QM12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351331; Chaf1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102208 CVCL_QM13 BayGenomics ES cell line YHD119 embryonic stem cell house mouse CVCL_QM13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97621; Plk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102209 CVCL_QM14 BayGenomics ES cell line YHD121 embryonic stem cell house mouse CVCL_QM14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102210 CVCL_QM15 BayGenomics ES cell line YHD122 embryonic stem cell house mouse CVCL_QM15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351329; Rps11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102211 CVCL_QM16 BayGenomics ES cell line YHD123 embryonic stem cell house mouse CVCL_QM16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921700; Pank2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102212 CVCL_QM17 BayGenomics ES cell line YHD124 embryonic stem cell house mouse CVCL_QM17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102213 CVCL_QM18 BayGenomics ES cell line YHD125 embryonic stem cell house mouse CVCL_QM18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102214 CVCL_QM19 BayGenomics ES cell line YHD126 embryonic stem cell house mouse CVCL_QM19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915392; Ino80 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102215 CVCL_I497 HGDP01321 transformed cell line human CVCL_I497 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102216 CVCL_HS97 ND02329 transformed cell line human CVCL_HS97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102217 CVCL_I498 HGDP01322 transformed cell line human CVCL_I498 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102218 CVCL_HS98 ND02339 transformed cell line human CVCL_HS98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102219 CVCL_I499 HGDP01323 transformed cell line human CVCL_I499 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102220 CVCL_HS99 ND02376 transformed cell line human CVCL_HS99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102221 CVCL_I493 HGDP01317 transformed cell line human CVCL_I493 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102222 CVCL_HS93 ND02175 transformed cell line human CVCL_HS93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102223 CVCL_I494 HGDP01318 transformed cell line human CVCL_I494 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102224 CVCL_HS94 ND02276 transformed cell line human CVCL_HS94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102225 CVCL_I495 HGDP01319 transformed cell line human CVCL_I495 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102226 CVCL_HS95 ND02300 transformed cell line human CVCL_HS95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102227 CVCL_I496 HGDP01320 transformed cell line human CVCL_I496 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102228 CVCL_HS96 ND02306 transformed cell line human CVCL_HS96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102229 CVCL_I490 HGDP00490 transformed cell line human CVCL_I490 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102230 CVCL_HS90 ND02156 transformed cell line human CVCL_HS90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102231 CVCL_I491 HGDP00491 transformed cell line human CVCL_I491 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102232 CVCL_HS91 ND02159 transformed cell line human CVCL_HS91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102233 CVCL_I492 HGDP01316 transformed cell line human CVCL_I492 CL:0000010 Population: Chinese/Asian ethnic group; Dai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102234 CVCL_HS92 ND02174 transformed cell line human CVCL_HS92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102235 CVCL_QM20 BayGenomics ES cell line YHD130 embryonic stem cell house mouse CVCL_QM20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109519; Msh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102236 CVCL_QM21 BayGenomics ES cell line YHD131 embryonic stem cell house mouse CVCL_QM21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332659; Bnip3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102237 CVCL_QM22 BayGenomics ES cell line YHD132 embryonic stem cell house mouse CVCL_QM22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933181; Eif3d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102238 CVCL_QM01 BayGenomics ES cell line YHD102 embryonic stem cell house mouse CVCL_QM01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102239 CVCL_QM02 BayGenomics ES cell line YHD105 embryonic stem cell house mouse CVCL_QM02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3714357; Srp54b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102240 CVCL_QM03 BayGenomics ES cell line YHD106 embryonic stem cell house mouse CVCL_QM03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102241 CVCL_QM04 BayGenomics ES cell line YHD109 embryonic stem cell house mouse CVCL_QM04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442456; Unk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102242 CVCL_QM05 BayGenomics ES cell line YHD110 embryonic stem cell house mouse CVCL_QM05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914535; Cwc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102243 CVCL_QM06 BayGenomics ES cell line YHD111 embryonic stem cell house mouse CVCL_QM06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102244 CVCL_QM07 BayGenomics ES cell line YHD112 embryonic stem cell house mouse CVCL_QM07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102245 CVCL_QM08 BayGenomics ES cell line YHD114 embryonic stem cell house mouse CVCL_QM08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97621; Plk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102246 CVCL_QM09 BayGenomics ES cell line YHD115 embryonic stem cell house mouse CVCL_QM09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109490; Sms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102247 CVCL_I468 HGDP00468 transformed cell line human CVCL_I468 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102248 CVCL_HS68 ND01809 transformed cell line human CVCL_HS68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102249 CVCL_I469 HGDP00469 transformed cell line human CVCL_I469 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102250 CVCL_HS69 ND01813 transformed cell line human CVCL_HS69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102251 CVCL_I464 HGDP00464 transformed cell line human CVCL_I464 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102252 CVCL_HS64 ND01769 transformed cell line human CVCL_HS64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102253 CVCL_I465 HGDP00465 transformed cell line human CVCL_I465 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102254 CVCL_HS65 ND01771 transformed cell line human CVCL_HS65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102255 CVCL_I466 HGDP00466 transformed cell line human CVCL_I466 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102256 CVCL_HS66 ND01773 transformed cell line human CVCL_HS66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102257 CVCL_I467 HGDP00467 transformed cell line human CVCL_I467 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102258 CVCL_HS67 ND01795 transformed cell line human CVCL_HS67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102259 CVCL_I460 HGDP00460 transformed cell line human CVCL_I460 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102260 CVCL_HS60 ND01712 transformed cell line human CVCL_HS60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102261 CVCL_I461 HGDP00461 transformed cell line human CVCL_I461 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102262 CVCL_HS61 ND01742 transformed cell line human CVCL_HS61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102263 CVCL_I462 HGDP00462 transformed cell line human CVCL_I462 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102264 CVCL_HS62 ND01763 transformed cell line human CVCL_HS62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102265 CVCL_I463 HGDP00463 transformed cell line human CVCL_I463 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102266 CVCL_HS63 ND01764 transformed cell line human CVCL_HS63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102267 CVCL_QM10 BayGenomics ES cell line YHD116 embryonic stem cell house mouse CVCL_QM10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102268 CVCL_QM11 BayGenomics ES cell line YHD117 embryonic stem cell house mouse CVCL_QM11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102269 CVCL_I479 HGDP00479 transformed cell line human CVCL_I479 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102270 CVCL_HS79 ND01990 transformed cell line human CVCL_HS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102271 CVCL_I475 HGDP00475 transformed cell line human CVCL_I475 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102272 CVCL_HS75 ND01920 transformed cell line human CVCL_HS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102273 CVCL_I476 HGDP00476 transformed cell line human CVCL_I476 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102274 CVCL_HS76 ND01921 transformed cell line human CVCL_HS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102275 CVCL_I477 HGDP00477 transformed cell line human CVCL_I477 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102276 CVCL_HS77 ND01949 transformed cell line human CVCL_HS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102277 CVCL_I478 HGDP00478 transformed cell line human CVCL_I478 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102278 CVCL_HS78 ND01950 transformed cell line human CVCL_HS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102279 CVCL_I471 HGDP00471 transformed cell line human CVCL_I471 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102280 CVCL_HS71 ND01820 transformed cell line human CVCL_HS71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102281 CVCL_I472 HGDP00472 transformed cell line human CVCL_I472 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102282 CVCL_HS72 ND01821 transformed cell line human CVCL_HS72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102283 CVCL_I473 HGDP00473 transformed cell line human CVCL_I473 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102284 CVCL_HS73 ND01849 transformed cell line human CVCL_HS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102285 CVCL_I474 HGDP00474 transformed cell line human CVCL_I474 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102286 CVCL_HS74 ND01850 transformed cell line human CVCL_HS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102287 CVCL_I470 HGDP00470 transformed cell line human CVCL_I470 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102288 CVCL_HS70 ND01815 transformed cell line human CVCL_HS70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102289 CVCL_QM00 BayGenomics ES cell line YHD099 embryonic stem cell house mouse CVCL_QM00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102290 CVCL_I446 HGDP01304 transformed cell line human CVCL_I446 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102291 CVCL_HS46 ND01255 transformed cell line human CVCL_HS46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102292 CVCL_I447 HGDP01305 transformed cell line human CVCL_I447 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102293 CVCL_HS47 ND01265 transformed cell line human CVCL_HS47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102294 CVCL_I448 HGDP00448 transformed cell line human CVCL_I448 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102295 CVCL_HS48 ND01337 transformed cell line human CVCL_HS48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102296 CVCL_I449 HGDP00449 transformed cell line human CVCL_I449 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102297 CVCL_HS49 ND01366 transformed cell line human CVCL_HS49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102298 CVCL_I442 HGDP01302 transformed cell line human CVCL_I442 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102299 CVCL_HS42 ND01126 transformed cell line human CVCL_HS42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102300 CVCL_I443 HGDP01303 transformed cell line human CVCL_I443 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102301 CVCL_HS43 ND01164 transformed cell line human CVCL_HS43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102302 CVCL_I444 HGDP00444 transformed cell line human CVCL_I444 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102303 CVCL_HS44 ND01169 transformed cell line human CVCL_HS44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102304 CVCL_I445 HGDP00445 transformed cell line human CVCL_I445 CL:0000010 Population: Burusho; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102305 CVCL_HS45 ND01192 transformed cell line human CVCL_HS45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102306 CVCL_I440 HGDP01300 transformed cell line human CVCL_I440 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102307 CVCL_HS40 ND01050 transformed cell line human CVCL_HS40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102308 CVCL_I441 HGDP01301 transformed cell line human CVCL_I441 CL:0000010 Population: Chinese/Asian ethnic group: Uyghur; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102309 CVCL_HS41 ND01052 transformed cell line human CVCL_HS41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102310 CVCL_I457 HGDP00457 transformed cell line human CVCL_I457 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102311 CVCL_HS57 ND01594 transformed cell line human CVCL_HS57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102312 CVCL_I458 HGDP00458 transformed cell line human CVCL_I458 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102313 CVCL_HS58 ND01596 transformed cell line human CVCL_HS58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102314 CVCL_I459 HGDP00459 transformed cell line human CVCL_I459 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102315 CVCL_HS59 ND01597 transformed cell line human CVCL_HS59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102316 CVCL_I453 HGDP00453 transformed cell line human CVCL_I453 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102317 CVCL_HS53 ND01460 transformed cell line human CVCL_HS53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102318 CVCL_I454 HGDP00454 transformed cell line human CVCL_I454 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102319 CVCL_HS54 ND01462 transformed cell line human CVCL_HS54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102320 CVCL_I455 HGDP00455 transformed cell line human CVCL_I455 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102321 CVCL_HS55 ND01472 transformed cell line human CVCL_HS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102322 CVCL_I456 HGDP00456 transformed cell line human CVCL_I456 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102323 CVCL_HS56 ND01537 transformed cell line human CVCL_HS56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102324 CVCL_I450 HGDP00450 transformed cell line human CVCL_I450 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102325 CVCL_HS50 ND01379 transformed cell line human CVCL_HS50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102326 CVCL_I451 HGDP00451 transformed cell line human CVCL_I451 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102327 CVCL_HS51 ND01380 transformed cell line human CVCL_HS51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102328 CVCL_I452 HGDP00452 transformed cell line human CVCL_I452 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102329 CVCL_HS52 ND01381 transformed cell line human CVCL_HS52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102330 CVCL_QL90 BayGenomics ES cell line YHD080 embryonic stem cell house mouse CVCL_QL90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2177308; Znrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102331 CVCL_QL91 BayGenomics ES cell line YHD085 embryonic stem cell house mouse CVCL_QL91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352483; Mga Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102332 CVCL_QL92 BayGenomics ES cell line YHD088 embryonic stem cell house mouse CVCL_QL92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102333 CVCL_QL93 BayGenomics ES cell line YHD090 embryonic stem cell house mouse CVCL_QL93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104871; Ppp1cb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102334 CVCL_QL94 BayGenomics ES cell line YHD091 embryonic stem cell house mouse CVCL_QL94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328328; Map7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102335 CVCL_QL95 BayGenomics ES cell line YHD092 embryonic stem cell house mouse CVCL_QL95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858896; Spast Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102336 CVCL_QL96 BayGenomics ES cell line YHD094 embryonic stem cell house mouse CVCL_QL96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102337 CVCL_QL97 BayGenomics ES cell line YHD096 embryonic stem cell house mouse CVCL_QL97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109601; Nck1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102338 CVCL_QL98 BayGenomics ES cell line YHD097 embryonic stem cell house mouse CVCL_QL98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102339 CVCL_QL99 BayGenomics ES cell line YHD098 embryonic stem cell house mouse CVCL_QL99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100520; Twf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102340 CVCL_QL79 BayGenomics ES cell line YHD050 embryonic stem cell house mouse CVCL_QL79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441844; Tmem87a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102341 CVCL_QL80 BayGenomics ES cell line YHD051 embryonic stem cell house mouse CVCL_QL80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95485; Fasn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102342 CVCL_QL81 BayGenomics ES cell line YHD052 embryonic stem cell house mouse CVCL_QL81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913337; Emc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102343 CVCL_QL82 BayGenomics ES cell line YHD054 embryonic stem cell house mouse CVCL_QL82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929492; Atl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102344 CVCL_QL83 BayGenomics ES cell line YHD056 embryonic stem cell house mouse CVCL_QL83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913809; Metap1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102345 CVCL_QL84 BayGenomics ES cell line YHD059 embryonic stem cell house mouse CVCL_QL84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102346 CVCL_QL85 BayGenomics ES cell line YHD061 embryonic stem cell house mouse CVCL_QL85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685031; Leo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102347 CVCL_QL86 BayGenomics ES cell line YHD064 embryonic stem cell house mouse CVCL_QL86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102348 CVCL_QL87 BayGenomics ES cell line YHD069 embryonic stem cell house mouse CVCL_QL87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102349 CVCL_QL88 BayGenomics ES cell line YHD072 embryonic stem cell house mouse CVCL_QL88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109580; Sf3b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102350 CVCL_QL89 BayGenomics ES cell line YHD079 embryonic stem cell house mouse CVCL_QL89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442697; Zfp473 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102351 CVCL_QL68 BayGenomics ES cell line YHD028 embryonic stem cell house mouse CVCL_QL68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278322; Epc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102352 CVCL_QL69 BayGenomics ES cell line YHD032 embryonic stem cell house mouse CVCL_QL69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102353 CVCL_QL70 BayGenomics ES cell line YHD033 embryonic stem cell house mouse CVCL_QL70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102354 CVCL_QL71 BayGenomics ES cell line YHD034 embryonic stem cell house mouse CVCL_QL71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102355 CVCL_QL72 BayGenomics ES cell line YHD035 embryonic stem cell house mouse CVCL_QL72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309511; Cdc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102356 CVCL_QL73 BayGenomics ES cell line YHD037 embryonic stem cell house mouse CVCL_QL73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894835; Rbbp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102357 CVCL_QL74 BayGenomics ES cell line YHD038 embryonic stem cell house mouse CVCL_QL74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139207; Sec16a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102358 CVCL_QL75 BayGenomics ES cell line YHD040 embryonic stem cell house mouse CVCL_QL75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102359 CVCL_QL76 BayGenomics ES cell line YHD041 embryonic stem cell house mouse CVCL_QL76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339984; Pak2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102360 CVCL_QL77 BayGenomics ES cell line YHD044 embryonic stem cell house mouse CVCL_QL77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924203; Emsy Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102361 CVCL_QL78 BayGenomics ES cell line YHD048 embryonic stem cell house mouse CVCL_QL78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104288; Pms2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102362 CVCL_QL57 BayGenomics ES cell line YHD007 embryonic stem cell house mouse CVCL_QL57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918023; Cwf19l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102363 CVCL_QL58 BayGenomics ES cell line YHD008 embryonic stem cell house mouse CVCL_QL58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143977; Mbtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102364 CVCL_QL59 BayGenomics ES cell line YHD011 embryonic stem cell house mouse CVCL_QL59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922471; Dpp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102365 CVCL_QL60 BayGenomics ES cell line YHD013 embryonic stem cell house mouse CVCL_QL60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914504; Bmerb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102366 CVCL_QL61 BayGenomics ES cell line YHD015 embryonic stem cell house mouse CVCL_QL61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102367 CVCL_QL62 BayGenomics ES cell line YHD018 embryonic stem cell house mouse CVCL_QL62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102368 CVCL_QL63 BayGenomics ES cell line YHD019 embryonic stem cell house mouse CVCL_QL63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921605; Smchd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102369 CVCL_QL64 BayGenomics ES cell line YHD020 embryonic stem cell house mouse CVCL_QL64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918335; Arhgap19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102370 CVCL_QL65 BayGenomics ES cell line YHD021 embryonic stem cell house mouse CVCL_QL65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929668; Rnf14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102371 CVCL_QL66 BayGenomics ES cell line YHD022 embryonic stem cell house mouse CVCL_QL66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102372 CVCL_QL67 BayGenomics ES cell line YHD026 embryonic stem cell house mouse CVCL_QL67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102373 CVCL_QL46 BayGenomics ES cell line YHC445 embryonic stem cell house mouse CVCL_QL46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918249; Naa40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102374 CVCL_QL47 BayGenomics ES cell line YHC446 embryonic stem cell house mouse CVCL_QL47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918249; Naa40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102375 CVCL_QL48 BayGenomics ES cell line YHC454 embryonic stem cell house mouse CVCL_QL48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914132; Bzw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102376 CVCL_QL49 BayGenomics ES cell line YHC459 embryonic stem cell house mouse CVCL_QL49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102377 CVCL_QL50 BayGenomics ES cell line YHC460 embryonic stem cell house mouse CVCL_QL50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861942; Gtf2ird1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102378 CVCL_QL51 BayGenomics ES cell line YHC465 embryonic stem cell house mouse CVCL_QL51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102379 CVCL_QL52 BayGenomics ES cell line YHC470 embryonic stem cell house mouse CVCL_QL52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144724; Ttc7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102380 CVCL_QL53 BayGenomics ES cell line YHC472 embryonic stem cell house mouse CVCL_QL53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102381 CVCL_QL54 BayGenomics ES cell line YHC475 embryonic stem cell house mouse CVCL_QL54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922845; Mzt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102382 CVCL_QL55 BayGenomics ES cell line YHD004 embryonic stem cell house mouse CVCL_QL55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102383 CVCL_QL56 BayGenomics ES cell line YHD005 embryonic stem cell house mouse CVCL_QL56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102384 CVCL_QL35 BayGenomics ES cell line YHC419 embryonic stem cell house mouse CVCL_QL35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88568; Cux1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102385 CVCL_QL36 BayGenomics ES cell line YHC421 embryonic stem cell house mouse CVCL_QL36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859333; Nfat5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102386 CVCL_QL37 BayGenomics ES cell line YHC426 embryonic stem cell house mouse CVCL_QL37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88568; Cux1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102387 CVCL_QL38 BayGenomics ES cell line YHC431 embryonic stem cell house mouse CVCL_QL38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102388 CVCL_QL39 BayGenomics ES cell line YHC432 embryonic stem cell house mouse CVCL_QL39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442842; Mtmr9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102389 CVCL_QL40 BayGenomics ES cell line YHC435 embryonic stem cell house mouse CVCL_QL40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107891; Nop2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102390 CVCL_QL41 BayGenomics ES cell line YHC436 embryonic stem cell house mouse CVCL_QL41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917132; Ints14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102391 CVCL_QL42 BayGenomics ES cell line YHC439 embryonic stem cell house mouse CVCL_QL42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387591; Arcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102392 CVCL_QL43 BayGenomics ES cell line YHC441 embryonic stem cell house mouse CVCL_QL43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449975; Iqgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102393 CVCL_QL44 BayGenomics ES cell line YHC442 embryonic stem cell house mouse CVCL_QL44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98117; Rps15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102394 CVCL_QL45 BayGenomics ES cell line YHC444 embryonic stem cell house mouse CVCL_QL45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925112; Thyn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102395 CVCL_I549 HGDP00549 transformed cell line human CVCL_I549 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102396 CVCL_HT49 ND03604 transformed cell line human CVCL_HT49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102397 CVCL_I545 HGDP00545 transformed cell line human CVCL_I545 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102398 CVCL_HT45 ND03516 transformed cell line human CVCL_HT45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102399 CVCL_I546 HGDP00546 transformed cell line human CVCL_I546 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102400 CVCL_HT46 ND03544 transformed cell line human CVCL_HT46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102401 CVCL_I547 HGDP00547 transformed cell line human CVCL_I547 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102402 CVCL_HT47 ND03545 transformed cell line human CVCL_HT47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102403 CVCL_I548 HGDP00548 transformed cell line human CVCL_I548 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102404 CVCL_HT48 ND03603 transformed cell line human CVCL_HT48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102405 CVCL_I541 HGDP00541 transformed cell line human CVCL_I541 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102406 CVCL_HT41 ND03325 transformed cell line human CVCL_HT41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102407 CVCL_I542 HGDP00542 transformed cell line human CVCL_I542 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced (low read coverage) Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102408 CVCL_HT42 ND03326 transformed cell line human CVCL_HT42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102409 CVCL_I543 HGDP00543 transformed cell line human CVCL_I543 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102410 CVCL_HT43 ND03499 transformed cell line human CVCL_HT43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102411 CVCL_I544 HGDP00544 transformed cell line human CVCL_I544 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102412 CVCL_HT44 ND03515 transformed cell line human CVCL_HT44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102413 CVCL_I540 HGDP00540 transformed cell line human CVCL_I540 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102414 CVCL_HT40 ND03306 transformed cell line human CVCL_HT40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102415 CVCL_I556 HGDP00556 transformed cell line human CVCL_I556 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102416 CVCL_HT56 ND03723 transformed cell line human CVCL_HT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102417 CVCL_I557 HGDP00557 transformed cell line human CVCL_I557 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102418 CVCL_HT57 ND03737 transformed cell line human CVCL_HT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102419 CVCL_I558 HGDP00558 transformed cell line human CVCL_I558 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102420 CVCL_HT58 ND03739 transformed cell line human CVCL_HT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102421 CVCL_I559 HGDP00559 transformed cell line human CVCL_I559 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102422 CVCL_HT59 ND03750 transformed cell line human CVCL_HT59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102423 CVCL_I552 HGDP00552 transformed cell line human CVCL_I552 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102424 CVCL_HT52 ND03642 transformed cell line human CVCL_HT52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102425 CVCL_I553 HGDP00553 transformed cell line human CVCL_I553 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102426 CVCL_HT53 ND03644 transformed cell line human CVCL_HT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102427 CVCL_I554 HGDP00554 transformed cell line human CVCL_I554 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102428 CVCL_HT54 ND03649 transformed cell line human CVCL_HT54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102429 CVCL_I555 HGDP00555 transformed cell line human CVCL_I555 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102430 CVCL_HT55 ND03690 transformed cell line human CVCL_HT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102431 CVCL_I550 HGDP00550 transformed cell line human CVCL_I550 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102432 CVCL_HT50 ND03616 transformed cell line human CVCL_HT50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102433 CVCL_I551 HGDP00551 transformed cell line human CVCL_I551 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102434 CVCL_HT51 ND03625 transformed cell line human CVCL_HT51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102435 CVCL_I527 HGDP00527 transformed cell line human CVCL_I527 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102436 CVCL_HT27 ND03021 transformed cell line human CVCL_HT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102437 CVCL_I528 HGDP00528 transformed cell line human CVCL_I528 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102438 CVCL_HT28 ND03058 transformed cell line human CVCL_HT28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102439 CVCL_I529 HGDP00529 transformed cell line human CVCL_I529 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102440 CVCL_HT29 ND03061 transformed cell line human CVCL_HT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102441 CVCL_I523 HGDP00523 transformed cell line human CVCL_I523 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102442 CVCL_HT23 ND02923 transformed cell line human CVCL_HT23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102443 CVCL_I524 HGDP00524 transformed cell line human CVCL_I524 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102444 CVCL_HT24 ND02993 transformed cell line human CVCL_HT24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102445 CVCL_I525 HGDP00525 transformed cell line human CVCL_I525 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102446 CVCL_HT25 ND03016 transformed cell line human CVCL_HT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102447 CVCL_I526 HGDP00526 transformed cell line human CVCL_I526 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102448 CVCL_HT26 ND03017 transformed cell line human CVCL_HT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102449 CVCL_I520 HGDP00520 transformed cell line human CVCL_I520 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102450 CVCL_HT20 ND02907 transformed cell line human CVCL_HT20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102451 CVCL_I521 HGDP00521 transformed cell line human CVCL_I521 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced (low read coverage) Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102452 CVCL_HT21 ND02908 transformed cell line human CVCL_HT21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102453 CVCL_I522 HGDP00522 transformed cell line human CVCL_I522 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102454 CVCL_HT22 ND02915 transformed cell line human CVCL_HT22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102455 CVCL_I538 HGDP00538 transformed cell line human CVCL_I538 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102456 CVCL_HT38 ND03217 transformed cell line human CVCL_HT38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102457 CVCL_I539 HGDP00539 transformed cell line human CVCL_I539 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102458 CVCL_HT39 ND03236 transformed cell line human CVCL_HT39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102459 CVCL_I534 HGDP00534 transformed cell line human CVCL_I534 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102460 CVCL_HT34 ND03157 transformed cell line human CVCL_HT34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102461 CVCL_I535 HGDP00535 transformed cell line human CVCL_I535 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102462 CVCL_HT35 ND03169 transformed cell line human CVCL_HT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102463 CVCL_I536 HGDP00536 transformed cell line human CVCL_I536 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102464 CVCL_HT36 ND03182 transformed cell line human CVCL_HT36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102465 CVCL_I537 HGDP00537 transformed cell line human CVCL_I537 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102466 CVCL_HT37 ND03194 transformed cell line human CVCL_HT37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102467 CVCL_I530 HGDP00530 transformed cell line human CVCL_I530 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102468 CVCL_HT30 ND03063 transformed cell line human CVCL_HT30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102469 CVCL_I531 HGDP00531 transformed cell line human CVCL_I531 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102470 CVCL_HT31 ND03098 transformed cell line human CVCL_HT31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102471 CVCL_I532 HGDP00532 transformed cell line human CVCL_I532 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102472 CVCL_HT32 ND03099 transformed cell line human CVCL_HT32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102473 CVCL_I533 HGDP00533 transformed cell line human CVCL_I533 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102474 CVCL_HT33 ND03143 transformed cell line human CVCL_HT33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102475 CVCL_I509 HGDP01333 transformed cell line human CVCL_I509 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102476 CVCL_HT09 ND02591 transformed cell line human CVCL_HT09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102477 CVCL_I505 HGDP01329 transformed cell line human CVCL_I505 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102478 CVCL_HT05 ND02500 transformed cell line human CVCL_HT05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102479 CVCL_I506 HGDP01330 transformed cell line human CVCL_I506 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102480 CVCL_HT06 ND02525 transformed cell line human CVCL_HT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102481 CVCL_I507 HGDP01331 transformed cell line human CVCL_I507 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102482 CVCL_HT07 ND02535 transformed cell line human CVCL_HT07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102483 CVCL_I508 HGDP01332 transformed cell line human CVCL_I508 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102484 CVCL_HT08 ND02573 transformed cell line human CVCL_HT08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102485 CVCL_I501 HGDP01325 transformed cell line human CVCL_I501 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102486 CVCL_HT01 ND02450 transformed cell line human CVCL_HT01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102487 CVCL_I502 HGDP01326 transformed cell line human CVCL_I502 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102488 CVCL_HT02 ND02477 transformed cell line human CVCL_HT02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102489 CVCL_I503 HGDP01327 transformed cell line human CVCL_I503 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102490 CVCL_HT03 ND02480 transformed cell line human CVCL_HT03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102491 CVCL_I504 HGDP01328 transformed cell line human CVCL_I504 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102492 CVCL_HT04 ND02496 transformed cell line human CVCL_HT04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102493 CVCL_I500 HGDP01324 transformed cell line human CVCL_I500 CL:0000010 Population: Chinese/Asian ethnic group; Lahu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102494 CVCL_HT00 ND02436 transformed cell line human CVCL_HT00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102495 CVCL_I516 HGDP00516 transformed cell line human CVCL_I516 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102496 CVCL_HT16 ND02765 transformed cell line human CVCL_HT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102497 CVCL_I517 HGDP00517 transformed cell line human CVCL_I517 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102498 CVCL_HT17 ND02767 transformed cell line human CVCL_HT17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102499 CVCL_I518 HGDP00518 transformed cell line human CVCL_I518 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102500 CVCL_HT18 ND02794 transformed cell line human CVCL_HT18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102501 CVCL_I519 HGDP00519 transformed cell line human CVCL_I519 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102502 CVCL_HT19 ND02901 transformed cell line human CVCL_HT19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102503 CVCL_I512 HGDP00512 transformed cell line human CVCL_I512 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102504 CVCL_HT12 ND02704 transformed cell line human CVCL_HT12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102505 CVCL_I513 HGDP00513 transformed cell line human CVCL_I513 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102506 CVCL_HT13 ND02706 transformed cell line human CVCL_HT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102507 CVCL_I514 HGDP00514 transformed cell line human CVCL_I514 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102508 CVCL_HT14 ND02707 transformed cell line human CVCL_HT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102509 CVCL_I515 HGDP00515 transformed cell line human CVCL_I515 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102510 CVCL_HT15 ND02729 transformed cell line human CVCL_HT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102511 CVCL_I510 HGDP01334 transformed cell line human CVCL_I510 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102512 CVCL_HT10 ND02621 transformed cell line human CVCL_HT10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102513 CVCL_I511 HGDP00511 transformed cell line human CVCL_I511 CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102514 CVCL_HT11 ND02703 transformed cell line human CVCL_HT11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102515 CVCL_QN66 BayGenomics ES cell line YTA005 embryonic stem cell house mouse CVCL_QN66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922312; Sf3a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102516 CVCL_QN67 BayGenomics ES cell line YTA007 embryonic stem cell house mouse CVCL_QN67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679923; Ttc37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102517 CVCL_QN68 BayGenomics ES cell line YTA011 embryonic stem cell house mouse CVCL_QN68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353633; Fus Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102518 CVCL_QN69 BayGenomics ES cell line YTA014 embryonic stem cell house mouse CVCL_QN69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102519 CVCL_QN70 BayGenomics ES cell line YTA015 embryonic stem cell house mouse CVCL_QN70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102520 CVCL_QN71 BayGenomics ES cell line YTA017 embryonic stem cell house mouse CVCL_QN71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142347; Zfp568 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102521 CVCL_QN72 BayGenomics ES cell line YTA019 embryonic stem cell house mouse CVCL_QN72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102944; Ube2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102522 CVCL_QN73 BayGenomics ES cell line YTA021 embryonic stem cell house mouse CVCL_QN73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101921; Ap2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102523 CVCL_QN74 BayGenomics ES cell line YTA022 embryonic stem cell house mouse CVCL_QN74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87989; Alas1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102524 CVCL_QN75 BayGenomics ES cell line YTA023 embryonic stem cell house mouse CVCL_QN75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102525 CVCL_QN76 BayGenomics ES cell line YTA024 embryonic stem cell house mouse CVCL_QN76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194921; Ttk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102526 CVCL_QN55 BayGenomics ES cell line YHD438 embryonic stem cell house mouse CVCL_QN55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1350917; Rps3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102527 CVCL_QN56 BayGenomics ES cell line YHD443 embryonic stem cell house mouse CVCL_QN56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346868; Map2k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102528 CVCL_QN57 BayGenomics ES cell line YHD445 embryonic stem cell house mouse CVCL_QN57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855688; Vti1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102529 CVCL_QN58 BayGenomics ES cell line YHD447 embryonic stem cell house mouse CVCL_QN58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2175912; Arid5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102530 CVCL_QN59 BayGenomics ES cell line YHD449 embryonic stem cell house mouse CVCL_QN59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108295; Pxn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102531 CVCL_QN60 BayGenomics ES cell line YHD454 embryonic stem cell house mouse CVCL_QN60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99256; Hdlbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102532 CVCL_QN61 BayGenomics ES cell line YHD457 embryonic stem cell house mouse CVCL_QN61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096875; Wdfy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102533 CVCL_QN62 BayGenomics ES cell line YHD460 embryonic stem cell house mouse CVCL_QN62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102534 CVCL_QN63 BayGenomics ES cell line YTA001 embryonic stem cell house mouse CVCL_QN63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102535 CVCL_QN64 BayGenomics ES cell line YTA002 embryonic stem cell house mouse CVCL_QN64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102536 CVCL_QN65 BayGenomics ES cell line YTA004 embryonic stem cell house mouse CVCL_QN65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102537 CVCL_QN44 BayGenomics ES cell line YHD412 embryonic stem cell house mouse CVCL_QN44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102538 CVCL_QN45 BayGenomics ES cell line YHD416 embryonic stem cell house mouse CVCL_QN45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316708; Ifrd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102539 CVCL_QN46 BayGenomics ES cell line YHD417 embryonic stem cell house mouse CVCL_QN46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354948; Klf13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102540 CVCL_QN47 BayGenomics ES cell line YHD419 embryonic stem cell house mouse CVCL_QN47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443930; Lcor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102541 CVCL_QN48 BayGenomics ES cell line YHD420 embryonic stem cell house mouse CVCL_QN48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180699; Mtmr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102542 CVCL_QN49 BayGenomics ES cell line YHD426 embryonic stem cell house mouse CVCL_QN49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351337; Ddx24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102543 CVCL_QN50 BayGenomics ES cell line YHD429 embryonic stem cell house mouse CVCL_QN50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913459; Inip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102544 CVCL_QN51 BayGenomics ES cell line YHD431 embryonic stem cell house mouse CVCL_QN51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109637; Erf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102545 CVCL_QN52 BayGenomics ES cell line YHD432 embryonic stem cell house mouse CVCL_QN52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109637; Erf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102546 CVCL_QN53 BayGenomics ES cell line YHD434 embryonic stem cell house mouse CVCL_QN53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334448; Aspm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102547 CVCL_QN54 BayGenomics ES cell line YHD437 embryonic stem cell house mouse CVCL_QN54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385297; Tpcn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102548 CVCL_QN33 BayGenomics ES cell line YHD388 embryonic stem cell house mouse CVCL_QN33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102549 CVCL_QN34 BayGenomics ES cell line YHD391 embryonic stem cell house mouse CVCL_QN34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923041; Fbxw8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102550 CVCL_QN35 BayGenomics ES cell line YHD392 embryonic stem cell house mouse CVCL_QN35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780541; Lncenc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102551 CVCL_QN36 BayGenomics ES cell line YHD400 embryonic stem cell house mouse CVCL_QN36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102552 CVCL_QN37 BayGenomics ES cell line YHD401 embryonic stem cell house mouse CVCL_QN37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109443; Gtpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102553 CVCL_QN38 BayGenomics ES cell line YHD402 embryonic stem cell house mouse CVCL_QN38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915120; Enoph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102554 CVCL_QN39 BayGenomics ES cell line YHD405 embryonic stem cell house mouse CVCL_QN39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102555 CVCL_QN40 BayGenomics ES cell line YHD406 embryonic stem cell house mouse CVCL_QN40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102556 CVCL_QN41 BayGenomics ES cell line YHD407 embryonic stem cell house mouse CVCL_QN41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102557 CVCL_QN42 BayGenomics ES cell line YHD409 embryonic stem cell house mouse CVCL_QN42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102558 CVCL_QN43 BayGenomics ES cell line YHD411 embryonic stem cell house mouse CVCL_QN43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921294; Ttf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102559 CVCL_QN22 BayGenomics ES cell line YHD368 embryonic stem cell house mouse CVCL_QN22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97616; Plcg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102560 CVCL_QN23 BayGenomics ES cell line YHD369 embryonic stem cell house mouse CVCL_QN23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923990; Efr3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102561 CVCL_QN24 BayGenomics ES cell line YHD372 embryonic stem cell house mouse CVCL_QN24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915385; Eif3h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102562 CVCL_QN25 BayGenomics ES cell line YHD374 embryonic stem cell house mouse CVCL_QN25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102563 CVCL_QN26 BayGenomics ES cell line YHD375 embryonic stem cell house mouse CVCL_QN26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202400; Supt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102564 CVCL_QN27 BayGenomics ES cell line YHD381 embryonic stem cell house mouse CVCL_QN27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917770; Glipr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102565 CVCL_QN28 BayGenomics ES cell line YHD383 embryonic stem cell house mouse CVCL_QN28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102566 CVCL_QN29 BayGenomics ES cell line YHD384 embryonic stem cell house mouse CVCL_QN29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915345; Ociad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102567 CVCL_I589 HGDP00589 transformed cell line human CVCL_I589 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102568 CVCL_HT89 ND04444 transformed cell line human CVCL_HT89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102569 CVCL_I585 HGDP00585 transformed cell line human CVCL_I585 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102570 CVCL_HT85 ND04369 transformed cell line human CVCL_HT85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102571 CVCL_I586 HGDP00586 transformed cell line human CVCL_I586 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102572 CVCL_HT86 ND04392 transformed cell line human CVCL_HT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102573 CVCL_I587 HGDP00587 transformed cell line human CVCL_I587 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102574 CVCL_HT87 ND04393 transformed cell line human CVCL_HT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102575 CVCL_I588 HGDP00588 transformed cell line human CVCL_I588 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102576 CVCL_HT88 ND04433 transformed cell line human CVCL_HT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102577 CVCL_I581 HGDP00581 transformed cell line human CVCL_I581 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102578 CVCL_HT81 ND04306 transformed cell line human CVCL_HT81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102579 CVCL_I582 HGDP00582 transformed cell line human CVCL_I582 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102580 CVCL_HT82 ND04309 transformed cell line human CVCL_HT82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102581 CVCL_I583 HGDP00583 transformed cell line human CVCL_I583 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102582 CVCL_HT83 ND04367 transformed cell line human CVCL_HT83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102583 CVCL_I584 HGDP00584 transformed cell line human CVCL_I584 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102584 CVCL_HT84 ND04368 transformed cell line human CVCL_HT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102585 CVCL_I580 HGDP00580 transformed cell line human CVCL_I580 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102586 CVCL_HT80 ND04223 transformed cell line human CVCL_HT80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102587 CVCL_QN30 BayGenomics ES cell line YHD385 embryonic stem cell house mouse CVCL_QN30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107745; Dctn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102588 CVCL_QN31 BayGenomics ES cell line YHD386 embryonic stem cell house mouse CVCL_QN31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107745; Dctn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102589 CVCL_QN32 BayGenomics ES cell line YHD387 embryonic stem cell house mouse CVCL_QN32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103198; Cdc25a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102590 CVCL_QN11 BayGenomics ES cell line YHD340 embryonic stem cell house mouse CVCL_QN11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109637; Erf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102591 CVCL_QN12 BayGenomics ES cell line YHD342 embryonic stem cell house mouse CVCL_QN12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135605; Pard6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102592 CVCL_QN13 BayGenomics ES cell line YHD343 embryonic stem cell house mouse CVCL_QN13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445193; Utp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102593 CVCL_QN14 BayGenomics ES cell line YHD344 embryonic stem cell house mouse CVCL_QN14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445193; Utp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102594 CVCL_QN15 BayGenomics ES cell line YHD348 embryonic stem cell house mouse CVCL_QN15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444798; Atad2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102595 CVCL_QN16 BayGenomics ES cell line YHD353 embryonic stem cell house mouse CVCL_QN16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2661061; Dsg4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102596 CVCL_QN17 BayGenomics ES cell line YHD355 embryonic stem cell house mouse CVCL_QN17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104819; Hnrnpa2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102597 CVCL_QN18 BayGenomics ES cell line YHD356 embryonic stem cell house mouse CVCL_QN18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102598 CVCL_QN19 BayGenomics ES cell line YHD360 embryonic stem cell house mouse CVCL_QN19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914318; Dynlrb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102599 CVCL_I596 HGDP01336 transformed cell line human CVCL_I596 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102600 CVCL_HT96 ND04720 transformed cell line human CVCL_HT96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102601 CVCL_I597 HGDP00597 transformed cell line human CVCL_I597 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102602 CVCL_HT97 ND04758 transformed cell line human CVCL_HT97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102603 CVCL_I598 HGDP00598 transformed cell line human CVCL_I598 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102604 CVCL_HT98 ND04767 transformed cell line human CVCL_HT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102605 CVCL_I599 HGDP00599 transformed cell line human CVCL_I599 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102606 CVCL_HT99 ND04785 transformed cell line human CVCL_HT99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102607 CVCL_I592 HGDP00592 transformed cell line human CVCL_I592 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102608 CVCL_HT92 ND04572 transformed cell line human CVCL_HT92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102609 CVCL_I593 HGDP01335 transformed cell line human CVCL_I593 CL:0000010 Population: Chinese/Asian ethnic group; She; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102610 CVCL_HT93 ND04589 transformed cell line human CVCL_HT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102611 CVCL_I594 HGDP00594 transformed cell line human CVCL_I594 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102612 CVCL_HT94 ND04663 transformed cell line human CVCL_HT94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102613 CVCL_I595 HGDP00595 transformed cell line human CVCL_I595 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102614 CVCL_HT95 ND04715 transformed cell line human CVCL_HT95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102615 CVCL_I590 HGDP00590 transformed cell line human CVCL_I590 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102616 CVCL_HT90 ND04492 transformed cell line human CVCL_HT90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102617 CVCL_I591 HGDP00591 transformed cell line human CVCL_I591 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102618 CVCL_HT91 ND04571 transformed cell line human CVCL_HT91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102619 CVCL_QN20 BayGenomics ES cell line YHD361 embryonic stem cell house mouse CVCL_QN20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102620 CVCL_QN21 BayGenomics ES cell line YHD364 embryonic stem cell house mouse CVCL_QN21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135605; Pard6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102621 CVCL_QN00 BayGenomics ES cell line YHD299 embryonic stem cell house mouse CVCL_QN00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917030; Smap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102622 CVCL_QN01 BayGenomics ES cell line YHD303 embryonic stem cell house mouse CVCL_QN01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97890; Rad51 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102623 CVCL_QN02 BayGenomics ES cell line YHD305 embryonic stem cell house mouse CVCL_QN02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102624 CVCL_QN03 BayGenomics ES cell line YHD306 embryonic stem cell house mouse CVCL_QN03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102625 CVCL_QN04 BayGenomics ES cell line YHD307 embryonic stem cell house mouse CVCL_QN04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102626 CVCL_QN05 BayGenomics ES cell line YHD309 embryonic stem cell house mouse CVCL_QN05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102627 CVCL_QN06 BayGenomics ES cell line YHD311 embryonic stem cell house mouse CVCL_QN06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102628 CVCL_QN07 BayGenomics ES cell line YHD313 embryonic stem cell house mouse CVCL_QN07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102629 CVCL_QN08 BayGenomics ES cell line YHD314 embryonic stem cell house mouse CVCL_QN08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96067; Htt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102630 CVCL_QN09 BayGenomics ES cell line YHD319 embryonic stem cell house mouse CVCL_QN09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924378; Crebrf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102631 CVCL_I567 HGDP00567 transformed cell line human CVCL_I567 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102632 CVCL_HT67 ND03819 transformed cell line human CVCL_HT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102633 CVCL_I568 HGDP00568 transformed cell line human CVCL_I568 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102634 CVCL_HT68 ND03849 transformed cell line human CVCL_HT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102635 CVCL_I569 HGDP00569 transformed cell line human CVCL_I569 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102636 CVCL_HT69 ND03915 transformed cell line human CVCL_HT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102637 CVCL_I563 HGDP00563 transformed cell line human CVCL_I563 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102638 CVCL_HT63 ND03809 transformed cell line human CVCL_HT63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102639 CVCL_I564 HGDP00564 transformed cell line human CVCL_I564 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102640 CVCL_HT64 ND03811 transformed cell line human CVCL_HT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102641 CVCL_I565 HGDP00565 transformed cell line human CVCL_I565 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102642 CVCL_HT65 ND03815 transformed cell line human CVCL_HT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102643 CVCL_I566 HGDP00566 transformed cell line human CVCL_I566 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102644 CVCL_HT66 ND03816 transformed cell line human CVCL_HT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102645 CVCL_I560 HGDP00560 transformed cell line human CVCL_I560 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102646 CVCL_HT60 ND03751 transformed cell line human CVCL_HT60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102647 CVCL_I561 HGDP00561 transformed cell line human CVCL_I561 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102648 CVCL_HT61 ND03760 transformed cell line human CVCL_HT61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102649 CVCL_I562 HGDP00562 transformed cell line human CVCL_I562 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102650 CVCL_HT62 ND03800 transformed cell line human CVCL_HT62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102651 CVCL_QN10 BayGenomics ES cell line YHD335 embryonic stem cell house mouse CVCL_QN10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103188; Nfib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102652 CVCL_I578 HGDP00578 transformed cell line human CVCL_I578 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102653 CVCL_HT78 ND04175 transformed cell line human CVCL_HT78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102654 CVCL_I579 HGDP00579 transformed cell line human CVCL_I579 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102655 CVCL_HT79 ND04205 transformed cell line human CVCL_HT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102656 CVCL_I574 HGDP00574 transformed cell line human CVCL_I574 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102657 CVCL_HT74 ND04089 transformed cell line human CVCL_HT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102658 CVCL_I575 HGDP00575 transformed cell line human CVCL_I575 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102659 CVCL_HT75 ND04100 transformed cell line human CVCL_HT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102660 CVCL_I576 HGDP00576 transformed cell line human CVCL_I576 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102661 CVCL_HT76 ND04136 transformed cell line human CVCL_HT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102662 CVCL_I577 HGDP00577 transformed cell line human CVCL_I577 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102663 CVCL_HT77 ND04167 transformed cell line human CVCL_HT77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102664 CVCL_I570 HGDP00570 transformed cell line human CVCL_I570 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102665 CVCL_HT70 ND03963 transformed cell line human CVCL_HT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102666 CVCL_I571 HGDP00571 transformed cell line human CVCL_I571 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102667 CVCL_HT71 ND03966 transformed cell line human CVCL_HT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102668 CVCL_I572 HGDP00572 transformed cell line human CVCL_I572 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102669 CVCL_HT72 ND03996 transformed cell line human CVCL_HT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102670 CVCL_I573 HGDP00573 transformed cell line human CVCL_I573 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102671 CVCL_HT73 ND04034 transformed cell line human CVCL_HT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102672 CVCL_7A18 DA01936 transformed cell line human CVCL_7A18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102673 CVCL_7A19 DA01937 transformed cell line human CVCL_7A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102674 CVCL_7A14 DA01931 transformed cell line human CVCL_7A14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102675 CVCL_7A15 DA01932 transformed cell line human CVCL_7A15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102676 CVCL_7A16 DA01933 transformed cell line human CVCL_7A16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01933; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102677 CVCL_7A17 DA01935 transformed cell line human CVCL_7A17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01935; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102678 CVCL_7A10 DA01927 transformed cell line human CVCL_7A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102679 CVCL_7A11 DA01928 transformed cell line human CVCL_7A11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102680 CVCL_7A12 DA01929 transformed cell line human CVCL_7A12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01929; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102681 CVCL_7A13 DA01930 transformed cell line human CVCL_7A13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102682 CVCL_7A29 DA01949 transformed cell line human CVCL_7A29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102683 CVCL_7A25 DA01944 transformed cell line human CVCL_7A25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102684 CVCL_7A26 DA01945 transformed cell line human CVCL_7A26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01945; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102685 CVCL_7A27 DA01947 transformed cell line human CVCL_7A27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102686 CVCL_7A28 DA01948 transformed cell line human CVCL_7A28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102687 CVCL_7A21 DA01939 transformed cell line human CVCL_7A21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102688 CVCL_7A22 DA01941 transformed cell line human CVCL_7A22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102689 CVCL_7A23 DA01942 transformed cell line human CVCL_7A23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102690 CVCL_7A24 DA01943 transformed cell line human CVCL_7A24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01943; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102691 CVCL_7A20 DA01938 transformed cell line human CVCL_7A20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102692 CVCL_7A07 DA01924 transformed cell line human CVCL_7A07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102693 CVCL_7A08 DA01925 transformed cell line human CVCL_7A08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01925; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102694 CVCL_7A09 DA01926 transformed cell line human CVCL_7A09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01926; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102695 CVCL_7A03 DA01920 transformed cell line human CVCL_7A03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102696 CVCL_7A04 DA01921 transformed cell line human CVCL_7A04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01921; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102697 CVCL_7A05 DA01922 transformed cell line human CVCL_7A05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102698 CVCL_7A06 DA01923 transformed cell line human CVCL_7A06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102699 CVCL_7A00 DA01917 transformed cell line human CVCL_7A00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102700 CVCL_7A01 DA01918 transformed cell line human CVCL_7A01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01918; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102701 CVCL_7A02 DA01919 transformed cell line human CVCL_7A02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102702 CVCL_QM89 BayGenomics ES cell line YHD269 embryonic stem cell house mouse CVCL_QM89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921285; Nol9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102703 CVCL_QM90 BayGenomics ES cell line YHD270 embryonic stem cell house mouse CVCL_QM90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102704 CVCL_QM91 BayGenomics ES cell line YHD273 embryonic stem cell house mouse CVCL_QM91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861776; Rbms2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102705 CVCL_QM92 BayGenomics ES cell line YHD274 embryonic stem cell house mouse CVCL_QM92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919016; Raver1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102706 CVCL_QM93 BayGenomics ES cell line YHD276 embryonic stem cell house mouse CVCL_QM93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890619; Gan Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102707 CVCL_QM94 BayGenomics ES cell line YHD279 embryonic stem cell house mouse CVCL_QM94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918817; Mcm9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102708 CVCL_QM95 BayGenomics ES cell line YHD284 embryonic stem cell house mouse CVCL_QM95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913974; Tab3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102709 CVCL_QM96 BayGenomics ES cell line YHD285 embryonic stem cell house mouse CVCL_QM96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88016; Ampd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102710 CVCL_QM97 BayGenomics ES cell line YHD288 embryonic stem cell house mouse CVCL_QM97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144564; Fam117a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102711 CVCL_QM98 BayGenomics ES cell line YHD289 embryonic stem cell house mouse CVCL_QM98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102712 CVCL_QM99 BayGenomics ES cell line YHD294 embryonic stem cell house mouse CVCL_QM99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102713 CVCL_QM78 BayGenomics ES cell line YHD246 embryonic stem cell house mouse CVCL_QM78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102714 CVCL_QM79 BayGenomics ES cell line YHD247 embryonic stem cell house mouse CVCL_QM79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104537; Brca1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102715 CVCL_QM80 BayGenomics ES cell line YHD248 embryonic stem cell house mouse CVCL_QM80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298227; Mcm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102716 CVCL_QM81 BayGenomics ES cell line YHD250 embryonic stem cell house mouse CVCL_QM81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917890; Dcp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102717 CVCL_QM82 BayGenomics ES cell line YHD252 embryonic stem cell house mouse CVCL_QM82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102718 CVCL_QM83 BayGenomics ES cell line YHD255 embryonic stem cell house mouse CVCL_QM83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925177; Ccdc88a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102719 CVCL_QM84 BayGenomics ES cell line YHD256 embryonic stem cell house mouse CVCL_QM84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349473; Ppp2r5e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102720 CVCL_QM85 BayGenomics ES cell line YHD257 embryonic stem cell house mouse CVCL_QM85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444629; Kctd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102721 CVCL_QM86 BayGenomics ES cell line YHD258 embryonic stem cell house mouse CVCL_QM86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102722 CVCL_QM87 BayGenomics ES cell line YHD259 embryonic stem cell house mouse CVCL_QM87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891704; Hbs1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102723 CVCL_QM88 BayGenomics ES cell line YHD268 embryonic stem cell house mouse CVCL_QM88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102724 CVCL_QM67 BayGenomics ES cell line YHD219 embryonic stem cell house mouse CVCL_QM67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146370; Cggbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102725 CVCL_QM68 BayGenomics ES cell line YHD221 embryonic stem cell house mouse CVCL_QM68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98299; Shmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102726 CVCL_QM69 BayGenomics ES cell line YHD223 embryonic stem cell house mouse CVCL_QM69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102727 CVCL_QM70 BayGenomics ES cell line YHD225 embryonic stem cell house mouse CVCL_QM70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102728 CVCL_QM71 BayGenomics ES cell line YHD226 embryonic stem cell house mouse CVCL_QM71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202301; Itch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102729 CVCL_QM72 BayGenomics ES cell line YHD229 embryonic stem cell house mouse CVCL_QM72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921020; Wdr70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102730 CVCL_QM73 BayGenomics ES cell line YHD232 embryonic stem cell house mouse CVCL_QM73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922004; Dhcr24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102731 CVCL_QM74 BayGenomics ES cell line YHD234 embryonic stem cell house mouse CVCL_QM74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917317; Ermard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102732 CVCL_QM75 BayGenomics ES cell line YHD235 embryonic stem cell house mouse CVCL_QM75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102733 CVCL_QM76 BayGenomics ES cell line YHD237 embryonic stem cell house mouse CVCL_QM76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102734 CVCL_QM77 BayGenomics ES cell line YHD241 embryonic stem cell house mouse CVCL_QM77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913208; Carm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102735 CVCL_QM56 BayGenomics ES cell line YHD191 embryonic stem cell house mouse CVCL_QM56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101772; Snta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102736 CVCL_QM57 BayGenomics ES cell line YHD192 embryonic stem cell house mouse CVCL_QM57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913617; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102737 CVCL_QM58 BayGenomics ES cell line YHD195 embryonic stem cell house mouse CVCL_QM58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926153; Wrnip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102738 CVCL_QM59 BayGenomics ES cell line YHD196 embryonic stem cell house mouse CVCL_QM59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202400; Supt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102739 CVCL_QM60 BayGenomics ES cell line YHD198 embryonic stem cell house mouse CVCL_QM60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346078; Twf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102740 CVCL_QM61 BayGenomics ES cell line YHD208 embryonic stem cell house mouse CVCL_QM61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338864; Stau1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102741 CVCL_QM62 BayGenomics ES cell line YHD210 embryonic stem cell house mouse CVCL_QM62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146468; Urb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102742 CVCL_QM63 BayGenomics ES cell line YHD214 embryonic stem cell house mouse CVCL_QM63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102743 CVCL_QM64 BayGenomics ES cell line YHD215 embryonic stem cell house mouse CVCL_QM64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102744 CVCL_QM65 BayGenomics ES cell line YHD217 embryonic stem cell house mouse CVCL_QM65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104673; Ptpn12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102745 CVCL_QM66 BayGenomics ES cell line YHD218 embryonic stem cell house mouse CVCL_QM66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646907; Gm6563 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21102746 CVCL_7A90 DA02010 transformed cell line human CVCL_7A90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102747 CVCL_7A91 DA02011 transformed cell line human CVCL_7A91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102748 CVCL_7A92 DA02012 transformed cell line human CVCL_7A92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102749 CVCL_7A93 DA02013 transformed cell line human CVCL_7A93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102750 CVCL_7A98 DA02018 transformed cell line human CVCL_7A98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102751 CVCL_7A99 DA02019 transformed cell line human CVCL_7A99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102752 CVCL_7A94 DA02014 transformed cell line human CVCL_7A94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102753 CVCL_7A95 DA02015 transformed cell line human CVCL_7A95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02015; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102754 CVCL_7A96 DA02016 transformed cell line human CVCL_7A96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102755 CVCL_7A97 DA02017 transformed cell line human CVCL_7A97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102756 CVCL_7A70 DA01990 transformed cell line human CVCL_7A70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102757 CVCL_7A71 DA01991 transformed cell line human CVCL_7A71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102758 CVCL_7A76 DA01996 transformed cell line human CVCL_7A76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01996; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102759 CVCL_7A77 DA01997 transformed cell line human CVCL_7A77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01997; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102760 CVCL_7A78 DA01998 transformed cell line human CVCL_7A78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01998; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102761 CVCL_7A79 DA01999 transformed cell line human CVCL_7A79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01999; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102762 CVCL_7A72 DA01992 transformed cell line human CVCL_7A72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102763 CVCL_7A73 DA01993 transformed cell line human CVCL_7A73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102764 CVCL_7A74 DA01994 transformed cell line human CVCL_7A74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01994; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102765 CVCL_7A75 DA01995 transformed cell line human CVCL_7A75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01995; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102766 CVCL_7A80 DA02000 transformed cell line human CVCL_7A80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102767 CVCL_7A81 DA02001 transformed cell line human CVCL_7A81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02001; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102768 CVCL_7A82 DA02002 transformed cell line human CVCL_7A82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102769 CVCL_7A87 DA02007 transformed cell line human CVCL_7A87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102770 CVCL_7A88 DA02008 transformed cell line human CVCL_7A88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102771 CVCL_7A89 DA02009 transformed cell line human CVCL_7A89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102772 CVCL_7A83 DA02003 transformed cell line human CVCL_7A83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102773 CVCL_7A84 DA02004 transformed cell line human CVCL_7A84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102774 CVCL_7A85 DA02005 transformed cell line human CVCL_7A85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102775 CVCL_7A86 DA02006 transformed cell line human CVCL_7A86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102776 CVCL_7A58 DA01978 transformed cell line human CVCL_7A58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102777 CVCL_7A59 DA01979 transformed cell line human CVCL_7A59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102778 CVCL_7A54 DA01974 transformed cell line human CVCL_7A54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102779 CVCL_7A55 DA01975 transformed cell line human CVCL_7A55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102780 CVCL_7A56 DA01976 transformed cell line human CVCL_7A56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102781 CVCL_7A57 DA01977 transformed cell line human CVCL_7A57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102782 CVCL_7A50 DA01970 transformed cell line human CVCL_7A50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102783 CVCL_7A51 DA01971 transformed cell line human CVCL_7A51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102784 CVCL_7A52 DA01972 transformed cell line human CVCL_7A52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102785 CVCL_7A53 DA01973 transformed cell line human CVCL_7A53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102786 CVCL_7A69 DA01989 transformed cell line human CVCL_7A69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102787 CVCL_7A60 DA01980 transformed cell line human CVCL_7A60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102788 CVCL_7A65 DA01985 transformed cell line human CVCL_7A65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102789 CVCL_7A66 DA01986 transformed cell line human CVCL_7A66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01986; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102790 CVCL_7A67 DA01987 transformed cell line human CVCL_7A67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102791 CVCL_7A68 DA01988 transformed cell line human CVCL_7A68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102792 CVCL_7A61 DA01981 transformed cell line human CVCL_7A61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102793 CVCL_7A62 DA01982 transformed cell line human CVCL_7A62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102794 CVCL_7A63 DA01983 transformed cell line human CVCL_7A63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102795 CVCL_7A64 DA01984 transformed cell line human CVCL_7A64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102796 CVCL_7A36 DA01956 transformed cell line human CVCL_7A36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102797 CVCL_7A37 DA01957 transformed cell line human CVCL_7A37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102798 CVCL_7A38 DA01958 transformed cell line human CVCL_7A38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102799 CVCL_7A39 DA01959 transformed cell line human CVCL_7A39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102800 CVCL_7A32 DA01952 transformed cell line human CVCL_7A32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01952; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102801 CVCL_7A33 DA01953 transformed cell line human CVCL_7A33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102802 CVCL_7A34 DA01954 transformed cell line human CVCL_7A34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102803 CVCL_7A35 DA01955 transformed cell line human CVCL_7A35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01955; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102804 CVCL_7A30 DA01950 transformed cell line human CVCL_7A30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102805 CVCL_7A31 DA01951 transformed cell line human CVCL_7A31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102806 CVCL_7A47 DA01967 transformed cell line human CVCL_7A47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102807 CVCL_7A48 DA01968 transformed cell line human CVCL_7A48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102808 CVCL_7A49 DA01969 transformed cell line human CVCL_7A49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102809 CVCL_7A43 DA01963 transformed cell line human CVCL_7A43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102810 CVCL_7A44 DA01964 transformed cell line human CVCL_7A44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102811 CVCL_7A45 DA01965 transformed cell line human CVCL_7A45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102812 CVCL_7A46 DA01966 transformed cell line human CVCL_7A46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102813 CVCL_7A40 DA01960 transformed cell line human CVCL_7A40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102814 CVCL_7A41 DA01961 transformed cell line human CVCL_7A41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01961; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102815 CVCL_7A42 DA01962 transformed cell line human CVCL_7A42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21102816 CVCL_R000 HG03024 transformed cell line human CVCL_R000 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102817 CVCL_R001 HG03025 transformed cell line human CVCL_R001 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102818 CVCL_R002 HG03027 transformed cell line human CVCL_R002 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102819 CVCL_R003 HG03028 transformed cell line human CVCL_R003 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102820 CVCL_R004 HG03033 transformed cell line human CVCL_R004 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102821 CVCL_R005 HG03034 transformed cell line human CVCL_R005 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102822 CVCL_R006 HG03039 transformed cell line human CVCL_R006 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102823 CVCL_R007 HG03040 transformed cell line human CVCL_R007 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102824 CVCL_R008 HG03045 transformed cell line human CVCL_R008 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102825 CVCL_R009 HG03046 transformed cell line human CVCL_R009 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102826 CVCL_I666 HGDP00666 transformed cell line human CVCL_I666 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102827 CVCL_HU66 ND06705 transformed cell line human CVCL_HU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102828 CVCL_I667 HGDP00667 transformed cell line human CVCL_I667 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102829 CVCL_HU67 ND06724 transformed cell line human CVCL_HU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102830 CVCL_I668 HGDP00668 transformed cell line human CVCL_I668 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102831 CVCL_HU68 ND06782 transformed cell line human CVCL_HU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102832 CVCL_I669 HGDP00669 transformed cell line human CVCL_I669 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102833 CVCL_HU69 ND06784 transformed cell line human CVCL_HU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102834 CVCL_I662 HGDP00662 transformed cell line human CVCL_I662 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102835 CVCL_HU62 ND06620 transformed cell line human CVCL_HU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102836 CVCL_I663 HGDP00663 transformed cell line human CVCL_I663 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102837 CVCL_HU63 ND06622 transformed cell line human CVCL_HU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102838 CVCL_I664 HGDP00664 transformed cell line human CVCL_I664 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102839 CVCL_HU64 ND06681 transformed cell line human CVCL_HU64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102840 CVCL_I665 HGDP00665 transformed cell line human CVCL_I665 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102841 CVCL_HU65 ND06700 transformed cell line human CVCL_HU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102842 CVCL_I660 HGDP00660 transformed cell line human CVCL_I660 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102843 CVCL_HU60 ND06554 transformed cell line human CVCL_HU60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102844 CVCL_I661 HGDP00661 transformed cell line human CVCL_I661 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102845 CVCL_HU61 ND04778 transformed cell line human CVCL_HU61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102846 CVCL_I677 HGDP00677 transformed cell line human CVCL_I677 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102847 CVCL_HU77 ND07060 transformed cell line human CVCL_HU77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102848 CVCL_I678 HGDP00678 transformed cell line human CVCL_I678 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102849 CVCL_HU78 ND07063 transformed cell line human CVCL_HU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102850 CVCL_I679 HGDP00679 transformed cell line human CVCL_I679 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102851 CVCL_HU79 ND07085 transformed cell line human CVCL_HU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102852 CVCL_I673 HGDP00673 transformed cell line human CVCL_I673 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102853 CVCL_HU73 ND06986 transformed cell line human CVCL_HU73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102854 CVCL_I674 HGDP00674 transformed cell line human CVCL_I674 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102855 CVCL_HU74 ND07010 transformed cell line human CVCL_HU74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102856 CVCL_I675 HGDP00675 transformed cell line human CVCL_I675 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102857 CVCL_HU75 ND07024 transformed cell line human CVCL_HU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102858 CVCL_I676 HGDP00676 transformed cell line human CVCL_I676 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102859 CVCL_HU76 ND07026 transformed cell line human CVCL_HU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102860 CVCL_I670 HGDP00670 transformed cell line human CVCL_I670 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102861 CVCL_HU70 ND04779 transformed cell line human CVCL_HU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102862 CVCL_I671 HGDP00671 transformed cell line human CVCL_I671 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102863 CVCL_HU71 ND06907 transformed cell line human CVCL_HU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102864 CVCL_I672 HGDP00672 transformed cell line human CVCL_I672 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102865 CVCL_HU72 ND06936 transformed cell line human CVCL_HU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102866 CVCL_I648 HGDP00648 transformed cell line human CVCL_I648 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102867 CVCL_HU48 ND06220 transformed cell line human CVCL_HU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102868 CVCL_I649 HGDP00649 transformed cell line human CVCL_I649 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102869 CVCL_HU49 ND06288 transformed cell line human CVCL_HU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102870 CVCL_I644 HGDP00644 transformed cell line human CVCL_I644 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102871 CVCL_HU44 ND06136 transformed cell line human CVCL_HU44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102872 CVCL_I645 HGDP00645 transformed cell line human CVCL_I645 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102873 CVCL_HU45 ND06157 transformed cell line human CVCL_HU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102874 CVCL_I646 HGDP00646 transformed cell line human CVCL_I646 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102875 CVCL_HU46 ND06160 transformed cell line human CVCL_HU46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102876 CVCL_I647 HGDP00647 transformed cell line human CVCL_I647 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102877 CVCL_HU47 ND06209 transformed cell line human CVCL_HU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102878 CVCL_I640 HGDP00640 transformed cell line human CVCL_I640 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102879 CVCL_HU40 ND05835 transformed cell line human CVCL_HU40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102880 CVCL_I641 HGDP00641 transformed cell line human CVCL_I641 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102881 CVCL_HU41 ND05984 transformed cell line human CVCL_HU41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102882 CVCL_I642 HGDP00642 transformed cell line human CVCL_I642 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102883 CVCL_HU42 ND06046 transformed cell line human CVCL_HU42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102884 CVCL_I643 HGDP00643 transformed cell line human CVCL_I643 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102885 CVCL_HU43 ND06100 transformed cell line human CVCL_HU43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102886 CVCL_I659 HGDP00659 transformed cell line human CVCL_I659 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102887 CVCL_HU59 ND06546 transformed cell line human CVCL_HU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102888 CVCL_I655 HGDP00655 transformed cell line human CVCL_I655 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102889 CVCL_HU55 ND06470 transformed cell line human CVCL_HU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102890 CVCL_I656 HGDP00656 transformed cell line human CVCL_I656 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102891 CVCL_HU56 ND06471 transformed cell line human CVCL_HU56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102892 CVCL_I657 HGDP00657 transformed cell line human CVCL_I657 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102893 CVCL_HU57 ND06472 transformed cell line human CVCL_HU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102894 CVCL_I658 HGDP00658 transformed cell line human CVCL_I658 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102895 CVCL_HU58 ND06523 transformed cell line human CVCL_HU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102896 CVCL_I651 HGDP00651 transformed cell line human CVCL_I651 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102897 CVCL_HU51 ND06290 transformed cell line human CVCL_HU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102898 CVCL_I652 HGDP00652 transformed cell line human CVCL_I652 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102899 CVCL_HU52 ND06341 transformed cell line human CVCL_HU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102900 CVCL_I653 HGDP00653 transformed cell line human CVCL_I653 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102901 CVCL_HU53 ND06389 transformed cell line human CVCL_HU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102902 CVCL_I654 HGDP00654 transformed cell line human CVCL_I654 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102903 CVCL_HU54 ND06427 transformed cell line human CVCL_HU54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102904 CVCL_I650 HGDP00650 transformed cell line human CVCL_I650 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102905 CVCL_HU50 ND06289 transformed cell line human CVCL_HU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102906 CVCL_I626 HGDP00626 transformed cell line human CVCL_I626 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102907 CVCL_HU26 ND05548 transformed cell line human CVCL_HU26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102908 CVCL_I627 HGDP00627 transformed cell line human CVCL_I627 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102909 CVCL_HU27 ND05550 transformed cell line human CVCL_HU27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102910 CVCL_I628 HGDP00628 transformed cell line human CVCL_I628 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Virology: Contains a chromosomally integrated human herpesvirus 6A (CI-HHV-6A) Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102911 CVCL_HU28 ND05554 transformed cell line human CVCL_HU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102912 CVCL_I629 HGDP00629 transformed cell line human CVCL_I629 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102913 CVCL_HU29 ND05567 transformed cell line human CVCL_HU29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102914 CVCL_I622 HGDP00622 transformed cell line human CVCL_I622 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102915 CVCL_HU22 ND05466 transformed cell line human CVCL_HU22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102916 CVCL_I623 HGDP00623 transformed cell line human CVCL_I623 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102917 CVCL_HU23 ND05511 transformed cell line human CVCL_HU23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102918 CVCL_I624 HGDP00624 transformed cell line human CVCL_I624 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102919 CVCL_HU24 ND05515 transformed cell line human CVCL_HU24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102920 CVCL_I625 HGDP00625 transformed cell line human CVCL_I625 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102921 CVCL_HU25 ND05517 transformed cell line human CVCL_HU25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102922 CVCL_I620 HGDP00620 transformed cell line human CVCL_I620 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102923 CVCL_HU20 ND05319 transformed cell line human CVCL_HU20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102924 CVCL_I621 HGDP00621 transformed cell line human CVCL_I621 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102925 CVCL_HU21 ND05432 transformed cell line human CVCL_HU21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102926 CVCL_I637 HGDP00637 transformed cell line human CVCL_I637 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102927 CVCL_HU37 ND05826 transformed cell line human CVCL_HU37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102928 CVCL_I638 HGDP00638 transformed cell line human CVCL_I638 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102929 CVCL_HU38 ND05827 transformed cell line human CVCL_HU38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102930 CVCL_I639 HGDP00639 transformed cell line human CVCL_I639 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102931 CVCL_HU39 ND05833 transformed cell line human CVCL_HU39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102932 CVCL_I633 HGDP00633 transformed cell line human CVCL_I633 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102933 CVCL_HU33 ND05708 transformed cell line human CVCL_HU33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102934 CVCL_I634 HGDP00634 transformed cell line human CVCL_I634 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102935 CVCL_HU34 ND05751 transformed cell line human CVCL_HU34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102936 CVCL_I635 HGDP00635 transformed cell line human CVCL_I635 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102937 CVCL_HU35 ND05798 transformed cell line human CVCL_HU35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102938 CVCL_I636 HGDP00636 transformed cell line human CVCL_I636 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102939 CVCL_HU36 ND05801 transformed cell line human CVCL_HU36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102940 CVCL_I630 HGDP00630 transformed cell line human CVCL_I630 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102941 CVCL_HU30 ND05611 transformed cell line human CVCL_HU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102942 CVCL_I631 HGDP00631 transformed cell line human CVCL_I631 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102943 CVCL_HU31 ND05612 transformed cell line human CVCL_HU31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102944 CVCL_I632 HGDP00632 transformed cell line human CVCL_I632 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102945 CVCL_HU32 ND05629 transformed cell line human CVCL_HU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102946 CVCL_I608 HGDP00608 transformed cell line human CVCL_I608 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102947 CVCL_HU08 ND05059 transformed cell line human CVCL_HU08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102948 CVCL_I609 HGDP00609 transformed cell line human CVCL_I609 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102949 CVCL_HU09 ND05090 transformed cell line human CVCL_HU09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102950 CVCL_I604 HGDP00604 transformed cell line human CVCL_I604 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102951 CVCL_HU04 ND04952 transformed cell line human CVCL_HU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102952 CVCL_I605 HGDP00605 transformed cell line human CVCL_I605 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102953 CVCL_HU05 ND05005 transformed cell line human CVCL_HU05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102954 CVCL_I606 HGDP00606 transformed cell line human CVCL_I606 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102955 CVCL_HU06 ND05006 transformed cell line human CVCL_HU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102956 CVCL_I607 HGDP00607 transformed cell line human CVCL_I607 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102957 CVCL_HU07 ND05043 transformed cell line human CVCL_HU07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102958 CVCL_I600 HGDP00600 transformed cell line human CVCL_I600 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102959 CVCL_HU00 ND04836 transformed cell line human CVCL_HU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102960 CVCL_I601 HGDP00601 transformed cell line human CVCL_I601 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102961 CVCL_HU01 ND04863 transformed cell line human CVCL_HU01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102962 CVCL_I602 HGDP00602 transformed cell line human CVCL_I602 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102963 CVCL_HU02 ND04890 transformed cell line human CVCL_HU02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102964 CVCL_I603 HGDP00603 transformed cell line human CVCL_I603 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102965 CVCL_HU03 ND04941 transformed cell line human CVCL_HU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102966 CVCL_I619 HGDP00619 transformed cell line human CVCL_I619 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102967 CVCL_HU19 ND05318 transformed cell line human CVCL_HU19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102968 CVCL_I615 HGDP00615 transformed cell line human CVCL_I615 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102969 CVCL_HU15 ND05249 transformed cell line human CVCL_HU15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102970 CVCL_I616 HGDP00616 transformed cell line human CVCL_I616 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102971 CVCL_HU16 ND05265 transformed cell line human CVCL_HU16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102972 CVCL_I617 HGDP00617 transformed cell line human CVCL_I617 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102973 CVCL_HU17 ND05276 transformed cell line human CVCL_HU17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102974 CVCL_I618 HGDP00618 transformed cell line human CVCL_I618 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102975 CVCL_HU18 ND05291 transformed cell line human CVCL_HU18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102976 CVCL_I611 HGDP00611 transformed cell line human CVCL_I611 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102977 CVCL_HU11 ND05134 transformed cell line human CVCL_HU11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102978 CVCL_I612 HGDP00612 transformed cell line human CVCL_I612 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102979 CVCL_HU12 ND05153 transformed cell line human CVCL_HU12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102980 CVCL_I613 HGDP00613 transformed cell line human CVCL_I613 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102981 CVCL_HU13 ND05203 transformed cell line human CVCL_HU13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102982 CVCL_I614 HGDP00614 transformed cell line human CVCL_I614 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102983 CVCL_HU14 ND05204 transformed cell line human CVCL_HU14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21102984 CVCL_I610 HGDP00610 transformed cell line human CVCL_I610 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21102985 CVCL_HU10 ND05104 transformed cell line human CVCL_HU10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21102986 CVCL_R087 HG03212 transformed cell line human CVCL_R087 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102987 CVCL_R088 HG03224 transformed cell line human CVCL_R088 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102988 CVCL_R089 HG03225 transformed cell line human CVCL_R089 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102989 CVCL_R090 HG03228 transformed cell line human CVCL_R090 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102990 CVCL_R091 HG03229 transformed cell line human CVCL_R091 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102991 CVCL_R092 HG03234 transformed cell line human CVCL_R092 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102992 CVCL_R093 HG03235 transformed cell line human CVCL_R093 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102993 CVCL_R094 HG03237 transformed cell line human CVCL_R094 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102994 CVCL_R095 HG03238 transformed cell line human CVCL_R095 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102995 CVCL_R096 HG03240 transformed cell line human CVCL_R096 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102996 CVCL_R097 HG03241 transformed cell line human CVCL_R097 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102997 CVCL_R076 HG03172 transformed cell line human CVCL_R076 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102998 CVCL_R077 HG03175 transformed cell line human CVCL_R077 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21102999 CVCL_R078 HG03189 transformed cell line human CVCL_R078 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103000 CVCL_R079 HG03190 transformed cell line human CVCL_R079 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103001 CVCL_R080 HG03193 transformed cell line human CVCL_R080 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103002 CVCL_R081 HG03195 transformed cell line human CVCL_R081 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103003 CVCL_R082 HG03196 transformed cell line human CVCL_R082 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103004 CVCL_R083 HG03198 transformed cell line human CVCL_R083 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103005 CVCL_R084 HG03199 transformed cell line human CVCL_R084 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103006 CVCL_R085 HG03202 transformed cell line human CVCL_R085 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103007 CVCL_R086 HG03209 transformed cell line human CVCL_R086 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103008 CVCL_R065 HG03136 transformed cell line human CVCL_R065 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103009 CVCL_R066 HG03139 transformed cell line human CVCL_R066 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103010 CVCL_R067 HG03157 transformed cell line human CVCL_R067 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103011 CVCL_R068 HG03159 transformed cell line human CVCL_R068 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103012 CVCL_R069 HG03160 transformed cell line human CVCL_R069 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103013 CVCL_R070 HG03162 transformed cell line human CVCL_R070 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103014 CVCL_R071 HG03163 transformed cell line human CVCL_R071 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103015 CVCL_R072 HG03166 transformed cell line human CVCL_R072 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103016 CVCL_R073 HG03168 transformed cell line human CVCL_R073 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103017 CVCL_R074 HG03169 transformed cell line human CVCL_R074 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103018 CVCL_R075 HG03171 transformed cell line human CVCL_R075 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103019 CVCL_R054 HG03120 transformed cell line human CVCL_R054 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103020 CVCL_R055 HG03121 transformed cell line human CVCL_R055 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103021 CVCL_R056 HG03123 transformed cell line human CVCL_R056 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103022 CVCL_R057 HG03124 transformed cell line human CVCL_R057 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103023 CVCL_R058 HG03126 transformed cell line human CVCL_R058 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103024 CVCL_R059 HG03127 transformed cell line human CVCL_R059 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103025 CVCL_R060 HG03129 transformed cell line human CVCL_R060 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103026 CVCL_R061 HG03130 transformed cell line human CVCL_R061 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103027 CVCL_R062 HG03132 transformed cell line human CVCL_R062 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103028 CVCL_R063 HG03133 transformed cell line human CVCL_R063 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103029 CVCL_R064 HG03135 transformed cell line human CVCL_R064 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103030 CVCL_R043 HG03100 transformed cell line human CVCL_R043 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103031 CVCL_R044 HG03103 transformed cell line human CVCL_R044 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103032 CVCL_R045 HG03105 transformed cell line human CVCL_R045 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103033 CVCL_R046 HG03108 transformed cell line human CVCL_R046 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103034 CVCL_R047 HG03109 transformed cell line human CVCL_R047 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103035 CVCL_R048 HG03111 transformed cell line human CVCL_R048 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103036 CVCL_R049 HG03112 transformed cell line human CVCL_R049 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103037 CVCL_R050 HG03114 transformed cell line human CVCL_R050 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103038 CVCL_R051 HG03115 transformed cell line human CVCL_R051 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103039 CVCL_R052 HG03117 transformed cell line human CVCL_R052 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103040 CVCL_R053 HG03118 transformed cell line human CVCL_R053 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103041 CVCL_R032 HG03081 transformed cell line human CVCL_R032 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103042 CVCL_R033 HG03082 transformed cell line human CVCL_R033 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103043 CVCL_R034 HG03084 transformed cell line human CVCL_R034 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103044 CVCL_R035 HG03085 transformed cell line human CVCL_R035 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103045 CVCL_R036 HG03086 transformed cell line human CVCL_R036 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103046 CVCL_R037 HG03088 transformed cell line human CVCL_R037 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103047 CVCL_R038 HG03091 transformed cell line human CVCL_R038 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103048 CVCL_R039 HG03095 transformed cell line human CVCL_R039 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103049 CVCL_R040 HG03096 transformed cell line human CVCL_R040 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103050 CVCL_R041 HG03097 transformed cell line human CVCL_R041 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103051 CVCL_R042 HG03099 transformed cell line human CVCL_R042 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103052 CVCL_R021 HG03063 transformed cell line human CVCL_R021 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103053 CVCL_R022 HG03064 transformed cell line human CVCL_R022 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103054 CVCL_R023 HG03066 transformed cell line human CVCL_R023 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103055 CVCL_R024 HG03069 transformed cell line human CVCL_R024 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103056 CVCL_R025 HG03072 transformed cell line human CVCL_R025 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103057 CVCL_R026 HG03073 transformed cell line human CVCL_R026 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103058 CVCL_R027 HG03074 transformed cell line human CVCL_R027 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103059 CVCL_R028 HG03076 transformed cell line human CVCL_R028 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103060 CVCL_R029 HG03077 transformed cell line human CVCL_R029 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103061 CVCL_I688 HGDP00688 transformed cell line human CVCL_I688 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103062 CVCL_HU88 ND07499 transformed cell line human CVCL_HU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103063 CVCL_I689 HGDP00689 transformed cell line human CVCL_I689 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103064 CVCL_HU89 ND07500 transformed cell line human CVCL_HU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103065 CVCL_I684 HGDP00684 transformed cell line human CVCL_I684 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103066 CVCL_HU84 ND07265 transformed cell line human CVCL_HU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103067 CVCL_I685 HGDP00685 transformed cell line human CVCL_I685 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103068 CVCL_HU85 ND07416 transformed cell line human CVCL_HU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103069 CVCL_I686 HGDP00686 transformed cell line human CVCL_I686 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103070 CVCL_HU86 ND07417 transformed cell line human CVCL_HU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103071 CVCL_I687 HGDP00687 transformed cell line human CVCL_I687 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103072 CVCL_HU87 ND07470 transformed cell line human CVCL_HU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103073 CVCL_I680 HGDP00680 transformed cell line human CVCL_I680 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103074 CVCL_HU80 ND07098 transformed cell line human CVCL_HU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103075 CVCL_I681 HGDP00681 transformed cell line human CVCL_I681 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103076 CVCL_HU81 ND07125 transformed cell line human CVCL_HU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103077 CVCL_I682 HGDP00682 transformed cell line human CVCL_I682 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103078 CVCL_HU82 ND07126 transformed cell line human CVCL_HU82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103079 CVCL_I683 HGDP00683 transformed cell line human CVCL_I683 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103080 CVCL_HU83 ND07166 transformed cell line human CVCL_HU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103081 CVCL_R030 HG03078 transformed cell line human CVCL_R030 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103082 CVCL_R031 HG03079 transformed cell line human CVCL_R031 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103083 CVCL_R010 HG03048 transformed cell line human CVCL_R010 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103084 CVCL_R011 HG03049 transformed cell line human CVCL_R011 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103085 CVCL_R012 HG03052 transformed cell line human CVCL_R012 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103086 CVCL_R013 HG03054 transformed cell line human CVCL_R013 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103087 CVCL_R014 HG03055 transformed cell line human CVCL_R014 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103088 CVCL_R015 HG03057 transformed cell line human CVCL_R015 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103089 CVCL_R016 HG00189 transformed cell line human CVCL_R016 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103090 CVCL_R017 HG01508 transformed cell line human CVCL_R017 CL:0000010 Population: Caucasian; Iberian populations in Spain (IBS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103091 CVCL_R018 HG03058 transformed cell line human CVCL_R018 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103092 CVCL_R019 HG03060 transformed cell line human CVCL_R019 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103093 CVCL_I699 HGDP00699 transformed cell line human CVCL_I699 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103094 CVCL_HU99 ND07717 transformed cell line human CVCL_HU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103095 CVCL_I695 HGDP00695 transformed cell line human CVCL_I695 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103096 CVCL_HU95 ND07643 transformed cell line human CVCL_HU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103097 CVCL_I696 HGDP00696 transformed cell line human CVCL_I696 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103098 CVCL_HU96 ND07708 transformed cell line human CVCL_HU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103099 CVCL_I697 HGDP00697 transformed cell line human CVCL_I697 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103100 CVCL_HU97 ND07714 transformed cell line human CVCL_HU97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103101 CVCL_I698 HGDP00698 transformed cell line human CVCL_I698 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103102 CVCL_HU98 ND07716 transformed cell line human CVCL_HU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103103 CVCL_I691 HGDP00691 transformed cell line human CVCL_I691 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103104 CVCL_HU91 ND07532 transformed cell line human CVCL_HU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103105 CVCL_I692 HGDP00692 transformed cell line human CVCL_I692 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103106 CVCL_HU92 ND07533 transformed cell line human CVCL_HU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103107 CVCL_I693 HGDP00693 transformed cell line human CVCL_I693 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103108 CVCL_HU93 ND07586 transformed cell line human CVCL_HU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103109 CVCL_I694 HGDP00694 transformed cell line human CVCL_I694 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103110 CVCL_HU94 ND07610 transformed cell line human CVCL_HU94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103111 CVCL_I690 HGDP00690 transformed cell line human CVCL_I690 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103112 CVCL_HU90 ND07505 transformed cell line human CVCL_HU90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103113 CVCL_R020 HG03061 transformed cell line human CVCL_R020 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103114 CVCL_7B39 DA02064 transformed cell line human CVCL_7B39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02064; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103115 CVCL_7B35 DA02060 transformed cell line human CVCL_7B35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103116 CVCL_7B36 DA02061 transformed cell line human CVCL_7B36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103117 CVCL_7B37 DA02062 transformed cell line human CVCL_7B37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103118 CVCL_7B38 DA02063 transformed cell line human CVCL_7B38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103119 CVCL_7B31 DA02054 transformed cell line human CVCL_7B31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103120 CVCL_7B32 DA02056 transformed cell line human CVCL_7B32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02056; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103121 CVCL_7B33 DA02058 transformed cell line human CVCL_7B33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103122 CVCL_7B34 DA02059 transformed cell line human CVCL_7B34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02059; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103123 CVCL_7B30 DA02053 transformed cell line human CVCL_7B30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103124 CVCL_7B46 DA02072 transformed cell line human CVCL_7B46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103125 CVCL_7B47 DA02073 transformed cell line human CVCL_7B47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103126 CVCL_7B48 DA02074 transformed cell line human CVCL_7B48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103127 CVCL_7B49 DA02076 transformed cell line human CVCL_7B49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103128 CVCL_7B42 DA02067 transformed cell line human CVCL_7B42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103129 CVCL_7B43 DA02068 transformed cell line human CVCL_7B43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103130 CVCL_7B44 DA02069 transformed cell line human CVCL_7B44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103131 CVCL_7B45 DA02070 transformed cell line human CVCL_7B45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103132 CVCL_7B40 DA02065 transformed cell line human CVCL_7B40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02065; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103133 CVCL_7B41 DA02066 transformed cell line human CVCL_7B41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02066; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103134 CVCL_7B17 DA02039 transformed cell line human CVCL_7B17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02039; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103135 CVCL_7B18 DA02040 transformed cell line human CVCL_7B18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103136 CVCL_7B19 DA02041 transformed cell line human CVCL_7B19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103137 CVCL_7B13 DA02035 transformed cell line human CVCL_7B13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103138 CVCL_7B14 DA02036 transformed cell line human CVCL_7B14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103139 CVCL_7B15 DA02037 transformed cell line human CVCL_7B15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02037; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103140 CVCL_7B16 DA02038 transformed cell line human CVCL_7B16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02038; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103141 CVCL_7B10 DA02030 transformed cell line human CVCL_7B10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103142 CVCL_7B11 DA02033 transformed cell line human CVCL_7B11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02033; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103143 CVCL_7B12 DA02034 transformed cell line human CVCL_7B12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103144 CVCL_7B28 DA02051 transformed cell line human CVCL_7B28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103145 CVCL_7B29 DA02052 transformed cell line human CVCL_7B29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103146 CVCL_7B24 DA02046 transformed cell line human CVCL_7B24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02046; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103147 CVCL_7B25 DA02048 transformed cell line human CVCL_7B25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103148 CVCL_7B26 DA02049 transformed cell line human CVCL_7B26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103149 CVCL_7B27 DA02050 transformed cell line human CVCL_7B27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103150 CVCL_7B20 DA02042 transformed cell line human CVCL_7B20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103151 CVCL_7B21 DA02043 transformed cell line human CVCL_7B21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103152 CVCL_7B22 DA02044 transformed cell line human CVCL_7B22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103153 CVCL_7B23 DA02045 transformed cell line human CVCL_7B23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103154 CVCL_QN99 BayGenomics ES cell line YTA056 embryonic stem cell house mouse CVCL_QN99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145219; Iars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103155 CVCL_7B06 DA02026 transformed cell line human CVCL_7B06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103156 CVCL_7B07 DA02027 transformed cell line human CVCL_7B07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103157 CVCL_7B08 DA02028 transformed cell line human CVCL_7B08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103158 CVCL_7B09 DA02029 transformed cell line human CVCL_7B09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02029; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103159 CVCL_7B02 DA02022 transformed cell line human CVCL_7B02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02022; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103160 CVCL_7B03 DA02023 transformed cell line human CVCL_7B03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103161 CVCL_7B04 DA02024 transformed cell line human CVCL_7B04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02024; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103162 CVCL_7B05 DA02025 transformed cell line human CVCL_7B05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02025; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103163 CVCL_7B00 DA02020 transformed cell line human CVCL_7B00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02020; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103164 CVCL_7B01 DA02021 transformed cell line human CVCL_7B01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103165 CVCL_QN88 BayGenomics ES cell line YTA041 embryonic stem cell house mouse CVCL_QN88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929492; Atl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103166 CVCL_QN89 BayGenomics ES cell line YTA042 embryonic stem cell house mouse CVCL_QN89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104560; Nsf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103167 CVCL_QN90 BayGenomics ES cell line YTA043 embryonic stem cell house mouse CVCL_QN90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929286; Amotl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103168 CVCL_QN91 BayGenomics ES cell line YTA044 embryonic stem cell house mouse CVCL_QN91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103169 CVCL_QN92 BayGenomics ES cell line YTA046 embryonic stem cell house mouse CVCL_QN92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915149; Cmc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103170 CVCL_QN93 BayGenomics ES cell line YTA048 embryonic stem cell house mouse CVCL_QN93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103171 CVCL_QN94 BayGenomics ES cell line YTA049 embryonic stem cell house mouse CVCL_QN94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682334; Smg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103172 CVCL_QN95 BayGenomics ES cell line YTA050 embryonic stem cell house mouse CVCL_QN95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103173 CVCL_QN96 BayGenomics ES cell line YTA052 embryonic stem cell house mouse CVCL_QN96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103174 CVCL_QN97 BayGenomics ES cell line YTA054 embryonic stem cell house mouse CVCL_QN97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103175 CVCL_QN98 BayGenomics ES cell line YTA055 embryonic stem cell house mouse CVCL_QN98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919787; Cdca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103176 CVCL_QN77 BayGenomics ES cell line YTA025 embryonic stem cell house mouse CVCL_QN77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103177 CVCL_QN78 BayGenomics ES cell line YTA028 embryonic stem cell house mouse CVCL_QN78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923802; Plekha5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103178 CVCL_QN79 BayGenomics ES cell line YTA029 embryonic stem cell house mouse CVCL_QN79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914404; Mtdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103179 CVCL_QN80 BayGenomics ES cell line YTA030 embryonic stem cell house mouse CVCL_QN80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916065; Btbd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103180 CVCL_QN81 BayGenomics ES cell line YTA031 embryonic stem cell house mouse CVCL_QN81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103181 CVCL_QN82 BayGenomics ES cell line YTA034 embryonic stem cell house mouse CVCL_QN82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103182 CVCL_QN83 BayGenomics ES cell line YTA035 embryonic stem cell house mouse CVCL_QN83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926163; Ltn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103183 CVCL_QN84 BayGenomics ES cell line YTA036 embryonic stem cell house mouse CVCL_QN84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103184 CVCL_QN85 BayGenomics ES cell line YTA037 embryonic stem cell house mouse CVCL_QN85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103185 CVCL_QN86 BayGenomics ES cell line YTA038 embryonic stem cell house mouse CVCL_QN86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441772; Eif5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103186 CVCL_QN87 BayGenomics ES cell line YTA039 embryonic stem cell house mouse CVCL_QN87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103187 CVCL_7B90 DA02127 transformed cell line human CVCL_7B90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103188 CVCL_7B91 DA02128 transformed cell line human CVCL_7B91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103189 CVCL_7B92 DA02130 transformed cell line human CVCL_7B92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103190 CVCL_7B97 DA02138 transformed cell line human CVCL_7B97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02138; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103191 CVCL_7B98 DA02139 transformed cell line human CVCL_7B98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02139; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103192 CVCL_7B99 DA02140 transformed cell line human CVCL_7B99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02140; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103193 CVCL_7B93 DA02131 transformed cell line human CVCL_7B93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103194 CVCL_7B94 DA02132 transformed cell line human CVCL_7B94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103195 CVCL_7B95 DA02133 transformed cell line human CVCL_7B95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103196 CVCL_7B96 DA02135 transformed cell line human CVCL_7B96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103197 CVCL_7B79 DA02112 transformed cell line human CVCL_7B79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103198 CVCL_7B70 DA02102 transformed cell line human CVCL_7B70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103199 CVCL_7B75 DA02107 transformed cell line human CVCL_7B75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103200 CVCL_7B76 DA02108 transformed cell line human CVCL_7B76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103201 CVCL_7B77 DA02110 transformed cell line human CVCL_7B77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103202 CVCL_7B78 DA02111 transformed cell line human CVCL_7B78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103203 CVCL_7B71 DA02103 transformed cell line human CVCL_7B71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02103; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103204 CVCL_7B72 DA02104 transformed cell line human CVCL_7B72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103205 CVCL_7B73 DA02105 transformed cell line human CVCL_7B73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103206 CVCL_7B74 DA02106 transformed cell line human CVCL_7B74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103207 CVCL_7B80 DA02113 transformed cell line human CVCL_7B80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02113; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103208 CVCL_7B81 DA02114 transformed cell line human CVCL_7B81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103209 CVCL_7B86 DA02119 transformed cell line human CVCL_7B86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103210 CVCL_7B87 DA02120 transformed cell line human CVCL_7B87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103211 CVCL_7B88 DA02121 transformed cell line human CVCL_7B88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02121; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103212 CVCL_7B89 DA02125 transformed cell line human CVCL_7B89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103213 CVCL_7B82 DA02115 transformed cell line human CVCL_7B82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02115; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103214 CVCL_7B83 DA02116 transformed cell line human CVCL_7B83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02116; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103215 CVCL_7B84 DA02117 transformed cell line human CVCL_7B84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103216 CVCL_7B85 DA02118 transformed cell line human CVCL_7B85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02118; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103217 CVCL_7B57 DA02084 transformed cell line human CVCL_7B57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103218 CVCL_7B58 DA02086 transformed cell line human CVCL_7B58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02086; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103219 CVCL_7B59 DA02089 transformed cell line human CVCL_7B59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103220 CVCL_7B53 DA02080 transformed cell line human CVCL_7B53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103221 CVCL_7B54 DA02081 transformed cell line human CVCL_7B54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103222 CVCL_7B55 DA02082 transformed cell line human CVCL_7B55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103223 CVCL_7B56 DA02083 transformed cell line human CVCL_7B56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103224 CVCL_7B50 DA02077 transformed cell line human CVCL_7B50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103225 CVCL_7B51 DA02078 transformed cell line human CVCL_7B51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103226 CVCL_7B52 DA02079 transformed cell line human CVCL_7B52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103227 CVCL_7B68 DA02098 transformed cell line human CVCL_7B68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103228 CVCL_7B69 DA02101 transformed cell line human CVCL_7B69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103229 CVCL_7B64 DA02094 transformed cell line human CVCL_7B64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103230 CVCL_7B65 DA02095 transformed cell line human CVCL_7B65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103231 CVCL_7B66 DA02096 transformed cell line human CVCL_7B66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02096; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103232 CVCL_7B67 DA02097 transformed cell line human CVCL_7B67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103233 CVCL_7B60 DA02090 transformed cell line human CVCL_7B60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02090; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103234 CVCL_7B61 DA02091 transformed cell line human CVCL_7B61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103235 CVCL_7B62 DA02092 transformed cell line human CVCL_7B62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02092; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103236 CVCL_7B63 DA02093 transformed cell line human CVCL_7B63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103237 CVCL_QP20 BayGenomics ES cell line YTA085 embryonic stem cell house mouse CVCL_QP20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103238 CVCL_R120 HG03306 transformed cell line human CVCL_R120 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103239 CVCL_QP21 BayGenomics ES cell line YTA086 embryonic stem cell house mouse CVCL_QP21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103240 CVCL_R121 HG03307 transformed cell line human CVCL_R121 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103241 CVCL_QP22 BayGenomics ES cell line YTA087 embryonic stem cell house mouse CVCL_QP22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103242 CVCL_R122 HG03309 transformed cell line human CVCL_R122 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103243 CVCL_QP23 BayGenomics ES cell line YTA088 embryonic stem cell house mouse CVCL_QP23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103244 CVCL_R123 HG03311 transformed cell line human CVCL_R123 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103245 CVCL_QP24 BayGenomics ES cell line YTA091 embryonic stem cell house mouse CVCL_QP24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916176; Ubap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103246 CVCL_R124 HG03312 transformed cell line human CVCL_R124 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103247 CVCL_QP25 BayGenomics ES cell line YTA092 embryonic stem cell house mouse CVCL_QP25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104689; Cct4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103248 CVCL_R125 HG03313 transformed cell line human CVCL_R125 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103249 CVCL_QP26 BayGenomics ES cell line YTA097 embryonic stem cell house mouse CVCL_QP26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921268; Als2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103250 CVCL_R126 HG03339 transformed cell line human CVCL_R126 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103251 CVCL_QP27 BayGenomics ES cell line YTA098 embryonic stem cell house mouse CVCL_QP27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103252 CVCL_R127 HG03342 transformed cell line human CVCL_R127 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103253 CVCL_QP28 BayGenomics ES cell line YTA100 embryonic stem cell house mouse CVCL_QP28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384725; Zfp553 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103254 CVCL_R128 HG03343 transformed cell line human CVCL_R128 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103255 CVCL_QP29 BayGenomics ES cell line YTA103 embryonic stem cell house mouse CVCL_QP29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387601; Hrob Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103256 CVCL_R129 HG03351 transformed cell line human CVCL_R129 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103257 CVCL_I787 HGDP00787 transformed cell line human CVCL_I787 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103258 CVCL_HV87 ND12475 transformed cell line human CVCL_HV87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103259 CVCL_I788 HGDP00788 transformed cell line human CVCL_I788 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103260 CVCL_HV88 ND12556 transformed cell line human CVCL_HV88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103261 CVCL_I789 HGDP00789 transformed cell line human CVCL_I789 CL:0000010 Population: Pacific; NAN Melanesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103262 CVCL_HV89 ND12581 transformed cell line human CVCL_HV89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103263 CVCL_I783 HGDP00783 transformed cell line human CVCL_I783 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103264 CVCL_HV83 ND12001 transformed cell line human CVCL_HV83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103265 CVCL_I784 HGDP00784 transformed cell line human CVCL_I784 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103266 CVCL_HV84 ND12256 transformed cell line human CVCL_HV84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103267 CVCL_I785 HGDP00785 transformed cell line human CVCL_I785 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103268 CVCL_HV85 ND12305 transformed cell line human CVCL_HV85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103269 CVCL_I786 HGDP00786 transformed cell line human CVCL_I786 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103270 CVCL_HV86 ND12341 transformed cell line human CVCL_HV86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103271 CVCL_I780 HGDP00780 transformed cell line human CVCL_I780 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103272 CVCL_HV80 ND11960 transformed cell line human CVCL_HV80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103273 CVCL_I781 HGDP00781 transformed cell line human CVCL_I781 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103274 CVCL_HV81 ND11966 transformed cell line human CVCL_HV81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103275 CVCL_I782 HGDP00782 transformed cell line human CVCL_I782 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103276 CVCL_HV82 ND11968 transformed cell line human CVCL_HV82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103277 CVCL_QP30 BayGenomics ES cell line YTA104 embryonic stem cell house mouse CVCL_QP30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103278 CVCL_R130 HG03352 transformed cell line human CVCL_R130 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103279 CVCL_QP10 BayGenomics ES cell line YTA072 embryonic stem cell house mouse CVCL_QP10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138865; Dlgap4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103280 CVCL_R110 HG03280 transformed cell line human CVCL_R110 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103281 CVCL_QP11 BayGenomics ES cell line YTA073 embryonic stem cell house mouse CVCL_QP11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338026; Tom1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103282 CVCL_R111 HG03291 transformed cell line human CVCL_R111 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103283 CVCL_QP12 BayGenomics ES cell line YTA074 embryonic stem cell house mouse CVCL_QP12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926209; Dek Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103284 CVCL_R112 HG03294 transformed cell line human CVCL_R112 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103285 CVCL_QP13 BayGenomics ES cell line YTA076 embryonic stem cell house mouse CVCL_QP13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913910; Sltm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103286 CVCL_R113 HG03295 transformed cell line human CVCL_R113 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103287 CVCL_QP14 BayGenomics ES cell line YTA077 embryonic stem cell house mouse CVCL_QP14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103288 CVCL_R114 HG03297 transformed cell line human CVCL_R114 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103289 CVCL_QP15 BayGenomics ES cell line YTA078 embryonic stem cell house mouse CVCL_QP15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922546; Cep43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103290 CVCL_R115 HG03298 transformed cell line human CVCL_R115 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103291 CVCL_QP16 BayGenomics ES cell line YTA080 embryonic stem cell house mouse CVCL_QP16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913910; Sltm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103292 CVCL_R116 HG03300 transformed cell line human CVCL_R116 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103293 CVCL_QP17 BayGenomics ES cell line YTA081 embryonic stem cell house mouse CVCL_QP17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107887; Gtf3c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103294 CVCL_R117 HG03301 transformed cell line human CVCL_R117 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103295 CVCL_QP18 BayGenomics ES cell line YTA082 embryonic stem cell house mouse CVCL_QP18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103296 CVCL_R118 HG03303 transformed cell line human CVCL_R118 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103297 CVCL_QP19 BayGenomics ES cell line YTA084 embryonic stem cell house mouse CVCL_QP19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913910; Sltm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103298 CVCL_R119 HG03304 transformed cell line human CVCL_R119 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103299 CVCL_I798 HGDP00798 transformed cell line human CVCL_I798 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103300 CVCL_HV98 ND13180 transformed cell line human CVCL_HV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103301 CVCL_I799 HGDP00799 transformed cell line human CVCL_I799 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103302 CVCL_HV99 ND13357 transformed cell line human CVCL_HV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103303 CVCL_I794 HGDP00794 transformed cell line human CVCL_I794 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103304 CVCL_HV94 ND12825 transformed cell line human CVCL_HV94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103305 CVCL_I795 HGDP00795 transformed cell line human CVCL_I795 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103306 CVCL_HV95 ND12928 transformed cell line human CVCL_HV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103307 CVCL_I796 HGDP00796 transformed cell line human CVCL_I796 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103308 CVCL_HV96 ND12967 transformed cell line human CVCL_HV96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103309 CVCL_I797 HGDP00797 transformed cell line human CVCL_I797 CL:0000010 Population: Caucasian; Orcadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103310 CVCL_HV97 ND13001 transformed cell line human CVCL_HV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103311 CVCL_I790 HGDP00790 transformed cell line human CVCL_I790 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103312 CVCL_HV90 ND12615 transformed cell line human CVCL_HV90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103313 CVCL_I791 HGDP00791 transformed cell line human CVCL_I791 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103314 CVCL_HV91 ND12657 transformed cell line human CVCL_HV91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103315 CVCL_I792 HGDP00792 transformed cell line human CVCL_I792 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103316 CVCL_HV92 ND12658 transformed cell line human CVCL_HV92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103317 CVCL_I793 HGDP00793 transformed cell line human CVCL_I793 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103318 CVCL_HV93 ND12824 transformed cell line human CVCL_HV93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103319 CVCL_QP00 BayGenomics ES cell line YTA058 embryonic stem cell house mouse CVCL_QP00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103320 CVCL_R100 HG03249 transformed cell line human CVCL_R100 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103321 CVCL_QP01 BayGenomics ES cell line YTA059 embryonic stem cell house mouse CVCL_QP01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103322 CVCL_R101 HG03250 transformed cell line human CVCL_R101 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103323 CVCL_QP02 BayGenomics ES cell line YTA061 embryonic stem cell house mouse CVCL_QP02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926209; Dek Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103324 CVCL_R102 HG03258 transformed cell line human CVCL_R102 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103325 CVCL_QP03 BayGenomics ES cell line YTA062 embryonic stem cell house mouse CVCL_QP03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918677; Ibtk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103326 CVCL_R103 HG03259 transformed cell line human CVCL_R103 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103327 CVCL_QP04 BayGenomics ES cell line YTA063 embryonic stem cell house mouse CVCL_QP04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103328 CVCL_R104 HG03265 transformed cell line human CVCL_R104 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103329 CVCL_QP05 BayGenomics ES cell line YTA065 embryonic stem cell house mouse CVCL_QP05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103330 CVCL_R105 HG03267 transformed cell line human CVCL_R105 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103331 CVCL_QP06 BayGenomics ES cell line YTA067 embryonic stem cell house mouse CVCL_QP06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103332 CVCL_R106 HG03268 transformed cell line human CVCL_R106 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103333 CVCL_I769 HGDP00769 transformed cell line human CVCL_I769 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103334 CVCL_HV69 ND11312 transformed cell line human CVCL_HV69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103335 CVCL_QP07 BayGenomics ES cell line YTA068 embryonic stem cell house mouse CVCL_QP07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103336 CVCL_R107 HG03270 transformed cell line human CVCL_R107 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103337 CVCL_QP08 BayGenomics ES cell line YTA070 embryonic stem cell house mouse CVCL_QP08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179723; Casc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103338 CVCL_R108 HG03271 transformed cell line human CVCL_R108 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103339 CVCL_QP09 BayGenomics ES cell line YTA071 embryonic stem cell house mouse CVCL_QP09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343961; Msh6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103340 CVCL_R109 HG03279 transformed cell line human CVCL_R109 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103341 CVCL_I765 HGDP00765 transformed cell line human CVCL_I765 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103342 CVCL_HV65 ND10439 transformed cell line human CVCL_HV65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103343 CVCL_I766 HGDP00766 transformed cell line human CVCL_I766 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103344 CVCL_HV66 ND10458 transformed cell line human CVCL_HV66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103345 CVCL_I767 HGDP00767 transformed cell line human CVCL_I767 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103346 CVCL_HV67 ND10924 transformed cell line human CVCL_HV67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103347 CVCL_I768 HGDP00768 transformed cell line human CVCL_I768 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103348 CVCL_HV68 ND10997 transformed cell line human CVCL_HV68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103349 CVCL_I761 HGDP00761 transformed cell line human CVCL_I761 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103350 CVCL_HV61 ND10321 transformed cell line human CVCL_HV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103351 CVCL_I762 HGDP00762 transformed cell line human CVCL_I762 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103352 CVCL_HV62 ND10340 transformed cell line human CVCL_HV62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103353 CVCL_I763 HGDP00763 transformed cell line human CVCL_I763 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103354 CVCL_HV63 ND10400 transformed cell line human CVCL_HV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103355 CVCL_I764 HGDP00764 transformed cell line human CVCL_I764 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103356 CVCL_HV64 ND10436 transformed cell line human CVCL_HV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103357 CVCL_I760 HGDP00760 transformed cell line human CVCL_I760 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103358 CVCL_HV60 ND10203 transformed cell line human CVCL_HV60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103359 CVCL_I776 HGDP00776 transformed cell line human CVCL_I776 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103360 CVCL_HV76 ND11523 transformed cell line human CVCL_HV76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103361 CVCL_I777 HGDP00777 transformed cell line human CVCL_I777 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103362 CVCL_HV77 ND11798 transformed cell line human CVCL_HV77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103363 CVCL_I778 HGDP00778 transformed cell line human CVCL_I778 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced (low read coverage) Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103364 CVCL_HV78 ND11799 transformed cell line human CVCL_HV78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103365 CVCL_I779 HGDP00779 transformed cell line human CVCL_I779 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103366 CVCL_HV79 ND11957 transformed cell line human CVCL_HV79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103367 CVCL_I772 HGDP00772 transformed cell line human CVCL_I772 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103368 CVCL_HV72 ND11404 transformed cell line human CVCL_HV72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103369 CVCL_I773 HGDP00773 transformed cell line human CVCL_I773 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103370 CVCL_HV73 ND11405 transformed cell line human CVCL_HV73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103371 CVCL_I774 HGDP00774 transformed cell line human CVCL_I774 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103372 CVCL_HV74 ND11475 transformed cell line human CVCL_HV74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103373 CVCL_I775 HGDP00775 transformed cell line human CVCL_I775 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103374 CVCL_HV75 ND11522 transformed cell line human CVCL_HV75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103375 CVCL_I770 HGDP00770 transformed cell line human CVCL_I770 CL:0000010 Population: Native American (was originally classified as Japanese); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103376 CVCL_HV70 ND11315 transformed cell line human CVCL_HV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103377 CVCL_I771 HGDP00771 transformed cell line human CVCL_I771 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103378 CVCL_HV71 ND11402 transformed cell line human CVCL_HV71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103379 CVCL_I747 HGDP00747 transformed cell line human CVCL_I747 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103380 CVCL_HV47 ND09642 transformed cell line human CVCL_HV47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103381 CVCL_I748 HGDP00748 transformed cell line human CVCL_I748 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103382 CVCL_HV48 ND09721 transformed cell line human CVCL_HV48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103383 CVCL_I749 HGDP00749 transformed cell line human CVCL_I749 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103384 CVCL_HV49 ND09749 transformed cell line human CVCL_HV49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103385 CVCL_I743 HGDP00743 transformed cell line human CVCL_I743 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103386 CVCL_HV43 ND09516 transformed cell line human CVCL_HV43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103387 CVCL_I744 HGDP00744 transformed cell line human CVCL_I744 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103388 CVCL_HV44 ND09534 transformed cell line human CVCL_HV44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103389 CVCL_I745 HGDP00745 transformed cell line human CVCL_I745 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103390 CVCL_HV45 ND09542 transformed cell line human CVCL_HV45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103391 CVCL_I746 HGDP00746 transformed cell line human CVCL_I746 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103392 CVCL_HV46 ND09588 transformed cell line human CVCL_HV46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103393 CVCL_I740 HGDP00740 transformed cell line human CVCL_I740 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103394 CVCL_HV40 ND09321 transformed cell line human CVCL_HV40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103395 CVCL_I741 HGDP00741 transformed cell line human CVCL_I741 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103396 CVCL_HV41 ND09358 transformed cell line human CVCL_HV41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103397 CVCL_I742 HGDP00742 transformed cell line human CVCL_I742 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103398 CVCL_HV42 ND09482 transformed cell line human CVCL_HV42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103399 CVCL_I758 HGDP00758 transformed cell line human CVCL_I758 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103400 CVCL_HV58 ND10169 transformed cell line human CVCL_HV58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103401 CVCL_I759 HGDP00759 transformed cell line human CVCL_I759 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103402 CVCL_HV59 ND10201 transformed cell line human CVCL_HV59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103403 CVCL_I754 HGDP00754 transformed cell line human CVCL_I754 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103404 CVCL_HV54 ND10055 transformed cell line human CVCL_HV54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103405 CVCL_I755 HGDP00755 transformed cell line human CVCL_I755 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103406 CVCL_HV55 ND10071 transformed cell line human CVCL_HV55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103407 CVCL_I756 HGDP00756 transformed cell line human CVCL_I756 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103408 CVCL_HV56 ND10154 transformed cell line human CVCL_HV56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103409 CVCL_I757 HGDP00757 transformed cell line human CVCL_I757 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103410 CVCL_HV57 ND10165 transformed cell line human CVCL_HV57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103411 CVCL_I750 HGDP00750 transformed cell line human CVCL_I750 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103412 CVCL_HV50 ND05021 transformed cell line human CVCL_HV50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103413 CVCL_I751 HGDP00751 transformed cell line human CVCL_I751 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103414 CVCL_HV51 ND09799 transformed cell line human CVCL_HV51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103415 CVCL_I752 HGDP00752 transformed cell line human CVCL_I752 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103416 CVCL_HV52 ND10026 transformed cell line human CVCL_HV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103417 CVCL_I753 HGDP00753 transformed cell line human CVCL_I753 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103418 CVCL_HV53 ND10027 transformed cell line human CVCL_HV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103419 CVCL_I729 HGDP00729 transformed cell line human CVCL_I729 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103420 CVCL_HV29 ND08849 transformed cell line human CVCL_HV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103421 CVCL_I725 HGDP00725 transformed cell line human CVCL_I725 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103422 CVCL_HV25 ND08825 transformed cell line human CVCL_HV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103423 CVCL_I726 HGDP00726 transformed cell line human CVCL_I726 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103424 CVCL_HV26 ND08826 transformed cell line human CVCL_HV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103425 CVCL_I727 HGDP00727 transformed cell line human CVCL_I727 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103426 CVCL_HV27 ND08827 transformed cell line human CVCL_HV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103427 CVCL_I728 HGDP00728 transformed cell line human CVCL_I728 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103428 CVCL_HV28 ND08848 transformed cell line human CVCL_HV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103429 CVCL_I721 HGDP00721 transformed cell line human CVCL_I721 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103430 CVCL_HV21 ND08747 transformed cell line human CVCL_HV21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103431 CVCL_I722 HGDP00722 transformed cell line human CVCL_I722 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103432 CVCL_HV22 ND08748 transformed cell line human CVCL_HV22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103433 CVCL_I723 HGDP00723 transformed cell line human CVCL_I723 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103434 CVCL_HV23 ND08762 transformed cell line human CVCL_HV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103435 CVCL_I724 HGDP00724 transformed cell line human CVCL_I724 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103436 CVCL_HV24 ND08797 transformed cell line human CVCL_HV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103437 CVCL_I720 HGDP00720 transformed cell line human CVCL_I720 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103438 CVCL_HV20 ND08715 transformed cell line human CVCL_HV20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103439 CVCL_I736 HGDP00736 transformed cell line human CVCL_I736 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103440 CVCL_HV36 ND09163 transformed cell line human CVCL_HV36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103441 CVCL_I737 HGDP00737 transformed cell line human CVCL_I737 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103442 CVCL_HV37 ND09207 transformed cell line human CVCL_HV37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103443 CVCL_I738 HGDP00738 transformed cell line human CVCL_I738 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103444 CVCL_HV38 ND09256 transformed cell line human CVCL_HV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103445 CVCL_I739 HGDP00739 transformed cell line human CVCL_I739 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103446 CVCL_HV39 ND09274 transformed cell line human CVCL_HV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103447 CVCL_I732 HGDP00732 transformed cell line human CVCL_I732 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103448 CVCL_HV32 ND09105 transformed cell line human CVCL_HV32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103449 CVCL_I733 HGDP00733 transformed cell line human CVCL_I733 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103450 CVCL_HV33 ND09130 transformed cell line human CVCL_HV33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103451 CVCL_I734 HGDP00734 transformed cell line human CVCL_I734 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103452 CVCL_HV34 ND09131 transformed cell line human CVCL_HV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103453 CVCL_I735 HGDP00735 transformed cell line human CVCL_I735 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103454 CVCL_HV35 ND09132 transformed cell line human CVCL_HV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103455 CVCL_I730 HGDP00730 transformed cell line human CVCL_I730 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103456 CVCL_HV30 ND08953 transformed cell line human CVCL_HV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103457 CVCL_I731 HGDP00731 transformed cell line human CVCL_I731 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103458 CVCL_HV31 ND08954 transformed cell line human CVCL_HV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103459 CVCL_QP97 BayGenomics ES cell line YTA210 embryonic stem cell house mouse CVCL_QP97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103460 CVCL_7D04 DA02271 transformed cell line human CVCL_7D04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02271; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103461 CVCL_R197 HG03518 transformed cell line human CVCL_R197 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103462 CVCL_QP98 BayGenomics ES cell line YTA211 embryonic stem cell house mouse CVCL_QP98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103463 CVCL_7D05 DA02276 transformed cell line human CVCL_7D05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02276; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103464 CVCL_R198 HG03520 transformed cell line human CVCL_R198 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103465 CVCL_QP99 BayGenomics ES cell line YTA212 embryonic stem cell house mouse CVCL_QP99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103466 CVCL_7D06 DA02277 transformed cell line human CVCL_7D06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02277; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103467 CVCL_R199 HG03521 transformed cell line human CVCL_R199 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103468 CVCL_7D07 DA02280 transformed cell line human CVCL_7D07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103469 CVCL_7D00 DA02265 transformed cell line human CVCL_7D00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02265; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103470 CVCL_7D01 DA02266 transformed cell line human CVCL_7D01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02266; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103471 CVCL_7D02 DA02269 transformed cell line human CVCL_7D02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02269; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103472 CVCL_7D03 DA02270 transformed cell line human CVCL_7D03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02270; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103473 CVCL_7D08 DA02281 transformed cell line human CVCL_7D08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02281; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103474 CVCL_7D09 DA02282 transformed cell line human CVCL_7D09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02282; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103475 CVCL_QP86 BayGenomics ES cell line YTA190 embryonic stem cell house mouse CVCL_QP86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103476 CVCL_R186 HG03487 transformed cell line human CVCL_R186 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103477 CVCL_QP87 BayGenomics ES cell line YTA191 embryonic stem cell house mouse CVCL_QP87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346869; Map2k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103478 CVCL_R187 HG03488 transformed cell line human CVCL_R187 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103479 CVCL_QP88 BayGenomics ES cell line YTA193 embryonic stem cell house mouse CVCL_QP88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98658; Tdgf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103480 CVCL_R188 HG03490 transformed cell line human CVCL_R188 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103481 CVCL_QP89 BayGenomics ES cell line YTA197 embryonic stem cell house mouse CVCL_QP89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918699; Eef1aknmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103482 CVCL_R189 HG03491 transformed cell line human CVCL_R189 CL:0000010 Population: Punjabi in Lahore (PJL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103483 CVCL_QP90 BayGenomics ES cell line YTA199 embryonic stem cell house mouse CVCL_QP90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136841; Morc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103484 CVCL_R190 HG03493 transformed cell line human CVCL_R190 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103485 CVCL_QP91 BayGenomics ES cell line YTA201 embryonic stem cell house mouse CVCL_QP91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914694; Ilkap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103486 CVCL_R191 HG03499 transformed cell line human CVCL_R191 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103487 CVCL_QP92 BayGenomics ES cell line YTA202 embryonic stem cell house mouse CVCL_QP92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925836; Srbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103488 CVCL_R192 HG03508 transformed cell line human CVCL_R192 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103489 CVCL_QP93 BayGenomics ES cell line YTA203 embryonic stem cell house mouse CVCL_QP93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109198; Eif4ebp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103490 CVCL_R193 HG03511 transformed cell line human CVCL_R193 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103491 CVCL_QP94 BayGenomics ES cell line YTA204 embryonic stem cell house mouse CVCL_QP94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353561; Vapa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103492 CVCL_R194 HG03514 transformed cell line human CVCL_R194 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103493 CVCL_QP95 BayGenomics ES cell line YTA208 embryonic stem cell house mouse CVCL_QP95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443312; Zscan22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103494 CVCL_R195 HG03515 transformed cell line human CVCL_R195 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103495 CVCL_QP96 BayGenomics ES cell line YTA209 embryonic stem cell house mouse CVCL_QP96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103496 CVCL_R196 HG03517 transformed cell line human CVCL_R196 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103497 CVCL_QP75 BayGenomics ES cell line YTA172 embryonic stem cell house mouse CVCL_QP75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349722; Pabpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103498 CVCL_R175 HG03462 transformed cell line human CVCL_R175 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103499 CVCL_QP76 BayGenomics ES cell line YTA173 embryonic stem cell house mouse CVCL_QP76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860267; Set Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103500 CVCL_R176 HG03464 transformed cell line human CVCL_R176 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103501 CVCL_QP77 BayGenomics ES cell line YTA174 embryonic stem cell house mouse CVCL_QP77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103502 CVCL_R177 HG03469 transformed cell line human CVCL_R177 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103503 CVCL_QP78 BayGenomics ES cell line YTA175 embryonic stem cell house mouse CVCL_QP78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045309; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103504 CVCL_R178 HG03470 transformed cell line human CVCL_R178 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103505 CVCL_QP79 BayGenomics ES cell line YTA176 embryonic stem cell house mouse CVCL_QP79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894687; Xrn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103506 CVCL_R179 HG03472 transformed cell line human CVCL_R179 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103507 CVCL_QP80 BayGenomics ES cell line YTA180 embryonic stem cell house mouse CVCL_QP80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352757; Iqgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103508 CVCL_R180 HG03473 transformed cell line human CVCL_R180 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103509 CVCL_QP81 BayGenomics ES cell line YTA182 embryonic stem cell house mouse CVCL_QP81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103510 CVCL_R181 HG03476 transformed cell line human CVCL_R181 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103511 CVCL_QP82 BayGenomics ES cell line YTA183 embryonic stem cell house mouse CVCL_QP82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103512 CVCL_R182 HG03478 transformed cell line human CVCL_R182 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103513 CVCL_QP83 BayGenomics ES cell line YTA185 embryonic stem cell house mouse CVCL_QP83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351656; Abcf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103514 CVCL_R183 HG03479 transformed cell line human CVCL_R183 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103515 CVCL_QP84 BayGenomics ES cell line YTA187 embryonic stem cell house mouse CVCL_QP84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103516 CVCL_R184 HG03484 transformed cell line human CVCL_R184 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103517 CVCL_QP85 BayGenomics ES cell line YTA189 embryonic stem cell house mouse CVCL_QP85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182465; Vrk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103518 CVCL_R185 HG03485 transformed cell line human CVCL_R185 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103519 CVCL_QP64 BayGenomics ES cell line YTA154 embryonic stem cell house mouse CVCL_QP64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104537; Brca1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103520 CVCL_R164 HG03445 transformed cell line human CVCL_R164 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103521 CVCL_QP65 BayGenomics ES cell line YTA155 embryonic stem cell house mouse CVCL_QP65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918972; Cic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103522 CVCL_R165 HG03446 transformed cell line human CVCL_R165 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103523 CVCL_QP66 BayGenomics ES cell line YTA156 embryonic stem cell house mouse CVCL_QP66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926162; Sp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103524 CVCL_R166 HG03449 transformed cell line human CVCL_R166 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103525 CVCL_QP67 BayGenomics ES cell line YTA159 embryonic stem cell house mouse CVCL_QP67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97621; Plk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103526 CVCL_R167 HG03451 transformed cell line human CVCL_R167 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103527 CVCL_QP68 BayGenomics ES cell line YTA162 embryonic stem cell house mouse CVCL_QP68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109281; Pkp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103528 CVCL_R168 HG03452 transformed cell line human CVCL_R168 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103529 CVCL_QP69 BayGenomics ES cell line YTA163 embryonic stem cell house mouse CVCL_QP69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103530 CVCL_R169 HG03454 transformed cell line human CVCL_R169 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103531 CVCL_QP70 BayGenomics ES cell line YTA164 embryonic stem cell house mouse CVCL_QP70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891704; Hbs1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103532 CVCL_R170 HG03455 transformed cell line human CVCL_R170 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103533 CVCL_QP71 BayGenomics ES cell line YTA165 embryonic stem cell house mouse CVCL_QP71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103534 CVCL_R171 HG03457 transformed cell line human CVCL_R171 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103535 CVCL_QP72 BayGenomics ES cell line YTA169 embryonic stem cell house mouse CVCL_QP72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103536 CVCL_R172 HG03458 transformed cell line human CVCL_R172 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103537 CVCL_QP73 BayGenomics ES cell line YTA170 embryonic stem cell house mouse CVCL_QP73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103538 CVCL_R173 HG03460 transformed cell line human CVCL_R173 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103539 CVCL_QP74 BayGenomics ES cell line YTA171 embryonic stem cell house mouse CVCL_QP74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99495; Brd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103540 CVCL_R174 HG03461 transformed cell line human CVCL_R174 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103541 CVCL_QP53 BayGenomics ES cell line YTA140 embryonic stem cell house mouse CVCL_QP53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353561; Vapa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103542 CVCL_R153 HG03408 transformed cell line human CVCL_R153 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103543 CVCL_QP54 BayGenomics ES cell line YTA142 embryonic stem cell house mouse CVCL_QP54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103544 CVCL_R154 HG03410 transformed cell line human CVCL_R154 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103545 CVCL_QP55 BayGenomics ES cell line YTA143 embryonic stem cell house mouse CVCL_QP55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103546 CVCL_R155 HG03419 transformed cell line human CVCL_R155 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103547 CVCL_QP56 BayGenomics ES cell line YTA144 embryonic stem cell house mouse CVCL_QP56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103548 CVCL_R156 HG03428 transformed cell line human CVCL_R156 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103549 CVCL_QP57 BayGenomics ES cell line YTA145 embryonic stem cell house mouse CVCL_QP57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103550 CVCL_R157 HG03431 transformed cell line human CVCL_R157 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103551 CVCL_QP58 BayGenomics ES cell line YTA146 embryonic stem cell house mouse CVCL_QP58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196256; Kdm1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103552 CVCL_R158 HG03432 transformed cell line human CVCL_R158 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103553 CVCL_QP59 BayGenomics ES cell line YTA148 embryonic stem cell house mouse CVCL_QP59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103554 CVCL_R159 HG03433 transformed cell line human CVCL_R159 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103555 CVCL_QP60 BayGenomics ES cell line YTA149 embryonic stem cell house mouse CVCL_QP60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679002; Prr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103556 CVCL_R160 HG03436 transformed cell line human CVCL_R160 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103557 CVCL_QP61 BayGenomics ES cell line YTA150 embryonic stem cell house mouse CVCL_QP61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104872; Ppp1cc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103558 CVCL_R161 HG03437 transformed cell line human CVCL_R161 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103559 CVCL_QP62 BayGenomics ES cell line YTA151 embryonic stem cell house mouse CVCL_QP62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103560 CVCL_R162 HG03439 transformed cell line human CVCL_R162 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103561 CVCL_QP63 BayGenomics ES cell line YTA153 embryonic stem cell house mouse CVCL_QP63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103257; Inpp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103562 CVCL_R163 HG03442 transformed cell line human CVCL_R163 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103563 CVCL_QP42 BayGenomics ES cell line YTA125 embryonic stem cell house mouse CVCL_QP42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932610; Noc3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103564 CVCL_R142 HG03380 transformed cell line human CVCL_R142 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103565 CVCL_QP43 BayGenomics ES cell line YTA126 embryonic stem cell house mouse CVCL_QP43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353651; Gnl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103566 CVCL_R143 HG03382 transformed cell line human CVCL_R143 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103567 CVCL_QP44 BayGenomics ES cell line YTA127 embryonic stem cell house mouse CVCL_QP44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143854; Nup107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103568 CVCL_R144 HG03383 transformed cell line human CVCL_R144 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103569 CVCL_QP45 BayGenomics ES cell line YTA130 embryonic stem cell house mouse CVCL_QP45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103570 CVCL_R145 HG03385 transformed cell line human CVCL_R145 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103571 CVCL_QP46 BayGenomics ES cell line YTA132 embryonic stem cell house mouse CVCL_QP46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859328; Cpsf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103572 CVCL_R146 HG03388 transformed cell line human CVCL_R146 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103573 CVCL_QP47 BayGenomics ES cell line YTA133 embryonic stem cell house mouse CVCL_QP47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107741; Pvr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103574 CVCL_R147 HG03391 transformed cell line human CVCL_R147 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103575 CVCL_QP48 BayGenomics ES cell line YTA134 embryonic stem cell house mouse CVCL_QP48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921590; Ahcyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103576 CVCL_R148 HG03393 transformed cell line human CVCL_R148 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103577 CVCL_QP49 BayGenomics ES cell line YTA135 embryonic stem cell house mouse CVCL_QP49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914475; Rnpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103578 CVCL_R149 HG03394 transformed cell line human CVCL_R149 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103579 CVCL_QP50 BayGenomics ES cell line YTA136 embryonic stem cell house mouse CVCL_QP50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913731; Rps21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103580 CVCL_R150 HG03397 transformed cell line human CVCL_R150 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103581 CVCL_QP51 BayGenomics ES cell line YTA138 embryonic stem cell house mouse CVCL_QP51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103582 CVCL_R151 HG03398 transformed cell line human CVCL_R151 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103583 CVCL_QP52 BayGenomics ES cell line YTA139 embryonic stem cell house mouse CVCL_QP52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103584 CVCL_R152 HG03401 transformed cell line human CVCL_R152 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103585 CVCL_QP31 BayGenomics ES cell line YTA105 embryonic stem cell house mouse CVCL_QP31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914934; Luc7l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103586 CVCL_R131 HG03354 transformed cell line human CVCL_R131 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103587 CVCL_QP32 BayGenomics ES cell line YTA106 embryonic stem cell house mouse CVCL_QP32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277214; Septin11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103588 CVCL_R132 HG03361 transformed cell line human CVCL_R132 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103589 CVCL_QP33 BayGenomics ES cell line YTA107 embryonic stem cell house mouse CVCL_QP33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103590 CVCL_R133 HG03363 transformed cell line human CVCL_R133 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103591 CVCL_QP34 BayGenomics ES cell line YTA109 embryonic stem cell house mouse CVCL_QP34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103592 CVCL_R134 HG03366 transformed cell line human CVCL_R134 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103593 CVCL_QP35 BayGenomics ES cell line YTA111 embryonic stem cell house mouse CVCL_QP35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103594 CVCL_R135 HG03367 transformed cell line human CVCL_R135 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103595 CVCL_QP36 BayGenomics ES cell line YTA112 embryonic stem cell house mouse CVCL_QP36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103596 CVCL_R136 HG03369 transformed cell line human CVCL_R136 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103597 CVCL_QP37 BayGenomics ES cell line YTA117 embryonic stem cell house mouse CVCL_QP37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103598 CVCL_R137 HG03370 transformed cell line human CVCL_R137 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103599 CVCL_QP38 BayGenomics ES cell line YTA118 embryonic stem cell house mouse CVCL_QP38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103600 CVCL_R138 HG03372 transformed cell line human CVCL_R138 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103601 CVCL_QP39 BayGenomics ES cell line YTA121 embryonic stem cell house mouse CVCL_QP39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103602 CVCL_R139 HG03373 transformed cell line human CVCL_R139 CL:0000010 Population: African; Esan from Nigeria (ESN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103603 CVCL_QP40 BayGenomics ES cell line YTA123 embryonic stem cell house mouse CVCL_QP40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103604 CVCL_R140 HG03376 transformed cell line human CVCL_R140 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103605 CVCL_QP41 BayGenomics ES cell line YTA124 embryonic stem cell house mouse CVCL_QP41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21103606 CVCL_R141 HG03378 transformed cell line human CVCL_R141 CL:0000010 Population: African; Mende in Sierra Leone (MSL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103607 CVCL_7C56 DA02209 transformed cell line human CVCL_7C56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103608 CVCL_7C57 DA02211 transformed cell line human CVCL_7C57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02211; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103609 CVCL_7C58 DA02212 transformed cell line human CVCL_7C58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103610 CVCL_7C59 DA02213 transformed cell line human CVCL_7C59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02213; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103611 CVCL_7C52 DA02203 transformed cell line human CVCL_7C52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103612 CVCL_7C53 DA02204 transformed cell line human CVCL_7C53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02204; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103613 CVCL_7C54 DA02205 transformed cell line human CVCL_7C54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103614 CVCL_7C55 DA02206 transformed cell line human CVCL_7C55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02206; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103615 CVCL_7C50 DA02200 transformed cell line human CVCL_7C50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103616 CVCL_7C51 DA02202 transformed cell line human CVCL_7C51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103617 CVCL_7C67 DA02221 transformed cell line human CVCL_7C67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103618 CVCL_7C68 DA02222 transformed cell line human CVCL_7C68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103619 CVCL_7C69 DA02223 transformed cell line human CVCL_7C69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02223; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103620 CVCL_7C63 DA02217 transformed cell line human CVCL_7C63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02217; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103621 CVCL_7C64 DA02218 transformed cell line human CVCL_7C64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02218; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103622 CVCL_7C65 DA02219 transformed cell line human CVCL_7C65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02219; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103623 CVCL_7C66 DA02220 transformed cell line human CVCL_7C66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103624 CVCL_7C60 DA02214 transformed cell line human CVCL_7C60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02214; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103625 CVCL_7C61 DA02215 transformed cell line human CVCL_7C61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02215; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103626 CVCL_7C62 DA02216 transformed cell line human CVCL_7C62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02216; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103627 CVCL_7C38 DA02180 transformed cell line human CVCL_7C38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103628 CVCL_7C39 DA02181 transformed cell line human CVCL_7C39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103629 CVCL_7C34 DA02176 transformed cell line human CVCL_7C34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103630 CVCL_7C35 DA02177 transformed cell line human CVCL_7C35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103631 CVCL_7C36 DA02178 transformed cell line human CVCL_7C36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103632 CVCL_7C37 DA02179 transformed cell line human CVCL_7C37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103633 CVCL_7C30 DA02172 transformed cell line human CVCL_7C30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103634 CVCL_7C31 DA02173 transformed cell line human CVCL_7C31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02173; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103635 CVCL_7C32 DA02174 transformed cell line human CVCL_7C32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02174; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103636 CVCL_7C33 DA02175 transformed cell line human CVCL_7C33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02175; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103637 CVCL_7C49 DA02199 transformed cell line human CVCL_7C49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103638 CVCL_7C45 DA02194 transformed cell line human CVCL_7C45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103639 CVCL_7C46 DA02195 transformed cell line human CVCL_7C46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02195; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103640 CVCL_7C47 DA02196 transformed cell line human CVCL_7C47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02196; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103641 CVCL_7C48 DA02197 transformed cell line human CVCL_7C48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103642 CVCL_7C41 DA02188 transformed cell line human CVCL_7C41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103643 CVCL_7C42 DA02189 transformed cell line human CVCL_7C42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103644 CVCL_7C43 DA02191 transformed cell line human CVCL_7C43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103645 CVCL_7C44 DA02192 transformed cell line human CVCL_7C44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103646 CVCL_7C40 DA02182 transformed cell line human CVCL_7C40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103647 CVCL_7C16 DA02157 transformed cell line human CVCL_7C16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103648 CVCL_7C17 DA02158 transformed cell line human CVCL_7C17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02158; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103649 CVCL_7C18 DA02159 transformed cell line human CVCL_7C18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103650 CVCL_7C19 DA02160 transformed cell line human CVCL_7C19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103651 CVCL_7C12 DA02153 transformed cell line human CVCL_7C12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103652 CVCL_7C13 DA02154 transformed cell line human CVCL_7C13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103653 CVCL_7C14 DA02155 transformed cell line human CVCL_7C14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02155; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103654 CVCL_7C15 DA02156 transformed cell line human CVCL_7C15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02156; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103655 CVCL_7C10 DA02151 transformed cell line human CVCL_7C10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103656 CVCL_7C11 DA02152 transformed cell line human CVCL_7C11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103657 CVCL_7C27 DA02169 transformed cell line human CVCL_7C27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103658 CVCL_7C28 DA02170 transformed cell line human CVCL_7C28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103659 CVCL_7C29 DA02171 transformed cell line human CVCL_7C29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103660 CVCL_7C23 DA02164 transformed cell line human CVCL_7C23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02164; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103661 CVCL_7C24 DA02165 transformed cell line human CVCL_7C24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02165; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103662 CVCL_7C25 DA02167 transformed cell line human CVCL_7C25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103663 CVCL_7C26 DA02168 transformed cell line human CVCL_7C26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103664 CVCL_7C20 DA02161 transformed cell line human CVCL_7C20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103665 CVCL_7C21 DA02162 transformed cell line human CVCL_7C21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103666 CVCL_7C22 DA02163 transformed cell line human CVCL_7C22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103667 CVCL_7C05 DA02146 transformed cell line human CVCL_7C05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103668 CVCL_R098 HG03246 transformed cell line human CVCL_R098 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103669 CVCL_7C06 DA02147 transformed cell line human CVCL_7C06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02147; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103670 CVCL_R099 HG03247 transformed cell line human CVCL_R099 CL:0000010 Population: African; Gambian in Western Division - Mandinka (GWD); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21103671 CVCL_7C07 DA02148 transformed cell line human CVCL_7C07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02148; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103672 CVCL_7C08 DA02149 transformed cell line human CVCL_7C08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02149; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103673 CVCL_7C01 DA02142 transformed cell line human CVCL_7C01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103674 CVCL_7C02 DA02143 transformed cell line human CVCL_7C02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103675 CVCL_7C03 DA02144 transformed cell line human CVCL_7C03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103676 CVCL_7C04 DA02145 transformed cell line human CVCL_7C04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02145; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103677 CVCL_7C09 DA02150 transformed cell line human CVCL_7C09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02150; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103678 CVCL_7C00 DA02141 transformed cell line human CVCL_7C00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103679 CVCL_I707 HGDP00707 transformed cell line human CVCL_I707 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103680 CVCL_HV07 ND08131 transformed cell line human CVCL_HV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103681 CVCL_I708 HGDP00708 transformed cell line human CVCL_I708 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103682 CVCL_HV08 ND08137 transformed cell line human CVCL_HV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103683 CVCL_I709 HGDP00709 transformed cell line human CVCL_I709 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103684 CVCL_HV09 ND08165 transformed cell line human CVCL_HV09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103685 CVCL_I703 HGDP00703 transformed cell line human CVCL_I703 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103686 CVCL_HV03 ND07967 transformed cell line human CVCL_HV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103687 CVCL_I704 HGDP00704 transformed cell line human CVCL_I704 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103688 CVCL_HV04 ND08014 transformed cell line human CVCL_HV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103689 CVCL_I705 HGDP00705 transformed cell line human CVCL_I705 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103690 CVCL_HV05 ND08066 transformed cell line human CVCL_HV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103691 CVCL_I706 HGDP00706 transformed cell line human CVCL_I706 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103692 CVCL_HV06 ND08130 transformed cell line human CVCL_HV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103693 CVCL_I700 HGDP00700 transformed cell line human CVCL_I700 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103694 CVCL_HV00 ND07720 transformed cell line human CVCL_HV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103695 CVCL_I701 HGDP00701 transformed cell line human CVCL_I701 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103696 CVCL_HV01 ND07763 transformed cell line human CVCL_HV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103697 CVCL_I702 HGDP00702 transformed cell line human CVCL_I702 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103698 CVCL_HV02 ND07894 transformed cell line human CVCL_HV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103699 CVCL_I718 HGDP00718 transformed cell line human CVCL_I718 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103700 CVCL_HV18 ND08653 transformed cell line human CVCL_HV18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103701 CVCL_I719 HGDP00719 transformed cell line human CVCL_I719 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103702 CVCL_HV19 ND08667 transformed cell line human CVCL_HV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103703 CVCL_I714 HGDP00714 transformed cell line human CVCL_I714 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103704 CVCL_HV14 ND08359 transformed cell line human CVCL_HV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103705 CVCL_I715 HGDP00715 transformed cell line human CVCL_I715 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103706 CVCL_HV15 ND08383 transformed cell line human CVCL_HV15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103707 CVCL_I716 HGDP00716 transformed cell line human CVCL_I716 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103708 CVCL_HV16 ND08517 transformed cell line human CVCL_HV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103709 CVCL_I717 HGDP00717 transformed cell line human CVCL_I717 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103710 CVCL_HV17 ND08518 transformed cell line human CVCL_HV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103711 CVCL_I710 HGDP00710 transformed cell line human CVCL_I710 CL:0000010 Population: Colombian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103712 CVCL_HV10 ND08203 transformed cell line human CVCL_HV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103713 CVCL_I711 HGDP00711 transformed cell line human CVCL_I711 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103714 CVCL_HV11 ND08204 transformed cell line human CVCL_HV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103715 CVCL_I712 HGDP00712 transformed cell line human CVCL_I712 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103716 CVCL_HV12 ND08314 transformed cell line human CVCL_HV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103717 CVCL_I713 HGDP00713 transformed cell line human CVCL_I713 CL:0000010 Population: Southeast Asian; Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human genome diversity (HGDP-CEPH) cell line panel 21103718 CVCL_HV13 ND08349 transformed cell line human CVCL_HV13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103719 CVCL_7C90 DA02254 transformed cell line human CVCL_7C90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02254; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103720 CVCL_7C91 DA02255 transformed cell line human CVCL_7C91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02255; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103721 CVCL_7C96 DA02261 transformed cell line human CVCL_7C96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02261; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103722 CVCL_7C97 DA02262 transformed cell line human CVCL_7C97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103723 CVCL_7C98 DA02263 transformed cell line human CVCL_7C98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02263; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103724 CVCL_7C99 DA02264 transformed cell line human CVCL_7C99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02264; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103725 CVCL_7C92 DA02256 transformed cell line human CVCL_7C92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103726 CVCL_7C93 DA02257 transformed cell line human CVCL_7C93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02257; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103727 CVCL_7C94 DA02258 transformed cell line human CVCL_7C94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02258; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103728 CVCL_7C95 DA02260 transformed cell line human CVCL_7C95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02260; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103729 CVCL_7C78 DA02237 transformed cell line human CVCL_7C78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103730 CVCL_7C79 DA02238 transformed cell line human CVCL_7C79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103731 CVCL_7C74 DA02229 transformed cell line human CVCL_7C74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02229; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103732 CVCL_7C75 DA02230 transformed cell line human CVCL_7C75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103733 CVCL_7C76 DA02231 transformed cell line human CVCL_7C76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02231; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103734 CVCL_7C77 DA02236 transformed cell line human CVCL_7C77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103735 CVCL_7C70 DA02224 transformed cell line human CVCL_7C70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103736 CVCL_7C71 DA02225 transformed cell line human CVCL_7C71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02225; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103737 CVCL_7C72 DA02227 transformed cell line human CVCL_7C72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103738 CVCL_7C73 DA02228 transformed cell line human CVCL_7C73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103739 CVCL_7C89 DA02253 transformed cell line human CVCL_7C89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02253; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103740 CVCL_7C80 DA02240 transformed cell line human CVCL_7C80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02240; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103741 CVCL_7C85 DA02249 transformed cell line human CVCL_7C85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103742 CVCL_7C86 DA02250 transformed cell line human CVCL_7C86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02250; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103743 CVCL_7C87 DA02251 transformed cell line human CVCL_7C87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02251; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103744 CVCL_7C88 DA02252 transformed cell line human CVCL_7C88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02252; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103745 CVCL_7C81 DA02242 transformed cell line human CVCL_7C81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103746 CVCL_7C82 DA02245 transformed cell line human CVCL_7C82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02245; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103747 CVCL_7C83 DA02246 transformed cell line human CVCL_7C83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103748 CVCL_7C84 DA02247 transformed cell line human CVCL_7C84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103749 CVCL_7M94 DA03401 transformed cell line human CVCL_7M94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103750 CVCL_7M95 DA03402 transformed cell line human CVCL_7M95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103751 CVCL_7M96 DA03403 transformed cell line human CVCL_7M96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103752 CVCL_7M97 DA03404 transformed cell line human CVCL_7M97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103753 CVCL_7M90 DA03397 transformed cell line human CVCL_7M90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103754 CVCL_7M91 DA03398 transformed cell line human CVCL_7M91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103755 CVCL_7M92 DA03399 transformed cell line human CVCL_7M92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103756 CVCL_7M93 DA03400 transformed cell line human CVCL_7M93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103757 CVCL_7M98 DA03405 transformed cell line human CVCL_7M98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103758 CVCL_7M99 DA03406 transformed cell line human CVCL_7M99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103759 CVCL_7M72 DA03374 transformed cell line human CVCL_7M72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103760 CVCL_7M73 DA03375 transformed cell line human CVCL_7M73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103761 CVCL_7M74 DA03376 transformed cell line human CVCL_7M74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103762 CVCL_7M75 DA03378 transformed cell line human CVCL_7M75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103763 CVCL_7M70 DA03372 transformed cell line human CVCL_7M70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103764 CVCL_7M71 DA03373 transformed cell line human CVCL_7M71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103765 CVCL_7M76 DA03379 transformed cell line human CVCL_7M76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103766 CVCL_7M77 DA03380 transformed cell line human CVCL_7M77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103767 CVCL_7M78 DA03381 transformed cell line human CVCL_7M78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103768 CVCL_7M79 DA03382 transformed cell line human CVCL_7M79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103769 CVCL_7M83 DA03389 transformed cell line human CVCL_7M83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103770 CVCL_7M84 DA03390 transformed cell line human CVCL_7M84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103771 CVCL_7M85 DA03392 transformed cell line human CVCL_7M85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103772 CVCL_7M86 DA03393 transformed cell line human CVCL_7M86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103773 CVCL_7M80 DA03385 transformed cell line human CVCL_7M80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103774 CVCL_7M81 DA03386 transformed cell line human CVCL_7M81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103775 CVCL_7M82 DA03387 transformed cell line human CVCL_7M82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103776 CVCL_7M87 DA03394 transformed cell line human CVCL_7M87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103777 CVCL_7M88 DA03395 transformed cell line human CVCL_7M88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103778 CVCL_7M89 DA03396 transformed cell line human CVCL_7M89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103779 CVCL_7M50 DA03351 transformed cell line human CVCL_7M50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103780 CVCL_7M51 DA03352 transformed cell line human CVCL_7M51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103781 CVCL_7M52 DA03354 transformed cell line human CVCL_7M52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103782 CVCL_7M53 DA03355 transformed cell line human CVCL_7M53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103783 CVCL_7M58 DA03360 transformed cell line human CVCL_7M58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103784 CVCL_7M59 DA03361 transformed cell line human CVCL_7M59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103785 CVCL_7M54 DA03356 transformed cell line human CVCL_7M54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103786 CVCL_7M55 DA03357 transformed cell line human CVCL_7M55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103787 CVCL_7M56 DA03358 transformed cell line human CVCL_7M56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103788 CVCL_7M57 DA03359 transformed cell line human CVCL_7M57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103789 CVCL_7M61 DA03363 transformed cell line human CVCL_7M61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103790 CVCL_7M62 DA03364 transformed cell line human CVCL_7M62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103791 CVCL_7M63 DA03365 transformed cell line human CVCL_7M63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103792 CVCL_7M64 DA03366 transformed cell line human CVCL_7M64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103793 CVCL_7M60 DA03362 transformed cell line human CVCL_7M60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103794 CVCL_7M69 DA03371 transformed cell line human CVCL_7M69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103795 CVCL_7M65 DA03367 transformed cell line human CVCL_7M65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103796 CVCL_7M66 DA03368 transformed cell line human CVCL_7M66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103797 CVCL_7M67 DA03369 transformed cell line human CVCL_7M67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103798 CVCL_7M68 DA03370 transformed cell line human CVCL_7M68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103799 CVCL_7M30 DA03330 transformed cell line human CVCL_7M30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103800 CVCL_7M31 DA03331 transformed cell line human CVCL_7M31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103801 CVCL_7M36 DA03336 transformed cell line human CVCL_7M36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103802 CVCL_7M37 DA03337 transformed cell line human CVCL_7M37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103803 CVCL_7M38 DA03338 transformed cell line human CVCL_7M38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103804 CVCL_7M39 DA03339 transformed cell line human CVCL_7M39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103805 CVCL_7M32 DA03332 transformed cell line human CVCL_7M32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103806 CVCL_7M33 DA03333 transformed cell line human CVCL_7M33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103807 CVCL_7M34 DA03334 transformed cell line human CVCL_7M34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103808 CVCL_7M35 DA03335 transformed cell line human CVCL_7M35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103809 CVCL_7M29 DA03329 transformed cell line human CVCL_7M29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103810 CVCL_7M40 DA03340 transformed cell line human CVCL_7M40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103811 CVCL_7M41 DA03342 transformed cell line human CVCL_7M41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103812 CVCL_7M42 DA03343 transformed cell line human CVCL_7M42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103813 CVCL_7M47 DA03348 transformed cell line human CVCL_7M47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103814 CVCL_7M48 DA03349 transformed cell line human CVCL_7M48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103815 CVCL_7M49 DA03350 transformed cell line human CVCL_7M49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103816 CVCL_7M43 DA03344 transformed cell line human CVCL_7M43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103817 CVCL_7M44 DA03345 transformed cell line human CVCL_7M44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103818 CVCL_7M45 DA03346 transformed cell line human CVCL_7M45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103819 CVCL_7M46 DA03347 transformed cell line human CVCL_7M46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103820 CVCL_IA45 ND02873 transformed cell line human CVCL_IA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103821 CVCL_IA46 ND02874 transformed cell line human CVCL_IA46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103822 CVCL_IA47 ND02895 transformed cell line human CVCL_IA47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103823 CVCL_IA48 ND02896 transformed cell line human CVCL_IA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103824 CVCL_IA41 ND02842 transformed cell line human CVCL_IA41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103825 CVCL_IA42 ND02851 transformed cell line human CVCL_IA42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103826 CVCL_IA43 ND02871 transformed cell line human CVCL_IA43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103827 CVCL_IA44 ND02872 transformed cell line human CVCL_IA44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103828 CVCL_IA40 ND02823 transformed cell line human CVCL_IA40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103829 CVCL_IA38 ND02818 transformed cell line human CVCL_IA38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103830 CVCL_IA39 ND02822 transformed cell line human CVCL_IA39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103831 CVCL_IA56 ND03054 transformed cell line human CVCL_IA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103832 CVCL_IA57 ND03073 transformed cell line human CVCL_IA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103833 CVCL_IA58 ND03086 transformed cell line human CVCL_IA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103834 CVCL_IA59 ND03087 transformed cell line human CVCL_IA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103835 CVCL_IA52 ND02983 transformed cell line human CVCL_IA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103836 CVCL_IA53 ND03048 transformed cell line human CVCL_IA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103837 CVCL_IA54 ND03050 transformed cell line human CVCL_IA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103838 CVCL_IA55 ND03052 transformed cell line human CVCL_IA55 CL:0000010 Population: Caucasian; Welsh; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103839 CVCL_IA50 ND02917 transformed cell line human CVCL_IA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103840 CVCL_IA51 ND02939 transformed cell line human CVCL_IA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103841 CVCL_IA49 ND02897 transformed cell line human CVCL_IA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103842 CVCL_IA23 ND02617 transformed cell line human CVCL_IA23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103843 CVCL_IA24 ND02672 transformed cell line human CVCL_IA24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103844 CVCL_IA25 ND02748 transformed cell line human CVCL_IA25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103845 CVCL_IA26 ND02749 transformed cell line human CVCL_IA26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103846 CVCL_IA20 ND02545 transformed cell line human CVCL_IA20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103847 CVCL_IA21 ND02546 transformed cell line human CVCL_IA21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103848 CVCL_IA22 ND02606 transformed cell line human CVCL_IA22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103849 CVCL_IA16 ND02517 transformed cell line human CVCL_IA16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103850 CVCL_IA17 ND02518 transformed cell line human CVCL_IA17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103851 CVCL_IA18 ND02519 transformed cell line human CVCL_IA18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103852 CVCL_IA19 ND02529 transformed cell line human CVCL_IA19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103853 CVCL_IA34 ND02803 transformed cell line human CVCL_IA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103854 CVCL_IA35 ND02804 transformed cell line human CVCL_IA35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103855 CVCL_IA36 ND02805 transformed cell line human CVCL_IA36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103856 CVCL_IA37 ND02814 transformed cell line human CVCL_IA37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103857 CVCL_IA30 ND02784 transformed cell line human CVCL_IA30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103858 CVCL_IA31 ND02787 transformed cell line human CVCL_IA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103859 CVCL_IA32 ND02788 transformed cell line human CVCL_IA32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103860 CVCL_IA33 ND02799 transformed cell line human CVCL_IA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103861 CVCL_IA27 ND02773 transformed cell line human CVCL_IA27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103862 CVCL_IA28 ND02774 transformed cell line human CVCL_IA28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103863 CVCL_IA29 ND02778 transformed cell line human CVCL_IA29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103864 CVCL_IA01 ND02443 transformed cell line human CVCL_IA01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103865 CVCL_IA02 ND02458 transformed cell line human CVCL_IA02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103866 CVCL_IA03 ND02461 transformed cell line human CVCL_IA03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103867 CVCL_IA04 ND02462 transformed cell line human CVCL_IA04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103868 CVCL_IA00 ND02440 transformed cell line human CVCL_IA00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103869 CVCL_IA12 ND02493 transformed cell line human CVCL_IA12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103870 CVCL_IA13 ND02495 transformed cell line human CVCL_IA13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103871 CVCL_IA14 ND02499 transformed cell line human CVCL_IA14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103872 CVCL_IA15 ND02507 transformed cell line human CVCL_IA15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103873 CVCL_IA10 ND02488 transformed cell line human CVCL_IA10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103874 CVCL_IA11 ND02489 transformed cell line human CVCL_IA11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21103875 CVCL_IA09 ND02487 transformed cell line human CVCL_IA09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103876 CVCL_IA05 ND02463 transformed cell line human CVCL_IA05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103877 CVCL_IA06 ND02464 transformed cell line human CVCL_IA06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103878 CVCL_IA07 ND02465 transformed cell line human CVCL_IA07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103879 CVCL_IA08 ND02481 transformed cell line human CVCL_IA08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21103880 CVCL_QY40 A-204/DasR cancer cell line human CVCL_QY40 CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gln182Alafs*28 (c.543_544delTC); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825) Omics: Deep phosphoproteome analysis. Female 21103881 CVCL_QY41 A-204/PazR cancer cell line human CVCL_QY41 CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gln182Alafs*28 (c.543_544delTC); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:71219; Pazopanib (Votrient) Omics: Deep phosphoproteome analysis. Female 21103882 CVCL_QY42 INT-MEL-14 cancer cell line human CVCL_QY42 CL:0000010 Derived from metastatic site: Lymph node. Male 21103883 CVCL_QY43 INT-MEL-18 cancer cell line human CVCL_QY43 CL:0000010 Derived from metastatic site: Lymph node. Male 21103884 CVCL_QY44 INT-MEL-22 cancer cell line human CVCL_QY44 CL:0000010 Derived from metastatic site: Lymph node. Female 21103885 CVCL_QY45 INT-MEL-25 cancer cell line human CVCL_QY45 CL:0000010 Derived from metastatic site: Lymph node. Female 21103886 CVCL_QY46 INT-MEL-26 cancer cell line human CVCL_QY46 CL:0000010 Derived from metastatic site: Lymph node. Male 21103887 CVCL_QY47 INT-MEL-27 cancer cell line human CVCL_QY47 CL:0000010 Derived from metastatic site: Lymph node. Male 21103888 CVCL_QY48 INT-MEL-28 cancer cell line human CVCL_QY48 CL:0000010 Derived from metastatic site: Lymph node. Male 21103889 CVCL_QY49 INT-MEL-31 cancer cell line human CVCL_QY49 CL:0000010 Derived from metastatic site: Lymph node. Female 21103890 CVCL_QY30 IBMS-iPSC-029-01 induced pluripotent stem cell human CVCL_QY30 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 2719; DDC; Simple; c.714+4A>T (IVS6+4A>T) (IVS6DS,A-T,+4); ClinVar=VCV000864024; Zygosity=Homozygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Female 21103891 CVCL_QY31 IBMS-iPSC-030-06 induced pluripotent stem cell human CVCL_QY31 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7470; MT-RNR1; Simple; m.1555A>G; ClinVar=VCV000009628; Zygosity=Unspecified (PubMed=29174977) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103892 CVCL_QY32 IBMS-iPSC-031-05 induced pluripotent stem cell human CVCL_QY32 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Unspecified (PubMed=29288969) Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21103893 CVCL_QY33 IBMS-iPSC-033-02 induced pluripotent stem cell human CVCL_QY33 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Ser182Gly (c.544A>G); ClinVar=VCV000430337; Zygosity=Unspecified (PubMed=29414417); Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Leu223Glufs*76 (c.667_679delCTGGAGCGGGACG); Zygosity=Unspecified (PubMed=29414417) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103894 CVCL_QY34 LSEC line undefined cell line type human CVCL_QY34 CL:0000010 Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Unspecified 21103895 CVCL_QY35 Karpas-1106A cancer cell line human CVCL_QY35 CL:0000010 Derived from sampling site: Ascites. Female 21103896 CVCL_QY36 ONHL-1 cancer cell line human CVCL_QY36 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 25 hours (PubMed=2249898) 21103897 CVCL_QY37 ONS-12/ACNU cancer cell line human CVCL_QY37 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:75270; Nimustine (ACNU); Derived from sampling site: Brain. Female 21103898 CVCL_QY38 WAe001-A-3 embryonic stem cell human CVCL_QY38 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7391; MSX1. Male 21103899 CVCL_QY39 MKN45/F2R cancer cell line human CVCL_QY39 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Liver. Female 21103900 CVCL_QY20 ESC 98B11 embryonic stem cell house mouse CVCL_QY20 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103901 CVCL_QY21 ESC 98B27 embryonic stem cell house mouse CVCL_QY21 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103902 CVCL_QY22 ESC 98B28 embryonic stem cell house mouse CVCL_QY22 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103903 CVCL_QY23 ESC 98B34 embryonic stem cell house mouse CVCL_QY23 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103904 CVCL_QY24 ESC 98B37 embryonic stem cell house mouse CVCL_QY24 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103905 CVCL_QY25 NHRI-iPSC-001-01 induced pluripotent stem cell human CVCL_QY25 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21103906 CVCL_QY26 NHRI-iPSC-005-01 induced pluripotent stem cell human CVCL_QY26 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21103907 CVCL_QY27 IBMS-iPSC-018-09 induced pluripotent stem cell human CVCL_QY27 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2385Arg (c.7153G>A); ClinVar=VCV000001943; Zygosity=Heterozygous (PubMed=29414410) Population: Asian; Derived from sampling site: Peripheral blood. Male 21103908 CVCL_QY28 IBMS-iPSC-020-01 induced pluripotent stem cell human CVCL_QY28 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2385Arg (c.7153G>A); ClinVar=VCV000001943; Zygosity=Heterozygous (PubMed=29414410) Population: Asian; Derived from sampling site: Peripheral blood. Male 21103909 CVCL_QY29 IBMS-iPSC-025-03 induced pluripotent stem cell human CVCL_QY29 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; c.640-801G>A (c.639+919G>A) (IVS4+919G>A); ClinVar=VCV000010768; Zygosity=Hemizygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21103910 CVCL_QY10 NTUH-iPSC-010-06 induced pluripotent stem cell human CVCL_QY10 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21103911 CVCL_QY11 TVGH-iPSC-003-12 induced pluripotent stem cell human CVCL_QY11 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21103912 CVCL_QY12 TVGH-iPSC-004-13 induced pluripotent stem cell human CVCL_QY12 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21103913 CVCL_QY13 TVGH-iPSC-005-05 induced pluripotent stem cell human CVCL_QY13 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21103914 CVCL_QY14 TVGH-iPSC-012-04 induced pluripotent stem cell human CVCL_QY14 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Glu119Glnfs*3 (c.346_355dupGGCAAGGACG); Zygosity=Unspecified (PubMed=29660606) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103915 CVCL_QY15 TVGH-iPSC-013-05 induced pluripotent stem cell human CVCL_QY15 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 10457; RS1; Simple; p.Trp163Ter (c.488G>A); ClinVar=VCV001687470; Zygosity=Hemizygous (PubMed=29674172) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21103916 CVCL_QY16 TVGH-iPSC-014-05 induced pluripotent stem cell human CVCL_QY16 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21103917 CVCL_QY17 TVGH-iPSC-020-10 induced pluripotent stem cell human CVCL_QY17 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21103918 CVCL_QY18 TVGH-iPSC-021-10 induced pluripotent stem cell human CVCL_QY18 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21103919 CVCL_QY19 ESC 98B02 embryonic stem cell house mouse CVCL_QY19 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21103920 CVCL_QY00 FMC-Hu-1-B cancer cell line human CVCL_QY00 CL:0000010 Derived from sampling site: Abdominal cavity. Male Characteristics: Produces IgM Doubling time: 36 hours (PubMed=3872973) 21103921 CVCL_QY01 HF-1 [Human foreskin] transformed cell line human CVCL_QY01 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Discontinued: ATCC; CRL-2867; true Male 21103922 CVCL_QY02 HT58 [Human lymphoma] cancer cell line human CVCL_QY02 CL:0000010 Derived from sampling site: Intestine. Male 21103923 CVCL_QY03 KAL-1 cancer cell line human CVCL_QY03 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: ~24 hours (PubMed=1913659) 21103924 CVCL_QY04 CQ4-iPSC clone 14 induced pluripotent stem cell human CVCL_QY04 From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 19693; COQ4; Simple; p.Glu161Asp (c.483G>C); ClinVar=VCV000380493; Zygosity=Heterozygous (PubMed=28465093) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21103925 CVCL_QY05 IBMS-iPSC-013-06 induced pluripotent stem cell human CVCL_QY05 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Gln533Ter (c.1597C>T); Zygosity=Heterozygous (PubMed=29121521) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21103926 CVCL_QY06 IBMS-iPSC-019-11 induced pluripotent stem cell human CVCL_QY06 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2012Thr (c.6035T>C); ClinVar=VCV000039218; Zygosity=Heterozygous (PubMed=29127874) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103927 CVCL_QY07 IBMS-iPSC-014-05 induced pluripotent stem cell human CVCL_QY07 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Simple; p.Arg803Ter (c.2407C>T); ClinVar=VCV000618321; Zygosity=Heterozygous (PubMed=29055226) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103928 CVCL_QY08 NTUH-iPSC-004-06 induced pluripotent stem cell human CVCL_QY08 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21103929 CVCL_QY09 NTUH-iPSC-007-03 induced pluripotent stem cell human CVCL_QY09 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21103930 CVCL_7M14 DA03313 transformed cell line human CVCL_7M14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103931 CVCL_7M15 DA03314 transformed cell line human CVCL_7M15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103932 CVCL_7M16 DA03315 transformed cell line human CVCL_7M16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103933 CVCL_7M17 DA03316 transformed cell line human CVCL_7M17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103934 CVCL_7M10 DA03309 transformed cell line human CVCL_7M10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103935 CVCL_7M11 DA03310 transformed cell line human CVCL_7M11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103936 CVCL_7M12 DA03311 transformed cell line human CVCL_7M12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103937 CVCL_7M13 DA03312 transformed cell line human CVCL_7M13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103938 CVCL_7M07 DA03306 transformed cell line human CVCL_7M07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103939 CVCL_7M08 DA03307 transformed cell line human CVCL_7M08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103940 CVCL_7M09 DA03308 transformed cell line human CVCL_7M09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103941 CVCL_7M20 DA03320 transformed cell line human CVCL_7M20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103942 CVCL_7M25 DA03325 transformed cell line human CVCL_7M25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103943 CVCL_7M26 DA03326 transformed cell line human CVCL_7M26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03326; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103944 CVCL_7M27 DA03327 transformed cell line human CVCL_7M27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03327; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103945 CVCL_7M28 DA03328 transformed cell line human CVCL_7M28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103946 CVCL_7M21 DA03321 transformed cell line human CVCL_7M21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103947 CVCL_7M22 DA03322 transformed cell line human CVCL_7M22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103948 CVCL_7M23 DA03323 transformed cell line human CVCL_7M23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103949 CVCL_7M24 DA03324 transformed cell line human CVCL_7M24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103950 CVCL_7M18 DA03317 transformed cell line human CVCL_7M18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103951 CVCL_7M19 DA03318 transformed cell line human CVCL_7M19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103952 CVCL_QY90 UM159-1 PGD embryonic stem cell human CVCL_QY90 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0393. 21103953 CVCL_QY91 UM160-3 embryonic stem cell human CVCL_QY91 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0395. 21103954 CVCL_QY92 UM161-1 PGD embryonic stem cell human CVCL_QY92 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0394. 21103955 CVCL_QY93 PW cancer cell line human CVCL_QY93 From: Giaccia A.J.; Stanford University; Stanford; USA. CL:0000010 21103956 CVCL_QY94 EPN-1 induced pluripotent stem cell human CVCL_QY94 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00318 21103957 CVCL_QY95 NIH 3T3 Atg5 KO spontaneously immortalized cell line house mouse CVCL_QY95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1277186; Atg5 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21103958 CVCL_7M03 DA03302 transformed cell line human CVCL_7M03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103959 CVCL_QY96 YUSEVi005-A induced pluripotent stem cell human CVCL_QY96 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Gly512Ser (c.1534G>A); ClinVar=VCV000585301; Zygosity=Hemizygous (PubMed=29065337) Population: Korean; Derived from sampling site: Cell type=Fibroblast. Male 21103960 CVCL_7M04 DA03303 transformed cell line human CVCL_7M04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103961 CVCL_QY97 YUSEVi006-A induced pluripotent stem cell human CVCL_QY97 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Ile657del (c.1968_1970delCAT); Zygosity=Hemizygous (PubMed=29065337) Population: Korean; Derived from sampling site: Cell type=Fibroblast. Male 21103962 CVCL_7M05 DA03304 transformed cell line human CVCL_7M05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103963 CVCL_QY98 KURNDi005-A induced pluripotent stem cell human CVCL_QY98 From: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg554His (c.1661G>A); ClinVar=VCV000166625; Zygosity=Hemizygous (PubMed=29128817) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21103964 CVCL_7M06 DA03305 transformed cell line human CVCL_7M06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103965 CVCL_QY99 WG1302 finite cell line human CVCL_QY99 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21103966 CVCL_7M00 DA03299 transformed cell line human CVCL_7M00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103967 CVCL_7M01 DA03300 transformed cell line human CVCL_7M01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103968 CVCL_7M02 DA03301 transformed cell line human CVCL_7M02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21103969 CVCL_QY80 ASUi001-A induced pluripotent stem cell human CVCL_QY80 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=29034886) Derived from sampling site: Peripheral blood. Female 21103970 CVCL_QY81 ASUi002-A induced pluripotent stem cell human CVCL_QY81 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=29034886) Derived from sampling site: Peripheral blood. Female 21103971 CVCL_QY82 SANi001-A induced pluripotent stem cell human CVCL_QY82 From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood Cell type=Megakaryoblast.. Male 21103972 CVCL_QY83 SANi002-A induced pluripotent stem cell human CVCL_QY83 From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood Cell type=Megakaryoblast.. Female 21103973 CVCL_QY84 SANi005-A induced pluripotent stem cell human CVCL_QY84 From: Sanquin; Amsterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4238; GFI1B; Simple; p.Gln287Ter (c.859C>T); ClinVar=VCV000102428; Zygosity=Heterozygous (PubMed=29055225) Derived from sampling site: Peripheral blood. Female 21103974 CVCL_QY85 NMSUNLi001-A induced pluripotent stem cell human CVCL_QY85 From: CEDOC, NOVA Medical School, Universidade Nova De Lisboa; Lisbon; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 26780; DAND5; Simple; p.Arg152His (c.455G>A); Zygosity=Heterozygous (PubMed=29136563) Population: Caucasian; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21103975 CVCL_QY86 SANi003-A induced pluripotent stem cell human CVCL_QY86 From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male Caution: Indicated in PubMed=29040913 to originate from a female donor, but the karyotype is X,Y and the amelogenin STR locus is also X,Y 21103976 CVCL_QY87 SANi003-B induced pluripotent stem cell human CVCL_QY87 From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21103977 CVCL_QY88 UM150-4 PGD embryonic stem cell human CVCL_QY88 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM150-1 PGD (Cellosaurus=CVCL_HF76) and UM150-3 PGD (Cellosaurus=CVCL_IS75). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0391 21103978 CVCL_QY89 UM152-1 PGS embryonic stem cell human CVCL_QY89 From: University of Michigan; Ann Arbor; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0392. 21103979 CVCL_QY70 INT-MEL-6 cancer cell line human CVCL_QY70 CL:0000010 Derived from metastatic site: Lymph node. Female 21103980 CVCL_QY71 INT-MEL-7 cancer cell line human CVCL_QY71 CL:0000010 Derived from metastatic site: Lymph node. Male 21103981 CVCL_QY72 INT-MEL-41 cancer cell line human CVCL_QY72 CL:0000010 Derived from metastatic site: Lymph node. Female 21103982 CVCL_QY73 INT-MEL-45 cancer cell line human CVCL_QY73 CL:0000010 Derived from metastatic site: Lymph node. Female 21103983 CVCL_QY74 IDVi002-A induced pluripotent stem cell human CVCL_QY74 From: Institut de la Vision; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Cys247Ter (c.709_734dup); Zygosity=Heterozygous (PubMed=29040912) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21103984 CVCL_QY75 WAe001-A-4 embryonic stem cell human CVCL_QY75 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1. Male 21103985 CVCL_QY76 WAe001-A-5 embryonic stem cell human CVCL_QY76 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1. Male 21103986 CVCL_QY77 WAe001-A-7 embryonic stem cell human CVCL_QY77 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31501; MIR122. Male 21103987 CVCL_QY78 WAe001-A-8 embryonic stem cell human CVCL_QY78 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31501; MIR122. Male 21103988 CVCL_QY79 WAe001-A-9 embryonic stem cell human CVCL_QY79 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31501; MIR122. Male 21103989 CVCL_QY60 INT-MEL-57 cancer cell line human CVCL_QY60 CL:0000010 Derived from metastatic site: Lymph node. Male 21103990 CVCL_QY61 INT-MEL-33 cancer cell line human CVCL_QY61 CL:0000010 Derived from metastatic site: Lymph node. Male 21103991 CVCL_QY62 INT-MEL-38/1 cancer cell line human CVCL_QY62 CL:0000010 Derived from metastatic site: Lymph node. Male 21103992 CVCL_QY63 INT-MEL-38/2 cancer cell line human CVCL_QY63 CL:0000010 Derived from metastatic site: Lymph node. Male 21103993 CVCL_QY64 INT-MEL-46 cancer cell line human CVCL_QY64 CL:0000010 Derived from metastatic site: Lymph node. Male 21103994 CVCL_QY65 INT-MEL-47/1 cancer cell line human CVCL_QY65 CL:0000010 Derived from metastatic site: Lymph node. Female 21103995 CVCL_QY66 INT-MEL-47/2 cancer cell line human CVCL_QY66 CL:0000010 Derived from metastatic site: Hypodermis. Female 21103996 CVCL_QY67 INT-MEL-47/3 cancer cell line human CVCL_QY67 CL:0000010 Derived from metastatic site: Hypodermis. Female 21103997 CVCL_QY68 INT-MEL-48/1 cancer cell line human CVCL_QY68 CL:0000010 Derived from metastatic site: Lymph node. Male 21103998 CVCL_QY69 INT-MEL-48/2 cancer cell line human CVCL_QY69 CL:0000010 Derived from metastatic site: Hypodermis. Male 21103999 CVCL_QY50 INT-MEL-32 cancer cell line human CVCL_QY50 CL:0000010 Derived from metastatic site: Lymph node. Female 21104000 CVCL_QY51 INT-MEL-40 cancer cell line human CVCL_QY51 CL:0000010 Derived from metastatic site: Lymph node. Female 21104001 CVCL_QY52 INT-MEL-42 cancer cell line human CVCL_QY52 CL:0000010 Derived from metastatic site: Lymph node. Female 21104002 CVCL_QY53 INT-MEL-44 cancer cell line human CVCL_QY53 CL:0000010 Derived from metastatic site: Lymph node. Male 21104003 CVCL_QY54 INT-MEL-49 cancer cell line human CVCL_QY54 CL:0000010 Derived from metastatic site: Lymph node. Female 21104004 CVCL_QY55 INT-MEL-51 cancer cell line human CVCL_QY55 CL:0000010 Derived from metastatic site: Lymph node. Female 21104005 CVCL_QY56 INT-MEL-53 cancer cell line human CVCL_QY56 CL:0000010 Female 21104006 CVCL_QY57 INT-MEL-54 cancer cell line human CVCL_QY57 CL:0000010 Derived from metastatic site: Lymph node. Female 21104007 CVCL_QY58 INT-MEL-55 cancer cell line human CVCL_QY58 CL:0000010 Derived from metastatic site: Lymph node. Female 21104008 CVCL_QY59 INT-MEL-56 cancer cell line human CVCL_QY59 CL:0000010 Derived from metastatic site: Lymph node. Male 21104009 CVCL_7N93 DA03512 transformed cell line human CVCL_7N93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104010 CVCL_7N94 DA03513 transformed cell line human CVCL_7N94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104011 CVCL_7N95 DA03514 transformed cell line human CVCL_7N95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104012 CVCL_7N96 DA03515 transformed cell line human CVCL_7N96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104013 CVCL_7N90 DA03509 transformed cell line human CVCL_7N90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104014 CVCL_7N91 DA03510 transformed cell line human CVCL_7N91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104015 CVCL_7N92 DA03511 transformed cell line human CVCL_7N92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104016 CVCL_7N97 DA03516 transformed cell line human CVCL_7N97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104017 CVCL_7N98 DA03517 transformed cell line human CVCL_7N98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104018 CVCL_7N99 DA03518 transformed cell line human CVCL_7N99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104019 CVCL_7N71 DA03487 transformed cell line human CVCL_7N71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104020 CVCL_7N72 DA03488 transformed cell line human CVCL_7N72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104021 CVCL_7N73 DA03489 transformed cell line human CVCL_7N73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104022 CVCL_7N74 DA03490 transformed cell line human CVCL_7N74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104023 CVCL_7N70 DA03486 transformed cell line human CVCL_7N70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104024 CVCL_7N79 DA03495 transformed cell line human CVCL_7N79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104025 CVCL_7N75 DA03491 transformed cell line human CVCL_7N75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104026 CVCL_7N76 DA03492 transformed cell line human CVCL_7N76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104027 CVCL_7N77 DA03493 transformed cell line human CVCL_7N77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104028 CVCL_7N78 DA03494 transformed cell line human CVCL_7N78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104029 CVCL_7N82 DA03499 transformed cell line human CVCL_7N82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104030 CVCL_7N83 DA03501 transformed cell line human CVCL_7N83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104031 CVCL_7N84 DA03502 transformed cell line human CVCL_7N84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104032 CVCL_7N85 DA03503 transformed cell line human CVCL_7N85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104033 CVCL_7N80 DA03496 transformed cell line human CVCL_7N80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104034 CVCL_7N81 DA03498 transformed cell line human CVCL_7N81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104035 CVCL_7N86 DA03505 transformed cell line human CVCL_7N86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104036 CVCL_7N87 DA03506 transformed cell line human CVCL_7N87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104037 CVCL_7N88 DA03507 transformed cell line human CVCL_7N88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104038 CVCL_7N89 DA03508 transformed cell line human CVCL_7N89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104039 CVCL_7N50 DA03464 transformed cell line human CVCL_7N50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104040 CVCL_7N51 DA03465 transformed cell line human CVCL_7N51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104041 CVCL_7N52 DA03466 transformed cell line human CVCL_7N52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104042 CVCL_7N57 DA03471 transformed cell line human CVCL_7N57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104043 CVCL_7N58 DA03472 transformed cell line human CVCL_7N58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104044 CVCL_7N59 DA03473 transformed cell line human CVCL_7N59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104045 CVCL_7N53 DA03467 transformed cell line human CVCL_7N53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104046 CVCL_7N54 DA03468 transformed cell line human CVCL_7N54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104047 CVCL_7N55 DA03469 transformed cell line human CVCL_7N55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104048 CVCL_7N56 DA03470 transformed cell line human CVCL_7N56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104049 CVCL_7N60 DA03474 transformed cell line human CVCL_7N60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104050 CVCL_7N61 DA03475 transformed cell line human CVCL_7N61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104051 CVCL_7N62 DA03476 transformed cell line human CVCL_7N62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104052 CVCL_7N63 DA03477 transformed cell line human CVCL_7N63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104053 CVCL_7N68 DA03484 transformed cell line human CVCL_7N68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104054 CVCL_7N69 DA03485 transformed cell line human CVCL_7N69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104055 CVCL_7N64 DA03478 transformed cell line human CVCL_7N64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104056 CVCL_7N65 DA03479 transformed cell line human CVCL_7N65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104057 CVCL_7N66 DA03481 transformed cell line human CVCL_7N66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104058 CVCL_7N67 DA03483 transformed cell line human CVCL_7N67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104059 CVCL_IB66 ND05380 transformed cell line human CVCL_IB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104060 CVCL_IB67 ND05381 transformed cell line human CVCL_IB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104061 CVCL_IB68 ND05382 transformed cell line human CVCL_IB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104062 CVCL_IB69 ND05383 transformed cell line human CVCL_IB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104063 CVCL_IB62 ND05376 transformed cell line human CVCL_IB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104064 CVCL_IB63 ND05377 transformed cell line human CVCL_IB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104065 CVCL_IB64 ND05378 transformed cell line human CVCL_IB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104066 CVCL_IB65 ND05379 transformed cell line human CVCL_IB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104067 CVCL_IB60 ND05354 transformed cell line human CVCL_IB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104068 CVCL_IB61 ND05374 transformed cell line human CVCL_IB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104069 CVCL_IB59 ND05353 transformed cell line human CVCL_IB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104070 CVCL_IB77 ND05487 transformed cell line human CVCL_IB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104071 CVCL_IB78 ND05503 transformed cell line human CVCL_IB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104072 CVCL_IB79 ND05506 transformed cell line human CVCL_IB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104073 CVCL_IB73 ND05453 transformed cell line human CVCL_IB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104074 CVCL_IB74 ND05454 transformed cell line human CVCL_IB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104075 CVCL_IB75 ND05474 transformed cell line human CVCL_IB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104076 CVCL_IB76 ND05486 transformed cell line human CVCL_IB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104077 CVCL_IB70 ND05384 transformed cell line human CVCL_IB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104078 CVCL_IB71 ND05398 transformed cell line human CVCL_IB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104079 CVCL_IB72 ND05452 transformed cell line human CVCL_IB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104080 CVCL_IB44 ND04999 transformed cell line human CVCL_IB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104081 CVCL_IB45 ND05000 transformed cell line human CVCL_IB45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104082 CVCL_IB46 ND05038 transformed cell line human CVCL_IB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104083 CVCL_IB47 ND05077 transformed cell line human CVCL_IB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104084 CVCL_IB40 ND04964 transformed cell line human CVCL_IB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104085 CVCL_IB41 ND04970 transformed cell line human CVCL_IB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104086 CVCL_IB42 ND04979 transformed cell line human CVCL_IB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104087 CVCL_IB43 ND04998 transformed cell line human CVCL_IB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104088 CVCL_IB37 ND04930 transformed cell line human CVCL_IB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104089 CVCL_IB38 ND04948 transformed cell line human CVCL_IB38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104090 CVCL_IB39 ND04949 transformed cell line human CVCL_IB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104091 CVCL_IB55 ND05263 transformed cell line human CVCL_IB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104092 CVCL_IB56 ND05269 transformed cell line human CVCL_IB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104093 CVCL_IB57 ND05305 transformed cell line human CVCL_IB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104094 CVCL_IB58 ND05326 transformed cell line human CVCL_IB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104095 CVCL_IB51 ND05179 transformed cell line human CVCL_IB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104096 CVCL_IB52 ND05180 transformed cell line human CVCL_IB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104097 CVCL_IB53 ND05187 transformed cell line human CVCL_IB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104098 CVCL_IB54 ND05235 transformed cell line human CVCL_IB54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104099 CVCL_IB50 ND05132 transformed cell line human CVCL_IB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104100 CVCL_IB48 ND05089 transformed cell line human CVCL_IB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104101 CVCL_IB49 ND05102 transformed cell line human CVCL_IB49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104102 CVCL_IB22 ND04412 transformed cell line human CVCL_IB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104103 CVCL_IB23 ND04470 transformed cell line human CVCL_IB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104104 CVCL_IB24 ND04488 transformed cell line human CVCL_IB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104105 CVCL_IB25 ND04526 transformed cell line human CVCL_IB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104106 CVCL_IB20 ND04389 transformed cell line human CVCL_IB20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104107 CVCL_IB21 ND04411 transformed cell line human CVCL_IB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104108 CVCL_IB19 ND04365 transformed cell line human CVCL_IB19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104109 CVCL_IB15 ND04281 transformed cell line human CVCL_IB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104110 CVCL_IB16 ND04292 transformed cell line human CVCL_IB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104111 CVCL_IB17 ND04304 transformed cell line human CVCL_IB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104112 CVCL_IB18 ND04347 transformed cell line human CVCL_IB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104113 CVCL_IB33 ND04842 transformed cell line human CVCL_IB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104114 CVCL_IB34 ND04891 transformed cell line human CVCL_IB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104115 CVCL_IB35 ND04917 transformed cell line human CVCL_IB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104116 CVCL_IB36 ND04919 transformed cell line human CVCL_IB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104117 CVCL_IB30 ND04718 transformed cell line human CVCL_IB30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104118 CVCL_IB31 ND04749 transformed cell line human CVCL_IB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104119 CVCL_IB32 ND04839 transformed cell line human CVCL_IB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104120 CVCL_IB26 ND04573 transformed cell line human CVCL_IB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104121 CVCL_IB27 ND04579 transformed cell line human CVCL_IB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104122 CVCL_IB28 ND04660 transformed cell line human CVCL_IB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104123 CVCL_IB29 ND04686 transformed cell line human CVCL_IB29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104124 CVCL_IB00 ND03878 transformed cell line human CVCL_IB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104125 CVCL_IB01 ND03881 transformed cell line human CVCL_IB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104126 CVCL_IB02 ND03917 transformed cell line human CVCL_IB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104127 CVCL_IB03 ND03953 transformed cell line human CVCL_IB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104128 CVCL_IB11 ND04202 transformed cell line human CVCL_IB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104129 CVCL_IB12 ND04222 transformed cell line human CVCL_IB12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104130 CVCL_IB13 ND04231 transformed cell line human CVCL_IB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104131 CVCL_IB14 ND04251 transformed cell line human CVCL_IB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104132 CVCL_IB10 ND04187 transformed cell line human CVCL_IB10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104133 CVCL_IB08 ND04124 transformed cell line human CVCL_IB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104134 CVCL_IB09 ND04125 transformed cell line human CVCL_IB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104135 CVCL_IB04 ND03956 transformed cell line human CVCL_IB04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104136 CVCL_IB05 ND03959 transformed cell line human CVCL_IB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104137 CVCL_IB06 ND03987 transformed cell line human CVCL_IB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104138 CVCL_IB07 ND04085 transformed cell line human CVCL_IB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104139 CVCL_QZ60 4T1-iRFP-Puro cancer cell line house mouse CVCL_QZ60 CL:0000010 Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104140 CVCL_QZ61 4T1-mNIS (monoclonal) cancer cell line house mouse CVCL_QZ61 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Transfected with the LV-mNIS vector encoding mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter 21104141 CVCL_QZ62 4T1-mNIS-Neo/eGFP-Puro cancer cell line house mouse CVCL_QZ62 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104142 CVCL_QZ63 4T1-mNIS-Neo/iRFP-Puro cancer cell line house mouse CVCL_QZ63 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104143 CVCL_QZ64 4T1-mNIS-Puro cancer cell line house mouse CVCL_QZ64 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with the LV-mNIS-PGK-Puro vector encoding for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104144 CVCL_QZ65 4T1-mNIS-Puro/Fluc-Neo cancer cell line house mouse CVCL_QZ65 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with both the LV-mNIS-PGK-Puro and LV-Fluc-P2A-Neo vectors LV-mNIS-PGK-Puro encodes for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104145 CVCL_QZ66 A20-Fluc-Puro cancer cell line house mouse CVCL_QZ66 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Breed/subspecies: BALB/cAnN. Unspecified Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104146 CVCL_QZ67 A375-eGFP-Puro cancer cell line human CVCL_QZ67 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104147 CVCL_QZ68 A375-Fluc-Neo/eGFP-Puro cancer cell line human CVCL_QZ68 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104148 CVCL_QZ69 A375-Fluc-Neo/hNIS-Puro cancer cell line human CVCL_QZ69 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-hNIS-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-hNIS-P2A-Puro encodes for human SLC5A5 linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104149 CVCL_QZ50 ROS-17 cancer cell line human CVCL_QZ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21104150 CVCL_QZ51 HEK293T shPARG transformed cell line human CVCL_QZ51 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Poly-ADP-ribosylation by proteomics Female 21104151 CVCL_QZ52 HCT 116 shPARG cancer cell line human CVCL_QZ52 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Omics: Poly-ADP-ribosylation by proteomics Male 21104152 CVCL_QZ53 RTFK-1 cancer cell line human CVCL_QZ53 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Bile duct. Male 21104153 CVCL_QZ54 RDLD-1 cancer cell line human CVCL_QZ54 CL:0000010 Sequence variation: Mutation; HGNC; 2704; DCK; Simple; p.Trp92Ter (c.276G>A); Zygosity=Unspecified (PubMed=22490663). Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar) Male 21104154 CVCL_QZ55 RMKN-28 cancer cell line human CVCL_QZ55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (PubMed=22490663) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Liver. Male Problematic cell line: Contaminated Parent cell line (MKN28) has been shown to be a MKN74 derivative. 21104155 CVCL_QZ56 4T1-eGFP-Puro cancer cell line house mouse CVCL_QZ56 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104156 CVCL_QZ57 4T1-Fluc-Neo cancer cell line house mouse CVCL_QZ57 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Neo vector encoding for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21104157 CVCL_QZ58 4T1-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_QZ58 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104158 CVCL_QZ59 4T1-Fluc-Neo/iRFP-Puro cancer cell line house mouse CVCL_QZ59 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104159 CVCL_QZ40 WG0679 finite cell line human CVCL_QZ40 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104160 CVCL_QZ41 WG0680 finite cell line human CVCL_QZ41 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104161 CVCL_QZ42 WG1836 finite cell line human CVCL_QZ42 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Leu576del (c.1726_1728delTTG); ClinVar=VCV000007028; Zygosity=Heterozygous (PubMed=9501215) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104162 CVCL_QZ43 ANBL-6 BR cancer cell line human CVCL_QZ43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21104163 CVCL_QZ44 HuCC-T1-G10 cancer cell line human CVCL_QZ44 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Ascites. Male 21104164 CVCL_QZ45 HuCC-T1-G100 cancer cell line human CVCL_QZ45 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Ascites. Male 21104165 CVCL_QZ46 YSCCC-G10 cancer cell line human CVCL_QZ46 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Ascites. Female 21104166 CVCL_QZ47 YSCCC-G100 cancer cell line human CVCL_QZ47 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Ascites. Female 21104167 CVCL_QZ48 SALT-12 cancer cell line human CVCL_QZ48 CL:0000010 Population: Japanese. Unspecified 21104168 CVCL_QZ49 ZZUi010-A induced pluripotent stem cell human CVCL_QZ49 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=29156377) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21104169 CVCL_QZ30 WG1575 finite cell line human CVCL_QZ30 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Cys405Arg (c.1213T>C); Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104170 CVCL_QZ31 WG1655 finite cell line human CVCL_QZ31 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104171 CVCL_QZ32 WG1663 finite cell line human CVCL_QZ32 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104172 CVCL_QZ33 WG1670 finite cell line human CVCL_QZ33 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104173 CVCL_QZ34 WG1671 finite cell line human CVCL_QZ34 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7468; MTR; Simple; c.340-166A>G; ClinVar=VCV000014281; Zygosity=Heterozygous (CelloPub=CLPUB00662); Sequence variation: Mutation; HGNC; 7468; MTR; Simple; p.Leu705Glnfs*4 (c.2114_2115delTC) (c.2112_2113delTC); ClinVar=VCV000014282; Zygosity=Heterozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104174 CVCL_QZ35 WG1892 finite cell line human CVCL_QZ35 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7468; MTR; Simple; p.Ile881del (c.2640_2642delAAT); ClinVar=VCV000014279; Zygosity=Heterozygous (PubMed=9235907); Sequence variation: Mutation; HGNC; 7468; MTR; Simple; p.Pro1173Leu (c.3518C>T); ClinVar=VCV000014278; Zygosity=Heterozygous (PubMed=9235907) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104175 CVCL_QZ36 WG2290 finite cell line human CVCL_QZ36 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7468; MTR; Simple; p.His920Asp (c.2758C>G); ClinVar=VCV000014280; Zygosity=Unspecified (PubMed=8968737; PubMed=9235907) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104176 CVCL_QZ37 WG2292 finite cell line human CVCL_QZ37 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104177 CVCL_QZ38 WG2366 finite cell line human CVCL_QZ38 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Gly487Arg (c.1459G>A); ClinVar=VCV000007030; Zygosity=Heterozygous (PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Gly554Arg (c.1660G>A); Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104178 CVCL_QZ39 WG2317 finite cell line human CVCL_QZ39 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Arg114Ter (c.340C>T); ClinVar=VCV000666994; Zygosity=Heterozygous (PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; c.903+469T>C; ClinVar=VCV000662553; Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104179 CVCL_IA89 ND03556 transformed cell line human CVCL_IA89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104180 CVCL_IA85 ND03506 transformed cell line human CVCL_IA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104181 CVCL_IA86 ND03529 transformed cell line human CVCL_IA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104182 CVCL_IA87 ND03531 transformed cell line human CVCL_IA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104183 CVCL_IA88 ND03536 transformed cell line human CVCL_IA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104184 CVCL_IA81 ND03382 transformed cell line human CVCL_IA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104185 CVCL_IA82 ND03421 transformed cell line human CVCL_IA82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104186 CVCL_IA83 ND03422 transformed cell line human CVCL_IA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104187 CVCL_QZ20 WG1205 finite cell line human CVCL_QZ20 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104188 CVCL_IA84 ND03446 transformed cell line human CVCL_IA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104189 CVCL_QZ21 WG1223 finite cell line human CVCL_QZ21 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104190 CVCL_QZ22 WG1296 finite cell line human CVCL_QZ22 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; c.903+469T>C; ClinVar=VCV000662553; Zygosity=Heterozygous (PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Val488_Lys519del (c.1557-4_1557+3del7) (c.1554del7); Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104191 CVCL_QZ23 WG1308 finite cell line human CVCL_QZ23 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104192 CVCL_QZ24 WG1352 finite cell line human CVCL_QZ24 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104193 CVCL_IA80 ND03381 transformed cell line human CVCL_IA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104194 CVCL_QZ25 WG1384 finite cell line human CVCL_QZ25 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Val54del (c.160_162delGTT); Zygosity=Heterozygous (PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Ala129Thr (c.385G>A); Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104195 CVCL_QZ26 WG1386 finite cell line human CVCL_QZ26 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104196 CVCL_QZ27 WG1401 finite cell line human CVCL_QZ27 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Leu6_Leu7del (c.16del6); Zygosity=Heterozygous (PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Leu333Val (c.997C>G); ClinVar=VCV000354359; Zygosity=Heterozygous (PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104197 CVCL_QZ28 WG1408 finite cell line human CVCL_QZ28 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104198 CVCL_QZ29 WG1505 finite cell line human CVCL_QZ29 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7468; MTR; Simple; p.Pro1173Leu (c.3518C>T); ClinVar=VCV000014278; Zygosity=Heterozygous (PubMed=9235907) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104199 CVCL_IA96 ND03622 transformed cell line human CVCL_IA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104200 CVCL_IA97 ND03719 transformed cell line human CVCL_IA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104201 CVCL_IA98 ND03755 transformed cell line human CVCL_IA98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104202 CVCL_IA99 ND03877 transformed cell line human CVCL_IA99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104203 CVCL_IA92 ND03588 transformed cell line human CVCL_IA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104204 CVCL_IA93 ND03589 transformed cell line human CVCL_IA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104205 CVCL_IA94 ND03590 transformed cell line human CVCL_IA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104206 CVCL_IA95 ND03596 transformed cell line human CVCL_IA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104207 CVCL_QZ10 WG1609 finite cell line human CVCL_QZ10 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly630Glu (c.1889G>A); ClinVar=VCV000426995; Zygosity=Homozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21104208 CVCL_QZ11 WG1611 finite cell line human CVCL_QZ11 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Heterozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 21104209 CVCL_QZ12 WG1613 finite cell line human CVCL_QZ12 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. 21104210 CVCL_IA90 ND03579 transformed cell line human CVCL_IA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104211 CVCL_QZ13 WG1618 finite cell line human CVCL_QZ13 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His265Tyr (c.791C>T); Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly426Arg (c.1276G>A); ClinVar=VCV000993879; Zygosity=Heterozygous (PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104212 CVCL_IA91 ND03580 transformed cell line human CVCL_IA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104213 CVCL_QZ14 WG1511 finite cell line human CVCL_QZ14 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.His678Arg (c.2033A>G); Zygosity=Homozygous (PubMed=7909321; PubMed=9285782) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104214 CVCL_QZ15 WG1610 finite cell line human CVCL_QZ15 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly717Val (c.2150G>T); ClinVar=VCV000001881; Zygosity=Homozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21104215 CVCL_QZ16 WG0955 finite cell line human CVCL_QZ16 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104216 CVCL_QZ17 3T3-L1 EGFP-ATA2 spontaneously immortalized cell line house mouse CVCL_QZ17 CL:0000010 Transfected with: MGI; MGI:1915010; Slc38a2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21104217 CVCL_QZ18 WG0788 finite cell line human CVCL_QZ18 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Val56Met (c.166G>A); ClinVar=VCV001176807; Zygosity=Heterozygous (PubMed=9501215; PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; c.1675del4; ClinVar=VCV000007027; Zygosity=Heterozygous (PubMed=9501215; PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104218 CVCL_QZ19 WG1146 finite cell line human CVCL_QZ19 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; p.Val56Met (c.166G>A); ClinVar=VCV001176807; Zygosity=Heterozygous (PubMed=9501215; PubMed=10484769); Sequence variation: Mutation; HGNC; 7473; MTRR; Simple; c.1675del4; ClinVar=VCV000007027; Zygosity=Heterozygous (PubMed=9501215; PubMed=10484769) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21104219 CVCL_IA67 ND03248 transformed cell line human CVCL_IA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104220 CVCL_IA68 ND03250 transformed cell line human CVCL_IA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104221 CVCL_IA69 ND03262 transformed cell line human CVCL_IA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104222 CVCL_IA63 ND03168 transformed cell line human CVCL_IA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104223 CVCL_IA64 ND03174 transformed cell line human CVCL_IA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104224 CVCL_IA65 ND03245 transformed cell line human CVCL_IA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104225 CVCL_IA66 ND03247 transformed cell line human CVCL_IA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104226 CVCL_IA60 ND03138 transformed cell line human CVCL_IA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104227 CVCL_IA61 ND03149 transformed cell line human CVCL_IA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104228 CVCL_IA62 ND03154 transformed cell line human CVCL_IA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104229 CVCL_QZ00 Karpas-160 transformed cell line human CVCL_QZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Highly cytotoxic (PubMed=300025); Characteristics: Produces lymphotoxin-alpha (PubMed=2784005) 21104230 CVCL_QZ01 Karpas-160b transformed cell line human CVCL_QZ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Produces lymphotoxin-alpha (PubMed=2784005) 21104231 CVCL_QZ02 Karpas-181 transformed cell line human CVCL_QZ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21104232 CVCL_QZ03 704A1 hybridoma house mouse CVCL_QZ03 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P22626; Human HNRNPA2B1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8302 21104233 CVCL_QZ04 PK136-SFM hybridoma house mouse CVCL_QZ04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse natural killer (NK) cells. Group: Serum/protein free medium cell line 21104234 CVCL_QZ05 H6-3C4 hybridoma house mouse CVCL_QZ05 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human carbohydrate moiety of male reproductive tract CD52. 21104235 CVCL_QZ06 WG1586 finite cell line human CVCL_QZ06 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104236 CVCL_QZ07 WG1588 finite cell line human CVCL_QZ07 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21104237 CVCL_QZ08 WG1599 finite cell line human CVCL_QZ08 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg108Gly (c.322C>G); ClinVar=VCV001499832; Zygosity=Heterozygous (PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg369His (c.1106G>A); ClinVar=VCV000203846; Zygosity=Heterozygous (PubMed=7909321; PubMed=9285782; PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21104238 CVCL_QZ09 WG1607 finite cell line human CVCL_QZ09 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Trp105Arg (c.313T>C); ClinVar=VCV000001878; Zygosity=Heterozygous (PubMed=7909321; PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Ala377Glu (c.1130C>A); ClinVar=VCV000001879; Zygosity=Heterozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21104239 CVCL_IA78 ND03341 transformed cell line human CVCL_IA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104240 CVCL_IA79 ND03359 transformed cell line human CVCL_IA79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104241 CVCL_IA74 ND03315 transformed cell line human CVCL_IA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104242 CVCL_IA75 ND03316 transformed cell line human CVCL_IA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104243 CVCL_IA76 ND03317 transformed cell line human CVCL_IA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104244 CVCL_IA77 ND03321 transformed cell line human CVCL_IA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104245 CVCL_IA70 ND03296 transformed cell line human CVCL_IA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104246 CVCL_IA71 ND03298 transformed cell line human CVCL_IA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104247 CVCL_IA72 ND03304 transformed cell line human CVCL_IA72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104248 CVCL_IA73 ND03312 transformed cell line human CVCL_IA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104249 CVCL_7N30 DA03441 transformed cell line human CVCL_7N30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104250 CVCL_7N35 DA03448 transformed cell line human CVCL_7N35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104251 CVCL_7N36 DA03449 transformed cell line human CVCL_7N36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104252 CVCL_7N37 DA03450 transformed cell line human CVCL_7N37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104253 CVCL_7N38 DA03451 transformed cell line human CVCL_7N38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104254 CVCL_7N31 DA03442 transformed cell line human CVCL_7N31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104255 CVCL_7N32 DA03444 transformed cell line human CVCL_7N32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104256 CVCL_7N33 DA03445 transformed cell line human CVCL_7N33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104257 CVCL_7N34 DA03447 transformed cell line human CVCL_7N34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104258 CVCL_7N28 DA03439 transformed cell line human CVCL_7N28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104259 CVCL_7N29 DA03440 transformed cell line human CVCL_7N29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104260 CVCL_7N40 DA03454 transformed cell line human CVCL_7N40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104261 CVCL_7N41 DA03455 transformed cell line human CVCL_7N41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104262 CVCL_7N46 DA03460 transformed cell line human CVCL_7N46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104263 CVCL_7N47 DA03461 transformed cell line human CVCL_7N47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104264 CVCL_7N48 DA03462 transformed cell line human CVCL_7N48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104265 CVCL_7N49 DA03463 transformed cell line human CVCL_7N49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104266 CVCL_7N42 DA03456 transformed cell line human CVCL_7N42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104267 CVCL_7N43 DA03457 transformed cell line human CVCL_7N43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104268 CVCL_7N44 DA03458 transformed cell line human CVCL_7N44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104269 CVCL_7N45 DA03459 transformed cell line human CVCL_7N45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104270 CVCL_7N39 DA03453 transformed cell line human CVCL_7N39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104271 CVCL_7N13 DA03420 transformed cell line human CVCL_7N13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104272 CVCL_7N14 DA03421 transformed cell line human CVCL_7N14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104273 CVCL_7N15 DA03422 transformed cell line human CVCL_7N15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104274 CVCL_7N16 DA03423 transformed cell line human CVCL_7N16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104275 CVCL_7N10 DA03417 transformed cell line human CVCL_7N10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104276 CVCL_7N11 DA03418 transformed cell line human CVCL_7N11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104277 CVCL_7N12 DA03419 transformed cell line human CVCL_7N12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104278 CVCL_7N06 DA03413 transformed cell line human CVCL_7N06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104279 CVCL_7N07 DA03414 transformed cell line human CVCL_7N07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104280 CVCL_7N08 DA03415 transformed cell line human CVCL_7N08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104281 CVCL_7N09 DA03416 transformed cell line human CVCL_7N09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104282 CVCL_7N24 DA03431 transformed cell line human CVCL_7N24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104283 CVCL_7N25 DA03436 transformed cell line human CVCL_7N25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104284 CVCL_7N26 DA03437 transformed cell line human CVCL_7N26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104285 CVCL_7N27 DA03438 transformed cell line human CVCL_7N27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104286 CVCL_7N20 DA03427 transformed cell line human CVCL_7N20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104287 CVCL_7N21 DA03428 transformed cell line human CVCL_7N21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104288 CVCL_7N22 DA03429 transformed cell line human CVCL_7N22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104289 CVCL_7N23 DA03430 transformed cell line human CVCL_7N23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104290 CVCL_7N17 DA03424 transformed cell line human CVCL_7N17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104291 CVCL_7N18 DA03425 transformed cell line human CVCL_7N18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104292 CVCL_7N19 DA03426 transformed cell line human CVCL_7N19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104293 CVCL_QZ90 B16F10-Fluc-Puro cancer cell line house mouse CVCL_QZ90 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104294 CVCL_QZ91 B16F10-iRFP-Puro cancer cell line house mouse CVCL_QZ91 CL:0000010 Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104295 CVCL_QZ92 B16F10-mNIS (monoclonal) cancer cell line house mouse CVCL_QZ92 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Transfected with the LV-mNIS vector encoding mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter 21104296 CVCL_QZ93 B16F10-mNIS-Neo/eGFP-Puro cancer cell line house mouse CVCL_QZ93 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104297 CVCL_QZ94 B16F10-mNIS-Neo/iRFP-Puro cancer cell line house mouse CVCL_QZ94 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104298 CVCL_QZ95 B16F10-mNIS-Puro cancer cell line house mouse CVCL_QZ95 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with the LV-mNIS-PGK-Puro vector encoding for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104299 CVCL_7N02 DA03409 transformed cell line human CVCL_7N02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104300 CVCL_QZ96 C1498-eGFP-Puro cancer cell line house mouse CVCL_QZ96 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Breed/subspecies: C57BL/6J. Female Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104301 CVCL_7N03 DA03410 transformed cell line human CVCL_7N03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104302 CVCL_QZ97 C1498-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_QZ97 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Breed/subspecies: C57BL/6J. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104303 CVCL_7N04 DA03411 transformed cell line human CVCL_7N04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104304 CVCL_QZ98 C1498-Fluc-Puro cancer cell line house mouse CVCL_QZ98 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Breed/subspecies: C57BL/6J. Female Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104305 CVCL_7N05 DA03412 transformed cell line human CVCL_7N05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104306 CVCL_QZ99 CT26.WT-eGFP-Puro cancer cell line house mouse CVCL_QZ99 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104307 CVCL_7N00 DA03407 transformed cell line human CVCL_7N00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104308 CVCL_7N01 DA03408 transformed cell line human CVCL_7N01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104309 CVCL_QZ80 A549-hNIS-Neo cancer cell line human CVCL_QZ80 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with the LV-hNIS-IRES-Neo vector encoding for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21104310 CVCL_QZ81 A549-hNIS-Neo/eGFP-Puro cancer cell line human CVCL_QZ81 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-eGFP-PGK-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104311 CVCL_QZ82 A549-hNIS-Neo/Fluc-Puro cancer cell line human CVCL_QZ82 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-Fluc-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104312 CVCL_QZ83 A549-hNIS-Neo/iRFP-Puro cancer cell line human CVCL_QZ83 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-iRFP-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104313 CVCL_QZ84 A549-iRFP-Neo cancer cell line human CVCL_QZ84 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Neo which encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104314 CVCL_QZ85 A549-iRFP-Puro cancer cell line human CVCL_QZ85 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104315 CVCL_QZ86 B16F10-eGFP-Puro cancer cell line house mouse CVCL_QZ86 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104316 CVCL_QZ87 B16F10-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_QZ87 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104317 CVCL_QZ88 B16F10-Fluc-Neo/iRFP-Puro cancer cell line house mouse CVCL_QZ88 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104318 CVCL_QZ89 B16F10-Fluc-Neo/mNIS-Puro cancer cell line house mouse CVCL_QZ89 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-mNIS-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-mNIS-PGK-Puro encodes for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104319 CVCL_QZ70 A375-Fluc-Puro cancer cell line human CVCL_QZ70 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104320 CVCL_QZ71 A375-hNIS-Neo/eGFP-Puro cancer cell line human CVCL_QZ71 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-eGFP-PGK-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104321 CVCL_QZ72 A375-hNIS-Puro cancer cell line human CVCL_QZ72 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with the LV-hNIS-P2A-Puro vector encoding for human SLC5A5 linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104322 CVCL_QZ73 A375-iRFP-Neo cancer cell line human CVCL_QZ73 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Neo which encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104323 CVCL_QZ74 A375-iRFP-Neo/Fluc-Puro cancer cell line human CVCL_QZ74 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with both the LV-iRFP-P2A-Neo and LV-Fluc-P2A-Puro vectors LV-iRFP-P2A-Neo encodes for iRFP linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104324 CVCL_QZ75 A375-iRFP-Neo/hNIS-Puro cancer cell line human CVCL_QZ75 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Reporter cell line, transfected with both the LV-iRFP-P2A-Neo and LV-hNIS-P2A-Puro vectors LV-iRFP-P2A-Neo encodes for iRFP linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-hNIS-P2A-Puro encodes for human SLC5A5 linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104325 CVCL_QZ76 A549-eGFP-Puro cancer cell line human CVCL_QZ76 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21104326 CVCL_QZ77 A549-Fluc-Neo/eGFP-Puro cancer cell line human CVCL_QZ77 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21104327 CVCL_QZ78 A549-Fluc-Neo/iRFP-Puro cancer cell line human CVCL_QZ78 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21104328 CVCL_QZ79 A549-Fluc-Puro cancer cell line human CVCL_QZ79 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21104329 CVCL_IC00 ND06345 transformed cell line human CVCL_IC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104330 CVCL_IC01 ND06354 transformed cell line human CVCL_IC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104331 CVCL_IC02 ND06364 transformed cell line human CVCL_IC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104332 CVCL_IC10 ND06507 transformed cell line human CVCL_IC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104333 CVCL_IC11 ND06515 transformed cell line human CVCL_IC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104334 CVCL_IC12 ND06529 transformed cell line human CVCL_IC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104335 CVCL_IC13 ND06536 transformed cell line human CVCL_IC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104336 CVCL_IC07 ND06456 transformed cell line human CVCL_IC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104337 CVCL_IC08 ND06492 transformed cell line human CVCL_IC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104338 CVCL_IC09 ND06499 transformed cell line human CVCL_IC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104339 CVCL_IC03 ND06365 transformed cell line human CVCL_IC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104340 CVCL_IC04 ND06366 transformed cell line human CVCL_IC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104341 CVCL_IC05 ND06375 transformed cell line human CVCL_IC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104342 CVCL_IC06 ND06384 transformed cell line human CVCL_IC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104343 CVCL_8092 BIC-1 cancer cell line human CVCL_8092 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00365 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=20075370). Originally thought to originate from a esophageal Barrett adenocarcinoma. 21104344 CVCL_8093 FL-18 cancer cell line human CVCL_8093 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Unspecified (PubMed=8878455) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36-48 hours (PubMed=3928551); 25.3 hours (PubMed=8847894) 21104345 CVCL_8094 FL-218 cancer cell line human CVCL_8094 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8878455) Population: Japanese; Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: 26.7 hours (PubMed=8847894) 21104346 CVCL_8095 FL-318 cancer cell line human CVCL_8095 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Leu (c.820G>C); ClinVar=VCV000376678; Zygosity=Unspecified (PubMed=8878455) Population: Japanese; Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: 45.2 hours (PubMed=8847894) 21104347 CVCL_8090 866MT cancer cell line human CVCL_8090 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.131_150+13del; Zygosity=Unspecified (PubMed=7972006); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=1855224); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Glu49Lys (c.145G>A); Zygosity=Unspecified (PubMed=1855224); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Ter (c.687T>A); Zygosity=Unspecified (PubMed=1855224). 21104348 CVCL_8091 A-2182 cancer cell line human CVCL_8091 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=1855224). Unspecified 21104349 CVCL_8096 HR-3Y1-1 transformed cell line Norway rat CVCL_8096 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21104350 CVCL_8097 HR-3Y1-2 transformed cell line Norway rat CVCL_8097 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21104351 CVCL_8098 JH-EsoAd1 cancer cell line human CVCL_8098 Genome ancestry: African=0.64%; Native American=0%; East Asian, North=1.94%; East Asian, South=0%; South Asian=0%; European, North=58.42%; European, South=38.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (PubMed=18787394; PubMed=20075370; DepMap) Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: shRNA library screening Male Doubling time: 20 hours (PubMed=18787394); 29 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104352 CVCL_8099 164T2 cancer cell line house mouse CVCL_8099 CL:0000010 Breed/subspecies: C57BL/Ka. 21104353 CVCL_8070 211-LCL-MUC1 transformed cell line human CVCL_8070 CL:0000010 Transfected with: HGNC; 7508; MUC1 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104354 CVCL_8071 141-LCL-MUC1 transformed cell line human CVCL_8071 CL:0000010 Transfected with: HGNC; 7508; MUC1 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: TKG; TKG 0499; probable Female 21104355 CVCL_8072 701-LCL transformed cell line human CVCL_8072 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104356 CVCL_8073 277-LCL transformed cell line human CVCL_8073 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104357 CVCL_8078 SK-MEL-145 cancer cell line human CVCL_8078 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104358 CVCL_8079 SK-MEL-150 cancer cell line human CVCL_8079 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104359 CVCL_8074 RPMI-6410 cancer cell line human CVCL_8074 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104360 CVCL_8075 SK-MEL-115 cancer cell line human CVCL_8075 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104361 CVCL_8076 SK-MEL-124 cancer cell line human CVCL_8076 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104362 CVCL_8077 SK-MEL-136 cancer cell line human CVCL_8077 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104363 CVCL_8081 SK-MEL-166 cancer cell line human CVCL_8081 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104364 CVCL_8082 SK-MEL-197 cancer cell line human CVCL_8082 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21104365 CVCL_8083 SK-MEL-241 cancer cell line human CVCL_8083 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104366 CVCL_8084 SK-MEL-34 cancer cell line human CVCL_8084 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21104367 CVCL_8080 SK-MEL-158 cancer cell line human CVCL_8080 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104368 CVCL_8089 2BNhTERT telomerase immortalized cell line human CVCL_8089 CL:0000010 Sequence variation: Mutation; HGNC; 25737; NHEJ1; Simple; p.Glu5Glyfs (c.11dupT) (ins11T); ClinVar=VCV000000985; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104369 CVCL_8085 SK-MEL-52 cancer cell line human CVCL_8085 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104370 CVCL_8086 SK-MEL-62 cancer cell line human CVCL_8086 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21104371 CVCL_8087 2BN finite cell line human CVCL_8087 CL:0000010 Sequence variation: Mutation; HGNC; 25737; NHEJ1; Simple; p.Glu5Glyfs (c.11dupT) (ins11T); ClinVar=VCV000000985; Zygosity=Homozygous (PubMed=19056826) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21104372 CVCL_8088 2BNneo finite cell line human CVCL_8088 CL:0000010 Sequence variation: Mutation; HGNC; 25737; NHEJ1; Simple; p.Glu5Glyfs (c.11dupT) (ins11T); ClinVar=VCV000000985; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: SV40-transformed but with a finite life span 21104373 CVCL_IC87 ND07770 transformed cell line human CVCL_IC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104374 CVCL_IC88 ND07771 transformed cell line human CVCL_IC88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104375 CVCL_IC89 ND07781 transformed cell line human CVCL_IC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104376 CVCL_IC83 ND07729 transformed cell line human CVCL_IC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104377 CVCL_IC84 ND07749 transformed cell line human CVCL_IC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104378 CVCL_IC85 ND07750 transformed cell line human CVCL_IC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104379 CVCL_IC86 ND07761 transformed cell line human CVCL_IC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104380 CVCL_IC80 ND07658 transformed cell line human CVCL_IC80 CL:0000010 Population: Latino or Hispanic; Dominican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Peripheral blood. Female 21104381 CVCL_IC81 ND07659 transformed cell line human CVCL_IC81 CL:0000010 Population: Latino or Hispanic; Dominican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Peripheral blood. Female 21104382 CVCL_IC82 ND07715 transformed cell line human CVCL_IC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104383 CVCL_IC98 ND07880 transformed cell line human CVCL_IC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104384 CVCL_IC99 ND07881 transformed cell line human CVCL_IC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104385 CVCL_IC94 ND07849 transformed cell line human CVCL_IC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104386 CVCL_IC95 ND07873 transformed cell line human CVCL_IC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104387 CVCL_IC96 ND07876 transformed cell line human CVCL_IC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104388 CVCL_IC97 ND07879 transformed cell line human CVCL_IC97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104389 CVCL_IC90 ND07784 transformed cell line human CVCL_IC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104390 CVCL_IC91 ND07803 transformed cell line human CVCL_IC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104391 CVCL_IC92 ND07823 transformed cell line human CVCL_IC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104392 CVCL_IC93 ND07839 transformed cell line human CVCL_IC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104393 CVCL_IC65 ND07294 transformed cell line human CVCL_IC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104394 CVCL_IC66 ND07295 transformed cell line human CVCL_IC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104395 CVCL_IC67 ND07330 transformed cell line human CVCL_IC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104396 CVCL_IC68 ND07332 transformed cell line human CVCL_IC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104397 CVCL_IC61 ND07251 transformed cell line human CVCL_IC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104398 CVCL_IC62 ND07253 transformed cell line human CVCL_IC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104399 CVCL_IC63 ND07279 transformed cell line human CVCL_IC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104400 CVCL_IC64 ND07280 transformed cell line human CVCL_IC64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104401 CVCL_IC60 ND07249 transformed cell line human CVCL_IC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104402 CVCL_IC58 ND07210 transformed cell line human CVCL_IC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104403 CVCL_IC59 ND07248 transformed cell line human CVCL_IC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104404 CVCL_IC76 ND07631 transformed cell line human CVCL_IC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104405 CVCL_IC77 ND07632 transformed cell line human CVCL_IC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104406 CVCL_IC78 ND07633 transformed cell line human CVCL_IC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104407 CVCL_IC79 ND07634 transformed cell line human CVCL_IC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104408 CVCL_IC72 ND07478 transformed cell line human CVCL_IC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104409 CVCL_IC73 ND07518 transformed cell line human CVCL_IC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104410 CVCL_IC74 ND07538 transformed cell line human CVCL_IC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104411 CVCL_IC75 ND07539 transformed cell line human CVCL_IC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104412 CVCL_IC70 ND07443 transformed cell line human CVCL_IC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104413 CVCL_IC71 ND07476 transformed cell line human CVCL_IC71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104414 CVCL_IC69 ND07407 transformed cell line human CVCL_IC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104415 CVCL_IC43 ND07042 transformed cell line human CVCL_IC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104416 CVCL_IC44 ND07044 transformed cell line human CVCL_IC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104417 CVCL_IC45 ND07053 transformed cell line human CVCL_IC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104418 CVCL_IC46 ND07055 transformed cell line human CVCL_IC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104419 CVCL_IC40 ND06982 transformed cell line human CVCL_IC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104420 CVCL_IC41 ND07001 transformed cell line human CVCL_IC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104421 CVCL_IC42 ND07034 transformed cell line human CVCL_IC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104422 CVCL_IC36 ND06959 transformed cell line human CVCL_IC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104423 CVCL_IC37 ND06960 transformed cell line human CVCL_IC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104424 CVCL_IC38 ND06980 transformed cell line human CVCL_IC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104425 CVCL_IC39 ND06981 transformed cell line human CVCL_IC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104426 CVCL_IC54 ND07206 transformed cell line human CVCL_IC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104427 CVCL_IC55 ND07207 transformed cell line human CVCL_IC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104428 CVCL_IC56 ND07208 transformed cell line human CVCL_IC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104429 CVCL_IC57 ND07209 transformed cell line human CVCL_IC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104430 CVCL_IC50 ND07135 transformed cell line human CVCL_IC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104431 CVCL_IC51 ND07136 transformed cell line human CVCL_IC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104432 CVCL_IC52 ND07195 transformed cell line human CVCL_IC52 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104433 CVCL_IC53 ND07205 transformed cell line human CVCL_IC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104434 CVCL_IC47 ND07127 transformed cell line human CVCL_IC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104435 CVCL_IC48 ND07133 transformed cell line human CVCL_IC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104436 CVCL_IC49 ND07134 transformed cell line human CVCL_IC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104437 CVCL_IC21 ND06599 transformed cell line human CVCL_IC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104438 CVCL_IC22 ND06630 transformed cell line human CVCL_IC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104439 CVCL_IC23 ND06632 transformed cell line human CVCL_IC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104440 CVCL_IC24 ND06645 transformed cell line human CVCL_IC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104441 CVCL_IC20 ND06584 transformed cell line human CVCL_IC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104442 CVCL_IC18 ND06580 transformed cell line human CVCL_IC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104443 CVCL_IC19 ND06581 transformed cell line human CVCL_IC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104444 CVCL_IC14 ND06537 transformed cell line human CVCL_IC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104445 CVCL_IC15 ND06557 transformed cell line human CVCL_IC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104446 CVCL_IC16 ND06578 transformed cell line human CVCL_IC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104447 CVCL_IC17 ND06579 transformed cell line human CVCL_IC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104448 CVCL_IC32 ND06869 transformed cell line human CVCL_IC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104449 CVCL_IC33 ND06870 transformed cell line human CVCL_IC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104450 CVCL_IC34 ND06957 transformed cell line human CVCL_IC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104451 CVCL_IC35 ND06958 transformed cell line human CVCL_IC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104452 CVCL_IC30 ND06779 transformed cell line human CVCL_IC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104453 CVCL_IC31 ND06801 transformed cell line human CVCL_IC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104454 CVCL_IC29 ND06778 transformed cell line human CVCL_IC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104455 CVCL_IC25 ND06647 transformed cell line human CVCL_IC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104456 CVCL_IC26 ND06664 transformed cell line human CVCL_IC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104457 CVCL_IC27 ND06685 transformed cell line human CVCL_IC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104458 CVCL_IC28 ND06694 transformed cell line human CVCL_IC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104459 CVCL_IB88 ND05877 transformed cell line human CVCL_IB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104460 CVCL_IB89 ND05903 transformed cell line human CVCL_IB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104461 CVCL_IB84 ND05683 transformed cell line human CVCL_IB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104462 CVCL_IB85 ND05743 transformed cell line human CVCL_IB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104463 CVCL_IB86 ND05768 transformed cell line human CVCL_IB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104464 CVCL_IB87 ND05815 transformed cell line human CVCL_IB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104465 CVCL_IB80 ND05530 transformed cell line human CVCL_IB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104466 CVCL_IB81 ND05561 transformed cell line human CVCL_IB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104467 CVCL_IB82 ND05614 transformed cell line human CVCL_IB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104468 CVCL_IB83 ND05659 transformed cell line human CVCL_IB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104469 CVCL_IB99 ND06240 transformed cell line human CVCL_IB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104470 CVCL_IB95 ND06056 transformed cell line human CVCL_IB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104471 CVCL_IB96 ND06103 transformed cell line human CVCL_IB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104472 CVCL_IB97 ND06104 transformed cell line human CVCL_IB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104473 CVCL_IB98 ND06212 transformed cell line human CVCL_IB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104474 CVCL_IB91 ND05955 transformed cell line human CVCL_IB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104475 CVCL_IB92 ND06048 transformed cell line human CVCL_IB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104476 CVCL_IB93 ND06053 transformed cell line human CVCL_IB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104477 CVCL_IB94 ND06055 transformed cell line human CVCL_IB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104478 CVCL_IB90 ND05954 transformed cell line human CVCL_IB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104479 CVCL_8050 397-mel cancer cell line human CVCL_8050 HLA typing: A*01,25 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Skin. Unspecified 21104480 CVCL_8051 526-mel cancer cell line human CVCL_8051 HLA typing: A*02:01,03; B*50,62; C*03 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Unspecified 21104481 CVCL_8056 697-mel cancer cell line human CVCL_8056 HLA typing: A*02,11 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Unspecified 21104482 CVCL_8057 836-mel cancer cell line human CVCL_8057 HLA typing: A*02,11 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104483 CVCL_8058 938-mel cancer cell line human CVCL_8058 HLA typing: A*01,24 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified 21104484 CVCL_8059 TF-1 D2 cancer cell line human CVCL_8059 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Growth factor independent clone of TF-1 21104485 CVCL_8052 537-mel cancer cell line human CVCL_8052 HLA typing: A*01,26 (PubMed=9670966); HLA typing: A*01:01,26:01; B*15:32,44:02; C*01:02,05:01 (PubMed=26589293) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 8598; PANK1; Zygosity=Homozygous (PubMed=36139163) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21104486 CVCL_8053 553-mel cancer cell line human CVCL_8053 HLA typing: A*02,23 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104487 CVCL_8054 624-mel cancer cell line human CVCL_8054 HLA typing: A*02:01,03:01; B*07:02,14:01; C*07:02,08:02; DPB1*15:01,20:01; DQB1*03:01:01,02:01; DRB1*04:01,07:01 (PubMed=15592718); HLA typing: A*02:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=26589293) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Trp (c.825T>G); ClinVar=VCV000485044; Zygosity=Unspecified (PubMed=23851445; PubMed=25485619) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21104488 CVCL_8055 677-mel cancer cell line human CVCL_8055 HLA typing: A*02,11 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104489 CVCL_8049 1520-mel cancer cell line human CVCL_8049 HLA typing: A*02,29 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104490 CVCL_8060 TF-1 D8 cancer cell line human CVCL_8060 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Growth factor independent clone of TF-1 21104491 CVCL_8061 MZ-MEL-19 cancer cell line human CVCL_8061 CL:0000010 Female 21104492 CVCL_8062 LT-1 [Mouse] cancer cell line house mouse CVCL_8062 CL:0000010 Transfected with: MGI; MGI:96556; Il4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=B-cell; Breed/subspecies: BALB/c. 21104493 CVCL_8067 T3M-10 cancer cell line human CVCL_8067 HLA typing: A*11:01,24:02; B*40:01,46:01; C*01:03,03:10; DQA1*01:03,05:02; DQB1*03:04,06:01; DRB1*08:03,11:01 (PubMed=26589293); Genome ancestry: African=1.75%; Native American=0%; East Asian, North=84.13%; East Asian, South=11.41%; South Asian=0%; European, North=0%; European, South=2.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21104494 CVCL_8068 AT805 cancer cell line house mouse CVCL_8068 CL:0000010 Breed/subspecies: 129. Male 21104495 CVCL_8069 211-LCL transformed cell line human CVCL_8069 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104496 CVCL_8063 Sa3 cancer cell line human CVCL_8063 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 55 hours (DOI=10.5794/jjoms.39.965) 21104497 CVCL_8064 T3M-5 cancer cell line human CVCL_8064 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly108Val (c.323G>T); Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Thyroid gland. Female Doubling time: 22 hours, at 60th passage (PubMed=6982994) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104498 CVCL_8065 T3M-3 cancer cell line human CVCL_8065 CL:0000010 Population: Japanese Female Characteristics: Established from a xenotransplanted choriocarcinoma grown in nude mice. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104499 CVCL_8066 T3M-11 cancer cell line human CVCL_8066 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21104500 CVCL_8034 1199-mel cancer cell line human CVCL_8034 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104501 CVCL_8035 1278-mel cancer cell line human CVCL_8035 HLA typing: A*11,28 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104502 CVCL_8036 1280-mel cancer cell line human CVCL_8036 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104503 CVCL_8037 1286-mel cancer cell line human CVCL_8037 HLA typing: A*02,29 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104504 CVCL_8030 1102-mel cancer cell line human CVCL_8030 HLA typing: A*02:01,24:02; B*15:01:01:01,55:01; C*03:02; DPB1*04:02,06:01; DQB1*06:02,03:01:01; DRB1*15:01,04:01 (PubMed=15592718) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified 21104505 CVCL_8031 1143-mel cancer cell line human CVCL_8031 HLA typing: A*02,11 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104506 CVCL_8032 1182-mel cancer cell line human CVCL_8032 HLA typing: A*02,11 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified 21104507 CVCL_8033 1195-mel cancer cell line human CVCL_8033 HLA typing: A*02,24 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified 21104508 CVCL_8027 ZR-82 spontaneously immortalized cell line CVCL_8027 CL:0000010 Derived from sampling site: Ovary. Female 21104509 CVCL_8028 ZR-87 spontaneously immortalized cell line CVCL_8028 CL:0000010 Derived from sampling site: Ovary. Female 21104510 CVCL_8029 1088-mel cancer cell line human CVCL_8029 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104511 CVCL_8040 1317-mel cancer cell line human CVCL_8040 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104512 CVCL_8045 1388-mel cancer cell line human CVCL_8045 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA. CL:0000010 Unspecified 21104513 CVCL_8046 1390-mel cancer cell line human CVCL_8046 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104514 CVCL_8047 1479-mel cancer cell line human CVCL_8047 HLA typing: A*02,03 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Asp464_Tyr467del (c.1392_1403del); Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Not specified. Female 21104515 CVCL_8048 1495-mel cancer cell line human CVCL_8048 HLA typing: A*02,03 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104516 CVCL_8041 1359-mel cancer cell line human CVCL_8041 HLA typing: A*01:01; B*08:01,40:01; C*07:01:01,03:04; DPB1*04:01,01:01:01; DQB1*03:01:01,02:01; DRB1*03:01:01,04:01:01 (PubMed=15592718) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Not specified. Unspecified 21104517 CVCL_8042 1363-mel cancer cell line human CVCL_8042 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104518 CVCL_8043 1376-mel cancer cell line human CVCL_8043 HLA typing: A*01,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104519 CVCL_8044 1383-mel cancer cell line human CVCL_8044 HLA typing: A*02,24 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104520 CVCL_8038 1287-mel cancer cell line human CVCL_8038 HLA typing: A*02,02 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104521 CVCL_8039 1300-mel cancer cell line human CVCL_8039 HLA typing: A*02,24 (PubMed=10048982) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21104522 CVCL_8012 WEG-1 transformed cell line house mouse CVCL_8012 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Uterus Cell type=Epithelial cell.; Breed/subspecies: CF-1. Female Characteristics: Retains the epithelial morphology of the parent uterine epithelial cells (UEC) 21104523 CVCL_8013 XP44RO(Mel) cancer cell line human CVCL_8013 CL:0000010 Derived from metastatic site: Testis. Male 21104524 CVCL_8014 YAM-RTK1 cancer cell line human CVCL_8014 From: Sugita K.; Yamanashi Medical University; Kofu; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Pro173Ser (c.517C>T); Zygosity=Unspecified (PubMed=11921280). Population: Japanese Male 21104525 CVCL_8015 YAMN-73 cancer cell line human CVCL_8015 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10942233; PubMed=12506034); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Female 21104526 CVCL_8010 VLN6H2 hybridoma human CVCL_8010 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8633 21104527 CVCL_8011 WART cancer cell line human CVCL_8011 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified Doubling time: ~15 hours (PubMed=9615717) 21104528 CVCL_8009 VLN3G2 hybridoma human CVCL_8009 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa (PubMed=3621203); IgG4 (ATCC) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8636 21104529 CVCL_8005 TTC-549 cancer cell line human CVCL_8005 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=10602515; PubMed=11921280) Derived from sampling site: Liver. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3 21104530 CVCL_8006 TTC-642 cancer cell line human CVCL_8006 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg40Ter (c.118C>T); ClinVar=VCV000410698; Zygosity=Unspecified (PubMed=10602515; PubMed=11921280; DepMap) Karyotypic information: 45,XX,-22 (PubMed=9559292); Derived from metastatic site: Neck. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21104531 CVCL_8007 TTC-709 cancer cell line human CVCL_8007 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=10602515) Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104532 CVCL_8008 UW-1 spontaneously immortalized cell line human CVCL_8008 From: Albert D.M.; University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Eye Cell type=Melanocyte.. Omics: Transcriptome analysis by microarray 21104533 CVCL_8023 YCU-T891 cancer cell line human CVCL_8023 HLA typing: A*24:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Doubling time: 14.93 hours (PubMed=21362583) Problematic cell line: Contaminated YCU-L891 and YCU-T891 have been shown to be identical (PubMed=26780976; PubMed=26781072). 21104534 CVCL_8024 YCU-T892 cancer cell line human CVCL_8024 HLA typing: A*29:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Male Doubling time: 18.24 hours (PubMed=21362583) 21104535 CVCL_8025 ZR-78 spontaneously immortalized cell line CVCL_8025 CL:0000010 Derived from sampling site: Ovary. Female 21104536 CVCL_8026 ZR-78.1 spontaneously immortalized cell line CVCL_8026 CL:0000010 Derived from sampling site: Ovary. Female 21104537 CVCL_8020 YCU-M911 cancer cell line human CVCL_8020 HLA typing: A*02:01,24:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Male Doubling time: 10.09 hours (PubMed=21362583) 21104538 CVCL_8021 YCU-MS861 cancer cell line human CVCL_8021 HLA typing: A*24:02,26:01 (Direct_author_submission) CL:0000010 Miscellaneous: Age of donor, HLA typing and STR profile from personal communication of Sano D Population: Japanese Omics: Transcriptome analysis by microarray Male Doubling time: 16.64 hours (PubMed=21362583) 21104539 CVCL_8022 YCU-OR891 cancer cell line human CVCL_8022 HLA typing: A*02:01,26:01 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Male Doubling time: 24.60 hours (PubMed=21362583) 21104540 CVCL_8016 YAMN-91 cancer cell line human CVCL_8016 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=12506034). Population: Japanese Unspecified 21104541 CVCL_8017 YCU-H891 cancer cell line human CVCL_8017 HLA typing: A*68:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 11.08 hours (PubMed=21362583) Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26780976; PubMed=26781072). Originally thought to originate from an hypopharyngeal squamous cell carcinoma. 21104542 CVCL_8018 YCU-L891 cancer cell line human CVCL_8018 HLA typing: A*24:02 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D Population: Japanese Doubling time: 16.58 hours (PubMed=21362583) Problematic cell line: Contaminated YCU-L891 and YCU-T891 have been shown to be identical (PubMed=26780976; PubMed=26781072). 21104543 CVCL_8019 YCU-M862 cancer cell line human CVCL_8019 HLA typing: A*24:02,33:03 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing and STR profile from personal communication of Sano D. Population: Japanese Omics: Transcriptome analysis by microarray Male Doubling time: 12.12 hours (PubMed=21362583) 21104544 CVCL_8001 Tm87-16 cancer cell line human CVCL_8001 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307; PubMed=10602515; PubMed=11921280) Population: Caucasian; Karyotypic information: 46,XY,t(11;22)(p15.5;q11.23) (PubMed=1747867); Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 45 hours (PubMed=1747867) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104545 CVCL_8002 TTC-1240 cancer cell line human CVCL_8002 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Glu216Ter (c.646G>T); Zygosity=Unspecified (PubMed=10602515; PubMed=11921280; PubMed=28945250) Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104546 CVCL_8003 TTC-445 cancer cell line human CVCL_8003 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA. CL:0000010 Unspecified 21104547 CVCL_8004 TTC-516 cancer cell line human CVCL_8004 CL:0000010 Derived from sampling site: Prostate. Male 21104548 CVCL_8000 STM91-01 cancer cell line human CVCL_8000 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=11921280) Derived from metastatic site: Lung. Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104549 CVCL_ID20 ND08371 transformed cell line human CVCL_ID20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104550 CVCL_ID21 ND08378 transformed cell line human CVCL_ID21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104551 CVCL_ID22 ND08384 transformed cell line human CVCL_ID22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104552 CVCL_ID23 ND08387 transformed cell line human CVCL_ID23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104553 CVCL_ID17 ND08317 transformed cell line human CVCL_ID17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104554 CVCL_ID18 ND08325 transformed cell line human CVCL_ID18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104555 CVCL_ID19 ND08334 transformed cell line human CVCL_ID19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104556 CVCL_ID13 ND08050 transformed cell line human CVCL_ID13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104557 CVCL_ID14 ND08053 transformed cell line human CVCL_ID14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104558 CVCL_ID15 ND08071 transformed cell line human CVCL_ID15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104559 CVCL_ID16 ND08092 transformed cell line human CVCL_ID16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104560 CVCL_ID31 ND08633 transformed cell line human CVCL_ID31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104561 CVCL_ID32 ND08649 transformed cell line human CVCL_ID32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104562 CVCL_ID33 ND08681 transformed cell line human CVCL_ID33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104563 CVCL_ID34 ND08683 transformed cell line human CVCL_ID34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104564 CVCL_ID30 ND08616 transformed cell line human CVCL_ID30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104565 CVCL_ID28 ND08555 transformed cell line human CVCL_ID28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104566 CVCL_ID29 ND08590 transformed cell line human CVCL_ID29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104567 CVCL_ID24 ND08408 transformed cell line human CVCL_ID24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104568 CVCL_ID25 ND08418 transformed cell line human CVCL_ID25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104569 CVCL_ID26 ND08423 transformed cell line human CVCL_ID26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104570 CVCL_ID27 ND08441 transformed cell line human CVCL_ID27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104571 CVCL_ID00 ND07882 transformed cell line human CVCL_ID00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104572 CVCL_ID01 ND07883 transformed cell line human CVCL_ID01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104573 CVCL_ID10 ND08047 transformed cell line human CVCL_ID10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104574 CVCL_ID11 ND08048 transformed cell line human CVCL_ID11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104575 CVCL_ID12 ND08049 transformed cell line human CVCL_ID12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104576 CVCL_ID06 ND07928 transformed cell line human CVCL_ID06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104577 CVCL_ID07 ND07930 transformed cell line human CVCL_ID07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104578 CVCL_ID08 ND08010 transformed cell line human CVCL_ID08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104579 CVCL_ID09 ND08019 transformed cell line human CVCL_ID09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104580 CVCL_ID02 ND07884 transformed cell line human CVCL_ID02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104581 CVCL_ID03 ND07886 transformed cell line human CVCL_ID03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104582 CVCL_ID04 ND07887 transformed cell line human CVCL_ID04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104583 CVCL_ID05 ND07926 transformed cell line human CVCL_ID05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104584 CVCL_7P91 DA03617 transformed cell line human CVCL_7P91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104585 CVCL_8191 Detroit 98/AH-R cancer cell line human CVCL_8191 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:136532; 8-azahypoxanthine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-18.4; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00021 Problematic cell line: Contaminated Ancestral cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 21104586 CVCL_7P92 DA03618 transformed cell line human CVCL_7P92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104587 CVCL_8192 Detroit 98S cancer cell line human CVCL_8192 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-18.1; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00022 Problematic cell line: Contaminated Parent cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 21104588 CVCL_7P93 DA03619 transformed cell line human CVCL_7P93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104589 CVCL_8193 EPLC-32M1 cancer cell line human CVCL_8193 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CRL-2182; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00118 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 68 year old male patient with lung squamous cell carcinoma. 21104590 CVCL_7P94 DA03620 transformed cell line human CVCL_7P94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104591 CVCL_8194 EPLC-65H cancer cell line human CVCL_8194 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00119 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from the lymph node metastasis of a 48 year old male patient with lung squamous cell carcinoma. 21104592 CVCL_7P90 DA03616 transformed cell line human CVCL_7P90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104593 CVCL_8190 Detroit 98/AH-2 cancer cell line human CVCL_8190 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:136532; 8-azahypoxanthine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-18.3; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00020 Problematic cell line: Contaminated Ancestral cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 21104594 CVCL_7P99 DA03625 transformed cell line human CVCL_7P99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104595 CVCL_8199 GHE cancer cell line human CVCL_8199 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00122 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from an astrocytoma. 21104596 CVCL_7P95 DA03621 transformed cell line human CVCL_7P95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104597 CVCL_8195 FC36.22 transformed cell line human CVCL_8195 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 21104598 CVCL_8196 COLO 357/FG cancer cell line human CVCL_8196 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21104599 CVCL_7P96 DA03622 transformed cell line human CVCL_7P96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104600 CVCL_7P97 DA03623 transformed cell line human CVCL_7P97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104601 CVCL_8197 FG-9307 spontaneously immortalized cell line CVCL_8197 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21104602 CVCL_7P98 DA03624 transformed cell line human CVCL_7P98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104603 CVCL_8198 G-415 cancer cell line human CVCL_8198 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (DepMap) Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours, at 30th passage (PubMed=7429092); 30 hours (PubMed=32293552) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104604 CVCL_ID86 ND10481 transformed cell line human CVCL_ID86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104605 CVCL_ID87 ND10486 transformed cell line human CVCL_ID87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104606 CVCL_ID88 ND10495 transformed cell line human CVCL_ID88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104607 CVCL_ID89 ND10503 transformed cell line human CVCL_ID89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104608 CVCL_ID82 ND10190 transformed cell line human CVCL_ID82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104609 CVCL_ID83 ND10256 transformed cell line human CVCL_ID83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104610 CVCL_ID84 ND10465 transformed cell line human CVCL_ID84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104611 CVCL_ID85 ND10467 transformed cell line human CVCL_ID85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104612 CVCL_ID80 ND10140 transformed cell line human CVCL_ID80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104613 CVCL_ID81 ND10188 transformed cell line human CVCL_ID81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104614 CVCL_ID79 ND10139 transformed cell line human CVCL_ID79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104615 CVCL_ID97 ND10657 transformed cell line human CVCL_ID97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104616 CVCL_ID98 ND10658 transformed cell line human CVCL_ID98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104617 CVCL_ID99 ND10661 transformed cell line human CVCL_ID99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104618 CVCL_ID93 ND10531 transformed cell line human CVCL_ID93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104619 CVCL_ID94 ND10600 transformed cell line human CVCL_ID94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104620 CVCL_ID95 ND10608 transformed cell line human CVCL_ID95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104621 CVCL_ID96 ND10610 transformed cell line human CVCL_ID96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104622 CVCL_ID90 ND10505 transformed cell line human CVCL_ID90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104623 CVCL_ID91 ND10506 transformed cell line human CVCL_ID91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104624 CVCL_ID92 ND10507 transformed cell line human CVCL_ID92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104625 CVCL_ID64 ND09544 transformed cell line human CVCL_ID64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104626 CVCL_ID65 ND09573 transformed cell line human CVCL_ID65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104627 CVCL_ID66 ND09641 transformed cell line human CVCL_ID66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104628 CVCL_ID67 ND09651 transformed cell line human CVCL_ID67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104629 CVCL_ID60 ND09443 transformed cell line human CVCL_ID60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104630 CVCL_ID61 ND09472 transformed cell line human CVCL_ID61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104631 CVCL_ID62 ND09473 transformed cell line human CVCL_ID62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104632 CVCL_ID63 ND09474 transformed cell line human CVCL_ID63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104633 CVCL_ID57 ND09293 transformed cell line human CVCL_ID57 CL:0000010 Population: Caucasian; English/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104634 CVCL_ID58 ND09379 transformed cell line human CVCL_ID58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104635 CVCL_ID59 ND09380 transformed cell line human CVCL_ID59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104636 CVCL_ID75 ND09850 transformed cell line human CVCL_ID75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104637 CVCL_ID76 ND09862 transformed cell line human CVCL_ID76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104638 CVCL_ID77 ND09983 transformed cell line human CVCL_ID77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104639 CVCL_ID78 ND09987 transformed cell line human CVCL_ID78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104640 CVCL_ID71 ND09662 transformed cell line human CVCL_ID71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104641 CVCL_ID72 ND09772 transformed cell line human CVCL_ID72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104642 CVCL_ID73 ND09812 transformed cell line human CVCL_ID73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104643 CVCL_ID74 ND09826 transformed cell line human CVCL_ID74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104644 CVCL_ID70 ND09654 transformed cell line human CVCL_ID70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104645 CVCL_ID68 ND09652 transformed cell line human CVCL_ID68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104646 CVCL_ID69 ND09653 transformed cell line human CVCL_ID69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104647 CVCL_ID42 ND09148 transformed cell line human CVCL_ID42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104648 CVCL_ID43 ND09169 transformed cell line human CVCL_ID43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104649 CVCL_ID44 ND09170 transformed cell line human CVCL_ID44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104650 CVCL_ID45 ND09193 transformed cell line human CVCL_ID45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104651 CVCL_ID40 ND09046 transformed cell line human CVCL_ID40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104652 CVCL_ID41 ND09086 transformed cell line human CVCL_ID41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104653 CVCL_ID39 ND08951 transformed cell line human CVCL_ID39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104654 CVCL_ID35 ND08706 transformed cell line human CVCL_ID35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104655 CVCL_ID36 ND08709 transformed cell line human CVCL_ID36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104656 CVCL_ID37 ND08772 transformed cell line human CVCL_ID37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104657 CVCL_ID38 ND08777 transformed cell line human CVCL_ID38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104658 CVCL_ID53 ND09271 transformed cell line human CVCL_ID53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104659 CVCL_ID54 ND09272 transformed cell line human CVCL_ID54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104660 CVCL_ID55 ND09273 transformed cell line human CVCL_ID55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104661 CVCL_ID56 ND09291 transformed cell line human CVCL_ID56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104662 CVCL_ID50 ND09255 transformed cell line human CVCL_ID50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104663 CVCL_ID51 ND09269 transformed cell line human CVCL_ID51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104664 CVCL_ID52 ND09270 transformed cell line human CVCL_ID52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104665 CVCL_ID46 ND09198 transformed cell line human CVCL_ID46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104666 CVCL_ID47 ND09222 transformed cell line human CVCL_ID47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104667 CVCL_ID48 ND09225 transformed cell line human CVCL_ID48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21104668 CVCL_ID49 ND09232 transformed cell line human CVCL_ID49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21104669 CVCL_7P00 DA03519 transformed cell line human CVCL_7P00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104670 CVCL_8100 M10K cancer cell line human CVCL_8100 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from metastatic site: Not specified. Male 21104671 CVCL_8101 267T2 cancer cell line house mouse CVCL_8101 CL:0000010 Breed/subspecies: C57BL/Ka. 21104672 CVCL_7P01 DA03520 transformed cell line human CVCL_7P01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104673 CVCL_7P02 DA03521 transformed cell line human CVCL_7P02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104674 CVCL_8102 M14K cancer cell line human CVCL_8102 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Omics: Transcriptome analysis by microarray. Male Doubling time: 55 hours (PubMed=23840376) 21104675 CVCL_7P03 DA03522 transformed cell line human CVCL_7P03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104676 CVCL_8103 M20 [Human mesothelioma] cancer cell line human CVCL_8103 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Male 21104677 CVCL_8170 AKI cancer cell line human CVCL_8170 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0408; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00172 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from a 42 year old male patient with a melanoma. 21104678 CVCL_7P70 DA03595 transformed cell line human CVCL_7P70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104679 CVCL_8171 AOK-B50 spontaneously immortalized cell line pig CVCL_8171 CL:0000010 Transfected with: UniProtKB; P25107; Opossum PTH1R Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21104680 CVCL_7P71 DA03596 transformed cell line human CVCL_7P71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104681 CVCL_8172 AR-C40 spontaneously immortalized cell line pig CVCL_8172 CL:0000010 Transfected with: RGD; 3442; Pth1r Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21104682 CVCL_7P72 DA03597 transformed cell line human CVCL_7P72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104683 CVCL_8177 CA-77 cancer cell line Norway rat CVCL_8177 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Female 21104684 CVCL_7P77 DA03602 transformed cell line human CVCL_7P77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104685 CVCL_8178 CEM-T4 cancer cell line human CVCL_8178 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21104686 CVCL_7P78 DA03603 transformed cell line human CVCL_7P78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104687 CVCL_8179 Chem 7 transformed cell line human CVCL_8179 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21104688 CVCL_7P79 DA03604 transformed cell line human CVCL_7P79 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104689 CVCL_8173 BLIN-1 cancer cell line human CVCL_8173 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00170 Problematic cell line: Contaminated Shown to be a NALM-6 derivative (PubMed=12592342; PubMed=20143388). 21104690 CVCL_7P73 DA03598 transformed cell line human CVCL_7P73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104691 CVCL_7P74 DA03599 transformed cell line human CVCL_7P74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104692 CVCL_8175 C125-PM cancer cell line human CVCL_8175 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Unspecified (PubMed=20570890; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=16418264) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104693 CVCL_7P75 DA03600 transformed cell line human CVCL_7P75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104694 CVCL_8176 C99 cancer cell line human CVCL_8176 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104695 CVCL_7P76 DA03601 transformed cell line human CVCL_7P76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104696 CVCL_8180 CPH-54A cancer cell line human CVCL_8180 CL:0000010 Derived from metastatic site: Lymph node. Male 21104697 CVCL_7P80 DA03605 transformed cell line human CVCL_7P80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104698 CVCL_8181 CPH-54B cancer cell line human CVCL_8181 CL:0000010 Derived from metastatic site: Lymph node. Male 21104699 CVCL_7P81 DA03606 transformed cell line human CVCL_7P81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104700 CVCL_8182 CSM14.1 conditionally immortalized cell line Norway rat CVCL_8182 CL:0000010 Derived from sampling site: Embryonic brain; mesencephalon. Omics: Proteome analysis by 2D-DE/MS Unspecified 21104701 CVCL_7P82 DA03608 transformed cell line human CVCL_7P82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104702 CVCL_8183 D407 spontaneously immortalized cell line human CVCL_8183 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male 21104703 CVCL_7P83 DA03609 transformed cell line human CVCL_7P83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104704 CVCL_7P88 DA03614 transformed cell line human CVCL_7P88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104705 CVCL_8188 Detroit 98 cancer cell line human CVCL_8188 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-18; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00005 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from the bone marrow of a non cancerous individual. 21104706 CVCL_7P89 DA03615 transformed cell line human CVCL_7P89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104707 CVCL_8189 Detroit 98/AG cancer cell line human CVCL_8189 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-18.2; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00019 Problematic cell line: Contaminated Grand-parent cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 21104708 CVCL_7P84 DA03610 transformed cell line human CVCL_7P84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104709 CVCL_8184 DD-761 cancer cell line house mouse CVCL_8184 CL:0000010 Breed/subspecies: DD/Tbr. Female Doubling time: 18 hours (CelloPub=CLPUB00034) 21104710 CVCL_7P85 DA03611 transformed cell line human CVCL_7P85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104711 CVCL_8185 DD-762 cancer cell line house mouse CVCL_8185 CL:0000010 Breed/subspecies: DD/Tbr. Discontinued: JCRB; NIHS0336; true Female Doubling time: 18 hours (CelloPub=CLPUB00034); 21 hours (lot 06232005) (JCRB) 21104712 CVCL_7P86 DA03612 transformed cell line human CVCL_7P86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104713 CVCL_8186 DD-763 cancer cell line house mouse CVCL_8186 CL:0000010 Breed/subspecies: DD/Tbr. Female Doubling time: 18 hours (CelloPub=CLPUB00034) 21104714 CVCL_7P87 DA03613 transformed cell line human CVCL_7P87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104715 CVCL_8187 DD-764 cancer cell line house mouse CVCL_8187 CL:0000010 Breed/subspecies: DD/Tbr. Female Doubling time: 14 hours (CelloPub=CLPUB00034) 21104716 CVCL_7P50 DA03572 transformed cell line human CVCL_7P50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104717 CVCL_8150 MOLT-15 cancer cell line human CVCL_8150 CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Gly477Ser (c.1429G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Gly831Glu (c.2492G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala353Val (c.1058C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Pro447Leu (c.1340C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala500Thr (c.1498G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gly1532Arg (c.4594G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Ser2523Ter (c.7568C>A); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 8804; PDGFRB; Simple; p.Met772Ile (c.2316G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys656Phe (c.1967G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Arg75Met (c.224G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys175Met (c.524A>T); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00147 Problematic cell line: Contaminated Shown to be a CTV-1 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). Originally thought to originate from a 33 year old male patient suffering from acute myeloid leukemia. 21104718 CVCL_7P55 DA03579 transformed cell line human CVCL_7P55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104719 CVCL_8155 UM-UC-2 cancer cell line human CVCL_8155 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 22 hours (PubMed=3761468) Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00281 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=19375735; PubMed=20143388). Originally thought to originate from a 61 year old male patient with a bladder transitional cell carcinoma. 21104720 CVCL_7P56 DA03580 transformed cell line human CVCL_7P56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104721 CVCL_8156 NCTC 3075 cancer cell line human CVCL_8156 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-19.1; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00027 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=20143388). 21104722 CVCL_8157 BSCC-93 cancer cell line human CVCL_8157 From: Usui K.; Jichi Medical School; Tochigi; Japan CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser144Ter (c.431C>G); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin. Discontinued: RCB; RCB1202; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00185 Problematic cell line: Contaminated Shown to be a DJM-1 derivative (PubMed=16643607; PubMed=20143388). 21104723 CVCL_7P57 DA03581 transformed cell line human CVCL_7P57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104724 CVCL_7P58 DA03582 transformed cell line human CVCL_7P58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104725 CVCL_8158 Mash-1 cancer cell line human CVCL_8158 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Japanese Discontinued: RCB; RCB1386; true. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00233 Problematic cell line: Contaminated Shown to be a MMAc derivative (PubMed=16643607; PubMed=20143388). 21104726 CVCL_7P51 DA03573 transformed cell line human CVCL_7P51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104727 CVCL_8151 MOLT-12 cancer cell line human CVCL_8151 CL:0000010 Miscellaneous: Cell line has been lost (DOI=10.1016/B978-0-12-221970-2.50457-5) Derived from sampling site: Bone marrow Cell type=T-cell.. Female 21104728 CVCL_7P52 DA03574 transformed cell line human CVCL_7P52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104729 CVCL_8152 MOLT-11 cancer cell line human CVCL_8152 CL:0000010 Miscellaneous: Cell line has been lost. Male 21104730 CVCL_7P53 DA03577 transformed cell line human CVCL_7P53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03577; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104731 CVCL_8153 GHE-L spontaneously immortalized cell line CVCL_8153 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21104732 CVCL_7P54 DA03578 transformed cell line human CVCL_7P54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104733 CVCL_8154 GH4I12 cancer cell line Norway rat CVCL_8154 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform long) Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21104734 CVCL_7P48 DA03570 transformed cell line human CVCL_7P48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104735 CVCL_8148 L3.2 cancer cell line human CVCL_8148 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21104736 CVCL_7P49 DA03571 transformed cell line human CVCL_7P49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104737 CVCL_8149 L3.1 cancer cell line human CVCL_8149 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21104738 CVCL_7P60 DA03584 transformed cell line human CVCL_7P60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104739 CVCL_8160 TCS cancer cell line human CVCL_8160 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 29.8 hours (PubMed=6520483) 21104740 CVCL_7P61 DA03585 transformed cell line human CVCL_7P61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104741 CVCL_8161 HKBML cancer cell line human CVCL_8161 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Brain. Male 21104742 CVCL_8166 67I transformed cell line Norway rat CVCL_8166 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer. Unspecified 21104743 CVCL_7P66 DA03590 transformed cell line human CVCL_7P66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104744 CVCL_8167 67T transformed cell line Norway rat CVCL_8167 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer. Unspecified 21104745 CVCL_7P67 DA03591 transformed cell line human CVCL_7P67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104746 CVCL_8168 AA-2 transformed cell line human CVCL_8168 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 21104747 CVCL_7P68 DA03592 transformed cell line human CVCL_7P68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104748 CVCL_8169 ADLC-5M2 cancer cell line human CVCL_8169 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00111 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 67 year old male patient with a lung adenocarcinoma. 21104749 CVCL_7P69 DA03594 transformed cell line human CVCL_7P69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104750 CVCL_7P62 DA03586 transformed cell line human CVCL_7P62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104751 CVCL_8162 HKBMM cancer cell line human CVCL_8162 CL:0000010 Population: Japanese; Derived from sampling site: Brain; frontal lobe. Female Doubling time: 28 hours, at 50th passage (PubMed=16035506) 21104752 CVCL_7P63 DA03587 transformed cell line human CVCL_7P63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104753 CVCL_8163 HMMME cancer cell line human CVCL_8163 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 45 hours (at 20th passage), 42 hours (at 50th passage) (PubMed=15147043) 21104754 CVCL_7P64 DA03588 transformed cell line human CVCL_7P64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104755 CVCL_8164 HLtat cancer cell line human CVCL_8164 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21104756 CVCL_8165 67-1 transformed cell line human CVCL_8165 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 21104757 CVCL_7P65 DA03589 transformed cell line human CVCL_7P65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104758 CVCL_7P59 DA03583 transformed cell line human CVCL_7P59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104759 CVCL_8159 SKG-II-SF cancer cell line human CVCL_8159 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Serum/protein free medium cell line 21104760 CVCL_7P33 DA03554 transformed cell line human CVCL_7P33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104761 CVCL_8133 MTLn2 cancer cell line Norway rat CVCL_8133 CL:0000010 Breed/subspecies: Fischer 344. Female 21104762 CVCL_7P34 DA03555 transformed cell line human CVCL_7P34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104763 CVCL_8134 MTLn2-Tf10 cancer cell line Norway rat CVCL_8134 CL:0000010 Breed/subspecies: Fischer 344. Female 21104764 CVCL_7P35 DA03556 transformed cell line human CVCL_7P35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104765 CVCL_8135 MTLn2-Tf20 cancer cell line Norway rat CVCL_8135 CL:0000010 Breed/subspecies: Fischer 344. Female 21104766 CVCL_7P36 DA03557 transformed cell line human CVCL_7P36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104767 CVCL_8136 MTLn3 cancer cell line Norway rat CVCL_8136 CL:0000010 Breed/subspecies: Fischer 344. Female 21104768 CVCL_7P30 DA03549 transformed cell line human CVCL_7P30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104769 CVCL_8130 HN-7 cancer cell line human CVCL_8130 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 72 hours (PubMed=7195729) 21104770 CVCL_7P31 DA03550 transformed cell line human CVCL_7P31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104771 CVCL_8131 HN-8 cancer cell line human CVCL_8131 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=2183872) Derived from sampling site: Larynx. Male Doubling time: 170 hours (PubMed=7195729) 21104772 CVCL_7P32 DA03553 transformed cell line human CVCL_7P32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104773 CVCL_8132 HN-9 cancer cell line human CVCL_8132 CL:0000010 Derived from sampling site: Oral cavity; tongue. Female Doubling time: 70 hours (PubMed=7195729) 21104774 CVCL_7P26 DA03545 transformed cell line human CVCL_7P26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104775 CVCL_8126 HN-3 cancer cell line human CVCL_8126 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 38 hours (PubMed=7195729) 21104776 CVCL_7P27 DA03546 transformed cell line human CVCL_7P27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104777 CVCL_8127 HN-4 cancer cell line human CVCL_8127 CL:0000010 Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Doubling time: 100 hours (PubMed=7195729) Part of: MD Anderson Cell Lines Project 21104778 CVCL_7P28 DA03547 transformed cell line human CVCL_7P28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104779 CVCL_8128 HN-5 cancer cell line human CVCL_8128 CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 34 hours (PubMed=7195729) Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21104780 CVCL_7P29 DA03548 transformed cell line human CVCL_7P29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104781 CVCL_8129 HN-6 cancer cell line human CVCL_8129 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 32 hours (PubMed=7195729) 21104782 CVCL_7P44 DA03566 transformed cell line human CVCL_7P44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104783 CVCL_8144 L3.6sl cancer cell line human CVCL_8144 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female Doubling time: 20 hours (PubMed=10935470) 21104784 CVCL_7P45 DA03567 transformed cell line human CVCL_7P45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104785 CVCL_8145 L3.5 cancer cell line human CVCL_8145 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21104786 CVCL_7P46 DA03568 transformed cell line human CVCL_7P46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104787 CVCL_8146 L3.4 cancer cell line human CVCL_8146 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21104788 CVCL_7P47 DA03569 transformed cell line human CVCL_7P47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104789 CVCL_8147 L3.3 cancer cell line human CVCL_8147 HLA typing: A*24:07,24:07; B*35:05,35:05; C*04:01,04:01; DQA1*04:01,04:01; DQB1*03:04,03:04; DRB1*12:02,14:46 (PubMed=26589293); Genome ancestry: African=82.98%; Native American=2.01%; East Asian, North=6.2%; East Asian, South=0%; South Asian=0%; European, North=2.94%; European, South=5.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (DepMap) Population: African American; Derived from metastatic site: Celiac axis lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21104790 CVCL_7P40 DA03561 transformed cell line human CVCL_7P40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03561; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104791 CVCL_8140 rMC-1 transformed cell line Norway rat CVCL_8140 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21104792 CVCL_7P41 DA03562 transformed cell line human CVCL_7P41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104793 CVCL_8141 JOSK-K cancer cell line human CVCL_8141 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00136 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21104794 CVCL_7P42 DA03563 transformed cell line human CVCL_7P42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104795 CVCL_8142 JOSK-S cancer cell line human CVCL_8142 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00138 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21104796 CVCL_7P43 DA03565 transformed cell line human CVCL_7P43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104797 CVCL_8143 NCC-RbC-70 cancer cell line human CVCL_8143 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Male Doubling time: 70 hours (PubMed=8263010) 21104798 CVCL_7P37 DA03558 transformed cell line human CVCL_7P37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104799 CVCL_7P38 DA03559 transformed cell line human CVCL_7P38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104800 CVCL_8138 ULTR transformed cell line human CVCL_8138 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus Cell type=Uterine smooth muscle cell.. Female 21104801 CVCL_7P39 DA03560 transformed cell line human CVCL_7P39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104802 CVCL_8139 ULTR-hT transformed cell line human CVCL_8139 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus Cell type=Uterine smooth muscle cell.. Female 21104803 CVCL_7P11 DA03530 transformed cell line human CVCL_7P11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104804 CVCL_8111 MH134-TC cancer cell line house mouse CVCL_8111 CL:0000010 Breed/subspecies: C3H/He. 21104805 CVCL_7P12 DA03531 transformed cell line human CVCL_7P12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03531; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104806 CVCL_8112 MMDD1 transformed cell line house mouse CVCL_8112 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; macula densa; Breed/subspecies: C57BL/6J-TgN(SV)7Bri transgenic. 21104807 CVCL_7P13 DA03532 transformed cell line human CVCL_7P13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03532; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104808 CVCL_8113 SEG-1 cancer cell line human CVCL_8113 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00366 Problematic cell line: Contaminated Shown to be a NCI-H460 derivative (PubMed=20075370). Originally thought to originate from an esophageal Barrett adenocarcinoma. 21104809 CVCL_7P14 DA03533 transformed cell line human CVCL_7P14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104810 CVCL_8114 SK-GT-5 cancer cell line human CVCL_8114 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Hispanic; Derived from sampling site: Stomach; fundus. Male Doubling time: 41 hours (PubMed=8334620) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00368 Problematic cell line: Contaminated Shown to be a SK-GT-2 derivative (PubMed=20075370). Originally thought to originate from a 67 year old male patient with an esophageal adenocarcinoma.; Caution: TP53 mutation indicated incorrectly as being at p.Asp281Glu (c.843C>G) in PubMed=7665247 21104811 CVCL_7P10 DA03529 transformed cell line human CVCL_7P10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104812 CVCL_8110 MH129 cancer cell line house mouse CVCL_8110 CL:0000010 Breed/subspecies: C3H/He. 21104813 CVCL_7P08 DA03527 transformed cell line human CVCL_7P08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104814 CVCL_8108 M38K cancer cell line human CVCL_8108 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21104815 CVCL_7P09 DA03528 transformed cell line human CVCL_7P09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104816 CVCL_8109 M9K cancer cell line human CVCL_8109 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from metastatic site: Not specified. Male 21104817 CVCL_7P04 DA03523 transformed cell line human CVCL_7P04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104818 CVCL_8104 M24K cancer cell line human CVCL_8104 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Omics: Transcriptome analysis by microarray Male 21104819 CVCL_7P05 DA03524 transformed cell line human CVCL_7P05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104820 CVCL_8105 M25K cancer cell line human CVCL_8105 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Omics: Transcriptome analysis by microarray. Male 21104821 CVCL_7P06 DA03525 transformed cell line human CVCL_7P06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104822 CVCL_8106 M28K cancer cell line human CVCL_8106 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228). 21104823 CVCL_7P07 DA03526 transformed cell line human CVCL_7P07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104824 CVCL_8107 M33K cancer cell line human CVCL_8107 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228). Male 21104825 CVCL_7P22 DA03541 transformed cell line human CVCL_7P22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104826 CVCL_8122 Hep1B cancer cell line house mouse CVCL_8122 CL:0000010 21104827 CVCL_7P23 DA03542 transformed cell line human CVCL_7P23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104828 CVCL_8123 HN-1 cancer cell line human CVCL_8123 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 36 hours (PubMed=7195729) 21104829 CVCL_7P24 DA03543 transformed cell line human CVCL_7P24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104830 CVCL_8124 HN-10 cancer cell line human CVCL_8124 CL:0000010 Derived from sampling site: Larynx. Male Doubling time: 60 hours (PubMed=7195729) 21104831 CVCL_7P25 DA03544 transformed cell line human CVCL_7P25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104832 CVCL_8125 HN-2 cancer cell line human CVCL_8125 CL:0000010 Derived from sampling site: Larynx. Male Doubling time: 48 hours (PubMed=7195729) 21104833 CVCL_7P20 DA03539 transformed cell line human CVCL_7P20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104834 CVCL_8120 H2K mdx conditionally immortalized cell line house mouse CVCL_8120 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Limb; muscle Cell type=Myoblast.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21104835 CVCL_7P21 DA03540 transformed cell line human CVCL_7P21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104836 CVCL_8121 H-69 transformed cell line human CVCL_8121 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Cholangiocyte.. Unspecified 21104837 CVCL_7P19 DA03538 transformed cell line human CVCL_7P19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104838 CVCL_8119 HMy.2 B transformed cell line human CVCL_8119 HLA typing: A*02:01; B*35:03; C*04:01 (IPD-IMGT/HLA=10744); HLA typing: A*02:01:01,03:01:01; B*15:01:01,35:03:01; C*03:04:01,04:01:01; DPB1*03:01:01,04:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRB1*04:01:01,12:01:01 (CLS=302008) CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: 24 hours (Patent=US4695538) Group: Hybridoma fusion partner cell line 21104839 CVCL_7P15 DA03534 transformed cell line human CVCL_7P15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104840 CVCL_8115 SR-3Y1-1 transformed cell line Norway rat CVCL_8115 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21104841 CVCL_7P16 DA03535 transformed cell line human CVCL_7P16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104842 CVCL_8116 SR-3Y1-2 transformed cell line Norway rat CVCL_8116 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21104843 CVCL_7P17 DA03536 transformed cell line human CVCL_7P17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104844 CVCL_8117 Tet-iNOS-293 transformed cell line human CVCL_8117 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21104845 CVCL_7P18 DA03537 transformed cell line human CVCL_7P18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104846 CVCL_8118 HT-29-D4 cancer cell line human CVCL_8118 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21104847 CVCL_7I10 DA02867 transformed cell line human CVCL_7I10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104848 CVCL_7I11 DA02868 transformed cell line human CVCL_7I11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104849 CVCL_7I12 DA02869 transformed cell line human CVCL_7I12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104850 CVCL_7I13 DA02870 transformed cell line human CVCL_7I13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104851 CVCL_7I18 DA02877 transformed cell line human CVCL_7I18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104852 CVCL_7I19 DA02878 transformed cell line human CVCL_7I19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104853 CVCL_7I14 DA02873 transformed cell line human CVCL_7I14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104854 CVCL_7I15 DA02874 transformed cell line human CVCL_7I15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104855 CVCL_7I16 DA02875 transformed cell line human CVCL_7I16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104856 CVCL_7I17 DA02876 transformed cell line human CVCL_7I17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104857 CVCL_7I21 DA02880 transformed cell line human CVCL_7I21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104858 CVCL_7I22 DA02881 transformed cell line human CVCL_7I22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104859 CVCL_7I23 DA02882 transformed cell line human CVCL_7I23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104860 CVCL_7I24 DA02883 transformed cell line human CVCL_7I24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104861 CVCL_7I20 DA02879 transformed cell line human CVCL_7I20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104862 CVCL_7I29 DA02889 transformed cell line human CVCL_7I29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104863 CVCL_7I25 DA02884 transformed cell line human CVCL_7I25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104864 CVCL_7I26 DA02885 transformed cell line human CVCL_7I26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104865 CVCL_7I27 DA02886 transformed cell line human CVCL_7I27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104866 CVCL_7I28 DA02887 transformed cell line human CVCL_7I28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104867 CVCL_QU92 BayGenomics ES cell line YTC479 embryonic stem cell house mouse CVCL_QU92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891829; Rbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104868 CVCL_R692 Hs 601.T cancer cell line human CVCL_R692 CL:0000010 Discontinued: ATCC; CRL-7361; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104869 CVCL_QU93 BayGenomics ES cell line YTC481 embryonic stem cell house mouse CVCL_QU93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270863; Prep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104870 CVCL_7I00 DA02856 transformed cell line human CVCL_7I00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104871 CVCL_R693 Hs 605.Mg finite cell line human CVCL_R693 CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7363; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104872 CVCL_QU94 BayGenomics ES cell line YTC482 embryonic stem cell house mouse CVCL_QU94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99919; Vcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104873 CVCL_7I01 DA02857 transformed cell line human CVCL_7I01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104874 CVCL_R694 Hs 606.Mg finite cell line human CVCL_R694 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Discontinued: ATCC; CRL-7366; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104875 CVCL_QU95 BayGenomics ES cell line YTC483 embryonic stem cell house mouse CVCL_QU95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104876 CVCL_7I02 DA02858 transformed cell line human CVCL_7I02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104877 CVCL_R695 Hs 623.T cancer cell line human CVCL_R695 CL:0000010 Discontinued: ATCC; CRL-7387; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104878 CVCL_QU96 BayGenomics ES cell line YTC485 embryonic stem cell house mouse CVCL_QU96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922066; Tpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104879 CVCL_R696 Hs 625.Ln finite cell line human CVCL_R696 CL:0000010 Derived from sampling site: Mesenteric lymph node. Discontinued: ATCC; CRL-7388; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104880 CVCL_QU97 BayGenomics ES cell line YTC486 embryonic stem cell house mouse CVCL_QU97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915364; Pwwp3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104881 CVCL_R697 Hs 625.T cancer cell line human CVCL_R697 CL:0000010 Derived from metastatic site: Ileal lymph node. Discontinued: ATCC; CRL-7389; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104882 CVCL_QU98 BayGenomics ES cell line YTC487 embryonic stem cell house mouse CVCL_QU98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106621; Myo1e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104883 CVCL_R698 Hs 626.T cancer cell line human CVCL_R698 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: ATCC; CRL-7390; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104884 CVCL_QU99 BayGenomics ES cell line YTC488 embryonic stem cell house mouse CVCL_QU99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919257; Fndc3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104885 CVCL_R699 Hs 626.Thd finite cell line human CVCL_R699 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: ATCC; CRL-7391; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104886 CVCL_7I07 DA02864 transformed cell line human CVCL_7I07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104887 CVCL_7I08 DA02865 transformed cell line human CVCL_7I08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104888 CVCL_7I09 DA02866 transformed cell line human CVCL_7I09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104889 CVCL_7I03 DA02859 transformed cell line human CVCL_7I03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104890 CVCL_7I04 DA02861 transformed cell line human CVCL_7I04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104891 CVCL_7I05 DA02862 transformed cell line human CVCL_7I05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104892 CVCL_7I06 DA02863 transformed cell line human CVCL_7I06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104893 CVCL_QU81 BayGenomics ES cell line YTC461 embryonic stem cell house mouse CVCL_QU81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104894 CVCL_R681 GM12830 transformed cell line human CVCL_R681 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145614 21104895 CVCL_QU82 BayGenomics ES cell line YTC463 embryonic stem cell house mouse CVCL_QU82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98447; Surf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104896 CVCL_R682 GM12832 transformed cell line human CVCL_R682 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145802 21104897 CVCL_QU83 BayGenomics ES cell line YTC466 embryonic stem cell house mouse CVCL_QU83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106340; Rcor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104898 CVCL_R683 GM12842 transformed cell line human CVCL_R683 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145812 21104899 CVCL_QU84 BayGenomics ES cell line YTC467 embryonic stem cell house mouse CVCL_QU84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202402; Pde7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104900 CVCL_R684 GM12843 transformed cell line human CVCL_R684 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145813 21104901 CVCL_QU85 BayGenomics ES cell line YTC468 embryonic stem cell house mouse CVCL_QU85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202402; Pde7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104902 CVCL_R685 GM12889 transformed cell line human CVCL_R685 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146313 21104903 CVCL_QU86 BayGenomics ES cell line YTC470 embryonic stem cell house mouse CVCL_QU86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104904 CVCL_R686 GM12890 transformed cell line human CVCL_R686 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146314 21104905 CVCL_QU87 BayGenomics ES cell line YTC471 embryonic stem cell house mouse CVCL_QU87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142572; Mtus1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104906 CVCL_R687 GM06984 transformed cell line human CVCL_R687 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132801/1328108/1329312 21104907 CVCL_QU88 BayGenomics ES cell line YTC472 embryonic stem cell house mouse CVCL_QU88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860513; Fnbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104908 CVCL_R688 Hs 593.Mg finite cell line human CVCL_R688 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7354; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104909 CVCL_QU89 BayGenomics ES cell line YTC473 embryonic stem cell house mouse CVCL_QU89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443207; Plekhm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104910 CVCL_R689 Hs 593.T cancer cell line human CVCL_R689 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7355; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104911 CVCL_QU90 BayGenomics ES cell line YTC476 embryonic stem cell house mouse CVCL_QU90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344381; Dnajb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104912 CVCL_R690 Hs 584.Mg finite cell line human CVCL_R690 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7349; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104913 CVCL_QU91 BayGenomics ES cell line YTC478 embryonic stem cell house mouse CVCL_QU91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933162; Lrba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104914 CVCL_R691 Hs 598.Af finite cell line human CVCL_R691 CL:0000010 Derived from sampling site: Amniotic fluid. Discontinued: ATCC; CRL-7358; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21104915 CVCL_QU70 BayGenomics ES cell line YTC442 embryonic stem cell house mouse CVCL_QU70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929472; Uqcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104916 CVCL_R670 GM12766 transformed cell line human CVCL_R670 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145101 21104917 CVCL_QU71 BayGenomics ES cell line YTC444 embryonic stem cell house mouse CVCL_QU71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95393; Eno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104918 CVCL_R671 GM12767 transformed cell line human CVCL_R671 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145102 21104919 CVCL_QU72 BayGenomics ES cell line YTC445 embryonic stem cell house mouse CVCL_QU72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338041; Tfg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104920 CVCL_R672 GM12775 transformed cell line human CVCL_R672 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145111 21104921 CVCL_QU73 BayGenomics ES cell line YTC446 embryonic stem cell house mouse CVCL_QU73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104922 CVCL_R673 GM12776 transformed cell line human CVCL_R673 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145112 21104923 CVCL_QU74 BayGenomics ES cell line YTC447 embryonic stem cell house mouse CVCL_QU74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142572; Mtus1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104924 CVCL_R674 GM12777 transformed cell line human CVCL_R674 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145113 21104925 CVCL_QU75 BayGenomics ES cell line YTC449 embryonic stem cell house mouse CVCL_QU75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920460; Nup54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104926 CVCL_R675 GM12778 transformed cell line human CVCL_R675 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145114 21104927 CVCL_QU76 BayGenomics ES cell line YTC450 embryonic stem cell house mouse CVCL_QU76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104928 CVCL_R676 GM12817 transformed cell line human CVCL_R676 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145601 21104929 CVCL_QU77 BayGenomics ES cell line YTC453 embryonic stem cell house mouse CVCL_QU77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104930 CVCL_R677 GM12818 transformed cell line human CVCL_R677 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145602 21104931 CVCL_QU78 BayGenomics ES cell line YTC454 embryonic stem cell house mouse CVCL_QU78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104932 CVCL_R678 GM12827 transformed cell line human CVCL_R678 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145611 21104933 CVCL_QU79 BayGenomics ES cell line YTC455 embryonic stem cell house mouse CVCL_QU79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858907; Blcap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104934 CVCL_R679 GM12828 transformed cell line human CVCL_R679 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145612 21104935 CVCL_QU80 BayGenomics ES cell line YTC457 embryonic stem cell house mouse CVCL_QU80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104936 CVCL_R680 GM12829 transformed cell line human CVCL_R680 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145613 21104937 CVCL_QU60 BayGenomics ES cell line YTC424 embryonic stem cell house mouse CVCL_QU60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104938 CVCL_R660 GM12546 transformed cell line human CVCL_R660 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135313 21104939 CVCL_QU61 BayGenomics ES cell line YTC425 embryonic stem cell house mouse CVCL_QU61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104940 CVCL_R661 GM12707 transformed cell line human CVCL_R661 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135801 21104941 CVCL_QU62 BayGenomics ES cell line YTC427 embryonic stem cell house mouse CVCL_QU62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104942 CVCL_R662 GM12708 transformed cell line human CVCL_R662 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135802 21104943 CVCL_QU63 BayGenomics ES cell line YTC430 embryonic stem cell house mouse CVCL_QU63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104944 CVCL_R663 GM12718 transformed cell line human CVCL_R663 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135814 21104945 CVCL_QU64 BayGenomics ES cell line YTC431 embryonic stem cell house mouse CVCL_QU64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443336; Gk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104946 CVCL_R664 GM12739 transformed cell line human CVCL_R664 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144401 21104947 CVCL_QU65 BayGenomics ES cell line YTC434 embryonic stem cell house mouse CVCL_QU65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261847; Vrk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104948 CVCL_R665 GM12740 transformed cell line human CVCL_R665 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144402 21104949 CVCL_QU66 BayGenomics ES cell line YTC436 embryonic stem cell house mouse CVCL_QU66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104950 CVCL_R666 GM12748 transformed cell line human CVCL_R666 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144411 21104951 CVCL_QU67 BayGenomics ES cell line YTC437 embryonic stem cell house mouse CVCL_QU67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105037; Ddx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104952 CVCL_R667 GM12749 transformed cell line human CVCL_R667 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144412 21104953 CVCL_QU68 BayGenomics ES cell line YTC440 embryonic stem cell house mouse CVCL_QU68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104954 CVCL_R668 GM12752 transformed cell line human CVCL_R668 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144701 21104955 CVCL_QU69 BayGenomics ES cell line YTC441 embryonic stem cell house mouse CVCL_QU69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104956 CVCL_R669 GM12753 transformed cell line human CVCL_R669 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144702 21104957 CVCL_QU50 BayGenomics ES cell line YTC409 embryonic stem cell house mouse CVCL_QU50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104958 CVCL_R650 GM12375 transformed cell line human CVCL_R650 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135301 21104959 CVCL_QU51 BayGenomics ES cell line YTC410 embryonic stem cell house mouse CVCL_QU51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102685; Cdc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104960 CVCL_R651 GM12376 transformed cell line human CVCL_R651 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135302 21104961 CVCL_QU52 BayGenomics ES cell line YTC411 embryonic stem cell house mouse CVCL_QU52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104962 CVCL_R652 GM12383 transformed cell line human CVCL_R652 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135312 21104963 CVCL_QU53 BayGenomics ES cell line YTC412 embryonic stem cell house mouse CVCL_QU53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104964 CVCL_R653 GM12386 transformed cell line human CVCL_R653 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135402 21104965 CVCL_QU54 BayGenomics ES cell line YTC413 embryonic stem cell house mouse CVCL_QU54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104966 CVCL_R654 GM12399 transformed cell line human CVCL_R654 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135415 21104967 CVCL_QU55 BayGenomics ES cell line YTC415 embryonic stem cell house mouse CVCL_QU55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104968 CVCL_R655 GM12400 transformed cell line human CVCL_R655 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135416 21104969 CVCL_QU56 BayGenomics ES cell line YTC417 embryonic stem cell house mouse CVCL_QU56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346341; Rnf13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104970 CVCL_R656 GM12413 transformed cell line human CVCL_R656 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135515 21104971 CVCL_QU57 BayGenomics ES cell line YTC418 embryonic stem cell house mouse CVCL_QU57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197010; Sumo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104972 CVCL_R657 GM12414 transformed cell line human CVCL_R657 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135516 21104973 CVCL_QU58 BayGenomics ES cell line YTC421 embryonic stem cell house mouse CVCL_QU58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442456; Unk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104974 CVCL_R658 GM12485 transformed cell line human CVCL_R658 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135501 21104975 CVCL_QU59 BayGenomics ES cell line YTC423 embryonic stem cell house mouse CVCL_QU59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21104976 CVCL_R659 GM12489 transformed cell line human CVCL_R659 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135314 21104977 CVCL_7I98 DA02963 transformed cell line human CVCL_7I98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104978 CVCL_7I99 DA02964 transformed cell line human CVCL_7I99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104979 CVCL_7I94 DA02959 transformed cell line human CVCL_7I94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104980 CVCL_7I95 DA02960 transformed cell line human CVCL_7I95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104981 CVCL_7I96 DA02961 transformed cell line human CVCL_7I96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104982 CVCL_7I97 DA02962 transformed cell line human CVCL_7I97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104983 CVCL_7I90 DA02955 transformed cell line human CVCL_7I90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104984 CVCL_7I91 DA02956 transformed cell line human CVCL_7I91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104985 CVCL_7I92 DA02957 transformed cell line human CVCL_7I92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104986 CVCL_7I93 DA02958 transformed cell line human CVCL_7I93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104987 CVCL_7I76 DA02939 transformed cell line human CVCL_7I76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104988 CVCL_7I77 DA02940 transformed cell line human CVCL_7I77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104989 CVCL_7I78 DA02941 transformed cell line human CVCL_7I78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104990 CVCL_7I79 DA02942 transformed cell line human CVCL_7I79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104991 CVCL_7I72 DA02933 transformed cell line human CVCL_7I72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104992 CVCL_7I73 DA02936 transformed cell line human CVCL_7I73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104993 CVCL_7I74 DA02937 transformed cell line human CVCL_7I74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104994 CVCL_7I75 DA02938 transformed cell line human CVCL_7I75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104995 CVCL_7I70 DA02931 transformed cell line human CVCL_7I70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104996 CVCL_7I71 DA02932 transformed cell line human CVCL_7I71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104997 CVCL_7I87 DA02952 transformed cell line human CVCL_7I87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104998 CVCL_7I88 DA02953 transformed cell line human CVCL_7I88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21104999 CVCL_7I89 DA02954 transformed cell line human CVCL_7I89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105000 CVCL_7I83 DA02947 transformed cell line human CVCL_7I83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105001 CVCL_7I84 DA02948 transformed cell line human CVCL_7I84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105002 CVCL_7I85 DA02949 transformed cell line human CVCL_7I85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105003 CVCL_7I86 DA02950 transformed cell line human CVCL_7I86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105004 CVCL_7I80 DA02943 transformed cell line human CVCL_7I80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105005 CVCL_7I81 DA02944 transformed cell line human CVCL_7I81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105006 CVCL_7I82 DA02945 transformed cell line human CVCL_7I82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105007 CVCL_7I54 DA02915 transformed cell line human CVCL_7I54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105008 CVCL_7I55 DA02916 transformed cell line human CVCL_7I55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105009 CVCL_7I56 DA02917 transformed cell line human CVCL_7I56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105010 CVCL_7I57 DA02918 transformed cell line human CVCL_7I57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105011 CVCL_7I50 DA02911 transformed cell line human CVCL_7I50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105012 CVCL_7I51 DA02912 transformed cell line human CVCL_7I51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105013 CVCL_7I52 DA02913 transformed cell line human CVCL_7I52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105014 CVCL_7I53 DA02914 transformed cell line human CVCL_7I53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105015 CVCL_7I58 DA02919 transformed cell line human CVCL_7I58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105016 CVCL_7I59 DA02920 transformed cell line human CVCL_7I59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02920; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105017 CVCL_7I65 DA02926 transformed cell line human CVCL_7I65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105018 CVCL_7I66 DA02927 transformed cell line human CVCL_7I66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105019 CVCL_7I67 DA02928 transformed cell line human CVCL_7I67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02928; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105020 CVCL_7I68 DA02929 transformed cell line human CVCL_7I68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105021 CVCL_7I61 DA02922 transformed cell line human CVCL_7I61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105022 CVCL_7I62 DA02923 transformed cell line human CVCL_7I62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105023 CVCL_7I63 DA02924 transformed cell line human CVCL_7I63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105024 CVCL_7I64 DA02925 transformed cell line human CVCL_7I64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105025 CVCL_7I69 DA02930 transformed cell line human CVCL_7I69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105026 CVCL_7I60 DA02921 transformed cell line human CVCL_7I60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105027 CVCL_7I32 DA02892 transformed cell line human CVCL_7I32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105028 CVCL_7I33 DA02893 transformed cell line human CVCL_7I33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105029 CVCL_7I34 DA02894 transformed cell line human CVCL_7I34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105030 CVCL_7I35 DA02895 transformed cell line human CVCL_7I35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105031 CVCL_7I30 DA02890 transformed cell line human CVCL_7I30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105032 CVCL_7I31 DA02891 transformed cell line human CVCL_7I31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105033 CVCL_7I36 DA02896 transformed cell line human CVCL_7I36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105034 CVCL_7I37 DA02897 transformed cell line human CVCL_7I37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105035 CVCL_7I38 DA02898 transformed cell line human CVCL_7I38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105036 CVCL_7I39 DA02899 transformed cell line human CVCL_7I39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105037 CVCL_7I43 DA02903 transformed cell line human CVCL_7I43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105038 CVCL_7I44 DA02905 transformed cell line human CVCL_7I44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105039 CVCL_7I45 DA02906 transformed cell line human CVCL_7I45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105040 CVCL_7I46 DA02907 transformed cell line human CVCL_7I46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105041 CVCL_7I40 DA02900 transformed cell line human CVCL_7I40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105042 CVCL_7I41 DA02901 transformed cell line human CVCL_7I41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105043 CVCL_7I42 DA02902 transformed cell line human CVCL_7I42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105044 CVCL_7I47 DA02908 transformed cell line human CVCL_7I47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105045 CVCL_7I48 DA02909 transformed cell line human CVCL_7I48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105046 CVCL_7I49 DA02910 transformed cell line human CVCL_7I49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105047 CVCL_7H99 DA02854 transformed cell line human CVCL_7H99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105048 CVCL_7H95 DA02850 transformed cell line human CVCL_7H95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105049 CVCL_7H96 DA02851 transformed cell line human CVCL_7H96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105050 CVCL_7H97 DA02852 transformed cell line human CVCL_7H97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105051 CVCL_7H98 DA02853 transformed cell line human CVCL_7H98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105052 CVCL_7H91 DA02846 transformed cell line human CVCL_7H91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105053 CVCL_7H92 DA02847 transformed cell line human CVCL_7H92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105054 CVCL_7H93 DA02848 transformed cell line human CVCL_7H93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105055 CVCL_7H94 DA02849 transformed cell line human CVCL_7H94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105056 CVCL_7H90 DA02845 transformed cell line human CVCL_7H90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105057 CVCL_QU40 BayGenomics ES cell line YTC396 embryonic stem cell house mouse CVCL_QU40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889206; Skap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105058 CVCL_R640 GM12329 transformed cell line human CVCL_R640 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 132804/1328102 21105059 CVCL_QU41 BayGenomics ES cell line YTC397 embryonic stem cell house mouse CVCL_QU41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859252; Fmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105060 CVCL_R641 GM12335 transformed cell line human CVCL_R641 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133001 21105061 CVCL_QU42 BayGenomics ES cell line YTC400 embryonic stem cell house mouse CVCL_QU42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918779; Kazn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105062 CVCL_R642 GM12336 transformed cell line human CVCL_R642 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133002 21105063 CVCL_QU43 BayGenomics ES cell line YTC401 embryonic stem cell house mouse CVCL_QU43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105064 CVCL_R643 GM12340 transformed cell line human CVCL_R643 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133008 21105065 CVCL_QU44 BayGenomics ES cell line YTC402 embryonic stem cell house mouse CVCL_QU44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105066 CVCL_R644 GM12341 transformed cell line human CVCL_R644 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133009 21105067 CVCL_QU45 BayGenomics ES cell line YTC403 embryonic stem cell house mouse CVCL_QU45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101919; Ap1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105068 CVCL_R645 GM12342 transformed cell line human CVCL_R645 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133010 21105069 CVCL_QU46 BayGenomics ES cell line YTC404 embryonic stem cell house mouse CVCL_QU46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105070 CVCL_R646 GM12343 transformed cell line human CVCL_R646 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133011 21105071 CVCL_QU47 BayGenomics ES cell line YTC405 embryonic stem cell house mouse CVCL_QU47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87948; Adss Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105072 CVCL_R647 GM12344 transformed cell line human CVCL_R647 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 1328101 21105073 CVCL_QU48 BayGenomics ES cell line YTC406 embryonic stem cell house mouse CVCL_QU48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923356; Kdm3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105074 CVCL_R648 GM12347 transformed cell line human CVCL_R648 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 1328106 21105075 CVCL_QU49 BayGenomics ES cell line YTC407 embryonic stem cell house mouse CVCL_QU49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99431; Arf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105076 CVCL_R649 GM12348 transformed cell line human CVCL_R649 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 1328107 21105077 CVCL_QU30 BayGenomics ES cell line YTC384 embryonic stem cell house mouse CVCL_QU30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105078 CVCL_R630 GM12058 transformed cell line human CVCL_R630 HLA typing: A*02:01,03:01; B*40:01; C*03:04:01; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*03:01,04:01; DQB1*03:02:01,04:02; DRB1*04:04,08:01 (IPD-IMGT/HLA=25865) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134415/137509 21105079 CVCL_QU31 BayGenomics ES cell line YTC385 embryonic stem cell house mouse CVCL_QU31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143755; AU041133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105080 CVCL_R631 GM12264 transformed cell line human CVCL_R631 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137511 21105081 CVCL_QU32 BayGenomics ES cell line YTC386 embryonic stem cell house mouse CVCL_QU32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109211; Pkn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105082 CVCL_R632 GM12272 transformed cell line human CVCL_R632 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141811 21105083 CVCL_QU33 BayGenomics ES cell line YTC389 embryonic stem cell house mouse CVCL_QU33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922542; Prkd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105084 CVCL_R633 GM12273 transformed cell line human CVCL_R633 HLA typing: A*02:01:01,32:01:01; B*35:01:01,44:02:01; C*04:01:01,07:04:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRB1*11:01:01,13:05:01; DRB3*02:02:01,02:02:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141812 21105085 CVCL_QU34 BayGenomics ES cell line YTC390 embryonic stem cell house mouse CVCL_QU34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147679; Patl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105086 CVCL_R634 GM12274 transformed cell line human CVCL_R634 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141813 21105087 CVCL_QU35 BayGenomics ES cell line YTC391 embryonic stem cell house mouse CVCL_QU35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147679; Patl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105088 CVCL_R635 GM12275 transformed cell line human CVCL_R635 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 141814 21105089 CVCL_QU36 BayGenomics ES cell line YTC392 embryonic stem cell house mouse CVCL_QU36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105090 CVCL_R636 GM12282 transformed cell line human CVCL_R636 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142109 21105091 CVCL_QU37 BayGenomics ES cell line YTC393 embryonic stem cell house mouse CVCL_QU37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105092 CVCL_R637 GM12283 transformed cell line human CVCL_R637 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142110 21105093 CVCL_QU38 BayGenomics ES cell line YTC394 embryonic stem cell house mouse CVCL_QU38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144013; Xpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105094 CVCL_R638 GM12286 transformed cell line human CVCL_R638 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142113 21105095 CVCL_QU39 BayGenomics ES cell line YTC395 embryonic stem cell house mouse CVCL_QU39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144113; Tmem199 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105096 CVCL_R639 GM12287 transformed cell line human CVCL_R639 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142114 21105097 CVCL_QU20 BayGenomics ES cell line YTC366 embryonic stem cell house mouse CVCL_QU20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105098 CVCL_R620 GM11892 transformed cell line human CVCL_R620 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137711 21105099 CVCL_QU21 BayGenomics ES cell line YTC367 embryonic stem cell house mouse CVCL_QU21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105100 CVCL_R621 GM11893 transformed cell line human CVCL_R621 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137712 21105101 CVCL_QU22 BayGenomics ES cell line YTC368 embryonic stem cell house mouse CVCL_QU22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105102 CVCL_R622 GM11894 transformed cell line human CVCL_R622 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137713 21105103 CVCL_QU23 BayGenomics ES cell line YTC371 embryonic stem cell house mouse CVCL_QU23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894684; Pa2g4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105104 CVCL_R623 GM11917 transformed cell line human CVCL_R623 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142311 21105105 CVCL_QU24 BayGenomics ES cell line YTC374 embryonic stem cell house mouse CVCL_QU24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333803; Top3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105106 CVCL_R624 GM11918 transformed cell line human CVCL_R624 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142312 21105107 CVCL_QU25 BayGenomics ES cell line YTC376 embryonic stem cell house mouse CVCL_QU25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105108 CVCL_R625 GM11919 transformed cell line human CVCL_R625 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142313 21105109 CVCL_QU26 BayGenomics ES cell line YTC377 embryonic stem cell house mouse CVCL_QU26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442572; Stk38 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105110 CVCL_R626 GM11920 transformed cell line human CVCL_R626 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142314 21105111 CVCL_QU27 BayGenomics ES cell line YTC379 embryonic stem cell house mouse CVCL_QU27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342307; Drg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105112 CVCL_R627 GM11930 transformed cell line human CVCL_R627 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142411 21105113 CVCL_QU28 BayGenomics ES cell line YTC380 embryonic stem cell house mouse CVCL_QU28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109382; Noct Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105114 CVCL_R628 GM11931 transformed cell line human CVCL_R628 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142412 21105115 CVCL_QU29 BayGenomics ES cell line YTC383 embryonic stem cell house mouse CVCL_QU29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349473; Ppp2r5e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105116 CVCL_R629 GM12045 transformed cell line human CVCL_R629 HLA typing: A*02:01,11:01; B*35:01,44:02; C*04:01,05:01; DPA1*01:03,01:03; DPB1*03:01,04:01:01; DQA1*01:01,01:03; DQB1*05:03:01,06:03; DRB1*13:01,14:01; DRB3*01,02 (IPD-IMGT/HLA=25888) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134613 21105117 CVCL_QU10 BayGenomics ES cell line YTC349 embryonic stem cell house mouse CVCL_QU10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917485; Poc1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105118 CVCL_R610 GM10855 transformed cell line human CVCL_R610 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135002 21105119 CVCL_QU11 BayGenomics ES cell line YTC350 embryonic stem cell house mouse CVCL_QU11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109130; Stip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105120 CVCL_R611 GM10856 transformed cell line human CVCL_R611 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135001 21105121 CVCL_QU12 BayGenomics ES cell line YTC352 embryonic stem cell house mouse CVCL_QU12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105122 CVCL_R612 GM10857 transformed cell line human CVCL_R612 HLA typing: A*02:01,02:06; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,01:03; DQB1*05:01,06:03; DRB1*01:01,13:01; DRB3*01 (IPD-IMGT/HLA=25889) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134601 21105123 CVCL_QU13 BayGenomics ES cell line YTC356 embryonic stem cell house mouse CVCL_QU13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105124 CVCL_R613 GM10859 transformed cell line human CVCL_R613 HLA typing: A*01:01,03:01; B*07:02,15:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,04:02; DQA1*01:02,03:01; DQB1*03:02,06:02; DRB1*04:01,15:01; DRB4*01 (IPD-IMGT/HLA=25906) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134702 21105125 CVCL_QU14 BayGenomics ES cell line YTC357 embryonic stem cell house mouse CVCL_QU14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107750; Dync1i2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105126 CVCL_R614 GM10861 transformed cell line human CVCL_R614 HLA typing: A*01:01,01:01; B*07:02,57:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,15:01; DQA1*01:03,03:01; DQB1*03:02:01,06:03; DRB1*04:04,13:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25932) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136202 21105127 CVCL_QU15 BayGenomics ES cell line YTC360 embryonic stem cell house mouse CVCL_QU15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105128 CVCL_R615 GM10863 transformed cell line human CVCL_R615 HLA typing: DPB1*04:01,06:01; DQA1*01:01,03:01; DQB1*03:02,05:03; DRB1*04:04,14:04; DRB3*02 (IPD-IMGT/HLA=10069) CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Virology: Contains a chromosomally integrated human herpesvirus 6B (CI-HHV-6B) Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 137502 21105129 CVCL_QU16 BayGenomics ES cell line YTC362 embryonic stem cell house mouse CVCL_QU16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3714357; Srp54b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105130 CVCL_R616 GM10864 transformed cell line human CVCL_R616 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137702 21105131 CVCL_QU17 BayGenomics ES cell line YTC363 embryonic stem cell house mouse CVCL_QU17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444022; Mapk1ip1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105132 CVCL_R617 GM10865 transformed cell line human CVCL_R617 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137701 21105133 CVCL_QU18 BayGenomics ES cell line YTC364 embryonic stem cell house mouse CVCL_QU18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347343; Usp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105134 CVCL_R618 GM11843 transformed cell line human CVCL_R618 HLA typing: A*02:01,11:01; B*15:01,51:01; C*03:04:01,15:02; DPA1*01:03,01:03; DPB1*03:01,04:01; DQA1*03:01,03:01; DQB1*03:01,03:02; DRB1*04:01,04:04; DRB4*01 (IPD-IMGT/HLA=25907) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134911 21105135 CVCL_QU19 BayGenomics ES cell line YTC365 embryonic stem cell house mouse CVCL_QU19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105136 CVCL_R619 GM11891 transformed cell line human CVCL_R619 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137710 21105137 CVCL_QU00 BayGenomics ES cell line YTC335 embryonic stem cell house mouse CVCL_QU00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921991; C2cd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105138 CVCL_R600 GM10840 transformed cell line human CVCL_R600 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142102 21105139 CVCL_QU01 BayGenomics ES cell line YTC336 embryonic stem cell house mouse CVCL_QU01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681836; Polr3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105140 CVCL_R601 GM10842 transformed cell line human CVCL_R601 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142301 21105141 CVCL_QU02 BayGenomics ES cell line YTC337 embryonic stem cell house mouse CVCL_QU02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105142 CVCL_R602 GM10843 transformed cell line human CVCL_R602 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142302 21105143 CVCL_QU03 BayGenomics ES cell line YTC339 embryonic stem cell house mouse CVCL_QU03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105144 CVCL_R603 GM10845 transformed cell line human CVCL_R603 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142401 21105145 CVCL_QU04 BayGenomics ES cell line YTC340 embryonic stem cell house mouse CVCL_QU04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105146 CVCL_R604 GM10846 transformed cell line human CVCL_R604 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133401 21105147 CVCL_QU05 BayGenomics ES cell line YTC343 embryonic stem cell house mouse CVCL_QU05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333799; Xrcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105148 CVCL_R605 GM10850 transformed cell line human CVCL_R605 HLA typing: A*02:01,03:01; B*40:01,51:01; C*01:02,03:04:01; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25872) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134402 21105149 CVCL_QU06 BayGenomics ES cell line YTC344 embryonic stem cell house mouse CVCL_QU06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928898; Usp14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105150 CVCL_R606 GM10851 transformed cell line human CVCL_R606 HLA typing: A*01:01,24:02; B*08:01,40:01; C*03:04:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*02:01,03:01; DQB1*03:02:01,03:03:02; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25875) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134401 21105151 CVCL_QU07 BayGenomics ES cell line YTC345 embryonic stem cell house mouse CVCL_QU07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342294; Uri1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105152 CVCL_R607 GM10852 transformed cell line human CVCL_R607 HLA typing: A*01:01,11:01; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:01,05:01; DQB1*02:01,05:03:01; DRB1*03:01,14:01; DRB3*01,02 (IPD-IMGT/HLA=25886) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134602 21105153 CVCL_QU08 BayGenomics ES cell line YTC347 embryonic stem cell house mouse CVCL_QU08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146156; Espl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105154 CVCL_R608 GM10853 transformed cell line human CVCL_R608 HLA typing: A*01:01,02:01; B*15:01,57:01; C*03:04:01,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:01,03:03; DRB1*04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25913) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134901 21105155 CVCL_QU09 BayGenomics ES cell line YTC348 embryonic stem cell house mouse CVCL_QU09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915092; Nop9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105156 CVCL_R609 GM10854 transformed cell line human CVCL_R609 HLA typing: A*02:01,02:01; B*27:03,44:02:01:01; C*02:02:02,05:01; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*03:01,03:01; DQB1*03:01,03:02; DRB1*04:01,04:04; DRB4*01 (IPD-IMGT/HLA=25914) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134902 21105157 CVCL_7J31 DA03000 transformed cell line human CVCL_7J31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105158 CVCL_7J32 DA03001 transformed cell line human CVCL_7J32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105159 CVCL_7J33 DA03002 transformed cell line human CVCL_7J33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105160 CVCL_7J34 DA03003 transformed cell line human CVCL_7J34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105161 CVCL_7J30 DA02999 transformed cell line human CVCL_7J30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105162 CVCL_7J39 DA03008 transformed cell line human CVCL_7J39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105163 CVCL_7J35 DA03004 transformed cell line human CVCL_7J35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105164 CVCL_7J36 DA03005 transformed cell line human CVCL_7J36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105165 CVCL_7J37 DA03006 transformed cell line human CVCL_7J37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105166 CVCL_7J38 DA03007 transformed cell line human CVCL_7J38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105167 CVCL_7J42 DA03011 transformed cell line human CVCL_7J42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105168 CVCL_7J43 DA03012 transformed cell line human CVCL_7J43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105169 CVCL_7J44 DA03013 transformed cell line human CVCL_7J44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105170 CVCL_7J45 DA03014 transformed cell line human CVCL_7J45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105171 CVCL_7J40 DA03009 transformed cell line human CVCL_7J40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105172 CVCL_7J41 DA03010 transformed cell line human CVCL_7J41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105173 CVCL_7J46 DA03015 transformed cell line human CVCL_7J46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105174 CVCL_7J47 DA03016 transformed cell line human CVCL_7J47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105175 CVCL_7J48 DA03017 transformed cell line human CVCL_7J48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105176 CVCL_7J49 DA03018 transformed cell line human CVCL_7J49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105177 CVCL_7J10 DA02979 transformed cell line human CVCL_7J10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105178 CVCL_7J11 DA02980 transformed cell line human CVCL_7J11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105179 CVCL_7J12 DA02981 transformed cell line human CVCL_7J12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105180 CVCL_7J17 DA02986 transformed cell line human CVCL_7J17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105181 CVCL_7J18 DA02987 transformed cell line human CVCL_7J18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105182 CVCL_7J19 DA02988 transformed cell line human CVCL_7J19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105183 CVCL_7J13 DA02982 transformed cell line human CVCL_7J13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105184 CVCL_7J14 DA02983 transformed cell line human CVCL_7J14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105185 CVCL_7J15 DA02984 transformed cell line human CVCL_7J15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105186 CVCL_7J16 DA02985 transformed cell line human CVCL_7J16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105187 CVCL_7J20 DA02989 transformed cell line human CVCL_7J20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105188 CVCL_7J21 DA02990 transformed cell line human CVCL_7J21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105189 CVCL_7J22 DA02991 transformed cell line human CVCL_7J22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02991; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105190 CVCL_7J23 DA02992 transformed cell line human CVCL_7J23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105191 CVCL_7J28 DA02997 transformed cell line human CVCL_7J28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105192 CVCL_7J29 DA02998 transformed cell line human CVCL_7J29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105193 CVCL_7J24 DA02993 transformed cell line human CVCL_7J24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105194 CVCL_7J25 DA02994 transformed cell line human CVCL_7J25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105195 CVCL_7J26 DA02995 transformed cell line human CVCL_7J26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105196 CVCL_7J27 DA02996 transformed cell line human CVCL_7J27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105197 CVCL_QV91 BayGenomics ES cell line YTC689 embryonic stem cell house mouse CVCL_QV91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105198 CVCL_R791 Drill H induced pluripotent stem cell CVCL_R791 CL:0000010 Anecdotal: Established from Loon, a drill that lived in the San Diego zoo and who was trained to accept regular blood sampling and insulin injection in order to treat his diabetes mellitus Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 21105199 CVCL_QV92 BayGenomics ES cell line YTC692 embryonic stem cell house mouse CVCL_QV92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388481; Ppp2r5d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105200 CVCL_R792 Drill J induced pluripotent stem cell CVCL_R792 CL:0000010 Anecdotal: Established from Loon, a drill that lived in the San Diego zoo and who was trained to accept regular blood sampling and insulin injection in order to treat his diabetes mellitus Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 21105201 CVCL_QV93 BayGenomics ES cell line YTC694 embryonic stem cell house mouse CVCL_QV93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101835; Traf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105202 CVCL_7J00 DA02965 transformed cell line human CVCL_7J00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105203 CVCL_R793 NWR A induced pluripotent stem cell CVCL_R793 CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21105204 CVCL_QV94 BayGenomics ES cell line YTC707 embryonic stem cell house mouse CVCL_QV94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917184; Trmt10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105205 CVCL_7J01 DA02966 transformed cell line human CVCL_7J01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105206 CVCL_R794 NWR B induced pluripotent stem cell CVCL_R794 CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21105207 CVCL_QV95 BayGenomics ES cell line YTC719 embryonic stem cell house mouse CVCL_QV95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917184; Trmt10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105208 CVCL_R795 NWR C induced pluripotent stem cell CVCL_R795 CL:0000010 Anecdotal: Established from Fatu, one the last two Northern white rhinoceros still alive Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21105209 CVCL_QV96 BayGenomics ES cell line YTC720 embryonic stem cell house mouse CVCL_QV96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105210 CVCL_R796 Machi transformed cell line CVCL_R796 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21105211 CVCL_QV97 BayGenomics ES cell line YTC725 embryonic stem cell house mouse CVCL_QV97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104667; Hmmr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105212 CVCL_R797 Shamba transformed cell line CVCL_R797 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21105213 CVCL_QV98 BayGenomics ES cell line YTC727 embryonic stem cell house mouse CVCL_QV98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918850; Ythdf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105214 CVCL_R798 Oko transformed cell line CVCL_R798 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21105215 CVCL_QV99 BayGenomics ES cell line YTC730 embryonic stem cell house mouse CVCL_QV99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932535; Glis2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105216 CVCL_R799 Beta transformed cell line CVCL_R799 From: Watkins D.; University of Wisconsin; Madison; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21105217 CVCL_7J06 DA02975 transformed cell line human CVCL_7J06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105218 CVCL_7J07 DA02976 transformed cell line human CVCL_7J07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105219 CVCL_7J08 DA02977 transformed cell line human CVCL_7J08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105220 CVCL_7J09 DA02978 transformed cell line human CVCL_7J09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105221 CVCL_7J02 DA02971 transformed cell line human CVCL_7J02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105222 CVCL_7J03 DA02972 transformed cell line human CVCL_7J03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105223 CVCL_7J04 DA02973 transformed cell line human CVCL_7J04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105224 CVCL_7J05 DA02974 transformed cell line human CVCL_7J05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105225 CVCL_QV80 BayGenomics ES cell line YTC650 embryonic stem cell house mouse CVCL_QV80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105226 CVCL_R780 Zos-M cancer cell line human CVCL_R780 CL:0000010 Population: Chinese; Derived from metastatic site: Bone; right femoral head (Note=From a skip lesion). Male Doubling time: 31.58 hours (PubMed=18298897) 21105227 CVCL_QV81 BayGenomics ES cell line YTC653 embryonic stem cell house mouse CVCL_QV81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105228 CVCL_R781 UM33-4 embryonic stem cell human CVCL_R781 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0279 21105229 CVCL_QV82 BayGenomics ES cell line YTC654 embryonic stem cell house mouse CVCL_QV82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105230 CVCL_R782 UM63-1 embryonic stem cell human CVCL_R782 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0277. 21105231 CVCL_QV83 BayGenomics ES cell line YTC662 embryonic stem cell house mouse CVCL_QV83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105232 CVCL_R783 UM77-2 embryonic stem cell human CVCL_R783 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0278 21105233 CVCL_QV84 BayGenomics ES cell line YTC673 embryonic stem cell house mouse CVCL_QV84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138080; Utp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105234 CVCL_R784 RPC-5 cancer cell line house mouse CVCL_R784 CL:0000010 Breed/subspecies: BALB/c. 21105235 CVCL_QV85 BayGenomics ES cell line YTC674 embryonic stem cell house mouse CVCL_QV85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107595; Sp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105236 CVCL_R785 OA4.K finite cell line CVCL_R785 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-6548; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105237 CVCL_QV86 BayGenomics ES cell line YTC678 embryonic stem cell house mouse CVCL_QV86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351329; Rps11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105238 CVCL_R786 OA3.Lu finite cell line CVCL_R786 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6541; true; Discontinued: ATCC; CRL-6545; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105239 CVCL_QV87 BayGenomics ES cell line YTC679 embryonic stem cell house mouse CVCL_QV87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105240 CVCL_R787 NAL1A spontaneously immortalized cell line house mouse CVCL_R787 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Female Doubling time: 21.5 +- 0.5 hours (PubMed=6522104) 21105241 CVCL_QV88 BayGenomics ES cell line YTC681 embryonic stem cell house mouse CVCL_QV88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444518; Samd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105242 CVCL_R788 NUL1 cancer cell line house mouse CVCL_R788 CL:0000010 Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: BALB/c. 21105243 CVCL_QV89 BayGenomics ES cell line YTC683 embryonic stem cell house mouse CVCL_QV89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914769; Dennd4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105244 CVCL_R789 Drill A induced pluripotent stem cell CVCL_R789 CL:0000010 Anecdotal: Established from Loon, a drill that lived in the San Diego zoo and who was trained to accept regular blood sampling and insulin injection in order to treat his diabetes mellitus Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 21105245 CVCL_QV90 BayGenomics ES cell line YTC687 embryonic stem cell house mouse CVCL_QV90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925219; Trmt13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105246 CVCL_R790 Drill C induced pluripotent stem cell CVCL_R790 CL:0000010 Anecdotal: Established from Loon, a drill that lived in the San Diego zoo and who was trained to accept regular blood sampling and insulin injection in order to treat his diabetes mellitus Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 21105247 CVCL_QV70 BayGenomics ES cell line YTC630 embryonic stem cell house mouse CVCL_QV70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105248 CVCL_R770 DA-1a cancer cell line house mouse CVCL_R770 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: BALB/c. Characteristics: IL3 dependent 21105249 CVCL_QV71 BayGenomics ES cell line YTC632 embryonic stem cell house mouse CVCL_QV71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99201; Zfp54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105250 CVCL_R771 mpkCCD transformed cell line house mouse CVCL_R771 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: SV-PK/Tag transgenic. Unspecified 21105251 CVCL_QV72 BayGenomics ES cell line YTC637 embryonic stem cell house mouse CVCL_QV72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445096; Dhtkd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105252 CVCL_R772 mpkIMCD transformed cell line house mouse CVCL_R772 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; inner medullary collecting duct; Breed/subspecies: SV-PK/Tag transgenic. Unspecified 21105253 CVCL_QV73 BayGenomics ES cell line YTC638 embryonic stem cell house mouse CVCL_QV73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105254 CVCL_R773 mpkDCT transformed cell line house mouse CVCL_R773 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; distal convoluted tubule; Breed/subspecies: SV-PK/Tag transgenic. Unspecified 21105255 CVCL_QV74 BayGenomics ES cell line YTC641 embryonic stem cell house mouse CVCL_QV74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105256 CVCL_R774 DK1 [Tursiops] finite cell line CVCL_R774 CL:0000010 Derived from sampling site: Kidney. Female Doubling time: 1.31 days (DOI=10.1111/j.1748-7692.1994.tb00389.x) Group: Cetacean cell line 21105257 CVCL_QV75 BayGenomics ES cell line YTC642 embryonic stem cell house mouse CVCL_QV75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105258 CVCL_R775 DS-T3 transformed cell line CVCL_R775 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIP SV 776-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21105259 CVCL_QV76 BayGenomics ES cell line YTC644 embryonic stem cell house mouse CVCL_QV76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105260 CVCL_R776 DS-T4 transformed cell line CVCL_R776 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIP SV 776-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis. Female Group: Cetacean cell line 21105261 CVCL_QV77 BayGenomics ES cell line YTC647 embryonic stem cell house mouse CVCL_QV77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105262 CVCL_R777 SW2 cancer cell line human CVCL_R777 From: Bernal S.D.; Dana-Farber Cancer Institute; Boston; USA. CL:0000010 21105263 CVCL_QV78 BayGenomics ES cell line YTC648 embryonic stem cell house mouse CVCL_QV78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105264 CVCL_R778 DK0064 transformed cell line human CVCL_R778 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly674Gly (c.2022A>G) (2101A>G); ClinVar=VCV000008307; Zygosity=Homozygous; Note=Silent mutation that causes increased levels of skipping exon 9 and activation of two cryptic splicing events from sites in exon 9 leading to termination in exon 10 (from autologous cell lines GM18366 and GM18367) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection Caution: Could be identical to GM18367 (Cellosaurus=CVCL_6G81) 21105265 CVCL_QV79 BayGenomics ES cell line YTC649 embryonic stem cell house mouse CVCL_QV79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105266 CVCL_R779 Zos cancer cell line human CVCL_R779 CL:0000010 Population: Chinese; Derived from sampling site: Bone; right distal femur. Male Doubling time: 33.65 hours (PubMed=18298897) 21105267 CVCL_7J97 DA03070 transformed cell line human CVCL_7J97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105268 CVCL_7J98 DA03071 transformed cell line human CVCL_7J98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105269 CVCL_7J99 DA03072 transformed cell line human CVCL_7J99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105270 CVCL_7J93 DA03066 transformed cell line human CVCL_7J93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105271 CVCL_7J94 DA03067 transformed cell line human CVCL_7J94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105272 CVCL_7J95 DA03068 transformed cell line human CVCL_7J95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105273 CVCL_7J96 DA03069 transformed cell line human CVCL_7J96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105274 CVCL_7J90 DA03063 transformed cell line human CVCL_7J90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105275 CVCL_7J91 DA03064 transformed cell line human CVCL_7J91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105276 CVCL_7J92 DA03065 transformed cell line human CVCL_7J92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105277 CVCL_7J75 DA03047 transformed cell line human CVCL_7J75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105278 CVCL_7J76 DA03048 transformed cell line human CVCL_7J76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105279 CVCL_7J77 DA03049 transformed cell line human CVCL_7J77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105280 CVCL_7J78 DA03050 transformed cell line human CVCL_7J78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105281 CVCL_7J71 DA03042 transformed cell line human CVCL_7J71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105282 CVCL_7J72 DA03044 transformed cell line human CVCL_7J72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105283 CVCL_7J73 DA03045 transformed cell line human CVCL_7J73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105284 CVCL_7J74 DA03046 transformed cell line human CVCL_7J74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105285 CVCL_7J79 DA03051 transformed cell line human CVCL_7J79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105286 CVCL_7J70 DA03041 transformed cell line human CVCL_7J70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105287 CVCL_7J86 DA03059 transformed cell line human CVCL_7J86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105288 CVCL_7J87 DA03060 transformed cell line human CVCL_7J87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105289 CVCL_7J88 DA03061 transformed cell line human CVCL_7J88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105290 CVCL_7J89 DA03062 transformed cell line human CVCL_7J89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105291 CVCL_7J82 DA03054 transformed cell line human CVCL_7J82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105292 CVCL_7J83 DA03055 transformed cell line human CVCL_7J83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105293 CVCL_7J84 DA03056 transformed cell line human CVCL_7J84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105294 CVCL_7J85 DA03057 transformed cell line human CVCL_7J85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105295 CVCL_7J80 DA03052 transformed cell line human CVCL_7J80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105296 CVCL_7J81 DA03053 transformed cell line human CVCL_7J81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105297 CVCL_7J53 DA03022 transformed cell line human CVCL_7J53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105298 CVCL_7J54 DA03024 transformed cell line human CVCL_7J54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105299 CVCL_7J55 DA03025 transformed cell line human CVCL_7J55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105300 CVCL_7J56 DA03026 transformed cell line human CVCL_7J56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105301 CVCL_7J50 DA03019 transformed cell line human CVCL_7J50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105302 CVCL_7J51 DA03020 transformed cell line human CVCL_7J51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105303 CVCL_7J52 DA03021 transformed cell line human CVCL_7J52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105304 CVCL_7J57 DA03027 transformed cell line human CVCL_7J57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105305 CVCL_7J58 DA03028 transformed cell line human CVCL_7J58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105306 CVCL_7J59 DA03029 transformed cell line human CVCL_7J59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105307 CVCL_7J64 DA03035 transformed cell line human CVCL_7J64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105308 CVCL_7J65 DA03036 transformed cell line human CVCL_7J65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105309 CVCL_7J66 DA03037 transformed cell line human CVCL_7J66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105310 CVCL_7J67 DA03038 transformed cell line human CVCL_7J67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105311 CVCL_7J60 DA03031 transformed cell line human CVCL_7J60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105312 CVCL_7J61 DA03032 transformed cell line human CVCL_7J61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105313 CVCL_7J62 DA03033 transformed cell line human CVCL_7J62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105314 CVCL_7J63 DA03034 transformed cell line human CVCL_7J63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105315 CVCL_7J68 DA03039 transformed cell line human CVCL_7J68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105316 CVCL_7J69 DA03040 transformed cell line human CVCL_7J69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105317 CVCL_QV60 BayGenomics ES cell line YTC608 embryonic stem cell house mouse CVCL_QV60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105318 CVCL_R760 Hs 724.Pl finite cell line human CVCL_R760 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7458; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105319 CVCL_QV61 BayGenomics ES cell line YTC611 embryonic stem cell house mouse CVCL_QV61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94865; Dbi Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105320 CVCL_R761 Hs 725.Pl finite cell line human CVCL_R761 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7459; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105321 CVCL_QV62 BayGenomics ES cell line YTC614 embryonic stem cell house mouse CVCL_QV62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351663; Skp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105322 CVCL_R762 Hs 728.K finite cell line human CVCL_R762 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7461; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105323 CVCL_QV63 BayGenomics ES cell line YTC615 embryonic stem cell house mouse CVCL_QV63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107380; Spag7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105324 CVCL_R763 Hs 732.Pl finite cell line human CVCL_R763 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7466; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105325 CVCL_QV64 BayGenomics ES cell line YTC617 embryonic stem cell house mouse CVCL_QV64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105326 CVCL_R764 Hs 732.Sk/Mu finite cell line human CVCL_R764 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Epithelial cell.. Discontinued: ATCC; CRL-7467; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105327 CVCL_QV65 BayGenomics ES cell line YTC618 embryonic stem cell house mouse CVCL_QV65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333870; Ate1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105328 CVCL_R765 Hs 732.Sp finite cell line human CVCL_R765 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7468; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105329 CVCL_QV66 BayGenomics ES cell line YTC622 embryonic stem cell house mouse CVCL_QV66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929455; Rpl23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105330 CVCL_R766 Hs 737.Sk finite cell line human CVCL_R766 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7472; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105331 CVCL_QV67 BayGenomics ES cell line YTC623 embryonic stem cell house mouse CVCL_QV67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105332 CVCL_R767 Hs 738.Bl finite cell line human CVCL_R767 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7474; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105333 CVCL_QV68 BayGenomics ES cell line YTC628 embryonic stem cell house mouse CVCL_QV68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141787; C87436 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105334 CVCL_R768 HeLa SS6 cancer cell line human CVCL_R768 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21105335 CVCL_R769 32D-c-fms factor-dependent cell line house mouse CVCL_R769 CL:0000010 Transfected with: HGNC; 2433; CSF1R Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent 21105336 CVCL_QV69 BayGenomics ES cell line YTC629 embryonic stem cell house mouse CVCL_QV69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105337 CVCL_R750 A375-12R8-3 cancer cell line human CVCL_R750 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105338 CVCL_QV50 BayGenomics ES cell line YTC586 embryonic stem cell house mouse CVCL_QV50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346870; Map2k6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105339 CVCL_R751 A375-16R5-2 cancer cell line human CVCL_R751 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105340 CVCL_QV51 BayGenomics ES cell line YTC588 embryonic stem cell house mouse CVCL_QV51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105341 CVCL_R752 A375-16R5-5 cancer cell line human CVCL_R752 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105342 CVCL_QV52 BayGenomics ES cell line YTC592 embryonic stem cell house mouse CVCL_QV52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105343 CVCL_R753 A375-16R6-2 cancer cell line human CVCL_R753 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105344 CVCL_QV53 BayGenomics ES cell line YTC593 embryonic stem cell house mouse CVCL_QV53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105345 CVCL_R754 A375-16R6-3 cancer cell line human CVCL_R754 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105346 CVCL_QV54 BayGenomics ES cell line YTC596 embryonic stem cell house mouse CVCL_QV54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100860; Frs2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105347 CVCL_R755 A375-16R6-4 cancer cell line human CVCL_R755 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105348 CVCL_QV55 BayGenomics ES cell line YTC598 embryonic stem cell house mouse CVCL_QV55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105349 CVCL_QV56 BayGenomics ES cell line YTC599 embryonic stem cell house mouse CVCL_QV56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105350 CVCL_R756 SNU-2535 cancer cell line human CVCL_R756 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (CelloPub=CLPUB00546; PubMed=35852680); Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Gly1269Ala (c.3806G>C); ClinVar=VCV000376132; Zygosity=Heterozygous (CelloPub=CLPUB00546; PubMed=35852680) Population: Korean; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Female Characteristics: Resistant to crizotinib (PubMed=23344087) Doubling time: 61 hours (CelloPub=CLPUB00546) Part of: Seoul National University (SNU) cell line collection 21105351 CVCL_QV57 BayGenomics ES cell line YTC601 embryonic stem cell house mouse CVCL_QV57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351663; Skp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105352 CVCL_R757 Hs 707(C).Sk finite cell line human CVCL_R757 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7450; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105353 CVCL_QV58 BayGenomics ES cell line YTC602 embryonic stem cell house mouse CVCL_QV58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351663; Skp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105354 CVCL_R758 Hs 708.T cancer cell line human CVCL_R758 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7451; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105355 CVCL_QV59 BayGenomics ES cell line YTC607 embryonic stem cell house mouse CVCL_QV59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105356 CVCL_R759 Hs 723.Pl finite cell line human CVCL_R759 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7457; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105357 CVCL_QV40 BayGenomics ES cell line YTC559 embryonic stem cell house mouse CVCL_QV40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913732; Exoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105358 CVCL_R740 UMT26 cancer cell line human CVCL_R740 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=23456173) Derived from sampling site: Eye; uvea. Male Doubling time: 3-4 months (PubMed=23456173) Group: Serum/protein free medium cell line 21105359 CVCL_QV41 BayGenomics ES cell line YTC560 embryonic stem cell house mouse CVCL_QV41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138080; Utp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105360 CVCL_R741 UMT33 cancer cell line human CVCL_R741 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=23456173) Karyotypic information: Monosomy of chromosome 3 (PubMed=23456173); Derived from sampling site: Eye; uvea. Female Doubling time: 33 days (PubMed=23456173) Group: Serum/protein free medium cell line 21105361 CVCL_QV42 BayGenomics ES cell line YTC561 embryonic stem cell house mouse CVCL_QV42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105362 CVCL_R742 UM-UC-15 cancer cell line human CVCL_R742 CL:0000010 Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index 21105363 CVCL_QV43 BayGenomics ES cell line YTC563 embryonic stem cell house mouse CVCL_QV43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913840; Farsa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105364 CVCL_R743 UM-UC-17 cancer cell line human CVCL_R743 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified Part of: UBC-40 urothelial bladder cancer cell line index 21105365 CVCL_QV44 BayGenomics ES cell line YTC565 embryonic stem cell house mouse CVCL_QV44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105366 CVCL_R744 UM-UC-18 cancer cell line human CVCL_R744 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified Part of: UBC-40 urothelial bladder cancer cell line index 21105367 CVCL_R745 A375PF11 cancer cell line human CVCL_R745 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 21105368 CVCL_QV45 BayGenomics ES cell line YTC571 embryonic stem cell house mouse CVCL_QV45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679923; Ttc37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105369 CVCL_R746 A375-12R5-1 cancer cell line human CVCL_R746 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105370 CVCL_QV46 BayGenomics ES cell line YTC580 embryonic stem cell house mouse CVCL_QV46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338822; Celf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105371 CVCL_R747 A375-12R5-3 cancer cell line human CVCL_R747 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105372 CVCL_QV47 BayGenomics ES cell line YTC582 embryonic stem cell house mouse CVCL_QV47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88549; Csrp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105373 CVCL_R748 A375-12R5-5 cancer cell line human CVCL_R748 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105374 CVCL_QV48 BayGenomics ES cell line YTC584 embryonic stem cell house mouse CVCL_QV48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104556; Cdkn1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105375 CVCL_R749 A375-12R8-1 cancer cell line human CVCL_R749 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from sampling site: Skin. Female 21105376 CVCL_QV49 BayGenomics ES cell line YTC585 embryonic stem cell house mouse CVCL_QV49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105377 CVCL_QV30 BayGenomics ES cell line YTC538 embryonic stem cell house mouse CVCL_QV30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105378 CVCL_R730 HCT 116b cancer cell line human CVCL_R730 CL:0000010 Derived from sampling site: Colon. Male 21105379 CVCL_QV31 BayGenomics ES cell line YTC542 embryonic stem cell house mouse CVCL_QV31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154441; Nop53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105380 CVCL_R731 MOSER cancer cell line human CVCL_R731 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (PubMed=7651727). Unspecified 21105381 CVCL_QV32 BayGenomics ES cell line YTC543 embryonic stem cell house mouse CVCL_QV32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105382 CVCL_R732 MOSERSF cancer cell line human CVCL_R732 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (from parent cell line). Unspecified Group: Serum/protein free medium cell line 21105383 CVCL_QV33 BayGenomics ES cell line YTC544 embryonic stem cell house mouse CVCL_QV33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105384 CVCL_R733 GLY cancer cell line human CVCL_R733 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=9000147). Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147) 21105385 CVCL_QV34 BayGenomics ES cell line YTC549 embryonic stem cell house mouse CVCL_QV34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105386 CVCL_R734 JVC cancer cell line human CVCL_R734 CL:0000010 21105387 CVCL_QV35 BayGenomics ES cell line YTC550 embryonic stem cell house mouse CVCL_QV35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105388 CVCL_R735 RCA cancer cell line human CVCL_R735 CL:0000010 Unspecified 21105389 CVCL_QV36 BayGenomics ES cell line YTC551 embryonic stem cell house mouse CVCL_QV36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105390 CVCL_R736 YUSIT1-B11 cancer cell line human CVCL_R736 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Not specified. Male 21105391 CVCL_QV37 BayGenomics ES cell line YTC555 embryonic stem cell house mouse CVCL_QV37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105392 CVCL_R737 YUSIT1-B31 cancer cell line human CVCL_R737 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Not specified. Male 21105393 CVCL_QV38 BayGenomics ES cell line YTC556 embryonic stem cell house mouse CVCL_QV38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448542; Samd4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105394 CVCL_R738 YUSIT1-B5 cancer cell line human CVCL_R738 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Not specified. Male 21105395 CVCL_QV39 BayGenomics ES cell line YTC557 embryonic stem cell house mouse CVCL_QV39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332659; Bnip3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105396 CVCL_R739 UMT2 cancer cell line human CVCL_R739 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=23456173) Derived from sampling site: Eye; uvea. Male Doubling time: 3-4 days (PubMed=23456173) Group: Serum/protein free medium cell line 21105397 CVCL_QV20 BayGenomics ES cell line YTC524 embryonic stem cell house mouse CVCL_QV20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098283; Per1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105398 CVCL_R720 Hs 699.Sk finite cell line human CVCL_R720 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7437; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105399 CVCL_QV21 BayGenomics ES cell line YTC526 embryonic stem cell house mouse CVCL_QV21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105400 CVCL_R721 Hs 699.T cancer cell line human CVCL_R721 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7438; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105401 CVCL_QV22 BayGenomics ES cell line YTC527 embryonic stem cell house mouse CVCL_QV22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105402 CVCL_R722 Hs 702.Thm finite cell line human CVCL_R722 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7441; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105403 CVCL_QV23 BayGenomics ES cell line YTC528 embryonic stem cell house mouse CVCL_QV23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105404 CVCL_R723 Hs 705.T cancer cell line human CVCL_R723 CL:0000010 Discontinued: ATCC; CRL-7445; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105405 CVCL_QV24 BayGenomics ES cell line YTC531 embryonic stem cell house mouse CVCL_QV24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105406 CVCL_R724 OHS-4 cancer cell line human CVCL_R724 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; distal femur. Male Doubling time: 39 hours (PubMed=1860886) 21105407 CVCL_QV25 BayGenomics ES cell line YTC532 embryonic stem cell house mouse CVCL_QV25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105408 CVCL_R725 HuO9-M112 cancer cell line human CVCL_R725 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Highly metastatic Doubling time: 42.4 hours (PubMed=14669798) 21105409 CVCL_QV26 BayGenomics ES cell line YTC534 embryonic stem cell house mouse CVCL_QV26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107202; Atm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105410 CVCL_R726 HuO9-M132 cancer cell line human CVCL_R726 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Omics: Transcriptome analysis by microarray Female Characteristics: Highly metastatic Doubling time: 44.9 hours (PubMed=14669798) 21105411 CVCL_QV27 BayGenomics ES cell line YTC535 embryonic stem cell house mouse CVCL_QV27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105412 CVCL_R727 M-OS cancer cell line human CVCL_R727 CL:0000010 Derived from metastatic site: Lung. Male Doubling time: ~48 hours (PubMed=22833358) 21105413 CVCL_QV28 BayGenomics ES cell line YTC536 embryonic stem cell house mouse CVCL_QV28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355321; Chek2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105414 CVCL_R728 SURE CHO-M spontaneously immortalized cell line CVCL_R728 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used for high yield production of therapeutic proteins and antibodies (Selexis); Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Doubling time: 15.7 hours (Selexis) Group: Patented cell line; Group: Serum/protein free medium cell line 21105415 CVCL_QV29 BayGenomics ES cell line YTC537 embryonic stem cell house mouse CVCL_QV29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105416 CVCL_R729 HCT 116a cancer cell line human CVCL_R729 CL:0000010 Derived from sampling site: Colon. Male 21105417 CVCL_QV10 BayGenomics ES cell line YTC506 embryonic stem cell house mouse CVCL_QV10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140651; C77080 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105418 CVCL_R710 Hs 677.Tr finite cell line human CVCL_R710 CL:0000010 Derived from sampling site: Fetal trachea. Discontinued: ATCC; CRL-7409; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105419 CVCL_QV11 BayGenomics ES cell line YTC508 embryonic stem cell house mouse CVCL_QV11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196246; Znrf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105420 CVCL_R711 Hs 679.T cancer cell line human CVCL_R711 CL:0000010 Discontinued: ATCC; CRL-7410; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105421 CVCL_QV12 BayGenomics ES cell line YTC510 embryonic stem cell house mouse CVCL_QV12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95753; Glud1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105422 CVCL_R712 Hs 680.Ad finite cell line human CVCL_R712 CL:0000010 Derived from sampling site: Fetal adrenal gland. Discontinued: ATCC; CRL-7411; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105423 CVCL_QV13 BayGenomics ES cell line YTC511 embryonic stem cell house mouse CVCL_QV13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95753; Glud1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105424 CVCL_R713 Hs 680.Cor finite cell line human CVCL_R713 CL:0000010 Derived from sampling site: Fetal eye; cornea. Discontinued: ATCC; CRL-7412; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105425 CVCL_QV14 BayGenomics ES cell line YTC512 embryonic stem cell house mouse CVCL_QV14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338056; Klf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105426 CVCL_R714 Hs 680.Int finite cell line human CVCL_R714 CL:0000010 Derived from sampling site: Fetal intestine. Discontinued: ATCC; CRL-7413; true Female Doubling time: 8-10 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105427 CVCL_QV15 BayGenomics ES cell line YTC513 embryonic stem cell house mouse CVCL_QV15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99147; Yes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105428 CVCL_R715 Hs 680.Ir finite cell line human CVCL_R715 CL:0000010 Derived from sampling site: Fetal eye; iris. Discontinued: ATCC; CRL-7414; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105429 CVCL_QV16 BayGenomics ES cell line YTC516 embryonic stem cell house mouse CVCL_QV16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342294; Uri1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105430 CVCL_R716 Hs 680.K finite cell line human CVCL_R716 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7415; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105431 CVCL_QV17 BayGenomics ES cell line YTC518 embryonic stem cell house mouse CVCL_QV17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917900; Zcchc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105432 CVCL_R717 Hs 680.Li finite cell line human CVCL_R717 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7416; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105433 CVCL_QV18 BayGenomics ES cell line YTC520 embryonic stem cell house mouse CVCL_QV18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105434 CVCL_R718 Hs 680.Pan finite cell line human CVCL_R718 CL:0000010 Derived from sampling site: Fetal pancreas. Discontinued: ATCC; CRL-7417; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105435 CVCL_QV19 BayGenomics ES cell line YTC521 embryonic stem cell house mouse CVCL_QV19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685179; Zfp407 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105436 CVCL_R719 Hs 680.St finite cell line human CVCL_R719 CL:0000010 Derived from sampling site: Fetal stomach. Discontinued: ATCC; CRL-7420; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105437 CVCL_QV00 BayGenomics ES cell line YTC489 embryonic stem cell house mouse CVCL_QV00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105438 CVCL_R700 Hs 627.T undefined cell line type human CVCL_R700 CL:0000010 Discontinued: ATCC; CRL-7392; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105439 CVCL_QV01 BayGenomics ES cell line YTC490 embryonic stem cell house mouse CVCL_QV01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105440 CVCL_R701 Hs 627.Thd finite cell line human CVCL_R701 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: ATCC; CRL-7393; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105441 CVCL_QV02 BayGenomics ES cell line YTC492 embryonic stem cell house mouse CVCL_QV02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442326; Zbtb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105442 CVCL_R702 Hs 630.T cancer cell line human CVCL_R702 CL:0000010 Derived from metastatic site: Fetal brain. Discontinued: ATCC; CRL-7394; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105443 CVCL_QV03 BayGenomics ES cell line YTC494 embryonic stem cell house mouse CVCL_QV03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99778; Gpd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105444 CVCL_R703 Hs 677.Bl finite cell line human CVCL_R703 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7401; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105445 CVCL_R704 10C9 [Human lymphoma] cancer cell line human CVCL_R704 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10236. 21105446 CVCL_QV04 BayGenomics ES cell line YTC497 embryonic stem cell house mouse CVCL_QV04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108405; Apbb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105447 CVCL_QV05 BayGenomics ES cell line YTC499 embryonic stem cell house mouse CVCL_QV05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914357; Ankrd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105448 CVCL_R705 MG63.2 cancer cell line human CVCL_R705 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone; left femur. Omics: Transcriptome analysis by microarray Male Doubling time: 36.1 hours (PubMed=19363654) 21105449 CVCL_QV06 BayGenomics ES cell line YTC500 embryonic stem cell house mouse CVCL_QV06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105450 CVCL_R706 Hs 677.Eye finite cell line human CVCL_R706 CL:0000010 Derived from sampling site: Fetal eye. Discontinued: ATCC; CRL-7402; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105451 CVCL_QV07 BayGenomics ES cell line YTC503 embryonic stem cell house mouse CVCL_QV07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924992; Fbxo42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105452 CVCL_R707 Hs 677.Int finite cell line human CVCL_R707 CL:0000010 Derived from sampling site: Fetal intestine. Discontinued: ATCC; CRL-7403; true Female Doubling time: 4-5 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105453 CVCL_QV08 BayGenomics ES cell line YTC504 embryonic stem cell house mouse CVCL_QV08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105454 CVCL_R708 Hs 677.K finite cell line human CVCL_R708 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7404; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105455 CVCL_QV09 BayGenomics ES cell line YTC505 embryonic stem cell house mouse CVCL_QV09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338056; Klf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105456 CVCL_R709 Hs 677.Rec finite cell line human CVCL_R709 CL:0000010 Derived from sampling site: Fetal rectum. Discontinued: ATCC; CRL-7405; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105457 CVCL_7K52 DA03132 transformed cell line human CVCL_7K52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105458 CVCL_7K53 DA03133 transformed cell line human CVCL_7K53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105459 CVCL_7K54 DA03134 transformed cell line human CVCL_7K54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105460 CVCL_7K55 DA03135 transformed cell line human CVCL_7K55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105461 CVCL_7K50 DA03130 transformed cell line human CVCL_7K50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105462 CVCL_7K51 DA03131 transformed cell line human CVCL_7K51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105463 CVCL_7K56 DA03136 transformed cell line human CVCL_7K56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105464 CVCL_7K57 DA03137 transformed cell line human CVCL_7K57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105465 CVCL_7K58 DA03138 transformed cell line human CVCL_7K58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105466 CVCL_7K59 DA03140 transformed cell line human CVCL_7K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105467 CVCL_7K63 DA03145 transformed cell line human CVCL_7K63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105468 CVCL_7K64 DA03146 transformed cell line human CVCL_7K64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105469 CVCL_7K65 DA03147 transformed cell line human CVCL_7K65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105470 CVCL_7K66 DA03148 transformed cell line human CVCL_7K66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105471 CVCL_7K60 DA03141 transformed cell line human CVCL_7K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105472 CVCL_7K61 DA03142 transformed cell line human CVCL_7K61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105473 CVCL_7K62 DA03143 transformed cell line human CVCL_7K62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105474 CVCL_7K67 DA03149 transformed cell line human CVCL_7K67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105475 CVCL_7K68 DA03150 transformed cell line human CVCL_7K68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105476 CVCL_7K69 DA03151 transformed cell line human CVCL_7K69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105477 CVCL_7K30 DA03107 transformed cell line human CVCL_7K30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105478 CVCL_7K31 DA03108 transformed cell line human CVCL_7K31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105479 CVCL_7K32 DA03111 transformed cell line human CVCL_7K32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105480 CVCL_7K33 DA03112 transformed cell line human CVCL_7K33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03112; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105481 CVCL_7K38 DA03117 transformed cell line human CVCL_7K38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105482 CVCL_7K39 DA03118 transformed cell line human CVCL_7K39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105483 CVCL_7K34 DA03113 transformed cell line human CVCL_7K34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105484 CVCL_7K35 DA03114 transformed cell line human CVCL_7K35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105485 CVCL_7K36 DA03115 transformed cell line human CVCL_7K36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105486 CVCL_7K37 DA03116 transformed cell line human CVCL_7K37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105487 CVCL_7K41 DA03120 transformed cell line human CVCL_7K41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105488 CVCL_7K42 DA03121 transformed cell line human CVCL_7K42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105489 CVCL_7K43 DA03122 transformed cell line human CVCL_7K43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105490 CVCL_7K44 DA03124 transformed cell line human CVCL_7K44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105491 CVCL_7K40 DA03119 transformed cell line human CVCL_7K40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03119; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105492 CVCL_7K49 DA03129 transformed cell line human CVCL_7K49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105493 CVCL_7K45 DA03125 transformed cell line human CVCL_7K45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105494 CVCL_7K46 DA03126 transformed cell line human CVCL_7K46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105495 CVCL_7K47 DA03127 transformed cell line human CVCL_7K47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105496 CVCL_7K48 DA03128 transformed cell line human CVCL_7K48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105497 CVCL_7K10 DA03084 transformed cell line human CVCL_7K10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105498 CVCL_7K11 DA03085 transformed cell line human CVCL_7K11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03085; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105499 CVCL_7K16 DA03091 transformed cell line human CVCL_7K16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105500 CVCL_7K17 DA03092 transformed cell line human CVCL_7K17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105501 CVCL_7K18 DA03093 transformed cell line human CVCL_7K18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03093; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105502 CVCL_7K19 DA03095 transformed cell line human CVCL_7K19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105503 CVCL_7K12 DA03086 transformed cell line human CVCL_7K12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105504 CVCL_7K13 DA03087 transformed cell line human CVCL_7K13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105505 CVCL_7K14 DA03088 transformed cell line human CVCL_7K14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105506 CVCL_7K15 DA03089 transformed cell line human CVCL_7K15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105507 CVCL_7K09 DA03083 transformed cell line human CVCL_7K09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105508 CVCL_7K20 DA03096 transformed cell line human CVCL_7K20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105509 CVCL_7K21 DA03097 transformed cell line human CVCL_7K21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105510 CVCL_7K22 DA03098 transformed cell line human CVCL_7K22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105511 CVCL_7K27 DA03104 transformed cell line human CVCL_7K27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105512 CVCL_7K28 DA03105 transformed cell line human CVCL_7K28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105513 CVCL_7K29 DA03106 transformed cell line human CVCL_7K29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105514 CVCL_7K23 DA03099 transformed cell line human CVCL_7K23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105515 CVCL_7K24 DA03101 transformed cell line human CVCL_7K24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105516 CVCL_7K25 DA03102 transformed cell line human CVCL_7K25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105517 CVCL_7K26 DA03103 transformed cell line human CVCL_7K26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105518 CVCL_R890 CoE 45 spontaneously immortalized cell line CVCL_R890 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Fish cell line 21105519 CVCL_QW90 GIST-T1-R9 cancer cell line human CVCL_QW90 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Tyr (c.2458G>T); ClinVar=VCV000375928; Zygosity=Heterozygous (PubMed=27997714) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21105520 CVCL_R891 CSTF spontaneously immortalized cell line CVCL_R891 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21105521 CVCL_QW91 GIST-T1-117 cancer cell line human CVCL_QW91 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21105522 CVCL_R892 EAGB spontaneously immortalized cell line CVCL_R892 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21105523 CVCL_QW92 JKB-1 cancer cell line human CVCL_QW92 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~24 hours (PubMed=8172177) Caution: The exact relationship between JKB-1 and JKB-2 is not explicited in the papers reporting their respective establishment 21105524 CVCL_7K00 DA03073 transformed cell line human CVCL_7K00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105525 CVCL_R893 EAGK spontaneously immortalized cell line CVCL_R893 CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) Group: Fish cell line 21105526 CVCL_QW93 JKB-2 cancer cell line human CVCL_QW93 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: ~72 hours (PubMed=8847892) Caution: The exact relationship between JKB-1 and JKB-2 is not explicited in the papers reporting their respective establishment 21105527 CVCL_R894 EAGL spontaneously immortalized cell line CVCL_R894 CL:0000010 Derived from sampling site: Liver. Unspecified Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) Group: Fish cell line 21105528 CVCL_QW94 KH-3A cancer cell line human CVCL_QW94 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~48 hours (PubMed=3128506) 21105529 CVCL_R895 EAGS spontaneously immortalized cell line CVCL_R895 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21105530 CVCL_QW95 KH-3B cancer cell line human CVCL_QW95 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~48 hours (PubMed=3128506) 21105531 CVCL_R896 EAGSB spontaneously immortalized cell line CVCL_R896 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Group: Fish cell line 21105532 CVCL_QW96 KH-4 cancer cell line human CVCL_QW96 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: ~72 hours (PubMed=3128506) 21105533 CVCL_R897 FF-11 spontaneously immortalized cell line CVCL_R897 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105534 CVCL_QW97 KMO-R cancer cell line human CVCL_QW97 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female 21105535 CVCL_7K05 DA03078 transformed cell line human CVCL_7K05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105536 CVCL_R898 FFN spontaneously immortalized cell line CVCL_R898 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105537 CVCL_QW98 LEF1 cancer cell line human CVCL_QW98 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=2143794; PubMed=10071072) Karyotypic information: 46,XX,t(9;22)(q34;q11) (PubMed=2143794); Derived from sampling site: Peripheral blood. Female 21105538 CVCL_7K06 DA03079 transformed cell line human CVCL_7K06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105539 CVCL_R899 FSP spontaneously immortalized cell line CVCL_R899 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21105540 CVCL_QW99 MR-B transformed cell line human CVCL_QW99 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: 24-36 hours (PubMed=3048438) 21105541 CVCL_7K07 DA03081 transformed cell line human CVCL_7K07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105542 CVCL_7K08 DA03082 transformed cell line human CVCL_7K08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105543 CVCL_7K01 DA03074 transformed cell line human CVCL_7K01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105544 CVCL_7K02 DA03075 transformed cell line human CVCL_7K02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105545 CVCL_7K03 DA03076 transformed cell line human CVCL_7K03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105546 CVCL_7K04 DA03077 transformed cell line human CVCL_7K04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105547 CVCL_7K96 DA03179 transformed cell line human CVCL_7K96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105548 CVCL_7K97 DA03180 transformed cell line human CVCL_7K97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105549 CVCL_7K98 DA03181 transformed cell line human CVCL_7K98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105550 CVCL_7K99 DA03182 transformed cell line human CVCL_7K99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105551 CVCL_7K92 DA03175 transformed cell line human CVCL_7K92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105552 CVCL_7K93 DA03176 transformed cell line human CVCL_7K93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105553 CVCL_7K94 DA03177 transformed cell line human CVCL_7K94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105554 CVCL_7K95 DA03178 transformed cell line human CVCL_7K95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105555 CVCL_7K90 DA03173 transformed cell line human CVCL_7K90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105556 CVCL_7K91 DA03174 transformed cell line human CVCL_7K91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105557 CVCL_7K74 DA03156 transformed cell line human CVCL_7K74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105558 CVCL_7K75 DA03157 transformed cell line human CVCL_7K75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105559 CVCL_7K76 DA03158 transformed cell line human CVCL_7K76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105560 CVCL_7K77 DA03159 transformed cell line human CVCL_7K77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105561 CVCL_7K70 DA03152 transformed cell line human CVCL_7K70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105562 CVCL_7K71 DA03153 transformed cell line human CVCL_7K71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105563 CVCL_7K72 DA03154 transformed cell line human CVCL_7K72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105564 CVCL_7K73 DA03155 transformed cell line human CVCL_7K73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105565 CVCL_7K78 DA03160 transformed cell line human CVCL_7K78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105566 CVCL_7K79 DA03161 transformed cell line human CVCL_7K79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105567 CVCL_7K85 DA03167 transformed cell line human CVCL_7K85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105568 CVCL_7K86 DA03168 transformed cell line human CVCL_7K86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105569 CVCL_7K87 DA03169 transformed cell line human CVCL_7K87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105570 CVCL_7K88 DA03170 transformed cell line human CVCL_7K88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105571 CVCL_7K81 DA03163 transformed cell line human CVCL_7K81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105572 CVCL_7K82 DA03164 transformed cell line human CVCL_7K82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105573 CVCL_7K83 DA03165 transformed cell line human CVCL_7K83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105574 CVCL_7K84 DA03166 transformed cell line human CVCL_7K84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105575 CVCL_7K89 DA03171 transformed cell line human CVCL_7K89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105576 CVCL_7K80 DA03162 transformed cell line human CVCL_7K80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105577 CVCL_QW00 BayGenomics ES cell line YTC732 embryonic stem cell house mouse CVCL_QW00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917184; Trmt10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105578 CVCL_R800 Rok transformed cell line CVCL_R800 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1854; true Male Group: Non-human primate cell line 21105579 CVCL_QW01 BayGenomics ES cell line YTC737 embryonic stem cell house mouse CVCL_QW01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444777; Ncaph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105580 CVCL_R801 DAC/E cancer cell line human CVCL_R801 CL:0000010 Derived from sampling site: Small intestine; duodenum. Male Doubling time: 42 hours (PubMed=16696042) 21105581 CVCL_QW02 BayGenomics ES cell line YTC745 embryonic stem cell house mouse CVCL_QW02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921134; Zdbf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105582 CVCL_R802 DAC/S cancer cell line human CVCL_R802 CL:0000010 Derived from sampling site: Small intestine; duodenum. Male Doubling time: 24 hours (PubMed=16696042) 21105583 CVCL_QW03 BayGenomics ES cell line YTC747 embryonic stem cell house mouse CVCL_QW03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914737; Dhx40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105584 CVCL_R803 WDC-1 cancer cell line human CVCL_R803 CL:0000010 Population: Japanese; Derived from sampling site: Small intestine; duodenum. Female Doubling time: 50 hours (PubMed=10721940) 21105585 CVCL_QW04 BayGenomics ES cell line YTC748 embryonic stem cell house mouse CVCL_QW04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346873; Map3k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105586 CVCL_R804 ESCC-DR cancer cell line Norway rat CVCL_R804 CL:0000010 Breed/subspecies: Wistar. Male 21105587 CVCL_QW05 BayGenomics ES cell line YTC751 embryonic stem cell house mouse CVCL_QW05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105588 CVCL_R805 CFF spontaneously immortalized cell line CVCL_R805 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC039 21105589 CVCL_QW06 BayGenomics ES cell line YTC752 embryonic stem cell house mouse CVCL_QW06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105590 CVCL_R806 PFF spontaneously immortalized cell line CVCL_R806 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105591 CVCL_QW07 BayGenomics ES cell line YTC753 embryonic stem cell house mouse CVCL_QW07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143854; Nup107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105592 CVCL_R807 Fugu eye spontaneously immortalized cell line CVCL_R807 CL:0000010 Derived from sampling site: Eye. Unspecified Doubling time: ~2.5 days (PubMed=9418286) Group: Fish cell line 21105593 CVCL_QW08 BayGenomics ES cell line YTC756 embryonic stem cell house mouse CVCL_QW08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105594 CVCL_R808 Fugu fry spontaneously immortalized cell line CVCL_R808 CL:0000010 Unspecified Doubling time: ~2.5 days (PubMed=9418286). Group: Fish cell line 21105595 CVCL_QW09 BayGenomics ES cell line YTC758 embryonic stem cell house mouse CVCL_QW09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918019; Nolc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105596 CVCL_R809 PSF [Etroplus] spontaneously immortalized cell line CVCL_R809 CL:0000010 Derived from sampling site: Fin. Unspecified Virology: Not susceptible to infection by Tilapia lake virus (TiLV) (DOI=10.1016/j.aquaculture.2021.737589) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC065 21105597 CVCL_QW80 MDA-T22 cancer cell line human CVCL_QW80 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25427145); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=25427145) Derived from sampling site: Thyroid gland. Female 21105598 CVCL_R880 TO-2 spontaneously immortalized cell line CVCL_R880 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Can grow between 15 to 34 Celsius, with an optimal growth temperature of 31 Celsius (PubMed=3346335) Doubling time: 12 hours (in 20% FCS), 27 hours (in 10% FCS), 30 hours (in 5% FCS), 50 hours (in 2% FCS) (DOI=10.3147/jsfp.18.13) Group: Fish cell line 21105599 CVCL_QW81 KU-Lu-MPPt3 cancer cell line human CVCL_QW81 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Heterozygous (PubMed=29090354) Population: Japanese; Derived from sampling site: Lung. Female Doubling time: 59.2-74.5 hours (PubMed=29090354) 21105600 CVCL_R881 TO-37c spontaneously immortalized cell line CVCL_R881 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Heat-resistant Grows at 37 Celsius. Group: Fish cell line 21105601 CVCL_QW82 GIST-T1-R2 cancer cell line human CVCL_QW82 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21105602 CVCL_R882 TZ-1 cancer cell line human CVCL_R882 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Doubling time: 36 hours (PubMed=16826222) 21105603 CVCL_R883 CAF spontaneously immortalized cell line CVCL_R883 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 0.8 day (at 33 Celsius), 1.2 days (at 26 Celsius), 1.6 days (at 20 Celsius) (CelloPub=CLPUB00025) Group: Fish cell line 21105604 CVCL_QW83 MDA-T68 cancer cell line human CVCL_QW83 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=25427145) Derived from sampling site: Thyroid gland. Male 21105605 CVCL_R884 CAF-MM1 spontaneously immortalized cell line CVCL_R884 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 18 hours (at 33 Celsius), 31 hours (at 26 Celsius), 60 hours (at 20 Celsius) (PubMed=7063616) Group: Fish cell line 21105606 CVCL_QW84 MDA-T85 cancer cell line human CVCL_QW84 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=25427145; PubMed=30737244); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Heterozygous (PubMed=25427145; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21105607 CVCL_R885 CHIE spontaneously immortalized cell line CVCL_R885 CL:0000010 Unspecified Group: Fish cell line. 21105608 CVCL_QW85 MDA-T120 cancer cell line human CVCL_QW85 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25427145; PubMed=30737244); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Glu182Ter (c.544G>T); ClinVar=VCV000003289; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=25427145; PubMed=30737244) Derived from metastatic site: Cervical lymph node. Omics: Transcriptome analysis by microarray Female 21105609 CVCL_R886 CHSE-TOF5 spontaneously immortalized cell line CVCL_R886 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Fish cell line 21105610 CVCL_QW86 GIST-T1-R8 cancer cell line human CVCL_QW86 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Tyr (c.2458G>T); ClinVar=VCV000375928; Zygosity=Heterozygous (PubMed=27997714) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21105611 CVCL_R887 CLA1RGB finite cell line human CVCL_R887 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105612 CVCL_QW87 RMS176 cancer cell line human CVCL_QW87 CL:0000010 21105613 CVCL_R888 CoE 115 spontaneously immortalized cell line CVCL_R888 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Fish cell line 21105614 CVCL_QW88 IMS32 spontaneously immortalized cell line house mouse CVCL_QW88 CL:0000010 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.; Breed/subspecies: CD-1. Unspecified 21105615 CVCL_R889 CoE 345 spontaneously immortalized cell line CVCL_R889 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Fish cell line 21105616 CVCL_QW89 GIST-T1-RA2 cancer cell line human CVCL_QW89 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21105617 CVCL_R870 MMC-E spontaneously immortalized cell line CVCL_R870 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Discontinued: ATCC; CRL-1575; true Unspecified 21105618 CVCL_QW70 Silvanus cancer cell line human CVCL_QW70 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: 2-3 days (PubMed=9444937) 21105619 CVCL_R871 MMC-F spontaneously immortalized cell line CVCL_R871 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Discontinued: ATCC; CRL-1577; true Unspecified 21105620 CVCL_QW71 TC-CTR-shRNA cancer cell line human CVCL_QW71 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Bone; humerus. Omics: Transcriptome analysis by microarray Male 21105621 CVCL_R872 AGF II spontaneously immortalized cell line CVCL_R872 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: 51.1 hours (PubMed=23266987) Group: Fish cell line 21105622 CVCL_QW72 TC-CD99-shRNA#1 cancer cell line human CVCL_QW72 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7082; CD99; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Bone; humerus. Omics: Transcriptome analysis by microarray Male 21105623 CVCL_R873 CSEC [Cynoglossus] spontaneously immortalized cell line CVCL_R873 CL:0000010 Unspecified Group: Fish cell line. 21105624 CVCL_QW73 TC-CD99-shRNA#2 cancer cell line human CVCL_QW73 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7082; CD99; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Bone; humerus. Omics: Transcriptome analysis by microarray Male 21105625 CVCL_QW74 BRZ-CTR-shRNA cancer cell line human CVCL_QW74 CL:0000010 Omics: Transcriptome analysis by microarray. 21105626 CVCL_R874 CSH spontaneously immortalized cell line CVCL_R874 CL:0000010 Derived from sampling site: Heart. Unspecified Doubling time: 73.39 hours (PubMed=20376698) Group: Fish cell line 21105627 CVCL_QW75 BRZ-CD99-shRNA#1 cancer cell line human CVCL_QW75 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7082; CD99 Omics: Transcriptome analysis by microarray. 21105628 CVCL_R875 FEC spontaneously immortalized cell line CVCL_R875 CL:0000010 Unspecified Group: Fish cell line. 21105629 CVCL_QW76 BRZ-CD99-shRNA#2 cancer cell line human CVCL_QW76 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7082; CD99 Omics: Transcriptome analysis by microarray. 21105630 CVCL_R876 HTLC spontaneously immortalized cell line CVCL_R876 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21105631 CVCL_QW77 9C3 [Mouse hybridoma against human WFDC2] hybridoma house mouse CVCL_QW77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q14508; Human WFDC2. 21105632 CVCL_R877 TSHKC spontaneously immortalized cell line CVCL_R877 CL:0000010 Derived from sampling site: Head kidney. Female Group: Fish cell line 21105633 CVCL_QW78 Caco-3 cancer cell line human CVCL_QW78 CL:0000010 Male 21105634 CVCL_R878 JF spontaneously immortalized cell line CVCL_R878 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105635 CVCL_QW79 T-67 cancer cell line human CVCL_QW79 CL:0000010 Female 21105636 CVCL_R879 TK-1 [Tilapia] spontaneously immortalized cell line CVCL_R879 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105637 CVCL_QW60 BW-1 cancer cell line human CVCL_QW60 CL:0000010 Population: Japanese Male Virology: EBV-negative Doubling time: 34.2 hours (PubMed=8847894) Caution: Indicated as originating from a 68 year old male patient in text of PubMed=8847894 and from a 52 year old in table 1 of same paper. 21105638 CVCL_R860 SAS-L1 cancer cell line human CVCL_R860 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Female Doubling time: 31.4 +- 2.2 hours (PubMed=9379426) 21105639 CVCL_QW61 ALL-1 cancer cell line human CVCL_QW61 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Derived from sampling site: Bone marrow. Female 21105640 CVCL_R861 J14 cancer cell line human CVCL_R861 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Deficient in the expression of LCP2 (SLP-76) (PubMed=9665884) 21105641 CVCL_QW62 ALL-2 cancer cell line human CVCL_QW62 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from child cell line ALL-2B). Female 21105642 CVCL_R862 J.CaM2 cancer cell line human CVCL_R862 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 18874; LAT; Simple; g.237C>T; Zygosity=Heterozygous (PubMed=27278128; PubMed=33562083); Sequence variation: Mutation; HGNC; 18874; LAT; Simple; p.Thr56Met (c.167C>T); Zygosity=Heterozygous (PubMed=27278128; PubMed=33562083); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Lacks LAT expression 21105643 CVCL_QW63 ALL-3 cancer cell line human CVCL_QW63 CL:0000010 Derived from sampling site: Bone marrow. Male 21105644 CVCL_R863 MCP-5 [Mouse] transformed cell line house mouse CVCL_R863 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Omics: Deep quantitative phosphoproteome analysis Unspecified 21105645 CVCL_QW64 BS transformed cell line human CVCL_QW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: 24-48 hours (PubMed=27467674) 21105646 CVCL_R864 CHO/IR spontaneously immortalized cell line CVCL_R864 CL:0000010 Transfected with: HGNC; 6091; INSR Derived from sampling site: Ovary. Female 21105647 CVCL_R865 CHO/IR/IRS-1 spontaneously immortalized cell line CVCL_R865 CL:0000010 Transfected with: HGNC; 6091; INSR; Transfected with: RGD; 2922; Irs1 Derived from sampling site: Ovary. Female 21105648 CVCL_QW65 OCI-Ly9 cancer cell line human CVCL_QW65 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Bone marrow. Male 21105649 CVCL_QW66 B1 [Human leukemia] cancer cell line human CVCL_QW66 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4; Note=In frame (PubMed=1423625; PubMed=8358709) Derived from sampling site: Bone marrow. Male Doubling time: 40-50 hours (PubMed=1648979) 21105650 CVCL_R866 CHO/IRS-1 spontaneously immortalized cell line CVCL_R866 CL:0000010 Transfected with: RGD; 2922; Irs1 Derived from sampling site: Ovary. Female 21105651 CVCL_QW67 ALL-2B cancer cell line human CVCL_QW67 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638). Female 21105652 CVCL_R867 CHO/IR/IRS-2 spontaneously immortalized cell line CVCL_R867 CL:0000010 Transfected with: HGNC; 6091; INSR; Transfected with: MGI; MGI:109334; Irs2 Derived from sampling site: Ovary. Female 21105653 CVCL_QW68 Dunatis cancer cell line human CVCL_QW68 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Derived from sampling site: Peripheral blood. Male Doubling time: 5-7 days (PubMed=9444937) 21105654 CVCL_R868 G2 [Human leukemia] cancer cell line human CVCL_R868 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: 72 hours (PubMed=1531243) 21105655 CVCL_QW69 Mieliki cancer cell line human CVCL_QW69 CL:0000010 Derived from sampling site: Bone marrow. Female Doubling time: ~5-6 days (PubMed=7630198) 21105656 CVCL_R869 PHM1-31 transformed cell line human CVCL_R869 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; myometrium Cell type=Myometrial cell.. Female 21105657 CVCL_QW50 BLIN-4 cancer cell line human CVCL_QW50 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Requires bone marrow stromal cells for optimal growth 21105658 CVCL_R850 RGH spontaneously immortalized cell line CVCL_R850 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105659 CVCL_QW51 BLIN-4E cancer cell line human CVCL_QW51 CL:0000010 Derived from sampling site: Bone marrow. Female 21105660 CVCL_R851 RTE [Carp embryo] spontaneously immortalized cell line CVCL_R851 CL:0000010 Unspecified Group: Fish cell line. 21105661 CVCL_QW52 BLIN-4L cancer cell line human CVCL_QW52 CL:0000010 Derived from sampling site: Bone marrow. Female 21105662 CVCL_R852 RTE-2 spontaneously immortalized cell line CVCL_R852 CL:0000010 Unspecified Group: Fish cell line. 21105663 CVCL_QW53 NB-NR cancer cell line human CVCL_QW53 CL:0000010 Population: Japanese. Male 21105664 CVCL_R853 RTT spontaneously immortalized cell line CVCL_R853 CL:0000010 Derived from sampling site: Tail; muscle. Unspecified Group: Fish cell line 21105665 CVCL_QW54 HEK293T SMARCB1-/- transformed cell line human CVCL_QW54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11103; SMARCB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21105666 CVCL_R854 S-TFE cancer cell line human CVCL_R854 CL:0000010 Sequence variation: Gene fusion; HGNC; 13825; ASPSCR1 + HGNC; 11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3; Note=In frame (PubMed=23760492) Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 98.2 hours (PubMed=23760492) 21105667 CVCL_QW55 G-401 BAF47 cancer cell line human CVCL_QW55 CL:0000010 Transfected with: HGNC; 11103; SMARCB1 Population: Caucasian; Derived from sampling site: Kidney. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Transfection of SMARCB1 rescues the phenotype of the parent cell line which is homozygous for its deletion Problematic cell line: Misclassified Parent cell line (G-401) was originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line. 21105668 CVCL_R855 SEH spontaneously immortalized cell line CVCL_R855 CL:0000010 Unspecified Group: Fish cell line. 21105669 CVCL_QW56 HS-ES-2M BAF47 cancer cell line human CVCL_QW56 CL:0000010 Transfected with: HGNC; 11103; SMARCB1 Population: Japanese; Derived from metastatic site: Lung. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Transfection of SMARCB1 rescues the phenotype of the parent cell line which is heterozygous for its deletion 21105670 CVCL_R856 SHH [Snakehead heart Japan] spontaneously immortalized cell line CVCL_R856 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105671 CVCL_QW57 TTC-1240 BAF47 cancer cell line human CVCL_QW57 CL:0000010 Transfected with: HGNC; 11103; SMARCB1 Derived from metastatic site: Brain. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfection of SMARCB1 rescues the phenotype of the parent cell line which has a deleterious mutation in that gene 21105672 CVCL_R857 WF-1 spontaneously immortalized cell line CVCL_R857 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105673 CVCL_R858 BHK-IR spontaneously immortalized cell line CVCL_R858 CL:0000010 Transfected with: HGNC; 6091; INSR Derived from sampling site: Kidney. Male 21105674 CVCL_QW58 VA-ES-BJ BAF47 cancer cell line human CVCL_QW58 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11103; SMARCB1 Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male 21105675 CVCL_QW59 2L1 cancer cell line human CVCL_QW59 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified; Note=Germline (PubMed=9616138) Derived from sampling site: Bone marrow. Female 21105676 CVCL_R859 SAS-H1 cancer cell line human CVCL_R859 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Female Doubling time: 30.4 +- 7.2 hours (PubMed=9379426) 21105677 CVCL_R840 CF4 spontaneously immortalized cell line zebrafish CVCL_R840 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105678 CVCL_QW40 EidheAEC.B-3 transformed cell line CVCL_QW40 CL:0000010 Miscellaneous: Age of donor from personal communication of Eckerle I. Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Unspecified Group: Bat cell line 21105679 CVCL_QW41 ATCi-rSD95 induced pluripotent stem cell Norway rat CVCL_QW41 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic trunk Cell type=Fibroblast.; Breed/subspecies: Sprague Dawley Tg(GFP)1BalRrrc. Female 21105680 CVCL_R841 EPG spontaneously immortalized cell line CVCL_R841 CL:0000010 Unspecified Group: Fish cell line. 21105681 CVCL_QW42 CERAi001-A-6 induced pluripotent stem cell human CVCL_QW42 From: Centre for Eye Research Australia, University of Melbourne; Melbourne; Australia CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Fibroblast.. Male 21105682 CVCL_R842 GI spontaneously immortalized cell line CVCL_R842 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105683 CVCL_QW43 CHiPSC-B induced pluripotent stem cell CVCL_QW43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21105684 CVCL_R843 GFTF spontaneously immortalized cell line CVCL_R843 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21105685 CVCL_QW44 JCLRIi001-A induced pluripotent stem cell human CVCL_QW44 From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Derived from sampling site: Fetal liver. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105686 CVCL_R844 MAF spontaneously immortalized cell line CVCL_R844 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105687 CVCL_QW45 JCLRIi001-A-1 induced pluripotent stem cell human CVCL_QW45 From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Derived from sampling site: Fetal liver. Female Characteristics: Using CRISPR/Cas9 Cas9 under the control of a tetracycline response element (TRE) promoter has been inserted at the safe harbor locus (AAVS1) Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105688 CVCL_R845 PBLE spontaneously immortalized cell line CVCL_R845 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21105689 CVCL_QW46 RbiPSC induced pluripotent stem cell CVCL_QW46 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Hycole hybrid. Female 21105690 CVCL_R846 RGB spontaneously immortalized cell line CVCL_R846 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21105691 CVCL_QW47 BLIN-3 cancer cell line human CVCL_QW47 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638) Derived from sampling site: Bone marrow. Female 21105692 CVCL_R847 RGE-2 spontaneously immortalized cell line CVCL_R847 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105693 CVCL_QW48 BLIN-2 cancer cell line human CVCL_QW48 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Requires bone marrow stromal cells or skin fibroblasts for optimal growth Doubling time: ~2 days (PubMed=9808575) 21105694 CVCL_R848 RGF [Salmo] spontaneously immortalized cell line CVCL_R848 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105695 CVCL_R849 RGG spontaneously immortalized cell line CVCL_R849 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105696 CVCL_QW49 XP3OS iPS induced pluripotent stem cell human CVCL_QW49 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27197874) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21105697 CVCL_QW30 BayGenomics ES cell line YTC813 embryonic stem cell house mouse CVCL_QW30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918313; Zfp597 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105698 CVCL_R830 Hs 761.T cancer cell line human CVCL_R830 CL:0000010 Male Doubling time: 12-14 days (PubMed=176412). 21105699 CVCL_QW31 BayGenomics ES cell line YTC814 embryonic stem cell house mouse CVCL_QW31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105700 CVCL_R831 Hs 760.T cancer cell line human CVCL_R831 CL:0000010 Discontinued: ATCC; CRL-7491; true; Discontinued: ECACC; 93071610; probable. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105701 CVCL_QW32 BayGenomics ES cell line YTC815 embryonic stem cell house mouse CVCL_QW32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96136; Hmgn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105702 CVCL_R832 Hs 762.T cancer cell line human CVCL_R832 CL:0000010 Discontinued: ATCC; CRL-7493; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105703 CVCL_QW33 BayGenomics ES cell line YTC816 embryonic stem cell house mouse CVCL_QW33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098658; Stag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105704 CVCL_R833 BGF spontaneously immortalized cell line CVCL_R833 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105705 CVCL_QW34 BayGenomics ES cell line YTC822 embryonic stem cell house mouse CVCL_QW34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914320; Lsm14a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105706 CVCL_R834 BGK spontaneously immortalized cell line CVCL_R834 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105707 CVCL_QW35 BayGenomics ES cell line YTC827 embryonic stem cell house mouse CVCL_QW35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926078; Rhot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105708 CVCL_R835 BTF spontaneously immortalized cell line CVCL_R835 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105709 CVCL_QW36 BayGenomics ES cell line YTC830 embryonic stem cell house mouse CVCL_QW36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105710 CVCL_R836 BTMS spontaneously immortalized cell line CVCL_R836 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 21105711 CVCL_QW37 BayGenomics ES cell line YTC833 embryonic stem cell house mouse CVCL_QW37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914737; Dhx40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105712 CVCL_R837 CCF [Cyprinus fin China] spontaneously immortalized cell line CVCL_R837 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105713 CVCL_QW38 BayGenomics ES cell line YTC837 embryonic stem cell house mouse CVCL_QW38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105714 CVCL_R838 CCG spontaneously immortalized cell line CVCL_R838 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105715 CVCL_QW39 CarperAEC.B-1 transformed cell line CVCL_QW39 CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Eckerle I. Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Male Group: Bat cell line 21105716 CVCL_R839 CCT [Cyprinus] spontaneously immortalized cell line CVCL_R839 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21105717 CVCL_QW20 BayGenomics ES cell line YTC785 embryonic stem cell house mouse CVCL_QW20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915209; Puf60 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105718 CVCL_R820 ZG spontaneously immortalized cell line zebrafish CVCL_R820 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105719 CVCL_QW21 BayGenomics ES cell line YTC786 embryonic stem cell house mouse CVCL_QW21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97805; Ptpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105720 CVCL_R821 CSG spontaneously immortalized cell line CVCL_R821 CL:0000010 Derived from sampling site: Gill. Unspecified Doubling time: ~37 hours (PubMed=23972731) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC046 21105721 CVCL_QW22 BayGenomics ES cell line YTC787 embryonic stem cell house mouse CVCL_QW22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333803; Top3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105722 CVCL_R822 CHSE-114 spontaneously immortalized cell line CVCL_R822 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) (CelloPub=CLPUB00703) Group: Fish cell line 21105723 CVCL_QW23 BayGenomics ES cell line YTC796 embryonic stem cell house mouse CVCL_QW23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105724 CVCL_R823 SSE-30 spontaneously immortalized cell line CVCL_R823 CL:0000010 Unspecified Group: Fish cell line. 21105725 CVCL_QW24 BayGenomics ES cell line YTC798 embryonic stem cell house mouse CVCL_QW24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97805; Ptpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105726 CVCL_R824 KO-6 spontaneously immortalized cell line CVCL_R824 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21105727 CVCL_QW25 BayGenomics ES cell line YTC799 embryonic stem cell house mouse CVCL_QW25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444098; Heatr5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105728 CVCL_R825 CCM spontaneously immortalized cell line CVCL_R825 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Macrophage.. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC034 21105729 CVCL_QW26 BayGenomics ES cell line YTC802 embryonic stem cell house mouse CVCL_QW26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444430; Pomt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105730 CVCL_R826 CTE spontaneously immortalized cell line CVCL_R826 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC029 21105731 CVCL_QW27 BayGenomics ES cell line YTC803 embryonic stem cell house mouse CVCL_QW27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921344; Tjap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105732 CVCL_R827 LRG spontaneously immortalized cell line CVCL_R827 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC023 21105733 CVCL_QW28 BayGenomics ES cell line YTC807 embryonic stem cell house mouse CVCL_QW28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915955; Gtf2f2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105734 CVCL_R828 LRTM spontaneously immortalized cell line CVCL_R828 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic macrophage.. Unspecified Group: Fish cell line 21105735 CVCL_QW29 BayGenomics ES cell line YTC812 embryonic stem cell house mouse CVCL_QW29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107164; Ppp3ca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105736 CVCL_R829 Hs 715.T cancer cell line human CVCL_R829 CL:0000010 Male Doubling time: 12-14 days (PubMed=176412). 21105737 CVCL_QW10 BayGenomics ES cell line YTC760 embryonic stem cell house mouse CVCL_QW10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921572; Cxxc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105738 CVCL_R810 RG-1 [Labeo] spontaneously immortalized cell line CVCL_R810 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21105739 CVCL_QW11 BayGenomics ES cell line YTC765 embryonic stem cell house mouse CVCL_QW11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858259; Tomm40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105740 CVCL_R811 SICH spontaneously immortalized cell line CVCL_R811 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC019 21105741 CVCL_QW12 BayGenomics ES cell line YTC769 embryonic stem cell house mouse CVCL_QW12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105742 CVCL_R812 SISS spontaneously immortalized cell line CVCL_R812 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC015 21105743 CVCL_QW13 BayGenomics ES cell line YTC770 embryonic stem cell house mouse CVCL_QW13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921579; Inava Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105744 CVCL_R813 TBE-1 [Human bronchial epithelial] transformed cell line human CVCL_R813 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Derived from sampling site: Bronchus; epithelium. Female 21105745 CVCL_QW14 BayGenomics ES cell line YTC771 embryonic stem cell house mouse CVCL_QW14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88549; Csrp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105746 CVCL_R814 TBE-1 [Scophthalmus] spontaneously immortalized cell line CVCL_R814 CL:0000010 Derived from sampling site: Tail. Unspecified Group: Fish cell line 21105747 CVCL_QW15 BayGenomics ES cell line YTC773 embryonic stem cell house mouse CVCL_QW15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97805; Ptpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105748 CVCL_R815 TK [Scophthalmus] spontaneously immortalized cell line CVCL_R815 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105749 CVCL_QW16 BayGenomics ES cell line YTC776 embryonic stem cell house mouse CVCL_QW16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346858; Mapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105750 CVCL_R816 MDCC-TV1 transformed cell line CVCL_R816 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Female Group: Bird cell line 21105751 CVCL_QW17 BayGenomics ES cell line YTC781 embryonic stem cell house mouse CVCL_QW17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918685; Arhgap21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105752 CVCL_R817 TV-1 spontaneously immortalized cell line CVCL_R817 CL:0000010 Unspecified Characteristics: Optimal growth temperature is 20 Celsius (DOI=10.1046/j.1365-2761.2002.00371.x; PubMed=8167908) Doubling time: 2 days (CelloPub=CLPUB00121). Group: Fish cell line Problematic cell line: Misidentified Originally thought to originate from the caudal fin of the turbot Scophthalmus maximus, but has been found to be a cell line from an undefined fish species (CelloPub=CLPUB00602). 21105753 CVCL_QW18 BayGenomics ES cell line YTC782 embryonic stem cell house mouse CVCL_QW18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917936; Dusp16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105754 CVCL_R818 ZEM spontaneously immortalized cell line zebrafish CVCL_R818 CL:0000010 Unspecified Group: Fish cell line. 21105755 CVCL_QW19 BayGenomics ES cell line YTC783 embryonic stem cell house mouse CVCL_QW19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21105756 CVCL_R819 ZEMH spontaneously immortalized cell line zebrafish CVCL_R819 CL:0000010 Unspecified Group: Fish cell line; Group: Haploid karyotype cell line. 21105757 CVCL_7L73 DA03272 transformed cell line human CVCL_7L73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105758 CVCL_7L74 DA03273 transformed cell line human CVCL_7L74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105759 CVCL_7L75 DA03274 transformed cell line human CVCL_7L75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105760 CVCL_7L76 DA03275 transformed cell line human CVCL_7L76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105761 CVCL_7L70 DA03269 transformed cell line human CVCL_7L70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105762 CVCL_7L71 DA03270 transformed cell line human CVCL_7L71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105763 CVCL_7L72 DA03271 transformed cell line human CVCL_7L72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105764 CVCL_7L77 DA03276 transformed cell line human CVCL_7L77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105765 CVCL_7L78 DA03277 transformed cell line human CVCL_7L78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105766 CVCL_7L79 DA03278 transformed cell line human CVCL_7L79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105767 CVCL_7L84 DA03283 transformed cell line human CVCL_7L84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105768 CVCL_7L85 DA03284 transformed cell line human CVCL_7L85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105769 CVCL_7L86 DA03285 transformed cell line human CVCL_7L86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105770 CVCL_7L87 DA03286 transformed cell line human CVCL_7L87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105771 CVCL_7L80 DA03279 transformed cell line human CVCL_7L80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105772 CVCL_7L81 DA03280 transformed cell line human CVCL_7L81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105773 CVCL_7L82 DA03281 transformed cell line human CVCL_7L82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105774 CVCL_7L83 DA03282 transformed cell line human CVCL_7L83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105775 CVCL_7L88 DA03287 transformed cell line human CVCL_7L88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105776 CVCL_7L89 DA03288 transformed cell line human CVCL_7L89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105777 CVCL_7L51 DA03249 transformed cell line human CVCL_7L51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105778 CVCL_7L52 DA03250 transformed cell line human CVCL_7L52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105779 CVCL_7L53 DA03251 transformed cell line human CVCL_7L53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105780 CVCL_7L54 DA03252 transformed cell line human CVCL_7L54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105781 CVCL_7L50 DA03248 transformed cell line human CVCL_7L50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105782 CVCL_7L59 DA03257 transformed cell line human CVCL_7L59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105783 CVCL_7L55 DA03253 transformed cell line human CVCL_7L55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105784 CVCL_7L56 DA03254 transformed cell line human CVCL_7L56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105785 CVCL_7L57 DA03255 transformed cell line human CVCL_7L57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105786 CVCL_7L58 DA03256 transformed cell line human CVCL_7L58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105787 CVCL_7L62 DA03261 transformed cell line human CVCL_7L62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105788 CVCL_7L63 DA03262 transformed cell line human CVCL_7L63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105789 CVCL_7L64 DA03263 transformed cell line human CVCL_7L64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105790 CVCL_7L65 DA03264 transformed cell line human CVCL_7L65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105791 CVCL_7L60 DA03258 transformed cell line human CVCL_7L60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105792 CVCL_7L61 DA03259 transformed cell line human CVCL_7L61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105793 CVCL_7L66 DA03265 transformed cell line human CVCL_7L66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105794 CVCL_7L67 DA03266 transformed cell line human CVCL_7L67 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105795 CVCL_7L68 DA03267 transformed cell line human CVCL_7L68 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105796 CVCL_7L69 DA03268 transformed cell line human CVCL_7L69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105797 CVCL_7L30 DA03215 transformed cell line human CVCL_7L30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105798 CVCL_7L31 DA03216 transformed cell line human CVCL_7L31 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105799 CVCL_7L32 DA03217 transformed cell line human CVCL_7L32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105800 CVCL_7L37 DA03224 transformed cell line human CVCL_7L37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105801 CVCL_7L38 DA03225 transformed cell line human CVCL_7L38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105802 CVCL_7L39 DA03226 transformed cell line human CVCL_7L39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105803 CVCL_7L33 DA03218 transformed cell line human CVCL_7L33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105804 CVCL_7L34 DA03221 transformed cell line human CVCL_7L34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105805 CVCL_7L35 DA03222 transformed cell line human CVCL_7L35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105806 CVCL_7L36 DA03223 transformed cell line human CVCL_7L36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105807 CVCL_7L40 DA03238 transformed cell line human CVCL_7L40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105808 CVCL_7L41 DA03239 transformed cell line human CVCL_7L41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105809 CVCL_7L42 DA03240 transformed cell line human CVCL_7L42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105810 CVCL_7L43 DA03241 transformed cell line human CVCL_7L43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105811 CVCL_7L48 DA03246 transformed cell line human CVCL_7L48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105812 CVCL_7L49 DA03247 transformed cell line human CVCL_7L49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105813 CVCL_7L44 DA03242 transformed cell line human CVCL_7L44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105814 CVCL_7L45 DA03243 transformed cell line human CVCL_7L45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105815 CVCL_7L46 DA03244 transformed cell line human CVCL_7L46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105816 CVCL_7L47 DA03245 transformed cell line human CVCL_7L47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105817 CVCL_7L10 DA03193 transformed cell line human CVCL_7L10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105818 CVCL_7L15 DA03199 transformed cell line human CVCL_7L15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105819 CVCL_7L16 DA03201 transformed cell line human CVCL_7L16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105820 CVCL_7L17 DA03202 transformed cell line human CVCL_7L17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105821 CVCL_7L18 DA03203 transformed cell line human CVCL_7L18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105822 CVCL_7L11 DA03194 transformed cell line human CVCL_7L11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105823 CVCL_7L12 DA03195 transformed cell line human CVCL_7L12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105824 CVCL_7L13 DA03196 transformed cell line human CVCL_7L13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105825 CVCL_7L14 DA03198 transformed cell line human CVCL_7L14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105826 CVCL_7L08 DA03191 transformed cell line human CVCL_7L08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105827 CVCL_7L09 DA03192 transformed cell line human CVCL_7L09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105828 CVCL_7L20 DA03205 transformed cell line human CVCL_7L20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105829 CVCL_7L21 DA03206 transformed cell line human CVCL_7L21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105830 CVCL_7L26 DA03211 transformed cell line human CVCL_7L26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105831 CVCL_7L27 DA03212 transformed cell line human CVCL_7L27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105832 CVCL_7L28 DA03213 transformed cell line human CVCL_7L28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105833 CVCL_7L29 DA03214 transformed cell line human CVCL_7L29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105834 CVCL_7L22 DA03207 transformed cell line human CVCL_7L22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105835 CVCL_7L23 DA03208 transformed cell line human CVCL_7L23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105836 CVCL_7L24 DA03209 transformed cell line human CVCL_7L24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105837 CVCL_7L25 DA03210 transformed cell line human CVCL_7L25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105838 CVCL_7L19 DA03204 transformed cell line human CVCL_7L19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105839 CVCL_7L95 DA03294 transformed cell line human CVCL_7L95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105840 CVCL_7L96 DA03295 transformed cell line human CVCL_7L96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105841 CVCL_7L97 DA03296 transformed cell line human CVCL_7L97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105842 CVCL_7L98 DA03297 transformed cell line human CVCL_7L98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105843 CVCL_7L91 DA03290 transformed cell line human CVCL_7L91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105844 CVCL_7L92 DA03291 transformed cell line human CVCL_7L92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105845 CVCL_7L93 DA03292 transformed cell line human CVCL_7L93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105846 CVCL_7L94 DA03293 transformed cell line human CVCL_7L94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105847 CVCL_7L99 DA03298 transformed cell line human CVCL_7L99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105848 CVCL_7L90 DA03289 transformed cell line human CVCL_7L90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105849 CVCL_QX20 K10M15 induced pluripotent stem cell human CVCL_QX20 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21105850 CVCL_R920 RSBF [Pagrus fin] spontaneously immortalized cell line CVCL_R920 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105851 CVCL_QX21 BALM-9L cancer cell line human CVCL_QX21 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21105852 CVCL_R921 RSBF-2 spontaneously immortalized cell line CVCL_R921 CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Group: Fish cell line 21105853 CVCL_QX22 FLuDero transformed cell line CVCL_QX22 CL:0000010 Miscellaneous: Doubling time and lack of info on sex of fetus from personal communication of Lacoste V Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung. Unspecified Doubling time: 48 hours (Direct_author_submission) Group: Bat cell line 21105854 CVCL_R922 SICE spontaneously immortalized cell line CVCL_R922 CL:0000010 Derived from sampling site: Eye. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC018 21105855 CVCL_QX23 HBPC/ci37 conditionally immortalized cell line human CVCL_QX23 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Pericyte.. Male Doubling time: 2.1 days (PubMed=29128907) 21105856 CVCL_R923 SIGE spontaneously immortalized cell line CVCL_R923 CL:0000010 Derived from sampling site: Eye. Unspecified Virology: Susceptible to infection by marine birnaviru isolate NC-1 (MABV NC-1) and marine birnavirus isolate Y-6 (MABV Y-6) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC016 21105857 CVCL_QX24 BSS3-PBMC-iPS4F8 induced pluripotent stem cell human CVCL_QX24 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4444; GP9; Simple; p.Phe71Ser (c.212T>C); ClinVar=VCV000013531; Zygosity=Homozygous (PubMed=28395735) Derived from sampling site: Peripheral blood. Female 21105858 CVCL_R924 SIMH spontaneously immortalized cell line CVCL_R924 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105859 CVCL_QX25 BSS2-PBMC-iPS4F24 induced pluripotent stem cell human CVCL_QX25 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4444; GP9; Simple; p.Asn61Ser (c.182A>G); ClinVar=VCV000013529; Zygosity=Homozygous (PubMed=27934591) Derived from sampling site: Peripheral blood. Female 21105860 CVCL_R925 SFK spontaneously immortalized cell line CVCL_R925 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105861 CVCL_QX26 ND50051 induced pluripotent stem cell human CVCL_QX26 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105862 CVCL_R926 SPH [Lateolabrax] spontaneously immortalized cell line CVCL_R926 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105863 CVCL_QX27 ND50052 induced pluripotent stem cell human CVCL_QX27 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105864 CVCL_R927 SPS spontaneously immortalized cell line CVCL_R927 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21105865 CVCL_QX28 ND50053 induced pluripotent stem cell human CVCL_QX28 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105866 CVCL_R928 WSBM spontaneously immortalized cell line CVCL_R928 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 21105867 CVCL_QX29 Mocha transformed cell line Norway rat CVCL_QX29 CL:0000010 Transformant: Adenovirus 12 [E1A 12S isoform](NCBI-Taxonomy; 28282); Derived from sampling site: Ear; inner ear; cochlea Cell type=Microglial cell.; Breed/subspecies: Sprague Dawley. Unspecified 21105868 CVCL_R929 WSF spontaneously immortalized cell line CVCL_R929 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105869 CVCL_QX10 HaCaT YAP-5SA spontaneously immortalized cell line human CVCL_QX10 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 16262; YAP1 (with p.Ser61Ala, p.Ser109Ala, p.Ser127Ala, p.Ser164Ala and p.Ser381Ala = YAP-5SA) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by RNAseq Male 21105870 CVCL_R910 JSKG spontaneously immortalized cell line CVCL_R910 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21105871 CVCL_QX11 A431 siYAP cancer cell line human CVCL_QX11 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 16262; YAP1; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Omics: Transcriptome analysis by RNAseq Female 21105872 CVCL_R911 KRE spontaneously immortalized cell line CVCL_R911 CL:0000010 Breed/subspecies: Epinephelus moara x Epinephelus akaara hybrid. Unspecified Group: Fish cell line 21105873 CVCL_QX12 A431 YAP-5SA cancer cell line human CVCL_QX12 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 16262; YAP1 (with p.Ser61Ala, p.Ser109Ala, p.Ser127Ala, p.Ser164Ala and p.Ser381Ala = YAP-5SA) Derived from sampling site: Skin; epidermis. Omics: Transcriptome analysis by RNAseq Female 21105874 CVCL_R912 MFF-1 spontaneously immortalized cell line CVCL_R912 CL:0000010 Unspecified Virology: Highly susceptible to infection by infectious spleen and kidney necrosis virus (ISKNV). Group: Fish cell line 21105875 CVCL_R913 NAMO-2 cancer cell line human CVCL_R913 CL:0000010 Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=17118759) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 30 hours (PubMed=17118759) 21105876 CVCL_QX13 P101M3 induced pluripotent stem cell human CVCL_QX13 CL:0000010 Sequence variation: Mutation; HGNC; 9942; PRPH2; Simple; p.Trp316Gly (c.946T>G); ClinVar=VCV001175304; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105877 CVCL_QX14 P101M6 induced pluripotent stem cell human CVCL_QX14 CL:0000010 Sequence variation: Mutation; HGNC; 9942; PRPH2; Simple; p.Trp316Gly (c.946T>G); ClinVar=VCV001175304; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105878 CVCL_R914 PAS [Seriola] spontaneously immortalized cell line CVCL_R914 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 21105879 CVCL_QX15 HNL1 induced pluripotent stem cell human CVCL_QX15 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21105880 CVCL_R915 PH [Sardinops] spontaneously immortalized cell line CVCL_R915 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105881 CVCL_QX16 59SCV3 induced pluripotent stem cell human CVCL_QX16 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (from autologous cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105882 CVCL_R916 PL [Sardinops] spontaneously immortalized cell line CVCL_R916 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21105883 CVCL_QX17 59SV3 induced pluripotent stem cell human CVCL_QX17 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (PubMed=24527394) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21105884 CVCL_R917 PSM-1 cancer cell line CVCL_R917 CL:0000010 Unspecified Doubling time: ~2 days (PubMed=6778612). Group: Fish cell line 21105885 CVCL_QX18 59SV4 induced pluripotent stem cell human CVCL_QX18 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (PubMed=24527394) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21105886 CVCL_R918 RBCF-1 spontaneously immortalized cell line CVCL_R918 CL:0000010 Karyotypic information: Diploid karyotype; Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21105887 CVCL_QX19 59SV9 induced pluripotent stem cell human CVCL_QX19 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (PubMed=24527394) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21105888 CVCL_R919 RBTE 45 spontaneously immortalized cell line CVCL_R919 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Group: Fish cell line 21105889 CVCL_R900 GBC1 spontaneously immortalized cell line CVCL_R900 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21105890 CVCL_QX00 NALM-14 cancer cell line human CVCL_QX00 CL:0000010 Derived from sampling site: Peripheral blood. 21105891 CVCL_QX01 B262 transformed cell line human CVCL_QX01 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21105892 CVCL_R901 GBC4 spontaneously immortalized cell line CVCL_R901 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21105893 CVCL_QX02 B391 transformed cell line human CVCL_QX02 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21105894 CVCL_R902 GK [Epinephelus awoara] spontaneously immortalized cell line CVCL_R902 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105895 CVCL_R903 GL spontaneously immortalized cell line CVCL_R903 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21105896 CVCL_QX03 INC cancer cell line human CVCL_QX03 CL:0000010 Population: Japanese Female Doubling time: 44.4 hours (PubMed=8847894). 21105897 CVCL_R904 GM00135 finite cell line human CVCL_R904 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21105898 CVCL_QX04 TA-1 [Human leukemia] cancer cell line human CVCL_QX04 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 96-120 hours (PubMed=8395908) 21105899 CVCL_R905 GM01661 finite cell line human CVCL_R905 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105900 CVCL_QX05 TC78 cancer cell line human CVCL_QX05 CL:0000010 Derived from sampling site: Bone marrow. Male 21105901 CVCL_R906 GM02226 finite cell line human CVCL_R906 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex6-9del/inv; Zygosity=Heterozygous (from familial inference of GM02227) Derived from sampling site: Cell type=Fibroblast. Female 21105902 CVCL_QX06 PE-1 [Human] cancer cell line human CVCL_QX06 CL:0000010 Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq. Characteristics: IL6 dependent 21105903 CVCL_R907 HEW spontaneously immortalized cell line CVCL_R907 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Group: Fish cell line 21105904 CVCL_QX07 PE-2 cancer cell line human CVCL_QX07 CL:0000010 Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq. 21105905 CVCL_QX08 ADBA10260AN transformed cell line human CVCL_QX08 HLA typing: A*01:AF,24; B*08:33,39:01:01; C*07:APUZ; DQB1*05:03,03:AF; DRB1*04:01,14:01; DRB3*02:AM; DRB4*01:DWH (IPD-IMGT/HLA=14782) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21105906 CVCL_R908 HINAE spontaneously immortalized cell line CVCL_R908 CL:0000010 Unspecified Group: Fish cell line. 21105907 CVCL_QX09 HaCaT siYAP spontaneously immortalized cell line human CVCL_QX09 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 16262; YAP1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by RNAseq Male 21105908 CVCL_R909 JFF07-1 spontaneously immortalized cell line CVCL_R909 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105909 CVCL_QX90 NUIGi001-A induced pluripotent stem cell human CVCL_QX90 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 14974; SNX10; Simple; c.212+1G>T; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29034896) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21105910 CVCL_R990 YNK spontaneously immortalized cell line CVCL_R990 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105911 CVCL_QX91 BIN-14 cancer cell line human CVCL_QX91 CL:0000010 Derived from metastatic site: Ascites. Female 21105912 CVCL_R991 YTK spontaneously immortalized cell line CVCL_R991 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105913 CVCL_QX92 BIN-36 cancer cell line human CVCL_QX92 CL:0000010 Derived from metastatic site: Ascites. Female 21105914 CVCL_R992 ZC-7901 spontaneously immortalized cell line CVCL_R992 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21105915 CVCL_QX93 CSCRMi001-A induced pluripotent stem cell human CVCL_QX93 From: Center for Stem Cell and Regenerative Medicine (CSCRM), University of Texas Health Science Center; Houston; USA CL:0000010 Sequence variation: Mutation; HGNC; 22954; POGLUT1; Simple; p.Asp233Glu (c.699T>G); ClinVar=VCV000372263; Zygosity=Homozygous (PubMed=29034878) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105916 CVCL_R993 ZC-7901S1 spontaneously immortalized cell line CVCL_R993 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21105917 CVCL_R994 BHK21/C13/SV28 transformed cell line CVCL_R994 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21105918 CVCL_QX94 TU-2 cancer cell line human CVCL_QX94 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875) Derived from sampling site: Bone marrow. Female 21105919 CVCL_R995 BHK 165-23 transformed cell line CVCL_R995 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21105920 CVCL_QX95 TU-3 cancer cell line human CVCL_QX95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875) Derived from sampling site: Bone marrow. Female 21105921 CVCL_R996 L1210/Ara-C cancer cell line house mouse CVCL_R996 From: Khwaja T; University of California, Los Angeles; Los Angeles; USA CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21105922 CVCL_QX96 OCI-AML-8 cancer cell line human CVCL_QX96 CL:0000010 Derived from sampling site: Peripheral blood. Female 21105923 CVCL_7L04 DA03187 transformed cell line human CVCL_7L04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105924 CVCL_R997 MEF3.8 spontaneously immortalized cell line house mouse CVCL_R997 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1 Derived from sampling site: Cell type=Fibroblast. Unspecified 21105925 CVCL_QX97 OCI-AML-11 cancer cell line human CVCL_QX97 CL:0000010 Derived from sampling site: Peripheral blood. Female 21105926 CVCL_QX98 BAL-KHc cancer cell line human CVCL_QX98 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 24 hours (PubMed=2709874) 21105927 CVCL_7L05 DA03188 transformed cell line human CVCL_7L05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105928 CVCL_R998 MEF3.8/T6400 spontaneously immortalized cell line house mouse CVCL_R998 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from sampling site: Cell type=Fibroblast. Unspecified 21105929 CVCL_7L06 DA03189 transformed cell line human CVCL_7L06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105930 CVCL_QX99 DS cancer cell line human CVCL_QX99 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type Derived from sampling site: Bone marrow. Female 21105931 CVCL_R999 MEF3.8/M32 spontaneously immortalized cell line house mouse CVCL_R999 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97570; Abcb1a; Knockout cell: Method=KO mouse; MGI; MGI:97568; Abcb1b; Knockout cell: Method=KO mouse; MGI; MGI:102676; Abcc1 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Cell type=Fibroblast. Unspecified 21105932 CVCL_7L07 DA03190 transformed cell line human CVCL_7L07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105933 CVCL_7L00 DA03183 transformed cell line human CVCL_7L00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105934 CVCL_7L01 DA03184 transformed cell line human CVCL_7L01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105935 CVCL_7L02 DA03185 transformed cell line human CVCL_7L02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105936 CVCL_7L03 DA03186 transformed cell line human CVCL_7L03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21105937 CVCL_R980 OLF-124 spontaneously immortalized cell line CVCL_R980 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105938 CVCL_QX80 UNIBSi003-A induced pluripotent stem cell human CVCL_QX80 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9005; PITX2; Simple; p.Met200Val (c.598A>G) (p.Met207Val, c.619A>G); ClinVar=VCV000559593; Zygosity=Heterozygous (PubMed=29034898) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21105939 CVCL_QX81 HHUUKDi001-A induced pluripotent stem cell human CVCL_QX81 HLA typing: A*03:01,33:01; B*08:01,53:01; C*04:01/09N,07:02; DQB1*02:02,06:03; DRB1*07:01,13:01 (PubMed=29035842) From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Population: African; Derived from sampling site: Urine. Male 21105940 CVCL_R981 PF spontaneously immortalized cell line CVCL_R981 CL:0000010 Unspecified Doubling time: ~1.5 days (CelloPub=CLPUB00098). Group: Fish cell line 21105941 CVCL_QX82 IDVi001-A induced pluripotent stem cell human CVCL_QX82 From: Institut de la Vision; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 7974; NR2E3; Simple; p.Gly56Arg (c.166G>A); ClinVar=VCV000005533; Zygosity=Heterozygous (PubMed=29034877) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21105942 CVCL_R982 PS-12 cancer cell line CVCL_R982 CL:0000010 Unspecified Group: Fish cell line. 21105943 CVCL_R983 RSBF [Pagrus fry] spontaneously immortalized cell line CVCL_R983 CL:0000010 Unspecified Group: Fish cell line. 21105944 CVCL_QX83 UAMi001-A induced pluripotent stem cell human CVCL_QX83 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Cys616_Val633del (c.1899+4_1899+7delAGTA) (1824IVS+3del4) (IVS21+3del4); Zygosity=Heterozygous (PubMed=28925364); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly477Glufs*9 (c.1430-?_1643+?del); Zygosity=Heterozygous (PubMed=28925364) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105945 CVCL_QX84 CIRAi001-A induced pluripotent stem cell human CVCL_QX84 CL:0000010 Sequence variation: Mutation; HGNC; 4193; GCH1; Simple; c.626+1G>C; ClinVar=VCV000529415; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29034893) Derived from sampling site: Peripheral blood. Male 21105946 CVCL_R984 RSF spontaneously immortalized cell line CVCL_R984 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21105947 CVCL_QX85 CIRAi002-A induced pluripotent stem cell human CVCL_QX85 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 6572; LGI1; Simple; p.Ser473Leu (c.1418C>T); ClinVar=VCV000208480; Zygosity=Heterozygous (PubMed=29034879) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21105948 CVCL_R985 SBF-1 spontaneously immortalized cell line CVCL_R985 CL:0000010 Unspecified Group: Fish cell line. 21105949 CVCL_QX86 CIRAi003-A induced pluripotent stem cell human CVCL_QX86 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10947; SLC20A2; Simple; p.Trp616Ter (c.1848G>A); Zygosity=Heterozygous (PubMed=29034894) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21105950 CVCL_R986 SBK [Lateolabrax] spontaneously immortalized cell line CVCL_R986 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105951 CVCL_QX87 IISHDOi003-A induced pluripotent stem cell human CVCL_QX87 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Ser545Arg (c.1635C>A); ClinVar=VCV000095712; Zygosity=Heterozygous (PubMed=29034899) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105952 CVCL_R987 SP-1 spontaneously immortalized cell line CVCL_R987 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Characteristics: Optimal growth at 26 Celsius Group: Fish cell line 21105953 CVCL_QX88 FAMRCi001-A induced pluripotent stem cell human CVCL_QX88 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Tyr119Metfs*23 (c.354delT); Zygosity=Heterozygous (PubMed=29034900); Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Lys859Arg (c.2576A>G); Zygosity=Heterozygous (PubMed=29034900) Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 21105954 CVCL_R988 SP-2 [Bairdiella] spontaneously immortalized cell line CVCL_R988 CL:0000010 Derived from sampling site: Spleen. Unspecified Characteristics: Optimal growth at 26 Celsius Group: Fish cell line 21105955 CVCL_QX89 FAMRCi002-A induced pluripotent stem cell human CVCL_QX89 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 2770; DES; Simple; c.735+1G>A (Ex3del); ClinVar=VCV000163027; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29034897) Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21105956 CVCL_R989 YEL-13 spontaneously immortalized cell line CVCL_R989 CL:0000010 Unspecified Group: Fish cell line. 21105957 CVCL_R970 BPS-4 spontaneously immortalized cell line CVCL_R970 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21105958 CVCL_QX70 UPSFRi011-A induced pluripotent stem cell human CVCL_QX70 From: Universite Paris-Sud 11; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Unexplicit; Ex17del; Zygosity=Heterozygous (PubMed=29034880) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21105959 CVCL_R971 CyA-1 spontaneously immortalized cell line CVCL_R971 CL:0000010 Derived from sampling site: Trunk; muscle Cell type=Fibroblast.. Male Characteristics: Capable of growing from 18 to 34 Celsius, the optimal temperature is 24-32 Celsius (DOI=10.1007/BF02626743) Group: Fish cell line 21105960 CVCL_QX71 IISHDOi001-A induced pluripotent stem cell human CVCL_QX71 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9726; PYGM; Simple; p.Arg50Ter (c.148C>T); ClinVar=VCV000002298; Zygosity=Homozygous (PubMed=28925366) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105961 CVCL_R972 CyA-2 spontaneously immortalized cell line CVCL_R972 CL:0000010 Derived from sampling site: Trunk; muscle Cell type=Fibroblast.. Male Characteristics: Capable of growing from 18 to 34 Celsius, the optimal temperature is 24-32 Celsius (DOI=10.1007/BF02626743) Group: Fish cell line 21105962 CVCL_QX72 KUCFRi002-A induced pluripotent stem cell human CVCL_QX72 From: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Ser140Thr (c.418T>A); ClinVar=VCV000447730; Zygosity=Heterozygous (PubMed=29034895) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21105963 CVCL_QX73 BML01 cancer cell line human CVCL_QX73 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: 16 hours (DOI=10.1016/j.jcyt.2015.03.422) 21105964 CVCL_R973 GCF spontaneously immortalized cell line CVCL_R973 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.. Unspecified Characteristics: Optimal growth temperature is 32 Celsius (PubMed=2108122); Virology: Susceptible to infection by chum salmon virus (CSV), golden shiner virus (GSV), infectious hematopoietic necrosis virus (IHNV), infectious pancreatic necrosis virus (IPNV), and spring viremia of carp virus (SVCV) (PubMed=2108122; CelloPub=CLPUB00704) Group: Fish cell line 21105965 CVCL_R974 GCS-2 spontaneously immortalized cell line CVCL_R974 CL:0000010 Derived from sampling site: Snout Cell type=Epithelial cell.. Unspecified Characteristics: Optimal growth temperature is 32 Celsius (PubMed=2108122); Virology: Susceptible to infection by chum salmon virus (CSV), golden shiner virus (GSV), infectious hematopoietic necrosis virus (IHNV), infectious pancreatic necrosis virus (IPNV), and spring viremia of carp virus (SVCV) (PubMed=2108122; CelloPub=CLPUB00704) Group: Fish cell line 21105966 CVCL_QX74 ISMMSi001-A induced pluripotent stem cell human CVCL_QX74 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1326Arg (c.3976T>C); Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105967 CVCL_R975 GCSB spontaneously immortalized cell line CVCL_R975 CL:0000010 Derived from sampling site: Swim bladder Cell type=Fibroblast.. Unspecified Characteristics: Optimal growth temperature is 32 Celsius (PubMed=2108122); Virology: Susceptible to infection by chum salmon virus (CSV), golden shiner virus (GSV), infectious hematopoietic necrosis virus (IHNV), infectious pancreatic necrosis virus (IPNV), and spring viremia of carp virus (SVCV) (PubMed=2108122; CelloPub=CLPUB00704) Group: Fish cell line 21105968 CVCL_QX75 ISMMSi001-B induced pluripotent stem cell human CVCL_QX75 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1326Arg (c.3976T>C); Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105969 CVCL_R976 INEM-1 spontaneously immortalized cell line CVCL_R976 CL:0000010 Unspecified Group: Fish cell line. 21105970 CVCL_QX76 VSMUi001-D induced pluripotent stem cell pig CVCL_QX76 From: Faculty of Veterinary Science, Mahidol University; Bangkok; Thailand CL:0000010 Breed/subspecies: Landrace x Large White x Duroc (LWD). Male 21105971 CVCL_QX77 JHUi001-A induced pluripotent stem cell human CVCL_QX77 From: Johns Hopkins University; Baltimore; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21105972 CVCL_R977 LBF-2 spontaneously immortalized cell line CVCL_R977 CL:0000010 Derived from sampling site: Caudal trunk. Unspecified Group: Fish cell line 21105973 CVCL_QX78 ESIBIe002-A-1 embryonic stem cell human CVCL_QX78 CL:0000010 Knockout cell: Method=CRISPR/Cas9n; HGNC; 14536; KLF15. Female 21105974 CVCL_R978 LTK spontaneously immortalized cell line CVCL_R978 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105975 CVCL_R979 LTL spontaneously immortalized cell line CVCL_R979 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21105976 CVCL_QX79 UNIBSi001-A induced pluripotent stem cell human CVCL_QX79 From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6224; KCNA5; Simple; p.Asp322His (c.964G>C); ClinVar=VCV000469603; Zygosity=Heterozygous (PubMed=29034891) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21105977 CVCL_R960 DNI.Ht finite cell line CVCL_R960 CL:0000010 Derived from sampling site: Heart. Discontinued: ATCC; CRL-6004; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105978 CVCL_QX60 KUCFRi001-A induced pluripotent stem cell human CVCL_QX60 From: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Val139Met (c.415G>A); ClinVar=VCV000010433; Zygosity=Heterozygous (PubMed=28677541) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21105979 CVCL_QX61 BIOTi628-A induced pluripotent stem cell human CVCL_QX61 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Derived from sampling site: Peripheral blood. Male 21105980 CVCL_R961 DNI.K finite cell line CVCL_R961 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6005; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105981 CVCL_R962 DNI.Lu finite cell line CVCL_R962 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6006; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105982 CVCL_QX62 RCPFi001-A induced pluripotent stem cell human CVCL_QX62 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 17340; PRPF8; Simple; p.Val2325_Glu2331del (c.6974_6994del21); ClinVar=VCV000916436; Zygosity=Heterozygous (PubMed=28677533) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21105983 CVCL_R963 DNI.Sk finite cell line CVCL_R963 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6007; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105984 CVCL_QX63 MPIMBMi011-A induced pluripotent stem cell human CVCL_QX63 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Fetal liver. Male 21105985 CVCL_R964 DNI.Sp finite cell line CVCL_R964 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6008; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21105986 CVCL_QX64 MPIMBMi011-A-3 induced pluripotent stem cell human CVCL_QX64 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9005; PITX2 Derived from sampling site: Fetal liver. Male 21105987 CVCL_R965 HeLa M cancer cell line human CVCL_R965 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21105988 CVCL_QX65 MPIMBMi011-A-4 induced pluripotent stem cell human CVCL_QX65 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9005; PITX2 Derived from sampling site: Fetal liver. Male 21105989 CVCL_R966 ASH spontaneously immortalized cell line CVCL_R966 From: Gillespie J.H.; Cornell University College of Veterinary Medicine; Ithaca; USA CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21105990 CVCL_QX66 Bag1KO-mESC embryonic stem cell house mouse CVCL_QX66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:108047; Bag1 Breed/subspecies: C57BL/6. Female 21105991 CVCL_R967 ASO spontaneously immortalized cell line CVCL_R967 From: Gillespie J.H.; Cornell University College of Veterinary Medicine; Ithaca; USA CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21105992 CVCL_QX67 P59M9 induced pluripotent stem cell human CVCL_QX67 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21105993 CVCL_R968 BPK spontaneously immortalized cell line CVCL_R968 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21105994 CVCL_QX68 UPSFRi010-A induced pluripotent stem cell human CVCL_QX68 From: Universite Paris-Sud 11; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Unspecified (PubMed=28925363) Derived from sampling site: Peripheral blood. Female 21105995 CVCL_R969 BPS-1 spontaneously immortalized cell line CVCL_R969 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21105996 CVCL_QX69 UPSFRi012-A induced pluripotent stem cell human CVCL_QX69 From: Universite Paris-Sud 11; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 6257; KCNJ11; Simple; p.Glu227Lys (c.679G>A); ClinVar=VCV000158682; Zygosity=Heterozygous (PubMed=28925365) Derived from sampling site: Peripheral blood. Male 21105997 CVCL_QX50 CEBe033-A-1 embryonic stem cell human CVCL_QX50 From: Hoffmann-La Roche Ltd; Basel; Switzerland CL:0000010 Knockout cell: Method=ZFN; HGNC; 4177; GBA1. Male 21105998 CVCL_R950 WKPT-1292 Cl.16 transformed cell line Norway rat CVCL_R950 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21105999 CVCL_QX51 MHHi001-A induced pluripotent stem cell human CVCL_QX51 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female 21106000 CVCL_R951 WKPT-1292 Cl.3 transformed cell line Norway rat CVCL_R951 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21106001 CVCL_QX52 MHHi002-A induced pluripotent stem cell human CVCL_QX52 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=28925369) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 21106002 CVCL_R952 WKPT-1292 Cl.4 transformed cell line Norway rat CVCL_R952 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21106003 CVCL_QX53 MHHi002-A-1 induced pluripotent stem cell human CVCL_QX53 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=28925369); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous; Note=By TALEN (PubMed=28925369) Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male 21106004 CVCL_R953 WKPT-1292 Cl.8 transformed cell line Norway rat CVCL_R953 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21106005 CVCL_R954 MCF-7-BAG cancer cell line human CVCL_R954 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21106006 CVCL_QX54 MUi001-A induced pluripotent stem cell human CVCL_QX54 From: Mahidol University; Bangkok; Thailand CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21106007 CVCL_R955 MCS-2 [Human breast carcinoma] cancer cell line human CVCL_R955 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11425; STS Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21106008 CVCL_QX55 MUi002-A induced pluripotent stem cell human CVCL_QX55 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu27Lys (c.79G>A) (E26K); ClinVar=VCV000015161; Zygosity=Heterozygous; Note=Hb E (PubMed=28213976); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-197C>T (IVS2-654C>T); ClinVar=VCV000015458; Zygosity=Heterozygous (PubMed=28213976) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21106009 CVCL_R956 MDA-MB-231-BAG cancer cell line human CVCL_R956 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21106010 CVCL_QX56 MUi009-A induced pluripotent stem cell human CVCL_QX56 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=28395745) Derived from sampling site: Peripheral blood. Male 21106011 CVCL_R957 MDA-MB-435-BAG cancer cell line human CVCL_R957 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21106012 CVCL_QX57 MUi017-A induced pluripotent stem cell human CVCL_QX57 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Simple; p.Ter143Glnext*32 (c.427T>C); ClinVar=VCV000015624; Zygosity=Homozygous; Note=Hb Constant Spring (PubMed=28395746) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21106013 CVCL_R958 DNI.Bl finite cell line CVCL_R958 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-6002; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106014 CVCL_QX58 MUi019-A induced pluripotent stem cell human CVCL_QX58 From: Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21106015 CVCL_R959 DNI.F finite cell line CVCL_R959 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-6003; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106016 CVCL_QX59 FDZSi001-A induced pluripotent stem cell human CVCL_QX59 From: Zhongshan Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Arg193Trp (c.577C>T); ClinVar=VCV000213941; Zygosity=Heterozygous (PubMed=28395736) Derived from sampling site: Peripheral blood. Female 21106017 CVCL_R940 B2.Bm finite cell line CVCL_R940 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6021; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106018 CVCL_QX40 DHMCi002-A induced pluripotent stem cell human CVCL_QX40 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4193; GCH1; Simple; p.Leu79_Ser80del (c.235_240del); Zygosity=Heterozygous (PubMed=28395739) Derived from sampling site: Cell type=Fibroblast. Female 21106019 CVCL_R941 EA1.Lu finite cell line CVCL_R941 CL:0000010 Derived from sampling site: Bronchus or lung. Discontinued: ATCC; CRL-6015; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106020 CVCL_QX41 MCDU1i-EPDC induced pluripotent stem cell human CVCL_QX41 CL:0000010 Derived from sampling site: Heart; epicardium. Omics: Transcriptome analysis by microarray Female 21106021 CVCL_QX42 MCDU2i-EPDC induced pluripotent stem cell human CVCL_QX42 CL:0000010 Derived from sampling site: Heart; epicardium. Omics: Transcriptome analysis by microarray Female 21106022 CVCL_R942 SKPT-0193 Cl.1 transformed cell line Norway rat CVCL_R942 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Spontaneously hypertensive rat (SHR). Male 21106023 CVCL_QX43 CSCR19i-indCFANCA induced pluripotent stem cell human CVCL_QX43 From: Centre for Stem Cell Research, Christian Medical College; Vellore; India CL:0000010 Transfected with: HGNC; 3582; FANCA Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Expression of transfected FANCA is doxycycline-inducible 21106024 CVCL_R943 SKPT-0193 Cl.2 transformed cell line Norway rat CVCL_R943 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Spontaneously hypertensive rat (SHR). Male 21106025 CVCL_QX44 GZHMUi001-A induced pluripotent stem cell human CVCL_QX44 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21106026 CVCL_R944 SKPT-0193 Cl.5 transformed cell line Norway rat CVCL_R944 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Spontaneously hypertensive rat (SHR). Male 21106027 CVCL_QX45 ISMMSi002-A induced pluripotent stem cell human CVCL_QX45 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1361Tyr (c.4082G>A); ClinVar=VCV000519726; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21106028 CVCL_R945 SKPT-1092 Cl.1 transformed cell line Norway rat CVCL_R945 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Spontaneously hypertensive rat (SHR). Male 21106029 CVCL_QX46 ISMMSi002-B induced pluripotent stem cell human CVCL_QX46 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys1361Tyr (c.4082G>A); ClinVar=VCV000519726; Zygosity=Heterozygous (PubMed=28925368) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21106030 CVCL_R946 SKPT-1092 Cl.2 transformed cell line Norway rat CVCL_R946 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Spontaneously hypertensive rat (SHR). Male 21106031 CVCL_QX47 BMSGDDi-GM11272-J8 induced pluripotent stem cell human CVCL_QX47 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Argfs*8 (c.1157_1188del32) (p.Leu398Argfs*8, c.1193_1224del32) (1155del32); ClinVar=VCV000143366; Zygosity=Unspecified (PubMed=28395743) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21106032 CVCL_R947 WKPT-0293 Cl.2 transformed cell line Norway rat CVCL_R947 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: Wistar Kyoto. Male 21106033 CVCL_QX48 MCCI0001i-HCM induced pluripotent stem cell human CVCL_QX48 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1391; CACNA1D; Simple; p.Glu847Lys (c.2539G>A); Zygosity=Heterozygous (PubMed=28395744); Sequence variation: Mutation; HGNC; 12582; UQCRB; Simple; p.Arg34Gln (c.101G>A) (p.Arg2Gln, c.5G>A); Zygosity=Heterozygous (PubMed=28395744) Derived from sampling site: Peripheral blood. Female 21106034 CVCL_R948 WKPT-0293 Cl.3 transformed cell line Norway rat CVCL_R948 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21106035 CVCL_QX49 MCCI0002i-HCM induced pluripotent stem cell human CVCL_QX49 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Val698Ala (c.2093T>C); ClinVar=VCV000042878; Zygosity=Heterozygous (PubMed=28395747) Derived from sampling site: Peripheral blood. Male 21106036 CVCL_R949 WKPT-1292 Cl.10 transformed cell line Norway rat CVCL_R949 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: Wistar Kyoto. Male 21106037 CVCL_QX30 ATCi-MF1 induced pluripotent stem cell CVCL_QX30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21106038 CVCL_R930 WSGO spontaneously immortalized cell line CVCL_R930 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21106039 CVCL_QX31 ATCe-rSD78 embryonic stem cell Norway rat CVCL_QX31 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Sprague Dawley Tg(GFP)1BalRrrc. Female 21106040 CVCL_R931 WSH-1 spontaneously immortalized cell line CVCL_R931 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21106041 CVCL_QX32 ATCe-rWK1 embryonic stem cell Norway rat CVCL_QX32 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Wistar Kyoto. Female 21106042 CVCL_R932 WSHO spontaneously immortalized cell line CVCL_R932 CL:0000010 Derived from sampling site: Meningeal myeloid tissue. Male Group: Fish cell line 21106043 CVCL_QX33 GM13495 finite cell line human CVCL_QX33 CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg394Leu (c.181G>T); Zygosity=Heterozygous (PubMed=35667217) Population: Caucasian; Derived from sampling site: Testis; tunica albuginea Cell type=Fibroblast.. Male 21106044 CVCL_R933 WSHST spontaneously immortalized cell line CVCL_R933 CL:0000010 Derived from sampling site: Head; hypodermis. Unspecified Group: Fish cell line 21106045 CVCL_QX34 GIS2014-SB2C20 induced pluripotent stem cell human CVCL_QX34 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)47 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=28395737) Derived from sampling site: Peripheral blood. Male 21106046 CVCL_R934 WSLV spontaneously immortalized cell line CVCL_R934 CL:0000010 Derived from sampling site: Liver. Male Group: Fish cell line 21106047 CVCL_QX35 GIS2014-SB3C16 induced pluripotent stem cell human CVCL_QX35 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)43 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=28395737) Derived from sampling site: Peripheral blood. Male 21106048 CVCL_R935 WSNV spontaneously immortalized cell line CVCL_R935 CL:0000010 Derived from sampling site: Brain. Male Group: Fish cell line 21106049 CVCL_QX36 GIS2014-WT2C15 induced pluripotent stem cell human CVCL_QX36 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)26 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=28395737) Derived from sampling site: Peripheral blood. Male 21106050 CVCL_R936 WSSB spontaneously immortalized cell line CVCL_R936 CL:0000010 Derived from sampling site: Swim bladder. Male Group: Fish cell line 21106051 CVCL_QX37 GIS2014-WT3C16 induced pluripotent stem cell human CVCL_QX37 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)22 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=28395737) Derived from sampling site: Peripheral blood. Male 21106052 CVCL_R937 WSS-2 spontaneously immortalized cell line CVCL_R937 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21106053 CVCL_QX38 GIS2014-WT4C10 induced pluripotent stem cell human CVCL_QX38 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)24 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=28395737) Derived from sampling site: Peripheral blood. Male 21106054 CVCL_R938 XM cancer cell line CVCL_R938 CL:0000010 Unspecified Doubling time: ~72 hours (PubMed=18377217). Group: Fish cell line 21106055 CVCL_R939 BPf finite cell line CVCL_R939 CL:0000010 Derived from sampling site: Peritoneum. Discontinued: ATCC; CRL-6018; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106056 CVCL_QX39 GPCCi001-A induced pluripotent stem cell human CVCL_QX39 From: Greater Poland Cancer Centre (GPCC), Poznan University of Medical Sciences; Poznan; Poland CL:0000010 Donor information: Established from a patient suffering from breast cancer; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106057 CVCL_RC60 STBCi054-B induced pluripotent stem cell human CVCL_RC60 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106058 CVCL_RC61 STBCi055-A induced pluripotent stem cell human CVCL_RC61 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106059 CVCL_RC62 STBCi055-B induced pluripotent stem cell human CVCL_RC62 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106060 CVCL_RC63 STBCi055-C induced pluripotent stem cell human CVCL_RC63 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106061 CVCL_RC64 STBCi056-A induced pluripotent stem cell human CVCL_RC64 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi056-A; true Male 21106062 CVCL_RC65 STBCi056-B induced pluripotent stem cell human CVCL_RC65 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi056-B; true Male 21106063 CVCL_RC66 STBCi056-C induced pluripotent stem cell human CVCL_RC66 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106064 CVCL_RC67 STBCi057-A induced pluripotent stem cell human CVCL_RC67 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106065 CVCL_RC68 STBCi057-B induced pluripotent stem cell human CVCL_RC68 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106066 CVCL_RC69 STBCi057-C induced pluripotent stem cell human CVCL_RC69 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106067 CVCL_RC50 STBCi051-A induced pluripotent stem cell human CVCL_RC50 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106068 CVCL_RC51 STBCi051-B induced pluripotent stem cell human CVCL_RC51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106069 CVCL_RC52 STBCi051-C induced pluripotent stem cell human CVCL_RC52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106070 CVCL_RC53 STBCi052-A induced pluripotent stem cell human CVCL_RC53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106071 CVCL_RC54 STBCi052-B induced pluripotent stem cell human CVCL_RC54 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106072 CVCL_RC55 STBCi052-C induced pluripotent stem cell human CVCL_RC55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106073 CVCL_RC56 STBCi053-A induced pluripotent stem cell human CVCL_RC56 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106074 CVCL_RC57 STBCi053-B induced pluripotent stem cell human CVCL_RC57 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106075 CVCL_RC58 STBCi053-C induced pluripotent stem cell human CVCL_RC58 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106076 CVCL_RC59 STBCi054-A induced pluripotent stem cell human CVCL_RC59 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106077 CVCL_RC40 STBCi047-B induced pluripotent stem cell human CVCL_RC40 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106078 CVCL_RC41 STBCi048-A induced pluripotent stem cell human CVCL_RC41 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106079 CVCL_RC42 STBCi048-B induced pluripotent stem cell human CVCL_RC42 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106080 CVCL_RC43 STBCi048-C induced pluripotent stem cell human CVCL_RC43 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106081 CVCL_RC44 STBCi049-A induced pluripotent stem cell human CVCL_RC44 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106082 CVCL_RC45 STBCi049-B induced pluripotent stem cell human CVCL_RC45 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106083 CVCL_RC46 STBCi049-C induced pluripotent stem cell human CVCL_RC46 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106084 CVCL_RC47 STBCi050-A induced pluripotent stem cell human CVCL_RC47 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106085 CVCL_RC48 STBCi050-B induced pluripotent stem cell human CVCL_RC48 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106086 CVCL_RC49 STBCi050-C induced pluripotent stem cell human CVCL_RC49 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106087 CVCL_II96 RCi005-A induced pluripotent stem cell human CVCL_II96 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Homozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Female 21106088 CVCL_II97 RCi007-C induced pluripotent stem cell human CVCL_II97 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Female 21106089 CVCL_II98 LUBi001-B induced pluripotent stem cell human CVCL_II98 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21106090 CVCL_II99 LUBi001-C induced pluripotent stem cell human CVCL_II99 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21106091 CVCL_RC30 STBCi043-B induced pluripotent stem cell human CVCL_RC30 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106092 CVCL_RC31 STBCi043-C induced pluripotent stem cell human CVCL_RC31 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106093 CVCL_RC32 STBCi044-A induced pluripotent stem cell human CVCL_RC32 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21106094 CVCL_RC33 STBCi044-B induced pluripotent stem cell human CVCL_RC33 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21106095 CVCL_RC34 STBCi045-A induced pluripotent stem cell human CVCL_RC34 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106096 CVCL_RC35 STBCi045-B induced pluripotent stem cell human CVCL_RC35 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106097 CVCL_RC36 STBCi045-C induced pluripotent stem cell human CVCL_RC36 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106098 CVCL_RC37 STBCi046-A induced pluripotent stem cell human CVCL_RC37 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106099 CVCL_RC38 STBCi046-B induced pluripotent stem cell human CVCL_RC38 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106100 CVCL_RC39 STBCi047-A induced pluripotent stem cell human CVCL_RC39 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106101 CVCL_II81 BIONi010-C-2 induced pluripotent stem cell human CVCL_II81 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple_edited; p.Arg130Cys (c.388C>T); Zygosity=Hemizygous; Note=ApoE3 allele By CRISPR/Cas9. The second allele is disrupted by a 3.4 kb insertion from the selection plasmid (PubMed=30660866; PubMed=32971461). Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106102 CVCL_II82 BIONi010-C-3 induced pluripotent stem cell human CVCL_II82 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106103 CVCL_II83 BIONi010-C-4 induced pluripotent stem cell human CVCL_II83 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple_edited; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Hemizygous; Note=ApoE4 allele By CRISPR/Cas9. The second allele is disrupted by a 5.4 kb insertion from the selection plasmid (PubMed=30660866; PubMed=32971461). Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106104 CVCL_II84 BIONi010-C-5 induced pluripotent stem cell human CVCL_II84 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1659; CD33 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106105 CVCL_II80 BIONi037-A induced pluripotent stem cell human CVCL_II80 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106106 CVCL_RC20 STBCi039-C induced pluripotent stem cell human CVCL_RC20 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106107 CVCL_RC21 STBCi040-A induced pluripotent stem cell human CVCL_RC21 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106108 CVCL_RC22 STBCi040-B induced pluripotent stem cell human CVCL_RC22 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106109 CVCL_RC23 STBCi040-C induced pluripotent stem cell human CVCL_RC23 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106110 CVCL_RC24 STBCi041-A induced pluripotent stem cell human CVCL_RC24 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106111 CVCL_RC25 STBCi041-B induced pluripotent stem cell human CVCL_RC25 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106112 CVCL_II78 HL-60/R3 cancer cell line human CVCL_II78 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Peripheral blood. Female 21106113 CVCL_RC26 STBCi042-A induced pluripotent stem cell human CVCL_RC26 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21106114 CVCL_RC27 STBCi042-B induced pluripotent stem cell human CVCL_RC27 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21106115 CVCL_II79 X9 spontaneously immortalized cell line house mouse CVCL_II79 CL:0000010 Derived from sampling site: Inguinal fat pad; adipose tissue Cell type=Beige adipocyte.; Breed/subspecies: 129S6/SvEvTac. Male 21106116 CVCL_RC28 STBCi042-C induced pluripotent stem cell human CVCL_RC28 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21106117 CVCL_RC29 STBCi043-A induced pluripotent stem cell human CVCL_RC29 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106118 CVCL_II74 HOB1/VCR0.5 cancer cell line human CVCL_II74 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Male 21106119 CVCL_II75 HOB1/VCR1.0 cancer cell line human CVCL_II75 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Male 21106120 CVCL_II76 HMC3 transformed cell line human CVCL_II76 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Microglial cell.. Unspecified 21106121 CVCL_II77 HL-60/S4 cancer cell line human CVCL_II77 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Characteristics: Differentiation to a granulocyte-like state can be induced by retinoic acid (RA) 21106122 CVCL_II92 SIGi001-A-10 induced pluripotent stem cell human CVCL_II92 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Homozygous; Note=By method not specified (EBiSC); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21106123 CVCL_II93 UNEWi017-A induced pluripotent stem cell human CVCL_II93 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21106124 CVCL_II94 UNEWi018-A induced pluripotent stem cell human CVCL_II94 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21106125 CVCL_II95 UNEWi019-A induced pluripotent stem cell human CVCL_II95 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21106126 CVCL_II90 UCLi004-C induced pluripotent stem cell human CVCL_II90 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21106127 CVCL_II91 SIGi001-A-2 induced pluripotent stem cell human CVCL_II91 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21106128 CVCL_RC10 STBCi035-C induced pluripotent stem cell human CVCL_RC10 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Leu869Phe (c.2605C>T) (p.Leu858Phe, c.2572C>T); ClinVar=VCV000006364; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21106129 CVCL_RC11 STBCi036-A induced pluripotent stem cell human CVCL_RC11 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Unexplicit; Not described; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106130 CVCL_RC12 STBCi037-A induced pluripotent stem cell human CVCL_RC12 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi037-A; true Female 21106131 CVCL_RC13 STBCi037-B induced pluripotent stem cell human CVCL_RC13 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21106132 CVCL_RC14 STBCi037-C induced pluripotent stem cell human CVCL_RC14 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21106133 CVCL_RC15 STBCi038-A induced pluripotent stem cell human CVCL_RC15 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106134 CVCL_II89 UCLi004-A induced pluripotent stem cell human CVCL_II89 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21106135 CVCL_RC16 STBCi038-B induced pluripotent stem cell human CVCL_RC16 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106136 CVCL_RC17 STBCi038-C induced pluripotent stem cell human CVCL_RC17 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106137 CVCL_RC18 STBCi039-A induced pluripotent stem cell human CVCL_RC18 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106138 CVCL_II85 BIONi010-C-6 induced pluripotent stem cell human CVCL_II85 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple_edited; p.Arg176Cys (c.526C>T); ClinVar=VCV000017848; Zygosity=Homozygous; Note=ApoE2 allele By CRISPR/Cas9. The second allele is disrupted by a 3.4 kb insertion from the selection plasmid (PubMed=30660866; PubMed=32971461). Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106139 CVCL_RC19 STBCi039-B induced pluripotent stem cell human CVCL_RC19 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106140 CVCL_II86 BIONi010-C-7 induced pluripotent stem cell human CVCL_II86 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Homozygous (EBiSC) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21106141 CVCL_II87 HPSI0713i-aehn_22 induced pluripotent stem cell human CVCL_II87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21106142 CVCL_II88 HPSI0613i-oomz_22 induced pluripotent stem cell human CVCL_II88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21106143 CVCL_II60 ND01144 transformed cell line human CVCL_II60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106144 CVCL_II61 ND01145 transformed cell line human CVCL_II61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106145 CVCL_II62 ND01147 transformed cell line human CVCL_II62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106146 CVCL_RC00 STBCi031-C induced pluripotent stem cell human CVCL_RC00 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106147 CVCL_RC01 STBCi032-A induced pluripotent stem cell human CVCL_RC01 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106148 CVCL_RC02 STBCi032-B induced pluripotent stem cell human CVCL_RC02 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106149 CVCL_RC03 STBCi033-A induced pluripotent stem cell human CVCL_RC03 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106150 CVCL_II56 ND01105 transformed cell line human CVCL_II56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106151 CVCL_RC04 STBCi033-B induced pluripotent stem cell human CVCL_RC04 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106152 CVCL_II57 ND01123 transformed cell line human CVCL_II57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106153 CVCL_RC05 STBCi033-C induced pluripotent stem cell human CVCL_RC05 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106154 CVCL_II58 ND01125 transformed cell line human CVCL_II58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106155 CVCL_RC06 STBCi034-A induced pluripotent stem cell human CVCL_RC06 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106156 CVCL_II59 ND01128 transformed cell line human CVCL_II59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106157 CVCL_RC07 STBCi034-B induced pluripotent stem cell human CVCL_RC07 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106158 CVCL_II52 ND01279 transformed cell line human CVCL_II52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106159 CVCL_RC08 STBCi035-A induced pluripotent stem cell human CVCL_RC08 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Leu869Phe (c.2605C>T) (p.Leu858Phe, c.2572C>T); ClinVar=VCV000006364; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21106160 CVCL_II53 ND01051 transformed cell line human CVCL_II53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106161 CVCL_RC09 STBCi035-B induced pluripotent stem cell human CVCL_RC09 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Leu869Phe (c.2605C>T) (p.Leu858Phe, c.2572C>T); ClinVar=VCV000006364; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21106162 CVCL_II54 ND01053 transformed cell line human CVCL_II54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106163 CVCL_II55 ND01104 transformed cell line human CVCL_II55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106164 CVCL_II70 ND01240 transformed cell line human CVCL_II70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106165 CVCL_II71 ND01257 transformed cell line human CVCL_II71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106166 CVCL_II72 ND01262 transformed cell line human CVCL_II72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106167 CVCL_II73 ND01266 transformed cell line human CVCL_II73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106168 CVCL_II67 ND01203 transformed cell line human CVCL_II67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106169 CVCL_II68 ND01221 transformed cell line human CVCL_II68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106170 CVCL_II69 ND01238 transformed cell line human CVCL_II69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106171 CVCL_II63 OCUM-8/GEM cancer cell line human CVCL_II63 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Ascites. Female 21106172 CVCL_II64 ND01148 transformed cell line human CVCL_II64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106173 CVCL_II65 ND01168 transformed cell line human CVCL_II65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106174 CVCL_II66 ND01198 transformed cell line human CVCL_II66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106175 CVCL_7V30 DA04202 transformed cell line human CVCL_7V30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106176 CVCL_8730 KU-SN cancer cell line human CVCL_8730 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21106177 CVCL_7V24 DA04196 transformed cell line human CVCL_7V24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106178 CVCL_8724 JTK-LCL transformed cell line human CVCL_8724 HLA typing: A*02:06,24:02 (RCB=RCB1873) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106179 CVCL_7V25 DA04197 transformed cell line human CVCL_7V25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106180 CVCL_8725 KLN205-MUC1 cancer cell line house mouse CVCL_8725 CL:0000010 Transfected with: HGNC; 7508; MUC1 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Lung; Breed/subspecies: DBA/2. Male 21106181 CVCL_7V26 DA04198 transformed cell line human CVCL_7V26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106182 CVCL_8726 KOIA-LCL transformed cell line human CVCL_8726 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Unspecified; Note=Germline (RCB) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21106183 CVCL_7V27 DA04199 transformed cell line human CVCL_7V27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106184 CVCL_8727 KP-4-1 cancer cell line human CVCL_8727 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male 21106185 CVCL_7V20 DA04192 transformed cell line human CVCL_7V20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106186 CVCL_8720 HTMM cancer cell line human CVCL_8720 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female 21106187 CVCL_7V21 DA04193 transformed cell line human CVCL_7V21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106188 CVCL_8721 HTMMT cancer cell line human CVCL_8721 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gly (c.388C>G); ClinVar=VCV000375958; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ter404Leuext*8 (c.1211G>T); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 72 hours (at 20th passage), 70 hours (at 40th passage), 60 hours (at 50th passage) (PubMed=15859158) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106189 CVCL_7V22 DA04194 transformed cell line human CVCL_7V22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106190 CVCL_8722 HTST finite cell line human CVCL_8722 CL:0000010 Population: Japanese; Derived from sampling site: Bone; coccyx. Female 21106191 CVCL_7V23 DA04195 transformed cell line human CVCL_7V23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106192 CVCL_8723 IGROV-1/25 ET cancer cell line human CVCL_8723 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:84050; Trabectedin (Ecteinascidin-743; Derived from sampling site: Ovary. Female Doubling time: ~23 hours (PubMed=10817511) 21106193 CVCL_7V28 DA04200 transformed cell line human CVCL_7V28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106194 CVCL_8728 KP-4-2 cancer cell line human CVCL_8728 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Male 21106195 CVCL_7V29 DA04201 transformed cell line human CVCL_7V29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106196 CVCL_8729 KP-4-3 cancer cell line human CVCL_8729 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Male 21106197 CVCL_7V40 DA04212 transformed cell line human CVCL_7V40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106198 CVCL_8740 NIL 2c2 spontaneously immortalized cell line CVCL_8740 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106199 CVCL_7V41 DA04213 transformed cell line human CVCL_7V41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106200 CVCL_8741 NIL 2c3 spontaneously immortalized cell line CVCL_8741 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106201 CVCL_7V35 DA04207 transformed cell line human CVCL_7V35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106202 CVCL_8735 MTHC-3 hybrid cell line CVCL_8735 CL:0000010 21106203 CVCL_7V36 DA04208 transformed cell line human CVCL_7V36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106204 CVCL_8736 MuSS cancer cell line house mouse CVCL_8736 CL:0000010 Breed/subspecies: A/J. Male 21106205 CVCL_7V37 DA04209 transformed cell line human CVCL_7V37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106206 CVCL_8737 NIL 1c1 spontaneously immortalized cell line CVCL_8737 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106207 CVCL_7V38 DA04210 transformed cell line human CVCL_7V38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106208 CVCL_8738 Nil-2 spontaneously immortalized cell line CVCL_8738 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Discontinued: ATCC; CRL-6443; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106209 CVCL_7V31 DA04203 transformed cell line human CVCL_7V31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106210 CVCL_8731 M-MOK cancer cell line human CVCL_8731 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Requires human fibroblast feeder cells for its viability; Characteristics: CSF2 dependent Doubling time: 45 +- 6 hours (PubMed=9096695) 21106211 CVCL_7V32 DA04204 transformed cell line human CVCL_7V32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106212 CVCL_8732 MG6 transformed cell line house mouse CVCL_8732 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Unspecified 21106213 CVCL_7V33 DA04205 transformed cell line human CVCL_7V33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106214 CVCL_8733 MTHC-1 cancer cell line Norway rat CVCL_8733 CL:0000010 Breed/subspecies: Buffalo/Mna. Female 21106215 CVCL_7V34 DA04206 transformed cell line human CVCL_7V34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106216 CVCL_8734 MTHC-2 hybrid cell line CVCL_8734 CL:0000010 21106217 CVCL_7V39 DA04211 transformed cell line human CVCL_7V39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106218 CVCL_8739 NIL 2c1 spontaneously immortalized cell line CVCL_8739 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106219 CVCL_7V02 DA04172 transformed cell line human CVCL_7V02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106220 CVCL_8702 HOC719-PE cancer cell line human CVCL_8702 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Met1043Val (c.3127A>G); ClinVar=VCV000376485; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Oral cavity; tongue. 21106221 CVCL_7V03 DA04173 transformed cell line human CVCL_7V03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106222 CVCL_8703 HOC815 cancer cell line human CVCL_8703 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from sampling site: Lymph node. 21106223 CVCL_7V04 DA04175 transformed cell line human CVCL_7V04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106224 CVCL_8704 HOC927 cancer cell line human CVCL_8704 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (PubMed=18097548); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1570156) Derived from sampling site: Lymph node. 21106225 CVCL_7V05 DA04176 transformed cell line human CVCL_7V05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106226 CVCL_8705 HOKUG cancer cell line human CVCL_8705 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 56 (HPV56)(NCBI-Taxonomy; 10596); Derived from sampling site: Uterus; cervix. Female Doubling time: 57 hours (at 5th passage), 45 hours (at 20th passage), 44 hours (at 50th passage) (PubMed=1698374) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106227 CVCL_7V00 DA04170 transformed cell line human CVCL_7V00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106228 CVCL_8700 HOC719 cancer cell line human CVCL_8700 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Met1043Val (c.3127A>G); ClinVar=VCV000376485; Zygosity=Homozygous (PubMed=18097548); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from sampling site: Oral cavity; tongue. 21106229 CVCL_7V01 DA04171 transformed cell line human CVCL_7V01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106230 CVCL_8701 HOC719-NE cancer cell line human CVCL_8701 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Met1043Val (c.3127A>G); ClinVar=VCV000376485; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Oral cavity; tongue. 21106231 CVCL_7V06 DA04178 transformed cell line human CVCL_7V06 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106232 CVCL_8706 HONE-1 cancer cell line human CVCL_8706 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by RNAseq Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00496 Problematic cell line: Seems to bear part of the HeLa genomic sequence; may be a derivative of HeLa and another cell of unknown origin (PubMed=24991015) 21106233 CVCL_7V07 DA04179 transformed cell line human CVCL_7V07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106234 CVCL_8707 HOTC-3 cancer cell line human CVCL_8707 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21106235 CVCL_7V08 DA04180 transformed cell line human CVCL_7V08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106236 CVCL_8708 HOTHC cancer cell line human CVCL_8708 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female Doubling time: 24 hours (PubMed=10457904); 24-28 hours (PubMed=17022149) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106237 CVCL_7V09 DA04181 transformed cell line human CVCL_7V09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106238 CVCL_8709 HOTHC-SF cancer cell line human CVCL_8709 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female Group: Serum/protein free medium cell line 21106239 CVCL_7V13 DA04185 transformed cell line human CVCL_7V13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106240 CVCL_8713 HS-ES-1 cancer cell line human CVCL_8713 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=26365879) Population: Japanese Omics: Transcriptome analysis by RNAseq. Male 21106241 CVCL_7V14 DA04186 transformed cell line human CVCL_7V14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106242 CVCL_8714 HS-ES-2M cancer cell line human CVCL_8714 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=28945250) Population: Japanese; Derived from metastatic site: Lung. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male 21106243 CVCL_7V15 DA04187 transformed cell line human CVCL_7V15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106244 CVCL_8715 HS-ES-2R cancer cell line human CVCL_8715 CL:0000010 Population: Japanese. Male 21106245 CVCL_7V16 DA04188 transformed cell line human CVCL_7V16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106246 CVCL_8716 HS-Os-1 cancer cell line human CVCL_8716 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; left humerus. Female Doubling time: ~58 hours (PubMed=1679269) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106247 CVCL_7V10 DA04182 transformed cell line human CVCL_7V10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106248 CVCL_8710 HP100-1 cancer cell line human CVCL_8710 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Derived from sampling site: Peripheral blood. Female 21106249 CVCL_7V11 DA04183 transformed cell line human CVCL_7V11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106250 CVCL_8711 HP50-2 cancer cell line human CVCL_8711 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Derived from sampling site: Peripheral blood. Female 21106251 CVCL_7V12 DA04184 transformed cell line human CVCL_7V12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106252 CVCL_8712 HPMEC-ST1.6R transformed cell line human CVCL_8712 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; endothelium Cell type=Lung microvascular endothelial cell.. Male 21106253 CVCL_7V17 DA04189 transformed cell line human CVCL_7V17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106254 CVCL_8717 HS-PSS cancer cell line human CVCL_8717 CL:0000010 Population: Japanese; Derived from sampling site: Prostate. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106255 CVCL_7V18 DA04190 transformed cell line human CVCL_7V18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106256 CVCL_8718 HS-Sch-2 cancer cell line human CVCL_8718 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=10891546; DepMap) Population: Japanese; Derived from sampling site: Left sciatic nerve. Female Doubling time: ~56 hours (PubMed=10891546) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106257 CVCL_7V19 DA04191 transformed cell line human CVCL_7V19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106258 CVCL_8719 HS-SY-2 cancer cell line human CVCL_8719 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=1331610; PubMed=7539744) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (PubMed=1331610) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106259 CVCL_RC90 STBCi069-A induced pluripotent stem cell human CVCL_RC90 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106260 CVCL_RC91 STBCi069-B induced pluripotent stem cell human CVCL_RC91 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106261 CVCL_RC92 STBCi069-C induced pluripotent stem cell human CVCL_RC92 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106262 CVCL_RC93 STBCi070-A induced pluripotent stem cell human CVCL_RC93 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106263 CVCL_RC94 STBCi070-B induced pluripotent stem cell human CVCL_RC94 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106264 CVCL_RC95 STBCi071-A induced pluripotent stem cell human CVCL_RC95 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106265 CVCL_RC96 STBCi071-B induced pluripotent stem cell human CVCL_RC96 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106266 CVCL_RC97 STBCi071-C induced pluripotent stem cell human CVCL_RC97 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106267 CVCL_RC98 STBCi072-A induced pluripotent stem cell human CVCL_RC98 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106268 CVCL_RC99 STBCi072-B induced pluripotent stem cell human CVCL_RC99 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106269 CVCL_RC80 STBCi062-A induced pluripotent stem cell human CVCL_RC80 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106270 CVCL_RC81 STBCi063-A induced pluripotent stem cell human CVCL_RC81 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21106271 CVCL_RC82 STBCi063-B induced pluripotent stem cell human CVCL_RC82 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106272 CVCL_RC83 STBCi063-C induced pluripotent stem cell human CVCL_RC83 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106273 CVCL_RC84 STBCi064-A induced pluripotent stem cell human CVCL_RC84 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21106274 CVCL_RC85 STBCi065-A induced pluripotent stem cell human CVCL_RC85 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106275 CVCL_RC86 STBCi066-A induced pluripotent stem cell human CVCL_RC86 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21106276 CVCL_RC87 STBCi068-A induced pluripotent stem cell human CVCL_RC87 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106277 CVCL_RC88 STBCi068-B induced pluripotent stem cell human CVCL_RC88 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106278 CVCL_RC89 STBCi068-C induced pluripotent stem cell human CVCL_RC89 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106279 CVCL_RC70 STBCi058-A induced pluripotent stem cell human CVCL_RC70 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106280 CVCL_RC71 STBCi058-B induced pluripotent stem cell human CVCL_RC71 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106281 CVCL_RC72 STBCi058-C induced pluripotent stem cell human CVCL_RC72 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106282 CVCL_RC73 STBCi059-A induced pluripotent stem cell human CVCL_RC73 From: StemBANCC; Oxford; United Kingdom. CL:0000010 Male 21106283 CVCL_RC74 STBCi059-B induced pluripotent stem cell human CVCL_RC74 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106284 CVCL_RC75 STBCi059-C induced pluripotent stem cell human CVCL_RC75 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106285 CVCL_RC76 STBCi060-A induced pluripotent stem cell human CVCL_RC76 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106286 CVCL_RC77 STBCi060-B induced pluripotent stem cell human CVCL_RC77 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106287 CVCL_RC78 STBCi060-C induced pluripotent stem cell human CVCL_RC78 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106288 CVCL_RC79 STBCi061-A induced pluripotent stem cell human CVCL_RC79 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21106289 CVCL_A028 UCSFB-5 embryonic stem cell human CVCL_A028 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106290 CVCL_A029 UCSFB-6 embryonic stem cell human CVCL_A029 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106291 CVCL_7U94 DA04164 transformed cell line human CVCL_7U94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106292 CVCL_8694 HOC1208 cancer cell line human CVCL_8694 CL:0000010 Population: Japanese. Unspecified 21106293 CVCL_A020 UCSF2 embryonic stem cell human CVCL_A020 From: University of California, San Francisco; San Francisco; USA. CL:0000010 Male 21106294 CVCL_7U95 DA04165 transformed cell line human CVCL_7U95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106295 CVCL_8695 HOC313 cancer cell line human CVCL_8695 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Unspecified (PubMed=18097548); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from metastatic site: Lymph node. Female 21106296 CVCL_A021 UCSF3 embryonic stem cell human CVCL_A021 From: University of California, San Francisco; San Francisco; USA. CL:0000010 Unspecified 21106297 CVCL_7U96 DA04166 transformed cell line human CVCL_7U96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106298 CVCL_8696 HOC512 cancer cell line human CVCL_8696 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Doubling time: 16.7 hours (DOI=10.11277/stomatology1952.44.47) 21106299 CVCL_A022 UCSF4 embryonic stem cell human CVCL_A022 From: University of California, San Francisco; San Francisco; USA CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0044 21106300 CVCL_7U97 DA04167 transformed cell line human CVCL_7U97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106301 CVCL_8697 HOC519 cancer cell line human CVCL_8697 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Doubling time: 28.1 hours (DOI=10.11277/stomatology1952.44.47) 21106302 CVCL_A023 UCSFB-1 embryonic stem cell human CVCL_A023 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106303 CVCL_7U90 DA04160 transformed cell line human CVCL_7U90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106304 CVCL_8690 HAEND cancer cell line human CVCL_8690 CL:0000010 Discontinued: Coriell; AG13420; probable. Male Doubling time: ~24 hours (PubMed=8096506) Problematic cell line: Contaminated Unknown origin but not an umbilical vein endothelium cell line (PubMed=12453433). 21106305 CVCL_A024 UCSFB-10 embryonic stem cell human CVCL_A024 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106306 CVCL_7U91 DA04161 transformed cell line human CVCL_7U91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106307 CVCL_8691 HFWT cancer cell line human CVCL_8691 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 48 hours (at 5th passage), 41 hours (at 20th passage), 40 hours (at 50th passage) (PubMed=1850701) 21106308 CVCL_A025 UCSFB-2 embryonic stem cell human CVCL_A025 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106309 CVCL_7U92 DA04162 transformed cell line human CVCL_7U92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106310 CVCL_8692 HOC-21 cancer cell line human CVCL_8692 CL:0000010 Female Doubling time: 28 hours (PubMed=4436993). 21106311 CVCL_A026 UCSFB-3 embryonic stem cell human CVCL_A026 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106312 CVCL_7U93 DA04163 transformed cell line human CVCL_7U93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106313 CVCL_8693 HOC119 cancer cell line human CVCL_8693 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Doubling time: 20.4 hours (DOI=10.11277/stomatology1952.44.47) 21106314 CVCL_A027 UCSFB-4 embryonic stem cell human CVCL_A027 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106315 CVCL_7U87 DA04154 transformed cell line human CVCL_7U87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106316 CVCL_8687 EVLC2 undefined cell line type human CVCL_8687 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00199. Problematic cell line: Contaminated Unknown origin but not an umbilical vein endothelium cell line (PubMed=12453433; PubMed=20143388). 21106317 CVCL_7U88 DA04158 transformed cell line human CVCL_7U88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106318 CVCL_8688 F255A4 cancer cell line human CVCL_8688 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00045 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). 21106319 CVCL_7U89 DA04159 transformed cell line human CVCL_7U89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106320 CVCL_8689 FELV3281-AD cancer cell line CVCL_8689 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). Unspecified 21106321 CVCL_A039 F2.4A3 finite cell line human CVCL_A039 CL:0000010 Derived from sampling site: Fetal thymus Cell type=Thymic epithelial cell.. Unspecified Problematic cell line: Possibly contaminated May originate from SK-HEP-1 as 4 other cell lines from the same paper (PubMed=7514905) have been shown to be contaminated. 21106322 CVCL_A031 UCSFB-8 embryonic stem cell human CVCL_A031 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106323 CVCL_A032 UCSFB-9 embryonic stem cell human CVCL_A032 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106324 CVCL_A033 BCC-1/KMC cancer cell line human CVCL_A033 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 38.86 hours (PubMed=8007045) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00112 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 65 year old female patient with a skin basal cell carcinoma. 21106325 CVCL_A034 JTC-3 cancer cell line human CVCL_A034 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00140 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). 21106326 CVCL_A035 BCWM.1 cancer cell line human CVCL_A035 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=23321251) Derived from sampling site: Bone marrow. Omics: SNP array analysis Female Doubling time: 3 days (PubMed=17761288) 21106327 CVCL_A036 WSU-ALCL cancer cell line human CVCL_A036 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00284 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a malignant pleural effusion of a 18 year old patient with primary refractory anaplastic large cell lymphoma. 21106328 CVCL_A037 PEC.1 finite cell line human CVCL_A037 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Unspecified 21106329 CVCL_A038 FEC.2 finite cell line human CVCL_A038 CL:0000010 Derived from sampling site: Fetal thymus Cell type=Thymic epithelial cell.. Unspecified 21106330 CVCL_7U98 DA04168 transformed cell line human CVCL_7U98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106331 CVCL_8698 HOC605 cancer cell line human CVCL_8698 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from sampling site: Lymph node. 21106332 CVCL_7U99 DA04169 transformed cell line human CVCL_7U99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106333 CVCL_8699 HOC621 cancer cell line human CVCL_8699 CL:0000010 Population: Japanese. 21106334 CVCL_A030 UCSFB-7 embryonic stem cell human CVCL_A030 From: University of California, San Francisco; San Francisco; USA CL:0000010 Donor information: Embryos giving rise to UCSFB-1 to UCSFB-10 are all siblings. Male Registration: NIH Human Embryonic Stem Cell Registry; pending review 21106335 CVCL_A006 UNEWe005-A embryonic stem cell human CVCL_A006 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-017, Steering comm appl. SCSC06-46(4).. 21106336 CVCL_A007 UNEWe006-A embryonic stem cell human CVCL_A007 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-018, Steering comm appl. SCSC06-46(5).. 21106337 CVCL_A008 UNEWe007-A embryonic stem cell human CVCL_A008 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-07-019, Steering comm appl. SCSC06-47(1).. 21106338 CVCL_A009 UNEWe008-A embryonic stem cell human CVCL_A009 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-07-020, Steering comm appl. SCSC06-47(2).. 21106339 CVCL_7U72 DA04139 transformed cell line human CVCL_7U72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106340 CVCL_8672 Detroit 116P cancer cell line human CVCL_8672 CL:0000010 Derived from sampling site: Pleural effusion. 21106341 CVCL_7U73 DA04140 transformed cell line human CVCL_7U73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106342 CVCL_8673 Detroit 173B undefined cell line type human CVCL_8673 CL:0000010 Female 21106343 CVCL_7U74 DA04141 transformed cell line human CVCL_7U74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106344 CVCL_8674 Detroit 30A cancer cell line human CVCL_8674 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00041 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). Originally thought to originate from the ascitic fluid of a 43 year old breast cancer patient. 21106345 CVCL_A000 NOTT1 embryonic stem cell human CVCL_A000 From: University of Nottingham; Nottingham; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-001, Steering comm appl. SCSC06-12.. 21106346 CVCL_7U75 DA04142 transformed cell line human CVCL_7U75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106347 CVCL_8675 Detroit 32 cancer cell line human CVCL_8675 CL:0000010 Derived from sampling site: Bone marrow. Female 21106348 CVCL_A001 NOTT2 embryonic stem cell human CVCL_A001 From: University of Nottingham; Nottingham; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-07-002, Steering comm appl. SCSC06-31.. 21106349 CVCL_A002 UNEWe001-A embryonic stem cell human CVCL_A002 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-05-015, Steering comm appl. SCSC04-01.. 21106350 CVCL_A003 UNEWe002-A embryonic stem cell human CVCL_A003 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-014, Steering comm appl. SCSC06-46(1).. 21106351 CVCL_7U70 DA04137 transformed cell line human CVCL_7U70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106352 CVCL_A004 UNEWe003-A embryonic stem cell human CVCL_A004 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-07-015, Steering comm appl. SCSC06-46(2).. 21106353 CVCL_8670 Rh41-807R cancer cell line human CVCL_8670 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line). Selected for resistance to: ChEBI; CHEBI:88339; BMS-754807 Female 21106354 CVCL_7U71 DA04138 transformed cell line human CVCL_7U71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106355 CVCL_8671 Detroit 143 undefined cell line type human CVCL_8671 CL:0000010 21106356 CVCL_A005 UNEWe004-A embryonic stem cell human CVCL_A005 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-07-016, Steering comm appl. SCSC06-46(3).. 21106357 CVCL_8669 D18T cancer cell line human CVCL_8669 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00039 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). 21106358 CVCL_7U69 DA04136 transformed cell line human CVCL_7U69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106359 CVCL_8665 CJM Cl5 cancer cell line human CVCL_8665 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106360 CVCL_7U65 DA04131 transformed cell line human CVCL_7U65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106361 CVCL_8666 CJM Cl6 cancer cell line human CVCL_8666 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106362 CVCL_7U66 DA04133 transformed cell line human CVCL_7U66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04133; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106363 CVCL_8667 CJM Cl7 cancer cell line human CVCL_8667 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106364 CVCL_7U67 DA04134 transformed cell line human CVCL_7U67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106365 CVCL_8668 CJM Cl8 cancer cell line human CVCL_8668 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106366 CVCL_7U68 DA04135 transformed cell line human CVCL_7U68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106367 CVCL_A017 ASBB spontaneously immortalized cell line CVCL_A017 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21106368 CVCL_A018 IGR-CaP1 cancer cell line human CVCL_A018 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (PubMed=20974126) Karyotypic information: Has lost chromosome Y; Derived from sampling site: Prostate. Male Doubling time: 43 hours (PubMed=20974126) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4126 21106369 CVCL_A019 UCSF1 embryonic stem cell human CVCL_A019 From: University of California, San Francisco; San Francisco; USA. CL:0000010 Female 21106370 CVCL_7U83 DA04150 transformed cell line human CVCL_7U83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106371 CVCL_8683 Detroit B78 undefined cell line type human CVCL_8683 CL:0000010 Female 21106372 CVCL_7U84 DA04151 transformed cell line human CVCL_7U84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106373 CVCL_8684 Detroit B96 undefined cell line type human CVCL_8684 CL:0000010 Female 21106374 CVCL_A010 UNEWe009-A embryonic stem cell human CVCL_A010 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-021, Steering comm appl. SCSC06-47(3).. 21106375 CVCL_7U85 DA04152 transformed cell line human CVCL_7U85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106376 CVCL_8685 EEB cancer cell line human CVCL_8685 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 38 hours (PubMed=16332389) 21106377 CVCL_A011 FEMX-I cancer cell line human CVCL_A011 CL:0000010 Derived from metastatic site: Lymph node. Female Characteristics: Established from a first generation nude mouse xenograft of the original tumor 21106378 CVCL_7U86 DA04153 transformed cell line human CVCL_7U86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106379 CVCL_8686 ElCo cancer cell line human CVCL_8686 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00042 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21106380 CVCL_A012 MEL-RC08 cancer cell line human CVCL_A012 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22529031); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=22529031) Population: Japanese; Derived from metastatic site: Pericranium. Female Doubling time: 24 hours (PubMed=22529031) 21106381 CVCL_A013 CH-3573 cancer cell line human CVCL_A013 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu201Cysfs*46 (c.602delT); ClinVar=VCV000924862; Zygosity=Homozygous (PubMed=22350793) Derived from sampling site: Pelvis. Male 21106382 CVCL_A014 BVK168 spontaneously immortalized cell line CVCL_A014 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Western lineage. Male Virology: Susceptible to infection by many bornaviruses, bunyaviruses, flaviviruses, poxviruses and togaviruses (PubMed=21729307) 21106383 CVCL_7U80 DA04147 transformed cell line human CVCL_7U80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106384 CVCL_8680 Detroit B110 undefined cell line type human CVCL_8680 CL:0000010 Female 21106385 CVCL_7U81 DA04148 transformed cell line human CVCL_7U81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106386 CVCL_8681 Detroit B16 undefined cell line type human CVCL_8681 CL:0000010 Female 21106387 CVCL_A015 ITAC-3 cancer cell line human CVCL_A015 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=21360264); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Heterozygous (PubMed=21360264) Derived from sampling site: Nose; ethmoid sinus. Omics: Array-based CGH Male Doubling time: ~18 hours (PubMed=21360264) 21106388 CVCL_7U82 DA04149 transformed cell line human CVCL_7U82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106389 CVCL_8682 Detroit B17 undefined cell line type human CVCL_8682 CL:0000010 Female 21106390 CVCL_A016 Leo cancer cell line dog CVCL_A016 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Male Doubling time: ~38 hours (PubMed=21321976) 21106391 CVCL_7U76 DA04143 transformed cell line human CVCL_7U76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106392 CVCL_8676 Detroit 34 cancer cell line human CVCL_8676 CL:0000010 Derived from metastatic site: Bone marrow. Male 21106393 CVCL_7U77 DA04144 transformed cell line human CVCL_7U77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106394 CVCL_8677 Detroit 501 undefined cell line type human CVCL_8677 CL:0000010 21106395 CVCL_7U78 DA04145 transformed cell line human CVCL_7U78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106396 CVCL_8678 Detroit 52 undefined cell line type human CVCL_8678 CL:0000010 Derived from sampling site: Bone marrow. Female 21106397 CVCL_7U79 DA04146 transformed cell line human CVCL_7U79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106398 CVCL_8679 Detroit 56A cancer cell line human CVCL_8679 CL:0000010 Derived from metastatic site: Ascites. Male 21106399 CVCL_7U50 DA04116 transformed cell line human CVCL_7U50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106400 CVCL_8650 HB2/CD82 transformed cell line human CVCL_8650 CL:0000010 Transfected with: HGNC; 6210; CD82; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21106401 CVCL_7U51 DA04117 transformed cell line human CVCL_7U51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106402 CVCL_8651 XR-V9B-4 spontaneously immortalized cell line CVCL_8651 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; Q60449; Xrcc5; Simple; p.Ile267_Gln350del84 (c.799_1050del252); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21106403 CVCL_7U52 DA04118 transformed cell line human CVCL_7U52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106404 CVCL_8652 LK-1 cancer cell line human CVCL_8652 CL:0000010 Population: Japanese. 21106405 CVCL_8653 1-1ras1000 transformed cell line house mouse CVCL_8653 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: Swiss albino. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00531 Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (PubMed=27844419). 21106406 CVCL_7U53 DA04119 transformed cell line human CVCL_7U53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106407 CVCL_7U47 DA04113 transformed cell line human CVCL_7U47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106408 CVCL_8647 MRSV2-1 transformed cell line human CVCL_8647 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21106409 CVCL_8648 ASB-410 transformed cell line CVCL_8648 CL:0000010 Transformant: Asbestos(ChEBI; CHEBI:46661). Male 21106410 CVCL_7U48 DA04114 transformed cell line human CVCL_7U48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106411 CVCL_7U49 DA04115 transformed cell line human CVCL_7U49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106412 CVCL_8649 HB2/zeo transformed cell line human CVCL_8649 CL:0000010 Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21106413 CVCL_7U43 DA04109 transformed cell line human CVCL_7U43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106414 CVCL_8643 VACO 786 cancer cell line human CVCL_8643 CL:0000010 21106415 CVCL_7U44 DA04110 transformed cell line human CVCL_7U44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106416 CVCL_8644 VACO 866 cancer cell line human CVCL_8644 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21106417 CVCL_7U45 DA04111 transformed cell line human CVCL_7U45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106418 CVCL_8645 MTSV1-7 transformed cell line human CVCL_8645 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21106419 CVCL_7U46 DA04112 transformed cell line human CVCL_7U46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106420 CVCL_8646 MRSV2-4 transformed cell line human CVCL_8646 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21106421 CVCL_7U61 DA04127 transformed cell line human CVCL_7U61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106422 CVCL_8662 C831L cancer cell line human CVCL_8662 HLA typing: A*02:06,26:01; B*07:02,35:01; C*07:02,08:01 (PubMed=12114371) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Gln22Ter (c.64C>T); Zygosity=Unspecified (PubMed=17725806) Population: Japanese; Derived from sampling site: Lung. Male 21106423 CVCL_7U62 DA04128 transformed cell line human CVCL_7U62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106424 CVCL_8663 CJM [Human OCSCC] cancer cell line human CVCL_8663 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106425 CVCL_7U63 DA04129 transformed cell line human CVCL_7U63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106426 CVCL_8664 CJM Cl4 cancer cell line human CVCL_8664 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic cavity. Male 21106427 CVCL_7U64 DA04130 transformed cell line human CVCL_7U64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106428 CVCL_8660 BREM cancer cell line human CVCL_8660 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21106429 CVCL_7U60 DA04126 transformed cell line human CVCL_7U60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106430 CVCL_8658 B1203L cancer cell line human CVCL_8658 HLA typing: A*24:02,24:02; B*52:01,54:01; C*12:02,01:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21106431 CVCL_7U58 DA04124 transformed cell line human CVCL_7U58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106432 CVCL_8659 BBF cancer cell line human CVCL_8659 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: Supports human herpesvirus 8 (HHV-8/KSHV) replication; Virology: EBV-negative 21106433 CVCL_7U59 DA04125 transformed cell line human CVCL_7U59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106434 CVCL_8654 1-1src transformed cell line house mouse CVCL_8654 CL:0000010 Transfected with: UniProtKB; P00524; Avian leukosis virus RSA v-Src Transformant: v-Src; Breed/subspecies: Swiss albino. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00532 Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (PubMed=27844419). 21106435 CVCL_7U54 DA04120 transformed cell line human CVCL_7U54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106436 CVCL_8655 A529L cancer cell line human CVCL_8655 HLA typing: A*24:02; B*52:01; C*12:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21106437 CVCL_7U55 DA04121 transformed cell line human CVCL_7U55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106438 CVCL_8656 AS-M cancer cell line human CVCL_8656 CL:0000010 Derived from sampling site: Scalp; skin. Male 21106439 CVCL_7U56 DA04122 transformed cell line human CVCL_7U56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106440 CVCL_8657 AS-M.5 cancer cell line human CVCL_8657 CL:0000010 Derived from sampling site: Scalp; skin. Male 21106441 CVCL_7U57 DA04123 transformed cell line human CVCL_7U57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106442 CVCL_7U30 DA04090 transformed cell line human CVCL_7U30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106443 CVCL_8630 VACO 364 cancer cell line human CVCL_8630 CL:0000010 21106444 CVCL_7U31 DA04091 transformed cell line human CVCL_7U31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106445 CVCL_8631 VACO 394 cancer cell line human CVCL_8631 CL:0000010 21106446 CVCL_8625 97-7 cancer cell line human CVCL_8625 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21106447 CVCL_7U25 DA04084 transformed cell line human CVCL_7U25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106448 CVCL_8626 ASB-10W transformed cell line CVCL_8626 CL:0000010 Transformant: Asbestos(ChEBI; CHEBI:46661). Female 21106449 CVCL_7U26 DA04085 transformed cell line human CVCL_7U26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106450 CVCL_8627 30F spontaneously immortalized cell line house mouse CVCL_8627 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21106451 CVCL_7U27 DA04086 transformed cell line human CVCL_7U27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106452 CVCL_8628 31E spontaneously immortalized cell line house mouse CVCL_8628 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21106453 CVCL_7U28 DA04087 transformed cell line human CVCL_7U28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106454 CVCL_8621 97-24 cancer cell line human CVCL_8621 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Part of: UBC-40 urothelial bladder cancer cell line index 21106455 CVCL_7U21 DA04079 transformed cell line human CVCL_7U21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106456 CVCL_8622 97-29 cancer cell line human CVCL_8622 CL:0000010 Derived from sampling site: Urinary bladder. 21106457 CVCL_7U22 DA04080 transformed cell line human CVCL_7U22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106458 CVCL_8623 97-5 cancer cell line human CVCL_8623 CL:0000010 Derived from sampling site: Urinary bladder. Female Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21106459 CVCL_7U23 DA04081 transformed cell line human CVCL_7U23 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106460 CVCL_8624 97-6 cancer cell line human CVCL_8624 CL:0000010 Derived from sampling site: Urinary bladder. Male 21106461 CVCL_7U24 DA04083 transformed cell line human CVCL_7U24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106462 CVCL_7U29 DA04089 transformed cell line human CVCL_7U29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106463 CVCL_8629 VACO 264 cancer cell line human CVCL_8629 CL:0000010 21106464 CVCL_7U40 DA04101 transformed cell line human CVCL_7U40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106465 CVCL_8640 VACO 489 cancer cell line human CVCL_8640 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=27004849); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Homozygous (PubMed=9715273) Derived from sampling site: Colon. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21106466 CVCL_7U41 DA04102 transformed cell line human CVCL_7U41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106467 CVCL_8641 VACO 503 cancer cell line human CVCL_8641 CL:0000010 21106468 CVCL_7U42 DA04103 transformed cell line human CVCL_7U42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106469 CVCL_8642 VACO 784 cancer cell line human CVCL_8642 CL:0000010 21106470 CVCL_7U36 DA04096 transformed cell line human CVCL_7U36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106471 CVCL_8636 VACO 459 cancer cell line human CVCL_8636 CL:0000010 21106472 CVCL_7U37 DA04097 transformed cell line human CVCL_7U37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106473 CVCL_8637 VACO 478 cancer cell line human CVCL_8637 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849). Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21106474 CVCL_7U38 DA04098 transformed cell line human CVCL_7U38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106475 CVCL_8638 VACO 481 cancer cell line human CVCL_8638 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Asp96fs*4 (c.278_279insA); Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Ala535fs*30 (c.1597_1598TG[4]) (c.1602_1603insTG); ClinVar=VCV000012501; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9715273) Omics: Transcriptome analysis by microarray. Microsatellite instability: Instable (MSI) (PubMed=25926053) 21106476 CVCL_7U39 DA04099 transformed cell line human CVCL_7U39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106477 CVCL_8639 VACO 486 cancer cell line human CVCL_8639 CL:0000010 21106478 CVCL_7U32 DA04092 transformed cell line human CVCL_7U32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106479 CVCL_8632 VACO 410 cancer cell line human CVCL_8632 CL:0000010 Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Arg528His (c.1583G>A); ClinVar=VCV000012511; Zygosity=Homozygous (PubMed=9927040) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=9927040) 21106480 CVCL_7U33 DA04093 transformed cell line human CVCL_7U33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106481 CVCL_8633 VACO 425 cancer cell line human CVCL_8633 CL:0000010 Sequence variation: Mutation; HGNC; 30881; ALG13; Simple; p.Glu729Ter (c.2185G>T); Zygosity=Unspecified (PubMed=27004849); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Ascites. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21106482 CVCL_7U34 DA04094 transformed cell line human CVCL_7U34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106483 CVCL_8634 VACO 444 cancer cell line human CVCL_8634 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Asp96fs*54 (c.278delA); Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714). 21106484 CVCL_7U35 DA04095 transformed cell line human CVCL_7U35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106485 CVCL_8635 VACO 451 cancer cell line human CVCL_8635 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849); Sequence variation: Mutation; HGNC; 10867; ST6GALNAC2; Simple; p.Arg115Trp (c.343C>T); Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Lymph node. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21106486 CVCL_II40 ND00884 transformed cell line human CVCL_II40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106487 CVCL_II38 ND00882 transformed cell line human CVCL_II38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106488 CVCL_II39 ND00883 transformed cell line human CVCL_II39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106489 CVCL_II34 ND00864 transformed cell line human CVCL_II34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106490 CVCL_II35 ND00877 transformed cell line human CVCL_II35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106491 CVCL_II36 ND00880 transformed cell line human CVCL_II36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106492 CVCL_II37 ND00881 transformed cell line human CVCL_II37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106493 CVCL_II30 ND00859 transformed cell line human CVCL_II30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106494 CVCL_II31 ND00860 transformed cell line human CVCL_II31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106495 CVCL_II32 ND00861 transformed cell line human CVCL_II32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106496 CVCL_II33 ND00863 transformed cell line human CVCL_II33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106497 CVCL_II50 ND00972 transformed cell line human CVCL_II50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106498 CVCL_II51 ND01059 transformed cell line human CVCL_II51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106499 CVCL_II49 ND00946 transformed cell line human CVCL_II49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106500 CVCL_II45 ND00902 transformed cell line human CVCL_II45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106501 CVCL_II46 ND00925 transformed cell line human CVCL_II46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106502 CVCL_II47 ND00926 transformed cell line human CVCL_II47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106503 CVCL_II48 ND00936 transformed cell line human CVCL_II48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106504 CVCL_II41 ND00885 transformed cell line human CVCL_II41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106505 CVCL_II42 ND00886 transformed cell line human CVCL_II42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106506 CVCL_II43 ND00898 transformed cell line human CVCL_II43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106507 CVCL_II44 ND00900 transformed cell line human CVCL_II44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106508 CVCL_A086 YCUB-5R cancer cell line human CVCL_A086 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21106509 CVCL_A087 YCUB-6 cancer cell line human CVCL_A087 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21106510 CVCL_A088 Kid92 cancer cell line human CVCL_A088 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36.5 hours (PubMed=8847894) Caution: Indicated as originating from a 16 year old male patient in text of PubMed=8847894 and from a 28 year old in table 1 of same paper 21106511 CVCL_A089 UT-SCC-60A cancer cell line human CVCL_A089 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Oral cavity; tonsil. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21106512 CVCL_A080 YAMN-92 cancer cell line human CVCL_A080 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Unspecified 21106513 CVCL_A081 YAMT-12 cancer cell line human CVCL_A081 CL:0000010 Miscellaneous: Only mentioned as a T-ALL cell line in PubMed=20519628. Unspecified 21106514 CVCL_II16 ND00648 transformed cell line human CVCL_II16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106515 CVCL_A082 YCUB-2 cancer cell line human CVCL_A082 CL:0000010 Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF (PubMed=11417493) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21106516 CVCL_II17 ND00649 transformed cell line human CVCL_II17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106517 CVCL_A083 YCUB-4 cancer cell line human CVCL_A083 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 1008; BCL9 + HGNC; 6997; MEF2D; Name(s)=MEF2D-BCL9; Note=MEF2D exon5/BCL9 exon 9 fusion (PubMed=34940123) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21106518 CVCL_II18 ND00652 transformed cell line human CVCL_II18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106519 CVCL_A084 YCUB-4R cancer cell line human CVCL_A084 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 1008; BCL9 + HGNC; 6997; MEF2D; Name(s)=MEF2D-BCL9; Note=MEF2D exon5/BCL9 exon 9 fusion (PubMed=34940123) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21106520 CVCL_II19 ND00654 transformed cell line human CVCL_II19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106521 CVCL_A085 YCUB-5 cancer cell line human CVCL_A085 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21106522 CVCL_II12 ND00638 transformed cell line human CVCL_II12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106523 CVCL_II13 ND00639 transformed cell line human CVCL_II13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106524 CVCL_II14 ND00642 transformed cell line human CVCL_II14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106525 CVCL_II15 ND00646 transformed cell line human CVCL_II15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106526 CVCL_II10 ND00616 transformed cell line human CVCL_II10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106527 CVCL_II11 ND00620 transformed cell line human CVCL_II11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106528 CVCL_A097 KYSE-1140 cancer cell line human CVCL_A097 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>T; ClinVar=VCV000649747; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Male 21106529 CVCL_A098 KYSE-1170 cancer cell line human CVCL_A098 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=8575860); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Val (c.763A>G); Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21106530 CVCL_A099 KYSE-1240 cancer cell line human CVCL_A099 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Val (c.580C>G); Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21106531 CVCL_A090 UT-SCC-60B cancer cell line human CVCL_A090 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21106532 CVCL_A091 UT-SCC-110B cancer cell line human CVCL_A091 CL:0000010 Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis Male 21106533 CVCL_A092 UT-SCC-75 cancer cell line human CVCL_A092 CL:0000010 Derived from sampling site: Larynx. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21106534 CVCL_II27 ND00855 transformed cell line human CVCL_II27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106535 CVCL_A093 UMB-SCC-745 cancer cell line human CVCL_A093 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Unspecified (PubMed=16203773) Male Caution: Indicated as originating from tonsil in PubMed=16035614 and from orapharynx in PubMed=16203773 and PubMed=19414362. 21106536 CVCL_II28 ND00857 transformed cell line human CVCL_II28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106537 CVCL_A094 UMB-SCC-864 cancer cell line human CVCL_A094 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Leufs*72 (c.810delT); ClinVar=VCV000634749; Zygosity=Unspecified (PubMed=16203773). Male 21106538 CVCL_II29 ND00858 transformed cell line human CVCL_II29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106539 CVCL_A095 UMB-SCC-969 cancer cell line human CVCL_A095 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Unspecified (PubMed=16203773). Male 21106540 CVCL_A096 LAP-35 cancer cell line human CVCL_A096 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=8040301; PubMed=11423975; PubMed=11891184) Omics: Array-based CGH. Female Doubling time: 49 hours (PubMed=2177080) 21106541 CVCL_II23 ND00820 transformed cell line human CVCL_II23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106542 CVCL_II24 ND00821 transformed cell line human CVCL_II24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106543 CVCL_II25 ND00827 transformed cell line human CVCL_II25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106544 CVCL_II26 ND00853 transformed cell line human CVCL_II26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106545 CVCL_II20 ND00655 transformed cell line human CVCL_II20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106546 CVCL_II21 ND00813 transformed cell line human CVCL_II21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106547 CVCL_II22 ND00817 transformed cell line human CVCL_II22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106548 CVCL_A064 201B3 induced pluripotent stem cell human CVCL_A064 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106549 CVCL_A065 201B6 induced pluripotent stem cell human CVCL_A065 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 28.97 hours (PubMed=24399248) 21106550 CVCL_A066 HPC-Y3 cancer cell line human CVCL_A066 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7961102). Population: Japanese Male 21106551 CVCL_A068 HPC-Y23 cancer cell line human CVCL_A068 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7961102). Population: Japanese Male 21106552 CVCL_A069 HPC-Y21 cancer cell line human CVCL_A069 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=7961102). Population: Japanese Male 21106553 CVCL_A060 CHLA-123 cancer cell line human CVCL_A060 CL:0000010 Male 21106554 CVCL_A061 CHI52 cancer cell line human CVCL_A061 CL:0000010 Female 21106555 CVCL_A062 201B1 induced pluripotent stem cell human CVCL_A062 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106556 CVCL_A063 201B2 induced pluripotent stem cell human CVCL_A063 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21106557 CVCL_A075 COGA-3 cancer cell line human CVCL_A075 CL:0000010 Derived from sampling site: Colon; right colic flexure. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=25926053) 21106558 CVCL_A076 COGA-5 cancer cell line human CVCL_A076 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=12096341) Derived from sampling site: Colon; right colic flexure. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21106559 CVCL_A077 COGA-5L cancer cell line human CVCL_A077 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=12096341) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21106560 CVCL_A078 COGA-8 cancer cell line human CVCL_A078 CL:0000010 Derived from sampling site: Colon; sigmoid. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (PubMed=25926053) Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21106561 CVCL_A079 YAMN-90 cancer cell line human CVCL_A079 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Unspecified 21106562 CVCL_II09 ND00609 transformed cell line human CVCL_II09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106563 CVCL_A070 HPC-YT cancer cell line human CVCL_A070 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Male 21106564 CVCL_A071 COGA-1 cancer cell line human CVCL_A071 CL:0000010 Derived from sampling site: Colon; ascending. Female Microsatellite instability: Instable (MSI) (PubMed=12096341) 21106565 CVCL_II05 ND00604 transformed cell line human CVCL_II05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106566 CVCL_A072 COGA-10 cancer cell line human CVCL_A072 CL:0000010 Derived from metastatic site: Liver. Female 21106567 CVCL_II06 ND00606 transformed cell line human CVCL_II06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106568 CVCL_A073 COGA-12 cancer cell line human CVCL_A073 CL:0000010 Derived from sampling site: Cecum. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=25926053) 21106569 CVCL_II07 ND00607 transformed cell line human CVCL_II07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106570 CVCL_A074 COGA-2 cancer cell line human CVCL_A074 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=12096341) Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (PubMed=25926053) 21106571 CVCL_II08 ND00608 transformed cell line human CVCL_II08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106572 CVCL_II01 ND01431 transformed cell line human CVCL_II01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106573 CVCL_II02 ND01551 transformed cell line human CVCL_II02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106574 CVCL_II03 ND01589 transformed cell line human CVCL_II03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106575 CVCL_II04 ND00369 transformed cell line human CVCL_II04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106576 CVCL_II00 ND01429 transformed cell line human CVCL_II00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106577 CVCL_A042 P1.1A3 cancer cell line human CVCL_A042 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00150 Problematic cell line: Contaminated Shown to be a SK-HEP-1 derivative (PubMed=10508494; PubMed=20143388). 21106578 CVCL_A043 P1.1C3 finite cell line human CVCL_A043 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Unspecified Problematic cell line: Possibly contaminated May originate from SK-HEP-1 as 4 other cell lines from the same paper (PubMed=7514905) have been shown to be contaminated. 21106579 CVCL_A044 P1.2C8 finite cell line human CVCL_A044 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Unspecified Problematic cell line: Possibly contaminated May originate from SK-HEP-1 as 4 other cell lines from the same paper (PubMed=7514905) have been shown to be contaminated. 21106580 CVCL_A045 P1.3F6 finite cell line human CVCL_A045 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Unspecified Problematic cell line: Possibly contaminated May originate from SK-HEP-1 as 4 other cell lines from the same paper (PubMed=7514905) have been shown to be contaminated. 21106581 CVCL_A046 P1.4D6 cancer cell line human CVCL_A046 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00151 Problematic cell line: Contaminated Shown to be a SK-HEP-1 derivative (PubMed=10508494; PubMed=20143388). Originally thought to be a thymic epithelial cell line from a 6 month old baby thymus. 21106582 CVCL_A047 HSG-AZA1 cancer cell line human CVCL_A047 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Discontinued: JCRB; CHB0003; probable Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00314 Problematic cell line: Contaminated Parent cell line (HSG) has been shown to be a HeLa derivative (PubMed=20143388). 21106583 CVCL_A048 HSG-AZA3 cancer cell line human CVCL_A048 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Discontinued: JCRB; CHB0002; probable Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00315 Problematic cell line: Contaminated Parent cell line (HSG) has been shown to be a HeLa derivative (PubMed=20143388). 21106584 CVCL_A049 WSU-CLL cancer cell line human CVCL_A049 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00285 Problematic cell line: Contaminated Shown to be a Reh derivative (PubMed=12200708; PubMed=12592342; PubMed=20143388; PubMed=24923861). Originally thought to originate from a 68 year old male patient with chronic lymphocytic leukemia. 21106585 CVCL_A040 F2.4E5 cancer cell line human CVCL_A040 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00120 Problematic cell line: Contaminated Shown to be a SK-HEP-1 derivative (PubMed=10508494; PubMed=20143388). Originally thought to be a thymic epithelial cell line from a 9 week old fetal thymus. 21106586 CVCL_A041 F2.5B6 cancer cell line human CVCL_A041 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00121 Problematic cell line: Contaminated Shown to be a SK-HEP-1 derivative (PubMed=10508494; PubMed=20143388). Originally thought to be a thymic epithelial cell line from a 9 week old fetal thymus. 21106587 CVCL_A053 ARA-10 cancer cell line human CVCL_A053 CL:0000010 21106588 CVCL_A054 CHLA-122 cancer cell line human CVCL_A054 CL:0000010 Female 21106589 CVCL_A055 CHLA-119 cancer cell line human CVCL_A055 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Leu (c.1025G>T); ClinVar=VCV001055894; Zygosity=Unspecified (PubMed=11507071). Male 21106590 CVCL_A056 CHLA-172 cancer cell line human CVCL_A056 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Leu (c.646G>C); ClinVar=VCV000406596; Zygosity=Unspecified (PubMed=11507071). Male 21106591 CVCL_A057 CHLA-225 cancer cell line human CVCL_A057 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071). Doubling time: 62 hours (COG) 21106592 CVCL_A058 CHLA-258 cancer cell line human CVCL_A058 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=25010205) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 71 hours (PubMed=20922763); 89 hours (PubMed=24312454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21106593 CVCL_A059 CHLA-150 cancer cell line human CVCL_A059 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359). 21106594 CVCL_A050 WIF-B hybrid cell line CVCL_A050 CL:0000010 Doubling time: 2.5 days (PubMed=8056838). 21106595 CVCL_A051 WIF12-1 hybrid cell line CVCL_A051 CL:0000010 Doubling time: 2.5 days (PubMed=8056838). 21106596 CVCL_A052 AP-217 cancer cell line human CVCL_A052 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9279364; PubMed=10071072) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Doubling time: 24-30 hours (PubMed=9279364) 21106597 CVCL_RD80 STBCi110-A induced pluripotent stem cell human CVCL_RD80 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106598 CVCL_RD81 STBCi111-A induced pluripotent stem cell human CVCL_RD81 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106599 CVCL_RD82 STBCi112-A induced pluripotent stem cell human CVCL_RD82 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106600 CVCL_RD83 STBCi113-A induced pluripotent stem cell human CVCL_RD83 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106601 CVCL_RD84 STBCi114-A induced pluripotent stem cell human CVCL_RD84 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106602 CVCL_RD85 STBCi115-A induced pluripotent stem cell human CVCL_RD85 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106603 CVCL_RD86 STBCi116-A induced pluripotent stem cell human CVCL_RD86 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106604 CVCL_RD87 STBCi117-A induced pluripotent stem cell human CVCL_RD87 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106605 CVCL_RD88 STBCi118-A induced pluripotent stem cell human CVCL_RD88 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106606 CVCL_RD89 STBCi119-A induced pluripotent stem cell human CVCL_RD89 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106607 CVCL_RD70 STBCi100-A induced pluripotent stem cell human CVCL_RD70 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106608 CVCL_RD71 STBCi101-A induced pluripotent stem cell human CVCL_RD71 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106609 CVCL_RD72 STBCi102-A induced pluripotent stem cell human CVCL_RD72 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106610 CVCL_RD73 STBCi103-A induced pluripotent stem cell human CVCL_RD73 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106611 CVCL_RD74 STBCi104-A induced pluripotent stem cell human CVCL_RD74 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106612 CVCL_RD75 STBCi105-A induced pluripotent stem cell human CVCL_RD75 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106613 CVCL_RD76 STBCi106-A induced pluripotent stem cell human CVCL_RD76 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106614 CVCL_RD77 STBCi107-A induced pluripotent stem cell human CVCL_RD77 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106615 CVCL_RD78 STBCi108-A induced pluripotent stem cell human CVCL_RD78 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106616 CVCL_RD79 STBCi109-A induced pluripotent stem cell human CVCL_RD79 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106617 CVCL_RD60 STBCi095-A induced pluripotent stem cell human CVCL_RD60 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21106618 CVCL_RD61 STBCi096-A induced pluripotent stem cell human CVCL_RD61 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21106619 CVCL_RD62 STBCi097-A induced pluripotent stem cell human CVCL_RD62 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106620 CVCL_RD63 STBCi097-B induced pluripotent stem cell human CVCL_RD63 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106621 CVCL_RD64 STBCi097-C induced pluripotent stem cell human CVCL_RD64 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106622 CVCL_RD65 STBCi098-A induced pluripotent stem cell human CVCL_RD65 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106623 CVCL_RD66 STBCi098-B induced pluripotent stem cell human CVCL_RD66 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106624 CVCL_RD67 STBCi098-C induced pluripotent stem cell human CVCL_RD67 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106625 CVCL_RD68 STBCi099-A induced pluripotent stem cell human CVCL_RD68 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106626 CVCL_RD69 STBCi099-B induced pluripotent stem cell human CVCL_RD69 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi099-B; true Male 21106627 CVCL_RD50 STBCi091-B induced pluripotent stem cell human CVCL_RD50 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106628 CVCL_RD51 STBCi091-C induced pluripotent stem cell human CVCL_RD51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106629 CVCL_RD52 STBCi092-A induced pluripotent stem cell human CVCL_RD52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106630 CVCL_RD53 STBCi092-B induced pluripotent stem cell human CVCL_RD53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106631 CVCL_RD54 STBCi092-C induced pluripotent stem cell human CVCL_RD54 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106632 CVCL_RD55 STBCi093-A induced pluripotent stem cell human CVCL_RD55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106633 CVCL_RD56 STBCi093-B induced pluripotent stem cell human CVCL_RD56 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106634 CVCL_RD57 STBCi094-A induced pluripotent stem cell human CVCL_RD57 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21106635 CVCL_RD58 STBCi094-B induced pluripotent stem cell human CVCL_RD58 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21106636 CVCL_RD59 STBCi094-C induced pluripotent stem cell human CVCL_RD59 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21106637 CVCL_RD40 STBCi087-C induced pluripotent stem cell human CVCL_RD40 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106638 CVCL_RD41 STBCi088-A induced pluripotent stem cell human CVCL_RD41 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106639 CVCL_RD42 STBCi088-B induced pluripotent stem cell human CVCL_RD42 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106640 CVCL_RD43 STBCi088-C induced pluripotent stem cell human CVCL_RD43 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106641 CVCL_RD44 STBCi089-A induced pluripotent stem cell human CVCL_RD44 From: StemBANCC; Oxford; United Kingdom. CL:0000010 Male 21106642 CVCL_RD45 STBCi089-B induced pluripotent stem cell human CVCL_RD45 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106643 CVCL_RD46 STBCi089-C induced pluripotent stem cell human CVCL_RD46 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106644 CVCL_IJ99 ND12721 transformed cell line human CVCL_IJ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106645 CVCL_RD47 STBCi090-A induced pluripotent stem cell human CVCL_RD47 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106646 CVCL_RD48 STBCi090-B induced pluripotent stem cell human CVCL_RD48 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106647 CVCL_RD49 STBCi091-A induced pluripotent stem cell human CVCL_RD49 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106648 CVCL_IJ95 ND12563 transformed cell line human CVCL_IJ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106649 CVCL_IJ96 ND12632 transformed cell line human CVCL_IJ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106650 CVCL_IJ97 ND12705 transformed cell line human CVCL_IJ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106651 CVCL_IJ98 ND12719 transformed cell line human CVCL_IJ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106652 CVCL_RD30 STBCi084-A induced pluripotent stem cell human CVCL_RD30 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106653 CVCL_RD31 STBCi084-B induced pluripotent stem cell human CVCL_RD31 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21106654 CVCL_RD32 STBCi084-C induced pluripotent stem cell human CVCL_RD32 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21106655 CVCL_RD33 STBCi085-A induced pluripotent stem cell human CVCL_RD33 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106656 CVCL_RD34 STBCi085-B induced pluripotent stem cell human CVCL_RD34 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106657 CVCL_RD35 STBCi085-C induced pluripotent stem cell human CVCL_RD35 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21106658 CVCL_RD36 STBCi086-A induced pluripotent stem cell human CVCL_RD36 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106659 CVCL_RD37 STBCi086-B induced pluripotent stem cell human CVCL_RD37 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106660 CVCL_RD38 STBCi087-A induced pluripotent stem cell human CVCL_RD38 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106661 CVCL_RD39 STBCi087-B induced pluripotent stem cell human CVCL_RD39 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106662 CVCL_IJ80 ND11555 transformed cell line human CVCL_IJ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106663 CVCL_IJ81 ND11586 transformed cell line human CVCL_IJ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106664 CVCL_IJ82 ND11618 transformed cell line human CVCL_IJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106665 CVCL_IJ83 ND11631 transformed cell line human CVCL_IJ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106666 CVCL_RD20 STBCi080-B induced pluripotent stem cell human CVCL_RD20 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106667 CVCL_RD21 STBCi080-C induced pluripotent stem cell human CVCL_RD21 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106668 CVCL_RD22 STBCi081-A induced pluripotent stem cell human CVCL_RD22 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106669 CVCL_RD23 STBCi081-B induced pluripotent stem cell human CVCL_RD23 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106670 CVCL_RD24 STBCi081-C induced pluripotent stem cell human CVCL_RD24 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106671 CVCL_IJ77 ND11323 transformed cell line human CVCL_IJ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106672 CVCL_RD25 STBCi082-A induced pluripotent stem cell human CVCL_RD25 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106673 CVCL_IJ78 ND11337 transformed cell line human CVCL_IJ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106674 CVCL_RD26 STBCi082-B induced pluripotent stem cell human CVCL_RD26 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106675 CVCL_IJ79 ND11434 transformed cell line human CVCL_IJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106676 CVCL_RD27 STBCi082-C induced pluripotent stem cell human CVCL_RD27 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106677 CVCL_RD28 STBCi083-A induced pluripotent stem cell human CVCL_RD28 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21106678 CVCL_IJ73 ND11156 transformed cell line human CVCL_IJ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106679 CVCL_RD29 STBCi083-B induced pluripotent stem cell human CVCL_RD29 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21106680 CVCL_IJ74 ND11158 transformed cell line human CVCL_IJ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106681 CVCL_IJ75 ND11284 transformed cell line human CVCL_IJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106682 CVCL_IJ76 ND11296 transformed cell line human CVCL_IJ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106683 CVCL_IJ91 ND12204 transformed cell line human CVCL_IJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106684 CVCL_IJ92 ND12446 transformed cell line human CVCL_IJ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106685 CVCL_IJ93 ND12560 transformed cell line human CVCL_IJ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106686 CVCL_IJ94 ND12562 transformed cell line human CVCL_IJ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106687 CVCL_IJ90 ND11942 transformed cell line human CVCL_IJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106688 CVCL_RD10 STBCi077-A induced pluripotent stem cell human CVCL_RD10 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106689 CVCL_RD11 STBCi077-B induced pluripotent stem cell human CVCL_RD11 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106690 CVCL_RD12 STBCi077-C induced pluripotent stem cell human CVCL_RD12 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106691 CVCL_RD13 STBCi078-A induced pluripotent stem cell human CVCL_RD13 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106692 CVCL_IJ88 ND11854 transformed cell line human CVCL_IJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106693 CVCL_RD14 STBCi078-B induced pluripotent stem cell human CVCL_RD14 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106694 CVCL_IJ89 ND11862 transformed cell line human CVCL_IJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106695 CVCL_RD15 STBCi078-C induced pluripotent stem cell human CVCL_RD15 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106696 CVCL_RD16 STBCi079-A induced pluripotent stem cell human CVCL_RD16 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106697 CVCL_RD17 STBCi079-B induced pluripotent stem cell human CVCL_RD17 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106698 CVCL_IJ84 ND11690 transformed cell line human CVCL_IJ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106699 CVCL_RD18 STBCi079-C induced pluripotent stem cell human CVCL_RD18 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106700 CVCL_IJ85 ND11729 transformed cell line human CVCL_IJ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106701 CVCL_RD19 STBCi080-A induced pluripotent stem cell human CVCL_RD19 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106702 CVCL_IJ86 ND11784 transformed cell line human CVCL_IJ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106703 CVCL_IJ87 ND11835 transformed cell line human CVCL_IJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106704 CVCL_8850 CHO-K1/SF spontaneously immortalized cell line CVCL_8850 CL:0000010 Derived from sampling site: Ovary. Omics: Genome sequenced Female Group: Serum/protein free medium cell line 21106705 CVCL_7W50 DA04324 transformed cell line human CVCL_7W50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106706 CVCL_8851 CKMM 14.15 hybridoma CVCL_8851 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9419 21106707 CVCL_7W51 DA04325 transformed cell line human CVCL_7W51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106708 CVCL_8845 CHO DP-12 clone#1934 spontaneously immortalized cell line CVCL_8845 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Expresses the variable light and heavy chains of the mAB 6G4.2.5 produced by the hybridoma of the same name (Cellosaurus=CVCL_J003) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12445 21106709 CVCL_7W45 DA04319 transformed cell line human CVCL_7W45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106710 CVCL_8846 CHO DP-12 clone#1933 spontaneously immortalized cell line CVCL_8846 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12444 21106711 CVCL_7W46 DA04320 transformed cell line human CVCL_7W46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106712 CVCL_8847 CHO-1C6 spontaneously immortalized cell line CVCL_8847 CL:0000010 Derived from sampling site: Ovary. Female 21106713 CVCL_7W47 DA04321 transformed cell line human CVCL_7W47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106714 CVCL_8848 CHO-CD36 spontaneously immortalized cell line CVCL_8848 CL:0000010 Transfected with: HGNC; 1663; CD36; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21106715 CVCL_7W48 DA04322 transformed cell line human CVCL_7W48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106716 CVCL_8841 Ca759 cancer cell line house mouse CVCL_8841 CL:0000010 Breed/subspecies: 615. Female 21106717 CVCL_7W41 DA04315 transformed cell line human CVCL_7W41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106718 CVCL_8842 Ca761 cancer cell line house mouse CVCL_8842 CL:0000010 Breed/subspecies: 615. Female 21106719 CVCL_7W42 DA04316 transformed cell line human CVCL_7W42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106720 CVCL_8843 Ca763 cancer cell line house mouse CVCL_8843 CL:0000010 Breed/subspecies: 615. Female 21106721 CVCL_7W43 DA04317 transformed cell line human CVCL_7W43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106722 CVCL_8844 CHO DP-12 spontaneously immortalized cell line CVCL_8844 CL:0000010 Derived from sampling site: Ovary. Female 21106723 CVCL_7W44 DA04318 transformed cell line human CVCL_7W44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106724 CVCL_8849 CHO-ICAM-1 spontaneously immortalized cell line CVCL_8849 CL:0000010 Transfected with: HGNC; 5344; ICAM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21106725 CVCL_7W49 DA04323 transformed cell line human CVCL_7W49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106726 CVCL_7W60 DA04340 transformed cell line human CVCL_7W60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106727 CVCL_7W61 DA04342 transformed cell line human CVCL_7W61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106728 CVCL_7W62 DA04343 transformed cell line human CVCL_7W62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106729 CVCL_8862 EU-4 cancer cell line human CVCL_8862 CL:0000010 Derived from sampling site: Bone marrow. 21106730 CVCL_7W56 DA04332 transformed cell line human CVCL_7W56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106731 CVCL_8856 EGC/PK060399egfr transformed cell line Norway rat CVCL_8856 CL:0000010 Transformant: egfr-neu chimer; Derived from sampling site: Small intestine; jejunum; myenteric nerve plexus Cell type=Enteric glial cell.; Breed/subspecies: Sprague Dawley. Male 21106732 CVCL_7W57 DA04333 transformed cell line human CVCL_7W57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106733 CVCL_8857 EU-1 cancer cell line human CVCL_8857 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00197 Problematic cell line: Contaminated Shown to be a Reh derivative (PubMed=12592342; PubMed=20143388). 21106734 CVCL_7W58 DA04334 transformed cell line human CVCL_7W58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106735 CVCL_8858 EU-12 cancer cell line human CVCL_8858 CL:0000010 21106736 CVCL_7W59 DA04339 transformed cell line human CVCL_7W59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106737 CVCL_8859 EU-13 cancer cell line human CVCL_8859 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9823951) Derived from sampling site: Bone marrow. 21106738 CVCL_8852 CKMM 14.5 hybridoma CVCL_8852 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9420 21106739 CVCL_7W52 DA04327 transformed cell line human CVCL_7W52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106740 CVCL_8853 CKMM 14.52 hybridoma CVCL_8853 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06732; Human CKM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9421 21106741 CVCL_7W53 DA04328 transformed cell line human CVCL_7W53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106742 CVCL_8854 CRF-1 spontaneously immortalized cell line CVCL_8854 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by red sea bream iridovirus (RSIV) Group: Fish cell line 21106743 CVCL_7W54 DA04330 transformed cell line human CVCL_7W54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106744 CVCL_8855 CRI-10P cancer cell line Norway rat CVCL_8855 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Discontinued: ECACC; 88031606; probable 21106745 CVCL_7W55 DA04331 transformed cell line human CVCL_7W55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106746 CVCL_7W23 DA04297 transformed cell line human CVCL_7W23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106747 CVCL_8823 SJNB-6 cancer cell line human CVCL_8823 Genome ancestry: African=0.42%; Native American=0%; East Asian, North=0.32%; East Asian, South=0.64%; South Asian=4.28%; European, North=52.61%; European, South=41.73% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21106748 CVCL_7W24 DA04298 transformed cell line human CVCL_7W24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106749 CVCL_8824 SJNB-7 cancer cell line human CVCL_8824 Genome ancestry: African=0.35%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=68.16%; European, South=31.49% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21106750 CVCL_7W25 DA04299 transformed cell line human CVCL_7W25 CL:0000010 Population: Caucasian; Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106751 CVCL_8825 SJNB-8 cancer cell line human CVCL_8825 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21106752 CVCL_7W26 DA04300 transformed cell line human CVCL_7W26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106753 CVCL_8826 SJNB-9 cancer cell line human CVCL_8826 CL:0000010 Omics: Array-based CGH. Female 21106754 CVCL_7W20 DA04293 transformed cell line human CVCL_7W20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106755 CVCL_8820 SJNB-3 cancer cell line human CVCL_8820 CL:0000010 Omics: SNP array analysis. Female 21106756 CVCL_7W21 DA04294 transformed cell line human CVCL_7W21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106757 CVCL_8821 SJNB-4 cancer cell line human CVCL_8821 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified Omics: Array-based CGH; Omics: SNP array analysis. Male 21106758 CVCL_7W22 DA04295 transformed cell line human CVCL_7W22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106759 CVCL_8822 SJNB-5 cancer cell line human CVCL_8822 Genome ancestry: African=87.26%; Native American=0%; East Asian, North=2.17%; East Asian, South=0%; South Asian=0.49%; European, North=5.14%; European, South=4.93% (PubMed=30894373) CL:0000010 Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21106760 CVCL_8827 3T3(+3) spontaneously immortalized cell line house mouse CVCL_8827 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6474; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21106761 CVCL_7W27 DA04301 transformed cell line human CVCL_7W27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106762 CVCL_8828 5C6 Clone 1 hybridoma Norway rat CVCL_8828 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05555; Mouse Itgam/Cd11b. 21106763 CVCL_7W28 DA04302 transformed cell line human CVCL_7W28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106764 CVCL_8829 7D2-1.4.1.5 hybridoma CVCL_8829 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Mouse IgG2. 21106765 CVCL_7W29 DA04303 transformed cell line human CVCL_7W29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106766 CVCL_8840 CA-2E cancer cell line human CVCL_8840 CL:0000010 Derived from metastatic site: Bone marrow. Male 21106767 CVCL_7W40 DA04314 transformed cell line human CVCL_7W40 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106768 CVCL_8834 B6/FA cancer cell line house mouse CVCL_8834 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Discontinued: ECACC; 94031008; probable 21106769 CVCL_7W34 DA04308 transformed cell line human CVCL_7W34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106770 CVCL_8835 Bet-1 hybridoma CVCL_8835 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse IgM (allotype Igh-6.5). 21106771 CVCL_7W35 DA04309 transformed cell line human CVCL_7W35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106772 CVCL_8836 Bet-2 hybridoma CVCL_8836 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse IgM. 21106773 CVCL_7W36 DA04310 transformed cell line human CVCL_7W36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106774 CVCL_8837 BHK21C13-2P spontaneously immortalized cell line CVCL_8837 CL:0000010 Derived from sampling site: Kidney. Male 21106775 CVCL_7W37 DA04311 transformed cell line human CVCL_7W37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106776 CVCL_8830 ABFTL-6 cancer cell line house mouse CVCL_8830 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788). 21106777 CVCL_7W30 DA04304 transformed cell line human CVCL_7W30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106778 CVCL_8831 AF5 transformed cell line Norway rat CVCL_8831 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon; Breed/subspecies: Sprague Dawley. Female 21106779 CVCL_7W31 DA04305 transformed cell line human CVCL_7W31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106780 CVCL_8832 ARBO C11 finite cell line Norway rat CVCL_8832 CL:0000010 Derived from sampling site: Brain; periventricular region. Unspecified 21106781 CVCL_7W32 DA04306 transformed cell line human CVCL_7W32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106782 CVCL_8833 ARBO C9 finite cell line Norway rat CVCL_8833 CL:0000010 Derived from sampling site: Brain; periventricular region. Unspecified 21106783 CVCL_7W33 DA04307 transformed cell line human CVCL_7W33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106784 CVCL_8838 BHK21C13-3P spontaneously immortalized cell line CVCL_8838 CL:0000010 Derived from sampling site: Kidney. Male 21106785 CVCL_7W38 DA04312 transformed cell line human CVCL_7W38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106786 CVCL_8839 C6/CH cancer cell line house mouse CVCL_8839 CL:0000010 Breed/subspecies: AKR. Discontinued: ECACC; 94031010; probable 21106787 CVCL_7W39 DA04313 transformed cell line human CVCL_7W39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106788 CVCL_7W01 DA04274 transformed cell line human CVCL_7W01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106789 CVCL_8801 OCI-Ly4 cancer cell line human CVCL_8801 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=8574164); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8574164) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: CNV analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21106790 CVCL_7W02 DA04275 transformed cell line human CVCL_7W02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106791 CVCL_8802 OCI-Ly6 cancer cell line human CVCL_8802 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Lymph node. 21106792 CVCL_7W03 DA04276 transformed cell line human CVCL_7W03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106793 CVCL_8803 OCI-Ly8 cancer cell line human CVCL_8803 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type Derived from sampling site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21106794 CVCL_8804 BE10 transformed cell line Norway rat CVCL_8804 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106795 CVCL_7W04 DA04277 transformed cell line human CVCL_7W04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106796 CVCL_7W00 DA04273 transformed cell line human CVCL_7W00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106797 CVCL_8800 OCI-Ly3 cancer cell line human CVCL_8800 HLA typing: A*01:01,03:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); HLA typing: A*01:01:01,03:01:01; B*08:01:01,08:01:01; C*07:01:01,07:01:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQA1*05:01:01,05:01:01; DQB1*02:01:01,02:01:01; DRA*01:02:02,01:02:02; DRB1*03:01:01,03:01:01 (DSMZCellDive=ACC-761); Genome ancestry: African=0.02%; Native American=0%; East Asian, North=4.08%; East Asian, South=0%; South Asian=0%; European, North=65.42%; European, South=30.48% (PubMed=30894373) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 11242; SPIB; Name(s)=IGH-SPIB (PubMed=31160637; DSMZ); Sequence variation: Mutation; HGNC; 16393; CARD11; Simple; p.Leu251Pro (c.752T>C) (L244P); ClinVar=VCV001017661; Zygosity=Homozygous (PubMed=18323416; DepMap); Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Homozygous (PubMed=21179087; PubMed=23321251; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~24 hours (DSMZ=ACC-761) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project Caution: A cell line, now termed GNE-587170 (Cellosaurus=CVCL_AT69), was mistakenly distributed by OCI to a number of groups under the designation OCI-Ly-3, the origin of that cell line is now known 21106798 CVCL_8809 BE10-Intermediate transformed cell line Norway rat CVCL_8809 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106799 CVCL_7W09 DA04282 transformed cell line human CVCL_7W09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106800 CVCL_8805 BE11 transformed cell line Norway rat CVCL_8805 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106801 CVCL_7W05 DA04278 transformed cell line human CVCL_7W05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106802 CVCL_8806 BE26 transformed cell line Norway rat CVCL_8806 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106803 CVCL_7W06 DA04279 transformed cell line human CVCL_7W06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106804 CVCL_8807 BE27 transformed cell line Norway rat CVCL_8807 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106805 CVCL_7W07 DA04280 transformed cell line human CVCL_7W07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106806 CVCL_8808 BE10-Early transformed cell line Norway rat CVCL_8808 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Discontinued: ECACC; 93040118; probable Unspecified 21106807 CVCL_7W08 DA04281 transformed cell line human CVCL_7W08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106808 CVCL_7W12 DA04285 transformed cell line human CVCL_7W12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106809 CVCL_8812 SJNB-1 cancer cell line human CVCL_8812 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male 21106810 CVCL_7W13 DA04286 transformed cell line human CVCL_7W13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106811 CVCL_8813 SJNB-11 cancer cell line human CVCL_8813 CL:0000010 21106812 CVCL_7W14 DA04287 transformed cell line human CVCL_7W14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106813 CVCL_8814 SJNB-15 cancer cell line human CVCL_8814 CL:0000010 Unspecified 21106814 CVCL_7W15 DA04288 transformed cell line human CVCL_7W15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106815 CVCL_8815 SJNB-16 cancer cell line human CVCL_8815 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH Female 21106816 CVCL_8810 BE10-Late transformed cell line Norway rat CVCL_8810 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21106817 CVCL_7W10 DA04283 transformed cell line human CVCL_7W10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106818 CVCL_7W11 DA04284 transformed cell line human CVCL_7W11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106819 CVCL_8811 NB4-LR1 cancer cell line human CVCL_8811 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21106820 CVCL_7W16 DA04289 transformed cell line human CVCL_7W16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106821 CVCL_8816 SJNB-18 cancer cell line human CVCL_8816 CL:0000010 Unspecified 21106822 CVCL_7W17 DA04290 transformed cell line human CVCL_7W17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106823 CVCL_8817 SJNB-19 cancer cell line human CVCL_8817 CL:0000010 Omics: Array-based CGH. Unspecified 21106824 CVCL_7W18 DA04291 transformed cell line human CVCL_7W18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106825 CVCL_8818 SJNB-2 cancer cell line human CVCL_8818 CL:0000010 Omics: SNP array analysis. Female 21106826 CVCL_7W19 DA04292 transformed cell line human CVCL_7W19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106827 CVCL_8819 SJNB-20 cancer cell line human CVCL_8819 CL:0000010 Unspecified 21106828 CVCL_RD90 STBCi120-A induced pluripotent stem cell human CVCL_RD90 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106829 CVCL_RD91 STBCi121-A induced pluripotent stem cell human CVCL_RD91 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106830 CVCL_RD92 STBCi122-A induced pluripotent stem cell human CVCL_RD92 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106831 CVCL_RD93 STBCi123-A induced pluripotent stem cell human CVCL_RD93 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106832 CVCL_RD94 STBCi124-A induced pluripotent stem cell human CVCL_RD94 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106833 CVCL_RD95 STBCi125-A induced pluripotent stem cell human CVCL_RD95 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106834 CVCL_RD96 STBCi126-A induced pluripotent stem cell human CVCL_RD96 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106835 CVCL_RD97 STBCi127-A induced pluripotent stem cell human CVCL_RD97 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21106836 CVCL_RD98 STBCi128-A induced pluripotent stem cell human CVCL_RD98 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21106837 CVCL_RD99 STBCi129-A induced pluripotent stem cell human CVCL_RD99 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21106838 CVCL_A149 Ma-Mel-136 cancer cell line human CVCL_A149 CL:0000010 21106839 CVCL_A141 Ma-Mel-121a cancer cell line human CVCL_A141 CL:0000010 Derived from metastatic site: Lymph node. Male 21106840 CVCL_A142 Ma-Mel-122 cancer cell line human CVCL_A142 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21106841 CVCL_A143 Ma-Mel-123 cancer cell line human CVCL_A143 CL:0000010 Derived from metastatic site: Cutaneous/subcutaneous. Female 21106842 CVCL_A144 Ma-Mel-126 cancer cell line human CVCL_A144 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106843 CVCL_A145 Ma-Mel-128a cancer cell line human CVCL_A145 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106844 CVCL_A146 Ma-Mel-13 cancer cell line human CVCL_A146 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=20544847) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis Male 21106845 CVCL_A147 Ma-Mel-130 cancer cell line human CVCL_A147 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106846 CVCL_A148 Ma-Mel-134 cancer cell line human CVCL_A148 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106847 CVCL_A140 Ma-Mel-120 cancer cell line human CVCL_A140 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21106848 CVCL_A152 Ma-Mel-150a cancer cell line human CVCL_A152 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106849 CVCL_A153 Ma-Mel-16 cancer cell line human CVCL_A153 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Small intestine. Male 21106850 CVCL_A154 Ma-Mel-16a cancer cell line human CVCL_A154 CL:0000010 Male 21106851 CVCL_A155 Ma-Mel-17 cancer cell line human CVCL_A155 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=20544847) Omics: SNP array analysis. 21106852 CVCL_A156 Ma-Mel-19 cancer cell line human CVCL_A156 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His118Leu (c.353A>T); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis Female 21106853 CVCL_A157 Ma-Mel-20 cancer cell line human CVCL_A157 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21106854 CVCL_A158 Ma-Mel-21 cancer cell line human CVCL_A158 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20544847); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Omics: SNP array analysis. 21106855 CVCL_A159 Ma-Mel-22 cancer cell line human CVCL_A159 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Kidney. Female 21106856 CVCL_A150 Ma-Mel-14 cancer cell line human CVCL_A150 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21106857 CVCL_A151 Ma-Mel-15 cancer cell line human CVCL_A151 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21106858 CVCL_A127 Ma-Mel-103a cancer cell line human CVCL_A127 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21106859 CVCL_A128 Ma-Mel-103b cancer cell line human CVCL_A128 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21106860 CVCL_A129 Ma-Mel-104 cancer cell line human CVCL_A129 CL:0000010 Derived from metastatic site: Lung. Female 21106861 CVCL_7V93 DA04266 transformed cell line human CVCL_7V93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106862 CVCL_8793 MM1.R(E) cancer cell line human CVCL_8793 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgA lambda; Characteristics: Resistant to dexamethasone 21106863 CVCL_7V94 DA04267 transformed cell line human CVCL_7V94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106864 CVCL_A120 Ma-Mel-07 cancer cell line human CVCL_A120 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21106865 CVCL_8794 MM1.R cancer cell line human CVCL_8794 CL:0000010 Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (PubMed=17692805) Population: African American; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA lambda; Characteristics: Resistant to dexamethasone Part of: MD Anderson Cell Lines Project 21106866 CVCL_7V95 DA04268 transformed cell line human CVCL_7V95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106867 CVCL_A121 Ma-Mel-08a cancer cell line human CVCL_A121 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu157Ter (c.469G>T); ClinVar=VCV000007814; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp162Val (c.485A>T); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Cys (c.847C>T); ClinVar=VCV000127824; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis Male 21106868 CVCL_8795 OCI-Ly10 cancer cell line human CVCL_8795 HLA typing: A*02:01,24:02; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.25%; Native American=0.93%; East Asian, North=0.48%; East Asian, South=0%; South Asian=0.05%; European, North=70.29%; European, South=28% (PubMed=30894373) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 1698; CD79A; Simple; p.Leu191_Gly208del; Zygosity=Heterozygous (PubMed=20054396); Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=21179087) Derived from sampling site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21106869 CVCL_7V96 DA04269 transformed cell line human CVCL_7V96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106870 CVCL_A122 Ma-Mel-08b cancer cell line human CVCL_A122 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Omics: Transcriptome analysis by microarray. Male 21106871 CVCL_8796 OCI-Ly12 cancer cell line human CVCL_8796 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Arg (c.712T>C); ClinVar=VCV000376576; Zygosity=Unspecified (DepMap) Derived from sampling site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106872 CVCL_A123 Ma-Mel-10 cancer cell line human CVCL_A123 CL:0000010 Omics: SNP array analysis. 21106873 CVCL_8790 Ba/F3IL-5R factor-dependent cell line house mouse CVCL_8790 CL:0000010 Transfected with: MGI; MGI:96558; Il5ra Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL5 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21106874 CVCL_7V90 DA04263 transformed cell line human CVCL_7V90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106875 CVCL_A124 Ma-Mel-100a cancer cell line human CVCL_A124 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Heterozygous (PubMed=25294904); Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis Male 21106876 CVCL_8791 Ba/F3MR factor-dependent cell line house mouse CVCL_8791 CL:0000010 Transfected with: MGI; MGI:1339758; Csf1r Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: CSF1 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21106877 CVCL_7V91 DA04264 transformed cell line human CVCL_7V91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106878 CVCL_A125 Ma-Mel-101 cancer cell line human CVCL_A125 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21106879 CVCL_7V92 DA04265 transformed cell line human CVCL_7V92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106880 CVCL_A126 Ma-Mel-102a cancer cell line human CVCL_A126 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11362; STAT1; Simple; p.Ser316Leu (c.947C>T); Zygosity=Homozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21106881 CVCL_8792 MM1.S cancer cell line human CVCL_8792 HLA typing: A*23,24; B*18,42; C*12,17 (PubMed=25688540); HLA typing: A*23:01,24:02; B*18:01,42:01; C*12:03,17:01 (PubMed=26589293); Genome ancestry: African=88.68%; Native American=0%; East Asian, North=4.01%; East Asian, South=0%; South Asian=0.43%; European, North=0%; European, South=6.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=21173094; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (PubMed=17692805) Population: African American; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA lambda; Characteristics: Sensitive to dexamethasone Doubling time: 80 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21106882 CVCL_7V86 DA04259 transformed cell line human CVCL_7V86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106883 CVCL_8786 M-1 [Mouse kidney] transformed cell line house mouse CVCL_8786 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: Tg(SV40E)Bri/7 transgenic. 21106884 CVCL_7V87 DA04260 transformed cell line human CVCL_7V87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106885 CVCL_8787 WM793 cancer cell line human CVCL_8787 HLA typing: A*01:01,29:01; B*35:01,57:01; C*04:01:01,06:02; DPB1*04:01,04:01; DQB1*03:01:01,03:01:01; DRB1*11:03:01,11:03:01 (PubMed=15592718); HLA typing: A*01:01,29:01; B*35:02,57:01; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=2.43%; Native American=0.27%; East Asian, North=4.02%; East Asian, South=1.29%; South Asian=5.85%; European, North=24.77%; European, South=61.38% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; PubMed=24576830; Cosmic-CLP; DepMap; Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (PubMed=23851445; Cosmic-CLP; DepMap; Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2806; true; Discontinued: Coriell; WC00062; probable. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21106886 CVCL_7V88 DA04261 transformed cell line human CVCL_7V88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106887 CVCL_8788 SNU-1272 cancer cell line human CVCL_8788 HLA typing: A*02:06,26:02; B*40:06,55:02; C*08:01,08:01 (PubMed=26589293); Genome ancestry: African=1.64%; Native American=0.63%; East Asian, North=63.53%; East Asian, South=33.83%; South Asian=0%; European, North=0%; European, South=0.37% (PubMed=30894373) CL:0000010 Population: Korean; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 153 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21106888 CVCL_8789 Ba/F3GR factor-dependent cell line house mouse CVCL_8789 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: CSF3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21106889 CVCL_7V89 DA04262 transformed cell line human CVCL_7V89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106890 CVCL_A138 Ma-Mel-119 cancer cell line human CVCL_A138 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21106891 CVCL_A139 Ma-Mel-12 cancer cell line human CVCL_A139 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21106892 CVCL_A130 Ma-Mel-105 cancer cell line human CVCL_A130 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-126C>T (c.230C>T) (C230T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Liver. Female 21106893 CVCL_A131 Ma-Mel-107 cancer cell line human CVCL_A131 CL:0000010 Derived from metastatic site: Lymph node. Male 21106894 CVCL_A132 Ma-Mel-108 cancer cell line human CVCL_A132 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21106895 CVCL_A133 Ma-Mel-11 cancer cell line human CVCL_A133 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe90_Pro95delinsLeu (c.270_284del); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis 21106896 CVCL_A134 Ma-Mel-110 cancer cell line human CVCL_A134 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21106897 CVCL_A135 Ma-Mel-112 cancer cell line human CVCL_A135 CL:0000010 Derived from metastatic site: Lymph node. Male 21106898 CVCL_A136 Ma-Mel-113 cancer cell line human CVCL_A136 CL:0000010 Derived from metastatic site: Lymph node. Male 21106899 CVCL_A137 Ma-Mel-114 cancer cell line human CVCL_A137 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-101C>T (c.205C>T) (C101T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Brain. Male 21106900 CVCL_7V97 DA04270 transformed cell line human CVCL_7V97 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106901 CVCL_8797 OCI-Ly13.2 cancer cell line human CVCL_8797 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106902 CVCL_7V98 DA04271 transformed cell line human CVCL_7V98 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106903 CVCL_8798 OCI-Ly17 cancer cell line human CVCL_8798 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21106904 CVCL_7V99 DA04272 transformed cell line human CVCL_7V99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106905 CVCL_8799 OCI-Ly2 cancer cell line human CVCL_8799 From: Ontario Cancer Institute (OCI); Toronto; Canada. CL:0000010 Male 21106906 CVCL_A105 KTA7 cancer cell line human CVCL_A105 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu861Gln (c.2582T>A); ClinVar=VCV000163380; Zygosity=Unspecified (PubMed=16105816) Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 28 hours (PubMed=1705538) Group: Serum/protein free medium cell line 21106907 CVCL_A106 KTSq-1 cancer cell line human CVCL_A106 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Unspecified (PubMed=16105816). Population: Japanese 21106908 CVCL_A107 KPAM1 cancer cell line human CVCL_A107 CL:0000010 Sequence variation: Mutation; HGNC; 4170; GATA1; Simple; p.Glu13Alafs*26 (c.38_39delAG); Zygosity=Unspecified (PubMed=18830255). Population: Japanese Female 21106909 CVCL_A108 OMC-4 cancer cell line human CVCL_A108 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=8380785) Population: Japanese; Derived from sampling site: Uterus; cervix. Female Doubling time: 63 hours (PubMed=3598280) 21106910 CVCL_A109 OMC-6 cancer cell line human CVCL_A109 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female 21106911 CVCL_7V71 DA04244 transformed cell line human CVCL_7V71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106912 CVCL_8771 XP20SE LCL transformed cell line human CVCL_8771 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106913 CVCL_7V72 DA04245 transformed cell line human CVCL_7V72 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106914 CVCL_8772 XP24SE LCL transformed cell line human CVCL_8772 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106915 CVCL_7V73 DA04246 transformed cell line human CVCL_7V73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106916 CVCL_8773 XP5SE LCL transformed cell line human CVCL_8773 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106917 CVCL_7V74 DA04247 transformed cell line human CVCL_7V74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106918 CVCL_A100 KYSE-1250 cancer cell line human CVCL_A100 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Male 21106919 CVCL_8774 Y-1K cancer cell line human CVCL_8774 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7918028; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: ~62 hours (PubMed=7918028) 21106920 CVCL_A101 KYSE-1860 cancer cell line human CVCL_A101 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21106921 CVCL_A102 KYSE-201 cancer cell line human CVCL_A102 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110fs*36; Zygosity=Unspecified (PubMed=9033652) Population: Japanese; Derived from sampling site: Esophagus. 21106922 CVCL_A103 KYSE-890 cancer cell line human CVCL_A103 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21106923 CVCL_7V70 DA04243 transformed cell line human CVCL_7V70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106924 CVCL_A104 KYSE-273 cancer cell line human CVCL_A104 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. 21106925 CVCL_8770 XP19SE LCL transformed cell line human CVCL_8770 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106926 CVCL_7V68 DA04241 transformed cell line human CVCL_7V68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106927 CVCL_8768 XP15SE LCL transformed cell line human CVCL_8768 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB1910; true Male 21106928 CVCL_7V69 DA04242 transformed cell line human CVCL_7V69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106929 CVCL_8769 XP17SE LCL transformed cell line human CVCL_8769 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21106930 CVCL_7V64 DA04237 transformed cell line human CVCL_7V64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106931 CVCL_8764 TT1TKB cancer cell line human CVCL_8764 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Tyr (c.422G>A); ClinVar=VCV000140801; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Rectum. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106932 CVCL_7V65 DA04238 transformed cell line human CVCL_7V65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106933 CVCL_8765 U-937 DE-4 cancer cell line human CVCL_8765 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21106934 CVCL_7V66 DA04239 transformed cell line human CVCL_7V66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106935 CVCL_8766 WA-hT cancer cell line human CVCL_8766 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21106936 CVCL_7V67 DA04240 transformed cell line human CVCL_7V67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106937 CVCL_8767 XP12SE LCL transformed cell line human CVCL_8767 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21106938 CVCL_A116 Ma-Mel-02 cancer cell line human CVCL_A116 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20544847); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20544847) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis Male 21106939 CVCL_A117 Ma-Mel-04 cancer cell line human CVCL_A117 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Urinary bladder. Omics: Transcriptome analysis by microarray Male 21106940 CVCL_A118 Ma-Mel-05 cancer cell line human CVCL_A118 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128Asn (c.384G>T); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis Female 21106941 CVCL_A119 Ma-Mel-06 cancer cell line human CVCL_A119 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20544847); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21106942 CVCL_7V82 DA04255 transformed cell line human CVCL_7V82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106943 CVCL_8782 PaCaDD-60 cancer cell line human CVCL_8782 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=21683373) Derived from metastatic site: Pleural effusion. Male Doubling time: 22.19 hours (PubMed=21683373) 21106944 CVCL_7V83 DA04256 transformed cell line human CVCL_7V83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106945 CVCL_8783 Ishikawa (London) 02 ER+ cancer cell line human CVCL_8783 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: ECACC; 98032301; probable Female 21106946 CVCL_7V84 DA04257 transformed cell line human CVCL_7V84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106947 CVCL_8784 K029AX cancer cell line human CVCL_8784 HLA typing: A*01:01,02:01; B*08:01,14:02; C*07:01,08:03; DQB1*02:02,06:07; DRB1*03:01,13:02 (PubMed=26589293); Genome ancestry: African=0.32%; Native American=0%; East Asian, North=1.49%; East Asian, South=0%; South Asian=0%; European, North=67.33%; European, South=30.86% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106948 CVCL_A110 OMA-AML-1 cancer cell line human CVCL_A110 CL:0000010 Derived from sampling site: Peripheral blood. Male 21106949 CVCL_7V85 DA04258 transformed cell line human CVCL_7V85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106950 CVCL_8785 K033 cancer cell line human CVCL_8785 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23418523). 21106951 CVCL_A111 KOPT-11 cancer cell line human CVCL_A111 CL:0000010 Population: Japanese. Unspecified 21106952 CVCL_A112 KOPT-4 cancer cell line human CVCL_A112 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Alafs*71 (c.526delT); Zygosity=Hemizygous (PubMed=10071127). Population: Japanese Unspecified Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21106953 CVCL_A113 KOPT-5 cancer cell line human CVCL_A113 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21106954 CVCL_8780 A15A5 cancer cell line Norway rat CVCL_8780 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Female 21106955 CVCL_7V80 DA04253 transformed cell line human CVCL_7V80 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106956 CVCL_A114 KOPT-6 cancer cell line human CVCL_A114 CL:0000010 Population: Japanese. Unspecified 21106957 CVCL_7V81 DA04254 transformed cell line human CVCL_7V81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106958 CVCL_A115 Ma-Mel-01 cancer cell line human CVCL_A115 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503). Female 21106959 CVCL_8781 PaCaDD-43 cancer cell line human CVCL_8781 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=21683373). Male Doubling time: 44.74 hours (PubMed=21683373) 21106960 CVCL_8779 144BR finite cell line human CVCL_8779 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21106961 CVCL_7V79 DA04252 transformed cell line human CVCL_7V79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106962 CVCL_7V75 DA04248 transformed cell line human CVCL_7V75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106963 CVCL_8775 YN-1 cancer cell line human CVCL_8775 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7918028; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 20-24 hours (PubMed=7918028) 21106964 CVCL_7V76 DA04249 transformed cell line human CVCL_7V76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106965 CVCL_8776 HKMUS cancer cell line human CVCL_8776 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 37 hours (PubMed=10457904) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00311 Problematic cell line: Contaminated Shown to be a SKG-II-SF derivative (PubMed=20143388). Originally thought to originate from a 50 year old female patient with an uterine large cell non-keratinizing squamous cell carcinoma. 21106966 CVCL_8777 A818-7 cancer cell line human CVCL_8777 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=8426738) Derived from metastatic site: Ascites. Female 21106967 CVCL_7V77 DA04250 transformed cell line human CVCL_7V77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106968 CVCL_8778 171BR finite cell line human CVCL_8778 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 90011811; probable Male 21106969 CVCL_7V78 DA04251 transformed cell line human CVCL_7V78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106970 CVCL_7V50 DA04223 transformed cell line human CVCL_7V50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106971 CVCL_8750 Rh10 cancer cell line human CVCL_8750 CL:0000010 Female Characteristics: Established from a immuno-deficient mice xenograft. 21106972 CVCL_7V51 DA04224 transformed cell line human CVCL_7V51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106973 CVCL_8751 Rh41-MAB391R cancer cell line human CVCL_8751 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line). Female 21106974 CVCL_7V52 DA04225 transformed cell line human CVCL_7V52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106975 CVCL_8752 Rh28 cancer cell line human CVCL_8752 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058) Derived from metastatic site: Axillary lymph node. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male Characteristics: Established from a immuno-deficient mice xenograft Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21106976 CVCL_7V46 DA04219 transformed cell line human CVCL_7V46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106977 CVCL_8746 OV1/VCR cancer cell line human CVCL_8746 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Ovary. Female 21106978 CVCL_7V47 DA04220 transformed cell line human CVCL_7V47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106979 CVCL_8747 PMF-ko14 cancer cell line human CVCL_8747 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Female Doubling time: 40 hours (at 30th passage), 24 hours (at 50th passage) (PubMed=10853016) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21106980 CVCL_7V48 DA04221 transformed cell line human CVCL_7V48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106981 CVCL_8748 RD-C2 spontaneously immortalized cell line house mouse CVCL_8748 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99829; Runx2 Derived from sampling site: Embryonic bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified 21106982 CVCL_7V49 DA04222 transformed cell line human CVCL_7V49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106983 CVCL_8749 RD-C6 spontaneously immortalized cell line house mouse CVCL_8749 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99829; Runx2 Derived from sampling site: Embryonic bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified 21106984 CVCL_7V42 DA04215 transformed cell line human CVCL_7V42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106985 CVCL_8742 Nil-2E spontaneously immortalized cell line CVCL_8742 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106986 CVCL_7V43 DA04216 transformed cell line human CVCL_7V43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106987 CVCL_8743 NIL B1 spontaneously immortalized cell line CVCL_8743 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21106988 CVCL_7V44 DA04217 transformed cell line human CVCL_7V44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106989 CVCL_8744 OV1/ADR cancer cell line human CVCL_8744 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21106990 CVCL_7V45 DA04218 transformed cell line human CVCL_7V45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106991 CVCL_8745 OV1/CDDP cancer cell line human CVCL_8745 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21106992 CVCL_7V60 DA04233 transformed cell line human CVCL_7V60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106993 CVCL_8760 T-289 cancer cell line human CVCL_8760 CL:0000010 Unspecified Characteristics: Established from a xenograft maintained in nude mice. 21106994 CVCL_7V61 DA04234 transformed cell line human CVCL_7V61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106995 CVCL_8761 T3M-1 Cl-10 cancer cell line human CVCL_8761 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21106996 CVCL_7V62 DA04235 transformed cell line human CVCL_7V62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106997 CVCL_8762 T3M-1 Cl-2 cancer cell line human CVCL_8762 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21106998 CVCL_7V63 DA04236 transformed cell line human CVCL_7V63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21106999 CVCL_8763 TSU cancer cell line human CVCL_8763 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Unspecified 21107000 CVCL_7V57 DA04230 transformed cell line human CVCL_7V57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107001 CVCL_8757 S/RR cancer cell line human CVCL_8757 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=1428233). Female 21107002 CVCL_7V58 DA04231 transformed cell line human CVCL_7V58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107003 CVCL_8758 S/RR/Cl cancer cell line human CVCL_8758 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Female 21107004 CVCL_7V59 DA04232 transformed cell line human CVCL_7V59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107005 CVCL_8759 SN-512 cancer cell line human CVCL_8759 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21107006 CVCL_7V53 DA04226 transformed cell line human CVCL_7V53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107007 CVCL_8753 RTH33 transformed cell line Norway rat CVCL_8753 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Male Doubling time: ~17 hours (CelloPub=CLPUB00285) 21107008 CVCL_7V54 DA04227 transformed cell line human CVCL_7V54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107009 CVCL_8754 S/AN cancer cell line human CVCL_8754 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2253215). Male 21107010 CVCL_7V55 DA04228 transformed cell line human CVCL_7V55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107011 CVCL_8755 S/BR cancer cell line human CVCL_8755 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=1428233). Male 21107012 CVCL_7V56 DA04229 transformed cell line human CVCL_7V56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107013 CVCL_8756 S/RG cancer cell line human CVCL_8756 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=2253215). Female 21107014 CVCL_IJ60 ND10627 transformed cell line human CVCL_IJ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107015 CVCL_IJ61 ND10643 transformed cell line human CVCL_IJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107016 CVCL_IJ59 ND10590 transformed cell line human CVCL_IJ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107017 CVCL_RD00 STBCi072-C induced pluripotent stem cell human CVCL_RD00 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107018 CVCL_RD01 STBCi073-A induced pluripotent stem cell human CVCL_RD01 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107019 CVCL_RD02 STBCi073-B induced pluripotent stem cell human CVCL_RD02 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107020 CVCL_IJ55 ND10516 transformed cell line human CVCL_IJ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107021 CVCL_RD03 STBCi074-A induced pluripotent stem cell human CVCL_RD03 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107022 CVCL_IJ56 ND10528 transformed cell line human CVCL_IJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107023 CVCL_RD04 STBCi074-B induced pluripotent stem cell human CVCL_RD04 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107024 CVCL_IJ57 ND10552 transformed cell line human CVCL_IJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107025 CVCL_RD05 STBCi074-C induced pluripotent stem cell human CVCL_RD05 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107026 CVCL_IJ58 ND10589 transformed cell line human CVCL_IJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107027 CVCL_RD06 STBCi075-A induced pluripotent stem cell human CVCL_RD06 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107028 CVCL_IJ51 ND10311 transformed cell line human CVCL_IJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107029 CVCL_RD07 STBCi075-B induced pluripotent stem cell human CVCL_RD07 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107030 CVCL_IJ52 ND10327 transformed cell line human CVCL_IJ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107031 CVCL_RD08 STBCi075-C induced pluripotent stem cell human CVCL_RD08 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107032 CVCL_IJ53 ND10397 transformed cell line human CVCL_IJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107033 CVCL_RD09 STBCi076-A induced pluripotent stem cell human CVCL_RD09 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107034 CVCL_IJ54 ND10452 transformed cell line human CVCL_IJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107035 CVCL_IJ70 ND10810 transformed cell line human CVCL_IJ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107036 CVCL_IJ71 ND10889 transformed cell line human CVCL_IJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107037 CVCL_IJ72 ND11095 transformed cell line human CVCL_IJ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107038 CVCL_IJ66 ND10721 transformed cell line human CVCL_IJ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107039 CVCL_IJ67 ND10781 transformed cell line human CVCL_IJ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107040 CVCL_IJ68 ND10783 transformed cell line human CVCL_IJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107041 CVCL_IJ69 ND10800 transformed cell line human CVCL_IJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107042 CVCL_IJ62 ND10651 transformed cell line human CVCL_IJ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107043 CVCL_IJ63 ND10662 transformed cell line human CVCL_IJ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107044 CVCL_IJ64 ND10718 transformed cell line human CVCL_IJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107045 CVCL_IJ65 ND10720 transformed cell line human CVCL_IJ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107046 CVCL_IJ37 GM08761 finite cell line human CVCL_IJ37 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Gly197Arg (c.589G>A); ClinVar=VCV000004451; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21107047 CVCL_IJ38 GM12367 finite cell line human CVCL_IJ38 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107048 CVCL_IJ39 GM13206 finite cell line human CVCL_IJ39 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107049 CVCL_IJ33 GM04305 transformed cell line human CVCL_IJ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107050 CVCL_IJ34 GM17885 finite cell line human CVCL_IJ34 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Gly308Arg (c.922G>A); ClinVar=VCV000267310; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107051 CVCL_IJ35 GM02438 finite cell line human CVCL_IJ35 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107052 CVCL_IJ36 GM05076 finite cell line human CVCL_IJ36 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21107053 CVCL_IJ30 LLC-PK1/BCRP spontaneously immortalized cell line pig CVCL_IJ30 CL:0000010 Transfected with: HGNC; 74; ABCG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21107054 CVCL_IJ31 GM23276 transformed cell line human CVCL_IJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107055 CVCL_IJ32 GM25952 finite cell line human CVCL_IJ32 CL:0000010 Sequence variation: Mutation; HGNC; 2745; DDX3X; Simple; p.Gln417Pro (c.1250A>C); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107056 CVCL_IJ50 ND10156 transformed cell line human CVCL_IJ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107057 CVCL_IJ48 ND09874 transformed cell line human CVCL_IJ48 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107058 CVCL_IJ49 ND10077 transformed cell line human CVCL_IJ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107059 CVCL_IJ44 ND12702 transformed cell line human CVCL_IJ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107060 CVCL_IJ45 ND20522 transformed cell line human CVCL_IJ45 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107061 CVCL_IJ46 ND09674 transformed cell line human CVCL_IJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107062 CVCL_IJ47 ND09714 transformed cell line human CVCL_IJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107063 CVCL_IJ40 GM13428 transformed cell line human CVCL_IJ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107064 CVCL_IJ41 GM17888 finite cell line human CVCL_IJ41 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Ile69Argfs*5 (c.206_210delTCCTT); ClinVar=VCV000455787; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; c.853-3C>G (IVS11-3C>G); ClinVar=VCV000004449; Zygosity=Heterozygous (PubMed=28649545) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107065 CVCL_IJ42 GM20266 finite cell line human CVCL_IJ42 CL:0000010 Sequence variation: Mutation; HGNC; 4801; HADHA; Simple; p.Glu510Gln (c.1528G>C); ClinVar=VCV000100085; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107066 CVCL_IJ43 GM21262 finite cell line human CVCL_IJ43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107067 CVCL_A185 Ma-Mel-50 cancer cell line human CVCL_A185 CL:0000010 Derived from metastatic site: Ascites. Male 21107068 CVCL_A186 Ma-Mel-51 cancer cell line human CVCL_A186 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21107069 CVCL_A187 Ma-Mel-52 cancer cell line human CVCL_A187 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107070 CVCL_A188 Ma-Mel-53 cancer cell line human CVCL_A188 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Gly780Arg (c.2338G>A); Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Arg68Thr (c.203G>C); ClinVar=VCV000933172; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107071 CVCL_A189 Ma-Mel-54a cancer cell line human CVCL_A189 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Gln959Pro (c.2876A>C); Zygosity=Homozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000007827; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21107072 CVCL_IJ19 BIOT-0708-EHMT1 induced pluripotent stem cell human CVCL_IJ19 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 24650; EHMT1; Simple; p.Trp1138Ter (c.3413G>A); ClinVar=VCV000221980; Zygosity=Heterozygous (PubMed=27789404) Derived from sampling site: Peripheral blood. Female 21107073 CVCL_A180 Ma-Mel-45a cancer cell line human CVCL_A180 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys13Argfs*10 (c.38_41del); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Brain. Omics: Transcriptome analysis by microarray Male 21107074 CVCL_IJ15 031M-CUMC/INSERM induced pluripotent stem cell human CVCL_IJ15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107075 CVCL_A181 Ma-Mel-46 cancer cell line human CVCL_A181 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female 21107076 CVCL_IJ16 066MD-CUMC/INSERM induced pluripotent stem cell human CVCL_IJ16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107077 CVCL_A182 Ma-Mel-47 cancer cell line human CVCL_A182 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu65Pro (c.194T>C); ClinVar=VCV000820351; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107078 CVCL_IJ17 129-CUMC/UF induced pluripotent stem cell human CVCL_IJ17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107079 CVCL_A183 Ma-Mel-48a cancer cell line human CVCL_A183 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Skin. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21107080 CVCL_IJ18 139-CUMC/UF induced pluripotent stem cell human CVCL_IJ18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107081 CVCL_A184 Ma-Mel-49 cancer cell line human CVCL_A184 CL:0000010 Derived from metastatic site: Ascites. Male 21107082 CVCL_IJ11 i11001 induced pluripotent stem cell human CVCL_IJ11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107083 CVCL_IJ12 B16-FLT3L cancer cell line house mouse CVCL_IJ12 CL:0000010 Transfected with: MGI; MGI:95560; Flt3l Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: 18.4 hours (PubMed=23890195) 21107084 CVCL_IJ13 A2780/Taxol cancer cell line human CVCL_IJ13 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female Doubling time: 24.22 +- 0.22 hours (PubMed=24175763) 21107085 CVCL_IJ14 Ishikawa-RP cancer cell line human CVCL_IJ14 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:6716; Medroxyprogesterone acetate (MPA); Derived from sampling site: Endometrium. Female Doubling time: 34.18 +- 3.15 hours (PubMed=23255909) 21107086 CVCL_IJ10 i10984 induced pluripotent stem cell human CVCL_IJ10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107087 CVCL_A197 Ma-Mel-62 cancer cell line human CVCL_A197 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21107088 CVCL_A198 Ma-Mel-63a cancer cell line human CVCL_A198 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=16827748); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female 21107089 CVCL_A199 Ma-Mel-64 cancer cell line human CVCL_A199 CL:0000010 Derived from metastatic site: Ascites. Male 21107090 CVCL_A190 Ma-Mel-55 cancer cell line human CVCL_A190 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21107091 CVCL_A191 Ma-Mel-56 cancer cell line human CVCL_A191 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107092 CVCL_A192 Ma-Mel-57 cancer cell line human CVCL_A192 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21107093 CVCL_IJ26 MCF-7/TAX cancer cell line human CVCL_IJ26 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Doubling time: 44.60 +- 1 hours (PubMed=24289639) 21107094 CVCL_IJ27 LCG-F finite cell line CVCL_IJ27 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Liaoning cashmere. Female Doubling time: 65.5 hours (PubMed=23065271) 21107095 CVCL_A193 Ma-Mel-58 cancer cell line human CVCL_A193 CL:0000010 Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21107096 CVCL_A194 Ma-Mel-59a cancer cell line human CVCL_A194 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21107097 CVCL_IJ28 YSWS-SF finite cell line CVCL_IJ28 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Yunnan semi-fine wool sheep. Male Doubling time: 26 hours (PubMed=24448770) 21107098 CVCL_A195 Ma-Mel-60 cancer cell line human CVCL_A195 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107099 CVCL_IJ29 PEE transformed cell line pig CVCL_IJ29 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endothelial cell.; Breed/subspecies: Jiangquhai. Female Doubling time: 40 hours (at 5th passage), 41.1 hours (at 15th passage), 36.6 hours (at 30th passage), 37 hours (at 50th passage) (PubMed=23220338) 21107100 CVCL_IJ22 L282F-hiPSC induced pluripotent stem cell human CVCL_IJ22 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu282Phe (c.844C>T); Zygosity=Heterozygous (PubMed=27789396) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107101 CVCL_IJ23 MPSII-1.3 induced pluripotent stem cell human CVCL_IJ23 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Gln29Ter (c.85C>T); Zygosity=Hemizygous (PubMed=27789399) Derived from sampling site: Peripheral blood. Male 21107102 CVCL_IJ24 MPSII-2.5 induced pluripotent stem cell human CVCL_IJ24 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Gln29Ter (c.85C>T); Zygosity=Hemizygous (PubMed=27789398) Derived from sampling site: Peripheral blood. Male 21107103 CVCL_IJ25 MPSII-mother.1 induced pluripotent stem cell human CVCL_IJ25 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Gln29Ter (c.85C>T); Zygosity=Heterozygous (PubMed=27789401) Derived from sampling site: Peripheral blood. Female 21107104 CVCL_IJ20 CTRL7-II induced pluripotent stem cell human CVCL_IJ20 From: Department of Neuroscience, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107105 CVCL_IJ21 iPS-SPG4-splice induced pluripotent stem cell human CVCL_IJ21 From: German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11233; SPAST; Simple; c.1687+2T>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27789400) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107106 CVCL_A163 Ma-Mel-27 cancer cell line human CVCL_A163 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445) Derived from metastatic site: Cutaneous/subcutaneous. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21107107 CVCL_A164 Ma-Mel-28 cancer cell line human CVCL_A164 HLA typing: A*02:01,03:01; B*18:01,40:01; C*03:04,07:01:01; DPB1*04:01,03:01; DQB1*06:04,03:02; DRB1*04:01,13:02 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female 21107108 CVCL_A165 Ma-Mel-30 cancer cell line human CVCL_A165 HLA typing: A*02:01,26:12; B*57:01; C*06:02; DPB1*04:01,03:01; DQB1*03:03:02; DRB1*07:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp594Asn (c.1780G>A); ClinVar=VCV000044813; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107109 CVCL_A166 Ma-Mel-31 cancer cell line human CVCL_A166 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107110 CVCL_A167 Ma-Mel-32 cancer cell line human CVCL_A167 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20544847); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro38Leu (c.113C>T); ClinVar=VCV000818421; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis Female 21107111 CVCL_A168 Ma-Mel-33 cancer cell line human CVCL_A168 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107112 CVCL_A169 Ma-Mel-34 cancer cell line human CVCL_A169 CL:0000010 21107113 CVCL_A160 Ma-Mel-23 cancer cell line human CVCL_A160 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20544847); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys71Trp (c.213 T>G); Zygosity=Unspecified (PubMed=23851445) Omics: SNP array analysis. Male 21107114 CVCL_A161 Ma-Mel-25 cancer cell line human CVCL_A161 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21107115 CVCL_A162 Ma-Mel-26a cancer cell line human CVCL_A162 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=20544847); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21107116 CVCL_A174 Ma-Mel-38 cancer cell line human CVCL_A174 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala60fs (c.181_202delinsAC) (p.Gly75fs, c.224_45delinsACG); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107117 CVCL_A175 Ma-Mel-39a cancer cell line human CVCL_A175 CL:0000010 Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female 21107118 CVCL_A176 Ma-Mel-40 cancer cell line human CVCL_A176 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107119 CVCL_A177 Ma-Mel-41 cancer cell line human CVCL_A177 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21107120 CVCL_A178 Ma-Mel-42 cancer cell line human CVCL_A178 CL:0000010 Derived from metastatic site: Ascites. Female 21107121 CVCL_A179 Ma-Mel-43 cancer cell line human CVCL_A179 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21107122 CVCL_IJ08 UOXFi004-B induced pluripotent stem cell human CVCL_IJ08 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: EBiSC; UOXFi004-B; true Male 21107123 CVCL_IJ09 UOXFi006-A induced pluripotent stem cell human CVCL_IJ09 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21107124 CVCL_A170 Ma-Mel-35 cancer cell line human CVCL_A170 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Female 21107125 CVCL_IJ04 UOXFi002-A induced pluripotent stem cell human CVCL_IJ04 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=30503143) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi002-A; true Male 21107126 CVCL_A171 Ma-Mel-36 cancer cell line human CVCL_A171 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Tyr281Ter (c.843C>A); Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21107127 CVCL_IJ05 UOXFi002-B induced pluripotent stem cell human CVCL_IJ05 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21107128 CVCL_A172 Ma-Mel-37a cancer cell line human CVCL_A172 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21107129 CVCL_IJ06 UOXFi002-C induced pluripotent stem cell human CVCL_IJ06 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: EBiSC; UOXFi002-C; true Male 21107130 CVCL_A173 Ma-Mel-37b cancer cell line human CVCL_A173 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107131 CVCL_IJ07 UOXFi004-A induced pluripotent stem cell human CVCL_IJ07 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: EBiSC; UOXFi004-A; true Male 21107132 CVCL_IJ00 PFIZi013-A induced pluripotent stem cell human CVCL_IJ00 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21107133 CVCL_IJ01 PFIZi014-A induced pluripotent stem cell human CVCL_IJ01 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Ala371Val (c.1112C>T); ClinVar=VCV000206759; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21107134 CVCL_IJ02 PFIZi015-A induced pluripotent stem cell human CVCL_IJ02 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Ser551Profs*6 (c.1650delC); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21107135 CVCL_IJ03 PFIZi016-A induced pluripotent stem cell human CVCL_IJ03 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Val1353Cysfs*5; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21107136 CVCL_RE90 STBCi220-A induced pluripotent stem cell human CVCL_RE90 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi220-A; true Male 21107137 CVCL_RE91 STBCi221-A induced pluripotent stem cell human CVCL_RE91 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi221-A; true Male 21107138 CVCL_RE92 STBCi222-A induced pluripotent stem cell human CVCL_RE92 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi222-A; true Female 21107139 CVCL_RE93 STBCi223-A induced pluripotent stem cell human CVCL_RE93 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107140 CVCL_RE94 STBCi224-A induced pluripotent stem cell human CVCL_RE94 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107141 CVCL_RE95 STBCi225-A induced pluripotent stem cell human CVCL_RE95 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107142 CVCL_RE96 STBCi226-A induced pluripotent stem cell human CVCL_RE96 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107143 CVCL_RE97 STBCi227-A induced pluripotent stem cell human CVCL_RE97 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107144 CVCL_RE98 STBCi228-A induced pluripotent stem cell human CVCL_RE98 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107145 CVCL_RE99 STBCi229-A induced pluripotent stem cell human CVCL_RE99 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi229-A; true Male 21107146 CVCL_RE80 STBCi210-A induced pluripotent stem cell human CVCL_RE80 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107147 CVCL_RE81 STBCi211-A induced pluripotent stem cell human CVCL_RE81 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi211-A; true Male 21107148 CVCL_RE82 STBCi212-A induced pluripotent stem cell human CVCL_RE82 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi212-A; true Female 21107149 CVCL_RE83 STBCi213-A induced pluripotent stem cell human CVCL_RE83 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi213-A; true Male 21107150 CVCL_RE84 STBCi214-A induced pluripotent stem cell human CVCL_RE84 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi214-A; true Male 21107151 CVCL_RE85 STBCi215-A induced pluripotent stem cell human CVCL_RE85 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi215-A; true Male 21107152 CVCL_RE86 STBCi216-A induced pluripotent stem cell human CVCL_RE86 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi216-A; true Female 21107153 CVCL_RE87 STBCi217-A induced pluripotent stem cell human CVCL_RE87 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi217-A; true Male 21107154 CVCL_RE88 STBCi218-A induced pluripotent stem cell human CVCL_RE88 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi218-A; true Male 21107155 CVCL_RE89 STBCi219-A induced pluripotent stem cell human CVCL_RE89 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107156 CVCL_RE70 STBCi200-A induced pluripotent stem cell human CVCL_RE70 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi200-A; true Male 21107157 CVCL_RE71 STBCi201-A induced pluripotent stem cell human CVCL_RE71 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107158 CVCL_RE72 STBCi202-A induced pluripotent stem cell human CVCL_RE72 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107159 CVCL_RE73 STBCi203-A induced pluripotent stem cell human CVCL_RE73 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107160 CVCL_RE74 STBCi204-A induced pluripotent stem cell human CVCL_RE74 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107161 CVCL_RE75 STBCi205-A induced pluripotent stem cell human CVCL_RE75 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi205-A; true Female 21107162 CVCL_RE76 STBCi206-A induced pluripotent stem cell human CVCL_RE76 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi206-A; true Male 21107163 CVCL_RE77 STBCi207-A induced pluripotent stem cell human CVCL_RE77 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107164 CVCL_RE78 STBCi208-A induced pluripotent stem cell human CVCL_RE78 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi208-A; true Female 21107165 CVCL_RE79 STBCi209-A induced pluripotent stem cell human CVCL_RE79 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi209-A; true Female 21107166 CVCL_RE60 STBCi190-A induced pluripotent stem cell human CVCL_RE60 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi190-A; true Male 21107167 CVCL_RE61 STBCi191-A induced pluripotent stem cell human CVCL_RE61 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107168 CVCL_RE62 STBCi192-A induced pluripotent stem cell human CVCL_RE62 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi192-A; true Female 21107169 CVCL_RE63 STBCi193-A induced pluripotent stem cell human CVCL_RE63 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107170 CVCL_RE64 STBCi194-A induced pluripotent stem cell human CVCL_RE64 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107171 CVCL_RE65 STBCi195-A induced pluripotent stem cell human CVCL_RE65 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107172 CVCL_RE66 STBCi196-A induced pluripotent stem cell human CVCL_RE66 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi196-A; true Female 21107173 CVCL_RE67 STBCi197-A induced pluripotent stem cell human CVCL_RE67 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi197-A; true Female 21107174 CVCL_RE68 STBCi198-A induced pluripotent stem cell human CVCL_RE68 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi198-A; true Male 21107175 CVCL_RE69 STBCi199-A induced pluripotent stem cell human CVCL_RE69 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi199-A; true Male 21107176 CVCL_RE50 STBCi180-A induced pluripotent stem cell human CVCL_RE50 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107177 CVCL_RE51 STBCi181-A induced pluripotent stem cell human CVCL_RE51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107178 CVCL_RE52 STBCi182-A induced pluripotent stem cell human CVCL_RE52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107179 CVCL_RE53 STBCi183-A induced pluripotent stem cell human CVCL_RE53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107180 CVCL_RE54 STBCi184-A induced pluripotent stem cell human CVCL_RE54 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107181 CVCL_RE55 STBCi185-A induced pluripotent stem cell human CVCL_RE55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi185-A; true Female 21107182 CVCL_RE56 STBCi186-A induced pluripotent stem cell human CVCL_RE56 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107183 CVCL_RE57 STBCi187-A induced pluripotent stem cell human CVCL_RE57 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107184 CVCL_RE58 STBCi188-A induced pluripotent stem cell human CVCL_RE58 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi188-A; true Male 21107185 CVCL_RE59 STBCi189-A induced pluripotent stem cell human CVCL_RE59 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi189-A; true Male 21107186 CVCL_RE40 STBCi170-A induced pluripotent stem cell human CVCL_RE40 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi170-A; true Male 21107187 CVCL_RE41 STBCi171-A induced pluripotent stem cell human CVCL_RE41 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi171-A; true Female 21107188 CVCL_RE42 STBCi172-A induced pluripotent stem cell human CVCL_RE42 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi172-A; true Female 21107189 CVCL_RE43 STBCi173-A induced pluripotent stem cell human CVCL_RE43 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi173-A; true Female 21107190 CVCL_RE44 STBCi174-A induced pluripotent stem cell human CVCL_RE44 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107191 CVCL_RE45 STBCi175-A induced pluripotent stem cell human CVCL_RE45 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107192 CVCL_IK98 H234 C2 GC induced pluripotent stem cell human CVCL_IK98 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple_corrected; p.Leu150Pro (c.449T>C); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=27789395) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107193 CVCL_RE46 STBCi176-A induced pluripotent stem cell human CVCL_RE46 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi176-A; true Female 21107194 CVCL_IK99 MS0812 cancer cell line human CVCL_IK99 CL:0000010 Population: Chinese Unspecified Doubling time: ~24 hours (PubMed=19724881). Group: Patented cell line 21107195 CVCL_RE47 STBCi177-A induced pluripotent stem cell human CVCL_RE47 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107196 CVCL_RE48 STBCi178-A induced pluripotent stem cell human CVCL_RE48 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi178-A; true Male 21107197 CVCL_RE49 STBCi179-A induced pluripotent stem cell human CVCL_RE49 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107198 CVCL_IK94 Lymph14-AD1-iPS induced pluripotent stem cell human CVCL_IK94 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21107199 CVCL_IK95 Lymph4-AD2-iPS induced pluripotent stem cell human CVCL_IK95 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (PubMed=27789408) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107200 CVCL_IK96 H224 C2 induced pluripotent stem cell human CVCL_IK96 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Ile (c.914G>T) (S622I, c.1865G>T or S640I, c.1919G>T); Zygosity=Heterozygous (PubMed=27789411) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107201 CVCL_IK97 H251 C3 GC induced pluripotent stem cell human CVCL_IK97 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=27789409) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21107202 CVCL_RE30 STBCi160-A induced pluripotent stem cell human CVCL_RE30 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107203 CVCL_RE31 STBCi161-A induced pluripotent stem cell human CVCL_RE31 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107204 CVCL_RE32 STBCi162-A induced pluripotent stem cell human CVCL_RE32 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107205 CVCL_RE33 STBCi163-A induced pluripotent stem cell human CVCL_RE33 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107206 CVCL_RE34 STBCi164-A induced pluripotent stem cell human CVCL_RE34 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107207 CVCL_RE35 STBCi165-A induced pluripotent stem cell human CVCL_RE35 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi165-A; true Female 21107208 CVCL_RE36 STBCi166-A induced pluripotent stem cell human CVCL_RE36 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi166-A; true Male 21107209 CVCL_RE37 STBCi167-A induced pluripotent stem cell human CVCL_RE37 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107210 CVCL_RE38 STBCi168-A induced pluripotent stem cell human CVCL_RE38 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi168-A; true Female 21107211 CVCL_RE39 STBCi169-A induced pluripotent stem cell human CVCL_RE39 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107212 CVCL_A303 UoC-B5 cancer cell line human CVCL_A303 CL:0000010 Population: African American. Female 21107213 CVCL_A304 UoC-B6 cancer cell line human CVCL_A304 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=8704231) Miscellaneous: STR profile from personal communication of Ryan R.J.H Population: Caucasian; Derived from sampling site: Bone marrow. Female 21107214 CVCL_A305 UoC-B7 cancer cell line human CVCL_A305 CL:0000010 Population: Caucasian. Male 21107215 CVCL_A306 UoC-B8 cancer cell line human CVCL_A306 CL:0000010 Population: African American. Male 21107216 CVCL_A307 UoC-B9 cancer cell line human CVCL_A307 CL:0000010 Population: African American. Female 21107217 CVCL_A308 SUP-B13 cancer cell line human CVCL_A308 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3162827; PubMed=10071072) Population: Caucasian; Derived from sampling site: Bone marrow. Male Doubling time: ~35 hours (PubMed=1434795; PubMed=3162827) 21107218 CVCL_A309 SUP-B1 cancer cell line human CVCL_A309 CL:0000010 21107219 CVCL_7X70 DA04475 transformed cell line human CVCL_7X70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107220 CVCL_8970 PV-1 hybridoma house mouse CVCL_8970 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P31041; Mouse Cd28. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11944; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12352 21107221 CVCL_7X71 DA04476 transformed cell line human CVCL_7X71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107222 CVCL_8971 R1E/TL8x.1 cancer cell line house mouse CVCL_8971 CL:0000010 Breed/subspecies: C58/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21107223 CVCL_7X72 DA04478 transformed cell line human CVCL_7X72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107224 CVCL_8972 R1E/TL8x.1.G1.OUAr.1 cancer cell line house mouse CVCL_8972 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C58/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21107225 CVCL_A300 UoC-B12 cancer cell line human CVCL_A300 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=8704231) Derived from sampling site: Bone marrow. Male Doubling time: 10-14 days (PubMed=8704231) 21107226 CVCL_A301 UoC-B10 cancer cell line human CVCL_A301 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21107227 CVCL_A302 UoC-B2 cancer cell line human CVCL_A302 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 50 hours (PubMed=7687517) 21107228 CVCL_7X66 DA04470 transformed cell line human CVCL_7X66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107229 CVCL_8966 N418 hybridoma house mouse CVCL_8966 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9QXH4; Mouse Itgax/Cd11c. 21107230 CVCL_7X67 DA04471 transformed cell line human CVCL_7X67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107231 CVCL_8967 ProPak-A.52 transformed cell line human CVCL_8967 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12479 21107232 CVCL_7X68 DA04472 transformed cell line human CVCL_7X68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107233 CVCL_8968 ProPak-A.6 transformed cell line human CVCL_8968 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12006 21107234 CVCL_7X69 DA04474 transformed cell line human CVCL_7X69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107235 CVCL_8969 ProPak-X.36 transformed cell line human CVCL_8969 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12007 21107236 CVCL_7X62 DA04465 transformed cell line human CVCL_7X62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107237 CVCL_8962 KL277 hybridoma house mouse CVCL_8962 CL:0000010 Monoclonal antibody isotype: IgG. 21107238 CVCL_7X63 DA04466 transformed cell line human CVCL_7X63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107239 CVCL_8963 mAb 64 hybridoma Norway rat CVCL_8963 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02709; Bovine CHRNA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8987 21107240 CVCL_7X64 DA04468 transformed cell line human CVCL_7X64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107241 CVCL_8964 MR1 hybridoma house mouse CVCL_8964 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P27548; Mouse Cd40lg/Cd154. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11048 21107242 CVCL_7X65 DA04469 transformed cell line human CVCL_7X65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107243 CVCL_8965 N22 hybridoma house mouse CVCL_8965 CL:0000010 Monoclonal antibody isotype: IgG. 21107244 CVCL_A314 SUP-B26 cancer cell line human CVCL_A314 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1; Note=ETV6 exon 5/RUNX1 exon 4 and RUNX1 exon 3/ETV6 exon 6 fusions (PubMed=8704231; PubMed=12127395; PubMed=34940123); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous; Note=In 15% of the reads (PubMed=34940123); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous; Note=In 35% of the reads (PubMed=34940123) Miscellaneous: STR profile from personal communication of Ryan R.J.H Population: Caucasian and Pacific; Polynesian; Derived from sampling site: Cerebrospinal fluid. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~5 days (PubMed=12127395) 21107245 CVCL_A315 SUP-B27 cancer cell line human CVCL_A315 CL:0000010 Population: Caucasian. Male 21107246 CVCL_A316 SUP-B28 cancer cell line human CVCL_A316 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1; Note=ETV6 exon 5/RUNX1 exon 4 and RUNX1 exon 3/ETV6 exon 6 fusions (PubMed=8704231; PubMed=12127395; PubMed=34940123); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous; Note=In 50% of the reads (PubMed=34940123); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous; Note=In 3% of the reads (PubMed=34940123) Miscellaneous: STR profile from personal communication of Ryan R.J.H Population: Caucasian and Pacific; Polynesian; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~3 days (PubMed=12127395) 21107247 CVCL_A317 SUP-B31 cancer cell line human CVCL_A317 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Female 21107248 CVCL_A318 SUP-B7 cancer cell line human CVCL_A318 CL:0000010 Derived from sampling site: Bone marrow. Female Doubling time: ~100 hours (PubMed=1434795); 7 days (PubMed=3469019) 21107249 CVCL_A319 SUP-B12 cancer cell line human CVCL_A319 CL:0000010 Male 21107250 CVCL_7X80 DA04487 transformed cell line human CVCL_7X80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107251 CVCL_8980 UC8-1B9 hybridoma house mouse CVCL_8980 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). 21107252 CVCL_7X81 DA04488 transformed cell line human CVCL_7X81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107253 CVCL_8981 WBC264-9C hybrid cell line CVCL_8981 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8902. 21107254 CVCL_7X82 DA04490 transformed cell line human CVCL_7X82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107255 CVCL_8982 Y13-238 hybridoma Norway rat CVCL_8982 CL:0000010 Monoclonal antibody isotype: IgG2a. 21107256 CVCL_7X83 DA04491 transformed cell line human CVCL_7X83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107257 CVCL_8983 Y13-259 hybridoma Norway rat CVCL_8983 CL:0000010 Monoclonal antibody isotype: IgG1. 21107258 CVCL_A310 SUP-B16 cancer cell line human CVCL_A310 CL:0000010 Population: Caucasian; Derived from sampling site: Cerebrospinal fluid. Female 21107259 CVCL_A312 SUP-B2 cancer cell line human CVCL_A312 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 50866; RNF217-AS1; Name(s)=ETV6-RNF217-AS1, ETV6-STL (PubMed=9087565). Population: Caucasian Male Doubling time: ~30 hours (PubMed=1434795) 21107260 CVCL_A313 SUP-B24 cancer cell line human CVCL_A313 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Female Doubling time: ~72 hours (PubMed=1434795) 21107261 CVCL_7X77 DA04483 transformed cell line human CVCL_7X77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107262 CVCL_8977 UC10-4F10-11 hybridoma house mouse CVCL_8977 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P09793; Mouse Ctla4/Cd152. 21107263 CVCL_7X78 DA04484 transformed cell line human CVCL_7X78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107264 CVCL_8978 UC3-10A6 hybridoma house mouse CVCL_8978 CL:0000010 Monoclonal antibody isotype: IgG. 21107265 CVCL_7X79 DA04485 transformed cell line human CVCL_7X79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107266 CVCL_8979 UC7-13D5 hybridoma house mouse CVCL_8979 CL:0000010 Monoclonal antibody isotype: IgG. 21107267 CVCL_7X73 DA04479 transformed cell line human CVCL_7X73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107268 CVCL_8973 R3 transformed cell line Norway rat CVCL_8973 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: Wistar. Unspecified 21107269 CVCL_7X74 DA04480 transformed cell line human CVCL_7X74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107270 CVCL_8974 RPC5.4 cancer cell line house mouse CVCL_8974 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21107271 CVCL_7X75 DA04481 transformed cell line human CVCL_7X75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107272 CVCL_8975 SA13 hybridoma human CVCL_8975 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8501 21107273 CVCL_7X76 DA04482 transformed cell line human CVCL_7X76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107274 CVCL_8976 SYF + c-Src transformed cell line house mouse CVCL_8976 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95602; Fyn; Knockout cell: Method=KO mouse; MGI; MGI:98397; Src; Knockout cell: Method=KO mouse; MGI; MGI:99147; Yes1; Transfected with: MGI; MGI:98397; Src; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21107275 CVCL_8950 CE-3 embryonic stem cell house mouse CVCL_8950 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21107276 CVCL_7X50 DA04450 transformed cell line human CVCL_7X50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107277 CVCL_8944 9F12 hybridoma CVCL_8944 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8177 21107278 CVCL_7X44 DA04444 transformed cell line human CVCL_7X44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107279 CVCL_8945 aBL5C2.870005 hybridoma house mouse CVCL_8945 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (BHV-1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9907 21107280 CVCL_7X45 DA04445 transformed cell line human CVCL_7X45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107281 CVCL_8946 aBL5C2.870009 hybridoma house mouse CVCL_8946 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (BHV-1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9908 21107282 CVCL_7X46 DA04446 transformed cell line human CVCL_7X46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107283 CVCL_8947 aBL5C2.870016 hybridoma house mouse CVCL_8947 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine herpesvirus 1 (BHV-1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9909 21107284 CVCL_7X47 DA04447 transformed cell line human CVCL_7X47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107285 CVCL_8940 448-D100,10,1 hybridoma CVCL_8940 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HIV-1 gp120 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10895 21107286 CVCL_7X40 DA04439 transformed cell line human CVCL_7X40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107287 CVCL_8941 558-D100,10,1 hybridoma CVCL_8941 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: HIV-1 gp120 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10894 21107288 CVCL_7X41 DA04441 transformed cell line human CVCL_7X41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107289 CVCL_8942 559/64-D100,10,1 hybridoma CVCL_8942 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: HIV-1 gp120 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10893 21107290 CVCL_7X42 DA04442 transformed cell line human CVCL_7X42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107291 CVCL_8943 5A1 [Rat hybridoma against mouse Csf1] hybridoma Norway rat CVCL_8943 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07141; Mouse Csf1. 21107292 CVCL_7X43 DA04443 transformed cell line human CVCL_7X43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107293 CVCL_8948 C58(NT)D.1.G.OUAR.1 cancer cell line Norway rat CVCL_8948 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Breed/subspecies: Wistar Furth. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21107294 CVCL_7X48 DA04448 transformed cell line human CVCL_7X48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107295 CVCL_8949 CE-1 embryonic stem cell house mouse CVCL_8949 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21107296 CVCL_7X49 DA04449 transformed cell line human CVCL_7X49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107297 CVCL_7X60 DA04463 transformed cell line human CVCL_7X60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107298 CVCL_8960 HAA1 hybridoma human CVCL_8960 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8534 21107299 CVCL_7X61 DA04464 transformed cell line human CVCL_7X61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107300 CVCL_8961 K204 hybridoma Norway rat CVCL_8961 CL:0000010 Monoclonal antibody isotype: IgG2a. 21107301 CVCL_7X55 DA04457 transformed cell line human CVCL_7X55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107302 CVCL_8955 FAK+/+ spontaneously immortalized cell line house mouse CVCL_8955 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21107303 CVCL_7X56 DA04458 transformed cell line human CVCL_7X56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107304 CVCL_8956 GP+E-86 transformed cell line house mouse CVCL_8956 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9642 21107305 CVCL_7X57 DA04460 transformed cell line human CVCL_7X57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107306 CVCL_8957 GP+envAM-12 transformed cell line house mouse CVCL_8957 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9641 21107307 CVCL_7X58 DA04461 transformed cell line human CVCL_7X58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107308 CVCL_8958 Gr431 hybridoma CVCL_8958 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8575 21107309 CVCL_8951 Ch13 hybridoma CVCL_8951 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8573 21107310 CVCL_7X51 DA04451 transformed cell line human CVCL_7X51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107311 CVCL_8952 D24 [Rat hybridoma against mouse Csf1] hybridoma Norway rat CVCL_8952 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2a; Monoclonal antibody target: UniProtKB; P07141; Mouse Csf1. 21107312 CVCL_7X52 DA04452 transformed cell line human CVCL_7X52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107313 CVCL_7X53 DA04453 transformed cell line human CVCL_7X53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107314 CVCL_8953 F3B6 hybrid cell line CVCL_8953 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8785 21107315 CVCL_7X54 DA04456 transformed cell line human CVCL_7X54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107316 CVCL_8954 FAK-/- spontaneously immortalized cell line house mouse CVCL_8954 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95481; Ptk2 Derived from sampling site: Cell type=Fibroblast. Unspecified 21107317 CVCL_7X59 DA04462 transformed cell line human CVCL_7X59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107318 CVCL_8959 H57-597 hybridoma house mouse CVCL_8959 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Mouse T cell receptor (TcR). 21107319 CVCL_7X22 DA04419 transformed cell line human CVCL_7X22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107320 CVCL_8922 Subclone 707 DAP4 cancer cell line house mouse CVCL_8922 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107321 CVCL_7X23 DA04421 transformed cell line human CVCL_7X23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107322 CVCL_8923 Subclone 707 DAP5 cancer cell line house mouse CVCL_8923 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107323 CVCL_7X24 DA04422 transformed cell line human CVCL_7X24 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107324 CVCL_8924 Subclone 707 DAP6 cancer cell line house mouse CVCL_8924 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107325 CVCL_7X25 DA04423 transformed cell line human CVCL_7X25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107326 CVCL_8925 Subclone 707 DAP7 cancer cell line house mouse CVCL_8925 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107327 CVCL_7X20 DA04417 transformed cell line human CVCL_7X20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107328 CVCL_8920 Subclone 707 DAP2 cancer cell line house mouse CVCL_8920 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107329 CVCL_7X21 DA04418 transformed cell line human CVCL_7X21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107330 CVCL_8921 Subclone 707 DAP3 cancer cell line house mouse CVCL_8921 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107331 CVCL_7X26 DA04425 transformed cell line human CVCL_7X26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107332 CVCL_8926 T11 [Human glioblastoma] cancer cell line human CVCL_8926 CL:0000010 Derived from sampling site: Brain. Female Doubling time: 74 hours (PubMed=19886054) 21107333 CVCL_7X27 DA04426 transformed cell line human CVCL_7X27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107334 CVCL_8927 U937(CD59+) cancer cell line human CVCL_8927 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: ECACC; 95102435; probable Male 21107335 CVCL_7X28 DA04427 transformed cell line human CVCL_7X28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107336 CVCL_8928 XF 498 cancer cell line human CVCL_8928 CL:0000010 21107337 CVCL_7X29 DA04428 transformed cell line human CVCL_7X29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107338 CVCL_8929 YD-10B cancer cell line human CVCL_8929 HLA typing: A*02:06,33:03; B*51:01,58:01; C*03:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=62.45%; East Asian, South=36.59%; South Asian=0%; European, North=0%; European, South=0.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Ter (c.262G>T); ClinVar=VCV000376305; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Homozygous (PubMed=16264262; DepMap) Population: Korean; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25.3 hours (PubMed=16264262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107339 CVCL_7X33 DA04432 transformed cell line human CVCL_7X33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107340 CVCL_8933 PG13/LN c8 transformed cell line house mouse CVCL_8933 CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol; Transfected with: UniProtKB; P21415; Gibbon ape leukemia virus (GALV) env Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10685 21107341 CVCL_7X34 DA04433 transformed cell line human CVCL_7X34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107342 CVCL_8934 Psi2 12S6 transformed cell line house mouse CVCL_8934 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with a retroviral vector LTR-hybrid adenovirus 2/5 E1A 12s-SV40 promoter-Neo-pBR ori-LTR This cell line can be used to transform epithelial cells (PubMed=2966895). 21107343 CVCL_7X35 DA04434 transformed cell line human CVCL_7X35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107344 CVCL_8935 Psi2 13s1 transformed cell line house mouse CVCL_8935 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with a retroviral vector LTR-hybrid adenovirus 2/5 E1A 13s-SV40 promoter-Neo-pBR ori-LTR This cell line can be used to transform epithelial cells (PubMed=2966895). 21107345 CVCL_7X36 DA04435 transformed cell line human CVCL_7X36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107346 CVCL_8936 Psi2 DAP transformed cell line house mouse CVCL_8936 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21107347 CVCL_7X30 DA04429 transformed cell line human CVCL_7X30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107348 CVCL_8930 YD-15 cancer cell line human CVCL_8930 Genome ancestry: African=0.84%; Native American=1.03%; East Asian, North=65.12%; East Asian, South=31.39%; South Asian=0%; European, North=0%; European, South=1.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Ala (c.773A>C); ClinVar=VCV000458563; Zygosity=Homozygous (PubMed=16264262; DepMap) Population: Korean; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 19.8 hours (PubMed=16264262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107349 CVCL_7X31 DA04430 transformed cell line human CVCL_7X31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107350 CVCL_8931 YJ cancer cell line human CVCL_8931 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00288 Problematic cell line: Contaminated Shown to be a HL-60 derivative (PubMed=12592342; PubMed=19344951; PubMed=20143388). 21107351 CVCL_7X32 DA04431 transformed cell line human CVCL_7X32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107352 CVCL_8932 U937(CD59-) cancer cell line human CVCL_8932 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21107353 CVCL_8937 16-10A1 hybridoma house mouse CVCL_8937 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q00609; Mouse Cd80. 21107354 CVCL_7X37 DA04436 transformed cell line human CVCL_7X37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107355 CVCL_8938 16M3F10 hybridoma CVCL_8938 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00588; Corynephage beta diphtheria toxin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8363 21107356 CVCL_7X38 DA04437 transformed cell line human CVCL_7X38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107357 CVCL_8939 2E6 [Mouse/hamster hybridoma against mouse Itgb2] hybridoma house mouse CVCL_8939 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18. 21107358 CVCL_7X39 DA04438 transformed cell line human CVCL_7X39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107359 CVCL_7X00 DA04395 transformed cell line human CVCL_7X00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107360 CVCL_8900 SNU-NCC-59 cancer cell line human CVCL_8900 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=22361929); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Unspecified (PubMed=22361929) Derived from metastatic site: Ascites. Omics: SNP array analysis Male Doubling time: 50 hours (PubMed=22361929); Microsatellite instability: Instable (MSI-high) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107361 CVCL_7X01 DA04396 transformed cell line human CVCL_7X01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107362 CVCL_8901 NMB-7 cancer cell line human CVCL_8901 CL:0000010 Derived from metastatic site: Bone marrow. Female 21107363 CVCL_7X02 DA04397 transformed cell line human CVCL_7X02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107364 CVCL_8902 p53NiS1 cancer cell line house mouse CVCL_8902 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:98834; Trp53; Unexplicit; Deletion in exon 5; Zygosity=Hemizygous (PubMed=11984000) Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Derived from sampling site: Leg; Breed/subspecies: C57BL/6 Trp53+/-. Unspecified 21107365 CVCL_7X03 DA04400 transformed cell line human CVCL_7X03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107366 CVCL_8903 Par-C10 transformed cell line Norway rat CVCL_8903 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; parotid gland; Breed/subspecies: Sprague Dawley. Male 21107367 CVCL_7X08 DA04405 transformed cell line human CVCL_7X08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107368 CVCL_8908 SA101 cancer cell line human CVCL_8908 CL:0000010 Derived from sampling site: Brain; fronto-temporal lobe. Female Doubling time: 4 days (PubMed=899730) 21107369 CVCL_7X09 DA04406 transformed cell line human CVCL_7X09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107370 CVCL_8909 SA39 cancer cell line human CVCL_8909 CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Doubling time: 3 days (PubMed=899730) 21107371 CVCL_7X04 DA04401 transformed cell line human CVCL_7X04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107372 CVCL_8904 PER-106 cancer cell line human CVCL_8904 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 10.5 days (for non-adherent), >30 days (for adherent) (PubMed=1581878) 21107373 CVCL_7X05 DA04402 transformed cell line human CVCL_7X05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107374 CVCL_8905 PER-107 cancer cell line human CVCL_8905 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 5.75 days (PubMed=1581878) 21107375 CVCL_7X06 DA04403 transformed cell line human CVCL_7X06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107376 CVCL_8906 PER-108 cancer cell line human CVCL_8906 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 3.25 days (PubMed=1581878) 21107377 CVCL_7X07 DA04404 transformed cell line human CVCL_7X07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107378 CVCL_8907 RED-3 cancer cell line human CVCL_8907 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=2659902) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Doubling time: 26 hours (CelloPub=CLPUB00690; CelloPub=CLPUB00691) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00260 Problematic cell line: Contaminated Shown to be a HL-60 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 24 year old male patient suffering from acute lymphoblastic leukemia in second relapse. 21107379 CVCL_7X11 DA04408 transformed cell line human CVCL_7X11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107380 CVCL_8911 SA44 cancer cell line human CVCL_8911 CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Doubling time: 1 day (PubMed=899730) 21107381 CVCL_7X12 DA04409 transformed cell line human CVCL_7X12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107382 CVCL_8912 SA45 cancer cell line human CVCL_8912 CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Doubling time: 1 day (PubMed=899730) 21107383 CVCL_7X13 DA04410 transformed cell line human CVCL_7X13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107384 CVCL_7X14 DA04411 transformed cell line human CVCL_7X14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107385 CVCL_8914 SNU-1750 cancer cell line human CVCL_8914 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Pro (c.818G>C); ClinVar=VCV000231060; Zygosity=Unspecified (PubMed=22361929). Population: Korean Male Doubling time: 74 hours (PubMed=22361929); Microsatellite instability: Stable (MSS) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107386 CVCL_7X10 DA04407 transformed cell line human CVCL_7X10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107387 CVCL_8910 SA-4 cancer cell line human CVCL_8910 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis Discontinued: ATCC; CRL-7938; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00085 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4469665; PubMed=20143388). Originally thought to originate from a male patient suffering from a liposarcoma. 21107388 CVCL_7X19 DA04416 transformed cell line human CVCL_7X19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107389 CVCL_8919 Subclone 707 DAP10 cancer cell line house mouse CVCL_8919 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112130; probable 21107390 CVCL_7X15 DA04412 transformed cell line human CVCL_7X15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107391 CVCL_8915 SNU-1967 cancer cell line human CVCL_8915 CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Female Doubling time: 49 hours (PubMed=22361929); Microsatellite instability: Stable (MSS) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107392 CVCL_7X16 DA04413 transformed cell line human CVCL_7X16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107393 CVCL_8916 ST88-14 cancer cell line human CVCL_8916 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg304Ter (c.910C>T); ClinVar=VCV000187722; Zygosity=Unspecified (PubMed=32642732). Male Doubling time: ~24 hours (PubMed=21084276) 21107394 CVCL_7X17 DA04414 transformed cell line human CVCL_7X17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107395 CVCL_8917 STS-26T cancer cell line human CVCL_8917 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=21084276) Derived from metastatic site: Bone; left scapula. Female Doubling time: ~16 hours (PubMed=21084276) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107396 CVCL_7X18 DA04415 transformed cell line human CVCL_7X18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107397 CVCL_8918 Subclone 707 DAP1 cancer cell line house mouse CVCL_8918 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21107398 CVCL_A262 KCL029 embryonic stem cell human CVCL_A262 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asp1152His (c.3454G>C); ClinVar=VCV000035867; Zygosity=Heterozygous (PubMed=27345811); Sequence variation: Mutation; HGNC; 12731; WAS; Simple; p.Ser272Pro (c.814T>C); ClinVar=VCV000029966; Zygosity=Hemizygous (PubMed=27345811) Omics: Array-based CGH. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0225; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-46. 21107399 CVCL_A263 KCL030 embryonic stem cell human CVCL_A263 From: King's College London; London; United Kingdom CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0226; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-45.. 21107400 CVCL_A264 KCL031 embryonic stem cell human CVCL_A264 HLA typing: A*02,24; B*51,52:01/04/07/13; C*14:01/07N/11/14,12:02/17/22/30; DRB1*11,15 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0263; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107401 CVCL_A265 KCL032 embryonic stem cell human CVCL_A265 HLA typing: A*02,11; B*15,51; C*03.04; DRB1*04:07,12:02/39/73/96 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0266; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107402 CVCL_A266 KCL033 embryonic stem cell human CVCL_A266 HLA typing: A*11,29; B*44,51; C*16,04; DRB1*04:07,07 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to KCL034 (Cellosaurus=CVCL_A267). Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0267; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-54. 21107403 CVCL_A267 KCL034 embryonic stem cell human CVCL_A267 HLA typing: A*11,29; B*44,51; C*16,04; DRB1*04:07,07 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to KCL033 (Cellosaurus=CVCL_A266). Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0268; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-54. 21107404 CVCL_A268 KCL035 embryonic stem cell human CVCL_A268 From: King's College London; London; United Kingdom CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0227; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-38.. 21107405 CVCL_A269 KCL036 embryonic stem cell human CVCL_A269 From: King's College London; London; United Kingdom CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0241; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-38.. 21107406 CVCL_A260 KCL027 embryonic stem cell human CVCL_A260 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=27345982) Donor information: Embryo is sibling to that giving rise to KCL028 (Cellosaurus=CVCL_A261). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0223; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-47. 21107407 CVCL_A261 KCL028 embryonic stem cell human CVCL_A261 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=27345983) Donor information: Embryo is sibling to that giving rise to KCL027 (Cellosaurus=CVCL_A260). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0224; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-47. 21107408 CVCL_A273 KCL040 embryonic stem cell human CVCL_A273 HLA typing: A*03,24; B*07,15; C*03,07; DRB1*04:04/23/42/56/0,15 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0272; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107409 CVCL_A274 KCL041 embryonic stem cell human CVCL_A274 From: King's College London; London; United Kingdom CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0273; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-38.. 21107410 CVCL_A275 SDUe002-A embryonic stem cell human CVCL_A275 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Female 21107411 CVCL_A276 SDUe007-A embryonic stem cell human CVCL_A276 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Female 21107412 CVCL_A277 SDUe003-A embryonic stem cell human CVCL_A277 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Female 21107413 CVCL_A278 SDUe004-A embryonic stem cell human CVCL_A278 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Female 21107414 CVCL_A279 SDUe005-A embryonic stem cell human CVCL_A279 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Male 21107415 CVCL_IK07 ND13486 transformed cell line human CVCL_IK07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107416 CVCL_IK08 ND13487 transformed cell line human CVCL_IK08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107417 CVCL_IK09 ND13525 transformed cell line human CVCL_IK09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107418 CVCL_IK03 ND13024 transformed cell line human CVCL_IK03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107419 CVCL_A270 KCL037 embryonic stem cell human CVCL_A270 HLA typing: A*02,03; B*35,40; C*03,04; DRB1*01,12:02/39/73/96 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0269; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107420 CVCL_IK04 ND13137 transformed cell line human CVCL_IK04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107421 CVCL_A271 KCL038 embryonic stem cell human CVCL_A271 HLA typing: A*03,11; B*07,15; C*03.07; DRB1*14,15 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0265; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107422 CVCL_IK05 ND13452 transformed cell line human CVCL_IK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107423 CVCL_A272 KCL039 embryonic stem cell human CVCL_A272 HLA typing: A*01,24; B*35:02/83,49:01/06/08; C*04.07; DRB1*3 (PubMed=23161805) From: King's College London; London; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0274; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-37. 21107424 CVCL_IK06 ND13453 transformed cell line human CVCL_IK06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107425 CVCL_IK00 ND12836 transformed cell line human CVCL_IK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107426 CVCL_IK01 ND12873 transformed cell line human CVCL_IK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107427 CVCL_IK02 ND12974 transformed cell line human CVCL_IK02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107428 CVCL_A248 KCL015 embryonic stem cell human CVCL_A248 From: King's College London; London; United Kingdom CL:0000010 Donor information: Embryo is sibling to those giving rise to KCL016 (Cellosaurus=CVCL_A249) and KCL017 (Cellosaurus=CVCL_A250). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0215; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-36. 21107429 CVCL_A249 KCL016 embryonic stem cell human CVCL_A249 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.676+3A>T; Zygosity=Heterozygous (PubMed=27345783) Donor information: Embryo is sibling to those giving rise to KCL015 (Cellosaurus=CVCL_A248) and KCL017 (Cellosaurus=CVCL_A250). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0216; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-35. 21107430 CVCL_A240 KCL004 embryonic stem cell human CVCL_A240 From: King's College London; London; United Kingdom. CL:0000010 Male 21107431 CVCL_A241 KCL005 embryonic stem cell human CVCL_A241 From: King's College London; London; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-07-013, Steering comm appl. SCSC07-11.. 21107432 CVCL_A242 KCL006 embryonic stem cell human CVCL_A242 From: King's College London; London; United Kingdom. CL:0000010 Unspecified 21107433 CVCL_A243 KCL008 embryonic stem cell human CVCL_A243 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (PubMed=20178004). Ambiguous Registration: UK Stem Cell Bank (UKSCB); R-08-010, Steering comm appl. SCSC07-49. 21107434 CVCL_A244 KCL009 embryonic stem cell human CVCL_A244 From: King's College London; London; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-08-011, Steering comm appl. SCSC07-49.. 21107435 CVCL_A245 KCL011 embryonic stem cell human CVCL_A245 From: King's College London; London; United Kingdom CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0212; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-31.. 21107436 CVCL_A246 KCL012 embryonic stem cell human CVCL_A246 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=27345979) Donor information: Embryo is sibling to that giving rise to KCL013 (Cellosaurus=CVCL_A247). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0213; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-32. 21107437 CVCL_A247 KCL013 embryonic stem cell human CVCL_A247 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=27345987) Donor information: Embryo is sibling to that giving rise to KCL012 (Cellosaurus=CVCL_A246). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0214; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-33. 21107438 CVCL_A259 KCL026 embryonic stem cell human CVCL_A259 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (PubMed=27345977). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0222; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-49. 21107439 CVCL_A251 KCL018 embryonic stem cell human CVCL_A251 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~2200] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (PubMed=27346000). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0218; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-30. 21107440 CVCL_A252 KCL019 embryonic stem cell human CVCL_A252 From: King's College London; London; United Kingdom CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0270; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-13. 21107441 CVCL_A253 KCL020 embryonic stem cell human CVCL_A253 From: King's College London; London; United Kingdom CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0271; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-13. 21107442 CVCL_A254 KCL021 embryonic stem cell human CVCL_A254 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=27345808). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0219; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-14. 21107443 CVCL_A255 KCL022 embryonic stem cell human CVCL_A255 From: King's College London; London; United Kingdom CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0264; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-13. 21107444 CVCL_A256 KCL023 embryonic stem cell human CVCL_A256 From: King's College London; London; United Kingdom CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0262; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-13.. 21107445 CVCL_A257 KCL024 embryonic stem cell human CVCL_A257 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (PubMed=27345975) Donor information: Embryo is sibling to that giving rise to KCL025 (Cellosaurus=CVCL_A258). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0220; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-48. 21107446 CVCL_A258 KCL025 embryonic stem cell human CVCL_A258 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (PubMed=27345978) Donor information: Embryo is sibling to that giving rise to KCL024 (Cellosaurus=CVCL_A257). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0221; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-48. 21107447 CVCL_A250 KCL017 embryonic stem cell human CVCL_A250 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.676+3A>T; Zygosity=Heterozygous (PubMed=27345980) Donor information: Embryo is sibling to those giving rise to KCL015 (Cellosaurus=CVCL_A248) and KCL016 (Cellosaurus=CVCL_A249). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0217; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-34. 21107448 CVCL_A226 Ma-Mel-92d cancer cell line human CVCL_A226 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21107449 CVCL_A227 Ma-Mel-93 cancer cell line human CVCL_A227 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (PubMed=17311103) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107450 CVCL_A228 Ma-Mel-94 cancer cell line human CVCL_A228 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21107451 CVCL_A229 Ma-Mel-95 cancer cell line human CVCL_A229 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21107452 CVCL_7W92 DA04384 transformed cell line human CVCL_7W92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107453 CVCL_8892 Lu 106 cancer cell line human CVCL_8892 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00075 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). Originally thought to originate from embryonic lung. 21107454 CVCL_7W93 DA04385 transformed cell line human CVCL_7W93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107455 CVCL_8893 MH11 factor-dependent cell line house mouse CVCL_8893 CL:0000010 Derived from sampling site: Embryonic liver Cell type=Pre-B cell.; Breed/subspecies: C57BL/6 x BALB/c. Unspecified Characteristics: Requires feeder cells Maintenance of MH11 depends on the presence of cell line ST2 (Cellosaurus=CVCL_2205).; Characteristics: IL7 dependent 21107456 CVCL_7W94 DA04386 transformed cell line human CVCL_7W94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107457 CVCL_A220 Ma-Mel-85 cancer cell line human CVCL_A220 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Phe516Leu (c.1548C>A); Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107458 CVCL_8894 MHH225 cancer cell line human CVCL_8894 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00238 Problematic cell line: Contaminated Shown to be a Jurkat derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the bone marrow of a 60 year old male patient with acute myeloid leukemia. 21107459 CVCL_7W95 DA04387 transformed cell line human CVCL_7W95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107460 CVCL_A221 Ma-Mel-86a cancer cell line human CVCL_A221 HLA typing: A*01:01,24:02; B*08:01,15:01; C*03:03,07:01 (PubMed=27261508) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503; PubMed=27261508); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; PTEN p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21107461 CVCL_8895 MTC-F cancer cell line human CVCL_8895 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=1972348) Population: Caucasian; Derived from sampling site: Thyroid gland. Female 21107462 CVCL_A222 Ma-Mel-86b cancer cell line human CVCL_A222 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Homozygous (PubMed=27261508); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=27261508); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; PTEN p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Has lost HLA class I surface expression due to the deletion of B2M (PubMed=27261508) 21107463 CVCL_A223 Ma-Mel-90 cancer cell line human CVCL_A223 CL:0000010 Derived from metastatic site: Cutaneous/subcutaneous. Male 21107464 CVCL_7W90 DA04380 transformed cell line human CVCL_7W90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107465 CVCL_8890 LHCN-M2 telomerase immortalized cell line human CVCL_8890 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Muscle; pectoralis major Cell type=Myoblast.. Male Doubling time: 35-40 hours (Evercyte) Part of: ENCODE project common cell types; tier 2 21107466 CVCL_A224 Ma-Mel-91 cancer cell line human CVCL_A224 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107467 CVCL_7W91 DA04381 transformed cell line human CVCL_7W91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107468 CVCL_8891 LT finite cell line human CVCL_8891 CL:0000010 Derived from sampling site: Lung. Discontinued: ECACC; 96061947; probable 21107469 CVCL_A225 Ma-Mel-92 cancer cell line human CVCL_A225 CL:0000010 21107470 CVCL_7W89 DA04379 transformed cell line human CVCL_7W89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107471 CVCL_8889 LH86 cancer cell line human CVCL_8889 HLA typing: A*24,25; B*07 (Patent=US8017391) CL:0000010 Derived from sampling site: Liver. Unspecified Doubling time: ~42 hours (Patent=US8017391) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7435 21107472 CVCL_7W85 DA04374 transformed cell line human CVCL_7W85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107473 CVCL_8885 KNA cancer cell line human CVCL_8885 CL:0000010 Population: Caucasian; Derived from sampling site: Adrenal gland; medulla Cell type=Chromaffin cell.. Discontinued: ECACC; 96020765; probable Female Doubling time: 3.5 days (PubMed=10640177) 21107474 CVCL_7W86 DA04375 transformed cell line human CVCL_7W86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107475 CVCL_8886 KRJ-I transformed cell line human CVCL_8886 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Small intestine; ileum. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 95041223; probable Male Doubling time: 1.8 days (PubMed=21544390) Problematic cell line: Misclassified Originally thought to arise from a multifocal carcinoid of the small intestine but shown to be an EBV-transformed lymphoblastoid cell line (PubMed=29444910; PubMed=31548718). Although misidentified, it has been argued that transcriptional regulation of the cells enough resemble gastroenteropancreatic neuroendocrine tumors to be used in studies (PubMed=31548719). 21107476 CVCL_7W87 DA04376 transformed cell line human CVCL_7W87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107477 CVCL_8887 L Cells (TK+, HBS Ag+) spontaneously immortalized cell line house mouse CVCL_8887 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21107478 CVCL_7W88 DA04377 transformed cell line human CVCL_7W88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107479 CVCL_8888 L-68 finite cell line human CVCL_8888 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ECACC; 97050223; probable Unspecified 21107480 CVCL_A237 KCL001 embryonic stem cell human CVCL_A237 From: King's College London; London; United Kingdom CL:0000010 Male Registration: Swiss research registry; BAG-hES-IMP-0019; Registration: UK Stem Cell Bank (UKSCB); R-06-021, Steering comm appl. SCSC05-05.. 21107481 CVCL_A238 KCL002 embryonic stem cell human CVCL_A238 From: King's College London; London; United Kingdom CL:0000010 Male Registration: Swiss research registry; BAG-hES-IMP-0018; Registration: UK Stem Cell Bank (UKSCB); R-06-028, Steering comm appl. SCSC06-28.. 21107482 CVCL_A239 KCL003 embryonic stem cell human CVCL_A239 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15820050). Male Registration: Swiss research registry; BAG-hES-IMP-0017; Registration: UK Stem Cell Bank (UKSCB); R-08-030, Steering comm appl. SCSC06-28. 21107483 CVCL_A230 Ma-Mel-96 cancer cell line human CVCL_A230 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107484 CVCL_A231 Ma-Mel-97 cancer cell line human CVCL_A231 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107485 CVCL_A232 Ma-Mel-99 cancer cell line human CVCL_A232 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21107486 CVCL_A233 Edi 1 embryonic stem cell human CVCL_A233 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Unspecified Registration: Swiss research registry; BAG-hES-IMP-0012; Registration: UK Stem Cell Bank (UKSCB); R-06-005, Steering comm appl. SCSC04-29.. 21107487 CVCL_A234 Edi 2 embryonic stem cell human CVCL_A234 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0032; Registration: UK Stem Cell Bank (UKSCB); R-07-023, Steering comm appl. SCSC07-12.. 21107488 CVCL_A235 Edi 3 embryonic stem cell human CVCL_A235 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-07-024, Steering comm appl. SCSC07-12.. 21107489 CVCL_A236 Edi 4 embryonic stem cell human CVCL_A236 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-07-025, Steering comm appl. SCSC07-13.. 21107490 CVCL_7W96 DA04388 transformed cell line human CVCL_7W96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107491 CVCL_8896 MTC-SK cancer cell line human CVCL_8896 CL:0000010 Population: Caucasian; Derived from sampling site: Thyroid gland. Discontinued: ECACC; 92013101; probable Female Doubling time: 2.4 days (PubMed=1972348) 21107492 CVCL_7W97 DA04389 transformed cell line human CVCL_7W97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107493 CVCL_8897 SNU-NCC-19 cancer cell line human CVCL_8897 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=22361929). Male Doubling time: 59 hours (PubMed=22361929); Microsatellite instability: Stable (MSS) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107494 CVCL_7W98 DA04390 transformed cell line human CVCL_7W98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107495 CVCL_8898 SNU-NCC-20 cancer cell line human CVCL_8898 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 135 hours (PubMed=22361929); Microsatellite instability: Stable (MSS) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107496 CVCL_7W99 DA04392 transformed cell line human CVCL_7W99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107497 CVCL_8899 SNU-NCC-24 cancer cell line human CVCL_8899 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Unspecified (PubMed=22361929); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=22361929) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 47 hours (PubMed=22361929); Microsatellite instability: Stable (MSS) (PubMed=22361929) Part of: Seoul National University (SNU) cell line collection 21107498 CVCL_A204 Ma-Mel-68 cancer cell line human CVCL_A204 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107499 CVCL_A205 Ma-Mel-69 cancer cell line human CVCL_A205 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male 21107500 CVCL_A206 Ma-Mel-70 cancer cell line human CVCL_A206 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21107501 CVCL_A207 Ma-Mel-71 cancer cell line human CVCL_A207 CL:0000010 Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107502 CVCL_A208 Ma-Mel-73a cancer cell line human CVCL_A208 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21107503 CVCL_A209 Ma-Mel-73b cancer cell line human CVCL_A209 CL:0000010 Derived from metastatic site: Lymph node. Male 21107504 CVCL_7W70 DA04351 transformed cell line human CVCL_7W70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107505 CVCL_8870 FLYA13 cancer cell line human CVCL_8870 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Omics: SNP array analysis Male Group: Retrovirus packaging cell line 21107506 CVCL_7W71 DA04352 transformed cell line human CVCL_7W71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107507 CVCL_8871 FLYRD18 cancer cell line human CVCL_8871 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Retrovirus packaging cell line 21107508 CVCL_7W72 DA04359 transformed cell line human CVCL_7W72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107509 CVCL_8872 GC-1spg transformed cell line house mouse CVCL_8872 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatocyte.; Breed/subspecies: BALB/c. Male 21107510 CVCL_7W73 DA04360 transformed cell line human CVCL_7W73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107511 CVCL_8873 GE11 transformed cell line house mouse CVCL_8873 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: 129S2/SvPas. Male 21107512 CVCL_A200 Ma-Mel-65 cancer cell line human CVCL_A200 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.204_205CC>TT (-100/101C>T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21107513 CVCL_A201 Ma-Mel-66a cancer cell line human CVCL_A201 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21107514 CVCL_A202 Ma-Mel-66b cancer cell line human CVCL_A202 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Omics: Transcriptome analysis by microarray. Female 21107515 CVCL_A203 Ma-Mel-67 cancer cell line human CVCL_A203 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21107516 CVCL_7W67 DA04348 transformed cell line human CVCL_7W67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107517 CVCL_8867 EU-9 cancer cell line human CVCL_8867 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21107518 CVCL_7W68 DA04349 transformed cell line human CVCL_7W68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107519 CVCL_8868 FIB21 hybridoma CVCL_8868 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26011; Mouse Itgb7. 21107520 CVCL_7W69 DA04350 transformed cell line human CVCL_7W69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107521 CVCL_8869 FIB504.64 hybridoma CVCL_8869 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26011; Mouse Itgb7. 21107522 CVCL_7W63 DA04344 transformed cell line human CVCL_7W63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107523 CVCL_8863 EU-5 cancer cell line human CVCL_8863 CL:0000010 Derived from sampling site: Bone marrow. Female 21107524 CVCL_7W64 DA04345 transformed cell line human CVCL_7W64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107525 CVCL_8864 EU-6 cancer cell line human CVCL_8864 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=7888679) Derived from sampling site: Bone marrow. Female 21107526 CVCL_7W65 DA04346 transformed cell line human CVCL_7W65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107527 CVCL_8865 EU-7 cancer cell line human CVCL_8865 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00198 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12592342; PubMed=20143388). 21107528 CVCL_7W66 DA04347 transformed cell line human CVCL_7W66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107529 CVCL_8866 EU-8 cancer cell line human CVCL_8866 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638) Derived from sampling site: Bone marrow. Female Doubling time: 75-85 hours (DOI=10.1016/B978-0-12-221970-2.50457-5) 21107530 CVCL_A215 Ma-Mel-80a cancer cell line human CVCL_A215 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21107531 CVCL_A216 Ma-Mel-81 cancer cell line human CVCL_A216 CL:0000010 Derived from metastatic site: Cutaneous/subcutaneous. Female 21107532 CVCL_A217 Ma-Mel-82 cancer cell line human CVCL_A217 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21107533 CVCL_A218 Ma-Mel-83 cancer cell line human CVCL_A218 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21107534 CVCL_A219 Ma-Mel-84 cancer cell line human CVCL_A219 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Omics: Transcriptome analysis by microarray. 21107535 CVCL_7W81 DA04369 transformed cell line human CVCL_7W81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107536 CVCL_8881 HTLA230 cancer cell line human CVCL_8881 CL:0000010 Derived from metastatic site: Bone marrow. Male 21107537 CVCL_7W82 DA04371 transformed cell line human CVCL_7W82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107538 CVCL_8882 IGR-N-835 cancer cell line human CVCL_8882 CL:0000010 Derived from sampling site: Abdomen. Female Doubling time: 65 hours (PubMed=2777412) 21107539 CVCL_7W83 DA04372 transformed cell line human CVCL_7W83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107540 CVCL_8883 IGR-N-91 cancer cell line human CVCL_8883 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex7-9dup; Zygosity=Unspecified (PubMed=14676279) Derived from metastatic site: Bone marrow. Male 21107541 CVCL_7W84 DA04373 transformed cell line human CVCL_7W84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107542 CVCL_8884 JIH-3 cancer cell line human CVCL_8884 CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male Doubling time: ~102.5 hours (PubMed=22340903) 21107543 CVCL_A210 Ma-Mel-74 cancer cell line human CVCL_A210 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21107544 CVCL_A211 Ma-Mel-75 cancer cell line human CVCL_A211 CL:0000010 21107545 CVCL_A212 Ma-Mel-76 cancer cell line human CVCL_A212 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21107546 CVCL_A213 Ma-Mel-79 cancer cell line human CVCL_A213 CL:0000010 Male 21107547 CVCL_7W80 DA04368 transformed cell line human CVCL_7W80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04368; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107548 CVCL_8880 HPL1D transformed cell line human CVCL_8880 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; parenchyma Cell type=Epithelial cell.. Female 21107549 CVCL_A214 Ma-Mel-79b cancer cell line human CVCL_A214 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103) Derived from metastatic site: Cutaneous/subcutaneous. Omics: Transcriptome analysis by microarray Male 21107550 CVCL_7W78 DA04366 transformed cell line human CVCL_7W78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107551 CVCL_8878 HEY A8 cancer cell line human CVCL_8878 Genome ancestry: African=1.54%; Native American=0%; East Asian, North=2.65%; East Asian, South=0%; South Asian=0%; European, North=62.34%; European, South=33.46% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 16 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21107552 CVCL_7W79 DA04367 transformed cell line human CVCL_7W79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107553 CVCL_8879 HeyA8-MDR cancer cell line human CVCL_8879 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol) Female 21107554 CVCL_7W74 DA04361 transformed cell line human CVCL_7W74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107555 CVCL_8874 GI-LA-N cancer cell line human CVCL_8874 CL:0000010 Derived from metastatic site: Lymph node. Male 21107556 CVCL_7W75 DA04362 transformed cell line human CVCL_7W75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107557 CVCL_8875 Grunt Fin spontaneously immortalized cell line CVCL_8875 CL:0000010 Derived from sampling site: Fin. Discontinued: ATCC; CCL-58; true Unspecified Group: Fish cell line 21107558 CVCL_7W76 DA04363 transformed cell line human CVCL_7W76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107559 CVCL_8876 GSS cancer cell line human CVCL_8876 Genome ancestry: African=6.73%; Native American=0%; East Asian, North=81.61%; East Asian, South=6.93%; South Asian=0%; European, North=0%; European, South=4.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Asn (c.250G>A); ClinVar=VCV000229806; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107560 CVCL_7W77 DA04365 transformed cell line human CVCL_7W77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107561 CVCL_8877 GSU cancer cell line human CVCL_8877 Genome ancestry: African=0.31%; Native American=0.03%; East Asian, North=77.2%; East Asian, South=22.13%; South Asian=0%; European, North=0.34%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21107562 CVCL_IK80 ND15739 transformed cell line human CVCL_IK80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107563 CVCL_IK81 ND15740 transformed cell line human CVCL_IK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107564 CVCL_IK82 ND15741 transformed cell line human CVCL_IK82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107565 CVCL_RE20 STBCi150-A induced pluripotent stem cell human CVCL_RE20 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi150-A; true Male 21107566 CVCL_RE21 STBCi151-A induced pluripotent stem cell human CVCL_RE21 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi151-A; true Female 21107567 CVCL_RE22 STBCi152-A induced pluripotent stem cell human CVCL_RE22 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi152-A; true Male 21107568 CVCL_RE23 STBCi153-A induced pluripotent stem cell human CVCL_RE23 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi153-A; true Female 21107569 CVCL_IK76 ND15621 transformed cell line human CVCL_IK76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107570 CVCL_RE24 STBCi154-A induced pluripotent stem cell human CVCL_RE24 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi154-A; true Male 21107571 CVCL_IK77 ND15626 transformed cell line human CVCL_IK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107572 CVCL_RE25 STBCi155-A induced pluripotent stem cell human CVCL_RE25 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi155-A; true Male 21107573 CVCL_IK78 ND15736 transformed cell line human CVCL_IK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107574 CVCL_RE26 STBCi156-A induced pluripotent stem cell human CVCL_RE26 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107575 CVCL_IK79 ND15738 transformed cell line human CVCL_IK79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107576 CVCL_RE27 STBCi157-A induced pluripotent stem cell human CVCL_RE27 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi157-A; true Female 21107577 CVCL_IK72 ND15288 transformed cell line human CVCL_IK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107578 CVCL_RE28 STBCi158-A induced pluripotent stem cell human CVCL_RE28 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi158-A; true Male 21107579 CVCL_IK73 ND15388 transformed cell line human CVCL_IK73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107580 CVCL_RE29 STBCi159-A induced pluripotent stem cell human CVCL_RE29 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi159-A; true Female 21107581 CVCL_IK74 ND15619 transformed cell line human CVCL_IK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107582 CVCL_IK75 ND15620 transformed cell line human CVCL_IK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107583 CVCL_IK90 ND15952 transformed cell line human CVCL_IK90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107584 CVCL_IK91 ND15953 transformed cell line human CVCL_IK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107585 CVCL_IK92 ND15954 transformed cell line human CVCL_IK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107586 CVCL_IK93 Lymph10-AD1-iPS induced pluripotent stem cell human CVCL_IK93 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21107587 CVCL_RE10 STBCi140-A induced pluripotent stem cell human CVCL_RE10 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi140-A; true Male 21107588 CVCL_RE11 STBCi141-A induced pluripotent stem cell human CVCL_RE11 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107589 CVCL_RE12 STBCi142-A induced pluripotent stem cell human CVCL_RE12 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi142-A; true Male 21107590 CVCL_IK87 ND15868 transformed cell line human CVCL_IK87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107591 CVCL_RE13 STBCi143-A induced pluripotent stem cell human CVCL_RE13 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi143-A; true Female 21107592 CVCL_IK88 ND15885 transformed cell line human CVCL_IK88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107593 CVCL_RE14 STBCi144-A induced pluripotent stem cell human CVCL_RE14 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi144-A; true Female 21107594 CVCL_IK89 ND15913 transformed cell line human CVCL_IK89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107595 CVCL_RE15 STBCi145-A induced pluripotent stem cell human CVCL_RE15 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi145-A; true Male 21107596 CVCL_RE16 STBCi146-A induced pluripotent stem cell human CVCL_RE16 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi146-A; true Male 21107597 CVCL_IK83 ND15742 transformed cell line human CVCL_IK83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107598 CVCL_RE17 STBCi147-A induced pluripotent stem cell human CVCL_RE17 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi147-A; true Female 21107599 CVCL_IK84 ND15819 transformed cell line human CVCL_IK84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107600 CVCL_RE18 STBCi148-A induced pluripotent stem cell human CVCL_RE18 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi148-A; true Female 21107601 CVCL_IK85 ND15856 transformed cell line human CVCL_IK85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107602 CVCL_RE19 STBCi149-A induced pluripotent stem cell human CVCL_RE19 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi149-A; true Female 21107603 CVCL_IK86 ND15857 transformed cell line human CVCL_IK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107604 CVCL_IK60 ND15095 transformed cell line human CVCL_IK60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107605 CVCL_IK58 ND15092 transformed cell line human CVCL_IK58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107606 CVCL_IK59 ND15094 transformed cell line human CVCL_IK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107607 CVCL_RE00 STBCi130-A induced pluripotent stem cell human CVCL_RE00 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107608 CVCL_RE01 STBCi131-A induced pluripotent stem cell human CVCL_RE01 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107609 CVCL_IK54 KC-1 [Koala] finite cell line CVCL_IK54 CL:0000010 Derived from sampling site: Eye; conjunctiva. Unspecified Doubling time: 16.5 hours (in 10% FCS), 26.5 hours (in 2% FCS), 86 hours (in absence of FCS) (PubMed=14505439) Group: Marsupial cell line 21107610 CVCL_RE02 STBCi132-A induced pluripotent stem cell human CVCL_RE02 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107611 CVCL_IK55 ND15022 transformed cell line human CVCL_IK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107612 CVCL_RE03 STBCi133-A induced pluripotent stem cell human CVCL_RE03 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107613 CVCL_IK56 ND15090 transformed cell line human CVCL_IK56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107614 CVCL_RE04 STBCi134-A induced pluripotent stem cell human CVCL_RE04 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi134-A; true Male 21107615 CVCL_IK57 ND15091 transformed cell line human CVCL_IK57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107616 CVCL_RE05 STBCi135-A induced pluripotent stem cell human CVCL_RE05 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi135-A; true Female 21107617 CVCL_IK50 ND03462 transformed cell line human CVCL_IK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107618 CVCL_RE06 STBCi136-A induced pluripotent stem cell human CVCL_RE06 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi136-A; true Female 21107619 CVCL_IK51 ACP02 cancer cell line human CVCL_IK51 CL:0000010 Derived from sampling site: Stomach; cardia. Omics: Array-based CGH Male 21107620 CVCL_RE07 STBCi137-A induced pluripotent stem cell human CVCL_RE07 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107621 CVCL_IK52 ACP03 cancer cell line human CVCL_IK52 CL:0000010 Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH Male 21107622 CVCL_RE08 STBCi138-A induced pluripotent stem cell human CVCL_RE08 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107623 CVCL_IK53 AGP01 cancer cell line human CVCL_IK53 CL:0000010 Derived from metastatic site: Ascites. Omics: Array-based CGH Male 21107624 CVCL_RE09 STBCi139-A induced pluripotent stem cell human CVCL_RE09 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107625 CVCL_IK70 ND15259 transformed cell line human CVCL_IK70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107626 CVCL_IK71 ND15270 transformed cell line human CVCL_IK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107627 CVCL_IK69 ND15219 transformed cell line human CVCL_IK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107628 CVCL_IK65 ND15130 transformed cell line human CVCL_IK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107629 CVCL_IK66 ND15160 transformed cell line human CVCL_IK66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107630 CVCL_IK67 ND15211 transformed cell line human CVCL_IK67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107631 CVCL_IK68 ND15218 transformed cell line human CVCL_IK68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107632 CVCL_IK61 ND15097 transformed cell line human CVCL_IK61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107633 CVCL_IK62 ND15098 transformed cell line human CVCL_IK62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107634 CVCL_IK63 ND15104 transformed cell line human CVCL_IK63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107635 CVCL_IK64 ND15117 transformed cell line human CVCL_IK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107636 CVCL_IK36 ND14674 transformed cell line human CVCL_IK36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107637 CVCL_IK37 ND14842 transformed cell line human CVCL_IK37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107638 CVCL_IK38 ND14844 transformed cell line human CVCL_IK38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107639 CVCL_IK39 ND14875 transformed cell line human CVCL_IK39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107640 CVCL_IK32 ND14492 transformed cell line human CVCL_IK32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107641 CVCL_IK33 ND14573 transformed cell line human CVCL_IK33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107642 CVCL_IK34 ND14595 transformed cell line human CVCL_IK34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107643 CVCL_IK35 ND14621 transformed cell line human CVCL_IK35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107644 CVCL_IK30 ND14428 transformed cell line human CVCL_IK30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107645 CVCL_IK31 ND14440 transformed cell line human CVCL_IK31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107646 CVCL_IK47 GM08246 finite cell line human CVCL_IK47 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21107647 CVCL_IK48 ND01039 transformed cell line human CVCL_IK48 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex4del; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107648 CVCL_IK49 ND02928 transformed cell line human CVCL_IK49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107649 CVCL_IK43 ND16716 transformed cell line human CVCL_IK43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107650 CVCL_IK44 ND19276 transformed cell line human CVCL_IK44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107651 CVCL_IK45 ND19784 transformed cell line human CVCL_IK45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107652 CVCL_IK46 GM08024 finite cell line human CVCL_IK46 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21107653 CVCL_IK40 ND16086 transformed cell line human CVCL_IK40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107654 CVCL_IK41 ND16712 transformed cell line human CVCL_IK41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107655 CVCL_IK42 ND16713 transformed cell line human CVCL_IK42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107656 CVCL_A284 GN3 transformed cell line Norway rat CVCL_A284 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107657 CVCL_A285 GN5 transformed cell line Norway rat CVCL_A285 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107658 CVCL_A286 GN6 transformed cell line Norway rat CVCL_A286 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107659 CVCL_A287 GP2 transformed cell line Norway rat CVCL_A287 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107660 CVCL_A288 GP4 transformed cell line Norway rat CVCL_A288 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107661 CVCL_A289 GP6 transformed cell line Norway rat CVCL_A289 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107662 CVCL_IK18 ND13680 transformed cell line human CVCL_IK18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107663 CVCL_IK19 ND13703 transformed cell line human CVCL_IK19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107664 CVCL_A280 CHRF-288-11 cancer cell line human CVCL_A280 CL:0000010 Derived from metastatic site: Eye socket. Omics: Transcriptome analysis by microarray Male Characteristics: Established from a nude mouse xenograft Doubling time: ~33 hours (PubMed=2310825) 21107665 CVCL_IK14 ND13640 transformed cell line human CVCL_IK14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107666 CVCL_A281 HSC-PQ spontaneously immortalized cell line Norway rat CVCL_A281 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Sprague Dawley. Male 21107667 CVCL_IK15 ND13661 transformed cell line human CVCL_IK15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107668 CVCL_A282 BRE-169 transformed cell line human CVCL_A282 CL:0000010 Sequence variation: Mutation; HGNC; 43; TAP1; Simple; p.Asp273fs (c.819delC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21107669 CVCL_IK16 ND13665 transformed cell line human CVCL_IK16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107670 CVCL_A283 Bre-80 finite cell line human CVCL_A283 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21107671 CVCL_IK17 ND13679 transformed cell line human CVCL_IK17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107672 CVCL_IK10 ND13526 transformed cell line human CVCL_IK10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107673 CVCL_IK11 ND13634 transformed cell line human CVCL_IK11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107674 CVCL_IK12 ND13636 transformed cell line human CVCL_IK12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107675 CVCL_IK13 ND13637 transformed cell line human CVCL_IK13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107676 CVCL_A295 YAMB-9 transformed cell line human CVCL_A295 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21107677 CVCL_A296 UoC-B1 cancer cell line human CVCL_A296 CL:0000010 Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF (PubMed=8164688) Population: Caucasian; Derived from sampling site: Bone marrow. Female 21107678 CVCL_A297 UoC-B4 cancer cell line human CVCL_A297 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=8704231) Population: Caucasian; Derived from sampling site: Cerebrospinal fluid. Female 21107679 CVCL_A298 UoC-B3 cancer cell line human CVCL_A298 CL:0000010 Population: African American. Female 21107680 CVCL_A299 UoC-B11 cancer cell line human CVCL_A299 CL:0000010 Unspecified 21107681 CVCL_IK29 ND14383 transformed cell line human CVCL_IK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107682 CVCL_A290 GP9 transformed cell line Norway rat CVCL_A290 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107683 CVCL_A291 GP10 transformed cell line Norway rat CVCL_A291 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21107684 CVCL_IK25 ND14288 transformed cell line human CVCL_IK25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107685 CVCL_IK26 ND14300 transformed cell line human CVCL_IK26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107686 CVCL_A292 YAMB-1 transformed cell line human CVCL_A292 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21107687 CVCL_IK27 ND14331 transformed cell line human CVCL_IK27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107688 CVCL_A293 YAMB-3 transformed cell line human CVCL_A293 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21107689 CVCL_IK28 ND14340 transformed cell line human CVCL_IK28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107690 CVCL_A294 YAMB-4 transformed cell line human CVCL_A294 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21107691 CVCL_IK21 ND14048 transformed cell line human CVCL_IK21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107692 CVCL_IK22 ND14061 transformed cell line human CVCL_IK22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107693 CVCL_IK23 ND14093 transformed cell line human CVCL_IK23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107694 CVCL_IK24 ND14219 transformed cell line human CVCL_IK24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107695 CVCL_IK20 ND13956 transformed cell line human CVCL_IK20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107696 CVCL_7Y00 DA04508 transformed cell line human CVCL_7Y00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107697 CVCL_7Y01 DA04509 transformed cell line human CVCL_7Y01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107698 CVCL_7Y02 DA04510 transformed cell line human CVCL_7Y02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107699 CVCL_7Y07 DA04515 transformed cell line human CVCL_7Y07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107700 CVCL_7Y08 DA04516 transformed cell line human CVCL_7Y08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107701 CVCL_7Y09 DA04517 transformed cell line human CVCL_7Y09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107702 CVCL_7Y03 DA04511 transformed cell line human CVCL_7Y03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107703 CVCL_7Y04 DA04512 transformed cell line human CVCL_7Y04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107704 CVCL_7Y05 DA04513 transformed cell line human CVCL_7Y05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107705 CVCL_7Y06 DA04514 transformed cell line human CVCL_7Y06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107706 CVCL_7Y10 DA04518 transformed cell line human CVCL_7Y10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107707 CVCL_7Y11 DA04519 transformed cell line human CVCL_7Y11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107708 CVCL_7Y12 DA04520 transformed cell line human CVCL_7Y12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107709 CVCL_7Y13 DA04521 transformed cell line human CVCL_7Y13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107710 CVCL_7Y18 DA04526 transformed cell line human CVCL_7Y18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107711 CVCL_7Y19 DA04527 transformed cell line human CVCL_7Y19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107712 CVCL_7Y14 DA04522 transformed cell line human CVCL_7Y14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107713 CVCL_7Y15 DA04523 transformed cell line human CVCL_7Y15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107714 CVCL_7Y16 DA04524 transformed cell line human CVCL_7Y16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107715 CVCL_7Y17 DA04525 transformed cell line human CVCL_7Y17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107716 CVCL_RF90 BIONi010-C-13 induced pluripotent stem cell human CVCL_RF90 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Transfected with: HGNC; 13805; NEUROG2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Expression of NEUROG2/NGN2 is doxycycline-inducible Using TALEN NEUROG2 under the control of a tetracycline response element and a 2A-Puro was inserted into one allele of the the safe harbor locus (AAVS1). At the second locus a 2A-Neo-CAG-rtTA construct was inserted (PubMed=33610017). 21107717 CVCL_RF91 BIONi037-A-1 induced pluripotent stem cell human CVCL_RF91 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21107718 CVCL_RF92 BIONi037-A-2 induced pluripotent stem cell human CVCL_RF92 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21107719 CVCL_RF93 BIONi037-A-3 induced pluripotent stem cell human CVCL_RF93 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21107720 CVCL_RF94 BIONi037-A-4 induced pluripotent stem cell human CVCL_RF94 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21107721 CVCL_RF95 RCi007-A induced pluripotent stem cell human CVCL_RF95 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21107722 CVCL_RF96 PFIZi017-A induced pluripotent stem cell human CVCL_RF96 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Cys1741Ser (c.5222G>C) (C1730S); ClinVar=VCV000577486; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21107723 CVCL_RF97 PFIZi018-A induced pluripotent stem cell human CVCL_RF97 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg1245Ter (c.3733C>T) (R1234*); ClinVar=VCV000167639; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21107724 CVCL_RF98 PFIZi019-A induced pluripotent stem cell human CVCL_RF98 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Tyr1508fs (c.4522delT); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21107725 CVCL_RF99 PFIZi021-A induced pluripotent stem cell human CVCL_RF99 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Thr1721Lys (c.5162C>A); ClinVar=VCV000206859; Zygosity=Heterozygous; Note=De novo mutation (hPSCreg) Derived from sampling site: Peripheral blood. Male 21107726 CVCL_RF80 STBCi310-A induced pluripotent stem cell human CVCL_RF80 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107727 CVCL_RF81 STBCi311-A induced pluripotent stem cell human CVCL_RF81 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107728 CVCL_RF82 STBCi312-A induced pluripotent stem cell human CVCL_RF82 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21107729 CVCL_RF83 STBCi313-A induced pluripotent stem cell human CVCL_RF83 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21107730 CVCL_RF84 STBCi314-A induced pluripotent stem cell human CVCL_RF84 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21107731 CVCL_RF85 STBCi315-A induced pluripotent stem cell human CVCL_RF85 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21107732 CVCL_RF86 STBCi316-A induced pluripotent stem cell human CVCL_RF86 From: StemBANCC; Oxford; United Kingdom CL:0000010 Discontinued: EBiSC; STBCi316-A; true. Unspecified 21107733 CVCL_RF87 STBCi317-A induced pluripotent stem cell human CVCL_RF87 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi317-A; true Unspecified 21107734 CVCL_RF88 STBCi318-A induced pluripotent stem cell human CVCL_RF88 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi318-A; true Unspecified 21107735 CVCL_RF89 STBCi319-A induced pluripotent stem cell human CVCL_RF89 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi319-A; true Unspecified 21107736 CVCL_RF70 STBCi300-A induced pluripotent stem cell human CVCL_RF70 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107737 CVCL_RF71 STBCi301-A induced pluripotent stem cell human CVCL_RF71 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107738 CVCL_RF72 STBCi302-A induced pluripotent stem cell human CVCL_RF72 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107739 CVCL_RF73 STBCi303-A induced pluripotent stem cell human CVCL_RF73 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107740 CVCL_RF74 STBCi304-A induced pluripotent stem cell human CVCL_RF74 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107741 CVCL_RF75 STBCi305-A induced pluripotent stem cell human CVCL_RF75 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107742 CVCL_RF76 STBCi306-A induced pluripotent stem cell human CVCL_RF76 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107743 CVCL_RF77 STBCi307-A induced pluripotent stem cell human CVCL_RF77 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107744 CVCL_RF78 STBCi308-A induced pluripotent stem cell human CVCL_RF78 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107745 CVCL_RF79 STBCi309-A induced pluripotent stem cell human CVCL_RF79 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107746 CVCL_RF60 STBCi290-A induced pluripotent stem cell human CVCL_RF60 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107747 CVCL_RF61 STBCi291-A induced pluripotent stem cell human CVCL_RF61 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107748 CVCL_RF62 STBCi292-A induced pluripotent stem cell human CVCL_RF62 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107749 CVCL_RF63 STBCi293-A induced pluripotent stem cell human CVCL_RF63 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107750 CVCL_RF64 STBCi294-A induced pluripotent stem cell human CVCL_RF64 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107751 CVCL_RF65 STBCi295-A induced pluripotent stem cell human CVCL_RF65 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107752 CVCL_RF66 STBCi296-A induced pluripotent stem cell human CVCL_RF66 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107753 CVCL_RF67 STBCi297-A induced pluripotent stem cell human CVCL_RF67 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107754 CVCL_RF68 STBCi298-A induced pluripotent stem cell human CVCL_RF68 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107755 CVCL_RF69 STBCi299-A induced pluripotent stem cell human CVCL_RF69 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107756 CVCL_RF50 STBCi280-A induced pluripotent stem cell human CVCL_RF50 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107757 CVCL_RF51 STBCi281-A induced pluripotent stem cell human CVCL_RF51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107758 CVCL_RF52 STBCi282-A induced pluripotent stem cell human CVCL_RF52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107759 CVCL_RF53 STBCi283-A induced pluripotent stem cell human CVCL_RF53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21107760 CVCL_RF54 STBCi284-A induced pluripotent stem cell human CVCL_RF54 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107761 CVCL_RF55 STBCi285-A induced pluripotent stem cell human CVCL_RF55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107762 CVCL_RF56 STBCi286-A induced pluripotent stem cell human CVCL_RF56 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21107763 CVCL_RF57 STBCi287-A induced pluripotent stem cell human CVCL_RF57 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21107764 CVCL_RF58 STBCi288-A induced pluripotent stem cell human CVCL_RF58 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107765 CVCL_RF59 STBCi289-A induced pluripotent stem cell human CVCL_RF59 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21107766 CVCL_A424 SW850 cancer cell line human CVCL_A424 From: Scott and White Clinic; Temple; USA CL:0000010 Omics: SNP array analysis. Male Part of: UBC-40 urothelial bladder cancer cell line index Problematic cell line: Possibly misidentified/contaminated Reported by PubMed=11787853 to contain the same HPV18 sequences as the cervix carcinoma cell line C-4-I (Cellosaurus=CVCL_2253) and to lack mutations in KRAS, TP53, CDKN2A and DPC4 often found in pancreatic adenocarcinoma. Considered by PubMed=25997541 to be a bladder carcinoma cell line. 21107767 CVCL_A425 KBM-3 cancer cell line human CVCL_A425 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=7627932) Derived from sampling site: Peripheral blood. Female Doubling time: 22.9 hours, at 255th passage (PubMed=1568450) 21107768 CVCL_A426 KBM-7 cancer cell line human CVCL_A426 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8609723; PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (PubMed=7627932; PubMed=24161985) Karyotypic information: Haploid except for a disomy of chromosome 8; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis Male Doubling time: 22 hours (PubMed=8609723) Group: Haploid karyotype cell line 21107769 CVCL_A427 HTh104 cancer cell line human CVCL_A427 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Pro16fs (c.46delC); Zygosity=Unspecified (PubMed=30737244); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ala (c.85C>G); Zygosity=Unspecified (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21107770 CVCL_A428 HTh112 cancer cell line human CVCL_A428 CL:0000010 Derived from sampling site: Thyroid gland. Male 21107771 CVCL_A429 CC-SW-1 cancer cell line human CVCL_A429 CL:0000010 Population: Caucasian; Derived from sampling site: Liver. Female Doubling time: 72 hours (PubMed=1355757) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107772 CVCL_7Y90 DA04604 transformed cell line human CVCL_7Y90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107773 CVCL_7Y91 DA04605 transformed cell line human CVCL_7Y91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107774 CVCL_7Y92 DA04606 transformed cell line human CVCL_7Y92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107775 CVCL_7Y93 DA04607 transformed cell line human CVCL_7Y93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107776 CVCL_A420 OUR-30 cancer cell line human CVCL_A420 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21107777 CVCL_A421 CAC-1 [Human endometrial adenocarcinoma] cancer cell line human CVCL_A421 CL:0000010 Derived from sampling site: Endometrium. Female 21107778 CVCL_A422 AG876 cancer cell line human CVCL_A422 CL:0000010 Population: African; Ghanaian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Virology: Contains a complete EBV genome (strain AG876) which has been sequenced (PubMed=16490228) Doubling time: 21 hours (PubMed=8402660) 21107779 CVCL_A423 EN-1078D cancer cell line human CVCL_A423 CL:0000010 Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ovary. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 14.3 hours (at 13th passage), 13.8 hours (at 23th passage) (PubMed=17894888) Part of: MD Anderson Cell Lines Project 21107780 CVCL_7Y87 DA04601 transformed cell line human CVCL_7Y87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107781 CVCL_7Y88 DA04602 transformed cell line human CVCL_7Y88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107782 CVCL_7Y89 DA04603 transformed cell line human CVCL_7Y89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107783 CVCL_7Y83 DA04595 transformed cell line human CVCL_7Y83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107784 CVCL_7Y84 DA04598 transformed cell line human CVCL_7Y84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107785 CVCL_7Y85 DA04599 transformed cell line human CVCL_7Y85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107786 CVCL_7Y86 DA04600 transformed cell line human CVCL_7Y86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107787 CVCL_A435 SK-MEL-93 DX-B transformed cell line human CVCL_A435 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107788 CVCL_A436 UHG-NP cancer cell line human CVCL_A436 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21107789 CVCL_A438 UT-MUC-1 cancer cell line human CVCL_A438 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8725545; PubMed=8782485) Derived from sampling site: Oral cavity; hard palate. Female Doubling time: 52 hours, at 9th passage (PubMed=1571132) 21107790 CVCL_A439 UT-MUC-2 cancer cell line human CVCL_A439 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Female 21107791 CVCL_A430 COLO 667 cancer cell line human CVCL_A430 CL:0000010 21107792 CVCL_A431 CTS cancer cell line human CVCL_A431 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (PubMed=8904886; PubMed=14671638) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 72 hours (PubMed=8904886); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21107793 CVCL_A432 SK-MEL-93 DX-4 cancer cell line human CVCL_A432 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Hypodermis. Female 21107794 CVCL_A433 SK-MEL-93 DX-5 cancer cell line human CVCL_A433 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Hypodermis. Female 21107795 CVCL_A434 SK-MEL-93 DX-6 cancer cell line human CVCL_A434 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Hypodermis. Female 21107796 CVCL_7Y98 DA04612 transformed cell line human CVCL_7Y98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107797 CVCL_7Y99 DA04613 transformed cell line human CVCL_7Y99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107798 CVCL_7Y94 DA04608 transformed cell line human CVCL_7Y94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107799 CVCL_7Y95 DA04609 transformed cell line human CVCL_7Y95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107800 CVCL_7Y96 DA04610 transformed cell line human CVCL_7Y96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107801 CVCL_7Y97 DA04611 transformed cell line human CVCL_7Y97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107802 CVCL_A402 OV167 cancer cell line human CVCL_A402 CL:0000010 Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray. Female Part of: MD Anderson Cell Lines Project 21107803 CVCL_A403 OV177 cancer cell line human CVCL_A403 CL:0000010 Omics: Genome sequenced. Female 21107804 CVCL_A404 OV207 cancer cell line human CVCL_A404 CL:0000010 Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays. Female Part of: MD Anderson Cell Lines Project 21107805 CVCL_A405 OV266 cancer cell line human CVCL_A405 CL:0000010 Female 21107806 CVCL_A406 ATL-1K cancer cell line human CVCL_A406 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21107807 CVCL_A407 ATL-2M cancer cell line human CVCL_A407 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21107808 CVCL_A408 ATL-3I cancer cell line human CVCL_A408 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21107809 CVCL_A409 ATL-4K cancer cell line human CVCL_A409 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21107810 CVCL_7Y70 DA04582 transformed cell line human CVCL_7Y70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107811 CVCL_7Y71 DA04583 transformed cell line human CVCL_7Y71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107812 CVCL_A400 OSC-40 cancer cell line human CVCL_A400 CL:0000010 Population: Japanese; Derived from metastatic site: Not specified. 21107813 CVCL_A401 OSC-70 cancer cell line human CVCL_A401 CL:0000010 Population: Japanese; Derived from metastatic site: Not specified. 21107814 CVCL_7Y65 DA04577 transformed cell line human CVCL_7Y65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107815 CVCL_7Y66 DA04578 transformed cell line human CVCL_7Y66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107816 CVCL_7Y67 DA04579 transformed cell line human CVCL_7Y67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107817 CVCL_7Y68 DA04580 transformed cell line human CVCL_7Y68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107818 CVCL_7Y61 DA04573 transformed cell line human CVCL_7Y61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107819 CVCL_7Y62 DA04574 transformed cell line human CVCL_7Y62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107820 CVCL_7Y63 DA04575 transformed cell line human CVCL_7Y63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107821 CVCL_7Y64 DA04576 transformed cell line human CVCL_7Y64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107822 CVCL_7Y69 DA04581 transformed cell line human CVCL_7Y69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107823 CVCL_A413 ATL-8K cancer cell line human CVCL_A413 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 21107824 CVCL_A414 ATL-9Y cancer cell line human CVCL_A414 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21107825 CVCL_A415 ATL-10Y cancer cell line human CVCL_A415 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21107826 CVCL_A416 OUR-10 cancer cell line human CVCL_A416 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: ~32 hours, at 50th passage (PubMed=40693) 21107827 CVCL_A417 OUR-20 cancer cell line human CVCL_A417 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Leufs*7 (c.1005dupA) (c.1005_1006insA); Zygosity=Unspecified (PubMed=11146448) Population: Japanese; Derived from sampling site: Kidney. Male 21107828 CVCL_A418 OUR-20P cancer cell line human CVCL_A418 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Leufs*7 (c.1005dupA) (c.1005_1006insA); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Kidney. Male 21107829 CVCL_A419 OUR-20S cancer cell line human CVCL_A419 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Leufs*7 (c.1005dupA) (c.1005_1006insA); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Kidney. Male 21107830 CVCL_7Y80 DA04592 transformed cell line human CVCL_7Y80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107831 CVCL_7Y81 DA04593 transformed cell line human CVCL_7Y81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107832 CVCL_7Y82 DA04594 transformed cell line human CVCL_7Y82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107833 CVCL_A410 ATL-5S cancer cell line human CVCL_A410 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21107834 CVCL_A411 ATL-6A cancer cell line human CVCL_A411 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 21107835 CVCL_A412 ATL-7S cancer cell line human CVCL_A412 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Lymph node Cell type=T-cell.. Male Characteristics: IL2 dependent 21107836 CVCL_7Y76 DA04588 transformed cell line human CVCL_7Y76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107837 CVCL_7Y77 DA04589 transformed cell line human CVCL_7Y77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107838 CVCL_7Y78 DA04590 transformed cell line human CVCL_7Y78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107839 CVCL_7Y79 DA04591 transformed cell line human CVCL_7Y79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107840 CVCL_7Y72 DA04584 transformed cell line human CVCL_7Y72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107841 CVCL_7Y73 DA04585 transformed cell line human CVCL_7Y73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107842 CVCL_7Y74 DA04586 transformed cell line human CVCL_7Y74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107843 CVCL_7Y75 DA04587 transformed cell line human CVCL_7Y75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107844 CVCL_7Y43 DA04553 transformed cell line human CVCL_7Y43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107845 CVCL_7Y44 DA04554 transformed cell line human CVCL_7Y44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107846 CVCL_7Y45 DA04555 transformed cell line human CVCL_7Y45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107847 CVCL_7Y46 DA04556 transformed cell line human CVCL_7Y46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107848 CVCL_7Y40 DA04550 transformed cell line human CVCL_7Y40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107849 CVCL_7Y41 DA04551 transformed cell line human CVCL_7Y41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107850 CVCL_7Y42 DA04552 transformed cell line human CVCL_7Y42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107851 CVCL_7Y47 DA04557 transformed cell line human CVCL_7Y47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107852 CVCL_7Y48 DA04558 transformed cell line human CVCL_7Y48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107853 CVCL_7Y49 DA04559 transformed cell line human CVCL_7Y49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107854 CVCL_7Y60 DA04572 transformed cell line human CVCL_7Y60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107855 CVCL_7Y54 DA04565 transformed cell line human CVCL_7Y54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107856 CVCL_7Y55 DA04567 transformed cell line human CVCL_7Y55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107857 CVCL_7Y56 DA04568 transformed cell line human CVCL_7Y56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107858 CVCL_7Y57 DA04569 transformed cell line human CVCL_7Y57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107859 CVCL_7Y50 DA04560 transformed cell line human CVCL_7Y50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107860 CVCL_7Y51 DA04561 transformed cell line human CVCL_7Y51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107861 CVCL_7Y52 DA04563 transformed cell line human CVCL_7Y52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107862 CVCL_7Y53 DA04564 transformed cell line human CVCL_7Y53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107863 CVCL_7Y58 DA04570 transformed cell line human CVCL_7Y58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107864 CVCL_7Y59 DA04571 transformed cell line human CVCL_7Y59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107865 CVCL_7Y21 DA04529 transformed cell line human CVCL_7Y21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107866 CVCL_7Y22 DA04530 transformed cell line human CVCL_7Y22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107867 CVCL_7Y23 DA04531 transformed cell line human CVCL_7Y23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107868 CVCL_7Y24 DA04532 transformed cell line human CVCL_7Y24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107869 CVCL_7Y20 DA04528 transformed cell line human CVCL_7Y20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107870 CVCL_7Y29 DA04537 transformed cell line human CVCL_7Y29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107871 CVCL_7Y25 DA04533 transformed cell line human CVCL_7Y25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107872 CVCL_7Y26 DA04534 transformed cell line human CVCL_7Y26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107873 CVCL_7Y27 DA04535 transformed cell line human CVCL_7Y27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107874 CVCL_7Y28 DA04536 transformed cell line human CVCL_7Y28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107875 CVCL_7Y32 DA04540 transformed cell line human CVCL_7Y32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107876 CVCL_7Y33 DA04541 transformed cell line human CVCL_7Y33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107877 CVCL_7Y34 DA04544 transformed cell line human CVCL_7Y34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107878 CVCL_7Y35 DA04545 transformed cell line human CVCL_7Y35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107879 CVCL_7Y30 DA04538 transformed cell line human CVCL_7Y30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107880 CVCL_7Y31 DA04539 transformed cell line human CVCL_7Y31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107881 CVCL_7Y36 DA04546 transformed cell line human CVCL_7Y36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107882 CVCL_7Y37 DA04547 transformed cell line human CVCL_7Y37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107883 CVCL_7Y38 DA04548 transformed cell line human CVCL_7Y38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107884 CVCL_7Y39 DA04549 transformed cell line human CVCL_7Y39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107885 CVCL_A383 HDC-142 cancer cell line human CVCL_A383 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21107886 CVCL_A384 HDC-143 cancer cell line human CVCL_A384 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21107887 CVCL_A385 HSC-39 cancer cell line human CVCL_A385 Genome ancestry: African=0.43%; Native American=0%; East Asian, North=78.69%; East Asian, South=18.67%; South Asian=0.72%; European, North=1.03%; European, South=0.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=11107048; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 28-30 hours (PubMed=1846312); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21107888 CVCL_A386 HSC-40A cancer cell line human CVCL_A386 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 28-30 hours (PubMed=1846312) 21107889 CVCL_A387 HSC-43 cancer cell line human CVCL_A387 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male Doubling time: ~55 hours (PubMed=8387462) Group: Serum/protein free medium cell line 21107890 CVCL_A388 HSC-44PE cancer cell line human CVCL_A388 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 24 hours (PubMed=15245593) 21107891 CVCL_A389 HSC-45 cancer cell line human CVCL_A389 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female 21107892 CVCL_IL17 ND00774 transformed cell line human CVCL_IL17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107893 CVCL_IL18 ND00814 transformed cell line human CVCL_IL18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107894 CVCL_IL19 ND00850 transformed cell line human CVCL_IL19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107895 CVCL_IL13 GM02715 finite cell line human CVCL_IL13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21107896 CVCL_IL14 GM02716 finite cell line human CVCL_IL14 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY (Coriell); Derived from sampling site: Testis; epididymis Cell type=Fibroblast.. Ambiguous 21107897 CVCL_A380 HDC-133 cancer cell line human CVCL_A380 CL:0000010 Derived from metastatic site: Liver. Female 21107898 CVCL_IL15 GM02717 finite cell line human CVCL_IL15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21107899 CVCL_A381 HDC-135 cancer cell line human CVCL_A381 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Female Microsatellite instability: Instable (MSI) (PubMed=25926053) 21107900 CVCL_A382 HDC-137 cancer cell line human CVCL_A382 CL:0000010 Female 21107901 CVCL_IL16 ND00641 transformed cell line human CVCL_IL16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107902 CVCL_IL10 GM02301 finite cell line human CVCL_IL10 CL:0000010 Population: African American; Derived from sampling site: Gonad Cell type=Fibroblast.. Ambiguous 21107903 CVCL_IL11 GM02682 finite cell line human CVCL_IL11 CL:0000010 Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Ambiguous 21107904 CVCL_IL12 GM02683 finite cell line human CVCL_IL12 CL:0000010 Population: African American; Derived from sampling site: Genital area; skin Cell type=Fibroblast.. Ambiguous 21107905 CVCL_A394 HKULC 3 cancer cell line human CVCL_A394 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Asn756_Leu760del; Zygosity=Unspecified (PubMed=17409975) Population: Chinese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: ~25 hours (PubMed=17409975) 21107906 CVCL_A395 HKULC 4 cancer cell line human CVCL_A395 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male Doubling time: 33.5 hours (PubMed=17409975) 21107907 CVCL_A396 WM1341B cancer cell line human CVCL_A396 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Heterozygous (from autologous cell line WM1341D) Derived from sampling site: Skin. Male Part of: Wistar Institute melanoma cell line collection 21107908 CVCL_A397 YCR-1 cancer cell line human CVCL_A397 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 26.5 hours (PubMed=3528602) 21107909 CVCL_A398 Tahr87 cancer cell line human CVCL_A398 CL:0000010 Male 21107910 CVCL_A399 OSC-30 cancer cell line human CVCL_A399 CL:0000010 Population: Japanese; Derived from metastatic site: Not specified. 21107911 CVCL_IL28 ND01193 transformed cell line human CVCL_IL28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107912 CVCL_IL29 ND01239 transformed cell line human CVCL_IL29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107913 CVCL_A390 HSC-45M2 cancer cell line human CVCL_A390 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 30 hours (PubMed=8242641) 21107914 CVCL_IL24 ND01146 transformed cell line human CVCL_IL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107915 CVCL_A391 HSC-58 cancer cell line human CVCL_A391 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 23 hours (PubMed=15245593) 21107916 CVCL_IL25 ND01167 transformed cell line human CVCL_IL25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107917 CVCL_A392 HKULC 1 cancer cell line human CVCL_A392 CL:0000010 Population: Chinese; Derived from metastatic site: Pericardial effusion. Omics: Transcriptome analysis by microarray Female Doubling time: ~25 hours (PubMed=17409975) 21107918 CVCL_IL26 ND01170 transformed cell line human CVCL_IL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107919 CVCL_A393 HKULC 2 cancer cell line human CVCL_A393 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Doubling time: ~25 hours (PubMed=17409975) 21107920 CVCL_IL27 ND01182 transformed cell line human CVCL_IL27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107921 CVCL_IL20 ND00854 transformed cell line human CVCL_IL20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21107922 CVCL_IL21 ND00973 transformed cell line human CVCL_IL21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107923 CVCL_IL22 ND01082 transformed cell line human CVCL_IL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107924 CVCL_IL23 ND01127 transformed cell line human CVCL_IL23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107925 CVCL_A369 HDC-87 cancer cell line human CVCL_A369 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 21107926 CVCL_A361 HDC-15 cancer cell line human CVCL_A361 CL:0000010 Derived from metastatic site: Liver. Female 21107927 CVCL_A362 HDC-54 cancer cell line human CVCL_A362 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21107928 CVCL_A363 HDC-57 cancer cell line human CVCL_A363 CL:0000010 Omics: Deep proteome analysis. Female 21107929 CVCL_A364 HDC-63 cancer cell line human CVCL_A364 CL:0000010 Derived from metastatic site: Liver. Male 21107930 CVCL_A365 HDC-73 cancer cell line human CVCL_A365 CL:0000010 Derived from metastatic site: Liver. Omics: Deep proteome analysis Male 21107931 CVCL_A366 HDC-75 cancer cell line human CVCL_A366 CL:0000010 Female 21107932 CVCL_A367 HDC-77 cancer cell line human CVCL_A367 CL:0000010 Male 21107933 CVCL_A368 HDC-82 cancer cell line human CVCL_A368 CL:0000010 Derived from metastatic site: Liver. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21107934 CVCL_A360 HDC-9 cancer cell line human CVCL_A360 CL:0000010 Derived from sampling site: Colon. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21107935 CVCL_A372 HDC-101 cancer cell line human CVCL_A372 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21107936 CVCL_A373 HDC-102 cancer cell line human CVCL_A373 CL:0000010 Derived from metastatic site: Lung. Male 21107937 CVCL_A374 HDC-108 cancer cell line human CVCL_A374 CL:0000010 Male 21107938 CVCL_A375 HDC-111 cancer cell line human CVCL_A375 CL:0000010 Omics: Deep proteome analysis. Female 21107939 CVCL_A376 HDC-114 cancer cell line human CVCL_A376 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21107940 CVCL_A377 HDC-117 cancer cell line human CVCL_A377 CL:0000010 Male 21107941 CVCL_A378 HDC-119 cancer cell line human CVCL_A378 CL:0000010 Female 21107942 CVCL_A379 HDC-120 cancer cell line human CVCL_A379 CL:0000010 Male 21107943 CVCL_IL06 GM00950 finite cell line human CVCL_IL06 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21107944 CVCL_IL07 GM00951 finite cell line human CVCL_IL07 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21107945 CVCL_IL08 GM02299 finite cell line human CVCL_IL08 CL:0000010 Population: African American; Derived from sampling site: Genital area; skin Cell type=Fibroblast.. Ambiguous 21107946 CVCL_IL09 GM02300 finite cell line human CVCL_IL09 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21107947 CVCL_IL02 S12 [Human iPSC] induced pluripotent stem cell human CVCL_IL02 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21107948 CVCL_IL03 NCI-N87/TR cancer cell line human CVCL_IL03 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from metastatic site: Liver. Male Characteristics: Parent cell line established from a nude mouse xenograft 21107949 CVCL_IL04 GM17822 transformed cell line human CVCL_IL04 CL:0000010 Sequence variation: Mutation; HGNC; 15894; PANK2; Simple; p.Phe311Profs*16 (c.927_933delTGTCTTT) (7-BP del); Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21107950 CVCL_A370 HDC-90 cancer cell line human CVCL_A370 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21107951 CVCL_IL05 GM00948 finite cell line human CVCL_IL05 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 21107952 CVCL_A371 HDC-97 cancer cell line human CVCL_A371 CL:0000010 Male 21107953 CVCL_IL00 OCUM-8/OXA cancer cell line human CVCL_IL00 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Ascites. Female 21107954 CVCL_IL01 S08 induced pluripotent stem cell human CVCL_IL01 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21107955 CVCL_A347 GCT 46 cancer cell line human CVCL_A347 CL:0000010 Derived from metastatic site: Lung. Male 21107956 CVCL_A348 GCT 48 cancer cell line human CVCL_A348 CL:0000010 Male 21107957 CVCL_A349 GCT 72 cancer cell line human CVCL_A349 CL:0000010 Male 21107958 CVCL_A340 WM3152 cancer cell line human CVCL_A340 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection. 21107959 CVCL_A341 WM1799 cancer cell line human CVCL_A341 HLA typing: A*26:01,26:01; B*38:01,44:02; C*12:03,12:03; DQA1*01:02,03:02; DQB1*03:02,06:11; DRB1*04:02,15:01 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0%; East Asian, North=4.29%; East Asian, South=0%; South Asian=2.08%; European, North=47.56%; European, South=45.7% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=15009714; DepMap; Wistar) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21107960 CVCL_A342 TSGH-8301 cancer cell line human CVCL_A342 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Miscellaneous: STR profile from personal communication of Chow N.-H Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Discontinued: BCRC; 60145; true Female Doubling time: 26 hours (PubMed=3352272) Problematic cell line: Contaminated Shown to be a ME-180 derivative (BCRC and STR profile). Originally thought to originate from a 56 year old male patient with a grade 2 stage A papillary transitional cell carcinoma. 21107961 CVCL_A343 HCDB-1 cancer cell line CVCL_A343 CL:0000010 Sequence variation: Mutation; UniProtKB; Q00366; TP53; Simple; p.Ala141Val (c.422T>C); Zygosity=Unspecified (PubMed=10943946) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032). Male Characteristics: Buccal pouch carcinoma cell line induced by DMBA and betel quid (BQ) Doubling time: 19 hours (PubMed=10943946) 21107962 CVCL_A344 GCT 27 cancer cell line human CVCL_A344 CL:0000010 Male Doubling time: ~35-40 hours (DSMZ=ACC-743). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107963 CVCL_A345 GCT 35 cancer cell line human CVCL_A345 CL:0000010 Male 21107964 CVCL_A346 GCT 44 cancer cell line human CVCL_A346 CL:0000010 Derived from metastatic site: Para-aortic lymph node. Male 21107965 CVCL_A358 HCE-8 cancer cell line human CVCL_A358 CL:0000010 Derived from sampling site: Esophagus. Male Doubling time: 66 hours (PubMed=2415247) 21107966 CVCL_A359 HDC-8 cancer cell line human CVCL_A359 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21107967 CVCL_A350 HCC2713 cancer cell line human CVCL_A350 CL:0000010 Female 21107968 CVCL_A351 HCC1588 cancer cell line human CVCL_A351 HLA typing: A*32:01,32:01; B*51:01,51:01; C*01:02,01:02; DRB1*11:101,13:07 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.886_910del25; Zygosity=Unspecified (PubMed=10353731) Population: African American; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21107969 CVCL_A352 HCC2108 cancer cell line human CVCL_A352 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*03:02,03:02; DQB1*03:04,03:04; DRB1*04:01,11:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (PubMed=10353731; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21107970 CVCL_A353 HCC2374 cancer cell line human CVCL_A353 CL:0000010 Population: African American Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Part of: MD Anderson Cell Lines Project 21107971 CVCL_A354 HCC970 cancer cell line human CVCL_A354 CL:0000010 Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male 21107972 CVCL_A355 HCE-3 cancer cell line human CVCL_A355 CL:0000010 Derived from sampling site: Esophagus. Male Doubling time: 33 hours (PubMed=2415247) 21107973 CVCL_A356 HCE-5 cancer cell line human CVCL_A356 CL:0000010 Derived from sampling site: Esophagus. Male Doubling time: 60 hours (PubMed=2415247) 21107974 CVCL_A357 HCE-6 cancer cell line human CVCL_A357 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (PubMed=2263646) Derived from sampling site: Esophagus. Male Doubling time: 27 hours (PubMed=2415247) 21107975 CVCL_A325 KOPN-32 cancer cell line human CVCL_A325 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Arg (c.733G>C); ClinVar=VCV000376604; Zygosity=Hemizygous (PubMed=8289498); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220fs (c.658delT); Zygosity=Unspecified (PubMed=20575032) Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified 21107976 CVCL_A326 KOPN-34 cancer cell line human CVCL_A326 CL:0000010 Population: Japanese. Unspecified 21107977 CVCL_A327 KOPN-35 cancer cell line human CVCL_A327 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu257Val (c.769C>G); ClinVar=VCV000827201; Zygosity=Hemizygous (PubMed=8289498; PubMed=20575032) Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified 21107978 CVCL_A328 KOPN-36 cancer cell line human CVCL_A328 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro219Ser (c.655C>T); ClinVar=VCV000245673; Zygosity=Unspecified (PubMed=20575032); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Unspecified Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526) 21107979 CVCL_A329 KOPN-54 cancer cell line human CVCL_A329 CL:0000010 Population: Japanese. 21107980 CVCL_8991 17a induced pluripotent stem cell human CVCL_8991 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21107981 CVCL_7X91 DA04499 transformed cell line human CVCL_7X91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107982 CVCL_8992 17b induced pluripotent stem cell human CVCL_8992 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21107983 CVCL_7X92 DA04500 transformed cell line human CVCL_7X92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107984 CVCL_8993 18a induced pluripotent stem cell human CVCL_8993 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female 21107985 CVCL_7X93 DA04501 transformed cell line human CVCL_7X93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107986 CVCL_8994 18b induced pluripotent stem cell human CVCL_8994 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21107987 CVCL_7X94 DA04502 transformed cell line human CVCL_7X94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107988 CVCL_A320 SUP-B6 transformed cell line human CVCL_A320 CL:0000010 21107989 CVCL_A321 SUP-B19 cancer cell line human CVCL_A321 CL:0000010 Population: Caucasian Female 21107990 CVCL_A322 SUP-B17 cancer cell line human CVCL_A322 CL:0000010 Derived from metastatic site: Ascites. Male 21107991 CVCL_A323 TS-2 cancer cell line human CVCL_A323 CL:0000010 Sequence variation: Gene fusion; HGNC; 2683; DAZAP1 + HGNC; 6997; MEF2D; Name(s)=MEF2D-DAZAP1 (PubMed=15182431; PubMed=15744350; PubMed=32504922) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21107992 CVCL_8990 15b induced pluripotent stem cell human CVCL_8990 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female 21107993 CVCL_A324 201B7 induced pluripotent stem cell human CVCL_A324 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; HPS0001; true Female Doubling time: 26.90 hours (PubMed=24399248) 21107994 CVCL_7X90 DA04498 transformed cell line human CVCL_7X90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107995 CVCL_8988 11b induced pluripotent stem cell human CVCL_8988 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21107996 CVCL_7X88 DA04496 transformed cell line human CVCL_7X88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107997 CVCL_8989 11c induced pluripotent stem cell human CVCL_8989 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21107998 CVCL_7X89 DA04497 transformed cell line human CVCL_7X89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21107999 CVCL_7X84 DA04492 transformed cell line human CVCL_7X84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108000 CVCL_8984 YB2/0 hybrid cell line Norway rat CVCL_8984 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Characteristics: Produced by fusing Y3-Ag1.2.3 with spleen cells from an AO strain rat (PubMed=6811596) Group: Hybridoma fusion partner cell line 21108001 CVCL_7X85 DA04493 transformed cell line human CVCL_7X85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108002 CVCL_8985 YN1/1.7.4 hybridoma Norway rat CVCL_8985 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13597; Mouse Icam1/Cd54. 21108003 CVCL_7X86 DA04494 transformed cell line human CVCL_7X86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108004 CVCL_8986 LNCaP-CR cancer cell line human CVCL_8986 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21108005 CVCL_8987 11a induced pluripotent stem cell human CVCL_8987 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male 21108006 CVCL_7X87 DA04495 transformed cell line human CVCL_7X87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108007 CVCL_A336 Py-4-1 cancer cell line house mouse CVCL_A336 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Breed/subspecies: Py-4 transgenic. Female 21108008 CVCL_A337 SK-CO-15 cancer cell line human CVCL_A337 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Male Caution: Beyotime seems to distribute a cell line under the designation 'SKCO-15' whose STR profile is 100% identical to that of the Caco-2 cell line and is thus contaminated MSKCC is in possession of original stocks and thus the STR profile shown in this entry is that of the original stock.. 21108009 CVCL_A338 WM983C cancer cell line human CVCL_A338 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21108010 CVCL_A339 WM1727A cancer cell line human CVCL_A339 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection 21108011 CVCL_A330 KOPN-60 cancer cell line human CVCL_A330 CL:0000010 Population: Japanese. 21108012 CVCL_A331 KOPN-61 cancer cell line human CVCL_A331 CL:0000010 Population: Japanese. Unspecified 21108013 CVCL_A332 KOPN-62 cancer cell line human CVCL_A332 CL:0000010 Population: Japanese. Unspecified 21108014 CVCL_A333 KOPN-63 cancer cell line human CVCL_A333 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209fs (c.627_632del6ins10); Zygosity=Hemizygous (PubMed=8289498); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly293fs (c.879_880insCC); Zygosity=Unspecified (PubMed=20575032) Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified 21108015 CVCL_A334 KOPN-79 cancer cell line human CVCL_A334 CL:0000010 Population: Japanese. 21108016 CVCL_A335 KOPN-84 cancer cell line human CVCL_A335 CL:0000010 Population: Japanese. 21108017 CVCL_8999 29a induced pluripotent stem cell human CVCL_8999 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21108018 CVCL_7X99 DA04507 transformed cell line human CVCL_7X99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108019 CVCL_8995 18c induced pluripotent stem cell human CVCL_8995 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female 21108020 CVCL_7X95 DA04503 transformed cell line human CVCL_7X95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108021 CVCL_8996 20b induced pluripotent stem cell human CVCL_8996 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male 21108022 CVCL_7X96 DA04504 transformed cell line human CVCL_7X96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108023 CVCL_8997 27b induced pluripotent stem cell human CVCL_8997 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Gly86Ser (c.256G>A) (G85S); ClinVar=VCV000932081; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21108024 CVCL_7X97 DA04505 transformed cell line human CVCL_7X97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108025 CVCL_8998 27e induced pluripotent stem cell human CVCL_8998 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Gly86Ser (c.256G>A) (G85S); ClinVar=VCV000932081; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21108026 CVCL_7X98 DA04506 transformed cell line human CVCL_7X98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108027 CVCL_RF40 STBCi270-A induced pluripotent stem cell human CVCL_RF40 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108028 CVCL_RF41 STBCi271-A induced pluripotent stem cell human CVCL_RF41 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108029 CVCL_RF42 STBCi272-A induced pluripotent stem cell human CVCL_RF42 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108030 CVCL_RF43 STBCi273-A induced pluripotent stem cell human CVCL_RF43 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108031 CVCL_RF44 STBCi274-A induced pluripotent stem cell human CVCL_RF44 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108032 CVCL_IL97 ND12799 transformed cell line human CVCL_IL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND12799; probable Female 21108033 CVCL_RF45 STBCi275-A induced pluripotent stem cell human CVCL_RF45 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108034 CVCL_IL98 ND12979 transformed cell line human CVCL_IL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND12979; probable Female 21108035 CVCL_RF46 STBCi276-A induced pluripotent stem cell human CVCL_RF46 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108036 CVCL_IL99 ND13076 transformed cell line human CVCL_IL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND13076; probable Female 21108037 CVCL_RF47 STBCi277-A induced pluripotent stem cell human CVCL_RF47 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108038 CVCL_RF48 STBCi278-A induced pluripotent stem cell human CVCL_RF48 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108039 CVCL_IL93 ND12174 transformed cell line human CVCL_IL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND12174; probable Female 21108040 CVCL_RF49 STBCi279-A induced pluripotent stem cell human CVCL_RF49 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108041 CVCL_IL94 ND12227 transformed cell line human CVCL_IL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND12227; probable Male 21108042 CVCL_IL95 ND12557 transformed cell line human CVCL_IL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108043 CVCL_IL96 ND12614 transformed cell line human CVCL_IL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108044 CVCL_RF30 STBCi260-A induced pluripotent stem cell human CVCL_RF30 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108045 CVCL_RF31 STBCi261-A induced pluripotent stem cell human CVCL_RF31 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108046 CVCL_RF32 STBCi262-A induced pluripotent stem cell human CVCL_RF32 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108047 CVCL_RF33 STBCi263-A induced pluripotent stem cell human CVCL_RF33 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108048 CVCL_RF34 STBCi264-A induced pluripotent stem cell human CVCL_RF34 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108049 CVCL_RF35 STBCi265-A induced pluripotent stem cell human CVCL_RF35 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108050 CVCL_RF36 STBCi266-A induced pluripotent stem cell human CVCL_RF36 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108051 CVCL_RF37 STBCi267-A induced pluripotent stem cell human CVCL_RF37 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108052 CVCL_RF38 STBCi268-A induced pluripotent stem cell human CVCL_RF38 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108053 CVCL_RF39 STBCi269-A induced pluripotent stem cell human CVCL_RF39 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Unspecified 21108054 CVCL_IL80 ND09569 transformed cell line human CVCL_IL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09569; probable Female 21108055 CVCL_IL81 ND09664 transformed cell line human CVCL_IL81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108056 CVCL_IL79 ND09566 transformed cell line human CVCL_IL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09566; probable Male 21108057 CVCL_RF20 STBCi250-A induced pluripotent stem cell human CVCL_RF20 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21108058 CVCL_RF21 STBCi251-A induced pluripotent stem cell human CVCL_RF21 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21108059 CVCL_RF22 STBCi252-A induced pluripotent stem cell human CVCL_RF22 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi252-A; true Male 21108060 CVCL_IL75 ND09367 transformed cell line human CVCL_IL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09367; probable Male 21108061 CVCL_RF23 STBCi253-A induced pluripotent stem cell human CVCL_RF23 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108062 CVCL_IL76 ND09391 transformed cell line human CVCL_IL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108063 CVCL_RF24 STBCi254-A induced pluripotent stem cell human CVCL_RF24 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108064 CVCL_IL77 ND09394 transformed cell line human CVCL_IL77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09394; probable Male 21108065 CVCL_RF25 STBCi255-A induced pluripotent stem cell human CVCL_RF25 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108066 CVCL_IL78 ND09524 transformed cell line human CVCL_IL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09524; probable Female 21108067 CVCL_RF26 STBCi256-A induced pluripotent stem cell human CVCL_RF26 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108068 CVCL_IL71 ND08500 transformed cell line human CVCL_IL71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08500; probable Male 21108069 CVCL_RF27 STBCi257-A induced pluripotent stem cell human CVCL_RF27 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108070 CVCL_IL72 ND08501 transformed cell line human CVCL_IL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08501; probable Male 21108071 CVCL_RF28 STBCi258-A induced pluripotent stem cell human CVCL_RF28 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108072 CVCL_IL73 ND08559 transformed cell line human CVCL_IL73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08559; probable Female 21108073 CVCL_RF29 STBCi259-A induced pluripotent stem cell human CVCL_RF29 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108074 CVCL_IL74 ND08963 transformed cell line human CVCL_IL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08963; probable Female 21108075 CVCL_RF09 STBCi239-A induced pluripotent stem cell human CVCL_RF09 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi239-A; true Female 21108076 CVCL_IL90 ND11093 transformed cell line human CVCL_IL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND11093; probable Male 21108077 CVCL_IL91 ND11759 transformed cell line human CVCL_IL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND11759; probable Female 21108078 CVCL_IL92 ND12071 transformed cell line human CVCL_IL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND12071; probable Female 21108079 CVCL_RF10 STBCi240-A induced pluripotent stem cell human CVCL_RF10 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi240-A; true Male 21108080 CVCL_RF11 STBCi241-A induced pluripotent stem cell human CVCL_RF11 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108081 CVCL_IL86 ND10908 transformed cell line human CVCL_IL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND10908; probable Male 21108082 CVCL_RF12 STBCi242-A induced pluripotent stem cell human CVCL_RF12 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi242-A; true Male 21108083 CVCL_IL87 ND10976 transformed cell line human CVCL_IL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND10976; probable Female 21108084 CVCL_RF13 STBCi243-A induced pluripotent stem cell human CVCL_RF13 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi243-A; true Male 21108085 CVCL_IL88 ND11063 transformed cell line human CVCL_IL88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND11063; probable Female 21108086 CVCL_RF14 STBCi244-A induced pluripotent stem cell human CVCL_RF14 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi244-A; true Male 21108087 CVCL_IL89 ND11079 transformed cell line human CVCL_IL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND11079; probable Female 21108088 CVCL_RF15 STBCi245-A induced pluripotent stem cell human CVCL_RF15 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi245-A; true Female 21108089 CVCL_IL82 ND09931 transformed cell line human CVCL_IL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108090 CVCL_RF16 STBCi246-A induced pluripotent stem cell human CVCL_RF16 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108091 CVCL_IL83 ND10222 transformed cell line human CVCL_IL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND10222; probable Female 21108092 CVCL_RF17 STBCi247-A induced pluripotent stem cell human CVCL_RF17 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi247-A; true Male 21108093 CVCL_IL84 ND10390 transformed cell line human CVCL_IL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND10390; probable Female 21108094 CVCL_RF18 STBCi248-A induced pluripotent stem cell human CVCL_RF18 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108095 CVCL_IL85 ND10902 transformed cell line human CVCL_IL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND10902; probable Male 21108096 CVCL_RF19 STBCi249-A induced pluripotent stem cell human CVCL_RF19 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108097 CVCL_IL57 ND06041 transformed cell line human CVCL_IL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108098 CVCL_IL58 ND06135 transformed cell line human CVCL_IL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108099 CVCL_IL59 ND06397 transformed cell line human CVCL_IL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND06397; probable Female 21108100 CVCL_RF00 STBCi230-A induced pluripotent stem cell human CVCL_RF00 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108101 CVCL_IL53 ND05825 transformed cell line human CVCL_IL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108102 CVCL_RF01 STBCi231-A induced pluripotent stem cell human CVCL_RF01 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108103 CVCL_IL54 ND05834 transformed cell line human CVCL_IL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108104 CVCL_RF02 STBCi232-A induced pluripotent stem cell human CVCL_RF02 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21108105 CVCL_IL55 ND05905 transformed cell line human CVCL_IL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND05905; probable Male 21108106 CVCL_RF03 STBCi233-A induced pluripotent stem cell human CVCL_RF03 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi233-A; true Female 21108107 CVCL_IL56 ND05999 transformed cell line human CVCL_IL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108108 CVCL_RF04 STBCi234-A induced pluripotent stem cell human CVCL_RF04 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108109 CVCL_RF05 STBCi235-A induced pluripotent stem cell human CVCL_RF05 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108110 CVCL_IL50 ND05314 transformed cell line human CVCL_IL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108111 CVCL_RF06 STBCi236-A induced pluripotent stem cell human CVCL_RF06 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108112 CVCL_IL51 ND05367 transformed cell line human CVCL_IL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND05367; probable Female 21108113 CVCL_RF07 STBCi237-A induced pluripotent stem cell human CVCL_RF07 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108114 CVCL_IL52 ND05626 transformed cell line human CVCL_IL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND05626; probable Female 21108115 CVCL_RF08 STBCi238-A induced pluripotent stem cell human CVCL_RF08 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21108116 CVCL_IL70 ND08406 transformed cell line human CVCL_IL70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08406; probable Female 21108117 CVCL_IL68 ND08231 transformed cell line human CVCL_IL68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08231; probable Male 21108118 CVCL_IL69 ND08307 transformed cell line human CVCL_IL69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND08307; probable Male 21108119 CVCL_IL64 ND06999 transformed cell line human CVCL_IL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108120 CVCL_IL65 ND07190 transformed cell line human CVCL_IL65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108121 CVCL_IL66 ND07501 transformed cell line human CVCL_IL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108122 CVCL_IL67 ND07685 transformed cell line human CVCL_IL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND07685; probable Male 21108123 CVCL_IL60 ND06571 transformed cell line human CVCL_IL60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108124 CVCL_IL61 ND06658 transformed cell line human CVCL_IL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108125 CVCL_IL62 ND06905 transformed cell line human CVCL_IL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108126 CVCL_IL63 ND06938 transformed cell line human CVCL_IL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108127 CVCL_IL39 ND02692 transformed cell line human CVCL_IL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND02692; probable Female 21108128 CVCL_IL35 ND02323 transformed cell line human CVCL_IL35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND02323; probable Male 21108129 CVCL_IL36 ND02331 transformed cell line human CVCL_IL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND02331; probable Male 21108130 CVCL_IL37 ND02409 transformed cell line human CVCL_IL37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108131 CVCL_IL38 ND02468 transformed cell line human CVCL_IL38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108132 CVCL_IL31 ND01382 transformed cell line human CVCL_IL31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108133 CVCL_IL32 ND01418 transformed cell line human CVCL_IL32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108134 CVCL_IL33 ND01645 transformed cell line human CVCL_IL33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108135 CVCL_IL34 ND02169 transformed cell line human CVCL_IL34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108136 CVCL_IL30 ND01263 transformed cell line human CVCL_IL30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108137 CVCL_IL46 ND03883 transformed cell line human CVCL_IL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108138 CVCL_IL47 ND04215 transformed cell line human CVCL_IL47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND04215; probable Female 21108139 CVCL_IL48 ND04510 transformed cell line human CVCL_IL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND04510; probable Female 21108140 CVCL_IL49 ND04849 transformed cell line human CVCL_IL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108141 CVCL_IL42 ND03293 transformed cell line human CVCL_IL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND03293; probable Female 21108142 CVCL_IL43 ND03323 transformed cell line human CVCL_IL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108143 CVCL_IL44 ND03442 transformed cell line human CVCL_IL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND03442; probable Female 21108144 CVCL_IL45 ND03810 transformed cell line human CVCL_IL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108145 CVCL_IL40 ND03237 transformed cell line human CVCL_IL40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108146 CVCL_IL41 ND03279 transformed cell line human CVCL_IL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND03279; probable Female 21108147 CVCL_IE41 ND11593 transformed cell line human CVCL_IE41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108148 CVCL_IE42 ND11643 transformed cell line human CVCL_IE42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108149 CVCL_IE43 ND11748 transformed cell line human CVCL_IE43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108150 CVCL_IE44 ND11763 transformed cell line human CVCL_IE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108151 CVCL_IE40 ND11567 transformed cell line human CVCL_IE40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108152 CVCL_IE38 ND11527 transformed cell line human CVCL_IE38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108153 CVCL_IE39 ND11529 transformed cell line human CVCL_IE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108154 CVCL_IE34 ND11230 transformed cell line human CVCL_IE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108155 CVCL_IE35 ND11232 transformed cell line human CVCL_IE35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108156 CVCL_IE36 ND11247 transformed cell line human CVCL_IE36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108157 CVCL_IE37 ND11425 transformed cell line human CVCL_IE37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108158 CVCL_IE52 ND12637 transformed cell line human CVCL_IE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108159 CVCL_IE53 ND12878 transformed cell line human CVCL_IE53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108160 CVCL_IE54 ND12885 transformed cell line human CVCL_IE54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108161 CVCL_IE55 ND12886 transformed cell line human CVCL_IE55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108162 CVCL_IE50 ND12459 transformed cell line human CVCL_IE50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108163 CVCL_IE51 ND12507 transformed cell line human CVCL_IE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108164 CVCL_IE49 ND12457 transformed cell line human CVCL_IE49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108165 CVCL_IE45 ND11884 transformed cell line human CVCL_IE45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108166 CVCL_IE46 ND12223 transformed cell line human CVCL_IE46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108167 CVCL_IE47 ND12439 transformed cell line human CVCL_IE47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108168 CVCL_IE48 ND12456 transformed cell line human CVCL_IE48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108169 CVCL_IE20 ND11029 transformed cell line human CVCL_IE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108170 CVCL_IE21 ND11049 transformed cell line human CVCL_IE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108171 CVCL_IE22 ND11112 transformed cell line human CVCL_IE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108172 CVCL_IE16 ND11014 transformed cell line human CVCL_IE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108173 CVCL_IE17 ND11015 transformed cell line human CVCL_IE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108174 CVCL_IE18 ND11022 transformed cell line human CVCL_IE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108175 CVCL_IE19 ND11024 transformed cell line human CVCL_IE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108176 CVCL_IE12 ND10917 transformed cell line human CVCL_IE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108177 CVCL_IE13 ND10920 transformed cell line human CVCL_IE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108178 CVCL_IE14 ND10961 transformed cell line human CVCL_IE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108179 CVCL_IE15 ND11012 transformed cell line human CVCL_IE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108180 CVCL_IE30 ND11198 transformed cell line human CVCL_IE30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108181 CVCL_IE31 ND11204 transformed cell line human CVCL_IE31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108182 CVCL_IE32 ND11205 transformed cell line human CVCL_IE32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108183 CVCL_IE33 ND11228 transformed cell line human CVCL_IE33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108184 CVCL_IE27 ND11162 transformed cell line human CVCL_IE27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108185 CVCL_IE28 ND11163 transformed cell line human CVCL_IE28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108186 CVCL_IE29 ND11165 transformed cell line human CVCL_IE29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108187 CVCL_IE23 ND11130 transformed cell line human CVCL_IE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108188 CVCL_IE24 ND11141 transformed cell line human CVCL_IE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108189 CVCL_IE25 ND11145 transformed cell line human CVCL_IE25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108190 CVCL_IE26 ND11146 transformed cell line human CVCL_IE26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108191 CVCL_IE00 ND10684 transformed cell line human CVCL_IE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108192 CVCL_IE10 ND10892 transformed cell line human CVCL_IE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108193 CVCL_IE11 ND10894 transformed cell line human CVCL_IE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108194 CVCL_IE09 ND10865 transformed cell line human CVCL_IE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108195 CVCL_IE05 ND10787 transformed cell line human CVCL_IE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108196 CVCL_IE06 ND10788 transformed cell line human CVCL_IE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108197 CVCL_IE07 ND10796 transformed cell line human CVCL_IE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108198 CVCL_IE08 ND10814 transformed cell line human CVCL_IE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108199 CVCL_IE01 ND10715 transformed cell line human CVCL_IE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108200 CVCL_IE02 ND10726 transformed cell line human CVCL_IE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108201 CVCL_IE03 ND10753 transformed cell line human CVCL_IE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108202 CVCL_IE04 ND10786 transformed cell line human CVCL_IE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108203 CVCL_IE85 ND13564 transformed cell line human CVCL_IE85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108204 CVCL_IE86 ND13565 transformed cell line human CVCL_IE86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108205 CVCL_IE87 ND13578 transformed cell line human CVCL_IE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108206 CVCL_IE88 ND13611 transformed cell line human CVCL_IE88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108207 CVCL_IE81 ND13493 transformed cell line human CVCL_IE81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108208 CVCL_IE82 ND13561 transformed cell line human CVCL_IE82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108209 CVCL_IE83 ND13562 transformed cell line human CVCL_IE83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108210 CVCL_IE84 ND13563 transformed cell line human CVCL_IE84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108211 CVCL_IE80 ND13492 transformed cell line human CVCL_IE80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108212 CVCL_IE78 ND13455 transformed cell line human CVCL_IE78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108213 CVCL_IE79 ND13491 transformed cell line human CVCL_IE79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108214 CVCL_IE96 ND13857 transformed cell line human CVCL_IE96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108215 CVCL_IE97 ND13872 transformed cell line human CVCL_IE97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108216 CVCL_IE98 ND14133 transformed cell line human CVCL_IE98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108217 CVCL_IE99 ND14158 transformed cell line human CVCL_IE99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108218 CVCL_IE92 ND13722 transformed cell line human CVCL_IE92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108219 CVCL_IE93 ND13724 transformed cell line human CVCL_IE93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108220 CVCL_IE94 ND13742 transformed cell line human CVCL_IE94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108221 CVCL_IE95 ND13824 transformed cell line human CVCL_IE95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108222 CVCL_IE90 ND13651 transformed cell line human CVCL_IE90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108223 CVCL_IE91 ND13652 transformed cell line human CVCL_IE91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108224 CVCL_IE89 ND13613 transformed cell line human CVCL_IE89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108225 CVCL_IE63 ND13131 transformed cell line human CVCL_IE63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108226 CVCL_IE64 ND13132 transformed cell line human CVCL_IE64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108227 CVCL_IE65 ND13133 transformed cell line human CVCL_IE65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108228 CVCL_IE66 ND13189 transformed cell line human CVCL_IE66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108229 CVCL_IE60 ND13022 transformed cell line human CVCL_IE60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108230 CVCL_IE61 ND13029 transformed cell line human CVCL_IE61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108231 CVCL_IE62 ND13091 transformed cell line human CVCL_IE62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108232 CVCL_IE56 ND12921 transformed cell line human CVCL_IE56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108233 CVCL_IE57 ND12925 transformed cell line human CVCL_IE57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108234 CVCL_IE58 ND12926 transformed cell line human CVCL_IE58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108235 CVCL_IE59 ND13008 transformed cell line human CVCL_IE59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108236 CVCL_IE74 ND13371 transformed cell line human CVCL_IE74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108237 CVCL_IE75 ND13398 transformed cell line human CVCL_IE75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108238 CVCL_IE76 ND13425 transformed cell line human CVCL_IE76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108239 CVCL_IE77 ND13426 transformed cell line human CVCL_IE77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108240 CVCL_IE70 ND13280 transformed cell line human CVCL_IE70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108241 CVCL_IE71 ND13296 transformed cell line human CVCL_IE71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108242 CVCL_IE72 ND13316 transformed cell line human CVCL_IE72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108243 CVCL_IE73 ND13317 transformed cell line human CVCL_IE73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108244 CVCL_IE67 ND13225 transformed cell line human CVCL_IE67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108245 CVCL_IE68 ND13246 transformed cell line human CVCL_IE68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108246 CVCL_IE69 ND13276 transformed cell line human CVCL_IE69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108247 CVCL_7Q10 DA03636 transformed cell line human CVCL_7Q10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108248 CVCL_8210 GLC-26 cancer cell line human CVCL_8210 CL:0000010 21108249 CVCL_7Q11 DA03637 transformed cell line human CVCL_7Q11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108250 CVCL_8211 GLC-28 cancer cell line human CVCL_8211 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=10408787). 21108251 CVCL_7Q12 DA03638 transformed cell line human CVCL_7Q12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108252 CVCL_8212 GLC-3 cancer cell line human CVCL_8212 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (PubMed=10408787) Derived from metastatic site: Pleural effusion. Male Doubling time: 56 hours (PubMed=2998591) 21108253 CVCL_7Q13 DA03639 transformed cell line human CVCL_7Q13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108254 CVCL_8213 GLC-33 cancer cell line human CVCL_8213 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Female 21108255 CVCL_7Q07 DA03633 transformed cell line human CVCL_7Q07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108256 CVCL_8207 GLC-2 cancer cell line human CVCL_8207 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex8del14; Zygosity=Unspecified (PubMed=10408787) Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Male Doubling time: 37 hours (PubMed=2998591) 21108257 CVCL_7Q08 DA03634 transformed cell line human CVCL_7Q08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108258 CVCL_8208 GLC-20 cancer cell line human CVCL_8208 CL:0000010 Male 21108259 CVCL_7Q09 DA03635 transformed cell line human CVCL_7Q09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108260 CVCL_8209 GLC-22 cancer cell line human CVCL_8209 CL:0000010 Male 21108261 CVCL_7Q03 DA03629 transformed cell line human CVCL_7Q03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108262 CVCL_8203 GLC-12 cancer cell line human CVCL_8203 CL:0000010 Derived from metastatic site: Lymph node. Male 21108263 CVCL_7Q04 DA03630 transformed cell line human CVCL_7Q04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108264 CVCL_8204 GLC-14 cancer cell line human CVCL_8204 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=10408787) Derived from metastatic site: Supraclavicular lymph node. Omics: Array-based CGH; Omics: SNP array analysis Female Doubling time: 65 hours (PubMed=2846164) 21108265 CVCL_7Q05 DA03631 transformed cell line human CVCL_7Q05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108266 CVCL_8205 GLC-16 cancer cell line human CVCL_8205 CL:0000010 Female Doubling time: 40 hours (PubMed=2846164). 21108267 CVCL_7Q06 DA03632 transformed cell line human CVCL_7Q06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108268 CVCL_8206 GLC-19 cancer cell line human CVCL_8206 CL:0000010 Female Doubling time: 40 hours (PubMed=2846164). 21108269 CVCL_7Q21 DA03647 transformed cell line human CVCL_7Q21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108270 CVCL_7Q22 DA03648 transformed cell line human CVCL_7Q22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108271 CVCL_7Q23 DA03649 transformed cell line human CVCL_7Q23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108272 CVCL_8223 hAG cancer cell line human CVCL_8223 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00124 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=10508494; PubMed=20143388). 21108273 CVCL_7Q24 DA03650 transformed cell line human CVCL_7Q24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108274 CVCL_8224 hPTC undefined cell line type pig CVCL_8224 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00127. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from pig (PubMed=10508494; PubMed=20143388). 21108275 CVCL_7Q20 DA03646 transformed cell line human CVCL_7Q20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108276 CVCL_7Q18 DA03644 transformed cell line human CVCL_7Q18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108277 CVCL_8218 GLC-8 cancer cell line human CVCL_8218 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Gly (c.838A>G); ClinVar=VCV000376658; Zygosity=Unspecified (PubMed=10408787) Omics: Array-based CGH; Omics: SNP array analysis. 21108278 CVCL_7Q19 DA03645 transformed cell line human CVCL_7Q19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108279 CVCL_7Q14 DA03640 transformed cell line human CVCL_7Q14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108280 CVCL_8214 GLC-34 cancer cell line human CVCL_8214 CL:0000010 21108281 CVCL_7Q15 DA03641 transformed cell line human CVCL_7Q15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108282 CVCL_8215 GLC-36 cancer cell line human CVCL_8215 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Unspecified (PubMed=10408787) Omics: SNP array analysis. Female 21108283 CVCL_7Q16 DA03642 transformed cell line human CVCL_7Q16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108284 CVCL_8216 GLC-42 cancer cell line human CVCL_8216 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile332Serfs*13 (c.994delA); Zygosity=Unspecified (PubMed=10408787). 21108285 CVCL_7Q17 DA03643 transformed cell line human CVCL_7Q17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108286 CVCL_8217 GLC-7 cancer cell line human CVCL_8217 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Pro (c.431A>C); ClinVar=VCV000186594; Zygosity=Unspecified (PubMed=10408787). 21108287 CVCL_7Q00 DA03626 transformed cell line human CVCL_7Q00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108288 CVCL_8200 GLC-1 cancer cell line human CVCL_8200 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis Male Doubling time: 21 hours (PubMed=2998591) 21108289 CVCL_7Q01 DA03627 transformed cell line human CVCL_7Q01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108290 CVCL_8201 GLC-1-M13 cancer cell line human CVCL_8201 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Proteome analysis by 2D-DE/MS Male Doubling time: 42 hours (PubMed=2998591) 21108291 CVCL_7Q02 DA03628 transformed cell line human CVCL_7Q02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108292 CVCL_8202 GLC-11 cancer cell line human CVCL_8202 CL:0000010 21108293 CVCL_8290 CoLo-TC cancer cell line human CVCL_8290 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Discontinued: RCB; RCB1984; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00300 Problematic cell line: Contaminated Shown to be a COLO 205 derivative (PubMed=20143388). 21108294 CVCL_7Q90 DA03719 transformed cell line human CVCL_7Q90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108295 CVCL_7Q91 DA03720 transformed cell line human CVCL_7Q91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108296 CVCL_8291 Subclone 707 DK 4.8 cancer cell line house mouse CVCL_8291 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112119; probable 21108297 CVCL_7Q92 DA03721 transformed cell line human CVCL_7Q92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108298 CVCL_8292 Subclone 707 DKA cancer cell line house mouse CVCL_8292 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112117; probable 21108299 CVCL_7Q93 DA03722 transformed cell line human CVCL_7Q93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108300 CVCL_8293 Subclone 707 DKE cancer cell line house mouse CVCL_8293 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112132; probable 21108301 CVCL_8298 B16-A cancer cell line house mouse CVCL_8298 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21108302 CVCL_7Q98 DA03728 transformed cell line human CVCL_7Q98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108303 CVCL_8299 B16-B cancer cell line house mouse CVCL_8299 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21108304 CVCL_7Q99 DA03729 transformed cell line human CVCL_7Q99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108305 CVCL_7Q94 DA03723 transformed cell line human CVCL_7Q94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108306 CVCL_8294 Subclone 707 DKH cancer cell line house mouse CVCL_8294 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112131; probable 21108307 CVCL_7Q95 DA03725 transformed cell line human CVCL_7Q95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108308 CVCL_8295 Subclone 707 DKJ cancer cell line house mouse CVCL_8295 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112118; probable 21108309 CVCL_7Q96 DA03726 transformed cell line human CVCL_7Q96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108310 CVCL_8296 Subclone 707 TG1 cancer cell line house mouse CVCL_8296 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112127; probable 21108311 CVCL_7Q97 DA03727 transformed cell line human CVCL_7Q97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108312 CVCL_8297 Subclone 707 TG2 cancer cell line house mouse CVCL_8297 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Discontinued: ECACC; 91112128; probable 21108313 CVCL_7Q70 DA03699 transformed cell line human CVCL_7Q70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108314 CVCL_8270 PBEI cancer cell line human CVCL_8270 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00152 Problematic cell line: Contaminated Shown to be a NALM-6 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21108315 CVCL_7Q71 DA03700 transformed cell line human CVCL_7Q71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108316 CVCL_8271 RAMAK-1 cancer cell line human CVCL_8271 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00154 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=10508494; PubMed=20143388). 21108317 CVCL_7Q76 DA03705 transformed cell line human CVCL_7Q76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108318 CVCL_8276 UTMB-460 cancer cell line human CVCL_8276 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00283 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12592342; PubMed=20143388). 21108319 CVCL_7Q77 DA03706 transformed cell line human CVCL_7Q77 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108320 CVCL_8277 X50-7 transformed cell line human CVCL_8277 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. 21108321 CVCL_7Q78 DA03707 transformed cell line human CVCL_7Q78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108322 CVCL_8278 IHH-A5 transformed cell line human CVCL_8278 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21108323 CVCL_7Q79 DA03708 transformed cell line human CVCL_7Q79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108324 CVCL_8279 J1.1 cancer cell line human CVCL_8279 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with HIV-1 The two main sites of integrations are in genes DEAF1 and CBX5 (PubMed=28086908). 21108325 CVCL_7Q72 DA03701 transformed cell line human CVCL_7Q72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108326 CVCL_8272 RL-19 spontaneously immortalized cell line Norway rat CVCL_8272 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21108327 CVCL_7Q73 DA03702 transformed cell line human CVCL_7Q73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108328 CVCL_8273 SQ-5 cancer cell line human CVCL_8273 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0110; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00269 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from a lung carcinoma. 21108329 CVCL_7Q74 DA03703 transformed cell line human CVCL_7Q74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108330 CVCL_8274 TF [Scophthalmus fin China] spontaneously immortalized cell line CVCL_8274 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line Caution: There are two turbot fin cell lines that were established and that were given the same name, TF, one by UK group in the 1980's (Cellosaurus=CVCL_A3AZ) and one from a Chines lab in 2010 (Cellosaurus=CVCL_8274) 21108331 CVCL_7Q75 DA03704 transformed cell line human CVCL_7Q75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108332 CVCL_8275 TuWi cancer cell line human CVCL_8275 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-31; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00028 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=566722; PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from a Wilms tumor. 21108333 CVCL_7Q69 DA03698 transformed cell line human CVCL_7Q69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108334 CVCL_8269 NK m-1 finite cell line human CVCL_8269 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Unspecified 21108335 CVCL_7Q80 DA03709 transformed cell line human CVCL_7Q80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108336 CVCL_8280 J-Lat 6.3 cancer cell line human CVCL_8280 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21108337 CVCL_7Q81 DA03710 transformed cell line human CVCL_7Q81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108338 CVCL_8281 J-Lat 10.6 cancer cell line human CVCL_8281 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with HIV-1 strain R7/E-/GFP The integrated HIV-1 genome is located in SEC16A 2nd intron (PubMed=28086908; PubMed=32354973). 21108339 CVCL_7Q82 DA03711 transformed cell line human CVCL_7Q82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108340 CVCL_8282 J-Lat 15.4 cancer cell line human CVCL_8282 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with HIV-1 strain R7/E-/GFP The integrated HIV-1 genome is located in UBA2 6th intron (PubMed=18692772; PubMed=28086908). 21108341 CVCL_7Q87 DA03716 transformed cell line human CVCL_7Q87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108342 CVCL_7Q88 DA03717 transformed cell line human CVCL_7Q88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108343 CVCL_8288 MUTZ-11 cancer cell line human CVCL_8288 CL:0000010 Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668) Derived from sampling site: Peripheral blood. Female Doubling time: 64-98 hours (PubMed=15068904) 21108344 CVCL_7Q89 DA03718 transformed cell line human CVCL_7Q89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108345 CVCL_8289 T3M-1 cancer cell line human CVCL_8289 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: ~17 hours (PubMed=308840) 21108346 CVCL_7Q83 DA03712 transformed cell line human CVCL_7Q83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108347 CVCL_8283 HuKo39 cancer cell line human CVCL_8283 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00066 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). 21108348 CVCL_7Q84 DA03713 transformed cell line human CVCL_7Q84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108349 CVCL_8284 J-Lat 8.4 cancer cell line human CVCL_8284 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with HIV-1 strain R7/E-/GFP The integrated HIV-1 genome is located in FUBP1 (PubMed=28086908). 21108350 CVCL_7Q85 DA03714 transformed cell line human CVCL_7Q85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108351 CVCL_8285 J-Lat 9.2 cancer cell line human CVCL_8285 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with HIV-1 strain R7/E-/GFP The integrated HIV-1 genome is located in PP5 4th intron (PubMed=18692772; PubMed=26912621; PubMed=28086908). 21108352 CVCL_8286 AML14 [Human leukemia] cancer cell line human CVCL_8286 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: Can be induced to eosinophilic differentiation with CSF2, IL3 and IL5 (Kerafast) Doubling time: 24-36 hours (PubMed=8443379) 21108353 CVCL_7Q86 DA03715 transformed cell line human CVCL_7Q86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108354 CVCL_7Q54 DA03683 transformed cell line human CVCL_7Q54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108355 CVCL_8254 KK47/ADM cancer cell line human CVCL_8254 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Urinary bladder. Male Doubling time: 30 hours (PubMed=1353119) 21108356 CVCL_7Q55 DA03684 transformed cell line human CVCL_7Q55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108357 CVCL_8255 KK47/DDP10 cancer cell line human CVCL_8255 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Male 21108358 CVCL_7Q56 DA03685 transformed cell line human CVCL_7Q56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108359 CVCL_8256 KK47/DDP20 cancer cell line human CVCL_8256 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Male 21108360 CVCL_7Q57 DA03686 transformed cell line human CVCL_7Q57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108361 CVCL_8257 KLM-2 transformed cell line human CVCL_8257 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108362 CVCL_7Q50 DA03679 transformed cell line human CVCL_7Q50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108363 CVCL_8250 JOV675 cancer cell line human CVCL_8250 CL:0000010 Female 21108364 CVCL_7Q51 DA03680 transformed cell line human CVCL_7Q51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108365 CVCL_8251 K-1034 spontaneously immortalized cell line human CVCL_8251 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Male 21108366 CVCL_7Q52 DA03681 transformed cell line human CVCL_7Q52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108367 CVCL_8252 KJ29 cancer cell line human CVCL_8252 CL:0000010 Derived from sampling site: Kidney. Male 21108368 CVCL_7Q53 DA03682 transformed cell line human CVCL_7Q53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108369 CVCL_8253 KK47 cancer cell line human CVCL_8253 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 23.5 hours (PubMed=470258); 27 hours (PubMed=1353119) Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21108370 CVCL_7Q47 DA03676 transformed cell line human CVCL_7Q47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108371 CVCL_8247 IMC-4 cancer cell line human CVCL_8247 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0728; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00319 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to originate from a male patient (from which IMC-2 and IMC-3 were also supposed to be derived) with maxillary carcinoma. 21108372 CVCL_7Q48 DA03677 transformed cell line human CVCL_7Q48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108373 CVCL_8248 Josh 4 transformed cell line human CVCL_8248 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21108374 CVCL_7Q49 DA03678 transformed cell line human CVCL_7Q49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108375 CVCL_8249 Josh 7 transformed cell line human CVCL_8249 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21108376 CVCL_7Q60 DA03689 transformed cell line human CVCL_7Q60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108377 CVCL_8260 LR10.6 cancer cell line human CVCL_8260 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00141 Problematic cell line: Contaminated Shown to be a NALM-6 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21108378 CVCL_7Q65 DA03694 transformed cell line human CVCL_7Q65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108379 CVCL_8265 MKB-1 cancer cell line human CVCL_8265 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Microsatellite instability: Instable (MSI) (PubMed=10739008) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00146 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). Originally thought to originate from a 17 year old female patient with acute myeloblastic leukemia. 21108380 CVCL_7Q66 DA03695 transformed cell line human CVCL_7Q66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108381 CVCL_8266 Naliaka cancer cell line human CVCL_8266 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21108382 CVCL_7Q67 DA03696 transformed cell line human CVCL_7Q67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108383 CVCL_8267 NK 62 finite cell line human CVCL_8267 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Unspecified 21108384 CVCL_7Q68 DA03697 transformed cell line human CVCL_7Q68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108385 CVCL_8268 NK 70 finite cell line human CVCL_8268 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Unspecified 21108386 CVCL_7Q61 DA03690 transformed cell line human CVCL_7Q61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108387 CVCL_8261 MA-160 cancer cell line human CVCL_8261 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00026 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=66218; PubMed=93571; PubMed=1246601; PubMed=4469665; PubMed=6451928; PubMed=20143388). Originally thought to originate from a benign prostatic hyperplasia biopsy from Monroe Vincent one of the authors of the original paper. 21108388 CVCL_7Q62 DA03691 transformed cell line human CVCL_7Q62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108389 CVCL_8262 SCLC-24H cancer cell line human CVCL_8262 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Male Doubling time: 70-75 hours, depending on growth medium (PubMed=3029138) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00159 Problematic cell line: Contaminated Shown to be a SCLC-21H (or SCLC-22H) derivative (PubMed=10508494; PubMed=20143388). 21108390 CVCL_7Q63 DA03692 transformed cell line human CVCL_7Q63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108391 CVCL_8263 SCLC-86M1 cancer cell line human CVCL_8263 CL:0000010 Derived from metastatic site: Pleural effusion. Female Characteristics: Established from a first passage xenograft maintained in nude mice Doubling time: 70 hours (PubMed=2438285) 21108392 CVCL_7Q64 DA03693 transformed cell line human CVCL_7Q64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108393 CVCL_8264 Minnesota EE cancer cell line human CVCL_8264 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-4; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00011 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from the esophageal epithelium of a male infant with a tracheo-esophageal fistula. 21108394 CVCL_7Q58 DA03687 transformed cell line human CVCL_7Q58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108395 CVCL_8258 LL58 transformed cell line human CVCL_8258 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Virology: Chronically infected with HIV-1 Doubling time: 24-48 hours (HIVReagentProgram) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9693 21108396 CVCL_7Q59 DA03688 transformed cell line human CVCL_7Q59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108397 CVCL_8259 Loukes cancer cell line human CVCL_8259 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Unspecified (PubMed=1915267) Male Virology: EBV-negative 21108398 CVCL_7Q32 DA03659 transformed cell line human CVCL_7Q32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108399 CVCL_8232 HL3T1 cancer cell line human CVCL_8232 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21108400 CVCL_7Q33 DA03660 transformed cell line human CVCL_7Q33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108401 CVCL_8233 HMV-I cancer cell line human CVCL_8233 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0004; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00126 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from female 65 year old patient with vaginal melanoma. 21108402 CVCL_7Q34 DA03661 transformed cell line human CVCL_7Q34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108403 CVCL_8234 HSKT-C cancer cell line human CVCL_8234 CL:0000010 Population: Japanese; Derived from metastatic site: Ovary. Female Doubling time: 60 hours (at 5th passage), 57 hours (at 10th passage), 52 hours (at 20th passage) (PubMed=2160890) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21108404 CVCL_7Q35 DA03662 transformed cell line human CVCL_7Q35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108405 CVCL_8235 HSKT-F cancer cell line human CVCL_8235 CL:0000010 Population: Japanese; Derived from metastatic site: Ovary. Female Doubling time: 120 hours, at 5th passage (PubMed=2160890) 21108406 CVCL_7Q30 DA03657 transformed cell line human CVCL_7Q30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108407 CVCL_8230 HKMUS-SF cancer cell line human CVCL_8230 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0686; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00210 Problematic cell line: Contaminated Parent cell line (HKMUS) has been shown to be a SKG-II-SF derivative (PubMed=16643607; PubMed=20143388). 21108408 CVCL_7Q31 DA03658 transformed cell line human CVCL_7Q31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108409 CVCL_8231 HL111783 cancer cell line human CVCL_8231 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0111; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00211 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=16643607; PubMed=20143388). 21108410 CVCL_7Q29 DA03656 transformed cell line human CVCL_7Q29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108411 CVCL_8229 HCV-29TMV cancer cell line human CVCL_8229 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00125 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=8105864; PubMed=20143388). Originally thought to be a derivative of HCV-29. 21108412 CVCL_7Q25 DA03651 transformed cell line human CVCL_7Q25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108413 CVCL_8225 HAG-1 cancer cell line human CVCL_8225 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 26 hours (PubMed=7881622) 21108414 CVCL_7Q26 DA03652 transformed cell line human CVCL_7Q26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108415 CVCL_8226 HANK1 cancer cell line human CVCL_8226 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Retroperitoneal lymph node. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female Characteristics: IL2 dependent Doubling time: 3 days (PubMed=9858215) 21108416 CVCL_7Q27 DA03653 transformed cell line human CVCL_7Q27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108417 CVCL_8227 HB11;19 cancer cell line human CVCL_8227 From: Hing S.; Institute of Cancer Research; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Met (c.374C>T); ClinVar=VCV000183748; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (DepMap) Omics: Array-based CGH; Omics: Deep exome analysis. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21108418 CVCL_7Q28 DA03655 transformed cell line human CVCL_7Q28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108419 CVCL_8228 HCV-29 cancer cell line human CVCL_8228 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (PubMed=23401075); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (PubMed=23401075) Derived from sampling site: Urinary bladder. Male Caution: HCV-29 is said to be a non-malignant bladder epithelial cell line But due to the fact that it is immortal and contains AKT and BRAF mutations we consider it to be a bladder carcinoma cell line. 21108420 CVCL_7Q43 DA03670 transformed cell line human CVCL_7Q43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108421 CVCL_8243 Hu961a cancer cell line human CVCL_8243 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Doubling time: 21 hours (PubMed=3708594) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00133 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=3708594; PubMed=8105864; PubMed=20143388). 21108422 CVCL_7Q44 DA03671 transformed cell line human CVCL_7Q44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108423 CVCL_8244 Hu961b finite cell line human CVCL_8244 HLA typing: A*02; B*18 (PubMed=7905254). CL:0000010 21108424 CVCL_7Q45 DA03674 transformed cell line human CVCL_7Q45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108425 CVCL_8245 IMC-2 cancer cell line human CVCL_8245 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0726; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00134 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a male patient (from which IMC-3 and IMC-4 were also supposed to be derived) with maxillary carcinoma. 21108426 CVCL_7Q46 DA03675 transformed cell line human CVCL_7Q46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108427 CVCL_8246 IMC-3 cancer cell line human CVCL_8246 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0727; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00215 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to originate from a male patient (from which IMC-2 and IMC-4 were also supposed to be derived) with maxillary carcinoma. 21108428 CVCL_7Q40 DA03667 transformed cell line human CVCL_7Q40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108429 CVCL_8240 Hu609 cancer cell line human CVCL_8240 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line). Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00131 Problematic cell line: Contaminated Shown to be a J82 derivative (PubMed=7905254; PubMed=20143388). Originally thought to originate from the histologically normal ureter of a female patient with clear cell renal carcinoma. 21108430 CVCL_7Q41 DA03668 transformed cell line human CVCL_7Q41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108431 CVCL_8241 Hu609T cancer cell line human CVCL_8241 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line). Male Problematic cell line: Contaminated Parent cell line (Hu609) has been shown to be a J82 derivative. 21108432 CVCL_7Q42 DA03669 transformed cell line human CVCL_7Q42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108433 CVCL_8242 Hu609Tmv cancer cell line human CVCL_8242 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00132 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=8105864; PubMed=20143388). 21108434 CVCL_7Q36 DA03663 transformed cell line human CVCL_7Q36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108435 CVCL_8236 Hu1703He cancer cell line human CVCL_8236 CL:0000010 Derived from sampling site: Urinary bladder; urothelium. Male Doubling time: 38 hours (PubMed=11848473) 21108436 CVCL_7Q37 DA03664 transformed cell line human CVCL_7Q37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108437 CVCL_8237 Hu1922 cancer cell line human CVCL_8237 CL:0000010 Derived from sampling site: Urinary bladder; urothelium. Male 21108438 CVCL_7Q38 DA03665 transformed cell line human CVCL_7Q38 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108439 CVCL_8238 Hu456 cancer cell line human CVCL_8238 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 21 hours (PubMed=3708594) Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00129 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=3708594; PubMed=8105864; PubMed=20143388). 21108440 CVCL_7Q39 DA03666 transformed cell line human CVCL_7Q39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108441 CVCL_8239 Hu549 cancer cell line human CVCL_8239 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00130 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=8105864; PubMed=20143388). 21108442 CVCL_IF62 ND19926 transformed cell line human CVCL_IF62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108443 CVCL_IF63 ND19945 transformed cell line human CVCL_IF63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108444 CVCL_IF64 ND20041 transformed cell line human CVCL_IF64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108445 CVCL_IF65 ND20070 transformed cell line human CVCL_IF65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108446 CVCL_IF60 ND19477 transformed cell line human CVCL_IF60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108447 CVCL_IF61 ND19766 transformed cell line human CVCL_IF61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108448 CVCL_IF59 ND19475 transformed cell line human CVCL_IF59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108449 CVCL_IF55 ND19446 transformed cell line human CVCL_IF55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108450 CVCL_IF56 ND19472 transformed cell line human CVCL_IF56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108451 CVCL_IF57 ND19473 transformed cell line human CVCL_IF57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108452 CVCL_IF58 ND19474 transformed cell line human CVCL_IF58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108453 CVCL_IF73 ND20258 transformed cell line human CVCL_IF73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108454 CVCL_IF74 ND20381 transformed cell line human CVCL_IF74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108455 CVCL_IF75 ND20497 transformed cell line human CVCL_IF75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108456 CVCL_IF76 ND20523 transformed cell line human CVCL_IF76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108457 CVCL_IF70 ND20157 transformed cell line human CVCL_IF70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108458 CVCL_IF71 ND20256 transformed cell line human CVCL_IF71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108459 CVCL_IF72 ND20257 transformed cell line human CVCL_IF72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108460 CVCL_IF66 ND20089 transformed cell line human CVCL_IF66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108461 CVCL_IF67 ND20090 transformed cell line human CVCL_IF67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108462 CVCL_IF68 ND20133 transformed cell line human CVCL_IF68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108463 CVCL_IF69 ND20135 transformed cell line human CVCL_IF69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108464 CVCL_IF40 ND16553 transformed cell line human CVCL_IF40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108465 CVCL_IF41 ND16577 transformed cell line human CVCL_IF41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108466 CVCL_IF42 ND16621 transformed cell line human CVCL_IF42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108467 CVCL_IF43 ND16622 transformed cell line human CVCL_IF43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108468 CVCL_IF37 ND16463 transformed cell line human CVCL_IF37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108469 CVCL_IF38 ND16471 transformed cell line human CVCL_IF38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108470 CVCL_IF39 ND16480 transformed cell line human CVCL_IF39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108471 CVCL_IF33 ND16358 transformed cell line human CVCL_IF33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108472 CVCL_IF34 ND16381 transformed cell line human CVCL_IF34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108473 CVCL_IF35 ND16388 transformed cell line human CVCL_IF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108474 CVCL_IF36 ND16462 transformed cell line human CVCL_IF36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108475 CVCL_IF51 ND19197 transformed cell line human CVCL_IF51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108476 CVCL_IF52 ND19348 transformed cell line human CVCL_IF52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108477 CVCL_IF53 ND19373 transformed cell line human CVCL_IF53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108478 CVCL_IF54 ND19404 transformed cell line human CVCL_IF54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108479 CVCL_IF50 ND19196 transformed cell line human CVCL_IF50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108480 CVCL_IF48 ND16691 transformed cell line human CVCL_IF48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108481 CVCL_IF49 ND19183 transformed cell line human CVCL_IF49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108482 CVCL_IF44 ND16623 transformed cell line human CVCL_IF44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108483 CVCL_IF45 ND16624 transformed cell line human CVCL_IF45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108484 CVCL_IF46 ND16625 transformed cell line human CVCL_IF46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108485 CVCL_IF47 ND16626 transformed cell line human CVCL_IF47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108486 CVCL_IF20 ND16015 transformed cell line human CVCL_IF20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108487 CVCL_IF21 ND16016 transformed cell line human CVCL_IF21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108488 CVCL_IF19 ND14998 transformed cell line human CVCL_IF19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108489 CVCL_IF15 ND14728 transformed cell line human CVCL_IF15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108490 CVCL_IF16 ND14760 transformed cell line human CVCL_IF16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108491 CVCL_IF17 ND14829 transformed cell line human CVCL_IF17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108492 CVCL_IF18 ND14857 transformed cell line human CVCL_IF18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108493 CVCL_IF11 ND14604 transformed cell line human CVCL_IF11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108494 CVCL_IF12 ND14605 transformed cell line human CVCL_IF12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108495 CVCL_IF13 ND14606 transformed cell line human CVCL_IF13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108496 CVCL_IF14 ND14700 transformed cell line human CVCL_IF14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108497 CVCL_IF30 ND16108 transformed cell line human CVCL_IF30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108498 CVCL_IF31 ND16218 transformed cell line human CVCL_IF31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108499 CVCL_IF32 ND16357 transformed cell line human CVCL_IF32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108500 CVCL_IF26 ND16103 transformed cell line human CVCL_IF26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108501 CVCL_IF27 ND16104 transformed cell line human CVCL_IF27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108502 CVCL_IF28 ND16105 transformed cell line human CVCL_IF28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108503 CVCL_IF29 ND16106 transformed cell line human CVCL_IF29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108504 CVCL_IF22 ND16017 transformed cell line human CVCL_IF22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108505 CVCL_IF23 ND16050 transformed cell line human CVCL_IF23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108506 CVCL_IF24 ND16051 transformed cell line human CVCL_IF24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108507 CVCL_IF25 ND16102 transformed cell line human CVCL_IF25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108508 CVCL_IF10 ND14564 transformed cell line human CVCL_IF10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108509 CVCL_IF08 ND14500 transformed cell line human CVCL_IF08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108510 CVCL_IF09 ND14563 transformed cell line human CVCL_IF09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108511 CVCL_IF04 ND14407 transformed cell line human CVCL_IF04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108512 CVCL_IF05 ND14435 transformed cell line human CVCL_IF05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108513 CVCL_IF06 ND14459 transformed cell line human CVCL_IF06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108514 CVCL_IF07 ND14490 transformed cell line human CVCL_IF07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108515 CVCL_IF00 ND14283 transformed cell line human CVCL_IF00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108516 CVCL_IF01 ND14320 transformed cell line human CVCL_IF01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108517 CVCL_IF02 ND14341 transformed cell line human CVCL_IF02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108518 CVCL_IF03 ND14358 transformed cell line human CVCL_IF03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108519 CVCL_IF99 ND22473 transformed cell line human CVCL_IF99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108520 CVCL_IF84 ND20594 transformed cell line human CVCL_IF84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108521 CVCL_IF85 ND20965 transformed cell line human CVCL_IF85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108522 CVCL_IF86 ND20990 transformed cell line human CVCL_IF86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108523 CVCL_IF87 ND21306 transformed cell line human CVCL_IF87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108524 CVCL_IF80 ND20559 transformed cell line human CVCL_IF80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108525 CVCL_IF81 ND20560 transformed cell line human CVCL_IF81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108526 CVCL_IF82 ND20561 transformed cell line human CVCL_IF82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108527 CVCL_IF83 ND20593 transformed cell line human CVCL_IF83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108528 CVCL_IF77 ND20553 transformed cell line human CVCL_IF77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108529 CVCL_IF78 ND20554 transformed cell line human CVCL_IF78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108530 CVCL_IF79 ND20556 transformed cell line human CVCL_IF79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108531 CVCL_IF95 ND21788 transformed cell line human CVCL_IF95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108532 CVCL_IF96 ND21975 transformed cell line human CVCL_IF96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108533 CVCL_IF97 ND22433 transformed cell line human CVCL_IF97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108534 CVCL_IF98 ND22446 transformed cell line human CVCL_IF98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108535 CVCL_IF91 ND21469 transformed cell line human CVCL_IF91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108536 CVCL_IF92 ND21690 transformed cell line human CVCL_IF92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108537 CVCL_IF93 ND21694 transformed cell line human CVCL_IF93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108538 CVCL_IF94 ND21695 transformed cell line human CVCL_IF94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108539 CVCL_IF90 ND21388 transformed cell line human CVCL_IF90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108540 CVCL_IF88 ND21307 transformed cell line human CVCL_IF88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108541 CVCL_IF89 ND21376 transformed cell line human CVCL_IF89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108542 CVCL_8331 M4Be 7GP cancer cell line human CVCL_8331 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic Was obtained after 8 sequential transplantation of the parental cell line in immunodepressed newborn rats. 21108543 CVCL_7R31 DA03762 transformed cell line human CVCL_7R31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108544 CVCL_8332 M4Be 7GP122 cancer cell line human CVCL_8332 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic Doubling time: 30 +- 0.5 hours (PubMed=8175891) 21108545 CVCL_7R32 DA03763 transformed cell line human CVCL_7R32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108546 CVCL_7R33 DA03764 transformed cell line human CVCL_7R33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108547 CVCL_8333 M4Be T1P26 cancer cell line human CVCL_8333 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic Was obtained after 2 sequential transplantation of the parental cell line in immunodepressed newborn rats. Doubling time: 30 +- 0.5 hours (PubMed=8175891) 21108548 CVCL_7R34 DA03765 transformed cell line human CVCL_7R34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108549 CVCL_8334 M4Be T1P26L cancer cell line human CVCL_8334 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Intermediate metastatic potential 21108550 CVCL_7R30 DA03761 transformed cell line human CVCL_7R30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108551 CVCL_8330 Sez-4 cancer cell line human CVCL_8330 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21108552 CVCL_7R28 DA03759 transformed cell line human CVCL_7R28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108553 CVCL_8328 MyLa 2000 cancer cell line human CVCL_8328 CL:0000010 Unspecified 21108554 CVCL_7R29 DA03760 transformed cell line human CVCL_7R29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108555 CVCL_8329 HuT 102B cancer cell line human CVCL_8329 CL:0000010 Population: African American; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Lymph node Cell type=T-cell.. Male 21108556 CVCL_7R24 DA03755 transformed cell line human CVCL_7R24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108557 CVCL_8324 TK-164 cancer cell line human CVCL_8324 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 43 hours (PubMed=3594443) 21108558 CVCL_7R25 DA03756 transformed cell line human CVCL_7R25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108559 CVCL_8325 TE-6/Hypo cancer cell line human CVCL_8325 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Characteristics: Hypoxia-resistant 21108560 CVCL_7R26 DA03757 transformed cell line human CVCL_7R26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108561 CVCL_8326 MyLa 3675 cancer cell line human CVCL_8326 CL:0000010 Unspecified 21108562 CVCL_7R27 DA03758 transformed cell line human CVCL_7R27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108563 CVCL_8327 MyLa 1885 finite cell line human CVCL_8327 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21108564 CVCL_7R42 DA03773 transformed cell line human CVCL_7R42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108565 CVCL_7R43 DA03774 transformed cell line human CVCL_7R43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108566 CVCL_8343 MRC-iPS-11 induced pluripotent stem cell human CVCL_8343 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0598; true; Discontinued: SKIP; SKIP000009; probable Male 21108567 CVCL_7R44 DA03775 transformed cell line human CVCL_7R44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108568 CVCL_8344 EB33 cancer cell line human CVCL_8344 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00023 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=93571; PubMed=6451928; PubMed=1246601; PubMed=20143388). Originally thought to originate from a prostate carcinoma. 21108569 CVCL_7R45 DA03777 transformed cell line human CVCL_7R45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108570 CVCL_8345 ED(27) cancer cell line human CVCL_8345 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00191 Problematic cell line: Contaminated Shown to be a WISH derivative (PubMed=11869090; PubMed=20143388). Originally thought to originate from a chorionic villus sample from a 35 year old female donor. 21108571 CVCL_8340 ATL-43T cancer cell line human CVCL_8340 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 21108572 CVCL_7R40 DA03771 transformed cell line human CVCL_7R40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108573 CVCL_8341 B78H1 cancer cell line house mouse CVCL_8341 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Unlike B16, B78H1 cells are MHC class I negative even after interferon-gamma induction; Characteristics: Amelanotic clone of B16 21108574 CVCL_7R41 DA03772 transformed cell line human CVCL_7R41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108575 CVCL_8339 ATL-35T transformed cell line human CVCL_8339 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 21108576 CVCL_7R39 DA03770 transformed cell line human CVCL_7R39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108577 CVCL_7R35 DA03766 transformed cell line human CVCL_7R35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108578 CVCL_8335 M4Be T1P26R cancer cell line human CVCL_8335 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Highly metastatic More metastatic than T1P26L. 21108579 CVCL_7R36 DA03767 transformed cell line human CVCL_7R36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108580 CVCL_8336 M3Da cancer cell line human CVCL_8336 CL:0000010 Derived from metastatic site: Skin. Unspecified Characteristics: Non-pigmented (DOI=10.1007/BF01753729) 21108581 CVCL_7R37 DA03768 transformed cell line human CVCL_7R37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108582 CVCL_8337 M4Be cancer cell line human CVCL_8337 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Pigmented (DOI=10.1007/BF01753729) 21108583 CVCL_8338 ATL-2 transformed cell line human CVCL_8338 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21108584 CVCL_7R38 DA03769 transformed cell line human CVCL_7R38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108585 CVCL_7R10 DA03741 transformed cell line human CVCL_7R10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108586 CVCL_8310 PL509 somatic stem cell human CVCL_8310 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0430; true Male 21108587 CVCL_7R11 DA03742 transformed cell line human CVCL_7R11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108588 CVCL_8311 RSMG-2 spontaneously immortalized cell line Norway rat CVCL_8311 CL:0000010 Derived from sampling site: Salivary gland; submandibular gland; epithelium; Breed/subspecies: Wistar. Male Doubling time: ~33 hours (DOI=10.11418/jtca1981.19.4_199) Group: Serum/protein free medium cell line 21108589 CVCL_7R12 DA03743 transformed cell line human CVCL_7R12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108590 CVCL_8312 KMS-24 cancer cell line human CVCL_8312 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa (JCRB) 21108591 CVCL_7R06 DA03736 transformed cell line human CVCL_7R06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108592 CVCL_8306 UE6E7T-1 transformed cell line human CVCL_8306 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0446; true Female 21108593 CVCL_7R07 DA03737 transformed cell line human CVCL_7R07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108594 CVCL_8307 UE6E7TC-4 transformed cell line human CVCL_8307 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0449; true Female 21108595 CVCL_7R08 DA03738 transformed cell line human CVCL_7R08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108596 CVCL_8308 RCR-1.P3 spontaneously immortalized cell line Norway rat CVCL_8308 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: JAR-2. Discontinued: JCRB; NIHS0198; true; Discontinued: JCRB; NIHS0355; true Unspecified Doubling time: ~30 hours (JCRB) Group: Serum/protein free medium cell line 21108597 CVCL_7R09 DA03740 transformed cell line human CVCL_7R09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108598 CVCL_8309 NCC-RbC-53 cancer cell line human CVCL_8309 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0496; true Female 21108599 CVCL_7R02 DA03732 transformed cell line human CVCL_7R02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108600 CVCL_8302 NM-1/E finite cell line CVCL_8302 CL:0000010 Derived from sampling site: Fetal artery; endothelium. Discontinued: JCRB; JCRB0155.1; probable Unspecified 21108601 CVCL_7R03 DA03733 transformed cell line human CVCL_7R03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108602 CVCL_8303 NM-1/F finite cell line CVCL_8303 CL:0000010 Derived from sampling site: Fetal artery; endothelium. Discontinued: JCRB; JCRB0155.2; probable Unspecified 21108603 CVCL_7R04 DA03734 transformed cell line human CVCL_7R04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108604 CVCL_8304 NCE16-IIB transformed cell line human CVCL_8304 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Discontinued: JCRB; JCRB1089; probable; Discontinued: JCRB; NIHS0266; true Female 21108605 CVCL_7R05 DA03735 transformed cell line human CVCL_7R05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108606 CVCL_8305 PL504 somatic stem cell human CVCL_8305 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0423; true Female 21108607 CVCL_7R20 DA03751 transformed cell line human CVCL_7R20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108608 CVCL_8320 NCC-CoC-K115L cancer cell line human CVCL_8320 CL:0000010 Population: Japanese; Derived from metastatic site: Peripheral lymph node. Discontinued: JCRB; NIHS0509; true Male 21108609 CVCL_7R21 DA03752 transformed cell line human CVCL_7R21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108610 CVCL_8321 NCC-CoC-K115B transformed cell line human CVCL_8321 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: JCRB; NIHS0510; true. Male 21108611 CVCL_7R22 DA03753 transformed cell line human CVCL_7R22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108612 CVCL_8322 PL520 somatic stem cell human CVCL_8322 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0576; true Female 21108613 CVCL_7R23 DA03754 transformed cell line human CVCL_7R23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108614 CVCL_8323 HSC-3-M3 cancer cell line human CVCL_8323 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Discontinued: JCRB; NIHS0589; true Male Characteristics: Has lymph node metastatizing potential Established from a xenograft obtained by injection of the parent cell line in the tongue of BALB/c nude mice. 21108615 CVCL_7R17 DA03748 transformed cell line human CVCL_7R17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108616 CVCL_8317 NCC-EC-2 cancer cell line human CVCL_8317 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male 21108617 CVCL_7R18 DA03749 transformed cell line human CVCL_7R18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108618 CVCL_8318 NCC-EC-3 cancer cell line human CVCL_8318 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male 21108619 CVCL_7R19 DA03750 transformed cell line human CVCL_7R19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108620 CVCL_8319 NCC-CoC-K115P cancer cell line human CVCL_8319 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Discontinued: JCRB; NIHS0508; true Male 21108621 CVCL_7R13 DA03744 transformed cell line human CVCL_7R13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108622 CVCL_8313 HEC-180 cancer cell line human CVCL_8313 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; JCRB1144; true; Discontinued: JCRB; NIHS0398; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00308 Problematic cell line: Contaminated HEC-155 and HEC-180 have been shown to be identical (PubMed=20143388). Originally thought to originate from a 64 year old female patient with endometrial carcinoma. 21108623 CVCL_7R14 DA03745 transformed cell line human CVCL_7R14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108624 CVCL_8314 PL517 somatic stem cell human CVCL_8314 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0570; true Female 21108625 CVCL_7R15 DA03746 transformed cell line human CVCL_7R15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108626 CVCL_8315 UC705 finite cell line human CVCL_8315 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord. Unspecified 21108627 CVCL_7R16 DA03747 transformed cell line human CVCL_7R16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108628 CVCL_8316 NCC-EC-1 cancer cell line human CVCL_8316 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male 21108629 CVCL_7R00 DA03730 transformed cell line human CVCL_7R00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108630 CVCL_8300 F9-41 cancer cell line house mouse CVCL_8300 CL:0000010 Breed/subspecies: 129/Sv. Male 21108631 CVCL_7R01 DA03731 transformed cell line human CVCL_7R01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108632 CVCL_8301 KYSE-190 cancer cell line human CVCL_8301 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val203Leu (c.607G>C); ClinVar=VCV000482235; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB1084; probable; Discontinued: JCRB; NIHS0348; true Female Doubling time: 75.6 hours (PubMed=1728357) 21108633 CVCL_7R90 DA03827 transformed cell line human CVCL_7R90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108634 CVCL_8390 OCUM-9 cancer cell line human CVCL_8390 CL:0000010 Population: Japanese. Unspecified 21108635 CVCL_7R91 DA03828 transformed cell line human CVCL_7R91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108636 CVCL_8391 OU-AML-1 cancer cell line human CVCL_8391 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00247 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108637 CVCL_7R92 DA03829 transformed cell line human CVCL_7R92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108638 CVCL_8392 OU-AML-2 cancer cell line human CVCL_8392 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00248 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108639 CVCL_7R97 DA03834 transformed cell line human CVCL_7R97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108640 CVCL_8397 OU-AML-7 cancer cell line human CVCL_8397 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00253 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108641 CVCL_7R98 DA03835 transformed cell line human CVCL_7R98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108642 CVCL_8398 OU-AML-8 cancer cell line human CVCL_8398 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00254 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108643 CVCL_7R99 DA03836 transformed cell line human CVCL_7R99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108644 CVCL_8399 OST cancer cell line human CVCL_8399 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: RCB; RCB0454; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00339 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to originate from a 15 year old female patient with an osteosarcoma. 21108645 CVCL_7R93 DA03830 transformed cell line human CVCL_7R93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03830; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108646 CVCL_8393 OU-AML-3 cancer cell line human CVCL_8393 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00249 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108647 CVCL_7R94 DA03831 transformed cell line human CVCL_7R94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108648 CVCL_8394 OU-AML-4 cancer cell line human CVCL_8394 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00250 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108649 CVCL_7R95 DA03832 transformed cell line human CVCL_7R95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108650 CVCL_8395 OU-AML-5 cancer cell line human CVCL_8395 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00251 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108651 CVCL_7R96 DA03833 transformed cell line human CVCL_7R96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108652 CVCL_8396 OU-AML-6 cancer cell line human CVCL_8396 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00252 Problematic cell line: Contaminated Shown to be a OCI-AML-2 derivative (PubMed=12592342; PubMed=20143388). 21108653 CVCL_7R70 DA03804 transformed cell line human CVCL_7R70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108654 CVCL_7R75 DA03810 transformed cell line human CVCL_7R75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108655 CVCL_8375 NCOL-1 cancer cell line human CVCL_8375 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Left supraclavicular lymph node. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00243 Problematic cell line: Contaminated Shown to be a LoVo derivative (PubMed=15771911; PubMed=20143388). Originally thought to originate from a normal colonic mucosa sample. 21108656 CVCL_7R76 DA03811 transformed cell line human CVCL_7R76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108657 CVCL_8376 NPTr spontaneously immortalized cell line pig CVCL_8376 CL:0000010 Derived from sampling site: Trachea. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 4.29 hours (PubMed=12505635) 21108658 CVCL_7R77 DA03812 transformed cell line human CVCL_7R77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108659 CVCL_8377 NS-3 cancer cell line human CVCL_8377 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Discontinued: JCRB; JCRB1076; true; Discontinued: JCRB; NIHS0335; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00336 Problematic cell line: Contaminated Shown to be a COLO 201 derivative (PubMed=20143388). 21108660 CVCL_7R78 DA03813 transformed cell line human CVCL_7R78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108661 CVCL_8378 NSK spontaneously immortalized cell line pig CVCL_8378 CL:0000010 Derived from sampling site: Kidney. Unspecified Doubling time: 4.14 hours (PubMed=12505635) 21108662 CVCL_7R71 DA03805 transformed cell line human CVCL_7R71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108663 CVCL_7R72 DA03806 transformed cell line human CVCL_7R72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108664 CVCL_7R73 DA03807 transformed cell line human CVCL_7R73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108665 CVCL_8373 NCE SVIA6 transformed cell line human CVCL_8373 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0263; true Female 21108666 CVCL_7R74 DA03808 transformed cell line human CVCL_7R74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108667 CVCL_8374 NCE SVIIA3 transformed cell line human CVCL_8374 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0264; true Female 21108668 CVCL_7R68 DA03802 transformed cell line human CVCL_7R68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108669 CVCL_8368 M1-T22 cancer cell line house mouse CVCL_8368 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: SL. 21108670 CVCL_7R69 DA03803 transformed cell line human CVCL_7R69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108671 CVCL_8369 MSK cancer cell line Norway rat CVCL_8369 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Breed/subspecies: Fischer 344. Female Doubling time: 18 hours (DOI=10.11277/stomatology1952.38.870) 21108672 CVCL_7R80 DA03815 transformed cell line human CVCL_7R80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108673 CVCL_8380 OCUM-12 cancer cell line human CVCL_8380 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 13.4 hours, at 190th passage (PubMed=20145613) 21108674 CVCL_7R81 DA03817 transformed cell line human CVCL_7R81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108675 CVCL_8381 OCUM-12/Hypo cancer cell line human CVCL_8381 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Characteristics: Hypoxia-resistant Doubling time: 24.9 hours, at 10th passage (PubMed=20145613) 21108676 CVCL_7R86 DA03823 transformed cell line human CVCL_7R86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108677 CVCL_8386 OCUM-2MLN cancer cell line human CVCL_8386 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Omics: Proteome analysis by 2D-DE/MS Female 21108678 CVCL_7R87 DA03824 transformed cell line human CVCL_7R87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108679 CVCL_8387 OCUM-6 cancer cell line human CVCL_8387 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00337 Problematic cell line: Contaminated Shown to be a OCUM-11 derivative (PubMed=20143388). Originally thought to originate from the ascites effusion of a 65 year old male patient with a scirrhous gastric carcinoma. 21108680 CVCL_7R88 DA03825 transformed cell line human CVCL_7R88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108681 CVCL_8388 OCUM-7 cancer cell line human CVCL_8388 CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Stomach. Male Doubling time: 23 hours, at 25th passage (PubMed=15254696); Microsatellite instability: Instable (MSI-high) (PubMed=15254696) 21108682 CVCL_7R89 DA03826 transformed cell line human CVCL_7R89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108683 CVCL_8389 OCUM-8 cancer cell line human CVCL_8389 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 13.4 hours (PubMed=15546507) 21108684 CVCL_7R82 DA03818 transformed cell line human CVCL_7R82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108685 CVCL_8382 OCUM-2D cancer cell line human CVCL_8382 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 23.6 hours (PubMed=7577468) 21108686 CVCL_7R83 DA03820 transformed cell line human CVCL_7R83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108687 CVCL_8383 OCUM-2M cancer cell line human CVCL_8383 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Omics: Proteome analysis by 2D-DE/MS Female Doubling time: 37.3 hours (PubMed=7577468) 21108688 CVCL_7R84 DA03821 transformed cell line human CVCL_7R84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108689 CVCL_8384 OCUM-2M/DDP cancer cell line human CVCL_8384 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Stomach. Female 21108690 CVCL_7R85 DA03822 transformed cell line human CVCL_7R85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108691 CVCL_8385 OCUM-2MD3 cancer cell line human CVCL_8385 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Female 21108692 CVCL_7R79 DA03814 transformed cell line human CVCL_7R79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108693 CVCL_8379 OCUM-11 cancer cell line human CVCL_8379 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 11.3 hours (PubMed=15546507) 21108694 CVCL_7R53 DA03786 transformed cell line human CVCL_7R53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108695 CVCL_8353 Ger cancer cell line human CVCL_8353 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Unspecified (PubMed=11787853). Female Doubling time: 36 hours, at 11th passage (PubMed=435363) 21108696 CVCL_7R54 DA03787 transformed cell line human CVCL_7R54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108697 CVCL_8354 HAC-2 cancer cell line human CVCL_8354 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=25846456) Population: Japanese; Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays Discontinued: JCRB; NIHS0567; true Female Doubling time: 46.8 hours (CelloPub=CLPUB00045) Part of: MD Anderson Cell Lines Project 21108698 CVCL_7R55 DA03788 transformed cell line human CVCL_7R55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108699 CVCL_8355 HSC-41 cancer cell line human CVCL_8355 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Discontinued: JCRB; JCRB1035; probable Doubling time: 23 hours (PubMed=8242641) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00312 Problematic cell line: Contaminated Shown to be a HSC-42 derivative (PubMed=20143388). Originally thought to originate from a 45 year old male patient with a stomach carcinoma. 21108700 CVCL_7R56 DA03789 transformed cell line human CVCL_7R56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108701 CVCL_7R50 DA03782 transformed cell line human CVCL_7R50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108702 CVCL_8350 EP-1 spontaneously immortalized cell line CVCL_8350 CL:0000010 Unspecified Characteristics: Infected with Heterosporis anguillarum. Group: Fish cell line 21108703 CVCL_7R51 DA03783 transformed cell line human CVCL_7R51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108704 CVCL_8351 ESP-1 cancer cell line human CVCL_8351 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00043 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). 21108705 CVCL_7R52 DA03785 transformed cell line human CVCL_7R52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108706 CVCL_8352 F2408 spontaneously immortalized cell line Norway rat CVCL_8352 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21108707 CVCL_7R46 DA03778 transformed cell line human CVCL_7R46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108708 CVCL_8346 EEK spontaneously immortalized cell line pig CVCL_8346 From: Mumford J.A.; Equine Virology Unit, Animal Health Trust; Newmarket; United Kingdom CL:0000010 Derived from sampling site: Kidney. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00192 Problematic cell line: Misidentified/contaminated Originally thought to be of horse origin but found to be a pig NSK derivative (PubMed=14505435; PubMed=20143388). 21108709 CVCL_7R47 DA03779 transformed cell line human CVCL_7R47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108710 CVCL_8347 EEL finite cell line CVCL_8347 CL:0000010 Derived from sampling site: Fetal lung. Unspecified Caution: Not certain if this is really a cell line or primary cells 21108711 CVCL_7R48 DA03780 transformed cell line human CVCL_7R48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108712 CVCL_8348 EK-1 spontaneously immortalized cell line CVCL_8348 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21108713 CVCL_7R49 DA03781 transformed cell line human CVCL_7R49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108714 CVCL_8349 EO-2 spontaneously immortalized cell line CVCL_8349 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21108715 CVCL_7R64 DA03797 transformed cell line human CVCL_7R64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108716 CVCL_8364 Edmin337 undefined cell line type CVCL_8364 CL:0000010 Caution: We are not certain that Edmin337 and L-337 are the same cell line. 21108717 CVCL_7R65 DA03799 transformed cell line human CVCL_7R65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108718 CVCL_8365 LAT 1 undefined cell line type house mouse CVCL_8365 CL:0000010 Breed/subspecies: C3H/An. Male 21108719 CVCL_7R66 DA03800 transformed cell line human CVCL_7R66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108720 CVCL_8366 LAT II undefined cell line type house mouse CVCL_8366 CL:0000010 Breed/subspecies: C3H/An. Male 21108721 CVCL_7R67 DA03801 transformed cell line human CVCL_7R67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108722 CVCL_8367 MRC-iPS-18 induced pluripotent stem cell human CVCL_8367 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: JCRB; NIHS0605; true; Discontinued: SKIP; SKIP000012; probable Male 21108723 CVCL_7R60 DA03793 transformed cell line human CVCL_7R60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108724 CVCL_8360 JTC-16 cancer cell line Norway rat CVCL_8360 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21108725 CVCL_7R61 DA03794 transformed cell line human CVCL_7R61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108726 CVCL_8361 JTC-16.P3 cancer cell line Norway rat CVCL_8361 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0368; true Group: Serum/protein free medium cell line 21108727 CVCL_7R62 DA03795 transformed cell line human CVCL_7R62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108728 CVCL_8362 JTC-17 cancer cell line human CVCL_8362 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; NIHS0009; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00139 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). 21108729 CVCL_7R63 DA03796 transformed cell line human CVCL_7R63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108730 CVCL_8363 KA-S1 undefined cell line type house mouse CVCL_8363 CL:0000010 Discontinued: JCRB; JCRB1013; true. Unspecified Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse. 21108731 CVCL_7R57 DA03790 transformed cell line human CVCL_7R57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108732 CVCL_8357 HuL-1 cancer cell line human CVCL_8357 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0231; true; Discontinued: RCB; RCB0077; true; Discontinued: RCB; RCB1457; true Female Part of: JFCR45 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00318 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to originate from a 4 month old male fetal liver. 21108733 CVCL_7R58 DA03791 transformed cell line human CVCL_7R58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108734 CVCL_8358 Int-3LL cancer cell line house mouse CVCL_8358 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Possesses enhanced intravasating ability compared to the parent cell line 21108735 CVCL_7R59 DA03792 transformed cell line human CVCL_7R59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108736 CVCL_8359 IRC-2 finite cell line human CVCL_8359 CL:0000010 Population: Japanese; Derived from sampling site: Placenta. Discontinued: JCRB; JCRB1068; true; Discontinued: JCRB; NIHS0322; true Female 21108737 CVCL_IG83 ND16498 transformed cell line human CVCL_IG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108738 CVCL_IG84 ND19739 transformed cell line human CVCL_IG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108739 CVCL_IG85 ND20071 transformed cell line human CVCL_IG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108740 CVCL_IG86 ND14157 transformed cell line human CVCL_IG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108741 CVCL_IG80 ND13013 transformed cell line human CVCL_IG80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108742 CVCL_IG81 ND03594 transformed cell line human CVCL_IG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108743 CVCL_IG82 ND13741 transformed cell line human CVCL_IG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108744 CVCL_RA20 Hepa1-6-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_RA20 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108745 CVCL_RA21 Hepa1-6-iRFP-Puro cancer cell line house mouse CVCL_RA21 CL:0000010 Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108746 CVCL_RA22 LL/2-eGFP-Puro cancer cell line house mouse CVCL_RA22 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108747 CVCL_RA23 LL/2-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_RA23 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108748 CVCL_RA24 LL/2-Fluc-Puro cancer cell line house mouse CVCL_RA24 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108749 CVCL_RA25 LL/2-iRFP-Puro cancer cell line house mouse CVCL_RA25 CL:0000010 Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108750 CVCL_RA26 LL/2-mNIS (monoclonal) cancer cell line house mouse CVCL_RA26 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Transfected with the LV-mNIS vector encoding mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter 21108751 CVCL_RA27 LL/2-mNIS-Neo/eGFP-Puro cancer cell line house mouse CVCL_RA27 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108752 CVCL_RA28 LL/2-mNIS-Neo/Fluc-Puro cancer cell line house mouse CVCL_RA28 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-Fluc-P2A-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108753 CVCL_RA29 LL/2-mNIS-Puro cancer cell line house mouse CVCL_RA29 CL:0000010 Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line, transfected with the LV-mNIS-PGK-Puro vector encoding for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108754 CVCL_IG76 ND01689 transformed cell line human CVCL_IG76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108755 CVCL_IG77 ND02060 transformed cell line human CVCL_IG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND02060; probable Female 21108756 CVCL_IG78 ND02221 transformed cell line human CVCL_IG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108757 CVCL_IG79 ND10645 transformed cell line human CVCL_IG79 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)41 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108758 CVCL_IG94 ND03159 transformed cell line human CVCL_IG94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108759 CVCL_IG95 ND03179 transformed cell line human CVCL_IG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108760 CVCL_IG96 ND03263 transformed cell line human CVCL_IG96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108761 CVCL_IG97 ND03452 transformed cell line human CVCL_IG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108762 CVCL_IG90 ND37127 transformed cell line human CVCL_IG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108763 CVCL_IG91 OCUM-8/5-FU cancer cell line human CVCL_IG91 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Ascites. Female 21108764 CVCL_IG92 ND38594 transformed cell line human CVCL_IG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108765 CVCL_IG93 ND02966 transformed cell line human CVCL_IG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108766 CVCL_RA10 HT1080-Fluc-Neo/eGFP-Puro cancer cell line human CVCL_RA10 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108767 CVCL_RA11 HT1080-Fluc-Neo/iRFP-Puro cancer cell line human CVCL_RA11 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108768 CVCL_RA12 HT1080-Fluc-Puro cancer cell line human CVCL_RA12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108769 CVCL_RA13 HT1080-hNIS-Neo/eGFP-Puro cancer cell line human CVCL_RA13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-eGFP-PGK-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108770 CVCL_RA14 HT1080-hNIS-Neo/Fluc-Puro cancer cell line human CVCL_RA14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-Fluc-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108771 CVCL_RA15 HT1080-hNIS-Neo/iRFP-Puro cancer cell line human CVCL_RA15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-iRFP-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108772 CVCL_RA16 HT1080-hNIS-Puro cancer cell line human CVCL_RA16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with the LV-hNIS-P2A-Puro vector encoding for human SLC5A5 linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108773 CVCL_RA17 HT1080-iRFP-Puro cancer cell line human CVCL_RA17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108774 CVCL_RA18 Hepa1-6-eGFP-Puro cancer cell line house mouse CVCL_RA18 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108775 CVCL_RA19 Hepa1-6-Fluc-Neo cancer cell line house mouse CVCL_RA19 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Neo vector encoding for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21108776 CVCL_IG87 ND20272 transformed cell line human CVCL_IG87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108777 CVCL_IG88 ND33447 transformed cell line human CVCL_IG88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108778 CVCL_IG89 ND36872 transformed cell line human CVCL_IG89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108779 CVCL_IG61 ND37177 transformed cell line human CVCL_IG61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108780 CVCL_IG62 ND38473 transformed cell line human CVCL_IG62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108781 CVCL_IG63 ND39876 transformed cell line human CVCL_IG63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108782 CVCL_IG64 ND40365 transformed cell line human CVCL_IG64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108783 CVCL_IG60 ND37145 transformed cell line human CVCL_IG60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108784 CVCL_RA00 CT26.WT-Fluc-Neo cancer cell line house mouse CVCL_RA00 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Neo vector encoding for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21108785 CVCL_RA01 CT26.WT-Fluc-Neo/eGFP-Puro cancer cell line house mouse CVCL_RA01 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108786 CVCL_RA02 CT26.WT-Fluc-Neo/iRFP-Puro cancer cell line house mouse CVCL_RA02 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108787 CVCL_RA03 CT26.WT-iRFP-Neo cancer cell line house mouse CVCL_RA03 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Neo which encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108788 CVCL_RA04 CT26.WT-iRFP-Neo/mNIS-Puro cancer cell line house mouse CVCL_RA04 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with both the LV-iRFP-P2A-Neo and LV-mNIS-PGK-Puro vectors LV-iRFP-P2A-Neo encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-mNIS-PGK-Puro encodes for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108789 CVCL_RA05 CT26.WT-mNIS (monoclonal) cancer cell line house mouse CVCL_RA05 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:2149330; Slc5a5 Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Transfected with the LV-mNIS vector encoding mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter 21108790 CVCL_RA06 CT26.WT-mNIS-Neo/eGFP-Puro cancer cell line house mouse CVCL_RA06 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108791 CVCL_IG58 ND36128 transformed cell line human CVCL_IG58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108792 CVCL_RA07 CT26.WT-mNIS-Neo/Fluc-Puro cancer cell line house mouse CVCL_RA07 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with both the LV-mNIS-P2A-Neo and LV-Fluc-P2A-Puro vectors LV-mNIS-P2A-Neo encodes for mouse Slc5a5 linked via a P2A cleavage peptide to the neo gene under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108793 CVCL_IG59 ND36369 transformed cell line human CVCL_IG59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108794 CVCL_RA08 CT26.WT-mNIS-Puro cancer cell line house mouse CVCL_RA08 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: MGI; MGI:2149330; Slc5a5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Reporter cell line, transfected with the LV-mNIS-PGK-Puro vector encoding for mouse Slc5a5 under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108795 CVCL_RA09 HT1080-eGFP-Puro cancer cell line human CVCL_RA09 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108796 CVCL_IG54 ND34212 transformed cell line human CVCL_IG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108797 CVCL_IG55 ND34448 transformed cell line human CVCL_IG55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108798 CVCL_IG56 ND35029 transformed cell line human CVCL_IG56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108799 CVCL_IG57 ND35604 transformed cell line human CVCL_IG57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108800 CVCL_IG72 ND01584 transformed cell line human CVCL_IG72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108801 CVCL_IG73 ND01585 transformed cell line human CVCL_IG73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108802 CVCL_IG74 ND01665 transformed cell line human CVCL_IG74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108803 CVCL_IG75 ND01680 transformed cell line human CVCL_IG75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108804 CVCL_IG70 ND01550 transformed cell line human CVCL_IG70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108805 CVCL_IG71 ND01576 transformed cell line human CVCL_IG71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108806 CVCL_IG69 ND01188 transformed cell line human CVCL_IG69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108807 CVCL_IG65 ND00061 transformed cell line human CVCL_IG65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND00061; probable Female 21108808 CVCL_IG66 ND00102 transformed cell line human CVCL_IG66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND00102; probable Female 21108809 CVCL_IG67 ND00503 transformed cell line human CVCL_IG67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND00503; probable Female 21108810 CVCL_IG68 ND01073 transformed cell line human CVCL_IG68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND01073; probable Female 21108811 CVCL_IG40 ND31480 transformed cell line human CVCL_IG40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108812 CVCL_IG41 ND31553 transformed cell line human CVCL_IG41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108813 CVCL_IG42 ND31666 transformed cell line human CVCL_IG42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108814 CVCL_IG36 ND30840 transformed cell line human CVCL_IG36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108815 CVCL_IG37 ND30842 transformed cell line human CVCL_IG37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108816 CVCL_IG38 ND31208 transformed cell line human CVCL_IG38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108817 CVCL_IG39 ND31477 transformed cell line human CVCL_IG39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108818 CVCL_IG32 ND30440 transformed cell line human CVCL_IG32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108819 CVCL_IG33 ND30683 transformed cell line human CVCL_IG33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108820 CVCL_IG34 ND30690 transformed cell line human CVCL_IG34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108821 CVCL_IG35 ND30839 transformed cell line human CVCL_IG35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108822 CVCL_IG50 ND33226 transformed cell line human CVCL_IG50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108823 CVCL_IG51 ND33390 transformed cell line human CVCL_IG51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108824 CVCL_IG52 ND33799 transformed cell line human CVCL_IG52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108825 CVCL_IG53 ND33800 transformed cell line human CVCL_IG53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108826 CVCL_IG47 ND32759 transformed cell line human CVCL_IG47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108827 CVCL_IG48 ND32771 transformed cell line human CVCL_IG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108828 CVCL_IG49 ND33144 transformed cell line human CVCL_IG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108829 CVCL_IG43 ND31912 transformed cell line human CVCL_IG43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108830 CVCL_IG44 ND32014 transformed cell line human CVCL_IG44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108831 CVCL_IG45 ND32119 transformed cell line human CVCL_IG45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108832 CVCL_IG46 ND32758 transformed cell line human CVCL_IG46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108833 CVCL_IG20 ND28470 transformed cell line human CVCL_IG20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108834 CVCL_IG18 ND28008 transformed cell line human CVCL_IG18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108835 CVCL_IG19 ND28046 transformed cell line human CVCL_IG19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108836 CVCL_IG14 ND26072 transformed cell line human CVCL_IG14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108837 CVCL_IG15 ND26336 transformed cell line human CVCL_IG15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108838 CVCL_IG16 ND26772 transformed cell line human CVCL_IG16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108839 CVCL_IG17 ND26978 transformed cell line human CVCL_IG17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108840 CVCL_IG10 ND24688 transformed cell line human CVCL_IG10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108841 CVCL_IG11 ND25722 transformed cell line human CVCL_IG11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108842 CVCL_IG12 ND25988 transformed cell line human CVCL_IG12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108843 CVCL_IG13 ND26014 transformed cell line human CVCL_IG13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108844 CVCL_IG30 ND30316 transformed cell line human CVCL_IG30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108845 CVCL_IG31 ND30386 transformed cell line human CVCL_IG31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108846 CVCL_IG29 ND29579 transformed cell line human CVCL_IG29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108847 CVCL_IG25 ND29084 transformed cell line human CVCL_IG25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108848 CVCL_IG26 ND29108 transformed cell line human CVCL_IG26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108849 CVCL_IG27 ND29117 transformed cell line human CVCL_IG27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108850 CVCL_IG28 ND29578 transformed cell line human CVCL_IG28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108851 CVCL_IG21 ND28559 transformed cell line human CVCL_IG21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108852 CVCL_IG22 ND28646 transformed cell line human CVCL_IG22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108853 CVCL_IG23 ND28647 transformed cell line human CVCL_IG23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108854 CVCL_IG24 ND28972 transformed cell line human CVCL_IG24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108855 CVCL_RA90 MDA-MB-231 shPARG cancer cell line human CVCL_RA90 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Poly-ADP-ribosylation by proteomics Female Group: Triple negative breast cancer (TNBC) cell line 21108856 CVCL_RA91 MDA-MB-468 shPARG cancer cell line human CVCL_RA91 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Poly-ADP-ribosylation by proteomics Female Group: Triple negative breast cancer (TNBC) cell line 21108857 CVCL_RA92 SK-BR-3 shPARG cancer cell line human CVCL_RA92 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Poly-ADP-ribosylation by proteomics Female 21108858 CVCL_RA93 SUM159PT shPARG cancer cell line human CVCL_RA93 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157_Arg158insLeu (c.472_473ins3); Zygosity=Unspecified (from parent cell line) Omics: Poly-ADP-ribosylation by proteomics. Female Group: Triple negative breast cancer (TNBC) cell line 21108859 CVCL_RA94 T-47D shPARG cancer cell line human CVCL_RA94 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: Poly-ADP-ribosylation by proteomics Female 21108860 CVCL_RA95 ZR-75-1 shPARG cancer cell line human CVCL_RA95 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Poly-ADP-ribosylation by proteomics Female 21108861 CVCL_RA96 1835_iPS1 induced pluripotent stem cell human CVCL_RA96 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21108862 CVCL_RA97 1835_iPS2 induced pluripotent stem cell human CVCL_RA97 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: ATAC-seq Female 21108863 CVCL_RA98 2E2A6 hybridoma house mouse CVCL_RA98 CL:0000010 Biotechnology: Used in a bioassay to measure botulinum toxin serotype A (BoNT/A) activity Together with neuroblastoma cell line SiMa (Cellosaurus=CVCL_1695). Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P60880; Human SNAP25 (with p.Arg198_Gly206del; SNAP25(197)). Group: Patented cell line 21108864 CVCL_RA99 3C1A5 hybridoma house mouse CVCL_RA99 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P60880; Human SNAP25 (with p.Arg198_Gly206del; SNAP25(197)). 21108865 CVCL_RA80 79-1 cancer cell line human CVCL_RA80 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Doubling time: 0.7 day (PubMed=7817386) 21108866 CVCL_RA81 87-13 cancer cell line human CVCL_RA81 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Female Doubling time: 11.7 days (PubMed=7817386) 21108867 CVCL_RA82 88-3 cancer cell line human CVCL_RA82 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female Doubling time: 1.7 days (PubMed=7817386) 21108868 CVCL_RA83 WG1226 finite cell line human CVCL_RA83 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21108869 CVCL_RA84 WG1282 finite cell line human CVCL_RA84 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21108870 CVCL_RA85 WG1283 finite cell line human CVCL_RA85 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21108871 CVCL_RA86 U-CH14 cancer cell line human CVCL_RA86 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=28515451); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; cranium; clivus. Omics: Transcriptome analysis by microarray Male Doubling time: ~10 days (PubMed=28515451); 44 days (Chordoma_Foundation) 21108872 CVCL_RA87 HCC1937 shPARG cancer cell line human CVCL_RA87 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Thr738_Arg775del38 (c.2212_2325del114); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Breast. Omics: Poly-ADP-ribosylation by proteomics Female Group: Triple negative breast cancer (TNBC) cell line 21108873 CVCL_RA88 MCF-10A shPARG spontaneously immortalized cell line human CVCL_RA88 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Poly-ADP-ribosylation by proteomics Female 21108874 CVCL_RA89 MCF-7 shPARG cancer cell line human CVCL_RA89 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 8605; PARG; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Poly-ADP-ribosylation by proteomics Female 21108875 CVCL_RA70 WG1925 finite cell line human CVCL_RA70 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108876 CVCL_RA71 WG2006 finite cell line human CVCL_RA71 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Gly387Asp (c.1160G>A); Zygosity=Heterozygous (PubMed=10679944); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Glu586Lys (c.1756G>A); Zygosity=Heterozygous (PubMed=10679944) Miscellaneous: Cell line no longer available Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21108877 CVCL_RA72 WG2184 finite cell line human CVCL_RA72 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala116Thr (c.346G>A); ClinVar=VCV001333614; Zygosity=Heterozygous (PubMed=10679944); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Tyr374Ter (c.1122C>G); Zygosity=Heterozygous (PubMed=10679944) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21108878 CVCL_RA73 WG2843 finite cell line human CVCL_RA73 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21108879 CVCL_RA74 WG2844 finite cell line human CVCL_RA74 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21108880 CVCL_RA75 88-2 cancer cell line human CVCL_RA75 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 36.0 +- 2.1 hours (PubMed=12111518) 21108881 CVCL_RA76 88-2F cancer cell line human CVCL_RA76 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 26.4 +- 1.8 hours (PubMed=12111518) 21108882 CVCL_RA77 88-2FA cancer cell line human CVCL_RA77 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 99.2 +- 2.9 hours (PubMed=12111518) 21108883 CVCL_RA78 88-2T cancer cell line human CVCL_RA78 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 91.2 +- 2.6 hours (PubMed=12111518) 21108884 CVCL_RA79 77-3 cancer cell line human CVCL_RA79 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 6 days (PubMed=7817386) 21108885 CVCL_RA60 QAU-Ms-E-10 spontaneously immortalized cell line CVCL_RA60 CL:0000010 Unspecified Doubling time: 46.2 hours (PubMed=28664308). Group: Insect cell line 21108886 CVCL_RA61 QAU-Ms-E-10c spontaneously immortalized cell line CVCL_RA61 CL:0000010 Unspecified Doubling time: 42.2 hours (PubMed=28664308). Group: Insect cell line 21108887 CVCL_RA62 WG1084 finite cell line human CVCL_RA62 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Thr227Met (c.680C>T); ClinVar=VCV000800827; Zygosity=Homozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21108888 CVCL_RA63 WG1554 finite cell line human CVCL_RA63 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg183Ter (c.547C>T); ClinVar=VCV000003518; Zygosity=Homozygous (PubMed=7920641; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Native North American; Hopi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108889 CVCL_RA64 WG1627 finite cell line human CVCL_RA64 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg183Ter (c.547C>T); ClinVar=VCV000003518; Zygosity=Homozygous (PubMed=7920641; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Native North American; Choctaw; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108890 CVCL_RA65 WG1779 finite cell line human CVCL_RA65 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg157Gln (c.470G>A); ClinVar=VCV000003519; Zygosity=Heterozygous (PubMed=7726158; PubMed=8940272; PubMed=10679944); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg567Ter (c.1699C>T); ClinVar=VCV000660609; Zygosity=Heterozygous (PubMed=10679944) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108891 CVCL_RA66 WG1794 finite cell line human CVCL_RA66 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Lys584Ter (c.1750A>T); ClinVar=VCV001066378; Zygosity=Homozygous (PubMed=10679944) Miscellaneous: Cell line no longer available Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108892 CVCL_RA67 WG1807 finite cell line human CVCL_RA67 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Pro251Leu (c.752C>T); Zygosity=Homozygous (PubMed=7726158; PubMed=8940272) Miscellaneous: Cell line no longer available Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21108893 CVCL_RA68 WG1834 finite cell line human CVCL_RA68 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg157Gln (c.470G>A); ClinVar=VCV000003519; Zygosity=Heterozygous (PubMed=7920641; PubMed=8940272; PubMed=10679944); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg567Ter (c.1699C>T); ClinVar=VCV000660609; Zygosity=Heterozygous (PubMed=7920641; PubMed=10679944) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108894 CVCL_RA69 WG1863 finite cell line human CVCL_RA69 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Arg157Gln (c.470G>A); ClinVar=VCV000003519; Zygosity=Heterozygous (PubMed=7920641; PubMed=8940272; PubMed=10679944); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Pro572Leu (c.1715C>T); Zygosity=Heterozygous (PubMed=7920641; PubMed=10679944) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21108895 CVCL_RA50 LE9415-RCC cancer cell line human CVCL_RA50 CL:0000010 21108896 CVCL_RA51 LE8915-EBV transformed cell line human CVCL_RA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21108897 CVCL_RA52 Mel 603 cancer cell line human CVCL_RA52 CL:0000010 21108898 CVCL_RA53 PC346Abi101 cancer cell line human CVCL_RA53 CL:0000010 Selected for resistance to: ChEBI; CHEBI:68642; Abiraterone; Derived from sampling site: Prostate. Male 21108899 CVCL_RA54 PC346Enza cancer cell line human CVCL_RA54 CL:0000010 Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from sampling site: Prostate. Male 21108900 CVCL_RA55 CWR-R1-EnzR cancer cell line human CVCL_RA55 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male 21108901 CVCL_RA56 LAPC-4-EnzR cancer cell line human CVCL_RA56 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21108902 CVCL_RA57 LNCaP-EnzR cancer cell line human CVCL_RA57 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by microarray Male 21108903 CVCL_RA58 VCaP-EnzR cancer cell line human CVCL_RA58 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Bone; vertebra. Omics: Transcriptome analysis by microarray Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21108904 CVCL_RA59 LJB spontaneously immortalized cell line CVCL_RA59 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21108905 CVCL_RA40 HCT116-Fluc-Puro cancer cell line human CVCL_RA40 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108906 CVCL_RA41 HCT116-hNIS-Neo cancer cell line human CVCL_RA41 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with the LV-hNIS-IRES-Neo vector encoding for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21108907 CVCL_RA42 HCT116-hNIS-Neo/eGFP-Puro cancer cell line human CVCL_RA42 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-eGFP-PGK-Puro vectors LV-hNIS-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108908 CVCL_RA43 HCT116-hNIS-Neo/Fluc-Puro cancer cell line human CVCL_RA43 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-Fluc-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-Fluc-P2A-Puro encodes for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108909 CVCL_RA44 HCT116-hNIS-Neo/iRFP-Puro cancer cell line human CVCL_RA44 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with both the LV-hNIS-IRES-Neo and LV-iRFP-P2A-Puro vectors LV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108910 CVCL_RA45 HCT116-iRFP-Puro cancer cell line human CVCL_RA45 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with the LV-iRFP-P2A-Puro vector encoding for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108911 CVCL_RA46 AB253 hybridoma house mouse CVCL_RA46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99572; Human P2RX7 (Note=Recognizes non-functional receptor). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 06080101 21108912 CVCL_RA47 LE8915-RCC cancer cell line human CVCL_RA47 CL:0000010 Unspecified 21108913 CVCL_RA48 LE9001-RCC cancer cell line human CVCL_RA48 CL:0000010 Unspecified 21108914 CVCL_RA49 LE9104-RCC cancer cell line human CVCL_RA49 CL:0000010 Unspecified 21108915 CVCL_IG98 ND03464 transformed cell line human CVCL_IG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21108916 CVCL_IG99 ND03674 transformed cell line human CVCL_IG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21108917 CVCL_RA30 Mel624-CMV-hNIS-Neo cancer cell line human CVCL_RA30 CL:0000010 Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Not specified. Male Characteristics: Reporter cell line, transfected with the CMV-hNIS-IRES-Neo vector encoding for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the CMV promoter 21108918 CVCL_RA31 Mel624-CMV-hNIS-Neo/eGFP-Puro cancer cell line human CVCL_RA31 CL:0000010 Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Not specified. Male Characteristics: Reporter cell line, transfected with both the CMV-hNIS-IRES-Neo and LV-eGFP-PGK-Puro vectors CMV-hNIS-IRES-Neo encodes for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the CMV promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108919 CVCL_RA32 Mel624-hNIS-Neo cancer cell line human CVCL_RA32 CL:0000010 Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Not specified. Male Characteristics: Reporter cell line, transfected with the LV-hNIS-IRES-Neo vector encoding for human SLC5A5 linked via an internal ribosomal entry site (IRES) to the Neo gene and under control of the spleen focus-forming virus (SFFV) promoter 21108920 CVCL_RA33 Nalm6-eGFP-Puro cancer cell line human CVCL_RA33 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108921 CVCL_RA34 Nalm6-Fluc-Neo/eGFP-Puro cancer cell line human CVCL_RA34 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108922 CVCL_RA35 Nalm6-Fluc-hNIS cancer cell line human CVCL_RA35 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Reporter cell line, transfected with the LV-Luc2-P2A-hNIS vector encoding for luciferase linked via a P2A cleavage peptide to the human SLC5A5 gene and under control of the spleen focus-forming virus (SFFV) promoter 21108923 CVCL_RA36 Nalm6-Fluc-Puro cancer cell line human CVCL_RA36 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Reporter cell line, transfected with the LV-Fluc-P2A-Puro vector encoding for luciferase linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter 21108924 CVCL_RA37 HCT116-eGFP-Puro cancer cell line human CVCL_RA37 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with the LV-eGFP-PGK-Puro vector encoding for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter 21108925 CVCL_RA38 HCT116-Fluc-Neo/eGFP-Puro cancer cell line human CVCL_RA38 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-eGFP-PGK-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-eGFP-PGK-Puro encodes for eGFP under control of the spleen focus-forming virus (SFFV) promoter and the pac gene under the control of the mouse PGK promoter. 21108926 CVCL_RA39 HCT116-Fluc-Neo/iRFP-Puro cancer cell line human CVCL_RA39 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; G1FNL7; Rhodopseudomonas palustris iRFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Reporter cell line, transfected with both the LV-Fluc-P2A-Neo and LV-iRFP-P2A-Puro vectors LV-Fluc-P2A-Neo encodes for luciferase linked via a P2A cleavage peptide to the neo gene and under control of the spleen focus-forming virus (SFFV) promoter. LV-iRFP-P2A-Puro encodes for iRFP linked via a P2A cleavage peptide to the pac gene and under control of the spleen focus-forming virus (SFFV) promoter. 21108927 CVCL_7S52 DA03894 transformed cell line human CVCL_7S52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108928 CVCL_8452 Hu1752 finite cell line human CVCL_8452 CL:0000010 Derived from sampling site: Urinary bladder; urothelium. Unspecified 21108929 CVCL_7S53 DA03895 transformed cell line human CVCL_7S53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108930 CVCL_8453 Hu564 cancer cell line human CVCL_8453 CL:0000010 21108931 CVCL_7S54 DA03896 transformed cell line human CVCL_7S54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108932 CVCL_7S55 DA03897 transformed cell line human CVCL_7S55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108933 CVCL_7S50 DA03892 transformed cell line human CVCL_7S50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108934 CVCL_8450 Hu1694 finite cell line human CVCL_8450 CL:0000010 Derived from sampling site: Urinary bladder; urothelium. Unspecified 21108935 CVCL_7S51 DA03893 transformed cell line human CVCL_7S51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108936 CVCL_8451 Hu1734 cancer cell line human CVCL_8451 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Urinary bladder. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00128 Problematic cell line: Contaminated Shown to be a HCV-29 derivative (PubMed=7905254; PubMed=20143388). 21108937 CVCL_7S49 DA03891 transformed cell line human CVCL_7S49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108938 CVCL_8449 Hu1125 finite cell line human CVCL_8449 HLA typing: A*11; B*27 (PubMed=7905254) CL:0000010 Derived from sampling site: Urinary bladder; urothelium. 21108939 CVCL_7S45 DA03887 transformed cell line human CVCL_7S45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108940 CVCL_8445 EBT-8 cancer cell line human CVCL_8445 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent Doubling time: 60-70 hours, at 50th passage (PubMed=8057683) 21108941 CVCL_7S46 DA03888 transformed cell line human CVCL_7S46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108942 CVCL_8446 HPC-36M cancer cell line human CVCL_8446 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00213 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to originate from a prostate carcinoma.; Caution: Was reported to derive from HPC-36 (Cellosaurus=CVCL_M169) 21108943 CVCL_7S47 DA03889 transformed cell line human CVCL_7S47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108944 CVCL_8447 HPRS-1 cancer cell line CVCL_8447 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Ovary Cell type=T-cell.; Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21108945 CVCL_7S48 DA03890 transformed cell line human CVCL_7S48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108946 CVCL_8448 HPRS-2 cancer cell line CVCL_8448 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Cell type=T-cell; Breed/subspecies: HPRS-RIR. Female Doubling time: 13.4 hours (PubMed=3273463) Group: Bird cell line 21108947 CVCL_7S63 DA03906 transformed cell line human CVCL_7S63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108948 CVCL_8463 RM10 cancer cell line human CVCL_8463 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00262 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=10516762; PubMed=12592342; PubMed=20143388). Originally thought to originate from the bone marrow of a 44 year old female patient with chronic myelogenous leukemia. 21108949 CVCL_7S64 DA03907 transformed cell line human CVCL_7S64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108950 CVCL_8464 TALL-107 cancer cell line human CVCL_8464 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: IL2 dependent 21108951 CVCL_7S65 DA03908 transformed cell line human CVCL_7S65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108952 CVCL_8465 TKS-1 cancer cell line human CVCL_8465 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=10803505) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21108953 CVCL_7S66 DA03909 transformed cell line human CVCL_7S66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108954 CVCL_8466 YAA cancer cell line human CVCL_8466 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00286 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=12592342; PubMed=20143388). 21108955 CVCL_7S60 DA03902 transformed cell line human CVCL_7S60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108956 CVCL_8460 MDCC-JP2 cancer cell line CVCL_8460 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Doubling time: 22 hours (PubMed=231432); 13.6 hours (PubMed=3273463) Group: Bird cell line 21108957 CVCL_7S61 DA03904 transformed cell line human CVCL_7S61 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108958 CVCL_8461 NK-YS cancer cell line human CVCL_8461 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female Characteristics: IL2 dependent Doubling time: ~48 hours (PubMed=9694726) 21108959 CVCL_7S62 DA03905 transformed cell line human CVCL_7S62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108960 CVCL_8462 NOI-90 cancer cell line human CVCL_8462 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00245 Problematic cell line: Contaminated Shown to be a Reh derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from peripheral blood of a 45 year old male patient with acute lymphoblastic leukemia. 21108961 CVCL_7S56 DA03898 transformed cell line human CVCL_7S56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108962 CVCL_8456 MDCC-MOB1 cancer cell line CVCL_8456 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387). Female Group: Bird cell line 21108963 CVCL_7S57 DA03899 transformed cell line human CVCL_7S57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108964 CVCL_8457 MDCC-MOB2 cancer cell line CVCL_8457 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21108965 CVCL_7S58 DA03900 transformed cell line human CVCL_7S58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108966 CVCL_8458 MDCC-MOB3 cancer cell line CVCL_8458 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Ovary. Female Group: Bird cell line 21108967 CVCL_7S59 DA03901 transformed cell line human CVCL_7S59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108968 CVCL_8459 MDCC-JP1 cancer cell line CVCL_8459 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Doubling time: 19 hours (PubMed=231432) Group: Bird cell line 21108969 CVCL_7S30 DA03869 transformed cell line human CVCL_7S30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108970 CVCL_8430 TDL-3 transformed cell line human CVCL_8430 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00099 Problematic cell line: Contaminated Shown to be a RPMI-1788 derivative (PubMed=6248453; PubMed=20143388). Originally thought to be a tonsillar lymphoid cell line from a male patient with recurrent exudative tonsillitis. 21108971 CVCL_7S31 DA03870 transformed cell line human CVCL_7S31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108972 CVCL_8431 TDL-4 cancer cell line human CVCL_8431 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00100 Problematic cell line: Contaminated Shown to be a Raji derivative (PubMed=6248453; PubMed=20143388). Originally thought to be a tonsillar lymphoid cell line from a female patient with recurrent exudative tonsillitis. 21108973 CVCL_7S32 DA03871 transformed cell line human CVCL_7S32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108974 CVCL_8432 TER-119 hybridoma CVCL_8432 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Mouse 52 kDa antigen on erythroid cells. 21108975 CVCL_7S33 DA03872 transformed cell line human CVCL_7S33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108976 CVCL_8433 MRC-iPS-25 induced pluripotent stem cell human CVCL_8433 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Glycosphingolipids analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0606; true; Discontinued: SKIP; SKIP000008; probable Male 21108977 CVCL_7S27 DA03866 transformed cell line human CVCL_7S27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108978 CVCL_8427 T-33 cancer cell line human CVCL_8427 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00271 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 62 year old female patient with chronic myelogenous leukemia. 21108979 CVCL_7S28 DA03867 transformed cell line human CVCL_7S28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108980 CVCL_8428 TDL-1 cancer cell line human CVCL_8428 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00097 Problematic cell line: Contaminated Shown to be a P3HR-1 derivative (PubMed=6248453; PubMed=20143388). Originally thought to be a tonsillar lymphoid cell line from a male patient with recurrent exudative tonsillitis. 21108981 CVCL_7S29 DA03868 transformed cell line human CVCL_7S29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108982 CVCL_8429 TDL-2 cancer cell line human CVCL_8429 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00098 Problematic cell line: Contaminated Shown to be a P3HR-1 derivative (PubMed=6248453; PubMed=20143388). Originally thought to be a tonsillar lymphoid cell line from a female patient with recurrent exudative tonsillitis. 21108983 CVCL_7S23 DA03861 transformed cell line human CVCL_7S23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108984 CVCL_8423 RS-1 [Human leukemia] cancer cell line human CVCL_8423 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00264 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 2 year old child with acute megakaryoblastic leukemia (AML-M7). 21108985 CVCL_7S24 DA03862 transformed cell line human CVCL_7S24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108986 CVCL_8424 RS-2 cancer cell line human CVCL_8424 CL:0000010 Population: Japanese; Derived from metastatic site: Perianal space. Discontinued: JCRB; NIHS0611; true Female Doubling time: 24 hours (PubMed=7894770) 21108987 CVCL_7S25 DA03864 transformed cell line human CVCL_7S25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108988 CVCL_8425 RS-A spontaneously immortalized cell line Norway rat CVCL_8425 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Donryu. Unspecified Doubling time: ~18 hours (PubMed=4270044) 21108989 CVCL_7S26 DA03865 transformed cell line human CVCL_7S26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108990 CVCL_8426 MRC-iPS-22 induced pluripotent stem cell human CVCL_8426 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: JCRB; NIHS0599; true; Discontinued: SKIP; SKIP000010; probable Male 21108991 CVCL_7S41 DA03883 transformed cell line human CVCL_7S41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108992 CVCL_8441 SR-91 cancer cell line human CVCL_8441 CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; p.Arg784Ter (c.2350C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Val (c.38G>T); ClinVar=VCV000375876; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+2T>G (IVS9+2T>G); ClinVar=VCV000635384; Zygosity=Unspecified; Note=Splice donor mutation (from parent cell line) Population: African American and Caucasian; Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00270 Problematic cell line: Contaminated Shown to be a AML-193 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 22 year old male patient with acute lymphoblastic leukemia. 21108993 CVCL_7S42 DA03884 transformed cell line human CVCL_7S42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108994 CVCL_8442 MOBS-1 cancer cell line human CVCL_8442 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Doubling time: 12 hours (DOI=10.15369/sujms1989.9.45) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00239 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 57 year old male patient with monocytic leukemia (M5b). 21108995 CVCL_7S43 DA03885 transformed cell line human CVCL_7S43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108996 CVCL_8443 PB-1 [Human] cancer cell line human CVCL_8443 CL:0000010 21108997 CVCL_8444 CaVe cancer cell line human CVCL_8444 CL:0000010 Anecdotal: Have been flown in space on Zond-5 to study growth in microgravity (PubMed=11942358) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Space-flown cell line (cellonaut); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00036 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=58478; PubMed=6451928; PubMed=20143388). Originally thought to originate from a gastric carcinoma. 21108998 CVCL_7S44 DA03886 transformed cell line human CVCL_7S44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21108999 CVCL_7S40 DA03882 transformed cell line human CVCL_7S40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109000 CVCL_8440 SAM-1 cancer cell line human CVCL_8440 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00265 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=12412578; PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 22 year old male patient with chronic myelogenous leukemia. 21109001 CVCL_7S38 DA03880 transformed cell line human CVCL_7S38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109002 CVCL_8438 Led-T1 cancer cell line human CVCL_8438 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00072 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). Originally thought to be a transformed Led-30 (Cellosaurus=CVCL_1E38) cell line. 21109003 CVCL_7S39 DA03881 transformed cell line human CVCL_7S39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109004 CVCL_8439 HIMeg-1 cancer cell line human CVCL_8439 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00208 Problematic cell line: Contaminated Shown to be a HL-60 derivative (PubMed=12592342; PubMed=20143388). 21109005 CVCL_7S34 DA03874 transformed cell line human CVCL_7S34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109006 CVCL_8434 MRC-iPS-27 induced pluripotent stem cell human CVCL_8434 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: JCRB; NIHS0607; true; Discontinued: SKIP; SKIP000011; probable Male 21109007 CVCL_7S35 DA03877 transformed cell line human CVCL_7S35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03877; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109008 CVCL_8435 WD PaCa cancer cell line CVCL_8435 CL:0000010 Transformant: Nitrosobis(2-oxopropyl)amine(ChEBI; CHEBI:134609); Derived from sampling site: Pancreas. Doubling time: ~24 hours (PubMed=3971476) 21109009 CVCL_7S36 DA03878 transformed cell line human CVCL_7S36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109010 CVCL_8436 PL519 somatic stem cell human CVCL_8436 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0575; true Female 21109011 CVCL_7S37 DA03879 transformed cell line human CVCL_7S37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109012 CVCL_8437 PEAZ-1 cancer cell line human CVCL_8437 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00257 Problematic cell line: Contaminated Shown to be a HT-1080 derivative (PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a prostate carcinoma. 21109013 CVCL_7S10 DA03848 transformed cell line human CVCL_7S10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109014 CVCL_8410 PT64 cancer cell line human CVCL_8410 CL:0000010 Unspecified 21109015 CVCL_7S11 DA03849 transformed cell line human CVCL_7S11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109016 CVCL_8411 PT89 cancer cell line human CVCL_8411 CL:0000010 Unspecified 21109017 CVCL_7S05 DA03843 transformed cell line human CVCL_7S05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109018 CVCL_8405 PT103 cancer cell line human CVCL_8405 CL:0000010 Unspecified 21109019 CVCL_7S06 DA03844 transformed cell line human CVCL_7S06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109020 CVCL_8406 PT115 cancer cell line human CVCL_8406 CL:0000010 Unspecified 21109021 CVCL_7S07 DA03845 transformed cell line human CVCL_7S07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109022 CVCL_8407 PT45 cancer cell line human CVCL_8407 From: DiRenzo M.F.; Department of Biomedical Sciences and Human Oncology, University of Turin; Turin; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (PubMed=1764370) Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray 21109023 CVCL_7S08 DA03846 transformed cell line human CVCL_7S08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109024 CVCL_8408 PT45-P1 cancer cell line human CVCL_8408 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=8426738; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (PubMed=8426738; PubMed=11787853) Derived from sampling site: Pancreas. 21109025 CVCL_7S01 DA03838 transformed cell line human CVCL_7S01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109026 CVCL_8401 PD PaCa cancer cell line CVCL_8401 CL:0000010 Derived from sampling site: Pancreas. Doubling time: ~18 hours (PubMed=3971476) 21109027 CVCL_7S02 DA03840 transformed cell line human CVCL_7S02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109028 CVCL_8402 PK-82 spontaneously immortalized cell line CVCL_8402 CL:0000010 Derived from sampling site: Kidney. 21109029 CVCL_7S03 DA03841 transformed cell line human CVCL_7S03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109030 CVCL_8403 PSVK1 transformed cell line human CVCL_8403 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0240; true Male 21109031 CVCL_7S04 DA03842 transformed cell line human CVCL_7S04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109032 CVCL_8404 PT101 cancer cell line human CVCL_8404 CL:0000010 Unspecified 21109033 CVCL_7S09 DA03847 transformed cell line human CVCL_7S09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109034 CVCL_8409 PT45-P1res cancer cell line human CVCL_8409 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pancreas. 21109035 CVCL_7S20 DA03858 transformed cell line human CVCL_7S20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109036 CVCL_8420 rMSC-LacZ somatic stem cell Norway rat CVCL_8420 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Lewis. Male 21109037 CVCL_7S21 DA03859 transformed cell line human CVCL_7S21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109038 CVCL_8421 rMSC-Luci somatic stem cell Norway rat CVCL_8421 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Lewis. Male 21109039 CVCL_7S22 DA03860 transformed cell line human CVCL_7S22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109040 CVCL_8422 RMZ cancer cell line human CVCL_8422 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Male Doubling time: ~48 hours (PubMed=3801282) 21109041 CVCL_7S16 DA03854 transformed cell line human CVCL_7S16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109042 CVCL_8416 RGS-5 spontaneously immortalized cell line Norway rat CVCL_8416 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified Doubling time: 28.8 hours (PubMed=599719) 21109043 CVCL_7S17 DA03855 transformed cell line human CVCL_7S17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109044 CVCL_8417 RGS-8 spontaneously immortalized cell line Norway rat CVCL_8417 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21109045 CVCL_7S18 DA03856 transformed cell line human CVCL_7S18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109046 CVCL_8418 Rhfs-MPMV transformed cell line CVCL_8418 CL:0000010 Transformant: Mason-Pfizer monkey virus (MPMV)(NCBI-Taxonomy; 11855); Derived from sampling site: Foreskin; skin. Male Group: Non-human primate cell line 21109047 CVCL_7S19 DA03857 transformed cell line human CVCL_7S19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109048 CVCL_8419 rMSC-GFP somatic stem cell Norway rat CVCL_8419 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Lewis. Male 21109049 CVCL_7S12 DA03850 transformed cell line human CVCL_7S12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109050 CVCL_8412 PT96 cancer cell line human CVCL_8412 CL:0000010 Unspecified 21109051 CVCL_7S13 DA03851 transformed cell line human CVCL_7S13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109052 CVCL_8413 R89 cancer cell line human CVCL_8413 CL:0000010 Unspecified 21109053 CVCL_7S14 DA03852 transformed cell line human CVCL_7S14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109054 CVCL_8414 RCCD2 transformed cell line Norway rat CVCL_8414 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: Sprague Dawley. Male 21109055 CVCL_7S15 DA03853 transformed cell line human CVCL_7S15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109056 CVCL_8415 RGS-2 spontaneously immortalized cell line Norway rat CVCL_8415 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21109057 CVCL_7S00 DA03837 transformed cell line human CVCL_7S00 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109058 CVCL_8400 Patscl-52 cancer cell line human CVCL_8400 CL:0000010 21109059 CVCL_IG07 ND24001 transformed cell line human CVCL_IG07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109060 CVCL_IG08 ND24202 transformed cell line human CVCL_IG08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109061 CVCL_IG09 ND24563 transformed cell line human CVCL_IG09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109062 CVCL_IG03 ND23164 transformed cell line human CVCL_IG03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109063 CVCL_IG04 ND23187 transformed cell line human CVCL_IG04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109064 CVCL_IG05 ND23359 transformed cell line human CVCL_IG05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109065 CVCL_IG06 ND23606 transformed cell line human CVCL_IG06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109066 CVCL_IG00 ND22533 transformed cell line human CVCL_IG00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109067 CVCL_IG01 ND22751 transformed cell line human CVCL_IG01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109068 CVCL_IG02 ND23074 transformed cell line human CVCL_IG02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109069 CVCL_7S90 DA03936 transformed cell line human CVCL_7S90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109070 CVCL_8490 KMP-2 cancer cell line human CVCL_8490 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=18380791) Population: Japanese; Derived from metastatic site: Liver. Female Doubling time: 16.6 hours (PubMed=10091760) 21109071 CVCL_7S91 DA03937 transformed cell line human CVCL_7S91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109072 CVCL_8491 KMP-3 cancer cell line human CVCL_8491 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: 23 hours (PubMed=10091760) 21109073 CVCL_7S96 DA03942 transformed cell line human CVCL_7S96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109074 CVCL_8496 KMP-8 cancer cell line human CVCL_8496 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Unspecified Doubling time: ~33 hours (lot 12202016) (JCRB) 21109075 CVCL_8497 ASF-4-3L finite cell line human CVCL_8497 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at ~52 PDL (JCRB=JCRB1431) 21109076 CVCL_7S97 DA03943 transformed cell line human CVCL_7S97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109077 CVCL_8498 ASF-4-4L1 finite cell line human CVCL_8498 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at 41 PDL (JCRB=JCRB1441) 21109078 CVCL_7S98 DA03944 transformed cell line human CVCL_7S98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109079 CVCL_8499 ASF-4-4L2 finite cell line human CVCL_8499 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at ~48 PDL (JCRB=JCRB1442) 21109080 CVCL_7S99 DA03945 transformed cell line human CVCL_7S99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109081 CVCL_7S92 DA03938 transformed cell line human CVCL_7S92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109082 CVCL_8492 KMP-4 cancer cell line human CVCL_8492 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Female Doubling time: 57 hours (PubMed=10091760) 21109083 CVCL_7S93 DA03939 transformed cell line human CVCL_7S93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109084 CVCL_8493 KMP-5 cancer cell line human CVCL_8493 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 28.9 hours (PubMed=10091760) 21109085 CVCL_7S94 DA03940 transformed cell line human CVCL_7S94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109086 CVCL_8494 KMP-6 cancer cell line human CVCL_8494 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Female Doubling time: 32.5 hours (PubMed=10091760) 21109087 CVCL_7S95 DA03941 transformed cell line human CVCL_7S95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109088 CVCL_8495 KMP-7 cancer cell line human CVCL_8495 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male 21109089 CVCL_7S89 DA03935 transformed cell line human CVCL_7S89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109090 CVCL_8489 KMP-1 cancer cell line human CVCL_8489 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 70.4 hours (PubMed=10091760) 21109091 CVCL_7S74 DA03918 transformed cell line human CVCL_7S74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109092 CVCL_8474 Mel20-06-045 cancer cell line human CVCL_8474 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (PubMed=21386926) Omics: Transcriptome analysis by microarray. Unspecified 21109093 CVCL_7S75 DA03919 transformed cell line human CVCL_7S75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109094 CVCL_8475 Mel20-07-070 cancer cell line human CVCL_8475 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Heterozygous (PubMed=22515704) Omics: Transcriptome analysis by microarray. Unspecified 21109095 CVCL_7S76 DA03920 transformed cell line human CVCL_7S76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109096 CVCL_8476 HTOXAR3 cancer cell line human CVCL_8476 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Female 21109097 CVCL_8477 862L cancer cell line house mouse CVCL_8477 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97306; Nf1 Breed/subspecies: C57BL/6 x 129S2/SvPas. Male 21109098 CVCL_7S77 DA03922 transformed cell line human CVCL_7S77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109099 CVCL_8470 AE1201 cancer cell line human CVCL_8470 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Group: Adeno-associated virus packaging cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C97001 21109100 CVCL_7S70 DA03914 transformed cell line human CVCL_7S70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109101 CVCL_8471 C918 cancer cell line human CVCL_8471 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=22383533) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000216) It was one of the sources for the STR profile of this entry.. Female 21109102 CVCL_7S71 DA03915 transformed cell line human CVCL_7S71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109103 CVCL_7S72 DA03916 transformed cell line human CVCL_7S72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109104 CVCL_8472 M619 cancer cell line human CVCL_8472 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000224) It was one of the sources for the STR profile of this entry.. Female 21109105 CVCL_7S73 DA03917 transformed cell line human CVCL_7S73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109106 CVCL_8473 Mel20-06-039 cancer cell line human CVCL_8473 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=21386926) Omics: Transcriptome analysis by microarray. Unspecified 21109107 CVCL_7S67 DA03910 transformed cell line human CVCL_7S67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109108 CVCL_8467 YAP cancer cell line human CVCL_8467 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00287 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=12592342; PubMed=20143388). Was originally thought to originate from the peripheral blood monocytes of a 42 year old male Japanese patient with psoriasis vulgaris. 21109109 CVCL_8468 293-Db transformed cell line human CVCL_8468 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21109110 CVCL_7S68 DA03912 transformed cell line human CVCL_7S68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109111 CVCL_8469 293-Kb transformed cell line human CVCL_8469 CL:0000010 Transfected with: MGI; MGI:95904; H2-K1 (allele H2-K1*02 (H2-Kb)) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21109112 CVCL_7S69 DA03913 transformed cell line human CVCL_7S69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109113 CVCL_8480 4/30PRR cancer cell line house mouse CVCL_8480 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97306; Nf1 Breed/subspecies: C57BL/6 x 129S2/SvPas. Male 21109114 CVCL_7S80 DA03925 transformed cell line human CVCL_7S80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109115 CVCL_7S85 DA03931 transformed cell line human CVCL_7S85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109116 CVCL_8485 Kasumi-10 cancer cell line human CVCL_8485 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7134; MLLT1; Name(s)=KMT2A-MLLT1, MLL-MLLT1; MLL-ENL (PubMed=32180206; PubMed=35354797); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=32180206) Miscellaneous: STR profile from personal communication of Leo I.R. Population: Japanese and Korean; Karyotypic information: While originating from a female patient, it has a XXY karyotype that could be explained by a disorder of sexual development (PubMed=32180206) Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21109117 CVCL_7S86 DA03932 transformed cell line human CVCL_7S86 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109118 CVCL_8486 Kasumi-7 cancer cell line human CVCL_8486 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32180206); Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=32504922) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21109119 CVCL_7S87 DA03933 transformed cell line human CVCL_7S87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109120 CVCL_8487 Kasumi-8 cancer cell line human CVCL_8487 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32180206); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=32180206) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21109121 CVCL_7S88 DA03934 transformed cell line human CVCL_7S88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109122 CVCL_8488 Kasumi-9 cancer cell line human CVCL_8488 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32180206); Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=32504922; PubMed=35354797) Miscellaneous: STR profile from personal communication of Leo I.R Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21109123 CVCL_8481 A-1207 cancer cell line human CVCL_8481 Genome ancestry: African=0.38%; Native American=0%; East Asian, North=3.29%; East Asian, South=0%; South Asian=0%; European, North=63.52%; European, South=32.81% (PubMed=30894373). From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray Unspecified Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21109124 CVCL_7S81 DA03926 transformed cell line human CVCL_7S81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109125 CVCL_7S82 DA03927 transformed cell line human CVCL_7S82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109126 CVCL_8483 CHL AIG spontaneously immortalized cell line CVCL_8483 CL:0000010 Derived from sampling site: Lung. Discontinued: JCRB; NIHS0387; true Female 21109127 CVCL_7S83 DA03928 transformed cell line human CVCL_7S83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109128 CVCL_7S84 DA03929 transformed cell line human CVCL_7S84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109129 CVCL_8484 TAS-5 hybridoma CVCL_8484 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q00651; Mouse Itga4/Cd49d. 21109130 CVCL_8478 10/9CRC1 cancer cell line house mouse CVCL_8478 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97306; Nf1 Breed/subspecies: C57BL/6 x 129S2/SvPas. Male 21109131 CVCL_7S78 DA03923 transformed cell line human CVCL_7S78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109132 CVCL_8479 9/3L cancer cell line house mouse CVCL_8479 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97306; Nf1 Breed/subspecies: C57BL/6 x 129S2/SvPas. Male 21109133 CVCL_7S79 DA03924 transformed cell line human CVCL_7S79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109134 CVCL_RB40 STBCi006-A induced pluripotent stem cell human CVCL_RB40 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21109135 CVCL_RB41 STBCi007-A induced pluripotent stem cell human CVCL_RB41 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109136 CVCL_RB42 STBCi007-B induced pluripotent stem cell human CVCL_RB42 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109137 CVCL_RB43 STBCi007-C induced pluripotent stem cell human CVCL_RB43 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109138 CVCL_RB44 STBCi009-A induced pluripotent stem cell human CVCL_RB44 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Pro264Leu (c.791C>T); ClinVar=VCV000098080; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Unspecified 21109139 CVCL_RB45 STBCi009-B induced pluripotent stem cell human CVCL_RB45 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Pro264Leu (c.791C>T); ClinVar=VCV000098080; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Unspecified 21109140 CVCL_RB46 STBCi009-C induced pluripotent stem cell human CVCL_RB46 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Pro264Leu (c.791C>T); ClinVar=VCV000098080; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Unspecified 21109141 CVCL_RB47 STBCi010-A induced pluripotent stem cell human CVCL_RB47 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu184Asp (c.552A>C); ClinVar=VCV000098049; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109142 CVCL_RB48 STBCi011-A induced pluripotent stem cell human CVCL_RB48 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Ile (c.438G>A); ClinVar=VCV000018137; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109143 CVCL_RB49 STBCi011-B induced pluripotent stem cell human CVCL_RB49 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Ile (c.438G>A); ClinVar=VCV000018137; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109144 CVCL_IH97 ND01349 transformed cell line human CVCL_IH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109145 CVCL_IH98 ND01362 transformed cell line human CVCL_IH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109146 CVCL_IH99 ND01428 transformed cell line human CVCL_IH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109147 CVCL_RB30 3AM clone 34 cancer cell line house mouse CVCL_RB30 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109148 CVCL_RB31 3AM clone 9 cancer cell line house mouse CVCL_RB31 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109149 CVCL_RB32 MLS cancer cell line human CVCL_RB32 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 24 hours (PubMed=3182331) 21109150 CVCL_RB33 MLS/ADRR2 cancer cell line human CVCL_RB33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female 21109151 CVCL_RB34 STBCi004-A induced pluripotent stem cell human CVCL_RB34 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21109152 CVCL_RB35 STBCi004-B induced pluripotent stem cell human CVCL_RB35 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=32359446) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; STBCi004-B; true Female 21109153 CVCL_RB36 STBCi004-C induced pluripotent stem cell human CVCL_RB36 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21109154 CVCL_RB37 STBCi005-A induced pluripotent stem cell human CVCL_RB37 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109155 CVCL_RB38 STBCi005-B induced pluripotent stem cell human CVCL_RB38 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109156 CVCL_RB39 STBCi005-C induced pluripotent stem cell human CVCL_RB39 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109157 CVCL_IH82 ND34437 transformed cell line human CVCL_IH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109158 CVCL_IH83 ND38208 transformed cell line human CVCL_IH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109159 CVCL_IH84 ND04062 transformed cell line human CVCL_IH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109160 CVCL_IH85 ND04063 transformed cell line human CVCL_IH85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109161 CVCL_IH80 ND33271 transformed cell line human CVCL_IH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109162 CVCL_IH81 ND34064 transformed cell line human CVCL_IH81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109163 CVCL_RB20 PSF [Poecilia] spontaneously immortalized cell line CVCL_RB20 CL:0000010 Derived from sampling site: Caudal fin. Male Group: Fish cell line 21109164 CVCL_RB21 GPSM4 cancer cell line human CVCL_RB21 CL:0000010 Unspecified 21109165 CVCL_RB22 GPSM5 cancer cell line human CVCL_RB22 CL:0000010 Unspecified 21109166 CVCL_RB23 3AM cancer cell line house mouse CVCL_RB23 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109167 CVCL_RB24 3AM clone 10 cancer cell line house mouse CVCL_RB24 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109168 CVCL_RB25 3AM clone 11 cancer cell line house mouse CVCL_RB25 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109169 CVCL_RB26 3AM clone 21 cancer cell line house mouse CVCL_RB26 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109170 CVCL_RB27 3AM clone 23 cancer cell line house mouse CVCL_RB27 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109171 CVCL_IH79 ND32904 transformed cell line human CVCL_IH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109172 CVCL_RB28 3AM clone 25 cancer cell line house mouse CVCL_RB28 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109173 CVCL_RB29 3AM clone 27 cancer cell line house mouse CVCL_RB29 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C3H/HeJ. Male 21109174 CVCL_IH75 ND28383 transformed cell line human CVCL_IH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109175 CVCL_IH76 ND29133 transformed cell line human CVCL_IH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109176 CVCL_IH77 ND29145 transformed cell line human CVCL_IH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109177 CVCL_IH78 ND31315 transformed cell line human CVCL_IH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109178 CVCL_IH93 ND04852 transformed cell line human CVCL_IH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109179 CVCL_IH94 ND01325 transformed cell line human CVCL_IH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109180 CVCL_IH95 ND01326 transformed cell line human CVCL_IH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109181 CVCL_IH96 ND01348 transformed cell line human CVCL_IH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109182 CVCL_IH90 ND04775 transformed cell line human CVCL_IH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109183 CVCL_IH91 ND04776 transformed cell line human CVCL_IH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109184 CVCL_IH92 ND04851 transformed cell line human CVCL_IH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109185 CVCL_RB10 Gibco CF6-Neo Mouse Embryonic Fibroblasts, MitC-Treated finite cell line house mouse CVCL_RB10 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1 x C57BL/6J-Tg(pPGKneobpA)3Ems/J. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C; Characteristics: Expresses neo from a pPGKneobPa transgene 21109186 CVCL_RB11 Gibco B6-Puro Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB11 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J-Tg(pPwL88puro)2EMS/J. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation; Characteristics: Expresses pac from a pPWL88puro transgene 21109187 CVCL_RB12 Gibco DR4 Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB12 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: DR4 x CF-1. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation; Characteristics: Expresses transgenes that make this cell line resistant to four different drugs: geneticin (G418), puromycin, hygromycin and 6-tioguanine 21109188 CVCL_RB13 Gibco ICR Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB13 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: ICR. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21109189 CVCL_RB14 IRR-MRC-5 finite cell line human CVCL_RB14 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; 55-X; true Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 10000 rads 21109190 CVCL_RB15 IRR-3T3 transformed cell line house mouse CVCL_RB15 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Discontinued: ATCC; 48-X; true Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 10000 rads 21109191 CVCL_RB16 IRR-STO finite cell line house mouse CVCL_RB16 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Discontinued: ATCC; 56-X; true Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21109192 CVCL_RB17 MITC-STO spontaneously immortalized cell line house mouse CVCL_RB17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21109193 CVCL_RB18 HCT R cancer cell line human CVCL_RB18 CL:0000010 21109194 CVCL_RB19 HPC-7 factor-dependent cell line house mouse CVCL_RB19 CL:0000010 Transfected with: MGI; MGI:96785; Lhx2 Breed/subspecies: 129S/SvEv-Gpi1. Male Characteristics: KITLG dependent 21109195 CVCL_IH86 ND04154 transformed cell line human CVCL_IH86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109196 CVCL_IH87 ND04155 transformed cell line human CVCL_IH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109197 CVCL_IH88 ND04261 transformed cell line human CVCL_IH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109198 CVCL_IH89 ND04262 transformed cell line human CVCL_IH89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109199 CVCL_IH60 ND21029 transformed cell line human CVCL_IH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109200 CVCL_IH61 ND21393 transformed cell line human CVCL_IH61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109201 CVCL_IH62 ND21806 transformed cell line human CVCL_IH62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109202 CVCL_IH63 ND23278 transformed cell line human CVCL_IH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109203 CVCL_RB00 GM10389 finite cell line human CVCL_RB00 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21109204 CVCL_RB01 74C3 transformed cell line CVCL_RB01 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Strain 2. Unspecified 21109205 CVCL_RB02 107C3 transformed cell line CVCL_RB02 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: Strain 2. Unspecified 21109206 CVCL_RB03 HM2C1 transformed cell line CVCL_RB03 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Breed/subspecies: Strain 2. Unspecified 21109207 CVCL_RB04 HM4C1 transformed cell line CVCL_RB04 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: Strain 2. Unspecified 21109208 CVCL_RB05 Gibco CF1 Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB05 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21109209 CVCL_IH57 ND20325 transformed cell line human CVCL_IH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109210 CVCL_RB06 Gibco CF1 Mouse Embryonic Fibroblasts, MitC-Treated finite cell line house mouse CVCL_RB06 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21109211 CVCL_IH58 ND20819 transformed cell line human CVCL_IH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109212 CVCL_RB07 Gibco C57BL/6 Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB07 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21109213 CVCL_IH59 ND20821 transformed cell line human CVCL_IH59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109214 CVCL_RB08 Gibco C57BL/6 Mouse Embryonic Fibroblasts, MitC-Treated finite cell line house mouse CVCL_RB08 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21109215 CVCL_RB09 Gibco CF6-Neo Mouse Embryonic Fibroblasts, Irradiated finite cell line house mouse CVCL_RB09 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1 x C57BL/6J-Tg(pPGKneobpA)3Ems/J. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21109216 CVCL_IH53 ND14895 transformed cell line human CVCL_IH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109217 CVCL_IH54 ND16721 transformed cell line human CVCL_IH54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109218 CVCL_IH55 ND19861 transformed cell line human CVCL_IH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109219 CVCL_IH56 ND20037 transformed cell line human CVCL_IH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109220 CVCL_IH71 ND26867 transformed cell line human CVCL_IH71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109221 CVCL_IH72 ND27254 transformed cell line human CVCL_IH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109222 CVCL_IH73 ND27390 transformed cell line human CVCL_IH73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109223 CVCL_IH74 ND27885 transformed cell line human CVCL_IH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109224 CVCL_IH70 ND25128 transformed cell line human CVCL_IH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109225 CVCL_IH68 ND25031 transformed cell line human CVCL_IH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109226 CVCL_IH69 ND25049 transformed cell line human CVCL_IH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109227 CVCL_IH64 ND24041 transformed cell line human CVCL_IH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109228 CVCL_IH65 ND24098 transformed cell line human CVCL_IH65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109229 CVCL_IH66 ND24955 transformed cell line human CVCL_IH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109230 CVCL_IH67 ND25010 transformed cell line human CVCL_IH67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109231 CVCL_IH40 ND10162 transformed cell line human CVCL_IH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109232 CVCL_IH41 ND10202 transformed cell line human CVCL_IH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109233 CVCL_IH39 ND10066 transformed cell line human CVCL_IH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109234 CVCL_IH35 ND09104 transformed cell line human CVCL_IH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109235 CVCL_IH36 ND09310 transformed cell line human CVCL_IH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109236 CVCL_IH37 ND09441 transformed cell line human CVCL_IH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109237 CVCL_IH38 ND09442 transformed cell line human CVCL_IH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109238 CVCL_IH31 ND08475 transformed cell line human CVCL_IH31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109239 CVCL_IH32 ND08896 transformed cell line human CVCL_IH32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109240 CVCL_IH33 ND09016 transformed cell line human CVCL_IH33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109241 CVCL_IH34 ND09048 transformed cell line human CVCL_IH34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109242 CVCL_IH50 ND14377 transformed cell line human CVCL_IH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109243 CVCL_IH51 ND14809 transformed cell line human CVCL_IH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109244 CVCL_IH52 ND14812 transformed cell line human CVCL_IH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109245 CVCL_IH46 ND35822 transformed cell line human CVCL_IH46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109246 CVCL_IH47 ND06576 transformed cell line human CVCL_IH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109247 CVCL_IH48 ND08398 transformed cell line human CVCL_IH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109248 CVCL_IH49 ND13128 transformed cell line human CVCL_IH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109249 CVCL_IH42 ND11000 transformed cell line human CVCL_IH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109250 CVCL_IH43 ND11474 transformed cell line human CVCL_IH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109251 CVCL_IH44 ND11477 transformed cell line human CVCL_IH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109252 CVCL_IH45 ND31212 transformed cell line human CVCL_IH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109253 CVCL_7U03 DA04059 transformed cell line human CVCL_7U03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109254 CVCL_8603 EL-4ad cancer cell line house mouse CVCL_8603 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21109255 CVCL_7U04 DA04060 transformed cell line human CVCL_7U04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109256 CVCL_7U05 DA04061 transformed cell line human CVCL_7U05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109257 CVCL_8606 BBG1 cancer cell line human CVCL_8606 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Peripheral blood. Male 21109258 CVCL_7U06 DA04062 transformed cell line human CVCL_7U06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109259 CVCL_7U00 DA04056 transformed cell line human CVCL_7U00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109260 CVCL_8600 SK-p53-3 cancer cell line human CVCL_8600 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109261 CVCL_7U01 DA04057 transformed cell line human CVCL_7U01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109262 CVCL_8601 HeNC2 transformed cell line house mouse CVCL_8601 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeN. Unspecified 21109263 CVCL_7U02 DA04058 transformed cell line human CVCL_7U02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109264 CVCL_8602 GG2EE transformed cell line house mouse CVCL_8602 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Unspecified 21109265 CVCL_8607 92-1 [Human uveal melanoma] cancer cell line human CVCL_8607 HLA typing: A*02:01,03:01; B*44:02,51:01; C*05:01,14:02 (PubMed=28018010) CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=22236444; PubMed=22383533; PubMed=23851445; PubMed=24994677; PubMed=28018010) Derived from sampling site: Eye; uvea. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 58 hours (PubMed=7622289); 38 hours (PubMed=24994677) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21109266 CVCL_7U07 DA04063 transformed cell line human CVCL_7U07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109267 CVCL_8608 94-10 cancer cell line human CVCL_8608 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Male 21109268 CVCL_7U08 DA04064 transformed cell line human CVCL_7U08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109269 CVCL_8609 96-1 cancer cell line human CVCL_8609 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21109270 CVCL_7U09 DA04065 transformed cell line human CVCL_7U09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109271 CVCL_8620 97-21-M cancer cell line human CVCL_8620 CL:0000010 Derived from metastatic site: Lymph node. Male 21109272 CVCL_7U20 DA04078 transformed cell line human CVCL_7U20 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109273 CVCL_8614 96-2 cancer cell line human CVCL_8614 CL:0000010 Derived from sampling site: Urinary bladder. Male 21109274 CVCL_7U14 DA04072 transformed cell line human CVCL_7U14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109275 CVCL_8615 96-9 cancer cell line human CVCL_8615 CL:0000010 Derived from sampling site: Urinary bladder. Male Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109276 CVCL_7U15 DA04073 transformed cell line human CVCL_7U15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109277 CVCL_8616 97-1 cancer cell line human CVCL_8616 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Arg692Ter (c.2074C>T); ClinVar=VCV000048885; Zygosity=Homozygous (PubMed=23401075) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21109278 CVCL_7U16 DA04074 transformed cell line human CVCL_7U16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109279 CVCL_8617 97-10 cancer cell line human CVCL_8617 CL:0000010 Derived from sampling site: Urinary bladder. Male Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109280 CVCL_7U17 DA04075 transformed cell line human CVCL_7U17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109281 CVCL_8610 96-11 cancer cell line human CVCL_8610 CL:0000010 Derived from sampling site: Urinary bladder. Female Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109282 CVCL_7U10 DA04068 transformed cell line human CVCL_7U10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109283 CVCL_8611 96-12 cancer cell line human CVCL_8611 CL:0000010 Derived from sampling site: Urinary bladder. Female Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109284 CVCL_7U11 DA04069 transformed cell line human CVCL_7U11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109285 CVCL_8612 96-13 cancer cell line human CVCL_8612 CL:0000010 Derived from sampling site: Urinary bladder. Female Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109286 CVCL_7U12 DA04070 transformed cell line human CVCL_7U12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109287 CVCL_8613 96-16 cancer cell line human CVCL_8613 CL:0000010 Derived from sampling site: Urinary bladder. Male Senescence: Does not grow continuously, undergoes crisis and senescence (PubMed=9436977) 21109288 CVCL_7U13 DA04071 transformed cell line human CVCL_7U13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109289 CVCL_8618 97-15 cancer cell line human CVCL_8618 CL:0000010 Derived from sampling site: Urinary bladder. 21109290 CVCL_7U18 DA04076 transformed cell line human CVCL_7U18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109291 CVCL_8619 97-18-I cancer cell line human CVCL_8619 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21109292 CVCL_7U19 DA04077 transformed cell line human CVCL_7U19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109293 CVCL_RB90 STBCi027-B induced pluripotent stem cell human CVCL_RB90 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109294 CVCL_RB91 STBCi028-A induced pluripotent stem cell human CVCL_RB91 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Arg582Gln (c.1745G>A) (p.Arg583Gln, c.1748G>A); ClinVar=VCV000008505; Zygosity=Heterozygous Derived from sampling site: Cell type=Fibroblast. Female 21109295 CVCL_RB92 STBCi028-B induced pluripotent stem cell human CVCL_RB92 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Arg582Gln (c.1745G>A) (p.Arg583Gln, c.1748G>A); ClinVar=VCV000008505; Zygosity=Heterozygous Derived from sampling site: Cell type=Fibroblast. Female 21109296 CVCL_RB93 STBCi028-C induced pluripotent stem cell human CVCL_RB93 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Arg582Gln (c.1745G>A) (p.Arg583Gln, c.1748G>A); ClinVar=VCV000008505; Zygosity=Heterozygous Derived from sampling site: Cell type=Fibroblast. Female 21109297 CVCL_RB94 STBCi029-A induced pluripotent stem cell human CVCL_RB94 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109298 CVCL_RB95 STBCi029-B induced pluripotent stem cell human CVCL_RB95 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109299 CVCL_RB96 STBCi030-A induced pluripotent stem cell human CVCL_RB96 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109300 CVCL_RB97 STBCi030-B induced pluripotent stem cell human CVCL_RB97 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109301 CVCL_RB98 STBCi031-A induced pluripotent stem cell human CVCL_RB98 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109302 CVCL_RB99 STBCi031-B induced pluripotent stem cell human CVCL_RB99 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109303 CVCL_RB80 STBCi024-B induced pluripotent stem cell human CVCL_RB80 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109304 CVCL_RB81 STBCi024-C induced pluripotent stem cell human CVCL_RB81 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109305 CVCL_RB82 STBCi025-A induced pluripotent stem cell human CVCL_RB82 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=26905200) Derived from sampling site: Cell type=Fibroblast. Male 21109306 CVCL_RB83 STBCi025-B induced pluripotent stem cell human CVCL_RB83 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=26905200) Derived from sampling site: Cell type=Fibroblast. Male 21109307 CVCL_RB84 STBCi025-C induced pluripotent stem cell human CVCL_RB84 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109308 CVCL_RB85 STBCi026-A induced pluripotent stem cell human CVCL_RB85 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109309 CVCL_RB86 STBCi026-B induced pluripotent stem cell human CVCL_RB86 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21109310 CVCL_RB87 STBCi026-C induced pluripotent stem cell human CVCL_RB87 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109311 CVCL_RB88 STBCi026-D induced pluripotent stem cell human CVCL_RB88 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109312 CVCL_RB89 STBCi027-A induced pluripotent stem cell human CVCL_RB89 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21109313 CVCL_RB70 STBCi018-C induced pluripotent stem cell human CVCL_RB70 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109314 CVCL_RB71 STBCi019-A induced pluripotent stem cell human CVCL_RB71 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109315 CVCL_RB72 STBCi019-B induced pluripotent stem cell human CVCL_RB72 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; STBCi019-B; true Female 21109316 CVCL_RB73 STBCi019-C induced pluripotent stem cell human CVCL_RB73 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109317 CVCL_RB74 STBCi020-A induced pluripotent stem cell human CVCL_RB74 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21109318 CVCL_RB75 STBCi020-B induced pluripotent stem cell human CVCL_RB75 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21109319 CVCL_RB76 STBCi023-A induced pluripotent stem cell human CVCL_RB76 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21109320 CVCL_RB77 STBCi023-B induced pluripotent stem cell human CVCL_RB77 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21109321 CVCL_RB78 STBCi023-C induced pluripotent stem cell human CVCL_RB78 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21109322 CVCL_RB79 STBCi024-A induced pluripotent stem cell human CVCL_RB79 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109323 CVCL_RB60 STBCi015-B induced pluripotent stem cell human CVCL_RB60 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109324 CVCL_RB61 STBCi015-C induced pluripotent stem cell human CVCL_RB61 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109325 CVCL_RB62 STBCi016-A induced pluripotent stem cell human CVCL_RB62 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi016-A; true Female 21109326 CVCL_RB63 STBCi016-B induced pluripotent stem cell human CVCL_RB63 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi016-B; true Female 21109327 CVCL_RB64 STBCi016-C induced pluripotent stem cell human CVCL_RB64 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi016-C; true Female 21109328 CVCL_RB65 STBCi017-A induced pluripotent stem cell human CVCL_RB65 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Arg841Ter (c.2521C>T) (p.Arg830Ter, c.2488C>T); ClinVar=VCV000440257; Zygosity=Heterozygous (EBiSC); Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Glu1784Glyfs*14 (c.5351delA) (p.Glu1773Glyfs, c.5318delA); ClinVar=VCV000471143; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109329 CVCL_RB66 STBCi017-B induced pluripotent stem cell human CVCL_RB66 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Arg841Ter (c.2521C>T) (p.Arg830Ter, c.2488C>T); ClinVar=VCV000440257; Zygosity=Heterozygous (EBiSC); Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Glu1784Glyfs*14 (c.5351delA) (p.Glu1773Glyfs, c.5318delA); ClinVar=VCV000471143; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109330 CVCL_RB67 STBCi017-C induced pluripotent stem cell human CVCL_RB67 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Arg841Ter (c.2521C>T) (p.Arg830Ter, c.2488C>T); ClinVar=VCV000440257; Zygosity=Heterozygous (EBiSC); Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Glu1784Glyfs*14 (c.5351delA) (p.Glu1773Glyfs, c.5318delA); ClinVar=VCV000471143; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109331 CVCL_RB68 STBCi018-A induced pluripotent stem cell human CVCL_RB68 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109332 CVCL_RB69 STBCi018-B induced pluripotent stem cell human CVCL_RB69 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Ser635Leu (c.1904C>T) (S581L); ClinVar=VCV000209157; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109333 CVCL_RB50 STBCi011-C induced pluripotent stem cell human CVCL_RB50 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Ile (c.438G>A); ClinVar=VCV000018137; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109334 CVCL_RB51 STBCi012-A induced pluripotent stem cell human CVCL_RB51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met139Val (c.415A>G); ClinVar=VCV000018128; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109335 CVCL_RB52 STBCi012-B induced pluripotent stem cell human CVCL_RB52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met139Val (c.415A>G); ClinVar=VCV000018128; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109336 CVCL_RB53 STBCi012-C induced pluripotent stem cell human CVCL_RB53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met139Val (c.415A>G); ClinVar=VCV000018128; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; STBCi012-C; true Female 21109337 CVCL_RB54 STBCi013-A induced pluripotent stem cell human CVCL_RB54 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Tyr115Cys (c.344A>G); ClinVar=VCV000098015; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109338 CVCL_RB55 STBCi013-B induced pluripotent stem cell human CVCL_RB55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Tyr115Cys (c.344A>G); ClinVar=VCV000098015; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21109339 CVCL_RB56 STBCi014-A induced pluripotent stem cell human CVCL_RB56 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; c.338+1delG (p.Leu113_Ile114insThr) (int4del); ClinVar=VCV000098013; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21109340 CVCL_RB57 STBCi014-B induced pluripotent stem cell human CVCL_RB57 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; c.338+1delG (p.Leu113_Ile114insThr) (int4del); ClinVar=VCV000098013; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21109341 CVCL_RB58 STBCi014-C induced pluripotent stem cell human CVCL_RB58 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; c.338+1delG (p.Leu113_Ile114insThr) (int4del); ClinVar=VCV000098013; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21109342 CVCL_RB59 STBCi015-A induced pluripotent stem cell human CVCL_RB59 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Unspecified (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21109343 CVCL_7T73 DA04023 transformed cell line human CVCL_7T73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109344 CVCL_8573 SK-MG-16 cancer cell line human CVCL_8573 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>C); Zygosity=Unspecified (PubMed=8934553). 21109345 CVCL_7T74 DA04024 transformed cell line human CVCL_7T74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109346 CVCL_8574 SK-MG-17 cancer cell line human CVCL_8574 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109347 CVCL_7T75 DA04025 transformed cell line human CVCL_7T75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109348 CVCL_8575 SK-MG-2 cancer cell line human CVCL_8575 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109349 CVCL_7T76 DA04027 transformed cell line human CVCL_7T76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109350 CVCL_8576 SK-MG-3 cancer cell line human CVCL_8576 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109351 CVCL_7T70 DA04019 transformed cell line human CVCL_7T70 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109352 CVCL_8570 SK-MG-12 cancer cell line human CVCL_8570 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109353 CVCL_7T71 DA04020 transformed cell line human CVCL_7T71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109354 CVCL_8571 SK-MG-13 cancer cell line human CVCL_8571 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109355 CVCL_7T72 DA04021 transformed cell line human CVCL_7T72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109356 CVCL_8572 SK-MG-15 cancer cell line human CVCL_8572 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109357 CVCL_7T66 DA04015 transformed cell line human CVCL_7T66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109358 CVCL_8566 PHM1-41 transformed cell line human CVCL_8566 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; myometrium Cell type=Myometrial cell.. Female 21109359 CVCL_7T67 DA04016 transformed cell line human CVCL_7T67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109360 CVCL_8567 SK-AO2 cancer cell line human CVCL_8567 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21109361 CVCL_7T68 DA04017 transformed cell line human CVCL_7T68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109362 CVCL_8568 SK-MG-10 cancer cell line human CVCL_8568 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109363 CVCL_7T69 DA04018 transformed cell line human CVCL_7T69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04018; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109364 CVCL_8569 SK-MG-11 cancer cell line human CVCL_8569 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109365 CVCL_7T84 DA04038 transformed cell line human CVCL_7T84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109366 CVCL_8584 UW19 cancer cell line human CVCL_8584 CL:0000010 Unspecified 21109367 CVCL_7T85 DA04039 transformed cell line human CVCL_7T85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109368 CVCL_8585 UW228 cancer cell line human CVCL_8585 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (PubMed=18505928; DepMap) Derived from sampling site: Brain; posterior fossa. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21109369 CVCL_7T86 DA04040 transformed cell line human CVCL_7T86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109370 CVCL_8586 UW28 cancer cell line human CVCL_8586 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18505928). Male 21109371 CVCL_7T87 DA04041 transformed cell line human CVCL_7T87 CL:0000010 Population: Caucasian and Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109372 CVCL_8587 UW281 cancer cell line human CVCL_8587 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18505928). Unspecified 21109373 CVCL_7T80 DA04034 transformed cell line human CVCL_7T80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109374 CVCL_8580 SMA-560 cancer cell line house mouse CVCL_8580 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: VM/Dk. Omics: Cell surface proteome 21109375 CVCL_7T81 DA04035 transformed cell line human CVCL_7T81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109376 CVCL_8581 ST 13 cancer cell line house mouse CVCL_8581 CL:0000010 Breed/subspecies: ddN. Female 21109377 CVCL_7T82 DA04036 transformed cell line human CVCL_7T82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109378 CVCL_8582 UW14 cancer cell line human CVCL_8582 CL:0000010 Unspecified 21109379 CVCL_7T83 DA04037 transformed cell line human CVCL_7T83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109380 CVCL_8583 UW15 cancer cell line human CVCL_8583 CL:0000010 Unspecified 21109381 CVCL_7T77 DA04029 transformed cell line human CVCL_7T77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109382 CVCL_8577 SK-MG-4 cancer cell line human CVCL_8577 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109383 CVCL_7T78 DA04032 transformed cell line human CVCL_7T78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109384 CVCL_8578 SK-MG-7 cancer cell line human CVCL_8578 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109385 CVCL_7T79 DA04033 transformed cell line human CVCL_7T79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109386 CVCL_8579 SK-MG-9 cancer cell line human CVCL_8579 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109387 CVCL_7T51 DA03998 transformed cell line human CVCL_7T51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109388 CVCL_8551 hs-171-1 transformed cell line CVCL_8551 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0380; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109389 CVCL_7T52 DA04000 transformed cell line human CVCL_7T52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109390 CVCL_8552 hs-172-3 transformed cell line CVCL_8552 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0381; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109391 CVCL_7T53 DA04001 transformed cell line human CVCL_7T53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109392 CVCL_8553 hs-211 transformed cell line CVCL_8553 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0382; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109393 CVCL_7T54 DA04002 transformed cell line human CVCL_7T54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109394 CVCL_8554 hs-222-3 transformed cell line CVCL_8554 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0383; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109395 CVCL_7T50 DA03997 transformed cell line human CVCL_7T50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109396 CVCL_8550 hs-164-2 transformed cell line CVCL_8550 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0379; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109397 CVCL_8548 cs-20-5 transformed cell line CVCL_8548 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0386; true Female Characteristics: Cold-sensitive mutant of CHL Unable to form colonies in soft agar at 34.5 Celsius. 21109398 CVCL_7T48 DA03995 transformed cell line human CVCL_7T48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109399 CVCL_7T49 DA03996 transformed cell line human CVCL_7T49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109400 CVCL_8549 hs-103-3 transformed cell line CVCL_8549 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0378; true Female Characteristics: Heat-sensitive mutant of CHL Unable to form colonies in soft agar at 39.5 Celsius. 21109401 CVCL_8544 AR-EcoScreen spontaneously immortalized cell line CVCL_8544 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Ovary. Biotechnology: Used in the AR STTA bioassay for the rapid evaluation of in vitro androgen receptor transcriptional activation Female Characteristics: The luciferase reporter gene is under the control of a construct bearing four tandem repeats of a prostate C3 gene androgen-responsive element driven by a minimal heat shock protein promoter 21109402 CVCL_7T44 DA03991 transformed cell line human CVCL_7T44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109403 CVCL_8545 CHO/HGPRT spontaneously immortalized cell line CVCL_8545 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: HGPRT-deficient 21109404 CVCL_7T45 DA03992 transformed cell line human CVCL_7T45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA03992; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109405 CVCL_8546 cs-17-25 transformed cell line CVCL_8546 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0384; true Female Characteristics: Cold-sensitive mutant of CHL Unable to form colonies in soft agar at 34.5 Celsius. 21109406 CVCL_7T46 DA03993 transformed cell line human CVCL_7T46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109407 CVCL_8547 cs-19-36 transformed cell line CVCL_8547 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung. Discontinued: JCRB; NIHS0385; true Female Characteristics: Cold-sensitive mutant of CHL Unable to form colonies in soft agar at 34.5 Celsius. 21109408 CVCL_7T47 DA03994 transformed cell line human CVCL_7T47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109409 CVCL_7T62 DA04011 transformed cell line human CVCL_7T62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109410 CVCL_8562 FF101 cancer cell line Norway rat CVCL_8562 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Discontinued: JCRB; NIHS0323; true Male Doubling time: 78 hours, at 25th passage (PubMed=2702652) Group: Serum/protein free medium cell line 21109411 CVCL_7T63 DA04012 transformed cell line human CVCL_7T63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109412 CVCL_8563 MGR1 cancer cell line human CVCL_8563 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (PubMed=18505928) Derived from sampling site: Brain. Male 21109413 CVCL_7T64 DA04013 transformed cell line human CVCL_7T64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109414 CVCL_8564 MGR2 cancer cell line human CVCL_8564 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=18505928) Derived from sampling site: Brain. Female 21109415 CVCL_7T65 DA04014 transformed cell line human CVCL_7T65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109416 CVCL_8565 MGR3 cancer cell line human CVCL_8565 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18505928) Derived from sampling site: Brain. Male 21109417 CVCL_7T60 DA04009 transformed cell line human CVCL_7T60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109418 CVCL_8560 HepG2-GS-CYP3A4 cancer cell line human CVCL_8560 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2637; CYP3A4; Transfected with: HGNC; 4341; GLUL Population: Caucasian; Derived from sampling site: Liver. Discontinued: JCRB; NIHS0617; true Male 21109419 CVCL_8561 COS-M6 transformed cell line CVCL_8561 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21109420 CVCL_7T61 DA04010 transformed cell line human CVCL_7T61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04010; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109421 CVCL_7T59 DA04008 transformed cell line human CVCL_7T59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109422 CVCL_8559 YG10008 spontaneously immortalized cell line CVCL_8559 CL:0000010 Transfected with: HGNC; 7646; NAT2 Derived from sampling site: Lung. Discontinued: JCRB; NIHS0162; true Female 21109423 CVCL_7T55 DA04003 transformed cell line human CVCL_7T55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109424 CVCL_8555 TG1 spontaneously immortalized cell line CVCL_8555 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21109425 CVCL_7T56 DA04005 transformed cell line human CVCL_7T56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109426 CVCL_8556 V79 HPRT~ spontaneously immortalized cell line CVCL_8556 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21109427 CVCL_7T57 DA04006 transformed cell line human CVCL_7T57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109428 CVCL_8557 YG10003 spontaneously immortalized cell line CVCL_8557 CL:0000010 Transfected with: UniProtKB; Q00267; Salmonella typhimurium nhoA Derived from sampling site: Lung. Discontinued: JCRB; NIHS0160; true Female 21109429 CVCL_7T58 DA04007 transformed cell line human CVCL_7T58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04007; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109430 CVCL_8558 YG10007 spontaneously immortalized cell line CVCL_8558 CL:0000010 Transfected with: HGNC; 7645; NAT1 Derived from sampling site: Lung. Discontinued: JCRB; NIHS0161; true Female 21109431 CVCL_7T30 DA03977 transformed cell line human CVCL_7T30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109432 CVCL_8530 PL521 somatic stem cell human CVCL_8530 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Male 21109433 CVCL_7T31 DA03978 transformed cell line human CVCL_7T31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109434 CVCL_8531 PL523 somatic stem cell human CVCL_8531 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Female 21109435 CVCL_7T32 DA03979 transformed cell line human CVCL_7T32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109436 CVCL_8532 PL551SF somatic stem cell human CVCL_8532 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Male 21109437 CVCL_7T26 DA03973 transformed cell line human CVCL_7T26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109438 CVCL_8526 KHM-2B cancer cell line human CVCL_8526 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21109439 CVCL_7T27 DA03974 transformed cell line human CVCL_7T27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109440 CVCL_8527 KMS-33 cancer cell line human CVCL_8527 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Discontinued: JCRB; NIHS0491; true Female Characteristics: Produces IgG lambda (JCRB) 21109441 CVCL_7T28 DA03975 transformed cell line human CVCL_7T28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109442 CVCL_8528 Minami-1 cancer cell line human CVCL_8528 CL:0000010 Population: Japanese; Derived from sampling site: Lymph node. Female 21109443 CVCL_7T29 DA03976 transformed cell line human CVCL_7T29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109444 CVCL_8529 Minami-2 cancer cell line human CVCL_8529 CL:0000010 Population: Japanese; Derived from sampling site: Lymph node. Male Virology: EBV-negative 21109445 CVCL_7T22 DA03969 transformed cell line human CVCL_7T22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109446 CVCL_8522 GM05089 finite cell line human CVCL_8522 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-5del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21109447 CVCL_7T23 DA03970 transformed cell line human CVCL_7T23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109448 CVCL_8523 KasumiA-541 cancer cell line human CVCL_8523 CL:0000010 Derived from sampling site: Peripheral blood. Male 21109449 CVCL_7T24 DA03971 transformed cell line human CVCL_7T24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109450 CVCL_8524 KasumiA-554 cancer cell line human CVCL_8524 CL:0000010 Derived from sampling site: Peripheral blood. Female 21109451 CVCL_7T25 DA03972 transformed cell line human CVCL_7T25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109452 CVCL_8525 KasumiA-568 cancer cell line human CVCL_8525 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 dependent (JCRB) 21109453 CVCL_7T40 DA03987 transformed cell line human CVCL_7T40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109454 CVCL_8540 Vn19-21 cancer cell line house mouse CVCL_8540 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109455 CVCL_7T41 DA03988 transformed cell line human CVCL_7T41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109456 CVCL_8541 Vn19-4 cancer cell line house mouse CVCL_8541 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109457 CVCL_7T42 DA03989 transformed cell line human CVCL_7T42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109458 CVCL_8542 Vn19-49 cancer cell line house mouse CVCL_8542 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109459 CVCL_7T43 DA03990 transformed cell line human CVCL_7T43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109460 CVCL_8543 Vn19-59 cancer cell line house mouse CVCL_8543 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109461 CVCL_8537 CAS-9 hybridoma CVCL_8537 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q00651; Mouse Itga4/Cd49d. 21109462 CVCL_7T37 DA03984 transformed cell line human CVCL_7T37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109463 CVCL_7T38 DA03985 transformed cell line human CVCL_7T38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109464 CVCL_8538 Vn19 cancer cell line house mouse CVCL_8538 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109465 CVCL_7T39 DA03986 transformed cell line human CVCL_7T39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109466 CVCL_8539 Vn19-15 cancer cell line house mouse CVCL_8539 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; Breed/subspecies: BALB/c. Unspecified 21109467 CVCL_7T33 DA03980 transformed cell line human CVCL_7T33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109468 CVCL_8533 STR-428 cancer cell line human CVCL_8533 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=17368758) Population: Japanese; Derived from sampling site: Ascites. Male Doubling time: ~48 hours (PubMed=17368758) 21109469 CVCL_7T34 DA03981 transformed cell line human CVCL_7T34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109470 CVCL_8534 HBs128 hybridoma house mouse CVCL_8534 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis B virus surface antigen. 21109471 CVCL_7T35 DA03982 transformed cell line human CVCL_7T35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109472 CVCL_8535 HBs320 hybridoma house mouse CVCL_8535 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis B virus surface antigen. 21109473 CVCL_8536 AS17 hybridoma house mouse CVCL_8536 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P09525; Human ANXA4. 21109474 CVCL_7T36 DA03983 transformed cell line human CVCL_7T36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109475 CVCL_7T10 DA03957 transformed cell line human CVCL_7T10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109476 CVCL_8510 KYSE-790 cancer cell line human CVCL_8510 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 24-83 hours (lot 12022016) (JCRB) 21109477 CVCL_7T04 DA03951 transformed cell line human CVCL_7T04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109478 CVCL_8504 KYSE-1440 cancer cell line human CVCL_8504 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Female 21109479 CVCL_7T05 DA03952 transformed cell line human CVCL_7T05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109480 CVCL_8505 KYSE-2400 cancer cell line human CVCL_8505 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109481 CVCL_7T06 DA03953 transformed cell line human CVCL_7T06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109482 CVCL_8506 KYSE-3410 cancer cell line human CVCL_8506 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109483 CVCL_7T07 DA03954 transformed cell line human CVCL_7T07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109484 CVCL_8507 KYSE-350 cancer cell line human CVCL_8507 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 37.7 hours (PubMed=1728357) 21109485 CVCL_8500 ASF-4-4R2 finite cell line human CVCL_8500 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: JCRB; JCRB1446; probable Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages 21109486 CVCL_7T00 DA03946 transformed cell line human CVCL_7T00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109487 CVCL_7T01 DA03947 transformed cell line human CVCL_7T01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109488 CVCL_8501 KYSE-1190 cancer cell line human CVCL_8501 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109489 CVCL_7T02 DA03948 transformed cell line human CVCL_7T02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109490 CVCL_8502 KYSE-1230 cancer cell line human CVCL_8502 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21109491 CVCL_7T03 DA03949 transformed cell line human CVCL_7T03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109492 CVCL_8503 KYSE-1260 cancer cell line human CVCL_8503 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342fs*2 (c.1024_1030del7); Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Male 21109493 CVCL_7T08 DA03955 transformed cell line human CVCL_7T08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109494 CVCL_8508 KYSE-590 cancer cell line human CVCL_8508 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=9033652); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109495 CVCL_7T09 DA03956 transformed cell line human CVCL_7T09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109496 CVCL_8509 KYSE-770 cancer cell line human CVCL_8509 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109497 CVCL_7T20 DA03967 transformed cell line human CVCL_7T20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109498 CVCL_8520 GM04569 finite cell line human CVCL_8520 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; None_reported; -; Zygosity=- (PubMed=21354051) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21109499 CVCL_7T21 DA03968 transformed cell line human CVCL_7T21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109500 CVCL_8521 GM04981 finite cell line human CVCL_8521 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-53del; Zygosity=Hemizygous (PubMed=21354051) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21109501 CVCL_7T15 DA03962 transformed cell line human CVCL_7T15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109502 CVCL_8515 GM00852 finite cell line human CVCL_8515 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu29Alafs*18 (c.84dupG) (c.84_85insG) (84GG); ClinVar=VCV000004302; Zygosity=Heterozygous (PubMed=19815695); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=19815695) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21109503 CVCL_7T16 DA03963 transformed cell line human CVCL_7T16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109504 CVCL_8516 GM01187 finite cell line human CVCL_8516 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21109505 CVCL_7T17 DA03964 transformed cell line human CVCL_7T17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109506 CVCL_8517 GM01390 finite cell line human CVCL_8517 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (PubMed=1346349; PubMed=1680289); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.1050_1054delGAAGA; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21109507 CVCL_7T18 DA03965 transformed cell line human CVCL_7T18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109508 CVCL_8518 GM02416 finite cell line human CVCL_8518 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21109509 CVCL_7T11 DA03958 transformed cell line human CVCL_7T11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109510 CVCL_8511 KYSE-850 cancer cell line human CVCL_8511 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male 21109511 CVCL_7T12 DA03959 transformed cell line human CVCL_7T12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109512 CVCL_8512 KYSE-960 cancer cell line human CVCL_8512 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Male Doubling time: ~30 hours (lot 10072016) (JCRB) 21109513 CVCL_7T13 DA03960 transformed cell line human CVCL_7T13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109514 CVCL_8513 STK 1 hybridoma house mouse CVCL_8513 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09884; Human POLA1. 21109515 CVCL_7T14 DA03961 transformed cell line human CVCL_7T14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109516 CVCL_8514 GM00013 finite cell line human CVCL_8514 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21109517 CVCL_7T19 DA03966 transformed cell line human CVCL_7T19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109518 CVCL_8519 GM04281 finite cell line human CVCL_8519 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=18691744; PubMed=25928884) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21109519 CVCL_IH17 ND06297 transformed cell line human CVCL_IH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109520 CVCL_IH18 ND06300 transformed cell line human CVCL_IH18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109521 CVCL_IH19 ND06444 transformed cell line human CVCL_IH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109522 CVCL_IH13 ND05709 transformed cell line human CVCL_IH13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109523 CVCL_IH14 ND05791 transformed cell line human CVCL_IH14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109524 CVCL_IH15 ND05885 transformed cell line human CVCL_IH15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109525 CVCL_IH16 ND05941 transformed cell line human CVCL_IH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109526 CVCL_IH10 ND05646 transformed cell line human CVCL_IH10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109527 CVCL_IH11 ND05647 transformed cell line human CVCL_IH11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109528 CVCL_IH12 ND05648 transformed cell line human CVCL_IH12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109529 CVCL_IH30 ND08397 transformed cell line human CVCL_IH30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109530 CVCL_IH28 ND08395 transformed cell line human CVCL_IH28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109531 CVCL_IH29 ND08396 transformed cell line human CVCL_IH29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109532 CVCL_IH24 ND07471 transformed cell line human CVCL_IH24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109533 CVCL_IH25 ND07709 transformed cell line human CVCL_IH25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109534 CVCL_IH26 ND07971 transformed cell line human CVCL_IH26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109535 CVCL_IH27 ND08255 transformed cell line human CVCL_IH27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109536 CVCL_IH20 ND06504 transformed cell line human CVCL_IH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109537 CVCL_IH21 ND06863 transformed cell line human CVCL_IH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109538 CVCL_IH22 ND07201 transformed cell line human CVCL_IH22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109539 CVCL_IH23 ND07281 transformed cell line human CVCL_IH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109540 CVCL_IH06 ND04794 transformed cell line human CVCL_IH06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109541 CVCL_IH07 ND05050 transformed cell line human CVCL_IH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109542 CVCL_IH08 ND05258 transformed cell line human CVCL_IH08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109543 CVCL_IH09 ND05481 transformed cell line human CVCL_IH09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109544 CVCL_IH02 ND04315 transformed cell line human CVCL_IH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109545 CVCL_IH03 ND04437 transformed cell line human CVCL_IH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109546 CVCL_IH04 ND04539 transformed cell line human CVCL_IH04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109547 CVCL_IH05 ND04710 transformed cell line human CVCL_IH05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109548 CVCL_IH00 ND03785 transformed cell line human CVCL_IH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109549 CVCL_IH01 ND03824 transformed cell line human CVCL_IH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109550 CVCL_7T90 DA04044 transformed cell line human CVCL_7T90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA04044; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109551 CVCL_8590 UW78 cancer cell line human CVCL_8590 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18505928). 21109552 CVCL_7T95 DA04050 transformed cell line human CVCL_7T95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109553 CVCL_8595 SK-Ala-21 cancer cell line human CVCL_8595 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109554 CVCL_7T96 DA04051 transformed cell line human CVCL_7T96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109555 CVCL_8596 SK-Ala-3 cancer cell line human CVCL_8596 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109556 CVCL_7T97 DA04053 transformed cell line human CVCL_7T97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109557 CVCL_8597 SK-Neo cancer cell line human CVCL_8597 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Lys (c.710T>A); ClinVar=VCV000376636; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109558 CVCL_7T98 DA04054 transformed cell line human CVCL_7T98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109559 CVCL_8598 SK-p53-1 cancer cell line human CVCL_8598 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109560 CVCL_7T91 DA04045 transformed cell line human CVCL_7T91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109561 CVCL_8591 SK-Ala-1 cancer cell line human CVCL_8591 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109562 CVCL_7T92 DA04046 transformed cell line human CVCL_7T92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109563 CVCL_8592 SK-Ala-10 cancer cell line human CVCL_8592 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109564 CVCL_7T93 DA04048 transformed cell line human CVCL_7T93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109565 CVCL_8593 SK-Ala-14 cancer cell line human CVCL_8593 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109566 CVCL_7T94 DA04049 transformed cell line human CVCL_7T94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109567 CVCL_8594 SK-Ala-2 cancer cell line human CVCL_8594 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109568 CVCL_7T88 DA04042 transformed cell line human CVCL_7T88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109569 CVCL_8588 UW35 cancer cell line human CVCL_8588 CL:0000010 Male 21109570 CVCL_7T89 DA04043 transformed cell line human CVCL_7T89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109571 CVCL_8589 UW5 cancer cell line human CVCL_8589 CL:0000010 21109572 CVCL_7T99 DA04055 transformed cell line human CVCL_7T99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21109573 CVCL_8599 SK-p53-2 cancer cell line human CVCL_8599 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21109574 CVCL_A942 chHES-29 embryonic stem cell human CVCL_A942 HLA typing: A*02,11; B*13,15(75); DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109575 CVCL_A941 chHES-28 embryonic stem cell human CVCL_A941 HLA typing: A*01,26; B*37,40(60); DRB1*10,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109576 CVCL_A944 chHES-30 embryonic stem cell human CVCL_A944 HLA typing: A*01,33; B*46,58; DRB1*09,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109577 CVCL_A943 chHES-3 embryonic stem cell human CVCL_A943 HLA typing: A*02,11; B*13,13 (PubMed=20224969). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109578 CVCL_A946 chHES-32 embryonic stem cell human CVCL_A946 HLA typing: A*01; B*35; DRB1*13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109579 CVCL_A945 chHES-31 embryonic stem cell human CVCL_A945 HLA typing: A*11,24; B*13,35; DRB1*11,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109580 CVCL_A948 chHES-34 embryonic stem cell human CVCL_A948 HLA typing: A*02; B*46; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109581 CVCL_A947 chHES-33 embryonic stem cell human CVCL_A947 HLA typing: A*11,33; B*27,44; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109582 CVCL_A940 chHES-27 embryonic stem cell human CVCL_A940 HLA typing: A*02,11; B*46,51; DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109583 CVCL_A939 chHES-26 embryonic stem cell human CVCL_A939 HLA typing: A*02,11; B*40(60),54; DRB1*12,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109584 CVCL_A938 chHES-25 embryonic stem cell human CVCL_A938 HLA typing: A*02,24; B*40(61),46; DRB1*11,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109585 CVCL_A953 chHES-39 embryonic stem cell human CVCL_A953 HLA typing: A*11; B*15(62),38; DRB1*04,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109586 CVCL_A952 chHES-38 embryonic stem cell human CVCL_A952 HLA typing: A*02,11; B*13,46; DRB1*15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109587 CVCL_A955 chHES-40 embryonic stem cell human CVCL_A955 HLA typing: A*24; B*15(75),46; DRB1*12,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109588 CVCL_A954 chHES-4 embryonic stem cell human CVCL_A954 HLA typing: A*02,24; B*15,38 (PubMed=20224969). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109589 CVCL_A957 chHES-42 embryonic stem cell human CVCL_A957 HLA typing: A*11,26; B*40(60),54; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109590 CVCL_A956 chHES-41 embryonic stem cell human CVCL_A956 HLA typing: A*02,31; B*48; DRB1*09,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109591 CVCL_A959 chHES-44 embryonic stem cell human CVCL_A959 HLA typing: A*02,31; B*40(60),58; DRB1*03,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109592 CVCL_A958 chHES-43 embryonic stem cell human CVCL_A958 HLA typing: A*02,11; B*40(60),51; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109593 CVCL_A951 chHES-37 embryonic stem cell human CVCL_A951 HLA typing: A*01,31; B*37,51; DRB1*10,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109594 CVCL_A950 chHES-36 embryonic stem cell human CVCL_A950 HLA typing: A*01,11; B*37,40(61); DRB1*11,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109595 CVCL_A949 chHES-35 embryonic stem cell human CVCL_A949 HLA typing: A*11,24; B*13,51; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109596 CVCL_A920 chHES-184 embryonic stem cell human CVCL_A920 HLA typing: A*33; B*58,67; DRB1*13,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109597 CVCL_A922 chHES-186 embryonic stem cell human CVCL_A922 HLA typing: A*11; B*15(75),51; DRB1*14,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109598 CVCL_A921 chHES-185 embryonic stem cell human CVCL_A921 HLA typing: A*02,11; B*15(75),46; DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109599 CVCL_A924 chHES-188 embryonic stem cell human CVCL_A924 HLA typing: A*02; B*46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109600 CVCL_A923 chHES-187 embryonic stem cell human CVCL_A923 HLA typing: A*01,02; B*13,37; DRB1*10,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109601 CVCL_A926 chHES-19 embryonic stem cell human CVCL_A926 HLA typing: A*02,11; B*40(60),48; DRB1*12,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109602 CVCL_A925 chHES-189 embryonic stem cell human CVCL_A925 HLA typing: A*11,30; B*13; DRB1*07,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109603 CVCL_A917 chHES-181 embryonic stem cell human CVCL_A917 HLA typing: A*02; B*15(71),40(61); DRB1*09,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109604 CVCL_A916 chHES-180 embryonic stem cell human CVCL_A916 HLA typing: A*11; B*40(60),46; DRB1*04,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109605 CVCL_A919 chHES-183 embryonic stem cell human CVCL_A919 HLA typing: A*02,11; B*08,15(75); DRB1*03,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109606 CVCL_A918 chHES-182 embryonic stem cell human CVCL_A918 HLA typing: A*01,11; B*40(60),52; DRB1*08,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109607 CVCL_A931 chHES-194 embryonic stem cell human CVCL_A931 HLA typing: A*02,11; B*46,54; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109608 CVCL_A930 chHES-193 embryonic stem cell human CVCL_A930 HLA typing: A*02,24; B*46,58; DRB1*03,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109609 CVCL_A933 chHES-20 embryonic stem cell human CVCL_A933 HLA typing: A*24; B*40(60),55; DRB1*04,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109610 CVCL_A932 chHES-195 embryonic stem cell human CVCL_A932 HLA typing: A*02,11; B*13,15(62); DRB1*04,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109611 CVCL_A935 chHES-22 embryonic stem cell human CVCL_A935 HLA typing: A*02,11; B*35,40(60); DRB1*03,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109612 CVCL_A934 chHES-21 embryonic stem cell human CVCL_A934 HLA typing: A*02,11; B*46; DRB1*04,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109613 CVCL_A937 chHES-24 embryonic stem cell human CVCL_A937 HLA typing: A*02,24; B*38,56; DRB1*11,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-23 (Cellosaurus=CVCL_A936). Female 21109614 CVCL_A936 chHES-23 embryonic stem cell human CVCL_A936 HLA typing: A*02,24; B*55,56; DRB1*11,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-24 (Cellosaurus=CVCL_A937). Male 21109615 CVCL_A928 chHES-191 embryonic stem cell human CVCL_A928 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Ambiguous 21109616 CVCL_A927 chHES-190 embryonic stem cell human CVCL_A927 HLA typing: A*11; B*15(62),54; DRB1*04 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109617 CVCL_A929 chHES-192 embryonic stem cell human CVCL_A929 HLA typing: A*02,11; B*13,55; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109618 CVCL_A900 chHES-166 embryonic stem cell human CVCL_A900 HLA typing: A*02,11; B*46,55; DRB1*12,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109619 CVCL_A902 chHES-168 embryonic stem cell human CVCL_A902 HLA typing: A*11,24; B*39,46; DRB1*08,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109620 CVCL_A901 chHES-167 embryonic stem cell human CVCL_A901 HLA typing: A*11; B*38,40(60); DRB1*08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109621 CVCL_A904 chHES-17 embryonic stem cell human CVCL_A904 HLA typing: A*11; B*15(75),35; DRB1*10,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109622 CVCL_A903 chHES-169 embryonic stem cell human CVCL_A903 HLA typing: A*24,33; B*54,58; DRB1*03,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109623 CVCL_A911 chHES-176 embryonic stem cell human CVCL_A911 HLA typing: A*02,11; B*13,46; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109624 CVCL_A910 chHES-175 embryonic stem cell human CVCL_A910 HLA typing: A*02,24; B*46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109625 CVCL_A913 chHES-178 embryonic stem cell human CVCL_A913 HLA typing: A*11; B*40(60),46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109626 CVCL_A912 chHES-177 embryonic stem cell human CVCL_A912 HLA typing: A*11; B*07; DRB1*01 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109627 CVCL_A915 chHES-18 embryonic stem cell human CVCL_A915 HLA typing: A*02,24; B*15(62),56; DRB1*11,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109628 CVCL_A914 chHES-179 embryonic stem cell human CVCL_A914 HLA typing: A*02,24; B*40(60),46; DRB1*08,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109629 CVCL_A906 chHES-171 embryonic stem cell human CVCL_A906 HLA typing: A*11,24; B*40(60),46; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109630 CVCL_A905 chHES-170 embryonic stem cell human CVCL_A905 HLA typing: A*11; B*15(75); DRB1*12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109631 CVCL_A908 chHES-173 embryonic stem cell human CVCL_A908 HLA typing: A*02,30; B*13,46; DRB1*07,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109632 CVCL_A907 chHES-172 embryonic stem cell human CVCL_A907 HLA typing: A*11; B*15(75); DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109633 CVCL_A909 chHES-174 embryonic stem cell human CVCL_A909 HLA typing: A*02; B*46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109634 CVCL_J359 FRI cancer cell line human CVCL_J359 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Homozygous (PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (PubMed=9000147; PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746) 21109635 CVCL_IR59 U3008MG cancer cell line human CVCL_IR59 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109636 CVCL_J356 MPNST-91 cancer cell line human CVCL_J356 CL:0000010 Derived from metastatic site: Right thigh. Female Doubling time: 26 hours (PubMed=19414372) 21109637 CVCL_IR56 U3002MG cancer cell line human CVCL_IR56 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109638 CVCL_IR55 GM7 cancer cell line human CVCL_IR55 CL:0000010 Derived from sampling site: Brain. Male Doubling time: ~18 hours (PubMed=19082452) 21109639 CVCL_J355 MPNST-90 cancer cell line human CVCL_J355 CL:0000010 Female Doubling time: 32 hours (PubMed=19414372). 21109640 CVCL_J358 ALA cancer cell line human CVCL_J358 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Unspecified (PubMed=9000147). Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147) 21109641 CVCL_IR58 U3005MG cancer cell line human CVCL_IR58 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109642 CVCL_J357 MPNST-92 cancer cell line human CVCL_J357 CL:0000010 Female Doubling time: 24 hours (PubMed=19414372). 21109643 CVCL_IR57 U3004MG cancer cell line human CVCL_IR57 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109644 CVCL_IR52 ncPNET1 cancer cell line human CVCL_IR52 CL:0000010 Omics: SNP array analysis. 21109645 CVCL_J352 T34 [Human lymphoma] cancer cell line human CVCL_J352 CL:0000010 Population: Japanese; Derived from sampling site: Lymph node Cell type=T-cell.. Male Doubling time: 36-48 hours (PubMed=3261629) 21109646 CVCL_J351 MES23.5 hybrid cell line CVCL_J351 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of rat embryonic mesencephalon cells with mouse neuroblastoma cell line N18TG2 21109647 CVCL_IR51 nOLIG1 cancer cell line human CVCL_IR51 CL:0000010 21109648 CVCL_IR54 HGG-02 cancer cell line human CVCL_IR54 CL:0000010 Sequence variation: Gene deletion; HGNC; 3236; EGFR; Zygosity=Heterozygous (PubMed=20195615); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=20195615). Male 21109649 CVCL_J354 Kobayashi cancer cell line human CVCL_J354 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Male Virology: EBV-negative Doubling time: 22.5 hours (PubMed=8847894) 21109650 CVCL_J353 FL-18-EB transformed cell line human CVCL_J353 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male 21109651 CVCL_IR53 GT9 cancer cell line human CVCL_IR53 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249_Pro250delinsSerAla (c.747_748delGCinsTG); Zygosity=Homozygous (PubMed=7757303) Derived from sampling site: Brain; right temporal lobe. Female Doubling time: 36 hours (PubMed=7757303) Group: Patented cell line 21109652 CVCL_IR50 nEPN2 cancer cell line human CVCL_IR50 CL:0000010 Omics: SNP array analysis. 21109653 CVCL_J350 OE cancer cell line human CVCL_J350 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00082 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). 21109654 CVCL_RL00 PI-1679-C20 induced pluripotent stem cell human CVCL_RL00 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=22567022) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21109655 CVCL_RL02 PI-1828-B2 induced pluripotent stem cell human CVCL_RL02 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=22567022) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21109656 CVCL_RL01 PI-1827-A34-1 induced pluripotent stem cell human CVCL_RL01 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21109657 CVCL_J367 c-WRT-7-LR cancer cell line Norway rat CVCL_J367 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Discontinued: JCRB; FDSC0004; true Female 21109658 CVCL_IR67 U3024MG cancer cell line human CVCL_IR67 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109659 CVCL_J366 c-WRT-7 cancer cell line Norway rat CVCL_J366 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Female 21109660 CVCL_IR66 U3021MG cancer cell line human CVCL_IR66 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109661 CVCL_J369 FM3A HPRT~ cancer cell line house mouse CVCL_J369 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21109662 CVCL_IR69 U3028MG cancer cell line human CVCL_IR69 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109663 CVCL_J368 FM3A APRT~ cancer cell line house mouse CVCL_J368 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88290; 5-hydroxy-1H-imidazole-4-carboxamide (4-carbamoylimidazolium 5-olate; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21109664 CVCL_IR68 U3027MG cancer cell line human CVCL_IR68 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109665 CVCL_J363 BALB-MC.E12 cancer cell line house mouse CVCL_J363 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cHe. Discontinued: JCRB; FDSC0003; true Female 21109666 CVCL_IR63 U3017MG cancer cell line human CVCL_IR63 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109667 CVCL_J362 BALB-MC.D3 cancer cell line house mouse CVCL_J362 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cHe. Discontinued: JCRB; FDSC0002; true Female 21109668 CVCL_IR62 U3016MG cancer cell line human CVCL_IR62 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109669 CVCL_J365 Nalm-6-MSH+ cancer cell line human CVCL_J365 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: NALM-6 has a partial C-terminal deletion of the MSH2 gene, Nalm-6-MSH+ repairs the gene by transfection of the missing exons 21109670 CVCL_IR65 U3020MG cancer cell line human CVCL_IR65 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109671 CVCL_J364 TWNT-1 telomerase immortalized cell line human CVCL_J364 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Female Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the TERT gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7843 21109672 CVCL_IR64 U3019MG cancer cell line human CVCL_IR64 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109673 CVCL_J361 BALB-MC cancer cell line house mouse CVCL_J361 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cHe. Female Doubling time: ~18-23 hours (PubMed=3680103); ~26-33 hours (lot 02162015) (JCRB) 21109674 CVCL_IR61 U3013MG cancer cell line human CVCL_IR61 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109675 CVCL_J360 CLAC cancer cell line dog CVCL_J360 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Pointer. Male Doubling time: ~51 hours (PubMed=21245282) 21109676 CVCL_IR60 U3009MG cancer cell line human CVCL_IR60 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21109677 CVCL_J338 CCCL-7 cancer cell line human CVCL_J338 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109678 CVCL_IR38 EC-82 cancer cell line human CVCL_IR38 CL:0000010 Derived from sampling site: Vagina. Female Doubling time: 20 hours (PubMed=629296) 21109679 CVCL_J337 CCCL-5 cancer cell line human CVCL_J337 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109680 CVCL_IR37 EC-50 cancer cell line human CVCL_IR37 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: ~16 hours (PubMed=629296) 21109681 CVCL_J339 CCCL-8 cancer cell line human CVCL_J339 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109682 CVCL_IR39 ROS 17/2 cancer cell line Norway rat CVCL_IR39 CL:0000010 Breed/subspecies: ACI 9935. 21109683 CVCL_J334 CCCL-30 cancer cell line human CVCL_J334 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Unspecified 21109684 CVCL_IR34 WTC-mEGFP-TUBA1B-cl105 induced pluripotent stem cell human CVCL_IR34 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 TUBA1B has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21109685 CVCL_J333 CCCL-3 cancer cell line human CVCL_J333 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=20570890). Male 21109686 CVCL_IR33 WTC-mEGFP-TOMM20-cl27 induced pluripotent stem cell human CVCL_IR33 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 TOMM20 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21109687 CVCL_J336 CCCL-6 cancer cell line human CVCL_J336 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890). Female 21109688 CVCL_IR36 MG-63.3A cancer cell line human CVCL_IR36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone; left femur. Male 21109689 CVCL_J335 CCCL-4 cancer cell line human CVCL_J335 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109690 CVCL_IR35 SW-8 finite cell line human CVCL_IR35 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21109691 CVCL_J330 CCCL-23 cancer cell line human CVCL_J330 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Homozygous (PubMed=20570890); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=20570890). Male 21109692 CVCL_IR30 WTC EGFP-PXN-cl50 induced pluripotent stem cell human CVCL_IR30 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 PXN has been endogenously tagged in one allele at the C-terminus with EGFP Part of: Allen Cell Collection 21109693 CVCL_J332 CCCL-28 cancer cell line human CVCL_J332 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=20570890). Unspecified 21109694 CVCL_IR32 WTC-mEGFP-LMNB1-cl210 induced pluripotent stem cell human CVCL_IR32 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 LMNB1 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21109695 CVCL_J331 CCCL-26 cancer cell line human CVCL_J331 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Unspecified 21109696 CVCL_IR31 WTC-mEGFP-DSP-cl65 induced pluripotent stem cell human CVCL_IR31 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 DSP has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21109697 CVCL_J349 C1R-B27 transformed cell line human CVCL_J349 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*27) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109698 CVCL_IR49 nEPN1 cancer cell line human CVCL_IR49 CL:0000010 Omics: SNP array analysis. 21109699 CVCL_J348 HS-42 cancer cell line human CVCL_J348 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Ovary. Female Doubling time: 34 hours (PubMed=8945624) 21109700 CVCL_IR48 MED2 cancer cell line human CVCL_IR48 CL:0000010 Omics: SNP array analysis. 21109701 CVCL_J345 HS-16 cancer cell line human CVCL_J345 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Male Doubling time: 40 hours (PubMed=8945624). 21109702 CVCL_IR45 IGR-CaP1-R100 cancer cell line human CVCL_IR45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from sampling site: Prostate. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4127 21109703 CVCL_J344 CCCL-22 cancer cell line human CVCL_J344 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109704 CVCL_IR44 Hepama-2 hybridoma house mouse CVCL_IR44 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human hepatocellular carcinoma cell lines. 21109705 CVCL_J347 HS-30 cancer cell line human CVCL_J347 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Male Doubling time: 39 hours (PubMed=8945624). 21109706 CVCL_IR47 MED1 cancer cell line human CVCL_IR47 CL:0000010 Male 21109707 CVCL_IR46 bGB1 cancer cell line human CVCL_IR46 CL:0000010 Omics: SNP array analysis Caution: Was originally classified as originating from a glioblastoma but seems to be from a malignant glioneuronal tumor (MGNT) which is a cancer type not recognized by WHO and NCIt. 21109708 CVCL_J346 HS-18 cancer cell line human CVCL_J346 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Female Doubling time: 33 hours (PubMed=8945624). 21109709 CVCL_J341 CCCL-13 cancer cell line human CVCL_J341 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890) Female 21109710 CVCL_IR41 UMR-201-10B transformed cell line Norway rat CVCL_IR41 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.. Unspecified 21109711 CVCL_J340 CCCL-9 cancer cell line human CVCL_J340 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21109712 CVCL_IR40 UMR-201-10A transformed cell line Norway rat CVCL_IR40 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.. Unspecified 21109713 CVCL_J343 CCCL-16 cancer cell line human CVCL_J343 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109714 CVCL_IR43 Hepama-1 hybridoma house mouse CVCL_IR43 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human hepatocellular carcinoma cell lines. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C95013 21109715 CVCL_J342 CCCL-15 cancer cell line human CVCL_J342 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21109716 CVCL_IR42 H22-H8D8 cancer cell line house mouse CVCL_IR42 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3HA. 21109717 CVCL_A986 chHES-70 embryonic stem cell human CVCL_A986 HLA typing: A*02,31; B*08,40(60); DRB1*03,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109718 CVCL_A985 chHES-7 embryonic stem cell human CVCL_A985 HLA typing: A*02,24; B*38,40 (PubMed=20224969). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109719 CVCL_A988 chHES-72 embryonic stem cell human CVCL_A988 HLA typing: A*02; B*46; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109720 CVCL_A987 chHES-71 embryonic stem cell human CVCL_A987 HLA typing: A*11; B*15(75),39; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109721 CVCL_A989 chHES-73 embryonic stem cell human CVCL_A989 HLA typing: A*02,11; B*13,15(62); DRB1*08,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109722 CVCL_J319 LSHM7 cancer cell line human CVCL_J319 CL:0000010 Unspecified 21109723 CVCL_IR19 MCCL-4 cancer cell line human CVCL_IR19 CL:0000010 Derived from sampling site: Thigh; skin. Male 21109724 CVCL_A980 chHES-65 embryonic stem cell human CVCL_A980 HLA typing: A*02; B*48,51; DRB1*09,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109725 CVCL_J316 201-45E9 hybridoma house mouse CVCL_J316 CL:0000010 Monoclonal antibody isotype: IgG1. 21109726 CVCL_A982 chHES-67 embryonic stem cell human CVCL_A982 HLA typing: A*02; B*40(60),46; DRB1*08,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109727 CVCL_IR16 EA-1 cancer cell line human CVCL_IR16 CL:0000010 Derived from sampling site: Endometrium. Female 21109728 CVCL_A981 chHES-66 embryonic stem cell human CVCL_A981 HLA typing: A*02,11; B*15(62),46; DRB1*04,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109729 CVCL_IR15 DL-95 cancer cell line human CVCL_IR15 CL:0000010 Population: Japanese Male Characteristics: IL6 dependent. 21109730 CVCL_J315 SC78.H81.C81.A9 hybridoma house mouse CVCL_J315 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16794; Scopolamine. 21109731 CVCL_J318 CEM-SS cancer cell line human CVCL_J318 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: Used for a quantitative syncytium-forming assay for the detection of human immunodeficiency virus-1 and -2 isolates Doubling time: ~1-2 days (HIVReagentProgram) 21109732 CVCL_A984 chHES-69 embryonic stem cell human CVCL_A984 HLA typing: A*11,24; B*27,40(61); DRB1*11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109733 CVCL_IR18 MCCL-3 cancer cell line human CVCL_IR18 CL:0000010 Female 21109734 CVCL_J317 202-11A8 hybridoma house mouse CVCL_J317 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8895 21109735 CVCL_A983 chHES-68 embryonic stem cell human CVCL_A983 HLA typing: A*02,24; B*38,56; DRB1*13,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109736 CVCL_IR17 MCCL-2 cancer cell line human CVCL_IR17 CL:0000010 Derived from metastatic site: Cutaneous. Male 21109737 CVCL_IR12 BHD-F59RSVT cancer cell line human CVCL_IR12 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Glu510del (c.1525GAG[1]) (c.1528_1530delGAG); ClinVar=VCV000253256; Zygosity=Unspecified (PubMed=27991910). Male 21109738 CVCL_J312 MJM cancer cell line human CVCL_J312 CL:0000010 Derived from sampling site: Skin. Male Doubling time: ~63 hours (PubMed=752115); 102.8 hours (PubMed=6819484) 21109739 CVCL_IR11 cST3232/10 hybridoma house mouse CVCL_IR11 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06004 21109740 CVCL_J311 OM482 cancer cell line human CVCL_J311 CL:0000010 Unspecified Doubling time: 22 hours (PubMed=1531323). 21109741 CVCL_IR14 DL-110 cancer cell line human CVCL_IR14 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: IL6 dependent 21109742 CVCL_J314 HUUCLEC cancer cell line human CVCL_J314 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 56 (HPV56)(NCBI-Taxonomy; 10596); Derived from sampling site: Uterus; cervix. Female Doubling time: ~82 hours (PubMed=12227504) 21109743 CVCL_J313 B-HM8 cancer cell line human CVCL_J313 CL:0000010 Derived from sampling site: Back; skin. Female Doubling time: 70.5 hours (PubMed=6819484) 21109744 CVCL_IR13 CHO-13D-35D spontaneously immortalized cell line CVCL_IR13 CL:0000010 Transfected with: HGNC; 775; SERPINC1 Derived from sampling site: Ovary. Female 21109745 CVCL_IR10 Jurkat 1G4 cancer cell line human CVCL_IR10 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: T-cell receptor 1G4 (TCR 1G4) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21109746 CVCL_J310 OM467 cancer cell line human CVCL_J310 CL:0000010 Unspecified Doubling time: 38 hours (PubMed=1531323). 21109747 CVCL_A997 chHES-80 embryonic stem cell human CVCL_A997 HLA typing: A*33; B*58; DRB1*03 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-79 (Cellosaurus=CVCL_A996). Female 21109748 CVCL_A996 chHES-8 embryonic stem cell human CVCL_A996 HLA typing: A*31,33; B*40(61),58; DRB1*11,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109749 CVCL_A999 chHES-82 embryonic stem cell human CVCL_A999 HLA typing: A*24,30; B*27,46; DRB1*09,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109750 CVCL_A998 chHES-81 embryonic stem cell human CVCL_A998 HLA typing: A*02,11; B*38,40(60); DRB1*11,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109751 CVCL_A991 chHES-75 embryonic stem cell human CVCL_A991 HLA typing: A*02,11; B*13,46; DRB1*08,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-74 (Cellosaurus=CVCL_A990). Female 21109752 CVCL_A990 chHES-74 embryonic stem cell human CVCL_A990 HLA typing: A*11,24; B*27,51; DRB1*11,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-75 (Cellosaurus=CVCL_A991). Female 21109753 CVCL_J327 CCCL-2 cancer cell line human CVCL_J327 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890). Female 21109754 CVCL_A993 chHES-77 embryonic stem cell human CVCL_A993 HLA typing: A*02; B*46; DRB1*09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-76 (Cellosaurus=CVCL_A992). Female 21109755 CVCL_IR27 U-CH12 cancer cell line human CVCL_IR27 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: Transcriptome analysis by microarray Male Doubling time: 7 days (PubMed=26183925); 11-13 days (Chordoma_Foundation) 21109756 CVCL_J326 CCCL-19 cancer cell line human CVCL_J326 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=20570890). Female 21109757 CVCL_A992 chHES-76 embryonic stem cell human CVCL_A992 HLA typing: A*02,26; B*15(62),46; DRB1*04,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-77 (Cellosaurus=CVCL_A993). Male 21109758 CVCL_IR26 U-CH6 cancer cell line human CVCL_IR26 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from metastatic site: Skin. Omics: Transcriptome analysis by microarray Male Doubling time: 14 days (PubMed=26183925) 21109759 CVCL_J329 CCCL-21 cancer cell line human CVCL_J329 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21109760 CVCL_A995 chHES-79 embryonic stem cell human CVCL_A995 HLA typing: A*11,33; B*13,58; DRB1*03,12 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-80 (Cellosaurus=CVCL_A996). Female 21109761 CVCL_IR29 MEL2-mCherry embryonic stem cell human CVCL_IR29 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female 21109762 CVCL_J328 CCCL-20 cancer cell line human CVCL_J328 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21109763 CVCL_A994 chHES-78 embryonic stem cell human CVCL_A994 HLA typing: A*11,33; B*40(60),58; DRB1*03,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109764 CVCL_IR28 HRC-99 cancer cell line human CVCL_IR28 CL:0000010 Population: Chinese; Derived from sampling site: Rectum. Female Doubling time: 24.8 hours (DOI=10.11569/wcjd.v13.i13.1510) 21109766 CVCL_IR23 U-CH7 cancer cell line human CVCL_IR23 CL:0000010 Derived from sampling site: Bone; sacrum. Omics: Transcriptome analysis by microarray Male Doubling time: 7 days (PubMed=26183925); 8 days (Chordoma_Foundation) 21109767 CVCL_J322 CCCL-11 cancer cell line human CVCL_J322 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890). Female 21109768 CVCL_IR22 ORS [Goat] finite cell line CVCL_IR22 CL:0000010 Derived from sampling site: Hair follicle; outer root sheath; Breed/subspecies: Jining Grey. Female Doubling time: ~52 hours (PubMed=22105552) 21109769 CVCL_J325 CCCL-18 cancer cell line human CVCL_J325 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Unspecified (PubMed=20570890); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=20570890). Female 21109770 CVCL_IR25 U-CH3 cancer cell line human CVCL_IR25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: Transcriptome analysis by microarray Female Senescence: Seems not to grow above ~17 PDL and is therefore not going to be distributed (personal communication of Cogswell P.); Doubling time: 8 days (PubMed=26183925) 21109771 CVCL_J324 CCCL-14 cancer cell line human CVCL_J324 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Unspecified 21109772 CVCL_IR24 ISH/DDP cancer cell line human CVCL_IR24 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Endometrium. Female Doubling time: 40.1 hours (PubMed=22041447) 21109773 CVCL_J321 CCCL-10 cancer cell line human CVCL_J321 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=20570890). Female 21109774 CVCL_IR21 MCCL-6 cancer cell line human CVCL_IR21 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=11992403) Derived from sampling site: Left calf; skin. Female 21109775 CVCL_J320 CCCL-1 cancer cell line human CVCL_J320 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21109776 CVCL_IR20 MCCL-5 cancer cell line human CVCL_IR20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=11992403) Derived from sampling site: Left clavicle; skin. Male 21109777 CVCL_A964 chHES-49 embryonic stem cell human CVCL_A964 HLA typing: A*02,24; B*40(60),54; DRB1*08,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109778 CVCL_A963 chHES-48 embryonic stem cell human CVCL_A963 HLA typing: A*02,31; B*46,67; DRB1*07,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109779 CVCL_A966 chHES-51 embryonic stem cell human CVCL_A966 HLA typing: A*02; B*40(60),40(61); DRB1*04,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109780 CVCL_A965 chHES-50 embryonic stem cell human CVCL_A965 HLA typing: A*02,11; B*13,51; DRB1*04,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109781 CVCL_A968 chHES-53 embryonic stem cell human CVCL_A968 HLA typing: A*02,30; B*13,46; DRB1*07 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109782 CVCL_A967 chHES-52 embryonic stem cell human CVCL_A967 HLA typing: A*02; B*46,50; DRB1*03,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109783 CVCL_A969 chHES-54 embryonic stem cell human CVCL_A969 HLA typing: A*11,31; B*46,51; DRB1*04,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109784 CVCL_A960 chHES-45 embryonic stem cell human CVCL_A960 HLA typing: A*11,24; B*40(60),51; DRB1*08,14 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-46 (Cellosaurus=CVCL_A961). Female 21109785 CVCL_A962 chHES-47 embryonic stem cell human CVCL_A962 HLA typing: A*11,24; B*39,54; DRB1*04,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109786 CVCL_A961 chHES-46 embryonic stem cell human CVCL_A961 HLA typing: A*11,24; B*40(60),46; DRB1*08,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-45 (Cellosaurus=CVCL_A960). Ambiguous 21109787 CVCL_A975 chHES-60 embryonic stem cell human CVCL_A975 HLA typing: A*11,26; B*40(60),56; DRB1*14,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109788 CVCL_A974 chHES-59 embryonic stem cell human CVCL_A974 HLA typing: A*02,11; B*13,35; DRB1*15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109789 CVCL_A977 chHES-62 embryonic stem cell human CVCL_A977 HLA typing: A*02; B*15(62),46; DRB1*04,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to those giving rise to chHES-63 (Cellosaurus=CVCL_A978) and chHES-64 (Cellosaurus=CVCL_A979). Female 21109790 CVCL_A976 chHES-61 embryonic stem cell human CVCL_A976 HLA typing: A*11; B*13,40(60); DRB1*08,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109791 CVCL_A979 chHES-64 embryonic stem cell human CVCL_A979 HLA typing: A*02; B*15(62),46; DRB1*04,14 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to those giving rise to chHES-62 (Cellosaurus=CVCL_A977) and chHES-63 (Cellosaurus=CVCL_A978). Male 21109792 CVCL_A978 chHES-63 embryonic stem cell human CVCL_A978 HLA typing: A*02,26; B*46,48; DRB1*09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to those giving rise to chHES-62 (Cellosaurus=CVCL_A977) and chHES-64 (Cellosaurus=CVCL_A979). Female 21109793 CVCL_J309 OM464 cancer cell line human CVCL_J309 CL:0000010 Unspecified Doubling time: >72 hours (PubMed=1531323). 21109794 CVCL_IR09 PSC-THP1-chondrocyte-like cancer cell line human CVCL_IR09 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06001 21109795 CVCL_J308 OM431 cancer cell line human CVCL_J308 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Male Doubling time: 24 hours (PubMed=1531323) 21109796 CVCL_IR08 PSC-THP1 cancer cell line human CVCL_IR08 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 05005 21109797 CVCL_A971 chHES-56 embryonic stem cell human CVCL_A971 HLA typing: A*02,11; B*15(75),46; DRB1*08,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109798 CVCL_IR05 Super-CHO C2.8 spontaneously immortalized cell line CVCL_IR05 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Characteristics: IGF1 expression is under control of the CMV promoter and TF expression is under control of the SV40 early promoter 21109799 CVCL_J305 VUP15 cancer cell line human CVCL_J305 CL:0000010 Transfected with: HGNC; 6156; ITGB3. Female 21109800 CVCL_A970 chHES-55 embryonic stem cell human CVCL_A970 HLA typing: A*11,33; B*38,58; DRB1*01,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109801 CVCL_IR04 Super-CHO C2 spontaneously immortalized cell line CVCL_IR04 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Characteristics: IGF1 expression is under control of the CMV promoter and TF expression is under control of the SV40 early promoter Doubling time: 21 hours (PubMed=19003411) 21109802 CVCL_J304 Thy19 cancer cell line house mouse CVCL_J304 CL:0000010 Breed/subspecies: BALB/c. 21109803 CVCL_A973 chHES-58 embryonic stem cell human CVCL_A973 HLA typing: A*11,24; B*40(60),51; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21109804 CVCL_IR07 NeuCHO spontaneously immortalized cell line CVCL_IR07 CL:0000010 Transfected with: HGNC; 4261; GH1 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Lacks both copies of the Dhfr gene Group: Patented cell line; Registration: International Depositary Authority, Cell Bank Australia; CBA20130024 21109805 CVCL_J307 VUP-1 cancer cell line human CVCL_J307 CL:0000010 Female Doubling time: 38.7 hours (PubMed=6819484). 21109806 CVCL_A972 chHES-57 embryonic stem cell human CVCL_A972 HLA typing: A*01,11; B*39,52; DRB1*08,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21109807 CVCL_IR06 Super-CHO ISS9 spontaneously immortalized cell line CVCL_IR06 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Characteristics: IGF1 expression is under control of the CMV promoter and TF expression is under control of the SV40 early promoter 21109808 CVCL_J306 VUP20 cancer cell line human CVCL_J306 CL:0000010 Selected for resistance to: ChEBI; CHEBI:17939; Puromycin. Female 21109809 CVCL_IR01 DB-81 hybridoma house mouse CVCL_IR01 CL:0000010 Miscellaneous: Registration number from personal communication of Burastero S.E. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4 (Note=In complex with HIV-1 env) Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 03002 21109810 CVCL_J301 LSTRA cancer cell line house mouse CVCL_J301 CL:0000010 Breed/subspecies: BALB/c. 21109811 CVCL_IR00 DO-24 hybridoma house mouse CVCL_IR00 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. 21109812 CVCL_J300 Lb 752 transformed cell line human CVCL_J300 From: Laboratorio Biochimica e Biologia Cellulare, Dip Biochimica Biotecnologie Mediche, Universita' degli Studi; Napoli; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109813 CVCL_J303 RBL-5 cancer cell line house mouse CVCL_J303 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21109814 CVCL_IR03 Super-CHO C1 spontaneously immortalized cell line CVCL_IR03 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Characteristics: IGF1 expression is under control of the CMV promoter and TF expression is under control of the SV40 early promoter Doubling time: 18 hours (PubMed=19003411) 21109815 CVCL_IR02 Hs578T-Dox cancer cell line human CVCL_IR02 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Breast. Female 21109816 CVCL_J302 MBL-2 [Mouse myeloma] cancer cell line house mouse CVCL_J302 CL:0000010 21109817 CVCL_RK59 HN-SCC-166 cancer cell line human CVCL_RK59 CL:0000010 Derived from sampling site: Oral cavity; hard palate and oral cavity; soft palate. Unspecified 21109818 CVCL_RK61 HN-SCC-170B cancer cell line human CVCL_RK61 CL:0000010 Unspecified 21109819 CVCL_RK60 HN-SCC-170A cancer cell line human CVCL_RK60 CL:0000010 Derived from sampling site: Larynx; subglottis. Unspecified 21109820 CVCL_RK63 HN-SCC-294 cancer cell line human CVCL_RK63 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Leu (c.736A>T); ClinVar=VCV000406586; Zygosity=Unspecified (PubMed=8339273). Unspecified 21109821 CVCL_RK62 HN-SCC-288B cancer cell line human CVCL_RK62 CL:0000010 Derived from sampling site: Larynx. Unspecified 21109822 CVCL_RK65 ScAP-23 telomerase immortalized cell line house mouse CVCL_RK65 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Adipose tissue; hypodermis Cell type=Preadipocyte.; Breed/subspecies: C57BL/6. Male Characteristics: This preadipocyte cell line can be onverted to adipocytes when treated with dexamethasone, 3-methylisobutylxanthine, insulin and indomethacin 21109823 CVCL_RK64 HN-SCC-296A cancer cell line human CVCL_RK64 CL:0000010 Unspecified 21109824 CVCL_RK67 HAP1 KDM1A(-) 1 cancer cell line human CVCL_RK67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21109825 CVCL_RK66 FT33-shp53-R24C telomerase immortalized cell line human CVCL_RK66 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis Discontinued: ABM; T0609; probable Female 21109826 CVCL_RK69 SMS-KCN-69n cancer cell line human CVCL_RK69 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (from parent cell line) Omics: Transcriptome analysis by microarray. Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) 21109827 CVCL_RK68 SF8403 finite cell line human CVCL_RK68 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0581; probable Senescence: Senesces at 34 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21109828 CVCL_RK49 HN-SCC-104 cancer cell line human CVCL_RK49 CL:0000010 Derived from sampling site: Pharynx; hypopharynx; pyriform sinus. Unspecified 21109829 CVCL_RK48 HN-SCC-80 cancer cell line human CVCL_RK48 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919_934del16; Zygosity=Unspecified (PubMed=8339273). Unspecified 21109830 CVCL_RK50 HN-SCC-109A cancer cell line human CVCL_RK50 CL:0000010 Derived from sampling site: Larynx. Unspecified 21109831 CVCL_RK52 HN-SCC-135 cancer cell line human CVCL_RK52 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Unspecified (PubMed=8339273) Derived from sampling site: Oral cavity; hard palate. Unspecified 21109832 CVCL_RK51 HN-SCC-131 cancer cell line human CVCL_RK51 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Ser (c.614A>C); ClinVar=VCV000376683; Zygosity=Unspecified (PubMed=8339273) Derived from sampling site: Oral cavity; tongue; anterior part. Unspecified 21109833 CVCL_RK54 HN-SCC-147 cancer cell line human CVCL_RK54 CL:0000010 Unspecified 21109834 CVCL_RK53 HN-SCC-143 cancer cell line human CVCL_RK53 CL:0000010 Derived from sampling site: Pharynx; oropharynx. Unspecified 21109835 CVCL_RK56 HN-SCC-152 cancer cell line human CVCL_RK56 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val203Trpfs*44 (c.607delG); Zygosity=Unspecified (PubMed=8339273). Unspecified 21109836 CVCL_RK55 HN-SCC-151 cancer cell line human CVCL_RK55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=8339273) Derived from sampling site: Oral cavity; tongue; anterior part. Unspecified 21109837 CVCL_RK58 HN-SCC-161 cancer cell line human CVCL_RK58 CL:0000010 Derived from sampling site: Oral cavity; tongue; base. Unspecified 21109838 CVCL_RK57 HN-SCC-153 cancer cell line human CVCL_RK57 CL:0000010 Derived from sampling site: Larynx. Unspecified 21109839 CVCL_RK38 KB [Cyprinus] spontaneously immortalized cell line CVCL_RK38 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: Koi. Unspecified Virology: Susceptible to infection by koi herpesvirus (KHV) Group: Fish cell line 21109840 CVCL_RK37 SGC-7901/B1 cancer cell line human CVCL_RK37 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (SGC-7901) has been shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 21109841 CVCL_RK39 RIT-2 cancer cell line human CVCL_RK39 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=1933904) Donor information: Established from a patient originally treated by radiation therapy for a breast carcinoma (PubMed=2253180). Female 21109842 CVCL_IQ97 B504 hybridoma house mouse CVCL_IQ97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12001 21109843 CVCL_J297 Lb 224 transformed cell line human CVCL_J297 From: Laboratorio Biochimica e Biologia Cellulare, Dip Biochimica Biotecnologie Mediche, Universita' degli Studi; Napoli; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21109844 CVCL_IQ96 B503 hybridoma house mouse CVCL_IQ96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11999 21109845 CVCL_J296 PA-23 cancer cell line Norway rat CVCL_J296 CL:0000010 21109846 CVCL_IQ99 DN-30 hybridoma house mouse CVCL_IQ99 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 05006 21109847 CVCL_J299 Lb 24 transformed cell line human CVCL_J299 From: Laboratorio Biochimica e Biologia Cellulare, Dip Biochimica Biotecnologie Mediche, Universita' degli Studi; Napoli; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21109848 CVCL_IQ98 B509 hybridoma house mouse CVCL_IQ98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12002 21109849 CVCL_J298 Lb 23 transformed cell line human CVCL_J298 From: Laboratorio Biochimica e Biologia Cellulare, Dip Biochimica Biotecnologie Mediche, Universita' degli Studi; Napoli; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21109850 CVCL_J293 MA-89 finite cell line house mouse CVCL_J293 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: C3H/He. Unspecified Doubling time: 24-36 hours (lots 623 and 625) (JCRB) 21109851 CVCL_IQ93 Pen-3 hybridoma CVCL_IQ93 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P26022; Human PTX3. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 04004 21109852 CVCL_RK41 RIT-5 cancer cell line human CVCL_RK41 CL:0000010 Donor information: Established from a patient originally treated by radiation therapy for a Hodgkin lymphoma (PubMed=2253180). Female 21109853 CVCL_J292 HPSV178-4-3 hybridoma house mouse CVCL_J292 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04156; Human PRNP (GPI-anchorless splice variant). 21109854 CVCL_IQ92 MNB10 hybridoma CVCL_IQ92 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P26022; Human PTX3. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 04001 21109855 CVCL_RK40 RIT-3 cancer cell line human CVCL_RK40 CL:0000010 Donor information: Established from a patient originally treated by radiation therapy for a rhabdomyosarcoma (PubMed=2253180). Female 21109856 CVCL_RK43 HN-SCC-3 cancer cell line human CVCL_RK43 CL:0000010 Derived from sampling site: Oral cavity; soft palate. Unspecified 21109857 CVCL_IQ95 ML-1 [Human bone marrow] spontaneously immortalized cell line human CVCL_IQ95 CL:0000010 Derived from sampling site: Bone marrow. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11451 21109858 CVCL_J295 RT-2 cancer cell line Norway rat CVCL_J295 CL:0000010 Transformant: Avian sarcoma virus (ASV)(NCBI-Taxonomy; 11876); Breed/subspecies: Fischer. 21109859 CVCL_IQ94 cST2146 hybridoma house mouse CVCL_IQ94 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P24821; Human TNC. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 02003 21109860 CVCL_RK42 RIT-6 cancer cell line human CVCL_RK42 CL:0000010 Donor information: Established from a patient originally treated by radiation therapy for a Wilms tumor (PubMed=2253180). Male 21109861 CVCL_J294 TF-1 BCR/ABL cancer cell line human CVCL_J294 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 76; ABL1 (BCR-ABL1 fusion); Transfected with: HGNC; 1014; BCR (BCR-ABL1 fusion) Population: Japanese; Derived from sampling site: Bone marrow. Male 21109862 CVCL_RK45 HN-SCC-28 cancer cell line human CVCL_RK45 CL:0000010 Derived from sampling site: Larynx. Unspecified 21109863 CVCL_RK44 HN-SCC-19 cancer cell line human CVCL_RK44 CL:0000010 Unspecified 21109864 CVCL_J291 DIG64.2B.5 hybridoma house mouse CVCL_J291 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 21109865 CVCL_RK47 HN-SCC-58 cancer cell line human CVCL_RK47 CL:0000010 Derived from sampling site: Oral cavity; tongue; base. Unspecified 21109866 CVCL_IQ91 Pz04.1F6 hybridoma house mouse CVCL_IQ91 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2684 21109867 CVCL_J290 DIG222.4D.5 hybridoma house mouse CVCL_J290 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 21109868 CVCL_RK46 HN-SCC-42 cancer cell line human CVCL_RK46 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=8339273). Unspecified 21109869 CVCL_IQ90 Pz02.1C11 hybridoma house mouse CVCL_IQ90 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2682 21109870 CVCL_RK27 OVC-106 cancer cell line human CVCL_RK27 CL:0000010 Derived from sampling site: Ovary. Female 21109871 CVCL_RK26 OVC-105 cancer cell line human CVCL_RK26 CL:0000010 Derived from sampling site: Ovary. Female 21109872 CVCL_RK29 DOVC-2 cancer cell line human CVCL_RK29 CL:0000010 Derived from sampling site: Ovary. Female 21109873 CVCL_RK28 DOVC-1 cancer cell line human CVCL_RK28 CL:0000010 Derived from sampling site: Ovary. Female 21109874 CVCL_RK30 MCH66 cancer cell line house mouse CVCL_RK30 CL:0000010 Breed/subspecies: C3H. Female Characteristics: Has poor metastatic potential Doubling time: 14.4 hours (PubMed=12057902); 21.6 hours (PubMed=25027251) 21109875 CVCL_RK32 MCH66 Lu1 cancer cell line house mouse CVCL_RK32 CL:0000010 Breed/subspecies: C3H. Female Characteristics: Has no metastatic potential Doubling time: 12.6 hours (PubMed=25027251) 21109876 CVCL_RK31 MCH66 Lu10 cancer cell line house mouse CVCL_RK31 CL:0000010 Breed/subspecies: C3H. Female Characteristics: Has high metastatic potential Doubling time: 18.6 hours (PubMed=25027251) 21109877 CVCL_RK34 MCH416 cancer cell line house mouse CVCL_RK34 CL:0000010 Breed/subspecies: C3H. Female Characteristics: Has high metastatic potential Doubling time: 12.0 hours (PubMed=12057902) 21109878 CVCL_RK33 MCH66 Lu5 cancer cell line house mouse CVCL_RK33 CL:0000010 Breed/subspecies: C3H. Female Doubling time: 14.4 hours (PubMed=25027251) 21109879 CVCL_RK36 SGC-7901/B2 cancer cell line human CVCL_RK36 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has high metastatic potential Problematic cell line: Contaminated Parent cell line (SGC-7901) has been shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 21109880 CVCL_RK35 MCH66C8 cancer cell line house mouse CVCL_RK35 CL:0000010 Breed/subspecies: C3H. Female Doubling time: 19.2 hours (PubMed=12057902) 21109881 CVCL_RK16 OVC-23 cancer cell line human CVCL_RK16 CL:0000010 Derived from sampling site: Ovary. Female 21109882 CVCL_RK15 OVC-2 cancer cell line human CVCL_RK15 CL:0000010 Derived from sampling site: Ovary. Female 21109883 CVCL_RK18 OVC-50 cancer cell line human CVCL_RK18 CL:0000010 Derived from sampling site: Ovary. Female 21109884 CVCL_RK17 OVC-44 cancer cell line human CVCL_RK17 CL:0000010 Derived from sampling site: Ovary. Female 21109885 CVCL_RK19 OVC-52 cancer cell line human CVCL_RK19 CL:0000010 Derived from sampling site: Ovary. Female 21109886 CVCL_J279 F25 [Mouse hybridoma against human FCRL5] hybridoma house mouse CVCL_J279 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96RD9; Human FCRL5/CD307e. 21109887 CVCL_IQ79 PIR-P8 spontaneously immortalized cell line CVCL_IQ79 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9367; Swainsonine (Sw); Derived from sampling site: Ovary. Female Group: Patented cell line 21109888 CVCL_J278 F119 hybridoma house mouse CVCL_J278 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96RD9; Human FCRL5/CD307e. 21109889 CVCL_IQ78 SLF [Rat] transformed cell line Norway rat CVCL_IQ78 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Ear; inner ear; cochlea; spiral ligament Cell type=Fibrocyte.; Breed/subspecies: Wistar Kyoto. Male Doubling time: 28.0 +- 8.2 hours (PubMed=17214269) 21109890 CVCL_IQ75 MDCK-SF103 spontaneously immortalized cell line dog CVCL_IQ75 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6503 21109891 CVCL_J275 MT-45-5-3 hybridoma house mouse CVCL_J275 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04355; Rat Mt2. 21109892 CVCL_J274 MB86 hybridoma house mouse CVCL_J274 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Mouse IgM (allotype Igh6b). 21109893 CVCL_IQ74 MDCK-SF102 spontaneously immortalized cell line dog CVCL_IQ74 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6502 21109894 CVCL_IQ77 CL97-L2G cancer cell line human CVCL_IQ77 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly719Ala (c.2156G>C); ClinVar=VCV000045225; Zygosity=Unspecified (PubMed=23024022); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified (PubMed=23024022); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Pleural effusion. Male 21109895 CVCL_J277 GHBP116 hybridoma house mouse CVCL_J277 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10912; Human GHR. 21109896 CVCL_J276 NKY113 hybridoma house mouse CVCL_J276 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). 21109897 CVCL_IQ76 TOK [Trachinotus] spontaneously immortalized cell line CVCL_IQ76 CL:0000010 Derived from sampling site: Kidney. Male Group: Fish cell line 21109898 CVCL_J271 19-7 hybridoma house mouse CVCL_J271 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human erythrocytes. 21109899 CVCL_IQ71 XWLC-05 cancer cell line human CVCL_IQ71 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Female Doubling time: 32.8 hours (PubMed=17222362) 21109900 CVCL_J270 16-8 hybridoma house mouse CVCL_J270 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human erythrocytes. Doubling time: 19 hours (lot 102997) (JCRB) 21109901 CVCL_IQ70 BW 495/36 hybridoma house mouse CVCL_IQ70 CL:0000010 Monoclonal antibody isotype: IgG3, kappa. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2415 21109902 CVCL_J273 4-2D hybridoma house mouse CVCL_J273 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Chicken DNA primase-DNA polymerase alpha complex. 21109903 CVCL_IQ73 MDCK-SF101 spontaneously immortalized cell line dog CVCL_IQ73 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6501 21109904 CVCL_RK21 OVC-66 cancer cell line human CVCL_RK21 CL:0000010 Derived from sampling site: Ovary. Female 21109905 CVCL_J272 4-8H hybridoma house mouse CVCL_J272 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; F1NR19; Chicken POLA1. 21109906 CVCL_IQ72 MDCK-S spontaneously immortalized cell line dog CVCL_IQ72 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6500 21109907 CVCL_RK20 OVC-62 cancer cell line human CVCL_RK20 CL:0000010 Derived from sampling site: Ovary. Female 21109908 CVCL_RK23 OVC-77 cancer cell line human CVCL_RK23 CL:0000010 Derived from sampling site: Ovary. Female 21109909 CVCL_RK22 OVC-73 cancer cell line human CVCL_RK22 CL:0000010 Derived from sampling site: Ovary. Female 21109910 CVCL_RK25 OVC-102 cancer cell line human CVCL_RK25 CL:0000010 Derived from sampling site: Ovary. Female 21109911 CVCL_RK24 OVC-100 cancer cell line human CVCL_RK24 CL:0000010 Derived from sampling site: Ovary. Female 21109912 CVCL_RK05 EV-SCC-10M cancer cell line human CVCL_RK05 CL:0000010 Derived from metastatic site: Lymph node. Male 21109913 CVCL_RK04 EV-SCC-7 cancer cell line human CVCL_RK04 CL:0000010 Male 21109914 CVCL_RK07 EV-SCC-17M cancer cell line human CVCL_RK07 CL:0000010 Derived from metastatic site: Lymph node. Male 21109915 CVCL_RK06 EV-SCC-14M cancer cell line human CVCL_RK06 CL:0000010 Derived from metastatic site: Lymph node. Male 21109916 CVCL_RK09 EV-SCC-18 cancer cell line human CVCL_RK09 CL:0000010 Male 21109917 CVCL_RK08 EV-SCC-17P cancer cell line human CVCL_RK08 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male 21109918 CVCL_J289 DIG104.10H.1 hybridoma house mouse CVCL_J289 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:4551; Digoxin. 21109919 CVCL_IQ89 N52.F4 transformed cell line human CVCL_IQ89 CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. 21109920 CVCL_J286 FA20P finite cell line human CVCL_J286 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000435134; Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1390; probable Male 21109921 CVCL_IQ86 RUES1-EGFP/SMAD7 embryonic stem cell human CVCL_IQ86 CL:0000010 Transfected with: HGNC; 6773; SMAD7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: Transfected with a Tet-inducible bi-cistronic expression cassette encoding EGFP and SMAD7 21109922 CVCL_IQ85 KMS-34/Cfz cancer cell line human CVCL_IQ85 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:65347; Carfilzomib (Kyprolis; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgA kappa 21109923 CVCL_J285 KYSE-3210 cancer cell line human CVCL_J285 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21109924 CVCL_IQ88 CAP transformed cell line human CVCL_IQ88 CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Used for stable production of recombinant proteins Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2416 21109925 CVCL_J288 PAI cancer cell line house mouse CVCL_J288 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21109926 CVCL_J287 AP7P finite cell line human CVCL_J287 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2152_2778del (Ex24-28del); Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1401; probable Female 21109927 CVCL_IQ87 RUES2-EGFP/SMAD7 embryonic stem cell human CVCL_IQ87 CL:0000010 Transfected with: HGNC; 6773; SMAD7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Transfected with a Tet-inducible bi-cistronic expression cassette encoding EGFP and SMAD7 21109928 CVCL_IQ82 HRPE-2S spontaneously immortalized cell line human CVCL_IQ82 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Doubling time: 26.6 +- 3.3 hours (at 6th passage), 25.7 +- 2.5 hours (at 15th passage), 23.1 +- 2.1 hours (at 26th passage), 22.7 +- 2.1 hours (at 34th passage), 22.2 +- 1.7 hours (at 40th passage), 22.3 +- 2.3 hours (at 55th passage), 22.3 +- 1.9 hours (at 65th passage) (PubMed=27943290) 21109929 CVCL_J282 RC1 hybridoma house mouse CVCL_J282 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Mouse radial glia and neural progenitor cells. Doubling time: ~24 hours (lot 06282002) (JCRB) 21109930 CVCL_J281 S.CET.M8.1.1 hybridoma house mouse CVCL_J281 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:28324; 11-deoxycortisol. 21109931 CVCL_IQ81 SHT-1 cancer cell line human CVCL_IQ81 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Colon. Male Doubling time: 39 hours (PubMed=17554590) 21109932 CVCL_RK10 EV-SCC-19M cancer cell line human CVCL_RK10 CL:0000010 Derived from metastatic site: Lymph node. Male 21109933 CVCL_IQ84 KMS-11/Cfz cancer cell line human CVCL_IQ84 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:65347; Carfilzomib (Kyprolis; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgG kappa 21109934 CVCL_J284 KYSE-2270 cancer cell line human CVCL_J284 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21109935 CVCL_J283 KYSE-2780 cancer cell line human CVCL_J283 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21109936 CVCL_IQ83 SHH-1 cancer cell line human CVCL_IQ83 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Colon. Male Doubling time: 36 hours (PubMed=17554590) 21109937 CVCL_RK12 JSQ-13 cancer cell line human CVCL_RK12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=8339273). Unspecified 21109938 CVCL_RK11 EV-SCC-19P cancer cell line human CVCL_RK11 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male 21109939 CVCL_J280 F56 [Mouse hybridoma against human FCRL5] hybridoma house mouse CVCL_J280 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96RD9; Human FCRL5/CD307e. 21109940 CVCL_RK14 OVC-1 cancer cell line human CVCL_RK14 CL:0000010 Derived from sampling site: Ovary. Female 21109941 CVCL_IQ80 Pz03.1C5 hybridoma house mouse CVCL_IQ80 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2683 21109942 CVCL_RK13 JSQ-11 cancer cell line human CVCL_RK13 CL:0000010 Unspecified 21109943 CVCL_J257 K562-Luc cancer cell line human CVCL_J257 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: JCRB; NIHS0657; true Female 21109944 CVCL_IQ57 SNUOT-Rb4 cancer cell line human CVCL_IQ57 CL:0000010 Population: Korean; Derived from sampling site: Eye. Omics: Array-based CGH Unspecified 21109945 CVCL_J256 HT-29-Luc cancer cell line human CVCL_J256 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0646; true. Female 21109946 CVCL_IQ56 TOV-112DR cancer cell line human CVCL_IQ56 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Ala (c.109T>G); ClinVar=VCV000376235; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Leu639fs (c.1915delC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from sampling site: Ovary. Omics: Deep proteome analysis Female 21109947 CVCL_IQ59 GMGE-3 spontaneously immortalized cell line CVCL_IQ59 CL:0000010 Derived from sampling site: Mammary gland Cell type=Glandular epithelial cell.. Female Doubling time: 38-51 hours (PubMed=17570337) 21109948 CVCL_J259 MCF-7-Luc cancer cell line human CVCL_J259 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: AddexBio; S0006002; probable; Discontinued: JCRB; NIHS0638; true Female 21109949 CVCL_IQ58 CLY cancer cell line human CVCL_IQ58 CL:0000010 Population: Chinese; Derived from metastatic site: Liver. Male Doubling time: ~29.5 hours (PubMed=17342324) 21109950 CVCL_J258 KM12-Luc cancer cell line human CVCL_J258 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0647; true. Unspecified 21109951 CVCL_J253 HCC1419-Luc cancer cell line human CVCL_J253 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala74fs*47 (c.220_226delGCCCCTG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Breast. Discontinued: JCRB; NIHS0706; true Female 21109952 CVCL_IQ53 Ms-3 cancer cell line human CVCL_IQ53 CL:0000010 Population: Japanese. Unspecified 21109953 CVCL_J252 G-401-Luc cancer cell line human CVCL_J252 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Kidney. Discontinued: JCRB; NIHS0654; true Male Problematic cell line: Misclassified Parent cell line (G-401) was originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line. 21109954 CVCL_IQ52 Ms-8 cancer cell line human CVCL_IQ52 CL:0000010 Population: Japanese. Unspecified 21109955 CVCL_J255 Hs578T-Luc cancer cell line human CVCL_J255 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Breast. Discontinued: JCRB; NIHS0636; true Female 21109956 CVCL_IQ55 Ms-1 cancer cell line human CVCL_IQ55 CL:0000010 Population: Japanese. Unspecified 21109957 CVCL_J254 HCT-116 clone#2-Luc cancer cell line human CVCL_J254 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Colon. Discontinued: JCRB; NIHS0649; true Male 21109958 CVCL_IQ54 Ms-2 cancer cell line human CVCL_IQ54 CL:0000010 Population: Japanese. Unspecified 21109959 CVCL_J251 DU-145-Luc cancer cell line human CVCL_J251 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Brain. Discontinued: JCRB; NIHS0655; true Male 21109960 CVCL_IQ51 Ms-16 cancer cell line human CVCL_IQ51 CL:0000010 Population: Japanese. Unspecified 21109961 CVCL_J250 DLD-1 clone#1-Luc cancer cell line human CVCL_J250 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0650; true. Male 21109962 CVCL_IQ50 Ms-13 cancer cell line human CVCL_IQ50 CL:0000010 Population: Japanese. Unspecified 21109963 CVCL_RK01 EV-SCC-2 cancer cell line human CVCL_RK01 CL:0000010 Derived from metastatic site: Lymph node. Male 21109964 CVCL_RK00 EV-SCC-1 cancer cell line human CVCL_RK00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (PubMed=1394225) Derived from sampling site: Oral cavity; alveolar ridge. Male 21109965 CVCL_RK03 EV-SCC-4 cancer cell line human CVCL_RK03 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Characteristics: Established from a nude mouse xenograft 21109966 CVCL_RK02 EV-SCC-3 cancer cell line human CVCL_RK02 CL:0000010 Derived from sampling site: Oral cavity; tonsil. Male Characteristics: Established from a nude mouse xenograft 21109967 CVCL_IQ68 BW 431/26 hybridoma house mouse CVCL_IQ68 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2414 21109968 CVCL_J268 SW620-Luc cancer cell line human CVCL_J268 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0648; true Male 21109969 CVCL_IQ67 BW 250/183 hybridoma house mouse CVCL_IQ67 CL:0000010 Biotechnology: Is used to produce the monoclonal antibody Besilesomab (Scintimun) to detect inflammatory lesions and metastases Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31997; Human CEACAM8/CD66b. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2412 21109970 CVCL_J267 SK-MEL-28-Luc cancer cell line human CVCL_J267 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0641; true. Male 21109971 CVCL_IQ69 BW 494/32 hybridoma house mouse CVCL_IQ69 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2410 21109972 CVCL_J269 U-251MG-Luc cancer cell line human CVCL_J269 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Discontinued: JCRB; NIHS0645; true Male 21109973 CVCL_IQ64 ARPE-19/CNTF-6A spontaneously immortalized cell line human CVCL_IQ64 CL:0000010 Transfected with: HGNC; 2169; CNTF Derived from sampling site: Eye; retina; retinal pigment epithelium. Male 21109974 CVCL_J264 NCI-H460-Luc cancer cell line human CVCL_J264 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS0658; true Male 21109975 CVCL_IQ63 ARPE-19/CNTF-10 spontaneously immortalized cell line human CVCL_IQ63 CL:0000010 Transfected with: HGNC; 2169; CNTF Derived from sampling site: Eye; retina; retinal pigment epithelium. Male 21109976 CVCL_J263 MM-RU-Luc cancer cell line human CVCL_J263 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Cervical lymph node. Discontinued: JCRB; NIHS0644; true Male 21109977 CVCL_IQ66 Pz01.F3 hybridoma house mouse CVCL_IQ66 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51681; Human CCR5/CD195. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2681 21109978 CVCL_J266 SK-MEL-2-Luc cancer cell line human CVCL_J266 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Thigh; skin. Discontinued: JCRB; NIHS0640; true Male 21109979 CVCL_IQ65 7G5.3B6 hybridoma house mouse CVCL_IQ65 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07333; Human CSF1R/CD115. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2921 21109980 CVCL_J265 PC-3-Luc cancer cell line human CVCL_J265 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Discontinued: JCRB; NIHS0656; true Male 21109981 CVCL_IQ60 ARPE-19/CNTF spontaneously immortalized cell line human CVCL_IQ60 CL:0000010 Transfected with: HGNC; 2169; CNTF Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2524 21109982 CVCL_J260 MeWo-Luc cancer cell line human CVCL_J260 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0643; true Male 21109983 CVCL_IQ62 ARPE-19/GDNF spontaneously immortalized cell line human CVCL_IQ62 CL:0000010 Transfected with: HGNC; 4232; GDNF Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2523 21109984 CVCL_J262 MKN45-Luc cancer cell line human CVCL_J262 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Liver. Discontinued: JCRB; NIHS0634; true; Discontinued: JCRB; NIHS1337; true Female 21109985 CVCL_IQ61 ARPE-19/EGFP spontaneously immortalized cell line human CVCL_IQ61 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2522 21109986 CVCL_J261 MKN1/CMV-Luc cancer cell line human CVCL_J261 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0720; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21109987 CVCL_RK90 SU223T-6 induced pluripotent stem cell human CVCL_RK90 CL:0000010 Female 21109988 CVCL_RK92 SCID215 transformed cell line human CVCL_RK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21109989 CVCL_RK91 SCID86730 transformed cell line human CVCL_RK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21109990 CVCL_RK94 MPSII-4.1 induced pluripotent stem cell human CVCL_RK94 From: BioTalentum, Ltd; Godollo; Hungary CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Ser61Phe (c.182C>T); ClinVar=VCV001065845; Zygosity=Hemizygous (PubMed=27789394) Derived from sampling site: Peripheral blood. Male 21109991 CVCL_RK93 SCID221 transformed cell line human CVCL_RK93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21109992 CVCL_RK96 PI-1815-C7 induced pluripotent stem cell human CVCL_RK96 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21109993 CVCL_RK95 PI-1761-C1 induced pluripotent stem cell human CVCL_RK95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21109994 CVCL_RK98 PI-1754-MIT induced pluripotent stem cell human CVCL_RK98 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=26610207) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21109995 CVCL_RK97 PI-1754-C7 induced pluripotent stem cell human CVCL_RK97 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=26610207) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21109996 CVCL_RK99 PI-1353-C7 induced pluripotent stem cell human CVCL_RK99 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=22567022) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21109997 CVCL_RK81 WT3 induced pluripotent stem cell human CVCL_RK81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21109998 CVCL_RK80 SU42T-5 induced pluripotent stem cell human CVCL_RK80 CL:0000010 Female 21109999 CVCL_RK83 SU223-A2 induced pluripotent stem cell human CVCL_RK83 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 10729; SEMA4A; Simple; p.Tyr589His; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110000 CVCL_RK82 JMC1 induced pluripotent stem cell human CVCL_RK82 CL:0000010 Derived from sampling site: Peripheral blood. Male 21110001 CVCL_RK85 SU223-A7 induced pluripotent stem cell human CVCL_RK85 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 10729; SEMA4A; Simple; p.Tyr589His; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110002 CVCL_RK84 SU223-A4 induced pluripotent stem cell human CVCL_RK84 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 10729; SEMA4A; Simple; p.Tyr589His; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110003 CVCL_RK87 SU223-B5 induced pluripotent stem cell human CVCL_RK87 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 10729; SEMA4A; Simple; p.Tyr589His; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110004 CVCL_RK86 SU223-B3 induced pluripotent stem cell human CVCL_RK86 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 10729; SEMA4A; Simple; p.Tyr589His; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110005 CVCL_RK89 SU223T-5 induced pluripotent stem cell human CVCL_RK89 CL:0000010 Female 21110006 CVCL_RK88 SU223T-4 induced pluripotent stem cell human CVCL_RK88 CL:0000010 Female 21110007 CVCL_RK70 UiPSC-016 induced pluripotent stem cell human CVCL_RK70 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21110008 CVCL_RK72 IMGE-5 conditionally immortalized cell line house mouse CVCL_RK72 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; epithelium Cell type=Epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Male 21110009 CVCL_RK71 LNCaP-CL2 cancer cell line human CVCL_RK71 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21110010 CVCL_RK74 SU042-2 induced pluripotent stem cell human CVCL_RK74 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val2193Ile (c.6577G>A); ClinVar=VCV000231987; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Ser837Ter (c.2510C>G); Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 30045; SMG1; Simple; p.Leu250Val; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Thr1673Ser; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110011 CVCL_RK73 SU042-1 induced pluripotent stem cell human CVCL_RK73 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val2193Ile (c.6577G>A); ClinVar=VCV000231987; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Ser837Ter (c.2510C>G); Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 30045; SMG1; Simple; p.Leu250Val; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Thr1673Ser; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110012 CVCL_RK76 SU042-4 induced pluripotent stem cell human CVCL_RK76 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val2193Ile (c.6577G>A); ClinVar=VCV000231987; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Ser837Ter (c.2510C>G); Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 30045; SMG1; Simple; p.Leu250Val; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Thr1673Ser; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110013 CVCL_RK75 SU042-3 induced pluripotent stem cell human CVCL_RK75 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val2193Ile (c.6577G>A); ClinVar=VCV000231987; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Ser837Ter (c.2510C>G); Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 30045; SMG1; Simple; p.Leu250Val; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Thr1673Ser; Zygosity=Unspecified; Note=Somatic (PubMed=28089908) Miscellaneous: Lacks the KRAS p.Gly13Asp mutations found in other clones. Female 21110014 CVCL_RK78 SU42T-2 induced pluripotent stem cell human CVCL_RK78 CL:0000010 Female 21110015 CVCL_RK77 SU042-5 induced pluripotent stem cell human CVCL_RK77 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val2193Ile (c.6577G>A); ClinVar=VCV000231987; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Ser837Ter (c.2510C>G); Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 30045; SMG1; Simple; p.Leu250Val; Zygosity=Unspecified; Note=Somatic (PubMed=28089908); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Thr1673Ser; Zygosity=Unspecified; Note=Somatic (PubMed=28089908). Female 21110016 CVCL_RK79 SU42T-4 induced pluripotent stem cell human CVCL_RK79 CL:0000010 Female 21110017 CVCL_J408 Ag104A-Ld cancer cell line house mouse CVCL_J408 CL:0000010 Breed/subspecies: C3H. 21110018 CVCL_IS08 MM14DY spontaneously immortalized cell line house mouse CVCL_IS08 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: BALB/c. Male Doubling time: 14-18 hours (PubMed=7286393) 21110019 CVCL_J407 Ag104A cancer cell line house mouse CVCL_J407 CL:0000010 Breed/subspecies: C3H. 21110020 CVCL_IS07 CBM1-Ral-Sto transformed cell line human CVCL_IS07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified Virology: Transformed by the EBV strain from the Rael-BL (Cellosaurus=CVCL_7208) cell line 21110021 CVCL_J409 DC2.4 transformed cell line house mouse CVCL_J409 CL:0000010 Transfected with: MGI; MGI:1339752; Csf2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6. Unspecified 21110022 CVCL_IS09 MM14DZ spontaneously immortalized cell line house mouse CVCL_IS09 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: BALB/c. Male Doubling time: 12-14 hours (PubMed=7286393) 21110023 CVCL_J404 STC 6-14 cancer cell line house mouse CVCL_J404 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: Polyoma small T antigen (PyST); Derived from sampling site: Small intestine; duodenum; Breed/subspecies: C57BL/6J double transgenic RIP1Tag2/Rip2pyST1. Unspecified 21110024 CVCL_IS04 U3129MG cancer cell line human CVCL_IS04 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis Female 21110025 CVCL_J403 CMT-U335 cancer cell line dog CVCL_J403 CL:0000010 Breed/subspecies: Jamthund. Female 21110026 CVCL_IS03 U3123MG cancer cell line human CVCL_IS03 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110027 CVCL_IS06 1301-U2 cancer cell line human CVCL_IS06 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Has unusually long telomeres 21110028 CVCL_J406 GLUTag cancer cell line house mouse CVCL_J406 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colon; Breed/subspecies: GLUTag-Y transgenic. Unspecified Characteristics: Established from fragments of a colonic tumour which were subcutaneously propagated in nude mice (PubMed=1491697) 21110029 CVCL_IS05 1301-U1 cancer cell line human CVCL_IS05 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Has unusually long telomeres 21110030 CVCL_J405 STC-1 cancer cell line house mouse CVCL_J405 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: Polyoma small T antigen (PyST); Derived from sampling site: Small intestine; duodenum; Breed/subspecies: C57BL/6J double transgenic RIP1Tag2/Rip2pyST1. Unspecified Doubling time: 54 hours (PubMed=29787051) 21110031 CVCL_J400 CMT-U304 cancer cell line dog CVCL_J400 CL:0000010 Breed/subspecies: Jamthund. Female 21110032 CVCL_IS00 U3117MG cancer cell line human CVCL_IS00 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110033 CVCL_J402 CMT-U334 cancer cell line dog CVCL_J402 CL:0000010 Breed/subspecies: Cocker Spaniel. Female 21110034 CVCL_IS02 U3121MG cancer cell line human CVCL_IS02 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex2-5del; Zygosity=Unspecified (PubMed=27974212) Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110035 CVCL_J401 CMT-U309 cancer cell line dog CVCL_J401 CL:0000010 Breed/subspecies: Newfoundland. Omics: Transcriptome analysis by microarray Female Doubling time: 103.8 hours (PubMed=20453304) 21110036 CVCL_IS01 U3118MG cancer cell line human CVCL_IS01 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110037 CVCL_RM14 CET.IPS.FFCYST-500 induced pluripotent stem cell human CVCL_RM14 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Thr7Phefs*7 (c.18_21delGACT); ClinVar=VCV000188834; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: CLS; 300619; true Male 21110038 CVCL_RM13 CET.IPS.FFCYSTFIB-500 induced pluripotent stem cell human CVCL_RM13 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: CLS; 300618; true Male 21110039 CVCL_RM16 CET.IPS.FFNPC-01 induced pluripotent stem cell human CVCL_RM16 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Discontinued: CLS; 300620; true Male 21110040 CVCL_RM15 CET.IPS.FFGAU-500 induced pluripotent stem cell human CVCL_RM15 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: CLS; 300617; true Male 21110041 CVCL_RM18 SAS413 cancer cell line human CVCL_RM18 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21110042 CVCL_RM17 CET.IPS.FFNPC-02 induced pluripotent stem cell human CVCL_RM17 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Discontinued: CLS; 300620-02; true Female 21110043 CVCL_RM19 SAS527 cancer cell line human CVCL_RM19 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21110044 CVCL_J477 MOR44.4.1 hybridoma house mouse CVCL_J477 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110045 CVCL_IS77 XLC002 embryonic stem cell human CVCL_IS77 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110046 CVCL_J476 MOR39.3.9 hybridoma house mouse CVCL_J476 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110047 CVCL_IS76 UM153-1 PGD embryonic stem cell human CVCL_IS76 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0388. 21110048 CVCL_J479 MOR8.2.1 hybridoma house mouse CVCL_J479 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110049 CVCL_IS79 XLC007 embryonic stem cell human CVCL_IS79 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110050 CVCL_J478 MOR76.7F.16 hybridoma house mouse CVCL_J478 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110051 CVCL_IS78 XLC004 embryonic stem cell human CVCL_IS78 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110052 CVCL_J473 MOR180.2.4 hybridoma house mouse CVCL_J473 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110053 CVCL_IS73 UCLA 19n embryonic stem cell human CVCL_IS73 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0385. 21110054 CVCL_IS72 EndoC-betaH3 conditionally immortalized cell line human CVCL_IS72 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: Cre-ERT2, Cre recombinase fused with ligand-binding domain of ESR mutated to only bind tamoxifen Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Unspecified Characteristics: The lentiviral vector insert containing the SV40 LT and hTERT can be excised by the Cre recombinase upon addition of tamixofen Following excision of immortalizing transgenes, cell proliferation sharply decreases and in parallel there is a massive enhancement of beta cell-specific features such as increased INS gene expression. 21110055 CVCL_J472 MOR158.1.3 hybridoma house mouse CVCL_J472 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110056 CVCL_J475 MOR35.4.12 hybridoma house mouse CVCL_J475 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110057 CVCL_IS75 UM150-3 PGD embryonic stem cell human CVCL_IS75 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM150-1 PGD (Cellosaurus=CVCL_HF76) and UM150-4 PGD (Cellosaurus=CVCL_QY88). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0387 21110058 CVCL_J474 MOR33.2.9 hybridoma house mouse CVCL_J474 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110059 CVCL_IS74 UCLA 20n embryonic stem cell human CVCL_IS74 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0386. 21110060 CVCL_IS71 EndoC-betaH2 conditionally immortalized cell line human CVCL_IS71 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Omics: Transcriptome analysis by microarray Unspecified Characteristics: The lentiviral vector insert containing the SV40 LT and hTERT can be excised by the Cre recombinase Following excision of immortalizing transgenes, cell proliferation sharply decreases and in parallel there is a massive enhancement of beta cell-specific features such as increased INS gene expression.; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=26901817) Doubling time: 5-7 days (PubMed=24667639) 21110061 CVCL_J471 MOR131.5.13 hybridoma house mouse CVCL_J471 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110062 CVCL_IS70 alphaPIG-AT25-miPSC induced pluripotent stem cell house mouse CVCL_IS70 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x 129S4/SvJae. Characteristics: Transduced with an alphaPIG vector that contains a myosin-alpha promoter controlling the expression of a PuroR/PAC-IRES-EGFP construct Also contains a pSV40-neo cassette (PubMed=27879210). 21110063 CVCL_J470 MOR124.2.2 hybridoma house mouse CVCL_J470 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110064 CVCL_RM21 Karpas-190 cancer cell line human CVCL_RM21 CL:0000010 Derived from sampling site: Bone marrow. Male 21110065 CVCL_RM20 TN922 cancer cell line human CVCL_RM20 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~36 hours (PubMed=10226566) 21110066 CVCL_RM23 PER-288 cancer cell line human CVCL_RM23 CL:0000010 21110067 CVCL_RM22 PER-271 cancer cell line human CVCL_RM22 CL:0000010 21110068 CVCL_RM03 MGLVA1 cancer cell line human CVCL_RM03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Female 21110069 CVCL_RM02 MKN45G cancer cell line human CVCL_RM02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Female Characteristics: Gastrin-producing Established through nine passages of the parent cell line in hypergastrinaemic nude mice. Doubling time: 16 hours (PubMed=2105279) 21110070 CVCL_RM05 M-MOK/TPO cancer cell line human CVCL_RM05 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: TPO dependent Doubling time: 54 +- 11 hours (PubMed=9096695) 21110071 CVCL_RM04 HU-3/TPO cancer cell line human CVCL_RM04 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: TPO dependent Doubling time: 65 +- 15 hours (PubMed=9096695) 21110072 CVCL_RM07 M-07e/TPO cancer cell line human CVCL_RM07 CL:0000010 Sequence variation: Gene fusion; HGNC; 31677; ANO7 + HGNC; 17887; DHDH; Name(s)=ANO7-DHDH (from parent cell line); Sequence variation: Gene fusion; HGNC; 1537; CBFA2T3 + HGNC; 29450; GLIS2; Name(s)=CBFA2T3-GLIS2, ETO2-GLIS2 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Characteristics: TPO dependent Doubling time: 59 +- 10 hours (PubMed=9096695) 21110073 CVCL_RM06 TF-1/TPO cancer cell line human CVCL_RM06 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: TPO dependent Doubling time: 74 +- 5 hours (PubMed=9096695) 21110074 CVCL_RM09 MG-S cancer cell line human CVCL_RM09 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36 hours (CelloPub=CLPUB00414) 21110075 CVCL_RM08 KH184 cancer cell line human CVCL_RM08 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36-60 hours (PubMed=8167181) 21110076 CVCL_J488 SRBC-F12-18-7 hybridoma house mouse CVCL_J488 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110077 CVCL_IS88 XLC020 embryonic stem cell human CVCL_IS88 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110078 CVCL_J487 SRBC-F12-1-19 hybridoma house mouse CVCL_J487 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110079 CVCL_IS87 XLC018 embryonic stem cell human CVCL_IS87 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110080 CVCL_J489 SRBC-F23-20-22 hybridoma house mouse CVCL_J489 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110081 CVCL_IS89 XLC021 embryonic stem cell human CVCL_IS89 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110082 CVCL_J484 OHP4B2.2.3 hybridoma house mouse CVCL_J484 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110083 CVCL_IS84 XLC015 embryonic stem cell human CVCL_IS84 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110084 CVCL_J483 OHP1E9.3.1 hybridoma house mouse CVCL_J483 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110085 CVCL_IS83 XLC013 embryonic stem cell human CVCL_IS83 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110086 CVCL_J486 OHP7D7.2.3 hybridoma house mouse CVCL_J486 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110087 CVCL_IS86 XLC017 embryonic stem cell human CVCL_IS86 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110088 CVCL_J485 OHP57.G6.1 hybridoma house mouse CVCL_J485 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110089 CVCL_IS85 XLC016 embryonic stem cell human CVCL_IS85 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110090 CVCL_J480 MOR83.3.10 hybridoma house mouse CVCL_J480 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110091 CVCL_IS80 XLC009 embryonic stem cell human CVCL_IS80 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110092 CVCL_J482 OHP138.H8.1 hybridoma house mouse CVCL_J482 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110093 CVCL_IS82 XLC012 embryonic stem cell human CVCL_IS82 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110094 CVCL_J481 OHP101.B11.1 hybridoma house mouse CVCL_J481 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:17252; 17alpha-hydroxyprogesterone. 21110095 CVCL_IS81 XLC011 embryonic stem cell human CVCL_IS81 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110096 CVCL_RM10 CET.IPS.FFALZ-500 induced pluripotent stem cell human CVCL_RM10 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA; From: John Paul II Medical Research Institute; Iowa City; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: CLS; 300616; true Female 21110097 CVCL_RM12 CET.IPS.FFCD34-500 induced pluripotent stem cell human CVCL_RM12 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Discontinued: CLS; 300615; true 21110098 CVCL_RM11 CET.IPS.FFAM-500 induced pluripotent stem cell human CVCL_RM11 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Mesenchymal stem cell.. 21110099 CVCL_IS59 DM745 cancer cell line human CVCL_IS59 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110100 CVCL_J459 HGH1.35.2 hybridoma house mouse CVCL_J459 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110101 CVCL_IS58 DM643 cancer cell line human CVCL_IS58 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110102 CVCL_J458 HGH1.32.4 hybridoma house mouse CVCL_J458 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110103 CVCL_IS55 DM589 cancer cell line human CVCL_IS55 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110104 CVCL_J455 HGH1.15.3 hybridoma house mouse CVCL_J455 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110105 CVCL_IS54 DM555 cancer cell line human CVCL_IS54 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110106 CVCL_J454 HGH1.11.1 hybridoma house mouse CVCL_J454 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110107 CVCL_IS57 DM602 cancer cell line human CVCL_IS57 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110108 CVCL_J457 HGH1.31.3 hybridoma house mouse CVCL_J457 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110109 CVCL_IS56 DM595 cancer cell line human CVCL_IS56 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110110 CVCL_J456 HGH1.17.2 hybridoma house mouse CVCL_J456 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110111 CVCL_J451 2B7 hybridoma house mouse CVCL_J451 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21110112 CVCL_IS51 DM459 cancer cell line human CVCL_IS51 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110113 CVCL_J450 2B5.3 hybridoma house mouse CVCL_J450 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Giardia muris trophozoite surface antigens of 31 kDa and 35 kDa. 21110114 CVCL_IS50 DM401 cancer cell line human CVCL_IS50 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110115 CVCL_IS53 DM497 cancer cell line human CVCL_IS53 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110116 CVCL_J453 HGH1.1.3 hybridoma house mouse CVCL_J453 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110117 CVCL_J452 2C1H7 hybridoma house mouse CVCL_J452 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human beta-tubulins Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2686 Caution: ATCC CRL-2746 indicates 'PTA-2846' as a synonym, but this is probably a misnomer as it corresponds to another patented hybridoma. 21110118 CVCL_IS52 DM467 cancer cell line human CVCL_IS52 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110119 CVCL_RM01 St16 cancer cell line human CVCL_RM01 CL:0000010 Unspecified 21110120 CVCL_RM00 St42 cancer cell line human CVCL_RM00 CL:0000010 Unspecified 21110121 CVCL_J469 MOR115.1.13 hybridoma house mouse CVCL_J469 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:17303; Morphine. 21110122 CVCL_IS69 TiB7-4 induced pluripotent stem cell house mouse CVCL_IS69 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x 129S4/SvJae. 21110123 CVCL_J466 HGH2.15.4 hybridoma house mouse CVCL_J466 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110124 CVCL_IS66 NEPS cancer cell line human CVCL_IS66 CL:0000010 Population: Japanese. Male 21110125 CVCL_J465 HGH1.9.3 hybridoma house mouse CVCL_J465 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110126 CVCL_IS65 RMG-I-H cancer cell line human CVCL_IS65 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 4012; FUT1 Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21110127 CVCL_J468 HGH2.6.1 hybridoma house mouse CVCL_J468 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110128 CVCL_IS68 TC289 cancer cell line human CVCL_IS68 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 48 hours, at 20th passage (PubMed=11115567) 21110129 CVCL_J467 HGH2.4.2 hybridoma house mouse CVCL_J467 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110130 CVCL_IS67 SFT-8606 cancer cell line human CVCL_IS67 CL:0000010 Population: Japanese; Derived from sampling site: Elbow. Male 21110131 CVCL_IS62 DM798 cancer cell line human CVCL_IS62 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110132 CVCL_J462 HGH1.46.1 hybridoma house mouse CVCL_J462 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110133 CVCL_IS61 DM787 cancer cell line human CVCL_IS61 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110134 CVCL_J461 HGH1.41.1 hybridoma house mouse CVCL_J461 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110135 CVCL_J464 HGH1.8.1 hybridoma house mouse CVCL_J464 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110136 CVCL_IS64 RMG-I-C cancer cell line human CVCL_IS64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21110137 CVCL_IS63 DM806 cancer cell line human CVCL_IS63 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110138 CVCL_J463 HGH1.6.5 hybridoma house mouse CVCL_J463 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110139 CVCL_IS60 DM779 cancer cell line human CVCL_IS60 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110140 CVCL_J460 HGH1.37.3 hybridoma house mouse CVCL_J460 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01241; Human GH1. 21110141 CVCL_J437 DT40 CL18 cancer cell line CVCL_J437 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21110142 CVCL_IS37 Mel Gerlach cancer cell line human CVCL_IS37 CL:0000010 21110143 CVCL_J436 FRTL-Tc spontaneously immortalized cell line Norway rat CVCL_J436 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 21110144 CVCL_IS36 GH [Carassius] spontaneously immortalized cell line CVCL_IS36 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21110145 CVCL_IS39 MM-194 cancer cell line human CVCL_IS39 CL:0000010 Derived from metastatic site: Armpit. Male Doubling time: 51.5 hours (PubMed=11943340) 21110146 CVCL_J439 PC12HS.P3 cancer cell line Norway rat CVCL_J439 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: JCRB; NIHS0374; true Male Group: Serum/protein free medium cell line 21110147 CVCL_IS38 MM-031 cancer cell line human CVCL_IS38 CL:0000010 Derived from metastatic site: Neck. Male 21110148 CVCL_J438 PC12HS cancer cell line Norway rat CVCL_J438 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: JCRB; JCRB0263; true; Discontinued: JCRB; NIHS0375; true Male 21110149 CVCL_IS33 FMS-1 cancer cell line human CVCL_IS33 CL:0000010 Population: Japanese Female Doubling time: ~38.5 hours (PubMed=19921253). 21110150 CVCL_J433 RPMI-8226/MDR10V cancer cell line human CVCL_J433 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Selected for resistance to: ChEBI; CHEBI:9948; Verapamil (VPL); Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 21110151 CVCL_IS32 QPCEF finite cell line CVCL_IS32 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Qingyuan partridge. Mixed Doubling time: ~72 hours (PubMed=20460668) Group: Bird cell line 21110152 CVCL_J432 RPMI-8226/Dox6 cancer cell line human CVCL_J432 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 21110153 CVCL_IS35 FROv spontaneously immortalized cell line CVCL_IS35 CL:0000010 Derived from sampling site: Fetal ovary; Breed/subspecies: Holstein Friesian. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2051 21110154 CVCL_J435 MDA 435TR cancer cell line human CVCL_J435 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21110155 CVCL_J434 RPMI-8226/LR-5 cancer cell line human CVCL_J434 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG lambda (from parent cell line) 21110156 CVCL_IS34 SBL-HSC-1802 cancer cell line human CVCL_IS34 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male 21110157 CVCL_IS31 HN51 cancer cell line human CVCL_IS31 CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Male Doubling time: 75 hours (PubMed=8603355) 21110158 CVCL_J431 RPMI-8226/Dox40 cancer cell line human CVCL_J431 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda 21110159 CVCL_IS30 HN4 cancer cell line human CVCL_IS30 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male Doubling time: 63 hours (PubMed=8603355) 21110160 CVCL_J430 PCC7-S-AzaRt clone 1009 cancer cell line house mouse CVCL_J430 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: C57BL/6 x 129. Male 21110161 CVCL_J448 2B5 hybridoma house mouse CVCL_J448 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01042; Human KNG1 (kininogen heavy chain). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8963 21110162 CVCL_IS48 A-mel-3 cancer cell line CVCL_IS48 CL:0000010 21110163 CVCL_J447 IAR 2 finite cell line Norway rat CVCL_J447 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21110164 CVCL_IS47 NCM460D spontaneously immortalized cell line human CVCL_IS47 CL:0000010 Population: Hispanic; Donor information: Established from the normal tissue of a patient suffering from gastric cancer; Derived from sampling site: Colon; mucosa Cell type=Epithelial cell.. Male Doubling time: 32-38 hours (INCELL) 21110165 CVCL_J449 C11C1 hybridoma house mouse CVCL_J449 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01042; Human KNG1 (kininogen light chain). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8964 21110166 CVCL_IS49 DM382 cancer cell line human CVCL_IS49 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21110167 CVCL_IS44 MM-358 cancer cell line human CVCL_IS44 CL:0000010 Derived from metastatic site: Axillary lymph node. Female Doubling time: 35.4 hours (PubMed=11943340) 21110168 CVCL_J444 TW-EBV-LCL transformed cell line human CVCL_J444 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110169 CVCL_IS43 MM-254 cancer cell line human CVCL_IS43 CL:0000010 Derived from metastatic site: Submandibular lymph node. Female Doubling time: 26.3 hours (PubMed=11943340) 21110170 CVCL_J443 RF/6A 135 spontaneously immortalized cell line CVCL_J443 CL:0000010 Derived from sampling site: Fetal eye; choroid and fetal eye; retina. Unspecified Group: Non-human primate cell line Problematic cell line: Probably misidentified Parent cell line (RF/6A) was originally thought to be an endothelial cell line but has been shown to lack functional and transcriptomic characteristics of such cell type. 21110171 CVCL_J446 FBT [Bovine] undefined cell line type CVCL_J446 CL:0000010 Derived from sampling site: Fetal nose; nasal cavity; nasal turbinate. Unspecified 21110172 CVCL_IS46 NCM356D spontaneously immortalized cell line human CVCL_IS46 CL:0000010 Population: African American; Donor information: Established from the normal tissue of a patient suffering from a rectal adenocarcinoma; Derived from sampling site: Colon; mucosa Cell type=Epithelial cell.. Male Doubling time: 32-35 hours (INCELL) 21110173 CVCL_J445 CG1 [Human nasopharyngeal carcinoma] cancer cell line human CVCL_J445 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Pharynx; nasopharynx. Male Doubling time: ~20 hours (in a medium with 10% FBS), ~29 hours (in a medium with 2.5% FBS) (PubMed=2479472) 21110174 CVCL_IS45 HTZ-19 dM cancer cell line human CVCL_IS45 CL:0000010 Derived from metastatic site: Brain. Unspecified Doubling time: 88.3 hours (PubMed=2208165) 21110175 CVCL_IS40 MM-195 cancer cell line human CVCL_IS40 CL:0000010 Derived from metastatic site: Bone; scapula. Male Doubling time: 86.7 hours (PubMed=11943340) 21110176 CVCL_J440 PC12IS cancer cell line Norway rat CVCL_J440 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: JCRB; JCRB0265; true; Discontinued: JCRB; NIHS0377; true Male 21110177 CVCL_IS42 MM-232 cancer cell line human CVCL_IS42 CL:0000010 Derived from metastatic site: Lower leg. Female Doubling time: 66.2 hours (PubMed=11943340) 21110178 CVCL_J442 PC12-AC cancer cell line Norway rat CVCL_J442 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21110179 CVCL_IS41 MM-201 cancer cell line human CVCL_IS41 CL:0000010 Derived from metastatic site: Axillary lymph node. Female Doubling time: 27.1 hours (PubMed=11943340) 21110180 CVCL_J441 PC12MS cancer cell line Norway rat CVCL_J441 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: JCRB; JCRB0264; true; Discontinued: JCRB; NIHS0376; true Male 21110181 CVCL_IS19 CHA-hES49 embryonic stem cell human CVCL_IS19 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014004. 21110182 CVCL_J419 K-KT transformed cell line human CVCL_J419 HLA typing: DRB1*12:06 (IPD-IMGT/HLA=10892) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21110183 CVCL_J418 6H transformed cell line house mouse CVCL_J418 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110184 CVCL_IS18 CHA-hES51 embryonic stem cell human CVCL_IS18 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014006. 21110185 CVCL_IS15 CHA-hES54 embryonic stem cell human CVCL_IS15 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016003. 21110186 CVCL_J415 ECL-41 transformed cell line house mouse CVCL_J415 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110187 CVCL_IS14 CHA-hES53 embryonic stem cell human CVCL_IS14 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016002. 21110188 CVCL_J414 ECL-38 transformed cell line house mouse CVCL_J414 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110189 CVCL_J417 1HB transformed cell line house mouse CVCL_J417 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110190 CVCL_IS17 CHA-hES50 embryonic stem cell human CVCL_IS17 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014005. 21110191 CVCL_J416 1H transformed cell line house mouse CVCL_J416 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110192 CVCL_IS16 CHA-hES55 embryonic stem cell human CVCL_IS16 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016004. 21110193 CVCL_J411 DC4.1 transformed cell line house mouse CVCL_J411 CL:0000010 Transfected with: MGI; MGI:1339752; Csf2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6. Unspecified 21110194 CVCL_IS11 SNUhES43 embryonic stem cell human CVCL_IS11 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12015002. 21110195 CVCL_J410 DC1.2 transformed cell line house mouse CVCL_J410 CL:0000010 Transfected with: MGI; MGI:1339752; Csf2 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6. Unspecified 21110196 CVCL_IS10 SNUhES42 embryonic stem cell human CVCL_IS10 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12015001. 21110197 CVCL_IS13 CHA-hES52 embryonic stem cell human CVCL_IS13 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016001. 21110198 CVCL_J413 ECL-32 transformed cell line house mouse CVCL_J413 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Unspecified 21110199 CVCL_J412 ECL-2 transformed cell line house mouse CVCL_J412 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; Breed/subspecies: FVB/N Nkx2.5-SV40Tag transgenic. Omics: Transcriptome analysis by microarray Unspecified 21110200 CVCL_IS12 SNUhES44 embryonic stem cell human CVCL_IS12 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016005. 21110201 CVCL_J429 PCC7-S cancer cell line house mouse CVCL_J429 CL:0000010 Breed/subspecies: C57BL/6 x 129. Male 21110202 CVCL_IS29 UOK117-5 cancer cell line human CVCL_IS29 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu158Pro (c.473T>C); ClinVar=VCV000182980; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Kidney. Male 21110203 CVCL_IS26 HRC78 cancer cell line human CVCL_IS26 CL:0000010 21110204 CVCL_J426 PCC7-Mz1 cancer cell line house mouse CVCL_J426 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: C57BL/6 x 129. Male 21110205 CVCL_IS25 HRC63 cancer cell line human CVCL_IS25 CL:0000010 Female 21110206 CVCL_J425 KO-1 cancer cell line CVCL_J425 CL:0000010 Derived from sampling site: Pleural effusion; Breed/subspecies: Domestic shorthair. Female Doubling time: 50 hours (PubMed=15541796) 21110207 CVCL_J428 t-HUE4 cancer cell line human CVCL_J428 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Doubling time: 45 hours (PubMed=1817644) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Grand-parent cell line (ECV-304) has been shown to be a T24 derivative. 21110208 CVCL_IS28 UOK136COL cancer cell line human CVCL_IS28 CL:0000010 Derived from metastatic site: Colon. Unspecified 21110209 CVCL_J427 t-HUE2 cancer cell line human CVCL_J427 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Doubling time: 35 hours (PubMed=1817644) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (ECV-304) has been shown to be a T24 derivative. 21110210 CVCL_IS27 UOK154LN cancer cell line human CVCL_IS27 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8319216) Derived from metastatic site: Lymph node. Female 21110211 CVCL_J422 CHO-LY-A spontaneously immortalized cell line CVCL_J422 CL:0000010 Derived from sampling site: Ovary. Female 21110212 CVCL_IS22 HRC24 cancer cell line human CVCL_IS22 CL:0000010 21110213 CVCL_IS21 Bo-786-O cancer cell line human CVCL_IS21 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Kidney. Male 21110214 CVCL_J421 RAC65 cancer cell line house mouse CVCL_J421 CL:0000010 Breed/subspecies: C3H/He. Male 21110215 CVCL_J424 G8-1 spontaneously immortalized cell line house mouse CVCL_J424 CL:0000010 Derived from sampling site: Embryonic skeletal muscle Cell type=Myoblast.; Breed/subspecies: Swiss Webster. Unspecified 21110216 CVCL_IS24 HRC45 cancer cell line human CVCL_IS24 CL:0000010 Male 21110217 CVCL_IS23 HRC31 cancer cell line human CVCL_IS23 CL:0000010 Male 21110218 CVCL_J423 R-3327-H-G8-A1 cancer cell line Norway rat CVCL_J423 CL:0000010 Breed/subspecies: Copenhagen. Male 21110219 CVCL_J420 PVD9902 spontaneously immortalized cell line pig CVCL_J420 CL:0000010 Derived from sampling site: Vas deferens Cell type=Epithelial cell.. Male 21110220 CVCL_IS20 SNUhES41 embryonic stem cell human CVCL_IS20 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014003. 21110221 CVCL_RL80 MT-ALL cancer cell line human CVCL_RL80 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: CSF2 or IL2 or IL3 dependent 21110222 CVCL_RL82 K-T1a cancer cell line human CVCL_RL82 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Doubling time: 56 hours (PubMed=2786436) 21110223 CVCL_RL81 MT-ALL MN1.1 cancer cell line human CVCL_RL81 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL3 dependent 21110224 CVCL_RL84 SMZ-1 cancer cell line human CVCL_RL84 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Ascites Cell type=T-cell.. Omics: Deep exome analysis Male Doubling time: 34 hours (PubMed=1316225) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21110225 CVCL_RL83 HPB-MLp-W cancer cell line human CVCL_RL83 CL:0000010 Population: Japanese; Derived from sampling site: Lymph node Cell type=T-cell.. Female Doubling time: 72-96 hours (PubMed=2046390) 21110226 CVCL_RL86 BRO/pFRmdr1.6 clone 1.1 cancer cell line human CVCL_RL86 CL:0000010 Transfected with: HGNC; 40; ABCB1 Population: Caucasian; Derived from sampling site: Shoulder; skin. Male 21110227 CVCL_RL85 SBH-1 cancer cell line human CVCL_RL85 CL:0000010 Derived from sampling site: Pleural effusion. Female Doubling time: 2-3 days (PubMed=7742544) Problematic cell line: Possibly misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be either a B-cell non-Hodgkin lymphoma or a diffuse large B-cell lymphoma (PubMed=29533902). 21110228 CVCL_RL88 Gli36 cancer cell line human CVCL_RL88 From: Campagnoni A.; University of California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex3-10del; Zygosity=Homozygous (PubMed=20215515) Omics: SNP array analysis. 21110229 CVCL_RL87 BRO/pFRmdr1.6 clone 1.4 cancer cell line human CVCL_RL87 CL:0000010 Transfected with: HGNC; 40; ABCB1 Population: Caucasian; Derived from sampling site: Shoulder; skin. Male 21110230 CVCL_RL89 WAe001-A-16 embryonic stem cell human CVCL_RL89 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO. Male 21110231 CVCL_RL69 LiPSC-PR3.0 induced pluripotent stem cell human CVCL_RL69 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110232 CVCL_RL71 LiPSC-TR1.2 induced pluripotent stem cell human CVCL_RL71 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110233 CVCL_RL70 LiPSC-TR1.1 induced pluripotent stem cell human CVCL_RL70 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110234 CVCL_RL73 GT1-7-OX1 transformed cell line house mouse CVCL_RL73 CL:0000010 Transfected with: HGNC; 4848; HCRTR1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 transgenic with rat Gnrh1 promoter-Tg(SV40). 21110235 CVCL_RL72 NCL1 induced pluripotent stem cell human CVCL_RL72 From: NxCell, Inc.; Novato; USA CL:0000010 Derived from sampling site: Umbilical cord blood. 21110236 CVCL_RL75 CHUQi001-A induced pluripotent stem cell human CVCL_RL75 From: CHU de Quebec Research Center, Universite Laval; Quebec; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~200] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (PubMed=29274549) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110237 CVCL_RL74 522-2666 transformed cell line human CVCL_RL74 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~200] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (PubMed=29274549) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110238 CVCL_RL77 WAe001-A-13 embryonic stem cell human CVCL_RL77 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 758; ASS1. Male 21110239 CVCL_RL76 HHUUKDi002-A induced pluripotent stem cell human CVCL_RL76 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110240 CVCL_RL79 MAT cancer cell line human CVCL_RL79 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21110241 CVCL_RL78 TC616 cancer cell line human CVCL_RL78 CL:0000010 Population: Japanese. Male 21110242 CVCL_RL59 CCH spontaneously immortalized cell line CVCL_RL59 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Unspecified Group: Fish cell line 21110243 CVCL_RL58 MUNIi004-A induced pluripotent stem cell human CVCL_RL58 From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.2623-3C>G; ClinVar=VCV000217186; Zygosity=Hemizygous (hPSCreg) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110244 CVCL_RL60 COLO 357-TRS4 cancer cell line human CVCL_RL60 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: African American; Derived from metastatic site: Celiac axis lymph node. Female Characteristics: Expresses tetracyclin-inducible SMAD4 siRNA 21110245 CVCL_RL62 LiPSC-ER2.1 induced pluripotent stem cell human CVCL_RL62 HLA typing: A*03,24; B*27,27; C*01,05; DQB1*03,05; DRB1*01,11 (PubMed=27283945) From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21110246 CVCL_RL61 HaCaT-TRS4 spontaneously immortalized cell line human CVCL_RL61 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 6770; SMAD4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Expresses tetracyclin-inducible SMAD4 siRNA 21110247 CVCL_RL64 LiPSC-ER2.3 induced pluripotent stem cell human CVCL_RL64 HLA typing: A*03,24; B*27,27; C*01,05; DQB1*03,05; DRB1*01,11 (PubMed=27283945) From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21110248 CVCL_RL63 LiPSC-ER2.2 induced pluripotent stem cell human CVCL_RL63 HLA typing: A*03,24; B*27,27; C*01,05; DQB1*03,05; DRB1*01,11 (PubMed=27283945) From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21110249 CVCL_RL66 LiPSC-GR1.2 induced pluripotent stem cell human CVCL_RL66 HLA typing: A*02,03; B*07,39; C*07,15; DQB1*03,04; DRB1*04,08 (PubMed=27283945) From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21110250 CVCL_RL65 LiPSC-GR1.1 induced pluripotent stem cell human CVCL_RL65 HLA typing: A*02,03; B*07,39; C*07,15; DQB1*03,04; DRB1*04,08 (PubMed=27283945) From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21110251 CVCL_RL68 LiPSC-PR2.0 induced pluripotent stem cell human CVCL_RL68 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110252 CVCL_RL67 LiPSC-PR1.0 induced pluripotent stem cell human CVCL_RL67 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110253 CVCL_RL48 CiRA00008 induced pluripotent stem cell human CVCL_RL48 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Glu2111Lys (c.6331G>A); ClinVar=VCV001194414; Zygosity=Unspecified (PubMed=27418197); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Arg2327Trp (c.6979C>T); ClinVar=VCV000618812; Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110254 CVCL_RL47 CiRA00007 induced pluripotent stem cell human CVCL_RL47 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Gly3818Arg (c.11452G>C); Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110255 CVCL_RL49 CiRA00009 induced pluripotent stem cell human CVCL_RL49 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Gln3955Ter (c.11863C>T) (p.Gln3895Ter) (12069C>T); ClinVar=VCV000974399; Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110256 CVCL_RL51 HNL2 induced pluripotent stem cell human CVCL_RL51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110257 CVCL_RL50 CiRA00010 induced pluripotent stem cell human CVCL_RL50 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Asp2273Alafs*145 (c.6818_6819delAC) (7024delAC); Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110258 CVCL_RL53 HNL5 induced pluripotent stem cell human CVCL_RL53 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110259 CVCL_RL52 HNL4 induced pluripotent stem cell human CVCL_RL52 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110260 CVCL_RL55 HNLp induced pluripotent stem cell human CVCL_RL55 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110261 CVCL_RL54 HNL6 induced pluripotent stem cell human CVCL_RL54 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110262 CVCL_RL57 T11 [Human ESC] induced pluripotent stem cell human CVCL_RL57 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110263 CVCL_RL56 T10 [Human iPSC] induced pluripotent stem cell human CVCL_RL56 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110264 CVCL_RL37 GE#81 induced pluripotent stem cell human CVCL_RL37 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110265 CVCL_RL36 GE#51 induced pluripotent stem cell human CVCL_RL36 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110266 CVCL_RL39 GE#91 induced pluripotent stem cell human CVCL_RL39 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110267 CVCL_RL38 GE#83 induced pluripotent stem cell human CVCL_RL38 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110268 CVCL_J399 DL-8 cancer cell line house mouse CVCL_J399 CL:0000010 Breed/subspecies: DBA/2. 21110269 CVCL_IR99 U3110MG cancer cell line human CVCL_IR99 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110270 CVCL_J396 CEM-AGR cancer cell line human CVCL_J396 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8081 21110271 CVCL_IR96 U3086MG cancer cell line human CVCL_IR96 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110272 CVCL_J395 CEM-ON cancer cell line human CVCL_J395 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Constitutively secretes CSF1 (PubMed=3259875); Characteristics: Can be used as a fusion partner for constructing T-cell hybridomas (ATCC) Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8199 21110273 CVCL_IR95 U3085MG cancer cell line human CVCL_IR95 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110274 CVCL_J398 DL-5 cancer cell line house mouse CVCL_J398 CL:0000010 Breed/subspecies: DBA/2. 21110275 CVCL_IR98 U3101MG cancer cell line human CVCL_IR98 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110276 CVCL_J397 DL-3 cancer cell line house mouse CVCL_J397 CL:0000010 Breed/subspecies: DBA/2. 21110277 CVCL_IR97 U3088MG cancer cell line human CVCL_IR97 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110278 CVCL_RL40 CAL-48A cancer cell line human CVCL_RL40 CL:0000010 Unspecified Doubling time: 58 hours (PubMed=2145926). 21110279 CVCL_J392 HOB1/ADR2.0 cancer cell line human CVCL_J392 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Male 21110280 CVCL_IR92 U3078MG cancer cell line human CVCL_IR92 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110281 CVCL_J391 HOB1 cancer cell line human CVCL_J391 CL:0000010 Population: Chinese; Taiwan Male Doubling time: 22 hours (PubMed=2159767). 21110282 CVCL_IR91 U3073MG cancer cell line human CVCL_IR91 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110283 CVCL_RL42 iPS-TIG975-e4 induced pluripotent stem cell human CVCL_RL42 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110284 CVCL_J394 MDTF finite cell line CVCL_J394 CL:0000010 Derived from sampling site: Tail. Female 21110285 CVCL_IR94 U3084MG cancer cell line human CVCL_IR94 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110286 CVCL_J393 HOB1/VCR0.1 cancer cell line human CVCL_J393 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Male 21110287 CVCL_RL41 iPS-TIG119-4f1 induced pluripotent stem cell human CVCL_RL41 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110288 CVCL_IR93 U3082MG cancer cell line human CVCL_IR93 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110289 CVCL_RL44 CiRA00004 induced pluripotent stem cell human CVCL_RL44 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; c.2986-15C>T; ClinVar=VCV000256939; Zygosity=Unspecified (PubMed=27418197); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; c.8161+38G>A; ClinVar=VCV000440080; Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110290 CVCL_RL43 iPS-TIG975-e2 induced pluripotent stem cell human CVCL_RL43 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110291 CVCL_J390 CHL-3A4 spontaneously immortalized cell line CVCL_J390 CL:0000010 Transfected with: HGNC; 2637; CYP3A4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21110292 CVCL_RL46 CiRA00006 induced pluripotent stem cell human CVCL_RL46 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Simple; p.Ala190Thr (c.568G>A); ClinVar=VCV000092796; Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110293 CVCL_IR90 U3071MG cancer cell line human CVCL_IR90 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110294 CVCL_RL45 CiRA00005 induced pluripotent stem cell human CVCL_RL45 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Trp429Ser (c.1286G>C); Zygosity=Unspecified (PubMed=27418197); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Ser2235Leu (c.6704C>T); Zygosity=Unspecified (PubMed=27418197); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Val3008Met (c.9022G>A); ClinVar=VCV000811571; Zygosity=Unspecified (PubMed=27418197); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Ser3405Tyr (c.10214C>A) (p.Ser3404Tyr, c.10211C>A); Zygosity=Unspecified (PubMed=27418197) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110295 CVCL_RL26 PDSH723R01#16 induced pluripotent stem cell human CVCL_RL26 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 21110296 CVCL_RL25 PDSH723R01#12 induced pluripotent stem cell human CVCL_RL25 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110297 CVCL_RL28 PDSHM147V#13 induced pluripotent stem cell human CVCL_RL28 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Met147Val (c.439A>G); ClinVar=VCV000691508; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110298 CVCL_RL27 PDSHM147V#3 induced pluripotent stem cell human CVCL_RL27 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Met147Val (c.439A>G); ClinVar=VCV000691508; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110299 CVCL_RL29 PDSHM147V#18 induced pluripotent stem cell human CVCL_RL29 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Met147Val (c.439A>G); ClinVar=VCV000691508; Zygosity=Heterozygous (PubMed=28052261); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Heterozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110300 CVCL_RL31 PDSHT410M#11 induced pluripotent stem cell human CVCL_RL31 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Thr410Met (c.1229C>T); ClinVar=VCV000043498; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110301 CVCL_RL30 PDSHT410M#3 induced pluripotent stem cell human CVCL_RL30 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Thr410Met (c.1229C>T); ClinVar=VCV000043498; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110302 CVCL_RL33 GE#21 induced pluripotent stem cell human CVCL_RL33 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 21110303 CVCL_RL32 PDSHT410M#12 induced pluripotent stem cell human CVCL_RL32 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.Thr410Met (c.1229C>T); ClinVar=VCV000043498; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110304 CVCL_RL35 GE#24 induced pluripotent stem cell human CVCL_RL35 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110305 CVCL_RL34 GE#22 induced pluripotent stem cell human CVCL_RL34 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple_corrected; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous; Note=By TALEN (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 21110306 CVCL_RL15 Con-005 induced pluripotent stem cell human CVCL_RL15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110307 CVCL_RL14 ALS-078 induced pluripotent stem cell human CVCL_RL14 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110308 CVCL_RL17 Con-010 induced pluripotent stem cell human CVCL_RL17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110309 CVCL_RL16 Con-006 induced pluripotent stem cell human CVCL_RL16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110310 CVCL_RL19 Con-CiPS induced pluripotent stem cell human CVCL_RL19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110311 CVCL_RL18 Con-018 induced pluripotent stem cell human CVCL_RL18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110312 CVCL_J378 FM3A tsFT101 cancer cell line house mouse CVCL_J378 CL:0000010 Sequence variation: Mutation; MGI; MGI:1927222; Diaph3; Simple; p.Ile733Asn (c.2198T>A); Zygosity=Homozygous (PubMed=33187357) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Cytokinesis is blocked at 39 Celsius. 21110313 CVCL_IR78 U3046MG cancer cell line human CVCL_IR78 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110314 CVCL_J377 NB1RGB finite cell line human CVCL_J377 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (PubMed=17395773) 21110315 CVCL_IR77 U3042MG cancer cell line human CVCL_IR77 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110316 CVCL_J379 TR-iBRB2 conditionally immortalized cell line Norway rat CVCL_J379 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Endothelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-6507 21110317 CVCL_IR79 U3047MG cancer cell line human CVCL_IR79 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110318 CVCL_J374 L5178Y ts39 cancer cell line house mouse CVCL_J374 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21110319 CVCL_IR74 U3035MG cancer cell line human CVCL_IR74 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110320 CVCL_J373 L5178Y ts2 cancer cell line house mouse CVCL_J373 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21110321 CVCL_IR73 U3034MG cancer cell line human CVCL_IR73 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110322 CVCL_J376 POLH KO cancer cell line human CVCL_J376 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9181; POLH; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21110323 CVCL_IR76 U3039MG cancer cell line human CVCL_IR76 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110324 CVCL_J375 N18-RE-105 hybrid cell line CVCL_J375 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Doubling time: ~33 hours (lot 10252010) (JCRB) 21110325 CVCL_IR75 U3037MG cancer cell line human CVCL_IR75 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110326 CVCL_J370 FM3A TK~ cancer cell line house mouse CVCL_J370 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21110327 CVCL_IR70 U3029MG cancer cell line human CVCL_IR70 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110328 CVCL_RL20 EtOH-1 induced pluripotent stem cell human CVCL_RL20 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21110329 CVCL_J372 RLC-10.P3 finite cell line Norway rat CVCL_J372 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Discontinued: JCRB; NIHS0367; true Female Group: Serum/protein free medium cell line 21110330 CVCL_IR72 U3033MG cancer cell line human CVCL_IR72 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110331 CVCL_IR71 U3031MG cancer cell line human CVCL_IR71 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110332 CVCL_J371 V79-379A spontaneously immortalized cell line CVCL_J371 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21110333 CVCL_RL22 EtOH-3 induced pluripotent stem cell human CVCL_RL22 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21110334 CVCL_RL21 EtOH-2 induced pluripotent stem cell human CVCL_RL21 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21110335 CVCL_RL24 PDSH723R01#5 induced pluripotent stem cell human CVCL_RL24 CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; p.His723Arg (c.2168A>G); ClinVar=VCV000004825; Zygosity=Homozygous (PubMed=28052261) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21110336 CVCL_RL23 1039A1 induced pluripotent stem cell human CVCL_RL23 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21110337 CVCL_RL04 Luc-LM8 cancer cell line house mouse CVCL_RL04 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: C3H/HeJ. Female Characteristics: The luciferase reporter gene is under the control of a minimal TATA promoter with multiple copies of the NF-kappaB response element 21110338 CVCL_RL03 Z-HL16C cancer cell line human CVCL_RL03 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00609 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from embryonic lung fibroblasts. 21110339 CVCL_RL06 ALS-004 induced pluripotent stem cell human CVCL_RL06 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110340 CVCL_RL05 ALS-002 induced pluripotent stem cell human CVCL_RL05 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110341 CVCL_RL08 ALS-028 induced pluripotent stem cell human CVCL_RL08 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110342 CVCL_RL07 ALS-017 induced pluripotent stem cell human CVCL_RL07 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110343 CVCL_RL09 ALS-033 induced pluripotent stem cell human CVCL_RL09 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110344 CVCL_J389 SR-1 cancer cell line human CVCL_J389 CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Female Doubling time: ~24 hours (PubMed=15381372) 21110345 CVCL_IR89 U3068MG cancer cell line human CVCL_IR89 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110346 CVCL_J388 C55.7Res spontaneously immortalized cell line CVCL_J388 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90282; N(1),N(12)-diethylspermine (N1,N12-bis(ethyl)spermine); Derived from sampling site: Ovary. Female 21110347 CVCL_IR88 U3067MG cancer cell line human CVCL_IR88 CL:0000010 Derived from sampling site: Brain. Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110348 CVCL_J385 RMA cancer cell line house mouse CVCL_J385 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21110349 CVCL_IR85 U3060MG cancer cell line human CVCL_IR85 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110350 CVCL_J384 ImM10 conditionally immortalized cell line house mouse CVCL_J384 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21110351 CVCL_IR84 U3056MG cancer cell line human CVCL_IR84 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110352 CVCL_J387 C55.7 spontaneously immortalized cell line CVCL_J387 CL:0000010 Derived from sampling site: Ovary. Female 21110353 CVCL_IR87 U3065MG cancer cell line human CVCL_IR87 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110354 CVCL_J386 C54 spontaneously immortalized cell line CVCL_J386 CL:0000010 Derived from sampling site: Ovary. Female 21110355 CVCL_IR86 U3062MG cancer cell line human CVCL_IR86 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110356 CVCL_J381 TR-rPCT1 conditionally immortalized cell line Norway rat CVCL_J381 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21110357 CVCL_IR81 U3051MG cancer cell line human CVCL_IR81 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110358 CVCL_J380 TR-MUL5 conditionally immortalized cell line Norway rat CVCL_J380 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21110359 CVCL_IR80 U3048MG cancer cell line human CVCL_IR80 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110360 CVCL_J383 TR-rPCT4 conditionally immortalized cell line Norway rat CVCL_J383 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21110361 CVCL_IR83 U3054MG cancer cell line human CVCL_IR83 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110362 CVCL_J382 TR-rPCT3 conditionally immortalized cell line Norway rat CVCL_J382 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; capillary Cell type=Pericyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21110363 CVCL_IR82 U3053MG cancer cell line human CVCL_IR82 CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Human Glioblastoma Cell Culture (HGCC) resource 21110364 CVCL_RL11 ALS-050 induced pluripotent stem cell human CVCL_RL11 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21110365 CVCL_RL10 ALS-034 induced pluripotent stem cell human CVCL_RL10 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110366 CVCL_RL13 ALS-077 induced pluripotent stem cell human CVCL_RL13 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21110367 CVCL_RL12 ALS-075 induced pluripotent stem cell human CVCL_RL12 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24139042) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21110368 CVCL_RL91 DOP-M1 cancer cell line human CVCL_RL91 CL:0000010 Population: Japanese; Derived from sampling site: Cerebrospinal fluid. Female Doubling time: ~48 hours (PubMed=1581583) 21110369 CVCL_RL90 LW/SO cancer cell line human CVCL_RL90 CL:0000010 Derived from sampling site: Bone marrow. Female 21110370 CVCL_RL93 IMS-M2 cancer cell line human CVCL_RL93 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 8033; NTRK3; Name(s)=ETV6-NTRK3, TEL-TRKC; Note=In frame (PubMed=19854508); Sequence variation: Mutation; HGNC; 7910; NPM1; Simple; p.Trp288Cysfs*12 (c.860_863dupTCTG); ClinVar=VCV000013998; Zygosity=Heterozygous (PubMed=19854508) Population: Japanese; Derived from sampling site: Bone marrow. Female 21110371 CVCL_RL92 FLG 29.1 cancer cell line human CVCL_RL92 CL:0000010 Derived from sampling site: Bone marrow. Female Doubling time: ~22 hours (PubMed=1309813) 21110372 CVCL_RL95 ME-2 cancer cell line human CVCL_RL95 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 2-3 days (PubMed=8018932) 21110373 CVCL_RL94 KP-1 cancer cell line human CVCL_RL94 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 96 hours (PubMed=8134164) 21110374 CVCL_RL97 HML-2 [Human leukemia] cancer cell line human CVCL_RL97 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 and KITLG dependent 21110375 CVCL_RL96 HML cancer cell line human CVCL_RL96 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 dependent 21110376 CVCL_RL99 X-376 cancer cell line human CVCL_RL99 CL:0000010 21110377 CVCL_RL98 HML/SE cancer cell line human CVCL_RL98 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 and KITLG dependent 21110378 CVCL_IT18 XLC070 embryonic stem cell human CVCL_IT18 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110379 CVCL_J518 YUCLAT cancer cell line human CVCL_J518 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Ser2496Phe (c.7487C>T); ClinVar=VCV000947131; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21110380 CVCL_IT17 XLC069 embryonic stem cell human CVCL_IT17 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110381 CVCL_J517 YUCHER cancer cell line human CVCL_J517 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21110382 CVCL_IT19 XLC072 embryonic stem cell human CVCL_IT19 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110383 CVCL_J519 YUDEW cancer cell line human CVCL_J519 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110384 CVCL_J514 WSB cancer cell line human CVCL_J514 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray 21110385 CVCL_IT14 XLC064 embryonic stem cell human CVCL_IT14 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110386 CVCL_J513 WM245 cancer cell line human CVCL_J513 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection. 21110387 CVCL_IT13 XLC061 embryonic stem cell human CVCL_IT13 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110388 CVCL_IT16 XLC068 embryonic stem cell human CVCL_IT16 From: Creative Bioarray; New York; USA CL:0000010 Unspecified Characteristics: Has Lox sites for Cre-mediated gene insertion and constitutive transgene expression. 21110389 CVCL_J516 YUBUNE cancer cell line human CVCL_J516 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110390 CVCL_IT15 XLC065 embryonic stem cell human CVCL_IT15 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110391 CVCL_J515 YUBEL cancer cell line human CVCL_J515 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110392 CVCL_J510 F422 cancer cell line CVCL_J510 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). 21110393 CVCL_IT10 XLC056 embryonic stem cell human CVCL_IT10 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110394 CVCL_J512 Esa-1 cancer cell line human CVCL_J512 CL:0000010 Discontinued: ATCC; HTB-83; true. Male 21110395 CVCL_IT12 XLC060 embryonic stem cell human CVCL_IT12 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110396 CVCL_J511 200-3-G6-4 hybridoma house mouse CVCL_J511 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08138; Human NGFR/CD271. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8737 21110397 CVCL_IT11 XLC057 embryonic stem cell human CVCL_IT11 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110398 CVCL_IT29 XLC449 embryonic stem cell human CVCL_IT29 From: Creative Bioarray; New York; USA. CL:0000010 Unspecified 21110399 CVCL_IT28 XLC090 embryonic stem cell human CVCL_IT28 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Unspecified Characteristics: Cardiac specific troponin T promoter driving GFP expression and Zeo resistance 21110400 CVCL_J528 YUTHO cancer cell line human CVCL_J528 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110401 CVCL_IT25 XLC081 embryonic stem cell human CVCL_IT25 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP. Male Characteristics: A GFP cassette is inserted to the OLIG2 locus via homologous recombination 21110402 CVCL_J525 YUNUVO cancer cell line human CVCL_J525 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110403 CVCL_IT24 XLC080 embryonic stem cell human CVCL_IT24 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Unspecified Characteristics: Has a EGFP-POU5F1 knock-in 21110404 CVCL_J524 YUNIGE cancer cell line human CVCL_J524 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110405 CVCL_IT27 XLC088 embryonic stem cell human CVCL_IT27 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Unspecified Characteristics: POU5F1 promoter driving GFP expression and Zeo resistance 21110406 CVCL_J527 YUSTE cancer cell line human CVCL_J527 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110407 CVCL_IT26 XLC083 embryonic stem cell human CVCL_IT26 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified 21110408 CVCL_J526 YUSAN cancer cell line human CVCL_J526 CL:0000010 Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110409 CVCL_IT21 XLC074 embryonic stem cell human CVCL_IT21 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110410 CVCL_J521 YUHOIN cancer cell line human CVCL_J521 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110411 CVCL_IT20 XLC073 embryonic stem cell human CVCL_IT20 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified 21110412 CVCL_J520 YUGASP cancer cell line human CVCL_J520 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110413 CVCL_IT23 XLC077 embryonic stem cell human CVCL_IT23 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110414 CVCL_J523 YULONE cancer cell line human CVCL_J523 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110415 CVCL_IT22 XLC076 embryonic stem cell human CVCL_IT22 From: Creative Bioarray; New York; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified 21110416 CVCL_J522 YULIN cancer cell line human CVCL_J522 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110417 CVCL_J507 CHO-K1 tsTM18 transformed cell line CVCL_J507 CL:0000010 Sequence variation: Mutation; UniProtKB; Q76B40; Smu1; Simple; p.Gly489Arg (c.1465G>A); Zygosity=Homozygous (PubMed=15878348) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature sensitive Exhibits chromosomal instability and cell-cycle arrest at S and G2 phases with decreased DNA synthesis at the non-permissive temperature of 39 Celsius (PubMed=15878348). Doubling time: 31 hours (PubMed=2237640) 21110418 CVCL_IT07 XLC053 embryonic stem cell human CVCL_IT07 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110419 CVCL_J506 GHFT1-5 cancer cell line house mouse CVCL_J506 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: GHF-Tag transgenic. Unspecified 21110420 CVCL_IT06 XLC052 embryonic stem cell human CVCL_IT06 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110421 CVCL_J509 FT-1/ADM cancer cell line CVCL_J509 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). 21110422 CVCL_IT09 XLC055 embryonic stem cell human CVCL_IT09 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110423 CVCL_J508 FT-1 cancer cell line CVCL_J508 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). 21110424 CVCL_IT08 XLC054 embryonic stem cell human CVCL_IT08 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110425 CVCL_J503 Don Q spontaneously immortalized cell line CVCL_J503 CL:0000010 Derived from sampling site: Lung. Male 21110426 CVCL_IT03 XLC049 embryonic stem cell human CVCL_IT03 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110427 CVCL_J502 CHEF/18 spontaneously immortalized cell line CVCL_J502 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21110428 CVCL_IT02 XLC048 embryonic stem cell human CVCL_IT02 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110429 CVCL_J505 MEQC2 transformed cell line CVCL_J505 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Cell type=Cardiomyocyte. Unspecified Group: Bird cell line 21110430 CVCL_IT05 XLC051 embryonic stem cell human CVCL_IT05 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110431 CVCL_J504 MEQC1 transformed cell line CVCL_J504 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Cell type=Cardiomyocyte. Unspecified Group: Bird cell line 21110432 CVCL_IT04 XLC050 embryonic stem cell human CVCL_IT04 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110433 CVCL_J501 CHEF/16 spontaneously immortalized cell line CVCL_J501 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21110434 CVCL_IT01 XLC046 embryonic stem cell human CVCL_IT01 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110435 CVCL_J500 MY-EBV-LCL transformed cell line human CVCL_J500 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110436 CVCL_IT00 XLC044 embryonic stem cell human CVCL_IT00 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110437 CVCL_8A81 GM22522 transformed cell line human CVCL_8A81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110438 CVCL_8A80 GM22521 transformed cell line human CVCL_8A80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110439 CVCL_8A83 GM22542 transformed cell line human CVCL_8A83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110440 CVCL_8A82 GM22525 transformed cell line human CVCL_8A82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110441 CVCL_8A89 GM22653 transformed cell line human CVCL_8A89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110442 CVCL_8A88 GM22652 transformed cell line human CVCL_8A88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110443 CVCL_8A85 GM06812 finite cell line human CVCL_8A85 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21110444 CVCL_8A84 GM22587 transformed cell line human CVCL_8A84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110445 CVCL_8A87 GM22635 transformed cell line human CVCL_8A87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110446 CVCL_8A86 GM22603 transformed cell line human CVCL_8A86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110447 CVCL_8A92 GM22683 transformed cell line human CVCL_8A92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110448 CVCL_8A91 GM22665 transformed cell line human CVCL_8A91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110449 CVCL_8A94 GM22699 transformed cell line human CVCL_8A94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110450 CVCL_8A93 GM22688 transformed cell line human CVCL_8A93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110451 CVCL_8A90 GM22657 transformed cell line human CVCL_8A90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110452 CVCL_8A99 GM22873 transformed cell line human CVCL_8A99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110453 CVCL_8A96 GM22708 transformed cell line human CVCL_8A96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110454 CVCL_8A95 GM22700 transformed cell line human CVCL_8A95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110455 CVCL_8A98 GM22807 transformed cell line human CVCL_8A98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110456 CVCL_8A97 GM22774 transformed cell line human CVCL_8A97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110457 CVCL_RN35 NOM1 cancer cell line human CVCL_RN35 CL:0000010 Population: Japanese. Female 21110458 CVCL_RN34 NOS3AR cancer cell line human CVCL_RN34 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Female 21110459 CVCL_RN37 A375P-5 cancer cell line human CVCL_RN37 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 21110460 CVCL_RN36 AS-M.5 SOCS3-Luc clone E cancer cell line human CVCL_RN36 CL:0000010 Transfected with: HGNC; 19391; SOCS3; Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Scalp; skin. Male 21110461 CVCL_RN39 WM98-2 cancer cell line human CVCL_RN39 CL:0000010 Derived from sampling site: Skin. Male Part of: Wistar Institute melanoma cell line collection 21110462 CVCL_RN38 Ma-Mel-50b cancer cell line human CVCL_RN38 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21110463 CVCL_J598 53-S hybridoma house mouse CVCL_J598 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06477; Human herpesvirus 1 (HHV-1) glycoprotein H (gH). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8182 21110464 CVCL_IT98 UNEWi026-B induced pluripotent stem cell human CVCL_IT98 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110465 CVCL_J597 52-S hybridoma house mouse CVCL_J597 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06477; Human herpesvirus 1 (HHV-1) glycoprotein H (gH). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8181 21110466 CVCL_IT97 UNEWi026-A induced pluripotent stem cell human CVCL_IT97 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110467 CVCL_J599 58-S hybridoma house mouse CVCL_J599 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8183 21110468 CVCL_IT99 UNEWi026-C induced pluripotent stem cell human CVCL_IT99 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110469 CVCL_J594 225 hybridoma house mouse CVCL_J594 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the chimeric (mouse/human) Erbitux (cetuximab) therapeutic antibody Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8508 21110470 CVCL_IT94 UNEWi025-A induced pluripotent stem cell human CVCL_IT94 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110471 CVCL_J593 NS-1-503 cancer cell line house mouse CVCL_J593 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21110472 CVCL_IT93 UNEWi024-C induced pluripotent stem cell human CVCL_IT93 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110473 CVCL_J596 528 [Mouse hybridoma against human EGFR] hybridoma house mouse CVCL_J596 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8509 21110474 CVCL_IT96 UNEWi025-C induced pluripotent stem cell human CVCL_IT96 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110475 CVCL_J595 579 hybridoma house mouse CVCL_J595 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8506 21110476 CVCL_IT95 UNEWi025-B induced pluripotent stem cell human CVCL_IT95 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110477 CVCL_J590 P43D09 hybridoma house mouse CVCL_J590 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00543; Feline sarcoma virus (strain Snyder-Theilen) V-Fes. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8594 21110478 CVCL_IT90 UNEWi023-C induced pluripotent stem cell human CVCL_IT90 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110479 CVCL_J592 S22C06 hybridoma house mouse CVCL_J592 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00543; Feline sarcoma virus (strain Snyder-Theilen) V-Fes. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8595 21110480 CVCL_IT92 UNEWi024-B induced pluripotent stem cell human CVCL_IT92 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110481 CVCL_RN40 WM806 cancer cell line human CVCL_RN40 CL:0000010 Derived from metastatic site: Not specified. Unspecified Part of: Wistar Institute melanoma cell line collection 21110482 CVCL_J591 S10F03 hybridoma house mouse CVCL_J591 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00543; Feline sarcoma virus (strain Snyder-Theilen) V-Fes. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8596 21110483 CVCL_IT91 UNEWi024-A induced pluripotent stem cell human CVCL_IT91 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110484 CVCL_RN42 WM918 cancer cell line human CVCL_RN42 CL:0000010 Derived from metastatic site: Not specified. Unspecified Part of: Wistar Institute melanoma cell line collection 21110485 CVCL_RN41 WM911 cancer cell line human CVCL_RN41 CL:0000010 Derived from metastatic site: Not specified. Unspecified Part of: Wistar Institute melanoma cell line collection 21110486 CVCL_RN44 UOK117C4 cancer cell line human CVCL_RN44 CL:0000010 Derived from sampling site: Kidney. Male 21110487 CVCL_RN43 UOK262-WT cancer cell line human CVCL_RN43 CL:0000010 Sequence variation: Mutation; HGNC; 3700; FH; Simple; p.Gln439Pro (c.1316A>C); Zygosity=Hemizygous (PubMed=19963135); Transfected with: HGNC; 3700; FH Derived from metastatic site: Kidney. Female Characteristics: Has a normal FH activity thanks to the transfection of the wild-type FH gene 21110488 CVCL_RN24 UTA.00106.hFF induced pluripotent stem cell human CVCL_RN24 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110489 CVCL_RN23 UTA.01006.WT induced pluripotent stem cell human CVCL_RN23 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110490 CVCL_RN26 ND50040 induced pluripotent stem cell human CVCL_RN26 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110491 CVCL_RN25 UTA.04602.WT induced pluripotent stem cell human CVCL_RN25 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110492 CVCL_RN28 ND50042 induced pluripotent stem cell human CVCL_RN28 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110493 CVCL_RN27 ND50041 induced pluripotent stem cell human CVCL_RN27 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110494 CVCL_RN29 NOS2CR cancer cell line human CVCL_RN29 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female 21110495 CVCL_RN31 NOS2VR cancer cell line human CVCL_RN31 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16). Female 21110496 CVCL_RN30 NOS2SNR cancer cell line human CVCL_RN30 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin). Female 21110497 CVCL_RN33 NOS2AR cancer cell line human CVCL_RN33 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Female 21110498 CVCL_RN32 NOS1 cancer cell line human CVCL_RN32 CL:0000010 Population: Japanese. Female 21110499 CVCL_RN13 MC-B11/14IgA- cancer cell line human CVCL_RN13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5478; IGHA1 Derived from sampling site: Bone marrow. Male Characteristics: Produces Ig kappa 21110500 CVCL_RN12 MC-B11/14 cancer cell line human CVCL_RN12 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA kappa 21110501 CVCL_RN15 UTA.05208.CPVT induced pluripotent stem cell human CVCL_RN15 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Pro2328Ser (c.6982C>T); ClinVar=VCV000012960; Zygosity=Unspecified (PubMed=22962621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110502 CVCL_RN14 UTA.05203.CPVT induced pluripotent stem cell human CVCL_RN14 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Pro2328Ser (c.6982C>T); ClinVar=VCV000012960; Zygosity=Unspecified (PubMed=22962621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110503 CVCL_RN17 UTA.00208.LQT1 induced pluripotent stem cell human CVCL_RN17 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly589Asp (c.1766G>A) (p.Gly462Asp, c.1385G>A); ClinVar=VCV000003140; Zygosity=Unspecified (PubMed=27026928; PubMed=28785673) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110504 CVCL_RN16 UTA.00112.hFF induced pluripotent stem cell human CVCL_RN16 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110505 CVCL_RN19 UTA.00303.LQT1 induced pluripotent stem cell human CVCL_RN19 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly589Asp (c.1766G>A) (p.Gly462Asp, c.1385G>A); ClinVar=VCV000003140; Zygosity=Unspecified (PubMed=27026928) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110506 CVCL_RN18 UTA.00211.LQT1 induced pluripotent stem cell human CVCL_RN18 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly589Asp (c.1766G>A) (p.Gly462Asp, c.1385G>A); ClinVar=VCV000003140; Zygosity=Unspecified (PubMed=27026928; PubMed=28785673) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110507 CVCL_J579 173-8D2 hybridoma house mouse CVCL_J579 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8896 21110508 CVCL_IT79 UKERi005-A induced pluripotent stem cell human CVCL_IT79 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110509 CVCL_J576 164-3F3 hybridoma house mouse CVCL_J576 CL:0000010 Discontinued: ATCC; CRL-2736; true. Monoclonal antibody isotype: Not specified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9040 21110510 CVCL_IT76 SC211A-1 induced pluripotent stem cell house mouse CVCL_IT76 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Transfected with: UniProtKB; Q9T221; Streptomyces phage phiC31 int Derived from sampling site: Embryo Cell type=Fibroblast.; Breed/subspecies: C57BL/6. Unspecified 21110511 CVCL_J575 155-9F6 hybridoma house mouse CVCL_J575 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9000 21110512 CVCL_IT75 SC608A/B-PD induced pluripotent stem cell human CVCL_IT75 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC608A/B-PD Male 21110513 CVCL_J578 172-12G7 hybridoma house mouse CVCL_J578 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9004 21110514 CVCL_IT78 UKERi004-A induced pluripotent stem cell human CVCL_IT78 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110515 CVCL_J577 165-34E4 hybridoma house mouse CVCL_J577 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9279 21110516 CVCL_IT77 UKERi001-A induced pluripotent stem cell human CVCL_IT77 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110517 CVCL_J572 152-6D11 hybridoma house mouse CVCL_J572 CL:0000010 Discontinued: ATCC; CRL-2665; true. Monoclonal antibody isotype: Not specified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8996 21110518 CVCL_IT72 SC604A/B-MD induced pluripotent stem cell human CVCL_IT72 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-6del; Zygosity=Hemizygous (SBI) Population: Latino; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC604A/B-MD Male 21110519 CVCL_J571 204-4 hybridoma house mouse CVCL_J571 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Coxsackievirus B4. 21110520 CVCL_IT71 SC603A/B-ALS induced pluripotent stem cell human CVCL_IT71 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Latino; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC603A/B-ALS Female 21110521 CVCL_J574 155-8G1 hybridoma house mouse CVCL_J574 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9001 21110522 CVCL_IT74 SC607A/B-PD induced pluripotent stem cell human CVCL_IT74 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC607A/B-PD Male 21110523 CVCL_J573 155-11C7 hybridoma house mouse CVCL_J573 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8976 21110524 CVCL_IT73 SC605A/B-GBM induced pluripotent stem cell human CVCL_IT73 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC605A/B-GBM Male 21110525 CVCL_J570 146-8D11 hybridoma house mouse CVCL_J570 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8999 21110526 CVCL_IT70 SC602A/B-DTI induced pluripotent stem cell human CVCL_IT70 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC602A/B-DTI Female 21110527 CVCL_RN20 UTA.00313.LQT1 induced pluripotent stem cell human CVCL_RN20 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly589Asp (c.1766G>A) (p.Gly462Asp, c.1385G>A); ClinVar=VCV000003140; Zygosity=Unspecified (PubMed=27026928) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110528 CVCL_RN22 UTA.00525.LQT2 induced pluripotent stem cell human CVCL_RN22 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Arg176Trp (c.526C>T); ClinVar=VCV000067509; Zygosity=Unspecified (PubMed=22052944; PubMed=27026928) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110529 CVCL_RN21 UTA.00514.LQT2 induced pluripotent stem cell human CVCL_RN21 From: Institute of Biomedical Technology, University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Arg176Trp (c.526C>T); ClinVar=VCV000067509; Zygosity=Unspecified (PubMed=22052944; PubMed=27026928) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110530 CVCL_RN02 ChiPSC22 induced pluripotent stem cell human CVCL_RN02 HLA typing: A*02,02; B*07,40; C*03,07; DQA1*01,01; DQB1*05,06; DRB1*13,14 (PubMed=29026098); HLA typing: A*02:01; B*07:02,40:01; C*03:04,07:02; DPB1*03:01,04:01; DQB1*05:03,06:04; DRB1*13:02,14:01 (Takara) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110531 CVCL_RN01 ChiPSC21 induced pluripotent stem cell human CVCL_RN01 HLA typing: A*02:01,30:02; B*18:01,51:01; C*02:02,05:01; DPB1*02:02,04:01; DQB1*02:01,03:01; DRB1*03:01,11:01 (Takara) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Takara/Clontech; Catalog number Y00310/Y00315 Male 21110532 CVCL_RN04 PDIS-1 transformed cell line human CVCL_RN04 CL:0000010 Knockout cell: Method=TALEN; HGNC; 7044; MGAT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21110533 CVCL_RN03 CHOZN GS-/- spontaneously immortalized cell line CVCL_RN03 CL:0000010 Knockout cell: Method=ZFN; UniProtKB; P04773; Glul Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21110534 CVCL_RN06 PDIS-14 spontaneously immortalized cell line CVCL_RN06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; O08520; Slc35a1 Derived from sampling site: Ovary. Female 21110535 CVCL_RN05 PDIS-12 transformed cell line human CVCL_RN05 CL:0000010 Knockout cell: Method=TALEN; HGNC; 7044; MGAT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21110536 CVCL_RN08 PDIS-22 transformed cell line human CVCL_RN08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11021; SLC35A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21110537 CVCL_RN07 PDIS-2 transformed cell line human CVCL_RN07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21110538 CVCL_RN09 PDIS-6 cancer cell line human CVCL_RN09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Brain; right temporal lobe. Male Problematic cell line: Contaminated Parent cell line (LN-319) has been shown to be a LN-992 derivative. 21110539 CVCL_J587 312-13E8 hybridoma house mouse CVCL_J587 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9208 21110540 CVCL_IT87 UNEWi022-C induced pluripotent stem cell human CVCL_IT87 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110541 CVCL_J586 310-5F5 hybridoma house mouse CVCL_J586 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9002 21110542 CVCL_IT86 UNEWi022-B induced pluripotent stem cell human CVCL_IT86 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110543 CVCL_J589 361-31C05 hybridoma house mouse CVCL_J589 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9227 21110544 CVCL_IT89 UNEWi023-B induced pluripotent stem cell human CVCL_IT89 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110545 CVCL_J588 360-27E06 hybridoma house mouse CVCL_J588 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9280 21110546 CVCL_IT88 UNEWi023-A induced pluripotent stem cell human CVCL_IT88 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110547 CVCL_J583 222-35C8 hybridoma house mouse CVCL_J583 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9052 21110548 CVCL_IT83 UNEWi021-B induced pluripotent stem cell human CVCL_IT83 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110549 CVCL_J582 203-6F5 hybridoma house mouse CVCL_J582 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8899 21110550 CVCL_IT82 UNEWi021-A induced pluripotent stem cell human CVCL_IT82 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110551 CVCL_J585 310-29F7 hybridoma house mouse CVCL_J585 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9053 21110552 CVCL_IT85 UNEWi022-A induced pluripotent stem cell human CVCL_IT85 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204C>T); ClinVar=VCV000294490; Zygosity=Homozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110553 CVCL_J584 250-9G06 hybridoma house mouse CVCL_J584 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9260 21110554 CVCL_IT84 UNEWi021-C induced pluripotent stem cell human CVCL_IT84 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110555 CVCL_J581 202-9D10 hybridoma house mouse CVCL_J581 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8900 21110556 CVCL_IT81 ULEIi001-A induced pluripotent stem cell human CVCL_IT81 From: Leipzig University Center for Biotechnology and Biomedicine; Leipzig; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110557 CVCL_J580 18-9B10 hybridoma house mouse CVCL_J580 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8800 21110558 CVCL_IT80 UKERi006-A induced pluripotent stem cell human CVCL_IT80 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110559 CVCL_RN11 CHOZN GS-/- Slc35a1-/- spontaneously immortalized cell line CVCL_RN11 CL:0000010 Knockout cell: Method=ZFN; UniProtKB; P04773; Glul; Knockout cell: Method=ZFN; UniProtKB; O08520; Slc35a1 Derived from sampling site: Ovary. Female Virology: Resistant to infection/contamination by minute virus of mice (MVM) Group: Serum/protein free medium cell line 21110560 CVCL_RN10 PDIS-9 spontaneously immortalized cell line CVCL_RN10 CL:0000010 Knockout cell: Method=TALEN; UniProtKB; Q924C0; Mgat1 Derived from sampling site: Ovary. Female 21110561 CVCL_J558 127-24C7 hybridoma house mouse CVCL_J558 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8965 21110562 CVCL_J557 121-9G10 hybridoma house mouse CVCL_J557 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8952 21110563 CVCL_IT57 CDIi001-A induced pluripotent stem cell human CVCL_IT57 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21110564 CVCL_J559 127-24E11 hybridoma house mouse CVCL_J559 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8966 21110565 CVCL_IT59 CUBi001-A induced pluripotent stem cell human CVCL_IT59 From: Charite, Universitatsmedizin Berlin; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1348; SAMD9; Simple; p.Arg685Gln (c.2054G>A); ClinVar=VCV000421898; Zygosity=Heterozygous; Note=De novo mutation (PubMed=28346228) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110566 CVCL_J554 121-5E5 hybridoma house mouse CVCL_J554 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8951 21110567 CVCL_IT54 BIHi001-A induced pluripotent stem cell human CVCL_IT54 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21110568 CVCL_J553 121-4F8 hybridoma house mouse CVCL_J553 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8950 21110569 CVCL_IT53 XLC348 induced pluripotent stem cell human CVCL_IT53 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110570 CVCL_J556 121-9E5 hybridoma house mouse CVCL_J556 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8953 21110571 CVCL_IT56 BIHi005-A induced pluripotent stem cell human CVCL_IT56 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110572 CVCL_J555 121-8D8 hybridoma house mouse CVCL_J555 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8956 21110573 CVCL_IT55 BIHi004-A induced pluripotent stem cell human CVCL_IT55 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110574 CVCL_J550 121-15B10 hybridoma house mouse CVCL_J550 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8954 21110575 CVCL_IT50 TTF-1 iPS induced pluripotent stem cell house mouse CVCL_IT50 CL:0000010 Derived from sampling site: Tail; tip Cell type=Fibroblast.. Omics: Cell surface proteome Female 21110576 CVCL_J552 121-3H5 hybridoma house mouse CVCL_J552 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8949 21110577 CVCL_IT52 XLC303 induced pluripotent stem cell human CVCL_IT52 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110578 CVCL_J551 121-1F9 hybridoma house mouse CVCL_J551 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8948 21110579 CVCL_IT51 159-2 embryonic stem cell house mouse CVCL_IT51 CL:0000010 Breed/subspecies: C57BL/6 x 129. Omics: Cell surface proteome; Omics: DNA methylation analysis Unspecified 21110580 CVCL_RN00 ChiPSC18 induced pluripotent stem cell human CVCL_RN00 HLA typing: A*23:01; B*07:02,49:01; C*07:01,07:02; DPB1*03:01,04:01; DQB1*02:02,04:02; DRB1*04:06,07:01 (Takara) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110581 CVCL_J569 146-17A3 hybridoma house mouse CVCL_J569 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8998 21110582 CVCL_IT69 SC601A/B-MLD induced pluripotent stem cell human CVCL_IT69 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC601A/B-MLD Unspecified 21110583 CVCL_J568 133-6C10 hybridoma house mouse CVCL_J568 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8897 21110584 CVCL_IT68 SC600A-WT induced pluripotent stem cell human CVCL_IT68 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC600A-WT Male 21110585 CVCL_J565 127-60F3 hybridoma house mouse CVCL_J565 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8971 21110586 CVCL_IT65 KSCBi002-B-1 induced pluripotent stem cell human CVCL_IT65 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21110587 CVCL_J564 127-53F8 hybridoma house mouse CVCL_J564 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8970 21110588 CVCL_IT64 KSCBi002-B induced pluripotent stem cell human CVCL_IT64 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21110589 CVCL_J567 133-1E10 hybridoma house mouse CVCL_J567 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8888 21110590 CVCL_IT67 SC201A-1 induced pluripotent stem cell house mouse CVCL_IT67 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Derived from sampling site: Embryo Cell type=Fibroblast.; Breed/subspecies: C57BL/6. Discontinued: Systems Biosciences; Catalog number SC201A-1 Unspecified 21110591 CVCL_J566 132-7C9 hybridoma house mouse CVCL_J566 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10242; Human MYB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8924 21110592 CVCL_IT66 SC102A-1 induced pluripotent stem cell human CVCL_IT66 From: Systems Biosciences (SBI), Inc.; Palo Alto; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Systems Biosciences; Catalog number SC102A-1 Male 21110593 CVCL_J561 127-42C11 hybridoma house mouse CVCL_J561 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9561 21110594 CVCL_IT61 IRFMNi001-A induced pluripotent stem cell human CVCL_IT61 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 21110595 CVCL_J560 127-38G2 hybridoma house mouse CVCL_J560 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8967 21110596 CVCL_IT60 CUBi002-B induced pluripotent stem cell human CVCL_IT60 From: Charite, Universitatsmedizin Berlin; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1348; SAMD9; Simple; p.Ile983Ser (c.2948T>G); Zygosity=Heterozygous (PubMed=28346228) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110597 CVCL_J563 127-50D4 hybridoma house mouse CVCL_J563 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8968 21110598 CVCL_IT63 KSCBi002-A induced pluripotent stem cell human CVCL_IT63 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21110599 CVCL_J562 127-50D12 hybridoma house mouse CVCL_J562 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8969 21110600 CVCL_IT62 KSCBi001-A induced pluripotent stem cell human CVCL_IT62 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Urine. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21110601 CVCL_IT39 SU-DIPG-IV cancer cell line human CVCL_IT39 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Gly328Val (c.983G>T); ClinVar=VCV000376363; Zygosity=Unspecified (PubMed=28823557); Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=25939062) Derived from sampling site: Brainstem; pons. Omics: Transcriptome analysis by RNAseq Female Doubling time: 3.0 days (PubMed=34215733) 21110602 CVCL_J539 YUTUR cancer cell line human CVCL_J539 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110603 CVCL_IT36 NEM163 cancer cell line human CVCL_IT36 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062). Male Doubling time: 36 hours (PubMed=25534822) 21110604 CVCL_J536 YUPAO cancer cell line human CVCL_J536 CL:0000010 Female Part of: Yale University (YU) melanoma cell collection. 21110605 CVCL_IT35 NEM157 cancer cell line human CVCL_IT35 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062). Female Doubling time: 30 hours (PubMed=25534822) 21110606 CVCL_J535 YUNIBO cancer cell line human CVCL_J535 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21110607 CVCL_J538 372 hybridoma house mouse CVCL_J538 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Murine leukemia viruses (MuLV) p15E. 21110608 CVCL_IT38 NEM168 cancer cell line human CVCL_IT38 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062). Female Doubling time: 34 hours (PubMed=25534822) 21110609 CVCL_IT37 NEM165 cancer cell line human CVCL_IT37 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062). Female Doubling time: 32 hours (PubMed=25534822) 21110610 CVCL_IT32 SDM4 cancer cell line human CVCL_IT32 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor, exact cancer type and sampling site from personal communication of Felley-Bosco E Derived from sampling site: Pleural effusion. Omics: Cell surface proteome Male 21110611 CVCL_J532 YUCAL cancer cell line human CVCL_J532 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21110612 CVCL_IT31 SDM34 cancer cell line human CVCL_IT31 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and exact cancer type from personal communication of Felley-Bosco E. Omics: Cell surface proteome Male 21110613 CVCL_J531 YUWIM cancer cell line human CVCL_J531 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110614 CVCL_IT34 SDM104 finite cell line human CVCL_IT34 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Felley-Bosco E. Omics: Cell surface proteome Male 21110615 CVCL_J534 YUMAG cancer cell line human CVCL_J534 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21110616 CVCL_IT33 SDM5 cancer cell line human CVCL_IT33 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor, exact cancer type and sampling site from personal communication of Felley-Bosco E Derived from sampling site: Pleural effusion. Omics: Cell surface proteome Male 21110617 CVCL_J533 YUCLIR cancer cell line human CVCL_J533 CL:0000010 Female Part of: Yale University (YU) melanoma cell collection. 21110618 CVCL_IT30 HCC4012 telomerase immortalized cell line human CVCL_IT30 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Mesothelial cell. Omics: Cell surface proteome; Omics: SNP array analysis 21110619 CVCL_J530 YUWERA cancer cell line human CVCL_J530 CL:0000010 Female Part of: Yale University (YU) melanoma cell collection. 21110620 CVCL_J547 290-4E10 hybridoma house mouse CVCL_J547 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9133 21110621 CVCL_IT47 JHH-DIPG-1 cancer cell line human CVCL_IT47 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=26115193) Omics: Transcriptome analysis by RNAseq. Male 21110622 CVCL_J546 171-19B10 hybridoma house mouse CVCL_J546 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9097 21110623 CVCL_IT46 SF8628 cancer cell line human CVCL_IT46 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=23603901) Omics: Transcriptome analysis by RNAseq. Female 21110624 CVCL_J549 114-50G2 hybridoma house mouse CVCL_J549 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8926 21110625 CVCL_IT49 1D4 iPS induced pluripotent stem cell house mouse CVCL_IT49 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21110626 CVCL_J548 114-50D4 hybridoma house mouse CVCL_J548 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8925 21110627 CVCL_IT48 2D4 iPS induced pluripotent stem cell house mouse CVCL_IT48 CL:0000010 Omics: Cell surface proteome; Omics: Transcriptome analysis by microarray. Female 21110628 CVCL_J543 203-7D10 hybridoma house mouse CVCL_J543 CL:0000010 Monoclonal antibody isotype: IgG2a+IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8898 21110629 CVCL_IT43 VUMC-DIPG-A cancer cell line human CVCL_IT43 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062) Derived from sampling site: Brainstem; pons. Female 21110630 CVCL_J542 P44E11 hybridoma house mouse CVCL_J542 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00543; Feline sarcoma virus (strain Snyder-Theilen) V-Fes. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8593 21110631 CVCL_IT42 SU-pcGBM-2 cancer cell line human CVCL_IT42 CL:0000010 Derived from sampling site: Brain; frontal lobe. Male 21110632 CVCL_J545 H1.6 hybridoma house mouse CVCL_J545 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P60852; Human ZP1. 21110633 CVCL_IT45 SF7761 telomerase immortalized cell line human CVCL_IT45 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=23603901; PubMed=34732238); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Glu540Ter (c.1618G>T); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238); Transfected with: HGNC; 11730; TERT Derived from sampling site: Brainstem; pons. Omics: CNV analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=22983601) 21110634 CVCL_J544 171-10E5 hybridoma house mouse CVCL_J544 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9098 21110635 CVCL_IT44 VUMC-DIPG-B cancer cell line human CVCL_IT44 CL:0000010 Sequence variation: Mutation; HGNC; 4776; H3C2; Simple; p.Lys28Met (c.83A>T) (H3.1K27M); Zygosity=Unspecified (PubMed=25939062) Derived from sampling site: Brainstem; pons. Female 21110636 CVCL_IT41 SU-DIPG-XIII cancer cell line human CVCL_IT41 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Unspecified (PubMed=34732238) Derived from sampling site: Brainstem; pons. Female Doubling time: 6.6 days (PubMed=34215733) 21110637 CVCL_J541 YUDAN3 cancer cell line human CVCL_J541 CL:0000010 Female Part of: Yale University (YU) melanoma cell collection. 21110638 CVCL_IT40 SU-DIPG-VI cancer cell line human CVCL_IT40 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=25939062; PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu198Ter (c.592G>T); ClinVar=VCV000634704; Zygosity=Unspecified (PubMed=34732238) Donor information: Established from a sample taken just after the death at age 7 of McKenna Wetzel When McKenna died, the Wetzels donated to researchers at Stanford University the tissues that allowed this cell line to be derived. They also created the McKenna Claire Foundation's whose mission is to help cure pediatric brain cancer by raising awareness, increasing community involvement and funding research.; Derived from sampling site: Brainstem; pons. Omics: Transcriptome analysis by RNAseq Female Doubling time: 5.8 days (PubMed=34215733) 21110639 CVCL_J540 YUGEK cancer cell line human CVCL_J540 CL:0000010 Female Part of: Yale University (YU) melanoma cell collection. 21110640 CVCL_RM90 iPSCWT2 induced pluripotent stem cell human CVCL_RM90 CL:0000010 Miscellaneous: Identification of parent cell line from personal communication of Zambidis E Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110641 CVCL_RM92 CBiPSC6.2 induced pluripotent stem cell human CVCL_RM92 CL:0000010 Miscellaneous: Age/sex of donor and identity of CBiPSC6.2 with Gibco cell line from personal communication of Zambidis E Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21110642 CVCL_RM91 iPSCWT4 induced pluripotent stem cell human CVCL_RM91 CL:0000010 Miscellaneous: Identification of parent cell line from personal communication of Zambidis E Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110643 CVCL_RM94 CBiPSC6.13 induced pluripotent stem cell human CVCL_RM94 CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Zambidis E Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21110644 CVCL_RM93 CBiPSC6.11 induced pluripotent stem cell human CVCL_RM93 CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Zambidis E Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by microarray Female 21110645 CVCL_RM96 DP028 finite cell line human CVCL_RM96 HLA typing: A*02,31; B*35,46 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: Transcriptome analysis by microarray Male 21110646 CVCL_RM95 CBiPSC19.11 induced pluripotent stem cell human CVCL_RM95 CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Zambidis E Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21110647 CVCL_RM98 ChiPSC7 induced pluripotent stem cell human CVCL_RM98 HLA typing: A*03:01; B*07:02,35:01; C*04:01,07:02; DPB1*04:01,04:02; DQB1*05:01,06:02; DRB1*01:01,15:01 (Takara) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110648 CVCL_RM97 ChiPSC4 induced pluripotent stem cell human CVCL_RM97 HLA typing: A*23,30; B*53,58; C*04,07; DQA1*01,01; DQB1*05,06; DRB1*15,16 (PubMed=29026098) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: Takara/Clontech; Catalog number Y00260/Y00265 Male 21110649 CVCL_RM99 ChiPSC12 induced pluripotent stem cell human CVCL_RM99 HLA typing: A*01:01; B*08:01,37:01; C*06:02,07:01; DPB1*01:01,04:01; DQB1*02:01,03:01; DRB1*03:01,11:04 (Takara) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110650 CVCL_RM79 UKKi032-C induced pluripotent stem cell human CVCL_RM79 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21110651 CVCL_RM81 STBCi006-A-4 induced pluripotent stem cell human CVCL_RM81 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110652 CVCL_RM80 STBCi006-A-1 induced pluripotent stem cell human CVCL_RM80 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110653 CVCL_RM83 UKBi011-A-4 induced pluripotent stem cell human CVCL_RM83 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous (PubMed=33556820); Sequence variation: Mutation; HGNC; 613; APOE; Simple_corrected; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33556820) Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: EBiSC; UKBi011-A-4; true Male 21110654 CVCL_RM82 UKBi011-A-1 induced pluripotent stem cell human CVCL_RM82 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21110655 CVCL_RM85 BIONi010-C-11 induced pluripotent stem cell human CVCL_RM85 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple_edited; p.Gly292Argfs*25 (c.872dupC) (p.Pro291fs); ClinVar=VCV000014927; Zygosity=Homozygous; Note=By CRISPR/Cas9 (EBiSC) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110656 CVCL_RM84 BIONi010-C-10 induced pluripotent stem cell human CVCL_RM84 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple_edited; p.Gly292Argfs*25 (c.872dupC) (p.Pro291fs); ClinVar=VCV000014927; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (EBiSC) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110657 CVCL_RM87 BIONi010-C-15 induced pluripotent stem cell human CVCL_RM87 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Transfected with: HGNC; 13805; NEUROG2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Expression of NEUROG2/NGN2-eGFP is doxycycline-inducible Using TALEN NEUROG2-T2A-eGFP under the control of a tetracycline response element and a 2A-Puro was inserted into one allele of the the safe harbor locus (AAVS1). At the second locus a 2A-Neo-CAG-rtTA construct was inserted (PubMed=33610017). 21110658 CVCL_RM86 BIONi010-C-12 induced pluripotent stem cell human CVCL_RM86 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple_edited; p.Arg331Cys (c.991C>T) (R309C); ClinVar=VCV000036364; Zygosity=Homozygous; Note=By CRISPR/Cas9 (EBiSC) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110659 CVCL_RM89 BIONi010-C-18 induced pluripotent stem cell human CVCL_RM89 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110660 CVCL_RM88 BIONi010-C-17 induced pluripotent stem cell human CVCL_RM88 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17761; TREM2 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21110661 CVCL_RM69 UKKi029-B induced pluripotent stem cell human CVCL_RM69 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Asp564His (c.1690G>T); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110662 CVCL_RM68 UKKi029-A induced pluripotent stem cell human CVCL_RM68 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Asp564His (c.1690G>T); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110663 CVCL_RM70 UKKi029-C induced pluripotent stem cell human CVCL_RM70 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Asp564His (c.1690G>T); Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110664 CVCL_RM72 UKKi030-B induced pluripotent stem cell human CVCL_RM72 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Gln646Argfs*5 (c.1936delC); ClinVar=VCV000179829; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21110665 CVCL_RM71 UKKi030-A induced pluripotent stem cell human CVCL_RM71 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Gln646Argfs*5 (c.1936delC); ClinVar=VCV000179829; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21110666 CVCL_RM74 UKKi031-A induced pluripotent stem cell human CVCL_RM74 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Arg94Leu (c.281G>T); ClinVar=VCV000043629; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110667 CVCL_RM73 UKKi030-C induced pluripotent stem cell human CVCL_RM73 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Gln646Argfs*5 (c.1936delC); ClinVar=VCV000179829; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21110668 CVCL_RM76 UKKi031-C induced pluripotent stem cell human CVCL_RM76 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Arg94Leu (c.281G>T); ClinVar=VCV000043629; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110669 CVCL_RM75 UKKi031-B induced pluripotent stem cell human CVCL_RM75 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11949; TNNT2; Simple; p.Arg94Leu (c.281G>T); ClinVar=VCV000043629; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21110670 CVCL_RM78 UKKi032-B induced pluripotent stem cell human CVCL_RM78 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21110671 CVCL_RM77 UKKi032-A induced pluripotent stem cell human CVCL_RM77 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21110672 CVCL_RM58 T7643-5 induced pluripotent stem cell human CVCL_RM58 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110673 CVCL_RM57 T7643-32 induced pluripotent stem cell human CVCL_RM57 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110674 CVCL_RM59 T7643-7 induced pluripotent stem cell human CVCL_RM59 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110675 CVCL_RM61 T9862-40 induced pluripotent stem cell human CVCL_RM61 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110676 CVCL_RM60 T9862-35 induced pluripotent stem cell human CVCL_RM60 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110677 CVCL_RM63 T9862-42 induced pluripotent stem cell human CVCL_RM63 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110678 CVCL_RM62 T9862-41 induced pluripotent stem cell human CVCL_RM62 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110679 CVCL_RM65 T9862-61 induced pluripotent stem cell human CVCL_RM65 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110680 CVCL_RM64 T9862-5 induced pluripotent stem cell human CVCL_RM64 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21110681 CVCL_RM67 RPTEC/TERT1 OAT1 telomerase immortalized cell line human CVCL_RM67 CL:0000010 Transfected with: HGNC; 10970; SLC22A6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Doubling time: ~70 hours (ATCC=CRL-4031-OAT1) 21110682 CVCL_RM66 RPTEC/TERT1 OCT2 telomerase immortalized cell line human CVCL_RM66 CL:0000010 Transfected with: HGNC; 10966; SLC22A2; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Doubling time: ~85 hours (ATCC=CRL-4031-OCT2) 21110683 CVCL_RM47 NPC1-3#47 induced pluripotent stem cell human CVCL_RM47 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110684 CVCL_RM46 NPC1-3#4 induced pluripotent stem cell human CVCL_RM46 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110685 CVCL_RM49 NPC1-4#20 induced pluripotent stem cell human CVCL_RM49 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110686 CVCL_RM48 NPC1-4#17 induced pluripotent stem cell human CVCL_RM48 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110687 CVCL_RM50 CHO-AS52 Ogg1(-/-)-Mutyh(-/-) spontaneously immortalized cell line CVCL_RM50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GX91; Ogg1; Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GYQ5; Mutyh; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Ovary. Female 21110688 CVCL_RM52 IM23-9 induced pluripotent stem cell human CVCL_RM52 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110689 CVCL_RM51 IM23-16 induced pluripotent stem cell human CVCL_RM51 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110690 CVCL_RM54 NH1-1 induced pluripotent stem cell human CVCL_RM54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray 21110691 CVCL_RM53 IM25-2 induced pluripotent stem cell human CVCL_RM53 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110692 CVCL_RM56 T7643-3 induced pluripotent stem cell human CVCL_RM56 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Unspecified (PubMed=21307850) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21110693 CVCL_RM55 NH2-6 induced pluripotent stem cell human CVCL_RM55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray 21110694 CVCL_RM36 Control-2Corr#9 induced pluripotent stem cell human CVCL_RM36 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110695 CVCL_RM35 Control-2Corr#7 induced pluripotent stem cell human CVCL_RM35 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110696 CVCL_RM38 Control-2Mut#13 induced pluripotent stem cell human CVCL_RM38 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110697 CVCL_RM37 Control-2Mut#11 induced pluripotent stem cell human CVCL_RM37 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110698 CVCL_RM39 NPC1-1#13 induced pluripotent stem cell human CVCL_RM39 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (PubMed=24936472) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110699 CVCL_J499 293/CrmA transformed cell line human CVCL_J499 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P07385; Cowpox virus crmA Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21110700 CVCL_IS99 XLC042 embryonic stem cell human CVCL_IS99 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110701 CVCL_J498 3Y1-B cl 1-6-K5-4-2 spontaneously immortalized cell line Norway rat CVCL_J498 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21110702 CVCL_IS98 XLC041 embryonic stem cell human CVCL_IS98 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110703 CVCL_J495 SRBC-RF29-1-3 hybridoma house mouse CVCL_J495 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110704 CVCL_IS95 XLC033 embryonic stem cell human CVCL_IS95 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110705 CVCL_J494 SRBC-P20-13-13 hybridoma house mouse CVCL_J494 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110706 CVCL_IS94 XLC030 embryonic stem cell human CVCL_IS94 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110707 CVCL_J497 SRBC-RP8-2-4 hybridoma house mouse CVCL_J497 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110708 CVCL_IS97 XLC038 embryonic stem cell human CVCL_IS97 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110709 CVCL_J496 SRBC-RP8-18-15 hybridoma house mouse CVCL_J496 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110710 CVCL_IS96 XLC034 embryonic stem cell human CVCL_IS96 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110711 CVCL_J491 SRBC-F31-2-11 hybridoma house mouse CVCL_J491 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110712 CVCL_IS91 XLC025 embryonic stem cell human CVCL_IS91 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110713 CVCL_J490 SRBC-F31-19-1 hybridoma house mouse CVCL_J490 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110714 CVCL_IS90 XLC023 embryonic stem cell human CVCL_IS90 From: Creative Bioarray; New York; USA. CL:0000010 Female 21110715 CVCL_RM41 NPC1-2#26 induced pluripotent stem cell human CVCL_RM41 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110716 CVCL_J493 SRBC-P18-3-8 hybridoma house mouse CVCL_J493 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110717 CVCL_IS93 XLC029 embryonic stem cell human CVCL_IS93 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110718 CVCL_RM40 NPC1-1#4 induced pluripotent stem cell human CVCL_RM40 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (PubMed=24936472) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110719 CVCL_J492 SRBC-P13-7-3 hybridoma house mouse CVCL_J492 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21110720 CVCL_IS92 XLC027 embryonic stem cell human CVCL_IS92 From: Creative Bioarray; New York; USA. CL:0000010 Male 21110721 CVCL_RM43 NPC1-2-Corr#31 induced pluripotent stem cell human CVCL_RM43 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple_corrected; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous; Note=By TALEN (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110722 CVCL_RM42 NPC1-2#9 induced pluripotent stem cell human CVCL_RM42 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110723 CVCL_RM45 NPC1-2-Corr#36 induced pluripotent stem cell human CVCL_RM45 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple_corrected; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous; Note=By TALEN (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110724 CVCL_RM44 NPC1-2-Corr#32 induced pluripotent stem cell human CVCL_RM44 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (PubMed=24936472); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple_corrected; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous; Note=By TALEN (PubMed=24936472) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110725 CVCL_RM25 ME-3 cancer cell line human CVCL_RM25 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 9-12 days (PubMed=8018932) 21110726 CVCL_RM24 CMK-6 cancer cell line human CVCL_RM24 CL:0000010 Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21110727 CVCL_RM27 iSPG3A-8 induced pluripotent stem cell human CVCL_RM27 CL:0000010 Sequence variation: Mutation; HGNC; 11231; ATL1; Simple; p.Pro342Ser (c.1024C>T); Zygosity=Heterozygous (PubMed=24908668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110728 CVCL_RM26 iSPG3A-6 induced pluripotent stem cell human CVCL_RM26 CL:0000010 Sequence variation: Mutation; HGNC; 11231; ATL1; Simple; p.Pro342Ser (c.1024C>T); Zygosity=Heterozygous (PubMed=24908668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110729 CVCL_RM29 HE20 finite cell line human CVCL_RM29 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Unspecified 21110730 CVCL_RM28 HE17 finite cell line human CVCL_RM28 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Unspecified 21110731 CVCL_RM30 HE4 finite cell line human CVCL_RM30 CL:0000010 Population: Japanese; Derived from sampling site: Fetal bone; femur Cell type=Fibroblast.. Unspecified 21110732 CVCL_RM32 HE7 finite cell line human CVCL_RM32 CL:0000010 Population: Japanese; Derived from sampling site: Fetal chest Cell type=Fibroblast.. Female 21110733 CVCL_RM31 HE6 finite cell line human CVCL_RM31 CL:0000010 Population: Japanese; Derived from sampling site: Fetal addomen Cell type=Fibroblast.. Unspecified 21110734 CVCL_RM34 Control-2#13 induced pluripotent stem cell human CVCL_RM34 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110735 CVCL_RM33 Control-2#11 induced pluripotent stem cell human CVCL_RM33 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (PubMed=24936472) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110736 CVCL_8A61 GM13411 finite cell line human CVCL_8A61 CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Unspecified (PubMed=8042671) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110737 CVCL_8A60 GM03672 finite cell line human CVCL_8A60 CL:0000010 Sequence variation: Mutation; HGNC; 7427; MT-CYB; Simple; p.Asp171Asn (m.15257G>A); ClinVar=VCV000009674; Zygosity=Heteroplasmic (from child cell line KUCFRi003-A) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21110738 CVCL_8A67 GM02317 finite cell line human CVCL_8A67 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21110739 CVCL_8A66 GM02316 finite cell line human CVCL_8A66 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21110740 CVCL_8A69 GM20015 finite cell line human CVCL_8A69 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Tyr36Cys (c.107A>G) (p.Tyr52Cys, c.155A>G); ClinVar=VCV000000093; Zygosity=Homozygous (Coriell) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110741 CVCL_8A68 GM18313 finite cell line human CVCL_8A68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110742 CVCL_8A63 GM13741 transformed cell line human CVCL_8A63 CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Heteroplasmic (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110743 CVCL_8A62 GM13740 transformed cell line human CVCL_8A62 CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Homoplasmic (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110744 CVCL_8A65 GM02315 finite cell line human CVCL_8A65 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Glu138Val (c.413A>T) (p.Glu154Val, c.461A>T); ClinVar=VCV000000092; Zygosity=Homozygous (PubMed=11241842) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110745 CVCL_8A64 GM02314 finite cell line human CVCL_8A64 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21110746 CVCL_8A70 GM20016 finite cell line human CVCL_8A70 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Asn320Asp (c.958A>G) (p.Asn336Asp, c.1006A>G); ClinVar=VCV000000094; Zygosity=Homozygous (Coriell) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110747 CVCL_8A72 GM20018 finite cell line human CVCL_8A72 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Thr222Lys (c.665C>A) (p.Thr238Lys, c.713C>A); ClinVar=VCV000000091; Zygosity=Homozygous (Coriell) Population: Caucasian; Belgian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110748 CVCL_8A71 GM20017 finite cell line human CVCL_8A71 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; c.1098+1G>T (IVS13+1G>T) (p.Asn348_Lys366del); ClinVar=VCV000812507; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110749 CVCL_8A78 GM22495 transformed cell line human CVCL_8A78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110750 CVCL_8A77 GM22296 transformed cell line human CVCL_8A77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110751 CVCL_8A79 GM22501 transformed cell line human CVCL_8A79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110752 CVCL_8A74 GM22241 transformed cell line human CVCL_8A74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110753 CVCL_8A73 GM20019 finite cell line human CVCL_8A73 CL:0000010 Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Gly128_Lys152del (c.412G>T); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 735; ASAH1; Simple; p.Asp331Asn (c.991G>A) (p.Asp347Asn, c.1039G>A); ClinVar=VCV000812495; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110754 CVCL_8A76 GM22264 transformed cell line human CVCL_8A76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110755 CVCL_8A75 GM22243 transformed cell line human CVCL_8A75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110756 CVCL_8A49 GM09645 transformed cell line human CVCL_8A49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110757 CVCL_8A48 GM09644 transformed cell line human CVCL_8A48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110758 CVCL_8A45 GM09544 transformed cell line human CVCL_8A45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110759 CVCL_8A44 GM09541 transformed cell line human CVCL_8A44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110760 CVCL_8A47 GM09610 transformed cell line human CVCL_8A47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110761 CVCL_8A46 GM09595 transformed cell line human CVCL_8A46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110762 CVCL_8A41 GM09512 transformed cell line human CVCL_8A41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110763 CVCL_8A40 GM09505 transformed cell line human CVCL_8A40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110764 CVCL_8A43 GM09523 transformed cell line human CVCL_8A43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110765 CVCL_8A42 GM09522 transformed cell line human CVCL_8A42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110766 CVCL_8A59 GM01503 finite cell line human CVCL_8A59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21110767 CVCL_8A50 GM09646 transformed cell line human CVCL_8A50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110768 CVCL_8A56 GM09608 transformed cell line human CVCL_8A56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110769 CVCL_8A55 GM08256 transformed cell line human CVCL_8A55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110770 CVCL_8A58 GM20833 transformed cell line human CVCL_8A58 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.His1327Arg (c.3980A>G) (H1299R); ClinVar=VCV000037345; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110771 CVCL_8A57 GM14899 transformed cell line human CVCL_8A57 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Homozygous; Note=Factor V Leiden (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110772 CVCL_8A52 GM09911 transformed cell line human CVCL_8A52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110773 CVCL_8A51 GM09656 transformed cell line human CVCL_8A51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110774 CVCL_8A54 GM10991 transformed cell line human CVCL_8A54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110775 CVCL_8A53 GM10990 transformed cell line human CVCL_8A53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110776 CVCL_8A27 GM09414 transformed cell line human CVCL_8A27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110777 CVCL_8A26 GM09413 transformed cell line human CVCL_8A26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110778 CVCL_8A29 GM09443 transformed cell line human CVCL_8A29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110779 CVCL_8A28 GM09415 transformed cell line human CVCL_8A28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110780 CVCL_8A23 GM09410 transformed cell line human CVCL_8A23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110781 CVCL_8A22 GM09409 transformed cell line human CVCL_8A22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110782 CVCL_8A25 GM09412 transformed cell line human CVCL_8A25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110783 CVCL_8A24 GM09411 transformed cell line human CVCL_8A24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110784 CVCL_8A21 GM09408 transformed cell line human CVCL_8A21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110785 CVCL_8A20 GM09407 transformed cell line human CVCL_8A20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110786 CVCL_8A38 GM09488 transformed cell line human CVCL_8A38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110787 CVCL_8A37 GM09487 transformed cell line human CVCL_8A37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110788 CVCL_8A39 GM09489 transformed cell line human CVCL_8A39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110789 CVCL_8A34 GM09483 transformed cell line human CVCL_8A34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110790 CVCL_8A33 GM09481 transformed cell line human CVCL_8A33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110791 CVCL_8A36 GM09485 transformed cell line human CVCL_8A36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110792 CVCL_8A35 GM09484 transformed cell line human CVCL_8A35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110793 CVCL_8A30 GM09478 transformed cell line human CVCL_8A30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110794 CVCL_8A32 GM09480 transformed cell line human CVCL_8A32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110795 CVCL_8A31 GM09479 transformed cell line human CVCL_8A31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110796 CVCL_8A09 GM09304 transformed cell line human CVCL_8A09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110797 CVCL_8A08 GM09303 transformed cell line human CVCL_8A08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110798 CVCL_8A05 GM04827 finite cell line human CVCL_8A05 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110799 CVCL_8A04 GM04825 finite cell line human CVCL_8A04 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110800 CVCL_8A07 GM04938 transformed cell line human CVCL_8A07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110801 CVCL_8A06 GM04937 finite cell line human CVCL_8A06 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110802 CVCL_8A01 GM04666 finite cell line human CVCL_8A01 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110803 CVCL_8A00 GM02642 finite cell line human CVCL_8A00 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21110804 CVCL_8A03 GM04764 transformed cell line human CVCL_8A03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110805 CVCL_8A02 GM04763 finite cell line human CVCL_8A02 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110806 CVCL_8A19 GM09385 transformed cell line human CVCL_8A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110807 CVCL_8A16 GM09382 transformed cell line human CVCL_8A16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110808 CVCL_8A15 GM09381 transformed cell line human CVCL_8A15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110809 CVCL_8A18 GM09384 transformed cell line human CVCL_8A18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110810 CVCL_8A17 GM09383 transformed cell line human CVCL_8A17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110811 CVCL_8A12 GM09329 transformed cell line human CVCL_8A12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110812 CVCL_8A11 GM09311 transformed cell line human CVCL_8A11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110813 CVCL_8A14 GM09331 transformed cell line human CVCL_8A14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110814 CVCL_8A13 GM09330 transformed cell line human CVCL_8A13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110815 CVCL_8A10 GM09310 transformed cell line human CVCL_8A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110816 CVCL_J639 4A6 [Mouse hybridoma against C.griseus Nsf] hybridoma house mouse CVCL_J639 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18708; Cricetulus griseus Nsf. 21110817 CVCL_IU39 YM cancer cell line human CVCL_IU39 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5853; IGL; Name(s)=IGL-BCL2 (PubMed=12967475); Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 6006; IL21R; Name(s)=BCL6-IL21R (PubMed=11821949; PubMed=12967475) Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Ascites. Male Doubling time: 36-48 hours (PubMed=9747876) 21110818 CVCL_J638 4B2-6C3-1C9 hybridoma house mouse CVCL_J638 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Norwalk virus. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12466 21110819 CVCL_IU38 Kimura cancer cell line human CVCL_IU38 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Unspecified Virology: EBV-negative 21110820 CVCL_J635 31-42-19 hybridoma house mouse CVCL_J635 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9726 21110821 CVCL_IU35 KD2.3 cancer cell line house mouse CVCL_IU35 CL:0000010 Breed/subspecies: DBA/2. 21110822 CVCL_J634 311-3D4 hybridoma house mouse CVCL_J634 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b. 21110823 CVCL_IU34 Patrick cancer cell line human CVCL_IU34 CL:0000010 Population: African; Kenyan; Derived from sampling site: Bone; jaw; maxilla. Male 21110824 CVCL_J637 317G5 hybridoma house mouse CVCL_J637 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8485; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8691 21110825 CVCL_IU37 H9-NSC somatic stem cell human CVCL_IU37 CL:0000010 Derived from sampling site: Cell type=Neural stem cell. Female 21110826 CVCL_J636 31-90-25 hybridoma house mouse CVCL_J636 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9725 21110827 CVCL_IU36 K3T103 cancer cell line house mouse CVCL_IU36 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Breed/subspecies: DBA/2. 21110828 CVCL_J631 2G3 [Mouse hybridoma against rat Fcgrt] hybridoma house mouse CVCL_J631 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13599; Rat Fcgrt. 21110829 CVCL_IU31 GM26017 induced pluripotent stem cell human CVCL_IU31 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110830 CVCL_J630 2F.11.15 hybridoma house mouse CVCL_J630 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: ChEBI; CHEBI:53067; 2,4,6-trinitrophenyl group (TNP). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21110831 CVCL_IU30 GM26029 induced pluripotent stem cell human CVCL_IU30 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110832 CVCL_J633 30/15 hybridoma house mouse CVCL_J633 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28177; Theophylline. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8152 21110833 CVCL_IU33 GM26025 induced pluripotent stem cell human CVCL_IU33 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110834 CVCL_J632 2T8-3E10 hybridoma house mouse CVCL_J632 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8213 21110835 CVCL_IU32 GM26093 finite cell line human CVCL_IU32 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.9619-2A>G; ClinVar=VCV000379231; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.His8159Glnfs*8 (c.24473_24476dupAACA); Zygosity=Heterozygous (Coriell) Population: Chinese and Jewish; Ashkenazi; Derived from sampling site: Hip; skin Cell type=Fibroblast.. Male 21110836 CVCL_J649 EBRTcH3 embryonic stem cell house mouse CVCL_J649 CL:0000010 Breed/subspecies: 129P2/Ola. Discontinued: RCB; RCB2325; true Male 21110837 CVCL_IU49 Ly74 cancer cell line human CVCL_IU49 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21110838 CVCL_J646 BALB/3T3 A31-1-1 spontaneously immortalized cell line house mouse CVCL_J646 CL:0000010 Breed/subspecies: Swiss albino. Discontinued: JCRB; NIHS0590; true Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00528 Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (PubMed=27844419). Therefore this cell line is not a clone of BALB/3T3 clone A31 (Cellosaurus=CVCL_0184) as originally reported. 21110839 CVCL_IU46 CHA-hES1 embryonic stem cell human CVCL_IU46 From: CHA University; Seongnam; South Korea. CL:0000010 Unspecified 21110840 CVCL_IU45 DL-4 cancer cell line human CVCL_IU45 CL:0000010 Population: Japanese Virology: EBV-negative. 21110841 CVCL_J645 GM02575 transformed cell line human CVCL_J645 CL:0000010 Population: Native Central American; Pima/Papago; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21110842 CVCL_J648 EB5 [Mouse ESC] embryonic stem cell house mouse CVCL_J648 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21110843 CVCL_IU48 Ly65 cancer cell line human CVCL_IU48 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21110844 CVCL_IU47 CHA-hES2 embryonic stem cell human CVCL_IU47 From: CHA University; Seongnam; South Korea. CL:0000010 Unspecified 21110845 CVCL_J647 EB3 [Mouse ESC] embryonic stem cell house mouse CVCL_J647 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Discontinued: RCB; RCB2717; true Male 21110846 CVCL_J642 4C5G hybridoma house mouse CVCL_J642 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A6QLN5; Bovine PI4K2A (Note=Also reacts with human and other species). 21110847 CVCL_IU42 FL-618 cancer cell line human CVCL_IU42 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Unspecified 21110848 CVCL_J641 4C2.4A7.5H11 hybridoma house mouse CVCL_J641 CL:0000010 Discontinued: ATCC; CRL-2744; true; Discontinued: ATCC; JHU-28; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mouse MHC class I Qa-1b 21110849 CVCL_IU41 FL-518 cancer cell line human CVCL_IU41 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.527G>C); Zygosity=Unspecified (PubMed=8878455) Population: Japanese Omics: Transcriptome analysis by microarray Male 21110850 CVCL_IU44 FL-818 cancer cell line human CVCL_IU44 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Unspecified 21110851 CVCL_J644 GM02574 finite cell line human CVCL_J644 CL:0000010 Population: Native Central American; Pima/Papago; Derived from sampling site: Cell type=Fibroblast. Male 21110852 CVCL_J643 61/7 hybridoma house mouse CVCL_J643 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28177; Theophylline. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8154 21110853 CVCL_IU43 FL-718 cancer cell line human CVCL_IU43 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Unspecified 21110854 CVCL_J640 4C hybridoma house mouse CVCL_J640 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8311 21110855 CVCL_IU40 FL-418 cancer cell line human CVCL_IU40 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=12967475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8878455) Population: Japanese Omics: Transcriptome analysis by microarray Unspecified 21110856 CVCL_IU17 FU-PNET-3 cancer cell line human CVCL_IU17 CL:0000010 Population: Japanese Male Doubling time: 40.8 hours (PubMed=27613543). 21110857 CVCL_J617 CHO-K1 tsTM4 transformed cell line CVCL_J617 CL:0000010 Sequence variation: Mutation; UniProtKB; P11414; Polr2a; Simple; p.Pro1006Ser (c.3016C>T); Zygosity=Homozygous (PubMed=9272869) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature sensitive Exhibits abnormal induction of sister chromatid exchanges along with a decrease of DNA synthesis in the cells arrested in S phase at the non-permissive temperature of 39 Celsius (PubMed=9272869). Doubling time: 34 hours (PubMed=2237640) 21110858 CVCL_IU16 ID8-Luc2 spontaneously immortalized cell line house mouse CVCL_IU16 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female 21110859 CVCL_J616 QCE-6 transformed cell line CVCL_J616 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Cardiac mesoderm. Unspecified Doubling time: 10.3 hours (PubMed=8575063) Group: Bird cell line 21110860 CVCL_J619 62.1E6 hybridoma house mouse CVCL_J619 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; E1C375; Chicken SNAI2. 21110861 CVCL_IU19 SM-1 cancer cell line human CVCL_IU19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by microarray. 21110862 CVCL_J618 413-15D12 hybridoma house mouse CVCL_J618 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b. 21110863 CVCL_IU18 FU-PNET-4 cancer cell line human CVCL_IU18 CL:0000010 Population: Japanese Female Doubling time: 45.6 hours (PubMed=27613543). 21110864 CVCL_IU13 ACI-35 cancer cell line human CVCL_IU13 CL:0000010 Female 21110865 CVCL_J613 S4-3-15-8 hybridoma CVCL_J613 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110866 CVCL_IU12 ACI-17 cancer cell line human CVCL_IU12 CL:0000010 Female 21110867 CVCL_J612 S4-3-15-7 hybridoma CVCL_J612 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110868 CVCL_IU15 ID8-Fluc spontaneously immortalized cell line house mouse CVCL_IU15 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female 21110869 CVCL_J615 SSK-HY-A3-22 hybridoma human CVCL_J615 CL:0000010 Monoclonal antibody isotype: IgG. 21110870 CVCL_IU14 ID8 spontaneously immortalized cell line house mouse CVCL_IU14 CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Characteristics: Physiologically and biologically closely resembles human epithelial ovarian cancer 21110871 CVCL_J614 SSK-HY-23-42 hybridoma human CVCL_J614 CL:0000010 Monoclonal antibody isotype: IgG. 21110872 CVCL_IU11 ACI-1 cancer cell line human CVCL_IU11 CL:0000010 Female 21110873 CVCL_J611 S4-3-15-6 hybridoma CVCL_J611 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110874 CVCL_J610 S4-3-15-14 hybridoma CVCL_J610 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110875 CVCL_IU10 TIG-1L finite cell line human CVCL_IU10 CL:0000010 Population: Japanese; Derived from sampling site: Fetal liver Cell type=Fibroblast.. Female Senescence: Senesces at 65 PDL (PubMed=7421303) 21110876 CVCL_J628 2C5-6 hybridoma house mouse CVCL_J628 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:16113; Cholesterol. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8995 21110877 CVCL_IU28 Dt81Hepa1-6 cancer cell line house mouse CVCL_IU28 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female Doubling time: 32.12 +- 2.11 hours (PubMed=28152020) 21110878 CVCL_J627 2A3A1H hybridoma house mouse CVCL_J627 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8555 21110879 CVCL_IU27 Issac IV cancer cell line human CVCL_IU27 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21110880 CVCL_J629 2D-7 hybridoma house mouse CVCL_J629 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07199; Human CENPB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9667 21110881 CVCL_IU29 UKBi010-A induced pluripotent stem cell human CVCL_IU29 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Ile110Valfs*10 (c.323_326dupTGTA); Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UKBi010-A; true Female 21110882 CVCL_J624 26ic hybridoma house mouse CVCL_J624 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 21110883 CVCL_IU24 Nyevu cancer cell line human CVCL_IU24 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified Virology: Contains 93 copies of the EBV genome (PubMed=6244869) 21110884 CVCL_J623 260-33C4 hybridoma house mouse CVCL_J623 CL:0000010 Monoclonal antibody isotype: IgM. 21110885 CVCL_IU23 Muriungi cancer cell line human CVCL_IU23 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21110886 CVCL_J626 2A2-6E10-1D8 hybridoma house mouse CVCL_J626 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Norwalk virus. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12465 21110887 CVCL_IU26 Onesmas cancer cell line human CVCL_IU26 CL:0000010 Population: African; Kenyan; Karyotypic information: Has lost chromosome Y (PubMed=4142009); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21110888 CVCL_J625 2A11 hybridoma house mouse CVCL_J625 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21110889 CVCL_IU25 Olare cancer cell line human CVCL_IU25 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified Virology: Contains 198 copies of the EBV genome (PubMed=6244869) 21110890 CVCL_J620 20.3 hybridoma house mouse CVCL_J620 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10646 21110891 CVCL_IU20 SPEL cancer cell line human CVCL_IU20 CL:0000010 Population: Japanese; Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Male Characteristics: Has a gourd-shaped form with a polarized nucleus 21110892 CVCL_J622 236L hybridoma house mouse CVCL_J622 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9QYE7; Rat Itgad/Cd11d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12593 21110893 CVCL_IU22 Sulubo cancer cell line human CVCL_IU22 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21110894 CVCL_J621 226H hybridoma house mouse CVCL_J621 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9QYE7; Rat Itgad/Cd11d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12592 21110895 CVCL_IU21 Ly46 cancer cell line human CVCL_IU21 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21110896 CVCL_J609 S4-3-15-13 hybridoma CVCL_J609 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110897 CVCL_IU09 TIG-1H finite cell line human CVCL_IU09 CL:0000010 Population: Japanese; Derived from sampling site: Fetal heart Cell type=Fibroblast.. Female Senescence: Senesces at 50 PDL (PubMed=7421303) 21110898 CVCL_IU06 LSM 2.7 hybrid cell line human CVCL_IU06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8121 21110899 CVCL_J606 S4-3-11-1 hybridoma CVCL_J606 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110900 CVCL_J605 S4-1-15-5 hybridoma CVCL_J605 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110901 CVCL_IU05 WIBR3 Oct4-2A-GFP embryonic stem cell human CVCL_IU05 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Registration: Swiss research registry; BAG-hES-IMP-0052 21110902 CVCL_J608 S4-3-15-10 hybridoma CVCL_J608 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110903 CVCL_IU08 TIG-2S finite cell line human CVCL_IU08 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 56 PDL (PubMed=7421303) 21110904 CVCL_J607 S4-3-11-3 hybridoma CVCL_J607 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown. 21110905 CVCL_IU07 TIG-2 finite cell line human CVCL_IU07 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Senescence: Senesces at 58 PDL (PubMed=7421303) 21110906 CVCL_J602 Farage 10.6.1 cancer cell line human CVCL_J602 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Female 21110907 CVCL_IU02 WISi005-A induced pluripotent stem cell human CVCL_IU02 From: Weizmann Institute of Science; Rehovot; Israel CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110908 CVCL_J601 44aacb hybridoma house mouse CVCL_J601 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21110909 CVCL_IU01 UNEWi003-A induced pluripotent stem cell human CVCL_IU01 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110910 CVCL_J604 TKHMY hybrid cell line human CVCL_J604 CL:0000010 21110911 CVCL_IU04 WIBR3 Oct4-deltaPE-GFP embryonic stem cell human CVCL_IU04 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Registration: Swiss research registry; BAG-hES-IMP-0053 21110912 CVCL_J603 RB6-8C5 hybridoma Norway rat CVCL_J603 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P35461; Mouse Ly6g. 21110913 CVCL_IU03 WISi006-A induced pluripotent stem cell human CVCL_IU03 From: Weizmann Institute of Science; Rehovot; Israel CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110914 CVCL_J600 39-S hybridoma house mouse CVCL_J600 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04296; Human herpesvirus 1 (HHV-1) major DNA-binding protein (DBP). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8180 21110915 CVCL_IU00 UNEWi027-A induced pluripotent stem cell human CVCL_IU00 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Arg372Glnfs*99 (c.1115_1125del11); ClinVar=VCV000004358; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21110916 CVCL_S056 Hs 797.Pl finite cell line human CVCL_S056 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7528; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110917 CVCL_S055 Hs 796.Pl finite cell line human CVCL_S055 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7527; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110918 CVCL_S058 Hs 802.T cancer cell line human CVCL_S058 CL:0000010 Derived from metastatic site: Cervical lymph node. Discontinued: ATCC; CRL-7532; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110919 CVCL_S057 Hs 800.T cancer cell line human CVCL_S057 CL:0000010 Discontinued: ATCC; CRL-7531; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110920 CVCL_S059 Hs 806.T cancer cell line human CVCL_S059 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7538; true Female Doubling time: 18-20 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110921 CVCL_S061 Hs 807.T cancer cell line human CVCL_S061 CL:0000010 Discontinued: ATCC; CRL-7540; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110922 CVCL_S060 Hs 807.K finite cell line human CVCL_S060 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7539; true Female Doubling time: 12-14 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110923 CVCL_S063 Hs 810.Bm finite cell line human CVCL_S063 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7542; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110924 CVCL_S062 Hs 808.Bm finite cell line human CVCL_S062 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7541; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110925 CVCL_S065 Hs 853.Sk finite cell line human CVCL_S065 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7893; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110926 CVCL_S064 Hs 787.Mg finite cell line human CVCL_S064 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7885; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110927 CVCL_S045 Hs 775.T cancer cell line human CVCL_S045 CL:0000010 Discontinued: ATCC; CRL-7504; true. Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110928 CVCL_S044 Hs 775.Li finite cell line human CVCL_S044 CL:0000010 Derived from sampling site: Liver. Discontinued: ATCC; CRL-7503; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110929 CVCL_S047 Hs 776.T cancer cell line human CVCL_S047 CL:0000010 Discontinued: ATCC; CRL-7506; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110930 CVCL_S046 Hs 776.Sk finite cell line human CVCL_S046 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7505; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110931 CVCL_S049 Hs 783.T cancer cell line human CVCL_S049 CL:0000010 Discontinued: ATCC; CRL-7883; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110932 CVCL_S048 Hs 783.Sk finite cell line human CVCL_S048 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7514; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110933 CVCL_S050 Hs 785.Co finite cell line human CVCL_S050 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7515; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110934 CVCL_S052 Hs 794.K finite cell line human CVCL_S052 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7525; true Male Doubling time: 12-14 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110935 CVCL_S051 Hs 788.T cancer cell line human CVCL_S051 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone; femur. Discontinued: ATCC; CRL-7517; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110936 CVCL_S054 ECF50.Ht finite cell line dog CVCL_S054 CL:0000010 Derived from sampling site: Fetal heart. Discontinued: ATCC; CRL-6252; true Unspecified 21110937 CVCL_S053 Hs 794.T cancer cell line human CVCL_S053 CL:0000010 Discontinued: ATCC; CRL-7887; true. Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110938 CVCL_S034 T-47D SimpleCell O-GalNAc cancer cell line human CVCL_S034 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110939 CVCL_S033 OVCAR-3 SimpleCell O-GalNAc cancer cell line human CVCL_S033 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110940 CVCL_S036 Hs 743.Sk finite cell line human CVCL_S036 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7483; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110941 CVCL_S035 Hs 738.Eye finite cell line human CVCL_S035 CL:0000010 Derived from sampling site: Fetal eye Cell type=Fibroblast.. Discontinued: ATCC; CRL-7475; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110942 CVCL_S038 Hs 768(A).T cancer cell line human CVCL_S038 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7496; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110943 CVCL_S037 Hs 767.Sk finite cell line human CVCL_S037 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7495; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110944 CVCL_S039 Hs 769.Mu finite cell line human CVCL_S039 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7497; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110945 CVCL_J697 GM16851 transformed cell line human CVCL_J697 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110946 CVCL_IU97 MCF-7 RR2 cancer cell line human CVCL_IU97 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3942; MTOR; Simple; p.Phe2108Leu; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=27279227); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin); Derived from metastatic site: Pleural effusion. Female 21110947 CVCL_IU96 MCF-7 RR1 cancer cell line human CVCL_IU96 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3942; MTOR; Simple; p.Ala2034Val (c.6101C>T); ClinVar=VCV000948357; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=27279227); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9168; Sirolimus (Rapamycin); Derived from metastatic site: Pleural effusion. Female 21110948 CVCL_J696 NCKA transformed cell line house mouse CVCL_J696 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/10 H-2k. Unspecified 21110949 CVCL_J699 GM17519 finite cell line human CVCL_J699 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110950 CVCL_IU99 M12 cancer cell line house mouse CVCL_IU99 CL:0000010 Breed/subspecies: BALB/c. Doubling time: 26 hours (PubMed=310843) 21110951 CVCL_J698 GM16852 finite cell line human CVCL_J698 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21110952 CVCL_IU98 MCF-7 TKi-R cancer cell line human CVCL_IU98 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3942; MTOR; Simple; p.Met2327Ile (c.6981G>A); ClinVar=VCV000242349; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=27279227); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:91329; AZD8055; Derived from metastatic site: Pleural effusion. Female 21110953 CVCL_J693 GM17517 finite cell line human CVCL_J693 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21110954 CVCL_IU93 IARC-582 transformed cell line human CVCL_IU93 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21110955 CVCL_IU92 IARC-317 cancer cell line human CVCL_IU92 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 Unspecified 21110956 CVCL_J692 N1.551 hybridoma house mouse CVCL_J692 CL:0000010 Monoclonal antibody isotype: IgM. 21110957 CVCL_J695 CF1TKB finite cell line human CVCL_J695 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21110958 CVCL_IU95 KN cancer cell line human CVCL_IU95 CL:0000010 21110959 CVCL_J694 GM17518 transformed cell line human CVCL_J694 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21110960 CVCL_IU94 RD/12 cancer cell line human CVCL_IU94 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female 21110961 CVCL_J691 HT 29/36 hybridoma house mouse CVCL_J691 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8248 21110962 CVCL_IU91 IARC-306 transformed cell line human CVCL_IU91 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21110963 CVCL_J690 HT 29/26 hybridoma house mouse CVCL_J690 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8247 21110964 CVCL_IU90 IARC-518 cancer cell line human CVCL_IU90 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 Unspecified 21110965 CVCL_S041 Hs 769.Vg finite cell line human CVCL_S041 CL:0000010 Derived from sampling site: Vagina. Discontinued: ATCC; CRL-7499; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110966 CVCL_S040 Hs 769.Ut finite cell line human CVCL_S040 CL:0000010 Derived from sampling site: Uterus. Discontinued: ATCC; CRL-7498; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110967 CVCL_S043 Hs 773.T cancer cell line human CVCL_S043 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7501; true Female Doubling time: 8-10 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110968 CVCL_S042 Hs 772.Vd finite cell line human CVCL_S042 CL:0000010 Derived from sampling site: Vas deferens Cell type=Fibroblast.. Discontinued: ATCC; CRL-7500; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110969 CVCL_S023 COLO 205 SimpleCell O-GalNAc cancer cell line human CVCL_S023 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110970 CVCL_S022 Capan-1 SimpleCell O-GalNAc cancer cell line human CVCL_S022 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 4039; FZD10; Simple; p.Asn54Lys (c.162C>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 23671; GLT6D1; Simple; p.Trp198Ter (c.593G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4593; GRM1; Simple; p.Tyr486Ter (c.1458C>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Glu221Ter (c.661G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser343Ter (c.1028C>G); ClinVar=VCV000822036; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 25082; SMAP2; Simple; p.Ser255Ter (c.764C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Liver. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110971 CVCL_S025 HEK293 SimpleCell O-GalNAc transformed cell line human CVCL_S025 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110972 CVCL_S024 HaCaT SimpleCell O-GalNAc spontaneously immortalized cell line human CVCL_S024 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110973 CVCL_S027 Hep-G2 SimpleCell O-GalNAc cancer cell line human CVCL_S027 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110974 CVCL_S026 HeLa SimpleCell O-GalNAc cancer cell line human CVCL_S026 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21110975 CVCL_S029 K-562 SimpleCell O-GalNAc cancer cell line human CVCL_S029 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110976 CVCL_S028 IMR-32 SimpleCell O-GalNAc cancer cell line human CVCL_S028 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1 Population: Caucasian; Derived from metastatic site: Abdomen. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110977 CVCL_S030 MCF-7 SimpleCell O-GalNAc cancer cell line human CVCL_S030 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21110978 CVCL_S032 MDA-MB-231 SimpleCell O-GalNAC/O-Man cancer cell line human CVCL_S032 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Knockout cell: Method=ZFN; HGNC; 19139; POMGNT1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Cell engineered to produce only truncated GalNAc, NeuAc-alpha-2-6-GalNAc and Man O-glycans Group: Triple negative breast cancer (TNBC) cell line 21110979 CVCL_S031 MDA-MB-231 SimpleCell O-GalNAc cancer cell line human CVCL_S031 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans Group: Triple negative breast cancer (TNBC) cell line 21110980 CVCL_S012 Hs 897.T cancer cell line human CVCL_S012 CL:0000010 Discontinued: ATCC; CRL-7639; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110981 CVCL_S011 Hs 897.Sk finite cell line human CVCL_S011 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7638; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110982 CVCL_S014 Hs 906(C).Sk finite cell line human CVCL_S014 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7655; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110983 CVCL_S013 Hs 902.T cancer cell line human CVCL_S013 CL:0000010 Discontinued: ATCC; CRL-7647; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110984 CVCL_S016 Hs 913(G).Sk finite cell line human CVCL_S016 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7662; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110985 CVCL_S015 Hs 906(D).Mu finite cell line human CVCL_S015 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7656; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110986 CVCL_S018 Hs 923.Sk finite cell line human CVCL_S018 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7673; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110987 CVCL_S017 Hs 918.Sk finite cell line human CVCL_S017 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7670; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110988 CVCL_S019 Hs 924.LiT cancer cell line human CVCL_S019 CL:0000010 Population: Pacific; Micronesian; Derived from metastatic site: Liver. Discontinued: ATCC; CRL-7675; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21110989 CVCL_J679 CLT 218 hybridoma house mouse CVCL_J679 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8249 21110990 CVCL_IU79 FA44 cancer cell line human CVCL_IU79 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: ~22 hours (PubMed=25653542) 21110991 CVCL_J678 CLT 174 hybridoma house mouse CVCL_J678 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8242 21110992 CVCL_IU78 FA34 cancer cell line human CVCL_IU78 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: ~34 hours (PubMed=25653542) 21110993 CVCL_J675 CLH 70 hybridoma house mouse CVCL_J675 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8245 21110994 CVCL_IU75 TJ-GBC2 cancer cell line human CVCL_IU75 CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Male 21110995 CVCL_J674 CLH 68 hybridoma house mouse CVCL_J674 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8243 21110996 CVCL_IU74 GBC-SD/M cancer cell line human CVCL_IU74 CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Male 21110997 CVCL_J677 CLT 152 hybridoma house mouse CVCL_J677 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8244 21110998 CVCL_IU77 Nd embryonic stem cell house mouse CVCL_IU77 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Provides an accurate and measurable read-out for the dynamic levels of Nanog expression; Characteristics: Contains a transgenic bacterial artificial chromosome (BAC) centered around the Nanog gene but where the Nanog coding sequence was replaced with VNP, a short-lived fluorescent reporter consisting of a Venus yellow fluorescent protein fused to a nuclear localization signal (NLS) and to a degradation signal (PEST) VNP expression is under the control of the Nanog regulatory regions. 21110999 CVCL_J676 CLT 15 hybridoma house mouse CVCL_J676 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8250 21111000 CVCL_IU76 PTHrP-GBK cancer cell line human CVCL_IU76 CL:0000010 Population: Japanese; Derived from sampling site: Gallbladder. Female Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP) 21111001 CVCL_J671 40.10.09 hybridoma house mouse CVCL_J671 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P13051; Human UNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9311 21111002 CVCL_IU71 IRB-1 cancer cell line human CVCL_IU71 CL:0000010 Population: Iranian Male Doubling time: 36 +- 4.6 hours (DOI=10.7287/peerj.preprints.2780v1). 21111003 CVCL_J670 37.04.12 hybridoma house mouse CVCL_J670 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13051; Human UNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9312 21111004 CVCL_IU70 ST88-3 cancer cell line human CVCL_IU70 CL:0000010 Female 21111005 CVCL_J673 CLH 6 hybridoma house mouse CVCL_J673 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8232 21111006 CVCL_IU73 EH-GB1 cancer cell line human CVCL_IU73 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Female Doubling time: 24 hours (PubMed=20403235) 21111007 CVCL_J672 42.08.07 hybridoma house mouse CVCL_J672 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13051; Human UNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9313 21111008 CVCL_IU72 Panc-4 cancer cell line human CVCL_IU72 CL:0000010 Derived from metastatic site: Lymph node. Male 21111009 CVCL_S021 Hs 928.T undefined cell line type human CVCL_S021 CL:0000010 Discontinued: ATCC; CRL-7680; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21111010 CVCL_S020 Hs 927.T cancer cell line human CVCL_S020 CL:0000010 Discontinued: ATCC; CRL-7679; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21111011 CVCL_S001 MAC 16 cancer cell line house mouse CVCL_S001 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: NMRI. 21111012 CVCL_S000 MAC 13 cancer cell line house mouse CVCL_S000 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: NMRI. 21111013 CVCL_S003 E2 cancer cell line house mouse CVCL_S003 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21111014 CVCL_S002 MAC 26 cancer cell line house mouse CVCL_S002 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: NMRI. 21111015 CVCL_S005 cE1 cancer cell line house mouse CVCL_S005 CL:0000010 Male 21111016 CVCL_S004 E4 cancer cell line house mouse CVCL_S004 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21111017 CVCL_S007 A9 [Mouse Lewis lung carcinoma] cancer cell line house mouse CVCL_S007 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Low metastatic potential 21111018 CVCL_S006 cE2 cancer cell line house mouse CVCL_S006 CL:0000010 Male 21111019 CVCL_S009 GEC spontaneously immortalized cell line CVCL_S009 CL:0000010 Omics: Proteome analysis. Unspecified Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) Group: Fish cell line 21111020 CVCL_S008 SF [Lates] spontaneously immortalized cell line CVCL_S008 CL:0000010 Unspecified Group: Fish cell line. 21111021 CVCL_J689 HT 29/15 hybridoma house mouse CVCL_J689 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8246 21111022 CVCL_IU89 Z-181 cancer cell line human CVCL_IU89 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8600166; PubMed=10071072) Population: Mexican-American; Derived from sampling site: Bone marrow. Male Doubling time: 30-40 hours (PubMed=8600166); ~24-36 hours (ATCC=CRL-3395) 21111023 CVCL_J686 hIL-15-M110 hybridoma house mouse CVCL_J686 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40933; Human IL15. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12061 21111024 CVCL_IU86 PSU-SK-1 finite cell line human CVCL_IU86 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Unspecified (PubMed=27698927); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg433Ter (c.1297C>T) (R413*) (R430*); Zygosity=Unspecified (PubMed=27698927). Male Senescence: Senesces at 35 PDL (PubMed=27698927); Doubling time: 24 hours (at 7th passage), 72 hours (at 30th passage) (PubMed=27698927) 21111025 CVCL_J685 HGH-B hybridoma house mouse CVCL_J685 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10241; Human GH1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10596 21111026 CVCL_IU85 Pre-Alp cancer cell line human CVCL_IU85 CL:0000010 Derived from sampling site: Bone marrow. Female Doubling time: ~24 hours (PubMed=8464241) 21111027 CVCL_J688 hIL-15-M112 hybridoma house mouse CVCL_J688 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40933; Human IL15. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12063 21111028 CVCL_IU88 Z-119 cancer cell line human CVCL_IU88 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8600166; PubMed=10071072) Population: Latino; Derived from sampling site: Bone marrow. Female Doubling time: 20-30 hours (PubMed=8600166); ~24-36 hours (ATCC=CRL-3394) 21111029 CVCL_J687 hIL-15-M111 hybridoma house mouse CVCL_J687 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P40933; Human IL15. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12062 21111030 CVCL_IU87 RD/18 cancer cell line human CVCL_IU87 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female 21111031 CVCL_J682 CLT 85 hybridoma house mouse CVCL_J682 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8240 21111032 CVCL_IU82 PME1 cancer cell line human CVCL_IU82 CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: ~22 hours (PubMed=25653542) 21111033 CVCL_J681 CLT 479 hybridoma house mouse CVCL_J681 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8241 21111034 CVCL_IU81 FA98 cancer cell line human CVCL_IU81 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: ~22 hours (PubMed=25653542) 21111035 CVCL_J684 HD2-4 hybridoma house mouse CVCL_J684 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02741; Human CRP. 21111036 CVCL_IU84 IARC-318 cancer cell line human CVCL_IU84 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 Unspecified 21111037 CVCL_IU83 CHDC cancer cell line CVCL_IU83 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle; Breed/subspecies: American Pekin. Doubling time: ~19 hours (PubMed=563848) Group: Bird cell line 21111038 CVCL_J683 CLT 86 hybridoma house mouse CVCL_J683 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8252 21111039 CVCL_J680 CLT 307 hybridoma house mouse CVCL_J680 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8251 21111040 CVCL_IU80 FA49 cancer cell line human CVCL_IU80 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: ~22 hours (PubMed=25653542) 21111041 CVCL_S010 PSP [Puntius] spontaneously immortalized cell line CVCL_S010 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Characteristics: Optimal growth at 30 Celsius; Virology: Susceptible to infection by snakehead retrovirus (SnRV) released from SSN-1 cell line (Cellosaurus=CVCL_4306) Group: Fish cell line 21111042 CVCL_IU57 GG618-13 cancer cell line human CVCL_IU57 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21111043 CVCL_J657 GM02548 finite cell line human CVCL_J657 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Heterozygous (PubMed=17407155; Coriell); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln752Ter (c.2328C>T); Zygosity=Heterozygous (PubMed=17407155; Coriell) Population: African American; Donor information: From Bloom Syndrome Registry patient 71(HaEn) (BSR71); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21111044 CVCL_IU56 FF452-3 cancer cell line human CVCL_IU56 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21111045 CVCL_J656 GM03403 transformed cell line human CVCL_J656 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 9(EmSh) (BSR9); Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=1900268) Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21111046 CVCL_J659 2-179-E11 hybridoma house mouse CVCL_J659 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01375; Human TNF. 21111047 CVCL_IU59 PTLD1 transformed cell line human CVCL_IU59 From: Rooney C.M.; Center for Cell and Gene Therapy, Baylor College of Medicine; Houston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21111048 CVCL_J658 GM03510 finite cell line human CVCL_J658 CL:0000010 Donor information: From Bloom Syndrome Registry patient 47(ArSmi) (BSR47); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03510; probable Male 21111049 CVCL_IU58 Kamoti cancer cell line human CVCL_IU58 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21111050 CVCL_IU53 BL-99 cancer cell line human CVCL_IU53 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=2052620) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21111051 CVCL_J653 CO cancer cell line human CVCL_J653 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00186 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12581897; PubMed=12592342; PubMed=20143388). Originally thought to originate from the lymph node biopsy of a patient with Hodgkin lymphoma. 21111052 CVCL_IU52 BL-84 cancer cell line human CVCL_IU52 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Male Virology: EBV-negative. 21111053 CVCL_J652 HBT-39b cancer cell line human CVCL_J652 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00053 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=884688; PubMed=1246601; PubMed=4469665; PubMed=6451928; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21111054 CVCL_J655 GM03402 finite cell line human CVCL_J655 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 9(EmSh) (BSR9); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21111055 CVCL_IU55 NAB9B cancer cell line human CVCL_IU55 CL:0000010 21111056 CVCL_IU54 CW678 cancer cell line human CVCL_IU54 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=2052620) Male Virology: EBV-negative 21111057 CVCL_J654 SV7 transformed cell line human CVCL_J654 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Discontinued: ATCC; CRL-2428; true Female 21111058 CVCL_IU51 BL-104 cancer cell line human CVCL_IU51 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Female Virology: EBV-negative. 21111059 CVCL_J651 DD cancer cell line human CVCL_J651 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00187 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a patient with malignant histiocytosis in the leukemic stage. 21111060 CVCL_IU50 DK1631 cancer cell line human CVCL_IU50 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=8344493). 21111061 CVCL_J650 Rx-GFP K/I EB5 embryonic stem cell house mouse CVCL_J650 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: 129P2/Ola. Male 21111062 CVCL_J668 359-238-8 hybridoma house mouse CVCL_J668 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01374; Human LTA. 21111063 CVCL_IU68 HCT-116RD cancer cell line human CVCL_IU68 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9177; Sodium deoxycholate (NaDOC); Derived from sampling site: Colon. Male 21111064 CVCL_J667 357-167-24 hybridoma house mouse CVCL_J667 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01375; Human TNF. 21111065 CVCL_IU67 HCT-116RC cancer cell line human CVCL_IU67 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9177; Sodium deoxycholate (NaDOC); Derived from sampling site: Colon. Male 21111066 CVCL_J669 359-81-11 hybridoma house mouse CVCL_J669 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01374; Human LTA. 21111067 CVCL_IU69 Faraz-ICR cancer cell line human CVCL_IU69 CL:0000010 Population: Iranian; Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.. Omics: Array-based CGH Female Doubling time: 35 hours (PubMed=28215484) 21111068 CVCL_J664 351D2/D7 hybridoma house mouse CVCL_J664 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18103; Escherichia coli K99 fanC. 21111069 CVCL_IU64 KNBCCS6 finite cell line human CVCL_IU64 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Pro643Thrfs*11 (c.1925insC) (H652X); Zygosity=Heterozygous (PubMed=18679421) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21111070 CVCL_J663 34 hybridoma house mouse CVCL_J663 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Murine leukemia viruses (MuLV) p15. 21111071 CVCL_IU63 TR-LCC-1 cancer cell line human CVCL_IU63 CL:0000010 Population: Chinese; Derived from sampling site: Larynx. Male Doubling time: 201.2 hours (PubMed=28104015) 21111072 CVCL_J666 357-101-4 hybridoma house mouse CVCL_J666 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01375; Human TNF. 21111073 CVCL_IU66 HCT-116RB cancer cell line human CVCL_IU66 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9177; Sodium deoxycholate (NaDOC); Derived from sampling site: Colon. Male 21111074 CVCL_J665 356-1 hybridoma house mouse CVCL_J665 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Coxsackievirus B4. 21111075 CVCL_IU65 KNBCCS6 E6/E7 transformed cell line human CVCL_IU65 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Pro643Thrfs*11 (c.1925insC) (H652X); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [pLE6/E7SN](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Group: Patented cell line 21111076 CVCL_J660 32.2 hybridoma house mouse CVCL_J660 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P12314; Human FCGR1A/CD64. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9469 21111077 CVCL_IU60 SK-L1 cancer cell line human CVCL_IU60 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: 30 hours (PubMed=5229525) 21111078 CVCL_J662 339-1 hybridoma house mouse CVCL_J662 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Coxsackievirus B4. 21111079 CVCL_IU62 PWC-HS01 cancer cell line dog CVCL_IU62 CL:0000010 Derived from sampling site: Brain; frontal lobe; Breed/subspecies: Pembroke Welsh Corgi. Female Doubling time: 64.8 hours (PubMed=28178429) 21111080 CVCL_J661 32B11 hybridoma house mouse CVCL_J661 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q0H0L1; Rhizophagus irregularis heat shock protein 60 (Glomalin). 21111081 CVCL_IU61 FCR-HS02 cancer cell line dog CVCL_IU61 CL:0000010 Derived from sampling site: Shoulder joint; Breed/subspecies: Flat-coated Retriever. Male Doubling time: 56.5 hours (PubMed=28178429) 21111082 CVCL_8B08 GM17897 transformed cell line human CVCL_8B08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111083 CVCL_8B07 GM17896 transformed cell line human CVCL_8B07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111084 CVCL_8B09 GM17933 transformed cell line human CVCL_8B09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111085 CVCL_8B04 GM23164 transformed cell line human CVCL_8B04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111086 CVCL_8B03 GM23104 transformed cell line human CVCL_8B03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111087 CVCL_8B06 GM12966 finite cell line human CVCL_8B06 CL:0000010 Karyotypic information: 46,XY,del(11)(pter->q23.1::q24->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21111088 CVCL_8B05 GM23165 transformed cell line human CVCL_8B05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111089 CVCL_8B00 GM23056 transformed cell line human CVCL_8B00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111090 CVCL_8B02 GM23092 transformed cell line human CVCL_8B02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111091 CVCL_8B01 GM23091 transformed cell line human CVCL_8B01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111092 CVCL_8B19 DA03228 transformed cell line human CVCL_8B19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111093 CVCL_8B18 DA03227 transformed cell line human CVCL_8B18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111094 CVCL_8B15 ID00061 transformed cell line human CVCL_8B15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21111095 CVCL_8B14 ID00060 transformed cell line human CVCL_8B14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21111096 CVCL_8B17 ID00059 transformed cell line human CVCL_8B17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21111097 CVCL_8B16 ID00030 transformed cell line human CVCL_8B16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21111098 CVCL_8B11 GM03558 finite cell line human CVCL_8B11 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Arg65Ter (c.193C>T); ClinVar=VCV000558291; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21111099 CVCL_8B10 GM03557 finite cell line human CVCL_8B10 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.His86Tyr (c.256C>T); ClinVar=VCV000555658; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21111100 CVCL_8B13 MRC-5 PDL5.51 finite cell line human CVCL_8B13 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21111101 CVCL_8B12 GM11851 finite cell line human CVCL_8B12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111102 CVCL_RN89 AD576ABR transformed cell line human CVCL_RN89 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111103 CVCL_RN91 ATH8ABR transformed cell line human CVCL_RN91 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21111104 CVCL_RN90 ATH3ABR transformed cell line human CVCL_RN90 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21111105 CVCL_RN93 C5ABR transformed cell line human CVCL_RN93 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111106 CVCL_RN92 C4ABR transformed cell line human CVCL_RN92 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111107 CVCL_RN95 C7ABR transformed cell line human CVCL_RN95 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111108 CVCL_RN94 C6ABR transformed cell line human CVCL_RN94 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111109 CVCL_RN97 C10ABR transformed cell line human CVCL_RN97 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21111110 CVCL_RN96 C8ABR transformed cell line human CVCL_RN96 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111111 CVCL_RN99 C13ABR transformed cell line human CVCL_RN99 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111112 CVCL_RN98 C11ABR transformed cell line human CVCL_RN98 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111113 CVCL_RN79 AD506ABR transformed cell line human CVCL_RN79 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111114 CVCL_RN78 AD505ABR transformed cell line human CVCL_RN78 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111115 CVCL_RN80 AD507ABR transformed cell line human CVCL_RN80 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111116 CVCL_RN82 AD509ABR transformed cell line human CVCL_RN82 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111117 CVCL_RN81 AD508ABR transformed cell line human CVCL_RN81 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111118 CVCL_RN84 AD515ABR transformed cell line human CVCL_RN84 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111119 CVCL_RN83 AD512ABR transformed cell line human CVCL_RN83 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111120 CVCL_RN86 AD518ABR transformed cell line human CVCL_RN86 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111121 CVCL_RN85 AD517ABR transformed cell line human CVCL_RN85 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111122 CVCL_RN88 AD528ABR transformed cell line human CVCL_RN88 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111123 CVCL_RN87 AD523ABR transformed cell line human CVCL_RN87 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111124 CVCL_RN68 APP1E311 induced pluripotent stem cell human CVCL_RN68 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693del (c.2079_2081delAGA); Zygosity=Homozygous (PubMed=23434393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111125 CVCL_RN67 APP1E211 induced pluripotent stem cell human CVCL_RN67 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693del (c.2079_2081delAGA); Zygosity=Homozygous (PubMed=23434393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111126 CVCL_RN69 APP2E22 induced pluripotent stem cell human CVCL_RN69 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Leu (c.2149G>C); ClinVar=VCV000018105; Zygosity=Heterozygous (PubMed=23434393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111127 CVCL_RN71 AD3E211 induced pluripotent stem cell human CVCL_RN71 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111128 CVCL_RN70 APP2E26 induced pluripotent stem cell human CVCL_RN70 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Leu (c.2149G>C); ClinVar=VCV000018105; Zygosity=Heterozygous (PubMed=23434393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111129 CVCL_RN73 N116213 induced pluripotent stem cell human CVCL_RN73 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111130 CVCL_RN72 AD8K213 induced pluripotent stem cell human CVCL_RN72 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111131 CVCL_RN75 RSCC-1 cancer cell line CVCL_RN75 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: New Zealand white. Unspecified Doubling time: 22.89 hours (PubMed=18691699) 21111132 CVCL_RN74 N117322 induced pluripotent stem cell human CVCL_RN74 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111133 CVCL_RN77 AD502ABR transformed cell line human CVCL_RN77 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111134 CVCL_RN76 AD501ABR transformed cell line human CVCL_RN76 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111135 CVCL_RN57 WM266-1 cancer cell line human CVCL_RN57 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell lines WM165-1, WM239A and WM266-4); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from autologous cell lines WM165-1, WM239A and WM266-4) Population: Caucasian; Derived from metastatic site: Skin. Female Part of: Wistar Institute melanoma cell line collection 21111136 CVCL_RN56 WM239B cancer cell line human CVCL_RN56 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell lines WM165-1, WM239A and WM266-4); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from autologous cell lines WM165-1, WM239A and WM266-4) Population: Caucasian; Derived from metastatic site: Not specified. Female Part of: Wistar Institute melanoma cell line collection 21111137 CVCL_RN59 WM266-3 cancer cell line human CVCL_RN59 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell lines WM165-1, WM239A and WM266-4); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from autologous cell lines WM165-1, WM239A and WM266-4) Population: Caucasian; Derived from metastatic site: Skin. Female Part of: Wistar Institute melanoma cell line collection 21111138 CVCL_RN58 WM266-2 cancer cell line human CVCL_RN58 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell lines WM165-1, WM239A and WM266-4); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from autologous cell lines WM165-1, WM239A and WM266-4) Population: Caucasian; Derived from metastatic site: Skin. Female Part of: Wistar Institute melanoma cell line collection 21111139 CVCL_RN60 WK93 cancer cell line human CVCL_RN60 CL:0000010 Population: Japanese. Unspecified 21111140 CVCL_RN62 T24T FL4 cancer cell line human CVCL_RN62 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Forms metastasis in the lung of mice Produced by passage of the parent cell line through nude mice. 21111141 CVCL_RN61 BR29 embryonic stem cell CVCL_RN61 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); UniProtKB; F7HJT1; ACTB; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Group: Non-human primate cell line 21111142 CVCL_RN64 T24T SL2 cancer cell line human CVCL_RN64 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by passage of the parent cell line through nude mice 21111143 CVCL_RN63 T24T SL1 cancer cell line human CVCL_RN63 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by passage of the parent cell line through nude mice 21111144 CVCL_RN66 APP1E111 induced pluripotent stem cell human CVCL_RN66 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693del (c.2079_2081delAGA); Zygosity=Homozygous (PubMed=23434393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21111145 CVCL_RN65 T24T SL3 cancer cell line human CVCL_RN65 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by passage of the parent cell line through nude mice 21111146 CVCL_RN46 OH94 cancer cell line human CVCL_RN46 CL:0000010 Population: Japanese. Unspecified 21111147 CVCL_RN45 RSE/PILS35 spontaneously immortalized cell line CVCL_RN45 CL:0000010 Unspecified Group: Tick cell line. 21111148 CVCL_RN48 TK91 cancer cell line human CVCL_RN48 CL:0000010 Population: Japanese. Unspecified 21111149 CVCL_RN47 SN-Ow1 cancer cell line human CVCL_RN47 CL:0000010 Population: Japanese. Unspecified 21111150 CVCL_RN49 WH94 cancer cell line human CVCL_RN49 CL:0000010 Population: Japanese. Unspecified 21111151 CVCL_RN51 WM747 cancer cell line human CVCL_RN51 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21111152 CVCL_RN50 PER-450 cancer cell line human CVCL_RN50 CL:0000010 21111153 CVCL_RN53 WM811P cancer cell line human CVCL_RN53 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21111154 CVCL_RN52 WM811M cancer cell line human CVCL_RN52 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21111155 CVCL_RN55 WM165-2 cancer cell line human CVCL_RN55 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from autologous cell lines WM165-1, WM239A and WM266-4); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from autologous cell lines WM165-1, WM239A and WM266-4) Population: Caucasian; Derived from metastatic site: Lymph node. Female Part of: Wistar Institute melanoma cell line collection 21111156 CVCL_RN54 WM862 cancer cell line human CVCL_RN54 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21111157 CVCL_8B80 AI0249 transformed cell line human CVCL_8B80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111158 CVCL_8B82 AX0049 transformed cell line human CVCL_8B82 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(1)(pter->cen->q21::q24->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111159 CVCL_8B81 AM0249 transformed cell line human CVCL_8B81 CL:0000010 Population: Caucasian; Karyotypic information: 6,XX,-16,+der(16),t(9;16)(p;p13.3) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111160 CVCL_8B88 B0403741 transformed cell line human CVCL_8B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111161 CVCL_8B87 B0317047 transformed cell line human CVCL_8B87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,add(5)(p15) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111162 CVCL_8B89 BB0111 transformed cell line human CVCL_8B89 CL:0000010 Karyotypic information: 46,XX,r(14) (PubMed=16152642); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93090516; true Female Part of: ECACC chromosomal abnormality collection 21111163 CVCL_8B84 AX0051 transformed cell line human CVCL_8B84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111164 CVCL_8B83 AX0050 transformed cell line human CVCL_8B83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111165 CVCL_8B86 AY0001 transformed cell line human CVCL_8B86 CL:0000010 Karyotypic information: 46,XY,t(4;?)(p1.16;?) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111166 CVCL_8B85 AX0052 transformed cell line human CVCL_8B85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111167 CVCL_8B91 BD0419 transformed cell line human CVCL_8B91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92102013; true Male Part of: ECACC chromosomal abnormality collection 21111168 CVCL_8B90 BD0245 transformed cell line human CVCL_8B90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21111169 CVCL_8B93 BE0002 transformed cell line human CVCL_8B93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111170 CVCL_8B92 BD0437 transformed cell line human CVCL_8B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92111009; true Male Part of: ECACC chromosomal abnormality collection 21111171 CVCL_8B99 BH0015 transformed cell line human CVCL_8B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111172 CVCL_8B98 BH0013 transformed cell line human CVCL_8B98 CL:0000010 Karyotypic information: 46,XY,t(X;15)(p22.33;q25.2)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111173 CVCL_8B95 BH0008 transformed cell line human CVCL_8B95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111174 CVCL_8B94 BH0005 transformed cell line human CVCL_8B94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111175 CVCL_8B97 BH0012 transformed cell line human CVCL_8B97 CL:0000010 Karyotypic information: 46,Y,X-,+der(X)t(X;15)(p22.33;q25.2)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111176 CVCL_8B96 BH0009 transformed cell line human CVCL_8B96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111177 CVCL_8B69 AG0655 transformed cell line human CVCL_8B69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92050712; true Female Part of: ECACC chromosomal abnormality collection 21111178 CVCL_8B60 AG0438 transformed cell line human CVCL_8B60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91091602; true Female Part of: ECACC chromosomal abnormality collection 21111179 CVCL_8B66 AG0449 transformed cell line human CVCL_8B66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91100411; true Male Part of: ECACC chromosomal abnormality collection 21111180 CVCL_8B65 AG0448 transformed cell line human CVCL_8B65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91100410; true Male Part of: ECACC chromosomal abnormality collection 21111181 CVCL_8B68 AG0650 transformed cell line human CVCL_8B68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92032522; true Female Part of: ECACC chromosomal abnormality collection 21111182 CVCL_8B67 AG0479 transformed cell line human CVCL_8B67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91102207; true Male Part of: ECACC chromosomal abnormality collection 21111183 CVCL_8B62 AG0440 transformed cell line human CVCL_8B62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91092530; true Male Part of: ECACC chromosomal abnormality collection 21111184 CVCL_8B61 AG0439 transformed cell line human CVCL_8B61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91092529; true Female Part of: ECACC chromosomal abnormality collection 21111185 CVCL_8B64 AG0442 transformed cell line human CVCL_8B64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91092608; true Male Part of: ECACC chromosomal abnormality collection 21111186 CVCL_8B63 AG0441 transformed cell line human CVCL_8B63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91092607; true Male Part of: ECACC chromosomal abnormality collection 21111187 CVCL_8B71 AG0819 transformed cell line human CVCL_8B71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93112202; true Female Part of: ECACC chromosomal abnormality collection 21111188 CVCL_8B70 AG0781 transformed cell line human CVCL_8B70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93071608; true Female Part of: ECACC chromosomal abnormality collection 21111189 CVCL_8B77 AG0883 transformed cell line human CVCL_8B77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94101410; true Female Part of: ECACC chromosomal abnormality collection 21111190 CVCL_8B76 AG0882 transformed cell line human CVCL_8B76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94101409; true Female Part of: ECACC chromosomal abnormality collection 21111191 CVCL_8B79 AI0009 transformed cell line human CVCL_8B79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(6;11)(q14.2;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111192 CVCL_8B78 AG0920 transformed cell line human CVCL_8B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95030321; true Female Part of: ECACC chromosomal abnormality collection 21111193 CVCL_8B73 AG0862 transformed cell line human CVCL_8B73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94080540; true Male Part of: ECACC chromosomal abnormality collection 21111194 CVCL_8B72 AG0861 transformed cell line human CVCL_8B72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94080539; true Female Part of: ECACC chromosomal abnormality collection 21111195 CVCL_8B75 AG0881 transformed cell line human CVCL_8B75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94101408; true Female Part of: ECACC chromosomal abnormality collection 21111196 CVCL_8B74 AG0880 transformed cell line human CVCL_8B74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94101407; true Female Part of: ECACC chromosomal abnormality collection 21111197 CVCL_8B48 AG0138 transformed cell line human CVCL_8B48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90070301; true Male Part of: ECACC chromosomal abnormality collection 21111198 CVCL_8B47 AG0124 transformed cell line human CVCL_8B47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90052207; true Female Part of: ECACC chromosomal abnormality collection 21111199 CVCL_8B49 AG0143 transformed cell line human CVCL_8B49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90072402; true Male Part of: ECACC chromosomal abnormality collection 21111200 CVCL_8B44 AC0360 transformed cell line human CVCL_8B44 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(21;21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111201 CVCL_8B43 AC0350 transformed cell line human CVCL_8B43 CL:0000010 Karyotypic information: 46,XX,dup21(qter->p13::q22.1->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111202 CVCL_8B46 AC0452 transformed cell line human CVCL_8B46 CL:0000010 Population: Asian; Karyotypic information: 46,XX,t(11;22)(q23.3;q13.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111203 CVCL_8B45 AC0451 transformed cell line human CVCL_8B45 CL:0000010 Population: Asian and Caucasian; Karyotypic information: 46,XX,t(11;22)(q23.3;q13.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111204 CVCL_8B40 AC0094 transformed cell line human CVCL_8B40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111205 CVCL_8B42 AC0302 transformed cell line human CVCL_8B42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,?dup(21)(p22.1->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111206 CVCL_8B41 AC0291 transformed cell line human CVCL_8B41 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111207 CVCL_8B59 AG0425 transformed cell line human CVCL_8B59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91082128; true Male Part of: ECACC chromosomal abnormality collection 21111208 CVCL_8B58 AG0423 transformed cell line human CVCL_8B58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91081204; true Female Part of: ECACC chromosomal abnormality collection 21111209 CVCL_8B55 AG0206 transformed cell line human CVCL_8B55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91010404; true Male Part of: ECACC chromosomal abnormality collection 21111210 CVCL_8B54 AG0179 transformed cell line human CVCL_8B54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90101202; true Female Part of: ECACC chromosomal abnormality collection 21111211 CVCL_8B57 AG0422 transformed cell line human CVCL_8B57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91081203; true Female Part of: ECACC chromosomal abnormality collection 21111212 CVCL_8B56 AG0406 transformed cell line human CVCL_8B56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91072504; true Female Part of: ECACC chromosomal abnormality collection 21111213 CVCL_8B51 AG0151 transformed cell line human CVCL_8B51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90081517; true Female Part of: ECACC chromosomal abnormality collection 21111214 CVCL_8B50 AG0150 transformed cell line human CVCL_8B50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90081516; true Female Part of: ECACC chromosomal abnormality collection 21111215 CVCL_8B53 AG0158 transformed cell line human CVCL_8B53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90091901; true Male Part of: ECACC chromosomal abnormality collection 21111216 CVCL_8B52 AG0152 transformed cell line human CVCL_8B52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90082301; true Female Part of: ECACC chromosomal abnormality collection 21111217 CVCL_8B29 UV.CB6-4.1D cancer cell line house mouse CVCL_8B29 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21111218 CVCL_8B26 DA03236 transformed cell line human CVCL_8B26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111219 CVCL_8B25 DA03234 transformed cell line human CVCL_8B25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111220 CVCL_8B28 UV.CB6-3.4B cancer cell line house mouse CVCL_8B28 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21111221 CVCL_8B27 DA03237 transformed cell line human CVCL_8B27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111222 CVCL_8B22 DA03231 transformed cell line human CVCL_8B22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111223 CVCL_8B21 DA03230 transformed cell line human CVCL_8B21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111224 CVCL_8B24 DA03233 transformed cell line human CVCL_8B24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111225 CVCL_8B23 DA03232 transformed cell line human CVCL_8B23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111226 CVCL_8B20 DA03229 transformed cell line human CVCL_8B20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111227 CVCL_8B37 AC0002 transformed cell line human CVCL_8B37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111228 CVCL_8B36 AC0001 transformed cell line human CVCL_8B36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111229 CVCL_8B39 AC0006 transformed cell line human CVCL_8B39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21111230 CVCL_8B38 AC0004 transformed cell line human CVCL_8B38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21111231 CVCL_8B33 DT40-ITRP2(-/-)-ITPR3(-/-) cancer cell line CVCL_8B33 CL:0000010 Knockout cell: Method=Targeted integration; ITPR2+ITPR3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21111232 CVCL_8B32 DT40-ITRP1(-/-)-ITPR3(-/-) cancer cell line CVCL_8B32 CL:0000010 Knockout cell: Method=Targeted integration; ITPR1+ITPR3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21111233 CVCL_8B35 AB0001 transformed cell line human CVCL_8B35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21111234 CVCL_8B31 DT40-ITRP1(-/-)-ITPR2(-/-) cancer cell line CVCL_8B31 CL:0000010 Knockout cell: Method=Targeted integration; ITPR1+ITPR2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21111235 CVCL_8B30 UV.CB6-4.1F cancer cell line house mouse CVCL_8B30 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21111236 CVCL_7Z21 DA04636 transformed cell line human CVCL_7Z21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111237 CVCL_7Z20 DA04635 transformed cell line human CVCL_7Z20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111238 CVCL_7Z23 DA04638 transformed cell line human CVCL_7Z23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111239 CVCL_7Z22 DA04637 transformed cell line human CVCL_7Z22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111240 CVCL_7Z29 DA04644 transformed cell line human CVCL_7Z29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111241 CVCL_7Z28 DA04643 transformed cell line human CVCL_7Z28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111242 CVCL_7Z25 DA04640 transformed cell line human CVCL_7Z25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111243 CVCL_7Z24 DA04639 transformed cell line human CVCL_7Z24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111244 CVCL_7Z27 DA04642 transformed cell line human CVCL_7Z27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111245 CVCL_7Z26 DA04641 transformed cell line human CVCL_7Z26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111246 CVCL_7Z32 DA04647 transformed cell line human CVCL_7Z32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111247 CVCL_7Z31 DA04646 transformed cell line human CVCL_7Z31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111248 CVCL_7Z34 DA04649 transformed cell line human CVCL_7Z34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111249 CVCL_7Z33 DA04648 transformed cell line human CVCL_7Z33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111250 CVCL_7Z30 DA04645 transformed cell line human CVCL_7Z30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111251 CVCL_7Z39 DA04654 transformed cell line human CVCL_7Z39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111252 CVCL_7Z36 DA04651 transformed cell line human CVCL_7Z36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111253 CVCL_7Z35 DA04650 transformed cell line human CVCL_7Z35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111254 CVCL_7Z38 DA04653 transformed cell line human CVCL_7Z38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111255 CVCL_7Z37 DA04652 transformed cell line human CVCL_7Z37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111256 CVCL_7Z01 DA04615 transformed cell line human CVCL_7Z01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111257 CVCL_7Z00 DA04614 transformed cell line human CVCL_7Z00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111258 CVCL_7Z07 DA04622 transformed cell line human CVCL_7Z07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111259 CVCL_7Z06 DA04621 transformed cell line human CVCL_7Z06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111260 CVCL_7Z09 DA04624 transformed cell line human CVCL_7Z09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111261 CVCL_7Z08 DA04623 transformed cell line human CVCL_7Z08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111262 CVCL_7Z03 DA04617 transformed cell line human CVCL_7Z03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111263 CVCL_7Z02 DA04616 transformed cell line human CVCL_7Z02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111264 CVCL_7Z05 DA04620 transformed cell line human CVCL_7Z05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111265 CVCL_7Z04 DA04618 transformed cell line human CVCL_7Z04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111266 CVCL_7Z10 DA04625 transformed cell line human CVCL_7Z10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111267 CVCL_7Z12 DA04627 transformed cell line human CVCL_7Z12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111268 CVCL_7Z11 DA04626 transformed cell line human CVCL_7Z11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111269 CVCL_7Z18 DA04633 transformed cell line human CVCL_7Z18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111270 CVCL_7Z17 DA04632 transformed cell line human CVCL_7Z17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111271 CVCL_7Z19 DA04634 transformed cell line human CVCL_7Z19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111272 CVCL_7Z14 DA04629 transformed cell line human CVCL_7Z14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111273 CVCL_7Z13 DA04628 transformed cell line human CVCL_7Z13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111274 CVCL_7Z16 DA04631 transformed cell line human CVCL_7Z16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111275 CVCL_7Z15 DA04630 transformed cell line human CVCL_7Z15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111276 CVCL_RG90 WG0555 finite cell line human CVCL_RG90 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111277 CVCL_RG92 WG0329 finite cell line human CVCL_RG92 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111278 CVCL_RG91 WG0571 finite cell line human CVCL_RG91 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111279 CVCL_RG94 WG1761 finite cell line human CVCL_RG94 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 18871; MMAA; Simple; p.Arg145Ter (c.433C>T); ClinVar=VCV000003160; Zygosity=Homozygous (CelloPub=CLPUB00662) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111280 CVCL_RG93 WG1516 finite cell line human CVCL_RG93 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111281 CVCL_RG96 WG1796 finite cell line human CVCL_RG96 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111282 CVCL_RG95 WG1776 finite cell line human CVCL_RG95 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111283 CVCL_RG98 WG1518 finite cell line human CVCL_RG98 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111284 CVCL_RG97 WG1798 finite cell line human CVCL_RG97 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111285 CVCL_RG99 WG1943 finite cell line human CVCL_RG99 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111286 CVCL_RG81 TTD351BE finite cell line human CVCL_RG81 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg378His (c.1133G>A); Zygosity=Heterozygous (PubMed=18470933); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=18470933) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111287 CVCL_RG80 GM17542 finite cell line human CVCL_RG80 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ser51Phe (c.152C>T); Zygosity=Heterozygous (PubMed=18470933); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=18470933) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM17542; probable Male 21111288 CVCL_RG83 WG1320 finite cell line human CVCL_RG83 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111289 CVCL_RG82 TTD355BE finite cell line human CVCL_RG82 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Glu731Argfs*14 (c.2190delG) (730fs); Zygosity=Heterozygous; Note=Other allele is not expressed (PubMed=18470933) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111290 CVCL_RG85 WG0160 finite cell line human CVCL_RG85 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111291 CVCL_RG84 WG0132 finite cell line human CVCL_RG84 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111292 CVCL_RG87 WG0223 finite cell line human CVCL_RG87 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111293 CVCL_RG86 WG0167 finite cell line human CVCL_RG86 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111294 CVCL_RG89 WG0386 finite cell line human CVCL_RG89 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21111295 CVCL_RG88 WG0330 finite cell line human CVCL_RG88 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111296 CVCL_RG70 MCH053 finite cell line human CVCL_RG70 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. 21111297 CVCL_RG72 WG0102 finite cell line human CVCL_RG72 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111298 CVCL_RG71 MCH023 finite cell line human CVCL_RG71 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21111299 CVCL_RG74 WG1032 finite cell line human CVCL_RG74 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111300 CVCL_RG73 WG0119 finite cell line human CVCL_RG73 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111301 CVCL_RG76 WG2249 finite cell line human CVCL_RG76 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111302 CVCL_RG75 WG1033 finite cell line human CVCL_RG75 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111303 CVCL_RG78 WG0676 finite cell line human CVCL_RG78 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21111304 CVCL_RG77 WG0100 finite cell line human CVCL_RG77 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111305 CVCL_RG79 GM16877 finite cell line human CVCL_RG79 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=18470933); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Cys663Arg (c.1987T>C); dbSNP=rs770367713; Zygosity=Heterozygous (PubMed=18470933) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM16877; probable Male 21111306 CVCL_A546 NCI-H2596 cancer cell line human CVCL_A546 HLA typing: A*01:01,30:02; B*27:05,49:01; C*02:02,07:06; DQA1*01:02,01:02; DQB1*06:13,06:13; DRB1*13:02,15:01 (PubMed=26589293) CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21111307 CVCL_A545 NCI-H2595 cancer cell line human CVCL_A545 HLA typing: A*02:01,29:02; B*35:01,44:03; C*04:01,16:01 (PubMed=26589293); Genome ancestry: African=0.03%; Native American=0.21%; East Asian, North=0%; East Asian, South=0.22%; South Asian=2.69%; European, North=64.92%; European, South=31.93% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111308 CVCL_A548 NCI-H2600 cancer cell line human CVCL_A548 CL:0000010 Unspecified 21111309 CVCL_A547 NCI-H2597 cancer cell line human CVCL_A547 CL:0000010 Unspecified 21111310 CVCL_A549 NCI-H2618 cancer cell line human CVCL_A549 CL:0000010 Unspecified 21111311 CVCL_A540 NCI-H2540 cancer cell line human CVCL_A540 CL:0000010 Derived from metastatic site: Lymph node. Female 21111312 CVCL_A542 NCI-H2580 cancer cell line human CVCL_A542 CL:0000010 Unspecified 21111313 CVCL_A541 NCI-H2552 cancer cell line human CVCL_A541 CL:0000010 Male 21111314 CVCL_A544 NCI-H2594 cancer cell line human CVCL_A544 CL:0000010 Unspecified 21111315 CVCL_A543 NCI-H2591 cancer cell line human CVCL_A543 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.61%; South Asian=1.63%; European, North=68.64%; European, South=29.11% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111316 CVCL_A557 NCI-H360 cancer cell line human CVCL_A557 CL:0000010 Derived from metastatic site: Hypodermis. Male 21111317 CVCL_A556 NCI-H298 cancer cell line human CVCL_A556 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21111318 CVCL_A559 NCI-H372 cancer cell line human CVCL_A559 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111319 CVCL_A558 NCI-H369 cancer cell line human CVCL_A558 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111320 CVCL_A551 NCI-H2691 cancer cell line human CVCL_A551 CL:0000010 Omics: Array-based CGH. Unspecified 21111321 CVCL_A550 NCI-H2679 cancer cell line human CVCL_A550 CL:0000010 Female 21111322 CVCL_A553 NCI-H285 cancer cell line human CVCL_A553 CL:0000010 Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-5829; true Male 21111323 CVCL_A552 NCI-H2706 cancer cell line human CVCL_A552 CL:0000010 Unspecified 21111324 CVCL_A555 NCI-H290 cancer cell line human CVCL_A555 Genome ancestry: African=0.1%; Native American=0.64%; East Asian, North=0%; East Asian, South=0.75%; South Asian=2.62%; European, North=66.44%; European, South=29.45% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Discontinued: KCLB; 90290; probable Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21111325 CVCL_A554 NCI-H289 cancer cell line human CVCL_A554 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female 21111326 CVCL_A524 NCI-H2086 cancer cell line human CVCL_A524 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=1311061); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Ser (c.659A>C); ClinVar=VCV000012383; Zygosity=Unspecified (PubMed=1565469) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 68.5 hours (PubMed=29681454) 21111327 CVCL_A523 NCI-H2058 cancer cell line human CVCL_A523 CL:0000010 Male 21111328 CVCL_A526 NCI-H2145 cancer cell line human CVCL_A526 CL:0000010 Derived from sampling site: Lung. Female 21111329 CVCL_A525 NCI-H2127 cancer cell line human CVCL_A525 CL:0000010 Unspecified 21111330 CVCL_A528 NCI-H2258 cancer cell line human CVCL_A528 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21111331 CVCL_A527 NCI-H2250 cancer cell line human CVCL_A527 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (PubMed=1311061) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5936; true. Male Part of: MD Anderson Cell Lines Project 21111332 CVCL_A529 NCI-H2284 cancer cell line human CVCL_A529 CL:0000010 Derived from sampling site: Lung. Female 21111333 CVCL_7Z90 DA04710 transformed cell line human CVCL_7Z90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111334 CVCL_7Z92 DA04712 transformed cell line human CVCL_7Z92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111335 CVCL_7Z91 DA04711 transformed cell line human CVCL_7Z91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111336 CVCL_A520 NCI-H1977 cancer cell line human CVCL_A520 CL:0000010 Derived from sampling site: Pleural effusion. Male 21111337 CVCL_A522 NCI-H2028 cancer cell line human CVCL_A522 CL:0000010 Male 21111338 CVCL_A521 NCI-H2007 cancer cell line human CVCL_A521 CL:0000010 Male 21111339 CVCL_7Z87 DA04707 transformed cell line human CVCL_7Z87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111340 CVCL_7Z86 DA04706 transformed cell line human CVCL_7Z86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111341 CVCL_7Z89 DA04709 transformed cell line human CVCL_7Z89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111342 CVCL_7Z88 DA04708 transformed cell line human CVCL_7Z88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111343 CVCL_7Z83 DA04703 transformed cell line human CVCL_7Z83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111344 CVCL_7Z82 DA04702 transformed cell line human CVCL_7Z82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111345 CVCL_7Z85 DA04705 transformed cell line human CVCL_7Z85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111346 CVCL_7Z84 DA04704 transformed cell line human CVCL_7Z84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111347 CVCL_A535 NCI-H2409 cancer cell line human CVCL_A535 CL:0000010 Male 21111348 CVCL_A534 NCI-H2380 cancer cell line human CVCL_A534 CL:0000010 Discontinued: ATCC; CRL-5986; true. Female 21111349 CVCL_A537 NCI-H249 cancer cell line human CVCL_A537 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5827; true; Discontinued: KCLB; 90249; probable Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00334 Problematic cell line: Contaminated Shown to be a NCI-H69 derivative (PubMed=20143388). Originally thought to originate from the bone marrow of a male patient with small cell lung cancer. 21111350 CVCL_A536 NCI-H2461 cancer cell line human CVCL_A536 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0.92%; Native American=0.07%; East Asian, North=1.1%; East Asian, South=1.25%; South Asian=0%; European, North=63.28%; European, South=33.37% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111351 CVCL_A539 NCI-H2527 cancer cell line human CVCL_A539 CL:0000010 Male 21111352 CVCL_A538 NCI-H2509 cancer cell line human CVCL_A538 CL:0000010 Unspecified 21111353 CVCL_A531 NCI-H2365 cancer cell line human CVCL_A531 CL:0000010 Unspecified 21111354 CVCL_A530 NCI-H2332 cancer cell line human CVCL_A530 CL:0000010 Male 21111355 CVCL_A533 NCI-H2373 cancer cell line human CVCL_A533 HLA typing: A*02:01,30:01; B*41:01,55:01; C*03:03,17:01 (PubMed=26589293); Genome ancestry: African=0.63%; Native American=0%; East Asian, North=0%; East Asian, South=0.91%; South Asian=2.63%; European, North=66.33%; European, South=29.5% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=16630136) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5943; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111356 CVCL_A532 NCI-H2369 cancer cell line human CVCL_A532 HLA typing: A*24:02,68:01; B*08:01,37:01; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=0.75%; Native American=0%; East Asian, North=0.77%; East Asian, South=0.91%; South Asian=0%; European, North=67.35%; European, South=30.22% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111357 CVCL_7Z98 DA04718 transformed cell line human CVCL_7Z98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111358 CVCL_7Z97 DA04717 transformed cell line human CVCL_7Z97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111359 CVCL_7Z99 DA04719 transformed cell line human CVCL_7Z99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111360 CVCL_7Z94 DA04714 transformed cell line human CVCL_7Z94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111361 CVCL_7Z93 DA04713 transformed cell line human CVCL_7Z93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111362 CVCL_7Z96 DA04716 transformed cell line human CVCL_7Z96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111363 CVCL_7Z95 DA04715 transformed cell line human CVCL_7Z95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111364 CVCL_A502 NCI-H1608 cancer cell line human CVCL_A502 CL:0000010 Derived from sampling site: Lung. Female 21111365 CVCL_A501 NCI-H1592 cancer cell line human CVCL_A501 CL:0000010 Female 21111366 CVCL_A504 NCI-H1652 cancer cell line human CVCL_A504 CL:0000010 Male 21111367 CVCL_A503 NCI-H1628 cancer cell line human CVCL_A503 CL:0000010 Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-5980; true Male 21111368 CVCL_A506 NCI-H1710 cancer cell line human CVCL_A506 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (PubMed=1311061); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>T (IVS8+1G>T); ClinVar=VCV000495326; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=1311061). Male 21111369 CVCL_A505 NCI-H1670 cancer cell line human CVCL_A505 CL:0000010 Female 21111370 CVCL_A508 NCI-H1725 cancer cell line human CVCL_A508 CL:0000010 Derived from metastatic site: Lymph node. Female 21111371 CVCL_A507 NCI-H1717 cancer cell line human CVCL_A507 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-5890; true Male 21111372 CVCL_7Z70 DA04689 transformed cell line human CVCL_7Z70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111373 CVCL_A500 NCI-H1570 cancer cell line human CVCL_A500 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21111374 CVCL_7Z65 DA04684 transformed cell line human CVCL_7Z65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111375 CVCL_7Z64 DA04683 transformed cell line human CVCL_7Z64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111376 CVCL_7Z67 DA04686 transformed cell line human CVCL_7Z67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111377 CVCL_7Z66 DA04685 transformed cell line human CVCL_7Z66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111378 CVCL_7Z61 DA04679 transformed cell line human CVCL_7Z61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111379 CVCL_7Z60 DA04676 transformed cell line human CVCL_7Z60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111380 CVCL_7Z63 DA04682 transformed cell line human CVCL_7Z63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111381 CVCL_7Z62 DA04681 transformed cell line human CVCL_7Z62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111382 CVCL_7Z69 DA04688 transformed cell line human CVCL_7Z69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111383 CVCL_7Z68 DA04687 transformed cell line human CVCL_7Z68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111384 CVCL_A513 NCI-H1881 cancer cell line human CVCL_A513 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=1312696) Population: Caucasian; Derived from metastatic site: Bone marrow. Male 21111385 CVCL_A512 NCI-H1824 cancer cell line human CVCL_A512 CL:0000010 Male 21111386 CVCL_A515 NCI-H1934 cancer cell line human CVCL_A515 CL:0000010 Male 21111387 CVCL_A514 NCI-H1904 cancer cell line human CVCL_A514 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Ter (c.625A>T); Zygosity=Unspecified (PubMed=1311061). Male 21111388 CVCL_A517 NCI-H1968 cancer cell line human CVCL_A517 CL:0000010 Female 21111389 CVCL_A516 NCI-H1954 cancer cell line human CVCL_A516 CL:0000010 Female 21111390 CVCL_A519 NCI-H1974 cancer cell line human CVCL_A519 CL:0000010 Female 21111391 CVCL_A518 NCI-H1971 cancer cell line human CVCL_A518 CL:0000010 Male 21111392 CVCL_7Z81 DA04701 transformed cell line human CVCL_7Z81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111393 CVCL_7Z80 DA04700 transformed cell line human CVCL_7Z80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111394 CVCL_A511 NCI-H182 cancer cell line human CVCL_A511 CL:0000010 Derived from metastatic site: Lymph node. Female 21111395 CVCL_A510 NCI-H1788 cancer cell line human CVCL_A510 CL:0000010 Derived from metastatic site: Bone marrow. Discontinued: ATCC; CRL-5981; true Male 21111396 CVCL_7Z76 DA04696 transformed cell line human CVCL_7Z76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111397 CVCL_7Z75 DA04694 transformed cell line human CVCL_7Z75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111398 CVCL_7Z78 DA04698 transformed cell line human CVCL_7Z78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111399 CVCL_7Z77 DA04697 transformed cell line human CVCL_7Z77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111400 CVCL_7Z72 DA04691 transformed cell line human CVCL_7Z72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111401 CVCL_7Z71 DA04690 transformed cell line human CVCL_7Z71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111402 CVCL_7Z74 DA04693 transformed cell line human CVCL_7Z74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111403 CVCL_7Z73 DA04692 transformed cell line human CVCL_7Z73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111404 CVCL_A509 NCI-H1769 cancer cell line human CVCL_A509 CL:0000010 Derived from metastatic site: Lymph node. Male 21111405 CVCL_7Z79 DA04699 transformed cell line human CVCL_7Z79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111406 CVCL_7Z43 DA04658 transformed cell line human CVCL_7Z43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111407 CVCL_7Z42 DA04657 transformed cell line human CVCL_7Z42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111408 CVCL_7Z45 DA04660 transformed cell line human CVCL_7Z45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111409 CVCL_7Z44 DA04659 transformed cell line human CVCL_7Z44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111410 CVCL_7Z41 DA04656 transformed cell line human CVCL_7Z41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111411 CVCL_7Z40 DA04655 transformed cell line human CVCL_7Z40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111412 CVCL_7Z47 DA04663 transformed cell line human CVCL_7Z47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111413 CVCL_7Z46 DA04662 transformed cell line human CVCL_7Z46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111414 CVCL_7Z49 DA04665 transformed cell line human CVCL_7Z49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111415 CVCL_7Z48 DA04664 transformed cell line human CVCL_7Z48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111416 CVCL_7Z54 DA04670 transformed cell line human CVCL_7Z54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111417 CVCL_7Z53 DA04669 transformed cell line human CVCL_7Z53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111418 CVCL_7Z56 DA04672 transformed cell line human CVCL_7Z56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111419 CVCL_7Z55 DA04671 transformed cell line human CVCL_7Z55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111420 CVCL_7Z50 DA04666 transformed cell line human CVCL_7Z50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111421 CVCL_7Z52 DA04668 transformed cell line human CVCL_7Z52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111422 CVCL_7Z51 DA04667 transformed cell line human CVCL_7Z51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111423 CVCL_7Z58 DA04674 transformed cell line human CVCL_7Z58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111424 CVCL_7Z57 DA04673 transformed cell line human CVCL_7Z57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111425 CVCL_7Z59 DA04675 transformed cell line human CVCL_7Z59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21111426 CVCL_IM39 S180-S1E11 cancer cell line house mouse CVCL_IM39 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21111427 CVCL_IM38 S180-S2H7 cancer cell line house mouse CVCL_IM38 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21111428 CVCL_IM35 SFEC spontaneously immortalized cell line CVCL_IM35 CL:0000010 Unspecified Group: Fish cell line. 21111429 CVCL_IM34 RIRI-PaDe-3 spontaneously immortalized cell line CVCL_IM34 CL:0000010 Unspecified Doubling time: 81.48 hours (DOI=10.16380/j.kcxb.2015.08.002). Group: Insect cell line 21111430 CVCL_IM37 S180-S3F5 cancer cell line house mouse CVCL_IM37 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21111431 CVCL_IM36 Uyghur-UCSCCL cancer cell line human CVCL_IM36 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Population: Chinese/Asian ethnic group: Uyghur; Derived from sampling site: Uterus; cervix. Female Doubling time: 51.9 hours (PubMed=22800521) 21111432 CVCL_IM31 MDEC-07114 spontaneously immortalized cell line CVCL_IM31 CL:0000010 Unspecified Doubling time: 44 hours (CelloPub=CLPUB00364). Group: Insect cell line 21111433 CVCL_IM30 NCC-c-CX-1 cancer cell line human CVCL_IM30 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761). Female Characteristics: There are about 16 copies of MYC in this cell line; Virology: Contains 50-100 copies of the HPV18 genome Doubling time: 21.8 hours (PubMed=1721614) 21111434 CVCL_IM33 RIRI-PaDe-2 spontaneously immortalized cell line CVCL_IM33 CL:0000010 Unspecified Doubling time: 67.42 hours (DOI=10.16380/j.kcxb.2015.08.002). Group: Insect cell line 21111435 CVCL_IM32 RIRI-PaDe-1 spontaneously immortalized cell line CVCL_IM32 CL:0000010 Unspecified Doubling time: 69.77 hours (DOI=10.16380/j.kcxb.2015.08.002). Group: Insect cell line 21111436 CVCL_IM49 XP6MO finite cell line human CVCL_IM49 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111437 CVCL_IM46 EDS 105 finite cell line human CVCL_IM46 From: Departement Scienze Biomediche e Biotecnologie, Universita degli Studi di Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111438 CVCL_IM45 EDS 101 finite cell line human CVCL_IM45 From: Departement Scienze Biomediche e Biotecnologie, Universita degli Studi di Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111439 CVCL_IM48 XP5MO finite cell line human CVCL_IM48 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111440 CVCL_IM47 XP4MO finite cell line human CVCL_IM47 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111441 CVCL_IM42 RIRI-PaDe-4 spontaneously immortalized cell line CVCL_IM42 CL:0000010 Unspecified Doubling time: 65.43 hours (DOI=10.16380/j.kcxb.2015.08.002). Group: Insect cell line 21111442 CVCL_IM41 NEAU-Ms-927311 spontaneously immortalized cell line CVCL_IM41 CL:0000010 Unspecified Doubling time: 58.8 hours (DOI=10.1111/j.1744-7917.1998.tb00302.x). Group: Insect cell line 21111443 CVCL_IM44 EDS 100 finite cell line human CVCL_IM44 From: Departement Scienze Biomediche e Biotecnologie, Universita degli Studi di Brescia; Brescia; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111444 CVCL_IM43 AD94IL2 finite cell line human CVCL_IM43 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;17)(p11.2;p13.2)mat (CLDB). Female Characteristics: IL2 dependent 21111445 CVCL_IM40 NEAU-Ms-921015 spontaneously immortalized cell line CVCL_IM40 CL:0000010 Unspecified Group: Insect cell line. 21111446 CVCL_A483 NCI-H1059 cancer cell line human CVCL_A483 CL:0000010 Discontinued: ATCC; CRL-5854; true. Female 21111447 CVCL_A482 NCI-H1011 cancer cell line human CVCL_A482 CL:0000010 Derived from metastatic site: Chest. Male 21111448 CVCL_A485 NCI-H1112 cancer cell line human CVCL_A485 CL:0000010 Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq. Unspecified 21111449 CVCL_A484 NCI-H1061 cancer cell line human CVCL_A484 CL:0000010 Derived from metastatic site: Bone marrow. Female 21111450 CVCL_A487 NCI-H123 cancer cell line human CVCL_A487 CL:0000010 Derived from metastatic site: Lymph node. Male 21111451 CVCL_A486 NCI-H1185 cancer cell line human CVCL_A486 CL:0000010 Female 21111452 CVCL_A489 NCI-H1330 cancer cell line human CVCL_A489 CL:0000010 Male 21111453 CVCL_A488 NCI-H1315 cancer cell line human CVCL_A488 CL:0000010 Male 21111454 CVCL_IM17 ND22391 transformed cell line human CVCL_IM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111455 CVCL_IM16 ND22374 transformed cell line human CVCL_IM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111456 CVCL_IM19 ND22456 transformed cell line human CVCL_IM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111457 CVCL_IM18 ND22427 transformed cell line human CVCL_IM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111458 CVCL_IM13 ND22274 transformed cell line human CVCL_IM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111459 CVCL_IM12 ND20277 transformed cell line human CVCL_IM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND20277; probable Male 21111460 CVCL_A481 NCI-H1008 cancer cell line human CVCL_A481 CL:0000010 Male 21111461 CVCL_IM15 ND22318 transformed cell line human CVCL_IM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111462 CVCL_IM14 ND22292 transformed cell line human CVCL_IM14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111463 CVCL_A480 UoC-M1 cancer cell line human CVCL_A480 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: ~50-60 hours (DSMZ=ACC-775) 21111464 CVCL_IM11 ND16561 transformed cell line human CVCL_IM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND16561; probable Male 21111465 CVCL_IM10 ND14360 transformed cell line human CVCL_IM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111466 CVCL_A494 NCI-H1447 cancer cell line human CVCL_A494 CL:0000010 Derived from metastatic site: Lymph node. Male 21111467 CVCL_A493 NCI-H1440 cancer cell line human CVCL_A493 CL:0000010 Unspecified 21111468 CVCL_A496 NCI-H1466 cancer cell line human CVCL_A496 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Unspecified (PubMed=1311061) Derived from metastatic site: Pleural effusion. Male 21111469 CVCL_A495 NCI-H1451 cancer cell line human CVCL_A495 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111470 CVCL_A498 NCI-H1512 cancer cell line human CVCL_A498 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21111471 CVCL_A497 NCI-H1498 cancer cell line human CVCL_A497 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21111472 CVCL_A499 NCI-H1548 cancer cell line human CVCL_A499 CL:0000010 Male 21111473 CVCL_IM28 TMCC-1 cancer cell line human CVCL_IM28 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from metastatic site: Pleural effusion. Female Doubling time: 53 hours (CelloPub=CLPUB00397) 21111474 CVCL_IM27 C-1300/HHT cancer cell line house mouse CVCL_IM27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; Breed/subspecies: A/J. Male 21111475 CVCL_IM29 QG-K cancer cell line human CVCL_IM29 CL:0000010 Population: Japanese Female Doubling time: 53 hours (PubMed=6991350). 21111476 CVCL_A490 NCI-H1378 cancer cell line human CVCL_A490 CL:0000010 Derived from sampling site: Lung. Male 21111477 CVCL_IM24 SKM-1/HHT cancer cell line human CVCL_IM24 CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; c.4619-1G>A; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; Derived from sampling site: Peripheral blood. Male 21111478 CVCL_IM23 haNK cancer cell line human CVCL_IM23 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val); Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: No longer dependent on IL2 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21111479 CVCL_IM26 L1210 HHT cancer cell line house mouse CVCL_IM26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21111480 CVCL_A492 NCI-H1412 cancer cell line human CVCL_A492 CL:0000010 Male 21111481 CVCL_IM25 K562 HHT cancer cell line human CVCL_IM25 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:71019; Omacetaxine mepesuccinate (Homoharringtonine; Derived from sampling site: Pleural effusion. Female 21111482 CVCL_A491 NCI-H1387 cancer cell line human CVCL_A491 CL:0000010 Derived from sampling site: Liver. Male 21111483 CVCL_IM20 GM02584 transformed cell line human CVCL_IM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111484 CVCL_IM22 GM20486 finite cell line human CVCL_IM22 CL:0000010 Population: Chinese; Taiwan; Karyotypic information: Chimera 46,XX/46,XY; Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21111485 CVCL_IM21 GM17477 finite cell line human CVCL_IM21 CL:0000010 Sequence variation: Mutation; HGNC; 91; ACADSB; Simple; p.Met389Val (c.1165A>G); ClinVar=VCV000664690; Zygosity=Homozygous (Coriell) Population: Chinese/Asian ethnic group; Hmong; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111486 CVCL_A469 NCI-H1045 cancer cell line human CVCL_A469 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21111487 CVCL_A468 MZ-MEL-5 cancer cell line human CVCL_A468 HLA typing: A*32:01,26:01; B*07:02,57:02; C*07:02,06:02; DPB1*04:01,04:02; DQB1*06:02,05:01; DRB1*15:01,01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg15Lys (c.44G>A); ClinVar=VCV000404147; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.782+1G>C; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=23851445). Male 21111488 CVCL_A460 Rh2 cancer cell line human CVCL_A460 CL:0000010 21111489 CVCL_A463 EW-19 cancer cell line human CVCL_A463 CL:0000010 Unspecified 21111490 CVCL_A462 QG-H cancer cell line human CVCL_A462 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female 21111491 CVCL_A465 NCI-H726 cancer cell line human CVCL_A465 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21111492 CVCL_A464 NCI-H3118 cancer cell line human CVCL_A464 Genome ancestry: African=0.85%; Native American=0.01%; East Asian, North=2.51%; East Asian, South=0%; South Asian=3.02%; European, North=59.54%; European, South=34.08% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=12539049); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21111493 CVCL_A467 NCI-H1607 cancer cell line human CVCL_A467 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469; PubMed=20557307) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21111494 CVCL_A466 NCI-H1450 cancer cell line human CVCL_A466 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469; PubMed=20557307) Derived from metastatic site: Bone marrow. Male 21111495 CVCL_A479 SBC-4 cancer cell line human CVCL_A479 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Omics: SNP array analysis Male Doubling time: 52.6 hours (PubMed=8286010) 21111496 CVCL_A472 NCI-H1339 cancer cell line human CVCL_A472 Genome ancestry: African=70.93%; Native American=1.01%; East Asian, North=4.29%; East Asian, South=0%; South Asian=0%; European, North=11.76%; European, South=12.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=1312696; PubMed=1565469; PubMed=20557307) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5979; true; Discontinued: DepMap; ACH-000921; true; Discontinued: DSMZ; ACC-506; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00534 Problematic cell line: Partially contaminated Some cultures of NCI-H1339 are contaminated with NCI-H157 or NCI-1264 (PubMed=25877200). 21111497 CVCL_A471 NCI-H1086 cancer cell line human CVCL_A471 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21111498 CVCL_A474 PER-365 cancer cell line human CVCL_A474 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: 6.6 days (PubMed=7536459) 21111499 CVCL_A473 RERF-LC-MT cancer cell line human CVCL_A473 CL:0000010 Population: Japanese. Unspecified 21111500 CVCL_A476 NCI-H1726 cancer cell line human CVCL_A476 CL:0000010 21111501 CVCL_IM09 ND14516 transformed cell line human CVCL_IM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND14516; probable Male 21111502 CVCL_A475 PER-377 cancer cell line human CVCL_A475 CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: 3.6 days (PubMed=7536459); 66 hours (PubMed=17117183) 21111503 CVCL_A478 SK-MM-1 cancer cell line human CVCL_A478 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=11157491) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces Ig kappa Doubling time: 32 hours (PubMed=2506399); ~48 hours (DSMZ=ACC-758) Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 440 21111504 CVCL_A477 SKW-4 cancer cell line human CVCL_A477 CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Male Doubling time: 48 hours (PubMed=6329938); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21111505 CVCL_IM06 ND13698 transformed cell line human CVCL_IM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111506 CVCL_IM05 ND13605 transformed cell line human CVCL_IM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND13605; probable Male 21111507 CVCL_IM08 ND14145 transformed cell line human CVCL_IM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111508 CVCL_IM07 ND13751 transformed cell line human CVCL_IM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND13751; probable Female 21111509 CVCL_IM02 ND13206 transformed cell line human CVCL_IM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111510 CVCL_IM01 ND13105 transformed cell line human CVCL_IM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND13105; probable Male 21111511 CVCL_A470 NCI-H1062 cancer cell line human CVCL_A470 CL:0000010 Derived from metastatic site: Bone marrow. Female 21111512 CVCL_IM04 ND13600 transformed cell line human CVCL_IM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111513 CVCL_IM03 ND13587 transformed cell line human CVCL_IM03 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND13587; probable Male 21111514 CVCL_IM00 ND13092 transformed cell line human CVCL_IM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111515 CVCL_A447 KMST-6/TNF transformed cell line human CVCL_A447 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11892; TNF Population: Japanese; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female Doubling time: ~50 hours (DSMZ=ACC-824) 21111516 CVCL_A446 KMS-5 cancer cell line human CVCL_A446 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgD lambda Doubling time: 24 hours (PubMed=2519219) 21111517 CVCL_A449 SUP-T7 cancer cell line human CVCL_A449 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21111518 CVCL_A448 KRC/Y cancer cell line human CVCL_A448 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=8621251) Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 73 hours, at 15th passage (PubMed=3338971) 21111519 CVCL_A441 THP-5 cancer cell line human CVCL_A441 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 42 hours (PubMed=6232734) 21111520 CVCL_A440 Vi-856 cancer cell line human CVCL_A440 From: Majdic O.; Institute for Immunology; Vienna; Austria. CL:0000010 Female 21111521 CVCL_A443 TNB1 cancer cell line human CVCL_A443 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male 21111522 CVCL_A442 TMD8 cancer cell line human CVCL_A442 HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,01:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1699; CD79B; Simple; p.Tyr196His (c.586T>C); Zygosity=Heterozygous (PubMed=20054396); Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=21179087) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572) Doubling time: ~30 hours (PubMed=16780947) 21111523 CVCL_A445 KMS-21-PE cancer cell line human CVCL_A445 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21111524 CVCL_A444 TTC-466 cancer cell line human CVCL_A444 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG; Note=In frame (PubMed=8162068; PubMed=16631476); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (DepMap) Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21111525 CVCL_A458 SK-OV-8 cancer cell line human CVCL_A458 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Ascites. Female 21111526 CVCL_A457 SK-OV-6 cancer cell line human CVCL_A457 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Part of: OCCP ovarian cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00470 Problematic cell line: Contaminated Shown to be a C-33 A derivative (PubMed=22710073). 21111527 CVCL_A459 SJES-4 cancer cell line human CVCL_A459 CL:0000010 21111528 CVCL_A450 STA-NB-12 cancer cell line human CVCL_A450 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21111529 CVCL_A452 STA-NB-15 cancer cell line human CVCL_A452 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Male 21111530 CVCL_A451 STA-NB-13 cancer cell line human CVCL_A451 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Male 21111531 CVCL_A454 JIH-4 cancer cell line human CVCL_A454 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG; Note=In frame (PubMed=21536242) Population: Chinese; Derived from sampling site: Bone marrow. Male Doubling time: ~84.4 hours (PubMed=21536242) 21111532 CVCL_A453 TOV-81D cancer cell line human CVCL_A453 CL:0000010 Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female Doubling time: 4-6 days (PubMed=10949993) 21111533 CVCL_A456 LIM2463B cancer cell line human CVCL_A456 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=19378335); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous (PubMed=19378335) Derived from sampling site: Rectum. Female Microsatellite instability: Stable (MSS) (PubMed=19378335) 21111534 CVCL_A455 TSU-1621MT cancer cell line human CVCL_A455 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG (PubMed=10354136). Population: Japanese Female Characteristics: CSF3 dependent 21111535 CVCL_RG61 EMK spontaneously immortalized cell line CVCL_RG61 CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Highly susceptible to infection by Singapore grouper iridovirus (SGIV) or nervous necrosis virus (NNV) Group: Fish cell line 21111536 CVCL_RG60 M4-1 transformed cell line Norway rat CVCL_RG60 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: Fischer 344. Male Doubling time: >72 hours (INSERM) 21111537 CVCL_RG63 iPS46 induced pluripotent stem cell human CVCL_RG63 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Unspecified 21111538 CVCL_RG62 iPS30 induced pluripotent stem cell human CVCL_RG62 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Male 21111539 CVCL_RG65 iPS65 induced pluripotent stem cell human CVCL_RG65 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Male 21111540 CVCL_RG64 iPS59 induced pluripotent stem cell human CVCL_RG64 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Unspecified 21111541 CVCL_RG67 iPS72 induced pluripotent stem cell human CVCL_RG67 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Unspecified 21111542 CVCL_RG66 iPS68 induced pluripotent stem cell human CVCL_RG66 CL:0000010 Derived from sampling site: Heart; right atrium Cell type=Cardiac muscle myoblast.. Unspecified 21111543 CVCL_RG69 MCH052 finite cell line human CVCL_RG69 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111544 CVCL_RG68 JSP cancer cell line dog CVCL_RG68 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Male 21111545 CVCL_RG50 M2-1 [Rat] transformed cell line Norway rat CVCL_RG50 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: Fischer 344. Male Doubling time: >72 hours (INSERM) 21111546 CVCL_RG52 iPSC A1 induced pluripotent stem cell human CVCL_RG52 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111547 CVCL_RG51 M3-1 [Rat] transformed cell line Norway rat CVCL_RG51 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: Fischer 344. Male Doubling time: 48-72 hours (INSERM) 21111548 CVCL_RG54 iPSC A2 induced pluripotent stem cell human CVCL_RG54 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111549 CVCL_RG53 iPSC A11 induced pluripotent stem cell human CVCL_RG53 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111550 CVCL_RG56 iPSC A9 induced pluripotent stem cell human CVCL_RG56 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111551 CVCL_RG55 iPSC A6 induced pluripotent stem cell human CVCL_RG55 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111552 CVCL_RG58 iPSC D1 induced pluripotent stem cell human CVCL_RG58 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21111553 CVCL_RG57 iPSC C1 induced pluripotent stem cell human CVCL_RG57 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111554 CVCL_RG59 iPSC D4 induced pluripotent stem cell human CVCL_RG59 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21111555 CVCL_RG41 WG3466 finite cell line human CVCL_RG41 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111556 CVCL_RG40 WG3465 finite cell line human CVCL_RG40 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111557 CVCL_RG43 J26-B7 spontaneously immortalized cell line house mouse CVCL_RG43 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele B*07); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21111558 CVCL_RG42 J26-A3 spontaneously immortalized cell line house mouse CVCL_RG42 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*03); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21111559 CVCL_IM97 BMPR2 LCL 176 transformed cell line human CVCL_IM97 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21111560 CVCL_RG45 EOT-3 spontaneously immortalized cell line CVCL_RG45 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Ovary. Female 21111561 CVCL_IM96 BMPR2 LCL 172 transformed cell line human CVCL_IM96 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21111562 CVCL_RG44 MS-5-Omi/HTRA2-mCherry stromal cell line house mouse CVCL_RG44 CL:0000010 Transfected with: HGNC; 14348; HTRA2; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. Male Characteristics: The HTRA2-mCherry fusion protein is expressed in mitochondria inter-membrane space and is rapidly degraded following mitochondrial outer membrane permeabilization (MOMP) 21111563 CVCL_IM99 BMPR2 LCL 186 transformed cell line human CVCL_IM99 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21111564 CVCL_RG47 GMA32 transformed cell line CVCL_RG47 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Female Characteristics: Deoxycytidine kinase (dCK)-deficient 21111565 CVCL_IM98 BMPR2 LCL 180 transformed cell line human CVCL_IM98 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21111566 CVCL_RG46 GM7S transformed cell line CVCL_RG46 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21111567 CVCL_RG49 F1-0 transformed cell line Norway rat CVCL_RG49 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: Fischer 344. Female Doubling time: 24-48 hours (INSERM) 21111568 CVCL_IM93 HEK-Blue mTLR9 transformed cell line human CVCL_IM93 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1932389; Tlr9; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111569 CVCL_IM92 HEK-Blue mTLR8 transformed cell line human CVCL_IM92 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:2176887; Tlr8; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111570 CVCL_RG48 M3-1 [Hamster] spontaneously immortalized cell line CVCL_RG48 CL:0000010 Derived from sampling site: Bone marrow. Male 21111571 CVCL_IM95 HEK-Blue hMD2-CD14 transformed cell line human CVCL_IM95 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 17156; LY96; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL-12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111572 CVCL_IM94 HEK-Blue mTLR13 transformed cell line human CVCL_IM94 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:3045213; Tlr13; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111573 CVCL_RG30 WG2193 finite cell line human CVCL_RG30 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111574 CVCL_RG32 WG2195 finite cell line human CVCL_RG32 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111575 CVCL_RG31 WG2194 finite cell line human CVCL_RG31 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111576 CVCL_RG34 WG2275 finite cell line human CVCL_RG34 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111577 CVCL_RG33 WG2274 finite cell line human CVCL_RG33 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21111578 CVCL_RG36 WG2413 finite cell line human CVCL_RG36 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21111579 CVCL_RG35 WG2276 finite cell line human CVCL_RG35 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111580 CVCL_RG38 WG2415 finite cell line human CVCL_RG38 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111581 CVCL_RG37 WG2414 finite cell line human CVCL_RG37 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111582 CVCL_RG39 WG3189 finite cell line human CVCL_RG39 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111583 CVCL_RG19 WG1976 finite cell line human CVCL_RG19 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111584 CVCL_IM80 HEK-Blue hTLR2 transformed cell line human CVCL_IM80 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11848; TLR2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111585 CVCL_IM79 HEK-TLR2 transformed cell line human CVCL_IM79 CL:0000010 Transfected with: HGNC; 11848; TLR2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21111586 CVCL_IM78 SVGR2 transformed cell line human CVCL_IM78 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Omics: Transcriptome analysis by microarray Male Virology: Not susceptible to infection by human polyomavirus JCV 21111587 CVCL_RG21 WG1978 finite cell line human CVCL_RG21 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111588 CVCL_RG20 WG1977 finite cell line human CVCL_RG20 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111589 CVCL_IM75 SK-MEL-28DDR1-PLXAZD cancer cell line human CVCL_IM75 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Male 21111590 CVCL_RG23 WG1984 finite cell line human CVCL_RG23 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111591 CVCL_IM74 M238R1-PLX cancer cell line human CVCL_IM74 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21111592 CVCL_RG22 WG1983 finite cell line human CVCL_RG22 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111593 CVCL_IM77 TR9-7 cancer cell line human CVCL_IM77 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Transcriptome analysis by microarray. Female Characteristics: Expresses wild-type TP53 under the control of a tetracycline-regulated promoter 21111594 CVCL_RG25 WG2065 finite cell line human CVCL_RG25 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111595 CVCL_IM76 SK-MEL-28R1-PLX cancer cell line human CVCL_IM76 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Male 21111596 CVCL_RG24 WG2064 finite cell line human CVCL_RG24 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21111597 CVCL_IM71 S19L cancer cell line human CVCL_IM71 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Unspecified (PubMed=22080063) Omics: Transcriptome analysis by microarray. Female 21111598 CVCL_RG27 WG2120 finite cell line human CVCL_RG27 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111599 CVCL_IM70 PomD-iPSC B03 induced pluripotent stem cell human CVCL_IM70 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Glu (c.1935C>A); ClinVar=VCV000004029; Zygosity=Heterozygous (PubMed=21926084); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.2040+1G>T; ClinVar=VCV000370998; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=21926084) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21111600 CVCL_RG26 WG2066 finite cell line human CVCL_RG26 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111601 CVCL_IM73 M229R5-PLX cancer cell line human CVCL_IM73 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21111602 CVCL_RG29 WG2122 finite cell line human CVCL_RG29 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21111603 CVCL_IM72 M229DDRpoly-PLXAZD cancer cell line human CVCL_IM72 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21111604 CVCL_RG28 WG2121 finite cell line human CVCL_RG28 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111605 CVCL_RG09 WG1309 finite cell line human CVCL_RG09 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111606 CVCL_RG08 WG1658 finite cell line human CVCL_RG08 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111607 CVCL_IM91 HEK-Blue mTLR7 transformed cell line human CVCL_IM91 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:2176882; Tlr7; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111608 CVCL_IM90 HEK-Blue mTLR5 transformed cell line human CVCL_IM90 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1858171; Tlr5; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111609 CVCL_IM89 HEK-Blue mTLR4 transformed cell line human CVCL_IM89 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:88318; Cd14; Transfected with: MGI; MGI:1341909; Ly96; Transfected with: MGI; MGI:96824; Tlr4; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111610 CVCL_RG10 WG1310 finite cell line human CVCL_RG10 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111611 CVCL_IM86 HEK-Blue hTLR9 transformed cell line human CVCL_IM86 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111612 CVCL_RG12 WG1513 finite cell line human CVCL_RG12 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111613 CVCL_IM85 HEK-Blue hTLR8 transformed cell line human CVCL_IM85 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 15632; TLR8; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111614 CVCL_RG11 WG1311 finite cell line human CVCL_RG11 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111615 CVCL_IM88 HEK-Blue mTLR3 transformed cell line human CVCL_IM88 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:2156367; Tlr3; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111616 CVCL_RG14 WG1635 finite cell line human CVCL_RG14 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21111617 CVCL_IM87 HEK-Blue mTLR2 transformed cell line human CVCL_IM87 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:88318; Cd14; Transfected with: MGI; MGI:1346060; Tlr2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111618 CVCL_RG13 WG1514 finite cell line human CVCL_RG13 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg91Lysfs*14 (c.271dupA); ClinVar=VCV000001421; Zygosity=Heterozygous (CelloPub=CLPUB00668) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111619 CVCL_IM82 HEK-Blue hTLR4 transformed cell line human CVCL_IM82 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 17156; LY96; Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IL-12 p40 minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111620 CVCL_RG16 WG1721 finite cell line human CVCL_RG16 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111621 CVCL_IM81 HEK-Blue hTLR3 transformed cell line human CVCL_IM81 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11849; TLR3; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111622 CVCL_RG15 WG1720 finite cell line human CVCL_RG15 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111623 CVCL_IM84 HEK-Blue hTLR7 transformed cell line human CVCL_IM84 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 15631; TLR7; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111624 CVCL_RG18 WG1926 finite cell line human CVCL_RG18 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111625 CVCL_IM83 HEK-Blue hTLR5 transformed cell line human CVCL_IM83 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11851; TLR5; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21111626 CVCL_RG17 WG1722 finite cell line human CVCL_RG17 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21111627 CVCL_IM57 IMG-990 XP3Br2 finite cell line human CVCL_IM57 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Caution: Could be identical to XP3BR (Cellosaurus=CVCL_M286) 21111628 CVCL_IM56 XP3MO finite cell line human CVCL_IM56 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111629 CVCL_IM59 CHO12RO transformed cell line CVCL_IM59 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21111630 CVCL_IM53 XP2MO finite cell line human CVCL_IM53 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111631 CVCL_RG01 PFIZi024-A induced pluripotent stem cell human CVCL_RG01 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4075; GABRA1; Simple; p.Arg147Gln (c.440G>A); ClinVar=VCV000807607; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21111632 CVCL_IM52 XP9MO finite cell line human CVCL_IM52 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111633 CVCL_RG00 PFIZi022-A induced pluripotent stem cell human CVCL_RG00 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 30881; ALG13; Simple; p.Asn107Ser (c.320A>G) (N29S); ClinVar=VCV000066086; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 21111634 CVCL_IM55 XP2LE finite cell line human CVCL_IM55 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111635 CVCL_RG03 PFIZi027-A induced pluripotent stem cell human CVCL_RG03 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 2714; DCX; Unexplicit; Ex5-8del; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 21111636 CVCL_IM54 XP3LE [Leningrad] finite cell line human CVCL_IM54 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111637 CVCL_RG02 PFIZi025-A induced pluripotent stem cell human CVCL_RG02 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6233; KCNC1; Simple; p.Arg320His (c.959G>A); ClinVar=VCV000162519; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 21111638 CVCL_RG05 SiMa GFP-VAMP2 cancer cell line human CVCL_RG05 CL:0000010 Transfected with: HGNC; 12643; VAMP2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Biotechnology: Used in a bioassay to measure botulinum toxin serotype B (BoNT/B) activity Male 21111639 CVCL_RG04 PFIZi009-A induced pluripotent stem cell human CVCL_RG04 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Thr105Ile (c.314C>T); ClinVar=VCV000206927; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21111640 CVCL_IM51 XP8MO finite cell line human CVCL_IM51 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111641 CVCL_RG07 WG1657 finite cell line human CVCL_RG07 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21111642 CVCL_IM50 XP7MO finite cell line human CVCL_IM50 From: MWCMG, Russian Academy of Medical Sciences; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21111643 CVCL_RG06 WG1656 finite cell line human CVCL_RG06 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21111644 CVCL_IM68 PomD-iPSC A17 induced pluripotent stem cell human CVCL_IM68 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Glu (c.1935C>A); ClinVar=VCV000004029; Zygosity=Homozygous (PubMed=21926084) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21111645 CVCL_IM67 PomD-iPSC A10 induced pluripotent stem cell human CVCL_IM67 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Glu (c.1935C>A); ClinVar=VCV000004029; Zygosity=Homozygous (PubMed=21926084) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21111646 CVCL_IM69 PomD-iPSC A25 induced pluripotent stem cell human CVCL_IM69 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Glu (c.1935C>A); ClinVar=VCV000004029; Zygosity=Homozygous (PubMed=21926084) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21111647 CVCL_IM64 293/pmiR-K12-11 transformed cell line human CVCL_IM64 CL:0000010 Transfected with: KSHV-miR-K12-11 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by microarray Female 21111648 CVCL_IM63 293/pmiR-155 transformed cell line human CVCL_IM63 CL:0000010 Transfected with: HGNC; 31542; MIR155 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by microarray Female 21111649 CVCL_IM66 OVCAR-8 RIIB cancer cell line human CVCL_IM66 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: HGNC; 9392; PRKAR2B Omics: Transcriptome analysis by microarray. Female 21111650 CVCL_IM65 OVCAR-8 RIA cancer cell line human CVCL_IM65 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: HGNC; 9388; PRKAR1A Omics: Transcriptome analysis by microarray. Female 21111651 CVCL_IM60 CHO33RO transformed cell line CVCL_IM60 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21111652 CVCL_IM62 HeLa LChm cancer cell line human CVCL_IM62 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21111653 CVCL_IM61 CHO43RO transformed cell line CVCL_IM61 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21111654 CVCL_RH91 UiPSC-007 induced pluripotent stem cell human CVCL_RH91 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111655 CVCL_RH90 UiPSC-006 induced pluripotent stem cell human CVCL_RH90 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111656 CVCL_RH93 UiPSC-009 induced pluripotent stem cell human CVCL_RH93 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=23940595); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-197C>T (IVS2-654C>T); ClinVar=VCV000015458; Zygosity=Heterozygous (PubMed=23940595) Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111657 CVCL_RH92 UiPSC-008 induced pluripotent stem cell human CVCL_RH92 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111658 CVCL_RH95 UiPSC-011 induced pluripotent stem cell human CVCL_RH95 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111659 CVCL_RH94 UiPSC-010 induced pluripotent stem cell human CVCL_RH94 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111660 CVCL_RH97 UiPSC-013 induced pluripotent stem cell human CVCL_RH97 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111661 CVCL_RH96 UiPSC-012 induced pluripotent stem cell human CVCL_RH96 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111662 CVCL_RH99 UiPSC-015 induced pluripotent stem cell human CVCL_RH99 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111663 CVCL_RH98 UiPSC-014 induced pluripotent stem cell human CVCL_RH98 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111664 CVCL_A667 SCMC-RM2 cancer cell line human CVCL_A667 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR; Note=Not found in original tumor (PubMed=23578105; CelloPub=CLPUB00599) Population: Japanese; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0044; true Female Doubling time: 50 hours (PubMed=2323848) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21111665 CVCL_A666 RO-H85-1 cancer cell line human CVCL_A666 CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Gln993Ter (c.2977C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6974; MDM4; Simple; p.Ser161Ter (c.482C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile162Asn (c.485T>A); ClinVar=VCV001408611; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Urinary bladder. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00481 Problematic cell line: Contaminated Shown to be a 647V derivative (PubMed=23472229). Originally thought to originate from a thyroid gland medullary carcinoma. 21111666 CVCL_A669 SH101-P4 cancer cell line human CVCL_A669 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified Doubling time: 18 hours (PubMed=8242641) 21111667 CVCL_A668 SCMC-RM2-1 cancer cell line human CVCL_A668 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line) Population: Japanese; Derived from metastatic site: Bone marrow. Female Doubling time: 52 hours (PubMed=2323848) 21111668 CVCL_A661 NG97ht cancer cell line human CVCL_A661 CL:0000010 Population: Brazilian; Derived from sampling site: Brain; right temporal lobe. Male Characteristics: Established from a nude mice xenotransplanted with NG97 21111669 CVCL_A660 NG97 cancer cell line human CVCL_A660 CL:0000010 Population: Brazilian; Derived from sampling site: Brain; right temporal lobe. Male Doubling time: ~72 hours (PubMed=11775071) 21111670 CVCL_A663 OM9;22 cancer cell line human CVCL_A663 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7686604; PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~80 hours (PubMed=7686604) 21111671 CVCL_A662 OHN-GM cancer cell line human CVCL_A662 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous (PubMed=27750403); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val172Phe (c.514G>T); ClinVar=VCV000428909; Zygosity=Heterozygous (PubMed=27750403); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Heterozygous (PubMed=27750403) Population: Japanese; Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Bone marrow. Omics: SNP array analysis Male Characteristics: CSF2 dependent Doubling time: ~60 hours (PubMed=9266938) 21111672 CVCL_A665 PM-WK cancer cell line human CVCL_A665 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9692547; PubMed=10766161) Derived from sampling site: Skin. Discontinued: ATCC; CRL-2624; true Unspecified 21111673 CVCL_A664 PFI-285 cancer cell line human CVCL_A664 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: ~24 hours (PubMed=2307225) 21111674 CVCL_A678 SPEC-1 cancer cell line human CVCL_A678 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female Doubling time: 48 hours (PubMed=2722053) 21111675 CVCL_A677 SNT-8 cancer cell line human CVCL_A677 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Female 21111676 CVCL_A679 SPEC-2 cancer cell line human CVCL_A679 CL:0000010 Derived from sampling site: Endometrium. Female 21111677 CVCL_A670 SHIN-3 cancer cell line human CVCL_A670 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=8980248) Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 48.3 hours (at 12th passage), 26.7 hours (at 20th passage) (PubMed=2314830) 21111678 CVCL_A672 SNK-10 transformed cell line human CVCL_A672 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: IL2 dependent 21111679 CVCL_A671 SNK-1 cancer cell line human CVCL_A671 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: IL2 dependent 21111680 CVCL_J008 AFRC MAC 2 hybridoma Norway rat CVCL_J008 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21111681 CVCL_A674 SNT-13 transformed cell line human CVCL_A674 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21111682 CVCL_J007 AFRC MAC 19 hybridoma Norway rat CVCL_J007 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21111683 CVCL_A673 SNK-6 cancer cell line human CVCL_A673 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Male Characteristics: IL2 dependent 21111684 CVCL_A676 SNT-16 transformed cell line human CVCL_A676 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female 21111685 CVCL_J009 AFRC MAC 20 hybridoma Norway rat CVCL_J009 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21111686 CVCL_A675 SNT-15 transformed cell line human CVCL_A675 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21111687 CVCL_J004 A5.12.14 hybridoma house mouse CVCL_J004 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P10145; Human IL8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11553 21111688 CVCL_J003 6G4.2.5 hybridoma house mouse CVCL_J003 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P19874; Rabbit IL8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11722 21111689 CVCL_J006 AFRC MAC 18 hybridoma Norway rat CVCL_J006 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21111690 CVCL_J005 AFRC MAC 15 hybridoma Norway rat CVCL_J005 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21111691 CVCL_J000 3C10 [Mouse hybridoma against human CD14] hybridoma house mouse CVCL_J000 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08571; Human CD14. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21111692 CVCL_J002 5D5.11.6 hybridoma house mouse CVCL_J002 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08581; Human MET. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11895 21111693 CVCL_J001 4D1.5.7 hybridoma house mouse CVCL_J001 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P25025; Human CXCR2/IL8RB/CD182. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11495 21111694 CVCL_A645 LK79 cancer cell line human CVCL_A645 HLA typing: A*24:02; B*40:02; C*03:03 (PubMed=9178645). CL:0000010 Population: Japanese Unspecified 21111695 CVCL_A644 LCSC#2 cancer cell line human CVCL_A644 CL:0000010 Population: Japanese. Unspecified 21111696 CVCL_A647 MDS92 cancer cell line human CVCL_A647 CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000851673; Zygosity=Heterozygous (PubMed=29955132); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Heterozygous (PubMed=7947263; PubMed=29955132); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29955132) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Characteristics: IL3 dependent Doubling time: 80-90 hours (PubMed=7947263) 21111697 CVCL_A646 LK87 cancer cell line human CVCL_A646 CL:0000010 Population: Japanese. Unspecified 21111698 CVCL_A649 MedB-1 cancer cell line human CVCL_A649 CL:0000010 Derived from sampling site: Thymus; anterior mediastinum. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: SNP array analysis Male 21111699 CVCL_A648 INT-MEL-12 cancer cell line human CVCL_A648 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Gly414Val (c.1241G>T); Zygosity=Heterozygous (PubMed=22383533) Female 21111700 CVCL_A641 L-SAK cancer cell line human CVCL_A641 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Hemizygous (PubMed=10071127) Population: Japanese Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21111701 CVCL_A640 L-MAT cancer cell line human CVCL_A640 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Glufs*51 (c.586delC); Zygosity=Unspecified (PubMed=10071127). Population: Japanese 21111702 CVCL_A643 LCSC#1 cancer cell line human CVCL_A643 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=16105816). Population: Japanese Unspecified 21111703 CVCL_A642 L-SMY cancer cell line human CVCL_A642 CL:0000010 Population: Japanese Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21111704 CVCL_A656 MZ-CRC-1 cancer cell line human CVCL_A656 CL:0000010 Sequence variation: Mutation; HGNC; 4778; H3-4; Simple; p.Arg3Ter (c.7C>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 6913; MAX; Simple; c.295+1G>A; ClinVar=VCV000186993; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30737244); Sequence variation: Mutation; HGNC; 30064; PBRM1; Simple; p.Arg534Ter (c.1600C>T); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Heterozygous (PubMed=19897677; PubMed=30737244) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 12-16 days (CelloPub=CLPUB00385) 21111705 CVCL_A655 MR-87 cancer cell line human CVCL_A655 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3048438; PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 120-144 hours (PubMed=3048438) 21111706 CVCL_A658 MZ-PC-2 cancer cell line human CVCL_A658 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=8026879) Derived from sampling site: Pancreas. Unspecified 21111707 CVCL_A659 MZ-PC-4 cancer cell line human CVCL_A659 From: Knuth A.; Johannes Gutenberg Universitat; Mainz; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Unspecified (PubMed=8026879). Unspecified 21111708 CVCL_A650 Mel-Swift cancer cell line human CVCL_A650 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714). 21111709 CVCL_A652 MGH-BO-1 cancer cell line human CVCL_A652 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714). Unspecified 21111710 CVCL_A651 MGH-BA-1 cancer cell line human CVCL_A651 CL:0000010 Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=9692547). Unspecified 21111711 CVCL_A654 MONO-7 cancer cell line human CVCL_A654 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Unspecified (PubMed=11843295) Population: Japanese; Karyotypic information: Monosomy of chromosome 7 (PubMed=11843295); Derived from sampling site: Peripheral blood. Male 21111712 CVCL_A653 MGH-PO-1 cancer cell line human CVCL_A653 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714). Unspecified 21111713 CVCL_A623 IMS-M1 cancer cell line human CVCL_A623 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=14671638) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: CSF2 dependent Doubling time: 36-48 hours (DOI=10.1016/B978-0-12-221970-2.50457-5) 21111714 CVCL_A622 ILKM3 cancer cell line human CVCL_A622 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 96 hours (PubMed=2783335) 21111715 CVCL_A625 IPH-926 cancer cell line human CVCL_A625 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Heterozygous (PubMed=19191266); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Val82fs*13 (c.240_241insGGTG); Zygosity=Heterozygous (PubMed=19191266); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=22945757) Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Characteristics: Expresses high level of ABCB1 mRNA (PubMed=22118813) Doubling time: ~2 weeks (PubMed=19191266); 200 hours (in the first 1-2 weeks), 80-120 hours (after 2 weeks) (DSMZ=ACC-827) Group: Triple negative breast cancer (TNBC) cell line 21111716 CVCL_A624 IOR/EW4 cancer cell line human CVCL_A624 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Derived from sampling site: Bone. Unspecified 21111717 CVCL_A627 Isreco-1 cancer cell line human CVCL_A627 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=9000147; PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E Derived from sampling site: Colon; ascending. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746) 21111718 CVCL_A626 ISI-1 cancer cell line human CVCL_A626 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. 21111719 CVCL_A629 Isreco-3 cancer cell line human CVCL_A629 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=9000147; PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E Derived from metastatic site: Peritoneum. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746) 21111720 CVCL_A628 Isreco-2 cancer cell line human CVCL_A628 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=9000147) Derived from metastatic site: Liver. Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147) 21111721 CVCL_A621 ILKM2 cancer cell line human CVCL_A621 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 120 hours (PubMed=2783335) 21111722 CVCL_A620 HUOCA-II cancer cell line human CVCL_A620 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 24 hours, at 45th passage (PubMed=2435943; PubMed=3593088) 21111723 CVCL_A619 HU-3 cancer cell line human CVCL_A619 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: CSF2 dependent Doubling time: 60 +- 11 hours (PubMed=9096695) 21111724 CVCL_A634 KHM-11ad cancer cell line human CVCL_A634 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgA kappa 21111725 CVCL_A633 KHM-11 cancer cell line human CVCL_A633 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=11157491) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgA kappa 21111726 CVCL_A636 KMO-90 cancer cell line human CVCL_A636 CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=8412323); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro177Leu (c.530C>T); ClinVar=VCV000406583; Zygosity=Unspecified (PubMed=7727782; PubMed=8412323) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~72 hours (PubMed=8412323) 21111727 CVCL_A635 KMC-2 cancer cell line human CVCL_A635 CL:0000010 Population: Japanese Male Characteristics: Established from a serially transplantable tumor established in nude mouse (nuKMC-2) Doubling time: 29.5 hours (on plastic dish), 35.4 hours (in collagen gel mixture) (PubMed=7742926). 21111728 CVCL_A638 KOPN-K cancer cell line human CVCL_A638 CL:0000010 Population: Japanese Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21111729 CVCL_A637 KMS-18 cancer cell line human CVCL_A637 Genome ancestry: African=0%; Native American=0%; East Asian, North=81.47%; East Asian, South=18.53%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6545; COG1 + HGNC; 37659; RNA28S5; Name(s)=COG1-RNA28S5, COG1-RN28S1 (PubMed=24504345); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0483; true Male Characteristics: Produces IgA lambda Doubling time: ~72 hours (PubMed=9472091) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21111730 CVCL_A639 L-KAW cancer cell line human CVCL_A639 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Hemizygous (PubMed=10071127) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 36 hours (PubMed=7543637) 21111731 CVCL_A630 JBL-2 cancer cell line human CVCL_A630 CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=6806672; PubMed=22120970) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21111732 CVCL_A632 KCMC-T cancer cell line human CVCL_A632 CL:0000010 Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526). 21111733 CVCL_A631 JD38 cancer cell line human CVCL_A631 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660) Derived from sampling site: Peripheral blood. Virology: EBV-negative Doubling time: 26 hours (PubMed=8402660) 21111734 CVCL_A601 CLA4 transformed cell line human CVCL_A601 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21111735 CVCL_A600 Gli-6 cancer cell line human CVCL_A600 CL:0000010 Male Doubling time: 36 hours (PubMed=14605880). 21111736 CVCL_A603 FB-1 cancer cell line human CVCL_A603 CL:0000010 Derived from sampling site: Thyroid gland. Female 21111737 CVCL_A602 CMY cancer cell line human CVCL_A602 CL:0000010 Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Tyr3Ter (c.9C>G); Zygosity=Unspecified (PubMed=23955599) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: ~46 hours (PubMed=9852262) 21111738 CVCL_A605 HCC9204 cancer cell line human CVCL_A605 CL:0000010 Male 21111739 CVCL_A604 FET cancer cell line human CVCL_A604 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=9000147) Omics: Transcriptome analysis by microarray. Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=25926053) 21111740 CVCL_A607 HCT C cancer cell line human CVCL_A607 CL:0000010 Male 21111741 CVCL_A606 HCC9724 cancer cell line human CVCL_A606 CL:0000010 21111742 CVCL_A612 HOM-2 transformed cell line human CVCL_A612 HLA typing: A*03:01:01:01; B*27:05:02; C*01:02:01:06; DPA1*01; DPB1*04:01:01; DQA1*01:01; DQB1*05:01:01; DRA*01:01; DRB1*01:01:01; DRB6*01:01 (IPD-IMGT/HLA=10755) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21111743 CVCL_A611 HOM-1 transformed cell line human CVCL_A611 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21111744 CVCL_A614 HSC-59 cancer cell line human CVCL_A614 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 22 hours (PubMed=15245593) 21111745 CVCL_A613 HSC-57 cancer cell line human CVCL_A613 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 28 hours (PubMed=15245593) 21111746 CVCL_A616 HSC-60 cancer cell line human CVCL_A616 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 26 hours (PubMed=15245593) 21111747 CVCL_A615 HSC-6 cancer cell line human CVCL_A615 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Unspecified (PubMed=18097548). Population: Japanese 21111748 CVCL_A618 HSC-7 cancer cell line human CVCL_A618 CL:0000010 Population: Japanese. 21111749 CVCL_A617 HSC-64 cancer cell line human CVCL_A617 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 30 hours (PubMed=15245593) 21111750 CVCL_A610 HMOA cancer cell line human CVCL_A610 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 60 hours (PubMed=3593088) 21111751 CVCL_A609 HGT-1 cancer cell line human CVCL_A609 CL:0000010 Male Doubling time: 27.86 +- 2.71 hours (at 40th passage), 19.48 +- 1.20 hours (at 59th passage) (PubMed=6277484). 21111752 CVCL_A608 HCT C Col cancer cell line human CVCL_A608 CL:0000010 Male 21111753 CVCL_IN59 12CFBE22o- transformed cell line human CVCL_IN59 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Unspecified 21111754 CVCL_IN56 CL1-5-F4 cancer cell line human CVCL_IN56 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male 21111755 CVCL_IN55 GM01617 finite cell line human CVCL_IN55 CL:0000010 Sequence variation: Mutation; HGNC; 6176; ITPA; Simple; p.Pro32Thr (c.94C>A); ClinVar=VCV000014746; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21111756 CVCL_IN58 3ACFSMEo- transformed cell line human CVCL_IN58 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln2Ter (c.4C>T); ClinVar=VCV000053980; Zygosity=Heterozygous (from autologous cell lines 6CFSMEo- and CFSMEo-); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from autologous cell lines 6CFSMEo- and CFSMEo-) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Unspecified 21111757 CVCL_IN57 CFTE29o- transformed cell line human CVCL_IN57 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=7683197; PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Male Characteristics: Useful model for cystic fibrosis and for studying chloride ion transport and ion transport in human airways The cells are useful for testing candidate chemotherapeutic drugs for their potential as treatments for ameliorating CF pathologies (Millipore). 21111758 CVCL_IN52 HOON cancer cell line human CVCL_IN52 CL:0000010 Population: Japanese Male Doubling time: 24 hours (PubMed=6230491). 21111759 CVCL_RH00 WG1742 finite cell line human CVCL_RH00 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111760 CVCL_IN51 Tesi transformed cell line human CVCL_IN51 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1) [Tax](NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Immortalized using a tetracycline-repressible HTLV-1 Tax gene; Characteristics: IL2 dependent 21111761 CVCL_IN54 SHG [Verasper] spontaneously immortalized cell line CVCL_IN54 CL:0000010 Derived from sampling site: Gill. Unspecified Doubling time: 43.6 hours (CelloPub=CLPUB00366) Group: Fish cell line 21111762 CVCL_RH02 WG0131 finite cell line human CVCL_RH02 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111763 CVCL_IN53 HYON cancer cell line human CVCL_IN53 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 36 hours (PubMed=6230491) 21111764 CVCL_RH01 WG1743 finite cell line human CVCL_RH01 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111765 CVCL_RH04 MCH040 finite cell line human CVCL_RH04 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21111766 CVCL_RH03 WG0347 finite cell line human CVCL_RH03 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111767 CVCL_IN50 GM03392 finite cell line human CVCL_IN50 CL:0000010 Sequence variation: Mutation; HGNC; 23026; GNPTG; Simple; p.Ala149Profs*13 (c.445delG); ClinVar=VCV000039080; Zygosity=Homozygous (Coriell) Population: Iranian; Derived from sampling site: Cell type=Fibroblast. Female 21111768 CVCL_RH06 WG0126 finite cell line human CVCL_RH06 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21111769 CVCL_RH05 MCH041 finite cell line human CVCL_RH05 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111770 CVCL_IN67 HSME6o- transformed cell line human CVCL_IN67 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 21111771 CVCL_IN66 CFNPE14o- transformed cell line human CVCL_IN66 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Unspecified 21111772 CVCL_IN69 JME/CF 12 transformed cell line human CVCL_IN69 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified 21111773 CVCL_IN68 HSME82o- transformed cell line human CVCL_IN68 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 21111774 CVCL_IN63 CFBE45o- transformed cell line human CVCL_IN63 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg117His (c.350G>A); ClinVar=VCV000007109; Zygosity=Heterozygous (PubMed=15463957); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified 21111775 CVCL_IN62 6CFSMEo- transformed cell line human CVCL_IN62 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln2Ter (c.4C>T); ClinVar=VCV000053980; Zygosity=Heterozygous (PubMed=15463957; PubMed=16037690); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=15463957; PubMed=16037690) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 21111776 CVCL_IN65 CFNPE9o- transformed cell line human CVCL_IN65 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Unspecified 21111777 CVCL_IN64 CFBE46o- transformed cell line human CVCL_IN64 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg117His (c.350G>A); ClinVar=VCV000007109; Zygosity=Unspecified (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified 21111778 CVCL_IN61 56FHTE8o- transformed cell line human CVCL_IN61 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal trachea; epithelium Cell type=Epithelial cell.. Unspecified Characteristics: Useful model for the study of epithelial ion transport, secretion and biochemistry (Millipore) 21111779 CVCL_IN60 2CFSMEo- transformed cell line human CVCL_IN60 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln2Ter (c.4C>T); ClinVar=VCV000053980; Zygosity=Heterozygous (from autologous cell lines 6CFSMEo- and CFSMEo-); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from autologous cell lines 6CFSMEo- and CFSMEo-) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 21111780 CVCL_IN38 A0031 iPS#34 induced pluripotent stem cell human CVCL_IN38 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111781 CVCL_IN37 A0031 iPS#23 induced pluripotent stem cell human CVCL_IN37 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111782 CVCL_IN39 A0031 iPS#64 induced pluripotent stem cell human CVCL_IN39 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111783 CVCL_IN34 GM17476 finite cell line human CVCL_IN34 CL:0000010 Sequence variation: Mutation; HGNC; 87; ACAD8; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000005359; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111784 CVCL_IN33 GM13567 finite cell line human CVCL_IN33 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21111785 CVCL_IN36 GM25268 transformed cell line human CVCL_IN36 CL:0000010 Sequence variation: Mutation; HGNC; 10990; SLC25A4; Simple; p.Gln175Argfs*38 (c.523delC); ClinVar=VCV000215174; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111786 CVCL_IN35 GM23628 transformed cell line human CVCL_IN35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111787 CVCL_IN30 GM11907 transformed cell line human CVCL_IN30 CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111788 CVCL_IN32 GM13537 transformed cell line human CVCL_IN32 CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[60]; Zygosity=Heterozygous; Note=The other allele has 32 repeats (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111789 CVCL_IN31 GM13536 transformed cell line human CVCL_IN31 CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[43]; Zygosity=Heterozygous; Note=The other allele has 31 repeats (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111790 CVCL_IN49 GM03391 finite cell line human CVCL_IN49 CL:0000010 Sequence variation: Mutation; HGNC; 23026; GNPTG; Simple; p.Ala149Profs*13 (c.445delG); ClinVar=VCV000039080; Zygosity=Homozygous (Coriell) Population: Iranian; Derived from sampling site: Cell type=Fibroblast. Male 21111791 CVCL_IN48 GM02958 finite cell line human CVCL_IN48 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21111792 CVCL_IN45 BFO spontaneously immortalized cell line CVCL_IN45 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 32.7 hours, at 60th passage (DOI=10.1007/s11802-015-2920-6) Group: Fish cell line 21111793 CVCL_IN44 BSBS spontaneously immortalized cell line CVCL_IN44 CL:0000010 Derived from sampling site: Spleen. Unspecified Characteristics: Optimal growth at 20 Celsius; Virology: Susceptible to infection by marine birnavirus (MABV Y-6), chum salmon virus (CSV), spring viremia of carp virus (SVCV) and hirame rhabdovirus (HIRRV) Group: Fish cell line 21111794 CVCL_IN47 GM01619 transformed cell line human CVCL_IN47 CL:0000010 Sequence variation: Mutation; HGNC; 6176; ITPA; Simple; p.Pro32Thr (c.94C>A); ClinVar=VCV000014746; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111795 CVCL_IN46 PSPA spontaneously immortalized cell line pig CVCL_IN46 CL:0000010 Derived from sampling site: Fetal hypodermis Cell type=Preadipocyte.; Breed/subspecies: ([(Landrace x Large White) x Duroc] x Landrace). Omics: Transcriptome analysis by microarray Female 21111796 CVCL_IN41 WSCU01 iPS#13 induced pluripotent stem cell human CVCL_IN41 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21111797 CVCL_IN40 WSCU01 iPS#02 induced pluripotent stem cell human CVCL_IN40 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21111798 CVCL_IN43 TIG-3 iPSC #10-2 induced pluripotent stem cell human CVCL_IN43 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111799 CVCL_IN42 WSCU01 iPS#14 induced pluripotent stem cell human CVCL_IN42 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21111800 CVCL_A589 NCI-N177 cancer cell line human CVCL_A589 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Established from a mouse xenograft 21111801 CVCL_A582 NCI-H689 cancer cell line human CVCL_A582 CL:0000010 Derived from metastatic site: Pleural effusion. Discontinued: KCLB; 90689; probable Male 21111802 CVCL_A581 NCI-H679 cancer cell line human CVCL_A581 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103Thrfs*20 (c.306delC) (p.Thr102fs); Zygosity=Unspecified (PubMed=1311061) Discontinued: ATCC; CRL-5977; true. Male 21111803 CVCL_A584 NCI-H854 cancer cell line human CVCL_A584 HLA typing: A*29:02,29:02; B*07:17,44:03; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=1.09%; Native American=0.03%; East Asian, North=1.91%; East Asian, South=0%; South Asian=0.45%; European, North=64.74%; European, South=31.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1311061; DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5847; true. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: Indicated as originating from colon in PubMed=8806092 and in ATCC, from lung in PubMed=11030152 and CCLE 21111804 CVCL_A583 NCI-H792 cancer cell line human CVCL_A583 CL:0000010 Omics: Array-based CGH. Male 21111805 CVCL_A586 NCI-H890 cancer cell line human CVCL_A586 CL:0000010 Derived from metastatic site: Bone marrow. Female 21111806 CVCL_IN19 MDA-MB-231 ERbetaDBD cancer cell line human CVCL_IN19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3468; ESR2 (ERE-binding defective) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Group: Triple negative breast cancer (TNBC) cell line 21111807 CVCL_A585 NCI-H862 cancer cell line human CVCL_A585 CL:0000010 Discontinued: ATCC; CRL-5848; probable. Female 21111808 CVCL_A588 NCI-H962 cancer cell line human CVCL_A588 CL:0000010 Derived from metastatic site: Lymph node. Male 21111809 CVCL_A587 NCI-H930 cancer cell line human CVCL_A587 CL:0000010 Derived from metastatic site: Lymph node. Female 21111810 CVCL_IN16 MDA-MB-231 CMV cancer cell line human CVCL_IN16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: Control cell line for the MDA-MB-231 ERalpha (Cellosaurus=CVCL_IN17), MDA-MB-231 ERalpha203/4/11 (Cellosaurus=CVCL_IN15), MDA-MB-231 ERbeta (Cellosaurus=CVCL_IN18) and MDA-MB-231 ERbetaDBD (Cellosaurus=CVCL_IN19) cell lines Group: Triple negative breast cancer (TNBC) cell line 21111811 CVCL_IN15 MDA-MB-231 ERalpha203/4/11 cancer cell line human CVCL_IN15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 (with p.Glu203Ala, p.Gly204Ala and Arg211Glu) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Group: Triple negative breast cancer (TNBC) cell line 21111812 CVCL_IN18 MDA-MB-231 ERbeta cancer cell line human CVCL_IN18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3468; ESR2 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Group: Triple negative breast cancer (TNBC) cell line 21111813 CVCL_IN17 MDA-MB-231 ERalpha cancer cell line human CVCL_IN17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Group: Triple negative breast cancer (TNBC) cell line 21111814 CVCL_IN12 hiPS 1-8 induced pluripotent stem cell human CVCL_IN12 HLA typing: A*01:01,02:06; B*38:01/09,39:05; C*06:02,07:02; DPB1*04:02,05:01; DQB1*03:01,04:02; DRB1*08:02,11:04/43 (PubMed=19383391) CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: ~48.5 hours (PubMed=19383391) 21111815 CVCL_IN11 iPSc-GD-C21 induced pluripotent stem cell human CVCL_IN11 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Gly241Arg (c.721G>A) (G202R); ClinVar=VCV000093459; Zygosity=Heterozygous (PubMed=23118351); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=23118351) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111816 CVCL_IN14 hiPS 3-2 induced pluripotent stem cell human CVCL_IN14 HLA typing: A*01:01,02:06; B*38:01/09,39:05; C*06:02;07:02; DPB1*04:02,05:01; DQB1*03:01,04:02; DRB1*08:02,11:04/43 (PubMed=19383391) CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111817 CVCL_A580 NCI-H678 cancer cell line human CVCL_A580 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Array-based CGH Male 21111818 CVCL_IN13 hiPS 2-4 induced pluripotent stem cell human CVCL_IN13 HLA typing: A*02:01; B*15:01,51:01; C*03:03,04:01; DPB1*02:01,03:01; DQB1*03:02,04:02; DRB1*04:01/33/38,08:01/26 (PubMed=19383391) CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111819 CVCL_IN10 iPSc-GD-A8 induced pluripotent stem cell human CVCL_IN10 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Gly241Arg (c.721G>A) (G202R); ClinVar=VCV000093459; Zygosity=Heterozygous (PubMed=23118351); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=23118351) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111820 CVCL_A593 JAMA-2 cancer cell line human CVCL_A593 CL:0000010 Female 21111821 CVCL_A592 NCI-H60 cancer cell line human CVCL_A592 CL:0000010 Sequence variation: Gene fusion; HGNC; 23139; CLVS1 + HGNC; 9709; PVT1; Name(s)=PVT1-CLVS1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Lys (c.1636C>A); ClinVar=VCV000013657; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5821; true Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00416 Problematic cell line: Contaminated Shown to be a NCI-N417 derivative. 21111822 CVCL_A595 TT2609-B02 cancer cell line human CVCL_A595 CL:0000010 Population: Caucasian; Karyotypic information: Near diploid karyotype (PubMed=11716037); Derived from sampling site: Thyroid gland. Male Doubling time: 23 hours (PubMed=11716037) 21111823 CVCL_A594 TT2609-A02 cancer cell line human CVCL_A594 CL:0000010 Population: Caucasian; Derived from sampling site: Thyroid gland. Male Doubling time: 68 hours (PubMed=11716037); ~100 hours (DSMZ=ACC-859) 21111824 CVCL_A597 44-2 cancer cell line Norway rat CVCL_A597 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Unspecified 21111825 CVCL_A599 6-23 cancer cell line Norway rat CVCL_A599 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Unspecified 21111826 CVCL_A598 44-3C1 cancer cell line Norway rat CVCL_A598 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Unspecified 21111827 CVCL_IN27 GM09894 finite cell line human CVCL_IN27 HLA typing: A*01,01; B*27,35 (PubMed=2916654) CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Male 21111828 CVCL_IN26 GM09893 finite cell line human CVCL_IN26 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21111829 CVCL_IN29 GM11906 transformed cell line human CVCL_IN29 CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111830 CVCL_IN28 GM09913 transformed cell line human CVCL_IN28 HLA typing: A*01,03; B*27,44; C*w02 (PubMed=2916654) CL:0000010 Population: Caucasian; Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21111831 CVCL_IN23 GM08383 transformed cell line human CVCL_IN23 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111832 CVCL_IN22 GM08382 transformed cell line human CVCL_IN22 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21111833 CVCL_IN25 GM09811 finite cell line human CVCL_IN25 HLA typing: A*02,03; B*07,44 (PubMed=2916654) CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111834 CVCL_A591 NCI-N691 cancer cell line human CVCL_A591 CL:0000010 Derived from metastatic site: Pleural effusion. Female Characteristics: Established from a nude mouse xenograft 21111835 CVCL_IN24 GM09498 finite cell line human CVCL_IN24 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21111836 CVCL_A590 NCI-N592 cancer cell line human CVCL_A590 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5832; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00415 Problematic cell line: Contaminated Shown to be a NCI-H69 derivative. 21111837 CVCL_IN21 GM03904 finite cell line human CVCL_IN21 CL:0000010 Population: Ecuadorian; Derived from sampling site: Cell type=Fibroblast. Male 21111838 CVCL_IN20 GM03903 finite cell line human CVCL_IN20 CL:0000010 Population: Ecuadorian; Derived from sampling site: Cell type=Fibroblast. Male 21111839 CVCL_A568 NCI-H463 cancer cell line human CVCL_A568 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111840 CVCL_A567 NCI-H462 cancer cell line human CVCL_A567 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111841 CVCL_A569 NCI-H478 cancer cell line human CVCL_A569 CL:0000010 Derived from sampling site: Lung. Female 21111842 CVCL_A560 NCI-H379 cancer cell line human CVCL_A560 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21111843 CVCL_A562 NCI-N408 cancer cell line human CVCL_A562 CL:0000010 Derived from metastatic site: Liver. Male Characteristics: Established from a nude mouse xenograft 21111844 CVCL_A561 NCI-N390 cancer cell line human CVCL_A561 CL:0000010 Population: African American; Derived from metastatic site: Lymph node. Male Characteristics: Established from a nude mouse xenograft 21111845 CVCL_A564 NCI-H433 cancer cell line human CVCL_A564 CL:0000010 Derived from metastatic site: Hypodermis. Male 21111846 CVCL_A563 NCI-H432 cancer cell line human CVCL_A563 CL:0000010 Derived from metastatic site: Hypodermis. Male 21111847 CVCL_A566 NCI-H450 cancer cell line human CVCL_A566 CL:0000010 Derived from metastatic site: Lymph node. Female 21111848 CVCL_A565 NCI-H449 cancer cell line human CVCL_A565 CL:0000010 Derived from metastatic site: Bone marrow. Female 21111849 CVCL_A579 NCI-H640 cancer cell line human CVCL_A579 CL:0000010 Derived from sampling site: Lung. Female 21111850 CVCL_A578 NCI-H620 cancer cell line human CVCL_A578 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH Male 21111851 CVCL_A571 NCI-H568 cancer cell line human CVCL_A571 CL:0000010 Derived from metastatic site: Lymph node. Male 21111852 CVCL_A570 NCI-H513 cancer cell line human CVCL_A570 Genome ancestry: African=83.85%; Native American=0%; East Asian, North=2.18%; East Asian, South=0%; South Asian=2.16%; European, North=5.9%; European, South=5.9% (PubMed=30894373) CL:0000010 Population: African American; Derived from metastatic site: Hypodermis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5830; true; Discontinued: DepMap; ACH-002341; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00414 Problematic cell line: Contaminated Shown to be a NCI-H125 derivative. Originally thought to originate with the pleural effusion of a mesothelioma in a 64 year old male patient. 21111853 CVCL_A573 NCI-H578 cancer cell line human CVCL_A573 CL:0000010 Derived from metastatic site: Lymph node. Male 21111854 CVCL_A572 NCI-H571 cancer cell line human CVCL_A572 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21111855 CVCL_A575 NCI-H606 cancer cell line human CVCL_A575 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21111856 CVCL_IN09 SKVCR2.0 cancer cell line human CVCL_IN09 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21111857 CVCL_A574 NCI-H580 cancer cell line human CVCL_A574 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111858 CVCL_IN08 SKVCR0.25 cancer cell line human CVCL_IN08 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Ascites. Female 21111859 CVCL_A577 NCI-H618 cancer cell line human CVCL_A577 CL:0000010 Derived from metastatic site: Bone marrow. Male 21111860 CVCL_A576 NCI-H615 cancer cell line human CVCL_A576 CL:0000010 Derived from metastatic site: Lymph node. Male 21111861 CVCL_IN05 SKVLB1 cancer cell line human CVCL_IN05 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Ascites. Female 21111862 CVCL_IN04 SKVLB0.06 cancer cell line human CVCL_IN04 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Ascites. Female 21111863 CVCL_IN07 SKVCR0.1 cancer cell line human CVCL_IN07 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Ascites. Female 21111864 CVCL_IN06 SKVCR0.015 cancer cell line human CVCL_IN06 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Ascites. Female 21111865 CVCL_IN01 BMPR2 LCL 266 transformed cell line human CVCL_IN01 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21111866 CVCL_IN00 BMPR2 LCL 264 transformed cell line human CVCL_IN00 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21111867 CVCL_IN03 SKVLB0.03 cancer cell line human CVCL_IN03 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Ascites. Female 21111868 CVCL_IN02 BMPR2 LCL 723 transformed cell line human CVCL_IN02 CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=18823550) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21111869 CVCL_RH80 TIGE-9 induced pluripotent stem cell human CVCL_RH80 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111870 CVCL_RH82 BIHi008-B induced pluripotent stem cell human CVCL_RH82 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21111871 CVCL_RH81 BIHi008-A induced pluripotent stem cell human CVCL_RH81 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21111872 CVCL_RH84 ISMMSi003-A induced pluripotent stem cell human CVCL_RH84 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21111873 CVCL_RH83 BIHi008-C induced pluripotent stem cell human CVCL_RH83 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21111874 CVCL_RH86 UiPSC-002 induced pluripotent stem cell human CVCL_RH86 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111875 CVCL_RH85 UiPSC-001 induced pluripotent stem cell human CVCL_RH85 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111876 CVCL_RH88 UiPSC-004 induced pluripotent stem cell human CVCL_RH88 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111877 CVCL_RH87 UiPSC-003 induced pluripotent stem cell human CVCL_RH87 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111878 CVCL_RH89 UiPSC-005 induced pluripotent stem cell human CVCL_RH89 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21111879 CVCL_RH71 51FSDNC18 induced pluripotent stem cell human CVCL_RH71 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111880 CVCL_RH70 40FSDNC15 induced pluripotent stem cell human CVCL_RH70 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111881 CVCL_RH73 FALS-2e2 induced pluripotent stem cell human CVCL_RH73 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111882 CVCL_RH72 79FSDNC1 induced pluripotent stem cell human CVCL_RH72 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111883 CVCL_RH75 FALS-2e23 induced pluripotent stem cell human CVCL_RH75 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111884 CVCL_RH74 FALS-2e3 induced pluripotent stem cell human CVCL_RH74 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111885 CVCL_RH77 FALS-e48 induced pluripotent stem cell human CVCL_RH77 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111886 CVCL_RH76 FALS-e46 induced pluripotent stem cell human CVCL_RH76 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111887 CVCL_RH79 YFE-16 induced pluripotent stem cell human CVCL_RH79 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111888 CVCL_RH78 FALS-e54 induced pluripotent stem cell human CVCL_RH78 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Asp (c.1549C>G); Zygosity=Heterozygous (PubMed=26997647) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21111889 CVCL_RH60 TPB8 (DNAVEC) induced pluripotent stem cell human CVCL_RH60 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111890 CVCL_RH62 FTD2E1 induced pluripotent stem cell human CVCL_RH62 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+14C>T (IVS10+14C>T) (c.915+14C>T) (g.123817C>T); ClinVar=VCV000014248; Zygosity=Unspecified (PubMed=27721502) Derived from sampling site: Peripheral blood. Female 21111891 CVCL_RH61 PL506 somatic stem cell human CVCL_RH61 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Unspecified 21111892 CVCL_RH64 ND40071E11 induced pluripotent stem cell human CVCL_RH64 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (PubMed=27721502) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111893 CVCL_RH63 FTD2E1 corrected 36-20 induced pluripotent stem cell human CVCL_RH63 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; c.1866+14C>T (IVS10+14C>T) (c.915+14C>T) (g.123817C>T); ClinVar=VCV000014248; Zygosity=Unspecified; Note=By CRISPR/Cas9 (PubMed=27721502) Derived from sampling site: Peripheral blood. Female 21111894 CVCL_RH66 60FSDNC1 induced pluripotent stem cell human CVCL_RH66 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin but did not experience cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111895 CVCL_RH65 59FSDNC3 induced pluripotent stem cell human CVCL_RH65 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin but did not experience cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111896 CVCL_RH68 65FSDNC2 induced pluripotent stem cell human CVCL_RH68 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin but did not experience cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111897 CVCL_RH67 64FSDNC1 induced pluripotent stem cell human CVCL_RH67 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin but did not experience cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111898 CVCL_RH69 31FSDNC14 induced pluripotent stem cell human CVCL_RH69 CL:0000010 Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111899 CVCL_RH51 TFK7 (DNAVEC) induced pluripotent stem cell human CVCL_RH51 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21111900 CVCL_RH50 KA23 induced pluripotent stem cell human CVCL_RH50 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21111901 CVCL_RH53 TKA14 (DNAVEC) induced pluripotent stem cell human CVCL_RH53 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111902 CVCL_RH52 TFK12 (DNAVEC) induced pluripotent stem cell human CVCL_RH52 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21111903 CVCL_RH55 TKA7 (DNAVEC) induced pluripotent stem cell human CVCL_RH55 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111904 CVCL_RH54 TKA4 (AIST) induced pluripotent stem cell human CVCL_RH54 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21111905 CVCL_RH57 TPB11 (DNAVEC) induced pluripotent stem cell human CVCL_RH57 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21111906 CVCL_RH56 TKA9 (AIST) induced pluripotent stem cell human CVCL_RH56 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21111907 CVCL_RH59 TPB4 (DNAVEC) induced pluripotent stem cell human CVCL_RH59 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111908 CVCL_RH58 TPB27 (DNAVEC) induced pluripotent stem cell human CVCL_RH58 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21111909 CVCL_RH40 ND50046 induced pluripotent stem cell human CVCL_RH40 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111910 CVCL_IN99 MDA435/LCC6 cancer cell line human CVCL_IN99 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21111911 CVCL_RH42 ND50048 induced pluripotent stem cell human CVCL_RH42 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111912 CVCL_RH41 ND50047 induced pluripotent stem cell human CVCL_RH41 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111913 CVCL_RH44 BRC6(feeder-free) embryonic stem cell house mouse CVCL_RH44 CL:0000010 Breed/subspecies: C57BL/6. Female Characteristics: Can be maintained in undifferentiated state on hydroxyapatite coated with gelatin Group: Serum/protein free medium cell line 21111914 CVCL_IN96 UACC-1940 cancer cell line human CVCL_IN96 CL:0000010 21111915 CVCL_RH43 B6-6(feeder-free) embryonic stem cell house mouse CVCL_RH43 CL:0000010 Breed/subspecies: C57BL/6NCrSlc. Male Characteristics: Can be maintained in undifferentiated state on hydroxyapatite coated with gelatin Group: Serum/protein free medium cell line 21111916 CVCL_IN95 HLY-1 eIF4E3 cancer cell line human CVCL_IN95 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Ser206Cys (c.617C>G) (p.Ser219Cys, c.656C>G) (S219C); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 31837; EIF4E3 Omics: Transcriptome analysis by microarray. Unspecified 21111917 CVCL_RH46 eKA4 induced pluripotent stem cell human CVCL_RH46 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111918 CVCL_IN98 SVOG-3e transformed cell line human CVCL_IN98 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21111919 CVCL_RH45 eKA3 induced pluripotent stem cell human CVCL_RH45 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21111920 CVCL_IN97 UACC-3291 cancer cell line human CVCL_IN97 CL:0000010 21111921 CVCL_RH48 eTKA5 induced pluripotent stem cell human CVCL_RH48 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111922 CVCL_IN92 JTC-6 finite cell line Norway rat CVCL_IN92 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Unspecified 21111923 CVCL_RH47 eTKA4 induced pluripotent stem cell human CVCL_RH47 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21111924 CVCL_IN91 JTC-20.P3 spontaneously immortalized cell line Norway rat CVCL_IN91 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.. Group: Serum/protein free medium cell line 21111925 CVCL_IN94 HLY-1 eIF4E1 cancer cell line human CVCL_IN94 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Ser206Cys (c.617C>G) (p.Ser219Cys, c.656C>G) (S219C); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3287; EIF4E Omics: Transcriptome analysis by microarray. Unspecified 21111926 CVCL_RH49 KA11 induced pluripotent stem cell human CVCL_RH49 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21111927 CVCL_IN93 SMU1-10 conditionally immortalized cell line house mouse CVCL_IN93 CL:0000010 Derived from sampling site: Uterus; myometrium Cell type=Uterine smooth muscle cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Female Characteristics: At the permissive temperature (33 Celsius) grow continuously At the restrictive temperature (39 Celsius) stop dividing and ultimately die within 3 weeks. 21111928 CVCL_RH29 DPZcjESC2 embryonic stem cell CVCL_RH29 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 21111929 CVCL_RH31 DPZcjESC4 embryonic stem cell CVCL_RH31 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Group: Non-human primate cell line 21111930 CVCL_RH30 DPZcjESC3 embryonic stem cell CVCL_RH30 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 21111931 CVCL_RH33 ND50036 induced pluripotent stem cell human CVCL_RH33 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21111932 CVCL_RH32 cjes001 embryonic stem cell CVCL_RH32 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 21111933 CVCL_RH35 ND50038 induced pluripotent stem cell human CVCL_RH35 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Discontinued: NHCDR; ND50038; true Male 21111934 CVCL_RH34 ND50037 induced pluripotent stem cell human CVCL_RH34 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111935 CVCL_RH37 ND50043 induced pluripotent stem cell human CVCL_RH37 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111936 CVCL_RH36 ND50039 induced pluripotent stem cell human CVCL_RH36 From: Lonza, Inc.; Basel; Switzerland CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 21111937 CVCL_RH39 ND50045 induced pluripotent stem cell human CVCL_RH39 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111938 CVCL_RH38 ND50044 induced pluripotent stem cell human CVCL_RH38 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111939 CVCL_RH19 CLC13 cancer cell line human CVCL_RH19 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ile (c.122C>T); ClinVar=VCV000017587; Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Asp (c.314G>A); ClinVar=VCV000141114; Zygosity=Unspecified (PubMed=27273737; PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: Liver Cancer Model Repository (LIMORE) 21111940 CVCL_RH18 CLC11 cancer cell line human CVCL_RH18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Phe (c.713G>T); ClinVar=VCV000376574; Zygosity=Unspecified (PubMed=27273737) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 21111941 CVCL_IN78 mTEC1-CF conditionally immortalized cell line house mouse CVCL_IN78 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88388; Cftr; Sequence variation: Mutation; MGI; MGI:88388; Cftr; Simple; p.Ser489Ter (c.1466C>A); Zygosity=Homozygous (PubMed=11121394) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x (C57BL/6J x 129)Cftr-/-]. Unspecified 21111942 CVCL_IN77 mTEC1 conditionally immortalized cell line house mouse CVCL_IN77 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21111943 CVCL_RH20 CLC16 cancer cell line human CVCL_RH20 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; c.934-2A>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783-2A>T; ClinVar=VCV000635385; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 21111944 CVCL_IN79 CFI-3 transformed cell line human CVCL_IN79 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Asn (c.1646G>A); ClinVar=VCV000007116; Zygosity=Heterozygous (PubMed=15463957); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Heterozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Doubling time: 24 hours (PubMed=1718974) 21111945 CVCL_RH22 DPZcj_iPSC1 induced pluripotent stem cell CVCL_RH22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21111946 CVCL_IN74 mPEC1-CF conditionally immortalized cell line house mouse CVCL_IN74 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88388; Cftr; Sequence variation: Mutation; MGI; MGI:88388; Cftr; Simple; p.Ser489Ter (c.1466C>A); Zygosity=Homozygous (PubMed=11121394) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Ductal cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x (C57BL/6J x 129)Cftr-/-]. Unspecified 21111947 CVCL_IN73 mPEC1 conditionally immortalized cell line house mouse CVCL_IN73 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Ductal cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21111948 CVCL_RH21 WG0707 finite cell line human CVCL_RH21 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21111949 CVCL_RH24 DPZcj_iPSC3 induced pluripotent stem cell CVCL_RH24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 21111950 CVCL_IN76 mSEC1-CF conditionally immortalized cell line house mouse CVCL_IN76 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88388; Cftr; Sequence variation: Mutation; MGI; MGI:88388; Cftr; Simple; p.Ser489Ter (c.1466C>A); Zygosity=Homozygous (PubMed=11121394) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x (C57BL/6J x 129)Cftr-/-]. Unspecified 21111951 CVCL_RH23 DPZcj_iPSC2 induced pluripotent stem cell CVCL_RH23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 21111952 CVCL_IN75 mSEC1 conditionally immortalized cell line house mouse CVCL_IN75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21111953 CVCL_RH26 DPZcj_iPSC5 induced pluripotent stem cell CVCL_RH26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 21111954 CVCL_IN70 JME/CF 15 transformed cell line human CVCL_IN70 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified 21111955 CVCL_RH25 DPZcj_iPSC4 induced pluripotent stem cell CVCL_RH25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 21111956 CVCL_RH28 DPZcjESC1 embryonic stem cell CVCL_RH28 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Group: Non-human primate cell line 21111957 CVCL_IN72 mCT1-CF conditionally immortalized cell line house mouse CVCL_IN72 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88388; Cftr; Sequence variation: Mutation; MGI; MGI:88388; Cftr; Simple; p.Ser489Ter (c.1466C>A); Zygosity=Homozygous (PubMed=11121394) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x (C57BL/6J x 129)Cftr-/-]. Unspecified 21111958 CVCL_RH27 DPZcj_iPSC6 induced pluripotent stem cell CVCL_RH27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Group: Non-human primate cell line 21111959 CVCL_IN71 mCT1 conditionally immortalized cell line house mouse CVCL_IN71 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct Cell type=Epithelial cell.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21111960 CVCL_RH08 SEES4 embryonic stem cell human CVCL_RH08 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan. CL:0000010 Female 21111961 CVCL_RH07 HPS1013 induced pluripotent stem cell human CVCL_RH07 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21111962 CVCL_IN90 JTC-24.P3 spontaneously immortalized cell line Norway rat CVCL_IN90 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified Group: Serum/protein free medium cell line 21111963 CVCL_RH09 SEES5 embryonic stem cell human CVCL_RH09 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan. CL:0000010 Female 21111964 CVCL_IN89 JTC-23.P3 spontaneously immortalized cell line Norway rat CVCL_IN89 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified Group: Serum/protein free medium cell line 21111965 CVCL_IN88 JTC-22.P3 spontaneously immortalized cell line Norway rat CVCL_IN88 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified Group: Serum/protein free medium cell line 21111966 CVCL_IN85 JTC-13 cancer cell line house mouse CVCL_IN85 CL:0000010 21111967 CVCL_RH11 SEES7 embryonic stem cell human CVCL_RH11 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan. CL:0000010 Female 21111968 CVCL_IN84 NCF3A transformed cell line human CVCL_IN84 CL:0000010 Transformant: Ad12-SV40 hybrid virus. Male 21111969 CVCL_RH10 SEES6 embryonic stem cell human CVCL_RH10 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan. CL:0000010 Male 21111970 CVCL_RH13 CLC2 cancer cell line human CVCL_RH13 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Leu618Profs*39 (c.1852dupC); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31.11 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21111971 CVCL_IN87 JTC-21.P3 spontaneously immortalized cell line Norway rat CVCL_IN87 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified Group: Serum/protein free medium cell line 21111972 CVCL_RH12 CLC1 cancer cell line human CVCL_RH12 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Arg (c.100G>A); ClinVar=VCV000376232; Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Met (c.427G>A); ClinVar=VCV000142657; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 33.28 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21111973 CVCL_IN86 JTC-14 cancer cell line house mouse CVCL_IN86 CL:0000010 21111974 CVCL_RH15 CLC5 cancer cell line human CVCL_RH15 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Glu709Ter (c.2125G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu68Ter (c.202G>T); ClinVar=VCV000224551; Zygosity=Unspecified (PubMed=27273737; PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: Liver Cancer Model Repository (LIMORE) 21111975 CVCL_IN81 MM-39 transformed cell line human CVCL_IN81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea gland Cell type=Serous cell of epithelium of trachea.. Male 21111976 CVCL_IN80 CF-KM4 transformed cell line human CVCL_IN80 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=10101000) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea gland Cell type=Serous cell of epithelium of trachea.. Unspecified 21111977 CVCL_RH14 CLC4 cancer cell line human CVCL_RH14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42.81 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21111978 CVCL_RH17 CLC7 cancer cell line human CVCL_RH17 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 21111979 CVCL_IN83 NCF3 transformed cell line human CVCL_IN83 CL:0000010 Transformant: Ad12-SV40 hybrid virus. Male 21111980 CVCL_RH16 CLC6 cancer cell line human CVCL_RH16 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys652Ter (c.1954A>T); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28.68 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21111981 CVCL_IN82 CuFi-2 transformed cell line human CVCL_IN82 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21111982 CVCL_A700 UKRV-Mel-02 cancer cell line human CVCL_A700 HLA typing: A*01:01,25:01; B*08:01,18:01; C*07:01:01,12:04:02; DPB1*02:01:02,15:01; DQB1*06:02,02:01; DRB1*15:01,07:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Pleural effusion. Female 21111983 CVCL_A702 UKRV-Mel-04 cancer cell line human CVCL_A702 CL:0000010 Derived from metastatic site: Liver. Female 21111984 CVCL_A701 UKRV-Mel-03 cancer cell line human CVCL_A701 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21111985 CVCL_A704 UKRV-Mel-06a cancer cell line human CVCL_A704 HLA typing: A*02:01,01:01; B*15:01:01:01,40:01; C*03:04,03:03; DPB1*04:01,03:01; DQB1*06:04,03:02; DRB1*04:01,13:02 (PubMed=15592718) CL:0000010 Derived from metastatic site: Skin. Female 21111986 CVCL_A703 UKRV-Mel-05 cancer cell line human CVCL_A703 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21111987 CVCL_A706 UKRV-Mel-07 cancer cell line human CVCL_A706 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Skin. Unspecified 21111988 CVCL_A705 UKRV-Mel-06b cancer cell line human CVCL_A705 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Female 21111989 CVCL_A711 UKRV-Mel-14b cancer cell line human CVCL_A711 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21111990 CVCL_A710 UKRV-Mel-14a cancer cell line human CVCL_A710 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala148Thr (c.442G>A); ClinVar=VCV000041580; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu326fs (c.976insGA); Zygosity=Unspecified (PubMed=23851445). Female 21111991 CVCL_A713 UKRV-Mel-15a cancer cell line human CVCL_A713 HLA typing: A*02:01,11:01; B*15:01:01:01,56:01; C*01:02,03:03; DPB1*04:01; DQB1*06:02,05:01; DRB1*01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=23851445). 21111992 CVCL_A712 UKRV-Mel-15 cancer cell line human CVCL_A712 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-149C>T (c.253C>T) (C253T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21111993 CVCL_A715 UKRV-Mel-16 cancer cell line human CVCL_A715 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21111994 CVCL_A714 UKRV-Mel-15d cancer cell line human CVCL_A714 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-149C>T (c.253C>T) (C253T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21111995 CVCL_A717 UKRV-Mel-18a cancer cell line human CVCL_A717 CL:0000010 Male 21111996 CVCL_A716 UKRV-Mel-17 cancer cell line human CVCL_A716 HLA typing: A*01:01,03:01; B*15:01:01:01,57:01:01; C*06:02,03:04; DPB1*04:01; DQB1*03:02,02:01; DRB1*04:01,03:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503; PubMed=23851445) Derived from metastatic site: Lymph node. Male 21111997 CVCL_A708 UKRV-Mel-11 cancer cell line human CVCL_A708 CL:0000010 Derived from metastatic site: Lymph node. Male 21111998 CVCL_A707 UKRV-Mel-10 cancer cell line human CVCL_A707 CL:0000010 Unspecified 21111999 CVCL_A709 UKRV-Mel-12 cancer cell line human CVCL_A709 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21112000 CVCL_A788 NCI-N231 cancer cell line human CVCL_A788 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=10536175) Derived from sampling site: Lung. Female Characteristics: Established from a mouse xenograft 21112001 CVCL_A787 PC-7/CPT cancer cell line human CVCL_A787 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly719Ser (c.2155G>A); ClinVar=VCV000016612; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Thr729Ala (c.2185G>A); Zygosity=Unspecified (PubMed=1332703) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Lymph node. Male 21112002 CVCL_A789 SCL-I cancer cell line human CVCL_A789 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val197Ter; Zygosity=Unspecified (PubMed=11992403) Population: Caucasian; Derived from sampling site: Face; skin. Female Doubling time: ~50-60 hours (CLS) 21112003 CVCL_A780 RXF 631L cancer cell line human CVCL_A780 CL:0000010 Part of: JFCR39 cancer cell line panel. 21112004 CVCL_A782 ILT-Mat transformed cell line human CVCL_A782 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908) Discontinued: RCB; RCB1880; true. Male Characteristics: IL2 dependent 21112005 CVCL_A781 N1511 spontaneously immortalized cell line house mouse CVCL_A781 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Rib; cartilage; Breed/subspecies: C57BL/6 Trp53-/-. Male 21112006 CVCL_J118 CNLMG-B5537SKIN finite cell line human CVCL_J118 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96002 21112007 CVCL_A784 HEK293S transformed cell line human CVCL_A784 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Genome sequenced Female Characteristics: Adapted to growth in suspension 21112008 CVCL_IP18 HL-60/AMSA cancer cell line human CVCL_IP18 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11989; TOP2A; Simple; p.Arg487Lys (c.1460G>A); ClinVar=VCV000016772; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=1311390) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Derived from sampling site: Peripheral blood. Female 21112009 CVCL_A783 293-LA transformed cell line human CVCL_A783 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21112010 CVCL_J117 CNLMG-B5537LC transformed cell line human CVCL_J117 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96001 21112011 CVCL_IP17 KB-CP5 cancer cell line human CVCL_IP17 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21112012 CVCL_A786 PC-7 cancer cell line human CVCL_A786 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly719Ser (c.2155G>A); ClinVar=VCV000016612; Zygosity=Unspecified (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from metastatic site: Lymph node. Male 21112013 CVCL_J119 CNLMG-B5538LC transformed cell line human CVCL_J119 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96003 21112014 CVCL_A785 HEK293S GnTI- transformed cell line human CVCL_A785 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Fetal kidney. Female Characteristics: Lacks N-acetylglucosaminyltransferase I activity and accordingly predominantly modifies glycoproteins with the Man5GlcNAc2 N-glycan Used for the production of homogenously N-glycosylated proteins (PubMed=25182477). 21112015 CVCL_IP19 KBM-3/AMSA cancer cell line human CVCL_IP19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11989; TOP2A; Simple; p.Arg487Lys (c.1460G>A); ClinVar=VCV000016772; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=1311390) Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Derived from sampling site: Peripheral blood. Female 21112016 CVCL_IP14 DIPG 4 cancer cell line human CVCL_IP14 CL:0000010 Characteristics: Low-passage-number culture. 21112017 CVCL_J114 GM01387 finite cell line human CVCL_J114 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,+der(9)(9pter->9q21.2::13q12.1->13qter)mat,-13 (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21112018 CVCL_IP13 BT 245 cancer cell line human CVCL_IP13 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022). Unspecified Characteristics: Low-passage-number culture 21112019 CVCL_J113 GM01388 transformed cell line human CVCL_J113 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21112020 CVCL_IP16 BEL-7404-CP.3 cancer cell line human CVCL_IP16 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (BEL-7404) has been shown to be a HeLa derivative. 21112021 CVCL_J116 GM01410 transformed cell line human CVCL_J116 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112022 CVCL_IP15 DIPG 6 cancer cell line human CVCL_IP15 CL:0000010 Characteristics: Low-passage-number culture. 21112023 CVCL_J115 GM01409 finite cell line human CVCL_J115 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21112024 CVCL_IP10 BT 145 cancer cell line human CVCL_IP10 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727). Characteristics: Low-passage-number culture 21112025 CVCL_J110 GM01311 transformed cell line human CVCL_J110 CL:0000010 Population: African American; Derived from sampling site: Bone marrow. Discontinued: Coriell; AG01311; probable Male Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21112026 CVCL_IP12 BT 172 cancer cell line human CVCL_IP12 CL:0000010 Characteristics: Low-passage-number culture. 21112027 CVCL_J112 GM01363 transformed cell line human CVCL_J112 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Ala11Ala (c.33G>C); ClinVar=VCV000640707; Zygosity=Heterozygous; Note=Silent mutation that may affect splicing (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112028 CVCL_IP11 BT 159 cancer cell line human CVCL_IP11 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727). Characteristics: Low-passage-number culture 21112029 CVCL_J111 GM01312 transformed cell line human CVCL_J111 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG01312; probable Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00201 Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=20143388). 21112030 CVCL_A799 TSA8 cancer cell line house mouse CVCL_A799 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21112031 CVCL_A798 BS-SHI-4M transformed cell line human CVCL_A798 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Peripheral blood. Male 21112032 CVCL_A791 HS-RMS-1 cancer cell line human CVCL_A791 CL:0000010 Population: Japanese; Derived from sampling site: Left gluteal muscle. Male Doubling time: ~60 hours (PubMed=10853028) 21112033 CVCL_A790 SCL-II cancer cell line human CVCL_A790 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=11992403) Population: Caucasian; Derived from sampling site: Face; skin. Male Doubling time: ~40-50 hours (CLS) 21112034 CVCL_A793 Deglis cancer cell line human CVCL_A793 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21112035 CVCL_A792 RMS-YM cancer cell line human CVCL_A792 CL:0000010 Population: Japanese; Derived from sampling site: Urachus. Omics: Transcriptome analysis by microarray Male Doubling time: ~30 hours (PubMed=1906291) 21112036 CVCL_IP29 LAU-Me204.A1 cancer cell line human CVCL_IP29 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112037 CVCL_A795 UPN1 cancer cell line human CVCL_A795 HLA typing: A*24,32; B*07,18; C*07,07 (PubMed=25688540) CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=17332242); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Homozygous (PubMed=16960149; PubMed=17332242) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21112038 CVCL_J129 XQH cancer cell line human CVCL_J129 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Infected with Ehrlichia Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11864 21112039 CVCL_A794 HL-60(TB) cancer cell line human CVCL_A794 HLA typing: A*01:01:01; B*57:01:01; C*06:02; DPB1*04:01,13:01; DQB1*03:03:02 (PubMed=15748285) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=17088437) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 28.6 hours (NCI-DTP) Part of: NCI-60 cancer cell line panel 21112040 CVCL_IP28 LAU-Me200 cancer cell line human CVCL_IP28 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Female 21112041 CVCL_J128 VXG3 cancer cell line human CVCL_J128 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Infected with Ehrlichia Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11865 21112042 CVCL_A796 UPN2 cancer cell line human CVCL_A796 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=16960149) Derived from sampling site: Pleural effusion. Omics: Array-based CGH Male 21112043 CVCL_IP25 MI8-5 spontaneously immortalized cell line CVCL_IP25 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Lacks glucosyltransferase I (ALG6) activity 21112044 CVCL_J125 SK-beta2.7 cancer cell line human CVCL_J125 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Male Problematic cell line: Contaminated Parent cell line (SKW-3) has been shown to be a KE-37 derivative. 21112045 CVCL_J124 J-beta2.7 cancer cell line human CVCL_J124 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21112046 CVCL_IP24 MI5-4 spontaneously immortalized cell line CVCL_IP24 CL:0000010 Derived from sampling site: Ovary. Female 21112047 CVCL_J127 HOP-1 somatic stem cell human CVCL_J127 CL:0000010 Derived from sampling site: Fetal brain Cell type=Oligodendrocyte precursor cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11881 21112048 CVCL_IP27 LAU-Me190 cancer cell line human CVCL_IP27 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112049 CVCL_J126 HY3-11.27 hybridoma house mouse CVCL_J126 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human H-Y antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8116 21112050 CVCL_IP26 TU-ECS-1 cancer cell line human CVCL_IP26 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27889902); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala189Val (c.566C>T); ClinVar=VCV000012382; Zygosity=Unspecified (PubMed=27889902); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=27889902) Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 18.2 +- 2.1 hours (PubMed=27889902) 21112051 CVCL_IP21 PC346DCC cancer cell line human CVCL_IP21 CL:0000010 Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Proliferation of this cell line is androgen-independent 21112052 CVCL_J121 SMC-1 cancer cell line human CVCL_J121 CL:0000010 Population: Chinese Male Doubling time: ~32 hours (PubMed=3159086). 21112053 CVCL_IP20 BT-474c1 cancer cell line human CVCL_IP20 From: AstraZeneca; Cambridge; United Kingdom CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female 21112054 CVCL_J120 CNLMG-B5538SKIN finite cell line human CVCL_J120 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96004 21112055 CVCL_IP23 PC346Flu2 cancer cell line human CVCL_IP23 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=15900601) Selected for resistance to: ChEBI; CHEBI:5132; Flutamide; Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Proliferation of this cell line is androgen-independent 21112056 CVCL_J123 T61577 cancer cell line Norway rat CVCL_J123 CL:0000010 Transformant: N-butyl-N-(3-carboxypropyl)nitrosamine (BCPN)(ChEBI; CHEBI:91112); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI. Male 21112057 CVCL_J122 804 G cancer cell line Norway rat CVCL_J122 CL:0000010 Transformant: N-butyl-N-(3-carboxypropyl)nitrosamine (BCPN)(ChEBI; CHEBI:91112); Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: ACI. Male 21112058 CVCL_IP22 PC346Flu1 cancer cell line human CVCL_IP22 CL:0000010 Selected for resistance to: ChEBI; CHEBI:5132; Flutamide; Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Proliferation of this cell line is androgen-independent 21112059 CVCL_A766 OH-3 cancer cell line human CVCL_A766 CL:0000010 21112060 CVCL_A765 OH-1 cancer cell line human CVCL_A765 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21112061 CVCL_A768 OVAS-21 cancer cell line human CVCL_A768 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 46 hours (CelloPub=CLPUB00096) 21112062 CVCL_A767 OK-92 cancer cell line human CVCL_A767 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Unspecified 21112063 CVCL_A769 OVHS-1 cancer cell line human CVCL_A769 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu914Lys (c.2740G>A); ClinVar=VCV000479250; Zygosity=Unspecified (PubMed=28273451); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala305Gly; Zygosity=Unspecified (PubMed=28273451); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Unspecified (PubMed=28273451); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Unspecified (PubMed=28273451) Omics: Transcriptome analysis by RNAseq Female 21112064 CVCL_A760 ARK cancer cell line human CVCL_A760 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=11157491) Derived from sampling site: Bone marrow. Unspecified 21112065 CVCL_A762 DFCI024 cancer cell line human CVCL_A762 HLA typing: A*24:02,33:01:01; B*04:02:01,35:02:01; C*08:02,04:01:01 (PubMed=26929325) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-001058; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21112066 CVCL_A761 AS283A cancer cell line human CVCL_A761 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu206Trpfs*41 (c.617delT); Zygosity=Unspecified (PubMed=2052620) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray 21112067 CVCL_A764 OEE-III cancer cell line human CVCL_A764 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Unspecified; Note=Somatic (CelloPub=CLPUB00412) Derived from metastatic site: Lymph node. Female 21112068 CVCL_A763 DFCI032 cancer cell line human CVCL_A763 HLA typing: A*02:01:01; B*44:02,51:01; C*05:01:01 (PubMed=26929325) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: MD Anderson Cell Lines Project 21112069 CVCL_A777 MM648 cancer cell line human CVCL_A777 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21112070 CVCL_A776 MM649 cancer cell line human CVCL_A776 CL:0000010 Sequence variation: Gene deletion; HGNC; 7989; NRAS; Zygosity=Homozygous (PubMed=15048078); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21112071 CVCL_A779 M14-A cancer cell line human CVCL_A779 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male 21112072 CVCL_A778 HOUA-II transformed cell line human CVCL_A778 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Endometrium. Female Doubling time: 60 hours (CelloPub=CLPUB00051) 21112073 CVCL_A771 XG-6 cancer cell line human CVCL_A771 HLA typing: A*02; B*15,37; C*03:03,06:02 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda; Characteristics: IL6 dependent 21112074 CVCL_A770 SMS-CTR cancer cell line human CVCL_A770 From: Reynolds C.P.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Homozygous (PubMed=22142829; DepMap) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21112075 CVCL_IP07 BEL-7404-CP1 cancer cell line human CVCL_IP07 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (BEL-7404) has been shown to be a HeLa derivative. 21112076 CVCL_J107 GM00736 transformed cell line human CVCL_J107 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112077 CVCL_A773 XG-8 cancer cell line human CVCL_A773 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgA lambda; Characteristics: IL6 dependent 21112078 CVCL_J106 GM00504 transformed cell line human CVCL_J106 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly542Ter (c.1624G>T); ClinVar=VCV000007115; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.His609Arg (c.1826A>G); ClinVar=VCV000053398; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112079 CVCL_IP06 KB-CP20 cancer cell line human CVCL_IP06 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21112080 CVCL_A772 XG-7 cancer cell line human CVCL_A772 HLA typing: A*02:01,24; B*07,40; C*02:02,07 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21112081 CVCL_IP09 BEL-7404-CP20 cancer cell line human CVCL_IP09 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (BEL-7404) has been shown to be a HeLa derivative. 21112082 CVCL_J109 GM01261 transformed cell line human CVCL_J109 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112083 CVCL_A775 NAN-1 cancer cell line human CVCL_A775 HLA typing: A*01,02; B*44; C*16:01 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000634687; Zygosity=Unspecified (PubMed=21173094) Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21112084 CVCL_IP08 BEL-7404-CP7.5 cancer cell line human CVCL_IP08 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (BEL-7404) has been shown to be a HeLa derivative. 21112085 CVCL_J108 GM00781 transformed cell line human CVCL_J108 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112086 CVCL_A774 XG-9 cancer cell line human CVCL_A774 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21112087 CVCL_IP03 A549-CR cancer cell line human CVCL_IP03 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Male 21112088 CVCL_J103 GM00235 transformed cell line human CVCL_J103 HLA typing: A*09,w31/33; B*w15,12 (Coriell=GM00235) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112089 CVCL_J102 1B7.11 hybridoma house mouse CVCL_J102 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53067; 2,4,6-trinitrophenyl group (TNP). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21112090 CVCL_IP02 V2387 cancer cell line human CVCL_IP02 CL:0000010 Derived from metastatic site: Lymph node. 21112091 CVCL_J105 GM00467 transformed cell line human CVCL_J105 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112092 CVCL_IP05 KB-CP10 cancer cell line human CVCL_IP05 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21112093 CVCL_J104 GM00390 transformed cell line human CVCL_J104 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112094 CVCL_IP04 KB-CP.5 cancer cell line human CVCL_IP04 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21112095 CVCL_J101 1B2-1B7 hybridoma house mouse CVCL_J101 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Terminal N-acetyllactosamine of glycosphingolipids. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21112096 CVCL_IP01 K457 cancer cell line human CVCL_IP01 CL:0000010 21112097 CVCL_J100 1A3.1 hybridoma house mouse CVCL_J100 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Giardia muris trophozoite surface antigens. 21112098 CVCL_IP00 MDA435/LCC6MDR1 cancer cell line human CVCL_IP00 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 40; ABCB1 Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21112099 CVCL_A744 YUGEN8 cancer cell line human CVCL_A744 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Brain. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21112100 CVCL_A743 YS9;22 cancer cell line human CVCL_A743 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7808006; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21112101 CVCL_A746 YUSAC2 cancer cell line human CVCL_A746 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136) Derived from metastatic site: Neck; hypodermis. Male Part of: Yale University (YU) melanoma cell collection 21112102 CVCL_A745 YUMAC cancer cell line human CVCL_A745 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Thigh; hypodermis. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21112103 CVCL_A748 SK-PN-LI cancer cell line human CVCL_A748 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=8040301; PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Ser704fs; Zygosity=Unspecified (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Unspecified (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=25010205) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21112104 CVCL_A747 YUSIT1 cancer cell line human CVCL_A747 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21112105 CVCL_A749 SMKT-R1 cancer cell line human CVCL_A749 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 180 hours (PubMed=2815432) 21112106 CVCL_A740 VMM5A cancer cell line human CVCL_A740 HLA typing: A*02:01; B*39 (PubMed=10752474) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21112107 CVCL_A742 Wx67 cancer cell line human CVCL_A742 CL:0000010 Unspecified 21112108 CVCL_A741 WDS3 cancer cell line human CVCL_A741 CL:0000010 21112109 CVCL_A755 TOS-3 cancer cell line human CVCL_A755 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 32 hours (PubMed=10775053) 21112110 CVCL_A754 TOS-2 cancer cell line human CVCL_A754 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary subcutaneous soft tissue. Male Doubling time: 37 hours (PubMed=10775053) 21112111 CVCL_A757 U-563MG cancer cell line human CVCL_A757 CL:0000010 Male 21112112 CVCL_A756 TOS-3LN cancer cell line human CVCL_A756 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 33 hours (PubMed=10775053) 21112113 CVCL_A759 Mel-2a cancer cell line human CVCL_A759 CL:0000010 Derived from metastatic site: Axillary lymph node. Female 21112114 CVCL_A758 U-178MG cancer cell line human CVCL_A758 HLA typing: A*01,02; B*07,12 (PubMed=77569); Genome ancestry: African=2.94%; Native American=0%; East Asian, North=4.06%; East Asian, South=0%; South Asian=0%; European, North=69.5%; European, South=23.49% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (PubMed=10560660; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Heterozygous (DepMap) Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 45 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21112115 CVCL_A751 SMKT-R3 cancer cell line human CVCL_A751 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Characteristics: Established from a xenotransplantable tumor at passage 1 in a nude mouse (PubMed=2815432) Doubling time: 55.7 hours (PubMed=2815432) 21112116 CVCL_A750 SMKT-R2 cancer cell line human CVCL_A750 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Characteristics: Established from a xenotransplantable tumor at passage 2 in a nude mouse (PubMed=2815432) Doubling time: 56.4 hours (PubMed=2815432) 21112117 CVCL_A753 TOS-1 cancer cell line human CVCL_A753 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Male Doubling time: 32 hours (PubMed=10775053) 21112118 CVCL_A752 SMKT-R4 cancer cell line human CVCL_A752 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21112119 CVCL_A722 UKRV-Mel-21a cancer cell line human CVCL_A722 HLA typing: A*02:01,23:01; B*44:02,44:03:01; C*04:01:01,05:01; DPB1*04:01; DQB1*03:01:01,02:01; DRB1*11:01,07:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Male 21112120 CVCL_A721 UKRV-Mel-20a cancer cell line human CVCL_A721 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21112121 CVCL_A724 UKRV-Mel-23 cancer cell line human CVCL_A724 CL:0000010 Unspecified 21112122 CVCL_A723 UKRV-Mel-22 cancer cell line human CVCL_A723 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21112123 CVCL_A726 UKRV-Mel-27 cancer cell line human CVCL_A726 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Unspecified 21112124 CVCL_A725 UKRV-Mel-24 cancer cell line human CVCL_A725 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503) Derived from metastatic site: Lymph node. Male 21112125 CVCL_A728 UKRV-Mel-31 cancer cell line human CVCL_A728 HLA typing: A*03:01,ND; B*44:03:01,27:05:02; DPB1*04:01,17:01; DQB1*03:01:01,02:01; DRB1*11:01,07:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21112126 CVCL_A727 UKRV-Mel-29 cancer cell line human CVCL_A727 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21112127 CVCL_A720 UKRV-Mel-19a cancer cell line human CVCL_A720 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-149C>T (c.253C>T) (C253T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21112128 CVCL_A719 UKRV-Mel-19 cancer cell line human CVCL_A719 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17311103) Derived from metastatic site: Lymph node. Female 21112129 CVCL_A718 UKRV-Mel-18b cancer cell line human CVCL_A718 CL:0000010 Male 21112130 CVCL_A733 VMM1040 cancer cell line human CVCL_A733 CL:0000010 Derived from sampling site: Shoulder; skin. Unspecified 21112131 CVCL_A732 VMM1 cancer cell line human CVCL_A732 HLA typing: A*03,26; B*51 (PubMed=10752474) CL:0000010 Derived from metastatic site: Brain. Omics: Transcriptome analysis by microarray Male 21112132 CVCL_A735 VMM14 cancer cell line human CVCL_A735 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21112133 CVCL_A734 VMM12 cancer cell line human CVCL_A734 HLA typing: A*01,03; B*07,14 (PubMed=10752474) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Unspecified 21112134 CVCL_A737 VMM18 cancer cell line human CVCL_A737 HLA typing: A*03,31/33; B*60 (PubMed=10752474) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21112135 CVCL_A736 VMM15 cancer cell line human CVCL_A736 HLA typing: A*01,25; B*08,18 (PubMed=10752474) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21112136 CVCL_A739 VMM39 cancer cell line human CVCL_A739 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21112137 CVCL_A738 VMM19 cancer cell line human CVCL_A738 CL:0000010 Unspecified 21112138 CVCL_A731 VAMT-1 cancer cell line human CVCL_A731 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Omics: SNP array analysis. Unspecified 21112139 CVCL_A730 UKRV-Mel-38 cancer cell line human CVCL_A730 HLA typing: A*01:01,32:01; B*08:01,44:02; C*05:01,07:01:01; DPB1*02:01:02,04:01; DQB1*03:01:01,03:03:02; DRB1*04:01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=23851445). Female 21112140 CVCL_A729 UKRV-Mel-37 cancer cell line human CVCL_A729 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Unspecified 21112141 CVCL_RI18 UiPSC-035 induced pluripotent stem cell human CVCL_RI18 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112142 CVCL_RI17 UiPSC-034 induced pluripotent stem cell human CVCL_RI17 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Unspecified 21112143 CVCL_RI19 UiPSC-036 induced pluripotent stem cell human CVCL_RI19 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112144 CVCL_J077 07-4D hybridoma house mouse CVCL_J077 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P33545; Bovine DSC2; Monoclonal antibody target: UniProtKB; Q28060; Bovine DSC3. 21112145 CVCL_J076 LND1 cancer cell line human CVCL_J076 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Unspecified (PubMed=23489693). 21112146 CVCL_J079 111A3 hybrid cell line house mouse CVCL_J079 CL:0000010 Group: Hybridoma fusion partner cell line. 21112147 CVCL_J078 11-5F hybridoma house mouse CVCL_J078 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01107; Bovine DSC1; Monoclonal antibody target: UniProtKB; P33545; Bovine DSC2. 21112148 CVCL_RI21 UiPSC-038 induced pluripotent stem cell human CVCL_RI21 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112149 CVCL_J073 YUHEIK cancer cell line human CVCL_J073 CL:0000010 Omics: Transcriptome analysis by microarray. Female Part of: Yale University (YU) melanoma cell collection 21112150 CVCL_RI20 UiPSC-037 induced pluripotent stem cell human CVCL_RI20 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112151 CVCL_J072 YUZOR cancer cell line human CVCL_J072 CL:0000010 Omics: Transcriptome analysis by microarray. Male Part of: Yale University (YU) melanoma cell collection 21112152 CVCL_J075 HBL cancer cell line human CVCL_J075 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Unspecified (PubMed=23489693). 21112153 CVCL_RI23 UiPSC-040 induced pluripotent stem cell human CVCL_RI23 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112154 CVCL_J074 LS174T-W4 cancer cell line human CVCL_J074 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Female 21112155 CVCL_RI22 UiPSC-039 induced pluripotent stem cell human CVCL_RI22 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112156 CVCL_RI25 UiPSC-042 induced pluripotent stem cell human CVCL_RI25 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112157 CVCL_RI24 UiPSC-041 induced pluripotent stem cell human CVCL_RI24 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-197C>T (IVS2-654C>T); ClinVar=VCV000015458; Zygosity=Heterozygous (PubMed=23940595) Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112158 CVCL_RI27 UiPSC-044 induced pluripotent stem cell human CVCL_RI27 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112159 CVCL_J071 YUTICA cancer cell line human CVCL_J071 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Pro1667Leu (c.5000C>T); Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112160 CVCL_RI26 UiPSC-043 induced pluripotent stem cell human CVCL_RI26 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112161 CVCL_J070 YUROL cancer cell line human CVCL_J070 CL:0000010 Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112162 CVCL_RI07 UiPSC-024 induced pluripotent stem cell human CVCL_RI07 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112163 CVCL_RI06 UiPSC-023 induced pluripotent stem cell human CVCL_RI06 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112164 CVCL_RI09 UiPSC-026 induced pluripotent stem cell human CVCL_RI09 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112165 CVCL_RI08 UiPSC-025 induced pluripotent stem cell human CVCL_RI08 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112166 CVCL_J088 162-46.2 hybridoma house mouse CVCL_J088 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. 21112167 CVCL_J087 162-21.2 hybridoma house mouse CVCL_J087 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16422; Human EPCAM/CD326. 21112168 CVCL_J089 16-3-1N hybridoma house mouse CVCL_J089 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21112169 CVCL_J084 15F3-1 hybridoma house mouse CVCL_J084 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17763; Dengue virus type 1 polyprotein. 21112170 CVCL_RI10 UiPSC-027 induced pluripotent stem cell human CVCL_RI10 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112171 CVCL_J083 151-6-A7-9 hybridoma house mouse CVCL_J083 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8324 21112172 CVCL_J086 16-1-2N hybridoma house mouse CVCL_J086 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21112173 CVCL_RI12 UiPSC-029 induced pluripotent stem cell human CVCL_RI12 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112174 CVCL_J085 16-1-11N hybridoma house mouse CVCL_J085 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21112175 CVCL_RI11 UiPSC-028 induced pluripotent stem cell human CVCL_RI11 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112176 CVCL_J080 15-79-2 hybridoma house mouse CVCL_J080 CL:0000010 Characteristics: The hybridoma produces, but do not secrete IgM chain No light chain is produced.; Monoclonal antibody isotype: IgM. 21112177 CVCL_RI14 UiPSC-031 induced pluripotent stem cell human CVCL_RI14 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112178 CVCL_RI13 UiPSC-030 induced pluripotent stem cell human CVCL_RI13 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112179 CVCL_J082 151-5-G3-5 hybridoma house mouse CVCL_J082 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A); Monoclonal antibody target: ChEBI; CHEBI:59440; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc (Lewis B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8323 21112180 CVCL_RI16 UiPSC-033 induced pluripotent stem cell human CVCL_RI16 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112181 CVCL_J081 151-5-G2-12 hybridoma house mouse CVCL_J081 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A); Monoclonal antibody target: ChEBI; CHEBI:59440; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc (Lewis B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8322 21112182 CVCL_RI15 UiPSC-032 induced pluripotent stem cell human CVCL_RI15 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112183 CVCL_J059 Z41 hybridoma house mouse CVCL_J059 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse IgG2a. 21112184 CVCL_J058 Z34 hybridoma house mouse CVCL_J058 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: Influenza A virus isolate A/Puerto Rico/8/1934. 21112185 CVCL_J055 Ab 23.1 hybridoma house mouse CVCL_J055 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11602 21112186 CVCL_J054 Ab 21.1 hybridoma house mouse CVCL_J054 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11601 21112187 CVCL_J057 Z26 hybridoma house mouse CVCL_J057 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse IgG2a. 21112188 CVCL_J056 Z2 hybridoma house mouse CVCL_J056 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse IgG2a. 21112189 CVCL_J051 94A1 hybridoma house mouse CVCL_J051 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Sheep red blood cells (SRBC). Group: Hybridoma fusion partner cell line 21112190 CVCL_J050 NB3 hybridoma house mouse CVCL_J050 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Doubling time: 34 hours (ATCC=HB-10205) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10205 21112191 CVCL_J053 AA5 hybridoma house mouse CVCL_J053 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P30944; Xenopus laevis cad1. 21112192 CVCL_RI01 UiPSC-018 induced pluripotent stem cell human CVCL_RI01 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112193 CVCL_J052 7R2/A4 hybridoma house mouse CVCL_J052 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. 21112194 CVCL_RI00 UiPSC-017 induced pluripotent stem cell human CVCL_RI00 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112195 CVCL_RI03 UiPSC-020 induced pluripotent stem cell human CVCL_RI03 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112196 CVCL_RI02 UiPSC-019 induced pluripotent stem cell human CVCL_RI02 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112197 CVCL_RI05 UiPSC-022 induced pluripotent stem cell human CVCL_RI05 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112198 CVCL_RI04 UiPSC-021 induced pluripotent stem cell human CVCL_RI04 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112199 CVCL_J069 YUPLA cancer cell line human CVCL_J069 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112200 CVCL_J066 YUCOT cancer cell line human CVCL_J066 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Yale University (YU) melanoma cell collection 21112201 CVCL_J065 YUCAS cancer cell line human CVCL_J065 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Ile679Aspfs*21 (c.2033dupC); ClinVar=VCV000141513; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112202 CVCL_J068 YUKSI cancer cell line human CVCL_J068 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112203 CVCL_J067 YUGOE cancer cell line human CVCL_J067 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000040470; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21112204 CVCL_J062 54B3 hybrid cell line house mouse CVCL_J062 CL:0000010 Group: Hybridoma fusion partner cell line. 21112205 CVCL_J061 53B3 hybrid cell line house mouse CVCL_J061 CL:0000010 Group: Hybridoma fusion partner cell line. 21112206 CVCL_J064 15-1-5P hybridoma house mouse CVCL_J064 CL:0000010 Monoclonal antibody isotype: IgG2b. 21112207 CVCL_J063 JR-1 cancer cell line human CVCL_J063 CL:0000010 Derived from metastatic site: Lung. Omics: Exosome proteome analysis Female Doubling time: ~29 hours (PubMed=3730258) 21112208 CVCL_J060 ZEM-2A spontaneously immortalized cell line zebrafish CVCL_J060 CL:0000010 Unspecified Group: Fish cell line. 21112209 CVCL_J037 127A hybridoma house mouse CVCL_J037 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; D3ZP29; Rat Icam4/Cd242. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11905 21112210 CVCL_J036 127H hybridoma house mouse CVCL_J036 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; D3ZP29; Rat Icam4/Cd242. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11911 21112211 CVCL_J039 129A3/1 hybridoma house mouse CVCL_J039 CL:0000010 Monoclonal antibody isotype: IgA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8087 21112212 CVCL_J038 173E hybridoma house mouse CVCL_J038 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q14773; Human ICAM4/CD242. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11912 21112213 CVCL_J033 XLA-07 cancer cell line human CVCL_J033 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Female Doubling time: 46.7 hours (PubMed=22883674) 21112214 CVCL_J032 PC14HM cancer cell line human CVCL_J032 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male Problematic cell line: Contaminated Parent cell line (PC-14) has been shown to be a PC-9 derivative. 21112215 CVCL_J035 110-5 hybridoma house mouse CVCL_J035 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04745; Human AMY1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8984 21112216 CVCL_J034 TYGBK-1 cancer cell line human CVCL_J034 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=22843894) Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~48 hours (PubMed=22843894) 21112217 CVCL_J031 X50-7.8 transformed cell line human CVCL_J031 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9694 21112218 CVCL_J030 GF-1 spontaneously immortalized cell line CVCL_J030 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-859 21112219 CVCL_J048 4B2 [Mouse hybridoma against human PTPRC] hybridoma house mouse CVCL_J048 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21112220 CVCL_J047 9-B1 hybridoma house mouse CVCL_J047 CL:0000010 Monoclonal antibody isotype: IgG1. 21112221 CVCL_J049 71A7 hybridoma house mouse CVCL_J049 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02866; Canavalia ensiformis concanavalin-A. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21112222 CVCL_J044 13-5-9-6-2 hybridoma house mouse CVCL_J044 CL:0000010 Discontinued: IZSLER; BS Hy 57; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08492; Human parainfluenza 3 virus (strain Wash/47885/57) Hemagglutinin-neuraminidase (HN) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8934 21112223 CVCL_J043 143-2-A6-11 hybridoma house mouse CVCL_J043 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:59440; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc (Lewis B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8325 21112224 CVCL_J046 14E5 hybridoma house mouse CVCL_J046 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human endothelial cells. 21112225 CVCL_J045 13.90.2 hybridoma house mouse CVCL_J045 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Eimeria tenella merozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8337 21112226 CVCL_J040 130C3/2B/8 hybridoma house mouse CVCL_J040 CL:0000010 Discontinued: IZSLER; BS Hy 58; probable. Monoclonal antibody isotype: IgG1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8088 21112227 CVCL_J042 130-3-F7-5 hybridoma house mouse CVCL_J042 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:59440; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc (Lewis B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8326 21112228 CVCL_J041 132C4A/4 hybridoma house mouse CVCL_J041 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8086 21112229 CVCL_A689 Tp365MG cancer cell line human CVCL_A689 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942). Unspecified 21112230 CVCL_A688 Tp336MG cancer cell line human CVCL_A688 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr27Asn (c.79T>A); Zygosity=Unspecified (PubMed=10560660). Unspecified 21112231 CVCL_A681 SS-ES-1 cancer cell line human CVCL_A681 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=20962673) Population: Iranian; Derived from sampling site: Chest; soft tissue. Female Doubling time: 35 hours (PubMed=20962673) 21112232 CVCL_A680 SPEC-3 cancer cell line human CVCL_A680 CL:0000010 Derived from sampling site: Endometrium. Female 21112233 CVCL_A683 SW1738 cancer cell line human CVCL_A683 From: Scott and White Clinic; Temple; USA. CL:0000010 21112234 CVCL_A682 SS9;22 cancer cell line human CVCL_A682 CL:0000010 Population: Japanese Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21112235 CVCL_J019 DLRP cancer cell line human CVCL_J019 CL:0000010 Derived from metastatic site: Cervical lymph node. Male Doubling time: ~1 week (DSMZ=ACC-881) 21112236 CVCL_A685 TP17 cancer cell line human CVCL_A685 CL:0000010 Derived from sampling site: Eye; uvea. Male 21112237 CVCL_J018 L 235 hybridoma house mouse CVCL_J018 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-19. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8446 21112238 CVCL_A684 SW800 cancer cell line human CVCL_A684 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21112239 CVCL_A687 Tp276MG cancer cell line human CVCL_A687 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His93Tyr (c.277C>T); ClinVar=VCV000646993; Zygosity=Unspecified (PubMed=10560660). Unspecified 21112240 CVCL_A686 Tp265MG cancer cell line human CVCL_A686 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942). Unspecified 21112241 CVCL_J015 L203 hybridoma house mouse CVCL_J015 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21112242 CVCL_J014 L18 hybridoma house mouse CVCL_J014 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human non-small cell lung carcinomas. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8628 21112243 CVCL_J017 L 230 hybridoma house mouse CVCL_J017 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human melanoma cell surface antigen M-23. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8448 21112244 CVCL_J016 L227 hybridoma house mouse CVCL_J016 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21112245 CVCL_J011 D8/17 hybridoma house mouse CVCL_J011 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human rheumatic fever antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8783 21112246 CVCL_J010 AFRC MAC 256 hybridoma Norway rat CVCL_J010 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13689; Maize auxin-binding protein 1 (ABP1). 21112247 CVCL_J013 L-14 hybridoma house mouse CVCL_J013 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cytomegalovirus immediate-early antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8554 21112248 CVCL_J012 L11/135 hybridoma house mouse CVCL_J012 CL:0000010 Monoclonal antibody isotype: IgG1. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21112249 CVCL_A699 UIA-MM8 cancer cell line human CVCL_A699 CL:0000010 21112250 CVCL_A692 UACC-3093 cancer cell line human CVCL_A692 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21112251 CVCL_A691 TS9;22 cancer cell line human CVCL_A691 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (CelloPub=CLPUB00588; PubMed=7808006; PubMed=10071072); Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Arg693Ter (c.2077C>T); ClinVar=VCV000620281; Zygosity=Homozygous Population: Japanese; Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21112252 CVCL_A694 UIA-MM1 cancer cell line human CVCL_A694 CL:0000010 21112253 CVCL_A693 UCONN-L2 cancer cell line human CVCL_A693 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=7824924; PubMed=9121481). Unspecified 21112254 CVCL_A696 UIA-MM3 cancer cell line human CVCL_A696 CL:0000010 21112255 CVCL_J029 MG-3 spontaneously immortalized cell line CVCL_J029 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line 21112256 CVCL_A695 UIA-MM2 cancer cell line human CVCL_A695 CL:0000010 21112257 CVCL_A698 UIA-MM7 cancer cell line human CVCL_A698 CL:0000010 21112258 CVCL_A697 UIA-MM5 cancer cell line human CVCL_A697 CL:0000010 21112259 CVCL_J026 TEC spontaneously immortalized cell line CVCL_J026 CL:0000010 Unspecified Group: Fish cell line. 21112260 CVCL_J025 C2C7 hybridoma house mouse CVCL_J025 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Candida albicans antigen(s). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8398 21112261 CVCL_J028 DIT29 cancer cell line CVCL_J028 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21112262 CVCL_J027 OLHNI-2 spontaneously immortalized cell line CVCL_J027 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: HNI. Unspecified Group: Fish cell line 21112263 CVCL_J022 3E9 [Mouse hybridoma against cell wall peptidoglycans] hybridoma house mouse CVCL_J022 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8514 21112264 CVCL_J021 14C2 hybridoma house mouse CVCL_J021 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8515 21112265 CVCL_J024 A2C7 hybridoma house mouse CVCL_J024 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30575; Candida albicans enolase 1 (ENO1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8397 21112266 CVCL_A690 Tp483MG cancer cell line human CVCL_A690 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly36Glu (c.107G>A); ClinVar=VCV000486972; Zygosity=Unspecified (PubMed=10560660); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.210-39A>G (IVS3-39A>G); ClinVar=VCV000255812; Zygosity=Unspecified (PubMed=10560660). Unspecified 21112267 CVCL_J023 4D3 [Mouse hybridoma against cell wall peptidoglycans] hybridoma house mouse CVCL_J023 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8517 21112268 CVCL_J020 15B2 hybridoma house mouse CVCL_J020 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8510 21112269 CVCL_RI90 TD70-c4 induced pluripotent stem cell human CVCL_RI90 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21112270 CVCL_RI92 WS17-c1 induced pluripotent stem cell human CVCL_RI92 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Male 21112271 CVCL_RI91 TD70-c5 induced pluripotent stem cell human CVCL_RI91 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Male 21112272 CVCL_RI94 WS17-c4 induced pluripotent stem cell human CVCL_RI94 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: Transcriptome analysis by microarray Male 21112273 CVCL_RI93 WS17-c2 induced pluripotent stem cell human CVCL_RI93 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21112274 CVCL_RI96 WS25-c3 induced pluripotent stem cell human CVCL_RI96 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21112275 CVCL_RI95 WS25-c1 induced pluripotent stem cell human CVCL_RI95 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Female 21112276 CVCL_RI98 WS77-c1 induced pluripotent stem cell human CVCL_RI98 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21112277 CVCL_RI97 WS25-c4 induced pluripotent stem cell human CVCL_RI97 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21112278 CVCL_RI99 WS77-c4 induced pluripotent stem cell human CVCL_RI99 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21112279 CVCL_RI81 TD55-c6 induced pluripotent stem cell human CVCL_RI81 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21112280 CVCL_RI80 TD55-c5 induced pluripotent stem cell human CVCL_RI80 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21112281 CVCL_RI83 TD59-c1 induced pluripotent stem cell human CVCL_RI83 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21112282 CVCL_RI82 TD55-c15 induced pluripotent stem cell human CVCL_RI82 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21112283 CVCL_RI85 TD59-c4 induced pluripotent stem cell human CVCL_RI85 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21112284 CVCL_RI84 TD59-c2 induced pluripotent stem cell human CVCL_RI84 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21112285 CVCL_RI87 TD63-c3 induced pluripotent stem cell human CVCL_RI87 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Female 21112286 CVCL_RI86 TD63-c1 induced pluripotent stem cell human CVCL_RI86 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21112287 CVCL_RI89 TD70-c2 induced pluripotent stem cell human CVCL_RI89 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21112288 CVCL_RI88 TD63-c6 induced pluripotent stem cell human CVCL_RI88 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21112289 CVCL_RI70 SP16.2 induced pluripotent stem cell human CVCL_RI70 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112290 CVCL_RI72 SP17.1 induced pluripotent stem cell human CVCL_RI72 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112291 CVCL_RI71 SP16.3 induced pluripotent stem cell human CVCL_RI71 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112292 CVCL_RI74 SP17.3 induced pluripotent stem cell human CVCL_RI74 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112293 CVCL_RI73 SP17.2 induced pluripotent stem cell human CVCL_RI73 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112294 CVCL_RI76 pWS88-c1 induced pluripotent stem cell human CVCL_RI76 CL:0000010 Donor information: Established from a patient that harbors a partial deletion in the WBS critical region; Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21112295 CVCL_RI75 pWS88-c0 induced pluripotent stem cell human CVCL_RI75 CL:0000010 Donor information: Established from a patient that harbors a partial deletion in the WBS critical region; Derived from sampling site: Tooth; dental pulp. Male 21112296 CVCL_RI78 pWS88-c15 induced pluripotent stem cell human CVCL_RI78 CL:0000010 Donor information: Established from a patient that harbors a partial deletion in the WBS critical region; Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Male 21112297 CVCL_RI77 pWS88-c2 induced pluripotent stem cell human CVCL_RI77 CL:0000010 Donor information: Established from a patient that harbors a partial deletion in the WBS critical region; Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis Male 21112298 CVCL_RI79 pWS88-c18 induced pluripotent stem cell human CVCL_RI79 CL:0000010 Donor information: Established from a patient that harbors a partial deletion in the WBS critical region; Derived from sampling site: Tooth; dental pulp. Male 21112299 CVCL_RI61 SP12.3 induced pluripotent stem cell human CVCL_RI61 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112300 CVCL_RI60 SP11.4 induced pluripotent stem cell human CVCL_RI60 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112301 CVCL_RI63 SP13.2 induced pluripotent stem cell human CVCL_RI63 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112302 CVCL_RI62 SP12.4 induced pluripotent stem cell human CVCL_RI62 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112303 CVCL_RI65 SP14.1 induced pluripotent stem cell human CVCL_RI65 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112305 CVCL_RI67 SP15.2 induced pluripotent stem cell human CVCL_RI67 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112306 CVCL_RI66 SP14.2 induced pluripotent stem cell human CVCL_RI66 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112307 CVCL_RI69 SP15.4 induced pluripotent stem cell human CVCL_RI69 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112308 CVCL_RI68 SP15.3 induced pluripotent stem cell human CVCL_RI68 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112309 CVCL_RI50 SP06.1 induced pluripotent stem cell human CVCL_RI50 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112310 CVCL_RI52 Hepa/8F5 cancer cell line house mouse CVCL_RI52 CL:0000010 Transfected with: MGI; MGI:99480; Cebpa; Transfected with: MGI; MGI:88373; Cebpb; Transfected with: MGI; MGI:104982; Cebpg; Transfected with: MGI; MGI:1347476; Foxa2; Transfected with: MGI; MGI:98504; Hnf1a; Transfected with: MGI; MGI:98505; Hnf1b; Transfected with: MGI; MGI:109128; Hnf4a; Transfected with: MGI; MGI:1196423; Onecut1 Derived from sampling site: Liver; Breed/subspecies: C57L. Omics: Transcriptome analysis by microarray Female Characteristics: When doxycycline-induced overexpresses 8 liver-enriched transcription factors (LETFs) 21112311 CVCL_RI51 SP06.2 induced pluripotent stem cell human CVCL_RI51 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112312 CVCL_RI54 SP08.3 induced pluripotent stem cell human CVCL_RI54 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112313 CVCL_RI53 SP08.2 induced pluripotent stem cell human CVCL_RI53 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112314 CVCL_RI56 SP09.4 induced pluripotent stem cell human CVCL_RI56 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112315 CVCL_RI55 SP09.2 induced pluripotent stem cell human CVCL_RI55 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112316 CVCL_RI58 SP10.2 induced pluripotent stem cell human CVCL_RI58 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112317 CVCL_RI57 SP10.1 induced pluripotent stem cell human CVCL_RI57 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112318 CVCL_RI59 SP11.1 induced pluripotent stem cell human CVCL_RI59 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21112319 CVCL_RI39 UHKT-7 transformed cell line human CVCL_RI39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112320 CVCL_J099 1A3 [Mouse hybridoma against HeLa] hybridoma house mouse CVCL_J099 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cancer cell line HeLa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8563 21112321 CVCL_J098 18C2.8.3 hybridoma house mouse CVCL_J098 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9571 21112322 CVCL_RI41 MCF-12F MNU transformed cell line human CVCL_RI41 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Breast; epithelium. Female 21112323 CVCL_RI40 MCF-12F DMBA transformed cell line human CVCL_RI40 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Breast; epithelium. Female 21112324 CVCL_RI43 SP01.4 induced pluripotent stem cell human CVCL_RI43 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112325 CVCL_J095 THG3-MP-2-19-3-8 hybridoma CVCL_J095 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21112326 CVCL_RI42 SP01.1 induced pluripotent stem cell human CVCL_RI42 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21112327 CVCL_J094 THG3-B5-13 hybridoma CVCL_J094 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21112328 CVCL_J097 17/14 hybridoma house mouse CVCL_J097 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28177; Theophylline. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8153 21112329 CVCL_RI45 SP02.2 induced pluripotent stem cell human CVCL_RI45 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112330 CVCL_RI44 836B3 induced pluripotent stem cell human CVCL_RI44 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21112331 CVCL_J096 SXC2 hybridoma CVCL_J096 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18893; Mouse Il10. 21112332 CVCL_RI47 SP04.2 induced pluripotent stem cell human CVCL_RI47 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112333 CVCL_J091 YW 62.3.20 hybridoma Norway rat CVCL_J091 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21112334 CVCL_J090 17aba hybridoma house mouse CVCL_J090 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b (Note=Also reacts with dog and rat). 21112335 CVCL_RI46 SP04.1 induced pluripotent stem cell human CVCL_RI46 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112336 CVCL_RI49 SP05.2 induced pluripotent stem cell human CVCL_RI49 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112337 CVCL_J093 U28 hybridoma house mouse CVCL_J093 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse IgG2a. 21112338 CVCL_RI48 SP05.1 induced pluripotent stem cell human CVCL_RI48 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112339 CVCL_J092 THM 7.3.5 hybridoma CVCL_J092 CL:0000010 Discontinued: ECACC; 87120201; probable. Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP) 21112340 CVCL_RI29 UiPSC-046 induced pluripotent stem cell human CVCL_RI29 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21112341 CVCL_RI28 UiPSC-045 induced pluripotent stem cell human CVCL_RI28 CL:0000010 Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21112342 CVCL_RI30 UHKT-40 cancer cell line human CVCL_RI30 CL:0000010 Derived from sampling site: Cell type=T-cell. Unspecified 21112343 CVCL_RI32 UHKT-1 transformed cell line human CVCL_RI32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112344 CVCL_RI31 2E12 [Mouse hybridoma against human VTN] hybridoma house mouse CVCL_RI31 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04004; Human VTN. 21112345 CVCL_RI34 UHKT-3 transformed cell line human CVCL_RI34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112346 CVCL_RI33 UHKT-2 transformed cell line human CVCL_RI33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112347 CVCL_RI36 UHKT-5 transformed cell line human CVCL_RI36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112348 CVCL_RI35 UHKT-4 transformed cell line human CVCL_RI35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112349 CVCL_RI38 IISHDOi002-A induced pluripotent stem cell human CVCL_RI38 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21112350 CVCL_RI37 UHKT-6 transformed cell line human CVCL_RI37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112351 CVCL_A821 CHB-10 embryonic stem cell human CVCL_A821 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0009 21112352 CVCL_A820 CHB-9 embryonic stem cell human CVCL_A820 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0008 21112353 CVCL_A823 CHB-12 embryonic stem cell human CVCL_A823 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0011 21112354 CVCL_A822 CHB-11 embryonic stem cell human CVCL_A822 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0010 21112355 CVCL_A825 CHB-14 embryonic stem cell human CVCL_A825 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 5961; IKBKG; Simple; p.Leu153Arg (c.458T>G) (T458G); ClinVar=VCV000011460; Zygosity=Unspecified (PubMed=22284529). Female 21112356 CVCL_A824 CHB-13 embryonic stem cell human CVCL_A824 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 5961; IKBKG; Simple; p.Leu153Arg (c.458T>G) (T458G); ClinVar=VCV000011460; Zygosity=Hemizygous (PubMed=22284529). Male 21112357 CVCL_A827 chHES-10 embryonic stem cell human CVCL_A827 HLA typing: A*11,33; B*13,44; DRB1*07,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112358 CVCL_A826 CHB-15 embryonic stem cell human CVCL_A826 From: Children's Hospital Boston; Boston; USA. CL:0000010 Unspecified 21112359 CVCL_A818 CHB-7 embryonic stem cell human CVCL_A818 From: Children's Hospital Boston; Boston; USA. CL:0000010 Unspecified 21112360 CVCL_A817 CHB-6 embryonic stem cell human CVCL_A817 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0006 21112361 CVCL_A819 CHB-8 embryonic stem cell human CVCL_A819 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0007 21112362 CVCL_A832 chHES-104 embryonic stem cell human CVCL_A832 HLA typing: A*02; B*40(60),46; DRB1*09,16 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-105 (Cellosaurus=CVCL_A833). Male 21112363 CVCL_A831 chHES-103 embryonic stem cell human CVCL_A831 HLA typing: A*24,33; B*35,58; DRB1*04,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112364 CVCL_A834 chHES-106 embryonic stem cell human CVCL_A834 HLA typing: A*02; B*40(60),67; DRB1*01,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112365 CVCL_A833 chHES-105 embryonic stem cell human CVCL_A833 From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-104 (Cellosaurus=CVCL_A832). Female 21112366 CVCL_A836 chHES-108 embryonic stem cell human CVCL_A836 HLA typing: A*01,02; B*37,48; DRB1*10,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112367 CVCL_A835 chHES-107 embryonic stem cell human CVCL_A835 HLA typing: A*02,11; B*15(75),46; DRB1*08,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112368 CVCL_A838 chHES-11 embryonic stem cell human CVCL_A838 HLA typing: A*02,11; B*13,51; DRB1*10,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112369 CVCL_A837 chHES-109 embryonic stem cell human CVCL_A837 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Ambiguous 21112370 CVCL_A830 chHES-102 embryonic stem cell human CVCL_A830 HLA typing: A*11,30; B*13,51; DRB1*07,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112371 CVCL_A829 chHES-101 embryonic stem cell human CVCL_A829 HLA typing: A*02,24; B*38,46; DRB1*14,16 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-100 (Cellosaurus=CVCL_A828). Male 21112372 CVCL_A828 chHES-100 embryonic stem cell human CVCL_A828 HLA typing: A*02,11; B*13,46; DRB1*14,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-101 (Cellosaurus=CVCL_A829). Female 21112373 CVCL_A801 WM793-P1N2 cancer cell line human CVCL_A801 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 1 passage of WM793 co-injected with Matrigel into nude mice 21112374 CVCL_A800 WM793-P1N1 cancer cell line human CVCL_A800 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 1 passage of WM793 co-injected with Matrigel into nude mice 21112375 CVCL_A803 WM793-P2N1 cancer cell line human CVCL_A803 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 2 passages of WM793 co-injected with Matrigel into nude mice 21112376 CVCL_A802 WM793-P1N3 cancer cell line human CVCL_A802 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 1 passage of WM793 co-injected with Matrigel into nude mice 21112377 CVCL_A805 WM793-P2N3 cancer cell line human CVCL_A805 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 2 passages of WM793 co-injected with Matrigel into nude mice 21112378 CVCL_A804 WM793-P2N2 cancer cell line human CVCL_A804 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Ter (c.821G>A); Zygosity=Heterozygous (from parent cell line). Male Characteristics: Established after 2 passages of WM793 co-injected with Matrigel into nude mice 21112379 CVCL_A810 WM35-P2N2 cancer cell line human CVCL_A810 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Female Characteristics: Established after 2 passages of WM35 co-injected with Matrigel into nude mice 21112380 CVCL_A812 CHB-1 embryonic stem cell human CVCL_A812 From: Children's Hospital Boston; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0001. 21112381 CVCL_A811 WM35-P2N3 cancer cell line human CVCL_A811 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Female Characteristics: Established after 2 passages of WM35 co-injected with Matrigel into nude mice 21112382 CVCL_A814 CHB-3 embryonic stem cell human CVCL_A814 From: Children's Hospital Boston; Boston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0003. 21112383 CVCL_A813 CHB-2 embryonic stem cell human CVCL_A813 From: Children's Hospital Boston; Boston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0002. 21112384 CVCL_A816 CHB-5 embryonic stem cell human CVCL_A816 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0005 21112385 CVCL_A815 CHB-4 embryonic stem cell human CVCL_A815 From: Children's Hospital Boston; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0004 21112386 CVCL_A807 WM35-P1N2 cancer cell line human CVCL_A807 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Female Characteristics: Established after 1 passage of WM35 co-injected with Matrigel into nude mice 21112387 CVCL_A806 WM35-P1N1 cancer cell line human CVCL_A806 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Female Characteristics: Established after 1 passage of WM35 co-injected with Matrigel into nude mice 21112388 CVCL_A809 WM35-P2N1 cancer cell line human CVCL_A809 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Female Characteristics: Established after 2 passages of WM35 co-injected with Matrigel into nude mice 21112389 CVCL_A808 WM35-P1N3 cancer cell line human CVCL_A808 CL:0000010 Female Characteristics: Established after 1 passage of WM35 co-injected with Matrigel into nude mice. 21112390 CVCL_J239 4T1-Luc cancer cell line house mouse CVCL_J239 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: JCRB; NIHS0696; true Female 21112391 CVCL_IQ39 6H4 hybridoma house mouse CVCL_IQ39 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Also reacts with hamster, human, mouse, pig and sheep). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2295 21112392 CVCL_J238 DR-Wildtype transformed cell line house mouse CVCL_J238 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Control cell line for the CHOP-KO-DR (Cellosaurus=CVCL_B046), GCN2-KO-DR (Cellosaurus=CVCL_B049) and PERK-KO-DR (Cellosaurus=CVCL_B067) cell lines 21112393 CVCL_IQ38 W3D2B10 hybridoma house mouse CVCL_IQ38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75084; Human FZD7. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2669 21112394 CVCL_IQ35 CCRF-RKB transformed cell line human CVCL_IQ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112395 CVCL_J235 FU-266 cancer cell line human CVCL_J235 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21112396 CVCL_J234 MAT-28b-12-11-30 hybridoma CVCL_J234 CL:0000010 Monoclonal antibody isotype: IgG. 21112397 CVCL_IQ34 OnyCap-23 transformed cell line human CVCL_IQ34 From: Onyvax, Ltd; London; United Kingdom CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 00032801 Caution: Was originally thought to arise from the ascitic fluid of a prostate carcinoma patient and described as such in patent application GB008032.5 from Jan 4, 2000. 21112398 CVCL_J237 F11G hybridoma CVCL_J237 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01027; Mouse C3. 21112399 CVCL_IQ37 W3C4E11 hybridoma house mouse CVCL_IQ37 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O60353; Human FZD6; Monoclonal antibody target: UniProtKB; O00144; Human FZD9/CD349. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2668 21112400 CVCL_IQ36 CH3A4A7 hybridoma house mouse CVCL_IQ36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9ULV1; Human FZD4/CD344. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2667 21112401 CVCL_J236 FU-266 clone E1 cancer cell line human CVCL_J236 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21112402 CVCL_J231 HSC-52a hybridoma house mouse CVCL_J231 CL:0000010 Monoclonal antibody isotype: IgM. 21112403 CVCL_IQ31 OVCA400 cancer cell line human CVCL_IQ31 CL:0000010 Derived from sampling site: Ovary. Female 21112404 CVCL_J230 4D4 [Mouse hybridoma against human VNN2] hybridoma house mouse CVCL_J230 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95498; Human VNN2. 21112405 CVCL_IQ30 OVCA424 cancer cell line human CVCL_IQ30 CL:0000010 Derived from sampling site: Ovary. Female 21112406 CVCL_J233 MAT-28-24 hybridoma CVCL_J233 CL:0000010 21112407 CVCL_IQ33 OnyCap-1 transformed cell line human CVCL_IQ33 From: Onyvax, Ltd; London; United Kingdom CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 00032802 Caution: Was originally thought to arise from the ascitic fluid of a prostate carcinoma patient and described as such in patent application GB008032.5 from Jan 4, 2000. 21112408 CVCL_J232 HSC-72 hybridoma house mouse CVCL_J232 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human spleen interstitial cells. 21112409 CVCL_IQ32 LAZ-444 transformed cell line human CVCL_IQ32 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112410 CVCL_J249 COLO 679-Luc cancer cell line human CVCL_J249 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0642; true. Female 21112411 CVCL_IQ49 Ms-11 cancer cell line human CVCL_IQ49 CL:0000010 Population: Japanese. Unspecified 21112412 CVCL_J246 BxPC-3-Luc#2 cancer cell line human CVCL_J246 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Pancreas. Discontinued: JCRB; NIHS0702; true Female 21112413 CVCL_IQ46 Ma-43 cancer cell line human CVCL_IQ46 CL:0000010 Population: Japanese. Unspecified 21112414 CVCL_J245 BT-549-Luc cancer cell line human CVCL_J245 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Breast. Discontinued: JCRB; NIHS0637; true Female Group: Triple negative breast cancer (TNBC) cell line 21112415 CVCL_IQ45 NM-F9 cancer cell line human CVCL_IQ45 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2606 21112416 CVCL_IQ48 7D10 [Mouse hybridoma against mouse Mif] hybridoma CVCL_IQ48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14174; Mouse Mif. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-418 21112417 CVCL_J248 COLO 205/CMV-Luc cancer cell line human CVCL_J248 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0703; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21112418 CVCL_IQ47 1C5 [Mouse hybridoma against human MIF] hybridoma house mouse CVCL_IQ47 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P14174; Human MIF. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-316 21112419 CVCL_J247 Caki-1-Luc cancer cell line human CVCL_J247 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Skin. Discontinued: JCRB; NIHS0653; true Male 21112420 CVCL_J242 A549-Luc cancer cell line human CVCL_J242 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Discontinued: JCRB; NIHS0659; true Male 21112421 CVCL_IQ42 hGP 5C4 hybridoma CVCL_IQ42 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9HCN6; Human GP6. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2631 21112422 CVCL_IQ41 15B3 hybridoma house mouse CVCL_IQ41 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Specifically recognizes infectious PrP(Sc)). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2298 21112423 CVCL_J241 A-498-Luc cancer cell line human CVCL_J241 CL:0000010 Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Val (c.3200A>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly144Serfs*14 (c.426_429delTGAC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Kidney. Discontinued: JCRB; NIHS0652; true Male 21112424 CVCL_J244 BT-20/CMV-Luc cancer cell line human CVCL_J244 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro539Arg (c.1616C>G); ClinVar=VCV000376243; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ile388Ser (c.1163T>G); ClinVar=VCV000665312; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Pro515Leu (c.1544C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian Discontinued: JCRB; NIHS0700; true. Female Characteristics: Expression of luciferase is under the control of the CMV promoter Group: Triple negative breast cancer (TNBC) cell line 21112425 CVCL_IQ44 NM-D4 cancer cell line human CVCL_IQ44 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2605 21112426 CVCL_IQ43 97A6 hybridoma house mouse CVCL_IQ43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14638; Human ENPP3/CD203c. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2297 21112427 CVCL_J243 AsPC-1/CMV-Luc cancer cell line human CVCL_J243 CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0697; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21112428 CVCL_IQ40 34C9 hybridoma house mouse CVCL_IQ40 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10279; Bovine PRNP (Note=Also reacts with human, mouse and pig). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2296 21112429 CVCL_J240 786-O-Luc cancer cell line human CVCL_J240 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Kidney. Discontinued: JCRB; NIHS0651; true Male 21112430 CVCL_A887 chHES-154 embryonic stem cell human CVCL_A887 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Unspecified 21112431 CVCL_A886 chHES-153 embryonic stem cell human CVCL_A886 HLA typing: A*24; B*46; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112432 CVCL_A889 chHES-156 embryonic stem cell human CVCL_A889 HLA typing: A*02,24; B*13,40(60); DRB1*14,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-157 (Cellosaurus=CVCL_A890). Female 21112433 CVCL_A888 chHES-155 embryonic stem cell human CVCL_A888 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Unspecified 21112434 CVCL_A881 chHES-149 embryonic stem cell human CVCL_A881 HLA typing: A*02,24; B*40(60),46; DRB1*09,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112435 CVCL_A880 chHES-148 embryonic stem cell human CVCL_A880 HLA typing: A*02; B*39,40(60); DRB1*11,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112436 CVCL_A883 chHES-150 embryonic stem cell human CVCL_A883 HLA typing: A*11,24; B*35,51; DRB1*12,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112437 CVCL_J217 OX-8 hybridoma house mouse CVCL_J217 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07725; Rat Cd8a. 21112438 CVCL_IQ17 THLE-5B-2C9 transformed cell line human CVCL_IQ17 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112439 CVCL_A882 chHES-15 embryonic stem cell human CVCL_A882 HLA typing: A*11,24; B*40(61),55; DRB1*04,07 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112440 CVCL_J216 OX-78 hybridoma Norway rat CVCL_J216 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P18181; Mouse Cd48. 21112441 CVCL_IQ16 THLE-5B-2C19 transformed cell line human CVCL_IQ16 CL:0000010 Transfected with: HGNC; 2621; CYP2C19 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112442 CVCL_A885 chHES-152 embryonic stem cell human CVCL_A885 HLA typing: A*33; B*58; DRB1*03 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112443 CVCL_J219 OX-85 hybridoma house mouse CVCL_J219 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30836; Rat Sell/Cd62l. 21112444 CVCL_IQ19 THLE-5B-2E1 transformed cell line human CVCL_IQ19 CL:0000010 Transfected with: HGNC; 2631; CYP2E1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112445 CVCL_A884 chHES-151 embryonic stem cell human CVCL_A884 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Female 21112446 CVCL_J218 OX-81 hybridoma house mouse CVCL_J218 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20096; Rat Il4. 21112447 CVCL_IQ18 THLE-5B-2D6 transformed cell line human CVCL_IQ18 CL:0000010 Transfected with: HGNC; 2625; CYP2D6 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112448 CVCL_J213 OX-7 hybridoma house mouse CVCL_J213 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01830; Rat Thy1/Cd90. 21112449 CVCL_IQ13 THLE-5B-1A2 transformed cell line human CVCL_IQ13 CL:0000010 Transfected with: HGNC; 2596; CYP1A2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112450 CVCL_J212 OX-68 hybridoma house mouse CVCL_J212 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21112451 CVCL_IQ12 THLE-5B-1A1 transformed cell line human CVCL_IQ12 CL:0000010 Transfected with: HGNC; 2595; CYP1A1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver. 21112452 CVCL_J215 OX-75 hybridoma house mouse CVCL_J215 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21112453 CVCL_IQ15 THLE-5B-2B6 transformed cell line human CVCL_IQ15 CL:0000010 Transfected with: HGNC; 2615; CYP2B6 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112454 CVCL_J214 OX-74 hybridoma house mouse CVCL_J214 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21112455 CVCL_IQ14 THLE-5B-2A6 transformed cell line human CVCL_IQ14 CL:0000010 Transfected with: HGNC; 2610; CYP2A6 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112456 CVCL_J211 OX-62 hybridoma house mouse CVCL_J211 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; M0R6T8; Rat Itgae/Cd103. 21112457 CVCL_IQ11 S/RG/C2 cancer cell line human CVCL_IQ11 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (from parent cell line). Female 21112458 CVCL_J210 OX-61 hybridoma house mouse CVCL_J210 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P14740; Rat Dpp4/Cd26. 21112459 CVCL_IQ10 PC/JW/FI cancer cell line human CVCL_IQ10 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.74+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (from parent cell line). Female 21112460 CVCL_A898 chHES-164 embryonic stem cell human CVCL_A898 HLA typing: A*02; B*40(60),46; DRB1*08,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-165 (Cellosaurus=CVCL_A899). Male 21112461 CVCL_A897 chHES-163 embryonic stem cell human CVCL_A897 HLA typing: A*02,31; B*46,51; DRB1*11,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112462 CVCL_A899 chHES-165 embryonic stem cell human CVCL_A899 HLA typing: A*02; B*40(60),46; DRB1*08,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-164 (Cellosaurus=CVCL_A898). Male 21112463 CVCL_A890 chHES-157 embryonic stem cell human CVCL_A890 HLA typing: A*11; B*40(60); DRB1*04,15 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-156 (Cellosaurus=CVCL_A889). Male 21112464 CVCL_A892 chHES-159 embryonic stem cell human CVCL_A892 HLA typing: A*11,24; B*15(71),40(60); DRB1*04,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112465 CVCL_A891 chHES-158 embryonic stem cell human CVCL_A891 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Ambiguous 21112466 CVCL_J228 3H9 [Mouse hybridoma against human VNN2] hybridoma house mouse CVCL_J228 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95498; Human VNN2. 21112467 CVCL_A894 chHES-160 embryonic stem cell human CVCL_A894 HLA typing: A*24; B*15(62),15(75); DRB1*04,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-161 (Cellosaurus=CVCL_A895). Male 21112468 CVCL_IQ28 LAZ-446 transformed cell line human CVCL_IQ28 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112469 CVCL_J227 3G8 [Mouse hybridoma against human FCGR3A] hybridoma house mouse CVCL_J227 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08637; Human FCGR3A/CD16. 21112470 CVCL_A893 chHES-16 embryonic stem cell human CVCL_A893 HLA typing: A*11,24; B*15(62),40(60); DRB1*11,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112471 CVCL_IQ27 LAZ-471 transformed cell line human CVCL_IQ27 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21112472 CVCL_A896 chHES-162 embryonic stem cell human CVCL_A896 HLA typing: A*02,11; B*13,46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112473 CVCL_J229 430F hybridoma house mouse CVCL_J229 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Sheep red blood cells (SRBC). 21112474 CVCL_A895 chHES-161 embryonic stem cell human CVCL_A895 HLA typing: A*24,30; B*13,15(62); DRB1*07,09 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-160 (Cellosaurus=CVCL_A894). Female 21112475 CVCL_IQ29 LAZ-434 finite cell line human CVCL_IQ29 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 24 hours (PubMed=6346879) 21112476 CVCL_IQ24 LAZ-156 transformed cell line human CVCL_IQ24 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified 21112477 CVCL_J224 MH55 hybridoma house mouse CVCL_J224 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8412 21112478 CVCL_IQ23 LAZ-461 transformed cell line human CVCL_IQ23 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified 21112479 CVCL_J223 MH1 hybridoma house mouse CVCL_J223 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9739 21112480 CVCL_J226 F1-3G8-1 hybridoma house mouse CVCL_J226 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; P26948; Yersina pestis F1 antigen (caf1). 21112481 CVCL_IQ26 LAZ-256 transformed cell line human CVCL_IQ26 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21112482 CVCL_J225 1A81 hybridoma house mouse CVCL_J225 CL:0000010 Monoclonal antibody isotype: IgM. 21112483 CVCL_IQ25 LAZ-007 transformed cell line human CVCL_IQ25 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified 21112484 CVCL_J220 OX-86 hybridoma CVCL_J220 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47741; Mouse Tnfrsf4/Cd134. 21112485 CVCL_IQ20 THLE-B5-3A4 transformed cell line human CVCL_IQ20 CL:0000010 Transfected with: HGNC; 2637; CYP3A4 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. 21112486 CVCL_IQ22 LAZ-509 transformed cell line human CVCL_IQ22 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21112487 CVCL_J222 MH01 hybridoma CVCL_J222 CL:0000010 Monoclonal antibody isotype: IgM. 21112488 CVCL_IQ21 IGROV-1/CP cancer cell line human CVCL_IQ21 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21112489 CVCL_J221 OX-87 hybridoma house mouse CVCL_J221 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20096; Rat Il4. 21112490 CVCL_A865 chHES-134 embryonic stem cell human CVCL_A865 HLA typing: A*11; B*07,40(60); DRB1*11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112491 CVCL_A864 chHES-133 embryonic stem cell human CVCL_A864 HLA typing: A*11; B*13,15(75); DRB1*03,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112492 CVCL_A867 chHES-136 embryonic stem cell human CVCL_A867 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Female 21112493 CVCL_A866 chHES-135 embryonic stem cell human CVCL_A866 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Female 21112494 CVCL_A869 chHES-138 embryonic stem cell human CVCL_A869 HLA typing: A*24; B*46,54; DRB1*11,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112495 CVCL_A868 chHES-137 embryonic stem cell human CVCL_A868 HLA typing: A*11; B*13,46; DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112496 CVCL_A861 chHES-130 embryonic stem cell human CVCL_A861 HLA typing: A*02,24; B*13,52; DRB1*15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112497 CVCL_A860 chHES-13 embryonic stem cell human CVCL_A860 HLA typing: A*11,24; B*40(60),48; DRB1*14,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112498 CVCL_A863 chHES-132 embryonic stem cell human CVCL_A863 HLA typing: A*02,11; B*38,46; DRB1*09,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112499 CVCL_A862 chHES-131 embryonic stem cell human CVCL_A862 HLA typing: A*02,11; B*15(75),39; DRB1*11,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112500 CVCL_A876 chHES-144 embryonic stem cell human CVCL_A876 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Ambiguous 21112501 CVCL_A875 chHES-143 embryonic stem cell human CVCL_A875 HLA typing: A*24,31; B*40(60),46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112502 CVCL_A878 chHES-146 embryonic stem cell human CVCL_A878 HLA typing: A*02; B*46,55; DRB1*09,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112503 CVCL_A877 chHES-145 embryonic stem cell human CVCL_A877 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Ambiguous 21112504 CVCL_A879 chHES-147 embryonic stem cell human CVCL_A879 HLA typing: A*24; B*15(62),51; DRB1*09,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112505 CVCL_J209 OX-60 hybridoma house mouse CVCL_J209 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat IgD. 21112506 CVCL_IQ09 PC/FF cancer cell line human CVCL_IQ09 CL:0000010 Female 21112507 CVCL_A870 chHES-139 embryonic stem cell human CVCL_A870 HLA typing: A*03,11; B*07,40(60); DRB1*13,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112508 CVCL_A872 chHES-140 embryonic stem cell human CVCL_A872 HLA typing: A*24,30; B*13,40(60); DRB1*07,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112509 CVCL_J206 OX-58 hybridoma house mouse CVCL_J206 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21112510 CVCL_IQ06 PC/AA/C1/SB10 cancer cell line human CVCL_IQ06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64103; Sodium butyrate; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759). Male 21112511 CVCL_A871 chHES-14 embryonic stem cell human CVCL_A871 HLA typing: A*11,24; B*15(62),15(75); DRB1*13,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112512 CVCL_J205 OX-57 hybridoma house mouse CVCL_J205 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21112513 CVCL_IQ05 PC/AA/C1/SB cancer cell line human CVCL_IQ05 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64103; Sodium butyrate. Male 21112514 CVCL_A874 chHES-142 embryonic stem cell human CVCL_A874 HLA typing: A*02; B*46; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112515 CVCL_J208 OX-6 hybridoma house mouse CVCL_J208 CL:0000010 Monoclonal antibody isotype: IgG1. 21112516 CVCL_IQ08 PC/BH/C1 cancer cell line human CVCL_IQ08 CL:0000010 Female 21112517 CVCL_A873 chHES-141 embryonic stem cell human CVCL_A873 HLA typing: A*02; B*46,51; DRB1*09,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112518 CVCL_J207 OX-59 hybridoma house mouse CVCL_J207 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat IgG. 21112519 CVCL_IQ07 PC/BH cancer cell line human CVCL_IQ07 CL:0000010 Female 21112520 CVCL_IQ02 184A1N4-T transformed cell line human CVCL_IQ02 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female 21112521 CVCL_J202 OX-53 hybridoma house mouse CVCL_J202 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08921; Rat Cd2. 21112522 CVCL_IQ01 184A1N4-H transformed cell line human CVCL_IQ01 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Transformant: Harvey murine sarcoma virus (Ha-MSV)(NCBI-Taxonomy; 11807); Derived from sampling site: Breast; epithelium. Female 21112523 CVCL_J201 OX-52 hybridoma house mouse CVCL_J201 CL:0000010 Monoclonal antibody isotype: IgG2a. 21112524 CVCL_J204 OX-55 hybridoma house mouse CVCL_J204 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08921; Rat Cd2. 21112525 CVCL_IQ04 PC/AA/C1 cancer cell line human CVCL_IQ04 CL:0000010 Male 21112526 CVCL_IQ03 184A1N4-TH transformed cell line human CVCL_IQ03 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: Harvey murine sarcoma virus (Ha-MSV)(NCBI-Taxonomy; 11807); Derived from sampling site: Breast; epithelium. Female 21112527 CVCL_J203 OX-54 hybridoma house mouse CVCL_J203 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08921; Rat Cd2. 21112528 CVCL_IQ00 B5KTu transformed cell line human CVCL_IQ00 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Female 21112529 CVCL_J200 OX-50 hybridoma house mouse CVCL_J200 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26051; Rat Cd44. 21112530 CVCL_A843 chHES-114 embryonic stem cell human CVCL_A843 HLA typing: A*02,33; B*55,58; DRB1*13,16 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-115 (Cellosaurus=CVCL_A844). Male 21112531 CVCL_A842 chHES-113 embryonic stem cell human CVCL_A842 HLA typing: A*24; B*46,51; DRB1*09,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112532 CVCL_A845 chHES-116 embryonic stem cell human CVCL_A845 HLA typing: A*11,24; B*07,55; DRB1*01,16 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-119 (Cellosaurus=CVCL_A848). Male 21112533 CVCL_A844 chHES-115 embryonic stem cell human CVCL_A844 HLA typing: A*02,11; B*40(60),55; DRB1*04,12 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-114 (Cellosaurus=CVCL_A843). Female 21112534 CVCL_A847 chHES-118 embryonic stem cell human CVCL_A847 HLA typing: A*02,11; B*15(75),46; DRB1*08,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112535 CVCL_A846 chHES-117 embryonic stem cell human CVCL_A846 HLA typing: A*02,03; B*38,52; DRB1*08,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112536 CVCL_A849 chHES-12 embryonic stem cell human CVCL_A849 HLA typing: A*11; B*07,40(60); DRB1*01,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112537 CVCL_A848 chHES-119 embryonic stem cell human CVCL_A848 HLA typing: A*02,24; B*40(61),48; DRB1*04,12 (PubMed=19896436) From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Donor information: Embryo is sibling to that giving rise to chHES-116 (Cellosaurus=CVCL_A845). Male 21112538 CVCL_A841 chHES-112 embryonic stem cell human CVCL_A841 HLA typing: A*02,24; B*46,54; DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112539 CVCL_A840 chHES-111 embryonic stem cell human CVCL_A840 HLA typing: A*24,30; B*35,40(60); DRB1*04,08 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112540 CVCL_A839 chHES-110 embryonic stem cell human CVCL_A839 HLA typing: A*11,24; B*40(60); DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112541 CVCL_A854 chHES-124 embryonic stem cell human CVCL_A854 HLA typing: A*02,11; B*15(75),46; DRB1*12,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112542 CVCL_A853 chHES-123 embryonic stem cell human CVCL_A853 HLA typing: A*02; B*13,46; DRB1*13,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Ambiguous 21112543 CVCL_A856 chHES-126 embryonic stem cell human CVCL_A856 HLA typing: A*24; B*46,48; DRB1*14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112544 CVCL_A855 chHES-125 embryonic stem cell human CVCL_A855 HLA typing: A*02,11; B*38,67; DRB1*08,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112545 CVCL_A858 chHES-128 embryonic stem cell human CVCL_A858 HLA typing: A*11,24; B*15(75),40(60); DRB1*09,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112546 CVCL_A857 chHES-127 embryonic stem cell human CVCL_A857 HLA typing: A*02,11; B*44,46; DRB1*03,14 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112547 CVCL_A859 chHES-129 embryonic stem cell human CVCL_A859 HLA typing: A*02; B*15(75),46; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21112548 CVCL_A850 chHES-120 embryonic stem cell human CVCL_A850 HLA typing: A*02,24; B*51,55; DRB1*04,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112549 CVCL_A852 chHES-122 embryonic stem cell human CVCL_A852 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Female 21112550 CVCL_A851 chHES-121 embryonic stem cell human CVCL_A851 HLA typing: A*02,23; B*27,50; DRB1*11,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21112551 CVCL_RJ39 PDB1lox-21GFP-19 induced pluripotent stem cell human CVCL_RJ39 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112552 CVCL_RJ38 PDB1lox-17Puro-33 induced pluripotent stem cell human CVCL_RJ38 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112553 CVCL_J198 OX-47 hybridoma house mouse CVCL_J198 CL:0000010 Discontinued: ECACC; 90071611; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26453; Rat Bsg/Cd147 21112554 CVCL_IP98 SV-HUC/ras-G transformed cell line human CVCL_IP98 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112555 CVCL_J197 OX-45 hybridoma house mouse CVCL_J197 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10252; Rat Cd48. 21112556 CVCL_IP97 SV-HUC/ras-F transformed cell line human CVCL_IP97 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112557 CVCL_RJ40 PDB1lox-21GFP-41 induced pluripotent stem cell human CVCL_RJ40 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112558 CVCL_IP99 18Nco transformed cell line human CVCL_IP99 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112559 CVCL_J199 OX-49 hybridoma house mouse CVCL_J199 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26051; Rat Cd44. 21112560 CVCL_J194 OX-42 hybridoma house mouse CVCL_J194 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9JI30; Rat Itgam/Cd11b. 21112561 CVCL_RJ42 PDB1lox-21Puro-12 induced pluripotent stem cell human CVCL_RJ42 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112562 CVCL_IP94 SV-HUC/ras-C transformed cell line human CVCL_IP94 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112563 CVCL_J193 OX-41 hybridoma house mouse CVCL_J193 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P97710; Rat Sirpa/Cd172a. 21112564 CVCL_RJ41 PDB1lox-21Puro-5 induced pluripotent stem cell human CVCL_RJ41 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112565 CVCL_IP93 SV-HUC/ras-B transformed cell line human CVCL_IP93 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112566 CVCL_J196 OX-44 hybridoma house mouse CVCL_J196 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24485; Rat Cd53. 21112567 CVCL_RJ44 PDB1lox-21Puro-18 induced pluripotent stem cell human CVCL_RJ44 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112568 CVCL_IP96 SV-HUC/ras-E transformed cell line human CVCL_IP96 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112569 CVCL_J195 OX-43 hybridoma house mouse CVCL_J195 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat 85 kDa antigen expressed on the luminal surface of blood vessels. 21112570 CVCL_RJ43 PDB1lox-21Puro-13 induced pluripotent stem cell human CVCL_RJ43 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112571 CVCL_IP95 SV-HUC/ras-D transformed cell line human CVCL_IP95 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112572 CVCL_IP90 MC-SV-HUC T-11 transformed cell line human CVCL_IP90 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112573 CVCL_J190 OX-38 hybridoma house mouse CVCL_J190 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21112574 CVCL_RJ46 PDB1lox-21Puro-26 induced pluripotent stem cell human CVCL_RJ46 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112575 CVCL_RJ45 PDB1lox-21Puro-20 induced pluripotent stem cell human CVCL_RJ45 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112576 CVCL_J192 OX-40 hybridoma house mouse CVCL_J192 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15725; Rat Tnfrsf4/Cd134. 21112577 CVCL_RJ48 PDB2lox-5 induced pluripotent stem cell human CVCL_RJ48 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112578 CVCL_IP92 SV-HUC/ras-A transformed cell line human CVCL_IP92 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112579 CVCL_IP91 MC-SV-HUC T-16 transformed cell line human CVCL_IP91 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112580 CVCL_J191 OX-39 hybridoma house mouse CVCL_J191 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26897; Rat Il2ra/Cd25. 21112581 CVCL_RJ47 PDB1lox-21Puro-28 induced pluripotent stem cell human CVCL_RJ47 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112582 CVCL_RJ28 TD1-10749-2 induced pluripotent stem cell human CVCL_RJ28 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (PubMed=25231866) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112583 CVCL_RJ27 TD1-714-3 induced pluripotent stem cell human CVCL_RJ27 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (PubMed=25231866) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112584 CVCL_RJ29 TD1-315H-2 induced pluripotent stem cell human CVCL_RJ29 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (PubMed=25231866) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21112585 CVCL_RJ31 HDF-11 induced pluripotent stem cell human CVCL_RJ31 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112586 CVCL_RJ30 KF4009-1 induced pluripotent stem cell human CVCL_RJ30 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112587 CVCL_RJ33 PDB1lox-17GFP-55 induced pluripotent stem cell human CVCL_RJ33 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112588 CVCL_RJ32 PDB1lox-17GFP-29 induced pluripotent stem cell human CVCL_RJ32 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112589 CVCL_RJ35 PDB1lox-17Puro-10 induced pluripotent stem cell human CVCL_RJ35 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112590 CVCL_RJ34 PDB1lox-17Puro-5 induced pluripotent stem cell human CVCL_RJ34 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112591 CVCL_RJ37 PDB1lox-17Puro-31 induced pluripotent stem cell human CVCL_RJ37 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112592 CVCL_RJ36 PDB1lox-17Puro-12 induced pluripotent stem cell human CVCL_RJ36 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112593 CVCL_RJ17 ACGII-2-#23 induced pluripotent stem cell human CVCL_RJ17 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly1182Ala; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112594 CVCL_RJ16 ACGII-2-#22 induced pluripotent stem cell human CVCL_RJ16 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly1182Ala; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112595 CVCL_RJ19 HCG-1-#31 induced pluripotent stem cell human CVCL_RJ19 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly450Arg (c.1348G>C); ClinVar=VCV001326897; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Donor information: Established from a patient said to be suffering from hypochondrogenesis; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112596 CVCL_RJ18 ACGII-2-iChon induced pluripotent stem cell human CVCL_RJ18 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly1182Ala; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112597 CVCL_J179 ER4.7G11 hybridoma house mouse CVCL_J179 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11642 21112598 CVCL_IP79 RHEK-1/ras transformed cell line human CVCL_IP79 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21112599 CVCL_J176 A 123 hybridoma house mouse CVCL_J176 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-26. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8451 21112600 CVCL_IP76 SNP cancer cell line dog CVCL_IP76 CL:0000010 Breed/subspecies: Mixed breed. Female Doubling time: 26.2 hours (PubMed=26726024) 21112601 CVCL_J175 A11.1 M hybridoma house mouse CVCL_J175 CL:0000010 Monoclonal antibody isotype: IgG3. 21112602 CVCL_IP75 LLC-PK1/Cl4 spontaneously immortalized cell line pig CVCL_IP75 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21112603 CVCL_J178 AA224 hybridoma house mouse CVCL_J178 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Edwardsiella ictaluri antigens of about 14, 39, 48, 60, 66, 83 and 93 Kda. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10183 21112604 CVCL_IP78 OCUM-8/PTX cancer cell line human CVCL_IP78 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21112605 CVCL_J177 A 124 hybridoma house mouse CVCL_J177 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human melanoma cell surface antigen M-27. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8452 21112606 CVCL_IP77 VPC-6 cancer cell line human CVCL_IP77 CL:0000010 21112607 CVCL_IP72 AM-HLH cancer cell line human CVCL_IP72 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male Virology: Contains multiple copies of integrated EBV genomes Doubling time: 35-40 hours (PubMed=27813134); ~48 hours (DSMZ=ACC-908) 21112608 CVCL_J172 B27M1 hybridoma house mouse CVCL_J172 CL:0000010 Monoclonal antibody isotype: IgG2a. 21112609 CVCL_RJ20 HCG-1-#32 induced pluripotent stem cell human CVCL_RJ20 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly450Arg (c.1348G>C); ClinVar=VCV001326897; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Donor information: Established from a patient said to be suffering from hypochondrogenesis; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112610 CVCL_IP71 RoBE-4 spontaneously immortalized cell line CVCL_IP71 CL:0000010 Unspecified Group: Fish cell line. 21112611 CVCL_J171 Sp2/08A2 cancer cell line house mouse CVCL_J171 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21112612 CVCL_J174 2.28 M1 hybridoma house mouse CVCL_J174 CL:0000010 Monoclonal antibody isotype: IgM. 21112613 CVCL_IP74 COLO 357/SG cancer cell line human CVCL_IP74 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21112614 CVCL_RJ22 HCG-1-iChon induced pluripotent stem cell human CVCL_RJ22 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly450Arg (c.1348G>C); ClinVar=VCV001326897; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Donor information: Established from a patient said to be suffering from hypochondrogenesis; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112615 CVCL_J173 B27M2 hybridoma house mouse CVCL_J173 CL:0000010 Monoclonal antibody isotype: IgM. 21112616 CVCL_RJ21 HCG-1-#33 induced pluripotent stem cell human CVCL_RJ21 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly450Arg (c.1348G>C); ClinVar=VCV001326897; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Donor information: Established from a patient said to be suffering from hypochondrogenesis; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112617 CVCL_RJ24 ACH-8857-1 induced pluripotent stem cell human CVCL_RJ24 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (PubMed=25231866) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112618 CVCL_RJ23 SPD-1-iChon induced pluripotent stem cell human CVCL_RJ23 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Lys1447Cysfs*18 (c.4337dupG); Zygosity=Heterozygous (PubMed=25187577) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21112619 CVCL_J170 8.03.4 hybridoma house mouse CVCL_J170 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella merozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8388 21112620 CVCL_RJ26 ACHhomo-8859-3 induced pluripotent stem cell human CVCL_RJ26 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Homozygous (PubMed=25231866) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21112621 CVCL_IP70 HAMOI-EnK spontaneously immortalized cell line CVCL_IP70 CL:0000010 Anecdotal: The first part of the name, HAMOI, is derived from the initial letter of the surnames of the 4 authors of the paper Derived from sampling site: Kidney. Unspecified Doubling time: 23.4-25.2 hours (PubMed=27499253) Group: Bat cell line 21112622 CVCL_RJ25 ACH-8858-6 induced pluripotent stem cell human CVCL_RJ25 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (PubMed=25231866) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21112623 CVCL_RJ06 SCD162-17-2 induced pluripotent stem cell human CVCL_RJ06 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[23] (c.6937CAG[23]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Homozygous (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21112624 CVCL_RJ05 SCD162-13-2 induced pluripotent stem cell human CVCL_RJ05 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[23] (c.6937CAG[23]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Homozygous (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112625 CVCL_RJ08 SCD166-2-14 induced pluripotent stem cell human CVCL_RJ08 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[26] (c.6937CAG[26]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[14] (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21112626 CVCL_RJ07 SCD166-2-3 induced pluripotent stem cell human CVCL_RJ07 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[26] (c.6937CAG[26]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[14] (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112627 CVCL_RJ09 SCD166-2-16 induced pluripotent stem cell human CVCL_RJ09 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[26] (c.6937CAG[26]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[14] (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112628 CVCL_IP87 MC-SV-HUC T-7 transformed cell line human CVCL_IP87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112629 CVCL_J187 OX-34 hybridoma house mouse CVCL_J187 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08921; Rat Cd2. 21112630 CVCL_IP86 MC-SV-HUC T-1 transformed cell line human CVCL_IP86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112631 CVCL_J186 OX-33 hybridoma house mouse CVCL_J186 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21112632 CVCL_IP89 MC-SV-HUC T-10 transformed cell line human CVCL_IP89 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112633 CVCL_J189 OX-36 clone 3 hybridoma house mouse CVCL_J189 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21112634 CVCL_IP88 MC-SV-HUC T-9 transformed cell line human CVCL_IP88 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male 21112635 CVCL_J188 OX-35 clone 5 hybridoma house mouse CVCL_J188 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21112636 CVCL_IP83 H16N-3 transformed cell line human CVCL_IP83 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21112637 CVCL_J183 OX-29 hybridoma house mouse CVCL_J183 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21112638 CVCL_IP82 H16N-2 transformed cell line human CVCL_IP82 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21112639 CVCL_J182 OX-27 hybridoma house mouse CVCL_J182 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rat MHC class I. 21112640 CVCL_RJ11 HCT 116 CMV-OsTIR1 cancer cell line human CVCL_RJ11 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q7XVM8; Oryza sativa subsp japonica TIR1-like protein Os04g0395600.; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Parent cell line to study the rapid depletion of a protein The expressed rice TIR1 can form a functional SCF(OsTIR1) E3 ligase complex with the endogenous components in human cells. In the presence of auxin, a protein of interest fused with mAID is rapidly degraded upon poly-ubiquitylation.; Characteristics: The CMV-OsTIR1-PRO (pMK232) vector was introduced in both alleles of the AAVS1 locus by using CRISPR/Cas9 21112641 CVCL_IP85 MCF-10A-erbB-2 spontaneously immortalized cell line human CVCL_IP85 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21112642 CVCL_J185 OX-30 hybridoma house mouse CVCL_J185 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21112643 CVCL_IP84 H16N2-erbB-2 transformed cell line human CVCL_IP84 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21112644 CVCL_J184 OX-3 hybridoma house mouse CVCL_J184 CL:0000010 Monoclonal antibody isotype: IgG1. 21112645 CVCL_RJ10 SCD16-2E induced pluripotent stem cell human CVCL_RJ10 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[22] (c.6937CAG[22]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[12] (PubMed=27806289) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21112646 CVCL_RJ13 ACGII-1-#2 induced pluripotent stem cell human CVCL_RJ13 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Unexplicit; Exon 41 acceptor site T>C substitution; Zygosity=Heterozygous (PubMed=25187577) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21112647 CVCL_RJ12 ACGII-1-#1 induced pluripotent stem cell human CVCL_RJ12 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Unexplicit; Exon 41 acceptor site T>C substitution; Zygosity=Heterozygous (PubMed=25187577) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21112648 CVCL_RJ15 ACGII-2-#21 induced pluripotent stem cell human CVCL_RJ15 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Gly1182Ala; Zygosity=Heterozygous (PubMed=25187577) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112649 CVCL_IP81 H16F1 transformed cell line human CVCL_IP81 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pleural effusion Cell type=Mesothelial cell.. Female 21112650 CVCL_J181 OX-26 hybridoma house mouse CVCL_J181 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99376; Rat Tfrc/Cd71. 21112651 CVCL_RJ14 ACGII-1-#3 induced pluripotent stem cell human CVCL_RJ14 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Unexplicit; Exon 41 acceptor site T>C substitution; Zygosity=Heterozygous (PubMed=25187577) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21112652 CVCL_IP80 H184B5-F5 transformed cell line human CVCL_IP80 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Female 21112653 CVCL_J180 OX-17 hybridoma house mouse CVCL_J180 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat MHC class II RT1-D. 21112654 CVCL_IP58 0308 cancer cell line human CVCL_IP58 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Cancer stem cell line 21112655 CVCL_J158 Aw3.18.14 hybridoma house mouse CVCL_J158 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ (Note=Recognizes peptide 66-80 bound to MHC class II I-Ak). Doubling time: 14 hours (ATCC=CRL-2826) 21112656 CVCL_J157 AP-3 hybridoma house mouse CVCL_J157 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 21112657 CVCL_IP57 CiRA00161 induced pluripotent stem cell human CVCL_IP57 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21112658 CVCL_IP59 0822 cancer cell line human CVCL_IP59 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Cancer stem cell line 21112659 CVCL_J159 LI 27 hybridoma house mouse CVCL_J159 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8437 21112660 CVCL_J154 2G7 [Mouse hybridoma against human endothelial cells] hybridoma house mouse CVCL_J154 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IL1-activated endothelial cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10137 21112661 CVCL_IP54 CiRA00139 induced pluripotent stem cell human CVCL_IP54 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21112662 CVCL_J153 1E7 [Mouse hybridoma against human IL1-activated endothelial cells] hybridoma house mouse CVCL_J153 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IL1-activated endothelial cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10136 21112663 CVCL_IP53 GM13864 transformed cell line human CVCL_IP53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112664 CVCL_J156 7C8 [Mouse hybridoma against synthetic peptide] hybridoma house mouse CVCL_J156 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Synthetic polypeptide DYKDDDDKGPKKG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8465 21112665 CVCL_IP56 CiRA00160 induced pluripotent stem cell human CVCL_IP56 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21112666 CVCL_J155 3A2 [Mouse hybridoma against human IL1-activated endothelial cells] hybridoma house mouse CVCL_J155 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human IL1-activated endothelial cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10138 21112667 CVCL_IP55 CiRA00142 induced pluripotent stem cell human CVCL_IP55 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21112668 CVCL_J150 6F4C5 hybridoma house mouse CVCL_J150 CL:0000010 Monoclonal antibody isotype: IgG1. 21112669 CVCL_IP50 LAU-T333A cancer cell line human CVCL_IP50 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Cutaneous. Male 21112670 CVCL_J152 7A9 hybridoma house mouse CVCL_J152 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IL1-activated endothelial cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10135 21112671 CVCL_IP52 LAU-T441A cancer cell line human CVCL_IP52 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Male 21112672 CVCL_RJ00 WS77-c5 induced pluripotent stem cell human CVCL_RJ00 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21112673 CVCL_J151 703D4 hybridoma house mouse CVCL_J151 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P22626; Human HNRNPA2B1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8301 21112674 CVCL_IP51 LAU-T42B cancer cell line human CVCL_IP51 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Male 21112675 CVCL_RJ02 WS79-c3 induced pluripotent stem cell human CVCL_RJ02 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21112676 CVCL_RJ01 WS79-c2 induced pluripotent stem cell human CVCL_RJ01 CL:0000010 Derived from sampling site: Tooth; dental pulp. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21112677 CVCL_RJ04 SCD162-6-2 induced pluripotent stem cell human CVCL_RJ04 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[23] (c.6937CAG[23]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Homozygous (PubMed=27806289) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112678 CVCL_RJ03 WS79-c5 induced pluripotent stem cell human CVCL_RJ03 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21112679 CVCL_J169 15.84.4 hybridoma house mouse CVCL_J169 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella merozoite antigen (Note=Also reacts with other Eimeria species). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8335 21112680 CVCL_IP69 IB-RS-2 clone 60 spontaneously immortalized cell line pig CVCL_IP69 CL:0000010 Derived from sampling site: Kidney. Female Virology: Susceptible to infection by foot-and-mouth disease virus Doubling time: ~48 hours (PubMed=4329431) 21112681 CVCL_J168 10.84.2 hybridoma house mouse CVCL_J168 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella merozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8387 21112682 CVCL_IP68 SRIK-NKL cancer cell line human CVCL_IP68 CL:0000010 Population: Caucasian Male Doubling time: 36-48 hours (PubMed=15927673). 21112683 CVCL_J165 1H10-6 hybridoma house mouse CVCL_J165 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09866; Dengue virus type 4 polyprotein. 21112684 CVCL_IP65 HPS0217 induced pluripotent stem cell human CVCL_IP65 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21112685 CVCL_J164 1G12 hybridoma house mouse CVCL_J164 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21112686 CVCL_IP64 HPS0186 induced pluripotent stem cell human CVCL_IP64 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21112687 CVCL_J167 2.03.7 hybridoma house mouse CVCL_J167 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Eimeria tenella merozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8389 21112688 CVCL_IP67 OSrb/N-M cancer cell line human CVCL_IP67 CL:0000010 Population: Japanese; Donor information: Established from a patient that suffered from bilateral retinoblastoma at infancy; Derived from metastatic site: Bone; left humerus. Female Doubling time: 84.7 hours (PubMed=10077219) 21112689 CVCL_J166 1H11 [Mouse hybridoma against human COL1A2] hybridoma house mouse CVCL_J166 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08123; Human COL1A2 (Note=Recognizes cross-linked N-telopeptides \"QYDGKGVG\" where K is involved in trivalent cross-linking). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10611 21112690 CVCL_IP66 HPS0414 induced pluripotent stem cell human CVCL_IP66 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21112691 CVCL_IP61 Lec4 spontaneously immortalized cell line CVCL_IP61 CL:0000010 Sequence variation: Mutation; UniProtKB; P97259; Mgat5; Simple; p.Asp135Valfs*22; Zygosity=Unspecified; Note=Truncated protein lacking enzymatic activity (PubMed=8910328); Sequence variation: Mutation; UniProtKB; P97259; Mgat5; Simple; p.Ile598fs; Zygosity=Unspecified; Note=Truncated protein lacking enzymatic activity (PubMed=8910328) Derived from sampling site: Ovary. Female 21112692 CVCL_J161 LS77-1C6 hybridoma house mouse CVCL_J161 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49682; Human CXCR3/CD183. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12330 21112693 CVCL_IP60 1228 cancer cell line human CVCL_IP60 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Cancer stem cell line 21112694 CVCL_J160 LI 66 hybridoma house mouse CVCL_J160 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-12. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8442 21112695 CVCL_J163 1D4 [Mouse hybridoma against human herpesvirus 1 p40] hybridoma house mouse CVCL_J163 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10210; Human herpesvirus 1 (HHV-1) capsid scaffolding protein (p40). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8068 21112696 CVCL_IP63 GM00606 transformed cell line human CVCL_IP63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00606; probable Unspecified 21112697 CVCL_J162 1D11.16.8 hybridoma house mouse CVCL_J162 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18341; Bovine TGFB1 (Note=Also reacts with human, mouse, rat and many other species); Monoclonal antibody target: UniProtKB; P21214; Bovine TGFB2 (Note=Also reacts with human, mouse, rat and many other species); Monoclonal antibody target: UniProtKB; A6QP91; Bovine TGFB3 (Note=Also reacts with human, mouse, rat and many other species). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9849 21112698 CVCL_IP62 Lec4A spontaneously immortalized cell line CVCL_IP62 CL:0000010 Sequence variation: Mutation; UniProtKB; P97259; Mgat5; Simple; p.Leu188Arg (c.563T>G); Zygosity=Homozygous; Note=Causes mistargeting of the protein to the ER (PubMed=8910328) Derived from sampling site: Ovary. Female 21112699 CVCL_IP39 LAU-Me305 cancer cell line human CVCL_IP39 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Female 21112700 CVCL_J139 T3-2G4 hybridoma house mouse CVCL_J139 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9058 21112701 CVCL_IP36 LAU-Me281.M1 cancer cell line human CVCL_IP36 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112702 CVCL_J136 T3-2A9 hybridoma house mouse CVCL_J136 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9028 21112703 CVCL_IP35 LAU-Me276 cancer cell line human CVCL_IP35 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Male 21112704 CVCL_J135 T3-1E7 hybridoma house mouse CVCL_J135 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9055 21112705 CVCL_IP38 LAU-Me300 cancer cell line human CVCL_IP38 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285). Male 21112706 CVCL_J138 T3-2D2 hybridoma house mouse CVCL_J138 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9061 21112707 CVCL_IP37 LAU-Me281.M3 cancer cell line human CVCL_IP37 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112708 CVCL_J137 T3-2B1 hybridoma house mouse CVCL_J137 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9057 21112709 CVCL_IP32 LAU-Me243 cancer cell line human CVCL_IP32 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Cutaneous. Male 21112710 CVCL_J132 T3-1D8 hybridoma house mouse CVCL_J132 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9032 21112711 CVCL_IP31 LAU-Me242.B1 cancer cell line human CVCL_IP31 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Female 21112712 CVCL_J131 T3-1C9 hybridoma house mouse CVCL_J131 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9033 21112713 CVCL_IP34 LAU-Me261 cancer cell line human CVCL_IP34 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Male 21112714 CVCL_J134 T3-1E5 hybridoma house mouse CVCL_J134 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9029 21112715 CVCL_IP33 LAU-Me248.3 cancer cell line human CVCL_IP33 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Cutaneous. Male 21112716 CVCL_J133 T3-1E10 hybridoma house mouse CVCL_J133 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9060 21112717 CVCL_IP30 LAU-Me215 cancer cell line human CVCL_IP30 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Female 21112718 CVCL_J130 T3-1C12 hybridoma house mouse CVCL_J130 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9030 21112719 CVCL_IP47 LAU-T1262A cancer cell line human CVCL_IP47 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Female 21112720 CVCL_J147 T3-8F5 hybridoma house mouse CVCL_J147 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9067 21112721 CVCL_IP46 LAU-T1257C cancer cell line human CVCL_IP46 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Male 21112722 CVCL_J146 T3-8B8 hybridoma house mouse CVCL_J146 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9066 21112723 CVCL_J149 FRAN4 hybridoma house mouse CVCL_J149 CL:0000010 Monoclonal antibody isotype: IgM (PubMed=8426087); IgG1, kappa (ATCC); Monoclonal antibody target: Francisella tularensis subsp holarctica strain LVS lipopolysaccharide.. Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10830 21112724 CVCL_IP49 LAU-T331A cancer cell line human CVCL_IP49 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Male 21112725 CVCL_IP48 LAU-T1262B cancer cell line human CVCL_IP48 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Female 21112726 CVCL_J148 T3-9E7 hybridoma house mouse CVCL_J148 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9065 21112727 CVCL_IP43 LAU-T1255A.b1 cancer cell line human CVCL_IP43 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Male 21112728 CVCL_J143 T3-3H1 hybridoma house mouse CVCL_J143 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9064 21112729 CVCL_IP42 LAU-Me337 cancer cell line human CVCL_IP42 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Male 21112730 CVCL_J142 T3-3F11 hybridoma house mouse CVCL_J142 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9059 21112731 CVCL_IP45 LAU-T1257A cancer cell line human CVCL_IP45 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland. CL:0000010 Male 21112732 CVCL_J145 T3-4C11 hybridoma house mouse CVCL_J145 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9031 21112733 CVCL_IP44 LAU-T1255A.g2 cancer cell line human CVCL_IP44 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Male 21112734 CVCL_J144 T3-4A7 hybridoma house mouse CVCL_J144 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9063 21112735 CVCL_IP41 LAU-Me317 cancer cell line human CVCL_IP41 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112736 CVCL_J141 T3-2H6 hybridoma house mouse CVCL_J141 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9062 21112737 CVCL_IP40 LAU-Me312 cancer cell line human CVCL_IP40 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Female 21112738 CVCL_J140 T3-2H5 hybridoma house mouse CVCL_J140 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P16154; Clostridioides difficile toxA; Monoclonal antibody target: UniProtKB; P18177; Clostridioides difficile toxB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9056 21112739 CVCL_RJ91 PCI-44 cancer cell line human CVCL_RJ91 CL:0000010 Male 21112740 CVCL_RJ90 PCI-43 [Human OCSCC] cancer cell line human CVCL_RJ90 CL:0000010 Male 21112741 CVCL_RJ93 PCI-46 cancer cell line human CVCL_RJ93 CL:0000010 Derived from metastatic site: Lymph node. Male 21112742 CVCL_RJ92 PCI-45 cancer cell line human CVCL_RJ92 CL:0000010 Derived from metastatic site: Lymph node. Male 21112743 CVCL_RJ95 UNIPDi002-A induced pluripotent stem cell human CVCL_RJ95 From: University of Padova; Padova; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15979; TP63; Simple; p.Arg343Gln (c.1028G>A) (R304Q); ClinVar=VCV000006534; Zygosity=Heterozygous (PubMed=29486400) Population: Caucasian; Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial stem cell.. Female 21112744 CVCL_RJ94 PCI-47 cancer cell line human CVCL_RJ94 CL:0000010 Female 21112745 CVCL_RJ97 UKWi001-A induced pluripotent stem cell human CVCL_RJ97 From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Gene amplification; HGNC; 11007; SLC2A3; Duplication; Zygosity=Unspecified (PubMed=29477591). Female 21112746 CVCL_RJ96 UNIPDi003-A induced pluripotent stem cell human CVCL_RJ96 From: University of Padova; Padova; Italy CL:0000010 Sequence variation: Mutation; HGNC; 15979; TP63; Simple; p.Arg318His (c.953G>A) (R279H); ClinVar=VCV000006533; Zygosity=Heterozygous (PubMed=29477592) Population: Caucasian; Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial stem cell.. Female 21112747 CVCL_RJ99 PCI-52 cancer cell line human CVCL_RJ99 CL:0000010 Male 21112748 CVCL_RJ98 PCI-51 cancer cell line human CVCL_RJ98 CL:0000010 Male 21112749 CVCL_RJ80 PCI-32 cancer cell line human CVCL_RJ80 CL:0000010 Derived from metastatic site: Lymph node. Male 21112750 CVCL_RJ82 PCI-34 cancer cell line human CVCL_RJ82 CL:0000010 Derived from metastatic site: Oral cavity; retromolar trigone. Male 21112751 CVCL_RJ81 PCI-33 cancer cell line human CVCL_RJ81 CL:0000010 Derived from metastatic site: Oral cavity; floor of mouth. Male 21112752 CVCL_RJ84 PCI-35 [Human OCSCC] cancer cell line human CVCL_RJ84 CL:0000010 Male 21112753 CVCL_RJ83 PCI-19 [Human HNSCC] cancer cell line human CVCL_RJ83 CL:0000010 Male 21112754 CVCL_RJ86 PCI-39 cancer cell line human CVCL_RJ86 CL:0000010 Male 21112755 CVCL_RJ85 PCI-36 cancer cell line human CVCL_RJ85 CL:0000010 Derived from metastatic site: Lymph node. Female 21112756 CVCL_RJ88 PCI-41 cancer cell line human CVCL_RJ88 CL:0000010 Female 21112757 CVCL_RJ87 PCI-40 cancer cell line human CVCL_RJ87 CL:0000010 Derived from metastatic site: Lymph node. Male 21112758 CVCL_RJ89 PCI-42 cancer cell line human CVCL_RJ89 CL:0000010 Male 21112759 CVCL_RJ71 CHOP-TU transformed cell line CVCL_RJ71 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Ovary. Female Characteristics: Supports the extrachromosomal replication of eukaryotic expression vector carrying a polyoma origin of replication 21112760 CVCL_RJ70 HAP1 TP53(-) 1 cancer cell line human CVCL_RJ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21112761 CVCL_RJ73 PCI-21 cancer cell line human CVCL_RJ73 CL:0000010 Male 21112762 CVCL_RJ72 PCI-20 cancer cell line human CVCL_RJ72 CL:0000010 Derived from metastatic site: Lymph node. Male 21112763 CVCL_RJ75 PCI-26 cancer cell line human CVCL_RJ75 CL:0000010 Derived from sampling site: Larynx. Male 21112764 CVCL_RJ74 PCI-25 cancer cell line human CVCL_RJ74 CL:0000010 Derived from metastatic site: Lymph node. Male 21112765 CVCL_RJ77 PCI-28 cancer cell line human CVCL_RJ77 CL:0000010 Derived from sampling site: Larynx. Male 21112766 CVCL_RJ76 PCI-27 cancer cell line human CVCL_RJ76 CL:0000010 Derived from metastatic site: Lymph node. Male 21112767 CVCL_RJ79 PCI-31 cancer cell line human CVCL_RJ79 CL:0000010 Male 21112768 CVCL_RJ78 PCI-29 cancer cell line human CVCL_RJ78 CL:0000010 Female 21112769 CVCL_RJ60 HC-6-1 induced pluripotent stem cell human CVCL_RJ60 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21112770 CVCL_RJ62 HeLa His10-SUMO-2 K0-Q87R cancer cell line human CVCL_RJ62 CL:0000010 Transfected with: HGNC; 11125; SUMO2 (with p.Lys11Arg, p.Lys32Arg, p.Lys32Arg, p.Lys34Arg, p.Lys41Arg, p.Lys44Arg and p.Gln87Arg); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Sumoylated proteins analysis by proteomics Female Characteristics: Transfected with a decahistidine (His10) tagged lysine-deficient (K0) and Q87R SUMO2 and GFP separated by an internal ribosome entry site (IRES) 21112771 CVCL_RJ61 HC-2-6 cancer cell line human CVCL_RJ61 CL:0000010 Female 21112772 CVCL_RJ64 C-HC-32 cancer cell line human CVCL_RJ64 CL:0000010 Population: Japanese. 21112773 CVCL_RJ63 U2OS His10-SUMO-2-K0-Q87R cancer cell line human CVCL_RJ63 CL:0000010 Transfected with: HGNC; 11125; SUMO2 (with p.Lys11Arg, p.Lys32Arg, p.Lys32Arg, p.Lys34Arg, p.Lys41Arg, p.Lys44Arg and p.Gln87Arg); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Omics: Sumoylated proteins analysis by proteomics Female Characteristics: Transfected with a decahistidine (His10) tagged lysine-deficient (K0) and Q87R SUMO2 and GFP separated by an internal ribosome entry site (IRES) 21112774 CVCL_RJ66 ClearCa-33 cancer cell line human CVCL_RJ66 CL:0000010 Unspecified 21112775 CVCL_RJ65 FCC-1 cancer cell line human CVCL_RJ65 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21112776 CVCL_RJ68 HCT 116 TP53 (R248W/-) cancer cell line human CVCL_RJ68 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Hemizygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a TP53 mutation 21112777 CVCL_RJ67 ClearCa-43 cancer cell line human CVCL_RJ67 CL:0000010 Unspecified 21112778 CVCL_RJ69 HCT 116 TP53 (R248W/+) cancer cell line human CVCL_RJ69 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a TP53 mutation 21112779 CVCL_RJ49 PDB2lox-17 induced pluripotent stem cell human CVCL_RJ49 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112780 CVCL_RJ51 PDB2lox-22 induced pluripotent stem cell human CVCL_RJ51 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112781 CVCL_RJ50 PDB2lox-21 induced pluripotent stem cell human CVCL_RJ50 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21112782 CVCL_RJ53 TkDA3-2 induced pluripotent stem cell human CVCL_RJ53 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112783 CVCL_RJ52 TkDA3-1 induced pluripotent stem cell human CVCL_RJ52 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112784 CVCL_RJ55 TkDA3-5 induced pluripotent stem cell human CVCL_RJ55 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112785 CVCL_RJ54 TkDA3-4 induced pluripotent stem cell human CVCL_RJ54 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112786 CVCL_RJ57 TkDA3-20 induced pluripotent stem cell human CVCL_RJ57 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112787 CVCL_RJ56 TkDA3-9 induced pluripotent stem cell human CVCL_RJ56 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112788 CVCL_RJ59 HC-4-EL1 induced pluripotent stem cell human CVCL_RJ59 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21112789 CVCL_RJ58 TkDN4-M induced pluripotent stem cell human CVCL_RJ58 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21112790 CVCL_S573 DHD/K12/TS cancer cell line Norway rat CVCL_S573 CL:0000010 Breed/subspecies: BDIX. 21112791 CVCL_RT73 GM26586 finite cell line human CVCL_RT73 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112792 CVCL_S572 DHD/K12/TR cancer cell line Norway rat CVCL_S572 CL:0000010 Breed/subspecies: BDIX. 21112793 CVCL_RT72 GM26585 transformed cell line human CVCL_RT72 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112794 CVCL_S575 EpH4-Be1a spontaneously immortalized cell line house mouse CVCL_S575 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112795 CVCL_RT75 GM26588 transformed cell line human CVCL_RT75 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112796 CVCL_RT74 GM26587 transformed cell line human CVCL_RT74 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112797 CVCL_S574 IM-Ep-1 spontaneously immortalized cell line house mouse CVCL_S574 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112798 CVCL_S577 EpH4-H1B spontaneously immortalized cell line house mouse CVCL_S577 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112799 CVCL_RT77 GM26591 transformed cell line human CVCL_RT77 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112800 CVCL_S576 EpH4-Be4a spontaneously immortalized cell line house mouse CVCL_S576 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112801 CVCL_RT76 GM26590 finite cell line human CVCL_RT76 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg458Lysfs*14 (c.1370dupG); ClinVar=VCV000126422; Zygosity=Homozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112802 CVCL_S579 EpH4-J3B1 spontaneously immortalized cell line house mouse CVCL_S579 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112803 CVCL_RT79 GM26593 transformed cell line human CVCL_RT79 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21112804 CVCL_S578 EpH4-I3G2 spontaneously immortalized cell line house mouse CVCL_S578 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112805 CVCL_RT78 GM26592 finite cell line human CVCL_RT78 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112806 CVCL_S580 EpH4-K3A3 spontaneously immortalized cell line house mouse CVCL_S580 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112807 CVCL_RT80 GM26594 finite cell line human CVCL_RT80 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112808 CVCL_RT82 GM26596 finite cell line human CVCL_RT82 CL:0000010 Sequence variation: Mutation; HGNC; 3157; EDA; Simple; p.Arg69Leu (c.206G>T); ClinVar=VCV000011032; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Trp535Ter (c.1604G>A); ClinVar=VCV000221577; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser636_Leu637insTer (c.1910delT) (p.Leu637Ter); ClinVar=VCV000221582; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Arg813Gln (c.2438G>A); ClinVar=VCV000643114; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10891; SIX5; Simple; p.Thr552Met (c.1655C>T); ClinVar=VCV000008601; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112809 CVCL_S582 VMM86 cancer cell line human CVCL_S582 CL:0000010 Unspecified 21112810 CVCL_RT81 GM26595 transformed cell line human CVCL_RT81 CL:0000010 Sequence variation: Mutation; HGNC; 3157; EDA; Simple; p.Arg69Leu (c.206G>T); ClinVar=VCV000011032; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Trp535Ter (c.1604G>A); ClinVar=VCV000221577; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser636_Leu637insTer (c.1910delT) (p.Leu637Ter); ClinVar=VCV000221582; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Arg813Gln (c.2438G>A); ClinVar=VCV000643114; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10891; SIX5; Simple; p.Thr552Met (c.1655C>T); ClinVar=VCV000008601; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21112811 CVCL_S581 VMM17 cancer cell line human CVCL_S581 HLA typing: A*0201,33; B*45,55/66 (PubMed=10752474) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21112812 CVCL_S562 731-mel cancer cell line human CVCL_S562 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=15467732). Unspecified 21112813 CVCL_RT62 RWD5700-1 cancer cell line human CVCL_RT62 CL:0000010 Unspecified 21112814 CVCL_S561 729-mel cancer cell line human CVCL_S561 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732). Unspecified 21112815 CVCL_RT61 RWD3051 cancer cell line human CVCL_RT61 CL:0000010 Unspecified 21112816 CVCL_S564 865-mel cancer cell line human CVCL_S564 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732). Unspecified 21112817 CVCL_RT64 GM26607 finite cell line human CVCL_RT64 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112818 CVCL_S563 798-mel cancer cell line human CVCL_S563 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732). Unspecified 21112819 CVCL_RT63 SLB-1 transformed cell line human CVCL_RT63 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21112820 CVCL_S566 894-mel cancer cell line human CVCL_S566 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA. CL:0000010 Unspecified 21112821 CVCL_RT66 GM26598 finite cell line human CVCL_RT66 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser116Ter (c.347C>G); ClinVar=VCV000221579; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; c.881+5G>T (IVS5+5G>T); ClinVar=VCV000221584; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112822 CVCL_S565 883-mel cancer cell line human CVCL_S565 HLA typing: A*01,03; B*07,08; C*07 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Unspecified 21112823 CVCL_RT65 GM26608 finite cell line human CVCL_RT65 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112824 CVCL_S568 BT4Cn cancer cell line Norway rat CVCL_S568 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Doubling time: 26.7 +- 1.4 hours (in serum-supplemented media), 38.7 +- 4.0 hours (in serum-free media) (PubMed=3178168) 21112825 CVCL_RT68 GM26600 finite cell line human CVCL_RT68 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; c.881+5G>T (IVS5+5G>T); ClinVar=VCV000221584; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112826 CVCL_S567 952-mel cancer cell line human CVCL_S567 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732). Unspecified 21112827 CVCL_RT67 GM26599 finite cell line human CVCL_RT67 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser116Ter (c.347C>G); ClinVar=VCV000221579; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112828 CVCL_S569 BT2C cancer cell line Norway rat CVCL_S569 CL:0000010 Breed/subspecies: BDIX. 21112829 CVCL_RT69 GM26582 finite cell line human CVCL_RT69 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21112830 CVCL_RT71 GM26584 finite cell line human CVCL_RT71 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112831 CVCL_S571 RH-PA undefined cell line type human CVCL_S571 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21112832 CVCL_RT70 GM26583 finite cell line human CVCL_RT70 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln631Serfs*7 (c.1891delC); ClinVar=VCV000050961; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21112833 CVCL_S570 RH [Human] undefined cell line type human CVCL_S570 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21112834 CVCL_RT51 AM9-1-4D6 hybridoma house mouse CVCL_RT51 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4156 21112835 CVCL_S551 GBM-18 cancer cell line human CVCL_S551 CL:0000010 Unspecified 21112836 CVCL_RT50 AM9-1-3C1 hybridoma house mouse CVCL_RT50 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4155 21112837 CVCL_S550 Hepa-1 cancer cell line house mouse CVCL_S550 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21112838 CVCL_RT53 AM9-1-7D2 hybridoma house mouse CVCL_RT53 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4144 21112839 CVCL_S553 GBM-18-B3 cancer cell line human CVCL_S553 CL:0000010 Transfected with: HGNC; 40; ABCB1. Selected for resistance to: ChEBI; CHEBI:23359; Colchicine Unspecified 21112840 CVCL_RT52 AM9-1-6D4 hybridoma house mouse CVCL_RT52 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4157 21112841 CVCL_S552 GBM-18-A3 cancer cell line human CVCL_S552 CL:0000010 Transfected with: HGNC; 40; ABCB1. Selected for resistance to: ChEBI; CHEBI:23359; Colchicine Unspecified 21112842 CVCL_RT55 AM9-9-11H11 hybridoma house mouse CVCL_RT55 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4159 21112843 CVCL_S555 M73.24 hybridoma house mouse CVCL_S555 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35918; Mouse Kdr/Cd309. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12153 21112844 CVCL_RT54 AM9-9-11G9 hybridoma house mouse CVCL_RT54 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4158 21112845 CVCL_S554 M25.18A1 hybridoma house mouse CVCL_S554 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35918; Mouse Kdr/Cd309. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12152 21112846 CVCL_RT57 AM9-9-6C3 hybridoma house mouse CVCL_RT57 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4146 21112847 CVCL_S557 MMM [Mouse] spontaneously immortalized cell line house mouse CVCL_S557 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NMRI. Unspecified Characteristics: Very effective in supporting the growth of human embryonic stem cells 21112848 CVCL_RT56 AM9-9-4F5 hybridoma house mouse CVCL_RT56 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4145 21112849 CVCL_S556 ARIP/PDX-1 cancer cell line Norway rat CVCL_S556 CL:0000010 Transfected with: RGD; 62387; Pdx1 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas; Breed/subspecies: Wistar. 21112850 CVCL_S559 MMG2 cancer cell line human CVCL_S559 From: Department of Dermatology, Gifu University; Gifu; Japan CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male 21112851 CVCL_RT59 WD0082 cancer cell line human CVCL_RT59 CL:0000010 Unspecified 21112852 CVCL_S558 MMMbz spontaneously immortalized cell line house mouse CVCL_S558 CL:0000010 Selected for resistance to: ChEBI; CHEBI:22905; Blasticidin; Selected for resistance to: ChEBI; CHEBI:75046; Phleomycin D1 (Zeocin); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NMRI. Unspecified Characteristics: Very effective in supporting the growth of human embryonic stem cells (Kerafast) Doubling time: 16 hours (PubMed=16683986) 21112853 CVCL_RT58 RDD8107-2 cancer cell line human CVCL_RT58 CL:0000010 Unspecified 21112854 CVCL_S560 1362-mel cancer cell line human CVCL_S560 HLA typing: A*01,25 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Unspecified 21112855 CVCL_RT60 RDD6960-2 cancer cell line human CVCL_RT60 CL:0000010 Unspecified 21112856 CVCL_S540 A3R5.7 cancer cell line human CVCL_S540 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Expresses CCR5 under the control of a CMV promoter (PubMed=24312168); Characteristics: Useful for the detection of weak neutralizing antibody responses against tier 2 strains of HIV-1 (PubMed=24607608) 21112857 CVCL_RT40 AM1-3B1 hybridoma house mouse CVCL_RT40 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140163; Cyclosporin A metabolite M17 (AM1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4154 21112858 CVCL_RT42 AM19-1-5B3 hybridoma house mouse CVCL_RT42 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4147 21112859 CVCL_S542 CHO-EE spontaneously immortalized cell line CVCL_S542 CL:0000010 Derived from sampling site: Ovary. Female 21112860 CVCL_RT41 AM1-7F5 hybridoma house mouse CVCL_RT41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:140163; Cyclosporin A metabolite M17 (AM1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4142 21112861 CVCL_S541 CHO-PI spontaneously immortalized cell line CVCL_S541 CL:0000010 Transfected with: UniProtKB; P04578; HIV-1 isolate HXB2 env Derived from sampling site: Ovary. Female Characteristics: Expresses GPI-anchored gp120 21112862 CVCL_RT44 AM19-1-7E12 hybridoma house mouse CVCL_RT44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4161 21112863 CVCL_S544 CHO-WT spontaneously immortalized cell line CVCL_S544 CL:0000010 Transfected with: UniProtKB; P04578; HIV-1 isolate HXB2 env Derived from sampling site: Ovary. Female Characteristics: Expresses wild-type Env proteins 21112864 CVCL_RT43 AM19-1-5D2 hybridoma house mouse CVCL_RT43 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4163 21112865 CVCL_S543 CHO-SEC spontaneously immortalized cell line CVCL_S543 CL:0000010 Transfected with: UniProtKB; P04578; HIV-1 isolate HXB2 env Derived from sampling site: Ovary. Female Characteristics: Expresses secreted gp120 21112866 CVCL_RT46 AM19-9-1D8 hybridoma house mouse CVCL_RT46 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4148 21112867 CVCL_S546 Ramos/DC-SIGN cancer cell line human CVCL_S546 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: Caucasian; Derived from sampling site: Ascites. Male 21112868 CVCL_RT45 AM19-9-1E11 hybridoma house mouse CVCL_RT45 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4149 21112869 CVCL_S545 MOLT-4/CCR5 cancer cell line human CVCL_S545 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21112870 CVCL_RT48 AM19-9-5A6 hybridoma house mouse CVCL_RT48 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4150 21112871 CVCL_S548 IM-2 spontaneously immortalized cell line house mouse CVCL_S548 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21112872 CVCL_RT47 AM19-9-2G9 hybridoma house mouse CVCL_RT47 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140158; Cyclosporin A metabolite M8 (AM19). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4160 21112873 CVCL_S547 NC-37/DC-SIGN cancer cell line human CVCL_S547 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Problematic cell line: Contaminated Parent cell line (NC-37) has been shown to be a Raji derivative. 21112874 CVCL_RT49 AM9-1-2A11 hybridoma house mouse CVCL_RT49 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:140152; Cyclosporin A metabolite M1 (AM9). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4143 21112875 CVCL_S549 HeB5 cancer cell line house mouse CVCL_S549 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21112876 CVCL_S531 RH/66A transformed cell line CVCL_S531 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified 21112877 CVCL_RT31 UM-UC-8 cancer cell line human CVCL_RT31 CL:0000010 Miscellaneous: Cell line has been discarded (PubMed=3761468) Derived from sampling site: Urinary bladder. Female Doubling time: 53 hours (PubMed=3761468) 21112878 CVCL_RT30 PH101 cancer cell line human CVCL_RT30 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21112879 CVCL_S530 YES-6 cancer cell line human CVCL_S530 HLA typing: A*02,24; B*01,15; C*03,04 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21112880 CVCL_RT33 JR cancer cell line human CVCL_RT33 CL:0000010 Omics: Deep exome analysis. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21112881 CVCL_S533 RH/66F transformed cell line CVCL_S533 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified 21112882 CVCL_RT32 M23 cancer cell line human CVCL_RT32 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23418523). Unspecified 21112883 CVCL_S532 RH/66E transformed cell line CVCL_S532 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified 21112884 CVCL_RT35 MDBK-221 spontaneously immortalized cell line CVCL_RT35 CL:0000010 Transfected with: UniProtKB; Q64843; Bovine adenovirus 3 E1B 157R; Transfected with: UniProtKB; Q64844; Bovine adenovirus 3 E1B 420R Derived from sampling site: Kidney. Male 21112885 CVCL_S535 RH/K30 transformed cell line CVCL_S535 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Discontinued: ATCC; CRL-2560; true Unspecified Virology: HTLV-1 producing cell line 21112886 CVCL_RT34 FBK-34 finite cell line CVCL_RT34 CL:0000010 Transfected with: UniProtKB; Q64843; Bovine adenovirus 3 E1B 157R; Transfected with: UniProtKB; Q64844; Bovine adenovirus 3 E1B 420R Derived from sampling site: Fetal kidney. Unspecified 21112887 CVCL_S534 RH/K29 transformed cell line CVCL_S534 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified 21112888 CVCL_S537 RH/K34 transformed cell line CVCL_S537 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified Virology: HTLV-1 producing cell line 21112889 CVCL_RT37 VIDO R2 transformed cell line CVCL_RT37 CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-156 21112890 CVCL_S536 RH/K32 transformed cell line CVCL_S536 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified Virology: HTLV-1 producing cell line 21112891 CVCL_IZ99 VACO 847 cancer cell line human CVCL_IZ99 CL:0000010 Derived from metastatic site: Lymph node. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21112892 CVCL_RT36 VIDO R1 transformed cell line pig CVCL_RT36 CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina. Unspecified 21112893 CVCL_RT39 AM1-2E10 hybridoma house mouse CVCL_RT39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:140163; Cyclosporin A metabolite M17 (AM1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4141 21112894 CVCL_S539 RHT-16 transformed cell line CVCL_S539 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: New Zealand white. Unspecified Virology: HTLV-1 producing cell line 21112895 CVCL_RT38 CSA-2G9 hybridoma house mouse CVCL_RT38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:4031; Cyclosporin A (CsA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4170 21112896 CVCL_S538 RHE-X76 cancer cell line CVCL_S538 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-2562; true Female 21112897 CVCL_IZ96 BJAB-K6 cancer cell line human CVCL_IZ96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21112898 CVCL_IZ95 BJAB-K43 cancer cell line human CVCL_IZ95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21112899 CVCL_IZ98 VACO 389 cancer cell line human CVCL_IZ98 CL:0000010 Male Microsatellite instability: Stable (MSS) (PubMed=27004849). 21112900 CVCL_IZ97 BJAB-K88 cancer cell line human CVCL_IZ97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Omics: N-glycan profiling Female Virology: EBV-negative 21112901 CVCL_IZ92 Mm 290-96 transformed cell line CVCL_IZ92 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112902 CVCL_IZ91 Mm 265-95 transformed cell line CVCL_IZ91 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112903 CVCL_IZ94 BJAB-K20 cancer cell line human CVCL_IZ94 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Omics: N-glycan profiling Female Characteristics: Lacks UDP-GlcNAc 2-epimerase activity; Virology: EBV-negative 21112904 CVCL_IZ93 Mm 303-97 transformed cell line CVCL_IZ93 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112905 CVCL_IZ90 Mm 256-95 transformed cell line CVCL_IZ90 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112906 CVCL_S520 MOCL4 spontaneously immortalized cell line CVCL_S520 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112907 CVCL_RT20 UKF-NB-2rCARBO2000 cancer cell line human CVCL_RT20 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112908 CVCL_S522 MOCL6 spontaneously immortalized cell line CVCL_S522 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112909 CVCL_RT22 Tn-NVN spontaneously immortalized cell line CVCL_RT22 CL:0000010 Derived from sampling site: Ovary. Female Virology: Cured of TnCLV infection by ribavirin-treatment Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line 21112910 CVCL_RT21 H446/CDDP cancer cell line human CVCL_RT21 CL:0000010 Sequence variation: Gene fusion; HGNC; 6728; LY6H + HGNC; 9709; PVT1; Name(s)=PVT1-LY6H (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling Male 21112911 CVCL_S521 MOCL5 spontaneously immortalized cell line CVCL_S521 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112912 CVCL_S524 MOCL8 spontaneously immortalized cell line CVCL_S524 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112913 CVCL_RT24 UKF-NB-3rYM155_20nM cancer cell line human CVCL_RT24 CL:0000010 Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112914 CVCL_S523 MOCL7 spontaneously immortalized cell line CVCL_S523 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112915 CVCL_RT23 Tnms42 spontaneously immortalized cell line CVCL_RT23 CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line 21112916 CVCL_RT26 UKF-NB-6rYM155_20nM cancer cell line human CVCL_RT26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112917 CVCL_S526 YES-2CSC cancer cell line human CVCL_S526 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21112918 CVCL_S525 HKESC-1/cis cancer cell line human CVCL_S525 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Male 21112919 CVCL_RT25 UKF-NB-6rIRINO1000 cancer cell line human CVCL_RT25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112920 CVCL_RT28 UKF-Rhb-1rDOX20 cancer cell line human CVCL_RT28 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112921 CVCL_S528 YES-4 cancer cell line human CVCL_S528 HLA typing: A*02,24; B*01,39; C*07 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21112922 CVCL_S527 KYSE-280 cancer cell line human CVCL_S527 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Female Doubling time: 17.7 hours (PubMed=1728357) 21112923 CVCL_RT27 UKF-Rhb-1rDOCE20 cancer cell line human CVCL_RT27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112924 CVCL_RT29 SH101 cancer cell line human CVCL_RT29 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21112925 CVCL_S529 YES-5 cancer cell line human CVCL_S529 HLA typing: A*01,02; B*11,15; C*03 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21112926 CVCL_S511 MDA-MB-231/5-FU cancer cell line human CVCL_S511 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21112927 CVCL_RT11 UKF-NB-3rOXALI4000 cancer cell line human CVCL_RT11 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112928 CVCL_S510 AGE1.CS transformed cell line CVCL_S510 From: ProBioGen AG; Berlin; Germany CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Somite; Breed/subspecies: ST4 compact. Unspecified Group: Bird cell line 21112929 CVCL_RT10 UKF-NB-3rGEMCI20 cancer cell line human CVCL_RT10 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112930 CVCL_RT13 A549 GFP-EGFR cancer cell line human CVCL_RT13 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Edited by ZFN at the EGFR locus to insert a TagGFP2 construct at the C-terminus of the gene 21112931 CVCL_S513 Tpit/F1 conditionally immortalized cell line house mouse CVCL_S513 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; adenohypophysis; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 31.6 hours (PubMed=24881870) 21112932 CVCL_S512 TtT/GF cancer cell line house mouse CVCL_S512 CL:0000010 Derived from sampling site: Pituitary gland Cell type=Folliculostellate cell.; Breed/subspecies: C57BL/6N x C3H/2N. Omics: Transcriptome analysis by microarray Doubling time: 14.4 hours (PubMed=24881870) 21112933 CVCL_RT12 UKF-NB-3rTOPO20 cancer cell line human CVCL_RT12 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112934 CVCL_RT15 COLO-679rNutlin20muM cancer cell line human CVCL_RT15 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Phe (c.713G>T); ClinVar=VCV000376574; Zygosity=Heterozygous (PubMed=22170099); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3 Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112935 CVCL_S515 HMB2-8 cancer cell line human CVCL_S515 CL:0000010 Derived from metastatic site: Lymph node. Female 21112936 CVCL_IZ78 Min19919 transformed cell line CVCL_IZ78 From: New Iberia Research Center, University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112937 CVCL_IZ77 4G11 1.C12 hybridoma house mouse CVCL_IZ77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P48023; Human FASLG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4018 21112938 CVCL_RT14 EFO-21rCDDP2000 cancer cell line human CVCL_RT14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Arg (c.370T>C); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112939 CVCL_S514 HMB2-5 cancer cell line human CVCL_S514 CL:0000010 Derived from metastatic site: Lymph node. Female 21112940 CVCL_RT17 IMR-5rCARBO5000 cancer cell line human CVCL_RT17 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21112941 CVCL_S517 MOCL1 spontaneously immortalized cell line CVCL_S517 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112942 CVCL_RT16 COLO-679rPLX4032_10muM cancer cell line human CVCL_RT16 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112943 CVCL_S516 HMB2-LacZ cancer cell line human CVCL_S516 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from metastatic site: Lymph node. Female 21112944 CVCL_IZ79 Min19913 transformed cell line CVCL_IZ79 From: New Iberia Research Center, University of Louisiana at Lafayette; Lafayette; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112945 CVCL_IZ74 MDBK/441 spontaneously immortalized cell line CVCL_IZ74 CL:0000010 Derived from sampling site: Kidney. Male 21112946 CVCL_S519 MOCL3 spontaneously immortalized cell line CVCL_S519 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112947 CVCL_RT19 NGPrDACARB18 cancer cell line human CVCL_RT19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21112948 CVCL_RT18 H446/EP cancer cell line human CVCL_RT18 CL:0000010 Sequence variation: Gene fusion; HGNC; 6728; LY6H + HGNC; 9709; PVT1; Name(s)=PVT1-LY6H (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21112949 CVCL_S518 MOCL2 spontaneously immortalized cell line CVCL_S518 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Monocyte.. Unspecified 21112950 CVCL_IZ73 SNB-7 cancer cell line human CVCL_IZ73 CL:0000010 Unspecified 21112951 CVCL_IZ76 3E11 1-G9 hybridoma house mouse CVCL_IZ76 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P48023; Human FASLG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4017 21112952 CVCL_IZ75 P388/ADR cancer cell line house mouse CVCL_IZ75 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21112953 CVCL_IZ70 NAMEC9 spontaneously immortalized cell line human CVCL_IZ70 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21112954 CVCL_IZ72 MNK-3 transformed cell line house mouse CVCL_IZ72 CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic thymus Cell type=Fetal thymocyte.; Breed/subspecies: NIH Swiss. Unspecified 21112955 CVCL_IZ71 MNK-1 transformed cell line house mouse CVCL_IZ71 CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic thymus Cell type=Fetal thymocyte.; Breed/subspecies: NIH Swiss. Unspecified 21112956 CVCL_S500 MA2T cancer cell line CVCL_S500 CL:0000010 Discontinued: ATCC; CRL-6285; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21112957 CVCL_RT00 SK-N-ASrVINB10 cancer cell line human CVCL_RT00 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112958 CVCL_S502 Mad/C3 cancer cell line house mouse CVCL_S502 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6367; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21112959 CVCL_RT02 UKF-NB-2rDACARB4 cancer cell line human CVCL_RT02 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112960 CVCL_S501 Mad/C1 cancer cell line house mouse CVCL_S501 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6366; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21112961 CVCL_RT01 SK-N-ASrVINOR20 cancer cell line human CVCL_RT01 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112962 CVCL_IZ89 Mm 249-97 transformed cell line CVCL_IZ89 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112963 CVCL_S504 R06E transformed cell line CVCL_S504 From: ProBioGen AG; Berlin; Germany CL:0000010 Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285). Unspecified Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: ~50 hours (PubMed=19540275); ~40 hours (DSMZ=ACC-756) Group: Bat cell line; Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2902 Problematic cell line: Partially contaminated Some cultures of R06E are contaminated with the Vero cell line (PubMed=22754654), this is the case of the culture used in PubMed=20808767. 21112964 CVCL_RT04 UKF-NB-2rETO400 cancer cell line human CVCL_RT04 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112965 CVCL_IZ88 Mm 181-96 transformed cell line CVCL_IZ88 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112966 CVCL_S503 R05T transformed cell line CVCL_S503 CL:0000010 Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal head. Unspecified Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: ~50 hours (PubMed=19540275; DSMZ) Group: Bat cell line 21112967 CVCL_RT03 UKF-NB-2rETO40 cancer cell line human CVCL_RT03 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112968 CVCL_S506 HD-MB03 cancer cell line human CVCL_S506 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=23054560) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male Doubling time: 23.32 hours (early passage), 23.98 hours (late passage) (PubMed=23054560); ~48 hours (DSMZ=ACC-740) 21112969 CVCL_RT06 UKF-NB-2rPCL20 cancer cell line human CVCL_RT06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112970 CVCL_S505 1618-K cancer cell line human CVCL_S505 CL:0000010 Derived from metastatic site: Retroperitoneal space. Male Doubling time: ~40 hours (DSMZ=ACC-752) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: This cell line is said to originate from a 'primary retroperitoneal embryonal carcinoma' The current view is that retroperitoneal embryonal carcinoma is a metastatic form of testicular embryonal carcinoma. 21112971 CVCL_RT05 UKF-NB-2rIRINO400 cancer cell line human CVCL_RT05 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21112972 CVCL_S508 AGE1.CR.pIX transformed cell line CVCL_S508 From: ProBioGen AG; Berlin; Germany CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina; Breed/subspecies: ST4 compact. Unspecified Virology: Permissive for a wide spectrum of animal and human viruses including influenza (broad strain spectrum), rabies virus, Newcastle disease virus (NDV), duck and goose parvovirus, egg drop syndrome virus (EDS), infectious bursal disease virus (IBDV), turkey rhinotracheitis virus (TRT), Marek's disease virus (MDV), vesicular stomatitis virus (VSV) and herpesvirus of turkey (HVT) (ProBioGen) Doubling time: 35 hours (PubMed=19531390) Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2749 21112973 CVCL_IZ85 Mm 150-99 transformed cell line CVCL_IZ85 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21112974 CVCL_RT08 UKF-NB-3rCABAZI2 cancer cell line human CVCL_RT08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112975 CVCL_IZ84 594S-1X1055 transformed cell line CVCL_IZ84 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332) Characteristics: Produced by infecting peripheral blood lymphocytes of baboon 1X1055 with the supernatant of cell line 594S (Cellosaurus=CVCL_E151); Virology: Produces large amounts of Papiine herpesvirus 1 Group: Non-human primate cell line 21112976 CVCL_S507 JoPaca-1 cancer cell line human CVCL_S507 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=23152778; DepMap) Omics: Deep exome analysis. Male Doubling time: 28 hours (PubMed=23152778); ~3-4 days (DSMZ=ACC-744) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21112977 CVCL_RT07 UKF-NB-3rBORTE20 cancer cell line human CVCL_RT07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112978 CVCL_IZ87 Mm 173-02 transformed cell line CVCL_IZ87 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21112979 CVCL_S509 AGE1.CR transformed cell line CVCL_S509 From: ProBioGen AG; Berlin; Germany CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina; Breed/subspecies: ST4 compact. Unspecified Doubling time: 23 hours (PubMed=19531390) Group: Bird cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21112980 CVCL_IZ86 Mm 153-99 transformed cell line CVCL_IZ86 From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21112981 CVCL_RT09 UKF-NB-3rETO200 cancer cell line human CVCL_RT09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21112982 CVCL_IZ81 O4-Cb-neu transformed cell line house mouse CVCL_IZ81 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated EGFR-neu; Derived from sampling site: Brain; cerebellum; Breed/subspecies: NMRI. 21112983 CVCL_IZ80 Cb-neu transformed cell line house mouse CVCL_IZ80 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated EGFR-neu; Derived from sampling site: Brain; cerebellum; Breed/subspecies: NMRI. 21112984 CVCL_IZ83 N20.1 conditionally immortalized cell line house mouse CVCL_IZ83 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pZIPSVtsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Oligodendrocyte.; Breed/subspecies: BALB/cByJ. Unspecified Doubling time: ~48-62 hours (at 34 Celsius), >8 days (at 39 Celsius) (PubMed=7678286) 21112985 CVCL_IZ82 Oli-neu transformed cell line house mouse CVCL_IZ82 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated EGFR-neu; Derived from sampling site: Embryonic brain Cell type=Oligodendrocyte.; Breed/subspecies: NMRI. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Can be induced to differentiate after application of dibutyryl cAMP 21112986 CVCL_8H46 DA05326 transformed cell line human CVCL_8H46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112987 CVCL_8H45 DA05325 transformed cell line human CVCL_8H45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112988 CVCL_8H48 DA05328 transformed cell line human CVCL_8H48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112989 CVCL_8H47 DA05327 transformed cell line human CVCL_8H47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112990 CVCL_8H42 DA05322 transformed cell line human CVCL_8H42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112991 CVCL_8H41 DA05321 transformed cell line human CVCL_8H41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112992 CVCL_8H44 DA05324 transformed cell line human CVCL_8H44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112993 CVCL_8H43 DA05323 transformed cell line human CVCL_8H43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112994 CVCL_8H49 DA05329 transformed cell line human CVCL_8H49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112995 CVCL_8H40 DA05320 transformed cell line human CVCL_8H40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112996 CVCL_8H57 DA05341 transformed cell line human CVCL_8H57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112997 CVCL_8H56 DA05337 transformed cell line human CVCL_8H56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112998 CVCL_8H59 DA05345 transformed cell line human CVCL_8H59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21112999 CVCL_8H58 DA05344 transformed cell line human CVCL_8H58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113000 CVCL_8H53 DA05333 transformed cell line human CVCL_8H53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113001 CVCL_8H52 DA05332 transformed cell line human CVCL_8H52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113002 CVCL_8H55 DA05336 transformed cell line human CVCL_8H55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113003 CVCL_8H54 DA05335 transformed cell line human CVCL_8H54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113004 CVCL_8H51 DA05331 transformed cell line human CVCL_8H51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113005 CVCL_8H50 DA05330 transformed cell line human CVCL_8H50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113006 CVCL_8H24 DA05301 transformed cell line human CVCL_8H24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113007 CVCL_8H23 DA05300 transformed cell line human CVCL_8H23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113008 CVCL_8H26 DA05303 transformed cell line human CVCL_8H26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113009 CVCL_8H25 DA05302 transformed cell line human CVCL_8H25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113010 CVCL_8H20 DA05297 transformed cell line human CVCL_8H20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113011 CVCL_8H22 DA05299 transformed cell line human CVCL_8H22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113012 CVCL_8H21 DA05298 transformed cell line human CVCL_8H21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113013 CVCL_8H28 DA05305 transformed cell line human CVCL_8H28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113014 CVCL_8H27 DA05304 transformed cell line human CVCL_8H27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113015 CVCL_8H29 DA05306 transformed cell line human CVCL_8H29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113016 CVCL_8H35 DA05313 transformed cell line human CVCL_8H35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113017 CVCL_8H34 DA05312 transformed cell line human CVCL_8H34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113018 CVCL_8H37 DA05315 transformed cell line human CVCL_8H37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113019 CVCL_8H36 DA05314 transformed cell line human CVCL_8H36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113020 CVCL_8H31 DA05309 transformed cell line human CVCL_8H31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113021 CVCL_8H30 DA05307 transformed cell line human CVCL_8H30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113022 CVCL_8H33 DA05311 transformed cell line human CVCL_8H33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113023 CVCL_8H32 DA05310 transformed cell line human CVCL_8H32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113024 CVCL_8H39 DA05319 transformed cell line human CVCL_8H39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113025 CVCL_8H38 DA05318 transformed cell line human CVCL_8H38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113026 CVCL_8H02 DA05276 transformed cell line human CVCL_8H02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113027 CVCL_8H01 DA05275 transformed cell line human CVCL_8H01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113028 CVCL_8H04 DA05278 transformed cell line human CVCL_8H04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113029 CVCL_8H03 DA05277 transformed cell line human CVCL_8H03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113030 CVCL_8H00 DA05274 transformed cell line human CVCL_8H00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113031 CVCL_8H09 DA05284 transformed cell line human CVCL_8H09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113032 CVCL_8H06 DA05280 transformed cell line human CVCL_8H06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113033 CVCL_8H05 DA05279 transformed cell line human CVCL_8H05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113034 CVCL_8H08 DA05282 transformed cell line human CVCL_8H08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113035 CVCL_8H07 DA05281 transformed cell line human CVCL_8H07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113036 CVCL_8H13 DA05288 transformed cell line human CVCL_8H13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113037 CVCL_8H12 DA05287 transformed cell line human CVCL_8H12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113038 CVCL_8H15 DA05292 transformed cell line human CVCL_8H15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113039 CVCL_8H14 DA05291 transformed cell line human CVCL_8H14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113040 CVCL_8H11 DA05286 transformed cell line human CVCL_8H11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113041 CVCL_8H10 DA05285 transformed cell line human CVCL_8H10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113042 CVCL_8H17 DA05294 transformed cell line human CVCL_8H17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113043 CVCL_8H16 DA05293 transformed cell line human CVCL_8H16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113044 CVCL_8H19 DA05296 transformed cell line human CVCL_8H19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113045 CVCL_8H18 DA05295 transformed cell line human CVCL_8H18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113046 CVCL_RT95 GM26614 finite cell line human CVCL_RT95 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21113047 CVCL_S595 LAU-Me256 cancer cell line human CVCL_S595 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland. CL:0000010 21113048 CVCL_RT94 GM26613 transformed cell line human CVCL_RT94 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113049 CVCL_S594 NW745 cancer cell line human CVCL_S594 CL:0000010 21113050 CVCL_RT97 GM26616 finite cell line human CVCL_RT97 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21113051 CVCL_S597 LAU-Me275 cancer cell line human CVCL_S597 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male 21113052 CVCL_RT96 GM26615 transformed cell line human CVCL_RT96 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113053 CVCL_S596 LAU-Me260.LN cancer cell line human CVCL_S596 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Female 21113054 CVCL_RT99 GM26073 transformed cell line human CVCL_RT99 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; c.1297-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation De novo mutation (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113055 CVCL_S599 NA8-MEL cancer cell line human CVCL_S599 From: Jotereau F.; U211 INSERM; Nantes; France. CL:0000010 21113056 CVCL_RT98 GM26663 induced pluripotent stem cell human CVCL_RT98 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113057 CVCL_S598 LAU-Me290 cancer cell line human CVCL_S598 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Lymph node. Female 21113058 CVCL_RT84 GM26601 transformed cell line human CVCL_RT84 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113059 CVCL_S584 VMM5B cancer cell line human CVCL_S584 CL:0000010 Male 21113060 CVCL_RT83 GM26597 transformed cell line human CVCL_RT83 CL:0000010 Sequence variation: Mutation; HGNC; 3157; EDA; Simple; p.Arg69Leu (c.206G>T); ClinVar=VCV000011032; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Trp535Ter (c.1604G>A); ClinVar=VCV000221577; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113061 CVCL_S583 VMM150 cancer cell line human CVCL_S583 CL:0000010 Unspecified 21113062 CVCL_RT86 GM26603 transformed cell line human CVCL_RT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113063 CVCL_S586 MDCK-MDR1 spontaneously immortalized cell line dog CVCL_S586 CL:0000010 Transfected with: HGNC; 40; ABCB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Caution: There is another MDCK-II cell line with transfected human ABCB1: MDCK2-ABCB1 (Cellosaurus=CVCL_A2JZ) 21113064 CVCL_RT85 GM26602 finite cell line human CVCL_RT85 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Leu318Pro (c.953T>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg390Pro (c.1169G>C); ClinVar=VCV000221580; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21113065 CVCL_S585 PLHC-1/dox cancer cell line CVCL_S585 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032). Female Group: Fish cell line 21113066 CVCL_RT88 GM26605 transformed cell line human CVCL_RT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113067 CVCL_S588 VBT2-EBV transformed cell line human CVCL_S588 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113068 CVCL_RT87 GM26604 finite cell line human CVCL_RT87 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21113069 CVCL_S587 VBT2 cancer cell line human CVCL_S587 CL:0000010 Derived from metastatic site: Not specified. Male Doubling time: 1.5 days (PubMed=7513255) 21113070 CVCL_RT89 GM26606 finite cell line human CVCL_RT89 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21113071 CVCL_S589 NW624 cancer cell line human CVCL_S589 CL:0000010 21113072 CVCL_RT91 GM26610 finite cell line human CVCL_RT91 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21113073 CVCL_S591 NW38 cancer cell line human CVCL_S591 CL:0000010 Derived from metastatic site: Lymph node. Female 21113074 CVCL_RT90 GM26609 transformed cell line human CVCL_RT90 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113075 CVCL_S590 NW1539 cancer cell line human CVCL_S590 HLA typing: A*03,11; B*44,51; C*w04,w05 (PubMed=12747757). CL:0000010 21113076 CVCL_RT93 GM26612 finite cell line human CVCL_RT93 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21113077 CVCL_S593 NW726 cancer cell line human CVCL_S593 CL:0000010 21113078 CVCL_RT92 GM26611 transformed cell line human CVCL_RT92 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113079 CVCL_S592 NW450 cancer cell line human CVCL_S592 CL:0000010 21113080 CVCL_AA40 GM04900 transformed cell line human CVCL_AA40 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (from autologous cell line GM04899) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113081 CVCL_AA39 GM04899 finite cell line human CVCL_AA39 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21113082 CVCL_AA38 GM04898 transformed cell line human CVCL_AA38 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113083 CVCL_AA31 GM04642 transformed cell line human CVCL_AA31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113084 CVCL_AA30 GM04638 finite cell line human CVCL_AA30 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM04638; probable Female 21113085 CVCL_AA33 GM04665 finite cell line human CVCL_AA33 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM04663) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21113086 CVCL_AA32 GM04643 finite cell line human CVCL_AA32 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113087 CVCL_AA35 GM04895 finite cell line human CVCL_AA35 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113088 CVCL_AA34 GM04761 transformed cell line human CVCL_AA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113089 CVCL_AA37 GM04897 finite cell line human CVCL_AA37 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113090 CVCL_AA36 GM04896 transformed cell line human CVCL_AA36 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113091 CVCL_AA51 GM05046 transformed cell line human CVCL_AA51 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19815695) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21113092 CVCL_AA50 GM05044 transformed cell line human CVCL_AA50 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113093 CVCL_AA49 GM05043 transformed cell line human CVCL_AA49 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113094 CVCL_AA42 GM04957 finite cell line human CVCL_AA42 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113095 CVCL_AA41 GM04956 transformed cell line human CVCL_AA41 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113096 CVCL_AA44 GM04960 transformed cell line human CVCL_AA44 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113097 CVCL_AA43 GM04959 finite cell line human CVCL_AA43 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113098 CVCL_AA46 GM05004 finite cell line human CVCL_AA46 CL:0000010 Sequence variation: Mutation; HGNC; 27960; SLC6A19; Simple; p.Asp173Asn (c.517G>A); ClinVar=VCV000002019; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21113099 CVCL_AA45 GM05003 finite cell line human CVCL_AA45 CL:0000010 Sequence variation: Mutation; HGNC; 27960; SLC6A19; Simple; p.Asp173Asn (c.517G>A); ClinVar=VCV000002019; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21113100 CVCL_AA48 GM05042 transformed cell line human CVCL_AA48 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113101 CVCL_AA47 GM05041 transformed cell line human CVCL_AA47 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113102 CVCL_8G87 DA05261 transformed cell line human CVCL_8G87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113103 CVCL_8G86 DA05260 transformed cell line human CVCL_8G86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113104 CVCL_8G89 DA05263 transformed cell line human CVCL_8G89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113105 CVCL_8G88 DA05262 transformed cell line human CVCL_8G88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113106 CVCL_AA17 GM01777 transformed cell line human CVCL_AA17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113107 CVCL_AA16 GM01466 transformed cell line human CVCL_AA16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113108 CVCL_AA19 GM02342 finite cell line human CVCL_AA19 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (from familial inference of GM02341 and GM09826) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21113109 CVCL_AA18 GM02341 finite cell line human CVCL_AA18 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Male 21113110 CVCL_8G83 DA05257 transformed cell line human CVCL_8G83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113111 CVCL_8G82 DA05256 transformed cell line human CVCL_8G82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113112 CVCL_8G85 DA05259 transformed cell line human CVCL_8G85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113113 CVCL_AA11 GM00600 transformed cell line human CVCL_AA11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113114 CVCL_8G84 DA05258 transformed cell line human CVCL_8G84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113115 CVCL_AA10 GM00599 transformed cell line human CVCL_AA10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113116 CVCL_AA13 GM00602 transformed cell line human CVCL_AA13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113117 CVCL_AA12 GM00601 transformed cell line human CVCL_AA12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113118 CVCL_8G81 DA05255 transformed cell line human CVCL_8G81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113119 CVCL_AA15 GM01465 transformed cell line human CVCL_AA15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113120 CVCL_8G80 DA05254 transformed cell line human CVCL_8G80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113121 CVCL_AA14 GM00603 transformed cell line human CVCL_AA14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113122 CVCL_8G98 DA05272 transformed cell line human CVCL_8G98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113123 CVCL_8G97 DA05271 transformed cell line human CVCL_8G97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113124 CVCL_8G99 DA05273 transformed cell line human CVCL_8G99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113125 CVCL_AA28 GM04632 finite cell line human CVCL_AA28 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02343) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113126 CVCL_AA27 GM04624 finite cell line human CVCL_AA27 CL:0000010 Population: Native North American; Derived from sampling site: Cell type=Fibroblast. Male 21113127 CVCL_AA29 GM04637 finite cell line human CVCL_AA29 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21113128 CVCL_8G94 DA05268 transformed cell line human CVCL_8G94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113129 CVCL_AA20 GM02343 finite cell line human CVCL_AA20 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Tyr (c.693C>T); ClinVar=VCV000197621; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21113130 CVCL_8G93 DA05267 transformed cell line human CVCL_8G93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113131 CVCL_8G96 DA05270 transformed cell line human CVCL_8G96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113132 CVCL_AA22 GM04585 transformed cell line human CVCL_AA22 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113133 CVCL_8G95 DA05269 transformed cell line human CVCL_8G95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113134 CVCL_AA21 GM02631 transformed cell line human CVCL_AA21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113135 CVCL_8G90 DA05264 transformed cell line human CVCL_8G90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113136 CVCL_AA24 GM04587 transformed cell line human CVCL_AA24 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113137 CVCL_AA23 GM04586 finite cell line human CVCL_AA23 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113138 CVCL_8G92 DA05266 transformed cell line human CVCL_8G92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113139 CVCL_AA26 GM04623 finite cell line human CVCL_AA26 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21113140 CVCL_8G91 DA05265 transformed cell line human CVCL_8G91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113141 CVCL_AA25 GM04589 finite cell line human CVCL_AA25 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30905397) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21113142 CVCL_8G69 DA05242 transformed cell line human CVCL_8G69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113143 CVCL_8G68 DA05241 transformed cell line human CVCL_8G68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113144 CVCL_8G65 DA05237 transformed cell line human CVCL_8G65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113145 CVCL_8G64 DA05236 transformed cell line human CVCL_8G64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113146 CVCL_8G67 DA05240 transformed cell line human CVCL_8G67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113147 CVCL_8G66 DA05238 transformed cell line human CVCL_8G66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113148 CVCL_8G61 DA05233 transformed cell line human CVCL_8G61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113149 CVCL_8G60 DA05232 transformed cell line human CVCL_8G60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113150 CVCL_8G63 DA05235 transformed cell line human CVCL_8G63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113151 CVCL_8G62 DA05234 transformed cell line human CVCL_8G62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113152 CVCL_8G79 DA05253 transformed cell line human CVCL_8G79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113153 CVCL_8G76 DA05250 transformed cell line human CVCL_8G76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113154 CVCL_8G75 DA05249 transformed cell line human CVCL_8G75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113155 CVCL_8G78 DA05252 transformed cell line human CVCL_8G78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113156 CVCL_8G77 DA05251 transformed cell line human CVCL_8G77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113157 CVCL_AA06 GM19801 transformed cell line human CVCL_AA06 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Phe96del (c.286_288delTTC); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113158 CVCL_AA05 GM19800 transformed cell line human CVCL_AA05 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Met514Val (c.1540A>G) (1539A>G); ClinVar=VCV000201125; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113159 CVCL_AA08 GM22206 transformed cell line human CVCL_AA08 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Lys159fs (c.476delA); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113160 CVCL_AA07 GM19802 transformed cell line human CVCL_AA07 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Leu542His (c.1625T>A); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113161 CVCL_AA09 GM23163 transformed cell line human CVCL_AA09 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; c.1026_1027delAG; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113162 CVCL_8G72 DA05246 transformed cell line human CVCL_8G72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113163 CVCL_8G71 DA05244 transformed cell line human CVCL_8G71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113164 CVCL_8G74 DA05248 transformed cell line human CVCL_8G74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113165 CVCL_AA00 GM09944 transformed cell line human CVCL_AA00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113166 CVCL_8G73 DA05247 transformed cell line human CVCL_8G73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113167 CVCL_AA02 GM11602 transformed cell line human CVCL_AA02 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1670Asnfs*7 (c.5010delG); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113168 CVCL_AA01 GM11601 transformed cell line human CVCL_AA01 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Alu Ins; ClinVar=VCV000000332; Zygosity=Heterozygous; Note=De novo Alu repeat insertion in intron between exons 5 and 6 that causes mis-splicing (PubMed=1719426) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113169 CVCL_8G70 DA05243 transformed cell line human CVCL_8G70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113170 CVCL_AA04 GM09307 transformed cell line human CVCL_AA04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113171 CVCL_AA03 GM09305 transformed cell line human CVCL_AA03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113172 CVCL_8G47 DA05217 transformed cell line human CVCL_8G47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113173 CVCL_8G46 DA05216 transformed cell line human CVCL_8G46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113174 CVCL_8G49 DA05219 transformed cell line human CVCL_8G49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113175 CVCL_8G48 DA05218 transformed cell line human CVCL_8G48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113176 CVCL_8G43 DA05213 transformed cell line human CVCL_8G43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113177 CVCL_8G42 DA05212 transformed cell line human CVCL_8G42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113178 CVCL_8G45 DA05215 transformed cell line human CVCL_8G45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113179 CVCL_8G44 DA05214 transformed cell line human CVCL_8G44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113180 CVCL_8G41 DA05211 transformed cell line human CVCL_8G41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113181 CVCL_8G40 DA05210 transformed cell line human CVCL_8G40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113182 CVCL_8G58 DA05229 transformed cell line human CVCL_8G58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113183 CVCL_8G57 DA05227 transformed cell line human CVCL_8G57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113184 CVCL_8G59 DA05231 transformed cell line human CVCL_8G59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113185 CVCL_8G54 DA05224 transformed cell line human CVCL_8G54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113186 CVCL_8G53 DA05223 transformed cell line human CVCL_8G53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113187 CVCL_8G56 DA05226 transformed cell line human CVCL_8G56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113188 CVCL_8G55 DA05225 transformed cell line human CVCL_8G55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113189 CVCL_8G50 DA05220 transformed cell line human CVCL_8G50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113190 CVCL_8G52 DA05222 transformed cell line human CVCL_8G52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113191 CVCL_8G51 DA05221 transformed cell line human CVCL_8G51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113192 CVCL_IZ59 GM07991 finite cell line human CVCL_IZ59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21113193 CVCL_IZ56 ND01097 transformed cell line human CVCL_IZ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113194 CVCL_IZ55 ND02380 transformed cell line human CVCL_IZ55 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113195 CVCL_IZ58 JVE017 cancer cell line human CVCL_IZ58 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=28931069); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=28931069); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Pro (c.848G>C); ClinVar=VCV000486555; Zygosity=Unspecified (PubMed=28931069) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~40-60 hours (DSMZ=ACC-803) 21113196 CVCL_IZ57 ND01244 transformed cell line human CVCL_IZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113197 CVCL_IZ52 GM17527 transformed cell line human CVCL_IZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113198 CVCL_IZ51 A72F cancer cell line dog CVCL_IZ51 CL:0000010 Derived from sampling site: Left thigh Cell type=Fibroblast.; Breed/subspecies: Golden Retriever. Female 21113199 CVCL_IZ54 GM09986 transformed cell line human CVCL_IZ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM09986; probable Female 21113200 CVCL_IZ53 GM23603 transformed cell line human CVCL_IZ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113201 CVCL_IZ50 A72E cancer cell line dog CVCL_IZ50 CL:0000010 Derived from sampling site: Left thigh Cell type=Fibroblast.; Breed/subspecies: Golden Retriever. Female 21113202 CVCL_IZ67 NAMEC6 spontaneously immortalized cell line human CVCL_IZ67 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113203 CVCL_IZ66 NAMEC5 spontaneously immortalized cell line human CVCL_IZ66 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113204 CVCL_IZ69 NAMEC8 spontaneously immortalized cell line human CVCL_IZ69 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Omics: H3K9me2 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis Female 21113205 CVCL_IZ68 NAMEC7 spontaneously immortalized cell line human CVCL_IZ68 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113206 CVCL_IZ63 NAMEC2 spontaneously immortalized cell line human CVCL_IZ63 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113207 CVCL_IZ62 NAMEC1 spontaneously immortalized cell line human CVCL_IZ62 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113208 CVCL_IZ65 NAMEC4 spontaneously immortalized cell line human CVCL_IZ65 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113209 CVCL_IZ64 NAMEC3 spontaneously immortalized cell line human CVCL_IZ64 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113210 CVCL_IZ61 NAMEC11 spontaneously immortalized cell line human CVCL_IZ61 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113211 CVCL_IZ60 NAMEC10 spontaneously immortalized cell line human CVCL_IZ60 CL:0000010 Derived from sampling site: Breast Cell type=Mesenchymal cell.. Female 21113212 CVCL_IZ38 GM01455 transformed cell line human CVCL_IZ38 HLA typing: A*11,03; B*w22,w40 (Coriell=GM01455) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113213 CVCL_IZ37 NUOC-1-A2 cancer cell line human CVCL_IZ37 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=28460465) Miscellaneous: Doubling time from personal communication of Edmondon R Derived from metastatic site: Ascites. Omics: SNP array analysis Female Characteristics: Established from a mixed ovarian carcinoma of the right ovary which was 80% endometrioid, 15% clear cell and 5% high grade serous (HGS) Doubling time: 58 hours (Direct_author_submission) 21113214 CVCL_IZ39 GM03998 finite cell line human CVCL_IZ39 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21113215 CVCL_IZ34 HMEL transformed cell line human CVCL_IZ34 Genome ancestry: African=74.68%; Native American=1.37%; East Asian, North=1.09%; East Asian, South=0%; South Asian=0%; European, North=12.54%; European, South=10.33% (PubMed=30894373) CL:0000010 Derived from sampling site: Breast. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21113216 CVCL_IZ33 HPSI0115i-qaqp_5 induced pluripotent stem cell human CVCL_IZ33 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21113217 CVCL_IZ36 NUOC-1-A1 cancer cell line human CVCL_IZ36 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=28460465) Miscellaneous: Doubling time from personal communication of Edmondon R Derived from metastatic site: Ascites. Omics: SNP array analysis Female Characteristics: Established from a mixed ovarian carcinoma of the right ovary which was 80% endometrioid, 15% clear cell and 5% high grade serous (HGS) Doubling time: 58 hours (Direct_author_submission) 21113218 CVCL_IZ35 NUOC-1 cancer cell line human CVCL_IZ35 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=28460465) Derived from metastatic site: Ascites. Female Characteristics: Established from a mixed ovarian carcinoma of the right ovary which was 80% endometrioid, 15% clear cell and 5% high grade serous (HGS) Doubling time: 58 hours (PubMed=28460465) 21113219 CVCL_IZ30 HPSI0516i-eosr_1 induced pluripotent stem cell human CVCL_IZ30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21113220 CVCL_IZ32 HPSI0115i-xaka_1 induced pluripotent stem cell human CVCL_IZ32 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21113221 CVCL_IZ31 HPSI0416i-eapo_2 induced pluripotent stem cell human CVCL_IZ31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21113222 CVCL_AA97 GM09792 transformed cell line human CVCL_AA97 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113223 CVCL_AA96 GM09791 transformed cell line human CVCL_AA96 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113224 CVCL_AA99 GM09794 transformed cell line human CVCL_AA99 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113225 CVCL_AA98 GM09793 transformed cell line human CVCL_AA98 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113226 CVCL_IZ49 3132 cancer cell line dog CVCL_IZ49 CL:0000010 Breed/subspecies: Belgian Malinois. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Caution: Originally classified as originating from a B-cell lymphoma, but is reclassified as a histiocytic sarcoma based on characteristic cytogenomic properties (PubMed=27639374) 21113227 CVCL_IZ48 DUS2 transformed cell line dog CVCL_IZ48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.; Breed/subspecies: Mixed breed. Female 21113228 CVCL_IZ45 SBT-E1 spontaneously immortalized cell line CVCL_IZ45 CL:0000010 Unspecified Group: Fish cell line. 21113229 CVCL_IZ44 KS spontaneously immortalized cell line CVCL_IZ44 CL:0000010 Derived from sampling site: Snout; Breed/subspecies: Koi. Unspecified Doubling time: 28 hours (DOI=10.1016/j.aquaculture.2014.10.006) Group: Fish cell line 21113230 CVCL_IZ47 DUS1 transformed cell line dog CVCL_IZ47 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.; Breed/subspecies: Mixed breed. Female 21113231 CVCL_IZ46 DUS transformed cell line dog CVCL_IZ46 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.; Breed/subspecies: Mixed breed. Female Characteristics: After dbcAMP-mediated in vitro decidualization, express a wide spectrum of decidualization markers 21113232 CVCL_IZ41 FeOSCC-Sidney cancer cell line CVCL_IZ41 CL:0000010 Derived from sampling site: Oral cavity; Breed/subspecies: Domestic shorthair. Male Doubling time: 39.9 hours (PubMed=24631063) 21113233 CVCL_IZ40 GM06978 finite cell line human CVCL_IZ40 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21113234 CVCL_IZ43 SKF-9 spontaneously immortalized cell line CVCL_IZ43 CL:0000010 Unspecified Doubling time: ~1-2 days (DOI=10.1016/j.aquaculture.2017.02.027). Group: Fish cell line 21113235 CVCL_IZ42 K9OSCC-Abby cancer cell line dog CVCL_IZ42 CL:0000010 Derived from sampling site: Oral cavity; Breed/subspecies: Shih Tzu. Female Doubling time: 32.7 hours (PubMed=24631063) 21113236 CVCL_IZ19 MDCK-P-gp spontaneously immortalized cell line dog CVCL_IZ19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Developed to assess drugs as substrates for p-glycoprotein (ABCB1/MDR) Expresses high level of ABCB1/MDR1. 21113237 CVCL_AA80 GM09551 finite cell line human CVCL_AA80 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous (Coriell) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113238 CVCL_AA82 GM09659 transformed cell line human CVCL_AA82 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113239 CVCL_IZ16 NR49 cancer cell line Norway rat CVCL_IZ16 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome Doubling time: 190 hours (PubMed=19816092) 21113240 CVCL_AA81 GM09613 finite cell line human CVCL_AA81 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,i(18)(qter->q10::q10->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21113241 CVCL_IZ15 NR45 cancer cell line Norway rat CVCL_IZ15 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome 21113242 CVCL_AA84 GM09661 transformed cell line human CVCL_AA84 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113243 CVCL_IZ18 NR64 cancer cell line Norway rat CVCL_IZ18 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome Doubling time: 171 hours (PubMed=19816092) 21113244 CVCL_AA83 GM09660 transformed cell line human CVCL_AA83 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113245 CVCL_IZ17 NR54 cancer cell line Norway rat CVCL_IZ17 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome 21113246 CVCL_IZ12 NR22 cancer cell line Norway rat CVCL_IZ12 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome Doubling time: 76 hours (PubMed=19816092) 21113247 CVCL_IZ11 CML-10 cancer cell line dog CVCL_IZ11 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Mixed breed. Omics: Genome sequenced Unspecified 21113248 CVCL_IZ14 NR32 cancer cell line Norway rat CVCL_IZ14 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome Doubling time: 52.6 hours (PubMed=19816092) 21113249 CVCL_IZ13 NR24 cancer cell line Norway rat CVCL_IZ13 CL:0000010 Sequence variation: Mutation; RGD; 735088; Flcn; Simple; c.462_463insC; Zygosity=Hemizygous (PubMed=19816092) Breed/subspecies: Sprague Dawley Nihon. Male Characteristics: Rat cell line model for Birt-Hogg-Dube syndrome Doubling time: 45 hours (PubMed=19816092) 21113250 CVCL_IZ10 CML-6MC2 cancer cell line dog CVCL_IZ10 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Mixed breed. Unspecified 21113251 CVCL_AA75 GM09297 transformed cell line human CVCL_AA75 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113252 CVCL_AA74 GM09296 transformed cell line human CVCL_AA74 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113253 CVCL_AA77 GM09299 transformed cell line human CVCL_AA77 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113254 CVCL_AA76 GM09298 transformed cell line human CVCL_AA76 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113255 CVCL_AA79 GM09302 transformed cell line human CVCL_AA79 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113256 CVCL_AA78 GM09300 transformed cell line human CVCL_AA78 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113257 CVCL_AA91 GM09753 transformed cell line human CVCL_AA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113258 CVCL_AA90 GM09752 transformed cell line human CVCL_AA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113259 CVCL_AA93 GM09788 transformed cell line human CVCL_AA93 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113260 CVCL_IZ27 HPSI0616i-kulz_3 induced pluripotent stem cell human CVCL_IZ27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21113261 CVCL_AA92 GM09786 transformed cell line human CVCL_AA92 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113262 CVCL_IZ26 HPSI1114i-kuul_2 induced pluripotent stem cell human CVCL_IZ26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21113263 CVCL_AA95 GM09790 transformed cell line human CVCL_AA95 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113264 CVCL_IZ29 HPSI0416i-cihd_4 induced pluripotent stem cell human CVCL_IZ29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21113265 CVCL_AA94 GM09789 transformed cell line human CVCL_AA94 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113266 CVCL_IZ28 HPSI0616i-kulz_6 induced pluripotent stem cell human CVCL_IZ28 From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom; From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21113267 CVCL_IZ23 HPSI1014i-xiyh_4 induced pluripotent stem cell human CVCL_IZ23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113268 CVCL_IZ22 HPSI1014i-boss_1 induced pluripotent stem cell human CVCL_IZ22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21113269 CVCL_IZ25 HPSI1114i-kuul_1 induced pluripotent stem cell human CVCL_IZ25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21113270 CVCL_IZ24 HPSI1113i-vuud_2 induced pluripotent stem cell human CVCL_IZ24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21113271 CVCL_IZ21 HPSI0914i-vaka_5 induced pluripotent stem cell human CVCL_IZ21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21113272 CVCL_IZ20 HPSI0914i-rejf_2 induced pluripotent stem cell human CVCL_IZ20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21113273 CVCL_AA86 GM09705 finite cell line human CVCL_AA86 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous; Note=Allele UGT1A1*2 (from child cell line HHUUKDi005-A) Derived from sampling site: Skin Cell type=Fibroblast.. Mixed Caution: Indicated as originating from a 1 year old female child in Coriell, but seems to contain both male and female cells (PubMed=33485181) 21113274 CVCL_AA85 GM09662 transformed cell line human CVCL_AA85 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113275 CVCL_AA88 GM09708 transformed cell line human CVCL_AA88 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113276 CVCL_AA87 GM09707 transformed cell line human CVCL_AA87 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113277 CVCL_AA89 GM09749 transformed cell line human CVCL_AA89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113278 CVCL_AA60 GM06873 finite cell line human CVCL_AA60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,i(13)(qter->q10::q10->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21113279 CVCL_AA62 GM08874 transformed cell line human CVCL_AA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113280 CVCL_AA61 GM08766 transformed cell line human CVCL_AA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113281 CVCL_AA53 GM05106 transformed cell line human CVCL_AA53 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=19815695) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21113282 CVCL_AA52 GM05105 transformed cell line human CVCL_AA52 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113283 CVCL_AA55 GM05108 transformed cell line human CVCL_AA55 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113284 CVCL_AA54 GM05107 transformed cell line human CVCL_AA54 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113285 CVCL_AA57 GM05110 transformed cell line human CVCL_AA57 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113286 CVCL_AA56 GM05109 transformed cell line human CVCL_AA56 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113287 CVCL_AA59 GM06799 finite cell line human CVCL_AA59 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,i(13)(qter->q10::q10->qter) [42]; 46,XX,r(13) [8] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21113288 CVCL_AA58 GM05111 transformed cell line human CVCL_AA58 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113289 CVCL_IZ09 D spontaneously immortalized cell line fruit fly CVCL_IZ09 CL:0000010 Discontinued: DGRC; 13; probable. Female Group: Insect cell line 21113290 CVCL_IZ08 S2-B2 spontaneously immortalized cell line fruit fly CVCL_IZ08 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by microarray Male Group: Insect cell line 21113291 CVCL_AA71 GM09218 transformed cell line human CVCL_AA71 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Ser375Phe (c.1124C>T) (p.Ser374Phe, c.1121C>T) (S376F); ClinVar=VCV000012267; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113292 CVCL_IZ05 PER-826 cancer cell line human CVCL_IZ05 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Peripheral blood. Female Doubling time: 192 hours (PubMed=27443263) 21113293 CVCL_AA70 GM09217 transformed cell line human CVCL_AA70 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Ser375Phe (c.1124C>T) (p.Ser374Phe, c.1121C>T) (S376F); ClinVar=VCV000012267; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113294 CVCL_IZ04 PER-785S cancer cell line human CVCL_IZ04 CL:0000010 Miscellaneous: Cell line is no longer in use (personal communication of Kotecha R.S.). Omics: Transcriptome analysis by RNAseq Female 21113295 CVCL_IZ07 529SU spontaneously immortalized cell line fruit fly CVCL_IZ07 CL:0000010 Transfected with: FlyBase_Gene; FBgn0010602; lwr; Transfected with: FlyBase_Gene; FBgn0264922; Smt3 Breed/subspecies: Oregon-R. Male Characteristics: Stably transfected with expression vectors for FLAG-tagged Smt3 and HA-tagged Ubc9 (lwr), both under the control of the Cu2+ inducible metallothionein promoter Group: Insect cell line 21113296 CVCL_AA73 GM09295 transformed cell line human CVCL_AA73 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Arg247Trp (c.739C>T); ClinVar=VCV000003922; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113297 CVCL_AA72 GM09294 transformed cell line human CVCL_AA72 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113298 CVCL_IZ06 S2c1 spontaneously immortalized cell line fruit fly CVCL_IZ06 CL:0000010 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21113299 CVCL_IZ01 PER-733S cancer cell line human CVCL_IZ01 CL:0000010 Miscellaneous: Cell line is no longer in use (personal communication of Kotecha R.S.). Omics: Transcriptome analysis by RNAseq Female 21113300 CVCL_IZ00 PER-703S cancer cell line human CVCL_IZ00 CL:0000010 Miscellaneous: Cell line is no longer in use (personal communication of Kotecha R.S.). Omics: Transcriptome analysis by RNAseq Female 21113301 CVCL_IZ03 PER-785 cancer cell line human CVCL_IZ03 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female Doubling time: 60 hours (PubMed=27443263) 21113302 CVCL_IZ02 PER-784 cancer cell line human CVCL_IZ02 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female 21113303 CVCL_AA64 GM08892 transformed cell line human CVCL_AA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113304 CVCL_AA63 GM08891 transformed cell line human CVCL_AA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113305 CVCL_AA66 GM08894 transformed cell line human CVCL_AA66 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113306 CVCL_AA65 GM08893 transformed cell line human CVCL_AA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113307 CVCL_AA68 GM08896 transformed cell line human CVCL_AA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM08895 (Cellosaurus=CVCL_AA67); Derived from sampling site: Peripheral blood. Male 21113308 CVCL_AA67 GM08895 transformed cell line human CVCL_AA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM08896 (Cellosaurus=CVCL_AA68); Derived from sampling site: Peripheral blood. Female 21113309 CVCL_AA69 GM09100 transformed cell line human CVCL_AA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113310 CVCL_S694 BICR 63 cancer cell line human CVCL_S694 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Phe (c.763A>T); ClinVar=VCV000376621; Zygosity=Unspecified (PubMed=9150362). Unspecified 21113311 CVCL_RU94 CHO191PV transformed cell line CVCL_RU94 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113312 CVCL_S693 BB64-EBV transformed cell line human CVCL_S693 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21113313 CVCL_RU93 CHO181PV transformed cell line CVCL_RU93 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113314 CVCL_RU96 CHO201PV transformed cell line CVCL_RU96 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113315 CVCL_S696 H191 [Human tongue SCC] cancer cell line human CVCL_S696 CL:0000010 Derived from sampling site: Oral cavity; tongue. Female 21113316 CVCL_S695 BICR 68 cancer cell line human CVCL_S695 CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 21113317 CVCL_RU95 CHO192PV transformed cell line CVCL_RU95 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113318 CVCL_RU98 CHO203PV transformed cell line CVCL_RU98 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113319 CVCL_S698 HCC4006-GR-high cancer cell line human CVCL_S698 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Pleural effusion. Male 21113320 CVCL_RU97 CHO202PV transformed cell line CVCL_RU97 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113321 CVCL_S697 H140 cancer cell line human CVCL_S697 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa. Male 21113322 CVCL_RU99 CHO204PV transformed cell line CVCL_RU99 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113323 CVCL_S699 HCC4006-GR-step cancer cell line human CVCL_S699 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Pleural effusion. Male 21113324 CVCL_0042 U2OS cancer cell line human CVCL_0042 HLA typing: A*01,02; B*12,w40; C*w02 (PubMed=77569); HLA typing: A*02:01,32:01; B*44:02,44:02; C*05:01,07:04; DQB1*03:04,05:03; DRB1*04:05,04:05 (PubMed=25960936); HLA typing: A*02:01,32:01; B*44:02,44:02; C*05:01,07:04; DQB1*03:02,05:03 (PubMed=26589293); Genome ancestry: African=2.75%; Native American=0%; East Asian, North=5.19%; East Asian, South=0%; South Asian=0%; European, North=60.98%; European, South=31.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Population: Caucasian; Derived from sampling site: Bone; tibia. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Female Doubling time: ~25-30 hours (DSMZ=ACC-785); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project 21113325 CVCL_0041 Rh30 cancer cell line human CVCL_0041 HLA typing: A*11:17,24:08; B*35:01,35:01; C*18:01,18:01 (PubMed=26589293); Genome ancestry: African=2.64%; Native American=0.36%; East Asian, North=1.57%; East Asian, South=0.14%; South Asian=4.15%; European, North=49.28%; European, South=41.87% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086; PubMed=17471488; PubMed=23578105; PubMed=25485619; PubMed=25806826); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=9802058; PubMed=19147553; PubMed=25749379; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-001189; true; Discontinued: DepMap; ACH-001741; true Male Doubling time: 37 hours (PubMed=20922763); 35.5 +- 3.6 hours (PubMed=35760101); ~35 hours (DSMZ=ACC-489); 35 hours (COG); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21113326 CVCL_0044 BeWo cancer cell line human CVCL_0044 HLA typing: C*04:01:01:01,07:01 (IPD-IMGT/HLA=10312) CL:0000010 Karyotypic information: Near triploid karyotype (PubMed=33096371); Derived from metastatic site: Fetal brain. Omics: Deep antibody staining analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Cells were initially transplanted to the cheek pouch of a hamster and maintained by serial passage for 8 years prior to the establishment of the cell line Doubling time: ~30 hours (DSMZ=ACC-458) 21113327 CVCL_0043 U-2197 cancer cell line human CVCL_0043 CL:0000010 Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~100-120 hours (DSMZ=ACC-406) 21113328 CVCL_0046 HTh83 cancer cell line human CVCL_0046 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gly456_Gly457insGly (c.1368_1369insGGA); Zygosity=Hemizygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21113329 CVCL_0045 HEK293 transformed cell line human CVCL_0045 HLA typing: A*02:01,03:01; B*07:02,07:02/35:08; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*03:01:01; B*07:02:01; C*07:02:01; DPB1*04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRB1*15:01:01 (CLS=300192) CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used for the production of the Gamaleya SARS-CoV-2 (COVID-19) vaccine (Trade name: Gam-COVID-Vac; also known as Sputnik V) (DrugBank=DB15848) Cautio.; Omics: Cell surface proteome; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep antibody staining analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Methylated arginine analysis by proteomics; Omics: Myristoylated proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Female Doubling time: ~30 hours (CLS); ~24-30 hours (DSMZ=ACC-305) Group: Vaccine production cell line; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4488 21113330 CVCL_0047 TIME telomerase immortalized cell line human CVCL_0047 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Foreskin; skin; dermis; microvascular endothelium. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq Male 21113331 CVCL_S683 KOSCC-25B cancer cell line human CVCL_S683 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 26 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113332 CVCL_RU83 TTDH1PV finite cell line human CVCL_RU83 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113333 CVCL_S682 KOSCC-25A cancer cell line human CVCL_S682 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 22 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113334 CVCL_RU82 TTDH12PV finite cell line human CVCL_RU82 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113335 CVCL_S685 KOSCC-25D cancer cell line human CVCL_S685 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 18 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113336 CVCL_RU85 TTDH3PV finite cell line human CVCL_RU85 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Asp673Gly (c.2018A>G); Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113337 CVCL_S684 KOSCC-25C cancer cell line human CVCL_S684 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 36 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113338 CVCL_RU84 TTDH2PV finite cell line human CVCL_RU84 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113339 CVCL_S687 KOSCC-33A cancer cell line human CVCL_S687 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean Unspecified Doubling time: 48 hours (PubMed=12011992); Microsatellite instability: Instable (MSI) (PubMed=12011992) Caution: KOSCC-33A and KOSCC-33B originate from the same patient, but in table 1 of PubMed=12011992 KOSCC-33A is indicated to originate from a 64 year old male patient while KOSCC-33B from a 64 year old female patient. 21113340 CVCL_RU87 TTDH5PV finite cell line human CVCL_RU87 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113341 CVCL_S686 KOSCC-25E cancer cell line human CVCL_S686 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 28 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113342 CVCL_RU86 TTDH4PV finite cell line human CVCL_RU86 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113343 CVCL_S689 HOC1119 cancer cell line human CVCL_S689 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Doubling time: 17.5 hours (DOI=10.11277/stomatology1952.44.47) 21113344 CVCL_RU89 TTDH7PV finite cell line human CVCL_RU89 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113345 CVCL_S688 KOSCC-33B cancer cell line human CVCL_S688 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (PubMed=12011992) Population: Korean Unspecified Doubling time: 36 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) Caution: KOSCC-33A and KOSCC-33B originate from the same patient, but in table 1 of PubMed=12011992 KOSCC-33A is indicated to originate from a 64 year old male patient while KOSCC-33B from a 64 year old female patient. 21113346 CVCL_RU88 TTDH6PV finite cell line human CVCL_RU88 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113347 CVCL_0060 NCI-H1299 cancer cell line human CVCL_0060 HLA typing: A*24:02,32:01; B*40:02,40:02; C*02:02,02:02; DRB1*01:01,01:01 (PubMed=26589293); HLA typing: A*24:02,32:01:01; B*40:01,40:02:01; C*03:03:01,02:02:02 (PubMed=26929325); Genome ancestry: African=0.33%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0%; European, North=62.86%; European, South=34.68% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307; ATCC); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=25984343); 22.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21113348 CVCL_0062 MDA-MB-231 cancer cell line human CVCL_0062 HLA typing: A*02/28; B*07,08; C*w02,w06 (PubMed=77569); HLA typing: A*02:01,02:17; B*40:02,41:01; C*02:02:02,17; DPB1*02:01:02,17:01; DQB1*02:02,03:01:01; DRB1*07:01,13:05 (PubMed=15748285); HLA typing: A*02:17,02:01; B*40:02,41:01; C*02:02,17:01; DQA1*02:01,02:01; DQB1*03:04,03:04; DRB1*07:01,13:05 (PubMed=25960936); HLA typing: A*02:17,02:17; B*40:02,41:01; C*02:02,17:01; DQA1*01:02,01:02; DQB1*02:02,03:04 (PubMed=26589293); Genome ancestry: African=1.95%; Native American=0%; East Asian, North=2.44%; East Asian, South=0%; South Asian=7.42%; European, North=28.16%; European, South=60.03% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17334996; PubMed=19593635; ATCC); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=17334996); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (PubMed=17088437; PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (PubMed=1961733; PubMed=15900046; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351; ATCC) Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300275; true Female Doubling time: 1.3 days (PubMed=9671407); 26.7 hours (PubMed=9815641); 24.7 hours (PubMed=24389870); 36.2 hours (PubMed=34238275); 41.9 hours (NCI-DTP); 38 hours (ATCC=HTB-26); ~25-30 hours (DSMZ=ACC-732); ~38 hours (PBCF); 31.43 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12532; Registration: Chiron Master Culture Collection; CMCC 10583 (CMCC #10583) 21113349 CVCL_0061 NPrEC finite cell line human CVCL_0061 CL:0000010 Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21113350 CVCL_0057 HUES 9 embryonic stem cell human CVCL_0057 From: Harvard University; Boston; USA CL:0000010 Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 24 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0022; Registration: Swiss research registry; BAG-hES-IMP-0039; Registration: UK Stem Cell Bank (UKSCB); R-05-037, Steering comm appl. SCSC04-25(9). 21113351 CVCL_0059 Vero spontaneously immortalized cell line green monkey CVCL_0059 CL:0000010 Anecdotal: Verda reno means green kidney in Esperanto and Vero means truth also in Esperanto Derived from sampling site: Kidney; epithelium. Biotechnology: Used for the production of the Japanese encephalitis virus (JEV) vaccine (Trade name: IXIARO/JESPECT); Biotechnology: Used for the production of the inactivated poliovirus vaccine (Trade name: Imovax Polio); Biotechnology: Used for the production of the Purified Vero-cell Rabies Vaccine (PVRV) (Trade name: VERORAB); Biotechnology: Used for the production of the Chromatographically Purified Rabies Vaccine (CPRV); Biotechnology: Used for the production of the live oral rotavirus vaccine (Trade Name: Rotarix); Biotechnology: Used for the production of the live smallpox (Vaccinia) vaccine (Trade name: ACAM2000); Biotechnology: Used for the production of the tetravalent dengue vaccine (Trade Name: Dengvaxia); Biotechnology: Used for the production of the Bharat Biotech SARS-CoV-2 (COVID-19) vaccine (Trade name: Covaxin; also known as BBV152) (DrugBank; DB15847) The cell line is used to produces a inactivated SARS-CoV-2 virus strain.; Biotechnology: Used for the production of the Sinovax SARS-CoV-2 (COVID-19) vaccine (Trade name: CoronaVac; also known as PiCoVacc) (DrugBank; DB15806) The cell line is used to produces the inactivated SARS-CoV-2 virus strain CN02 (PubMed=32376603).; Omics: Genome sequenced Discontinued: ATCC; CRL-6318; true Female Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) But Vero C1008 (often known as Vero E6) (Cellosaurus=CVCL_0574) seems to be more appropriate for amplification and quantification (PubMed=32511316; PubMed=33389257). Group: Non-human primate cell line; Group: Vaccine production cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113352 CVCL_0058 HeLa S3 cancer cell line human CVCL_0058 CL:0000010 Anecdotal: The 'S' series of HeLa clones was named after Dr Florence Sabin. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: ChIP-seq epigenome analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: Hi-C sequencing; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: scRNAseq analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7924; true Female Virology: Has at least 4 five HPV18 integration sites in the genome (PubMed=26550473) Doubling time: ~48 hours (DSMZ=ACC-161) Part of: ENCODE project common cell types; tier 2; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113353 CVCL_S690 ORL-115 cancer cell line human CVCL_S690 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>C; ClinVar=VCV000182416; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27050151); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113del (c.339_341delCTT); Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=17273794) 21113354 CVCL_RU90 TTDH8PV finite cell line human CVCL_RU90 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113355 CVCL_RU92 CHO10PV transformed cell line CVCL_RU92 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21113356 CVCL_S692 ORL-48 cancer cell line human CVCL_S692 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Serfs*51 (c.876delA) (p.Phe292fs); Zygosity=Unspecified (PubMed=17273794; PubMed=24224046; PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Unspecified (PubMed=17273794; PubMed=24224046; PubMed=27050151) Population: Indian; Sikh; Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=17273794) Part of: OPC-22 oral and pharyngeal cancer cell line panel 21113357 CVCL_S691 ORL-136 cancer cell line human CVCL_S691 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Gln3585Ter (c.10753C>T); Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=17273794; PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=17273794) 21113358 CVCL_RU91 TTDH9PV finite cell line human CVCL_RU91 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113359 CVCL_S672 M010322 cancer cell line human CVCL_S672 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Breast. Omics: Transcriptome analysis by microarray Male 21113360 CVCL_RU72 TTD2PV finite cell line human CVCL_RU72 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113361 CVCL_S671 M010119 cancer cell line human CVCL_S671 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Shoulder. Omics: Transcriptome analysis by microarray Male 21113362 CVCL_RU71 TTD1PV finite cell line human CVCL_RU71 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113363 CVCL_S674 M010817 cancer cell line human CVCL_S674 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Upper arm. Omics: Transcriptome analysis by microarray Female 21113364 CVCL_RU74 TTD4PV finite cell line human CVCL_RU74 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Thr482del (c.1445_1447delCCA); Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113365 CVCL_S673 M010718 cancer cell line human CVCL_S673 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Neck. Omics: Transcriptome analysis by microarray Male 21113366 CVCL_RU73 TTD3PV finite cell line human CVCL_RU73 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113367 CVCL_S676 M990115 cancer cell line human CVCL_S676 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Breast. Omics: Transcriptome analysis by microarray Female 21113368 CVCL_RU76 TTD6PV finite cell line human CVCL_RU76 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Asp673Gly (c.2018A>G); Zygosity=Heterozygous; Note=Other allele is not expressed (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113369 CVCL_S675 M980513 cancer cell line human CVCL_S675 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; DepMap) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Iliac lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21113370 CVCL_RU75 TTD5PV finite cell line human CVCL_RU75 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113371 CVCL_S678 M990802 cancer cell line human CVCL_S678 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Cervical lymph node. Male 21113372 CVCL_RU78 TTD8PV finite cell line human CVCL_RU78 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113373 CVCL_S677 M990514 cancer cell line human CVCL_S677 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Inguinal lymph node. Omics: Transcriptome analysis by microarray Male 21113374 CVCL_RU77 TTD7PV finite cell line human CVCL_RU77 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113375 CVCL_S679 M991121 cancer cell line human CVCL_S679 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Lower leg. Omics: Transcriptome analysis by microarray Female 21113376 CVCL_RU79 TTD9PV finite cell line human CVCL_RU79 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113377 CVCL_0020 U-138MG cancer cell line human CVCL_0020 Genome ancestry: African=1.64%; Native American=0%; East Asian, North=1.56%; East Asian, South=0%; South Asian=0%; European, North=96.13%; European, South=0.67% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (PubMed=10416987; DepMap) Population: Caucasian; Derived from sampling site: Brain. Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47 hours (PubMed=9842975); ~70 hours (DSMZ=ACC-291) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21113378 CVCL_0022 U-87MG ATCC cancer cell line human CVCL_0022 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,13:07 (PubMed=25960936); HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293); HLA typing: A*02:01:01; B*44:02; C*05:01:01 (PubMed=27412690); Genome ancestry: African=0.69%; Native American=0%; East Asian, North=3.92%; East Asian, South=0%; South Asian=0%; European, North=72.18%; European, South=23.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=9090379; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: HLA class I peptidome analysis by proteomics; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB0419; true. Male Doubling time: 39 hours (PubMed=9842975); 72 hours (PubMed=25984343); ~34 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00535 Problematic cell line: Misidentified This cell line is not the original glioblastoma cell line established in 1968 at the University of Uppsala. As described in PubMed=27582061 it is most probably also a glioblastoma cell line but whose origin is unknow. See U-87MG Uppsala (Cellosaurus=CVCL_GP63) for the original U-87MG cell line. 21113379 CVCL_0021 U-251MG cancer cell line human CVCL_0021 HLA typing: A*01,02; B*08,14 (PubMed=77569); HLA typing: A*02:01:01; B*18; C*05; DPB1*04:02; DQB1*02:01; DRB1*03:01:01 (PubMed=15748285); HLA typing: A*02:01,02:01; B*18:01,18:01; C*05:01,05:01 (PubMed=25960936); Genome ancestry: African=0.69%; Native American=0%; East Asian, North=2.21%; East Asian, South=0%; South Asian=0%; European, North=79.45%; European, South=17.65% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (PubMed=9090379; PubMed=10551321; PubMed=10560660); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=8878451; PubMed=9614553; PubMed=10416987; PubMed=14614447; PubMed=15900046) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB0461; true Male Doubling time: 23 hours (PubMed=9842975); 24 hours (PubMed=25984343); 23.8 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21113380 CVCL_0024 SCLC-21H cancer cell line human CVCL_0024 HLA typing: A*01:01,32:01; B*07:02,07:02; C*02:02,02:02 (PubMed=25960936); HLA typing: A*01:01,32:03; B*39:04,44:02; C*02:02,08:02 (PubMed=26589293); Genome ancestry: African=0.58%; Native American=1.19%; East Asian, North=1.82%; East Asian, South=0%; South Asian=0%; European, North=61.58%; European, South=34.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Arg (c.833C>G); ClinVar=VCV000376644; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: 45-85 hours, depending on growth medium (PubMed=3029138); >45 hours (PubMed=2438285); ~2 days (DSMZ=ACC-372) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21113381 CVCL_0023 A-549 cancer cell line human CVCL_0023 HLA typing: A*10,w19; B*08,12 (PubMed=77569); HLA typing: A*25:01,30:01; B*18,44:03:01; C*12:03:01,16:01; DQB1*02:02,03:01:01; DRB1*07:01,11:04:01 (PubMed=15748285); HLA typing: A*25:01,30:01; B*44:03,18:01; C*12:03,16:01; DQB1*02:02,02:02 (PubMed=25960936); HLA typing: A*26:03,30:01; B*18:01,44:03:01; C*12:03,16:01 (PubMed=9023415); HLA typing: A*25:01,30:01; B*07:02,44:03; C*12:03,12:03 (PubMed=26589293); HLA typing: A*25:01:01,30:01:01; B*18:01:01,20:03:01; C*12:03:01,16:01:01; DPB1*03:01,06:01; DQA1*02:01:01,05:05:01; DQB1*02:02:01,03:01:01; DRB1*07:01:01,11:04:01 (CLS=300114); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.72%; East Asian, South=0%; South Asian=0%; European, North=66.12%; European, South=33.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (PubMed=1855224; PubMed=12794755; PubMed=17088437); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=10536175; PubMed=15900046; PubMed=20557307) Population: Caucasian; Derived from sampling site: Lung. Omics: Acetylation analysis by proteomics; Omics: Array-based CGH; Omics: CNV analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep membrane proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Discontinued: ATCC; CRL-7909; true Male Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Doubling time: 18 hours (in RPMI 1640 + 10% FBS), 37 hours (in ACL-3), 36 hours (in ACL-3+BSA) (PubMed=3940644); 27.0 hours (PubMed=8286010); 22 hours (PubMed=25984343); 23.9 hours (PubMed=29681454); 27 hours (from cell counting), 27 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154); 26.08 hours (PubMed=35976051); 22.9 hours (NCI-DTP); ~28 hours (CLS=300114); ~40 hours (DSMZ=ACC-107); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 2; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2000 21113382 CVCL_0026 Capan-2 cancer cell line human CVCL_0026 HLA typing: A*29:02,29:02; B*44:03,44:03; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0.28%; Native American=0.63%; East Asian, North=0.28%; East Asian, South=0%; South Asian=0.34%; European, North=62.52%; European, South=35.95% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Thr18_Ala19dup (c.52_57dupACGGCC); ClinVar=VCV000579466; Zygosity=Homozygous (PubMed=7972006; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=7961102; PubMed=8026879; PubMed=8426738; PubMed=11169959; PubMed=15367885; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Homozygous; Note=Impairs TP53 splicing dramatically (PubMed=7961102; PubMed=8026879; PubMed=24700732; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 96 hours (PubMed=3019537); 45-60 hours (CLS); ~50-70 hours (DSMZ=ACC-245); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2000-049 Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814 21113383 CVCL_0025 Caco-2 cancer cell line human CVCL_0025 HLA typing: A*02:01,02:01; B*15:05,56/39; C*04:01,04:01 (PubMed=25960936); HLA typing: A*02:01,02:01; B*15:01,15:01; C*04:01,04:01 (PubMed=26589293); HLA typing: A*02:01:01; B*15:01:01; C*04:01:01; DPB1*04:01:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:04:01 (CLS=300137); Genome ancestry: African=3.33%; Native American=0%; East Asian, North=4.59%; East Asian, South=0%; South Asian=0%; European, North=47.35%; European, South=44.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (PubMed=9294210); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (PubMed=16418264; PubMed=24755471; PubMed=28683746; DepMap) Population: Caucasian; Derived from sampling site: Colon. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Discontinued: Abcam; ab275464; true Male Virology: Highly susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=15316659); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257; PubMed=34339474) Doubling time: 3-4 days (ATCC=HTB-37); ~60-70 hours (CLS=300137); ~80 hours (DSMZ=ACC-169); ~32 hours (PBCF); Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=25926053; PubMed=28683746) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project 21113384 CVCL_0028 AN3-CA cancer cell line human CVCL_0028 HLA typing: A*11:01,11:01; B*15:11,58:01; C*05:01,06:02 (PubMed=26589293); Genome ancestry: African=0.36%; Native American=0%; East Asian, North=0.85%; East Asian, South=1.08%; South Asian=3.21%; European, North=62.96%; European, South=31.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro373Ser (c.1117C>T); Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg557_Lys561delArgGluIleAspLysinsGln (c.1670_1681delGAGAAATTGACA); Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Glnfs*4 (c.389delG); ClinVar=VCV000192224; Zygosity=Homozygous (PubMed=20944090; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly389Trp (c.1165G>T); ClinVar=VCV000156517; Zygosity=Heterozygous (ATCC) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~45-50 hours (CLS=300119); ~55 hours (DSMZ=ACC-267); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Part of: MD Anderson Cell Lines Project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030) 21113385 CVCL_0027 Hep-G2 cancer cell line human CVCL_0027 HLA typing: A*02:01,24:02; B*35:14,51:01; C*04:01,16:02 (PubMed=25960936); HLA typing: A*02:19,24:02; B*35:14,51:08; C*04:01,16:02; DQB1*06:04,06:04 (PubMed=26589293); HLA typing: A*02:01,24:02; B*35,51:01; C*04:01,16:02; DQA1*01:02; DQB1*05:02,06:04; DRB1*13:02,16:02 (PubMed=9178645); Genome ancestry: African=2.83%; Native American=20.88%; East Asian, North=4.48%; East Asian, South=0%; South Asian=0%; European, North=22.82%; European, South=48.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=8389256; PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Liver. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Discontinued: JCRB; NIHS0326; true; Discontinued: RCB; RCB0459; true Male Doubling time: 25.65 hours (PubMed=31378681); ~50-60 hours (DSMZ=ACC-180) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 1; Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8065 Problematic cell line: Misclassified Originally thought to be a hepatocellular carcinoma cell line but shown to be from an hepatoblastoma (PubMed=19751877). 21113386 CVCL_0029 EFO-21 cancer cell line human CVCL_0029 HLA typing: A*26:01,32:01; B*07:02,14:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.88%; Native American=0%; East Asian, North=4.99%; East Asian, South=0%; South Asian=0%; European, North=61.52%; European, South=31.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Arg (c.370T>C); Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Ascites. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 42 hours (PubMed=25984343); ~40-60 hours (DSMZ=ACC-235); 43.71 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21113387 CVCL_S681 KOSCC-11 cancer cell line human CVCL_S681 CL:0000010 Population: Korean; Derived from sampling site: Oral cavity; gingiva. Female Doubling time: 36 hours (PubMed=12011992); Microsatellite instability: Stable (MSS) (PubMed=12011992) 21113388 CVCL_RU81 TTDH11PV finite cell line human CVCL_RU81 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Unexplicit; Ex6del; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113389 CVCL_S680 M34 cancer cell line human CVCL_S680 CL:0000010 Unspecified 21113390 CVCL_RU80 TTDH10PV finite cell line human CVCL_RU80 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113391 CVCL_S661 MOLT-3/ZD1694.C cancer cell line human CVCL_S661 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113392 CVCL_RU61 XPH2PV finite cell line human CVCL_RU61 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (from familial inference of XP10PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113393 CVCL_S660 MOLT-3/MTX.P-9 cancer cell line human CVCL_S660 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113394 CVCL_RU60 XPH20PV finite cell line human CVCL_RU60 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113395 CVCL_S663 K562/ZD1694.C cancer cell line human CVCL_S663 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Derived from sampling site: Pleural effusion. Female 21113396 CVCL_RU63 XPH4PV finite cell line human CVCL_RU63 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Heterozygous (from familial inference of XP12PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113397 CVCL_S662 MOLT-3/ZD1694.P9 cancer cell line human CVCL_S662 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113398 CVCL_RU62 XPH3PV finite cell line human CVCL_RU62 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (from familial inference of XP10PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113399 CVCL_S665 5-8F/Erbitux hybrid cell line human CVCL_S665 CL:0000010 Sequence variation: Gene fusion; HGNC; 1490; CAPZA2 + HGNC; 7029; MET; Name(s)=CAPZA2-MET (from parent cell line). Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux) Problematic cell line: Contaminated Parent cell line (5-8F) has been shown to be an hybrid of HeLa and a cell line of unknown origin. 21113400 CVCL_RU65 XPH6PV finite cell line human CVCL_RU65 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113401 CVCL_S664 SK-N-PI cancer cell line human CVCL_S664 CL:0000010 Miscellaneous: Only mentioned as a Ewing sarcoma cell line in PubMed=7591257. 21113402 CVCL_RU64 XPH5PV finite cell line human CVCL_RU64 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Heterozygous (from familial inference of XP12PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113403 CVCL_S667 Ma-Mel-61e cancer cell line human CVCL_S667 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lung. Omics: SNP array analysis Male 21113404 CVCL_RU67 XPH8PV finite cell line human CVCL_RU67 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113405 CVCL_S666 Ma-Mel-61c cancer cell line human CVCL_S666 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis Male 21113406 CVCL_RU66 XPH7PV finite cell line human CVCL_RU66 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113407 CVCL_S669 Ma-Mel-61g cancer cell line human CVCL_S669 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Gly600Trp (c.1798G>T); Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous. Omics: SNP array analysis Male 21113408 CVCL_RU69 TTD10PV finite cell line human CVCL_RU69 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113409 CVCL_S668 Ma-Mel-61f cancer cell line human CVCL_S668 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (from autologous cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503) Derived from metastatic site: Not specified. Male 21113410 CVCL_RU68 XPH9PV finite cell line human CVCL_RU68 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Heterozygous (from familial inference of XP15PV and XP16PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113411 CVCL_0040 WM115 cancer cell line human CVCL_0040 HLA typing: A*02:01,29:02; B*13:02,44:03:01; C*06:02,16:01; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01; DRB1*07:01,07:01 (PubMed=15592718); HLA typing: A*02:01,29:02; B*13:02,44:03; C*06:02,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.17%; East Asian, North=0%; East Asian, South=0%; South Asian=0.85%; European, North=67.47%; European, South=31.51% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=15009714; PubMed=15467732; Wistar) Population: Caucasian; Derived from metastatic site: Right anterior leg; skin. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-1675; probable; Discontinued: Coriell; WC00079; probable; Discontinued: ECACC; 91061232; probable Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21113412 CVCL_0031 MCF-7 cancer cell line human CVCL_0031 HLA typing: A*02:01:01; B*18,44; C*05; DPB1*02:01:02,04:01; DQB1*02:01,06:02; DRB1*03,15 (PubMed=15748285); HLA typing: A*02:01,02:01; B*18:01,44:02; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*02:01,02:01; B*18:01,35:01; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=0.74%; Native American=0%; East Asian, North=4.2%; East Asian, South=0%; South Asian=0%; European, North=56.91%; European, South=38.15% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (PubMed=15361840; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437; PubMed=19593635; PubMed=28889351); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046) Anecdotal: This is the first hormone-responsive breast cancer cell line to have been established; Anecdotal: Helen Marion Mallon (sister Catherine Frances), the patient from which this cell line is derived was a nun at the Immaculate Heart of Mary convent in Monroe, Michigan (CelloPub=CLPUB00336); Anecdotal: Have been flown in space on Foton-12 to study cytoskeleton architecture in microgravity (PubMed=11292682; PubMed=15002416); Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CTCF ChIP-seq epigenome analysis; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Myristoylated proteins analysis by proteomics; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE); Omics: Transcriptome analysis by single cell RNAseq; Omics: Virome analysis using proteomics Discontinued: JCRB; NIHS0200; true Female Doubling time: 1.8 days (PubMed=9671407); 80 hours (PubMed=25984343); 24 hours (PubMed=9488600); 31.2 hours (PubMed=22628656); 25.3 hours (PubMed=24389870); 24.4 hours (PubMed=34238275); 25.4 hours (NCI-DTP); ~50 hours, with a range of 30-72 hours (DSMZ=ACC-115); ~38 hours (PBCF); 56.47 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 2; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12584; Registration: Chiron Master Culture Collection; CMCC 10377 (CMCC #10377) 21113413 CVCL_0030 HeLa cancer cell line human CVCL_0030 HLA typing: A*03,28; B*w15,w35; C*w02,w03 (PubMed=77569); HLA typing: A*03:19,68:02; B*15:03,15:03; C*12:03,12:03; DRB1*01:02,01:02 (PubMed=25960936); HLA typing: A*68:02,68:02; B*15:03,15:03; C*12:03,12:03; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=26589293); Genome ancestry: African=64.74%; Native American=0.77%; East Asian, North=2.26%; East Asian, South=0%; South Asian=0%; European, North=19.45%; European, South=12.78% (PubMed=30894373) CL:0000010 Anecdotal: The HeLa cell line which was established in February 1951 is the oldest human immortal cell line; Anecdotal: The fascinating story of the HeLa cell line and of Henrietta Lacks from whom these cells originate are described in the book of Rebecca Skloot (CelloPub=CLPUB00377); Anecdotal: The HeLa cell line and its story inspired Australian artist Cynthia Verspaget to embark in 2003 on a artistic project 'The Anarchy Cell Line' (TAnCL) where she mixed her blood with HeLa cells This work later spawned a PhD thesis (CelloPub=CLPUB00376) where among other things she makes the observation that two main taxonomical distinctions present in the zombie, living/dead and human/nonhuman, are also present in the HeLa cell line.; Anecdotal: Was flown since the 1960s on at least ten different space missions: Korabl-Sputnik-2, Vostok-1, Vostok-4, Vostok-5 and Vostok-6, Voshkod 1 and Zond-5, Discoverer XVIII, Progress M-35/Mir and Shuttle STS-89; Miscellaneous: HeLa is the most frequent contributor to cell lines contamination Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep membrane proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Glycoproteome analysis by proteomics; Omics: Myristoylated proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: scRNAseq analysis; Omics: Secretome proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Discontinued: ATCC; CRL-7923; true Female Virology: HeLa has 5 five HPV18 integration sites: three on normal chromosomes 8 at 8q24 and two on derivative chromosomes, der(5)t(5;22;8)(q11;q11q13;q24) and der(22)t(8;22)(q24;q13); Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 1.3 days (PubMed=29156801); ~48 hours (DSMZ=ACC-57); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113414 CVCL_0033 SK-BR-3 cancer cell line human CVCL_0033 HLA typing: A*02:01,02:01; B*14:02,39/50/55; C*03:04,03:04; DQB1*02:02,06:04 (PubMed=25960936); HLA typing: A*02:01,11:01; B*14:02,35:21; C*03:04,03:04; DQB1*06:04,06:04; DRB1*01:05,01:05 (PubMed=26589293); HLA typing: DPB1*03:01; DRB1*13:02 (IPD-IMGT/HLA=12368); Genome ancestry: African=0.7%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0.26%; European, North=63.89%; European, South=33.02% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (PubMed=17334996; PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=28889351; ATCC; DepMap) Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Exosome proteome analysis; Omics: Genome sequenced; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB2132; true; Discontinued: TKG; TKG 0592; true Female Doubling time: 37.4 hours (PubMed=24389870); ~30 hours (CLS); ~2-3 days (DSMZ=ACC-736); 56.19 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=23671654) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 808 21113415 CVCL_0032 SiHa cancer cell line human CVCL_0032 HLA typing: A*24:02,24:02; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=84.36%; East Asian, South=15.4%; South Asian=0%; European, North=0%; European, South=0.24% (PubMed=30894373) CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (PubMed=24201445) Doubling time: 2.6 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21113416 CVCL_0035 PC-3 cancer cell line human CVCL_0035 HLA typing: A*01:01:01,24:02:01; B*13:02,55:01; C*01,06; DPB1*04:01; DQB1*02:02,06:03; DRB1*07:01,13:01:01 (PubMed=15748285); HLA typing: A*01:01,24:01; B*13:02,55:01; C*01:02,06:02 (PubMed=25960936); HLA typing: A*01:01,24:02; B*13:02,55:01; C*01:02,06:02; DRB1*13:01,13:01 (PubMed=26589293); Genome ancestry: African=0.41%; Native American=0%; East Asian, North=0.52%; East Asian, South=0%; South Asian=1.19%; European, North=65.73%; European, South=32.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=1873816; PubMed=8104329; PubMed=17088437; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7934; true Male Doubling time: 25.34 +- 0.02 hours (PubMed=32968452); 27.1 hours (NCI-DTP); 25 hours (ATCC=CRL-7934); ~50 hours (DSMZ=ACC-465); ~25 hours (PBCF); 40 +- 10 hours (CLS); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI-60 cancer cell line panel Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427 21113417 CVCL_0034 NTERA-2 cancer cell line human CVCL_0034 HLA typing: A*01; B*08; C*07; DQB1*02; DRB1*03; DRB3*01 (PubMed=16919167); HLA typing: A*01:01,01:01; B*08:01,37:04; C*07:01,07:01; DRB1*03:01,14:76 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Omics: Deep antibody staining analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-60 hours (DSMZ=ACC-527) 21113418 CVCL_0037 A-431 cancer cell line human CVCL_0037 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=25960936); HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DRB1*11:04,12:01 (PubMed=26589293); Genome ancestry: African=3.82%; Native American=0%; East Asian, North=7.84%; East Asian, South=0%; South Asian=6.03%; European, North=17.15%; European, South=65.16% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (PubMed=23637631); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=1394225) Karyotypic information: Hypertriploid karyotype (ATCC); Derived from sampling site: Skin; epidermis. Omics: Cell surface proteome; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7907; true Female Doubling time: ~80-100 hours (DSMZ=ACC-91); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113419 CVCL_0036 RT-4 cancer cell line human CVCL_0036 HLA typing: A*01,03; B*12 (PubMed=77569); HLA typing: A*02:01,03:01; B*44:02,44:02; C*05:01,05:01; DQA1*03:02,03:02; DQB1*05:03,05:03 (PubMed=25960936); HLA typing: A*02:01,03:01; B*44:02,44:02; C*05:01,05:01; DQA1*01:02,03:02; DQB1*05:03,05:03; DRB1*04:01,14:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.72%; East Asian, South=0%; South Asian=0.98%; European, North=64.69%; European, South=31.61% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064); Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (PubMed=28855393); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (PubMed=23401075; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7787250) Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7937; true. Male Doubling time: 37 hours (PubMed=3708594); 65.8 hours (PubMed=26055179); ~80 hours (DSMZ=ACC-412); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: TCGA-110-CL cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21113420 CVCL_0039 SK-MEL-30 cancer cell line human CVCL_0039 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:06 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.6%; East Asian, South=0%; South Asian=0%; European, North=62.41%; European, South=35.99% (PubMed=30894373). From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly1339Arg (c.4015G>C); ClinVar=VCV000233611; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1406Ter (c.4216C>T); ClinVar=VCV000142519; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=10766161; PubMed=15009714; PubMed=21725359; PubMed=24576830; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr284Argfs*21 (c.851_852delCA) (p.R283fs, c.849_850del2); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Pigmented Doubling time: ~30 hours (DSMZ=ACC-151); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-526 21113421 CVCL_0038 HaCaT spontaneously immortalized cell line human CVCL_0038 HLA typing: A*31:01:02; B*40:01:02,51:01:01; C*03:04:01,15:02:01; DPB1*03:01:01,04:01:01; DQA1*01:02:01,03:03:01; DQB1*03:01:01,06:02:01; DRB1*04:01:01,15:01:01 (CLS=300493) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (PubMed=8504475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (PubMed=8504475) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Omics: Deep antibody staining analysis; Omics: Deep proteome analysis; Omics: Metabolome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0341; true; Discontinued: DSMZ; ACC-771; true; Discontinued: ICLC; HL14001; true Male Virology: Susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Doubling time: 28 hours (PubMed=32938951) Caution: Although HaCaT is distributed by a number of sources, the only official DKFZ-approved supplier is CLS 21113422 CVCL_S670 Ma-Mel-61h cancer cell line human CVCL_S670 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous. Omics: SNP array analysis Male 21113423 CVCL_RU70 TTD11PV finite cell line human CVCL_RU70 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Unexplicit; Ex6del; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113424 CVCL_S650 CCRF-CEM/R2 cancer cell line human CVCL_S650 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21113425 CVCL_RU50 XPH11PV finite cell line human CVCL_RU50 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113426 CVCL_S652 MOLT-3/MTXt cancer cell line human CVCL_S652 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113427 CVCL_RU52 XPH13PV finite cell line human CVCL_RU52 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113428 CVCL_S651 CCRF-CEM/R3 cancer cell line human CVCL_S651 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21113429 CVCL_RU51 XPH12PV finite cell line human CVCL_RU51 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Heterozygous (from familial inference of XP17PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113430 CVCL_S654 MOLT-3/TMQ200-CB371730 cancer cell line human CVCL_S654 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113431 CVCL_RU54 XPH15PV finite cell line human CVCL_RU54 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Heterozygous (from familial inference of XP18PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113432 CVCL_S653 MOLT-3/TMQ200 cancer cell line human CVCL_S653 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113433 CVCL_RU53 XPH14PV finite cell line human CVCL_RU53 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Heterozygous (from familial inference of XP18PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113434 CVCL_S656 MOLT-3/TMQ800 cancer cell line human CVCL_S656 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113435 CVCL_RU56 XPH17PV finite cell line human CVCL_RU56 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113436 CVCL_S655 MOLT-3/TMQ2500 cancer cell line human CVCL_S655 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113437 CVCL_RU55 XPH16PV finite cell line human CVCL_RU55 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113438 CVCL_S658 MOLT-3/MTX10000 cancer cell line human CVCL_S658 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113439 CVCL_RU58 XPH19PV finite cell line human CVCL_RU58 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113440 CVCL_S657 MOLT-3/TMQ200-MTX500 cancer cell line human CVCL_S657 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Selected for resistance to: ChEBI; CHEBI:9737; Trimetrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113441 CVCL_RU57 XPH18PV finite cell line human CVCL_RU57 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113442 CVCL_S659 MOLT-3/MTX200 cancer cell line human CVCL_S659 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21113443 CVCL_RU59 XPH1PV finite cell line human CVCL_RU59 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg753fs*13 (c.2257delC); Zygosity=Heterozygous (from familial inference of XP9PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113444 CVCL_0002 HL-60 cancer cell line human CVCL_0002 HLA typing: A*01:01,24:15; B*57:01,57:01; C*06:02,06:02 (PubMed=26589293); HLA typing: B*57:01:01,57:01:01; C*06:02:01,06:02:01 (DSMZCellDive=ACC-3); Genome ancestry: African=1.15%; Native American=0.42%; East Asian, North=0.4%; East Asian, South=0%; South Asian=0%; European, North=71.71%; European, South=26.32% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2858093); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; Cosmic-CLP; DepMap) Anecdotal: Established at the 60th attempt to culture human leukemia biopsies in Gallo's lab All the preceding attempts having failed. Population: Caucasian; Derived from sampling site: Peripheral blood. Biotechnology: Used a source of mitochondrial DNA for USA forensic testing; Omics: Array-based CGH; Omics: Cell surface proteome; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Mitochondrial genome sequenced; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Abcam; ab282204; true; Discontinued: JCRB; NIHS0086; true Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 16 hours (PubMed=8343448); 28 hours (PubMed=25984343); ~40 hours (DSMZ=ACC-3); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; PubMed=12661003; Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035); Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2392-I 21113445 CVCL_0001 HEL cancer cell line human CVCL_0001 HLA typing: A*03:01,32:01; B*35:08,35:08; C*04:01,04:01; DQA1*05:01,05:01; DRB1*03:38,13:03 (PubMed=26589293); HLA typing: A*03:01:01,32:01:01; B*35:08:01,35:01:01; C*04:01:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02 (DSMZCellDive=ACC-11); Genome ancestry: African=2.4%; Native American=1.79%; East Asian, North=3.9%; East Asian, South=0%; South Asian=5.12%; European, North=13.33%; European, South=73.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~24 hours (PubMed=6177045); 17.8 +- 1.8 hours (in serum-containing medium), 23.3 +- 0.8 hours (in serum-free medium) (PubMed=7538619); ~36 hours (DSMZ=ACC-11); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21113446 CVCL_0004 K-562 cancer cell line human CVCL_0004 HLA typing: A*11:01:01,31:01:02; B*18,40; C*03; DPB1*04:01,04:02; DQB1*02:01,03:02; DRB1*03,04 (PubMed=15748285); HLA typing: A*11; B*40,35/39; C*03,05 (PubMed=25960936); HLA typing: A*31:01:02,31:01:02; B*40:01:01,50:01:01; C*03:04:01,05:01:01 (DSMZCellDive=ACC-10); Genome ancestry: African=5.19%; Native American=0%; East Asian, North=8.4%; East Asian, South=0%; South Asian=0%; European, North=43.44%; European, South=42.97% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=12506034; PubMed=20809971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (PubMed=17088437; PubMed=18277095) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CTCF ChIP-seq epigenome analysis; Omics: H2A.Z ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me1 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: Pol2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Female Doubling time: 47 hours (PubMed=25984343); 18 hours (PubMed=8142256); 19.6 hours (NCI-DTP); ~30-40 hours (DSMZ=ACC-10); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 1; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21113447 CVCL_0003 HMC-1 cancer cell line human CVCL_0003 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous (PubMed=7691885); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=7691885) Derived from sampling site: Peripheral blood Cell type=Mast cell.. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-283; true Male Doubling time: 3-4 days (PubMed=3131594) 21113448 CVCL_0006 THP-1 cancer cell line human CVCL_0006 HLA typing: A*02; B*15:11; C*03; DQB1*05,06; DRB1*01,15; DRB5*01/02 (PubMed=22674354); HLA typing: A*02:01,02:01; B*15:11,15:11; C*03:03,03:03 (PubMed=26589293); HLA typing: A*02:01:01; B*15:11:01; C*03:03:01; DPB1*02:01:02G,04:02:01G; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:02:01; DRB1*01:01:01,15:01:01 (CLS=300356); HLA typing: A*02:01:01,24:02:01; B*15:11:01,35:01:01; C*03:03:01,03:03:01; DPA1*01:03:01,02:02:02; DPB1*02:01:02,04:02:01; DQB1*05:01:01,06:02:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,15:01:01 (DSMZCellDive=ACC-16); Genome ancestry: African=0%; Native American=0.3%; East Asian, North=77.63%; East Asian, South=20.4%; South Asian=1.67%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (PubMed=31160637); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=11066077; PubMed=15843827); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (PubMed=1571549; PubMed=19220422; DepMap) Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=352912) Population: Japanese; Derived from sampling site: Peripheral blood. Biotechnology: Used in the human Cell Line Activation Test (h-CLAT), an in vitro skin sensitization test (PubMed=16311011; PubMed=16337770; PubMed=29901211); Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep promoter analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: HLA class I peptidome analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Can differentiate from monocytes into macrophage-like cells upon stimulation with PMA; Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 60-70 hours (PubMed=6970727); 26 hours (PubMed=25984343); ~35-50 hours (DSMZ=ACC-16); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: RAS genetic alteration cell panel (ATCC TCP-1031); Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) Caution: NRAS mutation indicated incorrectly as being p.Gly12Ser in PubMed=9379676 21113449 CVCL_0005 NB4 cancer cell line human CVCL_0005 HLA typing: A*11:01,11:01; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293); HLA typing: A*11:01:01; B*35:01:01,40:01:02; C*03:04:01,04:01:01; DPB1*01:01:01,04:01:01; DQA1*01:01,03:01:01; DQB1*03:02,05:01:01; DRB1*01:01:01,04:04:01 (CLS=300299); HLA typing: A*11:01:01,11:01:01; B*35:01:01,40:01:02; C*03:04:01,04:01:01 (DSMZCellDive=ACC-207); Genome ancestry: African=3.99%; Native American=0%; East Asian, North=4.75%; East Asian, South=0%; South Asian=0%; European, North=49.28%; European, South=41.98% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=12353268; PubMed=15843827); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP) Derived from sampling site: Bone marrow. Omics: Cell surface proteome; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36-40 hours (PubMed=1995093); 30 hours (PubMed=25984343); ~35-45 hours (DSMZ=ACC-207); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: LL-100 blood cancer cell line panel; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2030; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1045 21113450 CVCL_0008 Daudi cancer cell line human CVCL_0008 HLA typing: A*01:02,66:01; B*35:01,58:01; C*03:02,06:02; DQA1*01:03,01:03; DQB1*06:13,06:13; DRB1*13:02,03:27 (PubMed=25960936); HLA typing: A*01:02,66:01; B*58:01,58:01; C*03:02,06:02 (PubMed=26589293); HLA typing: A*01:02,66:01; B*58:01:01:01,58:02:01; C*03:02:02:01,06:02; DPA1*01:03:01,02:01:01:01; DPB1*02:01:02:01,106:01; DQA1*01:02,01:03; DQB1*06:04:01,06:02; DRB1*13:01:01,13:02:01; DRB3*02:02,03:01:01; DRB6*02 (IPD-IMGT/HLA=10471); HLA typing: A*01:02,66:01:01; B*58:01:01,58:02:01; C*03:02:02,06:02:01; DPA1*01:03:01,02:01:01; DPB1*02:01:02,106:01; DQA1*01:02:01,01:03:01; DQB1*06:09:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*13:01:01,13:02:01 (DSMZCellDive=ACC-78); Genome ancestry: African=91.6%; Native American=0.12%; East Asian, North=2.24%; East Asian, South=0%; South Asian=1.3%; European, North=0%; European, South=4.74% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=3116544; PubMed=6806672); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (PubMed=8197130; PubMed=11894933; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: ATCC; CRL-7917; true Male Doubling time: 23.7 hours (PubMed=8847894); ~48 hours (DSMZ=ACC-78); Microsatellite instability: Instable (MSI-low) (Sanger); Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Human variation panel; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project Caution: TP53 mutation indicated incorrectly as being at c.637C>T in PubMed=2052620 21113451 CVCL_0007 U-937 cancer cell line human CVCL_0007 HLA typing: DRB1*16:01 (IPD-IMGT/HLA=11507); HLA typing: A*03:01,03:01; B*18:01,51:01; C*01:02,07:01; DRB1*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.39%; East Asian, South=0%; South Asian=0%; European, North=71.54%; European, South=26.06% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (PubMed=8643484; PubMed=25485619); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (PubMed=10966170; DepMap); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=1571549; DepMap); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (DepMap) Anecdotal: Have been flown in space on shuttle flight STS-76 and on Shenzhou-8 to study growth and cytoskeletal changes in microgravity (PubMed=10352142; DOI=10.1016/j.actaastro.2013.06.007) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Pleural effusion. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-1593; true; Discontinued: RCB; RCB1978; true; Discontinued: TKG; TKG 0279; probable Male Characteristics: Can be induced to differentiate into macrophages by several factors such as phorbol ester (PMA) and 12-O-tetradecanoyl-13-phorbol acetate (TPA) Doubling time: 95-100 hours (PubMed=178611); ~30-40 hours (DSMZ=ACC-5); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00168 Problematic cell line: Partially contaminated Some ATCC stocks were cross-contaminated by K-562 initially (PubMed=7759961). The problem was corrected and subsequent stocks have been confirmed to carry only U-937. 21113452 CVCL_0009 HDLM-2 cancer cell line human CVCL_0009 HLA typing: A*01:01:01,02:01:01; B*08:01:01,44:02:01; C*05:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,04:01:01; DQA1*01:02:01,01:03:01; DQB1*06:02:01,06:03:01; DRA*01:02:02,01:02:03; DRB1*13:01:01,15:01:01 (DSMZCellDive=ACC-17); Genome ancestry: African=1.09%; Native American=0%; East Asian, North=1.64%; East Asian, South=0%; South Asian=0.05%; European, North=62.14%; European, South=35.08% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Simple; p.Met174fs (c.520_548dup) (dup 586-614); Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Fusion with an Alu-element at the Ex7-Ex8 junction; Zygosity=Unspecified (PubMed=17065008) Derived from sampling site: Pleural effusion. Omics: Cell surface proteome; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~70-75 hours (DSMZ=ACC-17); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21113453 CVCL_S641 KMH-2 cancer cell line human CVCL_S641 Genome ancestry: African=1.62%; Native American=0.61%; East Asian, North=81.17%; East Asian, South=14.36%; South Asian=0%; European, North=0.83%; European, South=1.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0268; true Male Doubling time: 58 hours (PubMed=11686581); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21113454 CVCL_RU41 XP18PV finite cell line human CVCL_RU41 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Homozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113455 CVCL_S640 RMS559 cancer cell line human CVCL_S640 CL:0000010 Sequence variation: Mutation; HGNC; 3691; FGFR4; Simple; p.Val550Leu (c.1648G>C); Zygosity=Unspecified (PubMed=22142829). Male 21113456 CVCL_RU40 XP17PV finite cell line human CVCL_RU40 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=7585650); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=7585650) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113457 CVCL_S643 EpH4 1424 cancer cell line house mouse CVCL_S643 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113458 CVCL_RU43 XP21PV finite cell line human CVCL_RU43 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113459 CVCL_S642 SUP-B15/RI cancer cell line human CVCL_S642 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Bone marrow. Male 21113460 CVCL_RU42 XP19PV finite cell line human CVCL_RU42 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Heterozygous (PubMed=10766188); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gln368Argfs*6 (c.1103_1104delAA) (delAA1208-1209); ClinVar=VCV000267279; Zygosity=Heterozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113461 CVCL_S645 EpH4 1424.2 cancer cell line house mouse CVCL_S645 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113462 CVCL_RU45 XP23PV finite cell line human CVCL_RU45 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Unexplicit; IVS7+1G>T (c.703_1023del321) (p.Leu235_Lys341del); Zygosity=Homozygous; Note=Splice donor mutation (PubMed=12812979) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113463 CVCL_S644 EpH4 1424.1 cancer cell line house mouse CVCL_S644 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113464 CVCL_RU44 XP22PV finite cell line human CVCL_RU44 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113465 CVCL_S647 EpH4 betaMEKDD-47 transformed cell line house mouse CVCL_S647 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113466 CVCL_RU47 XP5PV finite cell line human CVCL_RU47 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Ala109Argfs*5 (c.321_322insAA); Zygosity=Homozygous (PubMed=10766188) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113467 CVCL_S646 EpH4 betaMEKDD-116 transformed cell line house mouse CVCL_S646 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113468 CVCL_RU46 XP24PV finite cell line human CVCL_RU46 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113469 CVCL_S649 CCRF-CEM/R1 cancer cell line human CVCL_S649 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21113470 CVCL_RU49 XPH10PV finite cell line human CVCL_RU49 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Heterozygous (from familial inference of XP15PV and XP16PV) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113471 CVCL_S648 EpH4-Ev spontaneously immortalized cell line house mouse CVCL_S648 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113472 CVCL_RU48 XP9PV finite cell line human CVCL_RU48 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg753fs*13 (c.2257delC); Zygosity=Homozygous (PubMed=10766188) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113473 CVCL_0011 KM-3 cancer cell line human CVCL_0011 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00226 Problematic cell line: Contaminated Shown to be a Reh derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 12 year old male patient with acute lymphoblastic leukemia. 21113474 CVCL_0010 Karpas-707 cancer cell line human CVCL_0010 CL:0000010 Derived from sampling site: Bone marrow. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces Ig lambda Doubling time: 35 hours (PubMed=11172031) 21113475 CVCL_0013 MOLT-4 cancer cell line human CVCL_0013 HLA typing: A*01:01:01,25:01; B*18,57:01:01; C*06:02,12:03:01; DPB1*02:01:02; DQB1*02:02,03:01:01; DRB1*07,12 (PubMed=15748285); HLA typing: A*01:01:01:01,25:01; B*57:01:01,18:01; C*06:02,12:03; DPA1*01:03; DPB1*02:01:02; DRB1*07,12:01 (IPD-IMGT/HLA=11094); HLA typing: A*01:01:01,25:01:01; B*18:01:01,57:01:01; C*06:02:01,12:03:01 (DSMZCellDive=ACC-362); Genome ancestry: African=0.38%; Native American=0%; East Asian, North=1.74%; East Asian, South=0%; South Asian=0.94%; European, North=68.08%; European, South=28.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (PubMed=1206830; PubMed=17088437); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (PubMed=17088437) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31.56 +- 1.49 hours (PubMed=24762992); 33 hours (PubMed=17117183); 29 hours (PubMed=20922763); 27.9 hours (NCI-DTP); ~40 hours (DSMZ=ACC-362); 24-48 hours (CLS); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger) Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel; Part of: NCI-60 cancer cell line panel 21113476 CVCL_0012 LP-1 cancer cell line human CVCL_0012 HLA typing: A*03,24; B*07,18; C*07 (PubMed=25688540); HLA typing: A*26:01,30:01; B*18:01,35:03; C*04:01,07:01; DQA1*03:02,05:01; DQB1*03:02,03:02; DRB1*04:03,11:04 (PubMed=26589293); HLA typing: A*26:01:01,30:01:01; B*18:01:01,35:03:01; C*04:01:01;07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRA*01:01:01,01:01:01; DRB1*04:03:01,11:04:01 (DSMZCellDive=ACC-41); Genome ancestry: African=0.21%; Native American=0%; East Asian, North=3.2%; East Asian, South=0%; South Asian=2.32%; European, North=42.82%; European, South=51.44% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 12766; NSD2; Name(s)=IGH-NSD2, IGH-WHSC1 (PubMed=31160637); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Unspecified (PubMed=11157491); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys286Ilefs*7 (c.857_870delAGAGCATACAAAGT); Zygosity=Homozygous (PubMed=17692805); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda Doubling time: 50 hours (PubMed=2784066); 48 hours (PubMed=25984343); 35-80 hours, depending on cell density (DSMZ=ACC-41); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21113477 CVCL_0015 U-266/70 cancer cell line human CVCL_0015 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgE lambda 21113478 CVCL_0014 RPMI-8226 cancer cell line human CVCL_0014 HLA typing: A*30:01,68:02; B*15:03,15:10; C*02:02:04,03:04:02; DPB1*01:01:02,13:01; DQB1*02:01,02:02; DRB1*03:01:01,07:01 (PubMed=15748285); HLA typing: A*30:01,68:02; B*15:10,15:10; C*02:02,03:04 (PubMed=26589293); HLA typing: A*30,68:02; B*15,15; C*02:02,03:04 (Direct_author_submission); HLA typing: A*30:01:01,68:02:01; B*15:10:01,15:03:01; C*02:10:01,03:04:02; DPA1*02:01:01,02:01:01; DRA*01:01:01,01:01:01; DRB1*03:01:01,07:01:01 (DSMZCellDive=ACC-402); Genome ancestry: African=73.94%; Native American=0%; East Asian, North=1.06%; East Asian, South=0%; South Asian=0%; European, North=11.76%; European, South=13.24% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=11157491; PubMed=12068308; PubMed=17088437; PubMed=21173094; CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous; Note=Temperature-sensitive (PubMed=1373872; PubMed=17088437; PubMed=18277095; PubMed=21173094; CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (PubMed=17692805) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgG lambda Doubling time: 60 hours (PubMed=25984343); 33.5 hours (NCI-DTP); ~60-70 hours (DSMZ=ACC-402); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel 21113479 CVCL_0017 U-698-M cancer cell line human CVCL_0017 HLA typing: A*02:01,03:01; B*07:02,27:05; C*01:02,07:02; DQA1*01:02,03:02; DQB1*03:02,06:11; DRB1*04:01,15:01 (PubMed=26589293); Genome ancestry: African=3.7%; Native American=0%; East Asian, North=4.43%; East Asian, South=0%; South Asian=0%; European, North=69.32%; European, South=22.56% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1446Ter (c.4336C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 60-65 hours (PubMed=4136723); ~48 hours (DSMZ=ACC-4); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21113480 CVCL_0016 U-266/84 cancer cell line human CVCL_0016 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Omics: Deep antibody staining analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgE lambda 21113481 CVCL_0019 SH-SY5Y cancer cell line human CVCL_0019 Genome ancestry: African=0%; Native American=1.17%; East Asian, North=0.35%; East Asian, South=0.1%; South Asian=0.08%; European, North=69.09%; European, South=29.2% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=28350380) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep tyrosine phosphoproteome analysis; Omics: GPI-anchored proteins analysis by proteomics; Omics: Mitochondrial proteome analysis by 2D-DE/MS; Omics: N-glycan profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Neuroblastic type (N-type) (PubMed=15720811); Characteristics: There seem to be differences in the retinoic acid (RA)-induced neuronal phenotype of SH-SY5Y cells from ATCC and ECACC After 5 days of RA treatment, ECACC cells are slightly larger in size and contains significant amount of neuroblastic (N-type) cells and a small fraction of epithelial (S-type) cells (PubMed=18957096).; Virology: Low susceptibility to infection by Zika virus (ZIKV) (PubMed=29468137) Doubling time: >55 hours (DSMZ=ACC-209) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 810 Problematic cell line: Partially contaminated Some laboratories that are redistributing this cell line are in fact redistributing a contaminated cell line of mouse origin (PubMed=25182563). 21113482 CVCL_0018 D341 Med cancer cell line human CVCL_0018 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.21%; East Asian, South=0%; South Asian=0.49%; European, North=68.21%; European, South=30.09% (PubMed=30894373) CL:0000010 Miscellaneous: The values for the STR markers F13A01, F13B, FESFPS and LPL used to be shown on the ATCC website but are no longer displayed (see Internet archive link for archival version) Derived from sampling site: Brain; cerebellum. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 37 hours (ATCC=HTB-187) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3 21113483 CVCL_RU30 BT053 cancer cell line human CVCL_RU30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21113484 CVCL_S630 RB414 finite cell line human CVCL_S630 CL:0000010 Male 21113485 CVCL_RU32 IP2PV finite cell line human CVCL_RU32 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113486 CVCL_S632 RB529 finite cell line human CVCL_S632 CL:0000010 21113487 CVCL_RU31 IP1PV finite cell line human CVCL_RU31 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113488 CVCL_S631 RB430 cancer cell line human CVCL_S631 CL:0000010 Derived from metastatic site: Brain; meninges. Male 21113489 CVCL_S634 RB522A cancer cell line human CVCL_S634 CL:0000010 21113490 CVCL_RU34 XP11PV finite cell line human CVCL_RU34 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113491 CVCL_S633 RB544 finite cell line human CVCL_S633 CL:0000010 21113492 CVCL_RU33 XP10PV finite cell line human CVCL_RU33 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Homozygous (PubMed=10766188) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113493 CVCL_S636 KF-RMS-1 cancer cell line human CVCL_S636 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21113494 CVCL_RU36 XP13PV finite cell line human CVCL_RU36 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Ala109Argfs*5 (c.321_322insAA); Zygosity=Heterozygous (PubMed=10766188); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Trp690Ser (c.2069G>C); Zygosity=Heterozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113495 CVCL_S635 D-RHA1 cancer cell line human CVCL_S635 From: Benedict W.; University of Texas M.D Anderson Cancer Center; Houston; USA.. CL:0000010 Unspecified 21113496 CVCL_RU35 XP12PV finite cell line human CVCL_RU35 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro43Glnfs*36 (c.128delC); ClinVar=VCV000551235; Zygosity=Homozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113497 CVCL_S638 Rh12 cancer cell line human CVCL_S638 CL:0000010 21113498 CVCL_RU38 XP15PV finite cell line human CVCL_RU38 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Homozygous (PubMed=9238033) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113499 CVCL_S637 KFR cancer cell line human CVCL_S637 CL:0000010 Derived from metastatic site: Bone marrow. Female 21113500 CVCL_RU37 XP14PV finite cell line human CVCL_RU37 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113501 CVCL_S639 Rh6 cancer cell line human CVCL_S639 CL:0000010 Derived from metastatic site: Lymph node. Male 21113502 CVCL_RU39 XP16PV finite cell line human CVCL_RU39 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Homozygous (PubMed=9238033) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113503 CVCL_RU21 MEL2 somatic stem cell human CVCL_RU21 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Characteristics: Undergoes chondrogenesis in a progenitor with markers of head and limb mesenchyme and low levels of hypertrophic marker COL10A1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11150 21113504 CVCL_S621 RBL30 cancer cell line human CVCL_S621 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg255Ter (c.763C>T); ClinVar=VCV000126820; Zygosity=Homozygous (PubMed=25326674; PubMed=30584916). Unspecified Doubling time: 6 days (PubMed=2365495); 94 hours (PubMed=25326674) 21113505 CVCL_RU20 EN7 somatic stem cell human CVCL_RU20 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Senescence: Can undergo >50 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). 21113506 CVCL_S620 RBL20 cancer cell line human CVCL_S620 CL:0000010 Unspecified Doubling time: 14 days (PubMed=2365495). 21113507 CVCL_S623 HER-Xho1-CC2 transformed cell line human CVCL_S623 CL:0000010 Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina. Unspecified 21113508 CVCL_RU23 SM22 somatic stem cell human CVCL_RU23 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA.. CL:0000010 Female 21113509 CVCL_S622 RBL7 cancer cell line human CVCL_S622 CL:0000010 Unspecified Doubling time: 6 days (PubMed=2365495). 21113510 CVCL_RU22 SK11 somatic stem cell human CVCL_RU22 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Characteristics: Undergoes osteochondral differentiation in a facial neural crest progenitor Used for studies of related degenerative diseases. Senescence: Can undergo >50 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11152 21113511 CVCL_S625 RB381 cancer cell line human CVCL_S625 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21113512 CVCL_RU25 W10 somatic stem cell human CVCL_RU25 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Senescence: Can undergo >40 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). 21113513 CVCL_S624 RB1021 cancer cell line human CVCL_S624 CL:0000010 Miscellaneous: STR profile from personal communication of Bremner R. Female 21113514 CVCL_RU24 SM28 somatic stem cell human CVCL_RU24 CL:0000010 Discontinued: Millipore; SCC125; true; Discontinued: Millipore; SCR225; true. Female 21113515 CVCL_RU27 CHO-K1 AequoScreen ADORA1 spontaneously immortalized cell line CVCL_RU27 CL:0000010 Transfected with: HGNC; 262; ADORA1; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21113516 CVCL_S627 RB405 finite cell line human CVCL_S627 CL:0000010 Male 21113517 CVCL_S626 RB383 cancer cell line human CVCL_S626 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; None_reported; -; Zygosity=- (PubMed=30584916) Omics: Transcriptome analysis by microarray. Male Doubling time: 97 hours (PubMed=25326674) 21113518 CVCL_RU26 Z11 somatic stem cell human CVCL_RU26 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Senescence: Can undergo >50 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). 21113519 CVCL_RU29 BT048 cancer cell line human CVCL_RU29 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21113520 CVCL_S629 RB412 cancer cell line human CVCL_S629 CL:0000010 Female 21113521 CVCL_RU28 BT012 cancer cell line human CVCL_RU28 CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21113522 CVCL_S628 RB409 cancer cell line human CVCL_S628 CL:0000010 Male 21113523 CVCL_8I67 DA05475 transformed cell line human CVCL_8I67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113524 CVCL_8I66 DA05474 transformed cell line human CVCL_8I66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113525 CVCL_8I69 DA05477 transformed cell line human CVCL_8I69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113526 CVCL_8I68 DA05476 transformed cell line human CVCL_8I68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113527 CVCL_8I63 DA05471 transformed cell line human CVCL_8I63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113528 CVCL_8I62 DA05470 transformed cell line human CVCL_8I62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113529 CVCL_8I65 DA05473 transformed cell line human CVCL_8I65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113530 CVCL_8I64 DA05472 transformed cell line human CVCL_8I64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113531 CVCL_8I61 DA05469 transformed cell line human CVCL_8I61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113532 CVCL_8I60 DA05468 transformed cell line human CVCL_8I60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113533 CVCL_8I78 DA05490 transformed cell line human CVCL_8I78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113534 CVCL_8I77 DA05488 transformed cell line human CVCL_8I77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113535 CVCL_8I79 DA05491 transformed cell line human CVCL_8I79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113536 CVCL_8I74 DA05485 transformed cell line human CVCL_8I74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113537 CVCL_8I73 DA05481 transformed cell line human CVCL_8I73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113538 CVCL_8I76 DA05487 transformed cell line human CVCL_8I76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113539 CVCL_8I75 DA05486 transformed cell line human CVCL_8I75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113540 CVCL_AC04 NYSCF-10005-1076-1076-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC04 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113541 CVCL_AC03 NYSCF-10005-1073-1073-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC03 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113542 CVCL_AC06 NYSCF-10005-1082-1082-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC06 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113543 CVCL_AC05 NYSCF-10005-1081-1081-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC05 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113544 CVCL_AC08 NYSCF-10005-117-117-Skin-sv-iPSC induced pluripotent stem cell human CVCL_AC08 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113545 CVCL_AC07 NYSCF-10005-1085-1085-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC07 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113546 CVCL_AC09 NYSCF-10005-118-118-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC09 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113547 CVCL_8I70 DA05478 transformed cell line human CVCL_8I70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113548 CVCL_8I72 DA05480 transformed cell line human CVCL_8I72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113549 CVCL_8I71 DA05479 transformed cell line human CVCL_8I71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113550 CVCL_AC00 NYSCF-10005-1069-1069-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC00 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113551 CVCL_AC02 NYSCF-10005-1071-1071-Skin-mR-iPS induced pluripotent stem cell human CVCL_AC02 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113552 CVCL_AC01 NYSCF-10005-1070-1070-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC01 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113553 CVCL_8I45 DA05452 transformed cell line human CVCL_8I45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113554 CVCL_8I44 DA05450 transformed cell line human CVCL_8I44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113555 CVCL_8I47 DA05454 transformed cell line human CVCL_8I47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113556 CVCL_8I46 DA05453 transformed cell line human CVCL_8I46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113557 CVCL_8I41 DA05447 transformed cell line human CVCL_8I41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113558 CVCL_8I40 DA05446 transformed cell line human CVCL_8I40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113559 CVCL_8I43 DA05449 transformed cell line human CVCL_8I43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113560 CVCL_8I42 DA05448 transformed cell line human CVCL_8I42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113561 CVCL_8I49 DA05456 transformed cell line human CVCL_8I49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113562 CVCL_8I48 DA05455 transformed cell line human CVCL_8I48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113563 CVCL_8I56 DA05464 transformed cell line human CVCL_8I56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113564 CVCL_8I55 DA05463 transformed cell line human CVCL_8I55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113565 CVCL_8I58 DA05466 transformed cell line human CVCL_8I58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113566 CVCL_8I57 DA05465 transformed cell line human CVCL_8I57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113567 CVCL_8I52 DA05460 transformed cell line human CVCL_8I52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113568 CVCL_8I51 DA05459 transformed cell line human CVCL_8I51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113569 CVCL_8I54 DA05462 transformed cell line human CVCL_8I54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113570 CVCL_8I53 DA05461 transformed cell line human CVCL_8I53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113571 CVCL_8I59 DA05467 transformed cell line human CVCL_8I59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113572 CVCL_8I50 DA05458 transformed cell line human CVCL_8I50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113573 CVCL_8I23 DA05428 transformed cell line human CVCL_8I23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113574 CVCL_8I22 DA05427 transformed cell line human CVCL_8I22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113575 CVCL_8I25 DA05430 transformed cell line human CVCL_8I25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113576 CVCL_8I24 DA05429 transformed cell line human CVCL_8I24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113577 CVCL_8I21 DA05426 transformed cell line human CVCL_8I21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113578 CVCL_8I20 DA05425 transformed cell line human CVCL_8I20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113579 CVCL_0091 NALM-1 cancer cell line human CVCL_0091 HLA typing: A*02:01,33:03; B*52:01,53:01; C*16:01,16:01 (PubMed=26589293); HLA typing: A*02:01:01,33:03:01; B*52:01:02,53:01:01; C*04:01:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*18:01,104:01; DQA1*01:05:01,05:05:01; DQB1*03:01:01,05:01:01; DRA*01:01:01,01:02:02; DRB1*12:01:01,13:03:01 (DSMZCellDive=ACC-131); Genome ancestry: African=77.03%; Native American=6.08%; East Asian, North=2.94%; East Asian, South=0%; South Asian=0%; European, North=4.83%; European, South=9.12% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB0064; probable Female Doubling time: ~48 hours (DSMZ=ACC-131) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21113580 CVCL_0090 SNU-182 cancer cell line human CVCL_0090 HLA typing: A*11:01,30:01; B*13:02,55:02; C*01:02,06:02 (PubMed=26589293); Genome ancestry: African=1.29%; Native American=0%; East Asian, North=65.62%; East Asian, South=30.85%; South Asian=0%; European, North=0%; European, South=2.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Unspecified (PubMed=8824565; PubMed=31378681) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46 hours (PubMed=7543080); 37.62 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21113581 CVCL_8I27 DA05432 transformed cell line human CVCL_8I27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113582 CVCL_0093 RS4;11 cancer cell line human CVCL_0093 HLA typing: A*03:01,32:01; B*14:02,37:01; C*06:02,08:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.02%; East Asian, North=0%; East Asian, South=1.26%; South Asian=1.83%; European, North=65.49%; European, South=31.4% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4; Note=In frame (PubMed=1423625; PubMed=8358709; PubMed=32721124) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours (PubMed=20922763); 60 hours (PubMed=25984343); ~50 hours (DSMZ=ACC-508); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21113583 CVCL_8I26 DA05431 transformed cell line human CVCL_8I26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113584 CVCL_0092 NALM-6 cancer cell line human CVCL_0092 HLA typing: A*01,02; B*15 (PubMed=2939141); HLA typing: A*01,02; B*08,15 (PubMed=83966); HLA typing: A*01:01,02:01; B*08:01,15:01; C*04:01,07:01 (PubMed=26589293); HLA typing: A*01:01:01,02:01:01; B*08:01:01,15:01:01; C*04:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*02:01:01,02:01:01; DQB1*02:01:01,03:03:02; DRA*01:01:02,01:02:02; DRB1*03:01:01,07:01:01 (DSMZCellDive=ACC-128); Genome ancestry: African=0.12%; Native American=0.55%; East Asian, North=0%; East Asian, South=2.1%; South Asian=0%; European, North=75.01%; European, South=22.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (PubMed=16969076; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25 hours (PubMed=25984343); 19 hours (PubMed=20922763); 40.2 hours (PubMed=8847894); ~36 hours (DSMZ=ACC-128); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21113585 CVCL_8I29 DA05434 transformed cell line human CVCL_8I29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113586 CVCL_0095 SEM cancer cell line human CVCL_0095 HLA typing: A*01:01,32:01; B*08:01,15:01; C*03:03,07:01 (PubMed=26589293); HLA typing: A*01:01:01,32:01:01; B*08:01:01,15:01:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,02:01:02; DQA1*01:03:01,01:03:01; DQB1*03:01:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*11:01:01,13:01:01 (DSMZCellDive=ACC-546); Genome ancestry: African=0.88%; Native American=0.05%; East Asian, North=2.53%; East Asian, South=0%; South Asian=0.07%; European, North=64.12%; European, South=32.35% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638; PubMed=35354797); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours (PubMed=8199015); 24 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-546); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21113587 CVCL_8I28 DA05433 transformed cell line human CVCL_8I28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113588 CVCL_0094 SD-1 transformed cell line human CVCL_0094 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: AddexBio; C0003015; probable Female Doubling time: ~28-32 hours (DSMZ=ACC-366) 21113589 CVCL_0086 M0-91 cancer cell line human CVCL_0086 CL:0000010 Population: Japanese. 21113590 CVCL_0088 MCF-7L cancer cell line human CVCL_0088 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21113591 CVCL_0087 MC3 cancer cell line human CVCL_0087 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7787756; PubMed=10071072; PubMed=20809971) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21113592 CVCL_0089 MHH-CALL-3 cancer cell line human CVCL_0089 HLA typing: A*02:01,29:02; B*44:02,44:02; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=0.15%; Native American=1.07%; East Asian, North=0.95%; East Asian, South=0%; South Asian=0%; European, North=66.38%; European, South=31.45% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=15843827; PubMed=35354797; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~120 hours (DSMZ=ACC-339) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21113593 CVCL_8I34 DA05440 transformed cell line human CVCL_8I34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113594 CVCL_8I33 DA05439 transformed cell line human CVCL_8I33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113595 CVCL_8I36 DA05442 transformed cell line human CVCL_8I36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113596 CVCL_8I35 DA05441 transformed cell line human CVCL_8I35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113597 CVCL_8I30 DA05435 transformed cell line human CVCL_8I30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113598 CVCL_8I32 DA05438 transformed cell line human CVCL_8I32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113599 CVCL_8I31 DA05436 transformed cell line human CVCL_8I31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113600 CVCL_8I38 DA05444 transformed cell line human CVCL_8I38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113601 CVCL_8I37 DA05443 transformed cell line human CVCL_8I37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113602 CVCL_8I39 DA05445 transformed cell line human CVCL_8I39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113603 CVCL_0097 SIM/EW27 cancer cell line human CVCL_0097 From: Delattre O.; Institut Curie; Paris; France. CL:0000010 21113604 CVCL_0096 Bo Gin finite cell line human CVCL_0096 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113605 CVCL_0099 SNU-1 cancer cell line human CVCL_0099 HLA typing: A*02:07,30:04; B*14:01,51:01; C*08:05,01:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*02:265,30:04; B*14:01,14:01; C*01:02,08:02; DQB1*06:04,06:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.88%; East Asian, North=57.18%; East Asian, South=41.93%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu1154fs*12 (c.3457_3458insT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Lys860Asnfs*16 (c.2580delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1676761) Population: Korean Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26 hours (ATCC=CRL-5971; PubMed=2158397); Microsatellite instability: Instable (MSI-high) (PubMed=10674020; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21113606 CVCL_0098 SKM-1 cancer cell line human CVCL_0098 HLA typing: A*02:07,33:03; B*40:01,59:01; C*01:02,03:04; DQA1*01:02,03:02; DQB1*04:02,06:01; DRB1*04:05,08:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.67%; East Asian, North=75.52%; East Asian, South=22.98%; South Asian=0%; European, North=0.33%; European, South=0.5% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Tyr591Ter (c.1773C>A); ClinVar=VCV000451016; Zygosity=Homozygous (PubMed=27750403); Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; c.4619-1G>A; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=21989985; PubMed=27750403; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Cys (c.1937A>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=27750403; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0147; true Male Doubling time: ~48 hours (PubMed=8136267); ~48 hours (DSMZ=ACC-547); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutation indicated incorrectly as being at p.Tyr327His (c.981T>C) in PubMed=8136267 21113607 CVCL_8I01 DA05395 transformed cell line human CVCL_8I01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113608 CVCL_8I00 DA05394 transformed cell line human CVCL_8I00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113609 CVCL_8I03 DA05397 transformed cell line human CVCL_8I03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113610 CVCL_8I02 DA05396 transformed cell line human CVCL_8I02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113611 CVCL_8I09 DA05405 transformed cell line human CVCL_8I09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113612 CVCL_8I08 DA05404 transformed cell line human CVCL_8I08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113613 CVCL_0071 34T cancer cell line house mouse CVCL_0071 CL:0000010 Female 21113614 CVCL_8I05 DA05399 transformed cell line human CVCL_8I05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113615 CVCL_8I04 DA05398 transformed cell line human CVCL_8I04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113616 CVCL_0070 R4.2 spontaneously immortalized cell line CVCL_0070 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Mixed 21113617 CVCL_8I07 DA05402 transformed cell line human CVCL_8I07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113618 CVCL_0073 EpH4 spontaneously immortalized cell line house mouse CVCL_0073 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21113619 CVCL_0072 BaF-B03 factor-dependent cell line house mouse CVCL_0072 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21113620 CVCL_8I06 DA05401 transformed cell line human CVCL_8I06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113621 CVCL_0064 MV4-11 cancer cell line human CVCL_0064 HLA typing: A*03:01,68:01; B*14:02,18:01; C*08:02,15:02 (PubMed=26589293); HLA typing: A*03:01:01,20:01:02; B*14:02:01,18:01:01; C*08:02:01,15:02:01; DPB1*02:01,04:01; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:09:01; DRB1*01:01:01,13:02:01 (CLS=300295); Genome ancestry: African=0.59%; Native American=0%; East Asian, North=0.34%; East Asian, South=0%; South Asian=2.57%; European, North=67.58%; European, South=28.91% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=1423625; PubMed=8358709); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668) Population: Caucasian; Karyotypic information: 48,XY,t(4;11)(q21;q23),+8,+19 (ATCC); Derived from sampling site: Peripheral blood. Omics: Acetylation analysis by proteomics; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-189; true Male Characteristics: CSF2 and IL3 dependent Doubling time: 32 hours (PubMed=25984343); ~48 hours (CLS); ~50 hours (DSMZ=ACC-102); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9591 21113622 CVCL_0063 HEK293T transformed cell line human CVCL_0063 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Mitochondrial proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Doubling time: ~24-30 hours (DSMZ=ACC-635) Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project 21113623 CVCL_0065 Jurkat cancer cell line human CVCL_0065 HLA typing: A*03:01:01,03:01:01; B*07:02:01,35:03:01; C*04:01:01,07:02:01; DQB1*06:03:01,06:03:01 (DSMZCellDive=ACC-282); Genome ancestry: African=0.4%; Native American=0%; East Asian, North=0.13%; East Asian, South=1.21%; South Asian=1.08%; European, North=70.73%; European, South=26.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (PubMed=9583678); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (PubMed=9583678); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (PubMed=19473701); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (PubMed=19473701); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (PubMed=9583678); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (PubMed=9510473); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg1627His (c.4880G>A); ClinVar=VCV000409067; Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=19220422; PubMed=22675565; Cosmic-CLP) Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=352912) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Acetylation analysis by proteomics; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: N-glycan profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Ubiquitination analysis by proteomics; Omics: Virome analysis using proteomics Discontinued: CLS; 305018; true; Discontinued: ICLC; HTL01002; true Male Doubling time: 26 hours (PubMed=17117183); ~25-35 hours (DSMZ=ACC-282); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: International Histocompatibility Workshop cell lines; Part of: LL-100 blood cancer cell line panel 21113624 CVCL_0068 SK-MEL-1 cancer cell line human CVCL_0068 HLA typing: A*26:01,26:01; B*38:01,67:02; C*04:01,12:03; DQA1*03:02,03:02; DQB1*06:01,06:01; DRB1*14:76,14:76 (PubMed=26589293); Genome ancestry: African=1.29%; Native American=0%; East Asian, North=4.27%; East Asian, South=0%; South Asian=9.23%; European, North=23.14%; European, South=62.08% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21725359; PubMed=24576830; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Cys (c.98C>G); ClinVar=VCV000376231; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Thoracic lymph duct. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~100 hours (DSMZ=ACC-303); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2004-052 21113625 CVCL_0067 Namalwa cancer cell line human CVCL_0067 HLA typing: A*29:02,66:02; B*57:03,58:01; C*07:01,15:05; DQA1*01:02,03:02; DQB1*02:01,06:02; DRB1*07:01,15:03 (PubMed=25960936); HLA typing: A*03:01,68:02; B*07:02,49:01; C*04:01,07:01; DQA1*01:02,03:02; DQB1*03:02,06:02; DRB1*04:05,15:03 (PubMed=26589293); HLA typing: A*03:01:01,20:02:01; B*07:02:01,01:01:01; C*07:01:02,07:02:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,03:03:01; DQB1*03:02:01.06:02:01; DRB1*04:05:01,15:03:01 (CLS=300439); Genome ancestry: African=94.65%; Native American=0%; East Asian, North=1.43%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=3.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660; Cosmic-CLP; DepMap) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: RCB; RCB0445; true. Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1; Virology: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443) Doubling time: 18 hours (PubMed=8402660); ~20-30 hours (DSMZ=ACC-24); Microsatellite instability: Instable (MSI-low) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: Indicated to have an additional TP53 p.Arg248Trp (c.742C>T) mutation according to PubMed=2052620, but not confirmed by other references or by CCLE and Cosmic-CLP 21113626 CVCL_0069 SK-MEL-2 cancer cell line human CVCL_0069 HLA typing: A*03,26; B*35,38; C*04,12:03:01; DPB1*02:01:02,04:01; DQB1*03:01:01,06:03; DRB1*04:02,13:01:01 (PubMed=15748285); HLA typing: A*03:01,26:01; B*35:08,38:01; C*04:01,12:03 (PubMed=26589293); Genome ancestry: African=1.43%; Native American=0%; East Asian, North=2.36%; East Asian, South=1.87%; South Asian=7.21%; European, North=28.23%; European, South=58.89% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=17088437; PubMed=21725359; PubMed=24576830; PubMed=25728708; PubMed=27533468); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; PubMed=21912889; PubMed=27533468) Derived from metastatic site: Thigh; skin. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32 hours (PubMed=7718330); 45.5 hours (NCI-DTP); ~56 hours (PBCF); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 779 21113627 CVCL_8I12 DA05413 transformed cell line human CVCL_8I12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113628 CVCL_8I11 DA05408 transformed cell line human CVCL_8I11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113629 CVCL_8I14 DA05415 transformed cell line human CVCL_8I14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113630 CVCL_8I13 DA05414 transformed cell line human CVCL_8I13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113631 CVCL_8I10 DA05407 transformed cell line human CVCL_8I10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113632 CVCL_8I19 DA05424 transformed cell line human CVCL_8I19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113633 CVCL_0080 A-673 cancer cell line human CVCL_0080 HLA typing: A*01:01,02:01; B*07:02,07:02; C*07:02,07:02; DQB1*03:02,03:02; DRB1*15:01,14:76 (PubMed=26589293); Genome ancestry: African=0.54%; Native American=0%; East Asian, North=1.77%; East Asian, South=0%; South Asian=0%; European, North=69.11%; European, South=28.57% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; PubMed=25010205; PubMed=25223734; ATCC); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975; PubMed=25010205; PubMed=25485619); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=22142829; PubMed=25010205; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala119Glnfs*5 (c.353_354dupCA) (c.354_355insCA); Zygosity=Homozygous (PubMed=8378080; PubMed=19787792; PubMed=25010205; PubMed=25223734; ATCC; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7910; true. Female Doubling time: 24 hours (PubMed=16888811); 25 hours (PubMed=24312454); 28 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=10379870; PubMed=12606131; PubMed=14697648). 21113634 CVCL_0082 CL-01 cancer cell line human CVCL_0082 CL:0000010 Population: Africans south of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female 21113635 CVCL_8I16 DA05421 transformed cell line human CVCL_8I16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113636 CVCL_0081 BEL-1 cancer cell line human CVCL_0081 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638) Derived from sampling site: Peripheral blood. Female Doubling time: 38 +- 2 hours (PubMed=15327532) 21113637 CVCL_8I15 DA05420 transformed cell line human CVCL_8I15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113638 CVCL_8I18 DA05423 transformed cell line human CVCL_8I18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113639 CVCL_0084 HCMC finite cell line human CVCL_0084 CL:0000010 Derived from sampling site: Colon; mucosa. Discontinued: ATCC; CCL-239; true Male Senescence: Has been discontinued from ATCC because the cells senesced 21113640 CVCL_8I17 DA05422 transformed cell line human CVCL_8I17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113641 CVCL_0083 DeFew cancer cell line human CVCL_0083 CL:0000010 Omics: Transcriptome analysis by microarray Virology: EBV-negative 21113642 CVCL_0075 NMuMG spontaneously immortalized cell line house mouse CVCL_0075 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female 21113643 CVCL_0074 TL-Mor transformed cell line human CVCL_0074 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 independent 21113644 CVCL_0077 SNU-398 cancer cell line human CVCL_0077 HLA typing: A*02:01,24:02; B*15:32,40:02; C*01:02,04:01 (PubMed=26589293); Genome ancestry: African=1.33%; Native American=0.85%; East Asian, North=66.35%; East Asian, South=28.86%; South Asian=0%; European, North=0%; European, South=2.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Cys (c.110C>G); ClinVar=VCV000017579; Zygosity=Heterozygous (PubMed=31378681; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Heterozygous (PubMed=8824565) Population: Korean; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 39 hours (PubMed=7543080); 25.49 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21113645 CVCL_0076 SNU-16 cancer cell line human CVCL_0076 HLA typing: A*24:02,33:03; B*52:01,55:01; C*01:02,01:02; DQB1*06:13,06:13; DRB1*13:02,13:02 (PubMed=25960936); HLA typing: A*24:02,33:03; B*52:01,55:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=3.14%; Native American=0.82%; East Asian, North=65.94%; East Asian, South=27.38%; South Asian=0%; European, North=0%; European, South=2.71% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 1681; CD44 + HGNC; 10940; SLC1A2; Name(s)=CD44-SLC1A2 (PubMed=23637631); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4065_4066insTTGA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Phe (c.614A>T); ClinVar=VCV000376682; Zygosity=Homozygous (PubMed=1676761; Cosmic-CLP; DepMap) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (ATCC=CRL-5974; PubMed=2158397); Microsatellite instability: Stable (MSS) (PubMed=10674020; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: MD Anderson Cell Lines Project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21113646 CVCL_0079 697 cancer cell line human CVCL_0079 HLA typing: A*02:01:01,25:01:01; B*07:02:01,15:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02; DQA1*01:01:01,01:01:01; DQB1*05:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,01:01:01 (DSMZCellDive=ACC-42); HLA typing: A*02:01,25:01; B*07:02,15:01 (PubMed=26589293); Genome ancestry: African=0.56%; Native American=0.55%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=65.87%; European, South=33.02% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=11843816; PubMed=15843827; PubMed=35354797; DepMap) Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=25984343); ~30-40 hours (DSMZ=ACC-42); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21113647 CVCL_0078 SNU-5 cancer cell line human CVCL_0078 HLA typing: A*24:02,26:01; B*35:01,40:05; C*03:03,03:03; DQA1*05:01,05:01; DQB1*03:09,03:09; DRB1*11:01,12:01 (PubMed=25960936); HLA typing: A*24:02,26:01; B*35:01,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=65.54%; East Asian, South=33.69%; South Asian=0%; European, North=0%; European, South=0.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262_Ser269delGlyAsnLeuLeuGlyArgAsnSer (c.784_807del24); Zygosity=Unspecified (PubMed=1676761) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34 hours (PubMed=2158397); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: MET genetic alteration cell panel (ATCC TCP-1036); Part of: Seoul National University (SNU) cell line collection 21113648 CVCL_AB61 ND03685 transformed cell line human CVCL_AB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113649 CVCL_AB60 ND03679 transformed cell line human CVCL_AB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113650 CVCL_AB59 ND02813 transformed cell line human CVCL_AB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113651 CVCL_AB52 BHK-MMP1 spontaneously immortalized cell line CVCL_AB52 CL:0000010 Transfected with: HGNC; 7155; MMP1 Derived from sampling site: Kidney. Male 21113652 CVCL_AB51 GM17495 finite cell line human CVCL_AB51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113653 CVCL_AB54 BJNhem20-OCIAD1-OV embryonic stem cell human CVCL_AB54 CL:0000010 Transfected with: HGNC; 16074; OCIAD1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Population: Indian Female 21113654 CVCL_AB53 BHK-MMP3 spontaneously immortalized cell line CVCL_AB53 CL:0000010 Transfected with: HGNC; 7173; MMP3 Derived from sampling site: Kidney. Male 21113655 CVCL_AB56 ND02201 transformed cell line human CVCL_AB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113656 CVCL_AB55 ND00041 transformed cell line human CVCL_AB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113657 CVCL_AB58 ND02270 transformed cell line human CVCL_AB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113658 CVCL_AB57 ND02207 transformed cell line human CVCL_AB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113659 CVCL_AB70 ND06076 transformed cell line human CVCL_AB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113660 CVCL_AB72 ND06573 transformed cell line human CVCL_AB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113661 CVCL_AB71 ND06357 transformed cell line human CVCL_AB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113662 CVCL_AB63 ND03829 transformed cell line human CVCL_AB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113663 CVCL_AB62 ND03764 transformed cell line human CVCL_AB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113664 CVCL_AB65 ND03983 transformed cell line human CVCL_AB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113665 CVCL_AB64 ND03832 transformed cell line human CVCL_AB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113666 CVCL_AB67 ND04599 transformed cell line human CVCL_AB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113667 CVCL_AB66 ND04028 transformed cell line human CVCL_AB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113668 CVCL_AB69 ND05604 transformed cell line human CVCL_AB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113669 CVCL_AB68 ND04769 transformed cell line human CVCL_AB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113670 CVCL_AB38 GM16689 transformed cell line human CVCL_AB38 HLA typing: A*24:02:01,30:01:01; B*13:02:01,51:01:01; C*06:02:01,14:02:01; DPA1*01:03:01,02:01:01; DPB1*04:02:01G,17:01:01G; DQA1*02:01:01,05:07; DQB1*02:02:01,03:01:01; DRB1*07:01:01,14:03:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21113671 CVCL_AB37 GM16688 transformed cell line human CVCL_AB37 HLA typing: A*24:02:01,26:01:01; B*15:07:01,35:01:01; C*03:03:01,03:03:01; DPA1*01:03:01,02:02:02; DPB1*04:02:01,05:01:01; DQA1*03:03:01,05:05:01; DQB1*03:01:01,04:01:01; DRB1*04:05:01,12:01:01G; DRB3*01:01:02; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21113672 CVCL_AB39 GM17721 transformed cell line human CVCL_AB39 CL:0000010 Sequence variation: Mutation; HGNC; 10933; SLC17A5; Simple; p.Arg39Cys (c.115C>T); ClinVar=VCV000005615; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113673 CVCL_AB30 GM03194 transformed cell line human CVCL_AB30 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Thr66Ala (c.196A>G); ClinVar=VCV000038946; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113674 CVCL_AB32 GM03591 finite cell line human CVCL_AB32 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21113675 CVCL_AB31 GM03195 transformed cell line human CVCL_AB31 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Thr66Ala (c.196A>G); ClinVar=VCV000038946; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113676 CVCL_AB34 GM04376 finite cell line human CVCL_AB34 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXX (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21113677 CVCL_AB33 GM03650 transformed cell line human CVCL_AB33 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Thr66Ala (c.196A>G); ClinVar=VCV000038946; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113678 CVCL_AB36 GM16654 transformed cell line human CVCL_AB36 HLA typing: A*24:02:01,26:01:01; B*15:01:01,51:01:01; C*04:01:01,15:02:01; DPA1*01:03:01,02:02:02; DPB1*02:01:02,05:01:01; DQA1*01:03:01,06:01:01; DQB1*03:01:01,06:01:01; DRB1*08:03:02,12:02:01; DRB3*03:01:03 (PubMed=29959025) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21113679 CVCL_AB35 GM04939 finite cell line human CVCL_AB35 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXX (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21113680 CVCL_AB50 GM17489 finite cell line human CVCL_AB50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113681 CVCL_AB49 GM08940 transformed cell line human CVCL_AB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113682 CVCL_AB48 GM05157 finite cell line human CVCL_AB48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21113683 CVCL_AB41 GM17723 transformed cell line human CVCL_AB41 CL:0000010 Sequence variation: Mutation; HGNC; 10933; SLC17A5; Simple; p.Arg39Cys (c.115C>T); ClinVar=VCV000005615; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113684 CVCL_AB40 GM17722 transformed cell line human CVCL_AB40 CL:0000010 Sequence variation: Mutation; HGNC; 10933; SLC17A5; Simple; p.Arg39Cys (c.115C>T); ClinVar=VCV000005615; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113685 CVCL_AB43 GM00654 finite cell line human CVCL_AB43 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.Gln639Ter (c.1915C>T); ClinVar=VCV000001686; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.Arg750Trp (c.2248C>T); ClinVar=VCV000001687; Zygosity=Heterozygous (Coriell) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113686 CVCL_AB42 GM00620 finite cell line human CVCL_AB42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21113687 CVCL_AB45 GM02817 finite cell line human CVCL_AB45 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.Arg750Trp (c.2248C>T); ClinVar=VCV000001687; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113688 CVCL_AB44 GM02049 finite cell line human CVCL_AB44 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.His72Leu (c.215A>T) (H71L); ClinVar=VCV000001684; Zygosity=Heterozygous (Coriell) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113689 CVCL_AB47 GM05093 finite cell line human CVCL_AB47 CL:0000010 Sequence variation: Mutation; HGNC; 4422; GNS; Simple; p.Arg355Ter (c.1063C>T); ClinVar=VCV000002932; Zygosity=Homozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113690 CVCL_AB46 GM04518 finite cell line human CVCL_AB46 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.Pro356Arg (c.1067C>G); ClinVar=VCV000001688; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113691 CVCL_8H89 DA05383 transformed cell line human CVCL_8H89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113692 CVCL_8H86 DA05377 transformed cell line human CVCL_8H86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113693 CVCL_8H85 DA05376 transformed cell line human CVCL_8H85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113694 CVCL_8H88 DA05382 transformed cell line human CVCL_8H88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113695 CVCL_8H87 DA05378 transformed cell line human CVCL_8H87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113696 CVCL_AB16 GM16659 transformed cell line human CVCL_AB16 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys620Phe (c.1859G>T); ClinVar=VCV000013928; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113697 CVCL_AB15 GM16658 transformed cell line human CVCL_AB15 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys620Phe (c.1859G>T); ClinVar=VCV000013928; Zygosity=Heterozygous (PubMed=19767587) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21113698 CVCL_AB18 GM16768 transformed cell line human CVCL_AB18 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113699 CVCL_AB17 GM16660 transformed cell line human CVCL_AB17 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys618Ser (c.1853G>C); ClinVar=VCV000013914; Zygosity=Heterozygous (PubMed=19767587) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21113700 CVCL_AB19 GM16769 transformed cell line human CVCL_AB19 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113701 CVCL_8H82 DA05371 transformed cell line human CVCL_8H82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113702 CVCL_8H81 DA05367 transformed cell line human CVCL_8H81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113703 CVCL_8H84 DA05373 transformed cell line human CVCL_8H84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113704 CVCL_AB10 GM09984 transformed cell line human CVCL_AB10 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113705 CVCL_8H83 DA05372 transformed cell line human CVCL_8H83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113706 CVCL_AB12 GM11630 transformed cell line human CVCL_AB12 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Asp70Profs*51 (c.196_200dupAGCCC) (c.206_207insGCCCC) (317ins5); ClinVar=VCV000403814; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113707 CVCL_AB11 GM11629 transformed cell line human CVCL_AB11 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113708 CVCL_8H80 DA05366 transformed cell line human CVCL_8H80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113709 CVCL_AB14 GM16272 transformed cell line human CVCL_AB14 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113710 CVCL_AB13 GM16184 transformed cell line human CVCL_AB13 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113711 CVCL_8H97 DA05391 transformed cell line human CVCL_8H97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113712 CVCL_8H96 DA05390 transformed cell line human CVCL_8H96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113713 CVCL_8H99 DA05393 transformed cell line human CVCL_8H99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113714 CVCL_8H98 DA05392 transformed cell line human CVCL_8H98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113715 CVCL_AB27 GM50192 transformed cell line human CVCL_AB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113716 CVCL_AB26 GM50174 transformed cell line human CVCL_AB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113717 CVCL_AB29 GM03193 transformed cell line human CVCL_AB29 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Thr66Ala (c.196A>G); ClinVar=VCV000038946; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113718 CVCL_AB28 GM01322 finite cell line human CVCL_AB28 CL:0000010 Population: African American; Karyotypic information: 68,XX [1]; 69,XXY [49] (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21113719 CVCL_8H93 DA05387 transformed cell line human CVCL_8H93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113720 CVCL_8H92 DA05386 transformed cell line human CVCL_8H92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113721 CVCL_8H95 DA05389 transformed cell line human CVCL_8H95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113722 CVCL_AB21 GM16771 transformed cell line human CVCL_AB21 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM16772 (Cellosaurus=CVCL_AB22); Derived from sampling site: Peripheral blood. Female 21113723 CVCL_8H94 DA05388 transformed cell line human CVCL_8H94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113724 CVCL_AB20 GM16770 transformed cell line human CVCL_AB20 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113725 CVCL_AB23 GM18666 transformed cell line human CVCL_AB23 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Asn540Lys (c.1620C>A); ClinVar=VCV000016337; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113726 CVCL_AB22 GM16772 transformed cell line human CVCL_AB22 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM16771 (Cellosaurus=CVCL_AB21); Derived from sampling site: Peripheral blood. Female 21113727 CVCL_8H91 DA05385 transformed cell line human CVCL_8H91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113728 CVCL_AB25 GM50171 transformed cell line human CVCL_AB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113729 CVCL_8H90 DA05384 transformed cell line human CVCL_8H90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113730 CVCL_AB24 GM50149 transformed cell line human CVCL_AB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113731 CVCL_8H68 DA05354 transformed cell line human CVCL_8H68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113732 CVCL_8H67 DA05353 transformed cell line human CVCL_8H67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113733 CVCL_8H69 DA05355 transformed cell line human CVCL_8H69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113734 CVCL_8H64 DA05350 transformed cell line human CVCL_8H64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113735 CVCL_8H63 DA05349 transformed cell line human CVCL_8H63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113736 CVCL_8H66 DA05352 transformed cell line human CVCL_8H66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113737 CVCL_8H65 DA05351 transformed cell line human CVCL_8H65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113738 CVCL_8H60 DA05346 transformed cell line human CVCL_8H60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113739 CVCL_8H62 DA05348 transformed cell line human CVCL_8H62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113740 CVCL_8H61 DA05347 transformed cell line human CVCL_8H61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113741 CVCL_8H79 DA05365 transformed cell line human CVCL_8H79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113742 CVCL_8H78 DA05364 transformed cell line human CVCL_8H78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113743 CVCL_8H75 DA05361 transformed cell line human CVCL_8H75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113744 CVCL_8H74 DA05360 transformed cell line human CVCL_8H74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113745 CVCL_8H77 DA05363 transformed cell line human CVCL_8H77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113746 CVCL_8H76 DA05362 transformed cell line human CVCL_8H76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113747 CVCL_AB05 GM09829 transformed cell line human CVCL_AB05 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02341 and GM09826) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113748 CVCL_AB04 GM09828 transformed cell line human CVCL_AB04 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02341 and GM09826) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113749 CVCL_AB07 GM09838 transformed cell line human CVCL_AB07 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113750 CVCL_AB06 GM09830 transformed cell line human CVCL_AB06 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02341 and GM09826) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113751 CVCL_AB09 GM09910 transformed cell line human CVCL_AB09 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113752 CVCL_AB08 GM09909 transformed cell line human CVCL_AB08 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113753 CVCL_8H71 DA05357 transformed cell line human CVCL_8H71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113754 CVCL_8H70 DA05356 transformed cell line human CVCL_8H70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113755 CVCL_8H73 DA05359 transformed cell line human CVCL_8H73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113756 CVCL_8H72 DA05358 transformed cell line human CVCL_8H72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113757 CVCL_AB01 GM09796 transformed cell line human CVCL_AB01 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113758 CVCL_AB00 GM09795 transformed cell line human CVCL_AB00 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113759 CVCL_AB03 GM09827 transformed cell line human CVCL_AB03 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02341 and GM09826) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113760 CVCL_AB02 GM09826 transformed cell line human CVCL_AB02 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Tyr (c.693C>T); ClinVar=VCV000197621; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113761 CVCL_RU10 CCMCL1 cancer cell line human CVCL_RU10 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male 21113762 CVCL_S610 WERI-Rb-27 cancer cell line human CVCL_S610 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Eye; globe. Female Doubling time: 1.9 days (PubMed=2391623) Problematic cell line: Contaminated Shown to be a Y-79 derivative (PubMed=1679230). Originally thought to originate from a 2 year old boy with a bilateral retinoblastoma. 21113763 CVCL_RU12 Chem-2 HRH2 undefined cell line type human CVCL_RU12 CL:0000010 Transfected with: HGNC; 5183; HRH2. 21113764 CVCL_S612 TOTL-1 cancer cell line human CVCL_S612 CL:0000010 Population: Japanese Female Doubling time: 160 hours (PubMed=2476248). 21113765 CVCL_RU11 PPT2 cancer cell line human CVCL_RU11 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Discontinued: Millipore; SCC104; true Male Problematic cell line: Contaminated Shown to be a HCT 116 derivative (STR profile). Originally thought to originate from a male patient with prostate carcinoma. 21113766 CVCL_S611 RB355 cancer cell line human CVCL_S611 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Eye; globe. Female Doubling time: 81.4 +- 5.7 hours (PubMed=2751270); 66 hours (PubMed=25326674) Problematic cell line: Contaminated Shown to be a Y-79 derivative (PubMed=1679230). Originally thought to originate from a male patient with retinoblastoma. 21113767 CVCL_RU14 4D20.8 somatic stem cell human CVCL_RU14 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Discontinued: Millipore; SCC120; true; Discontinued: Millipore; SCR220; true. Female Characteristics: Has chondrogenic potential Senescence: Can undergo 15 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10231 21113768 CVCL_S614 RB110F/gpt transformed cell line human CVCL_S614 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767). Unspecified Doubling time: 46 hours (PubMed=1359829) 21113769 CVCL_RU13 Chem-3 HRH1 undefined cell line type house mouse CVCL_RU13 CL:0000010 Transfected with: HGNC; 5182; HRH1 Discontinued: Eurofin; Catalog number HTS050C. 21113770 CVCL_S613 RB80F/250R/ori- transformed cell line human CVCL_S613 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Transformant: X-Ray(NCIt; C17262). Male Doubling time: 19 hours (PubMed=1359829) 21113771 CVCL_RU16 7SMOO32 somatic stem cell human CVCL_RU16 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Discontinued: Millipore; SCC123; true; Discontinued: Millipore; SCR223; true. Female Senescence: Can undergo 15 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10233 21113772 CVCL_S616 RBL13 cancer cell line human CVCL_S616 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Heterozygous (PubMed=25326674); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu797Ter (c.2390T>G); Zygosity=Heterozygous (PubMed=25326674). Unspecified Doubling time: 6 days (PubMed=2365495); 97 hours (PubMed=25326674) 21113773 CVCL_RU15 7PEND24 somatic stem cell human CVCL_RU15 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Discontinued: Millipore; SCC122; true; Discontinued: Millipore; SCR222; true. Female Characteristics: Used to study chondrogenesis in a neural crest progenitor with low levels of hypertrophic marker COL10A1 Senescence: Can undergo 10 PDL (ESI_BIO); Doubling time: ~40 hours (ESI_BIO) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11149 21113774 CVCL_S615 FMC-RB1 cancer cell line human CVCL_S615 CL:0000010 Derived from sampling site: Eye. Male 21113775 CVCL_RU18 E15 somatic stem cell human CVCL_RU18 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Senescence: Can undergo >50 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10341 21113776 CVCL_S618 RBL15 cancer cell line human CVCL_S618 CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=25326674). Unspecified Doubling time: 8 days (PubMed=2365495); 45 hours (PubMed=25326674) 21113777 CVCL_RU17 4SKEL20 somatic stem cell human CVCL_RU17 CL:0000010 Discontinued: Millipore; SCC121; true; Discontinued: Millipore; SCR221; true. Female 21113778 CVCL_S617 RBL14 cancer cell line human CVCL_S617 CL:0000010 Unspecified Doubling time: 10 days (PubMed=2365495). 21113779 CVCL_RU19 E68 somatic stem cell human CVCL_RU19 CL:0000010 Discontinued: Millipore; SCC124; true; Discontinued: Millipore; SCR224; true. Female 21113780 CVCL_S619 RBL18 cancer cell line human CVCL_S619 CL:0000010 Unspecified Doubling time: 9 days (PubMed=2365495). 21113781 CVCL_RU01 GM26119 transformed cell line human CVCL_RU01 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg975Trp (c.2923C>T); ClinVar=VCV000451566; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113782 CVCL_S601 VAO1 cancer cell line human CVCL_S601 HLA typing: A*02 (PubMed=7681084). CL:0000010 Female 21113783 CVCL_RU00 GM26118 transformed cell line human CVCL_RU00 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg975Trp (c.2923C>T); ClinVar=VCV000451566; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113784 CVCL_S600 VAB5 cancer cell line human CVCL_S600 HLA typing: A*02,25; B*60,62; C*03 (PubMed=7681084). CL:0000010 Female 21113785 CVCL_RU03 GM26185 transformed cell line human CVCL_RU03 CL:0000010 Sequence variation: Mutation; HGNC; 10983; SLC25A13; Simple; p.Met285Profs*2 (c.852_855delTATG) (c.851_854delGTAT); ClinVar=VCV000225472; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10983; SLC25A13; Simple; p.Ala554Glyfs*16 (c.1638_1660dup23); ClinVar=VCV000006003; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113786 CVCL_S603 ob 17 spontaneously immortalized cell line house mouse CVCL_S603 CL:0000010 Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male Doubling time: 12.5 hours (in 10% FCS), 19 hours (in 1% FCS) (PubMed=216011) 21113787 CVCL_RU02 GM26120 transformed cell line human CVCL_RU02 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg975Trp (c.2923C>T); ClinVar=VCV000451566; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113788 CVCL_S602 T2.A3 hybrid cell line human CVCL_S602 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*03). 21113789 CVCL_RU05 GM26262 transformed cell line human CVCL_RU05 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Tyr8107Asnfs*74 (c.24318_24319insAA); ClinVar=VCV000422612; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113790 CVCL_S605 ob17PY transformed cell line house mouse CVCL_S605 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male 21113791 CVCL_RU04 GM26200 transformed cell line human CVCL_RU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113792 CVCL_S604 ob17MT transformed cell line house mouse CVCL_S604 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male 21113793 CVCL_RU07 GM26656 induced pluripotent stem cell human CVCL_RU07 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113794 CVCL_S607 SKK-1 cancer cell line human CVCL_S607 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 8033; NTRK3; Name(s)=ETV6-NTRK3, TEL-TRKC; Note=In frame (PubMed=28751768; PubMed=34707142); Sequence variation: Mutation; HGNC; 12453; U2AF1; Simple; p.Ser34Phe (c.101C>T); ClinVar=VCV000376025; Zygosity=Heterozygous (PubMed=27750403) Miscellaneous: STR profile from personal communication of Diesch J Population: Japanese; Karyotypic information: Has a chromosome 8 trisomy 47,XY,add(4)(p16),+8,add(12)(p13) (PubMed=15996938).; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Doubling time: 32 hours (PubMed=15996938) 21113795 CVCL_RU06 GM26644 induced pluripotent stem cell human CVCL_RU06 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21113796 CVCL_S606 Ob1754 spontaneously immortalized cell line house mouse CVCL_S606 CL:0000010 Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male 21113797 CVCL_RU09 293T R-Spondin1 expressing transformed cell line human CVCL_RU09 CL:0000010 Transfected with: MGI; MGI:2183426; Rspo1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses mouse Fc-Rspo1 which consist of the fusion of mouse IgG2a Fc region to the N-terminal of Rspo1 with a C-terminal HA epitope tag (Millipore) 21113798 CVCL_S609 WERI-Rb-24 cancer cell line human CVCL_S609 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg358Ter (c.1072C>T); ClinVar=VCV000013076; Zygosity=Unspecified (PubMed=2594029). Male Doubling time: 1.6 days (PubMed=2391623) 21113799 CVCL_RU08 HA-R-Spondin1-Fc 293T transformed cell line human CVCL_RU08 CL:0000010 Transfected with: MGI; MGI:2183426; Rspo1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses mouse Rspo1 with an N-terminal HA epitope tag fused to a C-terminal murine IgG2a Fc region 21113800 CVCL_S608 RB116 cancer cell line human CVCL_S608 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; None_reported; -; Zygosity=- (PubMed=23233783). Unspecified 21113801 CVCL_AB96 NYSCF-10005-1063-1063-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB96 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113802 CVCL_AB95 NYSCF-10005-1062-1062-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB95 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113803 CVCL_AB98 NYSCF-10005-1065-1065-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB98 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113804 CVCL_AB97 NYSCF-10005-1064-1064-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB97 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113805 CVCL_AB99 NYSCF-10005-1067-1067-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB99 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113806 CVCL_AB81 H196 C7 induced pluripotent stem cell human CVCL_AB81 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[36] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=27345814) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113807 CVCL_AB80 chHES-415 embryonic stem cell human CVCL_AB80 From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Arg459Leu (c.1376G>T); ClinVar=VCV000100058; Zygosity=Heterozygous (PubMed=27345785). Female 21113808 CVCL_AB83 LND554SV.3 induced pluripotent stem cell human CVCL_AB83 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7461; MT-ND5; Simple; p.Asp393Asn (m.13513G>A); ClinVar=VCV000009702; Zygosity=Heteroplasmic (PubMed=27345786) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21113809 CVCL_AB82 H266 C10 induced pluripotent stem cell human CVCL_AB82 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=27345805) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113810 CVCL_AB74 ND07124 transformed cell line human CVCL_AB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113811 CVCL_AB73 ND06574 transformed cell line human CVCL_AB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113812 CVCL_AB76 ND08663 transformed cell line human CVCL_AB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113813 CVCL_AB75 ND07255 transformed cell line human CVCL_AB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113814 CVCL_AB78 ND15886 transformed cell line human CVCL_AB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113815 CVCL_AB77 ND14534 transformed cell line human CVCL_AB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113816 CVCL_AB79 ND21706 transformed cell line human CVCL_AB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21113817 CVCL_AB90 NYSCF-10005-1049-1049-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB90 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113818 CVCL_AB92 NYSCF-10005-1051-1051-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB92 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113819 CVCL_AB91 NYSCF-10005-1050-1050-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB91 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113820 CVCL_AB94 NYSCF-10005-1059-1059-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB94 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21113821 CVCL_AB93 NYSCF-10005-1058-1058-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB93 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113822 CVCL_AB85 N44SV.5 induced pluripotent stem cell human CVCL_AB85 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21113823 CVCL_AB84 Lymph2-AD2-iPS induced pluripotent stem cell human CVCL_AB84 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (PubMed=29602048) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21113824 CVCL_AB87 NYSCF-10005-1046-1046-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB87 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113825 CVCL_AB86 NYSCF-10005-1044-1044-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB86 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113826 CVCL_AB89 NYSCF-10005-1048-1048-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB89 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113827 CVCL_AB88 NYSCF-10005-1047-1047-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AB88 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21113828 CVCL_8J00 DA05512 transformed cell line human CVCL_8J00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113829 CVCL_8J02 DA05514 transformed cell line human CVCL_8J02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113830 CVCL_8J01 DA05513 transformed cell line human CVCL_8J01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113831 CVCL_8J08 DA05520 transformed cell line human CVCL_8J08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113832 CVCL_8J07 DA05519 transformed cell line human CVCL_8J07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113833 CVCL_8J09 DA05521 transformed cell line human CVCL_8J09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113834 CVCL_0170 bEnd.3 transformed cell line house mouse CVCL_0170 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Brain Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Discontinued: JCRB; NIHS0319; true Unspecified Characteristics: Widely used for blood vascular research Doubling time: 26-30 hours (PubMed=14568334) 21113835 CVCL_8J04 DA05516 transformed cell line human CVCL_8J04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113836 CVCL_8J03 DA05515 transformed cell line human CVCL_8J03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113837 CVCL_0172 Beta-TC-3 transformed cell line house mouse CVCL_0172 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIPTag2. Doubling time: ~34 hours (DSMZ=ACC-324) 21113838 CVCL_8J06 DA05518 transformed cell line human CVCL_8J06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113839 CVCL_0171 BET-1A transformed cell line human CVCL_0171 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9442 21113840 CVCL_8J05 DA05517 transformed cell line human CVCL_8J05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113841 CVCL_0163 BC3H1 cancer cell line house mouse CVCL_0163 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from metastatic site: Brain; Breed/subspecies: C3H. Unspecified Characteristics: Closely resemble cells in an arrested state of skeletal muscle differentiation (PubMed=2715180); Characteristics: The scorpion toxin Acra3 exerts a very strong cytotoxic effect this cell line (PubMed=24055552) Doubling time: ~70 hours (DSMZ=ACC-171) 21113842 CVCL_0162 BAEC-1 finite cell line CVCL_0162 CL:0000010 Derived from sampling site: Aorta; endothelium. 21113843 CVCL_0165 BCBL-1 cancer cell line human CVCL_0165 HLA typing: A*01:01:01,31:01:02; B*51:01:01,55:01:01; C*03:03:01,15:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-683) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Heterozygous (PubMed=17121789) Karyotypic information: Has lost chromosome Y; Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (DSMZ=ACC-683) Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21113844 CVCL_0164 BCaP-37 cancer cell line human CVCL_0164 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000700009) It was one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: N-glycan profiling Female Doubling time: 34.1 +- 2.3 hours (PubMed=26782109) Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a breast squamous cell carcinoma. 21113845 CVCL_0167 SK-N-BE(2)-M17 cancer cell line human CVCL_0167 Genome ancestry: African=3.92%; Native American=1.22%; East Asian, North=3.24%; East Asian, South=0%; South Asian=6.24%; European, North=21.38%; European, South=64% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (Cosmic-CLP) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB9131; true; Discontinued: JCRB; NIHS0221; true Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) Doubling time: 20-24 hours (ECACC=95011816); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-531 21113846 CVCL_0166 BCL1 cancer cell line house mouse CVCL_0166 CL:0000010 Breed/subspecies: BALB/c. Female 21113847 CVCL_0169 BEND spontaneously immortalized cell line CVCL_0169 CL:0000010 Derived from sampling site: Endometrium; Breed/subspecies: Angus. Female 21113848 CVCL_0168 BEAS-2B transformed cell line human CVCL_0168 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Group: Patented cell line; Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9609 21113849 CVCL_8J11 DA05523 transformed cell line human CVCL_8J11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113850 CVCL_8J10 DA05522 transformed cell line human CVCL_8J10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113851 CVCL_8J13 DA05525 transformed cell line human CVCL_8J13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113852 CVCL_8J12 DA05524 transformed cell line human CVCL_8J12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113853 CVCL_8J19 DA05531 transformed cell line human CVCL_8J19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113854 CVCL_8J18 DA05530 transformed cell line human CVCL_8J18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113855 CVCL_0181 BV-173 cancer cell line human CVCL_0181 HLA typing: A*02:01,30:01; B*15:10,18:01; C*03:04,12:03 (PubMed=26589293); HLA typing: A*02:01:01,30:01:01; B*15:10:01,18:01:01; C*03:04:02,12:03:01; DPA1*01:03:01,02:01:02; DPB1*02:01:02,01:01:01; DQA1*01:02:01,01:02:02; DQB1*05:02:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*13:02:01,16:01:01 (DSMZCellDive=ACC-20); Genome ancestry: African=1.38%; Native American=0%; East Asian, North=2.14%; East Asian, South=0%; South Asian=2.51%; European, North=52.2%; European, South=41.77% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln4045Ter (c.12133C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30-35 hours (PubMed=6572735); ~48 hours (DSMZ=ACC-20); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21113856 CVCL_8J15 DA05527 transformed cell line human CVCL_8J15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113857 CVCL_0180 BU-11 spontaneously immortalized cell line house mouse CVCL_0180 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: C57BL/6. 21113858 CVCL_8J14 DA05526 transformed cell line human CVCL_8J14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113859 CVCL_0183 Ba/F3-Mpl factor-dependent cell line house mouse CVCL_0183 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21113860 CVCL_8J17 DA05529 transformed cell line human CVCL_8J17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113861 CVCL_0182 BV-2 transformed cell line house mouse CVCL_0182 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Omics: Secretome proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21113862 CVCL_8J16 DA05528 transformed cell line human CVCL_8J16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21113863 CVCL_0174 BM2 transformed cell line CVCL_0174 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line 21113864 CVCL_0173 BFC-1 spontaneously immortalized cell line house mouse CVCL_0173 CL:0000010 Derived from sampling site: Brown adipose tissue Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J. Male 21113865 CVCL_0176 BP8 cancer cell line Norway rat CVCL_0176 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21113866 CVCL_0175 BMS2 stromal cell line house mouse CVCL_0175 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.. 21113867 CVCL_0178 BT-20 cancer cell line human CVCL_0178 HLA typing: A*02:01,24:02; B*15:01,38:01; C*03:03,12:03; DQB1*06:03,06:03; DRB1*04:05,13:06 (PubMed=25960936); HLA typing: A*24:02,24:02; B*15:01,67:02; C*03:03,12:03; DQA1*01:02,01:02; DQB1*06:11,06:11; DRB1*04:05,13:01 (PubMed=26589293); HLA typing: A*24:02:01,24:03:01; B*15:01:01,14:01:01; C*03:03:01,12:03:01; DPB1*04:01:01G,06:01:01G; DQA1*01:03:01,03:01:01; DQB1*03:02:01,06:03:01; DRB1*04:04:01,13:01:01 (CLS=300130); Genome ancestry: African=5.3%; Native American=0%; East Asian, North=9.54%; East Asian, South=0%; South Asian=0%; European, North=43.6%; European, South=41.56% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro539Arg (c.1616C>G); ClinVar=VCV000376243; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351; ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351; ATCC); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ile388Ser (c.1163T>G); ClinVar=VCV000665312; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Pro515Leu (c.1544C>T); Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (PubMed=16541312; PubMed=28889351; ATCC) Population: Caucasian Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7912; true. Female Doubling time: 70 hours (PubMed=25984343); 66.15 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21113868 CVCL_0177 BRL-4 spontaneously immortalized cell line Norway rat CVCL_0177 CL:0000010 Transfected with: RGD; 2687; Ghr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver; Breed/subspecies: Buffalo. 21113869 CVCL_0179 BT-474 cancer cell line human CVCL_0179 HLA typing: A*29:02; B*07:02; C*07:02,16:01; DQB1*03:04,06:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*02:46,29:02; B*07:02,35:08; C*07:02,16:01; DQB1*03:02,06:02; DRB1*04:05,15:01 (PubMed=26589293); HLA typing: A*01:01:01,05:02:01; B*07:02:01,20:03:01; C*07:02:01,16:01:01; DPB1*04:01:01G,05:01:01G; DQA1*01:02:01,03:03:01; DQB1*06:02:01; DRB1*04:01,15:01 (CLS=300131); Genome ancestry: African=0.6%; Native American=0%; East Asian, North=2.47%; East Asian, South=0%; South Asian=0%; European, North=70.19%; European, South=26.74% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (PubMed=26865974); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (PubMed=21247443; PubMed=26865974); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (PubMed=21247443; PubMed=26865974); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (PubMed=26865974); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (PubMed=21247443; PubMed=26865974); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (PubMed=26865974; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (PubMed=26865974; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19593635; PubMed=26865974; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=26865974; PubMed=28889351; ATCC; Cosmic-CLP; DepMap) Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870) Population: Caucasian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Glycoproteome analysis by proteomics; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7913; true Female Doubling time: 3.5 days (PubMed=9671407); 78 hours (PubMed=25984343); 45.8 hours (PubMed=24389870); ~60-80 hours (CLS=300131); ~100 hours (DSMZ=ACC-64); 92.49 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113870 CVCL_RV93 CW60362 induced pluripotent stem cell human CVCL_RV93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60362; true Female 21113871 CVCL_S793 NCI-HPN-M2C Lung spontaneously immortalized cell line house mouse CVCL_S793 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113872 CVCL_RV92 CW60359 induced pluripotent stem cell human CVCL_RV92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60359; true Female 21113873 CVCL_S792 NCI-HPN-M2C Kid spontaneously immortalized cell line house mouse CVCL_S792 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113874 CVCL_RV95 CW60395 induced pluripotent stem cell human CVCL_RV95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60395; true Male 21113875 CVCL_S795 NCI-HPN-M2G Lung spontaneously immortalized cell line house mouse CVCL_S795 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113876 CVCL_RV94 CW60365 induced pluripotent stem cell human CVCL_RV94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60365; true Male 21113877 CVCL_S794 NCI-HPN-M2G Kid spontaneously immortalized cell line house mouse CVCL_S794 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113878 CVCL_RV97 CW60420 induced pluripotent stem cell human CVCL_RV97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60420; true Male 21113879 CVCL_S797 NCI-HPN-M4A Lung spontaneously immortalized cell line house mouse CVCL_S797 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113880 CVCL_RV96 CW60418 induced pluripotent stem cell human CVCL_RV96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60418; true Female 21113881 CVCL_S796 NCI-HPN-M2K Colon spontaneously immortalized cell line house mouse CVCL_S796 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Part of: NCI-45 mouse cell line panel 21113882 CVCL_RV99 CW60436 induced pluripotent stem cell human CVCL_RV99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60436; true Female 21113883 CVCL_S799 H7.s6 embryonic stem cell human CVCL_S799 CL:0000010 Karyotypic information: 47,XX,+del(1)(p22p22),der(6)t(6;17)(q27;q1) (PubMed=27829140). Female 21113884 CVCL_RV98 CW60428 induced pluripotent stem cell human CVCL_RV98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60428; true Male 21113885 CVCL_S798 H7.s14 embryonic stem cell human CVCL_S798 CL:0000010 Female 21113886 CVCL_0150 alphaTC1 Clone 9 cancer cell line house mouse CVCL_0150 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Alpha cell.; Breed/subspecies: C57BL/6 x DBA/2. 21113887 CVCL_0141 AML14.3D10 cancer cell line human CVCL_0141 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Doubling time: 48 hours (Kerafast) 21113888 CVCL_0140 AML12 spontaneously immortalized cell line house mouse CVCL_0140 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: CD-1 MT42 transgenic. Omics: Transcriptome analysis by microarray Male Characteristics: Produced in a transgenic mouse expressing human TGFA Doubling time: 37 hours (PubMed=7904757) 21113889 CVCL_0143 AR42J cancer cell line Norway rat CVCL_0143 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas; Breed/subspecies: Wistar. 21113890 CVCL_0142 ANA-1 [Mouse macrophage] transformed cell line house mouse CVCL_0142 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 21113891 CVCL_0145 ARPE-19 spontaneously immortalized cell line human CVCL_0145 CL:0000010 Anecdotal: The number 19 in the cell line name is due to the fact that this cell line was established from a 19-year-old male who died from head trauma in a motor vehicle accident Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Metabolome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 55 hours (from cell counting), 65 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154) 21113892 CVCL_0144 ARO cancer cell line human CVCL_0144 From: Juillard G.J.-F.; University of California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=8423216; PubMed=14522906) Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00177 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma. 21113893 CVCL_0147 ATL-16T transformed cell line human CVCL_0147 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Lost its original IL2 dependency 21113894 CVCL_0146 R-3327-AT-3 cancer cell line Norway rat CVCL_0146 CL:0000010 Breed/subspecies: Copenhagen. Male 21113895 CVCL_0149 AlphaT3-1 transformed cell line house mouse CVCL_0149 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6 x BALB/c transgenic. Male 21113896 CVCL_0148 Akata cancer cell line human CVCL_0148 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (PubMed=1915267) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains a complete EBV genome (strain Akata) which has been sequenced (PubMed=23152513; PubMed=25787276) 21113897 CVCL_RV82 CW60297 induced pluripotent stem cell human CVCL_RV82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60297; true Female 21113898 CVCL_S782 NCI-HPN-M1C Kid spontaneously immortalized cell line house mouse CVCL_S782 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113899 CVCL_RV81 CW60270 induced pluripotent stem cell human CVCL_RV81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60270; true Male 21113900 CVCL_S781 NCI-HPN-M1C Colon spontaneously immortalized cell line house mouse CVCL_S781 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113901 CVCL_RV84 CW60309 induced pluripotent stem cell human CVCL_RV84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60309; true Female 21113902 CVCL_S784 NCI-HPN-M1G Kid spontaneously immortalized cell line house mouse CVCL_S784 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113903 CVCL_RV83 CW60308 induced pluripotent stem cell human CVCL_RV83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60308; true Female 21113904 CVCL_S783 NCI-HPN-M1C Lung spontaneously immortalized cell line house mouse CVCL_S783 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113905 CVCL_RV86 CW60314 induced pluripotent stem cell human CVCL_RV86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60314; true Male 21113906 CVCL_S786 NCI-HPN-M1I Blad spontaneously immortalized cell line house mouse CVCL_S786 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113907 CVCL_RV85 CW60310 induced pluripotent stem cell human CVCL_RV85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60310; true Female 21113908 CVCL_S785 NCI-HPN-M1G Lung spontaneously immortalized cell line house mouse CVCL_S785 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113909 CVCL_RV88 CW60334 induced pluripotent stem cell human CVCL_RV88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60334; true Female 21113910 CVCL_S788 NCI-HPN-M1N Kid spontaneously immortalized cell line house mouse CVCL_S788 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113911 CVCL_RV87 CW60319 induced pluripotent stem cell human CVCL_RV87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60319; true Male 21113912 CVCL_S787 NCI-HPN-M1K Colon spontaneously immortalized cell line house mouse CVCL_S787 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Part of: NCI-45 mouse cell line panel 21113913 CVCL_RV89 CW60336 induced pluripotent stem cell human CVCL_RV89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60336; true Female 21113914 CVCL_S789 NCI-HPN-M1P Kid spontaneously immortalized cell line house mouse CVCL_S789 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113915 CVCL_0161 Ba/F3 factor-dependent cell line house mouse CVCL_0161 CL:0000010 Miscellaneous: Direct author submission of STR profile from Neve R.M.; STR performed by Labcorp Cell Line Testing Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Omics: SNP array analysis Characteristics: IL3 dependent Doubling time: ~20 hours (DSMZ=ACC-300) Caution: Originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse (DSMZ; RCB) 21113916 CVCL_0160 B78/TNF cancer cell line house mouse CVCL_0160 CL:0000010 Transfected with: HGNC; 11892; TNF Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21113917 CVCL_0152 AsPC-1 cancer cell line human CVCL_0152 HLA typing: A*01:01,26:01; B*15:01,15:01; C*03:04,03:04 (PubMed=26589293); HLA typing: A*01:01:01,02:01:01; B*15:01:01; C*03:03:01,03:04:01; DPB1*04:01:01G,10:01:01G; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:04:01; DRB1*04:01:01,13:02:01 (CLS=300158); Genome ancestry: African=0.97%; Native American=0%; East Asian, North=3.23%; East Asian, South=0%; South Asian=0%; European, North=58.23%; European, South=37.57% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (PubMed=9331070); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (PubMed=11787853; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=8026879; PubMed=11115575; PubMed=11169959; PubMed=11787853; PubMed=15367885; PubMed=21607521; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (PubMed=10408907; PubMed=18380791; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (PubMed=8026879; PubMed=11169959; PubMed=11787853; PubMed=15367885; PubMed=21607521; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Doubling time: ~38-40 hours (PubMed=7182348); 46 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel Caution: TP53 mutation indicated incorrectly as being at c.818G>A in PubMed=1630814 21113918 CVCL_0151 As4.1 cancer cell line house mouse CVCL_0151 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Ascites. Female 21113919 CVCL_0154 B104 [Rat neuroblastoma] cancer cell line Norway rat CVCL_0154 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21113920 CVCL_0153 B-CPAP cancer cell line human CVCL_0153 HLA typing: A*02:01,33:01; B*18:01,35:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=0.56%; Native American=1.26%; East Asian, North=0.45%; East Asian, South=1.09%; South Asian=1.92%; European, North=43.75%; European, South=50.97% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23162534; PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (PubMed=14522906; PubMed=23162534; PubMed=30737244; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (DSMZ=ACC-273); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel Caution: Originally classified a thyroid gland papillary carcinoma (PTC) but is now considered to be a poorly differentiated thyroid gland carcinoma (PDTC) (PubMed=23162534) 21113921 CVCL_0156 B10S transformed cell line house mouse CVCL_0156 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/10A Bcgs. Unspecified 21113922 CVCL_0155 B10R transformed cell line house mouse CVCL_0155 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/10A Bcgr. Unspecified 21113923 CVCL_0158 B16-F1 cancer cell line house mouse CVCL_0158 CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33596583); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Omics: Array-based CGH; Omics: SNP array analysis Male Characteristics: Obtained from the pulmonary melanoma module of the 1st serial passage of the B16-F0 parent cell line in C57BL/6 mice; Characteristics: Has a low metastatic potential Doubling time: 22 hours (PubMed=1109790) 21113924 CVCL_0157 B16-BL6 cancer cell line house mouse CVCL_0157 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21113925 CVCL_0159 B16-F10 cancer cell line house mouse CVCL_0159 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis Male Characteristics: Obtained from the pulmonary melanoma module of the 10th serial passage of the B16-F0 parent cell line in C57BL/6 mice; Characteristics: Has a high metastatic potential Doubling time: 17 hours (PubMed=1109790); 17.2 hours (PubMed=23890195) 21113926 CVCL_RV91 CW60354 induced pluripotent stem cell human CVCL_RV91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60354; true Female 21113927 CVCL_S791 NCI-HPN-M2C Colon spontaneously immortalized cell line house mouse CVCL_S791 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Male Part of: NCI-45 mouse cell line panel 21113928 CVCL_RV90 CW60338 induced pluripotent stem cell human CVCL_RV90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60338; true Female 21113929 CVCL_S790 NCI-HPN-M2C Blad spontaneously immortalized cell line house mouse CVCL_S790 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113930 CVCL_RV71 CW20311 induced pluripotent stem cell human CVCL_RV71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20311; true Female 21113931 CVCL_S771 NCI-HPN-F2L Cervix spontaneously immortalized cell line house mouse CVCL_S771 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113932 CVCL_RV70 CW20303 induced pluripotent stem cell human CVCL_RV70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20303; true Male 21113933 CVCL_S770 NCI-HPN-F2K Colon spontaneously immortalized cell line house mouse CVCL_S770 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female Part of: NCI-45 mouse cell line panel 21113934 CVCL_RV73 KTCTL-20 cancer cell line human CVCL_RV73 CL:0000010 Unspecified 21113935 CVCL_S773 NCI-HPN-F3K Colon spontaneously immortalized cell line house mouse CVCL_S773 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female Part of: NCI-45 mouse cell line panel 21113936 CVCL_RV72 CW20320 induced pluripotent stem cell human CVCL_RV72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20320; true Female 21113937 CVCL_S772 NCI-HPN-F3A Lung spontaneously immortalized cell line house mouse CVCL_S772 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113938 CVCL_RV75 CW20323 induced pluripotent stem cell human CVCL_RV75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20323; true Female 21113939 CVCL_S775 NCI-HPN-F43 Mam spontaneously immortalized cell line house mouse CVCL_S775 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113940 CVCL_RV74 CW20322 induced pluripotent stem cell human CVCL_RV74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20322; true Male 21113941 CVCL_S774 NCI-HPN-F3L Cervix spontaneously immortalized cell line house mouse CVCL_S774 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113942 CVCL_RV77 CW20325 induced pluripotent stem cell human CVCL_RV77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20325; true Male 21113943 CVCL_S777 NCI-HPN-F4K Colon spontaneously immortalized cell line house mouse CVCL_S777 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female Part of: NCI-45 mouse cell line panel 21113944 CVCL_RV76 CW20324 induced pluripotent stem cell human CVCL_RV76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20324; true Male 21113945 CVCL_S776 NCI-HPN-F44 Mam spontaneously immortalized cell line house mouse CVCL_S776 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113946 CVCL_RV79 CW60037 induced pluripotent stem cell human CVCL_RV79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW60037; true; Discontinued: FCDI; CW60037; probable. Male 21113947 CVCL_S779 NCI-HPN-M1A Lung spontaneously immortalized cell line house mouse CVCL_S779 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113948 CVCL_RV78 CW20326 induced pluripotent stem cell human CVCL_RV78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20326; true Male 21113949 CVCL_S778 NCI-HPN-F5A Cervix spontaneously immortalized cell line house mouse CVCL_S778 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113950 CVCL_0121 3T3-C2 spontaneously immortalized cell line house mouse CVCL_0121 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Caution: Could be identical to 3T3-M2 (Cellosaurus=CVCL_4U11) 21113951 CVCL_0120 3T3-Swiss albino spontaneously immortalized cell line house mouse CVCL_0120 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Omics: SNP array analysis Male Doubling time: ~40 hours (DSMZ=ACC-173); 36 hours (lot 090991), ~2 days (lots 04052005, 04232010, 03222011 and 08282012) (JCRB) 21113952 CVCL_0123 3T3-L1 spontaneously immortalized cell line house mouse CVCL_0123 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Discontinued: ATCC; CCL-92.1; true Male Doubling time: ~2.2 days (lot 12142004), 31 hours (lot 07032008), ~28 hours (lot 07232012), ~54 hours (lot 02202015), ~39 hours (lot 08012016), ~28 hours (lot 02212018) (JCRB) 21113953 CVCL_0122 3T3F442A spontaneously immortalized cell line house mouse CVCL_0122 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Doubling time: 18 hours (Kerafast) 21113954 CVCL_0125 4T1 cancer cell line house mouse CVCL_0125 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Omics: Transcriptome analysis by microarray Female Characteristics: Metastatic; Characteristics: Widely used model in cancer research due to its high similarity to human breast cancer The tumor growth and metastatic spread of 4T1 cells closely mimic the behavior of human breast cancer. The 4T1 cell line is considered an animal model for stage IV human breast cancer, as it is able to spontaneously metastasize in both post-operative and non-surgical models (CLS). Doubling time: 12.6 hours (ATCC=CRL-2539) 21113955 CVCL_0124 435.eB cancer cell line human CVCL_0124 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21113956 CVCL_0127 70Z/3 cancer cell line house mouse CVCL_0127 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: C57BL/6 x DBA/2. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21113957 CVCL_0126 5637 cancer cell line human CVCL_0126 Genome ancestry: African=30.56%; Native American=0.45%; East Asian, North=11.48%; East Asian, South=40.31%; South Asian=0.35%; European, North=4.97%; European, South=11.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (PubMed=27270441; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; Cosmic-CLP; DepMap) Derived from sampling site: Urinary bladder. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: GPI-anchored proteins analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 23 hours (PubMed=26055179); ~24 hours (DSMZ=ACC-35); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Part of: UBC-40 urothelial bladder cancer cell line index 21113958 CVCL_RV80 CW60079 induced pluripotent stem cell human CVCL_RV80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60079; true Male 21113959 CVCL_S780 NCI-HPN-M1C Blad spontaneously immortalized cell line house mouse CVCL_S780 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Male Part of: NCI-45 mouse cell line panel 21113960 CVCL_RV60 CW20202 induced pluripotent stem cell human CVCL_RV60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20202; true Male 21113961 CVCL_S760 NCI-HPN-F1K Colon spontaneously immortalized cell line house mouse CVCL_S760 CL:0000010 Derived from sampling site: Colon Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female Part of: NCI-45 mouse cell line panel 21113962 CVCL_RV62 CW20209 induced pluripotent stem cell human CVCL_RV62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20209; true Female 21113963 CVCL_S762 NCI-HPN-F1Q Kid spontaneously immortalized cell line house mouse CVCL_S762 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113964 CVCL_RV61 CW20207 induced pluripotent stem cell human CVCL_RV61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20207; true Male 21113965 CVCL_S761 NCI-HPN-F1L Cervix spontaneously immortalized cell line house mouse CVCL_S761 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113966 CVCL_RV64 CW20235 induced pluripotent stem cell human CVCL_RV64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20235; true Female 21113967 CVCL_S764 NCI-HPN-F24 Mam spontaneously immortalized cell line house mouse CVCL_S764 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113968 CVCL_RV63 CW20212 induced pluripotent stem cell human CVCL_RV63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: East Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20212; true Male 21113969 CVCL_S763 NCI-HPN-F23 Mam spontaneously immortalized cell line house mouse CVCL_S763 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113970 CVCL_RV66 CW20245 induced pluripotent stem cell human CVCL_RV66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20245; true Male 21113971 CVCL_S766 NCI-HPN-F2G Blad spontaneously immortalized cell line house mouse CVCL_S766 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113972 CVCL_RV65 CW20240 induced pluripotent stem cell human CVCL_RV65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20240; true Female 21113973 CVCL_S765 NCI-HPN-F2B Lung spontaneously immortalized cell line house mouse CVCL_S765 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113974 CVCL_RV68 CW20277 induced pluripotent stem cell human CVCL_RV68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20277; true Male 21113975 CVCL_S768 NCI-HPN-F2G Lung spontaneously immortalized cell line house mouse CVCL_S768 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113976 CVCL_RV67 CW20273 induced pluripotent stem cell human CVCL_RV67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20273; true Male 21113977 CVCL_S767 NCI-HPN-F2G Kid spontaneously immortalized cell line house mouse CVCL_S767 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113978 CVCL_RV69 CW20278 induced pluripotent stem cell human CVCL_RV69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20278; true Male 21113979 CVCL_S769 NCI-HPN-F2I Cervix spontaneously immortalized cell line house mouse CVCL_S769 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113980 CVCL_0130 A-10 spontaneously immortalized cell line Norway rat CVCL_0130 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Myoblast.; Breed/subspecies: BDIX. Discontinued: JCRB; IFO50275; true Unspecified Doubling time: ~70-100 hours (DSMZ=ACC-132) 21113981 CVCL_0132 A-375 cancer cell line human CVCL_0132 HLA typing: A*01,02; B*12,13 (PubMed=77569); HLA typing: A*01:01,02:01; B*44:03,57:01; C*06:02,16:02; DQA1*03:02,02:01; DQB1*03:03,03:03; DRB1*04:05,07:01 (PubMed=25960936); HLA typing: A*01:01,02:01; B*44:03,57:01; C*06:02,16:01; DQA1*03:02,02:01; DQB1*03:02,03:02; DRB1*04:05,07:01 (PubMed=26589293); Genome ancestry: African=0.84%; Native American=0.49%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0%; European, North=67.22%; European, South=29.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=26405815; PubMed=29492214; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (PubMed=29492214; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (PubMed=29492214; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Skin. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7904; true Female Doubling time: 26.9 +- 6.9 hours (PubMed=29275043); ~32 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21113982 CVCL_0131 A-172 cancer cell line human CVCL_0131 HLA typing: A*01,02; B*07,08 (PubMed=77569); HLA typing: A*01:01,03:01; B*07:02,08:01; C*07:01,07:01; DQB1*06:07,06:07; DRB1*11:26,13:09 (PubMed=26589293); HLA typing: A*01:01:01,03:01:01; B*07:02:01,08:01:01; C*07:01:01,07:02:01; DPB1*02:01:02G,04:02:01G; DQA1*05:01,05:05; DQB1*02:01,03:01; DRB1*03:01,11:01 (CLS=300108); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.05%; East Asian, South=0%; South Asian=1.21%; European, North=68.98%; European, South=27.77% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9090379); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1539; CBFB; Name(s)=ABL1-CBFB (PubMed=23637631); Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14614447; PubMed=15900046) Population: Caucasian; Derived from sampling site: Brain. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7899; true Male Doubling time: 44 hours (PubMed=9842975); 40 hours (PubMed=25984343); ~45 hours (lot 021999), ~30 hours (lot 06092006), ~42 hours (lot 06262015), ~26 hours (lot 12192018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: PTEN genetic alteration cell panel (ATCC TCP-1030) 21113983 CVCL_0134 A2780 cancer cell line human CVCL_0134 HLA typing: A*26:03,26:03; B*37:04,49:01; C*02:02,07:01; DQB1*06:07,06:07; DRB1*01:01,01:01 (PubMed=26589293); Genome ancestry: African=93.08%; Native American=0%; East Asian, North=2.76%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=4.17% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (PubMed=25846456); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (PubMed=25230021) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: GPI-anchored proteins analysis by proteomics; Omics: Metabolome analysis; Omics: N-glycan profiling by lectin array; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Doubling time: 25.3 +- 1 hours (PubMed=3539322); 16 hours (PubMed=25984343); 18.41 hours (GrayJW panel); Microsatellite instability: Instable (MSI-low) (PubMed=15677628; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21113984 CVCL_0133 A126-1B2 cancer cell line Norway rat CVCL_0133 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21113985 CVCL_0136 A375.S2 cancer cell line human CVCL_0136 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Miscellaneous: Not sure what is the relationship between A375.S2 and A375S1 Population: Caucasian; Derived from sampling site: Skin. Omics: SNP array analysis Female 21113986 CVCL_0135 A2780/CP70 cancer cell line human CVCL_0135 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Omics: Deep proteome analysis; Omics: N-glycan profiling by lectin array; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female Part of: MD Anderson Cell Lines Project 21113987 CVCL_0138 ACH-2 cancer cell line human CVCL_0138 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: Latently infected with HIV-1 isolate LAI The main site of integration of the HIV-1 genome is located in the NT5C3A gene. Additional integration sites are found in the SLC25A25-AS, EPT1 and NPLOC4 genes (PubMed=26912621; PubMed=28086908). 21113988 CVCL_0137 A7r5 spontaneously immortalized cell line Norway rat CVCL_0137 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: BDIX. Unspecified 21113989 CVCL_0139 AGS cancer cell line human CVCL_0139 HLA typing: A*02:01,02:01; B*52:01,52:01; C*03:03,03:03; DQB1*04:01,04:01 (PubMed=25960936); HLA typing: A*02:01,02:01; B*52:01,52:01; C*03:03,03:03; DQB1*04:02,04:02 (PubMed=26589293); Genome ancestry: African=3.44%; Native American=32.25%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0.23%; European, North=27.58%; European, South=31.12% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1370612) Population: Caucasian; Derived from sampling site: Stomach. Omics: ChIP-seq GATA4 analysis; Omics: ChIP-seq GATA6 analysis; Omics: ChIP-seq KLF5 analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Persistently infected with parainfluenza virus type 5 (PIV5) strain PIV5-AGS (PubMed=17509637; PubMed=27445371) Doubling time: 24 hours (PubMed=1370612); 22 hours (PubMed=25984343); 24.16 +- 0.07 hours (PubMed=35122114); 20 hours (ATCC=CRL-1739); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: JFCR45 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21113990 CVCL_RV51 CW20150 induced pluripotent stem cell human CVCL_RV51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20150; true Male 21113991 CVCL_S751 D-270MG cancer cell line human CVCL_S751 CL:0000010 Derived from sampling site: Brain. Male 21113992 CVCL_RV50 CW20125 induced pluripotent stem cell human CVCL_RV50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20125; true Female 21113993 CVCL_S750 PC-9/R cancer cell line human CVCL_S750 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22773810); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 21113994 CVCL_RV53 CW20158 induced pluripotent stem cell human CVCL_RV53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20158; true Female 21113995 CVCL_S753 NCI-HPN-F1B Kid spontaneously immortalized cell line house mouse CVCL_S753 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113996 CVCL_RV52 CW20156 induced pluripotent stem cell human CVCL_RV52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20156; true Male 21113997 CVCL_S752 NCI-HPN-F1A Mam spontaneously immortalized cell line house mouse CVCL_S752 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21113998 CVCL_RV55 CW20181 induced pluripotent stem cell human CVCL_RV55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20181; true Male 21113999 CVCL_S755 NCI-HPN-F1G Blad spontaneously immortalized cell line house mouse CVCL_S755 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114000 CVCL_RV54 CW20179 induced pluripotent stem cell human CVCL_RV54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20179; true Male 21114001 CVCL_S754 NCI-HPN-F1D Kid spontaneously immortalized cell line house mouse CVCL_S754 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114002 CVCL_RV57 CW20186 induced pluripotent stem cell human CVCL_RV57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20186; true Female 21114003 CVCL_S757 NCI-HPN-F1G Mam spontaneously immortalized cell line house mouse CVCL_S757 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114004 CVCL_RV56 CW20185 induced pluripotent stem cell human CVCL_RV56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20185; true Female 21114005 CVCL_S756 NCI-HPN-F1G Kid spontaneously immortalized cell line house mouse CVCL_S756 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114006 CVCL_RV59 CW20195 induced pluripotent stem cell human CVCL_RV59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20195; true Female 21114007 CVCL_S759 NCI-HPN-F1I Mam spontaneously immortalized cell line house mouse CVCL_S759 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114008 CVCL_RV58 CW20188 induced pluripotent stem cell human CVCL_RV58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20188; true Male 21114009 CVCL_S758 NCI-HPN-F1I Cervix spontaneously immortalized cell line house mouse CVCL_S758 CL:0000010 Derived from sampling site: Uterus; cervix Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Part of: NCI-45 mouse cell line panel 21114010 CVCL_0101 SNU-601 cancer cell line human CVCL_0101 HLA typing: A*11:01,26:01; B*15:01,40:01; C*04:01,15:02; DQB1*06:02,06:02 (PubMed=25960936); HLA typing: A*11:01,26:01; B*15:01,40:01; C*04:01,15:02; DQB1*06:02,06:02; DRB1*13:05,15:01 (PubMed=26589293); Genome ancestry: African=1.93%; Native American=0.43%; East Asian, North=63.23%; East Asian, South=33.73%; South Asian=0%; European, North=0%; European, South=0.68% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9033653; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=9033653; DepMap) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21114011 CVCL_0100 SNU-484 cancer cell line human CVCL_0100 HLA typing: A*24:02,24:02; B*44:05,51:01; C*05:01,14:02; DQB1*04:01,04:01 (PubMed=25960936); HLA typing: A*24:02,30:01; B*44:02,51:01; C*05:01,14:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Homozygous (PubMed=9033653) Population: Korean; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Seoul National University (SNU) cell line collection 21114012 CVCL_0103 SUP-B15 cancer cell line human CVCL_0103 HLA typing: A*03:01,11:01; B*51:02,52:01; C*12:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.5%; East Asian, North=0.25%; East Asian, South=0.2%; South Asian=1.01%; European, North=70.33%; European, South=27.71% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3162827; PubMed=10071072; PubMed=15843827; PubMed=25485619; PubMed=35354797; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: AddexBio; C0003019; probable; Discontinued: BCRJ; 0229; probable Male Doubling time: ~18 hours (PubMed=3162827); ~60 hours (DSMZ=ACC-389); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21114013 CVCL_0102 SNU-638 cancer cell line human CVCL_0102 HLA typing: A*03:19,24:02; B*44:02,52:01; C*05:01,12:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*03:19,24:02; B*44:02,52:01; C*05:01,12:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=9033653) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21114014 CVCL_0105 DU145 cancer cell line human CVCL_0105 HLA typing: A*03:01:01,33:03; B*50:01,57:01:01; C*06:02; DPB1*04:01; DQB1*03:03:02,05:01:01 (PubMed=15748285); HLA typing: A*33:03,33:03; B*50:01,57:01; C*06:02,06:02; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293); Genome ancestry: African=0.75%; Native American=0%; East Asian, North=2.66%; East Asian, South=0%; South Asian=0.04%; European, North=63.74%; European, South=32.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (PubMed=17088437; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (PubMed=17088437; ATCC); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (PubMed=1873816; PubMed=8104329; PubMed=8510267; PubMed=11304728; PubMed=17088437; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (PubMed=1873816; PubMed=8104329; PubMed=8510267; PubMed=11304728; PubMed=17088437; ATCC) Population: Caucasian; Derived from metastatic site: Brain. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 34 hours, at 39th passage (PubMed=631930); 32.3 hours (NCI-DTP); ~29 hours (ATCC=HTB-81); 28-38 hours (CLS); ~30-40 hours (DSMZ=ACC-261); ~29 hours (PBCF); 51.21 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=23671654; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: TCGA-110-CL cell line panel 21114015 CVCL_0104 UKE-1 cancer cell line human CVCL_0104 HLA typing: A*02:01,03:01; B*07:02,35:03; C*04:01,07:02; DQA1*01:02,04:01; DQB1*04:01,06:02; DRB1*08:01,15:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098) Donor information: Patient had a essential thrombocythemia transformed into acute leukemia; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114016 CVCL_0107 BCP-1 cancer cell line human CVCL_0107 HLA typing: A*24:02,68:01; B*38:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=1.81%; Native American=0.07%; East Asian, North=2%; East Asian, South=0.6%; South Asian=8.1%; European, North=24.92%; European, South=62.51% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=19608668); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=19608668); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Asn (c.775G>A); Zygosity=Heterozygous (PubMed=19608668; DepMap) Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21114017 CVCL_0106 VG-1 cancer cell line human CVCL_0106 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296) Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq. Male 21114018 CVCL_0109 123.7 cancer cell line Norway rat CVCL_0109 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21114019 CVCL_0108 JY transformed cell line human CVCL_0108 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02; DQA1*03:02,01:03; DQB1*06:11,03:02; DRB1*04:04,13:01 (PubMed=25960936); HLA typing: A*02:01:01:01; B*07:02:01:01; C*07:02:01:01,07:02:01:03; DPA1*01:03; DPB1*02:01:02:01,04:01; DQA1*01:03,03:01:01; DQB1*03:02;06:03; DRA*01:01:01:01,01:02:01; DRB1*04:04,13:01 (IPD-IMGT/HLA=10882) CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class I peptidome analysis by proteomics; Omics: MHC region genome; Omics: Transcriptome analysis by RNAseq Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=22238296) Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21114020 CVCL_S740 EWS-502 cancer cell line human CVCL_S740 Genome ancestry: African=5.9%; Native American=0%; East Asian, North=4.68%; East Asian, South=0%; South Asian=0%; European, North=38.28%; European, South=51.14% (PubMed=30894373). From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=23145994); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: shRNA library screening Unspecified Doubling time: 46 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21114021 CVCL_RV40 MZ2904RC cancer cell line human CVCL_RV40 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114022 CVCL_RV42 CW10186 induced pluripotent stem cell human CVCL_RV42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Nepali; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10186; true Male 21114023 CVCL_S742 DEX-Faza 967 cancer cell line Norway rat CVCL_S742 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41879; Dexamethasone; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21114024 CVCL_RV41 MZ2907RC cancer cell line human CVCL_RV41 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114025 CVCL_S741 UCLC11 cancer cell line human CVCL_S741 CL:0000010 21114026 CVCL_RV44 CW10208 induced pluripotent stem cell human CVCL_RV44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10208; true Female 21114027 CVCL_S744 p53HCT116 cancer cell line human CVCL_S744 CL:0000010 Knockout cell: Method=Gamma radiation; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21114028 CVCL_RV43 CW10190 induced pluripotent stem cell human CVCL_RV43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10190; true Female 21114029 CVCL_S743 HYVC cancer cell line human CVCL_S743 CL:0000010 Population: Japanese; Derived from sampling site: Vulva. Female Doubling time: 41-43 hours (PubMed=12889856) 21114030 CVCL_RV46 CW20100 induced pluripotent stem cell human CVCL_RV46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20100; true Male 21114031 CVCL_S746 HCC4006/R cancer cell line human CVCL_S746 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male 21114032 CVCL_S745 11-18/R cancer cell line human CVCL_S745 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22773810) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Unspecified 21114033 CVCL_RV45 CW20095 induced pluripotent stem cell human CVCL_RV45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20095; true Male 21114034 CVCL_RV48 CW20112 induced pluripotent stem cell human CVCL_RV48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20112; true Male 21114035 CVCL_S748 HCC827/R1 cancer cell line human CVCL_S748 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22773810); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21114036 CVCL_RV47 CW20101 induced pluripotent stem cell human CVCL_RV47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20101; true Male 21114037 CVCL_S747 HCC4011/R cancer cell line human CVCL_S747 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line). Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib Male 21114038 CVCL_RV49 CW20121 induced pluripotent stem cell human CVCL_RV49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20121; true Male 21114039 CVCL_S749 HCC827/R2 cancer cell line human CVCL_S749 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21114040 CVCL_0110 1321N1 cancer cell line human CVCL_0110 Genome ancestry: African=1.06%; Native American=0%; East Asian, North=1.62%; East Asian, South=0%; South Asian=0%; European, North=96.5%; European, South=0.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Contaminated Grand-parent cell line (U-118MG) has been shown to be a U-138MG derivative. 21114041 CVCL_0112 16HBE14o- transformed cell line human CVCL_0112 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Omics: Array-based CGH; Omics: Proteome analysis by 2D-DE/MS Male Characteristics: Widely used to model barrier function of the airway epithelium and to study respiratory ion transport as well as the function of CFTR (Millipore) 21114042 CVCL_0111 16610D9 cancer cell line house mouse CVCL_0111 CL:0000010 21114043 CVCL_0114 2008/C13*5.25 cancer cell line human CVCL_0114 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00522 Problematic cell line: Contaminated Parent cell line (OV-2008) has been shown to be a ME-180 derivative (PubMed=22710073). 21114044 CVCL_0113 1HAEo- transformed cell line human CVCL_0113 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Tracheobronchial epithelium. Unspecified Characteristics: Useful model for the study of epithelial ion transport, secretion and biochemistry (Millipore) 21114045 CVCL_0115 2fTGH cancer cell line human CVCL_0115 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21114046 CVCL_0118 32D factor-dependent cell line house mouse CVCL_0118 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Omics: SNP array analysis Male Characteristics: IL3 dependent Doubling time: ~15 hours (DSMZ=ACC-411) 21114047 CVCL_0117 30A-5 spontaneously immortalized cell line house mouse CVCL_0117 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21114048 CVCL_0119 32Dcl3 factor-dependent cell line house mouse CVCL_0119 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: Widely used for the in vitro study of hematopoietic cell proliferation, differentiation and apoptosis (PubMed=10877550); Characteristics: IL3 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11346 21114049 CVCL_8J88 DA05606 transformed cell line human CVCL_8J88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114050 CVCL_8J87 DA05605 transformed cell line human CVCL_8J87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114051 CVCL_8J89 DA05607 transformed cell line human CVCL_8J89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114052 CVCL_8J84 DA05602 transformed cell line human CVCL_8J84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114053 CVCL_8J83 DA05601 transformed cell line human CVCL_8J83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114054 CVCL_8J86 DA05604 transformed cell line human CVCL_8J86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114055 CVCL_8J85 DA05603 transformed cell line human CVCL_8J85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114056 CVCL_AD14 NYSCF-AD-1016-AG07768-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD14 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=24416243) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21114057 CVCL_AD13 NYSCF-AD-1015-AG07671-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD13 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=24416243) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21114058 CVCL_AD16 NYSCF-AD-1021-AG08446-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD16 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (PubMed=24416243) Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21114059 CVCL_AD15 NYSCF-AD-1019-AG07889-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD15 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21114060 CVCL_AD18 NYSCF-DE-1019-1019-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD18 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114061 CVCL_AD17 NYSCF-DE-1018-1018-Skin-RV-IPSC11 induced pluripotent stem cell human CVCL_AD17 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114062 CVCL_AD19 NYSCF-DE-1019-1019-Skin-RV-iPSC1 induced pluripotent stem cell human CVCL_AD19 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114063 CVCL_8J80 DA05597 transformed cell line human CVCL_8J80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114064 CVCL_8J82 DA05599 transformed cell line human CVCL_8J82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114065 CVCL_8J81 DA05598 transformed cell line human CVCL_8J81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114066 CVCL_AD10 NYSCF-AD-1011-ASC27-Dura-SV-iPSC2 induced pluripotent stem cell human CVCL_AD10 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 21114067 CVCL_AD12 NYSCF-AD-1013-AG06842-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD12 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21114068 CVCL_AD11 NYSCF-AD-1012-ASC30-Dura-SV-iPSC1 induced pluripotent stem cell human CVCL_AD11 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Female 21114069 CVCL_8J99 DA05617 transformed cell line human CVCL_8J99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114070 CVCL_8J98 DA05616 transformed cell line human CVCL_8J98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114071 CVCL_8J95 DA05613 transformed cell line human CVCL_8J95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114072 CVCL_8J94 DA05612 transformed cell line human CVCL_8J94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114073 CVCL_8J97 DA05615 transformed cell line human CVCL_8J97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114074 CVCL_8J96 DA05614 transformed cell line human CVCL_8J96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114075 CVCL_AD25 NYSCF-DE-1039-1039-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD25 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114076 CVCL_AD24 NYSCF-DE-1035-1035-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD24 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114077 CVCL_AD27 NYSCF-DE-1045-1045-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD27 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114078 CVCL_AD26 NYSCF-DE-1044-1044-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD26 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114079 CVCL_AD29 NYSCF-DE-1048-1048-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD29 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114080 CVCL_AD28 NYSCF-DE-1046-1046-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD28 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114081 CVCL_8J91 DA05609 transformed cell line human CVCL_8J91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114082 CVCL_8J90 DA05608 transformed cell line human CVCL_8J90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114083 CVCL_8J93 DA05611 transformed cell line human CVCL_8J93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114084 CVCL_8J92 DA05610 transformed cell line human CVCL_8J92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114085 CVCL_AD21 NYSCF-DE-1024-1024-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD21 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114086 CVCL_AD20 NYSCF-DE-1020-1020-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD20 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114087 CVCL_AD23 NYSCF-DE-1028-1028-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD23 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114088 CVCL_AD22 NYSCF-DE-1024-1024-Skin-RV-iPSC1 induced pluripotent stem cell human CVCL_AD22 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114089 CVCL_8J66 DA05583 transformed cell line human CVCL_8J66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114090 CVCL_8J65 DA05582 transformed cell line human CVCL_8J65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114091 CVCL_8J68 DA05585 transformed cell line human CVCL_8J68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114092 CVCL_8J67 DA05584 transformed cell line human CVCL_8J67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114093 CVCL_8J62 DA05579 transformed cell line human CVCL_8J62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114094 CVCL_8J61 DA05578 transformed cell line human CVCL_8J61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114095 CVCL_8J64 DA05581 transformed cell line human CVCL_8J64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114096 CVCL_8J63 DA05580 transformed cell line human CVCL_8J63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114097 CVCL_8J69 DA05586 transformed cell line human CVCL_8J69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114098 CVCL_8J60 DA05577 transformed cell line human CVCL_8J60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114099 CVCL_8J77 DA05594 transformed cell line human CVCL_8J77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114100 CVCL_8J76 DA05593 transformed cell line human CVCL_8J76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114101 CVCL_8J79 DA05596 transformed cell line human CVCL_8J79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114102 CVCL_8J78 DA05595 transformed cell line human CVCL_8J78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114103 CVCL_8J73 DA05590 transformed cell line human CVCL_8J73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114104 CVCL_8J72 DA05589 transformed cell line human CVCL_8J72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114105 CVCL_8J75 DA05592 transformed cell line human CVCL_8J75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114106 CVCL_8J74 DA05591 transformed cell line human CVCL_8J74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114107 CVCL_AD03 NYSCF-10005-900-900-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AD03 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114108 CVCL_AD02 NYSCF-10005-888-888-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AD02 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114109 CVCL_AD05 NYSCF-AD-1000-ASC2-Dura-SV-iPSC1 induced pluripotent stem cell human CVCL_AD05 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Female 21114110 CVCL_AD04 NYSCF-10005-901-901-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AD04 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114111 CVCL_AD07 NYSCF-AD-1001-ASC7-Dura-SV-iPSC1 induced pluripotent stem cell human CVCL_AD07 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Female 21114112 CVCL_AD06 NYSCF-AD-1000-ASC2-Skin-SV-iPSC1 induced pluripotent stem cell human CVCL_AD06 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114113 CVCL_AD09 NYSCF-AD-1011-ASC27-Dura-SV-iPSC1 induced pluripotent stem cell human CVCL_AD09 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 21114114 CVCL_AD08 NYSCF-AD-1007-ASC19-Dura-SV-iPSC1 induced pluripotent stem cell human CVCL_AD08 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 21114115 CVCL_8J71 DA05588 transformed cell line human CVCL_8J71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114116 CVCL_8J70 DA05587 transformed cell line human CVCL_8J70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114117 CVCL_AD01 NYSCF-10005-885-885-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AD01 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114118 CVCL_AD00 NYSCF-10005-882-882-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AD00 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114119 CVCL_8J44 DA05561 transformed cell line human CVCL_8J44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114120 CVCL_8J43 DA05560 transformed cell line human CVCL_8J43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114121 CVCL_8J46 DA05563 transformed cell line human CVCL_8J46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114122 CVCL_8J45 DA05562 transformed cell line human CVCL_8J45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114123 CVCL_8J40 DA05556 transformed cell line human CVCL_8J40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114124 CVCL_8J42 DA05559 transformed cell line human CVCL_8J42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114125 CVCL_8J41 DA05557 transformed cell line human CVCL_8J41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114126 CVCL_8J48 DA05565 transformed cell line human CVCL_8J48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114127 CVCL_8J47 DA05564 transformed cell line human CVCL_8J47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114128 CVCL_8J49 DA05566 transformed cell line human CVCL_8J49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114129 CVCL_8J55 DA05572 transformed cell line human CVCL_8J55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114130 CVCL_8J54 DA05571 transformed cell line human CVCL_8J54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114131 CVCL_8J57 DA05574 transformed cell line human CVCL_8J57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114132 CVCL_8J56 DA05573 transformed cell line human CVCL_8J56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114133 CVCL_8J51 DA05568 transformed cell line human CVCL_8J51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114134 CVCL_8J50 DA05567 transformed cell line human CVCL_8J50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114135 CVCL_8J53 DA05570 transformed cell line human CVCL_8J53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114136 CVCL_8J52 DA05569 transformed cell line human CVCL_8J52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114137 CVCL_8J59 DA05576 transformed cell line human CVCL_8J59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114138 CVCL_8J58 DA05575 transformed cell line human CVCL_8J58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114139 CVCL_8J22 DA05534 transformed cell line human CVCL_8J22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114140 CVCL_8J21 DA05533 transformed cell line human CVCL_8J21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114141 CVCL_8J24 DA05537 transformed cell line human CVCL_8J24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114142 CVCL_8J23 DA05535 transformed cell line human CVCL_8J23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114143 CVCL_8J20 DA05532 transformed cell line human CVCL_8J20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114144 CVCL_8J29 DA05542 transformed cell line human CVCL_8J29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114145 CVCL_0190 C3H/10T1/2 clone 8 spontaneously immortalized cell line house mouse CVCL_0190 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Omics: SNP array analysis Discontinued: JCRB; JCRB0602; true Unspecified Doubling time: 15.5 hours, at 9th passage (PubMed=4357355) Group: Space-flown cell line (cellonaut); Part of: ENCODE project mouse cell lines 21114146 CVCL_0192 C57/B1 cancer cell line house mouse CVCL_0192 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C57BL/6J. Female 21114147 CVCL_8J26 DA05539 transformed cell line human CVCL_8J26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114148 CVCL_0191 C50 transformed cell line house mouse CVCL_0191 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Female 21114149 CVCL_8J25 DA05538 transformed cell line human CVCL_8J25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114150 CVCL_0194 C6 cancer cell line Norway rat CVCL_0194 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Omics: Deep quantitative proteome analysis; Omics: Mitochondrial genome sequenced Male Doubling time: ~24 hours (CLS=500142); ~25-30 hours (DSMZ=ACC-550) 21114151 CVCL_8J28 DA05541 transformed cell line human CVCL_8J28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114152 CVCL_8J27 DA05540 transformed cell line human CVCL_8J27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114153 CVCL_0185 Beta-TC-tet conditionally immortalized cell line house mouse CVCL_0185 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C3HeB/FeJ. Unspecified Characteristics: Expression of the SV40 T-antigen is under the control of the tet operator sequence Shows growth arrest and further differentiation upon addition of 5 ng/ml tetracycline (PubMed=7724601). 21114154 CVCL_0184 BALB/3T3 clone A31 spontaneously immortalized cell line house mouse CVCL_0184 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Omics: SNP array analysis Discontinued: ATCC; CRL-6587; true; Discontinued: ATCC; CRL-6588; true; Discontinued: BioSample; SAMN11397624; true; Discontinued: RCB; RCB2647; true Unspecified Doubling time: 30-32 hours, at 33 Celsius (PubMed=4798834); 24 hours, at 38 Celsius (PubMed=182373) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: A STR profile for this cell line was available in Cellosaurus releases 30 and 31 and originated from a BioSample entry created using NIST data As this data has been since removed because of possible misidentification/contamination we also have removed it. 21114155 CVCL_0187 C-28/I2 transformed cell line human CVCL_0187 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.. Female 21114156 CVCL_0186 BxPC-3 cancer cell line human CVCL_0186 HLA typing: A*01:01,01:01; B*37:01,37:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=1.55%; Native American=0%; East Asian, North=1.41%; East Asian, South=0%; South Asian=0%; European, North=69.25%; European, South=27.79% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11169959); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907; PubMed=15367885; PubMed=18380791); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (PubMed=8026879; PubMed=11115575; PubMed=15367885); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=1630814; PubMed=7961102; PubMed=8026879; PubMed=8194712; PubMed=8426738; PubMed=11115575; PubMed=15367885; PubMed=21607521; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48-60 hours (PubMed=3754176); 48 hours (PubMed=25984343); ~48 hours (DSMZ=ACC-760); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project Caution: Additional TP53 mutation in c.793C>T indicated incorrectly in PubMed=1630814 21114157 CVCL_0189 C2C12N spontaneously immortalized cell line house mouse CVCL_0189 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21114158 CVCL_0188 C2C12 spontaneously immortalized cell line house mouse CVCL_0188 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Omics: Cell surface proteome; Omics: Deep proteome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K79me3 ChIP-seq epigenome analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Capable, upon starvation, of differentiating into contractile myotubes that express muscle-specific proteins Doubling time: 19.6 +- 0.4 hours (at 22th passage), 18.4 +- 0.2 (at 38th passage) (PubMed=22020321); ~20 hours (DSMZ=ACC-565) Part of: ENCODE project mouse cell lines 21114159 CVCL_8J33 DA05548 transformed cell line human CVCL_8J33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114160 CVCL_8J32 DA05547 transformed cell line human CVCL_8J32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114161 CVCL_8J35 DA05551 transformed cell line human CVCL_8J35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114162 CVCL_8J34 DA05550 transformed cell line human CVCL_8J34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114163 CVCL_8J31 DA05546 transformed cell line human CVCL_8J31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114164 CVCL_8J30 DA05545 transformed cell line human CVCL_8J30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114165 CVCL_8J37 DA05553 transformed cell line human CVCL_8J37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114166 CVCL_8J36 DA05552 transformed cell line human CVCL_8J36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114167 CVCL_8J39 DA05555 transformed cell line human CVCL_8J39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114168 CVCL_8J38 DA05554 transformed cell line human CVCL_8J38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114169 CVCL_0196 C8161.9 cancer cell line human CVCL_0196 CL:0000010 Derived from metastatic site: Abdominal wall. Female 21114170 CVCL_0195 C8166/45 transformed cell line human CVCL_0195 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood. Male 21114171 CVCL_0197 C91/PL transformed cell line human CVCL_0197 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Male Virology: HTLV-1 producing cell line 21114172 CVCL_0199 CAD transformed cell line house mouse CVCL_0199 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 x DBA/2 transgenic. Male Characteristics: Will differentiate to form neuronal processes in serum free conditions; Characteristics: Seems to have lost the expression of the parental cell SV40 T antigen Doubling time: 18-22 hours (PubMed=9006967) 21114173 CVCL_AC80 NYSCF-10005-733-733-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC80 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114174 CVCL_AC82 NYSCF-10005-743-743-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC82 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114175 CVCL_AC81 NYSCF-10005-739-739-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC81 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114176 CVCL_AC73 NYSCF-10005-694-694-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC73 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114177 CVCL_AC72 NYSCF-10005-689-689-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC72 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114178 CVCL_AC75 NYSCF-10005-700-700-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC75 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114179 CVCL_AC74 NYSCF-10005-699-699-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC74 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114180 CVCL_AC77 NYSCF-10005-705-705-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC77 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114181 CVCL_AC76 NYSCF-10005-702-702-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC76 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114182 CVCL_AC79 NYSCF-10005-716-716-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC79 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114183 CVCL_AC78 NYSCF-10005-709-709-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC78 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114184 CVCL_AC91 NYSCF-10005-819-819-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC91 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114185 CVCL_AC90 NYSCF-10005-818-818-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC90 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114186 CVCL_AC93 NYSCF-10005-825-825-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC93 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114187 CVCL_AC92 NYSCF-10005-824-824-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC92 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114188 CVCL_AC84 NYSCF-10005-752-752-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC84 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114189 CVCL_AC83 NYSCF-10005-750-750-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC83 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114190 CVCL_AC86 NYSCF-10005-773-773-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC86 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Female 21114191 CVCL_AC85 NYSCF-10005-767-767-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC85 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114192 CVCL_AC88 NYSCF-10005-794-794-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC88 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114193 CVCL_AC87 NYSCF-10005-780-780-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC87 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114194 CVCL_AC89 NYSCF-10005-808-808-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC89 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114195 CVCL_AC60 NYSCF-10005-636-636-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC60 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114196 CVCL_AC59 NYSCF-10005-635-635-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC59 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114197 CVCL_AC58 NYSCF-10005-632-632-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC58 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114198 CVCL_AC51 NYSCF-10005-596-596-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC51 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114199 CVCL_AC50 NYSCF-10005-592-592-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC50 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114200 CVCL_AC53 NYSCF-10005-598-598-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC53 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114201 CVCL_AC52 NYSCF-10005-597-597-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC52 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114202 CVCL_AC55 NYSCF-10005-611-611-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC55 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114203 CVCL_AC54 NYSCF-10005-605-605-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC54 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114204 CVCL_AC57 NYSCF-10005-623-623-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC57 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114205 CVCL_AC56 NYSCF-10005-617-617-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC56 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114206 CVCL_AC71 NYSCF-10005-686-686-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC71 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114207 CVCL_AC70 NYSCF-10005-684-684-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC70 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114208 CVCL_AC69 NYSCF-10005-675-675-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC69 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114209 CVCL_AC62 NYSCF-10005-644-644-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC62 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114210 CVCL_AC61 NYSCF-10005-642-642-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC61 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114211 CVCL_AC64 NYSCF-10005-648-648-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC64 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114212 CVCL_AC63 NYSCF-10005-645-645-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC63 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114213 CVCL_AC66 NYSCF-10005-660-660-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC66 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114214 CVCL_AC65 NYSCF-10005-650-650-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC65 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114215 CVCL_AC68 NYSCF-10005-669-669-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC68 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114216 CVCL_AC67 NYSCF-10005-661-661-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC67 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114217 CVCL_AC37 NYSCF-10005-491-491-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC37 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114218 CVCL_AC36 NYSCF-10005-478-478-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC36 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114219 CVCL_AC39 NYSCF-10005-558-558-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC39 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114220 CVCL_AC38 NYSCF-10005-555-555-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC38 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114221 CVCL_AC31 NYSCF-10005-460-460-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC31 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114222 CVCL_AC30 NYSCF-10005-459-459-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC30 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114223 CVCL_AC33 NYSCF-10005-469-469-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC33 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114224 CVCL_AC32 NYSCF-10005-465-465-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC32 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114225 CVCL_AC35 NYSCF-10005-476-476-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC35 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114226 CVCL_AC34 NYSCF-10005-470-470-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC34 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114227 CVCL_AC48 NYSCF-10005-585-585-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC48 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114228 CVCL_AC47 NYSCF-10005-583-583-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC47 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114229 CVCL_AC49 NYSCF-10005-590-590-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC49 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114230 CVCL_AC40 NYSCF-10005-562-562-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC40 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114231 CVCL_AC42 NYSCF-10005-568-568-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC42 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114232 CVCL_AC41 NYSCF-10005-566-566-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC41 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114233 CVCL_AC44 NYSCF-10005-570-570-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC44 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114234 CVCL_AC43 NYSCF-10005-569-569-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC43 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114235 CVCL_AC46 NYSCF-10005-582-582-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC46 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114236 CVCL_AC45 NYSCF-10005-580-580-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC45 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114237 CVCL_8I89 DA05501 transformed cell line human CVCL_8I89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114238 CVCL_8I88 DA05500 transformed cell line human CVCL_8I88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114239 CVCL_8I85 DA05497 transformed cell line human CVCL_8I85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114240 CVCL_8I84 DA05496 transformed cell line human CVCL_8I84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114241 CVCL_8I87 DA05499 transformed cell line human CVCL_8I87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114242 CVCL_8I86 DA05498 transformed cell line human CVCL_8I86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114243 CVCL_AC15 NYSCF-10005-375-375-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC15 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114244 CVCL_AC14 NYSCF-10005-370-370-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC14 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114245 CVCL_AC17 NYSCF-10005-392-392-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC17 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114246 CVCL_AC16 NYSCF-10005-384-384-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC16 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114247 CVCL_AC19 NYSCF-10005-405-405-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC19 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114248 CVCL_AC18 NYSCF-10005-401-401-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC18 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114249 CVCL_8I81 DA05493 transformed cell line human CVCL_8I81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114250 CVCL_8I80 DA05492 transformed cell line human CVCL_8I80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114251 CVCL_8I83 DA05495 transformed cell line human CVCL_8I83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114252 CVCL_8I82 DA05494 transformed cell line human CVCL_8I82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114253 CVCL_AC11 NYSCF-10005-141-141-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC11 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114254 CVCL_AC10 NYSCF-10005-128-128-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC10 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114255 CVCL_AC13 NYSCF-10005-186-186-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC13 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114256 CVCL_AC12 NYSCF-10005-177-177-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC12 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114257 CVCL_8I99 DA05511 transformed cell line human CVCL_8I99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114258 CVCL_8I96 DA05508 transformed cell line human CVCL_8I96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114259 CVCL_8I95 DA05507 transformed cell line human CVCL_8I95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114260 CVCL_8I98 DA05510 transformed cell line human CVCL_8I98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114261 CVCL_8I97 DA05509 transformed cell line human CVCL_8I97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114262 CVCL_AC26 NYSCF-10005-433-433-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC26 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114263 CVCL_AC25 NYSCF-10005-432-432-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC25 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114264 CVCL_AC28 NYSCF-10005-437-437-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC28 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114265 CVCL_AC27 NYSCF-10005-434-434-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC27 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114266 CVCL_AC29 NYSCF-10005-438-438-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC29 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114267 CVCL_8I92 DA05504 transformed cell line human CVCL_8I92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114268 CVCL_8I91 DA05503 transformed cell line human CVCL_8I91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114269 CVCL_8I94 DA05506 transformed cell line human CVCL_8I94 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114270 CVCL_AC20 NYSCF-10005-406-406-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC20 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114271 CVCL_8I93 DA05505 transformed cell line human CVCL_8I93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114272 CVCL_AC22 NYSCF-10005-415-415-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC22 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114273 CVCL_AC21 NYSCF-10005-411-411-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC21 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114274 CVCL_8I90 DA05502 transformed cell line human CVCL_8I90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114275 CVCL_AC24 NYSCF-10005-425-425-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC24 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114276 CVCL_AC23 NYSCF-10005-417-417-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC23 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114277 CVCL_RV31 MZ2931RC cancer cell line human CVCL_RV31 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114278 CVCL_S731 UACC-793 cancer cell line human CVCL_S731 CL:0000010 21114279 CVCL_RV30 MZ2175RC cancer cell line human CVCL_RV30 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114280 CVCL_S730 UACC-537 cancer cell line human CVCL_S730 CL:0000010 21114281 CVCL_RV33 OC1 cancer cell line human CVCL_RV33 CL:0000010 Population: Chinese; Taiwan Male Doubling time: 34 hours (PubMed=2156034). 21114282 CVCL_S733 ONS-75 cancer cell line human CVCL_S733 CL:0000010 Population: Japanese. Unspecified 21114283 CVCL_RV32 MZ2733SVNN transformed cell line human CVCL_RV32 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.. Omics: Proteome analysis by 2D-DE/MS Male 21114284 CVCL_S732 ONS-12 cancer cell line human CVCL_S732 CL:0000010 Population: Japanese; Derived from sampling site: Brain. Female Doubling time: 41.5 hours (PubMed=3740860) 21114285 CVCL_RV35 CUMC-2 cancer cell line human CVCL_RV35 CL:0000010 Population: Korean; Derived from sampling site: Ovary. Female 21114286 CVCL_S735 ONS-F11 cancer cell line human CVCL_S735 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: NCIt; C129643; Cesium-137 gamma radiation; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Brain. Female 21114287 CVCL_RV34 OC2 cancer cell line human CVCL_RV34 CL:0000010 Population: Chinese; Taiwan; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Male Doubling time: 31 hours (PubMed=2156034) 21114288 CVCL_S734 ONS-B11 cancer cell line human CVCL_S734 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: NCIt; C129643; Cesium-137 gamma radiation; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Brain. Female 21114289 CVCL_S737 ASPS-KY cancer cell line human CVCL_S737 CL:0000010 Sequence variation: Gene fusion; HGNC; 13825; ASPSCR1 + HGNC; 11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3 (PubMed=19380023); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala189Val (c.566C>T); ClinVar=VCV000012382; Zygosity=Unspecified (CelloPub=CLPUB00020); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (CelloPub=CLPUB00020) Population: Japanese; Derived from metastatic site: Lung. Female 21114290 CVCL_RV37 MZ2872RC cancer cell line human CVCL_RV37 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114291 CVCL_RV36 MZ2789RC cancer cell line human CVCL_RV36 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Unspecified 21114292 CVCL_S736 ONS-F8 cancer cell line human CVCL_S736 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: NCIt; C129643; Cesium-137 gamma radiation; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Brain. Female 21114293 CVCL_S739 Faza 967 clone 2 cancer cell line Norway rat CVCL_S739 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41879; Dexamethasone; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21114294 CVCL_RV39 MZ2901RC cancer cell line human CVCL_RV39 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114295 CVCL_S738 ASPS-1 cancer cell line human CVCL_S738 CL:0000010 Sequence variation: Gene fusion; HGNC; 13825; ASPSCR1 + HGNC; 11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3 (PubMed=21552147) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female Doubling time: ~3 days (PubMed=21552147) 21114296 CVCL_RV38 MZ2875RC cancer cell line human CVCL_RV38 CL:0000010 Derived from sampling site: Kidney. Unspecified 21114297 CVCL_RV20 GZKHQi001-A induced pluripotent stem cell human CVCL_RV20 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex51del; Zygosity=Hemizygous (PubMed=29414414) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21114298 CVCL_S720 MMTV-cmyc 116br cancer cell line house mouse CVCL_S720 CL:0000010 Female 21114299 CVCL_RV22 HUSTi001-A induced pluripotent stem cell human CVCL_RV22 From: Huazhong University of Science and Technology Tongji Medicine College; Wuhan; China CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114300 CVCL_S722 MMTV-cmyc 66a7 cancer cell line house mouse CVCL_S722 CL:0000010 Female 21114301 CVCL_RV21 GZWWTi001-A [2018] induced pluripotent stem cell human CVCL_RV21 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (PubMed=29414414); Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex56-60dup; Zygosity=Hemizygous (PubMed=29414414) Population: Chinese; Derived from sampling site: Peripheral blood. Male Caution: This group has named GZWWTi001-A two different iPSC cell lines 21114302 CVCL_S721 MMTV-cmyc 67a5 cancer cell line house mouse CVCL_S721 CL:0000010 Female 21114303 CVCL_S724 MMTV-cmyc myc Tg p53+/-67a3 cancer cell line house mouse CVCL_S724 CL:0000010 Female 21114304 CVCL_RV24 NERCe002-A-1 embryonic stem cell human CVCL_RV24 CL:0000010 Transfected with: UniProtKB; Q9U6Y5; Zoanthus sp GFP-like fluorescent chromoprotein FP506 (ZsGreen).. Male 21114305 CVCL_RV23 IDISi001-A induced pluripotent stem cell human CVCL_RV23 From: Health Research Institute of Santiago de Compostela; Santiago de Compostela; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg1242Cys (c.3724C>T); Zygosity=Heterozygous (PubMed=29414412) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21114306 CVCL_S723 MMTV-cmyc myc Tg myc3 cancer cell line house mouse CVCL_S723 CL:0000010 Female 21114307 CVCL_S726 MMTV-cmyc myc7 cancer cell line house mouse CVCL_S726 CL:0000010 Female 21114308 CVCL_RV26 ULUNDi002-A induced pluripotent stem cell human CVCL_RV26 From: University of Lund; Lund; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=29414418) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114309 CVCL_S725 MMTV-cmyc myc6 cancer cell line house mouse CVCL_S725 CL:0000010 Female 21114310 CVCL_RV25 NERCe002-A-2 embryonic stem cell human CVCL_RV25 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Male 21114311 CVCL_S728 UACC-182 cancer cell line human CVCL_S728 CL:0000010 21114312 CVCL_RV28 ULUNDi006-A induced pluripotent stem cell human CVCL_RV28 From: University of Lund; Lund; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=29353703); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6del; Zygosity=Heterozygous (PubMed=29353703) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114313 CVCL_S727 MMTV-cmyc myc83 cancer cell line house mouse CVCL_S727 CL:0000010 Female 21114314 CVCL_RV27 ULUNDi005-A induced pluripotent stem cell human CVCL_RV27 From: University of Lund; Lund; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114315 CVCL_RV29 SM30 somatic stem cell human CVCL_RV29 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Female Characteristics: Used to study robust osteochondral differentiation in a facial neural crest progenitor with low levels of hypertrophic marker COL10A1 Senescence: Can undergo >50 PDL (ESI_BIO); Doubling time: ~50 hours (ESI_BIO). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10232 21114316 CVCL_S729 UACC-239 cancer cell line human CVCL_S729 CL:0000010 21114317 CVCL_RV11 CHO50PV transformed cell line CVCL_RV11 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114318 CVCL_S711 SH-416 cancer cell line human CVCL_S711 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Thr751del (c.2240_2254delTAAGAGAAGCAACAT); ClinVar=VCV000177649; Zygosity=Unspecified (PubMed=21372829) Population: Chinese; Derived from sampling site: Lung. Female 21114319 CVCL_RV10 CHO4PV transformed cell line CVCL_RV10 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114320 CVCL_S710 SH-405 cancer cell line human CVCL_S710 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male 21114321 CVCL_RV13 CHO5PV transformed cell line CVCL_RV13 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114322 CVCL_S713 SH-450 cancer cell line human CVCL_S713 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male 21114323 CVCL_RV12 CHO51PV transformed cell line CVCL_RV12 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114324 CVCL_S712 SH-437 cancer cell line human CVCL_S712 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro848Leu (c.2543C>T); ClinVar=VCV000045282; Zygosity=Unspecified (PubMed=21372829) Population: Chinese; Derived from sampling site: Lung. Male 21114325 CVCL_RV15 CHO7PV transformed cell line CVCL_RV15 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114326 CVCL_S715 SH-543 cancer cell line human CVCL_S715 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Female 21114327 CVCL_RV14 CHO60PV transformed cell line CVCL_RV14 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114328 CVCL_S714 SH-498 cancer cell line human CVCL_S714 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male 21114329 CVCL_RV17 CCMi002-A induced pluripotent stem cell human CVCL_RV17 From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-55del; Zygosity=Hemizygous (PubMed=29414413) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21114330 CVCL_S717 UOK257 cancer cell line human CVCL_S717 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.His429Profs*27 (c.1285dupC) (1733insC); ClinVar=VCV000003363; Zygosity=Hemizygous (PubMed=18206534) Derived from sampling site: Kidney. Male 21114331 CVCL_RV16 CHO9PV transformed cell line CVCL_RV16 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114332 CVCL_S716 CMBS-BS cancer cell line human CVCL_S716 CL:0000010 Male 21114333 CVCL_RV19 CSSi002-A induced pluripotent stem cell human CVCL_RV19 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[~84] (c.52CAG(~84)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=29342448) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114334 CVCL_S719 SU706A cancer cell line human CVCL_S719 CL:0000010 Female 21114335 CVCL_S718 BK-10 cancer cell line human CVCL_S718 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 44.9 hours (in PEC medium), 30.48 hours (in F medium) (PubMed=9719413) 21114336 CVCL_RV18 WAe001-A-18 embryonic stem cell human CVCL_RV18 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous; Note=By TALEN (PubMed=29414603). Male 21114337 CVCL_RV00 CHO205PV transformed cell line CVCL_RV00 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114338 CVCL_S700 HCC4011 cancer cell line human CVCL_S700 HLA typing: A*02:01,32:01; B*40:02,44:02; C*02:02,05:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 49.9 hours (PubMed=29681454) Part of: MD Anderson Cell Lines Project 21114339 CVCL_RV02 CHO23PV transformed cell line CVCL_RV02 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114340 CVCL_S702 HCC4011-GR-step cancer cell line human CVCL_S702 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line). Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839 Male 21114341 CVCL_RV01 CHO211PV transformed cell line CVCL_RV01 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114342 CVCL_S701 HCC4011-GR-high cancer cell line human CVCL_S701 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line). Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839 Male 21114343 CVCL_RV04 CHO302PV transformed cell line CVCL_RV04 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114344 CVCL_S704 HCC827-GR-high2 cancer cell line human CVCL_S704 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21114345 CVCL_RV03 CHO2PV transformed cell line CVCL_RV03 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114346 CVCL_S703 HCC827-GR-high1 cancer cell line human CVCL_S703 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21114347 CVCL_RV06 CHO3PV transformed cell line CVCL_RV06 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114348 CVCL_S706 PC-9-GR-high cancer cell line human CVCL_S706 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21114349 CVCL_RV05 CHO30PV transformed cell line CVCL_RV05 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114350 CVCL_S705 HCC827-GR-step cancer cell line human CVCL_S705 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21114351 CVCL_RV08 CHO421PV transformed cell line CVCL_RV08 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114352 CVCL_S708 SH-224 cancer cell line human CVCL_S708 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Female 21114353 CVCL_RV07 CHO40PV transformed cell line CVCL_RV07 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114354 CVCL_S707 PC-9-GR-step cancer cell line human CVCL_S707 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21114355 CVCL_RV09 CHO423PV transformed cell line CVCL_RV09 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21114356 CVCL_S709 SH-289 cancer cell line human CVCL_S709 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Female 21114357 CVCL_AC95 NYSCF-10005-835-835-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC95 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114358 CVCL_AC94 NYSCF-10005-830-830-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC94 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114359 CVCL_AC97 NYSCF-10005-845-845-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC97 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114360 CVCL_AC96 NYSCF-10005-841-841-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC96 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114361 CVCL_AC99 NYSCF-10005-876-876-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC99 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114362 CVCL_AC98 NYSCF-10005-861-861-Skin-mR-iPSC induced pluripotent stem cell human CVCL_AC98 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114363 CVCL_8K21 DA05645 transformed cell line human CVCL_8K21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114364 CVCL_8K20 DA05644 transformed cell line human CVCL_8K20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114365 CVCL_8K23 DA05647 transformed cell line human CVCL_8K23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114366 CVCL_8K22 DA05646 transformed cell line human CVCL_8K22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114367 CVCL_8K29 DA05656 transformed cell line human CVCL_8K29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114368 CVCL_8K28 DA05655 transformed cell line human CVCL_8K28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114369 CVCL_8K25 DA05652 transformed cell line human CVCL_8K25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114370 CVCL_0291 HCT 116 cancer cell line human CVCL_0291 HLA typing: A*01,02; B*18,45:01; C*05,07; DPB1*03:01:01,04:02; DQB1*02,03 (PubMed=15748285); HLA typing: A*01:01,02:01; B*45:01; C*05:01,07:01 (PubMed=9178645); HLA typing: A*01:01,02:01; B*18:01,45:01; C*05:01,07:01; DQA1*05:02,05:02; DQB1*03:09,02:02; DRB1*03:05,11:02 (PubMed=25960936); HLA typing: A*01:01,02:01; B*18:01,45:01; C*05:01,07:01 (PubMed=26589293); HLA typing: A*01:01:01,02:01:01; B*18:01:01,21:01:01; C*05:01:01,07:01:01; DPB1*03:01:01G,04:02:01G; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:19:01; DRB1*03:01:01,11:02:01 (CLS=300195); Genome ancestry: African=0%; Native American=0.08%; East Asian, North=1.16%; East Asian, South=0%; South Asian=0.97%; European, North=64.85%; European, South=32.93% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (PubMed=17088437; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp74fs*21 (c.220delG); Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu33Argfs*20 (c.97delG); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (PubMed=9294210; PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (PubMed=10700188; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9715273; PubMed=15900046; PubMed=16418264) Derived from sampling site: Colon. Omics: Array-based CGH; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Extracellular vesicles proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: HLA class I peptidome analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS); Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 17.1 hours (PubMed=22628656); 22 hours (PubMed=23546019); 36 hours (PubMed=25984343); 18.14 +- 0.051 hours (PubMed=32927768); 17.4 hours (NCI-DTP); ~25-48 hours (DSMZ=ACC-581); ~21 hours (PBCF); Microsatellite instability: Instable (MSI-high) (PubMed=9000147; PubMed=10674020; PubMed=12714694; PubMed=23671654; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: NCI-60 cancer cell line panel 21114371 CVCL_8K24 DA05648 transformed cell line human CVCL_8K24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114372 CVCL_0290 HCC1937 cancer cell line human CVCL_0290 HLA typing: A*23:01,24:02; B*07:02,40:01; C*03:04,07:02; DQA1*04:01,04:01; DQB1*06:02,06:02; DRB1*15:01,08:01 (PubMed=25960936); HLA typing: A*23:01,24:02; B*40:16,81:03; C*03:04,07:02 (PubMed=26589293); Genome ancestry: African=2.19%; Native American=0%; East Asian, North=5.95%; East Asian, South=0%; South Asian=0%; European, North=57.75%; European, South=34.11% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17334996; PubMed=19593635); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Homozygous; Note=The lymphoblastoid cell line HCC1937 BL (Cellosaurus=CVCL_3281) is heterozygous for the same mutation (PubMed=9699648; PubMed=15162061; PubMed=16397213; PubMed=22032724; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Thr738_Arg775del38 (c.2212_2325del114); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Gly8Val (c.23G>T) (c.-57+99G>T); dbSNP=rs75603675; Zygosity=Homozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Val197Met (c.589G>A) (p.Val160Met, c.478G>A); dbSNP=rs12329760; Zygosity=Homozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (PubMed=9865903; PubMed=16541312; PubMed=28889351; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50 hours (DSMZ=ACC-513); ~61 hours (PBCF); 53.49 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21114373 CVCL_8K27 DA05654 transformed cell line human CVCL_8K27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114374 CVCL_0293 HEC-1-A cancer cell line human CVCL_0293 Genome ancestry: African=0%; Native American=1.14%; East Asian, North=91.32%; East Asian, South=6.71%; South Asian=0.34%; European, North=0.49%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (DepMap); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=15053063; PubMed=15901131; DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0388; true Female Doubling time: 31 hours (DOI=10.1007/978-4-431-53981-0_1); 27 hours (PubMed=25984343); Microsatellite instability: Instable (MSI) (PubMed=12714694; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21114375 CVCL_8K26 DA05653 transformed cell line human CVCL_8K26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114376 CVCL_0292 HCT 15 cancer cell line human CVCL_0292 HLA typing: A*02,24; B*08,35:01:01; C*04,07; DPB1*01:01:01,04:01; DQB1*02,05:03:01; DRB1*03,14 (PubMed=15748285); HLA typing: A*02:01,24:02; B*08:01,35:01; C*04:01,07:06 (PubMed=26589293); Genome ancestry: African=2.68%; Native American=0%; East Asian, North=5.84%; East Asian, South=0%; South Asian=0%; European, North=49.17%; European, South=42.32% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; c.68-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=8197130; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr30Ter (c.90C>A); Zygosity=Heterozygous (PubMed=8197130; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg145Trp (c.433C>T); ClinVar=VCV000005592; Zygosity=Heterozygous (PubMed=18167186; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Heterozygous (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (PubMed=9000147; PubMed=15900046; PubMed=17088437; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>C; ClinVar=VCV000635383; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=9000147; PubMed=15900046; PubMed=17088437; PubMed=28683746; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1958; true. Male Doubling time: 19 hours (PubMed=427742); ~20 hours (PubMed=7139607); 20.6 hours (NCI-DTP); ~20-25 hours (DSMZ=ACC-357); 15 hours (CLS); Microsatellite instability: Instable (MSI-high) (PubMed=11526487; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: NCI-60 cancer cell line panel; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028); Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21114377 CVCL_0284 H4-II-E cancer cell line Norway rat CVCL_0284 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9185 21114378 CVCL_0283 H3922 cancer cell line human CVCL_0283 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21114379 CVCL_0286 H9c2(2-1) spontaneously immortalized cell line Norway rat CVCL_0286 CL:0000010 Derived from sampling site: Embryonic heart; cardiac muscle; Breed/subspecies: BDIX. Unspecified 21114380 CVCL_0285 H4-II-E-C3 cancer cell line Norway rat CVCL_0285 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Omics: Transcriptome analysis by microarray Male 21114381 CVCL_0288 HC11 spontaneously immortalized cell line house mouse CVCL_0288 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female Doubling time: ~50-80 hours (DSMZ=ACC-780) 21114382 CVCL_0287 HBE1 transformed cell line human CVCL_0287 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Bronchus; epithelium. Female 21114383 CVCL_0289 HCA7 cancer cell line human CVCL_0289 HLA typing: A*01:01,02:01; B*37:01,51:01; C*06:02,14:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu582fs*20 (c.1742_1743insA); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Ter (c.1435C>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.898delC); Zygosity=Unspecified (PubMed=16418264; PubMed=24755471) Derived from sampling site: Colon. Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Ximbio; 152451; probable Female Microsatellite instability: Instable (MSI) (PubMed=25926053) Part of: KuDOS 95 cell line panel 21114384 CVCL_8K32 DA05660 transformed cell line human CVCL_8K32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114385 CVCL_8K31 DA05659 transformed cell line human CVCL_8K31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114386 CVCL_8K34 DA05662 transformed cell line human CVCL_8K34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114387 CVCL_8K33 DA05661 transformed cell line human CVCL_8K33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114388 CVCL_8K30 DA05657 transformed cell line human CVCL_8K30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114389 CVCL_8K39 DA05667 transformed cell line human CVCL_8K39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114390 CVCL_8K36 DA05664 transformed cell line human CVCL_8K36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114391 CVCL_8K35 DA05663 transformed cell line human CVCL_8K35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114392 CVCL_8K38 DA05666 transformed cell line human CVCL_8K38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114393 CVCL_8K37 DA05665 transformed cell line human CVCL_8K37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114394 CVCL_0295 HECV finite cell line human CVCL_0295 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord. Female 21114395 CVCL_0294 HEC-1-B cancer cell line human CVCL_0294 Genome ancestry: African=0%; Native American=0.76%; East Asian, North=92.48%; East Asian, South=6.76%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (DepMap); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; None_reported; -; Zygosity=- (PubMed=20944090); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0480; true Female Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21114396 CVCL_0297 HEY cancer cell line human CVCL_0297 HLA typing: A*02:01,29:02; B*44:02,45:01; C*05:01,06:02 (PubMed=26589293); Genome ancestry: African=0.88%; Native American=0.22%; East Asian, North=0.66%; East Asian, South=0.27%; South Asian=0%; European, North=67.37%; European, South=30.59% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30 hours (PubMed=4016745); 20.53 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21114397 CVCL_0296 HEK293 482R transformed cell line human CVCL_0296 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21114398 CVCL_0299 HIB 1B transformed cell line house mouse CVCL_0299 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brown adipose tissue Cell type=Preadipocyte.. Male 21114399 CVCL_0298 HFL1 finite cell line human CVCL_0298 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Capable of at least 57 PDL (JCRB=IFO50074) 21114400 CVCL_8K01 DA05619 transformed cell line human CVCL_8K01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114401 CVCL_8K00 DA05618 transformed cell line human CVCL_8K00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114402 CVCL_8K07 DA05627 transformed cell line human CVCL_8K07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114403 CVCL_8K06 DA05626 transformed cell line human CVCL_8K06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114404 CVCL_8K09 DA05629 transformed cell line human CVCL_8K09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114405 CVCL_8K08 DA05628 transformed cell line human CVCL_8K08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114406 CVCL_8K03 DA05621 transformed cell line human CVCL_8K03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA05621; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114407 CVCL_8K02 DA05620 transformed cell line human CVCL_8K02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114408 CVCL_8K05 DA05623 transformed cell line human CVCL_8K05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114409 CVCL_0271 GEO cancer cell line human CVCL_0271 Genome ancestry: African=61.65%; Native American=2.66%; East Asian, North=1.33%; East Asian, South=0%; South Asian=0%; European, North=19.42%; European, South=14.94% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Cys344fs*110 (c.1030delT); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1536Ter (c.4606G>T); ClinVar=VCV001050551; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=20570890; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Instable (MSI) (PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21114410 CVCL_8K04 DA05622 transformed cell line human CVCL_8K04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114411 CVCL_0270 G-401 cancer cell line human CVCL_0270 Genome ancestry: African=2.48%; Native American=0.75%; East Asian, North=2.12%; East Asian, South=0.55%; South Asian=8.63%; European, North=29.24%; European, South=56.23% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307; PubMed=10602515; PubMed=28945250) Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (PubMed=8382007; PubMed=30924592). 21114412 CVCL_0262 FL5.12 factor-dependent cell line house mouse CVCL_0262 CL:0000010 Derived from sampling site: Embryonic liver Cell type=Pro-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent 21114413 CVCL_0261 FGC4 cancer cell line Norway rat CVCL_0261 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21114414 CVCL_0264 FMA3 cancer cell line house mouse CVCL_0264 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Thr577_His583del; Zygosity=Unspecified; Note=Constitutive activation (PubMed=8547652) Breed/subspecies: LAF1. 21114415 CVCL_0266 FS-4 [Human foreskin] finite cell line human CVCL_0266 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21114416 CVCL_0265 FRTL-5 spontaneously immortalized cell line Norway rat CVCL_0265 CL:0000010 Anecdotal: Have been flown in space on the ISS in 2005 to study the effect of UVC radiation (PubMed=21087161) Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified Doubling time: 34 hours (CelloPub=CLPUB00429) Group: Patented cell line; Group: Space-flown cell line (cellonaut); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8305 21114417 CVCL_0268 Fa32 cancer cell line Norway rat CVCL_0268 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21114418 CVCL_0267 Fa2N-4 transformed cell line human CVCL_0267 From: MultiCell Technologies, Inc.; Woonsocket; USA CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5566 21114419 CVCL_0269 Fao cancer cell line Norway rat CVCL_0269 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21114420 CVCL_8K10 DA05630 transformed cell line human CVCL_8K10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114421 CVCL_8K12 DA05632 transformed cell line human CVCL_8K12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114422 CVCL_8K11 DA05631 transformed cell line human CVCL_8K11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114423 CVCL_8K18 DA05640 transformed cell line human CVCL_8K18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114424 CVCL_8K17 DA05637 transformed cell line human CVCL_8K17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114425 CVCL_8K19 DA05643 transformed cell line human CVCL_8K19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114426 CVCL_8K14 DA05634 transformed cell line human CVCL_8K14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114427 CVCL_0280 GP8 [Rat brain] finite cell line Norway rat CVCL_0280 CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Cerebral cortex endothelial cell.; Breed/subspecies: Lewis. Female 21114428 CVCL_8K13 DA05633 transformed cell line human CVCL_8K13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114429 CVCL_8K16 DA05636 transformed cell line human CVCL_8K16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114430 CVCL_8K15 DA05635 transformed cell line human CVCL_8K15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114431 CVCL_0281 GT1-7 transformed cell line house mouse CVCL_0281 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 transgenic with rat Gnrh1 promoter-Tg(SV40). Characteristics: Exhibits high levels of Gnrh1 expression and secretes GnRH in response to depolarization 21114432 CVCL_0273 GH3 cancer cell line Norway rat CVCL_0273 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female Doubling time: ~60-90 hours (DSMZ=ACC-469) 21114433 CVCL_0272 GF-D8 cancer cell line human CVCL_0272 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: CSF2 or IL3 dependent Doubling time: ~48-72 hours (DSMZ=ACC-615) 21114434 CVCL_0274 GH3B6 cancer cell line Norway rat CVCL_0274 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21114435 CVCL_0277 GH4ZR7 cancer cell line Norway rat CVCL_0277 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform short) Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21114436 CVCL_0276 GH4C1 cancer cell line Norway rat CVCL_0276 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female Doubling time: ~60-80 hours (DSMZ=ACC-482) 21114437 CVCL_0279 GLC-4 cancer cell line human CVCL_0279 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (PubMed=10408787) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH Male Doubling time: 26 hours (PubMed=3028613); 16.9 hours (PubMed=8980384) 21114438 CVCL_0278 GI-101A cancer cell line human CVCL_0278 CL:0000010 Derived from sampling site: Breast. Omics: miRNA expression profiling Female Characteristics: Established from a athymic mice xenograft Doubling time: 36 hours, in a medium with 10% serum (PubMed=14598885) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12420 21114439 CVCL_RW92 CML-3 cancer cell line dog CVCL_RW92 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Poodle. Unspecified 21114440 CVCL_S892 HGFu spontaneously immortalized cell line house mouse CVCL_S892 CL:0000010 Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J. Male Doubling time: 18 hours (in 10% FBS), 25.5 hours (in 5% FBS), 31 hours (in 2.5% FBS), 39 hours (with 1% FBS) (PubMed=6343228) 21114441 CVCL_RW91 CML-2M cancer cell line dog CVCL_RW91 CL:0000010 Derived from metastatic site: Liver; Breed/subspecies: Scottish Terrier. Unspecified 21114442 CVCL_S891 FD-LSC-1 cancer cell line human CVCL_S891 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (PubMed=24001612); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (PubMed=24001612) Population: Chinese; Derived from sampling site: Larynx. Male Characteristics: Highly tumorigenic in NOD/SCID mice Doubling time: 24 hours (PubMed=24001612) 21114443 CVCL_RW94 CML-5 cancer cell line dog CVCL_RW94 CL:0000010 Derived from sampling site: Oral cavity; palate; Breed/subspecies: Labrador Retriever. Unspecified 21114444 CVCL_S894 hTERT-GTCs telomerase immortalized cell line CVCL_S894 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Trophoblast; Breed/subspecies: Saanen. Female Doubling time: 26.79 hours (PubMed=24112823) 21114445 CVCL_RW93 CML-4 cancer cell line dog CVCL_RW93 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Poodle. Unspecified 21114446 CVCL_S893 T37i transformed cell line house mouse CVCL_S893 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brown adipose tissue; Breed/subspecies: C57BL/6 x DBA/2 SV40TAg transgenic. Female Characteristics: Can differentiate into brown adipocytes when incubated with triiodothyronine (T3) and insulin over 3-6 days Differentiation can also be induced by incubation with steroid hormones such as aldosterone, which induces differentiation through its interaction with mineralocorticoid receptor (MR) (Millipore). 21114447 CVCL_RW96 BSR-T7/5 spontaneously immortalized cell line CVCL_RW96 CL:0000010 Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Male Characteristics: Expression of the T7 RNA polymerase gene is under control of the cytomegalovirus promoter (PubMed=9847328) 21114448 CVCL_S896 cen3tel telomerase immortalized cell line human CVCL_S896 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21114449 CVCL_S895 cen2tel telomerase immortalized cell line human CVCL_S895 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21114450 CVCL_RW95 SK6-MxLuc spontaneously immortalized cell line pig CVCL_RW95 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Kidney. Female Characteristics: The expression of the luciferase reporter gene is under control of the mouse Mx1 gene promoter 21114451 CVCL_S898 HAC15 cancer cell line human CVCL_S898 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Exhibits hormonal responses, steroidogenesis and expression of steroid-metabolizing enzymes Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00518 Problematic cell line: Contaminated Shown to be a NCI-H295R derivative (PubMed=21924324). Originally thought to originate from a 11 month old female patient with adrenal cortex carcinoma. 21114452 CVCL_RW98 MN-R finite cell line house mouse CVCL_RW98 CL:0000010 Derived from sampling site: Kidney. 21114453 CVCL_RW97 Na 42/13 cancer cell line house mouse CVCL_RW97 CL:0000010 Breed/subspecies: A/J. Male 21114454 CVCL_S897 RCE1 spontaneously immortalized cell line CVCL_S897 CL:0000010 Derived from sampling site: Eye; cornea; epithelium; Breed/subspecies: Albino. Unspecified Doubling time: ~15 hours (PubMed=7527059) 21114455 CVCL_S899 CAR47 transformed cell line human CVCL_S899 CL:0000010 Sequence variation: Mutation; HGNC; 9388; PRKAR1A; Simple; c.177+1G>A (IVS2+1G>A); ClinVar=VCV000536896; Zygosity=Heterozygous (PubMed=18056771) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland. Female 21114456 CVCL_RW99 ABADRL-Cv-KC spontaneously immortalized cell line CVCL_RW99 CL:0000010 Breed/subspecies: AK laboratory colony. Unspecified Doubling time: ~14 hours (PubMed=12943114) Group: Insect cell line 21114457 CVCL_0240 MC-26 cancer cell line house mouse CVCL_0240 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female Doubling time: 15-20 hours (CLS) 21114458 CVCL_0242 D122 cancer cell line house mouse CVCL_0242 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: High metastatic potential 21114459 CVCL_0241 D10G41 factor-dependent cell line house mouse CVCL_0241 CL:0000010 Breed/subspecies: AKR/J. Male Characteristics: IL1A or IL1B dependent Doubling time: ~30 hours (DSMZ=ACC-45) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114460 CVCL_0244 DG-75 cancer cell line human CVCL_0244 HLA typing: A*02,11; B*39,41 (PubMed=3037521); Genome ancestry: African=1.72%; Native American=1.16%; East Asian, North=0%; East Asian, South=1.7%; South Asian=7.84%; European, North=25.56%; European, South=62.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Homozygous (PubMed=9583678); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283His (c.848G>A); ClinVar=VCV000142324; Zygosity=Heterozygous (PubMed=9525742) Population: Jewish; Ashkenazi; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Virology: EBV-negative; Virology: Infected by DG-75 retrovirus, a replication-competent, murine leukemia-related retrovirus Constitutively produces the virus. Doubling time: 18-20 hours (PubMed=188769); ~40-50 hours (DSMZ=ACC-83); Microsatellite instability: Instable (MSI-high) (PubMed=9583678; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21114461 CVCL_0243 DAN-G cancer cell line human CVCL_0243 HLA typing: A*02:01,02:01; B*07:02,13:02; C*06:02,06:02,07:02 (PubMed=26589293); Genome ancestry: African=0.9%; Native American=1.77%; East Asian, North=3.79%; East Asian, South=0%; South Asian=0%; European, North=49.25%; European, South=44.28% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (CLS; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.972_993+16del38; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a xenograft produced by implantation of cells from the tumor of a patient with cancer of the pancreas in a nude mouse (CLS) Doubling time: ~33 hours (DSMZ=ACC-249); 17.10 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21114462 CVCL_0245 DHD/K12/TRb cancer cell line Norway rat CVCL_0245 CL:0000010 Breed/subspecies: BDIX. 21114463 CVCL_0248 DLD-1 cancer cell line human CVCL_0248 HLA typing: A*02:01,24:02; B*08:01,35:01; C*04:01,07:01 (PubMed=25960936); HLA typing: A*02:01,24:02; B*08:01,08:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.31%; East Asian, North=0%; East Asian, South=0.3%; South Asian=2.26%; European, North=64.92%; European, South=32.2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 914; B2M; Simple; c.68-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=8197130); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr30Ter (c.90C>A); Zygosity=Heterozygous (PubMed=8197130); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Glu1014Ter (c.3040G>T); Zygosity=Heterozygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=7651727; PubMed=16418264; PubMed=28683746) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep phosphoproteome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1957; true. Male Doubling time: 20 hours (PubMed=427742); 33 hours (PubMed=25984343); ~15 hours (CLS); ~48 hours (DSMZ=ACC-278); Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=24042735; PubMed=28683746; PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21114464 CVCL_0247 DI TNC1 transformed cell line Norway rat CVCL_0247 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; diencephalon; Breed/subspecies: Sprague Dawley. Unspecified 21114465 CVCL_0249 DT40 cancer cell line CVCL_0249 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Omics: Deep proteome analysis; Omics: Genome sequenced Female Doubling time: ~48 hours (DSMZ=ACC-636); ~1 day (lot 02272006) (JCRB) Group: Bird cell line 21114466 CVCL_RW81 AT4JTOM finite cell line human CVCL_RW81 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1812; probable Female 21114467 CVCL_S881 TC7 cancer cell line human CVCL_S881 CL:0000010 Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E. Female Microsatellite instability: Instable (MSI) (PubMed=9000572) 21114468 CVCL_S880 621NST cancer cell line human CVCL_S880 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg611Gln (c.1832G>A); ClinVar=VCV000012397; Zygosity=Unspecified (from parent cell line). Female 21114469 CVCL_RW80 AT6KYM finite cell line human CVCL_RW80 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114470 CVCL_RW83 AT3KYM finite cell line human CVCL_RW83 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1637_Leu1668del32 (c.4910del96) (Ex35del); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114471 CVCL_S883 PFC6 spontaneously immortalized cell line house mouse CVCL_S883 CL:0000010 Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male 21114472 CVCL_RW82 AT1KYM finite cell line human CVCL_RW82 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114473 CVCL_S882 TC71 cancer cell line human CVCL_S882 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20570890; PubMed=28683746); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Unspecified (PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E Derived from sampling site: Colon; sigmoid. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Instable (MSI) (PubMed=9000572; PubMed=24042735; PubMed=28683746) 21114474 CVCL_S885 1246-3A cancer cell line house mouse CVCL_S885 CL:0000010 Breed/subspecies: C3H. Characteristics: Has lost the insulin dependence of the parent cell line 21114475 CVCL_RW85 AT2KYSV transformed cell line human CVCL_RW85 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1780; probable Female Doubling time: 23 hours, at 135th passage (PubMed=1978855) 21114476 CVCL_S884 1246 cancer cell line house mouse CVCL_S884 CL:0000010 Breed/subspecies: C3H. Characteristics: Insulin dependent 21114477 CVCL_RW84 AT1KYF finite cell line human CVCL_RW84 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114478 CVCL_S887 RBM-Ad spontaneously immortalized cell line Norway rat CVCL_S887 CL:0000010 Derived from sampling site: Bone marrow Cell type=Preadipocyte.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male 21114479 CVCL_RW87 ShispREC.B-6 transformed cell line CVCL_RW87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; epithelium. Male Virology: Susceptible to infection by vesicular stomatitis virus (VSV) strain Indiana, Rift Valley fever virus (RVFV) clone 13, West Nile virus (WNV) strain New York and tick-borne encephalitis virus (TBEV) strain K23; Virology: Not susceptible to infection by Moussa virus, Ferak virus and Cavally virus 21114480 CVCL_S886 HB2 spontaneously immortalized cell line house mouse CVCL_S886 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Brown adipose tissue. Unspecified Doubling time: 30-40 hours (PubMed=10049689) 21114481 CVCL_RW86 ShispAEC.B-2 transformed cell line CVCL_RW86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.. Male Virology: Susceptible to infection by vesicular stomatitis virus strain Indiana, Rift Valley fever virus (RVFV) clone 13, West Nile virus (WNV) strain New York and Tick-borne encephalitis virus strain K23; Virology: Not susceptible to infection by Moussa virus, Ferak virus and Cavally virus 21114482 CVCL_RW89 AT1OS TERT telomerase immortalized cell line human CVCL_RW89 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114483 CVCL_S889 PNUH-12 cancer cell line human CVCL_S889 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Unspecified (CelloPub=CLPUB00003) Population: Korean; Derived from sampling site: Pharynx; hypopharynx. Female Doubling time: 48 hours (CelloPub=CLPUB00003) 21114484 CVCL_S888 hTERT-HM telomerase immortalized cell line human CVCL_S888 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Uterus; myometrium Cell type=Myometrial cell.. Female Part of: ENCODE project common cell types; tier 3 21114485 CVCL_RW88 PESU-B5L telomerase immortalized cell line CVCL_RW88 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Derived from sampling site: Lung. Female Virology: Susceptible to infection by human coronavirus NL63 (HCoV-NL63) and SARS coronavirus (SARS-CoV) Group: Bat cell line 21114486 CVCL_0260 FDCW2 factor-dependent cell line house mouse CVCL_0260 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21114487 CVCL_0251 NAL1A clone C4E10 spontaneously immortalized cell line house mouse CVCL_0251 CL:0000010 Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: BALB/c. Omics: Proteome analysis by 2D-DE/MS Female 21114488 CVCL_0250 SNU-387 cancer cell line human CVCL_0250 HLA typing: A*02:06,02:06; B*15:27,35:14; C*03:03,04:01 (PubMed=26589293); Genome ancestry: African=0.32%; Native American=0.32%; East Asian, North=64.77%; East Asian, South=33.73%; South Asian=0%; European, North=0%; European, South=0.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (PubMed=8824565; PubMed=31378681; Cosmic-CLP; DepMap) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 61 hours (PubMed=7543080); 30.81 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21114489 CVCL_0253 EFM-19 cancer cell line human CVCL_0253 HLA typing: A*29:02,33:03; B*35:01,44:04; C*03:02,16:01 (PubMed=26589293); Genome ancestry: African=1.96%; Native American=0%; East Asian, North=3.54%; East Asian, South=0%; South Asian=0%; European, North=58.92%; European, South=35.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 81 hours (PubMed=25984343); ~50-60 hours (DSMZ=ACC-231); 51.18 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21114490 CVCL_0252 L8 E63 spontaneously immortalized cell line Norway rat CVCL_0252 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Unspecified 21114491 CVCL_0255 EL4 cancer cell line house mouse CVCL_0255 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Omics: HLA class I peptidome analysis by proteomics Discontinued: JCRB; IFO50027; true Unspecified Doubling time: ~15-20 hours (DSMZ=ACC-831); ~14 hours (lot 10262015), ~12 hours (lot 02052018) (JCRB) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114492 CVCL_0254 EL-4 6.1 C10 cancer cell line house mouse CVCL_0254 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21114493 CVCL_0257 EL4.NOB-1 cancer cell line house mouse CVCL_0257 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21114494 CVCL_0256 EL4.E1 cancer cell line house mouse CVCL_0256 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21114495 CVCL_0259 F9 cancer cell line house mouse CVCL_0259 CL:0000010 Breed/subspecies: 129/Sv. Male Doubling time: ~24 hours (DSMZ=ACC-112) 21114496 CVCL_0258 EoL-1 cancer cell line human CVCL_0258 HLA typing: A*24:02,29:02; B*35:03,44:03; C*04:01,16:01 (PubMed=26589293); HLA typing: A*24:02:01,29:02:01; B*35:03:01,44:03:01; C*04:01:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*03:03:01,03:03:01; DQB1*03:01:01,03:01:01; DRA*01:01:01,01:02:02; DRB1*04:07:01,12:01:01 (DSMZCellDive=ACC-386); Genome ancestry: African=1.14%; Native American=0%; East Asian, North=2.93%; East Asian, South=0%; South Asian=0%; European, North=52.17%; European, South=43.75% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 19124; FIP1L1 + HGNC; 8803; PDGFRA; Name(s)=FIP1L1-PDGFRA (PubMed=14630792) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB3679; true Male Doubling time: ~60 hours (DSMZ=ACC-386); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21114497 CVCL_RW90 CML-1R cancer cell line dog CVCL_RW90 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Toy Poodle. Unspecified 21114498 CVCL_S890 CNUH-HNSCC-1 cancer cell line human CVCL_S890 CL:0000010 Population: Korean; Derived from sampling site: Larynx. Unspecified Doubling time: 48 hours (PubMed=22111066) 21114499 CVCL_RW70 1704 cancer cell line human CVCL_RW70 CL:0000010 Miscellaneous: Only mentioned as a melanoma cell line in PubMed=16585582. Unspecified 21114500 CVCL_S870 FL-OH1 cancer cell line human CVCL_S870 CL:0000010 Male 21114501 CVCL_S872 HUMEMS cancer cell line human CVCL_S872 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17547718) Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21114502 CVCL_RW72 VH10 finite cell line human CVCL_RW72 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21114503 CVCL_RW71 STP-1 cancer cell line human CVCL_RW71 CL:0000010 Miscellaneous: Only mentioned as a melanoma cell line in PubMed=16585582. Unspecified 21114504 CVCL_S871 TC-280 cancer cell line human CVCL_S871 CL:0000010 Derived from metastatic site: Lymph node. Female 21114505 CVCL_S874 HUS-2 cancer cell line human CVCL_S874 CL:0000010 Derived from sampling site: Chest wall. Female 21114506 CVCL_RW74 ZMTH3 transformed cell line dog CVCL_RW74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland. Female 21114507 CVCL_S873 DI-OH1 cancer cell line human CVCL_S873 CL:0000010 Male 21114508 CVCL_RW73 VH12 finite cell line human CVCL_RW73 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21114509 CVCL_RW76 DH-BL cancer cell line human CVCL_RW76 CL:0000010 Population: Caucasian; British; Derived from sampling site: Ascites. Male Virology: EBV-negative 21114510 CVCL_S876 HCEnT-21T telomerase immortalized cell line human CVCL_S876 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Eye; cornea; endothelium. Male 21114511 CVCL_RW75 BWZ.36/CD8alpha cancer cell line house mouse CVCL_RW75 CL:0000010 Transfected with: MGI; MGI:88346; Cd8a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Transfected with the NFAT-lacZ construct containing the lacZ reporter gene under control of the NFAT response element; Characteristics: Does not express functional TCR alpha and beta chains Group: Hybridoma fusion partner cell line 21114512 CVCL_S875 PL377 cancer cell line human CVCL_S875 CL:0000010 Female 21114513 CVCL_RW78 AT1KY finite cell line human CVCL_RW78 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (PubMed=9600235); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114514 CVCL_S878 TIME-GFP telomerase immortalized cell line human CVCL_S878 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP) Derived from sampling site: Foreskin; skin; dermis; microvascular endothelium. Male Characteristics: Stably expresses emerald GFP (emGFP) under the control of the CMV promoter 21114515 CVCL_RW77 DH-LCL transformed cell line human CVCL_RW77 CL:0000010 Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114516 CVCL_S877 Ker-CT telomerase immortalized cell line human CVCL_S877 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21114517 CVCL_S879 621-101 cancer cell line human CVCL_S879 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg611Gln (c.1832G>A); ClinVar=VCV000012397; Zygosity=Unspecified (PubMed=12922981). Female 21114518 CVCL_RW79 AT1KY TERT telomerase immortalized cell line human CVCL_RW79 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1774; probable Female 21114519 CVCL_0220 COLO 320HSR cancer cell line human CVCL_0220 Genome ancestry: African=0%; Native American=2.14%; East Asian, North=0.47%; East Asian, South=2.14%; South Asian=10.52%; European, North=6.29%; European, South=78.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21114520 CVCL_0221 COLO 357 cancer cell line human CVCL_0221 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959) Population: African American; Derived from metastatic site: Celiac axis lymph node. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 94072245; probable Female Doubling time: 21 hours (PubMed=6989766) 21114521 CVCL_0224 COS-7 transformed cell line CVCL_0224 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Doubling time: ~35-48 hours (DSMZ=ACC-60); ~34 hours (lot 02292000), ~30 hours (lots 11222004 and 10052007), ~2 days (lot 03052018) (JCRB) Group: Non-human primate cell line 21114522 CVCL_0223 COS-1 transformed cell line CVCL_0223 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Doubling time: ~48 hours (DSMZ=ACC-63) Group: Non-human primate cell line 21114523 CVCL_0226 CSML-100 cancer cell line house mouse CVCL_0226 CL:0000010 Breed/subspecies: A/Sn. Female 21114524 CVCL_0225 CRI-G1 cancer cell line Norway rat CVCL_0225 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Omics: Transcriptome analysis by microarray 21114525 CVCL_0228 CTLL-4 factor-dependent cell line house mouse CVCL_0228 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. 21114526 CVCL_0227 CTLL-2 transformed cell line house mouse CVCL_0227 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Discontinued: BCRJ; 0281; probable; Discontinued: DSMZ; ACC-27; true Characteristics: IL2 dependent Doubling time: 24 hours (PubMed=145543) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114527 CVCL_0229 CV-1 finite cell line CVCL_0229 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6305; true Male Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729) Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21114528 CVCL_RW61 BW-1100.129 cancer cell line house mouse CVCL_RW61 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Does not express functional TCR alpha chain Doubling time: ~12 hours (PubMed=2778316) Group: Hybridoma fusion partner cell line 21114529 CVCL_S861 TSG6 cancer cell line human CVCL_S861 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~44 hours (PubMed=8054813) 21114530 CVCL_S860 SJ-89 cancer cell line human CVCL_S860 CL:0000010 Population: Chinese; Derived from metastatic site: Lymph node. Female Doubling time: ~33 hours (PubMed=11229593) Group: Serum/protein free medium cell line 21114531 CVCL_RW60 VD60 spontaneously immortalized cell line green monkey CVCL_RW60 CL:0000010 Transfected with: UniProtKB; Q69091; Human herpesvirus 1 glycoprotein D (gD) Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21114532 CVCL_RW63 BWZ.36 cancer cell line house mouse CVCL_RW63 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Transfected with the NFAT-lacZ construct containing the lacZ reporter gene under control of the NFAT response element; Characteristics: Does not express functional TCR alpha and beta chains Group: Hybridoma fusion partner cell line 21114533 CVCL_S863 SMB [Human] cancer cell line human CVCL_S863 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8378080) Derived from metastatic site: Skin. Male 21114534 CVCL_RW62 BW-1100.129.237 cancer cell line house mouse CVCL_RW62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Does not express functional TCR alpha and beta chains Doubling time: ~18 hours (PubMed=2778316) Group: Hybridoma fusion partner cell line 21114535 CVCL_S862 SAL1 cancer cell line human CVCL_S862 CL:0000010 Female 21114536 CVCL_RW65 4E12B2 hybridoma house mouse CVCL_RW65 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P60568; Human IL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8092 21114537 CVCL_S865 KN-OH1 cancer cell line human CVCL_S865 CL:0000010 Female 21114538 CVCL_RW64 4E12 [Mouse hybridoma against human IL2] hybridoma house mouse CVCL_RW64 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P60568; Human IL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8093 21114539 CVCL_S864 GR-OH1 cancer cell line human CVCL_S864 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=9393981). Female 21114540 CVCL_RW67 FLG-ID finite cell line CVCL_RW67 CL:0000010 Derived from sampling site: Brain. Group: Bat cell line 21114541 CVCL_S867 TC-212 cancer cell line human CVCL_S867 CL:0000010 Derived from metastatic site: Testis. Male 21114542 CVCL_RW66 4E12B2D10 hybridoma house mouse CVCL_RW66 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P60568; Human IL2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8091 21114543 CVCL_S866 TC-252 cancer cell line human CVCL_S866 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Derived from metastatic site: Not specified. 21114544 CVCL_RW69 1290-2 cancer cell line human CVCL_RW69 CL:0000010 Miscellaneous: Only mentioned as a melanoma cell line in PubMed=16585582 Could be a subline of 1290-mel (Cellosaurus=CVCL_7943).. Unspecified 21114545 CVCL_S869 HA-OH1 cancer cell line human CVCL_S869 CL:0000010 Female 21114546 CVCL_RW68 KAN-R finite cell line CVCL_RW68 CL:0000010 Derived from sampling site: Kidney. Group: Marsupial cell line 21114547 CVCL_S868 SW-OH1 cancer cell line human CVCL_S868 CL:0000010 Male 21114548 CVCL_0230 CY15 [Mouse histiocytic tumor] cancer cell line house mouse CVCL_0230 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: BALB/c Ifng-/-. 21114549 CVCL_0233 Caco-2/TC-7 cancer cell line human CVCL_0233 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21114550 CVCL_0232 Caco-2/15 cancer cell line human CVCL_0232 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21114551 CVCL_0235 Caki-2 cancer cell line human CVCL_0235 HLA typing: A*01:01,11:01; B*08:01,52:01; C*07:01,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.61%; East Asian, North=1.28%; East Asian, South=0%; South Asian=0%; European, North=64.34%; European, South=33.76% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: GPI-anchored proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~30-40 hours (DSMZ=ACC-54) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-068 Problematic cell line: Misclassified Originally thought to be a clear cell renal cell carcinoma but shown to be from a papillary renal cell carcinoma (PubMed=17409424; PubMed=27993170). 21114552 CVCL_0234 Caki-1 cancer cell line human CVCL_0234 HLA typing: A*23:01,24:02:01; B*35:02,44:03:01; C*04:01:01:01; DPB1*02:01:02,10:01; DQB1*02:02,03; DRB1*07:01,11:04:01 (PubMed=15748285); HLA typing: A*23:01,24:02; B*35:02,44:03; C*04:01,04:01; DRB1*11:118,11:118 (PubMed=26589293); HLA typing: A*23:01,24:02:01; B*35:02,44:03:01; C*04:01:01:01; DPB1*02:01:02,10:01; DQB1*02:02,03:AF; DRB1*07:01,11:04:01 (IPD-IMGT/HLA=13865); Genome ancestry: African=1.09%; Native American=0.91%; East Asian, North=2.59%; East Asian, South=0.47%; South Asian=7.88%; European, North=28.81%; European, South=58.26% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Skin. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-142; true; Discontinued: RCB; RCB1985; true; Discontinued: TKG; TKG 0436; probable Male Doubling time: 36 hours (PubMed=25984343); 39 hours (NCI-DTP); ~40-60 hours (DSMZ=ACC-731); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-534 21114553 CVCL_0237 Capan-1 cancer cell line human CVCL_0237 HLA typing: A*02,09; B*13,17 (CLS=300143); HLA typing: A*01:01,30:01; B*13:02,57:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=1.95%; Native American=0.56%; East Asian, North=4.79%; East Asian, South=0.11%; South Asian=7.09%; European, North=19.06%; European, South=66.44% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Hemizygous (PubMed=8968085; PubMed=15162061; PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 4039; FZD10; Simple; p.Asn54Lys (c.162C>A); Zygosity=Homozygous (PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 23671; GLT6D1; Simple; p.Trp198Ter (c.593G>A); Zygosity=Heterozygous (PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 4593; GRM1; Simple; p.Tyr486Ter (c.1458C>A); Zygosity=Homozygous (PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=8026879; PubMed=8426738; PubMed=15367885; PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Glu221Ter (c.661G>T); Zygosity=Homozygous (PubMed=9331070; PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser343Ter (c.1028C>G); ClinVar=VCV000822036; Zygosity=Homozygous (PubMed=10408907; PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 25082; SMAP2; Simple; p.Ser255Ter (c.764C>G); Zygosity=Heterozygous (PubMed=21750719; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (PubMed=8026879; PubMed=8426738; PubMed=15367885; Cosmic-CLP; DepMap) Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 60-80 hours (CLS); ~50-100 hours (DSMZ=ACC-244); ~49 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: TCGA-110-CL cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 923 21114554 CVCL_0236 Calu-6 cancer cell line human CVCL_0236 HLA typing: A*01:01,01:01; B*08:01,35:08; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.17%; Native American=0.95%; East Asian, North=0.74%; East Asian, South=0%; South Asian=0%; European, North=66.06%; European, South=32.08% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.180_181TC>CA) (c.180_181delinsCA); Zygosity=Heterozygous (PubMed=1855224; PubMed=12068308; PubMed=12794755; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (PubMed=1855224; PubMed=12794755; ATCC; Cosmic-CLP; DepMap) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 26 hours (in RPMI 1640 + 10% FBS), 32 hours (in ACL-3), 41 hours (in ACL-3+BSA) (PubMed=3940644); 31.9 hours (PubMed=29681454); ~2 days (CLS); ~72 hours (DSMZ=ACC-734); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21114555 CVCL_0239 Chub-S7 transformed cell line human CVCL_0239 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: HGNC; 11730; TERT Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Abdomen; adipose tissue Cell type=Preadipocyte.. Female Doubling time: 45.6 +- 0.8 hours (PubMed=12934077) 21114556 CVCL_0238 Chang Liver cancer cell line human CVCL_0238 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage); Omics: Ubiquitination analysis by proteomics Discontinued: BCRC; 60024; true; Discontinued: RCB; RCB0491; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00002 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=1246601; PubMed=20143388; PubMed=21656536). Originally thought to originate from normal hepatic cells obtained from a liver biopsy of an adult. 21114557 CVCL_AE35 HPSI0114i-vabj_3 induced pluripotent stem cell human CVCL_AE35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114558 CVCL_AE34 HPSI0114i-rozh_5 induced pluripotent stem cell human CVCL_AE34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114559 CVCL_AE37 HPSI0114i-veui_3 induced pluripotent stem cell human CVCL_AE37 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114560 CVCL_AE36 HPSI0114i-vass_1 induced pluripotent stem cell human CVCL_AE36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114561 CVCL_AE39 HPSI0114i-zapk_2 induced pluripotent stem cell human CVCL_AE39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114562 CVCL_AE38 HPSI0114i-wegi_1 induced pluripotent stem cell human CVCL_AE38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21114563 CVCL_AE31 HPSI0114i-lexy_1 induced pluripotent stem cell human CVCL_AE31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114564 CVCL_AE30 HPSI0114i-kolf_3 induced pluripotent stem cell human CVCL_AE30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114565 CVCL_AE33 HPSI0114i-rozh_4 induced pluripotent stem cell human CVCL_AE33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114566 CVCL_AE32 HPSI0114i-lexy_2 induced pluripotent stem cell human CVCL_AE32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114567 CVCL_AE46 HPSI0213i-nawk_55 induced pluripotent stem cell human CVCL_AE46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114568 CVCL_AE45 HPSI0213i-nawk_5 induced pluripotent stem cell human CVCL_AE45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21114569 CVCL_AE48 HPSI0214i-bute_2 induced pluripotent stem cell human CVCL_AE48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21114570 CVCL_AE47 HPSI0213i-xeaw_1 induced pluripotent stem cell human CVCL_AE47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21114571 CVCL_AE49 HPSI0214i-datg_2 induced pluripotent stem cell human CVCL_AE49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114572 CVCL_AE40 HPSI0114i-zapk_3 induced pluripotent stem cell human CVCL_AE40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114573 CVCL_AE42 HPSI0115i-uolo_5 induced pluripotent stem cell human CVCL_AE42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114574 CVCL_AE41 HPSI0114i-zoxy_3 induced pluripotent stem cell human CVCL_AE41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114575 CVCL_AE44 HPSI0213i-koun_4 induced pluripotent stem cell human CVCL_AE44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21114576 CVCL_AE43 HPSI0213i-koun_2 induced pluripotent stem cell human CVCL_AE43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114577 CVCL_8K87 DA05725 transformed cell line human CVCL_8K87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114578 CVCL_8K86 DA05724 transformed cell line human CVCL_8K86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114579 CVCL_8K89 DA05727 transformed cell line human CVCL_8K89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114580 CVCL_8K88 DA05726 transformed cell line human CVCL_8K88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114581 CVCL_8K83 DA05721 transformed cell line human CVCL_8K83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114582 CVCL_8K82 DA05720 transformed cell line human CVCL_8K82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114583 CVCL_8K85 DA05723 transformed cell line human CVCL_8K85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114584 CVCL_8K84 DA05722 transformed cell line human CVCL_8K84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114585 CVCL_AE13 GM10080 transformed cell line human CVCL_AE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114586 CVCL_AE12 GM24029 transformed cell line human CVCL_AE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114587 CVCL_AE15 GM10669 finite cell line human CVCL_AE15 CL:0000010 Population: Caucasian; Derived from sampling site: Thyroid gland (Note=From an adenoma nodule) Cell type=Fibroblast.. Female 21114588 CVCL_AE14 GM10081 transformed cell line human CVCL_AE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114589 CVCL_AE17 LAMA84R cancer cell line human CVCL_AE17 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Peripheral blood. Female 21114590 CVCL_AE16 oxMMNK1-L telomerase immortalized cell line human CVCL_AE16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver. Unspecified 21114591 CVCL_AE19 GM10012 finite cell line human CVCL_AE19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114592 CVCL_AE18 GM01453 transformed cell line human CVCL_AE18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114593 CVCL_8K81 DA05719 transformed cell line human CVCL_8K81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114594 CVCL_8K80 DA05718 transformed cell line human CVCL_8K80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114595 CVCL_AE11 GM24028 transformed cell line human CVCL_AE11 CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Asp120Glu (c.360C>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Arg217Ter (c.649C>T); ClinVar=VCV000203615; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114596 CVCL_AE10 GM24027 transformed cell line human CVCL_AE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21114597 CVCL_8K98 DA05738 transformed cell line human CVCL_8K98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114598 CVCL_8K97 DA05737 transformed cell line human CVCL_8K97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114599 CVCL_8K99 DA05739 transformed cell line human CVCL_8K99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114600 CVCL_8K94 DA05733 transformed cell line human CVCL_8K94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114601 CVCL_8K93 DA05732 transformed cell line human CVCL_8K93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114602 CVCL_8K96 DA05736 transformed cell line human CVCL_8K96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114603 CVCL_8K95 DA05735 transformed cell line human CVCL_8K95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114604 CVCL_AE24 HPSI0114i-bezi_1 induced pluripotent stem cell human CVCL_AE24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114605 CVCL_AE23 HPSI1113i-hayt_1 induced pluripotent stem cell human CVCL_AE23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114606 CVCL_AE26 HPSI0114i-fikt_2 induced pluripotent stem cell human CVCL_AE26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21114607 CVCL_AE25 HPSI0114i-bezi_3 induced pluripotent stem cell human CVCL_AE25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114608 CVCL_AE28 HPSI0114i-joxm_1 induced pluripotent stem cell human CVCL_AE28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114609 CVCL_AE27 HPSI0114i-fikt_3 induced pluripotent stem cell human CVCL_AE27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114610 CVCL_AE29 HPSI0114i-kolf_2 induced pluripotent stem cell human CVCL_AE29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Pro197Hisfs*12 (c.590_608delCTAAAATCATCACTTTACT); Zygosity=Heterozygous (PubMed=31216442; PubMed=31813827); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.3526-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31216442; PubMed=31813827); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly1176Ser (c.3526G>A); Zygosity=Heterozygous (PubMed=31216442; PubMed=31813827) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114611 CVCL_8K90 DA05729 transformed cell line human CVCL_8K90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114612 CVCL_8K92 DA05731 transformed cell line human CVCL_8K92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114613 CVCL_8K91 DA05730 transformed cell line human CVCL_8K91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114614 CVCL_AE20 GM10423 finite cell line human CVCL_AE20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114615 CVCL_AE22 HPSI0114i-iisa_1 induced pluripotent stem cell human CVCL_AE22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114616 CVCL_AE21 HPSI0114i-eipl_3 induced pluripotent stem cell human CVCL_AE21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114617 CVCL_8K65 DA05699 transformed cell line human CVCL_8K65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114618 CVCL_8K64 DA05698 transformed cell line human CVCL_8K64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114619 CVCL_8K67 DA05701 transformed cell line human CVCL_8K67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114620 CVCL_8K66 DA05700 transformed cell line human CVCL_8K66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114621 CVCL_8K61 DA05695 transformed cell line human CVCL_8K61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114622 CVCL_8K60 DA05693 transformed cell line human CVCL_8K60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114623 CVCL_8K63 DA05697 transformed cell line human CVCL_8K63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114624 CVCL_8K62 DA05696 transformed cell line human CVCL_8K62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114625 CVCL_8K69 DA05703 transformed cell line human CVCL_8K69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114626 CVCL_8K68 DA05702 transformed cell line human CVCL_8K68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114627 CVCL_8K76 DA05710 transformed cell line human CVCL_8K76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114628 CVCL_8K75 DA05709 transformed cell line human CVCL_8K75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114629 CVCL_8K78 DA05716 transformed cell line human CVCL_8K78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114630 CVCL_8K77 DA05711 transformed cell line human CVCL_8K77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114631 CVCL_8K72 DA05706 transformed cell line human CVCL_8K72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA05706; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114632 CVCL_8K71 DA05705 transformed cell line human CVCL_8K71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114633 CVCL_8K74 DA05708 transformed cell line human CVCL_8K74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114634 CVCL_8K73 DA05707 transformed cell line human CVCL_8K73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114635 CVCL_AE09 GM24023 transformed cell line human CVCL_AE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114636 CVCL_8K79 DA05717 transformed cell line human CVCL_8K79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114637 CVCL_AE02 FkMTp cancer cell line CVCL_AE02 CL:0000010 Derived from sampling site: Mammary gland. Female Doubling time: 24 hours (PubMed=26883919) 21114638 CVCL_AE01 KB/STP-2 cancer cell line human CVCL_AE01 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:91276; Saintopin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21114639 CVCL_AE04 HPSI0114i-oevr_3 induced pluripotent stem cell human CVCL_AE04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114640 CVCL_AE03 HPSI1113i-hayt_3 induced pluripotent stem cell human CVCL_AE03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114641 CVCL_AE06 HPSI0114i-eipl_1 induced pluripotent stem cell human CVCL_AE06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21114642 CVCL_AE05 HPSI0114i-iisa_3 induced pluripotent stem cell human CVCL_AE05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114643 CVCL_AE08 GM11631 transformed cell line human CVCL_AE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11631; probable Female 21114644 CVCL_AE07 HPSI1113i-uofv_1 induced pluripotent stem cell human CVCL_AE07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21114645 CVCL_8K70 DA05704 transformed cell line human CVCL_8K70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114646 CVCL_AE00 KB/STP-1 cancer cell line human CVCL_AE00 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:91276; Saintopin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21114647 CVCL_8K43 DA05671 transformed cell line human CVCL_8K43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114648 CVCL_8K42 DA05670 transformed cell line human CVCL_8K42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114649 CVCL_8K45 DA05674 transformed cell line human CVCL_8K45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114650 CVCL_8K44 DA05672 transformed cell line human CVCL_8K44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114651 CVCL_8K41 DA05669 transformed cell line human CVCL_8K41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114652 CVCL_8K40 DA05668 transformed cell line human CVCL_8K40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114653 CVCL_8K47 DA05677 transformed cell line human CVCL_8K47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114654 CVCL_8K46 DA05676 transformed cell line human CVCL_8K46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114655 CVCL_8K49 DA05680 transformed cell line human CVCL_8K49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114656 CVCL_8K48 DA05678 transformed cell line human CVCL_8K48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114657 CVCL_8K54 DA05687 transformed cell line human CVCL_8K54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114658 CVCL_8K53 DA05686 transformed cell line human CVCL_8K53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114659 CVCL_8K56 DA05689 transformed cell line human CVCL_8K56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114660 CVCL_8K55 DA05688 transformed cell line human CVCL_8K55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114661 CVCL_8K50 DA05681 transformed cell line human CVCL_8K50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114662 CVCL_8K52 DA05685 transformed cell line human CVCL_8K52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114663 CVCL_8K51 DA05684 transformed cell line human CVCL_8K51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114664 CVCL_8K58 DA05691 transformed cell line human CVCL_8K58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114665 CVCL_8K57 DA05690 transformed cell line human CVCL_8K57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114666 CVCL_8K59 DA05692 transformed cell line human CVCL_8K59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21114667 CVCL_AD94 NYSCF1 embryonic stem cell human CVCL_AD94 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Female 21114668 CVCL_AD93 NYSCF-DE-1034-1034-Skin-SV-IPSC1 induced pluripotent stem cell human CVCL_AD93 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114669 CVCL_AD96 GM2096-SV3 transformed cell line human CVCL_AD96 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro334His (c.1001C>A); ClinVar=VCV000000253; Zygosity=Homozygous (from parent cell line) Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21114670 CVCL_AD95 pPS1 embryonic stem cell human CVCL_AD95 CL:0000010 Female 21114671 CVCL_AD98 GM03521 finite cell line human CVCL_AD98 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114672 CVCL_AD97 GM2096-SV9 transformed cell line human CVCL_AD97 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro334His (c.1001C>A); ClinVar=VCV000000253; Zygosity=Homozygous (from parent cell line) Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21114673 CVCL_AD99 GM10259 finite cell line human CVCL_AD99 CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114674 CVCL_AD81 GM23799 transformed cell line human CVCL_AD81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114675 CVCL_AD80 GM23798 transformed cell line human CVCL_AD80 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg109Trp (c.325C>T); ClinVar=VCV000012988; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114676 CVCL_AD79 GM23797 transformed cell line human CVCL_AD79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114677 CVCL_AD72 GM10681 transformed cell line human CVCL_AD72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114678 CVCL_AD71 GM10680 transformed cell line human CVCL_AD71 CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; p.Asp431Asn (c.1291G>A); ClinVar=VCV000281932; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; p.Asp433Asn (c.1297G>A); ClinVar=VCV000281933; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114679 CVCL_AD74 GM10879 finite cell line human CVCL_AD74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114680 CVCL_AD73 GM10710 transformed cell line human CVCL_AD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114681 CVCL_AD76 GM10931 transformed cell line human CVCL_AD76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114682 CVCL_AD75 GM10930 transformed cell line human CVCL_AD75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114683 CVCL_AD78 GM23796 transformed cell line human CVCL_AD78 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg109Trp (c.325C>T); ClinVar=VCV000012988; Zygosity=Heterozygous (from familial inference of GM23800); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg2241Ter (c.6721C>T); Zygosity=Heterozygous (from familial inference of GM23800) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114684 CVCL_AD77 GM13360 transformed cell line human CVCL_AD77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114685 CVCL_AD90 GM24509 finite cell line human CVCL_AD90 CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; p.Asp394His (c.1180G>C); ClinVar=VCV000158902; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114686 CVCL_AD92 NYSCF-DE-1034-1034-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD92 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114687 CVCL_AD91 NYSCF-DE-1016-1016-Skin-RV-IPSC1 induced pluripotent stem cell human CVCL_AD91 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114688 CVCL_AD83 GM23803 transformed cell line human CVCL_AD83 CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114689 CVCL_AD82 GM23800 transformed cell line human CVCL_AD82 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg109Trp (c.325C>T); ClinVar=VCV000012988; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg2241Ter (c.6721C>T); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114690 CVCL_AD85 GM23984 transformed cell line human CVCL_AD85 CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; p.Lys363Serfs*14 (c.1088_1089delAA); ClinVar=VCV000158894; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114691 CVCL_AD84 GM23806 transformed cell line human CVCL_AD84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114692 CVCL_AD87 GM24392 transformed cell line human CVCL_AD87 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114693 CVCL_AD86 GM24346 finite cell line human CVCL_AD86 CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; c.1261-10A>G (IVS11-10A>G); ClinVar=VCV000011058; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114694 CVCL_AD89 GM24418 transformed cell line human CVCL_AD89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114695 CVCL_AD88 GM24417 transformed cell line human CVCL_AD88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114696 CVCL_AD58 GM00612 finite cell line human CVCL_AD58 CL:0000010 Sequence variation: Mutation; HGNC; 2698; DBT; Simple; p.Cys26Trpfs*2 (c.75_76delAT); ClinVar=VCV000011950; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2698; DBT; Simple; p.Glu224Ter (c.670G>T) (E163X); ClinVar=VCV000094009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114697 CVCL_AD57 chHES-427 embryonic stem cell human CVCL_AD57 From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7del; Zygosity=Homozygous (PubMed=27345972). Female 21114698 CVCL_AD59 GM00649 finite cell line human CVCL_AD59 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Gly288Valfs (c.861_868delAGGCCCCG); ClinVar=VCV000198433; Zygosity=Heterozygous (PubMed=8037208); Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Heterozygous (PubMed=8037208) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114699 CVCL_AD50 NYSCF-MS-1017-10006-113-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD50 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114700 CVCL_AD52 NYSCF-PD-1030-10001.130.01-Skin-SV-iPSC7 induced pluripotent stem cell human CVCL_AD52 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114701 CVCL_AD51 NYSCF-MS-1019-10006-115-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD51 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21114702 CVCL_AD54 NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC5 induced pluripotent stem cell human CVCL_AD54 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NYSCF) Donor information: Established from monozygotic twin of NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC4 (Cellosaurus=CVCL_AD55) and NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC5 (Cellosaurus=CVCL_AD56); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114703 CVCL_AD53 NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC2 induced pluripotent stem cell human CVCL_AD53 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NYSCF) Donor information: Established from monozygotic twin of NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC4 (Cellosaurus=CVCL_AD55) and NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC5 (Cellosaurus=CVCL_AD56); Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114704 CVCL_AD56 NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC5 induced pluripotent stem cell human CVCL_AD56 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NYSCF) Donor information: Established from monozygotic twin of NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC2 (Cellosaurus=CVCL_AD53) and NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC5 (Cellosaurus=CVCL_AD54); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114705 CVCL_AD55 NYSCF-PD-1040-10001.198.01-Skin-SV-iPSC4 induced pluripotent stem cell human CVCL_AD55 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NYSCF) Donor information: Established from monozygotic twin of NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC2 (Cellosaurus=CVCL_AD53) and NYSCF-PD-1039-10001.197.01-Skin-SV-iPSC5 (Cellosaurus=CVCL_AD54); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114706 CVCL_AD70 GM06813 finite cell line human CVCL_AD70 CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Simple; p.Tyr198Asnfs*52 (c.592_594delinsAA) (646delT and 648C>A); Zygosity=Hemizygous (PubMed=9305655) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114707 CVCL_AD69 GM11381 transformed cell line human CVCL_AD69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114708 CVCL_AD68 GM11151 finite cell line human CVCL_AD68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21114709 CVCL_AD61 GM00651 finite cell line human CVCL_AD61 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Gly288Valfs (c.861_868delAGGCCCCG); ClinVar=VCV000198433; Zygosity=Heterozygous (PubMed=8037208) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114710 CVCL_AD60 GM00650 finite cell line human CVCL_AD60 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Heterozygous (PubMed=8037208) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114711 CVCL_AD63 GM01744 finite cell line human CVCL_AD63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21114712 CVCL_AD62 GM01099 finite cell line human CVCL_AD62 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Homozygous (PubMed=2241958) Population: Caucasian; Mennonite; Derived from sampling site: Cell type=Fibroblast. Female 21114713 CVCL_AD65 GM02327 finite cell line human CVCL_AD65 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Homozygous (from familial inference of GM01099) Population: Caucasian; Mennonite; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Female 21114714 CVCL_AD64 GM01938 finite cell line human CVCL_AD64 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114715 CVCL_AD67 GM11150 transformed cell line human CVCL_AD67 CL:0000010 Population: Caucasian; Mennonite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114716 CVCL_AD66 GM05074 finite cell line human CVCL_AD66 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21114717 CVCL_AD36 NYSCF-DE-1091-1091-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD36 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114718 CVCL_AD35 NYSCF-DE-1086-1086-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD35 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114719 CVCL_AD38 NYSCF-DE-1113-1113-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD38 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114720 CVCL_AD37 NYSCF-DE-1109-1109-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD37 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114721 CVCL_AD39 NYSCF-DE-1158-1158-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD39 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21114722 CVCL_AD30 NYSCF-DE-1051-1051-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD30 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114723 CVCL_AD32 NYSCF-DE-1057-1057-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD32 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114724 CVCL_AD31 NYSCF-DE-1052-1052-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD31 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114725 CVCL_AD34 NYSCF-DE-1064-1064-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD34 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114726 CVCL_AD33 NYSCF-DE-1060-1060-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_AD33 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114727 CVCL_AD47 NYSCF-MS-1007-10006-108-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD47 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114728 CVCL_AD46 NYSCF-MS-1006-10006-107-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD46 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114729 CVCL_AD49 NYSCF-MS-1011-10006-112-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD49 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114730 CVCL_AD48 NYSCF-MS-1008-10006-109-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD48 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114731 CVCL_AD41 NYSCF-MS-1001-10006-102-Skin-mi-iPSC4 induced pluripotent stem cell human CVCL_AD41 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114732 CVCL_AD40 NYSCF-MS-1000-10006-101-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD40 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114733 CVCL_AD43 NYSCF-MS-1003-10006-104-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD43 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114734 CVCL_AD42 NYSCF-MS-1002-10006-103-Skin-mi-iPSC4 induced pluripotent stem cell human CVCL_AD42 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114735 CVCL_AD45 NYSCF-MS-1005-10006-106-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD45 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21114736 CVCL_AD44 NYSCF-MS-1004-10006-105-Skin-mi-iPSC1 induced pluripotent stem cell human CVCL_AD44 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21114737 CVCL_RW50 MR42D cancer cell line human CVCL_RW50 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Male 21114738 CVCL_S850 PC-6/SN2-5 cancer cell line human CVCL_S850 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin). Unspecified 21114739 CVCL_S852 HROC113 cancer cell line human CVCL_S852 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Doubling time: 23 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21114740 CVCL_RW52 MR49C cancer cell line human CVCL_RW52 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Male 21114741 CVCL_S851 HCT-8R cancer cell line human CVCL_S851 CL:0000010 Male 21114742 CVCL_RW51 MR42F cancer cell line human CVCL_RW51 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Male 21114743 CVCL_S854 HROC87 T0 M2 cancer cell line human CVCL_S854 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23300683) Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 26 hours (CLS); Microsatellite instability: Instable (MSI) (PubMed=25926053) 21114744 CVCL_RW54 MT4/HIV-1 transformed cell line human CVCL_RW54 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Male Virology: Persistently infected with HIV-1; Virology: HTLV-1 producing cell line 21114745 CVCL_S853 HROC24 cancer cell line human CVCL_S853 HLA typing: A*02:01,30:02; B*18:01,38:01; C*05:01,12:03; DQB1*02:01,06:01; DRB1*03:01,13:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21114746 CVCL_RW53 MR49F cancer cell line human CVCL_RW53 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Male 21114747 CVCL_S856 A04-GEH cancer cell line human CVCL_S856 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533); Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21114748 CVCL_RW56 N202.1A cancer cell line house mouse CVCL_RW56 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: FVB N#202 transgenic for HER-2/neu. Female 21114749 CVCL_S855 JA-M cancer cell line human CVCL_S855 CL:0000010 21114750 CVCL_RW55 MT4C5 transformed cell line human CVCL_RW55 CL:0000010 Transfected with: HGNC; 1606; CCR5 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Male Virology: Can be infected by both CXCR4-tropic and CCR5-tropic HIV-1 strains; Virology: HTLV-1 producing cell line 21114751 CVCL_RW58 CHO DRA10 spontaneously immortalized cell line CVCL_RW58 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with the DRneo construct which contains a hygromycin resistance gene and two non-functional copies of the neomycin resistance gene This cell line is sensitive to G418 but recombination recreates a functional Neo gene and recombinants become G418 resistant. 21114753 CVCL_S857 A06-MLC cancer cell line human CVCL_S857 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21114754 CVCL_RW57 N202.1E cancer cell line house mouse CVCL_RW57 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: FVB N#202 transgenic for HER-2/neu. Female 21114755 CVCL_S859 Mz-Sto-1 cancer cell line human CVCL_S859 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Male Doubling time: 28-36 hours (PubMed=2820743) 21114756 CVCL_RW59 RG37 transformed cell line human CVCL_RW59 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Transfected with the DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP. 21114757 CVCL_0200 Caov-1 cancer cell line human CVCL_0200 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Omentum. Female 21114758 CVCL_0202 Caov-4 cancer cell line human CVCL_0202 Genome ancestry: African=0.23%; Native American=0%; East Asian, North=4.8%; East Asian, South=0%; South Asian=0%; European, North=67.03%; European, South=27.94% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Asp (c.440T>A); ClinVar=VCV001351017; Zygosity=Homozygous (PubMed=25230021; ATCC) Population: Caucasian; Derived from metastatic site: Fallopian tube; subserosa. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: >120 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OCCP ovarian cancer cell line panel; Part of: TCGA-110-CL cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-070 21114759 CVCL_0201 Caov-3 cancer cell line human CVCL_0201 HLA typing: A*26:01,69:01; B*49:01,49:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=2.29%; Native American=0.12%; East Asian, North=2.22%; East Asian, South=0%; South Asian=15.22%; European, North=11.3%; European, South=68.85% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136Ter (c.406C>T); Zygosity=Homozygous (PubMed=24023729; PubMed=25230021; ATCC) Population: Caucasian; Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 78 hours (PubMed=4016745); 68 hours (PubMed=25984343); ~44 hours (PBCF); 65.81 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-069 21114760 CVCL_0204 CATH.a transformed cell line house mouse CVCL_0204 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 x DBA/2 transgenic. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11179 21114761 CVCL_0203 CAPE 1 finite cell line dog CVCL_0203 CL:0000010 Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Mixed breed. Male 21114762 CVCL_0206 CC531 cancer cell line Norway rat CVCL_0206 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: WAG/Rij. Male 21114763 CVCL_0205 CC-LP-1 cancer cell line human CVCL_0205 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from sampling site: Liver. Female Doubling time: 180 hours (PubMed=1355757) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: Indicated to derive from a female patient in PubMed=1355757, but has a X,Y amelogenin STR marker 21114764 CVCL_0208 X16C8.5 cancer cell line house mouse CVCL_0208 CL:0000010 Breed/subspecies: BALB/cAnN. Doubling time: 18 hours (PubMed=310843) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114765 CVCL_0207 CCRF-CEM cancer cell line human CVCL_0207 HLA typing: B*08,40; C*03:04:01,07; DPB1*04:01,13:01; DQB1*02:01,02:02; DRB1*03:01:01,07:01 (PubMed=15748285); HLA typing: DPB1*04:01,13:01 (IPD-IMGT/HLA=10403); HLA typing: A*01:01:01,07:01:02; B*08:01:01,16:01:02; C*03:04:01,07:01:01; DPB1*04:01:01,13:XX; DQA1*02:01:01,05:01:01; DQB1*02:01:01,02:02:01; DRB1*03:01:01,07:01:01 (CLS=300147); HLA typing: A*01:01:01,31:01:02; B*08:01:01,40:01:02; C*03:04:01,07:01:01 (DSMZCellDive=ACC-240); Genome ancestry: African=0.2%; Native American=0.21%; East Asian, North=0.43%; East Asian, South=0.09%; South Asian=0.81%; European, North=69.4%; European, South=28.85% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (PubMed=14500364; PubMed=17308084); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (PubMed=11565033; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=17088437; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Metabolome analysis; Omics: lncRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7916; true Female Doubling time: 23 hours (PubMed=17117183); 24 hours (PubMed=20922763); 22.0 hours (PubMed=25070259); 26.7 hours (NCI-DTP); ~24 hours (CLS); ~24-30 hours (DSMZ=ACC-240); Microsatellite instability: Instable (MSI-low) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8436 21114766 CVCL_0209 CESS transformed cell line human CVCL_0209 Genome ancestry: African=6.92%; Native American=0.8%; East Asian, North=5.8%; East Asian, South=0%; South Asian=5.27%; European, North=21.66%; European, South=59.54% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114767 CVCL_S841 HCC95 BL transformed cell line human CVCL_S841 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114768 CVCL_RW41 V79 SP5 spontaneously immortalized cell line CVCL_RW41 CL:0000010 Sequence variation: Mutation; UniProtKB; P00494; Hprt1; Unexplicit; Ex2dup; Zygosity=Unspecified (PubMed=1576714); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21114769 CVCL_S840 HCC827 BL transformed cell line human CVCL_S840 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114770 CVCL_RW40 OR6 [Chlorocebus aethiops] transformed cell line CVCL_RW40 CL:0000010 Transfected with: HGNC; 799; ATP1A1; Transfected with: MGI; MGI:88105; Atp1a1 (with p.Ile798Thr) Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21114771 CVCL_S843 HCC970 BL transformed cell line human CVCL_S843 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114772 CVCL_RW43 MTH52c transformed cell line dog CVCL_RW43 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland. Female 21114773 CVCL_S842 HCC1171 BL transformed cell line human CVCL_S842 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114774 CVCL_RW42 V79 SPD8 spontaneously immortalized cell line CVCL_RW42 CL:0000010 Sequence variation: Mutation; UniProtKB; P00494; Hprt1; Unexplicit; Ex7dup; Zygosity=Unspecified (PubMed=8914605); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21114775 CVCL_RW45 hTERT EP156T telomerase immortalized cell line human CVCL_RW45 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 60-68 hours (ATCC=CRL-3289) 21114776 CVCL_S845 NCI-BL2887 transformed cell line human CVCL_S845 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114777 CVCL_RW44 MTH53a transformed cell line dog CVCL_RW44 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland. Female 21114778 CVCL_S844 NCI-BL2882 transformed cell line human CVCL_S844 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114779 CVCL_RW47 HL116 cancer cell line human CVCL_RW47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: The luciferase reporter gene is under the control of a IFN-alpha inducible IFI6 (6-16) promoter 21114780 CVCL_S847 QG-95 cancer cell line human CVCL_S847 CL:0000010 Population: Japanese. Unspecified 21114781 CVCL_S846 HCE-9 cancer cell line human CVCL_S846 CL:0000010 Derived from sampling site: Esophagus. Male 21114782 CVCL_RW46 HG23 cancer cell line human CVCL_RW46 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Virology: Stably transfected with plasmid NV101, which contains a cloned cDNA consensus sequence of the RNA genome of Norwalk virus 21114783 CVCL_RW49 MLS-9 finite cell line Norway rat CVCL_RW49 CL:0000010 Derived from sampling site: Brain; neocortex Cell type=Microglial cell.; Breed/subspecies: Wistar. Unspecified 21114784 CVCL_S849 PC-6/TAX1-1 cancer cell line human CVCL_S849 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol). Unspecified 21114785 CVCL_RW48 HepJ5 cancer cell line human CVCL_RW48 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: GRP78-overexpressing 21114786 CVCL_S848 VMRC-LCF cancer cell line human CVCL_S848 From: Bean M.A.; Virginia Mason Research Center; Seattle; USA. CL:0000010 Unspecified 21114787 CVCL_0211 CH12.LX cancer cell line house mouse CVCL_0211 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis Part of: ENCODE project mouse cell lines 21114788 CVCL_0210 CG-4 finite cell line Norway rat CVCL_0210 CL:0000010 Derived from sampling site: Brain Cell type=Oligodendrocyte precursor cell.; Breed/subspecies: Sprague Dawley. 21114789 CVCL_0213 CHO spontaneously immortalized cell line CVCL_0213 CL:0000010 Derived from sampling site: Ovary. Female 21114790 CVCL_0212 CHL spontaneously immortalized cell line CVCL_0212 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Used in chemical substance-induced chromosomal aberration detection Doubling time: ~14 hours (PubMed=1370240) 21114791 CVCL_0215 V79/E36-ts20 spontaneously immortalized cell line CVCL_0215 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male Characteristics: Has a thermolabile ubiquitin-like modifier-activating enzyme 1 (Uba1) (PubMed=3049611) 21114792 CVCL_0214 CHO-K1 spontaneously immortalized cell line CVCL_0214 CL:0000010 Derived from sampling site: Ovary. Omics: Genome sequenced; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~24 hours (DSMZ=ACC-110) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9618 21114793 CVCL_0217 CMK-11-5 cancer cell line human CVCL_0217 Genome ancestry: African=0.58%; Native American=0%; East Asian, North=95.47%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=3.94% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (PubMed=16778363); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (PubMed=16778363) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~2 days (lot 12122008), ~34 hours (lot 12082016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21114794 CVCL_0216 CMK cancer cell line human CVCL_0216 HLA typing: A*02:01,24:02; B*15:18,40:02; C*08:01,08:01 (PubMed=26589293); HLA typing: A*02:01:01,24:02:01; B*15:18:01,40:02:01; C*03:04:01,08:01:01; DRA*01:01:01,01:01:01; DRB1*11:01:01,11:01:01 (DSMZCellDive=ACC-392); Genome ancestry: African=0.58%; Native American=0%; East Asian, North=93.95%; East Asian, South=3.14%; South Asian=0%; European, North=0%; European, South=2.33% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (from child cell lines & inference from Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (PubMed=2527057); ~40-50 hours (DSMZ=ACC-392); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: LL-100 blood cancer cell line panel 21114795 CVCL_0219 COLO 320DM cancer cell line human CVCL_0219 HLA typing: A*24:02,24:02; B*14:02,39:10; C*08:02,08:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (PubMed=24755471; PubMed=28179481); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=7651727; PubMed=16418264; PubMed=24755471) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: MD Anderson Cell Lines Project 21114796 CVCL_0218 COLO 205 cancer cell line human CVCL_0218 HLA typing: A*01,02; B*07,08; C*07:02:01,07; DPB1*04:01; DQB1*06:03; DRB1*04:01:01,13:01:01 (PubMed=15748285); HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02 (PubMed=9023415); HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:01; DQB1*06:11,06:11; DRB1*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.08%; East Asian, South=0%; South Asian=0%; European, North=61.39%; European, South=36.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (PubMed=17088437; PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (PubMed=9294210); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (PubMed=7651727; PubMed=17088437; PubMed=28683746) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25 hours (PubMed=25984343); 20-25 hours (CLS); 23.8 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel 21114797 CVCL_S830 H69VZ cancer cell line human CVCL_S830 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male Doubling time: 34.5 hours (PubMed=1662924) 21114798 CVCL_RW30 NTUB1/As cancer cell line human CVCL_RW30 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Urinary bladder. Female 21114799 CVCL_RW32 Hana3A transformed cell line human CVCL_RW32 CL:0000010 Transfected with: MGI; MGI:95774; Gnal; Transfected with: MGI; MGI:1098827; Reep1; Transfected with: MGI; MGI:2685450; Rtp1; Transfected with: MGI; MGI:2685451; Rtp2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Used for the recombinant expression of olfactory receptors 21114800 CVCL_S832 IGSK-1 cancer cell line human CVCL_S832 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Female Doubling time: ~34 hours (PubMed=17506773) 21114801 CVCL_S831 MOG-G-IJK cancer cell line human CVCL_S831 CL:0000010 Derived from sampling site: Brain. Unspecified 21114802 CVCL_RW31 NTUB1/P[14] cancer cell line human CVCL_RW31 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21114803 CVCL_S834 GPM-2 cancer cell line human CVCL_S834 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21114804 CVCL_RW34 SV-589 transformed cell line human CVCL_RW34 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21114805 CVCL_S833 GPM-1 cancer cell line human CVCL_S833 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21114806 CVCL_RW33 NCI-H460-LNM35 cancer cell line human CVCL_RW33 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Characteristics: Has lymphogenous metastactic properties Consistently and spontaneously metastasizes to lymph nodes when injected either subcutaneously or orthotopically. 21114807 CVCL_RW36 HAT-7 spontaneously immortalized cell line Norway rat CVCL_RW36 CL:0000010 Derived from sampling site: Tooth; incisor Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Unspecified 21114808 CVCL_S836 HEC-1D cancer cell line human CVCL_S836 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female 21114809 CVCL_RW35 DU249 cancer cell line CVCL_RW35 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Liver; Breed/subspecies: White Leghorn. Group: Bird cell line 21114810 CVCL_S835 HEC-1C cancer cell line human CVCL_S835 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female 21114811 CVCL_S838 HCC193 BL transformed cell line human CVCL_S838 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114812 CVCL_RW38 LS8 transformed cell line house mouse CVCL_RW38 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; enamel organ; dental epithelium Cell type=Ameloblast.; Breed/subspecies: Swiss Webster. Unspecified 21114813 CVCL_S837 CMT93tk cancer cell line house mouse CVCL_S837 CL:0000010 Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Transformant: Methylazoxymethanol acetate (MAM acetate)(ChEBI; CHEBI:82341); Derived from sampling site: Rectum; Breed/subspecies: C57BL/ICRF. Male 21114814 CVCL_RW37 PABSo-E transformed cell line pig CVCL_RW37 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth; enamel organ; dental epithelium. Unspecified 21114815 CVCL_S839 HCC515 BL transformed cell line human CVCL_S839 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114816 CVCL_RW39 OSU-2 finite cell line human CVCL_RW39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21114817 CVCL_RW21 AC-258 cancer cell line human CVCL_RW21 CL:0000010 Derived from metastatic site: Omentum. Female Doubling time: 22 hours (PubMed=7060993) 21114818 CVCL_S821 NCH57 cancer cell line human CVCL_S821 CL:0000010 Characteristics: Low-passage-number culture. 21114819 CVCL_RW20 Hi-5 Rix4446 spontaneously immortalized cell line CVCL_RW20 CL:0000010 Biotechnology: Used for the production of the papilloma vaccine Cervarix The C-terminally truncated proteins L1 of HPV-16 and HPV-18 are separately produced in this cell line using a recombinant baculovirus expression system.. Unspecified Group: Insect cell line; Group: Recombinant protein production insect cell line; Group: Vaccine production cell line 21114820 CVCL_S820 NCH37 cancer cell line human CVCL_S820 CL:0000010 Male Characteristics: Low-passage-number culture. 21114821 CVCL_RW23 IRSC-6M cancer cell line human CVCL_RW23 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Established from a tumor implanted into a nude mice Doubling time: 164 hours (in RPMI-1640 + 10% FCS), 93 hours (in 50% self conditioned medium + 50% (RPMI-1640+10% FCS)) (PubMed=7847823) 21114822 CVCL_S823 NCH89 cancer cell line human CVCL_S823 CL:0000010 Female Characteristics: Low-passage-number culture. 21114823 CVCL_RW22 IRSC-2M cancer cell line human CVCL_RW22 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Established from a tumor implanted into a nude mice Doubling time: 120 hours (in RPMI-1640 + 10% FCS), 72 hours (in 50% self conditioned medium + 50% (RPMI-1640+10% FCS)) (PubMed=7847823) 21114824 CVCL_S822 NCH82 cancer cell line human CVCL_S822 CL:0000010 Male Characteristics: Low-passage-number culture. 21114825 CVCL_S825 AY-27 cancer cell line Norway rat CVCL_S825 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Male Characteristics: Tumorigenic Doubling time: 0.927 +- 0.206 days (PubMed=2936252) 21114826 CVCL_RW25 IRSC-61M cancer cell line human CVCL_RW25 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Established from a tumor implanted into a nude mice Doubling time: 144 hours (in RPMI-1640 + 10% FCS), 72 hours (in 50% self conditioned medium + 50% (RPMI-1640+10% FCS)) (PubMed=7847823) 21114827 CVCL_RW24 IRSC-10M cancer cell line human CVCL_RW24 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Established from a tumor implanted into a nude mice Doubling time: 192 hours (in RPMI-1640 + 10% FCS), 144 hours (in 50% self conditioned medium + 50% (RPMI-1640+10% FCS)) (PubMed=7847823) 21114828 CVCL_S824 JHU-ESS1 cancer cell line human CVCL_S824 CL:0000010 Derived from sampling site: Endometrium. Female 21114829 CVCL_S827 GB-3 cancer cell line human CVCL_S827 CL:0000010 Population: Japanese. 21114830 CVCL_RW27 JFCF-6/T.1P transformed cell line human CVCL_RW27 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21114831 CVCL_S826 GB-2 cancer cell line human CVCL_S826 CL:0000010 Population: Japanese. 21114832 CVCL_RW26 IRSC-74M cancer cell line human CVCL_RW26 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Established from a tumor implanted into a nude mice Doubling time: 120 hours (in RPMI-1640 + 10% FCS), 67 hours (in 50% self conditioned medium + 50% (RPMI-1640+10% FCS)) (PubMed=7847823) 21114833 CVCL_RW29 NTUB1 cancer cell line human CVCL_RW29 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Urinary bladder. Female Doubling time: ~21 hours, at 32th passage (PubMed=1358347) 21114834 CVCL_S828 203-glioma cancer cell line house mouse CVCL_S828 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C57BL/6. 21114835 CVCL_RW28 JFCF-6/T.5K transformed cell line human CVCL_RW28 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21114836 CVCL_RW10 CW60576 induced pluripotent stem cell human CVCL_RW10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60576; true Female 21114837 CVCL_S810 MaWi cancer cell line human CVCL_S810 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=12068308). Female Characteristics: Established from a nude mice xenograft 21114838 CVCL_RW12 CW70384 induced pluripotent stem cell human CVCL_RW12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Norwegian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70384; true Male 21114839 CVCL_S812 HUBT-n cancer cell line human CVCL_S812 CL:0000010 Population: Japanese; Derived from sampling site: Brain. Male Characteristics: Established from a nude mice xenograft Doubling time: 32 hours (at 20th passage), 30 hours (at 50th passage) (PubMed=16130901) 21114840 CVCL_RW11 CW60594 induced pluripotent stem cell human CVCL_RW11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60594; true Male 21114841 CVCL_S811 T222 cancer cell line human CVCL_S811 CL:0000010 Unspecified 21114842 CVCL_S814 402-91/ET transformed cell line human CVCL_S814 CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Selected for resistance to: ChEBI; CHEBI:84050; Trabectedin (Ecteinascidin-743; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male 21114843 CVCL_RW14 KTCTL-61 cancer cell line human CVCL_RW14 CL:0000010 Unspecified 21114844 CVCL_S813 402-91 transformed cell line human CVCL_S813 CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=27270875); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=27270875) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Omics: SNP array analysis. Male 21114845 CVCL_RW13 KTCTL-31 cancer cell line human CVCL_RW13 CL:0000010 Unspecified 21114846 CVCL_S816 2645-94 transformed cell line human CVCL_S816 CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=16651630) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male 21114847 CVCL_RW16 RPMI-7932 COL-1 cancer cell line human CVCL_RW16 CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from metastatic site: Pleural effusion. Female 21114848 CVCL_S815 1955-91 transformed cell line human CVCL_S815 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male 21114849 CVCL_RW15 KTCTL-107 cancer cell line human CVCL_RW15 CL:0000010 Unspecified 21114850 CVCL_S818 NCH125 cancer cell line human CVCL_S818 CL:0000010 Male Characteristics: Low-passage-number culture. 21114851 CVCL_RW18 RPMI-7932 VCR-4.5/4 cancer cell line human CVCL_RW18 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Pleural effusion. Female 21114852 CVCL_S817 1765-92 transformed cell line human CVCL_S817 CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=27270875); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=27270875) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). 21114853 CVCL_RW17 RPMI-7932 VBL-4 cancer cell line human CVCL_RW17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Pleural effusion. Female 21114854 CVCL_RW19 KAIMRC1 cancer cell line human CVCL_RW19 CL:0000010 Population: Saudi Arabian; Derived from sampling site: Breast. Female Characteristics: ER-positive, PR-positive and ERBB2-negative Doubling time: ~24 hours (PubMed=29187162) 21114855 CVCL_S819 NCH149 cancer cell line human CVCL_S819 CL:0000010 Male Characteristics: Low-passage-number culture. 21114856 CVCL_RW01 CW60462 induced pluripotent stem cell human CVCL_RW01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60462; true Male 21114857 CVCL_S801 Hep-Y1 cancer cell line human CVCL_S801 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male 21114858 CVCL_RW00 CW60441 induced pluripotent stem cell human CVCL_RW00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60441; true Male 21114859 CVCL_S800 H7.s9 embryonic stem cell human CVCL_S800 CL:0000010 Female 21114860 CVCL_RW03 CW60477 induced pluripotent stem cell human CVCL_RW03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60477; true Male 21114861 CVCL_S803 HMVC cancer cell line human CVCL_S803 CL:0000010 Population: Japanese; Derived from sampling site: Vulva. Female Doubling time: 28-32 hours (PubMed=12889856) 21114862 CVCL_RW02 CW60469 induced pluripotent stem cell human CVCL_RW02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60469; true Male 21114863 CVCL_S802 Hep-Y2 cancer cell line human CVCL_S802 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Female 21114864 CVCL_RW05 CW60481 induced pluripotent stem cell human CVCL_RW05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60481; true Male 21114865 CVCL_S805 T265 cancer cell line human CVCL_S805 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Doubling time: ~28 hours (PubMed=21084276) 21114866 CVCL_RW04 CW60480 induced pluripotent stem cell human CVCL_RW04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60480; true Male 21114867 CVCL_S804 TY-ES cancer cell line human CVCL_S804 CL:0000010 Male Doubling time: 40 hours (CelloPub=CLPUB00122). 21114868 CVCL_RW07 CW60499 induced pluripotent stem cell human CVCL_RW07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60499; true Male 21114869 CVCL_S807 M000907 cancer cell line human CVCL_S807 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Shoulder. Omics: Transcriptome analysis by microarray Female 21114870 CVCL_RW06 CW60498 induced pluripotent stem cell human CVCL_RW06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60498; true Male 21114871 CVCL_S806 M000216 cancer cell line human CVCL_S806 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Inguinal lymph node. Omics: Transcriptome analysis by microarray Male 21114872 CVCL_RW09 CW60569 induced pluripotent stem cell human CVCL_RW09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60569; true Male 21114873 CVCL_S809 M010308 cancer cell line human CVCL_S809 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=16827748) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Occipital lymph node. Omics: Transcriptome analysis by microarray Male 21114874 CVCL_RW08 CW60509 induced pluripotent stem cell human CVCL_RW08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60509; true Female 21114875 CVCL_S808 M000921 cancer cell line human CVCL_S808 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; DepMap) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Epigastrium. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21114876 CVCL_IV59 10F11.B2.C3 hybridoma house mouse CVCL_IV59 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Newcastle disease viruses P protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8333 21114877 CVCL_J759 M 144 hybridoma house mouse CVCL_J759 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanocytes cell surface antigen M-26. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8440 21114878 CVCL_IV56 F4C1 cancer cell line Norway rat CVCL_IV56 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female Doubling time: 48 hours (PubMed=178673) 21114879 CVCL_J756 L 101 hybridoma house mouse CVCL_J756 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma cell surface antigen M-20. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8447 21114880 CVCL_IV55 HIAE-36/7-1 finite cell line human CVCL_IV55 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21114881 CVCL_J755 ILB1-H67 hybridoma house mouse CVCL_J755 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01584; Human IL1B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10222 21114882 CVCL_J758 M 138 hybridoma house mouse CVCL_J758 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanocytes cell surface antigen M-24. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8449 21114883 CVCL_IV58 NS1 cancer cell line Norway rat CVCL_IV58 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: Fischer 344. 21114884 CVCL_IV57 GK-7 spontaneously immortalized cell line CVCL_IV57 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21114885 CVCL_J757 M 111 hybridoma house mouse CVCL_J757 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanocytes cell surface antigen M-4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8438 21114886 CVCL_IV52 HIVE-79/7-2 finite cell line human CVCL_IV52 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21114887 CVCL_J752 ILB1-H21 hybridoma house mouse CVCL_J752 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01584; Human IL1B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10220 21114888 CVCL_J751 E 20 hybridoma house mouse CVCL_J751 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-13. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8443 21114889 CVCL_IV51 SK-LU-1b cancer cell line human CVCL_IV51 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asn1253fs*16 (c.3753delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Female 21114890 CVCL_IV54 HIVE-81/7-2 finite cell line human CVCL_IV54 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21114891 CVCL_J754 ILB1-H6 hybridoma house mouse CVCL_J754 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01584; Human IL1B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10219 21114892 CVCL_IV53 HIVE-54/7-2 finite cell line human CVCL_IV53 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21114893 CVCL_J753 ILB1-H34 hybridoma house mouse CVCL_J753 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01584; Human IL1B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10221 21114894 CVCL_J750 D 14 hybridoma house mouse CVCL_J750 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cell surface antigen M-8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8439 21114895 CVCL_IV50 RCC96 cancer cell line human CVCL_IV50 CL:0000010 Population: Chinese; Derived from metastatic site: Bone; spine. Male Doubling time: 52 hours (PubMed=28055232) 21114896 CVCL_J767 MH-SVM26 hybridoma house mouse CVCL_J767 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8872 21114897 CVCL_IV67 OCUM-2M/5-FU cancer cell line human CVCL_IV67 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Stomach. Female 21114898 CVCL_J766 MH-SVM25 hybridoma house mouse CVCL_J766 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8871 21114899 CVCL_IV66 OCUM-8/SN38 cancer cell line human CVCL_IV66 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from metastatic site: Ascites. Female 21114900 CVCL_J769 MMA hybridoma house mouse CVCL_J769 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). 21114901 CVCL_IV69 OCUM-2M/OXA cancer cell line human CVCL_IV69 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from sampling site: Stomach. Female 21114902 CVCL_J768 MH-SVM33C9 hybridoma house mouse CVCL_J768 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8975 21114903 CVCL_IV68 OCUM-2M/GEM cancer cell line human CVCL_IV68 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Stomach. Female 21114904 CVCL_IV63 21A7.B12.F8 hybridoma house mouse CVCL_IV63 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Newcastle disease viruses HN protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8641 21114905 CVCL_J763 MG38 hybridoma house mouse CVCL_J763 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60449; Human LY75/CD205. 21114906 CVCL_IV62 18E9.G3.D7 hybridoma house mouse CVCL_IV62 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Newcastle disease viruses HN protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8334 21114907 CVCL_J762 MF116 hybridoma house mouse CVCL_J762 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8411 21114908 CVCL_IV65 JEG-3/A3-1A7 cancer cell line human CVCL_IV65 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45327; Adenine arabinoside (Vidarabine; Selected for resistance to: ChEBI; CHEBI:46515; 9-beta-D-xylofuranosyl adenine (xyl-A); Derived from metastatic site: Fetal brain. Male 21114909 CVCL_J765 MH-SVM23 hybridoma house mouse CVCL_J765 CL:0000010 Monoclonal antibody isotype: IgG2, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8870 21114910 CVCL_IV64 7F8.C7 hybridoma house mouse CVCL_IV64 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Newcastle disease viruses HN protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8335 21114911 CVCL_J764 MH-SVM16 hybridoma house mouse CVCL_J764 CL:0000010 Monoclonal antibody isotype: IgM, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8880 21114912 CVCL_IV61 17F4.F4 hybridoma house mouse CVCL_IV61 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Newcastle disease viruses HN protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8332 21114913 CVCL_J761 ME361-S2a hybridoma house mouse CVCL_J761 CL:0000010 Characteristics: Isotype switched derivative of ME361; Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9326 21114914 CVCL_IV60 13F7.B6.A7 hybridoma house mouse CVCL_IV60 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Newcastle disease viruses HN protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8331 21114915 CVCL_J760 ME361 hybridoma house mouse CVCL_J760 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9325 21114916 CVCL_J738 9-A5 hybridoma house mouse CVCL_J738 CL:0000010 Monoclonal antibody isotype: IgG1. 21114917 CVCL_IV38 SU-LB-5 transformed cell line human CVCL_IV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. 21114918 CVCL_J737 9-1A11 hybridoma house mouse CVCL_J737 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05164; Human MPO. 21114919 CVCL_IV37 SU-LB-4 transformed cell line human CVCL_IV37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. 21114920 CVCL_J739 9.3F10 hybridoma house mouse CVCL_J739 CL:0000010 Monoclonal antibody isotype: IgG2a. 21114921 CVCL_IV39 SU-ALL-1 cancer cell line human CVCL_IV39 CL:0000010 Derived from sampling site: Peripheral blood. Female 21114922 CVCL_J734 8A3B.6 hybridoma house mouse CVCL_J734 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P18609; Bluetongue virus 17 VP7. 21114923 CVCL_IV34 SU-LB-1 transformed cell line human CVCL_IV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21114924 CVCL_J733 88B hybridoma house mouse CVCL_J733 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd; Monoclonal antibody target: UniProtKB; P02714; Tetronarce californica chrng. 21114925 CVCL_IV33 SE686 cancer cell line human CVCL_IV33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21114926 CVCL_J736 8C9 hybridoma house mouse CVCL_J736 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P16671; Human CD36. 21114927 CVCL_IV36 SU-LB-3 transformed cell line human CVCL_IV36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. 21114928 CVCL_J735 8B1B.1 hybridoma house mouse CVCL_J735 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P18609; Bluetongue virus 17 VP7. 21114929 CVCL_IV35 SU-LB-2 transformed cell line human CVCL_IV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. 21114930 CVCL_J730 4E11 [Mouse hybridoma against FLAG peptide] hybridoma house mouse CVCL_J730 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:189550; FLAG peptide (DYKDDDDK). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9259 21114931 CVCL_IV30 SU-AmB-2 cancer cell line human CVCL_IV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Inguinal lymph node. Male Virology: Contains mutliple copies of integrated and non-integrated (circular) copies of EBV genome 21114932 CVCL_J732 80 V 5B4 hybridoma house mouse CVCL_J732 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114933 CVCL_IV32 DH978 cancer cell line human CVCL_IV32 CL:0000010 Sequence variation: Mutation; HGNC; 1784; CDKN1A; Simple; p.Phe63Leu (c.189C>A); Zygosity=Heterozygous (PubMed=7882347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21114934 CVCL_J731 7G7B6 hybridoma house mouse CVCL_J731 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8784 21114935 CVCL_IV31 SU-AmB-3 cancer cell line human CVCL_IV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114936 CVCL_IV49 4143 cancer cell line human CVCL_IV49 CL:0000010 Female 21114937 CVCL_J749 BE2 hybridoma house mouse CVCL_J749 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Glycosphingolipids having type II chain H structure. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21114938 CVCL_J748 B 5 hybridoma house mouse CVCL_J748 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma cell surface antigen M-28. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8453 21114939 CVCL_IV48 BCIRL-AtE-CLG15A spontaneously immortalized cell line CVCL_IV48 CL:0000010 Unspecified Doubling time: 190 hours (PubMed=28205141). Group: Insect cell line 21114940 CVCL_J745 AF6-122.2.5 hybridoma house mouse CVCL_J745 CL:0000010 Monoclonal antibody isotype: IgG1. 21114941 CVCL_IV45 BML895 cancer cell line human CVCL_IV45 CL:0000010 Virology: EBV-negative. 21114942 CVCL_J744 AF6-120.1.2 hybridoma house mouse CVCL_J744 CL:0000010 Monoclonal antibody isotype: IgG2a. 21114943 CVCL_IV44 LW878 cancer cell line human CVCL_IV44 CL:0000010 Virology: EBV-negative. 21114944 CVCL_J747 AF6-88.5.3 hybridoma house mouse CVCL_J747 CL:0000010 Monoclonal antibody isotype: IgG2a. 21114945 CVCL_IV47 BCIRL-AtE-CLG15 spontaneously immortalized cell line CVCL_IV47 CL:0000010 Unspecified Group: Insect cell line. 21114946 CVCL_J746 AF6-78.25.4 hybridoma house mouse CVCL_J746 CL:0000010 Monoclonal antibody isotype: IgG1. 21114947 CVCL_IV46 BCIRL-AtE-CLG11 spontaneously immortalized cell line CVCL_IV46 CL:0000010 Unspecified Group: Insect cell line. 21114948 CVCL_J741 AL 1-27 hybridoma house mouse CVCL_J741 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma cell surface antigen M-11. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8441 21114949 CVCL_IV41 SU-DUL-1 cancer cell line human CVCL_IV41 CL:0000010 Derived from sampling site: Pleural effusion. Female 21114950 CVCL_J740 9AE10 hybridoma house mouse CVCL_J740 CL:0000010 Monoclonal antibody isotype: IgM. 21114951 CVCL_IV40 SU-ALL-2 cancer cell line human CVCL_IV40 CL:0000010 21114952 CVCL_J743 AF4-73.3.1 hybridoma house mouse CVCL_J743 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse IgD (allotype e, Igh-5.5). 21114953 CVCL_IV43 SU-DUL-3 cancer cell line human CVCL_IV43 CL:0000010 Derived from sampling site: Peritoneal effusion. Female 21114954 CVCL_J742 AF3-12.1.3 hybridoma house mouse CVCL_J742 CL:0000010 Monoclonal antibody isotype: IgG1. 21114955 CVCL_IV42 SU-DUL-2 cancer cell line human CVCL_IV42 CL:0000010 Derived from sampling site: Peritoneal effusion. Male 21114956 CVCL_J719 3-2H3 hybridoma house mouse CVCL_J719 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05164; Human MPO. 21114957 CVCL_IV19 IARC-247 transformed cell line human CVCL_IV19 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21114958 CVCL_J716 3.C2 hybridoma house mouse CVCL_J716 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Myelin basic protein from Oreochromine and other types of fish. 21114959 CVCL_IV16 BL-90 cancer cell line human CVCL_IV16 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21114960 CVCL_J715 25-32 hybridoma house mouse CVCL_J715 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5QBV7; Sheep CD44. 21114961 CVCL_IV15 BL-50 cancer cell line human CVCL_IV15 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21114962 CVCL_J718 33-3D hybridoma house mouse CVCL_J718 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q03763; Bovine DSG1. 21114963 CVCL_IV18 IARC-629 transformed cell line human CVCL_IV18 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21114964 CVCL_J717 32-2B hybridoma house mouse CVCL_J717 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03763; Bovine DSG1. 21114965 CVCL_IV17 IARC-261 transformed cell line human CVCL_IV17 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21114966 CVCL_IV12 BL-108 cancer cell line human CVCL_IV12 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21114967 CVCL_J712 WS2TKB finite cell line human CVCL_J712 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 12-15 PDL (RCB=RCB0407) 21114968 CVCL_IV11 IARC-385 transformed cell line human CVCL_IV11 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21114969 CVCL_J711 WS1TKB2 finite cell line human CVCL_J711 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 12-13 PDL (RCB=RCB0433) 21114970 CVCL_J714 1B1.1 hybridoma house mouse CVCL_J714 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Giardia muris trophozoite surface antigens. 21114971 CVCL_IV14 MCF 10A-H2B-mCherry spontaneously immortalized cell line human CVCL_IV14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Breast; epithelium. Female Characteristics: Retroviral transformation with an H2B-mCherry expression cassette 21114972 CVCL_J713 12-1B6 hybridoma house mouse CVCL_J713 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05164; Human MPO. 21114973 CVCL_IV13 BL-135 cancer cell line human CVCL_IV13 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 Female 21114974 CVCL_IV10 IARC-549 transformed cell line human CVCL_IV10 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans north of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21114975 CVCL_J710 WS1TKB finite cell line human CVCL_J710 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 12-13 PDL (RCB=RCB0409) 21114976 CVCL_J727 41-3.48 hybridoma house mouse CVCL_J727 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 21114977 CVCL_IV27 IARC-309 transformed cell line human CVCL_IV27 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114978 CVCL_J726 411-14E10 hybridoma house mouse CVCL_J726 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa. 21114979 CVCL_IV26 PA682 PE1 cancer cell line human CVCL_IV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male 21114980 CVCL_J729 4D9D4 hybridoma house mouse CVCL_J729 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02836; Drosophila melanogaster en; Monoclonal antibody target: UniProtKB; P05527; Drosophila melanogaster inv. 21114981 CVCL_IV29 SU-AmB-1 cancer cell line human CVCL_IV29 CL:0000010 Derived from metastatic site: Peritoneal effusion. Male Virology: EBV-negative 21114982 CVCL_J728 48 hybridoma house mouse CVCL_J728 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Murine leukemia viruses (MuLV) gp70. 21114983 CVCL_IV28 IARC-304 transformed cell line human CVCL_IV28 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: ~60 hours (DSMZ=ACC-897) 21114984 CVCL_J723 3C7.2 hybridoma house mouse CVCL_J723 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Giardia muris trophozoite surface antigens. 21114985 CVCL_IV23 IARC-174 transformed cell line human CVCL_IV23 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114986 CVCL_J722 3C5.1 hybridoma house mouse CVCL_J722 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q07864; Human POLE. 21114987 CVCL_IV22 IARC-171 transformed cell line human CVCL_IV22 HLA typing: A*11,32; B*35,49 (PubMed=3037521) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by microarray. Male 21114988 CVCL_J725 4-2C11 hybridoma house mouse CVCL_J725 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05164; Human MPO. 21114989 CVCL_IV25 PA682 BM1 cancer cell line human CVCL_IV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21114990 CVCL_J724 3Pt12B8 hybridoma house mouse CVCL_J724 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P30203; Human CD6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8136 21114991 CVCL_IV24 IARC-307 transformed cell line human CVCL_IV24 HLA typing: A*11,28; B*27,45 (PubMed=3037521) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21114992 CVCL_J721 3A21 hybridoma house mouse CVCL_J721 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P61823; Bovine RNASE1. 21114993 CVCL_IV21 IARC-139 transformed cell line human CVCL_IV21 HLA typing: A*01,11; B*08,16 (PubMed=3037521) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21114994 CVCL_J720 3-83P hybridoma house mouse CVCL_J720 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21114995 CVCL_IV20 L 660 cancer cell line human CVCL_IV20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Male 21114996 CVCL_IV09 IARC-151 transformed cell line human CVCL_IV09 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21114997 CVCL_J709 SK-MEL-172 cancer cell line human CVCL_J709 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21114998 CVCL_IV08 IARC-290B transformed cell line human CVCL_IV08 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21114999 CVCL_J708 SK-MEL-165 cancer cell line human CVCL_J708 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21115000 CVCL_IV05 IARC-176A transformed cell line human CVCL_IV05 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115001 CVCL_J705 NGR50 hybridoma house mouse CVCL_J705 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). 21115002 CVCL_J704 2F8 [Mouse hybridoma against human OXTR] hybridoma house mouse CVCL_J704 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P30559; Human OXTR. 21115003 CVCL_IV04 OSU-NB transformed cell line human CVCL_IV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Doubling time: ~30 hours (PubMed=24130782) 21115004 CVCL_IV07 IARC-632 transformed cell line human CVCL_IV07 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21115005 CVCL_J707 NMR52 hybridoma house mouse CVCL_J707 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: nLc4Cer. 21115006 CVCL_IV06 IARC-277 transformed cell line human CVCL_IV06 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115007 CVCL_J706 NGR54 hybridoma house mouse CVCL_J706 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: IV3-NeuAcalpha-nLc4Cer gangliosides. 21115008 CVCL_J701 GM17521 finite cell line human CVCL_J701 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21115009 CVCL_IV01 TGP48 cancer cell line house mouse CVCL_IV01 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21115010 CVCL_J700 GM17520 transformed cell line human CVCL_J700 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115011 CVCL_IV00 M12.4 cancer cell line house mouse CVCL_IV00 CL:0000010 Breed/subspecies: BALB/c. 21115012 CVCL_J703 Myc-CaP cancer cell line house mouse CVCL_J703 CL:0000010 Breed/subspecies: FVB Hi-Myc. Male 21115013 CVCL_IV03 TGP51 cancer cell line house mouse CVCL_IV03 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21115014 CVCL_J702 GM17522 transformed cell line human CVCL_J702 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115015 CVCL_IV02 TGP50 cancer cell line house mouse CVCL_IV02 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21115016 CVCL_RP77 B6-206 cancer cell line house mouse CVCL_RP77 CL:0000010 Breed/subspecies: C57BL/6NJ. Omics: SNP array analysis 21115017 CVCL_S177 HJ2.Tes finite cell line CVCL_S177 CL:0000010 Derived from sampling site: Fetal testis. Discontinued: ATCC; CRL-6279; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115018 CVCL_S176 HJ2.Sp finite cell line CVCL_S176 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6278; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115019 CVCL_RP76 TEPC-2372 cancer cell line house mouse CVCL_RP76 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/c.lambdaLIZ. Characteristics: Produces IgG2b lambda 21115020 CVCL_RP79 IBMS-iPSC-013-07 induced pluripotent stem cell human CVCL_RP79 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Gln533Ter (c.1597C>T); Zygosity=Heterozygous (from autologous cell line IBMS-iPSC-013-06) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21115021 CVCL_S179 Ig1.Sk/mu finite cell line CVCL_S179 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6259; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115022 CVCL_RP78 B6-207 cancer cell line house mouse CVCL_RP78 CL:0000010 Breed/subspecies: C57BL/6NJ. Omics: SNP array analysis 21115023 CVCL_S178 DB1.K finite cell line CVCL_S178 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6257; true Male Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115024 CVCL_RP80 IBMS-iPSC-027-01 induced pluripotent stem cell human CVCL_RP80 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 2719; DDC; Simple; c.714+4A>T (IVS6+4A>T) (IVS6DS,A-T,+4); ClinVar=VCV000864024; Zygosity=Homozygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21115025 CVCL_S180 Ig2.M finite cell line CVCL_S180 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6260; true Unspecified Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115026 CVCL_RP82 NHRI-iPSC-006-01 induced pluripotent stem cell human CVCL_RP82 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21115027 CVCL_S182 Tg1.K finite cell line CVCL_S182 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6263; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115028 CVCL_S181 Ig2.Sk finite cell line CVCL_S181 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6261; true Unspecified Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115029 CVCL_RP81 NHRI-iPSC-003-04 induced pluripotent stem cell human CVCL_RP81 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21115030 CVCL_S184 Tg1.Thy finite cell line CVCL_S184 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6265; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115031 CVCL_RP84 TVGH-iPSC-010-09 induced pluripotent stem cell human CVCL_RP84 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7459; MT-ND4; Simple; p.Arg340His (m.11778G>A); ClinVar=VCV000009708; Zygosity=Unspecified (PubMed=29427840) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Discontinued: hPSCreg; TVGHi001-A; true Female 21115032 CVCL_RP83 NHRI-iPSC-008-01 induced pluripotent stem cell human CVCL_RP83 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21115033 CVCL_S183 Tg1.Sp finite cell line CVCL_S183 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6264; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115034 CVCL_S186 A-382 cancer cell line human CVCL_S186 HLA typing: A*02,10; B*08,14 (PubMed=77569) CL:0000010 Miscellaneous: STR profile from personal communication of Aarsonson S.A and Korch C. Derived from sampling site: Brain. Discontinued: ATCC; CRL-7903; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115035 CVCL_RP86 TVGH-iPSC-007-08 induced pluripotent stem cell human CVCL_RP86 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21115036 CVCL_S185 SW210.5 cancer cell line human CVCL_S185 CL:0000010 21115037 CVCL_RP85 TVGH-iPSC-006-06 induced pluripotent stem cell human CVCL_RP85 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21115038 CVCL_S166 CHO IS1 spontaneously immortalized cell line CVCL_S166 CL:0000010 Derived from sampling site: Ovary. Female 21115039 CVCL_RP66 TEPC-2027 cancer cell line house mouse CVCL_RP66 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Characteristics: Produces IgG1; Characteristics: IL6 dependent 21115040 CVCL_S165 CHO-10B2 spontaneously immortalized cell line CVCL_S165 CL:0000010 Derived from sampling site: Ovary. Female 21115041 CVCL_RP65 TEPC-1198 cancer cell line house mouse CVCL_RP65 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Characteristics: IL6 dependent 21115042 CVCL_RP68 ABLS-1 cancer cell line house mouse CVCL_RP68 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21115043 CVCL_S168 SCGR-11 spontaneously immortalized cell line house mouse CVCL_S168 CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Cell type=Fibroblast. Unspecified 21115044 CVCL_RP67 BPC4 cancer cell line house mouse CVCL_RP67 CL:0000010 Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: C57BL/6NJ. Omics: SNP array analysis 21115045 CVCL_S167 CHO irs-20 spontaneously immortalized cell line CVCL_S167 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A061I8A6; Prkdc; Simple; p.Glu4090Lys (c.11268G>A); Zygosity=Heterozygous (PubMed=9518490) Derived from sampling site: Ovary. Female 21115046 CVCL_RP69 ABLS-5 cancer cell line house mouse CVCL_RP69 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21115047 CVCL_S169 SCGR-8 spontaneously immortalized cell line house mouse CVCL_S169 CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: 25.2 hours (PubMed=1709732) 21115048 CVCL_RP71 B6-1153 cancer cell line house mouse CVCL_RP71 CL:0000010 Transformant: LP-BM5 murine leukemia virus; Breed/subspecies: C57BL/6NJ. Omics: SNP array analysis 21115049 CVCL_S171 HJ1.K finite cell line CVCL_S171 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6271; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115050 CVCL_RP70 ABLS-8 cancer cell line house mouse CVCL_RP70 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Omics: SNP array analysis 21115051 CVCL_S170 V79/UC spontaneously immortalized cell line CVCL_S170 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21115052 CVCL_RP73 ABPC 4 cancer cell line house mouse CVCL_RP73 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Female Characteristics: Produces IgA kappa 21115053 CVCL_S173 HJ1.Lu finite cell line CVCL_S173 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6273; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115054 CVCL_RP72 B6-1710 cancer cell line house mouse CVCL_RP72 CL:0000010 Transformant: LP-BM5 murine leukemia virus; Breed/subspecies: C57BL/6NJ. Omics: SNP array analysis 21115055 CVCL_S172 HJ1.Ln finite cell line CVCL_S172 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6272; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115056 CVCL_RP75 ABPC 22 cancer cell line house mouse CVCL_RP75 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Female Characteristics: Produces IgM kappa 21115057 CVCL_S175 HJ2.K finite cell line CVCL_S175 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-6276; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115058 CVCL_RP74 ABPC 20 cancer cell line house mouse CVCL_RP74 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Transformant: Pristane(ChEBI; CHEBI:53181); Breed/subspecies: BALB/cAnPt. Omics: SNP array analysis Female Characteristics: Produces IgG2b kappa 21115059 CVCL_S174 HJ1.Th finite cell line CVCL_S174 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6275; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115060 CVCL_S155 26B spontaneously immortalized cell line CVCL_S155 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: Arlee 12. Male Doubling time: 1.4 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115061 CVCL_RP55 Aa23-T.wMelPop spontaneously immortalized cell line CVCL_RP55 CL:0000010 Omics: Metabolome analysis. Unspecified Characteristics: Infected by Wolbachia pipientis strain wMelPop; Characteristics: Cured of Wolbachia pipientis strain wAlbB infection by tetracycline Group: Insect cell line 21115062 CVCL_S154 25B spontaneously immortalized cell line CVCL_S154 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: Arlee 12. Male Group: Fish cell line 21115063 CVCL_RP54 Aa23-T.wMel spontaneously immortalized cell line CVCL_RP54 CL:0000010 Omics: Metabolome analysis. Unspecified Characteristics: Infected by Wolbachia pipientis strain wMel; Characteristics: Cured of Wolbachia pipientis strain wAlbB infection by tetracycline Group: Insect cell line 21115064 CVCL_S157 58B2C spontaneously immortalized cell line CVCL_S157 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: OSU 142. Female Doubling time: 3.4 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115065 CVCL_RP57 B3 HA-Ikaros-IRES-GFP cancer cell line house mouse CVCL_RP57 CL:0000010 Transfected with: HGNC; 13176; IKZF1; Transfected with: MGI; MGI:96561; Il7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 10-III-42 transgenic Tg(H2-Ea-Il7)10Rhdr. Omics: Deep scRNAseq analysis; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Characteristics: Transfected with a fusion protein of hemagglutinin-tagged wildtype Ikaros (HA-Ikaros) and the estrogen receptor hormone-binding domain (ERt2), followed by an internal ribosomal entry site (IRES) and GFP 21115066 CVCL_S156 49B2 spontaneously immortalized cell line CVCL_S156 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: OSU 142. Female Group: Fish cell line 21115067 CVCL_RP56 B3 cancer cell line house mouse CVCL_RP56 CL:0000010 Transfected with: MGI; MGI:96561; Il7 Breed/subspecies: 10-III-42 transgenic Tg(H2-Ea-Il7)10Rhdr. Omics: Deep scRNAseq analysis; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq 21115068 CVCL_S159 6B [Oncorhynchus] spontaneously immortalized cell line CVCL_S159 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: Hot Creek 71. Male Doubling time: 3.5 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115069 CVCL_RP59 MUSIi001-A induced pluripotent stem cell human CVCL_RP59 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Abdomen; skin; dermis (Note=From a cesarean section scar). Female 21115070 CVCL_S158 5C2 spontaneously immortalized cell line CVCL_S158 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: Hot Creek 71. Male Doubling time: 5.6 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115071 CVCL_RP58 B3 HA-159A Ikaros-IRES-GFP cancer cell line house mouse CVCL_RP58 CL:0000010 Transfected with: HGNC; 13176; IKZF1 (with p.Asn159Ala); Transfected with: MGI; MGI:96561; Il7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 10-III-42 transgenic Tg(H2-Ea-Il7)10Rhdr. Omics: Transcriptome analysis by microarray Characteristics: Transfected with a fusion protein of hemagglutinin-tagged wildtype Ikaros (HA-Ikaros) and the estrogen receptor hormone-binding domain (ERt2), followed by an internal ribosomal entry site (IRES) and GFP 21115072 CVCL_RP60 TL1 embryonic stem cell house mouse CVCL_RP60 From: Brigid Hogan B.L.M.; Duke University; Durham; USA CL:0000010 Breed/subspecies: 129S6/SvEvTAC. Omics: SNP array analysis Unspecified 21115073 CVCL_S160 TP-1 spontaneously immortalized cell line CVCL_S160 CL:0000010 Unspecified Group: Fish cell line. 21115074 CVCL_S162 GFSB spontaneously immortalized cell line CVCL_S162 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Group: Fish cell line 21115075 CVCL_RP62 NCC-UPS2-C1 cancer cell line human CVCL_RP62 CL:0000010 Population: Japanese Omics: Deep proteome analysis. Female Doubling time: 45 hours (PubMed=29359268) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21115076 CVCL_RP61 Cali-1 cancer cell line human CVCL_RP61 CL:0000010 Discontinued: ATCC; HTB-51; true. 21115077 CVCL_S161 GFM spontaneously immortalized cell line CVCL_S161 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 21115078 CVCL_RP64 AK7 embryonic stem cell house mouse CVCL_RP64 CL:0000010 Breed/subspecies: 129S4/SvJae. Omics: SNP array analysis Male 21115079 CVCL_S164 FM3A SR-1 cancer cell line house mouse CVCL_S164 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Doubling time: 15.4 hours (PubMed=2426230); 12 hours (PubMed=7528891) 21115080 CVCL_RP63 RPMI-1922 cancer cell line human CVCL_RP63 CL:0000010 Discontinued: ATCC; HTB-84; true. Female 21115081 CVCL_S163 FM3A SX10 cancer cell line house mouse CVCL_S163 CL:0000010 Sequence variation: Mutation; MGI; MGI:1335098; Lig4; Simple; p.Trp471Ter (c.1413G>A); Zygosity=Heterozygous (PubMed=11133995) Selected for resistance to: NCIt; C17262; X-Ray; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Radiation-sensitive The parent cell line was irradiated with 2 Gy and this clone was hypersensitive to X-ray killing (PubMed=2426230). Doubling time: 18.5 hours (PubMed=2426230); 24 hours (PubMed=7528891) 21115082 CVCL_RP44 LUTC-5 cancer cell line human CVCL_RP44 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115083 CVCL_S144 PYS-2/11 cancer cell line house mouse CVCL_S144 CL:0000010 Breed/subspecies: 129/Sv. Male 21115084 CVCL_RP43 LUTC-4 cancer cell line human CVCL_RP43 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115085 CVCL_S143 PYS-2/3 cancer cell line house mouse CVCL_S143 CL:0000010 Breed/subspecies: 129/Sv. Male 21115086 CVCL_RP46 LUTC-10 cancer cell line human CVCL_RP46 CL:0000010 Derived from sampling site: Thyroid gland. Male 21115087 CVCL_S146 XR-C1 spontaneously immortalized cell line CVCL_S146 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Ovary. Female 21115088 CVCL_RP45 LUTC-8 cancer cell line human CVCL_RP45 CL:0000010 Derived from sampling site: Thyroid gland. Male 21115089 CVCL_S145 PYS-2/12 cancer cell line house mouse CVCL_S145 CL:0000010 Breed/subspecies: 129/Sv. Male 21115090 CVCL_RP48 LUTC-13 cancer cell line human CVCL_RP48 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115091 CVCL_S148 SHHT spontaneously immortalized cell line CVCL_S148 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Unspecified Group: Fish cell line 21115092 CVCL_RP47 LUTC-12 cancer cell line human CVCL_RP47 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115093 CVCL_S147 RTHDF spontaneously immortalized cell line CVCL_S147 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Unspecified Group: Fish cell line 21115094 CVCL_RP49 LUTC-14 cancer cell line human CVCL_RP49 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115095 CVCL_S149 SHMS spontaneously immortalized cell line CVCL_S149 CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Unspecified Doubling time: 39 hours (at 20-25 Celsius), <33 hours (with 20% FBS at 30 Celsius), ~48 hours (with 10% FBS at 30 Celsius) (PubMed=15801161) Group: Fish cell line 21115096 CVCL_S151 11B spontaneously immortalized cell line CVCL_S151 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Arlee 12. Male Doubling time: 1.6 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115097 CVCL_RP51 Aa23E spontaneously immortalized cell line CVCL_RP51 CL:0000010 Unspecified Characteristics: Adapted to growth in Eagle's minimal medium; Characteristics: Infected by the intracellular symbiont Wolbachia pipientis strain wAlbB Doubling time: 4-5 days (PubMed=18401667). Group: Insect cell line 21115098 CVCL_RP50 LUTC-17 cancer cell line human CVCL_RP50 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115099 CVCL_S150 SHSB spontaneously immortalized cell line CVCL_S150 CL:0000010 Derived from sampling site: Swim bladder Cell type=Fibroblast.. Unspecified Doubling time: 43 hours (PubMed=15801161) Group: Fish cell line 21115100 CVCL_S153 24BC spontaneously immortalized cell line CVCL_S153 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: Arlee 12. Male Doubling time: 1.8 days (DOI=10.1577/1548-8667(1998)010<0075:DOLTCL>2.0.CO;2) Group: Fish cell line 21115101 CVCL_RP53 Aa23-T spontaneously immortalized cell line CVCL_RP53 CL:0000010 Omics: Metabolome analysis. Unspecified Characteristics: Cured of Wolbachia pipientis strain wAlbB infection by tetracycline Group: Insect cell line 21115102 CVCL_S152 23B2 spontaneously immortalized cell line CVCL_S152 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Arlee 12. Male Group: Fish cell line 21115103 CVCL_RP52 Aa23E(T) spontaneously immortalized cell line CVCL_RP52 CL:0000010 Unspecified Characteristics: Adapted to growth in Eagle's minimal medium; Characteristics: Cured of Wolbachia pipientis strain wAlbB infection by tetracycline Doubling time: 4-5 days (PubMed=18401667). Group: Insect cell line 21115104 CVCL_RP33 Ca 301 cancer cell line human CVCL_RP33 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115105 CVCL_S133 TKB-5 cancer cell line human CVCL_S133 CL:0000010 Population: Japanese. Unspecified 21115106 CVCL_RP32 Ca 300 cancer cell line human CVCL_RP32 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115107 CVCL_S132 TKB-4 cancer cell line human CVCL_S132 CL:0000010 Population: Japanese. Unspecified 21115108 CVCL_RP35 OGK-M cancer cell line human CVCL_RP35 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Tyr (c.830G>A); ClinVar=VCV000185722; Zygosity=Homozygous (PubMed=25365311) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 18 hours (PubMed=25365311) 21115109 CVCL_S135 TKB-7 cancer cell line human CVCL_S135 CL:0000010 Population: Japanese. Unspecified 21115110 CVCL_RP34 FF-1 cancer cell line human CVCL_RP34 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=14522906) Miscellaneous: STR profile from personal communication of Marlow L.A Derived from sampling site: Thyroid gland. Female 21115111 CVCL_S134 TKB-6 cancer cell line human CVCL_S134 CL:0000010 Population: Japanese. Unspecified 21115112 CVCL_RP37 JEM493 cancer cell line human CVCL_RP37 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Homozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 17087; ICOSLG; Simple; p.Glu153Ter (c.457G>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21115113 CVCL_S137 TKB-34 cancer cell line human CVCL_S137 CL:0000010 Population: Japanese. Unspecified 21115114 CVCL_RP36 OGK-P cancer cell line human CVCL_RP36 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Tyr (c.830G>A); ClinVar=VCV000185722; Zygosity=Homozygous (PubMed=25365311) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 23 hours (PubMed=25365311) 21115115 CVCL_S136 TKB-8 cancer cell line human CVCL_S136 CL:0000010 Population: Japanese. Unspecified 21115116 CVCL_RP39 THJ529 cancer cell line human CVCL_RP39 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21115117 CVCL_S139 TKB-21 cancer cell line human CVCL_S139 CL:0000010 Population: Japanese. Unspecified 21115118 CVCL_RP38 LAM136 cancer cell line human CVCL_RP38 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21115119 CVCL_S138 TKB-3 cancer cell line human CVCL_S138 CL:0000010 Population: Japanese. Unspecified 21115120 CVCL_IV99 GM19015 transformed cell line human CVCL_IV99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115121 CVCL_J799 YTS 177.9.6.1 hybridoma Norway rat CVCL_J799 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06332; Mouse Cd4. 21115122 CVCL_IV96 CAR #1 cancer cell line human CVCL_IV96 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Doubling time: 43 hours, at 16th passage (PubMed=994214) 21115123 CVCL_J796 YTS 154.7.7.10 hybridoma Norway rat CVCL_J796 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90. 21115124 CVCL_IV95 CHP-100S cancer cell line human CVCL_IV95 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line) Derived from sampling site: Bone; spine; epidural space. Female Doubling time: 26 hours (PubMed=6825097) Problematic cell line: Misclassified Parent cell line (CHP-100) was originally thought to originate from a neuroblastoma but was later shown to be from an Ewing sarcoma. 21115125 CVCL_J795 YTS 121.5.2 hybridoma Norway rat CVCL_J795 CL:0000010 Discontinued: ECACC; 87072283; probable. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13379; Mouse Cd5 21115126 CVCL_IV98 GM19014 transformed cell line human CVCL_IV98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115127 CVCL_J798 YTS 169.4.2.1 hybridoma Norway rat CVCL_J798 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 21115128 CVCL_IV97 ND13677 transformed cell line human CVCL_IV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115129 CVCL_J797 YTS 156.7.7 hybridoma Norway rat CVCL_J797 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10300; Mouse Cd8b. 21115130 CVCL_IV92 USPC-ARK-21 cancer cell line human CVCL_IV92 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115131 CVCL_J792 YTH 906.9HL hybridoma Norway rat CVCL_J792 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. 21115132 CVCL_IV91 USPC-ARK-20 cancer cell line human CVCL_IV91 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=23891627; PubMed=26325104) Population: Caucasian; Derived from sampling site: Endometrium. Female 21115133 CVCL_J791 YTH 89.1 hybridoma Norway rat CVCL_J791 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a. 21115134 CVCL_IV94 CHP-100L cancer cell line human CVCL_IV94 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His233fs (c.696_697ins4); Zygosity=Unspecified (PubMed=25010205) Derived from sampling site: Bone; spine; epidural space. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 21 hours (PubMed=6825097) Part of: MD Anderson Cell Lines Project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00610 Problematic cell line: Misclassified Parent cell line (CHP-100) was originally thought to originate from a neuroblastoma but was later shown to be from an Ewing sarcoma. 21115135 CVCL_J794 YTS 105.18.10 hybridoma Norway rat CVCL_J794 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 21115136 CVCL_IV93 USPC-ARK-22 cancer cell line human CVCL_IV93 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115137 CVCL_J793 YTH 913.12 hybridoma Norway rat CVCL_J793 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10747; Human CD28. 21115138 CVCL_IV90 USPC-ARK-19 cancer cell line human CVCL_IV90 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115139 CVCL_J790 YTH 862.2 hybridoma Norway rat CVCL_J790 CL:0000010 Monoclonal antibody isotype: IgG2b. 21115140 CVCL_RP40 THJ560 cancer cell line human CVCL_RP40 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21115141 CVCL_S140 TKB-14 cancer cell line human CVCL_S140 CL:0000010 Population: Japanese. Unspecified 21115142 CVCL_RP42 LUTC-2 cancer cell line human CVCL_RP42 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115143 CVCL_S142 NCI-H2280 cancer cell line human CVCL_S142 CL:0000010 Discontinued: ATCC; CRL-5937; true. Female 21115144 CVCL_S141 Hs 699.K finite cell line human CVCL_S141 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 8-10 days (PubMed=176412) 21115145 CVCL_RP41 LUTC-1 cancer cell line human CVCL_RP41 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115146 CVCL_RP22 MESO-7T cancer cell line human CVCL_RP22 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 84.4 hours (in 2% FCS), 62.5 hours (in 10% FCS) (PubMed=26891694) 21115147 CVCL_S122 RCS cancer cell line Norway rat CVCL_S122 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. Characteristics: Established from the transplantable Swarm rat chondrosarcoma Doubling time: <24 hours (PubMed=7499238) 21115148 CVCL_RP21 MESO-3T cancer cell line human CVCL_RP21 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 197.8 hours (in 2% FCS), 141.6 hours (in 10% FCS) (PubMed=26891694) 21115149 CVCL_S121 RMS772 cancer cell line house mouse CVCL_S121 CL:0000010 Derived from sampling site: Hypodermis; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115150 CVCL_RP24 MESO-9T cancer cell line human CVCL_RP24 CL:0000010 Omics: Transcriptome analysis by microarray. Female Senescence: Can only be cultured for up to 15 passages before displaying signs of senescence (PubMed=26891694); Doubling time: 40.8 hours (in 2% FCS), 41.9 hours (in 10% FCS) (PubMed=26891694) 21115151 CVCL_S124 NHBE-T transformed cell line human CVCL_S124 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Male 21115152 CVCL_RP23 MESO-8T cancer cell line human CVCL_RP23 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 32.4 hours (in 2% FCS), 38.6 hours (in 10% FCS) (PubMed=26891694) 21115153 CVCL_S123 RCS-LTC cancer cell line Norway rat CVCL_S123 CL:0000010 Derived from sampling site: Cell type=Chondrocyte; Breed/subspecies: Sprague Dawley. Characteristics: Established from the transplantable Swarm rat chondrosarcoma Doubling time: ~1 day (PubMed=12874833) 21115154 CVCL_RP26 MESO-14T cancer cell line human CVCL_RP26 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 69.6 hours (in 2% FCS), 67.0 hours (in 10% FCS) (PubMed=26891694) 21115155 CVCL_S126 TKB-12 cancer cell line human CVCL_S126 CL:0000010 Population: Japanese. Unspecified 21115156 CVCL_RP25 MESO-12T cancer cell line human CVCL_RP25 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 49.8 hours (in 2% FCS), 37.1 hours (in 10% FCS) (PubMed=26891694) 21115157 CVCL_S125 TKB-1 cancer cell line human CVCL_S125 CL:0000010 Population: Japanese. Unspecified 21115158 CVCL_RP28 MESO-27T cancer cell line human CVCL_RP28 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: Exhibits the ability to grow to high passage (>30) (PubMed=26891694) Doubling time: 37.8 hours (in 2% FCS), 31.6 hours (in 10% FCS) (PubMed=26891694) 21115159 CVCL_S128 TKB-16 cancer cell line human CVCL_S128 CL:0000010 Population: Japanese. Unspecified 21115160 CVCL_RP27 MESO-17T cancer cell line human CVCL_RP27 CL:0000010 Omics: Transcriptome analysis by microarray. Male Senescence: Can only be cultured for up to 15 passages before displaying signs of senescence (PubMed=26891694); Doubling time: 53.1 hours (in 2% FCS), 40.8 hours (in 10% FCS) (PubMed=26891694) 21115161 CVCL_S127 TKB-15 cancer cell line human CVCL_S127 CL:0000010 Population: Japanese. Unspecified 21115162 CVCL_RP29 Ca 18/3 cancer cell line human CVCL_RP29 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115163 CVCL_S129 TKB-17 cancer cell line human CVCL_S129 CL:0000010 Population: Japanese. Unspecified 21115164 CVCL_RP31 Ca 298 cancer cell line human CVCL_RP31 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115165 CVCL_S131 TKB-20 cancer cell line human CVCL_S131 CL:0000010 Population: Japanese. Unspecified 21115166 CVCL_RP30 Ca 286 cancer cell line human CVCL_RP30 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21115167 CVCL_S130 TKB-2 cancer cell line human CVCL_S130 CL:0000010 Population: Japanese; Derived from metastatic site: Supraclavicular lymph node. Unspecified 21115168 CVCL_S111 RMS123 cancer cell line house mouse CVCL_S111 CL:0000010 Derived from sampling site: Hypodermis; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115169 CVCL_RP11 Y-MESO-48 cancer cell line human CVCL_RP11 CL:0000010 Population: Japanese. Male 21115170 CVCL_RP10 JO38 cancer cell line human CVCL_RP10 CL:0000010 Omics: Exosome proteome analysis; Omics: Secretome proteome analysis. Male 21115171 CVCL_S110 RMS122 cancer cell line house mouse CVCL_S110 CL:0000010 Derived from sampling site: Bone; rib; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115172 CVCL_S113 RMS14 cancer cell line house mouse CVCL_S113 CL:0000010 Derived from sampling site: Hip; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115173 CVCL_RP13 Y-MESO-72 cancer cell line human CVCL_RP13 CL:0000010 Population: Japanese. 21115174 CVCL_S112 RMS13 cancer cell line house mouse CVCL_S112 CL:0000010 Derived from sampling site: Bone; rib; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115175 CVCL_RP12 Y-MESO-61 cancer cell line human CVCL_RP12 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Pro195Phefs*5 (c.580_581ins40); Zygosity=Unspecified (PubMed=26011428). Population: Japanese 21115176 CVCL_RP15 AE16 cancer cell line house mouse CVCL_RP15 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis Female 21115177 CVCL_S115 RMS31 cancer cell line house mouse CVCL_S115 CL:0000010 Derived from sampling site: Leg; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115178 CVCL_S114 RMS29 cancer cell line house mouse CVCL_S114 CL:0000010 Derived from sampling site: Uterus; cervix; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115179 CVCL_RP14 Y-MESO-76 cancer cell line human CVCL_RP14 CL:0000010 Population: Japanese. 21115180 CVCL_RP17 AE3 [Mouse mesothelioma] cancer cell line house mouse CVCL_RP17 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis Female 21115181 CVCL_S117 RMS43 cancer cell line house mouse CVCL_S117 CL:0000010 Derived from sampling site: Hypodermis; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115182 CVCL_RP16 AE19 cancer cell line house mouse CVCL_RP16 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis Female 21115183 CVCL_S116 RMS33 cancer cell line house mouse CVCL_S116 CL:0000010 Derived from sampling site: Leg; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115184 CVCL_RP19 BM109 cancer cell line house mouse CVCL_RP19 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis 21115185 CVCL_S119 RMS7 cancer cell line house mouse CVCL_S119 CL:0000010 Derived from sampling site: Bone; spine; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115186 CVCL_RP18 AC24 cancer cell line house mouse CVCL_RP18 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Omics: Deep exome analysis Female 21115187 CVCL_S118 RMS54 cancer cell line house mouse CVCL_S118 CL:0000010 Derived from sampling site: Sternum; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115188 CVCL_IV78 USPC-ARK-7 cancer cell line human CVCL_IV78 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115189 CVCL_J778 YAML 555.6 hybridoma Norway rat CVCL_J778 CL:0000010 Monoclonal antibody isotype: IgG2a. 21115190 CVCL_IV77 USPC-ARK-6 cancer cell line human CVCL_IV77 CL:0000010 Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.His67Asn (c.199C>A); ClinVar=VCV000473501; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asp368Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Ala832Thr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Cys1642Tyr; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Ala1967Val (c.5900C>T); ClinVar=VCV000246263; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Gly2076Val; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Leu2207Ile; Zygosity=Unspecified (PubMed=27894751; Direct_author_submission) Miscellaneous: Correct age of donor (not 62 year old as indicated in PubMed=19920829) and sequence variation in POLE by personal communication of Santin A Population: Caucasian; Derived from sampling site: Endometrium. Female Microsatellite instability: Instable (MSI-high); after >50 passages (PubMed=27894751) 21115191 CVCL_J777 YAML 501.4 hybridoma Norway rat CVCL_J777 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21115192 CVCL_IV79 USPC-ARK-8 cancer cell line human CVCL_IV79 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115193 CVCL_J779 YFC 118.12 hybridoma Norway rat CVCL_J779 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 21115194 CVCL_J774 SW73.2 hybridoma Norway rat CVCL_J774 CL:0000010 Monoclonal antibody isotype: IgG2a (PubMed=2431999); IgG2b (ECACC); Monoclonal antibody target: Sheep MHC class II beta chain. 21115195 CVCL_IV74 USPC-ARK-3 cancer cell line human CVCL_IV74 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115196 CVCL_J773 RFAL3 hybridoma house mouse CVCL_J773 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 21115197 CVCL_IV73 USPC-ARK-2 cancer cell line human CVCL_IV73 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115198 CVCL_IV76 USPC-ARK-5 cancer cell line human CVCL_IV76 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115199 CVCL_J776 WM1 [Mouse hybridoma against human C3] hybridoma house mouse CVCL_J776 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01024; Human C3. 21115200 CVCL_J775 THG1-24 hybridoma CVCL_J775 CL:0000010 Discontinued: ECACC; 87120202; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP) 21115201 CVCL_IV75 USPC-ARK-4 cancer cell line human CVCL_IV75 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115202 CVCL_IV70 OCUM-2M/PTX cancer cell line human CVCL_IV70 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Stomach. Female 21115203 CVCL_J770 PAP 7 hybridoma house mouse CVCL_J770 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05994; Papaya proteinase 4. 21115204 CVCL_J772 R73 hybridoma house mouse CVCL_J772 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat T-cell receptor (TcR). 21115205 CVCL_IV72 USPC-ARK-1 cancer cell line human CVCL_IV72 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=23891627; PubMed=26325104) Population: African American; Derived from sampling site: Endometrium. Female 21115206 CVCL_IV71 OCUM-2M/SN38 cancer cell line human CVCL_IV71 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Stomach. Female 21115207 CVCL_J771 PAP 8 hybridoma house mouse CVCL_J771 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10056; Papaya proteinase 3 (omega). 21115208 CVCL_RP20 BM163 cancer cell line house mouse CVCL_RP20 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis 21115209 CVCL_S120 RMS740 cancer cell line house mouse CVCL_S120 CL:0000010 Derived from sampling site: Diaphragm; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115210 CVCL_S100 AST [Human neuroblastoma] cancer cell line human CVCL_S100 CL:0000010 Derived from sampling site: Chest. Male Doubling time: 40.7 hours (PubMed=7073944) 21115211 CVCL_RP00 C14ABR transformed cell line human CVCL_RP00 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115212 CVCL_RP02 C21ABR transformed cell line human CVCL_RP02 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115213 CVCL_S102 JH cancer cell line human CVCL_S102 CL:0000010 Derived from sampling site: Mesentery. Male Doubling time: 35.7 hours (PubMed=7073944) 21115214 CVCL_RP01 C15ABR transformed cell line human CVCL_RP01 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115215 CVCL_S101 DG cancer cell line human CVCL_S101 CL:0000010 Derived from sampling site: Abdomen. Male Doubling time: 50 hours (PubMed=7073944) 21115216 CVCL_RP04 C23ABR transformed cell line human CVCL_RP04 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115217 CVCL_S104 NBE-3 finite cell line dog CVCL_S104 CL:0000010 Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6254; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115218 CVCL_RP03 C22ABR transformed cell line human CVCL_RP03 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115219 CVCL_S103 JM [Human neuroblastoma] cancer cell line human CVCL_S103 CL:0000010 Derived from sampling site: Mesentery. Female Doubling time: 35.2 hours (PubMed=7073944) 21115220 CVCL_RP06 HD513ABR transformed cell line human CVCL_RP06 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115221 CVCL_S106 RMS11 cancer cell line house mouse CVCL_S106 CL:0000010 Derived from sampling site: Abdomen; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115222 CVCL_RP05 HD511ABR transformed cell line human CVCL_RP05 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115223 CVCL_S105 RMS10 cancer cell line house mouse CVCL_S105 CL:0000010 Derived from sampling site: Bone; rib; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Highly metastatic phenotype 21115224 CVCL_RP08 ATH1ABR transformed cell line human CVCL_RP08 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Heterozygous (PubMed=12195425) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115225 CVCL_S108 RMS117 cancer cell line house mouse CVCL_S108 CL:0000010 Derived from sampling site: Ear; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115226 CVCL_RP07 C18ABR transformed cell line human CVCL_RP07 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115227 CVCL_S107 RMS114 cancer cell line house mouse CVCL_S107 CL:0000010 Derived from sampling site: Leg; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115228 CVCL_RP09 ATH2ABR transformed cell line human CVCL_RP09 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Heterozygous (PubMed=12195425) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115229 CVCL_S109 RMS119 cancer cell line house mouse CVCL_S109 CL:0000010 Derived from sampling site: Hypodermis; Breed/subspecies: FVB/N x C57BL/6 HGF/SF Ink4/Arf-/- transgenic. Omics: Transcriptome analysis by microarray Characteristics: Poor metastatic phenotype 21115230 CVCL_IV89 USPC-ARK-18 cancer cell line human CVCL_IV89 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115231 CVCL_J789 YTH 81.5 hybridoma Norway rat CVCL_J789 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20701; Human ITGAL/CD11a. 21115232 CVCL_IV88 USPC-ARK-17 cancer cell line human CVCL_IV88 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115233 CVCL_J788 YTH 80.103 hybridoma Norway rat CVCL_J788 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21115234 CVCL_IV85 USPC-ARK-14 cancer cell line human CVCL_IV85 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115235 CVCL_J785 YTH 30.15 hybridoma Norway rat CVCL_J785 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09564; Human CD7. 21115236 CVCL_IV84 USPC-ARK-13 cancer cell line human CVCL_IV84 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115237 CVCL_J784 YTA 74.4.4 hybridoma Norway rat CVCL_J784 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q62351; Mouse Tfrc/Cd71. 21115238 CVCL_IV87 USPC-ARK-16 cancer cell line human CVCL_IV87 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115239 CVCL_J787 YTH 76.3 hybridoma Norway rat CVCL_J787 CL:0000010 Monoclonal antibody isotype: IgG2a. 21115240 CVCL_IV86 USPC-ARK-15 cancer cell line human CVCL_IV86 CL:0000010 Population: Caucasian. Female 21115241 CVCL_J786 YTH 53.1 hybridoma Norway rat CVCL_J786 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13987; Human CD59. 21115242 CVCL_IV81 USPC-ARK-10 cancer cell line human CVCL_IV81 CL:0000010 Population: Caucasian; Derived from sampling site: Endometrium. Female 21115243 CVCL_J781 YL1/2 hybridoma Norway rat CVCL_J781 CL:0000010 Monoclonal antibody isotype: IgG2a. 21115244 CVCL_IV80 USPC-ARK-9 cancer cell line human CVCL_IV80 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115245 CVCL_J780 YFC 120.5 hybridoma Norway rat CVCL_J780 CL:0000010 Monoclonal antibody isotype: IgG2b. 21115246 CVCL_IV83 USPC-ARK-12 cancer cell line human CVCL_IV83 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115247 CVCL_J783 YTA 3.1.2 hybridoma Norway rat CVCL_J783 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06332; Mouse Cd4. 21115248 CVCL_IV82 USPC-ARK-11 cancer cell line human CVCL_IV82 CL:0000010 Population: African American; Derived from sampling site: Endometrium. Female 21115249 CVCL_J782 YOL1/34 hybridoma Norway rat CVCL_J782 CL:0000010 Monoclonal antibody isotype: IgG2a. 21115250 CVCL_8C29 DA04749 transformed cell line human CVCL_8C29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115251 CVCL_8C28 DA04748 transformed cell line human CVCL_8C28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115252 CVCL_8C25 DA04745 transformed cell line human CVCL_8C25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115253 CVCL_8C24 DA04744 transformed cell line human CVCL_8C24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115254 CVCL_8C27 DA04747 transformed cell line human CVCL_8C27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115255 CVCL_8C26 DA04746 transformed cell line human CVCL_8C26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115256 CVCL_8C21 DA04741 transformed cell line human CVCL_8C21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115257 CVCL_8C20 DA04740 transformed cell line human CVCL_8C20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115258 CVCL_8C23 DA04743 transformed cell line human CVCL_8C23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115259 CVCL_8C22 DA04742 transformed cell line human CVCL_8C22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115260 CVCL_8C39 DA04759 transformed cell line human CVCL_8C39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115261 CVCL_8C36 DA04756 transformed cell line human CVCL_8C36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115262 CVCL_8C35 DA04755 transformed cell line human CVCL_8C35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115263 CVCL_8C38 DA04758 transformed cell line human CVCL_8C38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115264 CVCL_8C37 DA04757 transformed cell line human CVCL_8C37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115265 CVCL_8C32 DA04752 transformed cell line human CVCL_8C32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115266 CVCL_8C31 DA04751 transformed cell line human CVCL_8C31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115267 CVCL_8C34 DA04754 transformed cell line human CVCL_8C34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115268 CVCL_8C33 DA04753 transformed cell line human CVCL_8C33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115269 CVCL_8C30 DA04750 transformed cell line human CVCL_8C30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115270 CVCL_8C07 DA04727 transformed cell line human CVCL_8C07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115271 CVCL_8C06 DA04726 transformed cell line human CVCL_8C06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115272 CVCL_8C09 DA04729 transformed cell line human CVCL_8C09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115273 CVCL_8C08 DA04728 transformed cell line human CVCL_8C08 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115274 CVCL_8C03 DA04723 transformed cell line human CVCL_8C03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115275 CVCL_8C02 DA04722 transformed cell line human CVCL_8C02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115276 CVCL_8C05 DA04725 transformed cell line human CVCL_8C05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115277 CVCL_8C04 DA04724 transformed cell line human CVCL_8C04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115278 CVCL_8C01 DA04721 transformed cell line human CVCL_8C01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115279 CVCL_8C00 DA04720 transformed cell line human CVCL_8C00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115280 CVCL_8C18 DA04738 transformed cell line human CVCL_8C18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115281 CVCL_8C17 DA04737 transformed cell line human CVCL_8C17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115282 CVCL_8C19 DA04739 transformed cell line human CVCL_8C19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115283 CVCL_8C14 DA04734 transformed cell line human CVCL_8C14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115284 CVCL_8C13 DA04733 transformed cell line human CVCL_8C13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115285 CVCL_8C16 DA04736 transformed cell line human CVCL_8C16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115286 CVCL_8C15 DA04735 transformed cell line human CVCL_8C15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115287 CVCL_8C10 DA04730 transformed cell line human CVCL_8C10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115288 CVCL_8C12 DA04732 transformed cell line human CVCL_8C12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115289 CVCL_8C11 DA04731 transformed cell line human CVCL_8C11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115290 CVCL_S099 AS [Human neuroblastoma] cancer cell line human CVCL_S099 CL:0000010 Derived from sampling site: Pelvis. Female Doubling time: 35.8 hours (PubMed=7073944) 21115291 CVCL_S089 Hs 74.Int finite cell line human CVCL_S089 CL:0000010 Derived from sampling site: Fetal small intestine. Discontinued: ATCC; CRL-7696; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: Could be identical to FHs 74 Int (Cellosaurus=CVCL_2899) 21115292 CVCL_S088 Hs 50.Bm finite cell line human CVCL_S088 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-7695; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115293 CVCL_S090 Hs 111.Bl finite cell line human CVCL_S090 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7697; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115294 CVCL_S092 HF 282 finite cell line human CVCL_S092 CL:0000010 Derived from sampling site: Fetal large intestine. Discontinued: ATCC; CRL-7700; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115295 CVCL_S091 Hs 193.Li finite cell line human CVCL_S091 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7698; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115296 CVCL_S094 HF 322.Li finite cell line human CVCL_S094 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7705; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115297 CVCL_S093 HF 322.Lu finite cell line human CVCL_S093 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7704; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115298 CVCL_S096 HF 277.Mu finite cell line human CVCL_S096 CL:0000010 Derived from sampling site: Fetal muscle. Discontinued: ATCC; CRL-7699; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115299 CVCL_S095 HF 344.Ht finite cell line human CVCL_S095 CL:0000010 Derived from sampling site: Fetal heart. Discontinued: ATCC; CRL-7707; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115300 CVCL_S098 TE 615.T cancer cell line human CVCL_S098 CL:0000010 Discontinued: ATCC; CRL-7773; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115302 CVCL_S078 Hs 827.Pl finite cell line human CVCL_S078 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7563; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115303 CVCL_S077 Hs 826.T cancer cell line human CVCL_S077 CL:0000010 Discontinued: ATCC; CRL-7562; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115304 CVCL_S079 Hs 828.T cancer cell line human CVCL_S079 CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7565; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115305 CVCL_S081 Hs 848.Mu finite cell line human CVCL_S081 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7580; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115306 CVCL_S080 Hs 843.T cancer cell line human CVCL_S080 CL:0000010 Discontinued: ATCC; CRL-7575; true. Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115307 CVCL_S083 Hs 853.Bm finite cell line human CVCL_S083 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7586; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115308 CVCL_S082 Hs 848.T cancer cell line human CVCL_S082 CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7582; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115309 CVCL_S085 Hs 887.Sk finite cell line human CVCL_S085 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7620; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115310 CVCL_S084 Hs 853.Lu finite cell line human CVCL_S084 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-7587; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115311 CVCL_S087 Hs 946.Pl finite cell line human CVCL_S087 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7694; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115312 CVCL_S086 Hs 929.T cancer cell line human CVCL_S086 CL:0000010 Discontinued: ATCC; CRL-7682; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115313 CVCL_S067 Hs 761.K finite cell line human CVCL_S067 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7879; true Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115314 CVCL_S066 Hs 758.T cancer cell line human CVCL_S066 CL:0000010 Discontinued: ATCC; CRL-7878; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115315 CVCL_S069 Hs 754.T cancer cell line human CVCL_S069 CL:0000010 Discontinued: ATCC; CRL-7874; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115316 CVCL_S068 Hs 767.T cancer cell line human CVCL_S068 CL:0000010 Derived from sampling site: Prostate. Discontinued: ATCC; CRL-7880; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115317 CVCL_S070 Hs 756.T cancer cell line human CVCL_S070 CL:0000010 Discontinued: ATCC; CRL-7875; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115318 CVCL_S072 Hs 819.Sk finite cell line human CVCL_S072 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7550; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115319 CVCL_S071 Hs 817.T undefined cell line type human CVCL_S071 CL:0000010 Discontinued: ATCC; CRL-7549; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Possibly misidentified: Not certain if this a human or mouse cell line 21115320 CVCL_S074 Hs 823.T cancer cell line human CVCL_S074 CL:0000010 Derived from metastatic site: Bone; femur. Discontinued: ATCC; CRL-7557; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115321 CVCL_S073 Hs 822.Sk finite cell line human CVCL_S073 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7555; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115322 CVCL_S076 Hs 825.T undefined cell line type human CVCL_S076 CL:0000010 Discontinued: ATCC; CRL-7560; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115323 CVCL_S075 Hs 824.T cancer cell line human CVCL_S075 CL:0000010 Discontinued: ATCC; CRL-7559; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115324 CVCL_8C81 DA04802 transformed cell line human CVCL_8C81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115325 CVCL_8C80 DA04801 transformed cell line human CVCL_8C80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115326 CVCL_8C87 DA04808 transformed cell line human CVCL_8C87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115327 CVCL_8C86 DA04807 transformed cell line human CVCL_8C86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115328 CVCL_8C89 DA04810 transformed cell line human CVCL_8C89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115329 CVCL_8C88 DA04809 transformed cell line human CVCL_8C88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115330 CVCL_8C83 DA04804 transformed cell line human CVCL_8C83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115331 CVCL_8C82 DA04803 transformed cell line human CVCL_8C82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115332 CVCL_8C85 DA04806 transformed cell line human CVCL_8C85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115333 CVCL_8C84 DA04805 transformed cell line human CVCL_8C84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115334 CVCL_8C90 DA04811 transformed cell line human CVCL_8C90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115335 CVCL_8C92 DA04813 transformed cell line human CVCL_8C92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115336 CVCL_8C91 DA04812 transformed cell line human CVCL_8C91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115337 CVCL_8C98 DA04820 transformed cell line human CVCL_8C98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115338 CVCL_8C97 DA04819 transformed cell line human CVCL_8C97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115339 CVCL_8C99 DA04821 transformed cell line human CVCL_8C99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115340 CVCL_8C94 DA04816 transformed cell line human CVCL_8C94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115341 CVCL_8C93 DA04814 transformed cell line human CVCL_8C93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115342 CVCL_8C96 DA04818 transformed cell line human CVCL_8C96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115343 CVCL_8C95 DA04817 transformed cell line human CVCL_8C95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115344 CVCL_8C69 DA04789 transformed cell line human CVCL_8C69 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115345 CVCL_8C68 DA04788 transformed cell line human CVCL_8C68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115346 CVCL_8C65 DA04785 transformed cell line human CVCL_8C65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115347 CVCL_8C64 DA04784 transformed cell line human CVCL_8C64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115348 CVCL_8C67 DA04787 transformed cell line human CVCL_8C67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115349 CVCL_8C66 DA04786 transformed cell line human CVCL_8C66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115350 CVCL_8C61 DA04781 transformed cell line human CVCL_8C61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115351 CVCL_8C60 DA04780 transformed cell line human CVCL_8C60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115352 CVCL_8C63 DA04783 transformed cell line human CVCL_8C63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115353 CVCL_8C62 DA04782 transformed cell line human CVCL_8C62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115354 CVCL_8C79 DA04800 transformed cell line human CVCL_8C79 CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115355 CVCL_8C70 DA04790 transformed cell line human CVCL_8C70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115356 CVCL_8C76 DA04796 transformed cell line human CVCL_8C76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115357 CVCL_8C75 DA04795 transformed cell line human CVCL_8C75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115358 CVCL_8C78 DA04799 transformed cell line human CVCL_8C78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115359 CVCL_8C77 DA04797 transformed cell line human CVCL_8C77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115360 CVCL_8C72 DA04792 transformed cell line human CVCL_8C72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115361 CVCL_8C71 DA04791 transformed cell line human CVCL_8C71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115362 CVCL_8C74 DA04794 transformed cell line human CVCL_8C74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115363 CVCL_8C73 DA04793 transformed cell line human CVCL_8C73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115364 CVCL_8C47 DA04767 transformed cell line human CVCL_8C47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115365 CVCL_8C46 DA04766 transformed cell line human CVCL_8C46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115366 CVCL_8C49 DA04769 transformed cell line human CVCL_8C49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115367 CVCL_8C48 DA04768 transformed cell line human CVCL_8C48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115368 CVCL_8C43 DA04763 transformed cell line human CVCL_8C43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115369 CVCL_8C42 DA04762 transformed cell line human CVCL_8C42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115370 CVCL_8C45 DA04765 transformed cell line human CVCL_8C45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115371 CVCL_8C44 DA04764 transformed cell line human CVCL_8C44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115372 CVCL_8C41 DA04761 transformed cell line human CVCL_8C41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115373 CVCL_8C40 DA04760 transformed cell line human CVCL_8C40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115374 CVCL_8C58 DA04778 transformed cell line human CVCL_8C58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115375 CVCL_8C57 DA04777 transformed cell line human CVCL_8C57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115376 CVCL_8C59 DA04779 transformed cell line human CVCL_8C59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115377 CVCL_8C54 DA04774 transformed cell line human CVCL_8C54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115378 CVCL_8C53 DA04773 transformed cell line human CVCL_8C53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115379 CVCL_8C56 DA04776 transformed cell line human CVCL_8C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115380 CVCL_8C55 DA04775 transformed cell line human CVCL_8C55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115381 CVCL_8C50 DA04770 transformed cell line human CVCL_8C50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115382 CVCL_8C52 DA04772 transformed cell line human CVCL_8C52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115383 CVCL_8C51 DA04771 transformed cell line human CVCL_8C51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115384 CVCL_RQ10 CHO-K1 (+Gqi5) AequoScreen S1P5 spontaneously immortalized cell line CVCL_RQ10 CL:0000010 Transfected with: HGNC; 14299; S1PR5; Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21115385 CVCL_S210 FC9WF finite cell line CVCL_S210 CL:0000010 Derived from sampling site: Whole fetus. Discontinued: ATCC; CRL-6087; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115386 CVCL_RQ12 CHO-K1 AequoScreen FFAR1 spontaneously immortalized cell line CVCL_RQ12 CL:0000010 Transfected with: HGNC; 4498; FFAR1; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21115387 CVCL_S212 FC6.Thm finite cell line CVCL_S212 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6085; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115388 CVCL_RQ11 CHO-K1 (+Galpha16) AequoScreen HTR2C (ne) spontaneously immortalized cell line CVCL_RQ11 CL:0000010 Transfected with: HGNC; 5295; HTR2C; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21115389 CVCL_S211 FC8 finite cell line CVCL_S211 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6086; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115390 CVCL_RQ14 BEC2 hybridoma house mouse CVCL_RQ14 CL:0000010 Characteristics: Was investigated under the name Mitumomab for the treatment of small cell lung carcinoma in combination with BCG vaccination; Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody R24. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10153 21115391 CVCL_S214 FC5.Thy finite cell line CVCL_S214 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6080; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115392 CVCL_RQ13 9EG7 hybridoma CVCL_RQ13 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P09055; Mouse Itgb1/Cd29. 21115393 CVCL_S213 FC6.Sp finite cell line CVCL_S213 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6083; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115394 CVCL_S216 FC5.Bm finite cell line CVCL_S216 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6077; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115395 CVCL_RQ16 ValiScreen human CHRM1 spontaneously immortalized cell line CVCL_RQ16 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115396 CVCL_RQ15 BEC3 hybridoma house mouse CVCL_RQ15 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody R24. 21115397 CVCL_S215 FC5.Sp finite cell line CVCL_S215 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6079; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115398 CVCL_S218 FC72C.Br finite cell line CVCL_S218 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-6148; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115399 CVCL_RQ18 ValiScreen human CHRM3 spontaneously immortalized cell line CVCL_RQ18 CL:0000010 Transfected with: HGNC; 1952; CHRM3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115400 CVCL_S217 FC3.Thy finite cell line CVCL_S217 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6075; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115401 CVCL_RQ17 ValiScreen human CHRM2 spontaneously immortalized cell line CVCL_RQ17 CL:0000010 Transfected with: HGNC; 1951; CHRM2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115402 CVCL_S219 FC72D.Br finite cell line CVCL_S219 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-6149; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115403 CVCL_RQ19 ValiScreen human CHRM4 spontaneously immortalized cell line CVCL_RQ19 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115404 CVCL_J877 38-1 hybridoma house mouse CVCL_J877 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Coxsackievirus B4. 21115405 CVCL_IW77 C30ABR transformed cell line human CVCL_IW77 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115406 CVCL_J876 9-4 hybridoma house mouse CVCL_J876 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Coxsackievirus B4. 21115407 CVCL_IW76 C28ABR transformed cell line human CVCL_IW76 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115408 CVCL_J879 3C6 [Mouse hybridoma against human CD40] hybridoma house mouse CVCL_J879 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11340 21115409 CVCL_IW79 C35ABR transformed cell line human CVCL_IW79 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115410 CVCL_J878 5D12 [Mouse hybridoma against human CD40] hybridoma house mouse CVCL_J878 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11339 21115411 CVCL_IW78 C31ABR transformed cell line human CVCL_IW78 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115412 CVCL_J873 337-3 hybridoma house mouse CVCL_J873 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Coxsackievirus B4. 21115413 CVCL_IW73 AT27RMO transformed cell line human CVCL_IW73 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Homozygous (PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21115414 CVCL_J872 302-1 hybridoma house mouse CVCL_J872 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Coxsackievirus B4. 21115415 CVCL_IW72 AT9ABR transformed cell line human CVCL_IW72 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115416 CVCL_J875 86-3 hybridoma house mouse CVCL_J875 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Coxsackievirus B4. 21115417 CVCL_IW75 C2ABR transformed cell line human CVCL_IW75 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115418 CVCL_J874 59-3 hybridoma house mouse CVCL_J874 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Coxsackievirus B4. 21115419 CVCL_IW74 AT79LA transformed cell line human CVCL_IW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115420 CVCL_J871 288-3 hybridoma house mouse CVCL_J871 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Coxsackievirus B4. 21115421 CVCL_IW71 AT8ABR transformed cell line human CVCL_IW71 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115422 CVCL_J870 287-3 hybridoma house mouse CVCL_J870 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Coxsackievirus B4. 21115423 CVCL_IW70 AT6ABR transformed cell line human CVCL_IW70 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Cys2824Tyr (c.8471G>A); ClinVar=VCV000234209; Zygosity=Heterozygous (PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115424 CVCL_RQ01 CU-ACC2 cancer cell line human CVCL_RQ01 CL:0000010 Sequence variation: Mutation; HGNC; 7325; MSH2; Unexplicit; Ex1-6del; Zygosity=Unspecified (PubMed=29371329); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=29371329) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29 hours, at 10th passage (PubMed=29371329) 21115425 CVCL_S201 FC72A.Br finite cell line CVCL_S201 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-6146; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115426 CVCL_RQ00 CU-ACC1 cancer cell line human CVCL_RQ00 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Arg (c.100G>A); ClinVar=VCV000376232; Zygosity=Unspecified (PubMed=29371329) Derived from metastatic site: Perinephric space. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours, at 10th passage (PubMed=29371329) 21115427 CVCL_S200 FC65.T cancer cell line CVCL_S200 CL:0000010 Discontinued: ATCC; CRL-6084; true; Discontinued: ATCC; CRL-6100; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115428 CVCL_RQ03 C2C12-R486Q-Bmpr1b spontaneously immortalized cell line house mouse CVCL_RQ03 CL:0000010 Transfected with: HGNC; 1077; BMPR1B (with p.Arg486Gln) Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21115429 CVCL_S203 FC60(A).Cvx finite cell line CVCL_S203 CL:0000010 Derived from sampling site: Fetal uterus; cervix Cell type=Fibroblast.. Discontinued: ATCC; CRL-6097; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115430 CVCL_RQ02 C2C12-Bmpr1b spontaneously immortalized cell line house mouse CVCL_RQ02 CL:0000010 Transfected with: HGNC; 1077; BMPR1B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21115431 CVCL_S202 FC72B.Br finite cell line CVCL_S202 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-6147; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115432 CVCL_RQ05 DLD-1 PIK3CA E545K KO cancer cell line human CVCL_RQ05 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 8975; . Male Characteristics: Knockout of PIK3CA mutant allele (E545K) in heterozygous parental cells 21115433 CVCL_S205 OHH1.Sp finite cell line CVCL_S205 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6196; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115434 CVCL_RQ04 C2C12-R486W-Bmpr1b spontaneously immortalized cell line house mouse CVCL_RQ04 CL:0000010 Transfected with: HGNC; 1077; BMPR1B (with p.Arg486Trp) Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21115435 CVCL_S204 FC55.Sp finite cell line CVCL_S204 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6096; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115436 CVCL_S207 FC42.Bm finite cell line CVCL_S207 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6092; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115437 CVCL_RQ07 ValiScreen human CXCR3 spontaneously immortalized cell line CVCL_RQ07 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Discontinued: PerkinElmer; ES-142-C; true Female 21115438 CVCL_S206 FC43 finite cell line CVCL_S206 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6093; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115439 CVCL_RQ06 HCT 116 PIK3CA H1047R KO cancer cell line human CVCL_RQ06 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 8975; ; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Knockout of PIK3CA mutant allele (H1047R) in heterozygous parental cells 21115440 CVCL_S209 FC11th cancer cell line CVCL_S209 CL:0000010 Discontinued: ATCC; CRL-6089; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115441 CVCL_RQ09 ValiScreen human CCR2b spontaneously immortalized cell line CVCL_RQ09 CL:0000010 Transfected with: HGNC; 1603; CCR2 (isoform B); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Discontinued: PerkinElmer; ES-133-C; true Female 21115442 CVCL_S208 FC26 finite cell line CVCL_S208 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6091; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115443 CVCL_RQ08 ValiScreen human CCR1 spontaneously immortalized cell line CVCL_RQ08 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115444 CVCL_J888 50-11-10 hybridoma house mouse CVCL_J888 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06127; Human CD5. 21115445 CVCL_IW88 U1I spontaneously immortalized cell line human CVCL_IW88 CL:0000010 Derived from sampling site: Eye; uvea Cell type=Melanocyte.. Male Doubling time: 27.2 hours (PubMed=6773878) 21115446 CVCL_J887 4SB3 hybridoma house mouse CVCL_J887 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. 21115447 CVCL_IW87 ARM-X cancer cell line human CVCL_IW87 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=23372829) Derived from sampling site: Breast. Female 21115448 CVCL_J889 CT6-1D7 hybridoma house mouse CVCL_J889 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21115449 CVCL_IW89 MMB-1 spontaneously immortalized cell line house mouse CVCL_IW89 CL:0000010 Derived from sampling site: Bone; cranium Cell type=Osteoblast.. Unspecified Characteristics: Osteoblast-like cell line 21115450 CVCL_J884 50 AZA SEL hybrid cell line CVCL_J884 CL:0000010 Group: Hybridoma fusion partner cell line. 21115451 CVCL_IW84 ARM-E cancer cell line human CVCL_IW84 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=23372829) Derived from sampling site: Breast. Female 21115452 CVCL_IW83 ARM-C cancer cell line human CVCL_IW83 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=23372829) Derived from sampling site: Breast. Female 21115453 CVCL_J883 GA4 hybrid cell line CVCL_J883 CL:0000010 21115454 CVCL_J886 4.6.5a114K hybridoma house mouse CVCL_J886 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Dog 144 kdA protein on MDCK cell line apical and basolateral surface. 21115455 CVCL_IW86 ARM-H cancer cell line human CVCL_IW86 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=23372829) Derived from sampling site: Breast. Female 21115456 CVCL_IW85 ARM-G cancer cell line human CVCL_IW85 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=23372829) Derived from sampling site: Breast. Female 21115457 CVCL_J885 E-8 hybridoma house mouse CVCL_J885 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Ictalurus punctatus Ig heavy chain. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10179 21115458 CVCL_J880 3A8 [Mouse hybridoma against human CD40] hybridoma house mouse CVCL_J880 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12024; Registration: Chiron Master Culture Collection; CMCC 11066 (CMCC #11066) 21115459 CVCL_IW80 C12ABR transformed cell line human CVCL_IW80 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115460 CVCL_J882 3B18 hybridoma house mouse CVCL_J882 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8654 21115461 CVCL_IW82 RTgill-W1-pf spontaneously immortalized cell line CVCL_IW82 CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Unspecified Characteristics: Developed to allow study of nanoparticle-cell interactions for extended time period Doubling time: 6 days (PubMed=27030289) Group: Fish cell line; Group: Serum/protein free medium cell line 21115462 CVCL_J881 3A5 [Mouse hybridoma against human HFE] hybridoma house mouse CVCL_J881 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21115463 CVCL_IW81 C17ABR transformed cell line human CVCL_IW81 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115464 CVCL_IW59 BMC2.3 transformed cell line house mouse CVCL_IW59 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 21115465 CVCL_J859 TFS-4 hybridoma house mouse CVCL_J859 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human small cell carcinoma of lung cell lines surface antigen. 21115466 CVCL_IW58 BMA3.1A7 transformed cell line house mouse CVCL_IW58 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Female 21115467 CVCL_J858 TFS-2 hybridoma house mouse CVCL_J858 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human small cell carcinoma of lung cell lines surface antigen. 21115468 CVCL_J855 KKB transformed cell line house mouse CVCL_J855 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2k. Unspecified 21115469 CVCL_IW55 U-47703 BL cancer cell line human CVCL_IW55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21115470 CVCL_J854 FM3A Had-1 cancer cell line house mouse CVCL_J854 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Deficient in UDP-galactose transport into Golgi vesicles (PubMed=2808320); Virology: Not susceptible to infection by Newcastle disease virus (NDV) and Sendai virus (PubMed=2535724) 21115471 CVCL_IW54 JBL-6 cancer cell line human CVCL_IW54 CL:0000010 Population: Japanese Male Virology: EBV-negative. 21115472 CVCL_IW57 BMA3.1A transformed cell line house mouse CVCL_IW57 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Female 21115473 CVCL_J857 KKF transformed cell line house mouse CVCL_J857 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=Thymocyte; Breed/subspecies: BALB.K. 21115474 CVCL_J856 KKC transformed cell line house mouse CVCL_J856 CL:0000010 Transformant: Gross passage A murine leukemia virus (Gross-MuLV)(NCBI-Taxonomy; 11841); Derived from sampling site: Cell type=T-cell; Breed/subspecies: BALB/C H-2k. Unspecified 21115475 CVCL_IW56 OELE transformed cell line human CVCL_IW56 Genome ancestry: African=3.73%; Native American=0.23%; East Asian, North=0%; East Asian, South=1.63%; South Asian=4.96%; European, North=40.72%; European, South=48.72% (PubMed=30894373) CL:0000010 Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 48 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21115476 CVCL_IW51 JBL-3 cancer cell line human CVCL_IW51 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Virology: EBV-negative 21115477 CVCL_J851 NI G 386/3D1-16 hybridoma house mouse CVCL_J851 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09919; Human CSF1. 21115478 CVCL_IW50 HOSC1 cancer cell line human CVCL_IW50 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Part of: MD Anderson Cell Lines Project 21115479 CVCL_J850 NI G 386/3B6-12 hybridoma house mouse CVCL_J850 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09919; Human CSF1. 21115480 CVCL_IW53 JBL-4 cancer cell line human CVCL_IW53 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Virology: EBV-negative 21115481 CVCL_J853 NORIg 7.16.2 hybridoma house mouse CVCL_J853 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat IgG2b heavy chain. 21115482 CVCL_IW52 JBL-5 cancer cell line human CVCL_IW52 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Virology: EBV-negative 21115483 CVCL_J852 NI GM 465/7A6-37 hybridoma house mouse CVCL_J852 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. 21115484 CVCL_J869 286-1 hybridoma house mouse CVCL_J869 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Coxsackievirus B4. 21115485 CVCL_IW69 AT2ABR transformed cell line human CVCL_IW69 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Homozygous (PubMed=7792600; PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115486 CVCL_J866 208-2 hybridoma house mouse CVCL_J866 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Coxsackievirus B4. 21115487 CVCL_IW66 KSNY cancer cell line human CVCL_IW66 CL:0000010 Anecdotal: Cell line name corresponds to the first letters of the names of the first three and of the last authors Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Established from a patient-derived xenograft established subcutaneously in nude mice Doubling time: 46 hours (PubMed=317053) 21115488 CVCL_J865 204-3 hybridoma house mouse CVCL_J865 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Coxsackievirus B4. 21115489 CVCL_J868 225-1 hybridoma house mouse CVCL_J868 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Coxsackievirus B4. 21115490 CVCL_IW68 AT13ABR transformed cell line human CVCL_IW68 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21115491 CVCL_J867 215-2 hybridoma house mouse CVCL_J867 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Coxsackievirus B4. 21115492 CVCL_IW67 Maska-98 cancer cell line human CVCL_IW67 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Produces high level of lactate dehydrogenase (LDH) Doubling time: 36-48 hours (PubMed=11279638) 21115493 CVCL_J862 17-1 hybridoma house mouse CVCL_J862 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Coxsackievirus B4. 21115494 CVCL_IW62 PKE5 transformed cell line pig CVCL_IW62 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Characteristics: Devoid of sodium-proton antiporter activity 21115495 CVCL_J861 128-2 hybridoma house mouse CVCL_J861 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Coxsackievirus B4. 21115496 CVCL_IW61 PKE20 spontaneously immortalized cell line pig CVCL_IW61 CL:0000010 Selected for resistance to: ChEBI; CHEBI:136538; Ethylisopropylamiloride (EIPA); Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21115497 CVCL_J864 187-1 hybridoma house mouse CVCL_J864 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Coxsackievirus B4. 21115498 CVCL_IW64 SNU_MM1393_SC cancer cell line human CVCL_IW64 CL:0000010 Male Characteristics: IL6 independent Doubling time: ~48 hours (PubMed=25343143). 21115499 CVCL_J863 183-1 hybridoma house mouse CVCL_J863 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Coxsackievirus B4. 21115500 CVCL_IW63 SNU_MM1393_BM cancer cell line human CVCL_IW63 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: IL6 dependent Doubling time: ~48 hours (PubMed=25343143) 21115501 CVCL_J860 38.1 hybridoma house mouse CVCL_J860 CL:0000010 Monoclonal antibody isotype: IgM. 21115502 CVCL_IW60 AFF spontaneously immortalized cell line CVCL_IW60 CL:0000010 Derived from sampling site: Caudal fin Cell type=Epithelial cell.. Unspecified Characteristics: Capable of growing from 20 to 37 Celsius, the optimal temperature is 28 Celsius (PubMed=27458084) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC051 21115503 CVCL_J837 MA1-3 hybridoma house mouse CVCL_J837 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (Note=Also reacts with other species). 21115504 CVCL_IW37 SK-UT-2 cancer cell line human CVCL_IW37 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21115505 CVCL_J836 LR-3 hybridoma CVCL_J836 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24. 21115506 CVCL_IW36 LS060208 cancer cell line human CVCL_IW36 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Part of: MD Anderson Cell Lines Project 21115507 CVCL_IW39 BS149 cancer cell line human CVCL_IW39 From: University of Basel; Basel; Switzerland CL:0000010 Omics: Transcriptome analysis by microarray. 21115508 CVCL_J839 MA1-8 hybridoma house mouse CVCL_J839 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (Note=Also reacts with other species). 21115509 CVCL_IW38 BS125 cancer cell line human CVCL_IW38 From: University of Basel; Basel; Switzerland. CL:0000010 21115510 CVCL_J838 MA1-6 hybridoma house mouse CVCL_J838 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9I4Z4; Pseudomonas aeruginosa oprL (H2) (Note=Also reacts with other species). 21115511 CVCL_IW33 IARC-100 transformed cell line human CVCL_IW33 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans south of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115512 CVCL_J833 LM2/1.6.11 hybridoma house mouse CVCL_J833 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21115513 CVCL_IW32 JBL-1 cancer cell line human CVCL_IW32 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female Virology: EBV-negative Doubling time: 30 hours (PubMed=201360) 21115514 CVCL_J832 La1 hybridoma house mouse CVCL_J832 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P10881; Bovine SSB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8609 21115515 CVCL_J835 LP4.4 hybridoma house mouse CVCL_J835 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Human IgM lambda light chains. 21115516 CVCL_IW35 LS030609 cancer cell line human CVCL_IW35 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Part of: MD Anderson Cell Lines Project 21115517 CVCL_IW34 HeyA8-IP cancer cell line human CVCL_IW34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Caucasian Omics: Protein expression by reverse-phase protein arrays. Female Characteristics: Established from a passage from a mouse intra peritoneal injected tumor Part of: MD Anderson Cell Lines Project 21115518 CVCL_J834 LP3IIG2 hybridoma house mouse CVCL_J834 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8472 21115519 CVCL_IW31 CS77iSMA-n5 induced pluripotent stem cell human CVCL_IW31 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Eye; ocular lens Cell type=Fibroblast.. Omics: ATAC-seq; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21115520 CVCL_J831 IV.3 hybridoma house mouse CVCL_J831 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12318; Human FCGR2A/CD32. 21115521 CVCL_IW30 CS32iSMA-n3 induced pluripotent stem cell human CVCL_IW30 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (CSMC) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: ATAC-seq; Omics: Transcriptome analysis by RNAseq Male 21115522 CVCL_J830 DD-6 hybridoma house mouse CVCL_J830 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28119; 2,3,7,8-tetrachlorodibenzodioxine (TCDD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9745 21115523 CVCL_J848 NI 4 426/7A3-3 hybridoma house mouse CVCL_J848 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05112; Human IL4. 21115524 CVCL_IW48 SPAC-1-S cancer cell line human CVCL_IW48 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 66.5 hours (PubMed=8063244) Part of: MD Anderson Cell Lines Project 21115525 CVCL_J847 NI 4 426/1A6-10 hybridoma house mouse CVCL_J847 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05112; Human IL4. 21115526 CVCL_IW47 SPAC-1-L cancer cell line human CVCL_IW47 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 27.4 hours (PubMed=8063244) Part of: MD Anderson Cell Lines Project 21115527 CVCL_J849 NI 4 426/8B1-7 hybridoma house mouse CVCL_J849 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05112; Human IL4. 21115528 CVCL_IW49 ZR75T cancer cell line human CVCL_IW49 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21115529 CVCL_IW44 Hattori cancer cell line human CVCL_IW44 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21115530 CVCL_J844 MH94 hybridoma house mouse CVCL_J844 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8413 21115531 CVCL_J843 MF61 hybridoma house mouse CVCL_J843 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8410 21115532 CVCL_IW43 NEC8 cl-1 cancer cell line human CVCL_IW43 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male 21115533 CVCL_J846 NI 3 416/7B5-5 hybridoma house mouse CVCL_J846 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08700; Human IL3. 21115534 CVCL_IW46 TTC-475 cancer cell line human CVCL_IW46 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21115535 CVCL_IW45 KU-SENL-1 spontaneously immortalized cell line CVCL_IW45 CL:0000010 Unspecified Virology: Highly susceptible to infection by Autographa californica multiple nucleopolyhedrovirus (AcMNPV) (DOI=10.18178/joaat.3.4.231-238) Doubling time: 45 hours (DOI=10.18178/joaat.3.4.231-238). Group: Insect cell line 21115536 CVCL_J845 NI 3 416/6C6-6 hybridoma house mouse CVCL_J845 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08700; Human IL3. 21115537 CVCL_IW40 BS1KY finite cell line human CVCL_IW40 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21115538 CVCL_J840 ME195 hybridoma house mouse CVCL_J840 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8431 21115539 CVCL_IW42 ITO-II cl-5 cancer cell line human CVCL_IW42 CL:0000010 Population: Japanese. Male 21115540 CVCL_J842 ME46 hybridoma house mouse CVCL_J842 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8430 21115541 CVCL_IW41 M328 cancer cell line human CVCL_IW41 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21115542 CVCL_J841 MD144 hybridoma house mouse CVCL_J841 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8409 21115543 CVCL_J819 94-H48 hybrid cell line house mouse CVCL_J819 CL:0000010 21115544 CVCL_IW19 SaTM-1C cancer cell line human CVCL_IW19 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 26.7 hours (PubMed=19724886) 21115545 CVCL_J818 94-H4 hybrid cell line house mouse CVCL_J818 CL:0000010 21115546 CVCL_IW18 SaTM-1B cancer cell line human CVCL_IW18 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 24.7 hours (PubMed=19724886) 21115547 CVCL_J815 101A hybridoma house mouse CVCL_J815 CL:0000010 Monoclonal antibody isotype: IgG1. 21115548 CVCL_IW15 M7609/ADR cancer cell line human CVCL_IW15 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. 21115549 CVCL_J814 LS-136 hybridoma house mouse CVCL_J814 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse Ig lambda 1 light chains. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21115550 CVCL_IW14 M7609 cancer cell line human CVCL_IW14 CL:0000010 Population: Japanese. 21115551 CVCL_J817 S91 cancer cell line house mouse CVCL_J817 CL:0000010 Breed/subspecies: DBA. Discontinued: ATCC; CCL-53; true Male 21115552 CVCL_IW17 SaTM-1A cancer cell line human CVCL_IW17 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 23.2 hours (PubMed=19724886) 21115553 CVCL_J816 S91 6neo cancer cell line house mouse CVCL_J816 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: DBA. Male 21115554 CVCL_IW16 SaTM-1 cancer cell line human CVCL_IW16 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female 21115555 CVCL_J811 280A hybridoma house mouse CVCL_J811 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02712; Tetronarce californica chrnb1. 21115556 CVCL_IW11 Colo829/R cancer cell line human CVCL_IW11 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Glyfs*51 (c.203_204delCG); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.493_634del142; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720); Derived from sampling site: Skin. Male 21115557 CVCL_J810 274D hybridoma house mouse CVCL_J810 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02714; Tetronarce californica chrng. 21115558 CVCL_IW10 A375/R cancer cell line human CVCL_IW10 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720); Derived from sampling site: Skin. Female 21115559 CVCL_J813 4D12 [Mouse hybridoma against human B2M/HLA-B] hybridoma house mouse CVCL_J813 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61769; Human B2M; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes allele B*05). 21115560 CVCL_IW13 G361/R cancer cell line human CVCL_IW13 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720) Male 21115561 CVCL_J812 280B hybridoma house mouse CVCL_J812 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd. 21115562 CVCL_IW12 SKMEL5/R cancer cell line human CVCL_IW12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720); Derived from metastatic site: Axillary lymph node. Female 21115563 CVCL_IW29 CS25iCTR-18n2 induced pluripotent stem cell human CVCL_IW29 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: ATAC-seq; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21115564 CVCL_J829 DD-5 hybridoma house mouse CVCL_J829 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28119; 2,3,7,8-tetrachlorodibenzodioxine (TCDD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9744 21115565 CVCL_J826 DD-1 [Mouse hybridoma against TCDD] hybridoma house mouse CVCL_J826 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28119; 2,3,7,8-tetrachlorodibenzodioxine (TCDD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9741 21115566 CVCL_IW26 UMMT-ARK-1 cancer cell line human CVCL_IW26 CL:0000010 Population: African American; Derived from sampling site: Uterus. Female 21115567 CVCL_J825 DAL K45 hybridoma house mouse CVCL_J825 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human kidney carcinoma cell lines. 21115568 CVCL_IW25 S-7512 cancer cell line human CVCL_IW25 CL:0000010 Population: Japanese; Derived from metastatic site: Perineus; hypodermis. Female Doubling time: ~57 hours (PubMed=598646) 21115569 CVCL_IW28 CS83iCTR33-n1 induced pluripotent stem cell human CVCL_IW28 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Transcriptome analysis by RNAseq Female 21115570 CVCL_J828 DD-4 hybridoma house mouse CVCL_J828 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:28119; 2,3,7,8-tetrachlorodibenzodioxine (TCDD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9743 21115571 CVCL_J827 DD-3 hybridoma house mouse CVCL_J827 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:28119; 2,3,7,8-tetrachlorodibenzodioxine (TCDD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9742 21115572 CVCL_IW27 UMMT-ARK-2 cancer cell line human CVCL_IW27 CL:0000010 Population: Caucasian; Derived from sampling site: Uterus. Female 21115573 CVCL_J822 95-H3 hybrid cell line house mouse CVCL_J822 CL:0000010 21115574 CVCL_IW22 SaTM-1F cancer cell line human CVCL_IW22 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 24.1 hours (PubMed=19724886) 21115575 CVCL_J821 95-H12 hybrid cell line house mouse CVCL_J821 CL:0000010 21115576 CVCL_IW21 SaTM-1E cancer cell line human CVCL_IW21 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 23.6 hours (PubMed=19724886) 21115577 CVCL_J824 DAL K29 hybridoma house mouse CVCL_J824 CL:0000010 Monoclonal antibody isotype: IgG1. 21115578 CVCL_IW24 OMMT-ARK-2 cancer cell line human CVCL_IW24 CL:0000010 Population: Caucasian; Derived from metastatic site: Ovary. Female 21115579 CVCL_J823 DAL K20 hybridoma house mouse CVCL_J823 CL:0000010 Monoclonal antibody isotype: IgG1. 21115580 CVCL_IW23 OMMT-ARK-1 cancer cell line human CVCL_IW23 CL:0000010 Population: African American; Derived from metastatic site: Ovary. Female 21115581 CVCL_J820 95-H1 hybrid cell line house mouse CVCL_J820 CL:0000010 21115582 CVCL_IW20 SaTM-1D cancer cell line human CVCL_IW20 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Female Doubling time: 24.6 hours (PubMed=19724886) 21115583 CVCL_S298 Hs 151.Pan finite cell line human CVCL_S298 CL:0000010 Derived from sampling site: Fetal pancreas. Discontinued: ATCC; CRL-7832; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115584 CVCL_RQ98 MCF10A APC (-/-) spontaneously immortalized cell line human CVCL_RQ98 CL:0000010 Knockout cell: Method=ZFN; HGNC; 583; APC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115585 CVCL_S297 Hs 151.K finite cell line human CVCL_S297 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7831; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115586 CVCL_RQ97 MCF10A AKT2 (-/-) spontaneously immortalized cell line human CVCL_RQ97 CL:0000010 Knockout cell: Method=ZFN; HGNC; 392; AKT2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115587 CVCL_S299 Hs 183.T cancer cell line human CVCL_S299 CL:0000010 Derived from sampling site: Testis. Discontinued: ATCC; CRL-7835; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115588 CVCL_RQ99 MCF10A BCR (-/-) spontaneously immortalized cell line human CVCL_RQ99 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1014; BCR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115589 CVCL_S287 PK-2a spontaneously immortalized cell line pig CVCL_S287 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21115590 CVCL_RQ87 U2OS-S1P1 cancer cell line human CVCL_RQ87 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: Thermofisher/BioImage; Catalog number R04-039-01 Female Characteristics: Expresses S1PR1-EGFP under the control of the CMV promoter 21115591 CVCL_RQ86 HAP1 NUDT1(-) 1 cancer cell line human CVCL_RQ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8048; NUDT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21115592 CVCL_S286 MM40.Ut finite cell line house mouse CVCL_S286 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6415; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115593 CVCL_RQ89 A549 GFP-STAT1 cancer cell line human CVCL_RQ89 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Edited by ZFN at the STAT1 locus to insert a TagGFP2 construct at the C-terminus of the gene 21115594 CVCL_S289 Hs 484.T cancer cell line human CVCL_S289 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7816; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115595 CVCL_S288 Hs 474.T cancer cell line human CVCL_S288 CL:0000010 Discontinued: ATCC; CRL-7812; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115596 CVCL_RQ88 U2OS GFP-NUP98 cancer cell line human CVCL_RQ88 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the NUP98 locus to insert a 3xFLAG-TagGFP2 construct at the N-terminus of the gene 21115597 CVCL_S290 Hs 485.T cancer cell line human CVCL_S290 CL:0000010 Derived from sampling site: Oral cavity; tonsil. Discontinued: ATCC; CRL-7817; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115598 CVCL_RQ90 U2OS GFP-ACTB cancer cell line human CVCL_RQ90 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the ACTB locus to insert a TagGFP2 construct at the N-terminus of the gene 21115599 CVCL_S292 Hs 1.Li finite cell line human CVCL_S292 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7821; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115600 CVCL_RQ92 U2OS GFP-LMNB1 cancer cell line human CVCL_RQ92 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the LMNB1 locus to insert a TagGFP2 construct at the N-terminus of the gene 21115601 CVCL_S291 Hs 767.Bl finite cell line human CVCL_S291 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7819; true Male Doubling time: 4-5 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115602 CVCL_RQ91 U2OS GFP-HMGA1 cancer cell line human CVCL_RQ91 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the HMGA1 locus to insert a TagGFP2 construct at the C-terminus of the gene 21115603 CVCL_S294 Hs 42.T cancer cell line human CVCL_S294 CL:0000010 Discontinued: ATCC; CRL-7827; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115604 CVCL_RQ94 U2OS RFP-TUBA1B cancer cell line human CVCL_RQ94 CL:0000010 Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the TUBA1B locus to insert a TagRFP construct at the N-terminus of the gene 21115605 CVCL_S293 Hs 34.T cancer cell line human CVCL_S293 CL:0000010 Discontinued: ATCC; CRL-7825; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115606 CVCL_RQ93 U2OS GFP-TUBA1B cancer cell line human CVCL_RQ93 CL:0000010 Transfected with: UniProtKB; Q8WTC6; Aequorea macrodactyla GFP (with p.Lys3Gly, p.Thr9Ala, p.Ser65Cys, p.Phe99Gln, p.Met128Lys, p.Asn144Ser, p.Met153Arg, p.Lys162Glu, p.Val163Ala, p.Ile167Thr, p.Ala206Lys, p.Thr214Ala, p.Phe220Leu, p.Phe223Ser, p.Gly228Cys and Lys238Arg = TagGFP2) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the TUBA1B locus to insert a TagGFP2 construct at the N-terminus of the gene 21115607 CVCL_S296 Hs 140.T cancer cell line human CVCL_S296 CL:0000010 Discontinued: ATCC; CRL-7830; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115608 CVCL_RQ96 MCF10A RFP-TUBA1B spontaneously immortalized cell line human CVCL_RQ96 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Derived from sampling site: Breast; epithelium. Female Characteristics: Edited by ZFN at the TUBA1B locus to insert a TagRFP construct at the N-terminus of the gene 21115609 CVCL_S295 Hs 99.T cancer cell line human CVCL_S295 CL:0000010 Discontinued: ATCC; CRL-7829; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115610 CVCL_RQ95 U2OS RFP-ACTB cancer cell line human CVCL_RQ95 CL:0000010 Transfected with: UniProtKB; D0VX33; Entacmaea quadricolor FP480 (with p.Thr6Lys, p.Gln41Met, p.His67Ser, p.Gln134Lys, p.Ala142Pro, p.His143Ser, p.Met146Lys, p.Tyr148Lys, p.Ala158Val, p.Leu160Met, p.Tyr197Arg, p.Arg201Ile, p.Val211Trp and p.Cys222Ser = TagRFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Edited by ZFN at the ACTB locus to insert a TagRFP construct at the N-terminus of the gene 21115611 CVCL_RQ76 HEK 293/TLR7/NF-kB Luciferase Reporter transformed cell line human CVCL_RQ76 CL:0000010 Transfected with: HGNC; 15631; TLR7; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a construct containing TLR7 and Renilla luciferase reporter gene under the transcriptional control of the NF-kappaB response element 21115612 CVCL_S276 MM21.Ut finite cell line house mouse CVCL_S276 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6399; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115613 CVCL_RQ75 HEK 293/TLR5/NF-kB Luciferase Reporter transformed cell line human CVCL_RQ75 CL:0000010 Transfected with: HGNC; 11851; TLR5; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a construct containing TLR5 and Renilla luciferase reporter gene under the transcriptional control of the NF-kappaB response element 21115614 CVCL_S275 MM35.Ut finite cell line house mouse CVCL_S275 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6409; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115615 CVCL_RQ78 HEK 293/TLR9/NF-kB Luciferase Reporter transformed cell line human CVCL_RQ78 CL:0000010 Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a construct containing TLR9 and Renilla luciferase reporter gene under the transcriptional control of the NF-kappaB response element 21115616 CVCL_S278 MM19.Ov finite cell line house mouse CVCL_S278 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6397; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115617 CVCL_RQ77 HEK 293/TLR8/NF-kB Luciferase Reporter transformed cell line human CVCL_RQ77 CL:0000010 Transfected with: HGNC; 15632; TLR8; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a construct containing TLR8 and Renilla luciferase reporter gene under the transcriptional control of the NF-kappaB response element 21115618 CVCL_S277 MM19.Sp finite cell line house mouse CVCL_S277 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6398; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115619 CVCL_S279 MM19.Ht finite cell line house mouse CVCL_S279 CL:0000010 Derived from sampling site: Heart; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6395; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115620 CVCL_RQ79 PrecisION hNav1.3-CHO spontaneously immortalized cell line CVCL_RQ79 CL:0000010 Transfected with: HGNC; 10590; SCN3A Derived from sampling site: Ovary. Discontinued: Millipore; CYL3003; true Female 21115621 CVCL_S281 MM17.Sp/Thy finite cell line house mouse CVCL_S281 CL:0000010 Derived from sampling site: Spleen and thymus; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6393; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115622 CVCL_RQ81 PrecisION hNav1.1-HEK transformed cell line human CVCL_RQ81 CL:0000010 Transfected with: HGNC; 10585; SCN1A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3009; true Female 21115623 CVCL_S280 MM19.Ft finite cell line house mouse CVCL_S280 CL:0000010 Derived from sampling site: Fallopian tube; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6394; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115624 CVCL_RQ80 PrecisION hNav1.7-HEK transformed cell line human CVCL_RQ80 CL:0000010 Transfected with: HGNC; 10597; SCN9A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3011; true Female 21115625 CVCL_S283 MM16.Sp finite cell line house mouse CVCL_S283 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6391; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115626 CVCL_RQ83 PrecisION hHCN3-HEK transformed cell line human CVCL_RQ83 CL:0000010 Transfected with: HGNC; 19183; HCN3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3042; true Female 21115627 CVCL_S282 MM17.Br finite cell line house mouse CVCL_S282 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6392; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115628 CVCL_RQ82 PrecisION hHCN4-CHO spontaneously immortalized cell line CVCL_RQ82 CL:0000010 Transfected with: HGNC; 16882; HCN4 Derived from sampling site: Ovary. Discontinued: Millipore; CYL3012; true Female 21115629 CVCL_S285 MM15.Ov finite cell line house mouse CVCL_S285 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6387; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115630 CVCL_RQ85 PrecisION hHCN2-HEK transformed cell line human CVCL_RQ85 CL:0000010 Transfected with: HGNC; 4846; HCN2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3041; true Female 21115631 CVCL_S284 MM16.Mg finite cell line house mouse CVCL_S284 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6389; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115632 CVCL_RQ84 PrecisION hHCN1-HEK transformed cell line human CVCL_RQ84 CL:0000010 Transfected with: HGNC; 4845; HCN1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3040; true Female 21115633 CVCL_S265 CF5.Thy finite cell line dog CVCL_S265 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6204; true Mixed Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115634 CVCL_RQ65 UKF-NB-3rOXALI2000 cancer cell line human CVCL_RQ65 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115635 CVCL_S264 CF3.Sp finite cell line dog CVCL_S264 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6203; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115636 CVCL_RQ64 UKF-NB-3rMEL400 cancer cell line human CVCL_RQ64 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115637 CVCL_S267 CF7.Ln finite cell line dog CVCL_S267 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6206; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115638 CVCL_RQ67 UKF-NB-3rTOPO15 cancer cell line human CVCL_RQ67 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115639 CVCL_S266 CF7.Bm finite cell line dog CVCL_S266 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6205; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115640 CVCL_RQ66 UKF-NB-3rPCL20 cancer cell line human CVCL_RQ66 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115641 CVCL_S269 CF8.Sp finite cell line dog CVCL_S269 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6210; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115642 CVCL_RQ69 PrecisION hCav1.2 alpha1C/beta2a/alpha2-delta1-HEK transformed cell line human CVCL_RQ69 CL:0000010 Transfected with: HGNC; 1390; CACNA1C; Transfected with: HGNC; 1400; CACNA2D2; Transfected with: HGNC; 1402; CACNB2 (isoform 2a) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3051; true Female 21115643 CVCL_S268 CF8.Ln finite cell line dog CVCL_S268 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6208; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115644 CVCL_RQ68 UKF-NB-3rVINOR20 cancer cell line human CVCL_RQ68 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115645 CVCL_RQ70 BHK-21A spontaneously immortalized cell line CVCL_RQ70 CL:0000010 Derived from sampling site: Kidney. Male 21115646 CVCL_S270 CF8.Lu finite cell line dog CVCL_S270 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6577; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115647 CVCL_RQ72 BHK-21A EPO40 spontaneously immortalized cell line CVCL_RQ72 CL:0000010 Transfected with: HGNC; 3415; EPO Derived from sampling site: Kidney. Male 21115648 CVCL_S272 MM30.Ut finite cell line house mouse CVCL_S272 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6404; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115649 CVCL_RQ71 BHK-21B spontaneously immortalized cell line CVCL_RQ71 CL:0000010 Derived from sampling site: Kidney. Male 21115650 CVCL_S271 PT1.K finite cell line CVCL_S271 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6310; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115651 CVCL_RQ74 HEK 293/TLR3/NF-kB Luciferase Reporter transformed cell line human CVCL_RQ74 CL:0000010 Transfected with: HGNC; 11849; TLR3; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a construct containing TLR3 and Renilla luciferase reporter gene under the transcriptional control of the NF-kappaB response element 21115652 CVCL_S274 MM33.Ut finite cell line house mouse CVCL_S274 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6407; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115653 CVCL_RQ73 BHK-21A EPO40-ST6NI spontaneously immortalized cell line CVCL_RQ73 CL:0000010 Transfected with: HGNC; 3415; EPO; Transfected with: HGNC; 10860; ST6GAL1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male 21115654 CVCL_S273 MM32.Ut finite cell line house mouse CVCL_S273 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6406; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115655 CVCL_S254 HT-755.Mg finite cell line human CVCL_S254 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7785; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115656 CVCL_RQ54 MelHOrDACARB20 cancer cell line human CVCL_RQ54 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21115657 CVCL_S253 Hs 578.Mg finite cell line human CVCL_S253 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7848; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115658 CVCL_RQ53 MelHOrCDDP1000 cancer cell line human CVCL_RQ53 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21115659 CVCL_S256 CEM/DNR cancer cell line human CVCL_S256 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21115660 CVCL_RQ56 UKF-Rhb-1rDOX10 cancer cell line human CVCL_RQ56 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115661 CVCL_S255 HT-800.T undefined cell line type human CVCL_S255 CL:0000010 Discontinued: ATCC; CRL-7791; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115662 CVCL_RQ55 MelHOrPLX4032_10muM cancer cell line human CVCL_RQ55 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21115663 CVCL_S258 TO 184.T cancer cell line human CVCL_S258 CL:0000010 Discontinued: ATCC; CRL-7953; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115664 CVCL_RQ58 UKF-Rhb-1rIRINO200 cancer cell line human CVCL_RQ58 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115665 CVCL_S257 TO 183.T cancer cell line human CVCL_S257 CL:0000010 Discontinued: ATCC; CRL-7952; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115666 CVCL_RQ57 UKF-Rhb-1rGEMCI10 cancer cell line human CVCL_RQ57 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115667 CVCL_S259 TE 596.T cancer cell line human CVCL_S259 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7950; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115668 CVCL_RQ59 UKF-Rhb-1rMEL400 cancer cell line human CVCL_RQ59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115669 CVCL_S261 TE 189.T cancer cell line human CVCL_S261 CL:0000010 Discontinued: ATCC; CRL-7947; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115670 CVCL_RQ61 UKF-NB-3rDACARB8 cancer cell line human CVCL_RQ61 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115671 CVCL_S260 TE 585.T cancer cell line human CVCL_S260 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7949; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115672 CVCL_RQ60 UKF-Rhb-1rOXALI1000 cancer cell line human CVCL_RQ60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115673 CVCL_S263 CF3.Ln finite cell line dog CVCL_S263 CL:0000010 Derived from sampling site: Mesenteric lymph node; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6202; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115674 CVCL_RQ63 UKF-NB-3rIRINO800 cancer cell line human CVCL_RQ63 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115675 CVCL_S262 TE 138.T cancer cell line human CVCL_S262 CL:0000010 Discontinued: ATCC; CRL-7946; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115676 CVCL_RQ62 UKF-NB-3rGEMCI10 cancer cell line human CVCL_RQ62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115677 CVCL_S243 CF10.Int finite cell line dog CVCL_S243 CL:0000010 Derived from sampling site: Fetal intestine; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6214; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115678 CVCL_RQ43 SU1 cancer cell line human CVCL_RQ43 CL:0000010 Population: Chinese; Derived from sampling site: Brain; right temporal lobe. Omics: Array-based CGH Female Group: Cancer stem cell line 21115679 CVCL_S242 CF10.Res finite cell line dog CVCL_S242 CL:0000010 Derived from sampling site: Fetal bronchus and fetal lung; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6215; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115680 CVCL_RQ42 Tni PRO spontaneously immortalized cell line CVCL_RQ42 CL:0000010 Derived from sampling site: Ovary. Discontinued: Expression Systems; Catalog number 94-004F/94-004S Female Virology: Infected with alphanodavirus TnCLV (PubMed=29133148) Group: Insect cell line; Group: Recombinant protein production insect cell line 21115681 CVCL_S245 CF10.Br finite cell line dog CVCL_S245 CL:0000010 Derived from sampling site: Fetal brain; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6212; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115682 CVCL_RQ45 SU3 cancer cell line human CVCL_RQ45 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male Group: Cancer stem cell line 21115683 CVCL_S244 CF10.Ht finite cell line dog CVCL_S244 CL:0000010 Derived from sampling site: Fetal heart; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6213; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115684 CVCL_RQ44 SU2 cancer cell line human CVCL_RQ44 CL:0000010 Population: Chinese; Derived from sampling site: Brain; right temporal lobe. Omics: Array-based CGH Female Group: Cancer stem cell line 21115685 CVCL_RQ47 A549rCDDP2000 cancer cell line human CVCL_RQ47 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115686 CVCL_S247 B/CMBA.Sp finite cell line house mouse CVCL_S247 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6332; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115687 CVCL_S246 Hs 444(A).T cancer cell line human CVCL_S246 CL:0000010 Discontinued: ATCC; CRL-7799; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115688 CVCL_RQ46 SU3-ihDCTC transformed cell line house mouse CVCL_RQ46 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: Transgenic EGFP. Characteristics: Dendritic cells transformed by co-cultivation with SU3 (Cellosaurus=CVCL_RQ45) glioma stem cells 21115689 CVCL_S249 Hs 574.Mg finite cell line human CVCL_S249 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7847; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115690 CVCL_RQ49 UKF-Rhb-1rDOCE10 cancer cell line human CVCL_RQ49 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115691 CVCL_S248 DBA B.Sp finite cell line house mouse CVCL_S248 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2J. Discontinued: ATCC; CRL-6341; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115692 CVCL_RQ48 UKF-Rhb-1rCDDP1000 cancer cell line human CVCL_RQ48 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21115693 CVCL_RQ50 COLO-679rVCR20 cancer cell line human CVCL_RQ50 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR) Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115694 CVCL_S250 V79/M12G spontaneously immortalized cell line CVCL_S250 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21115695 CVCL_S252 Hs 455.T cancer cell line human CVCL_S252 CL:0000010 Discontinued: ATCC; CRL-7803; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115696 CVCL_RQ52 MelHOrVCR20 cancer cell line human CVCL_RQ52 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21115697 CVCL_S251 Hs 444(B).T cancer cell line human CVCL_S251 CL:0000010 Discontinued: ATCC; CRL-7800; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115698 CVCL_RQ51 MelHOrNutlin20muM cancer cell line human CVCL_RQ51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=22170099) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21115699 CVCL_S232 RFGd8WE finite cell line CVCL_S232 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6188; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115700 CVCL_RQ32 TCG 580 transformed cell line human CVCL_RQ32 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). 21115701 CVCL_RQ31 CA130.14H2.1A5 hybridoma house mouse CVCL_RQ31 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: N-linked carbohydrate epitope (LUCA2) found on a variety of human cells and proteins Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5068 21115702 CVCL_S231 RFGd7WE finite cell line CVCL_S231 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6187; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115703 CVCL_RQ34 CADO-LC19 cancer cell line human CVCL_RQ34 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 101 hours (PubMed=7934063) 21115704 CVCL_S234 CF2.Sk finite cell line dog CVCL_S234 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6198; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115705 CVCL_RQ33 CADO-LC16 cancer cell line human CVCL_RQ33 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 46 hours (PubMed=7934063) 21115706 CVCL_S233 RFGd9WE finite cell line CVCL_S233 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6189; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115707 CVCL_RQ36 CADO-LC27 cancer cell line human CVCL_RQ36 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 199 hours (PubMed=7934063) 21115708 CVCL_S236 CF29.Mg cancer cell line dog CVCL_S236 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6224; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115709 CVCL_RQ35 CADO-LC2 cancer cell line human CVCL_RQ35 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 53 hours (PubMed=7934063) 21115710 CVCL_S235 CF27 finite cell line dog CVCL_S235 CL:0000010 Discontinued: ATCC; CRL-6222; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115711 CVCL_RQ38 CADO-LC29 cancer cell line human CVCL_RQ38 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 73 hours (PubMed=7934063) 21115712 CVCL_S238 CF2.Sp finite cell line dog CVCL_S238 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6200; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115713 CVCL_RQ37 CADO-LC28 cancer cell line human CVCL_RQ37 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 94 hours (PubMed=7934063) 21115714 CVCL_S237 CF2.Ln finite cell line dog CVCL_S237 CL:0000010 Derived from sampling site: Mesenteric lymph node; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6199; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115715 CVCL_RQ39 CADO-LC4 cancer cell line human CVCL_RQ39 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Unspecified Doubling time: 41 hours (PubMed=7934063) 21115716 CVCL_S239 CF3.Sk finite cell line dog CVCL_S239 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6201; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115717 CVCL_J899 EN9F10 hybridoma house mouse CVCL_J899 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:4822; Ergometrine (Ergonovine). 21115718 CVCL_IW99 MM-F1 cancer cell line human CVCL_IW99 CL:0000010 21115719 CVCL_J898 EL-NC-1S hybridoma house mouse CVCL_J898 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10145; Human IL8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9647 21115720 CVCL_IW98 MM-B1 cancer cell line human CVCL_IW98 CL:0000010 21115721 CVCL_J895 E6(2)2 hybridoma house mouse CVCL_J895 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:27306; Vitamin B6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8172 21115722 CVCL_IW95 Meso-CL2 cancer cell line human CVCL_IW95 CL:0000010 Group: Cancer stem cell line. 21115723 CVCL_J894 E5BB3IIA2 hybridoma house mouse CVCL_J894 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human IgE. 21115724 CVCL_IW94 Meso-CL1 cancer cell line human CVCL_IW94 CL:0000010 Group: Cancer stem cell line. 21115725 CVCL_J897 EH7a hybridoma house mouse CVCL_J897 CL:0000010 Monoclonal antibody isotype: IgG1. 21115726 CVCL_IW97 HM [Human mesothelioma] cancer cell line human CVCL_IW97 CL:0000010 21115727 CVCL_J896 EH17a hybridoma house mouse CVCL_J896 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04083; Human ANXA1. 21115728 CVCL_IW96 Meso-CL3 cancer cell line human CVCL_IW96 CL:0000010 Group: Cancer stem cell line. 21115729 CVCL_IW91 #40a cancer cell line house mouse CVCL_IW91 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from metastatic site: Peritoneum; Breed/subspecies: C57BL/6. Male Characteristics: Established from parent cell line after two passages in the peritoneal cavity of C57BL/6 mice (PubMed=28159921) 21115730 CVCL_J891 D3-2H2-9-21 hybridoma house mouse CVCL_J891 CL:0000010 Monoclonal antibody isotype: IgG2a. 21115731 CVCL_IW90 40 cancer cell line house mouse CVCL_IW90 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from metastatic site: Peritoneum; Breed/subspecies: C57BL/6. Male 21115732 CVCL_J890 D1-4G2-4-15 hybridoma house mouse CVCL_J890 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P12823; Dengue virus type 2 envelope protein E. 21115733 CVCL_J893 delta TA4-1 hybridoma house mouse CVCL_J893 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Human IgD. 21115734 CVCL_IW93 HBG BC2 cancer cell line human CVCL_IW93 CL:0000010 Karyotypic information: Has lost chromosome Y. Male Characteristics: Possesses the capacity of being reversibly differentiated in vitro and of maintaining a relatively higher metabolic rate when in the differentiated state (3 weeks) May be used for repeated toxicity testing on cells in culture. 21115735 CVCL_J892 DA4-4 hybridoma house mouse CVCL_J892 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01871; Human immunoglobulin heavy chain mu. 21115736 CVCL_IW92 HBG cancer cell line human CVCL_IW92 CL:0000010 Male 21115737 CVCL_S241 CF10.Sm finite cell line dog CVCL_S241 CL:0000010 Derived from sampling site: Fetal muscle and skin; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6216; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115738 CVCL_RQ41 SL221 spontaneously immortalized cell line CVCL_RQ41 CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Group: Insect cell line 21115739 CVCL_S240 CF15.T cancer cell line dog CVCL_S240 CL:0000010 Discontinued: ATCC; CRL-6218; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115740 CVCL_RQ40 CX-03 cancer cell line human CVCL_RQ40 CL:0000010 Population: Caucasian; Derived from sampling site: Uterus. Female Characteristics: Established after xenotransplantation in SCID-mice of primary tumor cells Doubling time: 48-72 hours (PubMed=30411161); ~4-7 days (DSMZ=ACC-816) 21115741 CVCL_RQ21 CHO-K1 (+Galpha16) AequoScreen CX3CR1 spontaneously immortalized cell line CVCL_RQ21 CL:0000010 Transfected with: HGNC; 2558; CX3CR1; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21115742 CVCL_S221 FC114A.Int finite cell line CVCL_S221 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-6159; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115743 CVCL_S220 FC103.En finite cell line CVCL_S220 CL:0000010 Derived from sampling site: Uterus. Discontinued: ATCC; CRL-6151; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115744 CVCL_RQ20 ValiScreen human CHRM5 spontaneously immortalized cell line CVCL_RQ20 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115745 CVCL_RQ23 EcR-293-MEN1 transformed cell line human CVCL_RQ23 CL:0000010 Transfected with: HGNC; 7010; MEN1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21115746 CVCL_S223 FC114B.Int finite cell line CVCL_S223 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-6161; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115747 CVCL_S222 FC114A.Tr finite cell line CVCL_S222 CL:0000010 Derived from sampling site: Fetal trachea Cell type=Fibroblast.. Discontinued: ATCC; CRL-6160; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115748 CVCL_RQ22 PathHunter U2OS CXCR5 beta-arrestin cancer cell line human CVCL_RQ22 CL:0000010 Transfected with: HGNC; 1060; CXCR5; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: DiscoverX; 93-0204C3; true Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21115749 CVCL_S225 FC114C.Tr finite cell line CVCL_S225 CL:0000010 Derived from sampling site: Fetal trachea Cell type=Fibroblast.. Discontinued: ATCC; CRL-6163; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115750 CVCL_RQ25 Sua5B wAlbB+ spontaneously immortalized cell line CVCL_RQ25 CL:0000010 Breed/subspecies: Suakoko 2La. Unspecified Characteristics: Infected by Wolbachia pipientis strain wAlbB Group: Insect cell line 21115751 CVCL_S224 FC114C.Int finite cell line CVCL_S224 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-6162; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115752 CVCL_RQ24 Sua5B spontaneously immortalized cell line CVCL_RQ24 CL:0000010 Breed/subspecies: Suakoko 2La. Unspecified Group: Insect cell line 21115753 CVCL_S227 FC114D.Tr finite cell line CVCL_S227 CL:0000010 Derived from sampling site: Fetal trachea Cell type=Fibroblast.. Discontinued: ATCC; CRL-6165; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115754 CVCL_RQ27 VMRC-LCR cancer cell line human CVCL_RQ27 From: Bean M.A.; Virginia Mason Research Center; Seattle; USA. CL:0000010 Unspecified 21115755 CVCL_S226 FC114D.Int finite cell line CVCL_S226 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-6164; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115756 CVCL_RQ26 Sua5B wMel+ spontaneously immortalized cell line CVCL_RQ26 CL:0000010 Breed/subspecies: Suakoko 2La. Unspecified Characteristics: Infected by Wolbachia pipientis strain wMel Group: Insect cell line 21115757 CVCL_S229 CF7.Thy finite cell line dog CVCL_S229 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6207; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115758 CVCL_RQ29 LuCa3 hybridoma house mouse CVCL_RQ29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 230/240 kDa protein on lung squamous cell carcinoma. 21115759 CVCL_S228 FC114E.Int finite cell line CVCL_S228 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-6166; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115760 CVCL_RQ28 LuCa2 hybridoma house mouse CVCL_RQ28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 135 kDa protein on lung squamous cell carcinoma. 21115761 CVCL_RQ30 LuCa4 hybridoma house mouse CVCL_RQ30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 150 kDa protein on lung squamous cell carcinoma. 21115762 CVCL_S230 RFGd6WE finite cell line CVCL_S230 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6186; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115763 CVCL_8D49 DA04875 transformed cell line human CVCL_8D49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115764 CVCL_8D46 DA04871 transformed cell line human CVCL_8D46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115765 CVCL_8D45 DA04870 transformed cell line human CVCL_8D45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115766 CVCL_8D48 DA04873 transformed cell line human CVCL_8D48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115767 CVCL_8D47 DA04872 transformed cell line human CVCL_8D47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115768 CVCL_8D42 DA04867 transformed cell line human CVCL_8D42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115769 CVCL_8D41 DA04866 transformed cell line human CVCL_8D41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115770 CVCL_8D44 DA04869 transformed cell line human CVCL_8D44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115771 CVCL_8D43 DA04868 transformed cell line human CVCL_8D43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115772 CVCL_8D40 DA04865 transformed cell line human CVCL_8D40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115773 CVCL_8D57 DA04883 transformed cell line human CVCL_8D57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115774 CVCL_8D56 DA04882 transformed cell line human CVCL_8D56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115775 CVCL_8D59 DA04885 transformed cell line human CVCL_8D59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115776 CVCL_8D58 DA04884 transformed cell line human CVCL_8D58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115777 CVCL_8D53 DA04879 transformed cell line human CVCL_8D53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115778 CVCL_8D52 DA04878 transformed cell line human CVCL_8D52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115779 CVCL_8D55 DA04881 transformed cell line human CVCL_8D55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115780 CVCL_8D54 DA04880 transformed cell line human CVCL_8D54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115781 CVCL_8D51 DA04877 transformed cell line human CVCL_8D51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115782 CVCL_8D50 DA04876 transformed cell line human CVCL_8D50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115783 CVCL_8D28 DA04851 transformed cell line human CVCL_8D28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115784 CVCL_8D27 DA04850 transformed cell line human CVCL_8D27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115785 CVCL_8D29 DA04852 transformed cell line human CVCL_8D29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115786 CVCL_8D24 DA04847 transformed cell line human CVCL_8D24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115787 CVCL_8D23 DA04846 transformed cell line human CVCL_8D23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115788 CVCL_8D26 DA04849 transformed cell line human CVCL_8D26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115789 CVCL_8D25 DA04848 transformed cell line human CVCL_8D25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115790 CVCL_8D20 DA04843 transformed cell line human CVCL_8D20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115791 CVCL_8D22 DA04845 transformed cell line human CVCL_8D22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115792 CVCL_8D21 DA04844 transformed cell line human CVCL_8D21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115793 CVCL_8D39 DA04864 transformed cell line human CVCL_8D39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115794 CVCL_8D38 DA04862 transformed cell line human CVCL_8D38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115795 CVCL_8D35 DA04859 transformed cell line human CVCL_8D35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115796 CVCL_8D34 DA04858 transformed cell line human CVCL_8D34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115797 CVCL_8D37 DA04861 transformed cell line human CVCL_8D37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115798 CVCL_8D36 DA04860 transformed cell line human CVCL_8D36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115799 CVCL_8D31 DA04855 transformed cell line human CVCL_8D31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115800 CVCL_8D30 DA04853 transformed cell line human CVCL_8D30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115801 CVCL_8D33 DA04857 transformed cell line human CVCL_8D33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115802 CVCL_8D32 DA04856 transformed cell line human CVCL_8D32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115803 CVCL_8D06 DA04828 transformed cell line human CVCL_8D06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115804 CVCL_8D05 DA04827 transformed cell line human CVCL_8D05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115805 CVCL_8D08 DA04830 transformed cell line human CVCL_8D08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115806 CVCL_8D07 DA04829 transformed cell line human CVCL_8D07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115807 CVCL_8D02 DA04824 transformed cell line human CVCL_8D02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115808 CVCL_8D01 DA04823 transformed cell line human CVCL_8D01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115809 CVCL_8D04 DA04826 transformed cell line human CVCL_8D04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115810 CVCL_8D03 DA04825 transformed cell line human CVCL_8D03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115811 CVCL_8D09 DA04831 transformed cell line human CVCL_8D09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115812 CVCL_8D00 DA04822 transformed cell line human CVCL_8D00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115813 CVCL_8D17 DA04840 transformed cell line human CVCL_8D17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115814 CVCL_8D16 DA04838 transformed cell line human CVCL_8D16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115815 CVCL_8D19 DA04842 transformed cell line human CVCL_8D19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115816 CVCL_8D18 DA04841 transformed cell line human CVCL_8D18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115817 CVCL_8D13 DA04835 transformed cell line human CVCL_8D13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115818 CVCL_8D12 DA04834 transformed cell line human CVCL_8D12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115819 CVCL_8D15 DA04837 transformed cell line human CVCL_8D15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115820 CVCL_8D14 DA04836 transformed cell line human CVCL_8D14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115821 CVCL_8D11 DA04833 transformed cell line human CVCL_8D11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115822 CVCL_8D10 DA04832 transformed cell line human CVCL_8D10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115823 CVCL_S199 FC71B.Sg finite cell line CVCL_S199 CL:0000010 Derived from sampling site: Fetal salivary gland; sublingual gland. Discontinued: ATCC; CRL-6144; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115824 CVCL_RP99 ValiScreen human CX3CR1 spontaneously immortalized cell line CVCL_RP99 CL:0000010 Transfected with: HGNC; 2558; CX3CR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21115825 CVCL_S198 FC63.Br finite cell line CVCL_S198 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-6142; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115826 CVCL_RP98 KC-16 hybridoma house mouse CVCL_RP98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8994 21115827 CVCL_S188 FC74 finite cell line CVCL_S188 CL:0000010 Derived from sampling site: Lymph node Cell type=Fibroblast.. Discontinued: ATCC; CRL-6104; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115828 CVCL_RP88 TVGH-iPSC-016-01 induced pluripotent stem cell human CVCL_RP88 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21115829 CVCL_S187 MSC 80 spontaneously immortalized cell line house mouse CVCL_S187 CL:0000010 Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: C57BL/6 x DBA/2. Omics: Cell surface proteome Characteristics: Can be infected in vitro with mouse scrapie prion (PrPSc) and will continue to produce PrPSc after 18 passages and is able to transmit the prion disease to mice Doubling time: 17 hours (PubMed=1629940) 21115830 CVCL_RP87 TVGH-iPSC-015-16 induced pluripotent stem cell human CVCL_RP87 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21115831 CVCL_S189 FC69 finite cell line CVCL_S189 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6101; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115832 CVCL_RP89 TVGH-iPSC-022-04 induced pluripotent stem cell human CVCL_RP89 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21115833 CVCL_S191 FC3.K finite cell line CVCL_S191 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-6128; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115834 CVCL_RP91 NTUH-iPSC-005-02 induced pluripotent stem cell human CVCL_RP91 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21115835 CVCL_S190 FC116.Sk finite cell line CVCL_S190 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6123; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115836 CVCL_RP90 NTUH-iPSC-008-11 induced pluripotent stem cell human CVCL_RP90 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21115837 CVCL_S193 FC28.Sp/Thy finite cell line CVCL_S193 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Discontinued: ATCC; CRL-6131; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115838 CVCL_RP93 JDSHCC39 hybridoma house mouse CVCL_RP93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis C virus core protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C94005 21115839 CVCL_S192 FC3.Lu finite cell line CVCL_S192 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6129; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115840 CVCL_RP92 NTUH-iPSC-011-05 induced pluripotent stem cell human CVCL_RP92 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21115841 CVCL_S195 FC54.Thy finite cell line CVCL_S195 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6133; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115842 CVCL_RP95 JDSHCNS3-1 hybridoma house mouse CVCL_RP95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis C virus NS3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C94006 21115843 CVCL_S194 FC54.Sp finite cell line CVCL_S194 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6095; true; Discontinued: ATCC; CRL-6132; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115844 CVCL_RP94 JDSHCE125 hybridoma house mouse CVCL_RP94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis C virus envelope glycoprotein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C94009 21115845 CVCL_S197 FC59.Sp finite cell line CVCL_S197 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6138; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115846 CVCL_RP97 JDSHCNS5-1 hybridoma house mouse CVCL_RP97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis C virus NS5. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C94008 21115847 CVCL_S196 FC57.Sp finite cell line CVCL_S196 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6135; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115848 CVCL_RP96 JDSHCNS4-93 hybridoma house mouse CVCL_RP96 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis C virus NS4. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C94007 21115849 CVCL_J808 264E hybridoma house mouse CVCL_J808 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd. 21115850 CVCL_IW08 GM09276 transformed cell line human CVCL_IW08 CL:0000010 Sequence variation: Mutation; HGNC; 2312; CPN1; Simple; p.Arg58Glufs (c.172insG) (385fsinsG); ClinVar=VCV000006622; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2312; CPN1; Simple; p.Gly178Asp (c.533G>A); ClinVar=VCV000006623; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115851 CVCL_J807 262C hybridoma house mouse CVCL_J807 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd. 21115852 CVCL_IW07 L-929 HH spontaneously immortalized cell line house mouse CVCL_IW07 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: 23.4 hours (PubMed=823777) 21115853 CVCL_J809 265A hybridoma house mouse CVCL_J809 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02712; Tetronarce californica chrnb1. 21115854 CVCL_IW09 GM25245 transformed cell line human CVCL_IW09 CL:0000010 Sequence variation: Mutation; HGNC; 25928; WDR73; Simple; p.Phe296Leufs*26 (c.888delT); ClinVar=VCV000225244; Zygosity=Homozygous (PubMed=26070982); Sequence variation: Mutation; HGNC; 30493; WHAMM; Simple; p.Ile422Lysfs*35 (c.1264_1270delATAAAAG); Zygosity=Heterozygous (PubMed=26070982) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115855 CVCL_J804 230C hybridoma house mouse CVCL_J804 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P02712; Tetronarce californica chrnb1. 21115856 CVCL_IW04 L-929 D spontaneously immortalized cell line house mouse CVCL_IW04 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: 20.8 hours (PubMed=823777) 21115857 CVCL_J803 147A hybridoma house mouse CVCL_J803 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd; Monoclonal antibody target: UniProtKB; P02714; Tetronarce californica chrng. 21115858 CVCL_IW03 GM16530 hybrid cell line human CVCL_IW03 CL:0000010 Characteristics: Cytoplasmic transfer (cybrid) produced by the fusion of Leigh syndrome enucleated cells GM13740 (Cellosaurus=CVCL_8A62) with cell line devoid of mitochondrial DNA (rho0) derived from 143B (Cellosaurus=CVCL_2270). 21115859 CVCL_J806 245A hybridoma house mouse CVCL_J806 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd. 21115860 CVCL_IW06 L-929 F spontaneously immortalized cell line house mouse CVCL_IW06 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: 24.9 hours (PubMed=823777) 21115861 CVCL_J805 240A hybridoma house mouse CVCL_J805 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02718; Tetronarce californica chrnd. 21115862 CVCL_IW05 L-929 E spontaneously immortalized cell line house mouse CVCL_IW05 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: 22.9 hours (PubMed=823777) 21115863 CVCL_IW00 GM19016 transformed cell line human CVCL_IW00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115864 CVCL_J800 YTS 191.1.1.2 hybridoma Norway rat CVCL_J800 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06332; Mouse Cd4. 21115865 CVCL_J802 139A hybridoma house mouse CVCL_J802 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02710; Tetronarce californica chrna1. 21115866 CVCL_IW02 MS4 cancer cell line CVCL_IW02 CL:0000010 Derived from sampling site: Pleural effusion; Breed/subspecies: Abyssinian. Male 21115867 CVCL_IW01 GM23710 transformed cell line human CVCL_IW01 CL:0000010 Sequence variation: Mutation; HGNC; 11411; CDKL5; Unexplicit; Ex17-18del; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21115868 CVCL_J801 YTS 213.1.1 hybridoma Norway rat CVCL_J801 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18. 21115869 CVCL_8D89 DA04919 transformed cell line human CVCL_8D89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115870 CVCL_8D80 DA04909 transformed cell line human CVCL_8D80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115871 CVCL_8D86 DA04916 transformed cell line human CVCL_8D86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115872 CVCL_8D85 DA04915 transformed cell line human CVCL_8D85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115873 CVCL_8D88 DA04918 transformed cell line human CVCL_8D88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115874 CVCL_8D87 DA04917 transformed cell line human CVCL_8D87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115875 CVCL_8D82 DA04912 transformed cell line human CVCL_8D82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115876 CVCL_8D81 DA04911 transformed cell line human CVCL_8D81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115877 CVCL_8D84 DA04914 transformed cell line human CVCL_8D84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115878 CVCL_8D83 DA04913 transformed cell line human CVCL_8D83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115879 CVCL_8D91 DA04921 transformed cell line human CVCL_8D91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115880 CVCL_8D90 DA04920 transformed cell line human CVCL_8D90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115881 CVCL_8D97 DA04927 transformed cell line human CVCL_8D97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115882 CVCL_8D96 DA04926 transformed cell line human CVCL_8D96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115883 CVCL_8D99 DA04929 transformed cell line human CVCL_8D99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115884 CVCL_8D98 DA04928 transformed cell line human CVCL_8D98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115885 CVCL_8D93 DA04923 transformed cell line human CVCL_8D93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115886 CVCL_8D92 DA04922 transformed cell line human CVCL_8D92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115887 CVCL_8D95 DA04925 transformed cell line human CVCL_8D95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115888 CVCL_8D94 DA04924 transformed cell line human CVCL_8D94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115889 CVCL_8D68 DA04896 transformed cell line human CVCL_8D68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115890 CVCL_8D67 DA04895 transformed cell line human CVCL_8D67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115891 CVCL_8D69 DA04897 transformed cell line human CVCL_8D69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115892 CVCL_8D64 DA04891 transformed cell line human CVCL_8D64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115893 CVCL_8D63 DA04890 transformed cell line human CVCL_8D63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115894 CVCL_8D66 DA04894 transformed cell line human CVCL_8D66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115895 CVCL_8D65 DA04892 transformed cell line human CVCL_8D65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115896 CVCL_8D60 DA04886 transformed cell line human CVCL_8D60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115897 CVCL_8D62 DA04889 transformed cell line human CVCL_8D62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115898 CVCL_8D61 DA04887 transformed cell line human CVCL_8D61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115899 CVCL_8D79 DA04908 transformed cell line human CVCL_8D79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115900 CVCL_8D78 DA04907 transformed cell line human CVCL_8D78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115901 CVCL_8D75 DA04904 transformed cell line human CVCL_8D75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115902 CVCL_8D74 DA04903 transformed cell line human CVCL_8D74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115903 CVCL_8D77 DA04906 transformed cell line human CVCL_8D77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115904 CVCL_8D76 DA04905 transformed cell line human CVCL_8D76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115905 CVCL_8D71 DA04900 transformed cell line human CVCL_8D71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115906 CVCL_8D70 DA04899 transformed cell line human CVCL_8D70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115907 CVCL_8D73 DA04902 transformed cell line human CVCL_8D73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115908 CVCL_8D72 DA04901 transformed cell line human CVCL_8D72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21115909 CVCL_RR31 SK-N-ASrVCR20 cancer cell line human CVCL_RR31 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115910 CVCL_S331 ZC15.Lu finite cell line CVCL_S331 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6606; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115911 CVCL_RR30 CALDOX cancer cell line human CVCL_RR30 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21115912 CVCL_S330 PV4.Pl finite cell line CVCL_S330 CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-6605; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115913 CVCL_RR33 IGR-39rPLX4032_20muM cancer cell line human CVCL_RR33 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Skin. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115914 CVCL_S333 TE 79.T cancer cell line human CVCL_S333 CL:0000010 Discontinued: ATCC; CRL-7733; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115915 CVCL_RR32 GI-ME-NrVCR14 cancer cell line human CVCL_RR32 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115916 CVCL_RR35 IGR-39rVCR10 cancer cell line human CVCL_RR35 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Skin. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115917 CVCL_S335 TE 112.T undefined cell line type human CVCL_S335 CL:0000010 Discontinued: ATCC; CRL-7742; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115918 CVCL_RR34 IGR-39rPLX4720_20muM cancer cell line human CVCL_RR34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720); Derived from sampling site: Skin. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115919 CVCL_S334 TE 86.T undefined cell line type human CVCL_S334 CL:0000010 Discontinued: ATCC; CRL-7736; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115920 CVCL_RR37 IMR-5rVCR10 cancer cell line human CVCL_RR37 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115921 CVCL_S337 TE 127.T undefined cell line type human CVCL_S337 CL:0000010 Discontinued: ATCC; CRL-7745; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115922 CVCL_RR36 IMR-32rVCR10 cancer cell line human CVCL_RR36 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115923 CVCL_S336 TE 114.T cancer cell line human CVCL_S336 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7743; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115924 CVCL_RR39 Rh30rVCR10 cancer cell line human CVCL_RR39 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Pro9Leu (c.26C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=19147553; PubMed=25749379); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115925 CVCL_S339 TE 139.T cancer cell line human CVCL_S339 CL:0000010 Discontinued: ATCC; CRL-7748; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115926 CVCL_RR38 KFRrVCR10 cancer cell line human CVCL_RR38 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115927 CVCL_S338 TE 131.T cancer cell line human CVCL_S338 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7747; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115928 CVCL_J998 GM03383 transformed cell line human CVCL_J998 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21115929 CVCL_IX98 HPSI0516i-eitu_3 induced pluripotent stem cell human CVCL_IX98 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21115930 CVCL_J997 XP1NE finite cell line human CVCL_J997 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly47Arg (c.139G>A); ClinVar=VCV001176084; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=9238033) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21115931 CVCL_IX97 HPSI0416i-zige_5 induced pluripotent stem cell human CVCL_IX97 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21115932 CVCL_J999 GM03398 finite cell line human CVCL_J999 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21115933 CVCL_IX99 HPSI0516i-eitu_4 induced pluripotent stem cell human CVCL_IX99 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21115934 CVCL_IX94 HPSI0416i-mefc_1 induced pluripotent stem cell human CVCL_IX94 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21115935 CVCL_J994 MIN7 transformed cell line house mouse CVCL_J994 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT7 transgenic. Unspecified 21115936 CVCL_IX93 HPSI0416i-fiwt_3 induced pluripotent stem cell human CVCL_IX93 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21115937 CVCL_J993 INS-2 cancer cell line Norway rat CVCL_J993 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Established from the transplantable insulinoma RIN 21115938 CVCL_J996 XP2NE finite cell line human CVCL_J996 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (PubMed=9238033; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 34 PDL (PubMed=6492896) 21115939 CVCL_IX96 HPSI0416i-zige_2 induced pluripotent stem cell human CVCL_IX96 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21115940 CVCL_J995 GM00303 finite cell line human CVCL_J995 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00055; true Female 21115941 CVCL_IX95 HPSI0416i-mefc_2 induced pluripotent stem cell human CVCL_IX95 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21115942 CVCL_J990 7B6.15.11 hybridoma house mouse CVCL_J990 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14836; Human TNFRSF13B/TACI/CD267. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5000 21115943 CVCL_IX90 HPSI0216i-iogu_6 induced pluripotent stem cell human CVCL_IX90 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21115944 CVCL_J992 153.8E2.D10.D6.12.12 hybridoma house mouse CVCL_J992 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5543; Registration: Chiron Master Culture Collection; CMCC 12056 (CMCC #12056) 21115945 CVCL_IX92 HPSI0216i-xanu_6 induced pluripotent stem cell human CVCL_IX92 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21115946 CVCL_J991 131.2F8.5.9 hybridoma house mouse CVCL_J991 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5542; Registration: Chiron Master Culture Collection; CMCC 12047 (CMCC #12047) 21115947 CVCL_IX91 HPSI0216i-xanu_5 induced pluripotent stem cell human CVCL_IX91 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21115948 CVCL_RR40 NGPrVCR10 cancer cell line human CVCL_RR40 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21115949 CVCL_S340 TE 141.T cancer cell line human CVCL_S340 CL:0000010 Discontinued: ATCC; CRL-7749; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115950 CVCL_S320 PAL1.Ov finite cell line CVCL_S320 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-6294; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115951 CVCL_RR20 RT4rGEMCI10 cancer cell line human CVCL_RR20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar) Male Doubling time: 56.2 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115952 CVCL_S322 PT1.Lu finite cell line CVCL_S322 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Lung. Discontinued: ATCC; CRL-6313; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115953 CVCL_RR22 T24rGEMCI20 cancer cell line human CVCL_RR22 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Urinary bladder. Female Doubling time: 25.9 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115954 CVCL_S321 PT1.Ln finite cell line CVCL_S321 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6312; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115955 CVCL_RR21 T24rCDDP1000 cancer cell line human CVCL_RR21 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female Doubling time: 24.7 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115956 CVCL_S324 LO1.Fas finite cell line CVCL_S324 CL:0000010 Derived from sampling site: Fascia. Discontinued: ATCC; CRL-6554; true Unspecified Group: Reptilian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115957 CVCL_RR24 TCC-SUPrCDDP1000 cancer cell line human CVCL_RR24 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Female Doubling time: 31.2 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115958 CVCL_S323 PT1.Sk finite cell line CVCL_S323 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Skin. Discontinued: ATCC; CRL-6314; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115959 CVCL_RR23 T24rVINB20 cancer cell line human CVCL_RR23 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Urinary bladder. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115960 CVCL_S326 LO1.HT finite cell line CVCL_S326 CL:0000010 Derived from sampling site: Heart. Discontinued: ATCC; CRL-6556; true Unspecified Group: Reptilian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115961 CVCL_RR26 TCC-SUPrVINB20 cancer cell line human CVCL_RR26 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine) Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115962 CVCL_S325 LO1.GAK finite cell line CVCL_S325 CL:0000010 Derived from sampling site: Adrenal gland, gonad and kidney. Discontinued: ATCC; CRL-6555; true Unspecified Group: Reptilian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115963 CVCL_RR25 TCC-SUPrGEMCI20 cancer cell line human CVCL_RR25 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar) Female Doubling time: 117.8 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115964 CVCL_S328 LO1.Mu finite cell line CVCL_S328 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-6558; true Unspecified Group: Reptilian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115965 CVCL_RR28 RB32SV transformed cell line human CVCL_RR28 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21115966 CVCL_S327 LO1.Lu finite cell line CVCL_S327 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6557; true Unspecified Group: Reptilian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115967 CVCL_RR27 RB17SV transformed cell line human CVCL_RR27 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21115968 CVCL_S329 QK2.K finite cell line CVCL_S329 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6559; true Unspecified Group: Marsupial cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115969 CVCL_RR29 SK-N-ASrOXALI4000 cancer cell line human CVCL_RR29 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21115970 CVCL_S311 Hs 729.Sk finite cell line human CVCL_S311 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7861; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115971 CVCL_RR11 MCF10A PVRL4 (-/-) spontaneously immortalized cell line human CVCL_RR11 CL:0000010 Knockout cell: Method=ZFN; HGNC; 19688; NECTIN4; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115972 CVCL_S310 Hs 728.Th finite cell line human CVCL_S310 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7860; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115973 CVCL_RR10 MCF10A H2AFX (-/-) spontaneously immortalized cell line human CVCL_RR10 CL:0000010 Knockout cell: Method=ZFN; HGNC; 4739; H2AX; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115974 CVCL_RR13 5637rCDDP1000 cancer cell line human CVCL_RR13 CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Male Doubling time: 29.5 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115975 CVCL_S313 Hs 732.Li finite cell line human CVCL_S313 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7864; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115976 CVCL_S312 Hs 732.K finite cell line human CVCL_S312 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7863; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115977 CVCL_RR12 MCF10A RICTOR (-/-) spontaneously immortalized cell line human CVCL_RR12 CL:0000010 Knockout cell: Method=ZFN; HGNC; 28611; RICTOR; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21115978 CVCL_S315 Hs 746.Sk finite cell line human CVCL_S315 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7871; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115979 CVCL_RR15 HT1376rCDDP1000 cancer cell line human CVCL_RR15 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female Doubling time: 31.2 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115980 CVCL_RR14 5637rGEMCI20 cancer cell line human CVCL_RR14 CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Urinary bladder. Male Doubling time: 41.8 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115981 CVCL_S314 Hs 738.K/Ad/Ts finite cell line human CVCL_S314 CL:0000010 Derived from sampling site: Fetal adrenal gland and fetal testis Cell type=Epithelial cell.. Discontinued: ATCC; CRL-7866; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115982 CVCL_S317 My.Sp finite cell line CVCL_S317 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6000; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115983 CVCL_RR17 RT112rCDDP1000 cancer cell line human CVCL_RR17 CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female Doubling time: 23.0 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115984 CVCL_S316 B2.Thy finite cell line CVCL_S316 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6025; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115985 CVCL_J979 B5 NIH hybridoma house mouse CVCL_J979 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10569 21115986 CVCL_IX79 HPSI0516i-jory_9 induced pluripotent stem cell human CVCL_IX79 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21115987 CVCL_RR16 HT1376rGEMCI20 cancer cell line human CVCL_RR16 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Urinary bladder. Female Doubling time: 41.8 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115988 CVCL_S319 PAL1.Ln finite cell line CVCL_S319 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6293; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115989 CVCL_RR19 RT4rCDDP1000 cancer cell line human CVCL_RR19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male Doubling time: 39.6 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115990 CVCL_S318 PAL1.K finite cell line CVCL_S318 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6292; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21115991 CVCL_RR18 RT112rGEMCI20 cancer cell line human CVCL_RR18 CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Urinary bladder. Female Doubling time: 26.6 hours (PubMed=26055179) Part of: Resistant Cancer Cell Line (RCCL) collection 21115992 CVCL_J976 B505 hybridoma house mouse CVCL_J976 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12000 21115993 CVCL_IX76 HPSI0216i-vieg_5 induced pluripotent stem cell human CVCL_IX76 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21115994 CVCL_J975 A33 hybridoma house mouse CVCL_J975 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99795; Human GPA33. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8779 21115995 CVCL_IX75 HPSI0216i-vieg_3 induced pluripotent stem cell human CVCL_IX75 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21115996 CVCL_J978 B3 NIH hybridoma house mouse CVCL_J978 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10573 21115997 CVCL_IX78 HPSI0316i-muwv_6 induced pluripotent stem cell human CVCL_IX78 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21115998 CVCL_J977 B1 NIH hybridoma house mouse CVCL_J977 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10572 21115999 CVCL_IX77 HPSI0316i-muwv_3 induced pluripotent stem cell human CVCL_IX77 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116000 CVCL_J972 240E1-1-2 cancer cell line CVCL_J972 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11870 21116001 CVCL_IX72 HPSI0216i-boho_3 induced pluripotent stem cell human CVCL_IX72 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116002 CVCL_J971 240E1-1 cancer cell line CVCL_J971 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11872. 21116003 CVCL_IX71 HPSI0316i-xaqm_6 induced pluripotent stem cell human CVCL_IX71 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bahraini; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116004 CVCL_J974 A1G3 hybridoma house mouse CVCL_J974 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21116005 CVCL_IX74 HPSI0216i-rihx_4 induced pluripotent stem cell human CVCL_IX74 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116006 CVCL_J973 A-HER2 hybridoma house mouse CVCL_J973 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized trastuzumab (herceptin) therapeutic antibody Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10463 21116007 CVCL_IX73 HPSI0216i-dacv_6 induced pluripotent stem cell human CVCL_IX73 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116008 CVCL_J970 99S9 hybridoma CVCL_J970 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6014; Registration: Chiron Master Culture Collection; CMCC 12336 (CMCC #12336) 21116009 CVCL_IX70 HPSI0316i-xaqm_4 induced pluripotent stem cell human CVCL_IX70 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bahraini; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116010 CVCL_S300 Hs 189.Int finite cell line human CVCL_S300 CL:0000010 Derived from sampling site: Fetal intestine. Discontinued: ATCC; CRL-7836; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116011 CVCL_RR00 MCF10A CDH1 (-/-) spontaneously immortalized cell line human CVCL_RR00 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1748; CDH1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116012 CVCL_S302 HT-806.Ut finite cell line human CVCL_S302 CL:0000010 Derived from sampling site: Uterus. Discontinued: ATCC; CRL-7795; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116013 CVCL_RR02 MCF10A GSK3B (-/-) spontaneously immortalized cell line human CVCL_RR02 CL:0000010 Knockout cell: Method=ZFN; HGNC; 4617; GSK3B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116014 CVCL_S301 Hs 791.T cancer cell line human CVCL_S301 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; distal femur. Discontinued: ATCC; CRL-7798; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116015 CVCL_RR01 MCF10A EEF2K (-/-) spontaneously immortalized cell line human CVCL_RR01 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24615; EEF2K; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116016 CVCL_S304 Hs 618.Lu finite cell line human CVCL_S304 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-7852; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116017 CVCL_RR04 MCF10A PARP2 (-/-) spontaneously immortalized cell line human CVCL_RR04 CL:0000010 Knockout cell: Method=ZFN; HGNC; 272; PARP2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116018 CVCL_S303 Hs 612.T cancer cell line human CVCL_S303 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7851; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116019 CVCL_RR03 MCF10A HER2 (-/-) spontaneously immortalized cell line human CVCL_RR03 CL:0000010 Knockout cell: Method=ZFN; HGNC; 3430; ERBB2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116020 CVCL_S306 Hs 702.T cancer cell line human CVCL_S306 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7856; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116021 CVCL_RR06 MCF10A TP53 (-/-) spontaneously immortalized cell line human CVCL_RR06 CL:0000010 Knockout cell: Method=ZFN; HGNC; 11998; TP53; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116022 CVCL_S305 Hs 653.T cancer cell line human CVCL_S305 CL:0000010 Discontinued: ATCC; CRL-7854; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116023 CVCL_RR05 MCF10A PTEN (-/-) spontaneously immortalized cell line human CVCL_RR05 CL:0000010 Knockout cell: Method=ZFN; HGNC; 9588; PTEN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116024 CVCL_S308 KAT45 cancer cell line human CVCL_S308 CL:0000010 Derived from sampling site: Adrenal gland; medulla Cell type=Chromaffin cell.. Female Characteristics: Produces corticotropin-releasing hormone (PubMed=9449645) Doubling time: 24-48 hours (PubMed=9449645) 21116025 CVCL_RR08 MCF10A CDC25B (-/-) spontaneously immortalized cell line human CVCL_RR08 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1726; CDC25B; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116026 CVCL_S307 Hs 718.T cancer cell line human CVCL_S307 CL:0000010 Derived from sampling site: Adrenal gland. Discontinued: ATCC; CRL-7858; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116027 CVCL_RR07 MCF10A SYK (-/-) spontaneously immortalized cell line human CVCL_RR07 CL:0000010 Knockout cell: Method=ZFN; HGNC; 11491; SYK; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116028 CVCL_J987 4C7.2.1 hybridoma house mouse CVCL_J987 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14836; Human TNFRSF13B/TACI/CD267. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4999 21116029 CVCL_IX87 HPSI0216i-heub_1 induced pluripotent stem cell human CVCL_IX87 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116030 CVCL_J986 1G10.1.5 hybridoma house mouse CVCL_J986 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14836; Human TNFRSF13B/TACI/CD267. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4297 21116031 CVCL_IX86 HPSI0216i-dewh_6 induced pluripotent stem cell human CVCL_IX86 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116032 CVCL_S309 Hs 728.Li finite cell line human CVCL_S309 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7859; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116033 CVCL_RR09 MCF10A ESR2 (-/-) spontaneously immortalized cell line human CVCL_RR09 CL:0000010 Knockout cell: Method=ZFN; HGNC; 3468; ESR2; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21116034 CVCL_J989 6D11.3.1 hybridoma house mouse CVCL_J989 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14836; Human TNFRSF13B/TACI/CD267. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4299 21116035 CVCL_IX89 HPSI0216i-iogu_5 induced pluripotent stem cell human CVCL_IX89 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116036 CVCL_J988 5B6.3.10 hybridoma house mouse CVCL_J988 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14836; Human TNFRSF13B/TACI/CD267. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4298 21116037 CVCL_IX88 HPSI0216i-heub_6 induced pluripotent stem cell human CVCL_IX88 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116038 CVCL_J983 C3.6 conditionally immortalized cell line human CVCL_J983 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Deep proteome analysis Female 21116039 CVCL_IX83 HPSI0216i-aiid_1 induced pluripotent stem cell human CVCL_IX83 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116040 CVCL_J982 HB4a conditionally immortalized cell line human CVCL_J982 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS) Female 21116041 CVCL_IX82 HPSI0516i-jory_10 induced pluripotent stem cell human CVCL_IX82 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116042 CVCL_J985 GGR41 hybridoma house mouse CVCL_J985 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Gangliosides GQ1balpha. 21116043 CVCL_IX85 HPSI0216i-dewh_4 induced pluripotent stem cell human CVCL_IX85 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116044 CVCL_J984 C5.2 conditionally immortalized cell line human CVCL_J984 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS) Female 21116045 CVCL_IX84 HPSI0216i-aiid_6 induced pluripotent stem cell human CVCL_IX84 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116046 CVCL_J981 B7-24-E1G4 hybridoma house mouse CVCL_J981 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P33681; Human CD80. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11341; Registration: Chiron Master Culture Collection; CMCC 11060 (CMCC #11060) 21116047 CVCL_IX81 HPSI0516i-zukb_3 induced pluripotent stem cell human CVCL_IX81 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116048 CVCL_J980 B6H12.2 hybridoma house mouse CVCL_J980 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q08722; Human CD47. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9771 21116049 CVCL_IX80 HPSI0516i-zukb_2 induced pluripotent stem cell human CVCL_IX80 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116050 CVCL_IX58 HPSI0416i-iooi_6 induced pluripotent stem cell human CVCL_IX58 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116051 CVCL_J958 JM8A1.N3 embryonic stem cell house mouse CVCL_J958 CL:0000010 Breed/subspecies: C57BL/6N. Male 21116052 CVCL_IX57 HPSI0416i-iooi_1 induced pluripotent stem cell human CVCL_IX57 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116053 CVCL_J957 JM8 embryonic stem cell house mouse CVCL_J957 CL:0000010 Breed/subspecies: C57BL/6N. Male 21116054 CVCL_IX59 HPSI0416i-jewl_5 induced pluripotent stem cell human CVCL_IX59 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116055 CVCL_J959 JM8A3 embryonic stem cell house mouse CVCL_J959 CL:0000010 Breed/subspecies: C57BL/6N. Omics: SNP array analysis Male 21116056 CVCL_IX54 HPSI0516i-oadp_5 induced pluripotent stem cell human CVCL_IX54 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116057 CVCL_J954 TR131 cancer cell line human CVCL_J954 CL:0000010 Male Doubling time: 34 hours (PubMed=2413234). 21116058 CVCL_IX53 HPSI0516i-oadp_4 induced pluripotent stem cell human CVCL_IX53 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116059 CVCL_J953 TR138 cancer cell line human CVCL_J953 CL:0000010 Male Doubling time: 22 hours (PubMed=2413234). 21116060 CVCL_J956 EAP1 embryonic stem cell house mouse CVCL_J956 CL:0000010 Breed/subspecies: C57BL/6NCrl. Unspecified 21116061 CVCL_IX56 HPSI0416i-aicq_4 induced pluripotent stem cell human CVCL_IX56 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116062 CVCL_IX55 HPSI0416i-aicq_1 induced pluripotent stem cell human CVCL_IX55 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116063 CVCL_J955 TR126 cancer cell line human CVCL_J955 CL:0000010 Female Doubling time: 21 hours (PubMed=2413234). 21116064 CVCL_J950 F25.2 hybridoma house mouse CVCL_J950 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8109 21116065 CVCL_IX50 HPSI0316i-ierp_4 induced pluripotent stem cell human CVCL_IX50 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116066 CVCL_IX52 HPSI0316i-qeti_2 induced pluripotent stem cell human CVCL_IX52 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116067 CVCL_J952 TRSC-1-8 transformed cell line CVCL_J952 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen. Unspecified 21116068 CVCL_J951 F64.5 hybridoma house mouse CVCL_J951 CL:0000010 Monoclonal antibody isotype: IgG2a. 21116069 CVCL_IX51 HPSI0316i-qeti_1 induced pluripotent stem cell human CVCL_IX51 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116070 CVCL_J969 99S6 hybridoma CVCL_J969 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis B virus surface antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6015; Registration: Chiron Master Culture Collection; CMCC 12337 (CMCC #12337) 21116071 CVCL_IX69 HPSI0316i-tezs_6 induced pluripotent stem cell human CVCL_IX69 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116072 CVCL_IX68 HPSI0216i-tony_5 induced pluripotent stem cell human CVCL_IX68 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116073 CVCL_J968 TP-3 transformed cell line CVCL_J968 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8761 21116074 CVCL_J965 C40-1.3.3 hybridoma house mouse CVCL_J965 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: Chiron Master Culture Collection; CMCC 11264 (CMCC #11264) 21116075 CVCL_IX65 HPSI0516i-jepf_3 induced pluripotent stem cell human CVCL_IX65 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116076 CVCL_J964 C33-1.6.1 hybridoma house mouse CVCL_J964 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: Chiron Master Culture Collection; CMCC 11263 (CMCC #11263) 21116077 CVCL_IX64 HPSI0416i-ruah_5 induced pluripotent stem cell human CVCL_IX64 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116078 CVCL_J967 C42-7.4.5 hybridoma house mouse CVCL_J967 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: Chiron Master Culture Collection; CMCC 11267 (CMCC #11267) 21116079 CVCL_IX67 HPSI0216i-puxp_1 induced pluripotent stem cell human CVCL_IX67 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116080 CVCL_J966 C28-3.7.1 hybridoma house mouse CVCL_J966 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: Chiron Master Culture Collection; CMCC 11266 (CMCC #11266) 21116081 CVCL_IX66 HPSI0516i-jepf_5 induced pluripotent stem cell human CVCL_IX66 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116082 CVCL_IX61 HPSI0416i-ourj_1 induced pluripotent stem cell human CVCL_IX61 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bangladeshi; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116083 CVCL_J961 JM8.F6 embryonic stem cell house mouse CVCL_J961 CL:0000010 Breed/subspecies: C57BL/6N. Male 21116084 CVCL_IX60 HPSI0416i-jewl_6 induced pluripotent stem cell human CVCL_IX60 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116085 CVCL_J960 JM8A3.N1 embryonic stem cell house mouse CVCL_J960 CL:0000010 Breed/subspecies: C57BL/6N. Male 21116086 CVCL_J963 443-17F9-1C6 hybridoma house mouse CVCL_J963 CL:0000010 Discontinued: ATCC; CRL-2694; probable. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-354; Registration: Chiron Master Culture Collection; CMCC 10747 (CMCC #10747) 21116087 CVCL_IX63 HPSI0416i-ruah_4 induced pluripotent stem cell human CVCL_IX63 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116088 CVCL_IX62 HPSI0416i-ourj_2 induced pluripotent stem cell human CVCL_IX62 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bangladeshi; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116089 CVCL_J962 JM8.N4 embryonic stem cell house mouse CVCL_J962 CL:0000010 Breed/subspecies: C57BL/6N. Male 21116090 CVCL_J939 807.33 hybridoma house mouse CVCL_J939 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8JPR1; Bunyavirus La Crosse GP (Note=Recognizes glycoprotein GC/G1). 21116091 CVCL_IX39 GM23842 transformed cell line human CVCL_IX39 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116092 CVCL_J936 803-15.6 hybridoma house mouse CVCL_J936 CL:0000010 Monoclonal antibody isotype: IgG1. 21116093 CVCL_IX36 GM02745 transformed cell line human CVCL_IX36 CL:0000010 Sequence variation: Mutation; HGNC; 1368; CA1; Simple; p.Arg247His (c.740G>A) (R246H); ClinVar=VCV000017606; Zygosity=Homozygous (CelloPub=CLPUB00556) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116094 CVCL_J935 7E3 hybridoma house mouse CVCL_J935 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the chimeric abciximab (ReoPro) therapeutic antibody which is used as a platelet aggregation inhibitor Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08514; Human ITGAB/CD41. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8832 21116095 CVCL_IX35 GM02744 transformed cell line human CVCL_IX35 CL:0000010 Sequence variation: Mutation; HGNC; 1368; CA1; Simple; p.Arg247His (c.740G>A) (R246H); ClinVar=VCV000017606; Zygosity=Homozygous (CelloPub=CLPUB00556) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116096 CVCL_J938 807.31 hybridoma house mouse CVCL_J938 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8JPR1; Bunyavirus La Crosse GP (Note=Recognizes glycoprotein GC/G1). 21116097 CVCL_IX38 GM21921 finite cell line human CVCL_IX38 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ile125fs*11 (r.378_384delTCCCCAG); Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21116098 CVCL_J937 807.15 hybridoma house mouse CVCL_J937 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8JPR1; Bunyavirus La Crosse GP (Note=Recognizes glycoprotein GC/G1). 21116099 CVCL_IX37 GM12896 finite cell line human CVCL_IX37 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-9,+der(9)t(2;9)(p21;p24) (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21116100 CVCL_J932 7D3A.2 hybridoma house mouse CVCL_J932 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P18609; Bluetongue virus 17 VP7. 21116101 CVCL_IX32 HPSI0514i-kooz_5 induced pluripotent stem cell human CVCL_IX32 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116102 CVCL_J931 7C6.5.4 hybridoma house mouse CVCL_J931 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9574 21116103 CVCL_IX31 HPSI0714i-xiry_5 induced pluripotent stem cell human CVCL_IX31 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116104 CVCL_J934 7E11C5 hybridoma house mouse CVCL_J934 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10494 21116105 CVCL_IX34 HPSI0514i-qajt_5 induced pluripotent stem cell human CVCL_IX34 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116106 CVCL_J933 9H10-A4 hybridoma house mouse CVCL_J933 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11430 21116107 CVCL_IX33 HPSI0514i-qajt_2 induced pluripotent stem cell human CVCL_IX33 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116108 CVCL_J930 6D3.4.4 hybridoma house mouse CVCL_J930 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9573 21116109 CVCL_IX30 HPSI0714i-xiry_1 induced pluripotent stem cell human CVCL_IX30 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116110 CVCL_J947 B6.2 hybridoma house mouse CVCL_J947 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8106 21116111 CVCL_IX47 SK-MBL-10 cancer cell line human CVCL_IX47 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21116112 CVCL_J946 B50.4 hybridoma house mouse CVCL_J946 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8111 21116113 CVCL_IX46 SK-EPD-2-R cancer cell line human CVCL_IX46 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21116114 CVCL_J949 CCK061 hybridoma house mouse CVCL_J949 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8786 21116115 CVCL_IX49 HPSI0316i-aask_4 induced pluripotent stem cell human CVCL_IX49 From: University of Manchester; Manchester; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116116 CVCL_J948 B84.1 hybridoma house mouse CVCL_J948 CL:0000010 Monoclonal antibody isotype: IgG1. 21116117 CVCL_IX48 SK-PBL-1-R cancer cell line human CVCL_IX48 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21116118 CVCL_J943 B38.1 hybridoma house mouse CVCL_J943 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8110 21116119 CVCL_IX43 HPSI0416i-sevr_1 induced pluripotent stem cell human CVCL_IX43 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2206; COL4A4; Simple; p.Pro1096Ser (c.3286C>T); Zygosity=Heterozygous (PubMed=35076391); Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Heterozygous (PubMed=35076391) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116120 CVCL_J942 B25.2 hybridoma house mouse CVCL_J942 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8107 21116121 CVCL_IX42 HPSI0416i-bife_2 induced pluripotent stem cell human CVCL_IX42 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116122 CVCL_J945 B50.1 hybridoma house mouse CVCL_J945 CL:0000010 Monoclonal antibody isotype: IgG1. 21116123 CVCL_IX45 IARC-186 cancer cell line human CVCL_IX45 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Derived from metastatic site: Cerebrospinal fluid. Male 21116124 CVCL_J944 B39.1 hybridoma house mouse CVCL_J944 CL:0000010 Monoclonal antibody isotype: IgG1. 21116125 CVCL_IX44 HPSI0416i-sevr_2 induced pluripotent stem cell human CVCL_IX44 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2206; COL4A4; Simple; p.Pro1096Ser (c.3286C>T); Zygosity=Heterozygous (from autologous cell line HPSI0416i-sevr_1); Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Heterozygous (from autologous cell line HPSI0416i-sevr_1) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116126 CVCL_J941 B14.2 hybridoma house mouse CVCL_J941 CL:0000010 Monoclonal antibody isotype: IgG1. 21116127 CVCL_IX41 K12-72.1 cancer cell line CVCL_IX41 CL:0000010 Derived from sampling site: Mammary gland. Female 21116128 CVCL_J940 A4.74 hybridoma house mouse CVCL_J940 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species). 21116129 CVCL_IX40 FMEC UCD-04-2 spontaneously immortalized cell line CVCL_IX40 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21116130 CVCL_8F04 DA05057 transformed cell line human CVCL_8F04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116131 CVCL_8F03 DA05056 transformed cell line human CVCL_8F03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116132 CVCL_8F06 DA05062 transformed cell line human CVCL_8F06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116133 CVCL_8F05 DA05058 transformed cell line human CVCL_8F05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116134 CVCL_8F00 DA05053 transformed cell line human CVCL_8F00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116135 CVCL_8F02 DA05055 transformed cell line human CVCL_8F02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116136 CVCL_8F01 DA05054 transformed cell line human CVCL_8F01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116137 CVCL_8F08 DA05064 transformed cell line human CVCL_8F08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116138 CVCL_8F07 DA05063 transformed cell line human CVCL_8F07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116139 CVCL_8F09 DA05065 transformed cell line human CVCL_8F09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116140 CVCL_8F15 DA05073 transformed cell line human CVCL_8F15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116141 CVCL_8F14 DA05072 transformed cell line human CVCL_8F14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116142 CVCL_8F17 DA05075 transformed cell line human CVCL_8F17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116143 CVCL_8F16 DA05074 transformed cell line human CVCL_8F16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116144 CVCL_8F11 DA05068 transformed cell line human CVCL_8F11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116145 CVCL_8F10 DA05066 transformed cell line human CVCL_8F10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116146 CVCL_8F13 DA05071 transformed cell line human CVCL_8F13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116147 CVCL_8F12 DA05070 transformed cell line human CVCL_8F12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116148 CVCL_8F19 DA05077 transformed cell line human CVCL_8F19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116149 CVCL_8F18 DA05076 transformed cell line human CVCL_8F18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116150 CVCL_S397 TE 453.T cancer cell line human CVCL_S397 CL:0000010 Discontinued: ATCC; CRL-7768; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116151 CVCL_RR97 UKF-NB-6rPCL20 cancer cell line human CVCL_RR97 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116152 CVCL_S396 TE 543.T cancer cell line human CVCL_S396 CL:0000010 Derived from sampling site: Cervical lymph node. Discontinued: ATCC; CRL-7771; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116153 CVCL_RR96 UKF-NB-6rOXALI4000 cancer cell line human CVCL_RR96 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116154 CVCL_S399 HT-804.Ut finite cell line human CVCL_S399 CL:0000010 Derived from sampling site: Endometrium. Discontinued: ATCC; CRL-7793; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116155 CVCL_RR99 UKF-NB-6rVINOR40 cancer cell line human CVCL_RR99 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116156 CVCL_S398 HT-801.T undefined cell line type human CVCL_S398 CL:0000010 Discontinued: ATCC; CRL-7792; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116157 CVCL_RR98 UKF-NB-6rTOPO20 cancer cell line human CVCL_RR98 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116158 CVCL_S386 Cu1.Ov finite cell line CVCL_S386 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-6522; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116159 CVCL_RR86 UKF-NB-2rTOPO10 cancer cell line human CVCL_RR86 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116160 CVCL_S385 30F73.Ur finite cell line CVCL_S385 CL:0000010 Derived from sampling site: Ureter. Discontinued: ATCC; CRL-6521; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116161 CVCL_RR85 UKF-NB-2rOXALI600 cancer cell line human CVCL_RR85 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116162 CVCL_S388 EB.Sk finite cell line CVCL_S388 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6524; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116163 CVCL_RR88 UKF-NB-2rVINOR10 cancer cell line human CVCL_RR88 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116164 CVCL_S387 Cu2.Tes finite cell line CVCL_S387 CL:0000010 Derived from sampling site: Testis. Discontinued: ATCC; CRL-6523; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116165 CVCL_RR87 UKF-NB-2rVINB10 cancer cell line human CVCL_RR87 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116166 CVCL_S389 Tt1.Th finite cell line CVCL_S389 CL:0000010 Discontinued: ATCC; CRL-6553; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116167 CVCL_RR89 UKF-NB-3rCARBO2000 cancer cell line human CVCL_RR89 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116168 CVCL_S391 GS1.K finite cell line CVCL_S391 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6561; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116169 CVCL_RR91 UKF-NB-3rETO100 cancer cell line human CVCL_RR91 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116170 CVCL_S390 EG.Lu finite cell line CVCL_S390 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6560; true Female Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116171 CVCL_RR90 UKF-NB-3rDOCE20 cancer cell line human CVCL_RR90 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116172 CVCL_S393 TN1.Lu finite cell line CVCL_S393 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6563; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116173 CVCL_RR93 UKF-NB-6rCARBO2000 cancer cell line human CVCL_RR93 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116174 CVCL_RR92 NCCSi003-A induced pluripotent stem cell human CVCL_RR92 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21116175 CVCL_S392 Wh-Ir finite cell line CVCL_S392 CL:0000010 Discontinued: ATCC; CRL-6562; true. Unspecified Group: Endangered species/breed cell line; Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116176 CVCL_S395 TE 491.T cancer cell line human CVCL_S395 CL:0000010 Discontinued: ATCC; CRL-7769; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116177 CVCL_RR95 UKF-NB-6rMEL1000 cancer cell line human CVCL_RR95 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116178 CVCL_S394 TE 501.T cancer cell line human CVCL_S394 CL:0000010 Derived from sampling site: Inguinal lymph node. Discontinued: ATCC; CRL-7770; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116179 CVCL_RR94 UKF-NB-6rETO200 cancer cell line human CVCL_RR94 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116180 CVCL_S375 CP81.Sk finite cell line CVCL_S375 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6303; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116181 CVCL_RR75 IMR-32rVINOR5 cancer cell line human CVCL_RR75 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116182 CVCL_S374 CP-81 transformed cell line CVCL_S374 CL:0000010 Transformant: Pongine herpesvirus 2 (Herpesvirus pongo)(NCBI-Taxonomy; 159603); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-6302; true Female Doubling time: ~20 hours (PubMed=198878) Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116183 CVCL_RR74 NLFrTOPO10 cancer cell line human CVCL_RR74 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63632; Topotecan Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116184 CVCL_S377 DBS/Rh.Lu finite cell line CVCL_S377 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-6306; true Unspecified Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116185 CVCL_RR77 NLFrVINB10 cancer cell line human CVCL_RR77 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116186 CVCL_RR76 NLFrPCL20 cancer cell line human CVCL_RR76 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116187 CVCL_S376 Oc2T(VX7) cancer cell line CVCL_S376 CL:0000010 Transformant: Rabbit fibroma virus (SFV)(NCBI-Taxonomy; 10271); Breed/subspecies: New Zealand white. Discontinued: ATCC; CRL-6594; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116188 CVCL_S379 ELC1.We finite cell line CVCL_S379 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6495; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116189 CVCL_RR79 SHEPrETO100 cancer cell line human CVCL_RR79 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116190 CVCL_S378 ECF50.Lu finite cell line dog CVCL_S378 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6346; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116191 CVCL_RR78 SHEPrCDDP1000 cancer cell line human CVCL_RR78 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116192 CVCL_S380 30F73.Ln finite cell line CVCL_S380 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6516; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116193 CVCL_RR80 SHEPrVCR1 cancer cell line human CVCL_RR80 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116194 CVCL_S382 30F73.Mu finite cell line CVCL_S382 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-6518; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116195 CVCL_RR82 UKF-NB-3rVINB10 cancer cell line human CVCL_RR82 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116196 CVCL_S381 30F73.Lu finite cell line CVCL_S381 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6517; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116197 CVCL_RR81 SH-SY5YrCDDP200 cancer cell line human CVCL_RR81 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116198 CVCL_S384 30F73.Sk finite cell line CVCL_S384 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6520; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116199 CVCL_RR84 UKF-NB-2rMEL600 cancer cell line human CVCL_RR84 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116200 CVCL_S383 30F73.Pla finite cell line CVCL_S383 CL:0000010 Derived from sampling site: Placenta. Discontinued: ATCC; CRL-6519; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116201 CVCL_RR83 UKF-NB-2rDOCE10 cancer cell line human CVCL_RR83 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116202 CVCL_RR64 IMR-5rTOPO20 cancer cell line human CVCL_RR64 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116203 CVCL_S364 OA4.Tes finite cell line CVCL_S364 CL:0000010 Derived from sampling site: Fetal testis. Discontinued: ATCC; CRL-6550; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116204 CVCL_RR63 IMR-5rPCL20 cancer cell line human CVCL_RR63 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116205 CVCL_S363 OA3.Bm finite cell line CVCL_S363 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-6540; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116206 CVCL_RR66 IMR-32rCARBO4000 cancer cell line human CVCL_RR66 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116207 CVCL_S366 ZC15.K finite cell line CVCL_S366 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6537; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116208 CVCL_RR65 IMR-5rVINOR20 cancer cell line human CVCL_RR65 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116209 CVCL_S365 MM53.T cancer cell line house mouse CVCL_S365 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6431; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116210 CVCL_S368 CF7.Sp finite cell line dog CVCL_S368 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6576; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116211 CVCL_RR68 IMR-32rDOX20 cancer cell line human CVCL_RR68 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116212 CVCL_RR67 IMR-32rCDDP1000 cancer cell line human CVCL_RR67 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116213 CVCL_S367 ZC2.Sk/Mu finite cell line CVCL_S367 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6536; true Unspecified Virology: Possibly infected by seal poxvirus Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116214 CVCL_S369 CF10.Li finite cell line dog CVCL_S369 CL:0000010 Derived from sampling site: Fetal liver; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6578; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116215 CVCL_RR69 IMR-32rETO100 cancer cell line human CVCL_RR69 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116216 CVCL_RR71 IMR-32rMEL500 cancer cell line human CVCL_RR71 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116217 CVCL_S371 VC1.Ov finite cell line CVCL_S371 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-6266; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116218 CVCL_S370 CF10.Sp finite cell line dog CVCL_S370 CL:0000010 Derived from sampling site: Fetal spleen; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6579; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116219 CVCL_RR70 IMR-32rGEMCI25 cancer cell line human CVCL_RR70 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116220 CVCL_S373 CP18.Sk finite cell line CVCL_S373 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6301; true Male Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116221 CVCL_RR73 IMR-32rTOPO7.5 cancer cell line human CVCL_RR73 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116222 CVCL_S372 GT1.Lu finite cell line CVCL_S372 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6268; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116223 CVCL_RR72 IMR-32rOXALI4000 cancer cell line human CVCL_RR72 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116224 CVCL_S353 B/CMBA.Ut finite cell line house mouse CVCL_S353 CL:0000010 Derived from sampling site: Uterus; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6333; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116225 CVCL_RR53 SH-SY5YrVCR10 cancer cell line human CVCL_RR53 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116226 CVCL_RR52 NLFrVCR5 cancer cell line human CVCL_RR52 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116227 CVCL_S352 PT1.Thy finite cell line CVCL_S352 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6316; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116228 CVCL_S355 MM14.Sp finite cell line house mouse CVCL_S355 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6385; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116229 CVCL_RR55 NGPrGEMCI20 cancer cell line human CVCL_RR55 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116230 CVCL_S354 C57L/J.Li finite cell line house mouse CVCL_S354 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: C57L/J. Discontinued: ATCC; CRL-6335; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116231 CVCL_RR54 RVH-421rPLX4720_10muM cancer cell line human CVCL_RR54 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52fs*71 (c.154delC); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Brain. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116232 CVCL_RR57 IMR-5rDOCE20 cancer cell line human CVCL_RR57 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116233 CVCL_S357 MM55.Ht/Lu finite cell line house mouse CVCL_S357 CL:0000010 Derived from sampling site: Heart and lung; Breed/subspecies: AKR. Discontinued: ATCC; CRL-6435; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116234 CVCL_RR56 IMR-5rCDDP1000 cancer cell line human CVCL_RR56 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116235 CVCL_S356 MM14.Thy finite cell line house mouse CVCL_S356 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6386; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116236 CVCL_RR59 IMR-5rETO100 cancer cell line human CVCL_RR59 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116237 CVCL_S359 SJL/JA finite cell line house mouse CVCL_S359 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: SJL/J. Discontinued: ATCC; CRL-6451; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116238 CVCL_RR58 IMR-5rDOX20 cancer cell line human CVCL_RR58 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116239 CVCL_S358 NMu2Li finite cell line house mouse CVCL_S358 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Namru. Discontinued: ATCC; CRL-6446; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116240 CVCL_RR60 IMR-5rGEMCI20 cancer cell line human CVCL_RR60 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116241 CVCL_S360 SWR/J.Li finite cell line house mouse CVCL_S360 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: SWR/J. Discontinued: ATCC; CRL-6457; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116242 CVCL_RR62 IMR-5rOXALI4000 cancer cell line human CVCL_RR62 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116243 CVCL_S362 OA2.Sk finite cell line CVCL_S362 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6539; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116244 CVCL_S361 +/+ (C) finite cell line house mouse CVCL_S361 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6472; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116245 CVCL_RR61 IMR-5rMEL3000 cancer cell line human CVCL_RR61 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116246 CVCL_S342 LFC12.Sp undefined cell line type CVCL_S342 CL:0000010 Derived from sampling site: Bone marrow, lymph node and spleen. Discontinued: ATCC; CRL-6172; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116247 CVCL_RR42 NLFrCARBO5000 cancer cell line human CVCL_RR42 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116248 CVCL_RR41 NGPrVCR100 cancer cell line human CVCL_RR41 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116249 CVCL_S341 TE 143.T cancer cell line human CVCL_S341 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7750; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116250 CVCL_S344 LB9.K finite cell line CVCL_S344 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6055; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116251 CVCL_RR44 NLFrDACARB20 cancer cell line human CVCL_RR44 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116252 CVCL_S343 LB9.Li finite cell line CVCL_S343 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6056; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116253 CVCL_RR43 NLFrCDDP1000 cancer cell line human CVCL_RR43 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116254 CVCL_S346 FB2.Bm finite cell line CVCL_S346 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-6032; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116255 CVCL_RR46 NLFrDOX40 cancer cell line human CVCL_RR46 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116256 CVCL_S345 7LBLN finite cell line CVCL_S345 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6051; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116257 CVCL_RR45 NLFrDOCE20 cancer cell line human CVCL_RR45 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116258 CVCL_S348 Mw2Lu finite cell line CVCL_S348 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6014; true Unspecified Group: Bat cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116259 CVCL_RR48 NLFrGEMCI20 cancer cell line human CVCL_RR48 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116260 CVCL_S347 Mw1Ht finite cell line CVCL_S347 CL:0000010 Derived from sampling site: Heart. Discontinued: ATCC; CRL-6013; true Unspecified Group: Bat cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116261 CVCL_RR47 NLFrETO100 cancer cell line human CVCL_RR47 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116262 CVCL_S349 D21 cancer cell line dog CVCL_S349 CL:0000010 Derived from sampling site: Bone. Discontinued: ATCC; CRL-6249; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116263 CVCL_RR49 NLFrMEL3000 cancer cell line human CVCL_RR49 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116264 CVCL_RR51 NLFrVCR10 cancer cell line human CVCL_RR51 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116265 CVCL_S351 PT1.Sp finite cell line CVCL_S351 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6315; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116266 CVCL_RR50 NLFrOXALI4000 cancer cell line human CVCL_RR50 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116267 CVCL_S350 PT1.Li finite cell line CVCL_S350 CL:0000010 Anecdotal: Established from Jama, the first chimpanzee diagnosed with trisomy 22 (equivalent to human Down syndrome) Jama died at 17 months during an operation to try to fix a heart problem. Derived from sampling site: Liver. Discontinued: ATCC; CRL-6311; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116268 CVCL_8E67 DA05013 transformed cell line human CVCL_8E67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116269 CVCL_8E66 DA05012 transformed cell line human CVCL_8E66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116270 CVCL_8E69 DA05016 transformed cell line human CVCL_8E69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116271 CVCL_8E68 DA05015 transformed cell line human CVCL_8E68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116272 CVCL_8E63 DA05007 transformed cell line human CVCL_8E63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116273 CVCL_8E62 DA05006 transformed cell line human CVCL_8E62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116274 CVCL_8E65 DA05011 transformed cell line human CVCL_8E65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116275 CVCL_8E64 DA05009 transformed cell line human CVCL_8E64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116276 CVCL_8E61 DA05005 transformed cell line human CVCL_8E61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116277 CVCL_8E60 DA05002 transformed cell line human CVCL_8E60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116278 CVCL_8E78 DA05026 transformed cell line human CVCL_8E78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116279 CVCL_8E77 DA05025 transformed cell line human CVCL_8E77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116280 CVCL_8E79 DA05028 transformed cell line human CVCL_8E79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116281 CVCL_8E74 DA05022 transformed cell line human CVCL_8E74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116282 CVCL_8E73 DA05021 transformed cell line human CVCL_8E73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116283 CVCL_8E76 DA05024 transformed cell line human CVCL_8E76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116284 CVCL_8E75 DA05023 transformed cell line human CVCL_8E75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116285 CVCL_8E70 DA05018 transformed cell line human CVCL_8E70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116286 CVCL_8E72 DA05020 transformed cell line human CVCL_8E72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116287 CVCL_8E71 DA05019 transformed cell line human CVCL_8E71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116288 CVCL_8E49 DA04988 transformed cell line human CVCL_8E49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116289 CVCL_8E48 DA04987 transformed cell line human CVCL_8E48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116290 CVCL_8E45 DA04982 transformed cell line human CVCL_8E45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116291 CVCL_8E44 DA04981 transformed cell line human CVCL_8E44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116292 CVCL_8E47 DA04984 transformed cell line human CVCL_8E47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116293 CVCL_8E46 DA04983 transformed cell line human CVCL_8E46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116294 CVCL_8E41 DA04976 transformed cell line human CVCL_8E41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116295 CVCL_8E40 DA04975 transformed cell line human CVCL_8E40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116296 CVCL_8E43 DA04980 transformed cell line human CVCL_8E43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116297 CVCL_8E42 DA04977 transformed cell line human CVCL_8E42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116298 CVCL_8E59 DA05001 transformed cell line human CVCL_8E59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116299 CVCL_8E56 DA04995 transformed cell line human CVCL_8E56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116300 CVCL_8E55 DA04994 transformed cell line human CVCL_8E55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116301 CVCL_8E58 DA04997 transformed cell line human CVCL_8E58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116302 CVCL_8E57 DA04996 transformed cell line human CVCL_8E57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116303 CVCL_8E52 DA04991 transformed cell line human CVCL_8E52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116304 CVCL_8E51 DA04990 transformed cell line human CVCL_8E51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116305 CVCL_8E54 DA04993 transformed cell line human CVCL_8E54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116306 CVCL_8E53 DA04992 transformed cell line human CVCL_8E53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116307 CVCL_8E50 DA04989 transformed cell line human CVCL_8E50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116308 CVCL_8E27 DA04961 transformed cell line human CVCL_8E27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116309 CVCL_8E26 DA04958 transformed cell line human CVCL_8E26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116310 CVCL_8E29 DA04963 transformed cell line human CVCL_8E29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116311 CVCL_8E28 DA04962 transformed cell line human CVCL_8E28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116312 CVCL_8E23 DA04955 transformed cell line human CVCL_8E23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116313 CVCL_8E22 DA04954 transformed cell line human CVCL_8E22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116314 CVCL_8E25 DA04957 transformed cell line human CVCL_8E25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116315 CVCL_8E24 DA04956 transformed cell line human CVCL_8E24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116316 CVCL_8E21 DA04953 transformed cell line human CVCL_8E21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116317 CVCL_8E20 DA04952 transformed cell line human CVCL_8E20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116318 CVCL_8E38 DA04973 transformed cell line human CVCL_8E38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116319 CVCL_8E37 DA04972 transformed cell line human CVCL_8E37 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116320 CVCL_8E39 DA04974 transformed cell line human CVCL_8E39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116321 CVCL_8E34 DA04968 transformed cell line human CVCL_8E34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116322 CVCL_8E33 DA04967 transformed cell line human CVCL_8E33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116323 CVCL_8E36 DA04971 transformed cell line human CVCL_8E36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116324 CVCL_8E35 DA04969 transformed cell line human CVCL_8E35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116325 CVCL_8E30 DA04964 transformed cell line human CVCL_8E30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116326 CVCL_8E32 DA04966 transformed cell line human CVCL_8E32 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116327 CVCL_8E31 DA04965 transformed cell line human CVCL_8E31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116328 CVCL_8E05 DA04935 transformed cell line human CVCL_8E05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116329 CVCL_8E04 DA04934 transformed cell line human CVCL_8E04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116330 CVCL_8E07 DA04937 transformed cell line human CVCL_8E07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116331 CVCL_8E06 DA04936 transformed cell line human CVCL_8E06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116332 CVCL_8E01 DA04931 transformed cell line human CVCL_8E01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116333 CVCL_8E00 DA04930 transformed cell line human CVCL_8E00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116334 CVCL_8E03 DA04933 transformed cell line human CVCL_8E03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116335 CVCL_8E02 DA04932 transformed cell line human CVCL_8E02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116336 CVCL_8E09 DA04939 transformed cell line human CVCL_8E09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116337 CVCL_8E08 DA04938 transformed cell line human CVCL_8E08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116338 CVCL_8E16 DA04947 transformed cell line human CVCL_8E16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116339 CVCL_8E15 DA04946 transformed cell line human CVCL_8E15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116340 CVCL_8E18 DA04949 transformed cell line human CVCL_8E18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116341 CVCL_8E17 DA04948 transformed cell line human CVCL_8E17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116342 CVCL_8E12 DA04942 transformed cell line human CVCL_8E12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116343 CVCL_8E11 DA04941 transformed cell line human CVCL_8E11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116344 CVCL_8E14 DA04945 transformed cell line human CVCL_8E14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116345 CVCL_8E13 DA04943 transformed cell line human CVCL_8E13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116346 CVCL_8E19 DA04950 transformed cell line human CVCL_8E19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116347 CVCL_8E10 DA04940 transformed cell line human CVCL_8E10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116348 CVCL_J918 133 hybridoma house mouse CVCL_J918 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9357 21116349 CVCL_IX18 NAC cancer cell line CVCL_IX18 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 19.1 hours (PubMed=10333454) 21116350 CVCL_J917 133B hybridoma house mouse CVCL_J917 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02710; Tetronarce californica chrna1. 21116351 CVCL_IX17 FYC cancer cell line CVCL_IX17 CL:0000010 Derived from sampling site: Mammary gland. Female 21116352 CVCL_J919 155 hybridoma house mouse CVCL_J919 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9354 21116353 CVCL_IX19 HPSI0115i-iinu_3 induced pluripotent stem cell human CVCL_IX19 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116354 CVCL_J914 6A8.6F10.1A6 hybridoma house mouse CVCL_J914 CL:0000010 Discontinued: ATCC; CRL-2743; true; Discontinued: ATCC; JHU-27; true. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse MHC class I Qa-1b 21116355 CVCL_IX14 PER-547 cancer cell line human CVCL_IX14 CL:0000010 Male Doubling time: ~75 hours (PubMed=19077040). 21116356 CVCL_J913 33F8 hybridoma house mouse CVCL_J913 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8697 21116357 CVCL_IX13 PER-480 cancer cell line human CVCL_IX13 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: 2.6 days (PubMed=9428362) 21116358 CVCL_IX16 DrG spontaneously immortalized cell line zebrafish CVCL_IX16 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC053 21116359 CVCL_J916 p53R cancer cell line human CVCL_J916 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line) Discontinued: ATCC; CRL-2781; true; Discontinued: ATCC; JHU-56; true. Unspecified Problematic cell line: Misidentified Originally thought to derive from Hs 766T but was later (erratum) shown to be derived from RKO (PubMed=12082016). 21116360 CVCL_IX15 PER-568 cancer cell line human CVCL_IX15 CL:0000010 Derived from metastatic site: Left caudate nucleus. Male Doubling time: ~209 hours (PubMed=19077040) 21116361 CVCL_J915 Rat1A-myc spontaneously immortalized cell line Norway rat CVCL_J915 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: ATCC; JHU-26; true Unspecified 21116362 CVCL_J910 113F1 hybridoma house mouse CVCL_J910 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human breast/ovarian cancer 55 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8490 21116363 CVCL_IX10 HepG2 CYP3A4G/7R clone 87 cancer cell line human CVCL_IX10 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with a dual reporter that express RFP under the transcriptional regulation of CYP3A7 in the hepatoblast-like cell state and EGFP under the transcriptional regulation of CYP3A4 21116364 CVCL_J912 266B2 hybridoma house mouse CVCL_J912 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8486 21116365 CVCL_IX12 PER-453 cancer cell line human CVCL_IX12 CL:0000010 Derived from metastatic site: Cerebrospinal fluid. Female Characteristics: Expresses FOXO1A at very high levels Doubling time: 2.73 days (PubMed=7513543) 21116366 CVCL_J911 280D11 hybridoma house mouse CVCL_J911 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8487 21116367 CVCL_IX11 PER-452 cancer cell line human CVCL_IX11 CL:0000010 Derived from metastatic site: Cerebrospinal fluid. Female Doubling time: 4.38 days (PubMed=7513543) 21116368 CVCL_J929 5C6.10.4 hybridoma house mouse CVCL_J929 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9572 21116369 CVCL_IX29 HPSI0614i-lipl_5 induced pluripotent stem cell human CVCL_IX29 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116370 CVCL_J928 5D4-11 hybridoma house mouse CVCL_J928 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27915; Dengue virus type 3 polyprotein. 21116371 CVCL_IX28 HPSI0614i-lipl_2 induced pluripotent stem cell human CVCL_IX28 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21116372 CVCL_J925 30 hybridoma house mouse CVCL_J925 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9366 21116373 CVCL_IX25 HPSI0414i-nolz_4 induced pluripotent stem cell human CVCL_IX25 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116374 CVCL_J924 296 hybridoma house mouse CVCL_J924 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9370 21116375 CVCL_IX24 HPSI0314i-kujn_5 induced pluripotent stem cell human CVCL_IX24 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116376 CVCL_J927 52 hybridoma house mouse CVCL_J927 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9361 21116377 CVCL_IX27 HPSI0614i-kecw_4 induced pluripotent stem cell human CVCL_IX27 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116378 CVCL_J926 514 hybridoma house mouse CVCL_J926 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Murine leukemia viruses (MuLV) gp70. 21116379 CVCL_IX26 HPSI0614i-kecw_3 induced pluripotent stem cell human CVCL_IX26 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21116380 CVCL_J921 191 hybridoma house mouse CVCL_J921 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9368 21116381 CVCL_IX21 HPSI0115i-qaqp_4 induced pluripotent stem cell human CVCL_IX21 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116382 CVCL_J920 162 hybridoma house mouse CVCL_J920 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9356 21116383 CVCL_IX20 HPSI0115i-iinu_5 induced pluripotent stem cell human CVCL_IX20 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116384 CVCL_J923 20 hybridoma house mouse CVCL_J923 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9355 21116385 CVCL_IX23 HPSI0314i-kujn_2 induced pluripotent stem cell human CVCL_IX23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116386 CVCL_J922 198 hybridoma house mouse CVCL_J922 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9369 21116387 CVCL_IX22 HPSI0115i-xaka_2 induced pluripotent stem cell human CVCL_IX22 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116388 CVCL_J907 369F10 hybridoma house mouse CVCL_J907 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8682 21116389 CVCL_IX07 UROtsa Cd#5 transformed cell line human CVCL_IX07 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 18.2 +- 0.8 hours (PubMed=19921857) 21116390 CVCL_J906 5c8 hybridoma house mouse CVCL_J906 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P29965; Human CD40LG/CD154. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10916 21116391 CVCL_IX06 UROtsa Cd#4 transformed cell line human CVCL_IX06 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 20.7 +- 1.1 hours (PubMed=19921857) 21116392 CVCL_J909 260F9-1C9 hybridoma house mouse CVCL_J909 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8662 21116393 CVCL_IX09 UROtsa Cd#7 transformed cell line human CVCL_IX09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 27.1 +- 1.3 hours (PubMed=19921857) 21116394 CVCL_J908 260F9 hybridoma house mouse CVCL_J908 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce 260F9-rRTA which was evaluated in two phase 1 clinical trials which were not pursued due to severe toxicity of the conjugate (DOI=10.3390/antib1010039) Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer 55 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8488 21116395 CVCL_IX08 UROtsa Cd#6 transformed cell line human CVCL_IX08 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 16.9 +- 1.0 hours (PubMed=19921857) 21116396 CVCL_J903 650E2 hybridoma house mouse CVCL_J903 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human breast/ovarian cancer 42 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10812; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10083; Registration: Chiron Master Culture Collection; CMCC 10121 (CMCC #10121) 21116397 CVCL_IX03 UROtsa Cd#1 transformed cell line human CVCL_IX03 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 27.8 +- 0.6 hours (PubMed=19921857) 21116398 CVCL_J902 2G3 [Mouse hybridoma against HMW mucin] hybridoma house mouse CVCL_J902 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8491 21116399 CVCL_IX02 T-85 cancer cell line human CVCL_IX02 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21116400 CVCL_J905 60bca hybridoma house mouse CVCL_J905 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08571; Human CD14. 21116401 CVCL_IX05 UROtsa Cd#3 transformed cell line human CVCL_IX05 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 16.4 +- 1.8 hours (PubMed=19921857) 21116402 CVCL_J904 245E7 hybridoma house mouse CVCL_J904 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human high molecular weight mucin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8489 21116403 CVCL_IX04 UROtsa Cd#2 transformed cell line human CVCL_IX04 CL:0000010 Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 18.8 +- 1.5 hours (PubMed=19921857) 21116404 CVCL_J901 NP cl.25 hybridoma house mouse CVCL_J901 CL:0000010 Monoclonal antibody isotype: IgG2a. 21116405 CVCL_IX01 RZ 328 cancer cell line Norway rat CVCL_IX01 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Breed/subspecies: Wistar. Unspecified 21116406 CVCL_J900 NP cl.120 hybridoma house mouse CVCL_J900 CL:0000010 Monoclonal antibody isotype: IgG2a. 21116407 CVCL_IX00 RPM spontaneously immortalized cell line Norway rat CVCL_IX00 CL:0000010 Derived from sampling site: Bone marrow Cell type=Megakaryoblast.; Breed/subspecies: Long-Evans. Unspecified 21116408 CVCL_8E89 DA05038 transformed cell line human CVCL_8E89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116409 CVCL_8E88 DA05037 transformed cell line human CVCL_8E88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116410 CVCL_8E85 DA05034 transformed cell line human CVCL_8E85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116411 CVCL_8E84 DA05033 transformed cell line human CVCL_8E84 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116412 CVCL_8E87 DA05036 transformed cell line human CVCL_8E87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116413 CVCL_8E86 DA05035 transformed cell line human CVCL_8E86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116414 CVCL_8E81 DA05030 transformed cell line human CVCL_8E81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116415 CVCL_8E80 DA05029 transformed cell line human CVCL_8E80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116416 CVCL_8E83 DA05032 transformed cell line human CVCL_8E83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116417 CVCL_8E82 DA05031 transformed cell line human CVCL_8E82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116418 CVCL_8E99 DA05050 transformed cell line human CVCL_8E99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116419 CVCL_8E90 DA05039 transformed cell line human CVCL_8E90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116420 CVCL_8E96 DA05045 transformed cell line human CVCL_8E96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116421 CVCL_8E95 DA05044 transformed cell line human CVCL_8E95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116422 CVCL_8E98 DA05049 transformed cell line human CVCL_8E98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116423 CVCL_8E97 DA05047 transformed cell line human CVCL_8E97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116424 CVCL_8E92 DA05041 transformed cell line human CVCL_8E92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116425 CVCL_8E91 DA05040 transformed cell line human CVCL_8E91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116426 CVCL_8E94 DA05043 transformed cell line human CVCL_8E94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116427 CVCL_8E93 DA05042 transformed cell line human CVCL_8E93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116428 CVCL_S452 Hs 396.We finite cell line human CVCL_S452 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7841; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116429 CVCL_RS52 IGR-1rDACARB40 cancer cell line human CVCL_RS52 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Inguinal lymph node. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116430 CVCL_S451 Hs 439.T cancer cell line human CVCL_S451 CL:0000010 Discontinued: ATCC; CRL-7844; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116431 CVCL_RS51 IGR-1rCDDP2000 cancer cell line human CVCL_RS51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Inguinal lymph node. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116432 CVCL_S454 Hs 291.T cancer cell line human CVCL_S454 CL:0000010 Discontinued: ATCC; CRL-7839; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116433 CVCL_RS54 IMR-32rMEL2000 cancer cell line human CVCL_RS54 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116434 CVCL_S453 Hs 430.T cancer cell line human CVCL_S453 CL:0000010 Discontinued: ATCC; CRL-7843; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116435 CVCL_RS53 IMR-32rGEMCI20 cancer cell line human CVCL_RS53 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116436 CVCL_S456 F.M. finite cell line CVCL_S456 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6169; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116437 CVCL_RS56 IMR-32rTOPO20 cancer cell line human CVCL_RS56 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116438 CVCL_RS55 IMR-32rOXALI800 cancer cell line human CVCL_RS55 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116439 CVCL_S455 Mvi/Mu finite cell line CVCL_S455 CL:0000010 Discontinued: ATCC; CRL-6011; true. Female Group: Bat cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116440 CVCL_RS58 IMR-32rVINOR20 cancer cell line human CVCL_RS58 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116441 CVCL_S458 PV2 finite cell line CVCL_S458 CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-6527; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116442 CVCL_S457 Fsp 62891 finite cell line human CVCL_S457 CL:0000010 Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10935. 21116443 CVCL_RS57 IMR-32rTOPO8 cancer cell line human CVCL_RS57 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116444 CVCL_RS59 IMR-5rDACARB20 cancer cell line human CVCL_RS59 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116445 CVCL_S459 PV3 finite cell line CVCL_S459 CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-6528; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116446 CVCL_S461 1283.Lu finite cell line CVCL_S461 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-6297; true Unspecified Group: Non-human primate cell line 21116447 CVCL_RS61 IMR-32rCARBO5000 cancer cell line human CVCL_RS61 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116448 CVCL_RS60 IMR-32rBORTE10 cancer cell line human CVCL_RS60 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116449 CVCL_S460 P.H. finite cell line CVCL_S460 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6177; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116450 CVCL_S441 NZM063 cancer cell line human CVCL_S441 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790). Male 21116451 CVCL_RS41 PC-3rYM155_20nM cancer cell line human CVCL_RS41 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from metastatic site: Bone. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116452 CVCL_RS40 HCC-1806rYM155_20nM cancer cell line human CVCL_RS40 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr256Lysfs*90 (c.766_767insAA); Zygosity=Heterozygous (from parent cell line) Population: African American; Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from sampling site: Breast. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116453 CVCL_S440 NZM033 cancer cell line human CVCL_S440 HLA typing: A*02:01,02:05; B*50:01,51:01; C*01:02,06:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=23658559; PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 62.4 hours (CelloPub=CLPUB00227) 21116454 CVCL_RS43 EMT6-LM2 cancer cell line house mouse CVCL_RS43 CL:0000010 Breed/subspecies: BALB/cCRGL. Female Characteristics: Established from parental cells by two passages in nude mice from spontaneous lung metastases following subcutaneous growth 21116455 CVCL_S443 LN-2669 cancer cell line human CVCL_S443 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from autologous cell line LN-2669GS); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323Valfs*19; Zygosity=Homozygous (from autologous cell line LN-2669GS) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21116456 CVCL_S442 LN-2207 cancer cell line human CVCL_S442 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from autologous cell line LN-2207GS) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21116457 CVCL_RS42 T24rYM155_20nM cancer cell line human CVCL_RS42 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from sampling site: Urinary bladder. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116458 CVCL_S445 Hs 206.T cancer cell line human CVCL_S445 CL:0000010 Discontinued: ATCC; CRL-7837; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116459 CVCL_RS45 PC-3rVCR20 cancer cell line human CVCL_RS45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116460 CVCL_RS44 ARB8 spontaneously immortalized cell line CVCL_RS44 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21116461 CVCL_S444 BS153 cancer cell line human CVCL_S444 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11431328) Derived from sampling site: Brain. Characteristics: Highly overexpresses EGFR (~50 fold) Overexpress the EGFRvIII splice isoform. 21116462 CVCL_RS47 HCC4006rGEFI1muM cancer cell line human CVCL_RS47 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116463 CVCL_S447 Hs 254.T cancer cell line human CVCL_S447 CL:0000010 Discontinued: ATCC; CRL-7838; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116464 CVCL_RS46 HCC4006rERLO1mUM cancer cell line human CVCL_RS46 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116465 CVCL_S446 Hs 924.T cancer cell line human CVCL_S446 CL:0000010 Population: Pacific; Micronesian Discontinued: ATCC; CRL-7918; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116466 CVCL_RS49 HL-60rARA-C2mug/ML cancer cell line human CVCL_RS49 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116467 CVCL_S449 NZM037 cancer cell line human CVCL_S449 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Thr599_Val600insThr (c.1794_1796dup) (p.Thr599dup); ClinVar=VCV000162793; Zygosity=Unspecified (PubMed=23658559); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21116468 CVCL_RS48 HELrARA-C2mug/ML cancer cell line human CVCL_RS48 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116469 CVCL_S448 Hs 313.Sk finite cell line human CVCL_S448 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7840; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116470 CVCL_RS50 MOLM13rARA-C2mug/ML cancer cell line human CVCL_RS50 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116471 CVCL_S450 NZM038 cancer cell line human CVCL_S450 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21116472 CVCL_RS30 NGPrCARBO5000 cancer cell line human CVCL_RS30 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116473 CVCL_S430 NZM025 cancer cell line human CVCL_S430 CL:0000010 Male Doubling time: 37.1 hours (CelloPub=CLPUB00227). 21116474 CVCL_RS32 NGPrDOCE20 cancer cell line human CVCL_RS32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116475 CVCL_S432 NZM027 cancer cell line human CVCL_S432 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21116476 CVCL_RS31 NGPrCDDP1000 cancer cell line human CVCL_RS31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116477 CVCL_S431 NZM026 cancer cell line human CVCL_S431 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23755070; PubMed=32567790). Doubling time: 63.1 hours (CelloPub=CLPUB00227) 21116478 CVCL_RS34 NGPrETO400 cancer cell line human CVCL_RS34 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116479 CVCL_S434 NZM029 cancer cell line human CVCL_S434 CL:0000010 Male 21116480 CVCL_RS33 NGPrDOX20 cancer cell line human CVCL_RS33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116481 CVCL_S433 NZM028 cancer cell line human CVCL_S433 HLA typing: A*01:01,03:01; B*35:01,44:02; C*04:01,05:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ala (c.1406G>C); ClinVar=VCV000013971; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu584Phe (c.1750C>T); ClinVar=VCV000802374; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 38.4 hours (CelloPub=CLPUB00227) 21116482 CVCL_RS36 NGPrOXALI4000 cancer cell line human CVCL_RS36 CL:0000010 Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116483 CVCL_S436 NZM016 cancer cell line human CVCL_S436 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). Doubling time: 50.4 hours (CelloPub=CLPUB00227) 21116484 CVCL_RS35 NGPrMEL3000 cancer cell line human CVCL_RS35 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116485 CVCL_S435 NZM021 cancer cell line human CVCL_S435 CL:0000010 Omics: Deep exome analysis. Male Doubling time: 22.8 hours (CelloPub=CLPUB00227) 21116486 CVCL_RS38 CLF-PED-015-T cancer cell line human CVCL_RS38 CL:0000010 Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Unspecified 21116487 CVCL_S438 NZM018 cancer cell line human CVCL_S438 CL:0000010 Doubling time: 62.5 hours (CelloPub=CLPUB00227). 21116488 CVCL_RS37 NGPrTOPO20 cancer cell line human CVCL_RS37 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116489 CVCL_S437 NZM017 cancer cell line human CVCL_S437 HLA typing: A*68:02,68:02; B*35:01,35:01; C*04:01,04:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by RNAseq. Doubling time: 43.2 hours (CelloPub=CLPUB00227) 21116490 CVCL_RS39 22RV1rYM155_300nM cancer cell line human CVCL_RS39 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:139608; Sepantronium bromide (YM155); Derived from sampling site: Prostate. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116491 CVCL_S439 NZM031 cancer cell line human CVCL_S439 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21116493 CVCL_IY96 HPSI0414i-uawq_2 induced pluripotent stem cell human CVCL_IY96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116494 CVCL_IY99 PER-703 cancer cell line human CVCL_IY99 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Doubling time: 60 hours (PubMed=27443263) 21116496 CVCL_IY93 HPSI0813i-peoj_1 induced pluripotent stem cell human CVCL_IY93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116497 CVCL_IY92 HPSI0813i-mioj_4 induced pluripotent stem cell human CVCL_IY92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116498 CVCL_IY95 HPSI0814i-siqu_4 induced pluripotent stem cell human CVCL_IY95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116499 CVCL_IY94 HPSI0814i-siqu_11 induced pluripotent stem cell human CVCL_IY94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116500 CVCL_IY91 HPSI0813i-mioj_1 induced pluripotent stem cell human CVCL_IY91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116501 CVCL_IY90 C168 cancer cell line human CVCL_IY90 CL:0000010 Unspecified Doubling time: 25 +- 2 hours (PubMed=3947514). 21116502 CVCL_S421 NZM050 cancer cell line human CVCL_S421 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Unspecified (PubMed=23755070). 21116503 CVCL_RS21 UKF-NB-3rRITA10muM cancer cell line human CVCL_RS21 CL:0000010 Selected for resistance to: ChEBI; CHEBI:94980; [5-[5-[5-(hydroxymethyl)-2-thiophenyl]-2-furanyl]-2-thiophenyl]methanol (RITA); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116504 CVCL_S420 NZM051 cancer cell line human CVCL_S420 CL:0000010 21116505 CVCL_RS20 UKF-NB-4AD169 cancer cell line human CVCL_RS20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Bone marrow. Virology: Persistently infected with human cytomegalovirus (HCMV) strain AD169 Doubling time: 24.5-26.6 hours (PubMed=8543403) 21116506 CVCL_S423 NZM048 cancer cell line human CVCL_S423 HLA typing: A*03:01,11:01; B*45:01,45:01; C*06:02,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21116507 CVCL_RS23 SH-SY5YrCDDP500 cancer cell line human CVCL_RS23 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116508 CVCL_RS22 GI-ME-NrCDDP500 cancer cell line human CVCL_RS22 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116509 CVCL_S422 NZM049 cancer cell line human CVCL_S422 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790). 21116510 CVCL_RS25 COG-AR-359 cancer cell line human CVCL_RS25 CL:0000010 Derived from sampling site: Brain. Omics: Deep exome analysis Male Doubling time: 53 hours (CelloPub=CLPUB00418) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21116511 CVCL_S425 NZM044 cancer cell line human CVCL_S425 CL:0000010 21116512 CVCL_S424 NZM047 cancer cell line human CVCL_S424 HLA typing: A*03:01,03:01; B*35:01,44:02; C*04:01,05:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Asn1112fs; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln2582Ter (c.7744C>T); Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21116513 CVCL_RS24 SK-N-ASrCDDP500 cancer cell line human CVCL_RS24 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116514 CVCL_RS27 IMR-32rCDDP500 cancer cell line human CVCL_RS27 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116515 CVCL_S427 NZM035 cancer cell line human CVCL_S427 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). Male 21116516 CVCL_RS26 COG-AR-382 cancer cell line human CVCL_RS26 CL:0000010 Male Doubling time: 82 hours (CelloPub=CLPUB00418). 21116517 CVCL_S426 NZM041 cancer cell line human CVCL_S426 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp594Asn (c.1780G>A); ClinVar=VCV000044813; Zygosity=Unspecified (PubMed=23658559); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Asn1112fs; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln2582Ter (c.7744C>T); Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21116518 CVCL_RS29 COLO-704rCDDP1000 cancer cell line human CVCL_RS29 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites (Note=From a colon metastasis). Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116519 CVCL_S429 NZM039 cancer cell line human CVCL_S429 CL:0000010 Male 21116520 CVCL_RS28 EFO-27rCDDP2000 cancer cell line human CVCL_RS28 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Omentum. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116521 CVCL_S428 NZM036 cancer cell line human CVCL_S428 HLA typing: A*02:01,11:01; B*44:02,48:01; C*05:01,08:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21116522 CVCL_S410 PIG1 transformed cell line human CVCL_S410 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Discontinued: ATCC; CRL-2208; true Male Doubling time: 1.16 days (PubMed=10937834) 21116523 CVCL_RS10 UKF-NB-6rDACARB8 cancer cell line human CVCL_RS10 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116524 CVCL_S412 MDW1 cancer cell line house mouse CVCL_S412 CL:0000010 Breed/subspecies: DBA/2. 21116525 CVCL_RS12 UKF-NB-6rDOX60 cancer cell line human CVCL_RS12 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116526 CVCL_S411 MDAY-D2 cancer cell line house mouse CVCL_S411 CL:0000010 Breed/subspecies: DBA/2. 21116527 CVCL_RS11 UKF-NB-6rDOCE10 cancer cell line human CVCL_RS11 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116528 CVCL_S414 MDW4 cancer cell line house mouse CVCL_S414 CL:0000010 Breed/subspecies: DBA/2. 21116529 CVCL_RS14 UKF-NB-6rMEL2000 cancer cell line human CVCL_RS14 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116530 CVCL_S413 MDW3 cancer cell line house mouse CVCL_S413 CL:0000010 Breed/subspecies: DBA/2. 21116531 CVCL_RS13 UKF-NB-6rGEMCI10 cancer cell line human CVCL_RS13 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116532 CVCL_IY79 HPSI0614i-qunz_2 induced pluripotent stem cell human CVCL_IY79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116533 CVCL_S416 NZM060 cancer cell line human CVCL_S416 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Homozygous (PubMed=32567790) Omics: Deep exome analysis. 21116534 CVCL_RS16 UKF-NB-6rVINB10 cancer cell line human CVCL_RS16 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116535 CVCL_IY78 HPSI0614i-puhk_5 induced pluripotent stem cell human CVCL_IY78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116536 CVCL_S415 MDW5 cancer cell line house mouse CVCL_S415 CL:0000010 Breed/subspecies: DBA/2. 21116537 CVCL_RS15 UKF-NB-6rNutlin10muM cancer cell line human CVCL_RS15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=22170099); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Unspecified (PubMed=22170099) Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116538 CVCL_S418 NZM056 cancer cell line human CVCL_S418 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=32567790). Doubling time: 33.6 hours (CelloPub=CLPUB00227) 21116539 CVCL_RS18 SHEPrSNS-032_2000nM cancer cell line human CVCL_RS18 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:91399; N-[5-[(5-tert-butyl-2-oxazolyl)methylthio]-2-thiazolyl]-4-piperidinecarboxamide (SNS-032; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116540 CVCL_S417 NZM061 cancer cell line human CVCL_S417 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). Male 21116541 CVCL_RS17 UKF-Rhb-1rNutlin10muM cancer cell line human CVCL_RS17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116542 CVCL_IY75 HPSI0614i-lirf_5 induced pluripotent stem cell human CVCL_IY75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116543 CVCL_IY74 HeLa Tet-On cancer cell line human CVCL_IY74 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Clontech; Catalog number 630901 Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21116544 CVCL_S419 NZM055 cancer cell line human CVCL_S419 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21116545 CVCL_RS19 UKF-NB-3rSNS-032_300nM cancer cell line human CVCL_RS19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:91399; N-[5-[(5-tert-butyl-2-oxazolyl)methylthio]-2-thiazolyl]-4-piperidinecarboxamide (SNS-032; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116546 CVCL_IY77 HPSI0614i-puhk_2 induced pluripotent stem cell human CVCL_IY77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116547 CVCL_IY76 HPSI0614i-lirf_6 induced pluripotent stem cell human CVCL_IY76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116548 CVCL_IY71 Ras[V12]-wts[RNAi] spontaneously immortalized cell line fruit fly CVCL_IY71 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP Omics: Transcriptome analysis by RNAseq. Male Characteristics: Established from embryos carrying Act5C-GAL4, UAS-Ras[V12] and UAS-wts[RNAi] transposons Doubling time: 2 days (DGRC) Group: Insect cell line 21116549 CVCL_IY70 Ras[V12]-line-7 spontaneously immortalized cell line fruit fly CVCL_IY70 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP Discontinued: DGRC; 188; probable. Unspecified Group: Insect cell line 21116550 CVCL_IY73 OSC spontaneously immortalized cell line fruit fly CVCL_IY73 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Part of: modENCODE project cell lines 21116551 CVCL_IY72 rumi[26]-Ras[V12]-4 spontaneously immortalized cell line fruit fly CVCL_IY72 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val) Omics: Transcriptome analysis by RNAseq. Female Characteristics: Contains a null mutant of rumi, which encodes a glycosyltransferase required for Notch signaling in Drosophila Doubling time: 28 hours (DGRC) Group: Insect cell line 21116552 CVCL_S401 AKR/JB.Sp finite cell line house mouse CVCL_S401 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: AKR/J. Discontinued: ATCC; CRL-6321; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116553 CVCL_RS01 UKF-NB-2rDOX20 cancer cell line human CVCL_RS01 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116554 CVCL_S400 HT-805.Ut finite cell line human CVCL_S400 CL:0000010 Derived from sampling site: Endometrium. Discontinued: ATCC; CRL-7794; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116555 CVCL_RS00 UKF-NB-2rVCR20 cancer cell line human CVCL_RS00 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116556 CVCL_S403 TE 193.T cancer cell line human CVCL_S403 CL:0000010 Discontinued: ATCC; CRL-7756; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116557 CVCL_RS03 UKF-NB-3rDOCE10 cancer cell line human CVCL_RS03 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116558 CVCL_S402 Hs 749.T cancer cell line human CVCL_S402 CL:0000010 Discontinued: ATCC; CRL-7872; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116559 CVCL_RS02 UKF-NB-2rNutlin10muM cancer cell line human CVCL_RS02 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116560 CVCL_S405 MM4 cancer cell line human CVCL_S405 From: Stierner U.; Gotenborg; Sweden. CL:0000010 21116561 CVCL_RS05 UKF-NB-3rNutlin10muM cancer cell line human CVCL_RS05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=22170099) Selected for resistance to: ChEBI; CHEBI:46742; Nutlin-3; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116562 CVCL_IY89 SW1736 eGFP-H2B cancer cell line human CVCL_IY89 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12373; TSHR; Simple; p.Ile486Phe (c.1456A>T); Zygosity=Heterozygous (from parent cell line); Transfected with: Human histone H2B (but which of the H2B genes is not specificied); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Thyroid gland. Female 21116563 CVCL_S404 TE 567.T finite cell line human CVCL_S404 CL:0000010 Derived from sampling site: Bone; coccyx. Discontinued: ATCC; CRL-7772; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116564 CVCL_RS04 UKF-NB-3rDOX20 cancer cell line human CVCL_RS04 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Doubling time: 18 +- 1.9 hours (PubMed=16142320) Part of: Resistant Cancer Cell Line (RCCL) collection 21116565 CVCL_RS07 GI-ME-NrDOX5 cancer cell line human CVCL_RS07 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116566 CVCL_S407 PG19T3 cancer cell line house mouse CVCL_S407 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C57BL/6J. Female 21116567 CVCL_S406 1123-mel cancer cell line human CVCL_S406 HLA typing: A*24,28 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21116568 CVCL_RS06 UKF-NB-3rMEL2000 cancer cell line human CVCL_RS06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116569 CVCL_IY86 HPSI0614i-wihj_4 induced pluripotent stem cell human CVCL_IY86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116570 CVCL_S409 PG19 cancer cell line house mouse CVCL_S409 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C57BL/6J. Female 21116571 CVCL_RS09 UKF-NB-6rCDDP2000 cancer cell line human CVCL_RS09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21116572 CVCL_S408 CHO-MK42 spontaneously immortalized cell line CVCL_S408 CL:0000010 Derived from sampling site: Ovary. Female 21116573 CVCL_IY85 HPSI0614i-wihj_1 induced pluripotent stem cell human CVCL_IY85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116574 CVCL_RS08 UKF-NB-3rVCR20 cancer cell line human CVCL_RS08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116575 CVCL_IY88 hPheo1 telomerase immortalized cell line human CVCL_IY88 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Adrenal gland. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~1.2 days (PubMed=23785438) 21116576 CVCL_IY87 A549/8 cancer cell line human CVCL_IY87 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung. Male 21116577 CVCL_IY82 HPSI0614i-uevq_6 induced pluripotent stem cell human CVCL_IY82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116578 CVCL_IY81 HPSI0614i-uevq_4 induced pluripotent stem cell human CVCL_IY81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116579 CVCL_IY84 HPSI0614i-voce_2 induced pluripotent stem cell human CVCL_IY84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116580 CVCL_IY83 HPSI0614i-voce_1 induced pluripotent stem cell human CVCL_IY83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116581 CVCL_IY80 HPSI0614i-qunz_3 induced pluripotent stem cell human CVCL_IY80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116582 CVCL_IY57 SK-MEL-29.4 cancer cell line human CVCL_IY57 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21116583 CVCL_IY56 SK-MEL-29.3 cancer cell line human CVCL_IY56 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21116584 CVCL_IY59 SK2 cancer cell line human CVCL_IY59 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000376033; Zygosity=Unspecified (PubMed=6087347). Population: Japanese 21116585 CVCL_IY58 SK-MEL-29.5 cancer cell line human CVCL_IY58 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21116586 CVCL_IY53 SK-MEL-152 cancer cell line human CVCL_IY53 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21116587 CVCL_IY52 HPSI0514i-oupf_6 induced pluripotent stem cell human CVCL_IY52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116588 CVCL_IY55 SK-MEL-29.2 cancer cell line human CVCL_IY55 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21116589 CVCL_IY54 SK-MEL-29.1 cancer cell line human CVCL_IY54 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21116590 CVCL_IY51 HPSI0514i-oupf_5 induced pluripotent stem cell human CVCL_IY51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116591 CVCL_IY50 HPSI0514i-oekw_2 induced pluripotent stem cell human CVCL_IY50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116592 CVCL_IY68 ML83-61 spontaneously immortalized cell line fruit fly CVCL_IY68 CL:0000010 Unspecified Group: Insect cell line. 21116593 CVCL_IY67 ML-DmD14 spontaneously immortalized cell line fruit fly CVCL_IY67 CL:0000010 Derived from sampling site: Imaginal disc. Discontinued: DGRC; 95; probable Unspecified Group: Insect cell line 21116594 CVCL_IY69 S2-Mt-mCherry-alphaTub84B+Mt-GFP-Orbit spontaneously immortalized cell line fruit fly CVCL_IY69 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Doubling time: 35 hours (DGRC) Group: Insect cell line 21116595 CVCL_IY64 HPSI0514i-xayd_5 induced pluripotent stem cell human CVCL_IY64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21116596 CVCL_IY63 HPSI0514i-xayd_4 induced pluripotent stem cell human CVCL_IY63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21116597 CVCL_IY66 ML-DmD16-c5 spontaneously immortalized cell line fruit fly CVCL_IY66 CL:0000010 Derived from sampling site: Imaginal disc; wing. Discontinued: DGRC; 99; probable Female Group: Insect cell line 21116598 CVCL_IY65 HPSI0613i-oesx_3 induced pluripotent stem cell human CVCL_IY65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116599 CVCL_IY60 HPSI0514i-sohd_2 induced pluripotent stem cell human CVCL_IY60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116600 CVCL_IY62 HPSI0514i-tert_3 induced pluripotent stem cell human CVCL_IY62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21116601 CVCL_IY61 HPSI0514i-tert_1 induced pluripotent stem cell human CVCL_IY61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116602 CVCL_8G25 DA05194 transformed cell line human CVCL_8G25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116603 CVCL_8G24 DA05193 transformed cell line human CVCL_8G24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116604 CVCL_8G27 DA05196 transformed cell line human CVCL_8G27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116605 CVCL_8G26 DA05195 transformed cell line human CVCL_8G26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116606 CVCL_8G21 DA05190 transformed cell line human CVCL_8G21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116607 CVCL_8G20 DA05189 transformed cell line human CVCL_8G20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116608 CVCL_8G23 DA05192 transformed cell line human CVCL_8G23 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116609 CVCL_8G22 DA05191 transformed cell line human CVCL_8G22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116610 CVCL_8G29 DA05199 transformed cell line human CVCL_8G29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116611 CVCL_8G28 DA05197 transformed cell line human CVCL_8G28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116612 CVCL_8G36 DA05206 transformed cell line human CVCL_8G36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116613 CVCL_8G35 DA05205 transformed cell line human CVCL_8G35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116614 CVCL_8G38 DA05208 transformed cell line human CVCL_8G38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116615 CVCL_8G37 DA05207 transformed cell line human CVCL_8G37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116616 CVCL_8G32 DA05202 transformed cell line human CVCL_8G32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116617 CVCL_8G31 DA05201 transformed cell line human CVCL_8G31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116618 CVCL_8G34 DA05204 transformed cell line human CVCL_8G34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116619 CVCL_8G33 DA05203 transformed cell line human CVCL_8G33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116620 CVCL_8G39 DA05209 transformed cell line human CVCL_8G39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116621 CVCL_8G30 DA05200 transformed cell line human CVCL_8G30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116622 CVCL_8G03 DA05172 transformed cell line human CVCL_8G03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116623 CVCL_8G02 DA05171 transformed cell line human CVCL_8G02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116624 CVCL_8G05 DA05174 transformed cell line human CVCL_8G05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116625 CVCL_8G04 DA05173 transformed cell line human CVCL_8G04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116626 CVCL_8G01 DA05170 transformed cell line human CVCL_8G01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116627 CVCL_8G00 DA05169 transformed cell line human CVCL_8G00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116628 CVCL_8G07 DA05176 transformed cell line human CVCL_8G07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116629 CVCL_8G06 DA05175 transformed cell line human CVCL_8G06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116630 CVCL_8G09 DA05178 transformed cell line human CVCL_8G09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116631 CVCL_8G08 DA05177 transformed cell line human CVCL_8G08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116632 CVCL_8G14 DA05183 transformed cell line human CVCL_8G14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116633 CVCL_8G13 DA05182 transformed cell line human CVCL_8G13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116634 CVCL_8G16 DA05185 transformed cell line human CVCL_8G16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116635 CVCL_8G15 DA05184 transformed cell line human CVCL_8G15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116636 CVCL_8G10 DA05179 transformed cell line human CVCL_8G10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116637 CVCL_8G12 DA05181 transformed cell line human CVCL_8G12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116638 CVCL_8G11 DA05180 transformed cell line human CVCL_8G11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116639 CVCL_8G18 DA05187 transformed cell line human CVCL_8G18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116640 CVCL_8G17 DA05186 transformed cell line human CVCL_8G17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116641 CVCL_8G19 DA05188 transformed cell line human CVCL_8G19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116642 CVCL_S496 HeLa-LAV cancer cell line human CVCL_S496 CL:0000010 Transfected with: HGNC; 1678; CD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21116643 CVCL_RS96 SK-N-ASrMEL1000 cancer cell line human CVCL_RS96 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116644 CVCL_S495 HeLa-T4+ cancer cell line human CVCL_S495 CL:0000010 Transfected with: HGNC; 1678; CD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21116645 CVCL_RS95 SK-N-ASrIRINO500 cancer cell line human CVCL_RS95 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116646 CVCL_S498 D39 cancer cell line dog CVCL_S498 CL:0000010 Derived from sampling site: Bone; Breed/subspecies: Weimaraner. Discontinued: ATCC; CRL-6251; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116647 CVCL_RS98 SK-N-ASrPCL20 cancer cell line human CVCL_RS98 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116648 CVCL_S497 GHOST(3).CCR4 cancer cell line human CVCL_S497 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1605; CCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Discontinued: HIVReagentProgram; ARP-3683; true Female Caution: Was discontinued from the HIVReagentProgram because the cell line was negative for CCR4 (personal communication of Rashid S.) 21116649 CVCL_RS97 SK-N-ASrOXALI4000(-) cancer cell line human CVCL_RS97 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116650 CVCL_S499 MA1K finite cell line CVCL_S499 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6284; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116651 CVCL_RS99 SK-N-ASrTOPO20 cancer cell line human CVCL_RS99 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116652 CVCL_S485 ABFTL-1 cancer cell line house mouse CVCL_S485 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NFS/N. 21116653 CVCL_RS85 SK-MEL-3rCDDP1000 cancer cell line human CVCL_RS85 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lymph node. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116654 CVCL_S484 J2-BM transformed cell line house mouse CVCL_S484 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. 21116655 CVCL_RS84 SHEPrVCR20 cancer cell line human CVCL_RS84 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116656 CVCL_S487 ABFTL-3 cancer cell line house mouse CVCL_S487 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NFS/N. 21116657 CVCL_RS87 SK-N-ASrCARBO2000 cancer cell line human CVCL_RS87 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116658 CVCL_S486 ABFTL-2 cancer cell line house mouse CVCL_S486 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NFS/N. 21116659 CVCL_RS86 SK-MEL-3rDACARB20 cancer cell line human CVCL_RS86 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Lymph node. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116660 CVCL_S489 GHOST(3) cancer cell line human CVCL_S489 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116661 CVCL_RS89 SK-N-ASrDACARB16 cancer cell line human CVCL_RS89 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116662 CVCL_RS88 SK-N-ASrCDDP1000 cancer cell line human CVCL_RS88 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116663 CVCL_S488 Ska-3-68 cancer cell line human CVCL_S488 CL:0000010 Female 21116664 CVCL_S490 GHOST(3).CCR3 cancer cell line human CVCL_S490 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1604; CCR3 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116666 CVCL_RS90 SK-N-ASrDOCE10 cancer cell line human CVCL_RS90 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116667 CVCL_S492 GHOST(3).CXCR4 cancer cell line human CVCL_S492 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116668 CVCL_RS92 SK-N-ASrETO100 cancer cell line human CVCL_RS92 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116669 CVCL_S491 GHOST(3).CCR5 cancer cell line human CVCL_S491 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116670 CVCL_RS91 SK-N-ASrDOX10 cancer cell line human CVCL_RS91 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116671 CVCL_S494 GHOST(3).CCR8 cancer cell line human CVCL_S494 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1609; CCR8 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116672 CVCL_RS94 SK-N-ASrGEMCI10 cancer cell line human CVCL_RS94 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116673 CVCL_S493 GHOST(3).CXCR6 cancer cell line human CVCL_S493 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 16647; CXCR6 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21116674 CVCL_RS93 SK-N-ASrETO200 cancer cell line human CVCL_RS93 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116675 CVCL_RS74 NGPrVCR20 cancer cell line human CVCL_RS74 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116676 CVCL_S474 U-343MGa Cl2 cancer cell line human CVCL_S474 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21116677 CVCL_RS73 NGPrPCL20 cancer cell line human CVCL_RS73 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116678 CVCL_S473 U-343MGa Cl2:6 cancer cell line human CVCL_S473 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21116679 CVCL_S476 A2780-E(80) cancer cell line human CVCL_S476 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21116680 CVCL_RS76 NGPrVINOR20 cancer cell line human CVCL_RS76 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116681 CVCL_RS75 NGPrVINB20 cancer cell line human CVCL_RS75 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116682 CVCL_S475 U-343MGa Cl3 cancer cell line human CVCL_S475 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21116683 CVCL_RS78 NLFrIRINO1000 cancer cell line human CVCL_RS78 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11 Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116684 CVCL_S478 UMR-104 cancer cell line Norway rat CVCL_S478 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Characteristics: Established from a transplantable tumor 21116685 CVCL_RS77 NLFrCDDP500 cancer cell line human CVCL_RS77 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116686 CVCL_S477 UMR-106-06 cancer cell line Norway rat CVCL_S477 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. 21116687 CVCL_RS79 NLFrVINOR10 cancer cell line human CVCL_RS79 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116688 CVCL_S479 UMR-105 cancer cell line Norway rat CVCL_S479 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Characteristics: Established from a transplantable tumor 21116689 CVCL_S481 AML-1 cancer cell line human CVCL_S481 CL:0000010 Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21116690 CVCL_RS81 SH-SY5YrDOX20 cancer cell line human CVCL_RS81 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116691 CVCL_S480 UV4 transformed cell line CVCL_S480 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21116692 CVCL_S483 MQ-NCSU transformed cell line CVCL_S483 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Spleen; Breed/subspecies: DeKalb XL. Female Characteristics: Used in the context of nitric oxide (NO) production experiments Group: Bird cell line 21116693 CVCL_RS83 SHEPrVCR10 cancer cell line human CVCL_RS83 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116694 CVCL_S482 INF-3A transformed cell line house mouse CVCL_S482 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeN. Unspecified 21116695 CVCL_RS82 SHEPrDOX100 cancer cell line human CVCL_RS82 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21116696 CVCL_S463 D-32MG cancer cell line human CVCL_S463 CL:0000010 Male 21116697 CVCL_RS63 IMR-5rIRINO1000 cancer cell line human CVCL_RS63 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116698 CVCL_RS62 IMR-5rMEL1000 cancer cell line human CVCL_RS62 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116699 CVCL_S462 MBA C57.Ut finite cell line house mouse CVCL_S462 CL:0000010 Derived from sampling site: Embryonic uterus. Discontinued: ATCC; CRL-6368; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21116700 CVCL_S465 CH31 cancer cell line house mouse CVCL_S465 CL:0000010 Breed/subspecies: B10.H-2aH-4bp/Wts. 21116701 CVCL_RS65 H69R cancer cell line human CVCL_RS65 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21116702 CVCL_S464 D-32MGCl2 cancer cell line human CVCL_S464 CL:0000010 Male 21116703 CVCL_RS64 IMR-5rVINB20 cancer cell line human CVCL_RS64 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116704 CVCL_RS67 MelHOrPLX4720_10muM cancer cell line human CVCL_RS67 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90295; PLX-4720 (PLX4720); Derived from sampling site: Skin. Female Part of: Resistant Cancer Cell Line (RCCL) collection Problematic cell line: Misidentified/contaminated Parent cell line (Mel-Ho) was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile. 21116705 CVCL_S467 RPG1/SV40 transformed cell line Norway rat CVCL_S467 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; parotid gland. Unspecified 21116706 CVCL_RS66 H82R cancer cell line human CVCL_RS66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Unspecified; Note=Impairs TP53 splicing dramatically (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21116707 CVCL_S466 SN4741 conditionally immortalized cell line house mouse CVCL_S466 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; substantia nigra Cell type=Dopaminergic neuron.; Breed/subspecies: (CBA/J x C57BL/6) F2 SV40-tsA58 transgenic. Unspecified 21116708 CVCL_RS69 NGPrETO200 cancer cell line human CVCL_RS69 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116709 CVCL_S469 U-2987-P3 cancer cell line human CVCL_S469 CL:0000010 Male 21116710 CVCL_RS68 NGPrBORTE20 cancer cell line human CVCL_RS68 CL:0000010 Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116711 CVCL_S468 U-2987MG cancer cell line human CVCL_S468 CL:0000010 Male 21116712 CVCL_RS70 NGPrIRINO1000 cancer cell line human CVCL_RS70 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116713 CVCL_S470 U-2987-P6 cancer cell line human CVCL_S470 CL:0000010 Male 21116714 CVCL_RS72 NGPrMEL4000 cancer cell line human CVCL_RS72 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116715 CVCL_S472 U-343MGa 31L cancer cell line human CVCL_S472 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21116716 CVCL_RS71 NGPrMEL2000 cancer cell line human CVCL_RS71 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Lung. Male Part of: Resistant Cancer Cell Line (RCCL) collection 21116717 CVCL_S471 U-343MG cancer cell line human CVCL_S471 HLA typing: A*02,03; B*07,27 (PubMed=77569) CL:0000010 Derived from sampling site: Brain; temporal lobe. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=25984343) 21116718 CVCL_8F88 DA05157 transformed cell line human CVCL_8F88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116719 CVCL_8F87 DA05156 transformed cell line human CVCL_8F87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116720 CVCL_8F89 DA05158 transformed cell line human CVCL_8F89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116721 CVCL_8F84 DA05153 transformed cell line human CVCL_8F84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116722 CVCL_8F83 DA05152 transformed cell line human CVCL_8F83 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116723 CVCL_8F86 DA05155 transformed cell line human CVCL_8F86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116724 CVCL_8F85 DA05154 transformed cell line human CVCL_8F85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116725 CVCL_8F80 DA05149 transformed cell line human CVCL_8F80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116726 CVCL_8F82 DA05151 transformed cell line human CVCL_8F82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116727 CVCL_8F81 DA05150 transformed cell line human CVCL_8F81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116728 CVCL_8F99 DA05168 transformed cell line human CVCL_8F99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116729 CVCL_8F98 DA05167 transformed cell line human CVCL_8F98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116730 CVCL_8F95 DA05164 transformed cell line human CVCL_8F95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116731 CVCL_8F94 DA05163 transformed cell line human CVCL_8F94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116732 CVCL_8F97 DA05166 transformed cell line human CVCL_8F97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116733 CVCL_8F96 DA05165 transformed cell line human CVCL_8F96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116734 CVCL_8F91 DA05160 transformed cell line human CVCL_8F91 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116735 CVCL_8F90 DA05159 transformed cell line human CVCL_8F90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116736 CVCL_8F93 DA05162 transformed cell line human CVCL_8F93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116737 CVCL_8F92 DA05161 transformed cell line human CVCL_8F92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116738 CVCL_8F69 DA05138 transformed cell line human CVCL_8F69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116739 CVCL_8F66 DA05135 transformed cell line human CVCL_8F66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116740 CVCL_8F65 DA05134 transformed cell line human CVCL_8F65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116741 CVCL_8F68 DA05137 transformed cell line human CVCL_8F68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116742 CVCL_8F67 DA05136 transformed cell line human CVCL_8F67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116743 CVCL_8F62 DA05130 transformed cell line human CVCL_8F62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116744 CVCL_8F61 DA05128 transformed cell line human CVCL_8F61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116745 CVCL_8F64 DA05132 transformed cell line human CVCL_8F64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116746 CVCL_8F63 DA05131 transformed cell line human CVCL_8F63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116747 CVCL_8F60 DA05127 transformed cell line human CVCL_8F60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116748 CVCL_8F77 DA05146 transformed cell line human CVCL_8F77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116749 CVCL_8F76 DA05145 transformed cell line human CVCL_8F76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116750 CVCL_8F79 DA05148 transformed cell line human CVCL_8F79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116751 CVCL_8F78 DA05147 transformed cell line human CVCL_8F78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116752 CVCL_8F73 DA05142 transformed cell line human CVCL_8F73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116753 CVCL_8F72 DA05141 transformed cell line human CVCL_8F72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116754 CVCL_8F75 DA05144 transformed cell line human CVCL_8F75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116755 CVCL_8F74 DA05143 transformed cell line human CVCL_8F74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116756 CVCL_8F71 DA05140 transformed cell line human CVCL_8F71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116757 CVCL_8F70 DA05139 transformed cell line human CVCL_8F70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116758 CVCL_8F48 DA05110 transformed cell line human CVCL_8F48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116759 CVCL_8F47 DA05109 transformed cell line human CVCL_8F47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116760 CVCL_8F49 DA05111 transformed cell line human CVCL_8F49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116761 CVCL_8F44 DA05106 transformed cell line human CVCL_8F44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116762 CVCL_8F43 DA05105 transformed cell line human CVCL_8F43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116763 CVCL_8F46 DA05108 transformed cell line human CVCL_8F46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116764 CVCL_8F45 DA05107 transformed cell line human CVCL_8F45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116765 CVCL_8F40 DA05099 transformed cell line human CVCL_8F40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116766 CVCL_8F42 DA05104 transformed cell line human CVCL_8F42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116767 CVCL_8F41 DA05103 transformed cell line human CVCL_8F41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116768 CVCL_8F59 DA05125 transformed cell line human CVCL_8F59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116769 CVCL_8F58 DA05124 transformed cell line human CVCL_8F58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116770 CVCL_8F55 DA05118 transformed cell line human CVCL_8F55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116771 CVCL_8F54 DA05117 transformed cell line human CVCL_8F54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116772 CVCL_8F57 DA05123 transformed cell line human CVCL_8F57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116773 CVCL_8F56 DA05119 transformed cell line human CVCL_8F56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116774 CVCL_8F51 DA05113 transformed cell line human CVCL_8F51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116775 CVCL_8F50 DA05112 transformed cell line human CVCL_8F50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116776 CVCL_8F53 DA05116 transformed cell line human CVCL_8F53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116777 CVCL_8F52 DA05114 transformed cell line human CVCL_8F52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116778 CVCL_8F26 DA05084 transformed cell line human CVCL_8F26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116779 CVCL_8F25 DA05083 transformed cell line human CVCL_8F25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116780 CVCL_8F28 DA05087 transformed cell line human CVCL_8F28 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116781 CVCL_8F27 DA05086 transformed cell line human CVCL_8F27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116782 CVCL_8F22 DA05080 transformed cell line human CVCL_8F22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116783 CVCL_8F21 DA05079 transformed cell line human CVCL_8F21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116784 CVCL_8F24 DA05082 transformed cell line human CVCL_8F24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116785 CVCL_8F23 DA05081 transformed cell line human CVCL_8F23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116786 CVCL_8F29 DA05088 transformed cell line human CVCL_8F29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116787 CVCL_8F20 DA05078 transformed cell line human CVCL_8F20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116788 CVCL_8F37 DA05096 transformed cell line human CVCL_8F37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116789 CVCL_8F36 DA05095 transformed cell line human CVCL_8F36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116790 CVCL_8F39 DA05098 transformed cell line human CVCL_8F39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116791 CVCL_8F38 DA05097 transformed cell line human CVCL_8F38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116792 CVCL_8F33 DA05092 transformed cell line human CVCL_8F33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116793 CVCL_8F32 DA05091 transformed cell line human CVCL_8F32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116794 CVCL_8F35 DA05094 transformed cell line human CVCL_8F35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116795 CVCL_8F34 DA05093 transformed cell line human CVCL_8F34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116796 CVCL_8F31 DA05090 transformed cell line human CVCL_8F31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116797 CVCL_8F30 DA05089 transformed cell line human CVCL_8F30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116798 CVCL_IY39 2-27-Ad transformed cell line human CVCL_IY39 CL:0000010 Derived from sampling site: Pharynx; nasopharynx Cell type=Epithelial cell.. Male Virology: EBV-negative 21116799 CVCL_IY38 FDC/HK transformed cell line human CVCL_IY38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Oral cavity; tonsil Cell type=Follicular dendritic cell.. Unspecified Caution: Was indicated to have been established in the absence of EBV (PubMed=7522246), but contains EBV (CLS) 21116800 CVCL_IY35 PPMX0510 hybridoma house mouse CVCL_IY35 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21038 21116801 CVCL_IY34 PPMX0509 hybridoma house mouse CVCL_IY34 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21037 21116802 CVCL_IY37 PPMX0519 hybridoma house mouse CVCL_IY37 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10813 21116803 CVCL_IY36 PPMX0511 hybridoma house mouse CVCL_IY36 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21039 21116804 CVCL_IY31 PPMX0504 hybridoma house mouse CVCL_IY31 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10810 21116805 CVCL_IY30 PPMX0503 hybridoma house mouse CVCL_IY30 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21019 21116806 CVCL_IY33 PPMX0508 hybridoma house mouse CVCL_IY33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10812 21116807 CVCL_IY32 PPMX0507 hybridoma house mouse CVCL_IY32 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10811 21116808 CVCL_IY49 IARC-262 transformed cell line human CVCL_IY49 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116809 CVCL_IY46 CHO/Gqs5 hygromycin-resistant spontaneously immortalized cell line CVCL_IY46 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqs5, with 355-QYELL-359 from GNAS); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21116810 CVCL_IY45 CHO/Gqs5 G418-resistant spontaneously immortalized cell line CVCL_IY45 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqs5, with 355-QYELL-359 from GNAS); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21116811 CVCL_IY48 CHO/Gqz5 hygromycin-resistant spontaneously immortalized cell line CVCL_IY48 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqz5, with 355-YIGLC-359 from GNAZ); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21116812 CVCL_IY47 CHO/Gqz5 G418-resistant spontaneously immortalized cell line CVCL_IY47 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqz5, with 355-YIGLC-359 from GNAZ); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21116813 CVCL_IY42 CHO/Gqi5 G418-resistant spontaneously immortalized cell line CVCL_IY42 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21116814 CVCL_IY41 CHO/Galpha16 spontaneously immortalized cell line CVCL_IY41 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21116815 CVCL_IY44 CHO/Gqo5 spontaneously immortalized cell line CVCL_IY44 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21116816 CVCL_IY43 CHO/Gqi5 hygromycin-resistant spontaneously immortalized cell line CVCL_IY43 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21116817 CVCL_IY40 hZK-1 cancer cell line human CVCL_IY40 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~36 hours (at 10th passage), ~33 hours (at 20th passage), ~29 hours (at 30th passage) (PubMed=28260147) 21116818 CVCL_IY17 SH-N cancer cell line human CVCL_IY17 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21116819 CVCL_IY16 SH-F cancer cell line human CVCL_IY16 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21116820 CVCL_IY19 IARC-105 transformed cell line human CVCL_IY19 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116821 CVCL_IY18 IARC-104 transformed cell line human CVCL_IY18 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116822 CVCL_IY13 HPSI0115i-paim_3 induced pluripotent stem cell human CVCL_IY13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116823 CVCL_IY12 HPSI0115i-paim_1 induced pluripotent stem cell human CVCL_IY12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116824 CVCL_IY15 NB4R cancer cell line human CVCL_IY15 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21116825 CVCL_IY14 HPSI0215i-zett_5 induced pluripotent stem cell human CVCL_IY14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116826 CVCL_IY11 HPSI0115i-gost_2 induced pluripotent stem cell human CVCL_IY11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21116827 CVCL_IY10 HPSI0115i-aoxv_3 induced pluripotent stem cell human CVCL_IY10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116828 CVCL_IY28 PPMX0501 hybridoma house mouse CVCL_IY28 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21017 21116829 CVCL_IY27 HD1B conditionally immortalized cell line house mouse CVCL_IY27 CL:0000010 Knockout cell: Method=KO mouse; MGI:96789; Lipa Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x Wild-type Lal-/-]. Male 21116830 CVCL_IY29 PPMX0502 hybridoma house mouse CVCL_IY29 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q86SJ2; Human AMIGO2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10809 21116831 CVCL_IY24 IARC-089 transformed cell line human CVCL_IY24 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116832 CVCL_IY23 IARC-079 transformed cell line human CVCL_IY23 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116833 CVCL_IY26 HD1A conditionally immortalized cell line house mouse CVCL_IY26 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: [(CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse x Wild-type]. Male 21116834 CVCL_IY25 IARC-090 transformed cell line human CVCL_IY25 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116835 CVCL_IY20 IARC-153 transformed cell line human CVCL_IY20 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116836 CVCL_IY22 IARC-067 transformed cell line human CVCL_IY22 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116837 CVCL_IY21 IARC-210 transformed cell line human CVCL_IY21 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 21116838 CVCL_IY09 HPSI0115i-aoxv_1 induced pluripotent stem cell human CVCL_IY09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21116839 CVCL_IY06 HPSI0516i-oazw_4 induced pluripotent stem cell human CVCL_IY06 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116840 CVCL_IY05 HPSI0516i-oazw_3 induced pluripotent stem cell human CVCL_IY05 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116841 CVCL_IY08 HPSI0516i-pews_3 induced pluripotent stem cell human CVCL_IY08 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116842 CVCL_IY07 HPSI0516i-pews_2 induced pluripotent stem cell human CVCL_IY07 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116843 CVCL_IY02 HPSI0516i-hapz_3 induced pluripotent stem cell human CVCL_IY02 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116844 CVCL_IY01 HPSI0516i-hapz_2 induced pluripotent stem cell human CVCL_IY01 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21116845 CVCL_IY04 HPSI0516i-iool_6 induced pluripotent stem cell human CVCL_IY04 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116846 CVCL_IY03 HPSI0516i-iool_4 induced pluripotent stem cell human CVCL_IY03 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116847 CVCL_IY00 HPSI0516i-goek_4 induced pluripotent stem cell human CVCL_IY00 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21116848 CVCL_AJ59 GM11480 transformed cell line human CVCL_AJ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116849 CVCL_AJ52 GM11430 transformed cell line human CVCL_AJ52 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116850 CVCL_AJ51 GM11429 transformed cell line human CVCL_AJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116851 CVCL_AJ54 GM11453 transformed cell line human CVCL_AJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116852 CVCL_AJ53 GM11452 transformed cell line human CVCL_AJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116853 CVCL_AJ56 GM11457 transformed cell line human CVCL_AJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116854 CVCL_AJ55 GM11456 transformed cell line human CVCL_AJ55 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116855 CVCL_AJ58 GM11479 transformed cell line human CVCL_AJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116856 CVCL_AJ57 GM11458 transformed cell line human CVCL_AJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116857 CVCL_AJ50 GM11402 transformed cell line human CVCL_AJ50 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116858 CVCL_JD00 TER67 transformed cell line human CVCL_JD00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21116859 CVCL_JD02 TER135 transformed cell line human CVCL_JD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21116860 CVCL_JD01 TER311 transformed cell line human CVCL_JD01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21116861 CVCL_AJ63 GM11567 transformed cell line human CVCL_AJ63 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116862 CVCL_AJ62 GM11566 transformed cell line human CVCL_AJ62 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116863 CVCL_AJ65 GM11569 transformed cell line human CVCL_AJ65 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116864 CVCL_AJ64 GM11568 transformed cell line human CVCL_AJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116865 CVCL_AJ67 GM11578 transformed cell line human CVCL_AJ67 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116866 CVCL_AJ66 GM11577 transformed cell line human CVCL_AJ66 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116867 CVCL_AJ69 GM11585 transformed cell line human CVCL_AJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116868 CVCL_AJ68 GM11579 transformed cell line human CVCL_AJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116869 CVCL_AJ61 GM11494 transformed cell line human CVCL_AJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116870 CVCL_AJ60 GM11493 transformed cell line human CVCL_AJ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116871 CVCL_AJ38 GM10290 transformed cell line human CVCL_AJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116872 CVCL_AJ37 GM10223 transformed cell line human CVCL_AJ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116873 CVCL_AJ39 GM10406 transformed cell line human CVCL_AJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116874 CVCL_AJ30 GM10168 transformed cell line human CVCL_AJ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116875 CVCL_AJ32 GM10170 transformed cell line human CVCL_AJ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116876 CVCL_AJ31 GM10169 transformed cell line human CVCL_AJ31 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116877 CVCL_AJ34 GM10185 transformed cell line human CVCL_AJ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116878 CVCL_AJ33 GM10171 transformed cell line human CVCL_AJ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116879 CVCL_AJ36 GM10222 transformed cell line human CVCL_AJ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116880 CVCL_AJ35 GM10211 transformed cell line human CVCL_AJ35 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116881 CVCL_AJ49 GM11401 transformed cell line human CVCL_AJ49 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116882 CVCL_AJ48 GM11333 transformed cell line human CVCL_AJ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116883 CVCL_AJ41 GM10723 transformed cell line human CVCL_AJ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116884 CVCL_AJ40 GM10668 transformed cell line human CVCL_AJ40 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116885 CVCL_AJ43 GM10725 transformed cell line human CVCL_AJ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116886 CVCL_AJ42 GM10724 transformed cell line human CVCL_AJ42 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116887 CVCL_AJ45 GM11330 transformed cell line human CVCL_AJ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116888 CVCL_AJ44 GM11090 transformed cell line human CVCL_AJ44 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116889 CVCL_AJ47 GM11332 transformed cell line human CVCL_AJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116890 CVCL_AJ46 GM11331 transformed cell line human CVCL_AJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116891 CVCL_8P82 DA06205 transformed cell line human CVCL_8P82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116892 CVCL_9182 IE-10 hybridoma CVCL_9182 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10761; Mouse Zp3. 21116893 CVCL_8P81 DA06204 transformed cell line human CVCL_8P81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116894 CVCL_9181 I/24.D6 hybridoma CVCL_9181 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21116895 CVCL_8P84 DA06207 transformed cell line human CVCL_8P84 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116896 CVCL_9184 IM7.8.1 hybridoma CVCL_9184 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116897 CVCL_8P83 DA06206 transformed cell line human CVCL_8P83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116898 CVCL_9183 IE-3 hybridoma CVCL_9183 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20239; Mouse Zp2. 21116899 CVCL_8P80 DA06202 transformed cell line human CVCL_8P80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116900 CVCL_9180 HIL12R1.2B10 hybridoma CVCL_9180 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42701; Human IL12RB1/CD212. 21116901 CVCL_AJ16 GM10119 transformed cell line human CVCL_AJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116902 CVCL_8P89 DA06213 transformed cell line human CVCL_8P89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116903 CVCL_AJ15 GM10117 transformed cell line human CVCL_AJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116904 CVCL_9189 KM201 hybridoma CVCL_9189 CL:0000010 Discontinued: ECACC; 93081113; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116905 CVCL_AJ18 GM10122 transformed cell line human CVCL_AJ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116906 CVCL_AJ17 GM10121 transformed cell line human CVCL_AJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116907 CVCL_8P86 DA06210 transformed cell line human CVCL_8P86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116908 CVCL_9186 J1j.10 hybridoma CVCL_9186 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.2). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116909 CVCL_8P85 DA06208 transformed cell line human CVCL_8P85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116910 CVCL_AJ19 GM10123 transformed cell line human CVCL_AJ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116911 CVCL_9185 J11d.2 hybridoma CVCL_9185 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116912 CVCL_8P88 DA06212 transformed cell line human CVCL_8P88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116913 CVCL_9188 KM114 hybridoma CVCL_9188 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116914 CVCL_8P87 DA06211 transformed cell line human CVCL_8P87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116915 CVCL_9187 JES3-19F1.1.1 hybridoma CVCL_9187 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P22301; Human IL10. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10487 21116916 CVCL_AJ10 GM10083 transformed cell line human CVCL_AJ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116917 CVCL_AJ12 GM10085 transformed cell line human CVCL_AJ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116918 CVCL_AJ11 GM10084 transformed cell line human CVCL_AJ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116919 CVCL_AJ14 GM10087 transformed cell line human CVCL_AJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116920 CVCL_AJ13 GM10086 transformed cell line human CVCL_AJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116921 CVCL_8P93 DA06217 transformed cell line human CVCL_8P93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116922 CVCL_9193 KMI6 hybridoma CVCL_9193 CL:0000010 Discontinued: BCRJ; 0136; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09055; Mouse Itgb1/Cd29 21116923 CVCL_8P92 DA06216 transformed cell line human CVCL_8P92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116924 CVCL_9192 KMC8.8 hybridoma CVCL_9192 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P40240; Mouse Cd9. 21116925 CVCL_8P95 DA06219 transformed cell line human CVCL_8P95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116926 CVCL_9195 LYK-12 hybridoma CVCL_9195 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116927 CVCL_8P94 DA06218 transformed cell line human CVCL_8P94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116928 CVCL_9194 LYK-1 hybridoma CVCL_9194 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116929 CVCL_8P91 DA06215 transformed cell line human CVCL_8P91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116930 CVCL_9191 KM81 hybridoma CVCL_9191 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116931 CVCL_8P90 DA06214 transformed cell line human CVCL_8P90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116932 CVCL_9190 KM703 hybridoma CVCL_9190 CL:0000010 Discontinued: BCRJ; 0137; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21116933 CVCL_AJ27 GM10164 transformed cell line human CVCL_AJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116934 CVCL_AJ26 GM10163 transformed cell line human CVCL_AJ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116935 CVCL_AJ29 GM10166 transformed cell line human CVCL_AJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116936 CVCL_AJ28 GM10165 transformed cell line human CVCL_AJ28 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116937 CVCL_8P97 DA06221 transformed cell line human CVCL_8P97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116938 CVCL_9197 LYK-5 hybridoma CVCL_9197 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116939 CVCL_8P96 DA06220 transformed cell line human CVCL_8P96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116940 CVCL_9196 LYK-16 hybridoma CVCL_9196 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116941 CVCL_8P99 DA06223 transformed cell line human CVCL_8P99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116942 CVCL_9199 LYK-8 hybridoma CVCL_9199 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116943 CVCL_8P98 DA06222 transformed cell line human CVCL_8P98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116944 CVCL_9198 LYK-7 hybridoma CVCL_9198 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21116945 CVCL_AJ21 GM10151 transformed cell line human CVCL_AJ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116946 CVCL_AJ20 GM10124 transformed cell line human CVCL_AJ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116947 CVCL_AJ23 GM10153 transformed cell line human CVCL_AJ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116948 CVCL_AJ22 GM10152 transformed cell line human CVCL_AJ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116949 CVCL_AJ25 GM10162 transformed cell line human CVCL_AJ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116950 CVCL_AJ24 GM10154 transformed cell line human CVCL_AJ24 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116951 CVCL_9160 4C4 hybridoma CVCL_9160 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11609; Mouse Cd1d1. 21116952 CVCL_8P60 DA06176 transformed cell line human CVCL_8P60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116953 CVCL_9162 53-6.72 hybridoma CVCL_9162 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116954 CVCL_8P62 DA06178 transformed cell line human CVCL_8P62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116955 CVCL_9161 4D11 [Rat hybridoma against mouse Klra7] hybridoma CVCL_9161 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q60654; Mouse Klra7 (isoform Ly-49G.2). 21116956 CVCL_8P61 DA06177 transformed cell line human CVCL_8P61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116957 CVCL_9168 CDR1 hybridoma CVCL_9168 CL:0000010 Monoclonal antibody isotype: IgG2a. 21116958 CVCL_8P68 DA06184 transformed cell line human CVCL_8P68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116959 CVCL_9167 BVD2-23B6.4 hybridoma CVCL_9167 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9568 21116960 CVCL_8P67 DA06183 transformed cell line human CVCL_8P67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116961 CVCL_8P69 DA06185 transformed cell line human CVCL_8P69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116962 CVCL_9169 DATK32 hybridoma CVCL_9169 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00651; Mouse Itga4/Cd49d; Monoclonal antibody target: UniProtKB; P26011; Mouse Itgb7. 21116963 CVCL_9164 B21-2 hybridoma CVCL_9164 CL:0000010 Monoclonal antibody isotype: IgG2b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116964 CVCL_8P64 DA06180 transformed cell line human CVCL_8P64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116965 CVCL_9163 53-7.313 hybridoma CVCL_9163 CL:0000010 Discontinued: BCRJ; 0025; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13379; Mouse Cd5 Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116966 CVCL_8P63 DA06179 transformed cell line human CVCL_8P63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116967 CVCL_9166 BVD2-21C11.3 hybridoma CVCL_9166 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9569 21116968 CVCL_8P66 DA06182 transformed cell line human CVCL_8P66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116969 CVCL_9165 BE29G1 hybridoma CVCL_9165 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13597; Mouse Icam1/Cd54. 21116970 CVCL_8P65 DA06181 transformed cell line human CVCL_8P65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116971 CVCL_8P71 DA06187 transformed cell line human CVCL_8P71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116972 CVCL_9171 DEC-205 hybridoma CVCL_9171 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q60767; Mouse Ly75/Cd205. 21116973 CVCL_8P70 DA06186 transformed cell line human CVCL_8P70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116974 CVCL_9170 DC101 hybridoma CVCL_9170 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P35918; Mouse Kdr/Cd309. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11534 21116975 CVCL_8P73 DA06190 transformed cell line human CVCL_8P73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116976 CVCL_9173 ED1-19-1-6-5 hybridoma CVCL_9173 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse IgG2. 21116977 CVCL_8P72 DA06189 transformed cell line human CVCL_8P72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116978 CVCL_9172 E13 161-7 hybridoma CVCL_9172 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05533; Mouse Ly6a. 21116979 CVCL_8P79 DA06201 transformed cell line human CVCL_8P79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116980 CVCL_AJ05 GM10058 transformed cell line human CVCL_AJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116981 CVCL_9179 HD168 hybridoma CVCL_9179 CL:0000010 Monoclonal antibody isotype: IgG2a. 21116982 CVCL_8P78 DA06200 transformed cell line human CVCL_8P78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116983 CVCL_AJ04 GM10057 transformed cell line human CVCL_AJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116984 CVCL_9178 GR-96 hybridoma CVCL_9178 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P15261; Mouse Ifngr1/Cd119. 21116985 CVCL_AJ07 GM10060 transformed cell line human CVCL_AJ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116986 CVCL_AJ06 GM10059 transformed cell line human CVCL_AJ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116987 CVCL_8P75 DA06197 transformed cell line human CVCL_8P75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116988 CVCL_9175 GL1 hybridoma CVCL_9175 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42082; Mouse Cd86. 21116989 CVCL_AJ09 GM10071 transformed cell line human CVCL_AJ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116990 CVCL_8P74 DA06191 transformed cell line human CVCL_8P74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116991 CVCL_9174 FD441.8 hybridoma CVCL_9174 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P24063; Mouse Itgal/Cd11a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21116992 CVCL_AJ08 GM10070 transformed cell line human CVCL_AJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116993 CVCL_8P77 DA06199 transformed cell line human CVCL_8P77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116994 CVCL_9177 GR-20 hybridoma CVCL_9177 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01580; Mouse Ifng. 21116995 CVCL_8P76 DA06198 transformed cell line human CVCL_8P76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21116996 CVCL_9176 GL7 hybridoma CVCL_9176 CL:0000010 Monoclonal antibody isotype: IgM. 21116997 CVCL_AJ01 GM10044 transformed cell line human CVCL_AJ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21116998 CVCL_AJ00 GM10043 transformed cell line human CVCL_AJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21116999 CVCL_AJ03 GM10056 transformed cell line human CVCL_AJ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117000 CVCL_AJ02 GM10045 transformed cell line human CVCL_AJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117001 CVCL_JD77 GM00984 finite cell line human CVCL_JD77 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00984; probable Female 21117002 CVCL_JD76 GM01087 finite cell line human CVCL_JD76 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01087; probable Female 21117003 CVCL_JD79 GM00453 finite cell line human CVCL_JD79 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00453; probable Female 21117004 CVCL_JD78 GM01581 finite cell line human CVCL_JD78 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01581; probable Female 21117005 CVCL_JD73 GM01620 finite cell line human CVCL_JD73 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (from autologous cell lines GM02085 and HG1947) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 53(StAs) (BSR53); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01620; probable; Discontinued: Coriell; GM01620; probable Female 21117006 CVCL_JD72 TER343 transformed cell line human CVCL_JD72 HLA typing: DPB1*02:01; DQA1*01:03,01:04; DQB1*05:03,06:03; DRB1*13:10,14:05; DRB3*01:01,02:02 (IPD-IMGT/HLA=14099) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117007 CVCL_JD75 GM02364 finite cell line human CVCL_JD75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM02364; probable Male 21117008 CVCL_JD74 GM00391 finite cell line human CVCL_JD74 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00391; probable Female 21117009 CVCL_JD71 41405 transformed cell line human CVCL_JD71 HLA typing: A*02:01,03:01; B*07:02,35:41; C*04:01,07:02; DQA1*05,01:01; DQB1*02:01,05:01; DRB1*01:03,03:AXS; DRB3*01 (IPD-IMGT/HLA=13256) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117010 CVCL_JD70 DSA31N transformed cell line human CVCL_JD70 HLA typing: A*29:02:01,31:14N; B*35:03,44; C*04:KBG,16; DQB1*02:02; DRB1*07:01; DRB4*01:01 (IPD-IMGT/HLA=14513) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117011 CVCL_JD69 UKNEQAS_H&I_411/2003 transformed cell line human CVCL_JD69 HLA typing: A*02:01,23:12; B*27:05,44:02; C*01:AFB,05:AG; DPA1*01:03,07; DPB1*04:01,04:02; DQA1*01:01,03; DQB1*05:01,03:01; DRB1*01:01,04:01; DRB4*01:03 (IPD-IMGT/HLA=13254) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117012 CVCL_JD88 GM01166 finite cell line human CVCL_JD88 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01166; probable Female 21117013 CVCL_JD87 GM01491 finite cell line human CVCL_JD87 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01491; probable Ambiguous 21117014 CVCL_JD89 GM01862 finite cell line human CVCL_JD89 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01862; probable Ambiguous 21117015 CVCL_JD84 GM01534 finite cell line human CVCL_JD84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01534; probable Female 21117016 CVCL_JD83 GM00993 finite cell line human CVCL_JD83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00993; probable Female 21117017 CVCL_JD86 GM00868 finite cell line human CVCL_JD86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00868; probable Ambiguous 21117018 CVCL_JD85 GM00805 finite cell line human CVCL_JD85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00805; probable Male 21117019 CVCL_JD80 GM01918 finite cell line human CVCL_JD80 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01918; probable Male 21117020 CVCL_JD82 GM00775 finite cell line human CVCL_JD82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00775; probable Female 21117021 CVCL_JD81 GM00446 finite cell line human CVCL_JD81 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00446; probable Male 21117022 CVCL_JD55 TER361 transformed cell line human CVCL_JD55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117023 CVCL_JD54 17933/00 transformed cell line human CVCL_JD54 HLA typing: A*11:01,24:33; B*27:06,51:06; C*03,12; DQB1*05:01,05:02; DRB1*15:02,12:02 (IPD-IMGT/HLA=12640) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117024 CVCL_JD57 TER308 transformed cell line human CVCL_JD57 HLA typing: DPB1*04:02; DQA1*01:01,03:01; DQB1*05:01,03:02; DRB1*01:01:01,04:15; DRB4*01:03 (IPD-IMGT/HLA=14087) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117025 CVCL_JD56 TER393 transformed cell line human CVCL_JD56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117026 CVCL_JD51 TER120 transformed cell line human CVCL_JD51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117027 CVCL_JD50 TER85 transformed cell line human CVCL_JD50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117028 CVCL_JD53 37057 transformed cell line human CVCL_JD53 HLA typing: A*24:21,31; B*07,49:01; C*07:01; DQA1*01:01,02:01; DQB1*02:02,05:01; DRB1*01:01,07:01; DRB4*01:MZ (IPD-IMGT/HLA=13396) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117029 CVCL_JD52 43623 transformed cell line human CVCL_JD52 HLA typing: A*01,24:48N; B*08; C*07:01; DPA1*01:CG; DPB1*02:01,03:AMYJ; DQA1*03,05; DQB1*02:01,03:04; DRB1*04:APPB,03:01/03:13/03:23; DRB3*01; DRB4*01 (IPD-IMGT/HLA=13546) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117030 CVCL_JD48 42989 transformed cell line human CVCL_JD48 HLA typing: A*01:16N,02:BAJC; B*08,44:02; C*05:01,07:VS; DPA1*01:CG; DPB1*03:AMYJ,04:AGGH; DQA1*01:02,05; DQB1*06:02,03:01; DRB1*11:04,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=13965) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117031 CVCL_JD47 TER300 transformed cell line human CVCL_JD47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117032 CVCL_JD49 11829109 transformed cell line human CVCL_JD49 HLA typing: A*01,68; B*08:19N,40; C*03:04,07:DBKP; DPA1*01:CG; DPB1*04:UR,04:AGGH; DQA1*03,05; DQB1*02:01,03:JV; DRB1*03:NNN,04:DPJ; DRB3*01; DRB4*01 (IPD-IMGT/HLA=13009) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117033 CVCL_JD66 GM01977 finite cell line human CVCL_JD66 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01977; probable Male 21117034 CVCL_JD65 GM01970 finite cell line human CVCL_JD65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01970; probable Male 21117035 CVCL_JD68 TER69 transformed cell line human CVCL_JD68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117036 CVCL_JD67 GM01986 finite cell line human CVCL_JD67 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01986; probable Female 21117037 CVCL_JD62 TER388 transformed cell line human CVCL_JD62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117038 CVCL_JD61 36777 transformed cell line human CVCL_JD61 HLA typing: A*02:01:01,11:15; B*27:05:02,35:01:01; C*02:02:02,04:01:01; DQA1*01:DF,03; DQB1*03:02,05:03; DRB1*04:04,14:01:01; DRB3*02:02:01; DRB4*01:03 (IPD-IMGT/HLA=13205) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117039 CVCL_JD64 GN00105 transformed cell line human CVCL_JD64 HLA typing: B*07:02:01:01,15:34 (IPD-IMGT/HLA=10619) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117040 CVCL_JD63 13703390 transformed cell line human CVCL_JD63 HLA typing: A*02:BAJC; B*39:04,15:11:01; C*03:03,07:02; DPA1*01:CG,02:02; DPB1*02:02,05:01/38:01/63:01/97:01; DQA1*03; DQB1*03:03; DRB1*09:01; DRB4*01 (IPD-IMGT/HLA=14033) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117041 CVCL_JD60 10913246 transformed cell line human CVCL_JD60 HLA typing: A*32,03:11N; B*07,40; C*07:AWNZ,15:AJA; DQA1*01,03; DQB1*06:US,03:JV; DRB1*04:01,15:01; DRB4*01; DRB5*01 (IPD-IMGT/HLA=13006) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117042 CVCL_JD59 UKNEQAS_ED04/02 transformed cell line human CVCL_JD59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117043 CVCL_JD58 1083933x transformed cell line human CVCL_JD58 HLA typing: A*24,32; B*14,18; C*07,08; DPB1*02:01:02,03:01:01; DQA1*02:01,05:05; DQB1*02:02,03:01:01; DRB1*07:01:01,13:11:01; DRB3*02:02:01; DRB4*01:01:01:01 (IPD-IMGT/HLA=11975) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117044 CVCL_JD33 19418 transformed cell line human CVCL_JD33 HLA typing: A*26:01,32:01; B*45:01,27:08; C*06:02; DQA1*02:01,05; DQB1*02:02,03; DRB1*07,11; DRB3*02; DRB4*01 (IPD-IMGT/HLA=10089) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117045 CVCL_JD32 21690 transformed cell line human CVCL_JD32 HLA typing: A*02,29; B*18,44; C*05:01,07; DPB1*02:01; DQA1*01:01,05:05; DQB1*05:01,03:01; DRB1*01:03,11:29; DRB3*02:02 (IPD-IMGT/HLA=12011) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117046 CVCL_JD35 TER283 transformed cell line human CVCL_JD35 HLA typing: A*11:01,33:03; B*18:01,52:01; C*07:02,07:04; DPB1*01:01,05:01; DQA1*01:01,01:04; DQB1*05:01,05:03; DRB1*15:02:01,14:10; DRB3*02:02; DRB5*01:02 (IPD-IMGT/HLA=14105) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117047 CVCL_JD34 TER271 transformed cell line human CVCL_JD34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117048 CVCL_JD31 TER181 transformed cell line human CVCL_JD31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117049 CVCL_JD30 46117 transformed cell line human CVCL_JD30 HLA typing: A*03,68; B*47:01,40; C*03:19,06:02; DPA1*01:CG,02:01; DPB1*04:01,13:01; DQA1*03; DQB1*03:02; DRB1*04:05,04:APPB; DRB4*01 (IPD-IMGT/HLA=14043) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117050 CVCL_AJ96 HPSI0514i-lako_1 induced pluripotent stem cell human CVCL_AJ96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117051 CVCL_AJ95 HPSI0514i-kuco_5 induced pluripotent stem cell human CVCL_AJ95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117052 CVCL_AJ98 HPSI0514i-toco_5 induced pluripotent stem cell human CVCL_AJ98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117053 CVCL_AJ97 HPSI0514i-lako_2 induced pluripotent stem cell human CVCL_AJ97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117054 CVCL_AJ99 HPSI0614i-ciwj_1 induced pluripotent stem cell human CVCL_AJ99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117055 CVCL_JD29 45305 transformed cell line human CVCL_JD29 HLA typing: A*02:BAJC,68; B*51,40:38; C*03:04,14:02; DPA1*01:CG; DPB1*02:01,03:AMYJ; DQA1*01:02,01:03; DQB1*06:03,06:04; DRB1*13:AGTW,13:AUW; DRB3*01,03:01 (IPD-IMGT/HLA=13894) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117056 CVCL_AJ90 HPSI0414i-oulr_2 induced pluripotent stem cell human CVCL_AJ90 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117057 CVCL_AJ92 HPSI0414i-sebn_3 induced pluripotent stem cell human CVCL_AJ92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117058 CVCL_JD26 UCLA 144 transformed cell line human CVCL_JD26 HLA typing: A*01:03,69:01; B*51:01,73:01; C*15,16:02; DQA1*01:02,05:01; DQB1*03:01,05:02; DRB1*11:01,15:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=11511) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117059 CVCL_AJ91 HPSI0414i-oulr_4 induced pluripotent stem cell human CVCL_AJ91 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117060 CVCL_JD25 TER257 transformed cell line human CVCL_JD25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117061 CVCL_AJ94 HPSI0514i-kuco_1 induced pluripotent stem cell human CVCL_AJ94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21117062 CVCL_JD28 TER146 transformed cell line human CVCL_JD28 HLA typing: DPB1*39:01,40:01; DQA1*01:02,02:01; DQB1*06:02,02:02; DRB1*15:03,13:03:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=14097) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117063 CVCL_AJ93 HPSI0414i-sebn_4 induced pluripotent stem cell human CVCL_AJ93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117064 CVCL_JD27 TER248 transformed cell line human CVCL_JD27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117065 CVCL_JD44 35285 transformed cell line human CVCL_JD44 HLA typing: A*01,02; B*40:52,37; C*03:04,06:BG; DQA1*01:DF,03; DQB1*05:03,03:JV; DRB1*04:APPJ,14:JCJ; DRB3*02; DRB4*01 (IPD-IMGT/HLA=13977) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117066 CVCL_JD43 HDB transformed cell line human CVCL_JD43 HLA typing: A*02,02; B*15,35; C*01,04; DPB1*04:02,04:02; DQA1*05:03,05:03; DQB1*03:01:01,03:01:01; DRB1*14:06:01,14:24; DRB3*01:01:02,01:01:02 (IPD-IMGT/HLA=10721) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117067 CVCL_JD46 TER367 transformed cell line human CVCL_JD46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117068 CVCL_JD45 32711 transformed cell line human CVCL_JD45 HLA typing: A*02:01:05,11; B*44:02,35; C*05:01,04:01; DQA1*05,01:01; DQB1*05:01,03:01; DRB1*01,11:01; DRB3*02:02 (IPD-IMGT/HLA=12294) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117069 CVCL_JD40 35980 transformed cell line human CVCL_JD40 HLA typing: A*02:01,68:01; B*40:01,57:08; C*03:04,06:02; DPA1*01:CG; DPB1*03:AMYJ,05:BAJU; DQA1*01,02:01; DQB1*02:02,06:04; DRB1*07:01,13:02; DRB3*03:01; DRB4*01:MZ (IPD-IMGT/HLA=12603) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117070 CVCL_JD42 TER230 transformed cell line human CVCL_JD42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117071 CVCL_JD41 TER299 transformed cell line human CVCL_JD41 HLA typing: A*01:01,26:01; B*08:01,38:09; C*07:AG,12:03 (IPD-IMGT/HLA=12916) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117072 CVCL_JD37 TER420 transformed cell line human CVCL_JD37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117073 CVCL_JD36 TER419 transformed cell line human CVCL_JD36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117074 CVCL_JD39 30733VTIS transformed cell line human CVCL_JD39 HLA typing: B*44:02:01,27:23; C*02:02,05:AB (IPD-IMGT/HLA=12315) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117075 CVCL_JD38 TER415 transformed cell line human CVCL_JD38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117076 CVCL_JD11 TER331 transformed cell line human CVCL_JD11 HLA typing: DPB1*01:01,03:01; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:01:01,13:06; DRB3*01:01 (IPD-IMGT/HLA=14098) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117077 CVCL_JD10 TER276 transformed cell line human CVCL_JD10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117078 CVCL_JD13 TER418 transformed cell line human CVCL_JD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117079 CVCL_JD12 TER529 transformed cell line human CVCL_JD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117080 CVCL_AJ74 GM11610 transformed cell line human CVCL_AJ74 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117081 CVCL_AJ73 GM11600 transformed cell line human CVCL_AJ73 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117082 CVCL_AJ76 GM11616 transformed cell line human CVCL_AJ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117083 CVCL_AJ75 GM11611 transformed cell line human CVCL_AJ75 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117084 CVCL_AJ78 GM11626 transformed cell line human CVCL_AJ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117085 CVCL_AJ77 GM11617 transformed cell line human CVCL_AJ77 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117086 CVCL_AJ79 GM11627 transformed cell line human CVCL_AJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117087 CVCL_JD08 TER320 transformed cell line human CVCL_JD08 HLA typing: DPB1*02:02,03:01; DQA1*01:02,05:01; DQB1*02:01,06:04; DRB1*03:01:01,13:29; DRB3*02:02,03:01 (IPD-IMGT/HLA=14101) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117088 CVCL_JD07 TER297 transformed cell line human CVCL_JD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117089 CVCL_JD09 29182 transformed cell line human CVCL_JD09 HLA typing: A*24:02,68:02; B*47:03,52:01; C*07:AG,12:02; DPA1*02:01,03:01; DPB1*04:AGGH,09:01; DQA1*01:03; DQB1*06:01,06:08; DRB1*13:01,15:02 (IPD-IMGT/HLA=10122) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117090 CVCL_AJ70 GM11586 transformed cell line human CVCL_AJ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117091 CVCL_JD04 TER264 transformed cell line human CVCL_JD04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117092 CVCL_JD03 TER268 transformed cell line human CVCL_JD03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117093 CVCL_JD06 1156492+ transformed cell line human CVCL_JD06 HLA typing: A*02:01; B*07:03,44; C*03:04,05:GS; DQA1*01:BF; DQB1*06:09,06:US; DRB1*13:02,15:ZF; DRB3*03:01; DRB5*01 (IPD-IMGT/HLA=14069) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117094 CVCL_AJ72 GM11599 transformed cell line human CVCL_AJ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117095 CVCL_AJ71 GM11598 transformed cell line human CVCL_AJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117096 CVCL_JD05 TER111 transformed cell line human CVCL_JD05 HLA typing: DPB1*01:01,17:01; DQA1*04:01,01:02; DQB1*05:01,03:01; DRB1*13:02:01,08:04:01; DRB3*03:01 (IPD-IMGT/HLA=14092) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117097 CVCL_JD22 TER172 transformed cell line human CVCL_JD22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117098 CVCL_JD21 TER365 transformed cell line human CVCL_JD21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117099 CVCL_JD24 TER363 transformed cell line human CVCL_JD24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117100 CVCL_JD23 TER73 transformed cell line human CVCL_JD23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117101 CVCL_JD20 35919 transformed cell line human CVCL_JD20 HLA typing: A*01,31; B*08,40:01; C*03:04,07; DPB1*04:01,06:01; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:04,04:04; DRB3*01:01; DRB4*01:03 (IPD-IMGT/HLA=12583) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21117102 CVCL_AJ85 HPSI0215i-deyz_2 induced pluripotent stem cell human CVCL_AJ85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117103 CVCL_AJ84 HPSI0115i-zihe_1 induced pluripotent stem cell human CVCL_AJ84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117104 CVCL_AJ87 HPSI0414i-eevy_6 induced pluripotent stem cell human CVCL_AJ87 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117105 CVCL_AJ86 HPSI0215i-deyz_3 induced pluripotent stem cell human CVCL_AJ86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117106 CVCL_AJ89 HPSI0414i-gesg_2 induced pluripotent stem cell human CVCL_AJ89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117107 CVCL_AJ88 HPSI0414i-eevy_7 induced pluripotent stem cell human CVCL_AJ88 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117108 CVCL_JD19 10843566 transformed cell line human CVCL_JD19 HLA typing: A*02,03; B*07,35; DPB1*02:01,03:01; DQA1*01:05,03:02; DQB1*05:01,03:03; DRB1*10:01,13:20; DRB3*01:01 (IPD-IMGT/HLA=10025) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117109 CVCL_JD18 TER336 transformed cell line human CVCL_JD18 HLA typing: DPB1*04:02; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:04,13:01:01; DRB3*01:01,02:02 (IPD-IMGT/HLA=14084) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117110 CVCL_AJ81 HPSI0115i-gifk_1 induced pluripotent stem cell human CVCL_AJ81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117111 CVCL_JD15 TER1132 transformed cell line human CVCL_JD15 HLA typing: A*24:37,34:01; B*15:21,15:35; C*04:03,07:02; DPB1*01:01:01,05:01; DRB1*04:03:01,15:01 (IPD-IMGT/HLA=12913) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117112 CVCL_JD14 26586 transformed cell line human CVCL_JD14 HLA typing: A*02:01,24:23; B*51:01,15:01; C*03:03,03:04; DPB1*02:01,03:01; DQA1*01:03,03:01; DQB1*06:03,03:02; DRB1*04:07,13:01; DRB3*02:02; DRB4*01:03:01 (IPD-IMGT/HLA=12247) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117113 CVCL_AJ80 GM13532 transformed cell line human CVCL_AJ80 CL:0000010 Sequence variation: Mutation; HGNC; 4195; GCK; Simple; p.Glu279Gln (c.835G>C); ClinVar=VCV000211076; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117114 CVCL_AJ83 HPSI0115i-melw_2 induced pluripotent stem cell human CVCL_AJ83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117115 CVCL_JD17 TER347 transformed cell line human CVCL_JD17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117116 CVCL_AJ82 HPSI0115i-melw_1 induced pluripotent stem cell human CVCL_AJ82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117117 CVCL_JD16 TER215 transformed cell line human CVCL_JD16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117118 CVCL_0729 Hs 357.T cancer cell line human CVCL_0729 CL:0000010 Derived from sampling site: Skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117119 CVCL_0728 Hs 350.T cancer cell line human CVCL_0728 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117120 CVCL_0721 Hs 313.T cancer cell line human CVCL_0721 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117121 CVCL_0720 Hs 3.T cancer cell line human CVCL_0720 CL:0000010 Population: African American; Derived from sampling site: Bone. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117122 CVCL_0723 Hs 324.T cancer cell line human CVCL_0723 CL:0000010 Derived from sampling site: Lymph node. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117123 CVCL_0722 Hs 319.T cancer cell line human CVCL_0722 CL:0000010 Discontinued: ATCC; CRL-7236; probable. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117124 CVCL_0725 Hs 329.T cancer cell line human CVCL_0725 CL:0000010 Discontinued: ATCC; CRL-7242; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117125 CVCL_0724 Hs 325.Ln finite cell line human CVCL_0724 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7240; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117126 CVCL_0727 Hs 344.T cancer cell line human CVCL_0727 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117127 CVCL_0726 Hs 343.T undefined cell line type human CVCL_0726 Genome ancestry: African=1.49%; Native American=0%; East Asian, North=0.52%; East Asian, South=1.3%; South Asian=6.72%; European, North=33.67%; European, South=56.3% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117128 CVCL_0739 Hs 389(B).Lu finite cell line human CVCL_0739 CL:0000010 Donor information: Established from dizygotic twin of Hs 389(A).Lu (Cellosaurus=CVCL_0738); Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7266; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117129 CVCL_0730 Hs 362.T cancer cell line human CVCL_0730 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117130 CVCL_0732 Hs 365.Ct finite cell line human CVCL_0732 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-7255; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117131 CVCL_0731 Hs 364.Ct finite cell line human CVCL_0731 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-7254; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117132 CVCL_0734 Hs 372.Sk finite cell line human CVCL_0734 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7257; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117133 CVCL_0733 Hs 371.T cancer cell line human CVCL_0733 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117134 CVCL_0736 Hs 383.Sk finite cell line human CVCL_0736 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7842; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117135 CVCL_0735 Hs 38.T cancer cell line human CVCL_0735 HLA typing: A*02:05,02:05; B*35:08,58:01; C*07:01,07:01; DQA1*03:02,03:02 (PubMed=26589293) CL:0000010 Derived from sampling site: Ovary. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117136 CVCL_0738 Hs 389(A).Lu finite cell line human CVCL_0738 CL:0000010 Donor information: Established from dizygotic twin of Hs 389(B).Lu (Cellosaurus=CVCL_0739); Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7265; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117137 CVCL_0737 Hs 387.T cancer cell line human CVCL_0737 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117138 CVCL_0707 Hs 255.T undefined cell line type human CVCL_0707 HLA typing: A*02:01,29:02; B*14:02,44:02; C*05:01,05:01; DQB1*04:01,04:01; DRB1*03:08,14:06 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from sampling site: Colon Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a colorectal carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117139 CVCL_0706 Hs 24.Fs finite cell line human CVCL_0706 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7016; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117140 CVCL_0709 Hs 268.T cancer cell line human CVCL_0709 CL:0000010 Discontinued: ATCC; CRL-7218; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117141 CVCL_0708 Hs 257.T cancer cell line human CVCL_0708 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117142 CVCL_0701 Hs 232.Sp finite cell line human CVCL_0701 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7198; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117143 CVCL_0700 Hs 230.Th finite cell line human CVCL_0700 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7195; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117144 CVCL_0703 Hs 234.Th finite cell line human CVCL_0703 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7200; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117145 CVCL_0702 Hs 232.Th finite cell line human CVCL_0702 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7197; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117146 CVCL_0705 Hs 238.Sk finite cell line human CVCL_0705 CL:0000010 Derived from sampling site: Muscle and skin. Discontinued: ATCC; CRL-7203; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117147 CVCL_0704 Hs 235.Sk finite cell line human CVCL_0704 CL:0000010 Derived from sampling site: Muscle and skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117148 CVCL_0718 Hs 295.T cancer cell line human CVCL_0718 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7233; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117149 CVCL_0717 Hs 295.Sk finite cell line human CVCL_0717 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7232; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117150 CVCL_0719 Hs 3.Sk finite cell line human CVCL_0719 CL:0000010 Population: African American; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7006; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117151 CVCL_0712 Hs 275.Sk finite cell line human CVCL_0712 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7223; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117152 CVCL_0711 Hs 274.T undefined cell line type human CVCL_0711 Genome ancestry: African=0.6%; Native American=0%; East Asian, North=1.24%; East Asian, South=0.53%; South Asian=0.28%; European, North=67.67%; European, South=29.67% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117153 CVCL_0714 Hs 280.T cancer cell line human CVCL_0714 CL:0000010 Discontinued: ATCC; CRL-7226; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117154 CVCL_0713 Hs 277.T finite cell line human CVCL_0713 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7225; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117155 CVCL_0716 Hs 284.Pe cancer cell line human CVCL_0716 CL:0000010 Discontinued: ATCC; CRL-7228; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117156 CVCL_0715 Hs 281.T undefined cell line type human CVCL_0715 Genome ancestry: African=1.57%; Native American=0.98%; East Asian, North=2.05%; East Asian, South=0%; South Asian=5.19%; European, North=31.57%; European, South=58.64% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7227; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117157 CVCL_JC99 TER327 transformed cell line human CVCL_JC99 HLA typing: DPB1*02:02,04:01; DQA1*01:04,05:01; DQB1*02:01,05:03; DRB1*03:01:01,11:13; DRB3*02:02 (IPD-IMGT/HLA=14095) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117158 CVCL_JC96 GRD transformed cell line human CVCL_JC96 HLA typing: DRB1*03:04,04; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=10686) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117159 CVCL_JC95 TER144 transformed cell line human CVCL_JC95 HLA typing: A*11,68; B*40,55; DPB1*02:02,26:01; DQA1*05:05:01,05:09; DQB1*03:01; DRB1*11:11:01,12:01:01; DRB3*01:01,02:02 (IPD-IMGT/HLA=13126) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117160 CVCL_JC98 TER278 transformed cell line human CVCL_JC98 HLA typing: A*02:01,24:02; B*08:01,15:01; C*03:03,07:01; DPB1*01:01,03:01; DQA1*05:01,05:05; DQB1*02:01,03:01; DRB1*03:01:01,11:19:01; DRB3*01:01,02:02 (IPD-IMGT/HLA=14096) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117161 CVCL_JC97 12827878 transformed cell line human CVCL_JC97 HLA typing: A*01; B*57; DPB1*06:01,09:01; DQA1*02:01,05:01; DQB1*02:01,03:03; DRB1*03:01,07:04; DRB3*01:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=10049) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117162 CVCL_JC92 GM01740 finite cell line human CVCL_JC92 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01740; probable Male 21117163 CVCL_JC91 GM01721 finite cell line human CVCL_JC91 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Ambiguous 21117164 CVCL_JC94 TER417 transformed cell line human CVCL_JC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117165 CVCL_JC93 GM01722 finite cell line human CVCL_JC93 CL:0000010 Population: Caucasian; Derived from sampling site: Gonad; skin. Discontinued: Coriell; GM01722; probable Ambiguous 21117166 CVCL_JC90 GM01404 finite cell line human CVCL_JC90 CL:0000010 Population: African American; Karyotypic information: 46,XY; but phenotypically female (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21117167 CVCL_JC78 TER329 transformed cell line human CVCL_JC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117168 CVCL_JC77 GM00917 finite cell line human CVCL_JC77 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00917; probable Female 21117169 CVCL_JC79 GM00913 finite cell line human CVCL_JC79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; AG00913; probable; Discontinued: Coriell; GM00913; probable Male 21117170 CVCL_JC74 GM01860 finite cell line human CVCL_JC74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01860; probable Male 21117171 CVCL_JC73 31854 transformed cell line human CVCL_JC73 HLA typing: A*01,11; B*15,57; C*04:01,06:02; DPB1*04:01,04:02; DQA1*02:01,05:05; DQB1*03:01,03:03; DRB1*07:01,13:14:02; DRB3*02:02; DRB4*01:03:01:02N (IPD-IMGT/HLA=11976) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117172 CVCL_JC76 GM00869 finite cell line human CVCL_JC76 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00869; probable Female 21117173 CVCL_JC75 GM00630 finite cell line human CVCL_JC75 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00630; probable Male 21117174 CVCL_JC70 29037 transformed cell line human CVCL_JC70 HLA typing: A*02:01,24:02; B*44:02,49:03; C*05:01,07:01; DQA1*01,03; DQB1*03:01,06:04; DRB1*04:01,13; DRB3*03:01; DRB4*01 (IPD-IMGT/HLA=12190) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117175 CVCL_JC72 TER337 transformed cell line human CVCL_JC72 HLA typing: DPB1*03:01,04:02; DQA1*03:01,05:05; DQB1*03:01,03:02; DRB1*04:03:02,11:04:01; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=14086) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117176 CVCL_JC71 13041452 transformed cell line human CVCL_JC71 HLA typing: A*01:01,02:24; B*07:02,37:01; C*06:02,07:02; DQA1*01,02:01; DQB1*02,05; DRB1*07,10:01 (IPD-IMGT/HLA=10066) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117177 CVCL_JC89 GM01845 transformed cell line human CVCL_JC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01845; probable Male 21117178 CVCL_JC88 GM01844 finite cell line human CVCL_JC88 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01844; probable Male 21117179 CVCL_JC85 GM01825 transformed cell line human CVCL_JC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01825; probable Male 21117180 CVCL_JC84 GM01824 finite cell line human CVCL_JC84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01824; probable Male 21117181 CVCL_JC87 GM01847 transformed cell line human CVCL_JC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01847; probable Male 21117182 CVCL_JC86 GM01846 finite cell line human CVCL_JC86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01846; probable Male 21117183 CVCL_JC81 GM01834 transformed cell line human CVCL_JC81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01834; probable Male 21117184 CVCL_JC80 GM01833 finite cell line human CVCL_JC80 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01833; probable Male 21117185 CVCL_JC83 GM01883 transformed cell line human CVCL_JC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01883; probable Female 21117186 CVCL_JC82 GM01882 finite cell line human CVCL_JC82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01882; probable Female 21117187 CVCL_9140 14.8 hybridoma CVCL_9140 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117188 CVCL_8P40 DA06153 transformed cell line human CVCL_8P40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117189 CVCL_9146 1D3 [Rat hybridoma against mouse Itgb1] hybridoma CVCL_9146 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P09055; Mouse Itgb1/Cd29. 21117190 CVCL_8P46 DA06159 transformed cell line human CVCL_8P46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117191 CVCL_9145 19F8 hybridoma CVCL_9145 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P11609; Mouse Cd1d1. 21117192 CVCL_8P45 DA06158 transformed cell line human CVCL_8P45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117193 CVCL_9148 2.4G2 hybridoma CVCL_9148 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08508; Mouse Fcgr3/Cd16; Monoclonal antibody target: UniProtKB; P08101; Mouse Fcgr2/Cd32. 21117194 CVCL_8P48 DA06161 transformed cell line human CVCL_8P48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117195 CVCL_9147 1G10 [Mouse/rat hybridoma against mouse Cd80] hybridoma CVCL_9147 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00609; Mouse Cd80. 21117196 CVCL_8P47 DA06160 transformed cell line human CVCL_8P47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117197 CVCL_9142 15C6 [Mouse/rat hybridoma against mouse Cd1d1] hybridoma CVCL_9142 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P11609; Mouse Cd1d1. 21117198 CVCL_8P42 DA06155 transformed cell line human CVCL_8P42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117199 CVCL_9141 158.2 hybridoma CVCL_9141 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse activated macrophages. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8466 21117200 CVCL_8P41 DA06154 transformed cell line human CVCL_8P41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117201 CVCL_9144 187.1 hybridoma CVCL_9144 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mouse Ig kappa light chains. 21117202 CVCL_8P44 DA06157 transformed cell line human CVCL_8P44 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117203 CVCL_9143 15F7 hybridoma CVCL_9143 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P11609; Mouse Cd1d1. 21117204 CVCL_8P43 DA06156 transformed cell line human CVCL_8P43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117205 CVCL_9139 11B11 hybridoma CVCL_9139 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07750; Mouse Il4. 21117206 CVCL_8P39 DA06151 transformed cell line human CVCL_8P39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117207 CVCL_9138 11-26c hybridoma CVCL_9138 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse IgD. 21117208 CVCL_8P38 DA06150 transformed cell line human CVCL_8P38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117209 CVCL_9151 23B6 hybridoma CVCL_9151 CL:0000010 Characteristics: T-cell hybridoma Produces IgE-binding protein (Iap).. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8521 21117210 CVCL_8P51 DA06165 transformed cell line human CVCL_8P51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117211 CVCL_9150 20H2 hybridoma CVCL_9150 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11609; Mouse Cd1d1. 21117212 CVCL_8P50 DA06164 transformed cell line human CVCL_8P50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117213 CVCL_9157 3.155 hybridoma CVCL_9157 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117214 CVCL_8P57 DA06173 transformed cell line human CVCL_8P57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117215 CVCL_9156 30-H12 hybridoma CVCL_9156 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.2). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117216 CVCL_8P56 DA06172 transformed cell line human CVCL_8P56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117217 CVCL_9159 33D1 hybridoma CVCL_9159 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse dendritic cell inhibitory receptor 2 (DCIR2). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117218 CVCL_8P59 DA06175 transformed cell line human CVCL_8P59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117219 CVCL_9158 331.12 hybridoma CVCL_9158 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01872; Mouse immunoglobulin heavy chain mu. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117220 CVCL_8P58 DA06174 transformed cell line human CVCL_8P58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117221 CVCL_9153 2D10 [Mouse/rat hybridoma against mouse Cd86] hybridoma CVCL_9153 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42082; Mouse Cd86. 21117222 CVCL_8P53 DA06169 transformed cell line human CVCL_8P53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117223 CVCL_8P52 DA06166 transformed cell line human CVCL_8P52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117224 CVCL_9152 LAM-I hybridoma CVCL_9152 CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: Mouse laminin GP-2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8210 21117225 CVCL_9155 30-C7 hybridoma CVCL_9155 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01965; Mouse Ly9/Cd229/Lgp100a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117226 CVCL_8P55 DA06171 transformed cell line human CVCL_8P55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117227 CVCL_9154 2E.6 hybridoma CVCL_9154 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mouse IgG3. 21117228 CVCL_8P54 DA06170 transformed cell line human CVCL_8P54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117229 CVCL_9149 20C2 hybridoma CVCL_9149 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29459; Human IL12A; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. 21117230 CVCL_8P49 DA06163 transformed cell line human CVCL_8P49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117231 CVCL_8P24 DA06136 transformed cell line human CVCL_8P24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117232 CVCL_9124 Horse undefined cell line type CVCL_9124 CL:0000010 Miscellaneous: Even if it was not a misidentified cell line, it would probably win the award of the dummest name for a cell line! (hope the originator of this cell line never reads this comment). Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misidentified Originally thought to be of horse origin but found to be from hamster (see WWW link). 21117233 CVCL_8P23 DA06132 transformed cell line human CVCL_8P23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117234 CVCL_9123 P388/Dx cancer cell line house mouse CVCL_9123 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21117235 CVCL_8P26 DA06138 transformed cell line human CVCL_8P26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117236 CVCL_9126 DM87 spontaneously immortalized cell line CVCL_9126 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Virology: Susceptible to infection by herpes simplex virus, vaccinia virus, vesicular stomatitis virus (VSV) and poliovirus type 1 (ATCC); Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21117237 CVCL_8P25 DA06137 transformed cell line human CVCL_8P25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117238 CVCL_9125 M. dunni (Clone III8C) spontaneously immortalized cell line CVCL_9125 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117239 CVCL_8P20 DA06129 transformed cell line human CVCL_8P20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117240 CVCL_9120 K562(A) cancer cell line human CVCL_9120 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21117241 CVCL_8P22 DA06131 transformed cell line human CVCL_8P22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117242 CVCL_9122 K562-L cancer cell line human CVCL_9122 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21117243 CVCL_8P21 DA06130 transformed cell line human CVCL_8P21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117244 CVCL_9121 K562-H cancer cell line human CVCL_9121 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21117245 CVCL_0781 Hs 517.Sk finite cell line human CVCL_0781 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7311; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117246 CVCL_0780 Hs 507.Sk finite cell line human CVCL_0780 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7307; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117247 CVCL_8P17 DA06124 transformed cell line human CVCL_8P17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117248 CVCL_0783 Hs 52.Sk finite cell line human CVCL_0783 CL:0000010 Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117249 CVCL_9117 MEF (C57BL/6) IRR finite cell line house mouse CVCL_9117 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 10000 rads 21117250 CVCL_8P16 DA06123 transformed cell line human CVCL_8P16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117251 CVCL_0782 Hs 518.T cancer cell line human CVCL_0782 CL:0000010 Discontinued: ATCC; CRL-7313; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117252 CVCL_9116 NIH 3T3-TK- spontaneously immortalized cell line house mouse CVCL_9116 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21117253 CVCL_8P19 DA06126 transformed cell line human CVCL_8P19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117254 CVCL_0785 Hs 523.Sk finite cell line human CVCL_0785 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7314; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117255 CVCL_9119 K562(S) cancer cell line human CVCL_9119 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21117256 CVCL_8P18 DA06125 transformed cell line human CVCL_8P18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117257 CVCL_0784 Hs 52.Th finite cell line human CVCL_0784 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7032; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117258 CVCL_9118 MEF (C57BL/6) MITC finite cell line house mouse CVCL_9118 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Discontinued: ATCC; SCRC-1008.2; true Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21117259 CVCL_0787 Hs 531.Sk finite cell line human CVCL_0787 CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin. Discontinued: ATCC; CRL-7315; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117260 CVCL_0786 Hs 53.T cancer cell line human CVCL_0786 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117261 CVCL_0789 Hs 544.Sk finite cell line human CVCL_0789 CL:0000010 Derived from sampling site: Trunk; skin. Discontinued: ATCC; CRL-7317; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117262 CVCL_0788 Hs 540.T cancer cell line human CVCL_0788 CL:0000010 Discontinued: ATCC; CRL-7316; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117263 CVCL_8P35 DA06147 transformed cell line human CVCL_8P35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117264 CVCL_9135 OUMS-33 spontaneously immortalized cell line house mouse CVCL_9135 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C3H/AnLCsb-Csb. Female Doubling time: ~21 hours (PubMed=10476912) 21117265 CVCL_8P34 DA06146 transformed cell line human CVCL_8P34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117266 CVCL_9134 OUMS-32 spontaneously immortalized cell line house mouse CVCL_9134 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C3H/AnLCsb-Csb. Female 21117267 CVCL_8P37 DA06149 transformed cell line human CVCL_8P37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117268 CVCL_9137 OUMS-35 spontaneously immortalized cell line house mouse CVCL_9137 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C3H/AnLCsa-Csa. Unspecified 21117269 CVCL_8P36 DA06148 transformed cell line human CVCL_8P36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117270 CVCL_9136 OUMS-34 spontaneously immortalized cell line house mouse CVCL_9136 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C3H/AnLCsa-Csa. Unspecified Doubling time: ~25 hours (PubMed=10476912) 21117271 CVCL_8P31 DA06143 transformed cell line human CVCL_8P31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117272 CVCL_9131 OUMS-21 [1993] finite cell line human CVCL_9131 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver. Unspecified Senescence: SV40-transformed but with a finite life span; Doubling time: 29.4 hours (PubMed=7683277) Caution: Two cell lines named OUMS-21 have been created at Okayama University Medical School, one in 1972 from the peripheral blood of a normal adult donor (Cellosaurus=CVCL_A7SC) and one in 1993 from the SV40-transformed liver of a fetus (Cellosaurus=CVCL_9131) 21117273 CVCL_8P30 DA06142 transformed cell line human CVCL_8P30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117274 CVCL_9130 OUMS-29 transformed cell line human CVCL_9130 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Male 21117275 CVCL_8P33 DA06145 transformed cell line human CVCL_8P33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117276 CVCL_9133 OUMS-25 transformed cell line Norway rat CVCL_9133 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colorectum Cell type=Epithelial cell.; Breed/subspecies: Donryu. Unspecified 21117277 CVCL_8P32 DA06144 transformed cell line human CVCL_8P32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117278 CVCL_9132 OUMS-22 [1993] transformed cell line human CVCL_9132 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver. Unspecified Doubling time: 41.1 hours (PubMed=7683277) Caution: Two cell lines named OUMS-22 have been created at Okayama University Medical School, one in 1972 from the peripheral blood of a normal adult donor (Cellosaurus=CVCL_A7SD) and one in 1993 from the SV40-transformed liver of a fetus (Cellosaurus=CVCL_9132) 21117279 CVCL_0790 Hs 545.Sk finite cell line human CVCL_0790 CL:0000010 Derived from sampling site: Trunk; skin. Discontinued: ATCC; CRL-7318; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117280 CVCL_0792 Hs 55.Fs finite cell line human CVCL_0792 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7035; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117281 CVCL_0791 Hs 548.Sk finite cell line human CVCL_0791 CL:0000010 Derived from sampling site: Trunk; skin. Discontinued: ATCC; CRL-7320; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117282 CVCL_8P28 DA06140 transformed cell line human CVCL_8P28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117283 CVCL_0794 Hs 559.Sk finite cell line human CVCL_0794 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7323; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117284 CVCL_9128 OUMS-37 spontaneously immortalized cell line Norway rat CVCL_9128 CL:0000010 Derived from sampling site: Fetal stomach; Breed/subspecies: Donryu. Male 21117285 CVCL_8P27 DA06139 transformed cell line human CVCL_8P27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117286 CVCL_0793 Hs 556.Sk finite cell line human CVCL_0793 CL:0000010 Derived from sampling site: Trunk; skin. Discontinued: ATCC; CRL-7321; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117287 CVCL_9127 SVM84 transformed cell line CVCL_9127 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117288 CVCL_0796 Hs 564(E).Mg finite cell line human CVCL_0796 CL:0000010 Derived from sampling site: Breast. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117289 CVCL_8P29 DA06141 transformed cell line human CVCL_8P29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117290 CVCL_0795 Hs 56.Fs finite cell line human CVCL_0795 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7036; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117291 CVCL_9129 OUMS-31 spontaneously immortalized cell line house mouse CVCL_9129 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C3H/AnLCsb-Csb. Female Doubling time: ~21 hours (PubMed=10476912) 21117292 CVCL_0798 Hs 565(D).Mg finite cell line human CVCL_0798 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7333; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117293 CVCL_0797 Hs 565(A).Mg finite cell line human CVCL_0797 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7330; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117294 CVCL_0799 Hs 566(B).T cancer cell line human CVCL_0799 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117295 CVCL_9102 BALB SFME spontaneously immortalized cell line house mouse CVCL_9102 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9392 21117296 CVCL_8P02 DA06102 transformed cell line human CVCL_8P02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117297 CVCL_9101 BALB/c CL.7 spontaneously immortalized cell line house mouse CVCL_9101 CL:0000010 Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117298 CVCL_8P01 DA06101 transformed cell line human CVCL_8P01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117299 CVCL_9104 c12 (B15ECiii2) cancer cell line house mouse CVCL_9104 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21117300 CVCL_8P04 DA06104 transformed cell line human CVCL_8P04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117301 CVCL_9103 c1 (B6NLxv1c2) cancer cell line house mouse CVCL_9103 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21117302 CVCL_8P03 DA06103 transformed cell line human CVCL_8P03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117303 CVCL_9100 BALB/c AMuLV A.6R.1 transformed cell line house mouse CVCL_9100 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117304 CVCL_8P00 DA06100 transformed cell line human CVCL_8P00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117305 CVCL_0761 Hs 445 transformed cell line human CVCL_0761 Genome ancestry: African=0.48%; Native American=0%; East Asian, North=1.04%; East Asian, South=0.01%; South Asian=0%; European, North=63.69%; European, South=34.78% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but is a B-lymphoblastoid cell line (PubMed=12592342; PubMed=29533902). 21117306 CVCL_0760 Hs 443.T undefined cell line type human CVCL_0760 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7300; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117307 CVCL_0763 Hs 45.Fs finite cell line human CVCL_0763 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7025; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117308 CVCL_0762 Hs 446.Sk finite cell line human CVCL_0762 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7801; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117309 CVCL_0765 Hs 456.Bt finite cell line human CVCL_0765 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7805; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117310 CVCL_0764 Hs 454.T cancer cell line human CVCL_0764 CL:0000010 Discontinued: ATCC; CRL-7802; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117311 CVCL_0767 Hs 46.Fs finite cell line human CVCL_0767 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117312 CVCL_0766 Hs 456.Sk finite cell line human CVCL_0766 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7804; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117313 CVCL_0769 Hs 467.Sk finite cell line human CVCL_0769 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7808; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117314 CVCL_0768 Hs 466.Sk finite cell line human CVCL_0768 CL:0000010 Derived from sampling site: Scalp; skin. Discontinued: ATCC; CRL-7807; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117315 CVCL_8P13 DA06118 transformed cell line human CVCL_8P13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117316 CVCL_9113 L-alpha-2C L-cells spontaneously immortalized cell line house mouse CVCL_9113 CL:0000010 Transfected with: HGNC; 283; ADRA2C Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11181 21117317 CVCL_8P12 DA06116 transformed cell line human CVCL_8P12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117318 CVCL_9112 L-alpha-2A L-cells spontaneously immortalized cell line house mouse CVCL_9112 CL:0000010 Transfected with: HGNC; 281; ADRA2A Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11180 21117319 CVCL_8P15 DA06122 transformed cell line human CVCL_8P15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117320 CVCL_9115 MEF (C57BL/6) finite cell line house mouse CVCL_9115 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Mixed 21117321 CVCL_8P14 DA06119 transformed cell line human CVCL_8P14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117322 CVCL_9114 L-NGC-alpha2B L-cells spontaneously immortalized cell line house mouse CVCL_9114 CL:0000010 Transfected with: HGNC; 282; ADRA2B Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10275 21117323 CVCL_8P11 DA06115 transformed cell line human CVCL_8P11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117324 CVCL_9111 L-alpha-1a L-cells spontaneously immortalized cell line house mouse CVCL_9111 CL:0000010 Transfected with: HGNC; 280; ADRA1D Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11138 21117325 CVCL_8P10 DA06111 transformed cell line human CVCL_8P10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117326 CVCL_9110 L-alpha-1b L-cells spontaneously immortalized cell line house mouse CVCL_9110 CL:0000010 Transfected with: HGNC; 278; ADRA1B Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11139 21117327 CVCL_8P09 DA06110 transformed cell line human CVCL_8P09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117328 CVCL_9109 G-Olig2 embryonic stem cell house mouse CVCL_9109 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: 129X1/SvJ. Male 21117329 CVCL_0770 Hs 468.Lu finite cell line human CVCL_0770 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7810; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117330 CVCL_9106 c37 (B7IFi1) cancer cell line house mouse CVCL_9106 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21117331 CVCL_8P06 DA06106 transformed cell line human CVCL_8P06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117332 CVCL_0772 Hs 479.T cancer cell line human CVCL_0772 CL:0000010 Discontinued: ATCC; CRL-7813; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117333 CVCL_9105 c35 (B16GBi1c3) cancer cell line house mouse CVCL_9105 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Derived from sampling site: Liver; Breed/subspecies: C57L. Discontinued: ATCC; CRL-2715; true Female 21117334 CVCL_8P05 DA06105 transformed cell line human CVCL_8P05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117335 CVCL_0771 Hs 469.Sk finite cell line human CVCL_0771 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7811; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117336 CVCL_8P08 DA06109 transformed cell line human CVCL_8P08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117337 CVCL_9108 ES-E14TG2a embryonic stem cell house mouse CVCL_9108 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Omics: Cell surface proteome; Omics: SNP array analysis Male 21117338 CVCL_0774 Hs 483.Sk finite cell line human CVCL_0774 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7815; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117339 CVCL_8P07 DA06107 transformed cell line human CVCL_8P07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117340 CVCL_9107 EML clone 1 factor-dependent cell line house mouse CVCL_9107 CL:0000010 Transfected with: HGNC; 9864; RARA (RARalpha403; truncated version AA 1-403) Derived from sampling site: Bone marrow Cell type=Basophil.; Breed/subspecies: C57BL/6 x DBA/2. Male Characteristics: KITLG dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11691 21117341 CVCL_0773 Hs 48.Fs finite cell line human CVCL_0773 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7027; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117342 CVCL_0776 Hs 49.Fs finite cell line human CVCL_0776 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7028; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117343 CVCL_0775 Hs 483.T finite cell line human CVCL_0775 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7814; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117344 CVCL_0778 Hs 5.T cancer cell line human CVCL_0778 CL:0000010 Derived from sampling site: Connective tissue. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117345 CVCL_0777 Hs 491.T cancer cell line human CVCL_0777 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7818; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117346 CVCL_0779 Hs 505.T cancer cell line human CVCL_0779 CL:0000010 Derived from sampling site: Lymph node. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117347 CVCL_0741 Hs 391.We finite cell line human CVCL_0741 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7267; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117348 CVCL_0740 Hs 39.T cancer cell line human CVCL_0740 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117349 CVCL_0743 Hs 394.Lu finite cell line human CVCL_0743 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7269; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117350 CVCL_0742 Hs 392.Sk finite cell line human CVCL_0742 CL:0000010 Population: African American; Derived from sampling site: Finger; Skin. Discontinued: ATCC; CRL-7268; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117351 CVCL_0745 Hs 397.Lu finite cell line human CVCL_0745 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7272; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117352 CVCL_0744 Hs 394.Sk finite cell line human CVCL_0744 CL:0000010 Derived from sampling site: Fetal muscle and skin. Discontinued: ATCC; CRL-7270; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117353 CVCL_0747 Hs 401.Lu finite cell line human CVCL_0747 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7275; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117354 CVCL_0746 Hs 399.Li finite cell line human CVCL_0746 CL:0000010 Derived from sampling site: Liver. Discontinued: ATCC; CRL-7274; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117355 CVCL_0749 Hs 404.Sk finite cell line human CVCL_0749 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7278; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117356 CVCL_0748 Hs 402.Sk finite cell line human CVCL_0748 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7276; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117357 CVCL_0750 Hs 405.Sk finite cell line human CVCL_0750 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7279; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117358 CVCL_0752 Hs 410.We finite cell line human CVCL_0752 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7282; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117359 CVCL_0751 Hs 409.We finite cell line human CVCL_0751 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7281; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117360 CVCL_0754 Hs 413.We finite cell line human CVCL_0754 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7286; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117361 CVCL_0753 Hs 412.Lu finite cell line human CVCL_0753 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7285; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117362 CVCL_0756 Hs 415.Sk finite cell line human CVCL_0756 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7288; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117363 CVCL_0755 Hs 414.T cancer cell line human CVCL_0755 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117364 CVCL_0758 Hs 417.Lu finite cell line human CVCL_0758 CL:0000010 Derived from sampling site: Fetal bronchus or fetal lung. Omics: SNP array analysis Discontinued: ATCC; CRL-7291; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117365 CVCL_0757 Hs 416.T cancer cell line human CVCL_0757 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117366 CVCL_0759 Hs 431.T cancer cell line human CVCL_0759 CL:0000010 Discontinued: ATCC; CRL-7298; true; Discontinued: ECACC; 90011205; probable. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117367 CVCL_JE10 GM00506 transformed cell line human CVCL_JE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00506; probable Female 21117368 CVCL_JE12 GM03808 finite cell line human CVCL_JE12 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117369 CVCL_JE11 GM01817 transformed cell line human CVCL_JE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01817; probable Male 21117370 CVCL_AK73 XP75TMA finite cell line human CVCL_AK73 CL:0000010 Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117371 CVCL_AK72 XP75TMA LCL transformed cell line human CVCL_AK72 CL:0000010 Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117372 CVCL_AK75 XP70TMA LCL transformed cell line human CVCL_AK75 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (from autologous cell line XP70TMA) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117373 CVCL_AK74 XP70TMA finite cell line human CVCL_AK74 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117374 CVCL_AK77 XPH95TMA LCL transformed cell line human CVCL_AK77 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Heterozygous (from autologous cell line XPH95TMA) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117375 CVCL_AK76 XPH95TMA finite cell line human CVCL_AK76 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Heterozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117376 CVCL_AK79 GM03824 finite cell line human CVCL_AK79 CL:0000010 Population: Caucasian; German; Derived from sampling site: Cell type=Fibroblast. Male 21117377 CVCL_AK78 GM03823 transformed cell line human CVCL_AK78 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117378 CVCL_JE07 GM01783 transformed cell line human CVCL_JE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01783; true Female 21117379 CVCL_JE06 GM03485 transformed cell line human CVCL_JE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03485; probable Female 21117380 CVCL_JE09 GM00505 transformed cell line human CVCL_JE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00505; probable Unspecified 21117381 CVCL_JE08 GM01785 transformed cell line human CVCL_JE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01785; probable Female 21117382 CVCL_JE03 11169540 transformed cell line human CVCL_JE03 HLA typing: A*02:01,23:01; B*44:03,40:14:03; C*03:04,04:01; DPA1*01:CG; DPB1*02:01,03:AMYJ; DQA1*01:BF,05; DQB1*03:01,06:04; DRB1*13:02,11:APYW; DRB3*02,03 (IPD-IMGT/HLA=14058) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117383 CVCL_JE02 TER121 transformed cell line human CVCL_JE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117384 CVCL_JE05 GM01020 transformed cell line human CVCL_JE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01020; probable Female 21117385 CVCL_AK71 XP74TMA finite cell line human CVCL_AK71 CL:0000010 Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117386 CVCL_JE04 11684232 transformed cell line human CVCL_JE04 HLA typing: A*02,25:01; B*40:01,18; C*03:04,12:03; DPB1*04:01; DQA1*03:03,05:05; DQB1*03:01; DRB1*04:01,13:14:01; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=12179) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21117387 CVCL_AK70 XP71TMA finite cell line human CVCL_AK70 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117388 CVCL_JE21 AG01964 finite cell line human CVCL_JE21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01964; probable Male 21117389 CVCL_JE20 AG01756 finite cell line human CVCL_JE20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01756; probable Male 21117390 CVCL_JE23 AG01966 finite cell line human CVCL_JE23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01966; probable Female 21117391 CVCL_JE22 AG01965 finite cell line human CVCL_JE22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01965; probable Female 21117392 CVCL_AK84 GM03833 finite cell line human CVCL_AK84 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117393 CVCL_AK83 GM03832 transformed cell line human CVCL_AK83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117394 CVCL_AK86 GM03835 finite cell line human CVCL_AK86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117395 CVCL_AK85 GM03834 transformed cell line human CVCL_AK85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117396 CVCL_AK88 GM03837 finite cell line human CVCL_AK88 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117397 CVCL_AK87 GM03836 transformed cell line human CVCL_AK87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117398 CVCL_AK89 GM03838 transformed cell line human CVCL_AK89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117399 CVCL_JE18 GM00894 transformed cell line human CVCL_JE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00894; probable Female 21117400 CVCL_JE17 GM00924 transformed cell line human CVCL_JE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00924; probable Female 21117401 CVCL_JE19 GM00891 transformed cell line human CVCL_JE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00891; probable Unspecified 21117402 CVCL_JE14 GM01919 transformed cell line human CVCL_JE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01919; probable Male 21117403 CVCL_AK80 GM03825 transformed cell line human CVCL_AK80 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117404 CVCL_JE13 GM01827 transformed cell line human CVCL_JE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01827; probable Female 21117405 CVCL_JE16 GM00923 transformed cell line human CVCL_JE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00923; probable Male 21117406 CVCL_AK82 GM03831 finite cell line human CVCL_AK82 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117407 CVCL_JE15 GM00463 transformed cell line human CVCL_JE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00463; probable Male 21117408 CVCL_AK81 GM03826 finite cell line human CVCL_AK81 CL:0000010 Population: Caucasian; German; Derived from sampling site: Cell type=Fibroblast. Male 21117409 CVCL_AK59 EUFA262 transformed cell line human CVCL_AK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117410 CVCL_AK58 EUFA255 transformed cell line human CVCL_AK58 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Gln1307Argfs*2 (c.3920delA); ClinVar=VCV000974357; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117411 CVCL_AK51 EUFA043 transformed cell line human CVCL_AK51 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.3061_3154del94 (Ex31-32del); Zygosity=Homozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117412 CVCL_AK50 EUFA007 transformed cell line human CVCL_AK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117413 CVCL_AK53 EUFA139 transformed cell line human CVCL_AK53 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4010+(1_18)del (IVS40+1-18del); Zygosity=Homozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117414 CVCL_AK52 EUFA127 transformed cell line human CVCL_AK52 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000550581; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117415 CVCL_AK55 EUFA223 transformed cell line human CVCL_AK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117416 CVCL_AK54 EUFA186 transformed cell line human CVCL_AK54 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser858Arg (c.2574C>G); ClinVar=VCV000134256; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117417 CVCL_AK57 EUFA245 transformed cell line human CVCL_AK57 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Asp598Asn (c.1792G>A); ClinVar=VCV000974125; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117418 CVCL_AK56 EUFA232 transformed cell line human CVCL_AK56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117419 CVCL_JE01 LUMC-C38 transformed cell line human CVCL_JE01 HLA typing: A*01:01; B*08:01,58:01; C*07:01,07:18; DPB1*01:01,17:01; DQA1*02:01,05:01; DQB1*02:01,02:02; DRB1*03:01,07:01; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=15413) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117420 CVCL_JE00 TER313 transformed cell line human CVCL_JE00 HLA typing: A*02:01,31:01:02; B*15:01,67:01; C*07:02; DPB1*02:01,05:01; DQA1*05:03; DQB1*03:01; DRB1*14:03:01,14:06; DRB3*01:01,02:02 (IPD-IMGT/HLA=14103) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21117421 CVCL_AK69 EUFA763 transformed cell line human CVCL_AK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117422 CVCL_AK62 EUFA388 transformed cell line human CVCL_AK62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117423 CVCL_AK61 EUFA337 transformed cell line human CVCL_AK61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117424 CVCL_AK64 EUFA445 transformed cell line human CVCL_AK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117425 CVCL_AK63 EUFA418 transformed cell line human CVCL_AK63 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Val372Alafs*42 (c.1111_1114TTGG[1]) (c.1115_1118delTTGG); ClinVar=VCV000003440; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117426 CVCL_AK66 EUFA483 transformed cell line human CVCL_AK66 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Phe1263del (c.3788_3790delTCT); ClinVar=VCV000041003; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117427 CVCL_AK65 EUFA471 transformed cell line human CVCL_AK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117428 CVCL_AK68 EUFA586 transformed cell line human CVCL_AK68 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.894_1359del466 (Ex11-14del); Zygosity=Homozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117429 CVCL_AK67 EUFA507 transformed cell line human CVCL_AK67 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Phe1263del (c.3788_3790delTCT); ClinVar=VCV000041003; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117430 CVCL_AK60 EUFA263 transformed cell line human CVCL_AK60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21117431 CVCL_AK37 HSC 72 transformed cell line human CVCL_AK37 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Unexplicit; Ex18-28del; Zygosity=Unspecified (PubMed=16166284) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117432 CVCL_AK36 HSC 536N transformed cell line human CVCL_AK36 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Leu554Pro (c.1661T>C); ClinVar=VCV000012043; Zygosity=Unspecified (Coriell); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117433 CVCL_AK39 HSC 230 transformed cell line human CVCL_AK39 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ala938Profs*21 (c.2808_2811del) (3033delAAAC) (3036delACAA); ClinVar=VCV000009322; Zygosity=Heterozygous (PubMed=12065746); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Heterozygous (PubMed=12065746) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117434 CVCL_AK31 GM10913 transformed cell line human CVCL_AK31 CL:0000010 Sequence variation: Mutation; HGNC; 11740; TF; Simple; p.Asp77Asn (c.229G>A); ClinVar=VCV000012621; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117435 CVCL_AK30 GM10912 transformed cell line human CVCL_AK30 CL:0000010 Sequence variation: Mutation; HGNC; 11740; TF; Simple; p.Asp77Asn (c.229G>A); ClinVar=VCV000012621; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117436 CVCL_AK33 GM10929 transformed cell line human CVCL_AK33 CL:0000010 Sequence variation: Mutation; HGNC; 11740; TF; Simple; p.Asp77Asn (c.229G>A); ClinVar=VCV000012621; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117437 CVCL_AK32 GM10914 transformed cell line human CVCL_AK32 CL:0000010 Sequence variation: Mutation; HGNC; 11740; TF; Simple; p.Asp77Asn (c.229G>A); ClinVar=VCV000012621; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117438 CVCL_AK35 XPPHBE transformed cell line human CVCL_AK35 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359fs (c.1078insG); Zygosity=Heterozygous (PubMed=10398605) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117439 CVCL_AK34 GM12794 transformed cell line human CVCL_AK34 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Asp23Ilefs*23 (c.67delG) (322delG); ClinVar=VCV000012049; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21117440 CVCL_AK48 PD352.F finite cell line human CVCL_AK48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117441 CVCL_AK47 MA148 cancer cell line human CVCL_AK47 CL:0000010 Derived from sampling site: Ovary. Female 21117442 CVCL_AK49 PD20 RV:D2 transformed cell line human CVCL_AK49 CL:0000010 Transfected with: HGNC; 3585; FANCD2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Transfection of wildtype FANCD2 restores the full activity of the protein which is mutated in the parent cell line 21117443 CVCL_AK40 GM16631 finite cell line human CVCL_AK40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117444 CVCL_AK42 HSC 72OT transformed cell line human CVCL_AK42 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Unexplicit; Ex18-28del; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117445 CVCL_AK41 GM16632 finite cell line human CVCL_AK41 CL:0000010 Transfected with: HGNC; 3582; FANCA Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117446 CVCL_AK44 GM16755 finite cell line human CVCL_AK44 CL:0000010 Transfected with: HGNC; 3584; FANCC Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117447 CVCL_AK43 GM16754 finite cell line human CVCL_AK43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117448 CVCL_AK46 GM20732 transformed cell line human CVCL_AK46 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117449 CVCL_AK45 GM20731 transformed cell line human CVCL_AK45 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117450 CVCL_8Q81 DA06388 transformed cell line human CVCL_8Q81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117451 CVCL_9281 Royan B1 embryonic stem cell house mouse CVCL_9281 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Omics: Proteome analysis by 2D-DE/MS Male 21117452 CVCL_8Q80 DA06387 transformed cell line human CVCL_8Q80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117453 CVCL_9280 SUIT-4 cancer cell line human CVCL_9280 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=15452375) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 43.9 hours (PubMed=15452375) 21117454 CVCL_8Q83 DA06390 transformed cell line human CVCL_8Q83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117455 CVCL_9283 Royan B11 embryonic stem cell house mouse CVCL_9283 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117456 CVCL_8Q82 DA06389 transformed cell line human CVCL_8Q82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117457 CVCL_9282 Royan B10 embryonic stem cell house mouse CVCL_9282 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117458 CVCL_8Q89 DA06398 transformed cell line human CVCL_8Q89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117459 CVCL_AK15 HPSI0914i-jejf_3 induced pluripotent stem cell human CVCL_AK15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117460 CVCL_9289 Royan B2 embryonic stem cell house mouse CVCL_9289 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Male 21117461 CVCL_8Q88 DA06397 transformed cell line human CVCL_8Q88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117462 CVCL_AK14 HPSI0914i-jejf_2 induced pluripotent stem cell human CVCL_AK14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117463 CVCL_9288 Royan B16 embryonic stem cell house mouse CVCL_9288 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117464 CVCL_AK17 GM01599 finite cell line human CVCL_AK17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117465 CVCL_AK16 EUFA423F transformed cell line human CVCL_AK16 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asp2489Terfs (c.7464_7465insTA) (7691insAT); Zygosity=Heterozygous (PubMed=12065746); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr3225Ilefs*30 (c.9672dupA) (9900insA); ClinVar=VCV000126217; Zygosity=Heterozygous (PubMed=12065746) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral blood. Female 21117466 CVCL_8Q85 DA06392 transformed cell line human CVCL_8Q85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117467 CVCL_AK19 GM01601 finite cell line human CVCL_AK19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117468 CVCL_9285 Royan B13 embryonic stem cell house mouse CVCL_9285 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117469 CVCL_8Q84 DA06391 transformed cell line human CVCL_8Q84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117470 CVCL_AK18 GM01600 finite cell line human CVCL_AK18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117471 CVCL_9284 Royan B12 embryonic stem cell house mouse CVCL_9284 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117472 CVCL_8Q87 DA06396 transformed cell line human CVCL_8Q87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117473 CVCL_9287 Royan B15 embryonic stem cell house mouse CVCL_9287 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117474 CVCL_8Q86 DA06393 transformed cell line human CVCL_8Q86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117475 CVCL_9286 Royan B14 embryonic stem cell house mouse CVCL_9286 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117476 CVCL_AK11 HPSI1014i-juuy_2 induced pluripotent stem cell human CVCL_AK11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117477 CVCL_AK10 HPSI0914i-qehq_7 induced pluripotent stem cell human CVCL_AK10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117478 CVCL_AK13 HPSI1014i-tuju_4 induced pluripotent stem cell human CVCL_AK13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117479 CVCL_AK12 HPSI1014i-tuju_1 induced pluripotent stem cell human CVCL_AK12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117480 CVCL_8Q92 DA06404 transformed cell line human CVCL_8Q92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117481 CVCL_9292 Royan B6 embryonic stem cell house mouse CVCL_9292 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117482 CVCL_8Q91 DA06401 transformed cell line human CVCL_8Q91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117483 CVCL_9291 Royan B4 embryonic stem cell house mouse CVCL_9291 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117484 CVCL_8Q94 DA06406 transformed cell line human CVCL_8Q94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117485 CVCL_9294 Royan B8 embryonic stem cell house mouse CVCL_9294 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117486 CVCL_8Q93 DA06405 transformed cell line human CVCL_8Q93 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117487 CVCL_9293 Royan B7 embryonic stem cell house mouse CVCL_9293 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117488 CVCL_8Q90 DA06400 transformed cell line human CVCL_8Q90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117489 CVCL_9290 Royan B3 embryonic stem cell house mouse CVCL_9290 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117490 CVCL_AK26 GM02976 finite cell line human CVCL_AK26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117491 CVCL_8Q99 DA06428 transformed cell line human CVCL_8Q99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117492 CVCL_AK25 GM02975 finite cell line human CVCL_AK25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117493 CVCL_9299 Royan C12 embryonic stem cell house mouse CVCL_9299 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21117494 CVCL_AK28 GM09543 finite cell line human CVCL_AK28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117495 CVCL_AK27 GM02977 finite cell line human CVCL_AK27 CL:0000010 Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 26.3 +- 1.7 hours (PubMed=1214005) 21117496 CVCL_8Q96 DA06411 transformed cell line human CVCL_8Q96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117497 CVCL_9296 Royan C1 embryonic stem cell house mouse CVCL_9296 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Male 21117498 CVCL_8Q95 DA06407 transformed cell line human CVCL_8Q95 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117499 CVCL_AK29 GM10911 transformed cell line human CVCL_AK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117500 CVCL_9295 Royan B9 embryonic stem cell house mouse CVCL_9295 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21117501 CVCL_8Q98 DA06416 transformed cell line human CVCL_8Q98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117502 CVCL_9298 Royan C11 embryonic stem cell house mouse CVCL_9298 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21117503 CVCL_8Q97 DA06415 transformed cell line human CVCL_8Q97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117504 CVCL_9297 Royan C10 embryonic stem cell house mouse CVCL_9297 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21117505 CVCL_AK20 GM01995 finite cell line human CVCL_AK20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117506 CVCL_AK22 GM02361 finite cell line human CVCL_AK22 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117507 CVCL_AK21 GM02061 finite cell line human CVCL_AK21 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117508 CVCL_AK24 GM02363 finite cell line human CVCL_AK24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117509 CVCL_AK23 GM02362 finite cell line human CVCL_AK23 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21117510 CVCL_JE98 DT40-MRE11(-/-) clone #190 cancer cell line CVCL_JE98 CL:0000010 Knockout cell: Method=Targeted integration; MRE11 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21117511 CVCL_JE97 WI-1 finite cell line human CVCL_JE97 CL:0000010 Anecdotal: First cell line derived by Hayflick from fetal cells; Anecdotal: The cell lines WI-1 to WI-25 derived by Hayflick were lost in 1961 when an electrical freezer failed at the Wistar Insitute (CelloPub=CLPUB00391) Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21117512 CVCL_JE99 DT40-MRE11(-/-) clone #194 cancer cell line CVCL_JE99 CL:0000010 Knockout cell: Method=Targeted integration; MRE11 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21117513 CVCL_JE94 GM13698 transformed cell line human CVCL_JE94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117514 CVCL_JE93 GM11605 transformed cell line human CVCL_JE93 CL:0000010 Sequence variation: Mutation; HGNC; 7455; MT-ND1; Simple; p.Ala52Thr (m.3460G>A); ClinVar=VCV000009722; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117515 CVCL_JE96 GM16499 finite cell line human CVCL_JE96 CL:0000010 Population: Caucasian; Donor information: Established from a donor with cleft hand and absent tibia; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117516 CVCL_JE95 GM13703 transformed cell line human CVCL_JE95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with infiltrating ductal carcinoma; Derived from sampling site: Peripheral blood. Female 21117517 CVCL_JE90 KM932 transformed cell line human CVCL_JE90 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117518 CVCL_JE92 H/Rb-M cancer cell line human CVCL_JE92 CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9884; RB1 Derived from sampling site: Urinary bladder. Male Characteristics: Corrects the lack of expression of RB1 in the parent cell line which is due to an homozygous mutation p.Tyr325Ter (c.975T>A) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10707 21117519 CVCL_JE91 H/Rb-CL2 cancer cell line human CVCL_JE91 CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9884; RB1 Derived from sampling site: Urinary bladder. Male Characteristics: Corrects the lack of expression of RB1 in the parent cell line which is due to an homozygous mutation p.Tyr325Ter (c.975T>A) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10708 21117520 CVCL_JE76 UCSF-OT-1109 cancer cell line human CVCL_JE76 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=28559012) Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Female Doubling time: 4-5 days (ATCC=CRL-3442) 21117521 CVCL_JE75 ESCDL-1 somatic stem cell CVCL_JE75 CL:0000010 Breed/subspecies: Brown Leghorn. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: ~40 hours (PubMed=28406989) Group: Bird cell line 21117522 CVCL_JE78 BV9 cancer cell line Norway rat CVCL_JE78 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: Wistar. Male Doubling time: ~28 hours (PubMed=498142; PubMed=510855) 21117523 CVCL_JE77 OAT cancer cell line human CVCL_JE77 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Male Doubling time: ~24 hours (PubMed=4334634) 21117524 CVCL_JE72 CCOC-T cancer cell line human CVCL_JE72 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=28559020) Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Omics: Transcriptome analysis by microarray Female 21117525 CVCL_JE71 SHGE-2 transformed cell line human CVCL_JE71 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Epithelial cell.. Unspecified 21117526 CVCL_JE74 TS ViPSC induced pluripotent stem cell human CVCL_JE74 From: School of Regenerative Medicine, Manipal University; Bengaluru; India CL:0000010 Derived from sampling site: Chorionic villus. Female 21117527 CVCL_JE73 PA-hTERT telomerase immortalized cell line human CVCL_JE73 CL:0000010 Transfected with: HGNC; 11730; TERT. Female 21117528 CVCL_JE70 SHGE-1 transformed cell line human CVCL_JE70 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Epithelial cell.. Unspecified 21117529 CVCL_JE69 OBA-9 transformed cell line human CVCL_JE69 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pMT10D](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Unspecified 21117530 CVCL_JE68 iOdE spontaneously immortalized cell line human CVCL_JE68 CL:0000010 Derived from sampling site: Tooth; periodontal ligament Cell type=Epithelial cell of Malassez.. Omics: Transcriptome analysis by microarray Unspecified 21117531 CVCL_JE87 KM9401 transformed cell line human CVCL_JE87 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117532 CVCL_JE86 KM9402 transformed cell line human CVCL_JE86 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117533 CVCL_JE89 KM933 transformed cell line human CVCL_JE89 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117534 CVCL_JE88 KM934 transformed cell line human CVCL_JE88 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117535 CVCL_JE83 KM9803 transformed cell line human CVCL_JE83 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117536 CVCL_JE82 KM9801 transformed cell line human CVCL_JE82 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117537 CVCL_JE85 KM9403 transformed cell line human CVCL_JE85 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117538 CVCL_JE84 KM9406 transformed cell line human CVCL_JE84 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117539 CVCL_JE81 UV.C3B6-1.1C transformed cell line house mouse CVCL_JE81 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x C3H/HeN. 21117540 CVCL_JE80 UV.BAL-8.1C transformed cell line house mouse CVCL_JE80 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21117541 CVCL_JE79 UHi007-B induced pluripotent stem cell human CVCL_JE79 From: University of Helsinki; Helsinki; Finland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21117542 CVCL_JE54 RASMC finite cell line Norway rat CVCL_JE54 CL:0000010 Derived from sampling site: Aorta; smooth muscle; Breed/subspecies: Sprague Dawley. Male 21117543 CVCL_JE53 GM08866 finite cell line human CVCL_JE53 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM08866; probable Female 21117544 CVCL_JE56 GM03713 hybridoma CVCL_JE56 CL:0000010 Discontinued: Coriell; GM03713; probable. Monoclonal antibody isotype: IgM 21117545 CVCL_JE55 GM03710 hybridoma CVCL_JE55 CL:0000010 Discontinued: Coriell; GM03710; probable. Monoclonal antibody isotype: IgG2c 21117546 CVCL_JE50 GM09333 finite cell line human CVCL_JE50 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117547 CVCL_JE52 GM23237 transformed cell line human CVCL_JE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117548 CVCL_JE51 GM23228 transformed cell line human CVCL_JE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117549 CVCL_JE47 AG02089 finite cell line human CVCL_JE47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02089; probable Female 21117550 CVCL_JE46 AG01895 finite cell line human CVCL_JE46 CL:0000010 Donor information: Established from the non-irradiated skin of a Wilm's tumor patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01895; probable Male 21117551 CVCL_JE49 GM03118 finite cell line human CVCL_JE49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117552 CVCL_JE48 AG02220 finite cell line human CVCL_JE48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02220; probable Male 21117553 CVCL_JE65 NDUSD-1 transformed cell line human CVCL_JE65 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Female Characteristics: Has the capability to deposit calcium in vitro Doubling time: 31.7 +- 2.8 hours (PubMed=19184294) 21117554 CVCL_JE64 Ori- transformed cell line human CVCL_JE64 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Female Doubling time: 36.7 +- 3.5 hours (PubMed=19184294) 21117555 CVCL_JE67 NDUSD-4 transformed cell line human CVCL_JE67 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Female Doubling time: 32.1 +- 3.2 hours (PubMed=19184294) 21117556 CVCL_JE66 NDUSD-2 transformed cell line human CVCL_JE66 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Female Doubling time: 25.3 +- 3.0 hours (PubMed=19184294) 21117557 CVCL_JE61 H-1D(H162) finite cell line house mouse CVCL_JE61 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C57BL/6. 21117558 CVCL_JE60 GM04181 transformed cell line human CVCL_JE60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117559 CVCL_JE63 MOE1b telomerase immortalized cell line human CVCL_JE63 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Oral cavity; epithelium. Unspecified 21117560 CVCL_JE62 MOE1a telomerase immortalized cell line human CVCL_JE62 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 11998; TP53 (with del 1-159) Population: Japanese; Derived from sampling site: Oral cavity; epithelium. Unspecified 21117561 CVCL_JE58 GM03809 finite cell line human CVCL_JE58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117562 CVCL_JE57 J11d hybridoma CVCL_JE57 CL:0000010 Discontinued: Coriell; GM03565; probable. Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24 21117563 CVCL_JE59 GM04180 finite cell line human CVCL_JE59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117564 CVCL_JE32 AG00716 finite cell line human CVCL_JE32 CL:0000010 Discontinued: Coriell; AG00716; probable. Female 21117565 CVCL_JE31 AG01732 finite cell line human CVCL_JE31 CL:0000010 Donor information: Established from the non-irradiated skin of a leukemia patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01732; probable Male 21117566 CVCL_JE34 AG02203 finite cell line human CVCL_JE34 CL:0000010 Donor information: Established from the irradiated skin of a neuroblastoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02203; probable Female 21117567 CVCL_JE33 AG02202 finite cell line human CVCL_JE33 CL:0000010 Donor information: Established from the non-irradiated skin of a neuroblastoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02202; probable Female 21117568 CVCL_JE30 AG01731 finite cell line human CVCL_JE30 CL:0000010 Donor information: Established from the irradiated skin of a leukemia patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01731; probable Male 21117569 CVCL_AK95 GM03911 transformed cell line human CVCL_AK95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117570 CVCL_AK94 GM03910 finite cell line human CVCL_AK94 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21117571 CVCL_AK97 GM05057 finite cell line human CVCL_AK97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117572 CVCL_AK96 GM04562 transformed cell line human CVCL_AK96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117573 CVCL_AK99 GM05059 finite cell line human CVCL_AK99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117574 CVCL_AK98 GM05058 transformed cell line human CVCL_AK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117575 CVCL_JE29 AG01950 finite cell line human CVCL_JE29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01950; probable Male 21117576 CVCL_JE28 AG01839 finite cell line human CVCL_JE28 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01839; probable Female 21117577 CVCL_JE25 AG01968 finite cell line human CVCL_JE25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01968; probable Female 21117578 CVCL_AK91 GM03894 transformed cell line human CVCL_AK91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117579 CVCL_JE24 AG01967 finite cell line human CVCL_JE24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01967; probable Male 21117580 CVCL_AK90 GM03893 finite cell line human CVCL_AK90 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117581 CVCL_JE27 AG01710 finite cell line human CVCL_JE27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01710; probable Male 21117582 CVCL_AK93 GM03907 transformed cell line human CVCL_AK93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117583 CVCL_JE26 AG01969 finite cell line human CVCL_JE26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01969; probable Female 21117584 CVCL_AK92 GM03906 finite cell line human CVCL_AK92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117585 CVCL_JE43 AG02129 finite cell line human CVCL_JE43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02129; probable Male 21117586 CVCL_JE42 AG01616 finite cell line human CVCL_JE42 CL:0000010 Donor information: Established from the irradiated skin of a nephroblastoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01616; probable Male 21117587 CVCL_JE45 AG01894 finite cell line human CVCL_JE45 CL:0000010 Donor information: Established from the irradiated skin of a Wilm's tumor patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01894; probable Male 21117588 CVCL_JE44 AG02130 transformed cell line human CVCL_JE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG02130; probable Male 21117589 CVCL_JE41 AG01262 finite cell line human CVCL_JE41 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01262; probable Female 21117590 CVCL_JE40 AG01980 finite cell line human CVCL_JE40 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01980; probable Female 21117591 CVCL_JE39 GM13635 transformed cell line human CVCL_JE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117592 CVCL_JE36 AG01360 finite cell line human CVCL_JE36 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01360; probable Male 21117593 CVCL_JE35 AG02272 finite cell line human CVCL_JE35 CL:0000010 Donor information: Established from a neuroblastoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02272; probable Male 21117594 CVCL_JE38 AG02086 finite cell line human CVCL_JE38 CL:0000010 Donor information: Established from an osteogenic sarcoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02086; probable Male 21117595 CVCL_JE37 AG01485 finite cell line human CVCL_JE37 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01485; probable Male 21117596 CVCL_0849 Hs 692(A).T cancer cell line human CVCL_0849 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117597 CVCL_0840 Hs 680.Rec finite cell line human CVCL_0840 CL:0000010 Derived from sampling site: Fetal rectum. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117598 CVCL_0842 Hs 680.Tg finite cell line human CVCL_0842 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-7421; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117599 CVCL_0841 Hs 680.Sk finite cell line human CVCL_0841 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7419; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117600 CVCL_0844 Hs 683 cancer cell line human CVCL_0844 HLA typing: A*32:01,32:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.33%; East Asian, North=0.16%; East Asian, South=0%; South Asian=0.7%; European, North=68.26%; European, South=30.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=10416987) Population: Caucasian; Derived from sampling site: Brain; left temporal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3-4 days (PubMed=176412); 49 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21117601 CVCL_0843 Hs 680.Tr finite cell line human CVCL_0843 CL:0000010 Derived from sampling site: Fetal trachea. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117602 CVCL_0846 Hs 688(A).T undefined cell line type human CVCL_0846 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.14%; East Asian, South=0%; South Asian=2.86%; European, North=65.65%; European, South=31.35% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117603 CVCL_0845 Hs 687.Sk finite cell line human CVCL_0845 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7424; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117604 CVCL_0848 Hs 69.Fs finite cell line human CVCL_0848 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7047; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117605 CVCL_0847 Hs 688(B).T cancer cell line human CVCL_0847 CL:0000010 Population: Caucasian; Derived from metastatic site: Inguinal lymph node. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117606 CVCL_0851 Hs 695T cancer cell line human CVCL_0851 HLA typing: A*02:01,02:01; B*49:01,49:01; C*07:01,07:01; DQA1*01:03,01:03; DQB1*06:03,06:03; DRB1*03:38,13:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.62%; East Asian, North=0.95%; East Asian, South=0.69%; South Asian=0.98%; European, North=71.17%; European, South=25.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (ATCC; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (ATCC=HTB-137) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21117607 CVCL_0850 Hs 695.Sk finite cell line human CVCL_0850 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7855; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117608 CVCL_0853 Hs 697.Ln finite cell line human CVCL_0853 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7434; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117609 CVCL_0852 Hs 696 cancer cell line human CVCL_0852 CL:0000010 Derived from metastatic site: Bone; sacrum. Discontinued: ATCC; CRL-7432; true Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117610 CVCL_0855 Hs 698.T undefined cell line type human CVCL_0855 Genome ancestry: African=0.32%; Native American=0%; East Asian, North=3.02%; East Asian, South=0%; South Asian=93.06%; European, North=0%; European, South=3.59% (PubMed=30894373) CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a colorectal carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap).; Caution: According to ATCC the ethnicity of the donor is Native American, but exome analysis finds it to be South Asian 21117611 CVCL_0854 Hs 697.Sp finite cell line human CVCL_0854 CL:0000010 Derived from sampling site: Spleen. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117612 CVCL_0857 Hs 700.Sk finite cell line human CVCL_0857 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7439; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117613 CVCL_0856 Hs 70.Fs finite cell line human CVCL_0856 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7048; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117614 CVCL_0859 Hs 701.T cancer cell line human CVCL_0859 CL:0000010 Discontinued: ATCC; CRL-7440; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117615 CVCL_0858 Hs 700T cancer cell line human CVCL_0858 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Unspecified (PubMed=1630814; PubMed=7961102) Derived from metastatic site: Pelvis. Omics: Array-based CGH; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays Male Doubling time: 4-5 days (PubMed=176412) Part of: MD Anderson Cell Lines Project 21117616 CVCL_0828 Hs 62.Fs finite cell line human CVCL_0828 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7042; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117617 CVCL_0827 Hs 618.T undefined cell line type human CVCL_0827 Genome ancestry: African=2.37%; Native American=21.61%; East Asian, North=1.07%; East Asian, South=1.4%; South Asian=1.63%; European, North=38.2%; European, South=33.72% (PubMed=30894373) CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7380; true; Discontinued: ATCC; CRL-7380_FL; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a lung adenocarcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117618 CVCL_0829 Hs 621.Sk finite cell line human CVCL_0829 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7383; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117619 CVCL_0820 Hs 606.Sk finite cell line human CVCL_0820 CL:0000010 Population: Caucasian; Derived from sampling site: Trunk; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7367; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117620 CVCL_0822 Hs 610.Sk finite cell line human CVCL_0822 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7372; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117621 CVCL_0821 Hs 61.Fs finite cell line human CVCL_0821 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7041; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117622 CVCL_0824 Hs 613.Sk finite cell line human CVCL_0824 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7375; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117623 CVCL_0823 Hs 611.T cancer cell line human CVCL_0823 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.5%; East Asian, South=0.05%; South Asian=1.24%; European, North=71.76%; European, South=26.44% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117624 CVCL_0826 Hs 617.Mg finite cell line human CVCL_0826 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Discontinued: ATCC; CRL-7379; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117625 CVCL_0825 Hs 616.T undefined cell line type human CVCL_0825 Genome ancestry: African=0%; Native American=0.47%; East Asian, North=0%; East Asian, South=0.96%; South Asian=2.19%; European, North=68.82%; European, South=27.55% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117626 CVCL_0839 Hs 68 finite cell line human CVCL_0839 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin. Omics: Transcriptome analysis by microarray Male Senescence: Senesces after 42 PDL (ATCC=CRL-1635); Doubling time: ~1.2 days (lot 01242005), ~2 days (lot 01222018) (JCRB) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117627 CVCL_0838 Hs 677.Tg finite cell line human CVCL_0838 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117628 CVCL_0831 Hs 63.T cancer cell line human CVCL_0831 CL:0000010 Derived from sampling site: Skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117629 CVCL_0830 Hs 622.Sk finite cell line human CVCL_0830 CL:0000010 Derived from sampling site: Scalp; skin. Discontinued: ATCC; CRL-7385; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117630 CVCL_0833 Hs 67 finite cell line human CVCL_0833 CL:0000010 Population: Caucasian; Derived from sampling site: Thymus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7828; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117631 CVCL_0832 Hs 633.T cancer cell line human CVCL_0832 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Pro (c.436G>C); ClinVar=VCV000375963; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Argfs*60 (c.852delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-7395; true. Female Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117632 CVCL_0835 Hs 674.Sk finite cell line human CVCL_0835 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7397; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117633 CVCL_0837 Hs 677.Sk finite cell line human CVCL_0837 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7406; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117634 CVCL_0836 Hs 675.T undefined cell line type human CVCL_0836 HLA typing: A*29:02,30:02; B*18:01,44:03; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.02%; East Asian, North=0.97%; East Asian, South=0%; South Asian=3.25%; European, North=70.6%; European, South=25.15% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Colon Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 6-7 days (PubMed=176412) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a colorectal carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117635 CVCL_0806 Hs 574.T cancer cell line human CVCL_0806 CL:0000010 Derived from sampling site: Breast. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117636 CVCL_0805 Hs 574.Sk finite cell line human CVCL_0805 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7346; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117637 CVCL_0808 Hs 579.Mg finite cell line human CVCL_0808 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7347; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117638 CVCL_0807 Hs 578Bst finite cell line human CVCL_0807 CL:0000010 Sequence variation: Mutation; HGNC; 7427; MT-CYB; Simple; p.Ala125Thr (m.15119G>A); ClinVar=VCV000693829; Zygosity=Heteroplasmic; Note=Less <1% while homoplasmic in autologous cell line Hs 578T (PubMed=29671673) Derived from sampling site: Breast. Omics: Mitochondrial genome sequenced Female Part of: ICBP43 breast cancer cell line panel Caution: Although it is part of a cancer cell line panel, it is a normal fibroblastic epithelial/myoepithelial cell line 21117639 CVCL_0809 Hs 58.Fs finite cell line human CVCL_0809 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7038; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117640 CVCL_0800 Hs 568.We finite cell line human CVCL_0800 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7340; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117641 CVCL_0802 Hs 571.T cancer cell line human CVCL_0802 Genome ancestry: African=0%; Native American=0.08%; East Asian, North=0.95%; East Asian, South=0%; South Asian=1.65%; European, North=57.56%; European, South=39.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Ala (c.109T>G); ClinVar=VCV000376235; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Ovary. Omics: Deep exome analysis Discontinued: ATCC; CRL-7846; probable Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117642 CVCL_0801 Hs 57.T cancer cell line human CVCL_0801 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117643 CVCL_0804 Hs 573.T cancer cell line human CVCL_0804 CL:0000010 Derived from sampling site: Lung. Omics: SNP array analysis Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117644 CVCL_0803 Hs 573.Lu finite cell line human CVCL_0803 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117645 CVCL_0817 Hs 605.Sk finite cell line human CVCL_0817 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117646 CVCL_0816 Hs 604.T undefined cell line type human CVCL_0816 Genome ancestry: African=0%; Native American=0.15%; East Asian, North=0%; East Asian, South=4.01%; South Asian=2.02%; European, North=84.03%; European, South=9.79% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Lymph node Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117647 CVCL_0819 Hs 606.T undefined cell line type human CVCL_0819 Genome ancestry: African=1.63%; Native American=1.87%; East Asian, North=0%; East Asian, South=0.76%; South Asian=7.27%; European, North=28.96%; European, South=59.5% (PubMed=30894373). CL:0000010 Population: Caucasian Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117648 CVCL_0818 Hs 605.T cancer cell line human CVCL_0818 CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117649 CVCL_0811 Hs 588.T cancer cell line human CVCL_0811 CL:0000010 Miscellaneous: STR profile from personal communication of Chu V Derived from sampling site: Uterus; cervix. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117650 CVCL_0810 Hs 587.Int cancer cell line human CVCL_0810 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7352; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117651 CVCL_0813 Hs 60.Fs finite cell line human CVCL_0813 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7040; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117652 CVCL_0812 Hs 590.We finite cell line human CVCL_0812 CL:0000010 Population: African American; Karyotypic information: Triploid (ATCC); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117653 CVCL_0815 Hs 602 cancer cell line human CVCL_0815 CL:0000010 Derived from sampling site: Cervical lymph node. Female 21117654 CVCL_0814 Hs 600.T undefined cell line type human CVCL_0814 Genome ancestry: African=0%; Native American=1.98%; East Asian, North=1.7%; East Asian, South=0%; South Asian=0%; European, North=65.3%; European, South=31.02% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117655 CVCL_JD99 GM01420 finite cell line human CVCL_JD99 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01420; probable Female 21117656 CVCL_JD98 GM02029 finite cell line human CVCL_JD98 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02029; probable Female 21117657 CVCL_JD95 GM00975 finite cell line human CVCL_JD95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00975; probable Female 21117658 CVCL_JD94 GM00322 finite cell line human CVCL_JD94 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00322; probable Male 21117659 CVCL_JD97 GM00236 finite cell line human CVCL_JD97 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00236; probable Male 21117660 CVCL_JD96 GM00009 finite cell line human CVCL_JD96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00009; probable Male 21117661 CVCL_JD91 GM00543 finite cell line human CVCL_JD91 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00543; probable Male 21117662 CVCL_JD90 GM01973 finite cell line human CVCL_JD90 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01973; probable Female 21117663 CVCL_JD93 GM00964 finite cell line human CVCL_JD93 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; GM00964; probable Male 21117664 CVCL_JD92 GM00185 finite cell line human CVCL_JD92 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00185; probable Female 21117665 CVCL_8Q61 DA06339 transformed cell line human CVCL_8Q61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117666 CVCL_9261 WEHI-3B/S cancer cell line house mouse CVCL_9261 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21117667 CVCL_8Q60 DA06336 transformed cell line human CVCL_8Q60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117668 CVCL_9260 WEHI-3B/NOVO cancer cell line house mouse CVCL_9260 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28368; Novobiocin; Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21117669 CVCL_8Q67 DA06359 transformed cell line human CVCL_8Q67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117670 CVCL_9267 MIZMe005-A embryonic stem cell human CVCL_9267 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117671 CVCL_8Q66 DA06352 transformed cell line human CVCL_8Q66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117672 CVCL_9266 MIZMe015-A embryonic stem cell human CVCL_9266 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117673 CVCL_8Q69 DA06367 transformed cell line human CVCL_8Q69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117674 CVCL_9269 MIZMe002-A embryonic stem cell human CVCL_9269 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Male 21117675 CVCL_8Q68 DA06362 transformed cell line human CVCL_8Q68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117676 CVCL_9268 MIZMe006-A embryonic stem cell human CVCL_9268 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117677 CVCL_8Q63 DA06342 transformed cell line human CVCL_8Q63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117678 CVCL_9263 MIZMe012-A embryonic stem cell human CVCL_9263 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Male 21117679 CVCL_8Q62 DA06340 transformed cell line human CVCL_8Q62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117680 CVCL_9262 MIZMe001-A embryonic stem cell human CVCL_9262 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Male 21117681 CVCL_8Q65 DA06346 transformed cell line human CVCL_8Q65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117682 CVCL_9265 MIZMe014-A embryonic stem cell human CVCL_9265 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117683 CVCL_8Q64 DA06345 transformed cell line human CVCL_8Q64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117684 CVCL_9264 MIZMe013-A embryonic stem cell human CVCL_9264 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117685 CVCL_8Q59 DA06335 transformed cell line human CVCL_8Q59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117686 CVCL_9259 F81 transformed cell line CVCL_9259 CL:0000010 Derived from sampling site: Kidney. Female 21117687 CVCL_8Q70 DA06369 transformed cell line human CVCL_8Q70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117688 CVCL_9270 MIZMe003-A embryonic stem cell human CVCL_9270 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117689 CVCL_8Q72 DA06373 transformed cell line human CVCL_8Q72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117690 CVCL_9272 MIZMe008-A embryonic stem cell human CVCL_9272 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Male 21117691 CVCL_8Q71 DA06372 transformed cell line human CVCL_8Q71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117692 CVCL_9271 MIZMe007-A embryonic stem cell human CVCL_9271 From: MizMedi Hospital; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010016. 21117693 CVCL_8Q78 DA06384 transformed cell line human CVCL_8Q78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117694 CVCL_AK04 HPSI0714i-jilk_4 induced pluripotent stem cell human CVCL_AK04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117695 CVCL_9278 NYGM cancer cell line human CVCL_9278 CL:0000010 Population: Japanese; Derived from sampling site: Brain; right temporo-parietal lobe. Female Doubling time: 24 hours (PubMed=15859160) 21117696 CVCL_8Q77 DA06383 transformed cell line human CVCL_8Q77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117697 CVCL_AK03 HPSI0714i-jilk_3 induced pluripotent stem cell human CVCL_AK03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117698 CVCL_9277 MUG-Chor1 cancer cell line human CVCL_9277 HLA typing: A*11 (Chordoma_Foundation) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~75-100 hours (DSMZ=ACC-755); 5 days (Chordoma_Foundation) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21117699 CVCL_AK06 HPSI0714i-pipw_5 induced pluripotent stem cell human CVCL_AK06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117700 CVCL_8Q79 DA06386 transformed cell line human CVCL_8Q79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117701 CVCL_AK05 HPSI0714i-pipw_4 induced pluripotent stem cell human CVCL_AK05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117702 CVCL_9279 PO714 spontaneously immortalized cell line CVCL_9279 CL:0000010 Derived from sampling site: Kidney. Virology: Infected with bovine leukemia virus of the Belgian subgroup 21117703 CVCL_8Q74 DA06379 transformed cell line human CVCL_8Q74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117704 CVCL_AK08 HPSI0914i-hidy_4 induced pluripotent stem cell human CVCL_AK08 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117705 CVCL_9274 MIZMe010-A embryonic stem cell human CVCL_9274 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117706 CVCL_8Q73 DA06377 transformed cell line human CVCL_8Q73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117707 CVCL_AK07 HPSI0914i-hidy_3 induced pluripotent stem cell human CVCL_AK07 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21117708 CVCL_9273 MIZMe009-A embryonic stem cell human CVCL_9273 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117709 CVCL_8Q76 DA06382 transformed cell line human CVCL_8Q76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117710 CVCL_9276 MIZMe004-A embryonic stem cell human CVCL_9276 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117711 CVCL_8Q75 DA06380 transformed cell line human CVCL_8Q75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117712 CVCL_AK09 HPSI0914i-qehq_3 induced pluripotent stem cell human CVCL_AK09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21117713 CVCL_9275 MIZMe011-A embryonic stem cell human CVCL_9275 From: MizMedi Hospital; Seoul; South Korea. CL:0000010 Female 21117714 CVCL_AK00 HPSI0614i-ciwj_2 induced pluripotent stem cell human CVCL_AK00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117715 CVCL_AK02 HPSI0614i-liqa_6 induced pluripotent stem cell human CVCL_AK02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117716 CVCL_AK01 HPSI0614i-liqa_1 induced pluripotent stem cell human CVCL_AK01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21117717 CVCL_9245 CHO clone B spontaneously immortalized cell line CVCL_9245 CL:0000010 Derived from sampling site: Ovary. Female 21117718 CVCL_8Q45 DA06298 transformed cell line human CVCL_8Q45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117719 CVCL_9244 CHO clone 13 spontaneously immortalized cell line CVCL_9244 CL:0000010 Derived from sampling site: Ovary. Female 21117720 CVCL_8Q44 DA06288 transformed cell line human CVCL_8Q44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117721 CVCL_8Q47 DA06300 transformed cell line human CVCL_8Q47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117722 CVCL_9247 THP-4 cancer cell line human CVCL_9247 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 52 hours (PubMed=2954268) 21117723 CVCL_8Q46 DA06299 transformed cell line human CVCL_8Q46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117724 CVCL_8Q41 DA06284 transformed cell line human CVCL_8Q41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117725 CVCL_9241 WFL4F12.3 hybridoma CVCL_9241 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8156 21117726 CVCL_8Q40 DA06283 transformed cell line human CVCL_8Q40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117727 CVCL_9240 WFL3C6.1 hybridoma CVCL_9240 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8157 21117728 CVCL_9243 CHO MT+ spontaneously immortalized cell line CVCL_9243 CL:0000010 Derived from sampling site: Ovary. Female 21117729 CVCL_8Q43 DA06287 transformed cell line human CVCL_8Q43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117730 CVCL_9242 ANN-1 transformed cell line house mouse CVCL_9242 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21117731 CVCL_8Q42 DA06285 transformed cell line human CVCL_8Q42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117732 CVCL_8Q38 DA06281 transformed cell line human CVCL_8Q38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117733 CVCL_9238 SFR8-B6 hybridoma CVCL_9238 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01889; Human HLA-B (Note=Recognizes HLA-Bw6 epitope). 21117734 CVCL_8Q37 DA06280 transformed cell line human CVCL_8Q37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117735 CVCL_9237 SFR3-DR5 hybridoma CVCL_9237 CL:0000010 Monoclonal antibody isotype: IgG2b. 21117736 CVCL_8Q39 DA06282 transformed cell line human CVCL_8Q39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117737 CVCL_9239 TR 310 hybridoma CVCL_9239 CL:0000010 Monoclonal antibody isotype: IgG2b. 21117738 CVCL_8Q50 DA06312 transformed cell line human CVCL_8Q50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117739 CVCL_9250 THP-3-1 cancer cell line human CVCL_9250 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 50-60 hours (PubMed=6605598) 21117740 CVCL_9256 D5 hybrid cell line pig CVCL_9256 CL:0000010 21117741 CVCL_8Q56 DA06326 transformed cell line human CVCL_8Q56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117742 CVCL_9255 C6-Russian hybrid cell line pig CVCL_9255 CL:0000010 21117743 CVCL_8Q55 DA06324 transformed cell line human CVCL_8Q55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117744 CVCL_9258 A4xC hybrid cell line pig CVCL_9258 CL:0000010 Characteristics: Hybrid of pig embryonic kidney cells with pig splenocytes (CelloPub=CLPUB00606). 21117745 CVCL_8Q58 DA06331 transformed cell line human CVCL_8Q58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117746 CVCL_9257 A4xL hybrid cell line pig CVCL_9257 CL:0000010 Characteristics: Hybrid of pig embryonic kidney cells with equine lymphocytes. 21117747 CVCL_8Q57 DA06330 transformed cell line human CVCL_8Q57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117748 CVCL_8Q52 DA06321 transformed cell line human CVCL_8Q52 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117749 CVCL_9252 THP-2 cancer cell line human CVCL_9252 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Virology: EBV-negative Doubling time: 24 hours (PubMed=6314596) 21117750 CVCL_8Q51 DA06320 transformed cell line human CVCL_8Q51 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117751 CVCL_9251 THP-3-2 cancer cell line human CVCL_9251 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 50-60 hours (PubMed=6605598) 21117752 CVCL_8Q54 DA06323 transformed cell line human CVCL_8Q54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117753 CVCL_9254 QEC(MC29) transformed cell line CVCL_9254 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Embryonic tibia; cartilage Cell type=Chondrocyte.. Unspecified Group: Bird cell line 21117754 CVCL_8Q53 DA06322 transformed cell line human CVCL_8Q53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117755 CVCL_9253 FBL-J5 spontaneously immortalized cell line CVCL_9253 CL:0000010 Derived from sampling site: Fetal lung; Breed/subspecies: Jersey. Female 21117756 CVCL_8Q49 DA06311 transformed cell line human CVCL_8Q49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117757 CVCL_9249 THP-9 cancer cell line human CVCL_9249 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Doubling time: 30 hours (PubMed=2954268) 21117758 CVCL_8Q48 DA06303 transformed cell line human CVCL_8Q48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117759 CVCL_9248 THP-7 cancer cell line human CVCL_9248 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow and peripheral blood Cell type=T-cell.. Female Doubling time: 50 hours (PubMed=2954268); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21117760 CVCL_8Q23 DA06264 transformed cell line human CVCL_8Q23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117761 CVCL_9223 MECA-89 hybridoma CVCL_9223 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q61826; Mouse Madcam1. 21117762 CVCL_8Q22 DA06263 transformed cell line human CVCL_8Q22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117763 CVCL_9222 MECA-79 hybridoma CVCL_9222 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Sulfated N-acetylglucosamine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9479 21117764 CVCL_8Q25 DA06267 transformed cell line human CVCL_8Q25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117765 CVCL_9225 PS/2 hybridoma CVCL_9225 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q00651; Mouse Itga4/Cd49d. 21117766 CVCL_8Q24 DA06265 transformed cell line human CVCL_8Q24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117767 CVCL_9224 MEL-14 hybridoma CVCL_9224 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P18337; Mouse Sell/Cd62l. 21117768 CVCL_8Q21 DA06262 transformed cell line human CVCL_8Q21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117769 CVCL_9221 MECA-367 hybridoma CVCL_9221 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q61826; Mouse Madcam1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9478 21117770 CVCL_8Q20 DA06261 transformed cell line human CVCL_8Q20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117771 CVCL_9220 MD2 hybridoma CVCL_9220 CL:0000010 Monoclonal antibody isotype: IgM. 21117772 CVCL_8Q19 DA06259 transformed cell line human CVCL_8Q19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117773 CVCL_9219 MB4B4 hybridoma CVCL_9219 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21117774 CVCL_0880 Hs 738.St/Int finite cell line human CVCL_0880 CL:0000010 Derived from sampling site: Fetal intestine and fetal stomach Cell type=Fibroblast.. Omics: SNP array analysis Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117775 CVCL_8Q16 DA06255 transformed cell line human CVCL_8Q16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117776 CVCL_0882 Hs 739.T undefined cell line type human CVCL_0882 Genome ancestry: African=0.34%; Native American=0.15%; East Asian, North=79.91%; East Asian, South=19.42%; South Asian=0.17%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Asian; Derived from sampling site: Breast Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117777 CVCL_9216 M5/49.4.1 hybridoma CVCL_9216 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117778 CVCL_8Q15 DA06254 transformed cell line human CVCL_8Q15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117779 CVCL_0881 Hs 739.Sk finite cell line human CVCL_0881 CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7476; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117780 CVCL_9215 M5/114.15.2 hybridoma CVCL_9215 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117781 CVCL_8Q18 DA06258 transformed cell line human CVCL_8Q18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117782 CVCL_0884 Hs 740.T cancer cell line human CVCL_0884 CL:0000010 Discontinued: ATCC; CRL-7870; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117783 CVCL_9218 MB23G2 hybridoma CVCL_9218 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21117784 CVCL_8Q17 DA06257 transformed cell line human CVCL_8Q17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117785 CVCL_0883 Hs 740.Sk finite cell line human CVCL_0883 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117786 CVCL_9217 mAb 270 hybridoma CVCL_9217 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Chicken neuronal nicotonic acetylcholine receptor (Note=Also reacts with mouse and rat). 21117787 CVCL_0886 Hs 741.T cancer cell line human CVCL_0886 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117788 CVCL_0885 Hs 741.Sk finite cell line human CVCL_0885 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7479; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117789 CVCL_0888 Hs 742.T undefined cell line type human CVCL_0888 Genome ancestry: African=0%; Native American=1.14%; East Asian, North=0%; East Asian, South=0.7%; South Asian=0%; European, North=72.94%; European, South=25.22% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Breast Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a breast carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117790 CVCL_0887 Hs 742.Sk finite cell line human CVCL_0887 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117791 CVCL_0889 Hs 748.T cancer cell line human CVCL_0889 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21117792 CVCL_8Q34 DA06276 transformed cell line human CVCL_8Q34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117793 CVCL_9234 RA3-2C2/1 hybridoma CVCL_9234 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117794 CVCL_8Q33 DA06275 transformed cell line human CVCL_8Q33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117795 CVCL_9233 R4-6A2 hybridoma CVCL_9233 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01580; Mouse Ifng. 21117796 CVCL_8Q36 DA06279 transformed cell line human CVCL_8Q36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117797 CVCL_9236 S4B6-1 hybridoma CVCL_9236 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04351; Mouse Il2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10968 21117798 CVCL_8Q35 DA06278 transformed cell line human CVCL_8Q35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117799 CVCL_9235 RA3-3A1/6.1 hybridoma CVCL_9235 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117800 CVCL_8Q30 DA06272 transformed cell line human CVCL_8Q30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117801 CVCL_9230 R187 hybridoma CVCL_9230 CL:0000010 Monoclonal antibody isotype: IgG1. 21117802 CVCL_8Q32 DA06274 transformed cell line human CVCL_8Q32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117803 CVCL_9232 R2-9A5 hybridoma CVCL_9232 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P43431; Mouse Il12a; Monoclonal antibody target: UniProtKB; P43432; Mouse Il12b. 21117804 CVCL_8Q31 DA06273 transformed cell line human CVCL_8Q31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117805 CVCL_9231 R2-10F6 hybridoma CVCL_9231 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P43432; Mouse Il12b. 21117806 CVCL_0891 Hs 751.T undefined cell line type human CVCL_0891 Genome ancestry: African=0.33%; Native American=0.12%; East Asian, North=0.59%; East Asian, South=0%; South Asian=0%; European, North=67.84%; European, South=31.12% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Lymph node Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-7488; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117807 CVCL_0890 Hs 749.Sk finite cell line human CVCL_0890 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7487; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117808 CVCL_8Q27 DA06269 transformed cell line human CVCL_8Q27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117809 CVCL_0893 Hs 757.T undefined cell line type human CVCL_0893 CL:0000010 Discontinued: ATCC; CRL-7490; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117810 CVCL_9227 R1-5D9 hybridoma CVCL_9227 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P43432; Mouse Il12b. 21117811 CVCL_8Q26 DA06268 transformed cell line human CVCL_8Q26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117812 CVCL_0892 Hs 755(B).T cancer cell line human CVCL_0892 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone; proximal tibia. Discontinued: ATCC; CRL-7489; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117813 CVCL_9226 R1-2 hybridoma CVCL_9226 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q00651; Mouse Itga4/Cd49d. 21117814 CVCL_8Q29 DA06271 transformed cell line human CVCL_8Q29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117815 CVCL_0895 Hs 764.Mu finite cell line human CVCL_0895 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7494; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117816 CVCL_9229 R17 217.1.3 hybridoma CVCL_9229 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q62351; Mouse Tfrc/Cd71. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117817 CVCL_8Q28 DA06270 transformed cell line human CVCL_8Q28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117818 CVCL_0894 Hs 762.Sk finite cell line human CVCL_0894 CL:0000010 Discontinued: ATCC; CRL-7492; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117819 CVCL_9228 R17 208.2 hybridoma CVCL_9228 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q62351; Mouse Tfrc/Cd71. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117820 CVCL_0897 Hs 77.Fs finite cell line human CVCL_0897 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7055; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117821 CVCL_0896 Hs 769.T cancer cell line human CVCL_0896 CL:0000010 Derived from sampling site: Urethra. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117822 CVCL_0899 Hs 777.T cancer cell line human CVCL_0899 CL:0000010 Derived from sampling site: Lymph node. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117823 CVCL_0898 Hs 774.Pl finite cell line human CVCL_0898 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7502; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117824 CVCL_8Q01 DA06225 transformed cell line human CVCL_8Q01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117825 CVCL_9201 M/K-1.9 hybridoma CVCL_9201 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P29533; Mouse Vcam1/Cd106. 21117826 CVCL_8Q00 DA06224 transformed cell line human CVCL_8Q00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117827 CVCL_9200 LYK-9 hybridoma CVCL_9200 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44. 21117828 CVCL_8Q03 DA06227 transformed cell line human CVCL_8Q03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117829 CVCL_9203 M1.4 hybridoma CVCL_9203 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q62005; Mouse Zp1. 21117830 CVCL_8Q02 DA06226 transformed cell line human CVCL_8Q02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117831 CVCL_9202 M/K-2.7 hybridoma CVCL_9202 CL:0000010 Discontinued: BCRJ; 0150; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P29533; Mouse Vcam1/Cd106 21117832 CVCL_0860 Hs 704.Sk finite cell line human CVCL_0860 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117833 CVCL_0862 Hs 706.Sk finite cell line human CVCL_0862 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7446; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117834 CVCL_0861 Hs 704.T cancer cell line human CVCL_0861 CL:0000010 Population: Caucasian; Derived from sampling site: Bone. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117835 CVCL_0864 Hs 707(A).T cancer cell line human CVCL_0864 CL:0000010 Population: Caucasian; Derived from sampling site: Bone. Omics: SNP array analysis Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117836 CVCL_0863 Hs 706.T cancer cell line human CVCL_0863 Genome ancestry: African=2.7%; Native American=0.03%; East Asian, North=2.51%; East Asian, South=0%; South Asian=0.07%; European, North=57.98%; European, South=36.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Bone. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117837 CVCL_0866 Hs 709.T cancer cell line human CVCL_0866 CL:0000010 Discontinued: ATCC; CRL-7453; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117838 CVCL_0865 Hs 707(B).Ep finite cell line human CVCL_0865 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117839 CVCL_0868 Hs 722.T cancer cell line human CVCL_0868 CL:0000010 Discontinued: ATCC; CRL-7456; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117840 CVCL_0867 Hs 72.Fs finite cell line human CVCL_0867 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7049; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117841 CVCL_0869 Hs 726.Pl finite cell line human CVCL_0869 CL:0000010 Population: African American; Derived from sampling site: Placenta Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117842 CVCL_8Q12 DA06248 transformed cell line human CVCL_8Q12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117843 CVCL_9212 M17/4.4.11.9 hybridoma CVCL_9212 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P24063; Mouse Itgal/Cd11a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117844 CVCL_8Q11 DA06247 transformed cell line human CVCL_8Q11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117845 CVCL_9211 M1/9.3.4.HL.2 hybridoma CVCL_9211 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117846 CVCL_8Q14 DA06252 transformed cell line human CVCL_8Q14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117847 CVCL_9214 M3/84.6.34 hybridoma CVCL_9214 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P17047; Mouse Lamp2/Cd107b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117848 CVCL_8Q13 DA06250 transformed cell line human CVCL_8Q13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117849 CVCL_9213 M17/5.2 hybridoma CVCL_9213 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P24063; Mouse Itgal/Cd11a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117850 CVCL_8Q10 DA06246 transformed cell line human CVCL_8Q10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117851 CVCL_9210 M1/89.18.7.HK hybridoma CVCL_9210 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117852 CVCL_8Q09 DA06243 transformed cell line human CVCL_8Q09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117853 CVCL_9209 M1/87.27.7.HLK hybridoma CVCL_9209 CL:0000010 Monoclonal antibody isotype: IgM. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117854 CVCL_8Q08 DA06240 transformed cell line human CVCL_8Q08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117855 CVCL_9208 M1/75.16.4.HLK hybridoma CVCL_9208 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117856 CVCL_8Q05 DA06233 transformed cell line human CVCL_8Q05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117857 CVCL_0871 Hs 729.T cancer cell line human CVCL_0871 Genome ancestry: African=1.21%; Native American=0%; East Asian, North=2.49%; East Asian, South=0%; South Asian=0.96%; European, North=57.58%; European, South=37.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7862; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117858 CVCL_9205 M1/42.3.9.8.HLK hybridoma CVCL_9205 CL:0000010 Monoclonal antibody isotype: IgG2a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117859 CVCL_8Q04 DA06229 transformed cell line human CVCL_8Q04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117860 CVCL_0870 Hs 728.Sk/Mu finite cell line human CVCL_0870 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7462; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117861 CVCL_9204 M1/22.25.8.HL hybridoma CVCL_9204 CL:0000010 Monoclonal antibody isotype: IgM. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117862 CVCL_8Q07 DA06235 transformed cell line human CVCL_8Q07 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117863 CVCL_0873 Hs 730.Pl finite cell line human CVCL_0873 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117864 CVCL_9207 M1/70.15.11.5.HL hybridoma CVCL_9207 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05555; Mouse Itgam/Cd11b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117865 CVCL_8Q06 DA06234 transformed cell line human CVCL_8Q06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21117866 CVCL_9206 M1/69.16.11.HL hybridoma CVCL_9206 CL:0000010 Monoclonal antibody isotype: IgG2b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21117867 CVCL_0875 Hs 733.Sk finite cell line human CVCL_0875 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117868 CVCL_0874 Hs 731.Sk finite cell line human CVCL_0874 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7465; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117869 CVCL_0877 Hs 735.T cancer cell line human CVCL_0877 CL:0000010 Derived from sampling site: Bone. Discontinued: ATCC; CRL-7471; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: Established from same individual as Hs 735.Sk (Cellosaurus=CVCL_G024) which is said to originate from a 26 year old female 21117870 CVCL_0876 Hs 734.Sk finite cell line human CVCL_0876 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7470; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117871 CVCL_0879 Hs 738.Lu finite cell line human CVCL_0879 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-7868; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21117872 CVCL_0878 Hs 737.T undefined cell line type human CVCL_0878 Genome ancestry: African=0%; Native American=0.61%; East Asian, North=1.03%; East Asian, South=0%; South Asian=0%; European, North=67.56%; European, South=30.8% (PubMed=30894373). CL:0000010 Population: Caucasian Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a giant cell tumor of bone cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21117873 CVCL_JF31 GM25396 transformed cell line human CVCL_JF31 CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Asp1237Ilefs*17 (c.3709delG); ClinVar=VCV000005490; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117874 CVCL_JF30 GM25395 transformed cell line human CVCL_JF30 CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Asp1237Ilefs*17 (c.3709delG); ClinVar=VCV000005490; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117875 CVCL_JF33 GM25522 transformed cell line human CVCL_JF33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117876 CVCL_JF32 GM25397 transformed cell line human CVCL_JF32 CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Asp1237Ilefs*17 (c.3709delG); ClinVar=VCV000005490; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117877 CVCL_AL94 GM09768 transformed cell line human CVCL_AL94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117878 CVCL_AL93 GM09767 transformed cell line human CVCL_AL93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117879 CVCL_AL96 GM09770 transformed cell line human CVCL_AL96 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117880 CVCL_AL95 GM09769 transformed cell line human CVCL_AL95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117881 CVCL_AL98 GM09773 transformed cell line human CVCL_AL98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117882 CVCL_AL97 GM09772 transformed cell line human CVCL_AL97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117883 CVCL_AL99 GM09774 transformed cell line human CVCL_AL99 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117884 CVCL_JF28 GM26198 transformed cell line human CVCL_JF28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117885 CVCL_JF27 GM26197 transformed cell line human CVCL_JF27 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln73Ter (c.217C>T); ClinVar=VCV000205480; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117886 CVCL_JF29 GM25246 finite cell line human CVCL_JF29 CL:0000010 Sequence variation: Mutation; HGNC; 25928; WDR73; Simple; p.Phe296Leufs*26 (c.888delT); ClinVar=VCV000225244; Zygosity=Homozygous (PubMed=26070982); Sequence variation: Mutation; HGNC; 30493; WHAMM; Simple; p.Ile422Lysfs*35 (c.1264_1270delATAAAAG); Zygosity=Heterozygous (PubMed=26070982) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21117887 CVCL_AL90 GM09763 transformed cell line human CVCL_AL90 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117888 CVCL_JF24 GM23363 finite cell line human CVCL_JF24 CL:0000010 Sequence variation: Mutation; HGNC; 9202; POMT1; Simple; p.Ser29Arg (c.85A>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9202; POMT1; Simple; p.Arg622Ter (c.1864C>T); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117889 CVCL_JF23 GM16372 transformed cell line human CVCL_JF23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117890 CVCL_AL92 GM09766 transformed cell line human CVCL_AL92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117891 CVCL_JF26 GM26063 transformed cell line human CVCL_JF26 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg262Profs*3 (c.784_785insCA); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117892 CVCL_AL91 GM09765 transformed cell line human CVCL_AL91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117893 CVCL_JF25 GM23894 finite cell line human CVCL_JF25 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21117894 CVCL_JF42 GM25994 finite cell line human CVCL_JF42 CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Gly484Ser (c.1450G>A); ClinVar=VCV000245898; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117895 CVCL_JF41 GM25982 transformed cell line human CVCL_JF41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117896 CVCL_JF44 GM07125 finite cell line human CVCL_JF44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21117897 CVCL_JF43 GM23424 transformed cell line human CVCL_JF43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117898 CVCL_JF40 GM25976 finite cell line human CVCL_JF40 CL:0000010 Sequence variation: Mutation; HGNC; 2745; DDX3X; Simple; p.Tyr462Ilefs*3 (c.1383dupA); dbSNP=rs796052228; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21117899 CVCL_JF39 GM25975 finite cell line human CVCL_JF39 CL:0000010 Sequence variation: Mutation; HGNC; 2745; DDX3X; Simple; p.Tyr462Ilefs*3 (c.1383dupA); dbSNP=rs796052228; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117900 CVCL_JF38 GM25974 finite cell line human CVCL_JF38 CL:0000010 Sequence variation: Mutation; HGNC; 2745; DDX3X; Simple; p.Tyr462Ilefs*3 (c.1383dupA); dbSNP=rs796052228; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117901 CVCL_JF35 GM25586 transformed cell line human CVCL_JF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117902 CVCL_JF34 GM25585 transformed cell line human CVCL_JF34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117903 CVCL_JF37 GM25594 transformed cell line human CVCL_JF37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117904 CVCL_JF36 GM25593 transformed cell line human CVCL_JF36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117905 CVCL_JF11 EBTr clone C6 finite cell line CVCL_JF11 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117906 CVCL_JF10 EBTr clone B8 finite cell line CVCL_JF10 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117907 CVCL_AL79 GM09011 transformed cell line human CVCL_AL79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117908 CVCL_AL72 GM09004 transformed cell line human CVCL_AL72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117909 CVCL_AL71 GM09003 transformed cell line human CVCL_AL71 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117910 CVCL_AL74 GM09006 transformed cell line human CVCL_AL74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117911 CVCL_AL73 GM09005 transformed cell line human CVCL_AL73 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117912 CVCL_AL76 GM09008 transformed cell line human CVCL_AL76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117913 CVCL_JF09 EBTr clone B7 finite cell line CVCL_JF09 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117914 CVCL_AL75 GM09007 transformed cell line human CVCL_AL75 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117915 CVCL_AL78 GM09010 transformed cell line human CVCL_AL78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117916 CVCL_AL77 GM09009 transformed cell line human CVCL_AL77 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117917 CVCL_JF06 RTSCC cancer cell line CVCL_JF06 CL:0000010 Miscellaneous: As no cell line name was provided in the patent and the paper, we assigned the name based on the abbreviation of the cell line description Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: New Zealand white. Unspecified Doubling time: 91 hours (at 5th passage), 84 hours (at 15th passage), 89 hours (at 25th passage), 37 hours (at 35th passage), 39 hours (at 53th passage), 35 hours (at 57th passage) (PubMed=21071263) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200504 21117918 CVCL_JF05 TBE-1SA transformed cell line human CVCL_JF05 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Derived from sampling site: Bronchus; epithelium. Female 21117919 CVCL_JF08 EBTr clone A11 finite cell line CVCL_JF08 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117920 CVCL_JF07 DEC 99 spontaneously immortalized cell line CVCL_JF07 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Doubling time: ~36 hours (at 20-30th passage), ~72 hours (at 60-70th passage) (CelloPub=CLPUB00393) Group: Bird cell line; Group: Vaccine production cell line 21117921 CVCL_JF02 GM14165 transformed cell line human CVCL_JF02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117922 CVCL_JF01 GM13678 transformed cell line human CVCL_JF01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117923 CVCL_AL70 GM09002 transformed cell line human CVCL_AL70 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117924 CVCL_JF04 GM22090 transformed cell line human CVCL_JF04 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21117925 CVCL_JF03 GM22060 finite cell line human CVCL_JF03 CL:0000010 Population: Jewish; Ashkenazi; Donor information: Established from a donor suffering from Pelizaeus-Merzbacher-like symptoms; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21117926 CVCL_JF20 PK15-A2 spontaneously immortalized cell line pig CVCL_JF20 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Doubling time: 10.7 +- 0.5 hours (PubMed=17889922) 21117927 CVCL_JF22 A-375 NRAS p.Q61K cancer cell line human CVCL_JF22 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Homozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Shows significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line in 2D and 3D culture systems Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC). 21117928 CVCL_JF21 PK15-C1 spontaneously immortalized cell line pig CVCL_JF21 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Highly susceptible to infection by porcine circovirus type 2 (PCV2) Doubling time: 16.9 +- 1.1 hours (PubMed=17889922) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8244 21117929 CVCL_AL83 GM09756 transformed cell line human CVCL_AL83 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117930 CVCL_AL82 GM09755 transformed cell line human CVCL_AL82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117931 CVCL_AL85 GM09758 transformed cell line human CVCL_AL85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117932 CVCL_AL84 GM09757 transformed cell line human CVCL_AL84 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117933 CVCL_AL87 GM09760 transformed cell line human CVCL_AL87 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117934 CVCL_AL86 GM09759 transformed cell line human CVCL_AL86 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117935 CVCL_AL89 GM09762 transformed cell line human CVCL_AL89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117936 CVCL_AL88 GM09761 transformed cell line human CVCL_AL88 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117937 CVCL_JF17 T17-17703A telomerase immortalized cell line CVCL_JF17 From: Transgene SA; Illkirch-Graffenstaden; France CL:0000010 Transfected with: UniProtKB; B7S5K9; Cairina moschata TERT Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285). Unspecified Doubling time: 47 hours (Patent=US8513018) Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 09070703 21117938 CVCL_JF16 T17-17703B2 telomerase immortalized cell line CVCL_JF16 From: Transgene SA; Illkirch-Graffenstaden; France CL:0000010 Transfected with: UniProtKB; B7S5K9; Cairina moschata TERT Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285). Unspecified Doubling time: 30 hours (Patent=US8513018) Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 09070702 21117939 CVCL_JF19 PK-15A spontaneously immortalized cell line pig CVCL_JF19 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Not infected with porcine circovirus type 1 (PCV1) 21117940 CVCL_JF18 DuckCelt-T17 telomerase immortalized cell line CVCL_JF18 From: Transgene SA; Illkirch-Graffenstaden; France CL:0000010 Transfected with: UniProtKB; B7S5K9; Cairina moschata TERT Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285). Unspecified Group: Bird cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21117941 CVCL_JF13 EBTr clone E7 finite cell line CVCL_JF13 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117942 CVCL_JF12 EBTr clone D10 finite cell line CVCL_JF12 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117943 CVCL_AL81 GM09754 transformed cell line human CVCL_AL81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117944 CVCL_JF15 T17-17703B telomerase immortalized cell line CVCL_JF15 From: Transgene SA; Illkirch-Graffenstaden; France CL:0000010 Transfected with: UniProtKB; B7S5K9; Cairina moschata TERT Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285). Unspecified Doubling time: 35 hours (Patent=US8513018) Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 09070701 21117945 CVCL_JF14 EBTr clone G9 finite cell line CVCL_JF14 CL:0000010 Derived from sampling site: Fetal trachea. Male 21117946 CVCL_AL80 GM09012 transformed cell line human CVCL_AL80 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117947 CVCL_AL58 GM08988 transformed cell line human CVCL_AL58 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117948 CVCL_AL57 GM08987 transformed cell line human CVCL_AL57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117949 CVCL_AL59 GM08989 transformed cell line human CVCL_AL59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117950 CVCL_AL50 GM08980 transformed cell line human CVCL_AL50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117951 CVCL_AL52 GM08982 transformed cell line human CVCL_AL52 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117952 CVCL_AL51 GM08981 transformed cell line human CVCL_AL51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117953 CVCL_AL54 GM08984 transformed cell line human CVCL_AL54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117954 CVCL_AL53 GM08983 transformed cell line human CVCL_AL53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117955 CVCL_AL56 GM08986 transformed cell line human CVCL_AL56 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117956 CVCL_AL55 GM08985 transformed cell line human CVCL_AL55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117957 CVCL_JF00 GM13666 transformed cell line human CVCL_JF00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21117958 CVCL_AL69 GM09001 transformed cell line human CVCL_AL69 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117959 CVCL_AL68 GM09000 transformed cell line human CVCL_AL68 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117960 CVCL_AL61 GM08991 transformed cell line human CVCL_AL61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117961 CVCL_AL60 GM08990 transformed cell line human CVCL_AL60 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117962 CVCL_AL63 GM08993 transformed cell line human CVCL_AL63 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117963 CVCL_AL62 GM08992 transformed cell line human CVCL_AL62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117964 CVCL_AL65 GM08996 transformed cell line human CVCL_AL65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117965 CVCL_AL64 GM08995 transformed cell line human CVCL_AL64 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117966 CVCL_AL67 GM08999 transformed cell line human CVCL_AL67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117967 CVCL_AL66 GM08997 transformed cell line human CVCL_AL66 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117968 CVCL_AL36 GM08964 transformed cell line human CVCL_AL36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117969 CVCL_AL35 GM08963 transformed cell line human CVCL_AL35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117970 CVCL_AL38 GM08966 transformed cell line human CVCL_AL38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117971 CVCL_AL37 GM08965 transformed cell line human CVCL_AL37 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117972 CVCL_AL39 GM08967 transformed cell line human CVCL_AL39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117973 CVCL_AL30 GM08958 transformed cell line human CVCL_AL30 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117974 CVCL_AL32 GM08960 transformed cell line human CVCL_AL32 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117975 CVCL_AL31 GM08959 transformed cell line human CVCL_AL31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117976 CVCL_AL34 GM08962 transformed cell line human CVCL_AL34 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117977 CVCL_AL33 GM08961 transformed cell line human CVCL_AL33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117978 CVCL_AL47 GM08975 transformed cell line human CVCL_AL47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117979 CVCL_AL46 GM08974 transformed cell line human CVCL_AL46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117980 CVCL_AL49 GM08979 transformed cell line human CVCL_AL49 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Homozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117981 CVCL_AL48 GM08978 transformed cell line human CVCL_AL48 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117982 CVCL_AL41 GM08969 transformed cell line human CVCL_AL41 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117983 CVCL_AL40 GM08968 transformed cell line human CVCL_AL40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117984 CVCL_AL43 GM08971 transformed cell line human CVCL_AL43 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117985 CVCL_AL42 GM08970 transformed cell line human CVCL_AL42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21117986 CVCL_AL45 GM08973 transformed cell line human CVCL_AL45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117987 CVCL_AL44 GM08972 transformed cell line human CVCL_AL44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21117988 CVCL_JF97 cyfH-3 induced pluripotent stem cell CVCL_JF97 CL:0000010 Derived from sampling site: Fetal liver. Unspecified Group: Non-human primate cell line 21117989 CVCL_JF96 cyfH-2 induced pluripotent stem cell CVCL_JF96 CL:0000010 Derived from sampling site: Fetal liver. Unspecified Group: Non-human primate cell line 21117990 CVCL_JF99 cyfH-5 induced pluripotent stem cell CVCL_JF99 CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 21117991 CVCL_JF98 cyfH-4 induced pluripotent stem cell CVCL_JF98 CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 21117992 CVCL_JF93 hTf26-9B/sf hybridoma house mouse CVCL_JF93 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. Group: Serum/protein free medium cell line 21117993 CVCL_JF92 HLE-LUC cancer cell line human CVCL_JF92 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Liver Cell type=Epithelial cell.. Male 21117994 CVCL_JF95 cyfH-1 induced pluripotent stem cell CVCL_JF95 CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 21117995 CVCL_JF94 HSC-3/CMV-Luc cancer cell line human CVCL_JF94 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Cervical lymph node. Discontinued: JCRB; NIHS1045; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21117996 CVCL_JF91 hTf2-9F/sf hybridoma house mouse CVCL_JF91 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. Group: Serum/protein free medium cell line 21117997 CVCL_JF90 VV-B6F4 hybridoma house mouse CVCL_JF90 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08714; Vaccinia virus HA. 21117998 CVCL_JF89 HSC-1 [Macaca fascicularis] transformed cell line CVCL_JF89 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21117999 CVCL_JF75 STIP-2 spontaneously immortalized cell line CVCL_JF75 CL:0000010 Derived from sampling site: Eye; iris. Unspecified Doubling time: ~80 hours (Patent=JP5702092) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-11274 21118000 CVCL_JF74 hTERT-PLCs telomerase immortalized cell line pig CVCL_JF74 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary; corpus luteum Cell type=Luteal cell.. Female 21118001 CVCL_JF77 XH1a cancer cell line human CVCL_JF77 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: 16.2 hours (PubMed=1911212) 21118002 CVCL_JF76 Sf-RVN spontaneously immortalized cell line CVCL_JF76 CL:0000010 Derived from sampling site: Ovary. Female Virology: Devoid of SfRV rhabdovirus Doubling time: ~20 hours (PubMed=26923062) Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line 21118003 CVCL_JF71 ATL-7 transformed cell line human CVCL_JF71 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21118004 CVCL_JF70 ED-40515(-) cancer cell line human CVCL_JF70 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Lost its original IL2 dependency 21118005 CVCL_JF73 CLEC213 spontaneously immortalized cell line CVCL_JF73 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: White Leghorn SPF PA12. Omics: Transcriptome analysis by microarray Female Group: Bird cell line 21118006 CVCL_JF72 ATL-12A transformed cell line human CVCL_JF72 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21118007 CVCL_JF68 ED-40515 cancer cell line human CVCL_JF68 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Characteristics: IL2 dependent 21118008 CVCL_JF67 KH-2 cancer cell line human CVCL_JF67 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: ~72 hours (PubMed=6982237) 21118009 CVCL_JF69 ED-40810 cancer cell line human CVCL_JF69 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21118010 CVCL_JF86 ITSM transformed cell line human CVCL_JF86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female 21118011 CVCL_JF85 VV-B2D10 hybridoma house mouse CVCL_JF85 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08714; Vaccinia virus HA. 21118012 CVCL_JF88 JHH-5-Luc cancer cell line human CVCL_JF88 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gln6Argfs*22 (c.17_18delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190_His193del (c.569_580del12); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Japanese Male 21118013 CVCL_JF87 hTf/CHO-S #29/sf spontaneously immortalized cell line CVCL_JF87 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21118014 CVCL_JF82 Fujimaki-I cancer cell line human CVCL_JF82 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21118015 CVCL_JF81 OG cancer cell line human CVCL_JF81 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female 21118016 CVCL_JF84 HuH-6-Luc cancer cell line human CVCL_JF84 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Liver. Male 21118017 CVCL_JF83 Fujimaki-II cancer cell line human CVCL_JF83 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion. Male 21118018 CVCL_JF80 NuE15-1 spontaneously immortalized cell line human CVCL_JF80 CL:0000010 Population: Japanese; Derived from sampling site: Fetal liver. Female 21118019 CVCL_JF79 HOG-1 cancer cell line human CVCL_JF79 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21118020 CVCL_JF78 XH1b cancer cell line human CVCL_JF78 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: 21.6 hours (PubMed=1911212) 21118021 CVCL_JF53 Vero RCB 10-87 spontaneously immortalized cell line green monkey CVCL_JF53 CL:0000010 Derived from sampling site: Kidney; epithelium. Omics: Genome sequenced Female Characteristics: A World Health Organisation (WHO) working cell bank of 1000 ampoules deposited at ECACC, derived from an original American Type Culture Collection (ATCC) ampoule Available free of charge to organisations producing vaccines following receipt of approval to supply from WHO. Group: Non-human primate cell line; Group: Vaccine production cell line 21118022 CVCL_JF52 GM14707 transformed cell line human CVCL_JF52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118023 CVCL_JF55 AGMK1-9T7 spontaneously immortalized cell line CVCL_JF55 CL:0000010 Derived from sampling site: Kidney. Female Doubling time: 96.7 hours (at 10th passage), 85.3 hours (at 20th passage), 28.9 hours (at 30th passage), 18.3 hours (at 40th passage) (PubMed=28434690) Group: Non-human primate cell line 21118024 CVCL_JF54 MRC-5 PDL12 finite cell line human CVCL_JF54 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Vaccine production cell line 21118025 CVCL_JF51 GM14706 transformed cell line human CVCL_JF51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118026 CVCL_JF50 GM13764 transformed cell line human CVCL_JF50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM13764; probable Female 21118027 CVCL_JF49 GM13395 finite cell line human CVCL_JF49 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Population: Saudi Arabian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118028 CVCL_JF46 GM11554 finite cell line human CVCL_JF46 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118029 CVCL_JF45 GM08177 finite cell line human CVCL_JF45 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118030 CVCL_JF48 GM12610 finite cell line human CVCL_JF48 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21118031 CVCL_JF47 GM12365 transformed cell line human CVCL_JF47 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118032 CVCL_JF64 B-ATL6 transformed cell line human CVCL_JF64 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 31 hours (PubMed=6092185) 21118033 CVCL_JF63 B-ATL5 transformed cell line human CVCL_JF63 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 53 hours (PubMed=6092185) 21118034 CVCL_JF66 KH-1 cancer cell line human CVCL_JF66 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: ~36 hours (PubMed=6982237) 21118035 CVCL_JF65 B-ATL7 transformed cell line human CVCL_JF65 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 20 hours (PubMed=6092185) 21118036 CVCL_JF60 B-ATL2 transformed cell line human CVCL_JF60 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood. Female Doubling time: 19 hours (PubMed=6092185) 21118037 CVCL_JF62 B-ATL4 transformed cell line human CVCL_JF62 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female Doubling time: 48 hours (PubMed=6092185) 21118038 CVCL_JF61 B-ATL3 transformed cell line human CVCL_JF61 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 38 hours (PubMed=6092185) 21118039 CVCL_JF57 OUMS-19 transformed cell line human CVCL_JF57 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118040 CVCL_JF56 QNR ts NY-68 transformed cell line CVCL_JF56 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin) [tsNY68](NCBI-Taxonomy; 11889); Derived from sampling site: Embryonic eye; retina; neuroretina. Unspecified Group: Bird cell line 21118041 CVCL_JF59 B-ATL1 transformed cell line human CVCL_JF59 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 23 hours (PubMed=6092185) 21118042 CVCL_JF58 NHAd-60 transformed cell line human CVCL_JF58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Adenoid. Female 21118043 CVCL_8R00 DA06429 transformed cell line human CVCL_8R00 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118044 CVCL_9300 Royan C13 embryonic stem cell house mouse CVCL_9300 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118045 CVCL_8R02 DA06431 transformed cell line human CVCL_8R02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118046 CVCL_9302 Royan C15 embryonic stem cell house mouse CVCL_9302 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118047 CVCL_8R01 DA06430 transformed cell line human CVCL_8R01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118048 CVCL_9301 Royan C14 embryonic stem cell house mouse CVCL_9301 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118049 CVCL_0961 Hs 864.T cancer cell line human CVCL_0961 CL:0000010 Discontinued: ATCC; CRL-7600; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118050 CVCL_0960 Hs 864.Sk finite cell line human CVCL_0960 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7599; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118051 CVCL_0963 Hs 866.T cancer cell line human CVCL_0963 CL:0000010 Derived from sampling site: Bone Cell type=Fibroblast.. Discontinued: ATCC; CRL-7602; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118052 CVCL_0962 Hs 865.Sk finite cell line human CVCL_0962 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118053 CVCL_0965 Hs 868.T cancer cell line human CVCL_0965 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118054 CVCL_0964 Hs 867.Sk finite cell line human CVCL_0964 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7603; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118055 CVCL_0967 Hs 871.Sk finite cell line human CVCL_0967 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7608; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118056 CVCL_0966 Hs 870.T undefined cell line type human CVCL_0966 Genome ancestry: African=5.79%; Native American=28.57%; East Asian, North=5.49%; East Asian, South=0%; South Asian=0.01%; European, North=21.38%; European, South=38.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a osteosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118057 CVCL_0969 Hs 874.T cancer cell line human CVCL_0969 CL:0000010 Discontinued: ATCC; CRL-7611; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118058 CVCL_0968 Hs 873.T cancer cell line human CVCL_0968 CL:0000010 Discontinued: ATCC; CRL-7610; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118059 CVCL_8R11 DA06444 transformed cell line human CVCL_8R11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118060 CVCL_9311 Royan C23 embryonic stem cell house mouse CVCL_9311 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118061 CVCL_8R10 DA06443 transformed cell line human CVCL_8R10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118062 CVCL_9310 Royan C22 embryonic stem cell house mouse CVCL_9310 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118063 CVCL_8R13 DA06447 transformed cell line human CVCL_8R13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118064 CVCL_9313 Royan C25 embryonic stem cell house mouse CVCL_9313 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118065 CVCL_8R12 DA06446 transformed cell line human CVCL_8R12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118066 CVCL_9312 Royan C24 embryonic stem cell house mouse CVCL_9312 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118067 CVCL_8R08 DA06441 transformed cell line human CVCL_8R08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118068 CVCL_9308 Royan C20 embryonic stem cell house mouse CVCL_9308 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118069 CVCL_8R07 DA06440 transformed cell line human CVCL_8R07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118070 CVCL_9307 Royan C2.3 embryonic stem cell house mouse CVCL_9307 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Male 21118071 CVCL_8R09 DA06442 transformed cell line human CVCL_8R09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118072 CVCL_9309 Royan C21 embryonic stem cell house mouse CVCL_9309 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118073 CVCL_8R04 DA06437 transformed cell line human CVCL_8R04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118074 CVCL_0970 Hs 875.T cancer cell line human CVCL_0970 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21118075 CVCL_9304 Royan C17 embryonic stem cell house mouse CVCL_9304 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118076 CVCL_8R03 DA06436 transformed cell line human CVCL_8R03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118077 CVCL_9303 Royan C16 embryonic stem cell house mouse CVCL_9303 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118078 CVCL_8R06 DA06439 transformed cell line human CVCL_8R06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118079 CVCL_0972 Hs 879(B).T undefined cell line type human CVCL_0972 CL:0000010 Discontinued: ATCC; CRL-7615; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118080 CVCL_9306 Royan C19 embryonic stem cell house mouse CVCL_9306 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118081 CVCL_8R05 DA06438 transformed cell line human CVCL_8R05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118082 CVCL_0971 Hs 877.T cancer cell line human CVCL_0971 CL:0000010 Discontinued: ATCC; CRL-7613; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118083 CVCL_9305 Royan C18 embryonic stem cell house mouse CVCL_9305 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118084 CVCL_0974 Hs 880.T cancer cell line human CVCL_0974 CL:0000010 Discontinued: ATCC; CRL-7616; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118085 CVCL_0973 Hs 88.T cancer cell line human CVCL_0973 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21118086 CVCL_0976 Hs 885.T cancer cell line human CVCL_0976 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7618; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118087 CVCL_0975 Hs 883.T cancer cell line human CVCL_0975 CL:0000010 Discontinued: ATCC; CRL-7617; true; Discontinued: IZSLER; BS TCL 142; probable. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118088 CVCL_0978 Hs 888.Sk finite cell line human CVCL_0978 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118089 CVCL_0977 Hs 888.Lu finite cell line human CVCL_0977 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118090 CVCL_0979 Hs 888.T undefined cell line type human CVCL_0979 Genome ancestry: African=2.45%; Native American=0.69%; East Asian, North=0.26%; East Asian, South=1.64%; South Asian=7.7%; European, North=29.88%; European, South=57.38% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a osteosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118091 CVCL_0949 Hs 851.T cancer cell line human CVCL_0949 CL:0000010 Discontinued: ATCC; CRL-7584; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118092 CVCL_0948 Hs 849.T cancer cell line human CVCL_0948 CL:0000010 Discontinued: ATCC; CRL-7583; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118093 CVCL_0941 Hs 839.T undefined cell line type human CVCL_0941 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DQA1*04:01,04:01; DQB1*06:04,06:04; DRB1*03:05,11:04 (PubMed=26589293); Genome ancestry: African=0.72%; Native American=0.18%; East Asian, North=0.79%; East Asian, South=0%; South Asian=0%; European, North=67.25%; European, South=31.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118094 CVCL_0940 Hs 836.Sk finite cell line human CVCL_0940 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7570; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118095 CVCL_0943 Hs 841.T cancer cell line human CVCL_0943 CL:0000010 Discontinued: ATCC; CRL-7574; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118096 CVCL_0942 Hs 840.T undefined cell line type human CVCL_0942 Genome ancestry: African=0%; Native American=0.34%; East Asian, North=0%; East Asian, South=1.56%; South Asian=0%; European, North=76.29%; European, South=21.8% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Pharynx Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a squamous cell papilloma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118097 CVCL_0945 Hs 845.T cancer cell line human CVCL_0945 CL:0000010 Derived from metastatic site: Bone. Discontinued: ATCC; CRL-7577; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118098 CVCL_0944 Hs 844.Sk finite cell line human CVCL_0944 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7576; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118099 CVCL_0947 Hs 846.T cancer cell line human CVCL_0947 CL:0000010 Discontinued: ATCC; CRL-7579; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118100 CVCL_0946 Hs 846.Sk finite cell line human CVCL_0946 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7578; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118101 CVCL_0959 Hs 863.T undefined cell line type human CVCL_0959 Genome ancestry: African=0%; Native American=0.35%; East Asian, North=4.46%; East Asian, South=1.13%; South Asian=0.95%; European, North=67.06%; European, South=26.04% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: IZSLER; BS TCL 146; probable Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Ewing sarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118102 CVCL_0950 Hs 852.T cancer cell line human CVCL_0950 HLA typing: A*24:02,24:02; B*07:02,35:01; C*03:04,07:02; DQA1*01:01,03:02; DQB1*04:01,05:01; DRB1*01:01,04:05 (PubMed=26589293); Genome ancestry: African=1.89%; Native American=0%; East Asian, North=80.03%; East Asian, South=16.58%; South Asian=0.19%; European, North=0%; European, South=1.3% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000040470; Zygosity=Heterozygous (ATCC) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21118103 CVCL_0952 Hs 855.Sk finite cell line human CVCL_0952 CL:0000010 Population: African American; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7591; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118104 CVCL_0951 Hs 854.Sk finite cell line human CVCL_0951 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7589; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118105 CVCL_0954 Hs 856.T cancer cell line human CVCL_0954 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21118106 CVCL_0953 Hs 855.T undefined cell line type human CVCL_0953 CL:0000010 Population: African American; Derived from sampling site: Bone. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118107 CVCL_0956 Hs 86.Fs finite cell line human CVCL_0956 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7059; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118108 CVCL_0955 Hs 859.T finite cell line human CVCL_0955 CL:0000010 Discontinued: ATCC; CRL-7594; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118109 CVCL_0958 Hs 861.T cancer cell line human CVCL_0958 CL:0000010 Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7596; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118110 CVCL_0957 Hs 860.T cancer cell line human CVCL_0957 CL:0000010 Population: Caucasian; Derived from sampling site: Bone. Discontinued: ATCC; CRL-7595; probable Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118111 CVCL_0927 Hs 815.Pl finite cell line human CVCL_0927 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118112 CVCL_0926 Hs 814.T cancer cell line human CVCL_0926 CL:0000010 Discontinued: ATCC; CRL-7547; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118113 CVCL_0929 Hs 820.Sk finite cell line human CVCL_0929 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7551; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118114 CVCL_0928 Hs 819.T undefined cell line type human CVCL_0928 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.16%; East Asian, South=0.22%; South Asian=1.63%; European, North=67.05%; European, South=29.93% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a chondrosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118115 CVCL_0921 Hs 803.T cancer cell line human CVCL_0921 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: ATCC; CRL-7534; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118116 CVCL_0920 Hs 803.Sk finite cell line human CVCL_0920 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7533; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118117 CVCL_0923 Hs 811.T cancer cell line human CVCL_0923 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7543; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118118 CVCL_0922 Hs 805.T cancer cell line human CVCL_0922 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone; proximal humerus. Discontinued: ATCC; CRL-7537; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118119 CVCL_0925 Hs 814.Sk finite cell line human CVCL_0925 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7546; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118120 CVCL_0924 Hs 813.Sk finite cell line human CVCL_0924 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7545; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118121 CVCL_0938 Hs 834.T undefined cell line type human CVCL_0938 CL:0000010 Derived from sampling site: Cervical lymph node Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7568; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118122 CVCL_0937 Hs 833(C).Sk finite cell line human CVCL_0937 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7567; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118123 CVCL_0939 Hs 835.T cancer cell line human CVCL_0939 CL:0000010 Male Doubling time: 3-4 days (PubMed=176412). Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118124 CVCL_0930 Hs 820.T cancer cell line human CVCL_0930 CL:0000010 Population: Caucasian; Derived from sampling site: Bone Cell type=Fibroblast.. Discontinued: ATCC; CRL-7552; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118125 CVCL_0932 Hs 821.T undefined cell line type human CVCL_0932 Genome ancestry: African=1.92%; Native American=46.51%; East Asian, North=5.29%; East Asian, South=0%; South Asian=1.88%; European, North=22.78%; European, South=21.62% (PubMed=30894373) CL:0000010 Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a giant cell tumor of bone cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118126 CVCL_0931 Hs 821.Sk finite cell line human CVCL_0931 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7553; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118127 CVCL_0934 Hs 824.Sk finite cell line human CVCL_0934 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7558; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118128 CVCL_0933 Hs 822.T undefined cell line type human CVCL_0933 Genome ancestry: African=0.59%; Native American=21.59%; East Asian, North=1.66%; East Asian, South=0%; South Asian=2.06%; European, North=43.77%; European, South=30.33% (PubMed=30894373) CL:0000010 Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Ewing sarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118129 CVCL_0936 Hs 832(C).T finite cell line human CVCL_0936 CL:0000010 Miscellaneous: This cell line was discontinued by ATCC due to slow grow rate and difficulties to maintain the cell (PubMed=32106286) Discontinued: ATCC; CRL-7566; true. Female Senescence: Senesces after 28 PDL (ATCC=CRL-7566); Doubling time: 8-12 days (PubMed=176412); 72 hours (ATCC=CRL-7566) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118130 CVCL_0935 Hs 828.Sk finite cell line human CVCL_0935 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7564; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118131 CVCL_0905 Hs 782.T undefined cell line type human CVCL_0905 CL:0000010 Discontinued: ATCC; CRL-7512; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118132 CVCL_0904 Hs 782.Sk finite cell line human CVCL_0904 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7513; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118133 CVCL_0907 Hs 789.Sk finite cell line human CVCL_0907 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118134 CVCL_0906 Hs 788.Sk finite cell line human CVCL_0906 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7516; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118135 CVCL_0909 Hs 791.Sk finite cell line human CVCL_0909 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7519; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118136 CVCL_0908 Hs 789.T cancer cell line human CVCL_0908 CL:0000010 Female Doubling time: 12-14 days (PubMed=176412). Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118137 CVCL_0901 Hs 778(B).T cancer cell line human CVCL_0901 CL:0000010 Discontinued: ATCC; CRL-7509; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118138 CVCL_0900 Hs 778(A).T cancer cell line human CVCL_0900 CL:0000010 Discontinued: ATCC; CRL-7508; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118139 CVCL_0903 Hs 781.T cancer cell line human CVCL_0903 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; tibia. Omics: SNP array analysis Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118140 CVCL_0902 Hs 781.Sk finite cell line human CVCL_0902 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7510; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118141 CVCL_0916 Hs 798.Pl finite cell line human CVCL_0916 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7529; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118142 CVCL_0915 Hs 795.Pl finite cell line human CVCL_0915 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118143 CVCL_0918 Hs 80.Fs finite cell line human CVCL_0918 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7058; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118144 CVCL_0917 Hs 799.Pl finite cell line human CVCL_0917 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7530; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118145 CVCL_0919 Hs 801.Pl finite cell line human CVCL_0919 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7888; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118146 CVCL_0910 Hs 792(A).T cancer cell line human CVCL_0910 CL:0000010 Discontinued: ATCC; CRL-7520; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118147 CVCL_0912 Hs 792(C).M finite cell line human CVCL_0912 CL:0000010 Derived from sampling site: Hypodermis and muscle Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118148 CVCL_0911 Hs 792(B).T cancer cell line human CVCL_0911 CL:0000010 Discontinued: ATCC; CRL-7521; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118149 CVCL_0914 Hs 793.T undefined cell line type human CVCL_0914 CL:0000010 Discontinued: ATCC; CRL-7524; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118150 CVCL_0913 Hs 793.Sk finite cell line human CVCL_0913 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118151 CVCL_8R80 DA06527 transformed cell line human CVCL_8R80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118152 CVCL_9380 Royan F8 embryonic stem cell house mouse CVCL_9380 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118153 CVCL_8R82 DA06529 transformed cell line human CVCL_8R82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118154 CVCL_9382 Royan H10 embryonic stem cell human CVCL_9382 From: Royan Institute; Theran; Iran. CL:0000010 Female 21118155 CVCL_8R81 DA06528 transformed cell line human CVCL_8R81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118156 CVCL_9381 Royan H1 embryonic stem cell human CVCL_9381 From: Royan Institute; Theran; Iran. CL:0000010 Female 21118157 CVCL_8R88 DA06536 transformed cell line human CVCL_8R88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118158 CVCL_AL14 GM07236 finite cell line human CVCL_AL14 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21118159 CVCL_9388 Royan H7 embryonic stem cell human CVCL_9388 From: Royan Institute; Theran; Iran. CL:0000010 Female 21118160 CVCL_8R87 DA06535 transformed cell line human CVCL_8R87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118161 CVCL_AL13 GM07235 transformed cell line human CVCL_AL13 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118162 CVCL_9387 Royan H6 embryonic stem cell human CVCL_9387 From: Royan Institute; Theran; Iran CL:0000010 Omics: Proteome analysis by 2D-DE/MS. Male Doubling time: 32.1 +- 0.8 hours (PubMed=16512855) 21118163 CVCL_AL16 GM07369 finite cell line human CVCL_AL16 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21118164 CVCL_8R89 DA06537 transformed cell line human CVCL_8R89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118165 CVCL_AL15 GM07368 transformed cell line human CVCL_AL15 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118166 CVCL_9389 Royan H8 embryonic stem cell human CVCL_9389 From: Royan Institute; Theran; Iran. CL:0000010 Female 21118167 CVCL_8R84 DA06532 transformed cell line human CVCL_8R84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118168 CVCL_AL18 GM07483 finite cell line human CVCL_AL18 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21118169 CVCL_9384 Royan H3 embryonic stem cell human CVCL_9384 From: Royan Institute; Theran; Iran CL:0000010 Karyotypic information: 69,XXY (PubMed=16512855). Ambiguous Doubling time: 23.8 +- 0.7 hours (PubMed=16512855) 21118170 CVCL_8R83 DA06530 transformed cell line human CVCL_8R83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118171 CVCL_AL17 GM07482 transformed cell line human CVCL_AL17 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118172 CVCL_9383 Royan H2 embryonic stem cell human CVCL_9383 From: Royan Institute; Theran; Iran CL:0000010 Female Doubling time: 31.5 +- 0.8 hours (PubMed=16512855). 21118173 CVCL_8R86 DA06534 transformed cell line human CVCL_8R86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118174 CVCL_9386 Royan H5 embryonic stem cell human CVCL_9386 From: Royan Institute; Theran; Iran CL:0000010 Omics: Proteome analysis by 2D-DE/MS. Female Doubling time: 32.9 +- 0.6 hours (PubMed=16512855) 21118175 CVCL_8R85 DA06533 transformed cell line human CVCL_8R85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118176 CVCL_AL19 GM08947 transformed cell line human CVCL_AL19 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118177 CVCL_9385 Royan H4 embryonic stem cell human CVCL_9385 From: Royan Institute; Theran; Iran CL:0000010 Ambiguous Doubling time: 23.2 +- 0.4 hours (PubMed=16512855). 21118178 CVCL_AL10 GM07232 finite cell line human CVCL_AL10 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21118179 CVCL_AL12 GM07234 finite cell line human CVCL_AL12 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21118180 CVCL_AL11 GM07233 transformed cell line human CVCL_AL11 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118181 CVCL_8R91 DA06539 transformed cell line human CVCL_8R91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118182 CVCL_9391 Royan N1 embryonic stem cell house mouse CVCL_9391 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118183 CVCL_8R90 DA06538 transformed cell line human CVCL_8R90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118184 CVCL_9390 Royan H9 embryonic stem cell human CVCL_9390 From: Royan Institute; Theran; Iran. CL:0000010 Female 21118185 CVCL_8R93 DA06541 transformed cell line human CVCL_8R93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118186 CVCL_9393 Royan N11 embryonic stem cell house mouse CVCL_9393 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118187 CVCL_8R92 DA06540 transformed cell line human CVCL_8R92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118188 CVCL_9392 Royan N10 embryonic stem cell house mouse CVCL_9392 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118189 CVCL_8R99 DA06548 transformed cell line human CVCL_8R99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118190 CVCL_AL25 GM08953 transformed cell line human CVCL_AL25 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118191 CVCL_9399 Royan N17 embryonic stem cell house mouse CVCL_9399 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118192 CVCL_8R98 DA06547 transformed cell line human CVCL_8R98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118193 CVCL_AL24 GM08952 transformed cell line human CVCL_AL24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118194 CVCL_9398 Royan N16 embryonic stem cell house mouse CVCL_9398 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118195 CVCL_AL27 GM08955 transformed cell line human CVCL_AL27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118196 CVCL_AL26 GM08954 transformed cell line human CVCL_AL26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118197 CVCL_8R95 DA06544 transformed cell line human CVCL_8R95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118198 CVCL_AL29 GM08957 transformed cell line human CVCL_AL29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118199 CVCL_9395 Royan N13 embryonic stem cell house mouse CVCL_9395 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118200 CVCL_8R94 DA06543 transformed cell line human CVCL_8R94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118201 CVCL_AL28 GM08956 transformed cell line human CVCL_AL28 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118202 CVCL_9394 Royan N12 embryonic stem cell house mouse CVCL_9394 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118203 CVCL_8R97 DA06546 transformed cell line human CVCL_8R97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118204 CVCL_9397 Royan N15 embryonic stem cell house mouse CVCL_9397 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118205 CVCL_8R96 DA06545 transformed cell line human CVCL_8R96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118206 CVCL_9396 Royan N14 embryonic stem cell house mouse CVCL_9396 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118207 CVCL_AL21 GM08949 transformed cell line human CVCL_AL21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118208 CVCL_AL20 GM08948 transformed cell line human CVCL_AL20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118209 CVCL_AL23 GM08951 transformed cell line human CVCL_AL23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118210 CVCL_AL22 GM08950 transformed cell line human CVCL_AL22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118211 CVCL_8R60 DA06503 transformed cell line human CVCL_8R60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118212 CVCL_9360 Royan D3 embryonic stem cell house mouse CVCL_9360 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118213 CVCL_8R66 DA06511 transformed cell line human CVCL_8R66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118214 CVCL_9366 Royan D35 embryonic stem cell house mouse CVCL_9366 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118215 CVCL_8R65 DA06510 transformed cell line human CVCL_8R65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118216 CVCL_9365 Royan D34 embryonic stem cell house mouse CVCL_9365 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118217 CVCL_8R68 DA06513 transformed cell line human CVCL_8R68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118218 CVCL_9368 Royan D5 embryonic stem cell house mouse CVCL_9368 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118219 CVCL_8R67 DA06512 transformed cell line human CVCL_8R67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118220 CVCL_9367 Royan D4 embryonic stem cell house mouse CVCL_9367 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118221 CVCL_8R62 DA06505 transformed cell line human CVCL_8R62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118222 CVCL_9362 Royan D31 embryonic stem cell house mouse CVCL_9362 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118223 CVCL_8R61 DA06504 transformed cell line human CVCL_8R61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118224 CVCL_9361 Royan D30 embryonic stem cell house mouse CVCL_9361 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118225 CVCL_8R64 DA06509 transformed cell line human CVCL_8R64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118226 CVCL_9364 Royan D33 embryonic stem cell house mouse CVCL_9364 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118227 CVCL_8R63 DA06508 transformed cell line human CVCL_8R63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118228 CVCL_9363 Royan D32 embryonic stem cell house mouse CVCL_9363 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118229 CVCL_8R59 DA06502 transformed cell line human CVCL_8R59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118230 CVCL_9359 Royan D29 embryonic stem cell house mouse CVCL_9359 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118231 CVCL_8R58 DA06501 transformed cell line human CVCL_8R58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118232 CVCL_9358 Royan D28 embryonic stem cell house mouse CVCL_9358 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118233 CVCL_8R71 DA06517 transformed cell line human CVCL_8R71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118234 CVCL_9371 Royan D8 embryonic stem cell house mouse CVCL_9371 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118235 CVCL_8R70 DA06516 transformed cell line human CVCL_8R70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118236 CVCL_9370 Royan D7 embryonic stem cell house mouse CVCL_9370 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118237 CVCL_8R77 DA06524 transformed cell line human CVCL_8R77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118238 CVCL_AL03 GM05345 finite cell line human CVCL_AL03 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118239 CVCL_9377 Royan F5 embryonic stem cell house mouse CVCL_9377 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118240 CVCL_8R76 DA06523 transformed cell line human CVCL_8R76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118241 CVCL_AL02 GM05321 finite cell line human CVCL_AL02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118242 CVCL_9376 Royan F4 embryonic stem cell house mouse CVCL_9376 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118243 CVCL_8R79 DA06526 transformed cell line human CVCL_8R79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118244 CVCL_AL05 GM05378 finite cell line human CVCL_AL05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118245 CVCL_9379 Royan F7 embryonic stem cell house mouse CVCL_9379 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118246 CVCL_8R78 DA06525 transformed cell line human CVCL_8R78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118247 CVCL_AL04 GM05346 transformed cell line human CVCL_AL04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118248 CVCL_9378 Royan F6 embryonic stem cell house mouse CVCL_9378 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118249 CVCL_8R73 DA06519 transformed cell line human CVCL_8R73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118250 CVCL_AL07 GM05852 transformed cell line human CVCL_AL07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118251 CVCL_9373 Royan F1 embryonic stem cell house mouse CVCL_9373 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118252 CVCL_8R72 DA06518 transformed cell line human CVCL_8R72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118253 CVCL_AL06 GM05379 transformed cell line human CVCL_AL06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118254 CVCL_9372 Royan D9 embryonic stem cell house mouse CVCL_9372 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118255 CVCL_8R75 DA06522 transformed cell line human CVCL_8R75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118256 CVCL_AL09 GM07231 transformed cell line human CVCL_AL09 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118257 CVCL_9375 Royan F3 embryonic stem cell house mouse CVCL_9375 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118258 CVCL_8R74 DA06521 transformed cell line human CVCL_8R74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118259 CVCL_AL08 GM05853 finite cell line human CVCL_AL08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118260 CVCL_9374 Royan F2 embryonic stem cell house mouse CVCL_9374 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: FVB/N. Unspecified 21118261 CVCL_8R69 DA06515 transformed cell line human CVCL_8R69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118262 CVCL_9369 Royan D6 embryonic stem cell house mouse CVCL_9369 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118263 CVCL_AL01 GM05320 transformed cell line human CVCL_AL01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118264 CVCL_AL00 GM05060 transformed cell line human CVCL_AL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118265 CVCL_8R44 DA06486 transformed cell line human CVCL_8R44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118266 CVCL_9344 Royan D15 embryonic stem cell house mouse CVCL_9344 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118267 CVCL_8R43 DA06485 transformed cell line human CVCL_8R43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118268 CVCL_9343 Royan D14 embryonic stem cell house mouse CVCL_9343 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118269 CVCL_8R46 DA06488 transformed cell line human CVCL_8R46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118270 CVCL_9346 Royan D17 embryonic stem cell house mouse CVCL_9346 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118271 CVCL_8R45 DA06487 transformed cell line human CVCL_8R45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118272 CVCL_9345 Royan D16 embryonic stem cell house mouse CVCL_9345 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118273 CVCL_8R40 DA06480 transformed cell line human CVCL_8R40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118274 CVCL_9340 Royan D11 embryonic stem cell house mouse CVCL_9340 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118275 CVCL_8R42 DA06484 transformed cell line human CVCL_8R42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118276 CVCL_9342 Royan D13 embryonic stem cell house mouse CVCL_9342 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118277 CVCL_8R41 DA06483 transformed cell line human CVCL_8R41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118278 CVCL_9341 Royan D12 embryonic stem cell house mouse CVCL_9341 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118279 CVCL_8R37 DA06477 transformed cell line human CVCL_8R37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118280 CVCL_9337 Royan C9 embryonic stem cell house mouse CVCL_9337 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118281 CVCL_8R36 DA06476 transformed cell line human CVCL_8R36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118282 CVCL_9336 Royan C8 embryonic stem cell house mouse CVCL_9336 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118283 CVCL_8R39 DA06479 transformed cell line human CVCL_8R39 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118284 CVCL_9339 Royan D10 embryonic stem cell house mouse CVCL_9339 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118285 CVCL_8R38 DA06478 transformed cell line human CVCL_8R38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118286 CVCL_9338 Royan D1 embryonic stem cell house mouse CVCL_9338 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118287 CVCL_8R55 DA06498 transformed cell line human CVCL_8R55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118288 CVCL_9355 Royan D25 embryonic stem cell house mouse CVCL_9355 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118289 CVCL_8R54 DA06497 transformed cell line human CVCL_8R54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118290 CVCL_9354 Royan D24 embryonic stem cell house mouse CVCL_9354 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118291 CVCL_8R57 DA06500 transformed cell line human CVCL_8R57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118292 CVCL_9357 Royan D27 embryonic stem cell house mouse CVCL_9357 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118293 CVCL_8R56 DA06499 transformed cell line human CVCL_8R56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118294 CVCL_9356 Royan D26 embryonic stem cell house mouse CVCL_9356 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118295 CVCL_8R51 DA06494 transformed cell line human CVCL_8R51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118296 CVCL_9351 Royan D21 embryonic stem cell house mouse CVCL_9351 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118297 CVCL_8R50 DA06492 transformed cell line human CVCL_8R50 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118298 CVCL_9350 Royan D20 embryonic stem cell house mouse CVCL_9350 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118299 CVCL_8R53 DA06496 transformed cell line human CVCL_8R53 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118300 CVCL_9353 Royan D23 embryonic stem cell house mouse CVCL_9353 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118301 CVCL_8R52 DA06495 transformed cell line human CVCL_8R52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118302 CVCL_9352 Royan D22 embryonic stem cell house mouse CVCL_9352 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118303 CVCL_8R48 DA06490 transformed cell line human CVCL_8R48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118304 CVCL_9348 Royan D19 embryonic stem cell house mouse CVCL_9348 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118305 CVCL_8R47 DA06489 transformed cell line human CVCL_8R47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118306 CVCL_9347 Royan D18 embryonic stem cell house mouse CVCL_9347 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118307 CVCL_8R49 DA06491 transformed cell line human CVCL_8R49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118308 CVCL_9349 Royan D2 embryonic stem cell house mouse CVCL_9349 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: DBA/2. Unspecified 21118309 CVCL_8R22 DA06460 transformed cell line human CVCL_8R22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118310 CVCL_9322 Royan C33 embryonic stem cell house mouse CVCL_9322 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118311 CVCL_8R21 DA06459 transformed cell line human CVCL_8R21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118312 CVCL_9321 Royan C32 embryonic stem cell house mouse CVCL_9321 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118313 CVCL_8R24 DA06464 transformed cell line human CVCL_8R24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118314 CVCL_9324 Royan C35 embryonic stem cell house mouse CVCL_9324 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118315 CVCL_8R23 DA06462 transformed cell line human CVCL_8R23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118316 CVCL_9323 Royan C34 embryonic stem cell house mouse CVCL_9323 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118317 CVCL_8R20 DA06458 transformed cell line human CVCL_8R20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118318 CVCL_9320 Royan C31 embryonic stem cell house mouse CVCL_9320 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118319 CVCL_8R19 DA06457 transformed cell line human CVCL_8R19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118320 CVCL_9319 Royan C30 embryonic stem cell house mouse CVCL_9319 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118321 CVCL_8R18 DA06456 transformed cell line human CVCL_8R18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118322 CVCL_9318 Royan C3.4 embryonic stem cell house mouse CVCL_9318 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Male 21118323 CVCL_8R15 DA06452 transformed cell line human CVCL_8R15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118324 CVCL_0981 Hs 889.Sk finite cell line human CVCL_0981 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7625; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118325 CVCL_9315 Royan C27 embryonic stem cell house mouse CVCL_9315 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118326 CVCL_8R14 DA06448 transformed cell line human CVCL_8R14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118327 CVCL_0980 GM07372 transformed cell line CVCL_0980 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.. Male Characteristics: Grows in monolayers 21118328 CVCL_9314 Royan C26 embryonic stem cell house mouse CVCL_9314 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118329 CVCL_8R17 DA06455 transformed cell line human CVCL_8R17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118330 CVCL_0983 Hs 890.Sk finite cell line human CVCL_0983 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7627; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118331 CVCL_9317 Royan C29 embryonic stem cell house mouse CVCL_9317 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118332 CVCL_8R16 DA06454 transformed cell line human CVCL_8R16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118333 CVCL_0982 Hs 889.T cancer cell line human CVCL_0982 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7626; probable. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118334 CVCL_9316 Royan C28 embryonic stem cell house mouse CVCL_9316 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118335 CVCL_0985 Hs 891.T cancer cell line human CVCL_0985 CL:0000010 Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis. Female Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118336 CVCL_0984 Hs 890.T cancer cell line human CVCL_0984 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21118337 CVCL_0987 Hs 894(A).T cancer cell line human CVCL_0987 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7631; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118338 CVCL_0986 Hs 892.T cancer cell line human CVCL_0986 CL:0000010 Discontinued: ATCC; CRL-7630; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118339 CVCL_0989 Hs 894(C).T cancer cell line human CVCL_0989 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7633; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118340 CVCL_0988 Hs 894(B).T cancer cell line human CVCL_0988 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7632; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118341 CVCL_8R33 DA06473 transformed cell line human CVCL_8R33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118342 CVCL_9333 Royan C5 embryonic stem cell house mouse CVCL_9333 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c x NMRI. Unspecified 21118343 CVCL_8R32 DA06472 transformed cell line human CVCL_8R32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118344 CVCL_9332 Royan C42 embryonic stem cell house mouse CVCL_9332 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118345 CVCL_8R35 DA06475 transformed cell line human CVCL_8R35 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118346 CVCL_9335 Royan C7 embryonic stem cell house mouse CVCL_9335 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118347 CVCL_8R34 DA06474 transformed cell line human CVCL_8R34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118348 CVCL_9334 Royan C6 embryonic stem cell house mouse CVCL_9334 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c x NMRI. Unspecified 21118349 CVCL_8R31 DA06471 transformed cell line human CVCL_8R31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118350 CVCL_9331 Royan C41 embryonic stem cell house mouse CVCL_9331 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118351 CVCL_8R30 DA06470 transformed cell line human CVCL_8R30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118352 CVCL_9330 Royan C40 embryonic stem cell house mouse CVCL_9330 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118353 CVCL_8R29 DA06469 transformed cell line human CVCL_8R29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118354 CVCL_9329 Royan C4 embryonic stem cell house mouse CVCL_9329 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118355 CVCL_0990 Hs 894(D).T cancer cell line human CVCL_0990 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7634; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118356 CVCL_8R26 DA06466 transformed cell line human CVCL_8R26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118357 CVCL_0992 Hs 895.Sk finite cell line human CVCL_0992 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Secretome proteome analysis Female Doubling time: 52.2 +- 0.1 hours (PubMed=29275043) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118358 CVCL_9326 Royan C37 embryonic stem cell house mouse CVCL_9326 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118359 CVCL_8R25 DA06465 transformed cell line human CVCL_8R25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118360 CVCL_0991 Hs 894(E).Lu finite cell line human CVCL_0991 CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Omics: SNP array analysis Discontinued: ATCC; CRL-7635; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118361 CVCL_9325 Royan C36 embryonic stem cell house mouse CVCL_9325 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118362 CVCL_8R28 DA06468 transformed cell line human CVCL_8R28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118363 CVCL_0994 Hs 898.Sk finite cell line human CVCL_0994 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7640; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118364 CVCL_9328 Royan C39 embryonic stem cell house mouse CVCL_9328 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118365 CVCL_8R27 DA06467 transformed cell line human CVCL_8R27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118366 CVCL_0993 Hs 895.T undefined cell line type human CVCL_0993 HLA typing: A*01:01,25:01; B*07:02,08:01; C*07:02,07:02; DQA1*01:02,03:02; DQB1*02:02,02:02; DRB1*04:05,11:09 (PubMed=26589293); Genome ancestry: African=0.77%; Native American=1.02%; East Asian, North=0.49%; East Asian, South=0%; South Asian=0.06%; European, North=67.7%; European, South=29.96% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Secretome proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.2 +- 1.45 hours (PubMed=29275043) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21118367 CVCL_9327 Royan C38 embryonic stem cell house mouse CVCL_9327 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: BALB/c. Unspecified 21118368 CVCL_0996 Hs 899(A).T cancer cell line human CVCL_0996 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7642; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118369 CVCL_0995 Hs 898.T cancer cell line human CVCL_0995 CL:0000010 Discontinued: ATCC; CRL-7641; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118370 CVCL_0998 Hs 899(C).T cancer cell line human CVCL_0998 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7644; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118371 CVCL_0997 Hs 899(B).T cancer cell line human CVCL_0997 CL:0000010 Population: Caucasian Discontinued: ATCC; CRL-7643; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118372 CVCL_0999 Hs 899(D).T cancer cell line human CVCL_0999 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7645; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118373 CVCL_JG52 Ishikawa 3-H-12-Luc cancer cell line human CVCL_JG52 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Endometrium. Female 21118374 CVCL_JG51 Huh-7-Luc cancer cell line human CVCL_JG51 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Liver. Male 21118375 CVCL_JG54 MIA PaCa-2/CMV-Luc cancer cell line human CVCL_JG54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Pancreas. Male 21118376 CVCL_JG53 MDA-MB-231-Luc cancer cell line human CVCL_JG53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21118377 CVCL_JG50 HSC-5-Luc cancer cell line human CVCL_JG50 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Skin. Male 21118378 CVCL_JG49 HSC-1-Luc cancer cell line human CVCL_JG49 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Hand; skin. Male 21118379 CVCL_JG48 HLF-Luc cancer cell line human CVCL_JG48 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21118380 CVCL_JG45 ACI-RCC-cbLuc cancer cell line Norway rat CVCL_JG45 CL:0000010 Transfected with: CBG, click beetle green luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Iron(III) nitrilotriacetate(ChEBI; CHEBI:132238); Derived from sampling site: Kidney; Breed/subspecies: ACI. Male 21118381 CVCL_JG44 ASF-4-5R1 finite cell line human CVCL_JG44 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at ~55 PDL (JCRB=JCRB1709) 21118382 CVCL_JG47 HepG2-Luc cancer cell line human CVCL_JG47 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Male 21118383 CVCL_JG46 ACI-RCC-ffLuc cancer cell line Norway rat CVCL_JG46 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Iron(III) nitrilotriacetate(ChEBI; CHEBI:132238); Derived from sampling site: Kidney; Breed/subspecies: ACI. Male 21118384 CVCL_JG63 AP38S finite cell line human CVCL_JG63 CL:0000010 Population: Japanese; Donor information: Established from monozygotic twin of AP38P (Cellosaurus=CVCL_JG62); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1433; probable Female 21118385 CVCL_JG62 AP38P finite cell line human CVCL_JG62 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Donor information: Established from monozygotic twin of AP38S (Cellosaurus=CVCL_JG63); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118386 CVCL_JG65 FA20F finite cell line human CVCL_JG65 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000435134; Zygosity=Heterozygous (from familial inference) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118387 CVCL_JG64 AP38P(SVT) transformed cell line human CVCL_JG64 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1432; probable Female 21118388 CVCL_JG61 AP38B finite cell line human CVCL_JG61 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1435; probable Male 21118389 CVCL_JG60 TKM47 finite cell line human CVCL_JG60 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Asp433His (c.1297G>C); ClinVar=VCV000003732; Zygosity=Heterozygous (JCRB) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118390 CVCL_JG59 RS53 finite cell line human CVCL_JG59 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.68-1G>C; ClinVar=VCV000251005; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=10200052) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118391 CVCL_JG56 HT-1080/CMV-Luc cancer cell line human CVCL_JG56 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 21118392 CVCL_JG55 HARA/CMV-Luc cancer cell line human CVCL_JG55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS1043; true Male Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP) 21118393 CVCL_JG58 CN46 finite cell line human CVCL_JG58 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex16-18del (nsv1067857); ClinVar=VCV000003711; Zygosity=Heterozygous (PubMed=6272292) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118394 CVCL_JG57 HeLa/CMV-Luc cancer cell line human CVCL_JG57 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21118395 CVCL_JG30 RM-P1 cancer cell line human CVCL_JG30 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pericardial effusion. Male 21118396 CVCL_JG32 hTf18-10C hybridoma house mouse CVCL_JG32 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21118397 CVCL_JG31 vdR2-4 embryonic stem cell house mouse CVCL_JG31 CL:0000010 Breed/subspecies: C57BL/6 x 129S4/SvJae. Male Characteristics: Both alleles of Blm locus were modified for tetracycline-dependent gene regulation A 4-hydroxytamoxifen-regulatable Cre recombinase, ERT2-iCre-ERT2 was knocked into the Rosa26 locus for constitutive expression. 21118398 CVCL_AM93 GM19484 transformed cell line human CVCL_AM93 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118399 CVCL_AM92 GM19483 finite cell line human CVCL_AM92 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118400 CVCL_AM95 GM19490 transformed cell line human CVCL_AM95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118401 CVCL_AM94 GM19485 finite cell line human CVCL_AM94 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118402 CVCL_AM97 GM20071 transformed cell line human CVCL_AM97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118403 CVCL_AM96 GM19491 finite cell line human CVCL_AM96 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21118404 CVCL_AM99 GM06261 finite cell line human CVCL_AM99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118405 CVCL_AM98 GM02022 finite cell line human CVCL_AM98 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118406 CVCL_JG27 hTf/CHO-S #17/sf spontaneously immortalized cell line CVCL_JG27 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21118407 CVCL_JG26 hTf/CHO-S #17 spontaneously immortalized cell line CVCL_JG26 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female 21118408 CVCL_JG29 HuS-L12/10 transformed cell line human CVCL_JG29 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21118409 CVCL_JG28 hTf/CHO-S #29 spontaneously immortalized cell line CVCL_JG28 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Transfected with: HGNC; 11740; TF Derived from sampling site: Ovary. Female 21118410 CVCL_JG23 HST-4 transformed cell line CVCL_JG23 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118411 CVCL_JG22 HST-3 transformed cell line CVCL_JG22 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118412 CVCL_AM91 GM19482 transformed cell line human CVCL_AM91 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118413 CVCL_JG25 HST-6 transformed cell line CVCL_JG25 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118414 CVCL_AM90 GM19481 transformed cell line human CVCL_AM90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118415 CVCL_JG24 HST-5 transformed cell line CVCL_JG24 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118416 CVCL_JG41 Yub2503c somatic stem cell human CVCL_JG41 CL:0000010 Female 21118417 CVCL_JG40 B16-F10/CMV-Luc#2 cancer cell line house mouse CVCL_JG40 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21118418 CVCL_JG43 ASF-4-5L2 finite cell line human CVCL_JG43 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at ~40 PDL (JCRB=JCRB1703) 21118419 CVCL_JG42 ASF-4-5L1 finite cell line human CVCL_JG42 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Senescence: Senesces at ~45 PDL (JCRB=JCRB1705) 21118420 CVCL_JG38 Yub2498c somatic stem cell human CVCL_JG38 CL:0000010 Female 21118421 CVCL_JG37 HuO9/CMV-Luc cancer cell line human CVCL_JG37 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Bone; right distal femur. Discontinued: JCRB; NIHS1047; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118422 CVCL_JG39 Yub2502c somatic stem cell human CVCL_JG39 CL:0000010 Female 21118423 CVCL_JG34 4T1/CMV-Luc #6 cancer cell line house mouse CVCL_JG34 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: JCRB; NIHS1044; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118424 CVCL_JG33 HOS/CMV-Luc#2(c-1) cancer cell line human CVCL_JG33 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Bone; right femur. Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118425 CVCL_JG36 RERF-LC-Sq1/CMV-Luc cancer cell line human CVCL_JG36 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Lung. Discontinued: JCRB; NIHS1048; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118426 CVCL_JG35 MMT-060562/CMV-Luc #3 cancer cell line house mouse CVCL_JG35 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6 x Af. Discontinued: JCRB; NIHS1046; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118427 CVCL_JG10 HSCj-109 transformed cell line CVCL_JG10 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri) [Strain 488-77](NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118428 CVCL_AM79 GM19476 transformed cell line human CVCL_AM79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118429 CVCL_AM78 GM15873 finite cell line human CVCL_AM78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118430 CVCL_AM71 GM15861 transformed cell line human CVCL_AM71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118431 CVCL_AM70 GM12655 finite cell line human CVCL_AM70 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21118432 CVCL_AM73 GM15863 transformed cell line human CVCL_AM73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118433 CVCL_AM72 GM15862 transformed cell line human CVCL_AM72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118434 CVCL_AM75 GM15870 finite cell line human CVCL_AM75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118435 CVCL_JG09 HSCj-101 transformed cell line CVCL_JG09 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri) [Strain 488-77](NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS1009; true Unspecified Group: Non-human primate cell line 21118436 CVCL_AM74 GM15864 transformed cell line human CVCL_AM74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118437 CVCL_JG08 HSCj-002 transformed cell line CVCL_JG08 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri) [Strain 488-77](NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118438 CVCL_AM77 GM15872 finite cell line human CVCL_AM77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118439 CVCL_AM76 GM15871 finite cell line human CVCL_AM76 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118440 CVCL_JG05 HSC-8230 transformed cell line CVCL_JG05 CL:0000010 Miscellaneous: Cell line not distributed due to difficulties to put in culture Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0972; true Unspecified Group: Non-human primate cell line 21118441 CVCL_JG04 HSC-3028 transformed cell line CVCL_JG04 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118442 CVCL_JG07 HSGm-6009 transformed cell line CVCL_JG07 CL:0000010 Miscellaneous: Cell line not distributed due to difficulties to put in culture Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0981; true Unspecified Group: Non-human primate cell line 21118443 CVCL_JG06 HSGm-2014 transformed cell line CVCL_JG06 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0980; probable Unspecified Group: Non-human primate cell line 21118444 CVCL_JG01 HSAt-005 transformed cell line CVCL_JG01 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS1008; true Unspecified Group: Non-human primate cell line 21118445 CVCL_JG00 cynS-1 induced pluripotent stem cell CVCL_JG00 CL:0000010 Derived from sampling site: Skin. Female Group: Non-human primate cell line 21118446 CVCL_JG03 HSC-3 [Macaca fascicularis] transformed cell line CVCL_JG03 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0969; probable Unspecified Group: Non-human primate cell line 21118447 CVCL_JG02 HSC-2015 transformed cell line CVCL_JG02 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0967; true Unspecified Group: Non-human primate cell line 21118448 CVCL_JG21 HST-1 [Saguinus midas] transformed cell line CVCL_JG21 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118449 CVCL_JG20 HSQ-115 transformed cell line CVCL_JG20 CL:0000010 Miscellaneous: Cell line not distributed due to difficulties to put in culture Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0990; true Unspecified Group: Non-human primate cell line 21118450 CVCL_AM89 GM19480 finite cell line human CVCL_AM89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118451 CVCL_AM82 GM01812 finite cell line human CVCL_AM82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21118452 CVCL_AM81 GM19543 transformed cell line human CVCL_AM81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118453 CVCL_AM84 GM02691 finite cell line human CVCL_AM84 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118454 CVCL_AM83 GM02007 finite cell line human CVCL_AM83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118455 CVCL_AM86 GM01691 finite cell line human CVCL_AM86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118456 CVCL_AM85 GM07207 finite cell line human CVCL_AM85 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118457 CVCL_JG19 HSMn-4613 transformed cell line CVCL_JG19 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0975; true Unspecified Group: Non-human primate cell line 21118458 CVCL_AM88 GM07089 finite cell line human CVCL_AM88 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118459 CVCL_AM87 GM01788 finite cell line human CVCL_AM87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118460 CVCL_JG16 HSJ-2178 transformed cell line CVCL_JG16 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118461 CVCL_JG15 HSJ-2099 transformed cell line CVCL_JG15 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118462 CVCL_JG18 HSMn-3943 transformed cell line CVCL_JG18 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0976; true Unspecified Group: Non-human primate cell line 21118463 CVCL_JG17 HSMn-3942 transformed cell line CVCL_JG17 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0977; true Unspecified Group: Non-human primate cell line 21118464 CVCL_JG12 HSF-10 transformed cell line CVCL_JG12 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118465 CVCL_JG11 HSCj-110 transformed cell line CVCL_JG11 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri) [Strain 488-77](NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118466 CVCL_AM80 GM19542 finite cell line human CVCL_AM80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118467 CVCL_JG14 HSF-9 transformed cell line CVCL_JG14 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118468 CVCL_JG13 HSF-11 transformed cell line CVCL_JG13 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118469 CVCL_AM57 GM11294 transformed cell line human CVCL_AM57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118470 CVCL_AM56 GM11293 transformed cell line human CVCL_AM56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118471 CVCL_AM59 GM11297 transformed cell line human CVCL_AM59 CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Asp383Asn (c.1147G>A); ClinVar=VCV000003775; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118472 CVCL_AM58 GM11296 transformed cell line human CVCL_AM58 CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Pro81Leu (c.242C>T); ClinVar=VCV000003772; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg217Trp (c.649C>T); ClinVar=VCV000003795; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118473 CVCL_AM51 GM10536 transformed cell line human CVCL_AM51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118474 CVCL_AM50 GM10535 transformed cell line human CVCL_AM50 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118475 CVCL_AM53 GM11031 transformed cell line human CVCL_AM53 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Pro23His (c.68C>A); ClinVar=VCV000013013; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118476 CVCL_AM52 GM10537 transformed cell line human CVCL_AM52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118477 CVCL_AM55 GM11292 transformed cell line human CVCL_AM55 CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Thr373Lys (c.1118C>A); ClinVar=VCV000003774; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Asn382Lys (c.1146C>A); ClinVar=VCV000003786; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118478 CVCL_AM54 GM11105 transformed cell line human CVCL_AM54 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Pro23His (c.68C>A); ClinVar=VCV000013013; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118479 CVCL_AM68 GM12645 finite cell line human CVCL_AM68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21118480 CVCL_AM67 GM10113 finite cell line human CVCL_AM67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118481 CVCL_AM69 GM12646 finite cell line human CVCL_AM69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21118482 CVCL_AM60 GM11345 transformed cell line human CVCL_AM60 CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Pro81Leu (c.242C>T); ClinVar=VCV000003772; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118483 CVCL_AM62 GM01161 finite cell line human CVCL_AM62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21118484 CVCL_AM61 GM00733 finite cell line human CVCL_AM61 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21118485 CVCL_AM64 GM02490 finite cell line human CVCL_AM64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118486 CVCL_AM63 GM01516 finite cell line human CVCL_AM63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21118487 CVCL_AM66 GM03850 finite cell line human CVCL_AM66 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118488 CVCL_AM65 GM02681 finite cell line human CVCL_AM65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21118489 CVCL_SA71 LCL 2011 transformed cell line CVCL_SA71 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118490 CVCL_SA70 LCL 2005 transformed cell line CVCL_SA70 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118491 CVCL_SA73 LCL 871 transformed cell line CVCL_SA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118492 CVCL_SA72 LCL 2147 transformed cell line CVCL_SA72 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118493 CVCL_SA75 FaDu-R cancer cell line human CVCL_SA75 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line) Population: Indian; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pharynx; hypopharynx. Male Characteristics: Established from parent cell line after a cumulative irradiation dose of 90 Gy 21118494 CVCL_SA74 LCL 919 transformed cell line CVCL_SA74 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118495 CVCL_SA77 KUMA-3 cancer cell line human CVCL_SA77 HLA typing: A*24:02,11:01 (PubMed=10741724) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=10741724). Population: Japanese Unspecified 21118496 CVCL_SA76 HJS-1 cancer cell line human CVCL_SA76 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Female 21118497 CVCL_SA79 NSC-89-20 D-2 finite cell line human CVCL_SA79 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118498 CVCL_SA78 MO24 transformed cell line human CVCL_SA78 HLA typing: A*02:01,24:02 (PubMed=10741724) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified 21118499 CVCL_SA60 TXNIP-null MEF spontaneously immortalized cell line house mouse CVCL_SA60 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1889549; Txnip Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6;129-Txniptm1Rlee/J. Unspecified 21118500 CVCL_SA62 LCL 1275 transformed cell line CVCL_SA62 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21118501 CVCL_SA61 LCL 1080 transformed cell line CVCL_SA61 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118502 CVCL_SA64 LCL 1615 transformed cell line CVCL_SA64 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118503 CVCL_SA63 LCL 1460 transformed cell line CVCL_SA63 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118504 CVCL_SA66 LCL 1659 transformed cell line CVCL_SA66 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21118505 CVCL_SA65 LCL 1620 transformed cell line CVCL_SA65 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118506 CVCL_SA68 LCL 1856 transformed cell line CVCL_SA68 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118507 CVCL_SA67 LCL 1660 transformed cell line CVCL_SA67 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21118508 CVCL_SA69 LCL 1948 transformed cell line CVCL_SA69 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118509 CVCL_SA51 V038 AGM BLCL transformed cell line green monkey CVCL_SA51 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Group: Non-human primate cell line 21118510 CVCL_SA50 GAB-LCL transformed cell line CVCL_SA50 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21118511 CVCL_SA53 SuperSOST G5 cancer cell line human CVCL_SA53 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Characteristics: Expresses SOST mRNA at 10x higher level than parental cell line 21118512 CVCL_SA52 SuperSOST C9 cancer cell line human CVCL_SA52 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Characteristics: Expresses SOST mRNA at 10x higher level than parental cell line 21118513 CVCL_SA55 LPS2 cancer cell line human CVCL_SA55 CL:0000010 Omics: Metabolome analysis; Omics: SNP array analysis. Male Characteristics: Derived from LPSX2, a mouse xenograft of a transplanted human liposarcoma 21118514 CVCL_SA54 LPS1 cancer cell line human CVCL_SA54 CL:0000010 Omics: Metabolome analysis; Omics: SNP array analysis. Female Characteristics: Derived from LPSX1, a mouse xenograft of a transplanted human liposarcoma 21118515 CVCL_SA57 HPSC-TAg transformed cell line human CVCL_SA57 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Unspecified Doubling time: 42 hours (PubMed=18245495) 21118516 CVCL_SA56 LPS3 cancer cell line human CVCL_SA56 CL:0000010 Omics: Metabolome analysis; Omics: SNP array analysis. Male Characteristics: Derived from LPSX3, a mouse xenograft of a transplanted human liposarcoma 21118517 CVCL_SA59 HPSC-TAg-TERT transformed cell line human CVCL_SA59 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Unspecified Doubling time: 12 hours (PubMed=18245495) 21118518 CVCL_SA58 HPSC-TERT telomerase immortalized cell line human CVCL_SA58 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Unspecified 21118519 CVCL_SA40 ND50103 finite cell line human CVCL_SA40 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118520 CVCL_SA42 ND50105 finite cell line human CVCL_SA42 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118521 CVCL_SA41 ND50104 finite cell line human CVCL_SA41 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118522 CVCL_SA44 ND50107 finite cell line human CVCL_SA44 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118523 CVCL_SA43 ND50106 finite cell line human CVCL_SA43 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118524 CVCL_SA46 KMPG-1 cancer cell line CVCL_SA46 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Bone marrow. Female Group: Non-human primate cell line 21118525 CVCL_SA45 ND50108 finite cell line human CVCL_SA45 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118526 CVCL_SA48 AG23 AGM BLCL transformed cell line CVCL_SA48 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Group: Non-human primate cell line 21118527 CVCL_SA47 SPG-1 cancer cell line CVCL_SA47 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Spleen. Female Group: Non-human primate cell line 21118528 CVCL_SA49 BLCL-C162 transformed cell line CVCL_SA49 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Group: Non-human primate cell line 21118529 CVCL_JG96 TYUC-1-Luc cancer cell line human CVCL_JG96 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Esophagus. Female 21118530 CVCL_JG95 NCI-H1781/CMV-Luc#6 cancer cell line human CVCL_JG95 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln245fs*6 (c.735_739delGCCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS1070; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118531 CVCL_JG98 POLZ Y2779F-POLK+/- cancer cell line human CVCL_JG98 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Tyr2779Phe; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21118532 CVCL_JG97 POLK KO-POLH-/- cancer cell line human CVCL_JG97 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9181; POLH; Knockout cell: Method=Homologous recombination; HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21118533 CVCL_JG92 Ex-3LL/CMV-Luc#1 cancer cell line house mouse CVCL_JG92 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS1068; true Characteristics: Expression of luciferase is under the control of the CMV promoter 21118534 CVCL_JG91 Hep-2040 telomerase immortalized cell line human CVCL_JG91 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21118535 CVCL_JG94 B16-F10/EF1a-Luc#1 cancer cell line house mouse CVCL_JG94 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21118536 CVCL_JG93 NCI-H1781/CMV-Luc polyclone cancer cell line human CVCL_JG93 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln245fs*6 (c.735_739delGCCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS1069; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21118537 CVCL_JG90 Hep-2020 telomerase immortalized cell line human CVCL_JG90 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21118538 CVCL_SA31 ND50087 induced pluripotent stem cell human CVCL_SA31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118539 CVCL_SA30 ND50084 induced pluripotent stem cell human CVCL_SA30 CL:0000010 Derived from sampling site: Peripheral blood. Female 21118540 CVCL_SA33 ND50089 induced pluripotent stem cell human CVCL_SA33 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)51 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118541 CVCL_SA32 ND50088 induced pluripotent stem cell human CVCL_SA32 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)51 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118542 CVCL_SA35 ND50091 induced pluripotent stem cell human CVCL_SA35 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)53 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118543 CVCL_SA34 ND50090 induced pluripotent stem cell human CVCL_SA34 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)62 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118544 CVCL_SA37 ND50095 induced pluripotent stem cell human CVCL_SA37 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (from parent cell line) Population: Latino or Hispanic; Dominican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118545 CVCL_SA36 ND50092 induced pluripotent stem cell human CVCL_SA36 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)68 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118546 CVCL_SA39 ND50102 finite cell line human CVCL_SA39 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118547 CVCL_SA38 ND50096 induced pluripotent stem cell human CVCL_SA38 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118548 CVCL_JG89 Hep-2018 telomerase immortalized cell line human CVCL_JG89 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Omics: Transcriptome analysis by microarray Female 21118549 CVCL_JG88 Hep-2013 telomerase immortalized cell line human CVCL_JG88 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Female 21118550 CVCL_SA20 ND50073 induced pluripotent stem cell human CVCL_SA20 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21118551 CVCL_SA22 ND50076 induced pluripotent stem cell human CVCL_SA22 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118552 CVCL_SA21 ND50074 induced pluripotent stem cell human CVCL_SA21 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118553 CVCL_SA24 ND50078 induced pluripotent stem cell human CVCL_SA24 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118554 CVCL_SA23 ND50077 induced pluripotent stem cell human CVCL_SA23 CL:0000010 Derived from sampling site: Peripheral blood. Male 21118555 CVCL_SA26 ND50080 induced pluripotent stem cell human CVCL_SA26 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118556 CVCL_SA25 ND50079 induced pluripotent stem cell human CVCL_SA25 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu50Lys (c.148G>A) (E49K); ClinVar=VCV000658902; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118557 CVCL_SA28 ND50082 induced pluripotent stem cell human CVCL_SA28 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21118558 CVCL_SA27 ND50081 induced pluripotent stem cell human CVCL_SA27 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118559 CVCL_SA29 ND50083 induced pluripotent stem cell human CVCL_SA29 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (NHCDR) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118560 CVCL_JG99 POLZ Y2779F-POLH+/- cancer cell line human CVCL_JG99 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9181; POLH; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Tyr2779Phe; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21118561 CVCL_JG74 BC-KP finite cell line human CVCL_JG74 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2713; probable Female 21118562 CVCL_JG73 AP48P finite cell line human CVCL_JG73 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg435Cys (c.1303C>T); ClinVar=VCV000555603; Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118563 CVCL_JG76 MK-1 [Human Down syndrome] finite cell line human CVCL_JG76 CL:0000010 Population: Japanese; Karyotypic information: 47,XY,+21 (JCRB) Discontinued: JCRB; KURB2765; probable. Male 21118564 CVCL_JG75 FA23P finite cell line human CVCL_JG75 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.3766_3828del (Ex38del); Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118565 CVCL_JG70 XP1SA [Sapporo] finite cell line human CVCL_JG70 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118566 CVCL_JG72 AP25P finite cell line human CVCL_JG72 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118567 CVCL_JG71 AP19P finite cell line human CVCL_JG71 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1638; probable Female 21118568 CVCL_SA11 MIHA transformed cell line human CVCL_SA11 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Omics: Transcriptome analysis by microarray Male Doubling time: 72 hours (PubMed=10613743) 21118569 CVCL_SA10 HKCI-11 cancer cell line human CVCL_SA10 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified Virology: Expresses chimeric hepatitis B virus (HBV)-human transcripts (PubMed=24582836) 21118570 CVCL_SA13 HKCI-5A cancer cell line human CVCL_SA13 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified 21118571 CVCL_SA12 IHBV6.7 transformed cell line human CVCL_SA12 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Male Virology: Transfected with a circular hepatitis B virus (HBV) genome Produces HBsAg. Group: Patented cell line 21118572 CVCL_SA15 CTD110.6 hybridoma house mouse CVCL_SA15 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:28009; N-acetyl-beta-D-glucosamine (Note=In beta-O-glycosidic linkage to serine and threonine). 21118573 CVCL_SA14 ND50060 induced pluripotent stem cell human CVCL_SA14 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118574 CVCL_SA17 ND50061 induced pluripotent stem cell human CVCL_SA17 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118575 CVCL_SA16 ND50059 induced pluripotent stem cell human CVCL_SA16 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: NHCDR; ND50059; true Male 21118576 CVCL_SA19 ND50067 induced pluripotent stem cell human CVCL_SA19 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118577 CVCL_SA18 ND50062 induced pluripotent stem cell human CVCL_SA18 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: NHCDR; ND50062; true Male 21118578 CVCL_JG67 PJS6JTO finite cell line human CVCL_JG67 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118579 CVCL_JG66 PJS3JTO finite cell line human CVCL_JG66 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118580 CVCL_JG69 RB188Tu cancer cell line human CVCL_JG69 CL:0000010 Population: Japanese; Derived from metastatic site: Eye socket. Female 21118581 CVCL_JG68 RB188 finite cell line human CVCL_JG68 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118582 CVCL_JG85 XP3KA finite cell line human CVCL_JG85 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1047; probable Male 21118583 CVCL_JG84 SEKI-45 cancer cell line human CVCL_JG84 CL:0000010 Discontinued: JCRB; KURB2687; probable. Unspecified 21118584 CVCL_JG87 Hep-2023D telomerase immortalized cell line human CVCL_JG87 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21118585 CVCL_JG86 G-361/CMV-Luc#2(c-2.5) cancer cell line human CVCL_JG86 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS1040; true. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21118586 CVCL_JG81 RB257(L) transformed cell line human CVCL_JG81 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21118587 CVCL_JG80 NF1 finite cell line human CVCL_JG80 CL:0000010 Population: Japanese Discontinued: JCRB; KURB2807; probable. Male 21118588 CVCL_JG83 RB257M(L) transformed cell line human CVCL_JG83 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118589 CVCL_JG82 RB257F(L) transformed cell line human CVCL_JG82 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB2447; probable Male 21118590 CVCL_SA00 HKCI-C1 cancer cell line human CVCL_SA00 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Unspecified 21118591 CVCL_SA02 HKCI-5 cancer cell line human CVCL_SA02 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Unspecified 21118592 CVCL_SA01 HKCI-C2 cancer cell line human CVCL_SA01 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Unspecified 21118593 CVCL_SA04 HKCI-6 cancer cell line human CVCL_SA04 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21118594 CVCL_SA03 HKCI-C3 cancer cell line human CVCL_SA03 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Unspecified 21118595 CVCL_SA06 HKCI-8 cancer cell line human CVCL_SA06 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified 21118596 CVCL_SA05 HKCI-7 cancer cell line human CVCL_SA05 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified Virology: Expresses chimeric hepatitis B virus (HBV)-human transcripts (PubMed=24582836) 21118597 CVCL_SA08 HKCI-10 cancer cell line human CVCL_SA08 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Unspecified 21118598 CVCL_SA07 HKCI-9 cancer cell line human CVCL_SA07 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified 21118599 CVCL_SA09 HKCI-5B cancer cell line human CVCL_SA09 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by RNAseq Unspecified Virology: Expresses chimeric hepatitis B virus (HBV)-human transcripts (PubMed=24582836) 21118600 CVCL_JG78 MKHD1 finite cell line human CVCL_JG78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1993; probable Male 21118601 CVCL_JG77 MK-51 finite cell line human CVCL_JG77 CL:0000010 Population: Japanese; Karyotypic information: 48,XXXX (JCRB); Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB2761; probable Female 21118602 CVCL_JG79 NBCCS-1AW finite cell line human CVCL_JG79 CL:0000010 Discontinued: JCRB; KURB2879; probable. Male 21118603 CVCL_8S21 DA06570 transformed cell line human CVCL_8S21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118604 CVCL_9421 Royan N37 embryonic stem cell house mouse CVCL_9421 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118605 CVCL_8S20 DA06569 transformed cell line human CVCL_8S20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118606 CVCL_9420 Royan N36 embryonic stem cell house mouse CVCL_9420 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118607 CVCL_8S23 DA06572 transformed cell line human CVCL_8S23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118608 CVCL_9423 Royan N39 embryonic stem cell house mouse CVCL_9423 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118609 CVCL_8S22 DA06571 transformed cell line human CVCL_8S22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118610 CVCL_9422 Royan N38 embryonic stem cell house mouse CVCL_9422 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118611 CVCL_8S18 DA06567 transformed cell line human CVCL_8S18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118612 CVCL_9418 Royan N34 embryonic stem cell house mouse CVCL_9418 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118613 CVCL_8S17 DA06566 transformed cell line human CVCL_8S17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118614 CVCL_9417 Royan N33 embryonic stem cell house mouse CVCL_9417 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118615 CVCL_8S19 DA06568 transformed cell line human CVCL_8S19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118616 CVCL_9419 Royan N35 embryonic stem cell house mouse CVCL_9419 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118617 CVCL_8S14 DA06563 transformed cell line human CVCL_8S14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118618 CVCL_9414 Royan N30 embryonic stem cell house mouse CVCL_9414 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118619 CVCL_8S13 DA06562 transformed cell line human CVCL_8S13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118620 CVCL_9413 Royan N3 embryonic stem cell house mouse CVCL_9413 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118621 CVCL_8S16 DA06565 transformed cell line human CVCL_8S16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118622 CVCL_9416 Royan N32 embryonic stem cell house mouse CVCL_9416 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118623 CVCL_8S15 DA06564 transformed cell line human CVCL_8S15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118624 CVCL_9415 Royan N31 embryonic stem cell house mouse CVCL_9415 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118625 CVCL_8S32 DA06585 transformed cell line human CVCL_8S32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118626 CVCL_9432 Royan N47 embryonic stem cell house mouse CVCL_9432 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118627 CVCL_8S31 DA06584 transformed cell line human CVCL_8S31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118628 CVCL_9431 Royan N46 embryonic stem cell house mouse CVCL_9431 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118629 CVCL_8S34 DA06587 transformed cell line human CVCL_8S34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118630 CVCL_9434 Royan N49 embryonic stem cell house mouse CVCL_9434 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118631 CVCL_8S33 DA06586 transformed cell line human CVCL_8S33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118632 CVCL_9433 Royan N48 embryonic stem cell house mouse CVCL_9433 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118633 CVCL_8S30 DA06583 transformed cell line human CVCL_8S30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118634 CVCL_9430 Royan N45 embryonic stem cell house mouse CVCL_9430 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118635 CVCL_8S29 DA06582 transformed cell line human CVCL_8S29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118636 CVCL_9429 Royan N44 embryonic stem cell house mouse CVCL_9429 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118637 CVCL_8S28 DA06579 transformed cell line human CVCL_8S28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118638 CVCL_9428 Royan N43 embryonic stem cell house mouse CVCL_9428 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118639 CVCL_8S25 DA06574 transformed cell line human CVCL_8S25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118640 CVCL_9425 Royan N40 embryonic stem cell house mouse CVCL_9425 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118641 CVCL_8S24 DA06573 transformed cell line human CVCL_8S24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118642 CVCL_9424 Royan N4 embryonic stem cell house mouse CVCL_9424 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118643 CVCL_8S27 DA06578 transformed cell line human CVCL_8S27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118644 CVCL_9427 Royan N42 embryonic stem cell house mouse CVCL_9427 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118645 CVCL_8S26 DA06577 transformed cell line human CVCL_8S26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118646 CVCL_9426 Royan N41 embryonic stem cell house mouse CVCL_9426 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118647 CVCL_8S01 DA06550 transformed cell line human CVCL_8S01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118648 CVCL_9401 Royan N19 embryonic stem cell house mouse CVCL_9401 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118649 CVCL_8S00 DA06549 transformed cell line human CVCL_8S00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118650 CVCL_9400 Royan N18 embryonic stem cell house mouse CVCL_9400 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118651 CVCL_8S10 DA06559 transformed cell line human CVCL_8S10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118652 CVCL_9410 Royan N27 embryonic stem cell house mouse CVCL_9410 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118653 CVCL_8S12 DA06561 transformed cell line human CVCL_8S12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118654 CVCL_9412 Royan N29 embryonic stem cell house mouse CVCL_9412 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118655 CVCL_8S11 DA06560 transformed cell line human CVCL_8S11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118656 CVCL_9411 Royan N28 embryonic stem cell house mouse CVCL_9411 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118657 CVCL_8S07 DA06556 transformed cell line human CVCL_8S07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118658 CVCL_9407 Royan N24 embryonic stem cell house mouse CVCL_9407 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118659 CVCL_8S06 DA06555 transformed cell line human CVCL_8S06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118660 CVCL_9406 Royan N23 embryonic stem cell house mouse CVCL_9406 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118661 CVCL_8S09 DA06558 transformed cell line human CVCL_8S09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118662 CVCL_9409 Royan N26 embryonic stem cell house mouse CVCL_9409 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118663 CVCL_8S08 DA06557 transformed cell line human CVCL_8S08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118664 CVCL_9408 Royan N25 embryonic stem cell house mouse CVCL_9408 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118665 CVCL_8S03 DA06552 transformed cell line human CVCL_8S03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118666 CVCL_9403 Royan N20 embryonic stem cell house mouse CVCL_9403 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118667 CVCL_8S02 DA06551 transformed cell line human CVCL_8S02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118668 CVCL_9402 Royan N2 embryonic stem cell house mouse CVCL_9402 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118669 CVCL_8S05 DA06554 transformed cell line human CVCL_8S05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118670 CVCL_9405 Royan N22 embryonic stem cell house mouse CVCL_9405 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118671 CVCL_8S04 DA06553 transformed cell line human CVCL_8S04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118672 CVCL_9404 Royan N21 embryonic stem cell house mouse CVCL_9404 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118673 CVCL_AM35 GM10515 finite cell line human CVCL_AM35 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (from familial inference of GM08971) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female Part of: Retinitis Pigmentosa Foundation Collection 21118674 CVCL_AM34 GM10149 transformed cell line human CVCL_AM34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118675 CVCL_AM37 GM10520 transformed cell line human CVCL_AM37 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with retinitis pigmentosa but at risk for disease; Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118676 CVCL_AM36 GM10519 transformed cell line human CVCL_AM36 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118677 CVCL_AM39 GM10523 transformed cell line human CVCL_AM39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118678 CVCL_AM38 GM10521 transformed cell line human CVCL_AM38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118679 CVCL_AM31 GM10146 transformed cell line human CVCL_AM31 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118680 CVCL_AM30 GM10145 transformed cell line human CVCL_AM30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118681 CVCL_AM33 GM10148 transformed cell line human CVCL_AM33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118682 CVCL_AM32 GM10147 transformed cell line human CVCL_AM32 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Homozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118683 CVCL_AM46 GM10531 transformed cell line human CVCL_AM46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118684 CVCL_AM45 GM10530 transformed cell line human CVCL_AM45 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118685 CVCL_AM48 GM10533 transformed cell line human CVCL_AM48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118686 CVCL_AM47 GM10532 transformed cell line human CVCL_AM47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118687 CVCL_AM49 GM10534 transformed cell line human CVCL_AM49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118688 CVCL_AM40 GM10524 transformed cell line human CVCL_AM40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118689 CVCL_AM42 GM10526 transformed cell line human CVCL_AM42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118690 CVCL_AM41 GM10525 transformed cell line human CVCL_AM41 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118691 CVCL_AM44 GM10529 transformed cell line human CVCL_AM44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118692 CVCL_AM43 GM10527 transformed cell line human CVCL_AM43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118693 CVCL_8S81 BH0109 transformed cell line human CVCL_8S81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98112616; true Ambiguous Part of: ECACC chromosomal abnormality collection 21118694 CVCL_9481 SNEC-MI cancer cell line human CVCL_9481 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~70.4 hours (PubMed=15218315) 21118695 CVCL_9480 AZ-H3c cancer cell line human CVCL_9480 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Phe (c.110C>T); ClinVar=VCV000017586; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Small intestine; duodenum. Male Problematic cell line: Contaminated Parent cell line (AZ-521) has been shown to be a Hutu 80 derivative. 21118696 CVCL_8S80 BH0106 transformed cell line human CVCL_8S80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98101809; true Female Part of: ECACC chromosomal abnormality collection 21118697 CVCL_8S87 BJ0003 transformed cell line human CVCL_8S87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118698 CVCL_AM13 GM10127 transformed cell line human CVCL_AM13 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118699 CVCL_9487 R1-miPSC4 induced pluripotent stem cell house mouse CVCL_9487 From: Royan Institute; Theran; Iran. CL:0000010 21118700 CVCL_8S86 BH0124 transformed cell line human CVCL_8S86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00070653; true Male Part of: ECACC chromosomal abnormality collection 21118701 CVCL_AM12 GM10126 transformed cell line human CVCL_AM12 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118702 CVCL_9486 R1-miPSC3 induced pluripotent stem cell house mouse CVCL_9486 From: Royan Institute; Theran; Iran. CL:0000010 21118703 CVCL_8S89 BM0067 finite cell line human CVCL_8S89 CL:0000010 Discontinued: ECACC; 90011882; true. Male Part of: ECACC chromosomal abnormality collection 21118704 CVCL_9489 CEMO-1 cancer cell line human CVCL_9489 CL:0000010 Sequence variation: Gene fusion; HGNC; 1008; BCL9 + HGNC; 5477; IGH; Name(s)=IGH-BCL9 (PubMed=9490669) Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=8642878) 21118705 CVCL_AM15 GM10130 transformed cell line human CVCL_AM15 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118706 CVCL_8S88 BK0015 transformed cell line human CVCL_8S88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99092421; true Male Part of: ECACC chromosomal abnormality collection 21118707 CVCL_AM14 GM10128 transformed cell line human CVCL_AM14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118708 CVCL_9488 R1-miPSC5 induced pluripotent stem cell house mouse CVCL_9488 From: Royan Institute; Theran; Iran. CL:0000010 21118709 CVCL_9483 BCLC-9 cancer cell line human CVCL_9483 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Arg (c.575A>G); ClinVar=VCV000182931; Zygosity=Unspecified (PubMed=15041736); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=15041736) Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Female Characteristics: Established from a xenograft produced by implantation of tumor cells in the liver of a Swiss nude mice Doubling time: 27.7 hours, at 17th passage (PubMed=15041736) 21118710 CVCL_8S83 BH0111 transformed cell line human CVCL_8S83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99021705; true Female Part of: ECACC chromosomal abnormality collection 21118711 CVCL_AM17 GM10132 transformed cell line human CVCL_AM17 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118712 CVCL_8S82 BH0110 transformed cell line human CVCL_8S82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99021704; true Female Part of: ECACC chromosomal abnormality collection 21118713 CVCL_AM16 GM10131 transformed cell line human CVCL_AM16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118714 CVCL_9482 MM17 cancer cell line human CVCL_9482 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=15067335) Population: Chinese; Derived from metastatic site: Bone; sacrum. Female Doubling time: ~72 hours (PubMed=15067335) 21118715 CVCL_8S85 BH0123 transformed cell line human CVCL_8S85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00070652; true Male Part of: ECACC chromosomal abnormality collection 21118716 CVCL_AM19 GM10134 transformed cell line human CVCL_AM19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118717 CVCL_9485 R1-miPSC2 induced pluripotent stem cell house mouse CVCL_9485 From: Royan Institute; Theran; Iran. CL:0000010 21118718 CVCL_8S84 BH0122 transformed cell line human CVCL_8S84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00070651; true Female Part of: ECACC chromosomal abnormality collection 21118719 CVCL_AM18 GM10133 transformed cell line human CVCL_AM18 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118720 CVCL_9484 R1-miPSC1 induced pluripotent stem cell house mouse CVCL_9484 From: Royan Institute; Theran; Iran. CL:0000010 21118721 CVCL_9479 AZ-H6c cancer cell line human CVCL_9479 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Phe (c.110C>T); ClinVar=VCV000017586; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Small intestine; duodenum. Male Problematic cell line: Contaminated Parent cell line (AZ-521) has been shown to be a Hutu 80 derivative. 21118722 CVCL_8S79 BH0101 transformed cell line human CVCL_8S79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98082703; true Male Part of: ECACC chromosomal abnormality collection 21118723 CVCL_AM11 GM10125 transformed cell line human CVCL_AM11 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118724 CVCL_AM10 GM09785 transformed cell line human CVCL_AM10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118725 CVCL_9490 ACP01 cancer cell line human CVCL_9490 CL:0000010 Population: African and Caucasian; Derived from sampling site: Stomach; pyloric antrum. Male Doubling time: ~40 hours (PubMed=15558189) 21118726 CVCL_8S90 BO0295 transformed cell line human CVCL_8S90 CL:0000010 Karyotypic information: 46,XY,t(5;9)(5pter->5q22::9p22->9pter::9qter->9p22::5q22->5qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118727 CVCL_8S92 BO0312 transformed cell line human CVCL_8S92 CL:0000010 Karyotypic information: 46,XXq- (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118728 CVCL_9492 ERY-1 cancer cell line human CVCL_9492 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: ~40 hours (PubMed=15475075) 21118729 CVCL_8S91 BO0307 transformed cell line human CVCL_8S91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118730 CVCL_9491 COST cancer cell line human CVCL_9491 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=15356659; PubMed=26657151) Derived from sampling site: Peripheral blood. Male 21118731 CVCL_8S98 BO0383 transformed cell line human CVCL_8S98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,r(22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118732 CVCL_AM24 GM10139 transformed cell line human CVCL_AM24 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118733 CVCL_9498 PO-2 undefined cell line type CVCL_9498 CL:0000010 Derived from sampling site: Kidney. Unspecified 21118734 CVCL_8S97 BO0382 transformed cell line human CVCL_8S97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(13)?(q22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118735 CVCL_AM23 GM10138 transformed cell line human CVCL_AM23 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118736 CVCL_9497 HeLa TK- cancer cell line human CVCL_9497 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21118737 CVCL_AM26 GM10141 transformed cell line human CVCL_AM26 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118738 CVCL_8S99 BO0387 transformed cell line human CVCL_8S99 CL:0000010 Karyotypic information: 46,XX,t(3;7)(p25;q36) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118739 CVCL_AM25 GM10140 transformed cell line human CVCL_AM25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118740 CVCL_9499 RS-537 spontaneously immortalized cell line CVCL_9499 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21118741 CVCL_8S94 BO0337 transformed cell line human CVCL_8S94 CL:0000010 Karyotypic information: 46,X,Xq+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118742 CVCL_AM28 GM10143 transformed cell line human CVCL_AM28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118743 CVCL_9494 M-1 [Human mantle cell lymphoma] cancer cell line human CVCL_9494 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 36 hours (PubMed=15360009) 21118744 CVCL_8S93 BO0329 transformed cell line human CVCL_8S93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118745 CVCL_AM27 GM10142 transformed cell line human CVCL_AM27 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with retinitis pigmentosa but at risk for disease; Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118746 CVCL_9493 HeLa-APL cancer cell line human CVCL_9493 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:90205; Plitidepsin (Dehydrodidemnin B; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Female 21118747 CVCL_8S96 BO0362 transformed cell line human CVCL_8S96 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,?t(2;12)(q32;q15),inv(6)(p21.1;p23) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118748 CVCL_9496 Royan B5 embryonic stem cell house mouse CVCL_9496 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21118749 CVCL_8S95 BO0338 transformed cell line human CVCL_8S95 CL:0000010 Karyotypic information: 46,XY,t(2;4)(11;14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118750 CVCL_AM29 GM10144 transformed cell line human CVCL_AM29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118751 CVCL_AM20 GM10135 transformed cell line human CVCL_AM20 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118752 CVCL_AM22 GM10137 transformed cell line human CVCL_AM22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118753 CVCL_AM21 GM10136 transformed cell line human CVCL_AM21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118754 CVCL_8S65 DA06623 transformed cell line human CVCL_8S65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118755 CVCL_9465 Royan H6-Wnt1 embryonic stem cell human CVCL_9465 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118756 CVCL_8S64 DA06622 transformed cell line human CVCL_8S64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118757 CVCL_9464 Royan H6-Lmx4 embryonic stem cell human CVCL_9464 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118758 CVCL_8S67 BH0017 transformed cell line human CVCL_8S67 CL:0000010 Karyotypic information: 46,XX,t(X;15)(p22.33;q25.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118759 CVCL_9467 Royan H6-Wnt3 embryonic stem cell human CVCL_9467 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118760 CVCL_8S66 BH0016 transformed cell line human CVCL_8S66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118761 CVCL_9466 Royan H6-Wnt2 embryonic stem cell human CVCL_9466 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118762 CVCL_8S61 DA06619 transformed cell line human CVCL_8S61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118763 CVCL_9461 Royan S6 embryonic stem cell house mouse CVCL_9461 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118764 CVCL_8S60 DA06618 transformed cell line human CVCL_8S60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118765 CVCL_9460 Royan S5 embryonic stem cell house mouse CVCL_9460 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118766 CVCL_8S63 DA06621 transformed cell line human CVCL_8S63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118767 CVCL_9463 Royan H6-Lmx2 embryonic stem cell human CVCL_9463 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118768 CVCL_8S62 DA06620 transformed cell line human CVCL_8S62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118769 CVCL_9462 Royan H6-Lmx1 embryonic stem cell human CVCL_9462 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118770 CVCL_8S58 DA06613 transformed cell line human CVCL_8S58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118771 CVCL_9458 Royan S3 embryonic stem cell house mouse CVCL_9458 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118772 CVCL_8S57 DA06612 transformed cell line human CVCL_8S57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118773 CVCL_9457 Royan S2 embryonic stem cell house mouse CVCL_9457 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118774 CVCL_8S59 DA06614 transformed cell line human CVCL_8S59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118775 CVCL_9459 Royan S4 embryonic stem cell house mouse CVCL_9459 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118776 CVCL_AM09 GM09784 transformed cell line human CVCL_AM09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118777 CVCL_9470 2fTGH-U4A cancer cell line human CVCL_9470 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21118778 CVCL_8S70 BH0050 transformed cell line human CVCL_8S70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118779 CVCL_8S76 BH0084 transformed cell line human CVCL_8S76 CL:0000010 Karyotypic information: 46,XX,inv(2)(p11;q13),t(3;11)(q23;p15.5) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21118780 CVCL_9476 GICIN-1 cancer cell line human CVCL_9476 CL:0000010 Male 21118781 CVCL_AM02 GM09777 transformed cell line human CVCL_AM02 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118782 CVCL_8S75 BH0083 transformed cell line human CVCL_8S75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118783 CVCL_AM01 GM09776 transformed cell line human CVCL_AM01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118784 CVCL_9475 TMC-1 cancer cell line human CVCL_9475 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep quantitative proteome analysis Discontinued: BCRC; 60379; true Male Doubling time: ~15 hours (PubMed=15237194) Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (BCRC). Originally thought to originate from the lymph nodes of a 67 year old female patient with a gastric carcinoma. 21118785 CVCL_9478 AR230 cancer cell line human CVCL_9478 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7606740; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21118786 CVCL_8S78 BH0096 transformed cell line human CVCL_8S78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98063003; true Male Part of: ECACC chromosomal abnormality collection 21118787 CVCL_AM04 GM09779 transformed cell line human CVCL_AM04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118788 CVCL_9477 AMC-106 cancer cell line human CVCL_9477 CL:0000010 Omics: Transcriptome analysis by microarray. 21118789 CVCL_8S77 BH0091 transformed cell line human CVCL_8S77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98012319; true Male Part of: ECACC chromosomal abnormality collection 21118790 CVCL_AM03 GM09778 transformed cell line human CVCL_AM03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118791 CVCL_8S72 BH0078 transformed cell line human CVCL_8S72 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X),(q27.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118792 CVCL_AM06 GM09781 transformed cell line human CVCL_AM06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118793 CVCL_9472 PM1 cancer cell line human CVCL_9472 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21118794 CVCL_8S71 BH0068 transformed cell line human CVCL_8S71 CL:0000010 Karyotypic information: 46,XY,add(2),(q37) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118795 CVCL_AM05 GM09780 transformed cell line human CVCL_AM05 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (PubMed=10391211; Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118796 CVCL_9471 Hayai transformed cell line human CVCL_9471 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 21118797 CVCL_9474 BALENLM 17 transformed cell line house mouse CVCL_9474 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BALB/cAnN. 21118798 CVCL_8S74 BH0082 transformed cell line human CVCL_8S74 CL:0000010 Karyotypic information: 46,XY,t(3;11)(q23;p15.5)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118799 CVCL_AM08 GM09783 transformed cell line human CVCL_AM08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118800 CVCL_8S73 BH0079 transformed cell line human CVCL_8S73 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(Y;14)(p11;p1); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118801 CVCL_AM07 GM09782 transformed cell line human CVCL_AM07 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Retinitis Pigmentosa Foundation Collection 21118802 CVCL_9473 LK 35.2 hybridoma house mouse CVCL_9473 CL:0000010 Monoclonal antibody isotype: Not specified. 21118803 CVCL_9469 2fTGH-U3A cancer cell line human CVCL_9469 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Lacks expression of STAT1 Unresponsive to interferon-alpha and interferon-gamma (ECACC).; Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21118804 CVCL_8S69 BH0046 transformed cell line human CVCL_8S69 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(9;17)(p13:?q23.3 or 24.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118805 CVCL_8S68 BH0022 transformed cell line human CVCL_8S68 CL:0000010 Population: Asian; Karyotypic information: 46,XY,t(X;15)(p22;qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21118806 CVCL_9468 Royan H6-Lmx3 embryonic stem cell human CVCL_9468 From: Royan Institute; Theran; Iran. CL:0000010 Male 21118807 CVCL_AM00 GM09775 transformed cell line human CVCL_AM00 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Arg677Ter (c.2029C>T); ClinVar=VCV000005965; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Retinitis Pigmentosa Foundation Collection 21118808 CVCL_8S43 DA06596 transformed cell line human CVCL_8S43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118809 CVCL_9443 Royan N57 embryonic stem cell house mouse CVCL_9443 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118810 CVCL_8S42 DA06595 transformed cell line human CVCL_8S42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118811 CVCL_9442 Royan N56 embryonic stem cell house mouse CVCL_9442 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118812 CVCL_8S45 DA06598 transformed cell line human CVCL_8S45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118813 CVCL_9445 Royan N59 embryonic stem cell house mouse CVCL_9445 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118814 CVCL_8S44 DA06597 transformed cell line human CVCL_8S44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118815 CVCL_9444 Royan N58 embryonic stem cell house mouse CVCL_9444 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118816 CVCL_8S41 DA06594 transformed cell line human CVCL_8S41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118817 CVCL_9441 Royan N55 embryonic stem cell house mouse CVCL_9441 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118818 CVCL_8S40 DA06593 transformed cell line human CVCL_8S40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118819 CVCL_9440 Royan N54 embryonic stem cell house mouse CVCL_9440 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118820 CVCL_8S39 DA06592 transformed cell line human CVCL_8S39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118821 CVCL_9439 Royan N53 embryonic stem cell house mouse CVCL_9439 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118822 CVCL_8S36 DA06589 transformed cell line human CVCL_8S36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118823 CVCL_9436 Royan N50 embryonic stem cell house mouse CVCL_9436 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118824 CVCL_8S35 DA06588 transformed cell line human CVCL_8S35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118825 CVCL_9435 Royan N5 embryonic stem cell house mouse CVCL_9435 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118826 CVCL_8S38 DA06591 transformed cell line human CVCL_8S38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118827 CVCL_9438 Royan N52 embryonic stem cell house mouse CVCL_9438 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118828 CVCL_8S37 DA06590 transformed cell line human CVCL_8S37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118829 CVCL_9437 Royan N51 embryonic stem cell house mouse CVCL_9437 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118830 CVCL_8S54 DA06609 transformed cell line human CVCL_8S54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118831 CVCL_9454 Royan N8 embryonic stem cell house mouse CVCL_9454 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118832 CVCL_8S53 DA06608 transformed cell line human CVCL_8S53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118833 CVCL_9453 Royan N7 embryonic stem cell house mouse CVCL_9453 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118834 CVCL_8S56 DA06611 transformed cell line human CVCL_8S56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118835 CVCL_9456 Royan S1 embryonic stem cell house mouse CVCL_9456 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: SW. Unspecified 21118836 CVCL_8S55 DA06610 transformed cell line human CVCL_8S55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118837 CVCL_9455 Royan N9 embryonic stem cell house mouse CVCL_9455 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118838 CVCL_8S50 DA06604 transformed cell line human CVCL_8S50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118839 CVCL_9450 Royan N63 embryonic stem cell house mouse CVCL_9450 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118840 CVCL_8S52 DA06607 transformed cell line human CVCL_8S52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118841 CVCL_9452 Royan N65 embryonic stem cell house mouse CVCL_9452 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118842 CVCL_8S51 DA06605 transformed cell line human CVCL_8S51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118843 CVCL_9451 Royan N64 embryonic stem cell house mouse CVCL_9451 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118844 CVCL_8S47 DA06600 transformed cell line human CVCL_8S47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118845 CVCL_9447 Royan N60 embryonic stem cell house mouse CVCL_9447 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118846 CVCL_8S46 DA06599 transformed cell line human CVCL_8S46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118847 CVCL_9446 Royan N6 embryonic stem cell house mouse CVCL_9446 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118848 CVCL_8S49 DA06602 transformed cell line human CVCL_8S49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118849 CVCL_9449 Royan N62 embryonic stem cell house mouse CVCL_9449 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118850 CVCL_8S48 DA06601 transformed cell line human CVCL_8S48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118851 CVCL_9448 Royan N61 embryonic stem cell house mouse CVCL_9448 From: Royan Institute; Theran; Iran CL:0000010 Breed/subspecies: NMRI. Unspecified 21118852 CVCL_8L42 DA05785 transformed cell line human CVCL_8L42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118853 CVCL_8L41 DA05784 transformed cell line human CVCL_8L41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118854 CVCL_8L44 DA05789 transformed cell line human CVCL_8L44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118855 CVCL_8L43 DA05788 transformed cell line human CVCL_8L43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118856 CVCL_8L40 DA05783 transformed cell line human CVCL_8L40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118857 CVCL_8L49 DA05794 transformed cell line human CVCL_8L49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118858 CVCL_8L46 DA05791 transformed cell line human CVCL_8L46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118859 CVCL_8L45 DA05790 transformed cell line human CVCL_8L45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118860 CVCL_8L48 DA05793 transformed cell line human CVCL_8L48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118861 CVCL_8L47 DA05792 transformed cell line human CVCL_8L47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118862 CVCL_8L53 DA05800 transformed cell line human CVCL_8L53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118863 CVCL_8L52 DA05799 transformed cell line human CVCL_8L52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118864 CVCL_8L55 DA05802 transformed cell line human CVCL_8L55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118865 CVCL_8L54 DA05801 transformed cell line human CVCL_8L54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118866 CVCL_8L51 DA05798 transformed cell line human CVCL_8L51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118867 CVCL_8L50 DA05795 transformed cell line human CVCL_8L50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118868 CVCL_8L57 DA05807 transformed cell line human CVCL_8L57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118869 CVCL_8L56 DA05806 transformed cell line human CVCL_8L56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118870 CVCL_8L59 DA05809 transformed cell line human CVCL_8L59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118871 CVCL_8L58 DA05808 transformed cell line human CVCL_8L58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118872 CVCL_8L20 DA05763 transformed cell line human CVCL_8L20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118873 CVCL_8L22 DA05765 transformed cell line human CVCL_8L22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118874 CVCL_8L21 DA05764 transformed cell line human CVCL_8L21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118875 CVCL_8L28 DA05771 transformed cell line human CVCL_8L28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118876 CVCL_8L27 DA05770 transformed cell line human CVCL_8L27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118877 CVCL_8L29 DA05772 transformed cell line human CVCL_8L29 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118878 CVCL_8L24 DA05767 transformed cell line human CVCL_8L24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118879 CVCL_0390 LI90 cancer cell line human CVCL_0390 CL:0000010 Population: Japanese; Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Omics: SNP array analysis Discontinued: JCRB; NIHS0234; true Female 21118880 CVCL_8L23 DA05766 transformed cell line human CVCL_8L23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118881 CVCL_8L26 DA05769 transformed cell line human CVCL_8L26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118882 CVCL_0392 LN-18 cancer cell line human CVCL_0392 HLA typing: A*02:01,24:02; B*35:03,51:01; C*04:01,14:02 (PubMed=26589293); Genome ancestry: African=0.83%; Native American=0.22%; East Asian, North=3.7%; East Asian, South=0%; South Asian=0.94%; European, North=53.19%; European, South=41.12% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Glu1051Lys (c.3151G>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Ser (c.713G>C); ClinVar=VCV000376575; Zygosity=Homozygous (PubMed=7732013; PubMed=10416987; PubMed=14614447; Cosmic-CLP; DepMap) Derived from sampling site: Brain; right temporal lobe. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=7211194); 33 hours (PubMed=9842975); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21118883 CVCL_8L25 DA05768 transformed cell line human CVCL_8L25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118884 CVCL_0391 LLC-PK1 spontaneously immortalized cell line pig CVCL_0391 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-1392; true Male Doubling time: ~24 hours (DSMZ=ACC-637) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-101 21118885 CVCL_0383 L2 spontaneously immortalized cell line Norway rat CVCL_0383 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: Lewis. Female 21118886 CVCL_0382 L1210 cancer cell line house mouse CVCL_0382 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Omics: SNP array analysis Female Doubling time: 10-12 hours (CLS); ~50 hours (DSMZ=ACC-123) Part of: ENCODE project mouse cell lines 21118887 CVCL_0385 L6 transformed cell line Norway rat CVCL_0385 CL:0000010 Anecdotal: Called L6 by David Yaffe because he and Sara Neuman established the cell line during the Six-Day war in 1967 (PubMed=33117511) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21118888 CVCL_0384 L3.6pl cancer cell line human CVCL_0384 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female Doubling time: 16 hours (PubMed=10935470) 21118889 CVCL_0387 LAD 2 factor-dependent cell line human CVCL_0387 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.. Male Characteristics: KITLG dependent Doubling time: ~14 days (DOI=10.1016/j.jaci.2018.12.550) 21118890 CVCL_0386 L6E9 transformed cell line Norway rat CVCL_0386 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21118891 CVCL_0389 LA-N-5 cancer cell line human CVCL_0389 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380) Miscellaneous: On the basis that LA-350 (Cellosaurus=CVCL_AR50) and LA-N-5 are both established by Seeger R.C., that they share identical STR profiles and that LA-350 is said to originate from a patient suffering from neuroblastoma we have annotated them as being autologous cell lines Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: ATAC-seq; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL96022; true Male Doubling time: ~100 hours (DSMZ=ACC-673) 21118892 CVCL_0388 LAMA-84 cancer cell line human CVCL_0388 HLA typing: A*02:01:01,25:01:01; B*18:01:01,44:02:01; C*05:01:01,12:03:01; DPA1*01:03:01,02:01:01; DQB1*06:02:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-168); Genome ancestry: African=14.08%; Native American=0%; East Asian, North=1.13%; East Asian, South=1.46%; South Asian=1.64%; European, North=29.64%; European, South=52.05% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=3476310); 36 hours (PubMed=25984343); ~50 hours (DSMZ=ACC-168); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21118893 CVCL_8L31 DA05774 transformed cell line human CVCL_8L31 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118894 CVCL_8L30 DA05773 transformed cell line human CVCL_8L30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118895 CVCL_8L33 DA05776 transformed cell line human CVCL_8L33 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118896 CVCL_8L32 DA05775 transformed cell line human CVCL_8L32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118897 CVCL_8L39 DA05782 transformed cell line human CVCL_8L39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118898 CVCL_8L38 DA05781 transformed cell line human CVCL_8L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118899 CVCL_8L35 DA05778 transformed cell line human CVCL_8L35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118900 CVCL_8L34 DA05777 transformed cell line human CVCL_8L34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118901 CVCL_8L37 DA05780 transformed cell line human CVCL_8L37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118902 CVCL_8L36 DA05779 transformed cell line human CVCL_8L36 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118903 CVCL_0394 LN-308 cancer cell line human CVCL_0394 Genome ancestry: African=0.02%; Native American=0.47%; East Asian, North=2.42%; East Asian, South=0%; South Asian=0%; European, North=44.33%; European, South=52.76% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=10416987; PubMed=14614447) Derived from sampling site: Brain; right parieto-occipital lobe. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 59 hours (PubMed=9842975); 30 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21118904 CVCL_0393 LN-229 cancer cell line human CVCL_0393 HLA typing: A*03:01:01; B*35:01; C*04:01:01 (PubMed=27412690); HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:01,11:19 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.23%; East Asian, South=0%; South Asian=0.02%; European, North=59.47%; European, South=38.27% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (PubMed=10416987; Cosmic-CLP) Derived from sampling site: Brain; right frontal parieto-occipital cortex. Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=9842975); 31 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21118905 CVCL_0396 B104-1-1 transformed cell line house mouse CVCL_0396 CL:0000010 Transfected with: RGD; 2561; Erbb2 (with p.Val661Glu) Transformant: Activated Erbb2/neu; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21118906 CVCL_0395 LNCaP cancer cell line human CVCL_0395 HLA typing: A*01:01,02:01; B*08:01,37:04; C*06:02,07:01; DQB1*05:01,05:01; DRB1*10:01,10:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=22213130); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from child cell line LNCaP clone FGC); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from child cell line LNCaP clone FGC); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (PubMed=9090379); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Glycoproteome analysis by proteomics; Omics: GPI-anchored proteins analysis by proteomics; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE); Omics: Virome analysis using proteomics Male Doubling time: ~60 hours (DSMZ=ACC-256); Microsatellite instability: Instable (MSI) (PubMed=23671654) Group: Space-flown cell line (cellonaut); Part of: ENCODE project common cell types; tier 3 21118907 CVCL_0398 LbetaT2 transformed cell line house mouse CVCL_0398 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6 x BALB/c transgenic. Female Characteristics: Widely used as an in vitro model for the study of gonadotropin gene regulation and GnRH signaling (Millipore); Characteristics: Expresses CGA, GnRH-R and the alpha and beta subunits of LH (PubMed=8770922) 21118908 CVCL_0397 LS180 cancer cell line human CVCL_0397 HLA typing: A*02; B*13,50 (ATCC=CL-187); HLA typing: A*30:01,30:01; B*07:12,15:50; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=1.1%; Native American=0%; East Asian, North=0.33%; East Asian, South=0.79%; South Asian=7.05%; European, North=35.25%; European, South=55.48% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Homozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=20570890; PubMed=24755471; ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: N-glycan profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CCL-187; probable Female Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Group: Patented cell line; Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: NCI RAS program mutant KRAS cell line panel; Part of: RAS genetic alteration cell panel (ATCC TCP-1031); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-187 21118909 CVCL_0399 LoVo cancer cell line human CVCL_0399 HLA typing: A*01:01,32:01; B*27:08,57:01; C*06:02,06:02; DQA1*03:02,05:02; DQB1*06:13,06:13; DRB1*09:07,13:10 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0.96%; European, North=71.69%; European, South=27.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (PubMed=8197130; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9715273; PubMed=15900046; PubMed=16418264) Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: TKG; TKG 0344; probable Male Doubling time: 37 hours (PubMed=1260746); 52 hours (PubMed=25984343); ~48 hours (DSMZ=ACC-350); ~34 hours (PBCF); Microsatellite instability: Instable (MSI-high) (PubMed=9000147; PubMed=10674020; PubMed=12661003; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21118910 CVCL_8L00 DA05740 transformed cell line human CVCL_8L00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118911 CVCL_8L06 DA05746 transformed cell line human CVCL_8L06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118912 CVCL_8L05 DA05745 transformed cell line human CVCL_8L05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118913 CVCL_8L08 DA05748 transformed cell line human CVCL_8L08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118914 CVCL_8L07 DA05747 transformed cell line human CVCL_8L07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118915 CVCL_8L02 DA05742 transformed cell line human CVCL_8L02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118916 CVCL_8L01 DA05741 transformed cell line human CVCL_8L01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118917 CVCL_8L04 DA05744 transformed cell line human CVCL_8L04 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118918 CVCL_0370 KAT-5 cancer cell line human CVCL_0370 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00223 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma. 21118919 CVCL_8L03 DA05743 transformed cell line human CVCL_8L03 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118920 CVCL_0361 JB6 Cl 30-7b spontaneously immortalized cell line house mouse CVCL_0361 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21118921 CVCL_0360 JAR cancer cell line human CVCL_0360 Genome ancestry: African=30.11%; Native American=0.66%; East Asian, North=2.4%; East Asian, South=0%; South Asian=1.4%; European, North=42.28%; European, South=23.14% (PubMed=30894373) CL:0000010 Karyotypic information: Near triploid karyotype (PubMed=33096371) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~20-30 hours (DSMZ=ACC-462); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Established from the trophoblastic tumor of the placenta of a 24 year old woman, but the cell line is from the male fetus. 21118922 CVCL_0363 JEG-3 cancer cell line human CVCL_0363 Genome ancestry: African=0.01%; Native American=0.09%; East Asian, North=0.97%; East Asian, South=0%; South Asian=0.9%; European, North=71.88%; European, South=26.16% (PubMed=30894373) CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33096371); Derived from metastatic site: Fetal brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Established by serial cloning into hamster cheek pouches Doubling time: ~24 hours (DSMZ=ACC-463); ~36 hours (CLS); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: A TP53 mutation is indicated as being at p.Gln167His (c.501G>T) in PubMed=7819056 but has not been confirmed by CCLE and Cosmic-CLP 21118923 CVCL_0362 JB6 Cl 41-5a spontaneously immortalized cell line house mouse CVCL_0362 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21118924 CVCL_0365 JR-St cancer cell line human CVCL_0365 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Unspecified (PubMed=1370612) Population: Japanese; Derived from metastatic site: Cerebrospinal fluid. Female Doubling time: 72 hours, at 20th passage (PubMed=2562403); 35 hours, at 30th passage (PubMed=1848829) 21118925 CVCL_0364 JHH-5 cancer cell line human CVCL_0364 HLA typing: A*24:02,24:02; B*08:01,67:02; C*01:02,12:02; DQA1*01:02,01:02; DQB1*03:02,03:02; DRB1*11:12,15:02 (PubMed=26589293); Genome ancestry: African=0.41%; Native American=0.04%; East Asian, North=81.84%; East Asian, South=17.72%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gln6Argfs*22 (c.17_18delAG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190_His193del (c.569_580del12); Zygosity=Unspecified (DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0279; true. Male Doubling time: 30.39 hours (PubMed=31378681); ~40 hours (lot 03112003), ~2 days (lot 03022011), ~29 hours (lot 09272018), ~1 day (lot 08252021) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Liver Cancer Model Repository (LIMORE); Part of: TCGA-110-CL cell line panel 21118926 CVCL_0367 Jurkat E6.1 cancer cell line human CVCL_0367 HLA typing: A*03:01,03:01; B*07:02,35:03; C*04:01,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (PubMed=29739316); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (PubMed=29739316); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (PubMed=29739316); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (PubMed=29739316); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (PubMed=29739316); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872; PubMed=29739316); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (PubMed=29739316) Anecdotal: Have been flown in space on shuttle flights STS-76, STS-80 and STS-95 to study apoptosis and cytoskeleton modifications (PubMed=9707173; PubMed=10832058; PubMed=11481229; PubMed=11669127) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Cell surface proteome; Omics: Deep phosphoproteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Genome sequenced; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20.7 +- 2.2 hours (PubMed=10468210) Group: Space-flown cell line (cellonaut); Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21118927 CVCL_0366 SNU-423 cancer cell line human CVCL_0366 HLA typing: A*11:01,33:03; B*15:02,58:01; C*03:02,08:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.82%; East Asian, North=62.68%; East Asian, South=36.24%; South Asian=0%; European, North=0%; European, South=0.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-2A>G; ClinVar=VCV000186236; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8824565; PubMed=31378681; DepMap) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=7543080); 36.62 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21118928 CVCL_0369 K562YO cancer cell line human CVCL_0369 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21118929 CVCL_0368 K562/A02 cancer cell line human CVCL_0368 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Pleural effusion. Female 21118930 CVCL_8L11 DA05754 transformed cell line human CVCL_8L11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118931 CVCL_8L10 DA05753 transformed cell line human CVCL_8L10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118932 CVCL_8L17 DA05760 transformed cell line human CVCL_8L17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118933 CVCL_8L16 DA05759 transformed cell line human CVCL_8L16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118934 CVCL_8L19 DA05762 transformed cell line human CVCL_8L19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118935 CVCL_8L18 DA05761 transformed cell line human CVCL_8L18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118936 CVCL_8L13 DA05756 transformed cell line human CVCL_8L13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118937 CVCL_8L12 DA05755 transformed cell line human CVCL_8L12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118938 CVCL_8L15 DA05758 transformed cell line human CVCL_8L15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118939 CVCL_0381 KYN-2 cancer cell line human CVCL_0381 HLA typing: A*24:02,24:02; B*52:01; C*12:02; DQA1*01:02,03:01; DQB1*04:01,05:02; DRB1*04:05,16:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 28 hours (in DMEMA + 10% FBS), 68 hours (in HB101), 42 hours (in CDM) (PubMed=2847482) 21118940 CVCL_8L14 DA05757 transformed cell line human CVCL_8L14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118941 CVCL_0380 KVL-1 cancer cell line house mouse CVCL_0380 CL:0000010 21118942 CVCL_0372 KB cancer cell line human CVCL_0372 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRC; 60017; true; Discontinued: DSMZ; ACC-136; true; Discontinued: ECACC; 86103004; probable; Discontinued: ICLC; HTL96014; true; Discontinued: RCB; RCB1888; true Female Doubling time: ~30 hours (DSMZ=ACC-136) Part of: KuDOS 95 cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00010 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=1246601; PubMed=20143388). Originally thought to originate from an epidermal carcinoma of the mouth. 21118943 CVCL_0371 KATO III cancer cell line human CVCL_0371 HLA typing: A*02,24:02; B*15:01,46:01; C*01:02,03:03 (PubMed=9023415); HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,01:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*08:03,15:01 (PubMed=25960936); HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,03:03; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*08:03,15:01 (PubMed=26589293); Genome ancestry: African=0.78%; Native American=0%; East Asian, North=78.55%; East Asian, South=19.58%; South Asian=1.02%; European, North=0.06%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1370612; PubMed=1933850; PubMed=11107048) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: ChIP-seq GATA4 analysis; Omics: ChIP-seq GATA6 analysis; Omics: ChIP-seq KLF5 analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0052; true Male Doubling time: 36 hours (PubMed=209229); 32-34 hours (PubMed=3962675); 37-41 hours (CelloPub=CLPUB00584); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: MD Anderson Cell Lines Project 21118944 CVCL_0374 KG-1 cancer cell line human CVCL_0374 HLA typing: A*30:02,30:02; B*53:01,78:01; C*04:01,16:01 (PubMed=26589293); HLA typing: A*30:02:01,30:02:01; B*53:01:01,78:01:01; C*04:01:01,16:01:01; DPA1*01:03:01,02:01:01; DPB1*11:01:01,105:01; DQB1*06:02:01,06:02:01; DRA*01:01:01,01:02:02; DRB1*11:01:02,14:54:01 (DSMZCellDive=ACC-14); Genome ancestry: African=84.82%; Native American=0%; East Asian, North=3.33%; East Asian, South=0%; South Asian=0.57%; European, North=3.95%; European, South=7.34% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3688; FGFR1 + HGNC; 23098; FGFR1OP2; Name(s)=FGFR1OP2-FGFR1 (PubMed=31160637); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=9379676); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=1571549; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1944; true; Discontinued: TKG; TKG 0400; true Male Characteristics: Mostly at the myeloblast or promyelocyte stage of maturation Doubling time: ~38 hours (DSMZ=ACC-14); 45 hours (CLS); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8031 21118945 CVCL_0373 KBM-5 cancer cell line human CVCL_0373 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8339266; PubMed=10071072); Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Gly710Ter (c.2128G>T); Zygosity=Homozygous (PubMed=26623729); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=7627932; PubMed=26623729) Derived from sampling site: Peripheral blood. Female Doubling time: 24-60 hours (PubMed=8339266) 21118946 CVCL_0376 KM-102 transformed cell line human CVCL_0376 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Male 21118947 CVCL_8L09 DA05749 transformed cell line human CVCL_8L09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21118948 CVCL_0375 KGN cancer cell line human CVCL_0375 Genome ancestry: African=0%; Native American=0.09%; East Asian, North=73.92%; East Asian, South=24.17%; South Asian=1.82%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1092; FOXL2; Simple; p.Cys134Trp (c.402C>G); ClinVar=VCV000376348; Zygosity=Heterozygous (PubMed=19956657; PubMed=20098707) Population: Japanese; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 46.4 hours (PubMed=11145608); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21118949 CVCL_0378 KNS-42 cancer cell line human CVCL_0378 HLA typing: A*24:02,26:01; B*07:02,54:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.32%; East Asian, North=85.4%; East Asian, South=14.06%; South Asian=0%; European, North=0%; European, South=0.22% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain; right fronto-parietal lobe. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (CelloPub=CLPUB00152; PubMed=19365568); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21118950 CVCL_0377 KRC-7 [Rat hepatoma] cancer cell line Norway rat CVCL_0377 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21118951 CVCL_0379 Ku812 cancer cell line human CVCL_0379 HLA typing: A*24:02,26:01; B*40:02,40:02; C*03:04,04:01; DQA1*03:02,03:02; DQB1*02:02,06:04; DRB1*10:01,14:05 (PubMed=26589293); HLA typing: A*24:02:01,26:01:01; B*40:01:02,40:02:01; C*03:04:01,04:82 (DSMZCellDive=ACC-378); Genome ancestry: African=0%; Native American=0.62%; East Asian, North=85.34%; East Asian, South=12.57%; South Asian=0.16%; European, North=0.88%; European, South=0.42% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Basophil progenitor cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~80-100 hours (DSMZ=ACC-378); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21118952 CVCL_RX91 19L4 induced pluripotent stem cell human CVCL_RX91 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ala469Thr (c.1405G>A) (p.Ala152Thr, c.454G>A); ClinVar=VCV000323645; Zygosity=Unspecified (PubMed=27594586) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118953 CVCL_S991 C1R-A31 transformed cell line human CVCL_S991 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*31) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118954 CVCL_RX90 19L3 induced pluripotent stem cell human CVCL_RX90 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ala469Thr (c.1405G>A) (p.Ala152Thr, c.454G>A); ClinVar=VCV000323645; Zygosity=Unspecified (PubMed=27594586) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118955 CVCL_S990 C1R-A24 transformed cell line human CVCL_S990 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*24:02) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21118956 CVCL_RX93 3L9 induced pluripotent stem cell human CVCL_RX93 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (PubMed=27594586) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118957 CVCL_S993 STY51 cancer cell line human CVCL_S993 CL:0000010 Omics: SNP array analysis. 21118958 CVCL_RX92 3L6 induced pluripotent stem cell human CVCL_RX92 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (PubMed=27594586) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21118959 CVCL_S992 UM-UC-12 cancer cell line human CVCL_S992 CL:0000010 Omics: CNV analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index 21118961 CVCL_S995 Mel-AT cancer cell line human CVCL_S995 CL:0000010 Derived from metastatic site: Lymph node. 21118962 CVCL_RX94 3L1 induced pluripotent stem cell human CVCL_RX94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21118963 CVCL_S994 Mel-RMu cancer cell line human CVCL_S994 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533; PubMed=23455323); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Lymph node. Unspecified 21118965 CVCL_S997 Mel-GL cancer cell line human CVCL_S997 CL:0000010 21118967 CVCL_S996 Mel-CV cancer cell line human CVCL_S996 CL:0000010 Derived from metastatic site: Lymph node. 21118968 CVCL_RX99 BC1 induced pluripotent stem cell human CVCL_RX99 CL:0000010 Discontinued: Thermofisher/MTI-GlobalStem; Catalog number GSC-4311. Female 21118969 CVCL_S999 Mel-JC cancer cell line human CVCL_S999 CL:0000010 Derived from metastatic site: Lymph node. 21118970 CVCL_RX98 EC/CUHK2 cancer cell line human CVCL_RX98 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Male 21118971 CVCL_S998 Mel-JB cancer cell line human CVCL_S998 CL:0000010 Derived from metastatic site: Lymph node. 21118972 CVCL_0341 IC-2 factor-dependent cell line house mouse CVCL_0341 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2. Female Characteristics: CSF2 and IL3 dependent 21118973 CVCL_0340 IBEP-2 cancer cell line human CVCL_0340 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 29 hours (PubMed=9610725) 21118974 CVCL_0343 IEC-6 finite cell line Norway rat CVCL_0343 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male Senescence: Capable of at least 10 PDL; Doubling time: ~20 hours (PubMed=88453); ~50 hours (DSMZ=ACC-111) 21118975 CVCL_0342 IEC-18 finite cell line Norway rat CVCL_0342 CL:0000010 Derived from sampling site: Small intestine; ileum Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Discontinued: IZSLER; BS CL 224; probable Unspecified Senescence: Capable of at least 20 PDL; Doubling time: 16.6 hours (PubMed=6273638) 21118976 CVCL_0345 IMIM-PC2 cancer cell line human CVCL_0345 HLA typing: A*25; B*18 (PubMed=8795137) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=8026879; PubMed=11787853) Karyotypic information: Has lost chromosome Y; Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Male Doubling time: 33.6 hours (PubMed=7723277) 21118977 CVCL_0344 IHKE-1 transformed cell line human CVCL_0344 CL:0000010 Transformant: Nickel(2+)(ChEBI; CHEBI:49786); Derived from sampling site: Fetal kidney; cortex Cell type=Epithelial cell.. Unspecified 21118978 CVCL_0347 IMR-90 finite cell line human CVCL_0347 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H2A.Z ChIP-seq epigenome analysis; Omics: H2AK5ac ChIP-seq epigenome analysis; Omics: H2AK9ac ChIP-seq epigenome analysis; Omics: H2BK120ac ChIP-seq epigenome analysis; Omics: H2BK12ac ChIP-seq epigenome analysis; Omics: H2BK15ac ChIP-seq epigenome analysis; Omics: H2BK20ac ChIP-seq epigenome analysis; Omics: H2BK5ac ChIP-seq epigenome analysis; Omics: H3K14ac ChIP-seq epigenome analysis; Omics: H3K18ac ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K56ac ChIP-seq epigenome analysis; Omics: H3K79me1 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me1 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: H4K5ac ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: H4K91ac ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7931; true; Discontinued: Coriell; I90-52; probable; Discontinued: Coriell; I90-78; probable Female Senescence: Capable of attaining 58 population doublings before the onset of senescence (ATCC=CCL-186) Part of: ENCODE project common cell types; tier 2; Part of: International Histocompatibility Workshop cell lines; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21118979 CVCL_0346 IMR-32 cancer cell line human CVCL_0346 HLA typing: A*24:02,24:02; B*07:05,07:05; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.56%; East Asian, North=1.01%; East Asian, South=0%; South Asian=3.99%; European, North=73.7%; European, South=20.72% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Abdomen. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; AG03320; probable; Discontinued: RCB; RCB1895; true Male Characteristics: Neuroblastic type (N-type) Doubling time: 48 hours (PubMed=5459762); ~20 hours (ATCC=CCL-127); ~40-50 hours (DSMZ=ACC-165) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21118980 CVCL_0349 iMycEmu-2 cancer cell line house mouse CVCL_0349 CL:0000010 Breed/subspecies: iMycEmu transgenic. 21118981 CVCL_0348 iMycEmu-1 cancer cell line house mouse CVCL_0348 CL:0000010 Breed/subspecies: iMycEmu transgenic. Female 21118982 CVCL_RX80 MZ-226 cancer cell line human CVCL_RX80 CL:0000010 Unspecified 21118983 CVCL_S980 QG-90 cancer cell line human CVCL_S980 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=11583962). Population: Japanese Unspecified 21118984 CVCL_S982 PC-3 [Human lung carcinoma] cancer cell line human CVCL_S982 Genome ancestry: African=0.27%; Native American=0%; East Asian, North=77.82%; East Asian, South=20.28%; South Asian=0%; European, North=0%; European, South=1.63% (PubMed=30894373) From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Ala750delinsPro (c.2239_2248delinsC) (c.2239_2248TTAAGAGAAG>C); ClinVar=VCV000177684; Zygosity=Unspecified (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 41.7 hours (PubMed=8286010); ~90 hours (lot 01072008), ~45 hours (lot 09302011), 2-4 days (lot 07162019) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21118985 CVCL_RX82 STBCi006-A-3 induced pluripotent stem cell human CVCL_RX82 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21118986 CVCL_RX81 MZ-290 cancer cell line human CVCL_RX81 CL:0000010 Unspecified 21118987 CVCL_S981 QG-96 cancer cell line human CVCL_S981 CL:0000010 Population: Japanese. Unspecified 21118988 CVCL_S984 BIN-16 cancer cell line human CVCL_S984 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21118989 CVCL_RX84 STKM-1 clone R3 cancer cell line human CVCL_RX84 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female 21118990 CVCL_S983 GIST-T1/829 cancer cell line human CVCL_S983 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=22665524); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Ala829Pro (c.2485G>C); ClinVar=VCV000375933; Zygosity=Heterozygous (PubMed=22665524) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Female 21118991 CVCL_RX83 UKBi011-A-3 induced pluripotent stem cell human CVCL_RX83 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple_corrected; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33556820) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21118992 CVCL_S986 BIN-53 cancer cell line human CVCL_S986 CL:0000010 Derived from metastatic site: Ascites. Female 21118993 CVCL_RX86 Dox-pDC conditionally immortalized cell line house mouse CVCL_RX86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Plasmacytoid dendritic cell.; Breed/subspecies: Rosa-rtTA-flox-Tag+ transgenic. Female Characteristics: Stably proliferates by doxycycline-induction of the expression of the SV40 large T antigen After withdrawal of doxycycline will stop proliferate and will undergo apoptosis within 3 days. Doubling time: 2.4 +- 0.3 days (PubMed=29489861) 21118994 CVCL_S985 BIN-22 cancer cell line human CVCL_S985 CL:0000010 Derived from metastatic site: Ascites. Female 21118995 CVCL_RX85 STKM-1 clone S4 cancer cell line human CVCL_RX85 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female 21118997 CVCL_S988 OS-1 cancer cell line human CVCL_S988 CL:0000010 Population: Japanese; Derived from metastatic site: Uterus. Female Doubling time: ~30 hours (PubMed=16035505) 21118998 CVCL_S987 BIN-67 cancer cell line human CVCL_S987 CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; c.2438+1G>A; ClinVar=VCV000537781; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=24658002; DepMap); Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; c.2439-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24658002; DepMap) Miscellaneous: STR profile from personal communication of Garson K Derived from metastatic site: Pelvis. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21118999 CVCL_RX87 FUi001-A-1 induced pluripotent stem cell human CVCL_RX87 From: Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University; Fukuoka; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple_corrected; p.Arg1645Ter (c.4933C>T); ClinVar=VCV000189921; Zygosity=Heterozygous; Note=By TALEN (PubMed=29453127) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119000 CVCL_RX89 ENAMI-1 cancer cell line human CVCL_RX89 CL:0000010 Population: Japanese Female Doubling time: 72 hours (CelloPub=CLPUB00142). 21119001 CVCL_S989 SKS cancer cell line human CVCL_S989 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn131del (c.390_392delCAA); Zygosity=Unspecified (PubMed=11408806) Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 44 hours (PubMed=11408806) 21119002 CVCL_0350 IN157 cancer cell line human CVCL_0350 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (PubMed=1620276); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Problematic cell line: Contaminated Shown to be a RD derivative (PubMed=1620276). Originally thought to originate from an oligodendroglioma. 21119003 CVCL_0352 INS-1 cancer cell line Norway rat CVCL_0352 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Established from the transplantable insulinoma RIN 21119004 CVCL_0351 INS-1E cancer cell line Norway rat CVCL_0351 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Discontinued: AddexBio; C0018009; true Male Characteristics: Used in numerous studies investigating the mechanisms of glucose stimulated insulin secretion Is glucose responsive in a physiological range with substantial insulin content levels and a robust metabolism-secretion coupling (PubMed=30310992). Caution: This cell line is owned by the University of Geneva, Switzerland, who is the sole authorized distributor for both commercial and non-commercial research use 21119005 CVCL_0354 J.CaM1.6 cancer cell line human CVCL_0354 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Deficient for LCK activity due to a deletion of exon 7 21119006 CVCL_0353 In-R1-G9 cancer cell line CVCL_0353 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Pancreas; islets of Langerhans. Characteristics: Produces glucagon (PubMed=2869020) 21119007 CVCL_0356 J7.DEF.3 cancer cell line house mouse CVCL_0356 CL:0000010 Breed/subspecies: BALB/c. Female 21119008 CVCL_0355 J2E transformed cell line house mouse CVCL_0355 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Embryonic liver Cell type=Erythroblast.; Breed/subspecies: CBA. Unspecified Characteristics: Differentiates and synthesizes hemoglobin following exposure to EPO 21119009 CVCL_0358 J774A1 cancer cell line house mouse CVCL_0358 CL:0000010 Breed/subspecies: BALB/c. Discontinued: JCRB; IFO50023; true Female Doubling time: ~17 hours (ATCC=TIB-67); ~35 hours (DSMZ=ACC-170) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21119010 CVCL_0357 J774.2 cancer cell line house mouse CVCL_0357 CL:0000010 Breed/subspecies: BALB/c. Omics: Cell surface proteome Female 21119011 CVCL_0359 J82 cancer cell line human CVCL_0359 HLA typing: A*02,w32; B*05,12; C*w02,w03 (PubMed=77569); HLA typing: A*02:01,32:01; B*44:02,51:01; C*05:01,15:02 (PubMed=26589293); Genome ancestry: African=0.13%; Native American=0%; East Asian, North=2.62%; East Asian, South=0%; South Asian=0.42%; European, North=70.61%; European, South=26.21% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=2594029; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (PubMed=7787250; PubMed=9850064; ATCC) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030); Part of: UBC-40 urothelial bladder cancer cell line index 21119012 CVCL_AF56 HPSI0513i-kesz_2 induced pluripotent stem cell human CVCL_AF56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119013 CVCL_AF55 HPSI0513i-kesz_1 induced pluripotent stem cell human CVCL_AF55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119014 CVCL_AF58 HPSI0513i-leeh_3 induced pluripotent stem cell human CVCL_AF58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119015 CVCL_AF57 HPSI0513i-leeh_2 induced pluripotent stem cell human CVCL_AF57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119016 CVCL_AF59 HPSI0513i-momt_2 induced pluripotent stem cell human CVCL_AF59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119017 CVCL_AF50 HPSI0513i-giuf_3 induced pluripotent stem cell human CVCL_AF50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119018 CVCL_AF52 HPSI0513i-huls_1 induced pluripotent stem cell human CVCL_AF52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119019 CVCL_AF51 HPSI0513i-golb_1 induced pluripotent stem cell human CVCL_AF51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119020 CVCL_AF54 HPSI0513i-iasn_3 induced pluripotent stem cell human CVCL_AF54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119021 CVCL_AF53 HPSI0513i-iasn_2 induced pluripotent stem cell human CVCL_AF53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119022 CVCL_AF67 HPSI0513i-sucd_3 induced pluripotent stem cell human CVCL_AF67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119023 CVCL_AF66 HPSI0513i-pedc_1 induced pluripotent stem cell human CVCL_AF66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119024 CVCL_AF69 HPSI0513i-uilw_1 induced pluripotent stem cell human CVCL_AF69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119025 CVCL_AF68 HPSI0513i-suzg_3 induced pluripotent stem cell human CVCL_AF68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119026 CVCL_AF61 HPSI0513i-oarz_2 induced pluripotent stem cell human CVCL_AF61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119027 CVCL_AF60 HPSI0513i-netf_2 induced pluripotent stem cell human CVCL_AF60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119028 CVCL_AF63 HPSI0513i-oeoo_2 induced pluripotent stem cell human CVCL_AF63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119029 CVCL_AF62 HPSI0513i-oarz_22 induced pluripotent stem cell human CVCL_AF62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119030 CVCL_AF65 HPSI0513i-oogu_2 induced pluripotent stem cell human CVCL_AF65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119031 CVCL_AF64 HPSI0513i-oibg_1 induced pluripotent stem cell human CVCL_AF64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119032 CVCL_AF34 HPSI0513i-coio_1 induced pluripotent stem cell human CVCL_AF34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119033 CVCL_AF33 HPSI0513i-cehw_3 induced pluripotent stem cell human CVCL_AF33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119034 CVCL_AF36 HPSI0513i-cuau_1 induced pluripotent stem cell human CVCL_AF36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119035 CVCL_AF35 HPSI0513i-coio_2 induced pluripotent stem cell human CVCL_AF35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119036 CVCL_AF38 HPSI0513i-debk_7 induced pluripotent stem cell human CVCL_AF38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119037 CVCL_AF37 HPSI0513i-cuau_2 induced pluripotent stem cell human CVCL_AF37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119038 CVCL_AF39 HPSI0513i-debk_9 induced pluripotent stem cell human CVCL_AF39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119039 CVCL_AF30 HPSI0513i-aipt_3 induced pluripotent stem cell human CVCL_AF30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119040 CVCL_AF32 HPSI0513i-bicb_3 induced pluripotent stem cell human CVCL_AF32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119041 CVCL_AF31 HPSI0513i-aipt_33 induced pluripotent stem cell human CVCL_AF31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119042 CVCL_AF45 HPSI0513i-euir_1 induced pluripotent stem cell human CVCL_AF45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119043 CVCL_AF44 HPSI0513i-dulv_2 induced pluripotent stem cell human CVCL_AF44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119044 CVCL_AF47 HPSI0513i-fejf_2 induced pluripotent stem cell human CVCL_AF47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119045 CVCL_AF46 HPSI0513i-euir_2 induced pluripotent stem cell human CVCL_AF46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119046 CVCL_AF49 HPSI0513i-giuf_1 induced pluripotent stem cell human CVCL_AF49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119047 CVCL_AF48 HPSI0513i-fejf_3 induced pluripotent stem cell human CVCL_AF48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119048 CVCL_AF41 HPSI0513i-dovq_3 induced pluripotent stem cell human CVCL_AF41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119049 CVCL_AF40 HPSI0513i-dipe_1 induced pluripotent stem cell human CVCL_AF40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119050 CVCL_AF43 HPSI0513i-dulv_1 induced pluripotent stem cell human CVCL_AF43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119051 CVCL_AF42 HPSI0513i-dovq_33 induced pluripotent stem cell human CVCL_AF42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119052 CVCL_8L86 DA05841 transformed cell line human CVCL_8L86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119053 CVCL_8L85 DA05840 transformed cell line human CVCL_8L85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119054 CVCL_8L88 DA05844 transformed cell line human CVCL_8L88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119055 CVCL_8L87 DA05843 transformed cell line human CVCL_8L87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119056 CVCL_8L82 DA05837 transformed cell line human CVCL_8L82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119057 CVCL_8L81 DA05836 transformed cell line human CVCL_8L81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119058 CVCL_8L84 DA05839 transformed cell line human CVCL_8L84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119059 CVCL_8L83 DA05838 transformed cell line human CVCL_8L83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119060 CVCL_AF19 HPSI0414i-kefk_2 induced pluripotent stem cell human CVCL_AF19 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Bulgarian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119061 CVCL_8L89 DA05845 transformed cell line human CVCL_8L89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119062 CVCL_AF12 HPSI0414i-ceik_2 induced pluripotent stem cell human CVCL_AF12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119063 CVCL_AF11 HPSI0414i-ceik_1 induced pluripotent stem cell human CVCL_AF11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119064 CVCL_AF14 HPSI0414i-eafb_1 induced pluripotent stem cell human CVCL_AF14 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119065 CVCL_AF13 HPSI0414i-cekz_1 induced pluripotent stem cell human CVCL_AF13 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119066 CVCL_AF16 HPSI0414i-fuai_1 induced pluripotent stem cell human CVCL_AF16 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian and Cuban; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21119067 CVCL_AF15 HPSI0414i-fixm_2 induced pluripotent stem cell human CVCL_AF15 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119068 CVCL_AF18 HPSI0414i-jetz_1 induced pluripotent stem cell human CVCL_AF18 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: DNA methylation analysis Female 21119069 CVCL_AF17 HPSI0414i-hutq_1 induced pluripotent stem cell human CVCL_AF17 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119070 CVCL_8L80 DA05834 transformed cell line human CVCL_8L80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119071 CVCL_AF10 HPSI0414i-biiw_1 induced pluripotent stem cell human CVCL_AF10 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21119072 CVCL_8L97 DA05854 transformed cell line human CVCL_8L97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119073 CVCL_8L96 DA05853 transformed cell line human CVCL_8L96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119074 CVCL_8L99 DA05856 transformed cell line human CVCL_8L99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119075 CVCL_8L98 DA05855 transformed cell line human CVCL_8L98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119076 CVCL_8L93 DA05850 transformed cell line human CVCL_8L93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119077 CVCL_8L92 DA05848 transformed cell line human CVCL_8L92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119078 CVCL_8L95 DA05852 transformed cell line human CVCL_8L95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119079 CVCL_8L94 DA05851 transformed cell line human CVCL_8L94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119080 CVCL_AF23 HPSI0414i-puvg_1 induced pluripotent stem cell human CVCL_AF23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119081 CVCL_AF22 HPSI0414i-mita_2 induced pluripotent stem cell human CVCL_AF22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119082 CVCL_AF25 HPSI0414i-reng_4 induced pluripotent stem cell human CVCL_AF25 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119083 CVCL_AF24 HPSI0414i-rauj_1 induced pluripotent stem cell human CVCL_AF24 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119084 CVCL_AF27 HPSI0414i-walu_1 induced pluripotent stem cell human CVCL_AF27 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119085 CVCL_AF26 HPSI0414i-tout_1 induced pluripotent stem cell human CVCL_AF26 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119086 CVCL_AF29 HPSI0414i-xugr_2 induced pluripotent stem cell human CVCL_AF29 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119087 CVCL_AF28 HPSI0414i-wize_1 induced pluripotent stem cell human CVCL_AF28 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119088 CVCL_8L91 DA05847 transformed cell line human CVCL_8L91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119089 CVCL_8L90 DA05846 transformed cell line human CVCL_8L90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119090 CVCL_AF21 HPSI0414i-lavd_2 induced pluripotent stem cell human CVCL_AF21 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119091 CVCL_AF20 HPSI0414i-kodf_2 induced pluripotent stem cell human CVCL_AF20 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119092 CVCL_8L64 DA05818 transformed cell line human CVCL_8L64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119093 CVCL_8L63 DA05817 transformed cell line human CVCL_8L63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119094 CVCL_8L66 DA05820 transformed cell line human CVCL_8L66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119095 CVCL_8L65 DA05819 transformed cell line human CVCL_8L65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119096 CVCL_8L60 DA05810 transformed cell line human CVCL_8L60 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119097 CVCL_8L62 DA05812 transformed cell line human CVCL_8L62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119098 CVCL_8L61 DA05811 transformed cell line human CVCL_8L61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119099 CVCL_8L68 DA05822 transformed cell line human CVCL_8L68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119100 CVCL_8L67 DA05821 transformed cell line human CVCL_8L67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119101 CVCL_8L69 DA05823 transformed cell line human CVCL_8L69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119102 CVCL_8L75 DA05829 transformed cell line human CVCL_8L75 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119103 CVCL_8L74 DA05828 transformed cell line human CVCL_8L74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119104 CVCL_8L77 DA05831 transformed cell line human CVCL_8L77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119105 CVCL_8L76 DA05830 transformed cell line human CVCL_8L76 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119106 CVCL_8L71 DA05825 transformed cell line human CVCL_8L71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119107 CVCL_8L70 DA05824 transformed cell line human CVCL_8L70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119108 CVCL_8L73 DA05827 transformed cell line human CVCL_8L73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119109 CVCL_8L72 DA05826 transformed cell line human CVCL_8L72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119110 CVCL_AF09 HPSI0413i-yuze_1 induced pluripotent stem cell human CVCL_AF09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119111 CVCL_AF08 HPSI0413i-yotv_3 induced pluripotent stem cell human CVCL_AF08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119112 CVCL_8L79 DA05833 transformed cell line human CVCL_8L79 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119113 CVCL_8L78 DA05832 transformed cell line human CVCL_8L78 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119114 CVCL_AF01 HPSI0413i-peop_2 induced pluripotent stem cell human CVCL_AF01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119115 CVCL_AF00 HPSI0413i-ougl_3 induced pluripotent stem cell human CVCL_AF00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119116 CVCL_AF03 HPSI0413i-sukz_1 induced pluripotent stem cell human CVCL_AF03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119117 CVCL_AF02 HPSI0413i-peop_4 induced pluripotent stem cell human CVCL_AF02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119118 CVCL_AF05 HPSI0413i-xekf_1 induced pluripotent stem cell human CVCL_AF05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119119 CVCL_AF04 HPSI0413i-uahf_3 induced pluripotent stem cell human CVCL_AF04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119120 CVCL_AF07 HPSI0413i-yotv_2 induced pluripotent stem cell human CVCL_AF07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119121 CVCL_AF06 HPSI0413i-xisg_2 induced pluripotent stem cell human CVCL_AF06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119122 CVCL_AE93 HPSI0413i-coxy_33 induced pluripotent stem cell human CVCL_AE93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119123 CVCL_AE92 HPSI0413i-coxy_3 induced pluripotent stem cell human CVCL_AE92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119124 CVCL_AE95 HPSI0413i-iakz_1 induced pluripotent stem cell human CVCL_AE95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119125 CVCL_AE94 HPSI0413i-gomv_3 induced pluripotent stem cell human CVCL_AE94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119126 CVCL_AE97 HPSI0413i-nudd_1 induced pluripotent stem cell human CVCL_AE97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119127 CVCL_AE96 HPSI0413i-iakz_2 induced pluripotent stem cell human CVCL_AE96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119128 CVCL_AE99 HPSI0413i-ougl_1 induced pluripotent stem cell human CVCL_AE99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119129 CVCL_AE98 HPSI0413i-nudd_6 induced pluripotent stem cell human CVCL_AE98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: EBiSC; WTSIi054-B; true Male 21119130 CVCL_AE80 HPSI0314i-cuhk_2 induced pluripotent stem cell human CVCL_AE80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119131 CVCL_AE79 HPSI0314i-cuhk_1 induced pluripotent stem cell human CVCL_AE79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119132 CVCL_AE78 HPSI0314i-bubh_3 induced pluripotent stem cell human CVCL_AE78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119133 CVCL_AE71 HPSI0313i-cesj_1 induced pluripotent stem cell human CVCL_AE71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119134 CVCL_AE70 HPSI0313i-airc_66 induced pluripotent stem cell human CVCL_AE70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119135 CVCL_AE73 HPSI0313i-fecs_3 induced pluripotent stem cell human CVCL_AE73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119136 CVCL_AE72 HPSI0313i-fecs_1 induced pluripotent stem cell human CVCL_AE72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119137 CVCL_AE75 HPSI0313i-xovo_2 induced pluripotent stem cell human CVCL_AE75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119138 CVCL_AE74 HPSI0313i-xovo_1 induced pluripotent stem cell human CVCL_AE74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119139 CVCL_AE77 HPSI0314i-bubh_1 induced pluripotent stem cell human CVCL_AE77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119140 CVCL_AE76 HPSI0314i-bipt_1 induced pluripotent stem cell human CVCL_AE76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119141 CVCL_AE91 HPSI0413i-corn_1 induced pluripotent stem cell human CVCL_AE91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119142 CVCL_AE90 HPSI0413i-bupo_4 induced pluripotent stem cell human CVCL_AE90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119143 CVCL_AE89 HPSI0314i-xugn_2 induced pluripotent stem cell human CVCL_AE89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119144 CVCL_AE82 HPSI0314i-hoik_1 induced pluripotent stem cell human CVCL_AE82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119145 CVCL_AE81 HPSI0314i-fafq_1 induced pluripotent stem cell human CVCL_AE81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119146 CVCL_AE84 HPSI0314i-qonc_1 induced pluripotent stem cell human CVCL_AE84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119147 CVCL_AE83 HPSI0314i-qaqx_1 induced pluripotent stem cell human CVCL_AE83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119148 CVCL_AE86 HPSI0314i-sojd_2 induced pluripotent stem cell human CVCL_AE86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119149 CVCL_AE85 HPSI0314i-qonc_2 induced pluripotent stem cell human CVCL_AE85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119150 CVCL_AE88 HPSI0314i-xugn_1 induced pluripotent stem cell human CVCL_AE88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119151 CVCL_AE87 HPSI0314i-sojd_3 induced pluripotent stem cell human CVCL_AE87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Gln348Ter (c.1042C>T); Zygosity=Heterozygous (PubMed=31813827) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119152 CVCL_AE57 HPSI0214i-heja_2 induced pluripotent stem cell human CVCL_AE57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119153 CVCL_AE56 HPSI0214i-heja_1 induced pluripotent stem cell human CVCL_AE56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119154 CVCL_AE59 HPSI0214i-kehc_2 induced pluripotent stem cell human CVCL_AE59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119155 CVCL_AE58 HPSI0214i-heth_1 induced pluripotent stem cell human CVCL_AE58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119156 CVCL_AE51 HPSI0214i-feec_2 induced pluripotent stem cell human CVCL_AE51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119157 CVCL_AE50 HPSI0214i-eiwy_1 induced pluripotent stem cell human CVCL_AE50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119158 CVCL_AE53 HPSI0214i-fiau_1 induced pluripotent stem cell human CVCL_AE53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119159 CVCL_AE52 HPSI0214i-feec_3 induced pluripotent stem cell human CVCL_AE52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119160 CVCL_AE55 HPSI0214i-giju_3 induced pluripotent stem cell human CVCL_AE55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119161 CVCL_AE54 HPSI0214i-giju_2 induced pluripotent stem cell human CVCL_AE54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119162 CVCL_AE68 HPSI0313i-airc_2 induced pluripotent stem cell human CVCL_AE68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119163 CVCL_AE67 HPSI0215i-hipn_2 induced pluripotent stem cell human CVCL_AE67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119164 CVCL_AE69 HPSI0313i-airc_6 induced pluripotent stem cell human CVCL_AE69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119165 CVCL_AE60 HPSI0214i-kucg_2 induced pluripotent stem cell human CVCL_AE60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119166 CVCL_AE62 HPSI0214i-pelm_3 induced pluripotent stem cell human CVCL_AE62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119167 CVCL_AE61 HPSI0214i-pelm_1 induced pluripotent stem cell human CVCL_AE61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119168 CVCL_AE64 HPSI0214i-wibj_1 induced pluripotent stem cell human CVCL_AE64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119169 CVCL_AE63 HPSI0214i-rayr_1 induced pluripotent stem cell human CVCL_AE63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119170 CVCL_AE66 HPSI0215i-hipn_1 induced pluripotent stem cell human CVCL_AE66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119171 CVCL_AE65 HPSI0214i-wibj_2 induced pluripotent stem cell human CVCL_AE65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119172 CVCL_RX71 Applied StemCell CF1-MEF irradiated finite cell line house mouse CVCL_RX71 CL:0000010 Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Unspecified Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation 21119173 CVCL_S971 H2T cancer cell line CVCL_S971 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U7QTX5; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Unspecified (PubMed=7809022) Transformant: N-nitrobis(2-hydroxypropyl)amine (BHP)(ChEBI; CHEBI:140063); Derived from sampling site: Pancreas. Male Doubling time: 24-28 hours (PubMed=7089870) 21119174 CVCL_S970 PC-2 [Human pancreatic carcinoma China] cancer cell line human CVCL_S970 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107) Population: Chinese; Derived from metastatic site: Omentum. Male Characteristics: Established from a xenograft established in a nude mice Doubling time: 58 hours (PubMed=2118052) 21119175 CVCL_RX70 XPEMB-1 iPS induced pluripotent stem cell human CVCL_RX70 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27197874) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Unspecified 21119176 CVCL_RX73 EpoNi/22.1 transformed cell line CVCL_RX73 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Bat cell line 21119177 CVCL_S973 HPDE-1/E6E7 transformed cell line human CVCL_S973 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from ampulla of Vater adenocarcinoma; Derived from sampling site: Pancreas Cell type=Ductal cell.. Male 21119178 CVCL_RX72 Applied StemCell CF1-MEF mitomycin-treated finite cell line house mouse CVCL_RX72 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Unspecified Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21119179 CVCL_S972 HPDE-6/E6E7 transformed cell line human CVCL_S972 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from a cystadenocarcinoma in the tail of her pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Female Part of: ENCODE project common cell types; tier 3 21119180 CVCL_RX75 HM02 cancer cell line human CVCL_RX75 CL:0000010 Unspecified 21119181 CVCL_S975 HPDE-5/E6E7 transformed cell line human CVCL_S975 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from multiloculated cystadenoma of pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Female 21119182 CVCL_RX74 HAP1 ANO6(-) 1 cancer cell line human CVCL_RX74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25240; ANO6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21119183 CVCL_S974 HPDE-4/E6E7 transformed cell line human CVCL_S974 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from acute and chronic pancreatitis; Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Proteome analysis by 2D-DE/MS Female 21119184 CVCL_RX77 CTV-2 cancer cell line human CVCL_RX77 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Problematic cell line: Possibly misidentified The sister cell line CTV-1 was originally thought to be a acute monoblastic leukemia but seems to be a T-ALL cell line. CTV-1 was also said to originate from a 40 year old female patient but has a male STR profile. 21119185 CVCL_S977 PC9-DPE2 cancer cell line human CVCL_S977 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3148; TYMP Population: Japanese; Derived from metastatic site: Lymph node. Male 21119186 CVCL_RX76 HM51 cancer cell line human CVCL_RX76 CL:0000010 Unspecified 21119187 CVCL_S976 PL4 cancer cell line human CVCL_S976 Genome ancestry: African=0.4%; Native American=0%; East Asian, North=1.3%; East Asian, South=1.55%; South Asian=0%; European, North=64.99%; European, South=31.75% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21119188 CVCL_RX79 hs SKOM C17 induced pluripotent stem cell pig CVCL_RX79 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Tibetan minipig. Male 21119189 CVCL_S979 PC-12 cancer cell line human CVCL_S979 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 21119190 CVCL_RX78 hs SKOM C13 induced pluripotent stem cell pig CVCL_RX78 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Tibetan minipig. Female 21119191 CVCL_S978 PC-1 [Human lung carcinoma] cancer cell line human CVCL_S978 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly334Val (c.1001G>T); Zygosity=Unspecified (PubMed=10536175) Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21119192 CVCL_0321 HT22 transformed cell line house mouse CVCL_0321 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Omics: Deep quantitative phosphoproteome analysis; Omics: Secretome proteome analysis Characteristics: Highly sensitive to glutamate and is therefore used to study glutamate-induced toxicity in neuronal cells 21119193 CVCL_0320 HT-29 cancer cell line human CVCL_0320 HLA typing: A*01/11,03; B*12,17 (PubMed=77569); HLA typing: A*01,24; B*35,44:03:01; C*04; DPB1*04:01; DQB1*02,03:02; DRB1*04:02,07:01 (PubMed=15748285); HLA typing: A*01:01,24:03; B*35:01,44:03; C*04:01,04:01 (PubMed=26589293); HLA typing: A*01:01:01,24:03:01; B*35:01:01,44:03:01; C*04:01:01; DPB1*04:01; DQA1*02:01:01,03:01:01; DQB1*02:02:01,03:02:01; DRB1*04:02:01,07:01:01 (CLS=300215); Genome ancestry: African=1.57%; Native American=1.05%; East Asian, North=3.24%; East Asian, South=0%; South Asian=4.8%; European, North=26.11%; European, South=63.24% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (PubMed=17088437; PubMed=20570890; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (PubMed=17088437; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=7651727; PubMed=9000147; PubMed=15900046; PubMed=17088437; PubMed=21912889; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap) Karyotypic information: Hypertriploid karyotype Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Extracellular vesicles proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 24 hours (PubMed=25984343); 24 hours (PubMed=23546019); 21.87 +- 0.12 hours (PubMed=32927768); 19.5 hours (NCI-DTP); ~24 hours (CLS); ~40-60 hours (DSMZ=ACC-299); ~23 hours (PBCF); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 809 Caution: Indicated in PubMed=11921276 as originating from an adenocarcinoma of the rectosigmoid part of the intestine, but is only indicated in the oldest publication (DOI=10.1007/978-1-4757-1647-4_5) as a colon adenocarcinoma 21119194 CVCL_0323 HT29-19A cancer cell line human CVCL_0323 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21119195 CVCL_0322 HT29 gluc C1 cancer cell line human CVCL_0322 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21119196 CVCL_0325 HuT78B1 cancer cell line human CVCL_0325 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21119197 CVCL_0324 HuCC-T1 cancer cell line human CVCL_0324 Genome ancestry: African=7.42%; Native American=0%; East Asian, North=82%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=10.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~55 hours (at 10th passage in RPMI + 10% FBS), ~74 hours (at 25th passage in RPMI + 0.2% LA) (PubMed=2544546); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21119198 CVCL_0327 Hepa 1-6 cancer cell line house mouse CVCL_0327 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 26.99 +- 1.93 hours (PubMed=28152020); ~30 hours (DSMZ=ACC-175) 21119199 CVCL_0326 Hep 3B2.1-7 cancer cell line human CVCL_0326 Genome ancestry: African=71.82%; Native American=0.52%; East Asian, North=3.16%; East Asian, South=0%; South Asian=0%; European, North=8.8%; European, South=15.69% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (PubMed=31395879; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (PubMed=31395879; Cosmic-CLP; DepMap) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB2090; true. Male Doubling time: 28.05 hours (PubMed=31378681); ~40-50 hours (DSMZ=ACC-93); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8064 21119200 CVCL_0329 Hepa-C12 cancer cell line house mouse CVCL_0329 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21119201 CVCL_0328 Hepa-1c1c7 cancer cell line house mouse CVCL_0328 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Omics: Transcriptome analysis by microarray Female 21119202 CVCL_S960 EoL-2 cancer cell line human CVCL_S960 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21119203 CVCL_RX60 MyDauDa/46 transformed cell line CVCL_RX60 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Intestine. Group: Bat cell line 21119204 CVCL_S962 HC45 transformed cell line human CVCL_S962 CL:0000010 Transformant: Simian virus 40 (SV40) [AD-SVR4](NCBI-Taxonomy; 1891767); Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21119205 CVCL_RX62 RhiEuLu transformed cell line CVCL_RX62 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119206 CVCL_RX61 PipNi/4 transformed cell line CVCL_RX61 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119207 CVCL_S961 UCI-VULV-1 cancer cell line human CVCL_S961 CL:0000010 Population: Caucasian; Derived from metastatic site: Left inguinal lymph node. Female Doubling time: 60 hours (PubMed=7729733) 21119208 CVCL_S964 CC3/CUHK3 cancer cell line human CVCL_S964 CL:0000010 Population: Chinese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: ~42 hours (PubMed=2334130) 21119209 CVCL_RX64 RhiNi/1.2 transformed cell line CVCL_RX64 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119210 CVCL_S963 HC49 transformed cell line human CVCL_S963 CL:0000010 Transformant: Simian virus 40 (SV40) [AD-SVR4](NCBI-Taxonomy; 1891767); Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21119211 CVCL_RX63 RhiBrain/4p transformed cell line CVCL_RX63 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21119212 CVCL_S966 NS-Meg cancer cell line human CVCL_S966 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7719248; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 72 hours (PubMed=7719248) 21119213 CVCL_RX66 RlKd transformed cell line CVCL_RX66 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119214 CVCL_S965 HSC-GRW cancer cell line human CVCL_S965 CL:0000010 Sequence variation: Mutation; HGNC; 4170; GATA1; Simple; p.Pro50fs*6 (c.150_184del35); Zygosity=Unspecified (PubMed=12586620). Unspecified Characteristics: KITLG dependent 21119215 CVCL_RX65 RhiFeLu transformed cell line CVCL_RX65 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119216 CVCL_S968 GP220 cancer cell line human CVCL_S968 CL:0000010 Derived from sampling site: Stomach; pyloric antrum. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Characteristics: Established from a second passage nude mice xenograft Doubling time: 22 hours (PubMed=8925130) 21119217 CVCL_RX68 Vero Mx-Luc spontaneously immortalized cell line green monkey CVCL_RX68 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Characteristics: Can be used as a reporter cell line to study interferon pathways; Characteristics: The expression of the luciferase reporter gene is under control of the mouse Mx1 gene promoter Group: Non-human primate cell line 21119218 CVCL_S967 GP202 cancer cell line human CVCL_S967 CL:0000010 Derived from sampling site: Stomach. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Characteristics: Established from a fourth passage nude mice xenograft Doubling time: 35 hours (PubMed=8925130) 21119219 CVCL_RX67 RoEnd/4 transformed cell line CVCL_RX67 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Group: Bat cell line 21119220 CVCL_RX69 HEK293 pcDNA5/FRT/TO-KAP1 transformed cell line human CVCL_RX69 CL:0000010 Transfected with: HGNC; 16384; TRIM28; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Can express TRIM28 inducibly by the addition of doxycyclin (DOX) 21119221 CVCL_S969 PC-1 [Human pancreatic carcinoma] cancer cell line human CVCL_S969 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107) Population: Chinese; Derived from metastatic site: Lymph node. Female Characteristics: Established from a xenograft established in a nude mice Doubling time: 47 hours (PubMed=2118052) 21119222 CVCL_0330 Hepa-C4 cancer cell line house mouse CVCL_0330 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21119223 CVCL_0332 Hs 578T cancer cell line human CVCL_0332 HLA typing: A*03,24; B*35,40; C*03:04:01,04; DPB1*04:01,78:01; DQB1*05:01:01,06:02; DRB1*01,15:01:01 (PubMed=15748285); HLA typing: A*03:01,24:02; B*35:03,40:01; C*03:04,04:01; DQA1*03:02,03:02 (PubMed=25960936); HLA typing: A*03:01,24:02; B*35:03,40:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=0.53%; Native American=0%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=63.73%; European, South=34.01% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (PubMed=17088437; PubMed=19593635; PubMed=28889351); Sequence variation: Mutation; HGNC; 7427; MT-CYB; Simple; p.Ala125Thr (m.15119G>A); ClinVar=VCV000693829; Zygosity=Homoplasmic (PubMed=29671673); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351) Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Mitochondrial genome sequenced; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7849; true Female Doubling time: 34 hours (PubMed=18386134); 53.8 hours (NCI-DTP); ~48 hours (DSMZ=ACC-781); 32.35 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI-60 cancer cell line panel 21119224 CVCL_0331 Hs 294T cancer cell line human CVCL_0331 HLA typing: A*01:01,25:01; B*07:02,08:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.39%; East Asian, North=0%; East Asian, South=0%; South Asian=0.34%; European, North=72.19%; European, South=27.07% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15467732; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119225 CVCL_0334 Hs 766T cancer cell line human CVCL_0334 HLA typing: A*03:01,26:01; B*35:01,38:01; C*04:01,12:03 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=0.92%; East Asian, North=1.96%; East Asian, South=0%; South Asian=1.54%; European, North=62.85%; European, South=32.62% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907; PubMed=15367885; PubMed=18380791); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Homozygous (PubMed=11169959; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8026879; PubMed=15367885) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 6-7 days (PubMed=176412); 30 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel Caution: Indicated as originating from a 46 year old male patient in ATCC and from a 64 year old male patient in PubMed=283258 and PubMed=761205; Caution: Incorrectly reported to have no KRAS mutation in PubMed=8026879 and PubMed=15367885; Caution: TP53 mutation indicated incorrectly as being at c.542G>A in PubMed=1630814 21119226 CVCL_0333 Hs 746.T cancer cell line human CVCL_0333 HLA typing: A*25:01,25:01; B*18:01,18:01; C*12:03,12:03; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.16%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0.58%; European, North=65.13%; European, South=31.23% (PubMed=30894373) CL:0000010 Derived from metastatic site: Left leg; skeletal muscle. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MET genetic alteration cell panel (ATCC TCP-1036) 21119227 CVCL_0336 Huh-7 cancer cell line human CVCL_0336 HLA typing: A*11:01,11:01; B*08:03,35:09; C*01:02,01:02 (PubMed=26589293); HLA typing: A*11:01:01; B*54:01:01; C*01:02:01; DPB1*02:01:02; DQA1*01:03:01; DQB1*06:01:01; DRB1*08:03:02 (CLS=300156); Genome ancestry: African=1.56%; Native American=0%; East Asian, North=79.68%; East Asian, South=13.08%; South Asian=0%; European, North=0%; European, South=5.69% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (PubMed=29774518); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (PubMed=33193621); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=8389256; PubMed=29774518; PubMed=31395879) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Mitochondrial proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32.2 hours (PubMed=31378681); ~48 hours (CLS); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21119228 CVCL_0335 Hs27 finite cell line human CVCL_0335 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21119229 CVCL_0338 IB3-1 transformed cell line human CVCL_0338 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=15463957); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (PubMed=15463957) Transformant: Ad12-SV40 hybrid virus Omics: Proteome analysis by 2D-DE/MS Discontinued: ATCC; CRL-2777; true; Discontinued: ATCC; JHU-52; true. Male 21119230 CVCL_0337 HuT 78 cancer cell line human CVCL_0337 Genome ancestry: African=0.32%; Native American=0.76%; East Asian, North=2.56%; East Asian, South=0%; South Asian=0.32%; European, North=68.01%; European, South=28.04% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (PubMed=2144611; DepMap) Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177) This created a controversy between the labs of Minna and Gallo (PubMed=2193399). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 26 hours (PubMed=6244013); 26 hours (HIVReagentProgram); ~65 hours (ATCC=TIB-161) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21119231 CVCL_0339 IB4 hybridoma house mouse CVCL_0339 CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10164 21119232 CVCL_RX51 EpoNi/22.3 transformed cell line CVCL_RX51 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Bat cell line 21119233 CVCL_S951 SWT spontaneously immortalized cell line CVCL_S951 CL:0000010 Unspecified Characteristics: Optimal growth at 26 to 30 Celsius, fails to grow at 16 and 37 Celsius. Group: Fish cell line 21119234 CVCL_RX50 EidLu/43 transformed cell line CVCL_RX50 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119235 CVCL_S950 SSN-3 spontaneously immortalized cell line CVCL_S950 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21119236 CVCL_RX53 HipEm/5 transformed cell line CVCL_RX53 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21119237 CVCL_S953 VSa16 spontaneously immortalized cell line CVCL_S953 CL:0000010 Derived from sampling site: Bone; vertebra. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21119238 CVCL_RX52 HipEm/28 transformed cell line CVCL_RX52 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21119239 CVCL_S952 VSa13 spontaneously immortalized cell line CVCL_S952 CL:0000010 Derived from sampling site: Bone; vertebra. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21119240 CVCL_S955 HHL-16 transformed cell line human CVCL_S955 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21119241 CVCL_RX55 HipaLu/27 transformed cell line CVCL_RX55 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119242 CVCL_RX54 HipaLu/24 transformed cell line CVCL_RX54 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119243 CVCL_S954 WSSK-1 spontaneously immortalized cell line CVCL_S954 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 21119244 CVCL_S957 HHL-7 transformed cell line human CVCL_S957 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21119245 CVCL_RX57 HypNi/21 transformed cell line CVCL_RX57 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Bat cell line 21119246 CVCL_S956 HHL-5 transformed cell line human CVCL_S956 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21119247 CVCL_RX56 HypLu/2 transformed cell line CVCL_RX56 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119248 CVCL_S959 C170 cancer cell line human CVCL_S959 HLA typing: A*02:01,24:02; B*08:01,35:01; C*04:01,07:01 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 26 +- 0.5 hours (PubMed=3947514); Microsatellite instability: Instable (MSI) (PubMed=25926053) 21119249 CVCL_RX59 MyDauBrain/48B transformed cell line CVCL_RX59 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21119250 CVCL_S958 C146 cancer cell line human CVCL_S958 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 16 +- 1 hours (PubMed=3947514); Microsatellite instability: Instable (MSI) (PubMed=25926053) 21119251 CVCL_RX58 MyDauBrain/48 transformed cell line CVCL_RX58 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21119252 CVCL_0301 HIT-T15 transformed cell line CVCL_0301 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Secretes insulin Maximal stimulation is obtained with glucose, arginine and leucine (PubMed=3535793). Doubling time: 33-34 hours (PubMed=6270673) 21119253 CVCL_0300 HIRcB spontaneously immortalized cell line Norway rat CVCL_0300 CL:0000010 Transfected with: HGNC; 6091; INSR Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21119254 CVCL_0303 HL-1 transformed cell line house mouse CVCL_0303 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; left atrium Cell type=Cardiomyocyte.; Breed/subspecies: C3HeB/FeJ transgenic. Female Characteristics: From transgenic mice expressing a fusion gene comprised of the atrial natriuretic factor promoter and the SV40 early region Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12197 21119255 CVCL_0302 HK-2 [Human kidney] transformed cell line human CVCL_0302 Genome ancestry: African=3.63%; Native American=0%; East Asian, North=3.68%; East Asian, South=0%; South Asian=0%; European, North=62.77%; European, South=29.92% (PubMed=30894373) CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Kidney. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119256 CVCL_0305 HL-60/VCR cancer cell line human CVCL_0305 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Peripheral blood. Female 21119257 CVCL_0304 HL-60/ADR cancer cell line human CVCL_0304 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Female 21119258 CVCL_0307 HMEC-1 transformed cell line human CVCL_0307 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; dermis Cell type=Endothelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10636 21119259 CVCL_0306 LS174T-HM3 cancer cell line human CVCL_0306 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Produces high amount of mucin in culture (PubMed=3664476) 21119260 CVCL_0309 HO-23 transformed cell line human CVCL_0309 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Cys135Val); Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21119261 CVCL_0308 HNE-1 cancer cell line human CVCL_0308 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by RNAseq. Male Virology: EBV-negative in established line Problematic cell line: Possibly contaminated The STR profile is very similar to that of the HeLa cell line and almost identical to that of HNE-2 (Cellosaurus=CVCL_FA07). 21119262 CVCL_RX40 KLu-R finite cell line CVCL_RX40 CL:0000010 Derived from sampling site: Fetal lung. Male Senescence: Senesces at <50 PDL (CCLV=CCLV-RIE 0031) 21119263 CVCL_S940 RH [Labeo] spontaneously immortalized cell line CVCL_S940 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21119264 CVCL_RX42 LGK-1-R finite cell line CVCL_RX42 CL:0000010 Derived from sampling site: Kidney. Male 21119265 CVCL_S942 SBB-W1 somatic stem cell CVCL_S942 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21119266 CVCL_RX41 KN-R finite cell line CVCL_RX41 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Senescence: Senesces at 60-80 PDL (CCLV=CCLV-RIE 0028) 21119267 CVCL_S941 RSB spontaneously immortalized cell line CVCL_S941 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Group: Fish cell line 21119268 CVCL_S944 SBES1 embryonic stem cell CVCL_S944 CL:0000010 Unspecified Group: Fish cell line. 21119269 CVCL_RX44 TT-R finite cell line CVCL_RX44 CL:0000010 Derived from sampling site: Umbilical cord. Male 21119270 CVCL_S943 SBES embryonic stem cell CVCL_S943 CL:0000010 Unspecified Group: Fish cell line. 21119271 CVCL_RX43 SLU-L cancer cell line CVCL_RX43 CL:0000010 Derived from sampling site: Lung. Male 21119272 CVCL_RX46 Crocsu-Lu transformed cell line CVCL_RX46 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. 21119273 CVCL_S946 SISE spontaneously immortalized cell line CVCL_S946 CL:0000010 Unspecified Group: Fish cell line. 21119274 CVCL_RX45 EidNi/41 transformed cell line CVCL_RX45 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119275 CVCL_S945 SH [Acipenser] spontaneously immortalized cell line CVCL_S945 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male Group: Fish cell line 21119276 CVCL_RX48 HypLu/45 transformed cell line CVCL_RX48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung. Unspecified Group: Bat cell line 21119277 CVCL_S948 SLN spontaneously immortalized cell line CVCL_S948 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21119278 CVCL_RX47 HypNi/1 transformed cell line CVCL_RX47 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119279 CVCL_S947 SLF [Leiostomus] spontaneously immortalized cell line CVCL_S947 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21119280 CVCL_RX49 MyDauLu/47 transformed cell line CVCL_RX49 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Unspecified Group: Bat cell line 21119281 CVCL_S949 SLW spontaneously immortalized cell line CVCL_S949 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21119282 CVCL_0310 HO-8910PM cancer cell line human CVCL_0310 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000281, 3131C0001000700025) They were the sole source for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Characteristics: Established from a 7th generation nude mice xenograft originating from HO-8910 Doubling time: 34.5 hours (PubMed=10464713) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00607 Problematic cell line: Contaminated Parent cell line (HO-8910) has been shown to be a HeLa derivative (CCRID). 21119283 CVCL_0312 HOS cancer cell line human CVCL_0312 HLA typing: A*02:11; B*52:01; C*12:02 (PubMed=15289353); HLA typing: A*02:11,02:11; B*52:01,52:01; C*12:02,12:02; DQA1*02:01,02:01; DRB1*15:02,13:60 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.17%; East Asian, South=3.52%; South Asian=35.51%; European, North=0%; European, South=59.79% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Bone; right femur. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21119284 CVCL_0311 HO15.19 spontaneously immortalized cell line Norway rat CVCL_0311 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21119285 CVCL_0314 HSC-5 [Human skin squamous cell carcinoma] cancer cell line human CVCL_0314 CL:0000010 Population: Japanese; Derived from sampling site: Skin. Omics: Deep exome analysis Discontinued: JCRB; NIHS0250; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119286 CVCL_0313 HPAF-II cancer cell line human CVCL_0313 HLA typing: A*01:01,26:01; B*08:01,55:01; C*03:03,07:01 (PubMed=26589293); Genome ancestry: African=0.96%; Native American=0.23%; East Asian, North=0.7%; East Asian, South=0%; South Asian=0%; European, North=64.61%; European, South=33.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg29_Ala34del (c.85_102del18); Zygosity=Heterozygous (PubMed=11787853; PubMed=15367885; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11787853; PubMed=12068308; PubMed=15367885; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Homozygous (PubMed=11787853; PubMed=15367885; Cosmic-CLP; DepMap) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26 hours (PubMed=2734279); 70 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel Caution: Could not find proof that the CD18 subline of HPAF is really HPAF-II but many indirect evidences points in this direction If someone read this comment and can help us, please do.; Caution: TP53 mutation indicated incorrectly as being at c.452C>T in PubMed=1764370 21119287 CVCL_0316 HSC-42 cancer cell line human CVCL_0316 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB1036; probable Doubling time: 26 hours (PubMed=8242641) Part of: JFCR45 cancer cell line panel 21119288 CVCL_0315 HSC-T6 transformed cell line Norway rat CVCL_0315 CL:0000010 Karyotypic information: 43,XX,der(1),+4,+7,-12,+mar (PubMed=35681478); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by RNAseq Female Doubling time: 10 hours (PubMed=26300973) Caution: Was originally (PubMed=10828080) reported to be established from a male rat, but was later shown (PubMed=35681478) to have a female karyotype 21119289 CVCL_0318 HT-144 cancer cell line human CVCL_0318 HLA typing: A*01,24; B*13; C*03 (ATCC=HTB-63); HLA typing: A*01:01,24:02; B*15:01,57:01; C*03:03,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.49%; East Asian, North=0.47%; East Asian, South=0%; South Asian=0%; European, North=73.18%; European, South=25.86% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15048078; PubMed=15467732; PubMed=17363583; PubMed=22383533; PubMed=26405815; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Derived from metastatic site: Hypodermis. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-544 21119290 CVCL_0317 HT-1080 cancer cell line human CVCL_0317 HLA typing: A*31:01,68:01; B*27:05,27:05; C*02:02,02:02 (PubMed=26589293); HLA typing: A*31:01:02,68:01:01; B*27:05:02; C*02:02:02; DPB1*03:01,04:01; DQA1*03:03:01,05:01:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,04:07:01 (CLS=300216); HLA typing: A*31:01:02,68:01:01; B*27:05:02,27:05:02; C*02:02:02,02:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DRA*01:01:01,01:02:02 (DSMZCellDive=ACC-315); Genome ancestry: African=0.86%; Native American=0.35%; East Asian, North=1.36%; East Asian, South=0.29%; South Asian=0%; European, North=68.21%; European, South=28.94% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (PubMed=26368816); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7951; true; Discontinued: RCB; RCB1956; true Male Doubling time: 26 hours (PubMed=4132053); ~30 hours (DSMZ=ACC-315); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119291 CVCL_0319 HT-2 clone A5E factor-dependent cell line house mouse CVCL_0319 CL:0000010 Breed/subspecies: BALB/c. Characteristics: IL2 and IL4 dependent Problematic cell line: Probably misidentified/contaminated While said to originate from a BALB/c mouse it exhibits a greater similarity with a C57BL strain. Its STR profile has three alleles or more at seven loci, high peak height imbalance and is discordant at eight STR markers. It therefore needs more characterization to determine if it is contaminated or misidentified due to the inconsistencies with the strain of origin and the increase of alleles per marker (PubMed=31220119). 21119292 CVCL_RX31 AOC49 transformed cell line pig CVCL_RX31 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium; Breed/subspecies: Large White. Unspecified 21119293 CVCL_S931 GF spontaneously immortalized cell line CVCL_S931 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21119294 CVCL_RX30 AOC45 transformed cell line pig CVCL_RX30 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium; Breed/subspecies: Large White. Unspecified 21119295 CVCL_S930 GE spontaneously immortalized cell line CVCL_S930 CL:0000010 Derived from sampling site: Eye. Unspecified Group: Fish cell line 21119296 CVCL_S933 GS spontaneously immortalized cell line CVCL_S933 CL:0000010 Derived from sampling site: Spleen. Unspecified Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) and Epinephelus tauvina nervous necrosis virus (ETNNV) Group: Fish cell line 21119297 CVCL_RX33 IB-RS-11 S6 spontaneously immortalized cell line pig CVCL_RX33 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Landrace. Female 21119298 CVCL_S932 GH [Epinephelus] spontaneously immortalized cell line CVCL_S932 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21119299 CVCL_RX32 MABS-1 cancer cell line human CVCL_RX32 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Doubling time: 20 hours (DOI=10.15369/sujms1989.9.45) Problematic cell line: Contaminated Parent cell line (MOBS-1) has been shown to be a U-937 derivative. 21119300 CVCL_S935 K1K spontaneously immortalized cell line CVCL_S935 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by channel catfish virus (CelloPub=CLPUB00706; DOI=10.1139/f81-125) Group: Fish cell line 21119301 CVCL_RX35 PfLu finite cell line CVCL_RX35 CL:0000010 Unspecified Doubling time: ~30 hours (CCLV). 21119302 CVCL_S934 GSB spontaneously immortalized cell line CVCL_S934 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Group: Fish cell line 21119303 CVCL_RX34 PFL-R finite cell line CVCL_RX34 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21119304 CVCL_S937 LCE spontaneously immortalized cell line CVCL_S937 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Group: Fish cell line 21119305 CVCL_RX37 PN-R finite cell line CVCL_RX37 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Virology: Susceptible to infection by equine herpesviruses (CCLV); Virology: Susceptible to infection by Middle East respiratory syndrome-related coronavirus (MERS-CoV) (PubMed=25531820) 21119306 CVCL_S936 GFT spontaneously immortalized cell line CVCL_S936 CL:0000010 Female Group: Fish cell line. 21119307 CVCL_RX36 PFN-R finite cell line CVCL_RX36 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Virology: Susceptible to infection by equine herpesviruses (CCLV); Virology: Susceptible to infection by Middle East respiratory syndrome-related coronavirus (MERS-CoV) (PubMed=25531820) 21119308 CVCL_RX39 Caki-3-R finite cell line CVCL_RX39 CL:0000010 Male 21119309 CVCL_S939 RF [Labeo] spontaneously immortalized cell line CVCL_S939 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC006 21119310 CVCL_RX38 Caki-3 finite cell line CVCL_RX38 CL:0000010 Male 21119311 CVCL_S938 LCF [Lates] spontaneously immortalized cell line CVCL_S938 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 21119312 CVCL_RX20 PipNi/1 transformed cell line CVCL_RX20 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119313 CVCL_S920 SMOV-2 cancer cell line human CVCL_S920 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female Doubling time: 48.2 hours (PubMed=10695021) 21119314 CVCL_RX22 RhiLu/1.1 transformed cell line CVCL_RX22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119315 CVCL_S922 RIC-2 cancer cell line human CVCL_S922 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21119316 CVCL_S921 MAC-2 cancer cell line human CVCL_S921 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21119317 CVCL_RX21 PipNi/3 transformed cell line CVCL_RX21 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119318 CVCL_RX24 RoNi/7.1 transformed cell line CVCL_RX24 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Bat cell line 21119319 CVCL_S924 SIB-1 cancer cell line human CVCL_S924 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21119320 CVCL_RX23 RoNi/7 transformed cell line CVCL_RX23 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Bat cell line 21119321 CVCL_S923 SCHM-1 cancer cell line human CVCL_S923 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21119322 CVCL_S926 BM spontaneously immortalized cell line CVCL_S926 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line 21119323 CVCL_RX26 LF-BK spontaneously immortalized cell line pig CVCL_RX26 CL:0000010 Omics: Transcriptome analysis by ESTs sequencing. Unspecified Virology: Susceptible to infection by foot-and-mouth disease virus Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00612 Problematic cell line: Misidentified Originally thought to be of bovine fetal kidney origin but found to be from pig (PubMed=25617444; PubMed=25787111). 21119324 CVCL_S925 ASF-1 spontaneously immortalized cell line CVCL_S925 CL:0000010 Derived from sampling site: Caudal trunk. Unspecified Group: Fish cell line 21119325 CVCL_RX25 CpLu finite cell line CVCL_RX25 CL:0000010 Derived from sampling site: Lung. Group: Bat cell line 21119326 CVCL_RX28 AOC31 transformed cell line pig CVCL_RX28 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium; Breed/subspecies: Large White. Unspecified 21119327 CVCL_S928 GB spontaneously immortalized cell line CVCL_S928 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21119328 CVCL_S927 BSB spontaneously immortalized cell line CVCL_S927 CL:0000010 Derived from sampling site: Swim bladder. Unspecified Group: Fish cell line 21119329 CVCL_RX27 LFBK-alphaVbeta6 spontaneously immortalized cell line pig CVCL_RX27 CL:0000010 Transfected with: VGNC; 30323; Bovine ITGAV; Transfected with: VGNC; 30331; Bovine ITGB6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Virology: More susceptible to infection by foot-and-mouth disease virus than parent cell line; Virology: Susceptible to infection by senecavirus A (SVA) which can be used as a surrogate for studies of goot-and-mouth disease virus (PubMed=36146682); Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=34092457; PubMed=34458357; PubMed=35112907) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00613; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-13047 Problematic cell line: Misidentified Parent cell line (LF-BK) was originally thought to be of bovine fetal kidney origin but originates from pig (PubMed=25617444). The derived cell line has also been shown to originate from pig (PubMed=34737324). 21119330 CVCL_RX29 AOC39 transformed cell line pig CVCL_RX29 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium; Breed/subspecies: Large White. Unspecified 21119331 CVCL_S929 GD1I spontaneously immortalized cell line CVCL_S929 CL:0000010 Derived from sampling site: Gonad. Unspecified Virology: Susceptible to infection by channel catfish virus (CelloPub=CLPUB00706; DOI=10.1139/f81-125) Group: Fish cell line 21119332 CVCL_S911 D1 [Mouse thymocyte] factor-dependent cell line house mouse CVCL_S911 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Thymus Cell type=Thymocyte.. Unspecified Characteristics: IL7 dependent Withdrawal of IL7 induces arrest in G1 phase of the cell cycle, followed by apoptosis (PubMed=12609543).; Characteristics: Does not express CD4 and CD8 (PubMed=12609543) 21119333 CVCL_RX11 EidLu/20 transformed cell line CVCL_RX11 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21119334 CVCL_S910 76NE7 transformed cell line human CVCL_S910 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21119335 CVCL_RX10 CarNi/1 transformed cell line CVCL_RX10 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119336 CVCL_S913 CUME-1 cancer cell line human CVCL_S913 HLA typing: DQA1*01:01,03; DQB1*03,06; DRB1*04,13 (PubMed=9352788) CL:0000010 Population: Korean; Derived from sampling site: Endometrium. Female Doubling time: ~56 hours (PubMed=9352788) 21119337 CVCL_RX13 EidNi/41.2 transformed cell line CVCL_RX13 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119338 CVCL_RX12 EidNi/41.1 transformed cell line CVCL_RX12 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119339 CVCL_S912 NOU-1 cancer cell line human CVCL_S912 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20944090) Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21119340 CVCL_S915 NuLi-2 transformed cell line human CVCL_S915 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Female 21119341 CVCL_RX15 SORMi001-A induced pluripotent stem cell human CVCL_RX15 From: School of Regenerative Medicine, Manipal University; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Female 21119342 CVCL_RX14 EidNi/41.3 transformed cell line CVCL_RX14 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119343 CVCL_S914 SNG-P cancer cell line human CVCL_S914 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 33 hours, at 45th passage (PubMed=858140) 21119344 CVCL_S917 GILM3 cancer cell line human CVCL_S917 CL:0000010 Derived from sampling site: Breast. Female Characteristics: Metastatic phenotype obtained by injection of parent cell line in nude mice and selection of cells from lung metastases 21119345 CVCL_RX17 HypNi/1.1 transformed cell line CVCL_RX17 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Group: Bat cell line 21119346 CVCL_RX16 HypLu/45.1 transformed cell line CVCL_RX16 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung. Unspecified Group: Bat cell line 21119347 CVCL_S916 SMOV-1 cancer cell line human CVCL_S916 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 61.4 hours (DOI=10.1007/BF02492857) 21119348 CVCL_S919 HNOA cancer cell line human CVCL_S919 CL:0000010 Population: Japanese Female Characteristics: Established from a nude mouse xenograft (PubMed=3593088) Doubling time: 26 hours (PubMed=3593088). 21119349 CVCL_RX19 MyDauNi/2 transformed cell line CVCL_RX19 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21119350 CVCL_S918 L-1 [Human ovarian carcinoma] cancer cell line human CVCL_S918 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 11.8 hours (PubMed=2480932) 21119351 CVCL_RX18 MyDauLu/47.1 transformed cell line CVCL_RX18 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Unspecified Group: Bat cell line 21119352 CVCL_RX00 MDBK-t2 spontaneously immortalized cell line CVCL_RX00 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Kidney. Male Characteristics: Can be used as a reporter cell line to study interferon pathways; Characteristics: The expression of the cat reporter gene is under control of the human Mx1 gene promoter 21119353 CVCL_S900 RL-251 cancer cell line human CVCL_S900 CL:0000010 Derived from sampling site: Adrenal gland. Male Doubling time: 36 hours (PubMed=11502840) 21119354 CVCL_RX02 MyglaAEC.B transformed cell line CVCL_RX02 CL:0000010 Miscellaneous: Age of donor from personal communication of Eckerle I Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Unspecified 21119355 CVCL_S902 NCI-H295R-S3 cancer cell line human CVCL_S902 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Grows in a serum called Hyclone Cosmic Calf 21119356 CVCL_S901 NCI-H295R-S2 cancer cell line human CVCL_S901 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Grows in a medium called Nu-Serum type I with a serum substitute called Ultroser-G 21119357 CVCL_RX01 ZLu-R finite cell line CVCL_RX01 CL:0000010 Derived from sampling site: Fetal lung. Male 21119358 CVCL_S904 cBAL111 telomerase immortalized cell line human CVCL_S904 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified 21119359 CVCL_RX04 HEp2-Mx2/EGFP L1D7 cancer cell line human CVCL_RX04 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency Female Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 21119360 CVCL_S903 JHTK-1 cancer cell line human CVCL_S903 CL:0000010 Population: Japanese Male Doubling time: ~24 hours (PubMed=3820395). 21119361 CVCL_RX03 Vero Mx13 spontaneously immortalized cell line green monkey CVCL_RX03 CL:0000010 Transfected with: HGNC; 4261; GH1 Derived from sampling site: Kidney; epithelium. Female Characteristics: Can be used as a reporter cell line to study interferon pathways; Characteristics: The expression of the growth hormone gene is under control of the mouse Mx1 gene promoter Group: Non-human primate cell line 21119362 CVCL_RX06 HeLa-Mx2/EGFP C5G6 cancer cell line human CVCL_RX06 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency Female Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter 21119363 CVCL_S906 SEMK2 cancer cell line human CVCL_S906 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119364 CVCL_RX05 HEp2-Mx2/EGFP L1G5 cancer cell line human CVCL_RX05 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency (PubMed=27346232) Female Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter (PubMed=27346232) Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 21119365 CVCL_S905 NKNT-3 transformed cell line human CVCL_S905 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: The SV40 T antigen is flanked by LoxP recombination targets so that it can be excised by Cre/Lox site-specific recombination Group: Serum/protein free medium cell line 21119366 CVCL_RX08 A549-Mx2/EGFP L2A6 cancer cell line human CVCL_RX08 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency Male Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter 21119367 CVCL_S908 FHL124 spontaneously immortalized cell line human CVCL_S908 CL:0000010 Derived from sampling site: Fetal eye; ocular lens; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Unspecified 21119368 CVCL_RX07 HeLa-Mx2/EGFP C6C3 cancer cell line human CVCL_RX07 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency (PubMed=27346232) Female Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter (PubMed=27346232) 21119369 CVCL_S907 SEMK2-M1 cancer cell line human CVCL_S907 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21119370 CVCL_S909 76NE6 transformed cell line human CVCL_S909 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21119371 CVCL_RX09 A549-Mx2/EGFP L2G9 cancer cell line human CVCL_RX09 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Biotechnology: Used for a reporter gene assay (RGA) of the human type 1 interferon potency (PubMed=27346232) Male Characteristics: Expression of eGFP is under the control of the control of the mouse Mx2 promoter (PubMed=27346232) 21119372 CVCL_8M63 DA05940 transformed cell line human CVCL_8M63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119373 CVCL_8M62 DA05938 transformed cell line human CVCL_8M62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119374 CVCL_8M65 DA05942 transformed cell line human CVCL_8M65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119375 CVCL_8M64 DA05941 transformed cell line human CVCL_8M64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119376 CVCL_8M61 DA05937 transformed cell line human CVCL_8M61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119377 CVCL_8M60 DA05936 transformed cell line human CVCL_8M60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119378 CVCL_8M67 DA05944 transformed cell line human CVCL_8M67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119379 CVCL_8M66 DA05943 transformed cell line human CVCL_8M66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119380 CVCL_8M69 DA05946 transformed cell line human CVCL_8M69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119381 CVCL_8M68 DA05945 transformed cell line human CVCL_8M68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119382 CVCL_8M74 DA05951 transformed cell line human CVCL_8M74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119383 CVCL_8M73 DA05950 transformed cell line human CVCL_8M73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119384 CVCL_8M76 DA05953 transformed cell line human CVCL_8M76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119385 CVCL_8M75 DA05952 transformed cell line human CVCL_8M75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119386 CVCL_8M70 DA05947 transformed cell line human CVCL_8M70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119387 CVCL_8M72 DA05949 transformed cell line human CVCL_8M72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119388 CVCL_8M71 DA05948 transformed cell line human CVCL_8M71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119389 CVCL_AG08 HPSI0613i-jorr_1 induced pluripotent stem cell human CVCL_AG08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119390 CVCL_AG07 HPSI0613i-iurx_1 induced pluripotent stem cell human CVCL_AG07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119391 CVCL_AG09 HPSI0613i-kewt_3 induced pluripotent stem cell human CVCL_AG09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119392 CVCL_8M78 DA05955 transformed cell line human CVCL_8M78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119393 CVCL_8M77 DA05954 transformed cell line human CVCL_8M77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119394 CVCL_8M79 DA05956 transformed cell line human CVCL_8M79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119395 CVCL_AG00 HPSI0613i-funp_2 induced pluripotent stem cell human CVCL_AG00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119396 CVCL_AG02 HPSI0613i-giuo_4 induced pluripotent stem cell human CVCL_AG02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119397 CVCL_AG01 HPSI0613i-funp_3 induced pluripotent stem cell human CVCL_AG01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119398 CVCL_AG04 HPSI0613i-hegp_3 induced pluripotent stem cell human CVCL_AG04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119399 CVCL_AG03 HPSI0613i-giuo_5 induced pluripotent stem cell human CVCL_AG03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119400 CVCL_AG06 HPSI0613i-hikj_2 induced pluripotent stem cell human CVCL_AG06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119401 CVCL_AG05 HPSI0613i-hikj_1 induced pluripotent stem cell human CVCL_AG05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119402 CVCL_8M41 DA05914 transformed cell line human CVCL_8M41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119403 CVCL_8M40 DA05913 transformed cell line human CVCL_8M40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119404 CVCL_8M43 DA05916 transformed cell line human CVCL_8M43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119405 CVCL_8M42 DA05915 transformed cell line human CVCL_8M42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119406 CVCL_8M49 DA05925 transformed cell line human CVCL_8M49 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119407 CVCL_8M48 DA05924 transformed cell line human CVCL_8M48 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119408 CVCL_8M45 DA05920 transformed cell line human CVCL_8M45 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119409 CVCL_8M44 DA05919 transformed cell line human CVCL_8M44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119410 CVCL_8M47 DA05922 transformed cell line human CVCL_8M47 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119411 CVCL_8M46 DA05921 transformed cell line human CVCL_8M46 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119412 CVCL_8M52 DA05928 transformed cell line human CVCL_8M52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119413 CVCL_8M51 DA05927 transformed cell line human CVCL_8M51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119414 CVCL_8M54 DA05930 transformed cell line human CVCL_8M54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119415 CVCL_8M53 DA05929 transformed cell line human CVCL_8M53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119416 CVCL_8M50 DA05926 transformed cell line human CVCL_8M50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119417 CVCL_8M59 DA05935 transformed cell line human CVCL_8M59 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119418 CVCL_8M56 DA05932 transformed cell line human CVCL_8M56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119419 CVCL_8M55 DA05931 transformed cell line human CVCL_8M55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119420 CVCL_8M58 DA05934 transformed cell line human CVCL_8M58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119421 CVCL_8M57 DA05933 transformed cell line human CVCL_8M57 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119422 CVCL_8M21 DA05887 transformed cell line human CVCL_8M21 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119423 CVCL_8M20 DA05885 transformed cell line human CVCL_8M20 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119424 CVCL_8M27 DA05897 transformed cell line human CVCL_8M27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119425 CVCL_8M26 DA05892 transformed cell line human CVCL_8M26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119426 CVCL_8M29 DA05901 transformed cell line human CVCL_8M29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119427 CVCL_8M28 DA05900 transformed cell line human CVCL_8M28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119428 CVCL_8M23 DA05889 transformed cell line human CVCL_8M23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119429 CVCL_8M22 DA05888 transformed cell line human CVCL_8M22 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119430 CVCL_8M25 DA05891 transformed cell line human CVCL_8M25 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119431 CVCL_0491 NBL-3-17 spontaneously immortalized cell line CVCL_0491 CL:0000010 Derived from sampling site: Kidney. Female Group: Marsupial cell line 21119432 CVCL_8M24 DA05890 transformed cell line human CVCL_8M24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119433 CVCL_0490 NBL-3-11 spontaneously immortalized cell line CVCL_0490 CL:0000010 Derived from sampling site: Kidney. Female Group: Marsupial cell line 21119434 CVCL_0482 PC-3U cancer cell line human CVCL_0482 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21119435 CVCL_0481 PC12 cancer cell line Norway rat CVCL_0481 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Responds reversibly to NGF by induction of a neuronal phenotype Doubling time: 40 hours (PubMed=9886495); ~50-60 hours (DSMZ=ACC-159); 92 hours (CLS; ECACC=88022401) Group: Space-flown cell line (cellonaut) 21119436 CVCL_0484 PKSV-PCT transformed cell line house mouse CVCL_0484 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal convoluted tubule; Breed/subspecies: L-PK/Tag1 transgenic. Male 21119437 CVCL_0483 PC2 cancer cell line Norway rat CVCL_0483 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21119438 CVCL_0486 PLJ-4.7 cancer cell line human CVCL_0486 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Arg (c.724T>C); ClinVar=VCV000449512; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1884; CFTR Derived from metastatic site: Liver. Male 21119439 CVCL_8M19 DA05884 transformed cell line human CVCL_8M19 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119440 CVCL_0485 PLC/PRF/5 cancer cell line human CVCL_0485 HLA typing: A*33:02; B*42:01,53:01; C*04:01,17:01 (PubMed=9178645); HLA typing: A*03:01,33:03; B*42:02,53:01; C*04:01,17:01; DQB1*06:07,06:07; DRB1*11:73,11:73 (PubMed=26589293); HLA typing: A*03:01:01,09:03:01; B*42:02:01,53:01:01; C*04:01,04; DPB1*17,18:01; DQA1*01:03:01,04:01:02; DQB1*03:19:01,06:03:01; DRB1*08:04:01,13:01:01 (CLS=300315); Genome ancestry: African=95.79%; Native American=0%; East Asian, North=1.61%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=2.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (PubMed=31378681; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (PubMed=8224613; PubMed=8389256; DepMap); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (DepMap) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1887; true Male Virology: Contains at least 7 copies of integrated hepatitis B virus (HBV) genomes Secretes hepatitis virus B surface antigen (HBsAg).; Virology: Susceptible to infection by adenovirus types 40 (Ad40) and 41 (Ad41) (PubMed=1317878) Doubling time: 35-40 hours (PubMed=63998); 20.05-28.76 hours (PubMed=31378681) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8024 Caution: Often called PLC8024 in Chinese literature probably because of a concatenation between PLC/PRF/5 and ATCC-8024 21119441 CVCL_0488 PS120 spontaneously immortalized cell line CVCL_0488 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21119442 CVCL_0487 PR1 [Rat pituitary tumor] cancer cell line Norway rat CVCL_0487 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female Doubling time: ~90 hours (DSMZ=ACC-486) 21119443 CVCL_0489 Pt K1 spontaneously immortalized cell line CVCL_0489 CL:0000010 Karyotypic information: As the diploid chromosome number of P.tridactylus is quite small (2n=12), this cell line is suited to the study of mitosis and to easily visualize the chromosomes under a microscope; Derived from sampling site: Kidney. Female Group: Marsupial cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119444 CVCL_8M30 DA05902 transformed cell line human CVCL_8M30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119445 CVCL_8M32 DA05904 transformed cell line human CVCL_8M32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119446 CVCL_8M31 DA05903 transformed cell line human CVCL_8M31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119447 CVCL_8M38 DA05911 transformed cell line human CVCL_8M38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119448 CVCL_8M37 DA05910 transformed cell line human CVCL_8M37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119449 CVCL_8M39 DA05912 transformed cell line human CVCL_8M39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119450 CVCL_8M34 DA05907 transformed cell line human CVCL_8M34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119451 CVCL_8M33 DA05906 transformed cell line human CVCL_8M33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119452 CVCL_8M36 DA05909 transformed cell line human CVCL_8M36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119453 CVCL_8M35 DA05908 transformed cell line human CVCL_8M35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119454 CVCL_0493 RAW 264.7 cancer cell line house mouse CVCL_0493 CL:0000010 Miscellaneous: PubMed=23430347 has a different value for STR 6-4 (17) than that of NIST (18) due to a change in the marker motif (personal communication of Almeida J.L.) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Omics: Metabolome analysis; Omics: Phagosome quantitative phosphoproteome analysis; Omics: Phagosome analysis by proteomics; Omics: SNP array analysis Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 11 hours (from cell counting), 12 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154); ~30 hours (CLS) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21119455 CVCL_0492 Rat1 spontaneously immortalized cell line Norway rat CVCL_0492 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified Doubling time: 16-20 hours (PubMed=8668197) 21119456 CVCL_0495 RBE4 transformed cell line Norway rat CVCL_0495 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 2 [E1A](NCBI-Taxonomy; 10515); Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: Sprague Dawley. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1142 Caution: Indicated as originating from a Sprague-Dawley rat in PubMed=7908023 and from a Lewis rat in Patent=WO1993006222A1 21119457 CVCL_0494 RBA-1 spontaneously immortalized cell line Norway rat CVCL_0494 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: JAR-2. Unspecified 21119458 CVCL_0497 SNU-475 cancer cell line human CVCL_0497 HLA typing: A*02:01,11:01; B*40:02,54:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.39%; Native American=0%; East Asian, North=63.9%; East Asian, South=34.56%; South Asian=0%; European, North=0%; European, South=1.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (PubMed=8824565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Asp (c.785G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Arg (c.823T>C); ClinVar=VCV000376584; Zygosity=Unspecified (PubMed=8824565); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn288Ser (c.863A>G); Zygosity=Unspecified (PubMed=8824565) Population: Korean; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 66 hours (PubMed=7543080); 35.6 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21119459 CVCL_0496 RBL-1 cancer cell line Norway rat CVCL_0496 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. Doubling time: ~24 hours (CLS); ~25 hours (DSMZ=ACC-147) 21119460 CVCL_0499 RGM1 spontaneously immortalized cell line Norway rat CVCL_0499 CL:0000010 Derived from sampling site: Stomach; epithelium Cell type=Epithelial cell.; Breed/subspecies: Wistar. Male 21119461 CVCL_0498 RCC4 cancer cell line human CVCL_0498 Genome ancestry: African=1.89%; Native American=0%; East Asian, North=3.32%; East Asian, South=0%; South Asian=0.27%; European, North=55.04%; European, South=39.47% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Trp (c.194C>G); ClinVar=VCV000043597; Zygosity=Hemizygous (PubMed=21258414) Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119462 CVCL_8M05 DA05866 transformed cell line human CVCL_8M05 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119463 CVCL_8M04 DA05865 transformed cell line human CVCL_8M04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119464 CVCL_8M07 DA05869 transformed cell line human CVCL_8M07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119465 CVCL_8M06 DA05867 transformed cell line human CVCL_8M06 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119466 CVCL_8M01 DA05861 transformed cell line human CVCL_8M01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119467 CVCL_8M00 DA05857 transformed cell line human CVCL_8M00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119468 CVCL_8M03 DA05864 transformed cell line human CVCL_8M03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119469 CVCL_8M02 DA05862 transformed cell line human CVCL_8M02 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119470 CVCL_0460 NCM460 spontaneously immortalized cell line human CVCL_0460 CL:0000010 Population: Hispanic; Donor information: Established from the normal tissue of a patient suffering from gastric cancer; Derived from sampling site: Colon; mucosa Cell type=Epithelial cell.. Male Doubling time: 32-38 hours (INCELL) 21119471 CVCL_0462 NCTC clone 929 spontaneously immortalized cell line house mouse CVCL_0462 CL:0000010 Anecdotal: First established continuous cell line; Miscellaneous: PubMed=23430347 has a different value for STR 6-4 (16) than that of NIST (17,18) due to a change in the marker motif (personal communication of Almeida J.L.) Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Omics: Deep quantitative proteome analysis Discontinued: ATCC; CRL-6364; true; Discontinued: RCB; RCB0081; true Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 28 hours (from cell counting), 32 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154); ~25 hours (CLS); ~21-24 hours (DSMZ=ACC-2) Group: Space-flown cell line (cellonaut); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119472 CVCL_0461 NCTC 2544 cancer cell line human CVCL_0461 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-19; true; Discontinued: ICLC; HL97002; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00012 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to be a normal skin epithelium cell line. 21119473 CVCL_0464 108CC15 hybrid cell line CVCL_0464 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12317 21119474 CVCL_0463 NCI-H157 cancer cell line human CVCL_0463 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=30038707); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=1311061; PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35fs*8 (c.102_103insT) (c.103_104insT); Zygosity=Unspecified (PubMed=10536175; PubMed=20557307); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1311061; PubMed=10536175; PubMed=20557307) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5802; true; Discontinued: KCLB; 90157; probable. Male Doubling time: 53 hours (in RPMI 1640 + 10% FBS), 90 hours (in ACL-3 + BSA) (PubMed=3940644); 20.8 hours (PubMed=29681454) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00412 Problematic cell line: Contaminated NCI-H157 and NCI-H1264 have been shown to be identical. 21119475 CVCL_0466 NKL cancer cell line human CVCL_0466 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Omics: Transcriptome analysis by microarray Male Characteristics: IL2 dependent Doubling time: 24-48 hours (PubMed=8599969) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119476 CVCL_0465 OVCAR-3 cancer cell line human CVCL_0465 HLA typing: A*02:01:01,29:02; B*07:02:01,58:01; C*07:02:01,07; DPB1*02:01:02,04:01; DQB1*04:02; DRB1*08:01:01,08:04:01 (PubMed=15748285); HLA typing: A*02:01,29:02; B*07:02,58:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=3.99%; East Asian, South=0%; South Asian=0%; European, North=60.92%; European, South=35.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=17088437; PubMed=18277095; PubMed=21912889; PubMed=24023729; PubMed=25230021; PubMed=28273451; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: N-glycan profiling; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL97004; true Female Doubling time: 48 hours (PubMed=6604576); 35 hours (PubMed=2653399); 64 hours (PubMed=25984343); 34.7 hours (NCI-DTP); ~69 hours (PBCF); 53.77 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: OCCP ovarian cancer cell line panel 21119477 CVCL_0468 NRK-52E spontaneously immortalized cell line Norway rat CVCL_0468 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Doubling time: ~45 hours (DSMZ=ACC-199) 21119478 CVCL_0467 NPA cancer cell line human CVCL_0467 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=8423216; PubMed=14522906) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00246 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland papillary carcinoma. 21119479 CVCL_0469 NS20Y cancer cell line house mouse CVCL_0469 CL:0000010 Breed/subspecies: A/J. Male Doubling time: ~30-50 hours (DSMZ=ACC-94) 21119480 CVCL_8M10 DA05872 transformed cell line human CVCL_8M10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119481 CVCL_8M16 DA05878 transformed cell line human CVCL_8M16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119482 CVCL_8M15 DA05877 transformed cell line human CVCL_8M15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119483 CVCL_8M18 DA05883 transformed cell line human CVCL_8M18 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119484 CVCL_8M17 DA05882 transformed cell line human CVCL_8M17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119485 CVCL_8M12 DA05874 transformed cell line human CVCL_8M12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119486 CVCL_8M11 DA05873 transformed cell line human CVCL_8M11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119487 CVCL_8M14 DA05876 transformed cell line human CVCL_8M14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119488 CVCL_0480 PANC-1 cancer cell line human CVCL_0480 HLA typing: A*02:01,11:01; B*01,38; C*03,12 (PubMed=9023415); HLA typing: A*02,11; B*01,38; C*03,12 (PubMed=18575732); HLA typing: A*02:01,11:01; B*38:01,38:01; C*12:03,12:03; DQB1*06:07,06:07; DRB1*11:20,14:43 (PubMed=26589293); HLA typing: A*02:01:01,11:01:01; B*38:01:01; C*12:03:01; DPB1*12:01:02G,04:02:01G; DQA1*01:03:01; DQB1*06:03:01; DRB1*13:01:01 (CLS=300228); Genome ancestry: African=2.26%; Native American=0%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=60%; European, South=35.65% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853; PubMed=15367885); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=7809022; PubMed=7961102; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=1630814; PubMed=1764370; PubMed=7961102; PubMed=8026879; PubMed=11115575; PubMed=11787853; PubMed=15367885; PubMed=21607521; DepMap) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 25.83 +- 2.03 hours (PubMed=25394408); 21 +- 1.6 hours (PubMed=21515691); 52 hours (CLS); ~42 hours (DSMZ=ACC-783); ~32 hours (PBCF); 15.02 hours (GrayJW panel) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project Caution: Additional TP53 mutation in c.815T>C indicated incorrectly in PubMed=1630814 21119489 CVCL_8M13 DA05875 transformed cell line human CVCL_8M13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119490 CVCL_0471 OE33 cancer cell line human CVCL_0471 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=1.2%; East Asian, South=0.55%; South Asian=0%; European, North=67.21%; European, South=31.03% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Unspecified (PubMed=20075370) Population: Caucasian; Derived from sampling site: Esophagus. Omics: Chromatin accessibility by ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Hi-C sequencing; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 33 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-706); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21119491 CVCL_0470 Neuro-2a cancer cell line house mouse CVCL_0470 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T Breed/subspecies: A/J. Omics: Deep proteome analysis; Omics: SNP array analysis Male Characteristics: Capable of differentiating into various types of neurons Doubling time: ~70 hours (DSMZ=ACC-148) 21119492 CVCL_0473 OV-2008 cancer cell line human CVCL_0473 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=25846456) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00466 Problematic cell line: Contaminated Shown to be a ME-180 derivative (PubMed=22710073). Originally thought to originate from a female patient with an ovarian serous carcinoma. 21119493 CVCL_0472 OK spontaneously immortalized cell line CVCL_0472 CL:0000010 Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Used to study X chromosome inactivation as well as to investigate proximal tubule ion transport and membrane trafficking Doubling time: 18 hours (PubMed=566717) Group: Marsupial cell line 21119494 CVCL_8M09 DA05871 transformed cell line human CVCL_8M09 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119495 CVCL_0475 OVCA433 cancer cell line human CVCL_0475 HLA typing: A*01:01,26:01; B*15:17,39:01; C*07:01,12:03 (PubMed=26589293); Genome ancestry: African=0.31%; Native American=1.3%; East Asian, North=0.31%; East Asian, South=0%; South Asian=0%; European, North=59.83%; European, South=38.24% (PubMed=30894373) CL:0000010 Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 102.24 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21119496 CVCL_8M08 DA05870 transformed cell line human CVCL_8M08 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119497 CVCL_0474 OV3121-1 cancer cell line house mouse CVCL_0474 CL:0000010 Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer; Breed/subspecies: C57BL/6N x C3H/He. Female 21119498 CVCL_0477 P388D1 cancer cell line house mouse CVCL_0477 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Omics: SNP array analysis Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) 21119499 CVCL_0476 Ob1771 spontaneously immortalized cell line house mouse CVCL_0476 CL:0000010 Derived from sampling site: Testis; epididymis; epididymal fat pad Cell type=Preadipocyte.; Breed/subspecies: C57BL/6J ob/ob. Male 21119500 CVCL_0479 PA-1 cancer cell line human CVCL_0479 HLA typing: A*68:02,68:02; B*37:04,44:03; C*07:01,07:01; DQB1*04:01,04:01; DRB1*03:02,03:02 (PubMed=26589293); Genome ancestry: African=21.08%; Native American=17.69%; East Asian, North=1.54%; East Asian, South=0.7%; South Asian=0.4%; European, North=26.01%; European, South=32.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous; Note=Not found in early passages (PubMed=6740333); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (Cosmic-CLP) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1946; true; Discontinued: TKG; TKG 0573; true Female Doubling time: 36 hours (PubMed=2653399); ~24 hours (lot 01212002) (JCRB); 22.77 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel Caution: TP53 mutation indicated to be at p.Asn239Asp (c.715A>G) in DOI=10.11418/jtca1981.16.3_173 and PubMed=9359923 21119501 CVCL_0478 P39 cancer cell line human CVCL_0478 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=9379676) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00255 Problematic cell line: Contaminated Shown to be a HL-60 derivative (PubMed=12592342; PubMed=20143388; PubMed=20421273). Originally thought to originate from the peripheral blood of a 69 year old male with acute myeloid leukemia. 21119502 CVCL_JA14 VACO 936 cancer cell line human CVCL_JA14 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119503 CVCL_JA13 VACO 922 cancer cell line human CVCL_JA13 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119504 CVCL_JA16 VACO 947 cancer cell line human CVCL_JA16 CL:0000010 Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119505 CVCL_JA15 VACO 940 cancer cell line human CVCL_JA15 CL:0000010 Male Microsatellite instability: Stable (MSS) (PubMed=27004849). 21119506 CVCL_JA10 VACO 911 cancer cell line human CVCL_JA10 CL:0000010 Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119507 CVCL_JA12 VACO 920 cancer cell line human CVCL_JA12 CL:0000010 Sequence variation: Mutation; HGNC; 15629; B3GNT2; Simple; p.Asp247His (c.739G>C); Zygosity=Unspecified; Note=Loss of activity (PubMed=27004849). Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119508 CVCL_JA11 VACO 915 cancer cell line human CVCL_JA11 CL:0000010 Sequence variation: Mutation; HGNC; 15629; B3GNT2; Simple; p.Pro186Thr (c.556C>A); Zygosity=Unspecified (PubMed=27004849); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=27004849); Sequence variation: Mutation; HGNC; 10867; ST6GALNAC2; Simple; p.Asp43His (c.127G>C); Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119509 CVCL_AG77 HPSI0714i-gibe_2 induced pluripotent stem cell human CVCL_AG77 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119510 CVCL_AG76 HPSI0714i-fasu_2 induced pluripotent stem cell human CVCL_AG76 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119511 CVCL_AG79 HPSI0714i-mitg_4 induced pluripotent stem cell human CVCL_AG79 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119512 CVCL_AG78 HPSI0714i-lutt_6 induced pluripotent stem cell human CVCL_AG78 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119513 CVCL_AG71 HPSI0713i-veku_2 induced pluripotent stem cell human CVCL_AG71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119514 CVCL_AG70 HPSI0713i-uimo_1 induced pluripotent stem cell human CVCL_AG70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119515 CVCL_AG73 HPSI0713i-yezj_3 induced pluripotent stem cell human CVCL_AG73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119516 CVCL_JA07 VACO 900 cancer cell line human CVCL_JA07 CL:0000010 Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119517 CVCL_AG72 HPSI0713i-wiol_1 induced pluripotent stem cell human CVCL_AG72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119518 CVCL_JA06 VACO 896 cancer cell line human CVCL_JA06 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119519 CVCL_AG75 HPSI0714i-burb_3 induced pluripotent stem cell human CVCL_AG75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119520 CVCL_JA09 VACO 909 cancer cell line human CVCL_JA09 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119521 CVCL_AG74 HPSI0714i-burb_1 induced pluripotent stem cell human CVCL_AG74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119522 CVCL_JA08 VACO 907 cancer cell line human CVCL_JA08 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119523 CVCL_JA25 UT-SCC-107 cancer cell line human CVCL_JA25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=29970484) Derived from sampling site: Larynx. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21119524 CVCL_JA24 UT-SCC-106B cancer cell line human CVCL_JA24 CL:0000010 Derived from sampling site: Larynx. Omics: miRNA expression profiling Male 21119525 CVCL_JA27 UT-SCC-116 cancer cell line human CVCL_JA27 CL:0000010 Omics: miRNA expression profiling. 21119526 CVCL_JA26 UT-SCC-108 cancer cell line human CVCL_JA26 CL:0000010 Omics: miRNA expression profiling. 21119527 CVCL_JA21 HeLa EV2 cancer cell line human CVCL_JA21 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21119528 CVCL_JA20 VACO 968 cancer cell line human CVCL_JA20 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849). Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119529 CVCL_JA23 UT-SCC-106A cancer cell line human CVCL_JA23 CL:0000010 Derived from sampling site: Larynx. Omics: Array-based CGH; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21119530 CVCL_JA22 HeLa PF cancer cell line human CVCL_JA22 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Serum/protein free medium cell line 21119531 CVCL_AG88 HPSI0813i-aizi_3 induced pluripotent stem cell human CVCL_AG88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119532 CVCL_AG87 HPSI0813i-aizi_1 induced pluripotent stem cell human CVCL_AG87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119533 CVCL_AG89 HPSI0813i-aomg_2 induced pluripotent stem cell human CVCL_AG89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119534 CVCL_AG80 HPSI0714i-oebj_1 induced pluripotent stem cell human CVCL_AG80 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Middle Eastern; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119535 CVCL_AG82 HPSI0714i-pirs_1 induced pluripotent stem cell human CVCL_AG82 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119536 CVCL_AG81 HPSI0714i-oojs_1 induced pluripotent stem cell human CVCL_AG81 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119537 CVCL_AG84 HPSI0714i-riya_2 induced pluripotent stem cell human CVCL_AG84 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Bulgarian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119538 CVCL_JA18 VACO 957 cancer cell line human CVCL_JA18 CL:0000010 Sequence variation: Mutation; HGNC; 925; B4GALT2; Simple; p.Ala146Val (c.437C>T); Zygosity=Unspecified; Note=Loss of activity (PubMed=27004849). Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119539 CVCL_AG83 HPSI0714i-rajk_1 induced pluripotent stem cell human CVCL_AG83 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119540 CVCL_JA17 VACO 954 cancer cell line human CVCL_JA17 CL:0000010 Female Microsatellite instability: Stable (MSS) (PubMed=27004849). 21119541 CVCL_AG86 HPSI0714i-zaos_1 induced pluripotent stem cell human CVCL_AG86 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119542 CVCL_AG85 HPSI0714i-xebt_2 induced pluripotent stem cell human CVCL_AG85 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119543 CVCL_JA19 VACO 964 cancer cell line human CVCL_JA19 CL:0000010 Sequence variation: Mutation; HGNC; 15629; B3GNT2; Simple; p.Arg6Ter (c.16C>T); Zygosity=Unspecified; Note=N-terminally truncated and mislocalized (PubMed=27004849); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119544 CVCL_AG55 HPSI0713i-foop_2 induced pluripotent stem cell human CVCL_AG55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119545 CVCL_AG54 HPSI0713i-foop_1 induced pluripotent stem cell human CVCL_AG54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119546 CVCL_AG57 HPSI0713i-javm_1 induced pluripotent stem cell human CVCL_AG57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119547 CVCL_AG56 HPSI0713i-gaab_1 induced pluripotent stem cell human CVCL_AG56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119548 CVCL_AG59 HPSI0713i-kaks_3 induced pluripotent stem cell human CVCL_AG59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119549 CVCL_AG58 HPSI0713i-kaks_2 induced pluripotent stem cell human CVCL_AG58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119550 CVCL_AG51 HPSI0713i-darw_1 induced pluripotent stem cell human CVCL_AG51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119551 CVCL_AG50 HPSI0713i-dard_2 induced pluripotent stem cell human CVCL_AG50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119552 CVCL_AG53 HPSI0713i-fett_3 induced pluripotent stem cell human CVCL_AG53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119553 CVCL_AG52 HPSI0713i-darw_2 induced pluripotent stem cell human CVCL_AG52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119554 CVCL_JA03 VACO 872 cancer cell line human CVCL_JA03 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119555 CVCL_JA02 VACO 871 cancer cell line human CVCL_JA02 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119556 CVCL_JA05 VACO 893 cancer cell line human CVCL_JA05 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119557 CVCL_JA04 VACO 874 cancer cell line human CVCL_JA04 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119558 CVCL_JA01 VACO 868 cancer cell line human CVCL_JA01 CL:0000010 Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119559 CVCL_JA00 VACO 865 cancer cell line human CVCL_JA00 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=27004849) Derived from metastatic site: Liver. Female Microsatellite instability: Stable (MSS) (PubMed=27004849) 21119560 CVCL_AG66 HPSI0713i-ruyv_3 induced pluripotent stem cell human CVCL_AG66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119561 CVCL_AG65 HPSI0713i-ruyv_1 induced pluripotent stem cell human CVCL_AG65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119562 CVCL_AG68 HPSI0713i-terl_1 induced pluripotent stem cell human CVCL_AG68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119563 CVCL_AG67 HPSI0713i-tadm_2 induced pluripotent stem cell human CVCL_AG67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119564 CVCL_AG69 HPSI0713i-terl_2 induced pluripotent stem cell human CVCL_AG69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119565 CVCL_AG60 HPSI0713i-nemb_1 induced pluripotent stem cell human CVCL_AG60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119566 CVCL_AG62 HPSI0713i-pusf_3 induced pluripotent stem cell human CVCL_AG62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119567 CVCL_AG61 HPSI0713i-nocf_2 induced pluripotent stem cell human CVCL_AG61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119568 CVCL_AG64 HPSI0713i-qimz_2 induced pluripotent stem cell human CVCL_AG64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119569 CVCL_AG63 HPSI0713i-qimz_1 induced pluripotent stem cell human CVCL_AG63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119570 CVCL_AG33 HPSI0613i-vorx_3 induced pluripotent stem cell human CVCL_AG33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119571 CVCL_AG32 HPSI0613i-vorx_1 induced pluripotent stem cell human CVCL_AG32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119572 CVCL_AG35 HPSI0613i-xavk_33 induced pluripotent stem cell human CVCL_AG35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119573 CVCL_AG34 HPSI0613i-xavk_3 induced pluripotent stem cell human CVCL_AG34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119574 CVCL_AG37 HPSI0613i-xucm_3 induced pluripotent stem cell human CVCL_AG37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119575 CVCL_AG36 HPSI0613i-xosg_2 induced pluripotent stem cell human CVCL_AG36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119576 CVCL_AG39 HPSI0614i-dixh_2 induced pluripotent stem cell human CVCL_AG39 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119577 CVCL_AG38 HPSI0613i-zisa_3 induced pluripotent stem cell human CVCL_AG38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119578 CVCL_AG31 HPSI0613i-uexy_2 induced pluripotent stem cell human CVCL_AG31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119579 CVCL_AG30 HPSI0613i-ueah_4 induced pluripotent stem cell human CVCL_AG30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119580 CVCL_AG44 HPSI0614i-uilk_2 induced pluripotent stem cell human CVCL_AG44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119581 CVCL_AG43 HPSI0614i-koqx_1 induced pluripotent stem cell human CVCL_AG43 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119582 CVCL_AG46 HPSI0713i-aehn_2 induced pluripotent stem cell human CVCL_AG46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119583 CVCL_AG45 HPSI0614i-uilk_3 induced pluripotent stem cell human CVCL_AG45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119584 CVCL_AG48 HPSI0713i-cicb_3 induced pluripotent stem cell human CVCL_AG48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119585 CVCL_AG47 HPSI0713i-cicb_2 induced pluripotent stem cell human CVCL_AG47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119586 CVCL_AG49 HPSI0713i-dard_1 induced pluripotent stem cell human CVCL_AG49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119587 CVCL_AG40 HPSI0614i-eavo_1 induced pluripotent stem cell human CVCL_AG40 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119588 CVCL_AG42 HPSI0614i-guyj_2 induced pluripotent stem cell human CVCL_AG42 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119589 CVCL_AG41 HPSI0614i-foyj_1 induced pluripotent stem cell human CVCL_AG41 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119590 CVCL_8M85 DA05964 transformed cell line human CVCL_8M85 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119591 CVCL_8M84 DA05963 transformed cell line human CVCL_8M84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119592 CVCL_8M87 DA05966 transformed cell line human CVCL_8M87 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119593 CVCL_8M86 DA05965 transformed cell line human CVCL_8M86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119594 CVCL_8M81 DA05959 transformed cell line human CVCL_8M81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119595 CVCL_8M80 DA05958 transformed cell line human CVCL_8M80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119596 CVCL_8M83 DA05962 transformed cell line human CVCL_8M83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119597 CVCL_8M82 DA05960 transformed cell line human CVCL_8M82 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119598 CVCL_AG19 HPSI0613i-pasj_3 induced pluripotent stem cell human CVCL_AG19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119599 CVCL_AG18 HPSI0613i-pasj_2 induced pluripotent stem cell human CVCL_AG18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119600 CVCL_8M89 DA05968 transformed cell line human CVCL_8M89 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119601 CVCL_8M88 DA05967 transformed cell line human CVCL_8M88 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119602 CVCL_AG11 HPSI0613i-liun_2 induced pluripotent stem cell human CVCL_AG11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119603 CVCL_AG10 HPSI0613i-lavp_3 induced pluripotent stem cell human CVCL_AG10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119604 CVCL_AG13 HPSI0613i-lizq_1 induced pluripotent stem cell human CVCL_AG13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119605 CVCL_AG12 HPSI0613i-liun_22 induced pluripotent stem cell human CVCL_AG12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119606 CVCL_AG15 HPSI0613i-lula_3 induced pluripotent stem cell human CVCL_AG15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119607 CVCL_AG14 HPSI0613i-lizq_3 induced pluripotent stem cell human CVCL_AG14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119608 CVCL_AG17 HPSI0613i-oefg_2 induced pluripotent stem cell human CVCL_AG17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119609 CVCL_AG16 HPSI0613i-nukw_1 induced pluripotent stem cell human CVCL_AG16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119610 CVCL_8M96 DA05975 transformed cell line human CVCL_8M96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119611 CVCL_8M95 DA05974 transformed cell line human CVCL_8M95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119612 CVCL_8M98 DA05977 transformed cell line human CVCL_8M98 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119613 CVCL_8M97 DA05976 transformed cell line human CVCL_8M97 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119614 CVCL_8M92 DA05971 transformed cell line human CVCL_8M92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119615 CVCL_8M91 DA05970 transformed cell line human CVCL_8M91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119616 CVCL_8M94 DA05973 transformed cell line human CVCL_8M94 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119617 CVCL_8M93 DA05972 transformed cell line human CVCL_8M93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119618 CVCL_AG29 HPSI0613i-ueah_1 induced pluripotent stem cell human CVCL_AG29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119619 CVCL_8M99 DA05978 transformed cell line human CVCL_8M99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119620 CVCL_AG22 HPSI0613i-qonr_1 induced pluripotent stem cell human CVCL_AG22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119621 CVCL_AG21 HPSI0613i-qanu_2 induced pluripotent stem cell human CVCL_AG21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119622 CVCL_AG24 HPSI0613i-qony_1 induced pluripotent stem cell human CVCL_AG24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119623 CVCL_AG23 HPSI0613i-qonr_2 induced pluripotent stem cell human CVCL_AG23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119624 CVCL_AG26 HPSI0613i-riiv_1 induced pluripotent stem cell human CVCL_AG26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21119625 CVCL_AG25 HPSI0613i-qony_2 induced pluripotent stem cell human CVCL_AG25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119626 CVCL_AG28 HPSI0613i-sucu_1 induced pluripotent stem cell human CVCL_AG28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119627 CVCL_AG27 HPSI0613i-riiv_3 induced pluripotent stem cell human CVCL_AG27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119628 CVCL_8M90 DA05969 transformed cell line human CVCL_8M90 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119629 CVCL_AG20 HPSI0613i-qanu_1 induced pluripotent stem cell human CVCL_AG20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119630 CVCL_RY10 HPS0470 induced pluripotent stem cell human CVCL_RY10 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21119631 CVCL_RY12 HPS0489 induced pluripotent stem cell human CVCL_RY12 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21119632 CVCL_RY11 HPS0488 induced pluripotent stem cell human CVCL_RY11 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21119633 CVCL_RY14 1027B3 induced pluripotent stem cell human CVCL_RY14 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 29.37 hours (PubMed=24399248) 21119634 CVCL_RY13 HPS0490 induced pluripotent stem cell human CVCL_RY13 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21119635 CVCL_RY16 1027B6 induced pluripotent stem cell human CVCL_RY16 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 29.05 hours (PubMed=24399248) 21119636 CVCL_RY15 1027B4 induced pluripotent stem cell human CVCL_RY15 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21119637 CVCL_RY18 1120C6 induced pluripotent stem cell human CVCL_RY18 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. 21119638 CVCL_RY17 1120C12 induced pluripotent stem cell human CVCL_RY17 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. 21119639 CVCL_RY19 1120C7 induced pluripotent stem cell human CVCL_RY19 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. 21119640 CVCL_RY01 P7731 cancer cell line human CVCL_RY01 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=28889351; PubMed=29468485); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Ter (c.687T>A); Zygosity=Unspecified (PubMed=28889351; PubMed=29468485) Miscellaneous: Doubling time and age of donor from personal communication of Chenevix-Trench G; Miscellaneous: Conflicts in the STR profile of markers TH01 and vWA between PubMed=28889351 and PubMed=29468485 are clerical errors and are thus not recorded in the relevant section (personal communication of Chenevix-Trench G.) Derived from metastatic site: Bone. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~24 hours (Direct_author_submission) Group: Triple negative breast cancer (TNBC) cell line 21119641 CVCL_RY00 BD [Dog histiocytic sarcoma] cancer cell line dog CVCL_RY00 CL:0000010 Breed/subspecies: Bernese mountain dog. Female Doubling time: ~36 hours (PubMed=29490634) 21119642 CVCL_RY03 ND41871 induced pluripotent stem cell human CVCL_RY03 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser116Ter (c.347C>A); Zygosity=Unspecified (PubMed=23063362) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41871; true Male 21119643 CVCL_RY02 ND41870 induced pluripotent stem cell human CVCL_RY02 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser116Ter (c.347C>A); Zygosity=Unspecified (PubMed=23063362) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41870; true Male 21119644 CVCL_RY05 1L12 induced pluripotent stem cell human CVCL_RY05 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21119645 CVCL_RY04 ND41872 induced pluripotent stem cell human CVCL_RY04 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ser116Ter (c.347C>A); Zygosity=Unspecified (PubMed=23063362) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41872; true Male 21119646 CVCL_RY07 1L9 induced pluripotent stem cell human CVCL_RY07 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21119647 CVCL_RY06 1L23 induced pluripotent stem cell human CVCL_RY06 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21119648 CVCL_RY09 ZZUi009-A induced pluripotent stem cell human CVCL_RY09 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.His214Arg (c.641A>G); Zygosity=Heterozygous (PubMed=29304399) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119649 CVCL_RY08 EC/CUHK1 cancer cell line human CVCL_RY08 CL:0000010 Male 21119650 CVCL_AF99 HPSI0613i-focm_1 induced pluripotent stem cell human CVCL_AF99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119651 CVCL_AF92 HPSI0613i-bawa_1 induced pluripotent stem cell human CVCL_AF92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119652 CVCL_AF91 HPSI0613i-auim_3 induced pluripotent stem cell human CVCL_AF91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119653 CVCL_AF94 HPSI0613i-dium_1 induced pluripotent stem cell human CVCL_AF94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119654 CVCL_AF93 HPSI0613i-bohf_1 induced pluripotent stem cell human CVCL_AF93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119655 CVCL_AF96 HPSI0613i-eojr_3 induced pluripotent stem cell human CVCL_AF96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119656 CVCL_AF95 HPSI0613i-eojr_2 induced pluripotent stem cell human CVCL_AF95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119657 CVCL_AF98 HPSI0613i-febc_2 induced pluripotent stem cell human CVCL_AF98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119658 CVCL_AF97 HPSI0613i-febc_1 induced pluripotent stem cell human CVCL_AF97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119659 CVCL_AF78 HPSI0514i-eoxi_6 induced pluripotent stem cell human CVCL_AF78 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21119660 CVCL_AF77 HPSI0513i-zaui_3 induced pluripotent stem cell human CVCL_AF77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119661 CVCL_AF79 HPSI0514i-fiaj_1 induced pluripotent stem cell human CVCL_AF79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119662 CVCL_AF70 HPSI0513i-uoxz_4 induced pluripotent stem cell human CVCL_AF70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119663 CVCL_AF72 HPSI0513i-veqz_4 induced pluripotent stem cell human CVCL_AF72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119664 CVCL_AF71 HPSI0513i-uoxz_5 induced pluripotent stem cell human CVCL_AF71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119665 CVCL_AF74 HPSI0513i-veve_2 induced pluripotent stem cell human CVCL_AF74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119666 CVCL_AF73 HPSI0513i-veqz_6 induced pluripotent stem cell human CVCL_AF73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119667 CVCL_AF76 HPSI0513i-xegx_2 induced pluripotent stem cell human CVCL_AF76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119668 CVCL_AF75 HPSI0513i-xegx_1 induced pluripotent stem cell human CVCL_AF75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119669 CVCL_AF90 HPSI0613i-auim_2 induced pluripotent stem cell human CVCL_AF90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119670 CVCL_AF89 HPSI0613i-aevs_2 induced pluripotent stem cell human CVCL_AF89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119671 CVCL_AF88 HPSI0613i-aevs_1 induced pluripotent stem cell human CVCL_AF88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119672 CVCL_AF81 HPSI0514i-kidt_1 induced pluripotent stem cell human CVCL_AF81 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119673 CVCL_AF80 HPSI0514i-fiaj_3 induced pluripotent stem cell human CVCL_AF80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119674 CVCL_AF83 HPSI0514i-qihv_1 induced pluripotent stem cell human CVCL_AF83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119675 CVCL_AF82 HPSI0514i-pulk_1 induced pluripotent stem cell human CVCL_AF82 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21119676 CVCL_AF85 HPSI0514i-wiii_2 induced pluripotent stem cell human CVCL_AF85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119677 CVCL_AF84 HPSI0514i-vuna_3 induced pluripotent stem cell human CVCL_AF84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119678 CVCL_AF87 HPSI0514i-yelp_3 induced pluripotent stem cell human CVCL_AF87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119679 CVCL_AF86 HPSI0514i-wiii_3 induced pluripotent stem cell human CVCL_AF86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119680 CVCL_RY90 EC-Cacna2d3tm1Dgen embryonic stem cell house mouse CVCL_RY90 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1338890; Cacna2d3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119681 CVCL_RY92 EC-Cacng4tm1Dgen embryonic stem cell house mouse CVCL_RY92 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1859167; Cacng4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119682 CVCL_RY91 EC-Cacng3tm1Dgen embryonic stem cell house mouse CVCL_RY91 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1859165; Cacng3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119683 CVCL_RY94 EC-Capn7tm1Dgen embryonic stem cell house mouse CVCL_RY94 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1338030; Capn7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119684 CVCL_RY93 EC-Capn5tm1Dgen embryonic stem cell house mouse CVCL_RY93 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1100859; Capn5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119685 CVCL_RY96 EC-Ccr6tm1Dgen embryonic stem cell house mouse CVCL_RY96 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1333797; Ccr6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119686 CVCL_RY95 EC-Ccr1l1tm1Dgen embryonic stem cell house mouse CVCL_RY95 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:104617; Ccr1l1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119687 CVCL_RY98 EC-Ccrl2tm1Dgen embryonic stem cell house mouse CVCL_RY98 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1920904; Ccrl2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119688 CVCL_RY97 EC-Ccr7tm1Dgen embryonic stem cell house mouse CVCL_RY97 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:103011; Ccr7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119689 CVCL_RY99 EC-Cd97tm1Dgen embryonic stem cell house mouse CVCL_RY99 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1347095; Adgre5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119690 CVCL_0440 MRC-5 finite cell line human CVCL_0440 HLA typing: A*02:01,29:02; B*07:02,44:02; C*05:01,07:02 (PubMed=31869419) CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Biotechnology: Used for the production of the Human Diploid Cell Vaccine (HDCV) against rabies (Trade name: Imovax Rabies); Biotechnology: Used for the production of the Hepatitis A vaccines Avaxim, Epaxal, Havrix and Vaqta; Biotechnology: Used for the production of the live varicella virus vaccine (Trade name: Varivax); Biotechnology: Used for the production of the live zoster vaccine (Trade name: Zostavax); Omics: DNA methylation analysis; Omics: Glycosphingolipids analysis; Omics: Proteome analysis by 2D-DE; Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300395; true; Discontinued: ECACC; 97112601; true Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Senescence: Capable of attaining 42-46 population doublings before the onset of senescence (ATCC=CCL-171) Senesces at 26 PDL (PubMed=17395773).; Doubling time: 36 hours (lot 041392), ~5 days (lot 031098), ~2 days (lot 05192003), ~1.5 days (lot 05202005), ~34 hours (lot 06022011), ~38 hours (lot 04212016) (JCRB) Group: Vaccine production cell line 21119691 CVCL_0442 MT58 spontaneously immortalized cell line CVCL_0442 CL:0000010 Sequence variation: Mutation; UniProtKB; P49584; Pcyt1a; Simple; p.Arg140His (c.419G>A); Zygosity=Unspecified (PubMed=8185307) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Displays a thermo-sensitive phenotype At a permissive temperature (33 Celsius), the cells grow at a rate of about 80% of the parental line while maintaining 80-90% phosphatidylcholine levels. At a non-permissive temperature (40 Celsius), the endogenous Pcyt1a/CCT activity decreases dramatically, blocking membrane synthesis and ultimately leading to apoptosis. 21119692 CVCL_0441 MT-1 [Human contaminated breast cancer] cancer cell line human CVCL_0441 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 42.4 +- 6.0 hours (PubMed=9150904); Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=15677628) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00148 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21119693 CVCL_0444 McA-RH7777 cancer cell line Norway rat CVCL_0444 CL:0000010 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21119694 CVCL_0443 MTEC1 spontaneously immortalized cell line house mouse CVCL_0443 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: BALB/c. Unspecified Doubling time: 17.1 hours (PubMed=1581557) 21119695 CVCL_0445 MeWo cancer cell line human CVCL_0445 HLA typing: A*02:01,26:01; B*14:02,38:01; C*08:02,12:03; DPB1*04:01,04:02; DQB1*03:01:01,05:01; DRB1*11:01,01:02 (PubMed=15592718); HLA typing: A*02:01,26:01 (PubMed=25960936); HLA typing: A*02:01,26:01; B*14:02,67:02; C*12:03,12:03; DQB1*06:13,06:13; DRB1*11:30,14:17 (PubMed=26589293); Genome ancestry: African=2.39%; Native American=1.31%; East Asian, North=0.6%; East Asian, South=0.77%; South Asian=7.24%; European, North=25.84%; European, South=61.86% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (PubMed=17260012; PubMed=23851445; ATCC; DepMap); Sequence variation: Mutation; HGNC; 3688; FGFR1; Simple; p.Pro252Ser (c.754C>T); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~32 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033) 21119696 CVCL_RY81 EC-Adamts5tm1Dgen embryonic stem cell house mouse CVCL_RY81 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346321; Adamts5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119697 CVCL_RY80 EC-Adamts4tm1Dgen embryonic stem cell house mouse CVCL_RY80 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1339949; Adamts4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119698 CVCL_RY83 EC-Adcy7tm1Dgen embryonic stem cell house mouse CVCL_RY83 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:102891; Adcy7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119699 CVCL_RY82 EC-Adcy3tm1Dgen embryonic stem cell house mouse CVCL_RY82 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:99675; Adcy3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119700 CVCL_RY85 EC-Atp8a1tm1Dgen embryonic stem cell house mouse CVCL_RY85 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1330848; Atp8a1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119701 CVCL_RY84 EC-Adipor2tm1Dgen embryonic stem cell house mouse CVCL_RY84 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:93830; Adipor2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119702 CVCL_RY87 EC-Axltm1Dgen embryonic stem cell house mouse CVCL_RY87 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1347244; Axl; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119703 CVCL_RY86 EC-Avpr1atm1Dgen embryonic stem cell house mouse CVCL_RY86 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1859216; Avpr1a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119704 CVCL_RY89 EC-Cacna1ctm1Dgen embryonic stem cell house mouse CVCL_RY89 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:103013; Cacna1c; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119705 CVCL_RY88 EC-Birc1atm1Dgen embryonic stem cell house mouse CVCL_RY88 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1298223; Naip1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119706 CVCL_0451 N1E-115 cancer cell line house mouse CVCL_0451 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Adrenergic clone of C-1300 21119707 CVCL_0450 N/N1003A spontaneously immortalized cell line CVCL_0450 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: New Zealand white. Female Doubling time: 24 hours (PubMed=3569698) 21119708 CVCL_0453 NBT-II cancer cell line Norway rat CVCL_0453 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male 21119709 CVCL_0452 N9 transformed cell line house mouse CVCL_0452 CL:0000010 Transformant: Recombinant retrovirus 3RV/VN-11; Derived from sampling site: Embryonic brain Cell type=Microglial cell.; Breed/subspecies: CD-1. Male 21119710 CVCL_0455 NCI-H292 cancer cell line human CVCL_0455 HLA typing: A*68:02,74:01; B*15:17,58:01; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=81.43%; Native American=0.17%; East Asian, North=2.03%; East Asian, South=0%; South Asian=0.28%; European, North=6.04%; European, South=10.06% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=12539049; PubMed=25485619); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Pro496Thrfs*8 (c.1484_1485insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: African American; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-000474; true; Discontinued: KCLB; 21848; probable Female Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21119711 CVCL_0454 SNU-449 cancer cell line human CVCL_0454 HLA typing: A*11:01,31:01; B*39:01,67:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0.29%; East Asian, North=60.93%; East Asian, South=36.75%; South Asian=0%; European, North=0%; European, South=1.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Glu2250Argfs*28 (c.6747dupA); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg712Ter (c.2134C>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Arg (c.416A>G); ClinVar=VCV001500748; Zygosity=Unspecified (PubMed=8824565); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (PubMed=8824565) Population: Korean; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=7543080); 27.74 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21119712 CVCL_0457 NCI-H295A cancer cell line human CVCL_0457 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Grows as monolayer 21119713 CVCL_0456 NCI-H295 cancer cell line human CVCL_0456 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (ATCC) Derived from sampling site: Adrenal gland. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10296 21119714 CVCL_0459 NCI-H460 cancer cell line human CVCL_0459 HLA typing: A*24,68; B*35,51; C*03,15; DQB1*03:01:01,05:01:01; DRB1*01,04 (PubMed=15748285); HLA typing: A*24:02,68:01; B*35:01,51:01; C*03:03,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=65.65%; European, South=32.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (PubMed=12068308; PubMed=12794755; PubMed=17088437; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1311061; PubMed=15900046; PubMed=20557307) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 33 hours (in RPMI 1640 + 10% FBS), 60 hours (in ACL-3), 42 hours (in ACL-3 + BSA) (PubMed=3940644); 19 hours (PubMed=7718330); 0.8 days (PubMed=11551417); 21.5 hours (PubMed=29681454); 18.39 +- 1.35 hours (PubMed=33425914); 17.8 hours (NCI-DTP); ~23 hours (DSMZ=ACC-737); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21119715 CVCL_0458 NCI-H295R cancer cell line human CVCL_0458 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Adrenal gland. Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Grows in a medium called Nu-Serum type I Doubling time: 25 hours (PubMed=29371329) 21119716 CVCL_RY70 HEK293 rLN10_hNid1 transformed cell line human CVCL_RY70 CL:0000010 Transfected with: HGNC; 6485; LAMA5; Transfected with: HGNC; 6486; LAMB1; Transfected with: HGNC; 6492; LAMC1; Transfected with: HGNC; 7821; NID1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119717 CVCL_RY72 293_hSyn1 transformed cell line human CVCL_RY72 CL:0000010 Transfected with: HGNC; 10658; SDC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119718 CVCL_RY71 HEK293 rLN8 transformed cell line human CVCL_RY71 CL:0000010 Transfected with: HGNC; 6484; LAMA4; Transfected with: HGNC; 6486; LAMB1; Transfected with: HGNC; 6492; LAMC1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119719 CVCL_RY74 AgMES embryonic stem cell CVCL_RY74 CL:0000010 Female Group: Non-human primate cell line. 21119720 CVCL_RY73 Tic-FX induced pluripotent stem cell human CVCL_RY73 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21119721 CVCL_RY76 SS23 finite cell line human CVCL_RY76 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.68-1G>C; ClinVar=VCV000251005; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=10200052) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119722 CVCL_RY75 KM8 finite cell line human CVCL_RY75 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Asp433His (c.1297G>C); ClinVar=VCV000003732; Zygosity=Homozygous (PubMed=3391611) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119723 CVCL_RY78 EC-Acvrl1tm1Dgen embryonic stem cell house mouse CVCL_RY78 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1338946; Acvrl1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119724 CVCL_RY77 STM38 finite cell line human CVCL_RY77 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Asp433His (c.1297G>C); ClinVar=VCV000003732; Zygosity=Heterozygous (PubMed=3391611) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119725 CVCL_RY79 EC-Adam21tm1Dgen embryonic stem cell house mouse CVCL_RY79 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1861229; Adam21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21119726 CVCL_0420 MDAH 2774 cancer cell line human CVCL_0420 CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; c.862-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11565033); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=12068308; PubMed=22705003); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=8557231; PubMed=25230021) Derived from sampling site: Ascites. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Discontinued: BCRJ; 0163; probable Female Part of: OCCP ovarian cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10303 21119727 CVCL_0422 MDCK spontaneously immortalized cell line dog CVCL_0422 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-6253; true Female Characteristics: Used for virus production for vaccine development, toxicology and industrial biotechnology research, and high-throughput screening (ATCC); Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Vaccine production cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C426 21119728 CVCL_0421 MDBK spontaneously immortalized cell line CVCL_0421 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6071; true Male Doubling time: ~35 hours (DSMZ=ACC-174); ~24 hours (lot 032699), ~31 hours (lot 07222019) (JCRB) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119729 CVCL_0424 MDCK-II spontaneously immortalized cell line dog CVCL_0424 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Deep proteome analysis Female Group: Vaccine production cell line 21119730 CVCL_0423 MDCK-C7 spontaneously immortalized cell line dog CVCL_0423 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21119731 CVCL_0426 MG-63 cancer cell line human CVCL_0426 HLA typing: A*01:01,01:01; B*08:01,35:08; C*07:01,07:01; DQA1*05:01,05:01; DQB1*02:02,03:04; DRB1*12:05,14:46 (PubMed=26589293); HLA typing: A*01:01:01; B*08:01:01; C*07:01:01; DPB1*01:01:01,04:02:01; DQA1*05:01:01; DQB1*02:01:01; DRB1*03:01:01 (CLS=300441); Genome ancestry: African=3.1%; Native American=0.69%; East Asian, North=2.05%; East Asian, South=0%; South Asian=5.07%; European, North=23.83%; European, South=65.26% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Anecdotal: Have been flown in space on Foton-10 and Foton-M3 to study if differentiation is altered in microgravity (PubMed=9144345; PubMed=9600771; PubMed=24903274) Population: Caucasian; Derived from metastatic site: Bone; left femur. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Can be induced to differentiate by treating the cells with 1,25-dihydroxyvitamin D3 and TGF-beta The cells do not differentiate into the mineralized state, but stop at the matrix maturation stage (PubMed=1577731). Doubling time: 38 hours (PubMed=218153); 28.3 hours (PubMed=19363654); Microsatellite instability: Stable (MSS) (Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: The reported STR profile from CLS of this cell line was changed in June 2019 Seven conflicts with other sources were resolved. 21119732 CVCL_0425 MEG-01 cancer cell line human CVCL_0425 Genome ancestry: African=1.14%; Native American=0%; East Asian, North=79.13%; East Asian, South=17.4%; South Asian=0%; European, North=0%; European, South=2.33% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His233del (c.697_699delCAC); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Can be induced to differentiate into megakaryocytes after application of 12-O-tetradecanoyl-13-phorbol acetate (TPA) or valproic acid (VPA) (PubMed=1742484; PubMed=30332548) Doubling time: 36-48 hours (PubMed=2998511); ~35 hours (DSMZ=ACC-364); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21119733 CVCL_0428 MIA PaCa-2 cancer cell line human CVCL_0428 HLA typing: A*02,24; B*01,46; C*03 (PubMed=18575732); HLA typing: A*24:02:01; B*14:02:01; C*08:02:01; DPB1*02:01:02; DQA1*01:01:02; DQB1*05:01:01; DRB1*01:02:01 (CLS=300438); Genome ancestry: African=1.15%; Native American=0%; East Asian, North=3.82%; East Asian, South=0%; South Asian=8.7%; European, North=22.54%; European, South=63.79% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=7961102; PubMed=8026879; PubMed=11115575; PubMed=11169959; PubMed=11787853; PubMed=12068308; PubMed=21607521; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=1630814; PubMed=1764370; PubMed=7961102; PubMed=8026879; PubMed=8194712; PubMed=11115575; PubMed=11169959; PubMed=11787853; PubMed=21607521; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26 hours (PubMed=25984343); 25.7 +- 4.3 hours (PubMed=27067801); 40 hours, 18 hours, in serum-free medium (PubMed=23386380); ~40 hours (ATCC=CRL-1420); ~30-40 hours (DSMZ=ACC-733); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel Caution: Additional TP53 mutation in c.818G>A indicated incorrectly in PubMed=1630814 21119734 CVCL_0427 MH7A transformed cell line human CVCL_0427 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Synovium Cell type=Fibroblast-like synoviocyte.. Female 21119735 CVCL_0429 mIMCD-3 transformed cell line house mouse CVCL_0429 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; inner medullary collecting duct; Breed/subspecies: Tg(SV40E)Bri/7 transgenic. Unspecified 21119736 CVCL_RY61 YSS37 finite cell line human CVCL_RY61 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.1845+2T>C; ClinVar=VCV000252070; Zygosity=Heterozygous; Note=Splice donor mutation (JCRB) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119737 CVCL_RY60 UM-U-95 finite cell line human CVCL_RY60 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; choroid Cell type=Melanocyte.. Omics: Transcriptome analysis by microarray Unspecified 21119738 CVCL_RY63 293_hSyn2 transformed cell line human CVCL_RY63 CL:0000010 Transfected with: HGNC; 10659; SDC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: JCRB; JCRB1732; probable Female 21119739 CVCL_RY62 293_hEcad/hSyn2 transformed cell line human CVCL_RY62 CL:0000010 Transfected with: HGNC; 1748; CDH1; Transfected with: HGNC; 10659; SDC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: JCRB; JCRB1731; probable Female 21119740 CVCL_RY65 2D5 [Mouse hybridoma against goose parvovirus VP3] hybridoma house mouse CVCL_RY65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; C8CE61; Goose parvovirus strain Ep22 protein VP3. 21119741 CVCL_RY64 293_hEcad transformed cell line human CVCL_RY64 CL:0000010 Transfected with: HGNC; 1748; CDH1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119742 CVCL_RY67 4E2 [Mouse hybridoma against goose parvovirus VP3] hybridoma house mouse CVCL_RY67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; C8CE61; Goose parvovirus strain Ep22 protein VP3. 21119743 CVCL_RY66 4A8 [Mouse hybridoma against goose parvovirus VP3] hybridoma house mouse CVCL_RY66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; C8CE61; Goose parvovirus strain Ep22 protein VP3. 21119744 CVCL_RY69 HEK293 rLN10 transformed cell line human CVCL_RY69 CL:0000010 Transfected with: HGNC; 6485; LAMA5; Transfected with: HGNC; 6486; LAMB1; Transfected with: HGNC; 6492; LAMC1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119745 CVCL_RY68 293_hSyn4 transformed cell line human CVCL_RY68 CL:0000010 Transfected with: HGNC; 10661; SDC4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119746 CVCL_0431 MIN6 transformed cell line house mouse CVCL_0431 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Omics: Cell surface proteome; Omics: Endoplasmic reticulum proteome analysis Unspecified 21119747 CVCL_0430 mIMCD-K2 transformed cell line house mouse CVCL_0430 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; inner medullary collecting duct; Breed/subspecies: Tg(SV40E)Bri/7 transgenic. Male Doubling time: 20.9 +- 1.4 hours (PubMed=7864176) 21119748 CVCL_0433 MIO-M1 spontaneously immortalized cell line human CVCL_0433 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Omics: Deep proteome analysis; Omics: Metabolome analysis Female 21119749 CVCL_0432 MIN6N8a transformed cell line house mouse CVCL_0432 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Unspecified 21119750 CVCL_0435 ML-1a cancer cell line human CVCL_0435 From: Takeda K.; Showa University; Tokyo; Japan CL:0000010 Population: Japanese. 21119751 CVCL_0434 MKN45 cancer cell line human CVCL_0434 HLA typing: A*24:02,24:02; B*52:01; C*12:02,12:02 (PubMed=25960936); HLA typing: A*24:02,24:02; B*52:01,67:02; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=1.54%; Native American=0%; East Asian, North=85.37%; East Asian, South=9.42%; South Asian=0%; European, North=0%; European, South=3.67% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30-33 hours (PubMed=3962675); 30-38 hours (CelloPub=CLPUB00584); 16 hours (PubMed=2105279); ~60 hours (DSMZ=ACC-409); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: MD Anderson Cell Lines Project Caution: Was indicated not to have a TP53 mutation in PubMed=1370612 and PubMed=15900046 21119752 CVCL_0437 MLg spontaneously immortalized cell line house mouse CVCL_0437 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: ddY. Omics: SNP array analysis Unspecified 21119753 CVCL_0436 ML-1 [Human leukemia] cancer cell line human CVCL_0436 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep quantitative phosphoproteome analysis Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21119754 CVCL_0439 MNNG/HOS Cl #5 cancer cell line human CVCL_0439 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Derived from sampling site: Bone; right femur. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7734; true; Discontinued: ATCC; CRL-7735; true Female Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119755 CVCL_0409 MC3T3-E1 spontaneously immortalized cell line house mouse CVCL_0409 CL:0000010 Anecdotal: Have been flown in space on shuttle flights STS-56, STS-76, STS-81 and STS-84 to study growth and differentiation in microgravity (PubMed=8612673; PubMed=12638602) Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Omics: SNP array analysis Discontinued: ATCC; CRL-2953; probable Unspecified Doubling time: ~1-2 days (DSMZ=ACC-210) Group: Space-flown cell line (cellonaut) 21119756 CVCL_RY50 ND50071 induced pluripotent stem cell human CVCL_RY50 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119757 CVCL_RY52 ND50057 induced pluripotent stem cell human CVCL_RY52 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: NHCDR; ND50057; true Female 21119758 CVCL_RY51 ND50072 induced pluripotent stem cell human CVCL_RY51 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Eye; ocular lens Cell type=Fibroblast.. Male 21119759 CVCL_RY54 ND50063 induced pluripotent stem cell human CVCL_RY54 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119760 CVCL_RY53 ND50058 induced pluripotent stem cell human CVCL_RY53 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: NHCDR; ND50058; true Female 21119761 CVCL_RY56 ND50065 induced pluripotent stem cell human CVCL_RY56 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119762 CVCL_RY55 ND50064 induced pluripotent stem cell human CVCL_RY55 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119763 CVCL_RY58 ND50097 induced pluripotent stem cell human CVCL_RY58 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119764 CVCL_RY57 RHB1 cancer cell line human CVCL_RY57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Gly (c.403T>G); ClinVar=VCV000376563; Zygosity=Unspecified (PubMed=28889351). Female 21119765 CVCL_RY59 GEE spontaneously immortalized cell line CVCL_RY59 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Doubling time: 16.3 hours (at 20th passage), 18.12 hours (at 45th passage), 18.98 hours (at 65th passage) (PubMed=29494688) Group: Bird cell line 21119766 CVCL_0400 M059J cancer cell line human CVCL_0400 HLA typing: A*01:01,02:01; B*08:01,40:01; C*03:04,07:01 (PubMed=26589293); Genome ancestry: African=1.01%; Native American=0%; East Asian, North=2.75%; East Asian, South=0%; South Asian=0%; European, North=67.68%; European, South=28.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9413; PRKDC; Simple; p.Thr1351Profs*8 (c.4051delA); Zygosity=Heterozygous (PubMed=11418067; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro204fs*17 (c.610delC); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286lys (c.856G>A); Zygosity=Homozygous (PubMed=11023613; Cosmic-CLP; DepMap) Karyotypic information: Has a near pentaploid phenotype Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Radiosensitive (PubMed=7494872) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3 Caution: Was incorrectly stated to have deleterious mutations in ATM in PubMed=12105990. 21119767 CVCL_0402 M12.4.1 cancer cell line house mouse CVCL_0402 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Breed/subspecies: BALB/c. 21119768 CVCL_0401 M059K cancer cell line human CVCL_0401 HLA typing: A*01:01,02:01; B*08:01,40:01; C*03:04,07:01 (PubMed=26589293); Genome ancestry: African=0.16%; Native American=0%; East Asian, North=2.3%; East Asian, South=0%; South Asian=0%; European, North=69.38%; European, South=28.16% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro204fs*17 (c.610delC); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286lys (c.856G>A); Zygosity=Homozygous (PubMed=11023613; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Radioresistant (PubMed=7494872) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21119769 CVCL_0404 M7TS90 cancer cell line human CVCL_0404 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21119770 CVCL_0403 M12.4.5 cancer cell line house mouse CVCL_0403 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Breed/subspecies: BALB/c. 21119771 CVCL_0406 MAIL8-3 transformed cell line human CVCL_0406 CL:0000010 Transfected with: HGNC; 16412; NLRC4 (with p.Leu152_Ala1024del, CARD domain, C12N2 construct); Transfected with: HGNC; 5331; NOD2 (with p.Met1_Ala216del, NACHT+LRR domains, C12N2 construct); Transfected with: HGNC; 16608; PYCARD; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21119772 CVCL_0405 Mahlavu cancer cell line human CVCL_0405 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=8224613; PubMed=31063779) Population: African; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 22.5 hours (CelloPub=CLPUB00076); 52.01 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21119773 CVCL_0408 MC/9 factor-dependent cell line house mouse CVCL_0408 CL:0000010 Derived from sampling site: Liver Cell type=Mast cell.; Breed/subspecies: C57BL/6 x A/J. Unspecified Characteristics: IL3 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8306 21119774 CVCL_0407 MBEC4 transformed cell line house mouse CVCL_0407 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 21119775 CVCL_RY41 ND50099 induced pluripotent stem cell human CVCL_RY41 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Non-edited control for NH50098 (Cellosaurus=CVCL_RY40) 21119776 CVCL_RY40 ND50098 induced pluripotent stem cell human CVCL_RY40 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119777 CVCL_RY43 ND50101 induced pluripotent stem cell human CVCL_RY43 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (NHCDR) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Non-edited control for NH50100 (Cellosaurus=CVCL_RY42) 21119778 CVCL_RY42 ND50100 induced pluripotent stem cell human CVCL_RY42 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple_corrected; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119779 CVCL_RY45 ND50055 induced pluripotent stem cell human CVCL_RY45 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119780 CVCL_RY44 ND50054 induced pluripotent stem cell human CVCL_RY44 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119781 CVCL_RY47 ND50070 induced pluripotent stem cell human CVCL_RY47 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119782 CVCL_RY46 ND50056 induced pluripotent stem cell human CVCL_RY46 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119783 CVCL_RY49 ND50068 induced pluripotent stem cell human CVCL_RY49 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Heterozygous (NHCDR) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119784 CVCL_RY48 ND50069 induced pluripotent stem cell human CVCL_RY48 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21119785 CVCL_0411 MCF10A-Myc spontaneously immortalized cell line human CVCL_0411 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21119786 CVCL_0410 MC615 transformed cell line house mouse CVCL_0410 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic limb; cartilage Cell type=Chondrocyte.; Breed/subspecies: CD-1. Unspecified 21119787 CVCL_0413 MCF7/BUS cancer cell line human CVCL_0413 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Shows a very high proliferative response to estradiol-17beta (PubMed=7498097) Doubling time: 32 +- 1.7 hours (in 10% FBS-DME), 46 + 3.0 hours (in CDHS-PhR DME) (PubMed=7498097) 21119788 CVCL_0412 MCF-7/2a cancer cell line human CVCL_0412 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:29063; L-mimosine; Derived from metastatic site: Pleural effusion. Female Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (Cellosaurus=CVCL_4Y53), L-mimosine-resistant MCF-7/2a (Cellosaurus=CVCL_0412) and EREwtcluc transfected MCF-7-2a (Cellosaurus=CVCL_4Y54) 21119789 CVCL_0415 MCF7mp53 cancer cell line human CVCL_0415 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21119790 CVCL_0417 MDA-MB-435 cancer cell line human CVCL_0417 HLA typing: A*11:01:01,24:02:01; B*15,35; C*03:03:01,04; DPB1*13:01,19:01; DQB1*03:02,06:03; DRB1*04:05:01,13:01:01 (PubMed=15748285); HLA typing: A*24:02,24:02; B*15:01,15:01; C*03:03,03:03 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17088437); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=28889351) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000351) It was one of the sources for the STR profile of this entry. Derived from metastatic site: Right buttock; hypodermis. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 25.8 hours (NCI-DTP); 38.72 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel; Part of: NCI-60 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00235; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12583 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=17004106; PubMed=18304946; PubMed=20143388; PubMed=28940260). Originally thought to originate from the pleural effusion of a breast carcinoma from a 31 year old patient. See also PubMed=19549886 for a dissenting but incorrect view that states that M14 is a breast cancer cell line. 21119791 CVCL_0416 MCT transformed cell line house mouse CVCL_0416 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; renal tubule Cell type=Epithelial cell.; Breed/subspecies: SJL. 21119792 CVCL_0419 MDA-MB-468 cancer cell line human CVCL_0419 HLA typing: A*23:01,30:02; B*27:03,53:01; C*02:02,04:01 (PubMed=25960936); HLA typing: A*23:01,30:02; B*27:03,53:01; C*02:02,04:01; DQA1*02:01,05:02; DQB1*03:04,06:13; DRB1*04:03,13:100 (PubMed=26589293); Genome ancestry: African=80.3%; Native American=0%; East Asian, North=6.19%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=13.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=19593635); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=28889351; ATCC) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300279; true Female Doubling time: 40.6 hours (PubMed=32576280); 62 hours (NCI-DTP); ~30-40 hours (DSMZ=ACC-738); ~47 hours (PBCF); 79.76 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21119793 CVCL_0418 MDA-MB-453 cancer cell line human CVCL_0418 HLA typing: A*01:01,24:02; B*37:04,58:05; C*07:01,07:01; DQB1*06:13,06:13 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.43%; East Asian, South=0%; South Asian=0.43%; European, North=63.01%; European, South=34.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gln868His (c.2604G>T); Zygosity=Unspecified (PubMed=22719059); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Trp638Ter (c.1913G>A); ClinVar=VCV000599651; Zygosity=Homozygous (PubMed=19593635; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=22121396); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu307Lys (c.919G>A); Zygosity=Heterozygous (PubMed=19593635; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex10-11del; Zygosity=Homozygous (PubMed=1961733) Population: Caucasian; Derived from metastatic site: Pericardial effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 38 hours (PubMed=25984343); 68.8 hours (PubMed=9815641); ~50-60 hours (DSMZ=ACC-65); 62.49 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21119794 CVCL_RY30 LE9004-RCC cancer cell line human CVCL_RY30 CL:0000010 Unspecified 21119795 CVCL_RY32 Tni-FNL spontaneously immortalized cell line CVCL_RY32 CL:0000010 Unspecified Characteristics: Can grow efficiently at 21 or 27 Celsius in adherent or suspension conditions Doubling time: 21 hours (Kerafast). Group: Insect cell line; Group: Serum/protein free medium cell line; Group: Recombinant protein production insect cell line 21119796 CVCL_RY31 Bre80hTert telomerase immortalized cell line human CVCL_RY31 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female 21119797 CVCL_RY34 ND50049 induced pluripotent stem cell human CVCL_RY34 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119798 CVCL_RY33 ND40996 finite cell line human CVCL_RY33 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119799 CVCL_RY36 ND50085 induced pluripotent stem cell human CVCL_RY36 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple_corrected; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119800 CVCL_RY35 ND50050 induced pluripotent stem cell human CVCL_RY35 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119801 CVCL_RY38 ND50093 induced pluripotent stem cell human CVCL_RY38 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119802 CVCL_RY37 ND50086 induced pluripotent stem cell human CVCL_RY37 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Non-edited control for NH50085 (Cellosaurus=CVCL_RY36) 21119803 CVCL_RY39 ND50094 induced pluripotent stem cell human CVCL_RY39 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21119804 CVCL_RY21 1156D2 induced pluripotent stem cell human CVCL_RY21 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. 21119805 CVCL_RY20 1156D15 induced pluripotent stem cell human CVCL_RY20 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. 21119806 CVCL_RY23 987A12 induced pluripotent stem cell human CVCL_RY23 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21119807 CVCL_RY22 1156D5 induced pluripotent stem cell human CVCL_RY22 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. 21119808 CVCL_RY25 987A7 induced pluripotent stem cell human CVCL_RY25 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 28.09 hours (PubMed=24399248) 21119809 CVCL_RY24 987A3 induced pluripotent stem cell human CVCL_RY24 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 26.00 hours (PubMed=24399248) 21119810 CVCL_RY27 K-562 CRISPRa+SaCas9 clone C7 cancer cell line human CVCL_RY27 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; J7RUA5; Staphylococcus aureus Cas9; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: This cell line is transfected by a nuclease-deficient mutant of SpCas9 (dCas9) under the control of a promoter containing 4 copies of the activating domain of HSV-1 VP16 (termed VP64) and to 24 copies of a short peptide epitope (from yeast GCN4) which is termed SunTag 21119811 CVCL_RY26 K-562 CRISPRa cancer cell line human CVCL_RY26 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: This cell line is transfected by a nuclease-deficient mutant of SpCas9 (dCas9) under the control of a promoter containing 4 copies of the activating domain of HSV-1 VP16 (termed VP64) and to 24 copies of a short peptide epitope (from yeast GCN4) which is termed SunTag 21119812 CVCL_RY29 LB1358-RCC cancer cell line human CVCL_RY29 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21119813 CVCL_RY28 K-562 CRISPRa+SaCas9 clone C11 cancer cell line human CVCL_RY28 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; J7RUA5; Staphylococcus aureus Cas9; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: This cell line is transfected by a nuclease-deficient mutant of SpCas9 (dCas9) under the control of a promoter containing 4 copies of the activating domain of HSV-1 VP16 (termed VP64) and to 24 copies of a short peptide epitope (from yeast GCN4) which is termed SunTag 21119814 CVCL_8N84 DA06080 transformed cell line human CVCL_8N84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119815 CVCL_8N83 DA06078 transformed cell line human CVCL_8N83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119816 CVCL_8N86 DA06083 transformed cell line human CVCL_8N86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119817 CVCL_8N85 DA06081 transformed cell line human CVCL_8N85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119818 CVCL_8N80 DA06073 transformed cell line human CVCL_8N80 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119819 CVCL_8N82 DA06076 transformed cell line human CVCL_8N82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119820 CVCL_8N81 DA06074 transformed cell line human CVCL_8N81 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119821 CVCL_AH18 HPSI0813i-vajx_2 induced pluripotent stem cell human CVCL_AH18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119822 CVCL_AH17 HPSI0813i-uaqe_1 induced pluripotent stem cell human CVCL_AH17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119823 CVCL_AH19 HPSI0813i-voas_2 induced pluripotent stem cell human CVCL_AH19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119824 CVCL_8N88 DA06085 transformed cell line human CVCL_8N88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119825 CVCL_8N87 DA06084 transformed cell line human CVCL_8N87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119826 CVCL_8N89 DA06086 transformed cell line human CVCL_8N89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119827 CVCL_AH10 HPSI0813i-iill_1 induced pluripotent stem cell human CVCL_AH10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119828 CVCL_AH12 HPSI0813i-meqo_2 induced pluripotent stem cell human CVCL_AH12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119829 CVCL_AH11 HPSI0813i-iill_3 induced pluripotent stem cell human CVCL_AH11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119830 CVCL_AH14 HPSI0813i-piun_3 induced pluripotent stem cell human CVCL_AH14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119831 CVCL_AH13 HPSI0813i-meqo_3 induced pluripotent stem cell human CVCL_AH13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119832 CVCL_AH16 HPSI0813i-robp_3 induced pluripotent stem cell human CVCL_AH16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119833 CVCL_AH15 HPSI0813i-raki_1 induced pluripotent stem cell human CVCL_AH15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119834 CVCL_8N95 DA06095 transformed cell line human CVCL_8N95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119835 CVCL_8N94 DA06094 transformed cell line human CVCL_8N94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119836 CVCL_8N97 DA06097 transformed cell line human CVCL_8N97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119837 CVCL_8N96 DA06096 transformed cell line human CVCL_8N96 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119838 CVCL_8N91 DA06088 transformed cell line human CVCL_8N91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119839 CVCL_8N90 DA06087 transformed cell line human CVCL_8N90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119840 CVCL_8N93 DA06092 transformed cell line human CVCL_8N93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119841 CVCL_8N92 DA06089 transformed cell line human CVCL_8N92 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119842 CVCL_AH29 HPSI0913i-duuy_1 induced pluripotent stem cell human CVCL_AH29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21119843 CVCL_AH28 HPSI0913i-diku_1 induced pluripotent stem cell human CVCL_AH28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119844 CVCL_8N99 DA06099 transformed cell line human CVCL_8N99 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119845 CVCL_8N98 DA06098 transformed cell line human CVCL_8N98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119846 CVCL_AH21 HPSI0813i-zexw_3 induced pluripotent stem cell human CVCL_AH21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119847 CVCL_AH20 HPSI0813i-wots_3 induced pluripotent stem cell human CVCL_AH20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119848 CVCL_AH23 HPSI0814i-bokz_6 induced pluripotent stem cell human CVCL_AH23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119849 CVCL_AH22 HPSI0814i-bokz_5 induced pluripotent stem cell human CVCL_AH22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119850 CVCL_AH25 HPSI0814i-doao_2 induced pluripotent stem cell human CVCL_AH25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119851 CVCL_AH24 HPSI0814i-doao_1 induced pluripotent stem cell human CVCL_AH24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119852 CVCL_AH27 HPSI0913i-coyi_3 induced pluripotent stem cell human CVCL_AH27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119853 CVCL_AH26 HPSI0913i-bulb_1 induced pluripotent stem cell human CVCL_AH26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119854 CVCL_8N62 DA06052 transformed cell line human CVCL_8N62 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119855 CVCL_8N61 DA06051 transformed cell line human CVCL_8N61 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119856 CVCL_8N64 DA06054 transformed cell line human CVCL_8N64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119857 CVCL_8N63 DA06053 transformed cell line human CVCL_8N63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119858 CVCL_8N60 DA06049 transformed cell line human CVCL_8N60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119859 CVCL_8N69 DA06059 transformed cell line human CVCL_8N69 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119860 CVCL_8N66 DA06056 transformed cell line human CVCL_8N66 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119861 CVCL_8N65 DA06055 transformed cell line human CVCL_8N65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119862 CVCL_8N68 DA06058 transformed cell line human CVCL_8N68 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119863 CVCL_8N67 DA06057 transformed cell line human CVCL_8N67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119864 CVCL_8N73 DA06065 transformed cell line human CVCL_8N73 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119865 CVCL_8N72 DA06063 transformed cell line human CVCL_8N72 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119866 CVCL_8N75 DA06067 transformed cell line human CVCL_8N75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119867 CVCL_8N74 DA06066 transformed cell line human CVCL_8N74 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119868 CVCL_8N71 DA06062 transformed cell line human CVCL_8N71 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119869 CVCL_8N70 DA06061 transformed cell line human CVCL_8N70 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119870 CVCL_AH07 HPSI0813i-guss_1 induced pluripotent stem cell human CVCL_AH07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119871 CVCL_AH06 HPSI0813i-fpdr_2 induced pluripotent stem cell human CVCL_AH06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119872 CVCL_AH09 HPSI0813i-iicq_3 induced pluripotent stem cell human CVCL_AH09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119873 CVCL_AH08 HPSI0813i-iicq_1 induced pluripotent stem cell human CVCL_AH08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119874 CVCL_8N77 DA06069 transformed cell line human CVCL_8N77 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119875 CVCL_8N76 DA06068 transformed cell line human CVCL_8N76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119876 CVCL_8N79 DA06071 transformed cell line human CVCL_8N79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119877 CVCL_8N78 DA06070 transformed cell line human CVCL_8N78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119878 CVCL_AH01 HPSI0813i-fpdj_3 induced pluripotent stem cell human CVCL_AH01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119879 CVCL_AH00 HPSI0813i-ffdr_3 induced pluripotent stem cell human CVCL_AH00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119880 CVCL_AH03 HPSI0813i-fpdl_1 induced pluripotent stem cell human CVCL_AH03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119881 CVCL_AH02 HPSI0813i-fpdk_2 induced pluripotent stem cell human CVCL_AH02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119882 CVCL_AH05 HPSI0813i-fpdm_2 induced pluripotent stem cell human CVCL_AH05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119883 CVCL_AH04 HPSI0813i-fpdl_2 induced pluripotent stem cell human CVCL_AH04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Peripheral blood. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119884 CVCL_8N40 DA06025 transformed cell line human CVCL_8N40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119885 CVCL_8N42 DA06027 transformed cell line human CVCL_8N42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119886 CVCL_8N41 DA06026 transformed cell line human CVCL_8N41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119887 CVCL_8N48 DA06037 transformed cell line human CVCL_8N48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119888 CVCL_8N47 DA06033 transformed cell line human CVCL_8N47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119889 CVCL_8N49 DA06038 transformed cell line human CVCL_8N49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119890 CVCL_8N44 DA06029 transformed cell line human CVCL_8N44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119891 CVCL_8N43 DA06028 transformed cell line human CVCL_8N43 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119892 CVCL_8N46 DA06032 transformed cell line human CVCL_8N46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119893 CVCL_8N45 DA06030 transformed cell line human CVCL_8N45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119894 CVCL_8N51 DA06040 transformed cell line human CVCL_8N51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119895 CVCL_8N50 DA06039 transformed cell line human CVCL_8N50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119896 CVCL_8N53 DA06042 transformed cell line human CVCL_8N53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119897 CVCL_8N52 DA06041 transformed cell line human CVCL_8N52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119898 CVCL_8N59 DA06048 transformed cell line human CVCL_8N59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119899 CVCL_8N58 DA06047 transformed cell line human CVCL_8N58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119900 CVCL_8N55 DA06044 transformed cell line human CVCL_8N55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119901 CVCL_8N54 DA06043 transformed cell line human CVCL_8N54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119902 CVCL_8N57 DA06046 transformed cell line human CVCL_8N57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119903 CVCL_8N56 DA06045 transformed cell line human CVCL_8N56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119904 CVCL_8N20 DA06001 transformed cell line human CVCL_8N20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119905 CVCL_8N26 DA06009 transformed cell line human CVCL_8N26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119906 CVCL_8N25 DA06007 transformed cell line human CVCL_8N25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119907 CVCL_8N28 DA06011 transformed cell line human CVCL_8N28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119908 CVCL_8N27 DA06010 transformed cell line human CVCL_8N27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119909 CVCL_8N22 DA06004 transformed cell line human CVCL_8N22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119910 CVCL_8N21 DA06002 transformed cell line human CVCL_8N21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119911 CVCL_8N24 DA06006 transformed cell line human CVCL_8N24 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119912 CVCL_0590 Kasumi-2 cancer cell line human CVCL_0590 HLA typing: A*24:02,26:02; B*40:06,54:01; C*01:02,08:01; DQA1*03:02,04:01; DQB1*03:04,03:04; DRB1*09:01,11:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.35%; East Asian, North=80.22%; East Asian, South=17.64%; South Asian=0%; European, North=1.01%; European, South=0.78% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=32180206; PubMed=35354797; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Ser (c.37G>A); ClinVar=VCV000376323; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val14Leu (c.40G>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~30 hours (DSMZ=ACC-526); ~45 hours (lot 01182019) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21119913 CVCL_8N23 DA06005 transformed cell line human CVCL_8N23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119914 CVCL_0581 WRL 68 cancer cell line human CVCL_0581 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: BCRC; 60338; true Female Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00351; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-48 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to be a hepatic fetal epithelial cell line. 21119915 CVCL_0580 WM35 cancer cell line human CVCL_0580 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.26%; East Asian, South=0.38%; South Asian=0.25%; European, North=72.7%; European, South=26.42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=18632627; Cosmic-CLP; DepMap; Wistar) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2807; true; Discontinued: Coriell; WC00060; probable. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21119916 CVCL_0583 WiT49 cancer cell line human CVCL_0583 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=14506735) Derived from metastatic site: Lung. Female Characteristics: Established from a first-generation nude mouse subcutaneous xenograft 21119917 CVCL_0582 WRO cancer cell line human CVCL_0582 Genome ancestry: African=2.33%; Native American=0%; East Asian, North=1.32%; East Asian, South=3.34%; South Asian=7.27%; European, North=24%; European, South=61.74% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23162534); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Homozygous (PubMed=8423216; PubMed=14522906; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 4 days (PubMed=2570483); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21119918 CVCL_8N19 DA06000 transformed cell line human CVCL_8N19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119919 CVCL_0585 Y1 cancer cell line house mouse CVCL_0585 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Omics: SNP array analysis Discontinued: ECACC; 85051002; probable Male Doubling time: ~30-40 hours (PubMed=423792) 21119920 CVCL_8N18 DA05999 transformed cell line human CVCL_8N18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119921 CVCL_0584 Jurkat Wurzburg cancer cell line human CVCL_0584 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 16.6 +- 2 hours (PubMed=10468210) 21119922 CVCL_0587 YPEN-1 transformed cell line Norway rat CVCL_0587 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Prostate Cell type=Endothelial cell.; Breed/subspecies: Copenhagen. Male Doubling time: 26 hours (PubMed=8900918) 21119923 CVCL_0586 YMB-A cancer cell line human CVCL_0586 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (YMB-1) has been shown to be a ZR-75-1 derivative. 21119924 CVCL_0589 Kasumi-1 cancer cell line human CVCL_0589 HLA typing: A*26:01,26:01; B*40:06,40:06; C*03:03,08:01 (PubMed=26589293); HLA typing: A*26:02:01,26:01:01; B*40:06:01,48:01:01; C*03:03:01,08:01:01; DPB1*02:01:02,02:01:02; DRA*01:01:01,01:01:01; DRB1*14:54:01,09:01:02 (DSMZCellDive=ACC-220); Genome ancestry: African=1.19%; Native American=0%; East Asian, North=74.84%; East Asian, South=22.29%; South Asian=0%; European, North=0%; European, South=1.67% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (PubMed=11753612; PubMed=15843827; PubMed=24976338; PubMed=25485619); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Heterozygous (PubMed=12111653; PubMed=18385756); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Lys330Profs*6 (c.987insCCGG); Zygosity=Unspecified (PubMed=23955599); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP) Population: Japanese; Karyotypic information: Has lost chromosome Y (PubMed=2018839) But some chromosome Y fragments are integrated into other chromosomes (PubMed=18292219).; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0235; true Male Doubling time: 40-45 hours (PubMed=2018839); 40 hours (PubMed=25984343); 53 hours (PubMed=20922763); ~48-72 hours (DSMZ=ACC-220); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21119925 CVCL_0588 ZR-75-1 cancer cell line human CVCL_0588 HLA typing: A*24/11,11; B*35:01; C*04:01,04:01; DQB1*05:01,05:01; DRB1*01:01,13:03 (PubMed=25960936); HLA typing: A*11:01,24:02; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.23%; East Asian, South=0%; South Asian=0.14%; European, North=65.96%; European, South=32.67% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (PubMed=19593635; DepMap) Anecdotal: Used in a study utilising the fruit fly's olfactory system to detect cancer cells (PubMed=24389870) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Discontinued: RCB; RCB1906; true Female Doubling time: 80 hours, at 40th passage (PubMed=688225); 79 hours (PubMed=24389870); ~54 hours (PBCF); 70.09 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21119926 CVCL_8N31 DA06014 transformed cell line human CVCL_8N31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119927 CVCL_8N30 DA06013 transformed cell line human CVCL_8N30 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119928 CVCL_8N37 DA06022 transformed cell line human CVCL_8N37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119929 CVCL_8N36 DA06020 transformed cell line human CVCL_8N36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119930 CVCL_8N39 DA06024 transformed cell line human CVCL_8N39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119931 CVCL_8N38 DA06023 transformed cell line human CVCL_8N38 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119932 CVCL_8N33 DA06016 transformed cell line human CVCL_8N33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119933 CVCL_8N32 DA06015 transformed cell line human CVCL_8N32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119934 CVCL_8N35 DA06019 transformed cell line human CVCL_8N35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119935 CVCL_8N34 DA06017 transformed cell line human CVCL_8N34 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119936 CVCL_0592 MDCK-I spontaneously immortalized cell line dog CVCL_0592 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Vaccine production cell line 21119937 CVCL_0591 RBL-2H3 cancer cell line Norway rat CVCL_0591 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. Doubling time: ~50-60 hours (DSMZ=ACC-312) 21119938 CVCL_0594 NIH 3T3 spontaneously immortalized cell line house mouse CVCL_0594 CL:0000010 Miscellaneous: PubMed=23430347 has a different value for STR 4-2 (19.3) than that of NIST (19.3,20.3) due to a change in the stutter rules (personal communication of Almeida J.L.); Miscellaneous: PubMed=23430347 has a different value for STR 6-4 (14.3) than that of NIST (15.3) due to a change in the marker motif (personal communication of Almeida J.L.) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-6442; true Male Doubling time: ~20 hours (DSMZ=ACC-59) Part of: ENCODE project mouse cell lines; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21119939 CVCL_0593 Mv1Lu spontaneously immortalized cell line CVCL_0593 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Discontinued: ATCC; CRL-6584; true Mixed Virology: Susceptible to infection and replication of influenza A and B viruses (PubMed=9817906) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3450 21119940 CVCL_0596 R1B-L17 spontaneously immortalized cell line CVCL_0596 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Mixed 21119941 CVCL_8N29 DA06012 transformed cell line human CVCL_8N29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21119942 CVCL_0595 R1B spontaneously immortalized cell line CVCL_0595 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Mixed 21119943 CVCL_0598 MCF-10A spontaneously immortalized cell line human CVCL_0598 HLA typing: A*01:01,33:01; B*40:01,55:01; C*03:03,07:02; DQA1*02:01,03:02; DQB1*03:05,03:05; DRB1*04:02,11:44 (PubMed=25960936); HLA typing: A*01:01,33:01; B*40:01,55:01; C*03:03,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17334996); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=17334996) Derived from sampling site: Breast; epithelium. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: Metabolome analysis; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 97.4 hours (PubMed=24389870); 20 hours (PubMed=34238275); 26.74 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10317 21119944 CVCL_0597 Ramos cancer cell line human CVCL_0597 HLA typing: A*03:01,03:01; B*44:03,51:01; C*16:01,16:01; DQA1*02:01,02:01; DQB1*02:01,02:01; DRB1*07:01,14:103 (PubMed=25960936); HLA typing: A*03:01,03:01; B*44:03,51:01; C*16:01,16:01; DQA1*02:01,02:01; DQB1*02:01,02:01; DRB1*07:01,14:05 (PubMed=26589293); HLA typing: A*03:01:01; B*44:160Q,51:01:01; C*16:01:01; DPB1*04:01:01,104:01:01; DQA1*02:01:01; DQB1*02:02:01; DRB1*07:01:01 (CLS=302007); HLA typing: A*03:01:01,03:01:01; B*44:03:01,51:01:01; C*16:01:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01; DQA1*02:01:01,02:01:01; DRA*01:01:01,01:01:01; DRB1*07:01:01,07:01:01 (DSMZCellDive=ACC-603) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=10918597); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (PubMed=1915267; PubMed=2052620; PubMed=8344493) Population: Caucasian; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: EBV-negative Doubling time: 20.4 +- 1.5 hours (PubMed=9225077); 23 hours (PubMed=8402660); 14 hours (PubMed=20922763); ~48 hours (DSMZ=ACC-603); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21119945 CVCL_0599 SK-MEL-24 cancer cell line human CVCL_0599 HLA typing: A*01:01,02:01; B*14:01,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=1.73%; Native American=0.82%; East Asian, North=1.82%; East Asian, South=0%; South Asian=0%; European, North=60.41%; European, South=35.21% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=26405815; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2003-078 21119946 CVCL_JB35 NLGIP-5420 transformed cell line human CVCL_JB35 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119947 CVCL_JB34 NLGIP-5370 transformed cell line human CVCL_JB34 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119948 CVCL_JB37 NLGIP-5519 transformed cell line human CVCL_JB37 CL:0000010 Population: Jewish; Lybian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119949 CVCL_JB36 NLGIP-5452 transformed cell line human CVCL_JB36 CL:0000010 Population: Jewish; Lybian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119950 CVCL_JB31 NLGIP-5341 transformed cell line human CVCL_JB31 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119951 CVCL_JB30 NLGIP-5257 transformed cell line human CVCL_JB30 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119952 CVCL_JB33 NLGIP-5366 transformed cell line human CVCL_JB33 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119953 CVCL_JB32 NLGIP-5365 transformed cell line human CVCL_JB32 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119954 CVCL_AH98 HPSI1113i-oaaz_3 induced pluripotent stem cell human CVCL_AH98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119955 CVCL_AH97 HPSI1113i-oaaz_2 induced pluripotent stem cell human CVCL_AH97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119956 CVCL_AH99 HPSI1113i-podx_1 induced pluripotent stem cell human CVCL_AH99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119957 CVCL_AH90 HPSI1113i-eofe_1 induced pluripotent stem cell human CVCL_AH90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119958 CVCL_AH92 HPSI1113i-hajc_1 induced pluripotent stem cell human CVCL_AH92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21119959 CVCL_AH91 HPSI1113i-fumb_2 induced pluripotent stem cell human CVCL_AH91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119960 CVCL_AH94 HPSI1113i-ieki_3 induced pluripotent stem cell human CVCL_AH94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119961 CVCL_JB28 NLGIP-5225 transformed cell line human CVCL_JB28 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119962 CVCL_AH93 HPSI1113i-ieki_2 induced pluripotent stem cell human CVCL_AH93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119963 CVCL_JB27 NLGIP-5048 transformed cell line human CVCL_JB27 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119964 CVCL_AH96 HPSI1113i-nibo_3 induced pluripotent stem cell human CVCL_AH96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119965 CVCL_AH95 HPSI1113i-nibo_2 induced pluripotent stem cell human CVCL_AH95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119966 CVCL_JB29 NLGIP-5232 transformed cell line human CVCL_JB29 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119967 CVCL_JB46 NLGIP-6417 transformed cell line human CVCL_JB46 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119968 CVCL_JB45 NLGIP-6398 transformed cell line human CVCL_JB45 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119969 CVCL_JB48 NLGIP-6423 transformed cell line human CVCL_JB48 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119970 CVCL_JB47 NLGIP-6421 transformed cell line human CVCL_JB47 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119971 CVCL_JB42 NLGIP-6203 transformed cell line human CVCL_JB42 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119972 CVCL_JB41 NLGIP-6153 transformed cell line human CVCL_JB41 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119973 CVCL_JB44 NLGIP-6343 transformed cell line human CVCL_JB44 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119974 CVCL_JB43 NLGIP-6333 transformed cell line human CVCL_JB43 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119975 CVCL_JB40 NLGIP-6037 transformed cell line human CVCL_JB40 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119976 CVCL_JB39 NLGIP-5876 transformed cell line human CVCL_JB39 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119977 CVCL_JB38 NLGIP-5534 transformed cell line human CVCL_JB38 CL:0000010 Population: Jewish; Lybian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119978 CVCL_JB13 NLGIP-4941 transformed cell line human CVCL_JB13 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119979 CVCL_JB12 NLGIP-4921 transformed cell line human CVCL_JB12 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119980 CVCL_JB15 NLGIP-4943 transformed cell line human CVCL_JB15 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119981 CVCL_JB14 NLGIP-4942 transformed cell line human CVCL_JB14 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119982 CVCL_JB11 GM28512 transformed cell line human CVCL_JB11 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119983 CVCL_JB10 GM28511 transformed cell line human CVCL_JB10 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119984 CVCL_AH76 HPSI1013i-woci_2 induced pluripotent stem cell human CVCL_AH76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119985 CVCL_AH75 HPSI1013i-woci_1 induced pluripotent stem cell human CVCL_AH75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21119986 CVCL_AH78 HPSI1013i-wuye_2 induced pluripotent stem cell human CVCL_AH78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119987 CVCL_AH77 HPSI1013i-wopl_1 induced pluripotent stem cell human CVCL_AH77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119988 CVCL_AH79 HPSI1013i-wuye_3 induced pluripotent stem cell human CVCL_AH79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119989 CVCL_JB09 GM28509 transformed cell line human CVCL_JB09 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119990 CVCL_AH70 HPSI1013i-kuxp_1 induced pluripotent stem cell human CVCL_AH70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119991 CVCL_AH72 HPSI1013i-pamv_1 induced pluripotent stem cell human CVCL_AH72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119992 CVCL_JB06 GM28502 transformed cell line human CVCL_JB06 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119993 CVCL_AH71 HPSI1013i-mijn_2 induced pluripotent stem cell human CVCL_AH71 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119994 CVCL_JB05 NLGIP-4297 transformed cell line human CVCL_JB05 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119995 CVCL_AH74 HPSI1013i-sebz_1 induced pluripotent stem cell human CVCL_AH74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21119996 CVCL_JB08 GM28508 transformed cell line human CVCL_JB08 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119997 CVCL_AH73 HPSI1013i-pamv_3 induced pluripotent stem cell human CVCL_AH73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21119998 CVCL_JB07 GM28504 transformed cell line human CVCL_JB07 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21119999 CVCL_JB24 NLGIP-5036 transformed cell line human CVCL_JB24 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120000 CVCL_JB23 NLGIP-5000 transformed cell line human CVCL_JB23 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120001 CVCL_JB26 NLGIP-5047 transformed cell line human CVCL_JB26 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120002 CVCL_JB25 NLGIP-5040 transformed cell line human CVCL_JB25 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120003 CVCL_JB20 NLGIP-4991 transformed cell line human CVCL_JB20 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120004 CVCL_JB22 NLGIP-4996 transformed cell line human CVCL_JB22 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120005 CVCL_JB21 NLGIP-4995 transformed cell line human CVCL_JB21 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120006 CVCL_AH87 HPSI1113i-bima_1 induced pluripotent stem cell human CVCL_AH87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120007 CVCL_AH86 HPSI1014i-toss_3 induced pluripotent stem cell human CVCL_AH86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120008 CVCL_AH89 HPSI1113i-dons_1 induced pluripotent stem cell human CVCL_AH89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120009 CVCL_AH88 HPSI1113i-bima_2 induced pluripotent stem cell human CVCL_AH88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120010 CVCL_AH81 HPSI1013i-yemz_3 induced pluripotent stem cell human CVCL_AH81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120011 CVCL_AH80 HPSI1013i-yemz_1 induced pluripotent stem cell human CVCL_AH80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120012 CVCL_AH83 HPSI1014i-bilx_2 induced pluripotent stem cell human CVCL_AH83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120013 CVCL_JB17 NLGIP-4973 transformed cell line human CVCL_JB17 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120014 CVCL_AH82 HPSI1014i-bilx_1 induced pluripotent stem cell human CVCL_AH82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120015 CVCL_JB16 NLGIP-4945 transformed cell line human CVCL_JB16 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120016 CVCL_AH85 HPSI1014i-suok_3 induced pluripotent stem cell human CVCL_AH85 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21120017 CVCL_JB19 NLGIP-4987 transformed cell line human CVCL_JB19 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120018 CVCL_AH84 HPSI1014i-eesb_1 induced pluripotent stem cell human CVCL_AH84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120019 CVCL_JB18 NLGIP-4983 transformed cell line human CVCL_JB18 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120020 CVCL_AH54 HPSI0913i-xomm_3 induced pluripotent stem cell human CVCL_AH54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120021 CVCL_AH53 HPSI0913i-xomm_2 induced pluripotent stem cell human CVCL_AH53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120022 CVCL_AH56 HPSI0914i-fuhz_1 induced pluripotent stem cell human CVCL_AH56 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21120023 CVCL_AH55 HPSI0914i-euts_3 induced pluripotent stem cell human CVCL_AH55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120024 CVCL_AH58 HPSI0914i-verf_1 induced pluripotent stem cell human CVCL_AH58 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21120025 CVCL_AH57 HPSI0914i-lopq_1 induced pluripotent stem cell human CVCL_AH57 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21120026 CVCL_AH59 HPSI1013i-aetc_1 induced pluripotent stem cell human CVCL_AH59 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120027 CVCL_AH50 HPSI0913i-tozk_1 induced pluripotent stem cell human CVCL_AH50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120028 CVCL_AH52 HPSI0913i-vopm_2 induced pluripotent stem cell human CVCL_AH52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120029 CVCL_AH51 HPSI0913i-tozk_3 induced pluripotent stem cell human CVCL_AH51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120030 CVCL_JB02 NLGIP-1823 transformed cell line human CVCL_JB02 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120031 CVCL_JB01 NLGIP-1820 transformed cell line human CVCL_JB01 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120032 CVCL_JB04 NLGIP-1976 transformed cell line human CVCL_JB04 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120033 CVCL_JB03 NLGIP-1830 transformed cell line human CVCL_JB03 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120034 CVCL_JB00 NLGIP-1816 transformed cell line human CVCL_JB00 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120035 CVCL_AH65 HPSI1013i-hiaf_2 induced pluripotent stem cell human CVCL_AH65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120036 CVCL_AH64 HPSI1013i-hiaf_1 induced pluripotent stem cell human CVCL_AH64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120037 CVCL_AH67 HPSI1013i-jogf_2 induced pluripotent stem cell human CVCL_AH67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120038 CVCL_AH66 HPSI1013i-jogf_1 induced pluripotent stem cell human CVCL_AH66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120039 CVCL_AH69 HPSI1013i-jufd_3 induced pluripotent stem cell human CVCL_AH69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120040 CVCL_AH68 HPSI1013i-jufd_2 induced pluripotent stem cell human CVCL_AH68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120041 CVCL_AH61 HPSI1013i-funy_1 induced pluripotent stem cell human CVCL_AH61 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120042 CVCL_AH60 HPSI1013i-cups_3 induced pluripotent stem cell human CVCL_AH60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120043 CVCL_AH63 HPSI1013i-garx_2 induced pluripotent stem cell human CVCL_AH63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120044 CVCL_AH62 HPSI1013i-funy_3 induced pluripotent stem cell human CVCL_AH62 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120045 CVCL_AH39 HPSI0913i-gooj_1 induced pluripotent stem cell human CVCL_AH39 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120046 CVCL_AH32 HPSI0913i-eorc_4 induced pluripotent stem cell human CVCL_AH32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120047 CVCL_AH31 HPSI0913i-eorc_2 induced pluripotent stem cell human CVCL_AH31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120048 CVCL_AH34 HPSI0913i-ffdp_3 induced pluripotent stem cell human CVCL_AH34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120049 CVCL_AH33 HPSI0913i-ffdl_1 induced pluripotent stem cell human CVCL_AH33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120050 CVCL_AH36 HPSI0913i-ffdz_2 induced pluripotent stem cell human CVCL_AH36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120051 CVCL_AH35 HPSI0913i-ffdp_33 induced pluripotent stem cell human CVCL_AH35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120052 CVCL_AH38 HPSI0913i-gedo_33 induced pluripotent stem cell human CVCL_AH38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120053 CVCL_AH37 HPSI0913i-gedo_3 induced pluripotent stem cell human CVCL_AH37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120054 CVCL_AH30 HPSI0913i-eika_2 induced pluripotent stem cell human CVCL_AH30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120055 CVCL_AH43 HPSI0913i-lise_1 induced pluripotent stem cell human CVCL_AH43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120056 CVCL_AH42 HPSI0913i-laia_4 induced pluripotent stem cell human CVCL_AH42 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Afghan; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21120057 CVCL_AH45 HPSI0913i-lofv_3 induced pluripotent stem cell human CVCL_AH45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120058 CVCL_AH44 HPSI0913i-lise_3 induced pluripotent stem cell human CVCL_AH44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120059 CVCL_AH47 HPSI0913i-oapg_5 induced pluripotent stem cell human CVCL_AH47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120060 CVCL_AH46 HPSI0913i-lofv_33 induced pluripotent stem cell human CVCL_AH46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120061 CVCL_AH49 HPSI0913i-ruql_3 induced pluripotent stem cell human CVCL_AH49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120062 CVCL_AH48 HPSI0913i-qiea_2 induced pluripotent stem cell human CVCL_AH48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120063 CVCL_AH41 HPSI0913i-kojv_2 induced pluripotent stem cell human CVCL_AH41 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120064 CVCL_AH40 HPSI0913i-iuqb_1 induced pluripotent stem cell human CVCL_AH40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120065 CVCL_JA98 NLGIP-1807 transformed cell line human CVCL_JA98 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120066 CVCL_JA97 NLGIP-1801 transformed cell line human CVCL_JA97 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120067 CVCL_JA99 NLGIP-1810 transformed cell line human CVCL_JA99 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120068 CVCL_RZ31 EC-Kcnq2tm1Dgen embryonic stem cell house mouse CVCL_RZ31 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1309503; Kcnq2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120069 CVCL_JA94 NLGIP-1747 transformed cell line human CVCL_JA94 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120070 CVCL_RZ30 EC-Insl5tm1Dgen embryonic stem cell house mouse CVCL_RZ30 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346085; Insl5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120071 CVCL_JA93 NLGIP-1740 transformed cell line human CVCL_JA93 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120072 CVCL_RZ33 EC-Lmbr1tm1Dgen embryonic stem cell house mouse CVCL_RZ33 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1861746; Lmbr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120073 CVCL_JA96 NLGIP-1754 transformed cell line human CVCL_JA96 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120074 CVCL_RZ32 EC-Lats2tm1Dgen embryonic stem cell house mouse CVCL_RZ32 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1354386; Lats2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120075 CVCL_JA95 NLGIP-1751 transformed cell line human CVCL_JA95 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120076 CVCL_RZ35 EC-Mapkapk2tm1Dgen embryonic stem cell house mouse CVCL_RZ35 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:109298; Mapkapk2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120077 CVCL_JA90 NLGIP-1590 transformed cell line human CVCL_JA90 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120078 CVCL_RZ34 EC-Lrp5tm1Dgen embryonic stem cell house mouse CVCL_RZ34 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1278315; Lrp5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120079 CVCL_RZ37 EC-Mtmr1tm1Dgen embryonic stem cell house mouse CVCL_RZ37 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1858271; Mtmr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120080 CVCL_JA92 NLGIP-1730 transformed cell line human CVCL_JA92 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120081 CVCL_RZ36 EC-Mmp17tm1Dgen embryonic stem cell house mouse CVCL_RZ36 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346076; Mmp17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120082 CVCL_JA91 NLGIP-1728 transformed cell line human CVCL_JA91 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120083 CVCL_RZ39 EC-Pkd2l2tm1Dgen embryonic stem cell house mouse CVCL_RZ39 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1858231; Pkd2l2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120084 CVCL_RZ38 EC-Ntsr1tm1Dgen embryonic stem cell house mouse CVCL_RZ38 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:97386; Ntsr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120085 CVCL_RZ20 EC-Gprk5tm1Dgen embryonic stem cell house mouse CVCL_RZ20 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:109161; Grk5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120086 CVCL_RZ22 EC-Grm1tm1Dgen embryonic stem cell house mouse CVCL_RZ22 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1351338; Grm1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120087 CVCL_RZ21 EC-Grik5tm1Dgen embryonic stem cell house mouse CVCL_RZ21 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95818; Grik5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120088 CVCL_RZ24 EC-Gsk3btm1Dgen embryonic stem cell house mouse CVCL_RZ24 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1861437; Gsk3b; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120089 CVCL_RZ23 EC-Grm3tm1Dgen embryonic stem cell house mouse CVCL_RZ23 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1351340; Grm3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120090 CVCL_RZ26 EC-Htr4tm1Dgen embryonic stem cell house mouse CVCL_RZ26 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:109246; Htr4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120091 CVCL_RZ25 EC-Hcrtr1tm1Dgen embryonic stem cell house mouse CVCL_RZ25 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2385650; Hcrtr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120092 CVCL_RZ28 EC-Htr7tm1Dgen embryonic stem cell house mouse CVCL_RZ28 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:99841; Htr7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120093 CVCL_RZ27 EC-Htr5atm1Dgen embryonic stem cell house mouse CVCL_RZ27 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96283; Htr5a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120094 CVCL_RZ29 EC-Il8ratm1Dgen embryonic stem cell house mouse CVCL_RZ29 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2448715; Cxcr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120095 CVCL_JA79 NLGIP-1363 transformed cell line human CVCL_JA79 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120096 CVCL_JA76 NLGIP-1235 transformed cell line human CVCL_JA76 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120097 CVCL_JA75 NLGIP-1156 transformed cell line human CVCL_JA75 CL:0000010 Population: Jewish; Yemenite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120098 CVCL_JA78 NLGIP-1354 transformed cell line human CVCL_JA78 CL:0000010 Population: Jewish; Ethiopian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120099 CVCL_JA77 NLGIP-1236 transformed cell line human CVCL_JA77 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120100 CVCL_JA72 NLGIP-1122 transformed cell line human CVCL_JA72 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120101 CVCL_JA71 NLGIP-1116 transformed cell line human CVCL_JA71 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120102 CVCL_RZ11 EC-Fzd8tm1Dgen embryonic stem cell house mouse CVCL_RZ11 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:108460; Fzd8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120103 CVCL_JA74 NLGIP-1149 transformed cell line human CVCL_JA74 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120104 CVCL_RZ10 EC-Fzd1tm1Dgen embryonic stem cell house mouse CVCL_RZ10 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1196625; Fzd1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120105 CVCL_JA73 NLGIP-1126 transformed cell line human CVCL_JA73 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120106 CVCL_RZ13 EC-Gabra4tm1Dgen embryonic stem cell house mouse CVCL_RZ13 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95616; Gabra4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120107 CVCL_RZ12 EC-Gabra3tm1Dgen embryonic stem cell house mouse CVCL_RZ12 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95615; Gabra3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120108 CVCL_RZ15 EC-Galr1tm1Dgen embryonic stem cell house mouse CVCL_RZ15 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1096364; Galr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120109 CVCL_JA70 NLGIP-1112 transformed cell line human CVCL_JA70 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120110 CVCL_RZ14 EC-Gabrptm1Dgen embryonic stem cell house mouse CVCL_RZ14 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2387597; Gabrp; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120111 CVCL_RZ17 EC-Gpr151tm1Dgen embryonic stem cell house mouse CVCL_RZ17 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2441887; Gpr151; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120112 CVCL_RZ16 EC-Glra3tm1Dgen embryonic stem cell house mouse CVCL_RZ16 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95749; Glra3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120113 CVCL_RZ19 EC-Gpr6tm1Dgen embryonic stem cell house mouse CVCL_RZ19 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2155249; Gpr6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120114 CVCL_RZ18 EC-Gpr37tm1Dgen embryonic stem cell house mouse CVCL_RZ18 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1313297; Gpr37; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120115 CVCL_JA87 NLGIP-1567 transformed cell line human CVCL_JA87 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120116 CVCL_JA86 NLGIP-1564 transformed cell line human CVCL_JA86 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120117 CVCL_JA89 NLGIP-1585 transformed cell line human CVCL_JA89 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120118 CVCL_JA88 NLGIP-1570 transformed cell line human CVCL_JA88 CL:0000010 Population: Jewish; Ethiopian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120119 CVCL_JA83 NLGIP-1515 transformed cell line human CVCL_JA83 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120120 CVCL_JA82 NLGIP-1427 transformed cell line human CVCL_JA82 CL:0000010 Population: Jewish; Ethiopian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120121 CVCL_RZ00 EC-Celsr2tm1Dgen embryonic stem cell house mouse CVCL_RZ00 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1858235; Celsr2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120122 CVCL_JA85 NLGIP-1562 transformed cell line human CVCL_JA85 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120123 CVCL_JA84 NLGIP-1516 transformed cell line human CVCL_JA84 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120124 CVCL_RZ02 EC-Chrna2tm1Dgen embryonic stem cell house mouse CVCL_RZ02 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:87886; Chrna2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120125 CVCL_RZ01 EC-Cer1tm1Dgen embryonic stem cell house mouse CVCL_RZ01 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1201414; Cer1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120126 CVCL_RZ04 EC-Ctsctm1Dgen embryonic stem cell house mouse CVCL_RZ04 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:109553; Ctsc; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120127 CVCL_JA81 NLGIP-1371 transformed cell line human CVCL_JA81 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120128 CVCL_RZ03 EC-Cnr2tm1Dgen embryonic stem cell house mouse CVCL_RZ03 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:104650; Cnr2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120129 CVCL_JA80 NLGIP-1369 transformed cell line human CVCL_JA80 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120130 CVCL_RZ06 EC-Drd5tm1Dgen embryonic stem cell house mouse CVCL_RZ06 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:94927; Drd5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120131 CVCL_RZ05 EC-Cxcr3tm1Dgen embryonic stem cell house mouse CVCL_RZ05 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1277207; Cxcr3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120132 CVCL_RZ08 EC-Esrratm1Dgen embryonic stem cell house mouse CVCL_RZ08 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346831; Esrra; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120133 CVCL_RZ07 EC-Efemp2tm1Dgen embryonic stem cell house mouse CVCL_RZ07 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1891209; Efemp2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120134 CVCL_RZ09 EC-Faim2tm1Dgen embryonic stem cell house mouse CVCL_RZ09 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1919643; Faim2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120135 CVCL_JA58 NT4 cancer cell line house mouse CVCL_JA58 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Female 21120136 CVCL_JA57 NT2 cancer cell line house mouse CVCL_JA57 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Female 21120137 CVCL_JA59 NT5 cancer cell line house mouse CVCL_JA59 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Female 21120138 CVCL_JA54 NCI-CHOdeltafurin spontaneously immortalized cell line CVCL_JA54 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Furin deficient 21120139 CVCL_JA53 NCI-H358M cancer cell line human CVCL_JA53 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung Cell type=Club cell.. Male Caution: NCI-H358 (Cellosaurus=CVCL_1559) and NCI-H358M could be identical 21120140 CVCL_JA56 GM23428 transformed cell line human CVCL_JA56 CL:0000010 Sequence variation: Mutation; HGNC; 9118; PMP22; Simple; p.His12Arg (c.35A>G); ClinVar=VCV000835185; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120141 CVCL_JA55 4G11 [Mouse hybridoma against human IGF1R] hybridoma house mouse CVCL_JA55 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. 21120142 CVCL_JA50 IIB-MEL-IAN cancer cell line human CVCL_JA50 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 61 hours, at 19th passage (PubMed=7567787) 21120143 CVCL_JA52 IIB-MEL-LES cancer cell line human CVCL_JA52 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 74-76 hours (at 10th passage), 72-74 hours (at 26th passage) (PubMed=7567787) 21120144 CVCL_JA51 IIB-MEL-J cancer cell line human CVCL_JA51 CL:0000010 Miscellaneous: Available from Asociacion Banco Argentino de Celulas (ABAC) Derived from metastatic site: Lung. Male Doubling time: 70-80 hours (PubMed=2602342) 21120145 CVCL_JA69 NLGIP-1105 transformed cell line human CVCL_JA69 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120146 CVCL_JA68 NLGIP-1103 transformed cell line human CVCL_JA68 CL:0000010 Population: Jewish; Lybian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120147 CVCL_JA65 NtG20.i7 cancer cell line human CVCL_JA65 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 29233; MAVS; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 10905; SLC10A1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Supports hepatitis B virus (HBV) replication for up to 35 days with production of infectious HBV in the culture supernatant 21120148 CVCL_JA64 NT2.5 LI3 cancer cell line house mouse CVCL_JA64 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by injection of NT2.5 cells into the left cardiac ventricle of neu-N mice resulting in the formation of metastatic lesions in liver These metastatic lesions were established in cell culture and subsequently reinjected into neu-N mice. This selection process was repeated until sublines with a liver preference were obtained. 21120149 CVCL_JA67 GM12644 finite cell line human CVCL_JA67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21120150 CVCL_JA66 GM23600 transformed cell line human CVCL_JA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120151 CVCL_JA61 NT2.5 BO3 cancer cell line house mouse CVCL_JA61 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by injection of NT2.5 cells into the left cardiac ventricle of neu-N mice resulting in the formation of metastatic lesions in bone These metastatic lesions were established in cell culture and subsequently reinjected into neu-N mice. This selection process was repeated until sublines with a bone preference were obtained. 21120152 CVCL_JA60 NT2.5 cancer cell line house mouse CVCL_JA60 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Omics: Transcriptome analysis by microarray Female 21120153 CVCL_JA63 NT2.5 LI1 cancer cell line house mouse CVCL_JA63 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by injection of NT2.5 cells into the left cardiac ventricle of neu-N mice resulting in the formation of metastatic lesions in liver These metastatic lesions were established in cell culture and subsequently reinjected into neu-N mice. This selection process was repeated until sublines with a liver preference were obtained. 21120154 CVCL_JA62 NT2.5 BO6 cancer cell line house mouse CVCL_JA62 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTVneu)202Mul/J transgenic. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by injection of NT2.5 cells into the left cardiac ventricle of neu-N mice resulting in the formation of metastatic lesions in bone These metastatic lesions were established in cell culture and subsequently reinjected into neu-N mice. This selection process was repeated until sublines with a bone preference were obtained. 21120155 CVCL_JA36 U255 spontaneously immortalized cell line human CVCL_JA36 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: 30-48 hours (PubMed=4097745); 36-48 hours (PubMed=4104421) 21120156 CVCL_JA35 HRRT cancer cell line Norway rat CVCL_JA35 CL:0000010 Female Doubling time: 21 hours (in 10% serum), 42 hours (in serum-free medium) (PubMed=6307857). 21120157 CVCL_JA38 4F10 [Human EBV-transformed] transformed cell line human CVCL_JA38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Accessible carbohydrate determinant of outer membrane lipopolysaccharide of Serratia marcescens Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9007 21120158 CVCL_JA37 4B9 [Human LCL mAb producing] transformed cell line human CVCL_JA37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Group B streptococci Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9008 21120159 CVCL_JA32 RPMI-1120 transformed cell line human CVCL_JA32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21120160 CVCL_JA31 L33-6-1 transformed cell line human CVCL_JA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120161 CVCL_JA34 RPMI-8057 transformed cell line human CVCL_JA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21120162 CVCL_JA33 RPMI-5287 transformed cell line human CVCL_JA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120163 CVCL_JA30 ESC-ICR embryonic stem cell house mouse CVCL_JA30 CL:0000010 Anecdotal: ESC-ICR and CCE (Cellosaurus=CVCL_C313) from Martin Evans and Matthew Kaufman are the first embryonic stem cell lines to have been established (in 1981) Breed/subspecies: ICR x SWR/J. Female 21120164 CVCL_AG99 HPSI0813i-ffdm_3 induced pluripotent stem cell human CVCL_AG99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120165 CVCL_AG98 HPSI0813i-ffdk_3 induced pluripotent stem cell human CVCL_AG98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120166 CVCL_AG91 HPSI0813i-civh_1 induced pluripotent stem cell human CVCL_AG91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21120167 CVCL_AG90 HPSI0813i-aomg_3 induced pluripotent stem cell human CVCL_AG90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120168 CVCL_AG93 HPSI0813i-eiqh_3 induced pluripotent stem cell human CVCL_AG93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120169 CVCL_AG92 HPSI0813i-civh_3 induced pluripotent stem cell human CVCL_AG92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120170 CVCL_AG95 HPSI0813i-ffdc_1 induced pluripotent stem cell human CVCL_AG95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120171 CVCL_JA29 SCC-S2 cancer cell line house mouse CVCL_JA29 CL:0000010 Breed/subspecies: 129/Sv-SlJ-CP. Male 21120172 CVCL_AG94 HPSI0813i-eiqh_6 induced pluripotent stem cell human CVCL_AG94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120173 CVCL_JA28 UT-SCC-57 cancer cell line human CVCL_JA28 CL:0000010 Omics: miRNA expression profiling. 21120174 CVCL_AG97 HPSI0813i-ffdj_1 induced pluripotent stem cell human CVCL_AG97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120175 CVCL_AG96 HPSI0813i-ffdc_11 induced pluripotent stem cell human CVCL_AG96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120176 CVCL_JA47 GM03448 finite cell line CVCL_JA47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03448; probable Male Group: Non-human primate cell line 21120177 CVCL_JA46 GM03446 finite cell line CVCL_JA46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03446; probable Male Group: Non-human primate cell line 21120178 CVCL_JA49 GM03452 finite cell line CVCL_JA49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03452; probable Male Group: Non-human primate cell line 21120179 CVCL_JA48 GM03450 finite cell line CVCL_JA48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03450; probable Male Group: Non-human primate cell line 21120180 CVCL_JA43 GM00758 finite cell line dog CVCL_JA43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00758; probable Female 21120181 CVCL_JA42 GM00757 finite cell line dog CVCL_JA42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00757; probable Female 21120182 CVCL_JA45 GM03444 finite cell line CVCL_JA45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03444; probable Male Group: Non-human primate cell line 21120183 CVCL_JA44 GM03442 finite cell line CVCL_JA44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03442; probable Female Group: Non-human primate cell line 21120184 CVCL_JA41 9C3 [Human lymphoblastoid] transformed cell line human CVCL_JA41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Accessible carbohydrate determinant of outer membrane lipopolysaccharide of Pseudomonas aeruginosa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9239 21120185 CVCL_JA40 9B10 transformed cell line human CVCL_JA40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Accessible carbohydrate determinant of outer membrane lipopolysaccharide of Escherichia coli K1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9006 21120186 CVCL_JA39 7D7 transformed cell line human CVCL_JA39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Accessible carbohydrate determinant of outer membrane lipopolysaccharide of Escherichia coli and Serratia marcescens Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9009 21120187 CVCL_8N04 DA05984 transformed cell line human CVCL_8N04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120188 CVCL_8N03 DA05982 transformed cell line human CVCL_8N03 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120189 CVCL_8N06 DA05986 transformed cell line human CVCL_8N06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120190 CVCL_8N05 DA05985 transformed cell line human CVCL_8N05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120191 CVCL_8N00 DA05979 transformed cell line human CVCL_8N00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120192 CVCL_8N02 DA05981 transformed cell line human CVCL_8N02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120193 CVCL_8N01 DA05980 transformed cell line human CVCL_8N01 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120194 CVCL_0561 TK6 transformed cell line human CVCL_0561 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=7859358); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7744731; PubMed=11221843) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 12.2 hours (PubMed=7744731) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8015 21120195 CVCL_0560 TIG-1 finite cell line human CVCL_0560 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Senescence: Senesces at 55 to 79 PDL (Coriell=AG06173); 82 PDL (PubMed=4083160); 68 PDL (PubMed=7421303) 21120196 CVCL_0563 TSE cancer cell line human CVCL_0563 From: Powell S.; Department of Radiation Oncology, Massachusetts General Hospital; Boston; USA CL:0000010 Derived from sampling site: Breast. Female 21120197 CVCL_0562 TRM-6/PDX-1 transformed cell line human CVCL_0562 CL:0000010 Transfected with: HGNC; 6107; PDX1; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal pancreas. Unspecified 21120198 CVCL_0565 U-1752 cancer cell line human CVCL_0565 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala347Thr (c.1039G>A); ClinVar=VCV000662690; Zygosity=Unspecified (PubMed=12820372) Derived from metastatic site: Pleural effusion. Male Doubling time: 36 hours (PubMed=6178358) 21120199 CVCL_0564 Tot2 factor-dependent cell line house mouse CVCL_0564 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:96395; Irf8 Derived from sampling site: Bone marrow. Unspecified Characteristics: CSF2 dependent 21120200 CVCL_0567 UF-1 cancer cell line human CVCL_0567 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=8781440); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Arg276Trp (c.826C>T); ClinVar=VCV000191350; Zygosity=Unspecified; Note=Equivalent to p.Arg611Trp in the PML-RARA fusion protein (PubMed=11438209) Population: Japanese; Derived from sampling site: Peripheral blood. Female Characteristics: Resistant to all-trans retinoic acid (ATRA) Doubling time: 72 hours (PubMed=8781440); 96 hours (PubMed=15234573) 21120201 CVCL_0566 U266B1 cancer cell line human CVCL_0566 HLA typing: A*02:01,03; B*07,40; C*03:04,07 (Direct_author_submission); HLA typing: A*02:01,03:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293); HLA typing: A*02:01:01;03:01:01; B*07:02:01,40:01:02; C*03:04:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRA*01:02:02,01:02:03; DRB1*03:01:01,15:01:01 (DSMZCellDive=ACC-9); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.78%; East Asian, South=0.29%; South Asian=0.45%; European, North=80.76%; European, South=15.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=1373872; PubMed=21173094; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (PubMed=17692805) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0240; probable Male Characteristics: Produces IgE lambda Doubling time: 108-144 hours (PubMed=4104421); ~55 hours (DSMZ=ACC-9); Microsatellite instability: Stable (MSS) (Sanger) Group: Hybridoma fusion partner cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120202 CVCL_0569 UM-SCV-6 cancer cell line human CVCL_0569 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7503188; PubMed=9887230) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Vulva. Female Virology: Contains an integrated HPV16 genome Doubling time: 53 hours (PubMed=15047230) 21120203 CVCL_0568 UM-SCV-1A cancer cell line human CVCL_0568 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7503188; PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 32 hours (PubMed=15047230); 30.12 +- 0.43 hours (PubMed=31654625) 21120204 CVCL_8N15 DA05996 transformed cell line human CVCL_8N15 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120205 CVCL_8N14 DA05995 transformed cell line human CVCL_8N14 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120206 CVCL_8N17 DA05998 transformed cell line human CVCL_8N17 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120207 CVCL_8N16 DA05997 transformed cell line human CVCL_8N16 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120208 CVCL_8N11 DA05991 transformed cell line human CVCL_8N11 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120209 CVCL_8N10 DA05990 transformed cell line human CVCL_8N10 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120210 CVCL_8N13 DA05994 transformed cell line human CVCL_8N13 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120211 CVCL_8N12 DA05993 transformed cell line human CVCL_8N12 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120212 CVCL_0570 UMNSAH/DF-1 spontaneously immortalized cell line CVCL_0570 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Omics: Transcriptome analysis by microarray Unspecified Virology: Low susceptibility to infection by aquatic bird bornavirus 1 (ABBV-1) strain UoG-CG (PubMed=32005267) Doubling time: 13.22 hours (in DMEM/F-12 medium), 33.64 hours (in MEM medium), 15.30 hours (in RPMI 1640 medium), 21.39 hours (in DMEM medium) (CelloPub=CLPUB00401) Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12203 21120213 CVCL_0572 UW228-2 cancer cell line human CVCL_0572 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Brain; posterior fossa. Female Doubling time: 33.4 +- 0.1 hours (PubMed=8866661) 21120214 CVCL_0571 UROtsa transformed cell line human CVCL_0571 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female Doubling time: 29.7 hours (PubMed=8788275); 33.2 +- 0.8 hours (PubMed=19921857; PubMed=20186695) Part of: ENCODE project common cell types; tier 3; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00484 Problematic cell line: Partially contaminated Some stocks of UROTsa are contaminated with T24 (PubMed=23691160). However it must be noted that the stocks from the laboratory distributing/curating this cell line are not contaminated; therefore the contamination event has probably occurred through secondary sources after UROtsa was given to other investigators (PubMed=26783756). 21120215 CVCL_8N08 DA05988 transformed cell line human CVCL_8N08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120216 CVCL_0574 Vero C1008 spontaneously immortalized cell line green monkey CVCL_0574 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Virology: Susceptible to infection by many viruses Supports the growth of slowly replicating viruses (ATCC).; Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32020029; PubMed=32511316; PubMed=33389257; PubMed=34339474) Doubling time: 22 hours (ATCC=CRL-1586) Group: Non-human primate cell line; Group: Vaccine production cell line 21120217 CVCL_8N07 DA05987 transformed cell line human CVCL_8N07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120218 CVCL_0573 UW228-3 cancer cell line human CVCL_0573 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Brain; posterior fossa. Female Doubling time: 29.0 +- 2.0 hours (PubMed=8866661) 21120219 CVCL_0576 WEHI-7.1 cancer cell line house mouse CVCL_0576 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120220 CVCL_8N09 DA05989 transformed cell line human CVCL_8N09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21120221 CVCL_0575 WAC2 cancer cell line human CVCL_0575 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21120222 CVCL_0578 WGA cancer cell line human CVCL_0578 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Derived from the parent cell line by metabolic selection using the ability to grow on fructose as the selection system 21120223 CVCL_0577 WEHI-231 cancer cell line house mouse CVCL_0577 CL:0000010 Breed/subspecies: BALB/c x NZB. Omics: Phosphoproteome analysis; Omics: SNP array analysis 21120224 CVCL_0579 WI-38 finite cell line human CVCL_0579 CL:0000010 Anecdotal: Hayflick when numbering diploid cell strains 'jumped' directly from WI-27 (which failed) to WI-38 (CelloPub=CLPUB00391); Anecdotal: Have been flown in space on Skylab-3 to study growth in microgravity (PubMed=352912) Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Biotechnology: Used for the production of RA27/3 - the first rubella virus vaccine; Biotechnology: Used for the production of live oral adenovirus type 4 and type 7 vaccine used by the US military Produced first by Wyeth Laboratories from 1971 to 1999 and from 2011 onward by Barr Pharmaceuticals.; Biotechnology: Was used in the early 1970's for the production of the Human Diploid Cell Vaccine (HDCV) vaccine against rabies by Institut Merieux; Omics: CTCF ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-7728; true; Discontinued: JCRB; JCRB9017; true; Discontinued: KCLB; 10075; probable Female Characteristics: Used in many context such as senescence and aging studies Senescence: Life expectancy of 50 +- 10 population doublings Senesces at 38 PDL (PubMed=17395773).; Doubling time: ~24 hours (ATCC=CCL-75; ECACC=90020107) Group: Space-flown cell line (cellonaut); Group: Vaccine production cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120225 CVCL_RZ91 v6.5 Mapk1ip1l-K1 embryonic stem cell house mouse CVCL_RZ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444022; Mapk1ip1l Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120226 CVCL_RZ90 v6.5 Gtf2h1-K1 embryonic stem cell house mouse CVCL_RZ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277216; Gtf2h1 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120227 CVCL_RZ93 v6.5 Pspc1-K1 embryonic stem cell house mouse CVCL_RZ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120228 CVCL_RZ92 v6.5 Mipol1-K1 embryonic stem cell house mouse CVCL_RZ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920740; Mipol1 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120229 CVCL_RZ95 v6.5 Slc39a14-K1 embryonic stem cell house mouse CVCL_RZ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384851; Slc39a14 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120230 CVCL_RZ94 v6.5 Rbpms-K1 embryonic stem cell house mouse CVCL_RZ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120231 CVCL_RZ97 XP3OSHF finite cell line human CVCL_RZ97 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP3OS) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1010; probable Male 21120232 CVCL_RZ96 v6.5 Trerf1-K1 embryonic stem cell house mouse CVCL_RZ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442086; Trerf1 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120233 CVCL_RZ99 NYSCF-AG0001-01-MR induced pluripotent stem cell human CVCL_RZ99 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Thr124Met (c.371C>T); ClinVar=VCV000014181; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 21120234 CVCL_RZ98 XP3OSHM finite cell line human CVCL_RZ98 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP3OS) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1011; probable Female 21120235 CVCL_0541 SV80 transformed cell line human CVCL_0541 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Discontinued: ATCC; CRL-7725; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Probably misidentified Said to originate from fibroblasts of the lung of a male black individual (CLS), but in reality seems to be established from skin fibroblast of an adult female (strain A). Note that some papers have probably missasigned it to be from a Fanconi anemia patient. 21120236 CVCL_0540 SV-A3 transformed cell line human CVCL_0540 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Fetal brain Cell type=Microglial cell.. Unspecified 21120237 CVCL_0543 SW1353 cancer cell line human CVCL_0543 HLA typing: A*24:02,29:02; B*44:02,44:02; C*02:02,16:01 (PubMed=26589293); Genome ancestry: African=0.24%; Native American=0%; East Asian, North=2.24%; East Asian, South=0%; South Asian=0%; European, North=66.16%; European, South=31.35% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 5383; IDH2; Simple; p.Arg172Ser (c.516G>C); ClinVar=VCV000375985; Zygosity=Heterozygous (PubMed=22057234; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val203Leu (c.607G>C); ClinVar=VCV000482235; Zygosity=Heterozygous (PubMed=19787792; DepMap) Population: Caucasian; Karyotypic information: Hyperdiploid, 47,XX,+7 (ATCC); Derived from sampling site: Bone; right humerus. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Ribosome profiling; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21120238 CVCL_0542 SW13 cancer cell line human CVCL_0542 Genome ancestry: African=2.01%; Native American=0%; East Asian, North=0%; East Asian, South=0.61%; South Asian=0.44%; European, North=72.28%; European, South=24.66% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Gln164Ter (c.490C>T); ClinVar=VCV001436624; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap) Derived from sampling site: Adrenal gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21120239 CVCL_0545 SW403 cancer cell line human CVCL_0545 HLA typing: A*02,03 (PubMed=8464898); HLA typing: A*02:05,03:01; B*07:02,49:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.6%; Native American=0.4%; East Asian, North=0.5%; East Asian, South=0%; South Asian=3.26%; European, North=62.34%; European, South=32.9% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn125Lys (c.375T>G); Zygosity=Heterozygous (PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1198Glnfs*67 (c.3591delC); Zygosity=Heterozygous (PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1278Ter (c.3833C>A); Zygosity=Heterozygous (PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Lys (c.1636C>A); ClinVar=VCV000013657; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Homozygous (PubMed=16418264; PubMed=28683746; Cosmic-CLP; DepMap) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 79 hours, at 31th passage (PubMed=1000501); ~40-50 hours (DSMZ=ACC-294); Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: NCI RAS program mutant KRAS cell line panel 21120240 CVCL_0544 SW1116 cancer cell line human CVCL_0544 HLA typing: A*23:01,23:01; B*44:03,44:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=1.32%; Native American=0%; East Asian, North=3.41%; East Asian, South=0%; South Asian=0%; European, North=62.64%; European, South=32.62% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln264Ter (c.790C>T); Zygosity=Heterozygous (PubMed=24755471; ATCC); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1429fs*41 (c.4287_4296delAACCATGCCA); Zygosity=Heterozygous (PubMed=24755471; ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Homozygous (PubMed=7651727; PubMed=9000147; PubMed=16418264; PubMed=24042735; PubMed=24755471; PubMed=28683746) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 163 hours (PubMed=1000501); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21120241 CVCL_0547 SW620 cancer cell line human CVCL_0547 HLA typing: A*02:01,24:02; B*07:02,15:18; C*07:02,07:04 (PubMed=9178645); HLA typing: A*02,24; B*07,15; C*07:02:01,07; DPB1*01:01:01,04:01; DQB1*05:01:01,06:03; DRB1*01:03,13:01:01 (PubMed=15748285); HLA typing: A*02:01,24:02; B*07:13,37:04; C*07:04,07:04; DQB1*05:01,05:01 (PubMed=26589293); Genome ancestry: African=2.02%; Native American=0%; East Asian, North=4.3%; East Asian, South=0%; South Asian=0%; European, North=50.01%; European, South=43.67% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (PubMed=17088437; PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=12068308; PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=17088437; PubMed=21912889; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (PubMed=17088437; PubMed=21912889; PubMed=24755471; PubMed=28683746) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Extracellular vesicles proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Nuclear proteome analysis; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20.4 hours (NCI-DTP); ~26 hours (PBCF); Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: NCI-60 cancer cell line panel 21120242 CVCL_0546 SW480 cancer cell line human CVCL_0546 HLA typing: A*02:01,24:02; B*07:02,15:18; C*07:04,07:04; DQA1*03:02,03:02; DQB1*05:01,06:11; DRB1*13:27,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.55%; East Asian, North=1.14%; East Asian, South=0.1%; South Asian=0.15%; European, North=58.36%; European, South=39.69% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=20570890; PubMed=24755471; PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=7651727; PubMed=9000147; PubMed=9715273; PubMed=16418264; PubMed=24755471; PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (PubMed=7651727; PubMed=9000147; PubMed=9715273; PubMed=16418264; PubMed=24755471; PubMed=28683746; DepMap) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Hi-C sequencing; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Nuclear proteome analysis; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1959; true; Discontinued: TKG; TKG 0505; true Male Doubling time: 50 hours, at 73th passage (PubMed=1000501); 24 hours (PubMed=25984343); 20-25 hours (CLS); ~25-30 hours (DSMZ=ACC-313); ~38 hours (PBCF); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=10674020; PubMed=24042735; PubMed=25926053; PubMed=28683746) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21120243 CVCL_0549 Sf9 spontaneously immortalized cell line CVCL_0549 CL:0000010 Anecdotal: Have been flown in space on shuttle flights STS-50 (USML-1), STS-54 and STS-57 (Spacehab-1) to study growth in microgravity (PubMed=8050503) Karyotypic information: Heterogeneous, contains a mixture of diploid and tetraploid cells; Derived from sampling site: Ovary. Biotechnology: Used for the production of the Novavax SARS-CoV-2 (COVID-19) vaccine (Trade name: NVX-CoV2373) (DrugBank; DB15810) The cell line is used to produce the recombinant SARS-CoV-2 spike protein rSARS-CoV-2 which is the active part of the vaccine formulation.; Omics: Transcriptome analysis by ESTs sequencing; Omics: Transcriptome analysis by microarray; Omics: Genome sequenced Discontinued: RCB; RCB0563; true Female Doubling time: 25.2 +- 2.8 hours, at 28 Celsius (PubMed=10718368); 27 hours (PubMed=21667340); ~50 hours (DSMZ=ACC-125) Group: Insect cell line; Group: Recombinant protein production insect cell line; Group: Space-flown cell line (cellonaut); Group: Vaccine production cell line Caution: The SfRV rhabdovirus found in Sf9 cells of ATCC CRL-1711 lot 5807852 (PubMed=24672045) does not seem to be expressed in CRL-1711 lot 5814 from 1987 (PubMed=28423032) The SfRV genome is integrated in the Sf9 genome. 21120244 CVCL_0548 SaOS-2 cancer cell line human CVCL_0548 Genome ancestry: African=1.32%; Native American=0.17%; East Asian, North=0.46%; East Asian, South=0.55%; South Asian=6.66%; European, North=52.25%; European, South=38.6% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2823272; PubMed=16888811; PubMed=19787792) Population: Caucasian; Derived from sampling site: Bone. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7939; true; Discontinued: KCLB; 80023; probable Female Doubling time: 48 hours (PubMed=16888811); 45.7 +- 3.3 hours (PubMed=10763916); 35-40 hours (CLS); ~43 hours (DSMZ=ACC-243); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 771 21120245 CVCL_RZ80 XYFMGG19M transformed cell line human CVCL_RZ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120246 CVCL_RZ82 XYFMGG24K transformed cell line human CVCL_RZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120247 CVCL_RZ81 XYFMGG23G transformed cell line human CVCL_RZ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120248 CVCL_RZ84 XYFMGC44W transformed cell line human CVCL_RZ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120249 CVCL_RZ83 XYFMGC28C transformed cell line human CVCL_RZ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120250 CVCL_RZ86 HEK293-YFV-prM/E-opt transformed cell line human CVCL_RZ86 CL:0000010 Transfected with: UniProtKB; P03314; Yellow fever virus strain 17D genome polyprotein (AA 102-778; protein prM + protein E, codons optimized for expression) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses the YFV prM/E proteins and capable of trans-packaging the transcribed RNA of a YFV reporter replicon, thereby generating pseudo-infectious viral particles 21120251 CVCL_RZ85 XYFMGC50H transformed cell line human CVCL_RZ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120252 CVCL_RZ88 v6.5 5830457O10Rik-K1 embryonic stem cell house mouse CVCL_RZ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443370; Chtf8 Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120253 CVCL_RZ87 F13 finite cell line human CVCL_RZ87 CL:0000010 Omics: Transcriptome analysis by microarray. 21120254 CVCL_RZ89 v6.5 Eapp-K1 embryonic stem cell house mouse CVCL_RZ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913516; Eapp Breed/subspecies: C57BL/6J x 129S4/SvJae. Male 21120255 CVCL_0550 SK-MEL-3 cancer cell line human CVCL_0550 HLA typing: A*24:02,24:02; B*44:03,51:01; C*04:01,15:04; DQA1*01:02,01:02; DQB1*04:01,04:01; DRB1*03:17,14:01 (PubMed=26589293); Genome ancestry: African=1.51%; Native American=0%; East Asian, North=2.94%; East Asian, South=0%; South Asian=8.82%; European, North=24.17%; European, South=62.57% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17260012; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Homozygous (PubMed=17260012; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~40-50 hours (DSMZ=ACC-321); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-523 21120256 CVCL_0552 Swiss-LAPA spontaneously immortalized cell line house mouse CVCL_0552 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21120257 CVCL_0551 SqCC/Y1 cancer cell line human CVCL_0551 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2980; probable. Part of: MD Anderson Cell Lines Project 21120258 CVCL_0554 T24 cancer cell line human CVCL_0554 HLA typing: A*01,03; B*08,18; C*w02,w06 (PubMed=77569); HLA typing: A*01:01,01:01; B*18:01,18:01; C*05:01,05:01 (PubMed=26589293); HLA typing: A*01,03; B*18,w35; C*w04 (ATCC=HTB-4); Genome ancestry: African=1.35%; Native American=0.28%; East Asian, North=4.67%; East Asian, South=0%; South Asian=0%; European, North=65.79%; European, South=27.92% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=12068308; ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=7787250; ATCC) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: GPI-anchored proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 19 hours (PubMed=4133950); 21 hours (PubMed=3708594); 23.2 hours (PubMed=26055179); ~48 hours (DSMZ=ACC-376); ~1 day (lot 02052018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index 21120259 CVCL_0553 T-47D cancer cell line human CVCL_0553 HLA typing: A*33:01; B*14:02; C*08:02; DPB1*02:01:02,04:01; DQB1*05:01:01; DRB1*01:02:01 (PubMed=15748285); HLA typing: A*33:01,33:01; B*14:02,14:02; C*08:02,08:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=25960936); HLA typing: A*33:03,33:03; B*14:02,14:02; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=0.86%; Native American=1.2%; East Asian, North=3.03%; East Asian, South=1.59%; South Asian=8.04%; European, North=22.59%; European, South=62.69% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=17088437; PubMed=19593635; PubMed=28889351); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=21912889; PubMed=28889351) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.6 days (PubMed=9671407); 59.7 hours, 33.8 hours (with 17-beta-estradiol) (PubMed=32576280); 49.2 hours (PubMed=8562478; PubMed=9815641); 45.5 hours (NCI-DTP); 32 hours (CLS); ~30-40 hours (DSMZ=ACC-739); ~43 hours (PBCF); 55.80 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel 21120260 CVCL_0556 T98G cancer cell line human CVCL_0556 HLA typing: A*02:01,02:01; B*35:03,39:06; C*04:01,07:02 (PubMed=26589293); HLA typing: A*02:01:01; B*36:06:02; C*07:02:01 (PubMed=27412690); Genome ancestry: African=1.56%; Native American=0.16%; East Asian, North=4.73%; East Asian, South=0%; South Asian=6.52%; European, North=26.22%; European, South=60.81% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-20del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu42Arg (c.125T>G); Zygosity=Unspecified (PubMed=9090379; PubMed=10560660; PubMed=28464039); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=10416987; PubMed=14614447) Karyotypic information: Hyperpentaploid karyotype Has almost twice as many chromosomes as its parental cell line (T98) (PubMed=222778). Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 22 hours (PubMed=9842975); 40 hours (PubMed=25984343); ~28 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3 21120261 CVCL_0555 T84 cancer cell line human CVCL_0555 HLA typing: A*02,09 (PubMed=8464898); HLA typing: A*02:01,24:02; B*18:01,35:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=2.33%; Native American=0%; East Asian, North=3.37%; East Asian, South=0%; South Asian=0%; European, North=57.21%; European, South=37.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu1488Phefs*19 (c.4464delA); Zygosity=Homozygous (PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=20570890; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=20570890; PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Lys340Asn (c.1020G>C); Zygosity=Homozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>T; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16418264; Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: N-glycan profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a xenograft produced by subcutaneous injection of the tumor cells into BALB/c nude mice Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21120262 CVCL_0558 TC10 transformed cell line house mouse CVCL_0558 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Heart; Breed/subspecies: MT-PLVT transgenic. Unspecified 21120263 CVCL_0557 TARL-2 transformed cell line Norway rat CVCL_0557 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Female 21120264 CVCL_0559 TF-1 cancer cell line human CVCL_0559 HLA typing: A*02:01,33:03; B*08:20,51:01; C*01:02,14:03 (PubMed=26589293); HLA typing: A*02:01:01,33:03:01; B*44:03:01;51:01:01; C*01:02:01;14:03; DPA1*01:03:01,02:02:02; DPB1*04:01:01,02:01:02; DQA1*01:02:01,03:02; DQB1*06:09:01,06:09:01; DRA*01:01:01,01:02:02; DRB1*09:01:02,13:02:01 (DSMZCellDive=ACC-334); Genome ancestry: African=0.64%; Native American=0.04%; East Asian, North=79.7%; East Asian, South=18.49%; South Asian=0%; European, North=0%; European, South=1.13% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (PubMed=31160637); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (PubMed=1571549) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0233; probable Male Characteristics: Proliferatively responsive to many growth factors; Characteristics: IL3 or CSF2 dependent Doubling time: 39 +- 6 hours (PubMed=9096695); 22 hours (ATCC=CRL-2003); ~70 hours (DSMZ=ACC-334) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21120265 CVCL_RZ71 XYFMGG04DP transformed cell line human CVCL_RZ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120266 CVCL_RZ70 XYFMGG04DM transformed cell line human CVCL_RZ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120267 CVCL_RZ73 XYFMGG06K transformed cell line human CVCL_RZ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120268 CVCL_RZ72 XYFMGC05H transformed cell line human CVCL_RZ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120269 CVCL_RZ75 XYFMGC08L transformed cell line human CVCL_RZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120270 CVCL_RZ74 XYFMGC07K transformed cell line human CVCL_RZ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120271 CVCL_RZ77 XYFMGC10S transformed cell line human CVCL_RZ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120272 CVCL_RZ76 XYFMGG09R transformed cell line human CVCL_RZ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120273 CVCL_RZ79 XYFMGG18B transformed cell line human CVCL_RZ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120274 CVCL_RZ78 XYFMGG16M transformed cell line human CVCL_RZ78 CL:0000010 Sequence variation: Mutation; HGNC; 11311; SRY; Simple; p.Arg62Gly (c.184C>G); Zygosity=Hemizygous (PubMed=8353496) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120275 CVCL_0521 SGHPL-4 transformed cell line human CVCL_0521 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Male 21120276 CVCL_0520 SGC-7901 cancer cell line human CVCL_0520 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000236, 3131C0001000700046) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00577 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; PubMed=28851942). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 21120277 CVCL_0523 SH-SY5Y-SPA4CT cancer cell line human CVCL_0523 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 620; APP (1-19 in frame with 672-770) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21120278 CVCL_0522 SH-EP007 cancer cell line human CVCL_0522 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21120279 CVCL_0525 SK-HEP-1 cancer cell line human CVCL_0525 HLA typing: A*02:01,24:02; B*35:04,44:03:01; C*04:01; DQA1*01:02; DQB1*05:02,06.04; DRB1*13:02,16:02 (PubMed=9178645); HLA typing: A*02:01,24:02; B*35:02,44:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0.65%; Native American=1.18%; East Asian, North=0%; East Asian, South=2.22%; South Asian=8.09%; European, North=23.66%; European, South=64.2% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites Cell type=Endothelial cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46.7 +- 10.3 hours, 94.2 hours (in CDM4-CHO medium), 289.8 hours (in 293 SFM II medium) (PubMed=25822314); ~30 hours (DSMZ=ACC-141); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-535 Problematic cell line: Misclassified Originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells (PubMed=1371504; PubMed=31938418). 21120280 CVCL_0524 SH-EP cancer cell line human CVCL_0524 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21120281 CVCL_0527 SK-MEL-5 cancer cell line human CVCL_0527 HLA typing: A*02:01:01,11:01:01; B*07,40; C*03:04:01,07:02:01; DPB1*03:01:01,16:01; DQB1*03:02,06:03; DRB1*04:01:01,13:01:01 (PubMed=15748285); HLA typing: A*02:01,11:01; B*40:01,40:01; C*03:03,03:03; DQA1*03:02,01:03; DQB1*03:02,06:11; DRB1*04:01,13:02 (PubMed=25960936); HLA typing: A*02:01,11:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293); Genome ancestry: African=1.41%; Native American=0%; East Asian, North=3.5%; East Asian, South=0%; South Asian=0%; European, North=60.03%; European, South=35.06% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15467732; PubMed=17088437; PubMed=17363583; PubMed=24576830; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Derived from metastatic site: Axillary lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: HLA class I peptidome analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 26 hours (PubMed=7718330); 70 hours (PubMed=25984343); 25.2 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-522 21120282 CVCL_0526 SK-MEL-28 cancer cell line human CVCL_0526 HLA typing: A*11:01:01; B*40:01; C*03:04:01; DPB1*03:01:01; DQB1*03:02; DRB1*04:04 (PubMed=15748285); HLA typing: A*11:01,11:01; B*40:01,40:01; C*03:03,03:03; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*04:04,04:04 (PubMed=25960936); HLA typing: A*11:01,11:01; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=1.75%; Native American=0.56%; East Asian, North=3%; East Asian, South=1.38%; South Asian=8.29%; European, North=20.11%; European, South=64.91% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=15467732; PubMed=17088437; PubMed=17260012; PubMed=17363583; PubMed=19799798; PubMed=24576830; PubMed=26405815; PubMed=29492214; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (PubMed=10766161; PubMed=17260012; PubMed=17363583; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (PubMed=17088437; PubMed=17260012; PubMed=18277095; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1930; true; Discontinued: TKG; TKG 0333; true. Male Characteristics: Lightly pigmented Doubling time: 27 hours (PubMed=7718330); 72 hours (PubMed=12479222); 26.9 hours (PubMed=20406486); 35.1 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-524 21120283 CVCL_0529 SK-N-BE(2)-C cancer cell line human CVCL_0529 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=11196202); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (PubMed=11196202) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: ATAC-seq; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by single cell RNAseq Male Characteristics: Intermediate type (I-type) (PubMed=15720811); Characteristics: MYCN-amplified NBL cell line Doubling time: 18 hours (ATCC=CRL-2268) Part of: ENCODE project common cell types; tier 3; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-532 21120284 CVCL_0528 SK-N-BE(2) cancer cell line human CVCL_0528 Genome ancestry: African=1.71%; Native American=0.88%; East Asian, North=1.41%; East Asian, South=0%; South Asian=7.87%; European, North=24.66%; European, South=63.46% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from child cell line SK-N-BE(2)-C); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=11507071; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep tyrosine phosphoproteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Abcam; ab275476; true Male Characteristics: Substrate-adherent type (S-type) (PubMed=15720811) Doubling time: 27 hours (PubMed=29704); ~36 hours (DSMZ=ACC-632) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-530 21120285 CVCL_RZ60 EC-Tmprss13tm1Dgen embryonic stem cell house mouse CVCL_RZ60 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2682935; Tmprss13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120286 CVCL_RZ62 EC-Trpm5tm1Dgen embryonic stem cell house mouse CVCL_RZ62 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1861718; Trpm5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120287 CVCL_RZ61 EC-Tpp1tm1Dgen embryonic stem cell house mouse CVCL_RZ61 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1336194; Tpp1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120288 CVCL_RZ64 In-1024 cancer cell line CVCL_RZ64 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Pancreas; islets of Langerhans. Unspecified 21120289 CVCL_RZ63 EC-Xcr1tm1Dgen embryonic stem cell house mouse CVCL_RZ63 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346338; Xcr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120290 CVCL_RZ66 XYFMGG01A transformed cell line human CVCL_RZ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120291 CVCL_RZ65 EC-Slc22a6tm1Dgen embryonic stem cell house mouse CVCL_RZ65 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:892001; Slc22a6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120292 CVCL_RZ68 XYFMGG03D transformed cell line human CVCL_RZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120293 CVCL_RZ67 XYFMGC02A transformed cell line human CVCL_RZ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120294 CVCL_RZ69 XYFMGG04D transformed cell line human CVCL_RZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21120295 CVCL_0530 SK-N-MC cancer cell line human CVCL_0530 HLA typing: A*01:01,25:01; B*08:01,08:01; C*07:01,07:01; DQA1*05:02,05:02; DQB1*02:02,05:01; DRB1*03:38,12:27 (PubMed=26589293); Genome ancestry: African=1.84%; Native American=0%; East Asian, North=0.61%; East Asian, South=0%; South Asian=0.27%; European, North=67.85%; European, South=29.43% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=7591257; PubMed=8040301; PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (PubMed=19787792; PubMed=26428435) Population: Caucasian; Derived from metastatic site: Supra-orbital region. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 32 hours (PubMed=4748425); 23 hours (PubMed=24312454); ~32 hours (CLS); ~48 hours (DSMZ=ACC-203) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00267; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 776 Problematic cell line: Misclassified Originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor (PubMed=20143388). 21120296 CVCL_0532 SK-OV-3 cancer cell line human CVCL_0532 HLA typing: A*03,68; B*18,35; C*04,05; DPB1*02:01:02,04:01; DQB1*02:01,05:01:01; DRB1*01,03:01:01 (PubMed=15748285); HLA typing: A*03:01,68:01; B*18:01,35:01; C*04:01,05:01 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=0%; East Asian, North=1.76%; East Asian, South=0%; South Asian=1.14%; European, North=59.05%; European, South=36.53% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (PubMed=11565033; PubMed=25846456); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=17088437; PubMed=22705003; PubMed=25846456; PubMed=28273451); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (PubMed=17088437; PubMed=20204287) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL01014; true Female Doubling time: 44 hours (PubMed=7718330); 19 hours (PubMed=2653399); 28 +- 2 hours (PubMed=3804493); 28.8 hours (PubMed=4016745); 75 hours (PubMed=25984343); 48.7 hours (NCI-DTP); ~35 hours (PBCF); 33.29 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: OCCP ovarian cancer cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-528 21120297 CVCL_0531 SK-N-SH cancer cell line human CVCL_0531 HLA typing: A*01:01,24:02; B*18:01,49:01; C*07:06,07:06 (PubMed=25960936); HLA typing: A*01:01,24:02; B*18:01,49:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0.07%; East Asian, North=1.63%; East Asian, South=0%; South Asian=0%; European, North=66.77%; European, South=31.16% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18724359; PubMed=18923523; PubMed=28350380; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: ATAC-Seq; Omics: ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 44 hours (PubMed=4748425); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-529 21120298 CVCL_0534 SMMC-7721 cancer cell line human CVCL_0534 CL:0000010 Miscellaneous: Formerly the CCRID database had 3 entries describing this cell line (3111C0001CCC000087, 3131C0001000700052, 3142C0001000000063) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00554 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; PubMed=28807831). Originally thought to originate from a hepatocellular carcinoma. 21120299 CVCL_0533 SK-UT-1 cancer cell line human CVCL_0533 HLA typing: A*02:01,03:01; B*44:02,55:01; C*01:02,05:01 (PubMed=26589293); Genome ancestry: African=1.59%; Native American=1.42%; East Asian, North=0%; East Asian, South=1.64%; South Asian=7.64%; European, North=32.8%; European, South=54.91% (PubMed=30894373). From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1096Ter (c.3286C>T); ClinVar=VCV000156475; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg88Gln (c.263G>A); ClinVar=VCV000376049; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323fs*2 (c.968_969insA); Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=2216456; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=2216456; ATCC) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-537 21120300 CVCL_0536 ST-1 [Mouse kidney] transformed cell line house mouse CVCL_0536 CL:0000010 Derived from sampling site: Kidney; nephron; thick ascending limb of loop of Henle. 21120301 CVCL_0535 SNB-19 cancer cell line human CVCL_0535 HLA typing: A*02:01:01; B*18; C*05; DPB1*04:02; DQB1*02:01; DRB1*03:01:01 (PubMed=15748285); Genome ancestry: African=0.48%; Native American=0%; East Asian, North=2.88%; East Asian, South=0%; South Asian=0%; European, North=78.25%; European, South=18.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=17088437) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2219; true; Discontinued: JCRB; NIHS0294; true Male Doubling time: 34.6 hours (NCI-DTP); ~24 hours (DSMZ=ACC-325) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI-60 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00268 Problematic cell line: Contaminated Shown to be a U-251MG derivative (PubMed=18304946; PubMed=20143388; PubMed=22570425). Originally thought to originate from a 47 year old patient with a left parieto-occipital glioblastoma. 21120302 CVCL_0538 SU-DHL-1 cancer cell line human CVCL_0538 HLA typing: A*02:01,68:02; B*55:01,55:01; C*03:03,06:02 (PubMed=26589293); HLA typing: A*02:01:01,68:02:01; B*55:01:01,55:01:01; C*03:03:01,06:02:01 (DSMZCellDive=ACC-356); Genome ancestry: African=3.76%; Native American=22.55%; East Asian, North=5.57%; East Asian, South=0%; South Asian=0%; European, North=43.3%; European, South=24.81% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=7824924; PubMed=9121481; PubMed=25485619; PubMed=26657151; PubMed=29899875); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~40-50 hours (DSMZ=ACC-356); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21120303 CVCL_0537 ST15A conditionally immortalized cell line Norway rat CVCL_0537 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebellum; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: At the permissive temperature (33 Celsius) proliferates At the restrictive temperature (39 Celsius) has reduced proliferation and the cells can differentiate into either neurons or glial cells depending on the culture conditions. 21120304 CVCL_0539 SU-DHL-4 cancer cell line human CVCL_0539 HLA typing: A*02:01,03:01; B*15:01,15:01; C*03:04,03:04 (PubMed=26589293); HLA typing: A*02:01:01,02:01:01; B*15:01:01,15:01:01; C*03:04:01,03:04:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-495); Genome ancestry: African=0%; Native American=1.07%; East Asian, North=0%; East Asian, South=0.49%; South Asian=0%; European, North=60.53%; European, South=37.92% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=2875799); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr666Asn (c.1996T>A) (Y661N); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=17363600; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peritoneal effusion. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: ICLC; HTL10002; true Male Doubling time: ~40 hours (DSMZ=ACC-495); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21120305 CVCL_0509 RPMI-8226/MR20 cancer cell line human CVCL_0509 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 21120306 CVCL_0508 ROS 17/2.8 cancer cell line Norway rat CVCL_0508 CL:0000010 Anecdotal: Have been flown in space on Cosmos-2229 (Bion-10), Foton-11 and Foton-12 to study growth and cytoskeletal changes in microgravity (PubMed=9028534; PubMed=11511518) Breed/subspecies: ACI 9935. Group: Space-flown cell line (cellonaut) 21120307 CVCL_RZ51 EC-Slc22a12tm1Dgen embryonic stem cell house mouse CVCL_RZ51 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1195269; Slc22a12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120308 CVCL_RZ50 EC-Slc18a1tm1Dgen embryonic stem cell house mouse CVCL_RZ50 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:106684; Slc18a1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120309 CVCL_RZ53 EC-Slc7a8tm1Dgen embryonic stem cell house mouse CVCL_RZ53 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1355323; Slc7a8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120310 CVCL_RZ52 EC-Slc6a9tm1Dgen embryonic stem cell house mouse CVCL_RZ52 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95760; Slc6a9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120311 CVCL_RZ55 EC-Sstr1tm1Dgen embryonic stem cell house mouse CVCL_RZ55 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:98327; Sstr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120312 CVCL_RZ54 EC-Slc9a6tm1Dgen embryonic stem cell house mouse CVCL_RZ54 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2443511; Slc9a6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120313 CVCL_RZ57 EC-Thbs4tm1Dgen embryonic stem cell house mouse CVCL_RZ57 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1101779; Thbs4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120314 CVCL_RZ56 EC-Tgfbr1tm1Dgen embryonic stem cell house mouse CVCL_RZ56 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:98728; Tgfbr1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120315 CVCL_RZ59 EC-Tmprss11atm1Dgen embryonic stem cell house mouse CVCL_RZ59 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2684853; Tmprss11a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120316 CVCL_RZ58 EC-Tlr2tm1Dgen embryonic stem cell house mouse CVCL_RZ58 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1346060; Tlr2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120317 CVCL_0501 RIN-m5F cancer cell line Norway rat CVCL_0501 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Secretes mainly insulin and little somatostatin (PubMed=6141566; PubMed=6295859) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11605 21120318 CVCL_0500 RIN-5AH cancer cell line Norway rat CVCL_0500 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 21120319 CVCL_0503 RK3E transformed cell line Norway rat CVCL_0503 CL:0000010 Transformant: Adenovirus E1A; Derived from sampling site: Kidney Cell type=Epithelial cell.; Breed/subspecies: Fischer. Unspecified 21120320 CVCL_0502 RIN-5AH-T2B cancer cell line Norway rat CVCL_0502 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Secretes more insulin than the RIN-5AH cell line 21120321 CVCL_0505 RL95-2 cancer cell line human CVCL_0505 HLA typing: A*02:10,24:02; B*55:01,55:01; C*03:03,03:03; DQA1*01:02,05:02; DQB1*05:03,05:03; DRB1*14:01,14:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.33%; East Asian, North=1.49%; East Asian, South=0%; South Asian=1.52%; European, North=68.38%; European, South=28.28% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg693Ter (c.2077C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61His (c.183G>T); ClinVar=VCV000376318; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323fs*2 (c.968_969insA); Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323Metfs*21 (c.968delA); ClinVar=VCV000653412; Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (PubMed=9887230; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Heterozygous (PubMed=9887230; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Endometrium. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 22 hours (PubMed=1541432); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21120322 CVCL_0504 RKO cancer cell line human CVCL_0504 HLA typing: A*03:01,03:01; B*18:01,35:08; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=81.43%; Native American=2.85%; East Asian, North=1.14%; East Asian, South=0%; South Asian=0%; European, North=7.64%; European, South=6.93% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20570890; PubMed=24042735; PubMed=24755471; PubMed=28683746; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=20570890; PubMed=24042735; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2253215; PubMed=9715273; PubMed=16418264) Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE); Omics: Virome analysis using proteomics Unspecified Doubling time: 21 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-high) (PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Part of: KuDOS 95 cell line panel; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21120323 CVCL_0507 ROB-C26 spontaneously immortalized cell line Norway rat CVCL_0507 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21120324 CVCL_0506 RMC transformed cell line Norway rat CVCL_0506 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; mesangium Cell type=Mesangial cell.; Breed/subspecies: Sprague Dawley. Male 21120325 CVCL_0519 SG231 cancer cell line human CVCL_0519 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Pro (c.373A>C); ClinVar=VCV000376666; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis Discontinued: ATCC; CRL-2126; true. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21120326 CVCL_RZ40 EC-Ppardtm1Dgen embryonic stem cell house mouse CVCL_RZ40 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:101884; Ppard; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120327 CVCL_RZ42 EC-Ptch2tm1Dgen embryonic stem cell house mouse CVCL_RZ42 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1095405; Ptch2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120328 CVCL_RZ41 EC-Ppm1ftm1Dgen embryonic stem cell house mouse CVCL_RZ41 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1918464; Ppm1f; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120329 CVCL_RZ44 EC-Rgs4tm1Dgen embryonic stem cell house mouse CVCL_RZ44 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:108409; Rgs4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120330 CVCL_RZ43 EC-Ptprotm1Dgen embryonic stem cell house mouse CVCL_RZ43 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1097152; Ptpro; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120331 CVCL_RZ46 EC-Scn11atm1Dgen embryonic stem cell house mouse CVCL_RZ46 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1345149; Scn11a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120332 CVCL_RZ45 EC-S1pr4tm1Dgen embryonic stem cell house mouse CVCL_RZ45 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1333809; S1pr4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120333 CVCL_RZ48 EC-Sema5atm1Dgen embryonic stem cell house mouse CVCL_RZ48 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:107556; Sema5a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120334 CVCL_RZ47 EC-Scn9atm1Dgen embryonic stem cell house mouse CVCL_RZ47 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:107636; Scn9a; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120335 CVCL_RZ49 EC-Sema6ctm1Dgen embryonic stem cell house mouse CVCL_RZ49 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1338032; Sema6c; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129P2/Ola. Male Characteristics: A IRES-LacZ-Neo cassette is inserted in the targeted gene region Part of: Deltagen knockout ES cell lines 21120336 CVCL_0510 Ra2 factor-dependent cell line house mouse CVCL_0510 CL:0000010 Derived from sampling site: Brain; meninges Cell type=Microglial cell.; Breed/subspecies: C57BL/6J(H-2b). Unspecified Characteristics: CSF2 dependent Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7061 21120337 CVCL_0512 Rat1A spontaneously immortalized cell line Norway rat CVCL_0512 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: ATCC; CRL-2786; true; Discontinued: ATCC; JHU-25; true Unspecified 21120338 CVCL_0511 Raji cancer cell line human CVCL_0511 HLA typing: A*03:01,03:01; B*15:10,15:10; C*04:01,03:04; DQA1*05:01,01:01; DQB1*05:01,02:01; DRB1*10:01,03:01 (PubMed=25960936); HLA typing: A*03:01:01:01; B*15:10,15:CXU; C*03:04:02,04:01:01:01; DPB1*01:01:01; DQA1*01:01:01,05:01:01:01; DQB1*02:01:01,05:01:01; DRA*01:01:01:01; DRB1*03:01:01:01,10:01:01:01; DRB3*02 (IPD-IMGT/HLA=11295); HLA typing: A*03:01:01; B*15:10:01; C*03:04:02,04:01:01; DPB1*01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*03:01:01,10:01:01 (CLS=300359); HLA typing: A*03:01:01,03:01:01; B*15:10:01,15:10:01; C*03:04:02,04:01:01; DPA1*02:02:02,02:02:02; DPB1*01:01:01,01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*03:01:01,10:01:01 (DSMZCellDive=ACC-319); Genome ancestry: African=99.39%; Native American=0%; East Asian, North=0.6%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6306472; PubMed=6419122; PubMed=6806672); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (PubMed=8344493; PubMed=15901131; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (PubMed=8344493; PubMed=15901131; Cosmic-CLP; DepMap) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: ATCC; CRL-7936; true Male Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572); Virology: Contains 50-60 integrated copies of the EBV genome One copy is integrated in intron 1 of the BACH2 gene (PubMed=14982850). Doubling time: 23.2 hours (PubMed=8847894); ~24-36 hours (DSMZ=ACC-319); ~20 hours (HIVReagentProgram); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120339 CVCL_0514 Pt K2 spontaneously immortalized cell line CVCL_0514 CL:0000010 Karyotypic information: As the diploid chromosome number of P.tridactylus is quite small (2n=12), this cell line is suited to the study of mitosis and to easily visualize the chromosomes under a microscope; Derived from sampling site: Kidney. Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-6494; true Male Group: Marsupial cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120340 CVCL_0513 Rat2 spontaneously immortalized cell line Norway rat CVCL_0513 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21120341 CVCL_0516 SB-2 cancer cell line human CVCL_0516 CL:0000010 21120342 CVCL_0515 SaOS-LM7 cancer cell line human CVCL_0515 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Metastatic Established by 7 cycling of parent cell line through the lungs of nude mice. 21120343 CVCL_0518 Sf21 spontaneously immortalized cell line CVCL_0518 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 26-30 hours (PubMed=68913); 33 +- 1 hours (in static culture), 26 +- 1 hours (in suspension culture) (PubMed=10585188); ~3 days (DSMZ=ACC-119); 24 hours (ECACC=05022801) Group: Insect cell line; Group: Recombinant protein production insect cell line 21120344 CVCL_0517 SCCTF cancer cell line human CVCL_0517 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Discontinued: RCB; RCB0442; true Male Doubling time: 22.2 hours (PubMed=1373668) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00266 Problematic cell line: Contaminated Shown to be a SCCKN derivative (PubMed=16643607; PubMed=20143388). 21120345 CVCL_AI39 GM07986 transformed cell line human CVCL_AI39 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120346 CVCL_AI38 GM07977 transformed cell line human CVCL_AI38 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120347 CVCL_AI31 GM01838 transformed cell line human CVCL_AI31 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120348 CVCL_AI30 GM01837 finite cell line human CVCL_AI30 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120349 CVCL_AI33 GM04421 finite cell line human CVCL_AI33 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21120350 CVCL_AI32 GM04420 finite cell line human CVCL_AI32 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21120351 CVCL_AI35 GM07974 transformed cell line human CVCL_AI35 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120352 CVCL_AI34 GM04422 finite cell line human CVCL_AI34 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21120353 CVCL_AI37 GM07976 transformed cell line human CVCL_AI37 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120354 CVCL_AI36 GM07975 transformed cell line human CVCL_AI36 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120355 CVCL_AI49 GM08086 transformed cell line human CVCL_AI49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120356 CVCL_AI42 GM08041 transformed cell line human CVCL_AI42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120357 CVCL_AI41 GM08008 transformed cell line human CVCL_AI41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120358 CVCL_AI44 GM08072 transformed cell line human CVCL_AI44 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120359 CVCL_AI43 GM08071 transformed cell line human CVCL_AI43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120360 CVCL_AI46 GM08083 transformed cell line human CVCL_AI46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120361 CVCL_AI45 GM08073 transformed cell line human CVCL_AI45 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120362 CVCL_AI48 GM08085 transformed cell line human CVCL_AI48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120363 CVCL_AI47 GM08084 transformed cell line human CVCL_AI47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120364 CVCL_AI40 GM08007 transformed cell line human CVCL_AI40 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120365 CVCL_9083 GENEA074 embryonic stem cell human CVCL_9083 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0194; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120366 CVCL_9082 GENEA073 embryonic stem cell human CVCL_9082 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0193; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120367 CVCL_9085 c4 (B13NBii1) cancer cell line house mouse CVCL_9085 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29865; Benzo[a]pyrene; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21120368 CVCL_9084 D33-3 cancer cell line CVCL_9084 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21120369 CVCL_9081 GENEA072 embryonic stem cell human CVCL_9081 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0192; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120370 CVCL_9080 GENEA071 embryonic stem cell human CVCL_9080 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0191; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120371 CVCL_AI17 HPSI1213i-hehd_1 induced pluripotent stem cell human CVCL_AI17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120372 CVCL_AI16 HPSI1213i-foqj_2 induced pluripotent stem cell human CVCL_AI16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120373 CVCL_AI19 HPSI1213i-nekd_1 induced pluripotent stem cell human CVCL_AI19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120374 CVCL_AI18 HPSI1213i-hehd_2 induced pluripotent stem cell human CVCL_AI18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120375 CVCL_9087 36 hybrid cell line CVCL_9087 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8193 21120376 CVCL_9089 C5 [Human hybridoma against lipid A] hybridoma human CVCL_9089 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:47040; Lipid A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8669 21120377 CVCL_9088 SHM-A6 hybrid cell line CVCL_9088 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8192 21120378 CVCL_AI11 HPSI1114i-ziyn_6 induced pluripotent stem cell human CVCL_AI11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120379 CVCL_AI10 HPSI1114i-qibk_3 induced pluripotent stem cell human CVCL_AI10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120380 CVCL_AI13 HPSI1213i-aegt_3 induced pluripotent stem cell human CVCL_AI13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120381 CVCL_AI12 HPSI1213i-aegt_2 induced pluripotent stem cell human CVCL_AI12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21120382 CVCL_AI15 HPSI1213i-foqj_1 induced pluripotent stem cell human CVCL_AI15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21120383 CVCL_AI14 HPSI1213i-babk_2 induced pluripotent stem cell human CVCL_AI14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120384 CVCL_9094 A9 [Mouse hybridoma against hamster Hmgcr] hybridoma house mouse CVCL_9094 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00347; Cricetulus griseus Hmgcr. 21120385 CVCL_9093 PT67 transformed cell line house mouse CVCL_9093 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12284 21120386 CVCL_9096 BALB/B 0.75BAE A.1R.1 HD A.8 transformed cell line house mouse CVCL_9096 CL:0000010 Transformant: Benz[a]anthracene 5,6-oxide (Epoxy-5,6-dihydrobenz(a)anthracene)(ChEBI; CHEBI:142240); Breed/subspecies: BALB.B. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120387 CVCL_9095 A9 L hD2 S.C. 18 transformed cell line house mouse CVCL_9095 CL:0000010 Transfected with: HGNC; 3023; DRD2 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10225 21120388 CVCL_9090 36.5 embryonic stem cell house mouse CVCL_9090 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:88346; Cd8a Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11116 21120389 CVCL_9092 3T3 MEFs WT spontaneously immortalized cell line house mouse CVCL_9092 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21120390 CVCL_9091 3T3 MEFs KO spontaneously immortalized cell line house mouse CVCL_9091 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:102709; Cav1 Derived from sampling site: Cell type=Fibroblast. Unspecified 21120391 CVCL_AI28 GM01497 finite cell line human CVCL_AI28 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21120392 CVCL_AI27 GM01496 finite cell line human CVCL_AI27 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21120393 CVCL_AI29 GM01498 transformed cell line human CVCL_AI29 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120394 CVCL_9098 BALB/c 10ME HD A.5R.1 transformed cell line house mouse CVCL_9098 CL:0000010 Transformant: 11,12-epoxy-methylcholanthrene (11,12-dihydro-11,12-epoxy-3-methylcholanthrene)(ChEBI; CHEBI:142244); Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120395 CVCL_9097 BALB/c 10CrMCA A.2R.1 transformed cell line house mouse CVCL_9097 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120396 CVCL_9099 BALB/c AMuLV A.3R.1 transformed cell line house mouse CVCL_9099 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120397 CVCL_AI20 HPSI1213i-nusw_2 induced pluripotent stem cell human CVCL_AI20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120398 CVCL_AI22 HPSI1213i-pahc_5 induced pluripotent stem cell human CVCL_AI22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120399 CVCL_AI21 HPSI1213i-pahc_4 induced pluripotent stem cell human CVCL_AI21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120400 CVCL_AI24 GM01243 transformed cell line human CVCL_AI24 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120401 CVCL_AI23 HPSI1213i-xuja_2 induced pluripotent stem cell human CVCL_AI23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120402 CVCL_AI26 GM01430 finite cell line human CVCL_AI26 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120403 CVCL_AI25 GM01244 transformed cell line human CVCL_AI25 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120404 CVCL_9061 GENEA052 embryonic stem cell human CVCL_9061 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0234; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-36. 21120405 CVCL_9060 GENEA051 embryonic stem cell human CVCL_9060 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1213; probable. Unspecified 21120406 CVCL_9063 GENEA054 embryonic stem cell human CVCL_9063 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-63.. 21120407 CVCL_9062 GENEA053 embryonic stem cell human CVCL_9062 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-63. 21120408 CVCL_9069 GENEA060 embryonic stem cell human CVCL_9069 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA061 (Cellosaurus=CVCL_9070). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0172; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-49. 21120409 CVCL_9068 GENEA059 embryonic stem cell human CVCL_9068 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0175; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120410 CVCL_9065 GENEA056 embryonic stem cell human CVCL_9065 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-63.. 21120411 CVCL_9064 GENEA055 embryonic stem cell human CVCL_9064 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61.. 21120412 CVCL_9067 GENEA058 embryonic stem cell human CVCL_9067 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0199; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-47.. 21120413 CVCL_9066 GENEA057 embryonic stem cell human CVCL_9066 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0233; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-39. 21120414 CVCL_9072 GENEA063 embryonic stem cell human CVCL_9072 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA062 (Cellosaurus=CVCL_9071). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0188; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21120415 CVCL_9071 GENEA062 embryonic stem cell human CVCL_9071 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA063 (Cellosaurus=CVCL_9072). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0187; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21120416 CVCL_9074 GENEA065 embryonic stem cell human CVCL_9074 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0200; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-48.. 21120417 CVCL_9073 GENEA064 embryonic stem cell human CVCL_9073 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0174; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-49.. 21120418 CVCL_9070 GENEA061 embryonic stem cell human CVCL_9070 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA060 (Cellosaurus=CVCL_9069). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0173; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-49. 21120419 CVCL_AI06 HPSI1113i-wetu_2 induced pluripotent stem cell human CVCL_AI06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120420 CVCL_9079 GENEA070 embryonic stem cell human CVCL_9079 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA069 (Cellosaurus=CVCL_9078). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0182; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-51. 21120421 CVCL_AI05 HPSI1113i-waus_1 induced pluripotent stem cell human CVCL_AI05 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120422 CVCL_AI08 HPSI1113i-zuta_3 induced pluripotent stem cell human CVCL_AI08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120423 CVCL_AI07 HPSI1113i-zuta_1 induced pluripotent stem cell human CVCL_AI07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120424 CVCL_9076 GENEA067 embryonic stem cell human CVCL_9076 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0190; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120425 CVCL_9075 GENEA066 embryonic stem cell human CVCL_9075 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0189; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21120426 CVCL_AI09 HPSI1114i-qibk_2 induced pluripotent stem cell human CVCL_AI09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120427 CVCL_9078 GENEA069 embryonic stem cell human CVCL_9078 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Phe305Ser (c.914T>C); ClinVar=VCV000099778; Zygosity=Unspecified (CelloPub=CLPUB00370) Donor information: Embryo is sibling to that giving rise to GENEA070 (Cellosaurus=CVCL_9079). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0181; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-51. 21120428 CVCL_9077 GENEA068 embryonic stem cell human CVCL_9077 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0168; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-44.. 21120429 CVCL_AI00 HPSI1113i-podx_2 induced pluripotent stem cell human CVCL_AI00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21120430 CVCL_AI02 HPSI1113i-qolg_3 induced pluripotent stem cell human CVCL_AI02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120431 CVCL_AI01 HPSI1113i-qolg_1 induced pluripotent stem cell human CVCL_AI01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120432 CVCL_AI04 HPSI1113i-qorq_2 induced pluripotent stem cell human CVCL_AI04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120433 CVCL_AI03 HPSI1113i-qorq_1 induced pluripotent stem cell human CVCL_AI03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21120434 CVCL_9041 GENEA032 embryonic stem cell human CVCL_9041 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA031 (Cellosaurus=CVCL_9040) and GENEA033 (Cellosaurus=CVCL_9042). Female Registration: NIH Human Embryonic Stem Cell Registry; not approved; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120435 CVCL_9040 GENEA031 embryonic stem cell human CVCL_9040 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA032 (Cellosaurus=CVCL_9041) and GENEA033 (Cellosaurus=CVCL_9042). Female Registration: NIH Human Embryonic Stem Cell Registry; not approved; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120436 CVCL_9047 GENEA038 embryonic stem cell human CVCL_9047 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1200; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120437 CVCL_9046 GENEA037 embryonic stem cell human CVCL_9046 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1199; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120438 CVCL_9049 GENEA040 embryonic stem cell human CVCL_9049 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Genea). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0171; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-45. 21120439 CVCL_9048 GENEA039 embryonic stem cell human CVCL_9048 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1201; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120440 CVCL_9043 GENEA034 embryonic stem cell human CVCL_9043 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1196; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-63. 21120441 CVCL_9042 GENEA033 embryonic stem cell human CVCL_9042 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA031 (Cellosaurus=CVCL_9040) and GENEA032 (Cellosaurus=CVCL_9041). Female Registration: NIH Human Embryonic Stem Cell Registry; not approved; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120442 CVCL_9045 GENEA036 embryonic stem cell human CVCL_9045 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1198; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120443 CVCL_9044 GENEA035 embryonic stem cell human CVCL_9044 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1197; probable. Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61. 21120444 CVCL_9039 GENEA030 embryonic stem cell human CVCL_9039 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Discontinued: ISCR; 1192; probable. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-63. 21120445 CVCL_9050 GENEA041 embryonic stem cell human CVCL_9050 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Genea); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Genea). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0167; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-44. 21120446 CVCL_9052 GENEA043 embryonic stem cell human CVCL_9052 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0232; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-40. 21120447 CVCL_9051 GENEA042 embryonic stem cell human CVCL_9051 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0231; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-40. 21120448 CVCL_9058 GENEA049 embryonic stem cell human CVCL_9058 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA050 (Cellosaurus=CVCL_9059). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0183; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-54. 21120449 CVCL_9057 GENEA048 embryonic stem cell human CVCL_9057 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA002 (Cellosaurus=CVCL_9011). Omics: Deep exome analysis; Omics: SNP array analysis Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0152; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-38. 21120450 CVCL_9059 GENEA050 embryonic stem cell human CVCL_9059 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA049 (Cellosaurus=CVCL_9058). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0184; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-54. 21120451 CVCL_9054 GENEA045 embryonic stem cell human CVCL_9054 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Male 21120452 CVCL_9053 GENEA044 embryonic stem cell human CVCL_9053 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Male 21120453 CVCL_9056 GENEA047 embryonic stem cell human CVCL_9056 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0230; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-41. 21120454 CVCL_9055 GENEA046-HD embryonic stem cell human CVCL_9055 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Omics: Proteome analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0180; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-46. 21120455 CVCL_JC56 GN00087 transformed cell line human CVCL_JC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120456 CVCL_JC55 GN00080 transformed cell line human CVCL_JC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120457 CVCL_JC58 GN00098 transformed cell line human CVCL_JC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120458 CVCL_JC57 GN00092 transformed cell line human CVCL_JC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120459 CVCL_JC52 GN00053 transformed cell line human CVCL_JC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120460 CVCL_JC51 GN00049 transformed cell line human CVCL_JC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120461 CVCL_JC54 GN00076 transformed cell line human CVCL_JC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120462 CVCL_JC53 GN00068 transformed cell line human CVCL_JC53 HLA typing: DQA1*01,02:01; DQB1*02:02,05:03:01; DRB1*07:01,14:01; DRB3*02:05; DRB4*01:01:01 (IPD-IMGT/HLA=10674) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120463 CVCL_JC50 GN00045 transformed cell line human CVCL_JC50 HLA typing: DQA1*01:02,02:01; DQB1*06:02,02:02; DRB1*15:03,13:03; DRB3*02:02; DRB5*01:04; DRB6*02:01 (IPD-IMGT/HLA=10672) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120464 CVCL_JC49 GN00027 transformed cell line human CVCL_JC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120465 CVCL_JC48 GN00020 transformed cell line human CVCL_JC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120466 CVCL_JC67 TER364 transformed cell line human CVCL_JC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120467 CVCL_JC66 TER362 transformed cell line human CVCL_JC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120468 CVCL_JC69 TER75 transformed cell line human CVCL_JC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120469 CVCL_JC68 TER119 transformed cell line human CVCL_JC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120470 CVCL_JC63 TER401 transformed cell line human CVCL_JC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120471 CVCL_JC62 24131 transformed cell line human CVCL_JC62 HLA typing: A*02,02; B*44,40; C*05:01,02:02; DPB1*02:01:02,04:01:01; DQA1*01:03,04:01:01; DQB1*04:02,06:03; DRB1*08:16,13:01:01; DRB3*01:01 (IPD-IMGT/HLA=12578) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120472 CVCL_JC65 TER381 transformed cell line human CVCL_JC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120473 CVCL_JC64 13976036 transformed cell line human CVCL_JC64 HLA typing: A*01,29; B*08,45:01; C*06,07; DPB1*04:01:01,04:02; DQA1*01:03,03:03; DQB1*03:01:01,06:03; DRB1*04:01:01,13:10; DRB3*01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=12582) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120474 CVCL_JC61 TER473 transformed cell line human CVCL_JC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120475 CVCL_JC60 TER392 transformed cell line human CVCL_JC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120476 CVCL_JC59 GN00151 transformed cell line human CVCL_JC59 HLA typing: A*30:02,68:01:01; B*44:02; C*05:ASHR,07; DQA1*01:02,05:03; DQB1*05:02,03:01; DRB1*16:01,11:01; DRB3*02:02; DRB5*02:04 (IPD-IMGT/HLA=10629) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120477 CVCL_JC34 TER416 transformed cell line human CVCL_JC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120478 CVCL_JC33 TER385 transformed cell line human CVCL_JC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120479 CVCL_JC36 TER512 transformed cell line human CVCL_JC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120480 CVCL_JC35 30638 transformed cell line human CVCL_JC35 HLA typing: A*23,32; B*44,41; C*17,04; DPB1*02:01,04:01; DQA1*01:02,02:01; DQB1*02:02,06:09; DRB1*07:01,13:36; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=12303) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120481 CVCL_JC30 TER295 transformed cell line human CVCL_JC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120482 CVCL_JC32 14513382 transformed cell line human CVCL_JC32 HLA typing: A*02:01/02:20/02:53N/02:64/02:66/02:67,25; B*38:01,15:78; C*12:03,03:04; DPA1*01:CG; DPB1*06:01/64:01,04:01; DQA1*03,01:DF; DQB1*05:01,03:02; DRB1*04:01,10:01; DRB4*01 (IPD-IMGT/HLA=14032) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120483 CVCL_JC31 VK [Human B-cell IHW] transformed cell line human CVCL_JC31 HLA typing: DPB1*04:01,17:01; DQA1*02:01,03:03; DQB1*02:02,03:01; DRB1*04:14,07:01; DRB4*01:01,01:03 (IPD-IMGT/HLA=11527) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120484 CVCL_AI97 GM10036 transformed cell line human CVCL_AI97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120485 CVCL_AI96 GM10018 transformed cell line human CVCL_AI96 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120486 CVCL_AI99 GM10042 transformed cell line human CVCL_AI99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120487 CVCL_AI98 GM10041 transformed cell line human CVCL_AI98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120488 CVCL_AI91 GM08756 transformed cell line human CVCL_AI91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120489 CVCL_AI90 GM08580 transformed cell line human CVCL_AI90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120490 CVCL_JC27 CS52iALS-C9n6 induced pluripotent stem cell human CVCL_JC27 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (CSMC) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21120491 CVCL_AI93 GM08758 transformed cell line human CVCL_AI93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120492 CVCL_JC26 CS28iALS-C9n2 induced pluripotent stem cell human CVCL_JC26 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (CSMC) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120493 CVCL_AI92 GM08757 transformed cell line human CVCL_AI92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120494 CVCL_AI95 GM10017 transformed cell line human CVCL_AI95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120495 CVCL_JC29 TER525 transformed cell line human CVCL_JC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120496 CVCL_AI94 GM08759 transformed cell line human CVCL_AI94 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120497 CVCL_JC28 HEp-5 cancer cell line human CVCL_JC28 CL:0000010 Derived from sampling site: Salivary gland; submandibular gland. Male 21120498 CVCL_JC45 GN00001 transformed cell line human CVCL_JC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120499 CVCL_JC44 TTH-18 transformed cell line human CVCL_JC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120500 CVCL_JC47 GN00017 transformed cell line human CVCL_JC47 HLA typing: DQA1*01,02:01; DQB1*02:02,05:03:01; DRB1*07:01,14:01; DRB3*02:01; DRB4*03:01N (IPD-IMGT/HLA=10666) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120501 CVCL_JC46 GN00016 transformed cell line human CVCL_JC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120502 CVCL_JC41 TER368 transformed cell line human CVCL_JC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120503 CVCL_JC40 TER261 transformed cell line human CVCL_JC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120504 CVCL_JC43 RXT transformed cell line human CVCL_JC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120505 CVCL_JC42 11845457 transformed cell line human CVCL_JC42 HLA typing: A*24; B*15:01,57:01:01; C*03:11:02,06:02; DPA1*01:CG; DPB1*02:01,04:01/94:01; DQA1*01:01; DQB1*05:01; DRB1*01:01,01:03 (IPD-IMGT/HLA=14053) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120506 CVCL_JC38 TER293 transformed cell line human CVCL_JC38 HLA typing: A*02:BDDU,23:RRF; B*44:03:01,35:28; C*04:01:01:01/04:01:01:02/04:09N,16:01:01; DPB1*04:02,14:01; DQA1*01:04,04:01; DQB1*05:03:01,04:02; DRB1*08:02:01,14:54; DRB3*02:02 (IPD-IMGT/HLA=14047) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120507 CVCL_JC37 37935 transformed cell line human CVCL_JC37 HLA typing: A*01:01:38L,02:01; B*57:01,15:17; C*06:02,07:02; DPA1*01:ACDV; DPB1*04:01; DQA1*01:01,02:01; DQB1*03:03,05:01; DRB1*01:01,07:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=15956) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120508 CVCL_JC39 TER356 transformed cell line human CVCL_JC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120509 CVCL_JC12 1328-8103 transformed cell line human CVCL_JC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120510 CVCL_JC11 1328-8097 transformed cell line human CVCL_JC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120511 CVCL_JC14 1328-8105 transformed cell line human CVCL_JC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120512 CVCL_JC13 1328-8104 transformed cell line human CVCL_JC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120513 CVCL_JC10 1328-1-8100 transformed cell line human CVCL_JC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120514 CVCL_AI75 GM08292 transformed cell line human CVCL_AI75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120515 CVCL_AI74 GM08291 transformed cell line human CVCL_AI74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120516 CVCL_AI77 GM08362 transformed cell line human CVCL_AI77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120517 CVCL_AI76 GM08353 transformed cell line human CVCL_AI76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120518 CVCL_AI79 GM08364 transformed cell line human CVCL_AI79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120519 CVCL_AI78 GM08363 transformed cell line human CVCL_AI78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120520 CVCL_JC09 1328-1-8099 transformed cell line human CVCL_JC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120521 CVCL_JC08 1328-1-8094 transformed cell line human CVCL_JC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120522 CVCL_JC05 1340-8309 transformed cell line human CVCL_JC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120523 CVCL_AI71 GM08287 transformed cell line human CVCL_AI71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120524 CVCL_JC04 1340-8308 transformed cell line human CVCL_JC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120525 CVCL_AI70 GM08286 transformed cell line human CVCL_AI70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120526 CVCL_JC07 1340-8392 transformed cell line human CVCL_JC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120527 CVCL_AI73 GM08290 transformed cell line human CVCL_AI73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120528 CVCL_JC06 1340-8336 transformed cell line human CVCL_JC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120529 CVCL_AI72 GM08289 transformed cell line human CVCL_AI72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120530 CVCL_JC23 1345-8334 transformed cell line human CVCL_JC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120531 CVCL_JC22 1345-8333 transformed cell line human CVCL_JC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120532 CVCL_JC25 1354-8476 transformed cell line human CVCL_JC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120533 CVCL_JC24 1354-8472 transformed cell line human CVCL_JC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120534 CVCL_JC21 1328-8140 transformed cell line human CVCL_JC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120535 CVCL_JC20 1328-8139 transformed cell line human CVCL_JC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120536 CVCL_AI86 GM08411 transformed cell line human CVCL_AI86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120537 CVCL_AI85 GM08410 transformed cell line human CVCL_AI85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120538 CVCL_AI88 GM08413 transformed cell line human CVCL_AI88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120539 CVCL_AI87 GM08412 transformed cell line human CVCL_AI87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120540 CVCL_AI89 GM08579 transformed cell line human CVCL_AI89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120541 CVCL_JC19 1328-8110 transformed cell line human CVCL_JC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120542 CVCL_AI80 GM08365 transformed cell line human CVCL_AI80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120543 CVCL_JC16 1328-8107 transformed cell line human CVCL_JC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120544 CVCL_AI82 GM08392 transformed cell line human CVCL_AI82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120545 CVCL_JC15 1328-8106 transformed cell line human CVCL_JC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120546 CVCL_AI81 GM08366 transformed cell line human CVCL_AI81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120547 CVCL_JC18 1328-8109 transformed cell line human CVCL_JC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120548 CVCL_AI84 GM08409 transformed cell line human CVCL_AI84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120549 CVCL_JC17 1328-8108 transformed cell line human CVCL_JC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21120550 CVCL_AI83 GM08393 transformed cell line human CVCL_AI83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120551 CVCL_AI53 GM08090 transformed cell line human CVCL_AI53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120552 CVCL_AI52 GM08089 transformed cell line human CVCL_AI52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120553 CVCL_AI55 GM08106 transformed cell line human CVCL_AI55 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120554 CVCL_AI54 GM08091 transformed cell line human CVCL_AI54 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120555 CVCL_AI57 GM08273 transformed cell line human CVCL_AI57 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120556 CVCL_AI56 GM08107 transformed cell line human CVCL_AI56 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120557 CVCL_AI59 GM08275 transformed cell line human CVCL_AI59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120558 CVCL_AI58 GM08274 transformed cell line human CVCL_AI58 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120559 CVCL_AI51 GM08088 transformed cell line human CVCL_AI51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120560 CVCL_AI50 GM08087 transformed cell line human CVCL_AI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120561 CVCL_JC01 1340-8305 transformed cell line human CVCL_JC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120562 CVCL_JC00 1340-8286 transformed cell line human CVCL_JC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120563 CVCL_JC03 1340-8307 transformed cell line human CVCL_JC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120564 CVCL_JC02 1340-8306 transformed cell line human CVCL_JC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120565 CVCL_AI64 GM08280 transformed cell line human CVCL_AI64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120566 CVCL_AI63 GM08279 transformed cell line human CVCL_AI63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120567 CVCL_AI66 GM08282 transformed cell line human CVCL_AI66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120568 CVCL_AI65 GM08281 transformed cell line human CVCL_AI65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120569 CVCL_AI68 GM08284 transformed cell line human CVCL_AI68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120570 CVCL_AI67 GM08283 transformed cell line human CVCL_AI67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120571 CVCL_AI69 GM08285 transformed cell line human CVCL_AI69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120572 CVCL_AI60 GM08276 transformed cell line human CVCL_AI60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120573 CVCL_AI62 GM08278 transformed cell line human CVCL_AI62 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21120574 CVCL_AI61 GM08277 transformed cell line human CVCL_AI61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120575 CVCL_0608 Calu-1 cancer cell line human CVCL_0608 HLA typing: A*10,11; B*15,w35 (CLS=300141); HLA typing: A*26:01,29:02; B*15:01,44:03; C*03:04,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.74%; East Asian, North=0.11%; East Asian, South=0%; South Asian=9.94%; European, North=31.4%; European, South=57.8% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (Sloan_Kettering); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=12068308; PubMed=12794755; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 37 hours (PubMed=25984343); 49.8 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 784 21120576 CVCL_0607 BS-C-1 spontaneously immortalized cell line CVCL_0607 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A7D5U6M6; MT-ND6; Simple; p.Tyr50fs*25 (c.147insG) (m.13952dupC); Zygosity=Heteroplasmic; Note=In a majority of mitochondria (PubMed=33458215) Derived from sampling site: Kidney. Omics: Mitochondrial genome sequenced Discontinued: JCRB; JCRB9011; true Unspecified Characteristics: Suitable for transfection by SV40 and may be used for the detection of viruses (ATCC) Doubling time: 72 hours, at 68th passage (PubMed=14071033) Group: Non-human primate cell line Problematic cell line: Misidentified Originally thought to be of Chlorocebus aethiops origin but found to be from Chlorocebus pygerythrus (PubMed=33458215). 21120577 CVCL_0609 Calu-3 cancer cell line human CVCL_0609 HLA typing: A*24:02,68:01; B*07:02,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0.63%; Native American=0%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=67.76%; European, South=29.51% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (PubMed=20557307; ATCC) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474) Doubling time: 35 hours (in RPMI 1640 + 10% FBS), 45 hours (in ACL-3), 37 hours (in ACL-3+BSA) (PubMed=3940644); 40.1 hours (PubMed=29681454); ~84 hours(PubMed=34339474); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-533 21120578 CVCL_0600 SK-MEL-31 cancer cell line human CVCL_0600 HLA typing: A*01:01,31:01; B*40:01,53:01; C*03:04,04:01; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*04:04,14:103 (PubMed=26589293); Genome ancestry: African=3.89%; Native American=0.03%; East Asian, North=4.7%; East Asian, South=0%; South Asian=4.17%; European, North=26.77%; European, South=60.44% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 30073; probable. Female Characteristics: Non-pigmented (PubMed=3473501) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-527 21120579 CVCL_0602 81.3 transformed cell line human CVCL_0602 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Unspecified 21120580 CVCL_0601 3T6-Swiss albino spontaneously immortalized cell line house mouse CVCL_0601 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Doubling time: ~15 hours (DSMZ=ACC-202) 21120581 CVCL_0604 B16-F0 cancer cell line house mouse CVCL_0604 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21120582 CVCL_0603 Vero 76 spontaneously immortalized cell line green monkey CVCL_0603 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Vaccine production cell line 21120583 CVCL_0606 BRL-3A spontaneously immortalized cell line Norway rat CVCL_0606 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Buffalo. Doubling time: 19.8 hours (lot 051388), 48 hours (lot 072398) (JCRB) 21120584 CVCL_0605 Beta-TC-6 transformed cell line house mouse CVCL_0605 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIP1Tag2. Omics: ChIP-seq epigenome analysis Characteristics: Secretes insulin in response to glucose challenge But this phenotype is unstable. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11506 21120585 CVCL_0619 MDA-MB-330 cancer cell line human CVCL_0619 Genome ancestry: African=0.4%; Native American=0%; East Asian, North=2.68%; East Asian, South=0%; South Asian=0%; European, North=67.3%; European, South=29.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=16541312; PubMed=28889351) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.7 days (PubMed=9671407); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21120586 CVCL_0618 MDA-MB-157 cancer cell line human CVCL_0618 HLA typing: A*11:01,68:02; B*15:03,55:02; C*01:02,02:02 (PubMed=25960936); HLA typing: A*02:01,30:01; B*53:01,53:01; C*04:01,06:02; DQA1*01:02,03:02; DQB1*06:02,06:02; DRB1*11:09,15:01 (PubMed=26589293); Genome ancestry: African=77.9%; Native American=0%; East Asian, North=4.71%; East Asian, South=0%; South Asian=0%; European, North=1.3%; European, South=16.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Pro42Ser (c.124C>T); ClinVar=VCV000089180; Zygosity=Heterozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Arg644Ser (c.1932G>C); ClinVar=VCV000089233; Zygosity=Heterozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro87fs*53 (c.261_286del26); Zygosity=Homozygous (PubMed=16541312; ATCC) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0319; probable; Discontinued: DepMap; ACH-001120; true Female Doubling time: 2.8 days (PubMed=9671407); 66.98 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120587 CVCL_0611 He We finite cell line human CVCL_0611 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120588 CVCL_0610 GH1 cancer cell line Norway rat CVCL_0610 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21120589 CVCL_0613 Kasumi-4 cancer cell line human CVCL_0613 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=32180206) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: DSMZ; ACC-715; true; Discontinued: JCRB; NIHS0237; true Female Doubling time: ~55 hours (PubMed=8611478); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21120590 CVCL_0612 Kasumi-3 cancer cell line human CVCL_0612 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=Myeloblast.. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0236; true Male Doubling time: 55-60 hours (PubMed=8613429); ~3-4 days (DSMZ=ACC-714); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: MD Anderson Cell Lines Project 21120591 CVCL_0615 Ku812E cancer cell line human CVCL_0615 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Basophil progenitor cell.. Male 21120592 CVCL_0614 Kasumi-6 cancer cell line human CVCL_0614 Genome ancestry: African=0.79%; Native American=0%; East Asian, North=75.55%; East Asian, South=23.65%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1833; CEBPA; Simple; p.Arg306Pro (c.917G>C); Zygosity=Heterozygous (PubMed=12508245; DepMap); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=32180206); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asp (c.700T>G); ClinVar=VCV000219759; Zygosity=Homozygous (DepMap) Population: Japanese and Korean; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0314; true Male Doubling time: ~70 hours (DSMZ=ACC-686) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21120593 CVCL_0617 MDA-MB-134-VI cancer cell line human CVCL_0617 HLA typing: A*11:02,24:02; B*35:01,40:01; C*03:04,04:01; DQB1*03:02,06:02; DRB1*13:27,13:27 (PubMed=25960936); HLA typing: A*11:01,24:02; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=2.96%; Native American=0%; East Asian, North=3.67%; East Asian, South=0%; South Asian=0%; European, North=64.3%; European, South=29.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Leu230fs*4 (c.688_832del145); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Ser184Leu (c.551C>T); Zygosity=Homozygous (PubMed=9331070; PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=16541312) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 6.4 days (PubMed=9671407); 82.67 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21120594 CVCL_0616 Ku812F cancer cell line human CVCL_0616 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Basophil progenitor cell.. Discontinued: RCB; RCB3053; true Male 21120595 CVCL_JB97 1340-8283 transformed cell line human CVCL_JB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120596 CVCL_JB96 1340-8209 transformed cell line human CVCL_JB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120597 CVCL_JB99 1340-8285 transformed cell line human CVCL_JB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120598 CVCL_JB98 1340-8284 transformed cell line human CVCL_JB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21120599 CVCL_JB93 GM01170 finite cell line human CVCL_JB93 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01170; probable Female 21120600 CVCL_JB92 GM01136 finite cell line human CVCL_JB92 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01136; probable Male 21120601 CVCL_JB95 1340-1371 transformed cell line human CVCL_JB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21120602 CVCL_JB94 GM00222 finite cell line human CVCL_JB94 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00222; probable Female 21120603 CVCL_JB91 GM03242 finite cell line human CVCL_JB91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120604 CVCL_JB90 GM02207 finite cell line human CVCL_JB90 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02207; probable Female 21120605 CVCL_JB79 GM00064 finite cell line human CVCL_JB79 CL:0000010 Population: Caucasian; Swiss; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00064; probable Male 21120606 CVCL_JB78 GM00623 finite cell line human CVCL_JB78 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00623; true Male 21120607 CVCL_JB75 H.S. #1 cancer cell line human CVCL_JB75 CL:0000010 Male 21120608 CVCL_JB74 H.Emb.Rh. #1 cancer cell line human CVCL_JB74 CL:0000010 Male 21120609 CVCL_JB77 HEp-3 cancer cell line human CVCL_JB77 CL:0000010 Population: African American; Derived from metastatic site: Cervical lymph node. Unspecified 21120610 CVCL_JB76 HEp-1 cancer cell line human CVCL_JB76 CL:0000010 Female 21120611 CVCL_JB71 GM01906 finite cell line human CVCL_JB71 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01906; probable Male 21120612 CVCL_JB70 GM00014 finite cell line human CVCL_JB70 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00014; probable Female 21120613 CVCL_JB73 ME 1 [Human melanoma] cancer cell line human CVCL_JB73 CL:0000010 21120614 CVCL_JB72 XP26RO finite cell line human CVCL_JB72 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Homozygous (from familial inference of XP25RO) Population: Palestinian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00518; probable Female 21120615 CVCL_JB89 GM02006 finite cell line human CVCL_JB89 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02006; probable Male 21120616 CVCL_JB86 GM01828 finite cell line human CVCL_JB86 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Thr10Ile (c.29C>T); ClinVar=VCV000066888; Zygosity=Heterozygous (from autologous cell line AG00990) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM01828; probable Male 21120617 CVCL_JB85 GM01009 finite cell line human CVCL_JB85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01009; probable Male 21120618 CVCL_JB88 GM02215 finite cell line human CVCL_JB88 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02215; probable Male 21120619 CVCL_JB87 GM01609 finite cell line human CVCL_JB87 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01609; probable Female 21120620 CVCL_JB82 GM01358 finite cell line human CVCL_JB82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01358; probable Male 21120621 CVCL_JB81 GM00066 finite cell line human CVCL_JB81 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00066; probable Male 21120622 CVCL_JB84 GM00851 finite cell line human CVCL_JB84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00851; probable Male 21120623 CVCL_JB83 GM00668 finite cell line human CVCL_JB83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00668; probable Male 21120624 CVCL_JB80 GM00065 finite cell line human CVCL_JB80 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00065; probable Male 21120625 CVCL_JB57 1123C1-G induced pluripotent stem cell CVCL_JB57 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Peripheral blood. Female Characteristics: Generated from an animal with an homozygous MHC haplotype (Mafa-HT1) Group: Non-human primate cell line 21120626 CVCL_JB56 1121A1 induced pluripotent stem cell CVCL_JB56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Generated from an animal with an homozygous MHC haplotype Group: Non-human primate cell line 21120627 CVCL_JB58 AG02257 finite cell line human CVCL_JB58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02257; probable Female 21120628 CVCL_JB53 NLGIP-6478 transformed cell line human CVCL_JB53 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120629 CVCL_JB52 NLGIP-6472 transformed cell line human CVCL_JB52 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120630 CVCL_JB55 ND12080 transformed cell line human CVCL_JB55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120631 CVCL_JB54 GM10337 finite cell line human CVCL_JB54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120632 CVCL_JB51 NLGIP-6445 transformed cell line human CVCL_JB51 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120633 CVCL_JB50 NLGIP-6429 transformed cell line human CVCL_JB50 CL:0000010 Population: Jewish; Sephardic (Bulgarian); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120634 CVCL_JB49 NLGIP-6425 transformed cell line human CVCL_JB49 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21120635 CVCL_JB68 GM00471 finite cell line human CVCL_JB68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00471; probable Female 21120636 CVCL_JB67 GM02211 finite cell line human CVCL_JB67 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02211; probable Male 21120637 CVCL_JB69 GM02027 finite cell line human CVCL_JB69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02027; probable Female 21120638 CVCL_JB64 GM01613 finite cell line human CVCL_JB64 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01613; probable Male 21120639 CVCL_JB63 GM01612 finite cell line human CVCL_JB63 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01612; probable Male 21120640 CVCL_JB66 GM02121 finite cell line human CVCL_JB66 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02121; probable Female 21120641 CVCL_JB65 GM01007 finite cell line human CVCL_JB65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01007; probable Female 21120642 CVCL_JB60 GM01177 finite cell line human CVCL_JB60 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01177; probable; Discontinued: Coriell; GM01177; probable Male 21120643 CVCL_JB62 GM01669 finite cell line human CVCL_JB62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01669; probable Female 21120644 CVCL_JB61 GM00645 finite cell line human CVCL_JB61 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00645; probable Female 21120645 CVCL_9025 GENEA016 embryonic stem cell human CVCL_9025 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA015 (Cellosaurus=CVCL_9024). Omics: Deep exome analysis; Omics: SNP array analysis Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0229; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-37. 21120646 CVCL_9024 GENEA015 embryonic stem cell human CVCL_9024 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA016 (Cellosaurus=CVCL_9025). Omics: Deep exome analysis; Omics: SNP array analysis Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0228; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-37. 21120647 CVCL_9027 GENEA018-HD embryonic stem cell human CVCL_9027 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Omics: Array-based CGH. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0169; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-45. 21120648 CVCL_9026 GENEA017-HD embryonic stem cell human CVCL_9026 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0166; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-44. 21120649 CVCL_9021 GENEA012 embryonic stem cell human CVCL_9021 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120650 CVCL_9020 GENEA011 embryonic stem cell human CVCL_9020 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Male 21120651 CVCL_9023 GENEA014 embryonic stem cell human CVCL_9023 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Male 21120652 CVCL_9022 GENEA013 embryonic stem cell human CVCL_9022 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Male 21120653 CVCL_0680 Hs 203.Sp finite cell line human CVCL_0680 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7164; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120654 CVCL_0682 Hs 204.Sp finite cell line human CVCL_0682 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7166; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120655 CVCL_0681 Hs 203.Th finite cell line human CVCL_0681 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7165; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120656 CVCL_9018 GENEA009 embryonic stem cell human CVCL_9018 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120657 CVCL_0684 Hs 208.Th finite cell line human CVCL_0684 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7170; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120658 CVCL_9017 GENEA008 embryonic stem cell human CVCL_9017 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120659 CVCL_0683 Hs 208.Sp finite cell line human CVCL_0683 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7169; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120660 CVCL_0686 Hs 21.Fs finite cell line human CVCL_0686 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7015; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120661 CVCL_9019 GENEA010 embryonic stem cell human CVCL_9019 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120662 CVCL_0685 Hs 209.Sp finite cell line human CVCL_0685 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7171; probable Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120663 CVCL_0688 Hs 215.Sp finite cell line human CVCL_0688 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-7176; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120664 CVCL_0687 Hs 215.Ln finite cell line human CVCL_0687 CL:0000010 Derived from sampling site: Mesenteric lymph node. Discontinued: ATCC; CRL-7175; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120665 CVCL_0689 Hs 215.Th finite cell line human CVCL_0689 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7177; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120666 CVCL_9030 GENEA021 embryonic stem cell human CVCL_9030 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA022 (Cellosaurus=CVCL_9031) and GENEA023 (Cellosaurus=CVCL_9032). Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Registration: Swiss research registry; BAG-hES-IMP-0027; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-60. 21120667 CVCL_9036 GENEA027 embryonic stem cell human CVCL_9036 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61.. 21120668 CVCL_9035 GENEA026 embryonic stem cell human CVCL_9035 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61.. 21120669 CVCL_9038 GENEA029 embryonic stem cell human CVCL_9038 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-60.. 21120670 CVCL_9037 GENEA028 embryonic stem cell human CVCL_9037 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61.. 21120671 CVCL_9032 GENEA023 embryonic stem cell human CVCL_9032 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA021 (Cellosaurus=CVCL_9030) and GENEA022 (Cellosaurus=CVCL_9031). Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Registration: Swiss research registry; BAG-hES-IMP-0029; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-60. 21120672 CVCL_9031 GENEA022 embryonic stem cell human CVCL_9031 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA021 (Cellosaurus=CVCL_9030) and GENEA023 (Cellosaurus=CVCL_9032). Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Registration: Swiss research registry; BAG-hES-IMP-0028; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-60. 21120673 CVCL_9034 GENEA025 embryonic stem cell human CVCL_9034 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-61.. 21120674 CVCL_9033 GENEA024 embryonic stem cell human CVCL_9033 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0170; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-45.. 21120675 CVCL_0691 Hs 218.Lu finite cell line human CVCL_0691 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7180; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120676 CVCL_0690 Hs 216.We finite cell line human CVCL_0690 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7178; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120677 CVCL_0693 Hs 221.Sp finite cell line human CVCL_0693 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7187; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120678 CVCL_0692 Hs 219.T cancer cell line human CVCL_0692 CL:0000010 Derived from sampling site: Rectum. Discontinued: ATCC; CRL-7184; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120679 CVCL_9029 GENEA020 embryonic stem cell human CVCL_9029 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[48] (c.52CAG(48)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Donor information: Embryo is sibling to that giving rise to GENEA019 (Cellosaurus=CVCL_9028). Omics: Array-based CGH Female Registration: NIH Human Embryonic Stem Cell Registry; not approved; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-62. 21120680 CVCL_0695 Hs 222.Sp finite cell line human CVCL_0695 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7189; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120681 CVCL_9028 GENEA019 embryonic stem cell human CVCL_9028 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA020 (Cellosaurus=CVCL_9029). Omics: Array-based CGH; Omics: Proteome analysis Female Registration: NIH Human Embryonic Stem Cell Registry; not approved; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-62. 21120682 CVCL_0694 Hs 221.Th finite cell line human CVCL_0694 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7188; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120683 CVCL_0697 Hs 228.T cancer cell line human CVCL_0697 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: BLA-40 bladder carcinoma cell line panel; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120684 CVCL_0696 Hs 225.Th finite cell line human CVCL_0696 CL:0000010 Derived from sampling site: Thymus. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120685 CVCL_0699 Hs 230.Sp finite cell line human CVCL_0699 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7196; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120686 CVCL_0698 Hs 229.T undefined cell line type human CVCL_0698 Genome ancestry: African=0%; Native American=0.3%; East Asian, North=0%; East Asian, South=1.25%; South Asian=0.49%; European, North=68.77%; European, South=29.18% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7194; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a lung adenocarcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21120687 CVCL_9003 Endeavour-2 embryonic stem cell human CVCL_9003 From: Prince of Wales Hospital; Sidney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0073. 21120688 CVCL_9002 29e induced pluripotent stem cell human CVCL_9002 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21120689 CVCL_9005 ULBe001-A embryonic stem cell human CVCL_9005 From: Universite Libre de Bruxelles; Brussels; Belgium. CL:0000010 Female 21120690 CVCL_9004 Envy embryonic stem cell human CVCL_9004 From: Monash University; Melbourne; Australia CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: The eGFP gene is under the control of an actin promoter 21120691 CVCL_9001 29d induced pluripotent stem cell human CVCL_9001 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120692 CVCL_9000 29b induced pluripotent stem cell human CVCL_9000 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=21293464) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120693 CVCL_0660 Hs 172.T undefined cell line type human CVCL_0660 Genome ancestry: African=0.56%; Native American=0.85%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0%; European, North=67.59%; European, South=29.31% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7833; true Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a urinary bladder carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21120694 CVCL_0662 Hs 173.We finite cell line human CVCL_0662 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7834; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120695 CVCL_0661 Hs 173.Sp finite cell line human CVCL_0661 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7123; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120696 CVCL_0664 Hs 18.Fs finite cell line human CVCL_0664 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7014; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120697 CVCL_0663 Hs 174.We finite cell line human CVCL_0663 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7124; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120698 CVCL_0666 Hs 181.Tes finite cell line human CVCL_0666 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal testis Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120699 CVCL_0665 Hs 181.Sk finite cell line human CVCL_0665 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7129; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120700 CVCL_0668 Hs 184.T cancer cell line human CVCL_0668 CL:0000010 Population: Caucasian; Derived from sampling site: Bone. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120701 CVCL_0667 Hs 184.Sk finite cell line human CVCL_0667 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7133; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120702 CVCL_0669 Hs 186.Sk finite cell line human CVCL_0669 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7138; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120703 CVCL_9014 GENEA005 embryonic stem cell human CVCL_9014 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120704 CVCL_9013 GENEA004 embryonic stem cell human CVCL_9013 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120705 CVCL_9016 GENEA007 embryonic stem cell human CVCL_9016 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120706 CVCL_9015 GENEA006 embryonic stem cell human CVCL_9015 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120707 CVCL_9010 GENEA001 embryonic stem cell human CVCL_9010 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0370; Registration: Swiss research registry; BAG-hES-IMP-0025. 21120708 CVCL_9012 GENEA003 embryonic stem cell human CVCL_9012 From: Genea Biocells, Ltd; Sydney; Australia. CL:0000010 Female 21120709 CVCL_9011 GENEA002 embryonic stem cell human CVCL_9011 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA048 (Cellosaurus=CVCL_9057). Omics: Deep exome analysis; Omics: SNP array analysis Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0151; Registration: Swiss research registry; BAG-hES-IMP-0026; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-38. 21120710 CVCL_0671 Hs 190.T cancer cell line human CVCL_0671 CL:0000010 Discontinued: ATCC; CRL-7145; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120711 CVCL_0670 Hs 188.T cancer cell line human CVCL_0670 CL:0000010 Derived from sampling site: Bone. Discontinued: ATCC; CRL-7140; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120712 CVCL_0673 Hs 195.T cancer cell line human CVCL_0673 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7150; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120713 CVCL_9007 ULBe003-A embryonic stem cell human CVCL_9007 From: Universite Libre de Bruxelles; Brussels; Belgium. CL:0000010 Female 21120714 CVCL_0672 Hs 193.Sp finite cell line human CVCL_0672 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7148; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120715 CVCL_9006 ULBe002-A embryonic stem cell human CVCL_9006 From: Universite Libre de Bruxelles; Brussels; Belgium. CL:0000010 Female 21120716 CVCL_0675 Hs 2.We finite cell line human CVCL_0675 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7003; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120717 CVCL_9009 ULBe005-A embryonic stem cell human CVCL_9009 From: Universite Libre de Bruxelles; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19549452); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Glu585Ter (c.1753G>T); ClinVar=VCV000053374; Zygosity=Heterozygous (PubMed=19549452). Female 21120718 CVCL_0674 Hs 198.Ton finite cell line human CVCL_0674 CL:0000010 Derived from sampling site: Fetal oral cavity; tonsil. Discontinued: ATCC; CRL-7156; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120719 CVCL_9008 ULBe004-A embryonic stem cell human CVCL_9008 From: Universite Libre de Bruxelles; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19549452); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.3718-2477C>T (3849+10KB,C>T); ClinVar=VCV000007166; Zygosity=Heterozygous (PubMed=19549452). Female 21120720 CVCL_0677 Hs 201.Sk finite cell line human CVCL_0677 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7161; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120721 CVCL_0676 Hs 200.T cancer cell line human CVCL_0676 CL:0000010 Discontinued: ATCC; CRL-7159; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120722 CVCL_0679 Hs 202.Th finite cell line human CVCL_0679 CL:0000010 Derived from sampling site: Fetal thymus. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120723 CVCL_0678 Hs 202.Sp finite cell line human CVCL_0678 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7162; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120724 CVCL_0640 Hs 1.Sk/Mu finite cell line human CVCL_0640 CL:0000010 Derived from sampling site: Muscle and skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120725 CVCL_0642 Hs 103.Sp/Th finite cell line human CVCL_0642 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Discontinued: ATCC; CRL-7068; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120726 CVCL_0641 Hs 1.Tes finite cell line human CVCL_0641 CL:0000010 Derived from sampling site: Fetal testis. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120727 CVCL_0644 Hs 112.Sk finite cell line human CVCL_0644 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7074; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120728 CVCL_0643 Hs 104.Sp/Th finite cell line human CVCL_0643 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Discontinued: ATCC; CRL-7070; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120729 CVCL_0646 Hs 127.T cancer cell line human CVCL_0646 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21120730 CVCL_0645 Hs 115.Lu finite cell line human CVCL_0645 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7077; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120731 CVCL_0648 Hs 132.T cancer cell line human CVCL_0648 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21120732 CVCL_0647 Hs 13.Sk finite cell line human CVCL_0647 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7011; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120733 CVCL_0649 Hs 137.Fs finite cell line human CVCL_0649 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7087; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120734 CVCL_0651 Hs 142.Sp finite cell line human CVCL_0651 CL:0000010 Derived from sampling site: Spleen. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120735 CVCL_0650 Hs 14.T cancer cell line human CVCL_0650 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21120736 CVCL_0653 Hs 143.We finite cell line human CVCL_0653 CL:0000010 Population: Caucasian; Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120737 CVCL_0652 Hs 142.Th finite cell line human CVCL_0652 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7091; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120738 CVCL_0655 Hs 15.T cancer cell line human CVCL_0655 CL:0000010 Discontinued: ATCC; CRL-7824; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120739 CVCL_0654 Hs 144.We finite cell line human CVCL_0654 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7093; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120740 CVCL_0657 Hs 156.T finite cell line human CVCL_0657 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7102; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120741 CVCL_0656 Hs 154.Fs finite cell line human CVCL_0656 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7098; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120742 CVCL_0659 Hs 168.Fs finite cell line human CVCL_0659 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7122; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120743 CVCL_0658 Hs 165.Fs finite cell line human CVCL_0658 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7118; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120744 CVCL_0629 SK-LU-1 cancer cell line human CVCL_0629 HLA typing: A*24:02,24:02; B*40:02,40:02; C*02:02,02:02 (PubMed=26589293); Genome ancestry: African=0.44%; Native American=0%; East Asian, North=1.91%; East Asian, South=0%; South Asian=0%; European, North=66.14%; European, South=31.5% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asn1253fs*16 (c.3753delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=1855224; PubMed=12068308; PubMed=12794755; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (PubMed=1855224; PubMed=12794755; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2005-049 21120745 CVCL_0620 MDA-MB-361 cancer cell line human CVCL_0620 HLA typing: A*01:01,24:02; B*39:06,51:08; C*07:02,16:02; DQB1*04:01,04:01; DRB1*08:01,08:01 (PubMed=25960936); HLA typing: A*01:01,24:02; B*39:06,51:08; C*07:02,16:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.71%; East Asian, North=0%; East Asian, South=0%; South Asian=0.9%; European, North=62.27%; European, South=36.11% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1657Ser (c.4970A>G); ClinVar=VCV000409419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met52Ile (c.156G>C); Zygosity=Homozygous (PubMed=19593635; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (PubMed=19593635; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=19593635; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys567Arg (c.1700A>G); Zygosity=Heterozygous (PubMed=19593635; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Homozygous (PubMed=16541312; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Brain. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 4.3 days (PubMed=9671407); 92.83 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21120746 CVCL_0622 MDA-MB-435S cancer cell line human CVCL_0622 HLA typing: A*24:02,24:02; B*15:01,15:01; C*03:03,03:03 (PubMed=26589293); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0%; European, North=65.23%; European, South=32.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19593635); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Leu827Pro (c.2480T>C); Zygosity=Hemizygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Glu1013Gly (c.3038A>G); ClinVar=VCV000562024; Zygosity=Hemizygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=16541312; DepMap) Derived from metastatic site: Right buttock; hypodermis. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300277; true Male Microsatellite instability: Stable (MSS) (PubMed=12661003) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00565 Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21120747 CVCL_0621 MDA-MB-415 cancer cell line human CVCL_0621 HLA typing: A*30:02,33:01; B*14:02,18:01; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=1.43%; Native American=12.27%; East Asian, North=1.2%; East Asian, South=1.74%; South Asian=0.34%; European, North=40.99%; European, South=42.03% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Ser280Ter (c.839C>A); Zygosity=Homozygous (PubMed=9331070; PubMed=19593635); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys136Tyr (c.407G>A); ClinVar=VCV000189406; Zygosity=Homozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Cys (c.707A>G); ClinVar=VCV000376693; Zygosity=Homozygous (PubMed=16541312; ATCC) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 88.87 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21120748 CVCL_0624 MOLT-3 cancer cell line human CVCL_0624 Genome ancestry: African=0.91%; Native American=0%; East Asian, North=2.31%; East Asian, South=0%; South Asian=0.44%; European, North=66.02%; European, South=30.32% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (PubMed=15472075; DepMap); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (PubMed=15472075; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (DepMap) Population: Caucasian; Karyotypic information: Hypertetraploid karyotype (ATCC); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24-48 hours (CLS); ~40 hours (DSMZ=ACC-84); Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21120749 CVCL_0623 MDA-MB-436 cancer cell line human CVCL_0623 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DQA1*02:01,05:02; DQB1*04:01,04:01; DRB1*03:01,11:30 (PubMed=26589293); Genome ancestry: African=1.41%; Native American=0%; East Asian, North=2.21%; East Asian, South=0%; South Asian=0%; European, North=63.9%; European, South=32.49% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 3701; FHIT; Zygosity=Homozygous (PubMed=9288768); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.5277+1G>A; ClinVar=VCV000037654; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=16397213; PubMed=19593635); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly203fs*9 (c.607_608ins227); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204fs*7 (c.610_612delinsGCGTGTGG); Zygosity=Unspecified (PubMed=16541312; PubMed=28889351) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: ATAC-seq; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300278; true Female Doubling time: 89.31 hours (GrayJW panel); Microsatellite instability: Instable (MSI-low) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21120750 CVCL_0626 SK-CO-1 cancer cell line human CVCL_0626 HLA typing: A*01:01,02:01; B*35:08,58:05; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0.04%; Native American=0.56%; East Asian, North=2.24%; East Asian, South=0%; South Asian=0%; European, North=68.7%; European, South=28.45% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Phe1089fs*37 (c.3266delT); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Pro1443fs*30 (c.4328delC); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 4392; GNAS; Simple; p.Arg201Cys (c.601C>T); ClinVar=VCV000015933; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: NCI RAS program mutant KRAS cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-072 21120751 CVCL_0625 P388D1 (IL-1) cancer cell line house mouse CVCL_0625 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Omics: SNP array analysis Female Characteristics: Produces high level of IL1 Doubling time: ~30-60 hours, depending on cell density (DSMZ=ACC-288) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21120752 CVCL_0628 SK-LMS-1 cancer cell line human CVCL_0628 HLA typing: A*02:01,32:01; B*07:02,51:01; C*07:02,15:02; DQA1*01:02,01:02; DRB1*11:14,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.76%; East Asian, South=0%; South Asian=1.17%; European, North=66.04%; European, South=31.02% (PubMed=30894373). From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Lys (c.710T>A); ClinVar=VCV000376636; Zygosity=Unspecified (PubMed=2216456; PubMed=16142349); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=2216456; PubMed=16142349) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21120753 CVCL_0627 SK-ES-1 cancer cell line human CVCL_0627 HLA typing: A*11:01,11:01; B*07:06,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0.13%; Native American=0%; East Asian, North=0.63%; East Asian, South=0%; South Asian=1.64%; European, North=63.44%; European, South=34.15% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777; PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=8040301; PubMed=9738976; PubMed=11423975; PubMed=11891184; PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln735Ter (c.2203C>T); Zygosity=Unspecified (PubMed=25010205; PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=8221663; PubMed=8378080; PubMed=19787792; PubMed=25010205; PubMed=25223734; PubMed=26428435) Miscellaneous: The signal for the amelogenin \"Y\" allele is quite weak (MSKCC). Population: Caucasian Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~35 hours (DSMZ=ACC-518); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-542 21120754 CVCL_0631 SK-NEP-1 cancer cell line human CVCL_0631 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.75%; East Asian, South=0%; South Asian=1.81%; European, North=66.07%; European, South=31.37% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=17154184; PubMed=25010205; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=25010205; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2008-052 Problematic cell line: Misclassified Originally thought to be a Wilm's tumor cell line but shown to be from an Ewing sarcoma (PubMed=17154184; PubMed=30924592). 21120755 CVCL_0630 SK-MES-1 cancer cell line human CVCL_0630 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); HLA typing: A*03:01:01; B*07:02:01; C*07:02:01; DPB1*04:01:01; DQA1*01:02:02; DQB1*05:02:01; DRB1*16:01:01 (CLS=300339); Genome ancestry: African=0.88%; Native American=0%; East Asian, North=1.52%; East Asian, South=0%; South Asian=0%; European, North=64.63%; European, South=32.97% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Homozygous (PubMed=12794755; PubMed=20557307; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 91091804; probable Male Doubling time: ~50 hours (DSMZ=ACC-353); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-091 21120756 CVCL_0633 U-118MG cancer cell line human CVCL_0633 Genome ancestry: African=1.71%; Native American=0%; East Asian, North=1.75%; East Asian, South=0%; South Asian=0%; European, North=96.54%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=10560660; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (PubMed=10416987; Cosmic-CLP) Population: Caucasian; Derived from sampling site: Brain. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7712; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00350 Problematic cell line: Contaminated Shown to be a U-138MG derivative (PubMed=20143388). 21120757 CVCL_0632 SW948 cancer cell line human CVCL_0632 HLA typing: A*01:01,01:01; B*08:01,58:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.47%; East Asian, North=0%; East Asian, South=0%; South Asian=1.25%; European, North=63.91%; European, South=33.37% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp537Tyr (c.1609G>T); ClinVar=VCV000376000; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr118Glnfs*5 (c.351delG) (p.G117fs); Zygosity=Unspecified (PubMed=28683746) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 120 hours, at 8th passage (PubMed=1000501); 2-4 days (DSMZ=ACC-326); Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21120758 CVCL_0635 L Wnt-3A spontaneously immortalized cell line house mouse CVCL_0635 CL:0000010 Transfected with: MGI; MGI:98956; Wnt3a Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21120759 CVCL_0637 BALB/3T12-3 spontaneously immortalized cell line house mouse CVCL_0637 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Discontinued: ECACC; 90030803; probable Unspecified 21120760 CVCL_0636 L Wnt-5A spontaneously immortalized cell line house mouse CVCL_0636 CL:0000010 Transfected with: MGI; MGI:98958; Wnt5a Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21120761 CVCL_0639 Hs 1.Lu finite cell line human CVCL_0639 CL:0000010 Derived from sampling site: Fetal lung. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120762 CVCL_0638 Hs 1.Int finite cell line human CVCL_0638 CL:0000010 Derived from sampling site: Fetal intestine. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21120763 CVCL_SF90 HAP1 BTD (-) 1 cancer cell line human CVCL_SF90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1122; BTD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120764 CVCL_SF92 HAP1 BTRC (-) 2 cancer cell line human CVCL_SF92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120765 CVCL_SF91 HAP1 BTRC (-) 1 cancer cell line human CVCL_SF91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120766 CVCL_SF94 HAP1 BUB1 (-) 2 cancer cell line human CVCL_SF94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1148; BUB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120767 CVCL_SF93 HAP1 BUB1 (-) 1 cancer cell line human CVCL_SF93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1148; BUB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120768 CVCL_SF96 HAP1 C10orf32 (-) 1 cancer cell line human CVCL_SF96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23516; BORCS7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120769 CVCL_SF95 HAP1 BUB1 (-) 3 cancer cell line human CVCL_SF95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1148; BUB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120770 CVCL_SF98 HAP1 C11orf30 (-) 1 cancer cell line human CVCL_SF98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18071; EMSY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120771 CVCL_SF97 HAP1 C10orf32 (-) 2 cancer cell line human CVCL_SF97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23516; BORCS7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120772 CVCL_SF99 HAP1 C11orf30 (-) 2 cancer cell line human CVCL_SF99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18071; EMSY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120773 CVCL_SF81 HAP1 BRSK1 (-) 2 cancer cell line human CVCL_SF81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18994; BRSK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120774 CVCL_SF80 HAP1 BRSK1 (-) 1 cancer cell line human CVCL_SF80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18994; BRSK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120775 CVCL_SF83 HAP1 BRSK2 (-) 2 cancer cell line human CVCL_SF83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11405; BRSK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120776 CVCL_SF82 HAP1 BRSK2 (-) 1 cancer cell line human CVCL_SF82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11405; BRSK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120777 CVCL_SF85 HAP1 BRWD1 (-) 2 cancer cell line human CVCL_SF85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12760; BRWD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120778 CVCL_SF84 HAP1 BRWD1 (-) 1 cancer cell line human CVCL_SF84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12760; BRWD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120779 CVCL_SF87 HAP1 BSG (-) cancer cell line human CVCL_SF87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1116; BSG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120780 CVCL_SF86 HAP1 BRWD3 (-) cancer cell line human CVCL_SF86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17342; BRWD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120781 CVCL_SF89 HAP1 BST2 (-) 2 cancer cell line human CVCL_SF89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1119; BST2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120782 CVCL_SF88 HAP1 BST2 (-) 1 cancer cell line human CVCL_SF88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1119; BST2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120783 CVCL_SF70 HAP1 BRDT (-) 2 cancer cell line human CVCL_SF70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1105; BRDT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120784 CVCL_SF72 HAP1 BRK1 (-) 1 cancer cell line human CVCL_SF72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23057; BRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120785 CVCL_SF71 HAP1 BRIP1 (-) 1 cancer cell line human CVCL_SF71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20473; BRIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120786 CVCL_SF74 HAP1 BRK1 (-) 3 cancer cell line human CVCL_SF74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23057; BRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120787 CVCL_SF73 HAP1 BRK1 (-) 2 cancer cell line human CVCL_SF73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23057; BRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120788 CVCL_SF76 HAP1 BRPF1 (-) 2 cancer cell line human CVCL_SF76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14255; BRPF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120789 CVCL_SF75 HAP1 BRPF1 (-) 1 cancer cell line human CVCL_SF75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14255; BRPF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120790 CVCL_SF78 HAP1 BRPF3 (-) 1 cancer cell line human CVCL_SF78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14256; BRPF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120791 CVCL_SF77 HAP1 BRPF1 (-) 3 cancer cell line human CVCL_SF77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14255; BRPF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120792 CVCL_SF79 HAP1 BRPF3 (-) 2 cancer cell line human CVCL_SF79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14256; BRPF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120793 CVCL_SF61 HAP1 BRD4 (-) 3 cancer cell line human CVCL_SF61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120794 CVCL_SF60 HAP1 BRD4 (-) 2 cancer cell line human CVCL_SF60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120795 CVCL_SF63 HAP1 BRD4 (-) 5 cancer cell line human CVCL_SF63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21120796 CVCL_SF62 HAP1 BRD4 (-) 4 cancer cell line human CVCL_SF62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120797 CVCL_SF65 HAP1 BRD8 (-) 1 cancer cell line human CVCL_SF65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19874; BRD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120798 CVCL_SF64 HAP1 BRD7 (-) cancer cell line human CVCL_SF64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14310; BRD7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120799 CVCL_SF67 HAP1 BRD9 (-) 1 cancer cell line human CVCL_SF67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120800 CVCL_SF66 HAP1 BRD8 (-) 2 cancer cell line human CVCL_SF66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19874; BRD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120801 CVCL_SF69 HAP1 BRDT (-) 1 cancer cell line human CVCL_SF69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1105; BRDT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120802 CVCL_SF68 HAP1 BRD9 (-) 2 cancer cell line human CVCL_SF68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21120803 CVCL_SF50 HAP1 BRCC3 (-) 1 cancer cell line human CVCL_SF50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24185; BRCC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120804 CVCL_SF52 HAP1 BRD1 (-) 1 cancer cell line human CVCL_SF52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120805 CVCL_SF51 HAP1 BRCC3 (-) 2 cancer cell line human CVCL_SF51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24185; BRCC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120806 CVCL_SF54 HAP1 BRD2 (-) 2 cancer cell line human CVCL_SF54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120807 CVCL_SF53 HAP1 BRD2 (-) 1 cancer cell line human CVCL_SF53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120808 CVCL_SF56 HAP1 BRD3 (-) 1 cancer cell line human CVCL_SF56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21120809 CVCL_SF55 HAP1 BRD2 (-) 3 cancer cell line human CVCL_SF55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21120810 CVCL_SF58 HAP1 BRD3 (-) 3 cancer cell line human CVCL_SF58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120811 CVCL_SF57 HAP1 BRD3 (-) 2 cancer cell line human CVCL_SF57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1104; BRD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120812 CVCL_SF59 HAP1 BRD4 (-) 1 cancer cell line human CVCL_SF59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13575; BRD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120813 CVCL_SF41 HAP1 BMPR2 (-) 1 cancer cell line human CVCL_SF41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1078; BMPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120814 CVCL_SF40 HAP1 BMPR1B (-) cancer cell line human CVCL_SF40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1077; BMPR1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120815 CVCL_SF43 HAP1 BNIP3 (-) 1 cancer cell line human CVCL_SF43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1084; BNIP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120816 CVCL_SF42 HAP1 BMPR2 (-) 2 cancer cell line human CVCL_SF42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1078; BMPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120817 CVCL_SF45 HAP1 BPTF (-) 1 cancer cell line human CVCL_SF45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3581; BPTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120818 CVCL_SF44 HAP1 BPGM (-) 1 cancer cell line human CVCL_SF44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1093; BPGM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120819 CVCL_SF47 HAP1 BRAF (-) 1 cancer cell line human CVCL_SF47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120820 CVCL_SF46 HAP1 BPTF (-) 2 cancer cell line human CVCL_SF46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3581; BPTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120821 CVCL_SF49 HAP1 BRAF (-) 3 cancer cell line human CVCL_SF49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120822 CVCL_SF48 HAP1 BRAF (-) 2 cancer cell line human CVCL_SF48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1097; BRAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120823 CVCL_JL91 GM04902 finite cell line human CVCL_JL91 CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Cell type=Fibroblast. Male 21120824 CVCL_JL90 GM04901 finite cell line human CVCL_JL90 CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Cell type=Fibroblast. Male 21120825 CVCL_JL93 GM12123 finite cell line human CVCL_JL93 CL:0000010 Sequence variation: Mutation; HGNC; 13666; AAAS; Simple; c.1331+1G>A (IVS14+1G>A); ClinVar=VCV000264994; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=12730363) Population: Hispanic; Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21120826 CVCL_JL92 GM08444 finite cell line human CVCL_JL92 CL:0000010 Population: Caucasian; Donor information: Donor had apparent defect in secondary scar formation in muscle, fascia and dermis; possible collagen or ground substance proteoglycan defect; Derived from sampling site: Cell type=Fibroblast. Male 21120827 CVCL_SF30 HAP1 BLVRB (-) 4 cancer cell line human CVCL_SF30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1063; BLVRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120828 CVCL_SF32 HAP1 BMI1 (-) 2 cancer cell line human CVCL_SF32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1066; BMI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120829 CVCL_SF31 HAP1 BMI1 (-) 1 cancer cell line human CVCL_SF31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1066; BMI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120830 CVCL_SF34 HAP1 BMP2K (-) 1 cancer cell line human CVCL_SF34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18041; BMP2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120831 CVCL_SF33 HAP1 BMI1 (-) 3 cancer cell line human CVCL_SF33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1066; BMI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120832 CVCL_SF36 HAP1 BMP4 (-) 1 cancer cell line human CVCL_SF36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1071; BMP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120833 CVCL_JL88 PD-BP44-iPSC induced pluripotent stem cell human CVCL_JL88 From: National Neuroscience Institute; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ser1647Thr (c.4939T>A); ClinVar=VCV000039201; Zygosity=Heterozygous (PubMed=28395805) Derived from sampling site: Peripheral blood. Male 21120834 CVCL_SF35 HAP1 BMP2K (-) 2 cancer cell line human CVCL_SF35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18041; BMP2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120835 CVCL_JL87 PD-BP26-iPSC induced pluripotent stem cell human CVCL_JL87 From: National Neuroscience Institute; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1398His (c.4193G>A); ClinVar=VCV000039178; Zygosity=Heterozygous (PubMed=28395803) Derived from sampling site: Peripheral blood. Female 21120836 CVCL_SF38 HAP1 BMPR1A (-) 1 cancer cell line human CVCL_SF38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120837 CVCL_SF37 HAP1 BMP7 (-) 1 cancer cell line human CVCL_SF37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1074; BMP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120838 CVCL_JL89 TVGH-iPSC-SCA3-04 induced pluripotent stem cell human CVCL_JL89 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21120839 CVCL_JL84 MML-6838-Cl2 induced pluripotent stem cell human CVCL_JL84 From: Sanquin; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Peripheral blood. Male 21120840 CVCL_SF39 HAP1 BMPR1A (-) 2 cancer cell line human CVCL_SF39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1076; BMPR1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120841 CVCL_JL83 MEN1 Son iPS induced pluripotent stem cell human CVCL_JL83 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Glu430Ter (c.1288G>T); Zygosity=Heterozygous (PubMed=28395810) Population: Chinese; Malaysian; Derived from sampling site: Urine. Male 21120842 CVCL_JL86 PD-BP19-iPSC induced pluripotent stem cell human CVCL_JL86 From: National Neuroscience Institute; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1628Pro (c.4883G>C); ClinVar=VCV000039198; Zygosity=Heterozygous (PubMed=28395802) Derived from sampling site: Peripheral blood. Male 21120843 CVCL_JL85 PD-BP15-iPSC induced pluripotent stem cell human CVCL_JL85 From: National Neuroscience Institute; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Asn551Lys (c.1653C>G); ClinVar=VCV000039139; Zygosity=Heterozygous (PubMed=28395804) Derived from sampling site: Peripheral blood. Male 21120844 CVCL_SF21 HAP1 BIRC6 (-) 1 cancer cell line human CVCL_SF21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13516; BIRC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120845 CVCL_SF20 HAP1 BIRC3 (-) 3 cancer cell line human CVCL_SF20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 591; BIRC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120846 CVCL_SF23 HAP1 BIVM-ERCC5 (-) 1 cancer cell line human CVCL_SF23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 43690; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120847 CVCL_SF22 HAP1 BIRC6 (-) 2 cancer cell line human CVCL_SF22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13516; BIRC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120848 CVCL_SF25 HAP1 BLM (-) 1 cancer cell line human CVCL_SF25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1058; BLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120849 CVCL_JL99 JX17 cancer cell line human CVCL_JL99 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21120850 CVCL_SF24 HAP1 BIVM-ERCC5 (-) 2 cancer cell line human CVCL_SF24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 43690; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120851 CVCL_JL98 JXBulk cancer cell line human CVCL_JL98 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21120852 CVCL_SF27 HAP1 BLVRB (-) 1 cancer cell line human CVCL_SF27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1063; BLVRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120853 CVCL_SF26 HAP1 BLM (-) 2 cancer cell line human CVCL_SF26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1058; BLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120854 CVCL_JL95 GM12262 transformed cell line human CVCL_JL95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120855 CVCL_SF29 HAP1 BLVRB (-) 3 cancer cell line human CVCL_SF29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1063; BLVRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21120856 CVCL_JL94 GM12261 transformed cell line human CVCL_JL94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21120857 CVCL_SF28 HAP1 BLVRB (-) 2 cancer cell line human CVCL_SF28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1063; BLVRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21120858 CVCL_JL97 JK28 cancer cell line human CVCL_JL97 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Tyr66His and p.Tyr145Phe = BFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (deactivated version with KRAB domain; dCas9-KRAB) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a dCas9-BFP-KRAB construct Doubling time: ~48 hours (ATCC=CRL-3358) 21120859 CVCL_JL96 JKBulk cancer cell line human CVCL_JL96 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Tyr66His and p.Tyr145Phe = BFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (deactivated version with KRAB domain; dCas9-KRAB) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a dCas9-BFP-KRAB construct 21120860 CVCL_8Y61 QQ0520 transformed cell line human CVCL_8Y61 CL:0000010 Karyotypic information: 46,XX,ins(4;11;16;18) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120861 CVCL_8Y60 QQ0486 transformed cell line human CVCL_8Y60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,?ins(p15.1;q11.21;q11.23)?del(7)(q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120862 CVCL_8Y56 QQ0468 transformed cell line human CVCL_8Y56 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)(q31.3->q33) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120863 CVCL_8Y55 QQ0456 transformed cell line human CVCL_8Y55 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(2;4)(p13;q35) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120864 CVCL_8Y58 QQ0483 transformed cell line human CVCL_8Y58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)(q33;q35.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120865 CVCL_8Y57 QQ0470 transformed cell line human CVCL_8Y57 CL:0000010 Karyotypic information: 46,XX,t(9;15)(q32;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120866 CVCL_8Y52 QQ0422 transformed cell line human CVCL_8Y52 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)(q13.1;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120867 CVCL_8Y51 QQ0377 transformed cell line human CVCL_8Y51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(4:11)(q35;q23.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120868 CVCL_8Y54 QQ0445 transformed cell line human CVCL_8Y54 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,-1,+der(1),t(1;4)(p36.3;q28.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120869 CVCL_8Y53 QQ0444 transformed cell line human CVCL_8Y53 CL:0000010 Karyotypic information: 46,XY,t(4;16)(q22;q23) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120870 CVCL_8Y59 QQ0484 transformed cell line human CVCL_8Y59 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)t(3:4)(p22;q35)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120871 CVCL_B404 HOK-16A transformed cell line human CVCL_B404 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21120872 CVCL_AS04 UTA-SF3-2 induced pluripotent stem cell human CVCL_AS04 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: JCRB; NIHS0695; true Female 21120873 CVCL_B403 HOK-1 cancer cell line human CVCL_B403 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Female Doubling time: 29.6 hours (PubMed=1714884) 21120874 CVCL_AS03 UTA-SF2-2 induced pluripotent stem cell human CVCL_AS03 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: JCRB; NIHS0693; true Female Doubling time: 28.2 +- 4.9 hours (PubMed=21124894) 21120875 CVCL_AS06 EFC-1 embryonic stem cell house mouse CVCL_AS06 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21120876 CVCL_B406 HOK-16B-BaP transformed cell line human CVCL_B406 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21120877 CVCL_B405 HOK-16B transformed cell line human CVCL_B405 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21120878 CVCL_AS05 LF2 [Mouse ESC] embryonic stem cell house mouse CVCL_AS05 CL:0000010 Breed/subspecies: 129P2/Ola. Omics: DNA methylation analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me2 ChIP-seq epigenome analysis Female 21120879 CVCL_B408 HT-17 cancer cell line human CVCL_B408 CL:0000010 Population: Japanese Discontinued: RCB; RCB1885; true. 21120880 CVCL_AS08 XT67E1 embryonic stem cell house mouse CVCL_AS08 CL:0000010 Breed/subspecies: PGK x 129P2/Ola/Hsd. Omics: DNA methylation analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis Female 21120881 CVCL_B407 HOK-16B-BaP-T1 transformed cell line human CVCL_B407 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21120882 CVCL_AS07 PGK12.1 embryonic stem cell house mouse CVCL_AS07 CL:0000010 Breed/subspecies: PGK x 129P2/Ola/Hsd. Omics: Transcriptome analysis by RNAseq Female 21120883 CVCL_B409 Hut292DM cancer cell line human CVCL_B409 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (from parent cell line); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Pro496Thrfs*8 (c.1484_1485insA); Zygosity=Heterozygous (from parent cell line) Population: African American; Derived from metastatic site: Lymph node. Female Caution: It is not clear if Hut292DM is derived from NCI-H292 or is identical to that cell line 21120884 CVCL_AS09 MCF-7/S9 cancer cell line human CVCL_AS09 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: ~44 hours, 34 hours (when estradiol added in medium) (PubMed=12732292) Group: Serum/protein free medium cell line 21120885 CVCL_8Y70 QQ0611 transformed cell line human CVCL_8Y70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120886 CVCL_8Y72 QQ0613 transformed cell line human CVCL_8Y72 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-7,+der(7)ins(7;?)(q31.2;?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120887 CVCL_8Y71 QQ0612 transformed cell line human CVCL_8Y71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120888 CVCL_AS00 KMRM-A1 cancer cell line human CVCL_AS00 CL:0000010 Population: Japanese; Derived from metastatic site: Not specified. Discontinued: JCRB; NIHS0350; true Unspecified 21120889 CVCL_B402 HMCa cancer cell line human CVCL_B402 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female Doubling time: 48 hours (PubMed=2891216) 21120890 CVCL_AS02 UTA1 induced pluripotent stem cell human CVCL_AS02 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 21120891 CVCL_B401 Hair-M cancer cell line human CVCL_B401 HLA typing: A*24:02:01,26:02:01; B*40:06:01,48:01:01; C*08:01:01,08:01:01; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*01:03:01,01:04:01; DQB1*05:03:01,06:01:01; DRA*01:01:01,01:02:02; DRB1*08:03:02,14:05:01 (DSMZCellDive=ACC-762) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 11648; TCL1A; Name(s)=IGH-TCL1A (PubMed=31160637) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=2418246); ~48 hours (DSMZ=ACC-762) Part of: LL-100 blood cancer cell line panel Problematic cell line: Possibly misclassified It is not certain that this cell line originate from a hairy cell leukemia (PubMed=22653958). 21120892 CVCL_AS01 T-47D-Luc cancer cell line human CVCL_AS01 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Discontinued: JCRB; JCRB1374; probable; Discontinued: JCRB; NIHS0639; true Female Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21120893 CVCL_8Y67 QQ0592 transformed cell line human CVCL_8Y67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120894 CVCL_8Y66 QQ0588 transformed cell line human CVCL_8Y66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120895 CVCL_8Y69 QQ0598 transformed cell line human CVCL_8Y69 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,4q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120896 CVCL_8Y68 QQ0594 transformed cell line human CVCL_8Y68 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,r(14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120897 CVCL_8Y63 QQ0526 transformed cell line human CVCL_8Y63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120898 CVCL_8Y62 QQ0525 transformed cell line human CVCL_8Y62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120899 CVCL_8Y65 QQ0528 transformed cell line human CVCL_8Y65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120900 CVCL_8Y64 QQ0527 transformed cell line human CVCL_8Y64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120901 CVCL_8Y34 QQ0113 transformed cell line human CVCL_8Y34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120902 CVCL_8Y33 QQ0112 transformed cell line human CVCL_8Y33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120903 CVCL_8Y36 QQ0233 transformed cell line human CVCL_8Y36 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(X)(Xpter->Xq21::Xq22->Xqter?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120904 CVCL_8Y35 QQ0167 transformed cell line human CVCL_8Y35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120905 CVCL_8Y30 QQ0082 transformed cell line human CVCL_8Y30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 46,XY,t(2;4)(2qter->2p15::4p12->4pter;4qter->4p12::2p16.2->2pter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120906 CVCL_8Y32 QQ0106 transformed cell line human CVCL_8Y32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120907 CVCL_8Y31 QQ0083 transformed cell line human CVCL_8Y31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;6)(p21;p21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120908 CVCL_8Y38 QQ0249 transformed cell line human CVCL_8Y38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120909 CVCL_8Y37 QQ0234 transformed cell line human CVCL_8Y37 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(X)(Xpter->Xq21::Xq22->Xqter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120910 CVCL_8Y39 QQ0253 transformed cell line human CVCL_8Y39 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(X)(Xpter->Xq21.1::Xq21.3->Xqter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120911 CVCL_8Y50 QQ0373 transformed cell line human CVCL_8Y50 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,dir dup (17)(p11.2->p12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120912 CVCL_8Y45 QQ0297 transformed cell line human CVCL_8Y45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120913 CVCL_8Y44 QQ0296 transformed cell line human CVCL_8Y44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120914 CVCL_8Y47 QQ0299 transformed cell line human CVCL_8Y47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120915 CVCL_8Y46 QQ0298 transformed cell line human CVCL_8Y46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120916 CVCL_8Y41 QQ0271 transformed cell line human CVCL_8Y41 CL:0000010 Population: Caucasian; Karyotypic information: 46,delXY,der(Xpter->Xq21.1::Xq21.3->Xqter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120917 CVCL_8Y40 QQ0270 transformed cell line human CVCL_8Y40 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(X)(Xpter->Xq21.1::Xq21.3->Xqter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120918 CVCL_8Y43 QQ0287 transformed cell line human CVCL_8Y43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120919 CVCL_8Y42 QQ0286 transformed cell line human CVCL_8Y42 CL:0000010 Karyotypic information: 46,XY,inv(5)(q15;q32) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120920 CVCL_8Y49 QQ0322 transformed cell line human CVCL_8Y49 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120921 CVCL_8Y48 QQ0300 transformed cell line human CVCL_8Y48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120922 CVCL_8Y12 MB0002 transformed cell line human CVCL_8Y12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00051801; true Unspecified Part of: ECACC chromosomal abnormality collection 21120923 CVCL_8Y11 LR0001 transformed cell line human CVCL_8Y11 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120924 CVCL_8Y14 MB0009 transformed cell line human CVCL_8Y14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00110317; true Female Part of: ECACC chromosomal abnormality collection 21120925 CVCL_8Y13 MB0008 transformed cell line human CVCL_8Y13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00110316; true Female Part of: ECACC chromosomal abnormality collection 21120926 CVCL_8Y10 LQ0001 transformed cell line human CVCL_8Y10 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;7)(p21.3;q11.21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120927 CVCL_8Y19 MG0001 transformed cell line human CVCL_8Y19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21120928 CVCL_8Y16 MB0014 transformed cell line human CVCL_8Y16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 01010504; true Female Part of: ECACC chromosomal abnormality collection 21120929 CVCL_8Y15 MB0012 transformed cell line human CVCL_8Y15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00121101; true Male Part of: ECACC chromosomal abnormality collection 21120930 CVCL_8Y18 MD0003 transformed cell line human CVCL_8Y18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21120931 CVCL_8Y17 MB0015 transformed cell line human CVCL_8Y17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 01012005; true Male Part of: ECACC chromosomal abnormality collection 21120932 CVCL_8Y23 NB0001 transformed cell line human CVCL_8Y23 CL:0000010 Population: Caucasian; Karyotypic information: XX,dup(7)(p11.2;p13); XX (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120933 CVCL_8Y22 MVA28C transformed cell line human CVCL_8Y22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120934 CVCL_8Y25 NW0004 transformed cell line human CVCL_8Y25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120935 CVCL_8Y24 NO0001 transformed cell line human CVCL_8Y24 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX.ish(del)(22)(q11.2;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120936 CVCL_8Y21 MS0011 transformed cell line human CVCL_8Y21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 03080864; true Female Part of: ECACC chromosomal abnormality collection 21120937 CVCL_8Y20 MS0010 transformed cell line human CVCL_8Y20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 03080863; true Female Part of: ECACC chromosomal abnormality collection 21120938 CVCL_8Y27 NW0006 transformed cell line human CVCL_8Y27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120939 CVCL_8Y26 NW0005 transformed cell line human CVCL_8Y26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120940 CVCL_8Y29 QQ0010 transformed cell line human CVCL_8Y29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120941 CVCL_8Y28 PM0001 transformed cell line human CVCL_8Y28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21120942 CVCL_8Y01 KW0001 transformed cell line human CVCL_8Y01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(7)(q22.1;q31.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120943 CVCL_8Y00 KQ0001 transformed cell line human CVCL_8Y00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120944 CVCL_8Y03 KW0008 transformed cell line human CVCL_8Y03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;7)(q22;q31.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120945 CVCL_8Y02 KW0002 transformed cell line human CVCL_8Y02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120946 CVCL_8Y09 LA0002 transformed cell line human CVCL_8Y09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120947 CVCL_8Y08 LA0001 transformed cell line human CVCL_8Y08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120948 CVCL_8Y05 KW0010 transformed cell line human CVCL_8Y05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(2;11)(q35;p15.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120949 CVCL_8Y04 KW0009 transformed cell line human CVCL_8Y04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120950 CVCL_8Y07 KW0012 transformed cell line human CVCL_8Y07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120951 CVCL_8Y06 KW0011 transformed cell line human CVCL_8Y06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;11)(q35;p15.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120952 CVCL_AR59 Mbd3KO embryonic stem cell house mouse CVCL_AR59 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1333812; Mbd3. Unspecified 21120953 CVCL_B359 Regea08/017 embryonic stem cell human CVCL_B359 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Female 21120954 CVCL_B352 JDM-iPS2 induced pluripotent stem cell human CVCL_B352 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120955 CVCL_AR52 Rolf B1.T spontaneously immortalized cell line Norway rat CVCL_AR52 CL:0000010 Derived from sampling site: Nose; nasal cavity; olfactory nerve; Breed/subspecies: Wistar. Unspecified 21120956 CVCL_B351 JDM-iPS10 induced pluripotent stem cell human CVCL_B351 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120957 CVCL_AR51 RaBE spontaneously immortalized cell line Norway rat CVCL_AR51 CL:0000010 Derived from sampling site: Bronchus; epithelium; Breed/subspecies: Wistar. Male 21120958 CVCL_AR54 HT-STAR cancer cell line human CVCL_AR54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Retrovirus packaging cell line 21120959 CVCL_B354 Regea06/015 embryonic stem cell human CVCL_B354 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Male 21120960 CVCL_B353 JDM-iPS4 induced pluripotent stem cell human CVCL_B353 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120961 CVCL_AR53 TKE2 spontaneously immortalized cell line house mouse CVCL_AR53 CL:0000010 Derived from sampling site: Eye; cornea; epithelium; Breed/subspecies: CD-1. Female Characteristics: Progenitor cell isolated from the basal layer of the limbal epithelium; Characteristics: Has applications in the cell biology of corneal epithelial cells, toxicity, and differentiation (ECACC); Characteristics: Can be induced to differentiate into stratified epithelium on increasing the calcium concentration and addition of FBS (ECACC) Doubling time: 34.2 hours (PubMed=18318692) 21120962 CVCL_AR56 CHO-WBL (IVGT) spontaneously immortalized cell line CVCL_AR56 CL:0000010 Derived from sampling site: Ovary. Female Part of: In Vitro Genetic Toxicity (IVGT) cell line panel 21120963 CVCL_B356 Regea07/027 embryonic stem cell human CVCL_B356 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Female 21120964 CVCL_AR55 HT-STAR-A cancer cell line human CVCL_AR55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Retrovirus packaging cell line 21120965 CVCL_B355 Regea06/040 embryonic stem cell human CVCL_B355 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Female 21120966 CVCL_AR58 L929/A spontaneously immortalized cell line house mouse CVCL_AR58 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21120967 CVCL_B358 Regea08/013 embryonic stem cell human CVCL_B358 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Male 21120968 CVCL_B357 Regea07/046 embryonic stem cell human CVCL_B357 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Female 21120969 CVCL_AR57 Shmac 1 transformed cell line human CVCL_AR57 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21120970 CVCL_B350 JDM-iPS1 induced pluripotent stem cell human CVCL_B350 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21120971 CVCL_AR50 LA-350 transformed cell line human CVCL_AR50 From: Seeger R.C.; UCLA Center for Health Sciences; Los Angeles; USA CL:0000010 Miscellaneous: On the basis that LA-350 and LA-N-5 (Cellosaurus=CVCL_0389) are both established by Seeger R.C., that they share identical STR profiles and that LA-350 is said to originate from a patient suffering from neuroblastoma we have annotated them as being autologous cell lines Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgM kappa Doubling time: 12-18 hours (PubMed=3033590) 21120972 CVCL_AR63 ES-R1/D4/XEGFP embryonic stem cell house mouse CVCL_AR63 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21120973 CVCL_B363 Relicell hES2 embryonic stem cell human CVCL_B363 From: Reliance Life Sciences, Ltd; Navi Mumbai; India. CL:0000010 Female 21120974 CVCL_AR62 ES-R1/CK8/ECFP embryonic stem cell house mouse CVCL_AR62 CL:0000010 Transfected with: UniProtKB; Q66PV6; CFP Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21120975 CVCL_B362 Relicell hES1 embryonic stem cell human CVCL_B362 HLA typing: A*01:02; B*56:01,35; C*01:04; DQB1*05; DRB1*01,01 (PubMed=16919167). From: Reliance Life Sciences, Ltd; Navi Mumbai; India CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8172 21120976 CVCL_AR65 CHO-K1-AC-free spontaneously immortalized cell line CVCL_AR65 CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21120977 CVCL_B365 RPE-340 finite cell line human CVCL_B365 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Senescence: Senesces afer 50-60 PDL Caution: Indicated as originating from a 1 year old male trauma victim (PubMed=10617776) but the TERT-immortalized derived cell line hTERT-RPE1 (Cellosaurus=CVCL_4388) is stated to originate from a female donor 21120978 CVCL_AR64 ES-R1/YC5/EYFP embryonic stem cell house mouse CVCL_AR64 CL:0000010 Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231) Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21120979 CVCL_B364 Relicell hES3 embryonic stem cell human CVCL_B364 From: Reliance Life Sciences, Ltd; Navi Mumbai; India. CL:0000010 Female 21120980 CVCL_B367 HD-Mar cancer cell line human CVCL_B367 CL:0000010 Derived from sampling site: Pleural effusion Cell type=T-cell.. Discontinued: ATCC; CRL-2626; true Male Doubling time: 24-30 hours (PubMed=6154663) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be a T lymphoblastic lymphoma (PubMed=29533902). 21120981 CVCL_AR67 HeLa-Mitotrap-Ap1g1-FKBP cancer cell line human CVCL_AR67 CL:0000010 Transfected with: Mitotrap, a construct composed of the import signal of yeast TOM70, a YFP and the rapamycin-binding (FRB) domain from MTOR; Transfected with: HGNC; 555; AP1G1 (tagged with the FKBP domain from FKBP1A) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21120982 CVCL_AR66 HeLa-Mitotrap cancer cell line human CVCL_AR66 CL:0000010 Transfected with: Mitotrap, a construct composed of the import signal of yeast TOM70, a YFP and the rapamycin-binding (FRB) domain from MTOR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Can be used to determine the function of a protein by rapidly inactivating the protein of interest by rapamycin-induced rerouting to the mitochondria This process is termed 'knocksideway'. 21120983 CVCL_B366 MTC-1 hybridoma house mouse CVCL_B366 CL:0000010 Characteristics: T-cell hybridoma. 21120984 CVCL_AR69 HeLa-Mitotrap-Ap2a2-FKBP cancer cell line human CVCL_AR69 CL:0000010 Transfected with: Mitotrap, a construct composed of the import signal of yeast TOM70, a YFP and the rapamycin-binding (FRB) domain from MTOR; Transfected with: HGNC; 562; AP2A2 (tagged with the FKBP domain from FKBP1A) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21120985 CVCL_B369 OUMS-24 finite cell line human CVCL_B369 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female Senescence: Senesces at 62 PDL (PubMed=8428798); Doubling time: 83.0 +- 5.16 hours (in 1% FBS), 40.8 +- 2.25 hours (in 10% FBS) (PubMed=8428798) 21120986 CVCL_B368 T98 cancer cell line human CVCL_B368 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male 21120987 CVCL_AR68 TK6 (IVGT) transformed cell line human CVCL_AR68 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (PubMed=33198927); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=33198927) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Omics: SNP array analysis Male Part of: In Vitro Genetic Toxicity (IVGT) cell line panel 21120988 CVCL_AR61 ES-R1/CK6/ECFP embryonic stem cell house mouse CVCL_AR61 CL:0000010 Transfected with: UniProtKB; Q66PV6; CFP Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21120989 CVCL_B361 Regea08/056 embryonic stem cell human CVCL_B361 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Female 21120990 CVCL_AR60 ES-R1/B5/EGFP embryonic stem cell house mouse CVCL_AR60 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male 21120991 CVCL_B360 Regea08/023 embryonic stem cell human CVCL_B360 From: Regea Institute for Regenerative Medicine; Tampere; Finland. CL:0000010 Male 21120992 CVCL_AR38 DD2985 transformed cell line human CVCL_AR38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21120993 CVCL_B338 DF508 5 induced pluripotent stem cell human CVCL_B338 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120994 CVCL_AR37 DD2965 transformed cell line human CVCL_AR37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120995 CVCL_B337 DF508 4 induced pluripotent stem cell human CVCL_B337 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120996 CVCL_AR39 DD2986 transformed cell line human CVCL_AR39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21120997 CVCL_B339 DF508 6 induced pluripotent stem cell human CVCL_B339 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21120998 CVCL_B330 ALT-I cancer cell line human CVCL_B330 CL:0000010 Male 21120999 CVCL_AR30 DD2850 transformed cell line human CVCL_AR30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121000 CVCL_AR32 DD2853 transformed cell line human CVCL_AR32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121001 CVCL_B332 Jurkat-JMN cancer cell line human CVCL_B332 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21121002 CVCL_AR31 DD2851 transformed cell line human CVCL_AR31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121003 CVCL_B331 TK-1B cancer cell line human CVCL_B331 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36-48 hours (PubMed=3457771) 21121004 CVCL_AR34 DD2857 transformed cell line human CVCL_AR34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121005 CVCL_B334 T1/HCVcon hybrid cell line human CVCL_B334 CL:0000010 21121006 CVCL_AR33 DD2856 transformed cell line human CVCL_AR33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121007 CVCL_B333 JVM-14 transformed cell line human CVCL_B333 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21121008 CVCL_AR36 DD2893 transformed cell line human CVCL_AR36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified Part of: ECACC chromosomal abnormality collection 21121009 CVCL_B336 DF508 2 induced pluripotent stem cell human CVCL_B336 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121010 CVCL_AR35 DD2875 transformed cell line human CVCL_AR35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121011 CVCL_B335 T1/NS3-4A hybrid cell line human CVCL_B335 CL:0000010 21121012 CVCL_8X97 KN0117 transformed cell line human CVCL_8X97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99081012; true Male Part of: ECACC chromosomal abnormality collection 21121013 CVCL_9997 SAML-1 cancer cell line human CVCL_9997 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: ATCC; CRL-2776; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00424 Problematic cell line: Contaminated Shown to be a U-937 derivative. Originally thought to originate from a bone marrow aspirate from a 50 year old male patient suffering from a secondary acute myelogenous leukemia (AML) following Hodgkin's disease. 21121014 CVCL_9996 IK-90 cancer cell line human CVCL_9996 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex10del; Zygosity=Heterozygous (PubMed=8105795); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=8105795) Population: Japanese; Derived from sampling site: Endometrium. Female 21121015 CVCL_8X96 KN0025 transformed cell line human CVCL_8X96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98112404; true Female Part of: ECACC chromosomal abnormality collection 21121016 CVCL_8X99 KN0120 transformed cell line human CVCL_8X99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99081015; true Female Part of: ECACC chromosomal abnormality collection 21121017 CVCL_9999 Yoruba68IPSC4 induced pluripotent stem cell human CVCL_9999 From: The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. 21121018 CVCL_8X98 KN0118 transformed cell line human CVCL_8X98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 99081013; true Male Part of: ECACC chromosomal abnormality collection 21121019 CVCL_9998 SAML-2 cancer cell line human CVCL_9998 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=12759925); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=12759925) Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-2840; probable Male Characteristics: CSF2 dependent 21121020 CVCL_AR49 C0107 transformed cell line human CVCL_AR49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21121021 CVCL_B349 FC018 embryonic stem cell human CVCL_B349 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Ambiguous 21121022 CVCL_AR48 N115-BU-1 cancer cell line house mouse CVCL_AR48 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21121023 CVCL_B348 SA002 embryonic stem cell human CVCL_B348 HLA typing: A*01:23; B*07,51; C*07,15; DQB1*05; DRB1*14,14; DRB3*02 (PubMed=16919167) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0086; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-14. 21121024 CVCL_B341 AS034.1 embryonic stem cell human CVCL_B341 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Male 21121025 CVCL_AR41 DD2993 transformed cell line human CVCL_AR41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121026 CVCL_B340 AS034 embryonic stem cell human CVCL_B340 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Omics: Transcriptome analysis by microarray. Male 21121027 CVCL_AR40 DD2987 transformed cell line human CVCL_AR40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121028 CVCL_B343 AS034.2 embryonic stem cell human CVCL_B343 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Male 21121029 CVCL_AR43 DD2999 transformed cell line human CVCL_AR43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121030 CVCL_B342 AS034.1.1 embryonic stem cell human CVCL_B342 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Male 21121031 CVCL_AR42 DD2998 transformed cell line human CVCL_AR42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121032 CVCL_B345 AS079 embryonic stem cell human CVCL_B345 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21121033 CVCL_AR45 FC4.14F8 hybridoma house mouse CVCL_AR45 CL:0000010 Monoclonal antibody isotype: IgG1. 21121034 CVCL_B344 AS038 embryonic stem cell human CVCL_B344 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Male 21121035 CVCL_AR44 BHK21-Hektor spontaneously immortalized cell line CVCL_AR44 CL:0000010 Derived from sampling site: Kidney. Male Characteristics: Adapted to growth in the chemically defined protein- and peptide-free Hektor-G medium from Cell Culture Technologies Group: Serum/protein free medium cell line 21121036 CVCL_AR47 FW3-151 hybridoma house mouse CVCL_AR47 CL:0000010 Monoclonal antibody isotype: IgG2b. 21121037 CVCL_B347 SA001 embryonic stem cell human CVCL_B347 HLA typing: A*01,02; B*07,35; C*04,07; DQB1*06; DRB1*13,15; DRB3*02; DRB5*01 (PubMed=16919167) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0085; Registration: Swiss research registry; BAG-hES-IMP-0031; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-14. 21121038 CVCL_B346 AS094 embryonic stem cell human CVCL_B346 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21121039 CVCL_AR46 FW3-132.6 hybridoma house mouse CVCL_AR46 CL:0000010 Monoclonal antibody isotype: IgG1. 21121040 CVCL_AR16 DD2727 finite cell line human CVCL_AR16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121041 CVCL_B316 SA611 embryonic stem cell human CVCL_B316 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-15.. 21121042 CVCL_AR15 DD2703 finite cell line human CVCL_AR15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121043 CVCL_B315 SA540 embryonic stem cell human CVCL_B315 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121044 CVCL_AR18 DD2735 finite cell line human CVCL_AR18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121045 CVCL_B318 NAN-3 cancer cell line human CVCL_B318 HLA typing: A*01,02; B*08,40; C*03,07 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248insGln (c.744insCAG); Zygosity=Unspecified (PubMed=21173094) Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21121046 CVCL_AR17 DD2733 finite cell line human CVCL_AR17 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21121047 CVCL_B317 NAN2 cancer cell line human CVCL_B317 From: Tachikawa T.; Department of Oral Pathology, Showa University; Tokyo; Japan CL:0000010 Population: Japanese. 21121048 CVCL_AR19 DD2736 transformed cell line human CVCL_AR19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121049 CVCL_B319 NAN-4 cancer cell line human CVCL_B319 CL:0000010 Miscellaneous: Cell line has been lost (from personal communication of Pellat-Deceunynck C.) Derived from sampling site: Peripheral blood. Unspecified Characteristics: Produces IgA kappa; Characteristics: IL6 dependent 21121050 CVCL_8X82 JJ0053 transformed cell line human CVCL_8X82 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121051 CVCL_9982 NCI-H768 cancer cell line human CVCL_9982 CL:0000010 Derived from sampling site: Cecum. Female 21121052 CVCL_8X81 JJ0052 transformed cell line human CVCL_8X81 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121053 CVCL_9981 NCI-H742 cancer cell line human CVCL_9981 CL:0000010 Derived from sampling site: Rectum. Male 21121054 CVCL_AR10 DD2609 transformed cell line human CVCL_AR10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121055 CVCL_8X84 JJ0055 transformed cell line human CVCL_8X84 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,fra(X)(q27.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121056 CVCL_9984 MOLP-6 cancer cell line human CVCL_9984 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Requires bone marrow stromal cells for optimal growth Doubling time: 48 hours (PubMed=10937346) 21121057 CVCL_B310 SA399 embryonic stem cell human CVCL_B310 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121058 CVCL_8X83 JJ0054 transformed cell line human CVCL_8X83 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,fra(X)(q27.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121059 CVCL_9983 NCI-H958 cancer cell line human CVCL_9983 CL:0000010 Derived from metastatic site: Liver. Male 21121060 CVCL_AR12 DD2682 transformed cell line human CVCL_AR12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121061 CVCL_B312 SA502 embryonic stem cell human CVCL_B312 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121062 CVCL_AR11 DD2654 transformed cell line human CVCL_AR11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121063 CVCL_B311 SA461 embryonic stem cell human CVCL_B311 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-31.. 21121064 CVCL_AR14 DD2700 finite cell line human CVCL_AR14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121065 CVCL_8X80 JJ0051 transformed cell line human CVCL_8X80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121066 CVCL_9980 NCI-H684 cancer cell line human CVCL_9980 HLA typing: A*03:01,03:01; B*39:01,44:02; C*05:01,12:03; DQB1*06:13,06:13; DRB1*03:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (DepMap) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21121067 CVCL_B314 SA521 embryonic stem cell human CVCL_B314 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121068 CVCL_AR13 DD2683 transformed cell line human CVCL_AR13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121069 CVCL_B313 SA506 embryonic stem cell human CVCL_B313 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121070 CVCL_9979 EE39LN cancer cell line human CVCL_9979 CL:0000010 Derived from metastatic site: Lymph node. Female 21121071 CVCL_8X79 JJ0049 transformed cell line human CVCL_8X79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121072 CVCL_9978 EE39C cancer cell line human CVCL_9978 CL:0000010 Derived from sampling site: Colon. Female 21121073 CVCL_8X78 JJ0048 transformed cell line human CVCL_8X78 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121074 CVCL_9975 COLO 239F cancer cell line human CVCL_9975 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078) Omics: Transcriptome analysis by microarray. Male 21121075 CVCL_8X75 JJ0039 transformed cell line human CVCL_8X75 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(16;17)(p13;q12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121076 CVCL_8X74 JJ0038 transformed cell line human CVCL_8X74 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121077 CVCL_9974 SUP-T19 cancer cell line human CVCL_9974 CL:0000010 21121078 CVCL_9977 COLO 200 finite cell line human CVCL_9977 CL:0000010 Derived from sampling site: Colon. Male 21121079 CVCL_8X77 JJ0042 transformed cell line human CVCL_8X77 CL:0000010 Karyotypic information: 46,Y,r(X)(p22.3;q28) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121080 CVCL_9976 COLO 197 finite cell line human CVCL_9976 CL:0000010 Derived from sampling site: Peripheral blood. Male 21121081 CVCL_8X76 JJ0040 transformed cell line human CVCL_8X76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121082 CVCL_AR27 DD2846 transformed cell line human CVCL_AR27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121083 CVCL_B327 TK-1D cancer cell line human CVCL_B327 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36-48 hours (PubMed=3457771) 21121084 CVCL_AR26 DD2826 transformed cell line human CVCL_AR26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121085 CVCL_B326 TK-1 [Human myeloid leukemia] cancer cell line human CVCL_B326 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 36-48 hours (PubMed=3457771) 21121086 CVCL_B329 ALT-G cancer cell line human CVCL_B329 CL:0000010 Derived from metastatic site: Lymph node. Male 21121087 CVCL_AR29 DD2849 transformed cell line human CVCL_AR29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121088 CVCL_B328 ALT-F cancer cell line human CVCL_B328 CL:0000010 Derived from metastatic site: Liver. Male 21121089 CVCL_AR28 DD2848 transformed cell line human CVCL_AR28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121090 CVCL_9993 IOR/OS18 cancer cell line human CVCL_9993 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex3-4del; Zygosity=Unspecified (PubMed=19787792) Derived from sampling site: Bone. Male 21121091 CVCL_8X93 KK0920 transformed cell line human CVCL_8X93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121092 CVCL_9992 IOR/OS17 cancer cell line human CVCL_9992 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy. CL:0000010 21121093 CVCL_8X92 KK0713 transformed cell line human CVCL_8X92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121094 CVCL_AR21 DD2753 transformed cell line human CVCL_AR21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121095 CVCL_9995 IOR/SARG cancer cell line human CVCL_9995 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Ter (c.615T>A); ClinVar=VCV000185498; Zygosity=Unspecified (PubMed=19787792) Derived from metastatic site: Bone. Male Doubling time: 58 +- 4 hours (PubMed=1622859) 21121096 CVCL_8X95 KM0027 transformed cell line human CVCL_8X95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 01033027; true Unspecified Part of: ECACC chromosomal abnormality collection 21121097 CVCL_B321 SNB-78 cancer cell line human CVCL_B321 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Ala (c.667C>G); Zygosity=Unspecified (PubMed=15900046) Derived from sampling site: Brain. Male Doubling time: 50 +- 2 hours (PubMed=3121170) Part of: JFCR39 cancer cell line panel 21121098 CVCL_AR20 DD2741 transformed cell line human CVCL_AR20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121099 CVCL_9994 IOR/OS19 cancer cell line human CVCL_9994 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy. CL:0000010 Unspecified 21121100 CVCL_8X94 KK1050 transformed cell line human CVCL_8X94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121101 CVCL_B320 SNB-56 cancer cell line human CVCL_B320 CL:0000010 Derived from sampling site: Brain. Male Doubling time: 33 +- 3 hours (PubMed=3121170) 21121102 CVCL_AR23 DD2764 finite cell line human CVCL_AR23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121103 CVCL_B323 NB16 cancer cell line human CVCL_B323 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female 21121104 CVCL_AR22 DD2761 transformed cell line human CVCL_AR22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121105 CVCL_AR25 DD2825 transformed cell line human CVCL_AR25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121106 CVCL_9991 IOR/OS15 cancer cell line human CVCL_9991 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone. Female 21121107 CVCL_8X91 KK0560 transformed cell line human CVCL_8X91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121108 CVCL_B325 TK-1 [Human astrocytoma] cancer cell line human CVCL_B325 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Discontinued: JCRB; NIHS0181; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00348 Problematic cell line: Contaminated Shown to be a U-251MG derivative. Originally thought to originate from a 22 year old female patient with a glioblastoma. 21121109 CVCL_AR24 DD2783 transformed cell line human CVCL_AR24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121110 CVCL_9990 IOR/OS14 cancer cell line human CVCL_9990 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone. Male 21121111 CVCL_8X90 KK0127 transformed cell line human CVCL_8X90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121112 CVCL_B324 NAN-5 cancer cell line human CVCL_B324 CL:0000010 Miscellaneous: Cell line has been lost (from personal communication of Pellat-Deceunynck C.) Derived from sampling site: Ascites. Unspecified Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21121113 CVCL_9989 IOR/OS10 cancer cell line human CVCL_9989 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone. Female 21121114 CVCL_8X89 KV0006 transformed cell line human CVCL_8X89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98071613; true Female Part of: ECACC chromosomal abnormality collection 21121115 CVCL_9986 IOR/MOS cancer cell line human CVCL_9986 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.249_572del322; Zygosity=Unspecified (PubMed=19787792) Derived from sampling site: Bone. Female 21121116 CVCL_8X86 JJ0057 transformed cell line human CVCL_8X86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121117 CVCL_8X85 JJ0056 transformed cell line human CVCL_8X85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121118 CVCL_9985 MOLP-7 cancer cell line human CVCL_9985 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Requires bone marrow stromal cells for optimal growth Doubling time: 168 hours (PubMed=10937346) 21121119 CVCL_9988 IOR/OS9 cancer cell line human CVCL_9988 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone. Male 21121120 CVCL_8X88 JJ0061 transformed cell line human CVCL_8X88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,+fra(X) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121121 CVCL_9987 IOR/OS7 cancer cell line human CVCL_9987 From: Laboratorio di Ricerca Oncologica, Istituti Ortopedici Rizzoli; Bologna; Italy. CL:0000010 Unspecified 21121122 CVCL_8X87 JJ0060 transformed cell line human CVCL_8X87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,+fra(X) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121123 CVCL_8X60 HH0356 finite cell line human CVCL_8X60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(12)(q15;q24.1) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21121124 CVCL_9960 UCLA 9 embryonic stem cell human CVCL_9960 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0145 21121125 CVCL_8X62 HH0370 finite cell line human CVCL_8X62 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,der(X),t(X;17)(p22.1;q23)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21121126 CVCL_9962 VAL-3 embryonic stem cell human CVCL_9962 HLA typing: A*02:01; B*07:02,38:01; C*07:02,12:03; DPB1*04:01,17:01; DQA1*01:03,06:03; DRB1*13:01; DRB3*01:01,02:02 (PubMed=17169214) From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Omics: Transcriptome analysis by microarray. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection; Registration: Swiss research registry; BAG-hES-IMP-0021 21121127 CVCL_8X61 HH0365 finite cell line human CVCL_8X61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(8;20)(q24.1;p13)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21121128 CVCL_9961 VAL-10B embryonic stem cell human CVCL_9961 HLA typing: A*29:02,30:02; B*44:03,58:01; C*07:18,16:01:01; DPB1*01:01,04:01; DQA1*01:01,01:02; DQB1*05:01,06:02; DRB1*01:02,15:01; DRB5*01:01:01 (Spanish_Stem_Cell_Bank). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121129 CVCL_8X57 HH0335 finite cell line human CVCL_8X57 CL:0000010 Karyotypic information: 46,XX,r(4)(p15;q33) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21121130 CVCL_9957 UCLA 6 embryonic stem cell human CVCL_9957 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0089 21121131 CVCL_8X56 HH0334 transformed cell line human CVCL_8X56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121132 CVCL_9956 UCLA 5 embryonic stem cell human CVCL_9956 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0088 21121133 CVCL_8X59 HH0354 finite cell line human CVCL_8X59 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-18+der(18)t(2;18)(q29:q21.33)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21121134 CVCL_9959 UCLA 8 embryonic stem cell human CVCL_9959 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0144 21121135 CVCL_8X58 HH0341 finite cell line human CVCL_8X58 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+i(12p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21121136 CVCL_9958 UCLA 7 embryonic stem cell human CVCL_9958 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0143 21121137 CVCL_8X53 HH0321 finite cell line human CVCL_8X53 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21121138 CVCL_9953 UCLA 2 embryonic stem cell human CVCL_9953 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0059 21121139 CVCL_8X52 HH0320 finite cell line human CVCL_8X52 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21121140 CVCL_9952 UCLA 10 embryonic stem cell human CVCL_9952 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0146 21121141 CVCL_8X55 HH0333 transformed cell line human CVCL_8X55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121142 CVCL_9955 UCLA 4 embryonic stem cell human CVCL_9955 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0087 21121143 CVCL_8X54 HH0332 transformed cell line human CVCL_8X54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121144 CVCL_9954 UCLA 3 embryonic stem cell human CVCL_9954 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0060 21121145 CVCL_AR05 DD2519 transformed cell line human CVCL_AR05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121146 CVCL_B305 SA218 embryonic stem cell human CVCL_B305 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121147 CVCL_AR04 DD2461 finite cell line human CVCL_AR04 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121148 CVCL_B304 SA211 embryonic stem cell human CVCL_B304 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21121149 CVCL_AR07 DD2562 transformed cell line human CVCL_AR07 CL:0000010 Karyotypic information: 46,XY,8p+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121150 CVCL_B307 SA279 embryonic stem cell human CVCL_B307 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21121151 CVCL_AR06 DD2522 transformed cell line human CVCL_AR06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121152 CVCL_B306 SA240 embryonic stem cell human CVCL_B306 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121153 CVCL_AR09 DD2586 transformed cell line human CVCL_AR09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121154 CVCL_B309 SA352 embryonic stem cell human CVCL_B309 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121155 CVCL_AR08 DD2584 transformed cell line human CVCL_AR08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121156 CVCL_B308 SA348 embryonic stem cell human CVCL_B308 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121157 CVCL_8X71 IS2260 transformed cell line human CVCL_8X71 CL:0000010 Karyotypic information: 46,XY,der(9)t(7:9) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121158 CVCL_9971 TE-3 cancer cell line human CVCL_9971 CL:0000010 Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: TKG; TKG 0254; probable. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00276 Problematic cell line: Contaminated TE-2, TE-3, TE-7, TE-12 and TE-13 have been shown to be identical (PubMed=17804709; PubMed=20143388). 21121159 CVCL_8X70 IS2259 transformed cell line human CVCL_8X70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121160 CVCL_9970 VAL-2 embryonic stem cell human CVCL_9970 From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain. CL:0000010 Female 21121161 CVCL_8X73 JJ0035 transformed cell line human CVCL_8X73 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27.3) 10% in 70 metaphases (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121162 CVCL_9973 SUP-T13 cancer cell line human CVCL_9973 CL:0000010 Sequence variation: Gene fusion; HGNC; 19124; FIP1L1 + HGNC; 8803; PDGFRA; Name(s)=FIP1L1-PDGFRA (PubMed=23637631); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu57Trp (c.170T>G); ClinVar=VCV000185713; Zygosity=Unspecified (PubMed=22675565) Derived from sampling site: Pleural effusion Cell type=T-cell.. Female 21121163 CVCL_8X72 JJ0016 transformed cell line human CVCL_8X72 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,fra(X)(q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121164 CVCL_9972 TE-7 cancer cell line human CVCL_9972 CL:0000010 Population: Japanese Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB1893; true; Discontinued: TKG; TKG 0258; true. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00277 Problematic cell line: Contaminated TE-2, TE-3, TE-7, TE-12 and TE-13 have been shown to be identical (PubMed=17804709; PubMed=20143388). 21121165 CVCL_AR01 DD2404 transformed cell line human CVCL_AR01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121166 CVCL_B301 SA196 embryonic stem cell human CVCL_B301 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121167 CVCL_AR00 DD2403 transformed cell line human CVCL_AR00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121168 CVCL_B300 SA191 embryonic stem cell human CVCL_B300 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121169 CVCL_AR03 DD2439 finite cell line human CVCL_AR03 CL:0000010 Derived from sampling site: Amnion Cell type=Fibroblast.. Unspecified Part of: ECACC chromosomal abnormality collection 21121170 CVCL_B303 SA203 embryonic stem cell human CVCL_B303 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Female 21121171 CVCL_AR02 DD2414 transformed cell line human CVCL_AR02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121172 CVCL_B302 SA202 embryonic stem cell human CVCL_B302 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21121173 CVCL_8X68 HY0007 transformed cell line human CVCL_8X68 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(12)(q21.33;q24.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121174 CVCL_9968 VAL-9 embryonic stem cell human CVCL_9968 HLA typing: A*02,11; B*07,51; C*02,07; DQA1*01,05; DQB1*03,06; DRB1*11,15 (PubMed=29026098). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-45. 21121175 CVCL_8X67 HY0003 transformed cell line human CVCL_8X67 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;4)(q25.2;q31.2); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121176 CVCL_9967 VAL-8 embryonic stem cell human CVCL_9967 HLA typing: A*02:01,31; B*07,40; C*03,07; DPB1*02:02,04:01; DQA1*01,03; DQB1*05:01,03:02; DRB1*01:03,04:04 (Spanish_Stem_Cell_Bank). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121177 CVCL_8X69 IS2258 transformed cell line human CVCL_8X69 CL:0000010 Karyotypic information: 46,XX,t(7:9) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121178 CVCL_9969 VAL-1 embryonic stem cell human CVCL_9969 From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain. CL:0000010 Female 21121179 CVCL_8X64 HH0377 finite cell line human CVCL_8X64 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,inv(8)(p23;q11.2),+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21121180 CVCL_9964 VAL-5 embryonic stem cell human CVCL_9964 HLA typing: A*01:01,24:02; B*08:01,44:03; C*02:02,07:01; DPB1*02:01,04:01; DQA1*05:01,03:01:01; DQB1*02:01,03:02; DRB1*03:01,04:02; DRB3*01:01; DRB4*01:03 (PubMed=17169214). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection; Registration: Swiss research registry; BAG-hES-IMP-0023 21121181 CVCL_8X63 HH0375 finite cell line human CVCL_8X63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(12)(q15;q24.1)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21121182 CVCL_9963 VAL-4 embryonic stem cell human CVCL_9963 HLA typing: A*02:01,24:02; B*18:01,44:03; C*04:01,07:01; DPB1*02:01,04:01; DQA1*05:05; DQB1*03:01; DRB1*11:01,11:04; DRB3*02:02 (PubMed=17169214). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection; Registration: Swiss research registry; BAG-hES-IMP-0022 21121183 CVCL_8X66 HQ0004 transformed cell line human CVCL_8X66 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(14),(q11.2;q13) Interstitial deletion of chromosome 14 long arm (ECACC).; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121184 CVCL_9966 VAL-7 embryonic stem cell human CVCL_9966 HLA typing: A*24,25; B*18,40; C*02,12; DRB1*04,11 (Spanish_Stem_Cell_Bank). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121185 CVCL_8X65 HH0378 transformed cell line human CVCL_8X65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121186 CVCL_9965 VAL-6M embryonic stem cell human CVCL_9965 HLA typing: A*02,24; B*14,52; C*02,15; DRB1*01,16 (Spanish_Stem_Cell_Bank). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121187 CVCL_JL71 PBMC2-iPS4F8 RM induced pluripotent stem cell human CVCL_JL71 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 14334; MRTFA (RBM15-MKL1 fusion); Transfected with: HGNC; 14959; RBM15 (RBM15-MKL1 fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121188 CVCL_JL70 PBMC2-iPS4F8 induced pluripotent stem cell human CVCL_JL70 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121189 CVCL_SF10 HAP1 BCR (-) 2 cancer cell line human CVCL_SF10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1014; BCR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121190 CVCL_JL69 H9 RM embryonic stem cell human CVCL_JL69 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 14334; MRTFA (RBM15-MKL1 fusion); Transfected with: HGNC; 14959; RBM15 (RBM15-MKL1 fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21121191 CVCL_SF12 HAP1 BEND3 (-) 1 cancer cell line human CVCL_SF12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23040; BEND3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121192 CVCL_SF11 HAP1 BCR (-) 3 cancer cell line human CVCL_SF11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1014; BCR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121193 CVCL_SF14 HAP1 BIN1 (-) 1 cancer cell line human CVCL_SF14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1052; BIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121194 CVCL_JL66 TIGEF transformed cell line CVCL_JL66 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16-SV40(ori-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal synovial membrane. Unspecified 21121195 CVCL_SF13 HAP1 BEND3 (-) 2 cancer cell line human CVCL_SF13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23040; BEND3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121196 CVCL_JL65 Ramos B7 cancer cell line human CVCL_JL65 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV strain B95-8 Doubling time: 15.6 +- 1.0 hours (PubMed=9225077) Caution: Ramos B7 and Ramos/B95-8 (Cellosaurus=CVCL_ZU79) could be identical 21121197 CVCL_SF16 HAP1 BIRC2 (-) 1 cancer cell line human CVCL_SF16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 590; BIRC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121198 CVCL_JL68 mMTSV-93 transformed cell line CVCL_JL68 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pMtSV-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal synovial membrane. Unspecified 21121199 CVCL_SF15 HAP1 BIN1 (-) 2 cancer cell line human CVCL_SF15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1052; BIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121200 CVCL_JL67 mMTSV-54 transformed cell line CVCL_JL67 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pMtSV-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal synovial membrane. Unspecified 21121201 CVCL_SF18 HAP1 BIRC3 (-) 1 cancer cell line human CVCL_SF18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 591; BIRC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121202 CVCL_JL62 VU-SCC-040 cancer cell line human CVCL_JL62 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 20250; AJUBA; Simple; p.Ser263fs (c.788_789delCT); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 1509; CASP8; Simple; p.Glu17Lys (c.49G>A); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asn390Lys (c.1170C>A); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Leu989Val (c.2965C>G); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15735012; PubMed=23613873) Omics: Genome sequenced (low read coverage). Female Doubling time: 27 +- 3 hours (PubMed=9139877) 21121203 CVCL_JL61 H9Keap1KO-A31 embryonic stem cell human CVCL_JL61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1 Female 21121204 CVCL_SF17 HAP1 BIRC2 (-) 2 cancer cell line human CVCL_SF17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 590; BIRC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121205 CVCL_JL64 VU-SCC-120 cancer cell line human CVCL_JL64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu415Ter (c.1243G>T); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg234His (c.701G>A); ClinVar=VCV000134959; Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Phe (c.481_482GC>TT); Zygosity=Heterozygous (PubMed=23613873; PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Heterozygous (PubMed=23613873; PubMed=31541927) Omics: Genome sequenced (low read coverage) Female Doubling time: 34 +- 3 hours (PubMed=9139877) Caution: TP53 mutation indicated to be at p.Ala159Phe (c.475_476GC>TT) in PubMed=15735012. 21121206 CVCL_SF19 HAP1 BIRC3 (-) 2 cancer cell line human CVCL_SF19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 591; BIRC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121207 CVCL_JL63 VU-SCC-096 cancer cell line human CVCL_JL63 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=23613873; PubMed=31541927) Derived from sampling site: Oral cavity; retromolar trigone. Omics: Genome sequenced (low read coverage) Male Doubling time: 41 +- 3 hours (PubMed=9139877) 21121208 CVCL_JL80 M494 induced pluripotent stem cell human CVCL_JL80 CL:0000010 Sequence variation: Mutation; HGNC; 7217; MPL; Simple; p.Val501Leu (c.1501G>C); Zygosity=Heterozygous (PubMed=28395806) Derived from sampling site: Peripheral blood. Female 21121209 CVCL_JL82 MEN1 point mutation iPS-M22 induced pluripotent stem cell human CVCL_JL82 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple_edited; p.Glu430Ter (c.1288G>T); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28395808) Derived from sampling site: Urine. Male 21121210 CVCL_JL81 MEN1 Mother iPS induced pluripotent stem cell human CVCL_JL81 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Glu430Ter (c.1288G>T); Zygosity=Heterozygous (PubMed=28395808) Population: Chinese; Malaysian; Derived from sampling site: Urine. Female 21121211 CVCL_SF01 HAP1 BCL7A (-) 1 cancer cell line human CVCL_SF01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1004; BCL7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121212 CVCL_SF00 HAP1 BCL6 (-) 1 cancer cell line human CVCL_SF00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121213 CVCL_SF03 HAP1 BCL7B (-) 2 cancer cell line human CVCL_SF03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1005; BCL7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121214 CVCL_JL77 iP2/14 induced pluripotent stem cell human CVCL_JL77 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Umbilical cord blood. Female 21121215 CVCL_SF02 HAP1 BCL7B (-) 1 cancer cell line human CVCL_SF02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1005; BCL7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121216 CVCL_JL76 PODO/TERT256 telomerase immortalized cell line human CVCL_JL76 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Evercyte Derived from sampling site: Kidney; glomerulus Cell type=Podocyte.. Female Doubling time: 36-48 hours (Evercyte) 21121217 CVCL_SF05 HAP1 BCL9 (-) 1 cancer cell line human CVCL_SF05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1008; BCL9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121218 CVCL_JL79 iPAI-005-B induced pluripotent stem cell human CVCL_JL79 From: Department of Medicine and Cardiovascular Center, Medical College of Wisconsin; Milwaukee; USA CL:0000010 Derived from sampling site: Urine. Female 21121219 CVCL_SF04 HAP1 BCL7B (-) 3 cancer cell line human CVCL_SF04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1005; BCL7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121220 CVCL_JL78 iPAI-015-2-F induced pluripotent stem cell human CVCL_JL78 From: Department of Medicine and Cardiovascular Center, Medical College of Wisconsin; Milwaukee; USA CL:0000010 Sequence variation: Mutation; HGNC; 8583; SERPINE1; Simple; c.4977insTA (2-BP INS,4977TA); ClinVar=VCV000013571; Zygosity=Heterozygous (PubMed=28395801) Derived from sampling site: Urine. Female 21121221 CVCL_JL73 KICRi002-A induced pluripotent stem cell human CVCL_JL73 From: Department of Neuroscience, Karolinska Institutet; Stockholm; Sweden CL:0000010 Donor information: Established from monozygotic twin of CTRL-9-II (Cellosaurus=CVCL_JL74); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21121222 CVCL_SF07 HAP1 BCOR (-) 1 cancer cell line human CVCL_SF07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20893; BCOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121223 CVCL_JL72 CMT2-FiPS4F1 induced pluripotent stem cell human CVCL_JL72 From: Facultad de Biologia, Universidad de Valencia; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 15968; GDAP1; Simple; p.Gln163Ter (c.487C>T); ClinVar=VCV000004193; Zygosity=Heterozygous (PubMed=28395795); Sequence variation: Mutation; HGNC; 15968; GDAP1; Simple; p.Thr288Asnfs*3 (c.862dupA); ClinVar=VCV000004194; Zygosity=Heterozygous (PubMed=28395795) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121224 CVCL_SF06 HAP1 BCL9 (-) 2 cancer cell line human CVCL_SF06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1008; BCL9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121225 CVCL_SF09 HAP1 BCR (-) 1 cancer cell line human CVCL_SF09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1014; BCR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121226 CVCL_JL75 RS-1 [Human primitive neuroectodermal tumor] cancer cell line human CVCL_JL75 CL:0000010 Population: Japanese; Derived from metastatic site: Perirectal space. Discontinued: JCRB; NIHS0610; true Female Doubling time: 48 hours (PubMed=7894770) 21121227 CVCL_JL74 CTRL-9-II induced pluripotent stem cell human CVCL_JL74 From: Department of Neuroscience, Karolinska Institutet; Stockholm; Sweden CL:0000010 Donor information: Established from monozygotic twin of KICRi002-A/CTRL-10-I (Cellosaurus=CVCL_JL73); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21121228 CVCL_SF08 HAP1 BCOR (-) 2 cancer cell line human CVCL_SF08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20893; BCOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121229 CVCL_JL48 HeLa-X4 cancer cell line human CVCL_JL48 CL:0000010 Transfected with: HIV-1 isolate NL4-3 env; Transfected with: UniProtKB; P04610; HIV-1 isolate BRU/LAI tat; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Engineered to express the gp160 envelope protein (Env) from a CXCR4-tropic HIV-1 isolate; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21121230 CVCL_JL47 HeLa-R5 cancer cell line human CVCL_JL47 CL:0000010 Transfected with: HIV-1 isolate 92US715 env; Transfected with: UniProtKB; P04610; HIV-1 isolate BRU/LAI tat; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Engineered to express the gp160 envelope protein (Env) from a CCR5-tropic HIV-1 isolate; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21121231 CVCL_JL49 CHO 1C T6 spontaneously immortalized cell line CVCL_JL49 CL:0000010 Derived from sampling site: Ovary. Female 21121232 CVCL_JL44 WA-3 embryonic stem cell dog CVCL_JL44 CL:0000010 Female 21121233 CVCL_JL43 WA-2 embryonic stem cell dog CVCL_JL43 CL:0000010 Male 21121234 CVCL_JL46 WI-2 embryonic stem cell dog CVCL_JL46 CL:0000010 Female 21121235 CVCL_JL45 WA-4 embryonic stem cell dog CVCL_JL45 CL:0000010 Male 21121236 CVCL_JL40 SK-1 embryonic stem cell dog CVCL_JL40 CL:0000010 Female 21121237 CVCL_JL42 WA-1 embryonic stem cell dog CVCL_JL42 CL:0000010 Female 21121238 CVCL_JL41 SK-4 embryonic stem cell dog CVCL_JL41 CL:0000010 Female 21121239 CVCL_JL60 MS-BP003-iPSC induced pluripotent stem cell human CVCL_JL60 From: Jilin University First Hospital; Changchun; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 21121240 CVCL_JL59 hTERT PF179T CAF telomerase immortalized cell line human CVCL_JL59 CL:0000010 Transfected with: HGNC; 11730; TERT Karyotypic information: Has lost chromosome Y; Derived from sampling site: Prostate Cell type=Fibroblast.. Male 21121241 CVCL_JL58 GCTTSC cancer cell line human CVCL_JL58 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Population: Japanese; Derived from sampling site: Ankle; tendon sheath. Female Doubling time: 150 hours, at 9th passage (PubMed=11845350) 21121242 CVCL_JL55 SR8 cancer cell line human CVCL_JL55 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 29 hours (PubMed=8695226; PubMed=10540202) 21121243 CVCL_JL54 HAK-6 cancer cell line human CVCL_JL54 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Unspecified 21121244 CVCL_JL57 BT-37 cancer cell line human CVCL_JL57 From: Biegel J.; Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Unspecified Characteristics: Established from a serially passaged xenograft. 21121245 CVCL_JL56 SR8CT cancer cell line human CVCL_JL56 CL:0000010 Derived from metastatic site: Ascites. Female Characteristics: Derived from parent cell line by adding cholera-toxin to the medium Doubling time: 39 hours (PubMed=10540202) 21121246 CVCL_JL51 Mlp3 cancer cell line house mouse CVCL_JL51 From: Meijne E.; NRG; Petten; Netherlands CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: CBA/H. Omics: Transcriptome analysis by microarray 21121247 CVCL_JL50 SA2 cancer cell line house mouse CVCL_JL50 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: CBA/Ca. 21121248 CVCL_JL53 HAK-5 cancer cell line human CVCL_JL53 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21121249 CVCL_JL52 HAK-4 cancer cell line human CVCL_JL52 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21121250 CVCL_AR96 BT-474 EEI cancer cell line human CVCL_AR96 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Breast. Female 21121251 CVCL_B396 CN1.4 conditionally immortalized cell line house mouse CVCL_B396 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; cerebral cortex Cell type=Neuron.; Breed/subspecies: BALB/c. Unspecified 21121252 CVCL_B395 Cl-66M2 cancer cell line house mouse CVCL_B395 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Doubling time: 28.1 +- 2.2 hours (PubMed=10651311) 21121253 CVCL_AR95 HEC-1-A-OZA6 cancer cell line human CVCL_AR95 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.6; true Female 21121254 CVCL_B398 ESKOL cancer cell line human CVCL_B398 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Problematic cell line: Possibly misclassified It is not certain that this cell line originate from a hairy cell leukemia (PubMed=22653958). 21121255 CVCL_AR98 KMF-1 undefined cell line type human CVCL_AR98 CL:0000010 Discontinued: JCRB; NIHS0349; true. 21121256 CVCL_B397 ENU-T-1 cancer cell line Norway rat CVCL_B397 CL:0000010 Breed/subspecies: Sprague Dawley. 21121257 CVCL_AR97 IRC-1 finite cell line human CVCL_AR97 CL:0000010 Discontinued: JCRB; NIHS0315; true. Female 21121258 CVCL_B399 FB8H3 hybridoma house mouse CVCL_B399 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:38221; Fumonisin B1. 21121259 CVCL_AR99 KMRC-21 cancer cell line human CVCL_AR99 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0351; true. Male 21121260 CVCL_JL29 OVC.ID.15 embryonic stem cell dog CVCL_JL29 CL:0000010 Unspecified 21121261 CVCL_AR90 HEC-1-A-OZA1 cancer cell line human CVCL_AR90 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.1; true Female 21121262 CVCL_B392 Ch-Huang-1 cancer cell line human CVCL_B392 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Female Doubling time: 36 hours (PubMed=22613331) 21121263 CVCL_AR92 HEC-1-A-OZA3 cancer cell line human CVCL_AR92 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.3; true Female 21121264 CVCL_JL26 OVC.ID.12 embryonic stem cell dog CVCL_JL26 CL:0000010 Unspecified 21121265 CVCL_B391 BW5147(T200-a)5.1 cancer cell line house mouse CVCL_B391 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Group: Hybridoma fusion partner cell line 21121266 CVCL_AR91 HEC-1-A-OZA2 cancer cell line human CVCL_AR91 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.2; true Female 21121267 CVCL_JL25 OVC.ID.11 embryonic stem cell dog CVCL_JL25 CL:0000010 Unspecified 21121268 CVCL_B394 Cl-66M1 cancer cell line house mouse CVCL_B394 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Doubling time: 29.1 +- 1.4 hours (PubMed=10651311) 21121269 CVCL_AR94 HEC-1-A-OZA5 cancer cell line human CVCL_AR94 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.5; true Female 21121270 CVCL_JL28 OVC.ID.14 embryonic stem cell dog CVCL_JL28 CL:0000010 Unspecified 21121271 CVCL_AR93 HEC-1-A-OZA4 cancer cell line human CVCL_AR93 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; NIHS0388.4; true Female 21121272 CVCL_JL27 OVC.ID.13 embryonic stem cell dog CVCL_JL27 CL:0000010 Unspecified 21121273 CVCL_JL22 OVC.ID.8 embryonic stem cell dog CVCL_JL22 CL:0000010 Unspecified 21121274 CVCL_JL21 OVC.ID.7 embryonic stem cell dog CVCL_JL21 CL:0000010 Unspecified 21121275 CVCL_JL24 OVC.ID.10 embryonic stem cell dog CVCL_JL24 CL:0000010 Unspecified 21121276 CVCL_JL23 OVC.ID.9 embryonic stem cell dog CVCL_JL23 CL:0000010 Unspecified 21121277 CVCL_JL20 OVC.ID.6 embryonic stem cell dog CVCL_JL20 CL:0000010 Unspecified 21121278 CVCL_JL37 OVC.ID.23 embryonic stem cell dog CVCL_JL37 CL:0000010 Unspecified 21121279 CVCL_JL36 OVC.ID.22 embryonic stem cell dog CVCL_JL36 CL:0000010 Unspecified 21121280 CVCL_JL39 K-6 embryonic stem cell dog CVCL_JL39 CL:0000010 Male 21121281 CVCL_JL38 I-2 embryonic stem cell dog CVCL_JL38 CL:0000010 Male 21121282 CVCL_JL33 OVC.ID.19 embryonic stem cell dog CVCL_JL33 CL:0000010 Unspecified 21121283 CVCL_JL32 OVC.ID.18 embryonic stem cell dog CVCL_JL32 CL:0000010 Unspecified 21121284 CVCL_JL35 OVC.ID.21 embryonic stem cell dog CVCL_JL35 CL:0000010 Unspecified 21121285 CVCL_JL34 OVC.ID.20 embryonic stem cell dog CVCL_JL34 CL:0000010 Unspecified 21121286 CVCL_JL31 OVC.ID.17 embryonic stem cell dog CVCL_JL31 CL:0000010 Unspecified 21121287 CVCL_JL30 OVC.ID.16 embryonic stem cell dog CVCL_JL30 CL:0000010 Unspecified 21121288 CVCL_B374 S-1 cancer cell line human CVCL_B374 CL:0000010 Population: Japanese; Derived from sampling site: Lung. 21121289 CVCL_AR74 STAR-A transformed cell line human CVCL_AR74 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121290 CVCL_B373 HuH-4 cancer cell line human CVCL_B373 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265_Phe270del (c.790_807del18); Zygosity=Unspecified (PubMed=8389256) Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21121291 CVCL_AR73 STAR transformed cell line human CVCL_AR73 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121292 CVCL_B376 10-1.D.2 hybridoma house mouse CVCL_B376 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P21855; Mouse Cd72. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21121293 CVCL_AR76 STAR-G+ transformed cell line human CVCL_AR76 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121294 CVCL_B375 #490 hybridoma house mouse CVCL_B375 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cronartium ribicola antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12029 21121295 CVCL_AR75 STAR-A-HV#2 transformed cell line human CVCL_AR75 CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121296 CVCL_B378 10-3.6.2 hybridoma house mouse CVCL_B378 CL:0000010 Monoclonal antibody isotype: IgG2a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21121297 CVCL_AR78 STAR-RDpro transformed cell line human CVCL_AR78 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121298 CVCL_B377 10-2.16 hybridoma house mouse CVCL_B377 CL:0000010 Monoclonal antibody isotype: IgG2b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21121299 CVCL_AR77 STAR-G+-HV#2 transformed cell line human CVCL_AR77 CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121300 CVCL_B379 10B9 hybridoma house mouse CVCL_B379 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human endothelial cells. 21121301 CVCL_AR79 STAR-RDpro-HV#1 transformed cell line human CVCL_AR79 CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121302 CVCL_JL08 OVC.EX.10 embryonic stem cell dog CVCL_JL08 CL:0000010 Unspecified 21121303 CVCL_JL07 OVC.EX.9 embryonic stem cell dog CVCL_JL07 CL:0000010 Unspecified 21121304 CVCL_JL09 OVC.EX.11 embryonic stem cell dog CVCL_JL09 CL:0000010 Unspecified 21121305 CVCL_AR70 HeLa-Mitotrap-GGA2-FKBP cancer cell line human CVCL_AR70 CL:0000010 Transfected with: Mitotrap, a construct composed of the import signal of yeast TOM70, a YFP and the rapamycin-binding (FRB) domain from MTOR; Transfected with: HGNC; 16064; GGA2 (tagged with the FKBP domain from FKBP1A) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21121306 CVCL_B370 OUMS-24F transformed cell line human CVCL_B370 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=8790940) Population: Japanese; Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Cell type=Fibroblast. Female Doubling time: 62.8 +- 8.99 hours (in 1% FBS), 39.7 +- 1.98 hours (in 10% FBS) (PubMed=8428798) 21121307 CVCL_JL04 OVC.EX.6 embryonic stem cell dog CVCL_JL04 CL:0000010 Unspecified 21121308 CVCL_JL03 OVC.EX.5 embryonic stem cell dog CVCL_JL03 CL:0000010 Unspecified 21121309 CVCL_AR72 293TGPRT+R1-A transformed cell line human CVCL_AR72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121310 CVCL_JL06 OVC.EX.8 embryonic stem cell dog CVCL_JL06 CL:0000010 Unspecified 21121311 CVCL_B372 YMB-1-C cancer cell line human CVCL_B372 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (YMB-1) has been shown to be a ZR-75-1 derivative. 21121312 CVCL_AR71 293TGPRT+R1 transformed cell line human CVCL_AR71 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121313 CVCL_JL05 OVC.EX.7 embryonic stem cell dog CVCL_JL05 CL:0000010 Unspecified 21121314 CVCL_B371 TL-1 cancer cell line human CVCL_B371 CL:0000010 Population: Japanese; Derived from sampling site: Ileocecal lymph node. Male Virology: EBV-negative Doubling time: ~36 hours (PubMed=2486610; PubMed=6268866) 21121315 CVCL_JL00 OVC.EX.2 embryonic stem cell dog CVCL_JL00 CL:0000010 Male 21121316 CVCL_JL02 OVC.EX.4 embryonic stem cell dog CVCL_JL02 CL:0000010 Unspecified 21121317 CVCL_JL01 OVC.EX.3 embryonic stem cell dog CVCL_JL01 CL:0000010 Unspecified 21121318 CVCL_B385 BALB/3T3 clone A31 ts20 transformed cell line house mouse CVCL_B385 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Temperature sensitive phenotype; Characteristics: In this cell line Uba1 is heat-inactivatable (PubMed=10848989) 21121319 CVCL_AR85 HL60 Ast.25 cancer cell line human CVCL_AR85 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Astatine-211 alpha radiation(NCIt; C129638); Derived from sampling site: Peripheral blood. Female 21121320 CVCL_B384 598RCC cancer cell line human CVCL_B384 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21121321 CVCL_AR84 Jurkat/A4 cancer cell line human CVCL_AR84 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21121322 CVCL_AR87 GCH-nu cancer cell line human CVCL_AR87 CL:0000010 Population: Japanese Male Caution: Established from gestational carcinoma of a woman patient, but the cell line is from the male fetus. 21121323 CVCL_B386 Amsalem cancer cell line human CVCL_B386 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: ATCC; CRL-2628; true Female Doubling time: 36-48 hours (PubMed=2981779) 21121324 CVCL_AR86 BT-474 Tam1 cancer cell line human CVCL_AR86 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from sampling site: Breast. Omics: Deep exome analysis Female 21121325 CVCL_B389 bcd mab23 hybridoma house mouse CVCL_B389 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09081; Drosophila melanogaster bcd. 21121326 CVCL_AR89 HL60 Sp1 cancer cell line human CVCL_AR89 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21121327 CVCL_B388 BALL-2 cancer cell line human CVCL_B388 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Doubling time: 36 hours (PubMed=1650133) 21121328 CVCL_AR88 HL60 Ast.1 cancer cell line human CVCL_AR88 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Astatine-211 alpha radiation(NCIt; C129638); Derived from sampling site: Peripheral blood. Female 21121329 CVCL_JL19 OVC.ID.5 embryonic stem cell dog CVCL_JL19 CL:0000010 Unspecified 21121330 CVCL_JL18 OVC.ID.4 embryonic stem cell dog CVCL_JL18 CL:0000010 Unspecified 21121331 CVCL_B381 14M stromal cell line house mouse CVCL_B381 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified 21121332 CVCL_AR81 IZD-MB-2006 spontaneously immortalized cell line CVCL_AR81 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21121333 CVCL_JL15 OVC.ID.1 embryonic stem cell dog CVCL_JL15 CL:0000010 Unspecified 21121334 CVCL_B380 14F stromal cell line house mouse CVCL_B380 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Doubling time: 20 hours (PubMed=2981238) 21121335 CVCL_AR80 IZD-MB-1203 spontaneously immortalized cell line CVCL_AR80 CL:0000010 Derived from sampling site: Ovary and dorsal vessel. Female Group: Insect cell line 21121336 CVCL_JL14 OVC.EX.16 embryonic stem cell dog CVCL_JL14 CL:0000010 Unspecified 21121337 CVCL_B383 4T07 cancer cell line house mouse CVCL_B383 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Non-metastatic 21121338 CVCL_AR83 IZD-MB-2506 spontaneously immortalized cell line CVCL_AR83 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21121339 CVCL_JL17 OVC.ID.3 embryonic stem cell dog CVCL_JL17 CL:0000010 Unspecified 21121340 CVCL_B382 14M1 stromal cell line house mouse CVCL_B382 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Doubling time: 15 hours (PubMed=2981238) 21121341 CVCL_AR82 IZD-MB-2007 spontaneously immortalized cell line CVCL_AR82 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21121342 CVCL_JL16 OVC.ID.2 embryonic stem cell dog CVCL_JL16 CL:0000010 Unspecified 21121343 CVCL_JL11 OVC.EX.13 embryonic stem cell dog CVCL_JL11 CL:0000010 Unspecified 21121344 CVCL_JL10 OVC.EX.12 embryonic stem cell dog CVCL_JL10 CL:0000010 Unspecified 21121345 CVCL_JL13 OVC.EX.15 embryonic stem cell dog CVCL_JL13 CL:0000010 Unspecified 21121346 CVCL_JL12 OVC.EX.14 embryonic stem cell dog CVCL_JL12 CL:0000010 Unspecified 21121347 CVCL_0A63 CTG1 cancer cell line house mouse CVCL_0A63 CL:0000010 Transfected with: UniProtKB; P03522; VSV G protein (truncated) Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21121348 CVCL_0A62 CG1 [Mouse mammary carcinoma] cancer cell line house mouse CVCL_0A62 CL:0000010 Transfected with: UniProtKB; P03522; VSV G protein Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21121349 CVCL_0A65 CT51 cancer cell line house mouse CVCL_0A65 CL:0000010 Breed/subspecies: BALB/c. 21121350 CVCL_0A64 CT36 cancer cell line house mouse CVCL_0A64 CL:0000010 Breed/subspecies: BALB/c. 21121351 CVCL_0A67 MC38Luc1 cancer cell line house mouse CVCL_0A67 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21121352 CVCL_0A66 LM17 cancer cell line house mouse CVCL_0A66 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female Characteristics: Highly metastatic to lung 21121353 CVCL_0A69 MC38/IL-12 cancer cell line house mouse CVCL_0A69 CL:0000010 Transfected with: MGI; MGI:96539; Il12a; Transfected with: MGI; MGI:96540; Il12b; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 21121354 CVCL_0A68 MC38/0 cancer cell line house mouse CVCL_0A68 CL:0000010 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 21121355 CVCL_0A61 tHmf-e spontaneously immortalized cell line Norway rat CVCL_0A61 CL:0000010 Derived from sampling site: Liver Cell type=Myofibroblast.; Breed/subspecies: Sprague Dawley. Male Doubling time: ~40 hours (PubMed=3515628) 21121356 CVCL_0A60 tHmf-f spontaneously immortalized cell line Norway rat CVCL_0A60 CL:0000010 Derived from sampling site: Liver Cell type=Myofibroblast.; Breed/subspecies: Sprague Dawley. Male Doubling time: ~17 hours (PubMed=3515628) 21121357 CVCL_0A74 OSCA-02 cancer cell line dog CVCL_0A74 CL:0000010 Breed/subspecies: Rottweiler. Omics: Genome sequenced Male 21121358 CVCL_0A73 OSCA-00 cancer cell line dog CVCL_0A73 CL:0000010 Breed/subspecies: Rottweiler. Female 21121359 CVCL_0A76 OSCA-05 cancer cell line dog CVCL_0A76 CL:0000010 Breed/subspecies: Rottweiler. Female 21121360 CVCL_0A75 OSCA-03 cancer cell line dog CVCL_0A75 CL:0000010 Breed/subspecies: Rottweiler. Male 21121361 CVCL_0A78 OSCA-09 cancer cell line dog CVCL_0A78 CL:0000010 Breed/subspecies: Irish Setter. Male 21121362 CVCL_0A77 OSCA-07 cancer cell line dog CVCL_0A77 CL:0000010 Breed/subspecies: Rottweiler. Female 21121363 CVCL_0A79 OSCA-10 cancer cell line dog CVCL_0A79 CL:0000010 Breed/subspecies: Golden Retriever. Male 21121364 CVCL_8Z00 TT0252 transformed cell line human CVCL_8Z00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91080908; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121365 CVCL_8Z02 WW0240 transformed cell line human CVCL_8Z02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95080208; true Female Part of: ECACC chromosomal abnormality collection 21121366 CVCL_8Z01 WW0008 transformed cell line human CVCL_8Z01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 89060702; true Female Part of: ECACC chromosomal abnormality collection 21121367 CVCL_8Z08 XP0011 transformed cell line human CVCL_8Z08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121368 CVCL_8Z07 XP0010 transformed cell line human CVCL_8Z07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121369 CVCL_8Z09 XP0012 transformed cell line human CVCL_8Z09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121370 CVCL_0A70 MA-101 finite cell line CVCL_0A70 CL:0000010 Derived from sampling site: Fetal lung. Unspecified Group: Non-human primate cell line 21121371 CVCL_8Z04 XP0007 transformed cell line human CVCL_8Z04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121372 CVCL_8Z03 XP0006 transformed cell line human CVCL_8Z03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121373 CVCL_0A72 MB-9812 cancer cell line human CVCL_0A72 CL:0000010 21121374 CVCL_8Z06 XP0009 transformed cell line human CVCL_8Z06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121375 CVCL_0A71 MACKI transformed cell line CVCL_0A71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: ATCC; CRL-6582; true. Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21121376 CVCL_8Z05 XP0008 transformed cell line human CVCL_8Z05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121377 CVCL_0A41 rh-r.1 spontaneously immortalized cell line CVCL_0A41 CL:0000010 Unspecified Group: Insect cell line. 21121378 CVCL_0A40 ec-rh.3 spontaneously immortalized cell line CVCL_0A40 CL:0000010 Unspecified Group: Insect cell line. 21121379 CVCL_0A43 rh-r.3 spontaneously immortalized cell line CVCL_0A43 CL:0000010 Unspecified Group: Insect cell line. 21121380 CVCL_0A42 rh-r.2 spontaneously immortalized cell line CVCL_0A42 CL:0000010 Unspecified Group: Insect cell line. 21121381 CVCL_0A45 rh-r.5 spontaneously immortalized cell line CVCL_0A45 CL:0000010 Unspecified Group: Insect cell line. 21121382 CVCL_0A44 rh-r.4 spontaneously immortalized cell line CVCL_0A44 CL:0000010 Unspecified Group: Insect cell line. 21121383 CVCL_0A47 S2-Mt-N spontaneously immortalized cell line fruit fly CVCL_0A47 CL:0000010 Transfected with: FlyBase_Gene; FBgn0004647; N Breed/subspecies: Oregon-R. Male Doubling time: 99 hours (DGRC) Group: Insect cell line 21121384 CVCL_0A46 rh-r.6 spontaneously immortalized cell line CVCL_0A46 CL:0000010 Unspecified Group: Insect cell line. 21121385 CVCL_0A49 IOZCAS-Spex-II spontaneously immortalized cell line CVCL_0A49 CL:0000010 Derived from sampling site: Fat body. Unspecified Virology: Susceptible to infection by Spodoptera exigua nuclear polyhedrosis virus (SeMNPV) (PubMed=16376374) Doubling time: 108.8 hours (CelloPub=CLPUB00225) Group: Insect cell line 21121386 CVCL_0A48 S2-Mt-Slit spontaneously immortalized cell line fruit fly CVCL_0A48 CL:0000010 Transfected with: FlyBase_Gene; FBgn0264089; sli Breed/subspecies: Oregon-R. Male Group: Insect cell line 21121387 CVCL_SG91 HAP1 CASP2 (-) 2 cancer cell line human CVCL_SG91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1503; CASP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121388 CVCL_SG90 HAP1 CASP2 (-) 1 cancer cell line human CVCL_SG90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1503; CASP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121389 CVCL_SG93 HAP1 CASP3 (-) cancer cell line human CVCL_SG93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1504; CASP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121390 CVCL_SG92 HAP1 CASP2 (-) 3 cancer cell line human CVCL_SG92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1503; CASP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121391 CVCL_SG95 HAP1 CASP6 (-) 2 cancer cell line human CVCL_SG95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1507; CASP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121392 CVCL_SG94 HAP1 CASP6 (-) 1 cancer cell line human CVCL_SG94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1507; CASP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121393 CVCL_SG97 HAP1 CASP7 (-) 2 cancer cell line human CVCL_SG97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1508; CASP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121394 CVCL_SG96 HAP1 CASP7 (-) 1 cancer cell line human CVCL_SG96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1508; CASP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121395 CVCL_SG99 HAP1 CASP8 (-) 2 cancer cell line human CVCL_SG99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121396 CVCL_SG98 HAP1 CASP8 (-) 1 cancer cell line human CVCL_SG98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1509; CASP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121397 CVCL_0A52 IOZCAS-Spex-IV spontaneously immortalized cell line CVCL_0A52 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21121398 CVCL_0A51 IOZCAS-Spex-III spontaneously immortalized cell line CVCL_0A51 CL:0000010 Derived from sampling site: Fat body. Unspecified Virology: Susceptible to infection by Spodoptera exigua nuclear polyhedrosis virus (SeMNPV) (PubMed=16376374) Group: Insect cell line 21121399 CVCL_0A54 IOZCAS-Spex-VI spontaneously immortalized cell line CVCL_0A54 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21121400 CVCL_0A53 IOZCAS-Spex-V spontaneously immortalized cell line CVCL_0A53 CL:0000010 Unspecified Group: Insect cell line. 21121401 CVCL_0A56 S2-SQH-GFP spontaneously immortalized cell line fruit fly CVCL_0A56 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003514; sqh; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Doubling time: 24 hours (DGRC) Group: Insect cell line 21121402 CVCL_0A55 IOZCAS-Spex-VII spontaneously immortalized cell line CVCL_0A55 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21121403 CVCL_0A58 S2R+-SQH-GFP spontaneously immortalized cell line fruit fly CVCL_0A58 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003514; sqh; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21121404 CVCL_0A57 S2-SQH-GFP+Mt-mCherry-actin spontaneously immortalized cell line fruit fly CVCL_0A57 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000042; Act5C; Transfected with: FlyBase_Gene; FBgn0003514; sqh; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Doubling time: 87 hours (DGRC) Group: Insect cell line 21121405 CVCL_0A59 Capan1M9 cancer cell line human CVCL_0A59 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 4039; FZD10; Simple; p.Asn54Lys (c.162C>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 23671; GLT6D1; Simple; p.Trp198Ter (c.593G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4593; GRM1; Simple; p.Tyr486Ter (c.1458C>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Glu221Ter (c.661G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser343Ter (c.1028C>G); ClinVar=VCV000822036; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 25082; SMAP2; Simple; p.Ser255Ter (c.764C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Liver. Male Characteristics: Highly migratory cell subclone of Capan-1 21121406 CVCL_SG80 HAP1 CARKD (-) 1 cancer cell line human CVCL_SG80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25576; NAXD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121407 CVCL_SG82 HAP1 CARM1 (-) 1 cancer cell line human CVCL_SG82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121408 CVCL_SG81 HAP1 CARKD (-) 2 cancer cell line human CVCL_SG81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25576; NAXD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121409 CVCL_SG84 HAP1 CARM1 (-) 3 cancer cell line human CVCL_SG84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121410 CVCL_SG83 HAP1 CARM1 (-) 2 cancer cell line human CVCL_SG83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23393; CARM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121411 CVCL_SG86 HAP1 CASC3 (-) 2 cancer cell line human CVCL_SG86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17040; CASC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121412 CVCL_SG85 HAP1 CASC3 (-) 1 cancer cell line human CVCL_SG85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17040; CASC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121413 CVCL_SG88 HAP1 CASD1 (-) cancer cell line human CVCL_SG88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16014; CASD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121414 CVCL_SG87 HAP1 CASC3 (-) 3 cancer cell line human CVCL_SG87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17040; CASC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121415 CVCL_SG89 HAP1 CASK (-) cancer cell line human CVCL_SG89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1497; CASK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121416 CVCL_0A50 IOZCAS-Spex-II-A spontaneously immortalized cell line CVCL_0A50 CL:0000010 Derived from sampling site: Fat body. Unspecified Virology: Highly susceptible to infection by Spodoptera exigua nuclear polyhedrosis virus (SeMNPV) (PubMed=19252957) Doubling time: 28 hours (PubMed=19252957) Group: Insect cell line 21121417 CVCL_0A21 Px-E-HNU12 spontaneously immortalized cell line CVCL_0A21 CL:0000010 Unspecified Group: Insect cell line. 21121418 CVCL_0A20 3T3-L1 MBX spontaneously immortalized cell line house mouse CVCL_0A20 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21121419 CVCL_0A23 RKC1-11 spontaneously immortalized cell line CVCL_0A23 CL:0000010 Transfected with: UniProtKB; P67986; Elk prion protein Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Unspecified 21121420 CVCL_0A22 elkRK13 spontaneously immortalized cell line CVCL_0A22 CL:0000010 Transfected with: UniProtKB; P67986; Elk prion protein Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21121421 CVCL_0A25 NEAU-Xc-730E spontaneously immortalized cell line CVCL_0A25 CL:0000010 Unspecified Group: Insect cell line. 21121422 CVCL_0A24 TZM-tfLC3B cancer cell line human CVCL_0A24 CL:0000010 Transfected with: HGNC; 13352; MAP1LC3B; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21121423 CVCL_0A27 SRCF spontaneously immortalized cell line CVCL_0A27 CL:0000010 Miscellaneous: Cell line no longer available; due to technical problems (DOI=10.4194/1303-2712-v21_2_05) Derived from sampling site: Caudal fin. Unspecified Doubling time: 48 hours (PubMed=23545061) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC002 21121424 CVCL_0A26 BRT cancer cell line CVCL_0A26 CL:0000010 Female Doubling time: ~20.64 hours (PubMed=25441618). 21121425 CVCL_0A29 SPH [Human pancreatic adenocarcinoma] cancer cell line human CVCL_0A29 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~35 hours (PubMed=17560620) 21121426 CVCL_0A28 FVMUT-CFMG-1 cancer cell line dog CVCL_0A28 CL:0000010 Breed/subspecies: Terrier. Omics: Proteome analysis by 2D-DE Female Doubling time: 25 hours (PubMed=23375365) 21121427 CVCL_SG71 HAP1 CAMKK2 (-) cancer cell line human CVCL_SG71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1470; CAMKK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121428 CVCL_SG70 HAP1 CAMKK1 (-) 3 cancer cell line human CVCL_SG70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1469; CAMKK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121429 CVCL_SG73 HAP1 CAMKV (-) 2 cancer cell line human CVCL_SG73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28788; CAMKV; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121430 CVCL_SG72 HAP1 CAMKV (-) 1 cancer cell line human CVCL_SG72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28788; CAMKV; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121431 CVCL_SG75 HAP1 CANX (-) 1 cancer cell line human CVCL_SG75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1473; CANX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121432 CVCL_SG74 HAP1 CAMKV (-) 3 cancer cell line human CVCL_SG74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28788; CAMKV; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121433 CVCL_SG77 HAP1 CAPN1 (-) cancer cell line human CVCL_SG77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1476; CAPN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121434 CVCL_SG76 HAP1 CANX (-) 2 cancer cell line human CVCL_SG76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1473; CANX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121435 CVCL_SG79 HAP1 CAPNS1 (-) 2 cancer cell line human CVCL_SG79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1481; CAPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121436 CVCL_SG78 HAP1 CAPNS1 (-) 1 cancer cell line human CVCL_SG78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1481; CAPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121437 CVCL_0A30 mbn-3 spontaneously immortalized cell line fruit fly CVCL_0A30 CL:0000010 Unspecified Group: Insect cell line. 21121438 CVCL_0A32 KB521 transformed cell line house mouse CVCL_0A32 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21121439 CVCL_0A31 KA31 transformed cell line house mouse CVCL_0A31 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21121440 CVCL_0A34 SM25/3 transformed cell line house mouse CVCL_0A34 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; jaw; mandible; condyle; Breed/subspecies: BALB/c. Unspecified Doubling time: 13 hours (PubMed=7570575) 21121441 CVCL_0A33 SM1/9 transformed cell line house mouse CVCL_0A33 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; jaw; mandible; condyle; Breed/subspecies: BALB/c. Unspecified Doubling time: 18 hours (PubMed=7570575) 21121442 CVCL_0A36 Chironomus tentans epithelial cell line spontaneously immortalized cell line CVCL_0A36 CL:0000010 Omics: Genome sequenced; Omics: Transcriptome analysis by ESTs sequencing. Unspecified Group: Insect cell line 21121443 CVCL_0A35 S2-Mt-Fog-myc spontaneously immortalized cell line fruit fly CVCL_0A35 CL:0000010 Transfected with: FlyBase_Gene; FBgn0000719; fog Breed/subspecies: Oregon-R. Male Doubling time: ~24 hours (DGRC) Group: Insect cell line 21121444 CVCL_0A38 ec-r.1 spontaneously immortalized cell line CVCL_0A38 CL:0000010 Unspecified Group: Insect cell line. 21121445 CVCL_0A37 ec-r.0 spontaneously immortalized cell line CVCL_0A37 CL:0000010 Unspecified Group: Insect cell line. 21121446 CVCL_0A39 ec-r.2 spontaneously immortalized cell line CVCL_0A39 CL:0000010 Unspecified Group: Insect cell line. 21121447 CVCL_SG60 HAP1 CALM3 (-) 2 cancer cell line human CVCL_SG60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1449; CALM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121448 CVCL_SG62 HAP1 CALR (-) 2 cancer cell line human CVCL_SG62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121449 CVCL_SG61 HAP1 CALR (-) 1 cancer cell line human CVCL_SG61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121450 CVCL_SG64 HAP1 CAMK1D (-) 1 cancer cell line human CVCL_SG64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19341; CAMK1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121451 CVCL_SG63 HAP1 CALR (-) 3 cancer cell line human CVCL_SG63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1455; CALR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121452 CVCL_SG66 HAP1 CAMK2D (-) cancer cell line human CVCL_SG66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1462; CAMK2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121453 CVCL_SG65 HAP1 CAMK1D (-) 2 cancer cell line human CVCL_SG65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19341; CAMK1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121454 CVCL_SG68 HAP1 CAMKK1 (-) 1 cancer cell line human CVCL_SG68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1469; CAMKK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121455 CVCL_SG67 HAP1 CAMK2G (-) cancer cell line human CVCL_SG67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1463; CAMK2G; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121456 CVCL_SG69 HAP1 CAMKK1 (-) 2 cancer cell line human CVCL_SG69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1469; CAMKK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121457 CVCL_0A01 KIZ-81A finite cell line CVCL_0A01 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Problematic cell line: Misidentified Originally thought to be of tufted deer origin (Elaphodus cephalophus) but seems to be (see ECACC 96011147) from another yet undefined deer species. 21121458 CVCL_0A00 Bm5 spontaneously immortalized cell line CVCL_0A00 CL:0000010 Female Doubling time: 43 +- 1 hours (in static culture), 38 +- 1 hours (in suspension culture) (PubMed=10585188). Group: Insect cell line 21121459 CVCL_0A03 ATCC-BYS0113 induced pluripotent stem cell human CVCL_0A03 CL:0000010 Population: Asian; Derived from sampling site: Bone marrow. Male 21121460 CVCL_0A02 Mshi spontaneously immortalized cell line fruit fly CVCL_0A02 CL:0000010 Discontinued: ECACC; 90070560; probable. Unspecified Group: Insect cell line 21121461 CVCL_0A05 ATCC-BYS0112 induced pluripotent stem cell human CVCL_0A05 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male 21121462 CVCL_0A04 ATCC-BYS0111 induced pluripotent stem cell human CVCL_0A04 CL:0000010 Population: Hispanic; Derived from sampling site: Bone marrow. Male 21121463 CVCL_0A07 ATCC-BXS0116 induced pluripotent stem cell human CVCL_0A07 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Female 21121464 CVCL_0A06 ATCC-BXS0115 induced pluripotent stem cell human CVCL_0A06 CL:0000010 Population: Hispanic; Derived from sampling site: Bone marrow. Female 21121465 CVCL_0A09 HuLEC-1 transformed cell line human CVCL_0A09 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; endothelium Cell type=Lung microvascular endothelial cell.. 21121466 CVCL_0A08 ATCC-BXS0117 induced pluripotent stem cell human CVCL_0A08 CL:0000010 Population: Asian; Derived from sampling site: Bone marrow. Female 21121467 CVCL_SG51 HAP1 CACNB2 (-) 2 cancer cell line human CVCL_SG51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1402; CACNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121468 CVCL_SG50 HAP1 CACNB2 (-) 1 cancer cell line human CVCL_SG50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1402; CACNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121469 CVCL_SG53 HAP1 CACNB3 (-) 2 cancer cell line human CVCL_SG53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1403; CACNB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121470 CVCL_SG52 HAP1 CACNB3 (-) 1 cancer cell line human CVCL_SG52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1403; CACNB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121471 CVCL_SG55 HAP1 CACNB4 (-) 2 cancer cell line human CVCL_SG55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1404; CACNB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121472 CVCL_SG54 HAP1 CACNB4 (-) 1 cancer cell line human CVCL_SG54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1404; CACNB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121473 CVCL_SG57 HAP1 CALM2 (-) 1 cancer cell line human CVCL_SG57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1445; CALM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121474 CVCL_SG56 HAP1 CALB1 (-) 1 cancer cell line human CVCL_SG56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1434; CALB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121475 CVCL_SG59 HAP1 CALM3 (-) 1 cancer cell line human CVCL_SG59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1449; CALM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121476 CVCL_SG58 HAP1 CALM2 (-) 2 cancer cell line human CVCL_SG58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1445; CALM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121477 CVCL_0A10 HuLEC-2 transformed cell line human CVCL_0A10 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; endothelium Cell type=Lung microvascular endothelial cell.. 21121478 CVCL_0A12 HNU-Tn-FB1 spontaneously immortalized cell line CVCL_0A12 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 22.9 hours (CelloPub=CLPUB00222) Group: Insect cell line; Group: Recombinant protein production insect cell line 21121479 CVCL_0A11 HuLEC-5a transformed cell line human CVCL_0A11 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; endothelium Cell type=Lung microvascular endothelial cell.. Male 21121480 CVCL_0A14 QB-Ha-E-1 spontaneously immortalized cell line CVCL_0A14 CL:0000010 Unspecified Doubling time: 63.7 hours (CelloPub=CLPUB00218). Group: Insect cell line 21121481 CVCL_0A13 NEAU-Xc-960716H spontaneously immortalized cell line CVCL_0A13 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: ~63 hours (CelloPub=CLPUB00221) Group: Insect cell line 21121482 CVCL_0A16 QB-Ms1-8 spontaneously immortalized cell line CVCL_0A16 CL:0000010 Unspecified Doubling time: 51 hours (CelloPub=CLPUB00219). Group: Insect cell line 21121483 CVCL_0A15 QB-Ha-E-5 spontaneously immortalized cell line CVCL_0A15 CL:0000010 Unspecified Doubling time: 66.9 hours (CelloPub=CLPUB00218). Group: Insect cell line 21121484 CVCL_0A18 QB-Ms2-7 spontaneously immortalized cell line CVCL_0A18 CL:0000010 Unspecified Doubling time: 49 hours (CelloPub=CLPUB00219). Group: Insect cell line 21121485 CVCL_0A17 QB-Ms2-2 spontaneously immortalized cell line CVCL_0A17 CL:0000010 Unspecified Doubling time: 31 hours (CelloPub=CLPUB00219). Group: Insect cell line; Group: Recombinant protein production insect cell line 21121486 CVCL_0A19 Sp-E-HNU11 spontaneously immortalized cell line CVCL_0A19 CL:0000010 Unspecified Doubling time: 42 hours (DOI=10.16380/j.kcxb.2011.05.007). Group: Insect cell line 21121487 CVCL_SG40 HAP1 C9orf72 (-) 2 cancer cell line human CVCL_SG40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121488 CVCL_SG42 HAP1 CA2 (-) 2 cancer cell line human CVCL_SG42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1373; CA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121489 CVCL_SG41 HAP1 CA2 (-) 1 cancer cell line human CVCL_SG41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1373; CA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121490 CVCL_SG44 HAP1 CACNA1H (-) 1 cancer cell line human CVCL_SG44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1395; CACNA1H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121491 CVCL_SG43 HAP1 CABIN1 (-) 1 cancer cell line human CVCL_SG43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24187; CABIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121492 CVCL_SG46 HAP1 CACNA2D1 (-) cancer cell line human CVCL_SG46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1399; CACNA2D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121493 CVCL_SG45 HAP1 CACNA1H (-) 2 cancer cell line human CVCL_SG45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1395; CACNA1H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121494 CVCL_SG48 HAP1 CACNA2D2 (-) 2 cancer cell line human CVCL_SG48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1400; CACNA2D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121495 CVCL_SG47 HAP1 CACNA2D2 (-) 1 cancer cell line human CVCL_SG47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1400; CACNA2D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121496 CVCL_SG49 HAP1 CACNB1 (-) cancer cell line human CVCL_SG49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1401; CACNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121497 CVCL_B514 253F2 induced pluripotent stem cell human CVCL_B514 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21121498 CVCL_AT14 GM12323 transformed cell line human CVCL_AT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21121499 CVCL_B513 253F1 induced pluripotent stem cell human CVCL_B513 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21121500 CVCL_AT13 GM12029 finite cell line human CVCL_AT13 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg402Trp (c.1204C>T); ClinVar=VCV000002085; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Unspecified 21121501 CVCL_B516 253F4 induced pluripotent stem cell human CVCL_B516 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21121502 CVCL_AT16 GM13936 transformed cell line human CVCL_AT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21121503 CVCL_B515 253F3 induced pluripotent stem cell human CVCL_B515 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21121504 CVCL_AT15 GM12659 finite cell line human CVCL_AT15 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21121505 CVCL_B518 253G1 induced pluripotent stem cell human CVCL_B518 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21121506 CVCL_AT18 GM15756 transformed cell line human CVCL_AT18 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121507 CVCL_B517 253F5 induced pluripotent stem cell human CVCL_B517 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21121508 CVCL_AT17 GM15755 transformed cell line human CVCL_AT17 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121509 CVCL_AT19 GM15757 transformed cell line human CVCL_AT19 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121510 CVCL_B519 HiPS-RIKEN-5A induced pluripotent stem cell human CVCL_B519 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121511 CVCL_8Z80 DD0407 finite cell line human CVCL_8Z80 CL:0000010 Karyotypic information: 46,XY,t(2;13)(q33;q?32) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21121512 CVCL_8Z82 DD0409 transformed cell line human CVCL_8Z82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121513 CVCL_8Z81 DD0408 transformed cell line human CVCL_8Z81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121514 CVCL_AT10 GM10652 finite cell line human CVCL_AT10 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Met191Thr (c.572T>C); ClinVar=VCV000198396; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21121515 CVCL_B510 HiPS-RIKEN-12A induced pluripotent stem cell human CVCL_B510 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21121516 CVCL_AT12 GM12028 finite cell line human CVCL_AT12 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg402Trp (c.1204C>T); ClinVar=VCV000002085; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM12028; probable Unspecified 21121517 CVCL_B512 HiPS-RIKEN-2A induced pluripotent stem cell human CVCL_B512 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21121518 CVCL_AT11 GM10653 finite cell line human CVCL_AT11 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; c.127+48T>C; ClinVar=VCV000255394; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Met191Thr (c.572T>C); ClinVar=VCV000198396; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21121519 CVCL_B511 HiPS-RIKEN-1A induced pluripotent stem cell human CVCL_B511 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21121520 CVCL_8Z77 DD0401 transformed cell line human CVCL_8Z77 CL:0000010 Karyotypic information: 46,XY,t(3;7)(q27;q32); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121521 CVCL_8Z76 DD0400 transformed cell line human CVCL_8Z76 CL:0000010 Karyotypic information: 46,XY,del(18)(q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121522 CVCL_8Z79 DD0406 transformed cell line human CVCL_8Z79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121523 CVCL_8Z78 DD0404 finite cell line human CVCL_8Z78 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21121524 CVCL_8Z73 DD0395 transformed cell line human CVCL_8Z73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121525 CVCL_8Z72 DD0394 transformed cell line human CVCL_8Z72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121526 CVCL_8Z75 DD0399 transformed cell line human CVCL_8Z75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121527 CVCL_8Z74 DD0398 transformed cell line human CVCL_8Z74 CL:0000010 Karyotypic information: 46,XX,t(8;15)(q22;q15); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121528 CVCL_B525 AMC-hES2 embryonic stem cell human CVCL_B525 From: Asan Medical Center; Seoul; South Korea. CL:0000010 Male 21121529 CVCL_AT25 GM15763 transformed cell line human CVCL_AT25 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121530 CVCL_B524 AMC-hES1 embryonic stem cell human CVCL_B524 From: Asan Medical Center; Seoul; South Korea. CL:0000010 Male 21121531 CVCL_AT24 GM15762 transformed cell line human CVCL_AT24 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121532 CVCL_B527 AND-2 embryonic stem cell human CVCL_B527 HLA typing: A*02:01,24:02; B*27:05,40:02; C*02:02,04:01; DQB1*02:01,03:01; DRB1*03:01,11:01 (Spanish_Stem_Cell_Bank). From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121533 CVCL_AT27 GM15765 transformed cell line human CVCL_AT27 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121534 CVCL_B526 AND-1 embryonic stem cell human CVCL_B526 HLA typing: A*24:02,33:01; B*07:02,44:03; C*02:20,07:02; DQB1*03:01,03:01; DRB1*11:01,11:02 (Spanish_Stem_Cell_Bank) From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Omics: Transcriptome analysis by microarray. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121535 CVCL_AT26 GM15764 transformed cell line human CVCL_AT26 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121536 CVCL_AT29 GM15883 transformed cell line human CVCL_AT29 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121537 CVCL_B529 GUCASe001-A embryonic stem cell human CVCL_B529 From: Graduate University of Chinese Academy of Sciences Institute of Zoology; Beijing; China. CL:0000010 Female 21121538 CVCL_B528 AND-3 embryonic stem cell human CVCL_B528 HLA typing: A*01:01,02:01; B*56:01,57:01; C*01:02,07:01; DQB1*02:01,05:01; DRB1*01:01,03:01 (Spanish_Stem_Cell_Bank). From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21121539 CVCL_AT28 GM15766 transformed cell line human CVCL_AT28 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121540 CVCL_8Z91 DD0424 transformed cell line human CVCL_8Z91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121541 CVCL_8Z90 DD0423 transformed cell line human CVCL_8Z90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121542 CVCL_8Z93 DD0426 transformed cell line human CVCL_8Z93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121543 CVCL_8Z92 DD0425 transformed cell line human CVCL_8Z92 CL:0000010 Karyotypic information: 46,XX,var(4) cen; de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121544 CVCL_AT21 GM15759 transformed cell line human CVCL_AT21 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121545 CVCL_AT20 GM15758 transformed cell line human CVCL_AT20 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121546 CVCL_B523 ACT-14 embryonic stem cell human CVCL_B523 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Anecdotal: First human embryonic stem cell line derived in feeder-free conditions. Female 21121547 CVCL_AT23 GM15761 transformed cell line human CVCL_AT23 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21121548 CVCL_B522 29c induced pluripotent stem cell human CVCL_B522 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=18669821) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121549 CVCL_AT22 GM15760 transformed cell line human CVCL_AT22 CL:0000010 Population: Caucasian; Icelandic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21121550 CVCL_8Z88 DD0418 transformed cell line human CVCL_8Z88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121551 CVCL_8Z87 DD0417 transformed cell line human CVCL_8Z87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121552 CVCL_8Z89 DD0422 transformed cell line human CVCL_8Z89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121553 CVCL_8Z84 DD0411 transformed cell line human CVCL_8Z84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121554 CVCL_8Z83 DD0410 transformed cell line human CVCL_8Z83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121555 CVCL_8Z86 DD0416 transformed cell line human CVCL_8Z86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121556 CVCL_8Z85 DD0415 transformed cell line human CVCL_8Z85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121557 CVCL_8Z60 DD0382 transformed cell line human CVCL_8Z60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121558 CVCL_8Z55 DD0377 transformed cell line human CVCL_8Z55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121559 CVCL_8Z54 DD0376 transformed cell line human CVCL_8Z54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121560 CVCL_8Z57 DD0379 transformed cell line human CVCL_8Z57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121561 CVCL_8Z56 DD0378 transformed cell line human CVCL_8Z56 CL:0000010 Karyotypic information: 46,XX,ins(7;18)(q32;q21.1q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121562 CVCL_8Z51 DD0372 transformed cell line human CVCL_8Z51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121563 CVCL_8Z50 DD0371 transformed cell line human CVCL_8Z50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121564 CVCL_8Z53 DD0375 transformed cell line human CVCL_8Z53 CL:0000010 Karyotypic information: 46,XX [22]; 47,XX,+mar(19) [28] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121565 CVCL_8Z52 DD0374 transformed cell line human CVCL_8Z52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121566 CVCL_8Z59 DD0381 transformed cell line human CVCL_8Z59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121567 CVCL_8Z58 DD0380 transformed cell line human CVCL_8Z58 CL:0000010 Karyotypic information: 46,X,fra(X)(q28) 42% FX (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121568 CVCL_AT03 GM03245 finite cell line human CVCL_AT03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121569 CVCL_B503 HFL9t finite cell line human CVCL_B503 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21121570 CVCL_AT02 GM02667 finite cell line human CVCL_AT02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21121571 CVCL_B502 K562 BZQR cancer cell line human CVCL_B502 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90193; NSC-224070 (BZQ; Derived from sampling site: Pleural effusion. Female 21121572 CVCL_AT05 GM04681 finite cell line human CVCL_AT05 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21121573 CVCL_B505 HiPS-1A induced pluripotent stem cell human CVCL_B505 From: Stanford University; Stanford; USA CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21121574 CVCL_AT04 GM03246 transformed cell line human CVCL_AT04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21121575 CVCL_B504 HFSK9t finite cell line human CVCL_B504 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121576 CVCL_AT07 GM05002 finite cell line human CVCL_AT07 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Cys115Tyr (c.344G>A); ClinVar=VCV000863301; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Pro248Leu (c.743C>T); ClinVar=VCV000370244; Zygosity=Heterozygous (Coriell) Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Male 21121577 CVCL_B507 HiPS-1D induced pluripotent stem cell human CVCL_B507 From: Stanford University; Stanford; USA CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21121578 CVCL_AT06 GM04916 transformed cell line human CVCL_AT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21121579 CVCL_B506 HiPS-1C induced pluripotent stem cell human CVCL_B506 From: Stanford University; Stanford; USA CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21121580 CVCL_AT09 GM10650 finite cell line human CVCL_AT09 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; c.127+48T>C; ClinVar=VCV000255394; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21121581 CVCL_B509 HiPS-3D induced pluripotent stem cell human CVCL_B509 From: Stanford University; Stanford; USA CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21121582 CVCL_AT08 GM08147 finite cell line human CVCL_AT08 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh- (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21121583 CVCL_B508 HiPS-2C induced pluripotent stem cell human CVCL_B508 From: Stanford University; Stanford; USA CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21121584 CVCL_8Z71 DD0393 transformed cell line human CVCL_8Z71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121585 CVCL_8Z70 DD0392 transformed cell line human CVCL_8Z70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121586 CVCL_AT01 GM02644 finite cell line human CVCL_AT01 CL:0000010 Population: Caucasian; French; Derived from sampling site: Cell type=Fibroblast. Female 21121587 CVCL_B501 REX cancer cell line human CVCL_B501 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Thr2466Met (c.7397C>T); ClinVar=VCV000241169; Zygosity=Heterozygous (PubMed=15472075). 21121588 CVCL_B500 BSY-2 cancer cell line human CVCL_B500 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21121589 CVCL_AT00 KLC-HSV2 cancer cell line human CVCL_AT00 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Virology: In vitro infected by human herpesvirus 2 (HHV-2) 21121590 CVCL_8Z66 DD0388 transformed cell line human CVCL_8Z66 CL:0000010 Karyotypic information: 46,XY/46,XY,del(18)(pter->q21.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121591 CVCL_8Z65 DD0387 transformed cell line human CVCL_8Z65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121592 CVCL_8Z68 DD0390 transformed cell line human CVCL_8Z68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121593 CVCL_8Z67 DD0389 transformed cell line human CVCL_8Z67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121594 CVCL_8Z62 DD0384 transformed cell line human CVCL_8Z62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121595 CVCL_8Z61 DD0383 transformed cell line human CVCL_8Z61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121596 CVCL_8Z64 DD0386 transformed cell line human CVCL_8Z64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121597 CVCL_8Z63 DD0385 transformed cell line human CVCL_8Z63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121598 CVCL_8Z69 DD0391 transformed cell line human CVCL_8Z69 CL:0000010 Karyotypic information: 46,XY,inv(6)(p21.3?q22),t(6;17)(?q22;q23); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121599 CVCL_8Z33 DD0344 transformed cell line human CVCL_8Z33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121600 CVCL_8Z32 DD0342 transformed cell line human CVCL_8Z32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121601 CVCL_8Z35 DD0350 finite cell line human CVCL_8Z35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21121602 CVCL_8Z34 DD0348 transformed cell line human CVCL_8Z34 CL:0000010 Karyotypic information: 46,XX,t(2;7)(p23.1;p22.1); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121603 CVCL_8Z31 DD0338 transformed cell line human CVCL_8Z31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121604 CVCL_8Z30 DD0337 transformed cell line human CVCL_8Z30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121605 CVCL_8Z37 DD0352 transformed cell line human CVCL_8Z37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121606 CVCL_8Z36 DD0351 transformed cell line human CVCL_8Z36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121607 CVCL_8Z39 DD0357 finite cell line human CVCL_8Z39 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(14) (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21121608 CVCL_8Z38 DD0353 transformed cell line human CVCL_8Z38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121609 CVCL_8Z44 DD0362 transformed cell line human CVCL_8Z44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121610 CVCL_8Z43 DD0361 transformed cell line human CVCL_8Z43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121611 CVCL_8Z46 DD0365 transformed cell line human CVCL_8Z46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121612 CVCL_8Z45 DD0363 transformed cell line human CVCL_8Z45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121613 CVCL_8Z40 DD0358 transformed cell line human CVCL_8Z40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121614 CVCL_8Z42 DD0360 transformed cell line human CVCL_8Z42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121615 CVCL_8Z41 DD0359 transformed cell line human CVCL_8Z41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121616 CVCL_8Z48 DD0367 transformed cell line human CVCL_8Z48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121617 CVCL_8Z47 DD0366 transformed cell line human CVCL_8Z47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121618 CVCL_8Z49 DD0370 finite cell line human CVCL_8Z49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Part of: ECACC chromosomal abnormality collection 21121619 CVCL_0A85 OSCA-26 cancer cell line dog CVCL_0A85 CL:0000010 Breed/subspecies: Rottweiler. Male 21121620 CVCL_0A84 OSCA-24 cancer cell line dog CVCL_0A84 CL:0000010 Breed/subspecies: Golden Retriever. Female 21121621 CVCL_0A87 OSCA-28 cancer cell line dog CVCL_0A87 CL:0000010 Breed/subspecies: Greyhound. Male 21121622 CVCL_0A86 OSCA-27 cancer cell line dog CVCL_0A86 CL:0000010 Breed/subspecies: Irish Setter. Female 21121623 CVCL_0A89 OSCA-35 cancer cell line dog CVCL_0A89 CL:0000010 Breed/subspecies: Rottweiler. Male 21121624 CVCL_0A88 OSCA-31 cancer cell line dog CVCL_0A88 CL:0000010 Breed/subspecies: Rottweiler. Male 21121625 CVCL_8Z11 XP0014 transformed cell line human CVCL_8Z11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121626 CVCL_8Z10 XP0013 transformed cell line human CVCL_8Z10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121627 CVCL_8Z13 MH129P-TC cancer cell line house mouse CVCL_8Z13 CL:0000010 Breed/subspecies: C3H/He. 21121628 CVCL_8Z12 MH129F-TC cancer cell line house mouse CVCL_8Z12 CL:0000010 Breed/subspecies: C3H/He. 21121629 CVCL_8Z19 DD0324 transformed cell line human CVCL_8Z19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121630 CVCL_8Z18 DD0322 finite cell line human CVCL_8Z18 CL:0000010 Karyotypic information: 46,XY,-5,+der(5),t(1;5)(q21;p15); de novo (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21121631 CVCL_8Z15 DD0317 transformed cell line human CVCL_8Z15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121632 CVCL_0A81 OSCA-14 cancer cell line dog CVCL_0A81 CL:0000010 Breed/subspecies: Rottweiler. Female 21121633 CVCL_8Z14 KBM-7/B5-1803 cancer cell line human CVCL_8Z14 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Karyotypic information: Haploid except for a disomy of chromosome 8; Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121634 CVCL_0A80 OSCA-13 cancer cell line dog CVCL_0A80 CL:0000010 Breed/subspecies: Golden Retriever. Male 21121635 CVCL_8Z17 DD0320 finite cell line human CVCL_8Z17 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21121636 CVCL_0A83 OSCA-18 cancer cell line dog CVCL_0A83 CL:0000010 Breed/subspecies: Rottweiler. Male 21121637 CVCL_8Z16 DD0318 finite cell line human CVCL_8Z16 CL:0000010 Karyotypic information: 46,XY,-5,+der(5),t(1;5)(q21;p15); de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21121638 CVCL_0A82 OSCA-15 cancer cell line dog CVCL_0A82 CL:0000010 Breed/subspecies: Rottweiler. Female 21121639 CVCL_0A96 OSCA-44 cancer cell line dog CVCL_0A96 CL:0000010 Breed/subspecies: Leonberger. Male 21121640 CVCL_0A95 OSCA-43 cancer cell line dog CVCL_0A95 CL:0000010 Breed/subspecies: Golden Retriever. Female 21121641 CVCL_0A98 OSCA-47 cancer cell line dog CVCL_0A98 CL:0000010 Breed/subspecies: Irish Setter. Female 21121642 CVCL_0A97 OSCA-46 cancer cell line dog CVCL_0A97 CL:0000010 Breed/subspecies: Rottweiler. Male 21121643 CVCL_0A99 OSCA-48 cancer cell line dog CVCL_0A99 CL:0000010 Breed/subspecies: Rottweiler. Female 21121644 CVCL_8Z22 DD0328 transformed cell line human CVCL_8Z22 CL:0000010 Karyotypic information: 45,X (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121645 CVCL_8Z21 DD0327 transformed cell line human CVCL_8Z21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121646 CVCL_8Z24 DD0330 transformed cell line human CVCL_8Z24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121647 CVCL_8Z23 DD0329 transformed cell line human CVCL_8Z23 CL:0000010 Karyotypic information: 46,XY,t(11;22)(q23;q11)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121648 CVCL_8Z20 DD0325 transformed cell line human CVCL_8Z20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121649 CVCL_8Z29 DD0336 transformed cell line human CVCL_8Z29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121650 CVCL_0A90 OSCA-36 cancer cell line dog CVCL_0A90 CL:0000010 Breed/subspecies: Doberman Pinscher. Male 21121651 CVCL_8Z26 DD0332 transformed cell line human CVCL_8Z26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121652 CVCL_0A92 OSCA-38 cancer cell line dog CVCL_0A92 CL:0000010 Breed/subspecies: Pyrenean mountain dog. Female 21121653 CVCL_8Z25 DD0331 transformed cell line human CVCL_8Z25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121654 CVCL_0A91 OSCA-37 cancer cell line dog CVCL_0A91 CL:0000010 Breed/subspecies: Greyhound. Female 21121655 CVCL_8Z28 DD0335 finite cell line human CVCL_8Z28 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21121656 CVCL_0A94 OSCA-42 cancer cell line dog CVCL_0A94 CL:0000010 Breed/subspecies: Pyrenean mountain dog. Male 21121657 CVCL_8Z27 DD0333 transformed cell line human CVCL_8Z27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121658 CVCL_0A93 OSCA-39 cancer cell line dog CVCL_0A93 CL:0000010 Breed/subspecies: Great Dane. Female 21121659 CVCL_AS73 TH202 cancer cell line human CVCL_AS73 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21121660 CVCL_B473 TL-Om1 cancer cell line human CVCL_B473 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Biotechnology: Used as a reference cell line to standardize the qPCR of HTLV-1 (PubMed=25502533; PubMed=30125970) Discontinued: RCB; RCB2086; true Male Characteristics: IL2 dependent; Virology: The HTLV-1 provirus is monoclonally integrated in chromosome 1 (PubMed=25502533) 21121661 CVCL_AS72 MIN22i-33113.2I induced pluripotent stem cell human CVCL_AS72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121662 CVCL_B472 TGBG3 cancer cell line human CVCL_B472 CL:0000010 Population: Japanese. Female 21121663 CVCL_AS75 DU145/RC0.1 cancer cell line human CVCL_AS75 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg364His (c.1091G>A); Zygosity=Homozygous (PubMed=11280753); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90225; Rubitecan (Orathecin; Derived from metastatic site: Brain. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21121664 CVCL_B475 TR170 cancer cell line human CVCL_B475 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 31 +- 2 hours (PubMed=3804493) 21121665 CVCL_AS74 786-O/Luc cancer cell line human CVCL_AS74 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (pRev_CMV_Luc2) Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21121666 CVCL_B474 TR14 cancer cell line human CVCL_B474 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 3 days (PubMed=6861117) 21121667 CVCL_AS77 HLSC somatic stem cell human CVCL_AS77 CL:0000010 Discontinued: Ximbio; 152715; probable. 21121668 CVCL_B477 TSG11 cancer cell line human CVCL_B477 CL:0000010 Population: Japanese Omics: Transcriptome analysis by microarray Female Part of: JFCR45 cancer cell line panel 21121669 CVCL_AS76 RL159 cancer cell line human CVCL_AS76 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21121670 CVCL_B476 TR175 cancer cell line human CVCL_B476 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 34 +- 1 hours (PubMed=3804493) 21121671 CVCL_AS79 HLSC SH2 somatic stem cell human CVCL_AS79 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 6876; MAPK14 Discontinued: Ximbio; 152717; probable. 21121672 CVCL_B479 UV-2237M cancer cell line house mouse CVCL_B479 CL:0000010 Breed/subspecies: C3H/HeN. Female 21121673 CVCL_AS78 HLSC SH3 somatic stem cell human CVCL_AS78 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 6876; MAPK14 Discontinued: Ximbio; 152716; probable. 21121674 CVCL_B478 TZM-bl cancer cell line human CVCL_B478 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21121675 CVCL_JM07 TIN2 F/F transformed cell line house mouse CVCL_JM07 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 1st coding exon of mouse Terf1 gene Terf1 knockout can be effected by transduction of Cre recombinase into the cell line. 21121676 CVCL_JM06 POT1a F/F transformed cell line house mouse CVCL_JM06 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 3rd coding exon of mouse Pot1a gene Pot1a knockout can be effected by transduction of Cre recombinase into the cell line. 21121677 CVCL_JM09 GM03130 finite cell line human CVCL_JM09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121678 CVCL_JM08 GM03129 finite cell line human CVCL_JM08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121679 CVCL_JM03 B11UVres transformed cell line CVCL_JM03 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female Doubling time: 27 hours (PubMed=8603488) 21121680 CVCL_JM02 AME-1 [Gastric carcinoma] cancer cell line human CVCL_JM02 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male Characteristics: Produces high level of AFP 21121681 CVCL_JM05 FVAF1 cancer cell line CVCL_JM05 CL:0000010 Unspecified 21121682 CVCL_AS71 MIN21i-34363.B induced pluripotent stem cell human CVCL_AS71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121683 CVCL_B471 TAMH spontaneously immortalized cell line house mouse CVCL_B471 CL:0000010 Karyotypic information: Quasi-tetraploid karyotype; Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: CD-1 MT42 transgenic. Male Doubling time: 15 hours (PubMed=7525051) 21121684 CVCL_JM04 BEL-A transformed cell line human CVCL_JM04 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Unspecified Characteristics: Differentiates efficiently into mature, functional reticulocytes Doubling time: 20 hours (PubMed=28290447); 18.7 +- 2.0 hours (PubMed=31753923) 21121685 CVCL_AS70 MIN20i-34363.A induced pluripotent stem cell human CVCL_AS70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121686 CVCL_B470 SU-CCS-1 cancer cell line human CVCL_B470 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=7753552; PubMed=15150091) Derived from metastatic site: Pleural effusion. Female Doubling time: ~52 hours (PubMed=6362860) 21121687 CVCL_JM01 KU-9 cancer cell line human CVCL_JM01 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=9738976) Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Retroperitoneal space. Male Doubling time: ~50 hours (PubMed=8636006) 21121688 CVCL_JM00 K-562-GFP cancer cell line human CVCL_JM00 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Stably expresses GFP under the control of the human EF-1 alpha promoter Doubling time: 18-24 hours (ATCC=CCL-243-GFP) 21121689 CVCL_AS84 HBEC34-KT telomerase immortalized cell line human CVCL_AS84 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21121690 CVCL_B484 Yumoto cancer cell line human CVCL_B484 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281His (c.841G>C); ClinVar=VCV000376588; Zygosity=Homozygous (PubMed=9790785). Female Doubling time: ~65 hours (PubMed=9790785) 21121691 CVCL_AS83 HBEC30-KT telomerase immortalized cell line human CVCL_AS83 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21121692 CVCL_B483 YULAC cancer cell line human CVCL_B483 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=20149136) Derived from metastatic site: Neck; hypodermis. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Yale University (YU) melanoma cell collection 21121693 CVCL_AS86 MPC-1 conditionally immortalized cell line house mouse CVCL_AS86 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21121694 CVCL_B486 YUROB cancer cell line human CVCL_B486 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Abdominal wall. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Yale University (YU) melanoma cell collection 21121695 CVCL_AS85 CHO-ICAM-1Fc spontaneously immortalized cell line CVCL_AS85 CL:0000010 Transfected with: HGNC; 5344; ICAM1 (five extracellular domains joined to the hinge, CH2 and CH3 domains of IgG1) Derived from sampling site: Ovary. Female 21121696 CVCL_B485 YURIF cancer cell line human CVCL_B485 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Thigh; hypodermis. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21121697 CVCL_AS88 MPC-8 conditionally immortalized cell line house mouse CVCL_AS88 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21121698 CVCL_B488 Plat-E transformed cell line human CVCL_B488 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121699 CVCL_AS87 MPC-5 conditionally immortalized cell line house mouse CVCL_AS87 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21121700 CVCL_B487 YUSIK cancer cell line human CVCL_B487 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21121701 CVCL_AS89 BC-M1 [Human breast carcinoma Taiwan] cancer cell line human CVCL_AS89 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Breast. Female Doubling time: 32 hours (PubMed=8083436) 21121702 CVCL_B489 Plat-A transformed cell line human CVCL_B489 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121703 CVCL_JM18 WTC-mEGFP-TJP1-cl20 induced pluripotent stem cell human CVCL_JM18 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 TJP1 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21121704 CVCL_JM17 WTC-mEGFP-FBL-cl6 induced pluripotent stem cell human CVCL_JM17 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 FBL has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21121705 CVCL_JM19 WTC-mEGFP-Safe harbor locus (AAVS1)-cl6 induced pluripotent stem cell human CVCL_JM19 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 mEGFP under the control of a CAG promoter was inserted into one allele of the AAVS1 safe harbor locus Part of: Allen Cell Collection 21121706 CVCL_AS80 HLSC PGK-EGFP somatic stem cell human CVCL_AS80 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Discontinued: Ximbio; 152718; probable. 21121707 CVCL_B480 VL-68 cancer cell line human CVCL_B480 CL:0000010 21121708 CVCL_JM14 WTC-mEGFP-SEC61B-cl55 induced pluripotent stem cell human CVCL_JM14 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 SEC61B has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21121709 CVCL_JM13 XP1KY finite cell line human CVCL_JM13 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121710 CVCL_AS82 MEF PKCe KO KI spontaneously immortalized cell line house mouse CVCL_AS82 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97599; Prkce; Transfected with: MGI; MGI:97599; Prkce Derived from sampling site: Cell type=Fibroblast. Unspecified 21121711 CVCL_JM16 WTC-mEGFP-ACTB-cl184 induced pluripotent stem cell human CVCL_JM16 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 ACTB has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21121712 CVCL_B482 YD-39 cancer cell line human CVCL_B482 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro27_Ser37del; Zygosity=Unspecified (PubMed=22776128). Population: Korean Male Doubling time: 23.8 +- 2.1 hours (PubMed=22621906) 21121713 CVCL_AS81 MEF PKCe KO spontaneously immortalized cell line house mouse CVCL_AS81 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97599; Prkce Derived from sampling site: Cell type=Fibroblast. Unspecified 21121714 CVCL_B481 WILTU-1 cancer cell line human CVCL_B481 CL:0000010 Discontinued: ATCC; HTB-50; probable. 21121715 CVCL_JM15 WTC-mEGFP-MYH10-cl80 induced pluripotent stem cell human CVCL_JM15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 MYH10 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21121716 CVCL_JM10 HuE 13 finite cell line human CVCL_JM10 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified 21121717 CVCL_JM12 RSb transformed cell line human CVCL_JM12 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified Doubling time: 40-48 hours (PubMed=186619) 21121718 CVCL_JM11 RSa transformed cell line human CVCL_JM11 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified 21121719 CVCL_AS59 MIN09i-33114.C induced pluripotent stem cell human CVCL_AS59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121720 CVCL_B459 RM-1 [Mouse prostate carcinoma] cancer cell line house mouse CVCL_B459 CL:0000010 Transformant: Recombinant retrovirus Zipras/myc9 (v-Ha-Ras and v-Myc); Derived from sampling site: Embryonic prostate; Breed/subspecies: C57BL/6. Male 21121721 CVCL_AS58 MIN08i-33114.B induced pluripotent stem cell human CVCL_AS58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; min08i-33114-b; true Male 21121722 CVCL_B458 PDSS-26 cancer cell line human CVCL_B458 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=14553945). Female Doubling time: ~72 hours, at 25-30th passages (PubMed=14553945) 21121723 CVCL_AS51 MIN01i-32517.A induced pluripotent stem cell human CVCL_AS51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121724 CVCL_B451 OX-CO-1 cancer cell line human CVCL_B451 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=25926053) 21121725 CVCL_B450 OHS cancer cell line human CVCL_B450 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Unspecified (PubMed=19787792) Population: Caucasian; Derived from sampling site: Bone; distal femur. Male 21121726 CVCL_AS50 Zeng02i-iPSH14 induced pluripotent stem cell human CVCL_AS50 CL:0000010 Male 21121727 CVCL_AS53 MIN03i-32642.B induced pluripotent stem cell human CVCL_AS53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121728 CVCL_B453 P1798 cancer cell line house mouse CVCL_B453 CL:0000010 Doubling time: 20-24 hours (PubMed=6892700). 21121729 CVCL_AS52 MIN02i-32517.B induced pluripotent stem cell human CVCL_AS52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121730 CVCL_B452 OX-CO-3 cancer cell line human CVCL_B452 CL:0000010 Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=25926053) 21121731 CVCL_AS55 MIN05i-33110.2F induced pluripotent stem cell human CVCL_AS55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121732 CVCL_B455 PAN-07-JCK cancer cell line human CVCL_B455 CL:0000010 Population: Japanese. 21121733 CVCL_AS54 MIN04i-33109.2B induced pluripotent stem cell human CVCL_AS54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121734 CVCL_B454 PAN-03-JCK cancer cell line human CVCL_B454 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Hemizygous (PubMed=11115575); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Gly (c.844C>G); ClinVar=VCV000140821; Zygosity=Unspecified (PubMed=11115575). Population: Japanese 21121735 CVCL_AS57 MIN07i-33113.2D induced pluripotent stem cell human CVCL_AS57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; min07i-33113-2d; true Male 21121736 CVCL_B457 PAN-09-JCK cancer cell line human CVCL_B457 CL:0000010 Population: Japanese. 21121737 CVCL_AS56 MIN06i-33110.2H induced pluripotent stem cell human CVCL_AS56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121738 CVCL_B456 PAN-08-JCK cancer cell line human CVCL_B456 CL:0000010 Population: Japanese. 21121739 CVCL_AS69 MIN19i-33811.D induced pluripotent stem cell human CVCL_AS69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121740 CVCL_B469 STA-BT-6 cancer cell line human CVCL_B469 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21121741 CVCL_AS62 MIN12i-33362.C induced pluripotent stem cell human CVCL_AS62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121742 CVCL_B462 SCKO-1 cancer cell line human CVCL_B462 CL:0000010 21121743 CVCL_AS61 MIN11i-33360.B induced pluripotent stem cell human CVCL_AS61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121744 CVCL_B461 RM-9 cancer cell line house mouse CVCL_B461 CL:0000010 Transformant: Recombinant retrovirus Zipras/myc9 (v-Ha-Ras and v-Myc); Derived from sampling site: Embryonic prostate; Breed/subspecies: C57BL/6. Male 21121745 CVCL_AS64 MIN14i-33363.C induced pluripotent stem cell human CVCL_AS64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121746 CVCL_B464 SOJ cancer cell line human CVCL_B464 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 50-70 hours (PubMed=2083222) 21121747 CVCL_AS63 MIN13i-33362.D induced pluripotent stem cell human CVCL_AS63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121748 CVCL_B463 SJ3.6 conditionally immortalized cell line house mouse CVCL_B463 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.; Breed/subspecies: SJL/J. Unspecified 21121749 CVCL_AS66 MIN16i-33808.A induced pluripotent stem cell human CVCL_AS66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121750 CVCL_B466 STA-BT-1 cancer cell line human CVCL_B466 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21121751 CVCL_AS65 MIN15i-33363.D induced pluripotent stem cell human CVCL_AS65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121752 CVCL_B465 SOJ-6 cancer cell line human CVCL_B465 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 40-50 hours (PubMed=2083222) 21121753 CVCL_AS68 MIN18i-33811.A induced pluripotent stem cell human CVCL_AS68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121754 CVCL_B468 STA-BT-3 cancer cell line human CVCL_B468 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21121755 CVCL_AS67 MIN17i-33808.B induced pluripotent stem cell human CVCL_AS67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; min17i-33808-b; true Male 21121756 CVCL_B467 STA-BT-15 cancer cell line human CVCL_B467 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21121757 CVCL_AS60 MIN10i-33360.A induced pluripotent stem cell human CVCL_AS60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121758 CVCL_B460 RM-2 [Mouse prostate carcinoma] cancer cell line house mouse CVCL_B460 CL:0000010 Transformant: Recombinant retrovirus Zipras/myc9 (v-Ha-Ras and v-Myc); Derived from sampling site: Embryonic prostate; Breed/subspecies: C57BL/6. Male 21121759 CVCL_AS37 JFMD2 induced pluripotent stem cell human CVCL_AS37 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121760 CVCL_B437 NC 14.3.36 transformed cell line house mouse CVCL_B437 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121761 CVCL_AS36 JFMD1 induced pluripotent stem cell human CVCL_AS36 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121762 CVCL_B436 NB2a/d1 cancer cell line house mouse CVCL_B436 CL:0000010 Breed/subspecies: A/J. Male 21121763 CVCL_AS39 JFMD4 induced pluripotent stem cell human CVCL_AS39 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121764 CVCL_B439 NC 14.4.6E transformed cell line house mouse CVCL_B439 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121765 CVCL_AS38 JFMD3 induced pluripotent stem cell human CVCL_AS38 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121766 CVCL_B438 NC 14.3.3G transformed cell line house mouse CVCL_B438 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121767 CVCL_AS31 GREG spontaneously immortalized cell line house mouse CVCL_AS31 CL:0000010 Sequence variation: Mutation; MGI; MGI:1349385; Dysf; Unexplicit; retrotransposon insertion in intron 4; Zygosity=Homozygous (PubMed=22020321) Derived from sampling site: Thigh; skeletal muscle Cell type=Myoblast.; Breed/subspecies: A/J. Unspecified Characteristics: Dysferlin-deficient myogenic cell line (PubMed=22020321) Doubling time: 34.5 +- 1.2 hours (at 20th passage), 18.6 +- 0.2 (at 40th passage) (PubMed=22020321) 21121768 CVCL_B431 MM48 cancer cell line house mouse CVCL_B431 CL:0000010 Breed/subspecies: C3H/He. Female 21121769 CVCL_AS30 BDEsp spontaneously immortalized cell line Norway rat CVCL_AS30 CL:0000010 Derived from sampling site: Bile duct Cell type=Cholangiocyte.; Breed/subspecies: Fischer 344. Male Characteristics: Spontaneous neoplastically transformed cholangiocytes capable of forming tumors after cell transplantation into the liver of isogenic rats Doubling time: ~20 hours (PubMed=18081149) 21121770 CVCL_B430 MM47 cancer cell line house mouse CVCL_B430 CL:0000010 Breed/subspecies: C3H/He. Female 21121771 CVCL_AS33 JFHZ1 induced pluripotent stem cell human CVCL_AS33 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: WiCell; jfhz1; true Male 21121772 CVCL_B433 MYB 2-3.76 hybridoma house mouse CVCL_B433 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01104; Avian myeloblastosis virus v-Myb (Note=Also reacts with chicken MYB). 21121773 CVCL_AS32 C2C12 Clone 5 DYSF shRNA spontaneously immortalized cell line house mouse CVCL_AS32 CL:0000010 Knockout cell: Method=shRNA knockdown; MGI; MGI:1349385; Dysf Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Doubling time: 48-72 hours (ATCC=CRL-3418) 21121774 CVCL_B432 MTT-95 cancer cell line human CVCL_B432 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21121775 CVCL_AS35 JFHZ3 induced pluripotent stem cell human CVCL_AS35 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21121776 CVCL_B435 MYB 2-7.77 hybridoma house mouse CVCL_B435 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01104; Avian myeloblastosis virus v-Myb (Note=Also reacts with chicken MYB). 21121777 CVCL_AS34 JFHZ2 induced pluripotent stem cell human CVCL_AS34 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21121778 CVCL_B434 MYB 2-37.63 hybridoma house mouse CVCL_B434 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01104; Avian myeloblastosis virus v-Myb (Note=Also reacts with chicken MYB). 21121779 CVCL_8Y99 TT0237 transformed cell line human CVCL_8Y99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91062105; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121780 CVCL_8Y96 TT0210 transformed cell line human CVCL_8Y96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91042503; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121781 CVCL_8Y95 TT0209 transformed cell line human CVCL_8Y95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91042502; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121782 CVCL_8Y98 TT0212 transformed cell line human CVCL_8Y98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91042505; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121783 CVCL_8Y97 TT0211 transformed cell line human CVCL_8Y97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91042504; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121784 CVCL_AS48 JFWT3 induced pluripotent stem cell human CVCL_AS48 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21121785 CVCL_B448 NHEM693 finite cell line human CVCL_B448 From: BioWhittaker (now part of Lonza); Walkersville; USA CL:0000010 Derived from sampling site: Cell type=Melanocyte. 21121786 CVCL_AS47 JFWT2 induced pluripotent stem cell human CVCL_AS47 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21121787 CVCL_B447 NHEM2493 finite cell line human CVCL_B447 From: BioWhittaker (now part of Lonza); Walkersville; USA CL:0000010 Derived from sampling site: Cell type=Melanocyte. 21121788 CVCL_B449 NPLC/PRF/5 cancer cell line human CVCL_B449 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21121789 CVCL_AS49 Zeng01i-iPSH9 induced pluripotent stem cell human CVCL_AS49 CL:0000010 Female 21121790 CVCL_AS40 JFMD5 induced pluripotent stem cell human CVCL_AS40 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121791 CVCL_B440 NC 14.4.8 transformed cell line house mouse CVCL_B440 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121792 CVCL_AS42 JFRBi1 induced pluripotent stem cell human CVCL_AS42 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121793 CVCL_B442 NC 14.9.1 transformed cell line house mouse CVCL_B442 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121794 CVCL_AS41 JFNY1 induced pluripotent stem cell human CVCL_AS41 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser1173Phefs*2 (c.3517dupT) (p.Ser1191Phefs*2, c.3571dupT); ClinVar=VCV000370730; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21121795 CVCL_B441 NC 14.4.9D transformed cell line house mouse CVCL_B441 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121796 CVCL_AS44 JFRBi3 induced pluripotent stem cell human CVCL_AS44 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121797 CVCL_B444 NC 14.9.8 transformed cell line house mouse CVCL_B444 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121798 CVCL_AS43 JFRBi2 induced pluripotent stem cell human CVCL_AS43 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121799 CVCL_B443 NC 14.9.10 transformed cell line house mouse CVCL_B443 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121800 CVCL_AS46 JFWT1 induced pluripotent stem cell human CVCL_AS46 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21121801 CVCL_B446 NC 15.2.56 transformed cell line house mouse CVCL_B446 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121802 CVCL_AS45 JFRBi4 induced pluripotent stem cell human CVCL_AS45 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21121803 CVCL_B445 NC 15.2.10H transformed cell line house mouse CVCL_B445 CL:0000010 Transformant: N-Myc+c-Myc; Derived from sampling site: Neural crest; Breed/subspecies: CBA. Unspecified 21121804 CVCL_AS15 Hepa1-3xFlag-AhR-HA-pCEP4(CAG)H12C1 cancer cell line house mouse CVCL_AS15 CL:0000010 Transfected with: MGI; MGI:105043; Ahr (with 3xFLAG and HA tags) Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21121805 CVCL_B415 M19-MEL cancer cell line human CVCL_B415 CL:0000010 Doubling time: 35 hours (PubMed=7718330); 24 hours (PubMed=9488600). 21121806 CVCL_AS14 Hepa1-cl19E4 cancer cell line house mouse CVCL_AS14 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Aryl hydrocarbon receptor deficient mutant (TKG) 21121807 CVCL_B414 LNCaP-34 cancer cell line human CVCL_B414 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 5155; HPN Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21121808 CVCL_B417 M9A cancer cell line house mouse CVCL_B417 CL:0000010 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21121809 CVCL_AS17 PhIP12-1 cancer cell line Norway rat CVCL_AS17 CL:0000010 Transformant: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)(ChEBI; CHEBI:76290); Breed/subspecies: Fischer 344 x Sprague Dawley. Female 21121810 CVCL_AS16 DI8 hybridoma house mouse CVCL_AS16 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:26829; Sulfoglycolipid. 21121811 CVCL_B416 M26 cancer cell line human CVCL_B416 CL:0000010 Unspecified 21121812 CVCL_B419 MBA-13 stromal cell line house mouse CVCL_B419 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Nude ICR. Unspecified Doubling time: 20 hours (PubMed=2981238) 21121813 CVCL_AS19 SL-1-TC cancer cell line Norway rat CVCL_AS19 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: ACI/N. 21121814 CVCL_B418 MBA-1 stromal cell line house mouse CVCL_B418 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: SJL/J. Unspecified Doubling time: 17 hours (PubMed=2981238) 21121815 CVCL_AS18 PhIP7-4 cancer cell line Norway rat CVCL_AS18 CL:0000010 Transformant: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP)(ChEBI; CHEBI:76290); Breed/subspecies: Fischer 344 x Sprague Dawley. Female 21121816 CVCL_8Y81 TT0114 transformed cell line human CVCL_8Y81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90062724; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121817 CVCL_8Y80 TT0113 transformed cell line human CVCL_8Y80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90062723; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121818 CVCL_8Y83 TT0122 transformed cell line human CVCL_8Y83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90081619; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121819 CVCL_8Y82 TT0115 transformed cell line human CVCL_8Y82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90062725; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121820 CVCL_AS11 ISO-HAS-B cancer cell line human CVCL_AS11 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser240Arg (c.720T>A); ClinVar=VCV001504304; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Ear; skin. Male 21121821 CVCL_B411 JA-1 cancer cell line human CVCL_B411 CL:0000010 Female Doubling time: 32 +- 2 hours (PubMed=3804493). 21121822 CVCL_AS10 HCT 116 BRCA2(-/-) clone 42 cancer cell line human CVCL_AS10 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1101; BRCA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21121823 CVCL_B410 IIB-BR-G cancer cell line human CVCL_B410 CL:0000010 Derived from sampling site: Breast. Female Doubling time: ~30 hours (PubMed=1661624) 21121824 CVCL_B413 LNCaP-17 cancer cell line human CVCL_B413 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 5155; HPN Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21121825 CVCL_AS13 Seki cancer cell line human CVCL_AS13 CL:0000010 Population: Japanese Male Doubling time: 36.3 hours (PubMed=2486607). 21121826 CVCL_B412 KPD cancer cell line human CVCL_B412 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; femur. Male Caution: Indicated as originating from a 7 year old female patient in PubMed=19787792 and from a 8 year old male patient in PubMed=17354236 The STR profile has Amelogenin X,Y. 21121827 CVCL_AS12 MO-LAS-B cancer cell line human CVCL_AS12 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21121828 CVCL_8Y78 TT0111 transformed cell line human CVCL_8Y78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90062721; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121829 CVCL_8Y77 QQ0706 transformed cell line human CVCL_8Y77 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(9;18)(q32;q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121830 CVCL_8Y79 TT0112 transformed cell line human CVCL_8Y79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90062722; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121831 CVCL_8Y74 QQ0662 transformed cell line human CVCL_8Y74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121832 CVCL_8Y73 QQ0661 transformed cell line human CVCL_8Y73 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(11)(p13:p14.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21121833 CVCL_8Y76 QQ0703 transformed cell line human CVCL_8Y76 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,(6;9)(p21;q21.2) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121834 CVCL_8Y75 QQ0663 transformed cell line human CVCL_8Y75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21121835 CVCL_AS26 iPS NIHi12 induced pluripotent stem cell human CVCL_AS26 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121836 CVCL_B426 MHM cancer cell line human CVCL_B426 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; pelvis. Female 21121837 CVCL_AS25 iPS NIHi5 induced pluripotent stem cell human CVCL_AS25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121838 CVCL_B425 Mel-Ab spontaneously immortalized cell line house mouse CVCL_B425 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Produces copious amounts of melanin in culture 21121839 CVCL_AS28 BDE1 spontaneously immortalized cell line Norway rat CVCL_AS28 CL:0000010 Derived from sampling site: Bile duct Cell type=Cholangiocyte.; Breed/subspecies: Fischer 344. Male Doubling time: ~25 hours (PubMed=18081149) 21121840 CVCL_B428 MM2 cancer cell line house mouse CVCL_B428 CL:0000010 Breed/subspecies: C3H/He. Female 21121841 CVCL_AS27 iPS NIHi13 induced pluripotent stem cell human CVCL_AS27 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121842 CVCL_B427 MM102-TC cancer cell line house mouse CVCL_B427 CL:0000010 Breed/subspecies: C3H/He. Female 21121843 CVCL_AS29 BDEneu transformed cell line Norway rat CVCL_AS29 CL:0000010 Transfected with: RGD; 2561; Erbb2 (with p.Val661Glu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated Erbb2/neu; Derived from sampling site: Bile duct Cell type=Cholangiocyte.; Breed/subspecies: Fischer 344. Male Doubling time: ~17-19 hours (PubMed=18081149) 21121844 CVCL_B429 MM46 [Mouse mammary carcinoma] cancer cell line house mouse CVCL_B429 CL:0000010 Discontinued: RCB; RCB2617; true. Female Caution: Not from strain C3H/He as originally assigned but from a NIH Swiss strain derivative (DOI=10.4051/ibc.2010.2.4.0014) 21121845 CVCL_8Y92 TT0201 transformed cell line human CVCL_8Y92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91032620; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121846 CVCL_8Y91 TT0165 transformed cell line human CVCL_8Y91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91020702; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121847 CVCL_AS20 HT2 [Mouse hybridoma against human HERPUD1] hybridoma house mouse CVCL_AS20 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15011; Human HERPUD1. 21121848 CVCL_B420 MBA-14 stromal cell line house mouse CVCL_B420 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified 21121849 CVCL_8Y94 TT0208 transformed cell line human CVCL_8Y94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91042501; true Female Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121850 CVCL_8Y93 TT0202 transformed cell line human CVCL_8Y93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91032621; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121851 CVCL_AS22 iPS NIHi1 induced pluripotent stem cell human CVCL_AS22 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121852 CVCL_B422 MBA-2 stromal cell line house mouse CVCL_B422 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: RF/J. Unspecified Doubling time: 26-48 hours (PubMed=2981238) 21121853 CVCL_B421 MBA-15 stromal cell line house mouse CVCL_B421 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: SJL/J. Unspecified Doubling time: 19 hours (PubMed=2981238) 21121854 CVCL_AS21 Pre2.8 conditionally immortalized cell line human CVCL_AS21 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: At the permissive temperature (33 Celsius) proliferates At the restrictive temperature (39 Celsius) proliferation ceases and the cells undergo morphological changes consistent with the early stages of differentiation. 21121855 CVCL_AS24 iPS NIHi4 induced pluripotent stem cell human CVCL_AS24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121856 CVCL_B424 MBA-2.4 stromal cell line house mouse CVCL_B424 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: RF/J. Unspecified 21121857 CVCL_8Y90 TT0164 transformed cell line human CVCL_8Y90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91020701; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121858 CVCL_AS23 iPS NIHi2 induced pluripotent stem cell human CVCL_AS23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121859 CVCL_B423 MBA-2.1 stromal cell line house mouse CVCL_B423 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: RF/J. Unspecified 21121860 CVCL_8Y89 TT0155 transformed cell line human CVCL_8Y89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012415; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121861 CVCL_8Y88 TT0154 transformed cell line human CVCL_8Y88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012414; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121862 CVCL_8Y85 TT0150 transformed cell line human CVCL_8Y85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012410; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121863 CVCL_8Y84 TT0148 transformed cell line human CVCL_8Y84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012408; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121864 CVCL_8Y87 TT0153 transformed cell line human CVCL_8Y87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012413; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121865 CVCL_8Y86 TT0151 transformed cell line human CVCL_8Y86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91012411; true Male Part of: ECACC chromosomal abnormality collection Caution: Was removed from the ECACC collection on demand of the person that established that cell line 21121866 CVCL_JM90 HPSI0214i-fiau_2 induced pluripotent stem cell human CVCL_JM90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121867 CVCL_JM92 HPSI0214i-heja_3 induced pluripotent stem cell human CVCL_JM92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121868 CVCL_JM91 HPSI0214i-fiau_3 induced pluripotent stem cell human CVCL_JM91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121869 CVCL_SG31 HAP1 C5 (-) 1 cancer cell line human CVCL_SG31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1331; C5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121870 CVCL_SG30 HAP1 C3orf33 (-) 1 cancer cell line human CVCL_SG30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26434; C3orf33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121871 CVCL_SG33 HAP1 C6orf203 (-) 1 cancer cell line human CVCL_SG33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17971; MTRES1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121872 CVCL_SG32 HAP1 C5 (-) 2 cancer cell line human CVCL_SG32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1331; C5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121873 CVCL_SG35 HAP1 C7orf49 (-) 1 cancer cell line human CVCL_SG35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22432; CYREN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121874 CVCL_JM87 HPSI0213i-nawk_44 induced pluripotent stem cell human CVCL_JM87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121875 CVCL_SG34 HAP1 C6orf203 (-) 2 cancer cell line human CVCL_SG34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17971; MTRES1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121876 CVCL_JM86 HPSI0115i-uolo_1 induced pluripotent stem cell human CVCL_JM86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121877 CVCL_SG37 HAP1 C9orf142 (-) 1 cancer cell line human CVCL_SG37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27849; PAXX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121878 CVCL_JM89 HPSI0214i-datg_1 induced pluripotent stem cell human CVCL_JM89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121879 CVCL_SG36 HAP1 C7orf49 (-) 2 cancer cell line human CVCL_SG36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22432; CYREN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121880 CVCL_JM88 HPSI0213i-nawk_66 induced pluripotent stem cell human CVCL_JM88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121881 CVCL_SG39 HAP1 C9orf72 (-) 1 cancer cell line human CVCL_SG39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121882 CVCL_JM83 HPSI0114i-zapk_1 induced pluripotent stem cell human CVCL_JM83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121883 CVCL_SG38 HAP1 C9orf142 (-) 2 cancer cell line human CVCL_SG38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27849; PAXX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121884 CVCL_JM82 HPSI0114i-wegi_2 induced pluripotent stem cell human CVCL_JM82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121885 CVCL_JM85 HPSI0114i-zoxy_2 induced pluripotent stem cell human CVCL_JM85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121886 CVCL_JM84 HPSI0114i-zoxy_1 induced pluripotent stem cell human CVCL_JM84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121887 CVCL_SG20 HAP1 C1orf115 (-) 2 cancer cell line human CVCL_SG20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25873; C1orf115; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121888 CVCL_SG22 HAP1 C1orf115 (-) 4 cancer cell line human CVCL_SG22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25873; C1orf115; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121889 CVCL_SG21 HAP1 C1orf115 (-) 3 cancer cell line human CVCL_SG21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25873; C1orf115; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121890 CVCL_SG24 HAP1 C1orf43 (-) 2 cancer cell line human CVCL_SG24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29876; C1orf43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121891 CVCL_JM98 HPSI0313i-fecs_2 induced pluripotent stem cell human CVCL_JM98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121892 CVCL_SG23 HAP1 C1orf43 (-) 1 cancer cell line human CVCL_SG23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29876; C1orf43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121893 CVCL_JM97 HPSI0313i-airc_55 induced pluripotent stem cell human CVCL_JM97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121894 CVCL_SG26 HAP1 C1orf43 (-) 4 cancer cell line human CVCL_SG26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29876; C1orf43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121895 CVCL_SG25 HAP1 C1orf43 (-) 3 cancer cell line human CVCL_SG25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29876; C1orf43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121896 CVCL_JM99 HPSI0313i-xovo_3 induced pluripotent stem cell human CVCL_JM99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121897 CVCL_SG28 HAP1 C20orf24 (-) 1 cancer cell line human CVCL_SG28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15870; RAB5IF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121898 CVCL_JM94 HPSI0313i-airc_1 induced pluripotent stem cell human CVCL_JM94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121899 CVCL_SG27 HAP1 C1QBP (-) cancer cell line human CVCL_SG27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1243; C1QBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121900 CVCL_JM93 HPSI0214i-pelm_2 induced pluripotent stem cell human CVCL_JM93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121901 CVCL_JM96 HPSI0313i-airc_44 induced pluripotent stem cell human CVCL_JM96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121902 CVCL_SG29 HAP1 C2orf69 (-) 1 cancer cell line human CVCL_SG29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26799; C2orf69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121903 CVCL_JM95 HPSI0313i-airc_3 induced pluripotent stem cell human CVCL_JM95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Transcriptome analysis by microarray Female 21121904 CVCL_SG09 HAP1 C17orf103 (-) 2 cancer cell line human CVCL_SG09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30770; NATD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121905 CVCL_JM70 HPSI0114i-iisa_2 induced pluripotent stem cell human CVCL_JM70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121906 CVCL_JM69 HPSI0114i-fikt_1 induced pluripotent stem cell human CVCL_JM69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121907 CVCL_JM68 GeneBLAzer Gqi5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_JM68 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21121908 CVCL_SG11 HAP1 C17orf70 (-) 1 cancer cell line human CVCL_SG11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26171; FAAP100; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121909 CVCL_SG10 HAP1 C17orf59 (-) cancer cell line human CVCL_SG10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25939; BORCS6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121910 CVCL_SG13 HAP1 C19orf70 (-) 1 cancer cell line human CVCL_SG13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33702; MICOS13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121911 CVCL_JM65 M019iCis cancer cell line human CVCL_JM65 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21121912 CVCL_SG12 HAP1 C17orf70 (-) 2 cancer cell line human CVCL_SG12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26171; FAAP100; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121913 CVCL_JM64 M019i cancer cell line human CVCL_JM64 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21121914 CVCL_SG15 HAP1 C1GALT1C1 (-) 1 cancer cell line human CVCL_SG15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24338; C1GALT1C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121915 CVCL_JM67 OC002Cis cancer cell line human CVCL_JM67 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21121916 CVCL_SG14 HAP1 C19orf70 (-) 2 cancer cell line human CVCL_SG14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33702; MICOS13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121917 CVCL_JM66 OC002 cancer cell line human CVCL_JM66 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21121918 CVCL_SG17 HAP1 C1orf112 (-) 1 cancer cell line human CVCL_SG17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25565; C1orf112; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121919 CVCL_JM61 Hnp-SWN-14O transformed cell line human CVCL_JM61 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by microarray Unspecified 21121920 CVCL_JM60 F4 G6PD Knockout spontaneously immortalized cell line house mouse CVCL_JM60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:105979; G6pdx Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified 21121921 CVCL_SG16 HAP1 C1GALT1C1 (-) 2 cancer cell line human CVCL_SG16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24338; C1GALT1C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121922 CVCL_SG19 HAP1 C1orf115 (-) 1 cancer cell line human CVCL_SG19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25873; C1orf115; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121923 CVCL_JM63 HPSI0114i-eipl_2 induced pluripotent stem cell human CVCL_JM63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Female 21121924 CVCL_SG18 HAP1 C1orf112 (-) 2 cancer cell line human CVCL_SG18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25565; C1orf112; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121925 CVCL_JM62 Hp-SWN-14F transformed cell line human CVCL_JM62 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: Transcriptome analysis by microarray Unspecified 21121926 CVCL_JM81 HPSI0114i-vabj_2 induced pluripotent stem cell human CVCL_JM81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121927 CVCL_JM80 HPSI0114i-vabj_1 induced pluripotent stem cell human CVCL_JM80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121928 CVCL_JM79 HPSI0114i-rozh_3 induced pluripotent stem cell human CVCL_JM79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121929 CVCL_SG00 HAP1 C12orf10 (-) 1 cancer cell line human CVCL_SG00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17590; MYG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121930 CVCL_SG02 HAP1 C12orf44 (-) 2 cancer cell line human CVCL_SG02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25679; ATG101; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121931 CVCL_JM76 HPSI0114i-posc_1 induced pluripotent stem cell human CVCL_JM76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121932 CVCL_SG01 HAP1 C12orf44 (-) 1 cancer cell line human CVCL_SG01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25679; ATG101; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121933 CVCL_JM75 HPSI0114i-oevr_2 induced pluripotent stem cell human CVCL_JM75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121934 CVCL_SG04 HAP1 C14orf2 (-) 1 cancer cell line human CVCL_SG04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1188; ATP5MJ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121935 CVCL_JM78 HPSI0114i-posc_3 induced pluripotent stem cell human CVCL_JM78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121936 CVCL_SG03 HAP1 C14orf159 (-) 1 cancer cell line human CVCL_SG03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20498; DGLUCY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121937 CVCL_JM77 HPSI0114i-posc_2 induced pluripotent stem cell human CVCL_JM77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121938 CVCL_SG06 HAP1 C15orf40 (-) 1 cancer cell line human CVCL_SG06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28443; C15orf40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121939 CVCL_JM72 HPSI0114i-joxm_3 induced pluripotent stem cell human CVCL_JM72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121940 CVCL_SG05 HAP1 C14orf2 (-) 2 cancer cell line human CVCL_SG05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1188; ATP5MJ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121941 CVCL_JM71 HPSI0114i-joxm_2 induced pluripotent stem cell human CVCL_JM71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121942 CVCL_SG08 HAP1 C17orf103 (-) 1 cancer cell line human CVCL_SG08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30770; NATD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121943 CVCL_JM74 HPSI0114i-lexy_3 induced pluripotent stem cell human CVCL_JM74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21121944 CVCL_SG07 HAP1 C15orf61 (-) 1 cancer cell line human CVCL_SG07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34453; C15orf61; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21121945 CVCL_JM73 HPSI0114i-kolf_1 induced pluripotent stem cell human CVCL_JM73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21121946 CVCL_JM47 PL19 finite cell line human CVCL_JM47 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121947 CVCL_JM46 PL18 finite cell line human CVCL_JM46 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121948 CVCL_JM49 PL22 finite cell line human CVCL_JM49 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121949 CVCL_JM48 PL21 finite cell line human CVCL_JM48 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121950 CVCL_JM43 PL9 finite cell line human CVCL_JM43 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121951 CVCL_JM42 PL81 finite cell line human CVCL_JM42 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121952 CVCL_JM45 PL17 finite cell line human CVCL_JM45 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121953 CVCL_JM44 PL11 finite cell line human CVCL_JM44 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121954 CVCL_JM41 PL80 finite cell line human CVCL_JM41 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121955 CVCL_JM40 PL8 finite cell line human CVCL_JM40 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121956 CVCL_JM58 A-673 clone Asp114 cancer cell line human CVCL_JM58 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 3508; ; Knockout cell: Method=shRNA knockdown; HGNC; 3749; ; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala119Glnfs*5 (c.353_354dupCA) (c.354_355insCA); Zygosity=Homozygous (from parent cell line) Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Female Characteristics: Transfected with a construct harboring a doxycycline-inducible shRNA against the EWSR1-FLI1 fusion protein Problematic cell line: Misclassified Parent cell line (A-673) was originally thought to be a rhabdomyosarcoma cell line but is an Ewing sarcoma cell line. 21121957 CVCL_JM57 PL14 [Human familial adenomatous polyposis] finite cell line human CVCL_JM57 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121958 CVCL_JM59 BNL CL.2 High Passage spontaneously immortalized cell line house mouse CVCL_JM59 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified Doubling time: ~40 hours (ATCC=CRL-3308) 21121959 CVCL_JM54 PL1 finite cell line human CVCL_JM54 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121960 CVCL_JM53 PL79 finite cell line human CVCL_JM53 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121961 CVCL_JM56 PL2 finite cell line human CVCL_JM56 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121962 CVCL_JM55 PL10 finite cell line human CVCL_JM55 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121963 CVCL_JM50 PL24 finite cell line human CVCL_JM50 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121964 CVCL_JM52 PL37 finite cell line human CVCL_JM52 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121965 CVCL_JM51 PL26 finite cell line human CVCL_JM51 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121966 CVCL_AS95 CuFi-7 transformed cell line human CVCL_AS95 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Discontinued: ATCC; CRL-4018; probable Male 21121967 CVCL_B495 KK125 cancer cell line human CVCL_B495 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=2052620) Male Caution: It is possible that KK124 (Cellosaurus=CVCL_N704) and KK125 are the same cell line. 21121968 CVCL_B494 CMT181 cancer cell line house mouse CVCL_B494 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Female 21121969 CVCL_AS94 Delta-Ubc9+cUbc9-DT40 cancer cell line CVCL_AS94 CL:0000010 Knockout cell: Method=Targeted integration; UBE2I; Transfected with: UniProtKB; P63283; Chicken UBE2I Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21121970 CVCL_B497 HBC-5 cancer cell line human CVCL_B497 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Unspecified (PubMed=15900046). Population: Japanese Female Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel 21121971 CVCL_AS97 NEC-DUE2 cancer cell line human CVCL_AS97 CL:0000010 Derived from metastatic site: Lymph node. Omics: Array-based CGH Male 21121972 CVCL_B496 HBC-4 cancer cell line human CVCL_B496 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046) Population: Japanese Omics: Transcriptome analysis by microarray. Female Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel 21121973 CVCL_AS96 NEC-DUE1 cancer cell line human CVCL_AS96 CL:0000010 Derived from metastatic site: Liver. Omics: Array-based CGH Male 21121974 CVCL_B499 BSY-1 cancer cell line human CVCL_B499 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=15900046) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel 21121975 CVCL_AS99 KLC cancer cell line human CVCL_AS99 CL:0000010 Population: African American; Karyotypic information: 46,XY,t(8;9)(q13;p24)x2,del(13)(q12;q14) [77%], 46,XY,t(8;9)(q13;p24)x2,del(13)(q12;q14),add(22)(q13.2) [23%] (PubMed=10509003); Derived from sampling site: Peripheral blood. Male 21121976 CVCL_B498 HBC-7 cancer cell line human CVCL_B498 CL:0000010 Population: Japanese. Female 21121977 CVCL_AS98 Hep-G2/SF cancer cell line human CVCL_AS98 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Discontinued: ATCC; HB-8065.1; true Male Group: Serum/protein free medium cell line 21121978 CVCL_JM29 PL16 finite cell line human CVCL_JM29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121979 CVCL_JM28 PL12 finite cell line human CVCL_JM28 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121980 CVCL_AS91 BC-M1 [Human breast carcinoma Germany] cancer cell line human CVCL_AS91 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Proteome analysis by 2D-DE Female 21121981 CVCL_B491 IGR-39D cancer cell line human CVCL_B491 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (PubMed=10070891) Population: Caucasian; Derived from sampling site: Skin. Male 21121982 CVCL_JM25 MCF-10A TP53(-/-) spontaneously immortalized cell line human CVCL_JM25 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 11998; TP53; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21121983 CVCL_JM24 AG0654 transformed cell line human CVCL_JM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92050711; probable Male Part of: ECACC chromosomal abnormality collection 21121984 CVCL_AS90 FS-M1 cancer cell line human CVCL_AS90 CL:0000010 Population: Chinese; Taiwan Doubling time: 14 hours (PubMed=8083436). 21121985 CVCL_B490 Plat-GP transformed cell line human CVCL_B490 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21121986 CVCL_B493 CMT175 cancer cell line house mouse CVCL_B493 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Female 21121987 CVCL_JM27 hTEC/SVTERT24-B transformed cell line human CVCL_JM27 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: STR profile and sex of donor from personal communication of Evercyte Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Thymic epithelial cell.. Female Doubling time: ~30 hours (Evercyte) 21121988 CVCL_AS93 OBGF400 telomerase immortalized cell line pig CVCL_AS93 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Neuroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: ~4 days (PubMed=18358537) 21121989 CVCL_B492 CMT170 cancer cell line house mouse CVCL_B492 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Omics: Proteome analysis by 2D-DE/MS Female 21121990 CVCL_JM26 MCF-10A PTEN(-/-) spontaneously immortalized cell line human CVCL_JM26 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9588; PTEN; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female 21121991 CVCL_AS92 Vero-SF-adapted spontaneously immortalized cell line green monkey CVCL_AS92 CL:0000010 Derived from sampling site: Kidney; epithelium. Discontinued: CLS; 605372-SF; true Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21121992 CVCL_JM21 Ich1M finite cell line human CVCL_JM21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121993 CVCL_JM20 Ich1 finite cell line human CVCL_JM20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21121994 CVCL_JM23 ND13955 transformed cell line human CVCL_JM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21121995 CVCL_JM22 Ich2 finite cell line human CVCL_JM22 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121996 CVCL_JM39 PL7 finite cell line human CVCL_JM39 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21121997 CVCL_JM36 PL40 finite cell line human CVCL_JM36 CL:0000010 Population: Japanese. Female 21121998 CVCL_JM35 PL36 finite cell line human CVCL_JM35 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21121999 CVCL_JM38 PL6 finite cell line human CVCL_JM38 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122000 CVCL_JM37 PL5 finite cell line human CVCL_JM37 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122001 CVCL_JM32 PL29 finite cell line human CVCL_JM32 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122002 CVCL_JM31 PL28 finite cell line human CVCL_JM31 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122003 CVCL_JM34 PL35 finite cell line human CVCL_JM34 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122004 CVCL_JM33 PL32 finite cell line human CVCL_JM33 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122005 CVCL_JM30 PL25 finite cell line human CVCL_JM30 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122006 CVCL_0B84 WM989 cancer cell line human CVCL_0B84 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: deletion of CSF1PO. 21122007 CVCL_0B83 WM3862 cancer cell line human CVCL_0B83 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection. 21122008 CVCL_0B86 LH6215 cancer cell line human CVCL_0B86 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D2S1338. 21122009 CVCL_0B85 ND238 cancer cell line human CVCL_0B85 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21122010 CVCL_0B88 FRE cancer cell line human CVCL_0B88 CL:0000010 Derived from sampling site: Lung. Unspecified 21122011 CVCL_0B87 MAR cancer cell line human CVCL_0B87 CL:0000010 Derived from sampling site: Lung. Unspecified 21122012 CVCL_0B89 POC cancer cell line human CVCL_0B89 CL:0000010 Derived from sampling site: Lung. Unspecified 21122013 CVCL_0B80 WM3755 cancer cell line human CVCL_0B80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21122014 CVCL_0B82 WM3792 cancer cell line human CVCL_0B82 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601del (c.1801_1803delAAA); ClinVar=VCV000376287; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21122015 CVCL_0B81 WM3772F cancer cell line human CVCL_0B81 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar) Derived from metastatic site: Lung. Omics: Transcriptome analysis by microarray Female Characteristics: Pigmented Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection 21122016 CVCL_0B95 KW13 cancer cell line human CVCL_0B95 CL:0000010 21122017 CVCL_0B94 KW10 cancer cell line human CVCL_0B94 CL:0000010 21122018 CVCL_0B97 KW17 cancer cell line human CVCL_0B97 CL:0000010 21122019 CVCL_0B96 KW15 cancer cell line human CVCL_0B96 CL:0000010 21122020 CVCL_0B99 KW22 cancer cell line human CVCL_0B99 CL:0000010 21122021 CVCL_0B98 KW2 cancer cell line human CVCL_0B98 CL:0000010 21122022 CVCL_0B91 DMS 406 cancer cell line human CVCL_0B91 CL:0000010 Unspecified 21122023 CVCL_0B90 HOV cancer cell line human CVCL_0B90 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=104087879). 21122024 CVCL_0B93 KW1 cancer cell line human CVCL_0B93 CL:0000010 21122025 CVCL_0B92 DMS 456 cancer cell line human CVCL_0B92 CL:0000010 Unspecified 21122026 CVCL_0B62 GLC-44 cancer cell line human CVCL_0B62 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu326Ter (c.976G>T); ClinVar=VCV000231815; Zygosity=Unspecified (PubMed=10408787). 21122027 CVCL_0B61 GLC-35 cancer cell line human CVCL_0B61 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.437G>A); ClinVar=VCV000634785; Zygosity=Unspecified (PubMed=10408787); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10408787). 21122028 CVCL_0B64 LC-T cancer cell line human CVCL_0B64 CL:0000010 Female Doubling time: 41.4 hours (PubMed=1311980). 21122029 CVCL_0B63 GLC-45 cancer cell line human CVCL_0B63 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Gly (c.653T>G); ClinVar=VCV000528249; Zygosity=Unspecified (PubMed=10408787). 21122030 CVCL_0B66 WM1963 cancer cell line human CVCL_0B66 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asn581Ser (c.1742A>G); ClinVar=VCV000177776; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Unspecified (Wistar) Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D13S317. 21122031 CVCL_0B65 WM1819 cancer cell line human CVCL_0B65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: FGA. 21122032 CVCL_0B68 WM2032 cancer cell line human CVCL_0B68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21122033 CVCL_0B67 WM1985 cancer cell line human CVCL_0B67 CL:0000010 Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Omics: Transcriptome analysis by microarray. Unspecified Part of: Wistar Institute melanoma cell line collection 21122034 CVCL_0B69 WM2044 cancer cell line human CVCL_0B69 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21122035 CVCL_0B60 GLC-P2 cancer cell line human CVCL_0B60 CL:0000010 21122036 CVCL_0B73 WM3533 cancer cell line human CVCL_0B73 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21122037 CVCL_0B72 WM3311 cancer cell line human CVCL_0B72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21122038 CVCL_0B75 WM3619 cancer cell line human CVCL_0B75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: FGA 21122039 CVCL_0B74 WM3618F cancer cell line human CVCL_0B74 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=32430489) Derived from metastatic site: Right axillary lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21122040 CVCL_0B77 WM3702 cancer cell line human CVCL_0B77 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (Wistar) Derived from metastatic site: Back; skin. Omics: Transcriptome analysis by microarray Male Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D16S539 21122041 CVCL_0B76 WM3630 cancer cell line human CVCL_0B76 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D13S317 21122042 CVCL_0B79 WM3743 cancer cell line human CVCL_0B79 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg15Ter (c.43A>T); ClinVar=VCV001422662; Zygosity=Homozygous (Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21122043 CVCL_0B78 WM3704 cancer cell line human CVCL_0B78 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Glnfs*4 (c.389delG); ClinVar=VCV000192224; Zygosity=Homozygous (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21122044 CVCL_0B71 WM3282 cancer cell line human CVCL_0B71 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Homozygous (Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Female Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection 21122045 CVCL_0B70 WM2090 cancer cell line human CVCL_0B70 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21122046 CVCL_0B40 HCLL-7876 cancer cell line human CVCL_0B40 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 21122047 CVCL_0B42 218A cancer cell line human CVCL_0B42 CL:0000010 Male 21122048 CVCL_0B41 169A [Human embryonal carcinoma] cancer cell line human CVCL_0B41 CL:0000010 Male 21122049 CVCL_0B44 27X1 cancer cell line human CVCL_0B44 CL:0000010 Male 21122050 CVCL_0B43 228A cancer cell line human CVCL_0B43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly279Glu (c.836G>A); ClinVar=VCV000419454; Zygosity=Unspecified (PubMed=9620551). Male 21122051 CVCL_0B46 HROC85 cancer cell line human CVCL_0B46 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Male Caution: While reported as a cell line in PubMed=24647592 (and thus Cosmic 2151371) this is a patient-derived xenograft Personal communication of Linnebacher M.. 21122052 CVCL_0B45 HROC18 cancer cell line human CVCL_0B45 HLA typing: A*01:01:01,02:01:01; B*08:01:01,15:24:01; C*07:01:01; DPB1*01:01,04:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,13:03:01 (CLS=300808) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cecum. Omics: Transcriptome analysis by microarray Female Doubling time: 35 +- 7.2 hours (PubMed=25574089); Microsatellite instability: Stable (MSS) (PubMed=25926053) 21122053 CVCL_0B48 CHLA-218 cancer cell line human CVCL_0B48 CL:0000010 Omics: Deep exome analysis. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21122054 CVCL_0B47 HROC86 cancer cell line human CVCL_0B47 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Female Caution: While reported as a cell line in PubMed=24647592 (and thus Cosmic 2151372) this is a patient-derived xenograft Personal communication of Linnebacher M.. 21122055 CVCL_0B49 CHLA-57 cancer cell line human CVCL_0B49 CL:0000010 Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21122056 CVCL_SH90 HAP1 CD63 (-) cancer cell line human CVCL_SH90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1692; CD63; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122057 CVCL_SH92 HAP1 CD81 (-) 2 cancer cell line human CVCL_SH92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122058 CVCL_SH91 HAP1 CD81 (-) 1 cancer cell line human CVCL_SH91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122059 CVCL_SH94 HAP1 CD81 (-) 4 cancer cell line human CVCL_SH94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122060 CVCL_SH93 HAP1 CD81 (-) 3 cancer cell line human CVCL_SH93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122061 CVCL_SH96 HAP1 CD81 (-) 6 cancer cell line human CVCL_SH96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122062 CVCL_SH95 HAP1 CD81 (-) 5 cancer cell line human CVCL_SH95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122063 CVCL_SH98 HAP1 CD81 (-) 8 cancer cell line human CVCL_SH98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122064 CVCL_SH97 HAP1 CD81 (-) 7 cancer cell line human CVCL_SH97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122065 CVCL_SH99 HAP1 CD81 (-) 9 cancer cell line human CVCL_SH99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122066 CVCL_0B51 NZM076 cancer cell line human CVCL_0B51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21122067 CVCL_0B50 CHLA-99 cancer cell line human CVCL_0B50 CL:0000010 Omics: Deep exome analysis. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21122068 CVCL_0B53 NZM100 cancer cell line human CVCL_0B53 HLA typing: A*01:01,11:01; B*08:01,08:01; C*04:01,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21122069 CVCL_0B52 NZM086 cancer cell line human CVCL_0B52 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790) Omics: Deep exome analysis. 21122070 CVCL_0B55 NZM082 cancer cell line human CVCL_0B55 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21122071 CVCL_0B54 NZM059 cancer cell line human CVCL_0B54 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21122072 CVCL_0B57 FME cancer cell line human CVCL_0B57 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Characteristics: Established from a xenograft produced in BALB/c nude mice Doubling time: 18 hours, in RPMI-1640 + 15% FCS (PubMed=7426299) 21122073 CVCL_0B56 NZM085 cancer cell line human CVCL_0B56 HLA typing: A*02:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21122074 CVCL_0B59 GLC-P1 cancer cell line human CVCL_0B59 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=10408787); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Unspecified (PubMed=10408787). 21122075 CVCL_0B58 NGP-C4 cancer cell line human CVCL_0B58 CL:0000010 Derived from metastatic site: Lung. Male 21122076 CVCL_SH81 HAP1 CD46 (-) 9 cancer cell line human CVCL_SH81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122077 CVCL_SH80 HAP1 CD46 (-) 8 cancer cell line human CVCL_SH80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122078 CVCL_SH83 HAP1 CD46 (-) 11 cancer cell line human CVCL_SH83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122079 CVCL_SH82 HAP1 CD46 (-) 10 cancer cell line human CVCL_SH82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122080 CVCL_SH85 HAP1 CD55 (-) 1 cancer cell line human CVCL_SH85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2665; CD55; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122081 CVCL_SH84 HAP1 CD47 (-) 1 cancer cell line human CVCL_SH84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1682; CD47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122082 CVCL_SH87 HAP1 CD58 (-) cancer cell line human CVCL_SH87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1688; CD58; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122083 CVCL_SH86 HAP1 CD55 (-) 2 cancer cell line human CVCL_SH86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2665; CD55; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122084 CVCL_SH89 HAP1 CD59 (-) 2 cancer cell line human CVCL_SH89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1689; CD59; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122085 CVCL_SH88 HAP1 CD59 (-) 1 cancer cell line human CVCL_SH88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1689; CD59; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122086 CVCL_0B20 S2-Mt-EB1-GFP spontaneously immortalized cell line fruit fly CVCL_0B20 CL:0000010 Transfected with: FlyBase_Gene; FBgn0027066; Eb1; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Doubling time: 25 hours (DGRC) Group: Insect cell line 21122087 CVCL_0B22 H69/DAU cancer cell line human CVCL_0B22 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from metastatic site: Pleural effusion. Male 21122088 CVCL_0B21 H69/BCNU cancer cell line human CVCL_0B21 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:3423; Carmustine (BCNU); Derived from metastatic site: Pleural effusion. Male 21122089 CVCL_0B24 NYH/187/162 cancer cell line human CVCL_0B24 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50223; (+)-dexrazoxane (Cardioxane; Derived from metastatic site: Pleural effusion. Male 21122090 CVCL_0B23 H69/VP cancer cell line human CVCL_0B23 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pleural effusion. Male 21122091 CVCL_0B26 NYH/CAM cancer cell line human CVCL_0B26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Derived from metastatic site: Pleural effusion. Male 21122092 CVCL_0B25 NYH/187/165 cancer cell line human CVCL_0B25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50223; (+)-dexrazoxane (Cardioxane; Derived from metastatic site: Pleural effusion. Male 21122093 CVCL_0B28 NYH/TPT cancer cell line human CVCL_0B28 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Pleural effusion. Male 21122094 CVCL_0B27 NYH/CIS cancer cell line human CVCL_0B27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21122095 CVCL_0B29 NYH/VM cancer cell line human CVCL_0B29 CL:0000010 Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from metastatic site: Pleural effusion. Male 21122096 CVCL_SH70 HAP1 CD2BP2 (-) 2 cancer cell line human CVCL_SH70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1656; CD2BP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122097 CVCL_SH72 HAP1 CD44 (-) 1 cancer cell line human CVCL_SH72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1681; CD44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122098 CVCL_SH71 HAP1 CD36 (-) 1 cancer cell line human CVCL_SH71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1663; CD36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122099 CVCL_SH74 HAP1 CD46 (-) 2 cancer cell line human CVCL_SH74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122100 CVCL_SH73 HAP1 CD46 (-) 1 cancer cell line human CVCL_SH73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122101 CVCL_SH76 HAP1 CD46 (-) 4 cancer cell line human CVCL_SH76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122102 CVCL_SH75 HAP1 CD46 (-) 3 cancer cell line human CVCL_SH75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122103 CVCL_SH78 HAP1 CD46 (-) 6 cancer cell line human CVCL_SH78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122104 CVCL_SH77 HAP1 CD46 (-) 5 cancer cell line human CVCL_SH77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122105 CVCL_SH79 HAP1 CD46 (-) 7 cancer cell line human CVCL_SH79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6953; CD46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122106 CVCL_0B31 RPK-1 cancer cell line human CVCL_0B31 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=22490663); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (PubMed=22490663) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Male 21122107 CVCL_0B30 Caki-dTub cancer cell line human CVCL_0B30 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:88246; 2'-deoxytubercidin; Derived from metastatic site: Skin. Male 21122108 CVCL_0B33 RPK-9 cancer cell line human CVCL_0B33 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22490663); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=22490663) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Male 21122109 CVCL_0B32 RPK-59 cancer cell line human CVCL_0B32 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22490663) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21122110 CVCL_0B35 B4B8 cancer cell line house mouse CVCL_0B35 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: BALB/c. 21122111 CVCL_0B34 38E6E7HFK transformed cell line human CVCL_0B34 CL:0000010 Transfected with: UniProtKB; Q80907; Human papillomavirus type 38 protein E6; Transfected with: UniProtKB; Q80908; Human papillomavirus type 38 protein E7 Transformant: Human papillomavirus type 38 (HPV38) [pLXSN HPV38E6/E7](NCBI-Taxonomy; 37959); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21122112 CVCL_0B37 B7E3 cancer cell line house mouse CVCL_0B37 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: BALB/c. 21122113 CVCL_0B36 B7E11 cancer cell line house mouse CVCL_0B36 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: BALB/c. 21122114 CVCL_0B39 ALL-7031-B cancer cell line human CVCL_0B39 CL:0000010 Unspecified 21122115 CVCL_0B38 KM20-C cancer cell line human CVCL_0B38 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Problematic cell line: Contaminated Parent cell line (KM20) has been shown to be a HT-29 derivative. 21122116 CVCL_SH61 HAP1 CD24 (-) 2 cancer cell line human CVCL_SH61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122117 CVCL_SH60 HAP1 CD24 (-) 1 cancer cell line human CVCL_SH60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122118 CVCL_SH63 HAP1 CD24 (-) 4 cancer cell line human CVCL_SH63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122119 CVCL_SH62 HAP1 CD24 (-) 3 cancer cell line human CVCL_SH62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122120 CVCL_SH65 HAP1 CD24 (-) 6 cancer cell line human CVCL_SH65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122121 CVCL_SH64 HAP1 CD24 (-) 5 cancer cell line human CVCL_SH64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122122 CVCL_SH67 HAP1 CD24 (-) 8 cancer cell line human CVCL_SH67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122123 CVCL_SH66 HAP1 CD24 (-) 7 cancer cell line human CVCL_SH66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1645; CD24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122124 CVCL_SH69 HAP1 CD2BP2 (-) 1 cancer cell line human CVCL_SH69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1656; CD2BP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122125 CVCL_SH68 HAP1 CD274 (-) 1 cancer cell line human CVCL_SH68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17635; CD274; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122126 CVCL_AU35 GM09060 transformed cell line human CVCL_AU35 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122127 CVCL_B635 RG-215 embryonic stem cell human CVCL_B635 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122128 CVCL_AU34 GM09059 transformed cell line human CVCL_AU34 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122129 CVCL_B634 RG-214 embryonic stem cell human CVCL_B634 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[138-450]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=24289922). Male 21122130 CVCL_AU37 GM09062 transformed cell line human CVCL_AU37 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122131 CVCL_B637 RG-217 embryonic stem cell human CVCL_B637 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122132 CVCL_AU36 GM09061 transformed cell line human CVCL_AU36 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122133 CVCL_B636 RG-216 embryonic stem cell human CVCL_B636 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122134 CVCL_AU39 GM09066 transformed cell line human CVCL_AU39 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122135 CVCL_B639 RG-219 embryonic stem cell human CVCL_B639 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122136 CVCL_AU38 GM09065 transformed cell line human CVCL_AU38 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122137 CVCL_B638 RG-218 embryonic stem cell human CVCL_B638 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122138 CVCL_AU31 GM09056 transformed cell line human CVCL_AU31 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122139 CVCL_B631 RG-210 embryonic stem cell human CVCL_B631 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122140 CVCL_AU30 GM09055 transformed cell line human CVCL_AU30 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122141 CVCL_B630 RG-21 embryonic stem cell human CVCL_B630 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122142 CVCL_AU33 GM09058 transformed cell line human CVCL_AU33 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122143 CVCL_B633 RG-213 embryonic stem cell human CVCL_B633 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Heterozygous (ISCR). Female 21122144 CVCL_AU32 GM09057 transformed cell line human CVCL_AU32 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122145 CVCL_B632 RG-211 embryonic stem cell human CVCL_B632 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122146 CVCL_AU46 GM09073 transformed cell line human CVCL_AU46 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122147 CVCL_B646 RG-227 embryonic stem cell human CVCL_B646 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122148 CVCL_AU45 GM09072 transformed cell line human CVCL_AU45 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122149 CVCL_B645 RG-226 embryonic stem cell human CVCL_B645 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122150 CVCL_AU48 GM09075 transformed cell line human CVCL_AU48 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122151 CVCL_B648 RG-230 embryonic stem cell human CVCL_B648 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122152 CVCL_AU47 GM09074 transformed cell line human CVCL_AU47 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122153 CVCL_B647 RG-228 embryonic stem cell human CVCL_B647 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122154 CVCL_AU49 GM09076 transformed cell line human CVCL_AU49 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122155 CVCL_B649 RG-231 embryonic stem cell human CVCL_B649 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122156 CVCL_AU40 GM09067 transformed cell line human CVCL_AU40 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122157 CVCL_B640 RG-220 embryonic stem cell human CVCL_B640 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122158 CVCL_AU42 GM09069 transformed cell line human CVCL_AU42 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122159 CVCL_B642 RG-222 embryonic stem cell human CVCL_B642 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122160 CVCL_AU41 GM09068 transformed cell line human CVCL_AU41 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122161 CVCL_B641 RG-221 embryonic stem cell human CVCL_B641 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122162 CVCL_AU44 GM09071 transformed cell line human CVCL_AU44 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122163 CVCL_B644 RG-224 embryonic stem cell human CVCL_B644 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122164 CVCL_AU43 GM09070 transformed cell line human CVCL_AU43 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122165 CVCL_B643 RG-223 embryonic stem cell human CVCL_B643 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122166 CVCL_B613 RG-192 embryonic stem cell human CVCL_B613 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122167 CVCL_AU13 RKO/5FUR cancer cell line human CVCL_AU13 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Unspecified 21122168 CVCL_AU12 KM12L4/OXR cancer cell line human CVCL_AU12 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Unspecified 21122169 CVCL_B612 RG-191 embryonic stem cell human CVCL_B612 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122170 CVCL_B615 RG-194 embryonic stem cell human CVCL_B615 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122171 CVCL_AU15 RKO/OXR cancer cell line human CVCL_AU15 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Unspecified 21122172 CVCL_B614 RG-193 embryonic stem cell human CVCL_B614 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122173 CVCL_AU14 RKO/BEVA cancer cell line human CVCL_AU14 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: DrugBank; DB00112; Bevacizumab (Avastin) Unspecified 21122174 CVCL_B617 RG-196 embryonic stem cell human CVCL_B617 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122175 CVCL_AU17 SW480/BEVA cancer cell line human CVCL_AU17 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: DrugBank; DB00112; Bevacizumab (Avastin); Derived from sampling site: Colon. Male 21122176 CVCL_B616 RG-195 embryonic stem cell human CVCL_B616 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122177 CVCL_AU16 SW480/5FUR cancer cell line human CVCL_AU16 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Colon. Male 21122178 CVCL_AU19 MPNST-642 cancer cell line human CVCL_AU19 CL:0000010 Male Doubling time: ~48 hours (PubMed=21084276). 21122179 CVCL_B619 RG-198 embryonic stem cell human CVCL_B619 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122180 CVCL_B618 RG-197 embryonic stem cell human CVCL_B618 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122181 CVCL_AU18 SW480/OXR cancer cell line human CVCL_AU18 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from sampling site: Colon. Male 21122182 CVCL_AU11 HCT116/SN38R cancer cell line human CVCL_AU11 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male 21122183 CVCL_B611 RG-189 embryonic stem cell human CVCL_B611 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122184 CVCL_AU10 HCT116/BEVA cancer cell line human CVCL_AU10 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00112; Bevacizumab (Avastin); Derived from sampling site: Colon. Male 21122185 CVCL_B610 RG-188 embryonic stem cell human CVCL_B610 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122186 CVCL_AU09 HCT116/5FUR cancer cell line human CVCL_AU09 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Colon. Male 21122187 CVCL_B609 RG-187 embryonic stem cell human CVCL_B609 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122188 CVCL_AU24 GM09049 transformed cell line human CVCL_AU24 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122189 CVCL_B624 RG-203 embryonic stem cell human CVCL_B624 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122190 CVCL_AU23 GM09048 transformed cell line human CVCL_AU23 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122191 CVCL_B623 RG-202 embryonic stem cell human CVCL_B623 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122192 CVCL_AU26 GM09051 transformed cell line human CVCL_AU26 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122193 CVCL_B626 RG-205 embryonic stem cell human CVCL_B626 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122194 CVCL_AU25 GM09050 transformed cell line human CVCL_AU25 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122195 CVCL_B625 RG-204 embryonic stem cell human CVCL_B625 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122196 CVCL_AU28 GM09053 transformed cell line human CVCL_AU28 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122197 CVCL_B628 RG-208 embryonic stem cell human CVCL_B628 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122198 CVCL_AU27 GM09052 transformed cell line human CVCL_AU27 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122199 CVCL_B627 RG-206 embryonic stem cell human CVCL_B627 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122200 CVCL_AU29 GM09054 transformed cell line human CVCL_AU29 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122201 CVCL_B629 RG-209 embryonic stem cell human CVCL_B629 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122202 CVCL_AU20 MPNST-724 cancer cell line human CVCL_AU20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.280delTCA; Zygosity=Unspecified (PubMed=21084276) Omics: Transcriptome analysis by microarray. Unspecified Doubling time: ~24 hours (PubMed=21084276) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21122203 CVCL_B620 RG-199 embryonic stem cell human CVCL_B620 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122204 CVCL_AU22 GM09047 transformed cell line human CVCL_AU22 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122205 CVCL_B622 RG-201 embryonic stem cell human CVCL_B622 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Gln472Argfs*83 (c.1415_1416delAG) (1801delAG); ClinVar=VCV000011303; Zygosity=Hemizygous (PubMed=15705304). Male 21122206 CVCL_AU21 MPNST-14 cancer cell line human CVCL_AU21 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21122207 CVCL_B621 RG-200 embryonic stem cell human CVCL_B621 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122208 CVCL_AU02 BR-4 embryonic stem cell human CVCL_AU02 From: Instituto de Biociencias; Sao Paulo; Brazil. CL:0000010 Male 21122209 CVCL_B602 RG-18 embryonic stem cell human CVCL_B602 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122210 CVCL_B601 RG-179 embryonic stem cell human CVCL_B601 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122211 CVCL_AU01 SK-HEP-1-FIX cancer cell line human CVCL_AU01 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3551; F9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21122212 CVCL_AU04 BR-2 embryonic stem cell human CVCL_AU04 From: Instituto de Biociencias; Sao Paulo; Brazil. CL:0000010 Female 21122213 CVCL_B604 RG-182 embryonic stem cell human CVCL_B604 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122214 CVCL_AU03 BR-5 embryonic stem cell human CVCL_AU03 From: Instituto de Biociencias; Sao Paulo; Brazil. CL:0000010 Female 21122215 CVCL_B603 RG-180 embryonic stem cell human CVCL_B603 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122216 CVCL_AU06 LPS224 cancer cell line human CVCL_AU06 CL:0000010 21122217 CVCL_B606 RG-184 embryonic stem cell human CVCL_B606 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122218 CVCL_AU05 KRIB cancer cell line human CVCL_AU05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Population: Caucasian; Derived from sampling site: Bone; right femur. Omics: Transcriptome analysis by microarray Female 21122219 CVCL_B605 RG-183 embryonic stem cell human CVCL_B605 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122220 CVCL_AU08 LPS863 cancer cell line human CVCL_AU08 CL:0000010 21122221 CVCL_B608 RG-186 embryonic stem cell human CVCL_B608 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122222 CVCL_AU07 LPS246 cancer cell line human CVCL_AU07 CL:0000010 21122223 CVCL_B607 RG-185 embryonic stem cell human CVCL_B607 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122224 CVCL_AU00 293T-FIX transformed cell line human CVCL_AU00 CL:0000010 Transfected with: HGNC; 3551; F9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21122225 CVCL_B600 RG-178 embryonic stem cell human CVCL_B600 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122226 CVCL_AT94 PCI-24 [Human OCSCC] cancer cell line human CVCL_AT94 CL:0000010 Derived from sampling site: Oral cavity. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21122227 CVCL_B594 RG-171 embryonic stem cell human CVCL_B594 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122228 CVCL_AT93 HBMEC-4 undefined cell line type human CVCL_AT93 CL:0000010 Discontinued: ATCC; CRL-3025; probable. Male 21122229 CVCL_B593 RG-170 embryonic stem cell human CVCL_B593 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122230 CVCL_AT96 AMOC-2 Subclone #4 cancer cell line human CVCL_AT96 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 30.06 hours (PubMed=9433040) 21122231 CVCL_B596 RG-174 embryonic stem cell human CVCL_B596 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122232 CVCL_AT95 AMOC-2 Subclone #2 cancer cell line human CVCL_AT95 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 32.58 hours (PubMed=9433040) 21122233 CVCL_B595 RG-172 embryonic stem cell human CVCL_B595 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122234 CVCL_AT98 AMOC-2 Subclone #10 cancer cell line human CVCL_AT98 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 26.89 hours (PubMed=9433040) 21122235 CVCL_B598 RG-176 embryonic stem cell human CVCL_B598 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122236 CVCL_AT97 AMOC-2 Subclone #6 cancer cell line human CVCL_AT97 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 25.40 hours (PubMed=9433040) 21122237 CVCL_B597 RG-175 embryonic stem cell human CVCL_B597 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122238 CVCL_AT99 AMOC-2 Subclone #11 cancer cell line human CVCL_AT99 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 23.26 hours (PubMed=9433040) 21122239 CVCL_B599 RG-177 embryonic stem cell human CVCL_B599 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122240 CVCL_JN28 HPSI0513i-aipt_2 induced pluripotent stem cell human CVCL_JN28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122241 CVCL_JN27 HPSI0513i-aipt_1 induced pluripotent stem cell human CVCL_JN27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122242 CVCL_JN29 HPSI0513i-bicb_1 induced pluripotent stem cell human CVCL_JN29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122243 CVCL_JN24 HPSI0413i-yuze_3 induced pluripotent stem cell human CVCL_JN24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122244 CVCL_B590 RG-167 embryonic stem cell human CVCL_B590 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122245 CVCL_AT90 Steele cancer cell line human CVCL_AT90 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714). 21122246 CVCL_JN23 HPSI0413i-yuze_2 induced pluripotent stem cell human CVCL_JN23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122247 CVCL_AT92 HBMEC-3 undefined cell line type human CVCL_AT92 CL:0000010 Discontinued: ATCC; CRL-3024; probable. Male 21122248 CVCL_JN26 HPSI0414i-mita_3 induced pluripotent stem cell human CVCL_JN26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122249 CVCL_B592 RG-169 embryonic stem cell human CVCL_B592 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122250 CVCL_AT91 HBMEC-2 cancer cell line human CVCL_AT91 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-3023; probable Female Problematic cell line: Probably contaminated The STR profile is identical to that of the T24 cell line. 21122251 CVCL_JN25 HPSI0414i-mita_1 induced pluripotent stem cell human CVCL_JN25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122252 CVCL_B591 RG-168 embryonic stem cell human CVCL_B591 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122253 CVCL_JN20 HPSI0413i-xisg_1 induced pluripotent stem cell human CVCL_JN20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122254 CVCL_JN22 HPSI0413i-xisg_33 induced pluripotent stem cell human CVCL_JN22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122255 CVCL_JN21 HPSI0413i-xisg_3 induced pluripotent stem cell human CVCL_JN21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122256 CVCL_JN39 HPSI0513i-fejf_1 induced pluripotent stem cell human CVCL_JN39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122257 CVCL_JN38 HPSI0513i-euir_3 induced pluripotent stem cell human CVCL_JN38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122258 CVCL_JN35 HPSI0513i-debk_8 induced pluripotent stem cell human CVCL_JN35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122259 CVCL_JN34 HPSI0513i-cuau_3 induced pluripotent stem cell human CVCL_JN34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122260 CVCL_JN37 HPSI0513i-dipe_3 induced pluripotent stem cell human CVCL_JN37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122261 CVCL_JN36 HPSI0513i-dipe_2 induced pluripotent stem cell human CVCL_JN36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122262 CVCL_JN31 HPSI0513i-cehw_1 induced pluripotent stem cell human CVCL_JN31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122263 CVCL_JN30 HPSI0513i-bicb_4 induced pluripotent stem cell human CVCL_JN30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122264 CVCL_JN33 HPSI0513i-coio_3 induced pluripotent stem cell human CVCL_JN33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122265 CVCL_JN32 HPSI0513i-cehw_2 induced pluripotent stem cell human CVCL_JN32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122266 CVCL_AT79 MDA-1686 cancer cell line human CVCL_AT79 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Gly (c.653T>G); ClinVar=VCV000528249; Zygosity=Unspecified (PubMed=7927946); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr256Hisfs*89 (c.766delA); Zygosity=Unspecified (PubMed=7927946) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21122267 CVCL_B579 RG-155 embryonic stem cell human CVCL_B579 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122268 CVCL_B572 RG-148 embryonic stem cell human CVCL_B572 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122269 CVCL_AT72 SRB-1 cancer cell line human CVCL_AT72 CL:0000010 21122270 CVCL_AT71 R1192 cancer cell line human CVCL_AT71 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Skin. Discontinued: ATCC; CRL-7935; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Probably contaminated Shown to be a Caki-1 derivative (based on STR profile). Originally thought to originate from abnormal skin from a 33 year old male donor. 21122271 CVCL_B571 RG-146 embryonic stem cell human CVCL_B571 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122272 CVCL_AT74 OSC-19LN1 cancer cell line human CVCL_AT74 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21122273 CVCL_B574 RG-15 embryonic stem cell human CVCL_B574 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122274 CVCL_B573 RG-149 embryonic stem cell human CVCL_B573 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122275 CVCL_AT73 SRB-12 cancer cell line human CVCL_AT73 CL:0000010 21122276 CVCL_AT76 OSC-19LN3 cancer cell line human CVCL_AT76 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21122277 CVCL_B576 RG-151 embryonic stem cell human CVCL_B576 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122278 CVCL_JN09 HPSI0413i-gomv_4 induced pluripotent stem cell human CVCL_JN09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122279 CVCL_AT75 OSC-19LN2 cancer cell line human CVCL_AT75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21122280 CVCL_B575 RG-150 embryonic stem cell human CVCL_B575 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122281 CVCL_AT78 OSC-19LN5 cancer cell line human CVCL_AT78 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21122282 CVCL_B578 RG-154 embryonic stem cell human CVCL_B578 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys2571Tyr (c.7712G>A); ClinVar=VCV000549422; Zygosity=Unspecified (PubMed=15705304). Male 21122283 CVCL_AT77 OSC-19LN4 cancer cell line human CVCL_AT77 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21122284 CVCL_B577 RG-153 embryonic stem cell human CVCL_B577 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122285 CVCL_JN06 HPSI0413i-bupo_6 induced pluripotent stem cell human CVCL_JN06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122286 CVCL_JN05 HPSI0413i-bupo_5 induced pluripotent stem cell human CVCL_JN05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122287 CVCL_JN08 HPSI0413i-gomv_2 induced pluripotent stem cell human CVCL_JN08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122288 CVCL_JN07 HPSI0413i-coxy_2 induced pluripotent stem cell human CVCL_JN07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122289 CVCL_JN02 HPSI0314i-hoik_2 induced pluripotent stem cell human CVCL_JN02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122290 CVCL_JN01 HPSI0314i-cuhk_3 induced pluripotent stem cell human CVCL_JN01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122291 CVCL_JN04 HPSI0314i-sojd_1 induced pluripotent stem cell human CVCL_JN04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122292 CVCL_AT70 NMFH-1 [JCRB] cancer cell line human CVCL_AT70 CL:0000010 Population: Japanese Male Caution: There seem to be two NMFH-1 cell lines, both from myxofibrosarcomas (malignant fibrous histiocytomas) One from Niigata University (Kawashima H. et al) established from a 89 year old male patient and distributed by RCB and one from Shimada Y. established from a 43 year old male patient and distributed by JCRB. The two cell lines have very different STR profiles.. 21122293 CVCL_B570 RG-145 embryonic stem cell human CVCL_B570 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Ambiguous 21122294 CVCL_JN03 HPSI0314i-hoik_3 induced pluripotent stem cell human CVCL_JN03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122295 CVCL_JN00 HPSI0314i-bubh_2 induced pluripotent stem cell human CVCL_JN00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122296 CVCL_AT83 NOM9-CT telomerase immortalized cell line human CVCL_AT83 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Oral cavity; buccal mucosa Cell type=Epithelial cell.. Male 21122297 CVCL_B583 RG-159 embryonic stem cell human CVCL_B583 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122298 CVCL_AT82 HTh74 clone 7 cancer cell line human CVCL_AT82 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu732fs (c.2195_2202delTGCCCAAC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (from parent cell line) Derived from sampling site: Thyroid gland Cell type=Epithelial cell.. Female 21122299 CVCL_B582 RG-158 embryonic stem cell human CVCL_B582 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Heterozygous (PubMed=15705304). Female 21122300 CVCL_AT85 K2 [Human melanoma] cancer cell line human CVCL_AT85 Genome ancestry: African=0.06%; Native American=0%; East Asian, North=0%; East Asian, South=1.34%; South Asian=0.87%; European, North=67.62%; European, South=30.11% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap; PubMed=15009714) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21122301 CVCL_B585 RG-161 embryonic stem cell human CVCL_B585 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122302 CVCL_AT84 NOM9/TKp53 telomerase immortalized cell line human CVCL_AT84 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Oral cavity; buccal mucosa Cell type=Epithelial cell.. Male 21122303 CVCL_B584 RG-160 embryonic stem cell human CVCL_B584 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122304 CVCL_AT87 MH-12 cancer cell line human CVCL_AT87 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714). Unspecified 21122305 CVCL_B587 RG-163 embryonic stem cell human CVCL_B587 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122306 CVCL_AT86 K4 [Human melanoma] cancer cell line human CVCL_AT86 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714). 21122307 CVCL_B586 RG-162 embryonic stem cell human CVCL_B586 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122308 CVCL_AT89 MH-2 [Human melanoma] cancer cell line human CVCL_AT89 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714). Unspecified 21122309 CVCL_B589 RG-165 embryonic stem cell human CVCL_B589 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122310 CVCL_AT88 MH-17 cancer cell line human CVCL_AT88 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714). Unspecified 21122311 CVCL_B588 RG-164 embryonic stem cell human CVCL_B588 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122312 CVCL_JN17 HPSI0413i-uahf_2 induced pluripotent stem cell human CVCL_JN17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122313 CVCL_JN16 HPSI0413i-uahf_1 induced pluripotent stem cell human CVCL_JN16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122314 CVCL_JN19 HPSI0413i-xekf_3 induced pluripotent stem cell human CVCL_JN19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122315 CVCL_JN18 HPSI0413i-xekf_2 induced pluripotent stem cell human CVCL_JN18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122316 CVCL_JN13 HPSI0413i-peop_3 induced pluripotent stem cell human CVCL_JN13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122317 CVCL_JN12 HPSI0413i-peop_1 induced pluripotent stem cell human CVCL_JN12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122318 CVCL_JN15 HPSI0413i-sukz_3 induced pluripotent stem cell human CVCL_JN15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122319 CVCL_AT81 MSK-Leuk1S cancer cell line human CVCL_AT81 CL:0000010 Derived from sampling site: Oral cavity; tongue Cell type=Keratinocyte.. Female 21122320 CVCL_B581 RG-157 embryonic stem cell human CVCL_B581 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122321 CVCL_JN14 HPSI0413i-sukz_2 induced pluripotent stem cell human CVCL_JN14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122322 CVCL_AT80 MDA-1986LN cancer cell line human CVCL_AT80 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00441 Problematic cell line: Partially contaminated Some stocks are contaminated by UM-SCC-1 (PubMed=21868764). 21122323 CVCL_B580 RG-156 embryonic stem cell human CVCL_B580 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122324 CVCL_JN11 HPSI0413i-ougl_2 induced pluripotent stem cell human CVCL_JN11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122325 CVCL_JN10 HPSI0413i-nudd_2 induced pluripotent stem cell human CVCL_JN10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122326 CVCL_AT58 M990203 cancer cell line human CVCL_AT58 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Female 21122327 CVCL_B558 RG-130 embryonic stem cell human CVCL_B558 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122328 CVCL_AT57 M971219 cancer cell line human CVCL_AT57 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122329 CVCL_B557 RG-128 embryonic stem cell human CVCL_B557 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122330 CVCL_AT59 M050829 cancer cell line human CVCL_AT59 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Retroauricular region. Omics: Transcriptome analysis by microarray Male 21122331 CVCL_B559 RG-131 embryonic stem cell human CVCL_B559 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122332 CVCL_AT50 M080326 cancer cell line human CVCL_AT50 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122333 CVCL_B550 RG-114 embryonic stem cell human CVCL_B550 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122334 CVCL_AT52 M080729 cancer cell line human CVCL_AT52 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122335 CVCL_B552 RG-122 embryonic stem cell human CVCL_B552 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122336 CVCL_AT51 M080423 cancer cell line human CVCL_AT51 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21122337 CVCL_B551 RG-115 embryonic stem cell human CVCL_B551 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122338 CVCL_AT54 M080904B cancer cell line human CVCL_AT54 From: URPP Biobank, University of Zurich; Zurich; Switzerland. CL:0000010 Male 21122339 CVCL_B554 RG-124 embryonic stem cell human CVCL_B554 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122340 CVCL_AT53 M080904 cancer cell line human CVCL_AT53 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122341 CVCL_B553 RG-123 embryonic stem cell human CVCL_B553 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122342 CVCL_AT56 M081028 cancer cell line human CVCL_AT56 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122343 CVCL_B556 RG-126 embryonic stem cell human CVCL_B556 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122344 CVCL_AT55 M081021 cancer cell line human CVCL_AT55 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Abdomen; skin. Male 21122345 CVCL_B555 RG-125 embryonic stem cell human CVCL_B555 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122346 CVCL_AT69 GNE-587170 undefined cell line type human CVCL_AT69 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00517. Problematic cell line: Misidentified This cell line was mistakenly distributed by OCI to a number of groups as being OCI-Ly-3 (Cellosaurus=CVCL_8800). The real identity of this cell line is not known. From personal communication of Neve R. 21122347 CVCL_B569 RG-144 embryonic stem cell human CVCL_B569 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122348 CVCL_B568 RG-141 embryonic stem cell human CVCL_B568 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Trp1831Ter (c.5492G>A) (p.Trp1810Ter, c.5429G>A); ClinVar=VCV000431656; Zygosity=Unspecified (PubMed=15705304). Female 21122349 CVCL_AT68 SW480R cancer cell line human CVCL_AT68 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21122350 CVCL_AT61 M080201 cancer cell line human CVCL_AT61 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Omics: Transcriptome analysis by microarray Female 21122351 CVCL_B561 RG-133 embryonic stem cell human CVCL_B561 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122352 CVCL_AT60 M061103 cancer cell line human CVCL_AT60 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Vertex. Omics: Transcriptome analysis by microarray Male 21122353 CVCL_B560 RG-132 embryonic stem cell human CVCL_B560 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122354 CVCL_AT63 M080310 cancer cell line human CVCL_AT63 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Omics: Transcriptome analysis by microarray Female 21122355 CVCL_B563 RG-135 embryonic stem cell human CVCL_B563 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122356 CVCL_AT62 M080214 cancer cell line human CVCL_AT62 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Thigh. Omics: Transcriptome analysis by microarray Female 21122357 CVCL_B562 RG-134 embryonic stem cell human CVCL_B562 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122358 CVCL_B565 RG-138 embryonic stem cell human CVCL_B565 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Trp1831Ter (c.5492G>A) (p.Trp1810Ter, c.5429G>A); ClinVar=VCV000431656; Zygosity=Unspecified (PubMed=15705304). Male 21122359 CVCL_AT65 SW480/nkS cancer cell line human CVCL_AT65 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21122360 CVCL_AT64 M081008 cancer cell line human CVCL_AT64 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Bone; temporal bone. Omics: Transcriptome analysis by microarray Male 21122361 CVCL_B564 RG-137 embryonic stem cell human CVCL_B564 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Trp1831Ter (c.5492G>A) (p.Trp1810Ter, c.5429G>A); ClinVar=VCV000431656; Zygosity=Unspecified (PubMed=15705304). Male 21122362 CVCL_B567 RG-140 embryonic stem cell human CVCL_B567 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Trp1831Ter (c.5492G>A) (p.Trp1810Ter, c.5429G>A); ClinVar=VCV000431656; Zygosity=Unspecified (PubMed=15705304). Female 21122363 CVCL_AT67 SW480E cancer cell line human CVCL_AT67 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21122364 CVCL_B566 RG-139 embryonic stem cell human CVCL_B566 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Trp1831Ter (c.5492G>A) (p.Trp1810Ter, c.5429G>A); ClinVar=VCV000431656; Zygosity=Unspecified (PubMed=15705304). Male 21122365 CVCL_AT66 SW480/nkR cancer cell line human CVCL_AT66 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21122366 CVCL_AT36 GM16188 transformed cell line human CVCL_AT36 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122367 CVCL_B536 IPS-5 induced pluripotent stem cell human CVCL_B536 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122368 CVCL_AT35 GM16186 transformed cell line human CVCL_AT35 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21122369 CVCL_B535 IPS-29 induced pluripotent stem cell human CVCL_B535 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122370 CVCL_AT38 GM16190 transformed cell line human CVCL_AT38 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122371 CVCL_B538 RG-100 embryonic stem cell human CVCL_B538 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122372 CVCL_AT37 GM16189 transformed cell line human CVCL_AT37 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122373 CVCL_B537 IPS-7 induced pluripotent stem cell human CVCL_B537 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122374 CVCL_AT39 GM16392 finite cell line human CVCL_AT39 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg257Trp (c.769C>T); ClinVar=VCV000188872; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122375 CVCL_B539 RG-101 embryonic stem cell human CVCL_B539 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122376 CVCL_AT30 GM15884 transformed cell line human CVCL_AT30 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122377 CVCL_B530 GUCASe002-A embryonic stem cell human CVCL_B530 From: Graduate University of Chinese Academy of Sciences Institute of Zoology; Beijing; China. CL:0000010 Female 21122378 CVCL_AT32 GM15886 transformed cell line human CVCL_AT32 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21122379 CVCL_B532 IPS-18 induced pluripotent stem cell human CVCL_B532 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21122380 CVCL_AT31 GM15885 transformed cell line human CVCL_AT31 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122381 CVCL_B531 IPS-1 induced pluripotent stem cell human CVCL_B531 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122382 CVCL_AT34 GM16185 transformed cell line human CVCL_AT34 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21122383 CVCL_B534 IPS-24 induced pluripotent stem cell human CVCL_B534 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122384 CVCL_AT33 GM15887 transformed cell line human CVCL_AT33 CL:0000010 Population: Caucasian; Basque; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21122385 CVCL_B533 IPS-2 induced pluripotent stem cell human CVCL_B533 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122386 CVCL_8Z99 DD3720 transformed cell line human CVCL_8Z99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21122387 CVCL_8Z98 DD3719 transformed cell line human CVCL_8Z98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21122388 CVCL_8Z95 DD3715 transformed cell line human CVCL_8Z95 CL:0000010 Karyotypic information: t(5;12)(q14.2;q14.2) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21122389 CVCL_8Z94 DD0429 transformed cell line human CVCL_8Z94 CL:0000010 Karyotypic information: 46,XX,inv(7)(q22.1;q34) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21122390 CVCL_8Z97 DD3717 transformed cell line human CVCL_8Z97 CL:0000010 Karyotypic information: 46,Y,dup(X)(q27.2;q28) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21122391 CVCL_8Z96 DD3716 transformed cell line human CVCL_8Z96 CL:0000010 Karyotypic information: inv(7)(p13;q11.23) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21122392 CVCL_AT47 M080221 cancer cell line human CVCL_AT47 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Female 21122393 CVCL_B547 RG-109 embryonic stem cell human CVCL_B547 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122394 CVCL_AT46 M070112 cancer cell line human CVCL_AT46 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122395 CVCL_B546 RG-108 embryonic stem cell human CVCL_B546 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122396 CVCL_AT49 M080306 cancer cell line human CVCL_AT49 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122397 CVCL_B549 RG-111 embryonic stem cell human CVCL_B549 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122398 CVCL_AT48 M080228 cancer cell line human CVCL_AT48 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (URPP Biobank) Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Not specified. Female 21122399 CVCL_B548 RG-110 embryonic stem cell human CVCL_B548 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122400 CVCL_AT41 GM16394 finite cell line human CVCL_AT41 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg88Ser (c.262C>A); ClinVar=VCV000529444; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg402Trp (c.1204C>T); ClinVar=VCV000002085; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122401 CVCL_B541 RG-103 embryonic stem cell human CVCL_B541 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122402 CVCL_AT40 GM16393 finite cell line human CVCL_AT40 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg227Pro (c.680G>C); ClinVar=VCV000002089; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Val400Met (c.1198G>A); ClinVar=VCV000002088; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122403 CVCL_B540 RG-102 embryonic stem cell human CVCL_B540 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122404 CVCL_AT43 GM16396 finite cell line human CVCL_AT43 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Ile67Serfs (c.198delC); ClinVar=VCV000371205; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Tyr74Cys (c.221A>G); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122405 CVCL_B543 RG-105 embryonic stem cell human CVCL_B543 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122406 CVCL_AT42 GM16395 finite cell line human CVCL_AT42 CL:0000010 Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg257Trp (c.769C>T); ClinVar=VCV000188872; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4189; GCDH; Simple; p.Arg294Gln (c.881G>A); ClinVar=VCV000859875; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122407 CVCL_B542 RG-104 embryonic stem cell human CVCL_B542 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Ambiguous 21122408 CVCL_AT45 M060621 cancer cell line human CVCL_AT45 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21122409 CVCL_B545 RG-107 embryonic stem cell human CVCL_B545 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122410 CVCL_AT44 M060125 cancer cell line human CVCL_AT44 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Bone; scapula. Omics: Transcriptome analysis by microarray Female 21122411 CVCL_B544 RG-106 embryonic stem cell human CVCL_B544 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122412 CVCL_0B00 OSCA-49 cancer cell line dog CVCL_0B00 CL:0000010 Breed/subspecies: Rottweiler. Female 21122413 CVCL_0B02 OSCA-52 cancer cell line dog CVCL_0B02 CL:0000010 Breed/subspecies: Rottweiler. Female 21122414 CVCL_0B01 OSCA-51 cancer cell line dog CVCL_0B01 CL:0000010 Breed/subspecies: Rottweiler. Female 21122415 CVCL_0B04 OSCA-54 cancer cell line dog CVCL_0B04 CL:0000010 Breed/subspecies: Boxer. Female 21122416 CVCL_0B03 OSCA-53M cancer cell line dog CVCL_0B03 CL:0000010 Breed/subspecies: Golden Retriever. Male 21122417 CVCL_0B06 OSCA-61 cancer cell line dog CVCL_0B06 CL:0000010 Breed/subspecies: Rottweiler. Male 21122418 CVCL_0B05 OSCA-58 cancer cell line dog CVCL_0B05 CL:0000010 Breed/subspecies: Rottweiler. Male 21122419 CVCL_0B08 OSCA-64M cancer cell line dog CVCL_0B08 CL:0000010 Derived from metastatic site: Not specified; Breed/subspecies: Rhodesian Ridgeback. Male 21122420 CVCL_0B07 OSCA-63 cancer cell line dog CVCL_0B07 CL:0000010 Breed/subspecies: Scottish Deerhound. Male 21122421 CVCL_0B09 OSCA-65 cancer cell line dog CVCL_0B09 CL:0000010 Breed/subspecies: American Bulldog. Female 21122422 CVCL_SH50 HAP1 CCNT2 (-) 1 cancer cell line human CVCL_SH50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1600; CCNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122423 CVCL_SH52 HAP1 CCNY (-) 1 cancer cell line human CVCL_SH52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23354; CCNY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122424 CVCL_SH51 HAP1 CCNT2 (-) 2 cancer cell line human CVCL_SH51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1600; CCNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122425 CVCL_SH54 HAP1 CCNYL1 (-) cancer cell line human CVCL_SH54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26868; CCNYL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122426 CVCL_SH53 HAP1 CCNY (-) 2 cancer cell line human CVCL_SH53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23354; CCNY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122427 CVCL_SH56 HAP1 CCR5 (-) 2 cancer cell line human CVCL_SH56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1606; CCR5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122428 CVCL_SH55 HAP1 CCR5 (-) 1 cancer cell line human CVCL_SH55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1606; CCR5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122429 CVCL_SH58 HAP1 CD226 (-) 1 cancer cell line human CVCL_SH58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16961; CD226; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122430 CVCL_SH57 HAP1 CCSER1 (-) 1 cancer cell line human CVCL_SH57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29349; CCSER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122431 CVCL_SH59 HAP1 CD226 (-) 2 cancer cell line human CVCL_SH59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16961; CD226; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122432 CVCL_0B11 OSCA-68 cancer cell line dog CVCL_0B11 CL:0000010 Breed/subspecies: Golden Retriever. Female 21122433 CVCL_0B10 OSCA-66 cancer cell line dog CVCL_0B10 CL:0000010 Breed/subspecies: Rottweiler. Female 21122434 CVCL_0B13 OSCA-70 cancer cell line dog CVCL_0B13 CL:0000010 Breed/subspecies: Golden Retriever. Female 21122435 CVCL_0B12 OSCA-69 cancer cell line dog CVCL_0B12 CL:0000010 Breed/subspecies: Rottweiler. Male 21122436 CVCL_0B15 OSCA-74 cancer cell line dog CVCL_0B15 CL:0000010 Breed/subspecies: Doberman Pinscher. Male 21122437 CVCL_0B14 OSCA-72 cancer cell line dog CVCL_0B14 CL:0000010 Breed/subspecies: Rottweiler. Female 21122438 CVCL_0B17 OSCA-62 cancer cell line dog CVCL_0B17 CL:0000010 Breed/subspecies: Golden Retriever. Female 21122439 CVCL_0B16 OSCA-76 cancer cell line dog CVCL_0B16 CL:0000010 Breed/subspecies: Rottweiler. Female 21122440 CVCL_0B19 OSW cancer cell line dog CVCL_0B19 CL:0000010 Sequence variation: Mutation; VGNC; 38196; ASXL1; Simple; p.Gly618fs (c.1850dupG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 40797; FBXW7; Simple; p.Arg694Gln (c.2081G>A); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 42490; KMT2C; Simple; p.Gly976fs (c.2922delG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 42491; KMT2D; Simple; p.Gln5395fs (c.16183delC); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 43761; NF1; Simple; p.Asn58fs (c.167delA); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 44567; PTEN; Simple; p.Lys245fs (c.734delA); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; -; SPEN; Simple; p.Ala8fs (c.13_14insG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg164His (c.491G>A); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Airedale Terrier. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 16 hours (PubMed=27257868) Group: Patented cell line; Part of: FACC canine tumor cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9116 21122441 CVCL_0B18 17-71 cancer cell line dog CVCL_0B18 CL:0000010 Sequence variation: Mutation; VGNC; 39270; CIC; Simple; p.Pro1551fs (c.4650_4653delCCCT); Zygosity=Heterozygous (PubMed=31175136) Derived from sampling site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Unspecified Doubling time: 24 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21122442 CVCL_SH41 HAP1 CCNG1 (-) 1 cancer cell line human CVCL_SH41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1592; CCNG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122443 CVCL_SH40 HAP1 CCNE2 (-) 2 cancer cell line human CVCL_SH40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1590; CCNE2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122444 CVCL_SH43 HAP1 CCNG2 (-) 1 cancer cell line human CVCL_SH43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1593; CCNG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122445 CVCL_SH42 HAP1 CCNG1 (-) 2 cancer cell line human CVCL_SH42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1592; CCNG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122446 CVCL_SH45 HAP1 CCNL2 (-) cancer cell line human CVCL_SH45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20570; CCNL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122447 CVCL_SH44 HAP1 CCNJ (-) cancer cell line human CVCL_SH44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23434; CCNJ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122448 CVCL_SH47 HAP1 CCNO (-) 2 cancer cell line human CVCL_SH47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18576; CCNO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122449 CVCL_SH46 HAP1 CCNO (-) 1 cancer cell line human CVCL_SH46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18576; CCNO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122450 CVCL_SH49 HAP1 CCNT1 (-) 2 cancer cell line human CVCL_SH49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1599; CCNT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122451 CVCL_SH48 HAP1 CCNT1 (-) 1 cancer cell line human CVCL_SH48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1599; CCNT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122452 CVCL_JN91 HPSI0613i-iurx_2 induced pluripotent stem cell human CVCL_JN91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122453 CVCL_JN90 HPSI0613i-hikj_3 induced pluripotent stem cell human CVCL_JN90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122454 CVCL_SH30 HAP1 CCNB1 (-) 1 cancer cell line human CVCL_SH30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1579; CCNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122455 CVCL_JN89 HPSI0613i-hegp_2 induced pluripotent stem cell human CVCL_JN89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122456 CVCL_SH32 HAP1 CCNB1IP1 (-) 1 cancer cell line human CVCL_SH32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19437; CCNB1IP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122457 CVCL_SH31 HAP1 CCNB1 (-) 2 cancer cell line human CVCL_SH31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1579; CCNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122458 CVCL_SH34 HAP1 CCND1 (-) 2 cancer cell line human CVCL_SH34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1582; CCND1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122459 CVCL_JN86 HPSI0613i-funp_1 induced pluripotent stem cell human CVCL_JN86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122460 CVCL_SH33 HAP1 CCND1 (-) 1 cancer cell line human CVCL_SH33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1582; CCND1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122461 CVCL_JN85 HPSI0613i-focm_3 induced pluripotent stem cell human CVCL_JN85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122462 CVCL_SH36 HAP1 CCND2 (-) 2 cancer cell line human CVCL_SH36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122463 CVCL_JN88 HPSI0613i-hegp_1 induced pluripotent stem cell human CVCL_JN88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122464 CVCL_SH35 HAP1 CCND2 (-) 1 cancer cell line human CVCL_SH35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1583; CCND2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122465 CVCL_JN87 HPSI0613i-giuo_6 induced pluripotent stem cell human CVCL_JN87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122466 CVCL_SH38 HAP1 CCNE1 (-) 1 cancer cell line human CVCL_SH38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1589; CCNE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122467 CVCL_JN82 HPSI0613i-eojr_1 induced pluripotent stem cell human CVCL_JN82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122468 CVCL_SH37 HAP1 CCND3 (-) cancer cell line human CVCL_SH37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1585; CCND3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122469 CVCL_JN81 HPSI0613i-dium_3 induced pluripotent stem cell human CVCL_JN81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122470 CVCL_JN84 HPSI0613i-focm_2 induced pluripotent stem cell human CVCL_JN84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122471 CVCL_SH39 HAP1 CCNE2 (-) 1 cancer cell line human CVCL_SH39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1590; CCNE2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122472 CVCL_JN83 HPSI0613i-febc_3 induced pluripotent stem cell human CVCL_JN83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122473 CVCL_SH19 HAP1 CCDC132 (-) cancer cell line human CVCL_SH19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25956; VPS50; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122474 CVCL_SH21 HAP1 CCDC53 (-) 1 cancer cell line human CVCL_SH21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24256; WASHC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122475 CVCL_SH20 HAP1 CCDC51 (-) 1 cancer cell line human CVCL_SH20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25714; CCDC51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122476 CVCL_SH23 HAP1 CCDC53 (-) 3 cancer cell line human CVCL_SH23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24256; WASHC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122477 CVCL_JN97 HPSI0613i-liun_3 induced pluripotent stem cell human CVCL_JN97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122478 CVCL_SH22 HAP1 CCDC53 (-) 2 cancer cell line human CVCL_SH22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24256; WASHC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122479 CVCL_JN96 HPSI0613i-liun_1 induced pluripotent stem cell human CVCL_JN96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122480 CVCL_SH25 HAP1 CCDC6 (-) 2 cancer cell line human CVCL_SH25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18782; CCDC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122481 CVCL_JN99 HPSI0613i-liun_60 induced pluripotent stem cell human CVCL_JN99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122482 CVCL_SH24 HAP1 CCDC6 (-) 1 cancer cell line human CVCL_SH24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18782; CCDC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122483 CVCL_JN98 HPSI0613i-liun_59 induced pluripotent stem cell human CVCL_JN98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21122484 CVCL_SH27 HAP1 CCKBR (-) 1 cancer cell line human CVCL_SH27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1571; CCKBR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122485 CVCL_JN93 HPSI0613i-kewt_1 induced pluripotent stem cell human CVCL_JN93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122486 CVCL_SH26 HAP1 CCDC6 (-) 3 cancer cell line human CVCL_SH26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18782; CCDC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122487 CVCL_JN92 HPSI0613i-iurx_3 induced pluripotent stem cell human CVCL_JN92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122488 CVCL_SH29 HAP1 CCL2 (-) 1 cancer cell line human CVCL_SH29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10618; CCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122489 CVCL_JN95 HPSI0613i-lavp_2 induced pluripotent stem cell human CVCL_JN95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122490 CVCL_SH28 HAP1 CCKBR (-) 2 cancer cell line human CVCL_SH28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1571; CCKBR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122491 CVCL_JN94 HPSI0613i-kewt_2 induced pluripotent stem cell human CVCL_JN94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122492 CVCL_SH09 HAP1 CBX3 (-) 1 cancer cell line human CVCL_SH09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1553; CBX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122493 CVCL_SH08 HAP1 CBX1 (-) 3 cancer cell line human CVCL_SH08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1551; CBX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122494 CVCL_JN68 HPSI0513i-veve_3 induced pluripotent stem cell human CVCL_JN68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122495 CVCL_JN67 HPSI0513i-veve_1 induced pluripotent stem cell human CVCL_JN67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122496 CVCL_SH10 HAP1 CBX3 (-) 2 cancer cell line human CVCL_SH10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1553; CBX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122497 CVCL_JN69 HPSI0513i-xegx_3 induced pluripotent stem cell human CVCL_JN69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122498 CVCL_SH12 HAP1 CBX5 (-) 1 cancer cell line human CVCL_SH12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122499 CVCL_JN64 HPSI0513i-uilw_3 induced pluripotent stem cell human CVCL_JN64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122500 CVCL_SH11 HAP1 CBX3 (-) 3 cancer cell line human CVCL_SH11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1553; CBX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122501 CVCL_JN63 HPSI0513i-uilw_2 induced pluripotent stem cell human CVCL_JN63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122502 CVCL_SH14 HAP1 CBX5 (-) 3 cancer cell line human CVCL_SH14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122503 CVCL_JN66 HPSI0513i-veqz_5 induced pluripotent stem cell human CVCL_JN66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122504 CVCL_SH13 HAP1 CBX5 (-) 2 cancer cell line human CVCL_SH13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122505 CVCL_JN65 HPSI0513i-uoxz_6 induced pluripotent stem cell human CVCL_JN65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122506 CVCL_SH16 HAP1 CBX5 (-) 5 cancer cell line human CVCL_SH16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122507 CVCL_JN60 HPSI0513i-sucd_2 induced pluripotent stem cell human CVCL_JN60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122508 CVCL_SH15 HAP1 CBX5 (-) 4 cancer cell line human CVCL_SH15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122509 CVCL_SH18 HAP1 CCDC101 (-) cancer cell line human CVCL_SH18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25156; SGF29; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122510 CVCL_JN62 HPSI0513i-suzg_2 induced pluripotent stem cell human CVCL_JN62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122511 CVCL_SH17 HAP1 CBX5 (-) 6 cancer cell line human CVCL_SH17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1555; CBX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122512 CVCL_JN61 HPSI0513i-suzg_1 induced pluripotent stem cell human CVCL_JN61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122513 CVCL_JN80 HPSI0613i-dium_2 induced pluripotent stem cell human CVCL_JN80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122514 CVCL_JN79 HPSI0613i-bohf_2 induced pluripotent stem cell human CVCL_JN79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122515 CVCL_JN78 HPSI0613i-bawa_3 induced pluripotent stem cell human CVCL_JN78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122516 CVCL_SH01 HAP1 CAST (-) 1 cancer cell line human CVCL_SH01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1515; CAST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122517 CVCL_JN75 HPSI0613i-aevs_3 induced pluripotent stem cell human CVCL_JN75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122518 CVCL_SH00 HAP1 CASP9 (-) cancer cell line human CVCL_SH00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1511; CASP9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122519 CVCL_JN74 HPSI0613i-aaeh_3 induced pluripotent stem cell human CVCL_JN74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21122520 CVCL_SH03 HAP1 CAT (-) 1 cancer cell line human CVCL_SH03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1516; CAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122521 CVCL_JN77 HPSI0613i-bawa_2 induced pluripotent stem cell human CVCL_JN77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122522 CVCL_SH02 HAP1 CAST (-) 2 cancer cell line human CVCL_SH02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1515; CAST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122523 CVCL_JN76 HPSI0613i-auim_1 induced pluripotent stem cell human CVCL_JN76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122524 CVCL_SH05 HAP1 CBL (-) 1 cancer cell line human CVCL_SH05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122525 CVCL_JN71 HPSI0513i-zaui_2 induced pluripotent stem cell human CVCL_JN71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122526 CVCL_SH04 HAP1 CAT (-) 2 cancer cell line human CVCL_SH04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1516; CAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122527 CVCL_JN70 HPSI0513i-zaui_1 induced pluripotent stem cell human CVCL_JN70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122528 CVCL_SH07 HAP1 CBX1 (-) 2 cancer cell line human CVCL_SH07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1551; CBX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122529 CVCL_JN73 HPSI0514i-yelp_4 induced pluripotent stem cell human CVCL_JN73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122530 CVCL_SH06 HAP1 CBX1 (-) 1 cancer cell line human CVCL_SH06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1551; CBX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122531 CVCL_JN72 HPSI0514i-vuna_2 induced pluripotent stem cell human CVCL_JN72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122532 CVCL_JN49 HPSI0513i-netf_1 induced pluripotent stem cell human CVCL_JN49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122533 CVCL_JN46 HPSI0513i-kesz_3 induced pluripotent stem cell human CVCL_JN46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122534 CVCL_JN45 HPSI0513i-iasn_1 induced pluripotent stem cell human CVCL_JN45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122535 CVCL_JN48 HPSI0513i-momt_3 induced pluripotent stem cell human CVCL_JN48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122536 CVCL_JN47 HPSI0513i-leeh_1 induced pluripotent stem cell human CVCL_JN47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122537 CVCL_JN42 HPSI0513i-golb_3 induced pluripotent stem cell human CVCL_JN42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122538 CVCL_JN41 HPSI0513i-golb_2 induced pluripotent stem cell human CVCL_JN41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122539 CVCL_JN44 HPSI0513i-huls_3 induced pluripotent stem cell human CVCL_JN44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122540 CVCL_JN43 HPSI0513i-huls_2 induced pluripotent stem cell human CVCL_JN43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122541 CVCL_JN40 HPSI0513i-giuf_2 induced pluripotent stem cell human CVCL_JN40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122542 CVCL_JN57 HPSI0513i-oogu_1 induced pluripotent stem cell human CVCL_JN57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122543 CVCL_JN56 HPSI0513i-oibg_3 induced pluripotent stem cell human CVCL_JN56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122544 CVCL_JN59 HPSI0513i-sucd_1 induced pluripotent stem cell human CVCL_JN59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122545 CVCL_JN58 HPSI0513i-oogu_3 induced pluripotent stem cell human CVCL_JN58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122546 CVCL_JN53 HPSI0513i-oeoo_1 induced pluripotent stem cell human CVCL_JN53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122547 CVCL_JN52 HPSI0513i-oarz_3 induced pluripotent stem cell human CVCL_JN52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122548 CVCL_JN55 HPSI0513i-oibg_2 induced pluripotent stem cell human CVCL_JN55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122549 CVCL_JN54 HPSI0513i-oeoo_3 induced pluripotent stem cell human CVCL_JN54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122550 CVCL_JN51 HPSI0513i-oarz_1 induced pluripotent stem cell human CVCL_JN51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21122551 CVCL_JN50 HPSI0513i-netf_3 induced pluripotent stem cell human CVCL_JN50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21122552 CVCL_0C83 TLM1 cancer cell line dog CVCL_0C83 CL:0000010 Derived from sampling site: Oral cavity; Breed/subspecies: Gordon Setter. Male Doubling time: ~20 hours (Kerafast) 21122553 CVCL_0C82 17CM98 cancer cell line dog CVCL_0C82 CL:0000010 Sequence variation: Mutation; VGNC; 42422; KIT; Simple; p.Val558_Glu560del (c.1673_1681delTTGTTGAGG); Zygosity=Heterozygous (PubMed=31175136) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Unspecified Doubling time: 22 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21122554 CVCL_0C85 NZM071 cancer cell line human CVCL_0C85 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790). 21122555 CVCL_0C84 SKOV3.ip1 cancer cell line human CVCL_0C84 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21122556 CVCL_0C87 MOCHA cancer cell line human CVCL_0C87 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Highly susceptible to infection by both CCR5-tropic and CXCR4-tropic HIV-1 strains SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a HIV-1 long terminal repeat. This cell line secretes human placental alkaline phosphatase into the culture supernatant during HIV-1 infection. 21122557 CVCL_0C86 PL-20 cancer cell line dog CVCL_0C86 CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 158 hours (PubMed=20453304) 21122558 CVCL_0C89 CHAD-G4 cancer cell line dog CVCL_0C89 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male 21122559 CVCL_0C88 CHAD-B7 cancer cell line dog CVCL_0C88 CL:0000010 Derived from sampling site: Heart; right atrium; Breed/subspecies: Border Collie. Male 21122560 CVCL_0C81 UCDK9M5 cancer cell line dog CVCL_0C81 CL:0000010 Miscellaneous: Breed and age/sex of donor from personal communication of Kent M.S Derived from metastatic site: Lymph node; Breed/subspecies: Cocker Spaniel. Female 21122561 CVCL_0C80 UCDK9M4 cancer cell line dog CVCL_0C80 CL:0000010 Miscellaneous: Breed and age/sex of donor from personal communication of Kent M.S Derived from sampling site: Oral cavity; Breed/subspecies: German Shorthaired Pointer. Male 21122562 CVCL_0C94 DD-1 [Dog hemangiosarcoma] cancer cell line dog CVCL_0C94 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever x Pyrenean mountain dog. Omics: Transcriptome analysis by microarray Male Doubling time: 5-7 days (Kerafast) Caution: Was incorrectly indicated to originate from a 9 year old dog (PubMed=19461996) but is in fact from a 11 year old dog (personal communication of Modiano J.F through Kerafast). 21122563 CVCL_0C93 Dal-4 cancer cell line dog CVCL_0C93 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Dalmatian. Omics: Transcriptome analysis by microarray Male Doubling time: 5-7 days (Kerafast) 21122564 CVCL_0C96 Emma-brain cancer cell line dog CVCL_0C96 CL:0000010 Derived from metastatic site: Brain; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Female Doubling time: ~5-7 days (Kerafast) 21122565 CVCL_0C95 SB-HSA cancer cell line dog CVCL_0C95 CL:0000010 Sequence variation: Mutation; VGNC; 84862; EP300; Simple; p.Asn1570fs (c.4704dupG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 44555; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ala150fs (c.447delG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Leu184Phe (c.550C>T); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: German Shepherd. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Established from a xenograft produced in bg/nu/XID nude mice (PubMed=15064773) Doubling time: ~20-24 hours (PubMed=15064773) 21122566 CVCL_0C98 Joey-HSA cancer cell line dog CVCL_0C98 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Rottweiler. Omics: Transcriptome analysis by microarray Male 21122567 CVCL_0C97 Frog-HSA cancer cell line dog CVCL_0C97 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Discontinued: Kerafast; EMN012; true Female Doubling time: ~24 hours (Kerafast) 21122568 CVCL_0C99 Journey-HSA cancer cell line dog CVCL_0C99 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Female 21122569 CVCL_0C90 CHAD-G6 cancer cell line dog CVCL_0C90 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Female 21122570 CVCL_0C92 CHAD-P9 cancer cell line dog CVCL_0C92 CL:0000010 Derived from metastatic site: Liver; Breed/subspecies: Portuguese water dog. Omics: Transcriptome analysis by microarray Male 21122571 CVCL_0C91 CHAD-G8 cancer cell line dog CVCL_0C91 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male 21122572 CVCL_0C61 PT1590 cancer cell line human CVCL_0C61 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Unspecified (PubMed=11156375) Derived from sampling site: Esophagus. Female Caution: TP53 mutation indicated (PubMed=11156375) to change a His-176 into Arg, but the DNA change corresponds to the mutation reported in this entry 21122573 CVCL_0C60 LN1590 cancer cell line human CVCL_0C60 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Unspecified (PubMed=11156375) Derived from metastatic site: Lymph node. Female Caution: TP53 mutation indicated (PubMed=11156375) to change a His-176 into Arg, but the DNA change corresponds to the mutation reported in this entry 21122574 CVCL_0C63 UTP-DSAL-1 cancer cell line human CVCL_0C63 CL:0000010 Population: Japanese. 21122575 CVCL_0C62 PT1590-GFP cancer cell line human CVCL_0C62 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Esophagus. Female 21122576 CVCL_0C65 INV-3 cancer cell line human CVCL_0C65 CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Asp61Val (c.182A>T); ClinVar=VCV000040496; Zygosity=Unspecified (PubMed=16518851). Unspecified 21122577 CVCL_0C64 W1 cancer cell line human CVCL_0C64 CL:0000010 Derived from sampling site: Peripheral blood. Male 21122578 CVCL_0C67 340529 cancer cell line dog CVCL_0C67 CL:0000010 Unspecified 21122579 CVCL_0C66 48-4 cancer cell line dog CVCL_0C66 CL:0000010 Derived from sampling site: Bone; distal radius; Breed/subspecies: Labrador Retriever. Male Doubling time: 52 hours (PubMed=19754807) 21122580 CVCL_0C69 UM-SCC-105 cancer cell line human CVCL_0C69 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Larynx. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21122581 CVCL_0C68 348617 cancer cell line dog CVCL_0C68 CL:0000010 Unspecified 21122582 CVCL_0C72 UM-SCC-109 cancer cell line human CVCL_0C72 CL:0000010 Male 21122583 CVCL_0C71 UM-SCC-108 cancer cell line human CVCL_0C71 CL:0000010 Omics: CNV analysis. Female 21122584 CVCL_0C74 UM-SCC-111 cancer cell line human CVCL_0C74 CL:0000010 Male 21122585 CVCL_0C73 UM-SCC-110 cancer cell line human CVCL_0C73 CL:0000010 Omics: CNV analysis. Male 21122586 CVCL_0C76 CMM2 cancer cell line dog CVCL_0C76 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468) Derived from sampling site: Oral cavity; Breed/subspecies: Mixed breed. Unspecified Doubling time: 21.0 +- 0.73 hours (PubMed=11217070) 21122587 CVCL_0C75 CMM1 cancer cell line dog CVCL_0C75 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468) Derived from sampling site: Oral cavity; Breed/subspecies: Toy Poodle. Male Doubling time: 18.4 +- 1.96 hours (PubMed=11217070) 21122588 CVCL_0C78 UCDK9M2 cancer cell line dog CVCL_0C78 CL:0000010 Miscellaneous: Breed and age/sex of donor from personal communication of Kent M.S Derived from metastatic site: Lymph node; Breed/subspecies: Irish Terrier. Male 21122589 CVCL_0C77 UCDK9M1 cancer cell line dog CVCL_0C77 CL:0000010 Miscellaneous: Breed and age/sex of donor from personal communication of Kent M.S Derived from metastatic site: Skin; Breed/subspecies: Miniature Poodle. Male 21122590 CVCL_0C79 UCDK9M3 cancer cell line dog CVCL_0C79 CL:0000010 Miscellaneous: Breed and age/sex of donor from personal communication of Kent M.S Derived from sampling site: Oral cavity; Breed/subspecies: Springer Spaniel x Chow. Female 21122591 CVCL_0C70 UM-SCC-106 cancer cell line human CVCL_0C70 CL:0000010 Male 21122592 CVCL_0C41 JK-6L cancer cell line human CVCL_0C41 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (DSMZ); Sequence variation: Mutation; HGNC; 7795; NFKB2; Simple; p.Arg725Glufs*18 (c.2171delC); Zygosity=Homozygous (PubMed=17692805); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Tyr64Asp (c.190T>G); dbSNP=rs752508313; Zygosity=Unspecified (DSMZ) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgG kappa; Characteristics: Compared to the parent cell line, it is no longer IL6 dependent Doubling time: ~48 hours (DSMZ=ACC-860) Caution: Indicated as JK-6 in DSMZ, but the original JK-6 was IL-dependent and the IL-6 independent subline was called JK-6L (PubMed=19621390) 21122593 CVCL_0C40 INA-6.Tu1 cancer cell line human CVCL_0C40 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Met (c.395A>T); ClinVar=VCV000376629; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent; Characteristics: Derived from a tumor that grew in a SCID mouse 21122594 CVCL_0C43 BLC-2 cancer cell line human CVCL_0C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21122595 CVCL_0C42 BLC-1 cancer cell line human CVCL_0C42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21122596 CVCL_0C45 BLC-6 cancer cell line human CVCL_0C45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21122597 CVCL_0C44 BLC-4 cancer cell line human CVCL_0C44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21122598 CVCL_0C47 MF-1 [Human] cancer cell line human CVCL_0C47 CL:0000010 Male 21122599 CVCL_0C46 BLC-7 cancer cell line human CVCL_0C46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21122600 CVCL_0C49 MF-3 cancer cell line human CVCL_0C49 CL:0000010 Male 21122601 CVCL_0C48 MF-2 cancer cell line human CVCL_0C48 CL:0000010 Male 21122602 CVCL_SI91 HAP1 CHD2 (-) 3 cancer cell line human CVCL_SI91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1917; CHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122603 CVCL_SI90 HAP1 CHD2 (-) 2 cancer cell line human CVCL_SI90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1917; CHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122604 CVCL_SI93 HAP1 CHD3 (-) 1 cancer cell line human CVCL_SI93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1918; CHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122605 CVCL_SI92 HAP1 CHD2 (-) 4 cancer cell line human CVCL_SI92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1917; CHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122606 CVCL_SI95 HAP1 CHEK2 (-) 1 cancer cell line human CVCL_SI95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16627; CHEK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122607 CVCL_SI94 HAP1 CHD3 (-) 2 cancer cell line human CVCL_SI94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1918; CHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122608 CVCL_SI97 HAP1 CHEK2 (-) 3 cancer cell line human CVCL_SI97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16627; CHEK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122609 CVCL_SI96 HAP1 CHEK2 (-) 2 cancer cell line human CVCL_SI96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16627; CHEK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122610 CVCL_SI99 HAP1 CHMP7 (-) 1 cancer cell line human CVCL_SI99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28439; CHMP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122611 CVCL_SI98 HAP1 CHMP1A (-) 1 cancer cell line human CVCL_SI98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122612 CVCL_0C50 MF-5 cancer cell line human CVCL_0C50 CL:0000010 Derived from metastatic site: Hypodermis. Female 21122613 CVCL_0C52 HCC-1.1 cancer cell line human CVCL_0C52 CL:0000010 Male 21122614 CVCL_0C51 MF-6 cancer cell line human CVCL_0C51 CL:0000010 Female 21122615 CVCL_0C54 HCC-2 cancer cell line human CVCL_0C54 CL:0000010 Male 21122616 CVCL_0C53 HCC-1.2 cancer cell line human CVCL_0C53 CL:0000010 Male 21122619 CVCL_0C58 LN6216c cancer cell line human CVCL_0C58 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=25070024) Derived from metastatic site: Subcarinal lymph node. Male 21122620 CVCL_0C57 HCC-3 cancer cell line human CVCL_0C57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Unspecified (PubMed=31063779) Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays. Male 21122621 CVCL_0C59 PT6216 cancer cell line human CVCL_0C59 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=25070024) Derived from sampling site: Esophagus. Male 21122622 CVCL_SI80 HAP1 CHCHD2 (-) 2 cancer cell line human CVCL_SI80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21645; CHCHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122623 CVCL_SI82 HAP1 CHCHD3 (-) 2 cancer cell line human CVCL_SI82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21906; CHCHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122624 CVCL_SI81 HAP1 CHCHD3 (-) 1 cancer cell line human CVCL_SI81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21906; CHCHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122625 CVCL_SI84 HAP1 CHCHD6 (-) 2 cancer cell line human CVCL_SI84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28184; CHCHD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122626 CVCL_SI83 HAP1 CHCHD6 (-) 1 cancer cell line human CVCL_SI83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28184; CHCHD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122627 CVCL_SI86 HAP1 CHD1 (-) 2 cancer cell line human CVCL_SI86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1915; CHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122628 CVCL_SI85 HAP1 CHD1 (-) 1 cancer cell line human CVCL_SI85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1915; CHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122629 CVCL_SI88 HAP1 CHD1L (-) 2 cancer cell line human CVCL_SI88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1916; CHD1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122630 CVCL_SI87 HAP1 CHD1L (-) 1 cancer cell line human CVCL_SI87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1916; CHD1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122631 CVCL_SI89 HAP1 CHD2 (-) 1 cancer cell line human CVCL_SI89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1917; CHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122632 CVCL_AV56 GM11503 transformed cell line human CVCL_AV56 CL:0000010 Population: Caucasian; English/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122633 CVCL_B756 RG-366 embryonic stem cell human CVCL_B756 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122634 CVCL_AV55 GM09716 finite cell line human CVCL_AV55 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21122635 CVCL_B755 RG-363 embryonic stem cell human CVCL_B755 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122636 CVCL_AV58 GM11504 transformed cell line human CVCL_AV58 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122637 CVCL_B758 RG-369 embryonic stem cell human CVCL_B758 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122638 CVCL_B757 RG-367 embryonic stem cell human CVCL_B757 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122639 CVCL_AV57 RWV366T cancer cell line human CVCL_AV57 CL:0000010 Miscellaneous: STR profile from personal communication of Marlow L.A Derived from sampling site: Kidney. Male 21122640 CVCL_AV59 MCJB2 cancer cell line human CVCL_AV59 CL:0000010 Miscellaneous: Cell line information from personal communication of Marlow L.A. Female Doubling time: 55 hours (Direct_author_submission) Group: Triple negative breast cancer (TNBC) cell line 21122641 CVCL_B759 RG-386 embryonic stem cell human CVCL_B759 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122642 CVCL_AV50 IPLB-HZ-1079 spontaneously immortalized cell line CVCL_AV50 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 21122643 CVCL_B750 RG-354 embryonic stem cell human CVCL_B750 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122644 CVCL_AV52 IPLB-HZ-124Q spontaneously immortalized cell line CVCL_AV52 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122645 CVCL_B752 RG-357 embryonic stem cell human CVCL_B752 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122646 CVCL_AV51 IPLB-HZ-110 spontaneously immortalized cell line CVCL_AV51 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122647 CVCL_B751 RG-356 embryonic stem cell human CVCL_B751 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122648 CVCL_AV54 KIJ265T cancer cell line human CVCL_AV54 CL:0000010 Miscellaneous: STR profile from personal communication of Marlow L.A Derived from sampling site: Kidney. Female 21122649 CVCL_B754 RG-359 embryonic stem cell human CVCL_B754 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122650 CVCL_AV53 HOVTAX2 cancer cell line human CVCL_AV53 CL:0000010 Female 21122651 CVCL_B753 RG-358 embryonic stem cell human CVCL_B753 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122652 CVCL_AV67 PLum-AI cancer cell line house mouse CVCL_AV67 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Rosa26-Cre(ER)Pten(fl/fl)P53(fl/fl). Male 21122653 CVCL_B767 RG-404 embryonic stem cell human CVCL_B767 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122654 CVCL_AV66 PLum-AD cancer cell line house mouse CVCL_AV66 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Rosa26-Cre(ER)Pten(fl/fl)P53(fl/fl). Male 21122655 CVCL_B766 RG-403 embryonic stem cell human CVCL_B766 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122656 CVCL_AV69 COLO 720E contaminated cancer cell line human CVCL_AV69 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites (Note=From a colon metastasis). Omics: Transcriptome analysis by microarray Discontinued: ECACC; 93072111; true Female Part of: OCCP ovarian cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00438 Problematic cell line: Contaminated The stock of COLO 720E distributed by ECACC was contaminated by COLO 704 (PubMed=25230021; PubMed=25877200). 21122657 CVCL_B769 RG-406 embryonic stem cell human CVCL_B769 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122658 CVCL_AV68 PLum-C cancer cell line house mouse CVCL_AV68 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Rosa26-Cre(ER)Pten(fl/fl)P53(fl/fl). Male 21122659 CVCL_B768 RG-405 embryonic stem cell human CVCL_B768 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122660 CVCL_AV61 GM11505 transformed cell line human CVCL_AV61 CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122661 CVCL_B761 RG-396 embryonic stem cell human CVCL_B761 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122662 CVCL_AV60 HOVTAX2-paclitaxel resistant cancer cell line human CVCL_AV60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol). Female 21122663 CVCL_B760 RG-395 embryonic stem cell human CVCL_B760 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122664 CVCL_B763 RG-399 embryonic stem cell human CVCL_B763 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122665 CVCL_AV63 SDAR1 cancer cell line human CVCL_AV63 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val54fs (c.160delG); Zygosity=Homozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Pro (c.845G>C); ClinVar=VCV000376659; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21122666 CVCL_AV62 EAM306 cancer cell line human CVCL_AV62 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu326Ter (c.976G>T); ClinVar=VCV000231815; Zygosity=Unspecified (PubMed=29846633; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21122667 CVCL_B762 RG-397 embryonic stem cell human CVCL_B762 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122668 CVCL_B765 RG-402 embryonic stem cell human CVCL_B765 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122669 CVCL_AV65 SDAR3 cancer cell line human CVCL_AV65 CL:0000010 Derived from metastatic site: Jugular vein. Male 21122670 CVCL_B764 RG-401 embryonic stem cell human CVCL_B764 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122671 CVCL_AV64 SDAR2 cancer cell line human CVCL_AV64 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val54fs (c.160delG); Zygosity=Homozygous (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=29846633; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val217fs (c.648delG); Zygosity=Homozygous (PubMed=29846633; PubMed=30737244) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21122672 CVCL_AV34 KU-HaPO1 spontaneously immortalized cell line CVCL_AV34 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122673 CVCL_B734 RG-334 embryonic stem cell human CVCL_B734 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122674 CVCL_AV33 KU-HaEmb2 spontaneously immortalized cell line CVCL_AV33 CL:0000010 Unspecified Group: Insect cell line. 21122675 CVCL_B733 RG-333 embryonic stem cell human CVCL_B733 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122676 CVCL_AV36 NEAU-Ms-980312 spontaneously immortalized cell line CVCL_AV36 CL:0000010 Unspecified Doubling time: 47.82 hours (CelloPub=CLPUB00314). Group: Insect cell line 21122677 CVCL_B736 RG-336 embryonic stem cell human CVCL_B736 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122678 CVCL_AV35 KU-HaPO2 spontaneously immortalized cell line CVCL_AV35 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122679 CVCL_B735 RG-335 embryonic stem cell human CVCL_B735 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122680 CVCL_AV38 QB-CL-A spontaneously immortalized cell line CVCL_AV38 CL:0000010 Unspecified Doubling time: 21.7 hours (PubMed=21979569). Group: Insect cell line 21122681 CVCL_B738 RG-338 embryonic stem cell human CVCL_B738 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122682 CVCL_AV37 QAU-BTI-Tn9-4s spontaneously immortalized cell line CVCL_AV37 CL:0000010 Unspecified Doubling time: 22.9-24.1 hours (in serum-free Sf-900 III medium), 27.4 hours (in TNM-FH medium) (PubMed=25373171); 22.6 hours (PubMed=21979569). Group: Insect cell line 21122683 CVCL_B737 RG-337 embryonic stem cell human CVCL_B737 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122684 CVCL_AV39 QB-CL-B spontaneously immortalized cell line CVCL_AV39 CL:0000010 Unspecified Doubling time: 20.2 hours (PubMed=21979569). Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201046 21122685 CVCL_B739 RG-339 embryonic stem cell human CVCL_B739 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122686 CVCL_AV30 IPLB-PiE spontaneously immortalized cell line CVCL_AV30 CL:0000010 Unspecified Group: Insect cell line. 21122687 CVCL_B730 RG-33 embryonic stem cell human CVCL_B730 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122688 CVCL_AV32 KU-HaEmb1 spontaneously immortalized cell line CVCL_AV32 CL:0000010 Unspecified Group: Insect cell line. 21122689 CVCL_B732 RG-331 embryonic stem cell human CVCL_B732 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122690 CVCL_AV31 KU-HaAO1 spontaneously immortalized cell line CVCL_AV31 CL:0000010 Derived from sampling site: Ovary. Female Virology: Highly susceptible to infection by Helicoverpa armigera nucleopolyhedrovirus (HearNPV) (DOI=10.11416/jibs.77.1_25) Group: Insect cell line 21122691 CVCL_B731 RG-330 embryonic stem cell human CVCL_B731 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122692 CVCL_B745 RG-345 embryonic stem cell human CVCL_B745 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122693 CVCL_AV45 UIV-SL-573 spontaneously immortalized cell line CVCL_AV45 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~30 hours (DOI=10.1007/BF02618358) Group: Insect cell line 21122694 CVCL_B744 RG-344 embryonic stem cell human CVCL_B744 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122695 CVCL_AV44 UIV-SL-373 spontaneously immortalized cell line CVCL_AV44 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122696 CVCL_B747 RG-350 embryonic stem cell human CVCL_B747 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122697 CVCL_AV47 UMN-MDH-1 spontaneously immortalized cell line CVCL_AV47 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Group: Insect cell line 21122698 CVCL_B746 RG-349 embryonic stem cell human CVCL_B746 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122699 CVCL_AV46 UIV-SL-673 spontaneously immortalized cell line CVCL_AV46 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122700 CVCL_AV49 IPLB-HZ-1074 spontaneously immortalized cell line CVCL_AV49 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122701 CVCL_B749 RG-353 embryonic stem cell human CVCL_B749 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122702 CVCL_AV48 NISES-AnPe-428 spontaneously immortalized cell line CVCL_AV48 CL:0000010 Unspecified Virology: Supports productive replication of Autographa californica multiple nucleopolyhedrovirus (AcMNPV), Antheraea pernyi nucleopolyhedrovirus (AnpeNPV), Bombyx mori nucleopolyhedrovirus (BmNPV) and Hyphantria cunea multiple nucleopolyhedrovirus (HycuMNPV) Upon infection with Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV), a subset of the cells population undergoes apoptosis. Refractory to infection by Lymantria dispar multiple nucleopolyhedrovirus (LdMNPV).. Group: Insect cell line; Group: Recombinant protein production insect cell line 21122703 CVCL_B748 RG-351 embryonic stem cell human CVCL_B748 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122704 CVCL_B741 RG-341 embryonic stem cell human CVCL_B741 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122705 CVCL_AV41 SIE-EO-801 spontaneously immortalized cell line CVCL_AV41 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122706 CVCL_B740 RG-340 embryonic stem cell human CVCL_B740 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122707 CVCL_AV40 SeHe920-1a spontaneously immortalized cell line CVCL_AV40 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 28 hours (PubMed=15638701) Group: Insect cell line 21122708 CVCL_B743 RG-343 embryonic stem cell human CVCL_B743 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122709 CVCL_AV43 UGA-CiE1 spontaneously immortalized cell line CVCL_AV43 CL:0000010 Unspecified Doubling time: 66.3 +- 5.5 hours (at 44th passage), 62.5 +- 4.3 hours (at 64th passage) (PubMed=20381615). Group: Insect cell line 21122710 CVCL_B742 RG-342 embryonic stem cell human CVCL_B742 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122711 CVCL_AV42 SIE-EO-803 spontaneously immortalized cell line CVCL_AV42 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122712 CVCL_AV12 CAF-Clan II spontaneously immortalized cell line CVCL_AV12 CL:0000010 Unspecified Group: Insect cell line. 21122713 CVCL_B712 RG-300 embryonic stem cell human CVCL_B712 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Ambiguous 21122714 CVCL_AV11 CAF-Clan I spontaneously immortalized cell line CVCL_AV11 CL:0000010 Unspecified Group: Insect cell line. 21122715 CVCL_B711 RG-299 embryonic stem cell human CVCL_B711 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122716 CVCL_AV14 CpDW2 spontaneously immortalized cell line CVCL_AV14 CL:0000010 Unspecified Group: Insect cell line. 21122717 CVCL_B714 RG-302 embryonic stem cell human CVCL_B714 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122718 CVCL_AV13 CpDW1 spontaneously immortalized cell line CVCL_AV13 CL:0000010 Unspecified Group: Insect cell line. 21122719 CVCL_B713 RG-301 embryonic stem cell human CVCL_B713 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122720 CVCL_AV16 CpDW4 spontaneously immortalized cell line CVCL_AV16 CL:0000010 Unspecified Group: Insect cell line. 21122721 CVCL_B716 RG-308 embryonic stem cell human CVCL_B716 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122722 CVCL_AV15 CpDW3 spontaneously immortalized cell line CVCL_AV15 CL:0000010 Unspecified Group: Insect cell line. 21122723 CVCL_B715 RG-304 embryonic stem cell human CVCL_B715 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122724 CVCL_AV18 CpDW6 spontaneously immortalized cell line CVCL_AV18 CL:0000010 Unspecified Group: Insect cell line. 21122725 CVCL_B718 RG-310 embryonic stem cell human CVCL_B718 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122726 CVCL_AV17 CpDW5 spontaneously immortalized cell line CVCL_AV17 CL:0000010 Unspecified Group: Insect cell line. 21122727 CVCL_B717 RG-31 embryonic stem cell human CVCL_B717 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122728 CVCL_AV10 BPMNU-MyCo-1 spontaneously immortalized cell line CVCL_AV10 CL:0000010 Derived from sampling site: Fat body. Unspecified Characteristics: Can be used for propagation of the microsporidian fungal parasite Nosema locustae Doubling time: 40 hours (CelloPub=CLPUB00442) Group: Insect cell line 21122729 CVCL_B710 RG-298 embryonic stem cell human CVCL_B710 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122730 CVCL_AV09 Ao/I spontaneously immortalized cell line CVCL_AV09 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~30 hours (CelloPub=CLPUB00496) Group: Insect cell line 21122731 CVCL_B709 RG-297 embryonic stem cell human CVCL_B709 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122732 CVCL_AV08 Chula3.hES embryonic stem cell human CVCL_AV08 From: Chulalongkorn University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Karyotypic information: Triploid karyotype. Ambiguous 21122733 CVCL_B708 RG-296 embryonic stem cell human CVCL_B708 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122734 CVCL_AV23 CpDW13 spontaneously immortalized cell line CVCL_AV23 CL:0000010 Unspecified Group: Insect cell line. 21122735 CVCL_B723 RG-320 embryonic stem cell human CVCL_B723 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; c.663+1G>A (IVS7+1G>A); ClinVar=VCV000049076; Zygosity=Heterozygous; Note=Splice donor mutation. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122736 CVCL_AV22 CpDW12 spontaneously immortalized cell line CVCL_AV22 CL:0000010 Unspecified Group: Insect cell line. 21122737 CVCL_B722 RG-316 embryonic stem cell human CVCL_B722 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; c.663+1G>A (IVS7+1G>A); ClinVar=VCV000049076; Zygosity=Heterozygous; Note=Splice donor mutation. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122738 CVCL_AV25 CpDW15 spontaneously immortalized cell line CVCL_AV25 CL:0000010 Unspecified Group: Insect cell line. 21122739 CVCL_B725 RG-325 embryonic stem cell human CVCL_B725 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122740 CVCL_AV24 CpDW14 spontaneously immortalized cell line CVCL_AV24 CL:0000010 Unspecified Group: Insect cell line. 21122741 CVCL_B724 RG-321 embryonic stem cell human CVCL_B724 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-03.. 21122742 CVCL_AV27 IMC-Hz-1 spontaneously immortalized cell line CVCL_AV27 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21122743 CVCL_B727 RG-327 embryonic stem cell human CVCL_B727 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122744 CVCL_AV26 EpN1.10 spontaneously immortalized cell line CVCL_AV26 CL:0000010 Unspecified Doubling time: ~36 hours (PubMed=20167219). Group: Insect cell line 21122745 CVCL_B726 RG-326 embryonic stem cell human CVCL_B726 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 6121; IRF6; Simple; p.Arg84His (c.251G>A); ClinVar=VCV000003415; Zygosity=Unspecified (ISCR). Male Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122746 CVCL_AV29 IOZCAS-Spex-XI spontaneously immortalized cell line CVCL_AV29 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 81.7 hours (DOI=10.1111/j.1439-0418.2011.01689.x) Group: Insect cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4807 21122747 CVCL_B729 RG-329 embryonic stem cell human CVCL_B729 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122748 CVCL_AV28 IOZCAS-Spex-X spontaneously immortalized cell line CVCL_AV28 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 56.98 hours (Patent=CN102807968B) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4505 21122749 CVCL_B728 RG-328 embryonic stem cell human CVCL_B728 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122750 CVCL_AV21 CpDW11 spontaneously immortalized cell line CVCL_AV21 CL:0000010 Unspecified Group: Insect cell line. 21122751 CVCL_B721 RG-315 embryonic stem cell human CVCL_B721 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg1968Ter (c.5902C>T) (p.Arg1947Ter, c.5839C>T); ClinVar=VCV000000343; Zygosity=Heterozygous (ISCR). Male Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122752 CVCL_AV20 CpDW10 spontaneously immortalized cell line CVCL_AV20 CL:0000010 Unspecified Group: Insect cell line. 21122753 CVCL_B720 RG-313 embryonic stem cell human CVCL_B720 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122754 CVCL_AV19 CpDW9 spontaneously immortalized cell line CVCL_AV19 CL:0000010 Unspecified Group: Insect cell line. 21122755 CVCL_B719 RG-311 embryonic stem cell human CVCL_B719 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122756 CVCL_AV01 HCEC 1CTA telomerase immortalized cell line human CVCL_AV01 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 583; APC; Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Colon Cell type=Epithelial cell.. Male 21122757 CVCL_B701 RG-284 embryonic stem cell human CVCL_B701 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122758 CVCL_AV00 PC-12 HD-Q74 cell 1b cancer cell line Norway rat CVCL_AV00 CL:0000010 Transfected with: HGNC; 4851; HTT (1st exon with 74-Q run); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21122759 CVCL_B700 RG-283 embryonic stem cell human CVCL_B700 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122760 CVCL_AV03 HCEC 1CTR telomerase immortalized cell line human CVCL_AV03 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Colon Cell type=Epithelial cell.. Male 21122761 CVCL_B703 RG-286 embryonic stem cell human CVCL_B703 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122762 CVCL_AV02 HCEC 1CTP telomerase immortalized cell line human CVCL_AV02 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Derived from sampling site: Colon Cell type=Epithelial cell.. Male 21122763 CVCL_B702 RG-285 embryonic stem cell human CVCL_B702 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122764 CVCL_AV05 MUG-CC1 cancer cell line human CVCL_AV05 HLA typing: A*24 (Chordoma_Foundation) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; cranium; clivus. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 109.16 +- 18.79 hours (PubMed=27072875); ~12 days (ATCC=CRL-3327); 15 days (Chordoma_Foundation) 21122765 CVCL_B705 RG-289 embryonic stem cell human CVCL_B705 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ISCR). Female Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122766 CVCL_AV04 Chor-IN-1 cancer cell line human CVCL_AV04 CL:0000010 Sequence variation: Mutation; HGNC; 6308; KEL; Simple; p.Ser726fs (c.2176delA); Zygosity=Unspecified; Note=Somatic (PubMed=28835717); Sequence variation: Mutation; HGNC; 7508; MUC1; Simple; p.Pro24Thr (c.70C>A); Zygosity=Unspecified; Note=Somatic (PubMed=28835717); Sequence variation: Mutation; HGNC; 16860; SART3; Simple; p.Glu556Lys (c.1666G>A); Zygosity=Unspecified; Note=Somatic (PubMed=28835717); Sequence variation: Mutation; HGNC; 11720; TECTA; Simple; p.Arg1450His (c.4349G>A); Zygosity=Unspecified; Note=Somatic (PubMed=28835717) Derived from sampling site: Bone; sacrum. Omics: CNV analysis Male Doubling time: ~7 days (PubMed=28835717) 21122767 CVCL_B704 RG-288 embryonic stem cell human CVCL_B704 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ISCR). Male Registration: NIH Human Embryonic Stem Cell Registry; not approved 21122768 CVCL_AV07 CV-iPS2 induced pluripotent stem cell human CVCL_AV07 CL:0000010 Derived from sampling site: Chorionic villus. Female 21122769 CVCL_B707 RG-295 embryonic stem cell human CVCL_B707 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122770 CVCL_AV06 CV-iPS1 induced pluripotent stem cell human CVCL_AV06 CL:0000010 Derived from sampling site: Chorionic villus. Female 21122771 CVCL_B706 RG-294 embryonic stem cell human CVCL_B706 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122772 CVCL_K049 184 finite cell line human CVCL_K049 CL:0000010 Derived from sampling site: Breast; epithelium. Female Doubling time: 2.5 days (PubMed=9671407) 21122773 CVCL_K048 Me45 cancer cell line human CVCL_K048 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21122774 CVCL_K045 IGEL b4 hybridoma house mouse CVCL_K045 CL:0000010 Monoclonal antibody isotype: IgE, Igb haplotype; Monoclonal antibody target: ChEBI; CHEBI:53067; 2,4,6-trinitrophenyl group (TNP). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21122775 CVCL_K044 IGEL a2 hybridoma house mouse CVCL_K044 CL:0000010 Monoclonal antibody isotype: IgE, Iga haplotype; Monoclonal antibody target: ChEBI; CHEBI:53067; 2,4,6-trinitrophenyl group (TNP). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21122776 CVCL_K047 NT2-Rho0 cancer cell line human CVCL_K047 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male 21122777 CVCL_K046 Neuro-2a-Luc cancer cell line house mouse CVCL_K046 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: A/J. Male 21122778 CVCL_K041 aIR-2 hybridoma house mouse CVCL_K041 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. 21122779 CVCL_K040 aIR-1 hybridoma house mouse CVCL_K040 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06213; Human INSR/CD220. 21122780 CVCL_K043 aM346C7C1 hybridoma house mouse CVCL_K043 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q1X7X6; Escherichia coli fimbrial adhesin fedF. Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11124 21122781 CVCL_K042 aIR-3 hybridoma house mouse CVCL_K042 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. 21122782 CVCL_K059 272E4 transformed cell line human CVCL_K059 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21122783 CVCL_K056 iPS-DF4-3-7T.A induced pluripotent stem cell human CVCL_K056 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21122784 CVCL_K055 iPS-DF19-9-7T induced pluripotent stem cell human CVCL_K055 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21122785 CVCL_K058 272E1 transformed cell line human CVCL_K058 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21122786 CVCL_K057 iPS-DF6-9-9T.B induced pluripotent stem cell human CVCL_K057 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21122787 CVCL_K052 90PE6E7 transformed cell line human CVCL_K052 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Heterozygous (PubMed=10739701); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; epithelium. Female 21122788 CVCL_K051 90P-hTERT telomerase immortalized cell line human CVCL_K051 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female 21122789 CVCL_K054 iPS-DF19-9-11T.H induced pluripotent stem cell human CVCL_K054 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis Male 21122790 CVCL_K053 184-hTERT telomerase immortalized cell line human CVCL_K053 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Female 21122791 CVCL_K050 90P finite cell line human CVCL_K050 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Heterozygous (PubMed=10739701) Derived from sampling site: Breast; epithelium. Female 21122792 CVCL_AU93 GM10505 transformed cell line human CVCL_AU93 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122793 CVCL_B693 RG-275 embryonic stem cell human CVCL_B693 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122794 CVCL_AU92 GM10359 transformed cell line human CVCL_AU92 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122795 CVCL_B692 RG-274 embryonic stem cell human CVCL_B692 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122796 CVCL_B695 RG-277 embryonic stem cell human CVCL_B695 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Homozygous (ISCR). Unspecified 21122797 CVCL_AU95 UP-029 cancer cell line human CVCL_AU95 CL:0000010 21122798 CVCL_AU94 GM10506 transformed cell line human CVCL_AU94 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122799 CVCL_B694 RG-276 embryonic stem cell human CVCL_B694 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122800 CVCL_AU97 PC-12 HD-Q23 cell 14 cancer cell line Norway rat CVCL_AU97 CL:0000010 Transfected with: HGNC; 4851; HTT (1st exon with 23-Q run); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21122801 CVCL_B697 RG-279 embryonic stem cell human CVCL_B697 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122802 CVCL_AU96 IN699 cancer cell line human CVCL_AU96 CL:0000010 Derived from sampling site: Brain. Male 21122803 CVCL_B696 RG-278 embryonic stem cell human CVCL_B696 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122804 CVCL_AU99 PC-12 HD-Q74 cell 10 cancer cell line Norway rat CVCL_AU99 CL:0000010 Transfected with: HGNC; 4851; HTT (1st exon with 74-Q run); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21122805 CVCL_B699 RG-282 embryonic stem cell human CVCL_B699 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122806 CVCL_AU98 PC-12 HD-Q23 cell 7 cancer cell line Norway rat CVCL_AU98 CL:0000010 Transfected with: HGNC; 4851; HTT (1st exon with 23-Q run); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21122807 CVCL_B698 RG-28 embryonic stem cell human CVCL_B698 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122808 CVCL_K027 YUWALI cancer cell line human CVCL_K027 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122809 CVCL_K026 YUWAGE cancer cell line human CVCL_K026 CL:0000010 Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21122810 CVCL_K029 YUZEAL cancer cell line human CVCL_K029 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122811 CVCL_K028 YUWHIM cancer cell line human CVCL_K028 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122812 CVCL_K023 YUSUBA cancer cell line human CVCL_K023 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122813 CVCL_K022 YUSARI cancer cell line human CVCL_K022 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122814 CVCL_AU91 GM10358 transformed cell line human CVCL_AU91 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122815 CVCL_B691 RG-273 embryonic stem cell human CVCL_B691 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122816 CVCL_K025 YUTER cancer cell line human CVCL_K025 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122817 CVCL_AU90 GM10357 transformed cell line human CVCL_AU90 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122818 CVCL_B690 RG-272 embryonic stem cell human CVCL_B690 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122819 CVCL_K024 YUSWI cancer cell line human CVCL_K024 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Small intestine. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122820 CVCL_K021 YURKEN cancer cell line human CVCL_K021 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Pro228Ser (c.682C>T); Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122821 CVCL_K020 YURED cancer cell line human CVCL_K020 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu972Pro (c.2915T>C); ClinVar=VCV000656765; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122822 CVCL_K038 CHO irs1SF spontaneously immortalized cell line CVCL_K038 CL:0000010 Derived from sampling site: Ovary. Female 21122823 CVCL_K037 Bruce-4 embryonic stem cell house mouse CVCL_K037 CL:0000010 Breed/subspecies: C57BL/6.Cg-Thy1. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: SNP array analysis Male Part of: ENCODE project mouse cell lines 21122824 CVCL_K039 V-3 spontaneously immortalized cell line CVCL_K039 CL:0000010 Derived from sampling site: Ovary. Female 21122825 CVCL_K034 EU-2 cancer cell line human CVCL_K034 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=7888679) Derived from sampling site: Bone marrow. Male 21122826 CVCL_K033 TU-OS-3 cancer cell line human CVCL_K033 CL:0000010 Population: Japanese. Female 21122827 CVCL_K036 DKO35 cancer cell line house mouse CVCL_K036 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96878; Blnk; Knockout cell: Method=KO mouse; MGI; MGI:88319; Cd19. 21122828 CVCL_K035 BKO84 cancer cell line house mouse CVCL_K035 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96878; Blnk. 21122829 CVCL_K030 COLO 321 cancer cell line human CVCL_K030 CL:0000010 Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 21122830 CVCL_K032 TU-OS-4 cancer cell line human CVCL_K032 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 53.3 +- 8.1 hours (PubMed=23274876) 21122831 CVCL_K031 SiHa/cDDP cancer cell line human CVCL_K031 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200903 21122832 CVCL_AU79 GM09719 transformed cell line human CVCL_AU79 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122833 CVCL_B679 RG-261 embryonic stem cell human CVCL_B679 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122834 CVCL_AU78 GM09476 transformed cell line human CVCL_AU78 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122835 CVCL_B678 RG-260 embryonic stem cell human CVCL_B678 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122836 CVCL_AU71 GM09469 transformed cell line human CVCL_AU71 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122837 CVCL_B671 RG-252 embryonic stem cell human CVCL_B671 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122838 CVCL_AU70 GM09465 transformed cell line human CVCL_AU70 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122839 CVCL_B670 RG-251 embryonic stem cell human CVCL_B670 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122840 CVCL_AU73 GM09471 transformed cell line human CVCL_AU73 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122841 CVCL_B673 RG-254 embryonic stem cell human CVCL_B673 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122842 CVCL_AU72 GM09470 transformed cell line human CVCL_AU72 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122843 CVCL_B672 RG-253 embryonic stem cell human CVCL_B672 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122844 CVCL_AU75 GM09473 transformed cell line human CVCL_AU75 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122845 CVCL_B675 RG-256 embryonic stem cell human CVCL_B675 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122846 CVCL_K009 YUGANK cancer cell line human CVCL_K009 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Brain. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122847 CVCL_AU74 GM09472 transformed cell line human CVCL_AU74 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122848 CVCL_B674 RG-255 embryonic stem cell human CVCL_B674 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122849 CVCL_K008 YUGAFFE cancer cell line human CVCL_K008 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122850 CVCL_AU77 GM09475 transformed cell line human CVCL_AU77 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122851 CVCL_B677 RG-259 embryonic stem cell human CVCL_B677 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122852 CVCL_AU76 GM09474 transformed cell line human CVCL_AU76 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122853 CVCL_B676 RG-257 embryonic stem cell human CVCL_B676 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122854 CVCL_K005 YUCRENA cancer cell line human CVCL_K005 CL:0000010 Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21122855 CVCL_K004 YUCINJ cancer cell line human CVCL_K004 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122856 CVCL_K007 YUDUTY cancer cell line human CVCL_K007 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122857 CVCL_K006 YUDATE cancer cell line human CVCL_K006 CL:0000010 Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122858 CVCL_K001 YUAVEY cancer cell line human CVCL_K001 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122859 CVCL_K000 GM03905 finite cell line CVCL_K000 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.. Male Senescence: Estimated life-span is ~80 PDL 21122860 CVCL_K003 YUCHUFA cancer cell line human CVCL_K003 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Female Part of: Yale University (YU) melanoma cell collection 21122861 CVCL_K002 YUBRUSE cancer cell line human CVCL_K002 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122862 CVCL_AU89 GM10355 transformed cell line human CVCL_AU89 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122863 CVCL_B689 RG-271 embryonic stem cell human CVCL_B689 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122864 CVCL_AU82 GM09722 transformed cell line human CVCL_AU82 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122865 CVCL_B682 RG-264 embryonic stem cell human CVCL_B682 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122866 CVCL_AU81 GM09721 transformed cell line human CVCL_AU81 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122867 CVCL_B681 RG-263 embryonic stem cell human CVCL_B681 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122868 CVCL_AU84 GM10001 transformed cell line human CVCL_AU84 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122869 CVCL_B684 RG-266 embryonic stem cell human CVCL_B684 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122870 CVCL_AU83 GM09723 transformed cell line human CVCL_AU83 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122871 CVCL_B683 RG-265 embryonic stem cell human CVCL_B683 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122872 CVCL_AU86 GM10198 transformed cell line human CVCL_AU86 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122873 CVCL_B686 RG-269 embryonic stem cell human CVCL_B686 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122874 CVCL_AU85 GM10197 transformed cell line human CVCL_AU85 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122875 CVCL_B685 RG-267 embryonic stem cell human CVCL_B685 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122876 CVCL_K019 YURDE cancer cell line human CVCL_K019 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122877 CVCL_AU88 GM10353 transformed cell line human CVCL_AU88 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122878 CVCL_B688 RG-270 embryonic stem cell human CVCL_B688 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Ambiguous 21122879 CVCL_AU87 GM10302 transformed cell line human CVCL_AU87 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122880 CVCL_B687 RG-27 embryonic stem cell human CVCL_B687 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122881 CVCL_K016 YUMINE cancer cell line human CVCL_K016 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122882 CVCL_K015 YULOMA cancer cell line human CVCL_K015 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122883 CVCL_K018 YUPEET cancer cell line human CVCL_K018 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21122884 CVCL_K017 YUNUFF cancer cell line human CVCL_K017 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122885 CVCL_K012 YUKARN cancer cell line human CVCL_K012 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122886 CVCL_K011 YUKADI cancer cell line human CVCL_K011 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122887 CVCL_AU80 GM09720 transformed cell line human CVCL_AU80 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122888 CVCL_B680 RG-262 embryonic stem cell human CVCL_B680 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122889 CVCL_K014 YULAXER cancer cell line human CVCL_K014 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21122890 CVCL_K013 YULAPE cancer cell line human CVCL_K013 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21122891 CVCL_K010 YUGLIDE cancer cell line human CVCL_K010 CL:0000010 Omics: Deep exome analysis. Female Part of: Yale University (YU) melanoma cell collection 21122892 CVCL_AU57 GM09085 transformed cell line human CVCL_AU57 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122893 CVCL_B657 RG-239 embryonic stem cell human CVCL_B657 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122894 CVCL_AU56 GM09084 transformed cell line human CVCL_AU56 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122895 CVCL_B656 RG-238 embryonic stem cell human CVCL_B656 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122896 CVCL_AU59 GM09087 transformed cell line human CVCL_AU59 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122897 CVCL_B659 RG-240 embryonic stem cell human CVCL_B659 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122898 CVCL_AU58 GM09086 transformed cell line human CVCL_AU58 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122899 CVCL_B658 RG-24 embryonic stem cell human CVCL_B658 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122900 CVCL_AU51 GM09078 transformed cell line human CVCL_AU51 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122901 CVCL_B651 RG-233 embryonic stem cell human CVCL_B651 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122902 CVCL_AU50 GM09077 transformed cell line human CVCL_AU50 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (from familial inference) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122903 CVCL_B650 RG-232 embryonic stem cell human CVCL_B650 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122904 CVCL_AU53 GM09080 transformed cell line human CVCL_AU53 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122905 CVCL_B653 RG-235 embryonic stem cell human CVCL_B653 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122906 CVCL_AU52 GM09079 transformed cell line human CVCL_AU52 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122907 CVCL_B652 RG-234 embryonic stem cell human CVCL_B652 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122908 CVCL_AU55 GM09082 transformed cell line human CVCL_AU55 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122909 CVCL_B655 RG-237 embryonic stem cell human CVCL_B655 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122910 CVCL_AU54 GM09081 transformed cell line human CVCL_AU54 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122911 CVCL_B654 RG-236 embryonic stem cell human CVCL_B654 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21122912 CVCL_AU68 GM09463 transformed cell line human CVCL_AU68 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122913 CVCL_B668 RG-249 embryonic stem cell human CVCL_B668 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122914 CVCL_AU67 GM09462 transformed cell line human CVCL_AU67 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122915 CVCL_B667 RG-248 embryonic stem cell human CVCL_B667 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122916 CVCL_AU69 GM09464 transformed cell line human CVCL_AU69 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122917 CVCL_B669 RG-250 embryonic stem cell human CVCL_B669 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122918 CVCL_AU60 GM09089 transformed cell line human CVCL_AU60 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122919 CVCL_B660 RG-241 embryonic stem cell human CVCL_B660 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122920 CVCL_AU62 GM09455 transformed cell line human CVCL_AU62 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122921 CVCL_B662 RG-243 embryonic stem cell human CVCL_B662 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122922 CVCL_AU61 GM09454 transformed cell line human CVCL_AU61 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122923 CVCL_B661 RG-242 embryonic stem cell human CVCL_B661 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122924 CVCL_AU64 GM09457 transformed cell line human CVCL_AU64 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122925 CVCL_B664 RG-245 embryonic stem cell human CVCL_B664 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Ambiguous Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122926 CVCL_AU63 GM09456 transformed cell line human CVCL_AU63 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122927 CVCL_B663 RG-244 embryonic stem cell human CVCL_B663 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21122928 CVCL_AU66 GM09461 transformed cell line human CVCL_AU66 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21122929 CVCL_B666 RG-247 embryonic stem cell human CVCL_B666 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21122930 CVCL_AU65 GM09459 transformed cell line human CVCL_AU65 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Heterozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21122931 CVCL_B665 RG-246 embryonic stem cell human CVCL_B665 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21122932 CVCL_0C21 MM-1 [Human small cell lung carcinoma] cancer cell line human CVCL_0C21 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified Doubling time: 66.6 hours (PubMed=1311980) 21122933 CVCL_0C20 LV-E cancer cell line human CVCL_0C20 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122934 CVCL_0C23 OS-A cancer cell line human CVCL_0C23 CL:0000010 Derived from metastatic site: Hypodermis. Unspecified 21122935 CVCL_0C22 MO-A cancer cell line human CVCL_0C22 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21122936 CVCL_0C25 SH-A cancer cell line human CVCL_0C25 CL:0000010 Derived from metastatic site: Lymph node. Male 21122937 CVCL_0C24 RG-1 [Human lung carcinoma] cancer cell line human CVCL_0C24 CL:0000010 Derived from metastatic site: Pericardial effusion. Unspecified Doubling time: 64.2 hours (PubMed=1311980) 21122938 CVCL_0C27 SV-E cancer cell line human CVCL_0C27 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122939 CVCL_0C26 SM-E cancer cell line human CVCL_0C26 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122940 CVCL_0C29 WL-E cancer cell line human CVCL_0C29 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 48 hours (PubMed=1311980) 21122941 CVCL_0C28 VT-E cancer cell line human CVCL_0C28 CL:0000010 Unspecified 21122942 CVCL_SI71 HAP1 CENPE (-) 2 cancer cell line human CVCL_SI71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1856; CENPE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122943 CVCL_SI70 HAP1 CENPE (-) 1 cancer cell line human CVCL_SI70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1856; CENPE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122944 CVCL_SI73 HAP1 CH25H (-) cancer cell line human CVCL_SI73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1907; CH25H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122945 CVCL_SI72 HAP1 CFLAR (-) 1 cancer cell line human CVCL_SI72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1876; CFLAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122946 CVCL_SI75 HAP1 CHCHD10 (-) 1 cancer cell line human CVCL_SI75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15559; CHCHD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122947 CVCL_SI74 HAP1 CHAMP1 (-) cancer cell line human CVCL_SI74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20311; CHAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122948 CVCL_SI77 HAP1 CHCHD10 (-) 3 cancer cell line human CVCL_SI77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15559; CHCHD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122949 CVCL_SI76 HAP1 CHCHD10 (-) 2 cancer cell line human CVCL_SI76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15559; CHCHD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122950 CVCL_SI79 HAP1 CHCHD2 (-) 1 cancer cell line human CVCL_SI79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21645; CHCHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122951 CVCL_SI78 HAP1 CHCHD10 (-) 4 cancer cell line human CVCL_SI78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15559; CHCHD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122952 CVCL_0C30 WO-E cancer cell line human CVCL_0C30 CL:0000010 Female 21122953 CVCL_0C32 YR-A cancer cell line human CVCL_0C32 CL:0000010 Derived from metastatic site: Hypodermis. Unspecified 21122954 CVCL_0C31 WT-E cancer cell line human CVCL_0C31 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122955 CVCL_0C34 L100 cancer cell line human CVCL_0C34 CL:0000010 21122956 CVCL_0C33 LGW01-G600 cancer cell line human CVCL_0C33 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=25997541) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Part of: UBC-40 urothelial bladder cancer cell line index 21122957 CVCL_0C36 L32 cancer cell line human CVCL_0C36 CL:0000010 21122958 CVCL_0C35 L266 cancer cell line human CVCL_0C35 CL:0000010 21122959 CVCL_0C38 L96 cancer cell line human CVCL_0C38 CL:0000010 21122960 CVCL_0C37 L361 cancer cell line human CVCL_0C37 CL:0000010 21122961 CVCL_0C39 WH cancer cell line human CVCL_0C39 CL:0000010 Derived from sampling site: Urinary bladder. Male 21122962 CVCL_SI60 HAP1 CDKN2B (-) cancer cell line human CVCL_SI60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1788; CDKN2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122963 CVCL_SI62 HAP1 CEBPA (-) 1 cancer cell line human CVCL_SI62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122964 CVCL_SI61 HAP1 CDS1 (-) cancer cell line human CVCL_SI61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1800; CDS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122965 CVCL_SI64 HAP1 CEBPA (-) 3 cancer cell line human CVCL_SI64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122966 CVCL_SI63 HAP1 CEBPA (-) 2 cancer cell line human CVCL_SI63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1833; CEBPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122967 CVCL_SI66 HAP1 CEBPB (-) 2 cancer cell line human CVCL_SI66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1834; CEBPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122968 CVCL_SI65 HAP1 CEBPB (-) 1 cancer cell line human CVCL_SI65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1834; CEBPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122969 CVCL_SI68 HAP1 CECR2 (-) 2 cancer cell line human CVCL_SI68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1840; CECR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122970 CVCL_SI67 HAP1 CECR2 (-) 1 cancer cell line human CVCL_SI67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1840; CECR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122971 CVCL_SI69 HAP1 CECR5 (-) 1 cancer cell line human CVCL_SI69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122972 CVCL_0C01 KW3 cancer cell line human CVCL_0C01 CL:0000010 21122973 CVCL_0C00 KW24 cancer cell line human CVCL_0C00 CL:0000010 21122974 CVCL_0C03 KW7 cancer cell line human CVCL_0C03 CL:0000010 21122975 CVCL_0C02 KW6 cancer cell line human CVCL_0C02 CL:0000010 21122976 CVCL_0C05 AD-A cancer cell line human CVCL_0C05 CL:0000010 Derived from metastatic site: Hypodermis. Female Doubling time: 45 hours (PubMed=1311980) 21122977 CVCL_0C04 KW9 cancer cell line human CVCL_0C04 CL:0000010 21122978 CVCL_0C07 BK-T cancer cell line human CVCL_0C07 CL:0000010 Male Doubling time: 51.2 hours (PubMed=1311980). 21122979 CVCL_0C06 BH-E cancer cell line human CVCL_0C06 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122980 CVCL_0C09 FN-E cancer cell line human CVCL_0C09 CL:0000010 Female 21122981 CVCL_0C08 EL-E cancer cell line human CVCL_0C08 CL:0000010 Female 21122982 CVCL_SI51 HAP1 CDKN1A (-) 1 cancer cell line human CVCL_SI51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122983 CVCL_SI50 HAP1 CDKL5 (-) 3 cancer cell line human CVCL_SI50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11411; CDKL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122984 CVCL_SI53 HAP1 CDKN1A (-) 3 cancer cell line human CVCL_SI53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122985 CVCL_SI52 HAP1 CDKN1A (-) 2 cancer cell line human CVCL_SI52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1784; CDKN1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122986 CVCL_SI55 HAP1 CDKN1B (-) 2 cancer cell line human CVCL_SI55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122987 CVCL_SI54 HAP1 CDKN1B (-) 1 cancer cell line human CVCL_SI54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122988 CVCL_SI57 HAP1 CDKN1C (-) 1 cancer cell line human CVCL_SI57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1786; CDKN1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122989 CVCL_SI56 HAP1 CDKN1B (-) 3 cancer cell line human CVCL_SI56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1785; CDKN1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122990 CVCL_SI59 HAP1 CDKN2A (-) 2 cancer cell line human CVCL_SI59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122991 CVCL_SI58 HAP1 CDKN2A (-) 1 cancer cell line human CVCL_SI58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21122992 CVCL_0C10 FR-E cancer cell line human CVCL_0C10 CL:0000010 Derived from metastatic site: Pericardial effusion. Unspecified 21122993 CVCL_0C12 HA-E cancer cell line human CVCL_0C12 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21122994 CVCL_0C11 GL-E cancer cell line human CVCL_0C11 CL:0000010 Derived from metastatic site: Pericardial effusion. Unspecified 21122995 CVCL_0C14 HU-E cancer cell line human CVCL_0C14 CL:0000010 Female 21122996 CVCL_0C13 HG-E cancer cell line human CVCL_0C13 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 37.8 hours (PubMed=1311980) 21122997 CVCL_0C16 JO-E cancer cell line human CVCL_0C16 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 79.2 hours (PubMed=1311980) 21122998 CVCL_0C15 JN-M cancer cell line human CVCL_0C15 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 48 hours (PubMed=1311980) 21122999 CVCL_0C18 LD-T cancer cell line human CVCL_0C18 CL:0000010 Unspecified 21123000 CVCL_0C17 JS-E cancer cell line human CVCL_0C17 CL:0000010 Derived from metastatic site: Pericardial effusion. Unspecified 21123001 CVCL_0C19 LG-T cancer cell line human CVCL_0C19 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Male Doubling time: 60 hours (PubMed=1311980) 21123002 CVCL_SI40 HAP1 CDK5RAP1 (-) 1 cancer cell line human CVCL_SI40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15880; CDK5RAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123003 CVCL_SI42 HAP1 CDK6 (-) cancer cell line human CVCL_SI42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1777; CDK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123004 CVCL_SI41 HAP1 CDK5RAP1 (-) 2 cancer cell line human CVCL_SI41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15880; CDK5RAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123005 CVCL_SI44 HAP1 CDKL1 (-) 1 cancer cell line human CVCL_SI44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1781; CDKL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123006 CVCL_SI43 HAP1 CDK8 (-) cancer cell line human CVCL_SI43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1779; CDK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123007 CVCL_SI46 HAP1 CDKL3 (-) 1 cancer cell line human CVCL_SI46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15483; CDKL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123008 CVCL_SI45 HAP1 CDKL1 (-) 2 cancer cell line human CVCL_SI45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1781; CDKL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123009 CVCL_SI48 HAP1 CDKL5 (-) 1 cancer cell line human CVCL_SI48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11411; CDKL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123010 CVCL_SI47 HAP1 CDKL3 (-) 2 cancer cell line human CVCL_SI47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15483; CDKL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123011 CVCL_SI49 HAP1 CDKL5 (-) 2 cancer cell line human CVCL_SI49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11411; CDKL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123012 CVCL_SI29 HAP1 CDK18 (-) 2 cancer cell line human CVCL_SI29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8751; CDK18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123013 CVCL_K090 SF8762 finite cell line human CVCL_K090 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123014 CVCL_K089 SF8761 finite cell line human CVCL_K089 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123015 CVCL_K088 SF8760 finite cell line human CVCL_K088 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123016 CVCL_SI31 HAP1 CDK19 (-) cancer cell line human CVCL_SI31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19338; CDK19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123017 CVCL_SI30 HAP1 CDK18 (-) 3 cancer cell line human CVCL_SI30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8751; CDK18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123018 CVCL_SI33 HAP1 CDK3 (-) 1 cancer cell line human CVCL_SI33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1772; CDK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123019 CVCL_K085 SF8657 finite cell line human CVCL_K085 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with stomach cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Part of: Ban's atomic bomb survivor-derived skin fibroblast library; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21123020 CVCL_SI32 HAP1 CDK2 (-) cancer cell line human CVCL_SI32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1771; CDK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123021 CVCL_K084 SF8656 finite cell line human CVCL_K084 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with thyroid and colon cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123022 CVCL_SI35 HAP1 CDK3 (-) 3 cancer cell line human CVCL_SI35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1772; CDK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123023 CVCL_K087 SF8759 finite cell line human CVCL_K087 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123024 CVCL_SI34 HAP1 CDK3 (-) 2 cancer cell line human CVCL_SI34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1772; CDK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123025 CVCL_K086 SF8758 finite cell line human CVCL_K086 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123026 CVCL_SI37 HAP1 CDK4 (-) 2 cancer cell line human CVCL_SI37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1773; CDK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123027 CVCL_K081 SF8650 finite cell line human CVCL_K081 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123028 CVCL_SI36 HAP1 CDK4 (-) 1 cancer cell line human CVCL_SI36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1773; CDK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123029 CVCL_K080 SF8649 finite cell line human CVCL_K080 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123030 CVCL_SI39 HAP1 CDK5 (-) 2 cancer cell line human CVCL_SI39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123031 CVCL_K083 SF8655 finite cell line human CVCL_K083 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123032 CVCL_SI38 HAP1 CDK5 (-) 1 cancer cell line human CVCL_SI38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1774; CDK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123033 CVCL_K082 SF8653 finite cell line human CVCL_K082 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with thyroid cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123034 CVCL_SI19 HAP1 CDK10 (-) cancer cell line human CVCL_SI19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1770; CDK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123035 CVCL_SI18 HAP1 CDH3 (-) 4 cancer cell line human CVCL_SI18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1762; CDH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123036 CVCL_K099 H-AE-IV finite cell line human CVCL_K099 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21123037 CVCL_SI20 HAP1 CDK11A (-) cancer cell line human CVCL_SI20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1730; CDK11A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123038 CVCL_SI22 HAP1 CDK13 (-) 2 cancer cell line human CVCL_SI22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1733; CDK13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123039 CVCL_K096 HSNT1 embryonic stem cell house mouse CVCL_K096 CL:0000010 Breed/subspecies: C57BL/6 x 129. Discontinued: RCB; RCB2702; true Male 21123040 CVCL_SI21 HAP1 CDK13 (-) 1 cancer cell line human CVCL_SI21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1733; CDK13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123041 CVCL_K095 TCNT1 embryonic stem cell house mouse CVCL_K095 CL:0000010 Breed/subspecies: C57BL/6 x 129. Discontinued: RCB; RCB2701; true Male 21123042 CVCL_SI24 HAP1 CDK14 (-) cancer cell line human CVCL_SI24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8883; CDK14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123043 CVCL_K098 HDC finite cell line human CVCL_K098 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21123044 CVCL_SI23 HAP1 CDK13 (-) 3 cancer cell line human CVCL_SI23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1733; CDK13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123045 CVCL_K097 HSNT2 embryonic stem cell house mouse CVCL_K097 CL:0000010 Breed/subspecies: C57BL/6 x 129. Discontinued: RCB; RCB2703; true Male 21123046 CVCL_K092 409B2 induced pluripotent stem cell human CVCL_K092 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21123047 CVCL_SI26 HAP1 CDK17 (-) 1 cancer cell line human CVCL_SI26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8750; CDK17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123048 CVCL_K091 GM00648 finite cell line human CVCL_K091 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21123049 CVCL_SI25 HAP1 CDK16 (-) cancer cell line human CVCL_SI25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8749; CDK16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123050 CVCL_K094 B6-6 embryonic stem cell house mouse CVCL_K094 CL:0000010 Breed/subspecies: C57BL/6NCrSlc. Male 21123051 CVCL_SI28 HAP1 CDK18 (-) 1 cancer cell line human CVCL_SI28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8751; CDK18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123052 CVCL_SI27 HAP1 CDK17 (-) 2 cancer cell line human CVCL_SI27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8750; CDK17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123053 CVCL_K093 rdES4 embryonic stem cell CVCL_K093 CL:0000010 Breed/subspecies: Dutch Belted. Unspecified 21123054 CVCL_SI08 HAP1 CDC42BPB (-) 2 cancer cell line human CVCL_SI08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1738; CDC42BPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123055 CVCL_SI07 HAP1 CDC42BPB (-) 1 cancer cell line human CVCL_SI07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1738; CDC42BPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123056 CVCL_SI09 HAP1 CDC42BPG (-) cancer cell line human CVCL_SI09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29829; CDC42BPG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123057 CVCL_K067 SF8413 finite cell line human CVCL_K067 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with chest cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123058 CVCL_K066 SF8410 finite cell line human CVCL_K066 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123059 CVCL_K069 SF8416 finite cell line human CVCL_K069 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 14 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123060 CVCL_K068 SF8414 finite cell line human CVCL_K068 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123061 CVCL_SI11 HAP1 CDCA2 (-) 2 cancer cell line human CVCL_SI11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14623; CDCA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123062 CVCL_K063 SF8404 finite cell line human CVCL_K063 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123063 CVCL_SI10 HAP1 CDCA2 (-) 1 cancer cell line human CVCL_SI10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14623; CDCA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123064 CVCL_K062 SF8402 finite cell line human CVCL_K062 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123065 CVCL_SI13 HAP1 CDCA7 (-) 2 cancer cell line human CVCL_SI13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14628; CDCA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123066 CVCL_K065 SF8406 finite cell line human CVCL_K065 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123067 CVCL_SI12 HAP1 CDCA7 (-) 1 cancer cell line human CVCL_SI12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14628; CDCA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123068 CVCL_K064 SF8405 finite cell line human CVCL_K064 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123069 CVCL_SI15 HAP1 CDH3 (-) 1 cancer cell line human CVCL_SI15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1762; CDH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123070 CVCL_SI14 HAP1 CDH2 (-) 1 cancer cell line human CVCL_SI14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1759; CDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123071 CVCL_SI17 HAP1 CDH3 (-) 3 cancer cell line human CVCL_SI17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1762; CDH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123072 CVCL_K061 TEN12F cancer cell line human CVCL_K061 CL:0000010 Male 21123073 CVCL_SI16 HAP1 CDH3 (-) 2 cancer cell line human CVCL_SI16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1762; CDH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123074 CVCL_K060 TEN12C cancer cell line human CVCL_K060 CL:0000010 Male 21123075 CVCL_K078 SF8546 finite cell line human CVCL_K078 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123076 CVCL_K077 SF8543 finite cell line human CVCL_K077 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 44 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123077 CVCL_K079 SF8647 finite cell line human CVCL_K079 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123078 CVCL_SI00 HAP1 CD9 (-) 1 cancer cell line human CVCL_SI00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1709; CD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123079 CVCL_K074 SF8536 finite cell line human CVCL_K074 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor without cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 38 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123080 CVCL_K073 SF8433 finite cell line human CVCL_K073 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123081 CVCL_SI02 HAP1 CDC25C (-) cancer cell line human CVCL_SI02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1727; CDC25C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123082 CVCL_K076 SF8541 finite cell line human CVCL_K076 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with uterus cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 34 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123083 CVCL_SI01 HAP1 CDC25A (-) 1 cancer cell line human CVCL_SI01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1725; CDC25A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123084 CVCL_K075 SF8538 finite cell line human CVCL_K075 CL:0000010 Population: Japanese; Donor information: Established from a nonexposed individual with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0613; probable Female Senescence: Senesces at 32 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123085 CVCL_SI04 HAP1 CDC34 (-) 2 cancer cell line human CVCL_SI04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1734; CDC34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123086 CVCL_K070 SF8425 finite cell line human CVCL_K070 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123087 CVCL_SI03 HAP1 CDC34 (-) 1 cancer cell line human CVCL_SI03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1734; CDC34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123088 CVCL_SI06 HAP1 CDC42 (-) 2 cancer cell line human CVCL_SI06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1736; CDC42; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123089 CVCL_K072 SF8429 finite cell line human CVCL_K072 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 38 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123090 CVCL_SI05 HAP1 CDC42 (-) 1 cancer cell line human CVCL_SI05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1736; CDC42; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123091 CVCL_K071 SF8428 finite cell line human CVCL_K071 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor with breast cancer; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 28 PDL (PubMed=17395773) Part of: Ban's atomic bomb survivor-derived skin fibroblast library 21123092 CVCL_JH73 CW20196 induced pluripotent stem cell human CVCL_JH73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20196; true Male 21123093 CVCL_JH72 CW20193 induced pluripotent stem cell human CVCL_JH72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20193; true Female 21123094 CVCL_JH75 CW20243 induced pluripotent stem cell human CVCL_JH75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20243; true Male 21123095 CVCL_JH74 CW20200 induced pluripotent stem cell human CVCL_JH74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20200; true Female 21123096 CVCL_JH71 CW20178 induced pluripotent stem cell human CVCL_JH71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20178; true Male 21123097 CVCL_JH70 CW20167 induced pluripotent stem cell human CVCL_JH70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20167; true Male 21123098 CVCL_SB10 HAP1 ABL2 (-) 1 cancer cell line human CVCL_SB10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123099 CVCL_SB12 HAP1 ABL2 (-) 3 cancer cell line human CVCL_SB12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123100 CVCL_SB11 HAP1 ABL2 (-) 2 cancer cell line human CVCL_SB11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 77; ABL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123101 CVCL_SB14 HAP1 ACACA (-) 2 cancer cell line human CVCL_SB14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 84; ACACA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC004903c012; true Male Group: Haploid karyotype cell line 21123102 CVCL_SB13 HAP1 ACACA (-) 1 cancer cell line human CVCL_SB13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 84; ACACA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123103 CVCL_SB16 HAP1 ACBD3 (-) cancer cell line human CVCL_SB16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15453; ACBD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123104 CVCL_SB15 HAP1 ACAD10 (-) 1 cancer cell line human CVCL_SB15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21597; ACAD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123105 CVCL_SB18 HAP1 ACD (-) 2 cancer cell line human CVCL_SB18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25070; ACD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123106 CVCL_JH69 CW20166 induced pluripotent stem cell human CVCL_JH69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20166; true Male 21123107 CVCL_SB17 HAP1 ACD (-) 1 cancer cell line human CVCL_SB17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25070; ACD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123108 CVCL_SB19 HAP1 ACE (-) 1 cancer cell line human CVCL_SB19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2707; ACE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123109 CVCL_JH66 CW20139 induced pluripotent stem cell human CVCL_JH66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20139; true Male 21123110 CVCL_JH65 CW20123 induced pluripotent stem cell human CVCL_JH65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Nepali; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20123; true Male 21123111 CVCL_JH68 CW20164 induced pluripotent stem cell human CVCL_JH68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20164; true Male 21123112 CVCL_JH67 CW20144 induced pluripotent stem cell human CVCL_JH67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20144; true Female 21123113 CVCL_JH84 CW30024 induced pluripotent stem cell human CVCL_JH84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30024; true. Male 21123114 CVCL_JH83 CW30019 induced pluripotent stem cell human CVCL_JH83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American Discontinued: Coriell; CW30019; true. Female 21123115 CVCL_JH86 CW30031 induced pluripotent stem cell human CVCL_JH86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30031; true. Male 21123116 CVCL_JH85 CW30030 induced pluripotent stem cell human CVCL_JH85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30030; true. Female 21123117 CVCL_JH80 CW20321 induced pluripotent stem cell human CVCL_JH80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20321; true Female 21123118 CVCL_JH82 CW30012 induced pluripotent stem cell human CVCL_JH82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic Discontinued: Coriell; CW30012; true. Male 21123119 CVCL_JH81 CW30005 induced pluripotent stem cell human CVCL_JH81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30005; true. Female 21123120 CVCL_SB01 HAP1 ABCB5 (-) 5 cancer cell line human CVCL_SB01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123121 CVCL_SB00 HAP1 ABCB5 (-) 4 cancer cell line human CVCL_SB00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123122 CVCL_SB03 HAP1 ABCC1 (-) 1 cancer cell line human CVCL_SB03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123123 CVCL_SB02 HAP1 ABCB5 (-) 6 cancer cell line human CVCL_SB02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123124 CVCL_SB05 HAP1 ABCC1 (-) 3 cancer cell line human CVCL_SB05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123125 CVCL_SB04 HAP1 ABCC1 (-) 2 cancer cell line human CVCL_SB04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 51; ABCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123126 CVCL_SB07 HAP1 ABCD1 (-) 1 cancer cell line human CVCL_SB07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 61; ABCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123127 CVCL_SB06 HAP1 ABCC4 (-) 1 cancer cell line human CVCL_SB06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 55; ABCC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123128 CVCL_SB09 HAP1 ABL1 (-) cancer cell line human CVCL_SB09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 76; ABL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123129 CVCL_SB08 HAP1 ABCD3 (-) 1 cancer cell line human CVCL_SB08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 67; ABCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123130 CVCL_JH77 CW20252 induced pluripotent stem cell human CVCL_JH77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20252; true Female 21123131 CVCL_JH76 La-K4DT telomerase immortalized cell line CVCL_JH76 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Ear. Female Group: Endangered species/breed cell line Caution: Title and abstract of paper (PubMed=27449922) states that cell line is from Bubalus quarlesi, but text correctly indicates this cell line is from Bubalus depressicornis 21123132 CVCL_JH79 CW20296 induced pluripotent stem cell human CVCL_JH79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20296; true Female 21123133 CVCL_JH78 CW20295 induced pluripotent stem cell human CVCL_JH78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20295; true Female 21123134 CVCL_JH51 CW10148 induced pluripotent stem cell human CVCL_JH51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10148; true Female 21123135 CVCL_JH50 CW10147 induced pluripotent stem cell human CVCL_JH50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10147; true Female 21123136 CVCL_JH53 CW10181 induced pluripotent stem cell human CVCL_JH53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10181; true Male 21123137 CVCL_JH52 CW10162 induced pluripotent stem cell human CVCL_JH52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10162; true Male 21123138 CVCL_JH48 CW10142 induced pluripotent stem cell human CVCL_JH48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10142; true Male 21123139 CVCL_JH47 CW10137 induced pluripotent stem cell human CVCL_JH47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10137; true Male 21123140 CVCL_JH49 CW10144 induced pluripotent stem cell human CVCL_JH49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10144; true Male 21123141 CVCL_JH44 CW10121 induced pluripotent stem cell human CVCL_JH44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10121; true Male 21123142 CVCL_JH43 CW10093 induced pluripotent stem cell human CVCL_JH43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10093; true Female 21123143 CVCL_JH46 CW10133 induced pluripotent stem cell human CVCL_JH46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10133; true Male 21123144 CVCL_JH45 CW10126 induced pluripotent stem cell human CVCL_JH45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10126; true Male 21123145 CVCL_JH62 CW20107 induced pluripotent stem cell human CVCL_JH62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20107; true Female 21123146 CVCL_JH61 CW20094 induced pluripotent stem cell human CVCL_JH61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20094; true Female 21123147 CVCL_JH64 CW20116 induced pluripotent stem cell human CVCL_JH64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20116; true Female 21123148 CVCL_JH63 CW20108 induced pluripotent stem cell human CVCL_JH63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20108; true Male 21123149 CVCL_JH60 CW20092 induced pluripotent stem cell human CVCL_JH60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20092; true Male 21123150 CVCL_JH59 CW20091 induced pluripotent stem cell human CVCL_JH59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20091; true Female 21123151 CVCL_JH58 BFF_NCC1 telomerase immortalized cell line CVCL_JH58 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Female 21123152 CVCL_JH55 CW20063 induced pluripotent stem cell human CVCL_JH55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20063; true Female 21123153 CVCL_JH54 CW20061 induced pluripotent stem cell human CVCL_JH54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20061; true Female 21123154 CVCL_JH57 CW20079 induced pluripotent stem cell human CVCL_JH57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20079; true Male 21123155 CVCL_JH56 CW20073 induced pluripotent stem cell human CVCL_JH56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20073; true Male 21123156 CVCL_JH31 KT-1/A3R cancer cell line human CVCL_JH31 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Interferon-alpha resistant Can proliferate and is resistant to apoptosis at high concentration of IFN-alpha. 21123157 CVCL_JH30 KT-1/B7 cancer cell line human CVCL_JH30 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Slightly interferon-alpha resistant 21123158 CVCL_AN99 CW30302 induced pluripotent stem cell human CVCL_AN99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30302; true Female 21123159 CVCL_AN92 CW30277 induced pluripotent stem cell human CVCL_AN92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30277; true; Discontinued: FCDI; CW30277; probable. Male 21123160 CVCL_AN91 CW30274 induced pluripotent stem cell human CVCL_AN91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30274; true Male 21123161 CVCL_AN94 CW30282 induced pluripotent stem cell human CVCL_AN94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30282; true Male 21123162 CVCL_AN93 CW30280 induced pluripotent stem cell human CVCL_AN93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30280; true Male 21123163 CVCL_AN96 CW30285 induced pluripotent stem cell human CVCL_AN96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30285; true Male 21123164 CVCL_AN95 CW30283 induced pluripotent stem cell human CVCL_AN95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30283; true Male 21123165 CVCL_JH29 KT-1/A3 cancer cell line human CVCL_JH29 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Interferon-alpha sensitive 21123166 CVCL_AN98 CW30299 induced pluripotent stem cell human CVCL_AN98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30299; true Female 21123167 CVCL_AN97 CW30292 induced pluripotent stem cell human CVCL_AN97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30292; true Male 21123168 CVCL_JH26 FA-AML1A cancer cell line human CVCL_JH26 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (PubMed=12750298); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Ter (c.8504C>G) (8732C>A); ClinVar=VCV000267091; Zygosity=Heterozygous; Note=Mutated This cell line contains both the mutated allele and the reverted allele (PubMed=12750298).; Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Glu (c.8503_8504TC>GA) (8731TC>GA); Zygosity=Heterozygous; Note=Reverted This cell line contains both the mutated allele and the reverted allele (PubMed=12750298). Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB2758; probable Male Characteristics: CSF2 dependent 21123169 CVCL_JH25 AP37P finite cell line human CVCL_JH25 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (PubMed=12065746); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Ter (c.8504C>G) (8732C>A); ClinVar=VCV000267091; Zygosity=Heterozygous (PubMed=12065746) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21123170 CVCL_JH28 Werner finite cell line human CVCL_JH28 CL:0000010 Population: Japanese Discontinued: JCRB; KURB2881; probable. Male 21123171 CVCL_JH27 ATYAMA finite cell line human CVCL_JH27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123172 CVCL_JH22 RB182F(L) transformed cell line human CVCL_JH22 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB2329; probable Male 21123173 CVCL_JH21 RB182F finite cell line human CVCL_JH21 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21123174 CVCL_AN90 CW30269 induced pluripotent stem cell human CVCL_AN90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30269; true Male 21123175 CVCL_JH24 XP18OS finite cell line human CVCL_JH24 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Tyr116Ter (c.348T>A); ClinVar=VCV000000997; Zygosity=Homozygous (PubMed=7947212) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1234; probable; Discontinued: JCRB; KURB1330; probable Female 21123176 CVCL_JH23 RB182M finite cell line human CVCL_JH23 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123177 CVCL_JH40 CW10081 induced pluripotent stem cell human CVCL_JH40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10081; true Female 21123178 CVCL_JH42 CW10090 induced pluripotent stem cell human CVCL_JH42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10090; true Male 21123179 CVCL_JH41 CW10086 induced pluripotent stem cell human CVCL_JH41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10086; true Male 21123180 CVCL_JH37 CW10034 induced pluripotent stem cell human CVCL_JH37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10034; true Female 21123181 CVCL_JH36 CW10002 induced pluripotent stem cell human CVCL_JH36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW10002; true. Female 21123182 CVCL_JH39 CW10068 induced pluripotent stem cell human CVCL_JH39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10068; true Male 21123183 CVCL_JH38 CW10063 induced pluripotent stem cell human CVCL_JH38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10063; true Male 21123184 CVCL_JH33 Y-AK spontaneously immortalized cell line house mouse CVCL_JH33 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: AKR. Unspecified Doubling time: 24-29 hours (PubMed=405267) 21123185 CVCL_JH32 OUN-1 cancer cell line human CVCL_JH32 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. 21123186 CVCL_JH35 Y-DD spontaneously immortalized cell line house mouse CVCL_JH35 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: DDD. Unspecified Doubling time: 24-29 hours (PubMed=405267) 21123187 CVCL_JH34 Y-CH spontaneously immortalized cell line house mouse CVCL_JH34 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: C3H. Unspecified Doubling time: 24-29 hours (PubMed=405267) 21123188 CVCL_AN78 CW30238 induced pluripotent stem cell human CVCL_AN78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30238; true Male 21123189 CVCL_AN77 CW30234 induced pluripotent stem cell human CVCL_AN77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30234; true Male 21123190 CVCL_AN79 CW30240 induced pluripotent stem cell human CVCL_AN79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30240; true Female 21123191 CVCL_AN70 CW30219 induced pluripotent stem cell human CVCL_AN70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30219; true Female 21123192 CVCL_AN72 CW30225 induced pluripotent stem cell human CVCL_AN72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30225; true Female 21123193 CVCL_AN71 CW30222 induced pluripotent stem cell human CVCL_AN71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30222; true Male 21123194 CVCL_AN74 CW30229 induced pluripotent stem cell human CVCL_AN74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30229; true Male 21123195 CVCL_JH08 POLZ CD MSH- cancer cell line human CVCL_JH08 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Asp2781Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (JCRB).; Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Asp2783Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (JCRB). Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123196 CVCL_AN73 CW30228 induced pluripotent stem cell human CVCL_AN73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30228; true Male 21123197 CVCL_JH07 POLK KO-comp cancer cell line human CVCL_JH07 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16); Transfected with: HGNC; 9183; POLK Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123198 CVCL_AN76 CW30232 induced pluripotent stem cell human CVCL_AN76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30232; true Male 21123199 CVCL_AN75 CW30230 induced pluripotent stem cell human CVCL_AN75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30230; true Female 21123200 CVCL_JH09 POLZ D2781N cancer cell line human CVCL_JH09 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Asp2781Asn; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123201 CVCL_JH04 POLZ L2618F cancer cell line human CVCL_JH04 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Leu2618Phe; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123202 CVCL_JH03 POLK SG MSH- cancer cell line human CVCL_JH03 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Tyr112Ala; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123203 CVCL_JH06 POLZ Y2779F cancer cell line human CVCL_JH06 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Tyr2779Phe; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123204 CVCL_JH05 POLK KO cancer cell line human CVCL_JH05 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123205 CVCL_JH00 POLK KO-CD comp cancer cell line human CVCL_JH00 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16); Transfected with: HGNC; 9183; POLK (with p.Asp198Ala and p.Asp199Ala) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123206 CVCL_JH02 POLK CD MSH- cancer cell line human CVCL_JH02 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Asp198Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (PubMed=24461735).; Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Asp199Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (PubMed=24461735).; Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123207 CVCL_JH01 POLK CD cancer cell line human CVCL_JH01 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Asp198Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (PubMed=24461735).; Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Asp199Ala; Zygosity=Unspecified; Note=Loss of activity By homologous recombination (PubMed=24461735).; Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21123208 CVCL_JH20 AP78P finite cell line human CVCL_JH20 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1360_2014del (Ex15-22del); Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1570; probable Male 21123209 CVCL_AN89 CW30268 induced pluripotent stem cell human CVCL_AN89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30268; true Female 21123210 CVCL_AN88 CW30259 induced pluripotent stem cell human CVCL_AN88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30259; true Female 21123211 CVCL_AN81 CW30243 induced pluripotent stem cell human CVCL_AN81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30243; true Male 21123212 CVCL_AN80 CW30242 induced pluripotent stem cell human CVCL_AN80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30242; true Female 21123213 CVCL_AN83 CW30247 induced pluripotent stem cell human CVCL_AN83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30247; true Female 21123214 CVCL_AN82 CW30245 induced pluripotent stem cell human CVCL_AN82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30245; true Female 21123215 CVCL_JH19 AP78M finite cell line human CVCL_JH19 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123216 CVCL_AN85 CW30253 induced pluripotent stem cell human CVCL_AN85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30253; true Male 21123217 CVCL_JH18 AP78F finite cell line human CVCL_JH18 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21123218 CVCL_AN84 CW30248 induced pluripotent stem cell human CVCL_AN84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30248; true Female 21123219 CVCL_AN87 CW30258 induced pluripotent stem cell human CVCL_AN87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30258; true Male 21123220 CVCL_AN86 CW30255 induced pluripotent stem cell human CVCL_AN86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30255; true; Discontinued: FCDI; CW30255; probable. Male 21123221 CVCL_JH15 AP38B(SVT) transformed cell line human CVCL_JH15 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1436; probable Male 21123222 CVCL_JH14 AP38M(SVT) transformed cell line human CVCL_JH14 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1439; probable Female 21123223 CVCL_JH17 AP39S(SVT) transformed cell line human CVCL_JH17 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123224 CVCL_JH16 AP39S finite cell line human CVCL_JH16 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1645; probable Female 21123225 CVCL_JH11 HSA/c cancer cell line human CVCL_JH11 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic lymph duct. Unspecified 21123226 CVCL_JH10 SUm/C cancer cell line human CVCL_JH10 CL:0000010 Population: Japanese; Derived from metastatic site: Thoracic lymph duct. Male 21123227 CVCL_JH13 AP38M finite cell line human CVCL_JH13 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1438; probable Female 21123228 CVCL_JH12 AP38S(SVT) transformed cell line human CVCL_JH12 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1434; probable Female 21123229 CVCL_SB90 HAP1 AFTPH (-) 2 cancer cell line human CVCL_SB90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25951; AFTPH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123230 CVCL_SB92 HAP1 AGL (-) 1 cancer cell line human CVCL_SB92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 321; AGL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123231 CVCL_SB91 HAP1 AGER (-) 1 cancer cell line human CVCL_SB91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 320; AGER; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123232 CVCL_SB94 HAP1 AGO1 (-) 1 cancer cell line human CVCL_SB94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3262; AGO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123233 CVCL_SB93 HAP1 AGL (-) 2 cancer cell line human CVCL_SB93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 321; AGL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123234 CVCL_SB96 HAP1 AGO1 (-) 3 cancer cell line human CVCL_SB96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3262; AGO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123235 CVCL_SB95 HAP1 AGO1 (-) 2 cancer cell line human CVCL_SB95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3262; AGO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123236 CVCL_SB98 HAP1 AGRN (-) 1 cancer cell line human CVCL_SB98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 329; AGRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123237 CVCL_SB97 HAP1 AGO1 (-) 4 cancer cell line human CVCL_SB97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3262; AGO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123238 CVCL_SB99 HAP1 AGRN (-) 2 cancer cell line human CVCL_SB99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 329; AGRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123239 CVCL_SB81 HAP1 ADRBK1 (-) cancer cell line human CVCL_SB81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 289; GRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123240 CVCL_SB80 HAP1 ADRA1A (-) 2 cancer cell line human CVCL_SB80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 277; ADRA1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123241 CVCL_SB83 HAP1 ADRBK2 (-) 2 cancer cell line human CVCL_SB83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 290; GRK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123242 CVCL_SB82 HAP1 ADRBK2 (-) 1 cancer cell line human CVCL_SB82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 290; GRK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123243 CVCL_SB85 HAP1 AEBP2 (-) 1 cancer cell line human CVCL_SB85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24051; AEBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123244 CVCL_SB84 HAP1 ADRBK2 (-) 3 cancer cell line human CVCL_SB84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 290; GRK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123245 CVCL_SB87 HAP1 AEBP2 (-) 3 cancer cell line human CVCL_SB87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24051; AEBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123246 CVCL_SB86 HAP1 AEBP2 (-) 2 cancer cell line human CVCL_SB86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24051; AEBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123247 CVCL_SB89 HAP1 AFTPH (-) 1 cancer cell line human CVCL_SB89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25951; AFTPH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123248 CVCL_SB88 HAP1 AEBP2 (-) 4 cancer cell line human CVCL_SB88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24051; AEBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123249 CVCL_SB70 HAP1 ADCY9 (-) 1 cancer cell line human CVCL_SB70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 240; ADCY9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123250 CVCL_SB72 HAP1 ADIPOR2 (-) 1 cancer cell line human CVCL_SB72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24041; ADIPOR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123251 CVCL_SB71 HAP1 ADIPOR1 (-) 1 cancer cell line human CVCL_SB71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24040; ADIPOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123252 CVCL_SB74 HAP1 ADK (-) 2 cancer cell line human CVCL_SB74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 257; ADK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123253 CVCL_SB73 HAP1 ADK (-) 1 cancer cell line human CVCL_SB73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 257; ADK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123254 CVCL_SB76 HAP1 ADORA2A (-) 2 cancer cell line human CVCL_SB76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 263; ADORA2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123255 CVCL_SB75 HAP1 ADORA2A (-) 1 cancer cell line human CVCL_SB75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 263; ADORA2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123256 CVCL_SB78 HAP1 ADORA2B (-) 2 cancer cell line human CVCL_SB78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 264; ADORA2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123257 CVCL_SB77 HAP1 ADORA2B (-) 1 cancer cell line human CVCL_SB77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 264; ADORA2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123258 CVCL_SB79 HAP1 ADRA1A (-) 1 cancer cell line human CVCL_SB79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 277; ADRA1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123259 CVCL_SB61 HAP1 ADCK3 (-) 1 cancer cell line human CVCL_SB61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16812; COQ8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123260 CVCL_SB60 HAP1 ADCK2 (-) 3 cancer cell line human CVCL_SB60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19039; ADCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123261 CVCL_SB63 HAP1 ADCK4 (-) 1 cancer cell line human CVCL_SB63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19041; COQ8B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123262 CVCL_SB62 HAP1 ADCK3 (-) 2 cancer cell line human CVCL_SB62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16812; COQ8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123263 CVCL_SB65 HAP1 ADCK5 (-) 1 cancer cell line human CVCL_SB65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21738; ADCK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123264 CVCL_SB64 HAP1 ADCK4 (-) 2 cancer cell line human CVCL_SB64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19041; COQ8B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123265 CVCL_SB67 HAP1 ADCY3 (-) 1 cancer cell line human CVCL_SB67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 234; ADCY3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123266 CVCL_SB66 HAP1 ADCK5 (-) 2 cancer cell line human CVCL_SB66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21738; ADCK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123267 CVCL_SB69 HAP1 ADCY7 (-) 1 cancer cell line human CVCL_SB69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 238; ADCY7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123268 CVCL_SB68 HAP1 ADCY6 (-) 1 cancer cell line human CVCL_SB68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 237; ADCY6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123269 CVCL_SB50 HAP1 ADAM9 (-) 2 cancer cell line human CVCL_SB50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 216; ADAM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123270 CVCL_SB52 HAP1 ADAM9 (-) 4 cancer cell line human CVCL_SB52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 216; ADAM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123271 CVCL_SB51 HAP1 ADAM9 (-) 3 cancer cell line human CVCL_SB51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 216; ADAM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123272 CVCL_SB54 HAP1 ADAR (-) 2 cancer cell line human CVCL_SB54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 225; ADAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123273 CVCL_SB53 HAP1 ADAR (-) 1 cancer cell line human CVCL_SB53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 225; ADAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123274 CVCL_SB56 HAP1 ADCK1 (-) 1 cancer cell line human CVCL_SB56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19038; ADCK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123275 CVCL_SB55 HAP1 ADARB1 (-) cancer cell line human CVCL_SB55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 226; ADARB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123276 CVCL_SB58 HAP1 ADCK2 (-) 1 cancer cell line human CVCL_SB58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19039; ADCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123277 CVCL_SB57 HAP1 ADCK1 (-) 2 cancer cell line human CVCL_SB57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19038; ADCK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123278 CVCL_SB59 HAP1 ADCK2 (-) 2 cancer cell line human CVCL_SB59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19039; ADCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123279 CVCL_SB41 HAP1 ACVR2B (-) 4 cancer cell line human CVCL_SB41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123280 CVCL_SB40 HAP1 ACVR2B (-) 3 cancer cell line human CVCL_SB40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123281 CVCL_SB43 HAP1 ACVR2B (-) 6 cancer cell line human CVCL_SB43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123282 CVCL_SB42 HAP1 ACVR2B (-) 5 cancer cell line human CVCL_SB42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123283 CVCL_SB45 HAP1 ADAM10 (-) 1 cancer cell line human CVCL_SB45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 188; ADAM10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123284 CVCL_SB44 HAP1 ADA (-) cancer cell line human CVCL_SB44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 186; ADA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123285 CVCL_SB47 HAP1 ADAM17 (-) 1 cancer cell line human CVCL_SB47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 195; ADAM17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123286 CVCL_SB46 HAP1 ADAM10 (-) 2 cancer cell line human CVCL_SB46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 188; ADAM10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123287 CVCL_SB49 HAP1 ADAM9 (-) 1 cancer cell line human CVCL_SB49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 216; ADAM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123288 CVCL_SB48 HAP1 ADAM17 (-) 2 cancer cell line human CVCL_SB48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 195; ADAM17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123289 CVCL_JH95 CW30156 induced pluripotent stem cell human CVCL_JH95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30156; true Male 21123290 CVCL_JH94 CW30143 induced pluripotent stem cell human CVCL_JH94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30143; true Male 21123291 CVCL_JH97 CW30163 induced pluripotent stem cell human CVCL_JH97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30163; true Female 21123292 CVCL_JH96 CW30158 induced pluripotent stem cell human CVCL_JH96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30158; true Male 21123293 CVCL_JH91 CW30095 induced pluripotent stem cell human CVCL_JH91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30095; true Male 21123294 CVCL_JH90 CW30080 induced pluripotent stem cell human CVCL_JH90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30080; true Female 21123295 CVCL_JH93 CW30131 induced pluripotent stem cell human CVCL_JH93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30131; true Male 21123296 CVCL_JH92 CW30107 induced pluripotent stem cell human CVCL_JH92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30107; true Male 21123297 CVCL_SB30 HAP1 ACTN4 (-) 1 cancer cell line human CVCL_SB30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 166; ACTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123298 CVCL_SB32 HAP1 ACVR1B (-) cancer cell line human CVCL_SB32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 172; ACVR1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123299 CVCL_SB31 HAP1 ACVR1 (-) cancer cell line human CVCL_SB31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 171; ACVR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123300 CVCL_SB34 HAP1 ACVR2A (-) 2 cancer cell line human CVCL_SB34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 173; ACVR2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123301 CVCL_SB33 HAP1 ACVR2A (-) 1 cancer cell line human CVCL_SB33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 173; ACVR2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123302 CVCL_SB36 HAP1 ACVR2A (-) 4 cancer cell line human CVCL_SB36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 173; ACVR2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123303 CVCL_SB35 HAP1 ACVR2A (-) 3 cancer cell line human CVCL_SB35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 173; ACVR2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123304 CVCL_SB38 HAP1 ACVR2B (-) 1 cancer cell line human CVCL_SB38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123305 CVCL_SB37 HAP1 ACVR2A (-) 5 cancer cell line human CVCL_SB37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 173; ACVR2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123306 CVCL_SB39 HAP1 ACVR2B (-) 2 cancer cell line human CVCL_SB39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 174; ACVR2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123307 CVCL_JH88 CW30040 induced pluripotent stem cell human CVCL_JH88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30040; true Male 21123308 CVCL_JH87 CW30035 induced pluripotent stem cell human CVCL_JH87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30035; true. Male 21123309 CVCL_JH89 CW30077 induced pluripotent stem cell human CVCL_JH89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30077; true Male 21123310 CVCL_SB21 HAP1 ACHE (-) 1 cancer cell line human CVCL_SB21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 108; ACHE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123311 CVCL_SB20 HAP1 ACE (-) 2 cancer cell line human CVCL_SB20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2707; ACE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123312 CVCL_SB23 HAP1 ACLY (-) 1 cancer cell line human CVCL_SB23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 115; ACLY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123313 CVCL_SB22 HAP1 ACHE (-) 2 cancer cell line human CVCL_SB22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 108; ACHE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123314 CVCL_SB25 HAP1 ACO2 (-) 2 cancer cell line human CVCL_SB25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 118; ACO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123315 CVCL_SB24 HAP1 ACO2 (-) 1 cancer cell line human CVCL_SB24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 118; ACO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123316 CVCL_SB27 HAP1 ACTB (-) 1 cancer cell line human CVCL_SB27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 132; ACTB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123317 CVCL_SB26 HAP1 ACSS2 (-) 1 cancer cell line human CVCL_SB26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15814; ACSS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123318 CVCL_SB29 HAP1 ACTN1 (-) 1 cancer cell line human CVCL_SB29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 163; ACTN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123319 CVCL_SB28 HAP1 ACTB (-) 2 cancer cell line human CVCL_SB28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 132; ACTB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123320 CVCL_JH99 CW30176 induced pluripotent stem cell human CVCL_JH99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30176; true Male 21123321 CVCL_JH98 CW30172 induced pluripotent stem cell human CVCL_JH98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30172; true Female 21123322 CVCL_8T42 BO0841 transformed cell line human CVCL_8T42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123323 CVCL_9542 DP-6 cancer cell line human CVCL_9542 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA lambda; Characteristics: IL6 dependent 21123324 CVCL_8T41 BO0819 transformed cell line human CVCL_8T41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123325 CVCL_9541 KPMM1 cancer cell line human CVCL_9541 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21123326 CVCL_8T44 BO0852 transformed cell line human CVCL_8T44 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;3)(p25;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123327 CVCL_9544 KAS-6/1 cancer cell line human CVCL_9544 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21123328 CVCL_8T43 BO0851 transformed cell line human CVCL_8T43 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,ringY; 46,X,marY; 47,X,ring,marY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123329 CVCL_9543 KP-6 cancer cell line human CVCL_9543 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21123330 CVCL_8T40 BO0813 transformed cell line human CVCL_8T40 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,dup(15)(q11.2;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123331 CVCL_9540 LAMA-88 cancer cell line human CVCL_9540 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female 21123332 CVCL_8T39 BO0812 transformed cell line human CVCL_8T39 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(7)(p15.1;q11.23),dup(15)(q11.2;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123333 CVCL_9539 SMS-LHN cancer cell line human CVCL_9539 CL:0000010 Omics: Array-based CGH. Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) Doubling time: 216 hours (COG) 21123334 CVCL_8T38 BO0800 transformed cell line human CVCL_8T38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123335 CVCL_9538 CLB-VolMo cancer cell line human CVCL_9538 CL:0000010 Miscellaneous: Sex of donor and metastatic site from personal communication of Combaret V Derived from metastatic site: Bone marrow. Female 21123336 CVCL_8T35 BO0794 transformed cell line human CVCL_8T35 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(8;20)(p23;p12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123337 CVCL_9535 CLB-Re cancer cell line human CVCL_9535 CL:0000010 Derived from metastatic site: Bone marrow. Male 21123338 CVCL_8T34 BO0790 transformed cell line human CVCL_8T34 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+marker (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123339 CVCL_9534 CLB-Pe cancer cell line human CVCL_9534 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=18534018). Female 21123340 CVCL_8T37 BO0799 transformed cell line human CVCL_8T37 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,5p-,inv(9)(p11;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123341 CVCL_9537 CLB-Tr cancer cell line human CVCL_9537 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3520T>C); ClinVar=VCV000217849; Zygosity=Heterozygous (PubMed=18923523) Derived from metastatic site: Bone marrow. Female 21123342 CVCL_8T36 BO0795 transformed cell line human CVCL_8T36 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+mar; 48,XX,+mar+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123343 CVCL_9536 CLB-Sedp cancer cell line human CVCL_9536 CL:0000010 Miscellaneous: Sex of donor from personal communication of Combaret V. Female 21123344 CVCL_8T53 BO0988 transformed cell line human CVCL_8T53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123345 CVCL_9553 Karpas-353 cancer cell line human CVCL_9553 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia (ALL-L2) Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 21123346 CVCL_8T52 BO0960 transformed cell line human CVCL_8T52 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,psce dic(Y),t(Y;15)(Ypter->cen->Yq11.2::15q11.2->15pter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123347 CVCL_9552 Karpas-707H cancer cell line human CVCL_9552 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Bone marrow. Male Characteristics: Produces Ig lambda Group: Hybridoma fusion partner cell line 21123348 CVCL_8T55 BO1029 transformed cell line human CVCL_8T55 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,dup(15)(q11.2->q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123349 CVCL_9555 PC-3M cancer cell line human CVCL_9555 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray Male 21123350 CVCL_8T54 BO1028 transformed cell line human CVCL_8T54 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,dup(15)(q11.2->q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123351 CVCL_9554 Karpas-1272 cancer cell line human CVCL_9554 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (PubMed=11157491) Derived from sampling site: Peripheral blood. Male 21123352 CVCL_8T51 BO0955 transformed cell line human CVCL_8T51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21123354 CVCL_8T50 BO0954 transformed cell line human CVCL_8T50 CL:0000010 Karyotypic information: 46,XX,inv(8)(p21;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123355 CVCL_9550 SU-DHL-2 cancer cell line human CVCL_9550 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Ser209Arg (c.627T>G) (p.Ser222Arg, c.666T>G) (S222R); Zygosity=Heterozygous (PubMed=21179087) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: ~24 hours (DSMZ=ACC-902) 21123356 CVCL_8T49 BO0939 transformed cell line human CVCL_8T49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123357 CVCL_9549 SN12C-PM6 cancer cell line human CVCL_9549 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Homozygous (from parent cell line) Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Male 21123358 CVCL_8T46 BO0885 transformed cell line human CVCL_8T46 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(10;22)(q26.3;q13.31) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123359 CVCL_9546 KHM-1A cancer cell line human CVCL_9546 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgA lambda Doubling time: ~5 days (PubMed=2458153) 21123360 CVCL_8T45 BO0877 transformed cell line human CVCL_8T45 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;7)(q29;q36.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123361 CVCL_9545 KHM-4 cancer cell line human CVCL_9545 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgA kappa 21123362 CVCL_8T48 BO0920 transformed cell line human CVCL_8T48 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;5)(q25.3;q33.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123363 CVCL_9548 KM12-SM cancer cell line human CVCL_9548 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line) Omics: miRNA expression profiling; Omics: Nuclear proteome analysis; Omics: Transcriptome analysis by microarray. Unspecified Microsatellite instability: Instable (MSI) (PubMed=25926053) 21123364 CVCL_8T47 BO0913 transformed cell line human CVCL_8T47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123365 CVCL_9547 KM12-C cancer cell line human CVCL_9547 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line) Omics: miRNA expression profiling; Omics: Nuclear proteome analysis; Omics: Transcriptome analysis by microarray. Unspecified Microsatellite instability: Instable (MSI) (PubMed=25926053) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12533; Registration: Chiron Master Culture Collection; CMCC 11611 (CMCC #11611) 21123366 CVCL_8T20 BO0706 transformed cell line human CVCL_8T20 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,12q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123367 CVCL_9520 CLB-Be cancer cell line human CVCL_9520 CL:0000010 Derived from metastatic site: Lymph node. Male 21123368 CVCL_8T22 BO0717 transformed cell line human CVCL_8T22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123369 CVCL_9522 CLB-BerLud1 cancer cell line human CVCL_9522 CL:0000010 Derived from metastatic site: Bone marrow. Male 21123370 CVCL_8T21 BO0707 transformed cell line human CVCL_8T21 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,12q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123371 CVCL_9521 CLB-Bel cancer cell line human CVCL_9521 CL:0000010 Miscellaneous: Sex of donor from personal communication of Combaret V. Male 21123372 CVCL_8T17 BO0662 transformed cell line human CVCL_8T17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123373 CVCL_9517 CLB-Ba cancer cell line human CVCL_9517 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3520T>C); ClinVar=VCV000217849; Zygosity=Heterozygous (PubMed=18923523) Derived from metastatic site: Bone marrow. Male 21123374 CVCL_8T16 BO0613 transformed cell line human CVCL_8T16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-5,+der5t(5;11)(p15;p14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123375 CVCL_9516 POG-1771 cancer cell line human CVCL_9516 CL:0000010 Male 21123376 CVCL_8T19 BO0705 transformed cell line human CVCL_8T19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,5p+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123377 CVCL_9519 CLB-Bar cancer cell line human CVCL_9519 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Unexplicit; Ex4-11; Zygosity=Unspecified (PubMed=30459281) Miscellaneous: Sex of donor from personal communication of Combaret V. Omics: Deep phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Female 21123378 CVCL_8T18 BO0663 transformed cell line human CVCL_8T18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123379 CVCL_9518 CLB-Bac cancer cell line human CVCL_9518 CL:0000010 Male 21123380 CVCL_8T13 BO0575 transformed cell line human CVCL_8T13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123381 CVCL_9513 POG-1382.2 cancer cell line human CVCL_9513 CL:0000010 Female 21123382 CVCL_8T12 BO0574 transformed cell line human CVCL_8T12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123383 CVCL_9512 KP-N-RT-RT-BMV-C6 cancer cell line human CVCL_9512 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female 21123384 CVCL_8T15 BO0603 transformed cell line human CVCL_8T15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;10)(q27;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123385 CVCL_9515 POG-1691 cancer cell line human CVCL_9515 CL:0000010 Male 21123386 CVCL_8T14 BO0576 transformed cell line human CVCL_8T14 CL:0000010 Karyotypic information: 46,XX,t(2;17) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123387 CVCL_9514 POG-1643 cancer cell line human CVCL_9514 CL:0000010 Male 21123388 CVCL_8T31 BO0770 transformed cell line human CVCL_8T31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123389 CVCL_9531 CLB-Ge2 cancer cell line human CVCL_9531 CL:0000010 Derived from metastatic site: Lymph node. Male 21123390 CVCL_8T30 BO0769 transformed cell line human CVCL_8T30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,13q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123391 CVCL_9530 CLB-Ge1 cancer cell line human CVCL_9530 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Val (c.3520T>G); ClinVar=VCV000065670; Zygosity=Unspecified (PubMed=18923523; PubMed=30459281) Derived from metastatic site: Bone marrow. Omics: Deep phosphoproteome analysis; Omics: Transcriptome analysis by RNAseq Male 21123392 CVCL_8T33 BO0789 transformed cell line human CVCL_8T33 CL:0000010 Population: Caucasian; Karyotypic information: 15q- de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123393 CVCL_9533 CLB-Ma2 cancer cell line human CVCL_9533 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18923523; PubMed=31452835) Derived from metastatic site: Bone marrow. Omics: Array-based CGH Female 21123394 CVCL_8T32 BO0772 transformed cell line human CVCL_8T32 CL:0000010 Karyotypic information: 46,XY,del(22)(q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123395 CVCL_9532 CLB-Ma1 cancer cell line human CVCL_9532 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous; Note=Only detected in 5% of the cells in early passages but increase to 50% in late passages (PubMed=31452835); Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Leu1196Met (c.3586C>A); ClinVar=VCV000376135; Zygosity=Heterozygous; Note=Only detected in 0.45% of the cells in early passages but increase to 32% in late passages (PubMed=31452835); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn235Ser (c.704A>G); ClinVar=VCV000127821; Zygosity=Unspecified (PubMed=18534018) Derived from sampling site: Abdomen. Omics: Array-based CGH Female 21123396 CVCL_8T28 BO0740 transformed cell line human CVCL_8T28 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;10)(q42;q22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123397 CVCL_9528 CLB-Es cancer cell line human CVCL_9528 CL:0000010 Derived from metastatic site: Bone marrow. Male 21123398 CVCL_8T27 BO0737 transformed cell line human CVCL_8T27 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-22,+der(22)(T) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123399 CVCL_9527 CLB-Chas cancer cell line human CVCL_9527 CL:0000010 Miscellaneous: Sex of donor from personal communication of Combaret V. Male 21123400 CVCL_8T29 BO0763 transformed cell line human CVCL_8T29 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,-8+der(8),t(8;20)(20pter->20p12::8p23->8qter)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123401 CVCL_9529 CLB-Ga cancer cell line human CVCL_9529 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Heterozygous (PubMed=18923523) Derived from metastatic site: Bone marrow. Male 21123402 CVCL_8T24 BO0719 transformed cell line human CVCL_8T24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123403 CVCL_9524 CLB-Bou cancer cell line human CVCL_9524 CL:0000010 Miscellaneous: Sex of donor from personal communication of Combaret V. Female 21123404 CVCL_8T23 BO0718 transformed cell line human CVCL_8T23 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(15)(pter->q11.2::q13->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123405 CVCL_9523 CLB-BerLud2 cancer cell line human CVCL_9523 CL:0000010 Derived from metastatic site: Bone marrow. Male 21123406 CVCL_8T26 BO0723 transformed cell line human CVCL_8T26 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,5q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123407 CVCL_9526 CLB-Ca cancer cell line human CVCL_9526 CL:0000010 Derived from metastatic site: Bone marrow. Female 21123408 CVCL_8T25 BO0720 transformed cell line human CVCL_8T25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123409 CVCL_9525 CLB-Br cancer cell line human CVCL_9525 CL:0000010 Derived from metastatic site: Bone marrow. Female 21123410 CVCL_8T00 BO0388 transformed cell line human CVCL_8T00 CL:0000010 Karyotypic information: 47,XX,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123411 CVCL_9500 WASMC finite cell line CVCL_9500 CL:0000010 Derived from sampling site: Aorta Cell type=Fibroblast.. Male 21123412 CVCL_8T11 BO0566 transformed cell line human CVCL_8T11 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,-X,+derX,t(X;6)(q28;p12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123413 CVCL_9511 KP-N-RT-LN cancer cell line human CVCL_9511 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary lymph node. Female 21123414 CVCL_8T10 BO0563 transformed cell line human CVCL_8T10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123415 CVCL_9510 KP-N-SI(FA) cancer cell line human CVCL_9510 CL:0000010 Population: Japanese; Derived from metastatic site: Bone. Male 21123416 CVCL_8T06 BO0436 transformed cell line human CVCL_8T06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;22)(p36;p12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123417 CVCL_9506 CHP-126BL cancer cell line human CVCL_9506 CL:0000010 Derived from sampling site: Peripheral blood. Female 21123418 CVCL_8T05 BO0430 transformed cell line human CVCL_8T05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123419 CVCL_9505 XPA-4 cancer cell line human CVCL_9505 From: Maitra A.; Johns Hopkins University; Baltimore; USA. CL:0000010 21123420 CVCL_8T08 BO0471 transformed cell line human CVCL_8T08 CL:0000010 Karyotypic information: 46,XX,t(4;6)(q31.3;p21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123421 CVCL_9508 KP-N-AY cancer cell line human CVCL_9508 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female 21123422 CVCL_8T07 BO0467 transformed cell line human CVCL_8T07 CL:0000010 Karyotypic information: 46,XY,t(2;3)(q27.3;p25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123423 CVCL_9507 CHP-166 cancer cell line human CVCL_9507 CL:0000010 Derived from metastatic site: Bone marrow. Male 21123424 CVCL_8T02 BO0392 transformed cell line human CVCL_8T02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123425 CVCL_9502 XPA-1 cancer cell line human CVCL_9502 From: Maitra A.; Johns Hopkins University; Baltimore; USA CL:0000010 Derived from sampling site: Pancreas. Unspecified 21123426 CVCL_9501 A7573 spontaneously immortalized cell line dog CVCL_9501 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Female 21123427 CVCL_8T01 BO0389 transformed cell line human CVCL_8T01 CL:0000010 Karyotypic information: 46,X,del(X)(qter-cen) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123428 CVCL_8T04 BO0401 transformed cell line human CVCL_8T04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123429 CVCL_9504 XPA-3 cancer cell line human CVCL_9504 From: Maitra A.; Johns Hopkins University; Baltimore; USA CL:0000010 Derived from sampling site: Pancreas. Unspecified 21123430 CVCL_8T03 BO0396 transformed cell line human CVCL_8T03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;9)(p26;q21)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123431 CVCL_9503 XPA-2 cancer cell line human CVCL_9503 From: Maitra A.; Johns Hopkins University; Baltimore; USA CL:0000010 Derived from sampling site: Pancreas. Unspecified 21123432 CVCL_8T09 BO0557 transformed cell line human CVCL_8T09 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY?,(4;11)(q22;q21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123433 CVCL_9509 KP-N-AYR cancer cell line human CVCL_9509 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female Characteristics: KP-N-AYR cell line is 3.0-fold more resistant to adriamycin and 2.7-fold more resistant to cis-platinum compared to KP-N-AY 21123434 CVCL_SA91 HAP1 ABCA1 (-) 2 cancer cell line human CVCL_SA91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29; ABCA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123435 CVCL_SA90 HAP1 ABCA1 (-) 1 cancer cell line human CVCL_SA90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29; ABCA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123436 CVCL_SA93 HAP1 ABCA7 (-) 1 cancer cell line human CVCL_SA93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37; ABCA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123437 CVCL_SA92 HAP1 ABCA3 (-) 1 cancer cell line human CVCL_SA92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33; ABCA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123438 CVCL_SA95 HAP1 ABCB1 (-) 1 cancer cell line human CVCL_SA95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123439 CVCL_SA94 HAP1 ABCA7 (-) 2 cancer cell line human CVCL_SA94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37; ABCA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123440 CVCL_SA97 HAP1 ABCB5 (-) 1 cancer cell line human CVCL_SA97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123441 CVCL_SA96 HAP1 ABCB1 (-) 2 cancer cell line human CVCL_SA96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123442 CVCL_SA99 HAP1 ABCB5 (-) 3 cancer cell line human CVCL_SA99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123443 CVCL_SA98 HAP1 ABCB5 (-) 2 cancer cell line human CVCL_SA98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 46; ABCB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123444 CVCL_SA80 NSC-89-20 D-3 finite cell line human CVCL_SA80 CL:0000010 Population: Japanese; Donor information: Established from an atomic bomb survivor; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123445 CVCL_SA82 HAP1 KDM1A(-) 2 cancer cell line human CVCL_SA82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29079; KDM1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123446 CVCL_SA81 HAP1 ANO6(-) 2 cancer cell line human CVCL_SA81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25240; ANO6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123447 CVCL_SA84 HAP1 TP53(-) 2 cancer cell line human CVCL_SA84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123448 CVCL_SA83 HAP1 NUDT1(-) 2 cancer cell line human CVCL_SA83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8048; NUDT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123449 CVCL_SA86 HAP1 AATK (-) 1 cancer cell line human CVCL_SA86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21; AATK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123450 CVCL_SA85 HAP1 AAK1 (-) cancer cell line human CVCL_SA85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19679; AAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123451 CVCL_SA88 HAP1 AATK (-) 3 cancer cell line human CVCL_SA88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21; AATK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123452 CVCL_SA87 HAP1 AATK (-) 2 cancer cell line human CVCL_SA87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21; AATK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123453 CVCL_SA89 HAP1 ABAT (-) cancer cell line human CVCL_SA89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23; ABAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123454 CVCL_AN56 CW30171 induced pluripotent stem cell human CVCL_AN56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30171; true Male 21123455 CVCL_AN55 CW30170 induced pluripotent stem cell human CVCL_AN55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30170; true Male 21123456 CVCL_AN58 CW30178 induced pluripotent stem cell human CVCL_AN58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30178; true Male 21123457 CVCL_AN57 CW30173 induced pluripotent stem cell human CVCL_AN57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30173; true; Discontinued: FCDI; CW30173; probable. Male 21123458 CVCL_AN59 CW30180 induced pluripotent stem cell human CVCL_AN59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30180; true Male 21123459 CVCL_AN50 CW30160 induced pluripotent stem cell human CVCL_AN50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30160; true; Discontinued: FCDI; CW30160; probable. Female 21123460 CVCL_AN52 CW30162 induced pluripotent stem cell human CVCL_AN52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30162; true; Discontinued: FCDI; CW30162; probable. Female 21123461 CVCL_AN51 CW30161 induced pluripotent stem cell human CVCL_AN51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30161; true Male 21123462 CVCL_AN54 CW30167 induced pluripotent stem cell human CVCL_AN54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30167; true Male 21123463 CVCL_AN53 CW30166 induced pluripotent stem cell human CVCL_AN53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30166; true Male 21123464 CVCL_AN67 CW30214 induced pluripotent stem cell human CVCL_AN67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30214; true Male 21123465 CVCL_AN66 CW30212 induced pluripotent stem cell human CVCL_AN66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30212; true Male 21123466 CVCL_AN69 CW30217 induced pluripotent stem cell human CVCL_AN69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30217; true; Discontinued: FCDI; CW30217; probable. Male 21123467 CVCL_AN68 CW30215 induced pluripotent stem cell human CVCL_AN68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30215; true Male 21123468 CVCL_AN61 CW30194 induced pluripotent stem cell human CVCL_AN61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30194; true Male 21123469 CVCL_AN60 CW30181 induced pluripotent stem cell human CVCL_AN60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30181; true Female 21123470 CVCL_AN63 CW30205 induced pluripotent stem cell human CVCL_AN63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30205; true Male 21123471 CVCL_AN62 CW30203 induced pluripotent stem cell human CVCL_AN62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30203; true Male 21123472 CVCL_AN65 CW30211 induced pluripotent stem cell human CVCL_AN65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30211; true Male 21123473 CVCL_AN64 CW30207 induced pluripotent stem cell human CVCL_AN64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30207; true Female 21123474 CVCL_AN34 CW30027 induced pluripotent stem cell human CVCL_AN34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic Discontinued: Coriell; CW30027; true. Male 21123475 CVCL_AN33 CW30017 induced pluripotent stem cell human CVCL_AN33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30017; true. Female 21123476 CVCL_AN36 CW30038 induced pluripotent stem cell human CVCL_AN36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30038; true. Male 21123477 CVCL_AN35 CW30033 induced pluripotent stem cell human CVCL_AN35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30033; true. Female 21123478 CVCL_AN38 CW30043 induced pluripotent stem cell human CVCL_AN38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30043; true Male 21123479 CVCL_AN37 CW30042 induced pluripotent stem cell human CVCL_AN37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30042; true Female 21123480 CVCL_AN39 CW30057 induced pluripotent stem cell human CVCL_AN39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30057; true Female 21123481 CVCL_AN30 CW20012 induced pluripotent stem cell human CVCL_AN30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20012; true Female 21123482 CVCL_AN32 CW30013 induced pluripotent stem cell human CVCL_AN32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30013; true; Discontinued: FCDI; CW30013; probable. Female 21123483 CVCL_AN31 CW30007 induced pluripotent stem cell human CVCL_AN31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30007; true. Female 21123484 CVCL_AN45 CW30119 induced pluripotent stem cell human CVCL_AN45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30119; true Female 21123485 CVCL_AN44 CW30116 induced pluripotent stem cell human CVCL_AN44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30116; true Male 21123486 CVCL_AN47 CW30148 induced pluripotent stem cell human CVCL_AN47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30148; true Female 21123487 CVCL_AN46 CW30145 induced pluripotent stem cell human CVCL_AN46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30145; true Female 21123488 CVCL_AN49 CW30159 induced pluripotent stem cell human CVCL_AN49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30159; true Male 21123489 CVCL_AN48 CW30149 induced pluripotent stem cell human CVCL_AN48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30149; true Male 21123490 CVCL_AN41 CW30106 induced pluripotent stem cell human CVCL_AN41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30106; true Male 21123491 CVCL_AN40 CW30104 induced pluripotent stem cell human CVCL_AN40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30104; true Female 21123492 CVCL_AN43 CW30110 induced pluripotent stem cell human CVCL_AN43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30110; true Female 21123493 CVCL_AN42 CW30109 induced pluripotent stem cell human CVCL_AN42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30109; true Female 21123494 CVCL_AN19 CW10074 induced pluripotent stem cell human CVCL_AN19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10074; true Male 21123495 CVCL_8T80 BQ0419 transformed cell line human CVCL_8T80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94020701; true Female Part of: ECACC chromosomal abnormality collection 21123496 CVCL_9580 MCF-7aro cancer cell line human CVCL_9580 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21123497 CVCL_8T86 BV0416 transformed cell line human CVCL_8T86 CL:0000010 Karyotypic information: 46,XX,t(14;18)(q13;q12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123498 CVCL_9586 GM06985 transformed cell line human CVCL_9586 HLA typing: A*02:01,03:01; B*07:02:01,57:01; C*07:02,06:02; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01; DRB5*01,01 (IPD-IMGT/HLA=25856) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134114 21123499 CVCL_AN12 HROC113 cT0 M1 cancer cell line human CVCL_AN12 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female 21123500 CVCL_8T85 BT0001 transformed cell line human CVCL_8T85 CL:0000010 Karyotypic information: 46,XY,del(11)(p14.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21123501 CVCL_AN11 GM07172 finite cell line human CVCL_AN11 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Female 21123502 CVCL_9585 SK-GT-1 cancer cell line human CVCL_9585 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.169_185del17; Zygosity=Unspecified (PubMed=7665247) Population: Caucasian; Derived from sampling site: Stomach; cardia. Male Doubling time: 48 hours (PubMed=8334620) 21123503 CVCL_8T88 BV0699 transformed cell line human CVCL_8T88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123504 CVCL_9588 GM06993 transformed cell line human CVCL_9588 HLA typing: A*01:01,02:01; B*07:02,50:01; C*07:02,06:02; DPA1*01:04; DPB1*06:01,15:01; DQA1*02:01,03:01; DQB1*02:01,03:02:01; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25857) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134113 21123505 CVCL_AN14 HROC24 T3 M1 #2 cancer cell line human CVCL_AN14 HLA typing: A*02:01,30:02; B*18:01,38:01; C*05:01,12:03; DQB1*02:01,06:01; DRB1*03:01,13:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in NMRI nu/nu mice 21123506 CVCL_8T87 BV0698 transformed cell line human CVCL_8T87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123507 CVCL_9587 GM06990 transformed cell line human CVCL_9587 HLA typing: A*02:01,24:02; B*51:01,07:02:01; C*15:03,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:03,03:01; DQB1*03:02,06:03; DRB1*13:01,04:04; DRB3*10:01; DRB4*01 (IPD-IMGT/HLA=25804) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133102 21123508 CVCL_AN13 HROC348 cancer cell line human CVCL_AN13 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; sigmoid. Male 21123509 CVCL_8T82 BQ0431 transformed cell line human CVCL_8T82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071518; true Female Part of: ECACC chromosomal abnormality collection 21123510 CVCL_AN16 CW10005 induced pluripotent stem cell human CVCL_AN16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10005; true Female 21123511 CVCL_9582 T-47Daro cancer cell line human CVCL_9582 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1 Derived from metastatic site: Pleural effusion. Female 21123512 CVCL_8T81 BQ0430 transformed cell line human CVCL_8T81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071517; true Male Part of: ECACC chromosomal abnormality collection 21123513 CVCL_AN15 CW10004 induced pluripotent stem cell human CVCL_AN15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10004; true. Female 21123514 CVCL_9581 MCF-7aro/ERE cancer cell line human CVCL_9581 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21123515 CVCL_8T84 BQ0464 transformed cell line human CVCL_8T84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97051603; true Female Part of: ECACC chromosomal abnormality collection 21123516 CVCL_AN18 CW10048 induced pluripotent stem cell human CVCL_AN18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10048; true; Discontinued: FCDI; CW10048; probable. Male 21123517 CVCL_9584 SK-GT-3 cancer cell line human CVCL_9584 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Stomach; fundus. Male Doubling time: 58 hours (PubMed=8334620) 21123518 CVCL_8T83 BQ0432 transformed cell line human CVCL_8T83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071519; true Male Part of: ECACC chromosomal abnormality collection 21123519 CVCL_AN17 CW10021 induced pluripotent stem cell human CVCL_AN17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10021; true. Male 21123520 CVCL_9583 PEL-5 cancer cell line human CVCL_9583 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296) Omics: Transcriptome analysis by microarray. 21123521 CVCL_8T79 BO2224 transformed cell line human CVCL_8T79 CL:0000010 Karyotypic information: 47,XY,+r(5); 46,XY(25)ish r(19)(wep19+) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123522 CVCL_9579 MCF-7/LY2 cancer cell line human CVCL_9579 HLA typing: A*02:01,02:01; B*44:02,18:01; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90187; Lilly 117018 (LY 117018); Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 56.10 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21123523 CVCL_8T78 BO2217 transformed cell line human CVCL_8T78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123524 CVCL_9578 LNC cancer cell line house mouse CVCL_9578 CL:0000010 Breed/subspecies: NZB. 21123525 CVCL_AN10 GM13427 finite cell line human CVCL_AN10 CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Gly678Arg (c.2032G>A); ClinVar=VCV000014366; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21123526 CVCL_8T91 BV0703 transformed cell line human CVCL_8T91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123527 CVCL_9591 GM07022 transformed cell line human CVCL_9591 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains a chromosomally integrated human herpesvirus 6B (CI-HHV-6B) Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134011 21123528 CVCL_8T90 BV0702 transformed cell line human CVCL_8T90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123529 CVCL_9590 GM07000 transformed cell line human CVCL_9590 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134010 21123530 CVCL_8T97 CB0001 transformed cell line human CVCL_8T97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012701; true Female Part of: ECACC chromosomal abnormality collection 21123531 CVCL_AN23 CW10102 induced pluripotent stem cell human CVCL_AN23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10102; true Male 21123532 CVCL_9597 GM11831 transformed cell line human CVCL_9597 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135012 21123533 CVCL_8T96 BY0002 transformed cell line human CVCL_8T96 CL:0000010 Population: Asian; Karyotypic information: 46,Y,t(x;4)(q24;q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123534 CVCL_AN22 CW10094 induced pluripotent stem cell human CVCL_AN22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10094; true Female 21123535 CVCL_9596 GM11830 transformed cell line human CVCL_9596 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135011 21123536 CVCL_8T99 CB0054 transformed cell line human CVCL_8T99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93111919; true Female Part of: ECACC chromosomal abnormality collection 21123537 CVCL_AN25 CW10114 induced pluripotent stem cell human CVCL_AN25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10114; true Female 21123538 CVCL_9599 GM11881 transformed cell line human CVCL_9599 HLA typing: A*03:01,26:01; B*07:02,07:02; C*07:02,07:02; DPA1*01:03,01:03; DPB1*02:01,04:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01; DRB5*01 (IPD-IMGT/HLA=25892) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134714 21123539 CVCL_8T98 CB0051 transformed cell line human CVCL_8T98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93111608; true Male Part of: ECACC chromosomal abnormality collection 21123540 CVCL_AN24 CW10107 induced pluripotent stem cell human CVCL_AN24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10107; true Male 21123541 CVCL_9598 GM11832 transformed cell line human CVCL_9598 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135013 21123542 CVCL_8T93 BV0763 transformed cell line human CVCL_8T93 CL:0000010 Population: Asian; Karyotypic information: 46,XY,4p- (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123543 CVCL_AN27 CW10122 induced pluripotent stem cell human CVCL_AN27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10122; true Male 21123544 CVCL_9593 GM07056 transformed cell line human CVCL_9593 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134012 21123545 CVCL_8T92 BV0704 transformed cell line human CVCL_8T92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123546 CVCL_AN26 CW10115 induced pluripotent stem cell human CVCL_AN26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10115; true Female 21123547 CVCL_9592 GM07034 transformed cell line human CVCL_9592 HLA typing: A*02:01,24:03; B*18:01,44:02:01:01; C*05:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*02:01,03:01; DQB1*02:01,03:01:01; DRB1*04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25860) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134111 21123548 CVCL_8T95 BX0006 transformed cell line human CVCL_8T95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123549 CVCL_AN29 CW10159 induced pluripotent stem cell human CVCL_AN29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10159; true Male 21123550 CVCL_9595 GM07357 transformed cell line human CVCL_9595 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation; CYP2C19*2 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 134512 21123551 CVCL_8T94 BV0968 transformed cell line human CVCL_8T94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123552 CVCL_AN28 CW10156 induced pluripotent stem cell human CVCL_AN28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10156; true Male 21123553 CVCL_9594 GM07345 transformed cell line human CVCL_9594 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134513 21123554 CVCL_8T89 BV0700 transformed cell line human CVCL_8T89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123555 CVCL_9589 GM06994 transformed cell line human CVCL_9589 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134009 21123556 CVCL_AN21 CW10083 induced pluripotent stem cell human CVCL_AN21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10083; true Male 21123557 CVCL_AN20 CW10078 induced pluripotent stem cell human CVCL_AN20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10078; true Male 21123558 CVCL_8T64 BO1093 transformed cell line human CVCL_8T64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123559 CVCL_9564 SaOS-LM2 cancer cell line human CVCL_9564 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Doubling time: 43.6 +- 4.2 hours (PubMed=10763916) 21123560 CVCL_8T63 BO1091 transformed cell line human CVCL_8T63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX; 47,XX,+r(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123561 CVCL_9563 SaOS-LM1 cancer cell line human CVCL_9563 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female 21123562 CVCL_8T66 BO2036 transformed cell line human CVCL_8T66 CL:0000010 Karyotypic information: 46,XY,10p+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123563 CVCL_9566 SaOS-LM4 cancer cell line human CVCL_9566 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Doubling time: 44.1 +- 0.9 hours (PubMed=10763916) 21123564 CVCL_8T65 BO2017 transformed cell line human CVCL_8T65 CL:0000010 Karyotypic information: 46,XY; 48,XY+mar1,+mar2; 48,XY,+mar1,+mar3; 49,XY,+mar1,+mar2,+mar3 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123565 CVCL_9565 SaOS-LM3 cancer cell line human CVCL_9565 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Doubling time: 44.1 +- 2.6 hours (PubMed=10763916) 21123566 CVCL_9560 AC1-1 cancer cell line human CVCL_9560 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Fetal brain. Male 21123567 CVCL_8T60 BO1060 transformed cell line human CVCL_8T60 CL:0000010 Karyotypic information: 46,XX,t(4;14)(q21;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123568 CVCL_9562 AC1-9 cancer cell line human CVCL_9562 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Fetal brain. Male 21123569 CVCL_8T62 BO1087 transformed cell line human CVCL_8T62 CL:0000010 Karyotypic information: 5p deletion (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123570 CVCL_9561 AC1-5 cancer cell line human CVCL_9561 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Fetal brain. Male 21123571 CVCL_8T61 BO1064 transformed cell line human CVCL_8T61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(5) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123572 CVCL_9557 2957/90 cancer cell line human CVCL_9557 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00108 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 51 year old male patient with a gastric carcinoma. 21123573 CVCL_8T57 BO1038 transformed cell line human CVCL_8T57 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,dup(15)(q11.2->q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123574 CVCL_9556 2474/90 cancer cell line human CVCL_9556 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00107 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 60 year old male patient with a gastric carcinoma. 21123575 CVCL_8T56 BO1035 transformed cell line human CVCL_8T56 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,dup(15)(q11.2->q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123576 CVCL_9559 AC1 [Human gestational choriocarcinoma] cancer cell line human CVCL_9559 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Fetal brain. Male 21123577 CVCL_8T59 BO1040 transformed cell line human CVCL_8T59 CL:0000010 Karyotypic information: 46,X,del(X),(qter->p22.31) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123578 CVCL_9558 3051/80 cancer cell line human CVCL_9558 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00109 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 66 year old male patient with a gastric carcinoma. 21123579 CVCL_8T58 BO1039 transformed cell line human CVCL_8T58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123580 CVCL_AN09 GM13426 finite cell line human CVCL_AN09 CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Glu532del (c.1594_1596delGAG); ClinVar=VCV000014367; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21123581 CVCL_AN08 GM13425 finite cell line human CVCL_AN08 CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Glu532del (c.1594_1596delGAG); ClinVar=VCV000014367; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Gly678Arg (c.2032G>A); ClinVar=VCV000014366; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21123582 CVCL_8T75 BO2170 transformed cell line human CVCL_8T75 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-9,+der t(4;9)(q34.2;p22)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123583 CVCL_AN01 GM10362 finite cell line human CVCL_AN01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21123584 CVCL_9575 KTA-4 cancer cell line human CVCL_9575 CL:0000010 Population: Japanese Omics: Transcriptome analysis by microarray. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7528 21123585 CVCL_8T74 BO2169 transformed cell line human CVCL_8T74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21123586 CVCL_AN00 GM10361 transformed cell line human CVCL_AN00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21123587 CVCL_9574 KTA-3 cancer cell line human CVCL_9574 CL:0000010 Population: Japanese Omics: Transcriptome analysis by microarray. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7526 21123588 CVCL_8T77 BO2216 transformed cell line human CVCL_8T77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123589 CVCL_AN03 GM19632 transformed cell line human CVCL_AN03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21123590 CVCL_9577 LLC-PK10 spontaneously immortalized cell line pig CVCL_9577 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21123591 CVCL_8T76 BO2199 transformed cell line human CVCL_8T76 CL:0000010 Karyotypic information: 46,XX,del(4)(q25;q27) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123592 CVCL_AN02 GM13636 finite cell line human CVCL_AN02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21123593 CVCL_9576 L1.2 cancer cell line house mouse CVCL_9576 From: Rosenberg N.; Tufts University; Boston; USA CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788). 21123594 CVCL_8T71 BO2128 transformed cell line human CVCL_8T71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123595 CVCL_AN05 GM01790 finite cell line human CVCL_AN05 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21123596 CVCL_9571 TTA-3 cancer cell line human CVCL_9571 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 29.6 hours (PubMed=8121182) 21123597 CVCL_8T70 BO2115 transformed cell line human CVCL_8T70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123598 CVCL_AN04 GM19633 finite cell line human CVCL_AN04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21123599 CVCL_9570 TTA-2 cancer cell line human CVCL_9570 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 144.5 hours (PubMed=8121182) Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7527 21123600 CVCL_8T73 BO2136 transformed cell line human CVCL_8T73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123601 CVCL_AN07 GM07206 finite cell line human CVCL_AN07 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21123602 CVCL_9573 KTA-2 cancer cell line human CVCL_9573 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 63.1 hours (PubMed=8121182) Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7525 21123603 CVCL_8T72 BO2135 transformed cell line human CVCL_8T72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123604 CVCL_AN06 GM01791 finite cell line human CVCL_AN06 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21123605 CVCL_9572 KTA-1 cancer cell line human CVCL_9572 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male Doubling time: 52.1 hours (PubMed=8121182) Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7524 21123606 CVCL_8T68 BO2108 transformed cell line human CVCL_8T68 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;2)(q42.3;q37.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123607 CVCL_9568 SaOS-LM6 cancer cell line human CVCL_9568 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Doubling time: 34.9 +- 1.4 hours (PubMed=10763916) 21123608 CVCL_8T67 BO2048 transformed cell line human CVCL_8T67 CL:0000010 Karyotypic information: 46,XX,?del(1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123609 CVCL_9567 SaOS-LM5 cancer cell line human CVCL_9567 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone. Female Doubling time: 37.2 +- 3.8 hours (PubMed=10763916) 21123610 CVCL_8T69 BO2110 transformed cell line human CVCL_8T69 CL:0000010 Karyotypic information: 46,XX,18pt (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123611 CVCL_9569 SLK cancer cell line human CVCL_9569 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Skin. Male Doubling time: 24-36 hours (PubMed=7520247) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00477 Problematic cell line: Contaminated Shown to be a Caki-1 derivative (PubMed=22987579). Originally thought to originate from a 28 year old male patient with HIV-1 negative Kaposi sarcoma. 21123612 CVCL_JI94 CW60286 induced pluripotent stem cell human CVCL_JI94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60286; true Female 21123613 CVCL_JI93 CW60280 induced pluripotent stem cell human CVCL_JI93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60280; true Male 21123614 CVCL_JI96 CW60290 induced pluripotent stem cell human CVCL_JI96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60290; true Female 21123615 CVCL_JI95 CW60289 induced pluripotent stem cell human CVCL_JI95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60289; true Female 21123616 CVCL_JI90 CW60277 induced pluripotent stem cell human CVCL_JI90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60277; true Male 21123617 CVCL_JI92 CW60279 induced pluripotent stem cell human CVCL_JI92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60279; true Female 21123618 CVCL_JI91 CW60278 induced pluripotent stem cell human CVCL_JI91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60278; true Male 21123619 CVCL_SC31 HAP1 ALG8 (-) 2 cancer cell line human CVCL_SC31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23161; ALG8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123620 CVCL_SC30 HAP1 ALG8 (-) 1 cancer cell line human CVCL_SC30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23161; ALG8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123621 CVCL_SC33 HAP1 ALG9 (-) 2 cancer cell line human CVCL_SC33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15672; ALG9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123622 CVCL_SC32 HAP1 ALG9 (-) 1 cancer cell line human CVCL_SC32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15672; ALG9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123623 CVCL_SC35 HAP1 ALK (-) 2 cancer cell line human CVCL_SC35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 427; ALK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123624 CVCL_SC34 HAP1 ALK (-) 1 cancer cell line human CVCL_SC34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 427; ALK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123625 CVCL_SC37 HAP1 ALKBH2 (-) 1 cancer cell line human CVCL_SC37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32487; ALKBH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123626 CVCL_SC36 HAP1 ALKBH1 (-) 1 cancer cell line human CVCL_SC36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17911; ALKBH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123627 CVCL_SC39 HAP1 ALKBH3 (-) 1 cancer cell line human CVCL_SC39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30141; ALKBH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123628 CVCL_SC38 HAP1 ALKBH2 (-) 2 cancer cell line human CVCL_SC38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32487; ALKBH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123629 CVCL_JI87 CW60247 induced pluripotent stem cell human CVCL_JI87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60247; true Female 21123630 CVCL_JI86 CW60245 induced pluripotent stem cell human CVCL_JI86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60245; true Female 21123631 CVCL_JI89 CW60261 induced pluripotent stem cell human CVCL_JI89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60261; true Female 21123632 CVCL_JI88 CW60252 induced pluripotent stem cell human CVCL_JI88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60252; true Female 21123633 CVCL_SC20 HAP1 ALAS1 (-) 2 cancer cell line human CVCL_SC20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 396; ALAS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123634 CVCL_SC22 HAP1 ALDH3A2 (-) 1 cancer cell line human CVCL_SC22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 403; ALDH3A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123635 CVCL_SC21 HAP1 ALCAM (-) 1 cancer cell line human CVCL_SC21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 400; ALCAM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123636 CVCL_SC24 HAP1 ALG12 (-) 1 cancer cell line human CVCL_SC24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19358; ALG12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123637 CVCL_SC23 HAP1 ALDH9A1 (-) 1 cancer cell line human CVCL_SC23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 412; ALDH9A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123638 CVCL_SC26 HAP1 ALG3 (-) 1 cancer cell line human CVCL_SC26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23056; ALG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123639 CVCL_SC25 HAP1 ALG12 (-) 2 cancer cell line human CVCL_SC25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19358; ALG12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123640 CVCL_SC28 HAP1 ALG6 (-) 1 cancer cell line human CVCL_SC28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23157; ALG6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123641 CVCL_SC27 HAP1 ALG3 (-) 2 cancer cell line human CVCL_SC27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23056; ALG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123642 CVCL_SC29 HAP1 ALG6 (-) 2 cancer cell line human CVCL_SC29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23157; ALG6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123643 CVCL_JI98 CW60302 induced pluripotent stem cell human CVCL_JI98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60302; true Male 21123644 CVCL_JI97 CW60298 induced pluripotent stem cell human CVCL_JI97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60298; true Female 21123645 CVCL_JI99 CW60303 induced pluripotent stem cell human CVCL_JI99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60303; true Female 21123646 CVCL_JI72 CW60092 induced pluripotent stem cell human CVCL_JI72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60092; true Female 21123647 CVCL_JI71 CW60088 induced pluripotent stem cell human CVCL_JI71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60088; true Female 21123648 CVCL_JI74 CW60145 induced pluripotent stem cell human CVCL_JI74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60145; true Female 21123649 CVCL_JI73 CW60143 induced pluripotent stem cell human CVCL_JI73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60143; true Female 21123650 CVCL_JI70 CW60084 induced pluripotent stem cell human CVCL_JI70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60084; true Male 21123651 CVCL_SC11 HAP1 AKT1 (-) 1 cancer cell line human CVCL_SC11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123652 CVCL_SC10 HAP1 AKR1B10 (-) cancer cell line human CVCL_SC10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 382; AKR1B10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123653 CVCL_SC13 HAP1 AKT1S1 (-) 1 cancer cell line human CVCL_SC13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28426; AKT1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123654 CVCL_SC12 HAP1 AKT1 (-) 2 cancer cell line human CVCL_SC12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 391; AKT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123655 CVCL_SC15 HAP1 AKT3 (-) 1 cancer cell line human CVCL_SC15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123656 CVCL_SC14 HAP1 AKT2 (-) cancer cell line human CVCL_SC14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 392; AKT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123657 CVCL_JI69 CW60070 induced pluripotent stem cell human CVCL_JI69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60070; true Male 21123658 CVCL_SC17 HAP1 AKTIP (-) 1 cancer cell line human CVCL_SC17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16710; AKTIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123659 CVCL_JI68 CW50167 induced pluripotent stem cell human CVCL_JI68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50167; true Female 21123660 CVCL_SC16 HAP1 AKT3 (-) 2 cancer cell line human CVCL_SC16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 393; AKT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123661 CVCL_SC19 HAP1 ALAS1 (-) 1 cancer cell line human CVCL_SC19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 396; ALAS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123662 CVCL_SC18 HAP1 AKTIP (-) 2 cancer cell line human CVCL_SC18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16710; AKTIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123663 CVCL_JI65 CW50161 induced pluripotent stem cell human CVCL_JI65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50161; true Female 21123664 CVCL_JI64 CW50159 induced pluripotent stem cell human CVCL_JI64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50159; true Male 21123665 CVCL_JI67 CW50165 induced pluripotent stem cell human CVCL_JI67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50165; true Female 21123666 CVCL_JI66 CW50162 induced pluripotent stem cell human CVCL_JI66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50162; true Female 21123667 CVCL_JI83 CW60209 induced pluripotent stem cell human CVCL_JI83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60209; true Male 21123668 CVCL_JI82 CW60208 induced pluripotent stem cell human CVCL_JI82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60208; true Female 21123669 CVCL_JI85 CW60243 induced pluripotent stem cell human CVCL_JI85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60243; true Male 21123670 CVCL_JI84 CW60242 induced pluripotent stem cell human CVCL_JI84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60242; true Female 21123671 CVCL_JI81 CW60205 induced pluripotent stem cell human CVCL_JI81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60205; true Male 21123672 CVCL_JI80 CW60193 induced pluripotent stem cell human CVCL_JI80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60193; true Male 21123673 CVCL_SC00 HAP1 AHR (-) 1 cancer cell line human CVCL_SC00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 348; AHR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123674 CVCL_SC02 HAP1 AIFM1 (-) cancer cell line human CVCL_SC02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8768; AIFM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123675 CVCL_SC01 HAP1 AHR (-) 2 cancer cell line human CVCL_SC01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 348; AHR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123676 CVCL_SC04 HAP1 AKAP1 (-) 2 cancer cell line human CVCL_SC04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 367; AKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123677 CVCL_SC03 HAP1 AKAP1 (-) 1 cancer cell line human CVCL_SC03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 367; AKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123678 CVCL_SC06 HAP1 AKAP11 (-) 2 cancer cell line human CVCL_SC06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 369; AKAP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123679 CVCL_JI79 CW60188 induced pluripotent stem cell human CVCL_JI79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60188; true Male 21123680 CVCL_SC05 HAP1 AKAP11 (-) 1 cancer cell line human CVCL_SC05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 369; AKAP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123681 CVCL_SC08 HAP1 AKAP9 (-) 2 cancer cell line human CVCL_SC08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 379; AKAP9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123682 CVCL_SC07 HAP1 AKAP9 (-) 1 cancer cell line human CVCL_SC07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 379; AKAP9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123683 CVCL_JI76 CW60175 induced pluripotent stem cell human CVCL_JI76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60175; true Female 21123684 CVCL_JI75 CW60174 induced pluripotent stem cell human CVCL_JI75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60174; true Male 21123685 CVCL_SC09 HAP1 AKR1B1 (-) 1 cancer cell line human CVCL_SC09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123686 CVCL_JI78 CW60184 induced pluripotent stem cell human CVCL_JI78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60184; true Female 21123687 CVCL_JI77 CW60182 induced pluripotent stem cell human CVCL_JI77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60182; true Female 21123688 CVCL_JI50 CW40057 induced pluripotent stem cell human CVCL_JI50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40057; true. Female 21123689 CVCL_JI52 CW40062 induced pluripotent stem cell human CVCL_JI52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40062; true. Female 21123690 CVCL_JI51 CW40061 induced pluripotent stem cell human CVCL_JI51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40061; true. Male 21123691 CVCL_JI47 CW40030 induced pluripotent stem cell human CVCL_JI47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40030; true. Male 21123692 CVCL_JI46 CW40012 induced pluripotent stem cell human CVCL_JI46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40012; true. Male 21123693 CVCL_JI49 CW40053 induced pluripotent stem cell human CVCL_JI49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40053; true. Male 21123694 CVCL_JI48 CW40052 induced pluripotent stem cell human CVCL_JI48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40052; true. Female 21123695 CVCL_JI43 CW30523 induced pluripotent stem cell human CVCL_JI43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30523; true Female 21123696 CVCL_JI42 CW30522 induced pluripotent stem cell human CVCL_JI42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30522; true Male 21123697 CVCL_JI45 CW40010 induced pluripotent stem cell human CVCL_JI45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40010; true Male 21123698 CVCL_JI44 CW30525 induced pluripotent stem cell human CVCL_JI44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30525; true Female 21123699 CVCL_JI61 CW40217 induced pluripotent stem cell human CVCL_JI61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40217; true Male 21123700 CVCL_JI60 CW40192 induced pluripotent stem cell human CVCL_JI60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40192; true Male 21123701 CVCL_JI63 CW50130 induced pluripotent stem cell human CVCL_JI63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50130; true Female 21123702 CVCL_JI62 CW50112 induced pluripotent stem cell human CVCL_JI62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50112; true Female 21123703 CVCL_JI58 CW40094 induced pluripotent stem cell human CVCL_JI58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40094; true Female 21123704 CVCL_JI57 CW40077 induced pluripotent stem cell human CVCL_JI57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40077; true. Male 21123705 CVCL_JI59 CW40101 induced pluripotent stem cell human CVCL_JI59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40101; true Female 21123706 CVCL_JI54 CW40066 induced pluripotent stem cell human CVCL_JI54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40066; true Male 21123707 CVCL_JI53 CW40063 induced pluripotent stem cell human CVCL_JI53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40063; true. Male 21123708 CVCL_JI56 CW40073 induced pluripotent stem cell human CVCL_JI56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40073; true. Male 21123709 CVCL_JI55 CW40070 induced pluripotent stem cell human CVCL_JI55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40070; true. Male 21123710 CVCL_JI30 CW30444 induced pluripotent stem cell human CVCL_JI30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30444; true Male 21123711 CVCL_B099 UOK120 cancer cell line human CVCL_B099 CL:0000010 Sequence variation: Gene fusion; HGNC; 9343; PRCC + HGNC; 11752; TFE3; Name(s)=PRCC-TFE3 (PubMed=8872474) Derived from sampling site: Kidney. Male 21123712 CVCL_B098 UOK119 cancer cell line human CVCL_B098 CL:0000010 Derived from sampling site: Kidney. Unspecified 21123713 CVCL_B091 UOK112 cancer cell line human CVCL_B091 CL:0000010 Derived from sampling site: Kidney. Male 21123714 CVCL_B090 UOK111 cancer cell line human CVCL_B090 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Gly (c.518T>G); ClinVar=VCV000376016; Zygosity=Unspecified (PubMed=8319216); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Trp117Arg (c.349T>A); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Female 21123715 CVCL_B093 UOK114 cancer cell line human CVCL_B093 CL:0000010 Derived from sampling site: Kidney. Unspecified 21123716 CVCL_B092 UOK113 cancer cell line human CVCL_B092 CL:0000010 Derived from sampling site: Kidney. Unspecified 21123717 CVCL_JI29 CW30441 induced pluripotent stem cell human CVCL_JI29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30441; true Male 21123718 CVCL_B095 UOK116 cancer cell line human CVCL_B095 CL:0000010 Derived from sampling site: Kidney. Unspecified 21123719 CVCL_JI28 CW30440 induced pluripotent stem cell human CVCL_JI28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30440; true Male 21123720 CVCL_B094 UOK115 cancer cell line human CVCL_B094 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.309delT); ClinVar=VCV000223180; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Male 21123721 CVCL_B097 UOK118 cancer cell line human CVCL_B097 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Tyr175Thrfs*27 (c.523delT); Zygosity=Unspecified (PubMed=7915601; PubMed=8493574) Derived from sampling site: Kidney. Unspecified 21123722 CVCL_B096 UOK117 cancer cell line human CVCL_B096 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu158Pro (c.473T>C); ClinVar=VCV000182980; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Male 21123723 CVCL_JI25 CW30389 induced pluripotent stem cell human CVCL_JI25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30389; true Male 21123724 CVCL_JI24 CW30348 induced pluripotent stem cell human CVCL_JI24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30348; true Male 21123725 CVCL_JI27 CW30437 induced pluripotent stem cell human CVCL_JI27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30437; true Male 21123726 CVCL_JI26 CW30397 induced pluripotent stem cell human CVCL_JI26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30397; true Male 21123727 CVCL_JI21 CW30287 induced pluripotent stem cell human CVCL_JI21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30287; true Male 21123728 CVCL_JI20 CW30286 induced pluripotent stem cell human CVCL_JI20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30286; true Male 21123729 CVCL_JI23 CW30320 induced pluripotent stem cell human CVCL_JI23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30320; true Female 21123730 CVCL_JI22 CW30305 induced pluripotent stem cell human CVCL_JI22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30305; true Female 21123731 CVCL_JI41 CW30520 induced pluripotent stem cell human CVCL_JI41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30520; true Male 21123732 CVCL_JI40 CW30519 induced pluripotent stem cell human CVCL_JI40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30519; true Male 21123733 CVCL_JI39 CW30516 induced pluripotent stem cell human CVCL_JI39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30516; true Male 21123734 CVCL_JI36 CW30512 induced pluripotent stem cell human CVCL_JI36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30512; true Male 21123735 CVCL_JI35 CW30503 induced pluripotent stem cell human CVCL_JI35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30503; true Female 21123736 CVCL_JI38 CW30515 induced pluripotent stem cell human CVCL_JI38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30515; true Male 21123737 CVCL_JI37 CW30513 induced pluripotent stem cell human CVCL_JI37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30513; true Female 21123738 CVCL_JI32 CW30474 induced pluripotent stem cell human CVCL_JI32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30474; true Male 21123739 CVCL_JI31 CW30452 induced pluripotent stem cell human CVCL_JI31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30452; true Female 21123740 CVCL_JI34 CW30483 induced pluripotent stem cell human CVCL_JI34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30483; true Male 21123741 CVCL_JI33 CW30482 induced pluripotent stem cell human CVCL_JI33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30482; true Female 21123742 CVCL_9704 CCF-RC2 cancer cell line human CVCL_9704 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male Doubling time: 36 hours (PubMed=2582448) 21123743 CVCL_8V04 DD0182 transformed cell line human CVCL_8V04 CL:0000010 Karyotypic information: 46,XX,t(5;18)(p13;q11)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123744 CVCL_9703 CCF-RC1 cancer cell line human CVCL_9703 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male Doubling time: 34 hours (PubMed=2582448) 21123745 CVCL_8V03 DD0179 transformed cell line human CVCL_8V03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123746 CVCL_8V06 DD0184 transformed cell line human CVCL_8V06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123747 CVCL_9706 FM-62 cancer cell line human CVCL_9706 From: Van Valen F.; University of Munster; Munster; Germany. CL:0000010 Male 21123748 CVCL_9705 293TsiLL transformed cell line human CVCL_9705 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21123749 CVCL_8V05 DD0183 transformed cell line human CVCL_8V05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123750 CVCL_8V00 DD0175 transformed cell line human CVCL_8V00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123751 CVCL_9700 HCjE telomerase immortalized cell line human CVCL_9700 CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Karyotypic information: Has lost chromosome Y (PubMed=29787296); Derived from sampling site: Eye; conjunctival epithelium Cell type=Keratinocyte.. Male 21123752 CVCL_8V02 DD0178 transformed cell line human CVCL_8V02 CL:0000010 Karyotypic information: 46,X,der(X),t(X;5)(p22.33;p15.1)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123753 CVCL_9702 GRB-PAP1 spontaneously immortalized cell line CVCL_9702 CL:0000010 Derived from sampling site: Kidney; renal papilla. Unspecified 21123754 CVCL_9701 CHO-T spontaneously immortalized cell line CVCL_9701 CL:0000010 Derived from sampling site: Ovary. Female 21123755 CVCL_8V01 DD0176 finite cell line human CVCL_8V01 CL:0000010 Karyotypic information: 46,XY,t(3;18)(p21.31;q23)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21123756 CVCL_8V08 DD0186 finite cell line human CVCL_8V08 CL:0000010 Karyotypic information: 46,XY,?dup(1)(q32->q42.1) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21123757 CVCL_9708 HS-80 cancer cell line human CVCL_9708 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Brain. Male 21123758 CVCL_8V07 DD0185 transformed cell line human CVCL_8V07 CL:0000010 Karyotypic information: 46,XY,t(11;22)(q23;q11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123759 CVCL_9707 GG-62 cancer cell line human CVCL_9707 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=15150091). Female 21123760 CVCL_8V09 DD0187 transformed cell line human CVCL_8V09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123761 CVCL_9709 HT-78 cancer cell line human CVCL_9709 From: Van Valen F.; University of Munster; Munster; Germany. CL:0000010 Male 21123762 CVCL_SC91 HAP1 APC (-) cancer cell line human CVCL_SC91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 583; APC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123763 CVCL_SC90 HAP1 APAF1 (-) 4 cancer cell line human CVCL_SC90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123764 CVCL_SC93 HAP1 APLP2 (-) 1 cancer cell line human CVCL_SC93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 598; APLP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123765 CVCL_SC92 HAP1 APEX1 (-) 1 cancer cell line human CVCL_SC92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 587; APEX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123766 CVCL_SC95 HAP1 APOBEC3C (-) 1 cancer cell line human CVCL_SC95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17353; APOBEC3C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123767 CVCL_SC94 HAP1 APLP2 (-) 2 cancer cell line human CVCL_SC94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 598; APLP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123768 CVCL_SC97 HAP1 APOE (-) 1 cancer cell line human CVCL_SC97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123769 CVCL_SC96 HAP1 APOBEC3C (-) 2 cancer cell line human CVCL_SC96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17353; APOBEC3C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123770 CVCL_SC99 HAP1 APOO (-) 2 cancer cell line human CVCL_SC99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28727; APOO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123771 CVCL_SC98 HAP1 APOO (-) 1 cancer cell line human CVCL_SC98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28727; APOO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123772 CVCL_SC80 HAP1 AP3D1 (-) 1 cancer cell line human CVCL_SC80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 568; AP3D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123773 CVCL_SC82 HAP1 AP4E1 (-) 1 cancer cell line human CVCL_SC82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 573; AP4E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123774 CVCL_SC81 HAP1 AP3D1 (-) 2 cancer cell line human CVCL_SC81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 568; AP3D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123775 CVCL_SC84 HAP1 AP4E1 (-) 3 cancer cell line human CVCL_SC84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 573; AP4E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123776 CVCL_SC83 HAP1 AP4E1 (-) 2 cancer cell line human CVCL_SC83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 573; AP4E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123777 CVCL_SC86 HAP1 AP5Z1 (-) 2 cancer cell line human CVCL_SC86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22197; AP5Z1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123778 CVCL_SC85 HAP1 AP5Z1 (-) 1 cancer cell line human CVCL_SC85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22197; AP5Z1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123779 CVCL_SC88 HAP1 APAF1 (-) 2 cancer cell line human CVCL_SC88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123780 CVCL_SC87 HAP1 APAF1 (-) 1 cancer cell line human CVCL_SC87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123781 CVCL_SC89 HAP1 APAF1 (-) 3 cancer cell line human CVCL_SC89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123782 CVCL_SC71 HAP1 AP1G2 (-) cancer cell line human CVCL_SC71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 556; AP1G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123783 CVCL_SC70 HAP1 AP1G1 (-) 2 cancer cell line human CVCL_SC70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 555; AP1G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123784 CVCL_SC73 HAP1 AP1S1 (-) 2 cancer cell line human CVCL_SC73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 559; AP1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123785 CVCL_SC72 HAP1 AP1S1 (-) 1 cancer cell line human CVCL_SC72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 559; AP1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123786 CVCL_SC75 HAP1 AP1S2 (-) 2 cancer cell line human CVCL_SC75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 560; AP1S2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123787 CVCL_SC74 HAP1 AP1S2 (-) 1 cancer cell line human CVCL_SC74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 560; AP1S2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123788 CVCL_SC77 HAP1 AP1S3 (-) 2 cancer cell line human CVCL_SC77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18971; AP1S3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123789 CVCL_SC76 HAP1 AP1S3 (-) 1 cancer cell line human CVCL_SC76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18971; AP1S3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123790 CVCL_SC79 HAP1 AP2M1 (-) 2 cancer cell line human CVCL_SC79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 564; AP2M1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123791 CVCL_SC78 HAP1 AP2M1 (-) 1 cancer cell line human CVCL_SC78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 564; AP2M1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123792 CVCL_SC60 HAP1 ANO10 (-) 1 cancer cell line human CVCL_SC60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25519; ANO10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123793 CVCL_SC62 HAP1 ANPEP (-) cancer cell line human CVCL_SC62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 500; ANPEP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123794 CVCL_SC61 HAP1 ANO5 (-) cancer cell line human CVCL_SC61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27337; ANO5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123795 CVCL_SC64 HAP1 ANTXR1 (-) 2 cancer cell line human CVCL_SC64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21014; ANTXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123796 CVCL_SC63 HAP1 ANTXR1 (-) 1 cancer cell line human CVCL_SC63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21014; ANTXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123797 CVCL_SC66 HAP1 ANXA1 (-) 1 cancer cell line human CVCL_SC66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 533; ANXA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123798 CVCL_SC65 HAP1 ANTXR2 (-) cancer cell line human CVCL_SC65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21732; ANTXR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123799 CVCL_SC68 HAP1 ANXA5 (-) 1 cancer cell line human CVCL_SC68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 543; ANXA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123800 CVCL_SC67 HAP1 ANXA1 (-) 2 cancer cell line human CVCL_SC67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 533; ANXA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123801 CVCL_SC69 HAP1 AP1G1 (-) 1 cancer cell line human CVCL_SC69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 555; AP1G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123802 CVCL_SC51 HAP1 ANGPTL4 (-) 1 cancer cell line human CVCL_SC51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16039; ANGPTL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123803 CVCL_SC50 HAP1 ANG (-) 2 cancer cell line human CVCL_SC50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 483; ANG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123804 CVCL_SC53 HAP1 ANKRD17 (-) 2 cancer cell line human CVCL_SC53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23575; ANKRD17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123805 CVCL_SC52 HAP1 ANKRD17 (-) 1 cancer cell line human CVCL_SC52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23575; ANKRD17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123806 CVCL_SC55 HAP1 ANKRD28 (-) 2 cancer cell line human CVCL_SC55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29024; ANKRD28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123807 CVCL_SC54 HAP1 ANKRD28 (-) 1 cancer cell line human CVCL_SC54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29024; ANKRD28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123808 CVCL_SC57 HAP1 ANKRD44 (-) 2 cancer cell line human CVCL_SC57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25259; ANKRD44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123809 CVCL_SC56 HAP1 ANKRD44 (-) 1 cancer cell line human CVCL_SC56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25259; ANKRD44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123810 CVCL_SC59 HAP1 ANKRD52 (-) 2 cancer cell line human CVCL_SC59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26614; ANKRD52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123811 CVCL_SC58 HAP1 ANKRD52 (-) 1 cancer cell line human CVCL_SC58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26614; ANKRD52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123812 CVCL_SC40 HAP1 ALPK1 (-) 1 cancer cell line human CVCL_SC40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20917; ALPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123813 CVCL_SC42 HAP1 ALPK1 (-) 3 cancer cell line human CVCL_SC42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20917; ALPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123814 CVCL_SC41 HAP1 ALPK1 (-) 2 cancer cell line human CVCL_SC41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20917; ALPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123815 CVCL_SC44 HAP1 ALPK2 (-) 2 cancer cell line human CVCL_SC44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20565; ALPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123816 CVCL_SC43 HAP1 ALPK2 (-) 1 cancer cell line human CVCL_SC43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20565; ALPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123817 CVCL_SC46 HAP1 ALPL (-) cancer cell line human CVCL_SC46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 438; ALPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123818 CVCL_SC45 HAP1 ALPK2 (-) 3 cancer cell line human CVCL_SC45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20565; ALPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123819 CVCL_SC48 HAP1 ANAPC7 (-) 2 cancer cell line human CVCL_SC48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17380; ANAPC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123820 CVCL_SC47 HAP1 ANAPC7 (-) 1 cancer cell line human CVCL_SC47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17380; ANAPC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123821 CVCL_SC49 HAP1 ANG (-) 1 cancer cell line human CVCL_SC49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 483; ANG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21123822 CVCL_8U63 DD0086 finite cell line human CVCL_8U63 CL:0000010 Karyotypic information: 46,XX; 46,XX,t(2;11) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123823 CVCL_9663 YCC-7 cancer cell line human CVCL_9663 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21123824 CVCL_8U62 DD0085 finite cell line human CVCL_8U62 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21123825 CVCL_9662 YCC-6 cancer cell line human CVCL_9662 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21123826 CVCL_9665 184A1N4 transformed cell line human CVCL_9665 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Female 21123827 CVCL_8U65 DD0097 finite cell line human CVCL_8U65 CL:0000010 Karyotypic information: 46,XX,-4,+der(4)t(X;4)(p22.1;p15.2); de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123828 CVCL_8U64 DD0090 finite cell line human CVCL_8U64 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21123829 CVCL_9664 YCC-9 cancer cell line human CVCL_9664 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Male 21123830 CVCL_8U61 DD0084 finite cell line human CVCL_8U61 CL:0000010 Karyotypic information: 46,XY; 47,XY,+i(12p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21123831 CVCL_9661 YCC-5 cancer cell line human CVCL_9661 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean. 21123832 CVCL_8U60 DD0074 finite cell line human CVCL_8U60 CL:0000010 Karyotypic information: 47,XX,+14 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21123833 CVCL_9660 YCC-4 cancer cell line human CVCL_9660 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean. 21123834 CVCL_8U59 DD0073 finite cell line human CVCL_8U59 CL:0000010 Karyotypic information: 46,XX; 47,XX,+mar mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21123835 CVCL_9659 YCC-3/TP cancer cell line human CVCL_9659 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 3148; TYMP Population: Korean; Derived from metastatic site: Ascites. Male 21123836 CVCL_8U56 DD0060 finite cell line human CVCL_8U56 CL:0000010 Karyotypic information: 46,X,t(X;8)(q13.1;p11) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123837 CVCL_9656 YCC-23 cancer cell line human CVCL_9656 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean. Female 21123838 CVCL_8U55 DD0058 finite cell line human CVCL_8U55 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21123839 CVCL_9655 YCC-22 cancer cell line human CVCL_9655 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: SNP array analysis. Male 21123840 CVCL_8U58 DD0072 finite cell line human CVCL_8U58 CL:0000010 Karyotypic information: 46,XX; 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123841 CVCL_9658 YCC-3/R cancer cell line human CVCL_9658 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Male 21123842 CVCL_8U57 DD0071 finite cell line human CVCL_8U57 CL:0000010 Karyotypic information: 46,XX; 47,XX,+i(12p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123843 CVCL_9657 YCC-3 cancer cell line human CVCL_9657 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=1676761) Population: Korean; Derived from metastatic site: Ascites. Omics: ChIP-seq GATA4 analysis; Omics: ChIP-seq GATA6 analysis; Omics: ChIP-seq KLF5 analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21123844 CVCL_B008 chHES-90 embryonic stem cell human CVCL_B008 HLA typing: A*11,33; B*13,58; DRB1*03,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21123845 CVCL_B007 chHES-9 embryonic stem cell human CVCL_B007 HLA typing: A*02,24; B*38,40(61); DRB1*11,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21123846 CVCL_B009 chHES-91 embryonic stem cell human CVCL_B009 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Female 21123847 CVCL_B000 chHES-83 embryonic stem cell human CVCL_B000 HLA typing: A*02,24; B*13,15(62); DRB1*15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21123848 CVCL_8U74 DD0116 finite cell line human CVCL_8U74 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21123849 CVCL_9674 FM45 cancer cell line human CVCL_9674 HLA typing: A*23,28; B*17,35; C*04 (PubMed=7656272); HLA typing: A*24:02,68:02; B*53:01,57:01; C*04:01:01,06:02; DPB1*04:01; DQB1*06:04,03:03:02; DRB1*07:01,13:02 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.165-18T>A; Zygosity=Unspecified (PubMed=9288767; PubMed=23851445) Derived from metastatic site: Not specified. Omics: Array-based CGH Unspecified 21123850 CVCL_8U73 DD0108 finite cell line human CVCL_8U73 CL:0000010 Karyotypic information: 47,XX,+dic(15)(pter->q11::q11->pter) (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21123851 CVCL_9673 FM39 cancer cell line human CVCL_9673 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr225fs*31 (c.675_676insTA) (675insTA); Zygosity=Unspecified (PubMed=9288767). Unspecified 21123852 CVCL_B002 chHES-85 embryonic stem cell human CVCL_B002 HLA typing: A*11,33; B*40(60),58; DRB1*11,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21123853 CVCL_8U76 DD0122 transformed cell line human CVCL_8U76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123854 CVCL_9676 FM62 cancer cell line human CVCL_9676 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu139Ter (c.416T>G); ClinVar=VCV000427590; Zygosity=Unspecified (PubMed=9288767; PubMed=17260012) Omics: Array-based CGH. Unspecified 21123855 CVCL_B001 chHES-84 embryonic stem cell human CVCL_B001 HLA typing: A*02; B*40(60),46; DRB1*08,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21123856 CVCL_8U75 DD0120 transformed cell line human CVCL_8U75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123857 CVCL_9675 FM49 cancer cell line human CVCL_9675 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val317_Lys322del (c.949_966del18); Zygosity=Unspecified (PubMed=9288767). Unspecified 21123858 CVCL_9670 4475 transformed cell line house mouse CVCL_9670 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Bone marrow Cell type=Pro-B cell.; Breed/subspecies: dcrfl/fl; R26R-yfp transgenic. 21123859 CVCL_B004 chHES-87 embryonic stem cell human CVCL_B004 HLA typing: A*11,33; B*51,58; DRB1*04,13 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21123860 CVCL_8U70 DD0104 finite cell line human CVCL_8U70 CL:0000010 Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21123861 CVCL_B003 chHES-86 embryonic stem cell human CVCL_B003 HLA typing: A*24; B*40(60); DRB1*04,11 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21123862 CVCL_B006 chHES-89 embryonic stem cell human CVCL_B006 HLA typing: A*02,24; B*13,46; DRB1*07,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21123863 CVCL_8U72 DD0106 finite cell line human CVCL_8U72 CL:0000010 Karyotypic information: 46,XY,19q+mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21123864 CVCL_9672 VH-64 cancer cell line human CVCL_9672 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=15150091); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from metastatic site: Pleural effusion. Male 21123865 CVCL_9671 4483 transformed cell line house mouse CVCL_9671 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788). 21123866 CVCL_B005 chHES-88 embryonic stem cell human CVCL_B005 HLA typing: A*02; B*48,67; DRB1*12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21123867 CVCL_8U71 DD0105 finite cell line human CVCL_8U71 CL:0000010 Karyotypic information: 46,XY,fra(X)(q28) 16/50 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21123868 CVCL_9667 BL41-K3 cancer cell line human CVCL_9667 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P12978; EBV EBNA2. Population: Caucasian Male Virology: EBV-negative 21123869 CVCL_8U67 DD0099 finite cell line human CVCL_8U67 CL:0000010 Karyotypic information: 46,X,t(X;9)(p21.2;q22.1); de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21123870 CVCL_9666 BJAB-K5 cancer cell line human CVCL_9666 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21123871 CVCL_8U66 DD0098 finite cell line human CVCL_8U66 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21123872 CVCL_9669 4470 transformed cell line house mouse CVCL_9669 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Bone marrow Cell type=Pro-B cell.; Breed/subspecies: dcrfl/fl; R26R-yfp transgenic. 21123873 CVCL_8U69 DD0102 finite cell line human CVCL_8U69 CL:0000010 Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21123874 CVCL_8U68 DD0100 finite cell line human CVCL_8U68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21123875 CVCL_9668 L3055 cancer cell line human CVCL_9668 CL:0000010 Population: Arab Male Virology: EBV-negative. 21123876 CVCL_9641 CFT-2 transformed cell line human CVCL_9641 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767) 21123877 CVCL_8U41 DD0031 transformed cell line human CVCL_8U41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123878 CVCL_9640 CFT-1 transformed cell line human CVCL_9640 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Asn (c.1646G>A); ClinVar=VCV000007116; Zygosity=Heterozygous (PubMed=15463957); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Heterozygous (PubMed=15463957) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). 21123879 CVCL_8U40 DD0029 transformed cell line human CVCL_8U40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123880 CVCL_8U43 DD0034 transformed cell line human CVCL_8U43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123881 CVCL_9643 NCI-H2282 cancer cell line human CVCL_9643 CL:0000010 21123882 CVCL_8U42 DD0033 transformed cell line human CVCL_8U42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123883 CVCL_9642 NCI-H2279 cancer cell line human CVCL_9642 CL:0000010 21123884 CVCL_8U38 DD0025 transformed cell line human CVCL_8U38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123885 CVCL_9638 IBL-1 cancer cell line human CVCL_9638 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21123886 CVCL_9637 BCKN-1 cancer cell line human CVCL_9637 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male 21123887 CVCL_8U37 DD0023 transformed cell line human CVCL_8U37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123888 CVCL_8U39 DD0026 transformed cell line human CVCL_8U39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123889 CVCL_9639 IBL-4 cancer cell line human CVCL_9639 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by microarray. 21123890 CVCL_8U34 DD0020 transformed cell line human CVCL_8U34 CL:0000010 Population: Caucasian; Karyotypic information: 46,Y,del(X)(pter->q21.1::q21.2->qter)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123891 CVCL_9634 GM19239 transformed cell line human CVCL_9634 HLA typing: A*02:01,68:02:01; B*35:01,52:01:02; C*04:01,16; DPA1*02:01:01,02:02:02; DPB1*01:01:01; DQA1*01:03:01,05; DQB1*03:01,05; DRB1*12,13 (PubMed=27792722) CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21123892 CVCL_8U33 DD0019 transformed cell line human CVCL_8U33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123893 CVCL_9633 GM19238 transformed cell line human CVCL_9633 HLA typing: A*30:01,36:01; B*53:01:01,57:03:01; C*04:01,18; DPA1*01:03:01,02:01:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,01:02:01; DQB1*05,06; DRB1*11:01:02,16 (PubMed=27792722) CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21123894 CVCL_8U36 DD0022 transformed cell line human CVCL_8U36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123895 CVCL_9636 UB/OC-1 conditionally immortalized cell line house mouse CVCL_9636 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti. 21123896 CVCL_8U35 DD0021 transformed cell line human CVCL_8U35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123897 CVCL_9635 GM19240 transformed cell line human CVCL_9635 HLA typing: A*30:01,68:02:01; B*35:01,57:03:01; C*04:01,18; DPA1*02:01:01,02:02:02; DPB1*01:01:01,01:01:01; DQA1*01:02,05; DQB1*03:01,05; DRB1*12,16 (PubMed=27792722) CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: ENCODE project common cell types; tier 3; Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21123898 CVCL_8U52 DD0054 transformed cell line human CVCL_8U52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123899 CVCL_9652 YCC-2 cancer cell line human CVCL_9652 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male 21123900 CVCL_8U51 DD0051 transformed cell line human CVCL_8U51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123901 CVCL_9651 YCC-19 cancer cell line human CVCL_9651 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: Transcriptome analysis by microarray. Male 21123902 CVCL_8U54 DD0057 finite cell line human CVCL_8U54 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21123903 CVCL_9654 YCC-21 cancer cell line human CVCL_9654 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: SNP array analysis. Female 21123904 CVCL_8U53 DD0056 finite cell line human CVCL_8U53 CL:0000010 Karyotypic information: 46,XY,t(4;9)(p16;q32)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21123905 CVCL_9653 YCC-20 cancer cell line human CVCL_9653 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: Transcriptome analysis by microarray. Female 21123906 CVCL_8U50 DD0049 transformed cell line human CVCL_8U50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123907 CVCL_9650 YCC-18 cancer cell line human CVCL_9650 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: Transcriptome analysis by microarray. Male 21123908 CVCL_8U49 DD0043 transformed cell line human CVCL_8U49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123909 CVCL_9649 YCC-16 cancer cell line human CVCL_9649 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21123910 CVCL_8U48 DD0042 transformed cell line human CVCL_8U48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123911 CVCL_9648 YCC-11 cancer cell line human CVCL_9648 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male 21123912 CVCL_8U45 DD0037 transformed cell line human CVCL_8U45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123913 CVCL_9645 MKN45/TP cancer cell line human CVCL_9645 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3148; TYMP Population: Japanese; Derived from metastatic site: Liver. Female 21123914 CVCL_8U44 DD0036 transformed cell line human CVCL_8U44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123915 CVCL_9644 NCI-H2287 cancer cell line human CVCL_9644 CL:0000010 21123916 CVCL_8U47 DD0041 transformed cell line human CVCL_8U47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123917 CVCL_9647 YCC-10 cancer cell line human CVCL_9647 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: Transcriptome analysis by microarray. Male 21123918 CVCL_8U46 DD0038 transformed cell line human CVCL_8U46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123919 CVCL_9646 YCC-1 cancer cell line human CVCL_9646 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male 21123920 CVCL_8U21 CU0003 transformed cell line human CVCL_8U21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123921 CVCL_9621 GM12763 transformed cell line human CVCL_9621 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144712 21123922 CVCL_8U20 CU0002 transformed cell line human CVCL_8U20 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(17)(q11.2;q24.3->q25.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21123923 CVCL_9620 GM12762 transformed cell line human CVCL_9620 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144711 21123924 CVCL_8U16 CR0010 transformed cell line human CVCL_8U16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123925 CVCL_9616 GM12717 transformed cell line human CVCL_9616 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135812 21123926 CVCL_8U15 CR0009 transformed cell line human CVCL_8U15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123927 CVCL_9615 GM12716 transformed cell line human CVCL_9615 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 135811 21123928 CVCL_8U18 CR0012 transformed cell line human CVCL_8U18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123929 CVCL_9618 GM12760 transformed cell line human CVCL_9618 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144709 21123930 CVCL_8U17 CR0011 transformed cell line human CVCL_8U17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123931 CVCL_9617 GM12750 transformed cell line human CVCL_9617 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144413 21123932 CVCL_8U12 CR0005 transformed cell line human CVCL_8U12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123933 CVCL_9612 GM12239 transformed cell line human CVCL_9612 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133413 21123934 CVCL_8U11 CR0004 transformed cell line human CVCL_8U11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123935 CVCL_9611 GM12236 transformed cell line human CVCL_9611 HLA typing: A*02:01,02:01; B*07:02,44:02; C*05:01,07:02; DPA1*01:03,02:01:01; DPB1*04:02,14:01; DQA1*03:01,05:01; DQB1*03:01,03:02; DRB1*04:03,12:01 (IPD-IMGT/HLA=25943) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM12236; probable Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140811 21123936 CVCL_8U14 CR0007 transformed cell line human CVCL_8U14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123937 CVCL_9614 GM12249 transformed cell line human CVCL_9614 HLA typing: A*02:01,25:01; B*40:01,44:02:/03; C*03:04:01,05:01; DPA1*01:03,01:03; DPB1*03:01:01,04:01; DQA1*01:02,03:01; DQB1*03:02,06:04; DRB1*04:01,13:02 (IPD-IMGT/HLA=25967) CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141612 21123938 CVCL_8U13 CR0006 transformed cell line human CVCL_8U13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123939 CVCL_9613 GM12248 transformed cell line human CVCL_9613 HLA typing: A*23:01,23:01; B*41:01,51:01; C*15:02,17:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01; DQA1*01:02,02:01; DQB1*02:01,06:02; DRB1*07:01,15:01 (IPD-IMGT/HLA=13827) CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141611 21123940 CVCL_8U19 CU0001 transformed cell line human CVCL_8U19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;17)(q21.3;q23.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123941 CVCL_9619 GM12761 transformed cell line human CVCL_9619 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 144710 21123942 CVCL_8U30 DD0012 transformed cell line human CVCL_8U30 CL:0000010 Karyotypic information: 46,XY,inv(6)(p21.33q23.3),t(7;13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123943 CVCL_9630 GM12891 transformed cell line human CVCL_9630 HLA typing: A*01,24; B*07,08; C*07,07; DPA1*01:03:01,01:03:01; DPB1*03,04:01:01; DQA1*01,05; DQB1*02,06; DRB1*03:01,15:01 (PubMed=27792722) CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146315 21123944 CVCL_8U32 DD0017 transformed cell line human CVCL_8U32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123945 CVCL_9632 GM18507 transformed cell line human CVCL_9632 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21123946 CVCL_8U31 DD0014 transformed cell line human CVCL_8U31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123947 CVCL_9631 GM12892 transformed cell line human CVCL_9631 HLA typing: A*02:01,11; B*15:01,56; C*01,04:01; DPA1*01:03,02:01:01; DPB1*06:01,14:01; DQA1*01,01; DQB1*05,05; DRB1*01,01 (PubMed=27792722) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146316 21123948 CVCL_8U27 DD0005 transformed cell line human CVCL_8U27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123949 CVCL_9627 GM12873 transformed cell line human CVCL_9627 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145910 21123950 CVCL_8U26 DD0001 transformed cell line human CVCL_8U26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123951 CVCL_9626 GM12872 transformed cell line human CVCL_9626 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145909 21123952 CVCL_8U29 DD0007 transformed cell line human CVCL_8U29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123953 CVCL_9629 GM12875 transformed cell line human CVCL_9629 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145811/145912 21123954 CVCL_8U28 DD0006 transformed cell line human CVCL_8U28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123955 CVCL_9628 GM12874 transformed cell line human CVCL_9628 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145810/145911 21123956 CVCL_8U23 CV0001 transformed cell line human CVCL_8U23 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,rec(21)dup q,inv(21)(p21;q22.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123957 CVCL_9623 GM12813 transformed cell line human CVCL_9623 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145413 21123958 CVCL_8U22 CU0004 transformed cell line human CVCL_8U22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123959 CVCL_9622 GM12812 transformed cell line human CVCL_9622 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145412 21123960 CVCL_8U25 CZ0004 transformed cell line human CVCL_8U25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123961 CVCL_9625 GM12815 transformed cell line human CVCL_9625 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145415 21123962 CVCL_8U24 CZ0003 transformed cell line human CVCL_8U24 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,(t2;14)(p12;q32.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123963 CVCL_9624 GM12814 transformed cell line human CVCL_9624 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145414 21123964 CVCL_8U10 CR0003 transformed cell line human CVCL_8U10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123965 CVCL_9610 GM12234 transformed cell line human CVCL_9610 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 137512 21123966 CVCL_8U05 CM0036 transformed cell line human CVCL_8U05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(18)(q22.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123967 CVCL_9605 GM12044 transformed cell line human CVCL_9605 HLA typing: A*01:01,02:01; B*07:02,07:02; C*07:02,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:01; DQA1*01:02,01:03; DQB1*06:02,06:03; DRB1*13:01,15:01; DRB3*01; DRB5*01 (IPD-IMGT/HLA=25884) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134612 21123968 CVCL_8U04 CM0035 transformed cell line human CVCL_8U04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123969 CVCL_9604 GM12043 transformed cell line human CVCL_9604 HLA typing: A*02:06,26:01; B*35:01,38:01; C*04:01,12:03; DPA1*01:03,01:03; DPB1*04:01,04:02; DQA1*01:01,03:01; DQB1*03:02,05:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25879) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134611 21123970 CVCL_8U07 COG583 transformed cell line human CVCL_8U07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123971 CVCL_9607 GM12146 transformed cell line human CVCL_9607 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133412 21123972 CVCL_8U06 COG203C transformed cell line human CVCL_8U06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123973 CVCL_9606 GM12144 transformed cell line human CVCL_9606 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133410 21123974 CVCL_8U01 CI0001 transformed cell line human CVCL_8U01 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+mar de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123975 CVCL_9601 GM12003 transformed cell line human CVCL_9601 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142009 21123976 CVCL_8U00 CE0001 transformed cell line human CVCL_8U00 CL:0000010 Population: Iranian; Karyotypic information: 46,XY,del(2)(q23->q24.5) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123977 CVCL_9600 GM11995 transformed cell line human CVCL_9600 HLA typing: A*01:01,01:01; B*57:01,08:01; C*06:02:01:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:02; DQA1*01:02,01:03; DQB1*06:02,06:03; DRB1*13:01,15:01 (IPD-IMGT/HLA=25934) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136216 21123978 CVCL_8U03 CM0007 transformed cell line human CVCL_8U03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,22q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123979 CVCL_9603 GM12005 transformed cell line human CVCL_9603 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142011/147712 21123980 CVCL_8U02 CI0004 transformed cell line human CVCL_8U02 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 47,XY,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123981 CVCL_9602 GM12004 transformed cell line human CVCL_9602 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142010 21123982 CVCL_8U09 CR0002 transformed cell line human CVCL_8U09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21123983 CVCL_9609 GM12156 transformed cell line human CVCL_9609 HLA typing: A*01:01,11:01; B*50:01,51:01; C*06:02,15:02; DPA1*01:03,01:03; DPB1*02:01,03:01:01; DQA1*02:01,03:01; DQB1*02:01,03:01; DRB1*04:07,07:01 (IPD-IMGT/HLA=25941) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140813 21123984 CVCL_8U08 CR0001 transformed cell line human CVCL_8U08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21123985 CVCL_9608 GM12154 transformed cell line human CVCL_9608 HLA typing: A*01:01,31:01; B*08:01,40:01; C*03:04:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:01,04:04 (IPD-IMGT/HLA=25944) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140810 21123986 CVCL_B077 Z-138 cancer cell line human CVCL_B077 HLA typing: A*01:01,23:01; B*08:01,44:05; C*02:02,07:06; DQA1*05:01,01:01; DQB1*05:01,02:01; DRB1*03:01,01:01 (PubMed=25960936); HLA typing: A*01,23; B*08,44; C*02,07 (PubMed=25688540) CL:0000010 Sequence variation: Mutation; HGNC; 12032; TRAF2; Simple; p.Trp114Ter (c.341G>A); Zygosity=Unspecified (PubMed=24362935) Miscellaneous: HLA*C loci for PubMed=24362935 was incorrect, modified version submitted by Pellat-Deceunynck C Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=25315077) Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank) 21123987 CVCL_B076 UOK101 cancer cell line human CVCL_B076 Genome ancestry: African=1.6%; Native American=0%; East Asian, North=2.72%; East Asian, South=0%; South Asian=1.25%; European, North=60.33%; European, South=34.1% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.341-3_341-2del; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: shRNA library screening Doubling time: 28 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21123988 CVCL_B079 UWB1.289 cancer cell line human CVCL_B079 Genome ancestry: African=0.18%; Native American=0%; East Asian, North=0.95%; East Asian, South=0%; South Asian=1.35%; European, North=70.57%; European, South=26.96% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1100; BRCA1; Zygosity=Heterozygous (PubMed=17259345); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asp825Glufs (c.2475delC); Zygosity=Heterozygous (PubMed=17259345) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: Transcriptome analysis by microarray Female Doubling time: 15.3 hours (PubMed=17259345); ~53 hours (ATCC=CRL-2945); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OCCP ovarian cancer cell line panel 21123989 CVCL_B078 UWB1.289+BRCA1 cancer cell line human CVCL_B078 CL:0000010 Sequence variation: Gene deletion; HGNC; 1100; BRCA1; Zygosity=Heterozygous (PubMed=17259345); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asp825Glufs (c.2475delC); Zygosity=Heterozygous (PubMed=17259345); Transfected with: HGNC; 1100; BRCA1 Omics: Transcriptome analysis by microarray. Female Characteristics: Due to the high expression of the transfected wild-type BRCA1 gene, this cell line is partially rescued in term of its response to DNA damage Doubling time: 20.0 hours (PubMed=17259345); ~36 hours (ATCC=CRL-2946) Part of: OCCP ovarian cancer cell line panel 21123990 CVCL_B071 PNEC30-3 cancer cell line house mouse CVCL_B071 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: CR2-TAg transgenic. Male 21123991 CVCL_B070 PNEC30 cancer cell line house mouse CVCL_B070 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: CR2-TAg transgenic. Male Doubling time: ~50 hours (ATCC=CRL-2930) 21123992 CVCL_JI07 CW30213 induced pluripotent stem cell human CVCL_JI07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30213; true Female 21123993 CVCL_B073 S16Y spontaneously immortalized cell line Norway rat CVCL_B073 CL:0000010 Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.. Unspecified Doubling time: ~20 hours (ATCC=CRL-2943) 21123994 CVCL_JI06 CW30210 induced pluripotent stem cell human CVCL_JI06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30210; true Male 21123995 CVCL_B072 S16 spontaneously immortalized cell line Norway rat CVCL_B072 CL:0000010 Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.. Unspecified Doubling time: ~40 hours (ATCC=CRL-2941) 21123996 CVCL_JI09 CW30220 induced pluripotent stem cell human CVCL_JI09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30220; true Male 21123997 CVCL_B075 SN-1 cancer cell line human CVCL_B075 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=T-cell.. Male Doubling time: 28 hours (PubMed=10706136); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21123998 CVCL_JI08 CW30216 induced pluripotent stem cell human CVCL_JI08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30216; true Female 21123999 CVCL_B074 S42 spontaneously immortalized cell line Norway rat CVCL_B074 CL:0000010 Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.. Unspecified Doubling time: ~48 hours (ATCC=CRL-2942) 21124000 CVCL_JI03 CW30193 induced pluripotent stem cell human CVCL_JI03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30193; true Female 21124001 CVCL_JI02 CW30191 induced pluripotent stem cell human CVCL_JI02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30191; true Male 21124002 CVCL_JI05 CW30208 induced pluripotent stem cell human CVCL_JI05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30208; true Male 21124003 CVCL_JI04 CW30204 induced pluripotent stem cell human CVCL_JI04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30204; true. Male 21124004 CVCL_JI01 CW30190 induced pluripotent stem cell human CVCL_JI01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30190; true Male 21124005 CVCL_JI00 CW30179 induced pluripotent stem cell human CVCL_JI00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30179; true Male 21124006 CVCL_B088 UOK109LN cancer cell line human CVCL_B088 CL:0000010 Derived from metastatic site: Lymph node. Male 21124007 CVCL_B087 UOK109 cancer cell line human CVCL_B087 CL:0000010 Sequence variation: Gene fusion; HGNC; 7871; NONO + HGNC; 11752; TFE3; Name(s)=NONO-TFE3 (PubMed=9393982) Derived from sampling site: Kidney. Male 21124008 CVCL_B089 UOK110 cancer cell line human CVCL_B089 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Gly (c.518T>G); ClinVar=VCV000376016; Zygosity=Unspecified (PubMed=8319216); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly114Ser (c.340G>A); ClinVar=VCV000583094; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124009 CVCL_B080 UOK102 cancer cell line human CVCL_B080 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Pro138Arg (c.413C>G); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124010 CVCL_B082 UOK104 cancer cell line human CVCL_B082 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124011 CVCL_B081 UOK103 cancer cell line human CVCL_B081 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124012 CVCL_JI18 CW30272 induced pluripotent stem cell human CVCL_JI18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30272; true Male 21124013 CVCL_B084 UOK106 cancer cell line human CVCL_B084 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124014 CVCL_JI17 CW30264 induced pluripotent stem cell human CVCL_JI17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30264; true Male 21124015 CVCL_B083 UOK105 cancer cell line human CVCL_B083 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124016 CVCL_B086 UOK108 cancer cell line human CVCL_B086 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124017 CVCL_JI19 CW30273 induced pluripotent stem cell human CVCL_JI19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30273; true Male 21124018 CVCL_B085 UOK107 cancer cell line human CVCL_B085 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=8319216) Derived from sampling site: Kidney. Unspecified 21124019 CVCL_JI14 CW30235 induced pluripotent stem cell human CVCL_JI14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30235; true Male 21124020 CVCL_JI13 CW30231 induced pluripotent stem cell human CVCL_JI13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30231; true Male 21124021 CVCL_JI16 CW30260 induced pluripotent stem cell human CVCL_JI16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30260; true Female 21124022 CVCL_JI15 CW30257 induced pluripotent stem cell human CVCL_JI15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30257; true Male 21124023 CVCL_JI10 CW30221 induced pluripotent stem cell human CVCL_JI10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30221; true Male 21124024 CVCL_JI12 CW30227 induced pluripotent stem cell human CVCL_JI12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30227; true Female 21124025 CVCL_JI11 CW30224 induced pluripotent stem cell human CVCL_JI11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30224; true Male 21124026 CVCL_B055 MDA-MB-435-LCC15 cancer cell line human CVCL_B055 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00231 Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative (PubMed=20143388). Was first thought to originate from the femoral metastasis of a breast carcinoma but was later shown to be contaminated by MDA-MB-435 (PubMed=15679051). 21124027 CVCL_B057 M4A4 cancer cell line human CVCL_B057 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Doubling time: 35.00 hours (GrayJW panel) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00375 Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124028 CVCL_B056 LUHMES conditionally immortalized cell line human CVCL_B056 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon. Female Characteristics: Embryonic neuronal precursor cells that can be maintained as proliferating cells due to the expression of a tetracycline-regulatable (Tet-Off) v-myc transgene Can be differentiated to post-mitotic neurons by the addition of tetracycline, GDNF and dibutyryl cAMP. 21124029 CVCL_B059 M4A4 LM3-2 GFP cancer cell line human CVCL_B059 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00562 Problematic cell line: Contaminated Ancestral cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124030 CVCL_B058 M4A4 GFP cancer cell line human CVCL_B058 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00561 Problematic cell line: Contaminated Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124031 CVCL_B051 GBM8401 cancer cell line human CVCL_B051 CL:0000010 Population: Chinese; Derived from sampling site: Brain; right parietal lobe. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~38 hours (PubMed=2839737) 21124032 CVCL_B050 GBM6840 cancer cell line human CVCL_B050 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10736064) Population: Chinese; Derived from sampling site: Brain; cerebellum. Omics: Array-based CGH Female Doubling time: 32 hours (PubMed=10736064) 21124033 CVCL_B053 HeLaRC32 cancer cell line human CVCL_B053 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Adeno-associated virus packaging cell line 21124034 CVCL_B052 GBM8901 cancer cell line human CVCL_B052 CL:0000010 Population: Chinese; Derived from sampling site: Brain; right parietal lobe. Female Problematic cell line: Contaminated Shown to be a GBM8401 derivative (BCRC). Originally thought to originate from a 73 year old female patient with glioblastoma. 21124035 CVCL_B066 P3H3 cancer cell line human CVCL_B066 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21124036 CVCL_B065 NM2C5 GFP cancer cell line human CVCL_B065 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00564 Problematic cell line: Contaminated Grand-parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124037 CVCL_B068 PNEC25 cancer cell line house mouse CVCL_B068 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Liver; Breed/subspecies: CR2-TAg transgenic. Male 21124038 CVCL_B067 PERK-KO-DR transformed cell line house mouse CVCL_B067 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1341830; Eif2ak3 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21124039 CVCL_B069 PNEC28 cancer cell line house mouse CVCL_B069 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Lymph node; Breed/subspecies: CR2-TAg transgenic. Male 21124040 CVCL_B060 M4A4 LM3-4 CL16 GFP cancer cell line human CVCL_B060 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00563 Problematic cell line: Contaminated Ancestral cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124041 CVCL_B062 Mu Islet (E6/E7) transformed cell line house mouse CVCL_B062 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Alpha cell.; Breed/subspecies: C57BLKS/J. Male 21124042 CVCL_B061 MESC2.10 conditionally immortalized cell line human CVCL_B061 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon. Female 21124043 CVCL_B064 NM2C5 cancer cell line human CVCL_B064 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Doubling time: 32.24 hours (GrayJW panel) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00377 Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21124044 CVCL_B063 NE-4C spontaneously immortalized cell line house mouse CVCL_B063 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Breed/subspecies: C57BL/6 x 129/Sv-Trp53-/-. Unspecified 21124045 CVCL_B033 MDCK.1 spontaneously immortalized cell line dog CVCL_B033 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21124046 CVCL_B032 HSY cancer cell line human CVCL_B032 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; CHB0001; probable Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00317 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388; PubMed=29923277). Originally thought to originate from a 51 year old female patient with a parotid gland adenocarcinoma. 21124047 CVCL_B035 alphaTC1 cancer cell line house mouse CVCL_B035 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Alpha cell.; Breed/subspecies: C57BL/6 x DBA/2. 21124048 CVCL_B034 MDCK.2 spontaneously immortalized cell line dog CVCL_B034 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21124049 CVCL_B037 A2780/AD10 cancer cell line human CVCL_B037 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21124050 CVCL_B036 alphaTC1 Clone 6 cancer cell line house mouse CVCL_B036 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Alpha cell.; Breed/subspecies: C57BL/6 x DBA/2. 21124051 CVCL_B039 B11F7 hybridoma house mouse CVCL_B039 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P20916; Human MAG (Note=Also reacts with rat). 21124052 CVCL_B038 B11 [Mouse hybridoma against mouse Odc] hybridoma house mouse CVCL_B038 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P00860; Mouse Odc. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8372 21124053 CVCL_8U99 DD0173 transformed cell line human CVCL_8U99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124054 CVCL_9699 HCC1159 cancer cell line human CVCL_9699 CL:0000010 Female 21124055 CVCL_B031 Chula2.hES embryonic stem cell human CVCL_B031 From: Chulalongkorn University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai. Male 21124056 CVCL_B030 IMHe011-A embryonic stem cell human CVCL_B030 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Male 21124057 CVCL_B044 CHLA-01-MED cancer cell line human CVCL_B044 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Heterozygous (PubMed=26380221) Derived from sampling site: Brain. Omics: Array-based CGH; Omics: CNV analysis Male 21124058 CVCL_B043 CCD-1142 FeAE (E6/E7) transformed cell line human CVCL_B043 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal bronchus; epithelium. Discontinued: ATCC; CRL-2997; probable 21124059 CVCL_B046 CHOP-KO-DR transformed cell line house mouse CVCL_B046 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109247; Ddit3 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21124060 CVCL_B045 CHLA-02-ATRT cancer cell line human CVCL_B045 CL:0000010 Derived from sampling site: Brain. Male 21124061 CVCL_B048 F98npEGFRvIII cancer cell line Norway rat CVCL_B048 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; cerebellum; Breed/subspecies: Fischer 344. Female Doubling time: ~17 hours (ATCC=CRL-2949) 21124062 CVCL_B047 F98 EGFR cancer cell line Norway rat CVCL_B047 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; cerebellum; Breed/subspecies: Fischer 344. Female 21124063 CVCL_B049 GCN2-KO-DR transformed cell line house mouse CVCL_B049 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1353427; Eif2ak4 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21124064 CVCL_B040 BC-5 cancer cell line human CVCL_B040 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. 21124065 CVCL_B042 C3842 cancer cell line human CVCL_B042 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 5383; IDH2; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15731924) Derived from sampling site: Bone; right proximal tibia. Male Doubling time: ~10 days (PubMed=15731924) 21124066 CVCL_B041 BCS-TC2 cancer cell line human CVCL_B041 CL:0000010 Derived from sampling site: Colon; ascending. Female Doubling time: 38 hours (PubMed=1366654) 21124067 CVCL_B019 SDUe001-A embryonic stem cell human CVCL_B019 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Female 21124068 CVCL_B018 SDUe006-A embryonic stem cell human CVCL_B018 From: University of Southern Denmark; Odense; Denmark. CL:0000010 Unspecified 21124069 CVCL_B011 chHES-93 embryonic stem cell human CVCL_B011 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Unspecified 21124070 CVCL_8U85 DD0142 transformed cell line human CVCL_8U85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124071 CVCL_9685 STA-ET-14 cancer cell line human CVCL_9685 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124072 CVCL_B010 chHES-92 embryonic stem cell human CVCL_B010 HLA typing: A*11,31; B*51,55; DRB1*08,09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21124073 CVCL_8U84 DD0141 transformed cell line human CVCL_8U84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124074 CVCL_9684 STA-ET-12 cancer cell line human CVCL_9684 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124075 CVCL_B013 chHES-95 embryonic stem cell human CVCL_B013 HLA typing: A*01,33; B*37,58; DRB1*03,10 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21124076 CVCL_8U87 DD0144 transformed cell line human CVCL_8U87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124077 CVCL_9687 STA-ET-2.2 cancer cell line human CVCL_9687 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Tyr (c.830G>A); ClinVar=VCV000185722; Zygosity=Unspecified (PubMed=8378080) Derived from metastatic site: Bone marrow. Male 21124078 CVCL_B012 chHES-94 embryonic stem cell human CVCL_B012 HLA typing: A*24,33; B*46,58; DRB1*09 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21124079 CVCL_8U86 DD0143 transformed cell line human CVCL_8U86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124080 CVCL_9686 STA-ET-2.1 cancer cell line human CVCL_9686 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=9393981); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Tyr (c.830G>A); ClinVar=VCV000185722; Zygosity=Unspecified (PubMed=8378080; PubMed=19787792). Male 21124081 CVCL_B015 chHES-97 embryonic stem cell human CVCL_B015 HLA typing: A*11; B*15(62),15(75); DRB1*12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21124082 CVCL_8U81 DD0133 transformed cell line human CVCL_8U81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124083 CVCL_9681 STA-ET-1 cancer cell line human CVCL_9681 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792; PubMed=25223734); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=9393981); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; humerus. Female 21124084 CVCL_B014 chHES-96 embryonic stem cell human CVCL_B014 HLA typing: A*11,24; B*40(60); DRB1*08,12 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Ambiguous 21124085 CVCL_8U80 DD0132 transformed cell line human CVCL_8U80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124086 CVCL_9680 FM93 cancer cell line human CVCL_9680 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.795_796GG>AA); Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21124087 CVCL_B017 chHES-99 embryonic stem cell human CVCL_B017 HLA typing: A*02,11; B*15(75),46; DRB1*09,15 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Female 21124088 CVCL_8U83 DD0140 transformed cell line human CVCL_8U83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124089 CVCL_9683 STA-ET-11 cancer cell line human CVCL_9683 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=9393981). 21124090 CVCL_B016 chHES-98 embryonic stem cell human CVCL_B016 HLA typing: A*02,24; B*40(60),46; DRB1*09,16 (PubMed=19896436). From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Male 21124091 CVCL_8U82 DD0136 transformed cell line human CVCL_8U82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124092 CVCL_9682 STA-ET-10 cancer cell line human CVCL_9682 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 18562; FEV; Name(s)=EWSR1-FEV, EWS-FEV (PubMed=9393981); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792). Female 21124093 CVCL_8U78 DD0127 transformed cell line human CVCL_8U78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124094 CVCL_9678 FM81 cancer cell line human CVCL_9678 HLA typing: A*02:01,68:01:02; B*15:01:01:01,44:02; C*03:03,07:04; DPB1*04:02; DQB1*05:01,03:01:01; DRB1*01:01,12:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799_1800delTGinsAA); ClinVar=VCV000376069; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro38Ser (c.112C>T); ClinVar=VCV000127688; Zygosity=Unspecified (PubMed=9288767; PubMed=23851445) Derived from metastatic site: Not specified. Male 21124095 CVCL_8U77 DD0126 transformed cell line human CVCL_8U77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124096 CVCL_9677 FM76 cancer cell line human CVCL_9677 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro38Ser (c.112C>T); ClinVar=VCV000127688; Zygosity=Unspecified (PubMed=9288767) Derived from metastatic site: Not specified. Omics: Array-based CGH Male 21124097 CVCL_8U79 DD0128 transformed cell line human CVCL_8U79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124098 CVCL_9679 FM88 cancer cell line human CVCL_9679 HLA typing: A*02:01,02:05; B*27:04,49:01; C*01:02,07:01:01; DPB1*04:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly127Glu (c.380G>A); ClinVar=VCV000428225; Zygosity=Unspecified (PubMed=9288767; PubMed=17260012; PubMed=23851445) Derived from metastatic site: Skin. Omics: Array-based CGH Male 21124099 CVCL_B029 IMHe018-A embryonic stem cell human CVCL_B029 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124100 CVCL_8U90 DD0147 transformed cell line human CVCL_8U90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124101 CVCL_9690 STA-ET-5 cancer cell line human CVCL_9690 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124102 CVCL_8U96 DD0162 transformed cell line human CVCL_8U96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124103 CVCL_B022 IMHe008-A embryonic stem cell human CVCL_B022 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124104 CVCL_9696 STA-ET-8.2 cancer cell line human CVCL_9696 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124105 CVCL_8U95 DD0155 transformed cell line human CVCL_8U95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124106 CVCL_B021 OxF1 embryonic stem cell human CVCL_B021 From: University of Oxford; Oxford; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-11-001, Steering comm appl. SCSC10-40.. 21124107 CVCL_9695 STA-ET-8.1 cancer cell line human CVCL_9695 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Thr (c.454C>A); Zygosity=Unspecified (PubMed=25223734). 21124108 CVCL_8U98 DD0172 transformed cell line human CVCL_8U98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124109 CVCL_B024 IMHe010-A embryonic stem cell human CVCL_B024 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124110 CVCL_9698 TC-135 cancer cell line human CVCL_9698 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA. CL:0000010 21124111 CVCL_8U97 DD0171 transformed cell line human CVCL_8U97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124112 CVCL_B023 IMHe009-A embryonic stem cell human CVCL_B023 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124113 CVCL_9697 STA-ET-9 cancer cell line human CVCL_9697 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124114 CVCL_8U92 DD0152 transformed cell line human CVCL_8U92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124115 CVCL_B026 IMHe015-A embryonic stem cell human CVCL_B026 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124116 CVCL_9692 STA-ET-7.1 cancer cell line human CVCL_9692 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8378080). 21124117 CVCL_8U91 DD0150 transformed cell line human CVCL_8U91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124118 CVCL_B025 IMHe014-A embryonic stem cell human CVCL_B025 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Male 21124119 CVCL_9691 STA-ET-6 cancer cell line human CVCL_9691 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from metastatic site: Pleural effusion. 21124120 CVCL_8U94 DD0154 transformed cell line human CVCL_8U94 CL:0000010 Karyotypic information: 46,XX,var(13p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124121 CVCL_B028 IMHe017-A embryonic stem cell human CVCL_B028 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124122 CVCL_9694 STA-ET-7.3 cancer cell line human CVCL_9694 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124123 CVCL_8U93 DD0153 transformed cell line human CVCL_8U93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124124 CVCL_B027 IMHe016-A embryonic stem cell human CVCL_B027 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21124125 CVCL_9693 STA-ET-7.2 cancer cell line human CVCL_9693 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8378080) Derived from metastatic site: Pleural effusion. 21124126 CVCL_8U89 DD0146 transformed cell line human CVCL_8U89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124127 CVCL_9689 STA-ET-4 cancer cell line human CVCL_9689 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 21124128 CVCL_8U88 DD0145 transformed cell line human CVCL_8U88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124129 CVCL_9688 STA-ET-3 cancer cell line human CVCL_9688 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from metastatic site: Not specified. 21124130 CVCL_B020 OSCAR embryonic stem cell human CVCL_B020 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE08-088-L1. 21124131 CVCL_SD50 HAP1 ARMC10 (-) 1 cancer cell line human CVCL_SD50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21706; ARMC10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124132 CVCL_SD52 HAP1 ARMC5 (-) 1 cancer cell line human CVCL_SD52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25781; ARMC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124133 CVCL_SD51 HAP1 ARMC10 (-) 2 cancer cell line human CVCL_SD51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21706; ARMC10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124134 CVCL_SD54 HAP1 ARNTL (-) 1 cancer cell line human CVCL_SD54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 701; BMAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124135 CVCL_SD53 HAP1 ARMC5 (-) 2 cancer cell line human CVCL_SD53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25781; ARMC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124136 CVCL_SD56 HAP1 ARRB1 (-) 1 cancer cell line human CVCL_SD56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 711; ARRB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124137 CVCL_SD55 HAP1 ARPC5 (-) cancer cell line human CVCL_SD55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 708; ARPC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124138 CVCL_SD58 HAP1 ASCC2 (-) cancer cell line human CVCL_SD58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24103; ASCC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124139 CVCL_SD57 HAP1 ASCC1 (-) 1 cancer cell line human CVCL_SD57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24268; ASCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124140 CVCL_SD59 HAP1 ASGR1 (-) 1 cancer cell line human CVCL_SD59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 742; ASGR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124141 CVCL_SD41 HAP1 ARID1A (-) 3 cancer cell line human CVCL_SD41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124142 CVCL_SD40 HAP1 ARID1A (-) 2 cancer cell line human CVCL_SD40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124143 CVCL_SD43 HAP1 ARID1A (-) 5 cancer cell line human CVCL_SD43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124144 CVCL_SD42 HAP1 ARID1A (-) 4 cancer cell line human CVCL_SD42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124145 CVCL_SD45 HAP1 ARID1B (-) 2 cancer cell line human CVCL_SD45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18040; ARID1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124146 CVCL_SD44 HAP1 ARID1B (-) 1 cancer cell line human CVCL_SD44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18040; ARID1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124147 CVCL_SD47 HAP1 ARID2 (-) 2 cancer cell line human CVCL_SD47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18037; ARID2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124148 CVCL_SD46 HAP1 ARID2 (-) 1 cancer cell line human CVCL_SD46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18037; ARID2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124149 CVCL_SD49 HAP1 ARIH1 (-) 1 cancer cell line human CVCL_SD49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 689; ARIH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124150 CVCL_SD48 HAP1 ARID5B (-) cancer cell line human CVCL_SD48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17362; ARID5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124151 CVCL_JJ93 ISMMSi006-B induced pluripotent stem cell human CVCL_JJ93 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 21124152 CVCL_JJ92 ISMMSi005-B induced pluripotent stem cell human CVCL_JJ92 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 21124153 CVCL_JJ95 ISMMSi009-A induced pluripotent stem cell human CVCL_JJ95 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Hispanic; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 21124154 CVCL_JJ94 ISMMSi008-A induced pluripotent stem cell human CVCL_JJ94 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Asian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 21124155 CVCL_JJ91 ISMMSi004-B induced pluripotent stem cell human CVCL_JJ91 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21124156 CVCL_JJ90 SB IV-6-2 hybridoma CVCL_JJ90 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; Q69467; Human herpesvirus 2 (HHV-2) glycoprotein D (gD). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9316 21124157 CVCL_SD30 HAP1 ARF6 (-) 1 cancer cell line human CVCL_SD30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 659; ARF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124158 CVCL_SD32 HAP1 ARF6 (-) 3 cancer cell line human CVCL_SD32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 659; ARF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124159 CVCL_SD31 HAP1 ARF6 (-) 2 cancer cell line human CVCL_SD31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 659; ARF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124160 CVCL_SD34 HAP1 ARHGAP31 (-) 2 cancer cell line human CVCL_SD34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29216; ARHGAP31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124161 CVCL_SD33 HAP1 ARHGAP31 (-) 1 cancer cell line human CVCL_SD33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29216; ARHGAP31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124162 CVCL_SD36 HAP1 ARHGAP32 (-) 2 cancer cell line human CVCL_SD36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17399; ARHGAP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124163 CVCL_SD35 HAP1 ARHGAP32 (-) 1 cancer cell line human CVCL_SD35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17399; ARHGAP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124164 CVCL_SD38 HAP1 ARHGEF1 (-) 2 cancer cell line human CVCL_SD38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 681; ARHGEF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124165 CVCL_JJ89 64-683 hybridoma CVCL_JJ89 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HSV-1 and HSV-2 glycoprotein gD. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12304 21124166 CVCL_SD37 HAP1 ARHGEF1 (-) 1 cancer cell line human CVCL_SD37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 681; ARHGEF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124167 CVCL_SD39 HAP1 ARID1A (-) 1 cancer cell line human CVCL_SD39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11110; ARID1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124168 CVCL_JJ86 DTK-F cancer cell line dog CVCL_JJ86 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Characteristics: Spindle-shaped, does not express HSP27, non-tumorigenic in nude mice and sensitive to doxorubicin 21124169 CVCL_JJ85 BFF_NCC2 telomerase immortalized cell line CVCL_JJ85 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Female 21124170 CVCL_JJ88 SPAZ-4 hybrid cell line CVCL_JJ88 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 21124171 CVCL_JJ87 Beta-TC-6-F7 transformed cell line house mouse CVCL_JJ87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIP1Tag2. Characteristics: Like parent cell line secretes insulin in response to glucose challenge, but this phenotype is stable over a long time in culture High glucokinase activity, low hexokinase activity. Group: Patented cell line 21124172 CVCL_SD21 HAP1 ARAF (-) 7 cancer cell line human CVCL_SD21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124173 CVCL_SD20 HAP1 ARAF (-) 6 cancer cell line human CVCL_SD20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124174 CVCL_SD23 HAP1 ARAP3 (-) 1 cancer cell line human CVCL_SD23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24097; ARAP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124175 CVCL_SD22 HAP1 ARAF (-) 8 cancer cell line human CVCL_SD22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124176 CVCL_SD25 HAP1 ARF1 (-) 1 cancer cell line human CVCL_SD25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 652; ARF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124177 CVCL_SD24 HAP1 ARAP3 (-) 2 cancer cell line human CVCL_SD24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24097; ARAP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124178 CVCL_SD27 HAP1 ARF3 (-) 1 cancer cell line human CVCL_SD27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 654; ARF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124179 CVCL_SD26 HAP1 ARF1 (-) 2 cancer cell line human CVCL_SD26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 652; ARF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124180 CVCL_SD29 HAP1 ARF4 (-) cancer cell line human CVCL_SD29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 655; ARF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124181 CVCL_SD28 HAP1 ARF3 (-) 2 cancer cell line human CVCL_SD28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 654; ARF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124182 CVCL_JJ97 ISMMSi012-B induced pluripotent stem cell human CVCL_JJ97 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 21124183 CVCL_JJ96 ISMMSi011-B induced pluripotent stem cell human CVCL_JJ96 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 21124184 CVCL_JJ99 CS83iSMA-n5 induced pluripotent stem cell human CVCL_JJ99 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: ATAC-seq; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21124185 CVCL_JJ98 ISMMSi013-B induced pluripotent stem cell human CVCL_JJ98 From: Icahn School of Medicine at Mount Sinai; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 21124186 CVCL_JJ71 RME1 spontaneously immortalized cell line CVCL_JJ71 CL:0000010 Unspecified Doubling time: 18.73 hours (grown with no fish embryo extract), 18.78 hours (with 1 ml-1 fish embryo extract) and 20.32 hours (with 2 ml-1 fish embryo extract) (PubMed=25832766). Group: Endangered species/breed cell line; Group: Fish cell line 21124187 CVCL_JJ70 USEM finite cell line CVCL_JJ70 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ujumqin. Female Doubling time: ~72 hours (PubMed=20383581) Group: Endangered species/breed cell line 21124188 CVCL_JJ73 RME-5-1 spontaneously immortalized cell line house mouse CVCL_JJ73 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: C3H/He. Unspecified Doubling time: 18.7 hours (PubMed=6983989) 21124189 CVCL_JJ72 RPEFC finite cell line CVCL_JJ72 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21124190 CVCL_SD10 HAP1 AQP3 (-) 1 cancer cell line human CVCL_SD10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 636; AQP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124191 CVCL_SD12 HAP1 AR (-) 2 cancer cell line human CVCL_SD12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124192 CVCL_SD11 HAP1 AR (-) 1 cancer cell line human CVCL_SD11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124193 CVCL_SD14 HAP1 AR (-) 4 cancer cell line human CVCL_SD14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124194 CVCL_SD13 HAP1 AR (-) 3 cancer cell line human CVCL_SD13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124195 CVCL_SD16 HAP1 ARAF (-) 2 cancer cell line human CVCL_SD16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124196 CVCL_JJ68 HepaRG CYP3A4G/7R clone 3 cancer cell line human CVCL_JJ68 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver. Female Characteristics: Transfected with a dual reporter that express RFP under the transcriptional regulation of CYP3A7 in the hepatoblast-like cell state and EGFP under the transcriptional regulation of CYP3A4 21124197 CVCL_SD15 HAP1 ARAF (-) 1 cancer cell line human CVCL_SD15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124198 CVCL_JJ67 PEF_NCC2 telomerase immortalized cell line pig CVCL_JJ67 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Female 21124199 CVCL_SD18 HAP1 ARAF (-) 4 cancer cell line human CVCL_SD18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124200 CVCL_SD17 HAP1 ARAF (-) 3 cancer cell line human CVCL_SD17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124201 CVCL_JJ69 SV40T PEF conditionally immortalized cell line pig CVCL_JJ69 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: The SV40 large T gene is flanked by two loxP sites that allow the excision of the transforming gene by transient expression of the Cre recombinase 21124202 CVCL_JJ64 CW70358 induced pluripotent stem cell human CVCL_JJ64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70358; true Male 21124203 CVCL_JJ63 CW70356 induced pluripotent stem cell human CVCL_JJ63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70356; true Male 21124204 CVCL_SD19 HAP1 ARAF (-) 5 cancer cell line human CVCL_SD19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 646; ARAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124205 CVCL_JJ66 PEF_NCC1 telomerase immortalized cell line pig CVCL_JJ66 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Female 21124206 CVCL_JJ65 CW70359 induced pluripotent stem cell human CVCL_JJ65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70359; true Female 21124207 CVCL_JJ82 TH::GFP;PrP::hSNCAA53T embryonic stem cell house mouse CVCL_JJ82 CL:0000010 Transfected with: HGNC; 11138; SNCA (with p.Ala53Thr); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: C57BL/6 x B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J transgenic. Unspecified Characteristics: Expresses GFP under the control of the rat TH promoter and human mutant SNCA p.Ala53Thr under the control of the mouse prion (PrP) promoter 21124208 CVCL_JJ81 TH::GFP embryonic stem cell house mouse CVCL_JJ81 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: C57BL/6. Unspecified Characteristics: Expresses GFP under the control of the rat TH promoter 21124209 CVCL_JJ84 H9Nrf2KO-A13 embryonic stem cell human CVCL_JJ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7782; . Female 21124210 CVCL_JJ83 PrP::hSNCAA53T embryonic stem cell house mouse CVCL_JJ83 CL:0000010 Transfected with: HGNC; 11138; SNCA (with p.Ala53Thr) Breed/subspecies: B6;C3-Tg(Prnp-SNCA*A53T)83Vle/J transgenic. Unspecified Characteristics: Expresses human mutant SNCA p.Ala53Thr under the control of the mouse prion (PrP) promoter 21124211 CVCL_JJ80 PD-BP001-iPSC induced pluripotent stem cell human CVCL_JJ80 From: Jilin University First Hospital; Changchun; China CL:0000010 Derived from sampling site: Peripheral blood. Male 21124212 CVCL_SD01 HAP1 APOOL (-) 1 cancer cell line human CVCL_SD01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24009; APOOL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124213 CVCL_SD00 HAP1 APOO (-) 3 cancer cell line human CVCL_SD00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28727; APOO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124214 CVCL_SD03 HAP1 APOOL (-) 3 cancer cell line human CVCL_SD03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24009; APOOL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124215 CVCL_SD02 HAP1 APOOL (-) 2 cancer cell line human CVCL_SD02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24009; APOOL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124216 CVCL_SD05 HAP1 APRT (-) 1 cancer cell line human CVCL_SD05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 626; APRT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124217 CVCL_JJ79 MS-BP002-iPSC induced pluripotent stem cell human CVCL_JJ79 From: Jilin University First Hospital; Changchun; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 21124218 CVCL_JJ78 AVP-Ser18del-iPSC induced pluripotent stem cell human CVCL_JJ78 From: Department of Paediatrics, Aarhus University Hospital; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 894; AVP; Simple; p.Ser18del (c.52_54delTCC) (g.276_278delTCC); Zygosity=Heterozygous (PubMed=28413003) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21124219 CVCL_SD04 HAP1 APP (-) 1 cancer cell line human CVCL_SD04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124220 CVCL_SD07 HAP1 APTX (-) 1 cancer cell line human CVCL_SD07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15984; APTX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124221 CVCL_SD06 HAP1 APRT (-) 2 cancer cell line human CVCL_SD06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 626; APRT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124222 CVCL_JJ75 A640-BB-2 transformed cell line house mouse CVCL_JJ75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA640](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: BALB/cAnN. Female 21124223 CVCL_SD09 HAP1 APTX (-) 3 cancer cell line human CVCL_SD09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15984; APTX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124224 CVCL_SD08 HAP1 APTX (-) 2 cancer cell line human CVCL_SD08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15984; APTX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124225 CVCL_JJ74 RME-5-1/TMT spontaneously immortalized cell line house mouse CVCL_JJ74 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: C3H/He. Unspecified Characteristics: Established from tumors induced by implantation of the parent cell line in C3H/He mice Doubling time: 14.4 hours (PubMed=6983989) 21124226 CVCL_JJ77 AD-BP001-iPSC induced pluripotent stem cell human CVCL_JJ77 From: Jilin University First Hospital; Changchun; China CL:0000010 Derived from sampling site: Peripheral blood. Male 21124227 CVCL_JJ76 TAB1/C2-2 cancer cell line human CVCL_JJ76 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa; Characteristics: Does not require bone marrow stromal cells for growth Doubling time: ~30 hours (PubMed=12579318) 21124228 CVCL_JJ51 CW70258 induced pluripotent stem cell human CVCL_JJ51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70258; true Female 21124229 CVCL_JJ50 CW70219 induced pluripotent stem cell human CVCL_JJ50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70219; true Male 21124230 CVCL_JJ49 CW70214 induced pluripotent stem cell human CVCL_JJ49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70214; true Female 21124231 CVCL_JJ46 CW70203 induced pluripotent stem cell human CVCL_JJ46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70203; true Female 21124232 CVCL_JJ45 CW70197 induced pluripotent stem cell human CVCL_JJ45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70197; true Male 21124233 CVCL_JJ48 CW70213 induced pluripotent stem cell human CVCL_JJ48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70213; true Female 21124234 CVCL_JJ47 CW70206 induced pluripotent stem cell human CVCL_JJ47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70206; true Female 21124235 CVCL_JJ42 CW70171 induced pluripotent stem cell human CVCL_JJ42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70171; true Female 21124236 CVCL_JJ41 CW70138 induced pluripotent stem cell human CVCL_JJ41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70138; true Male 21124237 CVCL_JJ44 CW70177 induced pluripotent stem cell human CVCL_JJ44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70177; true Female 21124238 CVCL_JJ43 CW70172 induced pluripotent stem cell human CVCL_JJ43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70172; true Male 21124239 CVCL_JJ60 CW70339 induced pluripotent stem cell human CVCL_JJ60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70339; true Male 21124240 CVCL_JJ62 CW70355 induced pluripotent stem cell human CVCL_JJ62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70355; true Male 21124241 CVCL_JJ61 CW70346 induced pluripotent stem cell human CVCL_JJ61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70346; true Male 21124242 CVCL_JJ57 CW70300 induced pluripotent stem cell human CVCL_JJ57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70300; true Male 21124243 CVCL_JJ56 CW70290 induced pluripotent stem cell human CVCL_JJ56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70290; true Female 21124244 CVCL_JJ59 CW70326 induced pluripotent stem cell human CVCL_JJ59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70326; true Female 21124245 CVCL_JJ58 CW70317 induced pluripotent stem cell human CVCL_JJ58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70317; true Male 21124246 CVCL_JJ53 CW70261 induced pluripotent stem cell human CVCL_JJ53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70261; true Female 21124247 CVCL_JJ52 CW70259 induced pluripotent stem cell human CVCL_JJ52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70259; true Male 21124248 CVCL_JJ55 CW70270 induced pluripotent stem cell human CVCL_JJ55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70270; true Male 21124249 CVCL_JJ54 CW70265 induced pluripotent stem cell human CVCL_JJ54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70265; true Male 21124250 CVCL_8W14 EM0001 transformed cell line human CVCL_8W14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21124251 CVCL_9814 OCUT-2 cancer cell line human CVCL_9814 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24357248; PubMed=30737244); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=24357248); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 21124252 CVCL_8W13 DZ0001 transformed cell line human CVCL_8W13 CL:0000010 Karyotypic information: 46,XY,del(14)(q22.1->q22.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124253 CVCL_9813 JOK-1 [Human gastric epithelial] transformed cell line human CVCL_9813 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; epithelium Cell type=Epithelial cell.. Unspecified 21124254 CVCL_8W16 FC0002 transformed cell line human CVCL_8W16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124255 CVCL_9816 KWS-I cancer cell line human CVCL_9816 HLA typing: A*02:06; B*13:01; C*03:03 (PubMed=9023415) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Ala (c.518T>C); ClinVar=VCV000376017; Zygosity=Homozygous (PubMed=1370612) Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male Doubling time: 35-38 hours (PubMed=3962675) Part of: JFCR45 cancer cell line panel 21124256 CVCL_8W15 FB0001 transformed cell line human CVCL_8W15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv ins(5;2)(q22.3:q32.1:q2+.3) or dir ins(q22.1:q24.3:q32.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124257 CVCL_9815 Okajima cancer cell line human CVCL_9815 HLA typing: A*11:01,31:01; B*15:27,51:01; C*03:03,15:02; DRB1*11:16,14:121 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=1933850) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36-40 hours (PubMed=3962675); 36-38 hours (CelloPub=CLPUB00584) 21124258 CVCL_8W10 DU0001 transformed cell line human CVCL_8W10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124259 CVCL_9810 UWOV2 cancer cell line human CVCL_9810 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 38.8 +- 4.8 hours (in 2.5% FBS), 28.0 +- 1.4 hours (in 5% FBS), 45.6 +- 14.4 hours (in 10% FBS) (PubMed=2351639) 21124260 CVCL_8W12 DW0002 hybrid cell line CVCL_8W12 CL:0000010 Part of: ECACC chromosomal abnormality collection. 21124261 CVCL_9812 Tet21N cancer cell line human CVCL_9812 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Female 21124262 CVCL_8W11 DW0001 hybrid cell line CVCL_8W11 CL:0000010 Part of: ECACC chromosomal abnormality collection. 21124263 CVCL_9811 UWOV2 Sf cancer cell line human CVCL_9811 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 74 +- 10 hours (PubMed=2351639) Group: Serum/protein free medium cell line 21124264 CVCL_8W18 FC0004 transformed cell line human CVCL_8W18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124265 CVCL_8W17 FC0003 transformed cell line human CVCL_8W17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124266 CVCL_8W19 FC0005 transformed cell line human CVCL_8W19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124267 CVCL_8W30 FE0030 transformed cell line human CVCL_8W30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 96091906; true Female Part of: ECACC chromosomal abnormality collection 21124268 CVCL_9830 VM-CUB-3 cancer cell line human CVCL_9830 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Homozygous (PubMed=27270441) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; HTB-6; true Doubling time: 26 hours (PubMed=3708594) Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00102 Problematic cell line: Partially contaminated Some stocks are contaminated by VM-CUB-1 (PubMed=3708594; PubMed=20143388). Although PubMed=26621286 shows it to be different from VM-CUB-1. 21124269 CVCL_8W25 FE0005 transformed cell line human CVCL_8W25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95011615; true Male Part of: ECACC chromosomal abnormality collection 21124270 CVCL_9825 MHH-TALL-2 cancer cell line human CVCL_9825 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: ~60-72 hours (DSMZ=ACC-728) 21124271 CVCL_8W24 FE0003 transformed cell line human CVCL_8W24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94120857; true Female Part of: ECACC chromosomal abnormality collection 21124272 CVCL_9824 MHH-TALL-1 cancer cell line human CVCL_9824 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21124273 CVCL_8W27 FE0010 transformed cell line human CVCL_8W27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95042117; true Female Part of: ECACC chromosomal abnormality collection 21124274 CVCL_9827 MGH-U3 cancer cell line human CVCL_9827 CL:0000010 Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Unspecified (PubMed=19802009); Sequence variation: Mutation; HGNC; 13726; KMT2C; Simple; p.Arg4139Ter (c.12415C>T); ClinVar=VCV000975272; Zygosity=Homozygous (PubMed=27270441); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21124275 CVCL_8W26 FE0008 transformed cell line human CVCL_8W26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95033056; true Female Part of: ECACC chromosomal abnormality collection 21124276 CVCL_9826 MGH-U2 cancer cell line human CVCL_9826 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Doubling time: 19 hours (PubMed=3708594) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00081 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=3708594; PubMed=20143388). 21124277 CVCL_8W21 FC0007 transformed cell line human CVCL_8W21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124278 CVCL_8W20 FC0006 transformed cell line human CVCL_8W20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124279 CVCL_8W23 FE0002 transformed cell line human CVCL_8W23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94110944; true Male Part of: ECACC chromosomal abnormality collection 21124280 CVCL_9823 MS18 cancer cell line human CVCL_9823 From: Shimizu E.; Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=10536175; PubMed=20557307) Population: Japanese Omics: SNP array analysis. Male 21124281 CVCL_8W22 FE0001 transformed cell line human CVCL_8W22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94100312; true Male Part of: ECACC chromosomal abnormality collection 21124282 CVCL_9822 MPSC1 cancer cell line human CVCL_9822 CL:0000010 Female 21124283 CVCL_8W29 FE0024 transformed cell line human CVCL_8W29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 96030619; true Female Part of: ECACC chromosomal abnormality collection 21124284 CVCL_9829 VM-CUB-2 cancer cell line human CVCL_9829 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from metastatic site: Obturator lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21124285 CVCL_8W28 FE0015 transformed cell line human CVCL_8W28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95090703; true Female Part of: ECACC chromosomal abnormality collection 21124286 CVCL_9828 MGH-U4 cancer cell line human CVCL_9828 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=27270441) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by ESTs sequencing; Omics: Transcriptome analysis by microarray. Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21124287 CVCL_8W03 DD3725 transformed cell line human CVCL_8W03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(4;8)(p14;q22.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124288 CVCL_9803 SZ95 transformed cell line human CVCL_9803 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Face; skin; sebaceous gland Cell type=Sebocyte.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 52.4 +- 1.6 hours (PubMed=10594745) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2383 21124289 CVCL_8W02 DD3723 transformed cell line human CVCL_8W02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124290 CVCL_9802 DKs-8 cancer cell line human CVCL_9802 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS. Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21124291 CVCL_8W05 DI0058 transformed cell line human CVCL_8W05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 00082507; true Male Part of: ECACC chromosomal abnormality collection 21124292 CVCL_9805 KS-IMM cancer cell line human CVCL_9805 CL:0000010 Male Doubling time: 24 hours (PubMed=9143602). 21124293 CVCL_9804 AD-293 transformed cell line human CVCL_9804 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Caution: Not the same cell line as 293AD from Cell Biolabs (Cellosaurus=CVCL_KA63) 21124294 CVCL_8W04 DD3748 transformed cell line human CVCL_8W04 CL:0000010 Karyotypic information: 46,XX,t(1;9)(q10;p21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124295 CVCL_8W01 DD3722 transformed cell line human CVCL_8W01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124296 CVCL_9801 DKs-5 cancer cell line human CVCL_9801 CL:0000010 Male 21124297 CVCL_8W00 DD3721 transformed cell line human CVCL_8W00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124298 CVCL_9800 DKO-4 cancer cell line human CVCL_9800 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS. Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21124299 CVCL_8W07 DK0006 transformed cell line human CVCL_8W07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(5)(5q) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124300 CVCL_9807 EcR-RKO/KLF4 cancer cell line human CVCL_9807 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line); Transfected with: MGI; MGI:1342287; Klf4. Unspecified 21124301 CVCL_8W06 DI0078 transformed cell line human CVCL_8W06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(Y)(q11;q12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124302 CVCL_9806 WB-F344 spontaneously immortalized cell line Norway rat CVCL_9806 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Omics: Transcriptome analysis by microarray Male Characteristics: Well-established and versatile model for studies of liver cell renewal, differentiation, and origination of hepatic cancers Expresses markers of liver progenitor cells, including EpCAM, Thy1, and Afp (Millipore). Group: Space-flown cell line (cellonaut) 21124303 CVCL_8W09 DP0002 transformed cell line human CVCL_8W09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124304 CVCL_9809 UWOV1 cancer cell line human CVCL_9809 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 34.0 +- 15.6 hours (in 2.5% FBS), 36.8 +- 6.5 hours (in 5% FBS), 36.5 +- 9.1 hours (in 10% FBS) (PubMed=2351639) 21124305 CVCL_8W08 DK0099 transformed cell line human CVCL_8W08 CL:0000010 Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Gly322Asp (c.965G>A); ClinVar=VCV000001762; Zygosity=Unspecified (ECACC) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124307 CVCL_SD90 HAP1 ATG12 (-) 1 cancer cell line human CVCL_SD90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 588; ATG12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124308 CVCL_SD92 HAP1 ATG13 (-) cancer cell line human CVCL_SD92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29091; ATG13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124309 CVCL_SD91 HAP1 ATG12 (-) 2 cancer cell line human CVCL_SD91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 588; ATG12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124310 CVCL_SD94 HAP1 ATG14 (-) 2 cancer cell line human CVCL_SD94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124311 CVCL_SD93 HAP1 ATG14 (-) 1 cancer cell line human CVCL_SD93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124312 CVCL_SD96 HAP1 ATG16L1 (-) 1 cancer cell line human CVCL_SD96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124313 CVCL_SD95 HAP1 ATG14 (-) 3 cancer cell line human CVCL_SD95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19962; ATG14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124314 CVCL_SD98 HAP1 ATG4B (-) 1 cancer cell line human CVCL_SD98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20790; ATG4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124315 CVCL_SD97 HAP1 ATG16L1 (-) 2 cancer cell line human CVCL_SD97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21498; ATG16L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124316 CVCL_SD99 HAP1 ATG4B (-) 2 cancer cell line human CVCL_SD99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20790; ATG4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124317 CVCL_SD81 HAP1 ATAD2B (-) 1 cancer cell line human CVCL_SD81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29230; ATAD2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124318 CVCL_SD80 HAP1 ATAD2 (-) 2 cancer cell line human CVCL_SD80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30123; ATAD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124319 CVCL_SD83 HAP1 ATF3 (-) 1 cancer cell line human CVCL_SD83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124320 CVCL_SD82 HAP1 ATAD2B (-) 2 cancer cell line human CVCL_SD82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29230; ATAD2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124321 CVCL_SD85 HAP1 ATF5 (-) 2 cancer cell line human CVCL_SD85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124322 CVCL_SD84 HAP1 ATF5 (-) 1 cancer cell line human CVCL_SD84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124323 CVCL_SD87 HAP1 ATF6 (-) 2 cancer cell line human CVCL_SD87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124324 CVCL_SD86 HAP1 ATF6 (-) 1 cancer cell line human CVCL_SD86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124325 CVCL_SD89 HAP1 ATF6 (-) 4 cancer cell line human CVCL_SD89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124326 CVCL_SD88 HAP1 ATF6 (-) 3 cancer cell line human CVCL_SD88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 791; ATF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124327 CVCL_SD70 HAP1 ASPSCR1 (-) 3 cancer cell line human CVCL_SD70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13825; ASPSCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124328 CVCL_SD72 HAP1 ASXL1 (-) 1 cancer cell line human CVCL_SD72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18318; ASXL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124329 CVCL_SD71 HAP1 ASS1 (-) 1 cancer cell line human CVCL_SD71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 758; ASS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124330 CVCL_SD74 HAP1 ASXL1 (-) 3 cancer cell line human CVCL_SD74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18318; ASXL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124331 CVCL_SD73 HAP1 ASXL1 (-) 2 cancer cell line human CVCL_SD73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18318; ASXL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124332 CVCL_SD76 HAP1 ASXL2 (-) 2 cancer cell line human CVCL_SD76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23805; ASXL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124333 CVCL_SD75 HAP1 ASXL2 (-) 1 cancer cell line human CVCL_SD75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23805; ASXL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124334 CVCL_SD78 HAP1 ATAD1 (-) cancer cell line human CVCL_SD78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25903; ATAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124335 CVCL_SD77 HAP1 ASXL2 (-) 3 cancer cell line human CVCL_SD77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23805; ASXL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124336 CVCL_SD79 HAP1 ATAD2 (-) 1 cancer cell line human CVCL_SD79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30123; ATAD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21124337 CVCL_SD61 HAP1 ASH1L (-) 1 cancer cell line human CVCL_SD61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19088; ASH1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124338 CVCL_SD60 HAP1 ASGR1 (-) 2 cancer cell line human CVCL_SD60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 742; ASGR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124339 CVCL_SD63 HAP1 ASIC1 (-) cancer cell line human CVCL_SD63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 100; ASIC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124340 CVCL_SD62 HAP1 ASH1L (-) 2 cancer cell line human CVCL_SD62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19088; ASH1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124341 CVCL_SD65 HAP1 ASPH (-) 1 cancer cell line human CVCL_SD65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 757; ASPH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124342 CVCL_SD64 HAP1 ASMTL (-) 1 cancer cell line human CVCL_SD64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 751; ASMTL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124343 CVCL_SD67 HAP1 ASPM (-) 1 cancer cell line human CVCL_SD67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19048; ASPM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124344 CVCL_SD66 HAP1 ASPH (-) 2 cancer cell line human CVCL_SD66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 757; ASPH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124345 CVCL_SD69 HAP1 ASPSCR1 (-) 2 cancer cell line human CVCL_SD69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13825; ASPSCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124346 CVCL_SD68 HAP1 ASPSCR1 (-) 1 cancer cell line human CVCL_SD68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13825; ASPSCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124347 CVCL_AP18 CW40039 induced pluripotent stem cell human CVCL_AP18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40039; true. Male 21124348 CVCL_B118 UOK139 cancer cell line human CVCL_B118 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Thr157Leufs*2 (c.469delA); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124349 CVCL_AP17 CW40037 induced pluripotent stem cell human CVCL_AP17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40037; true. Male 21124350 CVCL_B117 UOK135 cancer cell line human CVCL_B117 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asn90Ile (c.269A>T); ClinVar=VCV000223172; Zygosity=Unspecified (PubMed=7915601). Unspecified 21124351 CVCL_AP19 CW40043 induced pluripotent stem cell human CVCL_AP19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40043; true. Female 21124352 CVCL_B119 UOK140 cancer cell line human CVCL_B119 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asp126Gly (c.377A>G); ClinVar=VCV000456585; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124353 CVCL_AP10 CW30336 induced pluripotent stem cell human CVCL_AP10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30336; true Male 21124354 CVCL_8V84 DD0287 transformed cell line human CVCL_8V84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124355 CVCL_B110 UOK128 cancer cell line human CVCL_B110 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124356 CVCL_9784 WA23 embryonic stem cell human CVCL_9784 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0104 21124357 CVCL_8V83 DD0286 transformed cell line human CVCL_8V83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124358 CVCL_9783 WA22 embryonic stem cell human CVCL_9783 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0103 21124359 CVCL_9786 CTLL-20 transformed cell line house mouse CVCL_9786 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21124360 CVCL_AP12 CW30340 induced pluripotent stem cell human CVCL_AP12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30340; true Male 21124361 CVCL_8V86 DD0289 transformed cell line human CVCL_8V86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124362 CVCL_B112 UOK130 cancer cell line human CVCL_B112 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu153Pro (c.458T>C); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Male 21124363 CVCL_AP11 CW30338 induced pluripotent stem cell human CVCL_AP11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30338; true Male 21124364 CVCL_8V85 DD0288 transformed cell line human CVCL_8V85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124365 CVCL_B111 UOK129 cancer cell line human CVCL_B111 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124366 CVCL_9785 WA24 embryonic stem cell human CVCL_9785 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0105 21124367 CVCL_AP14 CW40003 induced pluripotent stem cell human CVCL_AP14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40003; true. Male 21124368 CVCL_8V80 DD0283 transformed cell line human CVCL_8V80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124369 CVCL_B114 UOK132 cancer cell line human CVCL_B114 CL:0000010 Derived from sampling site: Kidney. Female 21124370 CVCL_9780 WA19 embryonic stem cell human CVCL_9780 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0100 21124371 CVCL_AP13 CW40001 induced pluripotent stem cell human CVCL_AP13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40001; true; Discontinued: FCDI; CW40001; probable. Male 21124372 CVCL_B113 UOK131 cancer cell line human CVCL_B113 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124373 CVCL_AP16 CW40034 induced pluripotent stem cell human CVCL_AP16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40034; true. Male 21124374 CVCL_8V82 DD0285 transformed cell line human CVCL_8V82 CL:0000010 Karyotypic information: 46,XX,-18,+der(18),t(8;18)(q23.1;q23)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124375 CVCL_B116 UOK134 cancer cell line human CVCL_B116 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124376 CVCL_9782 WA21 embryonic stem cell human CVCL_9782 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0102 21124377 CVCL_AP15 CW40011 induced pluripotent stem cell human CVCL_AP15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40011; true. Male 21124378 CVCL_8V81 DD0284 transformed cell line human CVCL_8V81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124379 CVCL_B115 UOK133 cancer cell line human CVCL_B115 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124380 CVCL_9781 WA20 embryonic stem cell human CVCL_9781 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0101 21124381 CVCL_8V77 DD0280 transformed cell line human CVCL_8V77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124382 CVCL_9777 WA16 embryonic stem cell human CVCL_9777 From: University of Wisconsin; Madison; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0097. 21124383 CVCL_8V76 DD0279 transformed cell line human CVCL_8V76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124384 CVCL_9776 WA15 embryonic stem cell human CVCL_9776 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0096 21124385 CVCL_8V79 DD0282 transformed cell line human CVCL_8V79 CL:0000010 Karyotypic information: 46,XY,t(1;11)(q42.1;q21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124386 CVCL_9779 WA18 embryonic stem cell human CVCL_9779 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0099 21124387 CVCL_8V78 DD0281 transformed cell line human CVCL_8V78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124388 CVCL_9778 WA17 embryonic stem cell human CVCL_9778 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0098 21124389 CVCL_AP29 CW40090 induced pluripotent stem cell human CVCL_AP29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40090; true. Female 21124390 CVCL_B129 UOK162 cancer cell line human CVCL_B129 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu140Profs*19 (c.419del); Zygosity=Unspecified (PubMed=7915601). Unspecified 21124391 CVCL_AP28 CW40089 induced pluripotent stem cell human CVCL_AP28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40089; true. Male 21124392 CVCL_B128 UOK161 cancer cell line human CVCL_B128 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gln164Ter (c.490C>T); ClinVar=VCV000223228; Zygosity=Unspecified (PubMed=7915601). Unspecified 21124393 CVCL_AP21 CW40055 induced pluripotent stem cell human CVCL_AP21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40055; true. Male 21124394 CVCL_8V95 DD0300 transformed cell line human CVCL_8V95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124395 CVCL_9795 Shef8 embryonic stem cell human CVCL_9795 From: University of Sheffield; Sheffield; United Kingdom; From: Pfizer, Inc.; New York; USA CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-08-015, Steering comm appl. SCSC07-31.. 21124396 CVCL_B121 UOK142 cancer cell line human CVCL_B121 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asp121_Ala122del (c.362_367del); Zygosity=Unspecified (PubMed=7915601). Unspecified 21124397 CVCL_AP20 CW40045 induced pluripotent stem cell human CVCL_AP20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40045; true; Discontinued: FCDI; CW40045; probable. Male 21124398 CVCL_8V94 DD0299 transformed cell line human CVCL_8V94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124399 CVCL_9794 Shef7 embryonic stem cell human CVCL_9794 From: University of Sheffield; Sheffield; United Kingdom; From: Pfizer, Inc.; New York; USA CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-07-008, Steering comm appl. SCSC06-30.. 21124400 CVCL_B120 UOK141 cancer cell line human CVCL_B120 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Unspecified (PubMed=7915601). Unspecified 21124401 CVCL_AP23 CW40071 induced pluripotent stem cell human CVCL_AP23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40071; true. Female 21124402 CVCL_8V97 DD0308 transformed cell line human CVCL_8V97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124403 CVCL_9797 HKh-2 cancer cell line human CVCL_9797 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Omics: Transcriptome analysis by RNAseq Male Characteristics: In HCT 116 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21124404 CVCL_B123 UOK146 cancer cell line human CVCL_B123 CL:0000010 Sequence variation: Gene fusion; HGNC; 9343; PRCC + HGNC; 11752; TFE3; Name(s)=PRCC-TFE3 (PubMed=8872474) Derived from sampling site: Kidney. Female 21124405 CVCL_AP22 CW40065 induced pluripotent stem cell human CVCL_AP22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40065; true Male 21124406 CVCL_8V96 DD0304 transformed cell line human CVCL_8V96 CL:0000010 Karyotypic information: 45,X(m) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124407 CVCL_9796 HKe-3 cancer cell line human CVCL_9796 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Omics: Transcriptome analysis by RNAseq Male Characteristics: In HCT 116 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21124408 CVCL_B122 UOK145 cancer cell line human CVCL_B122 CL:0000010 Sequence variation: Gene fusion; HGNC; 10774; SFPQ + HGNC; 11752; TFE3; Name(s)=SFPQ-TFE3, PSF-TFE3 (PubMed=9393982). Female 21124409 CVCL_AP25 CW40080 induced pluripotent stem cell human CVCL_AP25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40080; true Male 21124410 CVCL_8V91 DD0294 transformed cell line human CVCL_8V91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124411 CVCL_9791 Shef4 embryonic stem cell human CVCL_9791 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-05-029, Steering comm appl. SCSC05-22.. 21124412 CVCL_B125 UOK150 cancer cell line human CVCL_B125 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Tyr98Asn (c.292T>A); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124413 CVCL_AP24 CW40075 induced pluripotent stem cell human CVCL_AP24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40075; true Female 21124414 CVCL_8V90 DD0293 transformed cell line human CVCL_8V90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124415 CVCL_9790 Shef3 embryonic stem cell human CVCL_9790 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0077; Registration: UK Stem Cell Bank (UKSCB); R-05-008, Steering comm appl. SCSC04-24.. 21124416 CVCL_B124 UOK147 cancer cell line human CVCL_B124 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124417 CVCL_AP27 CW40087 induced pluripotent stem cell human CVCL_AP27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40087; true. Female 21124418 CVCL_8V93 DD0296 transformed cell line human CVCL_8V93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124419 CVCL_9793 Shef6 embryonic stem cell human CVCL_9793 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0078; Registration: UK Stem Cell Bank (UKSCB); R-05-031, Steering comm appl. SCSC05-23.. 21124420 CVCL_B127 UOK154 cancer cell line human CVCL_B127 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8319216); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gln203Argfs*16 (c.607del); Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Female 21124421 CVCL_AP26 CW40083 induced pluripotent stem cell human CVCL_AP26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40083; true. Male 21124422 CVCL_8V92 DD0295 transformed cell line human CVCL_8V92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124423 CVCL_9792 Shef5 embryonic stem cell human CVCL_9792 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-08-009, Steering comm appl. SCSC05-22.. 21124424 CVCL_B126 UOK151 cancer cell line human CVCL_B126 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser183Ter (c.548C>A); ClinVar=VCV000002215; Zygosity=Unspecified (PubMed=7915601; PubMed=8493574) Derived from sampling site: Kidney. Unspecified 21124425 CVCL_8V88 DD0291 transformed cell line human CVCL_8V88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124426 CVCL_9788 Shef1 embryonic stem cell human CVCL_9788 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: UK Stem Cell Bank (UKSCB); R-05-007, Steering comm appl. SCSC04-23(1). 21124427 CVCL_9787 C8PA transformed cell line human CVCL_9787 CL:0000010 Transfected with: MGI; MGI:1890505; Plin1; Transfected with: MGI; MGI:1347098; Slc27a1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21124428 CVCL_8V87 DD0290 transformed cell line human CVCL_8V87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124429 CVCL_8V89 DD0292 transformed cell line human CVCL_8V89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124430 CVCL_9789 Shef2 embryonic stem cell human CVCL_9789 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-05-028, Steering comm appl. SCSC04-23(2). 21124431 CVCL_9762 CHA-hESR2 embryonic stem cell human CVCL_9762 HLA typing: A*02:01,33:03; B*27:05,58:01; C*01:02,03:02; DRB1*01:01,13:02 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010043 21124432 CVCL_8V62 DD0262 transformed cell line human CVCL_8V62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124433 CVCL_9761 CHA-hESR1 embryonic stem cell human CVCL_9761 HLA typing: A*02:06,24:02; B*07:02,59:01:01:01; C*01:02,07:02; DRB1*01:01,04:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010042 21124434 CVCL_8V61 DD0261 transformed cell line human CVCL_8V61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124435 CVCL_9764 CHA-hESR4 embryonic stem cell human CVCL_9764 HLA typing: A*03:01,24:02; B*07:02,27:05; C*02:02,07:02; DRB1*01:01,01:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010045 21124436 CVCL_8V64 DD0264 finite cell line human CVCL_8V64 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124437 CVCL_9763 CHA-hESR3 embryonic stem cell human CVCL_9763 HLA typing: A*02:06,02:07:01; B*46:01,51:01; C*01:02,14:02; DRB1*08:03,12:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010044 21124438 CVCL_8V63 DD0263 transformed cell line human CVCL_8V63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124439 CVCL_9760 CHA-hESM1 embryonic stem cell human CVCL_9760 HLA typing: A*11:01,31:01; B*15:01,40:02; C*03:04,04:01; DRB1*04:06,14:07 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010041 21124440 CVCL_8V60 DD0260 transformed cell line human CVCL_8V60 CL:0000010 Karyotypic information: 46,X,t(X;4)(p22;q27) de novo,var(13p+)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124441 CVCL_9759 CHA-hES9 embryonic stem cell human CVCL_9759 HLA typing: A*02:01,11:01; B*13:01,40:01; C*03:04,07:02; DRB1*12:02,14:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010021 21124442 CVCL_8V59 DD0257 transformed cell line human CVCL_8V59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124443 CVCL_9758 CHA-hES8 embryonic stem cell human CVCL_9758 HLA typing: A*11:01,24:02; B*15:27,48:01; C*04:01,08:01; DRB1*04:06,14:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010020 21124444 CVCL_8V58 DD0256 finite cell line human CVCL_8V58 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124445 CVCL_9755 CHA-hES5 embryonic stem cell human CVCL_9755 HLA typing: A*24:02,33:03; B*07:02,44:03; C*07:02,14:03; DRB1*01:01,07:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010017 21124446 CVCL_8V55 DD0253 transformed cell line human CVCL_8V55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124447 CVCL_9754 CHA-hES4 embryonic stem cell human CVCL_9754 HLA typing: A*02:07:01,11:01; B*18:01,46:01; C*01:02,12:03; DRB1*04:05,11:04 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010002 21124448 CVCL_8V54 DD0252 transformed cell line human CVCL_8V54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124449 CVCL_9757 CHA-hES7 embryonic stem cell human CVCL_9757 HLA typing: A*02:01,11:01; B*15:11,54:01:01; C*01:02,03:03; DRB1*04:05,12:02 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010019 21124450 CVCL_8V57 DD0255 finite cell line human CVCL_8V57 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124451 CVCL_9756 CHA-hES6 embryonic stem cell human CVCL_9756 HLA typing: A*02:01,02:03; B*38:02,40:01; C*03:04,07:02; DRB1*09:01,11:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010018 21124452 CVCL_8V56 DD0254 transformed cell line human CVCL_8V56 CL:0000010 Karyotypic information: 46,XY,10q- (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124453 CVCL_AP07 CW30328 induced pluripotent stem cell human CVCL_AP07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30328; true Male 21124454 CVCL_B107 UOK125 cancer cell line human CVCL_B107 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124455 CVCL_AP06 CW30314 induced pluripotent stem cell human CVCL_AP06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30314; true Male 21124456 CVCL_B106 UOK124LN cancer cell line human CVCL_B106 CL:0000010 Derived from metastatic site: Lymph node. Female 21124457 CVCL_AP09 CW30335 induced pluripotent stem cell human CVCL_AP09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30335; true Male 21124458 CVCL_B109 UOK127 cancer cell line human CVCL_B109 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124459 CVCL_AP08 CW30331 induced pluripotent stem cell human CVCL_AP08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30331; true Male 21124460 CVCL_B108 UOK126 cancer cell line human CVCL_B108 CL:0000010 Derived from sampling site: Kidney. Unspecified 21124461 CVCL_8V73 DD0275 finite cell line human CVCL_8V73 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124462 CVCL_9773 WA09 embryonic stem cell human CVCL_9773 HLA typing: A*02:03; B*35,44; C*04,07; DQB1*05,06; DRB1*15,16:01; DRB5*01 (PubMed=16919167) From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181His (c.542G>A); ClinVar=VCV000142320; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Anecdotal: WA01, WA07, WA09, WA13 and WA14 were the first human embryonic stem cells to be established. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H2AK5ac ChIP-seq epigenome analysis; Omics: H2BK12ac ChIP-seq epigenome analysis; Omics: H2BK15ac ChIP-seq epigenome analysis; Omics: H2BK5ac ChIP-seq epigenome analysis; Omics: H3K18ac ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K23me2 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K56ac ChIP-seq epigenome analysis; Omics: H3K79me1 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: H4K5ac ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: H4K91ac ChIP-seq epigenome analysis; Omics: Mitochondrial proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Group: Clinical grade hESC cell line; Part of: ENCODE project common cell types; tier 3; Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0062; Registration: Swiss research registry; BAG-hES-IMP-0016; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18/SCSC11-06. 21124463 CVCL_8V72 DD0274 transformed cell line human CVCL_8V72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124464 CVCL_9772 WA07 embryonic stem cell human CVCL_9772 HLA typing: A*02:25; B*18,35; C*04,12; DQB1*02,03; DRB1*07,11; DRB3*02 (PubMed=16919167) From: University of Wisconsin; Madison; USA CL:0000010 Anecdotal: WA01, WA07, WA09, WA13 and WA14 were the first human embryonic stem cells to be established Donor information: Embryo is sibling to those giving rise to WA13 (Cellosaurus=CVCL_9774) and WA14 (Cellosaurus=CVCL_9775). Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Part of: ENCODE project common cell types; tier 3; Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0061; Registration: Swiss research registry; BAG-hES-IMP-0034; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18/SCSC11-18. 21124465 CVCL_AP01 CW30306 induced pluripotent stem cell human CVCL_AP01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30306; true Female 21124466 CVCL_8V75 DD0278 transformed cell line human CVCL_8V75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124467 CVCL_B101 UOK121LN cancer cell line human CVCL_B101 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=8319216) Derived from metastatic site: Lymph node. Male 21124468 CVCL_9775 WA14 embryonic stem cell human CVCL_9775 From: University of Wisconsin; Madison; USA CL:0000010 Anecdotal: WA01, WA07, WA09, WA13 and WA14 were the first human embryonic stem cells to be established Donor information: Embryo is sibling to those giving rise to WA07 (Cellosaurus=CVCL_9772) and WA13 (Cellosaurus=CVCL_9774). Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0064; Registration: Swiss research registry; BAG-hES-IMP-0033; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18/SCSC11-18. 21124469 CVCL_AP00 CW30303 induced pluripotent stem cell human CVCL_AP00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30303; true Male 21124470 CVCL_8V74 DD0277 transformed cell line human CVCL_8V74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124471 CVCL_B100 UOK121 cancer cell line human CVCL_B100 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=8319216) Derived from sampling site: Kidney. Male 21124472 CVCL_9774 WA13 embryonic stem cell human CVCL_9774 From: University of Wisconsin; Madison; USA CL:0000010 Anecdotal: WA01, WA07, WA09, WA13 and WA14 were the first human embryonic stem cells to be established Donor information: Embryo is sibling to those giving rise to WA07 (Cellosaurus=CVCL_9772) and WA14 (Cellosaurus=CVCL_9775). Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0063; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18. 21124473 CVCL_AP03 CW30310 induced pluripotent stem cell human CVCL_AP03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30310; true Male 21124474 CVCL_B103 UOK122LN cancer cell line human CVCL_B103 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Unspecified (PubMed=8319216) Derived from metastatic site: Lymph node. Male 21124475 CVCL_AP02 CW30307 induced pluripotent stem cell human CVCL_AP02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30307; true Male 21124476 CVCL_B102 UOK122 cancer cell line human CVCL_B102 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Unspecified (PubMed=8319216) Derived from sampling site: Kidney. Male 21124477 CVCL_AP05 CW30312 induced pluripotent stem cell human CVCL_AP05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30312; true Male 21124478 CVCL_8V71 DD0273 transformed cell line human CVCL_8V71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124479 CVCL_B105 UOK124 cancer cell line human CVCL_B105 CL:0000010 Sequence variation: Gene fusion; HGNC; 9343; PRCC + HGNC; 11752; TFE3; Name(s)=PRCC-TFE3 (PubMed=8872474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=8319216) Derived from sampling site: Kidney. Female 21124480 CVCL_9771 WA01 embryonic stem cell human CVCL_9771 HLA typing: A*02:03; B*08,35; C*04,07; DQB1*02,05; DRB1*01,03; DRB3*01 (PubMed=16919167) From: University of Wisconsin; Madison; USA CL:0000010 Anecdotal: WA01, WA07, WA09, WA13 and WA14 were the first human embryonic stem cells to be established. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Part of: ENCODE project common cell types; tier 1; Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0043; Registration: Swiss research registry; BAG-hES-IMP-0001; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18/SCSC11-06. 21124481 CVCL_AP04 CW30311 induced pluripotent stem cell human CVCL_AP04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30311; true Male 21124482 CVCL_8V70 DD0272 finite cell line human CVCL_8V70 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124483 CVCL_B104 UOK123 cancer cell line human CVCL_B104 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.946del1; Zygosity=Unspecified (PubMed=8319216); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ile151Ser (c.452T>G); ClinVar=VCV000223215; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Unspecified 21124484 CVCL_9770 WIBR6 embryonic stem cell human CVCL_9770 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0082 21124485 CVCL_8V69 DD0270 finite cell line human CVCL_8V69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21124486 CVCL_9769 WIBR5 embryonic stem cell human CVCL_9769 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0081 21124487 CVCL_8V66 DD0266 transformed cell line human CVCL_8V66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124488 CVCL_9766 WIBR2 embryonic stem cell human CVCL_9766 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0075; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-58. 21124489 CVCL_8V65 DD0265 finite cell line human CVCL_8V65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21124490 CVCL_9765 WIBR1 embryonic stem cell human CVCL_9765 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0074 21124491 CVCL_8V68 DD0269 transformed cell line human CVCL_8V68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124492 CVCL_9768 WIBR4 embryonic stem cell human CVCL_9768 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0080. 21124493 CVCL_8V67 DD0268 transformed cell line human CVCL_8V67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124494 CVCL_9767 WIBR3 embryonic stem cell human CVCL_9767 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0079; Registration: Swiss research registry; BAG-hES-IMP-0051; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-58. 21124495 CVCL_9740 CHA-hES14 embryonic stem cell human CVCL_9740 HLA typing: A*11:01,33:03; B*44:03,51:01; C*14:02,14:03; DRB1*09:01,13:02 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010027 21124496 CVCL_8V40 DD0234 transformed cell line human CVCL_8V40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124497 CVCL_9742 CHA-hES16 embryonic stem cell human CVCL_9742 From: CHA University; Seongnam; South Korea CL:0000010 Ambiguous Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010029. 21124498 CVCL_8V42 DD0236 transformed cell line human CVCL_8V42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124499 CVCL_9741 CHA-hES15 embryonic stem cell human CVCL_9741 HLA typing: A*31:01,33:03; B*44:03,46:01; C*01:02,14:03; DRB1*04:03,13:02 (PubMed=20587141) From: CHA University; Seongnam; South Korea CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010028 21124500 CVCL_8V41 DD0235 transformed cell line human CVCL_8V41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124501 CVCL_9737 CHA-hES11 embryonic stem cell human CVCL_9737 HLA typing: A*02:01,31:01; B*15:18,54:01:01; C*01:02,07:04; DRB1*04:01,14:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010023 21124502 CVCL_8V37 DD0229 transformed cell line human CVCL_8V37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124503 CVCL_9736 CHA-hES10 embryonic stem cell human CVCL_9736 HLA typing: A*11:01,30:04:01; B*14:01:01:01,54:01:01; C*01:02,08:02; DRB1*04:04,14:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010022 21124504 CVCL_8V36 DD0228 transformed cell line human CVCL_8V36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124505 CVCL_9739 CHA-hES13 embryonic stem cell human CVCL_9739 HLA typing: A*24:02,30:01; B*07:02,13:02; C*06:02,07:02; DRB1*01:01,04:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010026 21124506 CVCL_8V39 DD0233 transformed cell line human CVCL_8V39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124507 CVCL_9738 CHA-hES12 embryonic stem cell human CVCL_9738 HLA typing: A*02:03,30:04:01; B*14:01:01:01,38:02; C*07:02,08:02; DRB1*08:02,11:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010024 21124508 CVCL_8V38 DD0231 finite cell line human CVCL_8V38 CL:0000010 Karyotypic information: 46,XX,15p+ (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124509 CVCL_9733 CHES2 embryonic stem cell human CVCL_9733 From: University Hospital of Basel; Basel; Switzerland CL:0000010 Female Registration: Swiss research registry; BAG-hES-GEW-0002. 21124510 CVCL_8V33 DD0225 transformed cell line human CVCL_8V33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124511 CVCL_9732 CHES1 embryonic stem cell human CVCL_9732 From: University of Geneva; Geneva; Switzerland CL:0000010 Female Registration: Swiss research registry; BAG-hES-GEW-0001. 21124512 CVCL_8V32 DD0223 transformed cell line human CVCL_8V32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124513 CVCL_9735 CHES5 embryonic stem cell human CVCL_9735 From: University Hospital of Basel; Basel; Switzerland CL:0000010 Male Registration: Swiss research registry; BAG-hES-GEW-0004. 21124514 CVCL_8V35 DD0227 transformed cell line human CVCL_8V35 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124515 CVCL_9734 CHES3 embryonic stem cell human CVCL_9734 From: University Hospital of Basel; Basel; Switzerland CL:0000010 Male Registration: Swiss research registry; BAG-hES-GEW-0003. 21124516 CVCL_8V34 DD0226 transformed cell line human CVCL_8V34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124517 CVCL_9751 CHA-hES25 embryonic stem cell human CVCL_9751 HLA typing: A*01:01,02:06; B*35:01,37:01; C*03:03,06:02; DRB1*04:05,10:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010040 21124518 CVCL_8V51 DD0248 finite cell line human CVCL_8V51 CL:0000010 Karyotypic information: 46,XY,t(3;7)(q27;q32); de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124519 CVCL_9750 CHA-hES24 embryonic stem cell human CVCL_9750 HLA typing: A*02:06,30:04:01; B*14:01:01:01,35:01; C*08:01,08:02; DRB1*04:04,12:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010035 21124520 CVCL_8V50 DD0247 transformed cell line human CVCL_8V50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124521 CVCL_9753 CHA-hES3 embryonic stem cell human CVCL_9753 HLA typing: A*24:02,31:01; B*15:07:01:01,46:01; C*01:02,03:03; DRB1*04:03,08:03 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010001 21124522 CVCL_8V53 DD0251 transformed cell line human CVCL_8V53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124523 CVCL_9752 CHA-hES26 embryonic stem cell human CVCL_9752 HLA typing: A*02:01,02:06; C*01:02,03:04; DRB1*04:05,14:05 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010036 21124524 CVCL_8V52 DD0249 finite cell line human CVCL_8V52 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21124525 CVCL_9748 CHA-hES22 embryonic stem cell human CVCL_9748 HLA typing: A*02:06,02:06; B*40:01,55:02; C*01:02,07:02; DRB1*12:02,15:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010039 21124526 CVCL_8V48 DD0245 transformed cell line human CVCL_8V48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124527 CVCL_9747 CHA-hES21 embryonic stem cell human CVCL_9747 HLA typing: A*01:01,33:03; B*37:01,44:03; C*06:02,07:01; DRB1*03:01,07:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010033 21124528 CVCL_8V47 DD0244 transformed cell line human CVCL_8V47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124529 CVCL_9749 CHA-hES23 embryonic stem cell human CVCL_9749 HLA typing: A*24:02,33:03; B*44:03,46:01; C*01:03,14:03; DRB1*09:01,15:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010034 21124530 CVCL_8V49 DD0246 transformed cell line human CVCL_8V49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124531 CVCL_9744 CHA-hES18 embryonic stem cell human CVCL_9744 HLA typing: A*24:02,26:03:01; B*15:01,55:02; C*01:02,03:03; DRB1*09:01,15:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010038 21124532 CVCL_8V44 DD0241 transformed cell line human CVCL_8V44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124533 CVCL_9743 CHA-hES17 embryonic stem cell human CVCL_9743 HLA typing: A*33:03,68:01; B*51:01,58:01; C*03:02,15:02; DRB1*13:02,14:07 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010030 21124534 CVCL_8V43 DD0239 finite cell line human CVCL_8V43 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124535 CVCL_9746 CHA-hES20 embryonic stem cell human CVCL_9746 HLA typing: A*02:01,02:07:01; B*15:01,46:01; C*01:03,04:01; DRB1*09:01,14:01 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010032 21124536 CVCL_8V46 DD0243 transformed cell line human CVCL_8V46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124537 CVCL_9745 CHA-hES19 embryonic stem cell human CVCL_9745 HLA typing: A*02:03,24:02; B*38:02,51:01; C*07:02,14:02; DRB1*08:03,15:02 (PubMed=20587141). From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010031 21124538 CVCL_8V45 DD0242 transformed cell line human CVCL_8V45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124539 CVCL_8V20 DD0202 transformed cell line human CVCL_8V20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124540 CVCL_9720 HepaRG cancer cell line human CVCL_9720 CL:0000010 Anecdotal: The 'RG' in the cell name stands for Rumin and Gripon, the two scientists that were influential in the establishment of this cell line; Miscellaneous: This cell line is exclusively produced and controlled by Biopredic International and owned by Inserm BioPredic sells undifferentiated cell line (HPR101) that can be expanded, passaged, and frozen in-house to prepare a cell bank and differentiated ready-to-use cells (HPR116) that can be used immediately or in a few days after thawing, as a single-use disposable product. Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Membrane proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: Transcriptome analysis by microarray Discontinued: Millipore; C103485; true Female Characteristics: Can be induced to differentiate into hepatocyte-like cells by exposure to DMSO; Characteristics: Cell line main applications are sugar and lipid metabolism, physiopathology; drug metabolism and toxicology and viral infection Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2652 21124541 CVCL_8V15 DD0196 transformed cell line human CVCL_8V15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124542 CVCL_9715 RS-63 cancer cell line human CVCL_9715 From: Van Valen F.; University of Munster; Munster; Germany. CL:0000010 Female 21124543 CVCL_8V14 DD0195 transformed cell line human CVCL_8V14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124544 CVCL_9714 RM-82 cancer cell line human CVCL_9714 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=15150091); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=8378080; PubMed=19787792) Derived from sampling site: Bone; femur. Male 21124545 CVCL_8V17 DD0198 transformed cell line human CVCL_8V17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124546 CVCL_9717 WE-68 cancer cell line human CVCL_9717 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=15150091); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; fibula. Female 21124547 CVCL_8V16 DD0197 transformed cell line human CVCL_8V16 CL:0000010 Karyotypic information: 46,X,del(X)(qter->p11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124548 CVCL_9716 TC-83 cancer cell line human CVCL_9716 From: Van Valen F.; University of Munster; Munster; Germany. CL:0000010 Female 21124549 CVCL_8V11 DD0189 transformed cell line human CVCL_8V11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124550 CVCL_9711 JS-73 cancer cell line human CVCL_9711 From: Van Valen F.; University of Munster; Munster; Germany. CL:0000010 Female 21124551 CVCL_8V10 DD0188 transformed cell line human CVCL_8V10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124552 CVCL_9710 HT-M1-78 cancer cell line human CVCL_9710 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Pleural effusion. Male 21124553 CVCL_8V13 DD0193 transformed cell line human CVCL_8V13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124554 CVCL_9713 NT-68 cancer cell line human CVCL_9713 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Pleural effusion. Male 21124555 CVCL_8V12 DD0191 transformed cell line human CVCL_8V12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124556 CVCL_9712 MM-83 cancer cell line human CVCL_9712 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Bone; foot. Unspecified 21124557 CVCL_8V19 DD0200 transformed cell line human CVCL_8V19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124558 CVCL_9719 WE-M2-68 cancer cell line human CVCL_9719 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Pleural effusion. Female 21124559 CVCL_8V18 DD0199 transformed cell line human CVCL_8V18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124560 CVCL_9718 WE-M1-68 cancer cell line human CVCL_9718 From: Van Valen F.; University of Munster; Munster; Germany CL:0000010 Derived from metastatic site: Chest wall. Female 21124561 CVCL_9731 BG04 embryonic stem cell human CVCL_9731 From: ViaCyte, Inc (originally from BresaGen); San Diego; USA. CL:0000010 Miscellaneous: Cell line has been lost. Unspecified 21124562 CVCL_8V31 DD0222 transformed cell line human CVCL_8V31 CL:0000010 Karyotypic information: 46,XY,t(6;22)(p21.3;q13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124563 CVCL_9730 BG03 embryonic stem cell human CVCL_9730 HLA typing: A*24,68; B*44:44; C*05; DQB1*03; DRB1*04,04 (PubMed=16919167); HLA typing: A*02:01,32:01; B*44:02; C*05:AC; DQB1*03:01,03:02; DRB1*04:01 (PubMed=15684826) From: ViaCyte, Inc (originally from BresaGen); San Diego; USA. CL:0000010 Omics: Transcriptome analysis by microarray. Female 21124564 CVCL_8V30 DD0220 transformed cell line human CVCL_8V30 CL:0000010 Karyotypic information: 46,X,del(X)(pter->q22.3::q26.1->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124565 CVCL_9726 BG01 embryonic stem cell human CVCL_9726 HLA typing: A*02,03; B*35,49; C*04,07; DQB1*02,03; DRB1*03,04; DRB3*01 (PubMed=16919167); HLA typing: A*02:01,03:01; B*35:03,49:01; C*04:01,07:01; DQB1*02:01,03:01; DRB1*03:01,04:05 (PubMed=15684826) From: ViaCyte, Inc (originally from BresaGen); San Diego; USA. CL:0000010 Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Male 21124566 CVCL_8V26 DD0213 transformed cell line human CVCL_8V26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124567 CVCL_8V25 DD0210 transformed cell line human CVCL_8V25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124568 CVCL_9728 BG01V/hOG embryonic stem cell human CVCL_9728 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP). Male Characteristics: Transfected with the gene for emerald GFP (EmGFP) under the control of a Oct-4 promoter 21124569 CVCL_8V28 DD0215 transformed cell line human CVCL_8V28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124570 CVCL_9727 BG01V embryonic stem cell human CVCL_9727 HLA typing: A*02,03; B*35,49; C*04,07; DQB1*02,03; DRB1*03,04; DRB3*01 (PubMed=16919167). From: National Institute on Drug Abuse; Bethesda; USA CL:0000010 Male 21124571 CVCL_8V27 DD0214 transformed cell line human CVCL_8V27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124572 CVCL_9722 66 [Mouse mammary tumor] cancer cell line house mouse CVCL_9722 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Doubling time: 30.8 +- 4.2 hours (PubMed=10651311) 21124573 CVCL_8V22 DD0204 transformed cell line human CVCL_8V22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124574 CVCL_9721 66cl-4 cancer cell line house mouse CVCL_9721 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Metastatic 21124575 CVCL_8V21 DD0203 transformed cell line human CVCL_8V21 CL:0000010 Karyotypic information: 46,XX,t(10;20)(q23;q13.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124576 CVCL_9724 A1847 cancer cell line human CVCL_9724 CL:0000010 Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female 21124577 CVCL_8V24 DD0207 transformed cell line human CVCL_8V24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124578 CVCL_9723 67NR cancer cell line house mouse CVCL_9723 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Non-metastatic 21124579 CVCL_8V23 DD0206 transformed cell line human CVCL_8V23 CL:0000010 Karyotypic information: 46,XX,t(2;12)(q37;q24.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124580 CVCL_9729 BG02 embryonic stem cell human CVCL_9729 HLA typing: A*24,68; B*35:11,35; C*03,04; DQB1*03,06:01; DRB1*15,16:02; DRB5*01 (PubMed=16919167); HLA typing: A*24:02,68:01; B*35:03:35:11; C*03:04,04:01; DQB1*03:01,06:01; DRB1*15:02,16:02 (PubMed=15684826) From: ViaCyte, Inc (originally from BresaGen); San Diego; USA. CL:0000010 Omics: Transcriptome analysis by massively parallel signature sequencing (MPSS); Omics: Transcriptome analysis by microarray. Male Part of: ENCODE project common cell types; tier 3 21124581 CVCL_8V29 DD0218 transformed cell line human CVCL_8V29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124582 CVCL_B198 HUES 63 embryonic stem cell human CVCL_B198 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 62 (Cellosaurus=CVCL_B197) and HUES 64 (Cellosaurus=CVCL_B199). Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0066 21124583 CVCL_AP98 IgSV195 cancer cell line house mouse CVCL_AP98 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6 x SJL) F2. Male 21124584 CVCL_AP97 HB60-ED cancer cell line house mouse CVCL_AP97 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Characteristics: EPO dependent 21124585 CVCL_B197 HUES 62 embryonic stem cell human CVCL_B197 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 63 (Cellosaurus=CVCL_B198) and HUES 64 (Cellosaurus=CVCL_B199). Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0065 21124586 CVCL_B199 HUES 64 embryonic stem cell human CVCL_B199 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 62 (Cellosaurus=CVCL_B197) and HUES 63 (Cellosaurus=CVCL_B198). Omics: Deep exome analysis; Omics: Genome sequenced; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0067; Registration: Swiss research registry; BAG-hES-IMP-0054 21124587 CVCL_AP99 SK-MEL-28-VR cancer cell line human CVCL_AP99 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Pro753Ser (c.2257C>T); ClinVar=VCV000376081; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr167Ala (c.499A>G); ClinVar=VCV001686107; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Male 21124588 CVCL_B190 HUES 56 embryonic stem cell human CVCL_B190 From: Harvard University; Boston; USA. CL:0000010 Male 21124589 CVCL_AP90 WM3406 cancer cell line human CVCL_AP90 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124590 CVCL_B192 HUES 58 embryonic stem cell human CVCL_B192 From: Harvard University; Boston; USA. CL:0000010 Female 21124591 CVCL_AP92 WM3482 cancer cell line human CVCL_AP92 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124592 CVCL_B191 HUES 57 embryonic stem cell human CVCL_B191 From: Harvard University; Boston; USA. CL:0000010 Female 21124593 CVCL_AP91 WM3456 cancer cell line human CVCL_AP91 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: vWA 21124594 CVCL_JJ28 CW60510 induced pluripotent stem cell human CVCL_JJ28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60510; true Female 21124595 CVCL_B194 HUES 6 embryonic stem cell human CVCL_B194 From: Harvard University; Boston; USA CL:0000010 Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 24 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0019; Registration: Swiss research registry; BAG-hES-IMP-0038; Registration: UK Stem Cell Bank (UKSCB); R-06-009, Steering comm appl. SCSC04-25(6). 21124596 CVCL_AP94 WM3540 cancer cell line human CVCL_AP94 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Asp97His (c.289G>C); ClinVar=VCV000408340; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124597 CVCL_JJ27 CW60507 induced pluripotent stem cell human CVCL_JJ27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60507; true Male 21124598 CVCL_B193 HUES 59 embryonic stem cell human CVCL_B193 From: Harvard University; Boston; USA. CL:0000010 Male 21124599 CVCL_AP93 WM3506 cancer cell line human CVCL_AP93 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D13S317 21124600 CVCL_AP96 A375-VR [2014] cancer cell line human CVCL_AP96 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Skin. Female 21124601 CVCL_B196 HUES 61 embryonic stem cell human CVCL_B196 From: Harvard University; Boston; USA. CL:0000010 Female 21124602 CVCL_JJ29 CW60517 induced pluripotent stem cell human CVCL_JJ29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60517; true Female 21124603 CVCL_B195 HUES 60 embryonic stem cell human CVCL_B195 From: Harvard University; Boston; USA. CL:0000010 Male 21124604 CVCL_AP95 WM3622 cancer cell line human CVCL_AP95 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe337Ser (c.1010T>C); Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124605 CVCL_JJ24 CW60474 induced pluripotent stem cell human CVCL_JJ24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60474; true Female 21124606 CVCL_JJ23 CW60473 induced pluripotent stem cell human CVCL_JJ23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60473; true Female 21124607 CVCL_JJ26 CW60504 induced pluripotent stem cell human CVCL_JJ26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60504; true Male 21124608 CVCL_JJ25 CW60483 induced pluripotent stem cell human CVCL_JJ25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60483; true Male 21124609 CVCL_JJ20 CW60457 induced pluripotent stem cell human CVCL_JJ20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60457; true Male 21124610 CVCL_JJ22 CW60465 induced pluripotent stem cell human CVCL_JJ22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60465; true Female 21124611 CVCL_JJ21 CW60458 induced pluripotent stem cell human CVCL_JJ21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60458; true Male 21124612 CVCL_JJ40 CW70131 induced pluripotent stem cell human CVCL_JJ40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70131; true Female 21124613 CVCL_JJ39 CW70106 induced pluripotent stem cell human CVCL_JJ39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70106; true Female 21124614 CVCL_JJ38 CW70104 induced pluripotent stem cell human CVCL_JJ38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70104; true Male 21124615 CVCL_JJ35 CW70092 induced pluripotent stem cell human CVCL_JJ35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Israeli; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70092; true Male 21124616 CVCL_JJ34 CW70090 induced pluripotent stem cell human CVCL_JJ34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70090; true Male 21124617 CVCL_JJ37 CW70103 induced pluripotent stem cell human CVCL_JJ37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70103; true Female 21124618 CVCL_JJ36 CW70100 induced pluripotent stem cell human CVCL_JJ36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70100; true Male 21124619 CVCL_JJ31 CW60521 induced pluripotent stem cell human CVCL_JJ31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60521; true Male 21124620 CVCL_JJ30 CW60520 induced pluripotent stem cell human CVCL_JJ30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60520; true Male 21124621 CVCL_JJ33 CW70060 induced pluripotent stem cell human CVCL_JJ33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70060; true Male 21124622 CVCL_JJ32 CW70033 induced pluripotent stem cell human CVCL_JJ32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70033; true Female 21124623 CVCL_B176 HUES 43 embryonic stem cell human CVCL_B176 From: Harvard University; Boston; USA. CL:0000010 Unspecified 21124624 CVCL_AP76 WM1960 cancer cell line human CVCL_AP76 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from metastatic site: Left axillary lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124625 CVCL_B175 HUES 42 embryonic stem cell human CVCL_B175 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0157 21124626 CVCL_AP75 MDCK-F spontaneously immortalized cell line dog CVCL_AP75 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21124627 CVCL_B178 HUES 45 embryonic stem cell human CVCL_B178 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0076 21124628 CVCL_AP78 WM3682 cancer cell line human CVCL_AP78 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124629 CVCL_B177 HUES 44 embryonic stem cell human CVCL_B177 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0158 21124630 CVCL_AP77 WM2013 cancer cell line human CVCL_AP77 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from metastatic site: Left axillary lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124631 CVCL_B179 HUES 46 embryonic stem cell human CVCL_B179 From: Harvard University; Boston; USA. CL:0000010 Female 21124632 CVCL_AP79 WM3758 cancer cell line human CVCL_AP79 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124633 CVCL_JJ09 CW60390 induced pluripotent stem cell human CVCL_JJ09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60390; true Female 21124634 CVCL_B170 HUES 38 embryonic stem cell human CVCL_B170 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 36 (Cellosaurus=CVCL_B168), HUES 37 (Cellosaurus=CVCL_B169) and HUES 39 (Cellosaurus=CVCL_B171). Male 21124635 CVCL_AP70 MDCK-C11 spontaneously immortalized cell line dog CVCL_AP70 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21124636 CVCL_JJ06 CW60342 induced pluripotent stem cell human CVCL_JJ06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60342; true Female 21124637 CVCL_B172 HUES 4 embryonic stem cell human CVCL_B172 From: Harvard University; Boston; USA CL:0000010 Male Doubling time: 48 hours (PubMed=14999088). Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0017; Registration: UK Stem Cell Bank (UKSCB); R-06-007, Steering comm appl. SCSC04-25(4). 21124638 CVCL_AP72 JNUCK-2 telomerase immortalized cell line dog CVCL_AP72 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal kidney; Breed/subspecies: Mixed breed. Unspecified 21124639 CVCL_JJ05 CW60335 induced pluripotent stem cell human CVCL_JJ05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60335; true Female 21124640 CVCL_B171 HUES 39 embryonic stem cell human CVCL_B171 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 36 (Cellosaurus=CVCL_B168), HUES 37 (Cellosaurus=CVCL_B169) and HUES 38 (Cellosaurus=CVCL_B170). Female 21124641 CVCL_AP71 JNUCK-1 telomerase immortalized cell line dog CVCL_AP71 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal kidney; Breed/subspecies: Mixed breed. Unspecified 21124642 CVCL_JJ08 CW60355 induced pluripotent stem cell human CVCL_JJ08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60355; true Female 21124643 CVCL_B174 HUES 41 embryonic stem cell human CVCL_B174 From: Harvard University; Boston; USA. CL:0000010 Female 21124644 CVCL_AP74 JNUBK-4 telomerase immortalized cell line CVCL_AP74 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Breed from personal communication of Hwang K.-K Derived from sampling site: Kidney; Breed/subspecies: Hanwoo. Female 21124645 CVCL_JJ07 CW60353 induced pluripotent stem cell human CVCL_JJ07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60353; true Female 21124646 CVCL_B173 HUES 40 embryonic stem cell human CVCL_B173 From: Harvard University; Boston; USA. CL:0000010 Female 21124647 CVCL_AP73 JNUBK-3 telomerase immortalized cell line CVCL_AP73 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Breed from personal communication of Hwang K.-K Derived from sampling site: Kidney; Breed/subspecies: Hanwoo. Female 21124648 CVCL_JJ02 CW60330 induced pluripotent stem cell human CVCL_JJ02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60330; true Female 21124649 CVCL_JJ01 CW60325 induced pluripotent stem cell human CVCL_JJ01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60325; true Female 21124650 CVCL_JJ04 CW60333 induced pluripotent stem cell human CVCL_JJ04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60333; true Male 21124651 CVCL_JJ03 CW60331 induced pluripotent stem cell human CVCL_JJ03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60331; true Female 21124652 CVCL_JJ00 CW60304 induced pluripotent stem cell human CVCL_JJ00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60304; true Male 21124653 CVCL_B187 HUES 53 embryonic stem cell human CVCL_B187 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0055 21124654 CVCL_AP87 WM3061 cancer cell line human CVCL_AP87 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124655 CVCL_B186 HUES 52 embryonic stem cell human CVCL_B186 From: Harvard University; Boston; USA. CL:0000010 Female 21124656 CVCL_AP86 WM3000 cancer cell line human CVCL_AP86 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124657 CVCL_B189 HUES 55 embryonic stem cell human CVCL_B189 From: Harvard University; Boston; USA. CL:0000010 Female 21124658 CVCL_AP89 WM3301 cancer cell line human CVCL_AP89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124659 CVCL_B188 HUES 54 embryonic stem cell human CVCL_B188 From: Harvard University; Boston; USA. CL:0000010 Female 21124660 CVCL_AP88 WM3246 cancer cell line human CVCL_AP88 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys80_Arg84del (c.238_252del); Zygosity=Unspecified (Wistar) Derived from metastatic site: Adrenal gland. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21124661 CVCL_B181 HUES 48 embryonic stem cell human CVCL_B181 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0053 21124662 CVCL_AP81 WM983B-BR cancer cell line human CVCL_AP81 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289; Wistar); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Phe (c.832_833CC>TT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:131882; SB-590885; Derived from metastatic site: Inguinal lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21124663 CVCL_B180 HUES 47 embryonic stem cell human CVCL_B180 From: Harvard University; Boston; USA. CL:0000010 Female 21124664 CVCL_AP80 WM3749 cancer cell line human CVCL_AP80 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21124665 CVCL_AP83 451Lu-BR cancer cell line human CVCL_AP83 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289; Wistar); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=21156289) Selected for resistance to: ChEBI; CHEBI:131882; SB-590885; Derived from metastatic site: Arm; skin. Male Part of: Wistar Institute melanoma cell line collection 21124666 CVCL_JJ17 CW60437 induced pluripotent stem cell human CVCL_JJ17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60437; true Female 21124667 CVCL_B183 HUES 5 embryonic stem cell human CVCL_B183 From: Harvard University; Boston; USA CL:0000010 Female Doubling time: 72 hours (PubMed=14999088). Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0018; Registration: Swiss research registry; BAG-hES-IMP-0037; Registration: UK Stem Cell Bank (UKSCB); R-06-008, Steering comm appl. SCSC04-25(5). 21124668 CVCL_JJ16 CW60416 induced pluripotent stem cell human CVCL_JJ16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60416; true Female 21124669 CVCL_B182 HUES 49 embryonic stem cell human CVCL_B182 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0054 21124670 CVCL_AP82 WM1716 cancer cell line human CVCL_AP82 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Omics: Transcriptome analysis by microarray. Unspecified Part of: Wistar Institute melanoma cell line collection 21124671 CVCL_JJ19 CW60456 induced pluripotent stem cell human CVCL_JJ19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60456; true Female 21124672 CVCL_B185 HUES 51 embryonic stem cell human CVCL_B185 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 50 (Cellosaurus=CVCL_B184). Female 21124673 CVCL_AP85 WM262 cancer cell line human CVCL_AP85 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21124674 CVCL_JJ18 CW60447 induced pluripotent stem cell human CVCL_JJ18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60447; true Male 21124675 CVCL_B184 HUES 50 embryonic stem cell human CVCL_B184 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 51 (Cellosaurus=CVCL_B185). Female 21124676 CVCL_AP84 WM1026 cancer cell line human CVCL_AP84 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21124677 CVCL_JJ13 CW60410 induced pluripotent stem cell human CVCL_JJ13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60410; true Female 21124678 CVCL_JJ12 CW60408 induced pluripotent stem cell human CVCL_JJ12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60408; true Male 21124679 CVCL_JJ15 CW60413 induced pluripotent stem cell human CVCL_JJ15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60413; true Female 21124680 CVCL_JJ14 CW60412 induced pluripotent stem cell human CVCL_JJ14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60412; true Female 21124681 CVCL_JJ11 CW60404 induced pluripotent stem cell human CVCL_JJ11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60404; true Female 21124682 CVCL_JJ10 CW60403 induced pluripotent stem cell human CVCL_JJ10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60403; true Female 21124683 CVCL_AP54 CW60095 induced pluripotent stem cell human CVCL_AP54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60095; true; Discontinued: FCDI; CW60095; probable Male 21124684 CVCL_B154 HUES 23 embryonic stem cell human CVCL_B154 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 22 (Cellosaurus=CVCL_B153). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0036 21124685 CVCL_AP53 CW60094 induced pluripotent stem cell human CVCL_AP53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60094; true Male 21124686 CVCL_B153 HUES 22 embryonic stem cell human CVCL_B153 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 23 (Cellosaurus=CVCL_B154). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0035 21124687 CVCL_B156 HUES 25 embryonic stem cell human CVCL_B156 CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124688 CVCL_AP56 UP-007 cancer cell line human CVCL_AP56 CL:0000010 Male 21124689 CVCL_B155 HUES 24 embryonic stem cell human CVCL_B155 From: Harvard University; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0037. 21124690 CVCL_AP55 YM-1 cancer cell line human CVCL_AP55 CL:0000010 Population: Iranian; Turkamans; Derived from sampling site: Esophagus. Female Doubling time: 40.66 hours (PubMed=26432330) 21124691 CVCL_B158 HUES 27 embryonic stem cell human CVCL_B158 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 26 (Cellosaurus=CVCL_B157). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0039 21124692 CVCL_AP58 UP-032 cancer cell line human CVCL_AP58 CL:0000010 Male 21124693 CVCL_B157 HUES 26 embryonic stem cell human CVCL_B157 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 27 (Cellosaurus=CVCL_B158). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0038 21124694 CVCL_AP57 UP-019 cancer cell line human CVCL_AP57 CL:0000010 Female 21124695 CVCL_AP59 HROC277Met2 T0 M1 cancer cell line human CVCL_AP59 HLA typing: A*02:01,32:01; B*15:17,35:03; C*0:401,07:01; DQB1*03:01,06:04; DRB1*11:01,13:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Discontinued: CLS; 300840; true Male Characteristics: Established from a patient-derived xenograft established in female NSG mice 21124696 CVCL_B159 HUES 28 embryonic stem cell human CVCL_B159 From: Harvard University; Boston; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0040 21124697 CVCL_AP50 CW40190 induced pluripotent stem cell human CVCL_AP50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40190; true Male 21124698 CVCL_B150 HUES 2 embryonic stem cell human CVCL_B150 From: Harvard University; Boston; USA CL:0000010 Omics: DNA methylation analysis. Female Doubling time: 24 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0015; Registration: UK Stem Cell Bank (UKSCB); R-06-006, Steering comm appl. SCSC04-25(2). Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin. 21124699 CVCL_AP52 CW40208 induced pluripotent stem cell human CVCL_AP52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40208; true Female 21124700 CVCL_B152 HUES 21 embryonic stem cell human CVCL_B152 From: Harvard University; Boston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0034. 21124701 CVCL_AP51 CW40201 induced pluripotent stem cell human CVCL_AP51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40201; true Female 21124702 CVCL_B151 HUES 20 embryonic stem cell human CVCL_B151 From: Harvard University; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0033. 21124703 CVCL_AP65 1.2C7 hybridoma house mouse CVCL_AP65 CL:0000010 Discontinued: Coriell; WC00053; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03460; Influenza B virus isolate B/Lee/1940 hemagglutinin (HA) 21124704 CVCL_B165 HUES 33 embryonic stem cell human CVCL_B165 From: Harvard University; Boston; USA. CL:0000010 Female 21124705 CVCL_AP64 1.5A9 hybridoma house mouse CVCL_AP64 CL:0000010 Discontinued: Coriell; WC00052; probable. Monoclonal antibody target: UniProtKB; P03460; Influenza B virus isolate B/Lee/1940 hemagglutinin (HA) 21124706 CVCL_B164 HUES 32 embryonic stem cell human CVCL_B164 From: Harvard University; Boston; USA. CL:0000010 Male 21124707 CVCL_B167 HUES 35 embryonic stem cell human CVCL_B167 From: Harvard University; Boston; USA. CL:0000010 Male 21124708 CVCL_AP67 MDCK Sky1023 spontaneously immortalized cell line dog CVCL_AP67 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3112 21124709 CVCL_B166 HUES 34 embryonic stem cell human CVCL_B166 From: Harvard University; Boston; USA. CL:0000010 Female 21124710 CVCL_AP66 MDCK-B-702 spontaneously immortalized cell line dog CVCL_AP66 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Serum/protein free medium cell line; Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7449 21124711 CVCL_B169 HUES 37 embryonic stem cell human CVCL_B169 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 36 (Cellosaurus=CVCL_B168), HUES 38 (Cellosaurus=CVCL_B170) and HUES 39 (Cellosaurus=CVCL_B171). Female 21124712 CVCL_AP69 MDCK Sky3851 spontaneously immortalized cell line dog CVCL_AP69 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3113 21124713 CVCL_B168 HUES 36 embryonic stem cell human CVCL_B168 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to HUES 37 (Cellosaurus=CVCL_B169), HUES 38 (Cellosaurus=CVCL_B170) and HUES 39 (Cellosaurus=CVCL_B171). Female 21124714 CVCL_AP68 MDCK Sky10234 spontaneously immortalized cell line dog CVCL_AP68 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3114 21124715 CVCL_AP61 HROC357 cancer cell line human CVCL_AP61 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Female Microsatellite instability: Stable (MSS) (Direct_author_submission) 21124716 CVCL_B161 HUES 3 embryonic stem cell human CVCL_B161 From: Harvard University; Boston; USA CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: 60 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0016; Registration: Swiss research registry; BAG-hES-IMP-0036; Registration: UK Stem Cell Bank (UKSCB); R-05-034, Steering comm appl. SCSC04-25(3). 21124717 CVCL_AP60 HROC313Met1 T0 M1 cancer cell line human CVCL_AP60 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male Characteristics: Established from a patient-derived xenograft established in male NSG mice 21124718 CVCL_B160 HUES 29 embryonic stem cell human CVCL_B160 From: Harvard University; Boston; USA. CL:0000010 Female 21124719 CVCL_B163 HUES 31 embryonic stem cell human CVCL_B163 From: Harvard University; Boston; USA. CL:0000010 Female 21124720 CVCL_AP63 MN16 transformed cell line house mouse CVCL_AP63 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: ICR. Unspecified Characteristics: Highly expresses osteocalcin and type I collagen (PubMed=23974965) 21124721 CVCL_AP62 HROC364 cancer cell line human CVCL_AP62 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon. Male Doubling time: 29 hours (CLS) 21124722 CVCL_B162 HUES 30 embryonic stem cell human CVCL_B162 From: Harvard University; Boston; USA. CL:0000010 Female 21124723 CVCL_AP39 CW40161 induced pluripotent stem cell human CVCL_AP39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40161; true Female 21124724 CVCL_B139 HUES 1 embryonic stem cell human CVCL_B139 From: Harvard University; Boston; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 24 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0014; Registration: Swiss research registry; BAG-hES-IMP-0035; Registration: UK Stem Cell Bank (UKSCB); R-05-033, Steering comm appl. SCSC04-25(1). 21124725 CVCL_AP32 CW40145 induced pluripotent stem cell human CVCL_AP32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40145; true Male 21124726 CVCL_B132 FES 21 embryonic stem cell human CVCL_B132 From: University of Helsinki; Helsinki; Finland CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-19.. 21124727 CVCL_AP31 CW40109 induced pluripotent stem cell human CVCL_AP31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40109; true Male 21124728 CVCL_B131 UOK164 cancer cell line human CVCL_B131 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Leu (c.194C>T); ClinVar=VCV000182975; Zygosity=Unspecified (PubMed=7915601). Unspecified 21124729 CVCL_AP34 CW40155 induced pluripotent stem cell human CVCL_AP34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40155; true; Discontinued: FCDI; CW40155; probable. Male 21124730 CVCL_B134 FES 29 embryonic stem cell human CVCL_B134 From: University of Helsinki; Helsinki; Finland CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-19.. 21124731 CVCL_AP33 CW40148 induced pluripotent stem cell human CVCL_AP33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40148; true Female 21124732 CVCL_B133 FES 22 embryonic stem cell human CVCL_B133 From: University of Helsinki; Helsinki; Finland CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-19.. 21124733 CVCL_AP36 CW40158 induced pluripotent stem cell human CVCL_AP36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40158; true. Female 21124734 CVCL_B136 FES 61 embryonic stem cell human CVCL_B136 From: University of Helsinki; Helsinki; Finland CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-19.. 21124735 CVCL_AP35 CW40157 induced pluripotent stem cell human CVCL_AP35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40157; true Male 21124736 CVCL_B135 FES 30 embryonic stem cell human CVCL_B135 From: University of Helsinki; Helsinki; Finland CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-19.. 21124737 CVCL_AP38 CW40160 induced pluripotent stem cell human CVCL_AP38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40160; true Male 21124738 CVCL_B138 FY-3PN embryonic stem cell human CVCL_B138 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124739 CVCL_AP37 CW40159 induced pluripotent stem cell human CVCL_AP37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40159; true Male 21124740 CVCL_B137 FES 75 embryonic stem cell human CVCL_B137 From: University of Helsinki; Helsinki; Finland. CL:0000010 Male 21124741 CVCL_8V99 DD0316 transformed cell line human CVCL_8V99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21124742 CVCL_9799 DKO-3 cancer cell line human CVCL_9799 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS. Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the mutant allele. 21124743 CVCL_8V98 DD0315 finite cell line human CVCL_8V98 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124744 CVCL_9798 DKO-1 cancer cell line human CVCL_9798 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6407; KRAS. Male Characteristics: In DLD-1 one of the two KRAS alleles has a p.Gly13Asp mutation This cell line is KO for the normal allele. 21124745 CVCL_AP30 CW40097 induced pluripotent stem cell human CVCL_AP30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40097; true Male 21124746 CVCL_B130 UOK163 cancer cell line human CVCL_B130 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Trp117Ter (c.351G>A); Zygosity=Unspecified (PubMed=7915601). Unspecified 21124747 CVCL_AP43 CW40174 induced pluripotent stem cell human CVCL_AP43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40174; true Male 21124748 CVCL_B143 HUES 13 embryonic stem cell human CVCL_B143 From: Harvard University; Boston; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 24 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0026; Registration: Swiss research registry; BAG-hES-IMP-0041; Registration: UK Stem Cell Bank (UKSCB); R-06-013, Steering comm appl. SCSC04-25(13). 21124749 CVCL_AP42 CW40169 induced pluripotent stem cell human CVCL_AP42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40169; true Male 21124750 CVCL_B142 HUES 12 embryonic stem cell human CVCL_B142 From: Harvard University; Boston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0025; Registration: Swiss research registry; BAG-hES-IMP-0040; Registration: UK Stem Cell Bank (UKSCB); R-06-012, Steering comm appl. SCSC04-25(12).. 21124751 CVCL_AP45 CW40176 induced pluripotent stem cell human CVCL_AP45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40176; true; Discontinued: FCDI; CW40176; probable. Male 21124752 CVCL_B145 HUES 15 embryonic stem cell human CVCL_B145 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 14 (Cellosaurus=CVCL_B144). Female Doubling time: 48 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0028; Registration: UK Stem Cell Bank (UKSCB); R-06-015, Steering comm appl. SCSC04-25(15). 21124753 CVCL_AP44 CW40175 induced pluripotent stem cell human CVCL_AP44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40175; true; Discontinued: FCDI; CW40175; probable. Male 21124754 CVCL_B144 HUES 14 embryonic stem cell human CVCL_B144 From: Harvard University; Boston; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to HUES 15 (Cellosaurus=CVCL_B145). Female Doubling time: 48 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0027; Registration: UK Stem Cell Bank (UKSCB); R-06-014, Steering comm appl. SCSC04-25(14). 21124755 CVCL_AP47 CW40182 induced pluripotent stem cell human CVCL_AP47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40182; true Male 21124756 CVCL_B147 HUES 17 embryonic stem cell human CVCL_B147 From: Harvard University; Boston; USA CL:0000010 Omics: miRNA expression profiling. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0030; Registration: UK Stem Cell Bank (UKSCB); R-06-017, Steering comm appl. SCSC04-25(17). 21124757 CVCL_AP46 CW40178 induced pluripotent stem cell human CVCL_AP46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40178; true Male 21124758 CVCL_B146 HUES 16 embryonic stem cell human CVCL_B146 From: Harvard University; Boston; USA CL:0000010 Male Doubling time: 48 hours (PubMed=14999088). Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0029; Registration: UK Stem Cell Bank (UKSCB); R-06-016, Steering comm appl. SCSC04-25(16). 21124759 CVCL_AP49 CW40186 induced pluripotent stem cell human CVCL_AP49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40186; true. Female 21124760 CVCL_B149 HUES 19 embryonic stem cell human CVCL_B149 From: Harvard University; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0032. 21124761 CVCL_AP48 CW40183 induced pluripotent stem cell human CVCL_AP48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40183; true Male 21124762 CVCL_B148 HUES 18 embryonic stem cell human CVCL_B148 From: Harvard University; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0031. 21124763 CVCL_AP41 CW40165 induced pluripotent stem cell human CVCL_AP41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40165; true Male 21124764 CVCL_B141 HUES 11 embryonic stem cell human CVCL_B141 From: Harvard University; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0024; Registration: UK Stem Cell Bank (UKSCB); R-06-011, Steering comm appl. SCSC04-25(11).. 21124765 CVCL_AP40 CW40164 induced pluripotent stem cell human CVCL_AP40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40164; true Male 21124766 CVCL_B140 HUES 10 embryonic stem cell human CVCL_B140 From: Harvard University; Boston; USA CL:0000010 Male Doubling time: 72 hours (PubMed=14999088). Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0023; Registration: UK Stem Cell Bank (UKSCB); R-06-010, Steering comm appl. SCSC04-25(10). 21124767 CVCL_SE71 HAP1 BAZ1A (-) 2 cancer cell line human CVCL_SE71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 960; BAZ1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124768 CVCL_SE70 HAP1 BAZ1A (-) 1 cancer cell line human CVCL_SE70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 960; BAZ1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124769 CVCL_SE73 HAP1 BAZ2A (-) 1 cancer cell line human CVCL_SE73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 962; BAZ2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124770 CVCL_SE72 HAP1 BAZ1B (-) cancer cell line human CVCL_SE72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 961; BAZ1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124771 CVCL_SE75 HAP1 BAZ2A (-) 3 cancer cell line human CVCL_SE75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 962; BAZ2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21124772 CVCL_SE74 HAP1 BAZ2A (-) 2 cancer cell line human CVCL_SE74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 962; BAZ2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124773 CVCL_SE77 HAP1 BAZ2B (-) 2 cancer cell line human CVCL_SE77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124774 CVCL_SE76 HAP1 BAZ2B (-) 1 cancer cell line human CVCL_SE76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124775 CVCL_SE79 HAP1 BAZ2B (-) 4 cancer cell line human CVCL_SE79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124776 CVCL_SE78 HAP1 BAZ2B (-) 3 cancer cell line human CVCL_SE78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124777 CVCL_SE60 HAP1 BAD (-) 1 cancer cell line human CVCL_SE60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 936; BAD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124778 CVCL_SE62 HAP1 BAG4 (-) 1 cancer cell line human CVCL_SE62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 940; BAG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124779 CVCL_SE61 HAP1 BAG3 (-) 1 cancer cell line human CVCL_SE61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 939; BAG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124780 CVCL_SE64 HAP1 BAG6 (-) 1 cancer cell line human CVCL_SE64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13919; BAG6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124781 CVCL_SE63 HAP1 BAG4 (-) 2 cancer cell line human CVCL_SE63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 940; BAG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124782 CVCL_SE66 HAP1 BAK1 (-) 1 cancer cell line human CVCL_SE66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124783 CVCL_SE65 HAP1 BAG6 (-) 2 cancer cell line human CVCL_SE65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13919; BAG6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124784 CVCL_SE68 HAP1 BAX (-) 1 cancer cell line human CVCL_SE68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124785 CVCL_SE67 HAP1 BAP1 (-) cancer cell line human CVCL_SE67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 950; BAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124786 CVCL_SE69 HAP1 BAX (-) 2 cancer cell line human CVCL_SE69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 959; BAX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124787 CVCL_SE51 HAP1 B4GALNT3 (-) 2 cancer cell line human CVCL_SE51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24137; B4GALNT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124788 CVCL_SE50 HAP1 B4GALNT3 (-) 1 cancer cell line human CVCL_SE50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24137; B4GALNT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124789 CVCL_SE53 HAP1 B4GALNT4 (-) 2 cancer cell line human CVCL_SE53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26315; B4GALNT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124790 CVCL_SE52 HAP1 B4GALNT4 (-) 1 cancer cell line human CVCL_SE52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26315; B4GALNT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124791 CVCL_SE55 HAP1 B4GALT1 (-) 2 cancer cell line human CVCL_SE55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 924; B4GALT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124792 CVCL_SE54 HAP1 B4GALT1 (-) 1 cancer cell line human CVCL_SE54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 924; B4GALT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124793 CVCL_SE57 HAP1 B4GALT7 (-) 2 cancer cell line human CVCL_SE57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 930; B4GALT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124794 CVCL_SE56 HAP1 B4GALT7 (-) 1 cancer cell line human CVCL_SE56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 930; B4GALT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124795 CVCL_SE59 HAP1 BACH1 (-) 1 cancer cell line human CVCL_SE59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 935; BACH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124796 CVCL_SE58 HAP1 BACE1 (-) 1 cancer cell line human CVCL_SE58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 933; BACE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124797 CVCL_SE40 HAP1 AZI2 (-) 1 cancer cell line human CVCL_SE40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24002; AZI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124798 CVCL_SE42 HAP1 B2M (-) 1 cancer cell line human CVCL_SE42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124799 CVCL_SE41 HAP1 AZI2 (-) 2 cancer cell line human CVCL_SE41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24002; AZI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124800 CVCL_SE44 HAP1 B3GALTL (-) 1 cancer cell line human CVCL_SE44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20207; B3GLCT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124801 CVCL_SE43 HAP1 B3GALNT2 (-) cancer cell line human CVCL_SE43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28596; B3GALNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124802 CVCL_SE46 HAP1 B3GNT1 (-) 1 cancer cell line human CVCL_SE46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15629; B3GNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124803 CVCL_SE45 HAP1 B3GALTL (-) 2 cancer cell line human CVCL_SE45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20207; B3GLCT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124804 CVCL_SE48 HAP1 B3GNT4 (-) 1 cancer cell line human CVCL_SE48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15683; B3GNT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124805 CVCL_SE47 HAP1 B3GNT1 (-) 2 cancer cell line human CVCL_SE47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15629; B3GNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124806 CVCL_SE49 HAP1 B4GALNT2 (-) 1 cancer cell line human CVCL_SE49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24136; B4GALNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124807 CVCL_JK92 MES25 embryonic stem cell CVCL_JK92 CL:0000010 Female 21124808 CVCL_JK91 MES24 embryonic stem cell CVCL_JK91 CL:0000010 Male 21124809 CVCL_JK94 MES27 embryonic stem cell CVCL_JK94 CL:0000010 Male 21124810 CVCL_JK93 MES26 embryonic stem cell CVCL_JK93 CL:0000010 Unspecified 21124811 CVCL_JK90 MES23 embryonic stem cell CVCL_JK90 CL:0000010 Unspecified 21124812 CVCL_SE31 HAP1 ATXN2 (-) 2 cancer cell line human CVCL_SE31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10555; ATXN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124813 CVCL_SE30 HAP1 ATXN2 (-) 1 cancer cell line human CVCL_SE30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10555; ATXN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124814 CVCL_SE33 HAP1 AXIN1 (-) 1 cancer cell line human CVCL_SE33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124815 CVCL_SE32 HAP1 ATXN3 (-) cancer cell line human CVCL_SE32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7106; ATXN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124816 CVCL_SE35 HAP1 AXIN1 (-) 3 cancer cell line human CVCL_SE35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124817 CVCL_SE34 HAP1 AXIN1 (-) 2 cancer cell line human CVCL_SE34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124818 CVCL_SE37 HAP1 AXIN1 (-) 5 cancer cell line human CVCL_SE37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124819 CVCL_JK89 MES22 embryonic stem cell CVCL_JK89 CL:0000010 Male 21124820 CVCL_SE36 HAP1 AXIN1 (-) 4 cancer cell line human CVCL_SE36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 903; AXIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124821 CVCL_JK88 MES21 embryonic stem cell CVCL_JK88 CL:0000010 Unspecified 21124822 CVCL_SE39 HAP1 AXL (-) cancer cell line human CVCL_SE39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 905; AXL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124823 CVCL_SE38 HAP1 AXIN2 (-) 1 cancer cell line human CVCL_SE38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 904; AXIN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124824 CVCL_JK85 MES17 embryonic stem cell CVCL_JK85 CL:0000010 Female 21124825 CVCL_JK84 MES16 embryonic stem cell CVCL_JK84 CL:0000010 Male 21124826 CVCL_JK87 MES20 embryonic stem cell CVCL_JK87 CL:0000010 Male 21124827 CVCL_JK86 MES19 embryonic stem cell CVCL_JK86 CL:0000010 Female 21124828 CVCL_SE20 HAP1 ATP6V1H (-) 2 cancer cell line human CVCL_SE20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18303; ATP6V1H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124829 CVCL_SE22 HAP1 ATP9B (-) 1 cancer cell line human CVCL_SE22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13541; ATP9B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124830 CVCL_SE21 HAP1 ATP9A (-) 1 cancer cell line human CVCL_SE21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13540; ATP9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124831 CVCL_SE24 HAP1 ATPAF1 (-) 2 cancer cell line human CVCL_SE24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18803; ATPAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124832 CVCL_SE23 HAP1 ATPAF1 (-) 1 cancer cell line human CVCL_SE23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18803; ATPAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124833 CVCL_SE26 HAP1 ATPAF2 (-) 2 cancer cell line human CVCL_SE26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18802; ATPAF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124834 CVCL_SE25 HAP1 ATPAF2 (-) 1 cancer cell line human CVCL_SE25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18802; ATPAF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124835 CVCL_JK99 OVC.EX.1 embryonic stem cell dog CVCL_JK99 CL:0000010 Unspecified 21124836 CVCL_SE28 HAP1 ATPIF1 (-) 2 cancer cell line human CVCL_SE28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 871; ATP5IF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124837 CVCL_SE27 HAP1 ATPIF1 (-) 1 cancer cell line human CVCL_SE27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 871; ATP5IF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124838 CVCL_JK96 MES29 embryonic stem cell CVCL_JK96 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21124839 CVCL_SE29 HAP1 ATRX (-) 1 cancer cell line human CVCL_SE29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124840 CVCL_JK95 MES28 embryonic stem cell CVCL_JK95 CL:0000010 Unspecified 21124841 CVCL_JK98 cES2 embryonic stem cell dog CVCL_JK98 CL:0000010 Breed/subspecies: Beagle. Unspecified 21124842 CVCL_JK97 cES1 embryonic stem cell dog CVCL_JK97 CL:0000010 Breed/subspecies: Beagle. Unspecified 21124843 CVCL_JK70 iNV14 induced pluripotent stem cell CVCL_JK70 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124844 CVCL_JK72 iNV16 induced pluripotent stem cell CVCL_JK72 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124845 CVCL_JK71 iNV15 induced pluripotent stem cell CVCL_JK71 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124846 CVCL_SE11 HAP1 ATP1A3 (-) 1 cancer cell line human CVCL_SE11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 801; ATP1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124847 CVCL_SE10 HAP1 ATP13A2 (-) 2 cancer cell line human CVCL_SE10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30213; ATP13A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124848 CVCL_SE13 HAP1 ATP5I (-) 2 cancer cell line human CVCL_SE13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 846; ATP5ME; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124849 CVCL_SE12 HAP1 ATP5I (-) 1 cancer cell line human CVCL_SE12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 846; ATP5ME; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124850 CVCL_SE15 HAP1 ATP5J (-) 1 cancer cell line human CVCL_SE15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 847; ATP5PF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124851 CVCL_JK67 iNV11 induced pluripotent stem cell CVCL_JK67 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Male 21124852 CVCL_SE14 HAP1 ATP5I (-) 3 cancer cell line human CVCL_SE14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 846; ATP5ME; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124853 CVCL_JK66 iNV10 induced pluripotent stem cell CVCL_JK66 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124854 CVCL_SE17 HAP1 ATP6V0A2 (-) 1 cancer cell line human CVCL_SE17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18481; ATP6V0A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124855 CVCL_JK69 iNV13 induced pluripotent stem cell CVCL_JK69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124856 CVCL_SE16 HAP1 ATP5J (-) 2 cancer cell line human CVCL_SE16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 847; ATP5PF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124857 CVCL_JK68 iNV12 induced pluripotent stem cell CVCL_JK68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124858 CVCL_SE19 HAP1 ATP6V1H (-) 1 cancer cell line human CVCL_SE19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18303; ATP6V1H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124859 CVCL_JK63 iNV7 induced pluripotent stem cell CVCL_JK63 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Male 21124860 CVCL_SE18 HAP1 ATP6V0A2 (-) 2 cancer cell line human CVCL_SE18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18481; ATP6V0A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124861 CVCL_JK62 iNV6 induced pluripotent stem cell CVCL_JK62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124862 CVCL_JK65 iNV9 induced pluripotent stem cell CVCL_JK65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124863 CVCL_JK64 iNV8 induced pluripotent stem cell CVCL_JK64 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124864 CVCL_JK81 MES13 embryonic stem cell CVCL_JK81 CL:0000010 Female 21124865 CVCL_JK80 MES12 embryonic stem cell CVCL_JK80 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21124866 CVCL_JK83 MES15 embryonic stem cell CVCL_JK83 CL:0000010 Female 21124867 CVCL_JK82 MES14 embryonic stem cell CVCL_JK82 CL:0000010 Male 21124868 CVCL_SE00 HAP1 ATG5 (-) 1 cancer cell line human CVCL_SE00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 589; ATG5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124869 CVCL_SE02 HAP1 ATG7 (-) 1 cancer cell line human CVCL_SE02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16935; ATG7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124870 CVCL_SE01 HAP1 ATG5 (-) 2 cancer cell line human CVCL_SE01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 589; ATG5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124871 CVCL_SE04 HAP1 ATG7 (-) 3 cancer cell line human CVCL_SE04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16935; ATG7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124872 CVCL_JK78 iNV22 induced pluripotent stem cell CVCL_JK78 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124873 CVCL_SE03 HAP1 ATG7 (-) 2 cancer cell line human CVCL_SE03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16935; ATG7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124874 CVCL_JK77 iNV21 induced pluripotent stem cell CVCL_JK77 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124875 CVCL_SE06 HAP1 ATG9A (-) 2 cancer cell line human CVCL_SE06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124876 CVCL_SE05 HAP1 ATG9A (-) 1 cancer cell line human CVCL_SE05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124877 CVCL_JK79 MES11 embryonic stem cell CVCL_JK79 CL:0000010 Male 21124878 CVCL_SE08 HAP1 ATP11C (-) 1 cancer cell line human CVCL_SE08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13554; ATP11C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124879 CVCL_JK74 iNV18 induced pluripotent stem cell CVCL_JK74 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124880 CVCL_SE07 HAP1 ATG9A (-) 3 cancer cell line human CVCL_SE07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124881 CVCL_JK73 iNV17 induced pluripotent stem cell CVCL_JK73 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124882 CVCL_JK76 iNV20 induced pluripotent stem cell CVCL_JK76 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124883 CVCL_SE09 HAP1 ATP13A2 (-) 1 cancer cell line human CVCL_SE09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30213; ATP13A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124884 CVCL_JK75 iNV19 induced pluripotent stem cell CVCL_JK75 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21124885 CVCL_9940 FY-hES-21 embryonic stem cell human CVCL_9940 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124886 CVCL_8X40 HH0307 finite cell line human CVCL_8X40 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;2)(q32;p25) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124887 CVCL_9935 FY-hES-16 embryonic stem cell human CVCL_9935 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124888 CVCL_8X35 HH0299 finite cell line human CVCL_8X35 CL:0000010 Population: Caucasian; Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124889 CVCL_9934 FY-hES-15 embryonic stem cell human CVCL_9934 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124890 CVCL_8X34 HH0297 finite cell line human CVCL_8X34 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(7)(q34) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124891 CVCL_9937 FY-hES-18 embryonic stem cell human CVCL_9937 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124892 CVCL_8X37 HH0302 transformed cell line human CVCL_8X37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21124893 CVCL_9936 FY-hES-17 embryonic stem cell human CVCL_9936 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124894 CVCL_8X36 HH0301 transformed cell line human CVCL_8X36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21124895 CVCL_9931 FY-hES-12 embryonic stem cell human CVCL_9931 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124896 CVCL_8X31 HH0273 finite cell line human CVCL_8X31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21124897 CVCL_9930 FY-hES-11 embryonic stem cell human CVCL_9930 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124898 CVCL_8X30 HH0244 finite cell line human CVCL_8X30 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21124899 CVCL_9933 FY-hES-14 embryonic stem cell human CVCL_9933 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124900 CVCL_8X33 HH0295 finite cell line human CVCL_8X33 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(7)(q34) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124901 CVCL_9932 FY-hES-13 embryonic stem cell human CVCL_9932 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124902 CVCL_8X32 HH0279 finite cell line human CVCL_8X32 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(1)(q25;q32) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124903 CVCL_9939 FY-hES-20 embryonic stem cell human CVCL_9939 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124904 CVCL_8X39 HH0305 finite cell line human CVCL_8X39 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;5)(p32;q35)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21124905 CVCL_9938 FY-hES-19 embryonic stem cell human CVCL_9938 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124906 CVCL_8X38 HH0304 finite cell line human CVCL_8X38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(11;22)(q23;q11.2) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124907 CVCL_8X51 HH0319 finite cell line human CVCL_8X51 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21124908 CVCL_9951 UCLA 1 embryonic stem cell human CVCL_9951 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0058 21124909 CVCL_8X50 HH0318 finite cell line human CVCL_8X50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21124910 CVCL_9950 SNUhES4 embryonic stem cell human CVCL_9950 From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean. Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010006 21124911 CVCL_8X46 HH0314 finite cell line human CVCL_8X46 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(4)(p15.2->pter) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124912 CVCL_9946 SNUhES11 embryonic stem cell human CVCL_9946 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010011. 21124913 CVCL_8X45 HH0313 finite cell line human CVCL_8X45 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,-15,+(15),t(15;Y)(p12;q12) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124914 CVCL_9945 SNUhES1 embryonic stem cell human CVCL_9945 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010003. 21124915 CVCL_8X48 HH0316 finite cell line human CVCL_8X48 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+18,t(1;6)(p32;q25) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124916 CVCL_9948 SNUhES2 embryonic stem cell human CVCL_9948 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010004. 21124917 CVCL_8X47 HH0315 transformed cell line human CVCL_8X47 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;21)(q11;p11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21124918 CVCL_9947 SNUhES16 embryonic stem cell human CVCL_9947 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010014. 21124919 CVCL_9942 FY-hES-23 embryonic stem cell human CVCL_9942 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124920 CVCL_8X42 HH0310 finite cell line human CVCL_8X42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;16)(p32;q22) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124921 CVCL_9941 FY-hES-22 embryonic stem cell human CVCL_9941 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124922 CVCL_8X41 HH0309 finite cell line human CVCL_8X41 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-18,+der(18)t(4;18)(q33;p11.2)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21124923 CVCL_9944 FY-hES-25 embryonic stem cell human CVCL_9944 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124924 CVCL_8X44 HH0312 finite cell line human CVCL_8X44 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;6)(q35;q15) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124925 CVCL_9943 FY-hES-24 embryonic stem cell human CVCL_9943 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124926 CVCL_8X43 HH0311 finite cell line human CVCL_8X43 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+der(22)t(11;22) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124927 CVCL_8X49 HH0317 finite cell line human CVCL_8X49 CL:0000010 Karyotypic information: 46,XX,del(13)(q12;q14) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124928 CVCL_9949 SNUhES3 embryonic stem cell human CVCL_9949 From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean. Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010005 21124929 CVCL_8X13 HH0115 finite cell line human CVCL_8X13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(2q) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124930 CVCL_9913 UKF-NB-4rCDDP1000 cancer cell line human CVCL_9913 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21124931 CVCL_8X12 HH0113 finite cell line human CVCL_8X12 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;4) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124932 CVCL_8X15 HH0118 finite cell line human CVCL_8X15 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124933 CVCL_9915 UKF-NB-4rVCR50 cancer cell line human CVCL_9915 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21124934 CVCL_8X14 HH0117 finite cell line human CVCL_8X14 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;9)(p11.2;p13) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124935 CVCL_9914 UKF-NB-4rDOX350 cancer cell line human CVCL_9914 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21124936 CVCL_8X11 HH0110 finite cell line human CVCL_8X11 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX; 47,XX,+2; 47,XX,+21 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124937 CVCL_8X10 HH0108 finite cell line human CVCL_8X10 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;14)(q21;q32) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21124938 CVCL_9910 UKF-NB-2rVCR10 cancer cell line human CVCL_9910 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Doubling time: 27 hours (PubMed=12532417) Part of: Resistant Cancer Cell Line (RCCL) collection 21124939 CVCL_9917 FB-2 cancer cell line human CVCL_9917 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00200 Problematic cell line: Contaminated Shown to be a TPC-1 derivative (PubMed=19087340; PubMed=20143388). Originally thought to originate from a 36 year old female patient with a well-differentiated thyroid papillary carcinoma. 21124940 CVCL_8X17 HH0121 finite cell line human CVCL_8X17 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+21 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124941 CVCL_8X16 HH0119 finite cell line human CVCL_8X16 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+22 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124942 CVCL_9916 XTC.UC1 cancer cell line human CVCL_9916 CL:0000010 Sequence variation: Mutation; HGNC; 7427; MT-CYB; Simple; p.Glu271Lys (m.15557G>A); ClinVar=VCV000693906; Zygosity=Heteroplasmic; Note=In 70.3% (PubMed=16778181); Sequence variation: Mutation; HGNC; 7455; MT-ND1; Simple; p.Gly101Ter (m.3571insC); Zygosity=Heteroplasmic; Note=In 94.3% (PubMed=16778181); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Val380Leu (c.1138G>C); ClinVar=VCV000041221; Zygosity=Homozygous; Note=Germline (PubMed=26354775); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Thr (c.451C>A); ClinVar=VCV000012369; Zygosity=Homozygous (PubMed=31443247) Miscellaneous: STR profile from personal communication of Marlow L.A Derived from metastatic site: Breast. Omics: Mitochondrial genome sequenced Female Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502) Doubling time: 103 +- 6.7 hours (PubMed=9669284) 21124943 CVCL_8X19 HH0123 finite cell line human CVCL_8X19 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+f (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124944 CVCL_9919 YK-M2 cancer cell line human CVCL_9919 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~60 hours (PubMed=3465438) 21124945 CVCL_9918 GLAG-66 cancer cell line human CVCL_9918 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from child cell line K1); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from child cell line K1); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from child cell line K1) Population: Caucasian; Italian; Derived from metastatic site: Thyroid gland. Male 21124946 CVCL_8X18 HH0122 finite cell line human CVCL_8X18 CL:0000010 Karyotypic information: 46,XX,del(1)(q31) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124947 CVCL_9924 FY-hES-4 embryonic stem cell human CVCL_9924 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124948 CVCL_8X24 HH0131 finite cell line human CVCL_8X24 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+(16) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124949 CVCL_9923 FY-hES-3 embryonic stem cell human CVCL_9923 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124950 CVCL_8X23 HH0130 finite cell line human CVCL_8X23 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124951 CVCL_9926 FY-hES-7 embryonic stem cell human CVCL_9926 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124952 CVCL_8X26 HH0133 finite cell line human CVCL_8X26 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+22 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124953 CVCL_9925 FY-hES-5 embryonic stem cell human CVCL_9925 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124954 CVCL_8X25 HH0132 finite cell line human CVCL_8X25 CL:0000010 Population: Caucasian; Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124955 CVCL_8X20 HH0127 finite cell line human CVCL_8X20 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,dup(X)(q26->q27) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124956 CVCL_9920 ZK-58 cancer cell line human CVCL_9920 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792). Male 21124957 CVCL_9922 FY-hES-1 embryonic stem cell human CVCL_9922 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124958 CVCL_8X22 HH0129 finite cell line human CVCL_8X22 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124959 CVCL_9921 ch-2879 cancer cell line human CVCL_9921 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 5383; IDH2; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Derived from sampling site: Bone; rib. Female 21124960 CVCL_8X21 HH0128 finite cell line human CVCL_8X21 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX; 47,XX,+f (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124961 CVCL_9928 FY-hES-9 embryonic stem cell human CVCL_9928 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21124962 CVCL_8X28 HH0135 finite cell line human CVCL_8X28 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(4;18)(q25;p11.2) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124963 CVCL_9927 FY-hES-8 embryonic stem cell human CVCL_9927 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21124964 CVCL_8X27 HH0134 finite cell line human CVCL_8X27 CL:0000010 Population: Caucasian; Derived from sampling site: Amniotic fluid. Unspecified Part of: ECACC chromosomal abnormality collection 21124965 CVCL_9929 FY-hES-10 embryonic stem cell human CVCL_9929 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21124966 CVCL_8X29 HH0139 finite cell line human CVCL_8X29 CL:0000010 Karyotypic information: 46,XX; 47,XX,+i(12p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124967 CVCL_8X02 HH0096 finite cell line human CVCL_8X02 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(2;14)(p11.2;11.2) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124968 CVCL_9902 UKF-NB-2 cancer cell line human CVCL_9902 CL:0000010 Derived from metastatic site: Bone marrow. Doubling time: 22.5-25.6 hours (PubMed=9443419); 25 hours (PubMed=12532417) 21124969 CVCL_8X01 HH0095 finite cell line human CVCL_8X01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 46,XY,inv(21) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124970 CVCL_9901 NBL-W S cancer cell line human CVCL_9901 CL:0000010 Male 21124971 CVCL_8X04 HH0102 finite cell line human CVCL_8X04 CL:0000010 Population: Caucasian; Karyotypic information: 48,XX,+i(Yq)+i(Yq) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124972 CVCL_9904 UKF-NB-3 cancer cell line human CVCL_9904 CL:0000010 Derived from metastatic site: Bone marrow. Female Doubling time: 22 +- 1.9 hours (PubMed=16142320) 21124973 CVCL_8X03 HH0098 finite cell line human CVCL_8X03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,+f (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124974 CVCL_9903 UKF-NB-2AD169 cancer cell line human CVCL_9903 CL:0000010 Derived from metastatic site: Bone marrow. Virology: Persistently infected with human cytomegalovirus (HCMV) strain AD169 Doubling time: 28.2-31.5 hours (PubMed=9443419) 21124975 CVCL_8X00 HH0094 finite cell line human CVCL_8X00 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+i(12p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124976 CVCL_9900 NBL-W N cancer cell line human CVCL_9900 CL:0000010 Male 21124977 CVCL_8X09 HH0107 finite cell line human CVCL_8X09 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(7)(q11;q34) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124978 CVCL_9909 UKF-NB-2rDOX100 cancer cell line human CVCL_9909 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Doubling time: 21 hours (PubMed=12532417) Part of: Resistant Cancer Cell Line (RCCL) collection 21124979 CVCL_8X06 HH0104 finite cell line human CVCL_8X06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(9;22) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21124980 CVCL_9906 UKF-NB-3rDOX100 cancer cell line human CVCL_9906 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21124981 CVCL_8X05 HH0103 finite cell line human CVCL_8X05 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+mar (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124982 CVCL_9905 UKF-NB-3rVCR10 cancer cell line human CVCL_9905 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (PubMed=16142320; PubMed=19147553; PubMed=22170099) Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female Doubling time: 19 +- 2.1 hours (PubMed=16142320) Part of: Resistant Cancer Cell Line (RCCL) collection 21124983 CVCL_8X08 HH0106 finite cell line human CVCL_8X08 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,dup(Xq) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21124984 CVCL_9908 UKF-NB-2rCDDP1000 cancer cell line human CVCL_9908 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21124985 CVCL_8X07 HH0105 finite cell line human CVCL_8X07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 46,XY,del(5p) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21124986 CVCL_9907 UKF-NB-4 cancer cell line human CVCL_9907 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=19147553) Derived from metastatic site: Bone marrow. Doubling time: 19.5-20.3 hours (PubMed=8543403) 21124987 CVCL_SE91 HAP1 BCL2 (-) 1 cancer cell line human CVCL_SE91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124988 CVCL_SE90 HAP1 BCL11B (-) 2 cancer cell line human CVCL_SE90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13222; BCL11B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124989 CVCL_SE93 HAP1 BCL2 (-) 3 cancer cell line human CVCL_SE93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124990 CVCL_SE92 HAP1 BCL2 (-) 2 cancer cell line human CVCL_SE92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124991 CVCL_SE95 HAP1 BCL2L2 (-) 1 cancer cell line human CVCL_SE95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 995; BCL2L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124992 CVCL_SE94 HAP1 BCL2 (-) 4 cancer cell line human CVCL_SE94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 990; BCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124993 CVCL_SE97 HAP1 BCL2L2 (-) 3 cancer cell line human CVCL_SE97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 995; BCL2L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124994 CVCL_SE96 HAP1 BCL2L2 (-) 2 cancer cell line human CVCL_SE96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 995; BCL2L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124995 CVCL_SE99 HAP1 BCL3 (-) 2 cancer cell line human CVCL_SE99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 998; BCL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124996 CVCL_SE98 HAP1 BCL3 (-) 1 cancer cell line human CVCL_SE98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 998; BCL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124997 CVCL_SE80 HAP1 BAZ2B (-) 5 cancer cell line human CVCL_SE80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124998 CVCL_SE82 HAP1 BBC3 (-) cancer cell line human CVCL_SE82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17868; BBC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21124999 CVCL_SE81 HAP1 BAZ2B (-) 6 cancer cell line human CVCL_SE81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 963; BAZ2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125000 CVCL_SE84 HAP1 BCHE (-) 2 cancer cell line human CVCL_SE84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 983; BCHE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125001 CVCL_SE83 HAP1 BCHE (-) 1 cancer cell line human CVCL_SE83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 983; BCHE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125002 CVCL_SE86 HAP1 BCKDK (-) cancer cell line human CVCL_SE86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16902; BCKDK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125003 CVCL_SE85 HAP1 BCHE (-) 3 cancer cell line human CVCL_SE85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 983; BCHE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125004 CVCL_SE88 HAP1 BCL11A (-) 2 cancer cell line human CVCL_SE88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13221; BCL11A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125005 CVCL_SE87 HAP1 BCL11A (-) 1 cancer cell line human CVCL_SE87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13221; BCL11A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125006 CVCL_SE89 HAP1 BCL11B (-) 1 cancer cell line human CVCL_SE89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13222; BCL11B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125007 CVCL_AQ39 CHLA-224 cancer cell line human CVCL_AQ39 CL:0000010 Male 21125008 CVCL_B239 LRB04 embryonic stem cell human CVCL_B239 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Male 21125009 CVCL_AQ38 CHLA-223 cancer cell line human CVCL_AQ38 CL:0000010 21125010 CVCL_B238 LRB03 embryonic stem cell human CVCL_B238 From: University Hospital of Copenhagen; Copenhagen; Denmark CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC08-16.. 21125011 CVCL_B231 KhES-1 embryonic stem cell human CVCL_B231 From: Institute for Frontier Medical Sciences, Kyoto University; Kyoto; Japan CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: SKIP; SKIP000147; probable. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0487 21125012 CVCL_AQ31 MDCK-E [Korea] spontaneously immortalized cell line dog CVCL_AQ31 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21125013 CVCL_B230 JB6 [Mouse] spontaneously immortalized cell line house mouse CVCL_B230 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21125014 CVCL_AQ30 SMS-SB cancer cell line human CVCL_AQ30 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125015 CVCL_B233 KhES-3 embryonic stem cell human CVCL_B233 From: Institute for Frontier Medical Sciences, Kyoto University; Kyoto; Japan CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male 21125016 CVCL_AQ33 TTC-1318 cancer cell line human CVCL_AQ33 CL:0000010 Male 21125017 CVCL_B232 KhES-2 embryonic stem cell human CVCL_B232 From: Institute for Frontier Medical Sciences, Kyoto University; Kyoto; Japan CL:0000010 Omics: Transcriptome analysis by microarray. Female 21125018 CVCL_AQ32 SJ-S6 cancer cell line human CVCL_AQ32 CL:0000010 Unspecified 21125019 CVCL_AQ35 CHLA-194 cancer cell line human CVCL_AQ35 CL:0000010 21125020 CVCL_B235 NIRRHe002-A embryonic stem cell human CVCL_B235 From: National Institute for Research in Reproductive Health; Mumbai; India. CL:0000010 Female 21125021 CVCL_AQ34 CHLA-192 cancer cell line human CVCL_AQ34 CL:0000010 21125022 CVCL_B234 NIRRHe001-A embryonic stem cell human CVCL_B234 From: National Institute for Research in Reproductive Health; Mumbai; India. CL:0000010 Female 21125023 CVCL_AQ37 CHLA-222 cancer cell line human CVCL_AQ37 CL:0000010 Male 21125024 CVCL_B237 LRB02 embryonic stem cell human CVCL_B237 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Male 21125025 CVCL_AQ36 CHLA-215 cancer cell line human CVCL_AQ36 CL:0000010 21125026 CVCL_B236 LRB01 embryonic stem cell human CVCL_B236 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Female 21125027 CVCL_8W98 HH0092 finite cell line human CVCL_8W98 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,inv(X)(p11;q28) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21125028 CVCL_9898 SK-N-BE(1) cancer cell line human CVCL_9898 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: ~4 days (PubMed=29704); 96 hours (COG) 21125029 CVCL_8W97 HH0091 finite cell line human CVCL_8W97 CL:0000010 Karyotypic information: 46,XY,-15,+der(15) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125030 CVCL_9897 NUB-7 cancer cell line human CVCL_9897 CL:0000010 Male Characteristics: Intermediate type (I-type) (PubMed=8043511) Doubling time: 38 hours (PubMed=3243386). 21125031 CVCL_8W99 HH0093 finite cell line human CVCL_8W99 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125032 CVCL_9899 NBL-W cancer cell line human CVCL_9899 CL:0000010 Male 21125033 CVCL_AQ49 COG-LL-402h cancer cell line human CVCL_AQ49 CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=35354797) Derived from sampling site: Bone marrow. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21125034 CVCL_B249 LRB16 embryonic stem cell human CVCL_B249 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125035 CVCL_AQ42 CHLA-06-ATRT cancer cell line human CVCL_AQ42 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His178Asp (c.532C>G); ClinVar=VCV000482223; Zygosity=Unspecified (DepMap) Derived from sampling site: Brain; cerebellum. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21125036 CVCL_B242 LRB07 embryonic stem cell human CVCL_B242 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125037 CVCL_AQ41 CHLA-05-ATRT cancer cell line human CVCL_AQ41 CL:0000010 Derived from sampling site: Brain; frontal lobe. Male 21125038 CVCL_B241 LRB06 embryonic stem cell human CVCL_B241 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125039 CVCL_AQ44 hTCEpi telomerase immortalized cell line human CVCL_AQ44 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Eye; cornea; epithelium. Male Doubling time: 24-32 hours (Evercyte) 21125040 CVCL_B244 LRB09 embryonic stem cell human CVCL_B244 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125041 CVCL_AQ43 CHLA-07-BSGBM cancer cell line human CVCL_AQ43 CL:0000010 Female 21125042 CVCL_B243 LRB08 embryonic stem cell human CVCL_B243 From: University Hospital of Copenhagen; Copenhagen; Denmark CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-05.. 21125043 CVCL_AQ46 HCEC 1CT+7 telomerase immortalized cell line human CVCL_AQ46 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Karyotypic information: Has acquired a chromosome 7 trisomy; Derived from sampling site: Colon Cell type=Epithelial cell.. Omics: Deep exome analysis Male 21125044 CVCL_B246 LRB11 embryonic stem cell human CVCL_B246 From: University Hospital of Copenhagen; Copenhagen; Denmark CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-51.. 21125045 CVCL_AQ45 HCEC 1CT telomerase immortalized cell line human CVCL_AQ45 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Colon Cell type=Epithelial cell.. Omics: Deep exome analysis Male Doubling time: 18-24 hours (Evercyte) 21125046 CVCL_B245 LRB10 embryonic stem cell human CVCL_B245 From: University Hospital of Copenhagen; Copenhagen; Denmark CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-51.. 21125047 CVCL_B248 LRB14 embryonic stem cell human CVCL_B248 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125048 CVCL_AQ48 RS transformed cell line human CVCL_AQ48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Discontinued: Evercyte; Catalog number CLT-003-0014 Male 21125049 CVCL_AQ47 HCEC 2CT telomerase immortalized cell line human CVCL_AQ47 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Colon Cell type=Epithelial cell.. Male 21125050 CVCL_B247 LRB13 embryonic stem cell human CVCL_B247 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125051 CVCL_AQ40 CHLA-246 cancer cell line human CVCL_AQ40 CL:0000010 21125052 CVCL_B240 LRB05 embryonic stem cell human CVCL_B240 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125053 CVCL_AQ17 CHLA-61 cancer cell line human CVCL_AQ17 CL:0000010 Male Doubling time: 102 hours (COG). 21125054 CVCL_B217 OP9/G stromal cell line house mouse CVCL_B217 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Discontinued: RCB; RCB2121; true Unspecified Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene 21125055 CVCL_AQ16 CHLA-53 cancer cell line human CVCL_AQ16 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 92 hours (COG) 21125056 CVCL_B216 HUES PGD 3 embryonic stem cell human CVCL_B216 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0091. 21125057 CVCL_AQ19 COG-N-316 cancer cell line human CVCL_AQ19 CL:0000010 Unspecified 21125058 CVCL_B219 OP9/N stromal cell line house mouse CVCL_B219 CL:0000010 Transfected with: HGNC; 7809; NGFR Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Discontinued: RCB; RCB2123; true Unspecified 21125059 CVCL_AQ18 COG-N-291 cancer cell line human CVCL_AQ18 CL:0000010 Characteristics: Has long and heterogeneous telomeres and no telomerase activity Its telomeres shortens continuously at an average rate of 80 base pairs per population doubling (PubMed=28636942). Doubling time: 3.4 days (PubMed=28636942); 224 hours (COG). 21125060 CVCL_B218 OP9/G-DLL1 stromal cell line house mouse CVCL_B218 CL:0000010 Transfected with: MGI; MGI:104659; Dll1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Discontinued: RCB; RCB2122; true Unspecified Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene 21125061 CVCL_8W83 HH0040 transformed cell line human CVCL_8W83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125062 CVCL_9883 STA-NB-1.1 cancer cell line human CVCL_9883 CL:0000010 Male 21125063 CVCL_8W82 HH0039 transformed cell line human CVCL_8W82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125064 CVCL_9882 MSN cancer cell line human CVCL_9882 CL:0000010 Female 21125065 CVCL_AQ11 CHLA-12 cancer cell line human CVCL_AQ11 CL:0000010 Doubling time: 65 hours (COG). 21125066 CVCL_8W85 HH0050 transformed cell line human CVCL_8W85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125067 CVCL_B211 HUES PGD 12 embryonic stem cell human CVCL_B211 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0095. 21125068 CVCL_9885 STA-NB-10 cancer cell line human CVCL_9885 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125069 CVCL_AQ10 CHLA-11 cancer cell line human CVCL_AQ10 CL:0000010 Doubling time: 53 hours (COG). 21125070 CVCL_8W84 HH0041 transformed cell line human CVCL_8W84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21125071 CVCL_B210 HUES PGD 11 embryonic stem cell human CVCL_B210 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0094. 21125072 CVCL_9884 STA-NB-1.2 cancer cell line human CVCL_9884 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125073 CVCL_AQ13 CHLA-145 cancer cell line human CVCL_AQ13 CL:0000010 21125074 CVCL_B213 HUES PGD 14 embryonic stem cell human CVCL_B213 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0136. 21125075 CVCL_AQ12 CHLA-144 cancer cell line human CVCL_AQ12 CL:0000010 21125076 CVCL_B212 HUES PGD 13 embryonic stem cell human CVCL_B212 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0090. 21125077 CVCL_AQ15 CHLA-253 cancer cell line human CVCL_AQ15 CL:0000010 Male 21125078 CVCL_8W81 HH0035 transformed cell line human CVCL_8W81 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;Y) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125079 CVCL_B215 HUES PGD 16 embryonic stem cell human CVCL_B215 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0150. 21125080 CVCL_9881 WSN cancer cell line human CVCL_9881 CL:0000010 Female 21125081 CVCL_AQ14 CHLA-247 cancer cell line human CVCL_AQ14 CL:0000010 Derived from metastatic site: Bone marrow. Male 21125082 CVCL_8W80 HH0033 transformed cell line human CVCL_8W80 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;6)(q27;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125083 CVCL_B214 HUES PGD 15 embryonic stem cell human CVCL_B214 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0149. 21125084 CVCL_9880 VA-N-BR cancer cell line human CVCL_9880 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen. Male Doubling time: 36 +- 6 hours (PubMed=1580564) 21125085 CVCL_8W79 HH0030 transformed cell line human CVCL_8W79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125086 CVCL_9879 MGH-MC-2 cancer cell line human CVCL_9879 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714). Unspecified 21125087 CVCL_9876 BJAB-K3 cancer cell line human CVCL_9876 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P12978; EBV EBNA2 Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21125088 CVCL_8W76 HH0025 transformed cell line human CVCL_8W76 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,-18,+i(18q); 47,XX,-18,+i(18q)+i(18p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125089 CVCL_9875 600MPE cancer cell line human CVCL_9875 HLA typing: A*29:02,29:02; B*44:02,44:02; C*16:02,16:02 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.1138-21_1138del22; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; c.219-1G>C; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19593635) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 85.17 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21125090 CVCL_8W75 HH0024 transformed cell line human CVCL_8W75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125091 CVCL_8W78 HH0029 transformed cell line human CVCL_8W78 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125092 CVCL_9878 MGH-MC-1 cancer cell line human CVCL_9878 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714). Unspecified 21125093 CVCL_9877 HCC1739 cancer cell line human CVCL_9877 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Discontinued: ATCC; CRL-2333; true Female Group: Triple negative breast cancer (TNBC) cell line 21125094 CVCL_8W77 HH0027 transformed cell line human CVCL_8W77 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,inv dup(15)(q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125095 CVCL_AQ28 SMS-KCL transformed cell line human CVCL_AQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21125096 CVCL_B228 Sup-M2-TS cancer cell line human CVCL_B228 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=26657151) Population: Caucasian; Derived from sampling site: Cerebrospinal fluid. Female 21125097 CVCL_AQ27 CHLA-255 cancer cell line human CVCL_AQ27 CL:0000010 Derived from metastatic site: Brain. Unspecified 21125098 CVCL_B227 UM-RC-5 cancer cell line human CVCL_B227 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Tyr175Serfs*27 (c.524delA); Zygosity=Unspecified (PubMed=7915601; PubMed=8493574). Unspecified Doubling time: ~43 hours (PubMed=4038766) 21125099 CVCL_B229 NB-39-nu cancer cell line human CVCL_B229 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male Characteristics: Established from a xenograft produced in athymic nude mice Doubling time: 41 hours (DOI=10.11418/jtca1981.8.2_6) 21125100 CVCL_AQ29 SMS-SAL transformed cell line human CVCL_AQ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21125101 CVCL_AQ20 COG-N-321 cancer cell line human CVCL_AQ20 CL:0000010 Male 21125102 CVCL_8W94 HH0068 transformed cell line human CVCL_8W94 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX; 47,XX,+18 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125103 CVCL_B220 OP9/N-DLL1 stromal cell line house mouse CVCL_B220 CL:0000010 Transfected with: HGNC; 7809; NGFR; Transfected with: MGI; MGI:104659; Dll1 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Discontinued: RCB; RCB2124; true Unspecified 21125104 CVCL_9894 STA-NB-9 cancer cell line human CVCL_9894 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Female 21125105 CVCL_8W93 HH0066 transformed cell line human CVCL_8W93 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125106 CVCL_9893 STA-NB-8 cancer cell line human CVCL_9893 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Female 21125107 CVCL_B222 A375-M cancer cell line human CVCL_B222 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Metastatic variant of A-375 Established from a tumor obtained in nude mice injected with the parent cell line. 21125108 CVCL_AQ22 COG-N-399 cancer cell line human CVCL_AQ22 CL:0000010 Male Doubling time: 40 hours (COG). 21125109 CVCL_8W96 HH0085 finite cell line human CVCL_8W96 CL:0000010 Population: Caucasian; Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125110 CVCL_9896 NUB-6 cancer cell line human CVCL_9896 CL:0000010 Unspecified Doubling time: 48 hours (PubMed=3243386). 21125111 CVCL_AQ21 COG-N-347 cancer cell line human CVCL_AQ21 CL:0000010 Male Doubling time: 126 hours (COG). 21125112 CVCL_8W95 HH0073 transformed cell line human CVCL_8W95 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 46,XY,5p- (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125113 CVCL_9895 RN-GA cancer cell line human CVCL_9895 CL:0000010 Derived from sampling site: Adrenal gland. Female Doubling time: 21 hours (PubMed=2703273) 21125114 CVCL_B221 UACC-3133 cancer cell line human CVCL_B221 CL:0000010 Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). 21125115 CVCL_AQ24 COG-N-421 cancer cell line human CVCL_AQ24 CL:0000010 Male Doubling time: 65 hours (COG). 21125116 CVCL_8W90 HH0059 transformed cell line human CVCL_8W90 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,18p- (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125117 CVCL_9890 STA-NB-5 cancer cell line human CVCL_9890 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125118 CVCL_B224 UOK181 cancer cell line human CVCL_B224 CL:0000010 Derived from sampling site: Kidney. Male 21125119 CVCL_AQ23 COG-N-415 cancer cell line human CVCL_AQ23 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=28350380) Omics: ATAC-seq; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 50 hours (COG) 21125120 CVCL_B223 UOK171 cancer cell line human CVCL_B223 CL:0000010 Derived from sampling site: Kidney. Female 21125121 CVCL_AQ26 HEK 293 STF transformed cell line human CVCL_AQ26 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Responds to activation of the canonical Wnt signaling pathway by increasing expression of firefly luciferase Luciferase reporter gene expression is under the control of a promoter with 7 LEF/TCF binding sites (PubMed=15035989). 21125122 CVCL_8W92 HH0063 transformed cell line human CVCL_8W92 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX; 47,XX,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125123 CVCL_9892 STA-NB-7 cancer cell line human CVCL_9892 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125124 CVCL_B226 UM-RC-11 cancer cell line human CVCL_B226 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.407_408ins?; Zygosity=Unspecified (PubMed=7915601). 21125125 CVCL_AQ25 COG-N-440 cancer cell line human CVCL_AQ25 CL:0000010 Omics: ATAC-seq; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 65 hours (COG) 21125126 CVCL_8W91 HH0061 transformed cell line human CVCL_8W91 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,dir ins(2;18)(q2.1;q11.2 q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125127 CVCL_9891 STA-NB-6 cancer cell line human CVCL_9891 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125128 CVCL_B225 UOK143 cancer cell line human CVCL_B225 CL:0000010 Derived from sampling site: Kidney. Male 21125129 CVCL_8W87 HH0055 transformed cell line human CVCL_8W87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;5;12)(q12;q11;p11),t(6;17)(p21;q21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125130 CVCL_9887 STA-NB-2 cancer cell line human CVCL_9887 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from metastatic site: Bone marrow. Male 21125131 CVCL_8W86 HH0052 transformed cell line human CVCL_8W86 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;13)(q31;q32) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125132 CVCL_9886 STA-NB-11 cancer cell line human CVCL_9886 From: Children's Cancer Research Institute; Vienna; Austria. CL:0000010 Male 21125133 CVCL_8W89 HH0057 transformed cell line human CVCL_8W89 CL:0000010 Population: Caucasian; Karyotypic information: 45,X (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125134 CVCL_9889 STA-NB-4 cancer cell line human CVCL_9889 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: SNP array analysis Male 21125135 CVCL_8W88 HH0056 transformed cell line human CVCL_8W88 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+i(Xq) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125136 CVCL_9888 STA-NB-3 cancer cell line human CVCL_9888 From: Children's Cancer Research Institute; Vienna; Austria CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Female 21125137 CVCL_8W61 HH0006 transformed cell line human CVCL_8W61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125138 CVCL_9861 VUB27 embryonic stem cell human CVCL_9861 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Male 21125139 CVCL_8W60 HH0005 transformed cell line human CVCL_8W60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125140 CVCL_9860 VUB26 embryonic stem cell human CVCL_9860 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125141 CVCL_8W63 HH0008 transformed cell line human CVCL_8W63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125142 CVCL_9863 HPL1A transformed cell line human CVCL_9863 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; parenchyma Cell type=Epithelial cell.. Female 21125143 CVCL_8W62 HH0007 transformed cell line human CVCL_8W62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125144 CVCL_9862 VUB28_HD_MFS embryonic stem cell human CVCL_9862 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125145 CVCL_8W58 GW0013 undefined cell line type human CVCL_8W58 CL:0000010 Population: Mexican. Unspecified Part of: ECACC chromosomal abnormality collection 21125146 CVCL_9858 VUB23_OI embryonic stem cell human CVCL_9858 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Unspecified 21125147 CVCL_8W57 GW0012 undefined cell line type human CVCL_8W57 CL:0000010 Population: Mexican. Unspecified Part of: ECACC chromosomal abnormality collection 21125148 CVCL_9857 VUB22_CF embryonic stem cell human CVCL_9857 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20224973). Female 21125149 CVCL_8W59 HH0004 finite cell line human CVCL_8W59 CL:0000010 Population: Caucasian; Karyotypic information: 46,Y,Xp- (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125150 CVCL_9859 VUB24_DM1 embryonic stem cell human CVCL_9859 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1800] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=20224973). Female 21125151 CVCL_8W54 GT0002 transformed cell line human CVCL_8W54 CL:0000010 Population: Asian; Karyotypic information: 46,XY,inv(13)(q31.3;q32.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125152 CVCL_9854 VUB19_DM1 embryonic stem cell human CVCL_9854 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~250] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=20224973). Female 21125153 CVCL_8W53 GT0001 transformed cell line human CVCL_8W53 CL:0000010 Population: Asian; Karyotypic information: 46,XY,inv(13)(q31.3;q32.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125154 CVCL_9853 VUB17 embryonic stem cell human CVCL_9853 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125155 CVCL_8W56 GW0011 undefined cell line type human CVCL_8W56 CL:0000010 Population: Mexican. Unspecified Part of: ECACC chromosomal abnormality collection 21125156 CVCL_9856 VUB21_HEMA embryonic stem cell human CVCL_9856 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Unspecified 21125157 CVCL_8W55 GT0013 transformed cell line human CVCL_8W55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125158 CVCL_9855 VUB20_CMT1A embryonic stem cell human CVCL_9855 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125159 CVCL_B206 HUES 70 embryonic stem cell human CVCL_B206 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0177 21125160 CVCL_AQ06 MJ-173 hybridoma house mouse CVCL_AQ06 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5302 21125161 CVCL_B205 HUES 7 embryonic stem cell human CVCL_B205 HLA typing: A*02:03; B*35,51; C*04,14; DQB1*03,06; DRB1*04,15; DRB5*01 (PubMed=16919167). From: Harvard University; Boston; USA CL:0000010 Male Doubling time: 48 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0020; Registration: UK Stem Cell Bank (UKSCB); R-05-035, Steering comm appl. SCSC04-25(7). 21125162 CVCL_AQ05 MJ-172 hybridoma house mouse CVCL_AQ05 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5288 21125163 CVCL_B208 HUES PGD 1 embryonic stem cell human CVCL_B208 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0148. 21125164 CVCL_AQ08 Py230 cancer cell line house mouse CVCL_AQ08 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6 MMTV-PyMT transgenic. Female 21125165 CVCL_AQ07 BT-474 Clone 5 cancer cell line human CVCL_AQ07 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from sampling site: Breast. Female 21125166 CVCL_B207 HUES 8 embryonic stem cell human CVCL_B207 From: Harvard University; Boston; USA CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: 48 hours (PubMed=14999088) Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0021; Registration: Swiss research registry; BAG-hES-IMP-0056; Registration: UK Stem Cell Bank (UKSCB); R-06-018, Steering comm appl. SCSC04-25(8). 21125167 CVCL_B209 HUES PGD 10 embryonic stem cell human CVCL_B209 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0179. 21125168 CVCL_AQ09 Py8119 cancer cell line house mouse CVCL_AQ09 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6 MMTV-PyMT transgenic. Female 21125169 CVCL_9872 HepG2-WT10 cancer cell line human CVCL_9872 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21125170 CVCL_8W72 HH0020 transformed cell line human CVCL_8W72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125171 CVCL_9871 267B1/Ki-ras transformed cell line human CVCL_9871 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21125172 CVCL_8W71 HH0019 transformed cell line human CVCL_8W71 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125173 CVCL_AQ00 A375-VR [2015] cancer cell line human CVCL_AQ00 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Skin. Female 21125174 CVCL_9874 HepG2-DM2 cancer cell line human CVCL_9874 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21125175 CVCL_8W74 HH0023 transformed cell line human CVCL_8W74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125176 CVCL_B200 HUES 65 embryonic stem cell human CVCL_B200 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0056 21125177 CVCL_9873 HepG2-SM1 cancer cell line human CVCL_9873 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21125178 CVCL_8W73 HH0021 transformed cell line human CVCL_8W73 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(9) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125179 CVCL_AQ02 D16 [Mouse fat cell] spontaneously immortalized cell line house mouse CVCL_AQ02 CL:0000010 Derived from sampling site: Inguinal subcutaneous fat depot; Breed/subspecies: 129S6/SvEvTac. Male 21125180 CVCL_B202 HUES 67 embryonic stem cell human CVCL_B202 From: Harvard University; Boston; USA. CL:0000010 Unspecified 21125181 CVCL_AQ01 D12 spontaneously immortalized cell line house mouse CVCL_AQ01 CL:0000010 Derived from sampling site: Inguinal fat pad; adipose tissue Cell type=Beige adipocyte.; Breed/subspecies: 129S6/SvEvTac. Male 21125182 CVCL_B201 HUES 66 embryonic stem cell human CVCL_B201 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0057 21125183 CVCL_9870 HEK-293CymR transformed cell line human CVCL_9870 CL:0000010 Transfected with: UniProtKB; O33453; Pseudomonas putida cymR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125184 CVCL_8W70 HH0018 transformed cell line human CVCL_8W70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125185 CVCL_B204 HUES 69 embryonic stem cell human CVCL_B204 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0178 21125186 CVCL_AQ04 MJ-171 hybridoma house mouse CVCL_AQ04 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5287 21125187 CVCL_B203 HUES 68 embryonic stem cell human CVCL_B203 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0176 21125188 CVCL_AQ03 MJ-170 hybridoma house mouse CVCL_AQ03 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5286 21125189 CVCL_9869 HEK-293B2 transformed cell line human CVCL_9869 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: UniProtKB; P42212; GFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125190 CVCL_8W69 HH0015 transformed cell line human CVCL_8W69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125191 CVCL_9868 HEK-293-TrkB transformed cell line human CVCL_9868 CL:0000010 Transfected with: HGNC; 8032; NTRK2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125192 CVCL_8W68 HH0013 transformed cell line human CVCL_8W68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125193 CVCL_8W65 HH0010 transformed cell line human CVCL_8W65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125194 CVCL_9865 HPL1C transformed cell line human CVCL_9865 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; parenchyma Cell type=Epithelial cell.. Female 21125195 CVCL_8W64 HH0009 transformed cell line human CVCL_8W64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125196 CVCL_9864 HPL1B transformed cell line human CVCL_9864 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; parenchyma Cell type=Epithelial cell.. Female 21125197 CVCL_9867 D1-HEK-293 transformed cell line human CVCL_9867 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125198 CVCL_8W67 HH0012 transformed cell line human CVCL_8W67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125199 CVCL_8W66 HH0011 transformed cell line human CVCL_8W66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125200 CVCL_9866 HPL1E transformed cell line human CVCL_9866 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; parenchyma Cell type=Epithelial cell.. Female 21125201 CVCL_8W41 FY0031 transformed cell line human CVCL_8W41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125202 CVCL_9841 VUB04_CF embryonic stem cell human CVCL_9841 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=16284066). Female 21125203 CVCL_8W40 FY0028 transformed cell line human CVCL_8W40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125204 CVCL_9840 VUB03_DM1 embryonic stem cell human CVCL_9840 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125205 CVCL_8W36 FE0043 transformed cell line human CVCL_8W36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98051806; true Male Part of: ECACC chromosomal abnormality collection 21125206 CVCL_9836 MS589 cancer cell line human CVCL_9836 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21125207 CVCL_8W35 FE0042 transformed cell line human CVCL_8W35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98051805; true Male Part of: ECACC chromosomal abnormality collection 21125208 CVCL_9835 MS428 cancer cell line human CVCL_9835 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21125209 CVCL_8W38 FU0045 transformed cell line human CVCL_8W38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125210 CVCL_9838 VUB01 embryonic stem cell human CVCL_9838 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-24.. 21125211 CVCL_8W37 FE0046 transformed cell line human CVCL_8W37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 98090704; true Male Part of: ECACC chromosomal abnormality collection 21125212 CVCL_9837 HEFX embryonic stem cell human CVCL_9837 From: Hebrew University; Jerusalem; Israel. CL:0000010 Male 21125213 CVCL_9832 293-CD40 transformed cell line human CVCL_9832 From: Schwandner R.; Tularik Inc.; South San Francisco; USA CL:0000010 Transfected with: HGNC; 11919; CD40 (with a FLAG tag) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125214 CVCL_8W32 FE0035 transformed cell line human CVCL_8W32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97012318; true Male Part of: ECACC chromosomal abnormality collection 21125215 CVCL_9831 293-IL-1RI transformed cell line human CVCL_9831 CL:0000010 Transfected with: HGNC; 5993; IL1R1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21125216 CVCL_8W31 FE0033 transformed cell line human CVCL_8W31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97012316; true Female Part of: ECACC chromosomal abnormality collection 21125217 CVCL_8W34 FE0037 transformed cell line human CVCL_8W34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97040402; true Male Part of: ECACC chromosomal abnormality collection 21125218 CVCL_9834 MS257 cancer cell line human CVCL_9834 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA. CL:0000010 21125219 CVCL_8W33 FE0036 transformed cell line human CVCL_8W33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 97040401; true Female Part of: ECACC chromosomal abnormality collection 21125220 CVCL_9833 MS924 cancer cell line human CVCL_9833 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA. CL:0000010 21125221 CVCL_8W39 FU0054 transformed cell line human CVCL_8W39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125222 CVCL_9839 VUB02 embryonic stem cell human CVCL_9839 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Male 21125223 CVCL_8W50 GK0001 transformed cell line human CVCL_8W50 CL:0000010 Karyotypic information: 46,XY,t(7;15)(p11;p11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125224 CVCL_9850 VUB14 embryonic stem cell human CVCL_9850 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125225 CVCL_8W52 GK0003 transformed cell line human CVCL_8W52 CL:0000010 Karyotypic information: 46,XY,t(7;15)(p11;p11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125226 CVCL_9852 VUB16 embryonic stem cell human CVCL_9852 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Unspecified 21125227 CVCL_8W51 GK0002 transformed cell line human CVCL_8W51 CL:0000010 Karyotypic information: 46,XY,t(7;15)(p11;p11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125228 CVCL_9851 VUB15 embryonic stem cell human CVCL_9851 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Unspecified 21125229 CVCL_8W47 GF1054 transformed cell line human CVCL_8W47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125230 CVCL_9847 VUB10_SCA7 embryonic stem cell human CVCL_9847 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[37] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Unspecified (PubMed=20224973). Female 21125231 CVCL_8W46 GF1053 transformed cell line human CVCL_8W46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125232 CVCL_9846 VUB09_FSHD embryonic stem cell human CVCL_9846 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125233 CVCL_8W49 GI0002 transformed cell line human CVCL_8W49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21125234 CVCL_9849 VUB13_FXS embryonic stem cell human CVCL_9849 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[2000]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=27690107). Female 21125235 CVCL_8W48 GI0001 transformed cell line human CVCL_8W48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21125236 CVCL_9848 VUB11_FXS embryonic stem cell human CVCL_9848 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[2000-2010]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=27690107). Female 21125237 CVCL_8W43 FY1197 transformed cell line human CVCL_8W43 CL:0000010 Karyotypic information: t(11;22)(q23.3;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125238 CVCL_9843 VUB06 embryonic stem cell human CVCL_9843 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125239 CVCL_8W42 FY1181 transformed cell line human CVCL_8W42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125240 CVCL_9842 VUB05_HD embryonic stem cell human CVCL_9842 From: Vrije Universiteit Brussel; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (PubMed=16284066). Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-24. 21125241 CVCL_8W45 FY1199 transformed cell line human CVCL_8W45 CL:0000010 Karyotypic information: t(11;22)(q23.3;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125242 CVCL_9845 VUB08_MFS embryonic stem cell human CVCL_9845 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125243 CVCL_8W44 FY1198 transformed cell line human CVCL_8W44 CL:0000010 Karyotypic information: t(11;22)(q23.3;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125244 CVCL_9844 VUB07 embryonic stem cell human CVCL_9844 From: Vrije Universiteit Brussel; Brussels; Belgium. CL:0000010 Female 21125245 CVCL_JK50 KH-AML-B2 cancer cell line human CVCL_JK50 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Ter (c.8504C>G) (8732C>A); ClinVar=VCV000267091; Zygosity=Heterozygous; Note=Mutated This cell line contains both the mutated allele and the reverted allele (from parent cell line).; Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Glu (c.8503_8504TC>GA) (8731TC>GA); Zygosity=Heterozygous; Note=Reverted This cell line contains both the mutated allele and the reverted allele (from parent cell line). Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: CSF2 dependent 21125246 CVCL_JK49 PJHINU finite cell line human CVCL_JK49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21125247 CVCL_JK48 AT7KYM finite cell line human CVCL_JK48 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21125248 CVCL_JK45 YUMM5.4 cancer cell line house mouse CVCL_JK45 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125249 CVCL_JK44 YUMM5.3 cancer cell line house mouse CVCL_JK44 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125250 CVCL_JK47 AT(L)7KYM transformed cell line human CVCL_JK47 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (from autologous cell line AT7KYM) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21125251 CVCL_JK46 YUMM6.1 cancer cell line house mouse CVCL_JK46 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125252 CVCL_JK41 YUMM4.4 cancer cell line house mouse CVCL_JK41 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Breed/subspecies: C57BL/6. Female 21125253 CVCL_JK40 YUMM4.3 cancer cell line house mouse CVCL_JK40 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Breed/subspecies: C57BL/6. Female 21125254 CVCL_JK43 YUMM5.2 cancer cell line house mouse CVCL_JK43 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125255 CVCL_JK42 YUMM5.1 cancer cell line house mouse CVCL_JK42 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125256 CVCL_JK61 iNV5 induced pluripotent stem cell CVCL_JK61 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21125257 CVCL_JK60 iNV4 induced pluripotent stem cell CVCL_JK60 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21125258 CVCL_JK59 iNV3 induced pluripotent stem cell CVCL_JK59 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21125259 CVCL_JK56 HOC1A cancer cell line human CVCL_JK56 CL:0000010 Population: Chinese Omics: Deep phosphoproteome analysis. Female Doubling time: 39.5 hours (PubMed=16174236) 21125260 CVCL_JK55 BUPH:OVSC-2 transformed cell line human CVCL_JK55 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Abdominal wall. Female Doubling time: ~41 hours (PubMed=12479096) 21125261 CVCL_JK58 iNV2 induced pluripotent stem cell CVCL_JK58 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21125262 CVCL_JK57 iNV1 induced pluripotent stem cell CVCL_JK57 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21125263 CVCL_JK52 AT-1 [Mouse cardiomyocyte] transformed cell line house mouse CVCL_JK52 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; left atrium Cell type=Cardiomyocyte.; Breed/subspecies: C3HeB/FeJ transgenic. Female Characteristics: From transgenic mice expressing a fusion gene comprised of the atrial natriuretic factor promoter and the SV40 early region 21125264 CVCL_JK51 RK-13-KY spontaneously immortalized cell line CVCL_JK51 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Virology: Used for isolation and propagation of equine arteritis virus (EAV); Virology: Contaminated with a noncytopathic bovine viral diarrhea virus 1 (PubMed=26430037) 21125265 CVCL_JK54 CS14iCTR28-n6 induced pluripotent stem cell human CVCL_JK54 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21125266 CVCL_JK53 AT-2 transformed cell line house mouse CVCL_JK53 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Cardiomyocyte.; Breed/subspecies: C3HeB/FeJ transgenic. Characteristics: From transgenic mice expressing a fusion gene comprised of the rat alpha-cardiac myosin heavy chain promoter and the SV40 early region (MHC-TAG) 21125267 CVCL_AQ97 DD2336 finite cell line human CVCL_AQ97 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125268 CVCL_B297 SA142 embryonic stem cell human CVCL_B297 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Female 21125269 CVCL_AQ96 DD2305 transformed cell line human CVCL_AQ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21125270 CVCL_B296 SA121 embryonic stem cell human CVCL_B296 HLA typing: A*32,68; B*07,44; C*07;07; DQA1*01,01; DQB1*06,06; DRB1*13,15 (PubMed=29026098). From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-31. 21125271 CVCL_AQ99 DD2388 transformed cell line human CVCL_AQ99 CL:0000010 Karyotypic information: 47,XY,+21 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125272 CVCL_B299 SA181 embryonic stem cell human CVCL_B299 HLA typing: A*02,68; B*08,39; C*07,12; DQA1*02,05; DQB1*02,02; DRB1*03,07 (PubMed=29026098). From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-31. 21125273 CVCL_AQ98 DD2341 finite cell line human CVCL_AQ98 CL:0000010 Karyotypic information: 46,XX.ish:22q11.2(cH748x22) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125274 CVCL_B298 SA167 embryonic stem cell human CVCL_B298 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0030; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-31.. 21125275 CVCL_AQ91 DD2221 finite cell line human CVCL_AQ91 CL:0000010 Karyotypic information: 46,XY; 47,XY,+7 (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21125276 CVCL_B291 SA003 embryonic stem cell human CVCL_B291 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21125277 CVCL_AQ90 DD2218 finite cell line human CVCL_AQ90 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125278 CVCL_B290 SA002.5 embryonic stem cell human CVCL_B290 HLA typing: A*01:23; B*07,51; C*07,15; DQB1*05; DRB1*14,14; DRB3*02 (PubMed=16919167). From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-14. 21125279 CVCL_AQ93 DD2243 transformed cell line human CVCL_AQ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125280 CVCL_B293 SA085 embryonic stem cell human CVCL_B293 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden. CL:0000010 Unspecified 21125281 CVCL_JK27 YUMM1.G3 cancer cell line house mouse CVCL_JK27 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6J-Mc1re/J. Female 21125282 CVCL_AQ92 DD2242 transformed cell line human CVCL_AQ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125283 CVCL_B292 SA046 embryonic stem cell human CVCL_B292 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21125284 CVCL_JK26 YUMM1.G2 cancer cell line house mouse CVCL_JK26 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6J-Mc1re/J. Female 21125285 CVCL_AQ95 DD2267 finite cell line human CVCL_AQ95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125286 CVCL_B295 SA111 embryonic stem cell human CVCL_B295 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21125287 CVCL_JK29 YUMM1.G5 cancer cell line house mouse CVCL_JK29 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6J-Mc1re/J. Female 21125288 CVCL_AQ94 DD2264 finite cell line human CVCL_AQ94 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125289 CVCL_B294 SA094 embryonic stem cell human CVCL_B294 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-21.. 21125290 CVCL_JK28 YUMM1.G4 cancer cell line house mouse CVCL_JK28 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6J-Mc1re/J. Female 21125291 CVCL_JK23 YUMM1.14 cancer cell line house mouse CVCL_JK23 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125292 CVCL_JK22 YUMM1.13 cancer cell line house mouse CVCL_JK22 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125293 CVCL_JK25 YUMM1.G1 cancer cell line house mouse CVCL_JK25 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6J-Mc1re/J. Female 21125294 CVCL_JK24 YUMM1.15 cancer cell line house mouse CVCL_JK24 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125295 CVCL_JK21 YUMM1.12 cancer cell line house mouse CVCL_JK21 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125296 CVCL_JK20 YUMM1.11 cancer cell line house mouse CVCL_JK20 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125297 CVCL_JK38 YUMM4.1 cancer cell line house mouse CVCL_JK38 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Breed/subspecies: C57BL/6. Female 21125298 CVCL_JK37 YUMM3.4 cancer cell line house mouse CVCL_JK37 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125299 CVCL_JK39 YUMM4.2 cancer cell line house mouse CVCL_JK39 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Breed/subspecies: C57BL/6. Female 21125300 CVCL_JK34 YUMM3.1 cancer cell line house mouse CVCL_JK34 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125301 CVCL_JK33 YUMM2.2R cancer cell line house mouse CVCL_JK33 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male Characteristics: Has full Bcat STA/wt recombination 21125302 CVCL_JK36 YUMM3.3 cancer cell line house mouse CVCL_JK36 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125303 CVCL_JK35 YUMM3.2 cancer cell line house mouse CVCL_JK35 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Female 21125304 CVCL_JK30 YUMM2.1 cancer cell line house mouse CVCL_JK30 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male Characteristics: Has partial Bcat STA/wt recombination 21125305 CVCL_JK32 YUMM2.2 cancer cell line house mouse CVCL_JK32 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male Characteristics: Has partial Bcat STA/wt recombination 21125306 CVCL_JK31 YUMM2.1R cancer cell line house mouse CVCL_JK31 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male Characteristics: Has full Bcat STA/wt recombination 21125307 CVCL_AQ75 DD1583 transformed cell line human CVCL_AQ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125308 CVCL_B275 KTCTL-187 cancer cell line human CVCL_B275 CL:0000010 Unspecified 21125309 CVCL_AQ74 DD1551 transformed cell line human CVCL_AQ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125310 CVCL_B274 KTCTL-128 cancer cell line human CVCL_B274 CL:0000010 Unspecified 21125311 CVCL_AQ77 DD1601 transformed cell line human CVCL_AQ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125312 CVCL_B277 KTCTL-33 cancer cell line human CVCL_B277 CL:0000010 Unspecified 21125313 CVCL_AQ76 DD1591 finite cell line human CVCL_AQ76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21125314 CVCL_B276 KTCTL-28 cancer cell line human CVCL_B276 CL:0000010 Unspecified 21125315 CVCL_AQ79 DD1610 transformed cell line human CVCL_AQ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125316 CVCL_B279 S2-007 cancer cell line human CVCL_B279 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 29.7 hours (PubMed=1391733); 41.8 hours (PubMed=10027404) 21125317 CVCL_AQ78 DD1602 transformed cell line human CVCL_AQ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125318 CVCL_B278 KTCTL-84 cancer cell line human CVCL_B278 CL:0000010 Unspecified 21125319 CVCL_JK09 TRI103 cancer cell line human CVCL_JK09 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 12363; TSC2; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760). Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7369 21125320 CVCL_JK08 TRI102 cancer cell line human CVCL_JK08 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg611Gln (c.1832G>A); ClinVar=VCV000012397; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760). Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7368 21125321 CVCL_AQ71 DD1369 transformed cell line human CVCL_AQ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125322 CVCL_JK05 GLI-H7 hybrid cell line CVCL_JK05 CL:0000010 Group: Hybridoma fusion partner cell line. 21125323 CVCL_AQ70 DD1368 transformed cell line human CVCL_AQ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125324 CVCL_B270 MEC cancer cell line human CVCL_B270 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Discontinued: RCB; RCB2129; true Male Doubling time: 40.8 hours (PubMed=1965684) 21125325 CVCL_JK04 RT4-67 cancer cell line Norway rat CVCL_JK04 CL:0000010 Transfected with: HGNC; 7773; NF2 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: BDIX. Characteristics: Expression of NF2 is doxycycline-inducible 21125326 CVCL_JK07 A549 EML4-ALK cancer cell line human CVCL_JK07 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: An EML4-ALK4 fusion was generated by CRISPR/Cas9; Characteristics: More sensitive to the ALK inhibitor crizotinib when compared to the parental cell line Can be a useful model to study tyrosine kinase signaling pathway and to screen ALK inhibitors. Doubling time: ~25 hours (ATCC=CCL-185IG) 21125327 CVCL_AQ73 DD1446 transformed cell line human CVCL_AQ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125328 CVCL_B273 KTCTL-104 cancer cell line human CVCL_B273 CL:0000010 Unspecified 21125329 CVCL_AQ72 DD1388 transformed cell line human CVCL_AQ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125330 CVCL_JK06 H73C11 hybrid cell line CVCL_JK06 CL:0000010 Group: Hybridoma fusion partner cell line. 21125331 CVCL_B272 KTCTL-111 cancer cell line human CVCL_B272 CL:0000010 Unspecified 21125332 CVCL_JK01 Ben-Men-1-LucB telomerase immortalized cell line human CVCL_JK01 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Leu214fs*6 (c.640delC); Zygosity=Hemizygous (PubMed=23151902); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Brain; falx cerebri. Female 21125333 CVCL_JK00 KT21-MG1-Luc5D cancer cell line human CVCL_JK00 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Brain; falx cerebri. Female 21125334 CVCL_JK03 SC4 [Mouse schwannoma] cancer cell line house mouse CVCL_JK03 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97307; Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. 21125335 CVCL_JK02 S462.TY cancer cell line human CVCL_JK02 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Tyr2285Ter (c.6792C>A); ClinVar=VCV000185082; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Thigh. Female Characteristics: Was created by passage of S462 as xenografts 21125336 CVCL_AQ86 DD1967 finite cell line human CVCL_AQ86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125337 CVCL_B286 MZ-MEL-13 cancer cell line human CVCL_B286 HLA typing: A*02:01; B*27:04,18:01; C*04:01:01,07:01:01; DPB1*04:01; DQB1*03:01:01; DRB1*11:03:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Male 21125338 CVCL_AQ85 DD1741 transformed cell line human CVCL_AQ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125339 CVCL_B285 HPAF/CD11 cancer cell line human CVCL_B285 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Ascites. Male Doubling time: 42 hours (PubMed=2734279) 21125340 CVCL_AQ88 DD2175 transformed cell line human CVCL_AQ88 CL:0000010 Karyotypic information: 47,XY,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125341 CVCL_B288 MC-38 cancer cell line house mouse CVCL_B288 CL:0000010 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Omics: Mitochondrial genome sequenced; Omics: SNP array analysis Female Caution: The authors of PubMed=25434994 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line MCA38 Their submitted DNA sequence (KM820832.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 406'. 21125342 CVCL_AQ87 DD2174 transformed cell line human CVCL_AQ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125343 CVCL_B287 MZ-MEL-4 cancer cell line human CVCL_B287 CL:0000010 Unspecified 21125344 CVCL_AQ89 DD2176 transformed cell line human CVCL_AQ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125345 CVCL_B289 PC-3H cancer cell line human CVCL_B289 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21125346 CVCL_JK19 YUMM1.10 cancer cell line house mouse CVCL_JK19 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125347 CVCL_AQ80 DD1611 transformed cell line human CVCL_AQ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125348 CVCL_B280 S2-013 cancer cell line human CVCL_B280 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 26.4 hours (PubMed=1391733) 21125349 CVCL_AQ82 DD1617 transformed cell line human CVCL_AQ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125350 CVCL_B282 S2-028 cancer cell line human CVCL_B282 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 24.5 hours (PubMed=1391733); 35.3 hours (PubMed=10027404) 21125351 CVCL_JK16 YUMM1.7 cancer cell line house mouse CVCL_JK16 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125352 CVCL_AQ81 DD1612 transformed cell line human CVCL_AQ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125353 CVCL_B281 S2-020 cancer cell line human CVCL_B281 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 24.8 hours (PubMed=1391733); 35.8 hours (PubMed=10027404) 21125354 CVCL_JK15 YUMM1.6 cancer cell line house mouse CVCL_JK15 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125355 CVCL_AQ84 DD1684 transformed cell line human CVCL_AQ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125356 CVCL_B284 HPAF cancer cell line human CVCL_B284 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=8026879; PubMed=8426738); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Homozygous (PubMed=8026879; PubMed=8194712; PubMed=8426738) Derived from metastatic site: Ascites. Male 21125357 CVCL_JK18 YUMM1.9 cancer cell line house mouse CVCL_JK18 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125358 CVCL_AQ83 DD1625 transformed cell line human CVCL_AQ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125359 CVCL_B283 S2/TXT cancer cell line human CVCL_B283 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Liver. Male 21125360 CVCL_JK17 YUMM1.8 cancer cell line house mouse CVCL_JK17 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125361 CVCL_JK12 YUMM1.3 cancer cell line house mouse CVCL_JK12 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125362 CVCL_JK11 YUMM1.2 cancer cell line house mouse CVCL_JK11 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125363 CVCL_JK14 YUMM1.5 cancer cell line house mouse CVCL_JK14 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125364 CVCL_JK13 YUMM1.4 cancer cell line house mouse CVCL_JK13 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125365 CVCL_JK10 YUMM1.1 cancer cell line house mouse CVCL_JK10 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (PubMed=27287723) Breed/subspecies: C57BL/6. Male 21125366 CVCL_B253 KBM-7 P1-55 cancer cell line human CVCL_B253 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Karyotypic information: Haploid except for a disomy of chromosome 8; Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125367 CVCL_AQ53 SK-N-RA cancer cell line human CVCL_AQ53 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Female Problematic cell line: Probably contaminated The STR profile is identical to that of the SK-N-AS cell line. Originally thought to originate from a neuroblastoma but the sex and age of the patient has not been reported. 21125368 CVCL_AQ52 Astro.4U finite cell line human CVCL_AQ52 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Astrocyte. 21125369 CVCL_B252 UOK152 cancer cell line human CVCL_B252 CL:0000010 Unspecified 21125370 CVCL_AQ55 DD0039 transformed cell line human CVCL_AQ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125371 CVCL_B255 TTC-442 cancer cell line human CVCL_B255 CL:0000010 Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21125372 CVCL_AQ54 DV-1 transformed cell line human CVCL_AQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from SCID and immunoblastic lymphoma; Derived from sampling site: Bone marrow. Male Characteristics: Secretes IgM Doubling time: 18-25 hours (PubMed=3033590) 21125373 CVCL_B254 KBM-7/B5 cancer cell line human CVCL_B254 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Karyotypic information: Haploid except for a disomy of chromosome 8; Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125374 CVCL_AQ57 DD0167 finite cell line human CVCL_AQ57 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125375 CVCL_B257 TTC-633 cancer cell line human CVCL_B257 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG; Note=In frame (PubMed=8162068) Derived from sampling site: Bone. Female 21125376 CVCL_AQ56 DD0046 finite cell line human CVCL_AQ56 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125377 CVCL_B256 TTC-487 cancer cell line human CVCL_B256 CL:0000010 Derived from metastatic site: Left thigh. Male 21125378 CVCL_AQ59 DD0757 transformed cell line human CVCL_AQ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125379 CVCL_B259 PC-13 cancer cell line human CVCL_B259 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly334Val (c.1001G>T); Zygosity=Unspecified (PubMed=10536175; PubMed=20557307). Population: Japanese Male 21125380 CVCL_AQ58 DD0554 transformed cell line human CVCL_AQ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125382 CVCL_AQ51 FU-NB-2006 cancer cell line human CVCL_AQ51 CL:0000010 Anecdotal: Established from a sample taken just after the death of Christi Thomas who died in September 2006 aged 9 The cell line was named by Christi's father to show how angry (FU..) he was against neuroblastoma (NB).. Female 21125383 CVCL_B251 LRB18 embryonic stem cell human CVCL_B251 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125384 CVCL_B250 LRB17 embryonic stem cell human CVCL_B250 From: University Hospital of Copenhagen; Copenhagen; Denmark. CL:0000010 Unspecified 21125385 CVCL_AQ50 TX-LY-172h cancer cell line human CVCL_AQ50 CL:0000010 21125386 CVCL_AQ64 DD1047 transformed cell line human CVCL_AQ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125387 CVCL_B264 TJ899 cancer cell line human CVCL_B264 CL:0000010 Population: Chinese Omics: Proteome analysis by 2D-DE. Male 21125388 CVCL_AQ63 DD1046 transformed cell line human CVCL_AQ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125389 CVCL_B263 RPC-9 cancer cell line human CVCL_B263 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21125390 CVCL_AQ66 DD1142 transformed cell line human CVCL_AQ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125391 CVCL_B266 TJ861 cancer cell line human CVCL_B266 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 21125392 CVCL_AQ65 DD1130 transformed cell line human CVCL_AQ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125393 CVCL_B265 TJ8510 cancer cell line human CVCL_B265 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 21125394 CVCL_AQ68 DD1183 finite cell line human CVCL_AQ68 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125395 CVCL_B268 MEL-TF19 cancer cell line house mouse CVCL_B268 CL:0000010 Transfected with: MGI; MGI:1913538; Pdcd5 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21125396 CVCL_B267 CHG-5 cancer cell line human CVCL_B267 CL:0000010 Population: Chinese Omics: Proteome analysis by 2D-DE. Male 21125397 CVCL_AQ67 DD1161 transformed cell line human CVCL_AQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125398 CVCL_AQ69 DD1279 transformed cell line human CVCL_AQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125399 CVCL_B269 KMC-1 cancer cell line human CVCL_B269 HLA typing: A*24:02; B*40:06,52:01; C*08:01,12:02; DRB1*12:01,15:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 54 hours, at 31th passage (PubMed=1332997) 21125400 CVCL_AQ60 DD0865 transformed cell line human CVCL_AQ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125401 CVCL_B260 PC-9 cancer cell line human CVCL_B260 HLA typing: A*02:06,24:02; B*07:02,55:02; C*03:03,07:02 (PubMed=9178645) From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (PubMed=16105816; PubMed=17332333; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep membrane proteome analysis; Omics: Deep phosphoproteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21125402 CVCL_AQ62 DD1045 transformed cell line human CVCL_AQ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125403 CVCL_B262 PC/JW cancer cell line human CVCL_B262 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.74+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=16418264) Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Female Part of: AstraZeneca Colorectal cell line (AZCL) panel 21125404 CVCL_AQ61 DD0951 finite cell line human CVCL_AQ61 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125405 CVCL_B261 PC/AA cancer cell line human CVCL_B261 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2253215). Male 21125406 CVCL_K607 C0851 transformed cell line human CVCL_K607 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125407 CVCL_JU07 JHU117i induced pluripotent stem cell human CVCL_JU07 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125408 CVCL_K606 C0850 transformed cell line human CVCL_K606 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125409 CVCL_JU06 JHU116i induced pluripotent stem cell human CVCL_JU06 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125410 CVCL_K609 C0853 transformed cell line human CVCL_K609 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608101; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125411 CVCL_JU09 JHU121i induced pluripotent stem cell human CVCL_JU09 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125412 CVCL_K608 C0852 transformed cell line human CVCL_K608 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608100; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125413 CVCL_JU08 JHU119i induced pluripotent stem cell human CVCL_JU08 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125414 CVCL_K603 C0847 transformed cell line human CVCL_K603 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125415 CVCL_JU03 JHU111i induced pluripotent stem cell human CVCL_JU03 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125416 CVCL_K602 C0846 transformed cell line human CVCL_K602 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090169; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125417 CVCL_JU02 JHU108i induced pluripotent stem cell human CVCL_JU02 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125418 CVCL_K605 C0849 transformed cell line human CVCL_K605 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125419 CVCL_JU05 JHU115i induced pluripotent stem cell human CVCL_JU05 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125420 CVCL_K604 C0848 transformed cell line human CVCL_K604 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125421 CVCL_JU04 JHU114i induced pluripotent stem cell human CVCL_JU04 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125422 CVCL_K601 C0845 transformed cell line human CVCL_K601 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125423 CVCL_JU01 JHU107i induced pluripotent stem cell human CVCL_JU01 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125424 CVCL_K600 C0844 transformed cell line human CVCL_K600 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090167; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125425 CVCL_JU00 JHU106i induced pluripotent stem cell human CVCL_JU00 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125426 CVCL_K618 C0862 transformed cell line human CVCL_K618 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125427 CVCL_JU18 JHU130i induced pluripotent stem cell human CVCL_JU18 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125428 CVCL_K617 C0861 transformed cell line human CVCL_K617 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125429 CVCL_JU17 JHU129i induced pluripotent stem cell human CVCL_JU17 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125430 CVCL_K619 C0863 transformed cell line human CVCL_K619 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125431 CVCL_JU19 JHU131i induced pluripotent stem cell human CVCL_JU19 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125432 CVCL_K614 C0858 transformed cell line human CVCL_K614 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125433 CVCL_JU14 JHU126i induced pluripotent stem cell human CVCL_JU14 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125434 CVCL_K613 C0857 transformed cell line human CVCL_K613 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125435 CVCL_JU13 JHU125i induced pluripotent stem cell human CVCL_JU13 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125436 CVCL_K616 C0860 transformed cell line human CVCL_K616 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608108; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125437 CVCL_JU16 JHU128i induced pluripotent stem cell human CVCL_JU16 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125438 CVCL_K615 C0859 transformed cell line human CVCL_K615 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608107; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125439 CVCL_JU15 JHU127i induced pluripotent stem cell human CVCL_JU15 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125440 CVCL_K610 C0854 transformed cell line human CVCL_K610 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125441 CVCL_JU10 JHU122i induced pluripotent stem cell human CVCL_JU10 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125442 CVCL_K612 C0856 transformed cell line human CVCL_K612 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125443 CVCL_JU12 JHU124i induced pluripotent stem cell human CVCL_JU12 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125444 CVCL_K611 C0855 transformed cell line human CVCL_K611 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125445 CVCL_JU11 JHU123i induced pluripotent stem cell human CVCL_JU11 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125446 CVCL_9B92 DD0764 transformed cell line human CVCL_9B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125447 CVCL_9B91 DD0763 transformed cell line human CVCL_9B91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125448 CVCL_9B94 DD0766 transformed cell line human CVCL_9B94 CL:0000010 Karyotypic information: 46,XY,t(5;10)(q35.1;q26.3)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125449 CVCL_9B93 DD0765 transformed cell line human CVCL_9B93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125450 CVCL_9B90 DD0762 transformed cell line human CVCL_9B90 CL:0000010 Karyotypic information: 46,XX,t(2;5)(q33;q12) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125451 CVCL_9B99 DD0772 transformed cell line human CVCL_9B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125452 CVCL_9B96 DD0769 transformed cell line human CVCL_9B96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125453 CVCL_9B95 DD0767 transformed cell line human CVCL_9B95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125454 CVCL_9B98 DD0771 transformed cell line human CVCL_9B98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125455 CVCL_9B97 DD0770 transformed cell line human CVCL_9B97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125456 CVCL_9B70 DD0733 finite cell line human CVCL_9B70 CL:0000010 Karyotypic information: 46,XX,del(13)(q21)?(q21.1 or q21.2) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125457 CVCL_9B72 DD0738 transformed cell line human CVCL_9B72 CL:0000010 Karyotypic information: 46,Y,inv(X)(?q11;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125458 CVCL_9B71 DD0734 transformed cell line human CVCL_9B71 CL:0000010 Karyotypic information: 46,XY,10q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125459 CVCL_9B78 DD0745 transformed cell line human CVCL_9B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125460 CVCL_9B77 DD0744 finite cell line human CVCL_9B77 CL:0000010 Karyotypic information: 46,XX; 47,XX,+20 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125461 CVCL_9B79 DD0746 transformed cell line human CVCL_9B79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125462 CVCL_9B74 DD0740 transformed cell line human CVCL_9B74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125463 CVCL_9B73 DD0739 transformed cell line human CVCL_9B73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125464 CVCL_9B76 DD0742 transformed cell line human CVCL_9B76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125465 CVCL_9B75 DD0741 transformed cell line human CVCL_9B75 CL:0000010 Karyotypic information: 46,XX,t(11;13)(p13;p12.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125466 CVCL_9B81 DD0750 finite cell line human CVCL_9B81 CL:0000010 Karyotypic information: 46,X,inv(Y)(p11;q11.23)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125467 CVCL_9B80 DD0749 transformed cell line human CVCL_9B80 CL:0000010 Karyotypic information: 46,XY,del(5)(qter->p14) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125468 CVCL_9B83 DD0753 transformed cell line human CVCL_9B83 CL:0000010 Karyotypic information: 46,XY,q5 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125469 CVCL_9B82 DD0752 transformed cell line human CVCL_9B82 CL:0000010 Karyotypic information: 47,XX,+psu dic(15)(pter->q15::?q11->p11:)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125470 CVCL_9B89 DD0761 transformed cell line human CVCL_9B89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125471 CVCL_9B88 DD0759 transformed cell line human CVCL_9B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125472 CVCL_9B85 DD0755 finite cell line human CVCL_9B85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125473 CVCL_9B84 DD0754 finite cell line human CVCL_9B84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21125474 CVCL_9B87 DD0758 finite cell line human CVCL_9B87 CL:0000010 Karyotypic information: 46,XY,inv(13)(q21.3;q22.3)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125475 CVCL_9B86 DD0756 transformed cell line human CVCL_9B86 CL:0000010 Karyotypic information: 46,X,inv(Y)(p11;q11.23)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125476 CVCL_T024 YT1 embryonic stem cell human CVCL_T024 From: Shandong Research Center of Stem Cell Engineering; Yantai; China. CL:0000010 Female 21125477 CVCL_T023 CS-1 [Human chondrosarcoma] cancer cell line human CVCL_T023 Genome ancestry: African=0%; Native American=0.36%; East Asian, North=1.25%; East Asian, South=0%; South Asian=0%; European, North=68.97%; European, South=29.41% (PubMed=30894373) CL:0000010 Derived from metastatic site: Bone; humerus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21125478 CVCL_T026 YT3 embryonic stem cell human CVCL_T026 From: Shandong Research Center of Stem Cell Engineering; Yantai; China. CL:0000010 Female 21125479 CVCL_T025 YT2 embryonic stem cell human CVCL_T025 From: Shandong Research Center of Stem Cell Engineering; Yantai; China. CL:0000010 Male 21125480 CVCL_T028 BCi-NS1 telomerase immortalized cell line human CVCL_T028 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Male 21125481 CVCL_T027 RT4v6 cancer cell line human CVCL_T027 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line). Male 21125482 CVCL_T029 BCi-NS1.1 telomerase immortalized cell line human CVCL_T029 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Male 21125483 CVCL_K687 C0933 transformed cell line human CVCL_K687 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125484 CVCL_JU87 JHU219i induced pluripotent stem cell human CVCL_JU87 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125485 CVCL_K686 C0932 transformed cell line human CVCL_K686 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125486 CVCL_JU86 JHU218i induced pluripotent stem cell human CVCL_JU86 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125487 CVCL_K689 C0936 transformed cell line human CVCL_K689 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125488 CVCL_JU89 JHU221i induced pluripotent stem cell human CVCL_JU89 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125489 CVCL_K688 C0935 transformed cell line human CVCL_K688 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125490 CVCL_JU88 JHU220i induced pluripotent stem cell human CVCL_JU88 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125491 CVCL_K683 C0929 transformed cell line human CVCL_K683 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125492 CVCL_JU83 JHU215i induced pluripotent stem cell human CVCL_JU83 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125493 CVCL_K682 C0928 transformed cell line human CVCL_K682 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125494 CVCL_JU82 JHU214i induced pluripotent stem cell human CVCL_JU82 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125495 CVCL_K685 C0931 transformed cell line human CVCL_K685 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125496 CVCL_JU85 JHU217i induced pluripotent stem cell human CVCL_JU85 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125497 CVCL_K684 C0930 transformed cell line human CVCL_K684 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082612; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125498 CVCL_JU84 JHU216i induced pluripotent stem cell human CVCL_JU84 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125499 CVCL_K681 C0927 transformed cell line human CVCL_K681 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125500 CVCL_JU81 JHU210i induced pluripotent stem cell human CVCL_JU81 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125501 CVCL_K680 C0926 transformed cell line human CVCL_K680 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125502 CVCL_JU80 JHU209i induced pluripotent stem cell human CVCL_JU80 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125503 CVCL_T031 U266/velR cancer cell line human CVCL_T031 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21125504 CVCL_T030 MUG-Myx1 cancer cell line human CVCL_T030 CL:0000010 Male Doubling time: 24 hours (PubMed=24289252). 21125505 CVCL_T033 LRPM spontaneously immortalized cell line CVCL_T033 CL:0000010 Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.. Unspecified Group: Fish cell line 21125506 CVCL_T032 CHO.1F8 spontaneously immortalized cell line CVCL_T032 CL:0000010 Transfected with: HGNC; 9582; PTAFR Derived from sampling site: Ovary. Female 21125507 CVCL_T013 SEM-1 cancer cell line human CVCL_T013 CL:0000010 Population: Hispanic; Derived from sampling site: Mediastinum. Male Doubling time: 50 hours (PubMed=23374840) 21125508 CVCL_T012 TCam-2 cancer cell line human CVCL_T012 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male Doubling time: 55.3 hours, at 10th passage (PubMed=8394948) 21125509 CVCL_T015 PC-9/BR cancer cell line human CVCL_T015 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:61390; Afatinib (BIBW-2992); Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 21125510 CVCL_T014 JKT-HM cancer cell line human CVCL_T014 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male Doubling time: 27.9 hours (PubMed=10210573) Problematic cell line: Misclassified Parent cell line (JKT-1) was originally thought to be a seminoma cell line but shown not to be from germ cells. Its real nature is not clear (PubMed=17705808; PubMed=18008088). 21125511 CVCL_T017 Mel-RMu/DR2 cancer cell line human CVCL_T017 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Lymph node. Unspecified 21125512 CVCL_T016 PC-9/S2 cancer cell line human CVCL_T016 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male 21125513 CVCL_T019 Mel-RMu/DR6 cancer cell line human CVCL_T019 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Lymph node. Unspecified 21125514 CVCL_T018 Mel-RMu/DR4 cancer cell line human CVCL_T018 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Lymph node. Unspecified 21125515 CVCL_K698 C0945 transformed cell line human CVCL_K698 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125516 CVCL_JU98 JHU231i induced pluripotent stem cell human CVCL_JU98 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125517 CVCL_K697 C0944 transformed cell line human CVCL_K697 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052711; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125518 CVCL_JU97 JHU230i induced pluripotent stem cell human CVCL_JU97 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125519 CVCL_K699 C0946 transformed cell line human CVCL_K699 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125520 CVCL_JU99 JHU232i induced pluripotent stem cell human CVCL_JU99 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125521 CVCL_K694 C0941 transformed cell line human CVCL_K694 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125522 CVCL_JU94 JHU227i induced pluripotent stem cell human CVCL_JU94 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125523 CVCL_K693 C0939 transformed cell line human CVCL_K693 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052006; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125524 CVCL_JU93 JHU226i induced pluripotent stem cell human CVCL_JU93 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125525 CVCL_K696 C0943 transformed cell line human CVCL_K696 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125526 CVCL_JU96 JHU229i induced pluripotent stem cell human CVCL_JU96 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125527 CVCL_K695 C0942 transformed cell line human CVCL_K695 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125528 CVCL_JU95 JHU228i induced pluripotent stem cell human CVCL_JU95 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125529 CVCL_K690 C0937 transformed cell line human CVCL_K690 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125530 CVCL_JU90 JHU222i induced pluripotent stem cell human CVCL_JU90 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125531 CVCL_JU92 JHU225i induced pluripotent stem cell human CVCL_JU92 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125532 CVCL_K692 TCAF-DAX cancer cell line human CVCL_K692 CL:0000010 Unspecified Characteristics: No information is available on this cell line apart that it is multidrug-resistant. 21125533 CVCL_K691 C0938 transformed cell line human CVCL_K691 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125534 CVCL_JU91 JHU224i induced pluripotent stem cell human CVCL_JU91 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125535 CVCL_T020 Mel-RMu/DR8 cancer cell line human CVCL_T020 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Lymph node. Unspecified 21125536 CVCL_T022 CS-1 [Human leukemia] cancer cell line human CVCL_T022 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Doubling time: 57.6 +- 10.8 hours (PubMed=12673685) 21125537 CVCL_T021 Mel-RMu/DR9 cancer cell line human CVCL_T021 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Lymph node. Unspecified 21125538 CVCL_T002 Mel-JS cancer cell line human CVCL_T002 CL:0000010 Derived from metastatic site: Lymph node. 21125539 CVCL_T001 Mel-JG cancer cell line human CVCL_T001 CL:0000010 21125540 CVCL_T004 Mel-LT cancer cell line human CVCL_T004 CL:0000010 21125541 CVCL_T003 Mel-KN cancer cell line human CVCL_T003 CL:0000010 21125542 CVCL_T006 Mel-MI cancer cell line human CVCL_T006 CL:0000010 21125543 CVCL_T005 Mel-MC cancer cell line human CVCL_T005 CL:0000010 Derived from metastatic site: Hypodermis. 21125544 CVCL_T008 Mel-MS cancer cell line human CVCL_T008 CL:0000010 21125545 CVCL_T007 Mel-MM cancer cell line human CVCL_T007 CL:0000010 21125546 CVCL_T009 Mel-SP cancer cell line human CVCL_T009 CL:0000010 21125547 CVCL_K669 C0914 transformed cell line human CVCL_K669 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94081529; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125548 CVCL_JU69 JHU197i induced pluripotent stem cell human CVCL_JU69 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125549 CVCL_K668 C0913 transformed cell line human CVCL_K668 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125550 CVCL_JU68 JHU196i induced pluripotent stem cell human CVCL_JU68 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125551 CVCL_K665 C0910 transformed cell line human CVCL_K665 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125552 CVCL_JU65 JHU191i induced pluripotent stem cell human CVCL_JU65 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125553 CVCL_K664 C0909 transformed cell line human CVCL_K664 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125554 CVCL_JU64 JHU190i induced pluripotent stem cell human CVCL_JU64 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125555 CVCL_K667 C0912 transformed cell line human CVCL_K667 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94081527; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125556 CVCL_JU67 JHU194i induced pluripotent stem cell human CVCL_JU67 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125557 CVCL_K666 C0911 transformed cell line human CVCL_K666 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125558 CVCL_JU66 JHU192i induced pluripotent stem cell human CVCL_JU66 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125559 CVCL_K661 C0906 transformed cell line human CVCL_K661 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125560 CVCL_JU61 JHU187i induced pluripotent stem cell human CVCL_JU61 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125561 CVCL_K660 C0905 transformed cell line human CVCL_K660 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94081520; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125562 CVCL_JU60 JHU186i induced pluripotent stem cell human CVCL_JU60 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125563 CVCL_K663 C0908 transformed cell line human CVCL_K663 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125564 CVCL_JU63 JHU189i induced pluripotent stem cell human CVCL_JU63 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125565 CVCL_K662 C0907 transformed cell line human CVCL_K662 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125566 CVCL_JU62 JHU188i induced pluripotent stem cell human CVCL_JU62 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125567 CVCL_T011 JKT-1 cancer cell line human CVCL_T011 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Male Doubling time: 28.5 hours (PubMed=10210573) Problematic cell line: Misclassified Originally thought to be a seminoma cell line but shown not to be from germ cells. Its real nature is not clear (PubMed=17705808; PubMed=18008088). 21125568 CVCL_T010 Mel-WB cancer cell line human CVCL_T010 CL:0000010 Derived from metastatic site: Lymph node. 21125569 CVCL_K679 C0925 transformed cell line human CVCL_K679 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125570 CVCL_JU79 JHU208i induced pluripotent stem cell human CVCL_JU79 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125571 CVCL_K676 C0921 transformed cell line human CVCL_K676 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125572 CVCL_JU76 JHU205i induced pluripotent stem cell human CVCL_JU76 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125573 CVCL_K675 C0920 transformed cell line human CVCL_K675 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125574 CVCL_JU75 JHU204i induced pluripotent stem cell human CVCL_JU75 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125575 CVCL_K678 C0924 transformed cell line human CVCL_K678 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082606; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125576 CVCL_JU78 JHU207i induced pluripotent stem cell human CVCL_JU78 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125577 CVCL_K677 C0922 transformed cell line human CVCL_K677 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125578 CVCL_JU77 JHU206i induced pluripotent stem cell human CVCL_JU77 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125579 CVCL_K672 C0917 transformed cell line human CVCL_K672 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125580 CVCL_JU72 JHU200i induced pluripotent stem cell human CVCL_JU72 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125581 CVCL_K671 C0916 transformed cell line human CVCL_K671 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94081531; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125582 CVCL_JU71 JHU199i induced pluripotent stem cell human CVCL_JU71 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125583 CVCL_K674 C0919 transformed cell line human CVCL_K674 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125584 CVCL_JU74 JHU203i induced pluripotent stem cell human CVCL_JU74 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125585 CVCL_K673 C0918 transformed cell line human CVCL_K673 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125586 CVCL_JU73 JHU201i induced pluripotent stem cell human CVCL_JU73 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125587 CVCL_K670 C0915 transformed cell line human CVCL_K670 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125588 CVCL_JU70 JHU198i induced pluripotent stem cell human CVCL_JU70 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125589 CVCL_T000 Mel-JF cancer cell line human CVCL_T000 CL:0000010 Derived from metastatic site: Hypodermis. 21125590 CVCL_K647 C0892 transformed cell line human CVCL_K647 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125591 CVCL_JU47 JHU170i induced pluripotent stem cell human CVCL_JU47 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125592 CVCL_K646 C0891 transformed cell line human CVCL_K646 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125593 CVCL_JU46 JHU167i induced pluripotent stem cell human CVCL_JU46 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125594 CVCL_K649 C0894 transformed cell line human CVCL_K649 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125595 CVCL_JU49 JHU172i induced pluripotent stem cell human CVCL_JU49 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125596 CVCL_K648 C0893 transformed cell line human CVCL_K648 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125597 CVCL_JU48 JHU171i induced pluripotent stem cell human CVCL_JU48 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125598 CVCL_K643 C0888 transformed cell line human CVCL_K643 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125599 CVCL_JU43 JHU164i induced pluripotent stem cell human CVCL_JU43 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125600 CVCL_K642 C0887 transformed cell line human CVCL_K642 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94070402; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125601 CVCL_JU42 JHU163i induced pluripotent stem cell human CVCL_JU42 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125602 CVCL_K645 C0890 transformed cell line human CVCL_K645 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125603 CVCL_JU45 JHU166i induced pluripotent stem cell human CVCL_JU45 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125604 CVCL_K644 C0889 transformed cell line human CVCL_K644 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94070404; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125605 CVCL_JU44 JHU165i induced pluripotent stem cell human CVCL_JU44 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125606 CVCL_K641 C0886 transformed cell line human CVCL_K641 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125607 CVCL_JU41 JHU162i induced pluripotent stem cell human CVCL_JU41 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125608 CVCL_K640 C0885 transformed cell line human CVCL_K640 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125609 CVCL_JU40 JHU160i induced pluripotent stem cell human CVCL_JU40 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125610 CVCL_K658 C0903 transformed cell line human CVCL_K658 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94081518; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125611 CVCL_JU58 JHU184i induced pluripotent stem cell human CVCL_JU58 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125612 CVCL_K657 C0902 transformed cell line human CVCL_K657 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125613 CVCL_JU57 JHU183i induced pluripotent stem cell human CVCL_JU57 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125614 CVCL_K659 C0904 transformed cell line human CVCL_K659 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125615 CVCL_JU59 JHU185i induced pluripotent stem cell human CVCL_JU59 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125616 CVCL_K654 C0899 transformed cell line human CVCL_K654 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125617 CVCL_JU54 JHU178i induced pluripotent stem cell human CVCL_JU54 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125618 CVCL_K653 C0898 transformed cell line human CVCL_K653 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125619 CVCL_JU53 JHU177i induced pluripotent stem cell human CVCL_JU53 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125620 CVCL_K656 C0901 transformed cell line human CVCL_K656 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125621 CVCL_JU56 JHU181i induced pluripotent stem cell human CVCL_JU56 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125622 CVCL_K655 C0900 transformed cell line human CVCL_K655 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94070415; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125623 CVCL_JU55 JHU180i induced pluripotent stem cell human CVCL_JU55 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125624 CVCL_K650 C0895 transformed cell line human CVCL_K650 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125625 CVCL_JU50 JHU173i induced pluripotent stem cell human CVCL_JU50 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125626 CVCL_K652 C0897 transformed cell line human CVCL_K652 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125627 CVCL_JU52 JHU176i induced pluripotent stem cell human CVCL_JU52 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125628 CVCL_K651 C0896 transformed cell line human CVCL_K651 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125629 CVCL_JU51 JHU174i induced pluripotent stem cell human CVCL_JU51 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125630 CVCL_K629 C0873 transformed cell line human CVCL_K629 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608121; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125631 CVCL_JU29 JHU148i induced pluripotent stem cell human CVCL_JU29 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125632 CVCL_K628 C0872 transformed cell line human CVCL_K628 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125633 CVCL_JU28 JHU146i induced pluripotent stem cell human CVCL_JU28 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125634 CVCL_K625 C0869 transformed cell line human CVCL_K625 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608117; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125635 CVCL_JU25 JHU142i induced pluripotent stem cell human CVCL_JU25 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125636 CVCL_K624 C0868 transformed cell line human CVCL_K624 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125637 CVCL_JU24 JHU141i induced pluripotent stem cell human CVCL_JU24 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125638 CVCL_K627 C0871 transformed cell line human CVCL_K627 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125639 CVCL_JU27 JHU145i induced pluripotent stem cell human CVCL_JU27 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125640 CVCL_K626 C0870 transformed cell line human CVCL_K626 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125641 CVCL_JU26 JHU143i induced pluripotent stem cell human CVCL_JU26 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125642 CVCL_K621 C0865 transformed cell line human CVCL_K621 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608113; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125643 CVCL_JU21 JHU133i induced pluripotent stem cell human CVCL_JU21 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125644 CVCL_K620 C0864 transformed cell line human CVCL_K620 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125645 CVCL_JU20 JHU132i induced pluripotent stem cell human CVCL_JU20 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125646 CVCL_K623 C0867 transformed cell line human CVCL_K623 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125647 CVCL_JU23 JHU140i induced pluripotent stem cell human CVCL_JU23 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125648 CVCL_K622 C0866 transformed cell line human CVCL_K622 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940608114; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125649 CVCL_JU22 JHU139i induced pluripotent stem cell human CVCL_JU22 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125650 CVCL_K639 C0884 transformed cell line human CVCL_K639 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125651 CVCL_JU39 JHU159i induced pluripotent stem cell human CVCL_JU39 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125652 CVCL_K636 C0881 transformed cell line human CVCL_K636 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125653 CVCL_JU36 JHU156i induced pluripotent stem cell human CVCL_JU36 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125654 CVCL_K635 C0880 transformed cell line human CVCL_K635 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125655 CVCL_JU35 JHU155i induced pluripotent stem cell human CVCL_JU35 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125656 CVCL_K638 C0883 transformed cell line human CVCL_K638 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125657 CVCL_JU38 JHU158i induced pluripotent stem cell human CVCL_JU38 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125658 CVCL_K637 C0882 transformed cell line human CVCL_K637 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125659 CVCL_JU37 JHU157i induced pluripotent stem cell human CVCL_JU37 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125660 CVCL_K632 C0877 transformed cell line human CVCL_K632 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125661 CVCL_JU32 JHU151i induced pluripotent stem cell human CVCL_JU32 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125662 CVCL_K631 C0875 transformed cell line human CVCL_K631 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125663 CVCL_JU31 JHU150i induced pluripotent stem cell human CVCL_JU31 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125664 CVCL_K634 C0879 transformed cell line human CVCL_K634 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060912; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125665 CVCL_JU34 JHU153i induced pluripotent stem cell human CVCL_JU34 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125666 CVCL_K633 C0878 transformed cell line human CVCL_K633 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125667 CVCL_JU33 JHU152i induced pluripotent stem cell human CVCL_JU33 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125668 CVCL_K630 C0874 transformed cell line human CVCL_K630 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125669 CVCL_JU30 JHU149i induced pluripotent stem cell human CVCL_JU30 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125670 CVCL_0H40 GM50090 hybrid cell line human CVCL_0H40 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125671 CVCL_0H42 GM50099 hybrid cell line human CVCL_0H42 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125672 CVCL_0H41 GM50091 hybrid cell line human CVCL_0H41 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125673 CVCL_0H44 HHW778 hybrid cell line human CVCL_0H44 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125674 CVCL_0H43 HHW659 hybrid cell line human CVCL_0H43 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125675 CVCL_0H46 GM14228 transformed cell line human CVCL_0H46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21125676 CVCL_0H45 HHW813 hybrid cell line human CVCL_0H45 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125677 CVCL_0H48 GM16449 transformed cell line human CVCL_0H48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125678 CVCL_0H47 GM16438 transformed cell line human CVCL_0H47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125679 CVCL_0H39 GM16585 hybrid cell line human CVCL_0H39 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125680 CVCL_0H38 GM16583 hybrid cell line human CVCL_0H38 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125681 CVCL_SN90 HAP1 FOXO1 (-) 1 cancer cell line human CVCL_SN90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125682 CVCL_SN92 HAP1 FOXRED1 (-) 2 cancer cell line human CVCL_SN92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26927; FOXRED1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125683 CVCL_SN91 HAP1 FOXRED1 (-) 1 cancer cell line human CVCL_SN91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26927; FOXRED1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125684 CVCL_SN94 HAP1 FSCN1 (-) cancer cell line human CVCL_SN94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11148; FSCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125685 CVCL_SN93 HAP1 FRYL (-) 1 cancer cell line human CVCL_SN93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29127; FRYL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125686 CVCL_SN96 HAP1 FTL (-) 2 cancer cell line human CVCL_SN96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125687 CVCL_SN95 HAP1 FTL (-) 1 cancer cell line human CVCL_SN95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125688 CVCL_SN98 HAP1 FTO (-) 2 cancer cell line human CVCL_SN98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125689 CVCL_SN97 HAP1 FTO (-) 1 cancer cell line human CVCL_SN97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125690 CVCL_SN99 HAP1 FTO (-) 3 cancer cell line human CVCL_SN99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24678; FTO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125691 CVCL_SN79 HAP1 FMR1 (-) 1 cancer cell line human CVCL_SN79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125692 CVCL_0H51 GM16455 transformed cell line human CVCL_0H51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21125693 CVCL_0H50 GM16453 transformed cell line human CVCL_0H50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125694 CVCL_0H53 GM16440 transformed cell line human CVCL_0H53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21125695 CVCL_0H52 GM16459 transformed cell line human CVCL_0H52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125696 CVCL_0H55 GM50186 transformed cell line human CVCL_0H55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21125697 CVCL_0H54 GM50143 transformed cell line human CVCL_0H54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125698 CVCL_0H57 GM16434 transformed cell line human CVCL_0H57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16434; probable Male 21125699 CVCL_0H56 GM50163 transformed cell line human CVCL_0H56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21125700 CVCL_0H59 GM16443 transformed cell line human CVCL_0H59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16443; probable Male 21125701 CVCL_0H58 GM16436 transformed cell line human CVCL_0H58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16436; probable Male 21125702 CVCL_0H49 GM16451 transformed cell line human CVCL_0H49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21125703 CVCL_SN81 HAP1 FN1 (-) 2 cancer cell line human CVCL_SN81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3778; FN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125704 CVCL_SN80 HAP1 FN1 (-) 1 cancer cell line human CVCL_SN80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3778; FN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125705 CVCL_SN83 HAP1 FOLH1 (-) cancer cell line human CVCL_SN83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3788; FOLH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125706 CVCL_SN82 HAP1 FNDC5 (-) 1 cancer cell line human CVCL_SN82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20240; FNDC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125707 CVCL_SN85 HAP1 FOS (-) 1 cancer cell line human CVCL_SN85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125708 CVCL_SN84 HAP1 FOLR1 (-) 1 cancer cell line human CVCL_SN84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3791; FOLR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125709 CVCL_SN87 HAP1 FOXA1 (-) 1 cancer cell line human CVCL_SN87 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125710 CVCL_SN86 HAP1 FOS (-) 2 cancer cell line human CVCL_SN86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125711 CVCL_SN89 HAP1 FOXM1 (-) 2 cancer cell line human CVCL_SN89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3818; FOXM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125712 CVCL_SN88 HAP1 FOXM1 (-) 1 cancer cell line human CVCL_SN88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3818; FOXM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125713 CVCL_SN69 HAP1 FKTN (-) 3 cancer cell line human CVCL_SN69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3622; FKTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125714 CVCL_SN68 HAP1 FKTN (-) 2 cancer cell line human CVCL_SN68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3622; FKTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125715 CVCL_0H20 M3F-2 induced pluripotent stem cell human CVCL_0H20 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Heterozygous (from familial inference of GM01774 and GM01775) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21125716 CVCL_0H22 GM13081 hybrid cell line human CVCL_0H22 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125717 CVCL_0H21 GM13080 hybrid cell line human CVCL_0H21 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125718 CVCL_0H24 GM14559 hybrid cell line human CVCL_0H24 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125719 CVCL_0H23 GM13696 hybrid cell line human CVCL_0H23 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125720 CVCL_0H26 GM14565 hybrid cell line human CVCL_0H26 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125721 CVCL_0H25 GM14560 hybrid cell line human CVCL_0H25 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125722 CVCL_0H17 PDE3F-3 induced pluripotent stem cell human CVCL_0H17 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21125723 CVCL_0H16 PDD4F-9 induced pluripotent stem cell human CVCL_0H16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125724 CVCL_0H19 M3F-1 induced pluripotent stem cell human CVCL_0H19 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Heterozygous (from familial inference of GM01774 and GM01775) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21125725 CVCL_0H18 PDE3F-4 induced pluripotent stem cell human CVCL_0H18 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21125726 CVCL_SN70 HAP1 FKTN (-) 4 cancer cell line human CVCL_SN70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3622; FKTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125727 CVCL_SN72 HAP1 FLNA (-) 1 cancer cell line human CVCL_SN72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3754; FLNA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125728 CVCL_SN71 HAP1 FLCN (-) cancer cell line human CVCL_SN71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27310; FLCN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125729 CVCL_SN74 HAP1 FLT1 (-) 1 cancer cell line human CVCL_SN74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3763; FLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125730 CVCL_SN73 HAP1 FLOT1 (-) 1 cancer cell line human CVCL_SN73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3757; FLOT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125731 CVCL_SN76 HAP1 FLT4 (-) cancer cell line human CVCL_SN76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3767; FLT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125732 CVCL_SN75 HAP1 FLT1 (-) 2 cancer cell line human CVCL_SN75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3763; FLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125733 CVCL_SN78 HAP1 FLVCR1 (-) 2 cancer cell line human CVCL_SN78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24682; FLVCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125734 CVCL_SN77 HAP1 FLVCR1 (-) 1 cancer cell line human CVCL_SN77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24682; FLVCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125735 CVCL_SN58 HAP1 FIG4 (-) 2 cancer cell line human CVCL_SN58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16873; FIG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125736 CVCL_SN57 HAP1 FIG4 (-) 1 cancer cell line human CVCL_SN57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16873; FIG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125737 CVCL_SN59 HAP1 FKBP15 (-) 1 cancer cell line human CVCL_SN59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23397; FKBP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125738 CVCL_0H31 GM16452 hybrid cell line human CVCL_0H31 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125739 CVCL_0H30 GM16450 hybrid cell line human CVCL_0H30 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125740 CVCL_0H33 GM16456 hybrid cell line human CVCL_0H33 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125741 CVCL_0H32 GM16454 hybrid cell line human CVCL_0H32 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125742 CVCL_0H35 GM16465 hybrid cell line human CVCL_0H35 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125743 CVCL_0H34 GM16460 hybrid cell line human CVCL_0H34 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125744 CVCL_0H37 GM16490 hybrid cell line human CVCL_0H37 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125745 CVCL_0H36 GM16466 hybrid cell line human CVCL_0H36 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125746 CVCL_0H28 GM16439 hybrid cell line human CVCL_0H28 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125747 CVCL_0H27 GM16437 hybrid cell line human CVCL_0H27 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125748 CVCL_0H29 GM16444 hybrid cell line human CVCL_0H29 CL:0000010 Group: Human/rodent somatic cell hybrid. 21125749 CVCL_SN61 HAP1 FKBP1A (-) 1 cancer cell line human CVCL_SN61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3711; FKBP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125750 CVCL_SN60 HAP1 FKBP15 (-) 2 cancer cell line human CVCL_SN60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23397; FKBP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125751 CVCL_SN63 HAP1 FKBP8 (-) 1 cancer cell line human CVCL_SN63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3724; FKBP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125752 CVCL_SN62 HAP1 FKBP5 (-) 1 cancer cell line human CVCL_SN62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3721; FKBP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125753 CVCL_SN65 HAP1 FKRP (-) 1 cancer cell line human CVCL_SN65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17997; FKRP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125754 CVCL_SN64 HAP1 FKBP8 (-) 2 cancer cell line human CVCL_SN64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3724; FKBP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125755 CVCL_SN67 HAP1 FKTN (-) 1 cancer cell line human CVCL_SN67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3622; FKTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125756 CVCL_SN66 HAP1 FKRP (-) 2 cancer cell line human CVCL_SN66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17997; FKRP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125757 CVCL_SN47 HAP1 FGD4 (-) 2 cancer cell line human CVCL_SN47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19125; FGD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125758 CVCL_SN46 HAP1 FGD4 (-) 1 cancer cell line human CVCL_SN46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19125; FGD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125759 CVCL_SN49 HAP1 FGF2 (-) 2 cancer cell line human CVCL_SN49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3676; FGF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125760 CVCL_SN48 HAP1 FGF2 (-) 1 cancer cell line human CVCL_SN48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3676; FGF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125761 CVCL_0H00 PDB3F-8 induced pluripotent stem cell human CVCL_0H00 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125762 CVCL_0H02 PDB3F-d12 induced pluripotent stem cell human CVCL_0H02 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125763 CVCL_0H01 PDB3F-9 induced pluripotent stem cell human CVCL_0H01 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125764 CVCL_0H04 PDB4F-2 induced pluripotent stem cell human CVCL_0H04 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125765 CVCL_0H03 PDB4F-1 induced pluripotent stem cell human CVCL_0H03 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125766 CVCL_SN50 HAP1 FGFR1 (-) 1 cancer cell line human CVCL_SN50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3688; FGFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125767 CVCL_SN52 HAP1 FGFR2 (-) cancer cell line human CVCL_SN52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3689; FGFR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125768 CVCL_SN51 HAP1 FGFR1 (-) 2 cancer cell line human CVCL_SN51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3688; FGFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125769 CVCL_SN54 HAP1 FGFR4 (-) cancer cell line human CVCL_SN54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3691; FGFR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125770 CVCL_SN53 HAP1 FGFR3 (-) cancer cell line human CVCL_SN53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3690; FGFR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125771 CVCL_SN56 HAP1 FHIT (-) cancer cell line human CVCL_SN56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3701; FHIT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125772 CVCL_SN55 HAP1 FGGY (-) 1 cancer cell line human CVCL_SN55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25610; FGGY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125773 CVCL_SN36 HAP1 FCHO1 (-) 5 cancer cell line human CVCL_SN36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29002; FCHO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125774 CVCL_SN35 HAP1 FCHO1 (-) 4 cancer cell line human CVCL_SN35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29002; FCHO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125775 CVCL_SN38 HAP1 FCHO2 (-) 2 cancer cell line human CVCL_SN38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25180; FCHO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125776 CVCL_SN37 HAP1 FCHO2 (-) 1 cancer cell line human CVCL_SN37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25180; FCHO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125777 CVCL_SN39 HAP1 FCHO2 (-) 3 cancer cell line human CVCL_SN39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25180; FCHO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125778 CVCL_0H11 PDD3F-7 induced pluripotent stem cell human CVCL_0H11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125779 CVCL_0H10 PDD3F-4 induced pluripotent stem cell human CVCL_0H10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125780 CVCL_0H13 PDD4F-4 induced pluripotent stem cell human CVCL_0H13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125781 CVCL_0H12 PDD4F-1 induced pluripotent stem cell human CVCL_0H12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125782 CVCL_0H15 PDD4F-8 induced pluripotent stem cell human CVCL_0H15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125783 CVCL_0H14 PDD4F-5 induced pluripotent stem cell human CVCL_0H14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125784 CVCL_0H06 PDB4F-4 induced pluripotent stem cell human CVCL_0H06 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125785 CVCL_0H05 PDB4F-3 induced pluripotent stem cell human CVCL_0H05 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125786 CVCL_0H08 PDC3F-1 induced pluripotent stem cell human CVCL_0H08 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125787 CVCL_0H07 PDB4F-5 induced pluripotent stem cell human CVCL_0H07 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125788 CVCL_0H09 PDD3F-1 induced pluripotent stem cell human CVCL_0H09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125789 CVCL_SN41 HAP1 FER (-) 1 cancer cell line human CVCL_SN41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3655; FER; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125790 CVCL_SN40 HAP1 FCHO2 (-) 4 cancer cell line human CVCL_SN40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25180; FCHO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125791 CVCL_SN43 HAP1 FES (-) 1 cancer cell line human CVCL_SN43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3657; FES; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125792 CVCL_SN42 HAP1 FER (-) 2 cancer cell line human CVCL_SN42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3655; FER; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125793 CVCL_SN45 HAP1 FES (-) 3 cancer cell line human CVCL_SN45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3657; FES; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125794 CVCL_SN44 HAP1 FES (-) 2 cancer cell line human CVCL_SN44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3657; FES; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125795 CVCL_SN25 HAP1 FBXO34 (-) 2 cancer cell line human CVCL_SN25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20201; FBXO34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125796 CVCL_SN24 HAP1 FBXO34 (-) 1 cancer cell line human CVCL_SN24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20201; FBXO34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125797 CVCL_SN27 HAP1 FBXO7 (-) 1 cancer cell line human CVCL_SN27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13586; FBXO7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125798 CVCL_SN26 HAP1 FBXO34 (-) 3 cancer cell line human CVCL_SN26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20201; FBXO34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125799 CVCL_SN29 HAP1 FBXW11 (-) 1 cancer cell line human CVCL_SN29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13607; FBXW11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125800 CVCL_SN28 HAP1 FBXO7 (-) 2 cancer cell line human CVCL_SN28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13586; FBXO7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125801 CVCL_K588 C0829 transformed cell line human CVCL_K588 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125802 CVCL_JT88 JHU094i induced pluripotent stem cell human CVCL_JT88 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125803 CVCL_K587 C0828 transformed cell line human CVCL_K587 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090151; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125804 CVCL_JT87 JHU093i induced pluripotent stem cell human CVCL_JT87 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125805 CVCL_K589 C0830 transformed cell line human CVCL_K589 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090153; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125806 CVCL_JT89 JHU095i induced pluripotent stem cell human CVCL_JT89 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125807 CVCL_K584 C0825 transformed cell line human CVCL_K584 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090148; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125808 CVCL_JT84 JHU089i induced pluripotent stem cell human CVCL_JT84 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125809 CVCL_K583 C0824 transformed cell line human CVCL_K583 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090147; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125810 CVCL_JT83 JHU088i induced pluripotent stem cell human CVCL_JT83 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125811 CVCL_K586 C0827 transformed cell line human CVCL_K586 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090150; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125812 CVCL_JT86 JHU091i induced pluripotent stem cell human CVCL_JT86 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125813 CVCL_K585 C0826 transformed cell line human CVCL_K585 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090149; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125814 CVCL_JT85 JHU090i induced pluripotent stem cell human CVCL_JT85 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125815 CVCL_K580 C0821 transformed cell line human CVCL_K580 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090144; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125816 CVCL_JT80 JHU085i induced pluripotent stem cell human CVCL_JT80 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125817 CVCL_K582 C0823 transformed cell line human CVCL_K582 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090146; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125818 CVCL_SN30 HAP1 FBXW7 (-) 1 cancer cell line human CVCL_SN30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16712; FBXW7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125819 CVCL_JT82 JHU087i induced pluripotent stem cell human CVCL_JT82 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125820 CVCL_K581 C0822 transformed cell line human CVCL_K581 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090145; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125821 CVCL_JT81 JHU086i induced pluripotent stem cell human CVCL_JT81 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125822 CVCL_SN32 HAP1 FCHO1 (-) 1 cancer cell line human CVCL_SN32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29002; FCHO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125823 CVCL_SN31 HAP1 FBXW7 (-) 2 cancer cell line human CVCL_SN31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16712; FBXW7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125824 CVCL_SN34 HAP1 FCHO1 (-) 3 cancer cell line human CVCL_SN34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29002; FCHO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125825 CVCL_SN33 HAP1 FCHO1 (-) 2 cancer cell line human CVCL_SN33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29002; FCHO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125826 CVCL_SN14 HAP1 FASLG (-) 1 cancer cell line human CVCL_SN14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11936; FASLG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125827 CVCL_SN13 HAP1 FAS (-) cancer cell line human CVCL_SN13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11920; FAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125828 CVCL_SN16 HAP1 FASN (-) 1 cancer cell line human CVCL_SN16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3594; FASN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125829 CVCL_SN15 HAP1 FASLG (-) 2 cancer cell line human CVCL_SN15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11936; FASLG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125830 CVCL_SN18 HAP1 FASTK (-) 1 cancer cell line human CVCL_SN18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24676; FASTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125831 CVCL_SN17 HAP1 FASN (-) 2 cancer cell line human CVCL_SN17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3594; FASN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125832 CVCL_SN19 HAP1 FASTK (-) 2 cancer cell line human CVCL_SN19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24676; FASTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125833 CVCL_K599 C0843 transformed cell line human CVCL_K599 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090166; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125834 CVCL_JT99 JHU105i induced pluripotent stem cell human CVCL_JT99 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125835 CVCL_K598 C0840 transformed cell line human CVCL_K598 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090163; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125836 CVCL_JT98 JHU104i induced pluripotent stem cell human CVCL_JT98 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125837 CVCL_K595 C0836 transformed cell line human CVCL_K595 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090159; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125838 CVCL_JT95 JHU101i induced pluripotent stem cell human CVCL_JT95 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125839 CVCL_K594 C0835 transformed cell line human CVCL_K594 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125840 CVCL_JT94 JHU100i induced pluripotent stem cell human CVCL_JT94 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125841 CVCL_K597 C0839 transformed cell line human CVCL_K597 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125842 CVCL_JT97 JHU103i induced pluripotent stem cell human CVCL_JT97 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125843 CVCL_K596 C0837 transformed cell line human CVCL_K596 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090160; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125844 CVCL_JT96 JHU102i induced pluripotent stem cell human CVCL_JT96 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125845 CVCL_K591 C0832 transformed cell line human CVCL_K591 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125846 CVCL_JT91 JHU097i induced pluripotent stem cell human CVCL_JT91 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125847 CVCL_K590 C0831 transformed cell line human CVCL_K590 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090154; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125848 CVCL_JT90 JHU096i induced pluripotent stem cell human CVCL_JT90 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125849 CVCL_K593 C0833 transformed cell line human CVCL_K593 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090156; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125850 CVCL_JT93 JHU099i induced pluripotent stem cell human CVCL_JT93 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125851 CVCL_JT92 JHU098i induced pluripotent stem cell human CVCL_JT92 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125852 CVCL_K592 TCAF cancer cell line human CVCL_K592 CL:0000010 Unspecified Characteristics: No information is available on this cell line. 21125853 CVCL_SN21 HAP1 FASTKD3 (-) 1 cancer cell line human CVCL_SN21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28758; FASTKD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125854 CVCL_SN20 HAP1 FASTK (-) 3 cancer cell line human CVCL_SN20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24676; FASTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125855 CVCL_SN23 HAP1 FBXO18 (-) 1 cancer cell line human CVCL_SN23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13620; FBH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125856 CVCL_SN22 HAP1 FAT1 (-) 1 cancer cell line human CVCL_SN22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3595; FAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21125857 CVCL_9B59 DD0721 transformed cell line human CVCL_9B59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125858 CVCL_9B50 DD0704 transformed cell line human CVCL_9B50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125859 CVCL_9B56 DD0711 finite cell line human CVCL_9B56 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125860 CVCL_9B55 DD0710 transformed cell line human CVCL_9B55 CL:0000010 Karyotypic information: 47,XXY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125861 CVCL_9B58 DD0718 transformed cell line human CVCL_9B58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125862 CVCL_9B57 DD0713 transformed cell line human CVCL_9B57 CL:0000010 Karyotypic information: 46,XX; 47,XX,+9 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125863 CVCL_9B52 DD0706 finite cell line human CVCL_9B52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21125864 CVCL_9B51 DD0705 transformed cell line human CVCL_9B51 CL:0000010 Karyotypic information: 46,XY,del(20)(p11.21;p11.23) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125865 CVCL_9B54 DD0709 transformed cell line human CVCL_9B54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125866 CVCL_9B53 DD0707 transformed cell line human CVCL_9B53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125867 CVCL_9B61 DD0723 transformed cell line human CVCL_9B61 CL:0000010 Karyotypic information: 46,XX,t(3;10)(p24.5;q25.2)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125868 CVCL_9B60 DD0722 transformed cell line human CVCL_9B60 CL:0000010 Karyotypic information: 46,XX,+10q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125869 CVCL_9B67 DD0730 transformed cell line human CVCL_9B67 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(13)(q21.3;q22.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125870 CVCL_9B66 DD0729 transformed cell line human CVCL_9B66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125871 CVCL_9B69 DD0732 transformed cell line human CVCL_9B69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125872 CVCL_9B68 DD0731 transformed cell line human CVCL_9B68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125873 CVCL_9B63 DD0725 transformed cell line human CVCL_9B63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125874 CVCL_9B62 DD0724 transformed cell line human CVCL_9B62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125875 CVCL_9B65 DD0728 transformed cell line human CVCL_9B65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125876 CVCL_9B64 DD0727 transformed cell line human CVCL_9B64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125877 CVCL_9B38 DD0677 finite cell line human CVCL_9B38 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125878 CVCL_9B37 DD0676 finite cell line human CVCL_9B37 CL:0000010 Karyotypic information: 46,XY; 46,X,+mar(Y) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21125879 CVCL_9B39 DD0679 transformed cell line human CVCL_9B39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125880 CVCL_9B34 DD0672 transformed cell line human CVCL_9B34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125881 CVCL_9B33 DD0671 transformed cell line human CVCL_9B33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125882 CVCL_9B36 DD0675 transformed cell line human CVCL_9B36 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),t(7;11)(q36.1;q23.3)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125883 CVCL_9B35 DD0674 transformed cell line human CVCL_9B35 CL:0000010 Karyotypic information: 46,XX,t(4;9)(q21;q13) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125884 CVCL_9B30 DD0666 transformed cell line human CVCL_9B30 CL:0000010 Karyotypic information: 46,XY,t(1;13)(p22;q32)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125885 CVCL_9B32 DD0670 finite cell line human CVCL_9B32 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125886 CVCL_9B31 DD0667 transformed cell line human CVCL_9B31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125887 CVCL_9B49 DD0701 transformed cell line human CVCL_9B49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125888 CVCL_9B48 DD0700 transformed cell line human CVCL_9B48 CL:0000010 Karyotypic information: 47,XY,+21 (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125889 CVCL_9B45 DD0693 transformed cell line human CVCL_9B45 CL:0000010 Karyotypic information: 46,XX,t(13;18)(q22;q21.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125890 CVCL_9B44 DD0689 finite cell line human CVCL_9B44 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21125891 CVCL_9B47 DD0698 transformed cell line human CVCL_9B47 CL:0000010 Karyotypic information: 47,XXY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125892 CVCL_9B46 DD0696 finite cell line human CVCL_9B46 CL:0000010 Karyotypic information: 46,XX,del(18)(pter->q21.1) de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21125893 CVCL_9B41 DD0683 transformed cell line human CVCL_9B41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125894 CVCL_9B40 DD0682 transformed cell line human CVCL_9B40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125895 CVCL_9B43 DD0685 transformed cell line human CVCL_9B43 CL:0000010 Karyotypic information: 46,XY,t(1;2)(2;14)(p22;q31)(p16;q22) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125896 CVCL_9B42 DD0684 transformed cell line human CVCL_9B42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125897 CVCL_9B19 DD0648 transformed cell line human CVCL_9B19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125898 CVCL_0H80 SMF No.21 induced pluripotent stem cell human CVCL_0H80 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125899 CVCL_9B16 DD0645 transformed cell line human CVCL_9B16 CL:0000010 Karyotypic information: 45,X0 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125900 CVCL_0H82 GM20124 finite cell line human CVCL_0H82 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125901 CVCL_9B15 DD0644 transformed cell line human CVCL_9B15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125902 CVCL_0H81 GM11661 finite cell line human CVCL_0H81 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125903 CVCL_9B18 DD0647 transformed cell line human CVCL_9B18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125904 CVCL_0H84 LOTPD-iPSC induced pluripotent stem cell human CVCL_0H84 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125905 CVCL_9B17 DD0646 transformed cell line human CVCL_9B17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125906 CVCL_0H83 ITPD-iPSC induced pluripotent stem cell human CVCL_0H83 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125907 CVCL_0H86 S1-M1-3.2 cancer cell line human CVCL_0H86 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Colon. Female 21125908 CVCL_0H85 S1-B1-20 cancer cell line human CVCL_0H85 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:88337; Bisantrene; Derived from sampling site: Colon. Female 21125909 CVCL_0H88 S1 cancer cell line human CVCL_0H88 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Female 21125910 CVCL_0H87 S1-M1-80 cancer cell line human CVCL_0H87 CL:0000010 Sequence variation: Mutation; HGNC; 74; ABCG2; Simple; p.Arg482Gly (c.1444A>G); Zygosity=Unspecified (PubMed=11559526); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Colon. Female 21125911 CVCL_0H89 39ER22 spontaneously immortalized cell line CVCL_0H89 CL:0000010 Transfected with: HGNC; 3236; EGFR Derived from sampling site: Lung Cell type=Fibroblast.. Female 21125912 CVCL_9B12 DD0636 transformed cell line human CVCL_9B12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125913 CVCL_9B11 DD0635 finite cell line human CVCL_9B11 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21125914 CVCL_9B14 DD0638 transformed cell line human CVCL_9B14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125915 CVCL_9B13 DD0637 transformed cell line human CVCL_9B13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125916 CVCL_9B10 DD0633 transformed cell line human CVCL_9B10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125917 CVCL_0H91 1F11 hybridoma house mouse CVCL_0H91 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11448 21125918 CVCL_0H90 GS1 embryonic stem cell house mouse CVCL_0H90 CL:0000010 Breed/subspecies: 129/Sv. Unspecified 21125919 CVCL_0H93 2E11 [Mouse hybridoma against human SPP1] hybridoma house mouse CVCL_0H93 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11449 21125920 CVCL_9B27 DD0661 transformed cell line human CVCL_9B27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125921 CVCL_0H92 2C5 hybridoma house mouse CVCL_0H92 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11447 21125922 CVCL_9B26 DD0660 transformed cell line human CVCL_9B26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125923 CVCL_0H95 2H9 [Mouse hybridoma against human SPP1] hybridoma house mouse CVCL_0H95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11446 21125924 CVCL_9B29 DD0665 transformed cell line human CVCL_9B29 CL:0000010 Karyotypic information: 46,XY,t(1;13)(p22;q32)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125925 CVCL_0H94 2F10 [Mouse hybridoma against human SPP1] hybridoma house mouse CVCL_0H94 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11450 21125926 CVCL_9B28 DD0664 transformed cell line human CVCL_9B28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125927 CVCL_0H97 15C9 hybridoma house mouse CVCL_0H97 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5106 21125928 CVCL_0H96 117.1 hybridoma house mouse CVCL_0H96 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4567 21125929 CVCL_0H99 16H9 hybridoma house mouse CVCL_0H99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5108 21125930 CVCL_0H98 16C7 hybridoma house mouse CVCL_0H98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5107 21125931 CVCL_9B23 DD0652 transformed cell line human CVCL_9B23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125932 CVCL_9B22 DD0651 transformed cell line human CVCL_9B22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125933 CVCL_9B25 DD0655 transformed cell line human CVCL_9B25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125934 CVCL_9B24 DD0654 transformed cell line human CVCL_9B24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125935 CVCL_9B21 DD0650 transformed cell line human CVCL_9B21 CL:0000010 Karyotypic information: 46,XY,-4,+?der(4)(qter->p16;?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125936 CVCL_9B20 DD0649 transformed cell line human CVCL_9B20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125937 CVCL_0H60 UMNi001-B induced pluripotent stem cell human CVCL_0H60 CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21125938 CVCL_0H62 DriPS16 induced pluripotent stem cell human CVCL_0H62 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21125939 CVCL_0H61 UCBiPS7 induced pluripotent stem cell human CVCL_0H61 CL:0000010 Derived from sampling site: Umbilical cord blood. Unspecified 21125940 CVCL_0H64 PMF No.1 induced pluripotent stem cell human CVCL_0H64 CL:0000010 Derived from sampling site: Bone marrow. Female 21125941 CVCL_0H63 GRiPS induced pluripotent stem cell human CVCL_0H63 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21125942 CVCL_0H66 PMF No.4 induced pluripotent stem cell human CVCL_0H66 CL:0000010 Derived from sampling site: Bone marrow. Female 21125943 CVCL_0H65 PMF No.2 induced pluripotent stem cell human CVCL_0H65 CL:0000010 Derived from sampling site: Bone marrow. Female 21125944 CVCL_0H68 PMF No.7 induced pluripotent stem cell human CVCL_0H68 CL:0000010 Derived from sampling site: Bone marrow. Female 21125945 CVCL_0H67 PMF No.5 induced pluripotent stem cell human CVCL_0H67 CL:0000010 Derived from sampling site: Bone marrow. Female 21125946 CVCL_0H69 PMF No.11 induced pluripotent stem cell human CVCL_0H69 CL:0000010 Derived from sampling site: Bone marrow. Female 21125947 CVCL_9B09 DD0632 transformed cell line human CVCL_9B09 CL:0000010 Karyotypic information: 46,XX,del(1)(pter->q43)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125948 CVCL_9B08 DD0631 transformed cell line human CVCL_9B08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125949 CVCL_9B05 DD0624 transformed cell line human CVCL_9B05 CL:0000010 Karyotypic information: 46,X,t(Y;15)(p11;q11)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125950 CVCL_0H71 SMF No.6 induced pluripotent stem cell human CVCL_0H71 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125951 CVCL_9B04 DD0623 transformed cell line human CVCL_9B04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125952 CVCL_0H70 SMF No.5 induced pluripotent stem cell human CVCL_0H70 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125953 CVCL_9B07 DD0630 transformed cell line human CVCL_9B07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125954 CVCL_0H73 SMF No.8 induced pluripotent stem cell human CVCL_0H73 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125955 CVCL_9B06 DD0628 transformed cell line human CVCL_9B06 CL:0000010 Karyotypic information: 46,XX,inv(21)(p11;q22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125956 CVCL_0H72 SMF No.7 induced pluripotent stem cell human CVCL_0H72 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125957 CVCL_0H75 SMF No.12 induced pluripotent stem cell human CVCL_0H75 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125958 CVCL_0H74 SMF No.9 induced pluripotent stem cell human CVCL_0H74 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125959 CVCL_0H77 SMF No.16 induced pluripotent stem cell human CVCL_0H77 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125960 CVCL_0H76 SMF No.15 induced pluripotent stem cell human CVCL_0H76 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=24859480) Derived from sampling site: Peripheral blood. Female 21125961 CVCL_0H79 SMF No.20 induced pluripotent stem cell human CVCL_0H79 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125962 CVCL_0H78 SMF No.17 induced pluripotent stem cell human CVCL_0H78 CL:0000010 Derived from sampling site: Peripheral blood. Female 21125963 CVCL_9B01 DD0616 transformed cell line human CVCL_9B01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125964 CVCL_9B00 DD0613 transformed cell line human CVCL_9B00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125965 CVCL_9B03 DD0618 transformed cell line human CVCL_9B03 CL:0000010 Karyotypic information: 6,XY; 47,XY,+mar(14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21125966 CVCL_9B02 DD0617 transformed cell line human CVCL_9B02 CL:0000010 Karyotypic information: 46,XX; 47,XX+mar(5 or 19) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21125967 CVCL_K728 C0975 transformed cell line human CVCL_K728 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061021; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125968 CVCL_JV28 SCRP0202i induced pluripotent stem cell human CVCL_JV28 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125969 CVCL_K727 C0974 transformed cell line human CVCL_K727 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061020; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125970 CVCL_JV27 SCRP0104i induced pluripotent stem cell human CVCL_JV27 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125971 CVCL_K729 C0976 transformed cell line human CVCL_K729 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125972 CVCL_JV29 SCRP0203i induced pluripotent stem cell human CVCL_JV29 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125973 CVCL_K724 C0971 transformed cell line human CVCL_K724 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125974 CVCL_JV24 HVRDi001-A-1 induced pluripotent stem cell human CVCL_JV24 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=24524897) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125975 CVCL_K723 C0970 transformed cell line human CVCL_K723 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125976 CVCL_JV23 HVRDi001-A induced pluripotent stem cell human CVCL_JV23 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=24524897) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21125977 CVCL_K726 C0973 transformed cell line human CVCL_K726 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061019; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125978 CVCL_JV26 HVRDi002-A-1 induced pluripotent stem cell human CVCL_JV26 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=24524897) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21125979 CVCL_K725 C0972 transformed cell line human CVCL_K725 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061018; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125980 CVCL_JV25 HVRDi002-A induced pluripotent stem cell human CVCL_JV25 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=24524897) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21125981 CVCL_K720 C0967 transformed cell line human CVCL_K720 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125982 CVCL_JV20 JHU257i induced pluripotent stem cell human CVCL_JV20 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125983 CVCL_K722 C0969 transformed cell line human CVCL_K722 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125984 CVCL_JV22 JHU154i induced pluripotent stem cell human CVCL_JV22 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125985 CVCL_K721 C0968 transformed cell line human CVCL_K721 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125986 CVCL_JV21 JHU259i induced pluripotent stem cell human CVCL_JV21 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125987 CVCL_K739 C0986 transformed cell line human CVCL_K739 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080503; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125988 CVCL_JV39 SCRP1002i induced pluripotent stem cell human CVCL_JV39 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125989 CVCL_K738 C0985 transformed cell line human CVCL_K738 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125990 CVCL_JV38 SCRP0802i induced pluripotent stem cell human CVCL_JV38 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125991 CVCL_K735 C0982 transformed cell line human CVCL_K735 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061704; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125992 CVCL_JV35 SCRP0601i induced pluripotent stem cell human CVCL_JV35 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125993 CVCL_K734 C0981 transformed cell line human CVCL_K734 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125994 CVCL_JV34 SCRP0517i induced pluripotent stem cell human CVCL_JV34 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125995 CVCL_K737 C0984 transformed cell line human CVCL_K737 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080501; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125996 CVCL_JV37 SCRP0709i induced pluripotent stem cell human CVCL_JV37 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125997 CVCL_K736 C0983 transformed cell line human CVCL_K736 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21125998 CVCL_JV36 SCRP0608i induced pluripotent stem cell human CVCL_JV36 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21125999 CVCL_K731 C0978 transformed cell line human CVCL_K731 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126000 CVCL_JV31 SCRP0307i induced pluripotent stem cell human CVCL_JV31 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126001 CVCL_K730 C0977 transformed cell line human CVCL_K730 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126002 CVCL_JV30 SCRP0302i induced pluripotent stem cell human CVCL_JV30 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126003 CVCL_K733 C0980 transformed cell line human CVCL_K733 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126004 CVCL_JV33 SCRP0404i induced pluripotent stem cell human CVCL_JV33 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126005 CVCL_K732 C0979 transformed cell line human CVCL_K732 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93061701; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126006 CVCL_JV32 SCRP0402i induced pluripotent stem cell human CVCL_JV32 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126007 CVCL_K709 C0956 transformed cell line human CVCL_K709 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126008 CVCL_JV09 JHU244i induced pluripotent stem cell human CVCL_JV09 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126009 CVCL_K706 C0953 transformed cell line human CVCL_K706 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126010 CVCL_JV06 JHU240i induced pluripotent stem cell human CVCL_JV06 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126011 CVCL_K705 C0952 transformed cell line human CVCL_K705 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052719; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126012 CVCL_JV05 JHU238i induced pluripotent stem cell human CVCL_JV05 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126013 CVCL_K708 C0955 transformed cell line human CVCL_K708 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93060308; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126014 CVCL_JV08 JHU243i induced pluripotent stem cell human CVCL_JV08 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126015 CVCL_K707 C0954 transformed cell line human CVCL_K707 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93060307; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126016 CVCL_JV07 JHU242i induced pluripotent stem cell human CVCL_JV07 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126017 CVCL_K702 C0949 transformed cell line human CVCL_K702 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052716; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126018 CVCL_JV02 JHU235i induced pluripotent stem cell human CVCL_JV02 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126019 CVCL_K701 C0948 transformed cell line human CVCL_K701 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126020 CVCL_JV01 JHU234i induced pluripotent stem cell human CVCL_JV01 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126021 CVCL_K704 C0951 transformed cell line human CVCL_K704 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126022 CVCL_JV04 JHU237i induced pluripotent stem cell human CVCL_JV04 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126023 CVCL_K703 C0950 transformed cell line human CVCL_K703 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052717; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126024 CVCL_JV03 JHU236i induced pluripotent stem cell human CVCL_JV03 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126025 CVCL_K700 C0947 transformed cell line human CVCL_K700 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93052714; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126026 CVCL_JV00 JHU233i induced pluripotent stem cell human CVCL_JV00 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126027 CVCL_K717 C0964 transformed cell line human CVCL_K717 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126028 CVCL_JV17 JHU253i induced pluripotent stem cell human CVCL_JV17 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126029 CVCL_K716 C0963 transformed cell line human CVCL_K716 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126030 CVCL_JV16 JHU252i induced pluripotent stem cell human CVCL_JV16 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126031 CVCL_K719 C0966 transformed cell line human CVCL_K719 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126032 CVCL_JV19 JHU256i induced pluripotent stem cell human CVCL_JV19 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126033 CVCL_K718 C0965 transformed cell line human CVCL_K718 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126034 CVCL_JV18 JHU255i induced pluripotent stem cell human CVCL_JV18 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126035 CVCL_K713 C0960 transformed cell line human CVCL_K713 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126036 CVCL_JV13 JHU248i induced pluripotent stem cell human CVCL_JV13 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126037 CVCL_K712 C0959 transformed cell line human CVCL_K712 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126038 CVCL_JV12 JHU247i induced pluripotent stem cell human CVCL_JV12 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126039 CVCL_K715 C0962 transformed cell line human CVCL_K715 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126040 CVCL_JV15 JHU251i induced pluripotent stem cell human CVCL_JV15 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126041 CVCL_K714 C0961 transformed cell line human CVCL_K714 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126042 CVCL_JV14 JHU250i induced pluripotent stem cell human CVCL_JV14 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126043 CVCL_K711 C0958 transformed cell line human CVCL_K711 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126044 CVCL_JV11 JHU246i induced pluripotent stem cell human CVCL_JV11 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126045 CVCL_K710 C0957 transformed cell line human CVCL_K710 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126046 CVCL_JV10 JHU245i induced pluripotent stem cell human CVCL_JV10 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126047 CVCL_9C91 DD0907 transformed cell line human CVCL_9C91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126048 CVCL_9C90 DD0903 transformed cell line human CVCL_9C90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126049 CVCL_9C93 DD0910 transformed cell line human CVCL_9C93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126050 CVCL_9C92 DD0909 finite cell line human CVCL_9C92 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21126051 CVCL_9C99 DD0922 transformed cell line human CVCL_9C99 CL:0000010 Karyotypic information: 46,XX [87]; 47,XX,+mar(14) [13] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126052 CVCL_9C98 DD0921 transformed cell line human CVCL_9C98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126053 CVCL_9C95 DD0913 transformed cell line human CVCL_9C95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126054 CVCL_9C94 DD0912 transformed cell line human CVCL_9C94 CL:0000010 Karyotypic information: 46,XY,t(8;16) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126055 CVCL_9C97 DD0915 transformed cell line human CVCL_9C97 CL:0000010 Karyotypic information: 46,XY,t(3;6)(p21.33;p21.33)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126056 CVCL_9C96 DD0914 transformed cell line human CVCL_9C96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126057 CVCL_SP45 HAP1 GABRB3 (-) 1 cancer cell line human CVCL_SP45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4083; GABRB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126058 CVCL_T145 HEV0134 transformed cell line human CVCL_T145 HLA typing: A*24:02,33:03; B*07:02,44:03; C*07:02,14:03; DPB1*04:01,04:02; DQB1*05:01,06:04; DRB1*01:01,13:02 (RCB=HEV0134) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126059 CVCL_SP44 HAP1 GABRA5 (-) 2 cancer cell line human CVCL_SP44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4079; GABRA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126060 CVCL_T144 HEV0131 transformed cell line human CVCL_T144 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126061 CVCL_SP47 HAP1 GAD1 (-) 1 cancer cell line human CVCL_SP47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4092; GAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126062 CVCL_T147 HEV0137 transformed cell line human CVCL_T147 HLA typing: A*02:01,24:02; B*46:01,67:01; C*01:02,07:02; DPB1*02:01,05:01; DQB1*03:03,06:01; DRB1*08:03,09:01 (RCB=HEV0137) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126063 CVCL_SP46 HAP1 GABRB3 (-) 2 cancer cell line human CVCL_SP46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4083; GABRB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126064 CVCL_T146 HEV0135 transformed cell line human CVCL_T146 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126065 CVCL_SP49 HAP1 GAK (-) 2 cancer cell line human CVCL_SP49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4113; GAK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126066 CVCL_T149 HEV0140 transformed cell line human CVCL_T149 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126067 CVCL_SP48 HAP1 GAK (-) 1 cancer cell line human CVCL_SP48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4113; GAK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126068 CVCL_T148 HEV0139 transformed cell line human CVCL_T148 HLA typing: A*02:06,26:01; B*40:02,54:01; C*01:02,03:04; DPB1*02:01,05:01; DQB1*03:03,06:02; DRB1*09:01,15:01 (RCB=HEV0139) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126069 CVCL_0J00 EGR-G101 embryonic stem cell house mouse CVCL_0J00 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: C57BL/6NCr. Male 21126070 CVCL_0J02 B6J-23^(UTR) embryonic stem cell house mouse CVCL_0J02 CL:0000010 Breed/subspecies: C57BL/6J. Male 21126071 CVCL_0J01 EGR-101 embryonic stem cell house mouse CVCL_0J01 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: C57BL/6N. Male 21126072 CVCL_SP50 HAP1 GAK (-) 3 cancer cell line human CVCL_SP50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4113; GAK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126073 CVCL_T150 HEV0141 transformed cell line human CVCL_T150 HLA typing: A*31:01,33:03; B*48:01,58:01; C*03:02,08:01; DPB1*03:01,04:02; DQB1*03:03,06:09; DRB1*09:01,13:02 (RCB=HEV0141) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126074 CVCL_SP52 HAP1 GALT (-) 2 cancer cell line human CVCL_SP52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4135; GALT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126075 CVCL_T152 HEV0145 transformed cell line human CVCL_T152 HLA typing: A*02:06,24:02; B*40:01,40:06; C*07:02,08:01; DPB1*02:01; DQB1*03:02,03:03; DRB1*04:06,09:01 (RCB=HEV0145) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126076 CVCL_SP51 HAP1 GALT (-) 1 cancer cell line human CVCL_SP51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4135; GALT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126077 CVCL_T151 HEV0144 transformed cell line human CVCL_T151 HLA typing: A*02:06,26:02; B*07:02,52:01; C*07:02,12:02; DPB1*04:02,09:01; DQB1*05:01,06:01; DRB1*01:01,15:02 (RCB=HEV0144) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126078 CVCL_SP54 HAP1 GANAB (-) 1 cancer cell line human CVCL_SP54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4138; GANAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126079 CVCL_T154 HEV0150 transformed cell line human CVCL_T154 HLA typing: A*24:02; B*15:18,52:01; C*08:01,12:02; DPB1*02:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0150) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126080 CVCL_SP53 HAP1 GAMT (-) cancer cell line human CVCL_SP53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4136; GAMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126081 CVCL_T153 HEV0149 transformed cell line human CVCL_T153 HLA typing: A*26:01,31:01; B*07:02,51:01; C*07:02,14:02; DPB1*02:01,05:01; DQB1*03:01,05:01; DRB1*01:01,14:03 (RCB=HEV0149) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126082 CVCL_SP34 HAP1 GABARAP (-) 3 cancer cell line human CVCL_SP34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4067; GABARAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126083 CVCL_T134 HEV0112 transformed cell line human CVCL_T134 HLA typing: A*24:02; B*35:01,52:01; C*12:02,15:02; DPB1*05:01,09:01; DQB1*03:01,06:01; DRB1*14:06,15:02 (RCB=HEV0112) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126084 CVCL_SP33 HAP1 GABARAP (-) 2 cancer cell line human CVCL_SP33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4067; GABARAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126085 CVCL_T133 HEV0110 transformed cell line human CVCL_T133 HLA typing: A*24:02; B*15:07,15:18; C*03:03,07:04:01; DPB1*02:01,05:01; DQB1*03:01,03:02; DRB1*04:01,04:03 (RCB=HEV0110) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126086 CVCL_SP36 HAP1 GABARAP (-) 5 cancer cell line human CVCL_SP36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4067; GABARAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126087 CVCL_T136 HEV0117 transformed cell line human CVCL_T136 HLA typing: A*02:06,33:03; B*44:03,56:01; C*04:01,14:03; DPB1*02:02,05:01; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0117) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126088 CVCL_SP35 HAP1 GABARAP (-) 4 cancer cell line human CVCL_SP35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4067; GABARAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126089 CVCL_T135 HEV0116 transformed cell line human CVCL_T135 HLA typing: A*02:10,24:02; B*40:06,52:01; C*08:01,12:02; DPB1*02:02,09:01; DQB1*05:03,06:01; DRB1*14:05,15:02 (RCB=HEV0116) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126090 CVCL_SP38 HAP1 GABARAPL1 (-) 2 cancer cell line human CVCL_SP38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4068; GABARAPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126091 CVCL_T138 HEV0121 transformed cell line human CVCL_T138 HLA typing: A*24:02,33:03; B*40:02,44:03; C*03:04,14:03; DPB1*02:01; DQB1*03:02,06:04; DRB1*04:06,13:02 (RCB=HEV0121) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126092 CVCL_SP37 HAP1 GABARAPL1 (-) 1 cancer cell line human CVCL_SP37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4068; GABARAPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126093 CVCL_T137 HEV0120 transformed cell line human CVCL_T137 HLA typing: A*01:01,26:01; B*37:01,39:01; C*06:02,07:02; DPB1*02:01,04:02; DQB1*05:01; DRB1*01:01,10:01 (RCB=HEV0120) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126094 CVCL_SP39 HAP1 GABARAPL2 (-) 1 cancer cell line human CVCL_SP39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13291; GABARAPL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126095 CVCL_T139 HEV0124 transformed cell line human CVCL_T139 HLA typing: A*24:02,26:01; B*35:01,40:02; C*03:04,08:01; DPB1*02:01,05:01; DQB1*03:03,04:02; DRB1*04:10,09:01 (RCB=HEV0124) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126096 CVCL_0J11 NAT1(-/-)ES(B12) embryonic stem cell house mouse CVCL_0J11 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126097 CVCL_0J10 NAT1(-/-)ES(B2) embryonic stem cell house mouse CVCL_0J10 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126098 CVCL_0J13 aBJ-2 embryonic stem cell house mouse CVCL_0J13 CL:0000010 Breed/subspecies: C57BL/6Cr x JF1. Male 21126099 CVCL_0J12 NAT1(-/-)ES(C3) embryonic stem cell house mouse CVCL_0J12 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126100 CVCL_0J04 B6N-22^(UTR) embryonic stem cell house mouse CVCL_0J04 CL:0000010 Breed/subspecies: C57BL/6NCrlCrlj. Male 21126101 CVCL_0J03 B6J-S1^(UTR) embryonic stem cell house mouse CVCL_0J03 CL:0000010 Breed/subspecies: C57BL/6J. Male 21126102 CVCL_0J06 NAT1(+/-)ES(A7) embryonic stem cell house mouse CVCL_0J06 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126103 CVCL_0J05 B6NJ-22^(UTR) embryonic stem cell house mouse CVCL_0J05 CL:0000010 Breed/subspecies: C57BL/6NCrlCrlj x C57BL/6J. Male 21126104 CVCL_0J08 NAT1(+/-)ES(B4) embryonic stem cell house mouse CVCL_0J08 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126105 CVCL_0J07 BXM3 embryonic stem cell house mouse CVCL_0J07 CL:0000010 Breed/subspecies: C57BL/6 x MSM. Discontinued: RCB; RCB2704; true Unspecified 21126106 CVCL_0J09 NAT1(+/-)ES(C1) embryonic stem cell house mouse CVCL_0J09 CL:0000010 Breed/subspecies: 129S4/SvJae. Unspecified 21126107 CVCL_SP41 HAP1 GABBR1 (-) 1 cancer cell line human CVCL_SP41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4070; GABBR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126108 CVCL_T141 HEV0127 transformed cell line human CVCL_T141 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126109 CVCL_SP40 HAP1 GABARAPL2 (-) 2 cancer cell line human CVCL_SP40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13291; GABARAPL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126110 CVCL_T140 HEV0126 transformed cell line human CVCL_T140 HLA typing: A*24:02,26:01; B*40:02,54:01; C*01:02,03:04; DPB1*05:01; DQB1*03:03,06:01; DRB1*08:03,09:01 (RCB=HEV0126) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126111 CVCL_SP43 HAP1 GABRA5 (-) 1 cancer cell line human CVCL_SP43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4079; GABRA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126112 CVCL_T143 HEV0130 transformed cell line human CVCL_T143 HLA typing: A*24:02,31:01; B*07:02,56:01; C*04:01,07:02; DPB1*04:02,05:01; DQB1*04:01,05:01; DRB1*01:01,04:05 (RCB=HEV0130) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126113 CVCL_SP42 HAP1 GABBR1 (-) 2 cancer cell line human CVCL_SP42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4070; GABBR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126114 CVCL_T142 HEV0128 transformed cell line human CVCL_T142 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126115 CVCL_SP23 HAP1 FZD8 (-) 1 cancer cell line human CVCL_SP23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4046; FZD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126116 CVCL_T123 HEV0095 transformed cell line human CVCL_T123 HLA typing: A*24:02,31:01; B*54:01; C*01:02,03:04; DPB1*02:01,05:01; DQB1*04:01,05:02; DRB1*04:05,14:01 (RCB=HEV0095) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126117 CVCL_SP22 HAP1 FZD7 (-) 2 cancer cell line human CVCL_SP22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4045; FZD7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126118 CVCL_T122 HEV0093 transformed cell line human CVCL_T122 HLA typing: A*02:01,24:02; B*35:01,40:01; C*03:03,03:04; DPB1*04:01,05:01; DQB1*03:02,05:03; DRB1*08:02,14:54 (RCB=HEV0093) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126119 CVCL_SP25 HAP1 FZD9 (-) 1 cancer cell line human CVCL_SP25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4047; FZD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126120 CVCL_T125 HEV0098 transformed cell line human CVCL_T125 HLA typing: A*24:02,33:03; B*44:03,52:01; C*12:02,14:03; DPB1*02:01,05:01; DQB1*03:01,06:04; DRB1*13:02,15:01 (RCB=HEV0098) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126121 CVCL_SP24 HAP1 FZD8 (-) 2 cancer cell line human CVCL_SP24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4046; FZD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126122 CVCL_T124 HEV0096 transformed cell line human CVCL_T124 HLA typing: A*02:01,26:03; B*51:01,54:01; C*03:04; DPB1*02:01,05:01; DQB1*04:01,05:02; DRB1*04:05,14:54 (RCB=HEV0096) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126123 CVCL_SP27 HAP1 FZD9 (-) 3 cancer cell line human CVCL_SP27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4047; FZD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126124 CVCL_T127 HEV0100 transformed cell line human CVCL_T127 HLA typing: A*24:02,26:01; B*48:01,59:01; C*01:02,08:03; DPB1*02:01,19:01; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0100) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126125 CVCL_SP26 HAP1 FZD9 (-) 2 cancer cell line human CVCL_SP26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4047; FZD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126126 CVCL_T126 HEV0099 transformed cell line human CVCL_T126 HLA typing: A*02:06,11:01; B*15:01,54:01; C*01:02,04:01; DPB1*02:01,03:01; DQB1*03:02,04:01; DRB1*04:05,04:06 (RCB=HEV0099) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126127 CVCL_SP29 HAP1 FZD9 (-) 5 cancer cell line human CVCL_SP29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4047; FZD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126128 CVCL_T129 HEV0102 transformed cell line human CVCL_T129 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126129 CVCL_SP28 HAP1 FZD9 (-) 4 cancer cell line human CVCL_SP28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4047; FZD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126130 CVCL_T128 HEV0101 transformed cell line human CVCL_T128 HLA typing: A*24:02; B*40:02,52:01; C*03:04,12:02; DPB1*02:01,05:01; DQB1*04:02,06:01; DRB1*04:10,15:02 (RCB=HEV0101) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126131 CVCL_K789 C2027 transformed cell line human CVCL_K789 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126132 CVCL_JV89 SCRP4603i induced pluripotent stem cell human CVCL_JV89 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126133 CVCL_K786 C2024 transformed cell line human CVCL_K786 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950220159; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126134 CVCL_JV86 SCRP4502i induced pluripotent stem cell human CVCL_JV86 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126135 CVCL_K785 C2023 transformed cell line human CVCL_K785 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126136 CVCL_JV85 SCRP4406i induced pluripotent stem cell human CVCL_JV85 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126137 CVCL_K788 C2026 transformed cell line human CVCL_K788 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126138 CVCL_JV88 SCRP4602i induced pluripotent stem cell human CVCL_JV88 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126139 CVCL_K787 C2025 transformed cell line human CVCL_K787 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126140 CVCL_JV87 SCRP4505i induced pluripotent stem cell human CVCL_JV87 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126141 CVCL_K782 C2020 transformed cell line human CVCL_K782 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126142 CVCL_JV82 SCRP4301i induced pluripotent stem cell human CVCL_JV82 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126143 CVCL_K781 C2019 transformed cell line human CVCL_K781 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208131; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126144 CVCL_JV81 SCRP4203i induced pluripotent stem cell human CVCL_JV81 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126145 CVCL_K784 C2022 transformed cell line human CVCL_K784 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126146 CVCL_JV84 SCRP4403i induced pluripotent stem cell human CVCL_JV84 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126147 CVCL_K783 C2021 transformed cell line human CVCL_K783 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126148 CVCL_JV83 SCRP4305i induced pluripotent stem cell human CVCL_JV83 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126149 CVCL_K780 C2018 transformed cell line human CVCL_K780 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126150 CVCL_JV80 SCRP4201i induced pluripotent stem cell human CVCL_JV80 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126151 CVCL_SP30 HAP1 GAA (-) cancer cell line human CVCL_SP30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4065; GAA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126152 CVCL_T130 HEV0104 transformed cell line human CVCL_T130 HLA typing: A*02:06,24:02; B*51:01,54:01; C*01:02,14:02; DPB1*02:01,05:01; DQB1*03:01,04:01; DRB1*04:05,11:01 (RCB=HEV0104) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126153 CVCL_SP32 HAP1 GABARAP (-) 1 cancer cell line human CVCL_SP32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4067; GABARAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126154 CVCL_T132 HEV0109 transformed cell line human CVCL_T132 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126155 CVCL_SP31 HAP1 GAB1 (-) 1 cancer cell line human CVCL_SP31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4066; GAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126156 CVCL_T131 HEV0106 transformed cell line human CVCL_T131 HLA typing: A*02:01,33:03; B*44:03,54:01; C*01:02,14:03; DPB1*05:01; DQB1*04:01,06:01; DRB1*04:05,08:03 (RCB=HEV0106) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126157 CVCL_SP12 HAP1 FZD2 (-) cancer cell line human CVCL_SP12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4040; FZD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126158 CVCL_T112 HEV0078 transformed cell line human CVCL_T112 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126159 CVCL_SP11 HAP1 FZD1 (-) 2 cancer cell line human CVCL_SP11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4038; FZD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126160 CVCL_T111 HEV0077 transformed cell line human CVCL_T111 HLA typing: A*11:01,24:02; B*07:02,48:01; C*07:02,08:01; DPB1*04:02,13:01; DQB1*03:01,05:01; DRB1*01:01,09:01 (RCB=HEV0077) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126161 CVCL_SP14 HAP1 FZD3 (-) 2 cancer cell line human CVCL_SP14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4041; FZD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126162 CVCL_T114 HEV0082 transformed cell line human CVCL_T114 HLA typing: A*24:02,33:03; B*44:03,52:01; C*12:02,14:03; DPB1*02:01,05:01; DQB1*06:02,06:04; DRB1*13:02,15:01 (RCB=HEV0082) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126163 CVCL_SP13 HAP1 FZD3 (-) 1 cancer cell line human CVCL_SP13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4041; FZD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126164 CVCL_T113 HEV0079 transformed cell line human CVCL_T113 HLA typing: A*02:06,33:03; B*40:02,44:03; C*03:04,14:03; DPB1*04:01,05:01; DQB1*06:01,06:04; DRB1*08:03,13:02 (RCB=HEV0079) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126165 CVCL_SP16 HAP1 FZD4 (-) 2 cancer cell line human CVCL_SP16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4042; FZD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126166 CVCL_T116 HEV0085 transformed cell line human CVCL_T116 HLA typing: A*24:02,31:01; B*07:02,55:02; C*03:03,07:02; DPB1*02:01,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0085) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126167 CVCL_SP15 HAP1 FZD4 (-) 1 cancer cell line human CVCL_SP15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4042; FZD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126168 CVCL_T115 HEV0083 transformed cell line human CVCL_T115 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126169 CVCL_SP18 HAP1 FZD5 (-) cancer cell line human CVCL_SP18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4043; FZD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126170 CVCL_T118 HEV0089 transformed cell line human CVCL_T118 HLA typing: A*02:06,02:07; B*15:18,46:01; C*01:03,08:01; DPB1*05:01; DQB1*03:01,03:03; DRB1*09:01,12:01 (RCB=HEV0089) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126171 CVCL_SP17 HAP1 FZD4 (-) 3 cancer cell line human CVCL_SP17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4042; FZD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126172 CVCL_T117 HEV0086 transformed cell line human CVCL_T117 HLA typing: A*24:02; B*52:01,54:01; C*01:02,12:02; DPB1*05:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0086) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126173 CVCL_SP19 HAP1 FZD6 (-) 1 cancer cell line human CVCL_SP19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4044; FZD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126174 CVCL_T119 HEV0090 transformed cell line human CVCL_T119 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126175 CVCL_K797 C2035 transformed cell line human CVCL_K797 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022093; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126176 CVCL_JV97 SCRP5707i induced pluripotent stem cell human CVCL_JV97 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126177 CVCL_K796 C2034 transformed cell line human CVCL_K796 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022092; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126178 CVCL_JV96 SCRP5603i induced pluripotent stem cell human CVCL_JV96 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126179 CVCL_K799 C2037 transformed cell line human CVCL_K799 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022095; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126180 CVCL_JV99 SCRP6007i induced pluripotent stem cell human CVCL_JV99 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126181 CVCL_K798 C2036 transformed cell line human CVCL_K798 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022094; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126182 CVCL_JV98 SCRP5803i induced pluripotent stem cell human CVCL_JV98 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126183 CVCL_K793 C2031 transformed cell line human CVCL_K793 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022089; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126184 CVCL_JV93 SCRP5003i induced pluripotent stem cell human CVCL_JV93 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126185 CVCL_K792 C2030 transformed cell line human CVCL_K792 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022088; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126186 CVCL_JV92 SCRP4903i induced pluripotent stem cell human CVCL_JV92 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126187 CVCL_K795 C2033 transformed cell line human CVCL_K795 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022091; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126188 CVCL_JV95 SCRP5508i induced pluripotent stem cell human CVCL_JV95 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126189 CVCL_K794 C2032 transformed cell line human CVCL_K794 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022090; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126190 CVCL_JV94 SCRP5402i induced pluripotent stem cell human CVCL_JV94 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126191 CVCL_K791 C2029 transformed cell line human CVCL_K791 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022087; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126192 CVCL_JV91 SCRP4803i induced pluripotent stem cell human CVCL_JV91 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126193 CVCL_K790 C2028 transformed cell line human CVCL_K790 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950220158; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126194 CVCL_JV90 SCRP4703i induced pluripotent stem cell human CVCL_JV90 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126195 CVCL_SP21 HAP1 FZD7 (-) 1 cancer cell line human CVCL_SP21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4045; FZD7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126196 CVCL_T121 HEV0092 transformed cell line human CVCL_T121 HLA typing: A*24:02; B*07:02,13:01; C*03:03,07:02; DPB1*02:01,04:02; DQB1*03:01,05:01; DRB1*01:01,12:02 (RCB=HEV0092) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126197 CVCL_SP20 HAP1 FZD6 (-) 2 cancer cell line human CVCL_SP20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4044; FZD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126198 CVCL_T120 HEV0091 transformed cell line human CVCL_T120 HLA typing: A*02:06,02:07; B*15:18,46:01; C*01:03,08:01; DPB1*05:01; DQB1*03:01,03:03; DRB1*09:01,12:01 (RCB=HEV0091) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126199 CVCL_SP01 HAP1 FUNDC2 (-) 1 cancer cell line human CVCL_SP01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24925; FUNDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126200 CVCL_T101 HEV0063 transformed cell line human CVCL_T101 HLA typing: A*02:06,33:03; B*39:01,44:03; C*07:02,14:03; DPB1*03:01,04:01; DQB1*04:01,06:04; DRB1*04:05,13:02 (RCB=HEV0063) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126201 CVCL_SP00 HAP1 FTSJ1 (-) 1 cancer cell line human CVCL_SP00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13254; FTSJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126202 CVCL_T100 HEV0060 transformed cell line human CVCL_T100 HLA typing: A*02:01,24:02; B*35:01,52:01; C*08:01,12:02; DPB1*04:02,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0060) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126203 CVCL_SP03 HAP1 FURIN (-) 2 cancer cell line human CVCL_SP03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8568; FURIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126204 CVCL_T103 HEV0065 transformed cell line human CVCL_T103 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126205 CVCL_SP02 HAP1 FURIN (-) 1 cancer cell line human CVCL_SP02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8568; FURIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126206 CVCL_T102 HEV0064 transformed cell line human CVCL_T102 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126207 CVCL_SP05 HAP1 FUS (-) 2 cancer cell line human CVCL_SP05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126208 CVCL_T105 HEV0067 transformed cell line human CVCL_T105 HLA typing: A*02:01,31:01; B*40:01,52:01; C*03:04,12:02; DPB1*05:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0067) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126209 CVCL_SP04 HAP1 FUS (-) 1 cancer cell line human CVCL_SP04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4010; FUS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126210 CVCL_T104 HEV0066 transformed cell line human CVCL_T104 HLA typing: A*24:02; B*35:01,52:01; C*03:03,12:02; DPB1*05:01,06:01; DQB1*03:01,06:01; DRB1*12:01,15:02 (RCB=HEV0066) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126211 CVCL_SP07 HAP1 FYN (-) 1 cancer cell line human CVCL_SP07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4037; FYN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126212 CVCL_T107 HEV0070 transformed cell line human CVCL_T107 HLA typing: A*24:02,26:01; B*39:04,54:01; C*01:02,07:02; DPB1*05:01; DQB1*03:02,04:01; DRB1*04:03,04:05 (RCB=HEV0070) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126213 CVCL_SP06 HAP1 FXR1 (-) 1 cancer cell line human CVCL_SP06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4023; FXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126214 CVCL_T106 HEV0068 transformed cell line human CVCL_T106 HLA typing: A*02:01,24:02; B*07:02,56:01; C*04:01,07:02; DPB1*04:02,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0068) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126215 CVCL_SP09 HAP1 FYN (-) 3 cancer cell line human CVCL_SP09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4037; FYN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126216 CVCL_T109 HEV0073 transformed cell line human CVCL_T109 HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02; DPB1*04:02,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0073) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126217 CVCL_SP08 HAP1 FYN (-) 2 cancer cell line human CVCL_SP08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4037; FYN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126218 CVCL_T108 HEV0071 transformed cell line human CVCL_T108 HLA typing: A*02:06,24:02; B*39:01,52:01; C*07:02,12:02; DPB1*02:01,09:01; DQB1*04:02,06:01; DRB1*08:02,15:02 (RCB=HEV0071) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126219 CVCL_K768 C2007 transformed cell line human CVCL_K768 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208106; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126220 CVCL_JV68 SCRP2508i induced pluripotent stem cell human CVCL_JV68 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126221 CVCL_K767 C1020 transformed cell line human CVCL_K767 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606285; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126222 CVCL_JV67 SCRP2506i induced pluripotent stem cell human CVCL_JV67 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126223 CVCL_K769 C2008 transformed cell line human CVCL_K769 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208105; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126224 CVCL_JV69 SCRP2706i induced pluripotent stem cell human CVCL_JV69 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126225 CVCL_K764 C1017 transformed cell line human CVCL_K764 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606318; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126226 CVCL_JV64 SCRP2411i induced pluripotent stem cell human CVCL_JV64 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126227 CVCL_K763 C1016 transformed cell line human CVCL_K763 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606317; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126228 CVCL_JV63 SCRP2409i induced pluripotent stem cell human CVCL_JV63 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126229 CVCL_K766 C1019 transformed cell line human CVCL_K766 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606319; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126230 CVCL_JV66 SCRP2503i induced pluripotent stem cell human CVCL_JV66 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126231 CVCL_K765 C1018 transformed cell line human CVCL_K765 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606321; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126232 CVCL_JV65 SCRP2501i induced pluripotent stem cell human CVCL_JV65 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126233 CVCL_K760 C1013 transformed cell line human CVCL_K760 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606195; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126234 CVCL_JV60 SCRP2307i induced pluripotent stem cell human CVCL_JV60 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126235 CVCL_K762 C1015 transformed cell line human CVCL_K762 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606316; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126236 CVCL_JV62 SCRP2407i induced pluripotent stem cell human CVCL_JV62 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126237 CVCL_K761 C1014 transformed cell line human CVCL_K761 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606315; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126238 CVCL_JV61 SCRP2310i induced pluripotent stem cell human CVCL_JV61 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126239 CVCL_SP10 HAP1 FZD1 (-) 1 cancer cell line human CVCL_SP10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4038; FZD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126240 CVCL_T110 HEV0074 transformed cell line human CVCL_T110 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126241 CVCL_K779 C2017 transformed cell line human CVCL_K779 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950220151; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126242 CVCL_JV79 SCRP4102i induced pluripotent stem cell human CVCL_JV79 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126243 CVCL_K778 C2016 transformed cell line human CVCL_K778 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950220150; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126244 CVCL_JV78 SCRP3901i induced pluripotent stem cell human CVCL_JV78 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126245 CVCL_K775 C2014 [1st copy] transformed cell line human CVCL_K775 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208138; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126246 CVCL_JV75 SCRP3601i induced pluripotent stem cell human CVCL_JV75 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126247 CVCL_K774 C2013 transformed cell line human CVCL_K774 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126248 CVCL_JV74 SCRP3510i induced pluripotent stem cell human CVCL_JV74 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126249 CVCL_K777 C2015 transformed cell line human CVCL_K777 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950220149; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126250 CVCL_JV77 SCRP3803i induced pluripotent stem cell human CVCL_JV77 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126251 CVCL_K776 C2014 [2nd copy] transformed cell line human CVCL_K776 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051587; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126252 CVCL_JV76 SCRP3702i induced pluripotent stem cell human CVCL_JV76 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126253 CVCL_K771 C2010 transformed cell line human CVCL_K771 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208108; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126254 CVCL_JV71 SCRP3202i induced pluripotent stem cell human CVCL_JV71 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126255 CVCL_K770 C2009 transformed cell line human CVCL_K770 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208107; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126256 CVCL_JV70 SCRP2801i induced pluripotent stem cell human CVCL_JV70 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126257 CVCL_K773 C2012 transformed cell line human CVCL_K773 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126258 CVCL_JV73 SCRP3401i induced pluripotent stem cell human CVCL_JV73 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126259 CVCL_K772 C2011 transformed cell line human CVCL_K772 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 941208104; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126260 CVCL_JV72 SCRP3304i induced pluripotent stem cell human CVCL_JV72 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126261 CVCL_K749 C0996 transformed cell line human CVCL_K749 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126262 CVCL_JV49 SCRP2001i induced pluripotent stem cell human CVCL_JV49 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126263 CVCL_K746 C0993 transformed cell line human CVCL_K746 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080510; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126264 CVCL_JV46 SCRP1307i induced pluripotent stem cell human CVCL_JV46 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126265 CVCL_K745 C0992 transformed cell line human CVCL_K745 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080509; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126266 CVCL_JV45 SCRP1203i induced pluripotent stem cell human CVCL_JV45 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126267 CVCL_K748 C0995 transformed cell line human CVCL_K748 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126268 CVCL_JV48 SCRP1702i induced pluripotent stem cell human CVCL_JV48 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126269 CVCL_K747 C0994 transformed cell line human CVCL_K747 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126270 CVCL_JV47 SCRP1602i induced pluripotent stem cell human CVCL_JV47 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126271 CVCL_K742 C0989 transformed cell line human CVCL_K742 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080506; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126272 CVCL_JV42 SCRP1031i induced pluripotent stem cell human CVCL_JV42 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126273 CVCL_K741 C0988 transformed cell line human CVCL_K741 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126274 CVCL_JV41 SCRP1021i induced pluripotent stem cell human CVCL_JV41 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126275 CVCL_K744 C0991 transformed cell line human CVCL_K744 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080508; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126276 CVCL_JV44 SCRP1103i induced pluripotent stem cell human CVCL_JV44 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126277 CVCL_K743 C0990 transformed cell line human CVCL_K743 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126278 CVCL_JV43 SCRP1041i induced pluripotent stem cell human CVCL_JV43 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126279 CVCL_K740 C0987 transformed cell line human CVCL_K740 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93080504; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126280 CVCL_JV40 SCRP1005i induced pluripotent stem cell human CVCL_JV40 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126281 CVCL_K757 C1010 transformed cell line human CVCL_K757 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126282 CVCL_JV57 SCRP2211i induced pluripotent stem cell human CVCL_JV57 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126283 CVCL_K756 C1009 transformed cell line human CVCL_K756 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606185; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126284 CVCL_JV56 SCRP2210i induced pluripotent stem cell human CVCL_JV56 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126285 CVCL_K759 C1012 transformed cell line human CVCL_K759 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606186; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126286 CVCL_JV59 SCRP2306i induced pluripotent stem cell human CVCL_JV59 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126287 CVCL_K758 C1011 transformed cell line human CVCL_K758 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126288 CVCL_JV58 SCRP2305i induced pluripotent stem cell human CVCL_JV58 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126289 CVCL_K753 C1005 transformed cell line human CVCL_K753 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 940606175; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126290 CVCL_JV53 SCRP2115i induced pluripotent stem cell human CVCL_JV53 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126291 CVCL_K752 C0999 transformed cell line human CVCL_K752 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93081209; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126292 CVCL_JV52 SCRP2106i induced pluripotent stem cell human CVCL_JV52 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126293 CVCL_K755 C1008 transformed cell line human CVCL_K755 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126294 CVCL_JV55 SCRP2208i induced pluripotent stem cell human CVCL_JV55 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126295 CVCL_K754 C1006 transformed cell line human CVCL_K754 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126296 CVCL_JV54 SCRP2201i induced pluripotent stem cell human CVCL_JV54 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126297 CVCL_K751 C0998 transformed cell line human CVCL_K751 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93081208; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126298 CVCL_JV51 SCRP2102i induced pluripotent stem cell human CVCL_JV51 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126299 CVCL_K750 C0997 transformed cell line human CVCL_K750 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126300 CVCL_JV50 SCRP2101i induced pluripotent stem cell human CVCL_JV50 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126301 CVCL_0I61 PF-R finite cell line CVCL_0I61 CL:0000010 Unspecified Group: Bird cell line. 21126302 CVCL_0I60 KNS-R spontaneously immortalized cell line CVCL_0I60 CL:0000010 21126303 CVCL_0I63 TGE-R finite cell line CVCL_0I63 CL:0000010 Unspecified Group: Bird cell line. 21126304 CVCL_0I62 SKH-R spontaneously immortalized cell line CVCL_0I62 CL:0000010 Derived from sampling site: Heart. Group: Reptilian cell line 21126305 CVCL_0I65 WT-R spontaneously immortalized cell line CVCL_0I65 CL:0000010 21126306 CVCL_0I64 WN-R finite cell line CVCL_0I64 CL:0000010 Derived from sampling site: Kidney. 21126307 CVCL_0I67 ZN-R finite cell line CVCL_0I67 CL:0000010 Derived from sampling site: Kidney. Female 21126308 CVCL_0I66 WSL-R spontaneously immortalized cell line pig CVCL_0I66 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Lung; Breed/subspecies: Wild boar. 21126309 CVCL_0I69 ENG-R spontaneously immortalized cell line CVCL_0I69 CL:0000010 Derived from sampling site: Fetal brain. Unspecified 21126310 CVCL_0I68 CBS-R spontaneously immortalized cell line pig CVCL_0I68 CL:0000010 Derived from sampling site: Fetal brain; cerebellum. Unspecified 21126311 CVCL_0I59 KMK-R spontaneously immortalized cell line CVCL_0I59 CL:0000010 Derived from sampling site: Bone marrow. 21126312 CVCL_9C08 DD0783 transformed cell line human CVCL_9C08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126313 CVCL_9C07 DD0782 transformed cell line human CVCL_9C07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126314 CVCL_9C09 DD0784 transformed cell line human CVCL_9C09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126315 CVCL_9C04 DD0778 transformed cell line human CVCL_9C04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126316 CVCL_0I70 GGE-R finite cell line CVCL_0I70 CL:0000010 Derived from sampling site: Fetal brain. Unspecified 21126317 CVCL_9C03 DD0777 transformed cell line human CVCL_9C03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126318 CVCL_9C06 DD0781 transformed cell line human CVCL_9C06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126319 CVCL_0I72 KMU-R finite cell line CVCL_0I72 CL:0000010 Derived from sampling site: Muscle. 21126320 CVCL_9C05 DD0779 transformed cell line human CVCL_9C05 CL:0000010 Karyotypic information: 47,XYY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126321 CVCL_0I71 KG-R spontaneously immortalized cell line CVCL_0I71 CL:0000010 Derived from sampling site: Brain. 21126322 CVCL_0I74 MDBK-PES spontaneously immortalized cell line CVCL_0I74 CL:0000010 Derived from sampling site: Kidney. Male 21126323 CVCL_0I73 KZ-R finite cell line CVCL_0I73 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. 21126324 CVCL_0I76 REN-R spontaneously immortalized cell line CVCL_0I76 CL:0000010 Derived from sampling site: Fetal kidney. 21126325 CVCL_0I75 REH-R finite cell line CVCL_0I75 CL:0000010 Derived from sampling site: Fetal testis. Male 21126326 CVCL_0I78 SE-R finite cell line CVCL_0I78 CL:0000010 21126327 CVCL_0I77 WSG-R spontaneously immortalized cell line pig CVCL_0I77 CL:0000010 Derived from sampling site: Fetal brain; Breed/subspecies: Wild boar. 21126328 CVCL_0I79 SFH-R finite cell line CVCL_0I79 CL:0000010 Derived from sampling site: Testis. Male Senescence: Senesces at 40 PDL (CCLV=CCLV-RIE 0042) 21126329 CVCL_9C00 DD0773 transformed cell line human CVCL_9C00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126330 CVCL_9C02 DD0776 transformed cell line human CVCL_9C02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126331 CVCL_9C01 DD0775 transformed cell line human CVCL_9C01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126332 CVCL_T089 HEV0047 transformed cell line human CVCL_T089 HLA typing: A*02:01,24:02; B*46:01,55:02; C*01:02; DPB1*02:01,02:02; DQB1*06:01,06:02; DRB1*08:03,15:01 (RCB=HEV0047) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126333 CVCL_0I41 GM11044 transformed cell line human CVCL_0I41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10411 21126334 CVCL_0I40 GM11043 transformed cell line human CVCL_0I40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10410 21126335 CVCL_0I43 GM11104 transformed cell line human CVCL_0I43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10405 21126336 CVCL_0I42 GM11045 transformed cell line human CVCL_0I42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10412 21126337 CVCL_0I45 GM13057 transformed cell line human CVCL_0I45 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10202/10416 21126338 CVCL_0I44 GM13055 transformed cell line human CVCL_0I44 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10201/10415 21126339 CVCL_0I47 RK13-DrdI spontaneously immortalized cell line CVCL_0I47 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21126340 CVCL_0I46 GM13356 transformed cell line human CVCL_0I46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10414 21126341 CVCL_0I38 GM11041 transformed cell line human CVCL_0I38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10408 21126342 CVCL_0I37 GM11040 transformed cell line human CVCL_0I37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10407 21126343 CVCL_0I39 GM11042 transformed cell line human CVCL_0I39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10409 21126344 CVCL_T091 HEV0049 transformed cell line human CVCL_T091 HLA typing: A*24:02; B*51:01,52:01; C*12:02,14:02; DPB1*05:01,09:01; DQB1*03:01,06:01; DRB1*14:03,15:02 (RCB=HEV0049) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126345 CVCL_T090 HEV0048 transformed cell line human CVCL_T090 HLA typing: A*02:06,33:03; B*44:03,59:01; C*01:02,14:03; DPB1*04:01,05:01; DQB1*04:01,06:04; DRB1*04:05,13:02 (RCB=HEV0048) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126346 CVCL_T093 HEV0051 transformed cell line human CVCL_T093 HLA typing: A*26:02,33:03; B*40:06,44:03; C*08:01,14:03; DPB1*03:01,05:01; DQB1*03:02,03:03; DRB1*08:02,09:01 (RCB=HEV0051) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126347 CVCL_T092 HEV0050 transformed cell line human CVCL_T092 HLA typing: A*24:02; B*35:01,54:01; C*01:02,08:01; DPB1*03:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0050) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126348 CVCL_T095 HEV0053 transformed cell line human CVCL_T095 HLA typing: A*02:01,33:03; B*35:01,44:03; C*03:03,14:03; DPB1*02:01,04:01; DQB1*04:01,06:04; DRB1*04:05,13:02 (RCB=HEV0053) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126349 CVCL_T094 HEV0052 transformed cell line human CVCL_T094 HLA typing: A*24:02,31:01; B*40:02,51:01; C*03:04,14:02; DPB1*05:01; DQB1*03:01,03:02; DRB1*08:02,14:03 (RCB=HEV0052) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126350 CVCL_T097 HEV0055 transformed cell line human CVCL_T097 HLA typing: A*11:01,24:02; B*39:01,48:01; C*03:03,07:02; DPB1*04:02,05:01; DQB1*05:03,06:01; DRB1*08:03,14:01 (RCB=HEV0055) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126351 CVCL_T096 HEV0054 transformed cell line human CVCL_T096 HLA typing: A*11:01,33:03; B*35:01,44:03; C*03:03,14:03; DPB1*02:01,05:01; DQB1*03:02,06:04; DRB1*04:05,13:02 (RCB=HEV0054) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126352 CVCL_T099 HEV0058 transformed cell line human CVCL_T099 HLA typing: A*26:03,33:03; B*15:01,44:03; C*03:03,14:03; DPB1*04:01,05:01; DQB1*03:01,06:04; DRB1*13:02,14:06 (RCB=HEV0058) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126353 CVCL_T098 HEV0057 transformed cell line human CVCL_T098 HLA typing: A*02:01,31:01; B*15:11; C*03:03; DPB1*02:01,09:01; DQB1*03:03; DRB1*09:01 (RCB=HEV0057) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126354 CVCL_T079 HEV0036 transformed cell line human CVCL_T079 HLA typing: A*24:02,26:03; B*15:01,40:06; C*03:03,15:02; DPB1*02:01; DQB1*03:03,04:02; DRB1*08:02,09:01 (RCB=HEV0036) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126355 CVCL_T078 HEV0035 transformed cell line human CVCL_T078 HLA typing: A*11:01,24:02; B*54:01,67:01; C*01:02,07:02; DPB1*05:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0035) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126356 CVCL_0I50 RTG-2/f spontaneously immortalized cell line CVCL_0I50 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Female Group: Fish cell line 21126357 CVCL_0I52 EGE-R finite cell line CVCL_0I52 CL:0000010 Unspecified Group: Bird cell line. 21126358 CVCL_0I51 KFC spontaneously immortalized cell line CVCL_0I51 CL:0000010 Derived from sampling site: Fin; Breed/subspecies: Koi. Unspecified Group: Fish cell line 21126359 CVCL_0I54 FMN-R finite cell line CVCL_0I54 CL:0000010 Donor information: Established from the kidneys of six newborn common voles minced together; Derived from sampling site: Kidney. Mixed Virology: Susceptible to infection by cowpox virus, encephalomyocarditis virus, murine gammaherpesvirus 68 (MHV-68), Rift Valley fever virus (RVFV), Sindbis virus, Tula orthohantavirus (TULV) and vaccinia virus 21126360 CVCL_0I53 FLN-R finite cell line CVCL_0I53 CL:0000010 Derived from sampling site: Kidney. Group: Bat cell line 21126361 CVCL_0I56 HN-R spontaneously immortalized cell line CVCL_0I56 CL:0000010 Derived from sampling site: Kidney. 21126362 CVCL_0I55 Fufe-R spontaneously immortalized cell line CVCL_0I55 CL:0000010 Unspecified 21126363 CVCL_0I58 KFT-R spontaneously immortalized cell line CVCL_0I58 CL:0000010 Derived from sampling site: Thymus. 21126364 CVCL_0I57 KE-R spontaneously immortalized cell line CVCL_0I57 CL:0000010 Unspecified 21126365 CVCL_0I49 QM9 cancer cell line CVCL_0I49 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line 21126366 CVCL_0I48 EFN-R finite cell line pig CVCL_0I48 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21126367 CVCL_T080 HEV0037 transformed cell line human CVCL_T080 HLA typing: A*11:01,24:02; B*54:01; C*01:02; DPB1*05:01; DQB1*04:01; DRB1*04:05 (RCB=HEV0037) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126368 CVCL_T082 HEV0039 transformed cell line human CVCL_T082 HLA typing: A*24:02,26:03; B*15:01,51:01; C*03:03,14:02; DPB1*09:01,13:01; DQB1*03:01,06:01; DRB1*11:01,15:02 (RCB=HEV0039) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126369 CVCL_T081 HEV0038 transformed cell line human CVCL_T081 HLA typing: A*02:01,24:02; B*13:01,51:01; C*03:04,15:02; DPB1*04:01,05:01; DQB1*03:01; DRB1*04:01,12:02 (RCB=HEV0038) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126370 CVCL_T084 HEV0041 transformed cell line human CVCL_T084 HLA typing: A*02:01,24:02; B*07:02,35:01; C*03:03,07:02; DPB1*02:01,04:02; DQB1*04:02,05:01; DRB1*01:01,08:02 (RCB=HEV0041) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126371 CVCL_T083 HEV0040 transformed cell line human CVCL_T083 HLA typing: A*24:02; B*35:01,51:01; C*04:01,14:02; DPB1*02:01,04:02; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0040) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126372 CVCL_T086 HEV0043 transformed cell line human CVCL_T086 HLA typing: A*02:06,02:07; B*07:02,46:01; C*01:02,07:02; DPB1*03:01,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0043) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126373 CVCL_T085 HEV0042 transformed cell line human CVCL_T085 HLA typing: A*24:02,26:01; B*40:01,40:03; C*03:04; DPB1*05:01; DQB1*04:01,06:03; DRB1*04:05,13:01 (RCB=HEV0042) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126374 CVCL_T088 HEV0046 transformed cell line human CVCL_T088 HLA typing: A*24:02; B*40:02,59:01; C*01:02,03:03; DPB1*04:01,05:01; DQB1*03:01,06:04; DRB1*04:01,13:02 (RCB=HEV0046) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126375 CVCL_T087 HEV0045 transformed cell line human CVCL_T087 HLA typing: A*02:01,02:07; B*40:01,46:01; C*01:02,03:04; DPB1*02:02,05:01; DQB1*06:01,06:02; DRB1*08:03,15:01 (RCB=HEV0045) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126376 CVCL_T068 HEV0011 transformed cell line human CVCL_T068 HLA typing: A*02:06; B*39:01,40:02; C*03:04,07:02; DPB1*02:01,05:01; DQB1*03:01,03:02; DRB1*08:02,14:06 (RCB=HEV0011) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126377 CVCL_T067 SmcMF spontaneously immortalized cell line house mouse CVCL_T067 CL:0000010 Derived from sampling site: Colon; mucosa Cell type=Myofibroblast.; Breed/subspecies: C57BL/6J. Unspecified Doubling time: 17.2 hours (PubMed=23674870) 21126378 CVCL_T069 HEV0012 transformed cell line human CVCL_T069 HLA typing: A*31:01,33:03; B*40:03,44:03; C*03:04,14:03; DPB1*05:01; DQB1*04:01,06:01; DRB1*04:05,08:03 (RCB=HEV0012) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126379 CVCL_0I21 Pt.Kich-1 cancer cell line human CVCL_0I21 CL:0000010 Derived from sampling site: Parathyroid gland. Female Doubling time: 5-6 days (PubMed=25655355) 21126380 CVCL_0I20 FLFMM-34 cancer cell line human CVCL_0I20 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25639772); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181His (c.542G>A); ClinVar=VCV000142320; Zygosity=Unspecified (PubMed=25639772) Population: Chinese; Han; Derived from metastatic site: Lymph node. Female Doubling time: 2-3 days (PubMed=25639772) 21126381 CVCL_0I23 Ar-13 spontaneously immortalized cell line CVCL_0I23 CL:0000010 Unspecified Doubling time: 3 days (PubMed=25761724). Group: Insect cell line 21126382 CVCL_0I22 sHPT-1 cancer cell line human CVCL_0I22 CL:0000010 Derived from sampling site: Parathyroid gland. Unspecified Doubling time: ~72 hours (PubMed=17126301) 21126383 CVCL_0I25 CMCSCC-1 cancer cell line human CVCL_0I25 CL:0000010 Population: Korean; Derived from sampling site: Oral cavity; tongue. Female Doubling time: 24 hours (PubMed=25784373) 21126384 CVCL_0I24 Ar-3 spontaneously immortalized cell line CVCL_0I24 CL:0000010 Unspecified Doubling time: 2.7 days (PubMed=25761724). Group: Insect cell line 21126385 CVCL_0I16 8B5 hybridoma house mouse CVCL_0I16 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5116 21126386 CVCL_0I15 8A1 hybridoma house mouse CVCL_0I15 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5115 21126387 CVCL_0I18 8E3 hybridoma house mouse CVCL_0I18 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5118 21126388 CVCL_0I17 8C3 hybridoma house mouse CVCL_0I17 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5246 21126389 CVCL_0I19 8G9 [Mouse hybridoma against human MUC16] hybridoma house mouse CVCL_0I19 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5119 21126390 CVCL_T071 HEV0019 transformed cell line human CVCL_T071 HLA typing: A*24:02,26:02; B*07:02,13:01; C*03:04,07:02; DPB1*02:02,04:02; DQB1*03:01,05:01; DRB1*01:01,12:02 (RCB=HEV0019) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126391 CVCL_T070 HEV0013 transformed cell line human CVCL_T070 HLA typing: A*11:01,26:03; B*40:01,55:02; C*01:02,03:03; DPB1*02:01,05:01; DQB1*03:01,04:01; DRB1*04:05,11:01 (RCB=HEV0013) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126392 CVCL_T073 HEV0023 transformed cell line human CVCL_T073 HLA typing: A*24:02,26:03; B*15:01,59:01; C*01:02,03:03; DPB1*02:01,04:02; DQB1*04:01,06:02; DRB1*04:05,15:01 (RCB=HEV0023) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126393 CVCL_T072 HEV0022 transformed cell line human CVCL_T072 HLA typing: A*24:02,26:01; B*48:01,52:01; C*08:03,12:02; DPB1*09:01,14:01; DQB1*05:02,06:01; DRB1*14:07,15:02 (RCB=HEV0022) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126394 CVCL_T075 HEV0031 transformed cell line human CVCL_T075 HLA typing: A*02:06,02:10; B*39:01,40:06; C*07:02,08:01; DPB1*02:01,05:01; DQB1*03:01,06:02; DRB1*14:03,15:01 (RCB=HEV0031) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126395 CVCL_T074 HEV0024 transformed cell line human CVCL_T074 HLA typing: A*24:02; B*13:01,40:02; C*03:04; DPB1*05:01,13:01; DQB1*03:01,04:02; DRB1*04:10,12:02 (RCB=HEV0024) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126396 CVCL_T077 HEV0034 transformed cell line human CVCL_T077 HLA typing: A*02:01,26:01; B*07:02,15:01; C*03:04,07:02; DPB1*05:01; DQB1*04:01,05:02; DRB1*04:05,14:01 (RCB=HEV0034) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126397 CVCL_T076 HEV0032 transformed cell line human CVCL_T076 HLA typing: A*24:02; B*52:01; C*12:02; DPB1*02:01,14:01; DQB1*06:01,06:02; DRB1*15:01,15:02 (RCB=HEV0032) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126398 CVCL_T057 T921 cancer cell line human CVCL_T057 CL:0000010 Population: Chinese; Derived from sampling site: Urinary bladder. Female Doubling time: 48-72 hours (PubMed=23813186) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201180 21126399 CVCL_T056 P6C cancer cell line human CVCL_T056 CL:0000010 Male Doubling time: ~20 hours (PubMed=23736004). Group: Cancer stem cell line 21126400 CVCL_T059 KL5B transformed cell line CVCL_T059 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U7QTX5; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Unspecified (PubMed=10069471) Transformant: Nitrosobis(2-oxopropyl)amine(ChEBI; CHEBI:134609); Derived from sampling site: Pancreas; islets of Langerhans. Male Doubling time: 26 hours, at 19th passage (PubMed=10069471) 21126401 CVCL_T058 Tca8113/CBP [Chongqing] cancer cell line human CVCL_T058 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21126402 CVCL_0I30 GM10431 transformed cell line human CVCL_0I30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126403 CVCL_0I32 GM04719 finite cell line human CVCL_0I32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21126404 CVCL_0I31 GM10155 transformed cell line human CVCL_0I31 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126405 CVCL_0I34 GM11035 transformed cell line human CVCL_0I34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10413 21126406 CVCL_0I33 GM04720 transformed cell line human CVCL_0I33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21126407 CVCL_0I36 GM11039 transformed cell line human CVCL_0I36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10406 21126408 CVCL_0I35 GM11038 transformed cell line human CVCL_0I35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10404 21126409 CVCL_0I27 HT-29/5-FU cancer cell line human CVCL_0I27 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female 21126410 CVCL_0I26 CTC-MCC-41 cancer cell line human CVCL_0I26 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25592149) Derived from metastatic site: Peripheral blood. Omics: CNV analysis Male Doubling time: 20 hours (PubMed=25592149) 21126411 CVCL_0I29 GM10383 transformed cell line human CVCL_0I29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126412 CVCL_0I28 GM10382 finite cell line human CVCL_0I28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21126413 CVCL_T060 KL5N spontaneously immortalized cell line CVCL_T060 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Male Doubling time: 48 hours (PubMed=10069471) 21126414 CVCL_T062 CHO-M1 transformed cell line CVCL_T062 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Ovary. Female 21126415 CVCL_T061 TAKA-1 spontaneously immortalized cell line CVCL_T061 CL:0000010 Derived from sampling site: Pancreas Cell type=Ductal cell.; Breed/subspecies: Eppley colony. Male Doubling time: 33 hours (at 17th passage), 20 hours (at 30th passage) (PubMed=8581919); 37.4 hours (at 11th passage), 33 hours (at 17th passage), 20.4 hours (at 31th passage) (PubMed=7728976) 21126416 CVCL_T064 GTO cancer cell line human CVCL_T064 CL:0000010 Population: Japanese; Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pericardial effusion. Male 21126417 CVCL_T063 CEL-im spontaneously immortalized cell line CVCL_T063 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: White Leghorn SPAFAS. Unspecified Virology: Highly susceptible to infection by avian metapneumovirus (AMPV) Weakly susceptible to infection by Marek's disease virus serotype 1 (MDV-1) and infectious laryngotracheitis virus (ILTV). Doubling time: 21.8-30 hours (PubMed=23687157) Group: Bird cell line 21126418 CVCL_T066 LmcMF transformed cell line house mouse CVCL_T066 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Colon; mucosa Cell type=Myofibroblast.; Breed/subspecies: C57BL/6J. Unspecified Doubling time: 19.1 hours (PubMed=23674870) 21126419 CVCL_T065 ihNP transformed cell line human CVCL_T065 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Intervertebral disc; nucleus pulposus. Male Doubling time: 53.16 +- 2.63 hours, at 25th passage (PubMed=23675702) 21126420 CVCL_T046 V-G8 transformed cell line CVCL_T046 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21126421 CVCL_T045 V-E5 transformed cell line CVCL_T045 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21126422 CVCL_T048 HTERT-AEC II telomerase immortalized cell line CVCL_T048 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: Holstein. 21126423 CVCL_T047 EC109/Taxol cancer cell line human CVCL_T047 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol). Female Doubling time: 31.3 +- 0.39 hours (PubMed=24002547) 21126424 CVCL_T049 NIV-BtEPC spontaneously immortalized cell line CVCL_T049 CL:0000010 Unspecified Virology: Susceptible to infection by Chandipura virus and bat adenovirus 1050597 (BtAdv-RLM 1050497). Group: Bat cell line 21126425 CVCL_0I01 368.1 hybridoma house mouse CVCL_0I01 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4568 21126426 CVCL_0I00 325.1 hybridoma house mouse CVCL_0I00 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5120 21126427 CVCL_0I03 4E7 hybridoma house mouse CVCL_0I03 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5109 21126428 CVCL_0I02 446.1 hybridoma house mouse CVCL_0I02 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5549 21126429 CVCL_T051 HoMel-L1 cancer cell line CVCL_T051 CL:0000010 Derived from sampling site: Tail; skin; Breed/subspecies: Grey Lipizzaner. Male Doubling time: 90 hours (PubMed=23982913) 21126430 CVCL_T050 HoMel-A1 cancer cell line CVCL_T050 CL:0000010 Derived from metastatic site: Tail; skin; Breed/subspecies: Arabian. Female Doubling time: 42 hours (PubMed=23982913) 21126431 CVCL_T053 HMCL-7304 telomerase immortalized cell line human CVCL_T053 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Skeletal muscle. Female 21126432 CVCL_T052 GAK14 cancer cell line house mouse CVCL_T052 CL:0000010 Female 21126433 CVCL_T055 METON cancer cell line human CVCL_T055 CL:0000010 Population: Japanese; Derived from sampling site: Salivary gland; palatine gland. Female 21126434 CVCL_T054 imHCE_GDLD transformed cell line human CVCL_T054 CL:0000010 Sequence variation: Mutation; HGNC; 11530; TACSTD2; Simple; p.Gln118Ter (c.352C>T); ClinVar=VCV000016182; Zygosity=Homozygous (PubMed=23818740; PubMed=23868985); Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.. Female 21126435 CVCL_T035 MBC1 cancer cell line human CVCL_T035 CL:0000010 Population: Malaysian; Derived from sampling site: Breast. Female Doubling time: 30.14 hours (PubMed=23106969) Group: Triple negative breast cancer (TNBC) cell line 21126436 CVCL_T034 Bge spontaneously immortalized cell line CVCL_T034 CL:0000010 Discontinued: BEI_Resources; NR-21959; true. Unspecified Group: Mollusk cell line 21126437 CVCL_T037 SNU-1528 cancer cell line human CVCL_T037 CL:0000010 Population: Korean; Derived from sampling site: Breast. Female Doubling time: 110 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126438 CVCL_T036 MBC2 cancer cell line human CVCL_T036 CL:0000010 Population: Chinese; Malaysian; Derived from sampling site: Breast. Female Doubling time: 35.6 hours (PubMed=23106969) 21126439 CVCL_T039 SNU-1581 cancer cell line human CVCL_T039 CL:0000010 Population: Korean; Derived from metastatic site: Pericardial effusion. Female Doubling time: 47 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126440 CVCL_T038 SNU-1553 cancer cell line human CVCL_T038 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Female Doubling time: 89 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126441 CVCL_0I10 7A11 [Mouse hybridoma against human MUC16] hybridoma house mouse CVCL_0I10 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5110 21126442 CVCL_0I12 7F10 hybridoma house mouse CVCL_0I12 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5112 21126443 CVCL_0I11 7C6 hybridoma house mouse CVCL_0I11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5111 21126444 CVCL_0I14 7H1 hybridoma house mouse CVCL_0I14 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5114 21126445 CVCL_0I13 7G10 hybridoma house mouse CVCL_0I13 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5245 21126446 CVCL_0I05 621.1 hybridoma house mouse CVCL_0I05 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5121 21126447 CVCL_0I04 501.1 hybridoma house mouse CVCL_0I04 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4569 21126448 CVCL_0I07 654.1 hybridoma house mouse CVCL_0I07 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5247 21126449 CVCL_0I06 633.1 hybridoma house mouse CVCL_0I06 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5122 21126450 CVCL_0I09 776.1 hybridoma house mouse CVCL_0I09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4570 21126451 CVCL_0I08 725.1 hybridoma house mouse CVCL_0I08 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5124 21126452 CVCL_T040 SNU-1958 cancer cell line human CVCL_T040 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Male Doubling time: 53 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00539 Problematic cell line: Contaminated Shown to be a LS513 derivative (ICLAC). Originally thought to originate from the ascitic fluid of a 55 year old female patient with triple-negative breast carcinoma. 21126453 CVCL_T042 SNU-306 cancer cell line human CVCL_T042 CL:0000010 Population: Korean; Derived from sampling site: Breast. Female Doubling time: 152 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126454 CVCL_T041 SNU-2372 cancer cell line human CVCL_T041 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Female Doubling time: 78 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126455 CVCL_T044 V-C4 transformed cell line CVCL_T044 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21126456 CVCL_T043 SNU-334 cancer cell line human CVCL_T043 CL:0000010 Population: Korean; Derived from sampling site: Breast. Female Doubling time: 80 hours (PubMed=24141649) Part of: Seoul National University (SNU) cell line collection 21126457 CVCL_9C71 DD0874 transformed cell line human CVCL_9C71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126458 CVCL_9C70 DD0873 transformed cell line human CVCL_9C70 CL:0000010 Karyotypic information: 46,XY,t(3;13)(q13.2;q32.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126459 CVCL_9C77 DD0880 transformed cell line human CVCL_9C77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126460 CVCL_9C76 DD0879 transformed cell line human CVCL_9C76 CL:0000010 Karyotypic information: 46,X,der(Y),t(Y;15)(q12;p11)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126461 CVCL_9C79 DD0882 finite cell line human CVCL_9C79 CL:0000010 Karyotypic information: 47,XY,+8 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21126462 CVCL_9C78 DD0881 transformed cell line human CVCL_9C78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126463 CVCL_9C73 DD0876 transformed cell line human CVCL_9C73 CL:0000010 Karyotypic information: 46,XY [13]; 47,XY,+mar [21] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126464 CVCL_9C72 DD0875 transformed cell line human CVCL_9C72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126465 CVCL_9C75 DD0878 transformed cell line human CVCL_9C75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126466 CVCL_9C74 DD0877 transformed cell line human CVCL_9C74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126467 CVCL_9C80 DD0884 transformed cell line human CVCL_9C80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126468 CVCL_9C82 DD0887 transformed cell line human CVCL_9C82 CL:0000010 Karyotypic information: 46,XY,-14,+t(14;21); de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126469 CVCL_9C81 DD0886 transformed cell line human CVCL_9C81 CL:0000010 Karyotypic information: 46,X,der(Y),t(Y;15)(q12;p11)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126470 CVCL_9C88 DD0901 transformed cell line human CVCL_9C88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126471 CVCL_9C87 DD0898 transformed cell line human CVCL_9C87 CL:0000010 Karyotypic information: 46,XY,t(3;10)(p24.2;q25.2)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126472 CVCL_9C89 DD0902 transformed cell line human CVCL_9C89 CL:0000010 Karyotypic information: 47,XXY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126473 CVCL_9C84 DD0892 transformed cell line human CVCL_9C84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126474 CVCL_9C83 DD0891 transformed cell line human CVCL_9C83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126475 CVCL_9C86 DD0897 transformed cell line human CVCL_9C86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126476 CVCL_9C85 DD0896 transformed cell line human CVCL_9C85 CL:0000010 Karyotypic information: 46,XY,t(3;10)(p24.2;q25.2)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126477 CVCL_9C59 DD0847 finite cell line human CVCL_9C59 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21126478 CVCL_9C58 DD0845 transformed cell line human CVCL_9C58 CL:0000010 Karyotypic information: 46,XX,t(8;16)(q22.1;q13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126479 CVCL_9C55 DD0841 transformed cell line human CVCL_9C55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126480 CVCL_9C54 DD0840 transformed cell line human CVCL_9C54 CL:0000010 Karyotypic information: 46,XX,del(13)(pter->q22.1::q32.3->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126481 CVCL_9C57 DD0844 transformed cell line human CVCL_9C57 CL:0000010 Karyotypic information: 46,XX,t(8;16)(q22.1;q13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126482 CVCL_9C56 DD0843 transformed cell line human CVCL_9C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126483 CVCL_9C51 DD0835 finite cell line human CVCL_9C51 CL:0000010 Karyotypic information: 46,XY; 46,XY,inv(9)(?p21;q12) de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21126484 CVCL_9C50 DD0834 finite cell line human CVCL_9C50 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21126485 CVCL_9C53 DD0839 finite cell line human CVCL_9C53 CL:0000010 Karyotypic information: 46,XY,t(12;13)(q24.31;q32.3) de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21126486 CVCL_9C52 DD0836 finite cell line human CVCL_9C52 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21126487 CVCL_9C69 DD0871 transformed cell line human CVCL_9C69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126488 CVCL_9C60 DD0849 transformed cell line human CVCL_9C60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126489 CVCL_9C66 DD0866 transformed cell line human CVCL_9C66 CL:0000010 Karyotypic information: 46,XY,del(5p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126490 CVCL_9C65 DD0864 finite cell line human CVCL_9C65 CL:0000010 Karyotypic information: 46,XX,t(2;10)(p25;p11) de novo (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21126491 CVCL_9C68 DD0868 finite cell line human CVCL_9C68 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21126492 CVCL_9C67 DD0867 transformed cell line human CVCL_9C67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126493 CVCL_9C62 DD0853 finite cell line human CVCL_9C62 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21126494 CVCL_9C61 DD0852 transformed cell line human CVCL_9C61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126495 CVCL_9C64 DD0863 finite cell line human CVCL_9C64 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21126496 CVCL_9C63 DD0855 transformed cell line human CVCL_9C63 CL:0000010 Karyotypic information: 46,XX,t(X;Y) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126497 CVCL_9C37 DD0819 transformed cell line human CVCL_9C37 CL:0000010 Karyotypic information: 46,XY,t(9;15)(q22;q13)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126498 CVCL_9C36 DD0818 transformed cell line human CVCL_9C36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126499 CVCL_9C39 DD0821 transformed cell line human CVCL_9C39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126500 CVCL_9C38 DD0820 transformed cell line human CVCL_9C38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126501 CVCL_9C33 DD0813 transformed cell line human CVCL_9C33 CL:0000010 Karyotypic information: 46,XY,19q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126502 CVCL_9C32 DD0812 transformed cell line human CVCL_9C32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126503 CVCL_9C35 DD0817 transformed cell line human CVCL_9C35 CL:0000010 Karyotypic information: 46,XX; 47,XY+mar(16) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126504 CVCL_9C34 DD0816 transformed cell line human CVCL_9C34 CL:0000010 Karyotypic information: 46,XY,t(5;10)(q35.3;q26.13)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126505 CVCL_9C31 DD0811 transformed cell line human CVCL_9C31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126506 CVCL_9C30 DD0810 transformed cell line human CVCL_9C30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126507 CVCL_9C48 DD0830 finite cell line human CVCL_9C48 CL:0000010 Karyotypic information: 49,XXXXY (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21126508 CVCL_9C47 DD0829 transformed cell line human CVCL_9C47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126509 CVCL_9C49 DD0832 transformed cell line human CVCL_9C49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126510 CVCL_9C44 DD0826 transformed cell line human CVCL_9C44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126511 CVCL_9C43 DD0825 transformed cell line human CVCL_9C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126512 CVCL_9C46 DD0828 transformed cell line human CVCL_9C46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126513 CVCL_9C45 DD0827 transformed cell line human CVCL_9C45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126514 CVCL_9C40 DD0822 transformed cell line human CVCL_9C40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126515 CVCL_9C42 DD0824 transformed cell line human CVCL_9C42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126516 CVCL_9C41 DD0823 transformed cell line human CVCL_9C41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126517 CVCL_9C19 DD0797 transformed cell line human CVCL_9C19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126518 CVCL_9C18 DD0796 transformed cell line human CVCL_9C18 CL:0000010 Karyotypic information: 46,XX,r(18)(p11;q23) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126519 CVCL_0I81 CaPi spontaneously immortalized cell line CVCL_0I81 CL:0000010 Derived from sampling site: Pituitary gland. Unspecified Group: Fish cell line 21126520 CVCL_9C15 DD0793 transformed cell line human CVCL_9C15 CL:0000010 Karyotypic information: 46,XX,t(12;22)(12p22p;12q22q)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126521 CVCL_9C14 DD0790 transformed cell line human CVCL_9C14 CL:0000010 Karyotypic information: 47,XX+?i(18p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126522 CVCL_0I80 SP-R spontaneously immortalized cell line CVCL_0I80 CL:0000010 Derived from sampling site: Brain; choroid plexus. 21126523 CVCL_0I83 44FT0 cancer cell line house mouse CVCL_0I83 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21126524 CVCL_9C17 DD0795 transformed cell line human CVCL_9C17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126525 CVCL_9C16 DD0794 transformed cell line human CVCL_9C16 CL:0000010 Karyotypic information: 46,XX,t(12;22)(12p22p;12q22q)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126526 CVCL_0I82 GS33JTO(SVT) transformed cell line human CVCL_0I82 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21126527 CVCL_0I85 168FAR cancer cell line house mouse CVCL_0I85 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21126528 CVCL_0I84 168 cancer cell line house mouse CVCL_0I84 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21126529 CVCL_0I87 67 [Mouse mammary tumor] cancer cell line house mouse CVCL_0I87 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21126530 CVCL_0I86 168FARN cancer cell line house mouse CVCL_0I86 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Non-metastatic 21126531 CVCL_0I89 D2.1 cancer cell line house mouse CVCL_0I89 CL:0000010 Breed/subspecies: BALB/c. Female 21126532 CVCL_0I88 D2.0R cancer cell line house mouse CVCL_0I88 CL:0000010 Breed/subspecies: BALB/c. Female 21126533 CVCL_9C11 DD0787 transformed cell line human CVCL_9C11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126534 CVCL_9C10 DD0785 transformed cell line human CVCL_9C10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126535 CVCL_9C13 DD0789 transformed cell line human CVCL_9C13 CL:0000010 Karyotypic information: 47,XX,+dic(15)(pter->q11::q11->pter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126536 CVCL_9C12 DD0788 transformed cell line human CVCL_9C12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126537 CVCL_9C29 DD0809 transformed cell line human CVCL_9C29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126538 CVCL_0I90 D2A1 cancer cell line house mouse CVCL_0I90 CL:0000010 Breed/subspecies: BALB/c. Female 21126539 CVCL_9C26 DD0806 transformed cell line human CVCL_9C26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126540 CVCL_0I92 KB/cSV transformed cell line house mouse CVCL_0I92 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: BALB/c. 21126541 CVCL_0I91 D2F2 cancer cell line house mouse CVCL_0I91 CL:0000010 Breed/subspecies: BALB/c. Female 21126542 CVCL_9C25 DD0804 transformed cell line human CVCL_9C25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126543 CVCL_0I94 CB34 transformed cell line human CVCL_0I94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified 21126544 CVCL_9C28 DD0808 transformed cell line human CVCL_9C28 CL:0000010 Karyotypic information: 46,XY; 47,XYY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126545 CVCL_0I93 CB57/C91PL transformed cell line human CVCL_0I93 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Male Virology: HTLV-1 producing cell line 21126546 CVCL_9C27 DD0807 transformed cell line human CVCL_9C27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126547 CVCL_0I96 PT [Sheep kidney] spontaneously immortalized cell line CVCL_0I96 CL:0000010 Derived from sampling site: Kidney. 21126548 CVCL_0I95 T47D/A1-2 cancer cell line human CVCL_0I95 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: RGD; 2741; Nr3c1 Derived from metastatic site: Pleural effusion. Omics: scRNAseq analysis; Omics: Transcriptome analysis by RNAseq Female 21126549 CVCL_0I98 CSPMG spontaneously immortalized cell line CVCL_0I98 CL:0000010 Derived from sampling site: Gonad. Female Doubling time: 45.03 hours, at 20th passage (PubMed=25724869) Group: Fish cell line 21126550 CVCL_0I97 FLG-R finite cell line CVCL_0I97 CL:0000010 Derived from sampling site: Brain. Group: Bat cell line 21126551 CVCL_0I99 Bf1-Venus K/I EB3 embryonic stem cell house mouse CVCL_0I99 CL:0000010 Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Breed/subspecies: 129P2/Ola. Male Characteristics: The gene for Venus is knocked-in in the Foxg1(Bf1) locus 21126552 CVCL_9C22 DD0801 transformed cell line human CVCL_9C22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126553 CVCL_9C21 DD0800 transformed cell line human CVCL_9C21 CL:0000010 Karyotypic information: 47,XXY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126554 CVCL_9C24 DD0803 transformed cell line human CVCL_9C24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126555 CVCL_9C23 DD0802 transformed cell line human CVCL_9C23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126556 CVCL_9C20 DD0799 transformed cell line human CVCL_9C20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126557 CVCL_K849 C2087 transformed cell line human CVCL_K849 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405172; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126558 CVCL_JW49 CREM028i-SS43-2 induced pluripotent stem cell human CVCL_JW49 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126559 CVCL_K848 C2086 transformed cell line human CVCL_K848 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040523; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126560 CVCL_JW48 CREM027i-SS41-1 induced pluripotent stem cell human CVCL_JW48 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126561 CVCL_K845 C2083 transformed cell line human CVCL_K845 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040520; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126562 CVCL_JW45 CREM024i-SS36-1 induced pluripotent stem cell human CVCL_JW45 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126563 CVCL_K844 C2082 transformed cell line human CVCL_K844 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040519; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126564 CVCL_JW44 CREM023i-SS35-1 induced pluripotent stem cell human CVCL_JW44 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126565 CVCL_K847 C2085 transformed cell line human CVCL_K847 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126566 CVCL_JW47 CREM026i-SS38-1 induced pluripotent stem cell human CVCL_JW47 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126567 CVCL_K846 C2084 transformed cell line human CVCL_K846 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040521; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126568 CVCL_JW46 CREM025i-SS37-1 induced pluripotent stem cell human CVCL_JW46 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126569 CVCL_K841 C2079 transformed cell line human CVCL_K841 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040534; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126570 CVCL_JW41 CREM020i-SS28-1 induced pluripotent stem cell human CVCL_JW41 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126571 CVCL_K840 C2078 transformed cell line human CVCL_K840 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126572 CVCL_JW40 CREM019i-SS25-1 induced pluripotent stem cell human CVCL_JW40 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126573 CVCL_K843 C2081 transformed cell line human CVCL_K843 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126574 CVCL_JW43 CREM022i-SS32-1 induced pluripotent stem cell human CVCL_JW43 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126575 CVCL_K842 C2080 transformed cell line human CVCL_K842 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040524; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126576 CVCL_JW42 CREM021i-SS29-1 induced pluripotent stem cell human CVCL_JW42 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126577 CVCL_K859 C2097 transformed cell line human CVCL_K859 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405177; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126578 CVCL_JW59 CREM038i-SA64-1 induced pluripotent stem cell human CVCL_JW59 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126579 CVCL_K856 C2094 transformed cell line human CVCL_K856 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405165; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126580 CVCL_JW56 CREM035i-SA36-1 induced pluripotent stem cell human CVCL_JW56 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126581 CVCL_K855 C2093 transformed cell line human CVCL_K855 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126582 CVCL_JW55 CREM034i-SA5-1 induced pluripotent stem cell human CVCL_JW55 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126583 CVCL_K858 C2096 transformed cell line human CVCL_K858 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405176; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126584 CVCL_JW58 CREM037i-SA53-1 induced pluripotent stem cell human CVCL_JW58 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126585 CVCL_K857 C2095 transformed cell line human CVCL_K857 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405175; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126586 CVCL_JW57 CREM036i-SA40-1 induced pluripotent stem cell human CVCL_JW57 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126587 CVCL_K852 C2090 transformed cell line human CVCL_K852 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126588 CVCL_JW52 CREM031i-SS47-1 induced pluripotent stem cell human CVCL_JW52 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126589 CVCL_K851 C2089 transformed cell line human CVCL_K851 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126590 CVCL_JW51 CREM030i-SS45-1 induced pluripotent stem cell human CVCL_JW51 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126591 CVCL_K854 C2092 transformed cell line human CVCL_K854 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405167; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126592 CVCL_JW54 CREM033i-SS49-1 induced pluripotent stem cell human CVCL_JW54 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126593 CVCL_K853 C2091 transformed cell line human CVCL_K853 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126594 CVCL_JW53 CREM032i-SS48-1 induced pluripotent stem cell human CVCL_JW53 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126595 CVCL_K850 C2088 transformed cell line human CVCL_K850 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405171; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126596 CVCL_JW50 CREM029i-SS44-1 induced pluripotent stem cell human CVCL_JW50 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126597 CVCL_K827 C2065 transformed cell line human CVCL_K827 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405157; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126598 CVCL_JW27 CREM004i-SS2-1 induced pluripotent stem cell human CVCL_JW27 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=28111279) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126599 CVCL_K826 C2064 transformed cell line human CVCL_K826 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405156; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126600 CVCL_JW26 CREM003i-BU3C2 induced pluripotent stem cell human CVCL_JW26 From: Steinberg M.; Boston University School of Medicine; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126601 CVCL_K829 C2067 transformed cell line human CVCL_K829 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405159; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126602 CVCL_JW29 CREM007i-SS5-1 induced pluripotent stem cell human CVCL_JW29 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126603 CVCL_K828 C2066 transformed cell line human CVCL_K828 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405158; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126604 CVCL_JW28 CREM006i-SS4-1 induced pluripotent stem cell human CVCL_JW28 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126605 CVCL_K823 C2061 transformed cell line human CVCL_K823 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405153; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126606 CVCL_JW23 SCRP9904i induced pluripotent stem cell human CVCL_JW23 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126607 CVCL_K822 C2060 transformed cell line human CVCL_K822 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405152; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126608 CVCL_JW22 SCRP9805i induced pluripotent stem cell human CVCL_JW22 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126609 CVCL_K825 C2063 transformed cell line human CVCL_K825 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405155; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126610 CVCL_JW25 CREM002i-BU2C10 induced pluripotent stem cell human CVCL_JW25 From: Steinberg M.; Boston University School of Medicine; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126611 CVCL_K824 C2062 transformed cell line human CVCL_K824 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405154; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126612 CVCL_JW24 CREM001i-bBU1C2 induced pluripotent stem cell human CVCL_JW24 From: Steinberg M.; Boston University School of Medicine; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126613 CVCL_K821 C2059 transformed cell line human CVCL_K821 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405151; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126614 CVCL_JW21 SCRP9602i induced pluripotent stem cell human CVCL_JW21 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126615 CVCL_K820 C2058 transformed cell line human CVCL_K820 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405150; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126616 CVCL_JW20 SCRP9501i induced pluripotent stem cell human CVCL_JW20 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126617 CVCL_K838 C2076 transformed cell line human CVCL_K838 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040531; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126618 CVCL_JW38 CREM017i-SS19-1 induced pluripotent stem cell human CVCL_JW38 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126619 CVCL_K837 C2075 transformed cell line human CVCL_K837 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040530; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126620 CVCL_JW37 CREM016i-SS18-1 induced pluripotent stem cell human CVCL_JW37 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126621 CVCL_K839 C2077 transformed cell line human CVCL_K839 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040532; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126622 CVCL_JW39 CREM018i-SS24-1 induced pluripotent stem cell human CVCL_JW39 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126623 CVCL_K834 C2072 transformed cell line human CVCL_K834 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126624 CVCL_JW34 CREM013i-SS14-1 induced pluripotent stem cell human CVCL_JW34 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126625 CVCL_K833 C2071 transformed cell line human CVCL_K833 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126626 CVCL_JW33 CREM012i-SS13-1 induced pluripotent stem cell human CVCL_JW33 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126627 CVCL_K836 C2074 transformed cell line human CVCL_K836 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126628 CVCL_JW36 CREM015i-SS16-1 induced pluripotent stem cell human CVCL_JW36 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126629 CVCL_K835 C2073 transformed cell line human CVCL_K835 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040528; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126630 CVCL_JW35 CREM014i-SS15-1 induced pluripotent stem cell human CVCL_JW35 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126631 CVCL_K830 C2068 transformed cell line human CVCL_K830 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405160; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126632 CVCL_JW30 CREM008i-SS6-1 induced pluripotent stem cell human CVCL_JW30 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126633 CVCL_K832 C2070 transformed cell line human CVCL_K832 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126634 CVCL_JW32 CREM010i-SS9-1 induced pluripotent stem cell human CVCL_JW32 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126635 CVCL_K831 C2069 transformed cell line human CVCL_K831 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405161; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126636 CVCL_JW31 CREM009i-SS8-2 induced pluripotent stem cell human CVCL_JW31 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126637 CVCL_K809 C2047 transformed cell line human CVCL_K809 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405103; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126638 CVCL_JW09 SCRP7903i induced pluripotent stem cell human CVCL_JW09 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126639 CVCL_K808 C2046 transformed cell line human CVCL_K808 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126640 CVCL_JW08 SCRP7803i induced pluripotent stem cell human CVCL_JW08 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126641 CVCL_K805 C2043 transformed cell line human CVCL_K805 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95040599; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126642 CVCL_JW05 SCRP6904i induced pluripotent stem cell human CVCL_JW05 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126643 CVCL_K804 C2042 transformed cell line human CVCL_K804 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405106; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126644 CVCL_JW04 SCRP6703i induced pluripotent stem cell human CVCL_JW04 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126645 CVCL_K807 C2045 transformed cell line human CVCL_K807 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405101; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126646 CVCL_JW07 SCRP7602i induced pluripotent stem cell human CVCL_JW07 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126647 CVCL_K806 C2044 transformed cell line human CVCL_K806 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405100; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126648 CVCL_JW06 SCRP7301i induced pluripotent stem cell human CVCL_JW06 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126649 CVCL_K801 C2039 transformed cell line human CVCL_K801 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126650 CVCL_JW01 SCRP6301i induced pluripotent stem cell human CVCL_JW01 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126651 CVCL_K800 C2038 transformed cell line human CVCL_K800 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95022096; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126652 CVCL_JW00 SCRP6101i induced pluripotent stem cell human CVCL_JW00 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126653 CVCL_K803 C2041 transformed cell line human CVCL_K803 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405108; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126654 CVCL_JW03 SCRP6504i induced pluripotent stem cell human CVCL_JW03 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126655 CVCL_K802 C2040 transformed cell line human CVCL_K802 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405107; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126656 CVCL_JW02 SCRP6401i induced pluripotent stem cell human CVCL_JW02 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126657 CVCL_K819 C2057 transformed cell line human CVCL_K819 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405149; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126658 CVCL_JW19 SCRP9403i induced pluripotent stem cell human CVCL_JW19 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126659 CVCL_K816 C2054 transformed cell line human CVCL_K816 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405146; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126660 CVCL_JW16 SCRP8901i induced pluripotent stem cell human CVCL_JW16 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126661 CVCL_K815 C2053 transformed cell line human CVCL_K815 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405145; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126662 CVCL_JW15 SCRP8717i induced pluripotent stem cell human CVCL_JW15 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126663 CVCL_K818 C2056 transformed cell line human CVCL_K818 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405148; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126664 CVCL_JW18 SCRP9301i induced pluripotent stem cell human CVCL_JW18 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126665 CVCL_K817 C2055 transformed cell line human CVCL_K817 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405147; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126666 CVCL_JW17 SCRP9001i induced pluripotent stem cell human CVCL_JW17 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126667 CVCL_K812 C2050 transformed cell line human CVCL_K812 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405141; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126668 CVCL_JW12 SCRP8401i induced pluripotent stem cell human CVCL_JW12 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126669 CVCL_K811 C2049 transformed cell line human CVCL_K811 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405140; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126670 CVCL_JW11 SCRP8305i induced pluripotent stem cell human CVCL_JW11 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126671 CVCL_K814 C2052 transformed cell line human CVCL_K814 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405144; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126672 CVCL_JW14 SCRP8601i induced pluripotent stem cell human CVCL_JW14 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126673 CVCL_K813 C2051 transformed cell line human CVCL_K813 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950405143; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126674 CVCL_JW13 SCRP8503i induced pluripotent stem cell human CVCL_JW13 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126675 CVCL_K810 C2048 transformed cell line human CVCL_K810 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126676 CVCL_JW10 SCRP8105i induced pluripotent stem cell human CVCL_JW10 From: Topol E.; The Scripps Research Institute; La Jolla; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126677 CVCL_SQ66 HAP1 GSK3B (-) 1 cancer cell line human CVCL_SQ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4617; GSK3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126678 CVCL_T266 HEV0465 transformed cell line human CVCL_T266 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126679 CVCL_SQ65 HAP1 GSK3A (-) 2 cancer cell line human CVCL_SQ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4616; GSK3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126680 CVCL_T265 HEV0463 transformed cell line human CVCL_T265 HLA typing: A*24:02,33:03; B*15:11,52:01; C*03:03,12:02; DPB1*05:01;09:01; DQB1*03:03,06:01; DRB1*09:01,15:02 (RCB=HEV0463) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126681 CVCL_SQ68 HAP1 GSN (-) 1 cancer cell line human CVCL_SQ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4620; GSN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126682 CVCL_T268 HEV0470 transformed cell line human CVCL_T268 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126683 CVCL_SQ67 HAP1 GSK3B (-) 2 cancer cell line human CVCL_SQ67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4617; GSK3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126684 CVCL_T267 HEV0469 transformed cell line human CVCL_T267 HLA typing: A*11:01,31:01; B*15:01; C*03:04,04:01; DPB1*02:01; DQB1*03:02; DRB1*04:06,11:01 (RCB=HEV0469) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126685 CVCL_SQ69 HAP1 GSR (-) cancer cell line human CVCL_SQ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4623; GSR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126686 CVCL_T269 HEV0477 transformed cell line human CVCL_T269 HLA typing: A*26:01,31:01; B*48:01,51:01; C*03:03,14:02; DPB1*02:01,05:01; DQB1*04:02,06:01; DRB1*08:02,08:03 (RCB=HEV0477) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126687 CVCL_0K21 AG19234 transformed cell line human CVCL_0K21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126688 CVCL_0K20 AG19233 transformed cell line human CVCL_0K20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126689 CVCL_0K23 AG19290 transformed cell line human CVCL_0K23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126690 CVCL_0K22 AG19267 transformed cell line human CVCL_0K22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21126691 CVCL_0K14 AG18919 transformed cell line human CVCL_0K14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126692 CVCL_0K13 AG18491 transformed cell line human CVCL_0K13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126693 CVCL_0K16 AG19032 transformed cell line human CVCL_0K16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126694 CVCL_0K15 AG19013 transformed cell line human CVCL_0K15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126695 CVCL_0K18 AG19231 transformed cell line human CVCL_0K18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126696 CVCL_0K17 AG19053 transformed cell line human CVCL_0K17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126697 CVCL_0K19 AG19232 transformed cell line human CVCL_0K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126698 CVCL_SQ71 HAP1 GSTP1 (-) cancer cell line human CVCL_SQ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4638; GSTP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126699 CVCL_T271 HEV0485 transformed cell line human CVCL_T271 HLA typing: A*02:01,24:02; B*39:01,48:01; C*07:02,08:01; DPB1*02:01,02:02; DQB1*03:01,04:01; DRB1*04:05,11:01 (RCB=HEV0485) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126700 CVCL_SQ70 HAP1 GSTM2 (-) 1 cancer cell line human CVCL_SQ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4634; GSTM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126701 CVCL_T270 HEV0482 transformed cell line human CVCL_T270 HLA typing: A*02:01,24:02; B*15:11,52:01; C*03:03,12:02; DPB1*05:01,13:01; DQB1*03:01,06:01; DRB1*14:54,15:02 (RCB=HEV0482) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126702 CVCL_SQ73 HAP1 GUSB (-) 1 cancer cell line human CVCL_SQ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4696; GUSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126703 CVCL_T273 HEV0492 transformed cell line human CVCL_T273 HLA typing: A*24:02,31:01; B*35:01,52:01; C*04:01,12:02; DPB1*02:01,05:01; DQB1*03:03,06:01; DRB1*09:01,15:02 (RCB=HEV0492) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126704 CVCL_SQ72 HAP1 GTF2I (-) 1 cancer cell line human CVCL_SQ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4659; GTF2I; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126705 CVCL_T272 HEV0487 transformed cell line human CVCL_T272 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126706 CVCL_SQ75 HAP1 H2AFX (-) cancer cell line human CVCL_SQ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4739; H2AX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126707 CVCL_T275 HEV0498 transformed cell line human CVCL_T275 HLA typing: A*24:02,26:02; B*07:43,40:02; C*03:04,07:02; DPB1*02:01; DQB1*02:02,05:03; DRB1*07:01,14:54 (RCB=HEV0498) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126708 CVCL_SQ74 HAP1 GUSB (-) 2 cancer cell line human CVCL_SQ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4696; GUSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126709 CVCL_T274 HEV0496 transformed cell line human CVCL_T274 HLA typing: A*02:01,24:02; B*40:01,52:01; C*03:04,12:02; DPB1*02:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0496) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126710 CVCL_SQ55 HAP1 GRK5 (-) 2 cancer cell line human CVCL_SQ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4544; GRK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126711 CVCL_T255 HEV0431 transformed cell line human CVCL_T255 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126712 CVCL_SQ54 HAP1 GRK5 (-) 1 cancer cell line human CVCL_SQ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4544; GRK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126713 CVCL_T254 HEV0430 transformed cell line human CVCL_T254 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126714 CVCL_SQ57 HAP1 GRK6 (-) 1 cancer cell line human CVCL_SQ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4545; GRK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126715 CVCL_T257 HEV0440 transformed cell line human CVCL_T257 HLA typing: A*02:01,26:01; B*40:02,54:01; C*01:02,03:04; DPB1*05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0440) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126716 CVCL_SQ56 HAP1 GRK5 (-) 3 cancer cell line human CVCL_SQ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4544; GRK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126717 CVCL_T256 HEV0436 transformed cell line human CVCL_T256 HLA typing: A*02:06,24:02; B*35:01,46:01; C*01:02,03:03; DPB1*02:02,05:01; DQB1*06:01,06:02; DRB1*08:03,15:01 (RCB=HEV0436) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126718 CVCL_SQ59 HAP1 GRM8 (-) 1 cancer cell line human CVCL_SQ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4600; GRM8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126719 CVCL_T259 HEV0444 transformed cell line human CVCL_T259 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126720 CVCL_SQ58 HAP1 GRK6 (-) 2 cancer cell line human CVCL_SQ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4545; GRK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126721 CVCL_T258 HEV0442 transformed cell line human CVCL_T258 HLA typing: A*02:06,24:02; B*15:11,59:01; C*01:02,03:03; DPB1*02:02,04:02; DQB1*03:01,04:01; DRB1*04:05,12:01 (RCB=HEV0442) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126722 CVCL_0K30 AG19303 transformed cell line human CVCL_0K30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126723 CVCL_0K32 AG19306 transformed cell line human CVCL_0K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126724 CVCL_0K31 AG19305 transformed cell line human CVCL_0K31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126725 CVCL_0K34 AG19337 transformed cell line human CVCL_0K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21126726 CVCL_0K33 AG19336 transformed cell line human CVCL_0K33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126727 CVCL_0K25 AG19298 transformed cell line human CVCL_0K25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126728 CVCL_0K24 AG19297 transformed cell line human CVCL_0K24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126729 CVCL_0K27 AG19300 transformed cell line human CVCL_0K27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126730 CVCL_0K26 AG19299 transformed cell line human CVCL_0K26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126731 CVCL_0K29 AG19302 transformed cell line human CVCL_0K29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126732 CVCL_0K28 AG19301 transformed cell line human CVCL_0K28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126733 CVCL_SQ60 HAP1 GRM8 (-) 2 cancer cell line human CVCL_SQ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4600; GRM8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126734 CVCL_T260 HEV0448 transformed cell line human CVCL_T260 HLA typing: A*02:01,26:01; B*40:01,40:02; C*03:04,15:02; DPB1*04:01,13:01; DQB1*03:03,06:01; DRB1*08:03,09:01 (RCB=HEV0448) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126735 CVCL_SQ62 HAP1 GRN (-) 2 cancer cell line human CVCL_SQ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4601; GRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126736 CVCL_T262 HEV0455 transformed cell line human CVCL_T262 HLA typing: A*02:01,11:01; B*13:01,48:01; C*03:04,08:03; DPB1*02:01; DQB1*03:01; DRB1*12:02,15:01 (RCB=HEV0455) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126737 CVCL_SQ61 HAP1 GRN (-) 1 cancer cell line human CVCL_SQ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4601; GRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126738 CVCL_T261 HEV0451 transformed cell line human CVCL_T261 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126739 CVCL_SQ64 HAP1 GSK3A (-) 1 cancer cell line human CVCL_SQ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4616; GSK3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126740 CVCL_T264 HEV0459 transformed cell line human CVCL_T264 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126741 CVCL_SQ63 HAP1 GSG2 (-) cancer cell line human CVCL_SQ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19682; HASPIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126742 CVCL_T263 HEV0456 transformed cell line human CVCL_T263 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126743 CVCL_SQ44 HAP1 GPR137B (-) 1 cancer cell line human CVCL_SQ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11862; GPR137B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126744 CVCL_T244 HEV0399 transformed cell line human CVCL_T244 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126745 CVCL_SQ43 HAP1 GPR137 (-) 4 cancer cell line human CVCL_SQ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24300; GPR137; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126746 CVCL_T243 HEV0396 transformed cell line human CVCL_T243 HLA typing: A*02:01,24:02; B*39:01,55:02; C*01:02,07:02; DPB1*02:02,03:01; DQB1*04:02,06:02; DRB1*04:10,15:01 (RCB=HEV0396) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126747 CVCL_SQ46 HAP1 GPR137C (-) 1 cancer cell line human CVCL_SQ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25445; GPR137C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126748 CVCL_T246 HEV0401 transformed cell line human CVCL_T246 HLA typing: A*02:01,33:03; B*40:02,44:03; C*03:04,14:03; DPB1*04:01,05:01; DQB1*03:03,06:04; DRB1*09:01,13:02 (RCB=HEV0401) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126749 CVCL_SQ45 HAP1 GPR137B (-) 2 cancer cell line human CVCL_SQ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11862; GPR137B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126750 CVCL_T245 HEV0400 transformed cell line human CVCL_T245 HLA typing: A*26:01,33:03; B*35:01,44:03; C*03:03,14:03; DPB1*05:01,14:01; DQB1*03:01,03:03; DRB1*04:01,12:01 (RCB=HEV0400) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126751 CVCL_SQ48 HAP1 GPT2 (-) 1 cancer cell line human CVCL_SQ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18062; GPT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126752 CVCL_T248 HEV0408 transformed cell line human CVCL_T248 HLA typing: A*02:06,24:02; B*15:01,40:06; C*04:01,08:01; DPB1*05:01; DQB1*03:02,03:03; DRB1*04:06,09:01 (RCB=HEV0408) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126753 CVCL_SQ47 HAP1 GPR137C (-) 2 cancer cell line human CVCL_SQ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25445; GPR137C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126754 CVCL_T247 HEV0404 transformed cell line human CVCL_T247 HLA typing: A*24:02; B*07:02,51:01; C*07:02,14:02; DPB1*04:02,13:01; DQB1*03:02,05:01; DRB1*01:01,04:06 (RCB=HEV0404) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126755 CVCL_SQ49 HAP1 GPT2 (-) 2 cancer cell line human CVCL_SQ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18062; GPT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126756 CVCL_T249 HEV0410 transformed cell line human CVCL_T249 HLA typing: A*02:01,11:01; B*44:03,67:01; C*07:02,14:03; DPB1*02:02,09:01; DQB1*05:02,06:01; DRB1*15:02,16:02 (RCB=HEV0410) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126757 CVCL_0K01 AG18173 transformed cell line human CVCL_0K01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126758 CVCL_0K00 AG04434 finite cell line human CVCL_0K00 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21126759 CVCL_SQ51 HAP1 GPX1 (-) 2 cancer cell line human CVCL_SQ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4553; GPX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126760 CVCL_T251 HEV0421 transformed cell line human CVCL_T251 HLA typing: A*02:01,11:01; B*40:01,48:01; C*03:04,08:03; DPB1*02:01; DQB1*03:03,06:02; DRB1*09:01,15:01 (RCB=HEV0421) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126761 CVCL_SQ50 HAP1 GPX1 (-) 1 cancer cell line human CVCL_SQ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4553; GPX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126762 CVCL_T250 HEV0415 transformed cell line human CVCL_T250 HLA typing: A*02:01,02:06; B*51:01; C*14:02; DPB1*02:01,03:01; DQB1*03:01,04:02; DRB1*04:10,14:03 (RCB=HEV0415) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126763 CVCL_SQ53 HAP1 GRINA (-) 1 cancer cell line human CVCL_SQ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4589; GRINA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126764 CVCL_T253 HEV0428 transformed cell line human CVCL_T253 HLA typing: A*24:02,26:01; B*40:02,52:01; C*03:04,12:02; DPB1*02:01,09:01; DQB1*03:02,06:01; DRB1*08:02,15:02 (RCB=HEV0428) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126765 CVCL_SQ52 HAP1 GPX4 (-) 1 cancer cell line human CVCL_SQ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4556; GPX4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126766 CVCL_T252 HEV0424 transformed cell line human CVCL_T252 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126767 CVCL_SQ33 HAP1 GPATCH2 (-) 2 cancer cell line human CVCL_SQ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25499; GPATCH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126768 CVCL_T233 HEV0351 transformed cell line human CVCL_T233 HLA typing: A*02:53N,26:01; B*39:01,54:01; C*01:02,07:02; DPB1*04:02,05:01; DQB1*05:03,06:02; DRB1*14:05,15:01 (RCB=HEV0351) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126769 CVCL_SQ32 HAP1 GPATCH2 (-) 1 cancer cell line human CVCL_SQ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25499; GPATCH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126770 CVCL_T232 HEV0350 transformed cell line human CVCL_T232 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126771 CVCL_SQ35 HAP1 GPATCH2 (-) 4 cancer cell line human CVCL_SQ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25499; GPATCH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126772 CVCL_T235 HEV0363 transformed cell line human CVCL_T235 HLA typing: A*02:07,24:20; B*46:01,55:02; C*01:02,07:02; DPB1*02:01,05:01; DQB1*06:01; DRB1*08:03 (RCB=HEV0363) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126773 CVCL_SQ34 HAP1 GPATCH2 (-) 3 cancer cell line human CVCL_SQ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25499; GPATCH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126774 CVCL_T234 HEV0356 transformed cell line human CVCL_T234 HLA typing: A*11:01,24:02; B*13:01,48:01; C*03:04,08:01; DPB1*02:01,04:02; DQB1*03:01,03:03; DRB1*09:01,12:02 (RCB=HEV0356) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126775 CVCL_SQ37 HAP1 GPC4 (-) 1 cancer cell line human CVCL_SQ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4452; GPC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126776 CVCL_T237 HEV0375 transformed cell line human CVCL_T237 HLA typing: A*24:02,33:03; B*44:03,52:01; C*12:02,14:03; DPB1*02:01,05:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0375) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126777 CVCL_SQ36 HAP1 GPC3 (-) cancer cell line human CVCL_SQ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4451; GPC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126778 CVCL_T236 HEV0370 transformed cell line human CVCL_T236 HLA typing: A*24:02,26:02; B*40:01,40:06; C*03:04,08:01; DPB1*04:01,05:01; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0370) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126779 CVCL_SQ39 HAP1 GPHN (-) cancer cell line human CVCL_SQ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15465; GPHN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126780 CVCL_T239 HEV0380 transformed cell line human CVCL_T239 HLA typing: A*02:06,24:02; B*35:01,52:01; C*03:03,12:02; DPB1*02:01,05:01; DQB1*05:03,06:02; DRB1*14:54,15:01 (RCB=HEV0380) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126781 CVCL_SQ38 HAP1 GPC4 (-) 2 cancer cell line human CVCL_SQ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4452; GPC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126782 CVCL_T238 HEV0378 transformed cell line human CVCL_T238 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126783 CVCL_0K10 AG18462 transformed cell line human CVCL_0K10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126784 CVCL_0K12 AG18490 transformed cell line human CVCL_0K12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126785 CVCL_0K11 AG18463 transformed cell line human CVCL_0K11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126786 CVCL_0K03 AG18176 transformed cell line human CVCL_0K03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21126787 CVCL_0K02 AG18175 transformed cell line human CVCL_0K02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126788 CVCL_0K05 AG18179 transformed cell line human CVCL_0K05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126789 CVCL_0K04 AG18177 transformed cell line human CVCL_0K04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21126790 CVCL_0K07 AG18206 transformed cell line human CVCL_0K07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126791 CVCL_0K06 AG18205 transformed cell line human CVCL_0K06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126792 CVCL_0K09 AG18258 transformed cell line human CVCL_0K09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126793 CVCL_0K08 AG18231 transformed cell line human CVCL_0K08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21126794 CVCL_SQ40 HAP1 GPR137 (-) 1 cancer cell line human CVCL_SQ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24300; GPR137; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126795 CVCL_T240 HEV0384 transformed cell line human CVCL_T240 HLA typing: A*02:01,26:01; B*40:02,51:02; C*03:04,08:01; DPB1*02:01,03:01; DQB1*03:03; DRB1*09:01 (RCB=HEV0384) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126796 CVCL_SQ42 HAP1 GPR137 (-) 3 cancer cell line human CVCL_SQ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24300; GPR137; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126797 CVCL_T242 HEV0388 transformed cell line human CVCL_T242 HLA typing: A*24:02,26:01; B*15:01,35:01; C*01:02,03:03; DPB1*03:01,19:01; DQB1*03:03,06:01; DRB1*08:03,09:01 (RCB=HEV0388) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126798 CVCL_SQ41 HAP1 GPR137 (-) 2 cancer cell line human CVCL_SQ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24300; GPR137; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126799 CVCL_T241 HEV0386 transformed cell line human CVCL_T241 HLA typing: A*01:01,02:01; B*15:01,40:06; C*06:02,08:01; DPB1*04:01,04:02; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0386) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126800 CVCL_SQ22 HAP1 GNPTG (-) 3 cancer cell line human CVCL_SQ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23026; GNPTG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126801 CVCL_T222 HEV0325 transformed cell line human CVCL_T222 HLA typing: A*11:01,24:02; B*35:01,51:01; C*03:03,15:02; DPB1*02:01,03:01; DQB1*04:01,04:02; DRB1*04:05,04:10 (RCB=HEV0325) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126802 CVCL_SQ21 HAP1 GNPTG (-) 2 cancer cell line human CVCL_SQ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23026; GNPTG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126803 CVCL_T221 HEV0324 transformed cell line human CVCL_T221 HLA typing: A*24:02,31:01; B*51:01,52:01; C*12:02,14:02; DPB1*04:02,09:01; DQB1*04:02,06:01; DRB1*08:02,15:02 (RCB=HEV0324) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126804 CVCL_SQ24 HAP1 GNPTG (-) 5 cancer cell line human CVCL_SQ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23026; GNPTG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126805 CVCL_T224 HEV0330 transformed cell line human CVCL_T224 HLA typing: A*24:02,26:03; B*15:01,52:01; C*03:03,12:02; DPB1*05:01,09:01; DQB1*06:01,06:04; DRB1*13:02,15:02 (RCB=HEV0330) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126806 CVCL_SQ23 HAP1 GNPTG (-) 4 cancer cell line human CVCL_SQ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23026; GNPTG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126807 CVCL_T223 HEV0327 transformed cell line human CVCL_T223 HLA typing: A*02:01,24:02; B*07:02,46:01; C*03:04,07:02; DPB1*04:02,05:01; DQB1*05:01,06:01; DRB1*01:01,08:03 (RCB=HEV0327) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126808 CVCL_SQ26 HAP1 GOLGB1 (-) 1 cancer cell line human CVCL_SQ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4429; GOLGB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126809 CVCL_T226 HEV0336 transformed cell line human CVCL_T226 HLA typing: A*11:01,31:01; B*40:02,55:02; C*01:02,03:04; DPB1*02:01,05:01; DQB1*03:02,06:02; DRB1*08:02,15:01 (RCB=HEV0336) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126810 CVCL_SQ25 HAP1 GOLGA2 (-) 1 cancer cell line human CVCL_SQ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4425; GOLGA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126811 CVCL_T225 HEV0333 transformed cell line human CVCL_T225 HLA typing: A*02:01,24:02; B*40:01,48:01; C*03:03,03:04; DPB1*04:02,05:01; DQB1*03:01,05:03; DRB1*11:01,14:54 (RCB=HEV0333) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126812 CVCL_SQ28 HAP1 GOLPH3 (-) 2 cancer cell line human CVCL_SQ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15452; GOLPH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126813 CVCL_T228 HEV0340 transformed cell line human CVCL_T228 HLA typing: A*24:02; B*15:07,52:01; C*01:02,12:02; DPB1*02:01,05:01; DQB1*03:02,06:02; DRB1*04:03,15:01 (RCB=HEV0340) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126814 CVCL_SQ27 HAP1 GOLPH3 (-) 1 cancer cell line human CVCL_SQ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15452; GOLPH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126815 CVCL_T227 HEV0337 transformed cell line human CVCL_T227 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126816 CVCL_SQ29 HAP1 GORAB (-) 1 cancer cell line human CVCL_SQ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25676; GORAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126817 CVCL_T229 HEV0342 transformed cell line human CVCL_T229 HLA typing: A*02:01,24:02; B*38:02,51:01; C*07:02,14:02; DPB1*05:01,14:01; DQB1*03:01,03:03; DRB1*08:03,09:01 (RCB=HEV0342) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126818 CVCL_K889 C2127 transformed cell line human CVCL_K889 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126819 CVCL_JW89 NYSCF-051140-01-MR induced pluripotent stem cell human CVCL_JW89 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian. Male Part of: Personal Genome Project (PGP) cell line collection 21126820 CVCL_K888 C2126 [2nd copy] transformed cell line human CVCL_K888 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061968; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126821 CVCL_JW88 NYSCF-051121-01-MR induced pluripotent stem cell human CVCL_JW88 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126822 CVCL_K885 C2124 transformed cell line human CVCL_K885 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515132; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126823 CVCL_JW85 NYSCF-051088-01-MR induced pluripotent stem cell human CVCL_JW85 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126824 CVCL_K884 C2123 transformed cell line human CVCL_K884 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515133; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126825 CVCL_JW84 NYSCF-051086-01-MR induced pluripotent stem cell human CVCL_JW84 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Male Part of: Personal Genome Project (PGP) cell line collection 21126826 CVCL_K887 C2126 [1st copy] transformed cell line human CVCL_K887 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515177; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126827 CVCL_JW87 NYSCF-051118-01-MR induced pluripotent stem cell human CVCL_JW87 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Female Part of: Personal Genome Project (PGP) cell line collection 21126828 CVCL_K886 C2125 transformed cell line human CVCL_K886 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126829 CVCL_JW86 NYSCF-051094-01-MR induced pluripotent stem cell human CVCL_JW86 From: New York Stem Cell Foundation; New York; USA CL:0000010 Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126830 CVCL_K881 C2120 transformed cell line human CVCL_K881 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126831 CVCL_JW81 NYSCF-051032-01-MR induced pluripotent stem cell human CVCL_JW81 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian. Female Part of: Personal Genome Project (PGP) cell line collection 21126832 CVCL_K880 C2119 transformed cell line human CVCL_K880 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126833 CVCL_JW80 NYSCF-051024-01-MR induced pluripotent stem cell human CVCL_JW80 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126834 CVCL_K883 C2122 transformed cell line human CVCL_K883 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126835 CVCL_JW83 NYSCF-051045-01-MR induced pluripotent stem cell human CVCL_JW83 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126836 CVCL_K882 C2121 transformed cell line human CVCL_K882 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126837 CVCL_JW82 NYSCF-051036-01-MR induced pluripotent stem cell human CVCL_JW82 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126838 CVCL_SQ31 HAP1 GOT1 (-) 2 cancer cell line human CVCL_SQ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4432; GOT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126839 CVCL_T231 HEV0349 transformed cell line human CVCL_T231 HLA typing: A*11:01,24:02; B*07:02,39:01; C*07:02; DPB1*05:01; DQB1*04:01,05:01; DRB1*01:01,04:05 (RCB=HEV0349) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126840 CVCL_SQ30 HAP1 GOT1 (-) 1 cancer cell line human CVCL_SQ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4432; GOT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126841 CVCL_T230 HEV0345 transformed cell line human CVCL_T230 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126842 CVCL_SQ11 HAP1 GLUL (-) 1 cancer cell line human CVCL_SQ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4341; GLUL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126843 CVCL_T211 HEV0296 transformed cell line human CVCL_T211 HLA typing: A*02:06,24:02; B*44:03,52:01; C*12:02,14:03; DPB1*04:01,05:01; DQB1*03:02,06:04; DRB1*04:06,13:02 (RCB=HEV0296) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126844 CVCL_SQ10 HAP1 GLUD1 (-) 1 cancer cell line human CVCL_SQ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4335; GLUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126845 CVCL_T210 HEV0295 transformed cell line human CVCL_T210 HLA typing: A*02:01,26:03; B*40:01,40:02; C*15:02; DPB1*02:01,04:02; DQB1*05:02,06:01; DRB1*08:03,14:54 (RCB=HEV0295) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126846 CVCL_SQ13 HAP1 GNAQ (-) 1 cancer cell line human CVCL_SQ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4390; GNAQ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126847 CVCL_T213 HEV0301 transformed cell line human CVCL_T213 HLA typing: A*02:01,02:06; B*35:01,39:01; C*03:03,07:02; DPB1*05:01; DQB1*03:01,03:03; DRB1*09:01,14:06 (RCB=HEV0301) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126848 CVCL_SQ12 HAP1 GMDS (-) cancer cell line human CVCL_SQ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4369; GMDS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126849 CVCL_T212 HEV0300 transformed cell line human CVCL_T212 HLA typing: A*02:06,24:02; B*15:27,35:01; C*03:03,04:01; DPB1*02:01,05:01; DQB1*03:01,03:02; DRB1*04:03,12:01 (RCB=HEV0300) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126850 CVCL_SQ15 HAP1 GNE (-) 1 cancer cell line human CVCL_SQ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23657; GNE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126851 CVCL_T215 HEV0304 transformed cell line human CVCL_T215 HLA typing: A*02:06,31:01; B*40:02,44:03; C*03:04,14:03; DPB1*04:01,05:01; DQB1*03:03,06:04; DRB1*09:01,13:02 (RCB=HEV0304) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126852 CVCL_SQ14 HAP1 GNAQ (-) 2 cancer cell line human CVCL_SQ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4390; GNAQ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126853 CVCL_T214 HEV0303 transformed cell line human CVCL_T214 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126854 CVCL_SQ17 HAP1 GNE (-) 3 cancer cell line human CVCL_SQ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23657; GNE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126855 CVCL_T217 HEV0311 transformed cell line human CVCL_T217 HLA typing: A*26:01; B*35:01,52:01; C*03:03,12:02; DPB1*02:01,09:01; DQB1*06:01,06:02; DRB1*15:01,15:02 (RCB=HEV0311) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126856 CVCL_SQ16 HAP1 GNE (-) 2 cancer cell line human CVCL_SQ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23657; GNE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126857 CVCL_T216 HEV0307 transformed cell line human CVCL_T216 HLA typing: A*24:02; B*46:01,54:01; C*01:02; DPB1*05:01; DQB1*04:01,06:01; DRB1*04:05,08:03 (RCB=HEV0307) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126858 CVCL_SQ19 HAP1 GNPTAB (-) cancer cell line human CVCL_SQ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29670; GNPTAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126859 CVCL_T219 HEV0315 transformed cell line human CVCL_T219 HLA typing: A*26:01,33:03; B*44:03,52:01; C*12:02,14:03; DPB1*04:01,09:01; DQB1*06:01,06:04; DRB1*13:02,15:02 (RCB=HEV0315) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126860 CVCL_SQ18 HAP1 GNG5 (-) 1 cancer cell line human CVCL_SQ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4408; GNG5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126861 CVCL_T218 HEV0312 transformed cell line human CVCL_T218 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126862 CVCL_K899 C2137 transformed cell line human CVCL_K899 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515160; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126863 CVCL_JW99 NYSCF-AG0008-01-MR induced pluripotent stem cell human CVCL_JW99 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Trp740Ser (c.2219G>C); ClinVar=VCV000002269; Zygosity=Unspecified (NYSCF). Population: Caucasian Female 21126864 CVCL_K896 C2134 transformed cell line human CVCL_K896 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515157; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126865 CVCL_JW96 NYSCF-AG0003-01-MR induced pluripotent stem cell human CVCL_JW96 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.His39Pro (c.116A>C); ClinVar=VCV000217232; Zygosity=Unspecified (NYSCF). Female 21126866 CVCL_K895 C2133 transformed cell line human CVCL_K895 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515169; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126867 CVCL_JW95 NYSCF-051015-01-MR induced pluripotent stem cell human CVCL_JW95 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Hispanic. Male Part of: Personal Genome Project (PGP) cell line collection 21126868 CVCL_K898 C2136 transformed cell line human CVCL_K898 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515159; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126869 CVCL_JW98 NYSCF-AG0007-01-MR induced pluripotent stem cell human CVCL_JW98 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Thr124Met (c.371C>T); ClinVar=VCV000014181; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 21126870 CVCL_K897 C2135 transformed cell line human CVCL_K897 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126871 CVCL_JW97 NYSCF-AG0005-01-SV induced pluripotent stem cell human CVCL_JW97 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Female 21126872 CVCL_K892 C2130 transformed cell line human CVCL_K892 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126873 CVCL_JW92 NYSCF-051167-01-MR induced pluripotent stem cell human CVCL_JW92 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126874 CVCL_K891 C2129 transformed cell line human CVCL_K891 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515180; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126875 CVCL_JW91 NYSCF-051162-01-MR induced pluripotent stem cell human CVCL_JW91 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian. Male Part of: Personal Genome Project (PGP) cell line collection 21126876 CVCL_K894 C2132 transformed cell line human CVCL_K894 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126877 CVCL_JW94 NYSCF-050956-01-MR induced pluripotent stem cell human CVCL_JW94 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian. Male Part of: Personal Genome Project (PGP) cell line collection 21126878 CVCL_K893 C2131 transformed cell line human CVCL_K893 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515182; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126879 CVCL_JW93 NYSCF-050921-01-MR induced pluripotent stem cell human CVCL_JW93 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126880 CVCL_K890 C2128 transformed cell line human CVCL_K890 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126881 CVCL_JW90 NYSCF-051141-01-MR induced pluripotent stem cell human CVCL_JW90 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126882 CVCL_SQ20 HAP1 GNPTG (-) 1 cancer cell line human CVCL_SQ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23026; GNPTG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126883 CVCL_T220 HEV0317 transformed cell line human CVCL_T220 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126884 CVCL_SQ00 HAP1 GHITM (-) 3 cancer cell line human CVCL_SQ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17281; GHITM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126885 CVCL_T200 HEV0262 transformed cell line human CVCL_T200 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126886 CVCL_SQ02 HAP1 GIT1 (-) 1 cancer cell line human CVCL_SQ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4272; GIT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126887 CVCL_T202 HEV0270 transformed cell line human CVCL_T202 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126888 CVCL_SQ01 HAP1 GID4 (-) 1 cancer cell line human CVCL_SQ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28453; GID4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126889 CVCL_T201 HEV0266 transformed cell line human CVCL_T201 HLA typing: A*02:01,33:03; B*35:01,44:03; C*03:03,14:03; DPB1*03:01,04:01; DQB1*04:02,06:04; DRB1*04:10,13:02 (RCB=HEV0266) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126890 CVCL_SQ04 HAP1 GLO1 (-) 1 cancer cell line human CVCL_SQ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4323; GLO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126891 CVCL_T204 HEV0272 transformed cell line human CVCL_T204 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126892 CVCL_SQ03 HAP1 GLA (-) 1 cancer cell line human CVCL_SQ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126893 CVCL_T203 HEV0271 transformed cell line human CVCL_T203 HLA typing: A*11:01; B*48:01,51:01; C*08:01,15:02; DPB1*04:02,05:01; DQB1*03:03; DRB1*09:01 (RCB=HEV0271) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126894 CVCL_SQ06 HAP1 GLRB (-) 1 cancer cell line human CVCL_SQ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4329; GLRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126895 CVCL_T206 HEV0284 transformed cell line human CVCL_T206 HLA typing: A*24:02; B*07:02,40:06; C*07:02,08:01; DPB1*05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0284) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126896 CVCL_SQ05 HAP1 GLOD4 (-) 1 cancer cell line human CVCL_SQ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14111; GLOD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126897 CVCL_T205 HEV0277 transformed cell line human CVCL_T205 HLA typing: A*31:01,33:03; B*44:03,51:01; C*14:02,14:03; DPB1*02:01,04:01; DQB1*03:01,06:04; DRB1*13:02,14:03 (RCB=HEV0277) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126898 CVCL_SQ08 HAP1 GLS (-) 1 cancer cell line human CVCL_SQ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4331; GLS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126899 CVCL_T208 HEV0288 transformed cell line human CVCL_T208 HLA typing: A*24:02,33:03; B*07:02,44:03; C*07:02,14:03; DPB1*04:02,05:01; DQB1*05:01,06:04; DRB1*01:01,13:02 (RCB=HEV0288) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126900 CVCL_SQ07 HAP1 GLRB (-) 2 cancer cell line human CVCL_SQ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4329; GLRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126901 CVCL_T207 HEV0285 transformed cell line human CVCL_T207 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21126902 CVCL_SQ09 HAP1 GLS (-) 2 cancer cell line human CVCL_SQ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4331; GLS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126903 CVCL_T209 HEV0292 transformed cell line human CVCL_T209 HLA typing: A*24:02; B*52:01; C*12:02; DPB1*02:01,04:02; DQB1*06:01; DRB1*15:02 (RCB=HEV0292) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126904 CVCL_K867 C2106 transformed cell line human CVCL_K867 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051585; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126905 CVCL_JW67 WISCi004-A-1 induced pluripotent stem cell human CVCL_JW67 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126906 CVCL_K866 C2105 transformed cell line human CVCL_K866 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051586; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126907 CVCL_JW66 H9-SOX2-GFP embryonic stem cell human CVCL_JW66 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: SOX2 reporter line expressing GFP only when SOX2 is expressed 21126908 CVCL_K869 C2108 transformed cell line human CVCL_K869 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126909 CVCL_JW69 WISCi004-A-3 induced pluripotent stem cell human CVCL_JW69 From: University of Wisconsin; Madison; USA CL:0000010 Knockout cell: Method=TALEN; HGNC; 2888; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126910 CVCL_K868 C2107 transformed cell line human CVCL_K868 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051596; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126911 CVCL_JW68 WISCi004-A-2 induced pluripotent stem cell human CVCL_JW68 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126912 CVCL_K863 C2101 transformed cell line human CVCL_K863 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126913 CVCL_JW63 CREM045i-SA106-1 induced pluripotent stem cell human CVCL_JW63 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126914 CVCL_K862 C2100 transformed cell line human CVCL_K862 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051591; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126915 CVCL_JW62 CREM044i-SA50-1 induced pluripotent stem cell human CVCL_JW62 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126916 CVCL_K865 C2103 transformed cell line human CVCL_K865 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126917 CVCL_JW65 CREM047i-SA170-1 induced pluripotent stem cell human CVCL_JW65 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126918 CVCL_K864 C2102 transformed cell line human CVCL_K864 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126919 CVCL_JW64 CREM046i-SA138-1 induced pluripotent stem cell human CVCL_JW64 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126920 CVCL_K861 C2099 transformed cell line human CVCL_K861 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95051592; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126921 CVCL_JW61 CREM042i-SA209-1 induced pluripotent stem cell human CVCL_JW61 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126922 CVCL_K860 C2098 transformed cell line human CVCL_K860 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126923 CVCL_JW60 CREM041i-SA208-2 induced pluripotent stem cell human CVCL_JW60 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Saudi Arabian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21126924 CVCL_K878 C2117 transformed cell line human CVCL_K878 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515139; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126925 CVCL_JW78 NYSCF-050985-01-MR induced pluripotent stem cell human CVCL_JW78 From: New York Stem Cell Foundation; New York; USA CL:0000010 Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126926 CVCL_K877 C2116 transformed cell line human CVCL_K877 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126927 CVCL_JW77 NYSCF-050974-01-MR induced pluripotent stem cell human CVCL_JW77 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126928 CVCL_K879 C2118 transformed cell line human CVCL_K879 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126929 CVCL_JW79 NYSCF-051001-01-MR induced pluripotent stem cell human CVCL_JW79 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Male Part of: Personal Genome Project (PGP) cell line collection 21126930 CVCL_K874 C2113 transformed cell line human CVCL_K874 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126931 CVCL_JW74 YZ1 induced pluripotent stem cell human CVCL_JW74 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126932 CVCL_K873 C2112 transformed cell line human CVCL_K873 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515144; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126933 CVCL_JW73 CA3/7 cancer cell line house mouse CVCL_JW73 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032). 21126934 CVCL_K876 C2115 transformed cell line human CVCL_K876 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515140; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126935 CVCL_JW76 NYSCF-050967-01-MR induced pluripotent stem cell human CVCL_JW76 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Male Part of: Personal Genome Project (PGP) cell line collection 21126936 CVCL_K875 C2114 transformed cell line human CVCL_K875 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126937 CVCL_JW75 NYSCF-050882-01-MR induced pluripotent stem cell human CVCL_JW75 From: New York Stem Cell Foundation; New York; USA CL:0000010 Population: Caucasian Omics: Genome sequenced. Female Part of: Personal Genome Project (PGP) cell line collection 21126938 CVCL_K870 C2109 transformed cell line human CVCL_K870 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126939 CVCL_JW70 WISCi004-A-4 induced pluripotent stem cell human CVCL_JW70 From: University of Wisconsin; Madison; USA CL:0000010 Knockout cell: Method=TALEN; HGNC; 2888; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126940 CVCL_JW72 B66BA cancer cell line house mouse CVCL_JW72 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from metastatic site: Lymph node; Breed/subspecies: SENCAR. 21126941 CVCL_K872 C2111 transformed cell line human CVCL_K872 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126942 CVCL_JW71 3PC transformed cell line house mouse CVCL_JW71 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: SENCAR. Unspecified 21126943 CVCL_K871 C2110 transformed cell line human CVCL_K871 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21126944 CVCL_9D18 DD0970 finite cell line human CVCL_9D18 CL:0000010 Karyotypic information: 47,XX+18 (ECACC); Derived from sampling site: Muscle Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21126945 CVCL_9D17 DD0969 transformed cell line human CVCL_9D17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126946 CVCL_9D19 DD0977 transformed cell line human CVCL_9D19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126947 CVCL_0J80 AG09558 finite cell line human CVCL_0J80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21126948 CVCL_9D14 DD0963 transformed cell line human CVCL_9D14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126949 CVCL_9D13 DD0962 transformed cell line human CVCL_9D13 CL:0000010 Karyotypic information: 46,XY,t(1;19)(p34.3;q13.3)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126950 CVCL_0J82 XP17CA finite cell line human CVCL_0J82 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126951 CVCL_9D16 DD0968 transformed cell line human CVCL_9D16 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126952 CVCL_0J81 AG09961 finite cell line human CVCL_0J81 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21126953 CVCL_9D15 DD0967 transformed cell line human CVCL_9D15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126954 CVCL_0J84 AG05243 finite cell line human CVCL_0J84 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126955 CVCL_0J83 AG05012 finite cell line human CVCL_0J83 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126956 CVCL_0J86 AG05809 finite cell line human CVCL_0J86 CL:0000010 Population: Jewish; Karyotypic information: 46,XX [56%]; 47,XX,+21 [44%] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126957 CVCL_0J85 AG05770 finite cell line human CVCL_0J85 CL:0000010 Population: Caucasian; Derived from sampling site: Calf; skin Cell type=Fibroblast.. Male 21126958 CVCL_0J88 AG06103 finite cell line human CVCL_0J88 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21126959 CVCL_0J87 AG05810 finite cell line human CVCL_0J87 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (Coriell) Population: Jewish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21126960 CVCL_0J89 AG06244 finite cell line human CVCL_0J89 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126961 CVCL_9D10 DD0955 finite cell line human CVCL_9D10 CL:0000010 Karyotypic information: 46,XY,inv(2)(q34:q36.3)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21126962 CVCL_9D12 DD0961 transformed cell line human CVCL_9D12 CL:0000010 Karyotypic information: 46,XX,t(1;19)(p34.3;q13.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126963 CVCL_9D11 DD0956 transformed cell line human CVCL_9D11 CL:0000010 Karyotypic information: 46,XX,t(12;17)(q24.31;q25.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126964 CVCL_9D29 DD0994 transformed cell line human CVCL_9D29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126965 CVCL_9D28 DD0991 transformed cell line human CVCL_9D28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126966 CVCL_0J91 AG06300 finite cell line human CVCL_0J91 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21126967 CVCL_9D25 DD0987 transformed cell line human CVCL_9D25 CL:0000010 Karyotypic information: 46,XX,t(3;20)(q13.2;p12.2) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126968 CVCL_0J90 AG06269 finite cell line human CVCL_0J90 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21126969 CVCL_9D24 DD0986 transformed cell line human CVCL_9D24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126970 CVCL_0J93 AG06869 finite cell line human CVCL_0J93 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21126971 CVCL_9D27 DD0989 transformed cell line human CVCL_9D27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126972 CVCL_0J92 AG06868 transformed cell line human CVCL_0J92 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (from autologous cell line AG06869) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21126973 CVCL_9D26 DD0988 transformed cell line human CVCL_9D26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126974 CVCL_0J95 AG04392 finite cell line human CVCL_0J95 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female Senescence: Senesces at 55 PDL (PubMed=9724752) 21126975 CVCL_0J94 AG10028 finite cell line human CVCL_0J94 CL:0000010 Population: Chilean; Derived from sampling site: Neck; skin Cell type=Fibroblast.. Female 21126976 CVCL_0J97 AG04431 finite cell line human CVCL_0J97 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female Senescence: Senesces at 54 PDL (PubMed=9724752) 21126977 CVCL_0J96 AG04393 finite cell line human CVCL_0J96 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126978 CVCL_0J99 AG04433 finite cell line human CVCL_0J99 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30-36 PDL (PubMed=9724752) 21126979 CVCL_0J98 AG04432 finite cell line human CVCL_0J98 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21126980 CVCL_9D21 DD0981 transformed cell line human CVCL_9D21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126981 CVCL_9D20 DD0980 transformed cell line human CVCL_9D20 CL:0000010 Karyotypic information: 46,XY,t(18;20)(q21.1;p12.2)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21126982 CVCL_9D23 DD0983 transformed cell line human CVCL_9D23 CL:0000010 Karyotypic information: 46,XX,del(2)(pter->q37.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126983 CVCL_9D22 DD0982 transformed cell line human CVCL_9D22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126984 CVCL_0J60 AH64D-TC cancer cell line Norway rat CVCL_0J60 CL:0000010 Breed/subspecies: Donryu. Female 21126985 CVCL_0J62 AH41A-TC cancer cell line Norway rat CVCL_0J62 CL:0000010 Breed/subspecies: Donryu. Male 21126986 CVCL_0J61 AH42B-TC cancer cell line Norway rat CVCL_0J61 CL:0000010 Breed/subspecies: Donryu. Male 21126987 CVCL_0J64 AH41C-TC cancer cell line Norway rat CVCL_0J64 CL:0000010 Breed/subspecies: Donryu. Male 21126988 CVCL_0J63 AH41B-TC cancer cell line Norway rat CVCL_0J63 CL:0000010 Breed/subspecies: Donryu. Male 21126989 CVCL_0J66 UV-2237-IP3 cancer cell line house mouse CVCL_0J66 CL:0000010 Breed/subspecies: C3H/HeN. Female 21126990 CVCL_0J65 S49.1TB.4 cancer cell line house mouse CVCL_0J65 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21126991 CVCL_0J68 FBL-3 cancer cell line house mouse CVCL_0J68 CL:0000010 Breed/subspecies: C57BL/6. 21126992 CVCL_0J67 LSR-SF (SR) cancer cell line Norway rat CVCL_0J67 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889). Male 21126993 CVCL_0J59 AH64C-2-TC cancer cell line Norway rat CVCL_0J59 CL:0000010 Breed/subspecies: Donryu. Female 21126994 CVCL_0J58 AH64C-1-TC cancer cell line Norway rat CVCL_0J58 CL:0000010 Breed/subspecies: Donryu. Female 21126995 CVCL_9D07 DD0949 finite cell line human CVCL_9D07 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21126996 CVCL_9D06 DD0946 transformed cell line human CVCL_9D06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21126997 CVCL_SP99 HAP1 GHITM (-) 2 cancer cell line human CVCL_SP99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17281; GHITM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21126998 CVCL_T199 HEV0260 transformed cell line human CVCL_T199 HLA typing: A*11:01,24:02; B*52:01,54:01; C*01:02,12:02; DPB1*05:01,14:01; DQB1*06:01,06:02; DRB1*08:03,15:01 (RCB=HEV0260) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21126999 CVCL_9D09 DD0953 transformed cell line human CVCL_9D09 CL:0000010 Karyotypic information: 46,XX,t(4;16)(q27;p13.3)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127000 CVCL_9D08 DD0950 finite cell line human CVCL_9D08 CL:0000010 Karyotypic information: 47,XXY (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21127001 CVCL_9D03 DD0936 transformed cell line human CVCL_9D03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127002 CVCL_9D02 DD0929 transformed cell line human CVCL_9D02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127003 CVCL_9D05 DD0942 finite cell line human CVCL_9D05 CL:0000010 Karyotypic information: 46,XX; 46,X,r(X) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127004 CVCL_0J71 POS-1 cancer cell line house mouse CVCL_0J71 CL:0000010 Breed/subspecies: C3H. 21127005 CVCL_9D04 DD0937 transformed cell line human CVCL_9D04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127006 CVCL_0J70 L7212K cancer cell line house mouse CVCL_0J70 CL:0000010 Breed/subspecies: Kunming. Female 21127007 CVCL_0J73 AH35TC2-TC cancer cell line Norway rat CVCL_0J73 CL:0000010 Breed/subspecies: ACI/N. 21127008 CVCL_0J72 Beta-TC-7 transformed cell line house mouse CVCL_0J72 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C3HeB/FeJ transgenic RIPTag. 21127009 CVCL_0J75 Atg5^(-/-)MEF transformed cell line house mouse CVCL_0J75 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1277186; Atg5 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x 129/Sv. Unspecified 21127010 CVCL_0J74 Atg5^(+/+)MEF transformed cell line house mouse CVCL_0J74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x 129/Sv. Unspecified 21127011 CVCL_0J77 XP10CA finite cell line human CVCL_0J77 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21127012 CVCL_0J76 COS-7L transformed cell line CVCL_0J76 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Discontinued: Thermofisher/Gibco; Catalog number 11622-016 Male Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21127013 CVCL_0J79 AG04144 finite cell line human CVCL_0J79 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21127014 CVCL_0J78 AG04058 finite cell line human CVCL_0J78 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21127015 CVCL_0J69 L615K cancer cell line house mouse CVCL_0J69 CL:0000010 Breed/subspecies: Kunming. Female 21127016 CVCL_9D01 DD0928 transformed cell line human CVCL_9D01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127017 CVCL_9D00 DD0923 transformed cell line human CVCL_9D00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127018 CVCL_SP89 HAP1 GEN1 (-) cancer cell line human CVCL_SP89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26881; GEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127019 CVCL_T189 HEV0232 transformed cell line human CVCL_T189 HLA typing: A*24:02,31:01; B*15:01,54:01; C*01:02,03:03; DPB1*05:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0232) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127020 CVCL_SP88 HAP1 GCN1L1 (-) 4 cancer cell line human CVCL_SP88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4199; GCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127021 CVCL_T188 HEV0230 transformed cell line human CVCL_T188 HLA typing: A*02:01,02:06; B*07:02,40:01; C*03:03,07:02; DPB1*03:01,05:01; DQB1*05:01,06:01; DRB1*01:01,08:03 (RCB=HEV0230) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127022 CVCL_0J40 MFS8 cancer cell line house mouse CVCL_0J40 CL:0000010 Transformant: 6,12-dimethyldibenzo[d,d']benzo[1,2-b:4,5-b']bisthiophene (6,12-dimethylbenzo(1,2-b:4,5-b')dithionaphthene)(ChEBI; CHEBI:142414); Breed/subspecies: Swiss. 21127023 CVCL_0J42 K1735-C11 cancer cell line house mouse CVCL_0J42 CL:0000010 Breed/subspecies: C3H/HeN. 21127024 CVCL_0J41 K1735-M1 cancer cell line house mouse CVCL_0J41 CL:0000010 Breed/subspecies: C3H/HeN. 21127025 CVCL_0J44 GM10665 finite cell line human CVCL_0J44 CL:0000010 Sequence variation: Mutation; HGNC; 10969; SLC22A5; Simple; p.Arg282Ter (c.844C>T); ClinVar=VCV000006416; Zygosity=Homozygous (PubMed=10051646) Population: Indian; Derived from sampling site: Cell type=Fibroblast. Male 21127026 CVCL_0J43 K1735-C26 cancer cell line house mouse CVCL_0J43 CL:0000010 Breed/subspecies: C3H/HeN. 21127027 CVCL_0J46 WEHI-5 cancer cell line house mouse CVCL_0J46 CL:0000010 Breed/subspecies: BALB/c x NZB. 21127028 CVCL_0J45 K1735-C16 cancer cell line house mouse CVCL_0J45 CL:0000010 Breed/subspecies: C3H/HeN. 21127029 CVCL_0J37 UM-CCS-1 cancer cell line human CVCL_0J37 CL:0000010 Female 21127030 CVCL_0J36 MST-3 cancer cell line human CVCL_0J36 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=15150091). Population: Chinese; Taiwan Male 21127031 CVCL_0J39 BAM [Mouse chondrosarcoma] cancer cell line house mouse CVCL_0J39 CL:0000010 Breed/subspecies: ST/Eh. 21127032 CVCL_0J38 EHSPEL cancer cell line house mouse CVCL_0J38 CL:0000010 Breed/subspecies: ST/Eh. 21127033 CVCL_SP90 HAP1 GFPT1 (-) cancer cell line human CVCL_SP90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4241; GFPT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127034 CVCL_T190 HEV0234 transformed cell line human CVCL_T190 HLA typing: A*11:01,33:03; B*40:01,44:03; C*03:04,14:03; DPB1*04:01,05:01; DQB1*05:03,06:04; DRB1*13:02,14:01 (RCB=HEV0234) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127035 CVCL_SP92 HAP1 GGA1 (-) 2 cancer cell line human CVCL_SP92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17842; GGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127036 CVCL_T192 HEV0238 transformed cell line human CVCL_T192 HLA typing: A*02:06,24:02; B*15:01,39:01; C*04:01,07:02; DPB1*02:01,05:01; DQB1*03:01,03:02; DRB1*04:06,12:01 (RCB=HEV0238) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127037 CVCL_SP91 HAP1 GGA1 (-) 1 cancer cell line human CVCL_SP91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17842; GGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127038 CVCL_T191 HEV0236 transformed cell line human CVCL_T191 HLA typing: A*11:01,31:01; B*51:01,54:01; C*01:02,15:02; DPB1*05:01; DQB1*06:01,06:02; DRB1*08:03,15:01 (RCB=HEV0236) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127039 CVCL_SP94 HAP1 GGA1 (-) 4 cancer cell line human CVCL_SP94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17842; GGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127040 CVCL_T194 HEV0244 transformed cell line human CVCL_T194 HLA typing: A*24:02; B*35:01,44:02; C*05:01,08:01; DPB1*02:01,09:01; DQB1*03:03,04:02; DRB1*04:10,12:01 (RCB=HEV0244) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127041 CVCL_SP93 HAP1 GGA1 (-) 3 cancer cell line human CVCL_SP93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17842; GGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127042 CVCL_T193 HEV0240 transformed cell line human CVCL_T193 HLA typing: A*24:02; B*48:01,52:01; C*08:01,12:02; DPB1*02:01,09:01; DQB1*06:01,06:02; DRB1*15:01,15:02 (RCB=HEV0240) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127043 CVCL_SP96 HAP1 GGCX (-) cancer cell line human CVCL_SP96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4247; GGCX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127044 CVCL_T196 HEV0248 transformed cell line human CVCL_T196 HLA typing: A*02:06,31:01; B*40:06,44:03; C*03:04,14:03; DPB1*02:01,05:01; DQB1*03:03,06:04; DRB1*09:01,13:02 (RCB=HEV0248) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127045 CVCL_SP95 HAP1 GGA1 (-) 5 cancer cell line human CVCL_SP95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17842; GGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127046 CVCL_T195 HEV0245 transformed cell line human CVCL_T195 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127047 CVCL_SP98 HAP1 GHITM (-) 1 cancer cell line human CVCL_SP98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17281; GHITM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127048 CVCL_T198 HEV0256 transformed cell line human CVCL_T198 HLA typing: A*02:01,33:03; B*15:01,44:03; C*03:03,14:03; DPB1*03:01,05:01; DQB1*03:01,06:01; DRB1*08:03,14:06 (RCB=HEV0256) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127049 CVCL_SP97 HAP1 GGT7 (-) cancer cell line human CVCL_SP97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4259; GGT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127050 CVCL_T197 HEV0251 transformed cell line human CVCL_T197 HLA typing: A*24:02,26:01; B*40:06; C*08:01; DPB1*02:01,05:01; DQB1*03:03; DRB1*09:01 (RCB=HEV0251) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127051 CVCL_SP78 HAP1 GCDH (-) 1 cancer cell line human CVCL_SP78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4189; GCDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127052 CVCL_T178 HEV0207 transformed cell line human CVCL_T178 HLA typing: A*02:06,24:02; B*07:02 X; C*03:03,07:02; DPB1*04:02,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0207) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127053 CVCL_SP77 HAP1 GBP5 (-) 2 cancer cell line human CVCL_SP77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19895; GBP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127054 CVCL_T177 HEV0203 transformed cell line human CVCL_T177 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127055 CVCL_SP79 HAP1 GCDH (-) 2 cancer cell line human CVCL_SP79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4189; GCDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127056 CVCL_T179 HEV0208 transformed cell line human CVCL_T179 HLA typing: A*02:06,24:20; B*15:18,40:06; C*08:01; DPB1*05:01; DQB1*03:01; DRB1*12:01,14:06 (RCB=HEV0208) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127057 CVCL_0J51 mEMS88 embryonic stem cell house mouse CVCL_0J51 CL:0000010 Breed/subspecies: C57BL/6J-Sxra x 129P3/JEms. Male 21127058 CVCL_0J50 DBA-252 embryonic stem cell house mouse CVCL_0J50 CL:0000010 Breed/subspecies: DBA/1lacJ. Male 21127059 CVCL_0J53 EPYP-2 transformed cell line Norway rat CVCL_0J53 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Copenhagen. Male 21127060 CVCL_0J52 YPEN-2 transformed cell line Norway rat CVCL_0J52 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Prostate Cell type=Endothelial cell.; Breed/subspecies: Copenhagen. Male Doubling time: 21 hours (PubMed=8900918) 21127061 CVCL_0J55 YPBE-1 transformed cell line Norway rat CVCL_0J55 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Endothelial cell.; Breed/subspecies: Copenhagen. Male 21127062 CVCL_0J54 EPYP-3 transformed cell line Norway rat CVCL_0J54 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Copenhagen. Male 21127063 CVCL_0J57 AH64B-TC cancer cell line Norway rat CVCL_0J57 CL:0000010 Breed/subspecies: Donryu. Female 21127064 CVCL_0J56 MOS-J cancer cell line house mouse CVCL_0J56 CL:0000010 Breed/subspecies: C57BL/6J. Female 21127065 CVCL_0J48 HUCL-1 cancer cell line house mouse CVCL_0J48 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21127066 CVCL_0J47 WEHI-164 clone 13 cancer cell line house mouse CVCL_0J47 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. 21127067 CVCL_0J49 IB-9 cancer cell line house mouse CVCL_0J49 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). 21127068 CVCL_SP81 HAP1 GCH1 (-) 1 cancer cell line human CVCL_SP81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4193; GCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127069 CVCL_T181 HEV0217 transformed cell line human CVCL_T181 HLA typing: A*02:06,11:01; B*15:01,35:01; C*03:03,04:01; DPB1*03:01,05:01; DQB1*03:02,06:02; DRB1*04:06,15:01 (RCB=HEV0217) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127070 CVCL_SP80 HAP1 GCDH (-) 3 cancer cell line human CVCL_SP80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4189; GCDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127071 CVCL_T180 HEV0213 transformed cell line human CVCL_T180 HLA typing: A*02:18,33:03; B*44:03,46:01; C*01:02,14:03; DPB1*02:01,02:02; DQB1*04:01,06:01; DRB1*04:05,08:03 (RCB=HEV0213) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127072 CVCL_SP83 HAP1 GCLM (-) 1 cancer cell line human CVCL_SP83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4312; GCLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127073 CVCL_T183 HEV0220 transformed cell line human CVCL_T183 HLA typing: A*02:01,24:02; B*54:01,55:02; C*01:02; DPB1*05:01,13:01; DQB1*03:01,03:03; DRB1*09:01,11:01 (RCB=HEV0220) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127074 CVCL_SP82 HAP1 GCH1 (-) 2 cancer cell line human CVCL_SP82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4193; GCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127075 CVCL_T182 HEV0218 transformed cell line human CVCL_T182 HLA typing: A*11:01,24:02; B*15:07,44:02; C*03:03,05:01; DPB1*02:01,05:01; DQB1*03:02,06:03; DRB1*04:03,13:01 (RCB=HEV0218) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127076 CVCL_SP85 HAP1 GCN1L1 (-) 1 cancer cell line human CVCL_SP85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4199; GCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127077 CVCL_T185 HEV0224 transformed cell line human CVCL_T185 HLA typing: A*02:01,02:07; B*40:01,46:01; C*01:02,15:02; DPB1*05:01; DQB1*05:03,06:01; DRB1*08:03,14:05 (RCB=HEV0224) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127078 CVCL_SP84 HAP1 GCLM (-) 2 cancer cell line human CVCL_SP84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4312; GCLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127079 CVCL_T184 HEV0221 transformed cell line human CVCL_T184 HLA typing: A*02:01,24:02; B*39:02,40:06; C*07:02,08:01; DPB1*02:01,05:01; DQB1*03:01,03:03; DRB1*09:01,12:01 (RCB=HEV0221) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127080 CVCL_SP87 HAP1 GCN1L1 (-) 3 cancer cell line human CVCL_SP87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4199; GCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127081 CVCL_T187 HEV0229 transformed cell line human CVCL_T187 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127082 CVCL_SP86 HAP1 GCN1L1 (-) 2 cancer cell line human CVCL_SP86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4199; GCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127083 CVCL_T186 HEV0227 transformed cell line human CVCL_T186 HLA typing: A*26:03,31:01; B*35:01,51:01; C*03:03,14:02; DPB1*02:01,05:01; DQB1*03:02,06:01; DRB1*04:03,15:02 (RCB=HEV0227) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127084 CVCL_SP67 HAP1 GBA (-) 8 cancer cell line human CVCL_SP67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127085 CVCL_T167 HEV0178 transformed cell line human CVCL_T167 HLA typing: A*11:01,31:01; B*15:01,56:01; C*04:01; DPB1*04:01,05:01; DQB1*03:02,03:03; DRB1*04:06,09:01 (RCB=HEV0178) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127086 CVCL_SP66 HAP1 GBA (-) 7 cancer cell line human CVCL_SP66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127087 CVCL_T166 HEV0177 transformed cell line human CVCL_T166 HLA typing: A*11:01,24:02; B*54:01,59:01; C*01:02; DPB1*04:02,05:01; DQB1*04:01; DRB1*04:05 (RCB=HEV0177) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127088 CVCL_SP69 HAP1 GBA2 (-) 2 cancer cell line human CVCL_SP69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18986; GBA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127089 CVCL_T169 HEV0182 transformed cell line human CVCL_T169 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127090 CVCL_SP68 HAP1 GBA2 (-) 1 cancer cell line human CVCL_SP68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18986; GBA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127091 CVCL_T168 HEV0181 transformed cell line human CVCL_T168 HLA typing: A*24:02,31:01; B*40:01,55:02; C*01:02,03:04; DPB1*05:01; DQB1*04:01; DRB1*04:05 (RCB=HEV0181) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127092 CVCL_0J20 BDM-3 [Mouse ESC] embryonic stem cell house mouse CVCL_0J20 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Male 21127093 CVCL_0J22 BAM3 transformed cell line house mouse CVCL_0J22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. 21127094 CVCL_0J21 BAM1 transformed cell line house mouse CVCL_0J21 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. 21127095 CVCL_0J24 BDM-1 factor-dependent cell line house mouse CVCL_0J24 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeN. Characteristics: CSF1 and CSF2 dependent 21127096 CVCL_0J23 BR15 transformed cell line house mouse CVCL_0J23 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: BALB/c. Unspecified 21127097 CVCL_0J15 aBJ-4 embryonic stem cell house mouse CVCL_0J15 CL:0000010 Breed/subspecies: C57BL/6Cr x JF1. Male 21127098 CVCL_0J14 aBJ-3 embryonic stem cell house mouse CVCL_0J14 CL:0000010 Breed/subspecies: C57BL/6Cr x JF1. Male 21127099 CVCL_0J17 Dnmt3b-/- ES (clone 8bb) embryonic stem cell house mouse CVCL_0J17 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1261819; Dnmt3b Breed/subspecies: 129S4/SvJae. Male 21127100 CVCL_0J16 Dnmt3a-/- ES (clone 6aa) embryonic stem cell house mouse CVCL_0J16 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1261827; Dnmt3a Breed/subspecies: 129S4/SvJae. Male 21127101 CVCL_0J19 Pat5 embryonic stem cell house mouse CVCL_0J19 CL:0000010 Breed/subspecies: 129X1/SvJ. Unspecified 21127102 CVCL_0J18 Lex-2 embryonic stem cell house mouse CVCL_0J18 CL:0000010 Breed/subspecies: 129S5/SvEvBrd. Unspecified 21127103 CVCL_SP70 HAP1 GBE1 (-) 1 cancer cell line human CVCL_SP70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4180; GBE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127104 CVCL_T170 HEV0186 transformed cell line human CVCL_T170 HLA typing: A*02:01,24:02; B*39:04,40:02; C*03:04,07:02; DPB1*02:01; DQB1*03:02,03:03; DRB1*04:06,09:01 (RCB=HEV0186) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127105 CVCL_SP72 HAP1 GBP1 (-) 2 cancer cell line human CVCL_SP72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4182; GBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127106 CVCL_T172 HEV0190 transformed cell line human CVCL_T172 HLA typing: A*02:06,24:02; B*15:28,52:01; C*03:03,12:02; DPB1*05:01,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0190) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127107 CVCL_SP71 HAP1 GBP1 (-) 1 cancer cell line human CVCL_SP71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4182; GBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127108 CVCL_T171 HEV0188 transformed cell line human CVCL_T171 HLA typing: A*24:20,33:03; B*44:03,51:01; C*14:02,14:03; DPB1*02:01,05:01; DQB1*03:02,03:03; DRB1*09:01,12:01 (RCB=HEV0188) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127109 CVCL_SP74 HAP1 GBP2 (-) 2 cancer cell line human CVCL_SP74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4183; GBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127110 CVCL_T174 HEV0195 transformed cell line human CVCL_T174 HLA typing: A*02:06,24:02; B*15:01,52:01; C*07:02,12:02; DPB1*02:01,09:01; DQB1*06:01,06:02; DRB1*15:01,15:02 (RCB=HEV0195) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127111 CVCL_SP73 HAP1 GBP2 (-) 1 cancer cell line human CVCL_SP73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4183; GBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127112 CVCL_T173 HEV0192 transformed cell line human CVCL_T173 HLA typing: A*02:07,24:02; B*46:01,52:01; C*01:02,12:02; DPB1*02:01,09:01; DQB1*06:01; DRB1*08:03,15:02 (RCB=HEV0192) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127113 CVCL_SP76 HAP1 GBP5 (-) 1 cancer cell line human CVCL_SP76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19895; GBP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127114 CVCL_T176 HEV0201 transformed cell line human CVCL_T176 HLA typing: A*01:01,11:01; B*07:02,54:01; C*01:02,07:02; DPB1*04:02,05:01; DQB1*03:03,05:01; DRB1*01:01,04:05 (RCB=HEV0201) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127115 CVCL_SP75 HAP1 GBP2 (-) 3 cancer cell line human CVCL_SP75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4183; GBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127116 CVCL_T175 HEV0198 transformed cell line human CVCL_T175 HLA typing: A*24:02,31:01; B*52:01,59:01; C*01:02,12:02; DPB1*04:02,09:01; DQB1*04:01,06:01; DRB1*04:05,15:02 (RCB=HEV0198) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127117 CVCL_SP56 HAP1 GANC (-) 1 cancer cell line human CVCL_SP56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4139; GANC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127118 CVCL_T156 HEV0154 transformed cell line human CVCL_T156 HLA typing: A*02:06,26:01; B*15:01,52:01; C*12:02,15:02; DPB1*03:01,09:01; DQB1*03:03,06:01; DRB1*09:01,15:02 (RCB=HEV0154) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127119 CVCL_SP55 HAP1 GANAB (-) 2 cancer cell line human CVCL_SP55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4138; GANAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127120 CVCL_T155 HEV0151 transformed cell line human CVCL_T155 HLA typing: A*26:02,31:01; B*07:02,40:06; C*07:02,08:01; DPB1*04:02,05:01; DQB1*03:03,05:01; DRB1*01:01,09:01 (RCB=HEV0151) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127121 CVCL_SP58 HAP1 GATA2 (-) 1 cancer cell line human CVCL_SP58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127122 CVCL_T158 HEV0156 transformed cell line human CVCL_T158 HLA typing: A*26:01,26:03; B*35:01,40:02; C*03:03,03:04; DPB1*05:01; DQB1*03:01,06:02; DRB1*14:06,15:01 (RCB=HEV0156) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127123 CVCL_SP57 HAP1 GANC (-) 2 cancer cell line human CVCL_SP57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4139; GANC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127124 CVCL_T157 HEV0155 transformed cell line human CVCL_T157 HLA typing: A*24:02,26:01; B*15:01,51:01; C*03:04,04:01; DPB1*02:01; DQB1*03:02,05:03; DRB1*04:06,14:54 (RCB=HEV0155) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127125 CVCL_SP59 HAP1 GATA3 (-) 1 cancer cell line human CVCL_SP59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4172; GATA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127126 CVCL_T159 HEV0157 transformed cell line human CVCL_T159 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127127 CVCL_0J31 DTC1 cancer cell line human CVCL_0J31 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=7753552; PubMed=15150091) Derived from metastatic site: Pleural effusion. Unspecified 21127128 CVCL_0J30 CCS292 cancer cell line human CVCL_0J30 CL:0000010 21127129 CVCL_0J33 MP-CCS-SY cancer cell line human CVCL_0J33 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; left femur. Female Doubling time: 36 hours (PubMed=12072203) 21127130 CVCL_0J32 Hewga-CCS cancer cell line human CVCL_0J32 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF; Note=EWSR1 exon 7 fused to ATF1 exon 5 (PubMed=24946937) Population: Japanese; Derived from metastatic site: Skin. Female Doubling time: ~44 hours (PubMed=24946937) 21127131 CVCL_0J35 MST-2 cancer cell line human CVCL_0J35 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=15150091). Population: Chinese; Taiwan Male 21127132 CVCL_0J34 MST-1 cancer cell line human CVCL_0J34 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=12966428). Population: Chinese; Taiwan Female Doubling time: 69 hours (PubMed=8664053) 21127133 CVCL_0J26 BDM-3 [Mouse macrophage] factor-dependent cell line house mouse CVCL_0J26 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeN. Characteristics: CSF2 and IL3 dependent 21127134 CVCL_0J25 BDM-2 factor-dependent cell line house mouse CVCL_0J25 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeN. Characteristics: CSF1 and CSF2 dependent 21127135 CVCL_0J28 A20.IIA-GFP cancer cell line house mouse CVCL_0J28 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: BALB/cAnN. Unspecified 21127136 CVCL_0J27 A20.IIA cancer cell line house mouse CVCL_0J27 CL:0000010 Breed/subspecies: BALB/cAnN. Unspecified 21127137 CVCL_0J29 38C13 cancer cell line house mouse CVCL_0J29 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C3H/eB. 21127138 CVCL_SP61 HAP1 GBA (-) 2 cancer cell line human CVCL_SP61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127139 CVCL_T161 HEV0164 transformed cell line human CVCL_T161 HLA typing: A*24:02,33:03; B*15:18,44:03; C*08:01,14:03; DPB1*04:01,05:01; DQB1*03:02,06:04; DRB1*04:03,13:02 (RCB=HEV0164) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127140 CVCL_SP60 HAP1 GBA (-) 1 cancer cell line human CVCL_SP60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127141 CVCL_T160 HEV0160 transformed cell line human CVCL_T160 HLA typing: A*11:01,24:02; B*40:01,67:01; C*03:04,07:02; DPB1*02:01,05:01; DQB1*03:01,06:02; DRB1*12:01,15:01 (RCB=HEV0160) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127142 CVCL_SP63 HAP1 GBA (-) 4 cancer cell line human CVCL_SP63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127143 CVCL_T163 HEV0170 transformed cell line human CVCL_T163 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21127144 CVCL_SP62 HAP1 GBA (-) 3 cancer cell line human CVCL_SP62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127145 CVCL_T162 HEV0168 transformed cell line human CVCL_T162 HLA typing: A*11:01,24:02; B*39:01,55:02; C*01:02,07:02; DPB1*05:01; DQB1*04:01,06:01; DRB1*04:05,08:03 (RCB=HEV0168) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127146 CVCL_SP65 HAP1 GBA (-) 6 cancer cell line human CVCL_SP65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127147 CVCL_T165 HEV0174 transformed cell line human CVCL_T165 HLA typing: A*02:06,33:03; B*35:01,44:03; C*03:03,14:03; DPB1*05:01; DQB1*04:01,06:02; DRB1*04:05,15:01 (RCB=HEV0174) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127148 CVCL_SP64 HAP1 GBA (-) 5 cancer cell line human CVCL_SP64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4177; GBA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127149 CVCL_T164 HEV0171 transformed cell line human CVCL_T164 HLA typing: A*02:01,24:02; B*40:02,59:01; C*01:02,03:04; DPB1*04:02,05:01; DQB1*03:03,04:01; DRB1*04:05,09:01 (RCB=HEV0171) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127150 CVCL_9D90 DD1098 transformed cell line human CVCL_9D90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127151 CVCL_9D92 DD1100 transformed cell line human CVCL_9D92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127152 CVCL_9D91 DD1099 transformed cell line human CVCL_9D91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127153 CVCL_9D98 DD1108 finite cell line human CVCL_9D98 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21127154 CVCL_9D97 DD1106 transformed cell line human CVCL_9D97 CL:0000010 Karyotypic information: 47,XX,+pseudic(15)(pter->q13::q13->pter) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127155 CVCL_9D99 DD1109 transformed cell line human CVCL_9D99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127156 CVCL_9D94 DD1103 finite cell line human CVCL_9D94 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),inv ins(7:12)?(p21.2;q15q22)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127157 CVCL_9D93 DD1102 finite cell line human CVCL_9D93 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127158 CVCL_9D96 DD1105 transformed cell line human CVCL_9D96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127159 CVCL_9D95 DD1104 transformed cell line human CVCL_9D95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127160 CVCL_9D79 DD1076 finite cell line human CVCL_9D79 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly542Ter (c.1624G>T); ClinVar=VCV000007115; Zygosity=Heterozygous (ECACC) Karyotypic information: 46,XX,t(1;14)(p34;q22)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21127161 CVCL_9D70 DD1058 transformed cell line human CVCL_9D70 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ECACC); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (ECACC) Karyotypic information: 46,XX,t(1;14)(p34.3;q22)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127162 CVCL_9D76 DD1073 transformed cell line human CVCL_9D76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127163 CVCL_9D75 DD1072 transformed cell line human CVCL_9D75 CL:0000010 Karyotypic information: 46,XY,inv(13)(q33.2;q34)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127164 CVCL_9D78 DD1075 transformed cell line human CVCL_9D78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127165 CVCL_9D77 DD1074 transformed cell line human CVCL_9D77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127166 CVCL_9D72 DD1062 finite cell line human CVCL_9D72 CL:0000010 Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21127167 CVCL_9D71 DD1059 transformed cell line human CVCL_9D71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127168 CVCL_9D74 DD1071 transformed cell line human CVCL_9D74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127169 CVCL_9D73 DD1069 transformed cell line human CVCL_9D73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127170 CVCL_9D81 DD1082 transformed cell line human CVCL_9D81 CL:0000010 Karyotypic information: 46,fra(X)(q27.3)Y (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127171 CVCL_9D80 DD1078 finite cell line human CVCL_9D80 CL:0000010 Karyotypic information: 48,XX,+7,+8 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21127172 CVCL_9D87 DD1092 transformed cell line human CVCL_9D87 CL:0000010 Karyotypic information: 46,X,del(X)(qter->p22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127173 CVCL_9D86 DD1091 transformed cell line human CVCL_9D86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127174 CVCL_9D89 DD1097 transformed cell line human CVCL_9D89 CL:0000010 Karyotypic information: 46,XX,17p+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127175 CVCL_9D88 DD1095 finite cell line human CVCL_9D88 CL:0000010 Karyotypic information: 46,XX,+13 [6/30] (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127176 CVCL_9D83 DD1085 finite cell line human CVCL_9D83 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),inv ins(7:12)?(p21.2;q15q22)pat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21127177 CVCL_9D82 DD1083 transformed cell line human CVCL_9D82 CL:0000010 Karyotypic information: 46,Y,Xp+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127178 CVCL_9D85 DD1090 transformed cell line human CVCL_9D85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127179 CVCL_9D84 DD1089 transformed cell line human CVCL_9D84 CL:0000010 Karyotypic information: 46,XY,del(1)(pter->q43) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127180 CVCL_9D58 DD1040 transformed cell line human CVCL_9D58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127181 CVCL_9D57 DD1039 transformed cell line human CVCL_9D57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127182 CVCL_9D59 DD1041 finite cell line human CVCL_9D59 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21127183 CVCL_9D54 DD1036 transformed cell line human CVCL_9D54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127184 CVCL_9D53 DD1035 transformed cell line human CVCL_9D53 CL:0000010 Karyotypic information: 46,XY,t(3;10)(p23;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127185 CVCL_9D56 DD1038 transformed cell line human CVCL_9D56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127186 CVCL_9D55 DD1037 transformed cell line human CVCL_9D55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127187 CVCL_9D50 DD1030 transformed cell line human CVCL_9D50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127188 CVCL_9D52 DD1034 transformed cell line human CVCL_9D52 CL:0000010 Karyotypic information: 46,XX,rec(5)del(q15;q22),ins(5)(q22.3;q14.2;q15)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127189 CVCL_9D51 DD1032 transformed cell line human CVCL_9D51 CL:0000010 Karyotypic information: 46,XY,17p+ de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127190 CVCL_9D69 DD1057 transformed cell line human CVCL_9D69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127191 CVCL_9D68 DD1056 transformed cell line human CVCL_9D68 CL:0000010 Karyotypic information: 46,XX,+13 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127192 CVCL_9D65 DD1052 transformed cell line human CVCL_9D65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127193 CVCL_9D64 DD1051 transformed cell line human CVCL_9D64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127194 CVCL_9D67 DD1055 transformed cell line human CVCL_9D67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127195 CVCL_9D66 DD1054 transformed cell line human CVCL_9D66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127196 CVCL_9D61 DD1044 transformed cell line human CVCL_9D61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127197 CVCL_9D60 DD1043 transformed cell line human CVCL_9D60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127198 CVCL_9D63 DD1049 finite cell line human CVCL_9D63 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(15) de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21127199 CVCL_9D62 DD1048 finite cell line human CVCL_9D62 CL:0000010 Karyotypic information: 47,XX,+15 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21127200 CVCL_9D39 DD1013 finite cell line human CVCL_9D39 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21127201 CVCL_9D36 DD1003 transformed cell line human CVCL_9D36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127202 CVCL_9D35 DD1002 finite cell line human CVCL_9D35 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21127203 CVCL_9D38 DD1012 finite cell line human CVCL_9D38 CL:0000010 Karyotypic information: 46,XX [38]; 47,XX,+i(8p) de novo [30] (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127204 CVCL_9D37 DD1009 transformed cell line human CVCL_9D37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127205 CVCL_9D32 DD0998 transformed cell line human CVCL_9D32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127206 CVCL_9D31 DD0997 transformed cell line human CVCL_9D31 CL:0000010 Karyotypic information: 46,XY,inv(2)(q34;q36.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127207 CVCL_9D34 DD1000 transformed cell line human CVCL_9D34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127208 CVCL_9D33 DD0999 transformed cell line human CVCL_9D33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127209 CVCL_9D30 DD0996 transformed cell line human CVCL_9D30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127210 CVCL_9D47 DD1027 transformed cell line human CVCL_9D47 CL:0000010 Karyotypic information: 46,XY,inv(7)(q22.1;q34)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127211 CVCL_9D46 DD1026 transformed cell line human CVCL_9D46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127212 CVCL_9D49 DD1029 transformed cell line human CVCL_9D49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127213 CVCL_9D48 DD1028 transformed cell line human CVCL_9D48 CL:0000010 Karyotypic information: 46,XY,inv(13)(q21.3;q22.3)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127214 CVCL_9D43 DD1018 finite cell line human CVCL_9D43 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127215 CVCL_9D42 DD1016 transformed cell line human CVCL_9D42 CL:0000010 Karyotypic information: 46,XY,inv(13)(q33.2;q34)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127216 CVCL_9D45 DD1025 transformed cell line human CVCL_9D45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127217 CVCL_9D44 DD1021 finite cell line human CVCL_9D44 CL:0000010 Karyotypic information: 46,XY,+18 (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21127218 CVCL_9D41 DD1015 transformed cell line human CVCL_9D41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127219 CVCL_9D40 DD1014 transformed cell line human CVCL_9D40 CL:0000010 Karyotypic information: 46,XX,inv(13)(q33.2;q34)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127220 CVCL_SR01 HAP1 HDAC1 (-) 4 cancer cell line human CVCL_SR01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127221 CVCL_T301 RPMI-8195 cancer cell line human CVCL_T301 CL:0000010 Female 21127222 CVCL_SR00 HAP1 HDAC1 (-) 3 cancer cell line human CVCL_SR00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21127223 CVCL_T300 RPMI-9154 cancer cell line human CVCL_T300 CL:0000010 Female 21127224 CVCL_SR03 HAP1 HDAC10 (-) 2 cancer cell line human CVCL_SR03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18128; HDAC10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127225 CVCL_T303 RPMI-8235 cancer cell line human CVCL_T303 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgG kappa 21127226 CVCL_SR02 HAP1 HDAC10 (-) 1 cancer cell line human CVCL_SR02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18128; HDAC10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127227 CVCL_T302 RPMI-8205 cancer cell line human CVCL_T302 CL:0000010 Female 21127228 CVCL_SR05 HAP1 HDAC11 (-) 2 cancer cell line human CVCL_SR05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19086; HDAC11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127229 CVCL_T305 UCT-Mel 2 cancer cell line human CVCL_T305 CL:0000010 Derived from metastatic site: Axillary lymph node. Female Characteristics: Pigmented Doubling time: 50 hours (PubMed=3091056) 21127230 CVCL_SR04 HAP1 HDAC11 (-) 1 cancer cell line human CVCL_SR04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19086; HDAC11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127231 CVCL_T304 UCT-Mel 1 cancer cell line human CVCL_T304 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Characteristics: Pigmented Doubling time: 41 hours (PubMed=3091056) 21127232 CVCL_SR07 HAP1 HDAC2 (-) 2 cancer cell line human CVCL_SR07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127233 CVCL_T307 UCT-Mel 4 cancer cell line human CVCL_T307 CL:0000010 Derived from metastatic site: Not specified. Unspecified Doubling time: 52 hours (PubMed=3091056) 21127234 CVCL_JX69 GM16555 finite cell line human CVCL_JX69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127235 CVCL_SR06 HAP1 HDAC2 (-) 1 cancer cell line human CVCL_SR06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4853; HDAC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127236 CVCL_T306 UCT-Mel 3 cancer cell line human CVCL_T306 CL:0000010 Derived from metastatic site: Liver. Female Doubling time: 50 hours (PubMed=3091056) 21127237 CVCL_K969 UKTS8770 transformed cell line human CVCL_K969 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91070910; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127238 CVCL_SR09 HAP1 HDAC4 (-) 1 cancer cell line human CVCL_SR09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14063; HDAC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127239 CVCL_T309 UCT-Mel 6 cancer cell line human CVCL_T309 CL:0000010 Derived from metastatic site: Inguinal lymph node. Unspecified Doubling time: 33 hours (PubMed=3091056) 21127240 CVCL_SR08 HAP1 HDAC3 (-) cancer cell line human CVCL_SR08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4854; HDAC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127241 CVCL_T308 UCT-Mel 5 cancer cell line human CVCL_T308 CL:0000010 Derived from metastatic site: Not specified. Unspecified Doubling time: 58 hours (PubMed=3091056) 21127242 CVCL_K966 UKTS8740 transformed cell line human CVCL_K966 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127243 CVCL_JX66 ZJLXB-1 hybridoma house mouse CVCL_JX66 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200518 21127244 CVCL_JX65 MCF7T2 cancer cell line human CVCL_JX65 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1589; CCNE1 (M-1--N-64 del, M-65 called 'truncation 2'); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 Part of: MD Anderson Cell Lines Project 21127245 CVCL_K965 UKTS8727 transformed cell line human CVCL_K965 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127246 CVCL_JX68 GM18260 transformed cell line human CVCL_JX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127247 CVCL_K968 UKTS8768 transformed cell line human CVCL_K968 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127248 CVCL_JX67 TTNT-1 telomerase immortalized cell line human CVCL_JX67 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the SV40 T gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7498 21127249 CVCL_K967 UKTS8754 transformed cell line human CVCL_K967 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127250 CVCL_JX62 SEWA1R cancer cell line house mouse CVCL_JX62 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21127251 CVCL_K962 UKTS8670 transformed cell line human CVCL_K962 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127252 CVCL_JX61 1F7 hybridoma house mouse CVCL_JX61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21127253 CVCL_K961 UKTS8660 transformed cell line human CVCL_K961 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91032121; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127254 CVCL_JX64 MCF7T1 cancer cell line human CVCL_JX64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1589; CCNE1 (M-1--L-39 del, M-40 called 'truncation 1'); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 Part of: MD Anderson Cell Lines Project 21127255 CVCL_K964 UKTS8713 transformed cell line human CVCL_K964 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127256 CVCL_JX63 MCF7EL cancer cell line human CVCL_JX63 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1589; CCNE1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 Part of: MD Anderson Cell Lines Project 21127257 CVCL_K963 UKTS8695 transformed cell line human CVCL_K963 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127258 CVCL_JX60 SpEBr-5 cancer cell line house mouse CVCL_JX60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:4883; Ethidium bromide; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21127259 CVCL_K960 UKTS8049 transformed cell line human CVCL_K960 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127260 CVCL_JX77 OX-111 hybridoma Norway rat CVCL_JX77 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ES57; Mouse Cd200r1. 21127261 CVCL_K977 UKTS8840 transformed cell line human CVCL_K977 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127262 CVCL_JX76 OX-107 hybridoma house mouse CVCL_JX76 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01830; Rat Thy1/Cd90. 21127263 CVCL_K976 UKTS8837 transformed cell line human CVCL_K976 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127264 CVCL_JX79 OX-93 hybridoma house mouse CVCL_JX79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15725; Rat Tnfrsf4/Cd134. 21127265 CVCL_K979 UKTS8964 transformed cell line human CVCL_K979 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91070916; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127266 CVCL_JX78 OX-91 hybridoma CVCL_JX78 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21127267 CVCL_K978 UKTS8878 transformed cell line human CVCL_K978 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127268 CVCL_JX73 OX-98 hybridoma CVCL_JX73 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21127269 CVCL_K973 UKTS8797 transformed cell line human CVCL_K973 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127270 CVCL_JX72 GM11902 finite cell line human CVCL_JX72 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; p.Lys1447Cysfs*18 (c.4337dupG); Zygosity=Heterozygous (PubMed=25187577) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21127271 CVCL_K972 UKTS8796 transformed cell line human CVCL_K972 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127272 CVCL_JX75 OX-100 hybridoma CVCL_JX75 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21127273 CVCL_K975 UKTS8825 transformed cell line human CVCL_K975 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127274 CVCL_JX74 OX-99 hybridoma CVCL_JX74 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21127275 CVCL_K974 UKTS8802 transformed cell line human CVCL_K974 CL:0000010 Sequence variation: Gene deletion; HGNC; 3620; FCGR3B; Zygosity=Homozygous (PubMed=27995740) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127276 CVCL_JX71 GM13085 finite cell line human CVCL_JX71 CL:0000010 Population: Caucasian; English; Derived from sampling site: Cell type=Fibroblast. Male 21127277 CVCL_K971 UKTS8792 transformed cell line human CVCL_K971 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127278 CVCL_JX70 GM02935 finite cell line human CVCL_JX70 CL:0000010 Population: Arab; Derived from sampling site: Labioscrotal fold; skin Cell type=Fibroblast.. Female 21127279 CVCL_K970 UKTS8791 transformed cell line human CVCL_K970 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127280 CVCL_K948 C2187 transformed cell line human CVCL_K948 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127281 CVCL_JX48 sVero p66 spontaneously immortalized cell line green monkey CVCL_JX48 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to suspension growth in serum-free media Doubling time: 24 hours (Patent=US20090203112) Group: Non-human primate cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2791 21127282 CVCL_K947 C2186 transformed cell line human CVCL_K947 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127283 CVCL_JX47 CCO-SFM spontaneously immortalized cell line CVCL_JX47 CL:0000010 Unspecified Group: Serum/protein free medium cell line; Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00619. Problematic cell line: Misidentified/contaminated Parent cell line (CCO) has been shown not to be from channel catfish (Ictalurus punctatus) but from brown bullhead (Ameiurus nebulosus). 21127284 CVCL_K949 C2188 transformed cell line human CVCL_K949 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127285 CVCL_JX49 NEO217 cancer cell line human CVCL_JX49 CL:0000010 Population: Chinese; Derived from sampling site: Bone; spine. Male Doubling time: 26 hours (PubMed=28551767) 21127286 CVCL_K944 C2183 transformed cell line human CVCL_K944 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127287 CVCL_JX44 L11 cancer cell line human CVCL_JX44 CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; c.895-2A>C; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=10338002). Population: Japanese Unspecified 21127288 CVCL_K943 C2182 transformed cell line human CVCL_K943 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127289 CVCL_JX43 TERT-NHUC N telomerase immortalized cell line human CVCL_JX43 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Male 21127290 CVCL_JX46 BSCC cancer cell line human CVCL_JX46 CL:0000010 Population: Japanese. 21127291 CVCL_K946 C2185 transformed cell line human CVCL_K946 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127292 CVCL_K945 C2184 transformed cell line human CVCL_K945 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127293 CVCL_JX45 L14 [Human leukemia] cancer cell line human CVCL_JX45 CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.His397Gln (c.1191C>A); Zygosity=Heterozygous (PubMed=10338002). Population: Japanese Female 21127294 CVCL_K940 C2179 transformed cell line human CVCL_K940 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127295 CVCL_JX40 CHO (protein free) spontaneously immortalized cell line CVCL_JX40 CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21127296 CVCL_K942 C2181 transformed cell line human CVCL_K942 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061986; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127297 CVCL_JX42 TERT-NHUC B telomerase immortalized cell line human CVCL_JX42 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Male 21127298 CVCL_K941 C2180 transformed cell line human CVCL_K941 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127299 CVCL_JX41 TERT-NHUC A telomerase immortalized cell line human CVCL_JX41 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Male 21127300 CVCL_K959 C2199 transformed cell line human CVCL_K959 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425339; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127301 CVCL_JX59 Sp2/0-Ag14 (serum-free Celox) cancer cell line house mouse CVCL_JX59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-1581.1; true Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21127302 CVCL_K958 C2198 transformed cell line human CVCL_K958 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425338; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127303 CVCL_JX58 DKFZ-BT66 cancer cell line human CVCL_JX58 CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 22219; KIAA1549; Name(s)=KIAA1549-BRAF; Note=KIAA1549 exon 16 fused to BRAF exon 9 (PubMed=28002790); Transfected with: UniProtKB; Q9U6Y8; RFP Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebellum. Male Characteristics: Transduced with a doxycycline-inducible system coding for SV40 large T antigen and RFP (PubMed=28002790) Senescence: Withdrawal of doxycyclin leads to senescence (PubMed=28002790); Doubling time: 45 hours (PubMed=28002790) 21127304 CVCL_JX55 AMCPAC04 cancer cell line human CVCL_JX55 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=28435405); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Unspecified (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 48 hours (PubMed=28435405) 21127305 CVCL_K955 C2195 transformed cell line human CVCL_K955 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425335; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127306 CVCL_JX54 AMCPAC03 cancer cell line human CVCL_JX54 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 68 hours (PubMed=28435405) 21127307 CVCL_K954 C2194 transformed cell line human CVCL_K954 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425334; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127308 CVCL_JX57 AMCPAC06 cancer cell line human CVCL_JX57 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=28435405); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 51 hours (PubMed=28435405) 21127309 CVCL_K957 C2197 transformed cell line human CVCL_K957 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425337; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127310 CVCL_JX56 AMCPAC05 cancer cell line human CVCL_JX56 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly60_Gln61insLeu; Zygosity=Heterozygous (PubMed=28435405); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Heterozygous (PubMed=28435405); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Unspecified (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 75 hours (PubMed=28435405) 21127311 CVCL_K956 C2196 transformed cell line human CVCL_K956 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425336; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127312 CVCL_K951 C2191 transformed cell line human CVCL_K951 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127313 CVCL_JX51 MGZRTcH2 embryonic stem cell house mouse CVCL_JX51 CL:0000010 Breed/subspecies: 129S/SvEv-Gpi1. Male 21127314 CVCL_K950 C2190 transformed cell line human CVCL_K950 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127315 CVCL_JX50 MGZ5 embryonic stem cell house mouse CVCL_JX50 CL:0000010 Breed/subspecies: 129S/SvEv-Gpi1. Male 21127316 CVCL_JX53 AMCPAC02 cancer cell line human CVCL_JX53 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Female Doubling time: 87 hours (PubMed=28435405) 21127317 CVCL_K953 C2193 transformed cell line human CVCL_K953 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425333; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127318 CVCL_JX52 AMCPAC01 cancer cell line human CVCL_JX52 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=28435405); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.384_393del10; Zygosity=Unspecified (PubMed=28435405) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 68 hours (PubMed=28435405) 21127319 CVCL_K952 C2192 transformed cell line human CVCL_K952 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 960425332; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127320 CVCL_K929 C2168 transformed cell line human CVCL_K929 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061974; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127321 CVCL_JX29 CMT7 cancer cell line dog CVCL_JX29 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Gly233Ala (c.698G>C); Zygosity=Hemizygous (PubMed=9042250) Derived from sampling site: Mammary gland. Female 21127322 CVCL_K926 C2165 transformed cell line human CVCL_K926 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061971; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127323 CVCL_JX26 SH3 [Dog mammary carcinoma] cancer cell line dog CVCL_JX26 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Bouvier des Flandres. Female Doubling time: 27 hours (in FCS medium), 32 hours (in SH-FCS medium) (PubMed=2795680) 21127324 CVCL_K925 C2164 transformed cell line human CVCL_K925 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061970; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127325 CVCL_JX25 SH1b cancer cell line dog CVCL_JX25 CL:0000010 Derived from metastatic site: Spleen; Breed/subspecies: Belgian Malinois. Female Doubling time: 19 hours (in FCS medium), 20 hours (in SH-FCS medium) (PubMed=2795680) 21127326 CVCL_K928 C2167 transformed cell line human CVCL_K928 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061973; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127327 CVCL_JX28 SH2 [Dog mammary carcinoma] cancer cell line dog CVCL_JX28 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Belgian Malinois. Female 21127328 CVCL_K927 C2166 transformed cell line human CVCL_K927 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061972; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127329 CVCL_JX27 SH1a cancer cell line dog CVCL_JX27 CL:0000010 Derived from metastatic site: Spleen; Breed/subspecies: Belgian Malinois. Female 21127330 CVCL_K922 C2160 transformed cell line human CVCL_K922 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127331 CVCL_JX22 LE-L2C cancer cell line CVCL_JX22 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21127332 CVCL_K921 C2159 transformed cell line human CVCL_K921 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127333 CVCL_JX21 GH-L2C cancer cell line CVCL_JX21 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21127334 CVCL_K924 C2163 transformed cell line human CVCL_K924 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061969; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127335 CVCL_JX24 P120 cancer cell line dog CVCL_JX24 CL:0000010 Derived from metastatic site: Lymph node. Female 21127336 CVCL_K923 C2161 transformed cell line human CVCL_K923 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127337 CVCL_JX23 LG-L2C cancer cell line CVCL_JX23 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21127338 CVCL_K920 C2158 transformed cell line human CVCL_K920 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127339 CVCL_JX20 EN-L2C cancer cell line CVCL_JX20 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21127340 CVCL_K937 C2176 transformed cell line human CVCL_K937 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127341 CVCL_JX37 Sf21 TiterHigh AC free spontaneously immortalized cell line CVCL_JX37 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line; Group: Serum/protein free medium cell line 21127342 CVCL_K936 C2175 transformed cell line human CVCL_K936 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127343 CVCL_JX36 Sf9 TiterHigh AC free spontaneously immortalized cell line CVCL_JX36 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line; Group: Serum/protein free medium cell line 21127344 CVCL_K939 C2178 transformed cell line human CVCL_K939 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061999; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127345 CVCL_JX39 CHO/dhFr-AC-free spontaneously immortalized cell line CVCL_JX39 CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21127346 CVCL_K938 C2177 transformed cell line human CVCL_K938 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061998; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127347 CVCL_JX38 Sp2/0-Ag14 (serum free) cancer cell line house mouse CVCL_JX38 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21127348 CVCL_K933 C2172 transformed cell line human CVCL_K933 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127349 CVCL_JX33 PNT1A serum free transformed cell line human CVCL_JX33 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Group: Serum/protein free medium cell line 21127350 CVCL_K932 C2171 transformed cell line human CVCL_K932 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061977; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127351 CVCL_JX32 GM06934 transformed cell line human CVCL_JX32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a donor suffering from mental retardation, microcephaly, short stature, hypogonadism, photosensitivity, abnormal neurologic exam and typical skin findings No defects in DNA repair or replication observed in fibroblasts.; Derived from sampling site: Peripheral blood. Male 21127352 CVCL_K935 C2174 transformed cell line human CVCL_K935 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127353 CVCL_JX35 MDCK-Protein Free spontaneously immortalized cell line dog CVCL_JX35 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Serum/protein free medium cell line 21127354 CVCL_K934 C2173 transformed cell line human CVCL_K934 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127355 CVCL_JX34 PNT2 serum free transformed cell line human CVCL_JX34 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Group: Serum/protein free medium cell line 21127356 CVCL_K931 C2170 transformed cell line human CVCL_K931 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061976; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127357 CVCL_JX31 MDA-SDC-04 telomerase immortalized cell line human CVCL_JX31 CL:0000010 Transfected with: HGNC; 11730; TERT Omics: Deep exome analysis. Male Doubling time: 62 +- 3 hours (PubMed=28559013) 21127358 CVCL_K930 C2169 transformed cell line human CVCL_K930 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 95061975; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127359 CVCL_JX30 CMT8 cancer cell line dog CVCL_JX30 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Tyr224Asn (c.670T>A); Zygosity=Hemizygous (PubMed=9042250) Derived from sampling site: Mammary gland. Female 21127360 CVCL_K908 C2146 transformed cell line human CVCL_K908 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127361 CVCL_JX08 NYSCF-AG0017-01-MR induced pluripotent stem cell human CVCL_JX08 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg364Trp (c.1090C>T); ClinVar=VCV000002278; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 21127362 CVCL_K907 C2145 transformed cell line human CVCL_K907 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127363 CVCL_JX07 NYSCF-AG0016-01-MR induced pluripotent stem cell human CVCL_JX07 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7739; NEFL; Simple; p.Asn98Ser (c.293A>G); ClinVar=VCV000041236; Zygosity=Unspecified (NYSCF). Female 21127364 CVCL_K909 C2147 transformed cell line human CVCL_K909 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515195; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127365 CVCL_JX09 NYSCF-AG0018-01-MR induced pluripotent stem cell human CVCL_JX09 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7739; NEFL; Simple; p.Glu396Lys (c.1186G>A); ClinVar=VCV000066671; Zygosity=Unspecified (NYSCF). Male 21127366 CVCL_K904 C2142 transformed cell line human CVCL_K904 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127367 CVCL_JX04 NYSCF-AG0013-01-MR induced pluripotent stem cell human CVCL_JX04 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Glu102Gly (c.305A>G); ClinVar=VCV000216038; Zygosity=Hemizygous (NYSCF). Male 21127368 CVCL_K903 C2141 transformed cell line human CVCL_K903 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127369 CVCL_JX03 NYSCF-AG0012-01-MR induced pluripotent stem cell human CVCL_JX03 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4283; GJB1; Simple; p.Arg75Trp (c.223C>T); ClinVar=VCV000021082; Zygosity=Hemizygous (NYSCF). Male 21127370 CVCL_K906 C2144 transformed cell line human CVCL_K906 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127371 CVCL_JX06 NYSCF-AG0015-01-MR induced pluripotent stem cell human CVCL_JX06 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg364Trp (c.1090C>T); ClinVar=VCV000002278; Zygosity=Unspecified (NYSCF). Female 21127372 CVCL_K905 C2143 transformed cell line human CVCL_K905 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127373 CVCL_JX05 NYSCF-AG0014-01-MR induced pluripotent stem cell human CVCL_JX05 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Gly97Glu (c.290G>A); ClinVar=VCV000218306; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 21127374 CVCL_K900 C2138 transformed cell line human CVCL_K900 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515161; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127375 CVCL_JX00 NYSCF-AG0009-02-MR induced pluripotent stem cell human CVCL_JX00 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Arg98Cys (c.292C>T); ClinVar=VCV000014175; Zygosity=Unspecified (NYSCF). Male 21127376 CVCL_K902 C2140 transformed cell line human CVCL_K902 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515171; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127377 CVCL_JX02 NYSCF-AG0011-01-MR induced pluripotent stem cell human CVCL_JX02 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 16873; FIG4; Simple; p.Ile41Thr (c.122T>C); ClinVar=VCV000001721; Zygosity=Unspecified (NYSCF); Sequence variation: Mutation; HGNC; 16873; FIG4; Simple; p.Arg183Ter (c.547C>T); ClinVar=VCV000001723; Zygosity=Unspecified (NYSCF). Population: Caucasian Male 21127378 CVCL_K901 C2139 transformed cell line human CVCL_K901 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127379 CVCL_JX01 NYSCF-AG0010-01-MR induced pluripotent stem cell human CVCL_JX01 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7739; NEFL; Simple; p.Glu396Lys (c.1186G>A); ClinVar=VCV000066671; Zygosity=Unspecified (NYSCF). Male 21127380 CVCL_JX19 BZ-L2C cancer cell line CVCL_JX19 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21127381 CVCL_K919 C2157 transformed cell line human CVCL_K919 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515236; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127382 CVCL_K918 C2156 transformed cell line human CVCL_K918 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127383 CVCL_JX18 MCS-8 cancer cell line CVCL_JX18 CL:0000010 Female Doubling time: 17.7 hours (PubMed=1667204). 21127384 CVCL_K915 C2153 transformed cell line human CVCL_K915 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127385 CVCL_JX15 SFCC cancer cell line human CVCL_JX15 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Doubling time: 67.6 hours (PubMed=2472868) 21127386 CVCL_K914 C2152 transformed cell line human CVCL_K914 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127387 CVCL_JX14 CAC-1 [Human cervical carcinoma] cancer cell line human CVCL_JX14 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761). Female Doubling time: 31 hours (CelloPub=CLPUB00398; DOI=10.15114/smj.57.603) 21127388 CVCL_K917 C2155 transformed cell line human CVCL_K917 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127389 CVCL_JX17 MCS-1 [Hamster chondrosarcoma] cancer cell line CVCL_JX17 CL:0000010 Female Doubling time: 17.2 hours (PubMed=1667204). 21127390 CVCL_K916 C2154 transformed cell line human CVCL_K916 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515227; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127391 CVCL_JX16 JSK-1 cancer cell line human CVCL_JX16 From: Sasaki H.; Jikei University School of Medicine; Tokyo; Japan CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761). Female 21127392 CVCL_K911 C2149 transformed cell line human CVCL_K911 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 950515197; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127393 CVCL_JX11 NYSCF-AG0020-01-MR induced pluripotent stem cell human CVCL_JX11 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (NYSCF). Population: Caucasian Female 21127394 CVCL_K910 C2148 transformed cell line human CVCL_K910 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127395 CVCL_JX10 NYSCF-AG0019-01-MR induced pluripotent stem cell human CVCL_JX10 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Arg98Cys (c.292C>T); ClinVar=VCV000014175; Zygosity=Unspecified (NYSCF). Male 21127396 CVCL_K913 C2151 transformed cell line human CVCL_K913 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127397 CVCL_JX13 OACM5 1.C SC1 cancer cell line human CVCL_JX13 CL:0000010 Derived from metastatic site: Lymph node. Female 21127398 CVCL_K912 C2150 transformed cell line human CVCL_K912 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127399 CVCL_JX12 NYSCF-AG0021-01-MR induced pluripotent stem cell human CVCL_JX12 From: New York Stem Cell Foundation; New York; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (NYSCF). Male 21127400 CVCL_SR87 HAP1 HTT (-) 2 cancer cell line human CVCL_SR87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4851; HTT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127401 CVCL_T387 Psi-CRIP-MFGhOncost-M transformed cell line house mouse CVCL_T387 CL:0000010 Transfected with: HGNC; 8506; OSM Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127402 CVCL_SR86 HAP1 HTT (-) 1 cancer cell line human CVCL_SR86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4851; HTT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127403 CVCL_T386 Psi-CRIP-MFGhMIF transformed cell line house mouse CVCL_T386 CL:0000010 Transfected with: HGNC; 7097; MIF Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127404 CVCL_SR89 HAP1 HUWE1 (-) 1 cancer cell line human CVCL_SR89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30892; HUWE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127405 CVCL_T389 Psi-CRIP-MFGhTNF-alpha transformed cell line house mouse CVCL_T389 CL:0000010 Transfected with: HGNC; 11892; TNF Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127406 CVCL_SR88 HAP1 HUNK (-) cancer cell line human CVCL_SR88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13326; HUNK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127407 CVCL_T388 Psi-CRIP-MFGHSVtk transformed cell line house mouse CVCL_T388 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127408 CVCL_0L40 AG20154 transformed cell line human CVCL_0L40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127409 CVCL_0L42 AG20205 transformed cell line human CVCL_0L42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127410 CVCL_0L41 AG20169 transformed cell line human CVCL_0L41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127411 CVCL_0L44 AG20221 transformed cell line human CVCL_0L44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127412 CVCL_0L43 AG20211 transformed cell line human CVCL_0L43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127413 CVCL_0L35 AG20134 transformed cell line human CVCL_0L35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127414 CVCL_0L34 AG20121 transformed cell line human CVCL_0L34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127415 CVCL_0L37 AG20137 transformed cell line human CVCL_0L37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127416 CVCL_0L36 AG20135 transformed cell line human CVCL_0L36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127417 CVCL_0L39 AG20139 transformed cell line human CVCL_0L39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127418 CVCL_0L38 AG20138 transformed cell line human CVCL_0L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127419 CVCL_SR90 HAP1 HUWE1 (-) 2 cancer cell line human CVCL_SR90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30892; HUWE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127420 CVCL_T390 Psi-CRIP-MFGmB7 transformed cell line house mouse CVCL_T390 CL:0000010 Transfected with: MGI; MGI:101775; Cd80 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127421 CVCL_SR92 HAP1 IBTK (-) 2 cancer cell line human CVCL_SR92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17853; IBTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127422 CVCL_T392 Psi-CRIP-MFGmG-CSF transformed cell line house mouse CVCL_T392 CL:0000010 Transfected with: MGI; MGI:1339751; Csf3 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127423 CVCL_SR91 HAP1 IBTK (-) 1 cancer cell line human CVCL_SR91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17853; IBTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127424 CVCL_T391 Psi-CRIP-MFGmB7-2 transformed cell line house mouse CVCL_T391 CL:0000010 Transfected with: MGI; MGI:101773; Cd86 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127425 CVCL_SR94 HAP1 ICAM5 (-) 1 cancer cell line human CVCL_SR94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5348; ICAM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127426 CVCL_T394 Psi-CRIP-MFGmIFN-gamma transformed cell line house mouse CVCL_T394 CL:0000010 Transfected with: MGI; MGI:107656; Ifng Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127427 CVCL_SR93 HAP1 ICAM1 (-) 1 cancer cell line human CVCL_SR93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5344; ICAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127428 CVCL_T393 Psi-CRIP-MFGmGM-CSF transformed cell line house mouse CVCL_T393 CL:0000010 Transfected with: MGI; MGI:1339752; Csf2 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127429 CVCL_SR96 HAP1 ICMT (-) 1 cancer cell line human CVCL_SR96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5350; ICMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127430 CVCL_T396 Psi-CRIP-MFGmIL-12p35 transformed cell line house mouse CVCL_T396 CL:0000010 Transfected with: MGI; MGI:96539; Il12a Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127431 CVCL_SR95 HAP1 ICK (-) cancer cell line human CVCL_SR95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21219; CILK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127432 CVCL_T395 Psi-CRIP-MFGmIL-10 transformed cell line house mouse CVCL_T395 CL:0000010 Transfected with: MGI; MGI:96537; Il10 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127433 CVCL_SR76 HAP1 HSPA1L (-) 2 cancer cell line human CVCL_SR76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5234; HSPA1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127434 CVCL_T376 RGB3T3-5 spontaneously immortalized cell line house mouse CVCL_T376 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21127435 CVCL_SR75 HAP1 HSPA1L (-) 1 cancer cell line human CVCL_SR75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5234; HSPA1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127436 CVCL_T375 RGB3T3-1 spontaneously immortalized cell line house mouse CVCL_T375 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21127437 CVCL_T378 Cle-H3^(neo+) spontaneously immortalized cell line house mouse CVCL_T378 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127438 CVCL_SR78 HAP1 HSPB1 (-) 2 cancer cell line human CVCL_SR78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5246; HSPB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127439 CVCL_SR77 HAP1 HSPB1 (-) 1 cancer cell line human CVCL_SR77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5246; HSPB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127440 CVCL_T377 Psi-CRE-MFGts-c-src transformed cell line house mouse CVCL_T377 CL:0000010 Transfected with: MGI; MGI:98397; Src Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127441 CVCL_SR79 HAP1 HSPB1 (-) 3 cancer cell line human CVCL_SR79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5246; HSPB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127442 CVCL_T379 Psi-CRIP-ATR-bsr transformed cell line house mouse CVCL_T379 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127443 CVCL_0L51 AG20308 transformed cell line human CVCL_0L51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127444 CVCL_0L50 AG20262 transformed cell line human CVCL_0L50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127445 CVCL_0L53 AG20353 transformed cell line human CVCL_0L53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127446 CVCL_0L52 AG20323 transformed cell line human CVCL_0L52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127447 CVCL_0L55 AG20370 transformed cell line human CVCL_0L55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127448 CVCL_0L54 AG20354 transformed cell line human CVCL_0L54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127449 CVCL_0L46 AG20227 transformed cell line human CVCL_0L46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127450 CVCL_0L45 AG20224 transformed cell line human CVCL_0L45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127451 CVCL_0L48 AG20229 transformed cell line human CVCL_0L48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127452 CVCL_0L47 AG20228 transformed cell line human CVCL_0L47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127453 CVCL_0L49 AG20257 transformed cell line human CVCL_0L49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127454 CVCL_SR81 HAP1 HSPG2 (-) 1 cancer cell line human CVCL_SR81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127455 CVCL_T381 Psi-CRIP-hp53-bsr transformed cell line house mouse CVCL_T381 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: HGNC; 11998; TP53 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127456 CVCL_SR80 HAP1 HSPB1 (-) 4 cancer cell line human CVCL_SR80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5246; HSPB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127457 CVCL_T380 Psi-CRIP-hBax-i-hCD25-CS transformed cell line house mouse CVCL_T380 CL:0000010 Transfected with: HGNC; 959; BAX Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127458 CVCL_SR83 HAP1 HSPG2 (-) 3 cancer cell line human CVCL_SR83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127459 CVCL_T383 Psi-CRIP-MFG-T37 transformed cell line house mouse CVCL_T383 CL:0000010 Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127460 CVCL_SR82 HAP1 HSPG2 (-) 2 cancer cell line human CVCL_SR82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127461 CVCL_T382 Psi-CRIP-hSSR-bsr transformed cell line house mouse CVCL_T382 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: HGNC; 11330; SSTR1 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127462 CVCL_SR85 HAP1 HTR6 (-) 2 cancer cell line human CVCL_SR85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5301; HTR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127463 CVCL_T385 Psi-CRIP-MFGhM-CSF transformed cell line house mouse CVCL_T385 CL:0000010 Transfected with: HGNC; 2432; CSF1 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127464 CVCL_SR84 HAP1 HTR6 (-) 1 cancer cell line human CVCL_SR84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5301; HTR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127465 CVCL_T384 Psi-CRIP-MFG-Z transformed cell line house mouse CVCL_T384 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21127466 CVCL_T365 B0001 transformed cell line human CVCL_T365 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: RCB; GMC0038; probable Female 21127467 CVCL_SR65 HAP1 HPSE (-) cancer cell line human CVCL_SR65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5164; HPSE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127468 CVCL_T364 A0001 finite cell line human CVCL_T364 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127469 CVCL_SR64 HAP1 HPS1 (-) 1 cancer cell line human CVCL_SR64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5163; HPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127470 CVCL_T367 1-8 transformed cell line CVCL_T367 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21127471 CVCL_SR67 HAP1 HRSP12 (-) 2 cancer cell line human CVCL_SR67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16897; RIDA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127472 CVCL_T366 2-7 transformed cell line CVCL_T366 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: A copy of CAG-loxP-neo-pA-loxP-LacZ was inserted Cre will delete neo-pA and induce LacZ (RCB=RCB1376). Group: Non-human primate cell line 21127473 CVCL_SR66 HAP1 HRSP12 (-) 1 cancer cell line human CVCL_SR66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16897; RIDA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127474 CVCL_SR69 HAP1 HSD17B4 (-) 1 cancer cell line human CVCL_SR69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5213; HSD17B4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127475 CVCL_T369 Verots S3(SF) transformed cell line green monkey CVCL_T369 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21127476 CVCL_SR68 HAP1 HRSP12 (-) 3 cancer cell line human CVCL_SR68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16897; RIDA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127477 CVCL_T368 Verots S3 transformed cell line green monkey CVCL_T368 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21127478 CVCL_0L20 AG20051 transformed cell line human CVCL_0L20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127479 CVCL_0L22 AG20062 transformed cell line human CVCL_0L22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127480 CVCL_0L21 AG20052 transformed cell line human CVCL_0L21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127481 CVCL_0L13 AG20023 transformed cell line human CVCL_0L13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127482 CVCL_0L12 AG20014 transformed cell line human CVCL_0L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127483 CVCL_0L15 AG20028 transformed cell line human CVCL_0L15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127484 CVCL_0L14 AG20025 transformed cell line human CVCL_0L14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127485 CVCL_0L17 AG20030 transformed cell line human CVCL_0L17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127486 CVCL_0L16 AG20029 transformed cell line human CVCL_0L16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127487 CVCL_0L19 AG20050 transformed cell line human CVCL_0L19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127488 CVCL_0L18 AG20036 transformed cell line human CVCL_0L18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127489 CVCL_SR70 HAP1 HSD17B4 (-) 2 cancer cell line human CVCL_SR70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5213; HSD17B4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127490 CVCL_T370 OT11 conditionally immortalized cell line house mouse CVCL_T370 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96522; Rbpj Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21127491 CVCL_T372 F9/LM(1+10) cancer cell line house mouse CVCL_T372 CL:0000010 Transfected with: MGI; MGI:105382; Lama5 Breed/subspecies: 129/Sv. Male 21127492 CVCL_SR72 HAP1 HSF1 (-) 2 cancer cell line human CVCL_SR72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5224; HSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127493 CVCL_SR71 HAP1 HSF1 (-) 1 cancer cell line human CVCL_SR71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5224; HSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127494 CVCL_T371 OT13 conditionally immortalized cell line house mouse CVCL_T371 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Control cell line for OT11 (Cellosaurus=CVCL_T370) 21127495 CVCL_SR74 HAP1 HSP90AA1 (-) 1 cancer cell line human CVCL_SR74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5253; HSP90AA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127496 CVCL_T374 Odf2-deficient F9 cells cancer cell line house mouse CVCL_T374 CL:0000010 Breed/subspecies: 129/Sv. Male 21127497 CVCL_T373 F9/LM10 cancer cell line house mouse CVCL_T373 CL:0000010 Transfected with: MGI; MGI:105382; Lama5 Breed/subspecies: 129/Sv. Male 21127498 CVCL_SR73 HAP1 HSF1 (-) 3 cancer cell line human CVCL_SR73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5224; HSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127499 CVCL_T354 A0050 finite cell line human CVCL_T354 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127500 CVCL_SR54 HAP1 HMGB2 (-) 2 cancer cell line human CVCL_SR54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5000; HMGB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127501 CVCL_T353 B0010 transformed cell line human CVCL_T353 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127502 CVCL_SR53 HAP1 HMGB2 (-) 1 cancer cell line human CVCL_SR53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5000; HMGB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127503 CVCL_T356 B0076 transformed cell line human CVCL_T356 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127504 CVCL_SR56 HAP1 HMMR (-) 2 cancer cell line human CVCL_SR56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5012; HMMR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127505 CVCL_T355 B0050 transformed cell line human CVCL_T355 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127506 CVCL_SR55 HAP1 HMMR (-) 1 cancer cell line human CVCL_SR55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5012; HMMR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127507 CVCL_T358 B0058 transformed cell line human CVCL_T358 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127508 CVCL_SR58 HAP1 HMOX2 (-) 1 cancer cell line human CVCL_SR58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5014; HMOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127509 CVCL_T357 A0058 finite cell line human CVCL_T357 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127510 CVCL_SR57 HAP1 HMOX1 (-) 1 cancer cell line human CVCL_SR57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5013; HMOX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127511 CVCL_T359 B0078 transformed cell line human CVCL_T359 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127512 CVCL_SR59 HAP1 HNRNPDL (-) 1 cancer cell line human CVCL_SR59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5037; HNRNPDL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127513 CVCL_0L31 AG20115 transformed cell line human CVCL_0L31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127514 CVCL_0L30 AG20099 transformed cell line human CVCL_0L30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127515 CVCL_0L33 AG20119 transformed cell line human CVCL_0L33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127516 CVCL_0L32 AG20116 transformed cell line human CVCL_0L32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127517 CVCL_0L24 AG20093 transformed cell line human CVCL_0L24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127518 CVCL_0L23 AG20077 transformed cell line human CVCL_0L23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127519 CVCL_0L26 AG20095 transformed cell line human CVCL_0L26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127520 CVCL_0L25 AG20094 transformed cell line human CVCL_0L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127521 CVCL_0L28 AG20097 transformed cell line human CVCL_0L28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127522 CVCL_0L27 AG20096 transformed cell line human CVCL_0L27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127523 CVCL_0L29 AG20098 transformed cell line human CVCL_0L29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127524 CVCL_T361 B0045 transformed cell line human CVCL_T361 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127525 CVCL_SR61 HAP1 HOOK3 (-) cancer cell line human CVCL_SR61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23576; HOOK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127526 CVCL_T360 B0086 transformed cell line human CVCL_T360 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127527 CVCL_SR60 HAP1 HNRNPDL (-) 2 cancer cell line human CVCL_SR60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5037; HNRNPDL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127528 CVCL_T363 B0026 transformed cell line human CVCL_T363 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127529 CVCL_SR63 HAP1 HPRT1 (-) 2 cancer cell line human CVCL_SR63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5157; HPRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127530 CVCL_T362 A0026 finite cell line human CVCL_T362 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127531 CVCL_SR62 HAP1 HPRT1 (-) 1 cancer cell line human CVCL_SR62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5157; HPRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127532 CVCL_T343 A0042 finite cell line human CVCL_T343 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127533 CVCL_SR43 HAP1 HIPK1 (-) 3 cancer cell line human CVCL_SR43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19006; HIPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127534 CVCL_T342 B0042 transformed cell line human CVCL_T342 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127535 CVCL_SR42 HAP1 HIPK1 (-) 2 cancer cell line human CVCL_SR42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19006; HIPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127536 CVCL_T345 A0022 finite cell line human CVCL_T345 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127537 CVCL_SR45 HAP1 HIPK2 (-) 2 cancer cell line human CVCL_SR45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14402; HIPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127538 CVCL_T344 B0022 transformed cell line human CVCL_T344 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127539 CVCL_SR44 HAP1 HIPK2 (-) 1 cancer cell line human CVCL_SR44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14402; HIPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127540 CVCL_T347 B0055 transformed cell line human CVCL_T347 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127541 CVCL_SR47 HAP1 HIPK3 (-) 1 cancer cell line human CVCL_SR47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4915; HIPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127542 CVCL_T346 A0055 finite cell line human CVCL_T346 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127543 CVCL_SR46 HAP1 HIPK2 (-) 3 cancer cell line human CVCL_SR46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14402; HIPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127544 CVCL_T349 B0036 transformed cell line human CVCL_T349 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21127545 CVCL_SR49 HAP1 HLA-G (-) 1 cancer cell line human CVCL_SR49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4964; HLA-G; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127546 CVCL_T348 B0090 transformed cell line human CVCL_T348 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127547 CVCL_SR48 HAP1 HIPK3 (-) 2 cancer cell line human CVCL_SR48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4915; HIPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127548 CVCL_0L00 AG19980 transformed cell line human CVCL_0L00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127549 CVCL_T350 A0072 finite cell line human CVCL_T350 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127550 CVCL_SR50 HAP1 HLTF (-) 1 cancer cell line human CVCL_SR50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11099; HLTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127551 CVCL_T352 A0010 finite cell line human CVCL_T352 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127552 CVCL_SR52 HAP1 HLTF (-) 3 cancer cell line human CVCL_SR52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11099; HLTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127553 CVCL_T351 B0072 transformed cell line human CVCL_T351 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127554 CVCL_SR51 HAP1 HLTF (-) 2 cancer cell line human CVCL_SR51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11099; HLTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127555 CVCL_SR32 HAP1 HEXDC (-) 1 cancer cell line human CVCL_SR32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26307; HEXD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127556 CVCL_T332 UN7RGB finite cell line human CVCL_T332 CL:0000010 Population: Japanese; Donor information: Was originally thought to be from a Werner syndrome patient but this is no longer thought to be the case; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0873; true Male Senescence: Senesces at >60 PDL (RCB=GMC0010) 21127557 CVCL_SR31 HAP1 HEXB (-) 3 cancer cell line human CVCL_SR31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4879; HEXB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127558 CVCL_T331 WS6RGB finite cell line human CVCL_T331 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0387; true Female Senescence: Senesces at 22 PDL (RCB=GMC0009) 21127559 CVCL_T334 B0082 transformed cell line human CVCL_T334 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127560 CVCL_SR34 HAP1 HGS (-) 1 cancer cell line human CVCL_SR34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4897; HGS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127561 CVCL_SR33 HAP1 HEXDC (-) 2 cancer cell line human CVCL_SR33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26307; HEXD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127562 CVCL_T333 UN8RGB finite cell line human CVCL_T333 CL:0000010 Population: Japanese; Donor information: Was originally thought to be from a Werner syndrome patient but this is no longer thought to be the case; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB1141; true Male Senescence: Senesces at >50 PDL (RCB=GMC0011) 21127563 CVCL_T336 B0006 transformed cell line human CVCL_T336 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127564 CVCL_SR36 HAP1 HGS (-) 3 cancer cell line human CVCL_SR36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4897; HGS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127565 CVCL_T335 A0082 finite cell line human CVCL_T335 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127566 CVCL_SR35 HAP1 HGS (-) 2 cancer cell line human CVCL_SR35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4897; HGS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127567 CVCL_T338 A0031 finite cell line human CVCL_T338 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=25390333); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25390333) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127568 CVCL_SR38 HAP1 HIF1A (-) 1 cancer cell line human CVCL_SR38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4910; HIF1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127569 CVCL_T337 A0065 finite cell line human CVCL_T337 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127570 CVCL_SR37 HAP1 HIAT1 (-) 1 cancer cell line human CVCL_SR37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23363; MFSD14A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127571 CVCL_T339 B0031 transformed cell line human CVCL_T339 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (from autologous cell line A0031); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (from autologous cell line A0031) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127572 CVCL_SR39 HAP1 HIF1A (-) 2 cancer cell line human CVCL_SR39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4910; HIF1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127573 CVCL_0L11 AG20006 transformed cell line human CVCL_0L11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127574 CVCL_0L10 AG20003 transformed cell line human CVCL_0L10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127575 CVCL_0L02 AG19986 transformed cell line human CVCL_0L02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127576 CVCL_0L01 AG19981 transformed cell line human CVCL_0L01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127577 CVCL_0L04 AG19990 transformed cell line human CVCL_0L04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127578 CVCL_0L03 AG19987 transformed cell line human CVCL_0L03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127579 CVCL_0L06 AG19992 transformed cell line human CVCL_0L06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127580 CVCL_0L05 AG19991 transformed cell line human CVCL_0L05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127581 CVCL_0L08 AG19994 transformed cell line human CVCL_0L08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127582 CVCL_0L07 AG19993 transformed cell line human CVCL_0L07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127583 CVCL_0L09 AG19998 transformed cell line human CVCL_0L09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127584 CVCL_T341 2-2 [Chlorocebus aethiops] transformed cell line CVCL_T341 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: 35 copies of CAG-loxP-neo-pA-loxP-LacZ were tandemly inserted Cre will delete neo-pA and induce LacZ (RCB=RCB1375). Group: Non-human primate cell line 21127585 CVCL_SR41 HAP1 HIPK1 (-) 1 cancer cell line human CVCL_SR41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19006; HIPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127586 CVCL_T340 B0096 transformed cell line human CVCL_T340 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127587 CVCL_SR40 HAP1 HIP1 (-) 1 cancer cell line human CVCL_SR40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4913; HIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127588 CVCL_SR21 HAP1 HDAC8 (-) 4 cancer cell line human CVCL_SR21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13315; HDAC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127589 CVCL_T321 RPMI-8002 transformed cell line human CVCL_T321 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127590 CVCL_SR20 HAP1 HDAC8 (-) 3 cancer cell line human CVCL_SR20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13315; HDAC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127591 CVCL_T320 RPMI-7972 cancer cell line human CVCL_T320 CL:0000010 Female Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma. 21127592 CVCL_SR23 HAP1 HDAC9 (-) 2 cancer cell line human CVCL_SR23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14065; HDAC9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127593 CVCL_T323 RPMI-8252 cancer cell line human CVCL_T323 CL:0000010 Derived from metastatic site: Lymph node. Male 21127594 CVCL_SR22 HAP1 HDAC9 (-) 1 cancer cell line human CVCL_SR22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14065; HDAC9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127595 CVCL_T322 RPMI-8072 transformed cell line human CVCL_T322 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127596 CVCL_T325 CaCL 74-36 cancer cell line human CVCL_T325 CL:0000010 Derived from metastatic site: Lymph node. Male 21127597 CVCL_SR25 HAP1 HELLS (-) cancer cell line human CVCL_SR25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4861; HELLS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127598 CVCL_T324 CaCL 73-36 cancer cell line human CVCL_T324 CL:0000010 Derived from metastatic site: Lung. Female Doubling time: 34 hours (PubMed=1127734) 21127599 CVCL_SR24 HAP1 HDHD3 (-) 1 cancer cell line human CVCL_SR24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28171; HDHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127600 CVCL_T327 CaCL 78-4 cancer cell line human CVCL_T327 CL:0000010 21127601 CVCL_SR27 HAP1 HES1 (-) cancer cell line human CVCL_SR27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5192; HES1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127602 CVCL_T326 CaCL 78-1 cancer cell line human CVCL_T326 CL:0000010 21127603 CVCL_SR26 HAP1 HERPUD2 (-) 1 cancer cell line human CVCL_SR26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21915; HERPUD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127604 CVCL_SR29 HAP1 HEXB (-) 1 cancer cell line human CVCL_SR29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4879; HEXB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127605 CVCL_T329 WS2RGB finite cell line human CVCL_T329 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0154; true Male Senescence: Senesces at 16.2 PDL (RCB=GMC0006) 21127606 CVCL_T328 CaCL 79-3 cancer cell line human CVCL_T328 CL:0000010 21127607 CVCL_SR28 HAP1 HEXA (-) cancer cell line human CVCL_SR28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4878; HEXA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC3073; probable Male Group: Haploid karyotype cell line 21127608 CVCL_JX88 PC12h cancer cell line Norway rat CVCL_JX88 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Shows NGF-mediated increase of tyrosine hydroxlyase activity 21127609 CVCL_K988 UKTS9034 transformed cell line human CVCL_K988 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127610 CVCL_JX87 PCTH-7 hybridoma house mouse CVCL_JX87 CL:0000010 Characteristics: The monoclonal antibody produced by this hybridoma inhibits the catalytic activity of TH; Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04177; Rat Th. 21127611 CVCL_K987 UKTS9025 transformed cell line human CVCL_K987 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127612 CVCL_JX89 PC12h-R cancer cell line Norway rat CVCL_JX89 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Shows NGF-mediated increase of tyrosine hydroxlyase activity Rapidly respond to NGF by extending its neurites without any delay. 21127613 CVCL_K989 UKTS9046 transformed cell line human CVCL_K989 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127614 CVCL_JX84 TFS-3 hybridoma house mouse CVCL_JX84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human small cell carcinoma of lung cell lines surface antigen. 21127615 CVCL_K984 UKTS9003 transformed cell line human CVCL_K984 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127616 CVCL_JX83 TFS-1 hybridoma house mouse CVCL_JX83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human small cell carcinoma of lung cell lines surface antigen. 21127617 CVCL_K983 UKTS9002 transformed cell line human CVCL_K983 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127618 CVCL_JX86 PCTH-4 hybridoma house mouse CVCL_JX86 CL:0000010 Characteristics: The monoclonal antibody produced by this hybridoma inhibits the catalytic activity of TH; Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04177; Rat Th. 21127619 CVCL_K986 UKTS9020 transformed cell line human CVCL_K986 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127620 CVCL_JX85 PCTH-3 hybridoma house mouse CVCL_JX85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04177; Rat Th. 21127621 CVCL_K985 UKTS9019 transformed cell line human CVCL_K985 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127622 CVCL_JX80 OX-94 hybridoma house mouse CVCL_JX80 CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; P15725; Rat Tnfrsf4/Cd134. 21127623 CVCL_K980 UKTS8966 transformed cell line human CVCL_K980 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127624 CVCL_JX82 OX-92 hybridoma CVCL_JX82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O54901; Mouse Cd200. 21127625 CVCL_K982 UKTS8992 transformed cell line human CVCL_K982 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127626 CVCL_JX81 OX-95 hybridoma house mouse CVCL_JX81 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P15725; Rat Tnfrsf4/Cd134. 21127627 CVCL_K981 UKTS8989 transformed cell line human CVCL_K981 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127628 CVCL_SR30 HAP1 HEXB (-) 2 cancer cell line human CVCL_SR30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4879; HEXB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127629 CVCL_T330 WS3RGB finite cell line human CVCL_T330 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0155; true Female Senescence: Senesces at 33.5 PDL (RCB=GMC0007) 21127630 CVCL_SR10 HAP1 HDAC4 (-) 2 cancer cell line human CVCL_SR10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14063; HDAC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127631 CVCL_T310 UCT-Mel 7 cancer cell line human CVCL_T310 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Doubling time: 95 hours (PubMed=3091056) 21127632 CVCL_SR12 HAP1 HDAC5 (-) 2 cancer cell line human CVCL_SR12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14068; HDAC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127633 CVCL_T312 NC 65-R cancer cell line human CVCL_T312 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=291478). Male 21127634 CVCL_SR11 HAP1 HDAC5 (-) 1 cancer cell line human CVCL_SR11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14068; HDAC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127635 CVCL_T311 NC 65-Sp cancer cell line human CVCL_T311 CL:0000010 Male 21127636 CVCL_SR14 HAP1 HDAC6 (-) 2 cancer cell line human CVCL_SR14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127637 CVCL_T314 RPMI-7272 cancer cell line human CVCL_T314 CL:0000010 Female Doubling time: 38 hours (PubMed=1127734) Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma. 21127638 CVCL_SR13 HAP1 HDAC6 (-) 1 cancer cell line human CVCL_SR13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127639 CVCL_T313 RPMI-7262 cancer cell line human CVCL_T313 CL:0000010 Female Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma. 21127640 CVCL_SR16 HAP1 HDAC7 (-) 1 cancer cell line human CVCL_SR16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14067; HDAC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127641 CVCL_T316 RPMI-7781 transformed cell line human CVCL_T316 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127642 CVCL_SR15 HAP1 HDAC6 (-) 3 cancer cell line human CVCL_SR15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14064; HDAC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127643 CVCL_T315 RPMI-7551 transformed cell line human CVCL_T315 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127644 CVCL_SR18 HAP1 HDAC8 (-) 1 cancer cell line human CVCL_SR18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13315; HDAC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127645 CVCL_T318 RPMI-7922 transformed cell line human CVCL_T318 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127646 CVCL_SR17 HAP1 HDAC7 (-) 2 cancer cell line human CVCL_SR17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14067; HDAC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127647 CVCL_T317 RPMI-7801 transformed cell line human CVCL_T317 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127648 CVCL_SR19 HAP1 HDAC8 (-) 2 cancer cell line human CVCL_SR19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13315; HDAC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127649 CVCL_T319 RPMI-7962 cancer cell line human CVCL_T319 CL:0000010 Female Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma. 21127650 CVCL_JX99 T-60 cancer cell line human CVCL_JX99 CL:0000010 21127651 CVCL_K999 UKTS9142 transformed cell line human CVCL_K999 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127652 CVCL_JX98 MI-31 cancer cell line human CVCL_JX98 CL:0000010 Derived from sampling site: Brain; parietal lobe. Male 21127653 CVCL_K998 UKTS9115 transformed cell line human CVCL_K998 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127654 CVCL_JX95 NK-92MIhCD16 cancer cell line human CVCL_JX95 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (extracellular domain); Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: Transfected with the CD16-BB-zeta construct that consist of a signal peptide, the FCGR3/CD16A extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD247/CD3Z signaling domain Caution: NantKwest exclusively owns, controls and distributes NK-92MI This CD16-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party. 21127655 CVCL_K995 UKTS9109 transformed cell line human CVCL_K995 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127656 CVCL_JX94 S87 cancer cell line CVCL_JX94 CL:0000010 Derived from sampling site: Peritoneal effusion; Breed/subspecies: European shorthair. Female 21127657 CVCL_K994 UKTS9087 transformed cell line human CVCL_K994 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91070901; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127658 CVCL_JX97 OX-79 hybridoma Norway rat CVCL_JX97 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q61451; Mouse Cd53. 21127659 CVCL_K997 UKTS9114 transformed cell line human CVCL_K997 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127660 CVCL_JX96 NK-92MIhCD64 cancer cell line human CVCL_JX96 CL:0000010 Transfected with: HGNC; 3613; FCGR1A (extracellular domain); Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with the CD64-BB-zeta construct that consist of a signal peptide, the FCGR1A/CD64 extracellular domain, the CD8A extracellular domain, the CD28 TM and co-activation domains, the 4-1BB co-activation domain and finally the CD247/CD3Z signaling domain Caution: NantKwest exclusively owns, controls and distributes NK-92MI This CD64-modified variant of NK-92MI was created by a research group and is governed by a Material Transfer Agreement that prevents them from legally distributing the cells to any third party. 21127661 CVCL_K996 UKTS9110 transformed cell line human CVCL_K996 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127662 CVCL_JX91 K562-AVB3 cancer cell line human CVCL_JX91 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6150; ITGAV; Transfected with: HGNC; 6156; ITGB3 Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21127663 CVCL_K991 UKTS9051 transformed cell line human CVCL_K991 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127664 CVCL_JX90 iMEPM spontaneously immortalized cell line house mouse CVCL_JX90 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a Derived from sampling site: Embryonic oral cavity; palate Cell type=Mesenchymal cell.. Unspecified Characteristics: Maintains the morphology, migration ability, transcript expression and responsiveness to exogenous growth factors of primary MEPM cells 21127665 CVCL_K990 UKTS9050 transformed cell line human CVCL_K990 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127666 CVCL_K993 UKTS9082 transformed cell line human CVCL_K993 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127667 CVCL_JX93 XMMBR-B14 hybridoma house mouse CVCL_JX93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human CEA/NCA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9308 21127668 CVCL_K992 UKTS9074 transformed cell line human CVCL_K992 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21127669 CVCL_JX92 XMMCO-228 hybridoma house mouse CVCL_JX92 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9174 21127670 CVCL_9E39 DD1187 transformed cell line human CVCL_9E39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127671 CVCL_9E38 DD1185 finite cell line human CVCL_9E38 CL:0000010 Karyotypic information: 46,XY,t(1;5)(1p5;1q5p) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21127672 CVCL_9E35 DD1177 transformed cell line human CVCL_9E35 CL:0000010 Karyotypic information: 46,XX,t(2;8)(q21.1;q24.13) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127673 CVCL_9E34 DD1175 transformed cell line human CVCL_9E34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127674 CVCL_9E37 DD1182 finite cell line human CVCL_9E37 CL:0000010 Karyotypic information: 46,XX [13]; 47,XX,+mar [21] (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21127675 CVCL_9E36 DD1180 transformed cell line human CVCL_9E36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127676 CVCL_9E31 DD1167 transformed cell line human CVCL_9E31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127677 CVCL_9E30 DD1166 finite cell line human CVCL_9E30 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127678 CVCL_9E33 DD1169 transformed cell line human CVCL_9E33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127679 CVCL_9E32 DD1168 transformed cell line human CVCL_9E32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127680 CVCL_9E49 DD1210 transformed cell line human CVCL_9E49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127681 CVCL_9E46 DD1206 transformed cell line human CVCL_9E46 CL:0000010 Karyotypic information: 46,XX,del(2)(q37.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127682 CVCL_9E45 DD1205 transformed cell line human CVCL_9E45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127683 CVCL_9E48 DD1209 transformed cell line human CVCL_9E48 CL:0000010 Karyotypic information: 46,XY,t(1;5)(1p5;1q5)(0?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127684 CVCL_9E47 DD1208 transformed cell line human CVCL_9E47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127685 CVCL_9E42 DD1199 transformed cell line human CVCL_9E42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC chromosomal abnormality collection 21127686 CVCL_9E41 DD1198 transformed cell line human CVCL_9E41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127687 CVCL_9E44 DD1203 transformed cell line human CVCL_9E44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127688 CVCL_9E43 DD1202 transformed cell line human CVCL_9E43 CL:0000010 Karyotypic information: 47,XX,+dic(15)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127689 CVCL_9E40 DD1189 transformed cell line human CVCL_9E40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127690 CVCL_9E17 DD1144 transformed cell line human CVCL_9E17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127691 CVCL_9E16 DD1143 transformed cell line human CVCL_9E16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127692 CVCL_9E19 DD1147 transformed cell line human CVCL_9E19 CL:0000010 Karyotypic information: 47,XY,+dic(15) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127693 CVCL_9E18 DD1145 transformed cell line human CVCL_9E18 CL:0000010 Karyotypic information: 46,XX; 47,XX,+mar(5;19) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127694 CVCL_9E13 DD1139 finite cell line human CVCL_9E13 CL:0000010 Karyotypic information: 46,XX,del(18)(q21.3) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21127695 CVCL_9E12 DD1136 transformed cell line human CVCL_9E12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127696 CVCL_0K81 AG19592 transformed cell line human CVCL_0K81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127697 CVCL_9E15 DD1141 transformed cell line human CVCL_9E15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127698 CVCL_0K80 AG19591 transformed cell line human CVCL_0K80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127699 CVCL_9E14 DD1140 transformed cell line human CVCL_9E14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127700 CVCL_0K83 AG19595 transformed cell line human CVCL_0K83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127701 CVCL_0K82 AG19594 transformed cell line human CVCL_0K82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127702 CVCL_0K85 AG19597 transformed cell line human CVCL_0K85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127703 CVCL_0K84 AG19596 transformed cell line human CVCL_0K84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127704 CVCL_0K87 AG19599 transformed cell line human CVCL_0K87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127705 CVCL_0K86 AG19598 transformed cell line human CVCL_0K86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127706 CVCL_0K89 AG19611 transformed cell line human CVCL_0K89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127707 CVCL_0K88 AG19600 transformed cell line human CVCL_0K88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127708 CVCL_0K79 AG19578 transformed cell line human CVCL_0K79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127709 CVCL_9E11 DD1135 transformed cell line human CVCL_9E11 CL:0000010 Karyotypic information: 47,XX,+mar(16) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127710 CVCL_9E10 DD1134 transformed cell line human CVCL_9E10 CL:0000010 Karyotypic information: 47,XX,+mar(14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127711 CVCL_9E28 DD1164 transformed cell line human CVCL_9E28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127712 CVCL_9E27 DD1163 finite cell line human CVCL_9E27 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21127713 CVCL_9E29 DD1165 transformed cell line human CVCL_9E29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127714 CVCL_0K90 AG19612 transformed cell line human CVCL_0K90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127715 CVCL_9E24 DD1159 transformed cell line human CVCL_9E24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127716 CVCL_9E23 DD1155 transformed cell line human CVCL_9E23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127717 CVCL_0K92 AG19627 transformed cell line human CVCL_0K92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127718 CVCL_9E26 DD1162 transformed cell line human CVCL_9E26 CL:0000010 Karyotypic information: 46,XX,t(11;22)(q23;q12)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127719 CVCL_0K91 AG19626 transformed cell line human CVCL_0K91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127720 CVCL_9E25 DD1160 transformed cell line human CVCL_9E25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127721 CVCL_0K94 AG19630 transformed cell line human CVCL_0K94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127722 CVCL_0K93 AG19628 transformed cell line human CVCL_0K93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127723 CVCL_0K96 AG19635 transformed cell line human CVCL_0K96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127724 CVCL_0K95 AG19631 transformed cell line human CVCL_0K95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127725 CVCL_0K98 AG19925 transformed cell line human CVCL_0K98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127726 CVCL_0K97 AG19636 transformed cell line human CVCL_0K97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127727 CVCL_0K99 AG19979 transformed cell line human CVCL_0K99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127728 CVCL_9E20 DD1151 transformed cell line human CVCL_9E20 CL:0000010 Karyotypic information: 46,XY,t(7;9)(q34.1;q24.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127729 CVCL_9E22 DD1154 transformed cell line human CVCL_9E22 CL:0000010 Karyotypic information: 46,XY,t(11;15)(q14.2;q26.3)(0?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127730 CVCL_9E21 DD1153 transformed cell line human CVCL_9E21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127731 CVCL_0K61 AG19488 transformed cell line human CVCL_0K61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127732 CVCL_0K60 AG19487 transformed cell line human CVCL_0K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127733 CVCL_0K63 AG19492 transformed cell line human CVCL_0K63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127734 CVCL_0K62 AG19489 transformed cell line human CVCL_0K62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127735 CVCL_0K65 AG19502 transformed cell line human CVCL_0K65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127736 CVCL_0K64 AG19501 transformed cell line human CVCL_0K64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127737 CVCL_0K67 AG19510 transformed cell line human CVCL_0K67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127738 CVCL_0K66 AG19509 transformed cell line human CVCL_0K66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127739 CVCL_0K58 AG19479 transformed cell line human CVCL_0K58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127740 CVCL_0K57 AG19477 transformed cell line human CVCL_0K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127741 CVCL_0K59 AG19486 transformed cell line human CVCL_0K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127742 CVCL_9E06 DD1118 finite cell line human CVCL_9E06 CL:0000010 Karyotypic information: 47,XXX (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21127743 CVCL_SQ99 HAP1 HDAC1 (-) 2 cancer cell line human CVCL_SQ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127744 CVCL_T299 RPMI-7865 cancer cell line human CVCL_T299 CL:0000010 Male 21127745 CVCL_9E05 DD1117 finite cell line human CVCL_9E05 CL:0000010 Karyotypic information: 46,XX,-9,+der(9),t(7:9)(q34.1;p24.1)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127746 CVCL_SQ98 HAP1 HDAC1 (-) 1 cancer cell line human CVCL_SQ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4852; HDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127747 CVCL_T298 RPMI-1695 cancer cell line human CVCL_T298 CL:0000010 Male 21127748 CVCL_9E08 DD1128 transformed cell line human CVCL_9E08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127749 CVCL_9E07 DD1123 finite cell line human CVCL_9E07 CL:0000010 Karyotypic information: 46,XX,del(18)(p11.2) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21127750 CVCL_9E02 DD1113 transformed cell line human CVCL_9E02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127751 CVCL_9E01 DD1112 transformed cell line human CVCL_9E01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127752 CVCL_0K70 AG19513 transformed cell line human CVCL_0K70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127753 CVCL_9E04 DD1116 transformed cell line human CVCL_9E04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127754 CVCL_9E03 DD1115 transformed cell line human CVCL_9E03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127755 CVCL_0K72 AG19527 transformed cell line human CVCL_0K72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127756 CVCL_0K71 AG19514 transformed cell line human CVCL_0K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127757 CVCL_0K74 AG19541 transformed cell line human CVCL_0K74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127758 CVCL_0K73 AG19528 transformed cell line human CVCL_0K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127759 CVCL_0K76 AG19575 transformed cell line human CVCL_0K76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127760 CVCL_0K75 AG19544 transformed cell line human CVCL_0K75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127761 CVCL_9E09 DD1129 transformed cell line human CVCL_9E09 CL:0000010 Karyotypic information: 46,XY,inv(3)(q21:q25)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127762 CVCL_0K78 AG19577 transformed cell line human CVCL_0K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127763 CVCL_0K77 AG19576 transformed cell line human CVCL_0K77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127764 CVCL_0K69 AG19512 transformed cell line human CVCL_0K69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127765 CVCL_0K68 AG19511 transformed cell line human CVCL_0K68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127766 CVCL_9E00 DD1110 transformed cell line human CVCL_9E00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127767 CVCL_SQ88 HAP1 HAGH (-) 2 cancer cell line human CVCL_SQ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4805; HAGH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127768 CVCL_T288 Rama 37-OPN cancer cell line Norway rat CVCL_T288 CL:0000010 Transfected with: RGD; 3752; Spp1 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21127769 CVCL_SQ87 HAP1 HAGH (-) 1 cancer cell line human CVCL_SQ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4805; HAGH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127770 CVCL_T287 Rama 800 cancer cell line Norway rat CVCL_T287 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21127771 CVCL_SQ89 HAP1 HARBI1 (-) cancer cell line human CVCL_SQ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26522; HARBI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127772 CVCL_T289 HPD-3NR cancer cell line CVCL_T289 CL:0000010 Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Female 21127773 CVCL_0K41 AG19364 transformed cell line human CVCL_0K41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127774 CVCL_0K40 AG19363 transformed cell line human CVCL_0K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127775 CVCL_0K43 AG19366 transformed cell line human CVCL_0K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127776 CVCL_0K42 AG19365 transformed cell line human CVCL_0K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127777 CVCL_0K45 AG19368 transformed cell line human CVCL_0K45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127778 CVCL_0K44 AG19367 transformed cell line human CVCL_0K44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127779 CVCL_0K36 AG19341 transformed cell line human CVCL_0K36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127780 CVCL_0K35 AG19340 transformed cell line human CVCL_0K35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127781 CVCL_0K38 AG19343 transformed cell line human CVCL_0K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127782 CVCL_0K37 AG19342 transformed cell line human CVCL_0K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127783 CVCL_0K39 AG19361 transformed cell line human CVCL_0K39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127784 CVCL_SQ91 HAP1 HAT1 (-) 2 cancer cell line human CVCL_SQ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4821; HAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127785 CVCL_T291 S12 [Human keratinocyte] transformed cell line human CVCL_T291 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21127786 CVCL_SQ90 HAP1 HAT1 (-) 1 cancer cell line human CVCL_SQ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4821; HAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127787 CVCL_T290 W12 [Human keratinocyte] transformed cell line human CVCL_T290 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Characteristics: Derived from a low-grade squamous intraepithelial lesion (LG-SIL); Virology: At early passages contains about 100 HPV16 episomes per cell 21127788 CVCL_T293 BOT-2 cancer cell line human CVCL_T293 CL:0000010 Derived from sampling site: Breast. Female Doubling time: 16-18 hours (PubMed=171063) 21127789 CVCL_SQ93 HAP1 HAX1 (-) 2 cancer cell line human CVCL_SQ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16915; HAX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127790 CVCL_SQ92 HAP1 HAX1 (-) 1 cancer cell line human CVCL_SQ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16915; HAX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127791 CVCL_T292 XH1 [Human cervical carcinoma] cancer cell line human CVCL_T292 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female 21127792 CVCL_SQ95 HAP1 HBEGF (-) 2 cancer cell line human CVCL_SQ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3059; HBEGF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127793 CVCL_T295 RPMI-3236 cancer cell line human CVCL_T295 CL:0000010 Unspecified Characteristics: Highly pigmented Doubling time: 44 hours (PubMed=1161259). 21127794 CVCL_SQ94 HAP1 HBEGF (-) 1 cancer cell line human CVCL_SQ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3059; HBEGF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127795 CVCL_T294 RPMI-5966 cancer cell line human CVCL_T294 CL:0000010 Unspecified Doubling time: 33 hours (PubMed=1127734); 48 hours (PubMed=1161259). 21127796 CVCL_SQ97 HAP1 HCK (-) 2 cancer cell line human CVCL_SQ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4840; HCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127797 CVCL_T297 RPMI-1694 cancer cell line human CVCL_T297 CL:0000010 Male 21127798 CVCL_SQ96 HAP1 HCK (-) 1 cancer cell line human CVCL_SQ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4840; HCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127799 CVCL_T296 RPMI-4445 cancer cell line human CVCL_T296 CL:0000010 Female Doubling time: 29 hours (PubMed=1127734); 50 hours (PubMed=1161259). 21127800 CVCL_SQ77 HAP1 H2AFZ (-) 1 cancer cell line human CVCL_SQ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4741; H2AZ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127801 CVCL_T277 MOPC-21 cancer cell line house mouse CVCL_T277 CL:0000010 Breed/subspecies: BALB/c. Female 21127802 CVCL_SQ76 HAP1 H2AFY (-) 1 cancer cell line human CVCL_SQ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4740; MACROH2A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127803 CVCL_T276 HEV0500 transformed cell line human CVCL_T276 HLA typing: A*02:01,02:07; B*15:01,46:01; C*01:02,03:03; DPB1*02:02,05:01; DQB1*03:03,06:01; DRB1*08:03,09:01 (RCB=HEV0500) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127804 CVCL_T279 FHs 738Bl finite cell line human CVCL_T279 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.226_278del53; Zygosity=Unspecified (PubMed=7787250) Derived from sampling site: Fetal urinary bladder Cell type=Fibroblast.. Discontinued: ATCC; HTB-160; true Male 21127805 CVCL_SQ79 HAP1 H2AFZ (-) 3 cancer cell line human CVCL_SQ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4741; H2AZ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127806 CVCL_SQ78 HAP1 H2AFZ (-) 2 cancer cell line human CVCL_SQ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4741; H2AZ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127807 CVCL_T278 P3K cancer cell line house mouse CVCL_T278 CL:0000010 Breed/subspecies: BALB/c. Female 21127808 CVCL_0K50 AG19422 transformed cell line human CVCL_0K50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127809 CVCL_0K52 AG19427 transformed cell line human CVCL_0K52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127810 CVCL_0K51 AG19426 transformed cell line human CVCL_0K51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: University of Georgia centenarian study 21127811 CVCL_0K54 AG19458 transformed cell line human CVCL_0K54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127812 CVCL_0K53 AG19442 transformed cell line human CVCL_0K53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127813 CVCL_0K56 AG19460 transformed cell line human CVCL_0K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127814 CVCL_0K55 AG19459 transformed cell line human CVCL_0K55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127815 CVCL_0K47 AG19388 transformed cell line human CVCL_0K47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127816 CVCL_0K46 AG19387 transformed cell line human CVCL_0K46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127817 CVCL_0K49 AG19405 transformed cell line human CVCL_0K49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127818 CVCL_0K48 AG19389 transformed cell line human CVCL_0K48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: University of Georgia centenarian study 21127819 CVCL_SQ80 HAP1 H3F3A (-) 1 cancer cell line human CVCL_SQ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4764; H3-3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127820 CVCL_T280 JDU finite cell line human CVCL_T280 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CCL-118; true Female 21127821 CVCL_SQ82 HAP1 H3F3A (-) 3 cancer cell line human CVCL_SQ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4764; H3-3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127822 CVCL_T282 TRK-1 transformed cell line CVCL_T282 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: New Zealand white. Discontinued: ATCC; CCL-143; probable Unspecified 21127823 CVCL_T281 Duck embryo spontaneously immortalized cell line CVCL_T281 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Virology: Highly susceptible to infection by aquatic bird bornavirus 1 (ABBV-1) strain UoG-CG (PubMed=32005267) Group: Bird cell line 21127824 CVCL_SQ81 HAP1 H3F3A (-) 2 cancer cell line human CVCL_SQ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4764; H3-3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127825 CVCL_SQ84 HAP1 H3F3B (-) 2 cancer cell line human CVCL_SQ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4765; H3-3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127826 CVCL_T284 SK-BR-2 III cancer cell line human CVCL_T284 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Ascites. Discontinued: ATCC; HTB-29; true Female 21127827 CVCL_SQ83 HAP1 H3F3B (-) 1 cancer cell line human CVCL_SQ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4765; H3-3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127828 CVCL_T283 SK-BR-1 III cancer cell line human CVCL_T283 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Pleural effusion. Discontinued: ATCC; HTB-28; true Female 21127829 CVCL_SQ86 HAP1 HADHA (-) 2 cancer cell line human CVCL_SQ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4801; HADHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127830 CVCL_T286 Rama 37 cancer cell line Norway rat CVCL_T286 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21127831 CVCL_SQ85 HAP1 HADHA (-) 1 cancer cell line human CVCL_SQ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4801; HADHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21127832 CVCL_T285 SK-ES-2 cancer cell line human CVCL_T285 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Discontinued: ATCC; HTB-87; probable. Female 21127833 CVCL_9E91 DD1276 transformed cell line human CVCL_9E91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127834 CVCL_9E90 DD1275 transformed cell line human CVCL_9E90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127835 CVCL_9E97 DD1287 transformed cell line human CVCL_9E97 CL:0000010 Karyotypic information: 47,XYY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127836 CVCL_9E96 DD1285 transformed cell line human CVCL_9E96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127837 CVCL_9E99 DD1289 transformed cell line human CVCL_9E99 CL:0000010 Karyotypic information: 46,X,der(X)t(X;11)(Xpter->Xq26.1::11p11.2-11pter) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127838 CVCL_9E98 DD1288 transformed cell line human CVCL_9E98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127839 CVCL_9E93 DD1282 transformed cell line human CVCL_9E93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127840 CVCL_9E92 DD1277 transformed cell line human CVCL_9E92 CL:0000010 Karyotypic information: 46,XX,t(3;10)(p23;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127841 CVCL_9E95 DD1284 transformed cell line human CVCL_9E95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127842 CVCL_9E94 DD1283 transformed cell line human CVCL_9E94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127843 CVCL_9E79 DD1256 transformed cell line human CVCL_9E79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127844 CVCL_9E78 DD1255 transformed cell line human CVCL_9E78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127845 CVCL_9E75 DD1252 transformed cell line human CVCL_9E75 CL:0000010 Karyotypic information: 47,XY,+mar(15)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127846 CVCL_9E74 DD1251 transformed cell line human CVCL_9E74 CL:0000010 Karyotypic information: 47,XX,+dic(15)(pter->q11::q11->pter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127847 CVCL_9E77 DD1254 transformed cell line human CVCL_9E77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127848 CVCL_9E76 DD1253 transformed cell line human CVCL_9E76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127849 CVCL_9E71 DD1247 finite cell line human CVCL_9E71 CL:0000010 Karyotypic information: 47,XX,+22 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21127850 CVCL_9E70 DD1244 transformed cell line human CVCL_9E70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127851 CVCL_9E73 DD1250 transformed cell line human CVCL_9E73 CL:0000010 Karyotypic information: 46,XX; 47,XX,+mar(4) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127852 CVCL_9E72 DD1249 transformed cell line human CVCL_9E72 CL:0000010 Karyotypic information: 46,XX [17]; 47,XX,+mar(4) [39] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127853 CVCL_9E89 DD1272 transformed cell line human CVCL_9E89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127854 CVCL_9E80 DD1257 transformed cell line human CVCL_9E80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127855 CVCL_9E86 DD1266 transformed cell line human CVCL_9E86 CL:0000010 Karyotypic information: 46,XY,t(6;10)(q21.1;q22.1)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127856 CVCL_9E85 DD1265 transformed cell line human CVCL_9E85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127857 CVCL_9E88 DD1271 transformed cell line human CVCL_9E88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127858 CVCL_9E87 DD1270 transformed cell line human CVCL_9E87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127859 CVCL_9E82 DD1259 transformed cell line human CVCL_9E82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127860 CVCL_9E81 DD1258 transformed cell line human CVCL_9E81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127861 CVCL_9E84 DD1261 transformed cell line human CVCL_9E84 CL:0000010 Karyotypic information: 46,XX [13]; 47,XX,+r(6) [37] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127862 CVCL_9E83 DD1260 transformed cell line human CVCL_9E83 CL:0000010 Karyotypic information: 46,XX,t(11;13)(q21;p13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127863 CVCL_9E57 DD1222 transformed cell line human CVCL_9E57 CL:0000010 Karyotypic information: 46,XY,19q+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127864 CVCL_9E56 DD1219 finite cell line human CVCL_9E56 CL:0000010 Karyotypic information: 46,XX,t(2;5)(p21;p13)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21127865 CVCL_9E59 DD1225 transformed cell line human CVCL_9E59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127866 CVCL_9E58 DD1224 transformed cell line human CVCL_9E58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127867 CVCL_9E53 DD1216 transformed cell line human CVCL_9E53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127868 CVCL_9E52 DD1215 transformed cell line human CVCL_9E52 CL:0000010 Karyotypic information: 46,XY,t(3;9)(?q13.32;p13)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127869 CVCL_9E55 DD1218 transformed cell line human CVCL_9E55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127870 CVCL_9E54 DD1217 transformed cell line human CVCL_9E54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127871 CVCL_9E51 DD1214 transformed cell line human CVCL_9E51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127872 CVCL_9E50 DD1211 finite cell line human CVCL_9E50 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21127873 CVCL_9E68 DD1237 transformed cell line human CVCL_9E68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127874 CVCL_9E67 DD1236 transformed cell line human CVCL_9E67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127875 CVCL_9E69 DD1243 transformed cell line human CVCL_9E69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127876 CVCL_9E64 DD1230 transformed cell line human CVCL_9E64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127877 CVCL_9E63 DD1229 transformed cell line human CVCL_9E63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127878 CVCL_9E66 DD1233 transformed cell line human CVCL_9E66 CL:0000010 Karyotypic information: 46,XX+mar(14)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127879 CVCL_9E65 DD1232 transformed cell line human CVCL_9E65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127880 CVCL_9E60 DD1226 transformed cell line human CVCL_9E60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21127881 CVCL_9E62 DD1228 finite cell line human CVCL_9E62 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21127882 CVCL_9E61 DD1227 transformed cell line human CVCL_9E61 CL:0000010 Karyotypic information: 46,XY; 47,XY,+dic(15) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21127883 CVCL_AW00 GM14179 finite cell line human CVCL_AW00 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21127884 CVCL_B800 RG-96 embryonic stem cell human CVCL_B800 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21127885 CVCL_AW02 R7T1 conditionally immortalized cell line house mouse CVCL_AW02 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; Breed/subspecies: RIP7-rtTA x tetTAG transgenic. Characteristics: Undergoes growth arrest within 6 days of transfer to culture in the absence of doxycycline (PubMed=11714200) 21127886 CVCL_B802 RG-98 embryonic stem cell human CVCL_B802 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21127887 CVCL_AW01 BN/MSV cancer cell line Norway rat CVCL_AW01 CL:0000010 Transformant: MSV; Breed/subspecies: Brown Norway. 21127888 CVCL_B801 RG-97 embryonic stem cell human CVCL_B801 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21127889 CVCL_B804 RG-421 embryonic stem cell human CVCL_B804 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21127890 CVCL_AW04 SOCS3-/- ESC embryonic stem cell house mouse CVCL_AW04 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1201791; Socs3 Omics: Transcriptome analysis by microarray. Unspecified 21127891 CVCL_AW03 m-ICcl2 transformed cell line house mouse CVCL_AW03 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic small intestine; ileum; intestinal crypt Cell type=Epithelial cell.; Breed/subspecies: (C57BL/6 x DBA) L-PK/TAg1 transgenic. Unspecified 21127892 CVCL_B803 RG-99 embryonic stem cell human CVCL_B803 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21127893 CVCL_AW06 Dicer -/- line 27H10 embryonic stem cell house mouse CVCL_AW06 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2177178; Dicer. Unspecified 21127894 CVCL_B806 RG-323 embryonic stem cell human CVCL_B806 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21127895 CVCL_AW05 Dicer +/- line D4 embryonic stem cell house mouse CVCL_AW05 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2177178; Dicer. Unspecified 21127896 CVCL_B805 RG-317 embryonic stem cell human CVCL_B805 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21127897 CVCL_0D82 GM00212 finite cell line human CVCL_0D82 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127898 CVCL_0D81 WG1681 finite cell line human CVCL_0D81 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly623Arg (c.1867G>A); ClinVar=VCV000001884; Zygosity=Heterozygous (PubMed=7909321; PubMed=16281286); Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Gly703Arg (c.2107G>C); ClinVar=VCV000001885; Zygosity=Heterozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21127899 CVCL_0D84 GM01673 finite cell line human CVCL_0D84 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21127900 CVCL_0D83 GM00424 finite cell line human CVCL_0D83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00424; probable Male 21127901 CVCL_0D86 JPX-9 cancer cell line human CVCL_0D86 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03409; Human T-cell leukemia virus 1 (HTLV-1) Tax; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21127902 CVCL_0D85 HSC 172 finite cell line human CVCL_0D85 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21127903 CVCL_0D88 RPE-28 finite cell line human CVCL_0D88 CL:0000010 Derived from sampling site: Fetal eye; retina; retinal pigment epithelium. Male 21127904 CVCL_0D87 RPE-18 SV2 transformed cell line human CVCL_0D87 CL:0000010 Transformant: Simian virus 40 (SV40) [Rh911](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal eye; retina; retinal pigment epithelium. Male 21127905 CVCL_0D89 RPE-28 SV4 transformed cell line human CVCL_0D89 CL:0000010 Transformant: Simian virus 40 (SV40) [Rh911](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal eye; retina; retinal pigment epithelium. Male 21127906 CVCL_0D80 CB59/MT2 transformed cell line human CVCL_0D80 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=Regulatory T-cell.. Male Virology: HTLV-1 producing cell line 21127907 CVCL_0D93 MCH046 finite cell line human CVCL_0D93 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127908 CVCL_0D92 MCH039 finite cell line human CVCL_0D92 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21127909 CVCL_0D95 AG02602 finite cell line human CVCL_0D95 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21127910 CVCL_0D94 RPE-30 finite cell line human CVCL_0D94 CL:0000010 Derived from sampling site: Fetal eye; retina; retinal pigment epithelium. Female 21127911 CVCL_0D97 AG02222 finite cell line human CVCL_0D97 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 21127912 CVCL_0D96 AG02603 finite cell line human CVCL_0D96 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21127913 CVCL_0D99 AG02262 finite cell line human CVCL_0D99 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21127914 CVCL_0D98 AG02261 finite cell line human CVCL_0D98 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 21127915 CVCL_0D91 MCH029 finite cell line human CVCL_0D91 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21127916 CVCL_0D90 MCH015 finite cell line human CVCL_0D90 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21127917 CVCL_0D60 NZM101 cancer cell line human CVCL_0D60 HLA typing: A*11:01,29:02; B*35:01,51:01; C*04:01,15:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21127918 CVCL_0D62 NZM103 cancer cell line human CVCL_0D62 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21127919 CVCL_0D61 NZM102 cancer cell line human CVCL_0D61 HLA typing: A*02:01,02:01; B*08:01,08:01; C*07:01,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21127920 CVCL_0D64 NZM105 cancer cell line human CVCL_0D64 CL:0000010 21127921 CVCL_0D63 NZM104 cancer cell line human CVCL_0D63 HLA typing: A*31:01,31:01; B*44:02,44:02; C*05:01,05:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21127922 CVCL_0D66 CMGD-2 cancer cell line dog CVCL_0D66 CL:0000010 Breed/subspecies: Mixed breed. Male Doubling time: ~24-48 hours (Kerafast) 21127923 CVCL_0D65 NZM106 cancer cell line human CVCL_0D65 CL:0000010 21127924 CVCL_0D68 CMGD-4 cancer cell line dog CVCL_0D68 CL:0000010 Derived from sampling site: Oral cavity; palate; Breed/subspecies: Mixed breed. Male 21127925 CVCL_0D67 CMGD-3 cancer cell line dog CVCL_0D67 CL:0000010 Breed/subspecies: Mixed breed. Female 21127926 CVCL_0D69 CMGD-5 cancer cell line dog CVCL_0D69 CL:0000010 Derived from sampling site: Oral cavity; palate; Breed/subspecies: Miniature Poodle. Male Doubling time: 24-48 hours (Kerafast) 21127927 CVCL_0D71 2A3 [Human squamous cell carcinoma] cancer cell line human CVCL_0D71 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line) Population: Indian; Derived from sampling site: Pharynx; hypopharynx. Male 21127928 CVCL_0D70 M [Dog melanoma] cancer cell line dog CVCL_0D70 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Boxer. Male Group: Patented cell line 21127929 CVCL_0D73 CII transformed cell line human CVCL_0D73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Doubling time: ~40-60 hours (DSMZ=ACC-773) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21127930 CVCL_0D72 L4.5 spontaneously immortalized cell line house mouse CVCL_0D72 CL:0000010 Transfected with: MGI; MGI:88337; Cd40lg Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: ~30-40 hours (DSMZ=ACC-772) 21127931 CVCL_0D75 ARL-15 finite cell line Norway rat CVCL_0D75 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21127932 CVCL_0D74 MC3T3 spontaneously immortalized cell line house mouse CVCL_0D74 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified 21127933 CVCL_0D77 ARL-15C1 finite cell line Norway rat CVCL_0D77 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21127934 CVCL_0D76 ARL-16 finite cell line Norway rat CVCL_0D76 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21127935 CVCL_0D79 CB58/MT2 transformed cell line human CVCL_0D79 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=Regulatory T-cell.. Male 21127936 CVCL_0D78 ARL-16T2 transformed cell line Norway rat CVCL_0D78 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21127937 CVCL_AW77 GM02453 finite cell line human CVCL_AW77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21127938 CVCL_B877 NYUES11 embryonic stem cell human CVCL_B877 From: New York University School of Medicine; New York; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0236. 21127939 CVCL_AW76 GM01674 finite cell line human CVCL_AW76 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21127940 CVCL_B876 NYUES10 embryonic stem cell human CVCL_B876 From: New York University School of Medicine; New York; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0240. 21127941 CVCL_AW79 GM20293 transformed cell line human CVCL_AW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127942 CVCL_B879 NYUES8 embryonic stem cell human CVCL_B879 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0238. 21127943 CVCL_AW78 GM10011 finite cell line human CVCL_AW78 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21127944 CVCL_B878 NYUES12 embryonic stem cell human CVCL_B878 From: New York University School of Medicine; New York; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0235. 21127945 CVCL_B871 NYUES3 embryonic stem cell human CVCL_B871 From: New York University School of Medicine; New York; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0047. 21127946 CVCL_AW70 GM04516 finite cell line human CVCL_AW70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21127947 CVCL_B870 NYUES2 embryonic stem cell human CVCL_B870 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0046. 21127948 CVCL_K207 CL3 [Mouse hybridoma against human SELE] hybridoma house mouse CVCL_K207 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. 21127949 CVCL_AW73 GM00596 finite cell line human CVCL_AW73 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21127950 CVCL_JQ07 HPSI1013i-wopl_3 induced pluripotent stem cell human CVCL_JQ07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127951 CVCL_B873 NYUES5 embryonic stem cell human CVCL_B873 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0049. 21127952 CVCL_K206 CL2 [Mouse hybridoma against human SELE] hybridoma house mouse CVCL_K206 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. 21127953 CVCL_AW72 GM00595 finite cell line human CVCL_AW72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21127954 CVCL_JQ06 HPSI1013i-wopl_2 induced pluripotent stem cell human CVCL_JQ06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127955 CVCL_B872 NYUES4 embryonic stem cell human CVCL_B872 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0048. 21127956 CVCL_K209 F19 hybridoma house mouse CVCL_K209 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human F19 antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8269 21127957 CVCL_AW75 GM00930 finite cell line human CVCL_AW75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00930; probable Female 21127958 CVCL_JQ09 HPSI1013i-yemz_2 induced pluripotent stem cell human CVCL_JQ09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127959 CVCL_B875 NYUES7 embryonic stem cell human CVCL_B875 From: New York University School of Medicine; New York; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0051. 21127960 CVCL_K208 CL37 hybridoma house mouse CVCL_K208 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. 21127961 CVCL_AW74 GM00876 finite cell line human CVCL_AW74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21127962 CVCL_JQ08 HPSI1013i-wuye_1 induced pluripotent stem cell human CVCL_JQ08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21127963 CVCL_B874 NYUES6 embryonic stem cell human CVCL_B874 From: New York University School of Medicine; New York; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0050. 21127964 CVCL_K203 CH-EB6 hybridoma house mouse CVCL_K203 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human IgA. 21127965 CVCL_JQ03 HPSI1013i-pamv_2 induced pluripotent stem cell human CVCL_JQ03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127966 CVCL_K202 AFRC MAC 257 hybridoma CVCL_K202 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13689; Maize auxin-binding protein 1 (ABP1). 21127967 CVCL_JQ02 HPSI1013i-jufd_1 induced pluripotent stem cell human CVCL_JQ02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127968 CVCL_K205 CL18/6 hybridoma house mouse CVCL_K205 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33729; Dog ICAM1/CD54. 21127969 CVCL_JQ05 HPSI1013i-woci_3 induced pluripotent stem cell human CVCL_JQ05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21127970 CVCL_K204 CL18/1D8 hybridoma house mouse CVCL_K204 CL:0000010 Discontinued: ATCC; CRL-2517; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33729; Dog ICAM1/CD54 21127971 CVCL_JQ04 HPSI1013i-sebz_3 induced pluripotent stem cell human CVCL_JQ04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21127972 CVCL_K201 AFRC MAC 25 hybridoma Norway rat CVCL_K201 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Rabbit low density lipoprotein (LDL). 21127973 CVCL_JQ01 HPSI1013i-jogf_3 induced pluripotent stem cell human CVCL_JQ01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127974 CVCL_K200 AFRC MAC 24 hybridoma Norway rat CVCL_K200 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Rabbit low density lipoprotein (LDL). 21127975 CVCL_JQ00 HPSI1013i-hiaf_3 induced pluripotent stem cell human CVCL_JQ00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127976 CVCL_B888 GENEA080 embryonic stem cell human CVCL_B888 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA078 (Cellosaurus=CVCL_B886) and GENEA079 (Cellosaurus=CVCL_B887). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0254; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21127977 CVCL_AW88 GM07547 transformed cell line human CVCL_AW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127978 CVCL_B887 GENEA079 embryonic stem cell human CVCL_B887 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to those giving rise to GENEA078 (Cellosaurus=CVCL_B886) and GENEA080 (Cellosaurus=CVCL_B888). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0253; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21127979 CVCL_AW87 GM07270 finite cell line human CVCL_AW87 CL:0000010 Population: Caucasian; Belgian; Derived from sampling site: Cell type=Fibroblast. Male 21127980 CVCL_B889 GENEA081 embryonic stem cell human CVCL_B889 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0255; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21127981 CVCL_AW89 GM08739 transformed cell line human CVCL_AW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127982 CVCL_AW80 GM06065 transformed cell line human CVCL_AW80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127983 CVCL_B880 NYUES9 embryonic stem cell human CVCL_B880 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0239. 21127984 CVCL_B882 CU2 embryonic stem cell human CVCL_B882 From: Columbia University; New York; USA. CL:0000010 Female 21127985 CVCL_AW82 GM06068 transformed cell line human CVCL_AW82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21127986 CVCL_B881 CU1 embryonic stem cell human CVCL_B881 From: Columbia University; New York; USA. CL:0000010 Female 21127987 CVCL_AW81 GM06066 transformed cell line human CVCL_AW81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127988 CVCL_B884 GENEA076 embryonic stem cell human CVCL_B884 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-64.. 21127989 CVCL_AW84 GM06073 finite cell line human CVCL_AW84 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21127990 CVCL_JQ18 HPSI1113i-hajc_2 induced pluripotent stem cell human CVCL_JQ18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21127991 CVCL_K218 L5 hybridoma house mouse CVCL_K218 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human non-small cell lung carcinomas. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8627 21127992 CVCL_B883 GENEA075 embryonic stem cell human CVCL_B883 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-64.. 21127993 CVCL_AW83 GM06071 finite cell line human CVCL_AW83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21127994 CVCL_JQ17 HPSI1113i-fumb_3 induced pluripotent stem cell human CVCL_JQ17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21127995 CVCL_K217 L3 [Mouse hybridoma] hybridoma house mouse CVCL_K217 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human non-small cell lung carcinomas. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8626 21127996 CVCL_B886 GENEA078 embryonic stem cell human CVCL_B886 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.15110dupA; Zygosity=Heterozygous (PubMed=27346006); Sequence variation: Mutation; HGNC; 7720; NEB; Unexplicit; Ex55del; Zygosity=Heterozygous (PubMed=27346006) Donor information: Embryo is sibling to those giving rise to GENEA079 (Cellosaurus=CVCL_B887) and GENEA080 (Cellosaurus=CVCL_B888). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0252; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21127997 CVCL_AW86 GM06119 transformed cell line human CVCL_AW86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21127998 CVCL_B885 GENEA077 embryonic stem cell human CVCL_B885 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0261; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-55.. 21127999 CVCL_AW85 GM06087 transformed cell line human CVCL_AW85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128000 CVCL_JQ19 HPSI1113i-hajc_3 induced pluripotent stem cell human CVCL_JQ19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128001 CVCL_K219 LB 27.4 hybridoma house mouse CVCL_K219 CL:0000010 Monoclonal antibody isotype: Not specified. 21128002 CVCL_K214 G2a.5 hybridoma house mouse CVCL_K214 CL:0000010 Monoclonal antibody isotype: IgG2a. 21128003 CVCL_JQ14 HPSI1113i-dons_3 induced pluripotent stem cell human CVCL_JQ14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128004 CVCL_K213 G253 hybridoma house mouse CVCL_K213 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P50895; Human BCAM/CD239. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9207; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9706 21128005 CVCL_JQ13 HPSI1113i-dons_2 induced pluripotent stem cell human CVCL_JQ13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128006 CVCL_K216 Genox 3.53 hybridoma house mouse CVCL_K216 CL:0000010 Monoclonal antibody isotype: IgG1. 21128007 CVCL_JQ16 HPSI1113i-eofe_3 induced pluripotent stem cell human CVCL_JQ16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128008 CVCL_K215 G2b.2 hybridoma house mouse CVCL_K215 CL:0000010 Monoclonal antibody isotype: IgG2b. 21128009 CVCL_JQ15 HPSI1113i-eofe_2 induced pluripotent stem cell human CVCL_JQ15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128010 CVCL_K210 F24 hybridoma house mouse CVCL_K210 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9527 21128011 CVCL_JQ10 HPSI1014i-boss_2 induced pluripotent stem cell human CVCL_JQ10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128012 CVCL_K212 G171 hybridoma house mouse CVCL_K212 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9254 21128013 CVCL_JQ12 HPSI1113i-bima_3 induced pluripotent stem cell human CVCL_JQ12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128014 CVCL_K211 FIGR hybridoma house mouse CVCL_K211 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06536; Rat Nr3c1/Grl (Note=Also reacts with mouse but not with human). 21128015 CVCL_JQ11 HPSI1014i-toss_1 induced pluripotent stem cell human CVCL_JQ11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128016 CVCL_B855 ESI-027 embryonic stem cell human CVCL_B855 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA.. CL:0000010 Female 21128017 CVCL_AW55 GM04647 finite cell line human CVCL_AW55 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128018 CVCL_B854 ESI-017 embryonic stem cell human CVCL_B854 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Donor information: Embryo is sibling to that giving rise to ESI-014 (Cellosaurus=CVCL_B853). Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0093 21128019 CVCL_AW54 GM04573 finite cell line human CVCL_AW54 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128020 CVCL_B857 ESI-049 embryonic stem cell human CVCL_B857 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0130 21128021 CVCL_AW57 GM05142 finite cell line human CVCL_AW57 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128022 CVCL_B856 ESI-035 embryonic stem cell human CVCL_B856 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Gly (c.817C>G); ClinVar=VCV000634682; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0129; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-01. 21128023 CVCL_AW56 GM04648 transformed cell line human CVCL_AW56 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (PubMed=32656337) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21128024 CVCL_B859 ESI-053 embryonic stem cell human CVCL_B859 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Donor information: Embryo is sibling to that giving rise to ESI-051 (Cellosaurus=CVCL_B858). Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0132 21128025 CVCL_AW59 GM05152 transformed cell line human CVCL_AW59 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21128026 CVCL_B858 ESI-051 embryonic stem cell human CVCL_B858 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Donor information: Embryo is sibling to that giving rise to ESI-053 (Cellosaurus=CVCL_B859). Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0131 21128027 CVCL_AW58 GM05151 finite cell line human CVCL_AW58 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128028 CVCL_B851 Cyth25 embryonic stem cell human CVCL_B851 From: ViaCyte, Inc (originally from CyThera, Novocell); San Diego; USA.. CL:0000010 Unspecified 21128029 CVCL_AW51 GM14172 transformed cell line human CVCL_AW51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128030 CVCL_B850 CyT49 embryonic stem cell human CVCL_B850 From: ViaCyte, Inc (originally from CyThera, Novocell); San Diego; USA. CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0041 21128031 CVCL_AW50 GM14137 transformed cell line human CVCL_AW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128032 CVCL_B853 ESI-014 embryonic stem cell human CVCL_B853 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Donor information: Embryo is sibling to that giving rise to ESI-017 (Cellosaurus=CVCL_B854). Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0092 21128033 CVCL_AW53 GM04567 transformed cell line human CVCL_AW53 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21128034 CVCL_B852 ESI-013 embryonic stem cell human CVCL_B852 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA.. CL:0000010 Female 21128035 CVCL_AW52 GM14173 transformed cell line human CVCL_AW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128036 CVCL_AW66 GM05213 finite cell line human CVCL_AW66 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500-1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128037 CVCL_B866 SCSe004-A embryonic stem cell human CVCL_B866 From: Monash University; Melbourne; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0142; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-21. 21128038 CVCL_AW65 GM05212 transformed cell line human CVCL_AW65 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500-1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128039 CVCL_B865 SCSe003-A embryonic stem cell human CVCL_B865 From: Monash University; Melbourne; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0141; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-21. 21128040 CVCL_AW68 GM05404 finite cell line human CVCL_AW68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128041 CVCL_B868 MFS5 embryonic stem cell human CVCL_B868 From: Stanford University; Stanford; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0052. 21128042 CVCL_AW67 GM05281 finite cell line human CVCL_AW67 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128043 CVCL_B867 IMHe007-A embryonic stem cell human CVCL_B867 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21128044 CVCL_AW69 GM04515 transformed cell line human CVCL_AW69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128045 CVCL_B869 NYUES1 embryonic stem cell human CVCL_B869 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0045. 21128046 CVCL_AW60 GM05163 finite cell line human CVCL_AW60 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~340] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128047 CVCL_B860 HAD-C 100 embryonic stem cell human CVCL_B860 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0123. 21128048 CVCL_AW62 GM05208 finite cell line human CVCL_AW62 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128049 CVCL_B862 HAD-C 106 embryonic stem cell human CVCL_B862 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0125. 21128050 CVCL_AW61 GM05164 transformed cell line human CVCL_AW61 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~340] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21128051 CVCL_B861 HAD-C 102 embryonic stem cell human CVCL_B861 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Male Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0124. 21128052 CVCL_AW64 GM05211 finite cell line human CVCL_AW64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21128053 CVCL_B864 SCSe002-A embryonic stem cell human CVCL_B864 From: Monash University; Melbourne; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis Discontinued: Millipore; SCC021; true. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0140; Registration: Swiss research registry; BAG-hES-IMP-0002; Registration: UK Stem Cell Bank (UKSCB); R-08-004, Steering comm appl. SCSC06-22. 21128054 CVCL_AW63 GM05209 finite cell line human CVCL_AW63 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128055 CVCL_B863 SCSe001-A embryonic stem cell human CVCL_B863 From: Monash University; Melbourne; Australia CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: Millipore; SCC020; true. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0139; Registration: Swiss research registry; BAG-hES-IMP-0003; Registration: UK Stem Cell Bank (UKSCB); R-08-001, Steering comm appl. SCSC04-30. 21128056 CVCL_B833 CSES22 embryonic stem cell human CVCL_B833 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0119 21128057 CVCL_AW33 K562 eGFP-KLF13 cancer cell line human CVCL_AW33 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13672; KLF13; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128058 CVCL_B832 CSES21 embryonic stem cell human CVCL_B832 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0118 21128059 CVCL_AW32 K562 eGFP-KLF1 cancer cell line human CVCL_AW32 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128060 CVCL_B835 CSES24 embryonic stem cell human CVCL_B835 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0121. 21128061 CVCL_AW35 K562 eGFP-NFE2L1 cancer cell line human CVCL_AW35 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7781; NFE2L1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128062 CVCL_B834 CSES23 embryonic stem cell human CVCL_B834 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0120. 21128063 CVCL_AW34 K562 eGFP-MAFG cancer cell line human CVCL_AW34 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6781; MAFG; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128064 CVCL_AW37 K562 eGFP-NR4A1 cancer cell line human CVCL_AW37 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7980; NR4A1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128065 CVCL_B837 UM11-1 PGD embryonic stem cell human CVCL_B837 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0153. 21128066 CVCL_B836 CSES25 embryonic stem cell human CVCL_B836 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0122 21128067 CVCL_AW36 K562 eGFP-NR2C1 cancer cell line human CVCL_AW36 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7971; NR2C1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128068 CVCL_AW39 K562 eGFP-PTTG1 cancer cell line human CVCL_AW39 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9690; PTTG1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128069 CVCL_B839 UM38-2 PGD embryonic stem cell human CVCL_B839 From: University of Michigan; Ann Arbor; USA CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Unexplicit; Not described; Zygosity=Unspecified (NIH). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0155 21128070 CVCL_AW38 K562 eGFP-PTRF cancer cell line human CVCL_AW38 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9688; CAVIN1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128071 CVCL_B838 UM15-4 PGD embryonic stem cell human CVCL_B838 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0161. 21128072 CVCL_B831 CSES20 embryonic stem cell human CVCL_B831 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0117 21128073 CVCL_AW31 K562 eGFP-JUND cancer cell line human CVCL_AW31 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6206; JUND; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128074 CVCL_B830 CSES19 embryonic stem cell human CVCL_B830 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0116. 21128075 CVCL_AW30 K562 eGFP-JUNB cancer cell line human CVCL_AW30 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6205; JUNB; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128076 CVCL_B829 CSES18 embryonic stem cell human CVCL_B829 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0135. 21128077 CVCL_AW29 K562 eGFP-IRF9 cancer cell line human CVCL_AW29 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6131; IRF9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128078 CVCL_AW44 K562 eGFP-TAF7 cancer cell line human CVCL_AW44 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11541; TAF7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128079 CVCL_B844 MSHRIe001-A embryonic stem cell human CVCL_B844 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0137; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-28.. 21128080 CVCL_B843 BJNhem20 embryonic stem cell human CVCL_B843 From: Jawaharlal Nehru Centre for Advanced Scientific Research; Jakkur; India CL:0000010 Population: Indian; Donor information: Embryo is sibling to that giving rise to BJNhem19 (Cellosaurus=CVCL_B842). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0084; Registration: UK Stem Cell Bank (UKSCB); R-08-021, Steering comm appl. SCSC07-43(2). 21128081 CVCL_AW43 K562 eGFP-SMARCA2 cancer cell line human CVCL_AW43 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11098; SMARCA2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128082 CVCL_B846 CT-1 [Human ESC] embryonic stem cell human CVCL_B846 From: University of Connecticut Health Center; Farmington; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0068 21128083 CVCL_AW46 K562 eGFP-TSC22D4 cancer cell line human CVCL_AW46 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 21696; TSC22D4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128084 CVCL_AW45 K562 eGFP-TEAD2 cancer cell line human CVCL_AW45 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11715; TEAD2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128085 CVCL_B845 MSHRIe002-A embryonic stem cell human CVCL_B845 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0138; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC05-28.. 21128086 CVCL_B848 CT-3 [Human ESC] embryonic stem cell human CVCL_B848 From: University of Connecticut Health Center; Farmington; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0070 21128087 CVCL_AW48 K562 eGFP-ZSCAN9 cancer cell line human CVCL_AW48 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12984; ZSCAN9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128088 CVCL_B847 CT-2 embryonic stem cell human CVCL_B847 From: University of Connecticut Health Center; Farmington; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0069 21128089 CVCL_AW47 K562 eGFP-ZNF24 cancer cell line human CVCL_AW47 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13032; ZNF24; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128090 CVCL_B849 CT-4 embryonic stem cell human CVCL_B849 From: University of Connecticut Health Center; Farmington; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0071 21128091 CVCL_AW49 GM13486 transformed cell line human CVCL_AW49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128092 CVCL_AW40 K562 eGFP-PYGO2 cancer cell line human CVCL_AW40 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 30257; PYGO2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128093 CVCL_B840 UM4-6 embryonic stem cell human CVCL_B840 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM4-9 (Cellosaurus=CVCL_5H77), UM4-11 (Cellosaurus=CVCL_5H75), UM4-12 (Cellosaurus=CVCL_5H76) and UM4-13 (Cellosaurus=CVCL_WW08). Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0147 21128094 CVCL_B842 BJNhem19 embryonic stem cell human CVCL_B842 From: Jawaharlal Nehru Centre for Advanced Scientific Research; Jakkur; India CL:0000010 Population: Indian; Donor information: Embryo is sibling to that giving rise to BJNhem20 (Cellosaurus=CVCL_B843). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0083; Registration: UK Stem Cell Bank (UKSCB); R-08-022, Steering comm appl. SCSC07-43(1). 21128095 CVCL_AW42 K562 eGFP-SMARCA1 cancer cell line human CVCL_AW42 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11097; SMARCA1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128096 CVCL_AW41 K562 eGFP-RELA cancer cell line human CVCL_AW41 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9955; RELA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128097 CVCL_B841 UM9-1 PGD embryonic stem cell human CVCL_B841 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0154. 21128098 CVCL_AW11 alphaTN6 transformed cell line house mouse CVCL_AW11 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 21128099 CVCL_B811 RUES3 embryonic stem cell human CVCL_B811 From: Rockefeller University; New York; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0042. 21128100 CVCL_AW10 alpha T2 line 6 transformed cell line house mouse CVCL_AW10 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 21128101 CVCL_B810 RUES2 embryonic stem cell human CVCL_B810 From: Rockefeller University; New York; USA CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0013; Registration: Swiss research registry; BAG-hES-IMP-0057 21128102 CVCL_B813 CSES2 embryonic stem cell human CVCL_B813 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0106; Registration: Swiss research registry; BAG-hES-IMP-0049 21128103 CVCL_AW13 K562 eGFP-ATF1 cancer cell line human CVCL_AW13 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 783; ATF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21128104 CVCL_AW12 B3180 transformed cell line human CVCL_AW12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21128105 CVCL_B812 CSES1 embryonic stem cell human CVCL_B812 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21128106 CVCL_B815 CSES4 embryonic stem cell human CVCL_B815 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0107 21128107 CVCL_AW15 K562 eGFP-CEBPB cancer cell line human CVCL_AW15 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1834; CEBPB; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21128108 CVCL_B814 CSES3 embryonic stem cell human CVCL_B814 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21128109 CVCL_AW14 K562 eGFP-BACH1 cancer cell line human CVCL_AW14 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 935; BACH1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: ChIP-seq epigenome analysis Female 21128110 CVCL_B817 CSES6 embryonic stem cell human CVCL_B817 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0134 21128111 CVCL_AW17 K562 eGFP-DDX20 cancer cell line human CVCL_AW17 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2743; DDX20; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128112 CVCL_B816 CSES5 embryonic stem cell human CVCL_B816 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0133. 21128113 CVCL_AW16 K562 eGFP-CREB3 cancer cell line human CVCL_AW16 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2347; CREB3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128114 CVCL_AW08 alphaTN4 transformed cell line house mouse CVCL_AW08 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 21128115 CVCL_B808 RG-TL embryonic stem cell human CVCL_B808 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128116 CVCL_B807 RG-324 embryonic stem cell human CVCL_B807 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128117 CVCL_AW07 RL(B77) transformed cell line Norway rat CVCL_AW07 CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain Bratislava-77 (B77)](NCBI-Taxonomy; 11876); Derived from sampling site: Embryonic liver; Breed/subspecies: Sprague Dawley. Unspecified 21128118 CVCL_AW09 alpha T1 transformed cell line house mouse CVCL_AW09 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 21128119 CVCL_B809 RUES1 embryonic stem cell human CVCL_B809 From: Rockefeller University; New York; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0012 21128120 CVCL_B822 CSES11 embryonic stem cell human CVCL_B822 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0110. 21128121 CVCL_AW22 K562 eGFP-GATA2 cancer cell line human CVCL_AW22 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4171; GATA2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128122 CVCL_B821 CSES10 embryonic stem cell human CVCL_B821 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21128123 CVCL_AW21 K562 eGFP-FOS cancer cell line human CVCL_AW21 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128124 CVCL_B824 CSES13 embryonic stem cell human CVCL_B824 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0112 21128125 CVCL_AW24 K562 eGFP-HINFP cancer cell line human CVCL_AW24 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 17850; HINFP; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128126 CVCL_B823 CSES12 embryonic stem cell human CVCL_B823 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0111 21128127 CVCL_AW23 K562 eGFP-HDAC8 cancer cell line human CVCL_AW23 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 13315; HDAC8; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128128 CVCL_B826 CSES15 embryonic stem cell human CVCL_B826 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0114 21128129 CVCL_AW26 K562 eGFP-ID3 cancer cell line human CVCL_AW26 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5362; ID3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128130 CVCL_B825 CSES14 embryonic stem cell human CVCL_B825 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0113. 21128131 CVCL_AW25 K562 eGFP-HMGB1 cancer cell line human CVCL_AW25 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4983; HMGB1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128132 CVCL_B828 CSES17 embryonic stem cell human CVCL_B828 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0115. 21128133 CVCL_AW28 K562 eGFP-IRF1 cancer cell line human CVCL_AW28 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6116; IRF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128134 CVCL_B827 CSES16 embryonic stem cell human CVCL_B827 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21128135 CVCL_AW27 K562 eGFP-ILK cancer cell line human CVCL_AW27 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6040; ILK; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128136 CVCL_B820 CSES9 embryonic stem cell human CVCL_B820 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21128137 CVCL_AW20 K562 eGFP-ETV1 cancer cell line human CVCL_AW20 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3490; ETV1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128138 CVCL_B819 CSES8 embryonic stem cell human CVCL_B819 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0109. 21128139 CVCL_AW19 K562 eGFP-E2F1 cancer cell line human CVCL_AW19 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3113; E2F1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128140 CVCL_B818 CSES7 embryonic stem cell human CVCL_B818 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0108 21128141 CVCL_AW18 K562 eGFP-DIDO1 cancer cell line human CVCL_AW18 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2680; DIDO1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21128142 CVCL_SJ07 HAP1 CIC (-) 3 cancer cell line human CVCL_SJ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14214; CIC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128143 CVCL_SJ06 HAP1 CIC (-) 2 cancer cell line human CVCL_SJ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14214; CIC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128144 CVCL_SJ09 HAP1 CISD2 (-) 1 cancer cell line human CVCL_SJ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24212; CISD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128145 CVCL_SJ08 HAP1 CIC (-) 4 cancer cell line human CVCL_SJ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14214; CIC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128146 CVCL_K169 EOC 9 factor-dependent cell line house mouse CVCL_K169 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21128147 CVCL_JP69 HPSI0813i-robp_2 induced pluripotent stem cell human CVCL_JP69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128148 CVCL_JP66 HPSI0813i-piun_2 induced pluripotent stem cell human CVCL_JP66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128149 CVCL_K166 L10.A 2J cancer cell line house mouse CVCL_K166 CL:0000010 Breed/subspecies: BALB/cAnN. 21128150 CVCL_JP65 HPSI0813i-piun_1 induced pluripotent stem cell human CVCL_JP65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128151 CVCL_K165 L10.A cancer cell line house mouse CVCL_K165 CL:0000010 Breed/subspecies: BALB/cAnN. Doubling time: 26 hours (PubMed=310843) 21128152 CVCL_K168 EOC 8 factor-dependent cell line house mouse CVCL_K168 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21128153 CVCL_JP68 HPSI0813i-raki_3 induced pluripotent stem cell human CVCL_JP68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128154 CVCL_K167 BALB/B CL.6 spontaneously immortalized cell line house mouse CVCL_K167 CL:0000010 Breed/subspecies: BALB.B. Unspecified 21128155 CVCL_JP67 HPSI0813i-raki_2 induced pluripotent stem cell human CVCL_JP67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128156 CVCL_SJ10 HAP1 CISD2 (-) 2 cancer cell line human CVCL_SJ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24212; CISD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128157 CVCL_JP62 HPSI0813i-iicq_2 induced pluripotent stem cell human CVCL_JP62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128158 CVCL_K162 NI 1 alpha 364/8C4-8 hybridoma house mouse CVCL_K162 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01583; Human IL1A. 21128159 CVCL_JP61 HPSI0813i-eiqh_2 induced pluripotent stem cell human CVCL_JP61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128160 CVCL_K161 NI 1 alpha 364/3B3-14 hybridoma house mouse CVCL_K161 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01583; Human IL1A. 21128161 CVCL_SJ12 HAP1 CKB (-) cancer cell line human CVCL_SJ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1991; CKB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128162 CVCL_JP64 HPSI0813i-meqo_1 induced pluripotent stem cell human CVCL_JP64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128163 CVCL_K164 sNF94.3 cancer cell line human CVCL_K164 CL:0000010 Derived from metastatic site: Lung Cell type=Schwann cell.. Female Doubling time: ~43 hours (ATCC=CRL-2886) 21128164 CVCL_SJ11 HAP1 CKAP4 (-) cancer cell line human CVCL_SJ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16991; CKAP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128165 CVCL_JP63 HPSI0813i-iill_2 induced pluripotent stem cell human CVCL_JP63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128166 CVCL_K163 K46 cancer cell line house mouse CVCL_K163 CL:0000010 Breed/subspecies: BALB/cAnN. Doubling time: 19 hours (PubMed=310843) 21128167 CVCL_SJ14 HAP1 CLASP1 (-) 2 cancer cell line human CVCL_SJ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17088; CLASP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128168 CVCL_SJ13 HAP1 CLASP1 (-) 1 cancer cell line human CVCL_SJ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17088; CLASP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128169 CVCL_K160 CAB 117-12D10 hybridoma house mouse CVCL_K160 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08709; Human F7. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10558 21128170 CVCL_SJ16 HAP1 CLCN2 (-) 2 cancer cell line human CVCL_SJ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2020; CLCN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128171 CVCL_JP60 HPSI0813i-eiqh_1 induced pluripotent stem cell human CVCL_JP60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128172 CVCL_SJ15 HAP1 CLCN2 (-) 1 cancer cell line human CVCL_SJ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2020; CLCN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128173 CVCL_JP77 HPSI0813i-zexw_2 induced pluripotent stem cell human CVCL_JP77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128174 CVCL_K177 MDCK-AD spontaneously immortalized cell line dog CVCL_K177 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21128175 CVCL_JP76 HPSI0813i-zexw_1 induced pluripotent stem cell human CVCL_JP76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128176 CVCL_K176 RDM-4 cancer cell line house mouse CVCL_K176 CL:0000010 21128177 CVCL_K179 AFRC MAC 10 hybridoma Norway rat CVCL_K179 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128178 CVCL_JP79 HPSI0913i-bulb_3 induced pluripotent stem cell human CVCL_JP79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128179 CVCL_K178 AFRC MAC 1 hybridoma Norway rat CVCL_K178 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128180 CVCL_JP78 HPSI0913i-bulb_2 induced pluripotent stem cell human CVCL_JP78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128181 CVCL_JP73 HPSI0813i-voas_3 induced pluripotent stem cell human CVCL_JP73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128182 CVCL_K173 Lec3.2.8.1 spontaneously immortalized cell line CVCL_K173 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Produces glycoproteins with high-mannose type glycans 21128183 CVCL_JP72 HPSI0813i-voas_1 induced pluripotent stem cell human CVCL_JP72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128184 CVCL_K172 HuZP3-CHOLec3.2.8.1 spontaneously immortalized cell line CVCL_K172 CL:0000010 Transfected with: HGNC; 13189; ZP3 Derived from sampling site: Ovary. Female 21128185 CVCL_SJ01 HAP1 CHRNB2 (-) 1 cancer cell line human CVCL_SJ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1962; CHRNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128186 CVCL_JP75 HPSI0813i-wots_2 induced pluripotent stem cell human CVCL_JP75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128187 CVCL_K175 LBRM-33 clone 5A4 cancer cell line house mouse CVCL_K175 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: B10.BR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8080 21128188 CVCL_SJ00 HAP1 CHRNA7 (-) cancer cell line human CVCL_SJ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1960; CHRNA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128189 CVCL_JP74 HPSI0813i-wots_1 induced pluripotent stem cell human CVCL_JP74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128190 CVCL_K174 LBRM-33 cancer cell line house mouse CVCL_K174 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: B10.BR. Characteristics: Produces IL2 in response to phytohemagglutinin (PHA) and concanavalin A (ConA) (PubMed=6975944) 21128191 CVCL_SJ03 HAP1 CHST10 (-) 1 cancer cell line human CVCL_SJ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19650; CHST10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128192 CVCL_SJ02 HAP1 CHRNB2 (-) 2 cancer cell line human CVCL_SJ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1962; CHRNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128193 CVCL_K171 GH364 cancer cell line human CVCL_K171 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CRL-13004; true Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3405 21128194 CVCL_SJ05 HAP1 CIC (-) 1 cancer cell line human CVCL_SJ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14214; CIC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128195 CVCL_JP71 HPSI0813i-vajx_1 induced pluripotent stem cell human CVCL_JP71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128196 CVCL_K170 FC4.K finite cell line CVCL_K170 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6076; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21128197 CVCL_SJ04 HAP1 CHUK (-) cancer cell line human CVCL_SJ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1974; CHUK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128198 CVCL_JP70 HPSI0813i-uaqe_2 induced pluripotent stem cell human CVCL_JP70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128199 CVCL_K148 AFRC MAC 54 hybridoma Norway rat CVCL_K148 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21128200 CVCL_JP48 HPSI0713i-tadm_1 induced pluripotent stem cell human CVCL_JP48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128201 CVCL_K147 AFRC MAC 52 hybridoma Norway rat CVCL_K147 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21128202 CVCL_JP47 HPSI0713i-ruyv_2 induced pluripotent stem cell human CVCL_JP47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128203 CVCL_K149 AFRC MAC 57 hybridoma Norway rat CVCL_K149 CL:0000010 Monoclonal antibody isotype: IgM. 21128204 CVCL_JP49 HPSI0713i-tadm_3 induced pluripotent stem cell human CVCL_JP49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128205 CVCL_JP44 HPSI0713i-ruyl_11 induced pluripotent stem cell human CVCL_JP44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128206 CVCL_K144 MATAG 12 hybridoma house mouse CVCL_K144 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9456 21128207 CVCL_K143 CC 92 hybridoma house mouse CVCL_K143 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9454 21128208 CVCL_JP43 HPSI0713i-ruyl_10 induced pluripotent stem cell human CVCL_JP43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128209 CVCL_K146 AFRC MAC 51 hybridoma Norway rat CVCL_K146 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21128210 CVCL_JP46 HPSI0713i-ruyl_3 induced pluripotent stem cell human CVCL_JP46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128211 CVCL_K145 AFRC MAC 50 hybridoma Norway rat CVCL_K145 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21128212 CVCL_JP45 HPSI0713i-ruyl_2 induced pluripotent stem cell human CVCL_JP45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128213 CVCL_K140 CC 46 hybridoma house mouse CVCL_K140 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9458 21128214 CVCL_JP40 HPSI0713i-pusf_2 induced pluripotent stem cell human CVCL_JP40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128215 CVCL_K142 CC 83 hybridoma house mouse CVCL_K142 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9453 21128216 CVCL_JP42 HPSI0713i-ruyl_1 induced pluripotent stem cell human CVCL_JP42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128217 CVCL_K141 CC 49 hybridoma house mouse CVCL_K141 CL:0000010 Biotechnology: Produces the monoclonal antibody minretumomab which has been used in phase 1 clinical trials for the treatment of various cancers Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9459 21128218 CVCL_JP41 HPSI0713i-qimz_3 induced pluripotent stem cell human CVCL_JP41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128219 CVCL_K159 AFRC MAC 9 hybridoma Norway rat CVCL_K159 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128220 CVCL_JP59 HPSI0813i-civh_2 induced pluripotent stem cell human CVCL_JP59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128221 CVCL_K158 AFRC MAC 8 hybridoma Norway rat CVCL_K158 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128222 CVCL_JP58 HPSI0813i-aizi_2 induced pluripotent stem cell human CVCL_JP58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128223 CVCL_K155 AFRC MAC 76 hybridoma Norway rat CVCL_K155 CL:0000010 Discontinued: ECACC; 85102261; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA 21128224 CVCL_JP55 HPSI0713i-yezj_1 induced pluripotent stem cell human CVCL_JP55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128225 CVCL_K154 AFRC MAC 75 hybridoma Norway rat CVCL_K154 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA. 21128226 CVCL_JP54 HPSI0713i-wiol_3 induced pluripotent stem cell human CVCL_JP54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128227 CVCL_K157 AFRC MAC 78 hybridoma Norway rat CVCL_K157 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA. 21128228 CVCL_JP57 HPSI0714i-wipe_3 induced pluripotent stem cell human CVCL_JP57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128229 CVCL_K156 AFRC MAC 77 hybridoma Norway rat CVCL_K156 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA. 21128230 CVCL_JP56 HPSI0713i-yezj_2 induced pluripotent stem cell human CVCL_JP56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128231 CVCL_K151 AFRC MAC 65 hybridoma Norway rat CVCL_K151 CL:0000010 Monoclonal antibody isotype: IgM. 21128232 CVCL_JP51 HPSI0713i-terl_3 induced pluripotent stem cell human CVCL_JP51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128233 CVCL_K150 AFRC MAC 63 hybridoma Norway rat CVCL_K150 CL:0000010 Monoclonal antibody isotype: IgM. 21128234 CVCL_JP50 HPSI0713i-tadm_4 induced pluripotent stem cell human CVCL_JP50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128235 CVCL_K153 AFRC MAC 74 hybridoma Norway rat CVCL_K153 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P23312; Spinacia oleracea NIA. 21128236 CVCL_JP53 HPSI0713i-wiol_2 induced pluripotent stem cell human CVCL_JP53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128237 CVCL_K152 AFRC MAC 7 hybridoma Norway rat CVCL_K152 CL:0000010 Discontinued: ECACC; 85102269; probable. Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII 21128238 CVCL_JP52 HPSI0713i-veku_1 induced pluripotent stem cell human CVCL_JP52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128239 CVCL_AV99 GM13539 transformed cell line human CVCL_AV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128240 CVCL_B799 RG-95 embryonic stem cell human CVCL_B799 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128241 CVCL_AV92 NRK-EGFP-H2B spontaneously immortalized cell line Norway rat CVCL_AV92 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128242 CVCL_B792 RG-62 embryonic stem cell human CVCL_B792 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21128243 CVCL_B791 RG-60 embryonic stem cell human CVCL_B791 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128244 CVCL_AV91 TERA-C3H cancer cell line house mouse CVCL_AV91 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: C3H. Female 21128245 CVCL_AV94 NRK-EGFP3-Seh1 spontaneously immortalized cell line Norway rat CVCL_AV94 CL:0000010 Transfected with: RGD; 6490353; Seh1l; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128246 CVCL_B794 RG-79 embryonic stem cell human CVCL_B794 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128247 CVCL_AV93 NRK-EGFP2-Nup50 spontaneously immortalized cell line Norway rat CVCL_AV93 CL:0000010 Transfected with: RGD; 3191; Npap60; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128248 CVCL_B793 RG-63 embryonic stem cell human CVCL_B793 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21128249 CVCL_AV96 NRK-Pom121-EGFP3 spontaneously immortalized cell line Norway rat CVCL_AV96 CL:0000010 Transfected with: RGD; 620680; Pom121; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128250 CVCL_B796 RG-81 embryonic stem cell human CVCL_B796 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21128251 CVCL_K129 C273 hybridoma house mouse CVCL_K129 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9303 21128252 CVCL_JP29 HPSI0713i-darw_3 induced pluripotent stem cell human CVCL_JP29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128253 CVCL_AV95 NRK-IBB-DiHcRed1 spontaneously immortalized cell line Norway rat CVCL_AV95 CL:0000010 Transfected with: UniProtKB; Q95W85; HcRed Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128254 CVCL_B795 RG-80 embryonic stem cell human CVCL_B795 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128255 CVCL_AV98 GM11592 transformed cell line human CVCL_AV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128256 CVCL_B798 RG-94 embryonic stem cell human CVCL_B798 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128257 CVCL_AV97 NRK-4xlambdaN22-3xmEGFP-M9 spontaneously immortalized cell line Norway rat CVCL_AV97 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21128258 CVCL_B797 RG-93 embryonic stem cell human CVCL_B797 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Male 21128259 CVCL_K126 C129 hybridoma house mouse CVCL_K126 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9516 21128260 CVCL_JP26 HPSI0713i-aehn_1 induced pluripotent stem cell human CVCL_JP26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128261 CVCL_K125 BD5-2d hybridoma house mouse CVCL_K125 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9689 21128262 CVCL_JP25 HPSI0613i-zisa_2 induced pluripotent stem cell human CVCL_JP25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128263 CVCL_K128 C180 hybridoma house mouse CVCL_K128 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01070; Soybean Kunitz-type trypsin inhibitor. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9517 21128264 CVCL_JP28 HPSI0713i-dard_3 induced pluripotent stem cell human CVCL_JP28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128265 CVCL_K127 C171 hybridoma house mouse CVCL_K127 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01070; Soybean Kunitz-type trypsin inhibitor. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9515 21128266 CVCL_JP27 HPSI0713i-cicb_1 induced pluripotent stem cell human CVCL_JP27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128267 CVCL_K122 alpha-ACE 3.1.1 hybridoma house mouse CVCL_K122 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P47820; Rat Ace. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8191 21128268 CVCL_JP22 HPSI0613i-xucm_1 induced pluripotent stem cell human CVCL_JP22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128269 CVCL_K121 a intermediate filament hybridoma house mouse CVCL_K121 CL:0000010 Monoclonal antibody isotype: IgG1. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21128270 CVCL_JP21 HPSI0613i-xosg_3 induced pluripotent stem cell human CVCL_JP21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128271 CVCL_K124 BA7.3C.9 hybridoma house mouse CVCL_K124 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10721; Human KIT/CD117. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10716 21128272 CVCL_AV90 DPSC somatic stem cell human CVCL_AV90 CL:0000010 Derived from sampling site: Tooth; dental pulp. Unspecified 21128273 CVCL_JP24 HPSI0613i-zisa_1 induced pluripotent stem cell human CVCL_JP24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128274 CVCL_B790 RG-53 embryonic stem cell human CVCL_B790 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Female 21128275 CVCL_K123 AMS 9.1.1.1 hybridoma house mouse CVCL_K123 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse IgD (allotype a, Igh-5.4). 21128276 CVCL_JP23 HPSI0613i-xucm_2 induced pluripotent stem cell human CVCL_JP23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128277 CVCL_K120 83-12-5 hybridoma house mouse CVCL_K120 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 21128278 CVCL_JP20 HPSI0613i-xavk_2 induced pluripotent stem cell human CVCL_JP20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128279 CVCL_K137 CC 11 hybridoma house mouse CVCL_K137 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9455 21128280 CVCL_JP37 HPSI0713i-nemb_3 induced pluripotent stem cell human CVCL_JP37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128281 CVCL_K136 CBL-1 hybridoma house mouse CVCL_K136 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8214 21128282 CVCL_JP36 HPSI0713i-nemb_2 induced pluripotent stem cell human CVCL_JP36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128283 CVCL_K139 CC 30 hybridoma house mouse CVCL_K139 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9457 21128284 CVCL_JP39 HPSI0713i-pusf_1 induced pluripotent stem cell human CVCL_JP39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128285 CVCL_K138 CC 15 hybridoma house mouse CVCL_K138 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9460 21128286 CVCL_JP38 HPSI0713i-nocf_1 induced pluripotent stem cell human CVCL_JP38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128287 CVCL_K133 CA3-F4 hybridoma house mouse CVCL_K133 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). 21128288 CVCL_JP33 HPSI0713i-gaab_2 induced pluripotent stem cell human CVCL_JP33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128289 CVCL_K132 C44 hybridoma house mouse CVCL_K132 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:23359; Colchicine. 21128290 CVCL_JP32 HPSI0713i-foop_3 induced pluripotent stem cell human CVCL_JP32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128291 CVCL_K135 DG4-1 hybridoma house mouse CVCL_K135 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). 21128292 CVCL_JP35 HPSI0713i-kaks_1 induced pluripotent stem cell human CVCL_JP35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128293 CVCL_K134 6.23.58K hybridoma house mouse CVCL_K134 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Dog 58 kdA protein on MDCK cell line basolateral surface. 21128294 CVCL_JP34 HPSI0713i-javm_2 induced pluripotent stem cell human CVCL_JP34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128295 CVCL_K131 C3-124 hybridoma house mouse CVCL_K131 CL:0000010 Monoclonal antibody isotype: IgG2b, lambda; Monoclonal antibody target: Human IgG heavy chain. 21128296 CVCL_JP31 HPSI0713i-fett_2 induced pluripotent stem cell human CVCL_JP31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128297 CVCL_K130 C305 hybridoma house mouse CVCL_K130 CL:0000010 Monoclonal antibody isotype: IgM, kappa. 21128298 CVCL_JP30 HPSI0713i-fett_1 induced pluripotent stem cell human CVCL_JP30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128299 CVCL_AV78 HHW764 hybrid cell line human CVCL_AV78 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128300 CVCL_B778 RG-416 embryonic stem cell human CVCL_B778 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1585-1G>A (IVS10AS,G>A,-1) (1717-1G>A); ClinVar=VCV000007112; Zygosity=Heterozygous; Note=Splice acceptor mutation (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128301 CVCL_AV77 HHW750 hybrid cell line human CVCL_AV77 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128302 CVCL_B777 RG-415 embryonic stem cell human CVCL_B777 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128303 CVCL_AV79 HHW792 hybrid cell line human CVCL_AV79 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128304 CVCL_B779 RG-417 embryonic stem cell human CVCL_B779 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1585-1G>A (IVS10AS,G>A,-1) (1717-1G>A); ClinVar=VCV000007112; Zygosity=Heterozygous; Note=Splice acceptor mutation (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128305 CVCL_AV70 HHW339 hybrid cell line human CVCL_AV70 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128306 CVCL_B770 RG-407 embryonic stem cell human CVCL_B770 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128307 CVCL_AV72 HHW441 hybrid cell line human CVCL_AV72 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128308 CVCL_B772 RG-410 embryonic stem cell human CVCL_B772 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Heterozygous (ISCR). Unspecified 21128309 CVCL_AV71 HHW342 hybrid cell line human CVCL_AV71 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128310 CVCL_B771 RG-408 embryonic stem cell human CVCL_B771 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128311 CVCL_K108 Ad2-3Y1-2 transformed cell line Norway rat CVCL_K108 CL:0000010 Transformant: Adenovirus 2(NCBI-Taxonomy; 10515); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128312 CVCL_AV74 HHW711 hybrid cell line human CVCL_AV74 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128313 CVCL_JP08 HPSI0613i-oomz_1 induced pluripotent stem cell human CVCL_JP08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128314 CVCL_B774 RG-412 embryonic stem cell human CVCL_B774 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ISCR). Unspecified 21128315 CVCL_K107 Ad2-3Y1-1 transformed cell line Norway rat CVCL_K107 CL:0000010 Transformant: Adenovirus 2(NCBI-Taxonomy; 10515); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128316 CVCL_AV73 HHW686 hybrid cell line human CVCL_AV73 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128317 CVCL_JP07 HPSI0613i-oefg_3 induced pluripotent stem cell human CVCL_JP07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128318 CVCL_B773 RG-411 embryonic stem cell human CVCL_B773 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ISCR). Unspecified 21128319 CVCL_AV76 HHW740 hybrid cell line human CVCL_AV76 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128320 CVCL_B776 RG-414 embryonic stem cell human CVCL_B776 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128321 CVCL_K109 Ad2-3Y1-3 transformed cell line Norway rat CVCL_K109 CL:0000010 Transformant: Adenovirus 2(NCBI-Taxonomy; 10515); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128322 CVCL_AV75 HHW720 hybrid cell line human CVCL_AV75 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128323 CVCL_JP09 HPSI0613i-oomz_2 induced pluripotent stem cell human CVCL_JP09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21128324 CVCL_B775 RG-413 embryonic stem cell human CVCL_B775 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128325 CVCL_K104 Chab1KMM finite cell line human CVCL_K104 CL:0000010 Population: Japanese; Karyotypic information: 46,XX,+(11;12)(q23.3;q15) (RCB); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128326 CVCL_JP04 HPSI0613i-lula_2 induced pluripotent stem cell human CVCL_JP04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128327 CVCL_K103 HFL-III finite cell line human CVCL_K103 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (PubMed=17395773) 21128328 CVCL_JP03 HPSI0613i-lula_1 induced pluripotent stem cell human CVCL_JP03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128329 CVCL_K106 3Y1-SB-16 transformed cell line Norway rat CVCL_K106 CL:0000010 Transformant: Sodium butyrate(ChEBI; CHEBI:64103); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128330 CVCL_JP06 HPSI0613i-oefg_1 induced pluripotent stem cell human CVCL_JP06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128331 CVCL_K105 3Y1-SB-15 transformed cell line Norway rat CVCL_K105 CL:0000010 Transformant: Sodium butyrate(ChEBI; CHEBI:64103); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128332 CVCL_JP05 HPSI0613i-nukw_3 induced pluripotent stem cell human CVCL_JP05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128333 CVCL_JP00 HPSI0613i-liun_62 induced pluripotent stem cell human CVCL_JP00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128334 CVCL_K100 HS-K finite cell line human CVCL_K100 CL:0000010 Population: Japanese; Derived from sampling site: Skin. Female 21128335 CVCL_K102 HFL-II finite cell line human CVCL_K102 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (PubMed=17395773) 21128336 CVCL_JP02 HPSI0613i-lizq_2 induced pluripotent stem cell human CVCL_JP02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128337 CVCL_K101 HFL-I finite cell line human CVCL_K101 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000200005) It was one of the sources for the STR profile of this entry. Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (PubMed=17395773) 21128338 CVCL_JP01 HPSI0613i-liun_64 induced pluripotent stem cell human CVCL_JP01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128339 CVCL_AV89 L1-S8R induced pluripotent stem cell human CVCL_AV89 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. 21128340 CVCL_B789 RG-428 embryonic stem cell human CVCL_B789 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; c.663+1G>A (IVS7+1G>A); ClinVar=VCV000049076; Zygosity=Heterozygous; Note=Splice donor mutation (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128341 CVCL_AV88 L1-S8 induced pluripotent stem cell human CVCL_AV88 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. 21128342 CVCL_B788 RG-427 embryonic stem cell human CVCL_B788 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128343 CVCL_AV81 HHW909 hybrid cell line human CVCL_AV81 CL:0000010 Group: Human/rodent somatic cell hybrid. 21128344 CVCL_B781 RG-419 embryonic stem cell human CVCL_B781 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128345 CVCL_AV80 HHW848 hybrid cell line human CVCL_AV80 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21128346 CVCL_B780 RG-418 embryonic stem cell human CVCL_B780 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Ser10Valfs*14 (c.27dupG) (c.27_28insG) (cd8/9+G); ClinVar=VCV000036308; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; g.71609_72227del619; ClinVar=VCV000038701; Zygosity=Heterozygous (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128347 CVCL_AV83 IPLB-DnEa4 spontaneously immortalized cell line CVCL_AV83 CL:0000010 Unspecified Group: Insect cell line. 21128348 CVCL_B783 RG-422 embryonic stem cell human CVCL_B783 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Heterozygous (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128349 CVCL_AV82 AUC finite cell line human CVCL_AV82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00328; probable Male 21128350 CVCL_B782 RG-420 embryonic stem cell human CVCL_B782 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Ser10Valfs*14 (c.27dupG) (c.27_28insG) (cd8/9+G); ClinVar=VCV000036308; Zygosity=Heterozygous (ISCR); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; g.71609_72227del619; ClinVar=VCV000038701; Zygosity=Heterozygous (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128351 CVCL_K119 548 hybridoma house mouse CVCL_K119 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Murine leukemia viruses (MuLV) p12. 21128352 CVCL_AV85 GM00632 finite cell line human CVCL_AV85 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21128353 CVCL_JP19 HPSI0613i-xavk_1 induced pluripotent stem cell human CVCL_JP19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128354 CVCL_B785 RG-424 embryonic stem cell human CVCL_B785 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Met918Thr (c.2753T>C); ClinVar=VCV000013919; Zygosity=Heterozygous (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128355 CVCL_K118 537-B1-1 hybridoma house mouse CVCL_K118 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Sheep lymphocytes/endothelium. 21128356 CVCL_JP18 HPSI0613i-vorx_2 induced pluripotent stem cell human CVCL_JP18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128357 CVCL_AV84 IPLB-DnEs2 spontaneously immortalized cell line CVCL_AV84 CL:0000010 Unspecified Group: Insect cell line. 21128358 CVCL_B784 RG-423 embryonic stem cell human CVCL_B784 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ISCR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved 21128359 CVCL_B787 RG-426 embryonic stem cell human CVCL_B787 From: Reproductive Genetics Institute; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128360 CVCL_AV87 XS20 spontaneously immortalized cell line house mouse CVCL_AV87 CL:0000010 Derived from sampling site: Trunk; skin; epidermis Cell type=Dendritic cell.; Breed/subspecies: BALB/c. Female 21128361 CVCL_AV86 GM01406 finite cell line human CVCL_AV86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21128362 CVCL_B786 RG-425 embryonic stem cell human CVCL_B786 From: Reproductive Genetics Institute; Chicago; USA. CL:0000010 Unspecified 21128363 CVCL_JP15 HPSI0613i-sucu_3 induced pluripotent stem cell human CVCL_JP15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128364 CVCL_K115 V13S-3Y1-4 transformed cell line Norway rat CVCL_K115 CL:0000010 Transformant: Adenovirus 12 [E1A 13S isoform](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128365 CVCL_JP14 HPSI0613i-sucu_2 induced pluripotent stem cell human CVCL_JP14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128366 CVCL_K114 V12S-3Y1-2 transformed cell line Norway rat CVCL_K114 CL:0000010 Transformant: Adenovirus 12 [E1A 12S isoform](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128367 CVCL_K117 52-3D hybridoma house mouse CVCL_K117 CL:0000010 Monoclonal antibody isotype: IgG1. 21128368 CVCL_JP17 HPSI0613i-ueah_2 induced pluripotent stem cell human CVCL_JP17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128369 CVCL_K116 348C6 hybridoma house mouse CVCL_K116 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18103; Escherichia coli K99 fanC. 21128370 CVCL_JP16 HPSI0613i-uait_6 induced pluripotent stem cell human CVCL_JP16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128371 CVCL_JP11 HPSI0613i-pasj_1 induced pluripotent stem cell human CVCL_JP11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128372 CVCL_K111 in203-3Y1-19 transformed cell line Norway rat CVCL_K111 CL:0000010 Transformant: Adenovirus 12 [in203S](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128373 CVCL_K110 dl-884-3Y1-KO1 transformed cell line Norway rat CVCL_K110 CL:0000010 Transformant: Simian virus 40 (SV40) [dl-884](NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128374 CVCL_JP10 HPSI0613i-oomz_3 induced pluripotent stem cell human CVCL_JP10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128375 CVCL_JP13 HPSI0613i-qony_3 induced pluripotent stem cell human CVCL_JP13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128376 CVCL_K113 in203-3Y1-7 transformed cell line Norway rat CVCL_K113 CL:0000010 Transformant: Adenovirus 12 [in203S](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128377 CVCL_JP12 HPSI0613i-qanu_3 induced pluripotent stem cell human CVCL_JP12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128378 CVCL_K112 in203-3Y1-23 transformed cell line Norway rat CVCL_K112 CL:0000010 Transformant: Adenovirus 12 [in203S](NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21128379 CVCL_0D40 NZM077 cancer cell line human CVCL_0D40 HLA typing: A*01:01,03:01; B*08:01,15:01; C*03:03,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Pro1323Ser (c.3967C>T); ClinVar=VCV000945186; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21128380 CVCL_0D42 NZM079 cancer cell line human CVCL_0D42 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). Male 21128381 CVCL_0D41 NZM078 cancer cell line human CVCL_0D41 HLA typing: A*02:01,11:01; B*07:02,51:08; C*07:02,16:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790) Omics: Transcriptome analysis by RNAseq. 21128382 CVCL_0D44 NZM081 cancer cell line human CVCL_0D44 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790). 21128383 CVCL_0D43 NZM080 cancer cell line human CVCL_0D43 CL:0000010 Omics: Deep exome analysis. Male 21128384 CVCL_0D46 NZM084 cancer cell line human CVCL_0D46 CL:0000010 21128385 CVCL_0D45 NZM083 cancer cell line human CVCL_0D45 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Heterozygous (PubMed=32567790). 21128386 CVCL_0D48 NZM088 cancer cell line human CVCL_0D48 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128387 CVCL_0D47 NZM087 cancer cell line human CVCL_0D47 HLA typing: A*02:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.His1170Tyr; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Glu996Lys (c.2986G>A); ClinVar=VCV000822435; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21128388 CVCL_0D49 NZM089 cancer cell line human CVCL_0D49 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790). Male 21128389 CVCL_SJ90 HAP1 CSNK1G3 (-) 2 cancer cell line human CVCL_SJ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2456; CSNK1G3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128390 CVCL_SJ92 HAP1 CSNK2A1 (-) 2 cancer cell line human CVCL_SJ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2457; CSNK2A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128391 CVCL_SJ91 HAP1 CSNK2A1 (-) 1 cancer cell line human CVCL_SJ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2457; CSNK2A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128392 CVCL_SJ94 HAP1 CSNK2A2 (-) 2 cancer cell line human CVCL_SJ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2459; CSNK2A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128393 CVCL_SJ93 HAP1 CSNK2A2 (-) 1 cancer cell line human CVCL_SJ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2459; CSNK2A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128394 CVCL_SJ96 HAP1 CSRNP2 (-) 2 cancer cell line human CVCL_SJ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16006; CSRNP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128395 CVCL_SJ95 HAP1 CSRNP2 (-) 1 cancer cell line human CVCL_SJ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16006; CSRNP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128396 CVCL_SJ98 HAP1 CTDNEP1 (-) 1 cancer cell line human CVCL_SJ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19085; CTDNEP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128397 CVCL_SJ97 HAP1 CST3 (-) cancer cell line human CVCL_SJ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2475; CST3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128398 CVCL_SJ99 HAP1 CTDNEP1 (-) 2 cancer cell line human CVCL_SJ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19085; CTDNEP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128399 CVCL_0D51 NZM091 cancer cell line human CVCL_0D51 HLA typing: A*02:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male 21128400 CVCL_0D50 NZM090 cancer cell line human CVCL_0D50 HLA typing: A*02:01,26:01; B*07:02,38:01; C*07:02,12:03 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21128401 CVCL_0D53 NZM093 cancer cell line human CVCL_0D53 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790) Omics: Deep exome analysis. 21128402 CVCL_0D52 NZM092 cancer cell line human CVCL_0D52 HLA typing: A*01:01,01:01; B*08:01,44:02; C*05:01,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. 21128403 CVCL_0D55 NZM095 cancer cell line human CVCL_0D55 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128404 CVCL_0D54 NZM094 cancer cell line human CVCL_0D54 CL:0000010 21128405 CVCL_0D57 NZM097 cancer cell line human CVCL_0D57 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21128406 CVCL_0D56 NZM096 cancer cell line human CVCL_0D56 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128407 CVCL_0D59 NZM099 cancer cell line human CVCL_0D59 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asp1071Asn (c.3211G>A); ClinVar=VCV000240346; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128408 CVCL_0D58 NZM098 cancer cell line human CVCL_0D58 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128409 CVCL_SJ81 HAP1 CSNK1D (-) 1 cancer cell line human CVCL_SJ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2452; CSNK1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128410 CVCL_SJ80 HAP1 CSMD1 (-) 2 cancer cell line human CVCL_SJ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14026; CSMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128411 CVCL_SJ83 HAP1 CSNK1E (-) cancer cell line human CVCL_SJ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2453; CSNK1E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128412 CVCL_SJ82 HAP1 CSNK1D (-) 2 cancer cell line human CVCL_SJ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2452; CSNK1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128413 CVCL_SJ85 HAP1 CSNK1G1 (-) 2 cancer cell line human CVCL_SJ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2454; CSNK1G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128414 CVCL_SJ84 HAP1 CSNK1G1 (-) 1 cancer cell line human CVCL_SJ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2454; CSNK1G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128415 CVCL_SJ87 HAP1 CSNK1G2 (-) 1 cancer cell line human CVCL_SJ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2455; CSNK1G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128416 CVCL_SJ86 HAP1 CSNK1G1 (-) 3 cancer cell line human CVCL_SJ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2454; CSNK1G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128417 CVCL_SJ89 HAP1 CSNK1G3 (-) 1 cancer cell line human CVCL_SJ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2456; CSNK1G3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128418 CVCL_SJ88 HAP1 CSNK1G2 (-) 2 cancer cell line human CVCL_SJ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2455; CSNK1G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128419 CVCL_0D20 Nialym cancer cell line human CVCL_0D20 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: ~46 hours (PubMed=25711304) 21128420 CVCL_0D22 CML-13 cancer cell line dog CVCL_0D22 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Unspecified 21128421 CVCL_0D21 Nialymx cancer cell line human CVCL_0D21 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: ~42 hours (PubMed=25711304) 21128422 CVCL_0D24 CML-6M cancer cell line dog CVCL_0D24 CL:0000010 Sequence variation: Mutation; VGNC; 43761; NF1; Simple; p.Pro1599fs (c.4795delCinsTT); Zygosity=Heterozygous (PubMed=31175136) Derived from metastatic site: Lymph node; Breed/subspecies: Mixed breed. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Unspecified Characteristics: Pigmented Doubling time: 15 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21128423 CVCL_0D23 CML-2 cancer cell line dog CVCL_0D23 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Scottish Terrier. Unspecified 21128424 CVCL_0D26 NZM062 cancer cell line human CVCL_0D26 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128425 CVCL_0D25 CML-10C2 cancer cell line dog CVCL_0D25 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Gly12Val (c.35G>T); Zygosity=Heterozygous (PubMed=31175136) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Unspecified Doubling time: 21 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21128426 CVCL_0D28 NZM032 cancer cell line human CVCL_0D28 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21128427 CVCL_0D27 NZM064 cancer cell line human CVCL_0D27 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128428 CVCL_0D29 NZM054 cancer cell line human CVCL_0D29 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21128429 CVCL_SJ70 HAP1 CRBN (-) 2 cancer cell line human CVCL_SJ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30185; CRBN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128430 CVCL_SJ72 HAP1 CREB1 (-) 1 cancer cell line human CVCL_SJ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2345; CREB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128431 CVCL_SJ71 HAP1 CRBN (-) 3 cancer cell line human CVCL_SJ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30185; CRBN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128432 CVCL_SJ74 HAP1 CREBBP (-) 1 cancer cell line human CVCL_SJ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128433 CVCL_SJ73 HAP1 CREB1 (-) 2 cancer cell line human CVCL_SJ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2345; CREB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128434 CVCL_SJ76 HAP1 CRELD1 (-) 2 cancer cell line human CVCL_SJ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14630; CRELD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128435 CVCL_SJ75 HAP1 CRELD1 (-) 1 cancer cell line human CVCL_SJ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14630; CRELD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128436 CVCL_SJ78 HAP1 CSK (-) cancer cell line human CVCL_SJ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2444; CSK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128437 CVCL_SJ77 HAP1 CSF1 (-) 1 cancer cell line human CVCL_SJ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128438 CVCL_SJ79 HAP1 CSMD1 (-) 1 cancer cell line human CVCL_SJ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14026; CSMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128439 CVCL_0D31 NZM066 cancer cell line human CVCL_0D31 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790). Male 21128440 CVCL_0D30 NZM065 cancer cell line human CVCL_0D30 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128441 CVCL_0D33 NZM068 cancer cell line human CVCL_0D33 CL:0000010 21128442 CVCL_0D32 NZM067 cancer cell line human CVCL_0D32 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128443 CVCL_0D35 NZM070 cancer cell line human CVCL_0D35 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). 21128444 CVCL_0D34 NZM069 cancer cell line human CVCL_0D34 HLA typing: A*01:01,25:01; B*35:03,40:01; C*03:04,12:03 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790) Omics: Transcriptome analysis by RNAseq. 21128445 CVCL_0D37 NZM073 cancer cell line human CVCL_0D37 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790). 21128446 CVCL_0D36 NZM072 cancer cell line human CVCL_0D36 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg416Ter (c.1246C>T); ClinVar=VCV000404597; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. 21128447 CVCL_0D39 NZM075 cancer cell line human CVCL_0D39 CL:0000010 Male 21128448 CVCL_0D38 NZM074 cancer cell line human CVCL_0D38 HLA typing: A*01:01,01:01; B*08:01,40:01; C*03:04,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by RNAseq. 21128449 CVCL_SJ61 HAP1 COQ7 (-) 1 cancer cell line human CVCL_SJ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2244; COQ7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128450 CVCL_SJ60 HAP1 COQ5 (-) cancer cell line human CVCL_SJ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28722; COQ5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128451 CVCL_SJ63 HAP1 COQ9 (-) 1 cancer cell line human CVCL_SJ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25302; COQ9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128452 CVCL_SJ62 HAP1 COQ7 (-) 2 cancer cell line human CVCL_SJ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2244; COQ7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128453 CVCL_SJ65 HAP1 COX11 (-) cancer cell line human CVCL_SJ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2261; COX11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128454 CVCL_SJ64 HAP1 COQ9 (-) 2 cancer cell line human CVCL_SJ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25302; COQ9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128455 CVCL_SJ67 HAP1 CPT1A (-) 2 cancer cell line human CVCL_SJ67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2328; CPT1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128456 CVCL_SJ66 HAP1 CPT1A (-) 1 cancer cell line human CVCL_SJ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2328; CPT1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128457 CVCL_SJ69 HAP1 CRBN (-) 1 cancer cell line human CVCL_SJ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30185; CRBN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128458 CVCL_SJ68 HAP1 CPT2 (-) cancer cell line human CVCL_SJ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2330; CPT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128459 CVCL_0D00 Mocha-HSA cancer cell line dog CVCL_0D00 CL:0000010 Unspecified 21128460 CVCL_0D02 Veronica-HSA cancer cell line dog CVCL_0D02 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Female 21128461 CVCL_0D01 Tucker-HSA cancer cell line dog CVCL_0D01 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male 21128462 CVCL_0D04 Grace-HSA cancer cell line dog CVCL_0D04 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Portuguese water dog. Female Doubling time: ~1 week (Kerafast) 21128463 CVCL_0D03 Connor-HSA cancer cell line dog CVCL_0D03 CL:0000010 Unspecified 21128464 CVCL_0D06 Max-ST cancer cell line dog CVCL_0D06 CL:0000010 Unspecified 21128465 CVCL_0D05 Spry-STS cancer cell line dog CVCL_0D05 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Modiano J.F.). Unspecified 21128466 CVCL_0D08 Mel 23 cancer cell line dog CVCL_0D08 CL:0000010 Derived from sampling site: Oral cavity. Unspecified 21128467 CVCL_0D07 Mel 12 cancer cell line dog CVCL_0D07 CL:0000010 Derived from sampling site: Oral cavity. Unspecified 21128468 CVCL_SJ50 HAP1 COMT (-) 2 cancer cell line human CVCL_SJ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2228; COMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128469 CVCL_SJ52 HAP1 COPS6 (-) 1 cancer cell line human CVCL_SJ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21749; COPS6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128470 CVCL_SJ51 HAP1 COMTD1 (-) cancer cell line human CVCL_SJ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26309; COMTD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128471 CVCL_SJ54 HAP1 COPS7A (-) 1 cancer cell line human CVCL_SJ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16758; COPS7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128472 CVCL_SJ53 HAP1 COPS6 (-) 2 cancer cell line human CVCL_SJ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21749; COPS6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128473 CVCL_SJ56 HAP1 COPS7B (-) 1 cancer cell line human CVCL_SJ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16760; COPS7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128474 CVCL_SJ55 HAP1 COPS7A (-) 2 cancer cell line human CVCL_SJ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16758; COPS7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128475 CVCL_SJ58 HAP1 COQ2 (-) 1 cancer cell line human CVCL_SJ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25223; COQ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128476 CVCL_SJ57 HAP1 COPS7B (-) 2 cancer cell line human CVCL_SJ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16760; COPS7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128477 CVCL_SJ59 HAP1 COQ2 (-) 2 cancer cell line human CVCL_SJ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25223; COQ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128478 CVCL_SJ39 HAP1 CNKSR2 (-) 2 cancer cell line human CVCL_SJ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19701; CNKSR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128479 CVCL_0D11 Mel 64 cancer cell line dog CVCL_0D11 CL:0000010 Unspecified 21128480 CVCL_0D10 Mel 50 cancer cell line dog CVCL_0D10 CL:0000010 Derived from sampling site: Oral cavity. Unspecified 21128481 CVCL_0D13 Mel 83 cancer cell line dog CVCL_0D13 CL:0000010 Derived from sampling site: Oral cavity. Unspecified 21128482 CVCL_0D12 Mel 69 cancer cell line dog CVCL_0D12 CL:0000010 Derived from sampling site: Oral cavity. Unspecified 21128483 CVCL_0D15 Jenny cancer cell line dog CVCL_0D15 CL:0000010 Derived from sampling site: Oral cavity. Female 21128484 CVCL_0D14 Bear cancer cell line dog CVCL_0D14 CL:0000010 Omics: Genome sequenced. Unspecified 21128485 CVCL_0D17 Shadow cancer cell line dog CVCL_0D17 CL:0000010 Derived from metastatic site: Lung. Unspecified 21128486 CVCL_0D16 Scooter cancer cell line dog CVCL_0D16 CL:0000010 Derived from sampling site: Oral cavity. Male 21128487 CVCL_0D19 CML-1 cancer cell line dog CVCL_0D19 CL:0000010 Derived from sampling site: Oral cavity; gingiva; Breed/subspecies: Toy Poodle. Unspecified 21128488 CVCL_0D18 G3/F11 hybridoma house mouse CVCL_0D18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q12797; Human ASPH. 21128489 CVCL_0D09 Mel 36 cancer cell line dog CVCL_0D09 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21128490 CVCL_SJ41 HAP1 CNP (-) 1 cancer cell line human CVCL_SJ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2158; CNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128491 CVCL_SJ40 HAP1 CNKSR2 (-) 3 cancer cell line human CVCL_SJ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19701; CNKSR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128492 CVCL_SJ43 HAP1 CNR1 (-) 2 cancer cell line human CVCL_SJ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2159; CNR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128493 CVCL_SJ42 HAP1 CNR1 (-) 1 cancer cell line human CVCL_SJ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2159; CNR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128494 CVCL_SJ45 HAP1 CNST (-) 2 cancer cell line human CVCL_SJ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26486; CNST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128495 CVCL_SJ44 HAP1 CNST (-) 1 cancer cell line human CVCL_SJ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26486; CNST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128496 CVCL_SJ47 HAP1 COL1A1 (-) 1 cancer cell line human CVCL_SJ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128497 CVCL_SJ46 HAP1 CNTNAP1 (-) 1 cancer cell line human CVCL_SJ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8011; CNTNAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128498 CVCL_SJ49 HAP1 COMT (-) 1 cancer cell line human CVCL_SJ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2228; COMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128499 CVCL_SJ48 HAP1 COL4A3BP (-) 1 cancer cell line human CVCL_SJ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2205; CERT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128500 CVCL_SJ29 HAP1 CLN6 (-) cancer cell line human CVCL_SJ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2077; CLN6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128501 CVCL_SJ28 HAP1 CLN3 (-) 2 cancer cell line human CVCL_SJ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2074; CLN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128502 CVCL_K188 AFRC MAC 132 hybridoma Norway rat CVCL_K188 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21128503 CVCL_JP88 HPSI0913i-oapg_4 induced pluripotent stem cell human CVCL_JP88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128504 CVCL_K187 AFRC MAC 131 hybridoma Norway rat CVCL_K187 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21128505 CVCL_JP87 HPSI0913i-lise_2 induced pluripotent stem cell human CVCL_JP87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128506 CVCL_SJ30 HAP1 CLPTM1 (-) 1 cancer cell line human CVCL_SJ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2087; CLPTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128507 CVCL_K189 AFRC MAC 133 hybridoma Norway rat CVCL_K189 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human low density lipoprotein (LDL). 21128508 CVCL_JP89 HPSI0913i-qiea_1 induced pluripotent stem cell human CVCL_JP89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128509 CVCL_K184 AFRC MAC 129 hybridoma Norway rat CVCL_K184 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21128510 CVCL_SJ32 HAP1 CMAS (-) cancer cell line human CVCL_SJ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18290; CMAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128511 CVCL_JP84 HPSI0913i-eika_1 induced pluripotent stem cell human CVCL_JP84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128512 CVCL_K183 AFRC MAC 128 hybridoma Norway rat CVCL_K183 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human low density lipoprotein (LDL). 21128513 CVCL_SJ31 HAP1 CLU (-) 1 cancer cell line human CVCL_SJ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2095; CLU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128514 CVCL_JP83 HPSI0913i-diku_3 induced pluripotent stem cell human CVCL_JP83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128515 CVCL_K186 AFRC MAC 130 hybridoma Norway rat CVCL_K186 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human low density lipoprotein (LDL). 21128516 CVCL_SJ34 HAP1 CMTR1 (-) 2 cancer cell line human CVCL_SJ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21077; CMTR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128517 CVCL_JP86 HPSI0913i-iuqb_3 induced pluripotent stem cell human CVCL_JP86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128518 CVCL_K185 AFRC MAC 13 hybridoma Norway rat CVCL_K185 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128519 CVCL_SJ33 HAP1 CMTR1 (-) 1 cancer cell line human CVCL_SJ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21077; CMTR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128520 CVCL_JP85 HPSI0913i-iuqb_2 induced pluripotent stem cell human CVCL_JP85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128521 CVCL_K180 AFRC MAC 11 hybridoma Norway rat CVCL_K180 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128522 CVCL_SJ36 HAP1 CNKSR1 (-) 2 cancer cell line human CVCL_SJ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19700; CNKSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128523 CVCL_JP80 HPSI0913i-coyi_1 induced pluripotent stem cell human CVCL_JP80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128524 CVCL_SJ35 HAP1 CNKSR1 (-) 1 cancer cell line human CVCL_SJ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19700; CNKSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128525 CVCL_K182 AFRC MAC 127 hybridoma Norway rat CVCL_K182 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21128526 CVCL_SJ38 HAP1 CNKSR2 (-) 1 cancer cell line human CVCL_SJ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19701; CNKSR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128527 CVCL_JP82 HPSI0913i-diku_2 induced pluripotent stem cell human CVCL_JP82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128528 CVCL_K181 AFRC MAC 12 hybridoma Norway rat CVCL_K181 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128529 CVCL_SJ37 HAP1 CNKSR1 (-) 3 cancer cell line human CVCL_SJ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19700; CNKSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128530 CVCL_JP81 HPSI0913i-coyi_2 induced pluripotent stem cell human CVCL_JP81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128531 CVCL_SJ18 HAP1 CLK1 (-) 1 cancer cell line human CVCL_SJ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2068; CLK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128532 CVCL_SJ17 HAP1 CLCN7 (-) cancer cell line human CVCL_SJ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2025; CLCN7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128533 CVCL_SJ19 HAP1 CLK1 (-) 2 cancer cell line human CVCL_SJ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2068; CLK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128534 CVCL_K199 AFRC MAC 23 hybridoma Norway rat CVCL_K199 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21128535 CVCL_JP99 HPSI1013i-garx_3 induced pluripotent stem cell human CVCL_JP99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128536 CVCL_K198 AFRC MAC 22 hybridoma Norway rat CVCL_K198 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21128537 CVCL_JP98 HPSI1013i-garx_1 induced pluripotent stem cell human CVCL_JP98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128538 CVCL_K195 AFRC MAC 160 hybridoma CVCL_K195 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:62881; N(6)-(Delta(2)-isopentenyl)adenosine (Riboprine). 21128539 CVCL_SJ21 HAP1 CLK2 (-) 2 cancer cell line human CVCL_SJ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2069; CLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128540 CVCL_JP95 HPSI0914i-euts_1 induced pluripotent stem cell human CVCL_JP95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128541 CVCL_K194 AFRC MAC 159 hybridoma CVCL_K194 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:62881; N(6)-(Delta(2)-isopentenyl)adenosine (Riboprine). 21128542 CVCL_SJ20 HAP1 CLK2 (-) 1 cancer cell line human CVCL_SJ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2069; CLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128543 CVCL_JP94 HPSI0913i-xomm_1 induced pluripotent stem cell human CVCL_JP94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128544 CVCL_K197 AFRC MAC 188 hybridoma Norway rat CVCL_K197 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20063; Rabbit LDLR. 21128545 CVCL_SJ23 HAP1 CLK3 (-) cancer cell line human CVCL_SJ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2071; CLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128546 CVCL_JP97 HPSI1013i-cups_2 induced pluripotent stem cell human CVCL_JP97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128547 CVCL_K196 AFRC MAC 17 hybridoma Norway rat CVCL_K196 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128548 CVCL_SJ22 HAP1 CLK2 (-) 3 cancer cell line human CVCL_SJ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2069; CLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128549 CVCL_JP96 HPSI1013i-cups_1 induced pluripotent stem cell human CVCL_JP96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128550 CVCL_K191 AFRC MAC 156 hybridoma CVCL_K191 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:62881; N(6)-(Delta(2)-isopentenyl)adenosine (Riboprine). 21128551 CVCL_SJ25 HAP1 CLK4 (-) 2 cancer cell line human CVCL_SJ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13659; CLK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128552 CVCL_JP91 HPSI0913i-ruql_2 induced pluripotent stem cell human CVCL_JP91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128553 CVCL_K190 AFRC MAC 14 hybridoma Norway rat CVCL_K190 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21128554 CVCL_SJ24 HAP1 CLK4 (-) 1 cancer cell line human CVCL_SJ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13659; CLK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128555 CVCL_JP90 HPSI0913i-ruql_1 induced pluripotent stem cell human CVCL_JP90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128556 CVCL_K193 AFRC MAC 158 hybridoma CVCL_K193 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:62881; N(6)-(Delta(2)-isopentenyl)adenosine (Riboprine). 21128557 CVCL_SJ27 HAP1 CLN3 (-) 1 cancer cell line human CVCL_SJ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2074; CLN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128558 CVCL_JP93 HPSI0913i-vopm_1 induced pluripotent stem cell human CVCL_JP93 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128559 CVCL_K192 AFRC MAC 157 hybridoma CVCL_K192 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:62881; N(6)-(Delta(2)-isopentenyl)adenosine (Riboprine). 21128560 CVCL_SJ26 HAP1 CLK4 (-) 3 cancer cell line human CVCL_SJ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13659; CLK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128561 CVCL_JP92 HPSI0913i-tozk_2 induced pluripotent stem cell human CVCL_JP92 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128562 CVCL_AX10 HPSI1213i-tolg_6 induced pluripotent stem cell human CVCL_AX10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21128563 CVCL_B910 RNJ20 embryonic stem cell human CVCL_B910 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0127. 21128564 CVCL_AX12 GM00406 finite cell line human CVCL_AX12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21128565 CVCL_B912 NMR-1 embryonic stem cell human CVCL_B912 From: University of Texas Health Science Center at Houston; Houston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0159. 21128566 CVCL_AX11 GM00165 finite cell line human CVCL_AX11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21128567 CVCL_B911 RNJ7 embryonic stem cell human CVCL_B911 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128568 CVCL_AX14 RC-138 finite cell line human CVCL_AX14 CL:0000010 Derived from sampling site: Kidney. Discontinued: CLS; 300482; true 21128569 CVCL_B914 UM14-1 embryonic stem cell human CVCL_B914 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0162 21128570 CVCL_AX13 RC-131 finite cell line human CVCL_AX13 CL:0000010 Derived from sampling site: Kidney. Discontinued: CLS; 300481; true Male 21128571 CVCL_B913 UM17-1 PGD embryonic stem cell human CVCL_B913 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0160. 21128572 CVCL_AX16 RC-134 finite cell line human CVCL_AX16 CL:0000010 Derived from sampling site: Kidney. Male 21128573 CVCL_B916 UM29-2 PGD embryonic stem cell human CVCL_B916 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM29-3 PGD (Cellosaurus=CVCL_B917). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0164 21128574 CVCL_AX15 RCC-AL4 cancer cell line human CVCL_AX15 CL:0000010 Discontinued: CLS; 300240; true. Unspecified 21128575 CVCL_B915 UM14-2 embryonic stem cell human CVCL_B915 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0163. 21128576 CVCL_AX07 GM06946 finite cell line human CVCL_AX07 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Male 21128577 CVCL_B907 RNJ12 embryonic stem cell human CVCL_B907 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128578 CVCL_AX06 GM06945 transformed cell line human CVCL_AX06 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128579 CVCL_B906 RNJ11 embryonic stem cell human CVCL_B906 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21128580 CVCL_AX09 HPSI0614i-fovu_5 induced pluripotent stem cell human CVCL_AX09 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21128581 CVCL_B909 RNJ19 embryonic stem cell human CVCL_B909 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0126. 21128582 CVCL_AX08 HPSI0215i-oilg_1 induced pluripotent stem cell human CVCL_AX08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21128583 CVCL_B908 RNJ18 embryonic stem cell human CVCL_B908 From: Reprogenetics, LLC; Livingston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-11-0128. 21128584 CVCL_AX21 GM02897 finite cell line human CVCL_AX21 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Male 21128585 CVCL_B921 WCMC-9 embryonic stem cell human CVCL_B921 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0368. 21128586 CVCL_AX20 GM02896 finite cell line human CVCL_AX20 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Female 21128587 CVCL_B920 WCMC-8 embryonic stem cell human CVCL_B920 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0369. 21128588 CVCL_AX23 GM03562 transformed cell line human CVCL_AX23 CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[62] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Heterozygous (from autologous cell line GM03561) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128589 CVCL_B923 Lis01_HEFX embryonic stem cell human CVCL_B923 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[180]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=21585244). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0329 21128590 CVCL_AX22 GM03561 finite cell line human CVCL_AX22 CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[62] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21128591 CVCL_B922 WCMC-2 embryonic stem cell human CVCL_B922 From: Weill Cornell Medical College; New York; USA CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-14.. 21128592 CVCL_AX25 GM13205 finite cell line human CVCL_AX25 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Phe333Serfs*52 (c.996delC) (P330fs, 990delC); ClinVar=VCV000002990; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21128593 CVCL_B925 Lis03_FXS4 embryonic stem cell human CVCL_B925 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[250]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0331 21128594 CVCL_AX24 GM04319 finite cell line human CVCL_AX24 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM04319; probable Male 21128595 CVCL_B924 Lis02_FXS2 embryonic stem cell human CVCL_B924 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[300]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0330 21128596 CVCL_AX27 1795/4A cancer cell line human CVCL_AX27 CL:0000010 Unspecified 21128597 CVCL_B927 Lis05_t(11,22) embryonic stem cell human CVCL_B927 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0333. 21128598 CVCL_AX26 GM16195 finite cell line human CVCL_AX26 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128599 CVCL_B926 Lis04_Twist1 embryonic stem cell human CVCL_B926 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 12428; TWIST1; Simple; p.Ala129Pro (c.385G>C); Zygosity=Unspecified (PubMed=20186514; PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0332 21128600 CVCL_B918 CSC14 embryonic stem cell human CVCL_B918 From: Caladrius Biosciences, Inc (Neostem, Inc.); Basking Ridge; USA. CL:0000010 Miscellaneous: Was first disapproved for use in NIH-funded research due to issues in the original informed consent form Later accepted because of a new consent form.. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0284 21128601 CVCL_AX18 GM00559 finite cell line human CVCL_AX18 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Phe333Serfs*52 (c.996delC) (P330fs, 990delC); ClinVar=VCV000002990; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21128602 CVCL_AX17 PA 3 cancer cell line human CVCL_AX17 CL:0000010 Unspecified 21128603 CVCL_B917 UM29-3 PGD embryonic stem cell human CVCL_B917 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM29-2 PGD (Cellosaurus=CVCL_B916). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0165 21128604 CVCL_AX19 GM02895 finite cell line human CVCL_AX19 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Male 21128605 CVCL_B919 WCMC-37 embryonic stem cell human CVCL_B919 From: Weill Cornell Medical College; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[142-450]; Zygosity=Hemizygous (PubMed=24289922). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0211 21128606 CVCL_AX01 HPSI0514i-tavh_2 induced pluripotent stem cell human CVCL_AX01 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21128607 CVCL_B901 MA136 embryonic stem cell human CVCL_B901 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21128608 CVCL_AX00 GM02885 finite cell line human CVCL_AX00 CL:0000010 Population: Caucasian; French; Derived from sampling site: Cell type=Fibroblast. Female 21128609 CVCL_B900 MA135 embryonic stem cell human CVCL_B900 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-10-0072. 21128610 CVCL_AX03 HPSI0514i-rutc_2 induced pluripotent stem cell human CVCL_AX03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21128611 CVCL_B903 MA138 embryonic stem cell human CVCL_B903 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21128612 CVCL_AX02 HPSI0414i-zazi_5 induced pluripotent stem cell human CVCL_AX02 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21128613 CVCL_B902 MA137 embryonic stem cell human CVCL_B902 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21128614 CVCL_AX05 HPSI0614i-miaj_6 induced pluripotent stem cell human CVCL_AX05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21128615 CVCL_B905 MA140 embryonic stem cell human CVCL_B905 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21128616 CVCL_AX04 HPSI1014i-babz_3 induced pluripotent stem cell human CVCL_AX04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21128617 CVCL_B904 MA139 embryonic stem cell human CVCL_B904 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21128618 CVCL_0E81 E10.3 transformed cell line house mouse CVCL_0E81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Discontinued: ATCC; CRL-2145; true. Unspecified 21128619 CVCL_0E83 E4D transformed cell line house mouse CVCL_0E83 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-2144; true Unspecified 21128620 CVCL_0E82 E15.3 transformed cell line house mouse CVCL_0E82 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Discontinued: ATCC; CRL-2152; true. Unspecified 21128621 CVCL_0E85 46-3 hybridoma house mouse CVCL_0E85 CL:0000010 Discontinued: ATCC; CRL-2191; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120 21128622 CVCL_0E84 ALC [Mouse bone marrow] stromal cell line house mouse CVCL_0E84 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. 21128623 CVCL_0E87 ADRI Cf2Th-69/EIAV spontaneously immortalized cell line dog CVCL_0E87 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-2251; true Female Virology: In vitro infected by equine infectious anemia virus 21128624 CVCL_0E86 55-100 hybridoma house mouse CVCL_0E86 CL:0000010 Discontinued: ATCC; CRL-2157; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120 21128625 CVCL_0E89 tCPC-B transformed cell line CVCL_0E89 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth bud; dental papilla; molar. Unspecified 21128626 CVCL_0E88 tCPC-12 transformed cell line CVCL_0E88 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth bud; dental papilla; molar. Unspecified 21128627 CVCL_0E92 Carl transformed cell line CVCL_0E92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1857; true Male Group: Non-human primate cell line 21128628 CVCL_0E91 tCPC-D transformed cell line CVCL_0E91 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth bud; dental papilla; molar. Unspecified 21128629 CVCL_0E94 Puti transformed cell line CVCL_0E94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1850; true Female Group: Non-human primate cell line 21128630 CVCL_0E93 Lena transformed cell line CVCL_0E93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1868; true Female Group: Non-human primate cell line 21128631 CVCL_0E96 10P8 transformed cell line house mouse CVCL_0E96 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/cAn. Discontinued: ATCC; CRL-2035; true Unspecified 21128632 CVCL_0E95 Tank transformed cell line CVCL_0E95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1847; true Male Group: Non-human primate cell line 21128633 CVCL_0E98 PA12 transformed cell line house mouse CVCL_0E98 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21128634 CVCL_0E97 OC15 cancer cell line house mouse CVCL_0E97 CL:0000010 Breed/subspecies: 129/Sv. Male 21128635 CVCL_0E99 PA12-Rb transformed cell line house mouse CVCL_0E99 CL:0000010 Transfected with: HGNC; 9884; RB1 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-1916; true Male Group: Retrovirus packaging cell line 21128636 CVCL_0E90 tCPC-C transformed cell line CVCL_0E90 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth bud; dental papilla; molar. Unspecified 21128637 CVCL_AX98 GM06907 transformed cell line human CVCL_AX98 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[85]; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128638 CVCL_B998 SNUhES10 embryonic stem cell human CVCL_B998 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010010. 21128639 CVCL_AX97 GM06906 transformed cell line human CVCL_AX97 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[85-90]; Zygosity=Hemizygous (PubMed=25776194) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128640 CVCL_B997 SNUhES19 embryonic stem cell human CVCL_B997 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010015. 21128641 CVCL_AX99 GM06910 transformed cell line human CVCL_AX99 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75-89]; Zygosity=Heterozygous (PubMed=25776194) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128642 CVCL_B999 SNUhES5 embryonic stem cell human CVCL_B999 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010007. 21128643 CVCL_B990 5A5-WASP hybridoma house mouse CVCL_B990 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42768; Human WAS. 21128644 CVCL_AX90 GM06892 transformed cell line human CVCL_AX90 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[80-85]; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128645 CVCL_B992 ARM193 hybridoma house mouse CVCL_B992 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0A7G6; Escherichia coli recA. 21128646 CVCL_AX92 GM06894 transformed cell line human CVCL_AX92 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[78]; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128647 CVCL_B991 7501 hybridoma house mouse CVCL_B991 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0CS90; Saccharomyces cerevisiae SSC1/ENS1. 21128648 CVCL_AX91 GM06893 transformed cell line human CVCL_AX91 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128649 CVCL_B994 BCL1-B20 cancer cell line house mouse CVCL_B994 CL:0000010 Breed/subspecies: BALB/c. Female 21128650 CVCL_K328 C0053 transformed cell line human CVCL_K328 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128651 CVCL_AX94 GM06897 transformed cell line human CVCL_AX94 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[477]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128652 CVCL_JR28 STAN156i-334C1 induced pluripotent stem cell human CVCL_JR28 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128653 CVCL_B993 ARM321 hybridoma house mouse CVCL_B993 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A7G6; Escherichia coli recA. 21128654 CVCL_K327 C0052 transformed cell line human CVCL_K327 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128655 CVCL_AX93 GM06896 transformed cell line human CVCL_AX93 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[33]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[95-140]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128656 CVCL_JR27 STAN155i-313C2 induced pluripotent stem cell human CVCL_JR27 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128657 CVCL_AX96 GM06905 transformed cell line human CVCL_AX96 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[70]; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128658 CVCL_B996 SNUhES14 embryonic stem cell human CVCL_B996 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010013. 21128659 CVCL_K329 C0054 transformed cell line human CVCL_K329 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128660 CVCL_AX95 GM06903 transformed cell line human CVCL_AX95 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[95]; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128661 CVCL_B995 SNUhES12 embryonic stem cell human CVCL_B995 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010012. 21128662 CVCL_JR29 STAN157i-334C2 induced pluripotent stem cell human CVCL_JR29 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128663 CVCL_K324 C0048 transformed cell line human CVCL_K324 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92031006; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128664 CVCL_JR24 STAN152i-307C2 induced pluripotent stem cell human CVCL_JR24 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128665 CVCL_K323 C0047 transformed cell line human CVCL_K323 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128666 CVCL_JR23 STAN151i-303C3 induced pluripotent stem cell human CVCL_JR23 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128667 CVCL_K326 C0050 transformed cell line human CVCL_K326 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92031007; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128668 CVCL_JR26 STAN154i-312C1 induced pluripotent stem cell human CVCL_JR26 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128669 CVCL_K325 C0049 transformed cell line human CVCL_K325 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128670 CVCL_JR25 STAN153i-307C3 induced pluripotent stem cell human CVCL_JR25 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128671 CVCL_K320 C0044 transformed cell line human CVCL_K320 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93010708; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128672 CVCL_JR20 STAN148i-291C3 induced pluripotent stem cell human CVCL_JR20 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128673 CVCL_K322 C0046 transformed cell line human CVCL_K322 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128674 CVCL_JR22 STAN150i-337C1 induced pluripotent stem cell human CVCL_JR22 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128675 CVCL_K321 C0045 transformed cell line human CVCL_K321 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128676 CVCL_JR21 STAN149i-298C1 induced pluripotent stem cell human CVCL_JR21 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128677 CVCL_K339 C0066 transformed cell line human CVCL_K339 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128678 CVCL_JR39 STAN167i-356C6 induced pluripotent stem cell human CVCL_JR39 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128679 CVCL_K338 C0065 transformed cell line human CVCL_K338 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128680 CVCL_JR38 STAN166i-356C4 induced pluripotent stem cell human CVCL_JR38 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128681 CVCL_K335 C0060 transformed cell line human CVCL_K335 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128682 CVCL_JR35 STAN163i-345C5 induced pluripotent stem cell human CVCL_JR35 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128683 CVCL_K334 C0059 transformed cell line human CVCL_K334 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128684 CVCL_JR34 STAN162i-345C2 induced pluripotent stem cell human CVCL_JR34 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128685 CVCL_K337 C0063 transformed cell line human CVCL_K337 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128686 CVCL_JR37 STAN165i-352C5 induced pluripotent stem cell human CVCL_JR37 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128687 CVCL_K336 C0061 transformed cell line human CVCL_K336 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128688 CVCL_JR36 STAN164i-352C1 induced pluripotent stem cell human CVCL_JR36 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128689 CVCL_K331 C0056 transformed cell line human CVCL_K331 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91081910; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128690 CVCL_JR31 STAN159i-336C3 induced pluripotent stem cell human CVCL_JR31 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128691 CVCL_K330 C0055 transformed cell line human CVCL_K330 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128692 CVCL_JR30 STAN158i-336C2 induced pluripotent stem cell human CVCL_JR30 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128693 CVCL_K333 C0058 transformed cell line human CVCL_K333 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128694 CVCL_JR33 STAN161i-341C5 induced pluripotent stem cell human CVCL_JR33 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128695 CVCL_K332 C0057 transformed cell line human CVCL_K332 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93011304; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128696 CVCL_JR32 STAN160i-341C4 induced pluripotent stem cell human CVCL_JR32 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128697 CVCL_AX76 GM03200 transformed cell line human CVCL_AX76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128698 CVCL_B976 TSt-4/N somatic stem cell house mouse CVCL_B976 CL:0000010 Transfected with: HGNC; 7809; NGFR Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Parent cell line is not from strain C57BL/6 as originally published but from strain BALB/c (DOI=10.4051/ibc.2010.2.4.0014) 21128699 CVCL_AX75 EC-RF7 transformed cell line human CVCL_AX75 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. 21128700 CVCL_B975 TSt-4/G-DLL1 somatic stem cell house mouse CVCL_B975 CL:0000010 Transfected with: MGI; MGI:104659; Dll1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Parent cell line is not from strain C57BL/6 as originally published but from strain BALB/c (DOI=10.4051/ibc.2010.2.4.0014) 21128701 CVCL_B978 BRC1 embryonic stem cell house mouse CVCL_B978 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x 129. Discontinued: RCB; RCB2004; true Unspecified 21128702 CVCL_AX78 GM05131 finite cell line human CVCL_AX78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128703 CVCL_AX77 GM04026 finite cell line human CVCL_AX77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21128704 CVCL_B977 TSt-4/N-DLL1 somatic stem cell house mouse CVCL_B977 CL:0000010 Transfected with: HGNC; 7809; NGFR; Transfected with: MGI; MGI:104659; Dll1 Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Parent cell line is not from strain C57BL/6 as originally published but from strain BALB/c (DOI=10.4051/ibc.2010.2.4.0014) 21128705 CVCL_B979 BRC2 embryonic stem cell house mouse CVCL_B979 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x (C57BL/6 x DBA/2). Discontinued: RCB; RCB2005; true Unspecified 21128706 CVCL_AX79 GM05132 finite cell line human CVCL_AX79 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21128707 CVCL_K309 C0030 transformed cell line human CVCL_K309 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128708 CVCL_JR09 STAN135i-230C1 induced pluripotent stem cell human CVCL_JR09 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128709 CVCL_B970 iPS-L2 induced pluripotent stem cell CVCL_B970 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Dutch Belted. Female 21128710 CVCL_AX70 NYSCF2 embryonic stem cell human CVCL_AX70 From: New York Stem Cell Foundation; New York; USA. CL:0000010 Unspecified 21128711 CVCL_K306 C0027 transformed cell line human CVCL_K306 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128712 CVCL_AX72 HMSc2 embryonic stem cell house mouse CVCL_AX72 CL:0000010 Breed/subspecies: C57BL/6 x 129. Female Group: Haploid karyotype cell line 21128713 CVCL_JR06 STAN132i-214C4 induced pluripotent stem cell human CVCL_JR06 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128714 CVCL_B972 UBT-5 telomerase immortalized cell line human CVCL_B972 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21128715 CVCL_K305 C0025 transformed cell line human CVCL_K305 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92031003; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128716 CVCL_AX71 HMSc1 embryonic stem cell house mouse CVCL_AX71 CL:0000010 Breed/subspecies: C57BL/6 x 129. Female Group: Haploid karyotype cell line 21128717 CVCL_JR05 STAN131i-214C3 induced pluripotent stem cell human CVCL_JR05 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128718 CVCL_B971 UBT-14 telomerase immortalized cell line human CVCL_B971 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21128719 CVCL_K308 C0029 transformed cell line human CVCL_K308 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128720 CVCL_AX74 EC-RF24 transformed cell line human CVCL_AX74 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. 21128721 CVCL_JR08 STAN134i-215C2 induced pluripotent stem cell human CVCL_JR08 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128722 CVCL_B974 TSt-4/G somatic stem cell house mouse CVCL_B974 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Parent cell line is not from strain C57BL/6 as originally published but from strain BALB/c (DOI=10.4051/ibc.2010.2.4.0014) 21128723 CVCL_K307 C0028 transformed cell line human CVCL_K307 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128724 CVCL_AX73 NCI-H226Br cancer cell line human CVCL_AX73 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Val (c.760A>G); ClinVar=VCV000406605; Zygosity=Homozygous (PubMed=8089864) Derived from sampling site: Pleural effusion. Male Characteristics: Established from brain metastasis tumor of athymic BALB/c mice after carotid artery injection of parent cell line 21128725 CVCL_JR07 STAN133i-215C1 induced pluripotent stem cell human CVCL_JR07 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128726 CVCL_B973 TSt-4 somatic stem cell house mouse CVCL_B973 CL:0000010 Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Not from strain C57BL/6 as originally published but from strain BALB/c (DOI=10.4051/ibc.2010.2.4.0014) 21128727 CVCL_K302 C0020 transformed cell line human CVCL_K302 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128728 CVCL_JR02 STAN128i-211C2 induced pluripotent stem cell human CVCL_JR02 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128729 CVCL_K301 C0019 transformed cell line human CVCL_K301 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128730 CVCL_JR01 STAN126i-202C3 induced pluripotent stem cell human CVCL_JR01 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128731 CVCL_K304 C0024 transformed cell line human CVCL_K304 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128732 CVCL_JR04 STAN130i-212C4 induced pluripotent stem cell human CVCL_JR04 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128733 CVCL_K303 C0022 transformed cell line human CVCL_K303 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128734 CVCL_JR03 STAN129i-212C2 induced pluripotent stem cell human CVCL_JR03 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128735 CVCL_K300 C0018 transformed cell line human CVCL_K300 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128736 CVCL_JR00 STAN125i-202C2 induced pluripotent stem cell human CVCL_JR00 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128737 CVCL_B987 BXM14 embryonic stem cell house mouse CVCL_B987 CL:0000010 Breed/subspecies: C57BL/6 x MSM. Discontinued: RCB; RCB2706; true Unspecified 21128738 CVCL_AX87 GM06889 transformed cell line human CVCL_AX87 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128739 CVCL_B986 BRC9 embryonic stem cell house mouse CVCL_B986 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2012; true Female 21128740 CVCL_AX86 GM06852 transformed cell line human CVCL_AX86 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128741 CVCL_B989 BXM7 embryonic stem cell house mouse CVCL_B989 CL:0000010 Breed/subspecies: C57BL/6 x MSM. Discontinued: RCB; RCB2705; true Unspecified 21128742 CVCL_AX89 GM06891 transformed cell line human CVCL_AX89 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[100-117]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128743 CVCL_B988 BXM15 embryonic stem cell house mouse CVCL_B988 CL:0000010 Breed/subspecies: C57BL/6 x MSM. Discontinued: RCB; RCB2707; true Unspecified 21128744 CVCL_AX88 GM06890 transformed cell line human CVCL_AX88 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21128745 CVCL_B981 BRC4 embryonic stem cell house mouse CVCL_B981 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2007; true Unspecified 21128746 CVCL_AX81 GM05282 finite cell line human CVCL_AX81 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128747 CVCL_B980 BRC3 embryonic stem cell house mouse CVCL_B980 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x (C57BL/6 x DBA/2). Discontinued: RCB; RCB2006; true Unspecified 21128748 CVCL_AX80 GM05185 finite cell line human CVCL_AX80 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21128749 CVCL_B983 BRC6 embryonic stem cell house mouse CVCL_B983 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2009; true Female 21128750 CVCL_K317 C0040 transformed cell line human CVCL_K317 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128751 CVCL_AX83 GM05848 finite cell line human CVCL_AX83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21128752 CVCL_JR17 STAN144i-285C3 induced pluripotent stem cell human CVCL_JR17 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128753 CVCL_B982 BRC5 embryonic stem cell house mouse CVCL_B982 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2008; true Male 21128754 CVCL_K316 C0039 transformed cell line human CVCL_K316 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128755 CVCL_AX82 GM05847 finite cell line human CVCL_AX82 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[21]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[650]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM05847; probable Female 21128756 CVCL_JR16 STAN142i-255C1 induced pluripotent stem cell human CVCL_JR16 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128757 CVCL_B985 BRC8 embryonic stem cell house mouse CVCL_B985 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2011; true Female 21128758 CVCL_K319 C0042 transformed cell line human CVCL_K319 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128759 CVCL_AX85 GM05855 transformed cell line human CVCL_AX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128760 CVCL_JR19 STAN146i-286C2 induced pluripotent stem cell human CVCL_JR19 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128761 CVCL_B984 BRC7 embryonic stem cell house mouse CVCL_B984 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2010; true Unspecified 21128762 CVCL_K318 C0041 transformed cell line human CVCL_K318 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128763 CVCL_AX84 GM05854 transformed cell line human CVCL_AX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21128764 CVCL_JR18 STAN145i-286C1 induced pluripotent stem cell human CVCL_JR18 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128765 CVCL_K313 C0036 transformed cell line human CVCL_K313 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128766 CVCL_JR13 STAN139i-239C5 induced pluripotent stem cell human CVCL_JR13 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128767 CVCL_K312 C0035 transformed cell line human CVCL_K312 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128768 CVCL_JR12 STAN138i-239C3 induced pluripotent stem cell human CVCL_JR12 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128769 CVCL_K315 C0038 transformed cell line human CVCL_K315 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128770 CVCL_JR15 STAN141i-250C4 induced pluripotent stem cell human CVCL_JR15 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128771 CVCL_K314 C0037 transformed cell line human CVCL_K314 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128772 CVCL_JR14 STAN140i-243C1 induced pluripotent stem cell human CVCL_JR14 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128773 CVCL_K311 C0034 transformed cell line human CVCL_K311 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128774 CVCL_JR11 STAN137i-231C3 induced pluripotent stem cell human CVCL_JR11 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128775 CVCL_K310 C0032 transformed cell line human CVCL_K310 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128776 CVCL_JR10 STAN136i-230C2 induced pluripotent stem cell human CVCL_JR10 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128777 CVCL_AX54 COG-N-261h cancer cell line human CVCL_AX54 CL:0000010 Male 21128778 CVCL_B954 PAb 419 hybridoma house mouse CVCL_B954 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen (Note=Recognizes N-terminus). 21128779 CVCL_B953 B13.29 hybridoma house mouse CVCL_B953 CL:0000010 Characteristics: IL6 dependent. 21128780 CVCL_AX53 COG-N-387h cancer cell line human CVCL_AX53 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced. Unspecified 21128781 CVCL_AX56 COG-N-276h cancer cell line human CVCL_AX56 CL:0000010 Unspecified 21128782 CVCL_B956 H36.12b hybrid cell line house mouse CVCL_B956 CL:0000010 21128783 CVCL_AX55 COG-N-265 cancer cell line human CVCL_AX55 CL:0000010 Male 21128784 CVCL_B955 H36.12a hybrid cell line house mouse CVCL_B955 CL:0000010 21128785 CVCL_AX58 COG-N-299 cancer cell line human CVCL_AX58 CL:0000010 Male 21128786 CVCL_B958 H36.12e hybrid cell line house mouse CVCL_B958 CL:0000010 21128787 CVCL_AX57 COG-N-297 cancer cell line human CVCL_AX57 CL:0000010 Unspecified 21128788 CVCL_B957 H36.12d hybrid cell line house mouse CVCL_B957 CL:0000010 21128789 CVCL_AX59 COG-N-324 cancer cell line human CVCL_AX59 CL:0000010 Male 21128790 CVCL_B959 H36.12j hybrid cell line house mouse CVCL_B959 CL:0000010 21128791 CVCL_AX50 COG-N-349 cancer cell line human CVCL_AX50 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced. Male 21128792 CVCL_B950 LAG spontaneously immortalized cell line house mouse CVCL_B950 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21128793 CVCL_AX52 COG-N-386h cancer cell line human CVCL_AX52 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced. Unspecified 21128794 CVCL_B952 D4 [Mouse NIH 3T3 ERBB2 transfected] spontaneously immortalized cell line house mouse CVCL_B952 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with C-terminal deletion) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21128795 CVCL_AX51 COG-N-367h cancer cell line human CVCL_AX51 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced. Male 21128796 CVCL_B951 LAG-MUC1 spontaneously immortalized cell line house mouse CVCL_B951 CL:0000010 Transfected with: HGNC; 7508; MUC1 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21128797 CVCL_B965 ARMD1-hiPSC8 induced pluripotent stem cell human CVCL_B965 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128798 CVCL_AX65 COG-N-354h cancer cell line human CVCL_AX65 CL:0000010 Unspecified 21128799 CVCL_B964 ARMD1-hiPSC5 induced pluripotent stem cell human CVCL_B964 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128800 CVCL_AX64 COG-N-354 cancer cell line human CVCL_AX64 CL:0000010 Unspecified 21128801 CVCL_AX67 COG-N-294 cancer cell line human CVCL_AX67 CL:0000010 Male 21128802 CVCL_B967 iPS-S1 induced pluripotent stem cell CVCL_B967 CL:0000010 Derived from sampling site: Stomach; Breed/subspecies: Dutch Belted. Female 21128803 CVCL_B966 ARMD1-hiPSC9 induced pluripotent stem cell human CVCL_B966 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128804 CVCL_AX66 COG-N-253 cancer cell line human CVCL_AX66 CL:0000010 21128805 CVCL_AX69 h-pES12 embryonic stem cell human CVCL_AX69 CL:0000010 Anecdotal: First human haploid embryonic stem cell line (with h-PES10 (Cellosaurus=CVCL_AX68)). Female Group: Haploid karyotype cell line 21128806 CVCL_B969 iPS-L1 induced pluripotent stem cell CVCL_B969 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Dutch Belted. Female 21128807 CVCL_AX68 h-pES10 embryonic stem cell human CVCL_AX68 CL:0000010 Anecdotal: First human haploid embryonic stem cell line (with h-PES12 (Cellosaurus=CVCL_AX69)). Female Group: Haploid karyotype cell line 21128808 CVCL_B968 iPS-S2 induced pluripotent stem cell CVCL_B968 CL:0000010 Derived from sampling site: Stomach; Breed/subspecies: Dutch Belted. Female 21128809 CVCL_B961 ARMD1-hiPSC11 induced pluripotent stem cell human CVCL_B961 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128810 CVCL_AX61 COG-N-331 cancer cell line human CVCL_AX61 CL:0000010 Unspecified 21128811 CVCL_B960 ARMD1-hiPSC1 induced pluripotent stem cell human CVCL_B960 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128812 CVCL_AX60 COG-N-328h cancer cell line human CVCL_AX60 CL:0000010 Male 21128813 CVCL_B963 ARMD1-hiPSC4 induced pluripotent stem cell human CVCL_B963 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128814 CVCL_AX63 COG-N-346h cancer cell line human CVCL_AX63 CL:0000010 Male 21128815 CVCL_B962 ARMD1-hiPSC2 induced pluripotent stem cell human CVCL_B962 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21128816 CVCL_AX62 COG-N-334 cancer cell line human CVCL_AX62 CL:0000010 Unspecified 21128817 CVCL_B932 Lis1 embryonic stem cell human CVCL_B932 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Female 21128818 CVCL_AX32 WSU-HN25 cancer cell line human CVCL_AX32 CL:0000010 Unspecified 21128819 CVCL_B931 Lis09_DYS1 embryonic stem cell human CVCL_B931 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0336. 21128820 CVCL_AX31 WSU-HN24 cancer cell line human CVCL_AX31 CL:0000010 Unspecified 21128821 CVCL_B934 Lis11_DMD2 embryonic stem cell human CVCL_B934 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex44-47del; Zygosity=Hemizygous (PubMed=20186514). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0338 21128822 CVCL_AX34 PLA-802 cancer cell line human CVCL_AX34 CL:0000010 Population: Chinese Male Doubling time: 42 hours (CelloPub=CLPUB00322). 21128823 CVCL_B933 Lis10_DMD1 embryonic stem cell human CVCL_B933 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex44-47del; Zygosity=Heterozygous (PubMed=20186514). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0337 21128824 CVCL_AX33 WSU-HN28 cancer cell line human CVCL_AX33 CL:0000010 Unspecified 21128825 CVCL_B936 Lis13_Alport2 embryonic stem cell human CVCL_B936 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Female 21128826 CVCL_AX36 S805 cancer cell line human CVCL_AX36 CL:0000010 Unspecified 21128827 CVCL_B935 Lis12_DM1 embryonic stem cell human CVCL_B935 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0339. 21128828 CVCL_AX35 S520 cancer cell line human CVCL_AX35 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (PubMed=15207265); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=15207265); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg440Ter (c.1318C>T); ClinVar=VCV000230673; Zygosity=Heterozygous (PubMed=15207265) Derived from sampling site: Shoulder. Male 21128829 CVCL_B938 MRIi005-A induced pluripotent stem cell human CVCL_B938 From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg190Gln (c.569G>A) (p.Arg63Gln, c.188G>A); ClinVar=VCV000003117; Zygosity=Heterozygous (PubMed=20660394) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21128830 CVCL_AX38 NGP.1A.TR1 cancer cell line human CVCL_AX38 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Lung. Male 21128831 CVCL_AX37 HT1080 FUS-DDIT3-EGFP cancer cell line human CVCL_AX37 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2726; DDIT3 (FUS-DDIT3 fusion); Transfected with: HGNC; 4010; FUS (FUS-DDIT3 fusion); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Omics: Transcriptome analysis by RNAseq Male 21128832 CVCL_B937 Lis14_Alport3 embryonic stem cell human CVCL_B937 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0340. 21128833 CVCL_B930 Lis08_AIS2 embryonic stem cell human CVCL_B930 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Unexplicit; Ex5 small deletion; Zygosity=Unspecified (PubMed=20186514). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0335 21128834 CVCL_AX30 WSU-HN18 cancer cell line human CVCL_AX30 CL:0000010 Unspecified 21128835 CVCL_B929 Lis07_AIS1 embryonic stem cell human CVCL_B929 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Unexplicit; Ex5 small deletion; Zygosity=Unspecified (PubMed=20186514). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0334 21128836 CVCL_AX29 WSU-HN14 cancer cell line human CVCL_AX29 CL:0000010 Unspecified 21128837 CVCL_B928 Lis06_Gaucher1 embryonic stem cell human CVCL_B928 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (PubMed=20186514; PubMed=21585244). Female 21128838 CVCL_AX28 WSU-HN11 cancer cell line human CVCL_AX28 CL:0000010 Unspecified 21128839 CVCL_AX43 COG-N-295 cancer cell line human CVCL_AX43 CL:0000010 Unspecified 21128840 CVCL_B943 iBM9 induced pluripotent stem cell human CVCL_B943 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Bone marrow. Female 21128841 CVCL_AX42 COG-N-305 cancer cell line human CVCL_AX42 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Tyr216Ter (c.648C>A); Zygosity=Unspecified (PubMed=23202128; DepMap) Omics: Deep exome analysis. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21128842 CVCL_B942 iBM5 induced pluripotent stem cell human CVCL_B942 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Bone marrow. Male 21128843 CVCL_AX45 COG-N-289 cancer cell line human CVCL_AX45 CL:0000010 Male 21128844 CVCL_B945 LACF-NaNaII finite cell line CVCL_B945 CL:0000010 Anecdotal: Established from Nana, an elephant kept in Asahiyama Zoo in Japan and that died in 2006 Derived from sampling site: Ear. Female 21128845 CVCL_AX44 COG-N-318 cancer cell line human CVCL_AX44 CL:0000010 Male 21128846 CVCL_B944 LACF-NaNaI finite cell line CVCL_B944 CL:0000010 Anecdotal: Established from Nana, an elephant kept in Asahiyama Zoo in Japan and that died in 2006 Derived from sampling site: Oral cavity; gingiva. Female 21128847 CVCL_B947 CMES30 embryonic stem cell CVCL_B947 CL:0000010 Female Group: Non-human primate cell line. 21128848 CVCL_AX47 COG-N-327h cancer cell line human CVCL_AX47 CL:0000010 Male 21128849 CVCL_B946 CMES40 embryonic stem cell CVCL_B946 CL:0000010 Omics: Transcriptome analysis by RNAseq Discontinued: RCB; AES0053; probable; Discontinued: RCB; RCB2294; true. Female Group: Non-human primate cell line Caution: Incorrectly indicated as male in RCB=AES0166 21128850 CVCL_AX46 COG-N-263 cancer cell line human CVCL_AX46 CL:0000010 Male 21128851 CVCL_AX49 COG-N-278 cancer cell line human CVCL_AX49 CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21128852 CVCL_B949 JLS-V9 6TG spontaneously immortalized cell line house mouse CVCL_B949 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Unspecified 21128853 CVCL_AX48 CHLA-253h cancer cell line human CVCL_AX48 CL:0000010 Male 21128854 CVCL_B948 CMES20 embryonic stem cell CVCL_B948 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Group: Non-human primate cell line 21128855 CVCL_B941 AMN iPSC-3 induced pluripotent stem cell human CVCL_B941 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Unexplicit; Ex8-10del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21128856 CVCL_AX41 CHLA-151 cancer cell line human CVCL_AX41 CL:0000010 Male 21128857 CVCL_B940 CCALD iPSC-2 induced pluripotent stem cell human CVCL_B940 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128858 CVCL_B939 CCALD iPSC-10 induced pluripotent stem cell human CVCL_B939 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21128859 CVCL_AX39 ES2 cancer cell line human CVCL_AX39 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Glu523Ter (c.1567G>T); Zygosity=Unspecified (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25010205). 21128860 CVCL_SK28 HAP1 CYR61 (-) 1 cancer cell line human CVCL_SK28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2654; CCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128861 CVCL_SK27 HAP1 CYP51A1 (-) 2 cancer cell line human CVCL_SK27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2649; CYP51A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128862 CVCL_SK29 HAP1 DAG1 (-) 1 cancer cell line human CVCL_SK29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2666; DAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128863 CVCL_K287 C0003 transformed cell line human CVCL_K287 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128864 CVCL_JQ87 STAN107i-121C2 induced pluripotent stem cell human CVCL_JQ87 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128865 CVCL_K286 C0002 transformed cell line human CVCL_K286 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128866 CVCL_JQ86 STAN106i-121C1 induced pluripotent stem cell human CVCL_JQ86 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128867 CVCL_K289 C0005 transformed cell line human CVCL_K289 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128868 CVCL_JQ89 STAN109i-123C3 induced pluripotent stem cell human CVCL_JQ89 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128869 CVCL_K288 C0004 transformed cell line human CVCL_K288 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128870 CVCL_JQ88 STAN108i-123C2 induced pluripotent stem cell human CVCL_JQ88 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128871 CVCL_SK31 HAP1 DAPK1 (-) 1 cancer cell line human CVCL_SK31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2674; DAPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128872 CVCL_JQ83 STAN099i-108C2 induced pluripotent stem cell human CVCL_JQ83 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128873 CVCL_K283 WPE-stem transformed cell line human CVCL_K283 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21128874 CVCL_SK30 HAP1 DAG1 (-) 2 cancer cell line human CVCL_SK30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2666; DAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128875 CVCL_JQ82 STAN098i-107C4 induced pluripotent stem cell human CVCL_JQ82 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128876 CVCL_K282 WPE-int transformed cell line human CVCL_K282 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21128877 CVCL_SK33 HAP1 DAPK2 (-) cancer cell line human CVCL_SK33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2675; DAPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128878 CVCL_JQ85 STAN104i-120C3 induced pluripotent stem cell human CVCL_JQ85 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128879 CVCL_K285 WPE1-NB26-65 transformed cell line human CVCL_K285 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Established from WPE1-NB26 cells that formed subcutaneous tumors following cell injection in athymic mice 21128880 CVCL_SK32 HAP1 DAPK1 (-) 2 cancer cell line human CVCL_SK32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2674; DAPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128881 CVCL_JQ84 STAN100i-108C4 induced pluripotent stem cell human CVCL_JQ84 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128882 CVCL_K284 WPE1-NB26-64 transformed cell line human CVCL_K284 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Established from WPE1-NB26 cells that formed subcutaneous tumors following cell injection in athymic mice 21128883 CVCL_SK35 HAP1 DAPK3 (-) 2 cancer cell line human CVCL_SK35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2676; DAPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128884 CVCL_SK34 HAP1 DAPK3 (-) 1 cancer cell line human CVCL_SK34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2676; DAPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128885 CVCL_SK37 HAP1 DAXX (-) 2 cancer cell line human CVCL_SK37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128886 CVCL_K281 sNF96.2 cancer cell line human CVCL_K281 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Asn1229Metfs*11 (c.3683delC); Zygosity=Hemizygous (PubMed=17876295) Derived from sampling site: Peripheral nervous system; lower leg nerve Cell type=Schwann cell.. Male Doubling time: ~33 hours (ATCC=CRL-2884) 21128887 CVCL_JQ81 STAN097i-107C3 induced pluripotent stem cell human CVCL_JQ81 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128888 CVCL_SK36 HAP1 DAXX (-) 1 cancer cell line human CVCL_SK36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2681; DAXX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128889 CVCL_K280 sNF02.2 cancer cell line human CVCL_K280 CL:0000010 Derived from metastatic site: Lung. Male Doubling time: ~26 hours (ATCC=CRL-2885) 21128890 CVCL_JQ80 STAN096i-102C6 induced pluripotent stem cell human CVCL_JQ80 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128891 CVCL_SK17 HAP1 CTTN (-) 1 cancer cell line human CVCL_SK17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3338; CTTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128892 CVCL_SK16 HAP1 CTSB (-) 1 cancer cell line human CVCL_SK16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128893 CVCL_SK19 HAP1 CTTN (-) 3 cancer cell line human CVCL_SK19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3338; CTTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128894 CVCL_SK18 HAP1 CTTN (-) 2 cancer cell line human CVCL_SK18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3338; CTTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128895 CVCL_K298 C0015 transformed cell line human CVCL_K298 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93010705; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128896 CVCL_JQ98 STAN121i-193C2 induced pluripotent stem cell human CVCL_JQ98 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128897 CVCL_K297 C0013 transformed cell line human CVCL_K297 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128898 CVCL_JQ97 STAN120i-192C2 induced pluripotent stem cell human CVCL_JQ97 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128899 CVCL_K299 C0016 transformed cell line human CVCL_K299 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128900 CVCL_JQ99 STAN122i-193C1 induced pluripotent stem cell human CVCL_JQ99 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128901 CVCL_K294 C0010 transformed cell line human CVCL_K294 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128902 CVCL_SK20 HAP1 CTTN (-) 4 cancer cell line human CVCL_SK20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3338; CTTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128903 CVCL_JQ94 STAN117i-182C4 induced pluripotent stem cell human CVCL_JQ94 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128904 CVCL_K293 C0009 transformed cell line human CVCL_K293 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128905 CVCL_JQ93 STAN116i-148C4 induced pluripotent stem cell human CVCL_JQ93 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128906 CVCL_K296 C0012 transformed cell line human CVCL_K296 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128907 CVCL_SK22 HAP1 CXXC1 (-) 1 cancer cell line human CVCL_SK22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24343; CXXC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128908 CVCL_JQ96 STAN119i-192C1 induced pluripotent stem cell human CVCL_JQ96 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128909 CVCL_K295 C0011 transformed cell line human CVCL_K295 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93010704; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128910 CVCL_SK21 HAP1 CXADR (-) 1 cancer cell line human CVCL_SK21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2559; CXADR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128911 CVCL_JQ95 STAN118i-182C7 induced pluripotent stem cell human CVCL_JQ95 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128912 CVCL_K290 C0006 transformed cell line human CVCL_K290 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128913 CVCL_SK24 HAP1 CYLD (-) 1 cancer cell line human CVCL_SK24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2584; CYLD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128914 CVCL_JQ90 STAN111i-125C4 induced pluripotent stem cell human CVCL_JQ90 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128915 CVCL_SK23 HAP1 CXXC1 (-) 2 cancer cell line human CVCL_SK23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24343; CXXC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128916 CVCL_K292 C0008 transformed cell line human CVCL_K292 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128917 CVCL_SK26 HAP1 CYP51A1 (-) 1 cancer cell line human CVCL_SK26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2649; CYP51A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128918 CVCL_JQ92 STAN115i-148C2 induced pluripotent stem cell human CVCL_JQ92 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128919 CVCL_K291 C0007 transformed cell line human CVCL_K291 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21128920 CVCL_SK25 HAP1 CYLD (-) 2 cancer cell line human CVCL_SK25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2584; CYLD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128921 CVCL_JQ91 STAN114i-135C2 induced pluripotent stem cell human CVCL_JQ91 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128922 CVCL_SK06 HAP1 CTDSPL (-) 3 cancer cell line human CVCL_SK06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16890; CTDSPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128923 CVCL_SK05 HAP1 CTDSPL (-) 2 cancer cell line human CVCL_SK05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16890; CTDSPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128924 CVCL_SK08 HAP1 CTIF (-) 1 cancer cell line human CVCL_SK08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23925; CTIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128925 CVCL_SK07 HAP1 CTH (-) 1 cancer cell line human CVCL_SK07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2501; CTH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128926 CVCL_SK09 HAP1 CTIF (-) 2 cancer cell line human CVCL_SK09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23925; CTIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128927 CVCL_K269 CC7T/VGH cancer cell line human CVCL_K269 CL:0000010 Population: Chinese; Derived from sampling site: Uterus; cervix. Female Doubling time: 34 hours (CelloPub=CLPUB00027) 21128928 CVCL_JQ69 STAN084i-041C1 induced pluripotent stem cell human CVCL_JQ69 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128929 CVCL_K268 LOC cancer cell line CVCL_K268 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Ovary. Female Group: Bird cell line 21128930 CVCL_JQ68 STAN083i-024C4 induced pluripotent stem cell human CVCL_JQ68 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128931 CVCL_K265 Don/a23 spontaneously immortalized cell line CVCL_K265 CL:0000010 Derived from sampling site: Lung. Male 21128932 CVCL_JQ65 STAN080i-023C2 induced pluripotent stem cell human CVCL_JQ65 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128933 CVCL_K264 A238 spontaneously immortalized cell line CVCL_K264 CL:0000010 Derived from sampling site: Lung. Male 21128934 CVCL_JQ64 STAN079i-018C3 induced pluripotent stem cell human CVCL_JQ64 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128935 CVCL_K267 PSGK-S-85 undefined cell line type CVCL_K267 CL:0000010 Unspecified 21128936 CVCL_JQ67 STAN082i-024C1 induced pluripotent stem cell human CVCL_JQ67 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128937 CVCL_K266 PSGK-60 undefined cell line type CVCL_K266 CL:0000010 Derived from sampling site: Kidney. Unspecified 21128938 CVCL_JQ66 STAN081i-023C3 induced pluripotent stem cell human CVCL_JQ66 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128939 CVCL_K261 PCH54-37 hybridoma house mouse CVCL_K261 CL:0000010 Monoclonal antibody isotype: IgM. 21128940 CVCL_JQ61 STAN076i-004C1 induced pluripotent stem cell human CVCL_JQ61 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128941 CVCL_JQ60 AN4Rppc7 transformed cell line house mouse CVCL_JQ60 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland. 21128942 CVCL_K260 PCH42-63 hybridoma house mouse CVCL_K260 CL:0000010 Monoclonal antibody isotype: IgM. 21128943 CVCL_K263 GM2-1TKB finite cell line human CVCL_K263 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21128944 CVCL_SK11 HAP1 CTNNB1 (-) 1 cancer cell line human CVCL_SK11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128945 CVCL_JQ63 STAN078i-018C2 induced pluripotent stem cell human CVCL_JQ63 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128946 CVCL_SK10 HAP1 CTNNA1 (-) 1 cancer cell line human CVCL_SK10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2509; CTNNA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128947 CVCL_K262 P20.1 hybridoma house mouse CVCL_K262 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96RI0; Human F2RL3/PAR4 (Note=Binds to the hexapeptide GYPGQV used in the TARGET tag system). 21128948 CVCL_JQ62 STAN077i-004C2 induced pluripotent stem cell human CVCL_JQ62 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128949 CVCL_SK13 HAP1 CTNNB1 (-) 3 cancer cell line human CVCL_SK13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128950 CVCL_SK12 HAP1 CTNNB1 (-) 2 cancer cell line human CVCL_SK12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128951 CVCL_SK15 HAP1 CTNS (-) 1 cancer cell line human CVCL_SK15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2518; CTNS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128952 CVCL_SK14 HAP1 CTNNB1 (-) 4 cancer cell line human CVCL_SK14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2514; CTNNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128953 CVCL_K279 SK-RST spontaneously immortalized cell line pig CVCL_K279 CL:0000010 Derived from sampling site: Kidney. Male 21128954 CVCL_JQ79 STAN095i-102C4 induced pluripotent stem cell human CVCL_JQ79 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128955 CVCL_K276 FHCR-1-2813/FDC-6 hybridoma house mouse CVCL_K276 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9018 21128956 CVCL_JQ76 STAN091i-071C2 induced pluripotent stem cell human CVCL_JQ76 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128957 CVCL_K275 FHCR-1-2624/FH6/FHOT-1-3019 hybridoma house mouse CVCL_K275 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:61093; Alpha-Neu5Ac-(2->3)-beta-D-Gal (1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-[alpha-L-Fuc-(1->3)]-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Cer (Ganglioside B6). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8873 21128958 CVCL_JQ75 STAN090i-070C4 induced pluripotent stem cell human CVCL_JQ75 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128959 CVCL_K278 RPTEC/TERT1 telomerase immortalized cell line human CVCL_K278 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Metabolome analysis Male Doubling time: ~96 hours (PubMed=18715936); 76.8 hours (PubMed=31078587); 72-96 hours (Evercyte) 21128960 CVCL_JQ78 STAN094i-081C2 induced pluripotent stem cell human CVCL_JQ78 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128961 CVCL_K277 RHCT-138 cancer cell line CVCL_K277 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Breed/subspecies: New Zealand white. Male 21128962 CVCL_JQ77 STAN093i-081C1 induced pluripotent stem cell human CVCL_JQ77 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128963 CVCL_K272 FHCR-1-2075/FH4 hybridoma house mouse CVCL_K272 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Difucosylated and trifucosylated type 2 chain glycolipids. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8775 21128964 CVCL_JQ72 STAN087i-054C2 induced pluripotent stem cell human CVCL_JQ72 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128965 CVCL_K271 NCTC 721 spontaneously immortalized cell line house mouse CVCL_K271 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3H/An. Male 21128966 CVCL_JQ71 STAN086i-054C1 induced pluripotent stem cell human CVCL_JQ71 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128967 CVCL_K274 FHCR-1-2516/FH7 hybridoma house mouse CVCL_K274 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8861 21128968 CVCL_SK00 HAP1 CTDSP1 (-) 1 cancer cell line human CVCL_SK00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21614; CTDSP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128969 CVCL_JQ74 STAN089i-070C2 induced pluripotent stem cell human CVCL_JQ74 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128970 CVCL_K273 FHCR-1-2075/FH5 hybridoma house mouse CVCL_K273 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Trifucosylated type 2 chain glycolipids. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8770 21128971 CVCL_JQ73 STAN088i-060C1 induced pluripotent stem cell human CVCL_JQ73 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128972 CVCL_SK02 HAP1 CTDSP2 (-) 1 cancer cell line human CVCL_SK02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17077; CTDSP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128973 CVCL_SK01 HAP1 CTDSP1 (-) 2 cancer cell line human CVCL_SK01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21614; CTDSP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128974 CVCL_SK04 HAP1 CTDSPL (-) 1 cancer cell line human CVCL_SK04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16890; CTDSPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128975 CVCL_JQ70 STAN085i-041C3 induced pluripotent stem cell human CVCL_JQ70 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21128976 CVCL_K270 XS52 spontaneously immortalized cell line house mouse CVCL_K270 CL:0000010 Derived from sampling site: Trunk; skin; epidermis Cell type=Dendritic cell.; Breed/subspecies: BALB/c. Female 21128977 CVCL_SK03 HAP1 CTDSP2 (-) 2 cancer cell line human CVCL_SK03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17077; CTDSP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21128978 CVCL_K247 Ba/F3-hGHR factor-dependent cell line house mouse CVCL_K247 CL:0000010 Transfected with: HGNC; 4263; GHR Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21128979 CVCL_JQ47 h-TREK-1/HEK transformed cell line human CVCL_JQ47 CL:0000010 Transfected with: HGNC; 6277; KCNK2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21128980 CVCL_JQ46 CMMT/CD4 cancer cell line CVCL_JQ46 CL:0000010 Transfected with: HGNC; 1678; CD4 Transformant: Mason-Pfizer monkey virus (MPMV)(NCBI-Taxonomy; 11855); Derived from sampling site: Mammary gland. Female Group: Non-human primate cell line 21128981 CVCL_K246 TonB210.1 factor-dependent cell line house mouse CVCL_K246 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21128982 CVCL_JQ49 CMT7364/5-FU cancer cell line dog CVCL_JQ49 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU). Female Doubling time: 48.6 +- 0.3 hours (PubMed=28525328) 21128983 CVCL_K249 MOHITO cancer cell line house mouse CVCL_K249 CL:0000010 Breed/subspecies: BALB/c. Female Characteristics: IL2 and IL7 dependent 21128984 CVCL_K248 Baf3/WSX E63x7 sort factor-dependent cell line house mouse CVCL_K248 CL:0000010 Transfected with: HGNC; 6554; LEPR Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12015 Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21128985 CVCL_JQ48 CMT7364 cancer cell line dog CVCL_JQ48 CL:0000010 Female Doubling time: 31.6 +- 0.6 hours (PubMed=28525328). 21128986 CVCL_JQ43 HPSI1213i-pahc_6 induced pluripotent stem cell human CVCL_JQ43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128987 CVCL_K243 UHKT-42 cancer cell line human CVCL_K243 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21128988 CVCL_JQ42 HPSI1213i-nusw_3 induced pluripotent stem cell human CVCL_JQ42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128989 CVCL_K242 PER-423 cancer cell line human CVCL_K242 CL:0000010 Male Characteristics: IL2 dependent. 21128990 CVCL_JQ45 HPSI1213i-xuja_3 induced pluripotent stem cell human CVCL_JQ45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128991 CVCL_K245 S21 transformed cell line house mouse CVCL_K245 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21128992 CVCL_JQ44 HPSI1213i-xuja_1 induced pluripotent stem cell human CVCL_JQ44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21128993 CVCL_K244 LALW-2 cancer cell line human CVCL_K244 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Established from a xenograft 21128994 CVCL_JQ41 HPSI1213i-nusw_1 induced pluripotent stem cell human CVCL_JQ41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128995 CVCL_K241 MDCK/60 spontaneously immortalized cell line dog CVCL_K241 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21128996 CVCL_JQ40 HPSI1213i-nekd_3 induced pluripotent stem cell human CVCL_JQ40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21128997 CVCL_K240 RH-L4 cancer cell line human CVCL_K240 CL:0000010 21128998 CVCL_JQ58 OPCT-1 clone P6D4 transformed cell line human CVCL_JQ58 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21128999 CVCL_K258 PCH41-44 hybridoma house mouse CVCL_K258 CL:0000010 Monoclonal antibody isotype: IgM. 21129000 CVCL_JQ57 OPCT-1 clone P5B3 transformed cell line human CVCL_JQ57 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21129001 CVCL_K257 PCH41-43 hybridoma house mouse CVCL_K257 CL:0000010 Monoclonal antibody isotype: IgM. 21129002 CVCL_JQ59 HBLAK spontaneously immortalized cell line human CVCL_JQ59 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=28035326); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28035326) Derived from sampling site: Urinary bladder Cell type=Urothelial cell.. Omics: Deep exome analysis Male Doubling time: ~30 hours (PubMed=28035326) 21129003 CVCL_K259 PCH42-58 hybridoma house mouse CVCL_K259 CL:0000010 Monoclonal antibody isotype: IgM. 21129004 CVCL_K254 CHO 4364 spontaneously immortalized cell line CVCL_K254 CL:0000010 Derived from sampling site: Ovary. Female 21129005 CVCL_JQ54 HeLa/SN100 cancer cell line human CVCL_JQ54 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21129006 CVCL_JQ53 HeLa/SN10 cancer cell line human CVCL_JQ53 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21129007 CVCL_K253 XR-1 spontaneously immortalized cell line CVCL_K253 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Both alleles of Xrcc4 are deleted in this cell line 21129008 CVCL_JQ56 OPCT-1 clone P4B6 transformed cell line human CVCL_JQ56 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21129009 CVCL_K256 TX-7F hybridoma house mouse CVCL_K256 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:9506; Tetrodotoxin. 21129010 CVCL_JQ55 OPCT-1 clone P2B9 transformed cell line human CVCL_JQ55 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21129011 CVCL_K255 T1.7 hybridoma house mouse CVCL_K255 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18266; Rat Gsk3b. 21129012 CVCL_K250 C30.1 factor-dependent cell line house mouse CVCL_K250 CL:0000010 Derived from sampling site: Cell type=Cytotoxic T-cell. Characteristics: IL2 dependent 21129013 CVCL_JQ50 MUG-Mel2 cancer cell line human CVCL_JQ50 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=28522871) Derived from sampling site: Shoulder; skin. Omics: Deep exome analysis Male Characteristics: Highly pigmented Tumorigenic in nude mice. Doubling time: 38.19 +- 4.09 hours (PubMed=28522871); ~48 hours (DSMZ=ACC-855) 21129014 CVCL_K252 8.2 [Mouse T cell] factor-dependent cell line house mouse CVCL_K252 CL:0000010 Derived from sampling site: Cell type=Cytotoxic T-cell. Characteristics: IL4 dependent 21129015 CVCL_JQ52 HeLa/SN1 cancer cell line human CVCL_JQ52 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21129016 CVCL_JQ51 BFH12 finite cell line CVCL_JQ51 CL:0000010 Transformant: Simian virus 40 (SV40) [pRetro-E2 SV40](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatocyte.; Breed/subspecies: Holstein Friesian. Unspecified Characteristics: Can be used for applications requiring a bovine hepatocyte-derived cell line with long cultivability and high reproducibility Senescence: SV40-transformed but with a finite life span Dies out during passages 40-45.; Doubling time: 23.5 hours (at 11th passage), 25.6 hours (at 31th passage) (PubMed=27071625) 21129017 CVCL_K251 LD8 factor-dependent cell line house mouse CVCL_K251 CL:0000010 Derived from sampling site: Cell type=Cytotoxic T-cell. Discontinued: BCRJ; 0144; probable Characteristics: IL4 dependent 21129018 CVCL_AW99 GM02663 finite cell line human CVCL_AW99 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21129019 CVCL_B899 MA133 embryonic stem cell human CVCL_B899 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21129020 CVCL_AW98 EDi002-A induced pluripotent stem cell human CVCL_AW98 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21129021 CVCL_B898 MA129 embryonic stem cell human CVCL_B898 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; pending review. 21129022 CVCL_AW91 GM08741 transformed cell line human CVCL_AW91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129023 CVCL_B891 SAB-113B embryonic stem cell human CVCL_B891 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21129024 CVCL_B890 GENEA082 embryonic stem cell human CVCL_B890 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0251; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-56.. 21129025 CVCL_AW90 GM08740 transformed cell line human CVCL_AW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129026 CVCL_AW93 GM08800 transformed cell line human CVCL_AW93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129027 CVCL_B893 Man-1 embryonic stem cell human CVCL_B893 From: University of Manchester; Manchester; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-08-017, Steering comm appl. SCSC08-02.. 21129028 CVCL_AW92 GM08799 transformed cell line human CVCL_AW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129029 CVCL_B892 SAB-113D embryonic stem cell human CVCL_B892 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21129030 CVCL_AW95 EWS-834 cancer cell line human CVCL_AW95 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21129031 CVCL_JQ29 HPSI1113i-wetu_1 induced pluripotent stem cell human CVCL_JQ29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129032 CVCL_B895 MA126 embryonic stem cell human CVCL_B895 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; pending review. 21129033 CVCL_K229 T47D-KBluc cancer cell line human CVCL_K229 HLA typing: A*33:01,33:01; B*14:02,14:02; C*08:02,08:02; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 70.61 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel 21129034 CVCL_AW94 GM08801 transformed cell line human CVCL_AW94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129035 CVCL_JQ28 HPSI1113i-uofv_3 induced pluripotent stem cell human CVCL_JQ28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129036 CVCL_B894 Man-2 embryonic stem cell human CVCL_B894 From: University of Manchester; Manchester; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-09-011, Steering comm appl. SCSC09-01.. 21129037 CVCL_K228 SNLP 76/7-4 transformed cell line house mouse CVCL_K228 CL:0000010 Transfected with: MGI; MGI:96787; Lif; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:17939; Puromycin; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Mixed Characteristics: Used as a feeder layer to support the growth of mouse ESCs and iPSCs 21129038 CVCL_AW97 EDi001-A induced pluripotent stem cell human CVCL_AW97 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=21863007) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21129039 CVCL_B897 MA128 embryonic stem cell human CVCL_B897 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; pending review. 21129040 CVCL_AW96 IRM2 cancer cell line human CVCL_AW96 CL:0000010 Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Unspecified 21129041 CVCL_B896 MA127 [Human ESC] embryonic stem cell human CVCL_B896 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; pending review. 21129042 CVCL_JQ25 HPSI1113i-qolg_2 induced pluripotent stem cell human CVCL_JQ25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129043 CVCL_K225 iAND-4 induced pluripotent stem cell human CVCL_K225 HLA typing: A*23:01,30:02; B*53:01,58:01; C*04:01,07:01; DQB1*05:02,06:02; DRB1*15:03,16:03 (Spanish_Stem_Cell_Bank) From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21129044 CVCL_K224 BG/G spontaneously immortalized cell line CVCL_K224 CL:0000010 Derived from sampling site: Gill. Unspecified Doubling time: 18-20 hours, at 36th passage (PubMed=2919396) Group: Fish cell line 21129045 CVCL_JQ24 HPSI1113i-podx_3 induced pluripotent stem cell human CVCL_JQ24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129046 CVCL_JQ27 HPSI1113i-uofv_2 induced pluripotent stem cell human CVCL_JQ27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129047 CVCL_K227 SNL 76/7 transformed cell line house mouse CVCL_K227 CL:0000010 Transfected with: MGI; MGI:96787; Lif; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Mixed Characteristics: Used as a feeder layer to support the growth of mouse ESCs and iPSCs 21129048 CVCL_K226 5H6 spontaneously immortalized cell line house mouse CVCL_K226 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Bone marrow; stroma. Male 21129049 CVCL_JQ26 HPSI1113i-qorq_3 induced pluripotent stem cell human CVCL_JQ26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129050 CVCL_K221 CDC 1C42H11 hybridoma house mouse CVCL_K221 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine distemper virus. 21129051 CVCL_JQ21 HPSI1113i-ieki_1 induced pluripotent stem cell human CVCL_JQ21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129052 CVCL_JQ20 HPSI1113i-hayt_2 induced pluripotent stem cell human CVCL_JQ20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129053 CVCL_K220 LS 102.9 hybridoma house mouse CVCL_K220 CL:0000010 Monoclonal antibody isotype: Not specified. 21129054 CVCL_K223 BG/F spontaneously immortalized cell line CVCL_K223 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 26 hours, at 34th passage (PubMed=2919396) Group: Fish cell line 21129055 CVCL_JQ23 HPSI1113i-oaaz_1 induced pluripotent stem cell human CVCL_JQ23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129056 CVCL_K222 CH26-1352 hybridoma house mouse CVCL_K222 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:4705; Double-stranded DNA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8329 21129057 CVCL_JQ22 HPSI1113i-nibo_1 induced pluripotent stem cell human CVCL_JQ22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129058 CVCL_JQ39 HPSI1213i-nekd_2 induced pluripotent stem cell human CVCL_JQ39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129059 CVCL_K239 Ltk-8-30-84 spontaneously immortalized cell line house mouse CVCL_K239 CL:0000010 Transfected with: HGNC; 5287; HTR1B Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10421 21129060 CVCL_JQ36 HPSI1213i-babk_3 induced pluripotent stem cell human CVCL_JQ36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129061 CVCL_K236 MO-LAS cancer cell line human CVCL_K236 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 91 hours (PubMed=23342252) 21129062 CVCL_JQ35 HPSI1213i-babk_1 induced pluripotent stem cell human CVCL_JQ35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129063 CVCL_K235 MCF-7/RU58R-1 cancer cell line human CVCL_K235 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90223; RU 58668; Derived from metastatic site: Pleural effusion. Female 21129064 CVCL_JQ38 HPSI1213i-hehd_3 induced pluripotent stem cell human CVCL_JQ38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129065 CVCL_JQ37 HPSI1213i-foqj_3 induced pluripotent stem cell human CVCL_JQ37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129066 CVCL_K237 J27.2 spontaneously immortalized cell line house mouse CVCL_K237 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21129067 CVCL_K232 CF-1 MEF IRR finite cell line house mouse CVCL_K232 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 10000 rads 21129068 CVCL_JQ32 HPSI1114i-qibk_1 induced pluripotent stem cell human CVCL_JQ32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129069 CVCL_JQ31 HPSI1113i-zuta_2 induced pluripotent stem cell human CVCL_JQ31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129070 CVCL_K231 WT 9-7 transformed cell line human CVCL_K231 CL:0000010 Transformant: Ad-SV40 hybrid virus Omics: Protein expression by reverse-phase protein arrays. Female Part of: MD Anderson Cell Lines Project 21129071 CVCL_K234 AML14 [Mouse liver] spontaneously immortalized cell line house mouse CVCL_K234 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: CD-1 MT42 transgenic. Male Characteristics: Produced in a transgenic mouse expressing human TGFA Doubling time: 32 hours (PubMed=7904757) 21129072 CVCL_JQ34 HPSI1213i-aegt_1 induced pluripotent stem cell human CVCL_JQ34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21129073 CVCL_K233 CF-1 MEF MITC finite cell line house mouse CVCL_K233 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21129074 CVCL_JQ33 HPSI1114i-ziyn_5 induced pluripotent stem cell human CVCL_JQ33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129075 CVCL_JQ30 HPSI1113i-wetu_3 induced pluripotent stem cell human CVCL_JQ30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21129076 CVCL_K230 WT 9-12 transformed cell line human CVCL_K230 CL:0000010 Transformant: Ad-SV40 hybrid virus. Female 21129077 CVCL_0E61 WG1270 finite cell line human CVCL_0E61 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129078 CVCL_0E60 WG1269 finite cell line human CVCL_0E60 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129079 CVCL_0E63 WG1273 finite cell line human CVCL_0E63 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129080 CVCL_0E62 WG1271 finite cell line human CVCL_0E62 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129081 CVCL_0E65 WG1288 finite cell line human CVCL_0E65 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129082 CVCL_0E64 WG1625 finite cell line human CVCL_0E64 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Unexplicit; IVS6-2A>G (Ex7del); Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8198124) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129083 CVCL_0E67 GM16481 transformed cell line human CVCL_0E67 CL:0000010 Sequence variation: Mutation; HGNC; 11025; SLC3A1; Simple; p.Met467Thr (c.1400T>C); ClinVar=VCV000018115; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129084 CVCL_0E66 GM16387 transformed cell line human CVCL_0E66 CL:0000010 Sequence variation: Mutation; HGNC; 11025; SLC3A1; Simple; p.Met467Thr (c.1400T>C); ClinVar=VCV000018115; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129085 CVCL_0E69 GM16483 transformed cell line human CVCL_0E69 CL:0000010 Sequence variation: Mutation; HGNC; 11025; SLC3A1; Simple; p.Met467Thr (c.1400T>C); ClinVar=VCV000018115; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129086 CVCL_0E68 GM16482 transformed cell line human CVCL_0E68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129087 CVCL_0E70 GM16500 transformed cell line human CVCL_0E70 CL:0000010 Sequence variation: Mutation; HGNC; 11025; SLC3A1; Simple; p.Met467Thr (c.1400T>C); ClinVar=VCV000018115; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129088 CVCL_0E72 GM17575 transformed cell line human CVCL_0E72 CL:0000010 Sequence variation: Mutation; HGNC; 11025; SLC3A1; Simple; p.Met467Thr (c.1400T>C); ClinVar=VCV000018115; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129089 CVCL_0E71 GM16753 transformed cell line human CVCL_0E71 CL:0000010 Sequence variation: Mutation; HGNC; 11067; SLC7A9; Simple; c.604+2T>C (789+2T-C); ClinVar=VCV000938724; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 11067; SLC7A9; Simple; p.Thr389Met (c.1166C>T); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129090 CVCL_0E74 CCD-978Sk finite cell line human CVCL_0E74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1905; true Male 21129091 CVCL_0E73 CCD-977Sk finite cell line human CVCL_0E73 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1900; true Female 21129092 CVCL_0E76 BHFTE finite cell line CVCL_0E76 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-1941; true Female Senescence: Can be propagated through at least 23 PDL 21129093 CVCL_0E75 11B7501 cancer cell line CVCL_0E75 CL:0000010 Discontinued: ATCC; CRL-1940; true. Male 21129094 CVCL_0E78 A4.1519 hybridoma house mouse CVCL_0E78 CL:0000010 Discontinued: ATCC; CRL-2045; true. Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species) 21129095 CVCL_0E41 CCD-864Sk finite cell line human CVCL_0E41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1791; true Male 21129096 CVCL_0E40 CCD-862Sk finite cell line human CVCL_0E40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1784; true Female 21129097 CVCL_0E43 CCD-922Sk finite cell line human CVCL_0E43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1828; true Female 21129098 CVCL_0E42 CCD-866Sk finite cell line human CVCL_0E42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1792; true Female 21129099 CVCL_0E45 AMOS-III cancer cell line human CVCL_0E45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Alafs*180 (c.518insC); Zygosity=Unspecified (PubMed=13679204) Population: Indian; Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: 34-36 hours (PubMed=13679204) Group: Patented cell line 21129100 CVCL_0E44 HMEEC-1 transformed cell line human CVCL_0E44 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ear; middle ear Cell type=Epithelial cell.. Discontinued: ATCC; CRL-13012; true Male Doubling time: 23.8 hours (PubMed=12090706) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-81 21129101 CVCL_0E47 PS 36 hybridoma house mouse CVCL_0E47 CL:0000010 Discontinued: ATCC; CRL-1801; true. Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01179; Rat Oxt 21129102 CVCL_0E46 NFS-1.0 C-1 cancer cell line house mouse CVCL_0E46 CL:0000010 Breed/subspecies: NFS.C58v1. Omics: SNP array analysis 21129103 CVCL_0E49 hTERT-hOd-1 telomerase immortalized cell line human CVCL_0E49 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Tooth bud; dental papilla Cell type=Odontoblast.. 21129104 CVCL_0E48 PS 46 hybridoma house mouse CVCL_0E48 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01186; Rat Avp. 21129105 CVCL_SK91 HAP1 DLAT (-) 1 cancer cell line human CVCL_SK91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2896; DLAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129106 CVCL_SK90 HAP1 DIS3L (-) 2 cancer cell line human CVCL_SK90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28698; DIS3L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129107 CVCL_SK93 HAP1 DMD (-) 1 cancer cell line human CVCL_SK93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2928; DMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129108 CVCL_SK92 HAP1 DLG2 (-) cancer cell line human CVCL_SK92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2901; DLG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129109 CVCL_SK95 HAP1 DMD (-) 3 cancer cell line human CVCL_SK95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2928; DMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129110 CVCL_SK94 HAP1 DMD (-) 2 cancer cell line human CVCL_SK94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2928; DMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129111 CVCL_SK97 HAP1 DMPK (-) 1 cancer cell line human CVCL_SK97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2933; DMPK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129112 CVCL_SK96 HAP1 DMD (-) 4 cancer cell line human CVCL_SK96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2928; DMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129113 CVCL_SK99 HAP1 DMPK (-) 3 cancer cell line human CVCL_SK99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2933; DMPK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129114 CVCL_SK98 HAP1 DMPK (-) 2 cancer cell line human CVCL_SK98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2933; DMPK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129115 CVCL_0E50 MDPC-23 spontaneously immortalized cell line house mouse CVCL_0E50 CL:0000010 Derived from sampling site: Embryonic tooth bud; dental papilla; Breed/subspecies: CD-1. Discontinued: ATCC; CRL-2537; true Unspecified 21129116 CVCL_0E52 RDP4-1 spontaneously immortalized cell line Norway rat CVCL_0E52 CL:0000010 Derived from sampling site: Tooth; dental pulp; Breed/subspecies: Wistar. Male 21129117 CVCL_0E51 MO6-G3 transformed cell line house mouse CVCL_0E51 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic tooth bud; dental papilla; molar Cell type=Odontoblast.; Breed/subspecies: Swiss Webster. Unspecified Characteristics: High constitutive expression of dentin phosphoprotein, type I collagen and alkaline phosphatase, characteristic of an odontoblast phenotype (PubMed=7554969) 21129118 CVCL_0E54 T4-4 telomerase immortalized cell line Norway rat CVCL_0E54 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Tooth bud; dental papilla; molar Cell type=Odontoblast.; Breed/subspecies: Sprague Dawley. 21129119 CVCL_0E53 RPC-C2A spontaneously immortalized cell line Norway rat CVCL_0E53 CL:0000010 Derived from sampling site: Tooth; incisor; dental pulp; Breed/subspecies: Wistar. Male Doubling time: 13.7 hours (PubMed=3256295) 21129120 CVCL_0E56 WG0919 finite cell line human CVCL_0E56 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129121 CVCL_0E55 WG0915 finite cell line human CVCL_0E55 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129122 CVCL_0E58 WG1264 finite cell line human CVCL_0E58 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129123 CVCL_0E57 WG1077 finite cell line human CVCL_0E57 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Simple; p.Arg184Gln (c.551G>A); ClinVar=VCV000000211; Zygosity=Heterozygous (PubMed=8900231); Sequence variation: Mutation; HGNC; 8840; PEPD; Simple; p.Gly278Asp (c.833G>A); ClinVar=VCV000000212; Zygosity=Heterozygous (PubMed=8900231) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129124 CVCL_0E59 WG1265 finite cell line human CVCL_0E59 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129125 CVCL_SK80 HAP1 DHX58 (-) 1 cancer cell line human CVCL_SK80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29517; DHX58; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129126 CVCL_SK82 HAP1 DIAPH1 (-) 1 cancer cell line human CVCL_SK82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2876; DIAPH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129127 CVCL_SK81 HAP1 DHX58 (-) 2 cancer cell line human CVCL_SK81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29517; DHX58; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129128 CVCL_SK84 HAP1 DICER1 (-) 1 cancer cell line human CVCL_SK84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17098; DICER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129129 CVCL_SK83 HAP1 DIAPH1 (-) 2 cancer cell line human CVCL_SK83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2876; DIAPH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129130 CVCL_SK86 HAP1 DICER1 (-) 3 cancer cell line human CVCL_SK86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17098; DICER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129131 CVCL_SK85 HAP1 DICER1 (-) 2 cancer cell line human CVCL_SK85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17098; DICER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129132 CVCL_SK88 HAP1 DIRC2 (-) 2 cancer cell line human CVCL_SK88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16628; SLC49A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129133 CVCL_SK87 HAP1 DIRC2 (-) 1 cancer cell line human CVCL_SK87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16628; SLC49A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129134 CVCL_SK89 HAP1 DIS3L (-) 1 cancer cell line human CVCL_SK89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28698; DIS3L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129135 CVCL_0E21 AG10427 transformed cell line human CVCL_0E21 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Iliac artery; endothelium. Male 21129136 CVCL_0E20 HIVE-87 finite cell line human CVCL_0E20 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21129137 CVCL_0E23 HIAE-32 finite cell line human CVCL_0E23 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21129138 CVCL_0E22 AG11082 transformed cell line human CVCL_0E22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Iliac artery; endothelium. Male 21129139 CVCL_0E25 HIVE-36 finite cell line human CVCL_0E25 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21129140 CVCL_0E24 HIVE-35 finite cell line human CVCL_0E24 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21129141 CVCL_0E27 18-26-4 hybridoma house mouse CVCL_0E27 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 3H5-1. 21129142 CVCL_0E26 HIVE-46 finite cell line human CVCL_0E26 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21129143 CVCL_0E29 28-4-3 hybridoma CVCL_0E29 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21129144 CVCL_0E28 28-2-7 hybridoma CVCL_0E28 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa (PubMed=9455702); IgG1, kappa (ATCC). 21129145 CVCL_0E19 HIVE-86 finite cell line human CVCL_0E19 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-89/Mir to study growth in microgravity (Coriell) Derived from sampling site: Iliac vein; endothelium. Male Group: Space-flown cell line (cellonaut); Part of: Wistar Institute Special Collection vascular cell lines 21129146 CVCL_SK71 HAP1 DDX58 (-) 2 cancer cell line human CVCL_SK71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19102; RIGI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129147 CVCL_SK70 HAP1 DDX58 (-) 1 cancer cell line human CVCL_SK70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19102; RIGI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129148 CVCL_SK73 HAP1 DDX6 (-) 2 cancer cell line human CVCL_SK73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2747; DDX6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129149 CVCL_SK72 HAP1 DDX6 (-) 1 cancer cell line human CVCL_SK72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2747; DDX6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129150 CVCL_SK75 HAP1 DEPDC5 (-) 2 cancer cell line human CVCL_SK75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18423; DEPDC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129151 CVCL_SK74 HAP1 DEPDC5 (-) 1 cancer cell line human CVCL_SK74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18423; DEPDC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129152 CVCL_SK77 HAP1 DHRS1 (-) 1 cancer cell line human CVCL_SK77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16445; DHRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129153 CVCL_SK76 HAP1 DHCR7 (-) 1 cancer cell line human CVCL_SK76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2860; DHCR7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129154 CVCL_SK79 HAP1 DHRS4 (-) 2 cancer cell line human CVCL_SK79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16985; DHRS4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129155 CVCL_SK78 HAP1 DHRS4 (-) 1 cancer cell line human CVCL_SK78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16985; DHRS4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129156 CVCL_0E30 28-5-15 hybridoma CVCL_0E30 CL:0000010 Monoclonal antibody isotype: IgG2a, lambda. 21129157 CVCL_0E32 44-6-1 hybridoma house mouse CVCL_0E32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 1D2. 21129158 CVCL_0E31 28-6-20 hybridoma CVCL_0E31 CL:0000010 Monoclonal antibody isotype: IgG1, kappa (PubMed=9455702); IgG1+IgG2a (ATCC). 21129159 CVCL_0E34 HS-27 transformed cell line human CVCL_0E34 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow; stroma. Male 21129160 CVCL_0E33 44-6-2 hybridoma house mouse CVCL_0E33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 1D2. 21129161 CVCL_0E36 HS-21 transformed cell line human CVCL_0E36 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow; stroma. Unspecified 21129162 CVCL_0E35 HS-23 transformed cell line human CVCL_0E35 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow; stroma. Discontinued: ATCC; CRL-2495; true Male 21129163 CVCL_0E38 MV522/MRP cancer cell line human CVCL_0E38 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 51; ABCC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Discontinued: ATCC; CRL-2521; true. Female Problematic cell line: Contaminated Parent cell line (MV-522) has been shown to be a HT-29 derivative. 21129164 CVCL_0E37 MV522/MDR1 cancer cell line human CVCL_0E37 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 40; ABCB1 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine) Discontinued: ATCC; CRL-2520; true. Female Problematic cell line: Contaminated Parent cell line (MV-522) has been shown to be a HT-29 derivative. 21129165 CVCL_0E39 CCD-860Sk finite cell line human CVCL_0E39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1782; true Male 21129166 CVCL_SK60 HAP1 DDR1 (-) cancer cell line human CVCL_SK60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2730; DDR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129167 CVCL_SK62 HAP1 DDR2 (-) 2 cancer cell line human CVCL_SK62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129168 CVCL_SK61 HAP1 DDR2 (-) 1 cancer cell line human CVCL_SK61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2731; DDR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129169 CVCL_SK64 HAP1 DDX31 (-) 1 cancer cell line human CVCL_SK64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16715; DDX31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129170 CVCL_SK63 HAP1 DDX1 (-) 1 cancer cell line human CVCL_SK63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2734; DDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129171 CVCL_SK66 HAP1 DDX3X (-) cancer cell line human CVCL_SK66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2745; DDX3X; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129172 CVCL_SK65 HAP1 DDX31 (-) 2 cancer cell line human CVCL_SK65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16715; DDX31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129173 CVCL_SK68 HAP1 DDX41 (-) 2 cancer cell line human CVCL_SK68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18674; DDX41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129174 CVCL_SK67 HAP1 DDX41 (-) 1 cancer cell line human CVCL_SK67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18674; DDX41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129175 CVCL_SK69 HAP1 DDX5 (-) 1 cancer cell line human CVCL_SK69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2746; DDX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129176 CVCL_SK49 HAP1 DCLRE1C (-) 2 cancer cell line human CVCL_SK49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17642; DCLRE1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129177 CVCL_0E01 EGC/PK240899egfr transformed cell line Norway rat CVCL_0E01 CL:0000010 Transformant: egfr-neu chimer; Derived from sampling site: Small intestine; jejunum; myenteric nerve plexus Cell type=Enteric glial cell.; Breed/subspecies: Sprague Dawley. Discontinued: ATCC; CRL-2621; true Male 21129178 CVCL_0E00 RN33B conditionally immortalized cell line Norway rat CVCL_0E00 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; medullary raphe nucleus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Profiferates at the permissive temperature (33 Celsius) At the restrictive temperature (38.5 Celsius) ceases mitotic activity and differentiates with phase bright cell bodies and 'neuritic-like' processes. Doubling time: 48 hours (PubMed=8364724) 21129179 CVCL_0E03 SV6 transformed cell line human CVCL_0E03 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Discontinued: ATCC; CRL-2427; true Female 21129180 CVCL_0E02 AR42J-B13 cancer cell line Norway rat CVCL_0E02 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas; Breed/subspecies: Wistar. Characteristics: When exposed to glucocorticoid, trans-differentiates into hepatocyte-like (B-13/H) cells B-13/H cells express a variety of liver-enriched and liver-specific genes, many at levels similar to hepatocytes in vivo. 21129181 CVCL_0E05 Ne8/4c6.3 hybridoma house mouse CVCL_0E05 CL:0000010 Discontinued: ATCC; CRL-2355; true. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Caenorhabditis elegans antigen on muscle cells 21129182 CVCL_0E04 Ne2/1b4.14 hybridoma house mouse CVCL_0E04 CL:0000010 Discontinued: ATCC; CRL-2356; true. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Caenorhabditis elegans seam cells 21129183 CVCL_0E07 19G4 hybridoma house mouse CVCL_0E07 CL:0000010 Discontinued: ATCC; CRL-2432; true. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; D3XDW6; Mouse cytomegalovirus MHC class I-like protein m144 21129184 CVCL_0E06 CCD-1110Sk finite cell line human CVCL_0E06 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-2412; true Male Senescence: Senesces at ~28 PDL (ATCC=CRL-2412) 21129185 CVCL_SK51 HAP1 DCTPP1 (-) 1 cancer cell line human CVCL_SK51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28777; DCTPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129186 CVCL_SK50 HAP1 DCLRE1C (-) 3 cancer cell line human CVCL_SK50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17642; DCLRE1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129187 CVCL_SK53 HAP1 DDI2 (-) 1 cancer cell line human CVCL_SK53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24578; DDI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129188 CVCL_SK52 HAP1 DCTPP1 (-) 2 cancer cell line human CVCL_SK52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28777; DCTPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129189 CVCL_SK55 HAP1 DDI2 (-) 3 cancer cell line human CVCL_SK55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24578; DDI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129190 CVCL_SK54 HAP1 DDI2 (-) 2 cancer cell line human CVCL_SK54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24578; DDI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129191 CVCL_SK57 HAP1 DDIT4 (-) 1 cancer cell line human CVCL_SK57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24944; DDIT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129192 CVCL_SK56 HAP1 DDI2 (-) 4 cancer cell line human CVCL_SK56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24578; DDI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129193 CVCL_SK59 HAP1 DDIT4L (-) cancer cell line human CVCL_SK59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30555; DDIT4L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129194 CVCL_SK58 HAP1 DDIT4 (-) 2 cancer cell line human CVCL_SK58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24944; DDIT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129195 CVCL_SK39 HAP1 DBF4B (-) 1 cancer cell line human CVCL_SK39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17883; DBF4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129196 CVCL_SK38 HAP1 DBF4 (-) cancer cell line human CVCL_SK38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17364; DBF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129197 CVCL_0E10 HUVE-31 finite cell line human CVCL_0E10 CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Endothelial cell of umbilical vein.. Female Part of: Wistar Institute Special Collection vascular cell lines 21129198 CVCL_0E12 HAAE-26 finite cell line human CVCL_0E12 CL:0000010 Derived from sampling site: Abdomen; aorta Cell type=Aortic endothelial cell.. Discontinued: ATCC; CRL-2602; true Male Part of: Wistar Institute Special Collection vascular cell lines 21129199 CVCL_0E11 HUVE-34 finite cell line human CVCL_0E11 CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Endothelial cell of umbilical vein.. Female Part of: Wistar Institute Special Collection vascular cell lines 21129200 CVCL_0E14 HAAE-27 finite cell line human CVCL_0E14 CL:0000010 Derived from sampling site: Abdomen; aorta Cell type=Aortic endothelial cell.. Male Part of: Wistar Institute Special Collection vascular cell lines 21129201 CVCL_0E13 HIAE-27 finite cell line human CVCL_0E13 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2604; true Male Part of: Wistar Institute Special Collection vascular cell lines 21129202 CVCL_0E16 HIVE-98/7-1 finite cell line human CVCL_0E16 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21129203 CVCL_0E15 HIAE-43/7-12 finite cell line human CVCL_0E15 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21129204 CVCL_0E18 HIVE-109 finite cell line human CVCL_0E18 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21129205 CVCL_0E17 HIAE-109 finite cell line human CVCL_0E17 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21129206 CVCL_0E09 HIVE-43 finite cell line human CVCL_0E09 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2477; true Male Part of: Wistar Institute Special Collection vascular cell lines 21129207 CVCL_0E08 4C11 [Mouse hybridoma against human FcRn] hybridoma house mouse CVCL_0E08 CL:0000010 Discontinued: ATCC; CRL-2436; probable. Monoclonal antibody isotype: IgG1 21129208 CVCL_SK40 HAP1 DBF4B (-) 2 cancer cell line human CVCL_SK40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17883; DBF4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129209 CVCL_SK42 HAP1 DBT (-) 1 cancer cell line human CVCL_SK42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2698; DBT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129210 CVCL_SK41 HAP1 DBN1 (-) 1 cancer cell line human CVCL_SK41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2695; DBN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129211 CVCL_SK44 HAP1 DCAKD (-) 1 cancer cell line human CVCL_SK44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26238; DCAKD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129212 CVCL_SK43 HAP1 DBT (-) 2 cancer cell line human CVCL_SK43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2698; DBT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129213 CVCL_SK46 HAP1 DCLK1 (-) 1 cancer cell line human CVCL_SK46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2700; DCLK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129214 CVCL_SK45 HAP1 DCK (-) 1 cancer cell line human CVCL_SK45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2704; DCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129215 CVCL_SK48 HAP1 DCLRE1C (-) 1 cancer cell line human CVCL_SK48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17642; DCLRE1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129216 CVCL_SK47 HAP1 DCLK1 (-) 2 cancer cell line human CVCL_SK47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2700; DCLK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129217 CVCL_AY31 GM09238 transformed cell line human CVCL_AY31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129218 CVCL_AY30 GM09237 transformed cell line human CVCL_AY30 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[935]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194; PubMed=32656337) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129219 CVCL_AY33 GM09317 transformed cell line human CVCL_AY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129220 CVCL_AY32 GM09316 transformed cell line human CVCL_AY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129221 CVCL_AY35 GM09497 finite cell line human CVCL_AY35 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;3)(3pter->3p22::1p32->1qter;1pter->1p32::3p22->3qter) [3]; 46,XY,t(3;12)(3pter->3q12::12q24.1->12qter;12pter->12q24.1:;3q12->3qter) [3]; 46,XY [13] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21129222 CVCL_AY34 GM09444 transformed cell line human CVCL_AY34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129223 CVCL_AY37 GM20230 transformed cell line human CVCL_AY37 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[53]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21129224 CVCL_AY36 GM13664 transformed cell line human CVCL_AY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129225 CVCL_AY28 GM09146 transformed cell line human CVCL_AY28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129226 CVCL_AY27 GM09145 transformed cell line human CVCL_AY27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129227 CVCL_AY29 GM09236 transformed cell line human CVCL_AY29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129228 CVCL_AY42 GM20235 transformed cell line human CVCL_AY42 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[45]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129229 CVCL_AY41 GM20234 transformed cell line human CVCL_AY41 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[31]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[46]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129230 CVCL_AY44 GM20237 transformed cell line human CVCL_AY44 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[100-104]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129231 CVCL_AY43 GM20236 transformed cell line human CVCL_AY43 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[31]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[53]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129232 CVCL_AY46 GM20239 transformed cell line human CVCL_AY46 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[20]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[183-193]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129233 CVCL_AY45 GM20238 transformed cell line human CVCL_AY45 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129234 CVCL_AY48 GM20241 transformed cell line human CVCL_AY48 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[93-110]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129235 CVCL_AY47 GM20240 transformed cell line human CVCL_AY47 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[20]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[80]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129236 CVCL_AY40 GM20233 transformed cell line human CVCL_AY40 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[117]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129237 CVCL_AY39 GM20232 transformed cell line human CVCL_AY39 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[46]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21129238 CVCL_AY38 GM20231 transformed cell line human CVCL_AY38 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[76]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21129239 CVCL_AY11 GM07292 transformed cell line human CVCL_AY11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129240 CVCL_AY10 GM07175 transformed cell line human CVCL_AY10 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; ClinVar=VCV000009972; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129241 CVCL_AY13 GM07365 transformed cell line human CVCL_AY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129242 CVCL_AY12 GM07294 transformed cell line human CVCL_AY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129243 CVCL_AY15 GM07496 transformed cell line human CVCL_AY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129244 CVCL_AY14 GM07494 transformed cell line human CVCL_AY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129245 CVCL_AY06 GM07072 finite cell line human CVCL_AY06 CL:0000010 Population: Jewish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21129246 CVCL_AY05 GM07071 finite cell line human CVCL_AY05 CL:0000010 Population: Jewish; Derived from sampling site: Fetal kidney Cell type=Fibroblast.. Male 21129247 CVCL_AY08 GM07132 transformed cell line human CVCL_AY08 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129248 CVCL_AY07 GM07131 transformed cell line human CVCL_AY07 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129249 CVCL_AY09 GM07174 transformed cell line human CVCL_AY09 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; ClinVar=VCV000009972; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129250 CVCL_AY20 GM07540 transformed cell line human CVCL_AY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129251 CVCL_AY22 GM07542 transformed cell line human CVCL_AY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM07536 (Cellosaurus=CVCL_AY16); Derived from sampling site: Peripheral blood. Male 21129252 CVCL_AY21 GM07541 transformed cell line human CVCL_AY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129253 CVCL_AY24 GM07730 finite cell line human CVCL_AY24 CL:0000010 Population: Caucasian; Derived from sampling site: Placenta Cell type=Fibroblast.. Male 21129254 CVCL_AY23 GM07543 transformed cell line human CVCL_AY23 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[20]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129255 CVCL_AY26 GM07862 transformed cell line human CVCL_AY26 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[501-550]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07861 (Cellosaurus=CVCL_AY25); Derived from sampling site: Peripheral blood. Male 21129256 CVCL_AY25 GM07861 transformed cell line human CVCL_AY25 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[351-400]; ClinVar=VCV000009972; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07862 (Cellosaurus=CVCL_AY26); Derived from sampling site: Peripheral blood. Male 21129257 CVCL_AY17 GM07537 transformed cell line human CVCL_AY17 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[28-29]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129258 CVCL_AY16 GM07536 transformed cell line human CVCL_AY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM07542 (Cellosaurus=CVCL_AY22); Derived from sampling site: Peripheral blood. Male 21129259 CVCL_AY19 GM07539 transformed cell line human CVCL_AY19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129260 CVCL_AY18 GM07538 transformed cell line human CVCL_AY18 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Homozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129261 CVCL_AY00 GM06911 transformed cell line human CVCL_AY00 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[?]; Zygosity=Heterozygous (PubMed=25776194) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129262 CVCL_AY02 GM06968 transformed cell line human CVCL_AY02 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[107]; Zygosity=Heterozygous (PubMed=25776194) Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129263 CVCL_AY01 GM06913 transformed cell line human CVCL_AY01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129264 CVCL_AY04 GM07064 transformed cell line human CVCL_AY04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129265 CVCL_AY03 GM07063 transformed cell line human CVCL_AY03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129266 CVCL_K449 C0184 transformed cell line human CVCL_K449 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129267 CVCL_JS49 STAN295i-836C1 induced pluripotent stem cell human CVCL_JS49 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129268 CVCL_K448 C0183 transformed cell line human CVCL_K448 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129269 CVCL_JS48 STAN294i-835C5 induced pluripotent stem cell human CVCL_JS48 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129270 CVCL_K445 C0180 transformed cell line human CVCL_K445 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129271 CVCL_JS45 STAN291i-827C1 induced pluripotent stem cell human CVCL_JS45 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129272 CVCL_K444 C0179 transformed cell line human CVCL_K444 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129273 CVCL_JS44 STAN288i-810C3 induced pluripotent stem cell human CVCL_JS44 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129274 CVCL_K447 C0182 transformed cell line human CVCL_K447 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129275 CVCL_JS47 STAN293i-835C1 induced pluripotent stem cell human CVCL_JS47 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129276 CVCL_K446 C0181 transformed cell line human CVCL_K446 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129277 CVCL_JS46 STAN292i-827C2 induced pluripotent stem cell human CVCL_JS46 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129278 CVCL_K441 C0175 transformed cell line human CVCL_K441 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129279 CVCL_JS41 STAN285i-780C2 induced pluripotent stem cell human CVCL_JS41 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129280 CVCL_K440 C0174 transformed cell line human CVCL_K440 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012806; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129281 CVCL_JS40 STAN284i-780C1 induced pluripotent stem cell human CVCL_JS40 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129282 CVCL_K443 C0178 transformed cell line human CVCL_K443 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129283 CVCL_JS43 STAN287i-810C1 induced pluripotent stem cell human CVCL_JS43 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129284 CVCL_K442 C0176 transformed cell line human CVCL_K442 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129285 CVCL_JS42 STAN286i-799C2 induced pluripotent stem cell human CVCL_JS42 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: WiCell; stan286i-799c2; true Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129286 CVCL_K459 C0194 transformed cell line human CVCL_K459 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129287 CVCL_JS59 STAN305i-865C2 induced pluripotent stem cell human CVCL_JS59 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129288 CVCL_K456 C0191 transformed cell line human CVCL_K456 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129289 CVCL_JS56 STAN302i-845AC4 induced pluripotent stem cell human CVCL_JS56 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129290 CVCL_K455 C0190 transformed cell line human CVCL_K455 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129291 CVCL_JS55 STAN301i-845AC2 induced pluripotent stem cell human CVCL_JS55 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129292 CVCL_K458 C0193 transformed cell line human CVCL_K458 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129293 CVCL_JS58 STAN304i-864C5 induced pluripotent stem cell human CVCL_JS58 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129294 CVCL_K457 C0192 transformed cell line human CVCL_K457 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129295 CVCL_JS57 STAN303i-864C2 induced pluripotent stem cell human CVCL_JS57 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129296 CVCL_K452 C0187 transformed cell line human CVCL_K452 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129297 CVCL_JS52 STAN298i-839C5 induced pluripotent stem cell human CVCL_JS52 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129298 CVCL_K451 C0186 transformed cell line human CVCL_K451 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129299 CVCL_JS51 STAN297i-839C1 induced pluripotent stem cell human CVCL_JS51 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129300 CVCL_K454 C0189 transformed cell line human CVCL_K454 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129301 CVCL_JS54 STAN300i-843C6 induced pluripotent stem cell human CVCL_JS54 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129302 CVCL_K453 C0188 transformed cell line human CVCL_K453 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129303 CVCL_JS53 STAN299i-843C5 induced pluripotent stem cell human CVCL_JS53 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129304 CVCL_K450 C0185 transformed cell line human CVCL_K450 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129305 CVCL_JS50 STAN296i-836C2 induced pluripotent stem cell human CVCL_JS50 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129306 CVCL_AY97 GM24061 transformed cell line human CVCL_AY97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129307 CVCL_AY96 GM24059 transformed cell line human CVCL_AY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129308 CVCL_AY99 GM24207 transformed cell line human CVCL_AY99 CL:0000010 Sequence variation: Mutation; HGNC; 12496; UBE3A; Simple; p.Thr126Lys (c.377C>A) (p.Thr106Lys, c.317C>A); ClinVar=VCV000155994; Zygosity=Unspecified (Coriell) Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129309 CVCL_AY98 GM24206 transformed cell line human CVCL_AY98 CL:0000010 Sequence variation: Mutation; HGNC; 12496; UBE3A; Simple; p.Thr126Lys (c.377C>A) (p.Thr106Lys, c.317C>A); ClinVar=VCV000155994; Zygosity=Unspecified (Coriell) Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129310 CVCL_AY91 GM23882 transformed cell line human CVCL_AY91 CL:0000010 Sequence variation: Mutation; HGNC; 2323; CPS1; Simple; c.3337-1G>T; ClinVar=VCV001343551; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 2323; CPS1; Simple; p.Ala1155Val (c.3464C>T); ClinVar=VCV000477855; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129311 CVCL_AY90 GM23855 transformed cell line human CVCL_AY90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129312 CVCL_K427 C0158 transformed cell line human CVCL_K427 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129313 CVCL_AY93 GM24009 transformed cell line human CVCL_AY93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129314 CVCL_JS27 STAN271i-726C3 induced pluripotent stem cell human CVCL_JS27 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129315 CVCL_K426 C0157 transformed cell line human CVCL_K426 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129316 CVCL_AY92 GM24008 transformed cell line human CVCL_AY92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129317 CVCL_JS26 STAN270i-720C3 induced pluripotent stem cell human CVCL_JS26 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129318 CVCL_K429 C0160 transformed cell line human CVCL_K429 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129319 CVCL_AY95 GM24046 transformed cell line human CVCL_AY95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129320 CVCL_JS29 STAN273i-729C1 induced pluripotent stem cell human CVCL_JS29 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129321 CVCL_K428 C0159 transformed cell line human CVCL_K428 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129322 CVCL_AY94 GM24045 transformed cell line human CVCL_AY94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129323 CVCL_JS28 STAN272i-726C4 induced pluripotent stem cell human CVCL_JS28 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129324 CVCL_K423 C0154 transformed cell line human CVCL_K423 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129325 CVCL_JS23 STAN265i-707C1 induced pluripotent stem cell human CVCL_JS23 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129326 CVCL_K422 C0153 transformed cell line human CVCL_K422 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129327 CVCL_JS22 STAN264i-703C2 induced pluripotent stem cell human CVCL_JS22 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129328 CVCL_K425 C0156 transformed cell line human CVCL_K425 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129329 CVCL_JS25 STAN269i-720C2 induced pluripotent stem cell human CVCL_JS25 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129330 CVCL_K424 C0155 transformed cell line human CVCL_K424 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129331 CVCL_JS24 STAN266i-707C4 induced pluripotent stem cell human CVCL_JS24 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129332 CVCL_K421 C0152 transformed cell line human CVCL_K421 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129333 CVCL_JS21 STAN263i-703C1 induced pluripotent stem cell human CVCL_JS21 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129334 CVCL_K420 C0151 transformed cell line human CVCL_K420 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012804; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129335 CVCL_JS20 STAN261i-698C5 induced pluripotent stem cell human CVCL_JS20 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129336 CVCL_K438 C0172 transformed cell line human CVCL_K438 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129337 CVCL_JS38 STAN282i-771C3 induced pluripotent stem cell human CVCL_JS38 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129338 CVCL_K437 C0170 transformed cell line human CVCL_K437 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91090407; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129339 CVCL_JS37 STAN281i-770C2 induced pluripotent stem cell human CVCL_JS37 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129340 CVCL_K439 C0173 transformed cell line human CVCL_K439 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93022515; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129341 CVCL_JS39 STAN283i-771C4 induced pluripotent stem cell human CVCL_JS39 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129342 CVCL_K434 C0167 transformed cell line human CVCL_K434 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129343 CVCL_JS34 STAN278i-767C2 induced pluripotent stem cell human CVCL_JS34 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129344 CVCL_K433 C0166 transformed cell line human CVCL_K433 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129345 CVCL_JS33 STAN277i-756C5 induced pluripotent stem cell human CVCL_JS33 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129346 CVCL_K436 C0169 transformed cell line human CVCL_K436 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129347 CVCL_JS36 STAN280i-770C1 induced pluripotent stem cell human CVCL_JS36 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129348 CVCL_K435 C0168 transformed cell line human CVCL_K435 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129349 CVCL_JS35 STAN279i-767C3 induced pluripotent stem cell human CVCL_JS35 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129350 CVCL_K430 C0161 transformed cell line human CVCL_K430 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93022511; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129351 CVCL_JS30 STAN274i-729C2 induced pluripotent stem cell human CVCL_JS30 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129352 CVCL_K432 C0165 transformed cell line human CVCL_K432 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060820; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129353 CVCL_JS32 STAN276i-756C4 induced pluripotent stem cell human CVCL_JS32 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129354 CVCL_K431 C0164 transformed cell line human CVCL_K431 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129355 CVCL_JS31 STAN275i-732C1 induced pluripotent stem cell human CVCL_JS31 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129356 CVCL_AY75 GM23507 transformed cell line human CVCL_AY75 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Cys967Ter (c.2901C>A); ClinVar=VCV000014301; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; c.6429+1G>T; ClinVar=VCV000556858; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129357 CVCL_AY74 GM23506 transformed cell line human CVCL_AY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129358 CVCL_AY77 GM23640 transformed cell line human CVCL_AY77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129359 CVCL_AY76 GM23508 transformed cell line human CVCL_AY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129360 CVCL_AY79 GM23658 transformed cell line human CVCL_AY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129361 CVCL_AY78 GM23641 transformed cell line human CVCL_AY78 CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Val178Met (c.532G>A); ClinVar=VCV000002402; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Met256Thr (c.767T>C); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129362 CVCL_K409 C0140 transformed cell line human CVCL_K409 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129363 CVCL_JS09 STAN250i-622C2 induced pluripotent stem cell human CVCL_JS09 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129364 CVCL_K408 C0139 transformed cell line human CVCL_K408 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129365 CVCL_JS08 STAN249i-617C2 induced pluripotent stem cell human CVCL_JS08 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129366 CVCL_K405 C0136 transformed cell line human CVCL_K405 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129367 CVCL_AY71 GM23437 transformed cell line human CVCL_AY71 CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Arg12Gln (c.35G>A); ClinVar=VCV000092360; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Gly280Glufs*4 (c.839delG); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129368 CVCL_JS05 STAN246i-601C5 induced pluripotent stem cell human CVCL_JS05 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129369 CVCL_K404 C0135 transformed cell line human CVCL_K404 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129370 CVCL_AY70 GM23436 transformed cell line human CVCL_AY70 CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Arg12Gln (c.35G>A); ClinVar=VCV000092360; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Gly280Glufs*4 (c.839delG); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129371 CVCL_JS04 STAN245i-601C4 induced pluripotent stem cell human CVCL_JS04 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129372 CVCL_K407 C0138 transformed cell line human CVCL_K407 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129373 CVCL_AY73 GM23494 transformed cell line human CVCL_AY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129374 CVCL_JS07 STAN248i-617C1 induced pluripotent stem cell human CVCL_JS07 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129375 CVCL_K406 C0137 transformed cell line human CVCL_K406 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129376 CVCL_AY72 GM23438 transformed cell line human CVCL_AY72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129377 CVCL_JS06 STAN247i-614C2 induced pluripotent stem cell human CVCL_JS06 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129378 CVCL_K401 C0132 transformed cell line human CVCL_K401 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129379 CVCL_JS01 STAN242i-573C2 induced pluripotent stem cell human CVCL_JS01 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129380 CVCL_K400 C0131 transformed cell line human CVCL_K400 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129381 CVCL_JS00 STAN241i-558C4 induced pluripotent stem cell human CVCL_JS00 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129382 CVCL_K403 C0134 transformed cell line human CVCL_K403 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129383 CVCL_JS03 STAN244i-589C4 induced pluripotent stem cell human CVCL_JS03 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129384 CVCL_K402 C0133 transformed cell line human CVCL_K402 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129385 CVCL_JS02 STAN243i-589C3 induced pluripotent stem cell human CVCL_JS02 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129386 CVCL_AY86 GM23794 transformed cell line human CVCL_AY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129387 CVCL_AY85 GM23793 transformed cell line human CVCL_AY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129388 CVCL_AY88 GM23823 transformed cell line human CVCL_AY88 CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Gln286Arg (c.857A>G); ClinVar=VCV000002399; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129389 CVCL_AY87 GM23795 transformed cell line human CVCL_AY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129390 CVCL_AY89 GM23845 transformed cell line human CVCL_AY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129391 CVCL_K419 C0150 transformed cell line human CVCL_K419 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129392 CVCL_JS19 STAN260i-688C3 induced pluripotent stem cell human CVCL_JS19 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129393 CVCL_AY80 GM23670 transformed cell line human CVCL_AY80 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Asp2498Ilefs*49 (c.7491delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; c.8244+3_8244+6delAAGT (c.8244+3_+6delAAGT); ClinVar=VCV000447695; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129394 CVCL_K416 C0147 transformed cell line human CVCL_K416 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129395 CVCL_AY82 GM23684 transformed cell line human CVCL_AY82 CL:0000010 Sequence variation: Mutation; HGNC; 2323; CPS1; Simple; p.Glu1034Gly (c.3101A>G); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129396 CVCL_JS16 STAN257i-685C3 induced pluripotent stem cell human CVCL_JS16 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129397 CVCL_K415 C0146 transformed cell line human CVCL_K415 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129398 CVCL_AY81 GM23673 transformed cell line human CVCL_AY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129399 CVCL_JS15 STAN256i-649C2 induced pluripotent stem cell human CVCL_JS15 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129400 CVCL_K418 C0149 transformed cell line human CVCL_K418 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129401 CVCL_AY84 GM23781 transformed cell line human CVCL_AY84 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Tyr3921Ter (c.11763C>A); ClinVar=VCV000161361; Zygosity=Heterozygous (Coriell) Population: Caucasian; German/Irish and Native North American; Cherokee; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129402 CVCL_JS18 STAN259i-688C1 induced pluripotent stem cell human CVCL_JS18 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129403 CVCL_K417 C0148 transformed cell line human CVCL_K417 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012803; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129404 CVCL_AY83 GM23768 transformed cell line human CVCL_AY83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129405 CVCL_JS17 STAN258i-685C4 induced pluripotent stem cell human CVCL_JS17 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129406 CVCL_K412 C0143 transformed cell line human CVCL_K412 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129407 CVCL_JS12 STAN253i-647C1 induced pluripotent stem cell human CVCL_JS12 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129408 CVCL_K411 C0142 transformed cell line human CVCL_K411 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129409 CVCL_JS11 STAN252i-637C2 induced pluripotent stem cell human CVCL_JS11 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129410 CVCL_K414 C0145 transformed cell line human CVCL_K414 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129411 CVCL_JS14 STAN255i-649C1 induced pluripotent stem cell human CVCL_JS14 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129412 CVCL_K413 C0144 transformed cell line human CVCL_K413 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129413 CVCL_JS13 STAN254i-647C3 induced pluripotent stem cell human CVCL_JS13 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129414 CVCL_K410 C0141 transformed cell line human CVCL_K410 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93021836; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129415 CVCL_JS10 STAN251i-637C1 induced pluripotent stem cell human CVCL_JS10 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129416 CVCL_AY53 NCI-H3122-CR1 cancer cell line human CVCL_AY53 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (from parent cell line). Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori) Male 21129417 CVCL_AY52 AN4;11 cancer cell line human CVCL_AY52 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4; Note=In frame (PubMed=8358709). Male Characteristics: Established from a tumor produced by injection of the leukemic cells into the peritoneum of SCID mice (PubMed=8353274) 21129418 CVCL_AY55 MGH045 cancer cell line human CVCL_AY55 CL:0000010 21129419 CVCL_AY54 MGH021-4 cancer cell line human CVCL_AY54 CL:0000010 21129420 CVCL_AY57 GM25431 finite cell line human CVCL_AY57 CL:0000010 Sequence variation: Mutation; HGNC; 4087; GABRG2; Simple; p.Pro282Ser (c.844C>T) (p.Pro322Ser, c.964C>T); ClinVar=VCV000625863; Zygosity=Heterozygous (Coriell) Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21129421 CVCL_AY56 MGH051 cancer cell line human CVCL_AY56 CL:0000010 21129422 CVCL_AY59 GM25429 transformed cell line human CVCL_AY59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129423 CVCL_AY58 GM25432 finite cell line human CVCL_AY58 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21129424 CVCL_AY51 GM20244 transformed cell line human CVCL_AY51 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[41]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21129425 CVCL_AY50 GM20243 transformed cell line human CVCL_AY50 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[41]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129426 CVCL_AY49 GM20242 transformed cell line human CVCL_AY49 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[30]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[73]; ClinVar=VCV000009972; Zygosity=Heterozygous (PubMed=25776194) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21129427 CVCL_AY64 GM12224 transformed cell line human CVCL_AY64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129428 CVCL_AY63 GM12223 transformed cell line human CVCL_AY63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129429 CVCL_AY66 GM23316 transformed cell line human CVCL_AY66 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Ser2099_Val2117dup (c.6295_6351dup57); ClinVar=VCV000478252; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129430 CVCL_AY65 GM23304 transformed cell line human CVCL_AY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129431 CVCL_AY68 GM23326 finite cell line human CVCL_AY68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129432 CVCL_AY67 GM23325 finite cell line human CVCL_AY67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129433 CVCL_AY69 GM23327 finite cell line human CVCL_AY69 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Met1Thr (c.2T>C); ClinVar=VCV000477459; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Gly16Alafs*29 (c.47delG); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129434 CVCL_AY60 GM03432 finite cell line human CVCL_AY60 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129435 CVCL_AY62 GM12222 transformed cell line human CVCL_AY62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129436 CVCL_AY61 GM04311 finite cell line human CVCL_AY61 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21129437 CVCL_SL49 HAP1 EGFL6 (-) 1 cancer cell line human CVCL_SL49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3235; EGFL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129438 CVCL_SL48 HAP1 EFR3A (-) cancer cell line human CVCL_SL48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28970; EFR3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129439 CVCL_0F00 17-G4 hybridoma house mouse CVCL_0F00 CL:0000010 Discontinued: ATCC; CRL-2574; probable. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P18428; Human LBP 21129440 CVCL_0F02 HIVE-27 finite cell line human CVCL_0F02 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2600; true Male Part of: Wistar Institute Special Collection vascular cell lines 21129441 CVCL_0F01 C166-lacZ spontaneously immortalized cell line house mouse CVCL_0F01 CL:0000010 Transfected with: HGNC; 3657; FES; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Yolk sac; Breed/subspecies: NMRI/GSF x CD-1 transgenic. Unspecified 21129442 CVCL_0F04 261-1F3 hybridoma house mouse CVCL_0F04 CL:0000010 Discontinued: ATCC; CRL-2666; true. 21129443 CVCL_0F03 416-20E10 hybridoma house mouse CVCL_0F03 CL:0000010 Discontinued: ATCC; CRL-2664; true. 21129444 CVCL_0F06 FDC-1 finite cell line human CVCL_0F06 CL:0000010 Derived from sampling site: Oral cavity; tonsil. Discontinued: ATCC; CRL-2729; true Male 21129445 CVCL_0F05 241-10C10 hybridoma house mouse CVCL_0F05 CL:0000010 Discontinued: ATCC; CRL-2671; true. 21129446 CVCL_SL50 HAP1 EGFL6 (-) 2 cancer cell line human CVCL_SL50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3235; EGFL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129447 CVCL_SL52 HAP1 EHMT1 (-) 1 cancer cell line human CVCL_SL52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129448 CVCL_SL51 HAP1 EGLN1 (-) cancer cell line human CVCL_SL51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1232; EGLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129449 CVCL_SL54 HAP1 EHMT1 (-) 3 cancer cell line human CVCL_SL54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129450 CVCL_SL53 HAP1 EHMT1 (-) 2 cancer cell line human CVCL_SL53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129451 CVCL_SL56 HAP1 EHMT2 (-) 1 cancer cell line human CVCL_SL56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129452 CVCL_SL55 HAP1 EHMT1 (-) 4 cancer cell line human CVCL_SL55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24650; EHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129453 CVCL_SL58 HAP1 EIF1 (-) 1 cancer cell line human CVCL_SL58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3249; EIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129454 CVCL_SL57 HAP1 EHMT2 (-) 2 cancer cell line human CVCL_SL57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129455 CVCL_SL38 HAP1 ECE2 (-) 2 cancer cell line human CVCL_SL38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13275; ECE2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129456 CVCL_SL37 HAP1 ECE2 (-) 1 cancer cell line human CVCL_SL37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13275; ECE2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129457 CVCL_SL39 HAP1 ECH1 (-) 1 cancer cell line human CVCL_SL39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3149; ECH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129458 CVCL_0F11 22D1 hybridoma house mouse CVCL_0F11 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q8CJ91; Mouse Cd209b. Doubling time: 12 hours (ATCC=CRL-2841) 21129459 CVCL_0F10 KIM185 hybridoma house mouse CVCL_0F10 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. Doubling time: 20 hours (ATCC=CRL-2839) 21129460 CVCL_0F13 IPAM 3D4/2 transformed cell line pig CVCL_0F13 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified 21129461 CVCL_0F12 IPAM 3D4 transformed cell line pig CVCL_0F12 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Doubling time: 25.5 hours (PubMed=12088830) 21129462 CVCL_0F15 IPAM 3D4/31 transformed cell line pig CVCL_0F15 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified 21129463 CVCL_0F14 IPAM 3D4/21 transformed cell line pig CVCL_0F14 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified 21129464 CVCL_0F17 12S transformed cell line human CVCL_0F17 CL:0000010 Transformant: Adenovirus E1A; Derived from sampling site: Fetal thyroid gland. Female Doubling time: ~36 hours (PubMed=2843357) 21129465 CVCL_0F16 CHON-003 telomerase immortalized cell line human CVCL_0F16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Discontinued: ATCC; CRL-2848; true Female 21129466 CVCL_0F08 MOVAS-1 transformed cell line house mouse CVCL_0F08 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.; Breed/subspecies: C57BL/6. Unspecified Doubling time: ~15 hours (ATCC=CRL-2797) 21129467 CVCL_0F07 165-28E7 hybridoma house mouse CVCL_0F07 CL:0000010 Discontinued: ATCC; CRL-2735; true. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00538; Moloney murine sarcoma virus V-Mos 21129468 CVCL_0F09 KIM127 hybridoma house mouse CVCL_0F09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. Doubling time: 18 hours (ATCC=CRL-2838) 21129469 CVCL_SL41 HAP1 EEA1 (-) cancer cell line human CVCL_SL41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3185; EEA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129470 CVCL_SL40 HAP1 ECI2 (-) 1 cancer cell line human CVCL_SL40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14601; ECI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129471 CVCL_SL43 HAP1 EED (-) 2 cancer cell line human CVCL_SL43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3188; EED; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129472 CVCL_SL42 HAP1 EED (-) 1 cancer cell line human CVCL_SL42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3188; EED; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129473 CVCL_SL45 HAP1 EEF1A2 (-) 2 cancer cell line human CVCL_SL45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3192; EEF1A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129474 CVCL_SL44 HAP1 EEF1A2 (-) 1 cancer cell line human CVCL_SL44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3192; EEF1A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129475 CVCL_SL47 HAP1 EEF2K (-) 2 cancer cell line human CVCL_SL47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24615; EEF2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129476 CVCL_SL46 HAP1 EEF2K (-) 1 cancer cell line human CVCL_SL46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24615; EEF2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129477 CVCL_SL27 HAP1 DYRK3 (-) cancer cell line human CVCL_SL27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3094; DYRK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129478 CVCL_SL26 HAP1 DYRK2 (-) 3 cancer cell line human CVCL_SL26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3093; DYRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129479 CVCL_SL29 HAP1 DZIP3 (-) cancer cell line human CVCL_SL29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30938; DZIP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129480 CVCL_SL28 HAP1 DYRK4 (-) cancer cell line human CVCL_SL28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3095; DYRK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129481 CVCL_K389 C0120 transformed cell line human CVCL_K389 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020407; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129482 CVCL_JR89 STAN230i-533C1 induced pluripotent stem cell human CVCL_JR89 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129483 CVCL_K386 C0117 transformed cell line human CVCL_K386 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129484 CVCL_JR86 STAN227i-516C5 induced pluripotent stem cell human CVCL_JR86 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129485 CVCL_K385 C0116 transformed cell line human CVCL_K385 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129486 CVCL_JR85 STAN226i-516C3 induced pluripotent stem cell human CVCL_JR85 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129487 CVCL_K388 C0119 transformed cell line human CVCL_K388 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020406; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129488 CVCL_JR88 STAN229i-523C2 induced pluripotent stem cell human CVCL_JR88 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129489 CVCL_K387 C0118 transformed cell line human CVCL_K387 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020405; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129490 CVCL_JR87 STAN228i-523C1 induced pluripotent stem cell human CVCL_JR87 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129491 CVCL_K382 C0113 transformed cell line human CVCL_K382 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020402; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129492 CVCL_SL30 HAP1 E2F1 (-) 1 cancer cell line human CVCL_SL30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129493 CVCL_JR82 STAN223i-509C3 induced pluripotent stem cell human CVCL_JR82 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129494 CVCL_K381 C0112 transformed cell line human CVCL_K381 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129495 CVCL_JR81 STAN222i-509C2 induced pluripotent stem cell human CVCL_JR81 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129496 CVCL_K384 C0115 transformed cell line human CVCL_K384 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020403; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129497 CVCL_SL32 HAP1 E2F8 (-) 1 cancer cell line human CVCL_SL32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24727; E2F8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129498 CVCL_JR84 STAN225i-514C4 induced pluripotent stem cell human CVCL_JR84 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129499 CVCL_K383 C0114 transformed cell line human CVCL_K383 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91081921; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129500 CVCL_SL31 HAP1 E2F1 (-) 2 cancer cell line human CVCL_SL31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3113; E2F1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129501 CVCL_JR83 STAN224i-514C3 induced pluripotent stem cell human CVCL_JR83 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129502 CVCL_SL34 HAP1 EAPP (-) 2 cancer cell line human CVCL_SL34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19312; EAPP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129503 CVCL_SL33 HAP1 EAPP (-) 1 cancer cell line human CVCL_SL33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19312; EAPP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129504 CVCL_K380 C0111 transformed cell line human CVCL_K380 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129505 CVCL_SL36 HAP1 EAPP (-) 4 cancer cell line human CVCL_SL36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19312; EAPP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129506 CVCL_JR80 STAN220i-504C2 induced pluripotent stem cell human CVCL_JR80 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129507 CVCL_SL35 HAP1 EAPP (-) 3 cancer cell line human CVCL_SL35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19312; EAPP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129508 CVCL_SL16 HAP1 DPP4 (-) 1 cancer cell line human CVCL_SL16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3009; DPP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129509 CVCL_SL15 HAP1 DPM1 (-) 2 cancer cell line human CVCL_SL15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3005; DPM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129510 CVCL_SL18 HAP1 DSG2 (-) 1 cancer cell line human CVCL_SL18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129511 CVCL_SL17 HAP1 DPP4 (-) 2 cancer cell line human CVCL_SL17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3009; DPP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129512 CVCL_SL19 HAP1 DSTYK (-) 1 cancer cell line human CVCL_SL19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29043; DSTYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129513 CVCL_K397 C0128 transformed cell line human CVCL_K397 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93021102; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129514 CVCL_JR97 STAN238i-553C5 induced pluripotent stem cell human CVCL_JR97 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129515 CVCL_K396 C0127 transformed cell line human CVCL_K396 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129516 CVCL_JR96 STAN237i-551C2 induced pluripotent stem cell human CVCL_JR96 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129517 CVCL_K399 C0130 transformed cell line human CVCL_K399 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93021103; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129518 CVCL_JR99 STAN240i-558C3 induced pluripotent stem cell human CVCL_JR99 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129519 CVCL_K398 C0129 transformed cell line human CVCL_K398 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129520 CVCL_JR98 STAN239i-553C8 induced pluripotent stem cell human CVCL_JR98 CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129521 CVCL_K393 C0124 transformed cell line human CVCL_K393 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129522 CVCL_JR93 STAN234i-546C1 induced pluripotent stem cell human CVCL_JR93 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129523 CVCL_K392 C0123 transformed cell line human CVCL_K392 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129524 CVCL_JR92 STAN233i-541C5 induced pluripotent stem cell human CVCL_JR92 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129525 CVCL_K395 C0126 transformed cell line human CVCL_K395 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129526 CVCL_SL21 HAP1 DXO (-) 1 cancer cell line human CVCL_SL21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2992; DXO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129527 CVCL_JR95 STAN236i-551C1 induced pluripotent stem cell human CVCL_JR95 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129528 CVCL_K394 C0125 transformed cell line human CVCL_K394 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129529 CVCL_SL20 HAP1 DSTYK (-) 2 cancer cell line human CVCL_SL20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29043; DSTYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129530 CVCL_JR94 STAN235i-546C2 induced pluripotent stem cell human CVCL_JR94 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129531 CVCL_SL23 HAP1 DYRK1B (-) cancer cell line human CVCL_SL23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3092; DYRK1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129532 CVCL_SL22 HAP1 DXO (-) 2 cancer cell line human CVCL_SL22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2992; DXO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129533 CVCL_K391 C0122 transformed cell line human CVCL_K391 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060816; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129534 CVCL_SL25 HAP1 DYRK2 (-) 2 cancer cell line human CVCL_SL25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3093; DYRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129535 CVCL_JR91 STAN232i-541C2 induced pluripotent stem cell human CVCL_JR91 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129536 CVCL_K390 C0121 transformed cell line human CVCL_K390 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129537 CVCL_SL24 HAP1 DYRK2 (-) 1 cancer cell line human CVCL_SL24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3093; DYRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129538 CVCL_JR90 STAN231i-533C2 induced pluripotent stem cell human CVCL_JR90 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129539 CVCL_SL05 HAP1 DNMT3A (-) 2 cancer cell line human CVCL_SL05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2978; DNMT3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129540 CVCL_SL04 HAP1 DNMT3A (-) 1 cancer cell line human CVCL_SL04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2978; DNMT3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129541 CVCL_SL07 HAP1 DNMT3B (-) 2 cancer cell line human CVCL_SL07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2979; DNMT3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129542 CVCL_SL06 HAP1 DNMT3B (-) 1 cancer cell line human CVCL_SL06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2979; DNMT3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129543 CVCL_SL09 HAP1 DPF1 (-) 1 cancer cell line human CVCL_SL09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20225; DPF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129544 CVCL_SL08 HAP1 DOT1L (-) cancer cell line human CVCL_SL08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24948; DOT1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129545 CVCL_K368 C0098 transformed cell line human CVCL_K368 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129546 CVCL_JR68 STAN206i-459C1 induced pluripotent stem cell human CVCL_JR68 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129547 CVCL_K367 C0097 transformed cell line human CVCL_K367 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129548 CVCL_JR67 STAN205i-448C2 induced pluripotent stem cell human CVCL_JR67 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129549 CVCL_K369 C0099 transformed cell line human CVCL_K369 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060808; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129550 CVCL_JR69 STAN207i-459C2 induced pluripotent stem cell human CVCL_JR69 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129551 CVCL_K364 C0094 transformed cell line human CVCL_K364 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060806; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129552 CVCL_JR64 STAN202i-445C1 induced pluripotent stem cell human CVCL_JR64 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129553 CVCL_K363 C0093 transformed cell line human CVCL_K363 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129554 CVCL_JR63 STAN201i-444C2 induced pluripotent stem cell human CVCL_JR63 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129555 CVCL_K366 C0096 transformed cell line human CVCL_K366 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91090406; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129556 CVCL_JR66 STAN204i-448C1 induced pluripotent stem cell human CVCL_JR66 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129557 CVCL_K365 C0095 transformed cell line human CVCL_K365 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129558 CVCL_JR65 STAN203i-445C2 induced pluripotent stem cell human CVCL_JR65 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129559 CVCL_K360 C0090 transformed cell line human CVCL_K360 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129560 CVCL_JR60 STAN197i-441C1 induced pluripotent stem cell human CVCL_JR60 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129561 CVCL_K362 C0092 transformed cell line human CVCL_K362 CL:0000010 Sequence variation: Gene deletion; HGNC; 3620; FCGR3B; Zygosity=Homozygous (PubMed=27995740) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129562 CVCL_SL10 HAP1 DPF1 (-) 2 cancer cell line human CVCL_SL10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20225; DPF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129563 CVCL_JR62 STAN200i-444C1 induced pluripotent stem cell human CVCL_JR62 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129564 CVCL_K361 C0091 transformed cell line human CVCL_K361 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129565 CVCL_JR61 STAN198i-441C2 induced pluripotent stem cell human CVCL_JR61 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129566 CVCL_SL12 HAP1 DPF3 (-) 1 cancer cell line human CVCL_SL12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17427; DPF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129567 CVCL_SL11 HAP1 DPF2 (-) cancer cell line human CVCL_SL11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9964; DPF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129568 CVCL_SL14 HAP1 DPM1 (-) 1 cancer cell line human CVCL_SL14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3005; DPM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129569 CVCL_SL13 HAP1 DPF3 (-) 2 cancer cell line human CVCL_SL13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17427; DPF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129570 CVCL_K379 C0110 transformed cell line human CVCL_K379 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129571 CVCL_JR79 STAN219i-501C6 induced pluripotent stem cell human CVCL_JR79 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129572 CVCL_K378 C0109 transformed cell line human CVCL_K378 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060814; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129573 CVCL_JR78 STAN218i-501C5 induced pluripotent stem cell human CVCL_JR78 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129574 CVCL_K375 C0105 transformed cell line human CVCL_K375 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060812(2); probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129575 CVCL_JR75 STAN213i-488C3 induced pluripotent stem cell human CVCL_JR75 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129576 CVCL_K374 C0104 transformed cell line human CVCL_K374 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129577 CVCL_JR74 STAN212i-488C2 induced pluripotent stem cell human CVCL_JR74 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129578 CVCL_K377 C0108 transformed cell line human CVCL_K377 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129579 CVCL_JR77 STAN217i-496C2 induced pluripotent stem cell human CVCL_JR77 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129580 CVCL_K376 C0106 transformed cell line human CVCL_K376 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129581 CVCL_JR76 STAN216i-496C1 induced pluripotent stem cell human CVCL_JR76 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129582 CVCL_K371 C0101 transformed cell line human CVCL_K371 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060810; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129583 CVCL_JR71 STAN209i-460C6 induced pluripotent stem cell human CVCL_JR71 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129584 CVCL_K370 C0100 transformed cell line human CVCL_K370 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129585 CVCL_JR70 STAN208i-460C2 induced pluripotent stem cell human CVCL_JR70 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129586 CVCL_K373 C0103 transformed cell line human CVCL_K373 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91071215; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129587 CVCL_JR73 STAN211i-475C1 induced pluripotent stem cell human CVCL_JR73 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129588 CVCL_K372 C0102 transformed cell line human CVCL_K372 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060811; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129589 CVCL_JR72 STAN210i-468C1 induced pluripotent stem cell human CVCL_JR72 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129590 CVCL_SL01 HAP1 DNAJA1 (-) 2 cancer cell line human CVCL_SL01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5229; DNAJA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129591 CVCL_SL00 HAP1 DNAJA1 (-) 1 cancer cell line human CVCL_SL00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5229; DNAJA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129592 CVCL_SL03 HAP1 DNMT1 (-) 2 cancer cell line human CVCL_SL03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2976; DNMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21129593 CVCL_SL02 HAP1 DNMT1 (-) 1 cancer cell line human CVCL_SL02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2976; DNMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21129594 CVCL_K349 C0077 transformed cell line human CVCL_K349 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 92031011; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129595 CVCL_JR49 STAN180i-408C2 induced pluripotent stem cell human CVCL_JR49 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129596 CVCL_K346 C0074 transformed cell line human CVCL_K346 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129597 CVCL_JR46 STAN175i-373C4 induced pluripotent stem cell human CVCL_JR46 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129598 CVCL_K345 C0073 transformed cell line human CVCL_K345 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129599 CVCL_JR45 STAN174i-371C3 induced pluripotent stem cell human CVCL_JR45 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129600 CVCL_K348 C0076 transformed cell line human CVCL_K348 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93011310; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129601 CVCL_JR48 STAN179i-400C2 induced pluripotent stem cell human CVCL_JR48 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129602 CVCL_K347 C0075 transformed cell line human CVCL_K347 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129603 CVCL_JR47 STAN176i-373C6 induced pluripotent stem cell human CVCL_JR47 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129604 CVCL_K342 C0070 transformed cell line human CVCL_K342 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129605 CVCL_JR42 STAN170i-364C3 induced pluripotent stem cell human CVCL_JR42 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129606 CVCL_K341 C0069 transformed cell line human CVCL_K341 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129607 CVCL_JR41 STAN169i-358C4 induced pluripotent stem cell human CVCL_JR41 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129608 CVCL_K344 C0072 transformed cell line human CVCL_K344 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93011308; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129609 CVCL_JR44 STAN173i-368C2 induced pluripotent stem cell human CVCL_JR44 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129610 CVCL_K343 C0071 transformed cell line human CVCL_K343 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93011307; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129611 CVCL_JR43 STAN171i-364C4 induced pluripotent stem cell human CVCL_JR43 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129612 CVCL_K340 C0068 transformed cell line human CVCL_K340 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129613 CVCL_JR40 STAN168i-358C1 induced pluripotent stem cell human CVCL_JR40 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129614 CVCL_K357 C0087 transformed cell line human CVCL_K357 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012116; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129615 CVCL_JR57 STAN193i-432C1 induced pluripotent stem cell human CVCL_JR57 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: WiCell; stan193i-432c1; true Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129616 CVCL_K356 C0086 transformed cell line human CVCL_K356 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90081923; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129617 CVCL_JR56 STAN192i-429C3 induced pluripotent stem cell human CVCL_JR56 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129618 CVCL_K359 C0089 transformed cell line human CVCL_K359 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93012118; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129619 CVCL_JR59 STAN195i-434C3 induced pluripotent stem cell human CVCL_JR59 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: WiCell; stan195i-434c3; true Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129620 CVCL_K358 C0088 transformed cell line human CVCL_K358 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129621 CVCL_JR58 STAN194i-432C3 induced pluripotent stem cell human CVCL_JR58 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: WiCell; stan194i-432c3; true Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129622 CVCL_K353 C0083 transformed cell line human CVCL_K353 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91070937; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129623 CVCL_JR53 STAN187i-420C6 induced pluripotent stem cell human CVCL_JR53 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129624 CVCL_K352 C0082 transformed cell line human CVCL_K352 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129625 CVCL_JR52 STAN183i-410C4 induced pluripotent stem cell human CVCL_JR52 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129626 CVCL_K355 C0085 transformed cell line human CVCL_K355 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129627 CVCL_JR55 STAN191i-429C2 induced pluripotent stem cell human CVCL_JR55 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129628 CVCL_K354 C0084 transformed cell line human CVCL_K354 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129629 CVCL_JR54 STAN190i-424C2 induced pluripotent stem cell human CVCL_JR54 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129630 CVCL_K351 C0081 transformed cell line human CVCL_K351 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129631 CVCL_JR51 STAN182i-410C3 induced pluripotent stem cell human CVCL_JR51 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129632 CVCL_K350 C0080 transformed cell line human CVCL_K350 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129633 CVCL_JR50 STAN181i-408C4 induced pluripotent stem cell human CVCL_JR50 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129634 CVCL_0F80 NBR4-RJK835 hybrid cell line CVCL_0F80 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129635 CVCL_0F82 UCW 10 spontaneously immortalized cell line CVCL_0F82 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21129636 CVCL_0F81 CHO-tsH1 spontaneously immortalized cell line CVCL_0F81 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature-sensitive leucyl-tRNA synthetase mutant (PubMed=4361675) 21129637 CVCL_0F84 HHW105 hybrid cell line human CVCL_0F84 CL:0000010 Characteristics: Hybrid for chromosome 5 mapping Contains a complete copy of chromosome 5.. Group: Human/rodent somatic cell hybrid 21129638 CVCL_0F83 UCW 56 spontaneously immortalized cell line CVCL_0F83 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4781; Emetine; Derived from sampling site: Ovary. Female 21129639 CVCL_0F86 GM13082 hybrid cell line human CVCL_0F86 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129640 CVCL_0F85 UCW 206 spontaneously immortalized cell line CVCL_0F85 CL:0000010 Derived from sampling site: Ovary. Female 21129641 CVCL_0F88 GM50120 transformed cell line human CVCL_0F88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21129642 CVCL_0F87 GM14562 hybrid cell line human CVCL_0F87 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129643 CVCL_0F89 GM14558 hybrid cell line human CVCL_0F89 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129644 CVCL_0F91 GM14563 hybrid cell line human CVCL_0F91 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129645 CVCL_0F90 GM50113 transformed cell line human CVCL_0F90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21129646 CVCL_0F93 GM14564 hybrid cell line human CVCL_0F93 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129647 CVCL_0F92 GM50122 transformed cell line human CVCL_0F92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21129648 CVCL_0F95 GM14561 hybrid cell line human CVCL_0F95 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129649 CVCL_0F94 GM50125 transformed cell line human CVCL_0F94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21129650 CVCL_0F97 GM50074 hybrid cell line human CVCL_0F97 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129651 CVCL_0F96 GM50116 transformed cell line human CVCL_0F96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21129652 CVCL_0F99 AG06881 finite cell line human CVCL_0F99 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG06881) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21129653 CVCL_0F98 GM50118 transformed cell line human CVCL_0F98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21129654 CVCL_0F60 CCD-973Sk finite cell line human CVCL_0F60 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1892; true Male 21129655 CVCL_0F62 HAPI undefined cell line type house mouse CVCL_0F62 CL:0000010 Omics: Deep proteome analysis Discontinued: ATCC; CRL-2815; true; Discontinued: Millipore; SCC103; true. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00602 Problematic cell line: Misidentified Originally thought to be a microgial cell of rat origin (3 day old Wistar rat) but found to be from mouse (Millipore). 21129656 CVCL_0F61 CCD-976Sk finite cell line human CVCL_0F61 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1904; true Male 21129657 CVCL_0F64 La Gay finite cell line human CVCL_0F64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1109; probable 21129658 CVCL_0F63 T-HEECs telomerase immortalized cell line human CVCL_0F63 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Endometrium Cell type=Epithelial cell.. Discontinued: ATCC; CRL-4026; true Female 21129659 CVCL_0F66 Mil Kin finite cell line human CVCL_0F66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1123; probable 21129660 CVCL_0F65 Le Fin finite cell line human CVCL_0F65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1115; probable 21129661 CVCL_0F68 Ro Hen finite cell line human CVCL_0F68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1118; probable 21129662 CVCL_0F67 Ric Mil finite cell line human CVCL_0F67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1125; probable 21129663 CVCL_0F69 Sel Ger finite cell line human CVCL_0F69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1122; probable 21129664 CVCL_0F71 MB63 cancer cell line house mouse CVCL_0F71 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/ICRF-a(t). Male 21129665 CVCL_0F70 Pi Kar finite cell line human CVCL_0F70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1102; true Unspecified 21129666 CVCL_0F73 K12 [Hamster] spontaneously immortalized cell line CVCL_0F73 CL:0000010 Derived from sampling site: Lung. Male 21129667 CVCL_0F72 Wg-1A spontaneously immortalized cell line CVCL_0F72 CL:0000010 Derived from sampling site: Lung. Male 21129668 CVCL_0F75 KBF11 hybrid cell line CVCL_0F75 CL:0000010 Discontinued: ATCC; CRL-2788; true. Group: Human/rodent somatic cell hybrid 21129669 CVCL_0F74 BARF7 hybrid cell line human CVCL_0F74 CL:0000010 Discontinued: ATCC; CRL-2789; true. Group: Human/rodent somatic cell hybrid 21129670 CVCL_0F77 PGME1 hybrid cell line CVCL_0F77 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129671 CVCL_0F76 LIX 7 hybrid cell line CVCL_0F76 CL:0000010 Discontinued: ATCC; CRL-2793; true. Group: Human/rodent somatic cell hybrid 21129672 CVCL_0F79 GM06853 hybrid cell line CVCL_0F79 CL:0000010 Group: Human/rodent somatic cell hybrid. 21129673 CVCL_0F78 7777-14b-aza cancer cell line Norway rat CVCL_0F78 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21129674 CVCL_0F40 SV7tert PDGFtu2 transformed cell line human CVCL_0F40 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Discontinued: ATCC; CRL-4009; true Female 21129675 CVCL_0F42 NeHepBaHT telomerase immortalized cell line human CVCL_0F42 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver Cell type=Hepatocyte.. Discontinued: ATCC; CRL-4022; true Male Group: Patented cell line 21129676 CVCL_0F41 NeHepMsHT telomerase immortalized cell line human CVCL_0F41 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. Discontinued: ATCC; CRL-4021; true Male Group: Patented cell line 21129677 CVCL_0F44 Cuta/ChaoA spontaneously immortalized cell line CVCL_0F44 CL:0000010 Discontinued: ATCC; CRL-6585; true. Unspecified Group: Insect cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21129678 CVCL_0F43 CF7.Lu finite cell line dog CVCL_0F43 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6209; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21129679 CVCL_0F46 ADRI-PFT-19 spontaneously immortalized cell line pig CVCL_0F46 CL:0000010 Derived from sampling site: Fallopian tube; Breed/subspecies: Large White. Discontinued: ATCC; CRL-2250; true Female Doubling time: 20-25 hours (PubMed=3274) 21129680 CVCL_0F45 Cuta/ChaoB spontaneously immortalized cell line CVCL_0F45 CL:0000010 Discontinued: ATCC; CRL-6586; true. Unspecified Group: Insect cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21129681 CVCL_0F48 Ba Del finite cell line human CVCL_0F48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1141; probable Male 21129682 CVCL_0F47 SH-EP1 cancer cell line human CVCL_0F47 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2269; true Female Characteristics: Substrate-adherent type (S-type) (PubMed=15720811) 21129683 CVCL_0F49 La Col finite cell line human CVCL_0F49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1119; probable Male 21129684 CVCL_SL90 HAP1 ELFN2 (-) 2 cancer cell line human CVCL_SL90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29396; ELFN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129685 CVCL_SL92 HAP1 ELOVL1 (-) 1 cancer cell line human CVCL_SL92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14418; ELOVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129686 CVCL_SL91 HAP1 ELK1 (-) 1 cancer cell line human CVCL_SL91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3321; ELK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129687 CVCL_SL94 HAP1 EMC6 (-) 2 cancer cell line human CVCL_SL94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28430; EMC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129688 CVCL_SL93 HAP1 EMC6 (-) 1 cancer cell line human CVCL_SL93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28430; EMC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129689 CVCL_SL96 HAP1 EME1 (-) 1 cancer cell line human CVCL_SL96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24965; EME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129690 CVCL_SL95 HAP1 EMD (-) 1 cancer cell line human CVCL_SL95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3331; EMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129691 CVCL_SL98 HAP1 EME2 (-) 1 cancer cell line human CVCL_SL98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27289; EME2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129692 CVCL_SL97 HAP1 EME1 (-) 2 cancer cell line human CVCL_SL97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24965; EME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129693 CVCL_SL99 HAP1 EME2 (-) 2 cancer cell line human CVCL_SL99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27289; EME2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129694 CVCL_0F51 CCD-1001Sk finite cell line human CVCL_0F51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1987; true Male Senescence: Senesces at ~35 PDL (ATCC=CRL-1987) 21129695 CVCL_0F50 Bo Mat finite cell line human CVCL_0F50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1146; true 21129696 CVCL_0F53 CCD-965Sk finite cell line human CVCL_0F53 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1876; true Male Senescence: Senesces at ~25 PDL (ATCC=CRL-1876) 21129697 CVCL_0F52 CCD-1066Sk finite cell line human CVCL_0F52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-2080; true Unspecified 21129698 CVCL_0F55 CCD-969Sk finite cell line human CVCL_0F55 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1885; true Male 21129699 CVCL_0F54 CCD-967Sk finite cell line human CVCL_0F54 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1884; true Female 21129700 CVCL_0F57 MCH024 finite cell line human CVCL_0F57 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129701 CVCL_0F56 WG1130 finite cell line human CVCL_0F56 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7526; MMUT; Simple; p.Arg93His (c.278G>A); ClinVar=VCV000001880; Zygosity=Homozygous (PubMed=7909321; PubMed=16281286) Miscellaneous: Cell line no longer available Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129702 CVCL_0F59 HIVE-24 finite cell line human CVCL_0F59 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Female Part of: Wistar Institute Special Collection vascular cell lines 21129703 CVCL_0F58 HIAE-24 finite cell line human CVCL_0F58 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: Coriell; AG10464; probable Female Part of: Wistar Institute Special Collection vascular cell lines 21129704 CVCL_SL81 HAP1 EIF4EBP2 (-) 2 cancer cell line human CVCL_SL81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3289; EIF4EBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129705 CVCL_SL80 HAP1 EIF4EBP2 (-) 1 cancer cell line human CVCL_SL80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3289; EIF4EBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129706 CVCL_SL83 HAP1 ELAVL1 (-) 1 cancer cell line human CVCL_SL83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3312; ELAVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129707 CVCL_SL82 HAP1 ELAC1 (-) cancer cell line human CVCL_SL82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14197; ELAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129708 CVCL_SL85 HAP1 ELAVL1 (-) 3 cancer cell line human CVCL_SL85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3312; ELAVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129709 CVCL_SL84 HAP1 ELAVL1 (-) 2 cancer cell line human CVCL_SL84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3312; ELAVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129710 CVCL_SL87 HAP1 ELFN1 (-) 1 cancer cell line human CVCL_SL87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33154; ELFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129711 CVCL_SL86 HAP1 ELAVL1 (-) 4 cancer cell line human CVCL_SL86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3312; ELAVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129712 CVCL_SL89 HAP1 ELFN2 (-) 1 cancer cell line human CVCL_SL89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29396; ELFN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129713 CVCL_SL88 HAP1 ELFN1 (-) 2 cancer cell line human CVCL_SL88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33154; ELFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129714 CVCL_0F20 CHON-006 telomerase immortalized cell line human CVCL_0F20 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Discontinued: ATCC; CRL-2858; true Female 21129715 CVCL_0F22 CBRN1/6 hybridoma house mouse CVCL_0F22 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21129716 CVCL_0F21 CBRM1/1 hybridoma house mouse CVCL_0F21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21129717 CVCL_0F24 CBRM1/23 hybridoma house mouse CVCL_0F24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21129718 CVCL_0F23 CBRM1/10 hybridoma house mouse CVCL_0F23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21129719 CVCL_0F26 CBRM1/32 hybridoma house mouse CVCL_0F26 CL:0000010 Discontinued: ATCC; CRL-2864; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b 21129720 CVCL_0F25 CBRM1/30 hybridoma house mouse CVCL_0F25 CL:0000010 Discontinued: ATCC; CRL-2863; true. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b 21129721 CVCL_0F28 MS1 mAKT transformed cell line house mouse CVCL_0F28 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58-3](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Discontinued: ATCC; CRL-2878; true Unspecified 21129722 CVCL_0F27 HUVEC-CS finite cell line human CVCL_0F27 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Discontinued: ATCC; CRL-2873; true Female 21129723 CVCL_0F19 CHON-005 telomerase immortalized cell line human CVCL_0F19 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Discontinued: ATCC; CRL-2857; true Female 21129724 CVCL_0F18 CHON-004 telomerase immortalized cell line human CVCL_0F18 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Discontinued: ATCC; CRL-2856; true Female 21129725 CVCL_SL70 HAP1 EIF2AK4 (-) 2 cancer cell line human CVCL_SL70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129726 CVCL_SL72 HAP1 EIF2D (-) 1 cancer cell line human CVCL_SL72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6583; EIF2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129727 CVCL_SL71 HAP1 EIF2AK4 (-) 3 cancer cell line human CVCL_SL71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129728 CVCL_SL74 HAP1 EIF2D (-) 3 cancer cell line human CVCL_SL74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6583; EIF2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129729 CVCL_SL73 HAP1 EIF2D (-) 2 cancer cell line human CVCL_SL73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6583; EIF2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129730 CVCL_SL76 HAP1 EIF4E2 (-) 1 cancer cell line human CVCL_SL76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3293; EIF4E2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129731 CVCL_SL75 HAP1 EIF2D (-) 4 cancer cell line human CVCL_SL75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6583; EIF2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129732 CVCL_SL78 HAP1 EIF4E2 (-) 3 cancer cell line human CVCL_SL78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3293; EIF4E2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129733 CVCL_SL77 HAP1 EIF4E2 (-) 2 cancer cell line human CVCL_SL77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3293; EIF4E2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129734 CVCL_SL79 HAP1 EIF4EBP1 (-) cancer cell line human CVCL_SL79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3288; EIF4EBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129735 CVCL_SL59 HAP1 EIF1 (-) 2 cancer cell line human CVCL_SL59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3249; EIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129736 CVCL_0F31 MARC.BGCF.1-3 finite cell line CVCL_0F31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Hereford. Omics: Genome sequenced Discontinued: ATCC; CRL-2875; true Female 21129737 CVCL_0F30 MARC.BGCF.2 finite cell line CVCL_0F30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Hereford. Omics: Genome sequenced Discontinued: ATCC; CRL-2874; true Female 21129738 CVCL_0F33 IgG-15A6 hybridoma house mouse CVCL_0F33 CL:0000010 Discontinued: ATCC; CRL-2933; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NBP7; Human PCSK9 21129739 CVCL_0F32 IgG-13D3 hybridoma house mouse CVCL_0F32 CL:0000010 Discontinued: ATCC; CRL-2932; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NBP7; Human PCSK9 21129740 CVCL_0F35 PTEN-P8 cancer cell line house mouse CVCL_0F35 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21129741 CVCL_0F34 PTEN-P2 cancer cell line house mouse CVCL_0F34 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21129742 CVCL_0F37 PTEN-CaP8 cancer cell line house mouse CVCL_0F37 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21129743 CVCL_0F36 PTEN-CaP2 cancer cell line house mouse CVCL_0F36 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten. Male 21129744 CVCL_0F39 SV7tert PDGF transformed cell line human CVCL_0F39 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Discontinued: ATCC; CRL-4007; true Female 21129745 CVCL_0F38 CHLA-04-ATRT cancer cell line human CVCL_0F38 CL:0000010 Derived from sampling site: Brain; lateral ventricle; third ventricle. Male 21129746 CVCL_0F29 DFCI-LU011 cancer cell line human CVCL_0F29 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Unspecified (PubMed=16983123) Derived from metastatic site: Pleural effusion. Discontinued: ATCC; CRL-2883; true Male 21129747 CVCL_SL61 HAP1 EIF1B (-) 2 cancer cell line human CVCL_SL61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30792; EIF1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129748 CVCL_SL60 HAP1 EIF1B (-) 1 cancer cell line human CVCL_SL60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30792; EIF1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129749 CVCL_SL63 HAP1 EIF2AK1 (-) cancer cell line human CVCL_SL63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24921; EIF2AK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129750 CVCL_SL62 HAP1 EIF2A (-) cancer cell line human CVCL_SL62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3254; EIF2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129751 CVCL_SL65 HAP1 EIF2AK2 (-) 2 cancer cell line human CVCL_SL65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9437; EIF2AK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129752 CVCL_SL64 HAP1 EIF2AK2 (-) 1 cancer cell line human CVCL_SL64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9437; EIF2AK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129753 CVCL_SL67 HAP1 EIF2AK3 (-) 2 cancer cell line human CVCL_SL67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3255; EIF2AK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129754 CVCL_SL66 HAP1 EIF2AK3 (-) 1 cancer cell line human CVCL_SL66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3255; EIF2AK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129755 CVCL_SL69 HAP1 EIF2AK4 (-) 1 cancer cell line human CVCL_SL69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129756 CVCL_SL68 HAP1 EIF2AK3 (-) 3 cancer cell line human CVCL_SL68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3255; EIF2AK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21129757 CVCL_AZ52 GM24374 finite cell line human CVCL_AZ52 CL:0000010 Sequence variation: Mutation; HGNC; 19743; POMT2; Simple; p.Gly353Ser (c.1057G>A); ClinVar=VCV000003231; Zygosity=Homozygous (Coriell) Population: Caucasian; German/Irish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129758 CVCL_AZ51 GM24369 transformed cell line human CVCL_AZ51 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Asn238Lysfs*63 (c.713dupA) (c.713_714insA); ClinVar=VCV000004494; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129759 CVCL_AZ54 GM24406 finite cell line human CVCL_AZ54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129760 CVCL_AZ53 GM24375 finite cell line human CVCL_AZ53 CL:0000010 Sequence variation: Mutation; HGNC; 19743; POMT2; Simple; p.Gly353Ser (c.1057G>A); ClinVar=VCV000003231; Zygosity=Homozygous (Coriell) Population: Caucasian; German/Irish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129761 CVCL_AZ56 GM24530 transformed cell line human CVCL_AZ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129762 CVCL_AZ55 GM24467 finite cell line human CVCL_AZ55 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Val48Serfs*18 (c.142delG); ClinVar=VCV002419559; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Gly315Ser (c.943G>A); ClinVar=VCV000004496; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129763 CVCL_AZ58 GM24539 transformed cell line human CVCL_AZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129764 CVCL_AZ57 GM24531 transformed cell line human CVCL_AZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129765 CVCL_AZ50 GM24343 transformed cell line human CVCL_AZ50 CL:0000010 Sequence variation: Mutation; HGNC; 2213; COL6A3; Simple; p.Asp563Gly (c.1688A>G); ClinVar=VCV000094910; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129766 CVCL_AZ49 GM24268 transformed cell line human CVCL_AZ49 CL:0000010 Sequence variation: Mutation; HGNC; 2974; DNM2; Simple; p.Glu368Lys (c.1102G>A); ClinVar=VCV000007282; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129767 CVCL_AZ48 GM24234 transformed cell line human CVCL_AZ48 CL:0000010 Sequence variation: Mutation; HGNC; 2213; COL6A3; Simple; p.Asp563Gly (c.1688A>G); ClinVar=VCV000094910; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129768 CVCL_AZ63 MeWo VIN 0.5 cancer cell line human CVCL_AZ63 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:36373; Vindesine; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21129769 CVCL_AZ62 MeWo ETO 1 cancer cell line human CVCL_AZ62 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21129770 CVCL_AZ65 SP1 cancer cell line house mouse CVCL_AZ65 CL:0000010 Breed/subspecies: CBA/J. Female 21129771 CVCL_AZ64 HEY-1B cancer cell line human CVCL_AZ64 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Female 21129772 CVCL_AZ67 AC2M2 cancer cell line house mouse CVCL_AZ67 CL:0000010 Breed/subspecies: CBA/J. Female Caution: Could be identical to SP1-3M (Cellosaurus=CVCL_AZ66) 21129773 CVCL_AZ66 SP1-3M cancer cell line house mouse CVCL_AZ66 CL:0000010 Breed/subspecies: CBA/J. Female Caution: Could be identical to AC2M2 (Cellosaurus=CVCL_AZ67) 21129774 CVCL_AZ69 CHO 14-2-1 spontaneously immortalized cell line CVCL_AZ69 CL:0000010 Derived from sampling site: Ovary. Female 21129775 CVCL_AZ68 CHO 13-5-1 spontaneously immortalized cell line CVCL_AZ68 CL:0000010 Derived from sampling site: Ovary. Female 21129776 CVCL_AZ61 MeWo ETO 0.1 cancer cell line human CVCL_AZ61 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21129777 CVCL_AZ60 MeWo CIS 0.01 cancer cell line human CVCL_AZ60 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21129778 CVCL_AZ59 GM25270 transformed cell line human CVCL_AZ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129779 CVCL_AZ30 GM24463 transformed cell line human CVCL_AZ30 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg1400Ter (c.4198C>T); ClinVar=VCV000557566; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg2236Arg (c.6706A>C); ClinVar=VCV000256082; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129780 CVCL_AZ32 GM24511 transformed cell line human CVCL_AZ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129781 CVCL_AZ31 GM24510 transformed cell line human CVCL_AZ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129782 CVCL_AZ34 GM24519 transformed cell line human CVCL_AZ34 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Arg425Gly (c.1273A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129783 CVCL_AZ33 GM24513 transformed cell line human CVCL_AZ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129784 CVCL_AZ36 GM24521 transformed cell line human CVCL_AZ36 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Arg425Gly (c.1273A>G); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129785 CVCL_AZ35 GM24520 transformed cell line human CVCL_AZ35 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Arg425Gly (c.1273A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129786 CVCL_9A93 DD0591 transformed cell line human CVCL_9A93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129787 CVCL_9A92 DD0590 transformed cell line human CVCL_9A92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129788 CVCL_9A95 DD0595 transformed cell line human CVCL_9A95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129789 CVCL_9A94 DD0592 transformed cell line human CVCL_9A94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129790 CVCL_9A91 DD0589 transformed cell line human CVCL_9A91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129791 CVCL_9A90 DD0588 transformed cell line human CVCL_9A90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129792 CVCL_AZ27 GM24367 transformed cell line human CVCL_AZ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129793 CVCL_AZ26 GM24366 transformed cell line human CVCL_AZ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129794 CVCL_AZ29 GM24396 transformed cell line human CVCL_AZ29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129795 CVCL_AZ28 GM24373 finite cell line human CVCL_AZ28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129796 CVCL_9A97 DD0602 transformed cell line human CVCL_9A97 CL:0000010 Karyotypic information: 46,XY,inv(3)(q21;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129797 CVCL_9A96 DD0596 transformed cell line human CVCL_9A96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129798 CVCL_9A99 DD0610 transformed cell line human CVCL_9A99 CL:0000010 Karyotypic information: 45,X0(P) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129799 CVCL_9A98 DD0609 transformed cell line human CVCL_9A98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129800 CVCL_AZ41 GM24593 transformed cell line human CVCL_AZ41 CL:0000010 Population: Bangladeshi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129801 CVCL_AZ40 GM24591 finite cell line human CVCL_AZ40 CL:0000010 Sequence variation: Mutation; HGNC; 17416; ADGRV1; Simple; c.14973-2A>G; ClinVar=VCV000046275; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129802 CVCL_AZ43 GM24696 transformed cell line human CVCL_AZ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129803 CVCL_AZ42 GM24646 finite cell line human CVCL_AZ42 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Arg80Profs*69 (c.238dupC) (c.238_239insC); ClinVar=VCV000005141; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129804 CVCL_AZ45 GM23301 transformed cell line human CVCL_AZ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129805 CVCL_AZ44 GM25500 transformed cell line human CVCL_AZ44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129806 CVCL_AZ47 GM23651 finite cell line human CVCL_AZ47 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Asn238Lysfs*63 (c.713dupA) (c.713_714insA); ClinVar=VCV000004494; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129807 CVCL_AZ46 GM23324 finite cell line human CVCL_AZ46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129808 CVCL_AZ38 GM24589 finite cell line human CVCL_AZ38 CL:0000010 Sequence variation: Mutation; HGNC; 17416; ADGRV1; Simple; p.Ser2934Ter (c.8801C>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17416; ADGRV1; Simple; c.14973-2A>G; ClinVar=VCV000046275; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129809 CVCL_AZ37 GM24585 finite cell line human CVCL_AZ37 CL:0000010 Sequence variation: Gene deletion; HGNC; 20444; MBD5; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129810 CVCL_AZ39 GM24590 finite cell line human CVCL_AZ39 CL:0000010 Sequence variation: Mutation; HGNC; 17416; ADGRV1; Simple; p.Ser2934Ter (c.8801C>A); Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129811 CVCL_AZ10 GM24245 transformed cell line human CVCL_AZ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129812 CVCL_AZ12 GM24247 transformed cell line human CVCL_AZ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129813 CVCL_AZ11 GM24246 transformed cell line human CVCL_AZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129814 CVCL_AZ14 GM24249 transformed cell line human CVCL_AZ14 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Leu12Arg (c.35T>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Gln2433Ter (c.7297C>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129815 CVCL_AZ13 GM24248 transformed cell line human CVCL_AZ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129816 CVCL_9A71 DD0548 transformed cell line human CVCL_9A71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129817 CVCL_9A70 DD0547 finite cell line human CVCL_9A70 CL:0000010 Karyotypic information: 46,XX,inv(2)?(p11,q13)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21129818 CVCL_9A73 DD0550 transformed cell line human CVCL_9A73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129819 CVCL_9A72 DD0549 transformed cell line human CVCL_9A72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129820 CVCL_9A79 DD0558 transformed cell line human CVCL_9A79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129821 CVCL_AZ05 GM24233 transformed cell line human CVCL_AZ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129822 CVCL_9A78 DD0557 transformed cell line human CVCL_9A78 CL:0000010 Karyotypic information: 46,XY,t(4;5)(q21.1;q35.1)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129823 CVCL_AZ04 GM24230 finite cell line human CVCL_AZ04 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Leu12Arg (c.35T>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Gln2433Ter (c.7297C>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129824 CVCL_AZ07 GM24241 transformed cell line human CVCL_AZ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129825 CVCL_AZ06 GM24235 transformed cell line human CVCL_AZ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129826 CVCL_9A75 DD0553 transformed cell line human CVCL_9A75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129827 CVCL_AZ09 GM24244 transformed cell line human CVCL_AZ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129828 CVCL_9A74 DD0551 transformed cell line human CVCL_9A74 CL:0000010 Karyotypic information: 46,XY,t(4;8)(?q34.2;q24.13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129829 CVCL_AZ08 GM24243 transformed cell line human CVCL_AZ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129830 CVCL_9A77 DD0556 transformed cell line human CVCL_9A77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129831 CVCL_9A76 DD0555 transformed cell line human CVCL_9A76 CL:0000010 Karyotypic information: 46,XY,del(22)(q11.21->q11.22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129832 CVCL_AZ21 GM24261 finite cell line human CVCL_AZ21 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Trp166Ter (c.498G>A); ClinVar=VCV000551094; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Val1138Met (c.3412G>A); ClinVar=VCV000092952; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129833 CVCL_AZ20 GM24260 finite cell line human CVCL_AZ20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129834 CVCL_AZ23 GM24353 transformed cell line human CVCL_AZ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129835 CVCL_AZ22 GM24264 transformed cell line human CVCL_AZ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129836 CVCL_AZ25 GM24365 transformed cell line human CVCL_AZ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129837 CVCL_AZ24 GM24354 transformed cell line human CVCL_AZ24 CL:0000010 Sequence variation: Mutation; HGNC; 2323; CPS1; Simple; p.Arg1262Ter (c.3784C>T); ClinVar=VCV000552571; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129838 CVCL_9A82 DD0561 finite cell line human CVCL_9A82 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21129839 CVCL_9A81 DD0560 finite cell line human CVCL_9A81 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21129840 CVCL_9A84 DD0569 transformed cell line human CVCL_9A84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129841 CVCL_9A83 DD0567 transformed cell line human CVCL_9A83 CL:0000010 Karyotypic information: 47,XXX,t(8;10)(q22.1;24.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129842 CVCL_9A80 DD0559 finite cell line human CVCL_9A80 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21129843 CVCL_AZ16 GM24254 transformed cell line human CVCL_AZ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129844 CVCL_9A89 DD0587 transformed cell line human CVCL_9A89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129845 CVCL_AZ15 GM24253 transformed cell line human CVCL_AZ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129846 CVCL_AZ18 GM24256 finite cell line human CVCL_AZ18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129847 CVCL_AZ17 GM24255 transformed cell line human CVCL_AZ17 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Trp166Ter (c.498G>A); ClinVar=VCV000551094; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Val1138Met (c.3412G>A); ClinVar=VCV000092952; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21129848 CVCL_9A86 DD0572 transformed cell line human CVCL_9A86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129849 CVCL_9A85 DD0571 transformed cell line human CVCL_9A85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129850 CVCL_AZ19 GM24258 finite cell line human CVCL_AZ19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21129851 CVCL_9A88 DD0585 transformed cell line human CVCL_9A88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129852 CVCL_9A87 DD0576 transformed cell line human CVCL_9A87 CL:0000010 Karyotypic information: 47,XY,+21 (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129853 CVCL_9A51 DD0512 transformed cell line human CVCL_9A51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129854 CVCL_9A50 DD0510 transformed cell line human CVCL_9A50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129855 CVCL_9A57 DD0523 transformed cell line human CVCL_9A57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129856 CVCL_9A56 DD0522 finite cell line human CVCL_9A56 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Amniotic fluid Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21129857 CVCL_9A59 DD0525 transformed cell line human CVCL_9A59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129858 CVCL_9A58 DD0524 transformed cell line human CVCL_9A58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129859 CVCL_9A53 DD0516 transformed cell line human CVCL_9A53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129860 CVCL_9A52 DD0515 finite cell line human CVCL_9A52 CL:0000010 Karyotypic information: 47,XX,+15 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21129861 CVCL_9A55 DD0521 finite cell line human CVCL_9A55 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21129862 CVCL_9A54 DD0520 transformed cell line human CVCL_9A54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129863 CVCL_AZ01 GM24218 finite cell line human CVCL_AZ01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129864 CVCL_AZ00 GM24217 transformed cell line human CVCL_AZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21129865 CVCL_AZ03 GM24228 finite cell line human CVCL_AZ03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129866 CVCL_AZ02 GM24219 finite cell line human CVCL_AZ02 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Cys314Trpfs*3 (c.939_940delAT); ClinVar=VCV000477529; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg1326Ter (c.3976C>T); ClinVar=VCV000092956; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21129867 CVCL_9A60 DD0528 transformed cell line human CVCL_9A60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129868 CVCL_9A62 DD0531 transformed cell line human CVCL_9A62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129869 CVCL_9A61 DD0530 transformed cell line human CVCL_9A61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129870 CVCL_9A68 DD0544 transformed cell line human CVCL_9A68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129871 CVCL_9A67 DD0543 transformed cell line human CVCL_9A67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129872 CVCL_9A69 DD0546 transformed cell line human CVCL_9A69 CL:0000010 Karyotypic information: 46,XY,inv(2)(p11q13)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129873 CVCL_9A64 DD0535 transformed cell line human CVCL_9A64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129874 CVCL_9A63 DD0532 transformed cell line human CVCL_9A63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129875 CVCL_9A66 DD0542 transformed cell line human CVCL_9A66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21129876 CVCL_9A65 DD0541 transformed cell line human CVCL_9A65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21129877 CVCL_SN03 HAP1 FANCB (-) cancer cell line human CVCL_SN03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3583; FANCB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129878 CVCL_SN02 HAP1 FANCA (-) 5 cancer cell line human CVCL_SN02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129879 CVCL_SN05 HAP1 FANCD2 (-) 2 cancer cell line human CVCL_SN05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129880 CVCL_SN04 HAP1 FANCD2 (-) 1 cancer cell line human CVCL_SN04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3585; FANCD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129881 CVCL_SN07 HAP1 FANCE (-) 2 cancer cell line human CVCL_SN07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3586; FANCE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129882 CVCL_SN06 HAP1 FANCE (-) 1 cancer cell line human CVCL_SN06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3586; FANCE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129883 CVCL_SN09 HAP1 FANCI (-) cancer cell line human CVCL_SN09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25568; FANCI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129884 CVCL_SN08 HAP1 FANCG (-) cancer cell line human CVCL_SN08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3588; FANCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129885 CVCL_K569 C0810 transformed cell line human CVCL_K569 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090133; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129886 CVCL_JT69 JHU073i induced pluripotent stem cell human CVCL_JT69 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129887 CVCL_K566 C0807 transformed cell line human CVCL_K566 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090130; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129888 CVCL_JT66 JHU070i induced pluripotent stem cell human CVCL_JT66 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129889 CVCL_K565 C0806(2) transformed cell line human CVCL_K565 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060894; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129890 CVCL_JT65 JHU067i induced pluripotent stem cell human CVCL_JT65 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129891 CVCL_K568 C0809 transformed cell line human CVCL_K568 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090132; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129892 CVCL_JT68 JHU072i induced pluripotent stem cell human CVCL_JT68 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129893 CVCL_K567 C0808 transformed cell line human CVCL_K567 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090131; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129894 CVCL_JT67 JHU071i induced pluripotent stem cell human CVCL_JT67 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129895 CVCL_K562 C0804 transformed cell line human CVCL_K562 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090127; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129896 CVCL_JT62 JHU064i induced pluripotent stem cell human CVCL_JT62 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129897 CVCL_K561 C0803 transformed cell line human CVCL_K561 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090126; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129898 CVCL_JT61 JHU063i induced pluripotent stem cell human CVCL_JT61 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129899 CVCL_K564 C0806 transformed cell line human CVCL_K564 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090129; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129900 CVCL_JT64 JHU066i induced pluripotent stem cell human CVCL_JT64 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129901 CVCL_K563 C0805 transformed cell line human CVCL_K563 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090128; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129902 CVCL_JT63 JHU065i induced pluripotent stem cell human CVCL_JT63 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129903 CVCL_K560 C0802 transformed cell line human CVCL_K560 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090125; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129904 CVCL_JT60 JHU062i induced pluripotent stem cell human CVCL_JT60 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129905 CVCL_SN10 HAP1 FANCL (-) cancer cell line human CVCL_SN10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20748; FANCL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129906 CVCL_SN12 HAP1 FARP1 (-) 2 cancer cell line human CVCL_SN12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3591; FARP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129907 CVCL_SN11 HAP1 FARP1 (-) 1 cancer cell line human CVCL_SN11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3591; FARP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129908 CVCL_K577 C0818 transformed cell line human CVCL_K577 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090141; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129909 CVCL_JT77 JHU082i induced pluripotent stem cell human CVCL_JT77 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129910 CVCL_K576 C0817 transformed cell line human CVCL_K576 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090140; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129911 CVCL_JT76 JHU081i induced pluripotent stem cell human CVCL_JT76 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129912 CVCL_K579 C0820 transformed cell line human CVCL_K579 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090143; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129913 CVCL_JT79 JHU084i induced pluripotent stem cell human CVCL_JT79 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129914 CVCL_K578 C0819 transformed cell line human CVCL_K578 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090142; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129915 CVCL_JT78 JHU083i induced pluripotent stem cell human CVCL_JT78 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129916 CVCL_K573 C0814 transformed cell line human CVCL_K573 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090137; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129917 CVCL_JT73 JHU078i induced pluripotent stem cell human CVCL_JT73 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129918 CVCL_K572 C0813 transformed cell line human CVCL_K572 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090136; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129919 CVCL_JT72 JHU077i induced pluripotent stem cell human CVCL_JT72 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129920 CVCL_K575 C0816 transformed cell line human CVCL_K575 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090139; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129921 CVCL_JT75 JHU080i induced pluripotent stem cell human CVCL_JT75 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129922 CVCL_K574 C0815 transformed cell line human CVCL_K574 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090138; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129923 CVCL_JT74 JHU079i induced pluripotent stem cell human CVCL_JT74 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129924 CVCL_K571 C0812 transformed cell line human CVCL_K571 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090135; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129925 CVCL_JT71 JHU075i induced pluripotent stem cell human CVCL_JT71 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129926 CVCL_K570 C0811 transformed cell line human CVCL_K570 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090134; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129927 CVCL_JT70 JHU074i induced pluripotent stem cell human CVCL_JT70 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129928 CVCL_SN01 HAP1 FANCA (-) 4 cancer cell line human CVCL_SN01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129929 CVCL_SN00 HAP1 FANCA (-) 3 cancer cell line human CVCL_SN00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21129930 CVCL_K548 C0790 transformed cell line human CVCL_K548 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090113; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129931 CVCL_JT48 JHU047i induced pluripotent stem cell human CVCL_JT48 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129932 CVCL_K547 C0789 transformed cell line human CVCL_K547 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090112; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129933 CVCL_JT47 JHU045i induced pluripotent stem cell human CVCL_JT47 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129934 CVCL_K549 C0791 transformed cell line human CVCL_K549 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090114; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129935 CVCL_JT49 JHU048i induced pluripotent stem cell human CVCL_JT49 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129936 CVCL_K544 C0786 transformed cell line human CVCL_K544 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129937 CVCL_JT44 JHU042i induced pluripotent stem cell human CVCL_JT44 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129938 CVCL_K543 C0785 transformed cell line human CVCL_K543 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090108; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129939 CVCL_JT43 JHU040i induced pluripotent stem cell human CVCL_JT43 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129940 CVCL_K546 C0788 transformed cell line human CVCL_K546 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090111; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129941 CVCL_JT46 JHU044i induced pluripotent stem cell human CVCL_JT46 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129942 CVCL_K545 C0787 transformed cell line human CVCL_K545 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090110; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129943 CVCL_JT45 JHU043i induced pluripotent stem cell human CVCL_JT45 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129944 CVCL_K540 C0782 transformed cell line human CVCL_K540 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090105; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129945 CVCL_JT40 JHU037i induced pluripotent stem cell human CVCL_JT40 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129946 CVCL_K542 C0784 transformed cell line human CVCL_K542 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090107; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129947 CVCL_JT42 JHU039i induced pluripotent stem cell human CVCL_JT42 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129948 CVCL_K541 C0783 transformed cell line human CVCL_K541 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090106; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129949 CVCL_JT41 JHU038i induced pluripotent stem cell human CVCL_JT41 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129950 CVCL_K559 C0801 transformed cell line human CVCL_K559 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090124; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129951 CVCL_JT59 JHU060i-2 induced pluripotent stem cell human CVCL_JT59 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129952 CVCL_K558 C0800 transformed cell line human CVCL_K558 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090123; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129953 CVCL_JT58 JHU058i induced pluripotent stem cell human CVCL_JT58 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129954 CVCL_K555 C0797 transformed cell line human CVCL_K555 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090120; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129955 CVCL_JT55 JHU055i induced pluripotent stem cell human CVCL_JT55 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129956 CVCL_K554 C0796 transformed cell line human CVCL_K554 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090119; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129957 CVCL_JT54 JHU054i induced pluripotent stem cell human CVCL_JT54 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129958 CVCL_K557 C0799 transformed cell line human CVCL_K557 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090122; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129959 CVCL_JT57 JHU057i induced pluripotent stem cell human CVCL_JT57 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129960 CVCL_K556 C0798 transformed cell line human CVCL_K556 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090121; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129961 CVCL_JT56 JHU056i induced pluripotent stem cell human CVCL_JT56 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129962 CVCL_K551 C0793 transformed cell line human CVCL_K551 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090116; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129963 CVCL_JT51 JHU050i induced pluripotent stem cell human CVCL_JT51 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129964 CVCL_K550 C0792 transformed cell line human CVCL_K550 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090115; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129965 CVCL_JT50 JHU049i induced pluripotent stem cell human CVCL_JT50 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129966 CVCL_K553 C0795 transformed cell line human CVCL_K553 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090118; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129967 CVCL_JT53 JHU053i induced pluripotent stem cell human CVCL_JT53 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129968 CVCL_K552 C0794 transformed cell line human CVCL_K552 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090117; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129969 CVCL_JT52 JHU052i induced pluripotent stem cell human CVCL_JT52 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129970 CVCL_AZ96 WE-cfin11e spontaneously immortalized cell line CVCL_AZ96 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21129971 CVCL_AZ95 WE-brain5 spontaneously immortalized cell line CVCL_AZ95 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21129972 CVCL_AZ98 WE-heart1 spontaneously immortalized cell line CVCL_AZ98 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21129973 CVCL_AZ97 WE-cfin11f spontaneously immortalized cell line CVCL_AZ97 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 21129974 CVCL_AZ99 WE-heart6 spontaneously immortalized cell line CVCL_AZ99 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21129975 CVCL_K529 C0770 transformed cell line human CVCL_K529 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060887; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129976 CVCL_JT29 JHU017i induced pluripotent stem cell human CVCL_JT29 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129977 CVCL_AZ90 RT-ovf1 spontaneously immortalized cell line CVCL_AZ90 CL:0000010 Derived from sampling site: Ovarian fluid. Female Group: Fish cell line 21129978 CVCL_K526 C0767 transformed cell line human CVCL_K526 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060884; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129979 CVCL_JT26 JHU004i-2 induced pluripotent stem cell human CVCL_JT26 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129980 CVCL_AZ92 TOGB spontaneously immortalized cell line CVCL_AZ92 CL:0000010 Derived from sampling site: Brain. Male Group: Fish cell line 21129981 CVCL_K525 C0766 transformed cell line human CVCL_K525 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060883; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129982 CVCL_JT25 JHU002i-1 induced pluripotent stem cell human CVCL_JT25 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129983 CVCL_AZ91 RTH transformed cell line CVCL_AZ91 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Heart. Unspecified Group: Fish cell line 21129984 CVCL_K528 C0769 transformed cell line human CVCL_K528 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060886; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129985 CVCL_JT28 JHU013i-2 induced pluripotent stem cell human CVCL_JT28 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129986 CVCL_AZ94 WE-brain3 spontaneously immortalized cell line CVCL_AZ94 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21129987 CVCL_K527 C0768 transformed cell line human CVCL_K527 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060885; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129988 CVCL_JT27 JHU012i-2 induced pluripotent stem cell human CVCL_JT27 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129989 CVCL_AZ93 WE-afin8e spontaneously immortalized cell line CVCL_AZ93 CL:0000010 Derived from sampling site: Anal fin. Unspecified Group: Fish cell line 21129990 CVCL_K522 C0763 transformed cell line human CVCL_K522 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060880; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129991 CVCL_JT22 STAN380i-092C2 induced pluripotent stem cell human CVCL_JT22 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129992 CVCL_K521 C0762 transformed cell line human CVCL_K521 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060879; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129993 CVCL_JT21 STAN379i-783C6 induced pluripotent stem cell human CVCL_JT21 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129994 CVCL_K524 C0765 transformed cell line human CVCL_K524 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060882; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129995 CVCL_JT24 JHU001i induced pluripotent stem cell human CVCL_JT24 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129996 CVCL_K523 C0764 transformed cell line human CVCL_K523 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060881; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129997 CVCL_JT23 STAN381i-652C1 induced pluripotent stem cell human CVCL_JT23 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21129998 CVCL_K520 C0761 transformed cell line human CVCL_K520 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060878; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21129999 CVCL_JT20 STAN378i-886C4 induced pluripotent stem cell human CVCL_JT20 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130000 CVCL_K537 C0779 transformed cell line human CVCL_K537 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090102; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130001 CVCL_JT37 JHU033i induced pluripotent stem cell human CVCL_JT37 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130002 CVCL_K536 C0778 transformed cell line human CVCL_K536 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090101; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130003 CVCL_JT36 JHU032i induced pluripotent stem cell human CVCL_JT36 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130004 CVCL_K539 C0781 transformed cell line human CVCL_K539 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130005 CVCL_JT39 JHU036i induced pluripotent stem cell human CVCL_JT39 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130006 CVCL_K538 C0780 transformed cell line human CVCL_K538 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090103; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130007 CVCL_JT38 JHU035i induced pluripotent stem cell human CVCL_JT38 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130008 CVCL_K533 C0774 transformed cell line human CVCL_K533 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060891; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130009 CVCL_JT33 JHU023i induced pluripotent stem cell human CVCL_JT33 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130010 CVCL_K532 C0773 transformed cell line human CVCL_K532 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060890; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130011 CVCL_JT32 JHU022i induced pluripotent stem cell human CVCL_JT32 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130012 CVCL_K535 C0777 transformed cell line human CVCL_K535 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060893; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130013 CVCL_JT35 JHU027i induced pluripotent stem cell human CVCL_JT35 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130014 CVCL_K534 C0775 transformed cell line human CVCL_K534 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060892; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130015 CVCL_JT34 JHU024i induced pluripotent stem cell human CVCL_JT34 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130016 CVCL_K531 C0772 transformed cell line human CVCL_K531 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060889; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130017 CVCL_JT31 JHU019i induced pluripotent stem cell human CVCL_JT31 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130018 CVCL_K530 C0771 transformed cell line human CVCL_K530 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060888; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130019 CVCL_JT30 JHU018i induced pluripotent stem cell human CVCL_JT30 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130020 CVCL_AZ74 MeWo CIS 1 cancer cell line human CVCL_AZ74 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21130021 CVCL_AZ73 K562/CP cancer cell line human CVCL_AZ73 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Pleural effusion. Female 21130022 CVCL_AZ76 MeWo FOTE 40 cancer cell line human CVCL_AZ76 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:131848; Fotemustine; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21130023 CVCL_AZ75 MeWo FOTE 4 cancer cell line human CVCL_AZ75 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:131848; Fotemustine; Derived from metastatic site: Lymph node. Male 21130024 CVCL_AZ78 H69/VDS cancer cell line human CVCL_AZ78 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:36373; Vindesine; Derived from metastatic site: Pleural effusion. Male 21130025 CVCL_AZ77 MeWo VIN 5 cancer cell line human CVCL_AZ77 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:36373; Vindesine; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE Male 21130026 CVCL_AZ79 L5178Y VCRR cancer cell line house mouse CVCL_AZ79 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21130027 CVCL_K508 C0749 transformed cell line human CVCL_K508 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130028 CVCL_JT08 STAN366i-282C2 induced pluripotent stem cell human CVCL_JT08 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130029 CVCL_K507 C0748 transformed cell line human CVCL_K507 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130030 CVCL_JT07 STAN365i-664C1 induced pluripotent stem cell human CVCL_JT07 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130031 CVCL_K509 C0750 transformed cell line human CVCL_K509 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130032 CVCL_JT09 STAN367i-894C1 induced pluripotent stem cell human CVCL_JT09 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130033 CVCL_K504 C0745 transformed cell line human CVCL_K504 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130034 CVCL_AZ70 Neu7 transformed cell line Norway rat CVCL_AZ70 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated Erbb2/neu; Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: CFHB Wistar. Unspecified Caution: Erroneously indicated as originating from mouse in BTO=BTO:0005800 21130035 CVCL_JT04 STAN362i-178C1 induced pluripotent stem cell human CVCL_JT04 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130036 CVCL_K503 C0744 transformed cell line human CVCL_K503 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130037 CVCL_JT03 STAN361i-531C6 induced pluripotent stem cell human CVCL_JT03 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130038 CVCL_K506 C0747 transformed cell line human CVCL_K506 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130039 CVCL_JT06 STAN364i-055C2 induced pluripotent stem cell human CVCL_JT06 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130040 CVCL_AZ72 T27A1 transformed cell line Norway rat CVCL_AZ72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: PVG. Unspecified 21130041 CVCL_K505 C0746 transformed cell line human CVCL_K505 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060863; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130042 CVCL_JT05 STAN363i-845C5 induced pluripotent stem cell human CVCL_JT05 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130043 CVCL_AZ71 T34-2 transformed cell line Norway rat CVCL_AZ71 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: CFHB Wistar. Unspecified 21130044 CVCL_K500 C0741 transformed cell line human CVCL_K500 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130045 CVCL_JT00 STAN358i-298C3 induced pluripotent stem cell human CVCL_JT00 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130046 CVCL_K502 C0743 transformed cell line human CVCL_K502 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130047 CVCL_JT02 STAN360i-465C2 induced pluripotent stem cell human CVCL_JT02 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130048 CVCL_K501 C0742 transformed cell line human CVCL_K501 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130049 CVCL_JT01 STAN359i-442C11 induced pluripotent stem cell human CVCL_JT01 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130050 CVCL_AZ85 B9V transformed cell line house mouse CVCL_AZ85 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Embryonic brain Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified 21130051 CVCL_AZ84 ASP409 spontaneously immortalized cell line CVCL_AZ84 CL:0000010 Derived from sampling site: Pituitary gland. Female Doubling time: 3 days (CelloPub=CLPUB00327) Group: Fish cell line 21130052 CVCL_AZ87 H5V transformed cell line house mouse CVCL_AZ87 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Embryonic heart Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Female 21130053 CVCL_AZ86 E10V transformed cell line house mouse CVCL_AZ86 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Whole embryo Cell type=Endothelial cell.; Breed/subspecies: C57BL/6. Unspecified 21130054 CVCL_AZ89 RT-milt5 spontaneously immortalized cell line CVCL_AZ89 CL:0000010 Derived from sampling site: Seminal fluid. Male Group: Fish cell line 21130055 CVCL_AZ88 EelB spontaneously immortalized cell line CVCL_AZ88 CL:0000010 Derived from sampling site: Brain Cell type=Endothelial cell.. Female Group: Fish cell line 21130056 CVCL_K519 C0760 transformed cell line human CVCL_K519 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060877; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130057 CVCL_JT19 STAN377i-572C5 induced pluripotent stem cell human CVCL_JT19 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130058 CVCL_K518 C0759 transformed cell line human CVCL_K518 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060876; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130059 CVCL_JT18 STAN376i-518C2 induced pluripotent stem cell human CVCL_JT18 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130060 CVCL_K515 C0756 transformed cell line human CVCL_K515 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130061 CVCL_AZ81 PK [Pig kidney] spontaneously immortalized cell line pig CVCL_AZ81 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21130062 CVCL_JT15 STAN373i-412C4 induced pluripotent stem cell human CVCL_JT15 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130063 CVCL_K514 C0755 transformed cell line human CVCL_K514 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130064 CVCL_AZ80 L5178Y VDSR cancer cell line house mouse CVCL_AZ80 CL:0000010 Selected for resistance to: ChEBI; CHEBI:36373; Vindesine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21130065 CVCL_JT14 STAN372i-411C8 induced pluripotent stem cell human CVCL_JT14 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130066 CVCL_AZ83 ASP309 spontaneously immortalized cell line CVCL_AZ83 CL:0000010 Derived from sampling site: Pituitary gland Cell type=Epithelial cell.. Female Doubling time: 9 days (CelloPub=CLPUB00327) Group: Fish cell line 21130067 CVCL_K517 C0758 transformed cell line human CVCL_K517 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060875; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130068 CVCL_JT17 STAN375i-961C1 induced pluripotent stem cell human CVCL_JT17 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130069 CVCL_AZ82 ASimf20 spontaneously immortalized cell line CVCL_AZ82 CL:0000010 Derived from sampling site: Intestine Cell type=Myofibroblast.. Female Group: Fish cell line 21130070 CVCL_K516 C0757 transformed cell line human CVCL_K516 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060874; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130071 CVCL_JT16 STAN374i-565C4 induced pluripotent stem cell human CVCL_JT16 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130072 CVCL_K511 C0752 transformed cell line human CVCL_K511 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060869; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130073 CVCL_JT11 STAN369i-088C3 induced pluripotent stem cell human CVCL_JT11 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130074 CVCL_K510 C0751 transformed cell line human CVCL_K510 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060868; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130075 CVCL_JT10 STAN368i-894C2 induced pluripotent stem cell human CVCL_JT10 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130076 CVCL_K513 C0754 transformed cell line human CVCL_K513 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060871; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130077 CVCL_JT13 STAN371i-868C5 induced pluripotent stem cell human CVCL_JT13 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130078 CVCL_K512 C0753 transformed cell line human CVCL_K512 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130079 CVCL_JT12 STAN370i-190C3 induced pluripotent stem cell human CVCL_JT12 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130080 CVCL_SM69 HAP1 EZR (-) 1 cancer cell line human CVCL_SM69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12691; EZR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130081 CVCL_0G21 HHW631 hybrid cell line human CVCL_0G21 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130082 CVCL_0G20 HHW484 hybrid cell line human CVCL_0G20 CL:0000010 Characteristics: Hybrid for chromosome 6 mapping Contains a complete copy of chromosome 6.. Group: Human/rodent somatic cell hybrid 21130083 CVCL_0G23 HHW939 hybrid cell line human CVCL_0G23 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130084 CVCL_0G22 HHW725 hybrid cell line human CVCL_0G22 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130085 CVCL_0G25 GM13083 hybrid cell line human CVCL_0G25 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130086 CVCL_0G24 HHW983 hybrid cell line human CVCL_0G24 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130087 CVCL_0G27 GM14111 hybrid cell line human CVCL_0G27 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130088 CVCL_0G26 GM13697 hybrid cell line human CVCL_0G26 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130089 CVCL_0G18 HHW1273 hybrid cell line human CVCL_0G18 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130090 CVCL_0G17 HHW1099 hybrid cell line human CVCL_0G17 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130091 CVCL_0G19 HHW416 hybrid cell line human CVCL_0G19 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping Contains a complete copy of chromosome 4.. Group: Human/rodent somatic cell hybrid 21130092 CVCL_SM71 HAP1 F2RL1 (-) 1 cancer cell line human CVCL_SM71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3538; F2RL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130093 CVCL_SM70 HAP1 F11R (-) 1 cancer cell line human CVCL_SM70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14685; F11R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130094 CVCL_SM73 HAP1 F3 (-) 2 cancer cell line human CVCL_SM73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3541; F3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130095 CVCL_SM72 HAP1 F3 (-) 1 cancer cell line human CVCL_SM72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3541; F3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130096 CVCL_SM75 HAP1 FADD (-) 2 cancer cell line human CVCL_SM75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3573; FADD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130097 CVCL_SM74 HAP1 FADD (-) 1 cancer cell line human CVCL_SM74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3573; FADD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130098 CVCL_SM77 HAP1 FADS1 (-) 2 cancer cell line human CVCL_SM77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3574; FADS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130099 CVCL_SM76 HAP1 FADS1 (-) 1 cancer cell line human CVCL_SM76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3574; FADS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130100 CVCL_SM79 HAP1 FAM111A (-) 2 cancer cell line human CVCL_SM79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24725; FAM111A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130101 CVCL_SM78 HAP1 FAM111A (-) 1 cancer cell line human CVCL_SM78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24725; FAM111A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130102 CVCL_SM59 HAP1 EXO5 (-) 1 cancer cell line human CVCL_SM59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26115; EXO5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130103 CVCL_SM58 HAP1 EXO1 (-) 1 cancer cell line human CVCL_SM58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3511; EXO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130104 CVCL_0G30 GM16435 hybrid cell line human CVCL_0G30 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130105 CVCL_0G32 GM50051 hybrid cell line human CVCL_0G32 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130106 CVCL_0G31 GM50050 hybrid cell line human CVCL_0G31 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130107 CVCL_0G34 GM50053 hybrid cell line human CVCL_0G34 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130108 CVCL_0G33 GM50052 hybrid cell line human CVCL_0G33 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130109 CVCL_0G36 GM50057 hybrid cell line human CVCL_0G36 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130110 CVCL_0G35 GM50056 hybrid cell line human CVCL_0G35 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130111 CVCL_0G38 GM50059 hybrid cell line human CVCL_0G38 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130112 CVCL_0G37 GM50058 hybrid cell line human CVCL_0G37 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130113 CVCL_0G29 GM15511 hybrid cell line human CVCL_0G29 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130114 CVCL_0G28 GM14113 hybrid cell line human CVCL_0G28 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130115 CVCL_SM60 HAP1 EXT1 (-) 1 cancer cell line human CVCL_SM60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3512; EXT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130116 CVCL_SM62 HAP1 EXT2 (-) 1 cancer cell line human CVCL_SM62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3513; EXT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130117 CVCL_SM61 HAP1 EXT1 (-) 2 cancer cell line human CVCL_SM61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3512; EXT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130118 CVCL_SM64 HAP1 EZH1 (-) 1 cancer cell line human CVCL_SM64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3526; EZH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130119 CVCL_SM63 HAP1 EXT2 (-) 2 cancer cell line human CVCL_SM63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3513; EXT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130120 CVCL_SM66 HAP1 EZH2 (-) 1 cancer cell line human CVCL_SM66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130121 CVCL_SM65 HAP1 EZH1 (-) 2 cancer cell line human CVCL_SM65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3526; EZH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130122 CVCL_SM68 HAP1 EZH2 (-) 3 cancer cell line human CVCL_SM68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130123 CVCL_SM67 HAP1 EZH2 (-) 2 cancer cell line human CVCL_SM67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3527; EZH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130124 CVCL_SM48 HAP1 ESYT2 (-) 1 cancer cell line human CVCL_SM48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22211; ESYT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130125 CVCL_SM47 HAP1 ESYT1 (-) 2 cancer cell line human CVCL_SM47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29534; ESYT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130126 CVCL_SM49 HAP1 ESYT2 (-) 2 cancer cell line human CVCL_SM49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22211; ESYT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130127 CVCL_0G01 IPAT-1 cancer cell line human CVCL_0G01 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21130128 CVCL_0G00 AG11247 finite cell line human CVCL_0G00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG11247) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21130129 CVCL_0G03 OMT-1 cancer cell line human CVCL_0G03 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent But can survive without IL2 for several weeks (PubMed=9596675). 21130130 CVCL_0G02 KPNT-1 cancer cell line human CVCL_0G02 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21130131 CVCL_0G05 ST-1 [Human leukemia] cancer cell line human CVCL_0G05 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 21130132 CVCL_0G04 SD-4 cancer cell line human CVCL_0G04 CL:0000010 Population: Japanese Characteristics: IL2 dependent Caution: It is uncertain if this is not a misspelling of the SO-4 (Cellosaurus=CVCL_VN48) cell line The only mention we can find of SD-4 is in PubMed=10570904.. 21130133 CVCL_SM51 HAP1 ETFB (-) 2 cancer cell line human CVCL_SM51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3482; ETFB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130134 CVCL_SM50 HAP1 ETFB (-) 1 cancer cell line human CVCL_SM50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3482; ETFB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130135 CVCL_SM53 HAP1 ETV6 (-) 2 cancer cell line human CVCL_SM53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130136 CVCL_SM52 HAP1 ETV6 (-) 1 cancer cell line human CVCL_SM52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130137 CVCL_SM55 HAP1 ETV6 (-) 4 cancer cell line human CVCL_SM55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130138 CVCL_SM54 HAP1 ETV6 (-) 3 cancer cell line human CVCL_SM54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3495; ETV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130139 CVCL_SM57 HAP1 EXD2 (-) 2 cancer cell line human CVCL_SM57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20217; EXD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130140 CVCL_SM56 HAP1 EXD2 (-) 1 cancer cell line human CVCL_SM56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20217; EXD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130141 CVCL_SM37 HAP1 ERCC6L (-) 2 cancer cell line human CVCL_SM37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20794; ERCC6L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130142 CVCL_SM36 HAP1 ERCC6L (-) 1 cancer cell line human CVCL_SM36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20794; ERCC6L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130143 CVCL_SM39 HAP1 ERCC6L (-) 4 cancer cell line human CVCL_SM39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20794; ERCC6L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130144 CVCL_SM38 HAP1 ERCC6L (-) 3 cancer cell line human CVCL_SM38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20794; ERCC6L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130145 CVCL_0G10 MSG1 cancer cell line human CVCL_0G10 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: IL6 dependent Also requires adhesion via fibronectin. Dependent on cell line HS-23 (Cellosaurus=CVCL_0E35) for its survival. 21130146 CVCL_0G12 NCU-L-3 cancer cell line human CVCL_0G12 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Virology: EBV-negative Doubling time: 30-46 hours (CelloPub=CLPUB00229) 21130147 CVCL_0G11 NCU-L-1 cancer cell line human CVCL_0G11 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Virology: EBV-negative Doubling time: 20-28 hours (PubMed=27457200) 21130148 CVCL_0G14 Handman cancer cell line human CVCL_0G14 From: Inghirami G.; Weill Cornell Medical College; New York; USA. CL:0000010 21130149 CVCL_0G13 NCU-L-4 cancer cell line human CVCL_0G13 CL:0000010 Population: Japanese. 21130150 CVCL_0G16 AST-1 cancer cell line human CVCL_0G16 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 36 hours (PubMed=1319986) 21130151 CVCL_0G15 Monca cancer cell line human CVCL_0G15 CL:0000010 21130152 CVCL_0G07 raTAL spontaneously immortalized cell line Norway rat CVCL_0G07 CL:0000010 Derived from sampling site: Kidney; nephron; thick ascending limb of loop of Henle; Breed/subspecies: Sprague Dawley. Male 21130153 CVCL_0G06 St-T1b telomerase immortalized cell line human CVCL_0G06 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Discontinued: ECACC; 09102901; probable Female 21130154 CVCL_0G09 ODA cancer cell line human CVCL_0G09 CL:0000010 Population: Japanese Female Characteristics: Produces IgD lambda. 21130155 CVCL_0G08 WHN2 cancer cell line human CVCL_0G08 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent Doubling time: ~3 days (PubMed=8390425) 21130156 CVCL_SM40 HAP1 ERCC6L2 (-) 1 cancer cell line human CVCL_SM40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26922; ERCC6L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130157 CVCL_SM42 HAP1 ERCC8 (-) 2 cancer cell line human CVCL_SM42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3439; ERCC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130158 CVCL_SM41 HAP1 ERCC8 (-) 1 cancer cell line human CVCL_SM41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3439; ERCC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130159 CVCL_SM44 HAP1 ESRRA (-) 1 cancer cell line human CVCL_SM44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3471; ESRRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130160 CVCL_SM43 HAP1 ERN1 (-) 1 cancer cell line human CVCL_SM43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3449; ERN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130161 CVCL_SM46 HAP1 ESYT1 (-) 1 cancer cell line human CVCL_SM46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29534; ESYT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130162 CVCL_SM45 HAP1 ESRRG (-) cancer cell line human CVCL_SM45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3474; ESRRG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130163 CVCL_SM26 HAP1 EPOR (-) 2 cancer cell line human CVCL_SM26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3416; EPOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130164 CVCL_SM25 HAP1 EPOR (-) 1 cancer cell line human CVCL_SM25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3416; EPOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130165 CVCL_SM28 HAP1 ERBB2 (-) 1 cancer cell line human CVCL_SM28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130166 CVCL_SM27 HAP1 EPS15 (-) 1 cancer cell line human CVCL_SM27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3419; EPS15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130167 CVCL_SM29 HAP1 ERBB2 (-) 2 cancer cell line human CVCL_SM29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130168 CVCL_K489 C0730 transformed cell line human CVCL_K489 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130169 CVCL_JS89 STAN341i-994C1 induced pluripotent stem cell human CVCL_JS89 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130170 CVCL_K488 C0729 transformed cell line human CVCL_K488 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93081923; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130171 CVCL_JS88 STAN340i-981C1 induced pluripotent stem cell human CVCL_JS88 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130172 CVCL_K485 C0726 transformed cell line human CVCL_K485 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93081920; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130173 CVCL_JS85 STAN337i-963C3 induced pluripotent stem cell human CVCL_JS85 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130174 CVCL_K484 C0725 transformed cell line human CVCL_K484 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130175 CVCL_JS84 STAN336i-963C1 induced pluripotent stem cell human CVCL_JS84 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130176 CVCL_K487 C0728 transformed cell line human CVCL_K487 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130177 CVCL_JS87 STAN339i-975C3 induced pluripotent stem cell human CVCL_JS87 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130178 CVCL_K486 C0727 transformed cell line human CVCL_K486 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93081921; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130179 CVCL_JS86 STAN338i-975C1 induced pluripotent stem cell human CVCL_JS86 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Latino; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130180 CVCL_K481 C0722 transformed cell line human CVCL_K481 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130181 CVCL_JS81 STAN332i-952C5 induced pluripotent stem cell human CVCL_JS81 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130182 CVCL_K480 C0215 transformed cell line human CVCL_K480 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130183 CVCL_JS80 STAN331i-952C3 induced pluripotent stem cell human CVCL_JS80 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130184 CVCL_K483 C0724 transformed cell line human CVCL_K483 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130185 CVCL_SM31 HAP1 ERBB3 (-) cancer cell line human CVCL_SM31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3431; ERBB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130186 CVCL_JS83 STAN334i-955C2 induced pluripotent stem cell human CVCL_JS83 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130187 CVCL_K482 C0723 transformed cell line human CVCL_K482 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130188 CVCL_SM30 HAP1 ERBB2 (-) 3 cancer cell line human CVCL_SM30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3430; ERBB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130189 CVCL_JS82 STAN333i-955C1 induced pluripotent stem cell human CVCL_JS82 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130190 CVCL_SM33 HAP1 ERCC6 (-) 1 cancer cell line human CVCL_SM33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3438; ERCC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130191 CVCL_SM32 HAP1 ERCC1 (-) cancer cell line human CVCL_SM32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3433; ERCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130192 CVCL_SM35 HAP1 ERCC6 (-) 3 cancer cell line human CVCL_SM35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3438; ERCC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130193 CVCL_SM34 HAP1 ERCC6 (-) 2 cancer cell line human CVCL_SM34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3438; ERCC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130194 CVCL_SM15 HAP1 EPHA4 (-) cancer cell line human CVCL_SM15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3388; EPHA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130195 CVCL_SM14 HAP1 EPHA3 (-) 2 cancer cell line human CVCL_SM14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3387; EPHA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130196 CVCL_SM17 HAP1 EPHA6 (-) 2 cancer cell line human CVCL_SM17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19296; EPHA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130197 CVCL_SM16 HAP1 EPHA6 (-) 1 cancer cell line human CVCL_SM16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19296; EPHA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130198 CVCL_SM19 HAP1 EPHB2 (-) 1 cancer cell line human CVCL_SM19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130199 CVCL_SM18 HAP1 EPHB1 (-) cancer cell line human CVCL_SM18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3392; EPHB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130200 CVCL_K499 C0740 transformed cell line human CVCL_K499 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130201 CVCL_JS99 STAN357i-298C2 induced pluripotent stem cell human CVCL_JS99 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130202 CVCL_K496 C0737 transformed cell line human CVCL_K496 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060854; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130203 CVCL_JS96 STAN349i-762C3 induced pluripotent stem cell human CVCL_JS96 CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130204 CVCL_K495 C0736 transformed cell line human CVCL_K495 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93082620; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130205 CVCL_JS95 STAN348i-851C1 induced pluripotent stem cell human CVCL_JS95 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130206 CVCL_K498 C0739 transformed cell line human CVCL_K498 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130207 CVCL_JS98 STAN351i-631C1 induced pluripotent stem cell human CVCL_JS98 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130208 CVCL_K497 C0738 transformed cell line human CVCL_K497 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130209 CVCL_JS97 STAN350i-694C5 induced pluripotent stem cell human CVCL_JS97 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130210 CVCL_K492 C0733 transformed cell line human CVCL_K492 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 930826921; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130211 CVCL_JS92 STAN345i-390C3 induced pluripotent stem cell human CVCL_JS92 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130212 CVCL_K491 C0732 transformed cell line human CVCL_K491 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93082617; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130213 CVCL_JS91 STAN343i-998C1 induced pluripotent stem cell human CVCL_JS91 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130214 CVCL_K494 C0735 transformed cell line human CVCL_K494 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130215 CVCL_SM20 HAP1 EPHB2 (-) 2 cancer cell line human CVCL_SM20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130216 CVCL_JS94 STAN347i-66C3 induced pluripotent stem cell human CVCL_JS94 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130217 CVCL_K493 C0734 transformed cell line human CVCL_K493 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93082618; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130218 CVCL_JS93 STAN346i-59C2 induced pluripotent stem cell human CVCL_JS93 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130219 CVCL_SM22 HAP1 EPHB3 (-) cancer cell line human CVCL_SM22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3394; EPHB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130220 CVCL_SM21 HAP1 EPHB2 (-) 3 cancer cell line human CVCL_SM21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3393; EPHB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130221 CVCL_K490 C0731 transformed cell line human CVCL_K490 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130222 CVCL_SM24 HAP1 EPHB6 (-) cancer cell line human CVCL_SM24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3396; EPHB6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130223 CVCL_JS90 STAN342i-994C3 induced pluripotent stem cell human CVCL_JS90 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130224 CVCL_SM23 HAP1 EPHB4 (-) cancer cell line human CVCL_SM23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130225 CVCL_SM04 HAP1 ENDOG (-) 4 cancer cell line human CVCL_SM04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3346; ENDOG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130226 CVCL_SM03 HAP1 ENDOG (-) 3 cancer cell line human CVCL_SM03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3346; ENDOG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130227 CVCL_SM06 HAP1 ENTHD2 (-) 1 cancer cell line human CVCL_SM06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26458; TEPSIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130228 CVCL_SM05 HAP1 ENDOV (-) cancer cell line human CVCL_SM05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26640; ENDOV; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130229 CVCL_SM08 HAP1 ENTHD2 (-) 3 cancer cell line human CVCL_SM08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26458; TEPSIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130230 CVCL_SM07 HAP1 ENTHD2 (-) 2 cancer cell line human CVCL_SM07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26458; TEPSIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130231 CVCL_SM09 HAP1 ENTPD1 (-) 1 cancer cell line human CVCL_SM09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3363; ENTPD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130232 CVCL_K467 C0202 transformed cell line human CVCL_K467 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130233 CVCL_JS67 STAN315i-909C1 induced pluripotent stem cell human CVCL_JS67 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130234 CVCL_K466 C0201 transformed cell line human CVCL_K466 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130235 CVCL_JS66 STAN314i-907C4 induced pluripotent stem cell human CVCL_JS66 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130236 CVCL_K469 C0204 transformed cell line human CVCL_K469 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130237 CVCL_JS69 STAN317i-910C2 induced pluripotent stem cell human CVCL_JS69 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130238 CVCL_K468 C0203 transformed cell line human CVCL_K468 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130239 CVCL_JS68 STAN316i-909C2 induced pluripotent stem cell human CVCL_JS68 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130240 CVCL_K463 C0198 transformed cell line human CVCL_K463 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060841; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130241 CVCL_JS63 STAN311i-906C1 induced pluripotent stem cell human CVCL_JS63 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130242 CVCL_K462 C0197 transformed cell line human CVCL_K462 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130243 CVCL_JS62 STAN308i-871C3 induced pluripotent stem cell human CVCL_JS62 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130244 CVCL_K465 C0200 transformed cell line human CVCL_K465 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130245 CVCL_JS65 STAN313i-907C1 induced pluripotent stem cell human CVCL_JS65 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130246 CVCL_K464 C0199 transformed cell line human CVCL_K464 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130247 CVCL_JS64 STAN312i-906C3 induced pluripotent stem cell human CVCL_JS64 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130248 CVCL_K461 C0196 transformed cell line human CVCL_K461 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130249 CVCL_JS61 STAN307i-871C2 induced pluripotent stem cell human CVCL_JS61 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130250 CVCL_K460 C0195 transformed cell line human CVCL_K460 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130251 CVCL_JS60 STAN306i-865C3 induced pluripotent stem cell human CVCL_JS60 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130252 CVCL_SM11 HAP1 EP300 (-) 2 cancer cell line human CVCL_SM11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21130253 CVCL_SM10 HAP1 EP300 (-) 1 cancer cell line human CVCL_SM10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3373; EP300; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130254 CVCL_SM13 HAP1 EPHA3 (-) 1 cancer cell line human CVCL_SM13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3387; EPHA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130255 CVCL_SM12 HAP1 EPHA2 (-) cancer cell line human CVCL_SM12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3386; EPHA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130256 CVCL_K478 C0213 transformed cell line human CVCL_K478 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130257 CVCL_JS78 STAN329i-949C3 induced pluripotent stem cell human CVCL_JS78 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130258 CVCL_K477 C0212 transformed cell line human CVCL_K477 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94060850; probable Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130259 CVCL_JS77 STAN328i-946C2 induced pluripotent stem cell human CVCL_JS77 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130260 CVCL_K479 C0214 transformed cell line human CVCL_K479 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130261 CVCL_JS79 STAN330i-949C4 induced pluripotent stem cell human CVCL_JS79 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130262 CVCL_K474 C0209 transformed cell line human CVCL_K474 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130263 CVCL_JS74 STAN323i-928C2 induced pluripotent stem cell human CVCL_JS74 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130264 CVCL_K473 C0208 transformed cell line human CVCL_K473 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130265 CVCL_JS73 STAN322i-924C2 induced pluripotent stem cell human CVCL_JS73 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130266 CVCL_K476 C0211 transformed cell line human CVCL_K476 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130267 CVCL_JS76 STAN327i-940C2 induced pluripotent stem cell human CVCL_JS76 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130268 CVCL_K475 C0210 transformed cell line human CVCL_K475 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130269 CVCL_JS75 STAN324i-928C6 induced pluripotent stem cell human CVCL_JS75 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130270 CVCL_K470 C0205 transformed cell line human CVCL_K470 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130271 CVCL_JS70 STAN318i-910C3 induced pluripotent stem cell human CVCL_JS70 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130272 CVCL_K472 C0207 transformed cell line human CVCL_K472 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130273 CVCL_JS72 STAN321i-924C1 induced pluripotent stem cell human CVCL_JS72 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130274 CVCL_K471 C0206 transformed cell line human CVCL_K471 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21130275 CVCL_JS71 STAN319i-922C1 induced pluripotent stem cell human CVCL_JS71 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21130276 CVCL_SM00 HAP1 EME2 (-) 3 cancer cell line human CVCL_SM00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27289; EME2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130277 CVCL_SM02 HAP1 ENDOG (-) 2 cancer cell line human CVCL_SM02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3346; ENDOG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130278 CVCL_SM01 HAP1 ENDOG (-) 1 cancer cell line human CVCL_SM01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3346; ENDOG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130279 CVCL_9A39 DD0495 transformed cell line human CVCL_9A39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130280 CVCL_9A38 DD0494 finite cell line human CVCL_9A38 CL:0000010 Derived from sampling site: Umbilical cord. Ambiguous Part of: ECACC chromosomal abnormality collection 21130281 CVCL_9A35 DD0488 transformed cell line human CVCL_9A35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130282 CVCL_9A34 DD0486 transformed cell line human CVCL_9A34 CL:0000010 Karyotypic information: 46,XY,t(11;16)(q13;p13.3)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130283 CVCL_9A37 DD0492 transformed cell line human CVCL_9A37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130284 CVCL_9A36 DD0489 transformed cell line human CVCL_9A36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130285 CVCL_9A31 DD0483 transformed cell line human CVCL_9A31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130286 CVCL_9A30 DD0482 transformed cell line human CVCL_9A30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130287 CVCL_9A33 DD0485 transformed cell line human CVCL_9A33 CL:0000010 Karyotypic information: 46,XY,t(11;16)(q13;p13.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130288 CVCL_9A32 DD0484 transformed cell line human CVCL_9A32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130289 CVCL_9A49 DD0509 transformed cell line human CVCL_9A49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130290 CVCL_9A40 DD0496 transformed cell line human CVCL_9A40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130291 CVCL_9A46 DD0505 transformed cell line human CVCL_9A46 CL:0000010 Karyotypic information: 46,XX,t(11;17)(p13;p13.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130292 CVCL_9A45 DD0503 finite cell line human CVCL_9A45 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21130293 CVCL_9A48 DD0508 transformed cell line human CVCL_9A48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130294 CVCL_9A47 DD0507 transformed cell line human CVCL_9A47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130295 CVCL_9A42 DD0498 transformed cell line human CVCL_9A42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130296 CVCL_9A41 DD0497 transformed cell line human CVCL_9A41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130297 CVCL_9A44 DD0502 transformed cell line human CVCL_9A44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130298 CVCL_9A43 DD0501 transformed cell line human CVCL_9A43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130299 CVCL_0G81 vWTa induced pluripotent stem cell human CVCL_0G81 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21130300 CVCL_0G80 GM50126 transformed cell line human CVCL_0G80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130301 CVCL_9A17 DD0455 finite cell line human CVCL_9A17 CL:0000010 Karyotypic information: 46,X,+mar(Y) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21130302 CVCL_0G83 eWT-1323-2 induced pluripotent stem cell human CVCL_0G83 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130303 CVCL_9A16 DD0454 finite cell line human CVCL_9A16 CL:0000010 Karyotypic information: 47,XX+18 (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130304 CVCL_0G82 vWTb induced pluripotent stem cell human CVCL_0G82 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130305 CVCL_9A19 DD0458 transformed cell line human CVCL_9A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130306 CVCL_0G85 eWT-BJ2 induced pluripotent stem cell human CVCL_0G85 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21130307 CVCL_9A18 DD0456 transformed cell line human CVCL_9A18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130308 CVCL_0G84 eWT-1323-4 induced pluripotent stem cell human CVCL_0G84 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130309 CVCL_0G87 HPS0191 induced pluripotent stem cell human CVCL_0G87 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130310 CVCL_0G86 eWT-BJ4 induced pluripotent stem cell human CVCL_0G86 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21130311 CVCL_0G89 WBS-B induced pluripotent stem cell human CVCL_0G89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130312 CVCL_0G88 WBS-A induced pluripotent stem cell human CVCL_0G88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130313 CVCL_9A13 DD0447 transformed cell line human CVCL_9A13 CL:0000010 Karyotypic information: 46,XX,?inv ins(7)(q33;q22.1q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130314 CVCL_9A12 DD0446 transformed cell line human CVCL_9A12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130315 CVCL_9A15 DD0450 finite cell line human CVCL_9A15 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21130316 CVCL_9A14 DD0448 transformed cell line human CVCL_9A14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130317 CVCL_9A11 DD0445 transformed cell line human CVCL_9A11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130318 CVCL_9A10 DD0444 transformed cell line human CVCL_9A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130319 CVCL_0G90 WBS-C induced pluripotent stem cell human CVCL_0G90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130320 CVCL_0G92 BJC induced pluripotent stem cell human CVCL_0G92 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21130321 CVCL_0G91 WBS-I induced pluripotent stem cell human CVCL_0G91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130322 CVCL_9A28 DD0480 finite cell line human CVCL_9A28 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130323 CVCL_0G94 GM01786 finite cell line human CVCL_0G94 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Heterozygous (from familial inference of GM01774 and GM01775) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130324 CVCL_0G93 BJD induced pluripotent stem cell human CVCL_0G93 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21130325 CVCL_9A27 DD0479 transformed cell line human CVCL_9A27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130326 CVCL_0G96 PDA3F-1 induced pluripotent stem cell human CVCL_0G96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130327 CVCL_9A29 DD0481 transformed cell line human CVCL_9A29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130328 CVCL_0G95 GM01787 finite cell line human CVCL_0G95 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Heterozygous (from familial inference of GM01774 and GM01775) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130329 CVCL_0G98 PDB3F-1 induced pluripotent stem cell human CVCL_0G98 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130330 CVCL_0G97 PDA3F-5 induced pluripotent stem cell human CVCL_0G97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130331 CVCL_0G99 PDB3F-5 induced pluripotent stem cell human CVCL_0G99 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130332 CVCL_9A24 DD0467 transformed cell line human CVCL_9A24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130333 CVCL_9A23 DD0466 transformed cell line human CVCL_9A23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130334 CVCL_9A26 DD0478 finite cell line human CVCL_9A26 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21130335 CVCL_9A25 DD0468 finite cell line human CVCL_9A25 CL:0000010 Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21130336 CVCL_9A20 DD0459 transformed cell line human CVCL_9A20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130337 CVCL_9A22 DD0463 transformed cell line human CVCL_9A22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130338 CVCL_9A21 DD0462 transformed cell line human CVCL_9A21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130339 CVCL_0G61 GM50167 transformed cell line human CVCL_0G61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130340 CVCL_0G60 GM50093 hybrid cell line human CVCL_0G60 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130341 CVCL_0G63 GM50173 transformed cell line human CVCL_0G63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130342 CVCL_0G62 GM50095 hybrid cell line human CVCL_0G62 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130343 CVCL_0G65 GM50097 hybrid cell line human CVCL_0G65 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130344 CVCL_0G64 GM50096 hybrid cell line human CVCL_0G64 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130345 CVCL_0G67 GM50178 transformed cell line human CVCL_0G67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130346 CVCL_0G66 GM50098 hybrid cell line human CVCL_0G66 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130347 CVCL_0G69 GM50101 hybrid cell line human CVCL_0G69 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130348 CVCL_0G68 GM50100 hybrid cell line human CVCL_0G68 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130349 CVCL_9A09 DD0443 transformed cell line human CVCL_9A09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130350 CVCL_0G70 GM50103 hybrid cell line human CVCL_0G70 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130351 CVCL_9A06 DD0436 transformed cell line human CVCL_9A06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130352 CVCL_0G72 GM50194 transformed cell line human CVCL_0G72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21130353 CVCL_9A05 DD0435 transformed cell line human CVCL_9A05 CL:0000010 Karyotypic information: 46,XX,inv(3p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130354 CVCL_0G71 GM50106 hybrid cell line human CVCL_0G71 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130355 CVCL_9A08 DD0442 transformed cell line human CVCL_9A08 CL:0000010 Karyotypic information: 46,XY,fra(X)(q28) 15% fra(X) +ve (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130356 CVCL_0G74 GM16584 transformed cell line human CVCL_0G74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130357 CVCL_9A07 DD0440 finite cell line human CVCL_9A07 CL:0000010 Karyotypic information: 46,XX-6,der(6)t(4;6)(q27;p25)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130358 CVCL_0G73 GM16582 transformed cell line human CVCL_0G73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21130359 CVCL_0G76 GM16587 hybrid cell line human CVCL_0G76 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130360 CVCL_0G75 GM16586 transformed cell line human CVCL_0G75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21130361 CVCL_0G78 GM50121 transformed cell line human CVCL_0G78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21130362 CVCL_0G77 GM50079 hybrid cell line human CVCL_0G77 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130363 CVCL_0G79 GM50081 hybrid cell line human CVCL_0G79 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130364 CVCL_9A02 DD0432 transformed cell line human CVCL_9A02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130365 CVCL_9A01 DD0431 transformed cell line human CVCL_9A01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130366 CVCL_9A04 DD0434 transformed cell line human CVCL_9A04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130367 CVCL_9A03 DD0433 transformed cell line human CVCL_9A03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130368 CVCL_9A00 DD0430 transformed cell line human CVCL_9A00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130369 CVCL_0G41 GM50063 hybrid cell line human CVCL_0G41 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130370 CVCL_0G40 GM50061 hybrid cell line human CVCL_0G40 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130371 CVCL_0G43 GM50068 hybrid cell line human CVCL_0G43 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130372 CVCL_0G42 GM50065 hybrid cell line human CVCL_0G42 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130373 CVCL_0G45 GM50069 hybrid cell line human CVCL_0G45 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130374 CVCL_0G44 GM50127 transformed cell line human CVCL_0G44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM50127; probable Female 21130375 CVCL_0G47 GM50071 hybrid cell line human CVCL_0G47 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130376 CVCL_0G46 GM50070 hybrid cell line human CVCL_0G46 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130377 CVCL_0G49 GM50072 hybrid cell line human CVCL_0G49 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130378 CVCL_0G48 GM50112 transformed cell line human CVCL_0G48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130379 CVCL_0G39 GM50060 hybrid cell line human CVCL_0G39 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130380 CVCL_SM91 HAP1 FAM195A (-) 1 cancer cell line human CVCL_SM91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14142; MCRIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130381 CVCL_SM90 HAP1 FAM175A (-) 2 cancer cell line human CVCL_SM90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25829; ABRAXAS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130382 CVCL_SM93 HAP1 FAM195A (-) 3 cancer cell line human CVCL_SM93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14142; MCRIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130383 CVCL_SM92 HAP1 FAM195A (-) 2 cancer cell line human CVCL_SM92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14142; MCRIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130384 CVCL_SM95 HAP1 FAM195B (-) 2 cancer cell line human CVCL_SM95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28007; MCRIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130385 CVCL_SM94 HAP1 FAM195B (-) 1 cancer cell line human CVCL_SM94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28007; MCRIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130386 CVCL_SM97 HAP1 FAM91A1 (-) 2 cancer cell line human CVCL_SM97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26306; FAM91A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130387 CVCL_SM96 HAP1 FAM91A1 (-) 1 cancer cell line human CVCL_SM96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26306; FAM91A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130388 CVCL_SM99 HAP1 FANCA (-) 2 cancer cell line human CVCL_SM99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130389 CVCL_SM98 HAP1 FANCA (-) 1 cancer cell line human CVCL_SM98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3582; FANCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130390 CVCL_0G50 GM50073 hybrid cell line human CVCL_0G50 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130391 CVCL_0G52 GM50077 hybrid cell line human CVCL_0G52 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130392 CVCL_0G51 GM50076 hybrid cell line human CVCL_0G51 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130393 CVCL_0G54 GM50085 hybrid cell line human CVCL_0G54 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130394 CVCL_0G53 GM50084 hybrid cell line human CVCL_0G53 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130395 CVCL_0G56 GM50088 hybrid cell line human CVCL_0G56 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130396 CVCL_0G55 GM50139 transformed cell line human CVCL_0G55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130397 CVCL_0G58 GM50092 hybrid cell line human CVCL_0G58 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130398 CVCL_0G57 GM50089 hybrid cell line human CVCL_0G57 CL:0000010 Group: Human/rodent somatic cell hybrid. 21130399 CVCL_0G59 GM50154 transformed cell line human CVCL_0G59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130400 CVCL_SM80 HAP1 FAM111A (-) 3 cancer cell line human CVCL_SM80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24725; FAM111A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130401 CVCL_SM82 HAP1 FAM122A (-) 1 cancer cell line human CVCL_SM82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23490; PABIR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130402 CVCL_SM81 HAP1 FAM111A (-) 4 cancer cell line human CVCL_SM81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24725; FAM111A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130403 CVCL_SM84 HAP1 FAM136A (-) 1 cancer cell line human CVCL_SM84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25911; FAM136A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130404 CVCL_SM83 HAP1 FAM134B (-) 1 cancer cell line human CVCL_SM83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25964; RETREG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130405 CVCL_SM86 HAP1 FAM173B (-) 1 cancer cell line human CVCL_SM86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27029; ATPSCKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130406 CVCL_SM85 HAP1 FAM173A (-) cancer cell line human CVCL_SM85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14152; ANTKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130407 CVCL_SM88 HAP1 FAM173B (-) 3 cancer cell line human CVCL_SM88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27029; ATPSCKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130408 CVCL_SM87 HAP1 FAM173B (-) 2 cancer cell line human CVCL_SM87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27029; ATPSCKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130409 CVCL_SM89 HAP1 FAM175A (-) 1 cancer cell line human CVCL_SM89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25829; ABRAXAS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130410 CVCL_0Q61 GM07893 finite cell line human CVCL_0Q61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(6)(6qter->6p25::4q31.3->4qter)mat (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130411 CVCL_1261 HCC2157 cancer cell line human CVCL_1261 HLA typing: A*02:02,30:01; B*41:02,42:01; C*17:01,17:01 (PubMed=26589293); Genome ancestry: African=87.84%; Native American=0%; East Asian, North=4.38%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP) Population: African American; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel 21130412 CVCL_0Q60 GM07082 finite cell line human CVCL_0Q60 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21130413 CVCL_1260 HCC1954 BL transformed cell line human CVCL_1260 CL:0000010 Population: East Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130414 CVCL_0Q52 GM02775 finite cell line human CVCL_0Q52 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Hemizygous (PubMed=29982630) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21130415 CVCL_1252 HCC1428 cancer cell line human CVCL_1252 HLA typing: A*01:01,02:01; B*07:02,07:02; C*07:02,07:02; DQB1*06:02,05:01 (PubMed=25960936); HLA typing: A*01:01,02:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=3.84%; Native American=0%; East Asian, North=5.45%; East Asian, South=0%; South Asian=0%; European, North=49.75%; European, South=40.96% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 73; ABCG1 + HGNC; 11024; SLC37A1; Name(s)=SLC37A1-ABCG1 (PubMed=25485619); Sequence variation: Mutation; HGNC; 3701; FHIT; Unexplicit; Ex4del; Zygosity=Homozygous (PubMed=9288768) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: SNP array analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 88.48 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130416 CVCL_0Q51 GM02769 finite cell line human CVCL_0Q51 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21130417 CVCL_1251 HCC1419 cancer cell line human CVCL_1251 HLA typing: A*02:01,24:02; B*46:01,52:01; C*01:02,03:03; DQB1*03:04,03:04; DRB1*03:35,03:35 (PubMed=25960936); HLA typing: A*02:01,24:02; B*15:01,52:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=5.31%; Native American=36.71%; East Asian, North=7.6%; East Asian, South=0%; South Asian=0%; European, North=17.9%; European, South=32.48% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala74fs*47 (c.220_226delGCCCCTG); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (Cosmic-CLP) Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 161.42 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130418 CVCL_0Q54 GM05794 finite cell line human CVCL_0Q54 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21130419 CVCL_1254 HCC1500 cancer cell line human CVCL_1254 HLA typing: A*02:02,02:02; B*15:80,37:19; C*03:04,04:01 (PubMed=25960936); HLA typing: A*02:02,02:02; B*15:10,15:10; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=75.35%; Native American=1.42%; East Asian, North=6.28%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=16.94% (PubMed=30894373) CL:0000010 Population: African American; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46.85 hours (GrayJW panel); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21130420 CVCL_0Q53 GM05793 transformed cell line human CVCL_0Q53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130421 CVCL_1253 HCC1428 BL transformed cell line human CVCL_1253 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130422 CVCL_0Q56 GM05795 transformed cell line human CVCL_0Q56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130423 CVCL_1256 HCC1599 cancer cell line human CVCL_1256 HLA typing: A*01:01,02:01; B*08:01,13:02; C*06:02,07:01; DQA1*03:02,03:02; DQB1*02:02,03:03; DRB1*04:01,13:60 (PubMed=25960936); HLA typing: A*01:01,02:01; B*08:01,13:02; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=4.77%; Native American=0.18%; East Asian, North=6.87%; East Asian, South=0%; South Asian=0%; European, North=46.32%; European, South=41.85% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~4-5 days (DSMZ=ACC-503); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130424 CVCL_0Q55 GM05368 finite cell line human CVCL_0Q55 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130425 CVCL_1255 HCC1569 cancer cell line human CVCL_1255 HLA typing: A*30:04,68:02; B*53:01,58:01; C*04:01,15:05 (PubMed=25960936); HLA typing: A*30:04,68:02; B*53:01,58:01; C*04:01,15:05 (PubMed=26589293); Genome ancestry: African=80.08%; Native American=0%; East Asian, North=2.86%; East Asian, South=0%; South Asian=0%; European, North=4.32%; European, South=12.74% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1100Thr (c.3299A>C); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1862fs*1 (c.5578delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3701; FHIT; Simple; p.Val97Phe (c.289G>T) (651G>T); dbSNP=rs139666727; Zygosity=Heterozygous; Note=Genomic (PubMed=9288768); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Heterozygous (PubMed=9865903; Cosmic-CLP; DepMap) Population: African American; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45.43 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130426 CVCL_0Q58 GM01751 finite cell line human CVCL_0Q58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;14)(9qter->9p24::14q21->14qter;14pter->14q21::9p24->9pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21130427 CVCL_1258 HCC1806 cancer cell line human CVCL_1258 HLA typing: A*23:01,68:01; B*15:03,51:01; C*02:02,02:02; DQB1*06:02,06:02 (PubMed=25960936); HLA typing: A*23:01,68:01; B*15:03,51:01; C*02:02,02:02 (PubMed=26589293); Genome ancestry: African=80.71%; Native American=0%; East Asian, North=3.77%; East Asian, South=0%; South Asian=0%; European, North=6.8%; European, South=8.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3701; FHIT; Unexplicit; Ex4del; Zygosity=Homozygous (PubMed=9288768); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr256Lysfs*90 (c.766_767insAA); Zygosity=Heterozygous (PubMed=9865903; Cosmic-CLP; DepMap) Population: African American; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H2A.Z ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: Pol2 ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36.66 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130428 CVCL_0Q57 GM05796 finite cell line human CVCL_0Q57 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130429 CVCL_1257 HCC1599 BL transformed cell line human CVCL_1257 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: ~48-72 hours (DSMZ=ACC-894) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130430 CVCL_0Q59 GM07081 finite cell line human CVCL_0Q59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21130431 CVCL_1259 HCC1954 cancer cell line human CVCL_1259 HLA typing: A*24:02,24:02; B*35:01,40:06; C*04:01,15:02; DQA1*03:02,01:02; DRB1*16:05,16:05 (PubMed=25960936); HLA typing: A*24:02,24:02; B*35:01,40:06; C*04:01,15:02 (PubMed=26589293); Genome ancestry: African=0.47%; Native American=0%; East Asian, North=5.83%; East Asian, South=0%; South Asian=78.3%; European, North=2.65%; European, South=12.74% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (PubMed=23637631); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (PubMed=28889351; ATCC) Population: East Indian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: Hi-C sequencing; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45 hours (PubMed=25984343); 43.81 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130432 CVCL_9K00 DD2415 transformed cell line human CVCL_9K00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130433 CVCL_T893 GM22393 transformed cell line human CVCL_T893 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130434 CVCL_SW93 HAP1 MAPK4 (-) 2 cancer cell line human CVCL_SW93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6878; MAPK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130435 CVCL_SW92 HAP1 MAPK4 (-) 1 cancer cell line human CVCL_SW92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6878; MAPK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130436 CVCL_T892 RECC-RP13 cancer cell line CVCL_T892 CL:0000010 Transformant: Chick syncytial virus(NCBI-Taxonomy; 353768). Female Group: Bird cell line 21130437 CVCL_9K02 DD2422 transformed cell line human CVCL_9K02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130438 CVCL_T895 GM22395 transformed cell line human CVCL_T895 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130439 CVCL_SW95 HAP1 MAPK6 (-) 1 cancer cell line human CVCL_SW95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6879; MAPK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130440 CVCL_9K01 DD2419 transformed cell line human CVCL_9K01 CL:0000010 Karyotypic information: 46,XX,t(8;11)(q24.11;q23.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130441 CVCL_T894 GM22394 finite cell line human CVCL_T894 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130442 CVCL_SW94 HAP1 MAPK4 (-) 3 cancer cell line human CVCL_SW94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6878; MAPK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130443 CVCL_SW97 HAP1 MAPK7 (-) 1 cancer cell line human CVCL_SW97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130444 CVCL_T897 VCP-#1 induced pluripotent stem cell human CVCL_T897 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130445 CVCL_T896 GM22396 finite cell line human CVCL_T896 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21130446 CVCL_SW96 HAP1 MAPK6 (-) 2 cancer cell line human CVCL_SW96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6879; MAPK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130447 CVCL_SW99 HAP1 MAPK8 (-) 1 cancer cell line human CVCL_SW99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6881; MAPK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130448 CVCL_T899 VCP-#4 induced pluripotent stem cell human CVCL_T899 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130449 CVCL_SW98 HAP1 MAPK7 (-) 2 cancer cell line human CVCL_SW98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130450 CVCL_T898 VCP-#2 induced pluripotent stem cell human CVCL_T898 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130451 CVCL_9K08 DD2452 finite cell line human CVCL_9K08 CL:0000010 Karyotypic information: 46,XY,del(9)(?p24) de novo (ECACC); Derived from sampling site: Testis Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21130452 CVCL_9K07 DD2451 finite cell line human CVCL_9K07 CL:0000010 Karyotypic information: 46,XY,-6,+der(6),t(6;16)(q2;q2)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21130453 CVCL_9K09 DD2456 finite cell line human CVCL_9K09 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130454 CVCL_9K04 DD2431 finite cell line human CVCL_9K04 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130455 CVCL_1270 HCC70 cancer cell line human CVCL_1270 HLA typing: A*03:01,30:02; B*15:16,78:01; C*16:01,16:01; DQB1*05:01,05:01; DRB1*01:02,07:01 (PubMed=25960936); HLA typing: A*03:01,30:02; B*15:16,78:01; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=70.85%; Native American=0%; East Asian, North=5.47%; East Asian, South=0%; South Asian=0%; European, North=3.61%; European, South=20.07% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=9865903; PubMed=28889351; ATCC) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Population: African American; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 93 hours (PubMed=25984343); 67.80 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130456 CVCL_0Q70 RGF [Rat liver] transformed cell line Norway rat CVCL_0Q70 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic portal fibroblast.; Breed/subspecies: Sprague Dawley. Male 21130457 CVCL_9K03 DD2428 transformed cell line human CVCL_9K03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130458 CVCL_0Q72 11Z transformed cell line human CVCL_0Q72 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female Doubling time: 39 hours (PubMed=11696444) 21130459 CVCL_9K06 DD2450 finite cell line human CVCL_9K06 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),t(7;19)(q36.1;q13.43)pat (ECACC); Derived from sampling site: Amnion Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130460 CVCL_1272 HCE-T transformed cell line human CVCL_1272 CL:0000010 Population: Japanese; Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Eye; cornea; epithelium. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0349; probable; Discontinued: RCB; RCB1384; probable Female Doubling time: 24.4 hours (PubMed=7534282) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130461 CVCL_9K05 DD2442 transformed cell line human CVCL_9K05 CL:0000010 Karyotypic information: 46,XX,ins(7)(q42.1;q34.1;q35) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130462 CVCL_1271 HCE-4 cancer cell line human CVCL_1271 Genome ancestry: African=93.38%; Native American=0%; East Asian, North=0.25%; East Asian, South=0%; South Asian=0%; European, North=1.6%; European, South=4.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Homozygous (PubMed=2263646; Cosmic-CLP; DepMap) Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 48 hours (PubMed=2415247); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130463 CVCL_0Q71 RGF-N2 transformed cell line Norway rat CVCL_0Q71 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic portal fibroblast.; Breed/subspecies: Sprague Dawley. Male 21130464 CVCL_0Q63 GM09994 finite cell line human CVCL_0Q63 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21130465 CVCL_1263 HCC2218 cancer cell line human CVCL_1263 HLA typing: A*24; B*35:08,15:17; C*07:01,06:02; DQB1*06:04,05:03 (PubMed=25960936); HLA typing: A*24:02,24:02; B*35:08,58:01; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=1.2%; Native American=0%; East Asian, North=1.97%; East Asian, South=0%; South Asian=2%; European, North=55.07%; European, South=39.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7029; MET; Simple; c.3083-1G>T; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Cys (c.847C>T); ClinVar=VCV000127824; Zygosity=Unspecified (PubMed=9865903) Population: Caucasian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 120 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130466 CVCL_0Q62 GM07901 finite cell line human CVCL_0Q62 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CNV analysis Male 21130467 CVCL_1262 HCC2157 BL transformed cell line human CVCL_1262 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130468 CVCL_0Q65 GM10794 finite cell line human CVCL_0Q65 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,t(4;9)(4pter->4q31.3::9q13->9qter;9pter->9q13::4q31.3->4qter)mat, +der(9)(9pter->9q13::4q31.3->4qter)mat (Coriell); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21130469 CVCL_1265 HCC2935 cancer cell line human CVCL_1265 HLA typing: A*02:01,26:01; B*37:01,49:01; C*06:02,07:01 (PubMed=26589293); HLA typing: A*02:01,26:01; B*37:01:01,49:01; C*06:02,07:01 (PubMed=26929325); Genome ancestry: African=3.09%; Native American=0.03%; East Asian, North=3.93%; East Asian, South=0%; South Asian=0.78%; European, North=54.96%; European, South=37.21% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 70.4 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21130470 CVCL_0Q64 GM10793 finite cell line human CVCL_0Q64 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,t(4;9)(4pter->4q31.3::9q13->9qter;9pter->9q13::4q31.3->4qter)mat, +der(9)(9pter->9q13::4q31.3->4qter)mat (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130471 CVCL_1264 HCC2218 BL transformed cell line human CVCL_1264 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130472 CVCL_0Q67 GM14514 finite cell line human CVCL_0Q67 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,rec(3)(qter->p25::q21->qter) (Coriell); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21130473 CVCL_1267 HCC38 cancer cell line human CVCL_1267 HLA typing: A*03:01,03:01; B*35:03,35:03; C*12:03,12:03; DRB1*09:07,09:07 (PubMed=25960936); HLA typing: A*03:01,03:01; B*35:03,35:03; C*12:03,12:03; DQA1*01:02,03:02; DQB1*06:02,06:02; DRB1*13:07,15:01 (PubMed=26589293); Genome ancestry: African=1.51%; Native American=0%; East Asian, North=2.67%; East Asian, South=0%; South Asian=0.58%; European, North=60.89%; European, South=34.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=9865903; ATCC) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 50.98 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21130474 CVCL_0Q66 GM14513 finite cell line human CVCL_0Q66 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21130475 CVCL_1266 HCC2998 cancer cell line human CVCL_1266 HLA typing: A*02,24; B*37:01,40:06:01; C*04,06:02; DPB1*04:01; DQB1*03:01:01,05:02:01; DRB1*11,16 (PubMed=15748285); Genome ancestry: African=1.41%; Native American=0%; East Asian, North=0%; East Asian, South=1.46%; South Asian=8.24%; European, North=35.72%; European, South=53.15% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg168Ile (c.503G>T); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu665Ter (c.1994T>A); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1864Tyr (c.5591C>A); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile2167Ser (c.6500T>G); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn2720Lys (c.8160T>G); Zygosity=Heterozygous (PubMed=17088437; PubMed=24755471; PubMed=28179481; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1989Ter (c.5965C>T); ClinVar=VCV000225842; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu277Ter (c.829G>T); ClinVar=VCV000234216; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000127327; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (PubMed=16969076; PubMed=20570890; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Heterozygous (PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe341Val (c.1021T>G); ClinVar=VCV000495806; Zygosity=Heterozygous (PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu137Ter (c.409G>T); ClinVar=VCV000126810; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ser276Leu (c.827C>T); Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Arg321Gln (c.962G>A); Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Ser266Leu (c.797C>T); ClinVar=VCV001417802; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (PubMed=15900046; PubMed=17088437; PubMed=18277095; PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 31.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21130476 CVCL_1269 HCC4006 cancer cell line human CVCL_1269 HLA typing: A*33:03,33:03; B*44:03,44:03; C*07:01,07:01; DQB1*02:02,02:02; DRB1*07:01,14:05 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=0%; East Asian, North=5.13%; East Asian, South=0%; South Asian=0%; European, North=54.8%; European, South=38.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Glu749del (c.2239_2247delTAAGAGAA); ClinVar=VCV000177765; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205His (c.613T>C); ClinVar=VCV000376685; Zygosity=Homozygous (DepMap) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46.8 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: TCGA-110-CL cell line panel 21130477 CVCL_0Q69 Panc1-bC2GnT-M cancer cell line human CVCL_0Q69 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7508; MUC1; Transfected with: VGNC; 56968; Bovine GCNT1 Population: Caucasian; Derived from sampling site: Pancreas. Male 21130478 CVCL_1268 HCC38 BL transformed cell line human CVCL_1268 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130479 CVCL_0Q68 Panc1-MUC1 cancer cell line human CVCL_0Q68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7508; MUC1 Population: Caucasian; Derived from sampling site: Pancreas. Male 21130480 CVCL_SW82 HAP1 MAP4K3 (-) 2 cancer cell line human CVCL_SW82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6865; MAP4K3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130481 CVCL_T882 PB2 induced pluripotent stem cell human CVCL_T882 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21130482 CVCL_SW81 HAP1 MAP4K3 (-) 1 cancer cell line human CVCL_SW81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6865; MAP4K3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130483 CVCL_T881 PB1 induced pluripotent stem cell human CVCL_T881 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21130484 CVCL_SW84 HAP1 MAP4K5 (-) cancer cell line human CVCL_SW84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6867; MAP4K5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130485 CVCL_T884 PB20 induced pluripotent stem cell human CVCL_T884 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21130486 CVCL_SW83 HAP1 MAP4K4 (-) cancer cell line human CVCL_SW83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6866; MAP4K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130487 CVCL_T883 PB18 induced pluripotent stem cell human CVCL_T883 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21130488 CVCL_SW86 HAP1 MAPK12 (-) cancer cell line human CVCL_SW86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6874; MAPK12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130489 CVCL_T886 PA22 induced pluripotent stem cell human CVCL_T886 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex2-4del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130490 CVCL_SW85 HAP1 MAPK11 (-) cancer cell line human CVCL_SW85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6873; MAPK11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130491 CVCL_T885 PA9 induced pluripotent stem cell human CVCL_T885 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex2-4del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130492 CVCL_SW88 HAP1 MAPK13 (-) 2 cancer cell line human CVCL_SW88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6875; MAPK13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130493 CVCL_T888 iGS1b8-6 induced pluripotent stem cell human CVCL_T888 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130494 CVCL_SW87 HAP1 MAPK13 (-) 1 cancer cell line human CVCL_SW87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6875; MAPK13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130495 CVCL_T887 PA1 induced pluripotent stem cell human CVCL_T887 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex2-4del; Zygosity=Homozygous (PubMed=23039195) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130496 CVCL_SW89 HAP1 MAPK14 (-) 1 cancer cell line human CVCL_SW89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130497 CVCL_1230 GDM-1 cancer cell line human CVCL_1230 HLA typing: A*02:01,68:02; B*35:03,38:01; C*04:01,12:03 (PubMed=26589293); Genome ancestry: African=1.71%; Native American=1.16%; East Asian, North=0%; East Asian, South=2.32%; South Asian=9.02%; European, North=27.3%; European, South=58.5% (PubMed=30894373) CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 96-12 hours (PubMed=6296552); ~40-50 hours (DSMZ=ACC-87); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21130498 CVCL_0Q30 GM15788 transformed cell line human CVCL_0Q30 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130499 CVCL_1232 GI-ME-N cancer cell line human CVCL_1232 Genome ancestry: African=1.35%; Native American=0.42%; East Asian, North=0.23%; East Asian, South=0%; South Asian=7.63%; European, North=34.54%; European, South=55.82% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (PubMed=20655465); Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Microdeletion; Zygosity=Heterozygous (PubMed=20655465) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~25 hours (CLS); ~24 hours (DSMZ=ACC-654); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130500 CVCL_0Q32 GM15790 transformed cell line human CVCL_0Q32 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130501 CVCL_1231 GI-1 cancer cell line human CVCL_1231 HLA typing: A*02:06,26:01; B*35:01,48:01; C*03:03,08:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.75%; East Asian, South=20.38%; South Asian=0.63%; European, North=0%; European, South=0.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Ser1680del (c.5036_5038CCT[1]) (c.5039_5041delCCT) (p.Ser1642del, c.4922_4924CCT[1]); ClinVar=VCV000158384; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg552Ter (c.1654C>T); ClinVar=VCV000126840; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain; left fronto-parietal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 18 hours (PubMed=1545891); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130502 CVCL_0Q31 GM15789 finite cell line human CVCL_0Q31 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Population: Caucasian; Czechoslovakian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM15789; probable Male 21130503 CVCL_0Q34 GM15811 transformed cell line human CVCL_0Q34 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21130504 CVCL_1234 GOTO cancer cell line human CVCL_1234 Genome ancestry: African=0%; Native American=0%; East Asian, North=74.22%; East Asian, South=25.78%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Adrenal gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~48 hours (PubMed=470188); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130505 CVCL_0Q33 GM15810 transformed cell line human CVCL_0Q33 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21130506 CVCL_1233 GMS-10 cancer cell line human CVCL_1233 HLA typing: A*02:01,02:01; B*38:01,44:02; C*12:03,12:03 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=0%; East Asian, North=3.91%; East Asian, South=0%; South Asian=0.08%; European, North=70.41%; European, South=25.49% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Cys (c.707A>G); ClinVar=VCV000376693; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=25984343); ~50-70 hours (DSMZ=ACC-405); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130507 CVCL_0Q36 GM15815 transformed cell line human CVCL_0Q36 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21130508 CVCL_1236 GR-ST cancer cell line human CVCL_1236 Genome ancestry: African=0%; Native American=0%; East Asian, North=74.6%; East Asian, South=25.39%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp361Gly (c.1082A>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys193fs*30 (c.576_580delCAAGT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Transfected with: HGNC; 2439; CSF3R Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130509 CVCL_0Q35 GM15813 transformed cell line human CVCL_0Q35 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130510 CVCL_1235 GP5d cancer cell line human CVCL_1235 HLA typing: A*24:02,24:02; B*44:02,44:02; C*05:01,05:01; DQB1*06:02,06:02; DRB1*04:05,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.21%; East Asian, South=0%; South Asian=0%; European, North=75.24%; European, South=24.54% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=20570890); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21130511 CVCL_0Q38 GM15817 transformed cell line human CVCL_0Q38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130512 CVCL_1238 H-EMC-SS cancer cell line human CVCL_1238 Genome ancestry: African=0.61%; Native American=0.67%; East Asian, North=77.11%; East Asian, South=20.07%; South Asian=0.1%; European, North=0.01%; European, South=1.42% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Muscle. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 17.3-42.8 hours (CelloPub=CLPUB00044); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Does not harbor a gene fusion involving EWSR1 which is a hallmark of extraskeletal myxoid chondrosarcoma (PubMed=34413129) 21130513 CVCL_0Q37 GM15816 transformed cell line human CVCL_0Q37 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21130514 CVCL_1237 GT3TKB cancer cell line human CVCL_1237 Genome ancestry: African=0%; Native American=0%; East Asian, North=89.7%; East Asian, South=9.37%; South Asian=0.05%; European, North=0.87%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB0885; true Male Microsatellite instability: Instable (MSI-low) (Sanger); Stable (MSS) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00202 Problematic cell line: Contaminated Shown to be a RERF-LC-A1 derivative (PubMed=16643607; PubMed=20143388). 21130515 CVCL_0Q39 GM15820 transformed cell line human CVCL_0Q39 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21130516 CVCL_1239 H4 cancer cell line human CVCL_1239 HLA typing: A*03:01,30:02; B*08:01,18:01; C*05:01,07:01; DQB1*02:02,02:02; DRB1*03:01,03:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.32%; East Asian, North=0.97%; East Asian, South=0%; South Asian=0%; European, North=68.05%; European, South=29.66% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10560660); Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Miscellaneous: Originally classified as originating from a neuroglioma, an obsolete classification This cell line has been reclassified as an astrocytoma. Population: Caucasian; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030); Part of: TCGA-110-CL cell line panel 21130517 CVCL_T891 FUi001-A induced pluripotent stem cell human CVCL_T891 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg1645Ter (c.4933C>T); ClinVar=VCV000189921; Zygosity=Heterozygous (PubMed=29453127) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: SKIP; SKIP000234; probable Female 21130518 CVCL_SW91 HAP1 MAPK15 (-) cancer cell line human CVCL_SW91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24667; MAPK15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130519 CVCL_T890 FUi001-B induced pluripotent stem cell human CVCL_T890 From: Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University; Fukuoka; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg1645Ter (c.4933C>T); ClinVar=VCV000189921; Zygosity=Heterozygous (PubMed=29453127) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: SKIP; SKIP000233; probable Female 21130520 CVCL_SW90 HAP1 MAPK14 (-) 2 cancer cell line human CVCL_SW90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6876; MAPK14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130521 CVCL_T871 AG09907 transformed cell line human CVCL_T871 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130522 CVCL_SW71 HAP1 MAP3K5 (-) cancer cell line human CVCL_SW71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6857; MAP3K5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130523 CVCL_SW70 HAP1 MAP3K4 (-) 3 cancer cell line human CVCL_SW70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6856; MAP3K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130524 CVCL_T870 PARK4-4 induced pluripotent stem cell human CVCL_T870 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=22848530) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130525 CVCL_SW73 HAP1 MAP3K7 (-) cancer cell line human CVCL_SW73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6859; MAP3K7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130526 CVCL_T873 PS1-2 induced pluripotent stem cell human CVCL_T873 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=21900357) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21130527 CVCL_T872 AG09908 finite cell line human CVCL_T872 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (Coriell; PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21130528 CVCL_SW72 HAP1 MAP3K6 (-) cancer cell line human CVCL_SW72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6858; MAP3K6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130529 CVCL_SW75 HAP1 MAP3K8 (-) 2 cancer cell line human CVCL_SW75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6860; MAP3K8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130530 CVCL_T875 PS2-1 induced pluripotent stem cell human CVCL_T875 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=21900357) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21130531 CVCL_SW74 HAP1 MAP3K8 (-) 1 cancer cell line human CVCL_SW74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6860; MAP3K8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130532 CVCL_T874 PS1-4 induced pluripotent stem cell human CVCL_T874 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=21900357) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21130533 CVCL_T877 AG07768 finite cell line human CVCL_T877 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=21900357; PubMed=24416243) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21130534 CVCL_SW77 HAP1 MAP3K9 (-) 1 cancer cell line human CVCL_SW77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6861; MAP3K9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130535 CVCL_SW76 HAP1 MAP3K8 (-) 3 cancer cell line human CVCL_SW76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6860; MAP3K8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130536 CVCL_T876 PS2-2 induced pluripotent stem cell human CVCL_T876 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=21900357) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21130537 CVCL_SW79 HAP1 MAP4 (-) 1 cancer cell line human CVCL_SW79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6862; MAP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130538 CVCL_T879 LQTS1-iPSC a1 induced pluripotent stem cell human CVCL_T879 CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Pro631fs*33 (c.1893delC); Zygosity=Heterozygous (PubMed=22739119) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000200; probable Male 21130539 CVCL_T878 AG07767 transformed cell line human CVCL_T878 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG07768) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21130540 CVCL_SW78 HAP1 MAP3K9 (-) 2 cancer cell line human CVCL_SW78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6861; MAP3K9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130541 CVCL_0Q50 BA-HAN-1C cancer cell line Norway rat CVCL_0Q50 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Lewis. Unspecified 21130542 CVCL_1250 HCC1395 BL transformed cell line human CVCL_1250 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130543 CVCL_0Q41 GM15822 transformed cell line human CVCL_0Q41 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130544 CVCL_1241 HA7-RCC cancer cell line human CVCL_1241 Genome ancestry: African=0.05%; Native American=0.85%; East Asian, North=0%; East Asian, South=0.47%; South Asian=1.99%; European, North=74.38%; European, South=22.26% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130545 CVCL_0Q40 GM15821 transformed cell line human CVCL_0Q40 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21130546 CVCL_1240 H9 cancer cell line human CVCL_1240 Genome ancestry: African=4.91%; Native American=1.41%; East Asian, North=5.59%; East Asian, South=0%; South Asian=0%; European, North=61.37%; European, South=26.72% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (Cosmic-CLP; DepMap) Anecdotal: For a number of years it was not known that H9 used by Gallo's lab to isolate HIV-1 (HTLV-III) was in fact a clone of Hut 78 from Minna's lab (PubMed=2567177) This created a controversy between the labs of Minna and Gallo (PubMed=2193399). Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: IZSLER; BS TCL 19; probable Male Virology: Permissive for HIV-1 replication Is accordingly used to isolate and propagate HIV-1 from the blood of patients with AIDS. Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130547 CVCL_0Q43 GM15825 transformed cell line human CVCL_0Q43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130548 CVCL_1243 HC-1 cancer cell line human CVCL_1243 HLA typing: A*03:01:01,03:01:01; B*15:01:01,35:03:01; C*03:04:01,03:04:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRA*01:01:01,01:01:01; DRB1*04:01:01,11:04:01 (DSMZCellDive=ACC-301); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.03%; East Asian, South=0%; South Asian=1.15%; European, North=70.39%; European, South=28.43% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~45 hours (DSMZ=ACC-301); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel Problematic cell line: Possibly misclassified It is not certain that this cell line originate from a hairy cell leukemia (PubMed=22653958). 21130549 CVCL_0Q42 GM15823 transformed cell line human CVCL_0Q42 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130550 CVCL_1242 HAL-01 cancer cell line human CVCL_1242 Genome ancestry: African=0%; Native American=0.89%; East Asian, North=78.59%; East Asian, South=19.2%; South Asian=0%; European, North=0%; European, South=1.33% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF; Note=In frame (PubMed=1516826) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 32 hours (PubMed=2027299); ~48 hours (DSMZ=ACC-610); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130551 CVCL_0Q45 GM15842 transformed cell line human CVCL_0Q45 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130552 CVCL_1245 HCC1143 cancer cell line human CVCL_1245 HLA typing: A*31:01,31:01; B*35:08,37:01; C*04:01,06:02; DQA1*04:01,04:01; DQB1*04:02,04:02; DRB1*03:01,08:01 (PubMed=25960936); HLA typing: A*31:01,31:01; B*35:08,37:01; C*04:01,06:02; DQA1*04:01,04:01; DQB1*04:02,04:02; DRB1*03:01,08:01 (PubMed=26589293); Genome ancestry: African=1.22%; Native American=0.04%; East Asian, North=3.69%; East Asian, South=0%; South Asian=0%; European, North=59.57%; European, South=35.48% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=28889351; ATCC) Population: Caucasian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Glycoproteome analysis by proteomics; Omics: HLA class I peptidome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~45-60 hours (DSMZ=ACC-517); 54.63 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21130553 CVCL_0Q44 GM15841 transformed cell line human CVCL_0Q44 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21130554 CVCL_1244 HCC1008 cancer cell line human CVCL_1244 CL:0000010 Population: African American; Derived from metastatic site: Axillary lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21130555 CVCL_0Q47 BA-HAN-1 cancer cell line Norway rat CVCL_0Q47 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Lewis. Unspecified Doubling time: 16 hours (PubMed=2900572) 21130556 CVCL_1247 HCC1187 cancer cell line human CVCL_1247 HLA typing: A*01:01,31:01; B*08:01,40:01; C*03:04,07:01 (PubMed=26589293); Genome ancestry: African=1.83%; Native American=0%; East Asian, North=3.32%; East Asian, South=0%; South Asian=0%; European, North=62.5%; European, South=32.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly108del (c.322_324delGGT); ClinVar=VCV000156516; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 100 hours (PubMed=25984343); 69.35 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130557 CVCL_0Q46 GM00882 finite cell line human CVCL_0Q46 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg301Gly (c.901C>G); ClinVar=VCV000179546; Zygosity=Hemizygous (PubMed=29982630) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21130558 CVCL_1246 HCC1143 BL transformed cell line human CVCL_1246 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Doubling time: ~40-50 hours (DSMZ=ACC-893) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130559 CVCL_0Q49 BA-HAN-1B cancer cell line Norway rat CVCL_0Q49 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Lewis. Unspecified 21130560 CVCL_1249 HCC1395 cancer cell line human CVCL_1249 HLA typing: A*29:02,29:02; B*08:01,45:01; C*06:02,07:01; DQA1*03:02,03:02; DRB1*03:01,04:05 (PubMed=25960936); HLA typing: A*29:02,29:02; B*08:01,45:01; C*06:02,07:01; DQA1*03:02,05:02; DQB1*02:02,05:01; DRB1*03:01,04:05 (PubMed=26589293); Genome ancestry: African=2%; Native American=0%; East Asian, North=1.43%; East Asian, South=0%; South Asian=0.64%; European, North=62.97%; European, South=32.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=9865903; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 72 hours (PubMed=25984343); 84.07 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130561 CVCL_0Q48 BA-HAN-1A cancer cell line Norway rat CVCL_0Q48 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Lewis. Unspecified 21130562 CVCL_1248 HCC1187 BL transformed cell line human CVCL_1248 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130563 CVCL_SW80 HAP1 MAP4 (-) 2 cancer cell line human CVCL_SW80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6862; MAP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130564 CVCL_T880 LQTS1-iPSC k1 induced pluripotent stem cell human CVCL_T880 CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Pro631fs*33 (c.1893delC); Zygosity=Heterozygous (PubMed=22739119) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000201; probable Male 21130565 CVCL_SW60 HAP1 MAP3K12 (-) 1 cancer cell line human CVCL_SW60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6851; MAP3K12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130566 CVCL_T860 ND29509 finite cell line human CVCL_T860 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29509; true Male 21130567 CVCL_SW62 HAP1 MAP3K12 (-) 3 cancer cell line human CVCL_SW62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6851; MAP3K12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130568 CVCL_T862 ND39026 finite cell line human CVCL_T862 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu50Lys (c.148G>A) (E49K); ClinVar=VCV000658902; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39026; true Female 21130569 CVCL_SW61 HAP1 MAP3K12 (-) 2 cancer cell line human CVCL_SW61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6851; MAP3K12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130570 CVCL_T861 ND35668 induced pluripotent stem cell human CVCL_T861 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu50Lys (c.148G>A) (E49K); ClinVar=VCV000658902; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35668; true Female 21130571 CVCL_SW64 HAP1 MAP3K2 (-) 1 cancer cell line human CVCL_SW64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130572 CVCL_T864 ND39025 finite cell line human CVCL_T864 CL:0000010 Sequence variation: Mutation; HGNC; 16873; FIG4; Simple; p.Ile9Ile (c.27C>T); ClinVar=VCV000137376; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39025; true Female 21130573 CVCL_SW63 HAP1 MAP3K14 (-) cancer cell line human CVCL_SW63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6853; MAP3K14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130574 CVCL_T863 ND35669 induced pluripotent stem cell human CVCL_T863 CL:0000010 Sequence variation: Mutation; HGNC; 16873; FIG4; Simple; p.Ile9Ile (c.27C>T); ClinVar=VCV000137376; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35669; true Female 21130575 CVCL_T866 100-1#8 induced pluripotent stem cell human CVCL_T866 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 21130576 CVCL_SW66 HAP1 MAP3K2 (-) 3 cancer cell line human CVCL_SW66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130577 CVCL_SW65 HAP1 MAP3K2 (-) 2 cancer cell line human CVCL_SW65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6854; MAP3K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130578 CVCL_T865 ND35671 induced pluripotent stem cell human CVCL_T865 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35671; true Female 21130579 CVCL_T868 100-2#1 induced pluripotent stem cell human CVCL_T868 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130580 CVCL_SW68 HAP1 MAP3K4 (-) 1 cancer cell line human CVCL_SW68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6856; MAP3K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130581 CVCL_T867 100-1#16 induced pluripotent stem cell human CVCL_T867 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21130582 CVCL_SW67 HAP1 MAP3K3 (-) cancer cell line human CVCL_SW67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6855; MAP3K3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130583 CVCL_SW69 HAP1 MAP3K4 (-) 2 cancer cell line human CVCL_SW69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6856; MAP3K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130584 CVCL_T869 PARK4-14 induced pluripotent stem cell human CVCL_T869 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=22848530) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21130585 CVCL_1210 EW-12 cancer cell line human CVCL_1210 Genome ancestry: African=21.92%; Native American=0%; East Asian, North=2.41%; East Asian, South=0.17%; South Asian=6.25%; European, North=15.31%; European, South=53.94% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130586 CVCL_0Q10 GM10224 finite cell line human CVCL_0Q10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130587 CVCL_1212 EW-16 cancer cell line human CVCL_1212 Genome ancestry: African=0.19%; Native American=1.1%; East Asian, North=0%; East Asian, South=0.45%; South Asian=0.79%; European, North=55.49%; European, South=41.99% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 8 fused to FLI1 exon 7 (PubMed=11423975); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys120Serfs*3 (c.359delA); Zygosity=Heterozygous (PubMed=25223734; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130588 CVCL_0Q12 GM10559 transformed cell line human CVCL_0Q12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130589 CVCL_1211 EW-13 cancer cell line human CVCL_1211 Genome ancestry: African=18.44%; Native American=0%; East Asian, North=0.58%; East Asian, South=2.48%; South Asian=1.96%; European, North=15.79%; European, South=60.76% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser315Leufs*30 (c.942delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130590 CVCL_0Q11 GM10463 transformed cell line human CVCL_0Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130591 CVCL_1214 EW-22 cancer cell line human CVCL_1214 Genome ancestry: African=0.31%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=1.44%; European, North=60.63%; European, South=37.61% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25223734) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130592 CVCL_0Q14 GM10614 transformed cell line human CVCL_0Q14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130593 CVCL_1213 EW-18 cancer cell line human CVCL_1213 Genome ancestry: African=0%; Native American=0.97%; East Asian, North=0.41%; East Asian, South=0%; South Asian=0.22%; European, North=68.25%; European, South=30.15% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=23637631); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=25223734) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130594 CVCL_0Q13 GM10566 transformed cell line human CVCL_0Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130595 CVCL_1216 EW-3 cancer cell line human CVCL_1216 Genome ancestry: African=0%; Native American=0.33%; East Asian, North=0.83%; East Asian, South=0.4%; South Asian=6.18%; European, North=47.05%; European, South=45.2% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=11423975; PubMed=16631476); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg216Ter (c.646C>T); Zygosity=Unspecified (PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.852_858del7; Zygosity=Unspecified (PubMed=19787792; PubMed=26428435) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130596 CVCL_0Q16 GM10628 transformed cell line human CVCL_0Q16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130597 CVCL_1215 EW-24 cancer cell line human CVCL_1215 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.24%; South Asian=0%; European, North=60.48%; European, South=38.28% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Glu (c.490A>G); ClinVar=VCV000246416; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130598 CVCL_0Q15 GM10627 transformed cell line human CVCL_0Q15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130599 CVCL_1218 FaDu cancer cell line human CVCL_1218 HLA typing: A*01:01,01:01; B*15:17,37:04; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=2.06%; Native American=0%; East Asian, North=11.01%; East Asian, South=0%; South Asian=79.51%; European, North=0%; European, South=7.42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (PubMed=1394225; PubMed=11799138; PubMed=23613873; ATCC; Cosmic-CLP; DepMap) Population: Indian; Derived from sampling site: Pharynx; hypopharynx. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~30 hours (DSMZ=ACC-784); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21130600 CVCL_0Q18 GM10692 transformed cell line human CVCL_0Q18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130601 CVCL_1217 EW-7 cancer cell line human CVCL_1217 Genome ancestry: African=0.24%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=3.39%; European, North=57.71%; European, South=38.66% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975; PubMed=16631476) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130602 CVCL_0Q17 GM10688 finite cell line human CVCL_0Q17 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p11::q13->p11::q13->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21130603 CVCL_1219 FTC-133 cancer cell line human CVCL_1219 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:01,06:01; DRB1*03:05 (PubMed=26589293); Genome ancestry: African=1.29%; Native American=1.18%; East Asian, North=4.32%; East Asian, South=0%; South Asian=0%; European, North=56.94%; European, South=36.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.His429Thrfs*39 (c.1285delC); ClinVar=VCV000003364; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Cys167Ter (c.501T>A); ClinVar=VCV001048706; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=23162534; PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906; PubMed=23162534; PubMed=30737244) Anecdotal: Have been flown in space on Shenzhou-8 and on the ISS to study growth in microgravity (PubMed=23866977; PubMed=24196587; PubMed=25930030) Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502) Microsatellite instability: Stable (MSS) (Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21130604 CVCL_0Q19 GM10693 transformed cell line human CVCL_0Q19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130605 CVCL_SW51 HAP1 MAP2K7 (-) 3 cancer cell line human CVCL_SW51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130606 CVCL_T851 ND29422 finite cell line human CVCL_T851 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29422; true Male 21130607 CVCL_SW50 HAP1 MAP2K7 (-) 2 cancer cell line human CVCL_SW50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130608 CVCL_T850 ND35660 induced pluripotent stem cell human CVCL_T850 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35660; true Female 21130609 CVCL_SW53 HAP1 MAP3K1 (-) 2 cancer cell line human CVCL_SW53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6848; MAP3K1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130610 CVCL_T853 ND35662 induced pluripotent stem cell human CVCL_T853 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu101Gly (c.302A>G) (E100G); ClinVar=VCV000014761; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35662; true Male 21130611 CVCL_SW52 HAP1 MAP3K1 (-) 1 cancer cell line human CVCL_SW52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6848; MAP3K1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130612 CVCL_T852 ND35661 induced pluripotent stem cell human CVCL_T852 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35661; true Male 21130613 CVCL_SW55 HAP1 MAP3K10 (-) 1 cancer cell line human CVCL_SW55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6849; MAP3K10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130614 CVCL_T855 ND39027 finite cell line human CVCL_T855 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39027; true Female 21130615 CVCL_SW54 HAP1 MAP3K1 (-) 3 cancer cell line human CVCL_SW54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6848; MAP3K1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130616 CVCL_T854 ND35663 induced pluripotent stem cell human CVCL_T854 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35663; true Female 21130617 CVCL_SW57 HAP1 MAP3K10 (-) 3 cancer cell line human CVCL_SW57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6849; MAP3K10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130618 CVCL_T857 ND10366 transformed cell line human CVCL_T857 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130619 CVCL_SW56 HAP1 MAP3K10 (-) 2 cancer cell line human CVCL_SW56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6849; MAP3K10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130620 CVCL_T856 ND29774 finite cell line human CVCL_T856 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29774; true Female 21130621 CVCL_SW59 HAP1 MAP3K11 (-) 2 cancer cell line human CVCL_SW59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130622 CVCL_T859 ND35666 induced pluripotent stem cell human CVCL_T859 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35666; true Male 21130623 CVCL_SW58 HAP1 MAP3K11 (-) 1 cancer cell line human CVCL_SW58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6850; MAP3K11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130624 CVCL_T858 ND35664 induced pluripotent stem cell human CVCL_T858 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35664; true Female 21130625 CVCL_1221 G-402 cancer cell line human CVCL_1221 HLA typing: A*24:02,24:02; B*07:02,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=32.1%; Native American=0.17%; East Asian, North=0.64%; East Asian, South=0%; South Asian=1.72%; European, North=46.83%; European, South=18.54% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24.4 hours (lot 062392) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: This cell line is said to originate from a 'renal leiomyoblastoma' This is an antiquated/imprecise terminology that can not be assigned to a precise cancer type. As there is no information on the exact origin of this cell line, except that it was deposited by Peebles P.T at ATCC, we have assigned it to the generic 'kidney neoplasm' of NCIt. 21130626 CVCL_0Q21 GM10695 transformed cell line human CVCL_0Q21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130627 CVCL_1220 G-361 cancer cell line human CVCL_1220 HLA typing: A*23:01,26:01; B*38:01,44:03; C*04:01,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.03%; East Asian, North=1.43%; East Asian, South=0%; South Asian=0%; European, North=70.33%; European, South=28.21% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=15467732; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21130628 CVCL_0Q20 GM10694 transformed cell line human CVCL_0Q20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130629 CVCL_1223 GA-10 clone 20 cancer cell line human CVCL_1223 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Virology: EBV-negative 21130630 CVCL_0Q23 GM10749 finite cell line human CVCL_0Q23 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130631 CVCL_1222 GA-10 cancer cell line human CVCL_1222 HLA typing: A*02:01,32:01; B*07:02,55:01; C*03:03,07:02 (PubMed=26589293); Genome ancestry: African=1.05%; Native American=0%; East Asian, North=0%; East Asian, South=0.44%; South Asian=1.46%; European, North=68.9%; European, South=28.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (PubMed=11482875); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (PubMed=11482875) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Virology: EBV-negative Doubling time: ~24 hours (PubMed=11482875); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130632 CVCL_0Q22 GM10729 transformed cell line human CVCL_0Q22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130633 CVCL_1225 GAK cancer cell line human CVCL_1225 Genome ancestry: African=0%; Native American=0%; East Asian, North=77.89%; East Asian, South=22.1%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Inguinal lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0034; true Female Doubling time: 72 hours (PubMed=6431036); ~32 hours (lot 02242012), ~55 hours (lot 07202012) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130634 CVCL_0Q25 GM10893 transformed cell line human CVCL_0Q25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130635 CVCL_1224 GA-10 clone 4 cancer cell line human CVCL_1224 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile232Asn (c.695T>A); ClinVar=VCV000850008; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Virology: EBV-negative 21130636 CVCL_0Q24 GM10892 finite cell line human CVCL_0Q24 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21130637 CVCL_1227 GB-1 cancer cell line human CVCL_1227 Genome ancestry: African=0%; Native American=1.07%; East Asian, North=80.28%; East Asian, South=17.3%; South Asian=0%; European, North=0%; European, South=1.34% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239_Ser240insAsn (c.716_717insTAA); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=25984343); ~35 hours (lot 01232006) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130638 CVCL_0Q27 GM10949 finite cell line human CVCL_0Q27 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130639 CVCL_1226 GaMG cancer cell line human CVCL_1226 HLA typing: A*02:01,03:01; B*07:02,15:01; C*03:03,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.47%; East Asian, South=0%; South Asian=0%; European, North=71.47%; European, South=27.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265Pro (c.794T>C); ClinVar=VCV000245777; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Female Doubling time: 32.3 +- 0.5 hours (in serum-supplemented media), 41.7 +- 1.4 hours (in serum-free media) (PubMed=3178168); ~40-50 hours (DSMZ=ACC-242); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130640 CVCL_0Q26 GM10894 transformed cell line human CVCL_0Q26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130641 CVCL_1229 GCT cancer cell line human CVCL_1229 HLA typing: A*01:01,23:01; B*08:01,15:17; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.07%; Native American=0%; East Asian, North=2.31%; East Asian, South=0%; South Asian=1.28%; European, North=63.83%; European, South=32.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu32Arg (c.95_96TG>GT); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.948_949delinsTT) (c.948_949CC>TT); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21130642 CVCL_0Q29 GM14089 finite cell line human CVCL_0Q29 CL:0000010 Population: Caucasian/Russian; Derived from sampling site: Muscle Cell type=Fibroblast.. Female 21130643 CVCL_1228 GCIY cancer cell line human CVCL_1228 Genome ancestry: African=0.08%; Native American=0.43%; East Asian, North=86.12%; East Asian, South=13.37%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Gln (c.537T>G); ClinVar=VCV000376607; Zygosity=Homozygous (Cosmic-CLP) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1883; true Female Characteristics: Produces AFP (PubMed=11314020) Doubling time: 55 hours (PubMed=1653599); 60 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel 21130644 CVCL_0Q28 GM14088 finite cell line human CVCL_0Q28 CL:0000010 Population: Caucasian/Russian; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21130645 CVCL_SW40 HAP1 MAP2K2 (-) 2 cancer cell line human CVCL_SW40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130646 CVCL_T840 iPS-TIG107-3f1 induced pluripotent stem cell human CVCL_T840 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0612; true Female 21130647 CVCL_SW42 HAP1 MAP2K3 (-) 1 cancer cell line human CVCL_SW42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6843; MAP2K3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130648 CVCL_T842 UC706 somatic stem cell human CVCL_T842 CL:0000010 Derived from sampling site: Umbilical cord. Unspecified 21130649 CVCL_T841 GM23476 induced pluripotent stem cell human CVCL_T841 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130650 CVCL_SW41 HAP1 MAP2K2 (-) 3 cancer cell line human CVCL_SW41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130651 CVCL_SW44 HAP1 MAP2K4 (-) 1 cancer cell line human CVCL_SW44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130652 CVCL_T844 ND34394 induced pluripotent stem cell human CVCL_T844 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34394; true Male 21130653 CVCL_SW43 HAP1 MAP2K3 (-) 2 cancer cell line human CVCL_SW43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6843; MAP2K3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130654 CVCL_T843 ND34393 induced pluripotent stem cell human CVCL_T843 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34393; true Male 21130655 CVCL_SW46 HAP1 MAP2K4 (-) 3 cancer cell line human CVCL_SW46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130656 CVCL_T846 ND35371 induced pluripotent stem cell human CVCL_T846 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35371; true Female 21130657 CVCL_SW45 HAP1 MAP2K4 (-) 2 cancer cell line human CVCL_SW45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6844; MAP2K4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130658 CVCL_T845 ND35367 induced pluripotent stem cell human CVCL_T845 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35367; true Male 21130659 CVCL_SW48 HAP1 MAP2K6 (-) cancer cell line human CVCL_SW48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6846; MAP2K6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130660 CVCL_T848 ND35659 induced pluripotent stem cell human CVCL_T848 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35659; true Female 21130661 CVCL_SW47 HAP1 MAP2K5 (-) cancer cell line human CVCL_SW47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6845; MAP2K5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130662 CVCL_T847 ND35658 induced pluripotent stem cell human CVCL_T847 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asn140Lys (c.420C>A) (N139K); ClinVar=VCV000586635; Zygosity=Unspecified (NHCDR) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35658; true Male 21130663 CVCL_SW49 HAP1 MAP2K7 (-) 1 cancer cell line human CVCL_SW49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6847; MAP2K7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130664 CVCL_T849 ND29149 finite cell line human CVCL_T849 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29149; true Female 21130665 CVCL_SW31 HAP1 MAP1A (-) 3 cancer cell line human CVCL_SW31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6835; MAP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130666 CVCL_T831 K10M19 induced pluripotent stem cell human CVCL_T831 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130667 CVCL_SW30 HAP1 MAP1A (-) 2 cancer cell line human CVCL_SW30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6835; MAP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130668 CVCL_T830 K10M17 induced pluripotent stem cell human CVCL_T830 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130669 CVCL_SW33 HAP1 MAP1LC3B (-) 2 cancer cell line human CVCL_SW33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13352; MAP1LC3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130670 CVCL_T833 K11M4 induced pluripotent stem cell human CVCL_T833 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130671 CVCL_SW32 HAP1 MAP1LC3B (-) 1 cancer cell line human CVCL_SW32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13352; MAP1LC3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130672 CVCL_T832 K10M5 induced pluripotent stem cell human CVCL_T832 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130673 CVCL_SW35 HAP1 MAP2 (-) 1 cancer cell line human CVCL_SW35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6839; MAP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130674 CVCL_T835 K11PD18 induced pluripotent stem cell human CVCL_T835 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130675 CVCL_SW34 HAP1 MAP1LC3C (-) cancer cell line human CVCL_SW34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13353; MAP1LC3C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130676 CVCL_T834 K11PD17 induced pluripotent stem cell human CVCL_T834 CL:0000010 Sequence variation: Mutation; HGNC; 10288; RP9; Simple; p.His137Leu (c.410A>T); ClinVar=VCV000003334; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21130677 CVCL_SW37 HAP1 MAP2K1 (-) 1 cancer cell line human CVCL_SW37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6840; MAP2K1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130678 CVCL_T837 P59M8 induced pluripotent stem cell human CVCL_T837 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Gly188Arg (c.562G>A); ClinVar=VCV000143081; Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21130679 CVCL_SW36 HAP1 MAP2 (-) 2 cancer cell line human CVCL_SW36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6839; MAP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130680 CVCL_T836 K21S4 induced pluripotent stem cell human CVCL_T836 CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Leu721Profs*2 (c.2161dupC) (c.2161_2162insC); Zygosity=Unspecified (PubMed=21347327) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: SKIP; SKIP000140; probable Female 21130681 CVCL_SW39 HAP1 MAP2K2 (-) 1 cancer cell line human CVCL_SW39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6842; MAP2K2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130682 CVCL_T839 K32M17 induced pluripotent stem cell human CVCL_T839 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: SKIP; SKIP000142; probable Female 21130683 CVCL_SW38 HAP1 MAP2K1 (-) 2 cancer cell line human CVCL_SW38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6840; MAP2K1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130684 CVCL_T838 K31M28 induced pluripotent stem cell human CVCL_T838 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: SKIP; SKIP000141; probable Female 21130685 CVCL_1201 ES5 cancer cell line human CVCL_1201 Genome ancestry: African=1.1%; Native American=0%; East Asian, North=1.85%; East Asian, South=0%; South Asian=0.47%; European, North=64.55%; European, South=32.03% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130686 CVCL_0Q01 GM01665 finite cell line human CVCL_0Q01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(12;21)(12qter->12p11::21p11->21pter;21qter->21p11::12p11->12pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21130687 CVCL_1200 ES4 cancer cell line human CVCL_1200 Genome ancestry: African=1.29%; Native American=7.84%; East Asian, North=0%; East Asian, South=1.09%; South Asian=1.81%; European, North=61.75%; European, South=26.22% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Unspecified (PubMed=25010205) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130688 CVCL_0Q00 GM01664 finite cell line human CVCL_0Q00 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(9;13)(9pter->9q13::13q12->13qter;13pter->13q12::9q13->9qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21130689 CVCL_1203 ES7 cancer cell line human CVCL_1203 Genome ancestry: African=1.94%; Native American=0%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=63.25%; European, South=33.1% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 4 fusion (Ex10/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Gln (c.537T>G); ClinVar=VCV000376607; Zygosity=Unspecified (PubMed=25010205) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130690 CVCL_0Q03 GM01683 finite cell line human CVCL_0Q03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;10)(2qter->2p23::10q26->10qter;10pter->10q26::2p23->2pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21130691 CVCL_1202 ES6 cancer cell line human CVCL_1202 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.57%; East Asian, South=0%; South Asian=2.66%; European, North=67.61%; European, South=29.16% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 9 fused to FLI1 exon 4 (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Leu264Pro (c.791T>C); Zygosity=Homozygous (PubMed=25010205; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130692 CVCL_0Q02 GM01678 finite cell line human CVCL_0Q02 CL:0000010 Karyotypic information: 46,XX,t(5;10)(5qter->5p15::10p13->10pter;10qter->10p13::5p15->5pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21130693 CVCL_1205 ESS-1 cancer cell line human CVCL_1205 Genome ancestry: African=0.37%; Native American=0%; East Asian, North=1.73%; East Asian, South=0%; South Asian=0.47%; European, North=65.49%; European, South=31.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Glu694Ter (c.2080G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg142Trp (c.424C>T); ClinVar=VCV000197662; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 63 hours (PubMed=9663606); ~120 hours (DSMZ=ACC-461); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21130694 CVCL_0Q05 GM08019 transformed cell line human CVCL_0Q05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130695 CVCL_1204 ES8 cancer cell line human CVCL_1204 Genome ancestry: African=1.48%; Native American=0.07%; East Asian, North=0.25%; East Asian, South=1.89%; South Asian=9.11%; European, North=26.16%; European, South=61.04% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (PubMed=25010205; Cosmic-CLP) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130696 CVCL_0Q04 GM08037 transformed cell line human CVCL_0Q04 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21130697 CVCL_1207 Evsa-T cancer cell line human CVCL_1207 Genome ancestry: African=0.86%; Native American=1.1%; East Asian, North=2.9%; East Asian, South=0%; South Asian=8.5%; European, North=19.45%; European, South=67.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.687+1_687+2delGT; ClinVar=VCV000483268; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.951_954delACTT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (PubMed=16541312; Cosmic-CLP) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 25 hours (PubMed=9488600); ~50 hours (DSMZ=ACC-433); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21130698 CVCL_0Q07 GM08856 finite cell line human CVCL_0Q07 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Male 21130699 CVCL_1206 ETK-1 cancer cell line human CVCL_1206 Genome ancestry: African=3.1%; Native American=0%; East Asian, North=74.88%; East Asian, South=17.31%; South Asian=0%; European, North=0.67%; European, South=4.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB1289; true Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Was incorrectly reported to be a SSP-25 contaminated cell line by Riken and thus also by ICLAC but it was later found out that SSP-25 was in fact contaminated by ETK-1 and not the other way around 21130700 CVCL_0Q06 GM08855 finite cell line human CVCL_0Q06 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130701 CVCL_1209 EW-11 cancer cell line human CVCL_1209 Genome ancestry: African=20.84%; Native American=0.67%; East Asian, North=0%; East Asian, South=2.32%; South Asian=4.42%; European, North=15.83%; European, South=55.92% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP) Derived from metastatic site: Mediastinal lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130702 CVCL_0Q09 GM09663 finite cell line human CVCL_0Q09 CL:0000010 Population: Caucasian; French Canadian; Derived from sampling site: Cell type=Fibroblast. Male 21130703 CVCL_1208 EW-1 cancer cell line human CVCL_1208 Genome ancestry: African=0.04%; Native American=1.76%; East Asian, North=0%; East Asian, South=0%; South Asian=0.17%; European, North=53.73%; European, South=44.3% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=11423975); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=25223734) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130704 CVCL_0Q08 GM08909 finite cell line human CVCL_0Q08 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Ser249Cys (c.746C>G); ClinVar=VCV000016339; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21130705 CVCL_9K77 DD2740 transformed cell line human CVCL_9K77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130706 CVCL_9K76 DD2739 transformed cell line human CVCL_9K76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130707 CVCL_9K79 DD2743 finite cell line human CVCL_9K79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130708 CVCL_9K78 DD2742 transformed cell line human CVCL_9K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130709 CVCL_9K73 DD2732 transformed cell line human CVCL_9K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130710 CVCL_9K72 DD2731 transformed cell line human CVCL_9K72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130711 CVCL_9K75 DD2738 transformed cell line human CVCL_9K75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130712 CVCL_9K74 DD2737 transformed cell line human CVCL_9K74 CL:0000010 Karyotypic information: 46,XX,t(11;13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130713 CVCL_BE03 ND10404 transformed cell line human CVCL_BE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130714 CVCL_BE02 ND10403 transformed cell line human CVCL_BE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130715 CVCL_BE05 ND10406 transformed cell line human CVCL_BE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130716 CVCL_BE04 ND10405 transformed cell line human CVCL_BE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130717 CVCL_BE07 ND10412 transformed cell line human CVCL_BE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130718 CVCL_BE06 ND10411 transformed cell line human CVCL_BE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130719 CVCL_BE09 ND10418 transformed cell line human CVCL_BE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130720 CVCL_BE08 ND10413 transformed cell line human CVCL_BE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130721 CVCL_9K71 DD2722 transformed cell line human CVCL_9K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130722 CVCL_9K70 DD2721 transformed cell line human CVCL_9K70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130723 CVCL_BE01 ND10398 transformed cell line human CVCL_BE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130724 CVCL_BE00 ND10396 transformed cell line human CVCL_BE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130725 CVCL_9K88 DD2760 transformed cell line human CVCL_9K88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130726 CVCL_9K87 DD2759 transformed cell line human CVCL_9K87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130727 CVCL_9K89 DD2762 transformed cell line human CVCL_9K89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130728 CVCL_9K84 DD2755 finite cell line human CVCL_9K84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130729 CVCL_9K83 DD2751 transformed cell line human CVCL_9K83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130730 CVCL_9K86 DD2758 transformed cell line human CVCL_9K86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130731 CVCL_9K85 DD2756 finite cell line human CVCL_9K85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130732 CVCL_BE14 ND10441 transformed cell line human CVCL_BE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130733 CVCL_BE13 ND10430 transformed cell line human CVCL_BE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130734 CVCL_BE16 ND10443 transformed cell line human CVCL_BE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130735 CVCL_BE15 ND10442 transformed cell line human CVCL_BE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130736 CVCL_BE18 ND10448 transformed cell line human CVCL_BE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130737 CVCL_BE17 ND10445 transformed cell line human CVCL_BE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130738 CVCL_BE19 ND10450 transformed cell line human CVCL_BE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130739 CVCL_9K80 DD2745 finite cell line human CVCL_9K80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130740 CVCL_9K82 DD2750 transformed cell line human CVCL_9K82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130741 CVCL_9K81 DD2749 transformed cell line human CVCL_9K81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130742 CVCL_BE10 ND10419 transformed cell line human CVCL_BE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130743 CVCL_BE12 ND10424 transformed cell line human CVCL_BE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130744 CVCL_BE11 ND10422 transformed cell line human CVCL_BE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130745 CVCL_9K55 DD2664 finite cell line human CVCL_9K55 CL:0000010 Karyotypic information: 46,XX,t(2;11)(p12.2;p15.1) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130746 CVCL_9K54 DD2660 transformed cell line human CVCL_9K54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130747 CVCL_9K57 DD2681 transformed cell line human CVCL_9K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130748 CVCL_9K56 DD2667 transformed cell line human CVCL_9K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130749 CVCL_9K51 DD2647 finite cell line human CVCL_9K51 CL:0000010 Karyotypic information: 47,XY,?dup(15)(q11;q13),+21 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21130750 CVCL_9K50 DD2644 finite cell line human CVCL_9K50 CL:0000010 Karyotypic information: 46,XY.ish 22q11-2(cH748x2) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21130751 CVCL_9K53 DD2651 transformed cell line human CVCL_9K53 CL:0000010 Karyotypic information: 46,XX,add(20)(q13.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130752 CVCL_9K52 DD2650 transformed cell line human CVCL_9K52 CL:0000010 Karyotypic information: 46,XY,dup(15)(q21;q24) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130753 CVCL_9K59 DD2685 finite cell line human CVCL_9K59 CL:0000010 Karyotypic information: 46,XX,del(2)(?q31.3;q33.3) de novo (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130754 CVCL_9K58 DD2684 finite cell line human CVCL_9K58 CL:0000010 Karyotypic information: 46,XY,?del(2)(p13;p12.1)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21130755 CVCL_9K66 DD2710 transformed cell line human CVCL_9K66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130756 CVCL_9K65 DD2707 transformed cell line human CVCL_9K65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130757 CVCL_9K68 DD2714 transformed cell line human CVCL_9K68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130758 CVCL_9K67 DD2711 transformed cell line human CVCL_9K67 CL:0000010 Karyotypic information: 46,XX,add(2)(q37.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130759 CVCL_9K62 DD2704 transformed cell line human CVCL_9K62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130760 CVCL_9K61 DD2699 finite cell line human CVCL_9K61 CL:0000010 Karyotypic information: 46,XX,der(8)t(2;8)(q37.3;p23.1)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130761 CVCL_9K64 DD2706 transformed cell line human CVCL_9K64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130762 CVCL_9K63 DD2705 transformed cell line human CVCL_9K63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130763 CVCL_9K69 DD2717 transformed cell line human CVCL_9K69 CL:0000010 Karyotypic information: 46,XY,dup(11)(p15.1;p15.3) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130764 CVCL_9K60 DD2687 transformed cell line human CVCL_9K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130765 CVCL_9K33 DD2563 transformed cell line human CVCL_9K33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130766 CVCL_9K32 DD2558 transformed cell line human CVCL_9K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130767 CVCL_9K35 DD2565 transformed cell line human CVCL_9K35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130768 CVCL_9K34 DD2564 transformed cell line human CVCL_9K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130769 CVCL_9K31 DD2553 finite cell line human CVCL_9K31 CL:0000010 Karyotypic information: 46,XY,der(2),ins(2;6) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130770 CVCL_9K30 DD2552 finite cell line human CVCL_9K30 CL:0000010 Karyotypic information: 46,XY,der(2),ins(2;6) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21130771 CVCL_9K37 DD2569 transformed cell line human CVCL_9K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130772 CVCL_9K36 DD2566 finite cell line human CVCL_9K36 CL:0000010 Karyotypic information: 46,XX,der(4),t(4;9) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130773 CVCL_9K39 DD2574 transformed cell line human CVCL_9K39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130774 CVCL_9K38 DD2570 transformed cell line human CVCL_9K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130775 CVCL_0Q96 AG10801 transformed cell line human CVCL_0Q96 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Ser (c.1822G>A); ClinVar=VCV000014501; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130776 CVCL_1296 HuH-6 Clone 5 cancer cell line human CVCL_1296 Genome ancestry: African=1.77%; Native American=1.36%; East Asian, North=76.85%; East Asian, South=16.52%; South Asian=0%; European, North=0%; European, South=3.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (PubMed=31378681; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 25.57 hours (PubMed=31378681); 35 hours (lot 05262008), 38-55 hours (lot 12142012), ~37 hours (lot 07222016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE) 21130777 CVCL_0Q95 AG10677 finite cell line human CVCL_0Q95 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu145Lys (c.433G>A); ClinVar=VCV000014502; Zygosity=Heterozygous (PubMed=12714972) Population: Caucasian; English/Irish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21130778 CVCL_1295 HTC-C3 cancer cell line human CVCL_1295 Genome ancestry: African=0.77%; Native American=0.3%; East Asian, North=74.17%; East Asian, South=22.11%; South Asian=0.65%; European, North=0.12%; European, South=1.88% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Homozygous (PubMed=1516062; PubMed=30737244; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0042; true Female Doubling time: ~100 hours (DSMZ=ACC-580); ~2 days (lot 04162002) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130779 CVCL_0Q98 AG11572 finite cell line human CVCL_0Q98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130780 CVCL_1298 HuO9 cancer cell line human CVCL_1298 HLA typing: A*24:01,33:03; B*44:03:01,51:01; C*14:02,14:03 (PubMed=15289353); Genome ancestry: African=2.89%; Native American=0%; East Asian, North=77.77%; East Asian, South=13.74%; South Asian=0%; European, North=1.78%; European, South=3.83% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9359923) Population: Japanese; Derived from sampling site: Bone; right distal femur. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Established from a xenograft established in athymic nude mice after five passages Doubling time: 57 hours (PubMed=2170070); 43.3 hours (PubMed=14669798); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130781 CVCL_0Q97 AG11513 finite cell line human CVCL_0Q97 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell; PubMed=12714972) Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21130782 CVCL_1297 HuO-3N1 cancer cell line human CVCL_1297 Genome ancestry: African=1.58%; Native American=0%; East Asian, North=72.02%; East Asian, South=23.28%; South Asian=1.73%; European, North=1.15%; European, South=0.24% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala76fs*73 (c.225_226insT); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Established from a xenograft established in a nude mice Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130783 CVCL_0Q99 AG13207 finite cell line human CVCL_0Q99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130784 CVCL_1299 HuP-T3 cancer cell line human CVCL_1299 HLA typing: A*02:07,24:02; B*40:06,40:06; C*01:02,08:01 (PubMed=26589293); Genome ancestry: African=0.94%; Native American=0%; East Asian, North=78.19%; East Asian, South=19.92%; South Asian=0%; European, North=0%; European, South=0.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40-50 hours (DSMZ=ACC-259); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130785 CVCL_9K44 DD2606 finite cell line human CVCL_9K44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21130786 CVCL_9K43 DD2592 transformed cell line human CVCL_9K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21130787 CVCL_9K46 DD2628 transformed cell line human CVCL_9K46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130788 CVCL_9K45 DD2620 finite cell line human CVCL_9K45 CL:0000010 Karyotypic information: 46,XY,t(5;19)(p10;q10)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21130789 CVCL_9K40 DD2587 transformed cell line human CVCL_9K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130790 CVCL_9K42 DD2591 transformed cell line human CVCL_9K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130791 CVCL_9K41 DD2589 transformed cell line human CVCL_9K41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130792 CVCL_9K48 DD2635 transformed cell line human CVCL_9K48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130793 CVCL_9K47 DD2634 transformed cell line human CVCL_9K47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130794 CVCL_9K49 DD2642 transformed cell line human CVCL_9K49 CL:0000010 Karyotypic information: 46,XX,der(4),t(4;12)(p16.2;q24.11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130795 CVCL_9K11 DD2468 transformed cell line human CVCL_9K11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130796 CVCL_9K10 DD2464 transformed cell line human CVCL_9K10 CL:0000010 Karyotypic information: 46,X,del(X)(qter->p21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130797 CVCL_9K13 DD2482 transformed cell line human CVCL_9K13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130798 CVCL_9K12 DD2470 transformed cell line human CVCL_9K12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130799 CVCL_9K19 DD2510 transformed cell line human CVCL_9K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130800 CVCL_9K18 DD2496 transformed cell line human CVCL_9K18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130801 CVCL_9K15 DD2486 transformed cell line human CVCL_9K15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130802 CVCL_1281 HLE cancer cell line human CVCL_1281 Genome ancestry: African=1.86%; Native American=0%; East Asian, North=85.81%; East Asian, South=8.43%; South Asian=0%; European, North=0%; European, South=3.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (PubMed=31378681; DepMap) Population: Japanese; Derived from sampling site: Liver Cell type=Epithelial cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=52570); 21.82 hours (PubMed=31378681); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project Caution: TP53 mutation indicated incorrectly as being at c.747G>T in PubMed=8389256 21130803 CVCL_0Q81 S2R+-NPT050 spontaneously immortalized cell line fruit fly CVCL_0Q81 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Group: Insect cell line 21130804 CVCL_9K14 DD2485 transformed cell line human CVCL_9K14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130805 CVCL_1280 HH [Human lymphoma] cancer cell line human CVCL_1280 HLA typing: A*01:01,01:01; B*08:01,37:01; C*06:02,07:01 (PubMed=26589293); HLA typing: A*01:01:01,01:01:01; B*08:01:01,37:01:01; C*06:02:01,07:01:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-707); Genome ancestry: African=2.42%; Native American=0%; East Asian, North=3.69%; East Asian, South=0%; South Asian=0%; European, North=61.06%; European, South=32.82% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6036; FOXK2 + HGNC; 15979; TP63; Name(s)=FOXK2-TP63 (PubMed=31160637); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~50-70 hours (DSMZ=ACC-707); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21130806 CVCL_0Q80 S2R+-NPT017 spontaneously immortalized cell line fruit fly CVCL_0Q80 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Group: Insect cell line 21130807 CVCL_9K17 DD2490 finite cell line human CVCL_9K17 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ECACC) Karyotypic information: 46,XX,inv(3)(q21::q25) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130808 CVCL_0Q83 GM04326 finite cell line human CVCL_0Q83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21130809 CVCL_1283 HN cancer cell line human CVCL_1283 HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02 (PubMed=26589293); Genome ancestry: African=0.89%; Native American=0%; East Asian, North=79.15%; East Asian, South=18.39%; South Asian=0%; European, North=0%; European, South=1.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=17390010); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly279Glu (c.836G>A); ClinVar=VCV000419454; Zygosity=Unspecified (PubMed=17390010) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (DSMZ=ACC-417); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130810 CVCL_9K16 DD2489 transformed cell line human CVCL_9K16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130811 CVCL_1282 HMV-II cancer cell line human CVCL_1282 Genome ancestry: African=0.4%; Native American=0%; East Asian, North=76.31%; East Asian, South=21.9%; South Asian=0.25%; European, North=0.78%; European, South=0.36% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; PubMed=15467732; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn268Ile (c.803A>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Pigmented Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130812 CVCL_0Q82 S2R+-NPT101 spontaneously immortalized cell line fruit fly CVCL_0Q82 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Group: Insect cell line 21130813 CVCL_0Q74 49Z transformed cell line human CVCL_0Q74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female Doubling time: 34 hours (PubMed=11696444) 21130814 CVCL_1274 HEC-1 cancer cell line human CVCL_1274 Genome ancestry: African=0%; Native American=0%; East Asian, North=89.14%; East Asian, South=10.41%; South Asian=0.45%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21130815 CVCL_0Q73 12Z transformed cell line human CVCL_0Q73 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female Doubling time: 31 hours (PubMed=11696444) 21130816 CVCL_1273 HD-MY-Z cancer cell line human CVCL_1273 Genome ancestry: African=0.65%; Native American=0%; East Asian, North=4.15%; East Asian, South=0%; South Asian=0%; European, North=66.43%; European, South=28.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Valfs*2 (c.696_706del11); Zygosity=Heterozygous (Cosmic-CLP) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~35 hours (DSMZ=ACC-346); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be an acute myeloid leukemia cell line (PubMed=29533902). 21130817 CVCL_0Q76 FbEM-1 spontaneously immortalized cell line human CVCL_0Q76 CL:0000010 Derived from sampling site: Endometrium. Female Doubling time: ~38 hours (PubMed=9286736) 21130818 CVCL_1276 HeLa 229 cancer cell line human CVCL_1276 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 11 hours (lot 032792), ~26 hours (lot 03152010) (JCRB) 21130819 CVCL_1275 D425 Med cancer cell line human CVCL_1275 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Cys (c.820_821GT>TG); Zygosity=Unspecified (PubMed=22343310; DepMap) Derived from sampling site: Brain; posterior fossa. Omics: Deep exome analysis Male Doubling time: 2.58 days (PubMed=1904513) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21130820 CVCL_0Q75 EEC145T transformed cell line human CVCL_0Q75 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female 21130821 CVCL_0Q78 DeltaWTNdeMYC spontaneously immortalized cell line fruit fly CVCL_0Q78 CL:0000010 Breed/subspecies: Oregon-R. Male Doubling time: 52 hours (DGRC) Group: Insect cell line 21130822 CVCL_1278 HeLaSF cancer cell line human CVCL_1278 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CCL-2.3; true Female Group: Serum/protein free medium cell line 21130823 CVCL_1277 HeLa NR1 cancer cell line human CVCL_1277 CL:0000010 Transfected with: UniProtKB; P27967; Barley nitrate reductase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12510 21130824 CVCL_0Q77 IPC-366 cancer cell line dog CVCL_0Q77 CL:0000010 Female Characteristics: Triple negative (ER-, PR-, ERBB2-) inflammatory mammary carcinoma cell line Doubling time: ~24 hours (PubMed=25807360). 21130825 CVCL_1279 HGC-27 cancer cell line human CVCL_1279 HLA typing: A*24:02:24:02; B*55:02,55:02; C*03:03,03:03 (PubMed=26589293); HLA typing: A*24:02:01; B*55:02:01; C*03:03:01; DPB1*05:01:01; DQA1*01:01:01; DQB1*05:01:01; DRB1*01:01:01 (CLS=300436); Genome ancestry: African=0%; Native American=0%; East Asian, North=77.61%; East Asian, South=21.46%; South Asian=0.22%; European, North=0%; European, South=0.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly2316fs*9 (c.6947delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: ~17 hours, at 21th passage (PubMed=136873); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel 21130826 CVCL_0Q79 S2R+-NPT005 spontaneously immortalized cell line fruit fly CVCL_0Q79 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: Oregon-R. Male Group: Insect cell line 21130827 CVCL_9K22 DD2521 transformed cell line human CVCL_9K22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130828 CVCL_9K21 DD2520 transformed cell line human CVCL_9K21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130829 CVCL_9K24 DD2530 transformed cell line human CVCL_9K24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130830 CVCL_9K23 DD2524 transformed cell line human CVCL_9K23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130831 CVCL_9K20 DD2513 transformed cell line human CVCL_9K20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130832 CVCL_9K29 DD2550 transformed cell line human CVCL_9K29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130833 CVCL_0Q90 AG10578 finite cell line human CVCL_0Q90 CL:0000010 Population: Caucasian; Dutch/South African; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21130834 CVCL_1290 HT cancer cell line human CVCL_1290 HLA typing: A*24:02,24:02; B*07:02,55:01; C*03:03,07:02 (PubMed=26589293); Genome ancestry: African=0.33%; Native American=0%; East Asian, North=0%; East Asian, South=0.35%; South Asian=0.95%; European, North=67.93%; European, South=30.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (Cosmic-CLP) Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~30-40 hours (DSMZ=ACC-567); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21130835 CVCL_0Q92 AG10583 transformed cell line human CVCL_0Q92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130836 CVCL_9K26 DD2540 transformed cell line human CVCL_9K26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130837 CVCL_1292 HT-1376 cancer cell line human CVCL_1292 HLA typing: A*24:02,24:02; B*15:01,15:01; C*03:03,03:03; DQA1*01:02,03:02; DQB1*06:03,06:03; DRB1*13:27,14:121 (PubMed=26589293); Genome ancestry: African=1.48%; Native American=1.4%; East Asian, North=1.78%; East Asian, South=1.08%; South Asian=9.04%; European, North=26.62%; European, South=58.6% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln702Ter (c.2104C>T); ClinVar=VCV000428683; Zygosity=Homozygous (PubMed=27270441); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Unspecified (PubMed=7787250; PubMed=9850064) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7927; true Female Doubling time: 31 hours (PubMed=3708594); 31 hours (PubMed=26055179); ~60 hours (DSMZ=ACC-397); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: UBC-40 urothelial bladder cancer cell line index 21130838 CVCL_0Q91 AG10579 transformed cell line human CVCL_0Q91 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130839 CVCL_9K25 DD2539 transformed cell line human CVCL_9K25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130840 CVCL_1291 HT-1197 cancer cell line human CVCL_1291 Genome ancestry: African=0%; Native American=0.12%; East Asian, North=1.86%; East Asian, South=0%; South Asian=0%; European, North=66.24%; European, South=31.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His365Arg (c.1094A>G); Zygosity=Unspecified (PubMed=7787250); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7926; true Male Doubling time: 61 hours (PubMed=3708594); 46 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: UBC-40 urothelial bladder cancer cell line index 21130841 CVCL_0Q94 AG10588 transformed cell line human CVCL_0Q94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130842 CVCL_9K28 DD2545 transformed cell line human CVCL_9K28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130843 CVCL_1294 HT-55 cancer cell line human CVCL_1294 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=1.79%; Native American=0%; East Asian, North=2.4%; East Asian, South=0%; South Asian=0%; European, North=61.97%; European, South=33.83% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1131Ter (c.3391C>T); ClinVar=VCV000236590; Zygosity=Heterozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1303Ter (c.3907C>T); ClinVar=VCV001076263; Zygosity=Heterozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1463Ser (c.4389A>T); Zygosity=Heterozygous (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asn581Tyr (c.1741A>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Lys241Ter (c.721A>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Leu (c.638G>T); ClinVar=VCV000376650; Zygosity=Homozygous (PubMed=16418264; PubMed=24755471; DepMap) Population: Caucasian; Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 28 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21130844 CVCL_0Q93 AG10585 transformed cell line human CVCL_0Q93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130845 CVCL_9K27 DD2544 transformed cell line human CVCL_9K27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130846 CVCL_1293 HT-3 cancer cell line human CVCL_1293 HLA typing: A*03,28; B*8,05/w35; C*w02,w03 (PubMed=77569); Genome ancestry: African=2.04%; Native American=0%; East Asian, North=3.34%; East Asian, South=0%; South Asian=1.53%; European, North=55.35%; European, South=37.73% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Unspecified (PubMed=1648218) Transformant: Human papillomavirus type 30 (HPV30)(NCBI-Taxonomy; 10611); Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.48 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 784-01 Caution: Indicated as originating from a 58 year old female patient in ATCC and from a 53 year old in Sloan Kettering tech transfer site 21130847 CVCL_0Q85 GM10396 finite cell line human CVCL_0Q85 CL:0000010 Population: Indian; Derived from sampling site: Cell type=Fibroblast. Male 21130848 CVCL_1285 HOP-62 cancer cell line human CVCL_1285 HLA typing: A*03:01:01; B*07,44; C*05,07:02:01; DPB1*04:02; DQB1*06,06; DRB1*13,15 (PubMed=15748285); HLA typing: A*03:01,11:01; B*40:01,56:01; C*01:02,03:04 (PubMed=26589293); Genome ancestry: African=0.83%; Native American=0.13%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0.11%; European, North=63.51%; European, South=33.3% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30.3 hours (PubMed=29681454); 39 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21130849 CVCL_0Q84 GM08108 finite cell line human CVCL_0Q84 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21130850 CVCL_1284 HO-1-N-1 cancer cell line human CVCL_1284 Genome ancestry: African=0%; Native American=0%; East Asian, North=77.94%; East Asian, South=20.55%; South Asian=0.47%; European, North=1.04%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~31 hours (lot 08212015) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130851 CVCL_0Q87 GM11428 transformed cell line human CVCL_0Q87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21130852 CVCL_1287 HSC-2 cancer cell line human CVCL_1287 HLA typing: A*24:02,33:02; B*44:03:01,54:01; C*01:02,14:03 (PubMed=9023415); HLA typing: A*24:02,33:03; B*08:01,54:01; C*01:02,14:03 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0%; East Asian, North=83.8%; East Asian, South=14.71%; South Asian=1.36%; European, North=0%; European, South=0.07% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=18097548); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=1570156) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~38 hours (lot 012999), 27 hours (lot 07152004), 34 hours (lot 02172009), ~32 hours (lot 08082012), ~30 hours (lot 06192015), ~18 hours (lot 06192017), ~26 hours (lot 02082021) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130853 CVCL_0Q86 GM10394 finite cell line human CVCL_0Q86 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(3)(qter->p25::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21130854 CVCL_1286 HOP-92 cancer cell line human CVCL_1286 HLA typing: A*03,24; B*27,47:01:01; C*01,06; DPB1*04:01,04:02; DQB1*05:01:01,06:02; DRB1*01,15:01_01 (PubMed=15748285); HLA typing: A*03:01,24:02; B*27:05,47:01; C*01:02,06:02 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0%; East Asian, North=1.34%; East Asian, South=0%; South Asian=0%; European, North=74.13%; European, South=24.16% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 62.3 hours (PubMed=22628656); 79.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21130855 CVCL_0Q89 AG07493 finite cell line human CVCL_0Q89 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21130856 CVCL_1289 HSC-4 cancer cell line human CVCL_1289 HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02 (PubMed=9023415); HLA typing: A*24:02,31:01; B*07:02,51:01; C*07:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=84.74%; East Asian, South=13.79%; South Asian=1.33%; European, North=0%; European, South=0.12% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=18097548; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1570156; PubMed=10741724) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~25 hours (lots 04012002 and 06292012), ~21 hours (lot 03202018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130857 CVCL_0Q88 AG10587 transformed cell line human CVCL_0Q88 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130858 CVCL_1288 HSC-3 cancer cell line human CVCL_1288 HLA typing: A*02:01,24:02; B*48:01,52:01; C*08:03,12:02 (PubMed=9023415); Genome ancestry: African=0.32%; Native American=0%; East Asian, North=85.88%; East Asian, South=12.09%; South Asian=0%; European, North=0%; European, South=1.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (PubMed=18097548); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (PubMed=1570156; PubMed=10741724; DepMap) Miscellaneous: STR profile from personal communication of Sano D Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20.28 hours (PubMed=21362583); 20 hours (PubMed=24627082); ~60 hours (lot 121498), ~44 hours (lot 07242009), ~52 hours (lot 02022015), 42-65 hours (lot 07112016), ~37 hours (lot 06112018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21130859 CVCL_BD71 ND10264 transformed cell line human CVCL_BD71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130860 CVCL_BD70 ND10261 transformed cell line human CVCL_BD70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130861 CVCL_BD69 ND10258 transformed cell line human CVCL_BD69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130862 CVCL_BD62 ND10246 transformed cell line human CVCL_BD62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130863 CVCL_BD61 ND10245 transformed cell line human CVCL_BD61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130864 CVCL_BD64 ND10248 transformed cell line human CVCL_BD64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130865 CVCL_BD63 ND10247 transformed cell line human CVCL_BD63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130866 CVCL_BD66 ND10254 transformed cell line human CVCL_BD66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130867 CVCL_BD65 ND10252 transformed cell line human CVCL_BD65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130868 CVCL_BD68 ND10257 transformed cell line human CVCL_BD68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130869 CVCL_BD67 ND10255 transformed cell line human CVCL_BD67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130870 CVCL_BD80 ND10296 transformed cell line human CVCL_BD80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130871 CVCL_BD82 ND10312 transformed cell line human CVCL_BD82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130872 CVCL_BD81 ND10302 transformed cell line human CVCL_BD81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130873 CVCL_BD73 ND10281 transformed cell line human CVCL_BD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130874 CVCL_BD72 ND10270 transformed cell line human CVCL_BD72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130875 CVCL_BD75 ND10283 transformed cell line human CVCL_BD75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130876 CVCL_BD74 ND10282 transformed cell line human CVCL_BD74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130877 CVCL_BD77 ND10292 transformed cell line human CVCL_BD77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130878 CVCL_BD76 ND10284 transformed cell line human CVCL_BD76 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130879 CVCL_BD79 ND10295 transformed cell line human CVCL_BD79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130880 CVCL_BD78 ND10294 transformed cell line human CVCL_BD78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130881 CVCL_BD48 ND10206 transformed cell line human CVCL_BD48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130882 CVCL_BD47 ND10205 transformed cell line human CVCL_BD47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130883 CVCL_BD49 ND10207 transformed cell line human CVCL_BD49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130884 CVCL_BD40 ND10146 transformed cell line human CVCL_BD40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130885 CVCL_BD42 ND10157 transformed cell line human CVCL_BD42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130886 CVCL_BD41 ND10155 transformed cell line human CVCL_BD41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130887 CVCL_BD44 ND10179 transformed cell line human CVCL_BD44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130888 CVCL_BD43 ND10161 transformed cell line human CVCL_BD43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130889 CVCL_BD46 ND10182 transformed cell line human CVCL_BD46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130890 CVCL_BD45 ND10181 transformed cell line human CVCL_BD45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130891 CVCL_BD60 ND10244 transformed cell line human CVCL_BD60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130892 CVCL_BD59 ND10236 transformed cell line human CVCL_BD59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130893 CVCL_BD58 ND10235 transformed cell line human CVCL_BD58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130894 CVCL_BD51 ND10209 transformed cell line human CVCL_BD51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130895 CVCL_BD50 ND10208 transformed cell line human CVCL_BD50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130896 CVCL_BD53 ND10221 transformed cell line human CVCL_BD53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130897 CVCL_BD52 ND10220 transformed cell line human CVCL_BD52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130898 CVCL_BD55 ND10224 transformed cell line human CVCL_BD55 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130899 CVCL_BD54 ND10223 transformed cell line human CVCL_BD54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130900 CVCL_BD57 ND10230 transformed cell line human CVCL_BD57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130901 CVCL_BD56 ND10226 transformed cell line human CVCL_BD56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130902 CVCL_9J99 DD2413 transformed cell line human CVCL_9J99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130903 CVCL_9J96 DD2405 transformed cell line human CVCL_9J96 CL:0000010 Karyotypic information: 46,XY,add(10)(q26) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130904 CVCL_9J95 DD2393 finite cell line human CVCL_9J95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21130905 CVCL_9J98 DD2411 transformed cell line human CVCL_9J98 CL:0000010 Karyotypic information: 46,XX,+psu dic(15) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130906 CVCL_9J97 DD2410 transformed cell line human CVCL_9J97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130907 CVCL_BD26 ND10105 transformed cell line human CVCL_BD26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130908 CVCL_BD25 ND10104 transformed cell line human CVCL_BD25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130909 CVCL_BD28 ND10117 transformed cell line human CVCL_BD28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130910 CVCL_BD27 ND10106 transformed cell line human CVCL_BD27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130911 CVCL_BD29 ND10118 transformed cell line human CVCL_BD29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130912 CVCL_9J92 DD2370 transformed cell line human CVCL_9J92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130913 CVCL_9J91 DD2363 transformed cell line human CVCL_9J91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130914 CVCL_9J94 DD2391 transformed cell line human CVCL_9J94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130915 CVCL_BD20 ND10095 transformed cell line human CVCL_BD20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130916 CVCL_9J93 DD2389 finite cell line human CVCL_9J93 CL:0000010 Karyotypic information: 46,XX,del(5)(p15.2) de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130917 CVCL_BD22 ND10098 transformed cell line human CVCL_BD22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130918 CVCL_BD21 ND10096 transformed cell line human CVCL_BD21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130919 CVCL_9J90 DD2361 transformed cell line human CVCL_9J90 CL:0000010 Karyotypic information: 46,X; 46,X,r(X) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130920 CVCL_BD24 ND10103 transformed cell line human CVCL_BD24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130921 CVCL_BD23 ND10101 transformed cell line human CVCL_BD23 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130922 CVCL_BD37 ND10143 transformed cell line human CVCL_BD37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130923 CVCL_BD36 ND10142 transformed cell line human CVCL_BD36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130924 CVCL_BD39 ND10145 transformed cell line human CVCL_BD39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130925 CVCL_BD38 ND10144 transformed cell line human CVCL_BD38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130926 CVCL_BD31 ND10122 transformed cell line human CVCL_BD31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130927 CVCL_BD30 ND10121 transformed cell line human CVCL_BD30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130928 CVCL_BD33 ND10124 transformed cell line human CVCL_BD33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130929 CVCL_BD32 ND10123 transformed cell line human CVCL_BD32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130930 CVCL_BD35 ND10141 transformed cell line human CVCL_BD35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130931 CVCL_BD34 ND10125 transformed cell line human CVCL_BD34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130932 CVCL_9J78 DD2344 transformed cell line human CVCL_9J78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130933 CVCL_9J77 DD2342 transformed cell line human CVCL_9J77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130934 CVCL_9J79 DD2345 transformed cell line human CVCL_9J79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130935 CVCL_9J74 DD2338 transformed cell line human CVCL_9J74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130936 CVCL_9J73 DD2337 transformed cell line human CVCL_9J73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130937 CVCL_9J76 DD2340 transformed cell line human CVCL_9J76 CL:0000010 Karyotypic information: 47,XY,+psu dic(15)(pter->q12::q12->pter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21130938 CVCL_9J75 DD2339 transformed cell line human CVCL_9J75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130939 CVCL_BD04 ND10016 transformed cell line human CVCL_BD04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130940 CVCL_BD03 ND10014 transformed cell line human CVCL_BD03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130941 CVCL_BD06 ND10023 transformed cell line human CVCL_BD06 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130942 CVCL_BD05 ND10022 transformed cell line human CVCL_BD05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130943 CVCL_BD08 ND10036 transformed cell line human CVCL_BD08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130944 CVCL_BD07 ND10035 transformed cell line human CVCL_BD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130945 CVCL_BD09 ND10041 transformed cell line human CVCL_BD09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130946 CVCL_9J70 DD2332 transformed cell line human CVCL_9J70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130947 CVCL_9J72 DD2335 transformed cell line human CVCL_9J72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130948 CVCL_9J71 DD2333 transformed cell line human CVCL_9J71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130949 CVCL_BD00 ND10002 transformed cell line human CVCL_BD00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130950 CVCL_BD02 ND10011 transformed cell line human CVCL_BD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130951 CVCL_BD01 ND10003 transformed cell line human CVCL_BD01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130952 CVCL_9J89 DD2360 finite cell line human CVCL_9J89 CL:0000010 Karyotypic information: 46,XX,var(6)cen (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21130953 CVCL_9J88 DD2358 transformed cell line human CVCL_9J88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130954 CVCL_9J85 DD2352 transformed cell line human CVCL_9J85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130955 CVCL_9J84 DD2351 finite cell line human CVCL_9J84 CL:0000010 Karyotypic information: 46,XX; 47,XX,+10 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21130956 CVCL_9J87 DD2356 transformed cell line human CVCL_9J87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130957 CVCL_9J86 DD2353 transformed cell line human CVCL_9J86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130958 CVCL_BD15 ND10076 transformed cell line human CVCL_BD15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130959 CVCL_BD14 ND10069 transformed cell line human CVCL_BD14 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg662Cys (c.1984C>T) (c.2373C>T); ClinVar=VCV000572697; Zygosity=Heterozygous (PubMed=22572540) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130960 CVCL_BD17 ND10080 transformed cell line human CVCL_BD17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130961 CVCL_BD16 ND10078 transformed cell line human CVCL_BD16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130962 CVCL_BD19 ND10094 transformed cell line human CVCL_BD19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130963 CVCL_BD18 ND10081 transformed cell line human CVCL_BD18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130964 CVCL_9J81 DD2348 transformed cell line human CVCL_9J81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130965 CVCL_9J80 DD2347 transformed cell line human CVCL_9J80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130966 CVCL_9J83 DD2350 transformed cell line human CVCL_9J83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130967 CVCL_9J82 DD2349 transformed cell line human CVCL_9J82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21130968 CVCL_BD11 ND10059 transformed cell line human CVCL_BD11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130969 CVCL_BD10 ND10042 transformed cell line human CVCL_BD10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130970 CVCL_BD13 ND10068 transformed cell line human CVCL_BD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130971 CVCL_BD12 ND10067 transformed cell line human CVCL_BD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130972 CVCL_T820 GM04078 finite cell line human CVCL_T820 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[341]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[480]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Caution: Indicated by Coriell to have 420 and 541 GAA repeats 21130973 CVCL_SW20 HAP1 MAD2L1 (-) 1 cancer cell line human CVCL_SW20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6763; MAD2L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130974 CVCL_T822 GM23937 induced pluripotent stem cell human CVCL_T822 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130975 CVCL_SW22 HAP1 MADD (-) 2 cancer cell line human CVCL_SW22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6766; MADD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130976 CVCL_T821 GM04079 transformed cell line human CVCL_T821 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[341]; ClinVar=VCV000561195; Zygosity=Heterozygous (from autologous cell line GM04078); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[480]; ClinVar=VCV000561195; Zygosity=Heterozygous (from autologous cell line GM04078) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Indicated by Coriell to have 420 and 541 GAA repeats 21130977 CVCL_SW21 HAP1 MADD (-) 1 cancer cell line human CVCL_SW21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6766; MADD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130978 CVCL_T824 GM11853 finite cell line human CVCL_T824 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21130979 CVCL_SW24 HAP1 MAK (-) 2 cancer cell line human CVCL_SW24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6816; MAK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130980 CVCL_T823 GM11852 transformed cell line human CVCL_T823 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21130981 CVCL_SW23 HAP1 MAK (-) 1 cancer cell line human CVCL_SW23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6816; MAK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130982 CVCL_T826 GM24474 induced pluripotent stem cell human CVCL_T826 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21130983 CVCL_SW26 HAP1 MAML2 (-) 2 cancer cell line human CVCL_SW26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16259; MAML2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130984 CVCL_T825 GM24468 induced pluripotent stem cell human CVCL_T825 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Problematic cell line: Misclassified Parent cell line originally thought to be a SMA type 1 (SMA1) cell line but shown to be from a SMA type 2 (SMA2). 21130985 CVCL_SW25 HAP1 MAML2 (-) 1 cancer cell line human CVCL_SW25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16259; MAML2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130986 CVCL_SW28 HAP1 MAOA (-) 2 cancer cell line human CVCL_SW28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6833; MAOA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130987 CVCL_T828 iOTC4 induced pluripotent stem cell human CVCL_T828 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130988 CVCL_SW27 HAP1 MAOA (-) 1 cancer cell line human CVCL_SW27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6833; MAOA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130989 CVCL_T827 iCK2 induced pluripotent stem cell human CVCL_T827 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21130990 CVCL_SW29 HAP1 MAP1A (-) 1 cancer cell line human CVCL_SW29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6835; MAP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130991 CVCL_T829 HiPS-RIKEN-7A induced pluripotent stem cell human CVCL_T829 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130992 CVCL_T811 GM01487 transformed cell line human CVCL_T811 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130993 CVCL_SW11 HAP1 LYPLA1 (-) 2 cancer cell line human CVCL_SW11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6737; LYPLA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130994 CVCL_T810 GM02497 finite cell line human CVCL_T810 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21130995 CVCL_SW10 HAP1 LYPLA1 (-) 1 cancer cell line human CVCL_SW10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6737; LYPLA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130996 CVCL_T813 GM01490 transformed cell line human CVCL_T813 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21130997 CVCL_SW13 HAP1 LYPLA2 (-) 2 cancer cell line human CVCL_SW13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6738; LYPLA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21130998 CVCL_T812 GM01489 transformed cell line human CVCL_T812 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21130999 CVCL_SW12 HAP1 LYPLA2 (-) 1 cancer cell line human CVCL_SW12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6738; LYPLA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131000 CVCL_T815 GM23396 induced pluripotent stem cell human CVCL_T815 CL:0000010 Population: African American; Karyotypic information: 46,XX [23]; 47,XXX [2] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131001 CVCL_SW15 HAP1 LYPLAL1 (-) 2 cancer cell line human CVCL_SW15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20440; LYPLAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131002 CVCL_T814 GM02503 finite cell line human CVCL_T814 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131003 CVCL_SW14 HAP1 LYPLAL1 (-) 1 cancer cell line human CVCL_SW14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20440; LYPLAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131004 CVCL_T817 GM23446 induced pluripotent stem cell human CVCL_T817 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131005 CVCL_SW17 HAP1 LYRM2 (-) 1 cancer cell line human CVCL_SW17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25229; LYRM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131006 CVCL_T816 GM23411 induced pluripotent stem cell human CVCL_T816 CL:0000010 Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131007 CVCL_SW16 HAP1 LYPLAL1 (-) 3 cancer cell line human CVCL_SW16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20440; LYPLAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131008 CVCL_T819 GM23913 induced pluripotent stem cell human CVCL_T819 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[341]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[480]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Caution: Indicated by Coriell to have 420 and 541 GAA repeats 21131009 CVCL_SW19 HAP1 M6PR (-) 2 cancer cell line human CVCL_SW19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6752; M6PR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131010 CVCL_T818 GM23720 induced pluripotent stem cell human CVCL_T818 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131011 CVCL_SW18 HAP1 M6PR (-) 1 cancer cell line human CVCL_SW18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6752; M6PR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131012 CVCL_SW00 HAP1 LRRK1 (-) 1 cancer cell line human CVCL_SW00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18608; LRRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131013 CVCL_T800 iTS2 induced pluripotent stem cell human CVCL_T800 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131014 CVCL_T802 GM23450 induced pluripotent stem cell human CVCL_T802 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131015 CVCL_SW02 HAP1 LRRK1 (-) 3 cancer cell line human CVCL_SW02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18608; LRRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131016 CVCL_SW01 HAP1 LRRK1 (-) 2 cancer cell line human CVCL_SW01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18608; LRRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131017 CVCL_T801 iTS3 induced pluripotent stem cell human CVCL_T801 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; HPS0151; probable Female 21131018 CVCL_T804 GM23760 induced pluripotent stem cell human CVCL_T804 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131019 CVCL_SW04 HAP1 LRRK2 (-) 2 cancer cell line human CVCL_SW04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131020 CVCL_T803 GM23716 induced pluripotent stem cell human CVCL_T803 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131021 CVCL_SW03 HAP1 LRRK2 (-) 1 cancer cell line human CVCL_SW03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131022 CVCL_T806 GM01793 transformed cell line human CVCL_T806 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131023 CVCL_SW06 HAP1 LRSAM1 (-) 2 cancer cell line human CVCL_SW06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25135; LRSAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131024 CVCL_T805 GM01792 finite cell line human CVCL_T805 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131025 CVCL_SW05 HAP1 LRSAM1 (-) 1 cancer cell line human CVCL_SW05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25135; LRSAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131026 CVCL_T808 GM23762 induced pluripotent stem cell human CVCL_T808 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131027 CVCL_SW08 HAP1 LTK (-) 2 cancer cell line human CVCL_SW08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6721; LTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131028 CVCL_T807 GM23761 induced pluripotent stem cell human CVCL_T807 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21131029 CVCL_SW07 HAP1 LTK (-) 1 cancer cell line human CVCL_SW07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6721; LTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131030 CVCL_T809 GM01488 transformed cell line human CVCL_T809 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131031 CVCL_SW09 HAP1 LYN (-) cancer cell line human CVCL_SW09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6735; LYN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131032 CVCL_BD91 ND10346 transformed cell line human CVCL_BD91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131033 CVCL_BD90 ND10335 transformed cell line human CVCL_BD90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131034 CVCL_BD93 ND10356 transformed cell line human CVCL_BD93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131035 CVCL_BD92 ND10347 transformed cell line human CVCL_BD92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131036 CVCL_BD84 ND10314 transformed cell line human CVCL_BD84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131037 CVCL_BD83 ND10313 transformed cell line human CVCL_BD83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131038 CVCL_BD86 ND10326 transformed cell line human CVCL_BD86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131039 CVCL_BD85 ND10324 transformed cell line human CVCL_BD85 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131040 CVCL_BD88 ND10329 transformed cell line human CVCL_BD88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131041 CVCL_BD87 ND10328 transformed cell line human CVCL_BD87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131042 CVCL_BD89 ND10330 transformed cell line human CVCL_BD89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131043 CVCL_BD95 GM08882 transformed cell line human CVCL_BD95 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu101Gly (c.302A>G) (E100G); ClinVar=VCV000014761; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131044 CVCL_BD94 ND10357 transformed cell line human CVCL_BD94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131045 CVCL_BD97 ND10379 transformed cell line human CVCL_BD97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131046 CVCL_BD96 ND10377 transformed cell line human CVCL_BD96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131047 CVCL_BD99 ND10395 transformed cell line human CVCL_BD99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131048 CVCL_BD98 ND10394 transformed cell line human CVCL_BD98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131049 CVCL_9L10 DD2795 transformed cell line human CVCL_9L10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131050 CVCL_9L12 DD2800 transformed cell line human CVCL_9L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131051 CVCL_9L11 DD2799 finite cell line human CVCL_9L11 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131052 CVCL_9L18 DD2812 transformed cell line human CVCL_9L18 CL:0000010 Karyotypic information: 46,XX,dup(3)(q25.3;q26.2).ish dup(3),(wcp3+) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131053 CVCL_9L17 DD2806 transformed cell line human CVCL_9L17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131054 CVCL_9L19 DD2817 transformed cell line human CVCL_9L19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131055 CVCL_9L14 DD2802 transformed cell line human CVCL_9L14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131056 CVCL_0R80 GM17454 transformed cell line human CVCL_0R80 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131057 CVCL_1380 Loucy cancer cell line human CVCL_1380 Genome ancestry: African=0.63%; Native American=0.51%; East Asian, North=1.01%; East Asian, South=2.78%; South Asian=9.99%; European, North=26.95%; European, South=58.12% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8064; NUP214 + HGNC; 10760; SET; Name(s)=SET-NUP214 (PubMed=19166587); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Homozygous (PubMed=22675565; Cosmic-CLP) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K79me1 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36-48 hours (PubMed=2208060); ~60 hours (DSMZ=ACC-394); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3 21131058 CVCL_9L13 DD2801 transformed cell line human CVCL_9L13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131059 CVCL_9L16 DD2804 transformed cell line human CVCL_9L16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131060 CVCL_0R82 GM17457 transformed cell line human CVCL_0R82 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131061 CVCL_1382 LS1034 cancer cell line human CVCL_1382 HLA typing: A*02:01,26:01; B*08:01,27:05; C*02:02,07:06 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.06%; East Asian, North=0.24%; East Asian, South=1.27%; South Asian=0.11%; European, North=62.34%; European, South=34.98% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Aspfs*4 (c.3927_3931delAAAGA); ClinVar=VCV000000816; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Homozygous (PubMed=16969076; PubMed=20570890; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=9000147; PubMed=16418264; PubMed=28683746; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131062 CVCL_9L15 DD2803 transformed cell line human CVCL_9L15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131063 CVCL_0R81 GM17456 transformed cell line human CVCL_0R81 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131064 CVCL_1381 LOX-IMVI cancer cell line human CVCL_1381 HLA typing: A*11:01:01,29:02; B*07:02:01,44:03:01; C*07:02:01,16:01; DPB1*04:01,11:01:01; DQB1*02:02,06:02; DRB1*07:01,15:01:01 (PubMed=15748285); HLA typing: A*11:01,29:02; B*07:02,44:03; C*07:02,16:01 (PubMed=26589293); Genome ancestry: African=1.11%; Native American=0%; East Asian, North=2.55%; East Asian, South=0%; South Asian=0%; European, North=67.19%; European, South=29.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Derived from metastatic site: Axillary lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a subcutaneous xenograft in nude mice Doubling time: 25 hours (PubMed=7718330); 19.9 hours (PubMed=22628656); 20.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: NCI-60 cancer cell line panel 21131065 CVCL_0R73 GM17446 transformed cell line human CVCL_0R73 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131066 CVCL_1373 LC-2/ad cancer cell line human CVCL_1373 Genome ancestry: African=3.51%; Native American=0.63%; East Asian, North=76.2%; East Asian, South=13.98%; South Asian=0.14%; European, North=0.91%; European, South=4.65% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (PubMed=23578175); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 58 hours, at 32th passage (PubMed=8291444); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Indicated to have a EGFR p.Leu858Arg (c.2573T>G) mutation according to PubMed=16105816) but this is in contradiction of results of exome sequencing in CCLE and Cosmic-CLP 21131067 CVCL_0R72 GM17445 transformed cell line human CVCL_0R72 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131068 CVCL_1372 LC-1F cancer cell line human CVCL_1372 HLA typing: A*11:01,24:02; B*39:01,46:01; C*04:01,07:02; DQA1*01:02,05:02; DQB1*05:01,06:02; DRB1*11:30,15:01 (PubMed=26589293); Genome ancestry: African=6.24%; Native American=0%; East Asian, North=88.7%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=5.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Arg1475Ter (c.4423C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21131069 CVCL_0R75 GM17449 transformed cell line human CVCL_0R75 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131070 CVCL_1375 LCLC-103H cancer cell line human CVCL_1375 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.78%; Native American=0%; East Asian, North=3.13%; East Asian, South=0%; South Asian=0%; European, North=61.54%; European, South=33.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Leu (c.646G>T); ClinVar=VCV000376670; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=2840315); 26 hours (CLS); ~40 hours (DSMZ=ACC-384); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131071 CVCL_0R74 GM17448 transformed cell line human CVCL_0R74 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131072 CVCL_1374 LC4-1 cancer cell line human CVCL_1374 Genome ancestry: African=0%; Native American=0%; East Asian, North=75.57%; East Asian, South=23.72%; South Asian=0.71%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=35354797) Miscellaneous: STR profile from personal communication of Leo I.R. Population: Japanese Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131073 CVCL_0R77 GM17451 transformed cell line human CVCL_0R77 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131074 CVCL_1377 LK-2 cancer cell line human CVCL_1377 HLA typing: A*11:01,11:01; B*51:01,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0.42%; Native American=0%; East Asian, North=82.35%; East Asian, South=16.15%; South Asian=0%; European, North=0%; European, South=1.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Trp685Ter (c.2055G>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32 hours (PubMed=25984343); ~27 hours (lot 04162009), ~26 hours (lot 11142016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131075 CVCL_0R76 GM17450 transformed cell line human CVCL_0R76 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131076 CVCL_1376 LCLC-97TM1 cancer cell line human CVCL_1376 HLA typing: A*02:19,24:02; B*15:01,18:01; C*03:03,12:03 (PubMed=26589293); Genome ancestry: African=4.96%; Native American=0.5%; East Asian, North=5.82%; East Asian, South=0%; South Asian=0%; European, North=49.41%; European, South=39.32% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35Cysfs*9 (c.102delC); ClinVar=VCV001072141; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26 hours (PubMed=2840315); >50 hours (DSMZ=ACC-388); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21131077 CVCL_0R79 GM17453 transformed cell line human CVCL_0R79 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131078 CVCL_1379 LNCaP clone FGC cancer cell line human CVCL_1379 Genome ancestry: African=2.89%; Native American=0.31%; East Asian, North=0%; East Asian, South=2.4%; South Asian=8.61%; European, North=28.39%; European, South=57.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 43 hours (PubMed=15389782); ~34 hours (ATCC=CRL-1740); ~36 hours (PBCF); 38.71 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21131079 CVCL_0R78 GM17452 transformed cell line human CVCL_0R78 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131080 CVCL_1378 LN-405 cancer cell line human CVCL_1378 Genome ancestry: African=1.81%; Native American=0%; East Asian, North=1.39%; East Asian, South=0%; South Asian=3.12%; European, North=55.54%; European, South=38.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu62Arg (c.185T>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=10416987; Cosmic-CLP; DepMap) Derived from sampling site: Brain; left fronto-temporal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~60 hours (DSMZ=ACC-189); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131081 CVCL_9L21 DD2829 transformed cell line human CVCL_9L21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131082 CVCL_9L20 DD2822 transformed cell line human CVCL_9L20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131083 CVCL_9L23 DD2831 transformed cell line human CVCL_9L23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131084 CVCL_9L22 DD2830 transformed cell line human CVCL_9L22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131085 CVCL_9L29 DD2847 transformed cell line human CVCL_9L29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131086 CVCL_9L28 DD2845 transformed cell line human CVCL_9L28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131087 CVCL_9L25 DD2835 transformed cell line human CVCL_9L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131088 CVCL_0R91 GM17467 transformed cell line human CVCL_0R91 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131089 CVCL_1391 Lu-165 cancer cell line human CVCL_1391 Genome ancestry: African=0%; Native American=0.53%; East Asian, North=28.73%; East Asian, South=70.74%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly36Arg (c.106G>A); ClinVar=VCV001334551; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Profs*9 (c.468_480delCGTCCGCGCCATG); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Indonesian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces high level of vasopressin Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131090 CVCL_9L24 DD2833 transformed cell line human CVCL_9L24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131091 CVCL_0R90 GM17466 transformed cell line human CVCL_0R90 HLA typing: A*11:01:01,23:01:01; B*44:03:01,44:03:01; C*04:01:01,04:01:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,14:01:01; DQA1*02:01:01,02:01:01; DQB1*02:02:01,02:02:01; DRB1*07:01:01,07:01:01; DRB4*01:01:01,01:01:01 (PubMed=29959025) CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21131092 CVCL_1390 Lu-139 cancer cell line human CVCL_1390 Genome ancestry: African=1.34%; Native American=0%; East Asian, North=86.97%; East Asian, South=5.88%; South Asian=2.89%; European, North=2.93%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175; PubMed=15901131; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 29 hours (PubMed=3022030); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131093 CVCL_9L27 DD2839 finite cell line human CVCL_9L27 CL:0000010 Karyotypic information: 46,XY,der(2),t(2;7)(2pter->2q37.2::7q36.3->7qter)mat (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21131094 CVCL_0R93 GM17615 transformed cell line human CVCL_0R93 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131095 CVCL_1393 Lu-99A cancer cell line human CVCL_1393 Genome ancestry: African=5.88%; Native American=0%; East Asian, North=75.94%; East Asian, South=8.76%; South Asian=0%; European, North=2.28%; European, South=7.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131096 CVCL_9L26 DD2838 transformed cell line human CVCL_9L26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131097 CVCL_0R92 GM17614 transformed cell line human CVCL_0R92 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131098 CVCL_1392 Lu-65 cancer cell line human CVCL_1392 HLA typing: A*24:02,24:02; B*15:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=79.97%; East Asian, South=18.08%; South Asian=0.48%; European, North=0.3%; European, South=1.17% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser82Ter (c.245C>A); ClinVar=VCV000837710; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21.7 hours (lot 101093), 35-40 hours (lot 12162008), ~46 hours (lot 01192016), ~27 hours (lot 01192022) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21131099 CVCL_0R84 GM17459 transformed cell line human CVCL_0R84 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131100 CVCL_1384 LS174T cancer cell line human CVCL_1384 HLA typing: A*02; B*13,50 (ATCC=CL-188); HLA typing: A*02,30 (PubMed=8464898); HLA typing: A*30:01,30:01; B*15:50,35:114; C*04:01,06:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Homozygous (PubMed=24755471; ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24042735; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046; PubMed=16418264; PubMed=24042735) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CCL-188; probable; Discontinued: RCB; RCB1961; true Female Doubling time: ~30-40 hours (DSMZ=ACC-759); Microsatellite instability: Instable (MSI) (PubMed=9000147; PubMed=10674020; PubMed=24042735; PubMed=25926053; PubMed=28683746) Group: Patented cell line; Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-188 21131101 CVCL_0R83 GM17458 transformed cell line human CVCL_0R83 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131102 CVCL_1383 LS123 cancer cell line human CVCL_1383 HLA typing: A*03:01,24:02; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.17%; East Asian, South=0%; South Asian=0%; European, North=70.48%; European, South=28.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln625Ter (c.1873C>T); ClinVar=VCV000232045; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=16418264; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131103 CVCL_0R86 GM17461 transformed cell line human CVCL_0R86 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131104 CVCL_1386 LS513 cancer cell line human CVCL_1386 Genome ancestry: African=0.3%; Native American=0%; East Asian, North=4.01%; East Asian, South=0%; South Asian=0%; European, North=52.68%; European, South=43% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21131105 CVCL_0R85 GM17460 transformed cell line human CVCL_0R85 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131106 CVCL_1385 LS411N cancer cell line human CVCL_1385 HLA typing: A*02:40,30:01; B*18:01,56:01; C*01:02,07:06 (PubMed=26589293); Genome ancestry: African=1.71%; Native American=0%; East Asian, North=2.86%; East Asian, South=0%; South Asian=7.57%; European, North=27.91%; European, South=59.95% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln789Ter (c.2365C>T); ClinVar=VCV000092341; Zygosity=Heterozygous (PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys105Valfs*8 (c.313delT); ClinVar=VCV000940879; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys164Argfs*3 (c.491delA); ClinVar=VCV000189448; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=16418264; PubMed=24755471; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 23 hours (PubMed=25984343); 24 hours (ATCC=CRL-2159); Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21131107 CVCL_0R88 GM17463 transformed cell line human CVCL_0R88 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131108 CVCL_1388 Lu-134-B cancer cell line human CVCL_1388 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp1029Tyr (c.3085G>T); Zygosity=Heterozygous (PubMed=19394761) Population: Japanese; Derived from sampling site: Lung. Omics: SNP array analysis Discontinued: JCRB; FDSC0038; true Male Doubling time: 57 hours (PubMed=3022030; PubMed=6098504) 21131109 CVCL_0R87 GM17462 transformed cell line human CVCL_0R87 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131110 CVCL_1387 Lu-134-A cancer cell line human CVCL_1387 Genome ancestry: African=0.6%; Native American=0%; East Asian, North=73.6%; East Asian, South=23.8%; South Asian=1.7%; European, North=0.3%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46 hours (PubMed=3022030; PubMed=6098504); 51.9 hours (PubMed=8286010); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131111 CVCL_0R89 GM17465 transformed cell line human CVCL_0R89 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131112 CVCL_1389 Lu-135 cancer cell line human CVCL_1389 Genome ancestry: African=1.7%; Native American=0.34%; East Asian, North=77.4%; East Asian, South=17.05%; South Asian=0%; European, North=0%; European, South=3.52% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0039; true Male Doubling time: 88 hours (PubMed=3022030); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131113 CVCL_0R60 GM15204 transformed cell line human CVCL_0R60 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131114 CVCL_1360 KYSE-50 cancer cell line human CVCL_1360 Genome ancestry: African=0.31%; Native American=0%; East Asian, North=73.2%; East Asian, South=24.47%; South Asian=2.01%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Glu539Ter (c.1615G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Val (c.50G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys101Ter (c.301A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 28.2 hours (PubMed=1728357); ~2-3 days (lot 02182005) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131115 CVCL_1351 KYSE-30 cancer cell line human CVCL_1351 HLA typing: A*02:06,24:02; B*15:58,54:01; C*04:01,08:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=75.07%; East Asian, South=24.93%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Unspecified (PubMed=9033652; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000376033; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-22del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20.8 hours (PubMed=1728357); 22 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-351) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel 21131116 CVCL_0R51 MC4-L5 cancer cell line house mouse CVCL_0R51 CL:0000010 Transformant: Medroxyprogesterone acetate (MPA)(ChEBI; CHEBI:6716); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21131117 CVCL_1350 KYSE-270 cancer cell line human CVCL_1350 HLA typing: A*11:01,11:01; B*13:01,13:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.68%; East Asian, South=20.54%; South Asian=0%; European, North=0%; European, South=0.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-25del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0366; true Male Doubling time: 29.9 hours (PubMed=1728357); ~24 hours (DSMZ=ACC-380); 24 hours (ECACC=94072021); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131118 CVCL_0R50 MC4-L3 cancer cell line house mouse CVCL_0R50 CL:0000010 Transformant: Medroxyprogesterone acetate (MPA)(ChEBI; CHEBI:6716); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21131119 CVCL_1353 KYSE-450 cancer cell line human CVCL_1353 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0.35%; Native American=0%; East Asian, North=79%; East Asian, South=19.85%; South Asian=0.58%; European, North=0%; European, South=0.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (PubMed=8575860; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu339Ter (c.1015G>T); ClinVar=VCV000438708; Zygosity=Heterozygous (PubMed=8575860; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24.4 hours (PubMed=1728357); 23 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-387); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131120 CVCL_0R53 MC7-2B cancer cell line house mouse CVCL_0R53 CL:0000010 Breed/subspecies: BALB/c. Female 21131121 CVCL_1352 KYSE-410 cancer cell line human CVCL_1352 Genome ancestry: African=0.02%; Native American=0%; East Asian, North=79.58%; East Asian, South=19.99%; South Asian=0.41%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24.2 hours (PubMed=1728357); ~45 hours (DSMZ=ACC-381); ~45 hours (ECACC=94072023); ~19 hours (lot 07202016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131122 CVCL_0R52 MC7-2A cancer cell line house mouse CVCL_0R52 CL:0000010 Breed/subspecies: BALB/c. Female 21131123 CVCL_0R55 GM15199 transformed cell line human CVCL_0R55 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131124 CVCL_1355 KYSE-520 cancer cell line human CVCL_1355 HLA typing: A*24:20,24:20; B*54:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=1.16%; East Asian, North=82.25%; East Asian, South=12.37%; South Asian=0%; European, North=0%; European, South=2.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-2A>T; ClinVar=VCV000458540; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30.2 hours (PubMed=1728357); ~30 hours (DSMZ=ACC-371); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131125 CVCL_1354 KYSE-510 cancer cell line human CVCL_1354 HLA typing: A*33:03,33:03; B*35:01,44:03; C*14:03,14:03 (PubMed=26589293); Genome ancestry: African=0.71%; Native American=0%; East Asian, North=82.59%; East Asian, South=14.53%; South Asian=0%; European, North=0%; European, South=2.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.721_752del32; Zygosity=Unspecified (PubMed=8575860); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu343Ter (c.1027G>T); Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 26.4 hours (PubMed=1728357); 30 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-374); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131126 CVCL_0R54 MC7-L1 cancer cell line house mouse CVCL_0R54 CL:0000010 Breed/subspecies: BALB/c. Female 21131127 CVCL_0R57 GM15201 transformed cell line human CVCL_0R57 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131128 CVCL_1357 L-363 cancer cell line human CVCL_1357 HLA typing: A*02:01,31; B*07,40:01; C*03:02/04,07 (Direct_author_submission); HLA typing: A*02:01,31:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293); HLA typing: A*02:01:01,31:01:02; B*07:02:01,40:01:02; C*03:04:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:02:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*04:04:01,15:01:01 (DSMZCellDive=ACC-49); Genome ancestry: African=0.73%; Native American=0.14%; East Asian, North=1.89%; East Asian, South=0%; South Asian=0%; European, North=70.35%; European, South=26.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (PubMed=11157491; PubMed=21173094; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser261Thr (c.782G>C); ClinVar=VCV000187005; Zygosity=Homozygous (Cosmic-CLP; DepMap) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 65-75 hours (PubMed=207377); 25 hours (PubMed=25984343); ~25 hours (DSMZ=ACC-49); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21131129 CVCL_0R56 GM15200 transformed cell line human CVCL_0R56 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131130 CVCL_1356 KYSE-70 cancer cell line human CVCL_1356 HLA typing: A*26:01,26:01; B*08:01,56:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.22%; Native American=0%; East Asian, North=75.55%; East Asian, South=23.91%; South Asian=0.33%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1989Ter (c.5965C>T); ClinVar=VCV000225842; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys120Asn (c.360G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*13 (c.751_752insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: 17.1 hours (PubMed=1728357); ~35 hours (DSMZ=ACC-363; ECACC=94072012); ~25 hours (lot 06102005) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutation indicated as c.750_751insC in PubMed=8575860 21131131 CVCL_0R59 GM15203 transformed cell line human CVCL_0R59 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131132 CVCL_1359 KYSE-220 cancer cell line human CVCL_1359 Genome ancestry: African=0.96%; Native American=0%; East Asian, North=75.9%; East Asian, South=20.19%; South Asian=0%; European, North=1.79%; European, South=1.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=9033652); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0365; true Male Doubling time: 20.5 hours (PubMed=1728357); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131133 CVCL_0R58 GM15202 transformed cell line human CVCL_0R58 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131134 CVCL_1358 KYSE-170 cancer cell line human CVCL_1358 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0346; true Female Doubling time: 32.5 hours (PubMed=1728357) 21131135 CVCL_T992 FMCp2 cancer cell line CVCL_T992 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Japanese domestic. Female Doubling time: 41.9 hours (PubMed=16397390) 21131136 CVCL_SX92 HAP1 METTL13 (-) 4 cancer cell line human CVCL_SX92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24248; METTL13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131137 CVCL_T991 FMCp1 cancer cell line CVCL_T991 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Japanese domestic. Female Doubling time: 37.9 hours (PubMed=16397390) 21131138 CVCL_SX91 HAP1 METTL13 (-) 3 cancer cell line human CVCL_SX91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24248; METTL13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131139 CVCL_9L01 DD2782 transformed cell line human CVCL_9L01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131140 CVCL_T994 FONm cancer cell line CVCL_T994 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Siamese. Female Doubling time: 54.0 hours (PubMed=16397390) 21131141 CVCL_SX94 HAP1 METTL15 (-) 1 cancer cell line human CVCL_SX94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26606; METTL15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131142 CVCL_9L00 DD2779 transformed cell line human CVCL_9L00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131143 CVCL_T993 FNNm cancer cell line CVCL_T993 CL:0000010 Derived from metastatic site: Pleural effusion; Breed/subspecies: Persian. Female Doubling time: 19.1 hours (PubMed=16397390) 21131144 CVCL_SX93 HAP1 METTL14 (-) cancer cell line human CVCL_SX93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29330; METTL14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC003575c010; true Male Group: Haploid karyotype cell line 21131145 CVCL_T996 FYMp cancer cell line CVCL_T996 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Japanese domestic. Female Doubling time: 24.0 hours (PubMed=16397390) 21131146 CVCL_SX96 HAP1 METTL18 (-) 1 cancer cell line human CVCL_SX96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28793; METTL18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131147 CVCL_T995 FONp cancer cell line CVCL_T995 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Siamese. Female Doubling time: 29.4 hours (PubMed=16397390) 21131148 CVCL_SX95 HAP1 METTL15 (-) 2 cancer cell line human CVCL_SX95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26606; METTL15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131149 CVCL_SX98 HAP1 METTL18 (-) 3 cancer cell line human CVCL_SX98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28793; METTL18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131150 CVCL_T998 K248C cancer cell line CVCL_T998 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Siamese. Female 21131151 CVCL_SX97 HAP1 METTL18 (-) 2 cancer cell line human CVCL_SX97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28793; METTL18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131152 CVCL_T997 REM 134 cancer cell line dog CVCL_T997 CL:0000010 Female 21131153 CVCL_9L07 DD2792 transformed cell line human CVCL_9L07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131154 CVCL_9L06 DD2791 transformed cell line human CVCL_9L06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131155 CVCL_SX99 HAP1 METTL21B (-) 1 cancer cell line human CVCL_SX99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24936; EEF1AKMT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131156 CVCL_T999 K248P cancer cell line CVCL_T999 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Siamese. Female 21131157 CVCL_9L09 DD2794 transformed cell line human CVCL_9L09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131158 CVCL_9L08 DD2793 transformed cell line human CVCL_9L08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131159 CVCL_9L03 DD2785 transformed cell line human CVCL_9L03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131160 CVCL_9L02 DD2784 transformed cell line human CVCL_9L02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131161 CVCL_9L05 DD2788 finite cell line human CVCL_9L05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131162 CVCL_0R71 GM17444 transformed cell line human CVCL_0R71 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131163 CVCL_1371 LB996-RCC cancer cell line human CVCL_1371 Genome ancestry: African=0%; Native American=1.05%; East Asian, North=0%; East Asian, South=0.4%; South Asian=2.91%; European, North=45.92%; European, South=49.72% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131164 CVCL_9L04 DD2786 finite cell line human CVCL_9L04 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131165 CVCL_0R70 GM17443 transformed cell line human CVCL_0R70 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131166 CVCL_1370 LB831-BLC cancer cell line human CVCL_1370 HLA typing: A*03,24:03; B*44:03,49:01; C*04:01,07 (PubMed=9637538); Genome ancestry: African=0%; Native American=0.49%; East Asian, North=0%; East Asian, South=0.01%; South Asian=2.75%; European, North=63.52%; European, South=33.23% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Tyr (c.722C>A); ClinVar=VCV000376663; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131167 CVCL_0R62 GM15206 transformed cell line human CVCL_0R62 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131168 CVCL_1362 L-540 cancer cell line human CVCL_1362 HLA typing: A*03:01,11:01; B*51:01,51:01; C*02:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.11%; East Asian, South=0.61%; South Asian=0.05%; European, North=70.77%; European, South=27.46% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: ~70 hours (DSMZ=ACC-72); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131169 CVCL_0R61 GM15205 transformed cell line human CVCL_0R61 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131170 CVCL_1361 L-428 cancer cell line human CVCL_1361 HLA typing: A*03:01; B*35:03; C*04:01/03/05/07; DQB1*03:01/09; DRB1*12:01/06; DRB3*02 (PubMed=12133989); HLA typing: A*03:01,03:01; B*35:03,35:03; C*04:01,04:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*03:17,12:01 (PubMed=26589293); HLA typing: A*03:01:01,03:01:01; B*35:03:01,35:03:01; C*04:01:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRA*01:02:02,01:02:02; DRB1*12:01:01,12:01:01 (DSMZCellDive=ACC-197); Genome ancestry: African=2.16%; Native American=0%; East Asian, North=3.23%; East Asian, South=0%; South Asian=0%; European, North=65.81%; European, South=28.79% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly112_Val122del11 (c.334_366del33); Zygosity=Heterozygous (PubMed=17065008; Cosmic-CLP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: 42-46 hours (PubMed=7216541); ~35 hours (DSMZ=ACC-197); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21131171 CVCL_0R64 GM15208 transformed cell line human CVCL_0R64 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131172 CVCL_1364 LB1047-RCC cancer cell line human CVCL_1364 HLA typing: A*02:01,24:02:101; B*35:01,51; C*04:01,16:02 (PubMed=11369790); Genome ancestry: African=0.9%; Native American=0%; East Asian, North=0.45%; East Asian, South=0%; South Asian=20.18%; European, North=20.14%; European, South=58.33% (PubMed=30894373) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI-high) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131173 CVCL_0R63 GM15207 transformed cell line human CVCL_0R63 CL:0000010 Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131174 CVCL_1363 LA-N-6 cancer cell line human CVCL_1363 Genome ancestry: African=2.47%; Native American=23.6%; East Asian, North=3.12%; East Asian, South=0%; South Asian=0%; European, North=42.61%; European, South=28.2% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=28636942); Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Asp1091Asn (c.3271G>A); ClinVar=VCV000218628; Zygosity=Heterozygous (PubMed=18724359; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Deep tyrosine phosphoproteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811); Characteristics: Has long and heterogeneous telomeres and no telomerase activity Its telomeres shortens continuously at an average rate of 55 base pairs per population doubling (PubMed=28636942). Doubling time: 3 days (PubMed=28636942); ~1 week (DSMZ=ACC-674); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131175 CVCL_0R66 GM17439 transformed cell line human CVCL_0R66 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131176 CVCL_1366 LB2518-MEL cancer cell line human CVCL_1366 Genome ancestry: African=0.84%; Native American=0%; East Asian, North=0%; East Asian, South=0.68%; South Asian=1.95%; European, North=61.82%; European, South=34.71% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131177 CVCL_0R65 GM17438 transformed cell line human CVCL_0R65 HLA typing: A*24:02:01,68:03:01; B*35:01:01,52:01:02; C*03:03:01,04:01:01; DPA1*01:03:01,02:01:01; DPB1*04:02:01,14:01:01; DQA1*03:01:01,05:03; DQB1*03:01:01,03:02:01; DRB1*04:07:01,14:06:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21131178 CVCL_1365 LB2241-RCC cancer cell line human CVCL_1365 Genome ancestry: African=0%; Native American=1.3%; East Asian, North=0%; East Asian, South=0.65%; South Asian=1.75%; European, North=69.13%; European, South=27.17% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131179 CVCL_0R68 GM17441 transformed cell line human CVCL_0R68 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131180 CVCL_1368 LB647-SCLC cancer cell line human CVCL_1368 Genome ancestry: African=0%; Native American=0.14%; East Asian, North=0%; East Asian, South=0.99%; South Asian=0.19%; European, North=66.53%; European, South=32.15% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Serfs*51 (c.880delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131181 CVCL_0R67 GM17440 transformed cell line human CVCL_0R67 HLA typing: A*02:01:01,02:06:01; B*15:15,35:23; C*01:02:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*04:01:01,04:01:01; DQB1*04:02:01,04:02:01; DRB1*08:02:01,08:02:01 (PubMed=29959025) CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21131182 CVCL_1367 LB373-MEL-D cancer cell line human CVCL_1367 Genome ancestry: African=1.8%; Native American=0.56%; East Asian, North=0.8%; East Asian, South=0%; South Asian=0.51%; European, North=65.32%; European, South=31.01% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131183 CVCL_0R69 GM17442 transformed cell line human CVCL_0R69 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131184 CVCL_1369 LB771-HNC cancer cell line human CVCL_1369 Genome ancestry: African=0.73%; Native American=0.55%; East Asian, North=0.07%; East Asian, South=0.71%; South Asian=0.51%; European, North=59.61%; European, South=37.83% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu94fs (c.281delT); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131185 CVCL_SX81 HAP1 MEN1 (-) 3 cancer cell line human CVCL_SX81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131186 CVCL_T981 YTH 470.5 hybridoma Norway rat CVCL_T981 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21131187 CVCL_SX80 HAP1 MEN1 (-) 2 cancer cell line human CVCL_SX80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC001139c008; true Male Group: Haploid karyotype cell line 21131188 CVCL_T980 TAT1 hybridoma house mouse CVCL_T980 CL:0000010 Monoclonal antibody isotype: IgG2a+IgG2b. 21131189 CVCL_SX83 HAP1 MERTK (-) 1 cancer cell line human CVCL_SX83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131190 CVCL_T983 Lu2 hybridoma house mouse CVCL_T983 CL:0000010 Monoclonal antibody isotype: IgM. 21131191 CVCL_SX82 HAP1 MEN1 (-) 4 cancer cell line human CVCL_SX82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131192 CVCL_T982 YTH 71.3 hybridoma Norway rat CVCL_T982 CL:0000010 Monoclonal antibody isotype: IgG2a. 21131193 CVCL_T985 F3-20-7 hybridoma house mouse CVCL_T985 CL:0000010 Discontinued: ECACC; 89062112; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; J9P7X2; Dog THY1/CD90 21131194 CVCL_SX85 HAP1 MERTK (-) 3 cancer cell line human CVCL_SX85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131195 CVCL_SX84 HAP1 MERTK (-) 2 cancer cell line human CVCL_SX84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131196 CVCL_T984 Lu6 hybridoma house mouse CVCL_T984 CL:0000010 Monoclonal antibody isotype: IgG3. 21131197 CVCL_T987 CAT-MT cancer cell line CVCL_T987 CL:0000010 Female Characteristics: Tumorigenic in athymic mice. 21131198 CVCL_SX87 HAP1 METTL10 (-) 1 cancer cell line human CVCL_SX87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33787; EEF1AKMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131199 CVCL_SX86 HAP1 MET (-) cancer cell line human CVCL_SX86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7029; MET; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131200 CVCL_T986 RCC BA85#21 cancer cell line human CVCL_T986 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Male Doubling time: 72 hours (PubMed=27278998); Microsatellite instability: Stable (MSS) (PubMed=27278998) Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 04006 21131201 CVCL_T989 FKNp cancer cell line CVCL_T989 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Persian. Female Doubling time: 36.6 hours (PubMed=16397390) 21131202 CVCL_SX89 HAP1 METTL13 (-) 1 cancer cell line human CVCL_SX89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24248; METTL13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131203 CVCL_T988 FRM [Cat mammary tumor] cancer cell line CVCL_T988 CL:0000010 Derived from metastatic site: Pleural effusion; Breed/subspecies: Domestic Japanese. Female Doubling time: 22.4 hours (PubMed=10333454) 21131204 CVCL_SX88 HAP1 METTL12 (-) cancer cell line human CVCL_SX88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33113; CSKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131205 CVCL_0R31 GM01260 finite cell line human CVCL_0R31 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Pro454Arg (c.1361C>G) (P415R); ClinVar=VCV000004289; Zygosity=Heterozygous (PubMed=30497978) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131206 CVCL_1331 KM12 cancer cell line human CVCL_1331 HLA typing: A*02; B*07:02:01; C*07:02:01; DPB1*13:01; DQB1*03:02; DRB1*04:01:01 (PubMed=15748285); HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.84%; Native American=0.44%; East Asian, North=1.48%; East Asian, South=0%; South Asian=0.59%; European, North=63.68%; European, South=32.97% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (PubMed=24962792; PubMed=25485619); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (PubMed=17088437; PubMed=28179481); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Ala404Cysfs*9 (c.1208dupC) (p.Pro403fs); dbSNP=rs777474487; Zygosity=Heterozygous (PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (PubMed=17088437; PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=17088437; PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (PubMed=15900046; PubMed=17088437; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (PubMed=15900046; PubMed=17088437; PubMed=28683746; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 23 hours (PubMed=25984343); 23.7 hours (NCI-DTP); Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21131207 CVCL_0R30 GM01031 transformed cell line human CVCL_0R30 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; c.115+1G>A (IVS2+1G>A) (IVS2DS,G-A,+1); ClinVar=VCV000093445; Zygosity=Heterozygous; Note=Splice donor mutation that causes skipping of exon 2 (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01031; probable Male 21131208 CVCL_1330 KM-H2 cancer cell line human CVCL_1330 HLA typing: A*24:02; B*15:01,52:01; C*04:01,12:02; DPB1*02:01,05:01; DQA1*03:01,05:05; DQB1*03:01,03:02; DRB1*04:65,11:01; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=15116); HLA typing: A*11:01,24:02; B*15:01,52:01; C*04:01,12:02; DQA1*03:02,05:01; DQB1*03:03,03:03; DRB1*04:06,11:01 (PubMed=26589293); HLA typing: A*11:01:01,24:02:01; B*15:01:01,52:01:01; C*04:01:01,12:02:02; DPA1*01:03:01,02:02:02; DPB1*05:01:01,02:01:02; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRA*01:01:01,01:01:01; DRB1*04:06:01,11:01:01 (DSMZCellDive=ACC-8); Genome ancestry: African=1.68%; Native American=0%; East Asian, North=78.89%; East Asian, South=17.68%; South Asian=0%; European, North=0%; European, South=1.75% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7067; CIITA + HGNC; 44654; PIERCE2; Name(s)=CIITA-C15orf65, CIITA-PIERCE2 (PubMed=21368758); Sequence variation: Gene fusion; HGNC; 7059; MGMT + HGNC; 28121; PRRC2B; Name(s)=PRRC2B-MGMT, BAT2L1-MGMT (PubMed=21368758); Sequence variation: Gene deletion; HGNC; 1787; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Unexplicit; In2-Ex6 del; Zygosity=Heterozygous (PubMed=19380639) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~48 hours (DSMZ=ACC-8); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21131209 CVCL_0R33 GM04394 finite cell line human CVCL_0R33 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21131210 CVCL_1333 KMS-12-PE cancer cell line human CVCL_1333 HLA typing: A*26,33; B*35,44; C*03,14 (PubMed=25688540); HLA typing: A*26:01,33:03; B*35:01,44:03; C*03:03,14:03 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Leu (c.1010G>T); ClinVar=VCV000142828; Zygosity=Homozygous (PubMed=21173094) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 62 hours (PubMed=2519219); Doubling time: ~60-80 hours (DSMZ=ACC-606) Part of: MD Anderson Cell Lines Project 21131211 CVCL_0R32 GM02627 finite cell line human CVCL_0R32 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Gly364Arg (c.1090G>A) (G325R); ClinVar=VCV000004318; Zygosity=Heterozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Cys381Gly (c.1141T>G) (C342G); ClinVar=VCV000004319; Zygosity=Heterozygous (PubMed=30497978) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131212 CVCL_1332 KMOE-2 cancer cell line human CVCL_1332 Genome ancestry: African=0.41%; Native American=0.02%; East Asian, North=78.12%; East Asian, South=19.8%; South Asian=1.43%; European, North=0.23%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 24.2 hours (PubMed=6949905); ~40-50 hours (DSMZ=ACC-37); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131213 CVCL_0R35 GM20273 finite cell line human CVCL_0R35 CL:0000010 Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131214 CVCL_1335 KNS-62 cancer cell line human CVCL_1335 HLA typing: A*26:01,26:01; B*15:01,46:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=2.64%; Native American=0%; East Asian, North=85.09%; East Asian, South=7%; South Asian=0%; European, North=0%; European, South=5.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.457+1G>A; ClinVar=VCV000635368; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2974; DNM2; Simple; p.Pro792del (c.2370_2372delGCC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000376033; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Leu69Pro (c.206T>C); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21131215 CVCL_0R34 GM07968 finite cell line human CVCL_0R34 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (Coriell) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131216 CVCL_1334 KMS-12-BM cancer cell line human CVCL_1334 HLA typing: A*26,33; B*35,44; C*03,14 (PubMed=25688540); HLA typing: A*26:01,33:03; B*35:01,44:03; C*03:03,14:03 (PubMed=26589293); HLA typing: A*26:01:01,33:03:01; B*35:01:01,44:03:01; C*03:03:01,14:03; DQA1*01:02:01,03:03:01; DRA*01:01:01,01:02:02; DRB1*04:10:01,13:02:01 (DSMZCellDive=ACC-551); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=81.71%; East Asian, South=16.28%; South Asian=0%; European, North=0%; European, South=2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Leu (c.1010G>T); ClinVar=VCV000142828; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 58 hours (PubMed=2519219); 60 hours (PubMed=25984343); ~60 hours (DSMZ=ACC-551); ~37 hours (lot 04072005), ~32 hours (lot 02142011), 1.5-4 days (lot 08172016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21131217 CVCL_0R37 GM10871 transformed cell line human CVCL_0R37 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131218 CVCL_1337 KOSC-2 cancer cell line human CVCL_1337 Genome ancestry: African=1.44%; Native American=0%; East Asian, North=72.8%; East Asian, South=22.55%; South Asian=0%; European, North=0%; European, South=3.2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Arg5Gln (c.14G>A); ClinVar=VCV000376520; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Glu40Gln (c.118G>C); ClinVar=VCV000376517; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52delinsProTer (c.154_155insCAT); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Oral cavity; floor of mouth. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: DepMap; ACH-002260; true Male Doubling time: 18.7 hours (PubMed=8314315); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131219 CVCL_0R36 GM10870 transformed cell line human CVCL_0R36 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21131220 CVCL_1336 KNS-81-FD cancer cell line human CVCL_1336 Genome ancestry: African=0%; Native American=1.58%; East Asian, North=77.83%; East Asian, South=20.58%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Group: Serum/protein free medium cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131221 CVCL_0R39 GM10915 finite cell line human CVCL_0R39 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=30497978) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21131222 CVCL_1339 KP-N-RT-BM-1 cancer cell line human CVCL_1339 HLA typing: A*24:02,31:01; B*35:03,56:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0.43%; Native American=0.27%; East Asian, North=72.99%; East Asian, South=24.04%; South Asian=0%; European, North=0%; European, South=2.27% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131223 CVCL_0R38 GM10874 transformed cell line human CVCL_0R38 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg159Gln (c.476G>A) (R120Q); ClinVar=VCV000004291; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131224 CVCL_1338 KP-4 cancer cell line human CVCL_1338 HLA typing: A*02:06,24:02; B*48:01,51:01; C*08:03,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.42%; East Asian, South=20.35%; South Asian=0%; European, North=1.23%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131225 CVCL_T990 FMCm cancer cell line CVCL_T990 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Japanese domestic. Female Doubling time: 29.7 hours (PubMed=16397390) 21131226 CVCL_SX90 HAP1 METTL13 (-) 2 cancer cell line human CVCL_SX90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24248; METTL13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131227 CVCL_SX70 HAP1 ME2 (-) 1 cancer cell line human CVCL_SX70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6984; ME2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131228 CVCL_T970 HPS0134 induced pluripotent stem cell human CVCL_T970 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131229 CVCL_SX72 HAP1 MECP2 (-) 2 cancer cell line human CVCL_SX72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6990; MECP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131230 CVCL_T972 HPS0215 induced pluripotent stem cell human CVCL_T972 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131231 CVCL_SX71 HAP1 MECP2 (-) 1 cancer cell line human CVCL_SX71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6990; MECP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131232 CVCL_T971 HPS0192 induced pluripotent stem cell human CVCL_T971 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131233 CVCL_SX74 HAP1 MED13L (-) 2 cancer cell line human CVCL_SX74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22962; MED13L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131234 CVCL_T974 HPS0209 induced pluripotent stem cell human CVCL_T974 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131235 CVCL_SX73 HAP1 MED13L (-) 1 cancer cell line human CVCL_SX73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22962; MED13L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131236 CVCL_T973 HPS0133 induced pluripotent stem cell human CVCL_T973 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131237 CVCL_T976 F3-87-8-1 hybridoma house mouse CVCL_T976 CL:0000010 Monoclonal antibody isotype: IgG1. 21131238 CVCL_SX76 HAP1 MEF2B (-) 2 cancer cell line human CVCL_SX76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6995; MEF2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131239 CVCL_T975 20.27 (SBU-T6, anti-CD1) hybridoma house mouse CVCL_T975 CL:0000010 Monoclonal antibody isotype: IgG1. 21131240 CVCL_SX75 HAP1 MEF2B (-) 1 cancer cell line human CVCL_SX75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6995; MEF2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131241 CVCL_T978 BBA4 hybridoma house mouse CVCL_T978 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Trypanosoma brucei basal bodies. 21131242 CVCL_SX78 HAP1 MELK (-) cancer cell line human CVCL_SX78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16870; MELK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131243 CVCL_T977 F8-11-13 hybridoma house mouse CVCL_T977 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45 (isoform CD45RA). 21131244 CVCL_SX77 HAP1 MEIS1 (-) 1 cancer cell line human CVCL_SX77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7000; MEIS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131245 CVCL_T979 C3B9 hybridoma house mouse CVCL_T979 CL:0000010 Monoclonal antibody isotype: IgG2b. 21131246 CVCL_SX79 HAP1 MEN1 (-) 1 cancer cell line human CVCL_SX79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131247 CVCL_0R40 GM20269 finite cell line human CVCL_0R40 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.His294Gln (c.882T>G) (H255Q); ClinVar=VCV000242810; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM20269; probable Male 21131248 CVCL_1340 KP-N-SI9s cancer cell line human CVCL_1340 Genome ancestry: African=0%; Native American=0%; East Asian, North=75.78%; East Asian, South=24.21%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from metastatic site: Left axillary lymph node. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Substrate-adherent type (S-type) (PubMed=2019470) Doubling time: ~49 hours (lot 12152017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21131249 CVCL_0R42 GM20272 finite cell line human CVCL_0R42 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131250 CVCL_1342 KP-N-YS cancer cell line human CVCL_1342 Genome ancestry: African=0%; Native American=1.29%; East Asian, North=74.96%; East Asian, South=23.74%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (Cosmic-CLP) Population: Japanese; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131251 CVCL_0R41 GM20270 finite cell line human CVCL_0R41 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; c.115+1G>A (IVS2+1G>A) (IVS2DS,G-A,+1); ClinVar=VCV000093445; Zygosity=Heterozygous; Note=Splice donor mutation that causes skipping of exon 2 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131252 CVCL_1341 KP-N-YN cancer cell line human CVCL_1341 HLA typing: A*24:02,26:02; B*40:02,52:01; C*03:04,07:41 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.15%; East Asian, North=73.42%; East Asian, South=25.67%; South Asian=0%; European, North=0%; European, South=0.76% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Right pararenal lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131253 CVCL_0R44 GM14606 transformed cell line human CVCL_0R44 CL:0000010 Sequence variation: Mutation; HGNC; 5163; HPS1; Simple; p.His497Glnfs (c.1472_1487dup16); ClinVar=VCV000005277; Zygosity=Homozygous (Coriell) Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131254 CVCL_1344 KU-19-19 cancer cell line human CVCL_1344 HLA typing: A*31:01,33:03; B*15:01,37:01; C*03:03,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=77.87%; East Asian, South=21.55%; South Asian=0%; European, North=0%; European, South=0.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Unspecified (PubMed=19802009) Population: Japanese; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (DSMZ=ACC-395); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131255 CVCL_0R43 GM13958 transformed cell line human CVCL_0R43 CL:0000010 Sequence variation: Mutation; HGNC; 5163; HPS1; Simple; p.Gln397Serfs*2 (c.1189delC); ClinVar=VCV000021091; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131256 CVCL_1343 KS-1 [Human glioblastoma] cancer cell line human CVCL_1343 HLA typing: A*02:06,24:02; B*39:01,54:01; C*01:03,07:02; DQA1*01:02,03:02; DQB1*03:02,06:01; DRB1*04:03,15:02 (PubMed=26589293); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=74.63%; East Asian, South=23.63%; South Asian=1.21%; European, North=0%; European, South=0.52% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~53 hours (lot 02232017) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131257 CVCL_0R46 GM17881 transformed cell line human CVCL_0R46 CL:0000010 Sequence variation: Mutation; HGNC; 18817; HPS6; Simple; p.Leu572Alafs (c.1714_1717delCTGT); ClinVar=VCV000003151; Zygosity=Homozygous (Coriell) Population: Caucasian; Flemish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131258 CVCL_1346 KY821 cancer cell line human CVCL_1346 Genome ancestry: African=0%; Native American=0%; East Asian, North=76.02%; East Asian, South=23.98%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=1571549; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain; meninges. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~2 days (lot 11022006) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131259 CVCL_0R45 GM14609 finite cell line human CVCL_0R45 CL:0000010 Sequence variation: Mutation; HGNC; 5163; HPS1; Simple; p.His497Glnfs (c.1472_1487dup16); ClinVar=VCV000005277; Zygosity=Homozygous (Coriell) Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131260 CVCL_1345 Kuramochi cancer cell line human CVCL_1345 HLA typing: A*26:02,26:02; B*40:06,40:06; C*08:01,08:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=85.58%; East Asian, South=11.82%; South Asian=0.12%; European, North=0%; European, South=2.48% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Tyr (c.841G>T); ClinVar=VCV000376585; Zygosity=Homozygous (PubMed=24023729) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24-27 hours (PubMed=6268719); 82 hours (PubMed=25984343); 60 hours (lot 10242008), ~43 hours (lot 06302015), ~40 hours (lot 06152016), ~2 days (lot 09042020) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21131261 CVCL_1348 KYSE-150 cancer cell line human CVCL_1348 Genome ancestry: African=0.41%; Native American=0%; East Asian, North=79.69%; East Asian, South=18.82%; South Asian=0%; European, North=0%; European, South=1.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB1095; probable Female Doubling time: 13.7 hours (PubMed=1728357); 23 hours (PubMed=25984343); <25 hours, less when serum amount is increased (DSMZ=ACC-375); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131262 CVCL_0R48 MC4-L1 cancer cell line house mouse CVCL_0R48 CL:0000010 Transformant: Medroxyprogesterone acetate (MPA)(ChEBI; CHEBI:6716); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21131263 CVCL_0R47 GM17890 finite cell line human CVCL_0R47 CL:0000010 Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; p.Arg509Ter (c.1525C>T); ClinVar=VCV000006377; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; p.Glu659Ter (c.1975G>T); ClinVar=VCV000006378; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131264 CVCL_1347 KYSE-140 cancer cell line human CVCL_1347 HLA typing: A*02:07,26:02; B*40:06,46:01; C*01:02,08:01 (PubMed=26589293); Genome ancestry: African=3.5%; Native American=0%; East Asian, North=83.8%; East Asian, South=6.46%; South Asian=0%; European, North=0%; European, South=6.23% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB1063; probable Male Doubling time: 27.4 hours (PubMed=1728357); ~24 hours (DSMZ=ACC-348); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131265 CVCL_1349 KYSE-180 cancer cell line human CVCL_1349 HLA typing: A*03:02,24:02; B*13:02,59:01; C*01:02,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=75.43%; East Asian, South=22.18%; South Asian=2.35%; European, North=0%; European, South=0.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0347; true Male Doubling time: 15.2 hours (PubMed=1728357); ~40-50 hours (DSMZ=ACC-379); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131266 CVCL_0R49 MC4-L2 cancer cell line house mouse CVCL_0R49 CL:0000010 Transformant: Medroxyprogesterone acetate (MPA)(ChEBI; CHEBI:6716); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21131267 CVCL_SX61 HAP1 MCOLN1 (-) 4 cancer cell line human CVCL_SX61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131268 CVCL_T961 LD7/4 transformed cell line Norway rat CVCL_T961 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: PVG. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1694 21131269 CVCL_SX60 HAP1 MCOLN1 (-) 3 cancer cell line human CVCL_SX60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131270 CVCL_T960 JG2/1 transformed cell line Norway rat CVCL_T960 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Retinal endothelial cell.; Breed/subspecies: Lewis. Female Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1695 21131271 CVCL_SX63 HAP1 MCOLN1 (-) 6 cancer cell line human CVCL_SX63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131272 CVCL_T963 LA3 induced pluripotent stem cell human CVCL_T963 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (from autologous cell lines LA5 and LA11) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21131273 CVCL_T962 GPNT transformed cell line Norway rat CVCL_T962 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Cerebral cortex endothelial cell.; Breed/subspecies: Lewis. Female Doubling time: ~10 hours (ECACC=09061601) 21131274 CVCL_SX62 HAP1 MCOLN1 (-) 5 cancer cell line human CVCL_SX62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131275 CVCL_SX65 HAP1 MCOLN3 (-) 1 cancer cell line human CVCL_SX65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13358; MCOLN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131276 CVCL_T965 PMD4-11 induced pluripotent stem cell human CVCL_T965 CL:0000010 Male 21131277 CVCL_SX64 HAP1 MCOLN1 (-) 7 cancer cell line human CVCL_SX64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131278 CVCL_T964 HPS0097 induced pluripotent stem cell human CVCL_T964 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Not described; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131279 CVCL_SX67 HAP1 MDM2 (-) 1 cancer cell line human CVCL_SX67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6973; MDM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131280 CVCL_T967 HPS0140 induced pluripotent stem cell human CVCL_T967 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131281 CVCL_SX66 HAP1 MDC1 (-) cancer cell line human CVCL_SX66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21163; MDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131282 CVCL_T966 HPS0143 induced pluripotent stem cell human CVCL_T966 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131283 CVCL_SX69 HAP1 ME1 (-) 1 cancer cell line human CVCL_SX69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6983; ME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131284 CVCL_T969 HPS0129 induced pluripotent stem cell human CVCL_T969 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131285 CVCL_SX68 HAP1 MDM2 (-) 2 cancer cell line human CVCL_SX68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6973; MDM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131286 CVCL_T968 HPS0146 induced pluripotent stem cell human CVCL_T968 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131287 CVCL_0R11 GM10816 transformed cell line human CVCL_0R11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131288 CVCL_1311 IST-Mes1 cancer cell line human CVCL_1311 Genome ancestry: African=2.78%; Native American=0%; East Asian, North=4.12%; East Asian, South=0%; South Asian=1.03%; European, North=38.45%; European, South=53.62% (PubMed=30894373) CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21131289 CVCL_0R10 GM10812 transformed cell line human CVCL_0R10 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131290 CVCL_1310 IST-MEL3 cancer cell line human CVCL_1310 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 21131291 CVCL_0R13 HC11-C24 spontaneously immortalized cell line house mouse CVCL_0R13 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21131292 CVCL_1313 IST-SL1 cancer cell line human CVCL_1313 Genome ancestry: African=0.24%; Native American=0%; East Asian, North=0.16%; East Asian, South=1.69%; South Asian=0%; European, North=34.83%; European, South=63.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2520+1G>A; ClinVar=VCV000126805; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap) Derived from metastatic site: Supraclavicular lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131293 CVCL_0R12 GM10818 transformed cell line human CVCL_0R12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131294 CVCL_1312 IST-Mes2 cancer cell line human CVCL_1312 HLA typing: A*24:02,26:01; B*38:01,39:01; C*12:03,12:03; DQA1*03:02,05:01; DQB1*02:02,02:02; DRB1*03:03,10:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.1%; East Asian, North=2.01%; East Asian, South=0%; South Asian=2.87%; European, North=43.48%; European, South=51.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (DepMap) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21131295 CVCL_1315 ITO-II cancer cell line human CVCL_1315 CL:0000010 Population: Japanese Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male 21131296 CVCL_0R15 QCPN hybridoma house mouse CVCL_0R15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Quail cell marker. 21131297 CVCL_0R14 HC11-C4 spontaneously immortalized cell line house mouse CVCL_0R14 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21131298 CVCL_1314 IST-SL2 cancer cell line human CVCL_1314 Genome ancestry: African=0.3%; Native American=0.72%; East Asian, North=0%; East Asian, South=0.93%; South Asian=4.5%; European, North=46.2%; European, South=47.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr424Ilefs*4 (c.1268dup) (p.Gly423Aspfs*34) (c.1266_1267insG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131299 CVCL_1317 Jiyoye cancer cell line human CVCL_1317 HLA typing: A*03:01,74:01; B*53:01,58:01; C*04:01,04:01; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:02,15:03 (PubMed=26589293); HLA typing: A*03:01:01,74:01:01; B*53:01:01,58:01:01; C*04:01:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:19:01,06:02:01; DRB1*11:02:01,15:03:01 (CLS=300366); Genome ancestry: African=92.69%; Native American=0%; East Asian, North=2.15%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=5.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (PubMed=1915267) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7933; true Male Virology: Contains a complete EBV genome (strain Jiyoye) which has been sequenced (PubMed=25787276) Doubling time: ~30-60 hours (DSMZ=ACC-590); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21131300 CVCL_0R17 KTR-R finite cell line CVCL_0R17 CL:0000010 Derived from sampling site: Fetal trachea. Male 21131301 CVCL_1316 J.RT3-T3.5 cancer cell line human CVCL_1316 CL:0000010 Sequence variation: Gene fusion; HGNC; 1777; CDK6 + HGNC; 28629; FAM133B; Name(s)=FAM133B-CDK6 (PubMed=23637631); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Does not express the beta chain of the T cell antigen receptor Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21131302 CVCL_0R16 NGM finite cell line human CVCL_0R16 CL:0000010 Derived from sampling site: Skin; dermis; nevus. Female 21131303 CVCL_0R19 B-THP-1 cancer cell line human CVCL_0R19 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Doubling time: ~20 hours (HIVReagentProgram) Problematic cell line: Misidentified Originally thought to be THP-1 (PubMed=10721995) but later shown to be a derivative of Raji (PubMed=14972530). 21131304 CVCL_1319 JVM-2 transformed cell line human CVCL_1319 HLA typing: A*24:02,26:01; B*38:01,44:02; C*05:01,12:03; DQA1*01:02,01:02; DQB1*06:03,05:01; DRB1*13:01,01:01 (PubMed=25960936); HLA typing: A*02,68; B*07,55; C*03,07 (PubMed=25688540); HLA typing: A*02:01,68:01; B*07:02,55:01; C*03:03,07:02 (PubMed=26589293); HLA typing: A*02:01:01,68:01:02; B*07:02:01,55:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*02:01:01,05:05:01; DQB1*02:02:01,03:01:01; DRA*01:01:01,01:01:01; DRB1*07:01:01,11:01:01 (DSMZCellDive=ACC-12); Genome ancestry: African=0.33%; Native American=0.51%; East Asian, North=0.25%; East Asian, South=0%; South Asian=0.43%; European, North=67.89%; European, South=30.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16448697) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=25315077); ~50-70 hours (DSMZ=ACC-12); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project 21131305 CVCL_0R18 CEM-TART clone 1A2 cancer cell line human CVCL_0R18 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21131306 CVCL_1318 JVM-13 transformed cell line human CVCL_1318 HLA typing: A*02:01,03:01; B*15:01,56:01; C*01:02,03:03; DQA1*01:03,01:03; DQB1*06:03,06:03; DRB1*13:01,03:38 (PubMed=25960936); HLA typing: A*02:01:01,03:01:01; B*15:01:01,56:01:01; C*01:02:01,03:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,06:01; DQA1*01:03:01,01:03:01; DQB1*06:03:01,06:03:01; DRA*01:02:02,01:02:02; DRB1*13:01:01,13:01:01 (DSMZCellDive=ACC-19) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 58 hours (PubMed=25315077); ~70 hours (DSMZ=ACC-19) Part of: LL-100 blood cancer cell line panel; Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project 21131307 CVCL_SX50 HAP1 MBD4 (-) 3 cancer cell line human CVCL_SX50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6919; MBD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131308 CVCL_T950 SV40T-DPC finite cell line human CVCL_T950 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Korean; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Scalp; skin; dermis; dermal papilla Cell type=Hair follicle dermal papilla cell.. Omics: Transcriptome analysis by microarray Male Senescence: SV40-transformed but with a finite life span 21131309 CVCL_SX52 HAP1 MBP (-) 1 cancer cell line human CVCL_SX52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6925; MBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131310 CVCL_T952 HO16.4C spontaneously immortalized cell line Norway rat CVCL_T952 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131311 CVCL_SX51 HAP1 MBD4 (-) 4 cancer cell line human CVCL_SX51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6919; MBD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131312 CVCL_T951 SV40T-hTERT-DPC transformed cell line human CVCL_T951 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Korean; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Scalp; skin; dermis; dermal papilla Cell type=Hair follicle dermal papilla cell.. Male 21131313 CVCL_SX54 HAP1 MBTPS1 (-) 2 cancer cell line human CVCL_SX54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15456; MBTPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131314 CVCL_T954 HET16 spontaneously immortalized cell line Norway rat CVCL_T954 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131315 CVCL_SX53 HAP1 MBTPS1 (-) 1 cancer cell line human CVCL_SX53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15456; MBTPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131316 CVCL_T953 HET15 spontaneously immortalized cell line Norway rat CVCL_T953 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131317 CVCL_SX56 HAP1 MBTPS2 (-) cancer cell line human CVCL_SX56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15455; MBTPS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131318 CVCL_T956 LACO16 spontaneously immortalized cell line Norway rat CVCL_T956 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131319 CVCL_SX55 HAP1 MBTPS1 (-) 3 cancer cell line human CVCL_SX55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15456; MBTPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131320 CVCL_T955 TGR-1 spontaneously immortalized cell line Norway rat CVCL_T955 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131321 CVCL_SX58 HAP1 MCOLN1 (-) 1 cancer cell line human CVCL_SX58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131322 CVCL_T958 SV-TGo finite cell line human CVCL_T958 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Parapharyngeal space Cell type=Epithelial cell.. Male Senescence: SV40-transformed but with a finite life span; Doubling time: ~22 hours (PubMed=208961) 21131323 CVCL_SX57 HAP1 MCAM (-) cancer cell line human CVCL_SX57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6934; MCAM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131324 CVCL_T957 LACO3 spontaneously immortalized cell line Norway rat CVCL_T957 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21131325 CVCL_T959 GP8.3 transformed cell line Norway rat CVCL_T959 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Cerebral cortex endothelial cell.; Breed/subspecies: Lewis. Female 21131326 CVCL_SX59 HAP1 MCOLN1 (-) 2 cancer cell line human CVCL_SX59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13356; MCOLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131327 CVCL_0R20 B-THP-1/DC-SIGN cancer cell line human CVCL_0R20 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21131328 CVCL_1320 JVM-3 transformed cell line human CVCL_1320 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); HLA typing: A*01:01:01,01:01:01; B*08:01:01,08:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,02:01:02; DPB1*04:01:01,01:01:01; DQA1*05:01:01,05:01:01; DQB1*02:01:01,02:01:01; DRA*01:02:02,01:02:02; DRB1*03:01:01,03:01:01 (DSMZCellDive=ACC-18); Genome ancestry: African=0.28%; Native American=0.22%; East Asian, North=1.54%; East Asian, South=0%; South Asian=0%; European, North=70.02%; European, South=27.94% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Pro1435Leu (c.4304C>T); Zygosity=Heterozygous (PubMed=29989027; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (PubMed=29989027; Cosmic-CLP; DepMap) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~30 hours (DSMZ=ACC-18); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21131329 CVCL_1322 K5 cancer cell line human CVCL_1322 Genome ancestry: African=1.75%; Native American=0%; East Asian, North=0%; East Asian, South=1.37%; South Asian=7.25%; European, North=35.45%; European, South=54.17% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Caucasian; Italian; Derived from metastatic site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00590 Problematic cell line: Contaminated Shown to be a GLAG-66 derivative (STR profile and somatic mutations from Cosmic-CLP). 21131330 CVCL_0R22 Raji/DC-SIGN cancer cell line human CVCL_0R22 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21131331 CVCL_1321 KO52 cancer cell line human CVCL_1321 Genome ancestry: African=0.61%; Native American=0.74%; East Asian, North=70.18%; East Asian, South=27.99%; South Asian=0%; European, North=0%; European, South=0.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882His (c.2645G>A); ClinVar=VCV000375881; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Heterozygous (PubMed=7693050; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=7693050; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0164; true Male Doubling time: ~48 hours (PubMed=7693050); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131332 CVCL_0R21 THP-1/DC-SIGN cancer cell line human CVCL_0R21 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21131333 CVCL_1324 Karpas-299 cancer cell line human CVCL_1324 HLA typing: A*03:01,11:01; B*07:02,35:01; C*04:01,07:02; DQA1*01:02,01:02; DQB1*05:01,06:13; DRB1*01:01,15:01 (PubMed=26589293); Genome ancestry: African=0.22%; Native American=0.18%; East Asian, North=0%; East Asian, South=0%; South Asian=1.17%; European, North=67.06%; European, South=31.36% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=26657151; PubMed=29899875); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: DSMZ; ACC-31; true Male Doubling time: 26 hours (PubMed=20922763); ~30 hours (ECACC=06072604); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21131334 CVCL_0R24 NIH 3T3/L-SIGN spontaneously immortalized cell line house mouse CVCL_0R24 CL:0000010 Transfected with: HGNC; 13523; CLEC4M Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21131335 CVCL_1323 KALS-1 cancer cell line human CVCL_1323 HLA typing: A*24:02,26:01; B*51:01,51:01; C*01:02,15:02 (PubMed=26589293); Genome ancestry: African=1.68%; Native American=0%; East Asian, North=78.93%; East Asian, South=16.7%; South Asian=1.01%; European, North=0%; European, South=1.68% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 90 hours (PubMed=25984343); ~38 hours (lot 09142016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131336 CVCL_0R23 NIH 3T3/DC-SIGN spontaneously immortalized cell line house mouse CVCL_0R23 CL:0000010 Transfected with: HGNC; 1641; CD209 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21131337 CVCL_1326 Karpas-45 cancer cell line human CVCL_1326 Genome ancestry: African=0.06%; Native American=0.47%; East Asian, North=0.03%; East Asian, South=0%; South Asian=2.75%; European, North=68.54%; European, South=28.16% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7139; FOXO4 + HGNC; 7132; KMT2A; Name(s)=KMT2A-FOXO4, MLL-MLLT7; MLL-AFX1 (PubMed=14671638; PubMed=15843827); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val2194Ala (c.6581T>C); ClinVar=VCV000565658; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ala586Gly (c.1757C>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3495; ETV6; Simple; p.His328Tyr (c.982C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3689; FGFR2; Simple; p.Met584Arg (c.1751T>G) (p.Met585Arg, c.1754T>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Arg962His (c.2885G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp131Asn (c.391G>A); ClinVar=VCV000409719; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Ala48Thr (c.142G>A); ClinVar=VCV000454188; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Glu157Gly (c.470A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Gly221Val (c.662G>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp1852Asn (c.5554G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Val2045Ile (c.6133G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8804; PDGFRB; Simple; p.His277Gln (c.831C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Asn879Ser (c.2636A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Asn288Lys (c.864C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg394Gln (c.1181G>A) (p.Arg467Gln, c.1400G>A); ClinVar=VCV000419332; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP) Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-105; true Male Doubling time: 50-100 hours (ECACC=06072602); Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131338 CVCL_0R26 THP-1(NCI)/DC-SIGN cancer cell line human CVCL_0R26 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~24 hours (HIVReagentProgram) 21131339 CVCL_1325 Karpas-422 cancer cell line human CVCL_1325 HLA typing: B*56/73,56/39; DQA1*03:02,03:02; DRB1*15:01,04:05 (PubMed=25960936); HLA typing: A*02:01,03:01; B*07:02,27:05; C*04:01,07:02; DQA1*01:02,03:02; DQB1*03:01,05:02; DRB1*04:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.49%; East Asian, North=0%; East Asian, South=0%; South Asian=0.34%; European, North=71.53%; European, South=27.64% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gln2176fs*48 (c.6527_6528delAG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: DSMZ; ACC-32; true Female Characteristics: Quite popular cell line because of its resistance to chemotherapy Doubling time: ~60-90 hours (ECACC=06101702; Ximbio=152419); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131340 CVCL_0R25 THP-1(NCI) cancer cell line human CVCL_0R25 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21131341 CVCL_0R28 GM00878 finite cell line human CVCL_0R28 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21131342 CVCL_1328 KINGS-1 cancer cell line human CVCL_1328 Genome ancestry: African=0%; Native American=0%; East Asian, North=73.94%; East Asian, South=26.06%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Indicated as originating from a 67 year old male patient in CelloPub=CLPUB00151 and from a 72 year old in JCRB=IFO50435 21131343 CVCL_0R27 GM00877 finite cell line human CVCL_0R27 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Ala495Pro (c.1483G>C) (A456P); ClinVar=VCV000093450; Zygosity=Heterozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Val499Val (c.1497G>C) (V460V); ClinVar=VCV000093451; Zygosity=Heterozygous (PubMed=30497978) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131344 CVCL_1327 KE-37 cancer cell line human CVCL_1327 HLA typing: A*11:01,30:01; B*35:01,44:02; C*04:01,05:01; DQB1*03:02,05:01; DRB1*01:03,11:01 (PubMed=26589293); Genome ancestry: African=0.86%; Native American=0.41%; East Asian, North=0.97%; East Asian, South=0%; South Asian=0.18%; European, North=66.92%; European, South=30.66% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (DSMZ=ACC-46); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131345 CVCL_0R29 GM01030 transformed cell line human CVCL_0R29 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131346 CVCL_1329 KLE cancer cell line human CVCL_1329 HLA typing: A*02:01,24:02; B*35:02,50:01; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=0.19%; Native American=0.23%; East Asian, North=3.62%; East Asian, South=0%; South Asian=0.32%; European, North=60.58%; European, South=35.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=9887230; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Endometrium. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 114 hours (PubMed=1541432); 104 hours (PubMed=7798295); Microsatellite instability: Stable (MSS) (Sanger) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21131347 CVCL_9L98 DD3034 transformed cell line human CVCL_9L98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131348 CVCL_9L97 DD3033 transformed cell line human CVCL_9L97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131349 CVCL_9L99 DD3036 transformed cell line human CVCL_9L99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131350 CVCL_9L94 DD3023 transformed cell line human CVCL_9L94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131351 CVCL_9L93 DD3017 transformed cell line human CVCL_9L93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131352 CVCL_9L96 DD3031 finite cell line human CVCL_9L96 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131353 CVCL_9L95 DD3030 transformed cell line human CVCL_9L95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131354 CVCL_BF24 ND10828 transformed cell line human CVCL_BF24 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131355 CVCL_BF23 ND10826 transformed cell line human CVCL_BF23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131356 CVCL_BF26 ND10831 transformed cell line human CVCL_BF26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131357 CVCL_BF25 ND10829 transformed cell line human CVCL_BF25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131358 CVCL_BF28 ND10835 transformed cell line human CVCL_BF28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131359 CVCL_BF27 ND10833 transformed cell line human CVCL_BF27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131360 CVCL_BF29 ND10839 transformed cell line human CVCL_BF29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131361 CVCL_9L90 DD3011 transformed cell line human CVCL_9L90 CL:0000010 Karyotypic information: 46,XX,t(9;20)(p24.1;p11.2?3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131362 CVCL_9L92 DD3013 transformed cell line human CVCL_9L92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131363 CVCL_9L91 DD3012 transformed cell line human CVCL_9L91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131364 CVCL_BF20 ND10809 transformed cell line human CVCL_BF20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131365 CVCL_BF22 ND10813 transformed cell line human CVCL_BF22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131366 CVCL_BF21 ND10812 transformed cell line human CVCL_BF21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131367 CVCL_BF35 ND10853 transformed cell line human CVCL_BF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131368 CVCL_BF34 ND10849 transformed cell line human CVCL_BF34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131369 CVCL_BF37 ND10855 transformed cell line human CVCL_BF37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131370 CVCL_BF36 ND10854 transformed cell line human CVCL_BF36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131371 CVCL_BF39 ND10890 transformed cell line human CVCL_BF39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131372 CVCL_BF38 ND10877 transformed cell line human CVCL_BF38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131373 CVCL_BF31 ND10844 transformed cell line human CVCL_BF31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131374 CVCL_BF30 ND10841 transformed cell line human CVCL_BF30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131375 CVCL_BF33 ND10848 transformed cell line human CVCL_BF33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131376 CVCL_BF32 ND10847 transformed cell line human CVCL_BF32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131377 CVCL_9L76 DD2969 transformed cell line human CVCL_9L76 CL:0000010 Karyotypic information: 46,XY,del(12)(q11.2;q13.11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131378 CVCL_9L75 DD2968 transformed cell line human CVCL_9L75 CL:0000010 Karyotypic information: 46,X,del(X)(p22.13;p22.31) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131379 CVCL_9L78 DD2976 finite cell line human CVCL_9L78 CL:0000010 Karyotypic information: 46,XY,inv(14)(q24.11;q32.1)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21131380 CVCL_9L77 DD2973 transformed cell line human CVCL_9L77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131381 CVCL_9L72 DD2952 transformed cell line human CVCL_9L72 CL:0000010 Karyotypic information: 46,XY,del(6)(p24.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131382 CVCL_9L71 DD2949 transformed cell line human CVCL_9L71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131383 CVCL_9L74 DD2958 finite cell line human CVCL_9L74 CL:0000010 Karyotypic information: 46,XY,t(17;20)(p13.3;q13.31) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21131384 CVCL_9L73 DD2955 finite cell line human CVCL_9L73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21131385 CVCL_BF09 ND10774 transformed cell line human CVCL_BF09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131386 CVCL_9L79 DD2977 transformed cell line human CVCL_9L79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131387 CVCL_BF02 ND10741 transformed cell line human CVCL_BF02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131388 CVCL_BF01 ND10740 transformed cell line human CVCL_BF01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131389 CVCL_BF04 ND10764 transformed cell line human CVCL_BF04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131390 CVCL_BF03 ND10763 transformed cell line human CVCL_BF03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131391 CVCL_BF06 ND10768 transformed cell line human CVCL_BF06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131392 CVCL_BF05 ND10767 transformed cell line human CVCL_BF05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131393 CVCL_BF08 ND10773 transformed cell line human CVCL_BF08 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131394 CVCL_BF07 ND10772 transformed cell line human CVCL_BF07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131395 CVCL_9L70 DD2947 finite cell line human CVCL_9L70 CL:0000010 Karyotypic information: 46,XX,t(4;5)(p12;q13.1)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131396 CVCL_BF00 ND10739 transformed cell line human CVCL_BF00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131397 CVCL_9L87 DD3004 finite cell line human CVCL_9L87 CL:0000010 Karyotypic information: 47,XX,+mar.ish der(22)(D22Z3+) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131398 CVCL_9L86 DD3000 finite cell line human CVCL_9L86 CL:0000010 Karyotypic information: 46,XX.ish der(X)t(X;Y)(pHU14+) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131399 CVCL_9L89 DD3007 transformed cell line human CVCL_9L89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131400 CVCL_9L88 DD3006 transformed cell line human CVCL_9L88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131401 CVCL_9L83 DD2994 finite cell line human CVCL_9L83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131402 CVCL_9L82 DD2992 finite cell line human CVCL_9L82 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21131403 CVCL_9L85 DD2997 finite cell line human CVCL_9L85 CL:0000010 Karyotypic information: 46,XY,inv(7)(p12.2;p21.3)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131404 CVCL_9L84 DD2996 finite cell line human CVCL_9L84 CL:0000010 Karyotypic information: 46,XY.ish 22q11.2(cH748X2) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131405 CVCL_BF13 ND10782 transformed cell line human CVCL_BF13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131406 CVCL_BF12 ND10780 transformed cell line human CVCL_BF12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131407 CVCL_BF15 ND10802 transformed cell line human CVCL_BF15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131408 CVCL_BF14 ND10801 transformed cell line human CVCL_BF14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131409 CVCL_BF17 ND10805 transformed cell line human CVCL_BF17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131410 CVCL_BF16 ND10803 transformed cell line human CVCL_BF16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131411 CVCL_BF19 ND10808 transformed cell line human CVCL_BF19 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131412 CVCL_BF18 ND10807 transformed cell line human CVCL_BF18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131413 CVCL_9L81 DD2989 finite cell line human CVCL_9L81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21131414 CVCL_9L80 DD2982 finite cell line human CVCL_9L80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21131415 CVCL_BF11 ND10778 transformed cell line human CVCL_BF11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131416 CVCL_BF10 ND10776 transformed cell line human CVCL_BF10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131417 CVCL_9L54 DD2912 finite cell line human CVCL_9L54 CL:0000010 Karyotypic information: 46,XX,t(8;16)(q22;q13)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131418 CVCL_9L53 DD2905 finite cell line human CVCL_9L53 CL:0000010 Karyotypic information: 46,XX,t(12;20)(q24;q13.3)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131419 CVCL_9L56 DD2918 transformed cell line human CVCL_9L56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131420 CVCL_9L55 DD2913 transformed cell line human CVCL_9L55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131421 CVCL_9L50 DD2898 finite cell line human CVCL_9L50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131422 CVCL_9L52 DD2904 transformed cell line human CVCL_9L52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131423 CVCL_9L51 DD2903 transformed cell line human CVCL_9L51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131424 CVCL_9L58 DD2922 transformed cell line human CVCL_9L58 CL:0000010 Karyotypic information: 46,XX,del(5)(p1?3.3;p14.2)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131425 CVCL_9L57 DD2919 finite cell line human CVCL_9L57 CL:0000010 Karyotypic information: 47,XX,+mar pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131426 CVCL_9L59 DD2923 transformed cell line human CVCL_9L59 CL:0000010 Karyotypic information: 46,XY,del(10)(qter->p15.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131427 CVCL_9L65 DD2938 transformed cell line human CVCL_9L65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131428 CVCL_9L64 DD2932 transformed cell line human CVCL_9L64 CL:0000010 Karyotypic information: 46,XY,der(2),t(2;7)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131429 CVCL_9L67 DD2941 transformed cell line human CVCL_9L67 CL:0000010 Karyotypic information: 46,XY,dup(11)(p15.1;p15.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131430 CVCL_9L66 DD2939 transformed cell line human CVCL_9L66 CL:0000010 Karyotypic information: 46,XX,add(2)(q37.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131431 CVCL_9L61 DD2928 transformed cell line human CVCL_9L61 CL:0000010 Karyotypic information: 6,XX,t(7;11),inv(11) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131432 CVCL_9L60 DD2925 transformed cell line human CVCL_9L60 CL:0000010 Karyotypic information: 46,XY,dup(17)(q25.1;q25.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131433 CVCL_9L63 DD2930 transformed cell line human CVCL_9L63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131434 CVCL_9L62 DD2929 transformed cell line human CVCL_9L62 CL:0000010 Karyotypic information: 47,XX,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131435 CVCL_9L69 DD2944 finite cell line human CVCL_9L69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21131436 CVCL_9L68 DD2943 transformed cell line human CVCL_9L68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131437 CVCL_9L32 DD2863 transformed cell line human CVCL_9L32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131438 CVCL_9L31 DD2859 transformed cell line human CVCL_9L31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131439 CVCL_9L34 DD2867 finite cell line human CVCL_9L34 CL:0000010 Karyotypic information: 46,XX,der(18)t(18;21)(q12;q22)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131440 CVCL_9L33 DD2866 finite cell line human CVCL_9L33 CL:0000010 Karyotypic information: 46,XY,der(15)t(10;15)(p11;p11)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131441 CVCL_9L30 DD2855 transformed cell line human CVCL_9L30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131442 CVCL_9L39 DD2873 transformed cell line human CVCL_9L39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131443 CVCL_9L36 DD2870 transformed cell line human CVCL_9L36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131444 CVCL_9L35 DD2868 transformed cell line human CVCL_9L35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131445 CVCL_9L38 DD2872 transformed cell line human CVCL_9L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131446 CVCL_9L37 DD2871 transformed cell line human CVCL_9L37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131447 CVCL_0R95 GM17617 transformed cell line human CVCL_0R95 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131448 CVCL_1395 M14 cancer cell line human CVCL_1395 HLA typing: A*11:01:01,24:02:01; B*15,35; C*03:03:01,04; DPB1*13:01,19:01; DQB1*03:02,06:03; DRB1*04:05:01,13:01:01 (PubMed=15748285); Genome ancestry: African=0.64%; Native American=0%; East Asian, North=0%; East Asian, South=1.08%; South Asian=0%; European, North=67.89%; European, South=30.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=19799798; PubMed=29492214; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=19799798; PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (PubMed=19799798; PubMed=29492214); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP; DepMap) Derived from metastatic site: Right buttock; hypodermis. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 26.3 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21131449 CVCL_0R94 GM17616 transformed cell line human CVCL_0R94 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131450 CVCL_1394 LXF 289 cancer cell line human CVCL_1394 HLA typing: A*32:01,32:01; B*38:01,38:01; C*12:03,12:03; DQA1*01:02,03:02; DQB1*06:11,06:11; DRB1*13:01,13:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.04%; East Asian, South=0%; South Asian=0.14%; European, North=66.88%; European, South=30.93% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: ~50 hours (DSMZ=ACC-265); 24-48 hours (CLS); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131451 CVCL_0R97 GM17619 transformed cell line human CVCL_0R97 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131452 CVCL_1397 MC/CAR transformed cell line human CVCL_1397 Genome ancestry: African=0.32%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=12068308; ATCC) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG1 kappa Doubling time: 19.94 hours (Patent=US4434230); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8083 Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762). 21131453 CVCL_0R96 GM17618 transformed cell line human CVCL_0R96 HLA typing: A*02:01:01,02:01:01; B*15:16:01,35:12:01; C*04:01:01,14:02:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,104:01:01; DQA1*01:01:02,04:01:01; DQB1*04:02:01,05:01:01; DRB1*01:02:01,08:02:01 (PubMed=29959025) CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21131454 CVCL_1396 MC-1010 cancer cell line human CVCL_1396 Genome ancestry: African=0.31%; Native American=0.93%; East Asian, North=2.01%; East Asian, South=0%; South Asian=0%; European, North=60.99%; European, South=35.76% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12253 21131455 CVCL_0R99 GM17624 transformed cell line human CVCL_0R99 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131456 CVCL_1399 MC116 cancer cell line human CVCL_1399 HLA typing: A*01:01,03:01; B*08:01,35:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.22%; East Asian, South=0%; South Asian=3.09%; European, North=64.91%; European, South=30.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 23 hours (PubMed=8402660); ~24-48 hours (DSMZ=ACC-82); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131457 CVCL_0R98 GM17622 transformed cell line human CVCL_0R98 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131458 CVCL_1398 SK-N-MC-IXC cancer cell line human CVCL_1398 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=74.37%; European, South=25.63% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Supra-orbital region. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-067 Problematic cell line: Misclassified Parent cell line (SK-N-MC) was originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor. 21131459 CVCL_9L43 DD2883 transformed cell line human CVCL_9L43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131460 CVCL_9L42 DD2880 transformed cell line human CVCL_9L42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131461 CVCL_9L45 DD2885 transformed cell line human CVCL_9L45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131462 CVCL_9L44 DD2884 transformed cell line human CVCL_9L44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131463 CVCL_9L41 DD2878 transformed cell line human CVCL_9L41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131464 CVCL_9L40 DD2876 transformed cell line human CVCL_9L40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131465 CVCL_9L47 DD2891 finite cell line human CVCL_9L47 CL:0000010 Karyotypic information: 46,XX,der(13)inv(13)(q31.2;q32.3)t(13;18)(q32.3;q23)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21131466 CVCL_9L46 DD2889 finite cell line human CVCL_9L46 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21131467 CVCL_9L49 DD2897 finite cell line human CVCL_9L49 CL:0000010 Karyotypic information: 46,XX,der(5,7)t(4;5;7)(q31:p13;q13:q21)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131468 CVCL_9L48 DD2896 finite cell line human CVCL_9L48 CL:0000010 Karyotypic information: 46,XX,t(14;16)(q24;q11.1) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131469 CVCL_BE90 ND10707 transformed cell line human CVCL_BE90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131470 CVCL_BE92 ND10710 transformed cell line human CVCL_BE92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131471 CVCL_BE91 ND10708 transformed cell line human CVCL_BE91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131472 CVCL_BE83 ND10695 transformed cell line human CVCL_BE83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131473 CVCL_BE82 ND10690 transformed cell line human CVCL_BE82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131474 CVCL_BE85 ND10697 transformed cell line human CVCL_BE85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131475 CVCL_BE84 ND10696 transformed cell line human CVCL_BE84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131476 CVCL_BE87 ND10700 transformed cell line human CVCL_BE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131477 CVCL_BE86 ND10698 transformed cell line human CVCL_BE86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131478 CVCL_BE89 ND10702 transformed cell line human CVCL_BE89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131479 CVCL_BE88 ND10701 transformed cell line human CVCL_BE88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131480 CVCL_BE94 ND10719 transformed cell line human CVCL_BE94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131481 CVCL_BE93 ND10711 transformed cell line human CVCL_BE93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131482 CVCL_BE96 ND10730 transformed cell line human CVCL_BE96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131483 CVCL_BE95 ND10729 transformed cell line human CVCL_BE95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131484 CVCL_BE98 GM08883 transformed cell line human CVCL_BE98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131485 CVCL_BE97 ND10732 transformed cell line human CVCL_BE97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131486 CVCL_BE99 GM08884 transformed cell line human CVCL_BE99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131487 CVCL_BE70 ND10646 transformed cell line human CVCL_BE70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131488 CVCL_BE69 ND10641 transformed cell line human CVCL_BE69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131489 CVCL_BE68 ND10626 transformed cell line human CVCL_BE68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131490 CVCL_BE61 ND10618 transformed cell line human CVCL_BE61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131491 CVCL_BE60 ND10617 transformed cell line human CVCL_BE60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131492 CVCL_BE63 ND10621 transformed cell line human CVCL_BE63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131493 CVCL_BE62 ND10620 transformed cell line human CVCL_BE62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131494 CVCL_BE65 ND10623 transformed cell line human CVCL_BE65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131495 CVCL_BE64 ND10622 transformed cell line human CVCL_BE64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131496 CVCL_BE67 ND10625 transformed cell line human CVCL_BE67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131497 CVCL_BE66 ND10624 transformed cell line human CVCL_BE66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131498 CVCL_BE81 ND10689 transformed cell line human CVCL_BE81 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131499 CVCL_BE80 ND10688 transformed cell line human CVCL_BE80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131500 CVCL_BE79 ND10687 transformed cell line human CVCL_BE79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131501 CVCL_BE72 ND10650 transformed cell line human CVCL_BE72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131502 CVCL_BE71 ND10649 transformed cell line human CVCL_BE71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131503 CVCL_BE74 ND10664 transformed cell line human CVCL_BE74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131504 CVCL_BE73 ND10663 transformed cell line human CVCL_BE73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131505 CVCL_BE76 ND10667 transformed cell line human CVCL_BE76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131506 CVCL_BE75 ND10666 transformed cell line human CVCL_BE75 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Unexplicit; 3'UTR*12C>T; Zygosity=Heterozygous; Note=VUS (PubMed=22572540) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131507 CVCL_BE78 ND10686 transformed cell line human CVCL_BE78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131508 CVCL_BE77 ND10685 transformed cell line human CVCL_BE77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131509 CVCL_BE47 ND10550 transformed cell line human CVCL_BE47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131510 CVCL_BE46 ND10549 transformed cell line human CVCL_BE46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131511 CVCL_BE49 ND10556 transformed cell line human CVCL_BE49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131512 CVCL_BE48 ND10554 transformed cell line human CVCL_BE48 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131513 CVCL_BE41 ND10537 transformed cell line human CVCL_BE41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131514 CVCL_BE40 ND10536 transformed cell line human CVCL_BE40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131515 CVCL_BE43 ND10539 transformed cell line human CVCL_BE43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131516 CVCL_BE42 ND10538 transformed cell line human CVCL_BE42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131517 CVCL_BE45 ND10547 transformed cell line human CVCL_BE45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131518 CVCL_BE44 ND10543 transformed cell line human CVCL_BE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131519 CVCL_BE58 ND10588 transformed cell line human CVCL_BE58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131520 CVCL_BE57 ND10586 transformed cell line human CVCL_BE57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131521 CVCL_BE59 ND10591 transformed cell line human CVCL_BE59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131522 CVCL_BE50 ND10557 transformed cell line human CVCL_BE50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131523 CVCL_BE52 ND10575 transformed cell line human CVCL_BE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131524 CVCL_BE51 ND10561 transformed cell line human CVCL_BE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131525 CVCL_BE54 ND10579 transformed cell line human CVCL_BE54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131526 CVCL_BE53 ND10578 transformed cell line human CVCL_BE53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131527 CVCL_BE56 ND10585 transformed cell line human CVCL_BE56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131528 CVCL_BE55 ND10584 transformed cell line human CVCL_BE55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131529 CVCL_9K99 DD2777 transformed cell line human CVCL_9K99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131530 CVCL_9K98 DD2776 transformed cell line human CVCL_9K98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131531 CVCL_9K95 DD2772 transformed cell line human CVCL_9K95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131532 CVCL_9K94 DD2771 transformed cell line human CVCL_9K94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131533 CVCL_9K97 DD2775 transformed cell line human CVCL_9K97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131534 CVCL_9K96 DD2773 transformed cell line human CVCL_9K96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131535 CVCL_BE25 ND10477 transformed cell line human CVCL_BE25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131536 CVCL_BE24 ND10476 transformed cell line human CVCL_BE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131537 CVCL_BE27 ND10485 transformed cell line human CVCL_BE27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131538 CVCL_BE26 ND10483 transformed cell line human CVCL_BE26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131539 CVCL_BE29 ND10492 transformed cell line human CVCL_BE29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131540 CVCL_BE28 ND10491 transformed cell line human CVCL_BE28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131541 CVCL_9K91 DD2767 transformed cell line human CVCL_9K91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131542 CVCL_9K90 DD2765 transformed cell line human CVCL_9K90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131543 CVCL_9K93 DD2770 finite cell line human CVCL_9K93 CL:0000010 Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131544 CVCL_9K92 DD2768 transformed cell line human CVCL_9K92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131545 CVCL_BE21 ND10461 transformed cell line human CVCL_BE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131546 CVCL_BE20 ND10451 transformed cell line human CVCL_BE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131547 CVCL_BE23 ND10473 transformed cell line human CVCL_BE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131548 CVCL_BE22 ND10464 transformed cell line human CVCL_BE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131549 CVCL_BE36 ND10532 transformed cell line human CVCL_BE36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131550 CVCL_BE35 ND10527 transformed cell line human CVCL_BE35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131551 CVCL_BE38 ND10534 transformed cell line human CVCL_BE38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131552 CVCL_BE37 ND10533 transformed cell line human CVCL_BE37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131553 CVCL_BE39 ND10535 transformed cell line human CVCL_BE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131554 CVCL_BE30 ND10514 transformed cell line human CVCL_BE30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131555 CVCL_BE32 ND10517 transformed cell line human CVCL_BE32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131556 CVCL_BE31 ND10515 transformed cell line human CVCL_BE31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131557 CVCL_BE34 ND10524 transformed cell line human CVCL_BE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131558 CVCL_BE33 ND10518 transformed cell line human CVCL_BE33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131559 CVCL_SX41 HAP1 MBD1 (-) 2 cancer cell line human CVCL_SX41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131560 CVCL_T941 HPS0270 induced pluripotent stem cell human CVCL_T941 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21131561 CVCL_SX40 HAP1 MBD1 (-) 1 cancer cell line human CVCL_SX40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131562 CVCL_T940 HPS0265 induced pluripotent stem cell human CVCL_T940 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male 21131563 CVCL_SX43 HAP1 MBD2 (-) 1 cancer cell line human CVCL_SX43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6917; MBD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131564 CVCL_T943 HPS0272 induced pluripotent stem cell human CVCL_T943 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21131565 CVCL_SX42 HAP1 MBD1 (-) 3 cancer cell line human CVCL_SX42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131566 CVCL_T942 HPS0271 induced pluripotent stem cell human CVCL_T942 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21131567 CVCL_SX45 HAP1 MBD3 (-) 1 cancer cell line human CVCL_SX45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131568 CVCL_T945 iGS1b8-2 induced pluripotent stem cell human CVCL_T945 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131569 CVCL_SX44 HAP1 MBD2 (-) 2 cancer cell line human CVCL_SX44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6917; MBD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131570 CVCL_T944 HPS0264 induced pluripotent stem cell human CVCL_T944 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131571 CVCL_SX47 HAP1 MBD3 (-) 3 cancer cell line human CVCL_SX47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131572 CVCL_T947 iPWS5 induced pluripotent stem cell human CVCL_T947 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131573 CVCL_SX46 HAP1 MBD3 (-) 2 cancer cell line human CVCL_SX46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131574 CVCL_T946 iMELA2 induced pluripotent stem cell human CVCL_T946 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131575 CVCL_SX49 HAP1 MBD4 (-) 2 cancer cell line human CVCL_SX49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6919; MBD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131576 CVCL_T949 iPWS3 induced pluripotent stem cell human CVCL_T949 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131577 CVCL_SX48 HAP1 MBD4 (-) 1 cancer cell line human CVCL_SX48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6919; MBD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131578 CVCL_T948 iPWS1 induced pluripotent stem cell human CVCL_T948 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131579 CVCL_SX30 HAP1 MAT2B (-) 1 cancer cell line human CVCL_SX30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6905; MAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131580 CVCL_T930 HPS0169 induced pluripotent stem cell human CVCL_T930 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131581 CVCL_SX32 HAP1 MAT2B (-) 3 cancer cell line human CVCL_SX32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6905; MAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131582 CVCL_T932 HPS0175 induced pluripotent stem cell human CVCL_T932 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Pro266Ser (c.796C>T); ClinVar=VCV000556117; Zygosity=Heterozygous (PubMed=26199952); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met439Lys (c.1316T>A); ClinVar=VCV000371305; Zygosity=Heterozygous (PubMed=26199952) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131583 CVCL_SX31 HAP1 MAT2B (-) 2 cancer cell line human CVCL_SX31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6905; MAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131584 CVCL_T931 HPS0174 induced pluripotent stem cell human CVCL_T931 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21131585 CVCL_SX34 HAP1 MATK (-) 1 cancer cell line human CVCL_SX34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6906; MATK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131586 CVCL_T934 HPS0177 induced pluripotent stem cell human CVCL_T934 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Pro266Ser (c.796C>T); ClinVar=VCV000556117; Zygosity=Heterozygous (PubMed=26199952); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met439Lys (c.1316T>A); ClinVar=VCV000371305; Zygosity=Heterozygous (PubMed=26199952) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131587 CVCL_SX33 HAP1 MAT2B (-) 4 cancer cell line human CVCL_SX33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6905; MAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131588 CVCL_T933 HPS0176 induced pluripotent stem cell human CVCL_T933 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Pro266Ser (c.796C>T); ClinVar=VCV000556117; Zygosity=Heterozygous (PubMed=26199952); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met439Lys (c.1316T>A); ClinVar=VCV000371305; Zygosity=Heterozygous (PubMed=26199952) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131589 CVCL_SX36 HAP1 MAVS (-) 1 cancer cell line human CVCL_SX36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29233; MAVS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131590 CVCL_T936 HPS0183 induced pluripotent stem cell human CVCL_T936 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131591 CVCL_SX35 HAP1 MATK (-) 2 cancer cell line human CVCL_SX35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6906; MATK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131592 CVCL_T935 HPS0178 induced pluripotent stem cell human CVCL_T935 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131593 CVCL_SX38 HAP1 MB21D1 (-) 1 cancer cell line human CVCL_SX38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21367; CGAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131594 CVCL_T938 HPS0214 induced pluripotent stem cell human CVCL_T938 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21131595 CVCL_SX37 HAP1 MAVS (-) 2 cancer cell line human CVCL_SX37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29233; MAVS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131596 CVCL_T937 HPS0184 induced pluripotent stem cell human CVCL_T937 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131597 CVCL_SX39 HAP1 MB21D1 (-) 2 cancer cell line human CVCL_SX39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21367; CGAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131598 CVCL_T939 HPS0224 induced pluripotent stem cell human CVCL_T939 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131599 CVCL_0R00 GM00517 finite cell line human CVCL_0R00 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21131600 CVCL_1300 HuP-T4 cancer cell line human CVCL_1300 HLA typing: A*02:06,02:06; B*15:01,51:01; C*07:02,15:02; DRB1*04:08,12:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.39%; East Asian, North=74.65%; East Asian, South=24.82%; South Asian=0%; European, North=0%; European, South=0.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Thr (c.764T>C); ClinVar=VCV000376623; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~38 hours (DSMZ=ACC-223); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: NCI RAS program mutant KRAS cell line panel 21131601 CVCL_0R02 GM07067 finite cell line human CVCL_0R02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21131602 CVCL_1302 IA-LM cancer cell line human CVCL_1302 Genome ancestry: African=0.16%; Native American=0.29%; East Asian, North=82.4%; East Asian, South=13.99%; South Asian=1.48%; European, North=0%; European, South=1.68% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131603 CVCL_0R01 GM04081 finite cell line human CVCL_0R01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21131604 CVCL_1301 HuTu 80 cancer cell line human CVCL_1301 Genome ancestry: African=77.36%; Native American=0%; East Asian, North=2.96%; East Asian, South=0%; South Asian=0%; European, North=8.45%; European, South=11.22% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Phe (c.110C>T); ClinVar=VCV000017586; Zygosity=Heterozygous (ATCC) Derived from sampling site: Small intestine; duodenum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7928; true Male Doubling time: 26 hours (PubMed=25984343); 26-30 hours (CLS); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21131605 CVCL_0R04 GM07291 transformed cell line human CVCL_0R04 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Leu110Pro (c.329T>C); ClinVar=VCV000018300; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131606 CVCL_1304 IGROV-1 cancer cell line human CVCL_1304 HLA typing: A*24:02:01,33:01; B*49:01; C*07; DPB1*05:01; DQB1*03; DRB1*11,11 (PubMed=15748285); HLA typing: A*24:02,33:03; B*45:01,49:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.69%; Native American=0%; East Asian, North=0%; East Asian, South=1.43%; South Asian=4.55%; European, North=46.04%; European, South=47.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (PubMed=17088437; PubMed=25230021; Cosmic-CLP); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=17088437; PubMed=25230021; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (PubMed=17088437; PubMed=24023729; PubMed=25230021; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (PubMed=17088437; PubMed=24023729; PubMed=25230021; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30 hours (PubMed=25984343); ~23 hours (PubMed=10817511); 28 +- 1 hours (PubMed=9636834); 28 hours (PubMed=9488600); 31 hours (NCI-DTP); 19.53 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: OCCP ovarian cancer cell line panel 21131607 CVCL_0R03 GM07290 transformed cell line human CVCL_0R03 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Leu110Pro (c.329T>C); ClinVar=VCV000018300; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131608 CVCL_1303 IGR-1 cancer cell line human CVCL_1303 HLA typing: A*02:01:01,03:01:01; B*11:01:01,44:02:01; C*04:01:01,05:01:01; DPB1*04:01:01G,04:02:01G; DQA1*01:01:01,03:03:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,04:01:01 (CLS=300219); Genome ancestry: African=0.53%; Native American=0%; East Asian, North=2.53%; East Asian, South=0%; South Asian=0.58%; European, North=60.87%; European, South=35.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=25056119; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Pro29Ser (c.85C>T); ClinVar=VCV000376362; Zygosity=Heterozygous (PubMed=25056119; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Inguinal lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~75-100 hours (DSMZ=ACC-236); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131609 CVCL_0R06 GM10807 transformed cell line human CVCL_0R06 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (Coriell) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131610 CVCL_1306 IMR-5 cancer cell line human CVCL_1306 Genome ancestry: African=0%; Native American=0.86%; East Asian, North=0%; East Asian, South=0.06%; South Asian=4.46%; European, North=75.37%; European, South=19.24% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Abdomen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131611 CVCL_0R05 GM10609 transformed cell line human CVCL_0R05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21131612 CVCL_1305 IM-9 transformed cell line human CVCL_1305 Genome ancestry: African=0%; Native American=0.41%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=68.16%; European, South=31.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~45 hours (DSMZ=ACC-117); ~1 day (lot 09172008), ~23 hours (lot 03302009) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10516762). 21131613 CVCL_0R08 GM10809 transformed cell line human CVCL_0R08 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131614 CVCL_1308 IST-MEL1 cancer cell line human CVCL_1308 Genome ancestry: African=1.49%; Native American=1.88%; East Asian, North=0%; East Asian, South=1.65%; South Asian=5.96%; European, North=29.45%; European, South=59.56% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn247Lys (c.741C>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131615 CVCL_0R07 GM10808 transformed cell line human CVCL_0R07 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131616 CVCL_1307 IPC-298 cancer cell line human CVCL_1307 HLA typing: A*03:01,24:02; B*07:02,35:02; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=0.17%; Native American=0.2%; East Asian, North=1.84%; East Asian, South=0%; South Asian=0.84%; European, North=52.05%; European, South=44.9% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg99Pro (c.296G>C); ClinVar=VCV000491572; Zygosity=Homozygous (PubMed=9354451; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=22383533; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34 hours (PubMed=8325707); ~30 hours (DSMZ=ACC-251); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131617 CVCL_0R09 GM10811 transformed cell line human CVCL_0R09 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131618 CVCL_1309 IST-MEL2 cancer cell line human CVCL_1309 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 21131619 CVCL_SX21 HAP1 MAST2 (-) cancer cell line human CVCL_SX21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19035; MAST2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131620 CVCL_T921 KhES-2 subline 2 embryonic stem cell human CVCL_T921 CL:0000010 Female 21131621 CVCL_SX20 HAP1 MAST1 (-) cancer cell line human CVCL_SX20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19034; MAST1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131622 CVCL_T920 KhES-2 subline 1 embryonic stem cell human CVCL_T920 CL:0000010 Female 21131623 CVCL_SX23 HAP1 MAST3 (-) 2 cancer cell line human CVCL_SX23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19036; MAST3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131624 CVCL_T923 KhES-3 subline 2 embryonic stem cell human CVCL_T923 CL:0000010 Male 21131625 CVCL_SX22 HAP1 MAST3 (-) 1 cancer cell line human CVCL_SX22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19036; MAST3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131626 CVCL_T922 KhES-3 subline 1 embryonic stem cell human CVCL_T922 CL:0000010 Male 21131627 CVCL_SX25 HAP1 MAST4 (-) 2 cancer cell line human CVCL_SX25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131628 CVCL_T925 HCM HJ 1-i induced pluripotent stem cell human CVCL_T925 CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Gly999_Gln1004del; Zygosity=Unspecified (PubMed=25389285) Derived from sampling site: Peripheral blood. Discontinued: SKIP; SKIP000213; probable Female 21131629 CVCL_SX24 HAP1 MAST4 (-) 1 cancer cell line human CVCL_SX24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131630 CVCL_T924 KhES-1 CAG-EGFP embryonic stem cell human CVCL_T924 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Discontinued: SKIP; SKIP000150; probable. Female 21131631 CVCL_SX27 HAP1 MAST4 (-) 4 cancer cell line human CVCL_SX27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131632 CVCL_T927 HPS0078 induced pluripotent stem cell human CVCL_T927 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21131633 CVCL_SX26 HAP1 MAST4 (-) 3 cancer cell line human CVCL_SX26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131634 CVCL_T926 HCM HJ 1-n induced pluripotent stem cell human CVCL_T926 CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Gly999_Gln1004del; Zygosity=Unspecified (PubMed=25389285) Derived from sampling site: Peripheral blood. Discontinued: SKIP; SKIP000212; probable Female 21131635 CVCL_SX29 HAP1 MAST4 (-) 6 cancer cell line human CVCL_SX29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131636 CVCL_T929 HPS0164 induced pluripotent stem cell human CVCL_T929 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex48-50del; Zygosity=Hemizygous (PubMed=28439558) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131637 CVCL_SX28 HAP1 MAST4 (-) 5 cancer cell line human CVCL_SX28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19037; MAST4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131638 CVCL_T928 HPS0156 induced pluripotent stem cell human CVCL_T928 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131639 CVCL_SX10 HAP1 MARK1 (-) 1 cancer cell line human CVCL_SX10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6896; MARK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131640 CVCL_T910 HCM090909-3G1 induced pluripotent stem cell human CVCL_T910 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000209; probable Male 21131641 CVCL_SX12 HAP1 MARK1 (-) 3 cancer cell line human CVCL_SX12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6896; MARK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131642 CVCL_T912 HCM512519-c1 induced pluripotent stem cell human CVCL_T912 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000211; probable Female 21131643 CVCL_SX11 HAP1 MARK1 (-) 2 cancer cell line human CVCL_SX11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6896; MARK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131644 CVCL_T911 HCM512519-b3 induced pluripotent stem cell human CVCL_T911 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000210; probable Female 21131645 CVCL_T914 090727 LQT3/BrS g2 induced pluripotent stem cell human CVCL_T914 CL:0000010 Discontinued: SKIP; SKIP000215; probable. 21131646 CVCL_SX14 HAP1 MARK2 (-) 2 cancer cell line human CVCL_SX14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3332; MARK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131647 CVCL_T913 090727 LQT3/BrS g1 induced pluripotent stem cell human CVCL_T913 CL:0000010 Discontinued: SKIP; SKIP000214; probable. 21131648 CVCL_SX13 HAP1 MARK2 (-) 1 cancer cell line human CVCL_SX13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3332; MARK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131649 CVCL_T916 100213 LQT2 theta4 induced pluripotent stem cell human CVCL_T916 CL:0000010 Discontinued: SKIP; SKIP000216; probable. 21131650 CVCL_SX16 HAP1 MARK3 (-) 2 cancer cell line human CVCL_SX16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6897; MARK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131651 CVCL_T915 100213 LQT2 theta10 induced pluripotent stem cell human CVCL_T915 CL:0000010 Discontinued: SKIP; SKIP000217; probable. 21131652 CVCL_SX15 HAP1 MARK3 (-) 1 cancer cell line human CVCL_SX15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6897; MARK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131653 CVCL_SX18 HAP1 MARK4 (-) 1 cancer cell line human CVCL_SX18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13538; MARK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131654 CVCL_T918 KhES-1 subline 2 embryonic stem cell human CVCL_T918 CL:0000010 Female 21131655 CVCL_SX17 HAP1 MARK3 (-) 3 cancer cell line human CVCL_SX17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6897; MARK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131656 CVCL_T917 KhES-1 subline 1 embryonic stem cell human CVCL_T917 CL:0000010 Female 21131657 CVCL_SX19 HAP1 MARK4 (-) 2 cancer cell line human CVCL_SX19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13538; MARK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131658 CVCL_T919 KhES-1 subline 3 embryonic stem cell human CVCL_T919 CL:0000010 Female 21131659 CVCL_SX01 HAP1 MAPK9 (-) cancer cell line human CVCL_SX01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6886; MAPK9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131660 CVCL_T901 KAS01 #3 induced pluripotent stem cell human CVCL_T901 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)47 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=23364790) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21131661 CVCL_SX00 HAP1 MAPK8 (-) 2 cancer cell line human CVCL_SX00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6881; MAPK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131662 CVCL_T900 KAS01 #2 induced pluripotent stem cell human CVCL_T900 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)47 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (PubMed=23364790) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21131663 CVCL_T903 GM06926 transformed cell line human CVCL_T903 CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[52]; Zygosity=Heterozygous; Note=The other allele has 29 repeats (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131664 CVCL_SX03 HAP1 MAPKAP1 (-) 2 cancer cell line human CVCL_SX03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18752; MAPKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131665 CVCL_T902 GM13716 finite cell line human CVCL_T902 CL:0000010 Sequence variation: Mutation; HGNC; 3033; ATN1; Repeat_expansion; CAG[68] (g.17267CAG[(54-68)]); ClinVar=VCV000590267; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[16] (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21131666 CVCL_SX02 HAP1 MAPKAP1 (-) 1 cancer cell line human CVCL_SX02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18752; MAPKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131667 CVCL_T905 GM13717 finite cell line human CVCL_T905 CL:0000010 Sequence variation: Mutation; HGNC; 3033; ATN1; Repeat_expansion; CAG[65] (g.17267CAG[(54-68)]); ClinVar=VCV000590267; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[15] (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21131668 CVCL_SX05 HAP1 MAPKAPK2 (-) 2 cancer cell line human CVCL_SX05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6887; MAPKAPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131669 CVCL_T904 GM06927 finite cell line human CVCL_T904 CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[52]; Zygosity=Heterozygous; Note=The other allele has 29 repeats (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21131670 CVCL_SX04 HAP1 MAPKAPK2 (-) 1 cancer cell line human CVCL_SX04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6887; MAPKAPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131671 CVCL_SX07 HAP1 MAPKAPK5 (-) 1 cancer cell line human CVCL_SX07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6889; MAPKAPK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC000217c004; true Male Group: Haploid karyotype cell line 21131672 CVCL_T907 PID0401 induced pluripotent stem cell human CVCL_T907 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. 21131673 CVCL_SX06 HAP1 MAPKAPK3 (-) cancer cell line human CVCL_SX06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6888; MAPKAPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131674 CVCL_T906 PID0102 induced pluripotent stem cell human CVCL_T906 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male Caution: Could be identical to HPS0265 (Cellosaurus=CVCL_T940) or HPS0266 (Cellosaurus=CVCL_6C85) or HPS0266 (Cellosaurus=CVCL_6C85) 21131675 CVCL_SX09 HAP1 MAPT (-) 2 cancer cell line human CVCL_SX09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6893; MAPT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131676 CVCL_T909 HCM090909-3F2 induced pluripotent stem cell human CVCL_T909 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: SKIP; SKIP000208; probable Male 21131677 CVCL_SX08 HAP1 MAPT (-) 1 cancer cell line human CVCL_SX08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6893; MAPT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131678 CVCL_T908 PID0402 induced pluripotent stem cell human CVCL_T908 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. 21131679 CVCL_9M31 DD3102 transformed cell line human CVCL_9M31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131680 CVCL_9M30 DD3100 transformed cell line human CVCL_9M30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131681 CVCL_9M33 DD3106 transformed cell line human CVCL_9M33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131682 CVCL_9M32 DD3105 transformed cell line human CVCL_9M32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131683 CVCL_9M39 DD3128 transformed cell line human CVCL_9M39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131684 CVCL_9M38 DD3127 transformed cell line human CVCL_9M38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131685 CVCL_9M35 DD3115 transformed cell line human CVCL_9M35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131686 CVCL_9M34 DD3113 transformed cell line human CVCL_9M34 CL:0000010 Karyotypic information: 46,XX,del(22)(q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131687 CVCL_9M37 DD3126 transformed cell line human CVCL_9M37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131688 CVCL_9M36 DD3117 transformed cell line human CVCL_9M36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131689 CVCL_0S94 GM17768 transformed cell line human CVCL_0S94 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131690 CVCL_1494 NCI-H1781 cancer cell line human CVCL_1494 HLA typing: A*03:01,31:01; B*07:02,55:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0.46%; European, North=65.63%; European, South=32.22% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln245fs*6 (c.735_739delGCCGT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131691 CVCL_0S93 GM17767 transformed cell line human CVCL_0S93 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131692 CVCL_1493 NCI-H1770 cancer cell line human CVCL_1493 Genome ancestry: African=2.3%; Native American=0.35%; East Asian, North=4.49%; East Asian, South=0%; South Asian=0%; European, North=59.77%; European, South=33.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131693 CVCL_0S96 GM17770 transformed cell line human CVCL_0S96 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131694 CVCL_1496 NCI-H1793 cancer cell line human CVCL_1496 HLA typing: A*01:01,30:01; B*15:141,35:08; C*06:02,07:02; DQA1*02:01,02:01; DRB1*07:01,15:02 (PubMed=26589293); Genome ancestry: African=0.24%; Native American=0.91%; East Asian, North=1.4%; East Asian, South=0.39%; South Asian=6.96%; European, North=36.54%; European, South=53.57% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Ter (c.625A>T); Zygosity=Heterozygous (PubMed=1311061; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131695 CVCL_0S95 GM17769 transformed cell line human CVCL_0S95 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131696 CVCL_1495 NCI-H1792 cancer cell line human CVCL_1495 HLA typing: A*02:01,26:08; B*08:01,15:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=2.29%; Native American=0.75%; East Asian, North=2.43%; East Asian, South=0%; South Asian=0.41%; European, North=59.22%; European, South=34.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=1311061; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=25984343); 32.6 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21131697 CVCL_0S98 GM17773 transformed cell line human CVCL_0S98 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131698 CVCL_1498 NCI-H1836 cancer cell line human CVCL_1498 Genome ancestry: African=0%; Native American=0.84%; East Asian, North=0.99%; East Asian, South=0%; South Asian=0.88%; European, North=70.01%; European, South=27.28% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1496Glufs*27 (c.4485delC) (p.S1495fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131699 CVCL_0S97 GM17771 transformed cell line human CVCL_0S97 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131700 CVCL_1497 NCI-H1819 cancer cell line human CVCL_1497 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=20557307; DepMap) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 51.3 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21131701 CVCL_0S99 GM17774 transformed cell line human CVCL_0S99 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131702 CVCL_1499 NCI-H1838 cancer cell line human CVCL_1499 HLA typing: A*26:01,26:01; B*40:01,45:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=2.12%; Native American=0%; East Asian, North=3.65%; East Asian, South=0%; South Asian=0%; European, North=58.09%; European, South=36.13% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp1279Ter (c.3836G>A); ClinVar=VCV000127376; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Asn184fs*17 (c.548_549insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 71.8 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21131703 CVCL_9M42 DD3131 transformed cell line human CVCL_9M42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131704 CVCL_9M41 DD3130 transformed cell line human CVCL_9M41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131705 CVCL_9M44 DD3133 transformed cell line human CVCL_9M44 CL:0000010 Karyotypic information: 46,X,del(X)(p22.33) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131706 CVCL_9M43 DD3132 transformed cell line human CVCL_9M43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131707 CVCL_9M40 DD3129 transformed cell line human CVCL_9M40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131708 CVCL_9M49 DD3150 finite cell line human CVCL_9M49 CL:0000010 Karyotypic information: 46,XX,der(3)t(2;3)?(p21;q26)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131709 CVCL_9M46 DD3136 transformed cell line human CVCL_9M46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131710 CVCL_9M45 DD3134 transformed cell line human CVCL_9M45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131711 CVCL_9M48 DD3145 finite cell line human CVCL_9M48 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21131712 CVCL_9M47 DD3144 finite cell line human CVCL_9M47 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21131713 CVCL_9M11 DD3076 finite cell line human CVCL_9M11 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131714 CVCL_9M10 DD3075 finite cell line human CVCL_9M10 CL:0000010 Karyotypic information: 46,XX,der(14;18)?(q10:q10) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131715 CVCL_9M17 DD3084 transformed cell line human CVCL_9M17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131716 CVCL_9M16 DD3083 transformed cell line human CVCL_9M16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131717 CVCL_9M19 DD3086 transformed cell line human CVCL_9M19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131718 CVCL_9M18 DD3085 transformed cell line human CVCL_9M18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131719 CVCL_9M13 DD3078 finite cell line human CVCL_9M13 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131720 CVCL_9M12 DD3077 finite cell line human CVCL_9M12 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131721 CVCL_9M15 DD3082 transformed cell line human CVCL_9M15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131722 CVCL_0S81 GM17753 transformed cell line human CVCL_0S81 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131723 CVCL_1481 NCI-H1623 cancer cell line human CVCL_1481 HLA typing: A*01:01,11:01; B*40:01,51:01; C*03:04,05:01 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=0.03%; East Asian, North=2.83%; East Asian, South=0%; South Asian=0%; European, North=60.22%; European, South=35.4% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131724 CVCL_9M14 DD3079 transformed cell line human CVCL_9M14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131725 CVCL_0S80 GM17752 transformed cell line human CVCL_0S80 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131726 CVCL_1480 NCI-H1618 cancer cell line human CVCL_1480 HLA typing: A*01:01,03:01; B*07:02,58:05; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.23%; Native American=0.54%; East Asian, North=0.24%; East Asian, South=0%; South Asian=3.51%; European, North=61.08%; European, South=34.4% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Pro39Argfs*26 (c.116delC); Zygosity=Homozygous (ATCC; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=1312696; PubMed=1565469; PubMed=20557307; ATCC; DepMap) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21131727 CVCL_0S72 GM17741 transformed cell line human CVCL_0S72 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131728 CVCL_1472 NCI-H1437 cancer cell line human CVCL_1472 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.16%; East Asian, North=1.67%; East Asian, South=0%; South Asian=0%; European, North=68.74%; European, South=28.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Pro (c.800G>C); ClinVar=VCV000428867; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307; ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 44 hours (PubMed=25984343); 28.7 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131729 CVCL_0S71 GM17740 transformed cell line human CVCL_0S71 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131730 CVCL_1471 NCI-H1436 cancer cell line human CVCL_1471 HLA typing: A*02:01,11:01; B*07:02,18:01; C*12:03,12:03 (PubMed=26589293); Genome ancestry: African=0.29%; Native American=0.28%; East Asian, North=3.22%; East Asian, South=0%; South Asian=1.4%; European, North=67.17%; European, South=27.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Gln (c.537T>G); ClinVar=VCV000376607; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131731 CVCL_0S74 GM17743 transformed cell line human CVCL_0S74 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131732 CVCL_1474 NCI-H1522 cancer cell line human CVCL_1474 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5874; true Male 21131733 CVCL_0S73 GM17742 transformed cell line human CVCL_0S73 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131734 CVCL_1473 NCI-H146 cancer cell line human CVCL_1473 HLA typing: A*01:01,03:01; B*14:02,14:02; C*08:02,16:01; DQB1*04:01,04:01 (PubMed=25960936); HLA typing: A*01:01,03:01; B*14:02,14:02; C*08:02,16:01 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0%; East Asian, North=2.05%; East Asian, South=0%; South Asian=0.45%; European, North=66.14%; European, South=30.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu2911Ter (c.8731G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu4588Ter (c.13762G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln850Ter (c.2548C>T); ClinVar=VCV000284733; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro318Leufs*21 (c.953_971del19); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131735 CVCL_0S76 GM17745 transformed cell line human CVCL_0S76 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131736 CVCL_1476 NCI-H1568 cancer cell line human CVCL_1476 HLA typing: A*03:01,32:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.1%; Native American=0%; East Asian, North=2.23%; East Asian, South=0%; South Asian=2.88%; European, North=56.39%; European, South=38.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gly506Phe (c.1516_1517GG>TT); Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 42.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131737 CVCL_9M09 DD3073 transformed cell line human CVCL_9M09 CL:0000010 Karyotypic information: 46,XY,t(1;8)(p32;q13) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131738 CVCL_0S75 GM17744 transformed cell line human CVCL_0S75 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131739 CVCL_1475 NCI-H1563 cancer cell line human CVCL_1475 HLA typing: A*02:01,24:02; B*35:02,51:01; C*04:01,15:02 (PubMed=26589293); Genome ancestry: African=0.33%; Native American=0%; East Asian, North=0.56%; East Asian, South=2.48%; South Asian=10.47%; European, North=24.17%; European, South=61.99% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131740 CVCL_0S78 GM17747 transformed cell line human CVCL_0S78 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131741 CVCL_1478 NCI-H1573 cancer cell line human CVCL_1478 HLA typing: A*30:01,30:01; B*14:02,14:02; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=1.85%; Native American=0%; East Asian, North=5.57%; East Asian, South=0%; South Asian=0%; European, North=54.36%; European, South=38.22% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Arg351Ter (c.1051C>T); ClinVar=VCV000372552; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131742 CVCL_1477 Ba Pot finite cell line human CVCL_1477 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131743 CVCL_0S77 GM17746 transformed cell line human CVCL_0S77 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131744 CVCL_0S79 GM17749 transformed cell line human CVCL_0S79 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131745 CVCL_1479 NCI-H1581 cancer cell line human CVCL_1479 HLA typing: A*02:01,26:01; B*38:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0.94%; Native American=0%; East Asian, North=1.51%; East Asian, South=0%; South Asian=0.71%; European, North=59.07%; European, South=37.76% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala1107fs*12 (c.3317_3318insG); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131746 CVCL_9M20 DD3087 transformed cell line human CVCL_9M20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131747 CVCL_9M22 DD3089 transformed cell line human CVCL_9M22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131748 CVCL_9M21 DD3088 transformed cell line human CVCL_9M21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131749 CVCL_9M28 DD3098 finite cell line human CVCL_9M28 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21131750 CVCL_9M27 DD3097 transformed cell line human CVCL_9M27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131751 CVCL_9M29 DD3099 transformed cell line human CVCL_9M29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131752 CVCL_9M24 DD3092 transformed cell line human CVCL_9M24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131753 CVCL_0S90 GM17764 transformed cell line human CVCL_0S90 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131754 CVCL_1490 NCI-H1703 cancer cell line human CVCL_1490 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=3.29%; Native American=0%; East Asian, North=5.58%; East Asian, South=0%; South Asian=0%; European, North=47.2%; European, South=43.93% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Val (c.251A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>T (IVS8+1G>T); ClinVar=VCV000495326; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=20557307; Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47.9 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: Indicated to have a TP53 p.Glu285Lys (c.853G>A) mutation according to PubMed=1311061 21131755 CVCL_9M23 DD3090 finite cell line human CVCL_9M23 CL:0000010 Karyotypic information: 47,XXY,t(3;4)(q26.32;q31.1)mat (ECACC); Derived from sampling site: Amniotic fluid. Ambiguous Part of: ECACC chromosomal abnormality collection 21131756 CVCL_9M26 DD3096 transformed cell line human CVCL_9M26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131757 CVCL_0S92 GM17766 transformed cell line human CVCL_0S92 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131758 CVCL_1492 NCI-H1755 cancer cell line human CVCL_1492 HLA typing: A*02:01,02:01; B*40:01,44:02; C*03:04,05:01 (PubMed=26589293); Genome ancestry: African=0.64%; Native American=0.15%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=61.65%; European, South=34.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ala (c.1406G>C); ClinVar=VCV000013971; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel 21131759 CVCL_9M25 DD3095 transformed cell line human CVCL_9M25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131760 CVCL_0S91 GM17765 transformed cell line human CVCL_0S91 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131761 CVCL_1491 NCI-H1734 cancer cell line human CVCL_1491 HLA typing: A*02:01,02:01; B*40:01,44:02; C*03:04,16:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.78%; East Asian, North=1.29%; East Asian, South=0%; South Asian=0%; European, North=67.8%; European, South=30.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln65Pro (c.194A>C); ClinVar=VCV000820386; Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Heterozygous (PubMed=1311061; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser127Ile (c.380G>T); ClinVar=VCV000958692; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21131762 CVCL_0S83 GM17755 transformed cell line human CVCL_0S83 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131763 CVCL_1483 NCI-H1650 cancer cell line human CVCL_1483 HLA typing: A*02:01,02:01; B*15:18,15:18; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=0.57%; Native American=0%; East Asian, North=3.27%; East Asian, South=0%; South Asian=0%; European, North=61.83%; European, South=34.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Heterozygous (PubMed=17332333; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42 hours (PubMed=25984343); 40.4 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131764 CVCL_0S82 GM17754 transformed cell line human CVCL_0S82 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131765 CVCL_1482 NCI-H1648 cancer cell line human CVCL_1482 HLA typing: A*11:01,34:02; B*07:02,53:01; C*04:01,07:02; DQA1*01:02,04:01; DQB1*04:02,06:02; DRB1*03:02,15:01 (PubMed=26589293); Genome ancestry: African=69.05%; Native American=0%; East Asian, North=4.46%; East Asian, South=0%; South Asian=0%; European, North=14.67%; European, South=11.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35fs*8 (c.102_103insT) (c.103_104insT); Zygosity=Heterozygous (PubMed=1311061; PubMed=20557307; Cosmic-CLP; DepMap) Population: African American; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 41.9 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131766 CVCL_0S85 GM17757 transformed cell line human CVCL_0S85 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131767 CVCL_1485 NCI-H1666 cancer cell line human CVCL_1485 HLA typing: A*01:01,02:01; B*44:02,67:02; C*07:04,12:03 (PubMed=26589293); Genome ancestry: African=1.25%; Native American=0%; East Asian, North=1.76%; East Asian, South=0%; South Asian=1.52%; European, North=63%; European, South=32.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Val (c.1397G>T); ClinVar=VCV000013967; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1565469) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45.2 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131768 CVCL_0S84 GM17756 transformed cell line human CVCL_0S84 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131769 CVCL_1484 NCI-H1651 cancer cell line human CVCL_1484 HLA typing: A*03:01,24:02; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=1.5%; Native American=0%; East Asian, North=2.72%; East Asian, South=0%; South Asian=0%; European, North=66.41%; European, South=29.37% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg997fs*15 (c.2990delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Homozygous (PubMed=1311061; ATCC; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131770 CVCL_0S87 GM17759 transformed cell line human CVCL_0S87 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131771 CVCL_1487 NCI-H1688 cancer cell line human CVCL_1487 Genome ancestry: African=0.98%; Native American=0%; East Asian, North=2.19%; East Asian, South=0%; South Asian=0%; European, North=61.82%; European, South=35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131772 CVCL_0S86 GM17758 transformed cell line human CVCL_0S86 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131773 CVCL_1486 NCI-H1672 cancer cell line human CVCL_1486 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His61Arg (c.182A>G); ClinVar=VCV000189402; Zygosity=Unspecified (PubMed=22961666); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Unspecified (PubMed=1312696) Derived from sampling site: Lung. Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male 21131774 CVCL_0S89 GM17762 transformed cell line human CVCL_0S89 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131775 CVCL_1489 NCI-H1694 cancer cell line human CVCL_1489 HLA typing: A*02:05,23:01; B*50:01,50:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=4.95%; Native American=1.28%; East Asian, North=5.88%; East Asian, South=0.17%; South Asian=2.13%; European, North=23.45%; European, South=62.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783-1G>T; ClinVar=VCV000634661; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131776 CVCL_0S88 GM17761 transformed cell line human CVCL_0S88 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131777 CVCL_1488 NCI-H1693 cancer cell line human CVCL_1488 HLA typing: A*03:01,03:01; B*07:02,44:02; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=0.99%; Native American=0.67%; East Asian, North=3.46%; East Asian, South=0%; South Asian=0%; European, North=63.68%; European, South=31.2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Leu1085Glnfs*32 (c.3254_3270del); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>T (IVS9+1G>T); ClinVar=VCV000634766; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 51.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131778 CVCL_0S50 GM17700 transformed cell line human CVCL_0S50 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131779 CVCL_1450 NBsusSR cancer cell line human CVCL_1450 Genome ancestry: African=1.34%; Native American=0%; East Asian, North=75.7%; East Asian, South=20.79%; South Asian=0.62%; European, North=0.87%; European, South=0.68% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131780 CVCL_0S52 GM17702 transformed cell line human CVCL_0S52 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131781 CVCL_1452 NCI-ADR-RES cancer cell line human CVCL_1452 HLA typing: A*01:01:01,25:01; B*57:01:01; C*06:02; DPB1*02:01:02,13:01; DQB1*03:03:02,06:02; DRB1*07:01,15:01:01 (PubMed=15748285) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 34 hours (NCI-DTP) Part of: NCI-60 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00234 Problematic cell line: Contaminated Shown to be a OVCAR-8 derivative (PubMed=16504380; PubMed=18304946; PubMed=20143388). Originally thought to be a derivative of MCF-7. 21131782 CVCL_0S51 GM17701 transformed cell line human CVCL_0S51 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131783 CVCL_1451 NCC-IT cancer cell line human CVCL_1451 Genome ancestry: African=0%; Native American=0%; East Asian, North=81.79%; East Asian, South=18.2%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (PubMed=9331070); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131784 CVCL_0S54 GM17704 transformed cell line human CVCL_0S54 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131785 CVCL_1454 NCI-H1092 cancer cell line human CVCL_1454 HLA typing: A*01:01,03:01; B*08:01,35:03; C*07:01,07:01; DQB1*06:13,06:13; DRB1*15:02,15:02 (PubMed=25960936); HLA typing: A*01:01,03:01; B*07:05,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=1.87%; Native American=0%; East Asian, North=4.65%; East Asian, South=0%; South Asian=0%; European, North=53.89%; European, South=39.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp6Gly (c.17A>G); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6204; JUN; Simple; p.Glu282Ter (c.844G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>C (IVS6-2A>C); ClinVar=VCV000635387; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1312696; PubMed=1565469; DepMap) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131786 CVCL_0S53 GM17703 transformed cell line human CVCL_0S53 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131787 CVCL_1453 NCI-H1048 cancer cell line human CVCL_1453 HLA typing: A*23:01,68:02; B*53:01,53:01; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=69.86%; Native American=0%; East Asian, North=6.8%; East Asian, South=0%; South Asian=0%; European, North=2.3%; European, South=21.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg552Ter (c.1654C>T); ClinVar=VCV000126840; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=1312696; PubMed=1565469; ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040) 21131788 CVCL_0S56 GM17706 transformed cell line human CVCL_0S56 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131789 CVCL_1456 NCI-H1155 cancer cell line human CVCL_1456 HLA typing: A*03:01,03:01; B*47:01,47:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=1.09%; Native American=1%; East Asian, North=2.22%; East Asian, South=0%; South Asian=0.79%; European, North=60.47%; European, South=34.42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg232Ter (c.694C>T); ClinVar=VCV000042248; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (PubMed=1311061; PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 91155; probable Male Doubling time: 23.2 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131790 CVCL_0S55 GM17705 transformed cell line human CVCL_0S55 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131791 CVCL_1455 NCI-H1105 cancer cell line human CVCL_1455 HLA typing: A*02:01,68:01; B*37:09,50:01; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=1.28%; Native American=0%; East Asian, North=1.06%; East Asian, South=0%; South Asian=0%; European, North=62.71%; European, South=34.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040) 21131792 CVCL_0S58 GM17708 transformed cell line human CVCL_0S58 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131793 CVCL_1458 NCI-H1184 cancer cell line human CVCL_1458 HLA typing: A*03:01,68:02; B*07:02,07:02; C*04:01,08:02 (PubMed=26589293); Genome ancestry: African=0.45%; Native American=0.52%; East Asian, North=0.92%; East Asian, South=0%; South Asian=0.72%; European, North=65.61%; European, South=31.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly334Val (c.1001G>T); Zygosity=Unspecified (PubMed=1312696; PubMed=1565469; PubMed=20557307) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-70 hours (DSMZ=ACC-502) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21131794 CVCL_0S57 GM17707 transformed cell line human CVCL_0S57 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131795 CVCL_1457 NCI-H1173 cancer cell line human CVCL_1457 CL:0000010 Derived from metastatic site: Soft tissue. Omics: Array-based CGH; Omics: SNP array analysis Discontinued: ATCC; CRL-5857; true Female 21131796 CVCL_0S59 GM17709 transformed cell line human CVCL_0S59 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131797 CVCL_1459 NCI-H1238 cancer cell line human CVCL_1459 CL:0000010 Derived from sampling site: Skin. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male 21131798 CVCL_SY91 HAP1 MSANTD3-TMEFF1 (-) 4 cancer cell line human CVCL_SY91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 38838; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131799 CVCL_SY90 HAP1 MSANTD3-TMEFF1 (-) 3 cancer cell line human CVCL_SY90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 38838; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131800 CVCL_9M00 DD3041 transformed cell line human CVCL_9M00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131801 CVCL_SY93 HAP1 MSH2 (-) 2 cancer cell line human CVCL_SY93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131802 CVCL_SY92 HAP1 MSH2 (-) 1 cancer cell line human CVCL_SY92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131803 CVCL_SY95 HAP1 MSH2 (-) 4 cancer cell line human CVCL_SY95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131804 CVCL_SY94 HAP1 MSH2 (-) 3 cancer cell line human CVCL_SY94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7325; MSH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131805 CVCL_SY97 HAP1 MSH3 (-) 2 cancer cell line human CVCL_SY97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131806 CVCL_SY96 HAP1 MSH3 (-) 1 cancer cell line human CVCL_SY96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131807 CVCL_9M06 DD3069 transformed cell line human CVCL_9M06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131808 CVCL_SY99 HAP1 MSH5 (-) 1 cancer cell line human CVCL_SY99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7328; MSH5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131809 CVCL_9M05 DD3067 transformed cell line human CVCL_9M05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131810 CVCL_SY98 HAP1 MSH3 (-) 3 cancer cell line human CVCL_SY98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131811 CVCL_9M08 DD3072 transformed cell line human CVCL_9M08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131812 CVCL_9M07 DD3071 transformed cell line human CVCL_9M07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131813 CVCL_9M02 DD3048 transformed cell line human CVCL_9M02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131814 CVCL_9M01 DD3047 finite cell line human CVCL_9M01 CL:0000010 Karyotypic information: 47,XXX (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131815 CVCL_9M04 DD3066 transformed cell line human CVCL_9M04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131816 CVCL_0S70 GM17739 transformed cell line human CVCL_0S70 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131817 CVCL_1470 NCI-H1435 cancer cell line human CVCL_1470 HLA typing: A*01:01,01:01; B*08:01,37:04; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=2.26%; Native American=15.63%; East Asian, North=9.39%; East Asian, South=0%; South Asian=0%; European, North=41.04%; European, South=31.67% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1158fs*7 (c.3471_3476GAGACC>AAAAA); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>A (c.228C>A) (C228A); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Trp (c.423C>G); ClinVar=VCV000376564; Zygosity=Homozygous (PubMed=1311061; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131818 CVCL_9M03 DD3062 finite cell line human CVCL_9M03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21131819 CVCL_0S61 GM17711 transformed cell line human CVCL_0S61 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131820 CVCL_1461 NCI-H1284 cancer cell line human CVCL_1461 CL:0000010 Derived from metastatic site: Bone marrow. Discontinued: ATCC; CRL-5861; true Male 21131821 CVCL_0S60 GM17710 transformed cell line human CVCL_0S60 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131822 CVCL_1460 NCI-H128 cancer cell line human CVCL_1460 Genome ancestry: African=69.81%; Native American=0%; East Asian, North=2.05%; East Asian, South=0%; South Asian=0.25%; European, North=17.44%; European, South=10.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Unspecified (PubMed=20557307) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CCL-258; true; Discontinued: CLS; 300181; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131823 CVCL_0S63 GM17713 transformed cell line human CVCL_0S63 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131824 CVCL_1463 NCI-H1341 cancer cell line human CVCL_1463 HLA typing: A*25:01,31:01; B*18:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.96%; East Asian, North=2.27%; East Asian, South=0%; South Asian=0.84%; European, North=70.16%; European, South=25.77% (PubMed=30894373) CL:0000010 Derived from metastatic site: Uterus; cervix. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131825 CVCL_0S62 GM17712 transformed cell line human CVCL_0S62 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131826 CVCL_1462 NCI-H1304 cancer cell line human CVCL_1462 Genome ancestry: African=1.09%; Native American=0.31%; East Asian, North=1.44%; East Asian, South=0.13%; South Asian=0%; European, North=72.97%; European, South=24.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Met761Ilefs*4 (c.2283delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5862; true. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00411 Problematic cell line: Contaminated NCI-H1304 and NCI-H1870 have been shown to be identical. 21131827 CVCL_0S65 GM17734 transformed cell line human CVCL_0S65 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131828 CVCL_1465 NCI-H1373 cancer cell line human CVCL_1465 HLA typing: A*68:02,68:02; B*15:10,53:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=71.79%; Native American=1.21%; East Asian, North=4.32%; East Asian, South=0%; South Asian=0%; European, North=11.21%; European, South=11.46% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=1311061; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro47Leu (c.140C>T); Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; DepMap) Population: African American Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36.7 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21131829 CVCL_0S64 GM17733 transformed cell line human CVCL_0S64 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis Female Part of: Human variation panel 21131830 CVCL_1464 NCI-H1355 cancer cell line human CVCL_1464 HLA typing: A*02:01,02:01; B*35:08,50:01; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=1.64%; Native American=0%; East Asian, North=2.95%; East Asian, South=0.42%; South Asian=4.77%; European, North=41.22%; European, South=49.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Gly2044Asp (c.6131G>A); ClinVar=VCV000495479; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 91355; probable Male Doubling time: 48.8 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131831 CVCL_0S67 GM17736 transformed cell line human CVCL_0S67 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21131832 CVCL_1467 NCI-H1395 cancer cell line human CVCL_1467 HLA typing: A*01:01,02:01; B*15:01,40:01; C*03:03,04:01 (PubMed=26589293); Genome ancestry: African=3.03%; Native American=0%; East Asian, North=6.76%; East Asian, South=0%; South Asian=0%; European, North=52.83%; European, South=37.38% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr2666Ala (c.7996A>G); ClinVar=VCV000219594; Zygosity=Homozygous (PubMed=27602502); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ala (c.1406G>C); ClinVar=VCV000013971; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20557307) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 50.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21131833 CVCL_0S66 GM17735 transformed cell line human CVCL_0S66 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131834 CVCL_1466 NCI-H1385 cancer cell line human CVCL_1466 HLA typing: A*03:01,34:02; B*58:02,58:02; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=69.29%; Native American=0%; East Asian, North=3.93%; East Asian, South=0%; South Asian=0%; European, North=10.32%; European, South=16.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (DepMap) Population: African American; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21131835 CVCL_0S69 GM17738 transformed cell line human CVCL_0S69 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21131836 CVCL_1469 NCI-H1417 cancer cell line human CVCL_1469 Genome ancestry: African=0.09%; Native American=0%; East Asian, North=1.05%; East Asian, South=0.15%; South Asian=4.06%; European, North=67.94%; European, South=26.71% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Homozygous (ATCC) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040) 21131837 CVCL_0S68 GM17737 transformed cell line human CVCL_0S68 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis Male Part of: Human variation panel 21131838 CVCL_1468 NCI-H1404 cancer cell line human CVCL_1468 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Unspecified (PubMed=1311061) Derived from metastatic site: Lymph node. Omics: SNP array analysis Discontinued: KCLB; 91404; probable Male 21131839 CVCL_SY80 HAP1 MPG (-) 2 cancer cell line human CVCL_SY80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7211; MPG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131840 CVCL_SY82 HAP1 MPI (-) 2 cancer cell line human CVCL_SY82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7216; MPI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131841 CVCL_SY81 HAP1 MPI (-) 1 cancer cell line human CVCL_SY81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7216; MPI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131842 CVCL_SY84 HAP1 MPND (-) 2 cancer cell line human CVCL_SY84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25934; MPND; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131843 CVCL_SY83 HAP1 MPND (-) 1 cancer cell line human CVCL_SY83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25934; MPND; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131844 CVCL_SY86 HAP1 MS4A2 (-) 1 cancer cell line human CVCL_SY86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7316; MS4A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131845 CVCL_SY85 HAP1 MPV17 (-) 1 cancer cell line human CVCL_SY85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7224; MPV17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131846 CVCL_SY88 HAP1 MSANTD3-TMEFF1 (-) 1 cancer cell line human CVCL_SY88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 38838; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131847 CVCL_SY87 HAP1 MS4A2 (-) 2 cancer cell line human CVCL_SY87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7316; MS4A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131848 CVCL_SY89 HAP1 MSANTD3-TMEFF1 (-) 2 cancer cell line human CVCL_SY89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 38838; ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131849 CVCL_0S30 GM17671 transformed cell line human CVCL_0S30 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131850 CVCL_1430 MSTO-211H cancer cell line human CVCL_1430 HLA typing: A*01:01,03:01; B*07:02,39:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.17%; East Asian, North=1.28%; East Asian, South=0%; South Asian=2.13%; European, North=62.92%; European, South=33.49% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Gene fusion; HGNC; 6514; LATS1 + HGNC; 9508; PSEN1; Name(s)=LATS1-PSEN1 (PubMed=25902174); Sequence variation: Mutation; HGNC; 6515; LATS2; Simple; p.Met785_Leu798del14 (c.2355_2396del42); Zygosity=Heterozygous (PubMed=21245096; Cosmic-CLP; DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20 hours (PubMed=2840315); 20 hours (CLS); ~30-40 hours (DSMZ=ACC-390); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21131851 CVCL_0S32 GM17673 transformed cell line human CVCL_0S32 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131852 CVCL_1432 MUTZ-2 cancer cell line human CVCL_1432 CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; p.Arg1420Ter (c.4258C>T); Zygosity=Unspecified (PubMed=21989985) Derived from sampling site: Peripheral blood. Male Doubling time: ~47 hours (DSMZ=ACC-271); 48 hours, in presence of supernatant of 5637 (Cellosaurus=CVCL_0126) cells (PubMed=8667638) 21131853 CVCL_0S31 GM17672 transformed cell line human CVCL_0S31 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131854 CVCL_1431 MUTZ-1 cancer cell line human CVCL_1431 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: DSMZ; ACC-13; true. Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00376 Problematic cell line: Contaminated Shown to be a Namalwa derivative (PubMed=19344951). Originally thought to originate from a 5 year old girl with myelodysplastic disorder. 21131855 CVCL_0S34 GM17676 transformed cell line human CVCL_0S34 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131856 CVCL_1434 MZ-PC-1 cancer cell line human CVCL_1434 Genome ancestry: African=0.66%; Native American=0%; East Asian, North=2.92%; East Asian, South=0%; South Asian=1.85%; European, North=62.36%; European, South=32.2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 45 hours (PubMed=7599790); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131857 CVCL_0S33 GM17674 transformed cell line human CVCL_0S33 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131858 CVCL_1433 MUTZ-3 cancer cell line human CVCL_1433 HLA typing: A*02:01,03:01; B*44:02,44:02; C*04:01,04:01 (PubMed=26589293); HLA typing: A*02:01:01,03:01:01; B*44:02:01,44:03:01; C*04:01:01,07:04:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,04:01:01; DQA1*01:05:01,01:05:01; DQB1*03:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*10:01:01,11:01:01 (DSMZCellDive=ACC-295) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly10_Ala11insGly (c.31_32insGAG); Zygosity=Unspecified (DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: H3K79me1 ChIP-seq epigenome analysis; Omics: HLA class II peptidome analysis by proteomics; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Contains both CD34+ stem cell and CD14+ monocyte/macrophage cell populations and can thus be considered as a hematopoietic progenitor/stem cell line Can differentiate into an osteoclast (OC)-like lineage (PubMed=17533051). Doubling time: ~110 hours (DSMZ=ACC-295); 90-110 hours, in presence of supernatant of 5637 (Cellosaurus=CVCL_0126) cells (PubMed=8667638) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21131859 CVCL_0S36 GM17678 transformed cell line human CVCL_0S36 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131860 CVCL_1436 MZ-MEL-7 cancer cell line human CVCL_1436 Genome ancestry: African=0.42%; Native American=0.24%; East Asian, North=1.19%; East Asian, South=0.69%; South Asian=0.03%; European, North=67.07%; European, South=30.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Spleen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131861 CVCL_0S35 GM17677 transformed cell line human CVCL_0S35 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131862 CVCL_1435 MZ-MEL-2 cancer cell line human CVCL_1435 Genome ancestry: African=0%; Native American=0.15%; East Asian, North=0.41%; East Asian, South=0.66%; South Asian=0.41%; European, North=64.57%; European, South=33.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25728708; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9829; RAF1; Simple; p.Ser257Leu (c.770C>T); ClinVar=VCV000013957; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Abdomen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131863 CVCL_0S38 GM17680 transformed cell line human CVCL_0S38 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131864 CVCL_1438 Malme-3M cancer cell line human CVCL_1438 HLA typing: A*02:01,02:01; B*13:02,40:01; C*06:02,03:04; DQB1*06:02,06:02; DRB1*15:02,15:02 (PubMed=25960936); Genome ancestry: African=0.63%; Native American=0%; East Asian, North=1.38%; East Asian, South=0%; South Asian=0.35%; European, North=66.47%; European, South=31.17% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=17088437; PubMed=24576830; PubMed=29492214; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (DepMap) Population: Caucasian; Derived from metastatic site: Lung. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 43 hours (PubMed=7718330); 46.2 hours (NCI-DTP) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: TCGA-110-CL cell line panel; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2009-092 21131865 CVCL_0S37 GM17679 transformed cell line human CVCL_0S37 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131866 CVCL_1437 Malme-3 finite cell line human CVCL_1437 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21131867 CVCL_0S39 GM17682 transformed cell line human CVCL_0S39 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131868 CVCL_1439 Mo cancer cell line human CVCL_1439 Genome ancestry: African=0%; Native American=0.37%; East Asian, North=0%; East Asian, South=1.84%; South Asian=0.34%; European, North=68.22%; European, South=29.24% (PubMed=30894373) CL:0000010 Anecdotal: John Moore, the patient from which this cell line is derived, sued David Golde and the University of California over the patent that they deposited on the Mo cell line Although his claims of ownership were rejected, his physician was deemed to have breached his fiduciary duty by not informing Moore of the economic and financial interests arising from the derivation of the cell line. Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Spleen Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8066 21131869 CVCL_SY71 HAP1 MNT (-) 1 cancer cell line human CVCL_SY71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7188; MNT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131870 CVCL_SY70 HAP1 MMP25 (-) 2 cancer cell line human CVCL_SY70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14246; MMP25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131871 CVCL_SY73 HAP1 MNT (-) 3 cancer cell line human CVCL_SY73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7188; MNT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131872 CVCL_SY72 HAP1 MNT (-) 2 cancer cell line human CVCL_SY72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7188; MNT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131873 CVCL_SY75 HAP1 MOK (-) 2 cancer cell line human CVCL_SY75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9833; MOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131874 CVCL_SY74 HAP1 MOK (-) 1 cancer cell line human CVCL_SY74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9833; MOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131875 CVCL_SY77 HAP1 MPDU1 (-) 1 cancer cell line human CVCL_SY77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7207; MPDU1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131876 CVCL_SY76 HAP1 MOK (-) 3 cancer cell line human CVCL_SY76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9833; MOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131877 CVCL_SY79 HAP1 MPG (-) 1 cancer cell line human CVCL_SY79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7211; MPG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131878 CVCL_SY78 HAP1 MPDU1 (-) 2 cancer cell line human CVCL_SY78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7207; MPDU1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21131879 CVCL_0S41 GM17684 transformed cell line human CVCL_0S41 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131880 CVCL_1441 SJNB-10 cancer cell line human CVCL_1441 Genome ancestry: African=0.93%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=1.43%; European, North=66.44%; European, South=31.2% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Partial deletion; Zygosity=Homozygous (PubMed=20655465) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131881 CVCL_0S40 GM17683 transformed cell line human CVCL_0S40 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131882 CVCL_1440 NB1 cancer cell line human CVCL_1440 Genome ancestry: African=2.29%; Native American=0.21%; East Asian, North=80.53%; East Asian, South=13.17%; South Asian=0%; European, North=0%; European, South=3.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40-50 hours (PubMed=174024); ~1 day (lot 12092005) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131883 CVCL_0S43 GM17686 transformed cell line human CVCL_0S43 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131884 CVCL_1443 SJNB-13 cancer cell line human CVCL_1443 Genome ancestry: African=68.95%; Native American=0.52%; East Asian, North=1.69%; East Asian, South=0%; South Asian=0.75%; European, North=16.7%; European, South=11.4% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Tyr869Ilefs*10 (c.2605delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 18410; ZNF292; Simple; p.Glu1009Ter (c.3025G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131885 CVCL_0S42 GM17685 transformed cell line human CVCL_0S42 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131886 CVCL_1442 SJNB-12 cancer cell line human CVCL_1442 Genome ancestry: African=0.78%; Native American=0%; East Asian, North=1.75%; East Asian, South=0%; South Asian=0%; European, North=67.42%; European, South=30.06% (PubMed=30894373) CL:0000010 Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131887 CVCL_0S45 GM17689 transformed cell line human CVCL_0S45 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131888 CVCL_1445 SJNB-17 cancer cell line human CVCL_1445 Genome ancestry: African=1.11%; Native American=0.8%; East Asian, North=1.46%; East Asian, South=0.35%; South Asian=0%; European, North=66.06%; European, South=30.22% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131889 CVCL_0S44 GM17687 transformed cell line human CVCL_0S44 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21131890 CVCL_1444 SJNB-14 cancer cell line human CVCL_1444 Genome ancestry: African=0.42%; Native American=0.13%; East Asian, North=0%; East Asian, South=0.23%; South Asian=5.64%; European, North=50.65%; European, South=42.92% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>T; ClinVar=VCV001210292; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131891 CVCL_0S47 GM17695 transformed cell line human CVCL_0S47 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131892 CVCL_0S46 GM17692 transformed cell line human CVCL_0S46 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131893 CVCL_0S49 GM17699 transformed cell line human CVCL_0S49 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131894 CVCL_0S48 GM17698 transformed cell line human CVCL_0S48 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21131895 CVCL_1448 NB69 cancer cell line human CVCL_1448 Genome ancestry: African=0%; Native American=0.26%; East Asian, North=0.67%; East Asian, South=0%; South Asian=0.54%; European, North=64.54%; European, South=34% (PubMed=30894373). CL:0000010 Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21131896 CVCL_BG45 ND11377 transformed cell line human CVCL_BG45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131897 CVCL_BG44 ND11375 transformed cell line human CVCL_BG44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131898 CVCL_BG47 ND11380 transformed cell line human CVCL_BG47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131899 CVCL_BG46 ND11378 transformed cell line human CVCL_BG46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131900 CVCL_BG49 ND11385 transformed cell line human CVCL_BG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131901 CVCL_BG48 ND11382 transformed cell line human CVCL_BG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131902 CVCL_BG41 ND11370 transformed cell line human CVCL_BG41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131903 CVCL_BG40 ND11369 transformed cell line human CVCL_BG40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131904 CVCL_BG43 ND11374 transformed cell line human CVCL_BG43 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131905 CVCL_BG42 ND11371 transformed cell line human CVCL_BG42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131906 CVCL_BG56 ND11433 transformed cell line human CVCL_BG56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131907 CVCL_BG55 ND11429 transformed cell line human CVCL_BG55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131908 CVCL_BG58 ND11436 transformed cell line human CVCL_BG58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131909 CVCL_BG57 ND11435 transformed cell line human CVCL_BG57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131910 CVCL_BG59 ND11437 transformed cell line human CVCL_BG59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131911 CVCL_BG50 ND11386 transformed cell line human CVCL_BG50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131912 CVCL_BG52 ND11407 transformed cell line human CVCL_BG52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131913 CVCL_BG51 ND11389 transformed cell line human CVCL_BG51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131914 CVCL_BG54 ND11411 transformed cell line human CVCL_BG54 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131915 CVCL_BG53 ND11410 transformed cell line human CVCL_BG53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131916 CVCL_9M97 DD3349 transformed cell line human CVCL_9M97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131917 CVCL_9M96 DD3341 transformed cell line human CVCL_9M96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131918 CVCL_9M99 DD3358 transformed cell line human CVCL_9M99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131919 CVCL_9M98 DD3356 finite cell line human CVCL_9M98 CL:0000010 Karyotypic information: 46,XY,t(2;13)(p25.1;q22.1)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131920 CVCL_9M93 DD3328 transformed cell line human CVCL_9M93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131921 CVCL_9M92 DD3327 transformed cell line human CVCL_9M92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131922 CVCL_9M95 DD3340 transformed cell line human CVCL_9M95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131923 CVCL_9M94 DD3335 transformed cell line human CVCL_9M94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131924 CVCL_BG23 ND11258 transformed cell line human CVCL_BG23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131925 CVCL_BG22 ND11254 transformed cell line human CVCL_BG22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131926 CVCL_BG25 ND11281 transformed cell line human CVCL_BG25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131927 CVCL_BG24 ND11261 transformed cell line human CVCL_BG24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131928 CVCL_BG27 ND11285 transformed cell line human CVCL_BG27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131929 CVCL_BG26 ND11283 transformed cell line human CVCL_BG26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131930 CVCL_BG29 ND11287 transformed cell line human CVCL_BG29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131931 CVCL_BG28 ND11286 transformed cell line human CVCL_BG28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131932 CVCL_9M91 DD3319 transformed cell line human CVCL_9M91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131933 CVCL_9M90 DD3316 transformed cell line human CVCL_9M90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131934 CVCL_BG21 ND11253 transformed cell line human CVCL_BG21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131935 CVCL_BG20 ND11252 transformed cell line human CVCL_BG20 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131936 CVCL_BG34 ND11319 transformed cell line human CVCL_BG34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131937 CVCL_BG33 ND11318 transformed cell line human CVCL_BG33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131938 CVCL_BG36 ND11321 transformed cell line human CVCL_BG36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131939 CVCL_BG35 ND11320 transformed cell line human CVCL_BG35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131940 CVCL_BG38 ND11343 transformed cell line human CVCL_BG38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131941 CVCL_BG37 ND11324 transformed cell line human CVCL_BG37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131942 CVCL_BG39 ND11356 transformed cell line human CVCL_BG39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131943 CVCL_BG30 ND11294 transformed cell line human CVCL_BG30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131944 CVCL_BG32 ND11297 transformed cell line human CVCL_BG32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131945 CVCL_BG31 ND11295 transformed cell line human CVCL_BG31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131946 CVCL_9M75 DD3263 transformed cell line human CVCL_9M75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131947 CVCL_9M74 DD3262 transformed cell line human CVCL_9M74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131948 CVCL_9M77 DD3265 transformed cell line human CVCL_9M77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131949 CVCL_9M76 DD3264 transformed cell line human CVCL_9M76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131950 CVCL_9M71 DD3254 transformed cell line human CVCL_9M71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131951 CVCL_9M70 DD3252 finite cell line human CVCL_9M70 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21131952 CVCL_9M73 DD3257 transformed cell line human CVCL_9M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131953 CVCL_9M72 DD3255 transformed cell line human CVCL_9M72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131954 CVCL_BG09 ND11148 transformed cell line human CVCL_BG09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131955 CVCL_BG08 ND11147 transformed cell line human CVCL_BG08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131956 CVCL_9M79 DD3288 transformed cell line human CVCL_9M79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131957 CVCL_9M78 DD3266 transformed cell line human CVCL_9M78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131958 CVCL_BG01 ND11094 transformed cell line human CVCL_BG01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131959 CVCL_BG00 ND11092 transformed cell line human CVCL_BG00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131960 CVCL_BG03 ND11111 transformed cell line human CVCL_BG03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131961 CVCL_BG02 ND11110 transformed cell line human CVCL_BG02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131962 CVCL_BG05 ND11139 transformed cell line human CVCL_BG05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131963 CVCL_BG04 ND11134 transformed cell line human CVCL_BG04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131964 CVCL_BG07 ND11142 transformed cell line human CVCL_BG07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131965 CVCL_BG06 ND11140 transformed cell line human CVCL_BG06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131966 CVCL_9M86 DD3302 transformed cell line human CVCL_9M86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131967 CVCL_9M85 DD3296 finite cell line human CVCL_9M85 CL:0000010 Karyotypic information: 46,XX,del(17)(qter->p13.3).ish del(17) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131968 CVCL_9M88 DD3310 transformed cell line human CVCL_9M88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131969 CVCL_9M87 DD3306 finite cell line human CVCL_9M87 CL:0000010 Karyotypic information: 46,XX,inv(17)(p?11q?12) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131970 CVCL_9M82 DD3291 transformed cell line human CVCL_9M82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131971 CVCL_9M81 DD3290 transformed cell line human CVCL_9M81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131972 CVCL_9M84 DD3293 transformed cell line human CVCL_9M84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131973 CVCL_9M83 DD3292 transformed cell line human CVCL_9M83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131974 CVCL_BG19 ND11251 transformed cell line human CVCL_BG19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131975 CVCL_9M89 DD3313 transformed cell line human CVCL_9M89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131976 CVCL_BG12 ND11154 transformed cell line human CVCL_BG12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131977 CVCL_BG11 ND11150 transformed cell line human CVCL_BG11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131978 CVCL_BG14 ND11157 transformed cell line human CVCL_BG14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131979 CVCL_BG13 ND11155 transformed cell line human CVCL_BG13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131980 CVCL_BG16 ND11168 transformed cell line human CVCL_BG16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131981 CVCL_BG15 ND11160 transformed cell line human CVCL_BG15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131982 CVCL_BG18 ND11170 transformed cell line human CVCL_BG18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21131983 CVCL_BG17 ND11169 transformed cell line human CVCL_BG17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131984 CVCL_9M80 DD3289 transformed cell line human CVCL_9M80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131985 CVCL_BG10 ND11149 transformed cell line human CVCL_BG10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21131986 CVCL_9M53 DD3177 transformed cell line human CVCL_9M53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131987 CVCL_9M52 DD3175 transformed cell line human CVCL_9M52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131988 CVCL_9M55 DD3194 transformed cell line human CVCL_9M55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131989 CVCL_9M54 DD3193 transformed cell line human CVCL_9M54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131990 CVCL_9M51 DD3173 transformed cell line human CVCL_9M51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131991 CVCL_9M50 DD3168 finite cell line human CVCL_9M50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21131992 CVCL_9M57 DD3196 transformed cell line human CVCL_9M57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131993 CVCL_9M56 DD3195 transformed cell line human CVCL_9M56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131994 CVCL_9M59 DD3199 transformed cell line human CVCL_9M59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131995 CVCL_9M58 DD3198 transformed cell line human CVCL_9M58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131996 CVCL_9M64 DD3206 transformed cell line human CVCL_9M64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131997 CVCL_9M63 DD3203 transformed cell line human CVCL_9M63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21131998 CVCL_9M66 DD3208 transformed cell line human CVCL_9M66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21131999 CVCL_9M65 DD3207 finite cell line human CVCL_9M65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21132000 CVCL_9M60 DD3200 transformed cell line human CVCL_9M60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132001 CVCL_9M62 DD3202 transformed cell line human CVCL_9M62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132002 CVCL_9M61 DD3201 transformed cell line human CVCL_9M61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132003 CVCL_9M68 DD3235 transformed cell line human CVCL_9M68 CL:0000010 Karyotypic information: 46,XX,t(2;5)(q31.1;q23.2) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132004 CVCL_9M67 DD3216 transformed cell line human CVCL_9M67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132005 CVCL_9M69 DD3236 transformed cell line human CVCL_9M69 CL:0000010 Karyotypic information: 46,XY,?dup(5)(p14.2;p15.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132006 CVCL_BF91 ND11041 transformed cell line human CVCL_BF91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132007 CVCL_BF90 ND11040 transformed cell line human CVCL_BF90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132008 CVCL_BF89 ND11037 transformed cell line human CVCL_BF89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132009 CVCL_BF82 ND11011 transformed cell line human CVCL_BF82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132010 CVCL_BF81 ND11009 transformed cell line human CVCL_BF81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132011 CVCL_BF84 ND11026 transformed cell line human CVCL_BF84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132012 CVCL_BF83 ND11025 transformed cell line human CVCL_BF83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132013 CVCL_BF86 ND11030 transformed cell line human CVCL_BF86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132014 CVCL_BF85 ND11027 transformed cell line human CVCL_BF85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132015 CVCL_BF88 ND11036 transformed cell line human CVCL_BF88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132016 CVCL_BF87 ND11031 transformed cell line human CVCL_BF87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132017 CVCL_BF93 ND11075 transformed cell line human CVCL_BF93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132018 CVCL_BF92 ND11074 transformed cell line human CVCL_BF92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132019 CVCL_BF95 ND11077 transformed cell line human CVCL_BF95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132020 CVCL_BF94 ND11076 transformed cell line human CVCL_BF94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132021 CVCL_BF97 ND11081 transformed cell line human CVCL_BF97 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132022 CVCL_BF96 ND11078 transformed cell line human CVCL_BF96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132023 CVCL_BF99 ND11087 transformed cell line human CVCL_BF99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132024 CVCL_BF98 ND11084 transformed cell line human CVCL_BF98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132025 CVCL_BF68 ND10967 transformed cell line human CVCL_BF68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132026 CVCL_BF67 ND10966 transformed cell line human CVCL_BF67 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132027 CVCL_BF69 ND10968 transformed cell line human CVCL_BF69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132028 CVCL_BF60 ND10938 transformed cell line human CVCL_BF60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132029 CVCL_BF62 ND10940 transformed cell line human CVCL_BF62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132030 CVCL_BF61 ND10939 transformed cell line human CVCL_BF61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132031 CVCL_BF64 ND10963 transformed cell line human CVCL_BF64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132032 CVCL_BF63 ND10941 transformed cell line human CVCL_BF63 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132033 CVCL_BF66 ND10965 transformed cell line human CVCL_BF66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132034 CVCL_BF65 ND10964 transformed cell line human CVCL_BF65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132035 CVCL_BF80 ND11008 transformed cell line human CVCL_BF80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132036 CVCL_BF79 ND10985 transformed cell line human CVCL_BF79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132037 CVCL_BF78 ND10984 transformed cell line human CVCL_BF78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132038 CVCL_BF71 ND10971 transformed cell line human CVCL_BF71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132039 CVCL_BF70 ND10969 transformed cell line human CVCL_BF70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132040 CVCL_BF73 ND10973 transformed cell line human CVCL_BF73 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132041 CVCL_BF72 ND10972 transformed cell line human CVCL_BF72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132042 CVCL_BF75 ND10979 transformed cell line human CVCL_BF75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132043 CVCL_BF74 ND10974 transformed cell line human CVCL_BF74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132044 CVCL_BF77 ND10983 transformed cell line human CVCL_BF77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132045 CVCL_BF76 ND10982 transformed cell line human CVCL_BF76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132046 CVCL_BF46 ND10903 transformed cell line human CVCL_BF46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132047 CVCL_BF45 ND10901 transformed cell line human CVCL_BF45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132048 CVCL_BF48 ND10905 transformed cell line human CVCL_BF48 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132049 CVCL_BF47 ND10904 transformed cell line human CVCL_BF47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132050 CVCL_BF49 ND10907 transformed cell line human CVCL_BF49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132051 CVCL_BF40 ND10893 transformed cell line human CVCL_BF40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132052 CVCL_BF42 ND10898 transformed cell line human CVCL_BF42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132053 CVCL_BF41 ND10895 transformed cell line human CVCL_BF41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132054 CVCL_BF44 ND10900 transformed cell line human CVCL_BF44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132055 CVCL_BF43 ND10899 transformed cell line human CVCL_BF43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132056 CVCL_BF57 ND10930 transformed cell line human CVCL_BF57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132057 CVCL_BF56 ND10928 transformed cell line human CVCL_BF56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132058 CVCL_BF59 ND10937 transformed cell line human CVCL_BF59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132059 CVCL_BF58 ND10935 transformed cell line human CVCL_BF58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132060 CVCL_BF51 ND10912 transformed cell line human CVCL_BF51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132061 CVCL_BF50 ND10911 transformed cell line human CVCL_BF50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132062 CVCL_BF53 ND10914 transformed cell line human CVCL_BF53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132063 CVCL_BF52 ND10913 transformed cell line human CVCL_BF52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132064 CVCL_BF55 ND10926 transformed cell line human CVCL_BF55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132065 CVCL_BF54 ND10915 transformed cell line human CVCL_BF54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132066 CVCL_SY60 HAP1 MMP15 (-) 1 cancer cell line human CVCL_SY60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7161; MMP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132067 CVCL_SY62 HAP1 MMP16 (-) 1 cancer cell line human CVCL_SY62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7162; MMP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132068 CVCL_SY61 HAP1 MMP15 (-) 2 cancer cell line human CVCL_SY61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7161; MMP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132069 CVCL_SY64 HAP1 MMP17 (-) 1 cancer cell line human CVCL_SY64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7163; MMP17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132070 CVCL_SY63 HAP1 MMP16 (-) 2 cancer cell line human CVCL_SY63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7162; MMP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132071 CVCL_SY66 HAP1 MMP24 (-) 1 cancer cell line human CVCL_SY66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7172; MMP24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132072 CVCL_SY65 HAP1 MMP17 (-) 2 cancer cell line human CVCL_SY65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7163; MMP17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132073 CVCL_SY68 HAP1 MMP24 (-) 3 cancer cell line human CVCL_SY68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7172; MMP24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132074 CVCL_SY67 HAP1 MMP24 (-) 2 cancer cell line human CVCL_SY67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7172; MMP24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132075 CVCL_SY69 HAP1 MMP25 (-) 1 cancer cell line human CVCL_SY69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14246; MMP25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132076 CVCL_0S10 GM17641 transformed cell line human CVCL_0S10 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132077 CVCL_1410 MHH-CALL-4 cancer cell line human CVCL_1410 HLA typing: A*03:01,24:02; B*07:02,37:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.24%; Native American=0%; East Asian, North=0.15%; East Asian, South=1.34%; South Asian=1.97%; European, North=65.48%; European, South=30.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Leu23Arg (c.68T>G); ClinVar=VCV000180860; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~80-100 hours (DSMZ=ACC-337); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132078 CVCL_0S12 GM17644 transformed cell line human CVCL_0S12 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132079 CVCL_1412 MHH-NB-11 cancer cell line human CVCL_1412 HLA typing: A*02:01,03:01; B*40:16,40:16; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.35%; Native American=0%; East Asian, North=1.33%; East Asian, South=0%; South Asian=2.27%; European, North=69.36%; European, South=26.69% (PubMed=30894373) CL:0000010 Derived from metastatic site: Adrenal gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42 hours (PubMed=3218965); ~100 hours (DSMZ=ACC-157); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132080 CVCL_0S11 GM17642 transformed cell line human CVCL_0S11 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132081 CVCL_1411 MHH-ES-1 cancer cell line human CVCL_1411 HLA typing: A*01:01,68:01; B*40:01,49:01; C*01:02,07:01 (PubMed=26589293); Genome ancestry: African=1.53%; Native American=0.83%; East Asian, North=4.32%; East Asian, South=3.68%; South Asian=6.47%; European, North=41.94%; European, South=41.22% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=25485619); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln735fs; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215del (c.643_645delAGT); Zygosity=Unspecified (PubMed=25223734) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~28 hours (DSMZ=ACC-167); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132082 CVCL_0S14 GM17646 transformed cell line human CVCL_0S14 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132083 CVCL_1414 MJ cancer cell line human CVCL_1414 HLA typing: A*01:01,01:01; B*08:01,27:05; C*07:01,15:02; DQA1*02:01,05:01; DQB1*02:01,02:01; DRB1*03:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.31%; South Asian=0%; European, North=70.84%; European, South=28.85% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8294 21132084 CVCL_0S13 GM17645 transformed cell line human CVCL_0S13 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132085 CVCL_1413 MHH-PREB-1 cancer cell line human CVCL_1413 HLA typing: A*02:01,02:01; B*35:03,35:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=1.87%; Native American=0.19%; East Asian, North=2.12%; East Asian, South=0.44%; South Asian=1.83%; European, North=34.51%; European, South=59.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~20-40 hours (DSMZ=ACC-354); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132086 CVCL_0S16 GM17650 transformed cell line human CVCL_0S16 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132087 CVCL_1416 MKN28 cancer cell line human CVCL_1416 HLA typing: A*31:01; B*51:01; C*03:04 (PubMed=9023415); HLA typing: B*51:01; C*03:04,03:04; DRB1*15:01,15:01 (PubMed=25960936); Genome ancestry: African=0%; Native American=0%; East Asian, North=83.28%; East Asian, South=16.71%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (PubMed=1370612; PubMed=11107048; PubMed=15900046; PubMed=15901131; PubMed=22490663) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0324; true; Discontinued: JCRB; NIHS0325; true; Discontinued: JCRB; FDSC0011; true; Discontinued: RCB; RCB1000; true Male Doubling time: 28-32 hours (PubMed=3962675); 30-34 hours (CelloPub=CLPUB00584); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00328 Problematic cell line: Contaminated Shown to be a MKN74 derivative (PubMed=20143388). 21132088 CVCL_0S15 GM17648 transformed cell line human CVCL_0S15 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132089 CVCL_1415 MKN1 cancer cell line human CVCL_1415 HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04; DQA1*04:01,04:01; DQB1*03:09,03:09; DRB1*11:01,03:17 (PubMed=25960936); HLA typing: A*24:02,26:02; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.31%; Native American=0%; East Asian, North=81.4%; East Asian, South=15.4%; South Asian=0%; European, North=0.44%; European, South=2.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Unspecified (PubMed=1370612; PubMed=11107048; PubMed=15900046) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 43-45 hours (CelloPub=CLPUB00584); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: MD Anderson Cell Lines Project 21132090 CVCL_0S18 GM17653 transformed cell line human CVCL_0S18 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132091 CVCL_1418 ML-2 cancer cell line human CVCL_1418 HLA typing: A*02:01,02:01; B*44:02,51:01; C*05:01,14:02; DRB1*14:103,14:103 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0.26%; European, North=70.54%; European, South=29.2% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (PubMed=14671638; PubMed=25485619); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (PubMed=16969076; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (DSMZ=ACC-15); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132092 CVCL_0S17 GM17651 transformed cell line human CVCL_0S17 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132093 CVCL_1417 MKN7 cancer cell line human CVCL_1417 HLA typing: A*24:02,24:02; B*07:02,48:01; C*04:01,08:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.09%; East Asian, North=81.05%; East Asian, South=18.37%; South Asian=0%; European, North=0%; European, South=0.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Homozygous (PubMed=11107048; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB0082; true; Discontinued: JCRB; FDSC0010; true Male Doubling time: 64-66 hours (PubMed=3962675); 86 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel Caution: TP53 mutation indicated incorrectly as being at p.Ile251Leu (c.751A>C) in PubMed=15900046 21132094 CVCL_0S19 GM17654 transformed cell line human CVCL_0S19 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132095 CVCL_1419 MLMA cancer cell line human CVCL_1419 Genome ancestry: African=0%; Native American=0.54%; East Asian, North=77.94%; East Asian, South=21.52%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Gly (c.838A>G); ClinVar=VCV000376658; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peritoneal effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0175; true Female Doubling time: ~62 hours (lot 08272014) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132096 CVCL_SY51 HAP1 MKNK2 (-) 2 cancer cell line human CVCL_SY51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7111; MKNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132097 CVCL_SY50 HAP1 MKNK2 (-) 1 cancer cell line human CVCL_SY50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7111; MKNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132098 CVCL_SY53 HAP1 MLH1 (-) 2 cancer cell line human CVCL_SY53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132099 CVCL_SY52 HAP1 MLH1 (-) 1 cancer cell line human CVCL_SY52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7127; MLH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132100 CVCL_SY55 HAP1 MLST8 (-) cancer cell line human CVCL_SY55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24825; MLST8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132101 CVCL_SY54 HAP1 MLKL (-) cancer cell line human CVCL_SY54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26617; MLKL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132102 CVCL_SY57 HAP1 MME (-) cancer cell line human CVCL_SY57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7154; MME; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132103 CVCL_SY56 HAP1 MLXIP (-) 1 cancer cell line human CVCL_SY56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17055; MLXIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132104 CVCL_SY59 HAP1 MMP11 (-) 2 cancer cell line human CVCL_SY59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7157; MMP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132105 CVCL_SY58 HAP1 MMP11 (-) 1 cancer cell line human CVCL_SY58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7157; MMP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132106 CVCL_0S21 GM17656 transformed cell line human CVCL_0S21 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132107 CVCL_1421 MN-60 cancer cell line human CVCL_1421 Genome ancestry: African=0.18%; Native American=0.16%; East Asian, North=2.87%; East Asian, South=0.48%; South Asian=0.82%; European, North=78.96%; European, South=16.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: EBV-negative Doubling time: 25 hours (PubMed=6296550); ~48-60 hours (DSMZ=ACC-138); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132108 CVCL_0S20 GM17655 transformed cell line human CVCL_0S20 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132109 CVCL_1420 MMAc-SF cancer cell line human CVCL_1420 Genome ancestry: African=0.62%; Native American=0.05%; East Asian, North=77.21%; East Asian, South=20.11%; South Asian=1.76%; European, North=0%; European, South=0.25% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Group: Serum/protein free medium cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132110 CVCL_0S23 GM17658 transformed cell line human CVCL_0S23 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132111 CVCL_1423 MOLT-14 cancer cell line human CVCL_1423 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~40-50 hours (DSMZ=ACC-437); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21132112 CVCL_0S22 GM17657 transformed cell line human CVCL_0S22 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132113 CVCL_1422 MOLT-13 cancer cell line human CVCL_1422 HLA typing: A*11:01,69:01; B*49:01,55:01; C*03:03,07:06 (PubMed=26589293); Genome ancestry: African=0.68%; Native American=0.55%; East Asian, North=0%; East Asian, South=0%; South Asian=4.38%; European, North=54.27%; European, South=40.12% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~80-120 hours (DSMZ=ACC-436); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132114 CVCL_0S25 GM17660 transformed cell line human CVCL_0S25 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132115 CVCL_1425 Mono-Mac-1 cancer cell line human CVCL_1425 HLA typing: A*03:01,03:01; B*07:02,51:01; C*07:02,15:02 (PubMed=26589293); Genome ancestry: African=1.61%; Native American=0.46%; East Asian, North=2.85%; East Asian, South=0%; South Asian=0%; European, North=54.45%; European, South=40.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16142349) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=25984343); ~30-50 hours (DSMZ=ACC-252) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21132116 CVCL_0S24 GM17659 transformed cell line human CVCL_0S24 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132117 CVCL_1424 MOLT-16 cancer cell line human CVCL_1424 HLA typing: A*23:01,30:02; B*14:02,14:02; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=79.1%; Native American=0.82%; East Asian, North=2.03%; East Asian, South=0%; South Asian=1.85%; European, North=7.73%; European, South=8.47% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7553; MYC + HGNC; 12027; TRA; Name(s)=TRA@-MYC (PubMed=9408752; PubMed=15843827); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1589His (c.4766G>A); ClinVar=VCV000127298; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg693His (c.2078G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg427Trp (c.1279C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (DSMZ=ACC-29); Microsatellite instability: Instable (MSI-low) (Sanger); Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutations indicated to be at p.Met237Arg (c.710T>G) and p.Gly244Cys (c.730G>T) (PubMed=2144611) 21132118 CVCL_0S27 GM17667 transformed cell line human CVCL_0S27 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132119 CVCL_1427 MPP 89 cancer cell line human CVCL_1427 HLA typing: A*01:01,02:01; B*51:08,57:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=5.06%; Native American=0%; East Asian, North=6.98%; East Asian, South=0%; South Asian=0%; European, North=33.57%; European, South=54.38% (PubMed=30894373) CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21132120 CVCL_0S26 GM17661 transformed cell line human CVCL_0S26 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132121 CVCL_1426 Mono-Mac-6 cancer cell line human CVCL_1426 HLA typing: A*03:01,03:01; B*07:02,51:01; C*07:02,15:02 (PubMed=26589293); HLA typing: A*03:01:01,03:01:01; B*07:02:01,51:01:01; C*07:02:01,15:02:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,01:01:01 (DSMZCellDive=ACC-124); Genome ancestry: African=2.82%; Native American=1.11%; East Asian, North=2.05%; East Asian, South=0%; South Asian=0%; European, North=54.71%; European, South=39.32% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=7833491; PubMed=14671638); Sequence variation: Gene fusion; HGNC; 13533; ATP8A2 + HGNC; 10471; RUNX1; Name(s)=RUNX1-ATP8A2 (PubMed=31160637); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from autologous cell line Mono-Mac-1) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Monocyte.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=25984343); ~60 hours (DSMZ=ACC-124); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21132122 CVCL_0S29 GM17670 transformed cell line human CVCL_0S29 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132123 CVCL_1429 MS-1 [Human lung carcinoma] cancer cell line human CVCL_1429 Genome ancestry: African=9.93%; Native American=0.17%; East Asian, North=64.82%; East Asian, South=12.65%; South Asian=0%; European, North=5.2%; European, South=7.23% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.1128-2A>G; ClinVar=VCV000428715; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Homozygous (PubMed=15901131; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0320; true; Discontinued: JCRB; NIHS0353; true Male Doubling time: 45 hours (PubMed=9183634); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132124 CVCL_0S28 GM17668 transformed cell line human CVCL_0S28 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132125 CVCL_1428 MRK-nu-1 cancer cell line human CVCL_1428 Genome ancestry: African=0.98%; Native American=1.19%; East Asian, North=73.82%; East Asian, South=23.21%; South Asian=0%; European, North=0.07%; European, South=0.74% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB0616; probable Female Characteristics: Established from the ascitic cells from BALB/c nu/nu mice injected intraperitoneal with the parent tumoral cells Doubling time: ~47 hours (lot 02072012) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132126 CVCL_SY40 HAP1 MIOS (-) cancer cell line human CVCL_SY40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21905; MIOS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132127 CVCL_SY42 HAP1 MITF (-) cancer cell line human CVCL_SY42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7105; MITF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132128 CVCL_SY41 HAP1 MIPEP (-) cancer cell line human CVCL_SY41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7104; MIPEP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132129 CVCL_SY44 HAP1 MKI67 (-) 2 cancer cell line human CVCL_SY44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132130 CVCL_SY43 HAP1 MKI67 (-) 1 cancer cell line human CVCL_SY43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132131 CVCL_SY46 HAP1 MKI67 (-) 4 cancer cell line human CVCL_SY46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132132 CVCL_SY45 HAP1 MKI67 (-) 3 cancer cell line human CVCL_SY45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7107; MKI67; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132133 CVCL_SY48 HAP1 MKNK1 (-) 2 cancer cell line human CVCL_SY48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7110; MKNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132134 CVCL_SY47 HAP1 MKNK1 (-) 1 cancer cell line human CVCL_SY47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7110; MKNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132135 CVCL_SY49 HAP1 MKNK1 (-) 3 cancer cell line human CVCL_SY49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7110; MKNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132136 CVCL_SY31 HAP1 MGME1 (-) 3 cancer cell line human CVCL_SY31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16205; MGME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132137 CVCL_SY30 HAP1 MGME1 (-) 2 cancer cell line human CVCL_SY30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16205; MGME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132138 CVCL_SY33 HAP1 MGME1 (-) 5 cancer cell line human CVCL_SY33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16205; MGME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132139 CVCL_SY32 HAP1 MGME1 (-) 4 cancer cell line human CVCL_SY32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16205; MGME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132140 CVCL_SY35 HAP1 MGMT (-) 2 cancer cell line human CVCL_SY35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132141 CVCL_SY34 HAP1 MGMT (-) 1 cancer cell line human CVCL_SY34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132142 CVCL_SY37 HAP1 MIF (-) 1 cancer cell line human CVCL_SY37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7097; MIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132143 CVCL_SY36 HAP1 MGMT (-) 3 cancer cell line human CVCL_SY36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7059; MGMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132144 CVCL_SY39 HAP1 MINOS1 (-) cancer cell line human CVCL_SY39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32068; MICOS10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132145 CVCL_SY38 HAP1 MINK1 (-) cancer cell line human CVCL_SY38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17565; MINK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132146 CVCL_0S01 GM17630 transformed cell line human CVCL_0S01 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132147 CVCL_1401 ME-180 cancer cell line human CVCL_1401 HLA typing: A*01,11; B*05,08; C*w07 (PubMed=77569); HLA typing: A*01:01,32:03; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=1.51%; Native American=0.16%; East Asian, North=1.49%; East Asian, South=0%; South Asian=0%; European, North=64.3%; European, South=32.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7932; true Female Virology: Contains a complete HPV68 genome Doubling time: 1.5 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21132148 CVCL_0S00 GM17626 transformed cell line human CVCL_0S00 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132149 CVCL_1400 MDA-MB-175-VII cancer cell line human CVCL_1400 HLA typing: A*24:02,68:02; B*08:01,35:08; C*04:01,07:01; DQB1*05:01,05:01; DRB1*13:02,04:22 (PubMed=25960936); HLA typing: A*24:02,68:02; B*08:01,53:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=83.61%; Native American=0%; East Asian, North=5.65%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=10.73% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7997; NRG1 + HGNC; 29945; TENM4; Name(s)=TENM4-NRG1, DOC4-NRG1; Note=In frame (PubMed=12800145; PubMed=29610121) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 112.26 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21132150 CVCL_0S03 GM17632 transformed cell line human CVCL_0S03 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132151 CVCL_1403 Mel JuSo cancer cell line human CVCL_1403 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.12%; South Asian=0%; European, North=63.28%; European, South=35.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=10766161; PubMed=15009714; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300282; true Female Doubling time: ~28 hours (DSMZ=ACC-74); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132152 CVCL_0S02 GM17631 transformed cell line human CVCL_0S02 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132153 CVCL_1402 Mel Ho cancer cell line human CVCL_1402 HLA typing: A*03:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.05%; East Asian, South=0%; South Asian=0%; European, North=64.35%; European, South=34.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~24 hours (DSMZ=ACC-62); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00144 Problematic cell line: Misidentified/contaminated Shown to be identical to MEL-Wei. This cell line was reported to be isogenic with LCL-Ho (Cellosaurus=CVCL_1868) but it does not have the same STR profile (PubMed=10508494; PubMed=20143388). According to DSMZ ACC-62 it is a human female cell line. 21132154 CVCL_0S05 GM17634 transformed cell line human CVCL_0S05 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132155 CVCL_1405 MFE-280 cancer cell line human CVCL_1405 HLA typing: A*02:01,31:01; B*07:02,51:01; C*07:02,12:03 (PubMed=26589293); Genome ancestry: African=1.51%; Native American=0.41%; East Asian, North=4.71%; East Asian, South=0%; South Asian=0%; European, North=55.75%; European, South=37.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Tyr (c.3139C>T); ClinVar=VCV000039705; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>C (IVS8+1G>C); ClinVar=VCV000428905; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap) Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~60-90 hours (DSMZ=ACC-410); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21132156 CVCL_0S04 GM17633 transformed cell line human CVCL_0S04 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132157 CVCL_1404 MES-SA cancer cell line human CVCL_1404 Genome ancestry: African=1.13%; Native American=0%; East Asian, North=1.61%; East Asian, South=0.25%; South Asian=2.44%; European, North=50.63%; European, South=43.94% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Uterus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 22-24 hours (ATCC=CRL-1976; ECACC=95051030); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132158 CVCL_0S07 GM17637 transformed cell line human CVCL_0S07 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132159 CVCL_1407 MFH-ino cancer cell line human CVCL_1407 Genome ancestry: African=0%; Native American=0%; East Asian, North=75.44%; East Asian, South=24.26%; South Asian=0.29%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 43 hours (at 41th passage), 32 hours (at 78th passage) (PubMed=1653597); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132160 CVCL_0S06 GM17636 transformed cell line human CVCL_0S06 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132161 CVCL_1406 MFE-296 cancer cell line human CVCL_1406 HLA typing: A*32:01,32:01; B*08:01,40:02; C*07:01,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0.72%; European, North=71.44%; European, South=27.84% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Cys186fs*20 (c.550delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Lys860Asnfs*16 (c.2580delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr321fs*23 (c.963delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50-60 hours (DSMZ=ACC-419); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132162 CVCL_0S09 GM17640 transformed cell line human CVCL_0S09 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132163 CVCL_1409 MHH-CALL-2 cancer cell line human CVCL_1409 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.65%; Native American=0%; East Asian, North=2.18%; East Asian, South=0%; South Asian=0%; European, North=73.49%; European, South=22.68% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~100 hours (DSMZ=ACC-341); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132164 CVCL_0S08 GM17639 transformed cell line human CVCL_0S08 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21132165 CVCL_1408 MFM-223 cancer cell line human CVCL_1408 Genome ancestry: African=0.51%; Native American=0%; East Asian, North=3.43%; East Asian, South=0%; South Asian=1.41%; European, North=55.91%; European, South=38.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 184 hours (at 12th passage), ~70 hours (at 35th passage) (PubMed=1913690); ~5-7 days (DSMZ=ACC-422); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21132166 CVCL_SY20 HAP1 MFSD7 (-) 1 cancer cell line human CVCL_SY20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26177; SLC49A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132167 CVCL_SY22 HAP1 MFSD8 (-) 1 cancer cell line human CVCL_SY22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28486; MFSD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132168 CVCL_SY21 HAP1 MFSD7 (-) 2 cancer cell line human CVCL_SY21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26177; SLC49A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132169 CVCL_SY24 HAP1 MGAT1 (-) 1 cancer cell line human CVCL_SY24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7044; MGAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132170 CVCL_SY23 HAP1 MFSD9 (-) 1 cancer cell line human CVCL_SY23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28158; MFSD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132171 CVCL_SY26 HAP1 MGAT2 (-) 2 cancer cell line human CVCL_SY26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7045; MGAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132172 CVCL_SY25 HAP1 MGAT2 (-) 1 cancer cell line human CVCL_SY25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7045; MGAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132173 CVCL_SY28 HAP1 MGEA5 (-) 1 cancer cell line human CVCL_SY28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7056; OGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132174 CVCL_SY27 HAP1 MGAT5 (-) cancer cell line human CVCL_SY27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7049; MGAT5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132175 CVCL_SY29 HAP1 MGME1 (-) 1 cancer cell line human CVCL_SY29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16205; MGME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132176 CVCL_SY11 HAP1 METTL6 (-) 3 cancer cell line human CVCL_SY11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28343; METTL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132177 CVCL_SY10 HAP1 METTL6 (-) 2 cancer cell line human CVCL_SY10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28343; METTL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132178 CVCL_SY13 HAP1 METTL8 (-) 1 cancer cell line human CVCL_SY13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25856; METTL8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132179 CVCL_SY12 HAP1 METTL6 (-) 4 cancer cell line human CVCL_SY12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28343; METTL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132180 CVCL_SY15 HAP1 METTL9 (-) 1 cancer cell line human CVCL_SY15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24586; METTL9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132181 CVCL_SY14 HAP1 METTL8 (-) 2 cancer cell line human CVCL_SY14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25856; METTL8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132182 CVCL_SY17 HAP1 MEX3C (-) cancer cell line human CVCL_SY17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28040; MEX3C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132183 CVCL_SY16 HAP1 METTL9 (-) 2 cancer cell line human CVCL_SY16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24586; METTL9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132184 CVCL_SY19 HAP1 MFSD2A (-) cancer cell line human CVCL_SY19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25897; MFSD2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132185 CVCL_SY18 HAP1 MFN1 (-) cancer cell line human CVCL_SY18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18262; MFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132186 CVCL_SY00 HAP1 METTL21B (-) 2 cancer cell line human CVCL_SY00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24936; EEF1AKMT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132187 CVCL_SY02 HAP1 METTL22 (-) 2 cancer cell line human CVCL_SY02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28368; METTL22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132188 CVCL_SY01 HAP1 METTL22 (-) 1 cancer cell line human CVCL_SY01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28368; METTL22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132189 CVCL_SY04 HAP1 METTL23 (-) 2 cancer cell line human CVCL_SY04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26988; METTL23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132190 CVCL_SY03 HAP1 METTL23 (-) 1 cancer cell line human CVCL_SY03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26988; METTL23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132191 CVCL_SY06 HAP1 METTL5 (-) 2 cancer cell line human CVCL_SY06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25006; METTL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132192 CVCL_SY05 HAP1 METTL5 (-) 1 cancer cell line human CVCL_SY05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25006; METTL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132193 CVCL_SY08 HAP1 METTL5 (-) 5 cancer cell line human CVCL_SY08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25006; METTL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132194 CVCL_SY07 HAP1 METTL5 (-) 3 cancer cell line human CVCL_SY07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25006; METTL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132195 CVCL_SY09 HAP1 METTL6 (-) 1 cancer cell line human CVCL_SY09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28343; METTL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132196 CVCL_9N52 DD3658 transformed cell line human CVCL_9N52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132197 CVCL_9N51 DD3657 transformed cell line human CVCL_9N51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132198 CVCL_9N54 DD3669 finite cell line human CVCL_9N54 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21132199 CVCL_9N53 DD3668 finite cell line human CVCL_9N53 CL:0000010 Karyotypic information: 47,XY,+der(15)t(11;15)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132200 CVCL_9N50 DD3639 transformed cell line human CVCL_9N50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132201 CVCL_9N59 DD3705 transformed cell line human CVCL_9N59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132202 CVCL_9N56 DD3702 transformed cell line human CVCL_9N56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132203 CVCL_9N55 DD3687 finite cell line human CVCL_9N55 CL:0000010 Karyotypic information: 46,XX.ish 22q11.2(cH748x2) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132204 CVCL_9N58 DD3704 transformed cell line human CVCL_9N58 CL:0000010 Karyotypic information: 46,XX,dup(15)(pter->q15::q11.2->q13::q15->qter) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132205 CVCL_9N57 DD3703 transformed cell line human CVCL_9N57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132206 CVCL_9N63 DD3709 transformed cell line human CVCL_9N63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132207 CVCL_9N62 DD3708 transformed cell line human CVCL_9N62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132208 CVCL_9N65 DD3680 finite cell line human CVCL_9N65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132209 CVCL_9N64 DD3710 transformed cell line human CVCL_9N64 CL:0000010 Karyotypic information: 46,XX,inv ins(9;2)(9p;2q3.?3->2q31) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132210 CVCL_9N61 DD3707 transformed cell line human CVCL_9N61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132211 CVCL_9N60 DD3706 transformed cell line human CVCL_9N60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132212 CVCL_9N67 DD3024 transformed cell line human CVCL_9N67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132213 CVCL_9N66 DD3005 transformed cell line human CVCL_9N66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132214 CVCL_9N69 DD3026 transformed cell line human CVCL_9N69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132215 CVCL_9N68 DD3025 transformed cell line human CVCL_9N68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132216 CVCL_9N30 DD3560 transformed cell line human CVCL_9N30 CL:0000010 Karyotypic information: 46,XY,inv(6)(p24;q16.2) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132217 CVCL_9N32 DD3573 transformed cell line human CVCL_9N32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132218 CVCL_9N31 DD3572 transformed cell line human CVCL_9N31 CL:0000010 Karyotypic information: 46,XY,t(2;7) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132219 CVCL_9N38 DD3599 finite cell line human CVCL_9N38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21132220 CVCL_9N37 DD3589 transformed cell line human CVCL_9N37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132221 CVCL_9N39 DD3606 transformed cell line human CVCL_9N39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132222 CVCL_9N34 DD3581 finite cell line human CVCL_9N34 CL:0000010 Karyotypic information: 46,XX,inv(13)t(13;18)(q31.2;q32.3)(q32.3;q23)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132223 CVCL_9N33 DD3576 finite cell line human CVCL_9N33 CL:0000010 Karyotypic information: 46,XY,t(5;11)(q13.1;p15.1)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132224 CVCL_9N36 DD3588 transformed cell line human CVCL_9N36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132225 CVCL_9N35 DD3583 transformed cell line human CVCL_9N35 CL:0000010 Karyotypic information: 46,XY,t(2;18) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132226 CVCL_0T93 HE41 finite cell line human CVCL_0T93 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132227 CVCL_1593 NCI-H835 cancer cell line human CVCL_1593 Genome ancestry: African=80.01%; Native American=0%; East Asian, North=2.97%; East Asian, South=0%; South Asian=0%; European, North=9.74%; European, South=7.28% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132228 CVCL_0T92 HE39 finite cell line human CVCL_0T92 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132229 CVCL_1592 NCI-H820 cancer cell line human CVCL_1592 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=0.6%; Native American=0%; East Asian, North=0.97%; East Asian, South=0%; South Asian=0.4%; European, North=65.84%; European, South=32.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr284Pro (c.850A>C); Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-001140; true Male Doubling time: 65.2 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21132230 CVCL_0T95 HE46 finite cell line human CVCL_0T95 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132231 CVCL_1595 NCI-H841 cancer cell line human CVCL_1595 Genome ancestry: African=1.52%; Native American=0%; East Asian, North=2.66%; East Asian, South=0%; South Asian=0%; European, North=55.47%; European, South=40.35% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Lys934Ter (c.2800A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132232 CVCL_0T94 HE42 finite cell line human CVCL_0T94 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132233 CVCL_1594 NCI-H838 cancer cell line human CVCL_1594 HLA typing: A*30:02,30:02; B*48:01,56:03; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0.84%; East Asian, North=0.79%; East Asian, South=1.88%; South Asian=3.04%; European, North=50.18%; European, South=43.22% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 55 hours (PubMed=25984343); 26.4 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132234 CVCL_0T97 HE48 finite cell line human CVCL_0T97 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132235 CVCL_1597 NCI-H865 cancer cell line human CVCL_1597 CL:0000010 Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female 21132236 CVCL_0T96 HE47 finite cell line human CVCL_0T96 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132237 CVCL_1596 NCI-H847 cancer cell line human CVCL_1596 HLA typing: A*03:01,23:01; B*07:02,44:03; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=5.07%; Native American=0.08%; East Asian, North=4.4%; East Asian, South=0%; South Asian=0%; European, North=55.14%; European, South=35.3% (PubMed=30894373) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132238 CVCL_0T99 HE50 finite cell line human CVCL_0T99 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132239 CVCL_1599 NCI-H920 cancer cell line human CVCL_1599 HLA typing: A*03:01,24:02; B*27:05,35:01; C*02:02,04:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=1311061; PubMed=1565469) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 42.5 hours (PubMed=29681454) Part of: MD Anderson Cell Lines Project 21132240 CVCL_0T98 HE49 finite cell line human CVCL_0T98 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132241 CVCL_1598 NCI-H889 cancer cell line human CVCL_1598 HLA typing: A*02:01,02:01; B*07:02,08:01; C*07:01,07:01 (PubMed=25960936); HLA typing: A*02:01,02:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.19%; Native American=0%; East Asian, North=1.86%; East Asian, South=0%; South Asian=0.01%; European, North=71.51%; European, South=26.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21132242 CVCL_9N41 DD3611 finite cell line human CVCL_9N41 CL:0000010 Derived from sampling site: Chorionic villus Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21132243 CVCL_9N40 DD3608 finite cell line human CVCL_9N40 CL:0000010 Derived from sampling site: Chorionic villus Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21132244 CVCL_9N43 DD3620 transformed cell line human CVCL_9N43 CL:0000010 Karyotypic information: 46,XY,del(4)(q2?5;q?28) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132245 CVCL_9N42 DD3617 transformed cell line human CVCL_9N42 CL:0000010 Karyotypic information: 46,XY,inv dup(16)(q11.2;q12.1)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132246 CVCL_9N49 DD3638 transformed cell line human CVCL_9N49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132247 CVCL_9N48 DD3637 transformed cell line human CVCL_9N48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132248 CVCL_9N45 DD3626 transformed cell line human CVCL_9N45 CL:0000010 Karyotypic information: 46,X,del(Xq) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132249 CVCL_9N44 DD3625 finite cell line human CVCL_9N44 CL:0000010 Karyotypic information: 46,XX,inv(9)(q?13;q22.33)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132250 CVCL_9N47 DD3635 finite cell line human CVCL_9N47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132251 CVCL_9N46 DD3627 transformed cell line human CVCL_9N46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132252 CVCL_9N10 DD3471 finite cell line human CVCL_9N10 CL:0000010 Karyotypic information: 46,XY,inv(4)(q15.32;q13.2)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132253 CVCL_9N16 DD3513 finite cell line human CVCL_9N16 CL:0000010 Karyotypic information: 46,XY,t(6;9)(q25.1;p24.1)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132254 CVCL_9N15 DD3512 transformed cell line human CVCL_9N15 CL:0000010 Karyotypic information: 46,Y,add(X)(q28) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132255 CVCL_9N18 DD3522 transformed cell line human CVCL_9N18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132256 CVCL_9N17 DD3517 transformed cell line human CVCL_9N17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132257 CVCL_9N12 DD3481 transformed cell line human CVCL_9N12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132258 CVCL_9N11 DD3477 finite cell line human CVCL_9N11 CL:0000010 Karyotypic information: 46,XY,t(5;13)(p11;p12) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132259 CVCL_9N14 DD3483 transformed cell line human CVCL_9N14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132260 CVCL_0T80 HE21 finite cell line human CVCL_0T80 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132261 CVCL_1580 NCI-H711 cancer cell line human CVCL_1580 CL:0000010 Derived from metastatic site: Bone marrow. Omics: SNP array analysis Discontinued: ATCC; CRL-5836; true Male 21132262 CVCL_9N13 DD3482 transformed cell line human CVCL_9N13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132263 CVCL_1571 NCI-H596 cancer cell line human CVCL_1571 HLA typing: A*03:01,03:01; B*08:01,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=0.07%; Native American=0%; East Asian, North=2.55%; East Asian, South=0%; South Asian=0%; European, North=62.11%; European, South=35.26% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser182fs*3 (c.541_542insT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Homozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 41.1 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028) 21132264 CVCL_0T71 TBCN-1 cancer cell line human CVCL_0T71 CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Doubling time: 54 hours (PubMed=9824643) 21132265 CVCL_0T70 IOSE4 telomerase immortalized cell line human CVCL_0T70 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis Female 21132266 CVCL_1570 NCI-H548 cancer cell line human CVCL_1570 CL:0000010 Derived from sampling site: Colon; sigmoid. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CCL-249; true Male Part of: AstraZeneca Colorectal cell line (AZCL) panel 21132267 CVCL_1573 NCI-H64 cancer cell line human CVCL_1573 Genome ancestry: African=67.82%; Native American=0.62%; East Asian, North=1.03%; East Asian, South=0%; South Asian=0%; European, North=19.2%; European, South=11.33% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Pro (c.848G>C); ClinVar=VCV000486555; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Indicated as originating from a female patient in ATCC and from a male patient in PubMed=2985257 and PubMed=2986243 21132268 CVCL_0T73 SJO transformed cell line human CVCL_0T73 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Ser78Argfs*7 (c.234delCTCAG); Zygosity=Homozygous (PubMed=7744245) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-2293; true Female 21132269 CVCL_0T72 KMBC-Hep cancer cell line human CVCL_0T72 CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male Characteristics: Established from the liver metastasis of a nude mice subcutaneously injected with the parent cell line Doubling time: 45 hours (PubMed=9824643) 21132270 CVCL_1572 NCI-H630 undefined cell line type human CVCL_1572 Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0%; East Asian, South=1.38%; South Asian=1.38%; European, North=67.59%; European, South=29.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5833; true; Discontinued: KCLB; 90630; probable. Unspecified Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00417 Problematic cell line: Contaminated The contaminant is not known. Seems to be a mixture of cell lines. Originally said to originate from a 60 year old male patient with a rectal carcinoma. 21132271 CVCL_9N09 DD3458 finite cell line human CVCL_9N09 CL:0000010 Karyotypic information: 46,XY,inv(12)?(p11.21;q21.2) de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132272 CVCL_0T75 HE12 finite cell line human CVCL_0T75 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132273 CVCL_1575 NCI-H650 cancer cell line human CVCL_1575 HLA typing: A*24:02,24:02; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.27%; East Asian, South=0.48%; South Asian=0%; European, North=65.1%; European, South=33.15% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser871Ter (c.2612C>A); ClinVar=VCV000051315; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Pro41Glnfs*6 (c.121delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Glu306Ter (c.916G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Asn (c.492G>T); Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 49.4 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132274 CVCL_9N08 DD3450 finite cell line human CVCL_9N08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132275 CVCL_0T74 Ia-270 cancer cell line human CVCL_0T74 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 76 hours (PubMed=3978245) 21132276 CVCL_1574 NCI-H647 cancer cell line human CVCL_1574 HLA typing: A*25:01,25:01; B*27:05,58:01; C*01:03,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.88%; East Asian, North=0%; East Asian, South=0%; South Asian=1.04%; European, North=70.95%; European, South=27.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.782+1G>T; ClinVar=VCV000496048; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=1311061; PubMed=1565469; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90647; probable Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21132277 CVCL_0T77 HE16 finite cell line human CVCL_0T77 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132278 CVCL_1577 NCI-H661 cancer cell line human CVCL_1577 HLA typing: A*02:01,24:02; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.22%; Native American=0.51%; East Asian, North=0.62%; East Asian, South=0%; South Asian=0.92%; European, North=63.58%; European, South=34.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.457+1G>T; ClinVar=VCV000635367; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6513; LASP1; Simple; p.Glu48Ter (c.142G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Heterozygous (PubMed=1311061; PubMed=20557307; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Heterozygous (PubMed=1311061; PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 61 hours (PubMed=25984343); 32.7 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: AKT genetic alteration cell panel (ATCC TCP-1029); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132279 CVCL_0T76 HE13 finite cell line human CVCL_0T76 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132280 CVCL_1576 NCI-H660 cancer cell line human CVCL_1576 HLA typing: A*01:01,68:01; B*44:02,57:01; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=2.18%; Native American=0%; East Asian, North=2.77%; East Asian, South=0%; South Asian=0%; European, North=58.05%; European, South=37% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (PubMed=17401460) Population: Caucasian; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 100 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Was originally published as originating from a small cell lung carcinoma (PubMed=2985257), but was later shown to originate from a prostate small cell carcinoma (PubMed=2569043) 21132281 CVCL_0T79 HE19 finite cell line human CVCL_0T79 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132282 CVCL_1579 NCI-H69 cancer cell line human CVCL_1579 HLA typing: A*02:01,23:01; B*42:02,58:05; C*07:01,14:02 (PubMed=26589293); HLA typing: A*02:01:01,23:01:01; B*01:01:01,51:01:01; C*07:01:01,14:02:01; DPB1*01:01:01G,03:01:01G; DQA1*03:01:01;03:03:01; DQB1*03:02:01; DRB1*04:04:01,04:05:01 (CLS=300185); Genome ancestry: African=0.79%; Native American=0%; East Asian, North=1.48%; East Asian, South=0%; South Asian=0.42%; European, North=61.96%; European, South=35.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (PubMed=19394761; ATCC); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (PubMed=2594029; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; ATCC) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 56.0 hours (PubMed=1662924); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132283 CVCL_0T78 HE18 finite cell line human CVCL_0T78 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132284 CVCL_1578 NCI-H676B cancer cell line human CVCL_1578 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val217Leu (c.649G>T); ClinVar=VCV001386154; Zygosity=Unspecified (PubMed=1311061); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=1311061) Derived from metastatic site: Pleural effusion. Male 21132285 CVCL_9N21 DD3536 finite cell line human CVCL_9N21 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132286 CVCL_9N20 DD3533 transformed cell line human CVCL_9N20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132287 CVCL_9N27 DD3545 finite cell line human CVCL_9N27 CL:0000010 Karyotypic information: 46,XY,t(15;17)(p10;p10)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132288 CVCL_9N26 DD3544 finite cell line human CVCL_9N26 CL:0000010 Karyotypic information: 46,XY,t(7;18)(q11.2;q23) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132289 CVCL_9N29 DD3555 finite cell line human CVCL_9N29 CL:0000010 Karyotypic information: 45,XY,der(14;21)(q10;q10)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21132290 CVCL_9N28 DD3547 finite cell line human CVCL_9N28 CL:0000010 Karyotypic information: 46,XY,t(7;21)(q22.1;q21.2)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132291 CVCL_9N23 DD3541 finite cell line human CVCL_9N23 CL:0000010 Karyotypic information: 46,XX,t(11;22)(23.3;q11.2)mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21132292 CVCL_9N22 DD3540 finite cell line human CVCL_9N22 CL:0000010 Karyotypic information: 46,XX,t(11;22)(q25;?q13.1) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132293 CVCL_9N25 DD3543 transformed cell line human CVCL_9N25 CL:0000010 Karyotypic information: 46,XX,ins(3;2)(p23;q13q23) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132294 CVCL_0T91 HE38 finite cell line human CVCL_0T91 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132295 CVCL_1591 NCI-H82 cancer cell line human CVCL_1591 HLA typing: A*01:01,02:01; B*58,08; C*07:01,01:02; DQA1*04:01,04:01; DQB1*04:02,02:02; DRB1*11:08,11:08 (PubMed=25960936); Genome ancestry: African=0.24%; Native American=0%; East Asian, North=1.21%; East Asian, South=0%; South Asian=0%; European, North=78.65%; European, South=19.9% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7577; MYH7 + HGNC; 9709; PVT1; Name(s)=PVT1-MYH7 (PubMed=23716474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Unspecified; Note=Impairs TP53 splicing dramatically (PubMed=1312696; PubMed=1565469; PubMed=20557307; PubMed=24700732) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=25984343); ~25 hours (CLS); ~30 hours (DSMZ=ACC-556); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21132296 CVCL_9N24 DD3542 finite cell line human CVCL_9N24 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21132297 CVCL_0T90 HE37 finite cell line human CVCL_0T90 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Unspecified 21132298 CVCL_1590 NCI-H810 cancer cell line human CVCL_1590 HLA typing: A*11:01,11:01; B*49:01,58:05; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=81.52%; Native American=0.47%; East Asian, North=4.23%; East Asian, South=0%; South Asian=0%; European, North=6.51%; European, South=7.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2731; DDR2; Simple; p.Asn373del (c.1117_1119del); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90810; probable. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21132299 CVCL_0T82 HE27 finite cell line human CVCL_0T82 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132300 CVCL_1582 NCI-H719 cancer cell line human CVCL_1582 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (ATCC) Derived from metastatic site: Bone marrow. Omics: SNP array analysis Female Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040) 21132301 CVCL_0T81 HE22 finite cell line human CVCL_0T81 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132302 CVCL_1581 NCI-H716 cancer cell line human CVCL_1581 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=3.04%; Native American=14.7%; East Asian, North=4.64%; East Asian, South=0%; South Asian=3.2%; European, North=30.38%; European, South=44.03% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 18261; NPLOC4 + HGNC; 8789; PDE6G; Name(s)=NPLOC4-PDE6G (PubMed=25485619); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Arg97Ile (c.290G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Asp (c.672G>T); ClinVar=VCV000635390; Zygosity=Homozygous (PubMed=16418264; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Secretes high level of glucagon-like peptide 1 (GLP-1) (PubMed=29787053) Doubling time: 50 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132303 CVCL_0T84 HE29 finite cell line human CVCL_0T84 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132304 CVCL_1584 NCI-H727 cancer cell line human CVCL_1584 HLA typing: A*32:01,32:01; B*38:01,67:02; C*12:03,12:03 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0.23%; East Asian, North=3.94%; East Asian, South=0%; South Asian=0.26%; European, North=62.32%; European, South=32.88% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 18053; PKD1L1 + HGNC; 21616; TNS3; Name(s)=TNS3-PKD1L1 (PubMed=25485619); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln165_Ser166insTyrLysGln (c.496_497insACAAGCAGT) (c.492_493ins9); Zygosity=Heterozygous (PubMed=1311061; PubMed=20557307; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 41 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21132305 CVCL_0T83 HE28 finite cell line human CVCL_0T83 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132306 CVCL_1583 NCI-H720 cancer cell line human CVCL_1583 Genome ancestry: African=2.64%; Native American=1.07%; East Asian, North=3.8%; East Asian, South=0%; South Asian=6.19%; European, North=25.94%; European, South=60.36% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln344Ter (c.1030C>T); Zygosity=Homozygous (PubMed=26087898; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Trp (c.528C>G); ClinVar=VCV000376572; Zygosity=Homozygous (PubMed=1311061; PubMed=26087898; ATCC; Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: KCLB; 90720; probable Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132307 CVCL_0T86 HE32 finite cell line human CVCL_0T86 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132308 CVCL_1586 NCI-H740 cancer cell line human CVCL_1586 Genome ancestry: African=1.71%; Native American=0%; East Asian, North=1.31%; East Asian, South=0%; South Asian=1.18%; European, North=64.24%; European, South=31.56% (PubMed=30894373) CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132309 CVCL_9N19 DD3532 transformed cell line human CVCL_9N19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132310 CVCL_0T85 HE30 finite cell line human CVCL_0T85 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132311 CVCL_1585 NCI-H735 cancer cell line human CVCL_1585 CL:0000010 Derived from metastatic site: Liver. Omics: SNP array analysis Female 21132312 CVCL_0T88 HE34 finite cell line human CVCL_0T88 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21132313 CVCL_1588 NCI-H748 cancer cell line human CVCL_1588 Genome ancestry: African=86.3%; Native American=0.85%; East Asian, North=1.88%; East Asian, South=0.4%; South Asian=0.04%; European, North=3.72%; European, South=6.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asp2237Metfs*4 (c.6709del); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132314 CVCL_0T87 HE33 finite cell line human CVCL_0T87 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132315 CVCL_1587 NCI-H747 cancer cell line human CVCL_1587 HLA typing: A*26:01,26:01; B*38:01,38:01; C*12:03,12:03; DQA1*03:02,03:02; DRB1*04:37,14:103 (PubMed=26589293); Genome ancestry: African=2.58%; Native American=0.23%; East Asian, North=4.27%; East Asian, South=0%; South Asian=8.5%; European, North=24.28%; European, South=60.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln161Ter (c.481C>T); ClinVar=VCV000229997; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1429Ter (c.4285C>T); ClinVar=VCV000376063; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Instable (MSI-low) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21132316 CVCL_0T89 HE36 finite cell line human CVCL_0T89 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21132317 CVCL_1589 NCI-H774 cancer cell line human CVCL_1589 CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (PubMed=9331070); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469; PubMed=10536175) Derived from metastatic site: Soft tissue. Omics: Deep proteome analysis; Omics: SNP array analysis Male 21132318 CVCL_0T51 GM17841 transformed cell line human CVCL_0T51 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132319 CVCL_1551 NCI-H2405 cancer cell line human CVCL_1551 HLA typing: A*02:01,32:01; B*14:02,51:01; C*08:02,15:02 (PubMed=26589293); Genome ancestry: African=3.18%; Native American=0%; East Asian, North=2.88%; East Asian, South=0%; South Asian=0.97%; European, North=58.28%; European, South=34.69% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu485_Pro490delinsTyr (c.1454_1469delinsA); Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132320 CVCL_0T50 GM17840 transformed cell line human CVCL_0T50 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132321 CVCL_1550 NCI-H2347 cancer cell line human CVCL_1550 HLA typing: A*01:01,02:01; B*15:01,15:01; C*03:04,03:04; DQA1*02:01,02:01; DQB1*03:02,06:13 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.74%; East Asian, South=0%; South Asian=0.59%; European, North=62.76%; European, South=35.9% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Gln28Ter (c.82C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Leu19Phe (c.57G>T); ClinVar=VCV000376034; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Homozygous; Note=Impairs TP53 splicing dramatically (PubMed=20557307; PubMed=24700732; Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 38.6 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132322 CVCL_0T53 GM17843 transformed cell line human CVCL_0T53 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132323 CVCL_1553 NCI-H2452 cancer cell line human CVCL_1553 HLA typing: A*01:01,02:01; B*35:01,57:01; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=0.27%; Native American=0%; East Asian, North=1.66%; East Asian, South=0%; South Asian=0%; European, North=63.32%; European, South=34.76% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Ala95Asp (c.284C>A); Zygosity=Homozygous (PubMed=21642991; PubMed=26011428) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21132324 CVCL_0T52 GM17842 transformed cell line human CVCL_0T52 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132325 CVCL_1552 NCI-H2444 cancer cell line human CVCL_1552 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.22%; East Asian, North=3%; East Asian, South=0%; South Asian=1.26%; European, North=58.66%; European, South=35.85% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Cys (c.707A>G); ClinVar=VCV000376693; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21132326 CVCL_0T55 GM17845 transformed cell line human CVCL_0T55 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132327 CVCL_1555 NCI-H28 cancer cell line human CVCL_1555 HLA typing: A*02:02,68:01; B*35:118,53:02; C*04:01,06:02 (PubMed=26589293); Genome ancestry: African=65.11%; Native American=0.21%; East Asian, North=3.2%; East Asian, South=0%; South Asian=0%; European, North=16.44%; European, South=15.05% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Arg146Alafs*48 (c.438-24_438-2del23); Zygosity=Homozygous (PubMed=21642991; PubMed=26011428); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90028; probable Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132328 CVCL_0T54 GM17844 transformed cell line human CVCL_0T54 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132329 CVCL_1554 NCI-H250 cancer cell line human CVCL_1554 Genome ancestry: African=91.03%; Native American=0.09%; East Asian, North=1.17%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly840fs (c.2518delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132330 CVCL_0T57 GM17847 transformed cell line human CVCL_0T57 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132331 CVCL_1557 NCI-H322M cancer cell line human CVCL_1557 HLA typing: A*29:02; B*44:03:01; C*16:01; DPB1*04:01; DQB1*02:02; DRB1*07:01 (PubMed=15748285); Genome ancestry: African=0.44%; Native American=0%; East Asian, North=0.73%; East Asian, South=0.88%; South Asian=0%; European, North=72.75%; European, South=25.2% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=17088437) Derived from sampling site: Lung Cell type=Club cell.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 35.3 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel Caution: We are not certain that NCI-H322 and NCI-H322M are identical 21132332 CVCL_0T56 GM17846 transformed cell line human CVCL_0T56 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132333 CVCL_1556 NCI-H322 cancer cell line human CVCL_1556 HLA typing: A*29:02,29:02; B*40:01,44:03; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=1.01%; Native American=0%; East Asian, North=2.38%; East Asian, South=0%; South Asian=0%; European, North=68.65%; European, South=27.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=10536175; PubMed=20557307) Derived from sampling site: Lung Cell type=Club cell.. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5806; true; Discontinued: KCLB; 90322; probable Male Doubling time: 50.6 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: We are not certain that NCI-H322 and NCI-H322M are identical 21132334 CVCL_0T59 GM17852 transformed cell line human CVCL_0T59 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132335 CVCL_1559 NCI-H358 cancer cell line human CVCL_1559 HLA typing: A*03:01,03:01; B*15:01,35:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=3.45%; Native American=0%; East Asian, North=4.63%; East Asian, South=0%; South Asian=0%; European, North=56.1%; European, South=35.82% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=1311061; PubMed=9649128; PubMed=12068308) Population: Caucasian; Derived from sampling site: Lung Cell type=Club cell.. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 76 hours (in ACL-3), 60 hours (in ACL-3 + BSA) (PubMed=3940644); 38 hours (PubMed=29681454); 38 hours (ECACC=95111733); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel Caution: NCI-H358 and NCI-H358M (Cellosaurus=CVCL_JA53) could be identical 21132336 CVCL_0T58 GM17850 transformed cell line human CVCL_0T58 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132337 CVCL_1558 NCI-H345 cancer cell line human CVCL_1558 HLA typing: A*02:01,23:01; B*58:05; C*02:02,07:01 (PubMed=25960936); HLA typing: A*02:01,23:01; B*07:55,58:05; C*02:02,07:01 (PubMed=26589293); Genome ancestry: African=1.67%; Native American=0.71%; East Asian, North=2.16%; East Asian, South=1.53%; South Asian=7.19%; European, North=25.58%; European, South=61.17% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Cys (c.707A>G); ClinVar=VCV000376693; Zygosity=Homozygous (PubMed=20557307; ATCC) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132338 CVCL_SZ90 HAP1 NANP (-) 3 cancer cell line human CVCL_SZ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16140; NANP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132339 CVCL_SZ92 HAP1 NANS (-) 2 cancer cell line human CVCL_SZ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19237; NANS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132340 CVCL_SZ91 HAP1 NANS (-) 1 cancer cell line human CVCL_SZ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19237; NANS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132341 CVCL_SZ94 HAP1 NAT14 (-) 2 cancer cell line human CVCL_SZ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28918; NAT14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132342 CVCL_SZ93 HAP1 NAT14 (-) 1 cancer cell line human CVCL_SZ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28918; NAT14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132343 CVCL_SZ96 HAP1 NAT14 (-) 4 cancer cell line human CVCL_SZ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28918; NAT14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132344 CVCL_SZ95 HAP1 NAT14 (-) 3 cancer cell line human CVCL_SZ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28918; NAT14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132345 CVCL_9N05 DD3439 transformed cell line human CVCL_9N05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132346 CVCL_SZ98 HAP1 NAT6 (-) 2 cancer cell line human CVCL_SZ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30252; NAA80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132347 CVCL_9N04 DD3420 finite cell line human CVCL_9N04 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132348 CVCL_SZ97 HAP1 NAT6 (-) 1 cancer cell line human CVCL_SZ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30252; NAA80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132349 CVCL_9N07 DD3447 transformed cell line human CVCL_9N07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132350 CVCL_9N06 DD3443 transformed cell line human CVCL_9N06 CL:0000010 Karyotypic information: 46,XX,del(2)(q14.1;q14.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132351 CVCL_SZ99 HAP1 NAT9 (-) 1 cancer cell line human CVCL_SZ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23133; NAT9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132352 CVCL_9N01 DD3372 transformed cell line human CVCL_9N01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132353 CVCL_9N00 DD3362 transformed cell line human CVCL_9N00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132354 CVCL_9N03 DD3400 finite cell line human CVCL_9N03 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132355 CVCL_9N02 DD3373 transformed cell line human CVCL_9N02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132356 CVCL_0T60 GM17853 transformed cell line human CVCL_0T60 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132357 CVCL_1560 NCI-H378 cancer cell line human CVCL_1560 Genome ancestry: African=2.92%; Native American=1.24%; East Asian, North=1.45%; East Asian, South=1.89%; South Asian=8.06%; European, North=26.04%; European, South=58.4% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (ATCC; Cosmic-CLP) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132358 CVCL_0T62 GM17855 transformed cell line human CVCL_0T62 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132359 CVCL_1562 NCI-H446 cancer cell line human CVCL_1562 HLA typing: A*03:01,03:01; B*07:02,51:01; C*03:04,03:04 (PubMed=25960936); HLA typing: A*03:01,03:01; B*07:02,51:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=2.76%; Native American=0%; East Asian, North=6.47%; East Asian, South=0%; South Asian=0%; European, North=63.72%; European, South=27.05% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6728; LY6H + HGNC; 9709; PVT1; Name(s)=PVT1-LY6H (PubMed=23716474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Karyotypic information: Hypertriploid karyotype; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21132360 CVCL_0T61 GM17854 transformed cell line human CVCL_0T61 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132361 CVCL_1561 NCI-H441 cancer cell line human CVCL_1561 HLA typing: A*02:01,03:01; B*38:01,44:03; C*16:02,16:02; DQB1*06:07,06:07; DRB1*13:23,14:103 (PubMed=26589293); Genome ancestry: African=0.09%; Native American=0%; East Asian, North=3.45%; East Asian, South=0%; South Asian=1.1%; European, North=61.67%; European, South=33.69% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=1311061; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Pericardial effusion Cell type=Club cell.. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 58 hours (in RPMI 1640 + 10% FBS), 138 hours (in ACL-3), 99 hours (in ACL-3 + BSA) (PubMed=3940644); 80 hours (PubMed=25984343); 46.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21132362 CVCL_0T64 Granta-56 cancer cell line human CVCL_0T64 CL:0000010 Unspecified 21132363 CVCL_1564 NCI-H508 cancer cell line human CVCL_1564 HLA typing: A*01:01,02:01; B*08:01,51:01; C*07:01,14:02 (PubMed=26589293); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=3.05%; East Asian, South=0%; South Asian=0%; European, North=58.76%; European, South=38.18% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly596Arg (c.1786G>C); ClinVar=VCV000375943; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24042735; PubMed=28683746; ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=28683746; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=28683746) Derived from metastatic site: Abdominal wall. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=24042735; PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132364 CVCL_0T63 GM17856 transformed cell line human CVCL_0T63 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21132365 CVCL_1563 NCI-H498 cancer cell line human CVCL_1563 CL:0000010 Derived from metastatic site: Peritoneum. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21132366 CVCL_0T66 HT-29/5-FU/S cancer cell line human CVCL_0T66 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female 21132367 CVCL_1566 NCI-H520 cancer cell line human CVCL_1566 HLA typing: A*11:01,11:01; B*15:18,15:18; C*07:04,07:04; DQB1*03:02,06:02; DRB1*11:04,11:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.92%; East Asian, South=0%; South Asian=0%; European, North=63.58%; European, South=35.5% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro383Ala (c.1147C>G); ClinVar=VCV001001330; Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly45Valfs*8 (c.134delG); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (PubMed=1311061; PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 61 hours (in RPMI 1640 + 10% FBS), 25 hours (in ACL-3), 32 hours (in ACL-3 + BSA) (PubMed=3940644); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132368 CVCL_0T65 Karpas-247 cancer cell line human CVCL_0T65 CL:0000010 21132369 CVCL_1565 NCI-H510A cancer cell line human CVCL_1565 HLA typing: A*01:01,01:01; B*07:02,58:05; C*07:01,07:01; DQA1*03:02,05:02; DRB1*04:05,04:05 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0.3%; East Asian, North=2.01%; East Asian, South=0%; South Asian=0%; European, North=64.53%; European, South=33.11% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys265Ter (c.793A>T); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly30Ter (c.88G>T); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Gly (c.844C>G); ClinVar=VCV000140821; Zygosity=Homozygous (PubMed=1312696; PubMed=1565469; PubMed=20557307; ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Adrenal gland. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 66 hours (PubMed=2985258); ~1 week (DSMZ=ACC-568); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132370 CVCL_0T68 IOSE11 telomerase immortalized cell line human CVCL_0T68 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: STR profile from personal communication of Monteiro A.N.A Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female 21132371 CVCL_1568 NCI-H524 cancer cell line human CVCL_1568 HLA typing: A*01:01,01:01; B*08:01,39:09; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.55%; Native American=0%; East Asian, North=1.32%; East Asian, South=0%; South Asian=0%; European, North=66.11%; European, South=32.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000127327; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90524; probable Male Doubling time: 100 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132372 CVCL_0T67 INOF2 telomerase immortalized cell line human CVCL_0T67 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21132373 CVCL_1567 NCI-H522 cancer cell line human CVCL_1567 HLA typing: A*02:01:01; B*44,55:01; C*03:03:01,05; DPB1*04:01; DQB1*03,06:02; DRB1*04:01:01,15:01:01 (PubMed=15748285); HLA typing: A*02:01,24:18; B*44:02,55:01; C*03:03,05:01; DQA1*03:02,03:02; DQB1*03:04,06:02 (PubMed=26589293); Genome ancestry: African=1.94%; Native American=0%; East Asian, North=1.91%; East Asian, South=0%; South Asian=3.27%; European, North=69.74%; European, South=23.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191fs*56 (c.571delC); Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=15900046; PubMed=17088437; PubMed=18277095; PubMed=20557307) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 25810; probable. Male Doubling time: 20 hours (PubMed=7718330); 48.1 hours (PubMed=29681454); 38.2 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21132374 CVCL_0T69 IOSE19 telomerase immortalized cell line human CVCL_0T69 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21132375 CVCL_1569 NCI-H526 cancer cell line human CVCL_1569 HLA typing: A*03:01,24:02; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.13%; East Asian, South=0%; South Asian=1.94%; European, North=63.44%; European, South=33.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.97-1G>C (IVS3-1G>C); Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1312696; PubMed=1565469; PubMed=20557307) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132376 CVCL_KB03 ACK30 hybridoma CVCL_KB03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05532; Mouse Kit/Cd117. 21132377 CVCL_KB02 ACK2 hybridoma CVCL_KB02 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05532; Mouse Kit/Cd117. 21132378 CVCL_KB05 ACK45 hybridoma CVCL_KB05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05532; Mouse Kit/Cd117. 21132379 CVCL_KB04 ACK4 hybridoma CVCL_KB04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05532; Mouse Kit/Cd117. 21132380 CVCL_KB01 ACD1 hybridoma CVCL_KB01 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P30285; Mouse Cdk4. 21132381 CVCL_KB00 A7R34 hybridoma CVCL_KB00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16872; Mouse Il7r/Cd127. 21132382 CVCL_BH66 ND11685 transformed cell line human CVCL_BH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132383 CVCL_BH65 ND11683 transformed cell line human CVCL_BH65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132384 CVCL_BH68 ND11687 transformed cell line human CVCL_BH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132385 CVCL_BH67 ND11686 transformed cell line human CVCL_BH67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132386 CVCL_BH69 ND11688 transformed cell line human CVCL_BH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132387 CVCL_BH60 ND11677 transformed cell line human CVCL_BH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132388 CVCL_BH62 ND11680 transformed cell line human CVCL_BH62 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132389 CVCL_BH61 ND11679 transformed cell line human CVCL_BH61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132390 CVCL_BH64 ND11682 transformed cell line human CVCL_BH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132391 CVCL_BH63 ND11681 transformed cell line human CVCL_BH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132392 CVCL_KB14 ACT II hybridoma house mouse CVCL_KB14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dictyostelium discoideum actins. 21132393 CVCL_KB13 9C2 hybridoma house mouse CVCL_KB13 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01479; Androctonus australis neurotoxin AaH1. Group: Animal toxin research hybridoma 21132394 CVCL_KB16 HLR-cJun cancer cell line human CVCL_KB16 CL:0000010 Transfected with: HGNC; 6204; JUN (with del ?-331); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04386; Yeast GAL4 (with del 148-881) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Agilent Technologies/Stratagene; Catalog number: 800070 Female Characteristics: The luciferase reporter gene expression is under the control of a synthetic promoter containing 5 direct repeats of the 17-mer GAL4-binding site; Characteristics: Transfected with the activation domain of JUN fused to the yeast GAL4 DNA-binding domain 21132395 CVCL_KB15 HLR cancer cell line human CVCL_KB15 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Agilent Technologies/Stratagene; Catalog number: 800050 Female Characteristics: The luciferase reporter gene expression is under the control of a synthetic promoter containing 5 direct repeats of the 17-mer GAL4-binding site 21132396 CVCL_KB10 R4A9 hybridoma Norway rat CVCL_KB10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse cell surface antigen of stromal cells in bone marrow and spleen. 21132397 CVCL_KB12 4C1 [Mouse hybridoma against A.australis AaH2] hybridoma house mouse CVCL_KB12 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01484; Androctonus australis neurotoxin AaH2. Group: Animal toxin research hybridoma 21132398 CVCL_KB11 3C5 [Mouse hybridoma against A.australis AaH2] hybridoma house mouse CVCL_KB11 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P01484; Androctonus australis neurotoxin AaH2. Group: Animal toxin research hybridoma 21132399 CVCL_BH77 ND11719 transformed cell line human CVCL_BH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132400 CVCL_BH76 ND11718 transformed cell line human CVCL_BH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132401 CVCL_BH79 ND11724 transformed cell line human CVCL_BH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132402 CVCL_BH78 ND11720 transformed cell line human CVCL_BH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132403 CVCL_BH71 ND11697 transformed cell line human CVCL_BH71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132404 CVCL_BH70 ND11694 transformed cell line human CVCL_BH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132405 CVCL_KB07 APA5 hybridoma CVCL_KB07 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26618; Mouse Pdgfra/Cd140a. 21132406 CVCL_BH73 ND11711 transformed cell line human CVCL_BH73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132407 CVCL_KB06 AFL4 hybridoma CVCL_KB06 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P35917; Mouse Flt4. 21132408 CVCL_BH72 ND11698 transformed cell line human CVCL_BH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132409 CVCL_KB09 AVAS12 hybridoma CVCL_KB09 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35918; Mouse Kdr/Cd309. 21132410 CVCL_BH75 ND11715 transformed cell line human CVCL_BH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132411 CVCL_KB08 APB5 hybridoma CVCL_KB08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05622; Mouse Pdgfrb/Cd140b. 21132412 CVCL_BH74 ND11714 transformed cell line human CVCL_BH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132413 CVCL_BH44 ND11627 transformed cell line human CVCL_BH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132414 CVCL_BH43 ND11626 transformed cell line human CVCL_BH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132415 CVCL_BH46 ND11629 transformed cell line human CVCL_BH46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132416 CVCL_BH45 ND11628 transformed cell line human CVCL_BH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132417 CVCL_BH48 ND11633 transformed cell line human CVCL_BH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132418 CVCL_BH47 ND11630 transformed cell line human CVCL_BH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132419 CVCL_BH49 ND11634 transformed cell line human CVCL_BH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132420 CVCL_BH40 ND11620 transformed cell line human CVCL_BH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132421 CVCL_BH42 ND11624 transformed cell line human CVCL_BH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132422 CVCL_BH41 ND11621 transformed cell line human CVCL_BH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132423 CVCL_BH55 ND11659 transformed cell line human CVCL_BH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132424 CVCL_BH54 ND11658 transformed cell line human CVCL_BH54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132425 CVCL_BH57 ND11664 transformed cell line human CVCL_BH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132426 CVCL_BH56 ND11662 transformed cell line human CVCL_BH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132427 CVCL_BH59 ND11668 transformed cell line human CVCL_BH59 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132428 CVCL_BH58 ND11665 transformed cell line human CVCL_BH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132429 CVCL_BH51 ND11637 transformed cell line human CVCL_BH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132430 CVCL_BH50 ND11636 transformed cell line human CVCL_BH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132431 CVCL_BH53 ND11654 transformed cell line human CVCL_BH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132432 CVCL_BH52 ND11638 transformed cell line human CVCL_BH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132433 CVCL_9N96 DD3241 transformed cell line human CVCL_9N96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132434 CVCL_9N95 DD3238 transformed cell line human CVCL_9N95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132435 CVCL_9N98 DD3245 transformed cell line human CVCL_9N98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132436 CVCL_9N97 DD3244 finite cell line human CVCL_9N97 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21132437 CVCL_9N92 DD3226 finite cell line human CVCL_9N92 CL:0000010 Karyotypic information: 46,XX,t(14;19)(q24.3;p13.3)mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21132438 CVCL_9N91 DD3225 transformed cell line human CVCL_9N91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132439 CVCL_9N94 DD3237 transformed cell line human CVCL_9N94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132440 CVCL_9N93 DD3230 finite cell line human CVCL_9N93 CL:0000010 Karyotypic information: 46,XY,t(4;12)(q32.2;21.2)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132441 CVCL_BH29 ND11599 transformed cell line human CVCL_BH29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132442 CVCL_9N99 DD3246 transformed cell line human CVCL_9N99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132443 CVCL_BH22 ND11587 transformed cell line human CVCL_BH22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132444 CVCL_BH21 ND11585 transformed cell line human CVCL_BH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132445 CVCL_BH24 ND11590 transformed cell line human CVCL_BH24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132446 CVCL_BH23 ND11589 transformed cell line human CVCL_BH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132447 CVCL_BH26 ND11592 transformed cell line human CVCL_BH26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132448 CVCL_BH25 ND11591 transformed cell line human CVCL_BH25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132449 CVCL_BH28 ND11598 transformed cell line human CVCL_BH28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132450 CVCL_BH27 ND11596 transformed cell line human CVCL_BH27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132451 CVCL_9N90 DD3224 transformed cell line human CVCL_9N90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132452 CVCL_BH20 ND11583 transformed cell line human CVCL_BH20 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132453 CVCL_BH33 ND11608 transformed cell line human CVCL_BH33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132454 CVCL_BH32 ND11606 transformed cell line human CVCL_BH32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132455 CVCL_BH35 ND11611 transformed cell line human CVCL_BH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132456 CVCL_BH34 ND11610 transformed cell line human CVCL_BH34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132457 CVCL_BH37 ND11616 transformed cell line human CVCL_BH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132458 CVCL_BH36 ND11612 transformed cell line human CVCL_BH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132459 CVCL_BH39 ND11619 transformed cell line human CVCL_BH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132460 CVCL_BH38 ND11617 transformed cell line human CVCL_BH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132461 CVCL_BH31 ND11601 transformed cell line human CVCL_BH31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132462 CVCL_BH30 ND11600 transformed cell line human CVCL_BH30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132463 CVCL_9N74 DD3045 transformed cell line human CVCL_9N74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132464 CVCL_9N73 DD3044 transformed cell line human CVCL_9N73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132465 CVCL_9N76 DD3108 transformed cell line human CVCL_9N76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132466 CVCL_9N75 DD3107 transformed cell line human CVCL_9N75 CL:0000010 Karyotypic information: 46,XY,(16q11.1v) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132467 CVCL_9N70 DD3027 transformed cell line human CVCL_9N70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132468 CVCL_9N72 DD3032 finite cell line human CVCL_9N72 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132469 CVCL_9N71 DD3028 transformed cell line human CVCL_9N71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132470 CVCL_BH08 ND11558 transformed cell line human CVCL_BH08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132471 CVCL_BH07 ND11556 transformed cell line human CVCL_BH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132472 CVCL_BH09 ND11561 transformed cell line human CVCL_BH09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132473 CVCL_9N78 DD3121 transformed cell line human CVCL_9N78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132474 CVCL_9N77 DD3120 transformed cell line human CVCL_9N77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132475 CVCL_9N79 DD3154 transformed cell line human CVCL_9N79 CL:0000010 Karyotypic information: 46,X,del(X)(p11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132476 CVCL_BH00 ND11539 transformed cell line human CVCL_BH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132477 CVCL_BH02 ND11542 transformed cell line human CVCL_BH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132478 CVCL_BH01 ND11541 transformed cell line human CVCL_BH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132479 CVCL_BH04 ND11548 transformed cell line human CVCL_BH04 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132480 CVCL_BH03 ND11543 transformed cell line human CVCL_BH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132481 CVCL_BH06 ND11554 transformed cell line human CVCL_BH06 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132482 CVCL_BH05 ND11553 transformed cell line human CVCL_BH05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132483 CVCL_9N85 DD3214 transformed cell line human CVCL_9N85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132484 CVCL_9N84 DD3213 transformed cell line human CVCL_9N84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132485 CVCL_9N87 DD3218 transformed cell line human CVCL_9N87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132486 CVCL_9N86 DD3215 transformed cell line human CVCL_9N86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132487 CVCL_9N81 DD3185 transformed cell line human CVCL_9N81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132488 CVCL_9N80 DD3156 transformed cell line human CVCL_9N80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132489 CVCL_9N83 DD3204 finite cell line human CVCL_9N83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132490 CVCL_9N82 DD3186 transformed cell line human CVCL_9N82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132491 CVCL_BH19 ND11582 transformed cell line human CVCL_BH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132492 CVCL_BH18 ND11581 transformed cell line human CVCL_BH18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132493 CVCL_9N89 DD3220 finite cell line human CVCL_9N89 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21132494 CVCL_9N88 DD3219 transformed cell line human CVCL_9N88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132495 CVCL_BH11 ND11563 transformed cell line human CVCL_BH11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132496 CVCL_BH10 ND11562 transformed cell line human CVCL_BH10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132497 CVCL_BH13 ND11570 transformed cell line human CVCL_BH13 CL:0000010 Population: Caucasian and Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132498 CVCL_BH12 ND11564 transformed cell line human CVCL_BH12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132499 CVCL_BH15 ND11573 transformed cell line human CVCL_BH15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132500 CVCL_BH14 ND11571 transformed cell line human CVCL_BH14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132501 CVCL_BH17 ND11580 transformed cell line human CVCL_BH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132502 CVCL_BH16 ND11578 transformed cell line human CVCL_BH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132503 CVCL_KA69 Lec13 spontaneously immortalized cell line CVCL_KA69 CL:0000010 Selected for resistance to: UniProtKB; P02867; Pisum sativum lectin; Derived from sampling site: Ovary. Female Characteristics: Useful for the production of fucose-negative antibodies; Characteristics: Deficient in GDP-mannose 4,6 dehydratase (GMDS) 21132504 CVCL_KA66 CHO-DG44 (cGMP banked) spontaneously immortalized cell line CVCL_KA66 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Lacks both copies of the Dhfr gene; Characteristics: Pre-adapted to CD DG44 medium and selected for superior cell growth and transfection efficiency Group: Serum/protein free medium cell line 21132505 CVCL_KA65 HEK293/NFAT/beta-lactamase transformed cell line human CVCL_KA65 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00146 Female Characteristics: Transfected with the 3xNFAT-beta-lactamase-Zeo plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21132506 CVCL_KA68 CHO-K1/EDG5/Galpha15 spontaneously immortalized cell line CVCL_KA68 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 3169; S1PR2 Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00197 Female 21132507 CVCL_KA67 CHO-K1/CT spontaneously immortalized cell line CVCL_KA67 CL:0000010 Transfected with: HGNC; 1440; CALCR Miscellaneous: Cell line under development; catalog number M00153 Derived from sampling site: Ovary. Female 21132508 CVCL_KA62 CHO-K1/VISTA spontaneously immortalized cell line CVCL_KA62 CL:0000010 Transfected with: HGNC; 30085; VSIR Derived from sampling site: Ovary. Female 21132509 CVCL_KA61 CHO-K1/SIRP gamma spontaneously immortalized cell line CVCL_KA61 CL:0000010 Transfected with: HGNC; 15757; SIRPG Derived from sampling site: Ovary. Female 21132510 CVCL_KA64 293AAV transformed cell line human CVCL_KA64 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Compared to parent HEK293 cell line has improved adeno-associated virus production capabilities Caution: Not the same cell line as AAV-293 from Stratagene (Cellosaurus=CVCL_6871) 21132511 CVCL_SZ01 HAP1 MSH6 (-) 1 cancer cell line human CVCL_SZ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132512 CVCL_KA63 293AD transformed cell line human CVCL_KA63 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Selected for flattened morphology and firm attachment to culture plates Larger surface area for superior transfection and greater adenoviral yields. Caution: Not the same cell line as AD-293 from Stratagene (Cellosaurus=CVCL_9804) 21132513 CVCL_SZ00 HAP1 MSH5 (-) 2 cancer cell line human CVCL_SZ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7328; MSH5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132514 CVCL_SZ03 HAP1 MSH6 (-) 3 cancer cell line human CVCL_SZ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132515 CVCL_SZ02 HAP1 MSH6 (-) 2 cancer cell line human CVCL_SZ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7329; MSH6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132516 CVCL_KA60 CHO-K1/SIRP alpha spontaneously immortalized cell line CVCL_KA60 CL:0000010 Transfected with: HGNC; 9662; SIRPA Derived from sampling site: Ovary. Female 21132517 CVCL_SZ05 HAP1 MSI2 (-) 1 cancer cell line human CVCL_SZ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18585; MSI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132518 CVCL_SZ04 HAP1 MSI1 (-) 1 cancer cell line human CVCL_SZ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7330; MSI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132519 CVCL_SZ07 HAP1 MST4 (-) 1 cancer cell line human CVCL_SZ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18174; STK26; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132520 CVCL_SZ06 HAP1 MSN (-) cancer cell line human CVCL_SZ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7373; MSN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132521 CVCL_SZ09 HAP1 MTAP (-) 1 cancer cell line human CVCL_SZ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132522 CVCL_SZ08 HAP1 MST4 (-) 2 cancer cell line human CVCL_SZ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18174; STK26; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132523 CVCL_KA77 CHO-K1/CRE/Luc spontaneously immortalized cell line CVCL_KA77 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Discontinued: Genscript; Catalog number M00145 Female 21132524 CVCL_KA76 293/GNRHR/Galpha15 transformed cell line human CVCL_KA76 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4421; GNRHR Miscellaneous: Cell line under development; catalog number M00210 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132525 CVCL_KA79 Lec13A spontaneously immortalized cell line CVCL_KA79 CL:0000010 Selected for resistance to: UniProtKB; P02867; Pisum sativum lectin; Derived from sampling site: Ovary. Female 21132526 CVCL_KA78 CHO-K1/P2Y9/Galpha15 spontaneously immortalized cell line CVCL_KA78 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 4478; LPAR4 Miscellaneous: Cell line under development; catalog number M00438 Derived from sampling site: Ovary. Female 21132527 CVCL_KA73 C243-3 transformed cell line house mouse CVCL_KA73 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21132528 CVCL_KA72 Ms709 spontaneously immortalized cell line CVCL_KA72 CL:0000010 Knockout cell: Method=Homologous recombination; FUT8 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Useful for the production of fucose-negative antibodies; Characteristics: Lacks both copies of the Dhfr gene 21132529 CVCL_KA75 HEK293/PTHR1/CRE/beta-lactamase transformed cell line human CVCL_KA75 CL:0000010 Transfected with: HGNC; 9608; PTH1R Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00148 Female 21132530 CVCL_KA74 HEK293/PAFR/NFAT/beta-lactamase transformed cell line human CVCL_KA74 CL:0000010 Transfected with: HGNC; 9582; PTAFR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Genscript; Catalog number M00147 Female Characteristics: Transfected with the 3xNFAT-beta-lactamase-Zeo plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21132531 CVCL_KA71 MS705 spontaneously immortalized cell line CVCL_KA71 CL:0000010 Knockout cell: Method=Homologous recombination; FUT8 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Useful for the production of fucose-negative antibodies; Characteristics: Lacks both copies of the Dhfr gene 21132532 CVCL_KA70 Ms704 spontaneously immortalized cell line CVCL_KA70 CL:0000010 Knockout cell: Method=Homologous recombination; FUT8 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Useful for the production of fucose-negative antibodies; Characteristics: Lacks both copies of the Dhfr gene 21132533 CVCL_KA48 CHO-K1/B7-H4 spontaneously immortalized cell line CVCL_KA48 CL:0000010 Transfected with: HGNC; 28873; VTCN1 Derived from sampling site: Ovary. Female 21132534 CVCL_KA47 CHO-K1/B7-H3 spontaneously immortalized cell line CVCL_KA47 CL:0000010 Transfected with: HGNC; 19137; CD276 Derived from sampling site: Ovary. Female 21132535 CVCL_KA49 CHO-K1/BTLA spontaneously immortalized cell line CVCL_KA49 CL:0000010 Transfected with: HGNC; 21087; BTLA Derived from sampling site: Ovary. Female 21132536 CVCL_KA44 CHO-K1/PD-L1 spontaneously immortalized cell line CVCL_KA44 CL:0000010 Transfected with: HGNC; 17635; CD274 Derived from sampling site: Ovary. Female 21132537 CVCL_KA43 CHO-K1/PD1 spontaneously immortalized cell line CVCL_KA43 CL:0000010 Transfected with: HGNC; 8760; PDCD1 Derived from sampling site: Ovary. Female 21132538 CVCL_KA46 CHO-K1/4-1BB spontaneously immortalized cell line CVCL_KA46 CL:0000010 Transfected with: HGNC; 11924; TNFRSF9 Derived from sampling site: Ovary. Female 21132539 CVCL_KA45 CHO-K1/Tim3 spontaneously immortalized cell line CVCL_KA45 CL:0000010 Transfected with: HGNC; 18437; HAVCR2 Derived from sampling site: Ovary. Female 21132540 CVCL_KA40 CHO-K1/Lag3 spontaneously immortalized cell line CVCL_KA40 CL:0000010 Transfected with: HGNC; 6476; LAG3 Derived from sampling site: Ovary. Female 21132541 CVCL_KA42 CHO-K1/OX-40L spontaneously immortalized cell line CVCL_KA42 CL:0000010 Transfected with: HGNC; 11934; TNFSF4 Derived from sampling site: Ovary. Female 21132542 CVCL_KA41 CHO-K1/OX-40 spontaneously immortalized cell line CVCL_KA41 CL:0000010 Transfected with: HGNC; 11918; TNFRSF4 Derived from sampling site: Ovary. Female 21132543 CVCL_KA59 CHO-K1/mouse PD-L1 spontaneously immortalized cell line CVCL_KA59 CL:0000010 Transfected with: MGI; MGI:1926446; Cd274 Derived from sampling site: Ovary. Female 21132544 CVCL_KA58 CHO-K1/mouse PD-1 spontaneously immortalized cell line CVCL_KA58 CL:0000010 Transfected with: MGI; MGI:104879; Pdcd1 Derived from sampling site: Ovary. Female 21132545 CVCL_KA55 CHO-K1/mouse 4-1BB spontaneously immortalized cell line CVCL_KA55 CL:0000010 Transfected with: MGI; MGI:1101059; Tnfrsf9 Derived from sampling site: Ovary. Female 21132546 CVCL_KA54 CHO-K1/cyno PD-L1 spontaneously immortalized cell line CVCL_KA54 CL:0000010 Transfected with: UniProtKB; G7PSE7; Macaca fascicularis CD274 Derived from sampling site: Ovary. Female 21132547 CVCL_KA57 CHO-K1/mouse FLT3 spontaneously immortalized cell line CVCL_KA57 CL:0000010 Transfected with: MGI; MGI:95559; Flt3 Derived from sampling site: Ovary. Female 21132548 CVCL_KA56 CHO-K1/mouse CTLA4 spontaneously immortalized cell line CVCL_KA56 CL:0000010 Transfected with: MGI; MGI:88556; Ctla4 Derived from sampling site: Ovary. Female 21132549 CVCL_KA51 CHO-K1/cyno CTLA4 spontaneously immortalized cell line CVCL_KA51 CL:0000010 Transfected with: UniProtKB; G7PL88; Macaca fascicularis CTLA4 Derived from sampling site: Ovary. Female 21132550 CVCL_KA50 CHO-K1/cyno 4-1BB spontaneously immortalized cell line CVCL_KA50 CL:0000010 Transfected with: UniProtKB; A9YYE7; Macaca fascicularis TNFRSF9 Derived from sampling site: Ovary. Female 21132551 CVCL_KA53 CHO-K1/cyno PD-1 spontaneously immortalized cell line CVCL_KA53 CL:0000010 Transfected with: UniProtKB; B0LAJ3; Macaca fascicularis PDCD1 Derived from sampling site: Ovary. Female 21132552 CVCL_KA52 CHO-K1/cyno FLT3 spontaneously immortalized cell line CVCL_KA52 CL:0000010 Transfected with: UniProtKB; G7PVX3; Macaca fascicularis FLT3 Derived from sampling site: Ovary. Female 21132553 CVCL_KA26 CHO-K1/CD27 spontaneously immortalized cell line CVCL_KA26 CL:0000010 Transfected with: HGNC; 11922; CD27 Derived from sampling site: Ovary. Female 21132554 CVCL_KA25 CHO-K1/CD200 R1 spontaneously immortalized cell line CVCL_KA25 CL:0000010 Transfected with: HGNC; 24235; CD200R1 Derived from sampling site: Ovary. Female 21132555 CVCL_KA28 CHO-K1/CD32A 131Arg spontaneously immortalized cell line CVCL_KA28 CL:0000010 Transfected with: HGNC; 3616; FCGR2A (with p.His167Arg) Derived from sampling site: Ovary. Female 21132556 CVCL_KA27 CHO-K1/CD32A 131His spontaneously immortalized cell line CVCL_KA27 CL:0000010 Transfected with: HGNC; 3616; FCGR2A Derived from sampling site: Ovary. Female 21132557 CVCL_KA22 CHO-K1/CD16A 158F spontaneously immortalized cell line CVCL_KA22 CL:0000010 Transfected with: HGNC; 3619; FCGR3A Derived from sampling site: Ovary. Female 21132558 CVCL_KA21 CHO-K1/CRE-Luc/VPAC2 spontaneously immortalized cell line CVCL_KA21 CL:0000010 Transfected with: HGNC; 12695; VIPR2; Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Female 21132559 CVCL_KA24 CHO-K1/CD160 spontaneously immortalized cell line CVCL_KA24 CL:0000010 Transfected with: HGNC; 17013; CD160 Derived from sampling site: Ovary. Female 21132560 CVCL_BG90 ND11512 transformed cell line human CVCL_BG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132561 CVCL_KA23 CHO-K1/CD16B spontaneously immortalized cell line CVCL_KA23 CL:0000010 Transfected with: HGNC; 3620; FCGR3B Derived from sampling site: Ovary. Female 21132562 CVCL_KA20 HEK293/CRE-Luc/GLP1R transformed cell line human CVCL_KA20 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132563 CVCL_BG89 ND11511 transformed cell line human CVCL_BG89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132564 CVCL_BG88 ND11510 transformed cell line human CVCL_BG88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132565 CVCL_BG81 ND11496 transformed cell line human CVCL_BG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132566 CVCL_BG80 ND11494 transformed cell line human CVCL_BG80 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132567 CVCL_BG83 ND11498 transformed cell line human CVCL_BG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132568 CVCL_BG82 ND11497 transformed cell line human CVCL_BG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132569 CVCL_KA19 CHO-K1/mouse ADORA2A spontaneously immortalized cell line CVCL_KA19 CL:0000010 Transfected with: MGI; MGI:99402; Adora2a Derived from sampling site: Ovary. Female 21132570 CVCL_BG85 ND11505 transformed cell line human CVCL_BG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132571 CVCL_BG84 ND11499 transformed cell line human CVCL_BG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132572 CVCL_KA18 RH7777/EDG3 cancer cell line Norway rat CVCL_KA18 CL:0000010 Transfected with: HGNC; 3167; S1PR3 Miscellaneous: Cell line under development; catalog number M00476 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female 21132573 CVCL_BG87 ND11507 transformed cell line human CVCL_BG87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132574 CVCL_BG86 ND11506 transformed cell line human CVCL_BG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132575 CVCL_KA37 CHO-K1/CTLA4 spontaneously immortalized cell line CVCL_KA37 CL:0000010 Transfected with: HGNC; 2505; CTLA4 Derived from sampling site: Ovary. Female 21132576 CVCL_KA36 CHO-K1/CD86 spontaneously immortalized cell line CVCL_KA36 CL:0000010 Transfected with: HGNC; 1705; CD86 Derived from sampling site: Ovary. Female 21132577 CVCL_KA39 CHO-K1/GITR spontaneously immortalized cell line CVCL_KA39 CL:0000010 Transfected with: HGNC; 11914; TNFRSF18 Derived from sampling site: Ovary. Female 21132578 CVCL_KA38 CHO-K1/FLT3 spontaneously immortalized cell line CVCL_KA38 CL:0000010 Transfected with: HGNC; 3765; FLT3 Derived from sampling site: Ovary. Female 21132579 CVCL_KA33 CHO-K1/CD40 spontaneously immortalized cell line CVCL_KA33 CL:0000010 Transfected with: HGNC; 11919; CD40 Derived from sampling site: Ovary. Female 21132580 CVCL_KA32 CHO-K1/CD38 spontaneously immortalized cell line CVCL_KA32 CL:0000010 Transfected with: HGNC; 1667; CD38 Derived from sampling site: Ovary. Female 21132581 CVCL_KA35 CHO-K1/CD80 spontaneously immortalized cell line CVCL_KA35 CL:0000010 Transfected with: HGNC; 1700; CD80 Derived from sampling site: Ovary. Female 21132582 CVCL_KA34 CHO-K1/CD47 spontaneously immortalized cell line CVCL_KA34 CL:0000010 Transfected with: HGNC; 1682; CD47 Derived from sampling site: Ovary. Female 21132583 CVCL_KA31 CHO-K1/CD32C 13Gln spontaneously immortalized cell line CVCL_KA31 CL:0000010 Transfected with: HGNC; 15626; FCGR2C Derived from sampling site: Ovary. Female 21132584 CVCL_KA30 CHO-K1/CD32B 232Thr spontaneously immortalized cell line CVCL_KA30 CL:0000010 Transfected with: HGNC; 3618; FCGR2B (with p.Ile232Thr) Derived from sampling site: Ovary. Female 21132585 CVCL_BG99 ND11536 transformed cell line human CVCL_BG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132586 CVCL_BG92 ND11514 transformed cell line human CVCL_BG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132587 CVCL_BG91 ND11513 transformed cell line human CVCL_BG91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132588 CVCL_BG94 ND11524 transformed cell line human CVCL_BG94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132589 CVCL_BG93 ND11517 transformed cell line human CVCL_BG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132590 CVCL_BG96 ND11528 transformed cell line human CVCL_BG96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132591 CVCL_KA29 CHO-K1/CD32B 232Ile spontaneously immortalized cell line CVCL_KA29 CL:0000010 Transfected with: HGNC; 3618; FCGR2B Derived from sampling site: Ovary. Female 21132592 CVCL_BG95 ND11526 transformed cell line human CVCL_BG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132593 CVCL_BG98 ND11533 transformed cell line human CVCL_BG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132594 CVCL_BG97 ND11530 transformed cell line human CVCL_BG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132595 CVCL_KA04 U2OS FKHRL1-EGFP cancer cell line human CVCL_KA04 CL:0000010 Transfected with: HGNC; 3821; FOXO3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: Thermofisher/BioImage; Catalog number R04-009-02 Female Characteristics: Transfected with a fusion FOXO3-eGFP protein under the control of the CMV promoter 21132596 CVCL_KA03 U2OS FKHR-EGFP cancer cell line human CVCL_KA03 CL:0000010 Transfected with: HGNC; 3819; FOXO1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: Thermofisher/BioImage; Catalog number R04-008-01 Female Characteristics: Transfected with a fusion FOXO1-eGFP protein under the control of the CMV promoter 21132597 CVCL_KA06 CHO-K1/mouse TIGIT spontaneously immortalized cell line CVCL_KA06 CL:0000010 Transfected with: MGI; MGI:3642260; Tigit Derived from sampling site: Ovary. Female 21132598 CVCL_KA05 CHO-K1/TIGIT spontaneously immortalized cell line CVCL_KA05 CL:0000010 Transfected with: HGNC; 26838; TIGIT Derived from sampling site: Ovary. Female 21132599 CVCL_KA00 M2590 hybridoma house mouse CVCL_KA00 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:84118; Ganglioside GM3. 21132600 CVCL_KA02 M622 hybridoma house mouse CVCL_KA02 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse melanoma cell line B16 antigen. 21132601 CVCL_KA01 M562 hybridoma house mouse CVCL_KA01 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse melanoma cell line B16 antigen. 21132602 CVCL_BG67 ND11449 transformed cell line human CVCL_BG67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132603 CVCL_BG66 ND11448 transformed cell line human CVCL_BG66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132604 CVCL_BG69 ND11453 transformed cell line human CVCL_BG69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132605 CVCL_BG68 ND11451 transformed cell line human CVCL_BG68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132606 CVCL_BG61 ND11439 transformed cell line human CVCL_BG61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132607 CVCL_BG60 ND11438 transformed cell line human CVCL_BG60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132608 CVCL_BG63 ND11444 transformed cell line human CVCL_BG63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132609 CVCL_BG62 ND11440 transformed cell line human CVCL_BG62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132610 CVCL_BG65 ND11447 transformed cell line human CVCL_BG65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132611 CVCL_BG64 ND11445 transformed cell line human CVCL_BG64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132612 CVCL_KA15 CHO-K1/Galpha15/CXCR3 spontaneously immortalized cell line CVCL_KA15 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132613 CVCL_KA14 CHO-K1/Galpha15/CXCR1 spontaneously immortalized cell line CVCL_KA14 CL:0000010 Transfected with: HGNC; 6026; CXCR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132614 CVCL_KA17 CHO-K1/Galpha15/CXCR5 spontaneously immortalized cell line CVCL_KA17 CL:0000010 Transfected with: HGNC; 1060; CXCR5; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132615 CVCL_KA16 CHO-K1/Galpha15/CXCR4 spontaneously immortalized cell line CVCL_KA16 CL:0000010 Transfected with: HGNC; 2561; CXCR4; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132616 CVCL_KA11 HEK293/Galpha15 transformed cell line human CVCL_KA11 CL:0000010 Transfected with: HGNC; 4383; GNA15 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132617 CVCL_KA10 CHO-K1/Galpha15/AMY3 spontaneously immortalized cell line CVCL_KA10 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9845; RAMP3 Derived from sampling site: Ovary. Female 21132618 CVCL_KA13 CHO-K1/Galpha15/CCR5 spontaneously immortalized cell line CVCL_KA13 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132619 CVCL_KA12 CHO-K1/Galpha15/CCR1 spontaneously immortalized cell line CVCL_KA12 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 4383; GNA15 Derived from sampling site: Ovary. Female 21132620 CVCL_BG78 ND11481 transformed cell line human CVCL_BG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132621 CVCL_BG77 ND11480 transformed cell line human CVCL_BG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132622 CVCL_BG79 ND11484 transformed cell line human CVCL_BG79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132623 CVCL_BG70 ND11457 transformed cell line human CVCL_BG70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132624 CVCL_BG72 ND11460 transformed cell line human CVCL_BG72 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Unexplicit; IVS12+9T>C; Zygosity=Heterozygous; Note=VUS (PubMed=22572540) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132625 CVCL_BG71 ND11459 transformed cell line human CVCL_BG71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132626 CVCL_KA08 CHO-K1/Galpha15/AMY1 spontaneously immortalized cell line CVCL_KA08 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9843; RAMP1 Derived from sampling site: Ovary. Female 21132627 CVCL_BG74 ND11464 transformed cell line human CVCL_BG74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132628 CVCL_KA07 HEK293/PD-L1 transformed cell line human CVCL_KA07 CL:0000010 Transfected with: HGNC; 17635; CD274 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132629 CVCL_BG73 ND11461 transformed cell line human CVCL_BG73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132630 CVCL_BG76 ND11479 transformed cell line human CVCL_BG76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132631 CVCL_KA09 CHO-K1/Galpha15/AMY2 spontaneously immortalized cell line CVCL_KA09 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 4383; GNA15; Transfected with: HGNC; 9844; RAMP2 Derived from sampling site: Ovary. Female 21132632 CVCL_BG75 ND11465 transformed cell line human CVCL_BG75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132633 CVCL_SZ81 HAP1 NAA40 (-) 6 cancer cell line human CVCL_SZ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132634 CVCL_SZ80 HAP1 NAA40 (-) 5 cancer cell line human CVCL_SZ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132635 CVCL_SZ83 HAP1 NAA60 (-) 2 cancer cell line human CVCL_SZ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25875; NAA60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132636 CVCL_SZ82 HAP1 NAA60 (-) 1 cancer cell line human CVCL_SZ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25875; NAA60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132637 CVCL_SZ85 HAP1 NAIF1 (-) 1 cancer cell line human CVCL_SZ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25446; NAIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132638 CVCL_SZ84 HAP1 NAGK (-) 1 cancer cell line human CVCL_SZ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17174; NAGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132639 CVCL_SZ87 HAP1 NAIF1 (-) 3 cancer cell line human CVCL_SZ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25446; NAIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132640 CVCL_SZ86 HAP1 NAIF1 (-) 2 cancer cell line human CVCL_SZ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25446; NAIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132641 CVCL_SZ89 HAP1 NANP (-) 2 cancer cell line human CVCL_SZ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16140; NANP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132642 CVCL_SZ88 HAP1 NANP (-) 1 cancer cell line human CVCL_SZ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16140; NANP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132643 CVCL_0T31 GM17812 transformed cell line human CVCL_0T31 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132644 CVCL_1531 NCI-H2122 cancer cell line human CVCL_1531 HLA typing: A*01:01,03:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.26%; East Asian, North=1.42%; East Asian, South=0%; South Asian=1.39%; European, North=65.92%; European, South=31.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln16Leu (c.47A>T); Zygosity=Heterozygous (PubMed=20557307; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=25984343); 31.6 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21132645 CVCL_0T30 GM17811 transformed cell line human CVCL_0T30 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132646 CVCL_1530 NCI-H2110 cancer cell line human CVCL_1530 HLA typing: A*30:01,30:01; B*42:02,57:01; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=82.92%; Native American=0%; East Asian, North=4.2%; East Asian, South=0%; South Asian=0%; European, North=0.75%; European, South=12.13% (PubMed=30894373) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132647 CVCL_0T33 GM17814 transformed cell line human CVCL_0T33 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132648 CVCL_1533 NCI-H2135 cancer cell line human CVCL_1533 HLA typing: A*03:01,03:01; B*41:01,41:01; C*17:01,17:01 (PubMed=26589293); Genome ancestry: African=5.4%; Native American=0%; East Asian, North=0%; East Asian, South=1.13%; South Asian=12.67%; European, North=21.96%; European, South=58.84% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.45_48delTTCT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg496Leu (c.1487G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132649 CVCL_0T32 GM17813 transformed cell line human CVCL_0T32 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132650 CVCL_1532 NCI-H2126 cancer cell line human CVCL_1532 HLA typing: A*02:05,03:01; B*08:20,15:01; C*01:02,04:01; DQA1*03:02,05:02; DQB1*06:02,06:02; DRB1*15:01,16:08 (PubMed=26589293); Genome ancestry: African=1.91%; Native American=0.65%; East Asian, North=3.65%; East Asian, South=0%; South Asian=0%; European, North=58.35%; European, South=35.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Trp764Arg (c.2290T>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5925; probable Male Doubling time: 41.1 hours (PubMed=29681454); ~57 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132651 CVCL_0T35 GM17816 transformed cell line human CVCL_0T35 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132652 CVCL_1535 NCI-H2170 cancer cell line human CVCL_1535 HLA typing: A*03:01,68:01; B*07:02,51:01; C*03:04,14:02 (PubMed=26589293); Genome ancestry: African=0.09%; Native American=0%; East Asian, North=0.85%; East Asian, South=0.49%; South Asian=0.94%; European, North=69.01%; European, South=28.61% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Val (c.50G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Gly (c.472C>G); ClinVar=VCV000856171; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21132653 CVCL_0T34 GM17815 transformed cell line human CVCL_0T34 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132654 CVCL_1534 NCI-H2141 cancer cell line human CVCL_1534 Genome ancestry: African=1.17%; Native American=0.27%; East Asian, North=1.08%; East Asian, South=0%; South Asian=1.16%; European, North=65.94%; European, South=30.38% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Ter (c.625A>T); Zygosity=Homozygous (PubMed=1312696; PubMed=20557307; ATCC) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132655 CVCL_0T37 GM17818 transformed cell line human CVCL_0T37 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132656 CVCL_1537 NCI-H2172 cancer cell line human CVCL_1537 HLA typing: A*30:02,30:02; B*08:01,35:08; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=81.79%; Native American=0.46%; East Asian, North=2.23%; East Asian, South=0%; South Asian=0%; European, North=5.77%; European, South=9.75% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132657 CVCL_0T36 GM17817 transformed cell line human CVCL_0T36 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132658 CVCL_1536 NCI-H2171 cancer cell line human CVCL_1536 HLA typing: A*23:01,66:01; B*41:02,48:03; C*05:01,17:01 (PubMed=26589293); Genome ancestry: African=3.06%; Native American=0%; East Asian, North=4.89%; East Asian, South=0.05%; South Asian=0%; European, North=56.36%; European, South=35.63% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 20202; CACNA2D4 + HGNC; 28945; WDR43; Name(s)=CACNA2D4-WDR43; Note=Out of frame (PubMed=18438408); Sequence variation: Gene fusion; HGNC; 19437; CCNB1IP1 + HGNC; 9709; PVT1; Name(s)=PVT1-CCNB1IP1 (PubMed=23716474); Sequence variation: Gene fusion; HGNC; 20626; CHD7 + HGNC; 9709; PVT1; Name(s)=PVT1-CHD7 (PubMed=18438408; PubMed=23716474); Sequence variation: Gene fusion; HGNC; 9709; PVT1 + HGNC; 11065; SLC7A7; Name(s)=PVT1-SLC7A7 (PubMed=23716474); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser567Ter (c.1700C>A); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Homozygous (PubMed=20557307; ATCC; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: BRD4 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40 hours (PubMed=25984343); ~35-60 hours (DSMZ=ACC-544); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132659 CVCL_0T39 GM17824 transformed cell line human CVCL_0T39 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132660 CVCL_1539 NCI-H2196 cancer cell line human CVCL_1539 HLA typing: A*01:01,02:24; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=2.17%; Native American=0%; East Asian, North=2.28%; East Asian, South=0%; South Asian=0%; European, North=66.73%; European, South=28.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132661 CVCL_0T38 GM17823 transformed cell line human CVCL_0T38 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132662 CVCL_1538 NCI-H2195 cancer cell line human CVCL_1538 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=20557307) Derived from metastatic site: Bone marrow. Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21132663 CVCL_SZ70 HAP1 MYT1 (-) 2 cancer cell line human CVCL_SZ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7622; MYT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132664 CVCL_SZ72 HAP1 N6AMT2 (-) cancer cell line human CVCL_SZ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27351; EEF1AKMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132665 CVCL_SZ71 HAP1 MYT1 (-) 3 cancer cell line human CVCL_SZ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7622; MYT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132666 CVCL_SZ74 HAP1 NAA30 (-) 1 cancer cell line human CVCL_SZ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19844; NAA30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132667 CVCL_SZ73 HAP1 NAA16 (-) cancer cell line human CVCL_SZ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26164; NAA16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132668 CVCL_SZ76 HAP1 NAA40 (-) 1 cancer cell line human CVCL_SZ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132669 CVCL_SZ75 HAP1 NAA35 (-) cancer cell line human CVCL_SZ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24340; NAA35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132670 CVCL_SZ78 HAP1 NAA40 (-) 3 cancer cell line human CVCL_SZ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132671 CVCL_SZ77 HAP1 NAA40 (-) 2 cancer cell line human CVCL_SZ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132672 CVCL_SZ79 HAP1 NAA40 (-) 4 cancer cell line human CVCL_SZ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25845; NAA40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132673 CVCL_0T40 GM17825 transformed cell line human CVCL_0T40 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132674 CVCL_1540 NCI-H2198 cancer cell line human CVCL_1540 HLA typing: A*01:01,02:24; B*07:02,08:01; C*07:01,07:01; DQA1*02:01,05:02; DQB1*02:01,02:01; DRB1*03:01,07:01 (PubMed=26589293) CL:0000010 Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21132675 CVCL_0T42 GM17827 transformed cell line human CVCL_0T42 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132676 CVCL_1542 NCI-H2227 cancer cell line human CVCL_1542 HLA typing: A*01:01,01:01; B*08:01,51:01; C*07:01,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.89%; East Asian, South=0%; South Asian=1.06%; European, North=65.68%; European, South=31.37% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783-2A>C; ClinVar=VCV000635386; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=1312696; PubMed=1565469) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 92227; probable. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132677 CVCL_0T41 GM17826 transformed cell line human CVCL_0T41 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132678 CVCL_1541 NCI-H220 cancer cell line human CVCL_1541 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21132679 CVCL_0T44 GM17831 transformed cell line human CVCL_0T44 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132680 CVCL_1544 NCI-H226 cancer cell line human CVCL_1544 HLA typing: A*01:01:01,24:02:01; B*07,39; C*07:02:01,12:03:01; DPB1*02:01:02,04:01; DQB1*05:02:01,06:02; DRB1*15:01:01,16:01:01 (PubMed=15748285); HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.16%; East Asian, South=0.88%; South Asian=1.48%; European, North=65.62%; European, South=31.86% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228; PubMed=20557307) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90226; probable Male Doubling time: 43 hours (PubMed=9488600); 52 hours (PubMed=29681454); 61 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel Caution: Indicated to have a TP53 p.Arg158Leu (c.473G>T) mutation according to PubMed=1311061, but no TP53 mutation detected according to PubMed=20557307, CCLE and Cosmic-CLP 21132681 CVCL_0T43 GM17828 transformed cell line human CVCL_0T43 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132682 CVCL_1543 NCI-H2228 cancer cell line human CVCL_1543 HLA typing: A*02:01,03:01; B*07:02,38:01; C*07:02,12:03 (PubMed=26589293); Genome ancestry: African=0.1%; Native American=0.08%; East Asian, North=0.5%; East Asian, South=0.06%; South Asian=0.85%; European, North=65.31%; European, South=33.09% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010; DepMap); Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 9655; PTPN3; Name(s)=ALK-PTPN3 (PubMed=22334442); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132683 CVCL_0T46 GM17835 transformed cell line human CVCL_0T46 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132684 CVCL_1546 NCI-H2291 cancer cell line human CVCL_1546 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.1%; Native American=0%; East Asian, North=3.67%; East Asian, South=0%; South Asian=1.55%; European, North=54.53%; European, South=39.15% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Phe (c.34_35GG>TT) (c.34_35delinsTT); Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Val (c.461G>T); ClinVar=VCV000651769; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132685 CVCL_0T45 GM17833 transformed cell line human CVCL_0T45 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132686 CVCL_1545 NCI-H2286 cancer cell line human CVCL_1545 HLA typing: A*02:01,24:21; B*51:01,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=2.79%; Native American=0%; East Asian, North=4.22%; East Asian, South=0%; South Asian=0%; European, North=60.65%; European, South=32.33% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys291Ter (c.871A>T); Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21132687 CVCL_0T48 GM17838 transformed cell line human CVCL_0T48 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132688 CVCL_1548 NCI-H2330 cancer cell line human CVCL_1548 CL:0000010 Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21132689 CVCL_0T47 GM17837 transformed cell line human CVCL_0T47 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132690 CVCL_1547 NCI-H23 cancer cell line human CVCL_1547 HLA typing: A*80:01; B*50:01; C*06:02; DPB1*19:01; DQB1*06:03; DRB1*13:01:01 (PubMed=15748285); HLA typing: A*80:01,80:01; B*50:01,50:01; C*06:02,06:02; DQB1*06:13,06:13 (PubMed=26589293); Genome ancestry: African=67.86%; Native American=2.12%; East Asian, North=2.83%; East Asian, South=0%; South Asian=0%; European, North=10.88%; European, South=16.3% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1919Pro (c.5756A>C); ClinVar=VCV000580726; Zygosity=Homozygous (PubMed=27602502); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=1311061; PubMed=17088437); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Trp332Ter (c.996G>A); ClinVar=VCV000376339; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>C); Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=10536175; PubMed=12820372; PubMed=15900046; PubMed=17088437; PubMed=20557307) Population: African American; Derived from sampling site: Lung. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 38 hours (in RPMI 1640 + 10% FBS), 71 hours (in ACL-3), 57 hours (in ACL-3 + BSA) (PubMed=3940644); 25 hours (PubMed=7718330); 35 hours (PubMed=25984343); 39.1 hours (PubMed=29681454); 33.4 hours (NCI-DTP); 38 hours (ATCC=CRL-5800); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: NCI-60 cancer cell line panel; Part of: NCI-7 clinical proteomics reference material cell line panel 21132691 CVCL_0T49 GM17839 transformed cell line human CVCL_0T49 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132692 CVCL_1549 NCI-H2342 cancer cell line human CVCL_1549 Genome ancestry: African=0.24%; Native American=0%; East Asian, North=4.52%; East Asian, South=0%; South Asian=0%; European, North=58.43%; European, South=36.81% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132693 CVCL_SZ61 HAP1 MYLK (-) 2 cancer cell line human CVCL_SZ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7590; MYLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132694 CVCL_SZ60 HAP1 MYLK (-) 1 cancer cell line human CVCL_SZ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7590; MYLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132695 CVCL_SZ63 HAP1 MYLK3 (-) 2 cancer cell line human CVCL_SZ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29826; MYLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132696 CVCL_SZ62 HAP1 MYLK3 (-) 1 cancer cell line human CVCL_SZ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29826; MYLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132697 CVCL_SZ65 HAP1 MYLK3 (-) 4 cancer cell line human CVCL_SZ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29826; MYLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132698 CVCL_SZ64 HAP1 MYLK3 (-) 3 cancer cell line human CVCL_SZ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29826; MYLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132699 CVCL_SZ67 HAP1 MYSM1 (-) 1 cancer cell line human CVCL_SZ67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29401; MYSM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132700 CVCL_SZ66 HAP1 MYO5B (-) 1 cancer cell line human CVCL_SZ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7603; MYO5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132701 CVCL_SZ69 HAP1 MYT1 (-) 1 cancer cell line human CVCL_SZ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7622; MYT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132702 CVCL_SZ68 HAP1 MYSM1 (-) 2 cancer cell line human CVCL_SZ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29401; MYSM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132703 CVCL_0T11 GM17792 transformed cell line human CVCL_0T11 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132704 CVCL_1511 NCI-H1975 cancer cell line human CVCL_1511 HLA typing: A*01:01,01:01; B*41:01,41:01; C*17:01,17:01 (PubMed=26589293); Genome ancestry: African=0.35%; Native American=0%; East Asian, North=1.32%; East Asian, South=0%; South Asian=7.46%; European, North=30.01%; European, South=60.85% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (PubMed=17332333; PubMed=21498706; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (PubMed=17332333; PubMed=21498706; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep membrane proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 38.7 +- 5.92 hours (PubMed=25008024); 30.531 +- 1.823 hours (PubMed=25483995); 28 hours (PubMed=25984343); 42.2 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: MD Anderson Cell Lines Project 21132705 CVCL_0T10 GM17791 transformed cell line human CVCL_0T10 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132706 CVCL_1510 NCI-H1963 cancer cell line human CVCL_1510 HLA typing: A*02:01,32:01; B*07:02,44:18; C*07:01,08:02 (PubMed=26589293); Genome ancestry: African=56.07%; Native American=0.5%; East Asian, North=4.15%; East Asian, South=0%; South Asian=0%; European, North=21.6%; European, South=17.68% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Cys61Ter (c.183T>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Asp (c.440T>A); ClinVar=VCV001351017; Zygosity=Heterozygous (PubMed=1312696; PubMed=20557307; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Heterozygous (PubMed=1312696; PubMed=20557307; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~3-4 days (DSMZ=ACC-540); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132707 CVCL_0T13 GM17794 transformed cell line human CVCL_0T13 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132708 CVCL_1513 NCI-H1994 cancer cell line human CVCL_1513 CL:0000010 Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-5910; true Female 21132709 CVCL_0T12 GM17793 transformed cell line human CVCL_0T12 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132710 CVCL_1512 NCI-H1993 cancer cell line human CVCL_1512 Genome ancestry: African=1.07%; Native American=0.66%; East Asian, North=0.47%; East Asian, South=1.32%; South Asian=0.09%; European, North=67.35%; European, South=29.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Trp (c.726C>G); ClinVar=VCV000376580; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 31.6 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132711 CVCL_0T15 GM17796 transformed cell line human CVCL_0T15 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132712 CVCL_1515 NCI-H2023 cancer cell line human CVCL_1515 HLA typing: A*02:01,02:01; B*07:02,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.48%; East Asian, North=0.88%; East Asian, South=0%; South Asian=0%; European, North=66.45%; European, South=32.18% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Ser828Profs*3 (c.2481delC) (p.Ala826fs) (c.2477delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser240Arg (c.720T>A); ClinVar=VCV001504304; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32.3 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132713 CVCL_0T14 GM17795 transformed cell line human CVCL_0T14 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132714 CVCL_1514 NCI-H2009 cancer cell line human CVCL_1514 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=5.66%; Native American=0%; East Asian, North=7.51%; East Asian, South=0%; South Asian=0%; European, North=48.63%; European, South=38.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000376369; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Gln28Ter (c.82C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=1311061; PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=1311061; PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29.8 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132715 CVCL_0T17 GM17798 transformed cell line human CVCL_0T17 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132716 CVCL_1517 NCI-H2030 cancer cell line human CVCL_1517 HLA typing: A*11:01,24:02; B*44:03,51:01; C*01:02,04:01 (PubMed=26589293); Genome ancestry: African=0.43%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.87%; European, North=64.18%; European, South=32.52% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21132717 CVCL_0T16 GM17797 transformed cell line human CVCL_0T16 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132718 CVCL_1516 NCI-H2029 cancer cell line human CVCL_1516 HLA typing: A*02:01,11:01; B*07:02,35:08; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=4.84%; Native American=0%; East Asian, North=5.65%; East Asian, South=0%; South Asian=0%; European, North=50.95%; European, South=38.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265-1G>T; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Asp (c.658T>G); ClinVar=VCV000376689; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132719 CVCL_0T19 GM17800 transformed cell line human CVCL_0T19 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132720 CVCL_1519 NCI-H2059 cancer cell line human CVCL_1519 CL:0000010 Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-5916; true Male 21132721 CVCL_0T18 GM17799 transformed cell line human CVCL_0T18 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132722 CVCL_1518 NCI-H2052 cancer cell line human CVCL_1518 HLA typing: A*25:01,29:02; B*18:01,44:03; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0.17%; Native American=0%; East Asian, North=2.33%; East Asian, South=0%; South Asian=0.22%; European, North=64.49%; European, South=32.79% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Gene deletion; HGNC; 6515; LATS2; Zygosity=Homozygous (PubMed=21245096); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg341Ter (c.1021C>T); ClinVar=VCV000003292; Zygosity=Homozygous (PubMed=16630136; PubMed=25902174; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9883; RASSF2; Simple; p.Glu294Ter (c.880G>T); Zygosity=Heterozygous (PubMed=25902174; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=25984343); 33.4 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132723 CVCL_SZ50 HAP1 MVP (-) 1 cancer cell line human CVCL_SZ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7531; MVP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132724 CVCL_SZ52 HAP1 MX2 (-) 1 cancer cell line human CVCL_SZ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7533; MX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132725 CVCL_SZ51 HAP1 MVP (-) 2 cancer cell line human CVCL_SZ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7531; MVP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132726 CVCL_SZ54 HAP1 MYD88 (-) 1 cancer cell line human CVCL_SZ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7562; MYD88; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132727 CVCL_SZ53 HAP1 MYB (-) 1 cancer cell line human CVCL_SZ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7545; MYB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132728 CVCL_SZ56 HAP1 MYEOV2 (-) 1 cancer cell line human CVCL_SZ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21314; COPS9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132729 CVCL_SZ55 HAP1 MYD88 (-) 2 cancer cell line human CVCL_SZ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7562; MYD88; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132730 CVCL_SZ58 HAP1 MYH9 (-) 1 cancer cell line human CVCL_SZ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7579; MYH9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132731 CVCL_SZ57 HAP1 MYEOV2 (-) 2 cancer cell line human CVCL_SZ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21314; COPS9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132732 CVCL_SZ59 HAP1 MYH9 (-) 2 cancer cell line human CVCL_SZ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7579; MYH9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132733 CVCL_0T20 GM17801 transformed cell line human CVCL_0T20 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132734 CVCL_1520 NCI-H2066 cancer cell line human CVCL_1520 HLA typing: A*03:01,03:01; B*08:20,42:02; C*01:02,17:01 (PubMed=26589293); Genome ancestry: African=3%; Native American=0%; East Asian, North=2.95%; East Asian, South=0%; South Asian=0%; European, North=59.43%; European, South=34.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 92066; probable. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132735 CVCL_0T22 GM17803 transformed cell line human CVCL_0T22 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132736 CVCL_1522 NCI-H2081 cancer cell line human CVCL_1522 HLA typing: A*24:02,68:01; B*08:01,35:08; C*04:01,07:04 (PubMed=25960936); HLA typing: A*24:02,68:01; B*08:01,35:08; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=2.93%; Native American=0%; East Asian, North=6.2%; East Asian, South=0%; South Asian=0%; European, North=47.59%; European, South=43.27% (PubMed=30894373) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132737 CVCL_0T21 GM17802 transformed cell line human CVCL_0T21 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132738 CVCL_1521 NCI-H2073 cancer cell line human CVCL_1521 HLA typing: A*02:01,25:01; B*18:01,40:01; C*03:04,12:03; DQA1*01:02,01:02; DQB1*06:07,06:07; DRB1*13:02,15:01' (PubMed=26589293); Genome ancestry: African=1.14%; Native American=0%; East Asian, North=2.07%; East Asian, South=0%; South Asian=0%; European, North=64.31%; European, South=32.48% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Trp (c.726C>G); ClinVar=VCV000376580; Zygosity=Homozygous (PubMed=1311061; DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45.3 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21132739 CVCL_0T24 GM17805 transformed cell line human CVCL_0T24 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132740 CVCL_1524 NCI-H2087 cancer cell line human CVCL_1524 HLA typing: A*02:01,02:01; B*44:03,44:03; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=3.19%; East Asian, South=0%; South Asian=0%; European, North=67.37%; European, South=29.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu848Gln (c.2542G>C); ClinVar=VCV001686474; Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Val (c.1789C>G); ClinVar=VCV000013969; Zygosity=Heterozygous (PubMed=12068308; PubMed=18397470; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Glu54Lys (c.160G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (PubMed=1311061; PubMed=1565469; PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 51 hours (PubMed=29681454); ~52 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132741 CVCL_0T23 GM17804 transformed cell line human CVCL_0T23 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132742 CVCL_1523 NCI-H2085 cancer cell line human CVCL_1523 Genome ancestry: African=0.71%; Native American=0%; East Asian, North=2.54%; East Asian, South=0%; South Asian=0%; European, North=61.81%; European, South=34.93% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Glu463Ter (c.1387G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 91.1 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132743 CVCL_0T26 GM17807 transformed cell line human CVCL_0T26 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132744 CVCL_1526 NCI-H2106 cancer cell line human CVCL_1526 HLA typing: A*32:01,32:01; B*15:01,15:01; C*03:03,03:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.71%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=64.26%; European, South=32.31% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=1565469; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21132745 CVCL_0T25 GM17806 transformed cell line human CVCL_0T25 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132746 CVCL_1525 NCI-H209 cancer cell line human CVCL_1525 HLA typing: A*34:02,34:02; B*07:04,14:01; C*03:07,08:02 (PubMed=26589293); Genome ancestry: African=1.88%; Native American=0%; East Asian, North=1.08%; East Asian, South=0%; South Asian=0.08%; European, North=65.94%; European, South=31.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Cys706Phe (c.2117G>T); ClinVar=VCV000376330; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Derived from metastatic site: Bone marrow. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-499; true Male Doubling time: ~50-70 hours (DSMZ=ACC-900); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132747 CVCL_0T28 GM17809 transformed cell line human CVCL_0T28 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132748 CVCL_1528 NCI-H2108 cancer cell line human CVCL_1528 CL:0000010 Derived from metastatic site: Bone marrow. Discontinued: ATCC; CRL-5984; true Male 21132749 CVCL_0T27 GM17808 transformed cell line human CVCL_0T27 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132750 CVCL_1527 NCI-H2107 cancer cell line human CVCL_1527 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys101Ter (c.301A>T); Zygosity=Unspecified (PubMed=20557307) Derived from metastatic site: Bone marrow. Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5983; true Male 21132751 CVCL_0T29 GM17810 transformed cell line human CVCL_0T29 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132752 CVCL_1529 NCI-H211 cancer cell line human CVCL_1529 HLA typing: A*02:01,02:01; B*07:06,51:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=3.08%; Native American=0%; East Asian, North=5.72%; East Asian, South=0%; South Asian=0%; European, North=51.87%; European, South=39.33% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90211; probable Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132753 CVCL_SZ41 HAP1 MUS81 (-) 5 cancer cell line human CVCL_SZ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132754 CVCL_SZ40 HAP1 MUS81 (-) 4 cancer cell line human CVCL_SZ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132755 CVCL_SZ43 HAP1 MUS81 (-) 7 cancer cell line human CVCL_SZ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132756 CVCL_SZ42 HAP1 MUS81 (-) 6 cancer cell line human CVCL_SZ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132757 CVCL_SZ45 HAP1 MUS81 (-) 9 cancer cell line human CVCL_SZ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132758 CVCL_SZ44 HAP1 MUS81 (-) 8 cancer cell line human CVCL_SZ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132759 CVCL_SZ47 HAP1 MUT (-) 2 cancer cell line human CVCL_SZ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7526; MMUT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132760 CVCL_SZ46 HAP1 MUT (-) 1 cancer cell line human CVCL_SZ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7526; MMUT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132761 CVCL_SZ49 HAP1 MUTYH (-) 2 cancer cell line human CVCL_SZ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7527; MUTYH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132762 CVCL_SZ48 HAP1 MUTYH (-) 1 cancer cell line human CVCL_SZ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7527; MUTYH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132763 CVCL_0T09 GM17790 transformed cell line human CVCL_0T09 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132764 CVCL_1509 NCI-H196 cancer cell line human CVCL_1509 HLA typing: A*29:01,33:03; B*07:05,50:01; C*06:02,15:05; DRB1*10:01,15:25 (PubMed=25960936); HLA typing: A*29:01,33:03; B*07:05,50:01; C*06:02,15:05 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.1%; East Asian, North=0%; East Asian, South=1.64%; South Asian=3.75%; European, North=50.92%; European, South=43.59% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 90196; probable Male Doubling time: 64 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132765 CVCL_SZ30 HAP1 MTMR4 (-) 1 cancer cell line human CVCL_SZ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7452; MTMR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132766 CVCL_SZ32 HAP1 MTMR6 (-) cancer cell line human CVCL_SZ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7453; MTMR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132767 CVCL_SZ31 HAP1 MTMR4 (-) 2 cancer cell line human CVCL_SZ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7452; MTMR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132768 CVCL_SZ34 HAP1 MTMR7 (-) 2 cancer cell line human CVCL_SZ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7454; MTMR7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132769 CVCL_SZ33 HAP1 MTMR7 (-) 1 cancer cell line human CVCL_SZ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7454; MTMR7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132770 CVCL_SZ36 HAP1 MTR (-) 2 cancer cell line human CVCL_SZ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7468; MTR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132771 CVCL_SZ35 HAP1 MTR (-) 1 cancer cell line human CVCL_SZ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7468; MTR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132772 CVCL_SZ38 HAP1 MUS81 (-) 2 cancer cell line human CVCL_SZ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132773 CVCL_SZ37 HAP1 MUS81 (-) 1 cancer cell line human CVCL_SZ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132774 CVCL_SZ39 HAP1 MUS81 (-) 3 cancer cell line human CVCL_SZ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29814; MUS81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132775 CVCL_0T00 GM17775 transformed cell line human CVCL_0T00 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132776 CVCL_1500 NCI-H1869 cancer cell line human CVCL_1500 HLA typing: A*03:01,11:01; B*07:02,18:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.87%; Native American=0%; East Asian, North=2.87%; East Asian, South=0%; South Asian=0%; European, North=62.8%; European, South=33.45% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 51.8 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132777 CVCL_0T02 GM17779 transformed cell line human CVCL_0T02 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132778 CVCL_1502 NCI-H1870 cancer cell line human CVCL_1502 CL:0000010 Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5901; true. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00413 Problematic cell line: Contaminated NCI-H1304 and NCI-H1870 have been shown to be identical. 21132779 CVCL_0T01 GM17776 transformed cell line human CVCL_0T01 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132780 CVCL_1501 NCI-H187 cancer cell line human CVCL_1501 HLA typing: A*03:01,24:02; B*07:02,37:04; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,03:17 (PubMed=25960936); HLA typing: A*03:01,24:02; B*07:02,37:04; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.56%; Native American=0.51%; East Asian, North=0.71%; East Asian, South=0.08%; South Asian=0%; European, North=64.51%; European, South=33.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (PubMed=20557307; ATCC) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21132781 CVCL_0T04 GM17782 transformed cell line human CVCL_0T04 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132782 CVCL_1504 NCI-H1882 cancer cell line human CVCL_1504 HLA typing: A*02:01,03:01; B*07:02,35:01; C*04:01,07:02; DQB1*06:07,06:07 (PubMed=25960936); HLA typing: A*02:01,03:01; B*07:02,35:01; C*04:01,07:02 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Small cell lung cancer p53 hotspot mutation cell panel (ATCC TCP-2040) 21132783 CVCL_0T03 GM17780 transformed cell line human CVCL_0T03 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132784 CVCL_1503 NCI-H1876 cancer cell line human CVCL_1503 HLA typing: A*02:01,03:01; B*07:02,35:01; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=0.78%; Native American=0.51%; East Asian, North=1.19%; East Asian, South=0%; South Asian=0%; European, North=70.91%; European, South=26.6% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132785 CVCL_0T06 GM17785 transformed cell line human CVCL_0T06 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132786 CVCL_1506 NCI-H1926 cancer cell line human CVCL_1506 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469) Omics: SNP array analysis Discontinued: ATCC; CRL-5905; true. Male 21132787 CVCL_0T05 GM17783 transformed cell line human CVCL_0T05 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21132788 CVCL_1505 NCI-H1915 cancer cell line human CVCL_1505 HLA typing: A*24:02,24:02; B*14:02,14:02; C*02:02,02:02 (PubMed=26589293); Genome ancestry: African=3.05%; Native American=0.18%; East Asian, North=4.07%; East Asian, South=0%; South Asian=6.45%; European, North=23.9%; European, South=62.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Phe90Leu (c.270C>G); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000376033; Zygosity=Heterozygous (PubMed=1311061; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys291Ter (c.871A>T); Zygosity=Homozygous (PubMed=1311061; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 91915; probable. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21132789 CVCL_0T08 GM17789 transformed cell line human CVCL_0T08 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132790 CVCL_1508 NCI-H1944 cancer cell line human CVCL_1508 HLA typing: A*03:01,24:03; B*15:18,51:01; C*07:04,07:04 (PubMed=26589293); Genome ancestry: African=0.85%; Native American=0.24%; East Asian, North=2.96%; East Asian, South=0%; South Asian=0.89%; European, North=61.33%; European, South=33.73% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Arg2363Ter (c.7087C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37.8 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21132791 CVCL_0T07 GM17787 transformed cell line human CVCL_0T07 CL:0000010 Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21132792 CVCL_1507 NCI-H1930 cancer cell line human CVCL_1507 HLA typing: A*02:01,29:02; B*44:03,15:01; C*03:03,16:01; DQB1*05:03,05:03; DRB1*14:07,14:07 (PubMed=25960936); HLA typing: A*02:01,29:02; B*15:27,44:03; C*03:03,16:01 (PubMed=26589293); Genome ancestry: African=2.23%; Native American=0%; East Asian, North=3.79%; East Asian, South=0%; South Asian=0%; European, North=56.29%; European, South=37.69% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Arg (c.733G>C); ClinVar=VCV000376604; Zygosity=Homozygous (ATCC) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21132793 CVCL_KA88 VPM 4 hybridoma house mouse CVCL_KA88 CL:0000010 Monoclonal antibody isotype: IgG2a. 21132794 CVCL_KA87 VPM 39 hybridoma house mouse CVCL_KA87 CL:0000010 Monoclonal antibody isotype: IgG1. 21132795 CVCL_KA89 VPM 29 hybridoma house mouse CVCL_KA89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5Q3P2; Sheep CD5. 21132796 CVCL_SZ21 HAP1 MTHFD2 (-) 1 cancer cell line human CVCL_SZ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7434; MTHFD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132797 CVCL_KA84 VPM 16 hybridoma house mouse CVCL_KA84 CL:0000010 Monoclonal antibody isotype: IgG1. 21132798 CVCL_SZ20 HAP1 MTHFD1L (-) 1 cancer cell line human CVCL_SZ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21055; MTHFD1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132799 CVCL_KA83 VPM 15 hybridoma house mouse CVCL_KA83 CL:0000010 Monoclonal antibody isotype: IgG3. 21132800 CVCL_SZ23 HAP1 MTM1 (-) 2 cancer cell line human CVCL_SZ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7448; MTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132801 CVCL_KA86 VPM 3 hybridoma house mouse CVCL_KA86 CL:0000010 Monoclonal antibody isotype: IgM. 21132802 CVCL_SZ22 HAP1 MTM1 (-) 1 cancer cell line human CVCL_SZ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7448; MTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132803 CVCL_KA85 VPM 17 hybridoma house mouse CVCL_KA85 CL:0000010 Monoclonal antibody isotype: IgG3. 21132804 CVCL_KA80 CHO-K1/GRM3/Gqi5 spontaneously immortalized cell line CVCL_KA80 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: HGNC; 4595; GRM3 Miscellaneous: Cell line under development; catalog number M00466 Derived from sampling site: Ovary. Female 21132805 CVCL_SZ25 HAP1 MTMR14 (-) 1 cancer cell line human CVCL_SZ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26190; MTMR14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132806 CVCL_SZ24 HAP1 MTMR1 (-) cancer cell line human CVCL_SZ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7449; MTMR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132807 CVCL_SZ27 HAP1 MTMR2 (-) 1 cancer cell line human CVCL_SZ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7450; MTMR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132808 CVCL_KA82 VPM 14 hybridoma house mouse CVCL_KA82 CL:0000010 Monoclonal antibody isotype: IgG2a. 21132809 CVCL_SZ26 HAP1 MTMR14 (-) 2 cancer cell line human CVCL_SZ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26190; MTMR14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132810 CVCL_KA81 VPM 1 hybridoma house mouse CVCL_KA81 CL:0000010 Monoclonal antibody isotype: IgM. 21132811 CVCL_SZ29 HAP1 MTMR3 (-) cancer cell line human CVCL_SZ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7451; MTMR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132812 CVCL_SZ28 HAP1 MTMR2 (-) 2 cancer cell line human CVCL_SZ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7450; MTMR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132813 CVCL_KA99 AFS98 hybridoma CVCL_KA99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09581; Mouse Csf1r/Cd115. 21132814 CVCL_KA98 A2F10 hybridoma CVCL_KA98 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q00342; Mouse Flt3/Cd135. 21132815 CVCL_KA95 BF-B6 hybridoma house mouse CVCL_KA95 CL:0000010 Discontinued: ATCC; HB-279; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine embryonic myosin heavy chain 21132816 CVCL_SZ10 HAP1 MTAP (-) 2 cancer cell line human CVCL_SZ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7413; MTAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132817 CVCL_KA94 OX-11 hybridoma CVCL_KA94 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Rat Ig kappa light chains (allotype IgK-1b). 21132818 CVCL_KA97 6E2 [Mouse hybridoma against SSEA-4] hybridoma house mouse CVCL_KA97 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:189546; NeuAcalpha2-3Galbeta1-3GalNAcbeta1-3Galalpha1-4Galbeta1-4Glcbeta-Cer(d18:1/22:0) (Stage-specific embryonic antigen-4; SSEA-4). 21132819 CVCL_SZ12 HAP1 MTCH1 (-) 2 cancer cell line human CVCL_SZ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17586; MTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132820 CVCL_KA96 #16-15 hybridoma CVCL_KA96 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q5T5X7; Human BEND3. 21132821 CVCL_SZ11 HAP1 MTCH1 (-) 1 cancer cell line human CVCL_SZ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17586; MTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132822 CVCL_SZ14 HAP1 MTF2 (-) 1 cancer cell line human CVCL_SZ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29535; MTF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132823 CVCL_KA91 OX-31 hybridoma house mouse CVCL_KA91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21132824 CVCL_SZ13 HAP1 MTCH1 (-) 3 cancer cell line human CVCL_SZ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17586; MTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132825 CVCL_KA90 OX-16 hybridoma house mouse CVCL_KA90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat IgG2b. 21132826 CVCL_SZ16 HAP1 MTF2 (-) 3 cancer cell line human CVCL_SZ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29535; MTF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21132827 CVCL_KA93 OX-56 hybridoma house mouse CVCL_KA93 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21132828 CVCL_SZ15 HAP1 MTF2 (-) 2 cancer cell line human CVCL_SZ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29535; MTF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132829 CVCL_KA92 OX-37 hybridoma house mouse CVCL_KA92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21132830 CVCL_SZ18 HAP1 MTF2 (-) 5 cancer cell line human CVCL_SZ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29535; MTF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132831 CVCL_SZ17 HAP1 MTF2 (-) 4 cancer cell line human CVCL_SZ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29535; MTF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21132832 CVCL_SZ19 HAP1 MTFR1L (-) 1 cancer cell line human CVCL_SZ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28836; MTFR1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132833 CVCL_SS20 HAP1 IFITM2 (-) 2 cancer cell line human CVCL_SS20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132834 CVCL_T420 Psi-CRIP-RxBcl-XL-i-bsr transformed cell line house mouse CVCL_T420 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132835 CVCL_SS22 HAP1 IFITM3 (-) 2 cancer cell line human CVCL_SS22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132836 CVCL_T422 Psi-CRIP-RxhFAS-i-CD80 transformed cell line house mouse CVCL_T422 CL:0000010 Transfected with: HGNC; 1700; CD80; Transfected with: HGNC; 11920; FAS Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132837 CVCL_SS21 HAP1 IFITM3 (-) 1 cancer cell line human CVCL_SS21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5414; IFITM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132838 CVCL_T421 Psi-CRIP-RxhCD82 transformed cell line house mouse CVCL_T421 CL:0000010 Transfected with: HGNC; 6210; CD82 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132839 CVCL_SS24 HAP1 IFNAR1 (-) 2 cancer cell line human CVCL_SS24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5432; IFNAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132840 CVCL_T424 Psi-CRIP-RxhVIPR-bsr transformed cell line house mouse CVCL_T424 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132841 CVCL_SS23 HAP1 IFNAR1 (-) 1 cancer cell line human CVCL_SS23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5432; IFNAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132842 CVCL_T423 Psi-CRIP-RxhSecR-bsr transformed cell line house mouse CVCL_T423 CL:0000010 Transfected with: HGNC; 10608; SCTR; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132843 CVCL_SS26 HAP1 IFNAR2 (-) 2 cancer cell line human CVCL_SS26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5433; IFNAR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132844 CVCL_T426 Psi-CRIP-RxnZ transformed cell line house mouse CVCL_T426 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132845 CVCL_SS25 HAP1 IFNAR2 (-) 1 cancer cell line human CVCL_SS25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5433; IFNAR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132846 CVCL_T425 Psi-CRIP-RxmPCNT1-i-bsr transformed cell line house mouse CVCL_T425 CL:0000010 Transfected with: MGI; MGI:107164; Ppp3ca; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132847 CVCL_SS28 HAP1 IFNGR1 (-) 2 cancer cell line human CVCL_SS28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132848 CVCL_T428 SC-2 [Mouse] spontaneously immortalized cell line house mouse CVCL_T428 CL:0000010 Unspecified 21132849 CVCL_SS27 HAP1 IFNGR1 (-) 1 cancer cell line human CVCL_SS27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5439; IFNGR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132850 CVCL_T427 Psi-CRIP-mPCNF1-bsr transformed cell line house mouse CVCL_T427 CL:0000010 Transfected with: MGI; MGI:107164; Ppp3ca; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132851 CVCL_SS29 HAP1 IFNGR2 (-) 1 cancer cell line human CVCL_SS29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5440; IFNGR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132852 CVCL_T429 U-2 OS R1 cancer cell line human CVCL_T429 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; tibia. Female 21132853 CVCL_JY87 A549/GFP cancer cell line human CVCL_JY87 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Lung. Male 21132854 CVCL_JY86 T47D/GFP cancer cell line human CVCL_JY86 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from metastatic site: Pleural effusion. Female 21132855 CVCL_JY89 HeLa/GFP cancer cell line human CVCL_JY89 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P42212; GFP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21132856 CVCL_JY88 293/GFP transformed cell line human CVCL_JY88 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P42212; GFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132857 CVCL_JY83 U87MG.DY4 cancer cell line human CVCL_JY83 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del, p.Tyr1016Phe, p.Tyr1092Phe, p.Tyr1110Phe and p.Tyr1172Phe = EGFRvIII and 4 TyrP site dead). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132858 CVCL_JY82 U87MG.DY3 cancer cell line human CVCL_JY82 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del, p.Tyr1092Phe, p.Tyr1172Phe and p.Tyr1197Phe = EGFRvIII and 3 TyrP site dead). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132859 CVCL_JY85 OVCAR-5/RFP cancer cell line human CVCL_JY85 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Ascites. Female Problematic cell line: Possibly misclassified Parent cell line (OVCAR-5) was originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin. 21132860 CVCL_JY84 U87MG.DY5 cancer cell line human CVCL_JY84 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del, p.Tyr1016Phe, p.Tyr1092Phe, p.Tyr1110Phe, p.Tyr1172Phe and p.Tyr1197Phe = EGFRvIII and 5 TyrP site dead). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132861 CVCL_JY81 U87MG.DY2 cancer cell line human CVCL_JY81 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del, p.Tyr1092Phe and p.Tyr1197Phe = EGFRvIII and 2 TyrP site dead). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132862 CVCL_JY80 U87MG.DY1 cancer cell line human CVCL_JY80 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del and p.Tyr1197Phe = EGFRvIII and 1 TyrP site dead). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132863 CVCL_SS11 HAP1 IFI16 (-) 1 cancer cell line human CVCL_SS11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5395; IFI16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132864 CVCL_T411 Psi-CRIP-MFGratGM-CSF transformed cell line house mouse CVCL_T411 CL:0000010 Transfected with: RGD; 621065; Csf2 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132865 CVCL_SS10 HAP1 IDUA (-) 2 cancer cell line human CVCL_SS10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5391; IDUA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132866 CVCL_T410 Psi-CRIP-MFGrab-IL1RA transformed cell line house mouse CVCL_T410 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132867 CVCL_SS13 HAP1 IFI35 (-) 1 cancer cell line human CVCL_SS13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5399; IFI35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132868 CVCL_T413 Psi-CRIP-MFGts-c-src transformed cell line house mouse CVCL_T413 CL:0000010 Transfected with: MGI; MGI:98397; Src Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132869 CVCL_SS12 HAP1 IFI16 (-) 2 cancer cell line human CVCL_SS12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5395; IFI16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132870 CVCL_T412 Psi-CRIP-MFGtr-gammaIFNR transformed cell line house mouse CVCL_T412 CL:0000010 Transfected with: MGI; MGI:107655; Ifngr1 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132871 CVCL_SS15 HAP1 IFIH1 (-) 1 cancer cell line human CVCL_SS15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18873; IFIH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132872 CVCL_T415 Psi-CRIP-MSHR transformed cell line house mouse CVCL_T415 CL:0000010 Transfected with: HGNC; 6929; MC1R Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132873 CVCL_SS14 HAP1 IFI35 (-) 2 cancer cell line human CVCL_SS14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5399; IFI35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132874 CVCL_T414 Psi-CRIP-MFGtsT transformed cell line house mouse CVCL_T414 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132875 CVCL_SS17 HAP1 IFITM1 (-) 1 cancer cell line human CVCL_SS17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132876 CVCL_T417 Psi-CRIP-P131 transformed cell line house mouse CVCL_T417 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132877 CVCL_SS16 HAP1 IFIH1 (-) 2 cancer cell line human CVCL_SS16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18873; IFIH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132878 CVCL_T416 Psi-CRIP-NCre transformed cell line house mouse CVCL_T416 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132879 CVCL_SS19 HAP1 IFITM2 (-) 1 cancer cell line human CVCL_SS19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132880 CVCL_T419 Psi-CRIP-Rx-ETBR-bsr transformed cell line house mouse CVCL_T419 CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132881 CVCL_SS18 HAP1 IFITM1 (-) 2 cancer cell line human CVCL_SS18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5412; IFITM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132882 CVCL_T418 Psi-CRIP-Rx-crmA-bsr transformed cell line house mouse CVCL_T418 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P07385; Cowpox virus crmA Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132883 CVCL_JY98 MDA-MB-436/GFP cancer cell line human CVCL_JY98 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.5277+1G>A; ClinVar=VCV000037654; Zygosity=Hemizygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly203fs*9 (c.607_608ins227); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204fs*7 (c.610_612delinsGCGTGTGG); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-203; probable Female Group: Triple negative breast cancer (TNBC) cell line 21132884 CVCL_JY97 NIH3T3/GFP spontaneously immortalized cell line house mouse CVCL_JY97 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132885 CVCL_JY99 MDA-MB-436/RFP cancer cell line human CVCL_JY99 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.5277+1G>A; ClinVar=VCV000037654; Zygosity=Hemizygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly203fs*9 (c.607_608ins227); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204fs*7 (c.610_612delinsGCGTGTGG); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-252; probable Female Group: Triple negative breast cancer (TNBC) cell line 21132886 CVCL_JY94 SKOV-3/GFP-Luc cancer cell line human CVCL_JY94 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: Cell_Biolabs; AKR-225; probable Female 21132887 CVCL_JY93 ES-2/GFP cancer cell line human CVCL_JY93 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Discontinued: Cell_Biolabs; AKR-206; probable Female Problematic cell line: Probably misclassified Parent cell line seems to originate from a Caucasian patient with an ovarian serous adenocarcinoma origin. 21132888 CVCL_JY96 293/YFP transformed cell line human CVCL_JY96 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Cell_Biolabs; AKR-280; probable Female 21132889 CVCL_JY95 293/Luc transformed cell line human CVCL_JY95 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Cell_Biolabs; AKR-230; probable Female 21132890 CVCL_JY90 ZR-75-1/GFP cancer cell line human CVCL_JY90 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: Cell_Biolabs; AKR-210; probable Female 21132891 CVCL_JY92 OVCA429/GFP cancer cell line human CVCL_JY92 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Discontinued: Cell_Biolabs; AKR-212; probable Female 21132892 CVCL_JY91 BT-549/RFP cancer cell line human CVCL_JY91 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Breast. Discontinued: Cell_Biolabs; AKR-255; probable Female Group: Triple negative breast cancer (TNBC) cell line 21132893 CVCL_SS00 HAP1 IDE (-) 2 cancer cell line human CVCL_SS00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5381; IDE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132894 CVCL_T400 Psi-CRIP-MFGmIL-2 transformed cell line house mouse CVCL_T400 CL:0000010 Transfected with: MGI; MGI:96548; Il2 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132895 CVCL_SS02 HAP1 IDE (-) 4 cancer cell line human CVCL_SS02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5381; IDE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132896 CVCL_T402 Psi-CRIP-MFGmIL-4 transformed cell line house mouse CVCL_T402 CL:0000010 Transfected with: MGI; MGI:96556; Il4 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132897 CVCL_SS01 HAP1 IDE (-) 3 cancer cell line human CVCL_SS01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5381; IDE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132898 CVCL_T401 Psi-CRIP-MFGmIL-3 transformed cell line house mouse CVCL_T401 CL:0000010 Transfected with: MGI; MGI:96552; Il3 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132899 CVCL_SS04 HAP1 IDH1 (-) 2 cancer cell line human CVCL_SS04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132900 CVCL_T404 Psi-CRIP-MFGmIL-7 transformed cell line house mouse CVCL_T404 CL:0000010 Transfected with: MGI; MGI:96561; Il7 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132901 CVCL_SS03 HAP1 IDH1 (-) 1 cancer cell line human CVCL_SS03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132902 CVCL_T403 Psi-CRIP-MFGmIL-6 transformed cell line house mouse CVCL_T403 CL:0000010 Transfected with: MGI; MGI:96559; Il6 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132903 CVCL_SS06 HAP1 IDH2 (-) 1 cancer cell line human CVCL_SS06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132904 CVCL_JY69 LAZ-467 transformed cell line human CVCL_JY69 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21132905 CVCL_T406 Psi-CRIP-MFGmLIF transformed cell line house mouse CVCL_T406 CL:0000010 Transfected with: MGI; MGI:96787; Lif Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132906 CVCL_JY68 H357-VB6 cancer cell line human CVCL_JY68 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Ser (c.37G>A); ClinVar=VCV000376323; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6150; ITGAV; Transfected with: HGNC; 6161; ITGB6 Derived from sampling site: Oral cavity; tongue. Male 21132907 CVCL_SS05 HAP1 IDH1 (-) 3 cancer cell line human CVCL_SS05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5382; IDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132908 CVCL_T405 Psi-CRIP-MFGmKitLigand transformed cell line house mouse CVCL_T405 CL:0000010 Transfected with: MGI; MGI:96974; Kitl Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132909 CVCL_SS08 HAP1 IDS (-) cancer cell line human CVCL_SS08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5389; IDS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132910 CVCL_T408 Psi-CRIP-MFGmTNF-alpha transformed cell line house mouse CVCL_T408 CL:0000010 Transfected with: MGI; MGI:104798; Tnf Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132911 CVCL_SS07 HAP1 IDH2 (-) 2 cancer cell line human CVCL_SS07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5383; IDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132912 CVCL_T407 Psi-CRIP-MFGmLT transformed cell line house mouse CVCL_T407 CL:0000010 Transfected with: MGI; MGI:104797; Lta Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132913 CVCL_JY65 272-17E6 hybridoma house mouse CVCL_JY65 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2160 21132914 CVCL_JY64 271-23G5 hybridoma house mouse CVCL_JY64 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. 21132915 CVCL_SS09 HAP1 IDUA (-) 1 cancer cell line human CVCL_SS09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5391; IDUA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132916 CVCL_T409 Psi-CRIP-MFGneo transformed cell line house mouse CVCL_T409 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21132917 CVCL_JY67 H357-V3 cancer cell line human CVCL_JY67 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Ser (c.37G>A); ClinVar=VCV000376323; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6150; ITGAV Derived from sampling site: Oral cavity; tongue. Male 21132918 CVCL_JY66 T45 cancer cell line human CVCL_JY66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Homozygous (PubMed=7633286) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). 21132919 CVCL_JY61 271-14E2 hybridoma house mouse CVCL_JY61 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human 200 kDa melanomas surface protein. 21132920 CVCL_JY60 271-14D9.F8 hybridoma house mouse CVCL_JY60 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. 21132921 CVCL_JY63 271-21H6 hybridoma house mouse CVCL_JY63 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human 200 kDa melanomas surface protein. 21132922 CVCL_JY62 271-20A9 hybridoma house mouse CVCL_JY62 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. 21132923 CVCL_JY79 AT506.C2 cancer cell line human CVCL_JY79 From: Burger C.; Merck Serono; Darmstadt; Germany CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Colon. Male Characteristics: Serves as a beta-catenin reporter cell line Transfected with a firefly luciferase reporter gene under the control of a minimal CMV promoter and tandem repeats of the TCF/LEF transcriptional response element (TRE). 21132924 CVCL_JY76 BR55-2-S2a hybridoma house mouse CVCL_JY76 CL:0000010 Characteristics: Isotype switched derivative of BR55-2; Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:59045; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc (Lewis Y). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9347 21132925 CVCL_JY75 BR55-2 hybridoma house mouse CVCL_JY75 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:59045; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc (Lewis Y). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9324 21132926 CVCL_JY78 U87MG.deltaEGFR cancer cell line human CVCL_JY78 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21132927 CVCL_JY77 BN-175 cancer cell line Norway rat CVCL_JY77 CL:0000010 Breed/subspecies: Brown Norway. 21132928 CVCL_JY72 SPV-L3 hybridoma house mouse CVCL_JY72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01909; Human HLA-DQA1. 21132929 CVCL_JY71 LAZ-475 transformed cell line human CVCL_JY71 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21132930 CVCL_JY74 CHO-3E7 spontaneously immortalized cell line CVCL_JY74 CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 (with del 1-335 = EBNA1c) Derived from sampling site: Ovary. Female Group: Patented cell line 21132931 CVCL_JY73 WEHI 1.14 cancer cell line house mouse CVCL_JY73 CL:0000010 Breed/subspecies: BALB/c. 21132932 CVCL_JY70 LAZ-470 transformed cell line human CVCL_JY70 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21132933 CVCL_JY47 PLT460F_(DDR2) transformed cell line human CVCL_JY47 CL:0000010 Transfected with: HGNC; 2731; DDR2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21132934 CVCL_JY46 PAS [Rat] spontaneously immortalized cell line Norway rat CVCL_JY46 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: Lewis. Characteristics: Encephalitogenic; recognizes myelin basic protein 21132935 CVCL_JY49 8B8 hybridoma house mouse CVCL_JY49 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12070 21132936 CVCL_JY48 3-8D6 hybridoma house mouse CVCL_JY48 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. 21132937 CVCL_JY43 OC3-IV2 cancer cell line human CVCL_JY43 CL:0000010 Population: Chinese; Taiwan Male Characteristics: Established from parent cell line through a passage in nude mice. 21132938 CVCL_JY42 CEF ST-2 transformed cell line CVCL_JY42 CL:0000010 Transfected with: UniProtKB; Q537V4; Chicken TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line; Group: Patented cell line 21132939 CVCL_JY45 Kasumi-1 PR48 cancer cell line human CVCL_JY45 CL:0000010 Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Lys330Profs*6 (c.987insCCGG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21132940 CVCL_JY44 Kasumi-1 R48 cancer cell line human CVCL_JY44 CL:0000010 Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Lys330Profs*6 (c.987insCCGG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21132941 CVCL_JY41 CEF ST-1 transformed cell line CVCL_JY41 CL:0000010 Transfected with: UniProtKB; Q537V4; Chicken TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line; Group: Patented cell line 21132942 CVCL_JY40 HepG2-hNTCP cancer cell line human CVCL_JY40 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 10905; SLC10A1 Population: Caucasian; Derived from sampling site: Liver. Male 21132943 CVCL_JY58 LAP1 spontaneously immortalized cell line house mouse CVCL_JY58 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: Has a complete defect in Na+/H+ antiporter activity 21132944 CVCL_JY57 AR300 spontaneously immortalized cell line CVCL_JY57 CL:0000010 Sequence variation: Mutation; UniProtKB; P48761; Slc9a1; Simple; p.Leu167Phe (c.499C>T); Zygosity=Homozygous (PubMed=8389452) Selected for resistance to: ChEBI; CHEBI:138016; 5-(N-methyl-N-propyl)amiloride (MPA); Derived from sampling site: Lung. Female 21132945 CVCL_JY59 Neuroscreen-1 cancer cell line Norway rat CVCL_JY59 CL:0000010 Miscellaneous: Cell line no longer available; was distributed by Cellomics, Inc which is now part of ThermoFisher Scientific. Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Compared to the parent cell line, possesses rapid growth and enhanced sensitivity to NGF 21132946 CVCL_JY54 OC3-I5 cancer cell line human CVCL_JY54 CL:0000010 Population: Chinese; Taiwan. Male 21132947 CVCL_JY53 ACC-LC-180 cancer cell line human CVCL_JY53 CL:0000010 Population: Japanese. Unspecified 21132948 CVCL_JY56 AR40 spontaneously immortalized cell line CVCL_JY56 CL:0000010 Sequence variation: Mutation; UniProtKB; P48761; Slc9a1; Simple; p.Leu167Phe (c.499C>T); Zygosity=Heterozygous (PubMed=8389452) Selected for resistance to: ChEBI; CHEBI:138016; 5-(N-methyl-N-propyl)amiloride (MPA); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21132949 CVCL_JY50 Z1a spontaneously immortalized cell line Norway rat CVCL_JY50 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: Lewis. Female Characteristics: T cell line specific for myelin basic protein 21132950 CVCL_JY52 Znp spontaneously immortalized cell line Norway rat CVCL_JY52 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: Lewis. Female 21132951 CVCL_JY51 Z1a-p spontaneously immortalized cell line Norway rat CVCL_JY51 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: Lewis. Female 21132952 CVCL_JY29 13699 cancer cell line human CVCL_JY29 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg333Valfs*12 (c.997delC); ClinVar=VCV002113651; Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 2-3 days (PubMed=25862976) 21132953 CVCL_JY28 13363 cancer cell line human CVCL_JY28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr170del (c.508_510delACG); Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 2-3 days (PubMed=25862976) 21132954 CVCL_JY25 NCI-hTERT-CL5 cancer cell line human CVCL_JY25 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from metastatic site: Liver. Male Characteristics: Overexpresses TERT; compared to the parent cell line, it has better adhesion properties, ability to be maintained in culture for longer periods after confluency and is more efficient in mucins MUC1, MUC2 and MUC13 secretion; Characteristics: Parent cell line established from a nude mouse xenograft 21132955 CVCL_JY24 RM22-F5 cancer cell line Norway rat CVCL_JY24 CL:0000010 Sequence variation: Mutation; RGD; 2827; Hras; Simple; p.Gly12Glu (c.35G>A); Zygosity=Hemizygous (PubMed=8056457) Derived from sampling site: Mammary gland; Breed/subspecies: Wistar. Female Characteristics: ER-positive and PR-negative Doubling time: 24 hours (PubMed=8056457) 21132956 CVCL_JY27 12370 cancer cell line human CVCL_JY27 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Pro (c.578A>C); ClinVar=VCV000376612; Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 6-9 days (PubMed=25862976) 21132957 CVCL_JY26 NCI-hTERT-CL6 cancer cell line human CVCL_JY26 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from metastatic site: Liver. Male Characteristics: Overexpresses TERT; compared to the parent cell line, it has better adhesion properties, ability to be maintained in culture for longer periods after confluency and is more efficient in mucins MUC1, MUC2 and MUC13 secretion; Characteristics: Parent cell line established from a nude mouse xenograft 21132958 CVCL_JY21 UHKBR-01 cancer cell line Norway rat CVCL_JY21 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Sprague Dawley. Female 21132959 CVCL_JY20 MCP-5 [Human cystosarcoma phyllodes] cancer cell line human CVCL_JY20 CL:0000010 Derived from sampling site: Breast. Female Group: Patented cell line 21132960 CVCL_JY23 RM17-5R cancer cell line Norway rat CVCL_JY23 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar. Female Characteristics: ER-negative and PR-negative Doubling time: 29 hours (PubMed=8056457) 21132961 CVCL_JY22 RM1-4 cancer cell line Norway rat CVCL_JY22 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar. Female Characteristics: ER-negative and PR-negative Doubling time: 16 hours (PubMed=8056457) 21132962 CVCL_JY39 HepaRG-hNTCP cancer cell line human CVCL_JY39 CL:0000010 Transfected with: HGNC; 10905; SLC10A1 Derived from sampling site: Liver. Female 21132963 CVCL_JY36 MFD-1 cancer cell line human CVCL_JY36 CL:0000010 Sequence variation: Mutation; HGNC; 40; ABCB1; Simple; p.Glu406Asp (c.1218T>G); Zygosity=Heterozygous (PubMed=27600491); Sequence variation: Mutation; HGNC; 40; ABCB1; Simple; p.Phe904Val (c.2710T>G); Zygosity=Heterozygous (PubMed=27600491); Sequence variation: Mutation; HGNC; 10736; SEMA5A; Simple; p.Lys378Arg; Zygosity=Homozygous (PubMed=27600491); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=27600491) Derived from sampling site: Esophagus. Omics: Chromatin accessibility by ATAC-seq; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21132964 CVCL_JY35 BE3 cancer cell line human CVCL_JY35 CL:0000010 21132965 CVCL_JY38 HepG2-rNTCP-eGFP cancer cell line human CVCL_JY38 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: RGD; 3681; Slc10a1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Liver. Male 21132966 CVCL_JY37 TYAE-1 cancer cell line human CVCL_JY37 CL:0000010 Population: Japanese. Male 21132967 CVCL_JY32 15233_nov cancer cell line human CVCL_JY32 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr170del (c.508_510delACG); Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 6-9 days (PubMed=25862976) 21132968 CVCL_JY31 14433_1 cancer cell line human CVCL_JY31 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2853Ter (c.8557A>T); ClinVar=VCV000372573; Zygosity=Homozygous (PubMed=25862976; PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 2-3 days (PubMed=25862976) 21132969 CVCL_JY34 Dnmt1-/- ES (clone 36) embryonic stem cell house mouse CVCL_JY34 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:94912; Dnmt1 Breed/subspecies: 129S4/SvJae. Male 21132970 CVCL_JY33 8587 cancer cell line human CVCL_JY33 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 6-9 days (PubMed=25862976) 21132971 CVCL_JY30 13914_1 cancer cell line human CVCL_JY30 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu1161Phefs*3 (c.3481_3491delGAAGATACTAG); Zygosity=Homozygous (PubMed=25862976; PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met340Serfs*2 (c.1019_1028del10); Zygosity=Unspecified (PubMed=25862976; PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female Doubling time: 6-9 days (PubMed=25862976) 21132972 CVCL_0M61 GM07466 transformed cell line human CVCL_0M61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132973 CVCL_0M60 GM07465 transformed cell line human CVCL_0M60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132974 CVCL_0M63 GM07468 transformed cell line human CVCL_0M63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132975 CVCL_0M62 GM07467 transformed cell line human CVCL_0M62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132976 CVCL_0M65 GM07526 transformed cell line human CVCL_0M65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132977 CVCL_0M64 GM07480 transformed cell line human CVCL_0M64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132978 CVCL_0M56 GM07458 transformed cell line human CVCL_0M56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132979 CVCL_0M55 GM07387 transformed cell line human CVCL_0M55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132980 CVCL_0M58 GM07461 transformed cell line human CVCL_0M58 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132981 CVCL_0M57 GM07460 transformed cell line human CVCL_0M57 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132982 CVCL_0M59 GM07464 transformed cell line human CVCL_0M59 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21132983 CVCL_9G04 DD1480 transformed cell line human CVCL_9G04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132984 CVCL_SS97 HAP1 IRF5 (-) 1 cancer cell line human CVCL_SS97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6120; IRF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132985 CVCL_T497 RECC-KU18 transformed cell line CVCL_T497 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21132986 CVCL_9G03 DD1479 finite cell line human CVCL_9G03 CL:0000010 Karyotypic information: 46,XY,t(9;11)(?q34;?q13)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21132987 CVCL_SS96 HAP1 IRF3 (-) 2 cancer cell line human CVCL_SS96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6118; IRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132988 CVCL_T496 RECC-KU17 transformed cell line CVCL_T496 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21132989 CVCL_9G06 DD1482 transformed cell line human CVCL_9G06 CL:0000010 Karyotypic information: 46,XX,del(8)(p23.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132990 CVCL_SS99 HAP1 IRF5 (-) 3 cancer cell line human CVCL_SS99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6120; IRF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132991 CVCL_T499 RECC-KU20 transformed cell line CVCL_T499 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21132992 CVCL_9G05 DD1481 transformed cell line human CVCL_9G05 CL:0000010 Karyotypic information: 46,XX,(*;18)(p21.3;p11.23)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132993 CVCL_SS98 HAP1 IRF5 (-) 2 cancer cell line human CVCL_SS98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6120; IRF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21132994 CVCL_T498 RECC-KU19 transformed cell line CVCL_T498 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21132995 CVCL_9G00 DD1474 finite cell line human CVCL_9G00 CL:0000010 Karyotypic information: 46,Y,inv(X)(?q11;q21.2)mat (ECACC); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21132996 CVCL_9G02 DD1478 transformed cell line human CVCL_9G02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21132997 CVCL_9G01 DD1477 transformed cell line human CVCL_9G01 CL:0000010 Karyotypic information: 46,XX,t(9;11)(q32;q12)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21132998 CVCL_0M70 GM07731 transformed cell line human CVCL_0M70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21132999 CVCL_0M72 GM07733 transformed cell line human CVCL_0M72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133000 CVCL_0M71 GM07732 transformed cell line human CVCL_0M71 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Glu60Ter (c.178G>T); ClinVar=VCV000038730; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133001 CVCL_9G08 DD1487 finite cell line human CVCL_9G08 CL:0000010 Karyotypic information: 46,XY; 46,XY,15+ de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133002 CVCL_0M74 GM07821 transformed cell line human CVCL_0M74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133003 CVCL_9G07 DD1485 transformed cell line human CVCL_9G07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133004 CVCL_0M73 GM07734 transformed cell line human CVCL_0M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07852 (Cellosaurus=CVCL_OM87); Derived from sampling site: Peripheral blood. Female 21133005 CVCL_0M76 GM07823 transformed cell line human CVCL_0M76 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133006 CVCL_9G09 DD1488 finite cell line human CVCL_9G09 CL:0000010 Karyotypic information: 46,XY [15]; 47,XY,+20 [5] (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133007 CVCL_0M75 GM07822 transformed cell line human CVCL_0M75 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133008 CVCL_0M67 GM07556 transformed cell line human CVCL_0M67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133009 CVCL_0M66 GM07553 transformed cell line human CVCL_0M66 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133010 CVCL_0M69 GM07674 transformed cell line human CVCL_0M69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133011 CVCL_0M68 GM07557 transformed cell line human CVCL_0M68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133012 CVCL_SS86 HAP1 IRAK3 (-) cancer cell line human CVCL_SS86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17020; IRAK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133013 CVCL_T486 RECC-KU2 transformed cell line CVCL_T486 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133014 CVCL_SS85 HAP1 IRAK2 (-) 1 cancer cell line human CVCL_SS85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6113; IRAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133015 CVCL_T485 RECC-KU1 transformed cell line CVCL_T485 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133016 CVCL_SS88 HAP1 IRF1 (-) 1 cancer cell line human CVCL_SS88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6116; IRF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133017 CVCL_T488 RECC-KU4 transformed cell line CVCL_T488 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133018 CVCL_SS87 HAP1 IRAK4 (-) cancer cell line human CVCL_SS87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17967; IRAK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133019 CVCL_T487 RECC-KU3 transformed cell line CVCL_T487 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133020 CVCL_SS89 HAP1 IRF1 (-) 2 cancer cell line human CVCL_SS89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6116; IRF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133021 CVCL_T489 RECC-KU10 transformed cell line CVCL_T489 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133022 CVCL_0M41 GM07225 transformed cell line human CVCL_0M41 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133023 CVCL_0M40 GM07224 transformed cell line human CVCL_0M40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133024 CVCL_0M43 GM07227 transformed cell line human CVCL_0M43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133025 CVCL_0M42 GM07226 transformed cell line human CVCL_0M42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133026 CVCL_0M34 GM04540 transformed cell line human CVCL_0M34 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133027 CVCL_0M33 GM04539 finite cell line human CVCL_0M33 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133028 CVCL_0M36 GM04543 finite cell line human CVCL_0M36 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133029 CVCL_0M35 GM04541 finite cell line human CVCL_0M35 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133030 CVCL_0M38 GM04547 finite cell line human CVCL_0M38 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133031 CVCL_0M37 GM04545 finite cell line human CVCL_0M37 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133032 CVCL_0M39 GM06966 finite cell line human CVCL_0M39 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Glu92Ter (c.274G>T); ClinVar=VCV000007186; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21133033 CVCL_SS91 HAP1 IRF2 (-) 2 cancer cell line human CVCL_SS91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133034 CVCL_T491 RECC-KU12 transformed cell line CVCL_T491 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133035 CVCL_SS90 HAP1 IRF2 (-) 1 cancer cell line human CVCL_SS90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133036 CVCL_T490 RECC-KU11 transformed cell line CVCL_T490 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133037 CVCL_SS93 HAP1 IRF2 (-) 4 cancer cell line human CVCL_SS93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133038 CVCL_T493 RECC-KU14 transformed cell line CVCL_T493 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133039 CVCL_SS92 HAP1 IRF2 (-) 3 cancer cell line human CVCL_SS92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6117; IRF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133040 CVCL_T492 RECC-KU13 transformed cell line CVCL_T492 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133041 CVCL_SS95 HAP1 IRF3 (-) 1 cancer cell line human CVCL_SS95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6118; IRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133042 CVCL_T495 RECC-KU16 transformed cell line CVCL_T495 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133043 CVCL_SS94 HAP1 IRF2BPL (-) 1 cancer cell line human CVCL_SS94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14282; IRF2BPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133044 CVCL_T494 RECC-KU15 transformed cell line CVCL_T494 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133045 CVCL_SS75 HAP1 INPPL1 (-) 2 cancer cell line human CVCL_SS75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6080; INPPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133046 CVCL_T475 LSCC-BK2 cancer cell line CVCL_T475 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line BK. Male Group: Bird cell line 21133047 CVCL_SS74 HAP1 INPPL1 (-) 1 cancer cell line human CVCL_SS74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6080; INPPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133048 CVCL_T474 QT54 cancer cell line CVCL_T474 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133049 CVCL_SS77 HAP1 IQGAP1 (-) 1 cancer cell line human CVCL_SS77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6110; IQGAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133050 CVCL_T477 RTAZ-1 transformed cell line CVCL_T477 CL:0000010 Transformant: Avian rous-associated virus type 1 (RAV-1)(NCBI-Taxonomy; 11950); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: White Leghorn. Male Group: Bird cell line 21133051 CVCL_SS76 HAP1 INSR (-) cancer cell line human CVCL_SS76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6091; INSR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133052 CVCL_T476 LSCC-BK3 cancer cell line CVCL_T476 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line BK. Male Group: Bird cell line 21133053 CVCL_SS79 HAP1 IQGAP2 (-) 1 cancer cell line human CVCL_SS79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6111; IQGAP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133054 CVCL_T479 LSCC-VA2 transformed cell line CVCL_T479 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line 21133055 CVCL_SS78 HAP1 IQGAP1 (-) 2 cancer cell line human CVCL_SS78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6110; IQGAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133056 CVCL_T478 LSCC-VA1 transformed cell line CVCL_T478 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133057 CVCL_0M50 GM07382 transformed cell line human CVCL_0M50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133058 CVCL_0M52 GM07384 transformed cell line human CVCL_0M52 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133059 CVCL_0M51 GM07383 transformed cell line human CVCL_0M51 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133060 CVCL_0M54 GM07386 transformed cell line human CVCL_0M54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133061 CVCL_0M53 GM07385 transformed cell line human CVCL_0M53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133062 CVCL_0M45 GM07337 transformed cell line human CVCL_0M45 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133063 CVCL_0M44 GM07228 transformed cell line human CVCL_0M44 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133064 CVCL_0M47 GM07339 transformed cell line human CVCL_0M47 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133065 CVCL_0M46 GM07338 transformed cell line human CVCL_0M46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133066 CVCL_0M49 GM07381 transformed cell line human CVCL_0M49 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.3718-2477C>T (3849+10KB,C>T); ClinVar=VCV000007166; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133067 CVCL_0M48 GM07380 transformed cell line human CVCL_0M48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133068 CVCL_SS80 HAP1 IQSEC1 (-) 1 cancer cell line human CVCL_SS80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29112; IQSEC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133069 CVCL_T480 Q3 transformed cell line CVCL_T480 CL:0000010 Transformant: Rous sarcoma virus [Bryan high titer(NCBI-Taxonomy; 11886); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133070 CVCL_SS82 HAP1 IQSEC2 (-) cancer cell line human CVCL_SS82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29059; IQSEC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133071 CVCL_T482 RECC-UG5 transformed cell line CVCL_T482 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Group: Bird cell line 21133072 CVCL_T481 16Q transformed cell line CVCL_T481 CL:0000010 Transformant: Rous sarcoma virus [Bryan high titer(NCBI-Taxonomy; 11886); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133073 CVCL_SS81 HAP1 IQSEC1 (-) 2 cancer cell line human CVCL_SS81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29112; IQSEC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133074 CVCL_SS84 HAP1 IRAK1 (-) 2 cancer cell line human CVCL_SS84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6112; IRAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133075 CVCL_T484 RECC-UG8 transformed cell line CVCL_T484 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Group: Bird cell line 21133076 CVCL_SS83 HAP1 IRAK1 (-) 1 cancer cell line human CVCL_SS83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6112; IRAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133077 CVCL_T483 RECC-UG6 transformed cell line CVCL_T483 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Group: Bird cell line 21133078 CVCL_SS64 HAP1 INPP4A (-) 2 cancer cell line human CVCL_SS64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6074; INPP4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133079 CVCL_T464 QT2 cancer cell line CVCL_T464 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133080 CVCL_SS63 HAP1 INPP4A (-) 1 cancer cell line human CVCL_SS63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6074; INPP4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133081 CVCL_T463 MDCC-RP4 cancer cell line CVCL_T463 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21133082 CVCL_SS66 HAP1 INPP4A (-) 4 cancer cell line human CVCL_SS66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6074; INPP4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133083 CVCL_T466 QT5 cancer cell line CVCL_T466 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133084 CVCL_SS65 HAP1 INPP4A (-) 3 cancer cell line human CVCL_SS65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6074; INPP4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133085 CVCL_T465 QT4 cancer cell line CVCL_T465 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133086 CVCL_SS68 HAP1 INPP5E (-) 1 cancer cell line human CVCL_SS68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21474; INPP5E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133087 CVCL_T468 QT24 cancer cell line CVCL_T468 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133088 CVCL_SS67 HAP1 INPP5A (-) 1 cancer cell line human CVCL_SS67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6076; INPP5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133089 CVCL_T467 QT7 cancer cell line CVCL_T467 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line 21133090 CVCL_SS69 HAP1 INPP5E (-) 2 cancer cell line human CVCL_SS69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21474; INPP5E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133091 CVCL_T469 QT27 cancer cell line CVCL_T469 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133092 CVCL_0M21 GM03465 finite cell line human CVCL_0M21 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Male 21133093 CVCL_0M20 GM03401 finite cell line human CVCL_0M20 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133094 CVCL_0M12 GM01957 finite cell line human CVCL_0M12 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133095 CVCL_0M11 GM01444 transformed cell line human CVCL_0M11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133096 CVCL_0M14 GM01959 finite cell line human CVCL_0M14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133097 CVCL_0M13 GM01958 finite cell line human CVCL_0M13 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133098 CVCL_0M16 GM02803 finite cell line human CVCL_0M16 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from familial inference of GM02827) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133099 CVCL_0M15 GM02801 finite cell line human CVCL_0M15 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Nose; nasal cavity (Note=From a polyp) Cell type=Fibroblast.. Male 21133100 CVCL_0M18 GM02827 finite cell line human CVCL_0M18 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133101 CVCL_0M17 GM02826 finite cell line human CVCL_0M17 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from familial inference of GM02827) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133102 CVCL_0M19 GM02828 finite cell line human CVCL_0M19 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Val520Phe (c.1558G>T); ClinVar=VCV000007150; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133103 CVCL_SS71 HAP1 INPP5J (-) cancer cell line human CVCL_SS71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8956; INPP5J; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133104 CVCL_T471 QT46 cancer cell line CVCL_T471 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133105 CVCL_SS70 HAP1 INPP5E (-) 3 cancer cell line human CVCL_SS70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21474; INPP5E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133106 CVCL_T470 QT29 cancer cell line CVCL_T470 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133107 CVCL_SS73 HAP1 INPP5K (-) 2 cancer cell line human CVCL_SS73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33882; INPP5K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133108 CVCL_T473 QT53 cancer cell line CVCL_T473 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133109 CVCL_SS72 HAP1 INPP5K (-) 1 cancer cell line human CVCL_SS72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33882; INPP5K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133110 CVCL_T472 QT51 cancer cell line CVCL_T472 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21133111 CVCL_SS53 HAP1 IMMP2L (-) 1 cancer cell line human CVCL_SS53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14598; IMMP2L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133112 CVCL_T453 MDTC-RP34 cancer cell line CVCL_T453 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Group: Bird cell line 21133113 CVCL_SS52 HAP1 ILKAP (-) 2 cancer cell line human CVCL_SS52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15566; ILKAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133114 CVCL_T452 MDTC-RP32 cancer cell line CVCL_T452 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Male Group: Bird cell line 21133115 CVCL_SS55 HAP1 IMMT (-) 2 cancer cell line human CVCL_SS55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6047; IMMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133116 CVCL_T455 MDTC-RP36 cancer cell line CVCL_T455 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Female Group: Bird cell line 21133117 CVCL_SS54 HAP1 IMMT (-) 1 cancer cell line human CVCL_SS54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6047; IMMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133118 CVCL_T454 MDTC-RP35 cancer cell line CVCL_T454 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Group: Bird cell line 21133119 CVCL_SS57 HAP1 IMPDH1 (-) 2 cancer cell line human CVCL_SS57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6052; IMPDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133120 CVCL_T457 MDTC-RP38 cancer cell line CVCL_T457 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Male Group: Bird cell line 21133121 CVCL_SS56 HAP1 IMPDH1 (-) 1 cancer cell line human CVCL_SS56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6052; IMPDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133122 CVCL_T456 MDTC-RP37 cancer cell line CVCL_T456 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Female Group: Bird cell line 21133123 CVCL_SS59 HAP1 INF2 (-) 2 cancer cell line human CVCL_SS59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23791; INF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133124 CVCL_T459 MDTC-RP40 cancer cell line CVCL_T459 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Female Group: Bird cell line 21133125 CVCL_SS58 HAP1 INF2 (-) 1 cancer cell line human CVCL_SS58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23791; INF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133126 CVCL_T458 MDTC-RP39 cancer cell line CVCL_T458 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Male Group: Bird cell line 21133127 CVCL_0M30 GM04339 finite cell line human CVCL_0M30 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly85Glu (c.254G>A); ClinVar=VCV000007143; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133128 CVCL_0M32 GM04346 finite cell line human CVCL_0M32 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133129 CVCL_0M31 GM04345 transformed cell line human CVCL_0M31 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133130 CVCL_0M23 GM04320 finite cell line human CVCL_0M23 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (PubMed=25772471); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=25772471) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: Was originally thought to be homozygous for CFTR p.Phe508del and is still described as such in Coriell 21133131 CVCL_0M22 GM03466 finite cell line human CVCL_0M22 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21133132 CVCL_0M25 GM04323 finite cell line human CVCL_0M25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133133 CVCL_0M24 GM04322 finite cell line human CVCL_0M24 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133134 CVCL_0M27 GM04331 finite cell line human CVCL_0M27 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile105Serfs*2 (c.313delA) (444delA); ClinVar=VCV000048684; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1680-1G>A (IVS11-1G>A) (1812-1G-A); ClinVar=VCV000048681; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21133135 CVCL_0M26 GM04330 transformed cell line human CVCL_0M26 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile105Serfs*2 (c.313delA) (444delA); ClinVar=VCV000048684; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1680-1G>A (IVS11-1G>A) (1812-1G-A); ClinVar=VCV000048681; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133136 CVCL_0M29 GM04338 finite cell line human CVCL_0M29 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133137 CVCL_0M28 GM04337 finite cell line human CVCL_0M28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133138 CVCL_SS60 HAP1 INF2 (-) 3 cancer cell line human CVCL_SS60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23791; INF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133139 CVCL_T460 MDTC-RP41 cancer cell line CVCL_T460 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21133140 CVCL_SS62 HAP1 INO80E (-) 2 cancer cell line human CVCL_SS62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26905; INO80E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133141 CVCL_T462 MDCC-RP2 cancer cell line CVCL_T462 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21133142 CVCL_SS61 HAP1 INO80E (-) 1 cancer cell line human CVCL_SS61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26905; INO80E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133143 CVCL_T461 MDCC-RP1 cancer cell line CVCL_T461 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Spleen; Breed/subspecies: P-line. Female Doubling time: 13.7 hours (PubMed=3273463) Group: Bird cell line 21133144 CVCL_T442 DT45 cancer cell line CVCL_T442 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21133145 CVCL_SS42 HAP1 IL11RA (-) 1 cancer cell line human CVCL_SS42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5967; IL11RA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133146 CVCL_T441 BM2L/A2b5 transformed cell line CVCL_T441 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10467 21133147 CVCL_SS41 HAP1 IKBKG (-) 2 cancer cell line human CVCL_SS41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5961; IKBKG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133148 CVCL_SS44 HAP1 IL17RA (-) 1 cancer cell line human CVCL_SS44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5985; IL17RA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133149 CVCL_T444 LSCC-RP9 cancer cell line CVCL_T444 CL:0000010 Transformant: Rous-associated virus type 2(NCBI-Taxonomy; 11948). Male Group: Bird cell line 21133150 CVCL_SS43 HAP1 IL11RA (-) 2 cancer cell line human CVCL_SS43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5967; IL11RA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133151 CVCL_T443 LSCC-RP12 cancer cell line CVCL_T443 CL:0000010 Transformant: Rous-associated virus type 2(NCBI-Taxonomy; 11948). Male Group: Bird cell line 21133152 CVCL_SS46 HAP1 IL6R (-) 1 cancer cell line human CVCL_SS46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6019; IL6R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133153 CVCL_T446 U-120MG cancer cell line human CVCL_T446 CL:0000010 21133154 CVCL_SS45 HAP1 IL4R (-) 1 cancer cell line human CVCL_SS45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6015; IL4R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133155 CVCL_T445 LSCC-SF-Mc29 cancer cell line CVCL_T445 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Breed/subspecies: White Leghorn. Female Group: Bird cell line 21133156 CVCL_SS48 HAP1 IL6ST (-) 1 cancer cell line human CVCL_SS48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6021; IL6ST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133157 CVCL_T448 MDCC-JM-1 cancer cell line CVCL_T448 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21133158 CVCL_T447 EH-118MG cancer cell line human CVCL_T447 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Rous sarcoma virus [Strain Engelbreth-Holm(NCBI-Taxonomy; 11886); Derived from sampling site: Brain. Discontinued: ATCC; CRL-7719; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Contaminated Parent cell line (U-118MG) has been shown to be a U-138MG derivative. 21133159 CVCL_SS47 HAP1 IL6R (-) 2 cancer cell line human CVCL_SS47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6019; IL6R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133160 CVCL_SS49 HAP1 IL6ST (-) 2 cancer cell line human CVCL_SS49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6021; IL6ST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133161 CVCL_T449 MDCC-JMV-1 transformed cell line CVCL_T449 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Derived from sampling site: Spleen Cell type=T-cell.. Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9093 21133162 CVCL_SS51 HAP1 ILKAP (-) 1 cancer cell line human CVCL_SS51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15566; ILKAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133163 CVCL_T451 MDTC-RP31 cancer cell line CVCL_T451 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Group: Bird cell line 21133164 CVCL_SS50 HAP1 ILK (-) cancer cell line human CVCL_SS50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6040; ILK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133165 CVCL_T450 MDTC-RP30 cancer cell line CVCL_T450 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Beltsville White (BSW). Male Group: Bird cell line 21133166 CVCL_SS31 HAP1 IGF1R (-) cancer cell line human CVCL_SS31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5465; IGF1R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133167 CVCL_T431 KH OS R1 cancer cell line human CVCL_T431 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Female 21133168 CVCL_SS30 HAP1 IFNGR2 (-) 2 cancer cell line human CVCL_SS30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5440; IFNGR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133169 CVCL_T430 U-2 OS R2 cancer cell line human CVCL_T430 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; tibia. Female 21133170 CVCL_SS33 HAP1 IGF2BP3 (-) 2 cancer cell line human CVCL_SS33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133171 CVCL_T433 KH OS R3 cancer cell line human CVCL_T433 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Female 21133172 CVCL_SS32 HAP1 IGF2BP3 (-) 1 cancer cell line human CVCL_SS32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133173 CVCL_T432 KH OS R2 cancer cell line human CVCL_T432 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Female 21133174 CVCL_SS35 HAP1 IKBKB (-) 1 cancer cell line human CVCL_SS35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5960; IKBKB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133175 CVCL_T435 V-1181N1 cancer cell line human CVCL_T435 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Male Virology: Infected with maedi visna virus (MVV) Problematic cell line: Contaminated Grand-parent cell line (U-118MG) has been shown to be a U-138MG derivative. 21133176 CVCL_SS34 HAP1 IGF2R (-) 1 cancer cell line human CVCL_SS34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5467; IGF2R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133177 CVCL_T434 SC-2 [Chicken] spontaneously immortalized cell line CVCL_T434 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Doubling time: ~40 hours, at 95th passage (PubMed=16813656) Group: Bird cell line 21133178 CVCL_T437 BM2/C3A transformed cell line CVCL_T437 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line 21133179 CVCL_SS37 HAP1 IKBKB (-) 3 cancer cell line human CVCL_SS37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5960; IKBKB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133180 CVCL_SS36 HAP1 IKBKB (-) 2 cancer cell line human CVCL_SS36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5960; IKBKB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133181 CVCL_T436 SC-1 [Chicken] spontaneously immortalized cell line CVCL_T436 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: White Leghorn SPAFAS. Unspecified Doubling time: ~44 hours, at 95 to 135th passages (PubMed=16313905) Group: Bird cell line 21133182 CVCL_T439 BM2L/A1b6 transformed cell line CVCL_T439 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10465 21133183 CVCL_SS39 HAP1 IKBKE (-) 2 cancer cell line human CVCL_SS39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14552; IKBKE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133184 CVCL_T438 BM2L transformed cell line CVCL_T438 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10468 21133185 CVCL_SS38 HAP1 IKBKE (-) 1 cancer cell line human CVCL_SS38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14552; IKBKE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133186 CVCL_0M10 GM01443 transformed cell line human CVCL_0M10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133187 CVCL_0M01 GM01426 finite cell line human CVCL_0M01 CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Glu153Lys (c.457G>A); ClinVar=VCV001067431; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133188 CVCL_0M00 GM01096 finite cell line human CVCL_0M00 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21133189 CVCL_0M03 GM01780 transformed cell line human CVCL_0M03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133190 CVCL_0M02 GM01739 finite cell line human CVCL_0M02 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Tyr432_Arg435delTrp432ins (c.1307del9); Zygosity=Heterozygous (from autologous cell line GM01094) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133191 CVCL_0M05 GM02931 finite cell line human CVCL_0M05 CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Pro358Leu (c.1073C>T); ClinVar=VCV000631771; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133192 CVCL_0M04 GM02552 finite cell line human CVCL_0M04 CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg297Ter (c.889C>T); ClinVar=VCV000001562; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg643His (c.1928G>A); ClinVar=VCV000001563; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133193 CVCL_0M07 GM11762 finite cell line human CVCL_0M07 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21133194 CVCL_0M06 GM06110 finite cell line human CVCL_0M06 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Arg245His (c.734G>A); ClinVar=VCV000005107; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133195 CVCL_0M09 GM01442 transformed cell line human CVCL_0M09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133196 CVCL_0M08 GM17491 finite cell line human CVCL_0M08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133197 CVCL_T440 BM2L/A2a2 transformed cell line CVCL_T440 CL:0000010 Transformant: Avian myeloblastosis virus (AMV)(NCBI-Taxonomy; 11866). Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10466 21133198 CVCL_SS40 HAP1 IKBKG (-) 1 cancer cell line human CVCL_SS40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5961; IKBKG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133199 CVCL_9F59 DD1393 transformed cell line human CVCL_9F59 CL:0000010 Karyotypic information: 46,XY [8]; 47,XY,+8 [22] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133200 CVCL_9F56 DD1386 transformed cell line human CVCL_9F56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133201 CVCL_9F55 DD1385 transformed cell line human CVCL_9F55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133202 CVCL_9F58 DD1392 transformed cell line human CVCL_9F58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133203 CVCL_9F57 DD1387 transformed cell line human CVCL_9F57 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(5;6)(q22;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133204 CVCL_9F52 DD1381 transformed cell line human CVCL_9F52 CL:0000010 Karyotypic information: 47,XX,+dic(15) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133205 CVCL_9F51 DD1379 transformed cell line human CVCL_9F51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133206 CVCL_9F54 DD1384 transformed cell line human CVCL_9F54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133207 CVCL_9F53 DD1383 transformed cell line human CVCL_9F53 CL:0000010 Karyotypic information: 46,XX [9]; 47,XX,+mar(9) [21] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133208 CVCL_9F50 DD1375 transformed cell line human CVCL_9F50 CL:0000010 Karyotypic information: 46,XY,var(20p)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133209 CVCL_9F67 DD1404 transformed cell line human CVCL_9F67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133210 CVCL_9F66 DD1401 finite cell line human CVCL_9F66 CL:0000010 Karyotypic information: 46,XX [74]; 47,XX,+r(?) [8] (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133211 CVCL_9F69 DD1407 transformed cell line human CVCL_9F69 CL:0000010 Karyotypic information: 46,XX,t(7;16)(p15;q22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133212 CVCL_9F68 DD1405 finite cell line human CVCL_9F68 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21133213 CVCL_9F63 DD1398 transformed cell line human CVCL_9F63 CL:0000010 Karyotypic information: 46,XY [49]; 47,XY,+mar [1] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133214 CVCL_9F62 DD1396 transformed cell line human CVCL_9F62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133215 CVCL_9F65 DD1400 finite cell line human CVCL_9F65 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21133216 CVCL_9F64 DD1399 finite cell line human CVCL_9F64 CL:0000010 Karyotypic information: 46,XY(9qh) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133217 CVCL_9F61 DD1395 transformed cell line human CVCL_9F61 CL:0000010 Karyotypic information: 46,XX,t(2;10)(p21;p15)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133218 CVCL_9F60 DD1394 transformed cell line human CVCL_9F60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133219 CVCL_9F38 DD1349 transformed cell line human CVCL_9F38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;6)(q22;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133220 CVCL_9F37 DD1348 transformed cell line human CVCL_9F37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133221 CVCL_9F39 DD1350 transformed cell line human CVCL_9F39 CL:0000010 Karyotypic information: 46,XY,t(12;17)(q13;q25) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133222 CVCL_9F34 DD1343 transformed cell line human CVCL_9F34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133223 CVCL_9F33 DD1342 transformed cell line human CVCL_9F33 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(15) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133224 CVCL_9F36 DD1347 transformed cell line human CVCL_9F36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133225 CVCL_9F35 DD1346 transformed cell line human CVCL_9F35 CL:0000010 Karyotypic information: 46,XY,var(9p)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133226 CVCL_9F30 DD1335 finite cell line human CVCL_9F30 CL:0000010 Karyotypic information: 46,XY,t(5;9)(q33;q22.3)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133227 CVCL_9F32 DD1340 transformed cell line human CVCL_9F32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133228 CVCL_9F31 DD1337 transformed cell line human CVCL_9F31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133229 CVCL_9F49 DD1374 transformed cell line human CVCL_9F49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133230 CVCL_9F48 DD1367 finite cell line human CVCL_9F48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133231 CVCL_9F45 DD1363 transformed cell line human CVCL_9F45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133232 CVCL_9F44 DD1362 transformed cell line human CVCL_9F44 CL:0000010 Karyotypic information: 46,XX; 47,XX,+mar(9)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133233 CVCL_9F47 DD1365 transformed cell line human CVCL_9F47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133234 CVCL_9F46 DD1364 transformed cell line human CVCL_9F46 CL:0000010 Karyotypic information: 46,XX,+mar(13;21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133235 CVCL_9F41 DD1355 transformed cell line human CVCL_9F41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133236 CVCL_9F40 DD1351 finite cell line human CVCL_9F40 CL:0000010 Karyotypic information: 46,XX,?var(9p)pat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Part of: ECACC chromosomal abnormality collection 21133237 CVCL_9F43 DD1359 finite cell line human CVCL_9F43 CL:0000010 Karyotypic information: 69,XXX (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133238 CVCL_9F42 DD1358 finite cell line human CVCL_9F42 CL:0000010 Karyotypic information: 47,XY,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133239 CVCL_9F16 DD1312 transformed cell line human CVCL_9F16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133240 CVCL_9F15 DD1311 transformed cell line human CVCL_9F15 CL:0000010 Karyotypic information: 47,XX,+mar(14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133241 CVCL_9F18 DD1314 transformed cell line human CVCL_9F18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133242 CVCL_9F17 DD1313 transformed cell line human CVCL_9F17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133243 CVCL_9F12 DD1308 transformed cell line human CVCL_9F12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133244 CVCL_9F11 DD1307 transformed cell line human CVCL_9F11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133245 CVCL_0L80 AG14741 transformed cell line human CVCL_0L80 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133246 CVCL_9F14 DD1310 transformed cell line human CVCL_9F14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133247 CVCL_9F13 DD1309 transformed cell line human CVCL_9F13 CL:0000010 Karyotypic information: 46,XX,t(14;16)(q35.1;p13.13)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133248 CVCL_0L82 AG14743 transformed cell line human CVCL_0L82 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133249 CVCL_0L81 AG14742 transformed cell line human CVCL_0L81 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133250 CVCL_0L84 AG14745 transformed cell line human CVCL_0L84 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133251 CVCL_0L83 AG14744 transformed cell line human CVCL_0L83 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133252 CVCL_0L86 WM1852 cancer cell line human CVCL_0L86 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21133253 CVCL_9F19 DD1315 transformed cell line human CVCL_9F19 CL:0000010 Karyotypic information: 46,XY,mar(22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133254 CVCL_0L85 WM2067 cancer cell line human CVCL_0L85 CL:0000010 Derived from metastatic site: Lymph node. Male Part of: Wistar Institute melanoma cell line collection 21133255 CVCL_0L88 WM3258 cancer cell line human CVCL_0L88 CL:0000010 Female Part of: Wistar Institute melanoma cell line collection. 21133256 CVCL_0L87 WM3214 cancer cell line human CVCL_0L87 CL:0000010 Female Part of: Wistar Institute melanoma cell line collection. 21133257 CVCL_0L79 AG14740 transformed cell line human CVCL_0L79 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133258 CVCL_0L78 AG14739 transformed cell line human CVCL_0L78 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133259 CVCL_9F10 DD1306 transformed cell line human CVCL_9F10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133260 CVCL_9F27 DD1329 transformed cell line human CVCL_9F27 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(6) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133261 CVCL_9F26 DD1328 transformed cell line human CVCL_9F26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133262 CVCL_9F29 DD1333 transformed cell line human CVCL_9F29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133263 CVCL_9F28 DD1331 transformed cell line human CVCL_9F28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133264 CVCL_9F23 DD1325 finite cell line human CVCL_9F23 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133265 CVCL_9F22 DD1322 finite cell line human CVCL_9F22 CL:0000010 Karyotypic information: 46,X,t(X;11)(p21;q13) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133266 CVCL_9F25 DD1327 transformed cell line human CVCL_9F25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133267 CVCL_0L91 GM00312 finite cell line human CVCL_0L91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133268 CVCL_9F24 DD1326 transformed cell line human CVCL_9F24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133269 CVCL_0L90 GM00156 finite cell line human CVCL_0L90 CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Arg626Ter (c.1876C>T); ClinVar=VCV000001561; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133270 CVCL_0L93 GM00643 finite cell line human CVCL_0L93 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Val361Serfs*52 (c.1080delC) (1091delC); ClinVar=VCV000518268; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133271 CVCL_0L92 GM00629 finite cell line human CVCL_0L92 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Ser66Trp (c.197C>G); ClinVar=VCV000005111; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21133272 CVCL_0L95 GM00879 finite cell line human CVCL_0L95 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Arg245His (c.734G>A); ClinVar=VCV000005107; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Glu447Lys (c.1339G>A); ClinVar=VCV000005114; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133273 CVCL_0L94 GM00737 finite cell line human CVCL_0L94 CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Tyr140Cys (c.419A>G); ClinVar=VCV000371634; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Leu682Arg (c.2045T>G); ClinVar=VCV001323323; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21133274 CVCL_0L97 GM00934 finite cell line human CVCL_0L97 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21133275 CVCL_0L96 GM00886 finite cell line human CVCL_0L96 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133276 CVCL_0L99 GM01095 finite cell line human CVCL_0L99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21133277 CVCL_0L98 GM01094 finite cell line human CVCL_0L98 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Tyr432_Arg435delTrp432ins (c.1307del9); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21133278 CVCL_0L89 SW691 cancer cell line human CVCL_0L89 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Skin. Unspecified 21133279 CVCL_9F21 DD1321 finite cell line human CVCL_9F21 CL:0000010 Karyotypic information: 46,X,t(X;5)(p21.2;q35.3) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133280 CVCL_9F20 DD1319 transformed cell line human CVCL_9F20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133281 CVCL_0L60 GM04599 finite cell line human CVCL_0L60 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM04599; probable Male 21133282 CVCL_0L62 GM11094 finite cell line human CVCL_0L62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21133283 CVCL_0L61 GM09026 finite cell line human CVCL_0L61 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21133284 CVCL_0L64 GM11149 finite cell line human CVCL_0L64 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;17)(1pter->1q21::17q25->17qter;17pter->17q25::1q21->1qter) (Coriell); Derived from sampling site: Amniotic fluid. Female 21133285 CVCL_0L63 GM11095 finite cell line human CVCL_0L63 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21133286 CVCL_0L66 AG15694 transformed cell line human CVCL_0L66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female 21133287 CVCL_0L65 AG15693 transformed cell line human CVCL_0L65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male 21133288 CVCL_0L57 AG17928 somatic stem cell human CVCL_0L57 CL:0000010 Derived from sampling site: Abdomen; skin; adipose tissue Cell type=Stromal cell.. Female 21133289 CVCL_0L56 AG17875 somatic stem cell human CVCL_0L56 CL:0000010 Derived from sampling site: Skin; adipose tissue Cell type=Stromal cell.. Female 21133290 CVCL_0L59 GM09024 transformed cell line human CVCL_0L59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21133291 CVCL_0L58 GM07158 transformed cell line human CVCL_0L58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21133292 CVCL_9F05 DD1299 transformed cell line human CVCL_9F05 CL:0000010 Karyotypic information: 46,XX,t(12;16)(q21.1;q23.2)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133293 CVCL_SR98 HAP1 ID1 (-) 1 cancer cell line human CVCL_SR98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5360; ID1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133294 CVCL_T398 Psi-CRIP-MFGmIL-1alpha transformed cell line house mouse CVCL_T398 CL:0000010 Transfected with: MGI; MGI:96542; Il1a Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21133295 CVCL_9F04 DD1297 transformed cell line human CVCL_9F04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133296 CVCL_SR97 HAP1 ICMT (-) 2 cancer cell line human CVCL_SR97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5350; ICMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133297 CVCL_T397 Psi-CRIP-MFGmIL-12p40 transformed cell line house mouse CVCL_T397 CL:0000010 Transfected with: MGI; MGI:96540; Il12b Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21133298 CVCL_9F07 DD1302 transformed cell line human CVCL_9F07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133299 CVCL_9F06 DD1300 finite cell line human CVCL_9F06 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133300 CVCL_SR99 HAP1 IDE (-) 1 cancer cell line human CVCL_SR99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5381; IDE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133301 CVCL_T399 Psi-CRIP-MFGmIL-1RA transformed cell line house mouse CVCL_T399 CL:0000010 Transfected with: MGI; MGI:96547; Il1rn Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21133302 CVCL_9F01 DD1292 transformed cell line human CVCL_9F01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133303 CVCL_9F00 DD1291 transformed cell line human CVCL_9F00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133304 CVCL_9F03 DD1296 transformed cell line human CVCL_9F03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133305 CVCL_9F02 DD1293 transformed cell line human CVCL_9F02 CL:0000010 Karyotypic information: 46,XY,t(5;15)(q13.1;q21.1)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133306 CVCL_0L71 AG14614 transformed cell line human CVCL_0L71 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133307 CVCL_0L70 AG14613 transformed cell line human CVCL_0L70 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133308 CVCL_0L73 AG14616 transformed cell line human CVCL_0L73 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133309 CVCL_0L72 AG14615 transformed cell line human CVCL_0L72 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133310 CVCL_0L75 AG14735 transformed cell line human CVCL_0L75 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133311 CVCL_9F09 DD1304 transformed cell line human CVCL_9F09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133312 CVCL_0L74 AG14617 transformed cell line human CVCL_0L74 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133313 CVCL_9F08 DD1303 transformed cell line human CVCL_9F08 CL:0000010 Karyotypic information: 46,XX; 47,XX+mar(15) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133314 CVCL_0L77 AG14738 transformed cell line human CVCL_0L77 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133315 CVCL_0L76 AG14737 transformed cell line human CVCL_0L76 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sardinian population of great age 21133316 CVCL_0L68 AG14939 transformed cell line human CVCL_0L68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Unspecified 21133317 CVCL_0L67 AG15695 transformed cell line human CVCL_0L67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female 21133318 CVCL_0L69 AG14612 transformed cell line human CVCL_0L69 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sardinian population of great age 21133319 CVCL_JY07 SCA-5 cancer cell line house mouse CVCL_JY07 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Salivary gland; submandibular gland; Breed/subspecies: Swiss Webster. Male Doubling time: 21.2 hours, at 9th passage (PubMed=6993784) 21133320 CVCL_JY06 SCA-10 cancer cell line house mouse CVCL_JY06 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Salivary gland; submandibular gland; Breed/subspecies: Swiss Webster. Male Doubling time: 23.9 hours, at 9th passage (PubMed=6993784) 21133321 CVCL_JY09 HMAM4A cancer cell line CVCL_JY09 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Mammary gland. Female 21133322 CVCL_JY08 SCA-9 cancer cell line house mouse CVCL_JY08 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Salivary gland; submandibular gland; Breed/subspecies: Swiss Webster. Male Doubling time: 23.9 hours, at 9th passage (PubMed=6993784) 21133323 CVCL_JY03 MCP-5.3 transformed cell line house mouse CVCL_JY03 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Unspecified 21133324 CVCL_JY02 MCP-5.2 transformed cell line house mouse CVCL_JY02 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Unspecified 21133325 CVCL_JY05 MCP-5.5 transformed cell line house mouse CVCL_JY05 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Unspecified 21133326 CVCL_JY04 MCP-5.4 transformed cell line house mouse CVCL_JY04 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Unspecified 21133327 CVCL_JY01 MCP-5.1 transformed cell line house mouse CVCL_JY01 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Unspecified 21133328 CVCL_JY00 LdlF spontaneously immortalized cell line CVCL_JY00 CL:0000010 Sequence variation: Mutation; UniProtKB; Q60445; Cope; Simple; p.Glu251Lys (c.751C>T); Zygosity=Homozygous (PubMed=8626666) Derived from sampling site: Ovary. Female Characteristics: At the non-permissive temperature of 39.5 Celsius exhibits rapid degradation of LDLRs, disruption of ER-through Golgi transport and disintegration of the Golgi apparatus 21133329 CVCL_JY18 KYD-44B cancer cell line Norway rat CVCL_JY18 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Hemizygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133330 CVCL_JY17 KYD-44A cancer cell line Norway rat CVCL_JY17 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Hemizygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133331 CVCL_JY19 KYD-49 cancer cell line Norway rat CVCL_JY19 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Hemizygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133332 CVCL_JY14 KYD-17 cancer cell line Norway rat CVCL_JY14 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Hemizygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133333 CVCL_JY13 KYD-12 cancer cell line Norway rat CVCL_JY13 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133334 CVCL_JY16 KYD-38 cancer cell line Norway rat CVCL_JY16 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Heterozygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133335 CVCL_JY15 KYD-32 cancer cell line Norway rat CVCL_JY15 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Heterozygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133336 CVCL_JY10 HMAM4B cancer cell line CVCL_JY10 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Mammary gland. Female Doubling time: ~24 hours (PubMed=21893382) 21133337 CVCL_JY12 KYD-10 cancer cell line Norway rat CVCL_JY12 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Hemizygous (PubMed=9209432) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Long-Evans. 21133338 CVCL_JY11 HMAM5 cancer cell line CVCL_JY11 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Mammary gland. Female Characteristics: Produced from a tumor derived from HMAM4B cells implanted into a syngeneic hamster Doubling time: ~24 hours (PubMed=21893382) 21133339 CVCL_9F99 DD1473 transformed cell line human CVCL_9F99 CL:0000010 Karyotypic information: 48,XXXX (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133340 CVCL_9F90 DD1448 transformed cell line human CVCL_9F90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133341 CVCL_9F96 DD1467 finite cell line human CVCL_9F96 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133342 CVCL_9F95 DD1456 transformed cell line human CVCL_9F95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133343 CVCL_9F98 DD1470 transformed cell line human CVCL_9F98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133344 CVCL_9F97 DD1468 transformed cell line human CVCL_9F97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133345 CVCL_9F92 DD1450 transformed cell line human CVCL_9F92 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133346 CVCL_9F91 DD1449 transformed cell line human CVCL_9F91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133347 CVCL_9F94 DD1455 transformed cell line human CVCL_9F94 CL:0000010 Karyotypic information: 47,XY,+mar(14) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133348 CVCL_9F93 DD1453 transformed cell line human CVCL_9F93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133349 CVCL_9F78 DD1424 transformed cell line human CVCL_9F78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133350 CVCL_9F77 DD1423 finite cell line human CVCL_9F77 CL:0000010 Karyotypic information: 46,X,del(Y)(?q11.2) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133351 CVCL_9F79 DD1425 transformed cell line human CVCL_9F79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133352 CVCL_9F74 DD1413 transformed cell line human CVCL_9F74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133353 CVCL_9F73 DD1412 transformed cell line human CVCL_9F73 CL:0000010 Karyotypic information: 46,XX [28]; 46,XX,-18,+dic(18q) [5]; 47,XX,+18 [19] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133354 CVCL_9F76 DD1421 finite cell line human CVCL_9F76 CL:0000010 Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Amniotic fluid. Ambiguous Part of: ECACC chromosomal abnormality collection 21133355 CVCL_9F75 DD1418 transformed cell line human CVCL_9F75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133356 CVCL_9F70 DD1408 transformed cell line human CVCL_9F70 CL:0000010 Karyotypic information: 46,XX,?invdup(2)(q36.2;q37.3) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133357 CVCL_9F72 DD1411 transformed cell line human CVCL_9F72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133358 CVCL_9F71 DD1410 finite cell line human CVCL_9F71 CL:0000010 Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21133359 CVCL_9F89 DD1445 transformed cell line human CVCL_9F89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133360 CVCL_9F88 DD1444 transformed cell line human CVCL_9F88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133361 CVCL_9F85 DD1438 transformed cell line human CVCL_9F85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133362 CVCL_9F84 DD1433 transformed cell line human CVCL_9F84 CL:0000010 Karyotypic information: 46,X,inv(Y) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133363 CVCL_9F87 DD1440 transformed cell line human CVCL_9F87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133364 CVCL_9F86 DD1439 transformed cell line human CVCL_9F86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133365 CVCL_9F81 DD1429 finite cell line human CVCL_9F81 CL:0000010 Karyotypic information: 46,XY,t(3;8)(p11.1;q13.2)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133366 CVCL_9F80 DD1426 transformed cell line human CVCL_9F80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133367 CVCL_9F83 DD1431 transformed cell line human CVCL_9F83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133368 CVCL_9F82 DD1430 transformed cell line human CVCL_9F82 CL:0000010 Karyotypic information: 47,XX,+mar(22)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133369 CVCL_ST41 HAP1 ITGAE (-) 3 cancer cell line human CVCL_ST41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133370 CVCL_T541 RECC-UT323 transformed cell line CVCL_T541 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133371 CVCL_ST40 HAP1 ITGAE (-) 2 cancer cell line human CVCL_ST40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133372 CVCL_T540 RECC-UT322 transformed cell line CVCL_T540 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133373 CVCL_ST43 HAP1 ITGB1 (-) 1 cancer cell line human CVCL_ST43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133374 CVCL_T543 RECC-UT328 transformed cell line CVCL_T543 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133375 CVCL_ST42 HAP1 ITGAE (-) 4 cancer cell line human CVCL_ST42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133376 CVCL_T542 RECC-UT327 transformed cell line CVCL_T542 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133377 CVCL_ST45 HAP1 ITGB1 (-) 3 cancer cell line human CVCL_ST45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133378 CVCL_T545 RECC-UT336 transformed cell line CVCL_T545 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133379 CVCL_ST44 HAP1 ITGB1 (-) 2 cancer cell line human CVCL_ST44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6153; ITGB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133380 CVCL_T544 RECC-UT331 transformed cell line CVCL_T544 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133381 CVCL_T547 CU-2 cancer cell line CVCL_T547 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: P-line. Female Group: Bird cell line 21133382 CVCL_ST47 HAP1 ITGB4 (-) 2 cancer cell line human CVCL_ST47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6158; ITGB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133383 CVCL_T546 CU-1 cancer cell line CVCL_T546 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: N-line. Female Group: Bird cell line 21133384 CVCL_ST46 HAP1 ITGB4 (-) 1 cancer cell line human CVCL_ST46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6158; ITGB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133385 CVCL_T549 CU-4 cancer cell line CVCL_T549 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: N-line. Female Group: Bird cell line 21133386 CVCL_ST49 HAP1 ITGB5 (-) 1 cancer cell line human CVCL_ST49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6160; ITGB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133387 CVCL_T548 CU-3 cancer cell line CVCL_T548 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: PDR. Female Group: Bird cell line 21133388 CVCL_ST48 HAP1 ITGB4 (-) 3 cancer cell line human CVCL_ST48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6158; ITGB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133389 CVCL_T550 CU-5 cancer cell line CVCL_T550 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: GB-1. Group: Bird cell line 21133390 CVCL_ST50 HAP1 ITGB5 (-) 2 cancer cell line human CVCL_ST50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6160; ITGB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133391 CVCL_ST30 HAP1 ITGA5 (-) 2 cancer cell line human CVCL_ST30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6141; ITGA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133392 CVCL_T530 RECC-KU9 transformed cell line CVCL_T530 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133393 CVCL_ST32 HAP1 ITGA6 (-) 2 cancer cell line human CVCL_ST32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6142; ITGA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133394 CVCL_T532 RECC-UT2 transformed cell line CVCL_T532 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: White Leghorn SPAFAS. Unspecified Group: Bird cell line 21133395 CVCL_ST31 HAP1 ITGA6 (-) 1 cancer cell line human CVCL_ST31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6142; ITGA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133396 CVCL_T531 RECC-UT1 transformed cell line CVCL_T531 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Derived from sampling site: Bone marrow. Group: Bird cell line 21133397 CVCL_ST34 HAP1 ITGA7 (-) 2 cancer cell line human CVCL_ST34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6143; ITGA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133398 CVCL_T534 RECC-UT311 transformed cell line CVCL_T534 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133399 CVCL_ST33 HAP1 ITGA7 (-) 1 cancer cell line human CVCL_ST33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6143; ITGA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133400 CVCL_T533 RECC-UT310 transformed cell line CVCL_T533 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Male Group: Bird cell line 21133401 CVCL_ST36 HAP1 ITGA7 (-) 4 cancer cell line human CVCL_ST36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6143; ITGA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133402 CVCL_T536 RECC-UT313 transformed cell line CVCL_T536 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133403 CVCL_ST35 HAP1 ITGA7 (-) 3 cancer cell line human CVCL_ST35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6143; ITGA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133404 CVCL_T535 RECC-UT312 transformed cell line CVCL_T535 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133405 CVCL_ST38 HAP1 ITGA9 (-) 2 cancer cell line human CVCL_ST38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6145; ITGA9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133406 CVCL_T538 RECC-UT316 transformed cell line CVCL_T538 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133407 CVCL_ST37 HAP1 ITGA9 (-) 1 cancer cell line human CVCL_ST37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6145; ITGA9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133408 CVCL_T537 RECC-UT314 transformed cell line CVCL_T537 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133409 CVCL_ST39 HAP1 ITGAE (-) 1 cancer cell line human CVCL_ST39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6147; ITGAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133410 CVCL_T539 RECC-UT317 transformed cell line CVCL_T539 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21133411 CVCL_0N00 GM08334 transformed cell line human CVCL_0N00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133412 CVCL_0N02 GM08336 transformed cell line human CVCL_0N02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133413 CVCL_0N01 GM08335 transformed cell line human CVCL_0N01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133414 CVCL_0N04 GM08339 transformed cell line human CVCL_0N04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133415 CVCL_0N03 GM08337 transformed cell line human CVCL_0N03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133416 CVCL_0N06 GM08341 transformed cell line human CVCL_0N06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133417 CVCL_0N05 GM08340 transformed cell line human CVCL_0N05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133418 CVCL_0N08 GM08344 transformed cell line human CVCL_0N08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133419 CVCL_0N07 GM08343 transformed cell line human CVCL_0N07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133420 CVCL_0N09 GM08889 finite cell line human CVCL_0N09 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg1162Ter (c.3484C>T); ClinVar=VCV000007137; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133421 CVCL_ST21 HAP1 ITGA2 (-) 1 cancer cell line human CVCL_ST21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133422 CVCL_T521 RECC-KU42 transformed cell line CVCL_T521 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133423 CVCL_ST20 HAP1 ITGA1 (-) 4 cancer cell line human CVCL_ST20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6134; ITGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133424 CVCL_T520 RECC-KU41 transformed cell line CVCL_T520 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133425 CVCL_ST23 HAP1 ITGA2B (-) 1 cancer cell line human CVCL_ST23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6138; ITGA2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133426 CVCL_T523 RECC-KU44 transformed cell line CVCL_T523 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133427 CVCL_ST22 HAP1 ITGA2 (-) 2 cancer cell line human CVCL_ST22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6137; ITGA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133428 CVCL_T522 RECC-KU43 transformed cell line CVCL_T522 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133429 CVCL_ST25 HAP1 ITGA3 (-) 1 cancer cell line human CVCL_ST25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6139; ITGA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133430 CVCL_T525 RECC-KU46 transformed cell line CVCL_T525 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133431 CVCL_ST24 HAP1 ITGA2B (-) 2 cancer cell line human CVCL_ST24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6138; ITGA2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133432 CVCL_T524 RECC-KU45 transformed cell line CVCL_T524 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133433 CVCL_ST27 HAP1 ITGA4 (-) 1 cancer cell line human CVCL_ST27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6140; ITGA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133434 CVCL_T527 RECC-KU6 transformed cell line CVCL_T527 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133435 CVCL_ST26 HAP1 ITGA3 (-) 2 cancer cell line human CVCL_ST26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6139; ITGA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133436 CVCL_JZ89 LICM 204 cancer cell line human CVCL_JZ89 CL:0000010 Derived from metastatic site: Bone marrow. Male 21133437 CVCL_T526 RECC-KU5 transformed cell line CVCL_T526 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133438 CVCL_ST29 HAP1 ITGA5 (-) 1 cancer cell line human CVCL_ST29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6141; ITGA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133439 CVCL_T529 RECC-KU8 transformed cell line CVCL_T529 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133440 CVCL_ST28 HAP1 ITGA4 (-) 2 cancer cell line human CVCL_ST28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6140; ITGA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133441 CVCL_T528 RECC-KU7 transformed cell line CVCL_T528 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Unspecified Group: Bird cell line 21133442 CVCL_JZ86 LICM 154 cancer cell line human CVCL_JZ86 CL:0000010 Derived from metastatic site: Bone marrow. Male 21133443 CVCL_JZ85 LICM 124 cancer cell line human CVCL_JZ85 CL:0000010 Derived from metastatic site: Breast. Female 21133444 CVCL_JZ88 LICM 196 cancer cell line human CVCL_JZ88 CL:0000010 Derived from metastatic site: Bone marrow. Male 21133445 CVCL_JZ87 LICM 158 cancer cell line human CVCL_JZ87 CL:0000010 Derived from metastatic site: Bone marrow. Male 21133446 CVCL_JZ82 LICM 44 cancer cell line human CVCL_JZ82 CL:0000010 Derived from metastatic site: Bone marrow. Female 21133447 CVCL_JZ81 COMMA-1D/PDK1 spontaneously immortalized cell line house mouse CVCL_JZ81 CL:0000010 Transfected with: HGNC; 8816; PDPK1 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21133448 CVCL_JZ84 LICM 107 cancer cell line human CVCL_JZ84 CL:0000010 Derived from metastatic site: Bone marrow. Male 21133449 CVCL_JZ83 LICM 56 cancer cell line human CVCL_JZ83 CL:0000010 Derived from metastatic site: Bone marrow. Female 21133450 CVCL_JZ80 NCI-H140 cancer cell line human CVCL_JZ80 CL:0000010 Derived from metastatic site: Lymph node. Male 21133451 CVCL_ST10 HAP1 ISL1 (-) 1 cancer cell line human CVCL_ST10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6132; ISL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133452 CVCL_T510 RECC-KU31 transformed cell line CVCL_T510 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133453 CVCL_ST12 HAP1 ISPD (-) 1 cancer cell line human CVCL_ST12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37276; CRPPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133454 CVCL_T512 RECC-KU33 transformed cell line CVCL_T512 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133455 CVCL_ST11 HAP1 ISOC2 (-) 1 cancer cell line human CVCL_ST11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26278; ISOC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133456 CVCL_T511 RECC-KU32 transformed cell line CVCL_T511 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133457 CVCL_ST14 HAP1 ISPD (-) 3 cancer cell line human CVCL_ST14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37276; CRPPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133458 CVCL_T514 RECC-KU35 transformed cell line CVCL_T514 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133459 CVCL_ST13 HAP1 ISPD (-) 2 cancer cell line human CVCL_ST13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37276; CRPPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133460 CVCL_T513 RECC-KU34 transformed cell line CVCL_T513 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133461 CVCL_ST16 HAP1 ITCH (-) cancer cell line human CVCL_ST16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13890; ITCH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133462 CVCL_T516 RECC-KU37 transformed cell line CVCL_T516 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133463 CVCL_ST15 HAP1 ISPD (-) 4 cancer cell line human CVCL_ST15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37276; CRPPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133464 CVCL_T515 RECC-KU36 transformed cell line CVCL_T515 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133465 CVCL_ST18 HAP1 ITGA1 (-) 2 cancer cell line human CVCL_ST18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6134; ITGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133466 CVCL_T518 RECC-KU39 transformed cell line CVCL_T518 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133467 CVCL_ST17 HAP1 ITGA1 (-) 1 cancer cell line human CVCL_ST17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6134; ITGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133468 CVCL_T517 RECC-KU38 transformed cell line CVCL_T517 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133469 CVCL_JZ97 HEK293_GS-KO transformed cell line human CVCL_JZ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4341; GLUL Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 12978BP 21133470 CVCL_JZ96 CHO-AFLE spontaneously immortalized cell line CVCL_JZ96 CL:0000010 Transfected with: HGNC; 399; ALB; Transfected with: HGNC; 3415; EPO Derived from sampling site: Ovary. Female Characteristics: Transfected with a albumin-EPO fusion protein AFLE (Albumin-Full-Linker-EPO) Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 11015BP 21133471 CVCL_ST19 HAP1 ITGA1 (-) 3 cancer cell line human CVCL_ST19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6134; ITGA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133472 CVCL_T519 RECC-KU40 transformed cell line CVCL_T519 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Female Group: Bird cell line 21133473 CVCL_JZ99 Jurkat-F9-1906LUC cancer cell line human CVCL_JZ99 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with luciferase under the control of the PTGS2/COX-2 promoter Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 99032405 21133474 CVCL_JZ98 LBHEL finite cell line human CVCL_JZ98 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Virology: Highly susceptible to infection by varicella-zoster virus (VZV) Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 0127BP 21133475 CVCL_JZ93 CHO dhfr(-) Bcl2 spontaneously immortalized cell line CVCL_JZ93 CL:0000010 Transfected with: HGNC; 990; BCL2 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 10142BP 21133476 CVCL_JZ92 6B4 hybridoma house mouse CVCL_JZ92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07359; Human GP1BA/CD42b. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 5108CB 21133477 CVCL_JZ95 CHO-ADLE spontaneously immortalized cell line CVCL_JZ95 CL:0000010 Transfected with: HGNC; 399; ALB; Transfected with: HGNC; 3415; EPO Derived from sampling site: Ovary. Female Characteristics: Transfected with a albumin-EPO fusion protein ADLE (Albumin-Domain-Linker-EPO) Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 11014BP 21133478 CVCL_JZ94 CHO dhfr(-) E1B-19K spontaneously immortalized cell line CVCL_JZ94 CL:0000010 Transfected with: UniProtKB; P03246; Adenovirus 5 E1B 19 kDa protein Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 10143BP 21133479 CVCL_JZ91 4B4-1-1 hybridoma house mouse CVCL_JZ91 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q07011; Human TNFRSF9/CD137. Group: Patented cell line; Registration: International Depositary Authority, Korean Collection for Type Culture; KCTC 0157BP 21133480 CVCL_JZ90 LICM 209 cancer cell line human CVCL_JZ90 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21133481 CVCL_ST01 HAP1 IRF7 (-) 2 cancer cell line human CVCL_ST01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133482 CVCL_T501 RECC-KU22 transformed cell line CVCL_T501 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133483 CVCL_ST00 HAP1 IRF7 (-) 1 cancer cell line human CVCL_ST00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133484 CVCL_T500 RECC-KU21 transformed cell line CVCL_T500 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133485 CVCL_ST03 HAP1 IRF8 (-) cancer cell line human CVCL_ST03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5358; IRF8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133486 CVCL_T503 RECC-KU24 transformed cell line CVCL_T503 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133487 CVCL_ST02 HAP1 IRF7 (-) 3 cancer cell line human CVCL_ST02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6122; IRF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133488 CVCL_T502 RECC-KU23 transformed cell line CVCL_T502 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133489 CVCL_ST05 HAP1 IRG1 (-) 2 cancer cell line human CVCL_ST05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33904; ACOD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133490 CVCL_JZ68 NMC-G2 cancer cell line human CVCL_JZ68 CL:0000010 Population: Japanese. Male 21133491 CVCL_T505 RECC-KU26 transformed cell line CVCL_T505 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133492 CVCL_ST04 HAP1 IRG1 (-) 1 cancer cell line human CVCL_ST04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33904; ACOD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133493 CVCL_JZ67 ONS-6 cancer cell line human CVCL_JZ67 CL:0000010 Population: Japanese Unspecified Doubling time: 30.5 hours (PubMed=3740860). 21133494 CVCL_T504 RECC-KU25 transformed cell line CVCL_T504 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133495 CVCL_ST07 HAP1 IRS1 (-) 2 cancer cell line human CVCL_ST07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6125; IRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133496 CVCL_T507 RECC-KU28 transformed cell line CVCL_T507 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133497 CVCL_ST06 HAP1 IRS1 (-) 1 cancer cell line human CVCL_ST06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6125; IRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133498 CVCL_JZ69 KMG-4 cancer cell line human CVCL_JZ69 CL:0000010 Population: Japanese; Derived from sampling site: Brain; occipital lobe. Female Doubling time: 29 hours, at 74th passage (CelloPub=CLPUB00587) 21133499 CVCL_T506 RECC-KU27 transformed cell line CVCL_T506 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133500 CVCL_ST09 HAP1 ISG15 (-) 2 cancer cell line human CVCL_ST09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4053; ISG15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133501 CVCL_T509 RECC-KU30 transformed cell line CVCL_T509 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133502 CVCL_JZ64 ZH-161 cancer cell line human CVCL_JZ64 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Cancer stem cell line 21133503 CVCL_ST08 HAP1 ISG15 (-) 1 cancer cell line human CVCL_ST08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4053; ISG15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133504 CVCL_T508 RECC-KU29 transformed cell line CVCL_T508 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636). Male Group: Bird cell line 21133505 CVCL_JZ63 TEL-2 spontaneously immortalized cell line house mouse CVCL_JZ63 CL:0000010 Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Doubling time: ~20 hours (PubMed=1968393) 21133506 CVCL_JZ66 ONS-M21 hybridoma house mouse CVCL_JZ66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. 21133507 CVCL_JZ65 ZH-305 cancer cell line human CVCL_JZ65 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Cancer stem cell line 21133508 CVCL_JZ60 MTE2 spontaneously immortalized cell line house mouse CVCL_JZ60 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: NIH Swiss. 21133509 CVCL_JZ62 MTE4-14 spontaneously immortalized cell line house mouse CVCL_JZ62 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: C3H/J. 21133510 CVCL_JZ61 MTE3-19 spontaneously immortalized cell line house mouse CVCL_JZ61 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: CBA-BR. 21133511 CVCL_JZ79 LICM 95 cancer cell line human CVCL_JZ79 CL:0000010 Derived from metastatic site: Spinal cord. Male 21133512 CVCL_JZ78 LICM 222 cancer cell line human CVCL_JZ78 CL:0000010 Derived from metastatic site: Bone marrow. Female 21133513 CVCL_JZ75 SEN31 hybridoma house mouse CVCL_JZ75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cluster-5A antigen on small cell lung cancer. 21133514 CVCL_JZ74 SEN3 hybridoma house mouse CVCL_JZ74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cluster-5A antigen on small cell lung cancer. 21133515 CVCL_JZ77 Sen15C6 hybridoma house mouse CVCL_JZ77 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Phaeosphaeria nodorum. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10185 21133516 CVCL_JZ76 SWA20 hybridoma house mouse CVCL_JZ76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human cluster-5A antigen on small cell lung cancer. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 88030201 21133517 CVCL_JZ71 SEN7.2a.4 hybridoma house mouse CVCL_JZ71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13591; Human NCAM1/CD56. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2050 21133518 CVCL_JZ70 ONS-16 cancer cell line human CVCL_JZ70 CL:0000010 Population: Japanese; Derived from sampling site: Brain. Doubling time: 60.9 hours (PubMed=3740860) 21133519 CVCL_JZ73 SEN12 hybridoma house mouse CVCL_JZ73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human cluster-5A antigen on small cell lung cancer. 21133520 CVCL_JZ72 SEN11 hybridoma house mouse CVCL_JZ72 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human cluster-5A antigen on small cell lung cancer. 21133521 CVCL_JZ49 CSL 234 spontaneously immortalized cell line CVCL_JZ49 CL:0000010 Derived from sampling site: Skin. Male Group: Marsupial cell line 21133522 CVCL_JZ46 CSL 225 spontaneously immortalized cell line CVCL_JZ46 CL:0000010 Derived from sampling site: Skin. Male Group: Marsupial cell line 21133523 CVCL_JZ45 CSL 224 spontaneously immortalized cell line CVCL_JZ45 CL:0000010 Female Group: Marsupial cell line. 21133524 CVCL_JZ48 CSL 227 spontaneously immortalized cell line CVCL_JZ48 CL:0000010 Derived from sampling site: Lung. Male Virology: Seems to be infected by an oncovirus Group: Marsupial cell line 21133525 CVCL_JZ47 CSL 226 spontaneously immortalized cell line CVCL_JZ47 CL:0000010 Derived from sampling site: Heart. Male Group: Marsupial cell line 21133526 CVCL_JZ42 MR-97 cancer cell line human CVCL_JZ42 CL:0000010 Derived from sampling site: Lung. Doubling time: 1 day (PubMed=2988594) 21133527 CVCL_JZ41 MR-90 cancer cell line human CVCL_JZ41 CL:0000010 Derived from sampling site: Lung. Doubling time: 1 day (PubMed=2988594) 21133528 CVCL_JZ44 M2.7.1 spontaneously immortalized cell line CVCL_JZ44 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Kidney. Male Group: Marsupial cell line 21133529 CVCL_JZ43 MR-103 cancer cell line human CVCL_JZ43 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified Doubling time: 3-5 days (PubMed=2988594) Caution: According to PubMed=2988594 is from small cell lung carcinoma while according to PubMed=2437618 it is from a large cell carcinoma 21133530 CVCL_JZ40 MR-86 cancer cell line human CVCL_JZ40 CL:0000010 Derived from metastatic site: Pleural effusion. Doubling time: 4 days (PubMed=2988594) 21133531 CVCL_JZ57 MTE1 spontaneously immortalized cell line house mouse CVCL_JZ57 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: NIH Swiss. 21133532 CVCL_JZ56 Sc9/01 spontaneously immortalized cell line CVCL_JZ56 CL:0000010 Derived from sampling site: Ovary. Female Group: Marsupial cell line 21133533 CVCL_JZ59 MTE1P spontaneously immortalized cell line house mouse CVCL_JZ59 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: NIH Swiss. 21133534 CVCL_JZ58 MTE1D spontaneously immortalized cell line house mouse CVCL_JZ58 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: NIH Swiss. 21133535 CVCL_JZ53 PtK2BN1 spontaneously immortalized cell line CVCL_JZ53 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Kidney. Male Group: Marsupial cell line 21133536 CVCL_JZ52 PtK1TG spontaneously immortalized cell line CVCL_JZ52 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney. Female Group: Marsupial cell line 21133537 CVCL_JZ55 Sc3F spontaneously immortalized cell line CVCL_JZ55 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Group: Marsupial cell line 21133538 CVCL_JZ54 PtK2TN1 spontaneously immortalized cell line CVCL_JZ54 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney. Male Group: Marsupial cell line 21133539 CVCL_JZ51 CSLEX1 hybridoma house mouse CVCL_JZ51 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8580 21133540 CVCL_JZ50 CSL 235 spontaneously immortalized cell line CVCL_JZ50 CL:0000010 Female Virology: Seems to be infected by an oncovirus. Group: Marsupial cell line 21133541 CVCL_9H14 DD1710 finite cell line human CVCL_9H14 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21133542 CVCL_9H13 DD1709 finite cell line human CVCL_9H13 CL:0000010 Karyotypic information: 69,XXX (ECACC); Derived from sampling site: Cell type=Fibroblast. Ambiguous Part of: ECACC chromosomal abnormality collection 21133543 CVCL_9H16 DD1715 transformed cell line human CVCL_9H16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133544 CVCL_9H15 DD1714 transformed cell line human CVCL_9H15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133545 CVCL_9H10 DD1706 transformed cell line human CVCL_9H10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133546 CVCL_9H12 DD1708 transformed cell line human CVCL_9H12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133547 CVCL_9H11 DD1707 transformed cell line human CVCL_9H11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133548 CVCL_0N80 AG09980 transformed cell line human CVCL_0N80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21133549 CVCL_0N82 AG10215 finite cell line human CVCL_0N82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133550 CVCL_0N81 AG10213 finite cell line human CVCL_0N81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21133551 CVCL_0N84 AG10390 finite cell line human CVCL_0N84 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21133552 CVCL_9H18 DD1717 transformed cell line human CVCL_9H18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133553 CVCL_0N83 AG10292 finite cell line human CVCL_0N83 CL:0000010 Karyotypic information: 47,XX,+13 (Coriell); Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21133554 CVCL_9H17 DD1716 transformed cell line human CVCL_9H17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133555 CVCL_0N86 AG10400 finite cell line human CVCL_0N86 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133556 CVCL_0N85 AG10391 finite cell line human CVCL_0N85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133557 CVCL_9H19 DD1719 transformed cell line human CVCL_9H19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133558 CVCL_0N77 AG09279 finite cell line human CVCL_0N77 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21133559 CVCL_0N76 AG09233 finite cell line human CVCL_0N76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21133560 CVCL_0N79 AG09950 transformed cell line human CVCL_0N79 CL:0000010 Sequence variation: Mutation; HGNC; 9449; PRNP; Simple; p.Ala117Val (c.350C>T); ClinVar=VCV000013396; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133561 CVCL_0N78 AG09387 transformed cell line human CVCL_0N78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133562 CVCL_9H25 DD1725 transformed cell line human CVCL_9H25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133563 CVCL_9H24 DD1724 transformed cell line human CVCL_9H24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133564 CVCL_9H27 DD1732 transformed cell line human CVCL_9H27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133565 CVCL_9H26 DD1727 transformed cell line human CVCL_9H26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133566 CVCL_9H21 DD1721 transformed cell line human CVCL_9H21 CL:0000010 Karyotypic information: 46,XY,t(4;18)(p13;q11)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133567 CVCL_9H20 DD1720 transformed cell line human CVCL_9H20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133568 CVCL_9H23 DD1723 transformed cell line human CVCL_9H23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133569 CVCL_9H22 DD1722 transformed cell line human CVCL_9H22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133570 CVCL_0N91 AG12723 transformed cell line human CVCL_0N91 CL:0000010 Population: Caucasian and Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133571 CVCL_0N90 AG12614 finite cell line human CVCL_0N90 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21133572 CVCL_0N93 AG12725 transformed cell line human CVCL_0N93 CL:0000010 Population: Caucasian and Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133573 CVCL_0N92 AG12724 finite cell line human CVCL_0N92 CL:0000010 Population: Caucasian and Indian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21133574 CVCL_0N95 AG12727 transformed cell line human CVCL_0N95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133575 CVCL_9H29 DD1735 finite cell line human CVCL_9H29 CL:0000010 Karyotypic information: 46,XX [59]; 47,XX,+mar [6] (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133576 CVCL_0N94 AG12726 finite cell line human CVCL_0N94 CL:0000010 Population: Caucasian and Indian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133577 CVCL_9H28 DD1733 transformed cell line human CVCL_9H28 CL:0000010 Karyotypic information: 46,XX,t(10;16;20) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133578 CVCL_0N97 AG13017 transformed cell line human CVCL_0N97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133579 CVCL_0N96 AG12728 finite cell line human CVCL_0N96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21133580 CVCL_0N88 AG12207 finite cell line human CVCL_0N88 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21133581 CVCL_0N87 AG12070 finite cell line human CVCL_0N87 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21133582 CVCL_0N89 AG12211 finite cell line human CVCL_0N89 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21133583 CVCL_0N60 AG06560 finite cell line human CVCL_0N60 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21133584 CVCL_0N62 AG06562 finite cell line human CVCL_0N62 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21133585 CVCL_0N61 AG06561 finite cell line human CVCL_0N61 CL:0000010 Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Female 21133586 CVCL_0N64 AG07075 transformed cell line human CVCL_0N64 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Ala205Pro (c.613G>C); ClinVar=VCV000001718; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133587 CVCL_0N63 AG06858 finite cell line human CVCL_0N63 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21133588 CVCL_0N55 AG06555 finite cell line human CVCL_0N55 CL:0000010 Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30-31 PDL (PubMed=9724752) 21133589 CVCL_0N54 AG04452 finite cell line human CVCL_0N54 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21133590 CVCL_0N57 AG06557 finite cell line human CVCL_0N57 CL:0000010 Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Male 21133591 CVCL_0N56 AG06556 finite cell line human CVCL_0N56 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21133592 CVCL_0N59 AG06559 finite cell line human CVCL_0N59 CL:0000010 Population: African American; Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Female Senescence: Senesces at 30-31 PDL (PubMed=9724752) 21133593 CVCL_0N58 AG06558 finite cell line human CVCL_0N58 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21133594 CVCL_9H03 DD1688 finite cell line human CVCL_9H03 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133595 CVCL_ST96 HAP1 KCNC1 (-) 2 cancer cell line human CVCL_ST96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6233; KCNC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133596 CVCL_T596 NYU10-230 cancer cell line human CVCL_T596 CL:0000010 Derived from metastatic site: Lymph node. Male 21133597 CVCL_9H02 DD1679 transformed cell line human CVCL_9H02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133598 CVCL_ST95 HAP1 KCNC1 (-) 1 cancer cell line human CVCL_ST95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6233; KCNC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133599 CVCL_T595 NYU10-040 cancer cell line human CVCL_T595 CL:0000010 Derived from metastatic site: Lymph node. Male 21133600 CVCL_9H05 DD1691 transformed cell line human CVCL_9H05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133601 CVCL_ST98 HAP1 KCND2 (-) 2 cancer cell line human CVCL_ST98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6238; KCND2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133602 CVCL_T598 SPCC-OU1 spontaneously immortalized cell line CVCL_T598 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133603 CVCL_T597 CHQC-QMC cancer cell line CVCL_T597 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Group: Bird cell line 21133604 CVCL_9H04 DD1689 transformed cell line human CVCL_9H04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133605 CVCL_ST97 HAP1 KCND2 (-) 1 cancer cell line human CVCL_ST97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6238; KCND2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133606 CVCL_T599 CHCC-OU1 transformed cell line CVCL_T599 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133607 CVCL_ST99 HAP1 KCNH2 (-) 1 cancer cell line human CVCL_ST99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6251; KCNH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133608 CVCL_9H01 DD1675 transformed cell line human CVCL_9H01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133609 CVCL_9H00 DD1674 transformed cell line human CVCL_9H00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133610 CVCL_0N71 AG08804 transformed cell line human CVCL_0N71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133611 CVCL_0N70 AG08016 finite cell line human CVCL_0N70 CL:0000010 Derived from sampling site: Ascites. Male 21133612 CVCL_0N73 AG08806 transformed cell line human CVCL_0N73 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu11Ter (c.31G>T); Zygosity=Heterozygous (PubMed=9447232) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133613 CVCL_9H07 DD1697 finite cell line human CVCL_9H07 CL:0000010 Karyotypic information: 47,XXX (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21133614 CVCL_0N72 AG08805 finite cell line human CVCL_0N72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133615 CVCL_9H06 DD1693 finite cell line human CVCL_9H06 CL:0000010 Karyotypic information: 45,X0 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133616 CVCL_0N75 AG09022 finite cell line human CVCL_0N75 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21133617 CVCL_9H09 DD1705 transformed cell line human CVCL_9H09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133618 CVCL_0N74 AG08807 finite cell line human CVCL_0N74 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu11Ter (c.31G>T); Zygosity=Heterozygous (from autologous cell line AG08806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21133619 CVCL_9H08 DD1699 transformed cell line human CVCL_9H08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133620 CVCL_0N66 AG07095 finite cell line human CVCL_0N66 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21133621 CVCL_0N65 AG07076 finite cell line human CVCL_0N65 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (from autologous cell line AG07075); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Ala205Pro (c.613G>C); ClinVar=VCV000001718; Zygosity=Heterozygous (from autologous cell line AG07075) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133622 CVCL_0N68 AG07443 finite cell line human CVCL_0N68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133623 CVCL_0N67 AG07167 finite cell line human CVCL_0N67 CL:0000010 Population: African American; Karyotypic information: 47,XX,+18 (Coriell); Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Female 21133624 CVCL_0N69 AG07549 finite cell line human CVCL_0N69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133625 CVCL_T585 CU-47 cancer cell line CVCL_T585 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21133626 CVCL_ST85 HAP1 JUN (-) 1 cancer cell line human CVCL_ST85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6204; JUN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133627 CVCL_T584 CU-43 cancer cell line CVCL_T584 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: P-2. Unspecified Group: Bird cell line 21133628 CVCL_ST84 HAP1 JOSD2 (-) cancer cell line human CVCL_ST84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28853; JOSD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133629 CVCL_T587 CU-49 cancer cell line CVCL_T587 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21133630 CVCL_ST87 HAP1 KAT2A (-) 1 cancer cell line human CVCL_ST87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4201; KAT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133631 CVCL_T586 CU-48 cancer cell line CVCL_T586 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21133632 CVCL_ST86 HAP1 JUN (-) 2 cancer cell line human CVCL_ST86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6204; JUN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133633 CVCL_ST89 HAP1 KAT2B (-) 1 cancer cell line human CVCL_ST89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8638; KAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133634 CVCL_T589 Q5 transformed cell line CVCL_T589 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line 21133635 CVCL_ST88 HAP1 KAT2A (-) 2 cancer cell line human CVCL_ST88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4201; KAT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133636 CVCL_T588 Ph 310 spontaneously immortalized cell line CVCL_T588 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line 21133637 CVCL_0N40 GM20925 transformed cell line human CVCL_0N40 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Arg (c.1645A>C); ClinVar=VCV000038733; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133638 CVCL_0N42 GM20929 transformed cell line human CVCL_0N42 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133639 CVCL_0N41 GM20928 transformed cell line human CVCL_0N41 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133640 CVCL_0N33 GM20741 transformed cell line human CVCL_0N33 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Lys1250Argfs*9 (c.3744delA) (3876delA); ClinVar=VCV000007231; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133641 CVCL_0N32 GM20737 transformed cell line human CVCL_0N32 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347His (c.1040G>A); ClinVar=VCV000007182; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133642 CVCL_0N35 GM20834 transformed cell line human CVCL_0N35 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347His (c.1040G>A); ClinVar=VCV000007182; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133643 CVCL_0N34 GM20745 transformed cell line human CVCL_0N34 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Asn (c.1646G>A); ClinVar=VCV000007116; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133644 CVCL_0N37 GM20837 transformed cell line human CVCL_0N37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133645 CVCL_0N36 GM20836 transformed cell line human CVCL_0N36 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Leu1258Phefs*7 (c.3773dupT) (3905insT); ClinVar=VCV000038726; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133646 CVCL_0N39 GM20924 transformed cell line human CVCL_0N39 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg75Ter (c.223C>T); ClinVar=VCV000048672; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133647 CVCL_0N38 GM20915 transformed cell line human CVCL_0N38 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Arg (c.1647T>G); ClinVar=VCV000040190; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133648 CVCL_ST90 HAP1 KAT2B (-) 2 cancer cell line human CVCL_ST90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8638; KAT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133649 CVCL_T590 Q8 transformed cell line CVCL_T590 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line 21133650 CVCL_ST92 HAP1 KAT6B (-) 1 cancer cell line human CVCL_ST92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17582; KAT6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133651 CVCL_T592 NYU08-175 cancer cell line human CVCL_T592 CL:0000010 Derived from sampling site: Skin. Male 21133652 CVCL_ST91 HAP1 KAT6A (-) 1 cancer cell line human CVCL_ST91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13013; KAT6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133653 CVCL_T591 Q10 transformed cell line CVCL_T591 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line 21133654 CVCL_ST94 HAP1 KAT7 (-) 2 cancer cell line human CVCL_ST94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133655 CVCL_T594 NYU09-203 cancer cell line human CVCL_T594 CL:0000010 Derived from metastatic site: Lymph node. Male 21133656 CVCL_ST93 HAP1 KAT7 (-) 1 cancer cell line human CVCL_ST93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133657 CVCL_T593 NYU09-085 cancer cell line human CVCL_T593 CL:0000010 Derived from metastatic site: Brain. Female 21133658 CVCL_T574 CU-32 cancer cell line CVCL_T574 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-2. Unspecified Group: Bird cell line 21133659 CVCL_ST74 HAP1 JARID2 (-) 2 cancer cell line human CVCL_ST74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6196; JARID2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133660 CVCL_T573 CU-31 cancer cell line CVCL_T573 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-254. Female Group: Bird cell line 21133661 CVCL_ST73 HAP1 JARID2 (-) 1 cancer cell line human CVCL_ST73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6196; JARID2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133662 CVCL_T576 CU-35 cancer cell line CVCL_T576 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: P-2. Female Group: Bird cell line 21133663 CVCL_ST76 HAP1 JMJD1C (-) 1 cancer cell line human CVCL_ST76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12313; JMJD1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133664 CVCL_T575 CU-33 cancer cell line CVCL_T575 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: P-2. Female Group: Bird cell line 21133665 CVCL_ST75 HAP1 JARID2 (-) 3 cancer cell line human CVCL_ST75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6196; JARID2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133666 CVCL_T578 CU-37 cancer cell line CVCL_T578 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-003. Female Group: Bird cell line 21133667 CVCL_ST78 HAP1 JMJD1C (-) 3 cancer cell line human CVCL_ST78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12313; JMJD1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133668 CVCL_T577 CU-36 cancer cell line CVCL_T577 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-003. Female Group: Bird cell line 21133669 CVCL_ST77 HAP1 JMJD1C (-) 2 cancer cell line human CVCL_ST77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12313; JMJD1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133670 CVCL_T579 CU-38 cancer cell line CVCL_T579 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-003. Female Group: Bird cell line 21133671 CVCL_ST79 HAP1 JMJD6 (-) cancer cell line human CVCL_ST79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19355; JMJD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133672 CVCL_0N51 HIVS-130T finite cell line human CVCL_0N51 CL:0000010 Derived from sampling site: Iliac vein; smooth muscle. Male Part of: Wistar Institute Special Collection vascular cell lines 21133673 CVCL_0N50 HIAS-130T finite cell line human CVCL_0N50 CL:0000010 Derived from sampling site: Iliac artery; smooth muscle. Male Part of: Wistar Institute Special Collection vascular cell lines 21133674 CVCL_0N53 AG04451 finite cell line human CVCL_0N53 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female Senescence: Senesces at 57 PDL (PubMed=9724752) 21133675 CVCL_0N52 AG02258 finite cell line human CVCL_0N52 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21133676 CVCL_0N44 GM21069 transformed cell line human CVCL_0N44 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Lys1250Argfs*9 (c.3744delA) (3876delA); ClinVar=VCV000007231; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133677 CVCL_0N43 GM20932 transformed cell line human CVCL_0N43 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser549Asn (c.1646G>A); ClinVar=VCV000007116; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133678 CVCL_0N46 GM21551 transformed cell line human CVCL_0N46 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507Val (c.1519A>G); ClinVar=VCV000188863; Zygosity=Heterozygous; Note=Benign (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133679 CVCL_0N45 GM21080 transformed cell line human CVCL_0N45 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Leu88Ilefs*22 (c.262_263delTT) (394delTT); ClinVar=VCV000007232; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133680 CVCL_0N48 LP-3 finite cell line human CVCL_0N48 CL:0000010 Derived from sampling site: Ascites Cell type=Mesothelial cell.. Female 21133681 CVCL_0N47 GM21572 transformed cell line human CVCL_0N47 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Leu1258Phefs*7 (c.3773dupT) (3905insT); ClinVar=VCV000038726; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133682 CVCL_0N49 LP-2 finite cell line human CVCL_0N49 CL:0000010 Derived from sampling site: Ascites Cell type=Mesothelial cell.. Female 21133683 CVCL_T581 CU-40 cancer cell line CVCL_T581 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: P-2. Male Group: Bird cell line 21133684 CVCL_ST81 HAP1 JMY (-) 2 cancer cell line human CVCL_ST81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28916; JMY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133685 CVCL_T580 CU-39 cancer cell line CVCL_T580 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: P-2. Female Group: Bird cell line 21133686 CVCL_ST80 HAP1 JMY (-) 1 cancer cell line human CVCL_ST80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28916; JMY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133687 CVCL_T583 CU-42 cancer cell line CVCL_T583 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: P-2. Female Group: Bird cell line 21133688 CVCL_ST83 HAP1 JOSD1 (-) cancer cell line human CVCL_ST83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28953; JOSD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133689 CVCL_T582 CU-41 cancer cell line CVCL_T582 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: P-2. Male Group: Bird cell line 21133690 CVCL_ST82 HAP1 JMY (-) 3 cancer cell line human CVCL_ST82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28916; JMY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133691 CVCL_T563 CU-21 cancer cell line CVCL_T563 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387); Breed/subspecies: N-2. Female Group: Bird cell line 21133692 CVCL_ST63 HAP1 ITPR2 (-) 4 cancer cell line human CVCL_ST63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133693 CVCL_T562 CU-20 cancer cell line CVCL_T562 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: L-7. Female Group: Bird cell line 21133694 CVCL_ST62 HAP1 ITPR2 (-) 3 cancer cell line human CVCL_ST62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133695 CVCL_T565 CU-23 cancer cell line CVCL_T565 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: N-2. Female Group: Bird cell line 21133696 CVCL_ST65 HAP1 IVNS1ABP (-) 1 cancer cell line human CVCL_ST65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16951; IVNS1ABP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133697 CVCL_T564 CU-22 cancer cell line CVCL_T564 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387); Breed/subspecies: N-2. Female Group: Bird cell line 21133698 CVCL_ST64 HAP1 ITPR3 (-) cancer cell line human CVCL_ST64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133699 CVCL_T567 CU-25 cancer cell line CVCL_T567 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-003. Male Group: Bird cell line 21133700 CVCL_ST67 HAP1 IVNS1ABP (-) 3 cancer cell line human CVCL_ST67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16951; IVNS1ABP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133701 CVCL_T566 CU-24 cancer cell line CVCL_T566 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387); Breed/subspecies: N-2. Female Group: Bird cell line 21133702 CVCL_ST66 HAP1 IVNS1ABP (-) 2 cancer cell line human CVCL_ST66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16951; IVNS1ABP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133703 CVCL_T569 CU-27 cancer cell line CVCL_T569 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: P-2. Female Group: Bird cell line 21133704 CVCL_ST69 HAP1 JAG1 (-) 1 cancer cell line human CVCL_ST69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133705 CVCL_T568 CU-26 cancer cell line CVCL_T568 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-336. Male Group: Bird cell line 21133706 CVCL_ST68 HAP1 IVNS1ABP (-) 4 cancer cell line human CVCL_ST68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16951; IVNS1ABP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133707 CVCL_0N20 GM12785 transformed cell line human CVCL_0N20 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347Pro (c.1040G>C); ClinVar=VCV000007110; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133708 CVCL_0N11 GM11370 transformed cell line human CVCL_0N11 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile105Serfs*2 (c.313delA) (444delA); ClinVar=VCV000048684; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1680-1G>A (IVS11-1G>A) (1812-1G-A); ClinVar=VCV000048681; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21133709 CVCL_0N10 GM08890 finite cell line human CVCL_0N10 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21133710 CVCL_0N13 GM11496 transformed cell line human CVCL_0N13 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly542Ter (c.1624G>T); ClinVar=VCV000007115; Zygosity=Homozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21133711 CVCL_0N12 GM11472 transformed cell line human CVCL_0N12 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly1349Asp (c.4046G>A); ClinVar=VCV000035881; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133712 CVCL_0N15 GM11723 transformed cell line human CVCL_0N15 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133713 CVCL_0N14 GM11497 transformed cell line human CVCL_0N14 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly542Ter (c.1624G>T); ClinVar=VCV000007115; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133714 CVCL_0N17 GM11859 transformed cell line human CVCL_0N17 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.2657+5G>A; ClinVar=VCV000038497; Zygosity=Homozygous; Note=Splicing defect (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133715 CVCL_0N16 GM11761 transformed cell line human CVCL_0N16 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133716 CVCL_0N19 GM12585 transformed cell line human CVCL_0N19 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg1162Ter (c.3484C>T); ClinVar=VCV000007137; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133717 CVCL_0N18 GM12444 transformed cell line human CVCL_0N18 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1585-1G>A (IVS10AS,G>A,-1) (1717-1G>A); ClinVar=VCV000007112; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133718 CVCL_T570 CU-28 cancer cell line CVCL_T570 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: UCD-335. Male Group: Bird cell line 21133719 CVCL_ST70 HAP1 JAK1 (-) 1 cancer cell line human CVCL_ST70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6190; JAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133720 CVCL_T572 CU-30 cancer cell line CVCL_T572 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-253. Male Group: Bird cell line 21133721 CVCL_ST72 HAP1 JAK2 (-) cancer cell line human CVCL_ST72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6192; JAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133722 CVCL_T571 CU-29 cancer cell line CVCL_T571 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: UCD-003. Female Group: Bird cell line 21133723 CVCL_ST71 HAP1 JAK1 (-) 2 cancer cell line human CVCL_ST71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6190; JAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133724 CVCL_T552 CU-10 cancer cell line CVCL_T552 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864). Female Doubling time: 17.0 hours (PubMed=3273463) Group: Bird cell line 21133725 CVCL_ST52 HAP1 ITGB5 (-) 4 cancer cell line human CVCL_ST52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6160; ITGB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133726 CVCL_T551 CU-6 cancer cell line CVCL_T551 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-line. Female Group: Bird cell line 21133727 CVCL_ST51 HAP1 ITGB5 (-) 3 cancer cell line human CVCL_ST51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6160; ITGB5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133728 CVCL_T554 CU-12 cancer cell line CVCL_T554 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-2. Unspecified Group: Bird cell line 21133729 CVCL_ST54 HAP1 ITPR1 (-) 1 cancer cell line human CVCL_ST54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133730 CVCL_T553 CU-11 cancer cell line CVCL_T553 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21133731 CVCL_ST53 HAP1 ITK (-) cancer cell line human CVCL_ST53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6171; ITK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133732 CVCL_T556 CU-14 cancer cell line CVCL_T556 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-2. Female Group: Bird cell line 21133733 CVCL_ST56 HAP1 ITPR1 (-) 3 cancer cell line human CVCL_ST56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133734 CVCL_T555 CU-13 cancer cell line CVCL_T555 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: GB-1. Unspecified Group: Bird cell line 21133735 CVCL_ST55 HAP1 ITPR1 (-) 2 cancer cell line human CVCL_ST55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133736 CVCL_T558 CU-16 cancer cell line CVCL_T558 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387); Breed/subspecies: S. Female Group: Bird cell line 21133737 CVCL_ST58 HAP1 ITPR1 (-) 5 cancer cell line human CVCL_ST58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133738 CVCL_T557 CU-15 cancer cell line CVCL_T557 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-2. Unspecified Group: Bird cell line 21133739 CVCL_ST57 HAP1 ITPR1 (-) 4 cancer cell line human CVCL_ST57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133740 CVCL_T559 CU-17 cancer cell line CVCL_T559 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: P-2. Unspecified Group: Bird cell line 21133741 CVCL_ST59 HAP1 ITPR1 (-) 6 cancer cell line human CVCL_ST59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6180; ITPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133742 CVCL_0N31 GM18886 transformed cell line human CVCL_0N31 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ser670_Leu671insTer (c.2012delT) (p.Leu671Terfs) (2143delT); ClinVar=VCV000035836; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133743 CVCL_0N30 GM18803 transformed cell line human CVCL_0N30 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Lys684Serfs*38 (c.2051_2052delAAinsG) (2183AA>G); ClinVar=VCV000035837; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133744 CVCL_0N22 GM12960 transformed cell line human CVCL_0N22 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg334Trp (c.1000C>T); ClinVar=VCV000007139; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133745 CVCL_0N21 GM12926 transformed cell line human CVCL_0N21 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln493Ter (c.1477C>T); ClinVar=VCV000007107; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133746 CVCL_0N24 GM13423 transformed cell line human CVCL_0N24 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly85Glu (c.254G>A); ClinVar=VCV000007143; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asp1152His (c.3454G>C); ClinVar=VCV000035867; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133747 CVCL_0N23 GM12961 transformed cell line human CVCL_0N23 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Val520Phe (c.1558G>T); ClinVar=VCV000007150; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133748 CVCL_0N26 GM18799 transformed cell line human CVCL_0N26 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Lys684Asnfs*38 (c.2052delA) (2184delA); ClinVar=VCV000038493; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133749 CVCL_0N25 GM18668 transformed cell line human CVCL_0N25 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Unexplicit; Ex2-3del; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133750 CVCL_0N28 GM18801 transformed cell line human CVCL_0N28 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.3140-26A>G (3272-26A>G); ClinVar=VCV000035864; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133751 CVCL_0N27 GM18800 transformed cell line human CVCL_0N27 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.1766+1G>A (1898+1G>A); ClinVar=VCV000007168; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133752 CVCL_0N29 GM18802 transformed cell line human CVCL_0N29 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Tyr122Ter (c.366T>A); ClinVar=VCV000038833; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133753 CVCL_T561 CU-19 cancer cell line CVCL_T561 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: GB-1. Male Group: Bird cell line 21133754 CVCL_ST61 HAP1 ITPR2 (-) 2 cancer cell line human CVCL_ST61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133755 CVCL_T560 CU-18 cancer cell line CVCL_T560 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387); Breed/subspecies: S. Female Group: Bird cell line 21133756 CVCL_ST60 HAP1 ITPR2 (-) 1 cancer cell line human CVCL_ST60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6181; ITPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21133757 CVCL_9G77 DD1622 finite cell line human CVCL_9G77 CL:0000010 Karyotypic information: 46,XY,del(2)(pter->?p22.1::?p21->qter) de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133758 CVCL_9G76 DD1620 finite cell line human CVCL_9G76 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21133759 CVCL_9G79 DD1624 transformed cell line human CVCL_9G79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133760 CVCL_9G78 DD1623 finite cell line human CVCL_9G78 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21133761 CVCL_BA07 GM21843 transformed cell line human CVCL_BA07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133762 CVCL_BA06 GM21640 finite cell line human CVCL_BA06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133763 CVCL_BA09 GM21845 transformed cell line human CVCL_BA09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133764 CVCL_BA08 GM21844 transformed cell line human CVCL_BA08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133765 CVCL_9G73 DD1614 transformed cell line human CVCL_9G73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133766 CVCL_9G72 DD1613 finite cell line human CVCL_9G72 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133767 CVCL_9G75 DD1619 transformed cell line human CVCL_9G75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133768 CVCL_BA01 WE-skin11f spontaneously immortalized cell line CVCL_BA01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Characteristics: Grows at temperatures from 4 to 26 Celsius but proliferated only at the higher temperatures (PubMed=31512261) Group: Fish cell line 21133769 CVCL_9G74 DD1618 transformed cell line human CVCL_9G74 CL:0000010 Karyotypic information: 47,XX,+der(22),t(11;22)(q23.3;q11.23)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133770 CVCL_BA00 WE-liver3 spontaneously immortalized cell line CVCL_BA00 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21133771 CVCL_BA03 WEBA spontaneously immortalized cell line CVCL_BA03 CL:0000010 Derived from sampling site: Bulbus arteriosus Cell type=Endothelial cell.. Unspecified Group: Fish cell line 21133772 CVCL_BA02 WE-spleen6 spontaneously immortalized cell line CVCL_BA02 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21133773 CVCL_9G71 DD1609 transformed cell line human CVCL_9G71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133774 CVCL_BA05 GM21639 transformed cell line human CVCL_BA05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133775 CVCL_9G70 DD1607 transformed cell line human CVCL_9G70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133776 CVCL_BA04 WErpe spontaneously immortalized cell line CVCL_BA04 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Unspecified Group: Fish cell line 21133777 CVCL_9G88 DD1648 finite cell line human CVCL_9G88 CL:0000010 Karyotypic information: 46,XX,del(22) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133778 CVCL_9G87 DD1646 transformed cell line human CVCL_9G87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133779 CVCL_9G89 DD1649 finite cell line human CVCL_9G89 CL:0000010 Karyotypic information: 46,XX,del(22) (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133780 CVCL_BA18 GM25370 transformed cell line human CVCL_BA18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133781 CVCL_BA17 GM25456 finite cell line human CVCL_BA17 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; c.62+1delGT; Zygosity=Unspecified; Note=De novo mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133782 CVCL_BA19 GM25371 finite cell line human CVCL_BA19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133783 CVCL_9G84 DD1642 finite cell line human CVCL_9G84 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133784 CVCL_BA10 GM21865 transformed cell line human CVCL_BA10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133785 CVCL_9G83 DD1641 finite cell line human CVCL_9G83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21133786 CVCL_9G86 DD1645 transformed cell line human CVCL_9G86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133787 CVCL_BA12 GM22063 transformed cell line human CVCL_BA12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133788 CVCL_9G85 DD1644 transformed cell line human CVCL_9G85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133789 CVCL_BA11 GM22279 finite cell line human CVCL_BA11 CL:0000010 Population: Caucasian. Male 21133790 CVCL_9G80 DD1632 transformed cell line human CVCL_9G80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133791 CVCL_BA14 GM23254 transformed cell line human CVCL_BA14 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133792 CVCL_BA13 GM22162 transformed cell line human CVCL_BA13 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133793 CVCL_9G82 DD1640 finite cell line human CVCL_9G82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133794 CVCL_BA16 GM25455 transformed cell line human CVCL_BA16 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; c.62+1delGT; Zygosity=Unspecified; Note=De novo mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133795 CVCL_9G81 DD1637 transformed cell line human CVCL_9G81 CL:0000010 Karyotypic information: 47,XY,+dic(15)(pter->q11::q11->pter)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133796 CVCL_BA15 GM23266 finite cell line human CVCL_BA15 CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21133797 CVCL_9G59 DD1582 transformed cell line human CVCL_9G59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133798 CVCL_9G58 DD1581 transformed cell line human CVCL_9G58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133799 CVCL_9G55 DD1578 transformed cell line human CVCL_9G55 CL:0000010 Karyotypic information: 46,XX,del(18)(q11.2;q21.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133800 CVCL_9G54 DD1576 transformed cell line human CVCL_9G54 CL:0000010 Karyotypic information: 46,XX,t(16;18)(q24;q21.1)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133801 CVCL_9G57 DD1580 transformed cell line human CVCL_9G57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133802 CVCL_9G56 DD1579 transformed cell line human CVCL_9G56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133803 CVCL_9G51 DD1573 transformed cell line human CVCL_9G51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133804 CVCL_9G50 DD1572 transformed cell line human CVCL_9G50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133805 CVCL_9G53 DD1575 transformed cell line human CVCL_9G53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133806 CVCL_9G52 DD1574 transformed cell line human CVCL_9G52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133807 CVCL_9G69 DD1604 transformed cell line human CVCL_9G69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133808 CVCL_9G66 DD1597 transformed cell line human CVCL_9G66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133809 CVCL_9G65 DD1595 finite cell line human CVCL_9G65 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133810 CVCL_9G68 DD1603 finite cell line human CVCL_9G68 CL:0000010 Karyotypic information: 46,XY,15p+ (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133811 CVCL_9G67 DD1599 finite cell line human CVCL_9G67 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133812 CVCL_9G62 DD1587 transformed cell line human CVCL_9G62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133813 CVCL_9G61 DD1586 transformed cell line human CVCL_9G61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133814 CVCL_9G64 DD1593 finite cell line human CVCL_9G64 CL:0000010 Karyotypic information: 46,XY,-7,+der(7),t(7;9)(q34.1;p24.1)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133815 CVCL_9G63 DD1589 transformed cell line human CVCL_9G63 CL:0000010 Karyotypic information: 46,XX,del(19)(q11.2;q21.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133816 CVCL_9G60 DD1585 transformed cell line human CVCL_9G60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133817 CVCL_9G37 DD1547 transformed cell line human CVCL_9G37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133818 CVCL_9G36 DD1546 transformed cell line human CVCL_9G36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133819 CVCL_9G39 DD1549 transformed cell line human CVCL_9G39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133820 CVCL_9G38 DD1548 transformed cell line human CVCL_9G38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133821 CVCL_9G33 DD1539 transformed cell line human CVCL_9G33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133822 CVCL_9G32 DD1538 transformed cell line human CVCL_9G32 CL:0000010 Karyotypic information: 46,XY,r(18)(p11.2;q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133823 CVCL_9G35 DD1544 finite cell line human CVCL_9G35 CL:0000010 Karyotypic information: 46,XY,inv(14)(?q22;?q24)(?) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133824 CVCL_9G34 DD1540 transformed cell line human CVCL_9G34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133825 CVCL_0M99 GM08211 transformed cell line human CVCL_0M99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133826 CVCL_9G31 DD1535 finite cell line human CVCL_9G31 CL:0000010 Karyotypic information: 46,XX; 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133827 CVCL_9G30 DD1531 transformed cell line human CVCL_9G30 CL:0000010 Karyotypic information: 46,XX,inv(12)(p13;q21)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133828 CVCL_9G48 DD1570 finite cell line human CVCL_9G48 CL:0000010 Karyotypic information: 46,XY,-7,+der(7)+(7;9)(q34.1;p24.1)pat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21133829 CVCL_9G47 DD1568 transformed cell line human CVCL_9G47 CL:0000010 Karyotypic information: 47,XY,+mar(13/21)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133830 CVCL_9G49 DD1571 transformed cell line human CVCL_9G49 CL:0000010 Karyotypic information: 47,XX,+dic(15) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133831 CVCL_9G44 DD1561 finite cell line human CVCL_9G44 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133832 CVCL_9G43 DD1560 finite cell line human CVCL_9G43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133833 CVCL_9G46 DD1566 transformed cell line human CVCL_9G46 CL:0000010 Karyotypic information: 46,XX,inv(7)(p15.1;q11.23)dup(15)(q11.2;q13)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133834 CVCL_9G45 DD1565 transformed cell line human CVCL_9G45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133835 CVCL_9G40 DD1550 transformed cell line human CVCL_9G40 CL:0000010 Karyotypic information: 46,X,der(X),t(X;10)(Xpter->q26;q24->10qter)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133836 CVCL_9G42 DD1554 transformed cell line human CVCL_9G42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133837 CVCL_9G41 DD1552 transformed cell line human CVCL_9G41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133838 CVCL_9G15 DD1497 transformed cell line human CVCL_9G15 CL:0000010 Karyotypic information: 46,XY,13p+ (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133839 CVCL_9G14 DD1496 transformed cell line human CVCL_9G14 CL:0000010 Karyotypic information: 46,XX,t(7;16)(p15;q22)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133840 CVCL_9G17 DD1503 transformed cell line human CVCL_9G17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133841 CVCL_9G16 DD1502 transformed cell line human CVCL_9G16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133842 CVCL_9G11 DD1493 finite cell line human CVCL_9G11 CL:0000010 Karyotypic information: 46,X,Yqs (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133843 CVCL_9G10 DD1491 transformed cell line human CVCL_9G10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133844 CVCL_9G13 DD1495 transformed cell line human CVCL_9G13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133845 CVCL_9G12 DD1494 transformed cell line human CVCL_9G12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133846 CVCL_0M81 GM07828 transformed cell line human CVCL_0M81 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133847 CVCL_0M80 GM07827 transformed cell line human CVCL_0M80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133848 CVCL_0M83 GM07830 transformed cell line human CVCL_0M83 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile142Phefs*11 (c.424delA) (556delA); ClinVar=VCV000007146; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133849 CVCL_0M82 GM07829 transformed cell line human CVCL_0M82 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile142Phefs*11 (c.424delA) (556delA); ClinVar=VCV000007146; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133850 CVCL_9G19 DD1507 finite cell line human CVCL_9G19 CL:0000010 Karyotypic information: 46,XY,inv(5)(p14;q14)mat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male Part of: ECACC chromosomal abnormality collection 21133851 CVCL_0M85 GM07832 transformed cell line human CVCL_0M85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133852 CVCL_9G18 DD1506 finite cell line human CVCL_9G18 CL:0000010 Karyotypic information: 46,XY; 46,XY,15p+ de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133853 CVCL_0M84 GM07831 transformed cell line human CVCL_0M84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133854 CVCL_0M87 GM07852 transformed cell line human CVCL_0M87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07734 (Cellosaurus=CVCL_0M73); Derived from sampling site: Peripheral blood. Female 21133855 CVCL_0M86 GM07850 transformed cell line human CVCL_0M86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133856 CVCL_0M78 GM07825 transformed cell line human CVCL_0M78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133857 CVCL_0M77 GM07824 transformed cell line human CVCL_0M77 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133858 CVCL_0M79 GM07826 transformed cell line human CVCL_0M79 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133859 CVCL_9G26 DD1519 transformed cell line human CVCL_9G26 CL:0000010 Karyotypic information: 46,XY,t(1;17)(q32;q13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133860 CVCL_9G25 DD1518 transformed cell line human CVCL_9G25 CL:0000010 Karyotypic information: 46,XY,t(1;17)(q32.3;p13.3)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133861 CVCL_9G28 DD1524 finite cell line human CVCL_9G28 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21133862 CVCL_9G27 DD1521 transformed cell line human CVCL_9G27 CL:0000010 Karyotypic information: 46,XX,t(16;18)(q24;q21.1)(?) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133863 CVCL_9G22 DD1515 transformed cell line human CVCL_9G22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133864 CVCL_9G21 DD1510 finite cell line human CVCL_9G21 CL:0000010 Karyotypic information: 46,XY [29]; 46,XY,15p+ [1] (ECACC); Derived from sampling site: Amnion Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21133865 CVCL_9G24 DD1517 transformed cell line human CVCL_9G24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133866 CVCL_0M90 GM07855 transformed cell line human CVCL_0M90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133867 CVCL_9G23 DD1516 finite cell line human CVCL_9G23 CL:0000010 Karyotypic information: 46,XY; 46,XY,15p+ (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21133868 CVCL_0M92 GM07857 transformed cell line human CVCL_0M92 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Met1101Lys (c.3302T>A); ClinVar=VCV000039516; Zygosity=Homozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21133869 CVCL_0M91 GM07856 transformed cell line human CVCL_0M91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133870 CVCL_0M94 GM07859 transformed cell line human CVCL_0M94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133871 CVCL_0M93 GM07858 transformed cell line human CVCL_0M93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133872 CVCL_0M96 GM07902 transformed cell line human CVCL_0M96 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from familial inference of GM07904) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07904 (Cellosaurus=CVCL_OM98); Derived from sampling site: Peripheral blood. Female 21133873 CVCL_9G29 DD1529 transformed cell line human CVCL_9G29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133874 CVCL_0M95 GM07860 transformed cell line human CVCL_0M95 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Met1101Lys (c.3302T>A); ClinVar=VCV000039516; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133875 CVCL_0M98 GM07904 transformed cell line human CVCL_0M98 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM07902 (Cellosaurus=CVCL_OM96); Derived from sampling site: Peripheral blood. Female 21133876 CVCL_0M97 GM07903 transformed cell line human CVCL_0M97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133877 CVCL_0M89 GM07854 transformed cell line human CVCL_0M89 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Met1101Lys (c.3302T>A); ClinVar=VCV000039516; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM07854; probable Male 21133878 CVCL_0M88 GM07853 transformed cell line human CVCL_0M88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133879 CVCL_9G20 DD1508 finite cell line human CVCL_9G20 CL:0000010 Karyotypic information: 46,XY [25]; 46,XY,15p+ [5] (ECACC); Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21133880 CVCL_BA90 ND08469 transformed cell line human CVCL_BA90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133881 CVCL_BA92 ND08531 transformed cell line human CVCL_BA92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133882 CVCL_BA91 ND08470 transformed cell line human CVCL_BA91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133883 CVCL_JZ28 MR-21 cancer cell line human CVCL_JZ28 CL:0000010 21133884 CVCL_BA94 ND08585 transformed cell line human CVCL_BA94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133885 CVCL_JZ27 MR-20 cancer cell line human CVCL_JZ27 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 3 days (PubMed=2986245) 21133886 CVCL_BA93 ND08554 transformed cell line human CVCL_BA93 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133887 CVCL_BA96 ND08618 transformed cell line human CVCL_BA96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133888 CVCL_JZ29 MR-22 cancer cell line human CVCL_JZ29 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 2 days (PubMed=2986245); 4 days (PubMed=2988594) 21133889 CVCL_BA95 ND08617 transformed cell line human CVCL_BA95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133890 CVCL_JZ24 MR-9 cancer cell line human CVCL_JZ24 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 1.5 days (PubMed=2986245; PubMed=2988594) 21133891 CVCL_JZ23 MR-8 cancer cell line human CVCL_JZ23 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 3 days (PubMed=2986245; PubMed=2988594) 21133892 CVCL_JZ26 MR-16 cancer cell line human CVCL_JZ26 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 3 days (PubMed=2986245) 21133893 CVCL_JZ25 MR-13 cancer cell line human CVCL_JZ25 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 6 days (PubMed=2986245; PubMed=2988594) 21133894 CVCL_JZ20 MR-4 cancer cell line human CVCL_JZ20 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 4 days (PubMed=2986245) 21133895 CVCL_JZ22 MR-7 cancer cell line human CVCL_JZ22 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 2 days (PubMed=2986245) 21133896 CVCL_JZ21 MR-5 cancer cell line human CVCL_JZ21 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 1-3 days (PubMed=2986245; PubMed=2988594) 21133897 CVCL_BA87 ND08360 transformed cell line human CVCL_BA87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133898 CVCL_BA86 ND08308 transformed cell line human CVCL_BA86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133899 CVCL_BA89 ND08466 transformed cell line human CVCL_BA89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133900 CVCL_BA88 ND08455 transformed cell line human CVCL_BA88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133901 CVCL_JZ39 MR-65 cancer cell line human CVCL_JZ39 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 1 day (PubMed=2986245; PubMed=2988594) 21133902 CVCL_JZ38 MR-58 cancer cell line human CVCL_JZ38 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 5 days (PubMed=2986245) 21133903 CVCL_JZ35 MR-33 cancer cell line human CVCL_JZ35 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 0.5 day (PubMed=2986245) 21133904 CVCL_JZ34 MR-32 cancer cell line human CVCL_JZ34 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 1.5 days (PubMed=2986245; PubMed=2988594) 21133905 CVCL_JZ37 MR-55 cancer cell line human CVCL_JZ37 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 5 days (PubMed=2986245; PubMed=2988594) 21133906 CVCL_JZ36 MR-50 cancer cell line human CVCL_JZ36 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 2 days (PubMed=2986245) 21133907 CVCL_JZ31 MR-26 cancer cell line human CVCL_JZ31 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 20 days (PubMed=2986245) 21133908 CVCL_JZ30 MR-25 cancer cell line human CVCL_JZ30 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 1 day (PubMed=2986245; PubMed=2988594) 21133909 CVCL_JZ33 MR-28 cancer cell line human CVCL_JZ33 CL:0000010 Derived from metastatic site: Bone marrow. Male Doubling time: 10 days (PubMed=2986245) 21133910 CVCL_JZ32 MR-27 cancer cell line human CVCL_JZ32 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 15 days (PubMed=2986245) 21133911 CVCL_BA98 ND08630 transformed cell line human CVCL_BA98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133912 CVCL_BA97 ND08619 transformed cell line human CVCL_BA97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133913 CVCL_BA99 ND08631 transformed cell line human CVCL_BA99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133914 CVCL_JZ09 293LTV transformed cell line human CVCL_JZ09 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Specifically selected for high level of lentiviral production Group: Retrovirus packaging cell line 21133915 CVCL_BA70 ND07475 transformed cell line human CVCL_BA70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133916 CVCL_JZ06 MDA-MB-231/RFP cancer cell line human CVCL_JZ06 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-251; probable Female Group: Triple negative breast cancer (TNBC) cell line 21133917 CVCL_BA72 ND07508 transformed cell line human CVCL_BA72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133918 CVCL_JZ05 MDA-MB-231/Luc cancer cell line human CVCL_JZ05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-231; probable Female Group: Triple negative breast cancer (TNBC) cell line 21133919 CVCL_BA71 ND07489 transformed cell line human CVCL_BA71 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133920 CVCL_JZ08 JK1 spontaneously immortalized cell line house mouse CVCL_JZ08 CL:0000010 Derived from sampling site: Testis Cell type=Stromal cell.; Breed/subspecies: C57BL/6. Male Characteristics: Supports the long-term proliferation of stem cells May be used to culture a variety of cell types including ES cells, germ-line derived stem cells and primordial germ cell-derived EG cells. 21133921 CVCL_BA74 ND07694 transformed cell line human CVCL_BA74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133922 CVCL_BA73 ND07669 transformed cell line human CVCL_BA73 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133923 CVCL_JZ07 SNLH9 transformed cell line house mouse CVCL_JZ07 CL:0000010 Transfected with: MGI; MGI:96787; Lif; Transfected with: UniProtKB; P09979; Streptomyces hygroscopicus hyg; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Mixed 21133924 CVCL_JZ02 293T/GFP-Puro transformed cell line human CVCL_JZ02 CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Cell_Biolabs; AKR-202; probable Female 21133925 CVCL_JZ01 293/CFP transformed cell line human CVCL_JZ01 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; Q66PV6; CFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Cell_Biolabs; AKR-270; probable Female 21133926 CVCL_JZ04 MDA-MB-231/GFP-RFP cancer cell line human CVCL_JZ04 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-221; probable Female Group: Triple negative breast cancer (TNBC) cell line 21133927 CVCL_JZ03 MDA-MB-231/GFP cancer cell line human CVCL_JZ03 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-201; probable Female Group: Triple negative breast cancer (TNBC) cell line 21133928 CVCL_JZ00 MDA-MB-468/GFP cancer cell line human CVCL_JZ00 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: African American; Derived from metastatic site: Pleural effusion. Discontinued: Cell_Biolabs; AKR-204; probable Female Group: Triple negative breast cancer (TNBC) cell line 21133929 CVCL_BA65 ND07156 transformed cell line human CVCL_BA65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133930 CVCL_BA64 ND07155 transformed cell line human CVCL_BA64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133931 CVCL_BA67 ND07314 transformed cell line human CVCL_BA67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133932 CVCL_BA66 ND07157 transformed cell line human CVCL_BA66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133933 CVCL_BA69 ND07474 transformed cell line human CVCL_BA69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133934 CVCL_BA68 ND07333 transformed cell line human CVCL_BA68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133935 CVCL_BA81 ND07995 transformed cell line human CVCL_BA81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133936 CVCL_BA80 ND07994 transformed cell line human CVCL_BA80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133937 CVCL_JZ17 NCI-H175 cancer cell line human CVCL_JZ17 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21133938 CVCL_BA83 ND08078 transformed cell line human CVCL_BA83 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133939 CVCL_BA82 ND08076 transformed cell line human CVCL_BA82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133940 CVCL_JZ16 RuGli cancer cell line Norway rat CVCL_JZ16 CL:0000010 Miscellaneous: Possibly identical to the C6 (Cellosaurus=CVCL_0194) rat glioma cell line (personal communication of Goodman S.-L.) Experimental confirmation of such a relationship would be very welcome.. Unspecified Problematic cell line: Misidentified Originally thought to be established from a human glioblastoma but found to be from rat (PubMed=2526967). 21133941 CVCL_JZ19 MR-2 cancer cell line human CVCL_JZ19 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 10 days (PubMed=2986245) 21133942 CVCL_BA85 ND08242 transformed cell line human CVCL_BA85 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND08243 (Cellosaurus=CVCL_DR38); Derived from sampling site: Peripheral blood. Male 21133943 CVCL_JZ18 DMS 240 cancer cell line human CVCL_JZ18 CL:0000010 Unspecified Doubling time: 4.6 days (PubMed=2986244). 21133944 CVCL_BA84 ND08127 transformed cell line human CVCL_BA84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133945 CVCL_JZ13 M21L4 cancer cell line human CVCL_JZ13 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6150; ITGAV; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Not specified. Female 21133946 CVCL_JZ12 M21L cancer cell line human CVCL_JZ12 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Not specified. Female Characteristics: Lacks expression of integrin alpha-V (ITGAV) 21133947 CVCL_JZ15 HeLa/crmA cancer cell line human CVCL_JZ15 CL:0000010 Transfected with: UniProtKB; P07385; Cowpox virus crmA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21133948 CVCL_JZ14 M21L22 cancer cell line human CVCL_JZ14 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6150; ITGAV; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Not specified. Female 21133949 CVCL_JZ11 HEY/GFP cancer cell line human CVCL_JZ11 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian Discontinued: Cell_Biolabs; AKR-205; probable. Female 21133950 CVCL_JZ10 293RTV transformed cell line human CVCL_JZ10 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Specifically selected for high level of retroviral production 21133951 CVCL_BA76 ND07738 transformed cell line human CVCL_BA76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133952 CVCL_BA75 ND07735 transformed cell line human CVCL_BA75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133953 CVCL_BA78 ND07920 transformed cell line human CVCL_BA78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133954 CVCL_BA77 ND07739 transformed cell line human CVCL_BA77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133955 CVCL_BA79 ND07921 transformed cell line human CVCL_BA79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133956 CVCL_BA50 ND06192 transformed cell line human CVCL_BA50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133957 CVCL_BA52 ND06594 transformed cell line human CVCL_BA52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133958 CVCL_BA51 ND06593 transformed cell line human CVCL_BA51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133959 CVCL_BA43 ND06184 transformed cell line human CVCL_BA43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133960 CVCL_BA42 ND06183 transformed cell line human CVCL_BA42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133961 CVCL_BA45 ND06186 transformed cell line human CVCL_BA45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133962 CVCL_BA44 ND06185 transformed cell line human CVCL_BA44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133963 CVCL_BA47 ND06189 transformed cell line human CVCL_BA47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133964 CVCL_BA46 ND06187 transformed cell line human CVCL_BA46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133965 CVCL_BA49 ND06191 transformed cell line human CVCL_BA49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133966 CVCL_BA48 ND06190 transformed cell line human CVCL_BA48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133967 CVCL_BA61 ND07066 transformed cell line human CVCL_BA61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133968 CVCL_BA60 ND07065 transformed cell line human CVCL_BA60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133969 CVCL_BA63 ND07154 transformed cell line human CVCL_BA63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133970 CVCL_BA62 ND07106 transformed cell line human CVCL_BA62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133971 CVCL_BA54 ND06751 transformed cell line human CVCL_BA54 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133972 CVCL_BA53 ND06595 transformed cell line human CVCL_BA53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133973 CVCL_BA56 ND06843 transformed cell line human CVCL_BA56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133974 CVCL_BA55 ND06769 transformed cell line human CVCL_BA55 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Welsh; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND06769; probable Female 21133975 CVCL_BA58 ND06987 transformed cell line human CVCL_BA58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133976 CVCL_BA57 ND06880 transformed cell line human CVCL_BA57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133977 CVCL_BA59 ND06988 transformed cell line human CVCL_BA59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133978 CVCL_9G99 DD1669 transformed cell line human CVCL_9G99 CL:0000010 Karyotypic information: 46,XY,t(1;18) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133979 CVCL_9G98 DD1668 transformed cell line human CVCL_9G98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133980 CVCL_BA30 ND06170 transformed cell line human CVCL_BA30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133981 CVCL_BA29 ND04064 transformed cell line human CVCL_BA29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133982 CVCL_BA28 ND04060 transformed cell line human CVCL_BA28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133983 CVCL_9G95 DD1661 transformed cell line human CVCL_9G95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133984 CVCL_BA21 ND04051 transformed cell line human CVCL_BA21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133985 CVCL_9G94 DD1660 transformed cell line human CVCL_9G94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133986 CVCL_BA20 ND02423 transformed cell line human CVCL_BA20 CL:0000010 Population: Caucasian; Welsh; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133987 CVCL_9G97 DD1666 transformed cell line human CVCL_9G97 CL:0000010 Karyotypic information: 46,XX,t(1;15)(q14.2;q26.3)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133988 CVCL_BA23 ND04054 transformed cell line human CVCL_BA23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133989 CVCL_9G96 DD1662 transformed cell line human CVCL_9G96 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+18 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133990 CVCL_BA22 ND04052 transformed cell line human CVCL_BA22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133991 CVCL_9G91 DD1655 transformed cell line human CVCL_9G91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133992 CVCL_BA25 ND04056 transformed cell line human CVCL_BA25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133993 CVCL_9G90 DD1654 finite cell line human CVCL_9G90 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21133994 CVCL_BA24 ND04055 transformed cell line human CVCL_BA24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21133995 CVCL_9G93 DD1658 transformed cell line human CVCL_9G93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21133996 CVCL_BA27 ND04059 transformed cell line human CVCL_BA27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133997 CVCL_9G92 DD1656 transformed cell line human CVCL_9G92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21133998 CVCL_BA26 ND04058 transformed cell line human CVCL_BA26 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21133999 CVCL_BA41 ND06182 transformed cell line human CVCL_BA41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134000 CVCL_BA40 ND06181 transformed cell line human CVCL_BA40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134001 CVCL_BA39 ND06180 transformed cell line human CVCL_BA39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134002 CVCL_BA32 ND06173 transformed cell line human CVCL_BA32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134003 CVCL_BA31 ND06171 transformed cell line human CVCL_BA31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134004 CVCL_BA34 ND06175 transformed cell line human CVCL_BA34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134005 CVCL_BA33 ND06174 transformed cell line human CVCL_BA33 CL:0000010 Population: Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134006 CVCL_BA36 ND06177 transformed cell line human CVCL_BA36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134007 CVCL_BA35 ND06176 transformed cell line human CVCL_BA35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134008 CVCL_BA38 ND06179 transformed cell line human CVCL_BA38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134009 CVCL_BA37 ND06178 transformed cell line human CVCL_BA37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134010 CVCL_SU62 HAP1 KIAA0196 (-) 3 cancer cell line human CVCL_SU62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28984; WASHC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134011 CVCL_T662 MDCC-MSB1-Clo. 18 cancer cell line CVCL_T662 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387). Female Characteristics: Transplantable subline of MDCC-MSB1 Group: Bird cell line 21134012 CVCL_SU61 HAP1 KIAA0196 (-) 2 cancer cell line human CVCL_SU61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28984; WASHC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134013 CVCL_T661 MDCC-MSB1-41C cancer cell line CVCL_T661 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387). Female Characteristics: Transplantable subline of MDCC-MSB1 Doubling time: 18.4 hours (PubMed=3273463) Group: Bird cell line 21134014 CVCL_SU64 HAP1 KIAA1244 (-) 2 cancer cell line human CVCL_SU64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21213; ARFGEF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134015 CVCL_T664 MDTC-CU45 cancer cell line CVCL_T664 CL:0000010 Male Group: Bird cell line. 21134016 CVCL_SU63 HAP1 KIAA1244 (-) 1 cancer cell line human CVCL_SU63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21213; ARFGEF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134017 CVCL_T663 MDTC-CU44 cancer cell line CVCL_T663 CL:0000010 Male Group: Bird cell line. 21134018 CVCL_SU66 HAP1 KIAA1804 (-) 1 cancer cell line human CVCL_SU66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29798; MAP3K21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134019 CVCL_T666 MDTC-HP114-1 cancer cell line CVCL_T666 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134020 CVCL_SU65 HAP1 KIAA1524 (-) 1 cancer cell line human CVCL_SU65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29302; CIP2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134021 CVCL_T665 MDTC-CU46 cancer cell line CVCL_T665 CL:0000010 Female Group: Bird cell line. 21134022 CVCL_SU68 HAP1 KIAA1804 (-) 3 cancer cell line human CVCL_SU68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29798; MAP3K21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134023 CVCL_T668 MDTC-HP115 cancer cell line CVCL_T668 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134024 CVCL_SU67 HAP1 KIAA1804 (-) 2 cancer cell line human CVCL_SU67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29798; MAP3K21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134025 CVCL_T667 MDTC-HP114-2 cancer cell line CVCL_T667 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134026 CVCL_SU69 HAP1 KIAA1804 (-) 4 cancer cell line human CVCL_SU69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29798; MAP3K21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134027 CVCL_T669 MDTC-HP116 cancer cell line CVCL_T669 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134028 CVCL_1010 Hs 910.Sk finite cell line human CVCL_1010 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7894; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134029 CVCL_1012 Hs 912.T cancer cell line human CVCL_1012 CL:0000010 Discontinued: ATCC; CRL-7661; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134030 CVCL_1011 Hs 910.Thm finite cell line human CVCL_1011 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-7660; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134031 CVCL_1014 Hs 913(C).T cancer cell line human CVCL_1014 CL:0000010 Discontinued: ATCC; CRL-7665; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134032 CVCL_1013 Hs 913(B).T cancer cell line human CVCL_1013 CL:0000010 Discontinued: ATCC; CRL-7664; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134033 CVCL_1016 Hs 913(F).T cancer cell line human CVCL_1016 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21134034 CVCL_1015 Hs 913(D).T cancer cell line human CVCL_1015 CL:0000010 Discontinued: ATCC; CRL-7666; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134035 CVCL_1018 Hs 914 undefined cell line type human CVCL_1018 CL:0000010 Discontinued: ATCC; CRL-7895; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134036 CVCL_1017 Hs 913T cancer cell line human CVCL_1017 CL:0000010 Male 21134037 CVCL_1019 Hs 915 undefined cell line type human CVCL_1019 CL:0000010 Discontinued: ATCC; CRL-7896; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134038 CVCL_SU71 HAP1 KIF15 (-) 2 cancer cell line human CVCL_SU71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17273; KIF15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134039 CVCL_T671 MDTC-HP118 cancer cell line CVCL_T671 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134040 CVCL_SU70 HAP1 KIF15 (-) 1 cancer cell line human CVCL_SU70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17273; KIF15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134041 CVCL_T670 MDTC-HP117 cancer cell line CVCL_T670 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134042 CVCL_SU51 HAP1 KDM6B (-) 1 cancer cell line human CVCL_SU51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134043 CVCL_T651 MDCC-BMCL2-20C1 cancer cell line CVCL_T651 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: BM-C. Group: Bird cell line 21134044 CVCL_SU50 HAP1 KDM6A (-) 3 cancer cell line human CVCL_SU50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134045 CVCL_T650 MDCC-BMCL2-1C2 cancer cell line CVCL_T650 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: BM-C. Group: Bird cell line 21134046 CVCL_SU53 HAP1 KDM7A (-) 1 cancer cell line human CVCL_SU53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22224; KDM7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134047 CVCL_T653 MDCC-RP23 cancer cell line CVCL_T653 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21134048 CVCL_SU52 HAP1 KDM6B (-) 2 cancer cell line human CVCL_SU52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134049 CVCL_T652 MDCC-RP22 cancer cell line CVCL_T652 CL:0000010 Female Group: Bird cell line. 21134050 CVCL_SU55 HAP1 KDR (-) 1 cancer cell line human CVCL_SU55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6307; KDR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134051 CVCL_T655 MDCC-RP25 cancer cell line CVCL_T655 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21134052 CVCL_SU54 HAP1 KDM7A (-) 2 cancer cell line human CVCL_SU54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22224; KDM7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134053 CVCL_T654 MDCC-RP24 cancer cell line CVCL_T654 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21134054 CVCL_SU57 HAP1 KEAP1 (-) 1 cancer cell line human CVCL_SU57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134055 CVCL_T657 MDCC-RP27 cancer cell line CVCL_T657 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Female Group: Bird cell line 21134056 CVCL_SU56 HAP1 KDR (-) 2 cancer cell line human CVCL_SU56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6307; KDR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134057 CVCL_T656 MDCC-RP26 cancer cell line CVCL_T656 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21134058 CVCL_SU59 HAP1 KIAA0100 (-) 1 cancer cell line human CVCL_SU59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28960; BLTP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134059 CVCL_T659 MDCC-RP29 cancer cell line CVCL_T659 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21134060 CVCL_SU58 HAP1 KEAP1 (-) 2 cancer cell line human CVCL_SU58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23177; KEAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134061 CVCL_T658 MDCC-RP28 cancer cell line CVCL_T658 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21134062 CVCL_1030 Hs 933.T undefined cell line type human CVCL_1030 CL:0000010 Discontinued: ATCC; CRL-7683; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134063 CVCL_1021 Hs 917.T finite cell line human CVCL_1021 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134064 CVCL_1020 Hs 916 undefined cell line type human CVCL_1020 CL:0000010 Discontinued: ATCC; CRL-7897; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134065 CVCL_1023 Hs 919.T cancer cell line human CVCL_1023 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21134066 CVCL_1022 Hs 919.Sk finite cell line human CVCL_1022 CL:0000010 Derived from sampling site: Skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134067 CVCL_1025 Hs 925.Sk finite cell line human CVCL_1025 CL:0000010 Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134068 CVCL_1024 Hs 924.Sk finite cell line human CVCL_1024 CL:0000010 Population: Pacific; Micronesian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7674; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134069 CVCL_1027 Hs 926.T cancer cell line human CVCL_1027 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21134070 CVCL_1026 Hs 925.T cancer cell line human CVCL_1026 CL:0000010 Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134071 CVCL_1029 Hs 93.T cancer cell line human CVCL_1029 CL:0000010 Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21134072 CVCL_1028 Hs 929.Sk finite cell line human CVCL_1028 CL:0000010 Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134073 CVCL_SU60 HAP1 KIAA0196 (-) 1 cancer cell line human CVCL_SU60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28984; WASHC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134074 CVCL_T660 MDCC-MSB1-33C cancer cell line CVCL_T660 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387). Female Group: Bird cell line 21134075 CVCL_SU40 HAP1 KDM5A (-) 1 cancer cell line human CVCL_SU40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9886; KDM5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134076 CVCL_T640 LSQC-17 transformed cell line CVCL_T640 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134077 CVCL_SU42 HAP1 KDM5B (-) 1 cancer cell line human CVCL_SU42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134078 CVCL_T642 LSQC-23 transformed cell line CVCL_T642 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134079 CVCL_SU41 HAP1 KDM5A (-) 2 cancer cell line human CVCL_SU41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9886; KDM5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134080 CVCL_T641 LSQC-18 transformed cell line CVCL_T641 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134081 CVCL_SU44 HAP1 KDM5B (-) 3 cancer cell line human CVCL_SU44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134082 CVCL_T644 LSCC-PR2 cancer cell line CVCL_T644 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Liver. Doubling time: 1.1 days (PubMed=18770161) Group: Bird cell line 21134083 CVCL_SU43 HAP1 KDM5B (-) 2 cancer cell line human CVCL_SU43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18039; KDM5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134084 CVCL_T643 LSCC-NV1 cancer cell line CVCL_T643 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864). Female Group: Bird cell line 21134085 CVCL_SU46 HAP1 KDM5C (-) 2 cancer cell line human CVCL_SU46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11114; KDM5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134086 CVCL_T646 MDCC-BP2 cancer cell line CVCL_T646 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21134087 CVCL_SU45 HAP1 KDM5C (-) 1 cancer cell line human CVCL_SU45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11114; KDM5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134088 CVCL_T645 MDCC-BP1 cancer cell line CVCL_T645 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21134089 CVCL_SU48 HAP1 KDM6A (-) 1 cancer cell line human CVCL_SU48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134090 CVCL_T648 MDCC-BP4 cancer cell line CVCL_T648 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21134091 CVCL_SU47 HAP1 KDM5C (-) 3 cancer cell line human CVCL_SU47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11114; KDM5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134092 CVCL_T647 MDCC-BP3 cancer cell line CVCL_T647 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Group: Bird cell line 21134093 CVCL_SU49 HAP1 KDM6A (-) 2 cancer cell line human CVCL_SU49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12637; KDM6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134094 CVCL_T649 MDCC-BMCL2-1C10 cancer cell line CVCL_T649 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: BM-C. Group: Bird cell line 21134095 CVCL_SU31 HAP1 KDM4B (-) 2 cancer cell line human CVCL_SU31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29136; KDM4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134096 CVCL_T631 LSQC-1 transformed cell line CVCL_T631 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134097 CVCL_SU30 HAP1 KDM4B (-) 1 cancer cell line human CVCL_SU30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29136; KDM4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134098 CVCL_T630 MDCC-PA9 cancer cell line CVCL_T630 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21134099 CVCL_SU33 HAP1 KDM4D (-) 1 cancer cell line human CVCL_SU33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25498; KDM4D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134100 CVCL_T633 LSQC-2 transformed cell line CVCL_T633 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134101 CVCL_SU32 HAP1 KDM4C (-) cancer cell line human CVCL_SU32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17071; KDM4C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134102 CVCL_T632 LSQC-1C transformed cell line CVCL_T632 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134103 CVCL_SU35 HAP1 KDM4E (-) 1 cancer cell line human CVCL_SU35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37098; KDM4E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134104 CVCL_T635 LSQC-6 transformed cell line CVCL_T635 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134105 CVCL_SU34 HAP1 KDM4D (-) 2 cancer cell line human CVCL_SU34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25498; KDM4D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134106 CVCL_T634 LSQC-3C transformed cell line CVCL_T634 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134107 CVCL_SU37 HAP1 KDM4E (-) 3 cancer cell line human CVCL_SU37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37098; KDM4E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134108 CVCL_T637 LSQC-9C transformed cell line CVCL_T637 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134109 CVCL_SU36 HAP1 KDM4E (-) 2 cancer cell line human CVCL_SU36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37098; KDM4E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134110 CVCL_T636 LSQC-7 transformed cell line CVCL_T636 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134111 CVCL_SU39 HAP1 KDM4E (-) 5 cancer cell line human CVCL_SU39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37098; KDM4E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134112 CVCL_T639 LSQC-14 transformed cell line CVCL_T639 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134113 CVCL_SU38 HAP1 KDM4E (-) 4 cancer cell line human CVCL_SU38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37098; KDM4E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134114 CVCL_T638 LSQC-11 transformed cell line CVCL_T638 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21134115 CVCL_1001 Hs 903.Sk finite cell line human CVCL_1001 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7648; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134116 CVCL_1000 Hs 900.T cancer cell line human CVCL_1000 CL:0000010 Discontinued: ATCC; CRL-7646; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134117 CVCL_1003 Hs 904.Sk finite cell line human CVCL_1003 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7650; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134118 CVCL_1002 Hs 903.T cancer cell line human CVCL_1002 CL:0000010 Discontinued: ATCC; CRL-7649; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134119 CVCL_1005 Hs 905.T cancer cell line human CVCL_1005 CL:0000010 Discontinued: ATCC; CRL-7652; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134120 CVCL_1004 Hs 904.T cancer cell line human CVCL_1004 CL:0000010 Discontinued: ATCC; CRL-7651; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134121 CVCL_1007 Hs 906(B).T cancer cell line human CVCL_1007 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134122 CVCL_1006 Hs 906(A).M cancer cell line human CVCL_1006 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134123 CVCL_1009 Hs 908.T cancer cell line human CVCL_1009 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Discontinued: ATCC; CRL-7658; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134124 CVCL_1008 Hs 907.Lu finite cell line human CVCL_1008 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-7657; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134125 CVCL_SU20 HAP1 KDM2A (-) 4 cancer cell line human CVCL_SU20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13606; KDM2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134126 CVCL_T620 MDCC-HP23 cancer cell line CVCL_T620 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: RPRL-6. Female Group: Bird cell line 21134127 CVCL_SU22 HAP1 KDM3A (-) 1 cancer cell line human CVCL_SU22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20815; KDM3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134128 CVCL_T622 MDCC-HP25 cancer cell line CVCL_T622 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134129 CVCL_SU21 HAP1 KDM2B (-) cancer cell line human CVCL_SU21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13610; KDM2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134130 CVCL_T621 MDCC-HP24 cancer cell line CVCL_T621 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Male Group: Bird cell line 21134131 CVCL_SU24 HAP1 KDM3B (-) 1 cancer cell line human CVCL_SU24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1337; KDM3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134132 CVCL_T624 MDCC-HP27 cancer cell line CVCL_T624 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Male Group: Bird cell line 21134133 CVCL_SU23 HAP1 KDM3A (-) 2 cancer cell line human CVCL_SU23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20815; KDM3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134134 CVCL_T623 MDCC-HP26 cancer cell line CVCL_T623 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134135 CVCL_SU26 HAP1 KDM3B (-) 3 cancer cell line human CVCL_SU26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1337; KDM3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134136 CVCL_T626 MDCC-HP29 cancer cell line CVCL_T626 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134137 CVCL_SU25 HAP1 KDM3B (-) 2 cancer cell line human CVCL_SU25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1337; KDM3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134138 CVCL_T625 MDCC-HP28 cancer cell line CVCL_T625 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: RPRL-6. Female Group: Bird cell line 21134139 CVCL_SU28 HAP1 KDM4A (-) 2 cancer cell line human CVCL_SU28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22978; KDM4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134140 CVCL_T628 MDCC-HP31 cancer cell line CVCL_T628 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Male Group: Bird cell line 21134141 CVCL_SU27 HAP1 KDM4A (-) 1 cancer cell line human CVCL_SU27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22978; KDM4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134142 CVCL_T627 MDCC-HP30 cancer cell line CVCL_T627 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134143 CVCL_SU29 HAP1 KDM4A (-) 3 cancer cell line human CVCL_SU29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22978; KDM4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134144 CVCL_T629 MDCC-PA5 cancer cell line CVCL_T629 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390). Male Group: Bird cell line 21134145 CVCL_SU11 HAP1 KCNQ1 (-) 4 cancer cell line human CVCL_SU11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6294; KCNQ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134146 CVCL_T611 MDCC-HP14 cancer cell line CVCL_T611 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134147 CVCL_SU10 HAP1 KCNQ1 (-) 3 cancer cell line human CVCL_SU10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6294; KCNQ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134148 CVCL_T610 MDCC-HP13 cancer cell line CVCL_T610 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134149 CVCL_SU13 HAP1 KCNQ2 (-) 2 cancer cell line human CVCL_SU13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6296; KCNQ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134150 CVCL_T613 MDCC-HP16 cancer cell line CVCL_T613 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: RPRL-6. Female Group: Bird cell line 21134151 CVCL_SU12 HAP1 KCNQ2 (-) 1 cancer cell line human CVCL_SU12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6296; KCNQ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134152 CVCL_T612 MDCC-HP15 cancer cell line CVCL_T612 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134153 CVCL_SU15 HAP1 KDM1B (-) 1 cancer cell line human CVCL_SU15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134154 CVCL_T615 MDCC-HP18 cancer cell line CVCL_T615 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134155 CVCL_SU14 HAP1 KDELR1 (-) 1 cancer cell line human CVCL_SU14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6304; KDELR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134156 CVCL_T614 MDCC-HP17 cancer cell line CVCL_T614 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134157 CVCL_SU17 HAP1 KDM2A (-) 1 cancer cell line human CVCL_SU17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13606; KDM2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134158 CVCL_T617 MDCC-HP20 cancer cell line CVCL_T617 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134159 CVCL_SU16 HAP1 KDM1B (-) 2 cancer cell line human CVCL_SU16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134160 CVCL_T616 MDCC-HP19 cancer cell line CVCL_T616 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Male Group: Bird cell line 21134161 CVCL_SU19 HAP1 KDM2A (-) 3 cancer cell line human CVCL_SU19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13606; KDM2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134162 CVCL_T619 MDCC-HP22 cancer cell line CVCL_T619 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134163 CVCL_SU18 HAP1 KDM2A (-) 2 cancer cell line human CVCL_SU18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13606; KDM2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134164 CVCL_T618 MDCC-HP21 cancer cell line CVCL_T618 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134165 CVCL_SU00 HAP1 KCNH2 (-) 2 cancer cell line human CVCL_SU00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6251; KCNH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134166 CVCL_T600 MDCC-HP3 cancer cell line CVCL_T600 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134167 CVCL_SU02 HAP1 KCNJ11 (-) 2 cancer cell line human CVCL_SU02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6257; KCNJ11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134168 CVCL_T602 MDCC-HP5 cancer cell line CVCL_T602 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134169 CVCL_SU01 HAP1 KCNJ11 (-) 1 cancer cell line human CVCL_SU01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6257; KCNJ11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134170 CVCL_T601 MDCC-HP4 cancer cell line CVCL_T601 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134171 CVCL_SU04 HAP1 KCNK1 (-) 2 cancer cell line human CVCL_SU04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6272; KCNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134172 CVCL_T604 MDCC-HP7 cancer cell line CVCL_T604 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134173 CVCL_SU03 HAP1 KCNK1 (-) 1 cancer cell line human CVCL_SU03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6272; KCNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134174 CVCL_T603 MDCC-HP6 cancer cell line CVCL_T603 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134175 CVCL_SU06 HAP1 KCNK2 (-) 1 cancer cell line human CVCL_SU06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6277; KCNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134176 CVCL_T606 MDCC-HP9 cancer cell line CVCL_T606 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: RPRL-7. Male Group: Bird cell line 21134177 CVCL_SU05 HAP1 KCNK1 (-) 3 cancer cell line human CVCL_SU05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6272; KCNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134178 CVCL_T605 MDCC-HP8 cancer cell line CVCL_T605 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: RPRL-7. Female Group: Bird cell line 21134179 CVCL_SU08 HAP1 KCNQ1 (-) 1 cancer cell line human CVCL_SU08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6294; KCNQ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134180 CVCL_T608 MDCC-HP11 cancer cell line CVCL_T608 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134181 CVCL_SU07 HAP1 KCNK2 (-) 2 cancer cell line human CVCL_SU07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6277; KCNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134182 CVCL_T607 MDCC-HP10 cancer cell line CVCL_T607 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134183 CVCL_SU09 HAP1 KCNQ1 (-) 2 cancer cell line human CVCL_SU09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6294; KCNQ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134184 CVCL_T609 MDCC-HP12 cancer cell line CVCL_T609 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus)(NCBI-Taxonomy; 10390); Breed/subspecies: HPRS-RIR. Female Group: Bird cell line 21134185 CVCL_9I35 DD2002 finite cell line human CVCL_9I35 CL:0000010 Karyotypic information: 46,X,del(X),(qter->p22)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134186 CVCL_9I34 DD1998 transformed cell line human CVCL_9I34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134187 CVCL_9I37 DD2011 transformed cell line human CVCL_9I37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134188 CVCL_9I36 DD2010 transformed cell line human CVCL_9I36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134189 CVCL_9I31 DD1993 transformed cell line human CVCL_9I31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134190 CVCL_9I30 DD1991 transformed cell line human CVCL_9I30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134191 CVCL_9I33 DD1996 transformed cell line human CVCL_9I33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134192 CVCL_9I32 DD1994 transformed cell line human CVCL_9I32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134193 CVCL_9I39 DD2025 transformed cell line human CVCL_9I39 CL:0000010 Karyotypic information: 46,XY,t(2;4)(q35;q35.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134194 CVCL_9I38 DD2022 finite cell line human CVCL_9I38 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(13/21) de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134195 CVCL_1098 Hep-G2/C3A cancer cell line human CVCL_1098 HLA typing: A*02:19,24:02; B*15:137,35:14; C*04:01,16:02 (PubMed=26589293); Genome ancestry: African=1.61%; Native American=22.36%; East Asian, North=0.85%; East Asian, South=1.57%; South Asian=0.18%; European, North=26.42%; European, South=47.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Susceptible to infection by Zika virus (ZIKV) (PubMed=29468137) Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10741 21134196 CVCL_1097 C32 [Human melanoma] cancer cell line human CVCL_1097 HLA typing: A*02:01,25:01; B*18:01,44:02; C*05:01,12:03; DQA1*03:02,01:02; DQB1*06:02,06:02; DRB1*15:01,04:01 (PubMed=25960936); HLA typing: A*02:01,25:01; B*18:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.03%; East Asian, North=2.04%; East Asian, South=0%; South Asian=0%; European, North=63.48%; European, South=33.45% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=15048078; PubMed=15467732; PubMed=17363583; PubMed=22383533; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ter157Serext*13 (c.470G>C); Zygosity=Homozygous (PubMed=9354451; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Skin. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 53 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MET genetic alteration cell panel (ATCC TCP-1036); Part of: PTEN genetic alteration cell panel (ATCC TCP-1030) 21134197 CVCL_1099 C8166 transformed cell line human CVCL_1099 Genome ancestry: African=0.3%; Native American=0.05%; East Asian, North=1.72%; East Asian, South=0%; South Asian=0%; European, North=64.43%; European, South=33.5% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap) Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134198 CVCL_9I46 DD2035 transformed cell line human CVCL_9I46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134199 CVCL_9I45 DD2032 finite cell line human CVCL_9I45 CL:0000010 Karyotypic information: 46,XX,-5,+der(5),t(5;11)(p15;p15)pat (ECACC); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134200 CVCL_9I48 DD2037 transformed cell line human CVCL_9I48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134201 CVCL_9I47 DD2036 transformed cell line human CVCL_9I47 CL:0000010 Karyotypic information: 46,XY,dir dup(1)(q32.1;q42.1) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134202 CVCL_9I42 DD2028 transformed cell line human CVCL_9I42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134203 CVCL_9I41 DD2027 transformed cell line human CVCL_9I41 CL:0000010 Karyotypic information: 46,XX,-4,+der(4),t(2;4)(q35;q35.1)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134204 CVCL_9I44 DD2031 finite cell line human CVCL_9I44 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(13/21) de novo (ECACC); Derived from sampling site: Amnion Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21134205 CVCL_9I43 DD2029 transformed cell line human CVCL_9I43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134206 CVCL_9I49 DD2038 transformed cell line human CVCL_9I49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134207 CVCL_9I40 DD2026 transformed cell line human CVCL_9I40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134208 CVCL_9I13 DD1951 finite cell line human CVCL_9I13 CL:0000010 Karyotypic information: 46,XX,-4,+der(4),t(4;16)(q35.1;p13.3)mat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134209 CVCL_9I12 DD1950 transformed cell line human CVCL_9I12 CL:0000010 Karyotypic information: 47,XY,+mar(14/22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134210 CVCL_9I15 DD1956 transformed cell line human CVCL_9I15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134211 CVCL_9I14 DD1953 transformed cell line human CVCL_9I14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134212 CVCL_9I11 DD1946 transformed cell line human CVCL_9I11 CL:0000010 Karyotypic information: 46,XY,t(2;4)(q13;q21)(?0) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134213 CVCL_9I10 DD1940 transformed cell line human CVCL_9I10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134214 CVCL_1081 BE-13 cancer cell line human CVCL_1081 Genome ancestry: African=3.02%; Native American=1.38%; East Asian, North=0%; East Asian, South=1.18%; South Asian=10.89%; European, North=13.65%; European, South=69.88% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 34 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~40-60 hours (DSMZ=ACC-396); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00178 Problematic cell line: Contaminated Shown to be a Peer derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the bone marrow of a 11 year old patient with T-ALL. 21134215 CVCL_1080 BC-3 cancer cell line human CVCL_1080 HLA typing: A*02:05:01,03:01:01; B*14:02:01,50:01:01; C*06:02:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01; DQA1*02:01:01,01:01:02; DQB1*02:02:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*01:02:01,07:01:01 (DSMZCellDive=ACC-679); Genome ancestry: African=7.13%; Native American=1.02%; East Asian, North=6.58%; East Asian, South=0%; South Asian=6.31%; European, North=25.3%; European, South=53.67% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19608668) Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-60 hours (DSMZ=ACC-679); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-2277 21134216 CVCL_1083 BFTC-905 cancer cell line human CVCL_1083 HLA typing: A*02:07,24:02; B*27:04,40:01; C*07:02,12:02 (PubMed=26589293); Genome ancestry: African=0.82%; Native American=0%; East Asian, North=33.39%; East Asian, South=61.81%; South Asian=0%; European, North=0%; European, South=3.98% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: Chinese; Taiwan; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 21.4 hours (PubMed=8712703); ~60-90 hours (DSMZ=ACC-361); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134217 CVCL_9I17 DD1961 transformed cell line human CVCL_9I17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134218 CVCL_1082 BEN cancer cell line human CVCL_1082 HLA typing: A*24:02,24:02; B*44:03,44:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=2.03%; Native American=0%; East Asian, North=4.23%; East Asian, South=0%; South Asian=0%; European, North=59.95%; European, South=33.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (Cosmic-CLP) Derived from metastatic site: Supraclavicular lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3.5 days (PubMed=1233082); ~40-50 hours (DSMZ=ACC-254); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134219 CVCL_9I16 DD1958 transformed cell line human CVCL_9I16 CL:0000010 Karyotypic information: 46,XX,+18 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134220 CVCL_1085 BHT-101 cancer cell line human CVCL_1085 Genome ancestry: African=0.56%; Native American=0.75%; East Asian, North=2.42%; East Asian, South=0%; South Asian=0.87%; European, North=57.43%; European, South=37.97% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thr (c.752T>C); ClinVar=VCV000439320; Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=8099464); ~2-3 days (DSMZ=ACC-279); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134221 CVCL_9I19 DD1966 finite cell line human CVCL_9I19 CL:0000010 Karyotypic information: 47,XY,-1,+der(1),+der(7),t(1;7)(p21;q21.2)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134222 CVCL_1084 BFTC-909 cancer cell line human CVCL_1084 HLA typing: A*02:07,26:01; B*08:01,46:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=27.83%; East Asian, South=71.15%; South Asian=0%; European, North=0%; European, South=1.02% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2151; CNGB1 + HGNC; 6326; KIFC3; Name(s)=KIFC3-CNGB1 (PubMed=25485619); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Heterozygous (Cosmic-CLP) Population: Chinese; Taiwan; Derived from sampling site: Kidney; renal pelvis. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 49.4 hours (PubMed=8712703); ~50 hours (DSMZ=ACC-367); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134223 CVCL_9I18 DD1962 transformed cell line human CVCL_9I18 CL:0000010 Karyotypic information: 46,X,+der(15),t(Y;15)(p11;q13)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134224 CVCL_1076 BB30-HNC cancer cell line human CVCL_1076 Genome ancestry: African=0.71%; Native American=0%; East Asian, North=0.53%; East Asian, South=0%; South Asian=0.89%; European, North=70.27%; European, South=27.6% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser144Ter (c.431C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.96+2T>G (IVS3+2T>G); Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134225 CVCL_1075 BALL-1 cancer cell line human CVCL_1075 Genome ancestry: African=0%; Native American=0%; East Asian, North=81.09%; East Asian, South=18.9%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Homozygous (PubMed=15901131; Cosmic-CLP) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 80 hours (in RPMI-1640 + 20% HCS), 66 hours (in RPMI-1640 + 20% FCS) (PubMed=195075); ~48-72 hours (DSMZ=ACC-742); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134226 CVCL_1078 BB65-RCC cancer cell line human CVCL_1078 Genome ancestry: African=0.53%; Native American=1.94%; East Asian, North=1.65%; East Asian, South=0%; South Asian=0.38%; European, North=59.69%; European, South=35.82% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (Cosmic-CLP) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134227 CVCL_1077 BB49-HNC cancer cell line human CVCL_1077 Genome ancestry: African=0.66%; Native American=0.55%; East Asian, North=0.98%; East Asian, South=0%; South Asian=2.14%; European, North=57.6%; European, South=38.06% (PubMed=30894373). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134228 CVCL_1079 BC-1 cancer cell line human CVCL_1079 Genome ancestry: African=0%; Native American=0.64%; East Asian, North=0.52%; East Asian, South=0%; South Asian=0.4%; European, North=67.92%; European, South=30.53% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~35-48 hours (DSMZ=ACC-677); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134229 CVCL_9I24 DD1977 transformed cell line human CVCL_9I24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134230 CVCL_9I23 DD1976 transformed cell line human CVCL_9I23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134231 CVCL_9I26 DD1986 transformed cell line human CVCL_9I26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134232 CVCL_9I25 DD1984 finite cell line human CVCL_9I25 CL:0000010 Karyotypic information: 46,XX,+der(5),t(5;11)(p15;p15.1)pat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21134233 CVCL_9I20 DD1969 transformed cell line human CVCL_9I20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134234 CVCL_9I22 DD1975 finite cell line human CVCL_9I22 CL:0000010 Karyotypic information: 46,XY,t(7;11)(p21.2;q23.1)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21134235 CVCL_9I21 DD1970 transformed cell line human CVCL_9I21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134236 CVCL_1090 BONNA-12 cancer cell line human CVCL_1090 HLA typing: A*11:01:01,68:01:02; B*35:01:01,40:01:02; C*03:04:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,02:01:02; DQA1*01:03:01,01:01:01; DQB1*05:01:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*01:01:01,13:01:01 (DSMZCellDive=ACC-150); Genome ancestry: African=0.35%; Native American=0%; East Asian, North=1.04%; East Asian, South=0%; South Asian=0%; European, North=71.7%; European, South=26.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Thr2466Met (c.7397C>T); ClinVar=VCV000241169; Zygosity=Heterozygous (PubMed=29989027; Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Spleen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36-48 hours (PubMed=27463354); ~50-60 hours (DSMZ=ACC-150); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel Problematic cell line: Possibly misidentified It is not certain that this cell line originate from a hairy cell leukemia (PubMed=22653958). 21134237 CVCL_1092 BT-549 cancer cell line human CVCL_1092 HLA typing: B*15:17:01,55:01; C*03:03:01,07; DPB1*02:01:02,04:01; DQB1*03:01:01,06:04:01; DRB1*11,13 (PubMed=15748285); HLA typing: A*01:01,02:01; B*15:17,56; C*03:03,07:01 (PubMed=25960936); HLA typing: A*01:01,02:01; B*15:17,56:01; C*03:03,07:01; DQA1*03:02,03:02; DRB1*11:01,11:01 (PubMed=26589293); Genome ancestry: African=0.21%; Native American=0%; East Asian, North=3.6%; East Asian, South=0%; South Asian=7.26%; European, North=26.05%; European, South=62.87% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (PubMed=23637631); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (PubMed=19593635; ATCC; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (PubMed=1961733; PubMed=16541312; PubMed=17088437; PubMed=18277095; PubMed=28889351; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Glycoproteome analysis by proteomics; Omics: lncRNA expression profiling; Omics: miRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 3.7 days (PubMed=9671407); 51 hours (PubMed=25984343); 53.9 hours (NCI-DTP); 25.46 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21134238 CVCL_1091 BPH-1 transformed cell line human CVCL_1091 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.5%; East Asian, South=0.02%; South Asian=2.82%; European, North=66.48%; European, South=29.17% (PubMed=30894373) CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~50 hours (DSMZ=ACC-143); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134239 CVCL_1094 C-33 A cancer cell line human CVCL_1094 HLA typing: A*02:01,03:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0.41%; Native American=0.33%; East Asian, North=0.48%; East Asian, South=0.19%; South Asian=0.82%; European, North=66.58%; European, South=31.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=1648218) Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.36 days (PubMed=29156801); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030) 21134240 CVCL_9I28 DD1988 transformed cell line human CVCL_9I28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134241 CVCL_1093 Becker cancer cell line human CVCL_1093 Genome ancestry: African=0.35%; Native American=0.96%; East Asian, North=1.31%; East Asian, South=0.09%; South Asian=10.35%; European, North=21.76%; European, South=65.17% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134242 CVCL_9I27 DD1987 transformed cell line human CVCL_9I27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134243 CVCL_1096 C2BBe1 cancer cell line human CVCL_1096 HLA typing: A*02:01,02:01; B*15:34,15:34; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.84%; East Asian, South=0.11%; South Asian=0%; European, North=57.43%; European, South=40.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 44 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134244 CVCL_1095 C-4-II cancer cell line human CVCL_1095 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7914; true Female Virology: Contains a complete HPV18 genome Doubling time: 2.4 days (PubMed=29156801) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134245 CVCL_9I29 DD1990 transformed cell line human CVCL_9I29 CL:0000010 Karyotypic information: 46,XX,t(11;22),(q23;q11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134246 CVCL_1087 BL-41 cancer cell line human CVCL_1087 HLA typing: A*11:01,32:01; B*35:01,49:01; C*04:01,07:01; DQA1*01:01,01:01; DQB1*05:03,05:03; DRB1*14:01,01:01 (PubMed=25960936); HLA typing: A*32:01,32:01; B*35:01,49:01; C*04:01,07:06 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0.06%; East Asian, North=0%; East Asian, South=0.52%; South Asian=1.34%; European, North=57.31%; European, South=40.71% (PubMed=30894373). From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=1915267) Population: Caucasian Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Virology: EBV-negative Doubling time: ~30 hours (DSMZ=ACC-160); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134247 CVCL_1086 BHY cancer cell line human CVCL_1086 HLA typing: A*24:02,24:02; B*51:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.12%; East Asian, North=81.47%; East Asian, South=16.1%; South Asian=0.22%; European, North=0%; European, South=1.09% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex6-15del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr118Glnfs*5 (c.351delG) (p.G117fs); Zygosity=Homozygous (PubMed=17390010; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met160Val (c.478A>G); ClinVar=VCV000444396; Zygosity=Unspecified (PubMed=17390010); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu369Pro (c.1106T>C); Zygosity=Unspecified (PubMed=17390010) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~70 hours (DSMZ=ACC-404); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21134248 CVCL_1089 BOKU cancer cell line human CVCL_1089 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~3 days (lot 11122010) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134249 CVCL_1088 BL-70 cancer cell line human CVCL_1088 HLA typing: A*26:01,32:01; B*49:01,51:01; C*07:01,14:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*13:01,15:01 (PubMed=25960936); HLA typing: A*26:01,32:01; B*49:01,51:01; C*07:01,14:02; DQA1*01:02,01:02; DQB1*06:11,06:11; DRB1*13:01,15:01 (PubMed=26589293); Genome ancestry: African=2.11%; Native American=1.03%; East Asian, North=0.85%; East Asian, South=0%; South Asian=1.04%; European, North=52.49%; European, South=42.5% (PubMed=30894373). From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP) Population: Caucasian Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Virology: EBV-negative Doubling time: ~44 hours (DSMZ=ACC-233); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134250 CVCL_1061 Jurkat clone A3 cancer cell line human CVCL_1061 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Metabolome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male 21134251 CVCL_1060 A-253 cancer cell line human CVCL_1060 HLA typing: A*32:01,32:01; B*44:02,44:02; C*03:04,05:01; DQB1*06:08,06:08; DRB1*13:10,13:10 (PubMed=26589293); Genome ancestry: African=0.97%; Native American=0%; East Asian, North=1.81%; East Asian, South=0%; South Asian=0%; European, North=61.82%; European, South=35.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7902; true; Discontinued: KCLB; 30041; probable Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134252 CVCL_1063 A-388 cancer cell line human CVCL_1063 Genome ancestry: African=4.06%; Native American=0.32%; East Asian, North=3.84%; East Asian, South=0%; South Asian=0%; European, North=50.76%; European, South=41.03% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg832Cys (c.2494C>T); ClinVar=VCV000936373; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (ATCC; Cosmic-CLP) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134253 CVCL_1062 A3/Kawakami cancer cell line human CVCL_1062 HLA typing: A*02:03,02:03; B*39:01,39:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=79.02%; East Asian, South=20.54%; South Asian=0%; European, North=0.43%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (PubMed=2144611); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (PubMed=2144611) Population: Japanese; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: 20-22 hours (PubMed=6601597); 38 hours (lot 01142009), ~39 hours (lot 03142016) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134254 CVCL_1054 8505C cancer cell line human CVCL_1054 HLA typing: A*02:01,26:01; B*39:01,51:01; C*07:02,15:02 (PubMed=26589293); Genome ancestry: African=0.58%; Native American=0%; East Asian, North=84.79%; East Asian, South=11.83%; South Asian=0%; European, North=0%; European, South=2.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Glu129Ter (c.385G>T); Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gly (c.742C>G); ClinVar=VCV000376652; Zygosity=Hemizygous (PubMed=1516062; PubMed=14522906; PubMed=21566963; PubMed=23162534; PubMed=30737244; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36 hours (PubMed=21566963); ~30-40 hours (DSMZ=ACC-219), ~1.5 days (lot 11252003) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21134255 CVCL_1053 8305C cancer cell line human CVCL_1053 HLA typing: A*11:01,11:01; B*15:01,54:01; C*01:02,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.04%; East Asian, North=74.78%; East Asian, South=24.09%; South Asian=0%; European, North=0%; European, South=0.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800Ter (c.8398C>T); ClinVar=VCV001171818; Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Phe90Leufs*14 (c.270delT); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=14522906; PubMed=21566963; PubMed=30737244; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 43 hours (PubMed=21566963); ~54 hours (DSMZ=ACC-133), ~50 hours (lot 07252003) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21134256 CVCL_1056 A-498 cancer cell line human CVCL_1056 HLA typing: A*02:01:01; B*08:01; C*07; DPB1*01:01:01; DQB1*02:01; DRB1*03:01:01 (PubMed=15748285); HLA typing: A*02:01,02:01; B*08:01,08:01; C*07:01,07:01; DQB1*02:02,06:07 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0%; East Asian, North=2.1%; East Asian, South=0%; South Asian=0%; European, North=63.47%; European, South=34.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Val (c.3200A>T); Zygosity=Heterozygous (PubMed=26759240; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly144Serfs*14 (c.426_429delTGAC); Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val142fs*30 (c.425_429delTTGAC); Zygosity=Unspecified (PubMed=8493574) Population: Caucasian; Derived from sampling site: Kidney. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7908; true Male Doubling time: 33 hours (PubMed=9488600); 58.4 hours (PubMed=22628656); 66.8 hours (NCI-DTP); ~62 hours (CLS=300113); ~60 hours (DSMZ=ACC-55); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI-60 cancer cell line panel 21134257 CVCL_1055 A-427 cancer cell line human CVCL_1055 HLA typing: A*03,10; B*w35; C*w04 (PubMed=77569); HLA typing: A*03:01,03:01; B*35:03,35:03; C*12:03,12:03; DQA1*01:02,01:02; DQB1*06:08,06:08; DRB1*11:02,11:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.4%; East Asian, North=1.31%; East Asian, South=0.28%; South Asian=1.59%; European, North=71.98%; European, South=24.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (ATCC; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=1855224; PubMed=3945555; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1312700; PubMed=10536175; PubMed=20557307) Population: Caucasian; Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7906; true Male Doubling time: 28 hours (in RPMI 1640 + 10% FBS), 38 hours (in ACL-3), 42 hours (in ACL-3+BSA) (PubMed=3940644); 36.6 hours (PubMed=29681454); ~60-70 hours (DSMZ=ACC-234); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134258 CVCL_1058 A-204 cancer cell line human CVCL_1058 HLA typing: A*01,02; B*08,14; C*w03 (PubMed=77569); HLA typing: A*01:01,02:01; B*35:20,35:20; C*03:04,07:01; DQA1*03:02,03:02; DQB1*04:01,04:01; DRB1*15:01,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.2%; East Asian, North=0.35%; East Asian, South=0%; South Asian=0.83%; European, North=70.8%; European, South=27.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gln182Alafs*28 (c.543_544delTC); Zygosity=Heterozygous (PubMed=10602515; Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7900; true. Female Doubling time: 28 hours (PubMed=25984343); 26-36 hours (CLS=300109); ~36 hours (DSMZ=ACC-250); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134259 CVCL_1057 A101D cancer cell line human CVCL_1057 HLA typing: A*01:01,25:01; B*07:02,08:01; C*07:02,07:02; DQA1*01:02,01:02; DQB1*02:01,06:02; DRB1*03:01,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.99%; East Asian, South=0%; South Asian=0.52%; European, North=71.28%; European, South=27.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134260 CVCL_1059 A2058 cancer cell line human CVCL_1059 HLA typing: A*03:01,25:01; B*07:02,35:08; C*07:02,07:02; DQA1*01:02,02:01; DQB1*06:02,06:02; DRB1*15:01,14:10 (PubMed=25960936); HLA typing: A*03:01,25:01; B*07:02,18:01; C*07:02,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.45%; East Asian, North=0.51%; East Asian, South=0%; South Asian=0.49%; European, North=71.7%; European, South=26.84% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=15048078; PubMed=15467732; PubMed=22383533; PubMed=24576830; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 15979; TP63; Simple; p.Arg379Cys (c.1135C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11147 21134261 CVCL_9I02 DD1917 transformed cell line human CVCL_9I02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134262 CVCL_SU95 HAP1 KLHL3 (-) 1 cancer cell line human CVCL_SU95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6354; KLHL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134263 CVCL_T695 XRpe2 spontaneously immortalized cell line African clawed frog CVCL_T695 CL:0000010 Derived from sampling site: Embryonic eye; optic cup; retinal pigment epithelium. Unspecified Group: Amphibian cell line 21134264 CVCL_9I01 DD1916 finite cell line human CVCL_9I01 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134265 CVCL_SU94 HAP1 KLF10 (-) 2 cancer cell line human CVCL_SU94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11810; KLF10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134266 CVCL_T694 XRpe1 spontaneously immortalized cell line African clawed frog CVCL_T694 CL:0000010 Derived from sampling site: Embryonic eye; optic cup; retinal pigment epithelium. Unspecified Group: Amphibian cell line 21134267 CVCL_9I04 DD1922 transformed cell line human CVCL_9I04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134268 CVCL_SU97 HAP1 KMT2A (-) 1 cancer cell line human CVCL_SU97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7132; KMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134269 CVCL_T697 XRpe5 spontaneously immortalized cell line African clawed frog CVCL_T697 CL:0000010 Derived from sampling site: Embryonic eye; optic cup; retinal pigment epithelium. Unspecified Group: Amphibian cell line 21134270 CVCL_9I03 DD1919 transformed cell line human CVCL_9I03 CL:0000010 Karyotypic information: 46,XX,t(1;10)(p36.1;q24.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134271 CVCL_SU96 HAP1 KLHL3 (-) 2 cancer cell line human CVCL_SU96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6354; KLHL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134272 CVCL_T696 XRpe4 spontaneously immortalized cell line African clawed frog CVCL_T696 CL:0000010 Derived from sampling site: Embryonic eye; optic cup; retinal pigment epithelium. Unspecified Group: Amphibian cell line 21134273 CVCL_T699 Bor II spontaneously immortalized cell line CVCL_T699 CL:0000010 Unspecified Doubling time: 71 hours (at 20 Celsius), 68 hours (at 25 Celsius), 64 hours (at 30 Celsius) (PubMed=6862516). Group: Amphibian cell line 21134274 CVCL_SU99 HAP1 KMT2B (-) 1 cancer cell line human CVCL_SU99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15840; KMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134275 CVCL_SU98 HAP1 KMT2A (-) 2 cancer cell line human CVCL_SU98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7132; KMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134276 CVCL_T698 RPKID spontaneously immortalized cell line CVCL_T698 CL:0000010 Derived from sampling site: Kidney. Group: Amphibian cell line 21134277 CVCL_9I00 DD1914 transformed cell line human CVCL_9I00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134278 CVCL_9I09 DD1935 transformed cell line human CVCL_9I09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134279 CVCL_1070 AM-38 cancer cell line human CVCL_1070 HLA typing: A*24:02,26:01; B*15:07,35:01; C*03:03,03:03; DQA1*03:02,04:01; DQB1*03:02,04:01; DRB1*04:05,14:103 (PubMed=26589293); Genome ancestry: African=1.14%; Native American=0%; East Asian, North=90.78%; East Asian, South=5.24%; South Asian=0%; European, North=0%; European, South=2.85% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain; left occipital lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25 hours (PubMed=7947440; PubMed=8145054); 72 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134280 CVCL_1072 ARH-77 transformed cell line human CVCL_1072 Genome ancestry: African=2.24%; Native American=0.38%; East Asian, North=0%; East Asian, South=2.18%; South Asian=8.63%; European, North=25.32%; European, South=61.25% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 110.4 hours (PubMed=566614); ~30 hours (DSMZ=ACC-512); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=4042077; PubMed=7579375; PubMed=10516762). 21134281 CVCL_9I06 DD1929 transformed cell line human CVCL_9I06 CL:0000010 Karyotypic information: 46,XX,dup(7)(q32.1;q34) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134282 CVCL_1071 AML-193 cancer cell line human CVCL_1071 HLA typing: A*68:02,74:01; B*15:10,15:10; C*03:02,08:02; DQA1*04:01,05:02; DQB1*06:07,06:07; DRB1*12:02,13:27 (PubMed=26589293); Genome ancestry: African=65.28%; Native American=0%; East Asian, North=3.56%; East Asian, South=0%; South Asian=0%; European, North=14.42%; European, South=16.74% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; p.Arg784Ter (c.2350C>T); Zygosity=Unspecified (PubMed=21989985; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Val (c.38G>T); ClinVar=VCV000375876; Zygosity=Heterozygous (PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+2T>G (IVS9+2T>G); ClinVar=VCV000635384; Zygosity=Unspecified; Note=Splice donor mutation (DepMap) Population: African American and Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0040; probable; Discontinued: ATCC; HTB-188; true Female Characteristics: CSF2, IL3 and IL6 dependent Doubling time: 65 hours (PubMed=25984343); ~50-60 hours (DSMZ=ACC-549) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9589 21134283 CVCL_9I05 DD1927 transformed cell line human CVCL_9I05 CL:0000010 Karyotypic information: 46,XX,t(2;4)(q13;q21)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134284 CVCL_1074 AU565 cancer cell line human CVCL_1074 HLA typing: A*02:01,03:01; B*14:01,40:01; C*03:04,08:02; DQB1*05:01,06:04 (PubMed=25960936); HLA typing: A*02:01,03:01; B*14:02,40:07; C*03:04,08:02; DQA1*02:01,02:01; DQB1*06:04,06:04; DRB1*11:30,11:30 (PubMed=26589293); Genome ancestry: African=0.17%; Native American=0%; East Asian, North=1.67%; East Asian, South=0%; South Asian=0.01%; European, North=64.07%; European, South=34.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (ATCC) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46.31 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: MET genetic alteration cell panel (ATCC TCP-1036) 21134285 CVCL_9I08 DD1933 transformed cell line human CVCL_9I08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134286 CVCL_1073 ATN-1 cancer cell line human CVCL_1073 Genome ancestry: African=0%; Native American=0.05%; East Asian, North=78.58%; East Asian, South=17.98%; South Asian=1.43%; European, North=0%; European, South=1.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>C); ClinVar=VCV000574679; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~24 hours (PubMed=3260813); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134287 CVCL_9I07 DD1930 transformed cell line human CVCL_9I07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134288 CVCL_1065 A-704 cancer cell line human CVCL_1065 HLA typing: A*01,03; B*08,12 (PubMed=77569); HLA typing: A*34:02,74:01; B*35:01,44:03; C*04:01,04:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*11:02,15:03 (PubMed=26589293); Genome ancestry: African=71.07%; Native American=0%; East Asian, North=6.26%; East Asian, South=0%; South Asian=0%; European, North=2.53%; European, South=20.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asp (c.376T>G); ClinVar=VCV000265333; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Ter (c.772G>T); ClinVar=VCV000486557; Zygosity=Heterozygous (Cosmic-CLP) Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7911; true Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134289 CVCL_1064 A4/Fukuda cancer cell line human CVCL_1064 HLA typing: A*24:02,24:02; B*52:01,59:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=75.76%; East Asian, South=24.23%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Homozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Characteristics: Produces IgM kappa Doubling time: 20-22 hours (PubMed=6601597); 38-43 hours (lot 02162007) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134290 CVCL_1067 ACHN cancer cell line human CVCL_1067 HLA typing: A*26:01; B*49:01; C*07; DPB1*02:01:02; DQB1*05:02:01; DRB1*16:01:01 (PubMed=15748285); HLA typing: A*26:01,26:01; B*49:01,49:01; C*07:01,07:01; DQB1*05:02,05:02 (PubMed=26589293); HLA typing: A*26:01:01; B*49:01:01; C*07:01:01; DPB1*02:01:02; DQA1*01:02:02; DQB1*05:02:01; DRB1*16:01:01 (CLS=300117); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.83%; East Asian, South=1.52%; South Asian=1.78%; European, North=70.53%; European, South=25.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1962; true; Discontinued: TKG; TKG 0578; true Male Doubling time: 32 hours (PubMed=25984343); ~30 hours (CLS=300117); 27.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21134291 CVCL_1066 ABC-1 cancer cell line human CVCL_1066 HLA typing: A*24:02,24:02; B*37:04,58:05; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.72%; Native American=0.92%; East Asian, North=78.6%; East Asian, South=18.68%; South Asian=0%; European, North=0%; European, South=1.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (DOI=10.4044/joma1947.97.7-8_691); 23.8 hours (PubMed=8286010); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134292 CVCL_1069 ALL-PO cancer cell line human CVCL_1069 Genome ancestry: African=0%; Native American=0.07%; East Asian, North=2.2%; East Asian, South=1.8%; South Asian=1.45%; European, North=52.99%; European, South=41.49% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638; PubMed=35354797); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134293 CVCL_1068 ACN cancer cell line human CVCL_1068 Genome ancestry: African=0.3%; Native American=0.69%; East Asian, North=0%; East Asian, South=0.16%; South Asian=1.02%; European, North=70.67%; European, South=27.16% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Probably contaminated The STR profile of ACN and LN-464 are identical. SNP analysis (DepMap) also shows identity of both cell lines. We believe this is a melanoma cell line based on the presence of the BRAF V600E mutation as well as the RNASeq expression profile of LN-464 (DepMap) which clusters with that of melanoma patient samples. Originally thought to originate from the bone marrow of a 36-month old boy with a metastatic adrenal stage-IV neuroblastoma. 21134294 CVCL_SU84 HAP1 KIF5B (-) 2 cancer cell line human CVCL_SU84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6324; KIF5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134295 CVCL_T684 XL-177 spontaneously immortalized cell line African clawed frog CVCL_T684 CL:0000010 Unspecified Group: Amphibian cell line. 21134296 CVCL_SU83 HAP1 KIF5B (-) 1 cancer cell line human CVCL_SU83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6324; KIF5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134297 CVCL_T683 JK [Boa] spontaneously immortalized cell line CVCL_T683 CL:0000010 Derived from sampling site: Kidney. Female Group: Reptilian cell line 21134298 CVCL_SU86 HAP1 KIF7 (-) 2 cancer cell line human CVCL_SU86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30497; KIF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134299 CVCL_T686 PRKT cancer cell line CVCL_T686 CL:0000010 Group: Amphibian cell line. 21134300 CVCL_SU85 HAP1 KIF7 (-) 1 cancer cell line human CVCL_SU85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30497; KIF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134301 CVCL_T685 PNKT-3 cancer cell line CVCL_T685 CL:0000010 Group: Amphibian cell line. 21134302 CVCL_SU88 HAP1 KIFC1 (-) 1 cancer cell line human CVCL_SU88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6389; KIFC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134303 CVCL_T688 PNKT-4B cancer cell line CVCL_T688 CL:0000010 Group: Amphibian cell line Caution: Could be identical to PNKT-4 (Cellosaurus=CVCL_T687). 21134304 CVCL_SU87 HAP1 KIF7 (-) 3 cancer cell line human CVCL_SU87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30497; KIF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134305 CVCL_T687 PNKT-4 cancer cell line CVCL_T687 CL:0000010 Group: Amphibian cell line Caution: Could be identical to PNKT-4B (Cellosaurus=CVCL_T688). 21134306 CVCL_SU89 HAP1 KIFC1 (-) 2 cancer cell line human CVCL_SU89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6389; KIFC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134307 CVCL_T689 WMPa spontaneously immortalized cell line CVCL_T689 CL:0000010 Unspecified Group: Amphibian cell line. 21134308 CVCL_1041 Hs 97.Fs finite cell line human CVCL_1041 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134309 CVCL_1040 Hs 944.T cancer cell line human CVCL_1040 HLA typing: A*02:01,03:01; B*07:02,44:02; C*05:01,07:02; DQA1*01:02,01:02; DQB1*03:01,06:02; DRB1*12:01,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.22%; East Asian, South=0%; South Asian=0%; European, North=66.41%; European, South=31.37% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=10766161; PubMed=15009714; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys163fs (c.486_487insA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7693; true. Male Doubling time: 30 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: TCGA-110-CL cell line panel 21134310 CVCL_1032 Hs 935.T cancer cell line human CVCL_1032 CL:0000010 Population: Caucasian; Derived from sampling site: Connective tissue Cell type=Fibroblast.. Discontinued: ATCC; CRL-7685; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134311 CVCL_1031 Hs 934.T undefined cell line type human CVCL_1031 Genome ancestry: African=0%; Native American=0.08%; East Asian, North=0.36%; East Asian, South=0.85%; South Asian=0%; European, North=69.72%; European, South=28.98% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Connective tissue Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7684; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21134312 CVCL_1034 Hs 936.T(C1) cancer cell line human CVCL_1034 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134313 CVCL_1033 Hs 936.T cancer cell line human CVCL_1033 HLA typing: A*02:01,03:01; B*07:02,37:04; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=26589293); Genome ancestry: African=1.32%; Native American=0%; East Asian, North=3.21%; East Asian, South=0%; South Asian=0.68%; European, North=60.44%; European, South=34.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap) Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7686; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134314 CVCL_1036 Hs 939.T cancer cell line human CVCL_1036 Genome ancestry: African=0.37%; Native American=0%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0.5%; European, North=68.28%; European, South=27.95% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15009714; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7690; probable. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: TCGA-110-CL cell line panel 21134315 CVCL_1035 Hs 938.T finite cell line human CVCL_1035 CL:0000010 Discontinued: ATCC; CRL-7688; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134316 CVCL_1038 Hs 940.T undefined cell line type human CVCL_1038 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:06,07:06; DQA1*02:01,05:02; DQB1*06:13,06:13; DRB1*03:01,03:01 (PubMed=26589293); Genome ancestry: African=0.79%; Native American=0.31%; East Asian, North=1.11%; East Asian, South=0%; South Asian=0%; European, North=71.04%; European, South=26.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=10766161; PubMed=15009714; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Leu (c.646G>T); ClinVar=VCV000376670; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a cutaneous melanoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21134317 CVCL_1037 Hs 94.T cancer cell line human CVCL_1037 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21134318 CVCL_1039 Hs 941.T cancer cell line human CVCL_1039 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7692; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134319 CVCL_SU91 HAP1 KIT (-) 2 cancer cell line human CVCL_SU91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134320 CVCL_T691 XR1 spontaneously immortalized cell line African clawed frog CVCL_T691 CL:0000010 Derived from sampling site: Embryonic eye; retina. Unspecified Group: Amphibian cell line 21134321 CVCL_T690 B3.2 spontaneously immortalized cell line African clawed frog CVCL_T690 From: Weber R.; University of Bern; Bern; Switzerland CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Amphibian cell line 21134322 CVCL_SU90 HAP1 KIT (-) 1 cancer cell line human CVCL_SU90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6342; KIT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134323 CVCL_SU93 HAP1 KLF10 (-) 1 cancer cell line human CVCL_SU93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11810; KLF10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134324 CVCL_T693 XR9 spontaneously immortalized cell line African clawed frog CVCL_T693 CL:0000010 Derived from sampling site: Embryonic eye; retina. Unspecified Group: Amphibian cell line 21134325 CVCL_SU92 HAP1 KITLG (-) cancer cell line human CVCL_SU92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6343; KITLG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134326 CVCL_T692 XR8 spontaneously immortalized cell line African clawed frog CVCL_T692 CL:0000010 Derived from sampling site: Embryonic eye; retina. Unspecified Group: Amphibian cell line 21134327 CVCL_SU73 HAP1 KIF1C (-) 1 cancer cell line human CVCL_SU73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134328 CVCL_T673 MDTC-HP121 cancer cell line CVCL_T673 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134329 CVCL_SU72 HAP1 KIF18B (-) 1 cancer cell line human CVCL_SU72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27102; KIF18B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134330 CVCL_T672 MDTC-HP119 cancer cell line CVCL_T672 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134331 CVCL_SU75 HAP1 KIF1C (-) 3 cancer cell line human CVCL_SU75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134332 CVCL_T675 MDTC-HP41-1 cancer cell line CVCL_T675 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134333 CVCL_SU74 HAP1 KIF1C (-) 2 cancer cell line human CVCL_SU74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134334 CVCL_T674 MDTC-HP122 cancer cell line CVCL_T674 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Female Group: Bird cell line 21134335 CVCL_SU77 HAP1 KIF1C (-) 5 cancer cell line human CVCL_SU77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134336 CVCL_T677 MDTC-HP48-3 cancer cell line CVCL_T677 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134337 CVCL_SU76 HAP1 KIF1C (-) 4 cancer cell line human CVCL_SU76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6317; KIF1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134338 CVCL_T676 MDTC-HP41-2 cancer cell line CVCL_T676 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388). Male Group: Bird cell line 21134339 CVCL_SU79 HAP1 KIF2A (-) 2 cancer cell line human CVCL_SU79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6318; KIF2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134340 CVCL_T679 LSCC-1104X5 cancer cell line CVCL_T679 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line 15. Male Group: Bird cell line 21134341 CVCL_SU78 HAP1 KIF2A (-) 1 cancer cell line human CVCL_SU78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6318; KIF2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134342 CVCL_T678 LSCC-1104B1 cancer cell line CVCL_T678 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line 15. Male Doubling time: 11.0 hours (PubMed=3273463) Group: Bird cell line 21134343 CVCL_1050 769-P cancer cell line human CVCL_1050 HLA typing: A*03:01,24:02; B*07:02,07:02; C*07:02,07:02; DQB1*06:07,06:07; DRB1*15:01,15:01 (PubMed=26589293); Genome ancestry: African=1.32%; Native American=0%; East Asian, North=3.45%; East Asian, South=0%; South Asian=0%; European, North=68.23%; European, South=27% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours (PubMed=721102); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134344 CVCL_1052 8-MG-BA cancer cell line human CVCL_1052 Genome ancestry: African=0%; Native American=0.1%; East Asian, North=2.53%; East Asian, South=0%; South Asian=2.29%; European, North=61.9%; European, South=33.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain; frontal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 20-24 hours (PubMed=9604998); ~100 hours (DSMZ=ACC-432); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134345 CVCL_1051 786-O cancer cell line human CVCL_1051 HLA typing: A*03:01:01; B*07,44; C*05,07:02:01; DPB1*04:02; DQB1*06,06; DRB1*13,15 (PubMed=15748285); HLA typing: A*03:01,03:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0.77%; Native American=0%; East Asian, North=4.36%; East Asian, South=0%; South Asian=0%; European, North=65.75%; European, South=29.12% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (PubMed=7915601; PubMed=17088437; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Kidney. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: GPI-anchored proteins analysis by proteomics; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=721102); 24 hours (PubMed=25984343); ~24 hours (CLS=300107); 22.4 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21134346 CVCL_1043 Hs 709.Sk finite cell line human CVCL_1043 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7452; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134347 CVCL_1042 Hs 696.Sk finite cell line human CVCL_1042 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7431; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134348 CVCL_1045 22Rv1 cancer cell line human CVCL_1045 Genome ancestry: African=0.89%; Native American=0.23%; East Asian, North=0.52%; East Asian, South=0%; South Asian=0.27%; European, North=67.46%; European, South=30.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (PubMed=14518029; ATCC; Cosmic-CLP; DepMap) Derived from sampling site: Prostate. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains at least 10 integrated copies of xenotropic murine leukemia virus-related virus (XMRV) genome and produces a high titer of the virus (PubMed=19403664; PubMed=30629668) Doubling time: ~49 hours (PubMed=10462204); 55 hours (PubMed=25984343); 63 hours (from cell counting), 94 hours (from absorbance) (DOI=10.5897/IJBMBR2013.0154); 40 hours (ATCC=CRL-2505); 40-60 hours (DSMZ=ACC-438); ~41 hours (PBCF); 24.07 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=23671654; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21134349 CVCL_1044 Hs 728.Sp finite cell line human CVCL_1044 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7463; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134350 CVCL_1047 380 cancer cell line human CVCL_1047 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3 days (PubMed=6334305); ~80 hours (DSMZ=ACC-39) 21134351 CVCL_1046 23132/87 cancer cell line human CVCL_1046 HLA typing: A*25:01,25:01; B*18:01,18:01; C*12:03,12:03; DQB1*05:01,05:01; DRB1*03:17,11:01 (PubMed=26589293); Genome ancestry: African=3.42%; Native American=0.35%; East Asian, North=1.75%; East Asian, South=0%; South Asian=0%; European, North=54.5%; European, South=39.98% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30-32 hours (PubMed=8100658); ~50 hours (DSMZ=ACC-201); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134352 CVCL_1049 647V cancer cell line human CVCL_1049 HLA typing: A*02:01; B*27:05,40:01; C*02:02,03:04 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=0%; East Asian, North=1.95%; East Asian, South=0%; South Asian=0%; European, North=64.01%; European, South=32.52% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Gln993Ter (c.2977C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6974; MDM4; Simple; p.Ser161Ter (c.482C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile162Asn (c.485T>A); ClinVar=VCV001408611; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-110; true Male Doubling time: 32 hours (PubMed=66978; PubMed=748774); ~30 hours (DSMZ=ACC-414); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134353 CVCL_1048 639V cancer cell line human CVCL_1048 HLA typing: A*01:01,02:01; B*44:02,57:01; C*05:01,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.6%; South Asian=0%; European, North=74.77%; European, South=24.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Ureter. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-109; true Male Doubling time: 24 hours (PubMed=66978; PubMed=748774); ~30 hours (DSMZ=ACC-413); Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: UBC-40 urothelial bladder cancer cell line index 21134354 CVCL_SU80 HAP1 KIF2C (-) 1 cancer cell line human CVCL_SU80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6393; KIF2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134355 CVCL_T680 LSCC-BK3A cancer cell line CVCL_T680 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line BK. Male Group: Bird cell line 21134356 CVCL_T682 GTS spontaneously immortalized cell line CVCL_T682 CL:0000010 Derived from sampling site: Skin. Female Group: Reptilian cell line 21134357 CVCL_SU82 HAP1 KIF4A (-) cancer cell line human CVCL_SU82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13339; KIF4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134358 CVCL_SU81 HAP1 KIF2C (-) 2 cancer cell line human CVCL_SU81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6393; KIF2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134359 CVCL_T681 LSCC-BK3C2 cancer cell line CVCL_T681 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line BK. Male Group: Bird cell line 21134360 CVCL_9H98 DD1911 transformed cell line human CVCL_9H98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134361 CVCL_9H97 DD1909 transformed cell line human CVCL_9H97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134362 CVCL_9H99 DD1912 finite cell line human CVCL_9H99 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134363 CVCL_BB28 ND09189 transformed cell line human CVCL_BB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134364 CVCL_BB27 ND09188 transformed cell line human CVCL_BB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134365 CVCL_BB29 ND09190 transformed cell line human CVCL_BB29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134366 CVCL_9H94 DD1905 transformed cell line human CVCL_9H94 CL:0000010 Karyotypic information: 46,XX,inv(2)(q31.3;q37.1)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134367 CVCL_BB20 ND09115 transformed cell line human CVCL_BB20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134368 CVCL_9H93 DD1904 transformed cell line human CVCL_9H93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134369 CVCL_9H96 DD1908 transformed cell line human CVCL_9H96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134370 CVCL_BB22 ND09136 transformed cell line human CVCL_BB22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134371 CVCL_9H95 DD1906 transformed cell line human CVCL_9H95 CL:0000010 Karyotypic information: 46,XY,inv(2)(q31.3;q37.1) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134372 CVCL_BB21 ND09134 transformed cell line human CVCL_BB21 CL:0000010 Population: Caucasian; German/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134373 CVCL_9H90 DD1894 finite cell line human CVCL_9H90 CL:0000010 Karyotypic information: 46,X,t(X;17)(Xp17;17p) de novo (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21134374 CVCL_BB24 ND09149 transformed cell line human CVCL_BB24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134375 CVCL_BB23 ND09137 transformed cell line human CVCL_BB23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134376 CVCL_9H92 DD1898 transformed cell line human CVCL_9H92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134377 CVCL_BB26 ND09185 transformed cell line human CVCL_BB26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134378 CVCL_9H91 DD1896 finite cell line human CVCL_9H91 CL:0000010 Karyotypic information: 46,X0 (ECACC); Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21134379 CVCL_BB25 ND09180 transformed cell line human CVCL_BB25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134380 CVCL_BB40 ND09288 transformed cell line human CVCL_BB40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134381 CVCL_BB39 ND09286 transformed cell line human CVCL_BB39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134382 CVCL_BB38 ND09285 transformed cell line human CVCL_BB38 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134383 CVCL_BB31 ND09192 transformed cell line human CVCL_BB31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134384 CVCL_BB30 ND09191 transformed cell line human CVCL_BB30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134385 CVCL_BB33 ND09197 transformed cell line human CVCL_BB33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134386 CVCL_BB32 ND09195 transformed cell line human CVCL_BB32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134387 CVCL_BB35 ND09204 transformed cell line human CVCL_BB35 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134388 CVCL_BB34 ND09199 transformed cell line human CVCL_BB34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134389 CVCL_BB37 ND09212 transformed cell line human CVCL_BB37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134390 CVCL_BB36 ND09210 transformed cell line human CVCL_BB36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134391 CVCL_9H79 DD1878 transformed cell line human CVCL_9H79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134392 CVCL_9H76 DD1862 transformed cell line human CVCL_9H76 CL:0000010 Karyotypic information: 46,X,t(X;17)(Xp17;17p) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134393 CVCL_9H75 DD1861 transformed cell line human CVCL_9H75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134394 CVCL_9H78 DD1877 transformed cell line human CVCL_9H78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134395 CVCL_9H77 DD1872 finite cell line human CVCL_9H77 CL:0000010 Karyotypic information: 46,XX,var(11)mat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Part of: ECACC chromosomal abnormality collection 21134396 CVCL_BB06 ND08705 transformed cell line human CVCL_BB06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134397 CVCL_BB05 ND08670 transformed cell line human CVCL_BB05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134398 CVCL_BB08 ND08789 transformed cell line human CVCL_BB08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134399 CVCL_BB07 ND08707 transformed cell line human CVCL_BB07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134400 CVCL_BB09 ND08791 transformed cell line human CVCL_BB09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134401 CVCL_9H72 DD1833 transformed cell line human CVCL_9H72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134402 CVCL_9H71 DD1832 finite cell line human CVCL_9H71 CL:0000010 Karyotypic information: 46,XX (ECACC); Derived from sampling site: Ovary Cell type=Fibroblast.. Ambiguous Part of: ECACC chromosomal abnormality collection 21134403 CVCL_9H74 DD1860 transformed cell line human CVCL_9H74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134404 CVCL_BB00 ND08657 transformed cell line human CVCL_BB00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134405 CVCL_9H73 DD1858 transformed cell line human CVCL_9H73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134406 CVCL_BB02 ND08659 transformed cell line human CVCL_BB02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134407 CVCL_BB01 ND08658 transformed cell line human CVCL_BB01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134408 CVCL_9H70 DD1822 finite cell line human CVCL_9H70 CL:0000010 Karyotypic information: 46,XX (ECACC); Derived from sampling site: Testis Cell type=Fibroblast.. Ambiguous Part of: ECACC chromosomal abnormality collection 21134409 CVCL_BB04 ND08661 transformed cell line human CVCL_BB04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134410 CVCL_BB03 ND08660 transformed cell line human CVCL_BB03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134411 CVCL_9H87 DD1891 finite cell line human CVCL_9H87 CL:0000010 Karyotypic information: 46,XY,t(2;4)(q13;q21)mat (ECACC); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21134412 CVCL_9H86 DD1890 transformed cell line human CVCL_9H86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134413 CVCL_9H89 DD1893 transformed cell line human CVCL_9H89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134414 CVCL_9H88 DD1892 transformed cell line human CVCL_9H88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134415 CVCL_BB17 ND09014 transformed cell line human CVCL_BB17 CL:0000010 Population: Caucasian; Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134416 CVCL_BB16 ND08987 transformed cell line human CVCL_BB16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134417 CVCL_BB19 ND09112 transformed cell line human CVCL_BB19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134418 CVCL_BB18 ND09070 transformed cell line human CVCL_BB18 CL:0000010 Population: Caucasian; Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134419 CVCL_9H83 DD1885 transformed cell line human CVCL_9H83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134420 CVCL_9H82 DD1883 transformed cell line human CVCL_9H82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134421 CVCL_9H85 DD1888 transformed cell line human CVCL_9H85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134422 CVCL_BB11 ND08852 transformed cell line human CVCL_BB11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134423 CVCL_9H84 DD1886 transformed cell line human CVCL_9H84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134424 CVCL_BB10 ND08850 transformed cell line human CVCL_BB10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134425 CVCL_BB13 ND08933 transformed cell line human CVCL_BB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134426 CVCL_BB12 ND08878 transformed cell line human CVCL_BB12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134427 CVCL_9H81 DD1882 transformed cell line human CVCL_9H81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134428 CVCL_BB15 ND08980 transformed cell line human CVCL_BB15 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134429 CVCL_9H80 DD1880 transformed cell line human CVCL_9H80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134430 CVCL_BB14 ND08957 transformed cell line human CVCL_BB14 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134431 CVCL_9H58 DD1785 transformed cell line human CVCL_9H58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134432 CVCL_9H57 DD1784 transformed cell line human CVCL_9H57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134433 CVCL_9H59 DD1787 transformed cell line human CVCL_9H59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134434 CVCL_9H54 DD1780 transformed cell line human CVCL_9H54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134435 CVCL_9H53 DD1778 finite cell line human CVCL_9H53 CL:0000010 Karyotypic information: 46,XY,-5,+der(5),t(5;11)(p15;p15)pat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134436 CVCL_9H56 DD1783 transformed cell line human CVCL_9H56 CL:0000010 Karyotypic information: 47,XY,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134437 CVCL_9H55 DD1781 transformed cell line human CVCL_9H55 CL:0000010 Karyotypic information: 46,XY,t(5;11)(p15.3;p15.1)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134438 CVCL_9H50 DD1773 transformed cell line human CVCL_9H50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134439 CVCL_9H52 DD1776 transformed cell line human CVCL_9H52 CL:0000010 Karyotypic information: 46,XY [18]; 47,XY,+8 [12] (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134440 CVCL_9H51 DD1775 transformed cell line human CVCL_9H51 CL:0000010 Karyotypic information: 46,X,inv(X),(p21.2?;q22.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134441 CVCL_9H69 DD1820 transformed cell line human CVCL_9H69 CL:0000010 Karyotypic information: 47,XX,+mar(13/21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134442 CVCL_9H68 DD1819 transformed cell line human CVCL_9H68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134443 CVCL_9H65 DD1811 transformed cell line human CVCL_9H65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134444 CVCL_9H64 DD1810 transformed cell line human CVCL_9H64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134445 CVCL_9H67 DD1815 finite cell line human CVCL_9H67 CL:0000010 Karyotypic information: 46,XYY (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21134446 CVCL_9H66 DD1812 transformed cell line human CVCL_9H66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134447 CVCL_9H61 DD1805 finite cell line human CVCL_9H61 CL:0000010 Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134448 CVCL_9H60 DD1793 transformed cell line human CVCL_9H60 CL:0000010 Karyotypic information: 46,XY,-12,+der(12)t(11;12)(q21;p13.3)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134449 CVCL_9H63 DD1808 finite cell line human CVCL_9H63 CL:0000010 Karyotypic information: 46,XY,var5(q11.1)mat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male Part of: ECACC chromosomal abnormality collection 21134450 CVCL_9H62 DD1807 transformed cell line human CVCL_9H62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134451 CVCL_9H36 DD1753 transformed cell line human CVCL_9H36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134452 CVCL_9H35 DD1752 transformed cell line human CVCL_9H35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134453 CVCL_9H38 DD1756 transformed cell line human CVCL_9H38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134454 CVCL_9H37 DD1755 finite cell line human CVCL_9H37 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21134455 CVCL_9H32 DD1747 transformed cell line human CVCL_9H32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134456 CVCL_9H31 DD1743 transformed cell line human CVCL_9H31 CL:0000010 Karyotypic information: 47,XY,+dic(15)(pter->q11::q11->p11)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134457 CVCL_9H34 DD1750 transformed cell line human CVCL_9H34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134458 CVCL_9H33 DD1748 transformed cell line human CVCL_9H33 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134459 CVCL_9H39 DD1759 transformed cell line human CVCL_9H39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134460 CVCL_0N99 AG14133 finite cell line human CVCL_0N99 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Male 21134461 CVCL_0N98 AG13565 transformed cell line human CVCL_0N98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134462 CVCL_9H30 DD1742 transformed cell line human CVCL_9H30 CL:0000010 Karyotypic information: 46,XX,-8,+dir(8),t(7;8)(p21.3;p23.1)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134463 CVCL_9H47 DD1770 transformed cell line human CVCL_9H47 CL:0000010 Karyotypic information: 46,XY,dup(15)(q12)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134464 CVCL_9H46 DD1769 transformed cell line human CVCL_9H46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134465 CVCL_9H49 DD1772 transformed cell line human CVCL_9H49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134466 CVCL_9H48 DD1771 transformed cell line human CVCL_9H48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134467 CVCL_9H43 DD1764 transformed cell line human CVCL_9H43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134468 CVCL_9H42 DD1763 transformed cell line human CVCL_9H42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134469 CVCL_9H45 DD1767 finite cell line human CVCL_9H45 CL:0000010 Karyotypic information: 46,XX,-5,+der(5),t(5;11)(p15;p15.1)pat (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134470 CVCL_9H44 DD1765 transformed cell line human CVCL_9H44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134471 CVCL_9H41 DD1762 transformed cell line human CVCL_9H41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134472 CVCL_9H40 DD1760 transformed cell line human CVCL_9H40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134473 CVCL_BB91 ND09548 transformed cell line human CVCL_BB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134474 CVCL_BB90 ND09547 transformed cell line human CVCL_BB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134475 CVCL_BB93 ND09550 transformed cell line human CVCL_BB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134476 CVCL_BB92 ND09549 transformed cell line human CVCL_BB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134477 CVCL_BB95 ND09553 transformed cell line human CVCL_BB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134478 CVCL_BB94 ND09551 transformed cell line human CVCL_BB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134479 CVCL_BB86 ND09498 transformed cell line human CVCL_BB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134480 CVCL_BB85 ND09496 transformed cell line human CVCL_BB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134481 CVCL_BB88 ND09508 transformed cell line human CVCL_BB88 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134482 CVCL_BB87 ND09500 transformed cell line human CVCL_BB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134483 CVCL_BB89 ND09546 transformed cell line human CVCL_BB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134484 CVCL_BB97 ND09575 transformed cell line human CVCL_BB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134485 CVCL_BB96 ND09574 transformed cell line human CVCL_BB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134486 CVCL_BB99 ND09578 transformed cell line human CVCL_BB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134487 CVCL_BB98 ND09576 transformed cell line human CVCL_BB98 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134488 CVCL_BB71 ND09437 transformed cell line human CVCL_BB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134489 CVCL_BB70 ND09436 transformed cell line human CVCL_BB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134490 CVCL_BB73 ND09439 transformed cell line human CVCL_BB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134491 CVCL_BB72 ND09438 transformed cell line human CVCL_BB72 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134492 CVCL_BB64 ND09406 transformed cell line human CVCL_BB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134493 CVCL_BB63 ND09405 transformed cell line human CVCL_BB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134494 CVCL_BB66 ND09420 transformed cell line human CVCL_BB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134495 CVCL_BB65 ND09407 transformed cell line human CVCL_BB65 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; English/Greek/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134496 CVCL_BB68 ND09432 transformed cell line human CVCL_BB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134497 CVCL_BB67 ND09421 transformed cell line human CVCL_BB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134498 CVCL_BB69 ND09435 transformed cell line human CVCL_BB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134499 CVCL_BB80 ND09491 transformed cell line human CVCL_BB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134500 CVCL_BB82 ND09493 transformed cell line human CVCL_BB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134501 CVCL_BB81 ND09492 transformed cell line human CVCL_BB81 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134502 CVCL_BB84 ND09495 transformed cell line human CVCL_BB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134503 CVCL_BB83 ND09494 transformed cell line human CVCL_BB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134504 CVCL_BB75 ND09466 transformed cell line human CVCL_BB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134505 CVCL_BB74 ND09464 transformed cell line human CVCL_BB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134506 CVCL_BB77 ND09487 transformed cell line human CVCL_BB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134507 CVCL_BB76 ND09486 transformed cell line human CVCL_BB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134508 CVCL_BB79 ND09490 transformed cell line human CVCL_BB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134509 CVCL_BB78 ND09489 transformed cell line human CVCL_BB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134510 CVCL_BB51 ND09362 transformed cell line human CVCL_BB51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134511 CVCL_BB50 ND09361 transformed cell line human CVCL_BB50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134512 CVCL_BB49 ND09360 transformed cell line human CVCL_BB49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134513 CVCL_BB42 ND09292 transformed cell line human CVCL_BB42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134514 CVCL_BB41 ND09290 transformed cell line human CVCL_BB41 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134515 CVCL_BB44 ND09314 transformed cell line human CVCL_BB44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134516 CVCL_BB43 ND09294 transformed cell line human CVCL_BB43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134517 CVCL_BB46 ND09346 transformed cell line human CVCL_BB46 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134518 CVCL_BB45 ND09329 transformed cell line human CVCL_BB45 CL:0000010 Population: Caucasian; Norwegian/Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134519 CVCL_BB48 ND09350 transformed cell line human CVCL_BB48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134520 CVCL_BB47 ND09348 transformed cell line human CVCL_BB47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134521 CVCL_BB60 ND09395 transformed cell line human CVCL_BB60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134522 CVCL_BB62 ND09404 transformed cell line human CVCL_BB62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134523 CVCL_BB61 ND09403 transformed cell line human CVCL_BB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09403; probable Male 21134524 CVCL_BB53 ND09368 transformed cell line human CVCL_BB53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134525 CVCL_BB52 ND09364 transformed cell line human CVCL_BB52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134526 CVCL_BB55 ND09373 transformed cell line human CVCL_BB55 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134527 CVCL_BB54 ND09369 transformed cell line human CVCL_BB54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134528 CVCL_BB57 ND09377 transformed cell line human CVCL_BB57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134529 CVCL_BB56 ND09375 transformed cell line human CVCL_BB56 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134530 CVCL_BB59 ND09393 transformed cell line human CVCL_BB59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134531 CVCL_BB58 ND09392 transformed cell line human CVCL_BB58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134532 CVCL_T783 CiRA00026 induced pluripotent stem cell human CVCL_T783 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Met337Val (c.1009A>G); ClinVar=VCV000005228; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21134533 CVCL_SV83 HAP1 LRBA (-) 4 cancer cell line human CVCL_SV83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1742; LRBA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134534 CVCL_T782 CiRA00025 induced pluripotent stem cell human CVCL_T782 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Met337Val (c.1009A>G); ClinVar=VCV000005228; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21134535 CVCL_SV82 HAP1 LRBA (-) 3 cancer cell line human CVCL_SV82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1742; LRBA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134536 CVCL_SV85 HAP1 LRP1 (-) 2 cancer cell line human CVCL_SV85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6692; LRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134537 CVCL_T785 iPS-MEF-Fb/Ng-440A-3 induced pluripotent stem cell house mouse CVCL_T785 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Female 21134538 CVCL_SV84 HAP1 LRP1 (-) 1 cancer cell line human CVCL_SV84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6692; LRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134539 CVCL_T784 iPS-Hep-FB/Ng/gfp-103C-1 induced pluripotent stem cell house mouse CVCL_T784 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP. Male 21134540 CVCL_SV87 HAP1 LRP1 (-) 4 cancer cell line human CVCL_SV87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6692; LRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134541 CVCL_T787 iPS-MEF-Ng-20D-17 induced pluripotent stem cell house mouse CVCL_T787 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Discontinued: RCB; RCB2698; true Male 21134542 CVCL_SV86 HAP1 LRP1 (-) 3 cancer cell line human CVCL_SV86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6692; LRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134543 CVCL_T786 iPS-MEF-Ng-178B-5 induced pluripotent stem cell house mouse CVCL_T786 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Male 21134544 CVCL_SV89 HAP1 LRP5 (-) 2 cancer cell line human CVCL_SV89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134545 CVCL_T789 iPS-Stm-FB/gfp-99-1 induced pluripotent stem cell house mouse CVCL_T789 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP. Male 21134546 CVCL_SV88 HAP1 LRP5 (-) 1 cancer cell line human CVCL_SV88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134547 CVCL_T788 iPS-MEF-Ng-492B-4 induced pluripotent stem cell house mouse CVCL_T788 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Male 21134548 CVCL_0P40 BRITER transformed cell line house mouse CVCL_0P40 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P27652; Renilla-type luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Bmp2/4 dKO x R26CreER. Characteristics: Responds robustly, promptly and specifically to exogenously added BMP2 protein; Characteristics: Transfected with a BRE-SV40minP-FFLuc-SV40P-HygR-IRES-RRLuc construct 21134549 CVCL_1140 COR-L279 cancer cell line human CVCL_1140 HLA typing: A*01:01,02:01; B*35:08,58:05; C*01:02,07:01; DRB1*09:01,15:01 (PubMed=25960936); HLA typing: A*01:01,02:01; B*35:08,58:05; C*01:02,07:01; DRB1*09:01,15:01 (PubMed=26589293); Genome ancestry: African=2.83%; Native American=0.3%; East Asian, North=2.65%; East Asian, South=0%; South Asian=0%; European, North=60.06%; European, South=34.17% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.1623-45_1623-41 (c.2822-43del3); Zygosity=Heterozygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-4_384del13; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134550 CVCL_1131 COLO 680N cancer cell line human CVCL_1131 HLA typing: A*02:01,30:02; B*15:16,57:01; C*06:02,14:02 (PubMed=26589293); Genome ancestry: African=83.09%; Native American=0%; East Asian, North=4.36%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=12.54% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a nude mice xenograft Doubling time: ~60 hours (CLS); ~60-70 hours (DSMZ=ACC-182); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134551 CVCL_0P31 NOY2 cancer cell line human CVCL_0P31 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 31 hours (PubMed=18547965) 21134552 CVCL_1130 COLO 679 cancer cell line human CVCL_1130 HLA typing: A*01:01,24:02; B*08:01,51:01; C*07:01,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.47%; East Asian, South=0.33%; South Asian=0.94%; European, North=65.46%; European, South=32.79% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~34 hours (DSMZ=ACC-264); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134553 CVCL_0P30 NOY1 cancer cell line human CVCL_0P30 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 28 hours (PubMed=18547965) 21134554 CVCL_1133 COLO 741 cancer cell line human CVCL_1133 HLA typing: A*03:01,03:01; B*07:02,51:01; C*07:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.14%; East Asian, North=1.84%; East Asian, South=0%; South Asian=2.44%; European, North=63.98%; European, South=31.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro322fs*24 (c.963_964insAA); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pelvic wall. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Problematic cell line: Misclassified Originally thought to be a colon adenocarcinoma cell line but shown to be from a Melanoma (PubMed=25926053). 21134555 CVCL_0P33 JTG-1 cancer cell line human CVCL_0P33 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21134556 CVCL_1132 COLO 684 cancer cell line human CVCL_1132 HLA typing: A*02:01,11:01; B*07:02,45:01; C*04:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.07%; East Asian, South=0%; South Asian=0%; European, North=67.5%; European, South=30.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134557 CVCL_0P32 NOY1-CR cancer cell line human CVCL_0P32 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21134558 CVCL_1135 COLO 800 cancer cell line human CVCL_1135 HLA typing: A*02:01,29:02; B*44:02,44:03:01; C*05:01,16:01; DPB1*04:01,17:01; DQB1*03:01:02,02:01; DRB1*12:01,07:01:01 (PubMed=15592718); HLA typing: A*29:02,29:02; B*44:02,44:02; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.05%; East Asian, South=0.97%; South Asian=2.89%; European, North=40.03%; European, South=56.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=23851445; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.69_70CC>AT); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap) Derived from metastatic site: Hypodermis. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (DSMZ=ACC-193); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134559 CVCL_0P35 JOG-9 cancer cell line human CVCL_0P35 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21134560 CVCL_1134 COLO 792 cancer cell line human CVCL_1134 HLA typing: A*03:02,11:01; B*08:01,52:01; C*07:01,12:02 (PubMed=26589293); Genome ancestry: African=3.5%; Native American=0%; East Asian, North=5.22%; East Asian, South=0%; South Asian=6.48%; European, North=22.34%; European, South=62.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Arg274Ter (c.820C>T); ClinVar=VCV001031208; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134561 CVCL_0P34 TG-1 cancer cell line human CVCL_0P34 CL:0000010 Male 21134562 CVCL_1137 COLO 829 cancer cell line human CVCL_1137 HLA typing: A*01:01,01:01; B*08:01,40:02; C*03:04,07:06 (PubMed=26589293); Genome ancestry: African=0.12%; Native American=0%; East Asian, North=2.63%; East Asian, South=0%; South Asian=0%; European, North=71.18%; European, South=26.07% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=27094764; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Glyfs*51 (c.203_204delCG); Zygosity=Homozygous (PubMed=27094764; ATCC); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.493_634del142; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Derived from sampling site: Skin. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Single cell genome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 93052611; probable Male Characteristics: Single cell sequencing has shown that it is composed of four major sub-clones (PubMed=32587328) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project 21134563 CVCL_0P37 HPDE6c11 transformed cell line human CVCL_0P37 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from a cystadenocarcinoma in the tail of her pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Female 21134564 CVCL_0P36 A2EN transformed cell line human CVCL_0P36 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female Characteristics: Established as a model for sexually transmitted pathogens infection, pathogenesis and innate immune response studies (Kerafast) 21134565 CVCL_1136 COLO 824 cancer cell line human CVCL_1136 Genome ancestry: African=85.4%; Native American=0.04%; East Asian, North=1.28%; East Asian, South=0%; South Asian=0%; European, North=5.62%; European, South=7.67% (PubMed=30894373) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~60-80 hours (DSMZ=ACC-200); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project Caution: Previously erroneously indicated as originating from a male patient, correct sex assignment from Moore G.E in a personal communication to the authors of PubMed=9892114. 21134566 CVCL_0P39 5H7 transformed cell line human CVCL_0P39 CL:0000010 Transfected with: HGNC; 3214; EEF2 (with p.Gly717Arg); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Kerafast; EP0006; true Female Characteristics: Is diphtheria toxin (DT) resistant due to transfection with a DT-resistant elongation factor-2 (EEF2) gene 21134567 CVCL_1139 COR-L23 cancer cell line human CVCL_1139 Genome ancestry: African=0%; Native American=0.14%; East Asian, North=1.45%; East Asian, South=0%; South Asian=0.98%; European, North=69.11%; European, South=28.32% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 35 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-882); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21134568 CVCL_1138 COR-L105 cancer cell line human CVCL_1138 Genome ancestry: African=0.7%; Native American=1.16%; East Asian, North=2.98%; East Asian, South=0%; South Asian=0.88%; European, North=66.49%; European, South=27.79% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134569 CVCL_0P38 HPDE6c7 transformed cell line human CVCL_0P38 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from a cystadenocarcinoma in the tail of her pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Proteome analysis by 2D-DE/MS Female 21134570 CVCL_SV90 HAP1 LRP5 (-) 3 cancer cell line human CVCL_SV90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6697; LRP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134571 CVCL_T790 iPS-Stm-FB/gfp-99-3 induced pluripotent stem cell house mouse CVCL_T790 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP. Male 21134572 CVCL_T792 253G4 induced pluripotent stem cell human CVCL_T792 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21134573 CVCL_SV92 HAP1 LRP6 (-) 2 cancer cell line human CVCL_SV92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6698; LRP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134574 CVCL_T791 454E2 induced pluripotent stem cell human CVCL_T791 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21134575 CVCL_SV91 HAP1 LRP6 (-) 1 cancer cell line human CVCL_SV91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6698; LRP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134576 CVCL_SV72 HAP1 LMTK2 (-) cancer cell line human CVCL_SV72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17880; LMTK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134577 CVCL_T772 HCT116-XRCC4(+/-) cancer cell line human CVCL_T772 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 12831; XRCC4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21134578 CVCL_SV71 HAP1 LMO4 (-) 2 cancer cell line human CVCL_SV71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6644; LMO4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134579 CVCL_T771 HCT116-Artemis(-/-) cancer cell line human CVCL_T771 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 17642; DCLRE1C; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21134580 CVCL_T774 G1MF285D hybridoma house mouse CVCL_T774 CL:0000010 Monoclonal antibody isotype: IgG1. 21134581 CVCL_SV74 HAP1 LMTK3 (-) 2 cancer cell line human CVCL_SV74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19295; LMTK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134582 CVCL_SV73 HAP1 LMTK3 (-) 1 cancer cell line human CVCL_SV73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19295; LMTK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134583 CVCL_T773 HCT116-XRCC4(-/-) cancer cell line human CVCL_T773 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 12831; XRCC4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21134584 CVCL_T776 CiRA086Ai-m1 induced pluripotent stem cell human CVCL_T776 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 16400; NLRP3; Simple; p.Gly309Ser (c.925G>A) (p.Gly307Ser, c.919G>A); Zygosity=Heterozygous; Note=Somatic mosaicism (PubMed=22723549) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21134585 CVCL_SV76 HAP1 LOH12CR1 (-) 1 cancer cell line human CVCL_SV76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17950; BORCS5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134586 CVCL_SV75 HAP1 LMTK3 (-) 3 cancer cell line human CVCL_SV75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19295; LMTK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134587 CVCL_T775 Nips-B2 induced pluripotent stem cell human CVCL_T775 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; epithelium. Female 21134588 CVCL_T778 CiRA188Ai-W1 induced pluripotent stem cell human CVCL_T778 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21134589 CVCL_SV78 HAP1 LOX (-) 1 cancer cell line human CVCL_SV78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6664; LOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134590 CVCL_T777 CiRA188Ai-M1 induced pluripotent stem cell human CVCL_T777 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 16400; NLRP3; Simple; p.Tyr572Cys (c.1715G>A) (p.Tyr570Cys, c.1709A>G); ClinVar=VCV000097946; Zygosity=Heterozygous; Note=Somatic mosaicism (PubMed=22723549) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21134591 CVCL_SV77 HAP1 LOH12CR1 (-) 2 cancer cell line human CVCL_SV77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17950; BORCS5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134592 CVCL_T779 CiRA00022 induced pluripotent stem cell human CVCL_T779 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gln343Arg (c.1028A>G); ClinVar=VCV000005235; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21134593 CVCL_SV79 HAP1 LPPR5 (-) cancer cell line human CVCL_SV79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31703; PLPPR5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134594 CVCL_1151 CW-2 cancer cell line human CVCL_1151 HLA typing: A*26:01,26:01; B*44:03,46:01; C*14:03,14:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=75.46%; East Asian, South=24.54%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro140His (c.419C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro47Pro (c.141G>A); ClinVar=VCV000184839; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134595 CVCL_0P51 GM05260 transformed cell line human CVCL_0P51 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Glu1064Ala (c.3191A>C); ClinVar=VCV000370081; Zygosity=Heterozygous (from familial inference of GM05257 and GM05258); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (from familial inference of GM05257 and GM05258) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134596 CVCL_1150 CTV-1 cancer cell line human CVCL_1150 Genome ancestry: African=1.02%; Native American=1.28%; East Asian, North=0%; East Asian, South=0.34%; South Asian=5.64%; European, North=45.18%; European, South=46.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Gly477Ser (c.1429G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Gly831Glu (c.2492G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala353Val (c.1058C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Pro447Leu (c.1340C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6524; LCK; Simple; p.Ala500Thr (c.1498G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gly1532Arg (c.4594G>A); ClinVar=VCV001462589; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Ser2523Ter (c.7568C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8804; PDGFRB; Simple; p.Met772Ile (c.2316G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys656Phe (c.1967G>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Arg75Met (c.224G>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys175Met (c.524A>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~36 hours (PubMed=6593267); ~40 hours (DSMZ=ACC-40); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Probably misidentified Originally thought to be a acute monoblastic leukemia but seems to be a T-ALL cell line (PubMed=15843827). Was also said to originate from a 40 year old female patient (PubMed=6593267) but has a male STR profile. 21134597 CVCL_0P50 GM05259 finite cell line human CVCL_0P50 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Glu1064Ala (c.3191A>C); ClinVar=VCV000370081; Zygosity=Heterozygous (from familial inference of GM05257 and GM05258); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (from familial inference of GM05257 and GM05258) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21134598 CVCL_1142 COR-L96-CAR cancer cell line human CVCL_1142 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21134599 CVCL_0P42 VM-M3/Fluc cancer cell line house mouse CVCL_0P42 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: VM/Dk. Male Doubling time: 2 days (Kerafast) 21134600 CVCL_1141 COR-L88 cancer cell line human CVCL_1141 HLA typing: A*01:01,01:01; B*37:04,58:05; C*07:06,07:06 (PubMed=25960936); HLA typing: A*01:01,01:01; B*37:04,58:05; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=2.68%; Native American=0%; East Asian, North=2.39%; East Asian, South=0%; South Asian=0%; European, North=58.19%; European, South=36.74% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134601 CVCL_0P41 VM-M2/Fluc cancer cell line house mouse CVCL_0P41 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: VM/Dk. Male Doubling time: 2 days (Kerafast) 21134602 CVCL_1144 CP66-MEL cancer cell line human CVCL_1144 Genome ancestry: African=0%; Native American=0.27%; East Asian, North=0.56%; East Asian, South=0%; South Asian=2.13%; European, North=67.46%; European, South=29.58% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134603 CVCL_0P44 GM04128 finite cell line human CVCL_0P44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134604 CVCL_1143 CP50-MEL-B cancer cell line human CVCL_1143 Genome ancestry: African=0%; Native American=0.34%; East Asian, North=0%; East Asian, South=2.1%; South Asian=3.16%; European, North=59.29%; European, South=35.11% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Tyr44fs*76 (c.128_129insT); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro246fs*11 (c.736_737insAA); Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134605 CVCL_0P43 VM-NM1/Fluc cancer cell line house mouse CVCL_0P43 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: VM/Dk. Female Doubling time: 2-5 days (Kerafast) 21134606 CVCL_1146 CPC-N cancer cell line human CVCL_1146 HLA typing: A*01:01,30:02; B*08:01,18:01; C*05:01,07:01 (PubMed=25960936); HLA typing: A*01:01,30:02; B*08:01,18:01; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0.41%; Native American=0%; East Asian, North=0.58%; East Asian, South=0.17%; South Asian=1.56%; European, North=55.27%; European, South=42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~4 days (DSMZ=ACC-306); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134607 CVCL_0P46 GM05255 finite cell line human CVCL_0P46 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21134608 CVCL_1145 CP67-MEL cancer cell line human CVCL_1145 Genome ancestry: African=0.09%; Native American=0.46%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=64.17%; European, South=35.28% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134609 CVCL_0P45 GM04268 finite cell line human CVCL_0P45 CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu285Ala (c.854A>C); ClinVar=VCV000002605; Zygosity=Homozygous (PubMed=19815695; PubMed=33304759) Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21134610 CVCL_1148 CRO-AP5 cancer cell line human CVCL_1148 HLA typing: A*24:02:01,30:01:01; B*13:02:01,15:18:01; C*06:02:01,07:04:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,16:01:01; DQA1*02:01:01,02:01:01; DQB1*02:02:01,03:01:01; DRA*01:01:01,01:01:01; DRB1*07:01:01,11:01:01 (DSMZCellDive=ACC-215) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains 30 to 60 copies of the human herpesvirus 8 (HHV-8/KSHV) genome per cell Doubling time: ~35-40 hours (DSMZ=ACC-215) Part of: LL-100 blood cancer cell line panel 21134611 CVCL_0P48 GM05257 finite cell line human CVCL_0P48 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Glu1064Ala (c.3191A>C); ClinVar=VCV000370081; Zygosity=Heterozygous (from autologous cell line GM05258); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (from autologous cell line GM05258) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21134612 CVCL_1147 CRO-AP2 cancer cell line human CVCL_1147 HLA typing: A*68:02:01,68:02:01; B*15:01:01,15:01:01; C*03:03:01,07:04:01; DPA1*01:03:01,02:01:01; DPB1*03:01:01,10:01:01; DQA1*03:01:01,03:01:01; DQB1*03:02:01,05:01:01; DRA*01:01:01,01:02:02; DRB1*04:02:01,14:54:01 (DSMZCellDive=ACC-48); Genome ancestry: African=0.25%; Native American=0.15%; East Asian, North=0.73%; East Asian, South=0.29%; South Asian=5.13%; European, North=44.53%; European, South=48.9% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~20-40 hours (DSMZ=ACC-48); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21134613 CVCL_0P47 GM05256 transformed cell line human CVCL_0P47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134614 CVCL_1149 CTB-1 cancer cell line human CVCL_1149 Genome ancestry: African=0%; Native American=0.23%; East Asian, North=25.3%; East Asian, South=74.47%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Ser462fs (c.1386delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pericardial effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=21533490); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134615 CVCL_0P49 GM05258 transformed cell line human CVCL_0P49 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Glu1064Ala (c.3191A>C); ClinVar=VCV000370081; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134616 CVCL_T781 CiRA00024 induced pluripotent stem cell human CVCL_T781 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Met337Val (c.1009A>G); ClinVar=VCV000005228; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21134617 CVCL_SV81 HAP1 LRBA (-) 2 cancer cell line human CVCL_SV81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1742; LRBA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134618 CVCL_T780 CiRA00023 induced pluripotent stem cell human CVCL_T780 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gln343Arg (c.1028A>G); ClinVar=VCV000005235; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21134619 CVCL_SV80 HAP1 LRBA (-) 1 cancer cell line human CVCL_SV80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1742; LRBA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134620 CVCL_T761 CHO-SPB-1/cLCB1 spontaneously immortalized cell line CVCL_T761 CL:0000010 Transfected with: UniProtKB; O54695; Cricetulus griseus Sptlc1 Derived from sampling site: Ovary. Female 21134621 CVCL_SV61 HAP1 LITAF (-) 1 cancer cell line human CVCL_SV61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16841; LITAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134622 CVCL_T760 CHO-SPB-1 spontaneously immortalized cell line CVCL_T760 CL:0000010 Derived from sampling site: Ovary. Female 21134623 CVCL_SV60 HAP1 LIMK2 (-) cancer cell line human CVCL_SV60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6614; LIMK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134624 CVCL_T763 CHO-FLAG-hBLT1 spontaneously immortalized cell line CVCL_T763 CL:0000010 Transfected with: HGNC; 6713; LTB4R Derived from sampling site: Ovary. Female 21134625 CVCL_SV63 HAP1 LMNA (-) 1 cancer cell line human CVCL_SV63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134626 CVCL_SV62 HAP1 LITAF (-) 2 cancer cell line human CVCL_SV62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16841; LITAF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134627 CVCL_T762 UPS-1 spontaneously immortalized cell line CVCL_T762 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A061HXB8; Atp11c; Simple; p.Trp836Ter (c.2508G>A) (W664X); Zygosity=Homozygous (PubMed=26420878) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Defective in the uptake of fluorescent phosphatidylserine analogs by the nonendocytic pathway (PubMed=7876305) 21134628 CVCL_T765 Ba/F3-CL1 factor-dependent cell line house mouse CVCL_T765 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21134629 CVCL_SV65 HAP1 LMNA (-) 3 cancer cell line human CVCL_SV65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134630 CVCL_T764 CHO-HA-hBLT2 spontaneously immortalized cell line CVCL_T764 CL:0000010 Transfected with: HGNC; 19260; LTB4R2 Derived from sampling site: Ovary. Female 21134631 CVCL_SV64 HAP1 LMNA (-) 2 cancer cell line human CVCL_SV64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6636; LMNA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134632 CVCL_SV67 HAP1 LMNB1 (-) 2 cancer cell line human CVCL_SV67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134633 CVCL_T767 hPSC-1 finite cell line human CVCL_T767 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Male Senescence: Senesces at 50 PDL (RCB=RCB3586) 21134634 CVCL_SV66 HAP1 LMNB1 (-) 1 cancer cell line human CVCL_SV66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134635 CVCL_T766 MOPC-70A cancer cell line house mouse CVCL_T766 CL:0000010 Breed/subspecies: BALB/c. Female 21134636 CVCL_SV69 HAP1 LMNB2 (-) 1 cancer cell line human CVCL_SV69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6638; LMNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134637 CVCL_T769 hPSC-5 finite cell line human CVCL_T769 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Female Senescence: Senesces at 50 PDL (RCB=RCB3588) 21134638 CVCL_SV68 HAP1 LMNB1 (-) 3 cancer cell line human CVCL_SV68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134639 CVCL_T768 hPSC-14 finite cell line human CVCL_T768 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Male Senescence: Senesces at 50 PDL (RCB=RCB3589) 21134640 CVCL_1111 CAL-54 cancer cell line human CVCL_1111 HLA typing: A*01:01,01:01; B*57:01,57:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.26%; Native American=0%; East Asian, North=0%; East Asian, South=0.56%; South Asian=2.72%; European, North=51.11%; European, South=45.35% (PubMed=30894373) CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 35 +- 2 hours, at 14th passage (PubMed=8868943); ~72 hours (DSMZ=ACC-365); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21134641 CVCL_0P11 GM00016 finite cell line human CVCL_0P11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21134642 CVCL_0P10 AG20456 transformed cell line human CVCL_0P10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21134643 CVCL_1110 CAL-51 cancer cell line human CVCL_1110 HLA typing: A*24:02,29:02; B*44:26,51:01; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.75%; East Asian, North=0.86%; East Asian, South=0%; South Asian=2.28%; European, North=55.8%; European, South=40.31% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474) Doubling time: 24 hours (PubMed=25984343); ~30 hours (PubMed=34339474); ~50-60 hours (DSMZ=ACC-302); Microsatellite instability: Instable (MSI-low) (PubMed=12661003; PubMed=15677628; PubMed=31068700; Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21134644 CVCL_1113 CAL-72 cancer cell line human CVCL_1113 Genome ancestry: African=67.94%; Native American=0.09%; East Asian, North=1.27%; East Asian, South=0%; South Asian=24.79%; European, North=0%; European, South=5.91% (PubMed=30894373) CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=10389764); Derived from sampling site: Bone; patella. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 66 hours, at 17th passage (PubMed=10389764); ~40-50 hours (DSMZ=ACC-439); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134645 CVCL_0P13 GM00033 finite cell line human CVCL_0P13 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21134646 CVCL_1112 CAL-62 cancer cell line human CVCL_1112 Genome ancestry: African=0.55%; Native American=0.27%; East Asian, North=1.91%; East Asian, South=0%; South Asian=1.04%; European, North=46.22%; European, South=50.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Glu1541Ter (c.4621G>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asp1485fs (c.4454delA); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Homozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Glu215Ter (c.643G>T); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Homozygous (PubMed=30737244) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~24 hours (DSMZ=ACC-448); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134647 CVCL_0P12 GM00032 finite cell line human CVCL_0P12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21134648 CVCL_1115 CAMA-1 cancer cell line human CVCL_1115 HLA typing: A*02:01,32:01; B*15:01,40:02; C*02:02,03:03; DQB1*03:01,03:01; DRB1*11:01,11:01 (PubMed=25960936); HLA typing: A*02:01,32:01; B*15:01,40:02; C*02:02,03:03; DQA1*05:02,03:02; DQB1*03:04,03:04; DRB1*11:30,13:07 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=0%; East Asian, North=1.38%; East Asian, South=0%; South Asian=0%; European, North=66.52%; European, South=31.74% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.1712-1G>A; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19593635); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp92His (c.274G>C); Zygosity=Heterozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=16541312; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 72.94 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 926 21134649 CVCL_0P15 GM00060 finite cell line human CVCL_0P15 CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Gly176Asp (c.527C>A); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Ala305Glu (c.914C>A); ClinVar=VCV000002607; Zygosity=Heterozygous (PubMed=33304759) Derived from sampling site: Brain Cell type=Fibroblast.. Male 21134650 CVCL_1114 CAL-85-1 cancer cell line human CVCL_1114 HLA typing: A*03:01,03:01; B*50:01,67:02; C*06:02,12:02 (PubMed=26589293); Genome ancestry: African=0.83%; Native American=0%; East Asian, North=4.79%; East Asian, South=0%; South Asian=87.38%; European, North=0%; European, South=7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1461Profs*2 (c.4381delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Breast. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~70 hours (DSMZ=ACC-440); 99.85 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21134651 CVCL_0P14 GM00059 finite cell line human CVCL_0P14 CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Gly176Asp (c.527C>A); Zygosity=Heterozygous (PubMed=33304759); Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Ala305Glu (c.914C>A); ClinVar=VCV000002607; Zygosity=Heterozygous (PubMed=19815695; PubMed=33304759); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Arg249Trp (c.745C>T); ClinVar=VCV000126510; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21134652 CVCL_1117 CAS-1 cancer cell line human CVCL_1117 HLA typing: A*02:01,02:01; B*50:01,51:01; C*01:02,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.58%; East Asian, North=0%; East Asian, South=0.08%; South Asian=3.36%; European, North=46.51%; European, South=49.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 60 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21134653 CVCL_0P17 R3230AC clone D cancer cell line Norway rat CVCL_0P17 CL:0000010 Breed/subspecies: Fischer 344. Female 21134654 CVCL_1116 CaR-1 cancer cell line human CVCL_1116 HLA typing: A*02:06,11:01; B*15:01,54:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=77.73%; East Asian, South=21.34%; South Asian=0.92%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Homozygous (PubMed=16418264; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Left inguinal lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 46 hours (CelloPub=CLPUB00026); ~55 hours (lot 110598), ~32 hours (lot 01232012) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutation indicated incorrectly as being at c.701A>G in PubMed=9290701 21134655 CVCL_0P16 L-M(TK-,APRT-) spontaneously immortalized cell line house mouse CVCL_0P16 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:77751; 8-azaadenine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21134656 CVCL_1119 CFPAC-1 cancer cell line human CVCL_1119 HLA typing: A*02:01,03:01; B*35:08,73:01; C*04:01,15:05 (PubMed=26589293); Genome ancestry: African=3.95%; Native American=0%; East Asian, North=5.48%; East Asian, South=0%; South Asian=0%; European, North=45.39%; European, South=45.18% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907; PubMed=11169959; PubMed=11787853; PubMed=15367885; PubMed=18380791); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957; ATCC); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Arg (c.724T>C); ClinVar=VCV000449512; Zygosity=Homozygous (PubMed=11169959; PubMed=11787853; PubMed=15367885; Cosmic-CLP) Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (at 17th passage), 32 hours (at 74th passage) (PubMed=1692630); 45 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21134657 CVCL_0P19 R3230AC clone I cancer cell line Norway rat CVCL_0P19 CL:0000010 Breed/subspecies: Fischer 344. Female 21134658 CVCL_1118 CCF-STTG1 cancer cell line human CVCL_1118 HLA typing: A*01:01,01:01; B*08:01,37:01; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=0.55%; Native American=0%; East Asian, North=1.13%; East Asian, South=0%; South Asian=0.6%; European, North=60.84%; European, South=36.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1977; true; Discontinued: TKG; TKG 0581; true. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030) 21134659 CVCL_0P18 R3230AC clone H cancer cell line Norway rat CVCL_0P18 CL:0000010 Breed/subspecies: Fischer 344. Female 21134660 CVCL_SV70 HAP1 LMO4 (-) 1 cancer cell line human CVCL_SV70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6644; LMO4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134661 CVCL_T770 HCT116-Artemis(+/-) cancer cell line human CVCL_T770 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 17642; DCLRE1C; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21134662 CVCL_SV50 HAP1 LGR4 (-) 2 cancer cell line human CVCL_SV50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13299; LGR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134663 CVCL_T750 RECC-RP15 cancer cell line CVCL_T750 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: RPRL-7. Female Group: Bird cell line 21134664 CVCL_SV52 HAP1 LGR4 (-) 4 cancer cell line human CVCL_SV52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13299; LGR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134665 CVCL_T752 PC12-F7 cancer cell line Norway rat CVCL_T752 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Devoid of Syt1 and Syt2 expression Survived selective killing with an anti-synaptotagmin antibody. 21134666 CVCL_SV51 HAP1 LGR4 (-) 3 cancer cell line human CVCL_SV51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13299; LGR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134667 CVCL_T751 RECC-RP20 cancer cell line CVCL_T751 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: RPRL-7. Group: Bird cell line 21134668 CVCL_SV54 HAP1 LIG3 (-) 2 cancer cell line human CVCL_SV54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6600; LIG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134669 CVCL_T754 SS-P cancer cell line Norway rat CVCL_T754 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21134670 CVCL_SV53 HAP1 LIG3 (-) 1 cancer cell line human CVCL_SV53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6600; LIG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134671 CVCL_T753 PC12-G11 cancer cell line Norway rat CVCL_T753 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21134672 CVCL_SV56 HAP1 LIG4 (-) 2 cancer cell line human CVCL_SV56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6601; LIG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134673 CVCL_T756 LDS-Falck 01 cancer cell line human CVCL_T756 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=17970070) Derived from metastatic site: Pleural effusion. Male Doubling time: <24 hours (PubMed=17970070) 21134674 CVCL_SV55 HAP1 LIG4 (-) 1 cancer cell line human CVCL_SV55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6601; LIG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134675 CVCL_T755 JK-GMS cancer cell line human CVCL_T755 CL:0000010 Population: Korean; Derived from sampling site: Chest wall. Male Doubling time: 38.4 hours (PubMed=11850535) 21134676 CVCL_SV58 HAP1 LIMK1 (-) 1 cancer cell line human CVCL_SV58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6613; LIMK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134677 CVCL_T758 IEC-14 finite cell line Norway rat CVCL_T758 CL:0000010 Derived from sampling site: Small intestine Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Male 21134678 CVCL_T757 EES1 cancer cell line human CVCL_T757 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=17077599) Population: Japanese; Derived from sampling site: Thigh. Female Characteristics: Established from a nude mouse xenograft Doubling time: 24 hours (PubMed=17077599) Caution: Not to be confused with Ewing sarcoma cell line EES-1 (Cellosaurus=CVCL_W468) 21134679 CVCL_SV57 HAP1 LIMCH1 (-) 1 cancer cell line human CVCL_SV57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29191; LIMCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134680 CVCL_SV59 HAP1 LIMK1 (-) 2 cancer cell line human CVCL_SV59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6613; LIMK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134681 CVCL_T759 IEC-17 finite cell line Norway rat CVCL_T759 CL:0000010 Derived from sampling site: Small intestine; duodenum Cell type=Epithelial cell.; Breed/subspecies: Charles River Sprague Dawley (CD(SD)). Unspecified Doubling time: 22.4 hours (PubMed=6273638) 21134682 CVCL_1120 CGTH-W-1 cancer cell line human CVCL_1120 Genome ancestry: African=0%; Native American=2.04%; East Asian, North=0.24%; East Asian, South=0%; South Asian=1.16%; European, North=64.53%; European, South=32.03% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Ser (c.764T>G); ClinVar=VCV000376622; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: DSMZ; ACC-360; true Male Doubling time: ~18 hours (PubMed=8888804); ~20-25 hours (DSMZ=ACC-360); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00536 Problematic cell line: Contaminated Shown to be a SW579 derivative (PubMed=25877200; DSMZ). Originally thought to originate from a thyroid gland follicular carcinoma metastasizing to the sternum of a 70 year old Chinese female patient. 21134683 CVCL_0P20 R3230AC clone L cancer cell line Norway rat CVCL_0P20 CL:0000010 Breed/subspecies: Fischer 344. Female 21134684 CVCL_1122 CHL-1 cancer cell line human CVCL_1122 HLA typing: A*02:01,02:01; B*07:13,57:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.39%; East Asian, South=0%; South Asian=0%; European, North=68.4%; European, South=31.21% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2352; CREM + HGNC; 3508; EWSR1; Name(s)=EWSR1-CREM (PubMed=23637631); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Ile228Val (c.682A>G); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ERK genetic alteration cell panel (ATCC TCP-1033); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9446 21134685 CVCL_0P22 H2K 2B4 conditionally immortalized cell line house mouse CVCL_0P22 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Muscle; extensor digitorum longus Cell type=Myoblast.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Male Characteristics: Under permissive conditions H2K 2B4 cells terminally differentiate in vitro to form uniform myotube (PubMed=21935475) 21134686 CVCL_1121 ChaGo-K-1 cancer cell line human CVCL_1121 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=1.18%; Native American=0%; East Asian, North=3.52%; East Asian, South=0%; South Asian=0.39%; European, North=59.93%; European, South=34.97% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; c.1921-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.His684Asp (c.2050C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu837Lys (c.2509G>A); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Hypodermis. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134687 CVCL_0P21 DPM conditionally immortalized cell line house mouse CVCL_0P21 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic tooth bud; dental papilla Cell type=Mesenchymal cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21134688 CVCL_1124 CHP-134 cancer cell line human CVCL_1124 Genome ancestry: African=0.04%; Native American=0%; East Asian, North=0.15%; East Asian, South=0%; South Asian=0.93%; European, North=70.26%; European, South=28.62% (PubMed=30894373) CL:0000010 Derived from metastatic site: Adrenal gland. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 57.6 hours (PubMed=10079); ~30 hours (DSMZ=ACC-653); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134689 CVCL_0P24 MLO-A5 transformed cell line house mouse CVCL_0P24 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; long bone Cell type=Osteocyte.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 Bgla promoter T-Ag transgenic. Unspecified Characteristics: Model for the osteoblast to osteocyte differentiation process, the mineralization process and the effects of mechanical loading on biomineralization (Kerafast) 21134690 CVCL_1123 CHP-126 cancer cell line human CVCL_1123 Genome ancestry: African=0%; Native American=0.41%; East Asian, North=1.27%; East Asian, South=0%; South Asian=0.75%; European, North=65.66%; European, South=31.9% (PubMed=30894373) CL:0000010 Derived from sampling site: Retroperitoneal space. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300432; true Female Doubling time: 44.5 hours (PubMed=10079); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134691 CVCL_0P23 IDG-SW3 conditionally immortalized cell line house mouse CVCL_0P23 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Gly, p.Ser72Ala, Lys79Arg, Thr203Tyr and His231Leu = Topaz) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.; Breed/subspecies: C57BL/6-Tg(Dmp1-Topaz)1Ikal/J x (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Expresses GFP Topaz under the control of the Dmp1 promoter 21134692 CVCL_0P26 AA9 [Mouse sarcoma] cancer cell line house mouse CVCL_0P26 CL:0000010 Transfected with: UniProtKB; A7LCJ3; Pig SIGLEC1 Breed/subspecies: BALB/c. Female Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Patented cell line 21134693 CVCL_1126 CML-T1 cancer cell line human CVCL_1126 HLA typing: A*26:01,26:01; B*40:06,46:01; C*01:02,03:04 (PubMed=26589293); HLA typing: A*26:01:01,26:01:01; B*40:06:01,46:01:01; C*01:02:01,03:04:01; DQB1*04:01:01,05:02:01 (DSMZCellDive=ACC-7); Genome ancestry: African=0%; Native American=0%; East Asian, North=71.95%; East Asian, South=26.83%; South Asian=0.3%; European, North=0%; European, South=0.92% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr321fs*23 (c.963delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg290Cys (c.868C>T); ClinVar=VCV000216472; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48-60 hours (DSMZ=ACC-7); Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21134694 CVCL_1125 CHP-212 cancer cell line human CVCL_1125 HLA typing: A*02:01,24:02; B*07:07,58:05; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=2.16%; Native American=0%; East Asian, North=1.09%; East Asian, South=0.43%; South Asian=0.86%; European, North=70.26%; European, South=25.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap) Derived from sampling site: Brain. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Intermediate type (I-type) (PubMed=15720811) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21134695 CVCL_0P25 L6-GLUT-4myc transformed cell line Norway rat CVCL_0P25 CL:0000010 Transfected with: RGD; 2711; Slc2a4; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male Characteristics: Stably expresses Slc2a4/Glut4 containing a 14 amino-acid epitope of human MYC within its first exofacial loop This construct allows the study of Slc2a4 translocation. 21134696 CVCL_1128 COLO 668 cancer cell line human CVCL_1128 Genome ancestry: African=2.4%; Native American=16.55%; East Asian, North=3.63%; East Asian, South=0%; South Asian=3.09%; European, North=28.55%; European, South=45.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=18397470); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu337Trpfs*12 (c.1010delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln436Ter (c.1306C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21134697 CVCL_0P28 D4M-5A cancer cell line house mouse CVCL_0P28 CL:0000010 Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous Breed/subspecies: C57BL/6 x Tyr::CreER;BrafCA;Ptenlox/lox transgenic. 21134698 CVCL_1127 CoCM-1 cancer cell line human CVCL_1127 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg1023Gln (c.3068G>A); Zygosity=Unspecified (PubMed=20570890); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=16418264) Population: Japanese; Derived from sampling site: Colon; descending. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=2570482); ~34 hours (lot 06302006), ~59 hours (lot 12222011) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=25926053) 21134699 CVCL_0P27 D4M-3A cancer cell line house mouse CVCL_0P27 CL:0000010 Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous Breed/subspecies: C57BL/6 x Tyr::CreER;BrafCA;Ptenlox/lox transgenic. Male 21134700 CVCL_1129 COLO 678 cancer cell line human CVCL_1129 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=2.56%; Native American=0.29%; East Asian, North=3.34%; East Asian, South=0%; South Asian=0%; European, North=57.97%; European, South=35.83% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=24755471; PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60-70 hours (DSMZ=ACC-194); Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134701 CVCL_0P29 D4M-7A cancer cell line house mouse CVCL_0P29 CL:0000010 Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous Breed/subspecies: C57BL/6 x Tyr::CreER;BrafCA;Ptenlox/lox transgenic. Female 21134702 CVCL_T741 Black93 cancer cell line human CVCL_T741 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Virology: EBV-negative Doubling time: 32.5 hours (PubMed=8847894) 21134703 CVCL_SV41 HAP1 LDHA (-) 2 cancer cell line human CVCL_SV41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6535; LDHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134704 CVCL_SV40 HAP1 LDHA (-) 1 cancer cell line human CVCL_SV40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6535; LDHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134705 CVCL_T740 HST2 cancer cell line human CVCL_T740 HLA typing: A*02:06,31:01; B*38:02,55:02; C*01:02,07:02 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21134706 CVCL_SV43 HAP1 LDLR (-) cancer cell line human CVCL_SV43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6547; LDLR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134707 CVCL_T743 KSU cancer cell line human CVCL_T743 CL:0000010 Population: Japanese; Derived from sampling site: Bone; left proximal tibia. Male Doubling time: 58.8 hours (PubMed=1449054) 21134708 CVCL_SV42 HAP1 LDHB (-) cancer cell line human CVCL_SV42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6541; LDHB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134709 CVCL_T742 IIB-BR-G-MT cancer cell line human CVCL_T742 CL:0000010 Derived from sampling site: Breast. Female 21134710 CVCL_SV45 HAP1 LEPR (-) cancer cell line human CVCL_SV45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6554; LEPR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134711 CVCL_T745 NOS-1.C8 cancer cell line human CVCL_T745 CL:0000010 Population: Japanese; Derived from sampling site: Bone; left proximal tibia. Male 21134712 CVCL_SV44 HAP1 LEF1 (-) 1 cancer cell line human CVCL_SV44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6551; LEF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134713 CVCL_T744 KSU.C3 cancer cell line human CVCL_T744 CL:0000010 Population: Japanese; Derived from sampling site: Bone; left proximal tibia. Male 21134714 CVCL_SV47 HAP1 LGALS1 (-) 1 cancer cell line human CVCL_SV47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6561; LGALS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134715 CVCL_T747 NOS2 cancer cell line human CVCL_T747 CL:0000010 Population: Japanese. Female 21134716 CVCL_SV46 HAP1 LETMD1 (-) 1 cancer cell line human CVCL_SV46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24241; LETMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134717 CVCL_T746 NOS3 cancer cell line human CVCL_T746 CL:0000010 Population: Japanese Female 21134718 CVCL_SV49 HAP1 LGR4 (-) 1 cancer cell line human CVCL_SV49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13299; LGR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134719 CVCL_T749 RECC-RP14 cancer cell line CVCL_T749 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: RPRL-7. Male Group: Bird cell line 21134720 CVCL_SV48 HAP1 LGALS3 (-) 1 cancer cell line human CVCL_SV48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6563; LGALS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134721 CVCL_T748 MDCC-AL1 cancer cell line CVCL_T748 CL:0000010 Breed/subspecies: N-line. Group: Bird cell line 21134722 CVCL_T730 117-13 hybridoma house mouse CVCL_T730 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:17292; Lactotetraosylceramide. 21134723 CVCL_SV30 HAP1 LAMTOR4 (-) 3 cancer cell line human CVCL_SV30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33772; LAMTOR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134724 CVCL_SV32 HAP1 LAT (-) 1 cancer cell line human CVCL_SV32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18874; LAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134725 CVCL_T732 HCC-48 cancer cell line human CVCL_T732 CL:0000010 Population: Japanese Discontinued: JCRB; JCRB0185; probable. Doubling time: 24 hours (PubMed=8242641) 21134726 CVCL_T731 1C7 [Mouse hybridoma against L.japonicum basal apparatus] hybridoma house mouse CVCL_T731 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Lygodium japonicum strain an-1 basal apparatus. 21134727 CVCL_SV31 HAP1 LARGE (-) cancer cell line human CVCL_SV31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6511; LARGE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134728 CVCL_SV34 HAP1 LATS1 (-) 2 cancer cell line human CVCL_SV34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134729 CVCL_T734 HEC-46 cancer cell line human CVCL_T734 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0258; true. Doubling time: 22 hours (PubMed=8242641) 21134730 CVCL_SV33 HAP1 LATS1 (-) 1 cancer cell line human CVCL_SV33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134731 CVCL_T733 HCC-50 cancer cell line human CVCL_T733 CL:0000010 Population: Japanese Discontinued: JCRB; JCRB0184; probable. Doubling time: 22 hours (PubMed=8242641) 21134732 CVCL_SV36 HAP1 LATS2 (-) 2 cancer cell line human CVCL_SV36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6515; LATS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134733 CVCL_T736 SPC78 cancer cell line human CVCL_T736 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Male Doubling time: 145 hours (PubMed=1373705). 21134734 CVCL_SV35 HAP1 LATS2 (-) 1 cancer cell line human CVCL_SV35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6515; LATS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134735 CVCL_T735 ZL92 cancer cell line human CVCL_T735 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 87 hours (PubMed=1373705) 21134736 CVCL_SV38 HAP1 LCMT1 (-) 2 cancer cell line human CVCL_SV38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17557; LCMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134737 CVCL_T738 KiKu-M cancer cell line human CVCL_T738 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female 21134738 CVCL_SV37 HAP1 LCMT1 (-) 1 cancer cell line human CVCL_SV37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17557; LCMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134739 CVCL_T737 KTHOS cancer cell line human CVCL_T737 CL:0000010 Population: Japanese; Derived from sampling site: Bone; distal femur. Female Doubling time: 35.6 hours (PubMed=15693848) 21134740 CVCL_SV39 HAP1 LCMT1 (-) 3 cancer cell line human CVCL_SV39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17557; LCMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134741 CVCL_T739 SSTW cancer cell line human CVCL_T739 HLA typing: A*24:01,26:01; B*15:01,46:01; C*01:02,03:03 (PubMed=19818766). CL:0000010 Population: Japanese 21134742 CVCL_1100 Ca Ski cancer cell line human CVCL_1100 HLA typing: A*02:01,03:01; B*07:02,37:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.02%; Native American=0%; East Asian, North=1.86%; East Asian, South=0%; South Asian=0%; European, North=68.36%; European, South=28.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln4079Ter (c.12235C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from metastatic site: Small intestine. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7915; true Female Virology: Contains from 100 to 800 copies of the HPV16 genome; some complete and others truncated Doubling time: 3.2 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Group: Space-flown cell line (cellonaut); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134743 CVCL_0P00 GM02074 finite cell line human CVCL_0P00 CL:0000010 Sequence variation: Mutation; HGNC; 4696; GUSB; Simple; p.Arg357Ter (c.1069C>T); ClinVar=VCV000000908; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21134744 CVCL_0P02 AG14412 finite cell line human CVCL_0P02 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21134745 CVCL_1102 Ca9-22 cancer cell line human CVCL_1102 HLA typing: A*02:07,24:02; B*35,46:01; C*01:02,14:02 (PubMed=9023415); Genome ancestry: African=0.96%; Native American=0%; East Asian, North=79.73%; East Asian, South=18.82%; South Asian=0%; European, North=0%; European, South=0.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=1570156; PubMed=10741724; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00437 Problematic cell line: Partially contaminated Some stocks of Ca9-22 are contaminated with MSK-922 (PubMed=21868764). 21134746 CVCL_0P01 AG14390 finite cell line human CVCL_0P01 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21134747 CVCL_1101 CA46 cancer cell line human CVCL_1101 HLA typing: A*26:03,26:03; B*27:04,27:04; C*12:02,12:02; DQA1*01:03,01:03; DQB1*06:01,06:01; DRB1*08:03,08:03 (PubMed=25960936); HLA typing: A*02:01,24:02; B*27:04,27:04; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=33.18%; Native American=0.85%; East Asian, North=7.55%; East Asian, South=35.68%; South Asian=0%; European, North=9.41%; European, South=13.32% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=3921823; PubMed=9643977); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=8344493; PubMed=8402660; PubMed=19220422; Cosmic-CLP; DepMap) Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Virology: EBV-negative Doubling time: 21 hours (PubMed=8402660); ~35 hours (DSMZ=ACC-73); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21134748 CVCL_0P04 AG14534 finite cell line human CVCL_0P04 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21134749 CVCL_1104 CAL-120 cancer cell line human CVCL_1104 HLA typing: A*03:01,03:01; B*44:02,56:01; C*01:02,05:01 (PubMed=26589293); Genome ancestry: African=1.62%; Native American=0%; East Asian, North=3.74%; East Asian, South=0%; South Asian=0.57%; European, North=51.79%; European, South=42.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+2T>G; ClinVar=VCV000635389; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45 hours (PubMed=25984343); ~50-60 hours (DSMZ=ACC-459); 34.01 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21134750 CVCL_0P03 AG14486 finite cell line human CVCL_0P03 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21134751 CVCL_1103 CADO-ES1 cancer cell line human CVCL_1103 HLA typing: A*11:01,24:02; B*15:01,40:01; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=1.63%; Native American=0.72%; East Asian, North=75.38%; East Asian, South=21.78%; South Asian=0%; European, North=0%; European, South=0.48% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=26428435; PubMed=33460449); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=25984343); ~40 hours (CLS); ~35 hours (DSMZ=ACC-255); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: Was incorrectly indicated to have an EWSR1-FLI1 (EWS-FLI1) gene fusion in PubMed=23637631 21134752 CVCL_0P06 AG14580 finite cell line human CVCL_0P06 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21134753 CVCL_1106 CAL-148 cancer cell line human CVCL_1106 HLA typing: A*11:01,24:18; B*15:78,45:01; C*06:02,15:02 (PubMed=26589293); Genome ancestry: African=3.17%; Native American=0.26%; East Asian, North=2.18%; East Asian, South=0%; South Asian=0.58%; European, North=44.85%; European, South=48.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Lys (c.670G>A); ClinVar=VCV000480767; Zygosity=Heterozygous (Cosmic-CLP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30-40 hours (DSMZ=ACC-460); 42.78 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21134754 CVCL_0P05 AG14572 finite cell line human CVCL_0P05 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female 21134755 CVCL_1105 CAL-12T cancer cell line human CVCL_1105 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=0.12%; Native American=0.91%; East Asian, North=2.34%; East Asian, South=0.23%; South Asian=0%; European, North=56.03%; European, South=40.37% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Gly1291Glufs*4 (c.3872del) (p.Val1290fs, c.3870delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Val (c.1397G>T); ClinVar=VCV000013967; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 35 hours (PubMed=1657424; PubMed=2145926); ~50 hours (DSMZ=ACC-443); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134756 CVCL_0P08 AG14607 finite cell line human CVCL_0P08 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21134757 CVCL_1108 CAL-33 cancer cell line human CVCL_1108 HLA typing: A*01:01,30:02; B*08:01,08:01; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0.92%; Native American=0%; East Asian, North=2.32%; East Asian, South=0.33%; South Asian=0%; European, North=46.86%; European, South=49.56% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Gly8Val (c.23G>T) (c.-57+99G>T); dbSNP=rs75603675; Zygosity=Homozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25275298) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 78 hours (PubMed=2145926); ~30-40 hours (DSMZ=ACC-447); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21134758 CVCL_0P07 AG14591 finite cell line human CVCL_0P07 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21134759 CVCL_1107 CAL-27 cancer cell line human CVCL_1107 HLA typing: A*26:08,26:08; B*44:03,51:01; C*07:02,16:01; DQA1*01:02,02:01; DQB1*05:01,05:01; DRB1*01:03,07:01 (PubMed=26589293); Genome ancestry: African=2.22%; Native American=0%; East Asian, North=2.6%; East Asian, South=0%; South Asian=0%; European, North=54.66%; European, South=40.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=25275298) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=2145926); ~20-40 hours (DSMZ=ACC-446); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21134760 CVCL_0P09 AG14608 finite cell line human CVCL_0P09 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21134761 CVCL_1109 CAL-39 cancer cell line human CVCL_1109 Genome ancestry: African=2.88%; Native American=0.78%; East Asian, North=0%; East Asian, South=1.64%; South Asian=9.08%; European, North=26.43%; European, South=59.19% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Arg2597Ter (c.7789C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Vulva. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 30 hours, at 34th passage (PubMed=21573363); ~50-70 hours (DSMZ=ACC-187); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134762 CVCL_SV21 HAP1 L3MBTL2 (-) 2 cancer cell line human CVCL_SV21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18594; L3MBTL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134763 CVCL_T721 OpC-94 spontaneously immortalized cell line CVCL_T721 CL:0000010 Derived from sampling site: Liver. Male Doubling time: 3-4 days (PubMed=4795513) Group: Reptilian cell line 21134764 CVCL_SV20 HAP1 L3MBTL2 (-) 1 cancer cell line human CVCL_SV20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18594; L3MBTL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134765 CVCL_T720 OpC-91 spontaneously immortalized cell line CVCL_T720 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 4-5 days (PubMed=4795513) Group: Reptilian cell line 21134766 CVCL_SV23 HAP1 LACTB2 (-) 1 cancer cell line human CVCL_SV23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18512; LACTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134767 CVCL_T723 OpC-109 spontaneously immortalized cell line CVCL_T723 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Reptilian cell line 21134768 CVCL_SV22 HAP1 L3MBTL2 (-) 3 cancer cell line human CVCL_SV22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18594; L3MBTL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134769 CVCL_T722 OpC-115 spontaneously immortalized cell line CVCL_T722 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 3-4 days (PubMed=4795513) Group: Reptilian cell line 21134770 CVCL_SV25 HAP1 LACTB2 (-) 3 cancer cell line human CVCL_SV25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18512; LACTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134771 CVCL_T725 Oc4T/cc cancer cell line CVCL_T725 CL:0000010 Transformant: Rabbit fibroma virus (SFV)(NCBI-Taxonomy; 10271); Breed/subspecies: New Zealand white. Discontinued: ATCC; CRL-6501; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134772 CVCL_T724 GE-1 spontaneously immortalized cell line CVCL_T724 CL:0000010 Unspecified Group: Reptilian cell line. 21134773 CVCL_SV24 HAP1 LACTB2 (-) 2 cancer cell line human CVCL_SV24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18512; LACTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134774 CVCL_SV27 HAP1 LAMP1 (-) 2 cancer cell line human CVCL_SV27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6499; LAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134775 CVCL_T727 LT4 factor-dependent cell line house mouse CVCL_T727 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2. Female Characteristics: IL3 dependent 21134776 CVCL_SV26 HAP1 LAMP1 (-) 1 cancer cell line human CVCL_SV26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6499; LAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134777 CVCL_T726 SME-1 spontaneously immortalized cell line CVCL_T726 CL:0000010 Unspecified Group: Fish cell line. 21134778 CVCL_T729 13D10 hybridoma house mouse CVCL_T729 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Lygodium japonicum strain an-1 basal apparatus. 21134779 CVCL_SV29 HAP1 LAMTOR4 (-) 2 cancer cell line human CVCL_SV29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33772; LAMTOR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134780 CVCL_SV28 HAP1 LAMTOR4 (-) 1 cancer cell line human CVCL_SV28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33772; LAMTOR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134781 CVCL_T728 LT4Tr factor-dependent cell line house mouse CVCL_T728 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: DBA/2. Female Characteristics: IL3 dependent 21134782 CVCL_T710 GT-PS spontaneously immortalized cell line CVCL_T710 CL:0000010 Derived from sampling site: Pancreas. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21134783 CVCL_SV10 HAP1 KRT8 (-) 1 cancer cell line human CVCL_SV10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6446; KRT8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134784 CVCL_T712 GT-SP spontaneously immortalized cell line CVCL_T712 CL:0000010 Derived from sampling site: Spleen. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21134785 CVCL_SV12 HAP1 KSR1 (-) 1 cancer cell line human CVCL_SV12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6465; KSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134786 CVCL_T711 GT-SK spontaneously immortalized cell line CVCL_T711 CL:0000010 Derived from sampling site: Skin. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21134787 CVCL_SV11 HAP1 KRT8 (-) 2 cancer cell line human CVCL_SV11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6446; KRT8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134788 CVCL_T714 GT-TS spontaneously immortalized cell line CVCL_T714 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21134789 CVCL_SV14 HAP1 KSR2 (-) 1 cancer cell line human CVCL_SV14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18610; KSR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134790 CVCL_T713 GT-TM cancer cell line CVCL_T713 CL:0000010 Male Doubling time: 30-36 hours (PubMed=10462202). Group: Reptilian cell line 21134791 CVCL_SV13 HAP1 KSR1 (-) 2 cancer cell line human CVCL_SV13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6465; KSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134792 CVCL_T716 CCf spontaneously immortalized cell line CVCL_T716 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Doubling time: 48-72 hours (PubMed=22358545) Group: Fish cell line 21134793 CVCL_SV16 HAP1 KXD1 (-) 1 cancer cell line human CVCL_SV16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28420; KXD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134794 CVCL_T715 GT-UB spontaneously immortalized cell line CVCL_T715 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21134795 CVCL_SV15 HAP1 KSR2 (-) 2 cancer cell line human CVCL_SV15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18610; KSR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134796 CVCL_SV18 HAP1 L1TD1 (-) 1 cancer cell line human CVCL_SV18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25595; L1TD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134797 CVCL_T718 OpC-89 cancer cell line CVCL_T718 CL:0000010 Male Doubling time: 7-8 days (PubMed=4795513). Group: Reptilian cell line 21134798 CVCL_SV17 HAP1 KXD1 (-) 2 cancer cell line human CVCL_SV17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28420; KXD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134799 CVCL_T717 OpC-80 spontaneously immortalized cell line CVCL_T717 CL:0000010 Derived from sampling site: Kidney. Unspecified Doubling time: 6-7 days (PubMed=4795513) Group: Reptilian cell line 21134800 CVCL_SV19 HAP1 L1TD1 (-) 2 cancer cell line human CVCL_SV19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25595; L1TD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134801 CVCL_T719 OpC-90 spontaneously immortalized cell line CVCL_T719 CL:0000010 Derived from sampling site: Spleen. Male Doubling time: 5-6 days (PubMed=4795513) Group: Reptilian cell line 21134802 CVCL_9J56 DD2310 transformed cell line human CVCL_9J56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134803 CVCL_9J55 DD2309 transformed cell line human CVCL_9J55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134804 CVCL_9J58 DD2312 transformed cell line human CVCL_9J58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134805 CVCL_9J57 DD2311 transformed cell line human CVCL_9J57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134806 CVCL_9J52 DD2301 finite cell line human CVCL_9J52 CL:0000010 Karyotypic information: 46,XY,-13,+der(13),t(Y;13)(q12;p11)mat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21134807 CVCL_9J51 DD2299 transformed cell line human CVCL_9J51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134808 CVCL_9J54 DD2308 transformed cell line human CVCL_9J54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134809 CVCL_9J53 DD2307 transformed cell line human CVCL_9J53 CL:0000010 Karyotypic information: 46,XX,dup(15)(q11:q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134810 CVCL_9J59 DD2313 transformed cell line human CVCL_9J59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134811 CVCL_9J50 DD2295 transformed cell line human CVCL_9J50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134812 CVCL_9J67 DD2326 transformed cell line human CVCL_9J67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134813 CVCL_9J66 DD2325 transformed cell line human CVCL_9J66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134814 CVCL_9J69 DD2331 transformed cell line human CVCL_9J69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134815 CVCL_9J68 DD2329 transformed cell line human CVCL_9J68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134816 CVCL_9J63 DD2320 transformed cell line human CVCL_9J63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134817 CVCL_9J62 DD2319 transformed cell line human CVCL_9J62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134818 CVCL_9J65 DD2324 transformed cell line human CVCL_9J65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134819 CVCL_9J64 DD2323 transformed cell line human CVCL_9J64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134820 CVCL_9J61 DD2315 transformed cell line human CVCL_9J61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134821 CVCL_9J60 DD2314 transformed cell line human CVCL_9J60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134822 CVCL_9J34 DD2235 finite cell line human CVCL_9J34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134823 CVCL_9J33 DD2233 transformed cell line human CVCL_9J33 CL:0000010 Karyotypic information: 46,XX,t(7;11)(p12.2;p14.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134824 CVCL_9J36 DD2248 finite cell line human CVCL_9J36 CL:0000010 Karyotypic information: 46,XX.ish,22q11.2(cH748x2) (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134825 CVCL_9J35 DD2236 transformed cell line human CVCL_9J35 CL:0000010 Karyotypic information: 46,XX,t(5;15)(q22.3;q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134826 CVCL_9J30 DD2226 transformed cell line human CVCL_9J30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134827 CVCL_9J32 DD2228 transformed cell line human CVCL_9J32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134828 CVCL_9J31 DD2227 transformed cell line human CVCL_9J31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134829 CVCL_9J38 DD2255 transformed cell line human CVCL_9J38 CL:0000010 Karyotypic information: 46,XY,inv(2)(q31.3;q37.1)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134830 CVCL_9J37 DD2253 transformed cell line human CVCL_9J37 CL:0000010 Karyotypic information: 46,XX,del(9)(qter->p22) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134831 CVCL_9J39 DD2259 finite cell line human CVCL_9J39 CL:0000010 Karyotypic information: 47,XY,+8 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21134832 CVCL_1197 EPLC-272H cancer cell line human CVCL_1197 HLA typing: A*03:01,03:01; B*15:01,15:01; C*03:04,03:04; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*04:03,15:01 (PubMed=26589293); Genome ancestry: African=7.58%; Native American=0%; East Asian, North=9.18%; East Asian, South=0%; South Asian=0%; European, North=35.01%; European, South=48.24% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr107Ter (c.321C>G); ClinVar=VCV001073381; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (DSMZ=ACC-383); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134833 CVCL_0P97 GM01580 finite cell line human CVCL_0P97 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(10;21)(10pter->10q26::21q21->21qter;21pter->21q21::10q26->10qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21134834 CVCL_1196 EM-2 cancer cell line human CVCL_1196 HLA typing: A*02:01,03:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); HLA typing: A*02:01:01,03:01:01; B*07:02:01,44:02:01; C*05:01:01,07:02:01; DQB1*06:02:01,06:03:01; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-135); Genome ancestry: African=0.62%; Native American=0%; East Asian, North=2.74%; East Asian, South=0%; South Asian=0%; European, North=68.28%; European, South=28.35% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=20809971; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2 days (CelloPub=CLPUB00038); ~35-40 hours (DSMZ=ACC-135); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21134835 CVCL_0P96 GM01579 finite cell line human CVCL_0P96 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21134836 CVCL_1199 ES3 cancer cell line human CVCL_1199 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.17%; South Asian=1.4%; European, North=64.94%; European, South=32.49% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Ter (c.708C>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134837 CVCL_0P99 GM00107 finite cell line human CVCL_0P99 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Trp162Ter (c.485G>A); ClinVar=VCV000196226; Zygosity=Hemizygous (PubMed=29982630) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21134838 CVCL_1198 ES1 cancer cell line human CVCL_1198 Genome ancestry: African=0.83%; Native American=0.47%; East Asian, North=0.13%; East Asian, South=0%; South Asian=0.81%; European, North=70.63%; European, South=27.13% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=25010205) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134839 CVCL_0P98 GM01605 finite cell line human CVCL_0P98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(6;11)(p23;q23) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21134840 CVCL_9J45 DD2281 transformed cell line human CVCL_9J45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134841 CVCL_9J44 DD2278 transformed cell line human CVCL_9J44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134842 CVCL_9J47 DD2285 transformed cell line human CVCL_9J47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134843 CVCL_9J46 DD2282 transformed cell line human CVCL_9J46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134844 CVCL_9J41 DD2261 finite cell line human CVCL_9J41 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21134845 CVCL_9J40 DD2260 finite cell line human CVCL_9J40 CL:0000010 Karyotypic information: 47,XX,+13 (ECACC); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134846 CVCL_9J43 DD2276 transformed cell line human CVCL_9J43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134847 CVCL_9J42 DD2274 transformed cell line human CVCL_9J42 CL:0000010 Karyotypic information: 46,XY,del(17)(p11.2;p11.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134848 CVCL_9J49 DD2291 finite cell line human CVCL_9J49 CL:0000010 Karyotypic information: 46,XY,del(17)(p11.2;p11.2) (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134849 CVCL_9J48 DD2286 transformed cell line human CVCL_9J48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134850 CVCL_9J12 DD2162 transformed cell line human CVCL_9J12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134851 CVCL_9J11 DD2160 transformed cell line human CVCL_9J11 CL:0000010 Karyotypic information: 46,X,del(X)(qter->p22)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134852 CVCL_9J14 DD2168 transformed cell line human CVCL_9J14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134853 CVCL_9J13 DD2163 transformed cell line human CVCL_9J13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134854 CVCL_9J10 DD2159 transformed cell line human CVCL_9J10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134855 CVCL_9J19 DD2182 finite cell line human CVCL_9J19 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21134856 CVCL_1180 DOK cancer cell line human CVCL_1180 HLA typing: A*02:01,29:02; B*08:01,44:03; C*07:01,16:01 (PubMed=26589293); Genome ancestry: African=0.41%; Native American=0.7%; East Asian, North=2.72%; East Asian, South=0%; South Asian=0%; European, North=66.66%; European, South=29.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex4-5del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu188_Pro191del (c.563_574del12); Zygosity=Unspecified (PubMed=7917902) Derived from sampling site: Oral cavity; tongue Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (PubMed=1459732); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134857 CVCL_0P80 TIMJ2-C4 transformed cell line house mouse CVCL_0P80 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from metastatic site: Lung Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21134858 CVCL_9J16 DD2173 finite cell line human CVCL_9J16 CL:0000010 Karyotypic information: 46,XX,t(1;12)(p22.1;q22)mat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Part of: ECACC chromosomal abnormality collection 21134859 CVCL_1182 DSH1 cancer cell line human CVCL_1182 Genome ancestry: African=0.74%; Native American=0%; East Asian, North=71.8%; East Asian, South=26.84%; South Asian=0%; European, North=0%; European, South=0.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134860 CVCL_0P82 GM00711 finite cell line human CVCL_0P82 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cartilage Cell type=Fibroblast.. Discontinued: Coriell; AG00711; probable Male 21134861 CVCL_9J15 DD2169 transformed cell line human CVCL_9J15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134862 CVCL_1181 DoTc2 4510 cancer cell line human CVCL_1181 Genome ancestry: African=1.27%; Native American=0.72%; East Asian, North=2.19%; East Asian, South=0%; South Asian=1.9%; European, North=68.76%; European, South=25.17% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134863 CVCL_0P81 TIMJ2-C7 transformed cell line house mouse CVCL_0P81 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from metastatic site: Lung Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21134864 CVCL_9J18 DD2181 transformed cell line human CVCL_9J18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134865 CVCL_1184 DV-90 cancer cell line human CVCL_1184 HLA typing: A*03:01,11:01; B*15:17,35:11; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0.68%; Native American=0%; East Asian, North=2.16%; East Asian, South=0%; South Asian=3.04%; European, North=41.86%; European, South=52.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=7839470); ~95 hours (DSMZ=ACC-307); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134866 CVCL_0P84 GM00713 finite cell line human CVCL_0P84 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: Coriell; AG00713; probable Male 21134867 CVCL_9J17 DD2180 transformed cell line human CVCL_9J17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134868 CVCL_1183 DU4475 cancer cell line human CVCL_1183 HLA typing: A*03:01,31:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293); Genome ancestry: African=0.87%; Native American=0%; East Asian, North=3.81%; East Asian, South=0%; South Asian=0%; European, North=61.27%; European, South=34.04% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1577Ter (c.4729G>T); Zygosity=Homozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=18397470; PubMed=19593635; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7921; true Female Doubling time: 2.9 days (PubMed=221108); 90 hours (PubMed=25984343); ~80-100 hours (DSMZ=ACC-427); ~32 hours (PBCF); Microsatellite instability: Stable (MSS) (Sanger) Group: Triple negative breast cancer (TNBC) cell line; Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21134869 CVCL_0P83 GM00712 finite cell line human CVCL_0P83 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Derived from sampling site: Spleen Cell type=Fibroblast.. Discontinued: Coriell; AG00712; probable Male 21134870 CVCL_1175 DMS 153 cancer cell line human CVCL_1175 Genome ancestry: African=0.64%; Native American=0.56%; East Asian, North=3.7%; East Asian, South=0%; South Asian=0%; European, North=51.44%; European, South=43.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Homozygous (PubMed=14660794; DepMap) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 days (PubMed=6266631); 5.8 days (PubMed=2986244) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134871 CVCL_0P75 HEK293-RyR1 transformed cell line human CVCL_0P75 CL:0000010 Transfected with: UniProtKB; P11716; Rabbit RYR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21134872 CVCL_1174 DMS 114 cancer cell line human CVCL_1174 Genome ancestry: African=0.44%; Native American=0.11%; East Asian, North=2.38%; East Asian, South=0%; South Asian=0%; European, North=55.93%; European, South=41.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex2-14del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (PubMed=15900046; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3.8 days (PubMed=6266631); 1.6 days (PubMed=2986244); 27 hours (PubMed=7718330); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel 21134873 CVCL_0P74 GM18929 transformed cell line human CVCL_0P74 CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Tyr231Ter (c.693C>A); ClinVar=VCV000002609; Zygosity=Heterozygous (PubMed=19815695) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21134874 CVCL_0P77 AMJ2-C10 transformed cell line house mouse CVCL_0P77 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21134875 CVCL_1177 DMS 53 cancer cell line human CVCL_1177 HLA typing: A*01:01,03:01; B*08:01,35:03; C*04:01,07:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,14:76 (PubMed=25960936); HLA typing: A*03:01,03:01; B*08:01,35:03; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=2.98%; Native American=0%; East Asian, North=4.32%; East Asian, South=0%; South Asian=0%; European, North=55.34%; European, South=37.36% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 5.7 days (PubMed=6266631); 4.9 days (PubMed=2986244); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134876 CVCL_1176 DMS 273 cancer cell line human CVCL_1176 HLA typing: A*03:01,23:01; B*35:03,44:03; C*04:01,04:01; DRB1*07:01,07:01 (PubMed=25960936); HLA typing: A*03:01,23:01; B*35:03,44:03; C*04:01,04:01; DRB1*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.51%; Native American=0.88%; East Asian, North=1.83%; East Asian, South=0%; South Asian=0%; European, North=66.84%; European, South=29.94% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7910; NPM1; Simple; p.Asp173del (c.511_513delGAT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Homozygous (PubMed=15900046; Cosmic-CLP; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 6.2 days (PubMed=2986244); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel 21134877 CVCL_0P76 iOECHHN transformed cell line human CVCL_0P76 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva. Unspecified 21134878 CVCL_1179 DoHH2 cancer cell line human CVCL_1179 HLA typing: A*01:01,01:01; B*08:01,44:02; C*07:04,07:04; DQA1*01:02,01:02; DQB1*05:01,06:02; DRB1*15:01,01:01 (PubMed=25960936); HLA typing: A*01:01,01:01; B*08:01,44:02; C*07:01,07:01 (PubMed=26589293); HLA typing: A*01:01:01,01:01:01; B*08:01:01,44:02:01; C*07:01:01,07:04:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,02:01:02; DQA1*01:02:01,01:01:01; DQB1*05:01:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*01:01:01,15:01:01 (DSMZCellDive=ACC-47); Genome ancestry: African=0.28%; Native American=1.29%; East Asian, North=0%; East Asian, South=0%; South Asian=1.29%; European, North=69.22%; European, South=27.92% (PubMed=30894373) CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, immunoblastic-type Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 48 hours, in RPMI 1640 + 5% FBS (PubMed=1849602); ~40 hours (DSMZ=ACC-47); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel Caution: A TP53 mutation is indicated as being at p.Ala138Pro (c.412G>C) in PubMed=17363600 but has not been confirmed by CCLE and Cosmic-CLP 21134879 CVCL_0P79 TIMJ2-C15 transformed cell line house mouse CVCL_0P79 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from metastatic site: Lung Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21134880 CVCL_0P78 AMJ2-C20 transformed cell line house mouse CVCL_0P78 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21134881 CVCL_1178 DMS 79 cancer cell line human CVCL_1178 HLA typing: A*01:01,02:01; B*08:01,35:01; C*04:01,07:01; DQB1*03:09,05:03; DRB1*11:30,11:30 (PubMed=25960936); HLA typing: A*01:01,02:01; B*08:01,35:01; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=0.52%; Native American=0%; East Asian, North=0.95%; East Asian, South=0%; South Asian=1.45%; European, North=66.84%; European, South=30.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9683; PTPRU; Simple; p.Glu442Ter (c.1324G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly801Ter (c.2401G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Glufs*65 (c.837delG) (p.G279fs); Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3.9 days (PubMed=6266631); 5.8 days (PubMed=2986244); ~4 days (CLS); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134882 CVCL_9J23 DD2205 transformed cell line human CVCL_9J23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134883 CVCL_9J22 DD2204 transformed cell line human CVCL_9J22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134884 CVCL_9J25 DD2207 transformed cell line human CVCL_9J25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134885 CVCL_9J24 DD2206 transformed cell line human CVCL_9J24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134886 CVCL_9J21 DD2187 transformed cell line human CVCL_9J21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134887 CVCL_9J20 DD2184 transformed cell line human CVCL_9J20 CL:0000010 Karyotypic information: 46,XY,inv(10)(p11;q21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134888 CVCL_1191 EFE-184 cancer cell line human CVCL_1191 HLA typing: A*01:01,03:01; B*08:01,51:01; C*01:02,07:01 (PubMed=26589293); Genome ancestry: African=0.39%; Native American=0.31%; East Asian, North=1.81%; East Asian, South=0%; South Asian=0%; European, North=58.73%; European, South=38.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; None_reported; -; Zygosity=- (PubMed=20944090); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 90 hours (PubMed=25984343); ~92 hours (DSMZ=ACC-230) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21134889 CVCL_0P91 GM01296 finite cell line human CVCL_0P91 CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,der(13;15)(13qter->13q10::15q10->15qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21134890 CVCL_1190 ECC4 cancer cell line human CVCL_1190 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 140 hours (PubMed=8392984) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134891 CVCL_0P90 GM01230 finite cell line human CVCL_0P90 CL:0000010 Population: Cuban; Karyotypic information: 46,XY,t(1;2)(1qter->1p36::2q31->2qter;2pter->2q31::1p36->1pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21134892 CVCL_9J27 DD2217 finite cell line human CVCL_9J27 CL:0000010 Karyotypic information: 46,XX,inv(10)?(p11;q11) (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21134893 CVCL_1193 EGI-1 cancer cell line human CVCL_1193 Genome ancestry: African=0%; Native American=0.79%; East Asian, North=0%; East Asian, South=0%; South Asian=0%; European, North=77.61%; European, South=21.59% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: >45 hours (DSMZ=ACC-385); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134894 CVCL_0P93 GM01422 finite cell line human CVCL_0P93 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Ser371Cys (c.1111A>T); ClinVar=VCV000016333; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21134895 CVCL_9J26 DD2208 transformed cell line human CVCL_9J26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134896 CVCL_1192 EFO-27 cancer cell line human CVCL_1192 HLA typing: A*02:01,03:01; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=0.18%; Native American=0%; East Asian, North=1.36%; East Asian, South=0%; South Asian=0%; European, North=70.88%; European, South=27.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29 hours (PubMed=25984343); ~50-80 hours (DSMZ=ACC-191); 26.68 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=12661003; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134897 CVCL_0P92 GM01411 finite cell line human CVCL_0P92 CL:0000010 Population: African American; Karyotypic information: 46,X,t(X;21)(q11;p11) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21134898 CVCL_9J29 DD2224 transformed cell line human CVCL_9J29 CL:0000010 Karyotypic information: 46,X,del(X)(qter->p11.4) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134899 CVCL_1195 EKVX cancer cell line human CVCL_1195 HLA typing: A*01:01:01; B*37:01; C*06:02; DPB1*04:01; DQB1*06:02; DRB1*15:01:01 (PubMed=15748285); HLA typing: A*01:01,01:01; B*37:01,37:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=0.21%; Native American=0.92%; East Asian, North=1.76%; East Asian, South=0.01%; South Asian=1.21%; European, North=67.1%; European, South=28.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (PubMed=17088437) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using proteomics Male Virology: Produces a human cell infectious xenotropic murine leukemia virus (X-MLV) (PubMed=21698104) Doubling time: 72 hours (PubMed=7718330); 43.6 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21134900 CVCL_0P95 GM01550 finite cell line human CVCL_0P95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21134901 CVCL_9J28 DD2222 finite cell line human CVCL_9J28 CL:0000010 Karyotypic information: 46,XX; 46,X,r(X) (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21134902 CVCL_1194 EHEB transformed cell line human CVCL_1194 HLA typing: A*02:01,02:01; B*15:01,27:05; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.03%; East Asian, North=0%; East Asian, South=0%; South Asian=1.9%; European, North=69.25%; European, South=27.82% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50-70 hours (DSMZ=ACC-67); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Problematic cell line: Probably misclassified Originally thought to be a leukemia cell line but is probably a B-lymphoblastoid cell line (PubMed=12592342). 21134903 CVCL_0P94 GM01512 finite cell line human CVCL_0P94 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(8;10)(8qter->8p21.1::10p15->10pter;10qter->10p15::8p21.1->8pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21134904 CVCL_1186 EB2 cancer cell line human CVCL_1186 HLA typing: A*29:02,31:04; B*47:03,57:03; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=92.74%; Native American=0%; East Asian, North=2.43%; East Asian, South=0%; South Asian=0.02%; European, North=0%; European, South=4.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gln501Ter (c.1501C>T); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (Cosmic-CLP) Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134905 CVCL_0P86 GM00705 finite cell line human CVCL_0P86 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;9)(q13.1;p24) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21134906 CVCL_1185 EB3 [Human Burkitt lymphoma] cancer cell line human CVCL_1185 HLA typing: A*03:01,30:02; B*15:03,47:03; C*02:02,07:01 (PubMed=26589293); Genome ancestry: African=83.99%; Native American=0.51%; East Asian, North=5.96%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=9.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn345Argfs*24 (c.1034_1037del); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>G; ClinVar=VCV000141332; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; IFO50028; true Male Doubling time: 48 hours (PubMed=5884338); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00380 Problematic cell line: Partially contaminated Some stocks (such as IFO50028) were contaminated by Daudi. 21134907 CVCL_0P85 GM00714 finite cell line human CVCL_0P85 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg248Cys (c.742C>T); ClinVar=VCV000016332; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG00714; probable Male 21134908 CVCL_1188 ECC10 cancer cell line human CVCL_1188 HLA typing: A*03:01,24:02; B*40:01,44:02; C*03:04,05:01 (PubMed=26589293); Genome ancestry: African=1.3%; Native American=0.44%; East Asian, North=81.45%; East Asian, South=16.3%; South Asian=0%; European, North=0%; European, South=0.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Leu755Ser (c.2264T>C); ClinVar=VCV000376035; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gln685Ter (c.2053C>T); ClinVar=VCV000237668; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 85 hours (PubMed=8392984); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134909 CVCL_0P88 GM01139 finite cell line human CVCL_0P88 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134910 CVCL_1187 EC-GI-10 cancer cell line human CVCL_1187 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02; DQB1*03:02,03:02; DRB1*10:01,11:30 (PubMed=26589293); Genome ancestry: African=2.68%; Native American=0%; East Asian, North=89.75%; East Asian, South=5.81%; South Asian=0.73%; European, North=0%; European, South=1.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a mouse xenograft Doubling time: ~31 hours (PubMed=2824416); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134911 CVCL_0P87 GM01101 finite cell line human CVCL_0P87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,(4qter->4p16::12p11->12pter;12qter->12p11::4p16->4pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21134912 CVCL_1189 ECC12 cancer cell line human CVCL_1189 HLA typing: A*24:02,26:01; B*35:21,51:01; C*03:03,14:02 (PubMed=26589293); Genome ancestry: African=2.31%; Native American=0.33%; East Asian, North=84.02%; East Asian, South=12.58%; South Asian=0%; European, North=0%; European, South=0.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 92 hours (PubMed=8392984); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134913 CVCL_0P89 GM01203 transformed cell line human CVCL_0P89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134914 CVCL_1160 D-423MG cancer cell line human CVCL_1160 Genome ancestry: African=0%; Native American=0.32%; East Asian, North=1.3%; East Asian, South=1.42%; South Asian=0.18%; European, North=68.67%; European, South=28.1% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134915 CVCL_0P60 GM05371 transformed cell line human CVCL_0P60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134916 CVCL_1162 D-502MG cancer cell line human CVCL_1162 Genome ancestry: African=0.57%; Native American=0%; East Asian, North=0.87%; East Asian, South=0.42%; South Asian=0%; European, North=69.07%; European, South=29.07% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134917 CVCL_0P62 GM05762 finite cell line human CVCL_0P62 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Thr977Met (c.2930C>T); ClinVar=VCV000035710; Zygosity=Heterozygous (from autologous cell line GM05761) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134918 CVCL_1161 D458 Med cancer cell line human CVCL_1161 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=22343310) Derived from sampling site: Cerebrospinal fluid. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 3.45 days (PubMed=1904513) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134919 CVCL_0P61 GM05761 transformed cell line human CVCL_0P61 CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Thr977Met (c.2930C>T); ClinVar=VCV000035710; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134920 CVCL_1153 D-247MG cancer cell line human CVCL_1153 Genome ancestry: African=0%; Native American=0.5%; East Asian, North=0%; East Asian, South=0%; South Asian=1.46%; European, North=67.83%; European, South=30.2% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.210-1G>C; ClinVar=VCV000428260; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14614447) Population: Caucasian; Derived from sampling site: Brain. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 30.17 hours (PubMed=2881426); 42 hours (PubMed=9842975); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134921 CVCL_0P53 GM05340 transformed cell line human CVCL_0P53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134922 CVCL_1152 D-245MG cancer cell line human CVCL_1152 Genome ancestry: African=1.72%; Native American=1.42%; East Asian, North=0.26%; East Asian, South=0.81%; South Asian=1.32%; European, North=65.72%; European, South=28.76% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 44.10 hours (PubMed=2881426); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134923 CVCL_0P52 GM05339 finite cell line human CVCL_0P52 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134924 CVCL_1155 D283 Med cancer cell line human CVCL_1155 Genome ancestry: African=1.87%; Native American=0%; East Asian, North=1.34%; East Asian, South=0%; South Asian=0%; European, North=63.61%; European, South=33.18% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Brain; cerebellum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134925 CVCL_0P55 GM05342 transformed cell line human CVCL_0P55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134926 CVCL_1154 D-263MG cancer cell line human CVCL_1154 Genome ancestry: African=0.41%; Native American=1.08%; East Asian, North=0.75%; East Asian, South=0%; South Asian=2.84%; European, North=63.92%; European, South=31.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu314Asnfs*3 (c.940del); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 30.77 hours (PubMed=2881426); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21134927 CVCL_0P54 GM05341 finite cell line human CVCL_0P54 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134928 CVCL_1157 D384 Med cancer cell line human CVCL_1157 CL:0000010 Derived from sampling site: Brain; cerebellum. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 2.44 days (PubMed=1904513) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134929 CVCL_0P57 GM05367 transformed cell line human CVCL_0P57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134930 CVCL_1156 D-336MG cancer cell line human CVCL_1156 Genome ancestry: African=0.62%; Native American=0.37%; East Asian, North=0.73%; East Asian, South=0%; South Asian=1.2%; European, North=68.29%; European, South=28.79% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134931 CVCL_0P56 GM05366 finite cell line human CVCL_0P56 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134932 CVCL_1159 D-397MG cancer cell line human CVCL_1159 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21134933 CVCL_0P59 GM00594 finite cell line human CVCL_0P59 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21134934 CVCL_1158 D-392MG cancer cell line human CVCL_1158 Genome ancestry: African=1.22%; Native American=0%; East Asian, North=2.63%; East Asian, South=0%; South Asian=0%; European, North=64.41%; European, South=31.73% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134935 CVCL_0P58 GM00417 finite cell line human CVCL_0P58 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21134936 CVCL_9J01 DD2142 transformed cell line human CVCL_9J01 CL:0000010 Karyotypic information: 46,X,mar(Y) de novo (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134937 CVCL_T794 Fbx15^(Beta geo/Beta geo)ES embryonic stem cell house mouse CVCL_T794 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1354755; Fbxo15 Breed/subspecies: 129S4/SvJae. Discontinued: RCB; RCB2661; true Male 21134938 CVCL_SV94 HAP1 LRRC8A (-) 1 cancer cell line human CVCL_SV94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19027; LRRC8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134939 CVCL_9J00 DD2136 finite cell line human CVCL_9J00 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21134940 CVCL_SV93 HAP1 LRP8 (-) cancer cell line human CVCL_SV93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6700; LRP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134941 CVCL_T793 RF8 embryonic stem cell house mouse CVCL_T793 CL:0000010 Breed/subspecies: 129S4/SvJae. Male 21134942 CVCL_9J03 DD2144 transformed cell line human CVCL_9J03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21134943 CVCL_SV96 HAP1 LRRC8D (-) 1 cancer cell line human CVCL_SV96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16992; LRRC8D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134944 CVCL_T796 Nanog^(Beta geo/Hyg) embryonic stem cell house mouse CVCL_T796 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1919200; Nanog Breed/subspecies: 129S4/SvJae. Discontinued: RCB; RCB2697; true Male 21134945 CVCL_9J02 DD2143 transformed cell line human CVCL_9J02 CL:0000010 Karyotypic information: 46,X,der(X),t(X;10)(q26.3;q23.2)mat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134946 CVCL_SV95 HAP1 LRRC8A (-) 2 cancer cell line human CVCL_SV95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19027; LRRC8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134947 CVCL_T795 Nanog^(Beta geo/+)ES embryonic stem cell house mouse CVCL_T795 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:1919200; Nanog Breed/subspecies: 129S4/SvJae. Discontinued: RCB; RCB2662; true Male 21134948 CVCL_SV98 HAP1 LRRC8D (-) 3 cancer cell line human CVCL_SV98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16992; LRRC8D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134949 CVCL_T798 KhES-5 embryonic stem cell human CVCL_T798 From: Institute for Frontier Medical Sciences, Kyoto University; Kyoto; Japan CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male 21134950 CVCL_SV97 HAP1 LRRC8D (-) 2 cancer cell line human CVCL_SV97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16992; LRRC8D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134951 CVCL_T797 KhES-4 embryonic stem cell human CVCL_T797 From: Institute for Frontier Medical Sciences, Kyoto University; Kyoto; Japan CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male 21134952 CVCL_SV99 HAP1 LRRC8D (-) 4 cancer cell line human CVCL_SV99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16992; LRRC8D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21134953 CVCL_T799 iTS1 induced pluripotent stem cell human CVCL_T799 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21134954 CVCL_9J09 DD2157 finite cell line human CVCL_9J09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134955 CVCL_9J08 DD2156 finite cell line human CVCL_9J08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21134956 CVCL_9J05 DD2146 transformed cell line human CVCL_9J05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134957 CVCL_1171 Detroit 562 cancer cell line human CVCL_1171 HLA typing: A*03,11; B*13 (PubMed=77569); HLA typing: A*26:01,30:01; B*13:02,55:01; C*01:02,06:02 (PubMed=26589293); Genome ancestry: African=0.82%; Native American=0%; East Asian, North=1.93%; East Asian, South=0%; South Asian=1.05%; European, North=61.34%; European, South=34.86% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25275298) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7919; true Female Doubling time: 88.5 +- 34.7 hours (PubMed=29423072); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: OPC-22 oral and pharyngeal cancer cell line panel 21134958 CVCL_0P71 GM12198 transformed cell line human CVCL_0P71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134959 CVCL_9J04 DD2145 transformed cell line human CVCL_9J04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134960 CVCL_1170 DEL cancer cell line human CVCL_1170 HLA typing: A*02:01,26:01; B*14:01,27:05; C*08:02,08:02 (PubMed=26589293); HLA typing: A*02:01:01,26:01:01; B*14:01:01,27:05:02; C*05:01:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,04:02:01; DQA1*02:01:01,04:01:01; DQB1*02:02:01,04:02:01; DRA*01:01:01,01:02:02; DRB1*07:01:01,08:01:01 (DSMZCellDive=ACC-338); Genome ancestry: African=0.65%; Native American=0%; East Asian, North=1.56%; East Asian, South=0%; South Asian=0.96%; European, North=56.65%; European, South=40.18% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=31160637); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Ala88Glu (c.263C>A); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Cys (c.643A>T); Zygosity=Homozygous (Cosmic-CLP) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Virology: Contains 4 copies of an integrated murine leukemia virus closely related to that found in EKVX Three of the integration sites are within the introns of genes OPA1, TNFRSF6B and ZNF767 (PubMed=25355872; PubMed=30629668). Doubling time: ~30 hours (DSMZ=ACC-338); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21134961 CVCL_0P70 GM12158 finite cell line human CVCL_0P70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134962 CVCL_9J07 DD2151 finite cell line human CVCL_9J07 CL:0000010 Karyotypic information: 46,XY,inv(3),?(p21;q23) (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male Part of: ECACC chromosomal abnormality collection 21134963 CVCL_1173 DK-MG cancer cell line human CVCL_1173 HLA typing: A*01:01,03:01; B*08:01,57:01; C*06:02,07:01; DQB1*03:04,03:04; DRB1*04:03,04:03 (PubMed=26589293); Genome ancestry: African=0.82%; Native American=0%; East Asian, North=4.28%; East Asian, South=0%; South Asian=0.04%; European, North=60.17%; European, South=34.69% (PubMed=30894373) CL:0000010 Derived from sampling site: Brain; right parietal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 80 hours (PubMed=25984343); ~50 hours (DSMZ=ACC-277); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134964 CVCL_0P73 GM17821 transformed cell line human CVCL_0P73 CL:0000010 Sequence variation: Mutation; HGNC; 756; ASPA; Simple; p.Glu285Ala (c.854A>C); ClinVar=VCV000002605; Zygosity=Heterozygous (PubMed=19815695) Population: Caucasian; Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21134965 CVCL_9J06 DD2149 transformed cell line human CVCL_9J06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21134966 CVCL_1172 DJM-1 cancer cell line human CVCL_1172 Genome ancestry: African=0%; Native American=0%; East Asian, North=79.62%; East Asian, South=19.44%; South Asian=0.93%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser144Ter (c.431C>G); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134967 CVCL_0P72 GM12199 transformed cell line human CVCL_0P72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134968 CVCL_1164 D-542MG cancer cell line human CVCL_1164 Genome ancestry: African=0.45%; Native American=2.46%; East Asian, North=53.35%; East Asian, South=39.58%; South Asian=0%; European, North=1%; European, South=3.16% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Ter (c.1003C>T); ClinVar=VCV000007833; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg556Ter (c.1666C>T); ClinVar=VCV000013090; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134969 CVCL_0P64 RMS/0 cancer cell line Norway rat CVCL_0P64 CL:0000010 Transformant: Nickel atom(ChEBI; CHEBI:28112); Breed/subspecies: Wistar AG. Female Characteristics: Strong lung metastatic phenotype 21134970 CVCL_1163 D-538MG cancer cell line human CVCL_1163 CL:0000010 Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 9829; RAF1; Name(s)=BCL6-RAF1 (PubMed=23637631) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21134971 CVCL_0P63 GM05370 finite cell line human CVCL_0P63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21134972 CVCL_1166 D-566MG cancer cell line human CVCL_1166 Genome ancestry: African=0.2%; Native American=0.49%; East Asian, North=0%; East Asian, South=1.47%; South Asian=0%; European, North=67.4%; European, South=30.44% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Ile941Serfs*13 (c.2820delC); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Ter (c.1003C>T); ClinVar=VCV000007833; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134973 CVCL_0P66 S4T cancer cell line Norway rat CVCL_0P66 CL:0000010 Transformant: Nickel atom(ChEBI; CHEBI:28112); Breed/subspecies: Wistar AG. Female 21134974 CVCL_1165 D556 Med cancer cell line human CVCL_1165 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21134975 CVCL_0P65 RMS/8 cancer cell line Norway rat CVCL_0P65 CL:0000010 Transformant: Nickel atom(ChEBI; CHEBI:28112); Breed/subspecies: Wistar AG. Female Characteristics: Weak lung metastatic phenotype 21134976 CVCL_1168 DB cancer cell line human CVCL_1168 HLA typing: A*02; B*52/58; DQA1*05:02,05:02; DRB1*13:27,13:27 (PubMed=25960936); HLA typing: A*02:01,02:01; B*07:02,18:01; C*05:01,07:14 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.4%; East Asian, South=0.73%; South Asian=1.98%; European, North=67.72%; European, South=29.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP) Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (DSMZ=ACC-539); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21134977 CVCL_0P68 GM05798 finite cell line human CVCL_0P68 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21134978 CVCL_1167 Daoy cancer cell line human CVCL_1167 Genome ancestry: African=0.45%; Native American=0%; East Asian, North=1.54%; East Asian, South=0%; South Asian=1.1%; European, North=64.36%; European, South=32.54% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (PubMed=22343310; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain; cerebellum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 33.6 hours, at 48th passage (PubMed=2993532); 32 +- 1.5 hours (PubMed=31346954); 34 hours (ATCC=HTB-186); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134979 CVCL_0P67 GM05797 transformed cell line human CVCL_0P67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134980 CVCL_1169 DBTRG-05MG cancer cell line human CVCL_1169 HLA typing: A*02:01,68:01; B*35:01,38:01; C*12:03,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.59%; East Asian, South=0%; South Asian=19.4%; European, North=16.56%; European, South=63.44% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; ATCC; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 54 hours (PubMed=25984343); ~48 hours (DSMZ=ACC-359); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21134981 CVCL_0P69 GM11778 finite cell line human CVCL_0P69 CL:0000010 Population: Saudi Arabian; Derived from sampling site: Cell type=Fibroblast. Male 21134982 CVCL_BC50 ND09787 transformed cell line human CVCL_BC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134983 CVCL_BC49 ND09786 transformed cell line human CVCL_BC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134984 CVCL_BC48 ND09785 transformed cell line human CVCL_BC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134985 CVCL_BC41 ND09735 transformed cell line human CVCL_BC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134986 CVCL_BC40 ND09734 transformed cell line human CVCL_BC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134987 CVCL_BC43 ND09774 transformed cell line human CVCL_BC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134988 CVCL_BC42 ND09736 transformed cell line human CVCL_BC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134989 CVCL_BC45 ND09781 transformed cell line human CVCL_BC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134990 CVCL_BC44 ND09775 transformed cell line human CVCL_BC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134991 CVCL_BC47 ND09783 transformed cell line human CVCL_BC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134992 CVCL_BC46 ND09782 transformed cell line human CVCL_BC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134993 CVCL_BC61 ND09832 transformed cell line human CVCL_BC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134994 CVCL_BC60 ND09831 transformed cell line human CVCL_BC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134995 CVCL_BC59 ND09829 transformed cell line human CVCL_BC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134996 CVCL_BC52 ND09800 transformed cell line human CVCL_BC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134997 CVCL_BC51 ND09788 transformed cell line human CVCL_BC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21134998 CVCL_BC54 ND09803 transformed cell line human CVCL_BC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21134999 CVCL_BC53 ND09801 transformed cell line human CVCL_BC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135000 CVCL_BC56 ND09805 transformed cell line human CVCL_BC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135001 CVCL_BC55 ND09804 transformed cell line human CVCL_BC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135002 CVCL_BC58 ND09821 transformed cell line human CVCL_BC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135003 CVCL_BC57 ND09815 transformed cell line human CVCL_BC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135004 CVCL_9I97 DD2133 transformed cell line human CVCL_9I97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135005 CVCL_9I96 DD2132 transformed cell line human CVCL_9I96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135006 CVCL_9I99 DD2135 finite cell line human CVCL_9I99 CL:0000010 Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135007 CVCL_9I98 DD2134 finite cell line human CVCL_9I98 CL:0000010 Derived from sampling site: Chorionic villus. Unspecified Part of: ECACC chromosomal abnormality collection 21135008 CVCL_BC27 ND09682 transformed cell line human CVCL_BC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135009 CVCL_BC26 ND09680 transformed cell line human CVCL_BC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135010 CVCL_BC29 ND09684 transformed cell line human CVCL_BC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135011 CVCL_BC28 ND09683 transformed cell line human CVCL_BC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135012 CVCL_9I93 DD2125 finite cell line human CVCL_9I93 CL:0000010 Karyotypic information: 46,XY,t(5;19)(p5:q19;q5:p19)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21135013 CVCL_9I92 DD2124 transformed cell line human CVCL_9I92 CL:0000010 Karyotypic information: 46,XX,?var(15),(q12) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135014 CVCL_9I95 DD2127 transformed cell line human CVCL_9I95 CL:0000010 Karyotypic information: 46,X,t(X;10)(q26.3;q23.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135015 CVCL_BC21 ND09673 transformed cell line human CVCL_BC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135016 CVCL_9I94 DD2126 finite cell line human CVCL_9I94 CL:0000010 Karyotypic information: 46,XY,-2,+der(2),t(2;8)(q37.3;p23.1)pat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21135017 CVCL_BC20 ND09670 transformed cell line human CVCL_BC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135018 CVCL_BC23 ND09677 transformed cell line human CVCL_BC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135019 CVCL_BC22 ND09675 transformed cell line human CVCL_BC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135020 CVCL_9I91 DD2123 finite cell line human CVCL_9I91 CL:0000010 Karyotypic information: 47,XY,+13 (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21135021 CVCL_BC25 ND09679 transformed cell line human CVCL_BC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135022 CVCL_9I90 DD2120 transformed cell line human CVCL_9I90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135023 CVCL_BC24 ND09678 transformed cell line human CVCL_BC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135024 CVCL_BC38 ND09715 transformed cell line human CVCL_BC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135025 CVCL_BC37 ND09713 transformed cell line human CVCL_BC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135026 CVCL_BC39 ND09718 transformed cell line human CVCL_BC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135027 CVCL_BC30 ND09685 transformed cell line human CVCL_BC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135028 CVCL_BC32 ND09696 transformed cell line human CVCL_BC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135029 CVCL_BC31 ND09694 transformed cell line human CVCL_BC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135030 CVCL_BC34 ND09710 transformed cell line human CVCL_BC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135031 CVCL_BC33 ND09698 transformed cell line human CVCL_BC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135032 CVCL_BC36 ND09712 transformed cell line human CVCL_BC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135033 CVCL_BC35 ND09711 transformed cell line human CVCL_BC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135034 CVCL_9I79 DD2101 finite cell line human CVCL_9I79 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135035 CVCL_9I78 DD2100 transformed cell line human CVCL_9I78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135036 CVCL_9I75 DD2095 finite cell line human CVCL_9I75 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21135037 CVCL_9I74 DD2093 finite cell line human CVCL_9I74 CL:0000010 Derived from sampling site: Amnion Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21135038 CVCL_9I77 DD2099 transformed cell line human CVCL_9I77 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),t(7;14)(q36.3;q31.3)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135039 CVCL_9I76 DD2098 transformed cell line human CVCL_9I76 CL:0000010 Karyotypic information: 46,XY,t(7;14)(q36.3;q31.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135040 CVCL_BC05 ND09599 transformed cell line human CVCL_BC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135041 CVCL_BC04 ND09597 transformed cell line human CVCL_BC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135042 CVCL_BC07 ND09603 transformed cell line human CVCL_BC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135043 CVCL_BC06 ND09601 transformed cell line human CVCL_BC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135044 CVCL_BC09 ND09607 transformed cell line human CVCL_BC09 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135045 CVCL_BC08 ND09605 transformed cell line human CVCL_BC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135046 CVCL_9I71 DD2090 finite cell line human CVCL_9I71 CL:0000010 Karyotypic information: 46,XX,t(1;3)(q21;q25)pat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21135047 CVCL_9I70 DD2089 transformed cell line human CVCL_9I70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135048 CVCL_9I73 DD2092 finite cell line human CVCL_9I73 CL:0000010 Karyotypic information: 46,XX,+13 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21135049 CVCL_9I72 DD2091 finite cell line human CVCL_9I72 CL:0000010 Karyotypic information: 46,XY,-11,+der(11),t(10;11)(q23.1;q25)pat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21135050 CVCL_BC01 ND09581 transformed cell line human CVCL_BC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135051 CVCL_BC00 ND09580 transformed cell line human CVCL_BC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135052 CVCL_BC03 ND09595 transformed cell line human CVCL_BC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135053 CVCL_BC02 ND09582 transformed cell line human CVCL_BC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135054 CVCL_9I89 DD2119 transformed cell line human CVCL_9I89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135055 CVCL_9I86 DD2112 transformed cell line human CVCL_9I86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135056 CVCL_9I85 DD2111 finite cell line human CVCL_9I85 CL:0000010 Karyotypic information: 47,XYY (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21135057 CVCL_9I88 DD2114 transformed cell line human CVCL_9I88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135058 CVCL_9I87 DD2113 transformed cell line human CVCL_9I87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135059 CVCL_BC16 ND09646 transformed cell line human CVCL_BC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135060 CVCL_BC15 ND09645 transformed cell line human CVCL_BC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135061 CVCL_BC18 ND09648 transformed cell line human CVCL_BC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135062 CVCL_BC17 ND09647 transformed cell line human CVCL_BC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135063 CVCL_BC19 ND09669 transformed cell line human CVCL_BC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135064 CVCL_9I82 DD2108 finite cell line human CVCL_9I82 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135065 CVCL_9I81 DD2105 transformed cell line human CVCL_9I81 CL:0000010 Karyotypic information: 46,XY,+(4;14)(q31.3;q24.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135066 CVCL_9I84 DD2110 finite cell line human CVCL_9I84 CL:0000010 Karyotypic information: 46,XX,+13 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21135067 CVCL_BC10 ND09614 transformed cell line human CVCL_BC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135068 CVCL_9I83 DD2109 finite cell line human CVCL_9I83 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135069 CVCL_BC12 ND09634 transformed cell line human CVCL_BC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135070 CVCL_BC11 ND09615 transformed cell line human CVCL_BC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135071 CVCL_9I80 DD2103 finite cell line human CVCL_9I80 CL:0000010 Karyotypic information: 46,XX,+13 (ECACC); Derived from sampling site: Amnion Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21135072 CVCL_BC14 ND09644 transformed cell line human CVCL_BC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135073 CVCL_BC13 ND09638 transformed cell line human CVCL_BC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135074 CVCL_9I57 DD2054 transformed cell line human CVCL_9I57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135075 CVCL_9I56 DD2048 finite cell line human CVCL_9I56 CL:0000010 Karyotypic information: 47,XY,+18 (ECACC); Derived from sampling site: Amnion Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135076 CVCL_9I59 DD2057 transformed cell line human CVCL_9I59 CL:0000010 Karyotypic information: 46,XX,t(1;9),(q42.13;p13.2)(?O) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135077 CVCL_9I58 DD2056 transformed cell line human CVCL_9I58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135078 CVCL_9I53 DD2043 transformed cell line human CVCL_9I53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135079 CVCL_9I52 DD2042 transformed cell line human CVCL_9I52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135080 CVCL_9I55 DD2046 transformed cell line human CVCL_9I55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135081 CVCL_9I54 DD2044 transformed cell line human CVCL_9I54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135082 CVCL_9I51 DD2041 finite cell line human CVCL_9I51 CL:0000010 Karyotypic information: 46,XY; 47,XY,+mar(13/21) de novo (ECACC); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male Part of: ECACC chromosomal abnormality collection 21135083 CVCL_9I50 DD2040 finite cell line human CVCL_9I50 CL:0000010 Karyotypic information: 47,XX,+9 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21135084 CVCL_9I68 DD2078 transformed cell line human CVCL_9I68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135085 CVCL_9I67 DD2077 finite cell line human CVCL_9I67 CL:0000010 Karyotypic information: 46,XX,-7,+der(7),t(7;11)(q36.1;q23.3)pat (ECACC); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21135086 CVCL_9I69 DD2080 transformed cell line human CVCL_9I69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135087 CVCL_9I64 DD2072 transformed cell line human CVCL_9I64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135088 CVCL_9I63 DD2069 finite cell line human CVCL_9I63 CL:0000010 Karyotypic information: 46,XY,inv(10)(q22.1;q23.2)mat (ECACC); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male Part of: ECACC chromosomal abnormality collection 21135089 CVCL_9I66 DD2075 transformed cell line human CVCL_9I66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135090 CVCL_9I65 DD2073 transformed cell line human CVCL_9I65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21135091 CVCL_9I60 DD2058 transformed cell line human CVCL_9I60 CL:0000010 Karyotypic information: 46,XX,t(1;19)(q42.13;p13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135092 CVCL_9I62 DD2068 finite cell line human CVCL_9I62 CL:0000010 Karyotypic information: 47,XX,+18 (ECACC); Derived from sampling site: Chorionic villus. Female Part of: ECACC chromosomal abnormality collection 21135093 CVCL_9I61 DD2064 transformed cell line human CVCL_9I61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21135094 CVCL_T701 DRP 153 spontaneously immortalized cell line CVCL_T701 CL:0000010 Unspecified Group: Amphibian cell line. 21135095 CVCL_SV01 HAP1 KMT2B (-) 3 cancer cell line human CVCL_SV01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15840; KMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135096 CVCL_T700 DRP 36 spontaneously immortalized cell line CVCL_T700 CL:0000010 Unspecified Doubling time: 48 hours (PubMed=3500873). Group: Amphibian cell line 21135097 CVCL_SV00 HAP1 KMT2B (-) 2 cancer cell line human CVCL_SV00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15840; KMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135098 CVCL_T703 GT-BR spontaneously immortalized cell line CVCL_T703 CL:0000010 Derived from sampling site: Brain. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135099 CVCL_SV03 HAP1 KMT2C (-) 2 cancer cell line human CVCL_SV03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13726; KMT2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135100 CVCL_SV02 HAP1 KMT2C (-) 1 cancer cell line human CVCL_SV02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13726; KMT2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135101 CVCL_T702 XL110 spontaneously immortalized cell line African clawed frog CVCL_T702 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Group: Amphibian cell line 21135102 CVCL_T705 GT-GB spontaneously immortalized cell line CVCL_T705 CL:0000010 Derived from sampling site: Gallbladder. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135103 CVCL_SV05 HAP1 KRAS (-) 1 cancer cell line human CVCL_SV05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6407; KRAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135104 CVCL_T704 GT-EYE spontaneously immortalized cell line CVCL_T704 CL:0000010 Derived from sampling site: Eye. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135105 CVCL_SV04 HAP1 KMT2D (-) cancer cell line human CVCL_SV04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7133; KMT2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135106 CVCL_T707 GT-KD spontaneously immortalized cell line CVCL_T707 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135107 CVCL_SV07 HAP1 KRT10 (-) 2 cancer cell line human CVCL_SV07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6413; KRT10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135108 CVCL_T706 GT-HT spontaneously immortalized cell line CVCL_T706 CL:0000010 Derived from sampling site: Heart. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135109 CVCL_SV06 HAP1 KRT10 (-) 1 cancer cell line human CVCL_SV06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6413; KRT10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135110 CVCL_T709 GT-LV spontaneously immortalized cell line CVCL_T709 CL:0000010 Derived from sampling site: Liver. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135111 CVCL_SV09 HAP1 KRT18 (-) 2 cancer cell line human CVCL_SV09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6430; KRT18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135112 CVCL_T708 GT-LG spontaneously immortalized cell line CVCL_T708 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 30-36 hours (PubMed=10462202) Group: Reptilian cell line 21135113 CVCL_SV08 HAP1 KRT18 (-) 1 cancer cell line human CVCL_SV08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6430; KRT18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135114 CVCL_BC90 ND09959 transformed cell line human CVCL_BC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135115 CVCL_BC92 ND09976 transformed cell line human CVCL_BC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135116 CVCL_BC91 ND09960 transformed cell line human CVCL_BC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135117 CVCL_BC94 ND09986 transformed cell line human CVCL_BC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135118 CVCL_BC93 ND09977 transformed cell line human CVCL_BC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135119 CVCL_BC85 ND09945 transformed cell line human CVCL_BC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135120 CVCL_BC84 ND09943 transformed cell line human CVCL_BC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135121 CVCL_BC87 ND09954 transformed cell line human CVCL_BC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135122 CVCL_BC86 ND09953 transformed cell line human CVCL_BC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135123 CVCL_BC89 ND09956 transformed cell line human CVCL_BC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135124 CVCL_BC88 ND09955 transformed cell line human CVCL_BC88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135125 CVCL_BC96 ND09995 transformed cell line human CVCL_BC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135126 CVCL_BC95 ND09988 transformed cell line human CVCL_BC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135127 CVCL_BC98 ND10000 transformed cell line human CVCL_BC98 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135128 CVCL_BC97 ND09996 transformed cell line human CVCL_BC97 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135129 CVCL_BC99 ND10001 transformed cell line human CVCL_BC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135130 CVCL_BC70 ND09873 transformed cell line human CVCL_BC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135131 CVCL_BC72 ND09878 transformed cell line human CVCL_BC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135132 CVCL_BC71 ND09876 transformed cell line human CVCL_BC71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135133 CVCL_BC63 ND09834 transformed cell line human CVCL_BC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135134 CVCL_BC62 ND09833 transformed cell line human CVCL_BC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135135 CVCL_BC65 ND09844 transformed cell line human CVCL_BC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135136 CVCL_BC64 ND09842 transformed cell line human CVCL_BC64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135137 CVCL_BC67 ND09846 transformed cell line human CVCL_BC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135138 CVCL_BC66 ND09845 transformed cell line human CVCL_BC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135139 CVCL_BC69 ND09859 transformed cell line human CVCL_BC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135140 CVCL_BC68 ND09858 transformed cell line human CVCL_BC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135141 CVCL_BC81 ND09913 transformed cell line human CVCL_BC81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135142 CVCL_BC80 ND09911 transformed cell line human CVCL_BC80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135143 CVCL_BC83 ND09915 transformed cell line human CVCL_BC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135144 CVCL_BC82 ND09914 transformed cell line human CVCL_BC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135145 CVCL_BC74 ND09884 transformed cell line human CVCL_BC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135146 CVCL_BC73 ND09881 transformed cell line human CVCL_BC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135147 CVCL_BC76 ND09889 transformed cell line human CVCL_BC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135148 CVCL_BC75 ND09885 transformed cell line human CVCL_BC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135149 CVCL_BC78 ND09907 transformed cell line human CVCL_BC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135150 CVCL_BC77 ND09890 transformed cell line human CVCL_BC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135151 CVCL_BC79 ND09909 transformed cell line human CVCL_BC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135152 CVCL_KG20 PCRP-ID4-1A10 hybridoma house mouse CVCL_KG20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135153 CVCL_KG22 PCRP-ID4-1B8 hybridoma house mouse CVCL_KG22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135154 CVCL_KG21 PCRP-ID4-1A6 hybridoma house mouse CVCL_KG21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135155 CVCL_BM83 ND13053 transformed cell line human CVCL_BM83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135156 CVCL_BM82 ND13049 transformed cell line human CVCL_BM82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135157 CVCL_BM85 ND13055 transformed cell line human CVCL_BM85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135158 CVCL_BM84 ND13054 transformed cell line human CVCL_BM84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135159 CVCL_BM87 ND13057 transformed cell line human CVCL_BM87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135160 CVCL_BM86 ND13056 transformed cell line human CVCL_BM86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135161 CVCL_BM89 ND13069 transformed cell line human CVCL_BM89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135162 CVCL_BM88 ND13058 transformed cell line human CVCL_BM88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135163 CVCL_KG17 PCRP-ID3-2H2 hybridoma house mouse CVCL_KG17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02535; Human ID3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135164 CVCL_KG16 PCRP-ID3-2G4 hybridoma house mouse CVCL_KG16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02535; Human ID3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135165 CVCL_KG19 PCRP-ID4-1A1 hybridoma house mouse CVCL_KG19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135166 CVCL_KG18 PCRP-ID3-3D6 hybridoma house mouse CVCL_KG18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02535; Human ID3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135167 CVCL_KG13 PCRP-ID1-2F11 hybridoma house mouse CVCL_KG13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P41134; Human ID1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135168 CVCL_KG12 PCRP-ID1-2C10 hybridoma house mouse CVCL_KG12 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P41134; Human ID1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135169 CVCL_BM81 ND13048 transformed cell line human CVCL_BM81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135170 CVCL_KG15 PCRP-ID3-2C8 hybridoma house mouse CVCL_KG15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q02535; Human ID3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135171 CVCL_BM80 ND13047 transformed cell line human CVCL_BM80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135172 CVCL_KG14 PCRP-ID2-1A8 hybridoma house mouse CVCL_KG14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q02363; Human ID2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135173 CVCL_KG31 PCRP-IRF2-1A4 hybridoma house mouse CVCL_KG31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14316; Human IRF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135174 CVCL_KG30 PCRP-INSM1-1A6 hybridoma house mouse CVCL_KG30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q01101; Human INSM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135175 CVCL_KG33 PCRP-IRF3-1D11 hybridoma house mouse CVCL_KG33 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135176 CVCL_KG32 PCRP-IRF2-1B2 hybridoma house mouse CVCL_KG32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14316; Human IRF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135177 CVCL_BM94 ND13075 transformed cell line human CVCL_BM94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135178 CVCL_BM93 ND13074 transformed cell line human CVCL_BM93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135179 CVCL_BM96 ND13079 transformed cell line human CVCL_BM96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135180 CVCL_BM95 ND13078 transformed cell line human CVCL_BM95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135181 CVCL_BM98 ND13096 transformed cell line human CVCL_BM98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135182 CVCL_BM97 ND13095 transformed cell line human CVCL_BM97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135183 CVCL_BM99 ND13098 transformed cell line human CVCL_BM99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135184 CVCL_KG28 PCRP-ING1-1C2 hybridoma house mouse CVCL_KG28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UK53; Human ING1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135185 CVCL_KG27 PCRP-IKZF1-1B8 hybridoma house mouse CVCL_KG27 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13422; Human IKZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135186 CVCL_KG29 PCRP-ING4-3B3 hybridoma house mouse CVCL_KG29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNL4; Human ING4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135187 CVCL_BM90 ND13070 transformed cell line human CVCL_BM90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135188 CVCL_KG24 PCRP-ID4-2D6 hybridoma house mouse CVCL_KG24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135189 CVCL_KG23 PCRP-ID4-1D6 hybridoma house mouse CVCL_KG23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135190 CVCL_BM92 ND13073 transformed cell line human CVCL_BM92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135191 CVCL_KG26 PCRP-IGF2BP1-2D4 hybridoma house mouse CVCL_KG26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZI8; Human IGF2BP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135192 CVCL_BM91 ND13071 transformed cell line human CVCL_BM91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135193 CVCL_KG25 PCRP-ID4-3C6 hybridoma house mouse CVCL_KG25 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P47928; Human ID4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135194 CVCL_KG00 PCRP-HOXB9-1E6 hybridoma house mouse CVCL_KG00 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P17482; Human HOXB9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135195 CVCL_BM69 ND13002 transformed cell line human CVCL_BM69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135196 CVCL_BM68 ND12998 transformed cell line human CVCL_BM68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135197 CVCL_BM61 ND12975 transformed cell line human CVCL_BM61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135198 CVCL_BM60 ND12972 transformed cell line human CVCL_BM60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135199 CVCL_BM63 ND12977 transformed cell line human CVCL_BM63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135200 CVCL_BM62 ND12976 transformed cell line human CVCL_BM62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135201 CVCL_BM65 ND12995 transformed cell line human CVCL_BM65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135202 CVCL_BM64 ND12994 transformed cell line human CVCL_BM64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135203 CVCL_BM67 ND12997 transformed cell line human CVCL_BM67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135204 CVCL_BM66 ND12996 transformed cell line human CVCL_BM66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135205 CVCL_KG11 PCRP-ID1-1E5 hybridoma house mouse CVCL_KG11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P41134; Human ID1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135206 CVCL_KG10 PCRP-HSF5-1A1 hybridoma house mouse CVCL_KG10 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q4G112; Human HSF5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135207 CVCL_BM79 ND13043 transformed cell line human CVCL_BM79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135208 CVCL_BM72 ND13011 transformed cell line human CVCL_BM72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135209 CVCL_BM71 ND13006 transformed cell line human CVCL_BM71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135210 CVCL_BM74 ND13021 transformed cell line human CVCL_BM74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135211 CVCL_BM73 ND13012 transformed cell line human CVCL_BM73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135212 CVCL_BM76 ND13034 transformed cell line human CVCL_BM76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135213 CVCL_BM75 ND13023 transformed cell line human CVCL_BM75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135214 CVCL_KG09 PCRP-HSF2-2C1 hybridoma house mouse CVCL_KG09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03933; Human HSF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135215 CVCL_BM78 ND13040 transformed cell line human CVCL_BM78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135216 CVCL_BM77 ND13039 transformed cell line human CVCL_BM77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135217 CVCL_KG06 PCRP-HSF1-1A9 hybridoma house mouse CVCL_KG06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135218 CVCL_KG05 PCRP-HSF1-1A8 hybridoma house mouse CVCL_KG05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135219 CVCL_KG08 PCRP-HSF1-1D11 hybridoma house mouse CVCL_KG08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135220 CVCL_KG07 PCRP-HSF1-1C1 hybridoma house mouse CVCL_KG07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135221 CVCL_KG02 PCRP-HOXD9-1A4 hybridoma house mouse CVCL_KG02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28356; Human HOXD9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135222 CVCL_KG01 PCRP-HOXC8-1D3 hybridoma house mouse CVCL_KG01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P31273; Human HOXC8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135223 CVCL_BM70 ND13003 transformed cell line human CVCL_BM70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135224 CVCL_KG04 PCRP-HSF1-1A6 hybridoma house mouse CVCL_KG04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135225 CVCL_KG03 PCRP-HSF1-1A10 hybridoma house mouse CVCL_KG03 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q00613; Human HSF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135226 CVCL_BM47 ND12919 transformed cell line human CVCL_BM47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135227 CVCL_BM46 ND12914 transformed cell line human CVCL_BM46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135228 CVCL_BM49 ND12924 transformed cell line human CVCL_BM49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135229 CVCL_BM48 ND12923 transformed cell line human CVCL_BM48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135230 CVCL_BM41 ND12905 transformed cell line human CVCL_BM41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135231 CVCL_BM40 ND12904 transformed cell line human CVCL_BM40 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135232 CVCL_BM43 ND12910 transformed cell line human CVCL_BM43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135233 CVCL_BM42 ND12909 transformed cell line human CVCL_BM42 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135234 CVCL_BM45 ND12913 transformed cell line human CVCL_BM45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135235 CVCL_BM44 ND12911 transformed cell line human CVCL_BM44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135236 CVCL_BM58 ND12947 transformed cell line human CVCL_BM58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135237 CVCL_BM57 ND12945 transformed cell line human CVCL_BM57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135238 CVCL_BM59 ND12970 transformed cell line human CVCL_BM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135239 CVCL_BM50 ND12932 transformed cell line human CVCL_BM50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135240 CVCL_BM52 ND12934 transformed cell line human CVCL_BM52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135241 CVCL_BM51 ND12933 transformed cell line human CVCL_BM51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135242 CVCL_BM54 ND12937 transformed cell line human CVCL_BM54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135243 CVCL_BM53 ND12935 transformed cell line human CVCL_BM53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135244 CVCL_BM56 ND12939 transformed cell line human CVCL_BM56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135245 CVCL_BM55 ND12938 transformed cell line human CVCL_BM55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135246 CVCL_9S91 GM08681 transformed cell line human CVCL_9S91 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+i(18)(pter->p10:p10->pter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135247 CVCL_9S90 GM07189 finite cell line human CVCL_9S90 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+15 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21135248 CVCL_9S93 GM09287 finite cell line human CVCL_9S93 CL:0000010 Population: African American; Karyotypic information: 47,XY,+9 (Coriell); Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21135249 CVCL_9S92 GM09286 finite cell line human CVCL_9S92 CL:0000010 Population: African American; Karyotypic information: 47,XY,+9 (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21135250 CVCL_9S99 MSU-1.0 transformed cell line human CVCL_9S99 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135251 CVCL_BM25 ND12849 transformed cell line human CVCL_BM25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135252 CVCL_BM24 ND12846 transformed cell line human CVCL_BM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135253 CVCL_9S98 TRT-HU2 telomerase immortalized cell line human CVCL_9S98 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Unspecified 21135254 CVCL_BM27 ND12862 transformed cell line human CVCL_BM27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135255 CVCL_BM26 ND12861 transformed cell line human CVCL_BM26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135256 CVCL_9S95 GM10061 finite cell line human CVCL_9S95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21135257 CVCL_BM29 ND12864 transformed cell line human CVCL_BM29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135258 CVCL_9S94 GM09704 finite cell line human CVCL_9S94 CL:0000010 Karyotypic information: 46,XX,rec(6)(pter->p12::q26->q16::p12->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21135259 CVCL_BM28 ND12863 transformed cell line human CVCL_BM28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135260 CVCL_9S97 GM10679 finite cell line human CVCL_9S97 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+i(12)(pter->p10::p10->pter) [37]; 46,XY [13] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21135261 CVCL_9S96 GM10315 finite cell line human CVCL_9S96 CL:0000010 Derived from sampling site: Chorionic villus. Omics: CNV analysis Female 21135262 CVCL_BM21 ND12842 transformed cell line human CVCL_BM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135263 CVCL_BM20 ND12841 transformed cell line human CVCL_BM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135264 CVCL_BM23 ND12845 transformed cell line human CVCL_BM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135265 CVCL_BM22 ND12843 transformed cell line human CVCL_BM22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135266 CVCL_BM36 ND12892 transformed cell line human CVCL_BM36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135267 CVCL_BM35 ND12888 transformed cell line human CVCL_BM35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135268 CVCL_BM38 ND12894 transformed cell line human CVCL_BM38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135269 CVCL_BM37 ND12893 transformed cell line human CVCL_BM37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135270 CVCL_BM39 ND12903 transformed cell line human CVCL_BM39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135271 CVCL_BM30 ND12868 transformed cell line human CVCL_BM30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135272 CVCL_BM32 ND12874 transformed cell line human CVCL_BM32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135273 CVCL_BM31 ND12869 transformed cell line human CVCL_BM31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135274 CVCL_BM34 ND12876 transformed cell line human CVCL_BM34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135275 CVCL_BM33 ND12875 transformed cell line human CVCL_BM33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135276 CVCL_TA41 HAP1 NEK4 (-) 2 cancer cell line human CVCL_TA41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11399; NEK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135277 CVCL_TA40 HAP1 NEK4 (-) 1 cancer cell line human CVCL_TA40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11399; NEK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135278 CVCL_TA43 HAP1 NEK7 (-) 2 cancer cell line human CVCL_TA43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13386; NEK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135279 CVCL_TA42 HAP1 NEK7 (-) 1 cancer cell line human CVCL_TA42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13386; NEK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135280 CVCL_TA45 HAP1 NEK8 (-) 1 cancer cell line human CVCL_TA45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13387; NEK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135281 CVCL_TA44 HAP1 NEK7 (-) 3 cancer cell line human CVCL_TA44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13386; NEK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135282 CVCL_TA47 HAP1 NEK8 (-) 3 cancer cell line human CVCL_TA47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13387; NEK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135283 CVCL_TA46 HAP1 NEK8 (-) 2 cancer cell line human CVCL_TA46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13387; NEK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135284 CVCL_TA49 HAP1 NEK9 (-) cancer cell line human CVCL_TA49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18591; NEK9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135285 CVCL_TA48 HAP1 NEK8 (-) 4 cancer cell line human CVCL_TA48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13387; NEK8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135286 CVCL_0Z04 GM21480 transformed cell line human CVCL_0Z04 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135287 CVCL_0Z03 GM21479 transformed cell line human CVCL_0Z03 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135288 CVCL_0Z06 GM21486 transformed cell line human CVCL_0Z06 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135289 CVCL_0Z05 GM21485 transformed cell line human CVCL_0Z05 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135290 CVCL_0Z08 GM21488 transformed cell line human CVCL_0Z08 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135291 CVCL_0Z07 GM21487 transformed cell line human CVCL_0Z07 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135292 CVCL_0Z09 GM21489 transformed cell line human CVCL_0Z09 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135293 CVCL_TA30 HAP1 NEK1 (-) 1 cancer cell line human CVCL_TA30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7744; NEK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135294 CVCL_TA32 HAP1 NEK10 (-) 1 cancer cell line human CVCL_TA32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18592; NEK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135295 CVCL_TA31 HAP1 NEK1 (-) 2 cancer cell line human CVCL_TA31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7744; NEK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135296 CVCL_TA34 HAP1 NEK10 (-) 3 cancer cell line human CVCL_TA34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18592; NEK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135297 CVCL_TA33 HAP1 NEK10 (-) 2 cancer cell line human CVCL_TA33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18592; NEK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135298 CVCL_TA36 HAP1 NEK2 (-) 2 cancer cell line human CVCL_TA36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7745; NEK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135299 CVCL_TA35 HAP1 NEK2 (-) 1 cancer cell line human CVCL_TA35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7745; NEK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135300 CVCL_TA38 HAP1 NEK3 (-) 2 cancer cell line human CVCL_TA38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7746; NEK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135301 CVCL_TA37 HAP1 NEK3 (-) 1 cancer cell line human CVCL_TA37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7746; NEK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135302 CVCL_TA39 HAP1 NEK3 (-) 3 cancer cell line human CVCL_TA39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7746; NEK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135303 CVCL_0Z00 GM21476 transformed cell line human CVCL_0Z00 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135304 CVCL_0Z02 GM21478 transformed cell line human CVCL_0Z02 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135305 CVCL_0Z01 GM21477 transformed cell line human CVCL_0Z01 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135306 CVCL_KG86 PCRP-KLF10-2A10 hybridoma house mouse CVCL_KG86 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135307 CVCL_KG85 PCRP-KLF10-1G2 hybridoma house mouse CVCL_KG85 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135308 CVCL_KG88 PCRP-KLF10-4B1 hybridoma house mouse CVCL_KG88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135309 CVCL_KG87 PCRP-KLF10-3E3 hybridoma house mouse CVCL_KG87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135310 CVCL_KG82 PCRP-KLF1-2C4 hybridoma house mouse CVCL_KG82 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q13351; Human KLF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135311 CVCL_KG81 PCRP-KIAA1967-1D10 hybridoma house mouse CVCL_KG81 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N163; Human CCAR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135312 CVCL_KG84 PCRP-KLF10-1D6 hybridoma house mouse CVCL_KG84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135313 CVCL_KG83 PCRP-KLF10-1D3 hybridoma house mouse CVCL_KG83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13118; Human KLF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135314 CVCL_KG80 PCRP-KIAA1967-1C8 hybridoma house mouse CVCL_KG80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N163; Human CCAR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135315 CVCL_TA21 HAP1 NDUFS4 (-) 2 cancer cell line human CVCL_TA21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7711; NDUFS4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135316 CVCL_TA20 HAP1 NDUFS4 (-) 1 cancer cell line human CVCL_TA20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7711; NDUFS4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135317 CVCL_TA23 HAP1 NEDD4 (-) 2 cancer cell line human CVCL_TA23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7727; NEDD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135318 CVCL_TA22 HAP1 NEDD4 (-) 1 cancer cell line human CVCL_TA22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7727; NEDD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135319 CVCL_TA25 HAP1 NEIL1 (-) cancer cell line human CVCL_TA25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18448; NEIL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135320 CVCL_TA24 HAP1 NEDD4L (-) 1 cancer cell line human CVCL_TA24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7728; NEDD4L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135321 CVCL_TA27 HAP1 NEIL2 (-) 2 cancer cell line human CVCL_TA27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18956; NEIL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135322 CVCL_TA26 HAP1 NEIL2 (-) 1 cancer cell line human CVCL_TA26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18956; NEIL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135323 CVCL_TA29 HAP1 NEIL3 (-) 2 cancer cell line human CVCL_TA29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24573; NEIL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135324 CVCL_TA28 HAP1 NEIL3 (-) 1 cancer cell line human CVCL_TA28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24573; NEIL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135325 CVCL_KG79 PCRP-KIAA1967-1B5 hybridoma house mouse CVCL_KG79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N163; Human CCAR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135326 CVCL_KG78 PCRP-KHDRBS3-1D3 hybridoma house mouse CVCL_KG78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75525; Human KHDRBS3 Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135327 CVCL_KG97 PCRP-KLF16-1E9 hybridoma house mouse CVCL_KG97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BXK1; Human KLF16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135328 CVCL_KG96 PCRP-KLF15-2A8 hybridoma house mouse CVCL_KG96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UIH9; Human KLF15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135329 CVCL_KG99 PCRP-KLF16-3B3 hybridoma house mouse CVCL_KG99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BXK1; Human KLF16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135330 CVCL_KG98 PCRP-KLF16-2E5 hybridoma house mouse CVCL_KG98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BXK1; Human KLF16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135331 CVCL_KG93 PCRP-KLF15-1F11 hybridoma house mouse CVCL_KG93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UIH9; Human KLF15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135332 CVCL_KG92 PCRP-KLF14-1H1 hybridoma house mouse CVCL_KG92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TD94; Human KLF14. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135333 CVCL_KG95 PCRP-KLF15-1H3 hybridoma house mouse CVCL_KG95 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UIH9; Human KLF15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135334 CVCL_KG94 PCRP-KLF15-1H1 hybridoma house mouse CVCL_KG94 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UIH9; Human KLF15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135335 CVCL_KG91 PCRP-KLF14-1C12 hybridoma house mouse CVCL_KG91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TD94; Human KLF14. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135336 CVCL_KG90 PCRP-KLF12-1H9 hybridoma house mouse CVCL_KG90 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y4X4; Human KLF12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135337 CVCL_TA10 HAP1 NCOA4 (-) 2 cancer cell line human CVCL_TA10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7671; NCOA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135338 CVCL_TA12 HAP1 NDUFA2 (-) 1 cancer cell line human CVCL_TA12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7685; NDUFA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135339 CVCL_TA11 HAP1 NCOA4 (-) 3 cancer cell line human CVCL_TA11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7671; NCOA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135340 CVCL_TA14 HAP1 NDUFA9 (-) 1 cancer cell line human CVCL_TA14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7693; NDUFA9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135341 CVCL_TA13 HAP1 NDUFA2 (-) 2 cancer cell line human CVCL_TA13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7685; NDUFA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135342 CVCL_TA16 HAP1 NDUFB10 (-) cancer cell line human CVCL_TA16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7696; NDUFB10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135343 CVCL_TA15 HAP1 NDUFA9 (-) 2 cancer cell line human CVCL_TA15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7693; NDUFA9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135344 CVCL_TA18 HAP1 NDUFS2 (-) 1 cancer cell line human CVCL_TA18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7708; NDUFS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135345 CVCL_TA17 HAP1 NDUFB8 (-) 1 cancer cell line human CVCL_TA17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7703; NDUFB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135346 CVCL_TA19 HAP1 NDUFS2 (-) 2 cancer cell line human CVCL_TA19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7708; NDUFS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135347 CVCL_KG89 PCRP-KLF12-1E3 hybridoma house mouse CVCL_KG89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y4X4; Human KLF12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135348 CVCL_KG64 PCRP-JAZF1-1C1 hybridoma house mouse CVCL_KG64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VZ6; Human JAZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135349 CVCL_KG63 PCRP-JAZF1-1B8 hybridoma house mouse CVCL_KG63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VZ6; Human JAZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135350 CVCL_KG66 PCRP-JUNB-3G11 hybridoma house mouse CVCL_KG66 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P17275; Human JUNB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135351 CVCL_KG65 PCRP-JAZF1-1C2 hybridoma house mouse CVCL_KG65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VZ6; Human JAZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135352 CVCL_KG60 PCRP-ISL1-1D4 hybridoma house mouse CVCL_KG60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P61371; Human ISL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135353 CVCL_KG62 PCRP-JAZF1-1A5 hybridoma house mouse CVCL_KG62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VZ6; Human JAZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135354 CVCL_KG61 PCRP-IVNS1ABP-1B10 hybridoma house mouse CVCL_KG61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y6Y0; Human IVNS1ABP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135355 CVCL_TA01 HAP1 NBEA (-) 1 cancer cell line human CVCL_TA01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7648; NBEA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135356 CVCL_TA00 HAP1 NAT9 (-) 2 cancer cell line human CVCL_TA00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23133; NAT9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135357 CVCL_TA03 HAP1 NBEAL1 (-) cancer cell line human CVCL_TA03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20681; NBEAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135358 CVCL_TA02 HAP1 NBEA (-) 2 cancer cell line human CVCL_TA02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7648; NBEA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135359 CVCL_TA05 HAP1 NBEAL2 (-) 2 cancer cell line human CVCL_TA05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31928; NBEAL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135360 CVCL_TA04 HAP1 NBEAL2 (-) 1 cancer cell line human CVCL_TA04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31928; NBEAL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135361 CVCL_TA07 HAP1 NCKAP1 (-) 2 cancer cell line human CVCL_TA07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7666; NCKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135362 CVCL_TA06 HAP1 NCKAP1 (-) 1 cancer cell line human CVCL_TA06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7666; NCKAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135363 CVCL_TA09 HAP1 NCKIPSD (-) 2 cancer cell line human CVCL_TA09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15486; NCKIPSD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135364 CVCL_TA08 HAP1 NCKIPSD (-) 1 cancer cell line human CVCL_TA08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15486; NCKIPSD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135365 CVCL_KG57 PCRP-IRX5-1C11 hybridoma house mouse CVCL_KG57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P78411; Human IRX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135366 CVCL_KG56 PCRP-IRX5-1B4 hybridoma house mouse CVCL_KG56 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P78411; Human IRX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135367 CVCL_KG59 PCRP-ISL1-1C2 hybridoma house mouse CVCL_KG59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61371; Human ISL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135368 CVCL_KG58 PCRP-ISL1-1A9 hybridoma house mouse CVCL_KG58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61371; Human ISL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135369 CVCL_KG75 PCRP-KDM8-1A2 hybridoma house mouse CVCL_KG75 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N371; Human KDM8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135370 CVCL_KG74 PCRP-KDM5C-1A11 hybridoma house mouse CVCL_KG74 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P41229; Human KDM5C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135371 CVCL_KG77 PCRP-KHDRBS3-1D11 hybridoma house mouse CVCL_KG77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75525; Human KHDRBS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135372 CVCL_KG76 PCRP-KHDRBS1-2E2 hybridoma house mouse CVCL_KG76 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q07666; Human KHDRBS1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135373 CVCL_KG71 PCRP-KDM1A-1A10 hybridoma house mouse CVCL_KG71 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O60341; Human KDM1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135374 CVCL_KG70 PCRP-KCMF1-1H4 hybridoma house mouse CVCL_KG70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9P0J7; Human KCMF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135375 CVCL_KG73 PCRP-KDM1A-1B2 hybridoma house mouse CVCL_KG73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60341; Human KDM1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135376 CVCL_KG72 PCRP-KDM1A-1A4 hybridoma house mouse CVCL_KG72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60341; Human KDM1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135377 CVCL_KG68 PCRP-JUP-1B1 hybridoma house mouse CVCL_KG68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14923; Human JUP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135378 CVCL_KG67 PCRP-JUNB-3G2 hybridoma house mouse CVCL_KG67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17275; Human JUNB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135379 CVCL_KG69 PCRP-KBTBD10-4B8 hybridoma house mouse CVCL_KG69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60662; Human KLHL41. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135380 CVCL_KG42 PCRP-IRF3-4F5 hybridoma house mouse CVCL_KG42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135381 CVCL_KG41 PCRP-IRF3-4D7 hybridoma house mouse CVCL_KG41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135382 CVCL_KG44 PCRP-IRF3-5B12 hybridoma house mouse CVCL_KG44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135383 CVCL_KG43 PCRP-IRF3-4G8 hybridoma house mouse CVCL_KG43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135384 CVCL_KG40 PCRP-IRF3-3B2 hybridoma house mouse CVCL_KG40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135385 CVCL_KG39 PCRP-IRF3-2F9 hybridoma house mouse CVCL_KG39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135386 CVCL_KG38 PCRP-IRF3-2D9 hybridoma house mouse CVCL_KG38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135387 CVCL_KG35 PCRP-IRF3-1E3 hybridoma house mouse CVCL_KG35 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135388 CVCL_KG34 PCRP-IRF3-1E11 hybridoma house mouse CVCL_KG34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135389 CVCL_KG37 PCRP-IRF3-2C5 hybridoma house mouse CVCL_KG37 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135390 CVCL_KG36 PCRP-IRF3-1G7 hybridoma house mouse CVCL_KG36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135391 CVCL_KG53 PCRP-IRF9-2F8 hybridoma house mouse CVCL_KG53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00978; Human IRF9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135392 CVCL_KG52 PCRP-IRF9-2B7 hybridoma house mouse CVCL_KG52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q00978; Human IRF9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135393 CVCL_KG55 PCRP-IRX2-1C1 hybridoma house mouse CVCL_KG55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BZI1; Human IRX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135394 CVCL_KG54 PCRP-IRX2-1B7 hybridoma house mouse CVCL_KG54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BZI1; Human IRX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135395 CVCL_KG51 PCRP-IRF8-1A12 hybridoma house mouse CVCL_KG51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02556; Human IRF8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135396 CVCL_KG50 PCRP-IRF4-1A8 hybridoma house mouse CVCL_KG50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15306; Human IRF4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135397 CVCL_KG49 PCRP-IRF4-1A5 hybridoma house mouse CVCL_KG49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15306; Human IRF4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135398 CVCL_KG46 PCRP-IRF3-6C2 hybridoma house mouse CVCL_KG46 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135399 CVCL_KG45 PCRP-IRF3-6A11 hybridoma house mouse CVCL_KG45 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135400 CVCL_KG48 PCRP-IRF3-6H10 hybridoma house mouse CVCL_KG48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135401 CVCL_KG47 PCRP-IRF3-6C8 hybridoma house mouse CVCL_KG47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14653; Human IRF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135402 CVCL_0Y59 GM21399 transformed cell line human CVCL_0Y59 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135403 CVCL_0Y50 GM21383 transformed cell line human CVCL_0Y50 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135404 CVCL_0Y52 GM21385 transformed cell line human CVCL_0Y52 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135405 CVCL_0Y51 GM21384 transformed cell line human CVCL_0Y51 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135406 CVCL_0Y54 GM21387 transformed cell line human CVCL_0Y54 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135407 CVCL_0Y53 GM21386 transformed cell line human CVCL_0Y53 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135408 CVCL_0Y56 GM21389 transformed cell line human CVCL_0Y56 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135409 CVCL_0Y55 GM21388 transformed cell line human CVCL_0Y55 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135410 CVCL_0Y58 GM21391 transformed cell line human CVCL_0Y58 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135411 CVCL_0Y57 GM21390 transformed cell line human CVCL_0Y57 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135412 CVCL_9S00 HS975 embryonic stem cell human CVCL_9S00 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female 21135413 CVCL_9S02 CAMi005-B induced pluripotent stem cell human CVCL_9S02 From: University of Cambridge; Cambridge; United Kingdom. CL:0000010 Female 21135414 CVCL_9S01 CAMi005-A induced pluripotent stem cell human CVCL_9S01 From: University of Cambridge; Cambridge; United Kingdom. CL:0000010 Female 21135415 CVCL_0Y61 GM21401 transformed cell line human CVCL_0Y61 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135416 CVCL_0Y60 GM21400 transformed cell line human CVCL_0Y60 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135417 CVCL_0Y63 GM21403 transformed cell line human CVCL_0Y63 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135418 CVCL_0Y62 GM21402 transformed cell line human CVCL_0Y62 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135419 CVCL_0Y65 GM21405 transformed cell line human CVCL_0Y65 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135420 CVCL_0Y64 GM21404 transformed cell line human CVCL_0Y64 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135421 CVCL_0Y67 GM21409 transformed cell line human CVCL_0Y67 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135422 CVCL_0Y66 GM21408 transformed cell line human CVCL_0Y66 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135423 CVCL_0Y69 GM21414 transformed cell line human CVCL_0Y69 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135424 CVCL_0Y68 GM21410 transformed cell line human CVCL_0Y68 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135425 CVCL_0Y38 GM21363 transformed cell line human CVCL_0Y38 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135426 CVCL_0Y37 GM21362 transformed cell line human CVCL_0Y37 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135427 CVCL_0Y39 GM21364 transformed cell line human CVCL_0Y39 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135428 CVCL_0Y30 GM21353 transformed cell line human CVCL_0Y30 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135429 CVCL_0Y32 GM21356 transformed cell line human CVCL_0Y32 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135430 CVCL_0Y31 GM21355 transformed cell line human CVCL_0Y31 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135431 CVCL_0Y34 GM21359 transformed cell line human CVCL_0Y34 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135432 CVCL_0Y33 GM21357 transformed cell line human CVCL_0Y33 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135433 CVCL_0Y36 GM21361 transformed cell line human CVCL_0Y36 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135434 CVCL_0Y35 GM21360 transformed cell line human CVCL_0Y35 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135435 CVCL_0Y49 GM21382 transformed cell line human CVCL_0Y49 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135436 CVCL_0Y48 GM21381 transformed cell line human CVCL_0Y48 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135437 CVCL_0Y41 GM21366 transformed cell line human CVCL_0Y41 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135438 CVCL_0Y40 GM21365 transformed cell line human CVCL_0Y40 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135439 CVCL_0Y43 GM21368 transformed cell line human CVCL_0Y43 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135440 CVCL_0Y42 GM21367 transformed cell line human CVCL_0Y42 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135441 CVCL_0Y45 GM21371 transformed cell line human CVCL_0Y45 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135442 CVCL_0Y44 GM21370 transformed cell line human CVCL_0Y44 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135443 CVCL_0Y47 GM21379 transformed cell line human CVCL_0Y47 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135444 CVCL_0Y46 GM21378 transformed cell line human CVCL_0Y46 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135445 CVCL_0Y16 GM21314 transformed cell line human CVCL_0Y16 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135446 CVCL_0Y15 GM21313 transformed cell line human CVCL_0Y15 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135447 CVCL_0Y18 GM21317 transformed cell line human CVCL_0Y18 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135448 CVCL_0Y17 GM21316 transformed cell line human CVCL_0Y17 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135449 CVCL_0Y19 GM21318 transformed cell line human CVCL_0Y19 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135450 CVCL_0Y10 GM21308 transformed cell line human CVCL_0Y10 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135451 CVCL_0Y12 GM21310 transformed cell line human CVCL_0Y12 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135452 CVCL_0Y11 GM21309 transformed cell line human CVCL_0Y11 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135453 CVCL_0Y14 GM21312 transformed cell line human CVCL_0Y14 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135454 CVCL_0Y13 GM21311 transformed cell line human CVCL_0Y13 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135455 CVCL_0Y27 GM21344 transformed cell line human CVCL_0Y27 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135456 CVCL_0Y26 GM21341 transformed cell line human CVCL_0Y26 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135457 CVCL_0Y29 GM21352 transformed cell line human CVCL_0Y29 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135458 CVCL_0Y28 GM21351 transformed cell line human CVCL_0Y28 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135459 CVCL_0Y21 GM21333 transformed cell line human CVCL_0Y21 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135460 CVCL_0Y20 GM21320 transformed cell line human CVCL_0Y20 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135461 CVCL_0Y23 GM21336 transformed cell line human CVCL_0Y23 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135462 CVCL_0Y22 GM21335 transformed cell line human CVCL_0Y22 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135463 CVCL_0Y25 GM21339 transformed cell line human CVCL_0Y25 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135464 CVCL_0Y24 GM21338 transformed cell line human CVCL_0Y24 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135465 CVCL_0Y05 GM21302 transformed cell line human CVCL_0Y05 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135466 CVCL_0Y04 GM21301 transformed cell line human CVCL_0Y04 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135467 CVCL_0Y07 GM21304 transformed cell line human CVCL_0Y07 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135468 CVCL_0Y06 GM21303 transformed cell line human CVCL_0Y06 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135469 CVCL_0Y09 GM21307 transformed cell line human CVCL_0Y09 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135470 CVCL_0Y08 GM21306 transformed cell line human CVCL_0Y08 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135471 CVCL_0Y01 GM21297 transformed cell line human CVCL_0Y01 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135472 CVCL_0Y00 GM21295 transformed cell line human CVCL_0Y00 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135473 CVCL_0Y03 GM21300 transformed cell line human CVCL_0Y03 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135474 CVCL_0Y02 GM21298 transformed cell line human CVCL_0Y02 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135475 CVCL_9S71 XP7TO finite cell line human CVCL_9S71 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135476 CVCL_9S70 XP6TO finite cell line human CVCL_9S70 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135477 CVCL_9S77 ihFib3.2 induced pluripotent stem cell human CVCL_9S77 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135478 CVCL_BM03 ND12795 transformed cell line human CVCL_BM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135479 CVCL_9S76 GENYOi006-A induced pluripotent stem cell human CVCL_9S76 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Population: Caucasian; Spanish; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135480 CVCL_BM02 ND12785 transformed cell line human CVCL_BM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135481 CVCL_9S79 MUi011-A induced pluripotent stem cell human CVCL_9S79 From: Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21135482 CVCL_BM05 ND12807 transformed cell line human CVCL_BM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135483 CVCL_9S78 MSC-iPSC 74 induced pluripotent stem cell human CVCL_9S78 From: Max Planck Institute for Molecular Genetics; Berlin; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 21135484 CVCL_BM04 ND12797 transformed cell line human CVCL_BM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135485 CVCL_9S73 iPSC 09-24 induced pluripotent stem cell human CVCL_9S73 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; c.1782+1072G>C; ClinVar=VCV000946832; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Arg788Serfs*14 (c.2362_2363delAGinsTCATCT); ClinVar=VCV000017618; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135486 CVCL_BM07 ND12814 transformed cell line human CVCL_BM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135487 CVCL_9S72 iPSC 08-26 induced pluripotent stem cell human CVCL_9S72 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Gene deletion; HGNC; 1480; CAPN3; Zygosity=Heterozygous (PubMed=33862537); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Ter822Leuext62 (c.2465G>T); ClinVar=VCV000571060; Zygosity=Heterozygous (PubMed=33862537) Derived from sampling site: Back; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135488 CVCL_BM06 ND12808 transformed cell line human CVCL_BM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135489 CVCL_9S75 epiHUVEC induced pluripotent stem cell human CVCL_9S75 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female 21135490 CVCL_BM09 ND12816 transformed cell line human CVCL_BM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135491 CVCL_9S74 BJNhem20-OCIAD1-CRISPR-20 embryonic stem cell human CVCL_9S74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16074; OCIAD1. Population: Indian Female 21135492 CVCL_BM08 ND12815 transformed cell line human CVCL_BM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135493 CVCL_9S69 XP27OS finite cell line human CVCL_9S69 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1372102; PubMed=1702221); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Heterozygous (PubMed=1372102; PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 21135494 CVCL_BM01 ND12783 transformed cell line human CVCL_BM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135495 CVCL_BM00 ND12782 transformed cell line human CVCL_BM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135496 CVCL_9S80 I1-12C induced pluripotent stem cell human CVCL_9S80 From: Edith Nourse Rogers Memorial Veterans Hospital; Bedford; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21135497 CVCL_9S82 GM15916 transformed cell line human CVCL_9S82 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135498 CVCL_9S81 MSU-1.1 transformed cell line human CVCL_9S81 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135499 CVCL_9S88 GM03535 finite cell line human CVCL_9S88 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21135500 CVCL_BM14 ND12830 transformed cell line human CVCL_BM14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135501 CVCL_9S87 GM16262 transformed cell line human CVCL_9S87 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135502 CVCL_BM13 ND12828 transformed cell line human CVCL_BM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135503 CVCL_BM16 ND12834 transformed cell line human CVCL_BM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135504 CVCL_9S89 GM03673 finite cell line human CVCL_9S89 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21135505 CVCL_BM15 ND12833 transformed cell line human CVCL_BM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135506 CVCL_9S84 GM15918 transformed cell line human CVCL_9S84 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135507 CVCL_BM18 ND12838 transformed cell line human CVCL_BM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135508 CVCL_9S83 GM15917 transformed cell line human CVCL_9S83 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135509 CVCL_BM17 ND12835 transformed cell line human CVCL_BM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135510 CVCL_9S86 GM15920 transformed cell line human CVCL_9S86 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135511 CVCL_9S85 GM15919 transformed cell line human CVCL_9S85 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21135512 CVCL_BM19 ND12840 transformed cell line human CVCL_BM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135513 CVCL_BM10 ND12817 transformed cell line human CVCL_BM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135514 CVCL_BM12 ND12827 transformed cell line human CVCL_BM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135515 CVCL_BM11 ND12818 transformed cell line human CVCL_BM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135516 CVCL_9S55 UCLi002-A induced pluripotent stem cell human CVCL_9S55 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135517 CVCL_9S54 UCLi001-A induced pluripotent stem cell human CVCL_9S54 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135518 CVCL_9S57 UCLi005-A induced pluripotent stem cell human CVCL_9S57 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10805; SGCA; Simple; p.Arg77Cys (c.229C>T); ClinVar=VCV000009437; Zygosity=Homozygous (PubMed=22745439) Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21135519 CVCL_9S56 UCLi003-A induced pluripotent stem cell human CVCL_9S56 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (EBiSC) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135520 CVCL_9S51 GM20912 finite cell line human CVCL_9S51 CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Fibroblast.. Male 21135521 CVCL_9S50 SCTi002-A induced pluripotent stem cell human CVCL_9S50 From: STEMCELL Technologies, Inc.; Vancouver; Canada CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21135522 CVCL_9S53 GM03932 finite cell line human CVCL_9S53 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21135523 CVCL_9S52 GM03931 transformed cell line human CVCL_9S52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135524 CVCL_9S48 RCi004-B induced pluripotent stem cell human CVCL_9S48 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[~40] (c.52CAG(~40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21135525 CVCL_9S47 RCi004-A induced pluripotent stem cell human CVCL_9S47 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[~40] (c.52CAG(~40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21135526 CVCL_9S49 SCTi001-A induced pluripotent stem cell human CVCL_9S49 From: STEMCELL Technologies, Inc.; Vancouver; Canada CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135527 CVCL_9S60 UKKi008-A induced pluripotent stem cell human CVCL_9S60 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val240Met (c.718G>A); ClinVar=VCV000068039; Zygosity=Heterozygous (PubMed=24349418) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135528 CVCL_9S66 XP39R induced pluripotent stem cell human CVCL_9S66 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135529 CVCL_9S65 XP3R induced pluripotent stem cell human CVCL_9S65 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135530 CVCL_9S68 XP15OS finite cell line human CVCL_9S68 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135531 CVCL_9S67 XP10OS finite cell line human CVCL_9S67 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21135532 CVCL_9S62 UKKi009-B induced pluripotent stem cell human CVCL_9S62 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Leu1012Profs*55 (c.3035_3045delTCCCTCGATGC); Zygosity=Heterozygous (PubMed=27345990) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135533 CVCL_9S61 UKKi009-A induced pluripotent stem cell human CVCL_9S61 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Leu1012Profs*55 (c.3035_3045delTCCCTCGATGC); Zygosity=Heterozygous (PubMed=27345990) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: ECACC; 66540031; probable Female 21135534 CVCL_9S64 UKKi012-A induced pluripotent stem cell human CVCL_9S64 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135535 CVCL_9S63 UKKi011-A induced pluripotent stem cell human CVCL_9S63 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135536 CVCL_9S59 UKKi006-A induced pluripotent stem cell human CVCL_9S59 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: DNA methylation analysis Female 21135537 CVCL_9S58 HPSI0114i-kolf_2-C1 induced pluripotent stem cell human CVCL_9S58 From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Pro197Hisfs*12 (c.590_608delCTAAAATCATCACTTTACT); Zygosity=Heterozygous (PubMed=31216442); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.3526-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31216442); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly1176Ser (c.3526G>A); Zygosity=Heterozygous (PubMed=31216442) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced Male 21135538 CVCL_9S33 PFIZi003-A induced pluripotent stem cell human CVCL_9S33 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ile859Thr (c.2576T>C) (p.Ile848Thr, c.2543T>C); ClinVar=VCV000006350; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Male 21135539 CVCL_9S32 PFIZi002-A induced pluripotent stem cell human CVCL_9S32 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ser241Thr (c.721T>A); ClinVar=VCV000006351; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Female 21135540 CVCL_9S35 RBi001-A induced pluripotent stem cell human CVCL_9S35 From: R Biomedical, Ltd; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135541 CVCL_9S34 PFIZi004-A induced pluripotent stem cell human CVCL_9S34 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ile859Thr (c.2576T>C) (p.Ile848Thr, c.2543T>C); ClinVar=VCV000006350; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Male 21135542 CVCL_9S31 PFIZi001-A induced pluripotent stem cell human CVCL_9S31 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Ser241Thr (c.721T>A); ClinVar=VCV000006351; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Female 21135543 CVCL_9S30 MUNIi003-A induced pluripotent stem cell human CVCL_9S30 From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex48-50del; Zygosity=Hemizygous (PubMed=30650618; PubMed=31526943) Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21135544 CVCL_9S29 MUNIi002-A induced pluripotent stem cell human CVCL_9S29 From: Masaryk University; Brno; Czech Republic CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21135545 CVCL_0Y90 GM21450 transformed cell line human CVCL_0Y90 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135546 CVCL_0Y92 GM21453 transformed cell line human CVCL_0Y92 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135547 CVCL_9S26 LUMCi001-A induced pluripotent stem cell human CVCL_9S26 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Derived from sampling site: Urine. Male 21135548 CVCL_9S25 CBiPS 4F-3a induced pluripotent stem cell human CVCL_9S25 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135549 CVCL_0Y91 GM21451 transformed cell line human CVCL_0Y91 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135550 CVCL_0Y94 GM21455 transformed cell line human CVCL_0Y94 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135551 CVCL_9S28 MUNIi001-A induced pluripotent stem cell human CVCL_9S28 From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (PubMed=30650618; PubMed=31526943) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21135552 CVCL_0Y93 GM21454 transformed cell line human CVCL_0Y93 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135553 CVCL_9S27 LUMCi001-B induced pluripotent stem cell human CVCL_9S27 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Derived from sampling site: Urine. Male 21135554 CVCL_0Y96 GM21457 transformed cell line human CVCL_0Y96 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135555 CVCL_0Y95 GM21456 transformed cell line human CVCL_0Y95 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135556 CVCL_0Y98 GM21473 transformed cell line human CVCL_0Y98 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135557 CVCL_0Y97 GM21458 transformed cell line human CVCL_0Y97 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135558 CVCL_0Y99 GM21475 transformed cell line human CVCL_0Y99 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135559 CVCL_9S44 RCi002-B induced pluripotent stem cell human CVCL_9S44 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Phe1460Val (c.4378T>G) (p.Phe1449Val, c.4345T>G); ClinVar=VCV000006352; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Female 21135560 CVCL_9S43 RCi002-A induced pluripotent stem cell human CVCL_9S43 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Phe1460Val (c.4378T>G) (p.Phe1449Val, c.4345T>G); ClinVar=VCV000006352; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Female 21135561 CVCL_9S46 RCi003-B induced pluripotent stem cell human CVCL_9S46 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10583; SCN11A; Unexplicit; Not described; Zygosity=Unspecified (EBiSC) Derived from sampling site: Peripheral blood. Female 21135562 CVCL_9S45 RCi003-A induced pluripotent stem cell human CVCL_9S45 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10583; SCN11A; Unexplicit; Not described; Zygosity=Unspecified (EBiSC) Derived from sampling site: Peripheral blood. Female 21135563 CVCL_9S40 UNEWi005-A induced pluripotent stem cell human CVCL_9S40 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Arg372Glnfs*99 (c.1115_1125del11); ClinVar=VCV000004358; Zygosity=Heterozygous (DOI=10.1101/232397) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135564 CVCL_9S42 RCi001-B induced pluripotent stem cell human CVCL_9S42 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Val400Met (c.1198G>A); ClinVar=VCV000538468; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Male 21135565 CVCL_9S41 RCi001-A induced pluripotent stem cell human CVCL_9S41 From: Pfizer, Inc.; New York; USA; From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 10597; SCN9A; Simple; p.Val400Met (c.1198G>A); ClinVar=VCV000538468; Zygosity=Heterozygous (PubMed=27099175) Derived from sampling site: Peripheral blood. Male 21135566 CVCL_9S37 UNEWi001-A induced pluripotent stem cell human CVCL_9S37 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; c.522_527del6+IVS6+1_+10del10; Zygosity=Heterozygous (DOI=10.1101/232397) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135567 CVCL_9S36 UKKi007-B induced pluripotent stem cell human CVCL_9S36 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Phe2483Ile (c.7447T>A); Zygosity=Heterozygous (PubMed=22178870) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135568 CVCL_9S39 UNEWi004-A induced pluripotent stem cell human CVCL_9S39 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Arg372Glnfs*99 (c.1115_1125del11); ClinVar=VCV000004358; Zygosity=Heterozygous (DOI=10.1101/232397) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21135569 CVCL_9S38 UNEWi002-A induced pluripotent stem cell human CVCL_9S38 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; c.522_527del6+IVS6+1_+10del10; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21135570 CVCL_9S11 ESi042-A induced pluripotent stem cell human CVCL_9S11 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp420Cys (c.1260G>C); ClinVar=VCV000003901; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1330+1G>A (IVS11+1G>A); ClinVar=VCV000371490; Zygosity=Heterozygous; Note=Splice donor mutation (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135571 CVCL_9S10 ESi043-A induced pluripotent stem cell human CVCL_9S10 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135572 CVCL_9S13 IB C1 (clon A201) induced pluripotent stem cell human CVCL_9S13 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135573 CVCL_9S12 ESi039-A induced pluripotent stem cell human CVCL_9S12 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135574 CVCL_9S08 FiPS-4F-8 induced pluripotent stem cell human CVCL_9S08 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135575 CVCL_9S07 FiPS-4F-7 induced pluripotent stem cell human CVCL_9S07 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135576 CVCL_9S09 ESi040-A induced pluripotent stem cell human CVCL_9S09 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Gln456Ter (c.1366C>T); ClinVar=VCV000002415; Zygosity=Homozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135577 CVCL_9S04 BCRTi002-A induced pluripotent stem cell human CVCL_9S04 From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (PubMed=27345784) Derived from sampling site: Urine. Female 21135578 CVCL_0Y70 GM21415 transformed cell line human CVCL_0Y70 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135579 CVCL_9S03 BCRTi001-A induced pluripotent stem cell human CVCL_9S03 From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (PubMed=27345784) Derived from sampling site: Urine. Male 21135580 CVCL_9S06 BCRTi005-A induced pluripotent stem cell human CVCL_9S06 From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female 21135581 CVCL_0Y72 GM21418 transformed cell line human CVCL_0Y72 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135582 CVCL_9S05 BCRTi004-A induced pluripotent stem cell human CVCL_9S05 From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female 21135583 CVCL_0Y71 GM21417 transformed cell line human CVCL_0Y71 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135584 CVCL_0Y74 GM21421 transformed cell line human CVCL_0Y74 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135585 CVCL_0Y73 GM21420 transformed cell line human CVCL_0Y73 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135586 CVCL_0Y76 GM21424 transformed cell line human CVCL_0Y76 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135587 CVCL_0Y75 GM21423 transformed cell line human CVCL_0Y75 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135588 CVCL_0Y78 GM21434 transformed cell line human CVCL_0Y78 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135589 CVCL_0Y77 GM21425 transformed cell line human CVCL_0Y77 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135590 CVCL_0Y79 GM21435 transformed cell line human CVCL_0Y79 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135591 CVCL_9S22 ESi045-C induced pluripotent stem cell human CVCL_9S22 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Scrotum; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135592 CVCL_9S21 ESi045-A induced pluripotent stem cell human CVCL_9S21 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Scrotum; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135593 CVCL_9S24 CBiPS 4F-10b induced pluripotent stem cell human CVCL_9S24 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135594 CVCL_9S23 CBiPS 2F-1c induced pluripotent stem cell human CVCL_9S23 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135595 CVCL_9S20 ESi045-B induced pluripotent stem cell human CVCL_9S20 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Scrotum; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135596 CVCL_9S19 ESi044-C induced pluripotent stem cell human CVCL_9S19 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135597 CVCL_9S18 ESi044-A induced pluripotent stem cell human CVCL_9S18 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135598 CVCL_0Y81 GM21438 transformed cell line human CVCL_0Y81 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135599 CVCL_9S15 IB PD-G2 induced pluripotent stem cell human CVCL_9S15 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135600 CVCL_0Y80 GM21436 transformed cell line human CVCL_0Y80 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135601 CVCL_9S14 IB PD-G1 induced pluripotent stem cell human CVCL_9S14 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135602 CVCL_0Y83 GM21440 transformed cell line human CVCL_0Y83 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135603 CVCL_9S17 IB SvC1 induced pluripotent stem cell human CVCL_9S17 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135604 CVCL_0Y82 GM21439 transformed cell line human CVCL_0Y82 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135605 CVCL_9S16 IB PD-I1 induced pluripotent stem cell human CVCL_9S16 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21135606 CVCL_0Y85 GM21442 transformed cell line human CVCL_0Y85 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135607 CVCL_0Y84 GM21441 transformed cell line human CVCL_0Y84 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135608 CVCL_0Y87 GM21447 transformed cell line human CVCL_0Y87 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135609 CVCL_0Y86 GM21443 transformed cell line human CVCL_0Y86 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135610 CVCL_0Y89 GM21449 transformed cell line human CVCL_0Y89 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135611 CVCL_0Y88 GM21448 transformed cell line human CVCL_0Y88 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135612 CVCL_KH41 PCRP-MBNL3-1D11 hybridoma house mouse CVCL_KH41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NUK0; Human MBNL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135613 CVCL_KH40 PCRP-MBD3-2C4 hybridoma house mouse CVCL_KH40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95983; Human MBD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135614 CVCL_KH43 PCRP-MED1-1A9 hybridoma house mouse CVCL_KH43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15648; Human MED1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135615 CVCL_KH42 PCRP-MED1-1A11 hybridoma house mouse CVCL_KH42 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15648; Human MED1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135616 CVCL_KH38 PCRP-MBD3-1C4 hybridoma house mouse CVCL_KH38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95983; Human MBD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135617 CVCL_KH37 PCRP-MBD2-1B6 hybridoma house mouse CVCL_KH37 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UBB5; Human MBD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135618 CVCL_KH39 PCRP-MBD3-1C5 hybridoma house mouse CVCL_KH39 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95983; Human MBD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135619 CVCL_KH34 PCRP-MAT2B-4B6 hybridoma house mouse CVCL_KH34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZL9; Human MAT2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135620 CVCL_KH33 PCRP-MAT2B-1G7 hybridoma house mouse CVCL_KH33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZL9; Human MAT2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135621 CVCL_KH36 PCRP-MAZ-1D5 hybridoma house mouse CVCL_KH36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56270; Human MAZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135622 CVCL_KH35 PCRP-MAX-1E7 hybridoma house mouse CVCL_KH35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61244; Human MAX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135623 CVCL_KH52 PCRP-MED7-1B8 hybridoma house mouse CVCL_KH52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43513; Human MED7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135624 CVCL_KH51 PCRP-MED6-3D10 hybridoma house mouse CVCL_KH51 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75586; Human MED6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135625 CVCL_KH54 PCRP-MED8-1A4 hybridoma house mouse CVCL_KH54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96G25; Human MED8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135626 CVCL_KH53 PCRP-MED7-1C4 hybridoma house mouse CVCL_KH53 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O43513; Human MED7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135627 CVCL_KH50 PCRP-MED4-1A6 hybridoma house mouse CVCL_KH50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NPJ6; Human MED4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135628 CVCL_KH49 PCRP-MED30-1C3 hybridoma house mouse CVCL_KH49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96HR3; Human MED30. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135629 CVCL_KH48 PCRP-MED30-1B12 hybridoma house mouse CVCL_KH48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96HR3; Human MED30. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135630 CVCL_KH45 PCRP-MED21-4F3 hybridoma house mouse CVCL_KH45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13503; Human MED21. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135631 CVCL_KH44 PCRP-MED21-4B5 hybridoma house mouse CVCL_KH44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13503; Human MED21. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135632 CVCL_KH47 PCRP-MED22-2A7 hybridoma house mouse CVCL_KH47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15528; Human MED22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135633 CVCL_KH46 PCRP-MED22-1E4 hybridoma house mouse CVCL_KH46 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q15528; Human MED22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135634 CVCL_KH21 PCRP-LHX4-1A8 hybridoma house mouse CVCL_KH21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q969G2; Human LHX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135635 CVCL_KH20 PCRP-LHX2-3B11 hybridoma house mouse CVCL_KH20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135636 CVCL_BN89 ND13441 transformed cell line human CVCL_BN89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135637 CVCL_BN82 ND13417 transformed cell line human CVCL_BN82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135638 CVCL_BN81 ND13411 transformed cell line human CVCL_BN81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135639 CVCL_BN84 ND13433 transformed cell line human CVCL_BN84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135640 CVCL_BN83 ND13432 transformed cell line human CVCL_BN83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135641 CVCL_BN86 ND13438 transformed cell line human CVCL_BN86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135642 CVCL_BN85 ND13437 transformed cell line human CVCL_BN85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135643 CVCL_KH19 PCRP-LHX2-2G5 hybridoma house mouse CVCL_KH19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135644 CVCL_BN88 ND13440 transformed cell line human CVCL_BN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135645 CVCL_BN87 ND13439 transformed cell line human CVCL_BN87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135646 CVCL_KH16 PCRP-LHX2-2C10 hybridoma house mouse CVCL_KH16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135647 CVCL_KH15 PCRP-LHX2-1C11 hybridoma house mouse CVCL_KH15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135648 CVCL_KH18 PCRP-LHX2-2E3 hybridoma house mouse CVCL_KH18 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135649 CVCL_KH17 PCRP-LHX2-2D12 hybridoma house mouse CVCL_KH17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50458; Human LHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135650 CVCL_KH12 PCRP-LDB2-1B10 hybridoma house mouse CVCL_KH12 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O43679; Human LDB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135651 CVCL_KH11 PCRP-LDB2-1B1 hybridoma house mouse CVCL_KH11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43679; Human LDB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135652 CVCL_BN80 ND13410 transformed cell line human CVCL_BN80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135653 CVCL_KH14 PCRP-LEUTX-1B8 hybridoma house mouse CVCL_KH14 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; A8MZ59; Human LEUTX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135654 CVCL_KH13 PCRP-LEUTX-1B6 hybridoma house mouse CVCL_KH13 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A8MZ59; Human LEUTX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135655 CVCL_KH30 PCRP-MAFG-1H7 hybridoma house mouse CVCL_KH30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15525; Human MAFG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135656 CVCL_KH32 PCRP-MAPK1-1D1 hybridoma house mouse CVCL_KH32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P28482; Human MAPK1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135657 CVCL_KH31 PCRP-MAP3K7-1B9 hybridoma house mouse CVCL_KH31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43318; Human MAP3K7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135658 CVCL_BN93 ND13450 transformed cell line human CVCL_BN93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135659 CVCL_BN92 ND13444 transformed cell line human CVCL_BN92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135660 CVCL_BN95 ND13454 transformed cell line human CVCL_BN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135661 CVCL_BN94 ND13451 transformed cell line human CVCL_BN94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135662 CVCL_BN97 ND13458 transformed cell line human CVCL_BN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135663 CVCL_BN96 ND13457 transformed cell line human CVCL_BN96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135664 CVCL_BN99 ND13462 transformed cell line human CVCL_BN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135665 CVCL_BN98 ND13459 transformed cell line human CVCL_BN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135666 CVCL_KH27 PCRP-LZTR1-1C7 hybridoma house mouse CVCL_KH27 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N653; Human LZTR1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135667 CVCL_KH26 PCRP-LRRFIP1-3A8 hybridoma house mouse CVCL_KH26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q32MZ4; Human LRRFIP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135668 CVCL_KH29 PCRP-MAFF-1A8 hybridoma house mouse CVCL_KH29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9ULX9; Human MAFF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135669 CVCL_KH28 PCRP-MAFB-1A10 hybridoma house mouse CVCL_KH28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y5Q3; Human MAFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135670 CVCL_KH23 PCRP-LHX4-1C11 hybridoma house mouse CVCL_KH23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q969G2; Human LHX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135671 CVCL_KH22 PCRP-LHX4-1B6 hybridoma house mouse CVCL_KH22 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q969G2; Human LHX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135672 CVCL_BN91 ND13443 transformed cell line human CVCL_BN91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135673 CVCL_KH25 PCRP-LIN28A-1E2 hybridoma house mouse CVCL_KH25 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H9Z2; Human LIN28A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135674 CVCL_BN90 ND13442 transformed cell line human CVCL_BN90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135675 CVCL_KH24 PCRP-LHX5-1B7 hybridoma house mouse CVCL_KH24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H2C1; Human LHX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135676 CVCL_BN68 ND13365 transformed cell line human CVCL_BN68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135677 CVCL_BN67 ND13364 transformed cell line human CVCL_BN67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135678 CVCL_BN69 ND13366 transformed cell line human CVCL_BN69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135679 CVCL_BN60 ND13347 transformed cell line human CVCL_BN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135680 CVCL_BN62 ND13358 transformed cell line human CVCL_BN62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135681 CVCL_BN61 ND13349 transformed cell line human CVCL_BN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135682 CVCL_BN64 ND13360 transformed cell line human CVCL_BN64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135683 CVCL_BN63 ND13359 transformed cell line human CVCL_BN63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135684 CVCL_BN66 ND13363 transformed cell line human CVCL_BN66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135685 CVCL_BN65 ND13361 transformed cell line human CVCL_BN65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135686 CVCL_KH10 PCRP-LDB2-1A10 hybridoma house mouse CVCL_KH10 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43679; Human LDB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135687 CVCL_BN79 ND13409 transformed cell line human CVCL_BN79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135688 CVCL_BN78 ND13408 transformed cell line human CVCL_BN78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135689 CVCL_BN71 ND13373 transformed cell line human CVCL_BN71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135690 CVCL_BN70 ND13372 transformed cell line human CVCL_BN70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135691 CVCL_BN73 ND13377 transformed cell line human CVCL_BN73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135692 CVCL_BN72 ND13374 transformed cell line human CVCL_BN72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135693 CVCL_BN75 ND13381 transformed cell line human CVCL_BN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135694 CVCL_KH09 PCRP-LDB1-1C5 hybridoma house mouse CVCL_KH09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86U70; Human LDB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135695 CVCL_BN74 ND13378 transformed cell line human CVCL_BN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135696 CVCL_KH08 PCRP-LCORL-1H11 hybridoma house mouse CVCL_KH08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N3X6; Human LCORL. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135697 CVCL_BN77 ND13391 transformed cell line human CVCL_BN77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135698 CVCL_BN76 ND13387 transformed cell line human CVCL_BN76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135699 CVCL_KH05 PCRP-L3MBTL4-4D1 hybridoma house mouse CVCL_KH05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NA19; Human L3MBTL4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135700 CVCL_KH04 PCRP-KLF7-1C4 hybridoma house mouse CVCL_KH04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75840; Human KLF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135701 CVCL_KH07 PCRP-LCOR-1B1 hybridoma house mouse CVCL_KH07 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96JN0; Human LCOR. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135702 CVCL_KH06 PCRP-LCOR-1A7 hybridoma house mouse CVCL_KH06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96JN0; Human LCOR. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135703 CVCL_KH01 PCRP-KLF17-2F4 hybridoma house mouse CVCL_KH01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5JT82; Human KLF17. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135704 CVCL_KH00 PCRP-KLF17-1G2 hybridoma house mouse CVCL_KH00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q5JT82; Human KLF17. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135705 CVCL_KH03 PCRP-KLF7-1C11 hybridoma house mouse CVCL_KH03 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75840; Human KLF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135706 CVCL_KH02 PCRP-KLF5-1A3 hybridoma house mouse CVCL_KH02 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13887; Human KLF5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135707 CVCL_BN46 ND13215 transformed cell line human CVCL_BN46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135708 CVCL_BN45 ND13212 transformed cell line human CVCL_BN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135709 CVCL_BN48 ND13258 transformed cell line human CVCL_BN48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135710 CVCL_BN47 ND13216 transformed cell line human CVCL_BN47 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135711 CVCL_BN49 ND13260 transformed cell line human CVCL_BN49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135712 CVCL_BN40 ND13193 transformed cell line human CVCL_BN40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135713 CVCL_BN42 ND13195 transformed cell line human CVCL_BN42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135714 CVCL_BN41 ND13194 transformed cell line human CVCL_BN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135715 CVCL_BN44 ND13199 transformed cell line human CVCL_BN44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135716 CVCL_BN43 ND13197 transformed cell line human CVCL_BN43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135717 CVCL_BN57 ND13331 transformed cell line human CVCL_BN57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135718 CVCL_BN56 ND13297 transformed cell line human CVCL_BN56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135719 CVCL_BN59 ND13340 transformed cell line human CVCL_BN59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135720 CVCL_BN58 ND13339 transformed cell line human CVCL_BN58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135721 CVCL_BN51 ND13273 transformed cell line human CVCL_BN51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135722 CVCL_BN50 ND13261 transformed cell line human CVCL_BN50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135723 CVCL_BN53 ND13275 transformed cell line human CVCL_BN53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135724 CVCL_BN52 ND13274 transformed cell line human CVCL_BN52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135725 CVCL_BN55 ND13295 transformed cell line human CVCL_BN55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135726 CVCL_BN54 ND13293 transformed cell line human CVCL_BN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135727 CVCL_TB60 HAP1 OCRL (-) 2 cancer cell line human CVCL_TB60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8108; OCRL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135728 CVCL_TB62 HAP1 OGG1 (-) 2 cancer cell line human CVCL_TB62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8125; OGG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135729 CVCL_TB61 HAP1 OGG1 (-) 1 cancer cell line human CVCL_TB61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8125; OGG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135730 CVCL_TB64 HAP1 OSR1 (-) 1 cancer cell line human CVCL_TB64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8111; OSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135731 CVCL_TB63 HAP1 OGG1 (-) 3 cancer cell line human CVCL_TB63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8125; OGG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135732 CVCL_TB66 HAP1 OSR1 (-) 3 cancer cell line human CVCL_TB66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8111; OSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135733 CVCL_TB65 HAP1 OSR1 (-) 2 cancer cell line human CVCL_TB65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8111; OSR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135734 CVCL_TB68 HAP1 OTUB2 (-) 1 cancer cell line human CVCL_TB68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20351; OTUB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135735 CVCL_TB67 HAP1 OTUB1 (-) cancer cell line human CVCL_TB67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23077; OTUB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135736 CVCL_TB69 HAP1 OTUB2 (-) 2 cancer cell line human CVCL_TB69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20351; OTUB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135737 CVCL_TB51 HAP1 NUSAP1 (-) 1 cancer cell line human CVCL_TB51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18538; NUSAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135738 CVCL_TB50 HAP1 NUP210 (-) 4 cancer cell line human CVCL_TB50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30052; NUP210; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135739 CVCL_TB53 HAP1 NXN (-) cancer cell line human CVCL_TB53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18008; NXN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135740 CVCL_TB52 HAP1 NUSAP1 (-) 2 cancer cell line human CVCL_TB52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18538; NUSAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135741 CVCL_TB55 HAP1 OBSCN (-) 2 cancer cell line human CVCL_TB55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15719; OBSCN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135742 CVCL_TB54 HAP1 OBSCN (-) 1 cancer cell line human CVCL_TB54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15719; OBSCN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135743 CVCL_TB57 HAP1 OCIAD1 (-) 1 cancer cell line human CVCL_TB57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16074; OCIAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135744 CVCL_TB56 HAP1 OBSCN (-) 3 cancer cell line human CVCL_TB56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15719; OBSCN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135745 CVCL_TB59 HAP1 OCRL (-) 1 cancer cell line human CVCL_TB59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8108; OCRL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135746 CVCL_TB58 HAP1 OCLN (-) 1 cancer cell line human CVCL_TB58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8104; OCLN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135747 CVCL_TB40 HAP1 NUDT3 (-) 1 cancer cell line human CVCL_TB40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8050; NUDT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135748 CVCL_TB42 HAP1 NUDT6 (-) 1 cancer cell line human CVCL_TB42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8053; NUDT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135749 CVCL_TB41 HAP1 NUDT3 (-) 2 cancer cell line human CVCL_TB41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8050; NUDT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135750 CVCL_TB44 HAP1 NUDT7 (-) 1 cancer cell line human CVCL_TB44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8054; NUDT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135751 CVCL_TB43 HAP1 NUDT6 (-) 2 cancer cell line human CVCL_TB43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8053; NUDT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135752 CVCL_TB46 HAP1 NUMB (-) 1 cancer cell line human CVCL_TB46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8060; NUMB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135753 CVCL_TB45 HAP1 NUDT7 (-) 2 cancer cell line human CVCL_TB45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8054; NUDT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135754 CVCL_TB48 HAP1 NUP210 (-) 2 cancer cell line human CVCL_TB48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30052; NUP210; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135755 CVCL_TB47 HAP1 NUP210 (-) 1 cancer cell line human CVCL_TB47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30052; NUP210; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135756 CVCL_TB49 HAP1 NUP210 (-) 3 cancer cell line human CVCL_TB49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30052; NUP210; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135757 CVCL_KH99 PCRP-NACC1-1B10 hybridoma house mouse CVCL_KH99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96RE7; Human NACC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135758 CVCL_TB31 HAP1 NUAK1 (-) cancer cell line human CVCL_TB31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14311; NUAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135759 CVCL_TB30 HAP1 NTRK1 (-) cancer cell line human CVCL_TB30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8031; NTRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135760 CVCL_TB33 HAP1 NUDT15 (-) 2 cancer cell line human CVCL_TB33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23063; NUDT15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135761 CVCL_TB32 HAP1 NUDT15 (-) 1 cancer cell line human CVCL_TB32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23063; NUDT15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135762 CVCL_TB35 HAP1 NUDT16 (-) 2 cancer cell line human CVCL_TB35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26442; NUDT16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135763 CVCL_TB34 HAP1 NUDT16 (-) 1 cancer cell line human CVCL_TB34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26442; NUDT16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135764 CVCL_TB37 HAP1 NUDT19 (-) 2 cancer cell line human CVCL_TB37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32036; NUDT19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135765 CVCL_TB36 HAP1 NUDT19 (-) 1 cancer cell line human CVCL_TB36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32036; NUDT19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135766 CVCL_TB39 HAP1 NUDT2 (-) 2 cancer cell line human CVCL_TB39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8049; NUDT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135767 CVCL_TB38 HAP1 NUDT2 (-) 1 cancer cell line human CVCL_TB38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8049; NUDT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135768 CVCL_KH85 PCRP-MXI1-1A3 hybridoma house mouse CVCL_KH85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P50539; Human MXI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135769 CVCL_KH84 PCRP-MXD4-2B6 hybridoma house mouse CVCL_KH84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14582; Human MXD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135770 CVCL_KH87 PCRP-MYCL1-2D5 hybridoma house mouse CVCL_KH87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12524; Human MYCL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135771 CVCL_KH86 PCRP-MYCL1-1A3 hybridoma house mouse CVCL_KH86 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P12524; Human MYCL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135772 CVCL_KH81 PCRP-MORF4L1-1G12 hybridoma house mouse CVCL_KH81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UBU8; Human MORF4L1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135773 CVCL_KH80 PCRP-MLXIP-1A10 hybridoma house mouse CVCL_KH80 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAP2; Human MLXIP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135774 CVCL_KH83 PCRP-MXD3-2B4 hybridoma house mouse CVCL_KH83 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BW11; Human MXD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135775 CVCL_KH82 PCRP-MXD3-1A3 hybridoma house mouse CVCL_KH82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BW11; Human MXD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135776 CVCL_TB20 HAP1 NT5C3A (-) 1 cancer cell line human CVCL_TB20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135777 CVCL_TB22 HAP1 NT5C3A (-) 3 cancer cell line human CVCL_TB22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135778 CVCL_TB21 HAP1 NT5C3A (-) 2 cancer cell line human CVCL_TB21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135779 CVCL_TB24 HAP1 NT5DC2 (-) 1 cancer cell line human CVCL_TB24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25717; NT5DC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135780 CVCL_TB23 HAP1 NT5C3A (-) 4 cancer cell line human CVCL_TB23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17820; NT5C3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135781 CVCL_TB26 HAP1 NTHL1 (-) 2 cancer cell line human CVCL_TB26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8028; NTHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135782 CVCL_TB25 HAP1 NTHL1 (-) 1 cancer cell line human CVCL_TB25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8028; NTHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135783 CVCL_TB28 HAP1 NTHL1 (-) 4 cancer cell line human CVCL_TB28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8028; NTHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135784 CVCL_TB27 HAP1 NTHL1 (-) 3 cancer cell line human CVCL_TB27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8028; NTHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135785 CVCL_TB29 HAP1 NTHL1 (-) 5 cancer cell line human CVCL_TB29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8028; NTHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135786 CVCL_KH78 PCRP-MLLT3-2B6 hybridoma house mouse CVCL_KH78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42568; Human MLLT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135787 CVCL_KH77 PCRP-MLLT10-1D4 hybridoma house mouse CVCL_KH77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55197; Human MLLT10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135788 CVCL_KH79 PCRP-MLX-1G8 hybridoma house mouse CVCL_KH79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UH92; Human MLX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135789 CVCL_KH96 PCRP-NAB2-2G1 hybridoma house mouse CVCL_KH96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15742; Human NAB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135790 CVCL_KH95 PCRP-MZF1-1E8 hybridoma house mouse CVCL_KH95 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P28698; Human MZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135791 CVCL_KH98 PCRP-NACC1-1A8 hybridoma house mouse CVCL_KH98 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96RE7; Human NACC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135792 CVCL_KH97 PCRP-NACC1-1A1 hybridoma house mouse CVCL_KH97 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96RE7; Human NACC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135793 CVCL_KH92 PCRP-MYOD1-2A5 hybridoma house mouse CVCL_KH92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15172; Human MYOD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135794 CVCL_KH91 PCRP-MYO1B-2B4 hybridoma house mouse CVCL_KH91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43795; Human MYO1B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135795 CVCL_KH94 PCRP-MZF1-1D7 hybridoma house mouse CVCL_KH94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P28698; Human MZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135796 CVCL_KH93 PCRP-MYOG-1C5 hybridoma house mouse CVCL_KH93 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15173; Human MYOG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135797 CVCL_KH90 PCRP-MYCN-2C7 hybridoma house mouse CVCL_KH90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04198; Human MYCN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135798 CVCL_TB11 HAP1 NSD1 (-) 1 cancer cell line human CVCL_TB11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14234; NSD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135799 CVCL_TB10 HAP1 NRP2 (-) 1 cancer cell line human CVCL_TB10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8005; NRP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135800 CVCL_TB13 HAP1 NSD1 (-) 3 cancer cell line human CVCL_TB13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14234; NSD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135801 CVCL_TB12 HAP1 NSD1 (-) 2 cancer cell line human CVCL_TB12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14234; NSD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135802 CVCL_TB15 HAP1 NSUN2 (-) 1 cancer cell line human CVCL_TB15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25994; NSUN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135803 CVCL_TB14 HAP1 NSD1 (-) 4 cancer cell line human CVCL_TB14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14234; NSD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135804 CVCL_TB17 HAP1 NSUN3 (-) 2 cancer cell line human CVCL_TB17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26208; NSUN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135805 CVCL_TB16 HAP1 NSUN3 (-) 1 cancer cell line human CVCL_TB16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26208; NSUN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135806 CVCL_TB19 HAP1 NSUN5 (-) 1 cancer cell line human CVCL_TB19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16385; NSUN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135807 CVCL_TB18 HAP1 NSUN3 (-) 3 cancer cell line human CVCL_TB18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26208; NSUN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135808 CVCL_KH89 PCRP-MYCN-1A9 hybridoma house mouse CVCL_KH89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04198; Human MYCN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135809 CVCL_KH88 PCRP-MYCL1-2E1 hybridoma house mouse CVCL_KH88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P12524; Human MYCL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135810 CVCL_KH63 PCRP-MEIS2-2B3 hybridoma house mouse CVCL_KH63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O14770; Human MEIS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135811 CVCL_KH62 PCRP-MEIS2-1A11 hybridoma house mouse CVCL_KH62 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O14770; Human MEIS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135812 CVCL_KH65 PCRP-MEIS3-1A10 hybridoma house mouse CVCL_KH65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99687; Human MEIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135813 CVCL_KH64 PCRP-MEIS2-2B4 hybridoma house mouse CVCL_KH64 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O14770; Human MEIS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135814 CVCL_KH61 PCRP-MEF2D-3A4 hybridoma house mouse CVCL_KH61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14814; Human MEF2D. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135815 CVCL_KH60 PCRP-MEF2C-1D4 hybridoma house mouse CVCL_KH60 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q06413; Human MEF2C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135816 CVCL_TB00 HAP1 NR2F2 (-) cancer cell line human CVCL_TB00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7976; NR2F2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135817 CVCL_TB02 HAP1 NR3C2 (-) 2 cancer cell line human CVCL_TB02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135818 CVCL_TB01 HAP1 NR3C2 (-) 1 cancer cell line human CVCL_TB01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135819 CVCL_TB04 HAP1 NRBP1 (-) 1 cancer cell line human CVCL_TB04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7993; NRBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135820 CVCL_TB03 HAP1 NR4A1 (-) 1 cancer cell line human CVCL_TB03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135821 CVCL_TB06 HAP1 NRBP2 (-) 2 cancer cell line human CVCL_TB06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19339; NRBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135822 CVCL_TB05 HAP1 NRBP2 (-) 1 cancer cell line human CVCL_TB05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19339; NRBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135823 CVCL_TB08 HAP1 NRD1 (-) cancer cell line human CVCL_TB08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7995; NRDC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135824 CVCL_TB07 HAP1 NRBP2 (-) 3 cancer cell line human CVCL_TB07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19339; NRBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135825 CVCL_KH59 PCRP-MEF2B-2F9 hybridoma house mouse CVCL_KH59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q02080; Human MEF2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135826 CVCL_TB09 HAP1 NRP1 (-) 1 cancer cell line human CVCL_TB09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8004; NRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135827 CVCL_KH56 PCRP-MEF2A-1B7 hybridoma house mouse CVCL_KH56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q02078; Human MEF2A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135828 CVCL_KH55 PCRP-MED9-1D6 hybridoma house mouse CVCL_KH55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NWA0; Human MED9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135829 CVCL_KH58 PCRP-MEF2B-2A11 hybridoma house mouse CVCL_KH58 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q02080; Human MEF2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135830 CVCL_KH57 PCRP-MEF2A-1F7 hybridoma house mouse CVCL_KH57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q02078; Human MEF2A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135831 CVCL_KH74 PCRP-MIS18BP1-1B10 hybridoma house mouse CVCL_KH74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6P0N0; Human MIS18BP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135832 CVCL_KH73 PCRP-MINA-1D1 hybridoma house mouse CVCL_KH73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IUF8; Human RIOX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135833 CVCL_KH76 PCRP-MLLT10-1C10 hybridoma house mouse CVCL_KH76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P55197; Human MLLT10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135834 CVCL_KH75 PCRP-MITF-1D9 hybridoma house mouse CVCL_KH75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75030; Human MITF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135835 CVCL_KH70 PCRP-MESP2-1D4 hybridoma house mouse CVCL_KH70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q0VG99; Human MESP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135836 CVCL_KH72 PCRP-MINA-1A7 hybridoma house mouse CVCL_KH72 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IUF8; Human RIOX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135837 CVCL_KH71 PCRP-METTL21A-2D2 hybridoma house mouse CVCL_KH71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WXB1; Human METTL21A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135838 CVCL_KH67 PCRP-MEN1-1H6 hybridoma house mouse CVCL_KH67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00255; Human MEN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135839 CVCL_KH66 PCRP-MEIS3-1D5 hybridoma house mouse CVCL_KH66 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99687; Human MEIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135840 CVCL_KH69 PCRP-MESP1-1D11 hybridoma house mouse CVCL_KH69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BRJ9; Human MESP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135841 CVCL_KH68 PCRP-MEN1-2B1 hybridoma house mouse CVCL_KH68 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00255; Human MEN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21135842 CVCL_9T10 NPK spontaneously immortalized cell line pig CVCL_9T10 CL:0000010 Derived from sampling site: Kidney. Unspecified 21135843 CVCL_9T12 OV-1369(R2) cancer cell line human CVCL_9T12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.45 +- 0.12 days (PubMed=22931248) 21135844 CVCL_9T11 NPTh spontaneously immortalized cell line pig CVCL_9T11 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21135845 CVCL_9T07 HFF Liver finite cell line human CVCL_9T07 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: IZSLER; BS CL 158; probable Unspecified 21135846 CVCL_9T06 HFF Heart finite cell line human CVCL_9T06 CL:0000010 Derived from sampling site: Fetal heart. Unspecified 21135847 CVCL_9T09 Huker finite cell line human CVCL_9T09 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Unspecified 21135848 CVCL_9T08 HFLung finite cell line human CVCL_9T08 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21135849 CVCL_9T03 MSCB9 spontaneously immortalized cell line house mouse CVCL_9T03 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Rosa26-lacZ. Male 21135850 CVCL_9T02 HPC0A07 conditionally immortalized cell line human CVCL_9T02 From: ReNeuron, Ltd; Pencoed; United Kingdom CL:0000010 Transfected with: HGNC; 7553; MYC Derived from sampling site: Fetal brain; hippocampus. Female Doubling time: ~2 days (Patent=US7666672) Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 04092302 21135851 CVCL_9T05 FLK transformed cell line CVCL_9T05 CL:0000010 Transformant: Bovine leukemia virus (BLV) (isolate American FLK)(NCBI-Taxonomy; 11902); Derived from sampling site: Fetal kidney. Unspecified 21135852 CVCL_0Z71 GM21683 transformed cell line human CVCL_0Z71 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135853 CVCL_0Z70 GM21682 transformed cell line human CVCL_0Z70 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135854 CVCL_9T04 MSCB9-Pax3 spontaneously immortalized cell line house mouse CVCL_9T04 CL:0000010 Transfected with: MGI; MGI:97487; Pax3 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Rosa26-lacZ. Male 21135855 CVCL_0Z73 GM21686 transformed cell line human CVCL_0Z73 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135856 CVCL_0Z72 GM21685 transformed cell line human CVCL_0Z72 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135857 CVCL_0Z75 GM21693 transformed cell line human CVCL_0Z75 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135858 CVCL_0Z74 GM21689 transformed cell line human CVCL_0Z74 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135859 CVCL_0Z77 GM21717 transformed cell line human CVCL_0Z77 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135860 CVCL_0Z76 GM21716 transformed cell line human CVCL_0Z76 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135861 CVCL_0Z79 GM21719 transformed cell line human CVCL_0Z79 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135862 CVCL_0Z78 GM21718 transformed cell line human CVCL_0Z78 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135863 CVCL_9T21 OV-4485 cancer cell line human CVCL_9T21 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.4485-1G>T; ClinVar=VCV000246501; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=26622941); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=26622941) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 1.85 +- 0.29 days (PubMed=26622941) 21135864 CVCL_9T20 OV-4453 cancer cell line human CVCL_9T20 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Glu1953Ter (c.5857G>T); ClinVar=VCV000051952; Zygosity=Unspecified (PubMed=26622941); Sequence variation: Mutation; HGNC; 19291; CSMD3; Simple; p.Ser646Thr (c.1937G>C); Zygosity=Unspecified (PubMed=26622941); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2490-5_2490-1del5; Zygosity=Unspecified (PubMed=26622941); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=26622941) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 2.44 +- 0.03 days (PubMed=26622941) 21135865 CVCL_9T23 GM09886 transformed cell line human CVCL_9T23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135866 CVCL_9T22 OV-866(2) cancer cell line human CVCL_9T22 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Trp (c.745A>T); ClinVar=VCV000141881; Zygosity=Unspecified (PubMed=26622941) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 1.77 +- 0.32 days (PubMed=26622941) 21135867 CVCL_9T18 TOV-2295(R) cancer cell line human CVCL_9T18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=22931248) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M. Female Doubling time: 2.49 +- 0.49 days (PubMed=22931248) 21135868 CVCL_9T17 TOV-1369 cancer cell line human CVCL_9T17 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.87 +- 0.03 days (PubMed=22931248) 21135869 CVCL_9T19 TOV-3133D cancer cell line human CVCL_9T19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M. Female Doubling time: 2.63 +- 0.11 days (PubMed=22931248) 21135870 CVCL_0Z80 GM21722 transformed cell line human CVCL_0Z80 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135871 CVCL_9T14 OV-2295(R2) cancer cell line human CVCL_9T14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.73 +- 0.12 days (PubMed=22931248) 21135872 CVCL_9T13 OV-2295 cancer cell line human CVCL_9T13 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.90 +- 0.10 days (PubMed=22931248) 21135873 CVCL_0Z82 GM21732 transformed cell line human CVCL_0Z82 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 21135874 CVCL_9T16 OV-3133(R2) cancer cell line human CVCL_9T16 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Female Doubling time: 3.23 +- 0.12 days (PubMed=22931248) 21135875 CVCL_0Z81 GM21723 transformed cell line human CVCL_0Z81 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135876 CVCL_9T15 OV-3133(R) cancer cell line human CVCL_9T15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.94 +- 0.07 days (PubMed=22931248) 21135877 CVCL_0Z84 GM21737 transformed cell line human CVCL_0Z84 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 21135878 CVCL_0Z83 GM21733 transformed cell line human CVCL_0Z83 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female 21135879 CVCL_0Z86 GM21739 transformed cell line human CVCL_0Z86 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135880 CVCL_0Z85 GM21738 transformed cell line human CVCL_0Z85 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135881 CVCL_0Z88 GM21741 transformed cell line human CVCL_0Z88 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135882 CVCL_0Z87 GM21740 transformed cell line human CVCL_0Z87 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135883 CVCL_0Z89 GM21742 transformed cell line human CVCL_0Z89 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135884 CVCL_0Z59 GM21631 transformed cell line human CVCL_0Z59 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135885 CVCL_0Z58 GM21622 transformed cell line human CVCL_0Z58 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135886 CVCL_0Z51 GM21613 transformed cell line human CVCL_0Z51 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135887 CVCL_0Z50 GM21611 transformed cell line human CVCL_0Z50 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135888 CVCL_0Z53 GM21615 transformed cell line human CVCL_0Z53 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135889 CVCL_0Z52 GM21614 transformed cell line human CVCL_0Z52 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135890 CVCL_0Z55 GM21617 transformed cell line human CVCL_0Z55 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135891 CVCL_0Z54 GM21616 transformed cell line human CVCL_0Z54 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135892 CVCL_0Z57 GM21620 transformed cell line human CVCL_0Z57 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135893 CVCL_0Z56 GM21619 transformed cell line human CVCL_0Z56 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135894 CVCL_0Z69 GM21679 transformed cell line human CVCL_0Z69 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21135895 CVCL_TA90 HAP1 NOXA1 (-) 2 cancer cell line human CVCL_TA90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10668; NOXA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135896 CVCL_TA92 HAP1 NPL (-) 1 cancer cell line human CVCL_TA92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16781; NPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135897 CVCL_TA91 HAP1 NPC1 (-) 1 cancer cell line human CVCL_TA91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7897; NPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135898 CVCL_TA94 HAP1 NPRL2 (-) 2 cancer cell line human CVCL_TA94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24969; NPRL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135899 CVCL_9T01 STR0C05 conditionally immortalized cell line human CVCL_9T01 From: ReNeuron, Ltd; Pencoed; United Kingdom CL:0000010 Transfected with: HGNC; 7553; MYC Derived from sampling site: Fetal brain; forebrain; striatum. Male Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 04110301 21135900 CVCL_9T00 CTX0E03 conditionally immortalized cell line human CVCL_9T00 From: ReNeuron, Ltd; Pencoed; United Kingdom CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Myc; Derived from sampling site: Fetal brain; cerebral cortex. Male Doubling time: 3-4 days (Patent=US7666672) Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 04091601 21135901 CVCL_TA93 HAP1 NPRL2 (-) 1 cancer cell line human CVCL_TA93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24969; NPRL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135902 CVCL_TA96 HAP1 NPRL3 (-) 1 cancer cell line human CVCL_TA96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14124; NPRL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135903 CVCL_TA95 HAP1 NPRL2 (-) 3 cancer cell line human CVCL_TA95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24969; NPRL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135904 CVCL_TA98 HAP1 NQO1 (-) cancer cell line human CVCL_TA98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2874; NQO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135905 CVCL_TA97 HAP1 NPRL3 (-) 2 cancer cell line human CVCL_TA97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14124; NPRL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135906 CVCL_TA99 HAP1 NQO2 (-) 1 cancer cell line human CVCL_TA99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7856; NQO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135907 CVCL_0Z60 GM21632 transformed cell line human CVCL_0Z60 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135908 CVCL_0Z62 GM21635 transformed cell line human CVCL_0Z62 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135909 CVCL_0Z61 GM21634 transformed cell line human CVCL_0Z61 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135910 CVCL_0Z64 GM21647 transformed cell line human CVCL_0Z64 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135911 CVCL_0Z63 GM21636 transformed cell line human CVCL_0Z63 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135912 CVCL_0Z66 GM21649 transformed cell line human CVCL_0Z66 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135913 CVCL_0Z65 GM21648 transformed cell line human CVCL_0Z65 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135914 CVCL_0Z68 GM21678 transformed cell line human CVCL_0Z68 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135915 CVCL_0Z67 GM21650 transformed cell line human CVCL_0Z67 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135916 CVCL_0Z37 GM21578 transformed cell line human CVCL_0Z37 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135917 CVCL_0Z36 GM21577 transformed cell line human CVCL_0Z36 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135918 CVCL_0Z39 GM21581 transformed cell line human CVCL_0Z39 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135919 CVCL_0Z38 GM21580 transformed cell line human CVCL_0Z38 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135920 CVCL_TA81 HAP1 NMT1 (-) 2 cancer cell line human CVCL_TA81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7857; NMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135921 CVCL_TA80 HAP1 NMT1 (-) 1 cancer cell line human CVCL_TA80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7857; NMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135922 CVCL_TA83 HAP1 NMT1 (-) 4 cancer cell line human CVCL_TA83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7857; NMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135923 CVCL_TA82 HAP1 NMT1 (-) 3 cancer cell line human CVCL_TA82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7857; NMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135924 CVCL_TA85 HAP1 NOS2 (-) 1 cancer cell line human CVCL_TA85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135925 CVCL_TA84 HAP1 NMT2 (-) cancer cell line human CVCL_TA84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7858; NMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135926 CVCL_TA87 HAP1 NOTCH1 (-) cancer cell line human CVCL_TA87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7881; NOTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135927 CVCL_TA86 HAP1 NOS2 (-) 2 cancer cell line human CVCL_TA86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7873; NOS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135928 CVCL_TA89 HAP1 NOXA1 (-) 1 cancer cell line human CVCL_TA89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10668; NOXA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135929 CVCL_TA88 HAP1 NOTCH3 (-) 1 cancer cell line human CVCL_TA88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7883; NOTCH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135930 CVCL_0Z31 GM21529 transformed cell line human CVCL_0Z31 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135931 CVCL_0Z30 GM21528 transformed cell line human CVCL_0Z30 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135932 CVCL_0Z33 GM21574 transformed cell line human CVCL_0Z33 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135933 CVCL_0Z32 GM21573 transformed cell line human CVCL_0Z32 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135934 CVCL_0Z35 GM21576 transformed cell line human CVCL_0Z35 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135935 CVCL_0Z34 GM21575 transformed cell line human CVCL_0Z34 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135936 CVCL_0Z48 GM21601 transformed cell line human CVCL_0Z48 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135937 CVCL_0Z47 GM21600 transformed cell line human CVCL_0Z47 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135938 CVCL_0Z49 GM21608 transformed cell line human CVCL_0Z49 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135939 CVCL_TA70 HAP1 NGLY1 (-) 1 cancer cell line human CVCL_TA70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17646; NGLY1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135940 CVCL_TA72 HAP1 NHEJ1 (-) 1 cancer cell line human CVCL_TA72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25737; NHEJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135941 CVCL_TA71 HAP1 NGLY1 (-) 2 cancer cell line human CVCL_TA71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17646; NGLY1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135942 CVCL_TA74 HAP1 NIPSNAP3A (-) 1 cancer cell line human CVCL_TA74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23619; NIPSNAP3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135943 CVCL_TA73 HAP1 NHEJ1 (-) 2 cancer cell line human CVCL_TA73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25737; NHEJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135944 CVCL_TA76 HAP1 NLK (-) 2 cancer cell line human CVCL_TA76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29858; NLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135945 CVCL_TA75 HAP1 NLK (-) 1 cancer cell line human CVCL_TA75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29858; NLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135946 CVCL_TA78 HAP1 NMNAT3 (-) 1 cancer cell line human CVCL_TA78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20989; NMNAT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135947 CVCL_TA77 HAP1 NMI (-) cancer cell line human CVCL_TA77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7854; NMI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135948 CVCL_TA79 HAP1 NMRAL1 (-) 1 cancer cell line human CVCL_TA79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24987; NMRAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135949 CVCL_0Z40 GM21582 transformed cell line human CVCL_0Z40 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135950 CVCL_0Z42 GM21584 transformed cell line human CVCL_0Z42 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135951 CVCL_0Z41 GM21583 transformed cell line human CVCL_0Z41 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135952 CVCL_0Z44 GM21596 transformed cell line human CVCL_0Z44 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135953 CVCL_0Z43 GM21587 transformed cell line human CVCL_0Z43 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135954 CVCL_0Z46 GM21599 transformed cell line human CVCL_0Z46 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135955 CVCL_0Z45 GM21597 transformed cell line human CVCL_0Z45 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135956 CVCL_0Z15 GM21510 transformed cell line human CVCL_0Z15 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135957 CVCL_0Z14 GM21509 transformed cell line human CVCL_0Z14 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135958 CVCL_0Z17 GM21513 transformed cell line human CVCL_0Z17 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135959 CVCL_0Z16 GM21512 transformed cell line human CVCL_0Z16 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135960 CVCL_0Z19 GM21515 transformed cell line human CVCL_0Z19 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135961 CVCL_0Z18 GM21514 transformed cell line human CVCL_0Z18 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135962 CVCL_TA61 HAP1 NFKB2 (-) 2 cancer cell line human CVCL_TA61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7795; NFKB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135963 CVCL_TA60 HAP1 NFKB2 (-) 1 cancer cell line human CVCL_TA60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7795; NFKB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135964 CVCL_TA63 HAP1 NFKBIA (-) 2 cancer cell line human CVCL_TA63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7797; NFKBIA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135965 CVCL_TA62 HAP1 NFKBIA (-) 1 cancer cell line human CVCL_TA62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7797; NFKBIA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135966 CVCL_TA65 HAP1 NFKBIB (-) cancer cell line human CVCL_TA65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7798; NFKBIB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135967 CVCL_TA64 HAP1 NFKBIA (-) 3 cancer cell line human CVCL_TA64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7797; NFKBIA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135968 CVCL_TA67 HAP1 NFKBIE (-) 2 cancer cell line human CVCL_TA67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7799; NFKBIE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135969 CVCL_TA66 HAP1 NFKBIE (-) 1 cancer cell line human CVCL_TA66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7799; NFKBIE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135970 CVCL_TA69 HAP1 NGFR (-) 2 cancer cell line human CVCL_TA69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7809; NGFR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135971 CVCL_TA68 HAP1 NGFR (-) 1 cancer cell line human CVCL_TA68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7809; NGFR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135972 CVCL_0Z11 GM21491 transformed cell line human CVCL_0Z11 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135973 CVCL_0Z10 GM21490 transformed cell line human CVCL_0Z10 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135974 CVCL_0Z13 GM21494 transformed cell line human CVCL_0Z13 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135975 CVCL_0Z12 GM21493 transformed cell line human CVCL_0Z12 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135976 CVCL_0Z26 GM21524 transformed cell line human CVCL_0Z26 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135977 CVCL_0Z25 GM21523 transformed cell line human CVCL_0Z25 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135978 CVCL_0Z28 GM21526 transformed cell line human CVCL_0Z28 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135979 CVCL_0Z27 GM21525 transformed cell line human CVCL_0Z27 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135980 CVCL_0Z29 GM21527 transformed cell line human CVCL_0Z29 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21135981 CVCL_TA50 HAP1 NES (-) 1 cancer cell line human CVCL_TA50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7756; NES; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135982 CVCL_TA52 HAP1 NF1 (-) 2 cancer cell line human CVCL_TA52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135983 CVCL_TA51 HAP1 NF1 (-) 1 cancer cell line human CVCL_TA51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135984 CVCL_TA54 HAP1 NF1 (-) 4 cancer cell line human CVCL_TA54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135985 CVCL_TA53 HAP1 NF1 (-) 3 cancer cell line human CVCL_TA53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7765; NF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135986 CVCL_TA56 HAP1 NFATC1 (-) 1 cancer cell line human CVCL_TA56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7775; NFATC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135987 CVCL_TA55 HAP1 NF2 (-) cancer cell line human CVCL_TA55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7773; NF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135988 CVCL_TA58 HAP1 NFKB1 (-) 1 cancer cell line human CVCL_TA58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7794; NFKB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135989 CVCL_TA57 HAP1 NFE2L1 (-) 1 cancer cell line human CVCL_TA57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7781; NFE2L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135990 CVCL_TA59 HAP1 NFKB1 (-) 2 cancer cell line human CVCL_TA59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7794; NFKB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21135991 CVCL_0Z20 GM21517 transformed cell line human CVCL_0Z20 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21135992 CVCL_0Z22 GM21520 transformed cell line human CVCL_0Z22 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135993 CVCL_0Z21 GM21519 transformed cell line human CVCL_0Z21 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135994 CVCL_0Z24 GM21522 transformed cell line human CVCL_0Z24 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135995 CVCL_0Z23 GM21521 transformed cell line human CVCL_0Z23 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21135996 CVCL_9T92 GM14978 finite cell line human CVCL_9T92 CL:0000010 Sequence variation: Mutation; HGNC; 6998; MEFV; Simple; p.Glu148Gln (c.442G>C); ClinVar=VCV000002542; Zygosity=Heterozygous (Coriell) Population: Caucasian; Sicilian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21135997 CVCL_9T91 DEE spontaneously immortalized cell line CVCL_9T91 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Doubling time: ~18 hours (PubMed=26739426) Group: Bird cell line 21135998 CVCL_9T98 HeLa ICRP cancer cell line human CVCL_9T98 CL:0000010 Transfected with: Initiator caspase reporter protein (IC-RP) FRET donor-acceptor pair (CFP and YFP) connected by a caspase cleavage sequence ('DEVDR') linker. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21135999 CVCL_BN24 ND13159 transformed cell line human CVCL_BN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136000 CVCL_BN23 ND13158 transformed cell line human CVCL_BN23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136001 CVCL_9T97 UHi007-A induced pluripotent stem cell human CVCL_9T97 From: University of Helsinki; Helsinki; Finland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136002 CVCL_BN26 ND13161 transformed cell line human CVCL_BN26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136003 CVCL_9T99 HeLa ICRP Bcl-2-mCherry cancer cell line human CVCL_9T99 CL:0000010 Transfected with: Initiator caspase reporter protein (IC-RP) FRET donor-acceptor pair (CFP and YFP) connected by a caspase cleavage sequence ('DEVDR') linker.; Transfected with: HGNC; 990; BCL2; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21136004 CVCL_BN25 ND13160 transformed cell line human CVCL_BN25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136005 CVCL_9T94 GM16479 finite cell line human CVCL_9T94 CL:0000010 Population: Caucasian; Sicilian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21136006 CVCL_BN28 ND13163 transformed cell line human CVCL_BN28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136007 CVCL_9T93 GM14979 finite cell line human CVCL_9T93 CL:0000010 Population: Caucasian; Sicilian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21136008 CVCL_BN27 ND13162 transformed cell line human CVCL_BN27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136009 CVCL_9T96 UHi006-A induced pluripotent stem cell human CVCL_9T96 From: University of Helsinki; Helsinki; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21136010 CVCL_9T95 hBSM spontaneously immortalized cell line human CVCL_9T95 CL:0000010 Donor information: Established from a the normal region of bladder tissue from a patient who underwent cystectomy for a transitional cell tumor; Derived from sampling site: Urinary bladder; smooth muscle. Female Doubling time: ~72 hours (PubMed=22259013) 21136011 CVCL_BN29 ND13164 transformed cell line human CVCL_BN29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136012 CVCL_BN20 ND13155 transformed cell line human CVCL_BN20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136013 CVCL_BN22 ND13157 transformed cell line human CVCL_BN22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136014 CVCL_BN21 ND13156 transformed cell line human CVCL_BN21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136015 CVCL_BN35 ND13183 transformed cell line human CVCL_BN35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136016 CVCL_BN34 ND13182 transformed cell line human CVCL_BN34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136017 CVCL_BN37 ND13187 transformed cell line human CVCL_BN37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136018 CVCL_BN36 ND13184 transformed cell line human CVCL_BN36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136019 CVCL_BN39 ND13192 transformed cell line human CVCL_BN39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136020 CVCL_BN38 ND13188 transformed cell line human CVCL_BN38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136021 CVCL_BN31 ND13166 transformed cell line human CVCL_BN31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136022 CVCL_BN30 ND13165 transformed cell line human CVCL_BN30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136023 CVCL_BN33 ND13168 transformed cell line human CVCL_BN33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136024 CVCL_BN32 ND13167 transformed cell line human CVCL_BN32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136025 CVCL_BN09 ND13140 transformed cell line human CVCL_BN09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136026 CVCL_9T70 UM-SCC-73A cancer cell line human CVCL_9T70 CL:0000010 Male 21136027 CVCL_9T76 mK1 transformed cell line house mouse CVCL_9T76 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. 21136028 CVCL_BN02 ND13107 transformed cell line human CVCL_BN02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136029 CVCL_9T75 mDD2 transformed cell line house mouse CVCL_9T75 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Vas deferens; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. Male 21136030 CVCL_BN01 ND13102 transformed cell line human CVCL_BN01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136031 CVCL_9T78 mK2 transformed cell line house mouse CVCL_9T78 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. 21136032 CVCL_BN04 ND13114 transformed cell line human CVCL_BN04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136033 CVCL_9T77 mK10 transformed cell line house mouse CVCL_9T77 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. 21136034 CVCL_BN03 ND13112 transformed cell line human CVCL_BN03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136035 CVCL_9T72 NAB cancer cell line human CVCL_9T72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21136036 CVCL_BN06 ND13136 transformed cell line human CVCL_BN06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136037 CVCL_BN05 ND13135 transformed cell line human CVCL_BN05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136038 CVCL_9T71 UM-SCC-17As cancer cell line human CVCL_9T71 CL:0000010 Derived from sampling site: Larynx. Female 21136039 CVCL_9T74 mDD1 transformed cell line house mouse CVCL_9T74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Vas deferens; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. Male 21136040 CVCL_BN08 ND13139 transformed cell line human CVCL_BN08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136041 CVCL_BN07 ND13138 transformed cell line human CVCL_BN07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136042 CVCL_9T73 OMC-1 [Human ovarian carcinoma] cancer cell line human CVCL_9T73 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 24 hours (DOI=10.15114/smj.55.153) 21136043 CVCL_9T69 BuMEC [Buffalo 2013] spontaneously immortalized cell line CVCL_9T69 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21136044 CVCL_9T68 BY00895 transformed cell line human CVCL_9T68 HLA typing: A*24:FVCV,32:FVDK; B*27:EKN,35:184; DRB1*13:01,11:01 (IPD-IMGT/HLA=25481) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136045 CVCL_BN00 ND13101 transformed cell line human CVCL_BN00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136046 CVCL_9T81 mU1 transformed cell line house mouse CVCL_9T81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Uterus; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. Female 21136047 CVCL_9T80 mK4 transformed cell line house mouse CVCL_9T80 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. Omics: ChIP-seq histone signature analysis; Omics: Transcriptome analysis by microarray 21136048 CVCL_9T87 CF [Chitala] spontaneously immortalized cell line CVCL_9T87 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Characteristics: Capable of growing from 15 to 35 Celsius, the optimal temperature is 28 Celsius (PubMed=23877365) Group: Fish cell line 21136049 CVCL_BN13 ND13148 transformed cell line human CVCL_BN13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136050 CVCL_9T86 CCRM8 embryonic stem cell human CVCL_9T86 From: Center of Clinical Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University; Nanjing; China. CL:0000010 Female 21136051 CVCL_BN12 ND13147 transformed cell line human CVCL_BN12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136052 CVCL_9T89 CO95 cancer cell line human CVCL_9T89 CL:0000010 21136053 CVCL_BN15 ND13150 transformed cell line human CVCL_BN15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136054 CVCL_9T88 chHES-419 embryonic stem cell human CVCL_9T88 From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Gln1179Argfs*25 (c.3536delA); Zygosity=Heterozygous (PubMed=26987927). Female 21136055 CVCL_BN14 ND13149 transformed cell line human CVCL_BN14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136056 CVCL_9T83 BSF spontaneously immortalized cell line CVCL_9T83 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21136057 CVCL_BN17 ND13152 transformed cell line human CVCL_BN17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136058 CVCL_9T82 AFKM-On-H spontaneously immortalized cell line CVCL_9T82 CL:0000010 Unspecified Doubling time: 40 hours (at 80th passage and 28 Celsius), 29 hours (at 125th passage and 28 Celsius), 35 hours (at 122th passage and 25 Celsius), 34 hours (at 169th passage and 25 Celsius) (PubMed=17846857). Group: Insect cell line 21136059 CVCL_BN16 ND13151 transformed cell line human CVCL_BN16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136060 CVCL_9T85 CCRM-hESC-23 embryonic stem cell human CVCL_9T85 From: Center of Clinical Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University; Nanjing; China. CL:0000010 Male 21136061 CVCL_BN19 ND13154 transformed cell line human CVCL_BN19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136062 CVCL_9T84 CCRM-hESC-22 embryonic stem cell human CVCL_9T84 From: Center of Clinical Reproductive Medicine, First Affiliated Hospital, Nanjing Medical University; Nanjing; China. CL:0000010 Male 21136063 CVCL_BN18 ND13153 transformed cell line human CVCL_BN18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136064 CVCL_9T79 mK3 transformed cell line house mouse CVCL_9T79 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6 x C3H/He Hoxa11-SV40Tag transgenic. Omics: ChIP-seq histone signature analysis; Omics: Transcriptome analysis by microarray 21136065 CVCL_BN11 ND13146 transformed cell line human CVCL_BN11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136066 CVCL_BN10 ND13145 transformed cell line human CVCL_BN10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136067 CVCL_9T54 BY00871 transformed cell line human CVCL_9T54 HLA typing: A*02:GKEH,02:GKEH; B*44:03,07:143; DRB1*03:01,04:05 (IPD-IMGT/HLA=25486) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136068 CVCL_9T53 BY00870 transformed cell line human CVCL_9T53 HLA typing: A*25:GC,32:ENRE; B*27:EKN,39:68; DRB1*07:01,14:BCAD (IPD-IMGT/HLA=25488) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136069 CVCL_9T56 BY00873 transformed cell line human CVCL_9T56 HLA typing: A*29:HDA,68:FUYG; B*15:10,53:22; C*04:FVTM,08:EUAV; DRB1*11:04,13:02 (IPD-IMGT/HLA=25479) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136070 CVCL_9T55 BY00872 transformed cell line human CVCL_9T55 HLA typing: A*02:GJJY,29:GJKP; B*46:30,07:EH; DRB1*09:01,10:AC (IPD-IMGT/HLA=25487) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136071 CVCL_9T50 BY00867 transformed cell line human CVCL_9T50 HLA typing: A*02:FDYX,26ENKW; B*50:01:01,38:01:01; DRB1*04:02,07:01 (IPD-IMGT/HLA=25491) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136072 CVCL_9T52 BY00869 transformed cell line human CVCL_9T52 HLA typing: A*11:BDFZ,31:DUKU; B*15:HHJY,51:126; DRB1*14:03,15:02 (IPD-IMGT/HLA=25489) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136073 CVCL_9T51 BY00868 transformed cell line human CVCL_9T51 HLA typing: A*02:GJKA,33:GJMC; B*15:11,58:36; DRB1*09:01,11:01 (IPD-IMGT/HLA=25490) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136074 CVCL_9T47 BY00862 transformed cell line human CVCL_9T47 HLA typing: A*02:01:51,03:JCRF; B*08:GMHM,15:GJNJ; C*07:GSTH; DRB1*03:01,13:01 (IPD-IMGT/HLA=25459) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136075 CVCL_9T46 BY00861 transformed cell line human CVCL_9T46 HLA typing: A*01:66,02:JGMS; B*08:GPCM,51:GPRY; C*01:CYS,07:GSTH; DRB1*03:01,14:BCAD (IPD-IMGT/HLA=25462) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136076 CVCL_9T49 BY00864 transformed cell line human CVCL_9T49 HLA typing: A*24:FUMX,33:FTHW; B*58:JCKC,40:177; C*03:02,12:EGG; DRB1*07:01,12:DUKV (IPD-IMGT/HLA=25483) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136077 CVCL_9T48 BY00863 transformed cell line human CVCL_9T48 HLA typing: A*02:WHG,02:05; B*14:02:01,18:68; DRB1*07:FX,07:FX (IPD-IMGT/HLA=25482) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136078 CVCL_9T65 BY00889 transformed cell line human CVCL_9T65 HLA typing: A*01:FVBG,02:ERMU; B*07:EREN,08:EREX; DRB1*03:75,08:01 (IPD-IMGT/HLA=25492) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136079 CVCL_9T64 BY00886 transformed cell line human CVCL_9T64 HLA typing: A*02:AZGG,03:FVHY; B*35:CWAD,50:01; C*04:FEAS,06:02; DRB1*08:02:01,14:120 (IPD-IMGT/HLA=25470) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136080 CVCL_9T67 BY00892 transformed cell line human CVCL_9T67 HLA typing: A*02:ERMW,24:FVCT; B*40:EVUJ,46:EVSP; DRB1*14:BUYP,13:134 (IPD-IMGT/HLA=25473) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136081 CVCL_9T66 BY00891 transformed cell line human CVCL_9T66 HLA typing: A*02:DZKN,02:DZKN; B*44:EAHB,51:EJYW; DRB1*04:98:02,13:03:01 (IPD-IMGT/HLA=25493) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136082 CVCL_9T61 BY00878 transformed cell line human CVCL_9T61 HLA typing: A*11:FMRP,32:EKYR; B*49:01:01,58:08:02; C*07:GSTG,12:AFB; DRB1*13:02,14:04 (IPD-IMGT/HLA=25480) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136083 CVCL_9T60 CBRA59109884011 transformed cell line human CVCL_9T60 HLA typing: A*01:BMMP,02:ANGA; B*44:AMUT,49:01; C*05:01,07:219; DRB1*11:JECW,13JECK (IPD-IMGT/HLA=25497) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136084 CVCL_9T63 BY00880 transformed cell line human CVCL_9T63 HLA typing: A*34:01,34:01; B*40:FXAR,40:FXAP; C*15:BJ,15:WCY; DRB1*15:02,04:05:13 (IPD-IMGT/HLA=25472) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136085 CVCL_9T62 BY00879 transformed cell line human CVCL_9T62 HLA typing: A*02:FNCN,30:02; B*14:BPYK,18:EMBS; C*05:FNTM,08:FRPM; DRB1*03:01,07:22 (IPD-IMGT/HLA=25471) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136086 CVCL_9T58 BY00875 transformed cell line human CVCL_9T58 HLA typing: A*24:FUMX,24:FUMX; B*07:EH,15:204; C*07:26,15:DF; DRB1*10:01,15:02 (IPD-IMGT/HLA=25476) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136087 CVCL_9T57 BY00874 transformed cell line human CVCL_9T57 HLA typing: A*02:EPUR,33:EMGN; B*35:HHKD,40:76; DRB1*12:02,09:01 (IPD-IMGT/HLA=25478) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136088 CVCL_9T59 BY00876 transformed cell line human CVCL_9T59 HLA typing: A*24:FUMX,26:ERTN; B*18:37,35:HHKD; C*04:FEAS,12:03; DRB1*04:AAHZ,11:04 (IPD-IMGT/HLA=25475) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136089 CVCL_9T32 VACO 670 cancer cell line human CVCL_9T32 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Homozygous (PubMed=9715273). 21136090 CVCL_9T31 VACO 457 cancer cell line human CVCL_9T31 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Ser (c.460G>A); ClinVar=VCV000133284; Zygosity=Heterozygous (PubMed=9715273); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=25926053) 21136091 CVCL_9T34 CHA08-023 transformed cell line human CVCL_9T34 HLA typing: A*01:01,02:328; B*37:01,44:03; DRB1*07:01,10:01 (IPD-IMGT/HLA=25439) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136092 CVCL_9T33 VACO 703 cancer cell line human CVCL_9T33 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly374Valfs*48 (c.1121delG) (Lys373fs); ClinVar=VCV000237940; Zygosity=Heterozygous (PubMed=9715273) Omics: Transcriptome analysis by microarray. Microsatellite instability: Instable (MSI) (PubMed=25926053) 21136093 CVCL_9T30 AFiPSC6 induced pluripotent stem cell human CVCL_9T30 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21136094 CVCL_9T29 AFiPSC5 induced pluripotent stem cell human CVCL_9T29 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21136095 CVCL_9T28 AFiPSC41 induced pluripotent stem cell human CVCL_9T28 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21136096 CVCL_0Z91 GM21744 transformed cell line human CVCL_0Z91 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21136097 CVCL_9T25 TOV-3291G cancer cell line human CVCL_9T25 CL:0000010 Sequence variation: Mutation; HGNC; 24224; CDK12; Simple; c.3095+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=26622941); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Trp (c.745A>T); ClinVar=VCV000141881; Zygosity=Unspecified (PubMed=26622941) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 2.28 +- 0.19 days (PubMed=26622941) 21136098 CVCL_0Z90 GM21743 transformed cell line human CVCL_0Z90 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21136099 CVCL_9T24 TOV-3041G cancer cell line human CVCL_9T24 CL:0000010 Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 1.33 +- 0.02 days (PubMed=26622941) 21136100 CVCL_9T27 AFiPSC4 induced pluripotent stem cell human CVCL_9T27 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21136101 CVCL_0Z93 GM21768 transformed cell line human CVCL_0Z93 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21136102 CVCL_9T26 AFiPSC10 induced pluripotent stem cell human CVCL_9T26 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21136103 CVCL_0Z92 GM21767 transformed cell line human CVCL_0Z92 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21136104 CVCL_0Z95 GM21770 transformed cell line human CVCL_0Z95 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136105 CVCL_0Z94 GM21769 transformed cell line human CVCL_0Z94 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136106 CVCL_0Z97 GM21775 transformed cell line human CVCL_0Z97 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136107 CVCL_0Z96 GM21774 transformed cell line human CVCL_0Z96 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21136108 CVCL_0Z99 GM21782 transformed cell line human CVCL_0Z99 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136109 CVCL_0Z98 GM21776 transformed cell line human CVCL_0Z98 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21136110 CVCL_9T43 BY00854 transformed cell line human CVCL_9T43 HLA typing: A*34:02:01,03:133; B*07:FPJG,53:FMAA; C*04:FEAS; DRB1*12:02,15:03 (IPD-IMGT/HLA=25469) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136111 CVCL_9T42 BY00852 transformed cell line human CVCL_9T42 HLA typing: A*24:JGMT,33:53; B*51:DVJA,57:AC; DRB1*07:01,13:01 (IPD-IMGT/HLA=25468) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136112 CVCL_9T45 BY00858 transformed cell line human CVCL_9T45 HLA typing: A*03:113,24:17; B*15:AUCX,51:EKEN; DRB1*04:ZX,07:FX (IPD-IMGT/HLA=25484) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136113 CVCL_9T44 BY00857 transformed cell line human CVCL_9T44 HLA typing: A*02:JGMS,03:108; B*35:EGUP,57:GWR; DRB1*01:01,07:FX (IPD-IMGT/HLA=25485) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136114 CVCL_9T41 BY00851 transformed cell line human CVCL_9T41 HLA typing: A*02:AZGG,11:01:35; B*13:VS,52:MX; DRB1*10:MN,15:02 (IPD-IMGT/HLA=25466) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136115 CVCL_9T40 BY00850 transformed cell line human CVCL_9T40 HLA typing: A*02:JGMS,11:109N; B*07:DUHX,44DUJX; DRB1*1301,1501 (IPD-IMGT/HLA=25465) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136116 CVCL_9T39 BY00849 transformed cell line human CVCL_9T39 HLA typing: A*11:JDXY,33:52; B*35:GPPZ,35:GNFZ; DRB1*07:01,11:01 (IPD-IMGT/HLA=25464) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136117 CVCL_9T36 BY00846 transformed cell line human CVCL_9T36 HLA typing: A*02:JGMS,68:84; B*35:16,51:GDWH; C*04:FEAS,15:AHR; DRB1*04:02,14:06 (IPD-IMGT/HLA=25460) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136118 CVCL_9T35 SZGSQ-12 transformed cell line human CVCL_9T35 HLA typing: A*11:01,26:01; B*15:02,46:01; DRB1*09:01,12:02 (IPD-IMGT/HLA=25445) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136119 CVCL_9T38 BY00848 transformed cell line human CVCL_9T38 HLA typing: A*02:JGMS,02:332; B*15:GTUV,27:GRGU; DRB1*04:01,01:AH (IPD-IMGT/HLA=25463) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136120 CVCL_9T37 BY00847 transformed cell line human CVCL_9T37 HLA typing: A*24:JGMT,02:331; B*39:06,48:AF; C*07:FEAU,08:DJRU; DRB1*14:02,14:EFMC (IPD-IMGT/HLA=25461) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21136121 CVCL_KI62 PCRP-NR5A2-1B8 hybridoma house mouse CVCL_KI62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00482; Human NR5A2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136122 CVCL_KI61 PCRP-NR5A2-1B2 hybridoma house mouse CVCL_KI61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00482; Human NR5A2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136123 CVCL_KI64 PCRP-NRF1-3H1 hybridoma house mouse CVCL_KI64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16656; Human NRF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136124 CVCL_KI63 PCRP-NRF1-3D4 hybridoma house mouse CVCL_KI63 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16656; Human NRF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136125 CVCL_KI60 PCRP-NR5A2-1A11 hybridoma house mouse CVCL_KI60 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00482; Human NR5A2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136126 CVCL_TC01 HAP1 PAN2 (-) 1 cancer cell line human CVCL_TC01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20074; PAN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136127 CVCL_TC00 HAP1 PALM (-) 3 cancer cell line human CVCL_TC00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8594; PALM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136128 CVCL_TC03 HAP1 PAPSS2 (-) 1 cancer cell line human CVCL_TC03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8604; PAPSS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136129 CVCL_TC02 HAP1 PAN2 (-) 2 cancer cell line human CVCL_TC02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20074; PAN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136130 CVCL_TC05 HAP1 PAPSS2 (-) 3 cancer cell line human CVCL_TC05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8604; PAPSS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136131 CVCL_TC04 HAP1 PAPSS2 (-) 2 cancer cell line human CVCL_TC04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8604; PAPSS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136132 CVCL_TC07 HAP1 PARK2 (-) 1 cancer cell line human CVCL_TC07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136133 CVCL_KI59 PCRP-NR5A1-1A4 hybridoma house mouse CVCL_KI59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13285; Human NR5A1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136134 CVCL_TC06 HAP1 PARG (-) 1 cancer cell line human CVCL_TC06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8605; PARG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136135 CVCL_KI58 PCRP-NR3C2-1E3 hybridoma house mouse CVCL_KI58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08235; Human NR3C2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136136 CVCL_TC09 HAP1 PARK7 (-) 1 cancer cell line human CVCL_TC09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16369; PARK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136137 CVCL_TC08 HAP1 PARK2 (-) 2 cancer cell line human CVCL_TC08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8607; PRKN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136138 CVCL_KI55 PCRP-NR2F1-1D5 hybridoma house mouse CVCL_KI55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10589; Human NR2F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136139 CVCL_KI54 PCRP-NR2E3-2B6 hybridoma house mouse CVCL_KI54 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9Y5X4; Human NR2E3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136140 CVCL_KI57 PCRP-NR3C2-1A3 hybridoma house mouse CVCL_KI57 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08235; Human NR3C2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136141 CVCL_KI56 PCRP-NR2F2-1G3 hybridoma house mouse CVCL_KI56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P24468; Human NR2F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136142 CVCL_KI73 PCRP-OTX2-1F7 hybridoma house mouse CVCL_KI73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P32243; Human OTX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136143 CVCL_KI72 PCRP-OTX2-1E10 hybridoma house mouse CVCL_KI72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P32243; Human OTX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136144 CVCL_KI75 PCRP-OVOL2-1H12 hybridoma house mouse CVCL_KI75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BRP0; Human OVOL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136145 CVCL_KI74 PCRP-OVOL2-1G9 hybridoma house mouse CVCL_KI74 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BRP0; Human OVOL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136146 CVCL_KI71 PCRP-ORC1-1C4 hybridoma house mouse CVCL_KI71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13415; Human ORC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136147 CVCL_KI70 PCRP-ONECUT2-1A1 hybridoma house mouse CVCL_KI70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95948; Human ONECUT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136148 CVCL_KI69 PCRP-ONECUT1-1A1 hybridoma house mouse CVCL_KI69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UBC0; Human ONECUT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136149 CVCL_KI66 PCRP-NRF1-4A3 hybridoma house mouse CVCL_KI66 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16656; Human NRF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136150 CVCL_KI65 PCRP-NRF1-3H3 hybridoma house mouse CVCL_KI65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16656; Human NRF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136151 CVCL_KI68 PCRP-OLIG2-1E9 hybridoma house mouse CVCL_KI68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13516; Human OLIG2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136152 CVCL_KI67 PCRP-OBFC1-1B4 hybridoma house mouse CVCL_KI67 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H668; Human STN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136153 CVCL_KI40 PCRP-NOC4L-1B2 hybridoma house mouse CVCL_KI40 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9BVI4; Human NOC4L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136154 CVCL_KI42 PCRP-NOC4L-1E3 hybridoma house mouse CVCL_KI42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BVI4; Human NOC4L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136155 CVCL_KI41 PCRP-NOC4L-1D12 hybridoma house mouse CVCL_KI41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BVI4; Human NOC4L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136156 CVCL_KI37 PCRP-NKX2-5-3F2 hybridoma house mouse CVCL_KI37 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52952; Human NKX2-5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136157 CVCL_KI36 PCRP-NKX2-5-3B4 hybridoma house mouse CVCL_KI36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52952; Human NKX2-5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136158 CVCL_KI39 PCRP-NMI-1C1 hybridoma house mouse CVCL_KI39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13287; Human NMI. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136159 CVCL_KI38 PCRP-NKX3-1-1E5 hybridoma house mouse CVCL_KI38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99801; Human NKX3-1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136160 CVCL_KI33 PCRP-NHLH2-1C9 hybridoma house mouse CVCL_KI33 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q02577; Human NHLH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136161 CVCL_KI32 PCRP-NFYC-1A11 hybridoma house mouse CVCL_KI32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13952; Human NFYC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136162 CVCL_KI35 PCRP-NKX2-5-1E6 hybridoma house mouse CVCL_KI35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52952; Human NKX2-5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136163 CVCL_KI34 PCRP-NINJ2-2B10 hybridoma house mouse CVCL_KI34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZG7; Human NINJ2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136164 CVCL_KI51 PCRP-NR1H3-1A1 hybridoma house mouse CVCL_KI51 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q13133; Human NR1H3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136165 CVCL_KI50 PCRP-NR1H2-1D11 hybridoma house mouse CVCL_KI50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P55055; Human NR1H2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136166 CVCL_KI53 PCRP-NR2C1-2C3 hybridoma house mouse CVCL_KI53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13056; Human NR2C1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136167 CVCL_KI52 PCRP-NR2C1-2B12 hybridoma house mouse CVCL_KI52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13056; Human NR2C1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136168 CVCL_KI48 PCRP-NR1D1-1F1 hybridoma house mouse CVCL_KI48 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P20393; Human NR1D1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136169 CVCL_KI47 PCRP-NR1D1-1D2 hybridoma house mouse CVCL_KI47 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20393; Human NR1D1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136170 CVCL_KI49 PCRP-NR1D2-1B12 hybridoma house mouse CVCL_KI49 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14995; Human NR1D2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136171 CVCL_KI44 PCRP-NPM3-1D5 hybridoma house mouse CVCL_KI44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75607; Human NPM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136172 CVCL_KI43 PCRP-NPM1-1B4 hybridoma house mouse CVCL_KI43 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P06748; Human NPM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136173 CVCL_KI46 PCRP-NR0B1-1F12 hybridoma house mouse CVCL_KI46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51843; Human NR0B1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136174 CVCL_KI45 PCRP-NR0B1-1A10 hybridoma house mouse CVCL_KI45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51843; Human NR0B1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136175 CVCL_KI20 PCRP-NFIA-1B8 hybridoma house mouse CVCL_KI20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q12857; Human NFIA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136176 CVCL_C089 STR-I-229-MTMX embryonic stem cell human CVCL_C089 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE08-085-L1. 21136177 CVCL_C088 STR-I-221-Sca2 embryonic stem cell human CVCL_C088 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE08-081-L1. 21136178 CVCL_C081 EVMSe003-A embryonic stem cell human CVCL_C081 From: Eastern Virginia Medical School; Norfolk; USA. CL:0000010 Unspecified 21136179 CVCL_C080 EVMSe002-A embryonic stem cell human CVCL_C080 From: Eastern Virginia Medical School; Norfolk; USA. CL:0000010 Unspecified 21136180 CVCL_C083 STR-I-171-GLA embryonic stem cell human CVCL_C083 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE08-056-L1. 21136181 CVCL_C082 STR-I-155-HD embryonic stem cell human CVCL_C082 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE07-051-L1. 21136182 CVCL_KI19 PCRP-NFE2L2-3D2 hybridoma house mouse CVCL_KI19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16236; Human NFE2L2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136183 CVCL_C085 STR-I-203-CFTR embryonic stem cell human CVCL_C085 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg347Pro (c.1040G>C); ClinVar=VCV000007110; Zygosity=Heterozygous (PubMed=20217271); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=20217271). Female Registration: French Agence de la Biomedecine; FE08-072-L1 21136184 CVCL_KI18 PCRP-NFE2L2-1D12 hybridoma house mouse CVCL_KI18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16236; Human NFE2L2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136185 CVCL_C084 STR-I-189-FRAXA embryonic stem cell human CVCL_C084 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE08-065-L1. 21136186 CVCL_C087 STR-I-211-MEN2a embryonic stem cell human CVCL_C087 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys634Arg (c.1900T>C); ClinVar=VCV000013917; Zygosity=Unspecified (PubMed=20217271). Male Registration: French Agence de la Biomedecine; FE08-076-L1 21136187 CVCL_C086 STR-I-209-MEN2a embryonic stem cell human CVCL_C086 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys634Arg (c.1900T>C); ClinVar=VCV000013917; Zygosity=Unspecified (PubMed=20217271). Male Registration: French Agence de la Biomedecine; FE08-075-L1 21136188 CVCL_KI15 PCRP-NFATC1-1A2 hybridoma house mouse CVCL_KI15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95644; Human NFATC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136189 CVCL_KI14 PCRP-NEUROG3-2A6 hybridoma house mouse CVCL_KI14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y4Z2; Human NEUROG3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136190 CVCL_KI17 PCRP-NFATC3-2A12 hybridoma house mouse CVCL_KI17 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q12968; Human NFATC3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136191 CVCL_KI16 PCRP-NFATC1-1F4 hybridoma house mouse CVCL_KI16 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95644; Human NFATC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136192 CVCL_KI11 PCRP-NEDD4L-2B4 hybridoma house mouse CVCL_KI11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96PU5; Human NEDD4L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136193 CVCL_KI10 PCRP-NCOA3-1C10 hybridoma house mouse CVCL_KI10 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9Y6Q9; Human NCOA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136194 CVCL_KI13 PCRP-NEUROD2-1G1 hybridoma house mouse CVCL_KI13 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15784; Human NEUROD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136195 CVCL_KI12 PCRP-NEDD4L-2B9 hybridoma house mouse CVCL_KI12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96PU5; Human NEDD4L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136196 CVCL_KI31 PCRP-NFYB-1A2 hybridoma house mouse CVCL_KI31 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P25208; Human NFYB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136197 CVCL_KI30 PCRP-NFX1-1A4 hybridoma house mouse CVCL_KI30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q12986; Human NFX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136198 CVCL_C099 RCM-1 [Human ESC] embryonic stem cell human CVCL_C099 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Miscellaneous: STR profile from personal communication of De Sousa P. Female Registration: UK Stem Cell Bank (UKSCB); R-08-019, Steering comm appl. SCSC08-12. 21136199 CVCL_C092 STR-I-251-CFTR embryonic stem cell human CVCL_C092 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20217271). Female Registration: French Agence de la Biomedecine; FE09-046-L1 21136200 CVCL_C091 STR-I-233-FRAXA embryonic stem cell human CVCL_C091 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE08-087-L1. 21136201 CVCL_C094 STR-I-305-APC embryonic stem cell human CVCL_C094 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE09-073-L1. 21136202 CVCL_C093 STR-I-301-MFS embryonic stem cell human CVCL_C093 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE09-071-L1. 21136203 CVCL_C096 STR-I-347-FRAXA embryonic stem cell human CVCL_C096 From: INSERM; Paris; France CL:0000010 Unspecified Registration: French Agence de la Biomedecine; FE09-094-L1. 21136204 CVCL_KI29 PCRP-NFKB2-7H5 hybridoma house mouse CVCL_KI29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q00653; Human NFKB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136205 CVCL_C095 STR-I-315-CMT1a embryonic stem cell human CVCL_C095 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE09-078-L1. 21136206 CVCL_C098 STR-I-359-APC embryonic stem cell human CVCL_C098 From: INSERM; Paris; France. CL:0000010 Female 21136207 CVCL_C097 STR-I-355-APC embryonic stem cell human CVCL_C097 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE09-271-L1. 21136208 CVCL_KI26 PCRP-NFIX-3B4 hybridoma house mouse CVCL_KI26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14938; Human NFIX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136209 CVCL_KI25 PCRP-NFIX-2D3 hybridoma house mouse CVCL_KI25 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14938; Human NFIX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136210 CVCL_KI28 PCRP-NFKB2-1E1 hybridoma house mouse CVCL_KI28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q00653; Human NFKB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136211 CVCL_KI27 PCRP-NFKB1-2B9 hybridoma house mouse CVCL_KI27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P19838; Human NFKB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136212 CVCL_KI22 PCRP-NFIA-2C6 hybridoma house mouse CVCL_KI22 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q12857; Human NFIA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136213 CVCL_KI21 PCRP-NFIA-2B12 hybridoma house mouse CVCL_KI21 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q12857; Human NFIA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136214 CVCL_KI24 PCRP-NFIL3-2B5 hybridoma house mouse CVCL_KI24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16649; Human NFIL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136215 CVCL_C090 STR-I-231-MTMX embryonic stem cell human CVCL_C090 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE08-086-L1. 21136216 CVCL_KI23 PCRP-NFIB-1B5 hybridoma house mouse CVCL_KI23 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00712; Human NFIB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136217 CVCL_C067 SYSUe001-A embryonic stem cell human CVCL_C067 From: Sun Yat-sen University; Guangzhou; China. CL:0000010 Female 21136218 CVCL_C066 PKU-2 embryonic stem cell human CVCL_C066 From: Peking University Third Hospital; Beijing; China. CL:0000010 Male 21136219 CVCL_C069 HAD1 embryonic stem cell human CVCL_C069 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Female 21136220 CVCL_C068 SYSUe002-A embryonic stem cell human CVCL_C068 From: Sun Yat-sen University; Guangzhou; China. CL:0000010 Female 21136221 CVCL_C061 UPCI-SCC-192 cancer cell line human CVCL_C061 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male 21136222 CVCL_C060 UPCI-SCC-182 cancer cell line human CVCL_C060 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; retromolar trigone. Male Doubling time: ~60-80 hours, ~100 hours (after recovery from liquid nitrogen freezing) (DSMZ=ACC-887) 21136223 CVCL_C063 chESC-3 embryonic stem cell human CVCL_C063 From: Central South University; Changsha; China. CL:0000010 Unspecified 21136224 CVCL_C062 BR-1 embryonic stem cell human CVCL_C062 From: Instituto de Biociencias; Sao Paulo; Brazil. CL:0000010 Male 21136225 CVCL_C065 PKU-1 embryonic stem cell human CVCL_C065 From: Peking University Third Hospital; Beijing; China. CL:0000010 Female 21136226 CVCL_C064 HUSTe002-A embryonic stem cell human CVCL_C064 From: Huazhong University of Science and Technology Tongji Medicine College; Wuhan; China. CL:0000010 Male 21136227 CVCL_C078 CyT203 embryonic stem cell human CVCL_C078 From: ViaCyte, Inc (originally from CyThera, Novocell); San Diego; USA.. CL:0000010 Unspecified 21136228 CVCL_C077 HAD6 embryonic stem cell human CVCL_C077 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Unspecified 21136229 CVCL_C079 EVMSe001-A embryonic stem cell human CVCL_C079 From: Eastern Virginia Medical School; Norfolk; USA. CL:0000010 Unspecified 21136230 CVCL_C070 HAD17 embryonic stem cell human CVCL_C070 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Female 21136231 CVCL_C072 HAD19 embryonic stem cell human CVCL_C072 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Male 21136232 CVCL_C071 HAD18 embryonic stem cell human CVCL_C071 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Male 21136233 CVCL_C074 HAD3 embryonic stem cell human CVCL_C074 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Male 21136234 CVCL_KI08 PCRP-NCOA3-1A11 hybridoma house mouse CVCL_KI08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y6Q9; Human NCOA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136235 CVCL_C073 HAD2 embryonic stem cell human CVCL_C073 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel. CL:0000010 Female 21136236 CVCL_KI07 PCRP-NCOA1-1E8 hybridoma house mouse CVCL_KI07 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15788; Human NCOA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136237 CVCL_C076 HAD5 embryonic stem cell human CVCL_C076 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[300]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=27690107). Female 21136238 CVCL_C075 HAD4 embryonic stem cell human CVCL_C075 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=26437462). Male 21136239 CVCL_KI09 PCRP-NCOA3-1B9 hybridoma house mouse CVCL_KI09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y6Q9; Human NCOA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136240 CVCL_KI04 PCRP-NAP1L5-1A7 hybridoma house mouse CVCL_KI04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96NT1; Human NAP1L5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136241 CVCL_KI03 PCRP-NANOGP1-2D8 hybridoma house mouse CVCL_KI03 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N7R0; Human NANOGP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136242 CVCL_KI06 PCRP-NCOA1-1B11 hybridoma house mouse CVCL_KI06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15788; Human NCOA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136243 CVCL_KI05 PCRP-NCBP1-1C7 hybridoma house mouse CVCL_KI05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q09161; Human NCBP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136244 CVCL_KI00 PCRP-NACC2-1C7 hybridoma house mouse CVCL_KI00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96BF6; Human NACC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136245 CVCL_KI02 PCRP-NACC2-4B7 hybridoma house mouse CVCL_KI02 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96BF6; Human NACC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136246 CVCL_KI01 PCRP-NACC2-3E5 hybridoma house mouse CVCL_KI01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96BF6; Human NACC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136247 CVCL_TC81 HAP1 PDK2 (-) 2 cancer cell line human CVCL_TC81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8810; PDK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136248 CVCL_TC80 HAP1 PDK2 (-) 1 cancer cell line human CVCL_TC80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8810; PDK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136249 CVCL_TC83 HAP1 PDK3 (-) cancer cell line human CVCL_TC83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8811; PDK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136250 CVCL_TC82 HAP1 PDK2 (-) 3 cancer cell line human CVCL_TC82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8810; PDK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136251 CVCL_TC85 HAP1 PDP2 (-) cancer cell line human CVCL_TC85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30263; PDP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136252 CVCL_TC84 HAP1 PDP1 (-) cancer cell line human CVCL_TC84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9279; PDP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136253 CVCL_TC87 HAP1 PDPN (-) 1 cancer cell line human CVCL_TC87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136254 CVCL_TC86 HAP1 PDPK1 (-) cancer cell line human CVCL_TC86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8816; PDPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136255 CVCL_TC89 HAP1 PEAK1 (-) cancer cell line human CVCL_TC89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29431; PEAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136256 CVCL_TC88 HAP1 PDXK (-) 1 cancer cell line human CVCL_TC88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8819; PDXK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136257 CVCL_TC70 HAP1 PDE7A (-) 2 cancer cell line human CVCL_TC70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8791; PDE7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136258 CVCL_TC72 HAP1 PDGFRA (-) cancer cell line human CVCL_TC72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8803; PDGFRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136259 CVCL_TC71 HAP1 PDE8A (-) cancer cell line human CVCL_TC71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8793; PDE8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136260 CVCL_TC74 HAP1 PDIA3 (-) 1 cancer cell line human CVCL_TC74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4606; PDIA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136261 CVCL_TC73 HAP1 PDIA2 (-) 1 cancer cell line human CVCL_TC73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14180; PDIA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136262 CVCL_TC76 HAP1 PDIK1L (-) 2 cancer cell line human CVCL_TC76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18981; PDIK1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136263 CVCL_TC75 HAP1 PDIK1L (-) 1 cancer cell line human CVCL_TC75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18981; PDIK1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136264 CVCL_TC78 HAP1 PDK1 (-) 1 cancer cell line human CVCL_TC78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8809; PDK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136265 CVCL_TC77 HAP1 PDIK1L (-) 3 cancer cell line human CVCL_TC77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18981; PDIK1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136266 CVCL_TC79 HAP1 PDK1 (-) 2 cancer cell line human CVCL_TC79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8809; PDK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136267 CVCL_TC61 HAP1 PDCD4 (-) 2 cancer cell line human CVCL_TC61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8763; PDCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136268 CVCL_TC60 HAP1 PDCD4 (-) 1 cancer cell line human CVCL_TC60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8763; PDCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136269 CVCL_TC63 HAP1 PDE10A (-) 1 cancer cell line human CVCL_TC63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8772; PDE10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136270 CVCL_TC62 HAP1 PDCD5 (-) 1 cancer cell line human CVCL_TC62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8764; PDCD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136271 CVCL_TC65 HAP1 PDE4A (-) 1 cancer cell line human CVCL_TC65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8780; PDE4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136272 CVCL_TC64 HAP1 PDE10A (-) 2 cancer cell line human CVCL_TC64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8772; PDE10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136273 CVCL_TC67 HAP1 PDE5A (-) cancer cell line human CVCL_TC67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8784; PDE5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136274 CVCL_TC66 HAP1 PDE4A (-) 2 cancer cell line human CVCL_TC66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8780; PDE4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136275 CVCL_TC69 HAP1 PDE7A (-) 1 cancer cell line human CVCL_TC69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8791; PDE7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136276 CVCL_TC68 HAP1 PDE6D (-) 1 cancer cell line human CVCL_TC68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8788; PDE6D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136277 CVCL_TC50 HAP1 PCDHA1 (-) 1 cancer cell line human CVCL_TC50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8663; PCDHA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136278 CVCL_TC52 HAP1 PCDHA3 (-) cancer cell line human CVCL_TC52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8669; PCDHA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136279 CVCL_TC51 HAP1 PCDHA1 (-) 2 cancer cell line human CVCL_TC51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8663; PCDHA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136280 CVCL_TC54 HAP1 PCMT1 (-) 2 cancer cell line human CVCL_TC54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8728; PCMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136281 CVCL_TC53 HAP1 PCMT1 (-) 1 cancer cell line human CVCL_TC53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8728; PCMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136282 CVCL_TC56 HAP1 PCSK6 (-) 2 cancer cell line human CVCL_TC56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8569; PCSK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136283 CVCL_TC55 HAP1 PCSK6 (-) 1 cancer cell line human CVCL_TC55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8569; PCSK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136284 CVCL_TC58 HAP1 PDCD10 (-) 1 cancer cell line human CVCL_TC58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8761; PDCD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136285 CVCL_TC57 HAP1 PCSK6 (-) 3 cancer cell line human CVCL_TC57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8569; PCSK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136286 CVCL_TC59 HAP1 PDCD1LG2 (-) 1 cancer cell line human CVCL_TC59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136287 CVCL_TC41 HAP1 PCDH1 (-) 1 cancer cell line human CVCL_TC41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8655; PCDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136288 CVCL_TC40 HAP1 PCCA (-) 1 cancer cell line human CVCL_TC40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8653; PCCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136289 CVCL_TC43 HAP1 PCDH1 (-) 3 cancer cell line human CVCL_TC43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8655; PCDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136290 CVCL_TC42 HAP1 PCDH1 (-) 2 cancer cell line human CVCL_TC42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8655; PCDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136291 CVCL_TC45 HAP1 PCDH7 (-) 1 cancer cell line human CVCL_TC45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8659; PCDH7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136292 CVCL_TC44 HAP1 PCDH1 (-) 4 cancer cell line human CVCL_TC44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8655; PCDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136293 CVCL_TC47 HAP1 PCDH9 (-) 1 cancer cell line human CVCL_TC47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8661; PCDH9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136294 CVCL_TC46 HAP1 PCDH7 (-) 2 cancer cell line human CVCL_TC46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8659; PCDH7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136295 CVCL_TC49 HAP1 PCDH9 (-) 3 cancer cell line human CVCL_TC49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8661; PCDH9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136296 CVCL_TC48 HAP1 PCDH9 (-) 2 cancer cell line human CVCL_TC48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8661; PCDH9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136297 CVCL_KI99 PCRP-PGBD1-3H9 hybridoma house mouse CVCL_KI99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96JS3; Human PGBD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136298 CVCL_KI98 PCRP-PGBD1-3E1 hybridoma house mouse CVCL_KI98 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96JS3; Human PGBD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136299 CVCL_TC30 HAP1 PASK (-) 3 cancer cell line human CVCL_TC30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17270; PASK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136300 CVCL_TC32 HAP1 PAXIP1 (-) 1 cancer cell line human CVCL_TC32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8624; PAXIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136301 CVCL_TC31 HAP1 PAX8 (-) 1 cancer cell line human CVCL_TC31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8622; PAX8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136302 CVCL_TC34 HAP1 PBK (-) 1 cancer cell line human CVCL_TC34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136303 CVCL_TC33 HAP1 PAXIP1 (-) 2 cancer cell line human CVCL_TC33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8624; PAXIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136304 CVCL_TC36 HAP1 PBRM1 (-) 1 cancer cell line human CVCL_TC36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC001135c006; true Male Group: Haploid karyotype cell line 21136305 CVCL_TC35 HAP1 PBK (-) 2 cancer cell line human CVCL_TC35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136306 CVCL_TC38 HAP1 PBRM1 (-) 3 cancer cell line human CVCL_TC38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136307 CVCL_TC37 HAP1 PBRM1 (-) 2 cancer cell line human CVCL_TC37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30064; PBRM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136308 CVCL_TC39 HAP1 PC (-) cancer cell line human CVCL_TC39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8636; PC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136309 CVCL_KI84 PCRP-PAX9-1G1 hybridoma house mouse CVCL_KI84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55771; Human PAX9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136310 CVCL_KI83 PCRP-PAX5-1B7 hybridoma house mouse CVCL_KI83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02548; Human PAX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136311 CVCL_KI86 PCRP-PBX1-3C8 hybridoma house mouse CVCL_KI86 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P40424; Human PBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136312 CVCL_KI85 PCRP-PBX1-2D10 hybridoma house mouse CVCL_KI85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P40424; Human PBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136313 CVCL_KI80 PCRP-PAX2-1A7 hybridoma house mouse CVCL_KI80 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q02962; Human PAX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136314 CVCL_KI82 PCRP-PAX5-1B1 hybridoma house mouse CVCL_KI82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02548; Human PAX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136315 CVCL_KI81 PCRP-PAX3-1B3 hybridoma house mouse CVCL_KI81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23760; Human PAX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136316 CVCL_TC21 HAP1 PARP6 (-) 1 cancer cell line human CVCL_TC21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26921; PARP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136317 CVCL_TC20 HAP1 PARP4 (-) 2 cancer cell line human CVCL_TC20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 271; PARP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136318 CVCL_TC23 HAP1 PARP6 (-) 3 cancer cell line human CVCL_TC23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26921; PARP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136319 CVCL_TC22 HAP1 PARP6 (-) 2 cancer cell line human CVCL_TC22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26921; PARP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136320 CVCL_TC25 HAP1 PARP9 (-) 2 cancer cell line human CVCL_TC25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24118; PARP9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136321 CVCL_TC24 HAP1 PARP9 (-) 1 cancer cell line human CVCL_TC24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24118; PARP9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136322 CVCL_TC27 HAP1 PARPBP (-) 2 cancer cell line human CVCL_TC27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26074; PARPBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136323 CVCL_TC26 HAP1 PARPBP (-) 1 cancer cell line human CVCL_TC26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26074; PARPBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136324 CVCL_TC29 HAP1 PASK (-) 2 cancer cell line human CVCL_TC29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17270; PASK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136325 CVCL_TC28 HAP1 PASK (-) 1 cancer cell line human CVCL_TC28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17270; PASK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136326 CVCL_KI77 PCRP-PARP11-1C4 hybridoma house mouse CVCL_KI77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NR21; Human PARP11. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136327 CVCL_KI76 PCRP-OVOL2-2A1 hybridoma house mouse CVCL_KI76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BRP0; Human OVOL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136328 CVCL_KI79 PCRP-PAWR-1C3 hybridoma house mouse CVCL_KI79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96IZ0; Human PAWR. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136329 CVCL_KI78 PCRP-PARP11-1H1 hybridoma house mouse CVCL_KI78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NR21; Human PARP11. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136330 CVCL_KI95 PCRP-PDX1-2C11 hybridoma house mouse CVCL_KI95 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P52945; Human PDX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136331 CVCL_KI94 PCRP-PCGF6-1A2 hybridoma house mouse CVCL_KI94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYE7; Human PCGF6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136332 CVCL_KI97 PCRP-PGBD1-3C5 hybridoma house mouse CVCL_KI97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JS3; Human PGBD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136333 CVCL_KI96 PCRP-PGBD1-2A3 hybridoma house mouse CVCL_KI96 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q96JS3; Human PGBD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136334 CVCL_KI91 PCRP-PCGF3-1B4 hybridoma house mouse CVCL_KI91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q3KNV8; Human PCGF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136335 CVCL_KI90 PCRP-PBX4-2H1 hybridoma house mouse CVCL_KI90 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYU1; Human PBX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136336 CVCL_KI93 PCRP-PCGF6-1A11 hybridoma house mouse CVCL_KI93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BYE7; Human PCGF6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136337 CVCL_KI92 PCRP-PCGF3-1D5 hybridoma house mouse CVCL_KI92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q3KNV8; Human PCGF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136338 CVCL_TC10 HAP1 PARK7 (-) 2 cancer cell line human CVCL_TC10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16369; PARK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136339 CVCL_TC12 HAP1 PARP1 (-) 2 cancer cell line human CVCL_TC12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136340 CVCL_TC11 HAP1 PARP1 (-) 1 cancer cell line human CVCL_TC11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 270; PARP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136341 CVCL_TC14 HAP1 PARP16 (-) 1 cancer cell line human CVCL_TC14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26040; PARP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136342 CVCL_TC13 HAP1 PARP12 (-) 1 cancer cell line human CVCL_TC13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21919; PARP12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136343 CVCL_TC16 HAP1 PARP2 (-) 2 cancer cell line human CVCL_TC16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136344 CVCL_TC15 HAP1 PARP2 (-) 1 cancer cell line human CVCL_TC15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136345 CVCL_TC18 HAP1 PARP3 (-) 2 cancer cell line human CVCL_TC18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136346 CVCL_TC17 HAP1 PARP3 (-) 1 cancer cell line human CVCL_TC17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 273; PARP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136347 CVCL_TC19 HAP1 PARP4 (-) 1 cancer cell line human CVCL_TC19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 271; PARP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136348 CVCL_KI88 PCRP-PBX4-1C11 hybridoma house mouse CVCL_KI88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYU1; Human PBX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136349 CVCL_KI87 PCRP-PBX2-1C4 hybridoma house mouse CVCL_KI87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P40425; Human PBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136350 CVCL_KI89 PCRP-PBX4-1H1 hybridoma house mouse CVCL_KI89 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYU1; Human PBX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136351 CVCL_9U31 MDA-MB-231-5a-D cancer cell line human CVCL_9U31 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21136352 CVCL_9U30 MDA-MB-231-5a cancer cell line human CVCL_9U30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21136353 CVCL_9U33 MDA-MB-231-5a-D-TbetaFluc/Rluc-ZsGreen cancer cell line human CVCL_9U33 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P27652; Renilla-type luciferase; Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1). Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21136354 CVCL_9U32 MDA-MB-231-5a-D-TbetaFluc/Rluc cancer cell line human CVCL_9U32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P27652; Renilla-type luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21136355 CVCL_9U28 LN1 cancer cell line human CVCL_9U28 CL:0000010 Anecdotal: Have been flown in space on the ISS in 2001 and 2011 to study growth in microgravity (PubMed=16044626) Derived from metastatic site: Not specified. Female Doubling time: 33 hours (PubMed=9196889) Group: Space-flown cell line (cellonaut) 21136356 CVCL_9U27 LNCaP-OM cancer cell line human CVCL_9U27 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21136357 CVCL_9U29 LSC-1 spontaneously immortalized cell line Norway rat CVCL_9U29 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Unspecified Doubling time: 46 hours (PubMed=26722391) 21136358 CVCL_9U24 LISP-1 cancer cell line human CVCL_9U24 CL:0000010 Derived from metastatic site: Liver. Unspecified Doubling time: 20 +- 1 hours (PubMed=12886464) 21136359 CVCL_9U23 LACC-1 cancer cell line human CVCL_9U23 CL:0000010 Population: Chinese; Derived from sampling site: Lacrimal gland. Female Doubling time: ~37.1 hours (PubMed=25962898) 21136360 CVCL_9U26 LISP-E11 cancer cell line human CVCL_9U26 CL:0000010 Derived from metastatic site: Liver. Unspecified Doubling time: 30.4 hours (PubMed=11323753) 21136361 CVCL_9U25 LISP-A10 cancer cell line human CVCL_9U25 CL:0000010 Derived from metastatic site: Liver. Unspecified Doubling time: 38.3 hours (PubMed=11323753) 21136362 CVCL_9U42 OMC-5 cancer cell line house mouse CVCL_9U42 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Uterus; cervix; Breed/subspecies: ICR. Female Doubling time: 69 hours (DOI=10.11437/sanpunosinpo1949.40.17) 21136363 CVCL_9U41 OKTr-23 transformed cell line CVCL_9U41 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Oka organ. Group: Crustacean cell line 21136364 CVCL_9U44 GENYOi001-A induced pluripotent stem cell human CVCL_9U44 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21136365 CVCL_9U43 P11-90 cancer cell line house mouse CVCL_9U43 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Kunming. Female 21136366 CVCL_9U40 OKTr-1 transformed cell line CVCL_9U40 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Oka organ. Group: Crustacean cell line 21136367 CVCL_9U39 MSU-TnT4 spontaneously immortalized cell line CVCL_9U39 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9384. 21136368 CVCL_9U38 MNNG/HOS/DXR1000 cancer cell line human CVCL_9U38 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; right femur. Female 21136369 CVCL_9U35 MMGT1 transformed cell line house mouse CVCL_9U35 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: NMRI. Male 21136370 CVCL_9U34 MG63/DXR1000 cancer cell line human CVCL_9U34 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone; left femur. Male 21136371 CVCL_9U37 MMGT16 transformed cell line house mouse CVCL_9U37 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: NMRI. Male 21136372 CVCL_9U36 MMGT12 transformed cell line house mouse CVCL_9U36 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: NMRI. Male 21136373 CVCL_9U11 IPLB-OlE505A spontaneously immortalized cell line CVCL_9U11 CL:0000010 Unspecified Group: Insect cell line. 21136374 CVCL_9U10 IOZCAS-Spex-12 transformed cell line CVCL_9U10 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Doubling time: 71.06 hours (Patent=CN103060258B; PubMed=22549336) Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.4804 21136375 CVCL_9U06 HuMI transformed cell line human CVCL_9U06 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 21136376 CVCL_9U05 HPR600 cancer cell line human CVCL_9U05 CL:0000010 Unspecified 21136377 CVCL_9U08 HuMI-TTu1 transformed cell line human CVCL_9U08 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 21136378 CVCL_9U07 HuMI-T transformed cell line human CVCL_9U07 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 21136379 CVCL_9U02 HeLa ICRP FLIP-S-mCherry cancer cell line human CVCL_9U02 CL:0000010 Transfected with: Initiator caspase reporter protein (IC-RP) FRET donor-acceptor pair (CFP and YFP) connected by a caspase cleavage sequence ('DEVDR') linker.; Transfected with: HGNC; 1876; CFLAR (isoform FLIP-S); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21136380 CVCL_9U01 HeLa ICRP FLIP-L-mCherry cancer cell line human CVCL_9U01 CL:0000010 Transfected with: Initiator caspase reporter protein (IC-RP) FRET donor-acceptor pair (CFP and YFP) connected by a caspase cleavage sequence ('DEVDR') linker.; Transfected with: HGNC; 1876; CFLAR (isoform FLIP-L); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21136381 CVCL_9U04 HFK-1 finite cell line human CVCL_9U04 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified Senescence: SV40-transformed but with a finite life span 21136382 CVCL_9U03 HeLa-UGT1A9 cancer cell line human CVCL_9U03 CL:0000010 Transfected with: HGNC; 12541; UGT1A9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21136383 CVCL_9U09 HuMI-TTu2 transformed cell line human CVCL_9U09 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk. Female 21136384 CVCL_9U20 JT4C8 hybridoma house mouse CVCL_9U20 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01730; Human CD4 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9385 21136385 CVCL_9U22 L10-90 cancer cell line house mouse CVCL_9U22 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Kunming. Female 21136386 CVCL_9U21 KU_FMF_iPSC_1 induced pluripotent stem cell human CVCL_9U21 From: School of Medicine, Koc University; Istanbul; Turkey CL:0000010 Sequence variation: Mutation; HGNC; 6998; MEFV; Simple; p.Met694Val (c.2080A>G); ClinVar=VCV000002538; Zygosity=Homozygous (PubMed=26987928) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21136387 CVCL_9U17 JT2-N15 hybridoma house mouse CVCL_9U17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1684 21136388 CVCL_9U16 JT1-1F3-E5 hybridoma house mouse CVCL_9U16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 87062502 21136389 CVCL_9U19 JT4C16 hybridoma house mouse CVCL_9U19 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9386 21136390 CVCL_9U18 JT4C12 hybridoma house mouse CVCL_9U18 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P01730; Human CD4 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9387 21136391 CVCL_9U13 IPLB-OlE7 spontaneously immortalized cell line CVCL_9U13 CL:0000010 Unspecified Group: Insect cell line. 21136392 CVCL_9U12 IPLB-OlE505s spontaneously immortalized cell line CVCL_9U12 CL:0000010 Unspecified Group: Insect cell line. 21136393 CVCL_9U15 JT1-1F3 hybridoma house mouse CVCL_9U15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 87062501 21136394 CVCL_9U14 JT1-1D7 hybridoma house mouse CVCL_9U14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1685 21136395 CVCL_TB91 HAP1 PAK2 (-) 2 cancer cell line human CVCL_TB91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136396 CVCL_TB90 HAP1 PAK2 (-) 1 cancer cell line human CVCL_TB90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136397 CVCL_TB93 HAP1 PAK2 (-) 4 cancer cell line human CVCL_TB93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136398 CVCL_9U00 HeLa ICRP Bcl-XL-mCherry cancer cell line human CVCL_9U00 CL:0000010 Transfected with: Initiator caspase reporter protein (IC-RP) FRET donor-acceptor pair (CFP and YFP) connected by a caspase cleavage sequence ('DEVDR') linker.; Transfected with: HGNC; 992; BCL2L1; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21136399 CVCL_TB92 HAP1 PAK2 (-) 3 cancer cell line human CVCL_TB92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8591; PAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136400 CVCL_TB95 HAP1 PAK4 (-) 2 cancer cell line human CVCL_TB95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136401 CVCL_TB94 HAP1 PAK4 (-) 1 cancer cell line human CVCL_TB94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136402 CVCL_TB97 HAP1 PAK6 (-) cancer cell line human CVCL_TB97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16061; PAK6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136403 CVCL_TB96 HAP1 PAK4 (-) 3 cancer cell line human CVCL_TB96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16059; PAK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136404 CVCL_TB99 HAP1 PALM (-) 2 cancer cell line human CVCL_TB99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8594; PALM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136405 CVCL_TB98 HAP1 PALM (-) 1 cancer cell line human CVCL_TB98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8594; PALM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136406 CVCL_TB80 HAP1 OXLD1 (-) 1 cancer cell line human CVCL_TB80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27901; OXLD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136407 CVCL_TB82 HAP1 OXNAD1 (-) 1 cancer cell line human CVCL_TB82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25128; OXNAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136408 CVCL_TB81 HAP1 OXLD1 (-) 2 cancer cell line human CVCL_TB81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27901; OXLD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136409 CVCL_TB84 HAP1 PABPC4 (-) 2 cancer cell line human CVCL_TB84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8557; PABPC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136410 CVCL_TB83 HAP1 PABPC4 (-) 1 cancer cell line human CVCL_TB83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8557; PABPC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136411 CVCL_TB86 HAP1 PACRG (-) 1 cancer cell line human CVCL_TB86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19152; PACRG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136412 CVCL_TB85 HAP1 PABPC4 (-) 3 cancer cell line human CVCL_TB85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8557; PABPC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136413 CVCL_TB88 HAP1 PAK1 (-) 2 cancer cell line human CVCL_TB88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136414 CVCL_TB87 HAP1 PAK1 (-) 1 cancer cell line human CVCL_TB87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136415 CVCL_TB89 HAP1 PAK1 (-) 3 cancer cell line human CVCL_TB89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8590; PAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136416 CVCL_TB71 HAP1 OTUD1 (-) 2 cancer cell line human CVCL_TB71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27346; OTUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136417 CVCL_TB70 HAP1 OTUD1 (-) 1 cancer cell line human CVCL_TB70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27346; OTUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136418 CVCL_TB73 HAP1 OTUD3 (-) 2 cancer cell line human CVCL_TB73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29038; OTUD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136419 CVCL_TB72 HAP1 OTUD3 (-) 1 cancer cell line human CVCL_TB72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29038; OTUD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136420 CVCL_TB75 HAP1 OTUD5 (-) 1 cancer cell line human CVCL_TB75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25402; OTUD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136421 CVCL_TB74 HAP1 OTUD4 (-) cancer cell line human CVCL_TB74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24949; OTUD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136422 CVCL_TB77 HAP1 OTUD6B (-) cancer cell line human CVCL_TB77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24281; OTUD6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136423 CVCL_TB76 HAP1 OTUD5 (-) 2 cancer cell line human CVCL_TB76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25402; OTUD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136424 CVCL_TB79 HAP1 OTUD7B (-) 2 cancer cell line human CVCL_TB79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16683; OTUD7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136425 CVCL_TB78 HAP1 OTUD7B (-) 1 cancer cell line human CVCL_TB78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16683; OTUD7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136426 CVCL_C045 UPCI-SCC-080 cancer cell line human CVCL_C045 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136427 CVCL_C044 UPCI-SCC-078 cancer cell line human CVCL_C044 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Gly (c.472C>G); ClinVar=VCV000856171; Zygosity=Unspecified (DSMZ) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: ~60 hours (DSMZ=ACC-867) 21136428 CVCL_C047 UPCI-SCC-084 cancer cell line human CVCL_C047 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220fs*27 (c.655delC) (p.P219Lfs); Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; retromolar trigone. Male Doubling time: ~22 hours (DSMZ=ACC-878) 21136429 CVCL_C046 UPCI-SCC-081 cancer cell line human CVCL_C046 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Female Doubling time: ~48 hours (DSMZ=ACC-868) 21136430 CVCL_C049 UPCI-SCC-103 cancer cell line human CVCL_C049 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Female Doubling time: ~25-30 hours (DSMZ=ACC-879) 21136431 CVCL_C048 UPCI-SCC-089 cancer cell line human CVCL_C048 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tonsil. Male 21136432 CVCL_C041 UPCI-SCC-070 cancer cell line human CVCL_C041 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; retromolar trigone. Female 21136433 CVCL_C040 UPCI-SCC-068 cancer cell line human CVCL_C040 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136434 CVCL_C043 UPCI-SCC-077 cancer cell line human CVCL_C043 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Hisfs*28 (c.951del); Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: ~60-70 hours (DSMZ=ACC-866) 21136435 CVCL_C042 UPCI-SCC-075 cancer cell line human CVCL_C042 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136436 CVCL_C056 UPCI-SCC-142 cancer cell line human CVCL_C056 CL:0000010 Population: Caucasian. Male 21136437 CVCL_C055 UPCI-SCC-136 cancer cell line human CVCL_C055 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Ter (c.670G>T); Zygosity=Unspecified (PubMed=12872257). Population: Caucasian Female 21136438 CVCL_C058 UPCI-SCC-152 cancer cell line human CVCL_C058 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 2 days (PubMed=29156801) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21136439 CVCL_C057 UPCI-SCC-143 cancer cell line human CVCL_C057 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Female Doubling time: ~40-50 hours (DSMZ=ACC-886) 21136440 CVCL_C059 UPCI-SCC-153 cancer cell line human CVCL_C059 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: Protein expression by reverse-phase protein arrays. Male Part of: MD Anderson Cell Lines Project 21136441 CVCL_C050 UPCI-SCC-104 cancer cell line human CVCL_C050 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male 21136442 CVCL_C052 UPCI-SCC-121 cancer cell line human CVCL_C052 CL:0000010 Population: African American; Derived from sampling site: Oral cavity; retromolar trigone. Male 21136443 CVCL_C051 UPCI-SCC-105 cancer cell line human CVCL_C051 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male 21136444 CVCL_C054 UPCI-SCC-125 cancer cell line human CVCL_C054 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: ~40-50 hours (DSMZ=ACC-885) Part of: MD Anderson Cell Lines Project 21136445 CVCL_C053 UPCI-SCC-122 cancer cell line human CVCL_C053 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136446 CVCL_9U91 EFC007 transformed cell line house mouse CVCL_9U91 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136447 CVCL_9U90 CFT012 transformed cell line house mouse CVCL_9U90 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136448 CVCL_C023 Ki-PeCa-P1 cancer cell line human CVCL_C023 CL:0000010 Derived from sampling site: Penis. Male 21136449 CVCL_9U97 OVC1-PI 32 cancer cell line human CVCL_9U97 CL:0000010 Population: Iranian; Derived from sampling site: Ovary. Female 21136450 CVCL_9U96 BC43 cancer cell line Norway rat CVCL_9U96 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21136451 CVCL_C022 Ki-PeCa-L1 cancer cell line human CVCL_C022 CL:0000010 Derived from metastatic site: Lymph node. Male 21136452 CVCL_9U99 BE [Human melanoma] cancer cell line human CVCL_9U99 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21136453 CVCL_C025 UPCI-SCC-003 cancer cell line human CVCL_C025 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tonsil. Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays Female Doubling time: ~45 hours (DSMZ=ACC-863) Part of: MD Anderson Cell Lines Project 21136454 CVCL_9U98 C1R-A2 transformed cell line human CVCL_9U98 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*02) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136455 CVCL_C024 UPCI-SCC-002 cancer cell line human CVCL_C024 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Female 21136456 CVCL_9U93 Delta-Rad54+hRad54-DT40 cancer cell line CVCL_9U93 CL:0000010 Knockout cell: Method=Targeted integration; RAD54L; Transfected with: HGNC; 9826; RAD54L Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21136457 CVCL_C027 UPCI-SCC-016 cancer cell line human CVCL_C027 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: ~50 hours (DSMZ=ACC-884) Part of: MD Anderson Cell Lines Project 21136458 CVCL_9U92 Delta-Rad51+hRad51-DT40 cancer cell line CVCL_9U92 CL:0000010 Knockout cell: Method=Targeted integration; RAD51; Transfected with: HGNC; 9817; RAD51 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21136459 CVCL_C026 UPCI-SCC-013 cancer cell line human CVCL_C026 CL:0000010 Population: Caucasian. Female 21136460 CVCL_9U95 BC31 cancer cell line Norway rat CVCL_9U95 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21136461 CVCL_C029 UPCI-SCC-032 cancer cell line human CVCL_C029 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu289fs (c.867_868del2); Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; retromolar trigone. Male Doubling time: ~50-60 hours (DSMZ=ACC-864) 21136462 CVCL_9U94 CHO-K1-SFM spontaneously immortalized cell line CVCL_9U94 CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21136463 CVCL_C028 UPCI-SCC-030 cancer cell line human CVCL_C028 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male 21136464 CVCL_9U89 CFC034 transformed cell line house mouse CVCL_9U89 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136465 CVCL_C021 M1(D+) cancer cell line house mouse CVCL_C021 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: SL. 21136466 CVCL_C020 CNS2-hiPSC8 induced pluripotent stem cell human CVCL_C020 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136467 CVCL_C034 UPCI-SCC-052 cancer cell line human CVCL_C034 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Female 21136468 CVCL_C033 UPCI-SCC-051 cancer cell line human CVCL_C033 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; retromolar trigone. Male 21136469 CVCL_C036 UPCI-SCC-056 cancer cell line human CVCL_C036 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136470 CVCL_C035 UPCI-SCC-053 cancer cell line human CVCL_C035 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male 21136471 CVCL_C038 UPCI-SCC-065 cancer cell line human CVCL_C038 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21136472 CVCL_C037 UPCI-SCC-062 cancer cell line human CVCL_C037 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Female 21136473 CVCL_C039 UPCI-SCC-066 cancer cell line human CVCL_C039 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Female 21136474 CVCL_C030 UPCI-SCC-036 cancer cell line human CVCL_C030 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Phe (c.583A>T); ClinVar=VCV000376617; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; tonsil. Omics: DNA methylation analysis Male Virology: The tumor is positive to HPV (PubMed=17112776), but the cell line is HPV negative (PubMed=23419152; PubMed=24403267) Doubling time: ~48 hours (DSMZ=ACC-865) 21136475 CVCL_C032 UPCI-SCC-045 cancer cell line human CVCL_C032 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; retromolar trigone. Male 21136476 CVCL_C031 UPCI-SCC-044 cancer cell line human CVCL_C031 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Female 21136477 CVCL_C009 CNS1-hiPSC6 induced pluripotent stem cell human CVCL_C009 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136478 CVCL_C008 CNS1-hiPSC5 induced pluripotent stem cell human CVCL_C008 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136479 CVCL_9U75 CHOPWT9 induced pluripotent stem cell human CVCL_9U75 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21136480 CVCL_C001 SNUhES7 embryonic stem cell human CVCL_C001 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010009. 21136481 CVCL_C000 SNUhES6 embryonic stem cell human CVCL_C000 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010008. 21136482 CVCL_9U74 VACO 143 cancer cell line human CVCL_9U74 CL:0000010 21136483 CVCL_9U77 GFM1SV.25 induced pluripotent stem cell human CVCL_9U77 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 13780; GFM1; Simple; p.Gly469Valfs*84 (c.1404delA); ClinVar=VCV000812087; Zygosity=Heterozygous (PubMed=27345796); Sequence variation: Mutation; HGNC; 13780; GFM1; Simple; p.Arg671Cys (c.2011C>T); ClinVar=VCV000214500; Zygosity=Heterozygous (PubMed=27345796) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21136484 CVCL_C003 Ramos-EHRA cancer cell line human CVCL_C003 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) 21136485 CVCL_9U76 CON8 transformed cell line human CVCL_9U76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136486 CVCL_C002 PC-6 cancer cell line human CVCL_C002 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 21136487 CVCL_C005 CNS1-hiPSC10 induced pluripotent stem cell human CVCL_C005 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136488 CVCL_9U71 MEL-STV transformed cell line human CVCL_9U71 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21136489 CVCL_C004 CNS1-hiPSC1 induced pluripotent stem cell human CVCL_C004 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136490 CVCL_9U70 MEL-STM transformed cell line human CVCL_9U70 CL:0000010 Transfected with: HGNC; 7029; MET (activated TPR-MET); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21136491 CVCL_C007 CNS1-hiPSC4 induced pluripotent stem cell human CVCL_C007 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136492 CVCL_9U73 TOV-2978G cancer cell line human CVCL_9U73 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920-2A>G (IVS8-2A>G); ClinVar=VCV000043595; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=26622941) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 1.87 +- 0.11 days (PubMed=26622941) 21136493 CVCL_C006 CNS1-hiPSC2 induced pluripotent stem cell human CVCL_C006 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136494 CVCL_9U72 MDCKII-MRP2/UGT1A1 spontaneously immortalized cell line dog CVCL_9U72 CL:0000010 Transfected with: HGNC; 53; ABCC2; Transfected with: HGNC; 12530; UGT1A1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21136495 CVCL_9U68 PrEC LHMK transformed cell line human CVCL_9U68 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 8975; PIK3CA; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21136496 CVCL_9U67 TeLFBASAF cancer cell line human CVCL_9U67 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Group: Retrovirus packaging cell line Problematic cell line: Contaminated Parent cell line (TE 671) has been shown to be a RD derivative. 21136497 CVCL_9U69 PrEC LHS transformed cell line human CVCL_9U69 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21136498 CVCL_C019 CNS2-hiPSC7 induced pluripotent stem cell human CVCL_C019 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136499 CVCL_9U80 Lymph8-iPS induced pluripotent stem cell human CVCL_9U80 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136500 CVCL_9U86 CFC004 transformed cell line house mouse CVCL_9U86 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136501 CVCL_C012 CNS1-hiPSC9 induced pluripotent stem cell human CVCL_C012 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136502 CVCL_9U85 BFC023 transformed cell line house mouse CVCL_9U85 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136503 CVCL_C011 CNS1-hiPSC8 induced pluripotent stem cell human CVCL_C011 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136504 CVCL_9U88 CFC032 transformed cell line house mouse CVCL_9U88 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136505 CVCL_C014 CNS2-hiPSC2 induced pluripotent stem cell human CVCL_C014 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136506 CVCL_9U87 CFC008 transformed cell line house mouse CVCL_9U87 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136507 CVCL_C013 CNS2-hiPSC1 induced pluripotent stem cell human CVCL_C013 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136508 CVCL_C016 CNS2-hiPSC4 induced pluripotent stem cell human CVCL_C016 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136509 CVCL_9U82 MSC-iPS(fetal)#2 induced pluripotent stem cell human CVCL_9U82 CL:0000010 Derived from sampling site: Fetal bone; femur Cell type=Mesenchymal stem cell.. Female 21136510 CVCL_C015 CNS2-hiPSC3 induced pluripotent stem cell human CVCL_C015 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136511 CVCL_9U81 MSC-iPS(fetal)#1 induced pluripotent stem cell human CVCL_9U81 CL:0000010 Derived from sampling site: Fetal bone; femur Cell type=Mesenchymal stem cell.. Female 21136512 CVCL_9U84 AFT011 transformed cell line house mouse CVCL_9U84 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136513 CVCL_C018 CNS2-hiPSC6 induced pluripotent stem cell human CVCL_C018 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136514 CVCL_9U83 AFC003 transformed cell line house mouse CVCL_9U83 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21136515 CVCL_C017 CNS2-hiPSC5 induced pluripotent stem cell human CVCL_C017 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136516 CVCL_9U79 HS5-SV.hiPS induced pluripotent stem cell human CVCL_9U79 From: Chulalongkorn University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Skin (Note=From a scar) Cell type=Fibroblast.. Female 21136517 CVCL_9U78 H271 C1 induced pluripotent stem cell human CVCL_9U78 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=27345803) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21136518 CVCL_C010 CNS1-hiPSC7 induced pluripotent stem cell human CVCL_C010 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Leu413Pro; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21136519 CVCL_9U53 Tca8113/CBP [Chengdu] cancer cell line human CVCL_9U53 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21136520 CVCL_9U52 SCO1 spontaneously immortalized cell line CVCL_9U52 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21136521 CVCL_9U55 Tca8113/PYM [Chengdu] cancer cell line human CVCL_9U55 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:78160; Bleomycin A5 (Pingyangmycin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21136522 CVCL_9U54 Tca8113/PYM [Changsha] cancer cell line human CVCL_9U54 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:78160; Bleomycin A5 (Pingyangmycin); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Tca8113) has been shown to be a HeLa derivative. 21136523 CVCL_9U51 ScSFT-2 transformed cell line CVCL_9U51 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Cetacean cell line 21136524 CVCL_9U50 ScSFT-1 transformed cell line CVCL_9U50 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 41.53 hours (PubMed=23661087) Group: Endangered species/breed cell line; Group: Cetacean cell line 21136525 CVCL_9U49 SCC60 cancer cell line human CVCL_9U49 CL:0000010 Female 21136526 CVCL_9U46 RIRI-PaDe spontaneously immortalized cell line CVCL_9U46 CL:0000010 Unspecified Doubling time: 55 hours (PubMed=23299317). Group: Insect cell line 21136527 CVCL_9U45 RC cancer cell line human CVCL_9U45 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=26515759); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=26515759) Miscellaneous: STR profile in PubMed=26515759 table 3 is erroneous; correct STR profile obtained by personal communication of Pham L.V Derived from sampling site: Pleural effusion. Female Doubling time: ~4-5 days (PubMed=26515759) 21136528 CVCL_9U48 SB-3 cancer cell line human CVCL_9U48 CL:0000010 Derived from metastatic site: Adrenal gland. Male 21136529 CVCL_9U47 Saos2-I cancer cell line human CVCL_9U47 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone. Omics: Transcriptome analysis by microarray Female Characteristics: Increased developement of pulmonary metastases compared to the parent cell line 21136530 CVCL_9U64 TE-FLY-GALV cancer cell line human CVCL_9U64 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol; Transfected with: UniProtKB; P21415; Gibbon ape leukemia virus (GALV) env Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Group: Retrovirus packaging cell line Problematic cell line: Contaminated Parent cell line (TE 671) has been shown to be a RD derivative. 21136531 CVCL_9U63 TE-FLY-A8 cancer cell line human CVCL_9U63 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Group: Retrovirus packaging cell line Problematic cell line: Contaminated Parent cell line (TE 671) has been shown to be a RD derivative. 21136532 CVCL_9U66 TELCeB6 cancer cell line human CVCL_9U66 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Group: Retrovirus packaging cell line Problematic cell line: Contaminated Grand-parent cell line (TE 671) has been shown to be a RD derivative. 21136533 CVCL_9U65 TELac2 cancer cell line human CVCL_9U65 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female Group: Retrovirus packaging cell line Problematic cell line: Contaminated Parent cell line (TE 671) has been shown to be a RD derivative. 21136534 CVCL_9U60 XPTS-1 cancer cell line human CVCL_9U60 CL:0000010 Population: Chinese Female Doubling time: 22 hours (PubMed=21575431) 21136535 CVCL_9U62 YFLF finite cell line CVCL_9U62 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Doubling time: 30 hours (PubMed=23161386) 21136536 CVCL_9U61 YFEF finite cell line CVCL_9U61 CL:0000010 Derived from sampling site: Fetal ear Cell type=Fibroblast.. Male Doubling time: 35 hours (PubMed=23161386) 21136537 CVCL_9U57 U14-GFP cancer cell line house mouse CVCL_9U57 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Kunming. Female 21136538 CVCL_9U56 U14 cancer cell line house mouse CVCL_9U56 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Kunming. Female 21136539 CVCL_9U59 vNBS8-iPS-c2 induced pluripotent stem cell human CVCL_9U59 From: Max Planck Institute for Molecular Genetics; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (PubMed=26987925) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136540 CVCL_9U58 vNBS8-iPS-c1 induced pluripotent stem cell human CVCL_9U58 From: Max Planck Institute for Molecular Genetics; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (PubMed=26987925) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21136541 CVCL_KJ83 PCRP-PROX2-1E1 hybridoma house mouse CVCL_KJ83 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q3B8N5; Human PROX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136542 CVCL_KJ82 PCRP-PROX1-1A6 hybridoma house mouse CVCL_KJ82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92786; Human PROX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136543 CVCL_KJ85 PCRP-PRRX2-1G11 hybridoma house mouse CVCL_KJ85 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99811; Human PRRX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136544 CVCL_KJ84 PCRP-PROX2-1F5 hybridoma house mouse CVCL_KJ84 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q3B8N5; Human PROX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136545 CVCL_KJ81 PCRP-PRMT7-1A7 hybridoma house mouse CVCL_KJ81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NVM4; Human PRMT7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136546 CVCL_KJ80 PCRP-PRMT7-1A4 hybridoma house mouse CVCL_KJ80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NVM4; Human PRMT7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136547 CVCL_TD20 HAP1 PHF6 (-) 4 cancer cell line human CVCL_TD20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136548 CVCL_TD22 HAP1 PHF8 (-) 2 cancer cell line human CVCL_TD22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20672; PHF8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136549 CVCL_TD21 HAP1 PHF8 (-) 1 cancer cell line human CVCL_TD21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20672; PHF8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136550 CVCL_TD24 HAP1 PHGDH (-) 2 cancer cell line human CVCL_TD24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8923; PHGDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136551 CVCL_TD23 HAP1 PHGDH (-) 1 cancer cell line human CVCL_TD23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8923; PHGDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136552 CVCL_TD26 HAP1 PHIP (-) 2 cancer cell line human CVCL_TD26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15673; PHIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136553 CVCL_TD25 HAP1 PHIP (-) 1 cancer cell line human CVCL_TD25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15673; PHIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136554 CVCL_TD28 HAP1 PHKG1 (-) 2 cancer cell line human CVCL_TD28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8930; PHKG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136555 CVCL_TD27 HAP1 PHKG1 (-) 1 cancer cell line human CVCL_TD27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8930; PHKG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136556 CVCL_KJ79 PCRP-PRMT6-2C9 hybridoma house mouse CVCL_KJ79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96LA8; Human PRMT6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136557 CVCL_TD29 HAP1 PHKG1 (-) 3 cancer cell line human CVCL_TD29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8930; PHKG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136558 CVCL_KJ76 PCRP-PRKRA-3A4 hybridoma house mouse CVCL_KJ76 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75569; Human PRKRA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136559 CVCL_KJ75 PCRP-PRDM8-1A1 hybridoma house mouse CVCL_KJ75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NQV8; Human PRDM8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136560 CVCL_KJ78 PCRP-PRMT6-1H4 hybridoma house mouse CVCL_KJ78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96LA8; Human PRMT6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136561 CVCL_KJ77 PCRP-PRKRIR-1B11 hybridoma house mouse CVCL_KJ77 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43422; Human THAP12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136562 CVCL_KJ94 PCRP-RAX-1C8 hybridoma house mouse CVCL_KJ94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2V3; Human RAX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136563 CVCL_KJ93 PCRP-RAX-1B4 hybridoma house mouse CVCL_KJ93 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2V3; Human RAX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136564 CVCL_KJ96 PCRP-RAX-2D12 hybridoma house mouse CVCL_KJ96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2V3; Human RAX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136565 CVCL_KJ95 PCRP-RAX-1G11 hybridoma house mouse CVCL_KJ95 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9Y2V3; Human RAX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136566 CVCL_KJ90 PCRP-PWWP2B-1C8 hybridoma house mouse CVCL_KJ90 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6NUJ5; Human PWWP2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136567 CVCL_KJ92 PCRP-RARB-1E7 hybridoma house mouse CVCL_KJ92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10826; Human RARB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136568 CVCL_KJ91 PCRP-QKI-2F10 hybridoma house mouse CVCL_KJ91 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q96PU8; Human QKI. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136569 CVCL_TD11 HAP1 PHF2 (-) 1 cancer cell line human CVCL_TD11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8920; PHF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136570 CVCL_TD10 HAP1 PHF13 (-) 2 cancer cell line human CVCL_TD10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22983; PHF13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136571 CVCL_TD13 HAP1 PHF3 (-) 1 cancer cell line human CVCL_TD13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8921; PHF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136572 CVCL_TD12 HAP1 PHF2 (-) 2 cancer cell line human CVCL_TD12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8920; PHF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136573 CVCL_TD15 HAP1 PHF3 (-) 3 cancer cell line human CVCL_TD15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8921; PHF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136574 CVCL_TD14 HAP1 PHF3 (-) 2 cancer cell line human CVCL_TD14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8921; PHF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136575 CVCL_TD17 HAP1 PHF6 (-) 1 cancer cell line human CVCL_TD17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136576 CVCL_TD16 HAP1 PHF3 (-) 4 cancer cell line human CVCL_TD16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8921; PHF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136577 CVCL_TD19 HAP1 PHF6 (-) 3 cancer cell line human CVCL_TD19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136578 CVCL_TD18 HAP1 PHF6 (-) 2 cancer cell line human CVCL_TD18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136579 CVCL_KJ87 PCRP-PRRX2-5A10 hybridoma house mouse CVCL_KJ87 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99811; Human PRRX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136580 CVCL_KJ86 PCRP-PRRX2-4F12 hybridoma house mouse CVCL_KJ86 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99811; Human PRRX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136581 CVCL_KJ89 PCRP-PUM2-1B11 hybridoma house mouse CVCL_KJ89 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8TB72; Human PUM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136582 CVCL_KJ88 PCRP-PUM1-1C3 hybridoma house mouse CVCL_KJ88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14671; Human PUM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136583 CVCL_KJ61 PCRP-PRDM16-2B8 hybridoma house mouse CVCL_KJ61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136584 CVCL_KJ60 PCRP-PRDM16-2B2 hybridoma house mouse CVCL_KJ60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136585 CVCL_KJ63 PCRP-PRDM16-2D7 hybridoma house mouse CVCL_KJ63 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136586 CVCL_KJ62 PCRP-PRDM16-2B9 hybridoma house mouse CVCL_KJ62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136587 CVCL_TD00 HAP1 PGF (-) 1 cancer cell line human CVCL_TD00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8893; PGF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136588 CVCL_TD02 HAP1 PGLS (-) cancer cell line human CVCL_TD02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8903; PGLS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136589 CVCL_TD01 HAP1 PGF (-) 2 cancer cell line human CVCL_TD01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8893; PGF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136590 CVCL_TD04 HAP1 PGP (-) 2 cancer cell line human CVCL_TD04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8909; PGP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136591 CVCL_TD03 HAP1 PGP (-) 1 cancer cell line human CVCL_TD03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8909; PGP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136592 CVCL_TD06 HAP1 PGP (-) 4 cancer cell line human CVCL_TD06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8909; PGP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136593 CVCL_KJ58 PCRP-PRDM16-1C10 hybridoma house mouse CVCL_KJ58 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136594 CVCL_TD05 HAP1 PGP (-) 3 cancer cell line human CVCL_TD05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8909; PGP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136595 CVCL_KJ57 PCRP-PRDM16-1B9 hybridoma house mouse CVCL_KJ57 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136596 CVCL_TD08 HAP1 PHF10 (-) 2 cancer cell line human CVCL_TD08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18250; PHF10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136597 CVCL_TD07 HAP1 PHF10 (-) 1 cancer cell line human CVCL_TD07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18250; PHF10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136598 CVCL_KJ59 PCRP-PRDM16-1E6 hybridoma house mouse CVCL_KJ59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136599 CVCL_KJ54 PCRP-PRDM13-1D8 hybridoma house mouse CVCL_KJ54 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H4Q3; Human PRDM13. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136600 CVCL_TD09 HAP1 PHF13 (-) 1 cancer cell line human CVCL_TD09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22983; PHF13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136601 CVCL_KJ53 PCRP-PRDM1-2C5 hybridoma house mouse CVCL_KJ53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75626; Human PRDM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136602 CVCL_KJ56 PCRP-PRDM16-1A11 hybridoma house mouse CVCL_KJ56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAZ2; Human PRDM16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136603 CVCL_KJ55 PCRP-PRDM13-2C12 hybridoma house mouse CVCL_KJ55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H4Q3; Human PRDM13. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136604 CVCL_KJ72 PCRP-PRDM7-3C6 hybridoma house mouse CVCL_KJ72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NQW5; Human PRDM7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136605 CVCL_KJ71 PCRP-PRDM7-2C10 hybridoma house mouse CVCL_KJ71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NQW5; Human PRDM7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136606 CVCL_KJ74 PCRP-PRDM7-3F10 hybridoma house mouse CVCL_KJ74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NQW5; Human PRDM7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136607 CVCL_KJ73 PCRP-PRDM7-3D3 hybridoma house mouse CVCL_KJ73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NQW5; Human PRDM7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136608 CVCL_KJ70 PCRP-PRDM7-1B11 hybridoma house mouse CVCL_KJ70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NQW5; Human PRDM7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136609 CVCL_KJ69 PCRP-PRDM5-1H5 hybridoma house mouse CVCL_KJ69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NQX1; Human PRDM5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136610 CVCL_KJ68 PCRP-PRDM4-2D1 hybridoma house mouse CVCL_KJ68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKN5; Human PRDM4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136611 CVCL_KJ65 PCRP-PRDM2-2A4 hybridoma house mouse CVCL_KJ65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13029; Human PRDM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136612 CVCL_KJ64 PCRP-PRDM2-2A1 hybridoma house mouse CVCL_KJ64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13029; Human PRDM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136613 CVCL_KJ67 PCRP-PRDM4-2B4 hybridoma house mouse CVCL_KJ67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKN5; Human PRDM4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136614 CVCL_KJ66 PCRP-PRDM4-2B3 hybridoma house mouse CVCL_KJ66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKN5; Human PRDM4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136615 CVCL_KJ41 PCRP-PPARD-2C10 hybridoma house mouse CVCL_KJ41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136616 CVCL_KJ40 PCRP-PPARD-1F7 hybridoma house mouse CVCL_KJ40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136617 CVCL_KJ39 PCRP-PPARD-1E3 hybridoma house mouse CVCL_KJ39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136618 CVCL_KJ36 PCRP-POU6F1-1A1 hybridoma house mouse CVCL_KJ36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14863; Human POU6F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136619 CVCL_KJ35 PCRP-POU5F1-1D9 hybridoma house mouse CVCL_KJ35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01860; Human POU5F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136620 CVCL_KJ38 PCRP-PPARD-1D5 hybridoma house mouse CVCL_KJ38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136621 CVCL_KJ37 PCRP-PPARA-2B9 hybridoma house mouse CVCL_KJ37 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q07869; Human PPARA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136622 CVCL_KJ32 PCRP-POU3F2-3E6 hybridoma house mouse CVCL_KJ32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20265; Human POU3F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136623 CVCL_KJ31 PCRP-POU3F2-1A3 hybridoma house mouse CVCL_KJ31 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P20265; Human POU3F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136624 CVCL_KJ34 PCRP-POU5F1-1D2 hybridoma house mouse CVCL_KJ34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01860; Human POU5F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136625 CVCL_KJ33 PCRP-POU5F1-1A4 hybridoma house mouse CVCL_KJ33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01860; Human POU5F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136626 CVCL_KJ50 PCRP-PPP5C-1F7 hybridoma house mouse CVCL_KJ50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P53041; Human PPP5C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136627 CVCL_KJ52 PCRP-PRDM1-2B9 hybridoma house mouse CVCL_KJ52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75626; Human PRDM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136628 CVCL_KJ51 PCRP-PPP5C-1H9 hybridoma house mouse CVCL_KJ51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P53041; Human PPP5C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136629 CVCL_KJ47 PCRP-PPP1R10-1A2 hybridoma house mouse CVCL_KJ47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96QC0; Human PPP1R10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136630 CVCL_KJ46 PCRP-PPARD-4H2 hybridoma house mouse CVCL_KJ46 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136631 CVCL_KJ49 PCRP-PPP1R13L-2G4 hybridoma house mouse CVCL_KJ49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8WUF5; Human PPP1R13L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136632 CVCL_KJ48 PCRP-PPP1R10-1G12 hybridoma house mouse CVCL_KJ48 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96QC0; Human PPP1R10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136633 CVCL_KJ43 PCRP-PPARD-4A11 hybridoma house mouse CVCL_KJ43 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136634 CVCL_KJ42 PCRP-PPARD-2H3 hybridoma house mouse CVCL_KJ42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136635 CVCL_KJ45 PCRP-PPARD-4C2 hybridoma house mouse CVCL_KJ45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136636 CVCL_KJ44 PCRP-PPARD-4B7 hybridoma house mouse CVCL_KJ44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03181; Human PPARD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136637 CVCL_C188 MEL-c88 cancer cell line house mouse CVCL_C188 CL:0000010 Breed/subspecies: DBA/2. 21136638 CVCL_BP88 ND13825 transformed cell line human CVCL_BP88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136639 CVCL_BP87 ND13822 transformed cell line human CVCL_BP87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136640 CVCL_C187 PCI-18 cancer cell line human CVCL_C187 CL:0000010 Derived from sampling site: Larynx. Male 21136641 CVCL_C189 C1-iPSC-1 induced pluripotent stem cell human CVCL_C189 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21136642 CVCL_BP89 ND13826 transformed cell line human CVCL_BP89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136643 CVCL_BP80 ND13785 transformed cell line human CVCL_BP80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136644 CVCL_C180 PCI-11 cancer cell line human CVCL_C180 CL:0000010 Derived from sampling site: Pharynx; hypopharynx; pyriform sinus. Male 21136645 CVCL_BP82 ND13787 transformed cell line human CVCL_BP82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136646 CVCL_C182 PCI-13 cancer cell line human CVCL_C182 CL:0000010 Derived from sampling site: Oral cavity; retromolar trigone. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21136647 CVCL_BP81 ND13786 transformed cell line human CVCL_BP81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136648 CVCL_C181 PCI-12 cancer cell line human CVCL_C181 CL:0000010 Derived from sampling site: Lymph node. Male 21136649 CVCL_BP84 ND13808 transformed cell line human CVCL_BP84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136650 CVCL_C184 PCI-15A cancer cell line human CVCL_C184 Genome ancestry: African=0.36%; Native American=0.21%; East Asian, North=2.01%; East Asian, South=0%; South Asian=0.21%; European, North=62.27%; European, South=34.95% (PubMed=30894373) CL:0000010 Derived from sampling site: Pharynx; hypopharynx; pyriform sinus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21136651 CVCL_KJ18 PCRP-PKNOX2-2F8 hybridoma house mouse CVCL_KJ18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96KN3; Human PKNOX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136652 CVCL_BP83 ND13803 transformed cell line human CVCL_BP83 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136653 CVCL_C183 PCI-14 cancer cell line human CVCL_C183 CL:0000010 Derived from sampling site: Lymph node. Male 21136654 CVCL_KJ17 PCRP-PIKFYVE-4G10 hybridoma house mouse CVCL_KJ17 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136655 CVCL_BP86 ND13815 transformed cell line human CVCL_BP86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136656 CVCL_C186 PCI-17 cancer cell line human CVCL_C186 CL:0000010 Female 21136657 CVCL_BP85 ND13809 transformed cell line human CVCL_BP85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136658 CVCL_C185 PCI-16 cancer cell line human CVCL_C185 CL:0000010 Derived from metastatic site: Lymph node. Male 21136659 CVCL_KJ19 PCRP-PKNOX2-3C6 hybridoma house mouse CVCL_KJ19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96KN3; Human PKNOX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136660 CVCL_KJ14 PCRP-PIKFYVE-1H2 hybridoma house mouse CVCL_KJ14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136661 CVCL_KJ13 PCRP-PIKFYVE-1F9 hybridoma house mouse CVCL_KJ13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136662 CVCL_KJ16 PCRP-PIKFYVE-3C9 hybridoma house mouse CVCL_KJ16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136663 CVCL_KJ15 PCRP-PIKFYVE-2B2 hybridoma house mouse CVCL_KJ15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136664 CVCL_KJ10 PCRP-PHF7-1F3 hybridoma house mouse CVCL_KJ10 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9BWX1; Human PHF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136665 CVCL_KJ12 PCRP-PIKFYVE-1B8 hybridoma house mouse CVCL_KJ12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136666 CVCL_KJ11 PCRP-PIKFYVE-1A5 hybridoma house mouse CVCL_KJ11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2I7; Human PIKFYVE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136667 CVCL_KJ30 PCRP-POLE3-4E1 hybridoma house mouse CVCL_KJ30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136668 CVCL_C199 HS346 embryonic stem cell human CVCL_C199 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0201; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-20. 21136669 CVCL_BP99 ND13864 transformed cell line human CVCL_BP99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136670 CVCL_C198 HS306 embryonic stem cell human CVCL_C198 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0011; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18.. 21136671 CVCL_BP98 ND13863 transformed cell line human CVCL_BP98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136672 CVCL_C191 IHOK transformed cell line human CVCL_C191 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. 21136673 CVCL_BP91 ND13828 transformed cell line human CVCL_BP91 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136674 CVCL_C190 BTI-Tn-5B1-4 spontaneously immortalized cell line CVCL_C190 CL:0000010 Omics: Genome sequenced Discontinued: ECACC; 94020901; probable. Unspecified Virology: Infected with alphanodavirus TnCLV Doubling time: 26 hours (DOI=10.1111/j.1744-7917.2004.tb00236.x; PubMed=21667340); 34 +- 1 hours (in static culture), 27 +- 2 hours (in suspension culture) (PubMed=10585188) Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10859 21136675 CVCL_BP90 ND13827 transformed cell line human CVCL_BP90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136676 CVCL_C193 cFA404-KiPS4F-3 induced pluripotent stem cell human CVCL_C193 HLA typing: A*02,24; B*35,51; C*02,04; DQB1*02,03; DRB1*03,04 (Spanish_Stem_Cell_Bank) From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Transfected with: HGNC; 3582; FANCA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21136677 CVCL_BP93 ND13831 transformed cell line human CVCL_BP93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136678 CVCL_C192 cFA404-KiPS4F-1 induced pluripotent stem cell human CVCL_C192 HLA typing: A*02,24; B*35,51; C*02,04; DQB1*02,03; DRB1*03,04 (Spanish_Stem_Cell_Bank) From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Transfected with: HGNC; 3582; FANCA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: EBiSC; ESi005-A; true; Discontinued: ECACC; 66540065; true Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21136679 CVCL_BP92 ND13829 transformed cell line human CVCL_BP92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136680 CVCL_C195 CF-RiPS-1.3 induced pluripotent stem cell human CVCL_C195 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21136681 CVCL_BP95 ND13834 transformed cell line human CVCL_BP95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136682 CVCL_KJ29 PCRP-POLE3-3D3 hybridoma house mouse CVCL_KJ29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136683 CVCL_C194 CF-RiPS-1.2 induced pluripotent stem cell human CVCL_C194 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21136684 CVCL_BP94 ND13833 transformed cell line human CVCL_BP94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136685 CVCL_KJ28 PCRP-POLE3-3A4 hybridoma house mouse CVCL_KJ28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136686 CVCL_C197 HS293 embryonic stem cell human CVCL_C197 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Male Registration: Swiss research registry; BAG-hES-IMP-0010; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18.. 21136687 CVCL_BP97 ND13837 transformed cell line human CVCL_BP97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136688 CVCL_C196 CF-RiPS-1.4 induced pluripotent stem cell human CVCL_C196 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Unspecified 21136689 CVCL_BP96 ND13835 transformed cell line human CVCL_BP96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136690 CVCL_KJ25 PCRP-POLE3-2B11 hybridoma house mouse CVCL_KJ25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136691 CVCL_KJ24 PCRP-POGZ-1B2 hybridoma house mouse CVCL_KJ24 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z3K3; Human POGZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136692 CVCL_KJ27 PCRP-POLE3-2F4 hybridoma house mouse CVCL_KJ27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136693 CVCL_KJ26 PCRP-POLE3-2F10 hybridoma house mouse CVCL_KJ26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NRF9; Human POLE3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136694 CVCL_KJ21 PCRP-PLXNB1-3A7 hybridoma house mouse CVCL_KJ21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43157; Human PLXNB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136695 CVCL_KJ20 PCRP-PLAG1-1F5 hybridoma house mouse CVCL_KJ20 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6DJT9; Human PLAG1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136696 CVCL_KJ23 PCRP-PMS1-2E11 hybridoma house mouse CVCL_KJ23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54277; Human PMS1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136697 CVCL_KJ22 PCRP-PLXNB1-3G4 hybridoma house mouse CVCL_KJ22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43157; Human PLXNB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136698 CVCL_TD91 HAP1 PIP4K2C (-) cancer cell line human CVCL_TD91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23786; PIP4K2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136699 CVCL_TD90 HAP1 PIP4K2B (-) 2 cancer cell line human CVCL_TD90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8998; PIP4K2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136700 CVCL_TD93 HAP1 PIP5K1A (-) 2 cancer cell line human CVCL_TD93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8994; PIP5K1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136701 CVCL_TD92 HAP1 PIP5K1A (-) 1 cancer cell line human CVCL_TD92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8994; PIP5K1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136702 CVCL_TD95 HAP1 PIP5K1C (-) 2 cancer cell line human CVCL_TD95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8996; PIP5K1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136703 CVCL_TD94 HAP1 PIP5K1C (-) 1 cancer cell line human CVCL_TD94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8996; PIP5K1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136704 CVCL_TD97 HAP1 PKD2 (-) cancer cell line human CVCL_TD97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9009; PKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136705 CVCL_TD96 HAP1 PITPNB (-) cancer cell line human CVCL_TD96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9002; PITPNB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136706 CVCL_TD99 HAP1 PKDCC (-) 2 cancer cell line human CVCL_TD99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25123; PKDCC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136707 CVCL_TD98 HAP1 PKDCC (-) 1 cancer cell line human CVCL_TD98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25123; PKDCC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136708 CVCL_TD80 HAP1 PIM2 (-) 2 cancer cell line human CVCL_TD80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8987; PIM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136709 CVCL_TD82 HAP1 PIM3 (-) 1 cancer cell line human CVCL_TD82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19310; PIM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136710 CVCL_TD81 HAP1 PIM2 (-) 3 cancer cell line human CVCL_TD81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8987; PIM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136711 CVCL_TD84 HAP1 PIM3 (-) 3 cancer cell line human CVCL_TD84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19310; PIM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136712 CVCL_TD83 HAP1 PIM3 (-) 2 cancer cell line human CVCL_TD83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19310; PIM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136713 CVCL_TD86 HAP1 PINK1 (-) 2 cancer cell line human CVCL_TD86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136714 CVCL_TD85 HAP1 PINK1 (-) 1 cancer cell line human CVCL_TD85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14581; PINK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136715 CVCL_TD88 HAP1 PIP4K2A (-) 2 cancer cell line human CVCL_TD88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8997; PIP4K2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136716 CVCL_TD87 HAP1 PIP4K2A (-) 1 cancer cell line human CVCL_TD87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8997; PIP4K2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136717 CVCL_TD89 HAP1 PIP4K2B (-) 1 cancer cell line human CVCL_TD89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8998; PIP4K2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136718 CVCL_TD71 HAP1 PIK3R3 (-) 2 cancer cell line human CVCL_TD71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8981; PIK3R3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136719 CVCL_TD70 HAP1 PIK3R3 (-) 1 cancer cell line human CVCL_TD70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8981; PIK3R3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136720 CVCL_TD73 HAP1 PIK3R6 (-) 2 cancer cell line human CVCL_TD73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27101; PIK3R6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136721 CVCL_TD72 HAP1 PIK3R6 (-) 1 cancer cell line human CVCL_TD72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27101; PIK3R6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136722 CVCL_TD75 HAP1 PIKFYVE (-) 2 cancer cell line human CVCL_TD75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23785; PIKFYVE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136723 CVCL_TD74 HAP1 PIKFYVE (-) 1 cancer cell line human CVCL_TD74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23785; PIKFYVE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136724 CVCL_TD77 HAP1 PIM1 (-) 2 cancer cell line human CVCL_TD77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8986; PIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136725 CVCL_TD76 HAP1 PIM1 (-) 1 cancer cell line human CVCL_TD76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8986; PIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136726 CVCL_TD79 HAP1 PIM2 (-) 1 cancer cell line human CVCL_TD79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8987; PIM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136727 CVCL_TD78 HAP1 PIM1 (-) 3 cancer cell line human CVCL_TD78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8986; PIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136728 CVCL_TD60 HAP1 PIK3CA (-) 1 cancer cell line human CVCL_TD60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136729 CVCL_TD62 HAP1 PIK3CB (-) cancer cell line human CVCL_TD62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8976; PIK3CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136730 CVCL_TD61 HAP1 PIK3CA (-) 2 cancer cell line human CVCL_TD61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136731 CVCL_TD64 HAP1 PIK3CD (-) 2 cancer cell line human CVCL_TD64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136732 CVCL_TD63 HAP1 PIK3CD (-) 1 cancer cell line human CVCL_TD63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136733 CVCL_TD66 HAP1 PIK3R1 (-) 1 cancer cell line human CVCL_TD66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136734 CVCL_TD65 HAP1 PIK3CD (-) 3 cancer cell line human CVCL_TD65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136735 CVCL_TD68 HAP1 PIK3R2 (-) 1 cancer cell line human CVCL_TD68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136736 CVCL_TD67 HAP1 PIK3R1 (-) 2 cancer cell line human CVCL_TD67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8979; PIK3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136737 CVCL_TD69 HAP1 PIK3R2 (-) 2 cancer cell line human CVCL_TD69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8980; PIK3R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136738 CVCL_TD51 HAP1 PIGM (-) 2 cancer cell line human CVCL_TD51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18858; PIGM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136739 CVCL_TD50 HAP1 PIGM (-) 1 cancer cell line human CVCL_TD50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18858; PIGM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136740 CVCL_TD53 HAP1 PIGT (-) 1 cancer cell line human CVCL_TD53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14938; PIGT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136741 CVCL_TD52 HAP1 PIGM (-) 3 cancer cell line human CVCL_TD52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18858; PIGM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136742 CVCL_TD55 HAP1 PIGT (-) 3 cancer cell line human CVCL_TD55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14938; PIGT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136743 CVCL_TD54 HAP1 PIGT (-) 2 cancer cell line human CVCL_TD54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14938; PIGT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136744 CVCL_TD57 HAP1 PIK3C2A (-) 2 cancer cell line human CVCL_TD57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8971; PIK3C2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136745 CVCL_TD56 HAP1 PIK3C2A (-) 1 cancer cell line human CVCL_TD56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8971; PIK3C2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136746 CVCL_TD59 HAP1 PIK3C2B (-) 2 cancer cell line human CVCL_TD59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8972; PIK3C2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136747 CVCL_TD58 HAP1 PIK3C2B (-) 1 cancer cell line human CVCL_TD58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8972; PIK3C2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136748 CVCL_TD40 HAP1 PI4KB (-) 1 cancer cell line human CVCL_TD40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8984; PI4KB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136749 CVCL_TD42 HAP1 PIAS1 (-) cancer cell line human CVCL_TD42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2752; PIAS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136750 CVCL_TD41 HAP1 PI4KB (-) 2 cancer cell line human CVCL_TD41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8984; PI4KB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21136751 CVCL_TD44 HAP1 PIAS2 (-) 2 cancer cell line human CVCL_TD44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17311; PIAS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136752 CVCL_TD43 HAP1 PIAS2 (-) 1 cancer cell line human CVCL_TD43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17311; PIAS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136753 CVCL_TD46 HAP1 PIEZO1 (-) 2 cancer cell line human CVCL_TD46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28993; PIEZO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136754 CVCL_TD45 HAP1 PIEZO1 (-) 1 cancer cell line human CVCL_TD45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28993; PIEZO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136755 CVCL_TD48 HAP1 PIGA (-) 1 cancer cell line human CVCL_TD48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8957; PIGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136756 CVCL_TD47 HAP1 PIF1 (-) cancer cell line human CVCL_TD47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26220; PIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136757 CVCL_TD49 HAP1 PIGA (-) 2 cancer cell line human CVCL_TD49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8957; PIGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136758 CVCL_KJ98 PCRP-RBM8A-1A5 hybridoma house mouse CVCL_KJ98 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9Y5S9; Human RBM8A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136759 CVCL_KJ97 PCRP-RBBP5-1C3 hybridoma house mouse CVCL_KJ97 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15291; Human RBBP5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136760 CVCL_KJ99 PCRP-RBM8A-1B4 hybridoma house mouse CVCL_KJ99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y5S9; Human RBM8A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136761 CVCL_TD31 HAP1 PHLPP1 (-) 1 cancer cell line human CVCL_TD31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20610; PHLPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136762 CVCL_TD30 HAP1 PHKG2 (-) cancer cell line human CVCL_TD30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8931; PHKG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136763 CVCL_TD33 HAP1 PHLPP2 (-) 1 cancer cell line human CVCL_TD33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29149; PHLPP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136764 CVCL_TD32 HAP1 PHLPP1 (-) 2 cancer cell line human CVCL_TD32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20610; PHLPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136765 CVCL_TD35 HAP1 PHLPP2 (-) 3 cancer cell line human CVCL_TD35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29149; PHLPP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136766 CVCL_TD34 HAP1 PHLPP2 (-) 2 cancer cell line human CVCL_TD34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29149; PHLPP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136767 CVCL_TD37 HAP1 PI4K2A (-) 2 cancer cell line human CVCL_TD37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30031; PI4K2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136768 CVCL_TD36 HAP1 PI4K2A (-) 1 cancer cell line human CVCL_TD36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30031; PI4K2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136769 CVCL_TD39 HAP1 PI4K2B (-) 2 cancer cell line human CVCL_TD39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18215; PI4K2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136770 CVCL_TD38 HAP1 PI4K2B (-) 1 cancer cell line human CVCL_TD38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18215; PI4K2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136771 CVCL_9V52 LCL-PI 8 transformed cell line human CVCL_9V52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136772 CVCL_9V51 LCL-PI 7 transformed cell line human CVCL_9V51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136773 CVCL_9V54 LCL-PI 12 transformed cell line human CVCL_9V54 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21136774 CVCL_9V53 LCL-PI 11 transformed cell line human CVCL_9V53 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21136775 CVCL_9V50 LCL-PI 6 transformed cell line human CVCL_9V50 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136776 CVCL_9V49 LCL-PI 5 transformed cell line human CVCL_9V49 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136777 CVCL_9V48 LCL-PI 4 transformed cell line human CVCL_9V48 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136778 CVCL_9V45 HNFF-PI 8 finite cell line human CVCL_9V45 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21136779 CVCL_9V44 HBMF-SPH finite cell line human CVCL_9V44 CL:0000010 Derived from sampling site: Bone marrow. Unspecified 21136780 CVCL_9V47 LCL-PI 1 transformed cell line human CVCL_9V47 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136781 CVCL_9V46 LCL CL-PI 50 transformed cell line human CVCL_9V46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136782 CVCL_9V63 LCL-PI 129 transformed cell line human CVCL_9V63 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136783 CVCL_9V62 LCL-PI 117 transformed cell line human CVCL_9V62 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136784 CVCL_9V65 LCL-PI 146 transformed cell line human CVCL_9V65 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136785 CVCL_9V64 LCL-PI 133 transformed cell line human CVCL_9V64 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136786 CVCL_9V61 LCL-PI 104 transformed cell line human CVCL_9V61 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136787 CVCL_9V60 LCL-PI 101 transformed cell line human CVCL_9V60 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136788 CVCL_9V59 LCL-PI 78 transformed cell line human CVCL_9V59 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Indicated as originating from a healthy female in NCBI_Iran=C289, but the STR profile is that of a male 21136789 CVCL_9V56 LCL-PI 35 transformed cell line human CVCL_9V56 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21136790 CVCL_9V55 LCL-PI 33 transformed cell line human CVCL_9V55 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136791 CVCL_9V58 LCL-PI 65 transformed cell line human CVCL_9V58 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136792 CVCL_9V57 LCL-PI 58 transformed cell line human CVCL_9V57 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136793 CVCL_9V30 KDI/20 cancer cell line human CVCL_9V30 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Pleural effusion. Female 21136794 CVCL_9V32 B6B11 hybrid cell line CVCL_9V32 CL:0000010 Doubling time: 20-22 hours (PubMed=12454369). Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12481 21136795 CVCL_9V31 GC-3spc(ts) conditionally immortalized cell line house mouse CVCL_9V31 CL:0000010 Transfected with: MGI; MGI:98834; Trp53 (with p.Ala132Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatocyte.; Breed/subspecies: BALB/c. Male 21136796 CVCL_9V27 7E2 hybrid cell line house mouse CVCL_9V27 CL:0000010 Group: Hybridoma fusion partner cell line. 21136797 CVCL_9V26 HM-5 [Pig/mouse/bovine heteromyeloma] hybrid cell line CVCL_9V26 CL:0000010 Group: Hybridoma fusion partner cell line. 21136798 CVCL_9V29 K4IM transformed cell line human CVCL_9V29 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Synovium Cell type=Fibroblast-like synoviocyte.. Male 21136799 CVCL_9V28 IRKHBK spontaneously immortalized cell line CVCL_9V28 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Holstein. Male 21136800 CVCL_9V23 HM-2 [Pig/mouse/bovine heteromyeloma] hybrid cell line CVCL_9V23 CL:0000010 Group: Hybridoma fusion partner cell line. 21136801 CVCL_9V22 HM-1 [Pig/mouse heteromyeloma] hybrid cell line CVCL_9V22 CL:0000010 Group: Hybridoma fusion partner cell line. 21136802 CVCL_9V25 HM-4 hybrid cell line CVCL_9V25 CL:0000010 Group: Hybridoma fusion partner cell line. 21136803 CVCL_9V24 HM-3 [Pig/mouse/bovine heteromyeloma] hybrid cell line CVCL_9V24 CL:0000010 Group: Hybridoma fusion partner cell line. 21136804 CVCL_9V41 H209/CP cancer cell line human CVCL_9V41 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Cys706Phe (c.2117G>T); ClinVar=VCV000376330; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Male 21136805 CVCL_9V40 GC-6spg transformed cell line Norway rat CVCL_9V40 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatogonial stem cell.; Breed/subspecies: Wistar. Male 21136806 CVCL_9V43 TY-E cancer cell line human CVCL_9V43 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21136807 CVCL_9V42 H209/VP cancer cell line human CVCL_9V42 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Cys706Phe (c.2117G>T); ClinVar=VCV000376330; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Male 21136808 CVCL_9V38 Thr.C1-PI 33 cancer cell line human CVCL_9V38 CL:0000010 Population: Iranian; Derived from sampling site: Thyroid gland. Female 21136809 CVCL_9V37 XTUU D10 hybrid cell line CVCL_9V37 CL:0000010 Group: Hybridoma fusion partner cell line. 21136810 CVCL_9V39 GC-5spg transformed cell line Norway rat CVCL_9V39 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Spermatogonial stem cell.; Breed/subspecies: Wistar. Male 21136811 CVCL_9V34 MFP-2 hybrid cell line CVCL_9V34 CL:0000010 Doubling time: 20-22 hours (PubMed=12454369). Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12482 21136812 CVCL_9V33 HFLF-PI 4 finite cell line human CVCL_9V33 CL:0000010 Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21136813 CVCL_9V36 XTUU 139/30 hybrid cell line CVCL_9V36 CL:0000010 Group: Hybridoma fusion partner cell line. 21136814 CVCL_9V35 SFTF-PI 43 finite cell line CVCL_9V35 CL:0000010 Derived from sampling site: Fetal testis Cell type=Fibroblast.. Male 21136815 CVCL_9V10 CB-HIV2 hybridoma CVCL_9V10 CL:0000010 Monoclonal antibody isotype: IgG1. Doubling time: 24-28 hours (PubMed=2828478) 21136816 CVCL_9V05 71-31 transformed cell line human CVCL_9V05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HIV-1 p24 21136817 CVCL_9V04 50-69 transformed cell line human CVCL_9V04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: HIV-1 gp41 21136818 CVCL_9V07 98-6 transformed cell line human CVCL_9V07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: HIV-1 gp41 21136819 CVCL_9V06 98-43 transformed cell line human CVCL_9V06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: HIV-1 gp41 21136820 CVCL_9V01 FMS cancer cell line human CVCL_9V01 CL:0000010 Unspecified 21136821 CVCL_9V00 DL [Human melanoma] cancer cell line human CVCL_9V00 CL:0000010 Unspecified 21136822 CVCL_9V03 91-5 transformed cell line human CVCL_9V03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HIV-1 p24 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10038 21136823 CVCL_9V02 126-6 transformed cell line human CVCL_9V02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: HIV-1 gp41 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10037 21136824 CVCL_9V09 CB-HIV1 hybridoma CVCL_9V09 CL:0000010 Monoclonal antibody isotype: IgG1. Doubling time: 24-28 hours (PubMed=2828478) 21136825 CVCL_9V08 CB-F7 hybrid cell line CVCL_9V08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain. Group: Hybridoma fusion partner cell line 21136826 CVCL_9V21 SPM4-0 hybrid cell line CVCL_9V21 CL:0000010 Group: Hybridoma fusion partner cell line. 21136827 CVCL_9V20 SPAM-8 hybrid cell line CVCL_9V20 CL:0000010 Group: Hybridoma fusion partner cell line. 21136828 CVCL_9V16 CT26-DsRed cancer cell line house mouse CVCL_9V16 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21136829 CVCL_9V15 CRE8 transformed cell line human CVCL_9V15 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21136830 CVCL_9V18 DFW cancer cell line human CVCL_9V18 CL:0000010 Unspecified 21136831 CVCL_9V17 DFB cancer cell line human CVCL_9V17 CL:0000010 Unspecified 21136832 CVCL_9V12 1-A2 hybridoma CVCL_9V12 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Varicella-zoster virus (VZV). 21136833 CVCL_9V11 SBC-H21 hybrid cell line CVCL_9V11 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8463 21136834 CVCL_9V14 293/KDR transformed cell line human CVCL_9V14 CL:0000010 Transfected with: HGNC; 6307; KDR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21136835 CVCL_9V13 2-1D5 hybridoma CVCL_9V13 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: Varicella-zoster virus (VZV). 21136836 CVCL_9V19 HAB-1 hybrid cell line CVCL_9V19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Doubling time: 25-30 hours (PubMed=2223577) Group: Hybridoma fusion partner cell line 21136837 CVCL_TC90 HAP1 PEG10 (-) 1 cancer cell line human CVCL_TC90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14005; PEG10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136838 CVCL_TC92 HAP1 PELO (-) 2 cancer cell line human CVCL_TC92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8829; PELO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136839 CVCL_TC91 HAP1 PELO (-) 1 cancer cell line human CVCL_TC91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8829; PELO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136840 CVCL_TC94 HAP1 PEX13 (-) 2 cancer cell line human CVCL_TC94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8855; PEX13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136841 CVCL_TC93 HAP1 PEX13 (-) 1 cancer cell line human CVCL_TC93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8855; PEX13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136842 CVCL_TC96 HAP1 PFKFB3 (-) 2 cancer cell line human CVCL_TC96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8874; PFKFB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136843 CVCL_TC95 HAP1 PFKFB3 (-) 1 cancer cell line human CVCL_TC95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8874; PFKFB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136844 CVCL_TC98 HAP1 PFN2 (-) 1 cancer cell line human CVCL_TC98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8882; PFN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136845 CVCL_TC97 HAP1 PFN1 (-) 1 cancer cell line human CVCL_TC97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8881; PFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136846 CVCL_TC99 HAP1 PGAP3 (-) cancer cell line human CVCL_TC99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23719; PGAP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21136847 CVCL_C166 BL-89 cancer cell line human CVCL_C166 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21136848 CVCL_BP66 ND13708 transformed cell line human CVCL_BP66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136849 CVCL_C165 BL-79 cancer cell line human CVCL_C165 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21136850 CVCL_BP65 ND13686 transformed cell line human CVCL_BP65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136851 CVCL_BP68 ND13726 transformed cell line human CVCL_BP68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136852 CVCL_C168 PCI-02 cancer cell line human CVCL_C168 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male 21136853 CVCL_BP67 ND13712 transformed cell line human CVCL_BP67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136854 CVCL_C167 PCI-01 cancer cell line human CVCL_C167 CL:0000010 Derived from sampling site: Larynx. Male 21136855 CVCL_BP69 ND13747 transformed cell line human CVCL_BP69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136856 CVCL_C169 PCI-03 cancer cell line human CVCL_C169 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00420 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=21868764). Originally thought to originate from a 50 year old male patient with a retromolar trigone squamous cell carcinoma. 21136857 CVCL_C160 BL-121 cancer cell line human CVCL_C160 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21136858 CVCL_BP60 ND13681 transformed cell line human CVCL_BP60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136859 CVCL_C162 BL-62 cancer cell line human CVCL_C162 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans north of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21136860 CVCL_BP62 ND13683 transformed cell line human CVCL_BP62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136861 CVCL_C161 BL-125 cancer cell line human CVCL_C161 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21136862 CVCL_BP61 ND13682 transformed cell line human CVCL_BP61 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136863 CVCL_C164 BL-73 cancer cell line human CVCL_C164 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21136864 CVCL_BP64 ND13685 transformed cell line human CVCL_BP64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136865 CVCL_C163 BL-65 cancer cell line human CVCL_C163 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female 21136866 CVCL_BP63 ND13684 transformed cell line human CVCL_BP63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136867 CVCL_BP77 ND13768 transformed cell line human CVCL_BP77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136868 CVCL_C177 PCI-09A cancer cell line human CVCL_C177 CL:0000010 Derived from sampling site: Oral cavity; tongue; base. Male 21136869 CVCL_BP76 ND13763 transformed cell line human CVCL_BP76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136870 CVCL_C176 PCI-08 cancer cell line human CVCL_C176 CL:0000010 Derived from metastatic site: Lymph node. Male 21136871 CVCL_BP79 ND13782 transformed cell line human CVCL_BP79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136872 CVCL_C179 PCI-10 [Human HNSCC] cancer cell line human CVCL_C179 CL:0000010 Derived from sampling site: Oral cavity; tongue; base. Male 21136873 CVCL_BP78 ND13770 transformed cell line human CVCL_BP78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136874 CVCL_C178 PCI-09B cancer cell line human CVCL_C178 CL:0000010 Derived from metastatic site: Lymph node. Male 21136875 CVCL_BP71 ND13750 transformed cell line human CVCL_BP71 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136876 CVCL_C171 PCI-04B cancer cell line human CVCL_C171 Genome ancestry: African=0.38%; Native American=0%; East Asian, North=1.29%; East Asian, South=0%; South Asian=0%; European, North=61.21%; European, South=37.12% (PubMed=30894373) CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21136877 CVCL_BP70 ND13748 transformed cell line human CVCL_BP70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136878 CVCL_C170 PCI-04A cancer cell line human CVCL_C170 CL:0000010 Derived from sampling site: Larynx. Male 21136879 CVCL_BP73 ND13754 transformed cell line human CVCL_BP73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136880 CVCL_C173 PCI-06A cancer cell line human CVCL_C173 Genome ancestry: African=0.89%; Native American=0%; East Asian, North=1.02%; East Asian, South=0%; South Asian=0.59%; European, North=68.64%; European, South=28.85% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Glu (c.50G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>T; ClinVar=VCV001264355; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Derived from sampling site: Oral cavity; tonsil. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21136881 CVCL_KJ07 PCRP-PHF21B-1A4 hybridoma house mouse CVCL_KJ07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96EK2; Human PHF21B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136882 CVCL_BP72 ND13753 transformed cell line human CVCL_BP72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136883 CVCL_C172 PCI-05 cancer cell line human CVCL_C172 CL:0000010 Derived from sampling site: Pharynx; hypopharynx. Male 21136884 CVCL_KJ06 PCRP-PHF19-2D9 hybridoma house mouse CVCL_KJ06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5T6S3; Human PHF19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136885 CVCL_BP75 ND13756 transformed cell line human CVCL_BP75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136886 CVCL_C175 PCI-07 cancer cell line human CVCL_C175 CL:0000010 Derived from sampling site: Oral cavity; tongue; base. Male 21136887 CVCL_KJ09 PCRP-PHF7-1A1 hybridoma house mouse CVCL_KJ09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BWX1; Human PHF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136888 CVCL_BP74 ND13755 transformed cell line human CVCL_BP74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136889 CVCL_C174 PCI-06B cancer cell line human CVCL_C174 CL:0000010 Derived from metastatic site: Lymph node. Male 21136890 CVCL_KJ08 PCRP-PHF21B-1G3 hybridoma house mouse CVCL_KJ08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96EK2; Human PHF21B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136891 CVCL_KJ03 PCRP-PHF17-1H6 hybridoma house mouse CVCL_KJ03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6IE81; Human JADE1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136892 CVCL_KJ02 PCRP-PHF10-2A10 hybridoma house mouse CVCL_KJ02 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8WUB8; Human PHF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136893 CVCL_KJ05 PCRP-PHF19-2C7 hybridoma house mouse CVCL_KJ05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q5T6S3; Human PHF19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136894 CVCL_KJ04 PCRP-PHF19-2B8 hybridoma house mouse CVCL_KJ04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5T6S3; Human PHF19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136895 CVCL_KJ01 PCRP-PGD-1A2 hybridoma house mouse CVCL_KJ01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52209; Human PGD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136896 CVCL_KJ00 PCRP-PGBD1-4C8 hybridoma house mouse CVCL_KJ00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JS3; Human PGBD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21136897 CVCL_C144 BL-32 cancer cell line human CVCL_C144 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21136898 CVCL_BP44 ND13626 transformed cell line human CVCL_BP44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136899 CVCL_C143 BL-31 cancer cell line human CVCL_C143 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672) Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21136900 CVCL_BP43 ND13625 transformed cell line human CVCL_BP43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136901 CVCL_C146 BL-36 cancer cell line human CVCL_C146 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw. Female Virology: Contains a complete EBV genome (strain BL36) which has been sequenced (PubMed=25787276) Also contains from 5 to 10 episomal copies of EBV (PubMed=8382295). 21136902 CVCL_BP46 ND13629 transformed cell line human CVCL_BP46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136903 CVCL_C145 BL-35 cancer cell line human CVCL_C145 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21136904 CVCL_BP45 ND13628 transformed cell line human CVCL_BP45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136905 CVCL_C148 BL-38 cancer cell line human CVCL_C148 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21136906 CVCL_BP48 ND13632 transformed cell line human CVCL_BP48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136907 CVCL_C147 BL-37 cancer cell line human CVCL_C147 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6422306); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=1915267; PubMed=2052620) Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Virology: Contains a complete EBV genome (strain BL37) which has been sequenced (PubMed=25787276) 21136908 CVCL_BP47 ND13631 transformed cell line human CVCL_BP47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136909 CVCL_C149 BL-40 cancer cell line human CVCL_C149 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21136910 CVCL_BP49 ND13633 transformed cell line human CVCL_BP49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136911 CVCL_C140 BL-22 cancer cell line human CVCL_C140 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Female 21136912 CVCL_BP40 ND13612 transformed cell line human CVCL_BP40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136913 CVCL_C142 BL-30 cancer cell line human CVCL_C142 HLA typing: A*01:01,11:01; B*08:01,39:01; C*02:02,07:01; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:01,13:01 (PubMed=25960936) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Unspecified (PubMed=1915267) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Virology: EBV-negative Doubling time: 15-24 hours, depending on cell density (DSMZ=ACC-916) 21136914 CVCL_BP42 ND13624 transformed cell line human CVCL_BP42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136915 CVCL_C141 BL-29 cancer cell line human CVCL_C141 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672) Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21136916 CVCL_BP41 ND13615 transformed cell line human CVCL_BP41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136917 CVCL_C155 BL-64 cancer cell line human CVCL_C155 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=3458667; PubMed=22120970) Population: Africans north of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21136918 CVCL_BP55 ND13662 transformed cell line human CVCL_BP55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136919 CVCL_C154 BL-63 cancer cell line human CVCL_C154 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian Male Virology: EBV-negative. 21136920 CVCL_BP54 ND13642 transformed cell line human CVCL_BP54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136921 CVCL_C157 BL-72 cancer cell line human CVCL_C157 HLA typing: A*11,28; B*27,45 (PubMed=3037521) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Ile (c.218C>T); ClinVar=VCV000376300; Zygosity=Unspecified (PubMed=8108117) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21136922 CVCL_BP57 ND13667 transformed cell line human CVCL_BP57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136923 CVCL_C156 BL-67 cancer cell line human CVCL_C156 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro75Ser (c.223C>T); Zygosity=Unspecified (PubMed=8108117) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female 21136924 CVCL_BP56 ND13664 transformed cell line human CVCL_BP56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136925 CVCL_C159 CH22 cancer cell line human CVCL_C159 CL:0000010 Miscellaneous: STR profile from personal communication of Duan Z Derived from sampling site: Bone; sacrum. Female Doubling time: 33 hours (PubMed=22504929); 2.3 days (Chordoma_Foundation) 21136926 CVCL_BP59 ND13673 transformed cell line human CVCL_BP59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136927 CVCL_C158 BL-74 cancer cell line human CVCL_C158 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female 21136928 CVCL_BP58 ND13668 transformed cell line human CVCL_BP58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136929 CVCL_C151 BL-53 cancer cell line human CVCL_C151 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian Male Virology: EBV-negative. 21136930 CVCL_BP51 ND13638 transformed cell line human CVCL_BP51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136931 CVCL_C150 BL-49 cancer cell line human CVCL_C150 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=2052620); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=2052620) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Virology: EBV-negative 21136932 CVCL_BP50 ND13635 transformed cell line human CVCL_BP50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136933 CVCL_C153 BL-58 cancer cell line human CVCL_C153 HLA typing: A*03:01,03:01; B*15:10,15:10; C*04:01,04:01; DQA1*05:01,05:01; DQB1*02:01,02:01; DRB1*03:01,14:46 (PubMed=25960936) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian Omics: Transcriptome analysis by RNAseq. Unspecified Virology: EBV-negative 21136934 CVCL_BP53 ND13641 transformed cell line human CVCL_BP53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136935 CVCL_C152 BL-57 cancer cell line human CVCL_C152 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Virology: EBV-negative 21136936 CVCL_BP52 ND13639 transformed cell line human CVCL_BP52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136937 CVCL_BP29 ND13552 transformed cell line human CVCL_BP29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136938 CVCL_C129 PC12nnr6 cancer cell line Norway rat CVCL_C129 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21136939 CVCL_9V90 SFLSF-PI 36 finite cell line CVCL_9V90 CL:0000010 Derived from sampling site: Fetal liver and fetal spleen Cell type=Fibroblast.. Male 21136940 CVCL_9V96 HFSF-PI 3 finite cell line human CVCL_9V96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21136941 CVCL_BP22 ND13522 transformed cell line human CVCL_BP22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136942 CVCL_C122 SP-53 cancer cell line human CVCL_C122 HLA typing: A*02,24; B*40,56; C*03,04 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Doubling time: 57 hours (PubMed=11061568) 21136943 CVCL_9V95 HFLF-PI 5 finite cell line human CVCL_9V95 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21136944 CVCL_BP21 ND13520 transformed cell line human CVCL_BP21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136945 CVCL_C121 SP-50B transformed cell line human CVCL_C121 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Virology: Contains an EBV genome in a circular episomal form 21136946 CVCL_9V98 HGF2-PI 2 finite cell line human CVCL_9V98 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Unspecified 21136947 CVCL_BP24 ND13542 transformed cell line human CVCL_BP24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136948 CVCL_C124 SKH1 [Human leukemia] cancer cell line human CVCL_C124 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8313895). Population: Japanese Unspecified 21136949 CVCL_9V97 HGF1-PI 1 finite cell line human CVCL_9V97 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Female 21136950 CVCL_BP23 ND13539 transformed cell line human CVCL_BP23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136951 CVCL_C123 SSK41 cancer cell line human CVCL_C123 CL:0000010 Miscellaneous: Originally assigned to be from a follicular lymphoma Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified Characteristics: Expresses surface IgM but can spontaneously switch to the production of IgG1 or IgG3 21136952 CVCL_BP26 ND13544 transformed cell line human CVCL_BP26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136953 CVCL_C126 PC12nnr14 cancer cell line Norway rat CVCL_C126 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21136954 CVCL_9V92 SFTF-PI 40 finite cell line CVCL_9V92 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue Cell type=Fibroblast.. Male 21136955 CVCL_C125 AFLB8 transformed cell line Norway rat CVCL_C125 CL:0000010 Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Female 21136956 CVCL_BP25 ND13543 transformed cell line human CVCL_BP25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136957 CVCL_9V91 SFSF-PI 45 finite cell line CVCL_9V91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21136958 CVCL_9V94 HFFF-PI 6 finite cell line human CVCL_9V94 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21136959 CVCL_BP28 ND13550 transformed cell line human CVCL_BP28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136960 CVCL_C128 PC12nnr5 cancer cell line Norway rat CVCL_C128 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21136961 CVCL_BP27 ND13549 transformed cell line human CVCL_BP27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136962 CVCL_C127 PC12nnr3 cancer cell line Norway rat CVCL_C127 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21136963 CVCL_9V93 SFTF-PI 42 finite cell line CVCL_9V93 CL:0000010 Derived from sampling site: Fetal tail Cell type=Fibroblast.. Male 21136964 CVCL_9V89 SFLF-PI 35 finite cell line CVCL_9V89 CL:0000010 Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21136965 CVCL_9V88 SFKF-PI 37 finite cell line CVCL_9V88 CL:0000010 Derived from sampling site: Fetal kidney Cell type=Fibroblast.. Male 21136966 CVCL_C120 LF1 [Human fetal lung] finite cell line human CVCL_C120 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Senescence: Senesces at 48 PDL (PubMed=9242615) 21136967 CVCL_BP20 ND13519 transformed cell line human CVCL_BP20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136968 CVCL_C133 BL-116 cancer cell line human CVCL_C133 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21136969 CVCL_BP33 ND13595 transformed cell line human CVCL_BP33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136970 CVCL_C132 BL-113 cancer cell line human CVCL_C132 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=2052620) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21136971 CVCL_BP32 ND13593 transformed cell line human CVCL_BP32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136972 CVCL_C135 BL-13 cancer cell line human CVCL_C135 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21136973 CVCL_BP35 ND13598 transformed cell line human CVCL_BP35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136974 CVCL_C134 BL-126 cancer cell line human CVCL_C134 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21136975 CVCL_BP34 ND13597 transformed cell line human CVCL_BP34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136976 CVCL_C137 BL-16 cancer cell line human CVCL_C137 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans south of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Female Part of: Human variation panel 21136977 CVCL_BP37 ND13606 transformed cell line human CVCL_BP37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136978 CVCL_C136 BL-136 cancer cell line human CVCL_C136 From: International Agency of Research on Cancer (IARC); Lyon; France. CL:0000010 21136979 CVCL_BP36 ND13604 transformed cell line human CVCL_BP36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136980 CVCL_C139 BL-18 cancer cell line human CVCL_C139 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Ala (c.217A>G); Zygosity=Unspecified (PubMed=8108117) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Part of: Human variation panel 21136981 CVCL_BP39 ND13610 transformed cell line human CVCL_BP39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136982 CVCL_C138 BL-17 cancer cell line human CVCL_C138 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21136983 CVCL_BP38 ND13608 transformed cell line human CVCL_BP38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136984 CVCL_9V99 HGF3-PI 53 finite cell line human CVCL_9V99 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Unspecified 21136985 CVCL_C131 BL-10 cancer cell line human CVCL_C131 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian Male Virology: EBV-negative. 21136986 CVCL_BP31 ND13591 transformed cell line human CVCL_BP31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136987 CVCL_BP30 ND13589 transformed cell line human CVCL_BP30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136988 CVCL_C130 PC12-615 cancer cell line Norway rat CVCL_C130 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21136989 CVCL_BP08 ND13489 transformed cell line human CVCL_BP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136990 CVCL_C108 NTUe001-A embryonic stem cell human CVCL_C108 From: National Taiwan University; Taipei; Taiwan. CL:0000010 Female 21136991 CVCL_BP07 ND13488 transformed cell line human CVCL_BP07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21136992 CVCL_C107 XFiPS-F44-3F-2 induced pluripotent stem cell human CVCL_C107 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21136993 CVCL_BP09 ND13490 transformed cell line human CVCL_BP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136994 CVCL_C109 NTUe002-A embryonic stem cell human CVCL_C109 From: National Taiwan University; Taipei; Taiwan. CL:0000010 Female 21136995 CVCL_9V74 MCF-hGH cancer cell line human CVCL_9V74 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4261; GH1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21136996 CVCL_BP00 ND13478 transformed cell line human CVCL_BP00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21136997 CVCL_C100 WAe009-A-10 embryonic stem cell human CVCL_C100 From: Central South University; Changsha; China CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1. Female 21136998 CVCL_9V73 HM-5 [Human/mouse heteromyeloma] hybrid cell line CVCL_9V73 CL:0000010 Group: Hybridoma fusion partner cell line. 21136999 CVCL_C102 243H1 induced pluripotent stem cell human CVCL_C102 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Synovium Cell type=Fibroblast-like synoviocyte.. Male 21137000 CVCL_9V76 CC1-PI 19 cancer cell line human CVCL_9V76 CL:0000010 Female 21137001 CVCL_BP02 ND13480 transformed cell line human CVCL_BP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137002 CVCL_9V75 CHO CD28 spontaneously immortalized cell line CVCL_9V75 CL:0000010 Transfected with: HGNC; 1653; CD28 Derived from sampling site: Ovary. Female 21137003 CVCL_C101 ESe027-A embryonic stem cell human CVCL_C101 HLA typing: A*02; B*18; C*07; DQB1*03; DRB1*11 (Spanish_Stem_Cell_Bank). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21137004 CVCL_BP01 ND13479 transformed cell line human CVCL_BP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137005 CVCL_C104 ADA-iPS2 induced pluripotent stem cell human CVCL_C104 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.1050_1054delGAAGA; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21137006 CVCL_9V70 LCL-PI 184 transformed cell line human CVCL_9V70 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137007 CVCL_BP04 ND13483 transformed cell line human CVCL_BP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137008 CVCL_C103 243H7 induced pluripotent stem cell human CVCL_C103 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Synovium Cell type=Fibroblast-like synoviocyte.. Male 21137009 CVCL_BP03 ND13482 transformed cell line human CVCL_BP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137010 CVCL_9V72 HCL BMF-PI 51 finite cell line human CVCL_9V72 CL:0000010 Female 21137011 CVCL_BP06 ND13485 transformed cell line human CVCL_BP06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137012 CVCL_C106 XFiPS-F44-3F-1 induced pluripotent stem cell human CVCL_C106 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21137013 CVCL_C105 ADA-iPS3 induced pluripotent stem cell human CVCL_C105 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.1050_1054delGAAGA; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21137014 CVCL_BP05 ND13484 transformed cell line human CVCL_BP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137015 CVCL_9V71 WM1-LCL-PI 13 transformed cell line human CVCL_9V71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen Cell type=Lymphocyte.. Male 21137016 CVCL_9V67 LCL-PI 170 transformed cell line human CVCL_9V67 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137017 CVCL_9V66 LCL-PI 162 transformed cell line human CVCL_9V66 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137018 CVCL_9V69 LCL-PI 179 transformed cell line human CVCL_9V69 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137019 CVCL_9V68 LCL-PI 171 transformed cell line human CVCL_9V68 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137020 CVCL_C119 Hs 692(B).T cancer cell line human CVCL_C119 CL:0000010 Discontinued: ATCC; CRL-7429; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137021 CVCL_BP19 ND13517 transformed cell line human CVCL_BP19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137022 CVCL_C118 C7 spontaneously immortalized cell line house mouse CVCL_C118 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: 129/Sv-Trp53-/-. Male Characteristics: Can be induced to differentiate into osteoclasts (PubMed=9464281) Doubling time: ~80-100 hours (DSMZ=ACC-416) 21137023 CVCL_BP18 ND13514 transformed cell line human CVCL_BP18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137024 CVCL_BP11 ND13503 transformed cell line human CVCL_BP11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137025 CVCL_9V85 SFBF-PI 39 finite cell line CVCL_9V85 CL:0000010 Derived from sampling site: Fetal brain Cell type=Fibroblast.. Male 21137026 CVCL_C111 SYSUe004-A embryonic stem cell human CVCL_C111 From: Sun Yat-sen University Second Affiliated Hospital; Guangzhou; China. CL:0000010 Unspecified 21137027 CVCL_BP10 ND13502 transformed cell line human CVCL_BP10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137028 CVCL_C110 NTUe003-A embryonic stem cell human CVCL_C110 From: National Taiwan University; Taipei; Taiwan. CL:0000010 Male 21137029 CVCL_9V84 SFAF-PI 38 finite cell line CVCL_9V84 CL:0000010 Derived from sampling site: Fetal abdomen Cell type=Fibroblast.. Male 21137030 CVCL_BP13 ND13506 transformed cell line human CVCL_BP13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137031 CVCL_9V87 SFIF-PI 44 finite cell line CVCL_9V87 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Male 21137032 CVCL_C113 SYSUe006-A embryonic stem cell human CVCL_C113 From: Sun Yat-sen University Second Affiliated Hospital; Guangzhou; China. CL:0000010 Unspecified 21137033 CVCL_BP12 ND13505 transformed cell line human CVCL_BP12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137034 CVCL_9V86 SFBF-PI 41 finite cell line CVCL_9V86 CL:0000010 Derived from sampling site: Fetal bone Cell type=Fibroblast.. Male 21137035 CVCL_C112 SYSUe005-A embryonic stem cell human CVCL_C112 From: Sun Yat-sen University Second Affiliated Hospital; Guangzhou; China. CL:0000010 Unspecified 21137036 CVCL_C115 Elf1 embryonic stem cell human CVCL_C115 From: University of Washington; Seattle; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0156 21137037 CVCL_9V81 HTHCL-PI 47 transformed cell line human CVCL_9V81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137038 CVCL_BP15 ND13511 transformed cell line human CVCL_BP15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137039 CVCL_9V80 HSF-PI 19 finite cell line human CVCL_9V80 CL:0000010 Derived from sampling site: Skin. Female 21137040 CVCL_BP14 ND13510 transformed cell line human CVCL_BP14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137041 CVCL_C114 Relicell hES4 embryonic stem cell human CVCL_C114 From: Reliance Life Sciences, Ltd; Navi Mumbai; India. CL:0000010 Male 21137042 CVCL_9V83 HNCF-PI 52 finite cell line human CVCL_9V83 CL:0000010 Derived from sampling site: Uterus; cervix. Female 21137043 CVCL_C117 HUSTe001-A embryonic stem cell human CVCL_C117 From: Huazhong University of Science and Technology Tongji Medicine College; Wuhan; China. CL:0000010 Female 21137044 CVCL_BP17 ND13513 transformed cell line human CVCL_BP17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137045 CVCL_9V82 HHCL-PI 48 cancer cell line human CVCL_9V82 CL:0000010 Derived from sampling site: Peripheral blood. Male 21137046 CVCL_C116 MA141 embryonic stem cell human CVCL_C116 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Unspecified 21137047 CVCL_BP16 ND13512 transformed cell line human CVCL_BP16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137048 CVCL_9V78 HSF-PI 17 finite cell line human CVCL_9V78 CL:0000010 Derived from sampling site: Skin. Female 21137049 CVCL_9V77 HSF-PI 16 finite cell line human CVCL_9V77 CL:0000010 Derived from sampling site: Skin. Female 21137050 CVCL_9V79 HSF-PI 18 finite cell line human CVCL_9V79 CL:0000010 Derived from sampling site: Skin. Female 21137051 CVCL_BI07 ND11775 transformed cell line human CVCL_BI07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137052 CVCL_BI06 ND11774 transformed cell line human CVCL_BI06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137053 CVCL_BI09 ND11777 transformed cell line human CVCL_BI09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137054 CVCL_BI08 ND11776 transformed cell line human CVCL_BI08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137055 CVCL_BI01 ND11764 transformed cell line human CVCL_BI01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137056 CVCL_BI00 ND11762 transformed cell line human CVCL_BI00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137057 CVCL_BI03 ND11767 transformed cell line human CVCL_BI03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137058 CVCL_BI02 ND11765 transformed cell line human CVCL_BI02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137059 CVCL_BI05 ND11773 transformed cell line human CVCL_BI05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137060 CVCL_BI04 ND11768 transformed cell line human CVCL_BI04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137061 CVCL_BI18 ND11808 transformed cell line human CVCL_BI18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137062 CVCL_BI17 ND11807 transformed cell line human CVCL_BI17 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (PubMed=22572540) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137063 CVCL_BI19 ND11809 transformed cell line human CVCL_BI19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137064 CVCL_BI10 ND11778 transformed cell line human CVCL_BI10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137065 CVCL_BI12 ND11780 transformed cell line human CVCL_BI12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137066 CVCL_BI11 ND11779 transformed cell line human CVCL_BI11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137067 CVCL_BI14 ND11782 transformed cell line human CVCL_BI14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137068 CVCL_BI13 ND11781 transformed cell line human CVCL_BI13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137069 CVCL_BI16 ND11785 transformed cell line human CVCL_BI16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137070 CVCL_BI15 ND11783 transformed cell line human CVCL_BI15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137071 CVCL_0U92 GM15847 transformed cell line human CVCL_0U92 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[760]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137072 CVCL_1692 SH-4 cancer cell line human CVCL_1692 HLA typing: A*02:01,26:01; B*51:01,56:01; C*01:02,15:02 (PubMed=26589293); Genome ancestry: African=2.19%; Native American=0.74%; East Asian, North=4.52%; East Asian, South=0%; South Asian=0%; European, North=64.08%; European, South=28.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 31 +- 1.1 hours (PubMed=29275043); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137073 CVCL_0U91 GM14519 transformed cell line human CVCL_0U91 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[9]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~1285]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137074 CVCL_1691 SF539 cancer cell line human CVCL_1691 HLA typing: A*02:01:01; B*08,35; C*04,07; DPB1*01:01:01,04:01; DQB1*02:01,03:01:01; DRB1*03:01:01,12 (PubMed=15748285); HLA typing: A*02:01,02:01; B*08:01,35:03; C*04:01,07:01 (PubMed=26589293); Genome ancestry: African=1.47%; Native American=1.68%; East Asian, North=1.5%; East Asian, South=2.04%; South Asian=6.93%; European, North=25.95%; European, South=60.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Thr116Leufs*8 (c.346_349delACTT); Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Glufs*3 (c.1024delC); ClinVar=VCV000428885; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain; right temporo-parietal lobe. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.4 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137075 CVCL_0U94 GM15849 transformed cell line human CVCL_0U94 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[920]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137076 CVCL_1694 SIG-M5 cancer cell line human CVCL_1694 HLA typing: A*01:01,24:02; B*07:02,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=2.46%; Native American=0%; East Asian, North=4.98%; East Asian, South=0%; South Asian=0%; European, North=48.84%; European, South=43.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~72 hours (DSMZ=ACC-468); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137077 CVCL_0U93 GM15848 transformed cell line human CVCL_0U93 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137078 CVCL_1693 SHP-77 cancer cell line human CVCL_1693 HLA typing: A*02:01,24:02; B*40:08,54:01; C*03:08,07:01 (PubMed=26589293); Genome ancestry: African=3.14%; Native American=0.63%; East Asian, North=3.39%; East Asian, South=0%; South Asian=0%; European, North=49.1%; European, South=43.74% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Val1128Glu (c.3383T>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Tyr32Cys (c.95A>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Trp (c.528C>G); ClinVar=VCV000376572; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 85 hours (PubMed=212181); 96 hours (ECACC=98110201); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21137079 CVCL_0U96 GM21070 transformed cell line human CVCL_0U96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21137080 CVCL_0U95 GM16201 transformed cell line human CVCL_0U95 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[450]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[640]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137081 CVCL_1695 SiMa cancer cell line human CVCL_1695 HLA typing: A*03:01,03:01; B*40:01,51:01; C*06:02,12:02 (PubMed=26589293); Genome ancestry: African=0.65%; Native American=0%; East Asian, North=2.52%; East Asian, South=0%; South Asian=1.24%; European, North=63.44%; European, South=32.14% (PubMed=30894373). CL:0000010 Biotechnology: Used in a bioassay to measure botulinum toxin serotype A (BoNT/B) activity Together with the monoclonal antibody produced by hybridoma 2E2A6 (Cellosaurus=CVCL_RA98).; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48-100 hours (PubMed=10686945); ~34-100 hours, highly variable (DSMZ=ACC-164); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137082 CVCL_0U98 GM16205 transformed cell line human CVCL_0U98 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~530]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137083 CVCL_1698 SK-MG-1 cancer cell line human CVCL_1698 Genome ancestry: African=2.66%; Native American=0.87%; East Asian, North=0.78%; East Asian, South=2.54%; South Asian=8.48%; European, North=25.75%; European, South=58.92% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg2635Ter (c.7903C>T); ClinVar=VCV000196692; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; IFO50344; probable. Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00345 Problematic cell line: Contaminated Shown to be a Marcus derivative (PubMed=20143388). 21137084 CVCL_0U97 GM16204 transformed cell line human CVCL_0U97 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[350]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137085 CVCL_1697 SJSA-1 cancer cell line human CVCL_1697 HLA typing: A*30:02,74:01; B*07:06,57:03; C*15:05,18:02 (PubMed=26589293); Genome ancestry: African=90.72%; Native American=0%; East Asian, North=1.2%; East Asian, South=0%; South Asian=0%; European, North=2.05%; European, South=6.03% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792) Population: African American; Derived from sampling site: Bone; femur. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137086 CVCL_0U99 GM16218 transformed cell line human CVCL_0U99 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137087 CVCL_1699 SK-MM-2 cancer cell line human CVCL_1699 HLA typing: A*30,68; B*49,51; C*07,07 (PubMed=25688540); HLA typing: A*30:01,68:01; B*49:01,51:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=3.65%; Native American=0%; East Asian, North=2.84%; East Asian, South=0%; South Asian=3.06%; European, North=38.09%; European, South=52.35% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 1582; CCND1 + HGNC; 5477; IGH; Name(s)=IGH-CCND1 (PubMed=8695815); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces Ig kappa Doubling time: 60 hours (PubMed=2506399); 85 hours (PubMed=25984343); ~100 hours (DSMZ=ACC-430); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1989-002 21137088 CVCL_0U70 AG22858 finite cell line house mouse CVCL_0U70 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137089 CVCL_1670 RT-112 cancer cell line human CVCL_1670 HLA typing: A*26:01,26:01; B*08:01,27:05; C*01:02,01:02; DRB1*03:17,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.6%; East Asian, South=0%; South Asian=0%; European, North=65.6%; European, South=32.8% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (PubMed=25485619; PubMed=28855393); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=3708594); 25 hours (PubMed=25984343); 25.7 hours (PubMed=26055179); 21.6 +- 0.1 hours (PubMed=2144165); ~35 hours (DSMZ=ACC-418); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21137090 CVCL_0U72 AG22874 finite cell line house mouse CVCL_0U72 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137091 CVCL_1672 RVH-421 cancer cell line human CVCL_1672 Genome ancestry: African=0.31%; Native American=0%; East Asian, North=2.07%; East Asian, South=0%; South Asian=1.58%; European, North=67.75%; European, South=28.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52fs*71 (c.154delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~54 hours (PubMed=6838761); ~50-60 hours (DSMZ=ACC-127); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137092 CVCL_0U71 AG22866 finite cell line house mouse CVCL_0U71 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137093 CVCL_1671 RTSG cancer cell line human CVCL_1671 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; IFO50318; true Female Doubling time: 48 hours (PubMed=2083225) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00423 Problematic cell line: Contaminated Shown to be a SNG-II derivative (JCRB). Originally thougth to originate from the pleural effusion of a 66 year old female patient with metastatic ovarian epithelial carcinoma. 21137094 CVCL_0U74 AG22890 finite cell line house mouse CVCL_0U74 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137095 CVCL_1674 S-117 cancer cell line human CVCL_1674 HLA typing: A*01:01,01:01; B*37:01,37:01; C*06:02,06:02; DQA1*05:01,05:01; DRB1*11:30,14:76 (PubMed=26589293); Genome ancestry: African=3.26%; Native American=0%; East Asian, North=3.68%; East Asian, South=0%; South Asian=0%; European, North=51.13%; European, South=41.93% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu326Ter (c.976G>T); ClinVar=VCV000231815; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: ~37 hours (DSMZ=ACC-266); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137096 CVCL_0U73 AG22882 finite cell line house mouse CVCL_0U73 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137097 CVCL_1673 RXF 393L cancer cell line human CVCL_1673 HLA typing: A*02,24; B*14:01,44; C*05,08:02; DPB1*01:01:01,04:01; DQB1*03:01:01,06:02; DRB1*11:01:01,15:01:01 (PubMed=15748285); Genome ancestry: African=0.51%; Native American=0.1%; East Asian, North=0%; East Asian, South=0.68%; South Asian=3.61%; European, North=57.95%; European, South=37.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 62.9 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137098 CVCL_0U76 IAC/hPPE transformed cell line Norway rat CVCL_0U76 CL:0000010 Transfected with: HGNC; 8831; PENK Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. 21137099 CVCL_1676 SBC-1 cancer cell line human CVCL_1676 Genome ancestry: African=0%; Native American=0.47%; East Asian, North=73.66%; East Asian, South=25.87%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Gly48Ter (c.142G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu112Ter (c.334G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys120Ter (c.358A>T); ClinVar=VCV000012363; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0676; true Male Doubling time: 20.4 hours (PubMed=8286010); ~40 hours (lot 11012007) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Possibly misidentified/contaminated Shown to be identical to SBC-2 (JCRB web site and STR profile). 21137100 CVCL_0U75 AG23017 finite cell line house mouse CVCL_0U75 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137101 CVCL_1675 SAS cancer cell line human CVCL_1675 HLA typing: A*24; B*52:01; C*12:02 (PubMed=9178645); Genome ancestry: African=1.4%; Native American=0%; East Asian, North=79.62%; East Asian, South=16.48%; South Asian=1.04%; European, North=0%; European, South=1.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 33 hours (PubMed=24627082); ~30 hours (lot 07312007), ~21 hours (lot 08022016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137102 CVCL_0U78 GM17629 transformed cell line human CVCL_0U78 CL:0000010 Population: Mexican-American (from Los Angeles); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21137103 CVCL_1678 SBC-3 cancer cell line human CVCL_1678 Genome ancestry: African=0%; Native American=0.39%; East Asian, North=77.93%; East Asian, South=21.68%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=3012965); 21.6 hours (PubMed=8286010; PubMed=9615743; PubMed=10628341); 14 hours (PubMed=9914787); ~30 hours (lots 012699 and 07262007), ~21 hours (lot 09082011) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137104 CVCL_0U77 AG22846 finite cell line house mouse CVCL_0U77 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137105 CVCL_1677 SBC-2 [Human contaminated bladder carcinoma] cancer cell line human CVCL_1677 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: DSMZ; ACC-228; true Female Doubling time: ~40 hours (DSMZ=ACC-228) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00156 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from an urinary bladder carcinoma. 21137106 CVCL_0U79 AG22787 finite cell line house mouse CVCL_0U79 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137107 CVCL_1679 SBC-5 cancer cell line human CVCL_1679 HLA typing: A*02:07,33:03; B*46:01,58:01; C*01:02,03:02; DQB1*06:07,06:07; DRB1*13:02,14:46 (PubMed=26589293); Genome ancestry: African=0.28%; Native American=0%; East Asian, North=78.17%; East Asian, South=20.72%; South Asian=0.15%; European, North=0.14%; European, South=0.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2901; DLG2; Unexplicit; Ex7-9del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=10536175; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (DOI=10.4044/joma1947.104.9-10_905); 31.6 hours (PubMed=8286010); ~40 hours (lot 111898), 21 hours (lot 08082007), ~21 hours (lot 09142018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137108 CVCL_0U90 AG07946 finite cell line human CVCL_0U90 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21137109 CVCL_1690 SF295 cancer cell line human CVCL_1690 HLA typing: A*01:01:01,26:01; B*07:02:01,55:01; C*03,07; DPB1*04:01; DQB1*05:03:01,06:02; DRB1*14,15 (PubMed=15748285); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.31%; East Asian, South=0%; South Asian=0%; European, North=72.83%; European, South=25.86% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=15900046; PubMed=17088437; PubMed=18277095) Derived from sampling site: Brain; left temporal lobe. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=25984343); 27.9 hours (PubMed=22628656); 31.5 hours (PubMed=17984197); 29.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137110 CVCL_0U81 AG10076 finite cell line human CVCL_0U81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: SV40-transformed but with a finite life span 21137111 CVCL_1681 SCC-15 cancer cell line human CVCL_1681 HLA typing: A*01:01,01:01; B*08:01,51:01; C*07:01,14:02; DQA1*04:01,04:01; DQB1*04:02,04:02; DRB1*03:01,08:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.32%; East Asian, South=0%; South Asian=0%; European, North=67.04%; European, South=30.64% (PubMed=30894373) CL:0000010 Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0218; probable Male Doubling time: 1.5-1.7 days (PubMed=6201865); 1.93 + 0.19 days (PubMed=27664486); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel; Part of: TCGA-110-CL cell line panel 21137112 CVCL_0U80 MCF-7/HER2-18 cancer cell line human CVCL_0U80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21137113 CVCL_1680 SBC-7 [Human contaminated bladder carcinoma] cancer cell line human CVCL_1680 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: DSMZ; ACC-229; true Female Doubling time: ~15-17 hours (DSMZ=ACC-229) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00157 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from an urinary bladder carcinoma. 21137114 CVCL_0U83 AG05322 finite cell line human CVCL_0U83 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21137115 CVCL_1683 SCC-3 cancer cell line human CVCL_1683 HLA typing: A*02:01,26:02; B*35:01,40:06; C*03:03,08:01; DQB1*04:01,04:01 (PubMed=26589293); Genome ancestry: African=4.47%; Native American=0%; East Asian, North=76.44%; East Asian, South=12.26%; South Asian=0%; European, North=0%; European, South=6.83% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~2 days (PubMed=3095281); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137116 CVCL_0U82 AG10589 transformed cell line human CVCL_0U82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137117 CVCL_1682 SCC-25 cancer cell line human CVCL_1682 HLA typing: A*02:01,02:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=2.72%; Native American=0.24%; East Asian, North=4.71%; East Asian, South=0%; South Asian=0%; European, North=56.41%; European, South=35.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 2.4 + 0.16 days (PubMed=27664486); 32.8 +- 2.4 hours (PubMed=29423072); ~50 hours (DSMZ=ACC-617); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel; Part of: TCGA-110-CL cell line panel 21137118 CVCL_0U85 AG05325 transformed cell line human CVCL_0U85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG05325; probable Male 21137119 CVCL_1685 SCC-9 cancer cell line human CVCL_1685 HLA typing: A*01:01,02:01; B*35:03,44:03; C*04:01,16:02; DQA1*01:02,05:02; DRB1*01:16,13:14 (PubMed=26589293); Genome ancestry: African=0.25%; Native American=0.1%; East Asian, North=1.78%; East Asian, South=0.03%; South Asian=6.17%; European, North=30.07%; European, South=61.6% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274_Glu285del (c.820_851del32); Zygosity=Unspecified (PubMed=1423286; PubMed=25275298) Derived from sampling site: Oral cavity; tongue; anterior part. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB0718; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21137120 CVCL_0U84 AG05324 finite cell line human CVCL_0U84 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21137121 CVCL_1684 SCC-4 cancer cell line human CVCL_1684 HLA typing: A*02:01,02:01; B*07:02,44:03; C*04:01,07:02; DQA1*01:02,02:01; DQB1*02:02,06:02; DRB1*07:01,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0%; East Asian, South=1.1%; South Asian=0.53%; European, North=69.79%; European, South=28.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=8390283) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB0745; true Male Doubling time: ~60-70 hours (DSMZ=ACC-618); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137122 CVCL_0U87 AG05327 transformed cell line human CVCL_0U87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137123 CVCL_1687 SCH cancer cell line human CVCL_1687 Genome ancestry: African=0%; Native American=0%; East Asian, North=77.74%; East Asian, South=22.24%; South Asian=0.01%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249dup (c.745_747dupAGG) (p.Arg249_Pro250insArg) (c.747_748insAGG); Zygosity=Heterozygous (PubMed=7819056; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 54 hours (CelloPub=CLPUB00142); 36-37 hours (CelloPub=CLPUB00584); ~1.5 days (lot 07022010) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137124 CVCL_0U86 AG05326 finite cell line human CVCL_0U86 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21137125 CVCL_1686 SCCH-26 cancer cell line human CVCL_1686 CL:0000010 Population: Japanese Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 3 days (lot 03082000) (JCRB) 21137126 CVCL_0U89 AG06205 finite cell line human CVCL_0U89 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21137127 CVCL_1689 SF268 cancer cell line human CVCL_1689 HLA typing: A*01:01:01,32:01; B*08:01,40:02; C*02:02:02,07; DPB1*04:01,06:01; DQB1*02:01,03:02; DRB1*03,04 (PubMed=15748285); HLA typing: A*01:01,32:01; B*08:01,40:02; C*02:02,07:01 (PubMed=26589293); Genome ancestry: African=0.25%; Native American=0.34%; East Asian, North=0.35%; East Asian, South=0%; South Asian=1.04%; European, North=65.25%; European, South=32.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=15900046; PubMed=17088437; PubMed=18277095) Derived from sampling site: Brain; right parietal lobe. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 33.1 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21137128 CVCL_0U88 AG06204 transformed cell line human CVCL_0U88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137129 CVCL_1688 SF126 cancer cell line human CVCL_1688 HLA typing: A*02:01,24:02; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=0.24%; Native American=0%; East Asian, North=1.63%; East Asian, South=0%; South Asian=2.77%; European, North=51.32%; European, South=44.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Arg1653Ter (c.4957C>T); ClinVar=VCV000224559; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Arg (c.385G>A); ClinVar=VCV000189484; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro75Hisfs*13 (c.224_750del); Zygosity=Heterozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Brain; left frontal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours (PubMed=25984343); ~28 hours (lot 06202011) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137130 CVCL_KC24 PCRP-ARNTL-1C12 hybridoma house mouse CVCL_KC24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00327; Human BMAL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137131 CVCL_KC23 PCRP-ARNT2-1A3 hybridoma house mouse CVCL_KC23 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HBZ2; Human ARNT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137132 CVCL_KC26 PCRP-ASF1A-1H3 hybridoma house mouse CVCL_KC26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y294; Human ASF1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137133 CVCL_KC25 PCRP-ASCL4-2G8 hybridoma house mouse CVCL_KC25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6XD76; Human ASCL4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137134 CVCL_KC20 PCRP-ARID3A-1E9 hybridoma house mouse CVCL_KC20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99856; Human ARID3A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137135 CVCL_KC22 PCRP-ARNT-2D12 hybridoma house mouse CVCL_KC22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27540; Human ARNT. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137136 CVCL_KC21 PCRP-ARNT-2D11 hybridoma house mouse CVCL_KC21 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27540; Human ARNT. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137137 CVCL_BI87 ND12028 transformed cell line human CVCL_BI87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137138 CVCL_BI86 ND12027 transformed cell line human CVCL_BI86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137139 CVCL_BI89 ND12035 transformed cell line human CVCL_BI89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137140 CVCL_BI88 ND12034 transformed cell line human CVCL_BI88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137141 CVCL_BI81 ND12011 transformed cell line human CVCL_BI81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137142 CVCL_BI80 ND12008 transformed cell line human CVCL_BI80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137143 CVCL_BI83 ND12015 transformed cell line human CVCL_BI83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137144 CVCL_KC17 PCRP-ANKZF1-1C11 hybridoma house mouse CVCL_KC17 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H8Y5; Human ANKZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137145 CVCL_BI82 ND12012 transformed cell line human CVCL_BI82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137146 CVCL_KC16 PCRP-ANKZF1-1A12 hybridoma house mouse CVCL_KC16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H8Y5; Human ANKZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137147 CVCL_BI85 ND12025 transformed cell line human CVCL_BI85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137148 CVCL_KC19 PCRP-ARID2-1A1 hybridoma house mouse CVCL_KC19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q68CP9; Human ARID2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137149 CVCL_BI84 ND12017 transformed cell line human CVCL_BI84 CL:0000010 Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137150 CVCL_KC18 PCRP-ANKZF1-1C6 hybridoma house mouse CVCL_KC18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H8Y5; Human ANKZF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137151 CVCL_KC35 PCRP-ATRX-1E4 hybridoma house mouse CVCL_KC35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46100; Human ATRX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137152 CVCL_KC34 PCRP-ATF7-2C10 hybridoma house mouse CVCL_KC34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17544; Human ATF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137153 CVCL_KC37 PCRP-BACH1-2G3 hybridoma house mouse CVCL_KC37 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14867; Human BACH1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137154 CVCL_KC36 PCRP-BACH1-1A2 hybridoma house mouse CVCL_KC36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14867; Human BACH1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137155 CVCL_KC31 PCRP-ATAD2-2D9 hybridoma house mouse CVCL_KC31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137156 CVCL_KC30 PCRP-ATAD2-2C3 hybridoma house mouse CVCL_KC30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137157 CVCL_KC33 PCRP-ATF2-1B4 hybridoma house mouse CVCL_KC33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15336; Human ATF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137158 CVCL_KC32 PCRP-ATAD2-2E5 hybridoma house mouse CVCL_KC32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137159 CVCL_BI98 ND12052 transformed cell line human CVCL_BI98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137160 CVCL_BI97 ND12051 transformed cell line human CVCL_BI97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137161 CVCL_BI99 ND12053 transformed cell line human CVCL_BI99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137162 CVCL_BI90 ND12036 transformed cell line human CVCL_BI90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137163 CVCL_BI92 ND12046 transformed cell line human CVCL_BI92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137164 CVCL_BI91 ND12038 transformed cell line human CVCL_BI91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137165 CVCL_BI94 ND12048 transformed cell line human CVCL_BI94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137166 CVCL_KC28 PCRP-ATAD2-1F12 hybridoma house mouse CVCL_KC28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137167 CVCL_BI93 ND12047 transformed cell line human CVCL_BI93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137168 CVCL_KC27 PCRP-ATAD2-1D11 hybridoma house mouse CVCL_KC27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137169 CVCL_BI96 ND12050 transformed cell line human CVCL_BI96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137170 CVCL_BI95 ND12049 transformed cell line human CVCL_BI95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137171 CVCL_KC29 PCRP-ATAD2-2A8 hybridoma house mouse CVCL_KC29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6PL18; Human ATAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137172 CVCL_KC02 PCRP-ABTB1-1C5 hybridoma house mouse CVCL_KC02 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q969K4; Human ABTB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137173 CVCL_KC01 AS11 hybridoma house mouse CVCL_KC01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09525; Human ANXA4. 21137174 CVCL_KC04 PCRP-AKNA-1C7 hybridoma house mouse CVCL_KC04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z591; Human AKNA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137175 CVCL_KC03 PCRP-AGO3-1C5 hybridoma house mouse CVCL_KC03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H9G7; Human AGO3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137176 CVCL_KC00 MX hybridoma house mouse CVCL_KC00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01112; Human HRAS Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9158 Caution: This is a mixture of 5 different hybridoma cell lines: M8, M30, M38, M70 and M90. 21137177 CVCL_BI65 ND11931 transformed cell line human CVCL_BI65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137178 CVCL_BI64 ND11930 transformed cell line human CVCL_BI64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137179 CVCL_BI67 ND11933 transformed cell line human CVCL_BI67 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137180 CVCL_BI66 ND11932 transformed cell line human CVCL_BI66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137181 CVCL_BI69 ND11935 transformed cell line human CVCL_BI69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137182 CVCL_BI68 ND11934 transformed cell line human CVCL_BI68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137183 CVCL_BI61 ND11922 transformed cell line human CVCL_BI61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137184 CVCL_BI60 ND11917 transformed cell line human CVCL_BI60 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137185 CVCL_BI63 ND11926 transformed cell line human CVCL_BI63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137186 CVCL_BI62 ND11923 transformed cell line human CVCL_BI62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137187 CVCL_KC13 PCRP-ANAPC2-4F2 hybridoma house mouse CVCL_KC13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137188 CVCL_KC12 PCRP-ANAPC2-3H7 hybridoma house mouse CVCL_KC12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137189 CVCL_KC15 PCRP-ANKHD1-1B3 hybridoma house mouse CVCL_KC15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HA95; Human ANKHD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137190 CVCL_KC14 PCRP-ANAPC2-5F1 hybridoma house mouse CVCL_KC14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137191 CVCL_KC11 PCRP-ANAPC2-3H3 hybridoma house mouse CVCL_KC11 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137192 CVCL_KC10 PCRP-ANAPC2-3F7 hybridoma house mouse CVCL_KC10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137193 CVCL_BI76 ND11970 transformed cell line human CVCL_BI76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137194 CVCL_BI75 ND11943 transformed cell line human CVCL_BI75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137195 CVCL_BI78 ND11972 transformed cell line human CVCL_BI78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137196 CVCL_BI77 ND11971 transformed cell line human CVCL_BI77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137197 CVCL_BI79 ND11974 transformed cell line human CVCL_BI79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137198 CVCL_KC09 PCRP-ANAPC2-3D1 hybridoma house mouse CVCL_KC09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137199 CVCL_BI70 ND11936 transformed cell line human CVCL_BI70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137200 CVCL_BI72 ND11938 transformed cell line human CVCL_BI72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137201 CVCL_KC06 PCRP-ANAPC2-2D1 hybridoma house mouse CVCL_KC06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137202 CVCL_BI71 ND11937 transformed cell line human CVCL_BI71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137203 CVCL_KC05 PCRP-ANAPC2-2B6 hybridoma house mouse CVCL_KC05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137204 CVCL_BI74 ND11941 transformed cell line human CVCL_BI74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137205 CVCL_KC08 PCRP-ANAPC2-2F2 hybridoma house mouse CVCL_KC08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137206 CVCL_BI73 ND11939 transformed cell line human CVCL_BI73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137207 CVCL_KC07 PCRP-ANAPC2-2D2 hybridoma house mouse CVCL_KC07 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UJX6; Human ANAPC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137208 CVCL_BI43 ND11883 transformed cell line human CVCL_BI43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137209 CVCL_BI42 ND11881 transformed cell line human CVCL_BI42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137210 CVCL_BI45 ND11887 transformed cell line human CVCL_BI45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137211 CVCL_BI44 ND11886 transformed cell line human CVCL_BI44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137212 CVCL_BI47 ND11894 transformed cell line human CVCL_BI47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137213 CVCL_BI46 ND11889 transformed cell line human CVCL_BI46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137214 CVCL_BI49 ND11896 transformed cell line human CVCL_BI49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137215 CVCL_BI48 ND11895 transformed cell line human CVCL_BI48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137216 CVCL_BI41 ND11880 transformed cell line human CVCL_BI41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137217 CVCL_BI40 ND11879 transformed cell line human CVCL_BI40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137218 CVCL_BI54 ND11911 transformed cell line human CVCL_BI54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137219 CVCL_BI53 ND11901 transformed cell line human CVCL_BI53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137220 CVCL_BI56 ND11913 transformed cell line human CVCL_BI56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137221 CVCL_BI55 ND11912 transformed cell line human CVCL_BI55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137222 CVCL_BI58 ND11915 transformed cell line human CVCL_BI58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137223 CVCL_BI57 ND11914 transformed cell line human CVCL_BI57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137224 CVCL_BI59 ND11916 transformed cell line human CVCL_BI59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137225 CVCL_BI50 ND11897 transformed cell line human CVCL_BI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137226 CVCL_BI52 ND11900 transformed cell line human CVCL_BI52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137227 CVCL_BI51 ND11898 transformed cell line human CVCL_BI51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137228 CVCL_BI29 ND11838 transformed cell line human CVCL_BI29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137229 CVCL_BI28 ND11837 transformed cell line human CVCL_BI28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137230 CVCL_BI21 ND11817 transformed cell line human CVCL_BI21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137231 CVCL_BI20 ND11813 transformed cell line human CVCL_BI20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137232 CVCL_BI23 ND11821 transformed cell line human CVCL_BI23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137233 CVCL_BI22 ND11818 transformed cell line human CVCL_BI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137234 CVCL_BI25 ND11824 transformed cell line human CVCL_BI25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137235 CVCL_BI24 ND11823 transformed cell line human CVCL_BI24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137236 CVCL_BI27 ND11836 transformed cell line human CVCL_BI27 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137237 CVCL_BI26 ND11833 transformed cell line human CVCL_BI26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137238 CVCL_BI39 ND11878 transformed cell line human CVCL_BI39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137239 CVCL_BI32 ND11859 transformed cell line human CVCL_BI32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137240 CVCL_BI31 ND11858 transformed cell line human CVCL_BI31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137241 CVCL_BI34 ND11866 transformed cell line human CVCL_BI34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137242 CVCL_BI33 ND11863 transformed cell line human CVCL_BI33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137243 CVCL_BI36 ND11869 transformed cell line human CVCL_BI36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137244 CVCL_BI35 ND11867 transformed cell line human CVCL_BI35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137245 CVCL_BI38 ND11875 transformed cell line human CVCL_BI38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137246 CVCL_BI37 ND11871 transformed cell line human CVCL_BI37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137247 CVCL_BI30 ND11856 transformed cell line human CVCL_BI30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137248 CVCL_KB87 h5.1.3 hybridoma house mouse CVCL_KB87 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12640 21137249 CVCL_KB86 h5.1.2 hybridoma house mouse CVCL_KB86 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12627 21137250 CVCL_KB89 h5.2.2 hybridoma house mouse CVCL_KB89 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12634 21137251 CVCL_KB88 h5.2.1 hybridoma house mouse CVCL_KB88 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12626 21137252 CVCL_KB83 NGFR5 hybridoma house mouse CVCL_KB83 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08138; Human NGFR/CD271 (Note=Also reacts with many other mammalian species). 21137253 CVCL_KB82 8F8 hybridoma CVCL_KB82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04823; Rat Il3. 21137254 CVCL_KB85 h5.1.1 hybridoma house mouse CVCL_KB85 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12637 21137255 CVCL_KB84 V1 hybridoma house mouse CVCL_KB84 CL:0000010 Monoclonal antibody isotype: IgG1 Caution: Indicated in Patent=US4935344 to have been deposited at ATCC under the catalog number HB-8424 But HB-8424 is another patent deposition (Cellosaurus=CVCL_N310).. 21137256 CVCL_KB81 19B3 hybridoma CVCL_KB81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04823; Rat Il3. 21137257 CVCL_KB80 14A3 hybridoma CVCL_KB80 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04823; Rat Il3. 21137258 CVCL_KB98 h5.7.2 hybridoma house mouse CVCL_KB98 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12629 21137259 CVCL_KB97 h5.7.1 hybridoma house mouse CVCL_KB97 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12631 21137260 CVCL_KB99 h5.7.3 hybridoma house mouse CVCL_KB99 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12632 21137261 CVCL_KB94 h5.4 hybridoma house mouse CVCL_KB94 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12630 21137262 CVCL_KB93 h5.3.2 hybridoma house mouse CVCL_KB93 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12628 21137263 CVCL_KB96 h5.6 hybridoma house mouse CVCL_KB96 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12639 21137264 CVCL_KB95 h5.5 hybridoma house mouse CVCL_KB95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12635 21137265 CVCL_KB90 h5.2.3 hybridoma house mouse CVCL_KB90 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12636 21137266 CVCL_KB92 h5.3.1 hybridoma house mouse CVCL_KB92 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12633 21137267 CVCL_KB91 h5.2.4 hybridoma house mouse CVCL_KB91 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05113; Human IL5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12638 21137268 CVCL_KB69 LYK-3 hybridoma CVCL_KB69 CL:0000010 Discontinued: ATCC; HB-308; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21137269 CVCL_KB68 AO92 hybridoma house mouse CVCL_KB68 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8348 21137270 CVCL_KB65 AO10 hybridoma house mouse CVCL_KB65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human 110 kDa cell surface glycoprotein (Gp110). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8346 21137271 CVCL_KB64 AJ9 hybridoma house mouse CVCL_KB64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen MSK1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8340 21137272 CVCL_KB67 AO50 hybridoma house mouse CVCL_KB67 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8347 21137273 CVCL_KB66 AO122 hybridoma house mouse CVCL_KB66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16112; Human ACAN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8349 21137274 CVCL_KB61 AJ225 hybridoma house mouse CVCL_KB61 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8344 21137275 CVCL_KB60 AJ2 hybridoma house mouse CVCL_KB60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8338 21137276 CVCL_KB63 AJ60 hybridoma house mouse CVCL_KB63 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8343 21137277 CVCL_KB62 AJ425 hybridoma house mouse CVCL_KB62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen MSK10. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8345 21137278 CVCL_KB79 224-1A6-A1 hybridoma house mouse CVCL_KB79 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P13590; Chicken NCAM1. 21137279 CVCL_KB76 MECA-32 hybridoma CVCL_KB76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q91VC4; Mouse Plvap. 21137280 CVCL_KB75 JG1.1.20 hybridoma CVCL_KB75 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Human addressin (PNAd). 21137281 CVCL_KB78 186-NWT cancer cell line human CVCL_KB78 CL:0000010 Derived from metastatic site: Ascites. Female 21137282 CVCL_KB77 H572 hybridoma house mouse CVCL_KB77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H8L6; Human MMRN2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11608 21137283 CVCL_KB72 LAM-II hybridoma CVCL_KB72 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse laminin GP-2. 21137284 CVCL_KB71 LYK-15 hybridoma CVCL_KB71 CL:0000010 Discontinued: ATCC; HB-318; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21137285 CVCL_KB74 Hermes-1 hybridoma CVCL_KB74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21137286 CVCL_KB73 M1536-B3 cancer cell line house mouse CVCL_KB73 CL:0000010 Breed/subspecies: 129/Sv. Male 21137287 CVCL_KB70 LYK-14 hybridoma CVCL_KB70 CL:0000010 Discontinued: ATCC; HB-317; true. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21137288 CVCL_KB47 CellSensor NFkB-bla RA-1 cancer cell line human CVCL_KB47 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137289 CVCL_KB46 CellSensor NFkB-bla THP-1 cancer cell line human CVCL_KB46 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137290 CVCL_KB49 TOHK spontaneously immortalized cell line CVCL_KB49 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21137291 CVCL_KB48 CellSensor NFkB-bla Freestyle 293F transformed cell line human CVCL_KB48 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137292 CVCL_KB43 CellSensor NFkB-bla Jurkat cancer cell line human CVCL_KB43 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137293 CVCL_KB42 CellSensor NFAT-bla Jurkat cancer cell line human CVCL_KB42 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137294 CVCL_KB45 CellSensor NFkB-bla RAW 264.7 cancer cell line house mouse CVCL_KB45 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137295 CVCL_KB44 CellSensor NFkB-bla ME-180 cancer cell line human CVCL_KB44 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21137296 CVCL_KB41 CellSensor TrkC-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB41 CL:0000010 Transfected with: HGNC; 8033; NTRK3; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137297 CVCL_KB40 CellSensor TrkB-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB40 CL:0000010 Transfected with: HGNC; 8032; NTRK2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137298 CVCL_KB39 CellSensor TrkA-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB39 CL:0000010 Transfected with: HGNC; 8031; NTRK1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137299 CVCL_KB58 AJ10 hybridoma house mouse CVCL_KB58 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8341 21137300 CVCL_KB57 OP9-K stromal cell line house mouse CVCL_KB57 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene; Characteristics: Differentiates rapidly, robustly and reproducibly 21137301 CVCL_KB59 AJ17 hybridoma house mouse CVCL_KB59 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8342 21137302 CVCL_KB54 RTH1B2C cancer cell line CVCL_KB54 CL:0000010 Transformant: Dibenzo[a,l]pyrene (DBP)(ChEBI; CHEBI:35861); Derived from sampling site: Liver; Breed/subspecies: Shasta. Unspecified Doubling time: 4.5 +- 0.4 days, at 135th passage (PubMed=15311963) Group: Fish cell line 21137303 CVCL_KB53 RTH1B2A cancer cell line CVCL_KB53 CL:0000010 Transformant: Dibenzo[a,l]pyrene (DBP)(ChEBI; CHEBI:35861); Derived from sampling site: Liver; Breed/subspecies: Shasta. Unspecified Doubling time: 3.0 +- 0.2 days, at 135th passage (PubMed=15311963) Group: Fish cell line 21137304 CVCL_KB56 GloFish spontaneously immortalized cell line zebrafish CVCL_KB56 CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Abdomen; Breed/subspecies: GloFish. Unspecified Group: Fish cell line 21137305 CVCL_KB55 RTBrain spontaneously immortalized cell line CVCL_KB55 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21137306 CVCL_KB50 HK1532 spontaneously immortalized cell line CVCL_KB50 CL:0000010 Derived from sampling site: Head kidney. Unspecified Characteristics: IL15 dependent Group: Fish cell line 21137307 CVCL_KB52 RTH1B1D cancer cell line CVCL_KB52 CL:0000010 Transformant: Dibenzo[a,l]pyrene (DBP)(ChEBI; CHEBI:35861); Derived from sampling site: Liver; Breed/subspecies: Shasta. Unspecified Doubling time: 3.5 +- 0.2 days, at 135th passage (PubMed=15311963) Group: Fish cell line 21137308 CVCL_KB51 RTH1B1A cancer cell line CVCL_KB51 CL:0000010 Transformant: Dibenzo[a,l]pyrene (DBP)(ChEBI; CHEBI:35861); Derived from sampling site: Liver; Breed/subspecies: Shasta. Unspecified Doubling time: 3.9 +- 0.3 days, at 135th passage (PubMed=15311963) Group: Fish cell line 21137309 CVCL_KB25 MBr1 hybridoma house mouse CVCL_KB25 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:59296; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc (Globo-H). 21137310 CVCL_KB24 RTM cancer cell line CVCL_KB24 CL:0000010 Unspecified Group: Fish cell line. 21137311 CVCL_KB27 GeneBLAzer CCKBR-NFAT-bla HEK 293T transformed cell line human CVCL_KB27 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137312 CVCL_KB26 CellSensor NFAT-bla HEK 293T transformed cell line human CVCL_KB26 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137313 CVCL_KB21 MEM-53 hybridoma house mouse CVCL_KB21 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19397; Human CD53. 21137314 CVCL_KB20 MEM-56 hybridoma house mouse CVCL_KB20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21137315 CVCL_KB23 MARK-3 hybridoma house mouse CVCL_KB23 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Rat Ig kappa light chains (allotype IgK-1a). 21137316 CVCL_KB22 MEM-102 hybridoma house mouse CVCL_KB22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09326; Human CD48. 21137317 CVCL_BH88 ND11741 transformed cell line human CVCL_BH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137318 CVCL_BH87 ND11739 transformed cell line human CVCL_BH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137319 CVCL_BH89 ND11742 transformed cell line human CVCL_BH89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137320 CVCL_BH80 ND11727 transformed cell line human CVCL_BH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137321 CVCL_BH82 ND11730 transformed cell line human CVCL_BH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137322 CVCL_BH81 ND11728 transformed cell line human CVCL_BH81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137323 CVCL_KB18 HLR-CREB cancer cell line human CVCL_KB18 CL:0000010 Transfected with: HGNC; 2345; CREB1 (with del 281-341); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04386; Yeast GAL4 (with del 148-881) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Agilent Technologies/Stratagene; Catalog number: 800065 Female Characteristics: The luciferase reporter gene expression is under the control of a synthetic promoter containing 5 direct repeats of the 17-mer GAL4-binding site; Characteristics: Transfected with the activation domain of CREB1 fused to the yeast GAL4 DNA-binding domain 21137324 CVCL_BH84 ND11736 transformed cell line human CVCL_BH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137325 CVCL_KB17 HLR-CHOP cancer cell line human CVCL_KB17 CL:0000010 Transfected with: HGNC; 2726; DDIT3 (with del 102-169); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04386; Yeast GAL4 (with del 148-881) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Agilent Technologies/Stratagene; Catalog number: 800060 Female Characteristics: The luciferase reporter gene expression is under the control of a synthetic promoter containing 5 direct repeats of the 17-mer GAL4-binding site; Characteristics: Transfected with the activation domain of DDIT3 fused to the yeast GAL4 DNA-binding domain 21137326 CVCL_BH83 ND11735 transformed cell line human CVCL_BH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137327 CVCL_BH86 ND11738 transformed cell line human CVCL_BH86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137328 CVCL_KB19 HLR-Elk1 cancer cell line human CVCL_KB19 CL:0000010 Transfected with: HGNC; 3321; ELK1 (with del 1-307); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04386; Yeast GAL4 (with del 148-881) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Agilent Technologies/Stratagene; Catalog number: 800055 Female Characteristics: The luciferase reporter gene expression is under the control of a synthetic promoter containing 5 direct repeats of the 17-mer GAL4-binding site; Characteristics: Transfected with the activation domain of ELK1 fused to the yeast GAL4 DNA-binding domain 21137329 CVCL_BH85 ND11737 transformed cell line human CVCL_BH85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137330 CVCL_KB36 GeneBLAzer GPR10-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB36 CL:0000010 Transfected with: HGNC; 4464; PRLHR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137331 CVCL_KB35 GeneBLAzer Galpha15-NFAT-bla HEK 293T transformed cell line human CVCL_KB35 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137332 CVCL_KB38 GeneBLAzer M3-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB38 CL:0000010 Transfected with: HGNC; 1952; CHRM3; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137333 CVCL_KB37 GeneBLAzer GPR54-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB37 CL:0000010 Transfected with: HGNC; 4510; KISS1R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137334 CVCL_KB32 GeneBLAzer BDKRB1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB32 CL:0000010 Transfected with: HGNC; 1029; BDKRB1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137335 CVCL_KB31 GeneBLAzer ADRA1B-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB31 CL:0000010 Transfected with: HGNC; 278; ADRA1B; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137336 CVCL_KB34 GeneBLAzer EDNRA-NFAT-bla HEK 293T transformed cell line human CVCL_KB34 CL:0000010 Transfected with: HGNC; 3179; EDNRA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137337 CVCL_KB33 GeneBLAzer Bradykinin-B2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB33 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137338 CVCL_KB30 GeneBLAzer ADRA1A-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB30 CL:0000010 Transfected with: HGNC; 277; ADRA1A; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137339 CVCL_BH99 ND11760 transformed cell line human CVCL_BH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND11760; probable Male 21137340 CVCL_BH98 ND11758 transformed cell line human CVCL_BH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137341 CVCL_BH91 ND11744 transformed cell line human CVCL_BH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137342 CVCL_BH90 ND11743 transformed cell line human CVCL_BH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137343 CVCL_BH93 ND11750 transformed cell line human CVCL_BH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137344 CVCL_BH92 ND11749 transformed cell line human CVCL_BH92 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137345 CVCL_KB29 CellSensor NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KB29 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21137346 CVCL_BH95 ND11755 transformed cell line human CVCL_BH95 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137347 CVCL_KB28 HGrC1 transformed cell line human CVCL_KB28 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: Has FSH-responsive aromatase activity, inducible FSHR expression and responsiveness to the TGF-beta superfamily (PubMed=22467494) Doubling time: ~40 hours (PubMed=22467494) 21137348 CVCL_BH94 ND11754 transformed cell line human CVCL_BH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137349 CVCL_BH97 ND11757 transformed cell line human CVCL_BH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137350 CVCL_BH96 ND11756 transformed cell line human CVCL_BH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137351 CVCL_0U50 LiCo 16-88 spontaneously immortalized cell line human CVCL_0U50 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Female Monoclonal antibody isotype: IgM Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8495 21137352 CVCL_1650 Reh cancer cell line human CVCL_1650 HLA typing: A*23:01:01,32:01:01; B*35:02:01,50:01:01; C*04:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRA*01:02:02,01:02:02; DRB1*11:01:01,12:01:01 (DSMZCellDive=ACC-22); Genome ancestry: African=21.18%; Native American=0.09%; East Asian, North=1.57%; East Asian, South=2%; South Asian=1.52%; European, North=15.6%; European, South=58.04% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=8704231; PubMed=9067587; PubMed=15843827; PubMed=35354797); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep antibody staining analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ=ACC-22); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger); Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8286 21137353 CVCL_0U52 GM00028 finite cell line human CVCL_0U52 CL:0000010 Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Female 21137354 CVCL_1652 RERF-LC-Ad2 cancer cell line human CVCL_1652 Genome ancestry: African=0.21%; Native American=0%; East Asian, North=77.51%; East Asian, South=19.75%; South Asian=0%; European, North=0%; European, South=2.52% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Ala750delinsPro (c.2239_2248delinsC) (c.2239_2248TTAAGAGAAG>C); ClinVar=VCV000177684; Zygosity=Unspecified (PubMed=16105816); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0278; true Male Doubling time: ~2.4 days (lot 07022019) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21137355 CVCL_0U51 NALM-6/SP-B cancer cell line human CVCL_0U51 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90235; Spiruchostatin B (SP-B); Derived from sampling site: Peripheral blood. Male 21137356 CVCL_1651 RERF-LC-Ad1 cancer cell line human CVCL_1651 Genome ancestry: African=0%; Native American=0%; East Asian, North=76.75%; East Asian, South=22.67%; South Asian=0%; European, North=0%; European, South=0.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Phe (c.832_833CC>TT); Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0277; true Male Doubling time: ~65 hours (lot 04132008) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21137357 CVCL_0U54 GM19226 transformed cell line human CVCL_0U54 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137358 CVCL_1654 RERF-LC-KJ cancer cell line human CVCL_1654 HLA typing: A*24:02,26:01; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293); Genome ancestry: African=3.56%; Native American=0%; East Asian, North=81.6%; East Asian, South=9.57%; South Asian=0%; European, North=0%; European, South=5.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Valfs (c.670_671insTGTCT); Zygosity=Unspecified (PubMed=15901131) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0210; true. Male Doubling time: 56 hours (lot 092499), 53 hours (lot 070599) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137359 CVCL_0U53 GM19224 transformed cell line human CVCL_0U53 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137360 CVCL_1653 RERF-LC-FM cancer cell line human CVCL_1653 Genome ancestry: African=0.25%; Native American=0%; East Asian, North=77.86%; East Asian, South=20.45%; South Asian=0.87%; European, North=0%; European, South=0.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 58.9 hours (PubMed=8286010); 60 hours (lot 101698) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137361 CVCL_0U56 GM23250 finite cell line human CVCL_0U56 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Personal Genome Project (PGP) cell line collection 21137362 CVCL_1656 RERF-LC-Sq1 cancer cell line human CVCL_1656 Genome ancestry: African=0%; Native American=0%; East Asian, North=81.28%; East Asian, South=17.4%; South Asian=0%; European, North=0%; European, South=1.32% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0276; true Female Doubling time: 4-5 days (lot 09022008) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137363 CVCL_0U55 GM21846 transformed cell line human CVCL_0U55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21137364 CVCL_1655 RERF-LC-MS cancer cell line human CVCL_1655 HLA typing: A*11:01; B*54:01; C*01:02 (PubMed=9023415); HLA typing: A*11:01,11:01; B*54:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=1.74%; Native American=0.17%; East Asian, North=85.02%; East Asian, South=8.67%; South Asian=0%; European, North=0%; European, South=4.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 39.9 hours (PubMed=8286010); 42.7 hours (lot 012194), 30-38 hours (lot 08102009) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137365 CVCL_0U58 AG22795 finite cell line house mouse CVCL_0U58 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137366 CVCL_1658 EW-8 cancer cell line human CVCL_1658 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.08%; East Asian, South=0%; South Asian=0%; European, North=66.53%; European, South=32.38% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=17154184; PubMed=25010205); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg55Trp (c.163A>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=25010205; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=25984343); ~30-40 hours (DSMZ=ACC-493); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified Originally thought to be a rhabdomyosarcoma cell line but shown to be from an Ewing sarcoma (PubMed=17154184). 21137367 CVCL_0U57 GM21687 transformed cell line human CVCL_0U57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21137368 CVCL_1657 RF-48 cancer cell line human CVCL_1657 Genome ancestry: African=5.29%; Native American=31.68%; East Asian, North=3.25%; East Asian, South=0%; South Asian=2.87%; European, North=27.68%; European, South=29.24% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-1863; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Misclassified From a B-cell lymphoma and not from a gastric cancer (PubMed=12226758). 21137369 CVCL_0U59 AG22803 finite cell line house mouse CVCL_0U59 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137370 CVCL_1659 Rh18 cancer cell line human CVCL_1659 Genome ancestry: African=74.53%; Native American=0.16%; East Asian, North=4.19%; East Asian, South=0%; South Asian=0%; European, North=5.05%; European, South=16.06% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086; PubMed=23578105); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a immuno-deficient mice xenograft Doubling time: 83 hours (PubMed=20922763); ~60-70 hours (DSMZ=ACC-491); 65 hours (COG); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21137371 CVCL_0U61 AG22812 finite cell line house mouse CVCL_0U61 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137372 CVCL_1661 ZR-75-30 cancer cell line human CVCL_1661 HLA typing: A*03:01,23:01; B*07:02,35:08; C*04:01,07:02; DQB1*06:04,06:04 (PubMed=25960936); HLA typing: A*03:01,23:01; B*07:02,35:01; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=71.64%; Native American=0.74%; East Asian, North=3.41%; East Asian, South=0%; South Asian=0%; European, North=9.83%; European, South=14.38% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 622; APPBP2 + HGNC; 24280; PHF20L1; Name(s)=APPBP2-PHF20L1; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 14347; BCAS3 + HGNC; 5120; HOXB9; Name(s)=BCAS3-HOXB9 (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 2191; COL14A1 + HGNC; 15605; SKAP1; Name(s)=COL14A1-SKAP1; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 2746; DDX5 + HGNC; 22953; DEPTOR; Name(s)=DDX5-DEPTOR; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 14347; BCAS3 + HGNC; 3430; ERBB2; Name(s)=ERBB2-BCAS3; Note=Out of frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 3357; ENPP2 + HGNC; 9069; PLEC; Name(s)=PLEC-ENPP2, PLEC1-ENPP2; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 12929; PCGF2 + HGNC; 29259; TAOK1; Name(s)=TAOK1-PCGF2; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 8001; NRIP1 + HGNC; 11805; TIAM1; Name(s)=TIAM1-NRIP1; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 17399; ARHGAP32 + HGNC; 17312; TIMM23; Name(s)=TIMM23-ARHGAP32; Note=Out of frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 6513; LASP1 + HGNC; 12340; TRPS1; Name(s)=TRPS1-LASP1; Note=In frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 25989; CWC25 + HGNC; 19143; USP32; Name(s)=USP32-CWC25, USP32-CCDC49; Note=Out of frame (PubMed=23260012); Sequence variation: Gene fusion; HGNC; 8153; OPRD1 + HGNC; 13055; ZMYM4; Name(s)=ZMYM4-OPRD1; Note=Out of frame (PubMed=23260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Ile326Thr (c.977T>C); ClinVar=VCV000424419; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Glu243Ter (c.727G>T); Zygosity=Homozygous (PubMed=19593635) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 110 hours, at 17th passage (PubMed=688225); 60 hours (PubMed=25984343); 324.46 hours (GrayJW panel); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21137373 CVCL_0U60 AG22808 finite cell line house mouse CVCL_0U60 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137374 CVCL_1660 RL cancer cell line human CVCL_1660 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:03,01:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.05%; East Asian, North=0.17%; East Asian, South=0%; South Asian=1.47%; European, North=68.96%; European, South=28.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala138Pro (c.412G>C); ClinVar=VCV000012376; Zygosity=Homozygous (PubMed=17363600; Cosmic-CLP; DepMap) Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~5-8 days (DSMZ=ACC-613); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137375 CVCL_0U63 AG22824 finite cell line house mouse CVCL_0U63 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137376 CVCL_0U62 AG22816 finite cell line house mouse CVCL_0U62 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137377 CVCL_1662 RMG-I cancer cell line human CVCL_1662 HLA typing: A*24:02,24:02; B*40:02,40:02; C*03:04,03:04 (PubMed=25960936); HLA typing: A*24:02,24:02; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.61%; East Asian, North=81.67%; East Asian, South=17.3%; South Asian=0%; European, North=0.42%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Arg (c.174A>C) (p.Ser73Arg, c.217A>C); ClinVar=VCV000128200; Zygosity=Unspecified (PubMed=25846456); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0027; true Female Doubling time: 60 hours (PubMed=3154025); 40 hours (PubMed=25984343); ~3 days (lot 07022008), ~30 hours (lot 07052011), ~72 hours (lot 12252012), ~31 hours (lot 07142017), ~57 hours (lot 01212019), ~33 hours (lot 02042020) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137378 CVCL_0U65 AG22834 finite cell line house mouse CVCL_0U65 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137379 CVCL_1665 RPMI-6666 transformed cell line human CVCL_1665 HLA typing: A*02:01,03:01; B*07:02/15,18:01/05; C*07:02,07:01/06; DQB1*06:02/11; DRB1*15:01; DRB5*01 (PubMed=12133989); Genome ancestry: African=0%; Native American=0.17%; East Asian, North=0.15%; East Asian, South=0%; South Asian=0.52%; European, North=71.83%; European, South=27.33% (PubMed=30894373). CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00263 Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but is a B-lymphoblastoid cell line (PubMed=12592342; PubMed=20143388; PubMed=29533902). 21137380 CVCL_0U64 AG22830 finite cell line house mouse CVCL_0U64 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137381 CVCL_1664 RPMI-2650 cancer cell line human CVCL_1664 HLA typing: A*02,03; B*07,w22; C*w03,w06 (PubMed=77569); HLA typing: A*02:01,03:01; B*07:02,35:08; C*03:03,07:02 (PubMed=26589293); Genome ancestry: African=0.38%; Native American=0.9%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=68.78%; European, South=28.23% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 13575; BRD4 + HGNC; 29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT (PubMed=25485619) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40-50 hours (DSMZ=ACC-287); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel 21137382 CVCL_0U67 AG22842 finite cell line house mouse CVCL_0U67 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137383 CVCL_1667 RPMI-8402 cancer cell line human CVCL_1667 HLA typing: A*01:01,29:01; B*07:05,38:01; C*12:03,15:05 (PubMed=26589293); HLA typing: A*01:01:01,29:01:01; B*07:05:01,38:01:01; C*12:03:01,15:05:02 (DSMZCellDive=ACC-290); Genome ancestry: African=0.88%; Native American=0%; East Asian, North=2.78%; East Asian, South=0%; South Asian=0%; European, North=60.56%; European, South=35.77% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6641; LMO1 + HGNC; 12252; TRD; Name(s)=LMO1-TRD (PubMed=2501659; PubMed=29496689); Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=2255914; PubMed=29496689); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=22675565; PubMed=26870252; Cosmic-CLP); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-1994; true Female Characteristics: Genetically heterogenous Doubling time: ~48 hours (DSMZ=ACC-290); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21137384 CVCL_0U66 AG22838 finite cell line house mouse CVCL_0U66 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137385 CVCL_1666 RPMI-7951 cancer cell line human CVCL_1666 HLA typing: A*01:01,02:01; B*08:01,13:02; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.85%; East Asian, North=0.16%; East Asian, South=0%; South Asian=0%; European, North=64.75%; European, South=33.24% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=15467732; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser166Ter (c.497C>A); Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 30066; probable Female Doubling time: 50 hours (PubMed=1161259); ~60 hours (DSMZ=ACC-66); Microsatellite instability: Stable (MSS) (Sanger) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030); Part of: TCGA-110-CL cell line panel 21137386 CVCL_0U69 AG22854 finite cell line house mouse CVCL_0U69 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137387 CVCL_1669 SerW3 transformed cell line Norway rat CVCL_1669 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male Doubling time: ~40-50 hours (DSMZ=ACC-420) 21137388 CVCL_0U68 AG22850 finite cell line house mouse CVCL_0U68 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21137389 CVCL_1668 RPMI-8866 transformed cell line human CVCL_1668 HLA typing: A*02,03; B*07 (PubMed=6967232); Genome ancestry: African=0%; Native American=0.14%; East Asian, North=0%; East Asian, South=0%; South Asian=3.24%; European, North=67.29%; European, South=29.33% (PubMed=30894373) CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137390 CVCL_0U30 Onc-M10 hybridoma house mouse CVCL_0U30 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9244 21137391 CVCL_1630 P12-Ichikawa cancer cell line human CVCL_1630 HLA typing: A*02:01,24:02; B*52:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.9%; Native American=0.31%; East Asian, North=84.31%; East Asian, South=13.48%; South Asian=0%; European, North=0.65%; European, South=0.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly253Ser (c.757G>A); ClinVar=VCV000236647; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Ala1720_Val1721ins14 (c.5161_5162ins42); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=10071127; PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Heterozygous (PubMed=10071127; PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Pro (c.743G>C); ClinVar=VCV000237954; Zygosity=Heterozygous (PubMed=10071127; PubMed=22675565; Cosmic-CLP) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40-50 hours (DSMZ=ACC-34); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137392 CVCL_0U32 Onc-M12 hybridoma house mouse CVCL_0U32 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9246 21137393 CVCL_1632 P31/FUJ cancer cell line human CVCL_1632 HLA typing: A*02:06,31:01; B*48:01,51:01; C*08:01,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=79.39%; East Asian, South=20.61%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7132; KMT2A; Simple; p.Arg158fs*13 (c.472_473insTTCC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu7Ter (c.19G>T); ClinVar=VCV000493079; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.His208Arg (c.623A>G); Zygosity=Heterozygous (PubMed=23955599; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Cys (c.707A>G); ClinVar=VCV000376693; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~80 hours (PubMed=6962783); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: NRAS mutation indicated to be at p.Gly12Asp (c.35G>A) in PubMed=9379676 21137394 CVCL_0U31 Onc-M11 hybridoma house mouse CVCL_0U31 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9245 21137395 CVCL_1631 P30/OHK cancer cell line human CVCL_1631 Genome ancestry: African=0%; Native American=0%; East Asian, North=75.09%; East Asian, South=24.91%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 6997; MEF2D + HGNC; 17011; HNRNPUL1; Name(s)=MEF2D-HNRNPUL1 (PubMed=35354797) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (PubMed=6983990); ~30 hours (DSMZ=ACC-727); Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137396 CVCL_0U34 Onc-M16 hybridoma house mouse CVCL_0U34 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9216 21137397 CVCL_1634 Panc 02.13 cancer cell line human CVCL_1634 Genome ancestry: African=2.03%; Native American=0.98%; East Asian, North=0.28%; East Asian, South=0%; South Asian=0.04%; European, North=63.98%; European, South=32.69% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 33.9 hours (PubMed=9612602) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21137398 CVCL_0U33 Onc-M15 hybridoma house mouse CVCL_0U33 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9247 21137399 CVCL_1633 Panc 02.03 cancer cell line human CVCL_1633 HLA typing: A*02:05,31:01; B*08:01,49:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=1.78%; Native American=0.75%; East Asian, North=2.77%; East Asian, South=0%; South Asian=0%; European, North=59.53%; European, South=35.18% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9612602; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 28.2 hours (PubMed=9612602); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21137400 CVCL_0U36 Onc-M22 hybridoma house mouse CVCL_0U36 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9249 21137401 CVCL_1636 Panc 04.03 cancer cell line human CVCL_1636 HLA typing: A*32:01,32:01; B*27:05,27:05; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.36%; Native American=0.03%; East Asian, North=3.59%; East Asian, South=0%; South Asian=1.72%; European, North=75.12%; European, South=19.17% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 16935; ATG7 + HGNC; 9829; RAF1; Name(s)=ATG7-RAF1 (PubMed=23637631); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556fs*3 (c.4660_4661insA) (E1554fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9612602; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 50.5 hours (PubMed=9612602); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21137402 CVCL_0U35 Onc-M21 hybridoma house mouse CVCL_0U35 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9248 21137403 CVCL_1635 Panc 03.27 cancer cell line human CVCL_1635 HLA typing: A*02:01,24:02; B*07:02,56:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=1.16%; Native American=0%; East Asian, North=2.19%; East Asian, South=0%; South Asian=0.9%; European, North=56.57%; European, South=39.18% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+5G>T; ClinVar=VCV000634777; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37.5 hours (PubMed=9612602); 51 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: RAS genetic alteration cell panel (ATCC TCP-1031); Part of: TCGA-110-CL cell line panel 21137404 CVCL_0U38 Onc-M25 hybridoma house mouse CVCL_0U38 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9217 21137405 CVCL_1638 Panc 08.13 cancer cell line human CVCL_1638 HLA typing: A*02:01,02:01; B*07:02,15:40; C*02:02,05:01 (PubMed=26589293); Genome ancestry: African=2.26%; Native American=0.57%; East Asian, North=2.49%; East Asian, South=0%; South Asian=0%; European, North=62.31%; European, South=32.37% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=9612602; ATCC); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Cys123Metfs*2 (c.366dupA) (c.366_367insA); Zygosity=Homozygous (ATCC) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 20.0 hours (PubMed=9612602); 117 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21137406 CVCL_0U37 Onc-M23 hybridoma house mouse CVCL_0U37 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9250 21137407 CVCL_1637 Panc 05.04 cancer cell line human CVCL_1637 HLA typing: A*02:06,11:01; B*27:05,55:01; C*03:03,03:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.48%; East Asian, South=0%; South Asian=2.41%; European, North=67.06%; European, South=30.05% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9612602; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46.0 hours (PubMed=9612602) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00614 Problematic cell line: Partially contaminated Some stocks of this cell line such as the one used by Sanger cell line project were contaminated with OCUG-1 derivative (STR profile; DepMap SNP fingerprinting analysis). 21137408 CVCL_0U39 Onc-M26 hybridoma house mouse CVCL_0U39 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9212 21137409 CVCL_1639 Panc 10.05 cancer cell line human CVCL_1639 Genome ancestry: African=0.61%; Native American=1.14%; East Asian, North=0.96%; East Asian, South=0%; South Asian=0.11%; European, North=66.18%; European, South=31% (PubMed=30894373). From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=9612602; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Asn (c.764T>A); ClinVar=VCV000232289; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 19.2 hours (PubMed=9612602); 30 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21137410 CVCL_0U41 Onc-M29 hybridoma house mouse CVCL_0U41 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9210 21137411 CVCL_1641 PF-382 cancer cell line human CVCL_1641 HLA typing: A*01:01,11:01; B*08:01,44:02; C*05:01,07:06; DQB1*02:02,03:04; DRB1*03:05,12:27 (PubMed=26589293); Genome ancestry: African=0.02%; Native American=0%; East Asian, North=0.88%; East Asian, South=0.06%; South Asian=8.99%; European, North=36.79%; European, South=53.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2493fs*67 (c.7476_7477ins11); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Pleural effusion Cell type=T-cell.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 40 hours (PubMed=2410652); ~70 hours (DSMZ=ACC-38); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137412 CVCL_0U40 Onc-M27 hybridoma house mouse CVCL_0U40 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9229 21137413 CVCL_1640 PC-14 cancer cell line human CVCL_1640 HLA typing: A*02:06,24:02; B*39:01,55:01; C*03:03,07:02; DQB1*05:01,06:02; DRB1*01:01,15:05 (PubMed=26589293); Genome ancestry: African=0.88%; Native American=0%; East Asian, North=83.17%; East Asian, South=13.42%; South Asian=0.81%; European, North=0%; European, South=1.72% (PubMed=30894373) From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=15901131; Cosmic-CLP) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB0446; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Contaminated Shown to be a PC-9 derivative (RCB).; Caution: TP53 mutation indicated incorrectly as being at c.742C>T in PubMed=10536175 and PubMed=20557307 21137414 CVCL_1643 KYSE-110 cancer cell line human CVCL_1643 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Discontinued: JCRB; JCRB1064; probable Male Doubling time: 19.1 hours (PubMed=1728357) 21137415 CVCL_0U43 Onc-M30 hybridoma house mouse CVCL_0U43 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9211 21137416 CVCL_0U42 Onc-M29.41 hybridoma house mouse CVCL_0U42 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9243 21137417 CVCL_1642 PFSK-1 cancer cell line human CVCL_1642 Genome ancestry: African=0.31%; Native American=0%; East Asian, North=2.03%; East Asian, South=0%; South Asian=0.77%; European, North=66.34%; European, South=30.55% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Gly (c.823T>G); ClinVar=VCV001414106; Zygosity=Homozygous (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3 21137418 CVCL_0U45 Onc-M8 hybridoma house mouse CVCL_0U45 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9209 21137419 CVCL_1645 QIMR-WIL cancer cell line human CVCL_1645 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=0.26%; European, North=70.81%; European, South=28.92% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137420 CVCL_0U44 Onc-M38 hybridoma house mouse CVCL_0U44 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9365 21137421 CVCL_1644 PSN1 cancer cell line human CVCL_1644 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=83.56%; East Asian, South=16.44%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853; PubMed=18380791); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=3778442; PubMed=11787853; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (PubMed=1764370; PubMed=11787853; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a frozen tumor that had been stored at -80 Celsius for 1.5 years and which has then been passaged into a nude mice Doubling time: 21 hours (PubMed=3778442); 35 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21137422 CVCL_0U47 LiCo 6a3-1 hybridoma CVCL_0U47 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8493 21137423 CVCL_1647 RCC10RGB cancer cell line human CVCL_1647 HLA typing: A*02:06,24:02; B*39:01,54:01; C*01:02,07:02; DQA1*01:02,03:02; DQB1*04:01,06:02; DRB1*11:02,15:01 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=0%; East Asian, North=84.52%; East Asian, South=15.29%; South Asian=0%; European, North=0%; European, South=0.08% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137424 CVCL_1646 Ramos.2G6.4C10 cancer cell line human CVCL_1646 Genome ancestry: African=4.71%; Native American=43.61%; East Asian, North=3.64%; East Asian, South=0%; South Asian=0%; European, North=22.74%; European, South=25.29% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Virology: EBV-negative Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137425 CVCL_0U46 RPMI-4788 cancer cell line human CVCL_0U46 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; JCRB1309; true; Discontinued: JCRB; NIHS0553; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00387 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=23136038). 21137426 CVCL_0U49 LiCo 16-86 spontaneously immortalized cell line human CVCL_0U49 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Female Monoclonal antibody isotype: IgM Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8496 21137427 CVCL_1649 RD cancer cell line human CVCL_1649 HLA typing: A*01; B*08,w15 (PubMed=77569); HLA typing: A*01:01,01:01; B*37:01,37:01; C*06:02,06:02; DQA1*04:01,04:01; DQB1*06:04,06:04; DRB1*10:01,13:05 (PubMed=26589293); Genome ancestry: African=3.96%; Native American=0%; East Asian, North=4.77%; East Asian, South=0%; South Asian=0%; European, North=53.65%; European, South=37.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (PubMed=3158613; PubMed=12068308; PubMed=16518851; PubMed=22142829; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=2216456; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7713; true; Discontinued: ATCC; CRL-7731; true; Discontinued: ATCC; HTB-97; true Female Doubling time: 23 hours (PubMed=20922763); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21137428 CVCL_0U48 LiCo 7a4 hybridoma CVCL_0U48 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8494 21137429 CVCL_1648 RCM-1 [Human rectal adenocarcinoma] cancer cell line human CVCL_1648 HLA typing: A*24:02,24:02; B*51:01,54:01; C*01:02,14:02; DQA1*01:02,05:02; DQB1*05:01,05:01; DRB1*01:01,12:01 (PubMed=26589293); Genome ancestry: African=0.97%; Native American=0%; East Asian, North=75.44%; East Asian, South=22.81%; South Asian=0.01%; European, North=0%; European, South=0.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg216Ter (c.646C>T); ClinVar=VCV000127312; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Gln1740Ter (c.5218C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (PubMed=16418264; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 71.4 hours (PubMed=2570482); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21137430 CVCL_0U19 BRN-5 transformed cell line Norway rat CVCL_0U19 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137431 CVCL_1619 OCI-AML-2 cancer cell line human CVCL_1619 HLA typing: A*02:01,02:01; B*15:01,18:01; C*03:03,07:01 (PubMed=26589293); Genome ancestry: African=1.2%; Native American=0%; East Asian, North=1.51%; East Asian, South=0%; South Asian=2.28%; European, North=62.12%; European, South=32.89% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (PubMed=25485619) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: ATAC-seq; Omics: CTCF ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Hi-C sequencing; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=25984343); ~30-50 hours (DSMZ=ACC-99); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137432 CVCL_0U10 AD-iPS26B induced pluripotent stem cell human CVCL_0U10 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21137433 CVCL_1610 NOS-1 [Human osteosarcoma] cancer cell line human CVCL_1610 Genome ancestry: African=0%; Native American=0.97%; East Asian, North=79.98%; East Asian, South=18.61%; South Asian=0.44%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Bone; left proximal tibia. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Established from a xenograft established in a nude mice Doubling time: 49.6 hours (PubMed=1449054); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137434 CVCL_0U12 KP-2N cancer cell line human CVCL_0U12 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp415Glufs*20 (c.1245_1248delCAGA); ClinVar=VCV000142253; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Pancreas. Female 21137435 CVCL_1612 NUGC-3 cancer cell line human CVCL_1612 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02; DQA1*05:02,05:02; DQB1*06:01,06:01; DRB1*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.09%; East Asian, North=82.25%; East Asian, South=16.95%; South Asian=0%; European, North=0%; European, South=0.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=1370612) Population: Japanese; Derived from metastatic site: Brachialis muscle. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 38.2 hours (PubMed=3172586); ~26 hours (lot 06062005), 28-45 hours (lot 04272009), ~32 hours (lot 11042011), ~28 hours (lot 02262016), ~1 day (lot 11162017) (JCRB); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel; Part of: MD Anderson Cell Lines Project 21137436 CVCL_0U11 CEM/MX1 cancer cell line human CVCL_0U11 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: ATCC; CRL-2259; true Female 21137437 CVCL_1611 NUGC-2 cancer cell line human CVCL_1611 HLA typing: A*02:07,24:02; B*46:01,55:02; C*01:02,08:01; DQA1*03:02,03:02; DQB1*06:02,06:02; DRB1*08:02,09:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=74.56%; East Asian, South=24.67%; South Asian=0.16%; European, North=0%; European, South=0.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Thr58Ile (c.173C>T); ClinVar=VCV000012588; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Paragastric lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36.1 hours (PubMed=3172586) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21137438 CVCL_0U14 KMT-17 clone A3 cancer cell line Norway rat CVCL_0U14 CL:0000010 Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). 21137439 CVCL_1614 OAW28 cancer cell line human CVCL_1614 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.74%; Native American=0%; East Asian, North=2.29%; East Asian, South=0%; South Asian=1.87%; European, North=63.18%; European, South=31.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (PubMed=25230021) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37 hours (PubMed=2653399); ~60 hours, at 20th passage (PubMed=8795574); 53.97 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21137440 CVCL_0U13 KP-3N cancer cell line human CVCL_0U13 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Glu538Ter (c.1612G>T); ClinVar=VCV000581974; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male 21137441 CVCL_1613 NY cancer cell line human CVCL_1613 HLA typing: A*26:01; B*55:02; C*03:03 (PubMed=15289353); Genome ancestry: African=0.02%; Native American=0.2%; East Asian, North=78.63%; East Asian, South=19.14%; South Asian=0.88%; European, North=0.59%; European, South=0.55% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Bone; right femur. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 21 days, at 18th passage (PubMed=6596455); ~60 hours (lot 091198), ~30 hours (lot 09262016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137442 CVCL_0U16 BRN-2 transformed cell line Norway rat CVCL_0U16 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137443 CVCL_1616 OC 314 cancer cell line human CVCL_1616 Genome ancestry: African=0%; Native American=1.66%; East Asian, North=1.17%; East Asian, South=0%; South Asian=0%; European, North=75.37%; European, South=21.79% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 10447; RRAS; Simple; p.Pro26fs (c.74delC); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL98015; true Female Doubling time: 19.19 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=15677628; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137444 CVCL_0U15 BRN-1 transformed cell line Norway rat CVCL_0U15 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137445 CVCL_1615 OAW42 cancer cell line human CVCL_1615 HLA typing: A*03:01,03:01; B*07:02,18:01; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=2.28%; Native American=0%; East Asian, North=3.68%; East Asian, South=0%; South Asian=0%; European, North=61.75%; European, South=32.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=25230021) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 19 hours (PubMed=2653399); ~34 hours, at 97th passage (PubMed=8795574); 40 hours (PubMed=25984343); 25-30 hours (CLS); 28.75 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21137446 CVCL_0U18 BRN-4 transformed cell line Norway rat CVCL_0U18 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137447 CVCL_1618 OC 316 cancer cell line human CVCL_1618 Genome ancestry: African=0%; Native American=1.57%; East Asian, North=1.31%; East Asian, South=0%; South Asian=0%; European, North=75.5%; European, South=21.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 10447; RRAS; Simple; p.Pro26fs (c.74delC); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ICLC; HTL98014; true Female Microsatellite instability: Instable (MSI-high) (PubMed=15677628; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project Problematic cell line: Contaminated Identical to OC 314 according to STR profiling done at ICLC, to MSI data (PubMed=15677628) and to omic data (DepMap). Originally thought to originate from a 60 year old patient with a FIGO stage IV ovarian cancer. 21137448 CVCL_0U17 BRN-3 transformed cell line Norway rat CVCL_0U17 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137449 CVCL_1617 OC 315 cancer cell line human CVCL_1617 CL:0000010 Discontinued: ICLC; HTL98013; true. Female Microsatellite instability: Instable (MSI-high) (PubMed=15677628) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Possibly contaminated May be identical to OC 314 (Cellosaurus=CVCL_1616) according to STR profiling done at ICLC and to MSI data (PubMed=15677628). 21137450 CVCL_0U21 BRN-7 transformed cell line Norway rat CVCL_0U21 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137451 CVCL_1621 OCUB-M cancer cell line human CVCL_1621 Genome ancestry: African=2.46%; Native American=1.63%; East Asian, North=78.49%; East Asian, South=13.1%; South Asian=0%; European, North=0%; European, South=4.31% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1919; CHD4; Simple; p.Lys945fs*28 (c.2835delA); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Gly383Asp (c.1148G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI-low) (PubMed=15677628; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137452 CVCL_0U20 BRN-6 transformed cell line Norway rat CVCL_0U20 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137453 CVCL_1620 OCI-AML-5 cancer cell line human CVCL_1620 HLA typing: A*11:01,32:01; B*51:01,57:01; C*07:01,14:02 (PubMed=26589293); Genome ancestry: African=1.01%; Native American=0.08%; East Asian, North=2.79%; East Asian, South=0%; South Asian=0%; European, North=64.96%; European, South=31.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; p.Lys1085Argfs*7 (c.3252delT); Zygosity=Unspecified (PubMed=21989985) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 hours (PubMed=25984343); ~30-50 hours (DSMZ=ACC-247); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137454 CVCL_0U23 JHK-3 transformed cell line human CVCL_0U23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient with a 3-year history of chronic fatigue syndrome (PubMed=9201810); Derived from sampling site: Peripheral blood. Female Virology: Infected by the JHK retrovirus (JHKV), a murine leukemia-related retrovirus Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10991 21137455 CVCL_1623 OMC-1 [Human cervical carcinoma] cancer cell line human CVCL_1623 Genome ancestry: African=0%; Native American=0%; East Asian, North=76.41%; East Asian, South=22.8%; South Asian=0%; European, North=0.62%; European, South=0.16% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 43 hours, at 15th passage (PubMed=2486664); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137456 CVCL_0U22 BRN-9 transformed cell line Norway rat CVCL_0U22 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21137457 CVCL_1622 OE19 cancer cell line human CVCL_1622 HLA typing: A*02:01,02:01; B*07:17,51:01; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=15.01%; Native American=0.16%; East Asian, North=1.83%; East Asian, South=0%; South Asian=11.79%; European, North=8.22%; European, South=62.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn310Lysfs*27 (c.929dup) (c.929_930ins1); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476) Doubling time: ~50-60 hours (DSMZ=ACC-700); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21137458 CVCL_1625 OPM-2 cancer cell line human CVCL_1625 HLA typing: A*24; B*07,15; C*04,07 (PubMed=25688540); HLA typing: A*24:02,24:02; B*07:02,15:27; C*04:01,07:02 (PubMed=26589293); HLA typing: A*24:02:01,24:02:01; B*07:02:01,15:27:01; C*04:01:01,07:02:01; DRA*01:01:01,01:01:01 (DSMZCellDive=ACC-50); Genome ancestry: African=0.58%; Native American=0%; East Asian, North=74.2%; East Asian, South=23.62%; South Asian=0%; European, North=0.08%; European, South=1.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (PubMed=11157491; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces Ig lambda Doubling time: 30-36 hours (PubMed=3926660); 50 hours (PubMed=25984343); ~50-60 hours (DSMZ=ACC-50); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21137459 CVCL_0U25 VAT-39 cancer cell line human CVCL_0U25 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 34 hours, at 50th passage (PubMed=24481592) 21137460 CVCL_0U24 21B8 transformed cell line human CVCL_0U24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21184; Pseudomonas aeruginosa A-type flagellin (fliC) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9301 21137461 CVCL_1624 ONS-76 cancer cell line human CVCL_1624 HLA typing: A*24:02,26:03; B*54:01,54:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=3.13%; Native American=0%; East Asian, North=83.83%; East Asian, South=8.46%; South Asian=0%; European, North=0%; European, South=4.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 18.6 hours (CelloPub=CLPUB00094; PubMed=2504489; PubMed=2818910); 22 +- 0.3 hours (PubMed=31346954); ~24 hours (lot 08192008), ~32 hours (lot 12042014) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137462 CVCL_1627 OVCAR-4 cancer cell line human CVCL_1627 HLA typing: A*01:01:01,32:01; B*08:01,40:02; C*07,15; DPB1*04:01,13:01; DQB1*02:01,03:01:01; DRB1*03:01:01,04:01:01 (PubMed=15748285); HLA typing: A*01:01,32:03; B*08:01,40:02; C*07:01,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=3.58%; East Asian, South=0%; South Asian=0%; European, North=53.46%; European, South=42.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Homozygous (PubMed=17088437; PubMed=24023729) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34 hours (PubMed=7718330); 43 hours (PubMed=25984343); 41.4 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137463 CVCL_0U27 XGC9811-L cancer cell line human CVCL_0U27 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Omics: Proteome analysis by 2D-DE 21137464 CVCL_1626 OS-RC-2 cancer cell line human CVCL_1626 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0.1%; Native American=0%; East Asian, North=77.03%; East Asian, South=20.25%; South Asian=0%; European, North=0.95%; European, South=1.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys211Serfs (c.631_634+12del16); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours, at 30th passage (PubMed=4008433); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137465 CVCL_0U26 XGC9811 cancer cell line human CVCL_0U26 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Omics: Proteome analysis by 2D-DE 21137466 CVCL_0U29 Calu-1 W5-6 cancer cell line human CVCL_0U29 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Derived from metastatic site: Pleural effusion. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9267 21137467 CVCL_1629 OVCAR-8 cancer cell line human CVCL_1629 HLA typing: A*01:01:01,25:01; B*57:01:01; C*06:02; DPB1*02:01:02,13:01; DQB1*03:03:02,06:02; DRB1*07:01,15:01:01 (PubMed=15748285); HLA typing: A*01:01,25:01; B*57:01,57:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=0.22%; Native American=0%; East Asian, North=3.41%; East Asian, South=0%; South Asian=0.98%; European, North=60.74%; European, South=34.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (PubMed=28273451; Cosmic-CLP); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (PubMed=17088437); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (PubMed=28273451; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=20204287; PubMed=21912889; PubMed=28273451; Cosmic-CLP) Omics: Array-based CGH; Omics: ATAC-seq; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=7718330); 25 hours (PubMed=25984343); 26.1 hours (NCI-DTP); 31.93 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137468 CVCL_0U28 GC9811-P cancer cell line human CVCL_0U28 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. 21137469 CVCL_1628 OVCAR-5 cancer cell line human CVCL_1628 HLA typing: A*01,02; B*08,44; C*05,07; DPB1*04:01; DQB1*02:01,03:01:01; DRB1*03:01:01,04:01:01 (PubMed=15748285); HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.13%; East Asian, North=0.98%; East Asian, South=0%; South Asian=0.37%; European, North=67.06%; European, South=31.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=17088437; PubMed=28273451; Cosmic-CLP; DepMap) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: Fluorescence phenotype profiling; Omics: Genome sequenced; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=7718330); 48.8 hours (NCI-DTP); 24.37 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel Problematic cell line: Possibly misclassified Originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin (PubMed=27353327). 21137470 CVCL_0U09 AD-iPS5 induced pluripotent stem cell human CVCL_0U09 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21137471 CVCL_1609 NOMO-1 cancer cell line human CVCL_1609 Genome ancestry: African=0.4%; Native American=0.99%; East Asian, North=76.88%; East Asian, South=20.48%; South Asian=0%; European, North=0.98%; European, South=0.27% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=14671638); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.730-10T>C; dbSNP=rs201058616; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 55 hours (PubMed=25984343); ~35 hours (DSMZ=ACC-542); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137472 CVCL_1608 NMC-G1 cancer cell line human CVCL_1608 Genome ancestry: African=0%; Native American=0%; East Asian, North=81.52%; East Asian, South=18.48%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137473 CVCL_0U08 SO-Rb50/CBP cancer cell line human CVCL_0U08 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP. Female Doubling time: 50.9 hours (CelloPub=CLPUB00236) 21137474 CVCL_0U01 HE52 finite cell line human CVCL_0U01 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21137475 CVCL_1601 NCI-H969 cancer cell line human CVCL_1601 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5852; true Male Part of: MD Anderson Cell Lines Project 21137476 CVCL_0U00 HE51 finite cell line human CVCL_0U00 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21137477 CVCL_1600 NCI-H929 cancer cell line human CVCL_1600 HLA typing: A*26,30; B*18,35; C*04,07 (PubMed=25688540); HLA typing: A*03:01,24:02; B*07:02,18:01; C*07:02,07:02; DQA1*01:02,03:02; DQB1*02:02,06:13; DRB1*04:05,16:05 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.61%; East Asian, North=2.52%; East Asian, South=0%; South Asian=0.16%; European, North=68.5%; European, South=28.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (PubMed=11157491; PubMed=12068308; PubMed=21173094; ATCC) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA kappa Doubling time: ~50 hours (Patent=US4892829; PubMed=2423157); ~70 hours (DSMZ=ACC-163); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035); Part of: RAS genetic alteration cell panel (ATCC TCP-1031); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9068 21137478 CVCL_0U03 HE54 finite cell line human CVCL_0U03 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21137479 CVCL_1603 NCI-N87 cancer cell line human CVCL_1603 HLA typing: A*01:01,23:01; B*07:02,37:01; C*02:02,07:02; DQB1*05:02,05:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*23:01,23:01; B*07:02,37:01; C*02:02,02:02 (PubMed=26589293); Genome ancestry: African=61.23%; Native American=0%; East Asian, North=2.17%; East Asian, South=0%; South Asian=0%; European, North=20.57%; European, South=16.04% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=1676761; ATCC) Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: KCLB; 60187; probable Male Characteristics: Established from a nude mouse xenograft Doubling time: 47 hours (PubMed=2158397); 86 hours (PubMed=25984343); 23 hours (PubMed=26919099); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MET genetic alteration cell panel (ATCC TCP-1036) 21137480 CVCL_0U02 HE53 finite cell line human CVCL_0U02 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21137481 CVCL_1602 NCI-N417 cancer cell line human CVCL_1602 HLA typing: A*26:01,23:01; B*08:01,08:01; C*07:01 (PubMed=25960936); HLA typing: A*23:01,26:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Gene fusion; HGNC; 23139; CLVS1 + HGNC; 9709; PVT1; Name(s)=PVT1-CLVS1 (PubMed=23716474); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Lys (c.1636C>A); ClinVar=VCV000013657; Zygosity=Heterozygous (PubMed=19394761); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1565469; PubMed=10536175; PubMed=20557307) Derived from sampling site: Lung. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5809; true Female Characteristics: Established from a nude mouse xenograft; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21750403) Doubling time: 26 hours (PubMed=2985258) 21137482 CVCL_0U05 HE57 finite cell line human CVCL_0U05 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21137483 CVCL_1605 NH-12 cancer cell line human CVCL_1605 Genome ancestry: African=0%; Native American=0%; East Asian, North=74.87%; East Asian, South=25.12%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137484 CVCL_0U04 HE55 finite cell line human CVCL_0U04 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21137485 CVCL_1604 NEC8 cancer cell line human CVCL_1604 Genome ancestry: African=2.09%; Native American=0.61%; East Asian, North=79.76%; East Asian, South=13.39%; South Asian=0%; European, North=0%; European, South=4.15% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Testis. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0005; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137486 CVCL_0U07 CHL-CYP2C18 spontaneously immortalized cell line CVCL_0U07 CL:0000010 Transfected with: HGNC; 2620; CYP2C18; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21137487 CVCL_1607 NKM-1 cancer cell line human CVCL_1607 Genome ancestry: African=0%; Native American=0%; East Asian, North=76.96%; East Asian, South=21.17%; South Asian=0.96%; European, North=0.9%; European, South=0.01% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 36-48 hours (PubMed=1701353); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137488 CVCL_0U06 HBC2 cancer cell line human CVCL_0U06 CL:0000010 Population: Chinese; Derived from sampling site: Bone; cranium; clivus. Male 21137489 CVCL_1606 NH-6 cancer cell line human CVCL_1606 HLA typing: A*02:06,24:02; B*07:02,35:08; C*03:03,07:02; DQB1*06:04,06:04 (PubMed=26589293); Genome ancestry: African=2.3%; Native American=0%; East Asian, North=79.85%; East Asian, South=14.99%; South Asian=0%; European, North=0%; European, South=2.86% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: >3 days (lot 06262000) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21137490 CVCL_9P94 DD3546 finite cell line human CVCL_9P94 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21137491 CVCL_9P93 DD3535 transformed cell line human CVCL_9P93 CL:0000010 Karyotypic information: 46,Y,inv(X)(q13.1;q24) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137492 CVCL_9P96 DD3551 transformed cell line human CVCL_9P96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137493 CVCL_9P95 DD3550 transformed cell line human CVCL_9P95 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(X)(qter->p22.31 or p22.32) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137494 CVCL_9P90 DD3521 transformed cell line human CVCL_9P90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137495 CVCL_9P92 DD3531 finite cell line human CVCL_9P92 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137496 CVCL_9P91 DD3528 finite cell line human CVCL_9P91 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21137497 CVCL_BJ28 ND12115 transformed cell line human CVCL_BJ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137498 CVCL_BJ27 ND12114 transformed cell line human CVCL_BJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137499 CVCL_BJ29 ND12117 transformed cell line human CVCL_BJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137500 CVCL_9P98 DD3556 transformed cell line human CVCL_9P98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137501 CVCL_9P97 DD3553 transformed cell line human CVCL_9P97 CL:0000010 Karyotypic information: 46,XY,del(1)(p36.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137502 CVCL_9P99 DD3559 transformed cell line human CVCL_9P99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137503 CVCL_BJ20 ND12101 transformed cell line human CVCL_BJ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137504 CVCL_BJ22 ND12103 transformed cell line human CVCL_BJ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137505 CVCL_BJ21 ND12102 transformed cell line human CVCL_BJ21 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137506 CVCL_BJ24 ND12105 transformed cell line human CVCL_BJ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137507 CVCL_BJ23 ND12104 transformed cell line human CVCL_BJ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137508 CVCL_BJ26 ND12113 transformed cell line human CVCL_BJ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137509 CVCL_BJ25 ND12112 transformed cell line human CVCL_BJ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137510 CVCL_BJ39 ND12132 transformed cell line human CVCL_BJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137511 CVCL_BJ38 ND12131 transformed cell line human CVCL_BJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137512 CVCL_BJ31 ND12120 transformed cell line human CVCL_BJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137513 CVCL_BJ30 ND12119 transformed cell line human CVCL_BJ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137514 CVCL_BJ33 ND12122 transformed cell line human CVCL_BJ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137515 CVCL_BJ32 ND12121 transformed cell line human CVCL_BJ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137516 CVCL_BJ35 ND12126 transformed cell line human CVCL_BJ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137517 CVCL_BJ34 ND12124 transformed cell line human CVCL_BJ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137518 CVCL_BJ37 ND12130 transformed cell line human CVCL_BJ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137519 CVCL_BJ36 ND12128 transformed cell line human CVCL_BJ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137520 CVCL_9P72 DD3466 finite cell line human CVCL_9P72 CL:0000010 Karyotypic information: 46,XX,t(10;11)(q24.?31;p15.5) de novo (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137521 CVCL_9P71 DD3460 transformed cell line human CVCL_9P71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137522 CVCL_9P74 DD3470 finite cell line human CVCL_9P74 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137523 CVCL_9P73 DD3467 finite cell line human CVCL_9P73 CL:0000010 Karyotypic information: 46,XX,inv(13)(q33.2;q34)pat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137524 CVCL_9P70 DD3459 finite cell line human CVCL_9P70 CL:0000010 Karyotypic information: 46,XY,t(2;9)?(q34;p21.2) de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137525 CVCL_BJ06 ND12079 transformed cell line human CVCL_BJ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137526 CVCL_9P79 DD3499 finite cell line human CVCL_9P79 CL:0000010 Karyotypic information: 47,XX,+mar (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137527 CVCL_BJ05 ND12078 transformed cell line human CVCL_BJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137528 CVCL_BJ08 ND12084 transformed cell line human CVCL_BJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137529 CVCL_BJ07 ND12081 transformed cell line human CVCL_BJ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137530 CVCL_9P76 DD3480 finite cell line human CVCL_9P76 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21137531 CVCL_9P75 DD3479 transformed cell line human CVCL_9P75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137532 CVCL_BJ09 ND12088 transformed cell line human CVCL_BJ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137533 CVCL_9P78 DD3493 finite cell line human CVCL_9P78 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137534 CVCL_9P77 DD3484 transformed cell line human CVCL_9P77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137535 CVCL_BJ00 ND12054 transformed cell line human CVCL_BJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137536 CVCL_BJ02 ND12069 transformed cell line human CVCL_BJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137537 CVCL_BJ01 ND12068 transformed cell line human CVCL_BJ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137538 CVCL_BJ04 ND12072 transformed cell line human CVCL_BJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137539 CVCL_BJ03 ND12070 transformed cell line human CVCL_BJ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137540 CVCL_9P83 DD3506 transformed cell line human CVCL_9P83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137541 CVCL_9P82 DD3505 transformed cell line human CVCL_9P82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137542 CVCL_9P85 DD3509 finite cell line human CVCL_9P85 CL:0000010 Karyotypic information: 46,XY,inv(2)(p24.2;q35)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137543 CVCL_9P84 DD3508 transformed cell line human CVCL_9P84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137544 CVCL_9P81 DD3503 transformed cell line human CVCL_9P81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137545 CVCL_9P80 DD3502 transformed cell line human CVCL_9P80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137546 CVCL_BJ17 ND12098 transformed cell line human CVCL_BJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137547 CVCL_BJ16 ND12097 transformed cell line human CVCL_BJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137548 CVCL_BJ19 ND12100 transformed cell line human CVCL_BJ19 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137549 CVCL_BJ18 ND12099 transformed cell line human CVCL_BJ18 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137550 CVCL_9P87 DD3514 transformed cell line human CVCL_9P87 CL:0000010 Karyotypic information: 69,XXX; 46,XY (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137551 CVCL_9P86 DD3510 finite cell line human CVCL_9P86 CL:0000010 Karyotypic information: 46,XX,inv(9)(q22.33;q34.3)mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137552 CVCL_9P89 DD3520 transformed cell line human CVCL_9P89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137553 CVCL_9P88 DD3518 transformed cell line human CVCL_9P88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137554 CVCL_BJ11 ND12090 transformed cell line human CVCL_BJ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137555 CVCL_BJ10 ND12089 transformed cell line human CVCL_BJ10 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137556 CVCL_BJ13 ND12094 transformed cell line human CVCL_BJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137557 CVCL_BJ12 ND12093 transformed cell line human CVCL_BJ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137558 CVCL_BJ15 ND12096 transformed cell line human CVCL_BJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137559 CVCL_BJ14 ND12095 transformed cell line human CVCL_BJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137560 CVCL_9P50 DD3382 transformed cell line human CVCL_9P50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137561 CVCL_9P52 DD3384 transformed cell line human CVCL_9P52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137562 CVCL_9P51 DD3383 transformed cell line human CVCL_9P51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137563 CVCL_9P58 DD3410 transformed cell line human CVCL_9P58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137564 CVCL_9P57 DD3409 finite cell line human CVCL_9P57 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Part of: ECACC chromosomal abnormality collection 21137565 CVCL_9P59 DD3416 finite cell line human CVCL_9P59 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21137566 CVCL_9P54 DD3390 transformed cell line human CVCL_9P54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137567 CVCL_9P53 DD3389 transformed cell line human CVCL_9P53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137568 CVCL_9P56 DD3406 transformed cell line human CVCL_9P56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137569 CVCL_9P55 DD3398 transformed cell line human CVCL_9P55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137570 CVCL_9P61 DD3418 transformed cell line human CVCL_9P61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137571 CVCL_9P60 DD3417 transformed cell line human CVCL_9P60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137572 CVCL_9P63 DD3421 finite cell line human CVCL_9P63 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21137573 CVCL_9P62 DD3419 transformed cell line human CVCL_9P62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137574 CVCL_9P69 DD3455 transformed cell line human CVCL_9P69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137575 CVCL_9P68 DD3454 transformed cell line human CVCL_9P68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137576 CVCL_9P65 DD3435 finite cell line human CVCL_9P65 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137577 CVCL_9P64 DD3422 finite cell line human CVCL_9P64 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137578 CVCL_9P67 DD3445 transformed cell line human CVCL_9P67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137579 CVCL_9P66 DD3444 transformed cell line human CVCL_9P66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137580 CVCL_9P30 DD3312 finite cell line human CVCL_9P30 CL:0000010 Karyotypic information: 46,XY,der(1)t(1;13)(q32.3;q32.3)mat (ECACC); Derived from sampling site: Chorionic villus. Male Part of: ECACC chromosomal abnormality collection 21137581 CVCL_9P36 DD3330 finite cell line human CVCL_9P36 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21137582 CVCL_9P35 DD3329 finite cell line human CVCL_9P35 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Part of: ECACC chromosomal abnormality collection 21137583 CVCL_9P38 DD3344 transformed cell line human CVCL_9P38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137584 CVCL_9P37 DD3333 finite cell line human CVCL_9P37 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Part of: ECACC chromosomal abnormality collection 21137585 CVCL_9P32 DD3322 transformed cell line human CVCL_9P32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137586 CVCL_9P31 DD3320 transformed cell line human CVCL_9P31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137587 CVCL_9P34 DD3324 transformed cell line human CVCL_9P34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137588 CVCL_9P33 DD3323 transformed cell line human CVCL_9P33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137589 CVCL_0V91 GM18111 transformed cell line human CVCL_0V91 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137590 CVCL_1791 VMRC-RCZ cancer cell line human CVCL_1791 HLA typing: A*02:01,24:02; B*07:02,38:01; C*07:02,12:03; DQA1*02:01,05:02; DQB1*03:04,03:04; DRB1*11:77,13:10' (PubMed=26589293); Genome ancestry: African=0.43%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=1.38%; European, North=61.8%; European, South=34.32% (PubMed=30894373) From: Bean M.A.; Virginia Mason Research Center; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp48Valfs*74 (c.143_146del4); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.463+2T>C; ClinVar=VCV000569414; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137591 CVCL_0V90 GM18110 transformed cell line human CVCL_0V90 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137592 CVCL_1790 VMRC-RCW cancer cell line human CVCL_1790 HLA typing: A*02:01,33:03; B*07:02,18:01; C*04:01,07:06 (PubMed=26589293); Genome ancestry: African=2.21%; Native American=0.43%; East Asian, North=1.64%; East Asian, South=0%; South Asian=1.16%; European, North=69.86%; European, South=24.69% (PubMed=30894373). From: Bean M.A.; Virginia Mason Research Center; Seattle; USA CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (lot 102398), ~27 hours (lot 10052009), ~35 hours (lot 11082016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137593 CVCL_0V93 GM18113 transformed cell line human CVCL_0V93 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137594 CVCL_1793 WSU-NHL cancer cell line human CVCL_1793 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,07:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0%; East Asian, South=0.46%; South Asian=3.25%; European, North=71.53%; European, South=24.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-NHL Female Doubling time: 57 hours (PubMed=3143865); ~45 hours (DSMZ=ACC-58); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11584 Caution: Was originally classified as originating from a follicular lymphoma 21137595 CVCL_0V92 GM18112 transformed cell line human CVCL_0V92 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137596 CVCL_1792 WERI-Rb-1 cancer cell line human CVCL_1792 CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Homozygous (PubMed=25326674) Population: Caucasian; Derived from sampling site: Eye; globe. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; KURB2683; probable Female Doubling time: 96 hours (PubMed=844036); 50 hours (PubMed=25326674); 84 hours (PubMed=31781967); ~49 hours (DSMZ=ACC-90) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3 21137597 CVCL_9P29 DD3309 transformed cell line human CVCL_9P29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137598 CVCL_0V95 GM18115 transformed cell line human CVCL_0V95 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137599 CVCL_1795 YH-13 cancer cell line human CVCL_1795 HLA typing: A*11:01,24:02; B*35:01,52:01; C*12:02,12:02; DQA1*01:02,05:02; DQB1*05:02,06:11; DRB1*07:01,11:30 (PubMed=26589293); Genome ancestry: African=0.04%; Native American=0%; East Asian, North=83.27%; East Asian, South=16.69%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln75Glu (c.223C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Val (c.337T>G); ClinVar=VCV000141302; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Brain; left fronto-parietal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=7947440; PubMed=8145054); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137600 CVCL_9P28 DD3303 transformed cell line human CVCL_9P28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137601 CVCL_0V94 GM18114 transformed cell line human CVCL_0V94 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137602 CVCL_1794 YAPC cancer cell line human CVCL_1794 HLA typing: A*24:02,24:02; B*35:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.82%; East Asian, North=85.11%; East Asian, South=13.9%; South Asian=0.15%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (DSMZ=ACC-382); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21137603 CVCL_0V97 GM18117 transformed cell line human CVCL_0V97 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137604 CVCL_1797 YT cancer cell line human CVCL_1797 HLA typing: A*26:01:01,31:01:02; B*48:01:01,48:01:01; C*01:02:01,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:01:01; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-434); Genome ancestry: African=0.12%; Native American=0.69%; East Asian, North=74.01%; East Asian, South=25.17%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion Cell type=Natural killer cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40-50 hours (DSMZ=ACC-434); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21137605 CVCL_0V96 GM18116 transformed cell line human CVCL_0V96 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137606 CVCL_1796 YKG-1 cancer cell line human CVCL_1796 Genome ancestry: African=0.57%; Native American=0.77%; East Asian, North=82.14%; East Asian, South=15.9%; South Asian=0%; European, North=0.28%; European, South=0.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146_Ser149delinsCys (c.438_446delGGTTGATTC); Zygosity=Heterozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Brain; right temporo-occipital lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 28 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137607 CVCL_1799 AC-1M32 hybrid cell line human CVCL_1799 CL:0000010 Characteristics: Fusion of the AC1-1 choriocarcinoma cell line with normal human trophoblast cells (from parent cell line) Doubling time: ~20-30 hours (DSMZ=ACC-442). 21137608 CVCL_0V99 GM18119 transformed cell line human CVCL_0V99 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137609 CVCL_1798 42-MG-BA cancer cell line human CVCL_1798 HLA typing: A*33:03,33:03; B*39:01,39:01; C*12:03,12:03; DRB1*11:11,11:11 (PubMed=26589293); Genome ancestry: African=0.01%; Native American=0%; East Asian, North=4.88%; East Asian, South=0%; South Asian=0%; European, North=63.22%; European, South=31.9% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.164+1_164+2insG; Zygosity=Heterozygous; Note=Aberrant splicing (PubMed=28464039; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr211Ile (c.632C>T); ClinVar=VCV001503185; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Gln (c.845G>A); ClinVar=VCV000237956; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain; temporal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48-54 hours (PubMed=9604998); ~40 hours (DSMZ=ACC-431); Microsatellite instability: Stable (MSS) (Sanger; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137610 CVCL_0V98 GM18118 transformed cell line human CVCL_0V98 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137611 CVCL_9P41 DD3364 transformed cell line human CVCL_9P41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137612 CVCL_9P40 DD3359 transformed cell line human CVCL_9P40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137613 CVCL_9P47 DD3379 transformed cell line human CVCL_9P47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137614 CVCL_9P46 DD3377 transformed cell line human CVCL_9P46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137615 CVCL_9P49 DD3381 transformed cell line human CVCL_9P49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137616 CVCL_9P48 DD3380 transformed cell line human CVCL_9P48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137617 CVCL_9P43 DD3374 transformed cell line human CVCL_9P43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137618 CVCL_9P42 DD3365 finite cell line human CVCL_9P42 CL:0000010 Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137619 CVCL_9P45 DD3376 transformed cell line human CVCL_9P45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137620 CVCL_9P44 DD3375 transformed cell line human CVCL_9P44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137621 CVCL_9P39 DD3354 transformed cell line human CVCL_9P39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137622 CVCL_KD45 PCRP-CTBP1-1A1 hybridoma house mouse CVCL_KD45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13363; Human CTBP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137623 CVCL_KD44 PCRP-CSTF2T-1A3 hybridoma house mouse CVCL_KD44 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H0L4; Human CSTF2T. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137624 CVCL_KD47 PCRP-CTBP2-2B11 hybridoma house mouse CVCL_KD47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56545; Human CTBP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137625 CVCL_KD46 PCRP-CTBP1-1A4 hybridoma house mouse CVCL_KD46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13363; Human CTBP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137626 CVCL_KD41 PCRP-CSDE1-1B2 hybridoma house mouse CVCL_KD41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75534; Human CSDE1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137627 CVCL_KD40 PCRP-CREBL2-1A3 hybridoma house mouse CVCL_KD40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60519; Human CREBL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137628 CVCL_KD43 PCRP-CSTF2-1A5 hybridoma house mouse CVCL_KD43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33240; Human CSTF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137629 CVCL_KD42 PCRP-CSTF2-1A11 hybridoma house mouse CVCL_KD42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P33240; Human CSTF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137630 CVCL_KD38 PCRP-CREB5-1G8 hybridoma house mouse CVCL_KD38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q02930; Human CREB5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137631 CVCL_KD37 PCRP-CREB5-1B8 hybridoma house mouse CVCL_KD37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q02930; Human CREB5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137632 CVCL_KD39 PCRP-CREBL2-1A11 hybridoma house mouse CVCL_KD39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60519; Human CREBL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137633 CVCL_KD56 PCRP-CXXC1-2D3 hybridoma house mouse CVCL_KD56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137634 CVCL_KD55 PCRP-CXXC1-2C3 hybridoma house mouse CVCL_KD55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137635 CVCL_KD58 PCRP-DAXX-1D7 hybridoma house mouse CVCL_KD58 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137636 CVCL_KD57 PCRP-DACH1-1C9 hybridoma house mouse CVCL_KD57 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UI36; Human DACH1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137637 CVCL_KD52 PCRP-CXXC1-1E5 hybridoma house mouse CVCL_KD52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137638 CVCL_KD51 PCRP-CXXC1-1C7 hybridoma house mouse CVCL_KD51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137639 CVCL_KD54 PCRP-CXXC1-2A7 hybridoma house mouse CVCL_KD54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137640 CVCL_KD53 PCRP-CXXC1-2A1 hybridoma house mouse CVCL_KD53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137641 CVCL_KD50 PCRP-CXXC1-1B6 hybridoma house mouse CVCL_KD50 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9P0U4; Human CXXC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137642 CVCL_KD49 PCRP-CTBP2-2D11 hybridoma house mouse CVCL_KD49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56545; Human CTBP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137643 CVCL_KD48 PCRP-CTBP2-2C7 hybridoma house mouse CVCL_KD48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P56545; Human CTBP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137644 CVCL_KD23 PCRP-CHEK2-2A2 hybridoma house mouse CVCL_KD23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O96017; Human CHEK2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137645 CVCL_KD22 PCRP-CHEK2-1C4 hybridoma house mouse CVCL_KD22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O96017; Human CHEK2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137646 CVCL_KD25 PCRP-CIZ1-1A2 hybridoma house mouse CVCL_KD25 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9ULV3; Human CIZ1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137647 CVCL_KD24 PCRP-CIAO1-2C11 hybridoma house mouse CVCL_KD24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O76071; Human CIAO1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137648 CVCL_KD21 PCRP-CHEK2-1A9 hybridoma house mouse CVCL_KD21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O96017; Human CHEK2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137649 CVCL_KD20 PCRP-CHEK2-1A4 hybridoma house mouse CVCL_KD20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O96017; Human CHEK2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137650 CVCL_BJ86 ND12249 transformed cell line human CVCL_BJ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137651 CVCL_BJ85 ND12239 transformed cell line human CVCL_BJ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137652 CVCL_BJ88 ND12264 transformed cell line human CVCL_BJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137653 CVCL_BJ87 ND12252 transformed cell line human CVCL_BJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137654 CVCL_BJ89 ND12266 transformed cell line human CVCL_BJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137655 CVCL_KD19 PCRP-CHAMP1-1F8 hybridoma house mouse CVCL_KD19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JM3; Human CHAMP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137656 CVCL_BJ80 ND12226 transformed cell line human CVCL_BJ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137657 CVCL_BJ82 ND12236 transformed cell line human CVCL_BJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137658 CVCL_KD16 PCRP-CEBPZ-3C7 hybridoma house mouse CVCL_KD16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03701; Human CEBPZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137659 CVCL_BJ81 ND12231 transformed cell line human CVCL_BJ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137660 CVCL_KD15 PCRP-CEBPZ-2D8 hybridoma house mouse CVCL_KD15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q03701; Human CEBPZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137661 CVCL_BJ84 ND12238 transformed cell line human CVCL_BJ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137662 CVCL_KD18 PCRP-CELF6-1A4 hybridoma house mouse CVCL_KD18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96J87; Human CELF6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137663 CVCL_BJ83 ND12237 transformed cell line human CVCL_BJ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137664 CVCL_KD17 PCRP-CELF4-1C3 hybridoma house mouse CVCL_KD17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BZC1; Human CELF4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137665 CVCL_KD34 PCRP-CREB3L3-2D10 hybridoma house mouse CVCL_KD34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q68CJ9; Human CREB3L3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137666 CVCL_KD33 PCRP-CREB3L1-1B1 hybridoma house mouse CVCL_KD33 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96BA8; Human CREB3L1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137667 CVCL_KD36 PCRP-CREB3L4-1E4 hybridoma house mouse CVCL_KD36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEY5; Human CREB3L4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137668 CVCL_KD35 PCRP-CREB3L4-1A3 hybridoma house mouse CVCL_KD35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TEY5; Human CREB3L4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137669 CVCL_KD30 PCRP-CPEB3-1H4 hybridoma house mouse CVCL_KD30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NE35; Human CPEB3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137670 CVCL_KD32 PCRP-CREB1-1A6 hybridoma house mouse CVCL_KD32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16220; Human CREB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137671 CVCL_KD31 PCRP-CPEB4-1B5 hybridoma house mouse CVCL_KD31 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q17RY0; Human CPEB4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137672 CVCL_BJ97 ND12277 transformed cell line human CVCL_BJ97 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137673 CVCL_BJ96 ND12276 transformed cell line human CVCL_BJ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137674 CVCL_BJ99 ND12281 transformed cell line human CVCL_BJ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137675 CVCL_BJ98 ND12278 transformed cell line human CVCL_BJ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137676 CVCL_BJ91 ND12268 transformed cell line human CVCL_BJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137677 CVCL_BJ90 ND12267 transformed cell line human CVCL_BJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137678 CVCL_BJ93 ND12270 transformed cell line human CVCL_BJ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137679 CVCL_KD27 PCRP-CNOT10-1D5 hybridoma house mouse CVCL_KD27 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9H9A5; Human CNOT10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137680 CVCL_BJ92 ND12269 transformed cell line human CVCL_BJ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137681 CVCL_KD26 PCRP-CLOCK-1A10 hybridoma house mouse CVCL_KD26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15516; Human CLOCK. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137682 CVCL_BJ95 ND12274 transformed cell line human CVCL_BJ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137683 CVCL_KD29 PCRP-CPEB3-1C1 hybridoma house mouse CVCL_KD29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NE35; Human CPEB3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137684 CVCL_BJ94 ND12272 transformed cell line human CVCL_BJ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137685 CVCL_KD28 PCRP-COPS3-2D9 hybridoma house mouse CVCL_KD28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNS2; Human COPS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137686 CVCL_KD01 PCRP-CCDC101-1D10 hybridoma house mouse CVCL_KD01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96ES7; Human SGF29. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137687 CVCL_KD00 PCRP-CCDC101-1B12 hybridoma house mouse CVCL_KD00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96ES7; Human SGF29. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137688 CVCL_KD03 PCRP-CDC5L-2C6 hybridoma house mouse CVCL_KD03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99459; Human CDC5L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137689 CVCL_KD02 PCRP-CCDC97-4B11 hybridoma house mouse CVCL_KD02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96F63; Human CCDC97. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137690 CVCL_BJ64 ND12195 transformed cell line human CVCL_BJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137691 CVCL_BJ63 ND12194 transformed cell line human CVCL_BJ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137692 CVCL_BJ66 ND12199 transformed cell line human CVCL_BJ66 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137693 CVCL_BJ65 ND12196 transformed cell line human CVCL_BJ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137694 CVCL_BJ68 ND12202 transformed cell line human CVCL_BJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137695 CVCL_BJ67 ND12200 transformed cell line human CVCL_BJ67 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137696 CVCL_BJ69 ND12203 transformed cell line human CVCL_BJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137697 CVCL_BJ60 ND12180 transformed cell line human CVCL_BJ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137698 CVCL_BJ62 ND12190 transformed cell line human CVCL_BJ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137699 CVCL_BJ61 ND12182 transformed cell line human CVCL_BJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137700 CVCL_KD12 PCRP-CEBPE-2A9 hybridoma house mouse CVCL_KD12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137701 CVCL_KD11 PCRP-CEBPE-1H1 hybridoma house mouse CVCL_KD11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137702 CVCL_KD14 PCRP-CEBPE-4F2 hybridoma house mouse CVCL_KD14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137703 CVCL_KD13 PCRP-CEBPE-4E10 hybridoma house mouse CVCL_KD13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137704 CVCL_KD10 PCRP-CEBPE-1G12 hybridoma house mouse CVCL_KD10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137705 CVCL_BJ75 ND12214 transformed cell line human CVCL_BJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137706 CVCL_BJ74 ND12213 transformed cell line human CVCL_BJ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137707 CVCL_BJ77 ND12216 transformed cell line human CVCL_BJ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137708 CVCL_BJ76 ND12215 transformed cell line human CVCL_BJ76 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137709 CVCL_BJ79 ND12218 transformed cell line human CVCL_BJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND14318 (Cellosaurus=CVCL_DR43); Derived from sampling site: Peripheral blood. Male 21137710 CVCL_BJ78 ND12217 transformed cell line human CVCL_BJ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137711 CVCL_KD09 PCRP-CEBPE-1F8 hybridoma house mouse CVCL_KD09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137712 CVCL_KD08 PCRP-CEBPE-1B2 hybridoma house mouse CVCL_KD08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15744; Human CEBPE. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137713 CVCL_BJ71 ND12206 transformed cell line human CVCL_BJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137714 CVCL_KD05 PCRP-CDX2-1A6 hybridoma house mouse CVCL_KD05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99626; Human CDX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137715 CVCL_BJ70 ND12205 transformed cell line human CVCL_BJ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137716 CVCL_KD04 PCRP-CDX2-1A3 hybridoma house mouse CVCL_KD04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99626; Human CDX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137717 CVCL_BJ73 ND12210 transformed cell line human CVCL_BJ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137718 CVCL_KD07 PCRP-CEBPB-3D10 hybridoma house mouse CVCL_KD07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17676; Human CEBPB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137719 CVCL_BJ72 ND12209 transformed cell line human CVCL_BJ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137720 CVCL_KD06 PCRP-CEBPB-2A12 hybridoma house mouse CVCL_KD06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17676; Human CEBPB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137721 CVCL_BJ49 ND12163 transformed cell line human CVCL_BJ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137722 CVCL_BJ42 ND12139 transformed cell line human CVCL_BJ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137723 CVCL_BJ41 ND12136 transformed cell line human CVCL_BJ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137724 CVCL_BJ44 ND12150 transformed cell line human CVCL_BJ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137725 CVCL_BJ43 ND12140 transformed cell line human CVCL_BJ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137726 CVCL_BJ46 ND12158 transformed cell line human CVCL_BJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137727 CVCL_BJ45 ND12155 transformed cell line human CVCL_BJ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137728 CVCL_BJ48 ND12161 transformed cell line human CVCL_BJ48 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137729 CVCL_BJ47 ND12159 transformed cell line human CVCL_BJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137730 CVCL_BJ40 ND12135 transformed cell line human CVCL_BJ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137731 CVCL_BJ53 ND12167 transformed cell line human CVCL_BJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137732 CVCL_BJ52 ND12166 transformed cell line human CVCL_BJ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137733 CVCL_BJ55 ND12171 transformed cell line human CVCL_BJ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137734 CVCL_BJ54 ND12168 transformed cell line human CVCL_BJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137735 CVCL_BJ57 ND12175 transformed cell line human CVCL_BJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137736 CVCL_BJ56 ND12172 transformed cell line human CVCL_BJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137737 CVCL_BJ59 ND12178 transformed cell line human CVCL_BJ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137738 CVCL_BJ58 ND12176 transformed cell line human CVCL_BJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137739 CVCL_BJ51 ND12165 transformed cell line human CVCL_BJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137740 CVCL_BJ50 ND12164 transformed cell line human CVCL_BJ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137741 CVCL_0V08 GM16237 transformed cell line human CVCL_0V08 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[700]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137742 CVCL_1708 SNU-C1 cancer cell line human CVCL_1708 HLA typing: A*02:06,11:01; B*15:01,54:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=3.6%; Native American=0%; East Asian, North=70.54%; East Asian, South=21.43%; South Asian=0%; European, North=0%; European, South=4.43% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 17581; APIP + HGNC; 10940; SLC1A2; Name(s)=APIP-SLC1A2; Note=In frame (PubMed=23637631); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser166Ter (c.497C>A); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Korean; Derived from metastatic site: Peritoneum. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Hi-C sequencing; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21137743 CVCL_0V07 GM16236 transformed cell line human CVCL_0V07 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1070]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137744 CVCL_1707 SNG-M cancer cell line human CVCL_1707 HLA typing: A*11:01,26:03; B*51:01,54:01; C*01:02,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.03%; East Asian, North=75.48%; East Asian, South=24.49%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr46fs*10 (c.136_137delTA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Thr93fs*2 (c.276_277insC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg88Gln (c.263G>A); ClinVar=VCV000376049; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Obturator lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0030; true Female Doubling time: 30 hours, at 50th passage (PubMed=858140); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137745 CVCL_0V09 GM16239 transformed cell line human CVCL_0V09 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[800]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137746 CVCL_1709 SNU-C2A cancer cell line human CVCL_1709 HLA typing: A*24:02,26:01; B*07:02,48:01; C*08:03,14:02 (PubMed=26589293); Genome ancestry: African=0.61%; Native American=0%; East Asian, North=62.55%; East Asian, South=35.74%; South Asian=0%; European, North=0.97%; European, South=0.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (DepMap) Population: Korean; Derived from sampling site: Cecum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a nude mouse xenograft Doubling time: 50 hours (PubMed=25984343); Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel; Part of: Seoul National University (SNU) cell line collection 21137747 CVCL_0V00 GM16219 transformed cell line human CVCL_0V00 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[570]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137748 CVCL_1700 SK-N-AS cancer cell line human CVCL_1700 HLA typing: A*24:02,26:01; B*14:01,40:01; C*03:04,08:02 (PubMed=26589293); Genome ancestry: African=1.49%; Native American=0%; East Asian, North=2.41%; East Asian, South=0%; South Asian=2.58%; European, North=53.12%; European, South=40.39% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137749 CVCL_0V02 GM16225 transformed cell line human CVCL_0V02 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137750 CVCL_1702 SK-N-FI cancer cell line human CVCL_1702 HLA typing: A*03:01,23:01; B*08:01,44:02; C*04:01,07:01; DQA1*01:02,04:01; DQB1*02:01,03:04; DRB1*01:02,13:67 (PubMed=26589293); Genome ancestry: African=24.58%; Native American=8.08%; East Asian, North=2.3%; East Asian, South=0.57%; South Asian=1.35%; European, North=35.17%; European, South=27.95% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Partial deletion; Zygosity=Homozygous (PubMed=20655465); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Arg (c.737T>G); ClinVar=VCV000127822; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137751 CVCL_0V01 GM16222 transformed cell line human CVCL_0V01 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137752 CVCL_1701 SK-N-DZ cancer cell line human CVCL_1701 Genome ancestry: African=1.63%; Native American=20.53%; East Asian, North=2.39%; East Asian, South=0%; South Asian=0.6%; European, North=47.7%; European, South=27.16% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137753 CVCL_0V04 GM16229 transformed cell line human CVCL_0V04 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137754 CVCL_1704 SKG-IIIa cancer cell line human CVCL_1704 Genome ancestry: African=0.18%; Native American=0%; East Asian, North=84.88%; East Asian, South=14.94%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>C); ClinVar=VCV000376624; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137755 CVCL_0V03 GM16226 transformed cell line human CVCL_0V03 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137756 CVCL_1703 SK-PN-DW cancer cell line human CVCL_1703 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.81%; East Asian, South=0%; South Asian=0%; European, North=62.77%; European, South=35.42% (PubMed=30894373). From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=8040301); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Trp78Ter (c.234G>A); ClinVar=VCV001456015; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Has lost chromosome Y as well as one copy each of chromosomes 11, 13, 17 and 18 (PubMed=31046733) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137757 CVCL_0V06 GM16232 transformed cell line human CVCL_0V06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137758 CVCL_1706 SNB-75 cancer cell line human CVCL_1706 HLA typing: A*02:01:01,11:01:01; B*35,39; C*04,12:03:01; DPB1*04:01,04:02; DQB1*03,05:01:01; DRB1*01:03,11 (PubMed=15748285); Genome ancestry: African=0.77%; Native American=0.06%; East Asian, North=2.51%; East Asian, South=0%; South Asian=0.24%; European, North=57.46%; European, South=38.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Lys (c.772G>A); ClinVar=VCV000012348; Zygosity=Homozygous (PubMed=15900046; PubMed=17088437; PubMed=18277095) Derived from sampling site: Brain. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 58 +- 2 hours (PubMed=3121170); 62.8 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR39 cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137759 CVCL_0V05 GM16231 transformed cell line human CVCL_0V05 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[380]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137760 CVCL_1705 SN12C cancer cell line human CVCL_1705 HLA typing: A*03,24; B*07,44; C*05,07:02:01; DQB1*03,06:02; DRB1*04:01:01,15:01:01 (PubMed=15748285); Genome ancestry: African=0.58%; Native American=1.06%; East Asian, North=0.47%; East Asian, South=0%; South Asian=1.82%; European, North=64.97%; European, South=31.1% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Homozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 29.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137761 CVCL_KC89 PCRP-CBFB-3B9 hybridoma house mouse CVCL_KC89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137762 CVCL_KC86 PCRP-CBFB-1E6 hybridoma house mouse CVCL_KC86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137763 CVCL_KC85 PCRP-CBFB-1E12 hybridoma house mouse CVCL_KC85 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137764 CVCL_KC88 PCRP-CBFB-2C12 hybridoma house mouse CVCL_KC88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137765 CVCL_KC87 PCRP-CBFB-1F6 hybridoma house mouse CVCL_KC87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137766 CVCL_KC82 PCRP-CBFB-1B2 hybridoma house mouse CVCL_KC82 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137767 CVCL_KC81 PCRP-CBFB-1A8 hybridoma house mouse CVCL_KC81 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137768 CVCL_KC84 PCRP-CBFB-1C5 hybridoma house mouse CVCL_KC84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137769 CVCL_KC83 PCRP-CBFB-1B5 hybridoma house mouse CVCL_KC83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137770 CVCL_KC80 PCRP-CASP8AP2-2A5 hybridoma house mouse CVCL_KC80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UKL3; Human CASP8AP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137771 CVCL_KC97 PCRP-CC2D1A-1A1 hybridoma house mouse CVCL_KC97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6P1N0; Human CC2D1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137772 CVCL_KC96 PCRP-CBX5-2D8 hybridoma house mouse CVCL_KC96 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P45973; Human CBX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137773 CVCL_KC99 PCRP-CC2D1A-1C2 hybridoma house mouse CVCL_KC99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6P1N0; Human CC2D1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137774 CVCL_KC98 PCRP-CC2D1A-1B1 hybridoma house mouse CVCL_KC98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6P1N0; Human CC2D1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137775 CVCL_KC93 PCRP-CBX2-2B10 hybridoma house mouse CVCL_KC93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14781; Human CBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137776 CVCL_KC92 PCRP-CBX1-1A4 hybridoma house mouse CVCL_KC92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P83916; Human CBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137777 CVCL_KC95 PCRP-CBX5-2A7 hybridoma house mouse CVCL_KC95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P45973; Human CBX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137778 CVCL_KC94 PCRP-CBX3-2E1 hybridoma house mouse CVCL_KC94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13185; Human CBX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137779 CVCL_KC91 PCRP-CBFB-4D9 hybridoma house mouse CVCL_KC91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137780 CVCL_KC90 PCRP-CBFB-3D4 hybridoma house mouse CVCL_KC90 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13951; Human CBFB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137781 CVCL_KC68 PCRP-BRPF1-1E2 hybridoma house mouse CVCL_KC68 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55201; Human BRPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137782 CVCL_KC67 PCRP-BRPF1-1B2 hybridoma house mouse CVCL_KC67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55201; Human BRPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137783 CVCL_KC69 PCRP-BRPF1-2A12 hybridoma house mouse CVCL_KC69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P55201; Human BRPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137784 CVCL_KC64 PCRP-BRD3-1C12 hybridoma house mouse CVCL_KC64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15059; Human BRD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137785 CVCL_KC63 PCRP-BRD1-2H2 hybridoma house mouse CVCL_KC63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95696; Human BRD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137786 CVCL_KC66 PCRP-BRD9-1H8 hybridoma house mouse CVCL_KC66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H8M2; Human BRD9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137787 CVCL_KC65 PCRP-BRD3-1D12 hybridoma house mouse CVCL_KC65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15059; Human BRD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137788 CVCL_KC60 PCRP-BRD1-1B5 hybridoma house mouse CVCL_KC60 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O95696; Human BRD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137789 CVCL_KC62 PCRP-BRD1-2E4 hybridoma house mouse CVCL_KC62 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95696; Human BRD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137790 CVCL_KC61 PCRP-BRD1-2B7 hybridoma house mouse CVCL_KC61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95696; Human BRD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137791 CVCL_KC79 PCRP-CASP8AP2-1D6 hybridoma house mouse CVCL_KC79 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UKL3; Human CASP8AP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137792 CVCL_KC78 PCRP-CASP8AP2-1D2 hybridoma house mouse CVCL_KC78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UKL3; Human CASP8AP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137793 CVCL_KC75 PCRP-BSX-8F2 hybridoma house mouse CVCL_KC75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q3C1V8; Human BSX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137794 CVCL_KC74 PCRP-BSX-5H1 hybridoma house mouse CVCL_KC74 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q3C1V8; Human BSX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137795 CVCL_KC77 PCRP-CARM1-1B4 hybridoma house mouse CVCL_KC77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86X55; Human CARM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137796 CVCL_KC76 PCRP-CAMKK2-1H7 hybridoma house mouse CVCL_KC76 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96RR4; Human CAMKK2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137797 CVCL_KC71 PCRP-BRWD1-1E12 hybridoma house mouse CVCL_KC71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NSI6; Human BRWD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137798 CVCL_KC70 PCRP-BRPF1-2E11 hybridoma house mouse CVCL_KC70 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P55201; Human BRPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137799 CVCL_KC73 PCRP-BSX-4D10 hybridoma house mouse CVCL_KC73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q3C1V8; Human BSX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137800 CVCL_KC72 PCRP-BRWD1-2C12 hybridoma house mouse CVCL_KC72 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NSI6; Human BRWD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137801 CVCL_KC46 PCRP-BATF2-2B9 hybridoma house mouse CVCL_KC46 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N1L9; Human BATF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137802 CVCL_KC45 PCRP-BATF-4G2 hybridoma house mouse CVCL_KC45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16520; Human BATF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137803 CVCL_KC48 PCRP-BATF3-1H12 hybridoma house mouse CVCL_KC48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NR55; Human BATF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137804 CVCL_KC47 PCRP-BATF3-1E5 hybridoma house mouse CVCL_KC47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NR55; Human BATF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137805 CVCL_KC42 PCRP-BATF-1C10 hybridoma house mouse CVCL_KC42 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16520; Human BATF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137806 CVCL_KC41 PCRP-BACH2-5B11 hybridoma house mouse CVCL_KC41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BYV9; Human BACH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137807 CVCL_KC44 PCRP-BATF-2E8 hybridoma house mouse CVCL_KC44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16520; Human BATF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137808 CVCL_KC43 PCRP-BATF-1E10 hybridoma house mouse CVCL_KC43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16520; Human BATF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137809 CVCL_KC40 PCRP-BACH2-3B8 hybridoma house mouse CVCL_KC40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYV9; Human BACH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137810 CVCL_KC39 PCRP-BACH2-2C5 hybridoma house mouse CVCL_KC39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BYV9; Human BACH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137811 CVCL_KC38 PCRP-BACH2-1E4 hybridoma house mouse CVCL_KC38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BYV9; Human BACH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137812 CVCL_KC57 PCRP-BOLA3-1A5 hybridoma house mouse CVCL_KC57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q53S33; Human BOLA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137813 CVCL_KC56 PCRP-BMI1-1H1 hybridoma house mouse CVCL_KC56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35226; Human BMI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137814 CVCL_KC59 PCRP-BOLA3-2B8 hybridoma house mouse CVCL_KC59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q53S33; Human BOLA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137815 CVCL_KC58 PCRP-BOLA3-1C10 hybridoma house mouse CVCL_KC58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q53S33; Human BOLA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137816 CVCL_KC53 PCRP-BCL6-1D3 hybridoma house mouse CVCL_KC53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P41182; Human BCL6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137817 CVCL_KC52 PCRP-BCL6-1B1 hybridoma house mouse CVCL_KC52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P41182; Human BCL6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137818 CVCL_KC55 PCRP-BMI1-1G9 hybridoma house mouse CVCL_KC55 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35226; Human BMI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137819 CVCL_KC54 PCRP-BHLHA9-1D1 hybridoma house mouse CVCL_KC54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7RTU4; Human BHLHA9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137820 CVCL_KC51 PCRP-BCL2L2-1A4 hybridoma house mouse CVCL_KC51 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92843; Human BCL2L2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137821 CVCL_KC50 PCRP-BBX-2F6 hybridoma house mouse CVCL_KC50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8WY36; Human BBX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137822 CVCL_KC49 PCRP-BATF3-1H3 hybridoma house mouse CVCL_KC49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NR55; Human BATF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21137823 CVCL_9P14 DD3276 transformed cell line human CVCL_9P14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137824 CVCL_9P13 DD3275 transformed cell line human CVCL_9P13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137825 CVCL_9P16 DD3278 transformed cell line human CVCL_9P16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137826 CVCL_9P15 DD3277 transformed cell line human CVCL_9P15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137827 CVCL_9P10 DD3272 transformed cell line human CVCL_9P10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137828 CVCL_9P12 DD3274 transformed cell line human CVCL_9P12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137829 CVCL_9P11 DD3273 transformed cell line human CVCL_9P11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137830 CVCL_0V71 GM17991 transformed cell line human CVCL_0V71 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137831 CVCL_1771 TGW cancer cell line human CVCL_1771 Genome ancestry: African=0%; Native American=0%; East Asian, North=71.87%; East Asian, South=26.74%; South Asian=0.97%; European, North=0.42%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 32 hours (lot 06012007), ~27 hours (lot 04172014) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137832 CVCL_0V70 GM17990 transformed cell line human CVCL_0V70 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137833 CVCL_1770 TGBC24TKB cancer cell line human CVCL_1770 Genome ancestry: African=0%; Native American=0%; East Asian, North=75.8%; East Asian, South=23.94%; South Asian=0%; European, North=0.26%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137834 CVCL_9P07 DD3269 transformed cell line human CVCL_9P07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137835 CVCL_0V73 GM17993 transformed cell line human CVCL_0V73 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137836 CVCL_1773 TK-10 cancer cell line human CVCL_1773 HLA typing: A*33:01; B*14:02; C*08:02; DPB1*04:02; DQB1*05:01:01; DRB1*01:02:01 (PubMed=15748285); HLA typing: A*33:01,33:01; B*14:02,14:02; C*08:02,08:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=26589293); Genome ancestry: African=1.52%; Native American=2.2%; East Asian, North=0.11%; East Asian, South=1.52%; South Asian=12.26%; European, North=9%; European, South=73.4% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu264Arg (c.791T>G); Zygosity=Heterozygous (PubMed=17088437; PubMed=18277095; Cosmic-CLP; DepMap) Derived from sampling site: Kidney. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25 hours, at 155th passage (PubMed=3594443); 51.3 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137837 CVCL_9P06 DD3268 transformed cell line human CVCL_9P06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137838 CVCL_0V72 GM17992 transformed cell line human CVCL_0V72 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137839 CVCL_9P09 DD3271 transformed cell line human CVCL_9P09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137840 CVCL_0V75 GM17995 transformed cell line human CVCL_0V75 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137841 CVCL_1775 TUR cancer cell line human CVCL_1775 Genome ancestry: African=0%; Native American=0.04%; East Asian, North=0.5%; East Asian, South=0%; South Asian=1.33%; European, North=75.18%; European, South=22.94% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (DepMap); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (DepMap); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-high) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137842 CVCL_9P08 DD3270 transformed cell line human CVCL_9P08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137843 CVCL_0V74 GM17994 transformed cell line human CVCL_0V74 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137844 CVCL_1774 TT cancer cell line human CVCL_1774 HLA typing: A*02:01,03:01; B*51:01,67:02; C*12:03,14:02; DQB1*05:01,06:07; DRB1*01:01,11:10 (PubMed=26589293); Genome ancestry: African=2.11%; Native American=0%; East Asian, North=2.03%; East Asian, South=0%; South Asian=6.11%; European, North=32.67%; European, South=57.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Cys634Trp (c.1902C>G); ClinVar=VCV000013918; Zygosity=Heterozygous (PubMed=7736432; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11602; TBX3; Simple; p.Trp197Ter (c.591G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 83 hours (ATCC=CRL-1803); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137845 CVCL_0V77 GM17997 transformed cell line human CVCL_0V77 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137846 CVCL_0V76 GM17996 transformed cell line human CVCL_0V76 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137847 CVCL_1776 TYK-nu cancer cell line human CVCL_1776 HLA typing: A*02:01,26:03; B*35:102,40:05; C*03:03,07:02; DRB1*13:07,15:01 (PubMed=26589293); Genome ancestry: African=0.42%; Native American=0.15%; East Asian, North=83.85%; East Asian, South=15.58%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=25846456; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25846456; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=25846456; Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137848 CVCL_0V79 GM17999 transformed cell line human CVCL_0V79 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137849 CVCL_1779 UACC-257 cancer cell line human CVCL_1779 HLA typing: A*02:01:01; B*18,44; C*05,07; DPB1*04:01; DQB1*03:01:01,03:02; DRB1*04:01:01 (PubMed=15748285); HLA typing: A*02:01,02:01; B*37:09,44:02; C*05:01,07:04; DQA1*03:02,03:02; DQB1*03:02,03:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.57%; East Asian, North=0.83%; East Asian, South=0%; South Asian=0%; European, North=65.94%; European, South=32.65% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17088437; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 38.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel; Part of: TCGA-110-CL cell line panel 21137850 CVCL_1778 1.1B4 hybrid cell line CVCL_1778 CL:0000010 Discontinued: ECACC; 10012801; true. Characteristics: Insulin secreting Doubling time: 23 +- 1.7 hours (PubMed=21515691); ~20 hours (ECACC=10012801) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00599; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 00112811 Problematic cell line: Misidentified/contaminated Originally thought to be an hybrid cell line obtained by electrofusion of a primary culture of human pancreatic islets with the PANC-1 but found to contain rat DNA (ECACC). 21137851 CVCL_0V78 GM17998 transformed cell line human CVCL_0V78 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137852 CVCL_9P25 DD3287 transformed cell line human CVCL_9P25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137853 CVCL_9P24 DD3286 transformed cell line human CVCL_9P24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137854 CVCL_9P27 DD3300 transformed cell line human CVCL_9P27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137855 CVCL_9P26 DD3298 transformed cell line human CVCL_9P26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137856 CVCL_9P21 DD3283 transformed cell line human CVCL_9P21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137857 CVCL_9P20 DD3282 transformed cell line human CVCL_9P20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137858 CVCL_9P23 DD3285 transformed cell line human CVCL_9P23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137859 CVCL_9P22 DD3284 transformed cell line human CVCL_9P22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137860 CVCL_0V80 GM18000 transformed cell line human CVCL_0V80 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137861 CVCL_1780 UACC-62 cancer cell line human CVCL_1780 HLA typing: A*02,32; B*39,44; C*05,12; DPB1*04:01,14:01; DQB1*03:01:01,06:03; DRB1*12,13:01:01 (PubMed=15748285); HLA typing: A*02:01,32:03; B*39:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0.45%; Native American=0%; East Asian, North=0.45%; East Asian, South=0%; South Asian=1.83%; European, North=67.39%; European, South=29.88% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=12068308; PubMed=17088437; PubMed=29492214; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (PubMed=17088437; Cosmic-CLP; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 31.3 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137862 CVCL_0V82 GM18102 transformed cell line human CVCL_0V82 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137863 CVCL_1782 UACC-893 cancer cell line human CVCL_1782 HLA typing: B*46:01; C*16:01,06:02 (PubMed=25960936); HLA typing: A*01:01,29:02; B*07:17,15:50; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=1.96%; Native American=0%; East Asian, North=4.64%; East Asian, South=0%; South Asian=0%; European, North=57.9%; European, South=35.5% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.His233Gln (c.699C>G); ClinVar=VCV000233773; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635; ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=16541312; ATCC) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 120 hours (PubMed=1674877); 248.53 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21137864 CVCL_0V81 GM18101 transformed cell line human CVCL_0V81 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137865 CVCL_1781 UACC-812 cancer cell line human CVCL_1781 HLA typing: A*68:01,02:05; B*15:03,51:01; C*08:01,12:03; DQB1*02:01,04:01; DRB1*08:04,04:04 (PubMed=25960936); HLA typing: A*02:14,68:01; B*46:01,51:01; C*08:01,12:03 (PubMed=26589293); Genome ancestry: African=6.53%; Native American=50.48%; East Asian, North=6.42%; East Asian, South=0%; South Asian=1.78%; European, North=13.71%; European, South=21.07% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ser1140Gly (c.3418A>G); ClinVar=VCV000041817; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Thr522Ile (c.1565C>T); ClinVar=VCV000216588; Zygosity=Heterozygous (PubMed=19593635) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H2BK120ub ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K23ac ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: H4K8ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 100 hours (PubMed=1674877); 104.68 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21137866 CVCL_9P18 DD3280 transformed cell line human CVCL_9P18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137867 CVCL_0V84 GM18104 transformed cell line human CVCL_0V84 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137868 CVCL_1784 UMC-11 cancer cell line human CVCL_1784 HLA typing: A*03:02,29:02; B*35:08,51:09; C*04:01,16:01 (PubMed=26589293); Genome ancestry: African=0.55%; Native American=0%; East Asian, North=1.07%; East Asian, South=0.34%; South Asian=2.02%; European, North=69.48%; European, South=26.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu536fs*14 (c.1606_1612delCTAGACG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp228fs*19 (c.681delT) (p.S227fs); Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137869 CVCL_9P17 DD3279 transformed cell line human CVCL_9P17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137870 CVCL_0V83 GM18103 transformed cell line human CVCL_0V83 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137871 CVCL_1783 UM-UC-3 cancer cell line human CVCL_1783 HLA typing: A*02:01,33:01; B*07:02,14:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=3.66%; Native American=0%; East Asian, North=3.71%; East Asian, South=0%; South Asian=0%; European, North=55.69%; European, South=36.94% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; Cosmic-CLP; DepMap) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: GPI-anchored proteins analysis by proteomics; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=3761468); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: UBC-40 urothelial bladder cancer cell line index 21137872 CVCL_0V86 GM18106 transformed cell line human CVCL_0V86 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137873 CVCL_1786 VM-CUB-1 cancer cell line human CVCL_1786 Genome ancestry: African=1.21%; Native American=0%; East Asian, North=3.22%; East Asian, South=0%; South Asian=0%; European, North=60.31%; European, South=35.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=27270441) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~30-45 hours (DSMZ=ACC-400); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: UBC-40 urothelial bladder cancer cell line index 21137874 CVCL_9P19 DD3281 transformed cell line human CVCL_9P19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137875 CVCL_0V85 GM18105 transformed cell line human CVCL_0V85 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137876 CVCL_1785 VA-ES-BJ cancer cell line human CVCL_1785 Genome ancestry: African=0.49%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=3.35%; European, North=67.75%; European, South=28.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Near triploid karyotype Trisomy of chromosomes 2, 5, 8, 10, 12, 13, 16, 17, 18 and 19, tetrasomy of chromosomes 6, 20 and 21 and pentasomy of chromosome 7 (PubMed=21552805).; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36-39 hours (PubMed=21552805); ~32 hours (PubMed=21357725); ~60-90 hours (DSMZ=ACC-328); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137877 CVCL_0V88 GM18108 transformed cell line human CVCL_0V88 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137878 CVCL_1788 VMRC-LCP cancer cell line human CVCL_1788 Genome ancestry: African=0.95%; Native American=0%; East Asian, North=1.52%; East Asian, South=0%; South Asian=0.62%; European, North=62.75%; European, South=34.15% (PubMed=30894373) From: Bean M.A.; Virginia Mason Research Center; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Doubling time: 93 hours (lot 082994), ~79 hours (lot 11132014) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21137879 CVCL_0V87 GM18107 transformed cell line human CVCL_0V87 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137880 CVCL_1787 VMRC-LCD cancer cell line human CVCL_1787 HLA typing: A*02:01,02:01; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0.98%; Native American=0%; East Asian, North=3.69%; East Asian, South=0%; South Asian=0%; European, North=56.21%; European, South=39.12% (PubMed=30894373) From: Bean M.A.; Virginia Mason Research Center; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=10536175; PubMed=12794755; PubMed=20557307; Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~51 hours (lot 01182010) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137881 CVCL_0V89 GM18109 transformed cell line human CVCL_0V89 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137882 CVCL_1789 VMRC-MELG cancer cell line human CVCL_1789 Genome ancestry: African=4.63%; Native American=0%; East Asian, North=0.15%; East Asian, South=2.24%; South Asian=0.66%; European, North=63.56%; European, South=28.76% (PubMed=30894373). From: Bean M.A.; Virginia Mason Research Center; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 60-80 hours (lot 06232008) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137883 CVCL_0V51 GM17969 transformed cell line human CVCL_0V51 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137884 CVCL_1751 TE 381.T cancer cell line human CVCL_1751 CL:0000010 Omics: SNP array analysis. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137885 CVCL_0V50 GM17968 transformed cell line human CVCL_0V50 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137886 CVCL_1750 TE 354.T cancer cell line human CVCL_1750 CL:0000010 Derived from sampling site: Skin. Discontinued: BCRJ; 0290; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137887 CVCL_0V53 GM17971 transformed cell line human CVCL_0V53 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137888 CVCL_1753 TE 418.T cancer cell line human CVCL_1753 CL:0000010 Discontinued: ATCC; CRL-7766; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137889 CVCL_0V52 GM17970 transformed cell line human CVCL_0V52 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137890 CVCL_1752 TE 417.T cancer cell line human CVCL_1752 CL:0000010 Discontinued: ATCC; CRL-7765; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137891 CVCL_0V55 GM17973 transformed cell line human CVCL_0V55 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137892 CVCL_1755 TE 617.T cancer cell line human CVCL_1755 HLA typing: A*24:03,24:03; B*07:02,51:09; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.43%; East Asian, North=0%; East Asian, South=0%; South Asian=2.79%; European, North=65.86%; European, South=29.92% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7774; true. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137893 CVCL_0V54 GM17972 transformed cell line human CVCL_0V54 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137894 CVCL_1754 TE 441.T cancer cell line human CVCL_1754 HLA typing: A*03:01,24:02; B*15:01,44:03; C*02:02,04:01 (PubMed=26589293); Genome ancestry: African=87.48%; Native American=0.35%; East Asian, North=1.73%; East Asian, South=0%; South Asian=0.48%; European, North=4.76%; European, South=5.2% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137895 CVCL_0V57 GM17975 transformed cell line human CVCL_0V57 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137896 CVCL_1757 TE 76.T finite cell line human CVCL_1757 CL:0000010 Derived from sampling site: Bone; coccyx. Discontinued: ATCC; CRL-7732; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137897 CVCL_0V56 GM17974 transformed cell line human CVCL_0V56 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137898 CVCL_1756 TE 671 cancer cell line human CVCL_1756 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Discontinued: ATCC; HTB-139; true; Discontinued: DSMZ; ACC-263; true; Discontinued: ECACC; 89071904; true Female Doubling time: ~70-80 hours (DSMZ=ACC-263) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00101 Problematic cell line: Contaminated Shown to be a RD derivative (PubMed=2650908; PubMed=2739733; PubMed=2911385; PubMed=20143388). Originally thought to originate from a 6 year old female patient with a medulloblastoma. 21137899 CVCL_0V59 GM17977 transformed cell line human CVCL_0V59 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137900 CVCL_1759 TE-1 cancer cell line human CVCL_1759 HLA typing: A*24:02,26:01; B*35:01,39:01; C*03:03,07:02 (PubMed=26589293); Genome ancestry: African=0.32%; Native American=0%; East Asian, North=85.61%; East Asian, South=11.65%; South Asian=0%; European, North=0%; European, South=2.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Unspecified (PubMed=9096669) Population: Japanese; Derived from sampling site: Esophagus. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 60 hours (PubMed=520749); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137901 CVCL_0V58 GM17976 transformed cell line human CVCL_0V58 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137902 CVCL_1758 TE 84.T cancer cell line human CVCL_1758 CL:0000010 Discontinued: ATCC; CRL-7944; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137903 CVCL_9P03 DD3259 finite cell line human CVCL_9P03 CL:0000010 Karyotypic information: 46,XX,t(1;4)(q23;p15.3)mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21137904 CVCL_9P02 DD3250 transformed cell line human CVCL_9P02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21137905 CVCL_9P05 DD3261 transformed cell line human CVCL_9P05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137906 CVCL_9P04 DD3260 finite cell line human CVCL_9P04 CL:0000010 Karyotypic information: 46,XY,der(11)t(3;11)(q27.3;q24.2)pat (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21137907 CVCL_9P01 DD3249 transformed cell line human CVCL_9P01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137908 CVCL_9P00 DD3248 transformed cell line human CVCL_9P00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21137909 CVCL_0V60 GM17978 transformed cell line human CVCL_0V60 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137910 CVCL_1760 TE-10 cancer cell line human CVCL_1760 HLA typing: A*02,24:02; C*01:02,03:02 (PubMed=9178645); HLA typing: A*02:19,24:02; B*51:01,56:01; C*01:02,14:02; DQB1*03:02,03:02; DRB1*01:01,13:17 (PubMed=26589293); Genome ancestry: African=5.82%; Native American=0%; East Asian, North=81.86%; East Asian, South=7.66%; South Asian=0%; European, North=0%; European, South=4.65% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=9096669) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137911 CVCL_0V62 GM17980 transformed cell line human CVCL_0V62 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137912 CVCL_1762 TE-12 cancer cell line human CVCL_1762 Genome ancestry: African=0%; Native American=0.13%; East Asian, North=76.19%; East Asian, South=22.61%; South Asian=0.51%; European, North=0.56%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: TKG; TKG 0263; probable. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00273 Problematic cell line: Contaminated TE-2, TE-3, TE-7, TE-12 and TE-13 have been shown to be identical (PubMed=17804709; PubMed=20143388). 21137913 CVCL_0V61 GM17979 transformed cell line human CVCL_0V61 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137914 CVCL_1761 TE-11 cancer cell line human CVCL_1761 HLA typing: A*24:02,26:01; C*14:01 (PubMed=9178645); HLA typing: A*24:02,24:02; B*51:01,51:01; C*03:04,03:04; DQB1*06:07,06:07 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=89.62%; East Asian, South=10.38%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Unspecified (PubMed=7732013; PubMed=10741724) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137915 CVCL_0V64 GM17982 transformed cell line human CVCL_0V64 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21137916 CVCL_1764 TE-5 cancer cell line human CVCL_1764 Genome ancestry: African=0.34%; Native American=0.66%; East Asian, North=86.45%; East Asian, South=11.83%; South Asian=0.36%; European, North=0%; European, South=0.36% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Unspecified (PubMed=7732013) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137917 CVCL_0V63 GM17981 transformed cell line human CVCL_0V63 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21137918 CVCL_1763 TE-15 cancer cell line human CVCL_1763 Genome ancestry: African=0%; Native American=0%; East Asian, North=83.86%; East Asian, South=15.31%; South Asian=0.83%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>A; ClinVar=VCV000634769; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=9096669) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137919 CVCL_0V66 GM17986 transformed cell line human CVCL_0V66 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137920 CVCL_1766 TE-8 cancer cell line human CVCL_1766 HLA typing: A*24:02,26:01; B*55; C*01:02 (PubMed=9178645); HLA typing: A*26:01,26:01; B*55:02,55:02; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=1.28%; Native American=0%; East Asian, North=88.72%; East Asian, South=6.31%; South Asian=0%; European, North=0%; European, South=3.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137921 CVCL_0V65 GM17983 transformed cell line human CVCL_0V65 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137922 CVCL_1765 TE-6 cancer cell line human CVCL_1765 HLA typing: A*24:02,24:02; B*40:06,40:06; C*03:03,08:01 (PubMed=26589293); Genome ancestry: African=0.98%; Native American=0%; East Asian, North=84.09%; East Asian, South=13.31%; South Asian=0%; European, North=0%; European, South=1.62% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137923 CVCL_0V68 GM17988 transformed cell line human CVCL_0V68 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137924 CVCL_1768 TGBC11TKB cancer cell line human CVCL_1768 HLA typing: A*26:01,26:01; B*35:10,35:10; C*03:03,03:03; DQA1*01:02,05:02; DRB1*13:60,13:60 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=81.43%; East Asian, South=18.57%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137925 CVCL_0V67 GM17987 transformed cell line human CVCL_0V67 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137926 CVCL_1767 TE-9 cancer cell line human CVCL_1767 HLA typing: A*33:02; B*15:03 (PubMed=9023415); HLA typing: A*24:02,24:02; B*15:07,40:06; C*03:03,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.49%; East Asian, North=84.82%; East Asian, South=14.68%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: TKG; TKG 0572; probable Male Doubling time: 25 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21137927 CVCL_0V69 GM17989 transformed cell line human CVCL_0V69 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137928 CVCL_1769 TGBC1TKB cancer cell line human CVCL_1769 Genome ancestry: African=0%; Native American=0.16%; East Asian, North=75.35%; East Asian, South=24.48%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176fs*6 (c.525_526insGCGC); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 41 hours (PubMed=9824643); 45 hours (PubMed=32293552); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137929 CVCL_0V31 GM18583 transformed cell line human CVCL_0V31 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137930 CVCL_1731 SW900 cancer cell line human CVCL_1731 HLA typing: A*33:01,33:01; B*14:02,14:02; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=0.45%; Native American=0%; East Asian, North=1.4%; East Asian, South=0%; South Asian=1.83%; European, North=65.68%; European, South=30.63% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln167Ter (c.499C>T); ClinVar=VCV000528250; Zygosity=Homozygous (Cosmic-CLP) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: TCGA-110-CL cell line panel 21137931 CVCL_0V30 GM18581 transformed cell line human CVCL_0V30 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137932 CVCL_1730 SW872 cancer cell line human CVCL_1730 HLA typing: A*02:01:01G; B*27:05:02,40:01:02; C*01:02:01,03:04:01; DPB1*02:01:02; DQA1*04:01:01,05:05:01; DQB1*03:01:01,04:02:01; DRB1*08:01:01;13:03:01 (CLS=300405); Genome ancestry: African=1.25%; Native American=0%; East Asian, North=2.4%; East Asian, South=0.14%; South Asian=1.73%; European, North=69.64%; European, South=24.84% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=26643872; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (PubMed=26643872; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Asn (c.752T>A); ClinVar=VCV000528254; Zygosity=Homozygous (PubMed=16888811; PubMed=26643872; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=16888811); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137933 CVCL_0V33 GM18644 transformed cell line human CVCL_0V33 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137934 CVCL_1733 SW962 cancer cell line human CVCL_1733 Genome ancestry: African=4.03%; Native American=0.7%; East Asian, North=4.56%; East Asian, South=0%; South Asian=0%; European, North=58.72%; European, South=31.99% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137935 CVCL_0V32 GM18598 transformed cell line human CVCL_0V32 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137936 CVCL_1732 SW954 cancer cell line human CVCL_1732 Genome ancestry: African=0.24%; Native American=0%; East Asian, North=0.14%; East Asian, South=0.57%; South Asian=1.33%; European, North=70.36%; European, South=27.38% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137937 CVCL_0V35 GM07340 transformed cell line human CVCL_0V35 HLA typing: A*02:01,03:01; B*13:02,07:02; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*03:01,04:01:01; DQA1*01:02,02:01; DQB1*02:01,06:02; DRB1*07:01,15:01; DRB4*01; DRB5*01 (IPD-IMGT/HLA=25812) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133113 21137938 CVCL_1735 SU-DHL-5 cancer cell line human CVCL_1735 HLA typing: A*03:01,24:02; B*07:02,52:01; C*07:02,12:02 (PubMed=26589293); Genome ancestry: African=1.37%; Native American=0%; East Asian, North=1.36%; East Asian, South=0%; South Asian=1.05%; European, North=63.92%; European, South=32.3% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572) Doubling time: ~40 hours (DSMZ=ACC-571); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137939 CVCL_0V34 GM18646 transformed cell line human CVCL_0V34 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137940 CVCL_1734 SW982 cancer cell line human CVCL_1734 HLA typing: A*02:01,02:01; B*07:02,49:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.11%; East Asian, North=0%; East Asian, South=0%; South Asian=2.82%; European, North=67.54%; European, South=29.52% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Synovium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: Stated to originate from a patient with a biphasic synovial sarcoma, however does not contain the SST-SSX1/SSX2 translocation which is typical of synovial sarcoma 21137941 CVCL_0V37 GM07342 transformed cell line human CVCL_0V37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134007 21137942 CVCL_1737 TC-YIK cancer cell line human CVCL_1737 Genome ancestry: African=0%; Native American=0%; East Asian, North=74.47%; East Asian, South=25.52%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9885; ARID4A; Simple; p.Glu565Ter (c.1693G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Established from the YIK-1 xenograft which was obtained by mutliple serial transplantation of the original tumor in nude mice Doubling time: ~21.6 hours, at 119th passage (PubMed=1849445); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137943 CVCL_0V36 GM07341 transformed cell line human CVCL_0V36 HLA typing: A*02:01,03:01; B*07:02,37:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*02:01,04:01; DQA1*01:01,04:01; DQB1*04:02,05:01; DRB1*08:01,10:01 (IPD-IMGT/HLA=25836) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133314 21137944 CVCL_1736 TALL-1 [Human adult T-ALL] cancer cell line human CVCL_1736 Genome ancestry: African=0%; Native American=0.7%; East Asian, North=75.83%; East Asian, South=19.85%; South Asian=1.99%; European, North=0%; European, South=1.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=10071127; PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 73 hours (PubMed=305872); ~50-70 hours (DSMZ=ACC-521); 36.2 hours (lot 062994), ~2 days (lot 08072008), ~41 hours (lot 12172015), ~39 hours (lot 11112021) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutation indicated to be at p.Arg175His (c.524G>A) in PubMed=10071127 21137945 CVCL_0V39 GM07344 transformed cell line human CVCL_0V39 HLA typing: A*02:01,03:01; B*07:02:01,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01; DRB4*01; DRB5*01 (IPD-IMGT/HLA=25861) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134106 21137946 CVCL_1739 TE 115.T finite cell line human CVCL_1739 CL:0000010 Derived from metastatic site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-7744; probable Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137947 CVCL_0V38 GM07343 transformed cell line human CVCL_0V38 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01; DQA1*01:02,03:01; DQB1*03:02:01,06:02; DRB1*04:04,15:01; DRB4*01 (IPD-IMGT/HLA=25858) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134103 21137948 CVCL_1738 TCCSUP cancer cell line human CVCL_1738 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.27%; East Asian, South=0.03%; South Asian=1.48%; European, North=68.68%; European, South=28.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Homozygous (PubMed=7787250; PubMed=9850064; PubMed=27270441) Population: Caucasian Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 28 hours (PubMed=3708594); 46 hours (PubMed=25984343); 49.2 hours (PubMed=26055179); ~30-40 hours (DSMZ=ACC-377); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index 21137949 CVCL_0V40 GM11932 transformed cell line human CVCL_0V40 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142413 21137950 CVCL_1740 TE 125.T undefined cell line type human CVCL_1740 HLA typing: A*02:06,11:01; B*35:21,51:01; C*04:01,15:09; DQA1*01:02,01:02; DRB1*13:02,15:66 (PubMed=26589293); Genome ancestry: African=5.57%; Native American=41.29%; East Asian, North=1.9%; East Asian, South=0.18%; South Asian=0%; European, North=25.13%; European, South=25.92% (PubMed=30894373) CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7945; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a rhabdomyosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21137951 CVCL_0V42 GM12046 transformed cell line human CVCL_0V42 HLA typing: A*01:01,02:05; B*50:01,57:01; C*06:02,06:02; DPA1*01:03,02:01:01; DPB1*03:01:01,11:01; DQA1*02:01,05:01; DQB1*02:01,02:01; DRB1*03:01,07:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25887) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134614 21137952 CVCL_1742 TE 149.T cancer cell line human CVCL_1742 CL:0000010 Discontinued: ATCC; CRL-7751; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137953 CVCL_0V41 GM11933 transformed cell line human CVCL_0V41 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 142414 21137954 CVCL_1741 TE 130.T finite cell line human CVCL_1741 CL:0000010 Derived from sampling site: Bone; coccyx. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137955 CVCL_0V44 GM12097 transformed cell line human CVCL_0V44 HLA typing: A*02:01,03:01; B*56:01,07:02; C*01:02,07:02; DPA1*01:03,02:01:01; DPB1*04:01,11:01:01; DQA1*01:02,04:01; DQB1*04:02,06:02; DRB1*08:01,15:01; DRB5*01:01 (IPD-IMGT/HLA=25833) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133214 21137956 CVCL_1744 TE 161.T cancer cell line human CVCL_1744 CL:0000010 Derived from sampling site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-7753; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137957 CVCL_0V43 GM12096 transformed cell line human CVCL_0V43 HLA typing: A*01:01,03:01; B*35:01,08:01; C*04:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*04:01,05:01; DQB1*02:01,04:02; DRB1*03:01,08:01; DRB3*10:01 (IPD-IMGT/HLA=25832) CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133213 21137958 CVCL_1743 TE 159.T undefined cell line type human CVCL_1743 HLA typing: A*02:01,11:01; B*15:01,52:01; C*04:01,12:02; DRB1*01:03,15:01 (PubMed=26589293); Genome ancestry: African=1.8%; Native American=21.64%; East Asian, North=2.4%; East Asian, South=0%; South Asian=1.76%; European, North=45.27%; European, South=27.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Unspecified (DepMap) Derived from sampling site: Cell type=Fibroblast. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a rhabdomyosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21137959 CVCL_0V46 GM17963 transformed cell line human CVCL_0V46 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137960 CVCL_1746 TE 175.T cancer cell line human CVCL_1746 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7755; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137961 CVCL_0V45 GM17962 transformed cell line human CVCL_0V45 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137962 CVCL_1745 TE 170.M finite cell line human CVCL_1745 CL:0000010 Derived from sampling site: Fascia. Discontinued: ATCC; CRL-7754; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137963 CVCL_0V48 GM17966 transformed cell line human CVCL_0V48 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137964 CVCL_1748 TE 206.T cancer cell line human CVCL_1748 CL:0000010 Discontinued: ATCC; CRL-7758; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137965 CVCL_0V47 GM17965 transformed cell line human CVCL_0V47 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137966 CVCL_1747 TE 199.T undefined cell line type human CVCL_1747 CL:0000010 Discontinued: ATCC; CRL-7757; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137967 CVCL_0V49 GM17967 transformed cell line human CVCL_0V49 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137968 CVCL_1749 TE 353.Sk finite cell line human CVCL_1749 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21137969 CVCL_0V19 GM18484 transformed cell line human CVCL_0V19 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137970 CVCL_1719 SW156 cancer cell line human CVCL_1719 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21137971 CVCL_0V18 HCC3303 cancer cell line human CVCL_0V18 CL:0000010 21137972 CVCL_1718 SW1463 cancer cell line human CVCL_1718 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:06 (PubMed=26589293); Genome ancestry: African=5.61%; Native American=0%; East Asian, North=8.03%; East Asian, South=0%; South Asian=0%; European, North=41.75%; European, South=44.61% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val452Serfs*7 (c.1348_1349GT[3]) (c.1354_1355delGT); ClinVar=VCV000537527; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=12068308; PubMed=28683746; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=28683746; ATCC; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21137973 CVCL_0V11 GM16241 transformed cell line human CVCL_0V11 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137974 CVCL_1711 SR cancer cell line human CVCL_1711 HLA typing: A*02,03; B*37:01,39:01; C*06:02,12:03:01; DPB1*04:01; DQB1*05:01:01,05:02:01; DRB1*01,16:01:01 (PubMed=15748285); HLA typing: A*02:01,03:01; B*37:01,39:01; C*06:02,12:03; DQA1*01:01,01:01; DQB1*05:02,05:02; DRB1*01:01,16:01 (PubMed=26589293); HLA typing: A*02:01:01,03:01:01; B*37:01:01,39:01:01; C*06:02:01,12:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:02,01:01:01; DQB1*05:01:01,05:02:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,16:01:01 (DSMZCellDive=ACC-369); Genome ancestry: African=0%; Native American=0%; East Asian, North=3.12%; East Asian, South=0%; South Asian=0%; European, North=62.78%; European, South=34.1% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=25485619; PubMed=29899875) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: DepMap; ACH-001665; true Male Doubling time: ~30 hours (DSMZ=ACC-369); 28.7 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21137975 CVCL_0V10 GM16240 transformed cell line human CVCL_0V10 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21137976 CVCL_1710 SNU-C2B cancer cell line human CVCL_1710 Genome ancestry: African=0%; Native American=0.36%; East Asian, North=60.61%; East Asian, South=39.03%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=20570890); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (PubMed=16418264); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=16418264) Population: Korean; Derived from sampling site: Cecum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI-high) (PubMed=2592653; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: Seoul National University (SNU) cell line collection 21137977 CVCL_0V13 293T GNE transformed cell line human CVCL_0V13 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21137978 CVCL_1713 SUP-B8 cancer cell line human CVCL_1713 Genome ancestry: African=0.05%; Native American=0%; East Asian, North=0.63%; East Asian, South=0.05%; South Asian=1.61%; European, North=69.66%; European, South=28% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Arg1192Cys (c.3574C>T); ClinVar=VCV000570308; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (DepMap) Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137979 CVCL_0V12 OVAS cancer cell line human CVCL_0V12 From: Minaguchi H.; Yokohama City University; Yokohama; Japan CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=23430509) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0403; true Female 21137980 CVCL_1712 ST486 cancer cell line human CVCL_1712 HLA typing: A*02:11,25:01; B*18:01,52:01; C*12:03,15:02 (PubMed=26589293); Genome ancestry: African=0.3%; Native American=2.43%; East Asian, North=1.27%; East Asian, South=0%; South Asian=1.74%; European, North=54.96%; European, South=39.3% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6328505; PubMed=9643977); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493) Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Virology: EBV-negative Doubling time: 20 hours (PubMed=8402660); 19-20 hours (ATCC=CRL-1647); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21137981 CVCL_0V15 NCE-G 28T cancer cell line human CVCL_0V15 HLA typing: A*01:01,31:01; B*08:01,13:02; C*06:02,07:01 (PubMed=26589293) CL:0000010 Derived from sampling site: Brain; left parietal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21137982 CVCL_1715 SW1088 cancer cell line human CVCL_1715 HLA typing: A*01:01,03:01; B*08:01,44:02; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.6%; East Asian, North=1.08%; East Asian, South=0.34%; South Asian=0%; European, North=68.27%; European, South=29.71% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030); Part of: TCGA-110-CL cell line panel 21137983 CVCL_0V14 Mel501A cancer cell line human CVCL_0V14 HLA typing: A*02:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Trp (c.825T>G); ClinVar=VCV000485044; Zygosity=Unspecified (PubMed=29045385) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21137984 CVCL_1714 SUP-T1 cancer cell line human CVCL_1714 Genome ancestry: African=0.14%; Native American=1.61%; East Asian, North=0%; East Asian, South=0%; South Asian=9.49%; European, North=46.77%; European, South=41.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP) Derived from sampling site: Pleural effusion Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Characteristics: Has chromosomal translocations involving the genes for the alpha and beta subunits of TCR thus preventing surface expression of the endogenous TCR complex; Virology: Useful for studies of cell fusion and cytopathic effects of HIV-1 as well as cytopathic isolates of HIV-2; Virology: Susceptible to infection by herpesvirus 6B (HHV-6B) strain Z29 (PubMed=29304865) Doubling time: 28 hours (PubMed=3004618); ~30 hours (DSMZ=ACC-140); ~24-36 hours (HIVReagentProgram); Microsatellite instability: Stable (MSS) (Sanger); Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137985 CVCL_0V17 HCC3212 cancer cell line human CVCL_0V17 CL:0000010 Unspecified 21137986 CVCL_1717 SW1417 cancer cell line human CVCL_1717 HLA typing: A*03 (PubMed=8464898); HLA typing: A*03:01,24:02; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0.86%; European, North=62.18%; European, South=34.82% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Arg274Gly (c.820A>G); Zygosity=Homozygous (PubMed=9331070; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Hisfs*21 (c.712_725delTGTAACAGTTCCTG); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL00005; true Female Doubling time: 68 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21137987 CVCL_0V16 HCC2911 cancer cell line human CVCL_0V16 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21137988 CVCL_1716 SW1271 cancer cell line human CVCL_1716 HLA typing: A*02:01,26:01; B*07:02,13:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.42%; Native American=1.29%; East Asian, North=2.56%; East Asian, South=0%; South Asian=0%; European, North=63.53%; European, South=32.2% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=1855224; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (PubMed=1855224; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: RAS genetic alteration cell panel (ATCC TCP-1031) 21137989 CVCL_0V29 GM18575 transformed cell line human CVCL_0V29 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21137990 CVCL_1729 SW837 cancer cell line human CVCL_1729 HLA typing: A*32:01,32:01; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=2.4%; Native American=0%; East Asian, North=1.12%; East Asian, South=0.53%; South Asian=0%; European, North=65.15%; European, South=30.8% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Leu403fs*34 (c.1208_1209insT); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=12068308; PubMed=20570890; PubMed=24755471; PubMed=28683746); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Hemizygous (PubMed=7651727; PubMed=9715273; PubMed=16418264; PubMed=24755471; PubMed=28683746) Derived from sampling site: Rectum. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: O-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Doubling time: 169 hours, at 5th passage (PubMed=1000501); Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: FGFR genetic alteration cell panel (ATCC TCP-1034); Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: TCGA-110-CL cell line panel 21137991 CVCL_0V20 GM18485 transformed cell line human CVCL_0V20 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137992 CVCL_1720 SW1573 cancer cell line human CVCL_1720 HLA typing: A*02:01,24:02; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=0.36%; Native American=0.18%; East Asian, North=0.45%; East Asian, South=0%; South Asian=0%; European, North=66.92%; European, South=32.09% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (ATCC); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (ATCC); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (ATCC; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=12068308; ATCC; Cosmic-CLP); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (ATCC; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 23 hours (PubMed=9256160); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21137993 CVCL_0V22 GM18500 transformed cell line human CVCL_0V22 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137994 CVCL_1722 SW1783 cancer cell line human CVCL_1722 HLA typing: A*29:02,32:01; B*44:02,49:01; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.24%; East Asian, North=1.93%; East Asian, South=1.02%; South Asian=0%; European, North=65.97%; European, South=30.84% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (ATCC; Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 55 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21137995 CVCL_0V21 GM18497 transformed cell line human CVCL_0V21 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137996 CVCL_1721 SW1710 cancer cell line human CVCL_1721 HLA typing: A*02:01,24:02; B*07:02,44:02; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=0.06%; Native American=0%; East Asian, North=1.26%; East Asian, South=0%; South Asian=1.43%; European, North=65.29%; European, South=31.96% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~25-32 hours (DSMZ=ACC-426); Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: UBC-40 urothelial bladder cancer cell line index 21137997 CVCL_0V24 GM18509 transformed cell line human CVCL_0V24 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21137998 CVCL_1724 SW48 cancer cell line human CVCL_1724 HLA typing: A*24:02,24:02; B*44:02,44:02; C*05:01,07:06 (PubMed=26589293); Genome ancestry: African=0.09%; Native American=0%; East Asian, North=0%; East Asian, South=1.44%; South Asian=0%; European, North=69.25%; European, South=29.21% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (PubMed=8197130); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (PubMed=8197130); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (PubMed=9294210; PubMed=24755471; ATCC); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 70 hours, at 63th passage (PubMed=1000501); 33 hours (PubMed=25984343); Microsatellite instability: Instable (MSI-high) (PubMed=9000572; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: EGFR genetic alteration cell panel (ATCC TCP-1027); Part of: MD Anderson Cell Lines Project 21137999 CVCL_0V23 GM18503 transformed cell line human CVCL_0V23 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138000 CVCL_1723 SW1990 cancer cell line human CVCL_1723 HLA typing: A*26:01,26:01; B*27:05,38:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.49%; Native American=0.78%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=60.78%; European, South=35.04% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=12068308; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=25984343); 35.8 +- 4.4 hours (PubMed=27067801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21138001 CVCL_0V26 GM18518 transformed cell line human CVCL_0V26 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138002 CVCL_1726 SW684 cancer cell line human CVCL_1726 Genome ancestry: African=0.49%; Native American=0.15%; East Asian, North=1.06%; East Asian, South=1.15%; South Asian=0.61%; European, North=67.56%; European, South=28.98% (PubMed=30894373). From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 3432; ERBB4; Simple; p.Glu452Lys (c.1354G>A); ClinVar=VCV000091898; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138003 CVCL_0V25 GM18515 transformed cell line human CVCL_0V25 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138004 CVCL_1725 SW626 cancer cell line human CVCL_1725 Genome ancestry: African=0.06%; Native American=0.08%; East Asian, North=0.77%; East Asian, South=0%; South Asian=2.55%; European, North=65.38%; European, South=31.17% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg976fs*9 (c.2926_2927insA); Zygosity=Homozygous (ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12068308; PubMed=25846456; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (PubMed=25846456; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Problematic cell line: Misclassified Although established from a surgical specimen from a cystadenocarcinoma of the ovary in a 46 year old female Caucasian, it now seems likely that it was established from an ovarian metastasis of a colonic carcinoma (PubMed=10433623). 21138005 CVCL_0V28 GM18568 transformed cell line human CVCL_0V28 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138006 CVCL_1728 SW780 cancer cell line human CVCL_1728 HLA typing: A*03:01,23:01; B*07:02,41:02; C*07:02,17:01 (PubMed=26589293); Genome ancestry: African=0.52%; Native American=0.16%; East Asian, North=0.43%; East Asian, South=0.73%; South Asian=3.11%; European, North=68.95%; European, South=26.09% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21138007 CVCL_0V27 GM18521 transformed cell line human CVCL_0V27 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138008 CVCL_1727 SW756 cancer cell line human CVCL_1727 Genome ancestry: African=3.44%; Native American=0%; East Asian, North=3.59%; East Asian, South=0%; South Asian=0.36%; European, North=58.26%; European, South=34.34% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=12068308; Cosmic-CLP; DepMap) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Contains a complete HPV18 genome Doubling time: 1.6 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10302 21138009 CVCL_BK49 ND12391 transformed cell line human CVCL_BK49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138010 CVCL_BK48 ND12390 transformed cell line human CVCL_BK48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138011 CVCL_BK41 ND12376 transformed cell line human CVCL_BK41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138012 CVCL_BK40 ND12375 transformed cell line human CVCL_BK40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138013 CVCL_BK43 ND12381 transformed cell line human CVCL_BK43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138014 CVCL_BK42 ND12380 transformed cell line human CVCL_BK42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138015 CVCL_BK45 ND12387 transformed cell line human CVCL_BK45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138016 CVCL_BK44 ND12382 transformed cell line human CVCL_BK44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138017 CVCL_BK47 ND12389 transformed cell line human CVCL_BK47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138018 CVCL_BK46 ND12388 transformed cell line human CVCL_BK46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138019 CVCL_BK59 ND12421 transformed cell line human CVCL_BK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND12422 (Cellosaurus=CVCL_DR42); Derived from sampling site: Peripheral blood. Female 21138020 CVCL_BK52 ND12400 transformed cell line human CVCL_BK52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138021 CVCL_BK51 ND12393 transformed cell line human CVCL_BK51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138022 CVCL_BK54 ND12403 transformed cell line human CVCL_BK54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138023 CVCL_BK53 ND12402 transformed cell line human CVCL_BK53 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138024 CVCL_BK56 ND12417 transformed cell line human CVCL_BK56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138025 CVCL_BK55 ND12416 transformed cell line human CVCL_BK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138026 CVCL_BK58 ND12420 transformed cell line human CVCL_BK58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138027 CVCL_BK57 ND12419 transformed cell line human CVCL_BK57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138028 CVCL_BK50 ND12392 transformed cell line human CVCL_BK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138029 CVCL_9Q93 GM03066 finite cell line human CVCL_9Q93 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Thr284Leufs*5 (c.850delA) (1012delA); ClinVar=VCV000038434; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Cys528Valfs*19 (c.1581delC) (1744delC); ClinVar=VCV000038414; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138030 CVCL_9Q92 GM02687 transformed cell line human CVCL_9Q92 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Ser581Ilefs*8 (c.1738TATA[3]) (c.1738_1741[3]) (1902_1905tripTATA); ClinVar=VCV000038415; Zygosity=Heterozygous (PubMed=16465621) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138031 CVCL_9Q95 GM04107 finite cell line human CVCL_9Q95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138032 CVCL_9Q94 GM04106 transformed cell line human CVCL_9Q94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138033 CVCL_9Q91 GM02660 transformed cell line human CVCL_9Q91 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138034 CVCL_9Q90 GM02273 finite cell line human CVCL_9Q90 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Arg46Ter (c.136C>T); ClinVar=VCV000039031; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138035 CVCL_BK27 ND12334 transformed cell line human CVCL_BK27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138036 CVCL_BK26 ND12332 transformed cell line human CVCL_BK26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138037 CVCL_BK29 ND12347 transformed cell line human CVCL_BK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138038 CVCL_BK28 ND12345 transformed cell line human CVCL_BK28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138039 CVCL_9Q97 GM14729 finite cell line human CVCL_9Q97 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138040 CVCL_9Q96 GM14728 transformed cell line human CVCL_9Q96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138041 CVCL_9Q99 GM08830 transformed cell line human CVCL_9Q99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138042 CVCL_9Q98 GM08829 transformed cell line human CVCL_9Q98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138043 CVCL_BK21 ND12321 transformed cell line human CVCL_BK21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138044 CVCL_BK20 ND12319 transformed cell line human CVCL_BK20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138045 CVCL_BK23 ND12327 transformed cell line human CVCL_BK23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138046 CVCL_BK22 ND12325 transformed cell line human CVCL_BK22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138047 CVCL_BK25 ND12331 transformed cell line human CVCL_BK25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138048 CVCL_BK24 ND12329 transformed cell line human CVCL_BK24 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Asn387Thr (c.1160A>C) (c.1549A>C); ClinVar=VCV000448854; Zygosity=Heterozygous (PubMed=22572540) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138049 CVCL_BK38 ND12369 transformed cell line human CVCL_BK38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138050 CVCL_BK37 ND12368 transformed cell line human CVCL_BK37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138051 CVCL_BK39 ND12374 transformed cell line human CVCL_BK39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138052 CVCL_BK30 ND12351 transformed cell line human CVCL_BK30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138053 CVCL_BK32 ND12355 transformed cell line human CVCL_BK32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138054 CVCL_BK31 ND12352 transformed cell line human CVCL_BK31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138055 CVCL_BK34 ND12358 transformed cell line human CVCL_BK34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138056 CVCL_BK33 ND12357 transformed cell line human CVCL_BK33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138057 CVCL_BK36 ND12364 transformed cell line human CVCL_BK36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138058 CVCL_BK35 ND12363 transformed cell line human CVCL_BK35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138059 CVCL_9Q71 GM06080 transformed cell line human CVCL_9Q71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138060 CVCL_9Q70 GM05954 transformed cell line human CVCL_9Q70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138061 CVCL_9Q73 GM06082 transformed cell line human CVCL_9Q73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138062 CVCL_9Q72 GM06081 finite cell line human CVCL_9Q72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138063 CVCL_9Q79 GM02526 finite cell line human CVCL_9Q79 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11013137); Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (PubMed=11013137) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21138064 CVCL_BK05 ND12288 transformed cell line human CVCL_BK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138065 CVCL_9Q78 GM02525 finite cell line human CVCL_9Q78 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Homozygous (PubMed=11013137) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21138066 CVCL_BK04 ND12287 transformed cell line human CVCL_BK04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138067 CVCL_BK07 ND12290 transformed cell line human CVCL_BK07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138068 CVCL_BK06 ND12289 transformed cell line human CVCL_BK06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138069 CVCL_9Q75 GM06196 finite cell line human CVCL_9Q75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138070 CVCL_BK09 ND12294 transformed cell line human CVCL_BK09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138071 CVCL_9Q74 GM06195 transformed cell line human CVCL_9Q74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138072 CVCL_BK08 ND12292 transformed cell line human CVCL_BK08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138073 CVCL_9Q77 GM21652 transformed cell line human CVCL_9Q77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138074 CVCL_9Q76 GM06197 transformed cell line human CVCL_9Q76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138075 CVCL_BK01 ND12283 transformed cell line human CVCL_BK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138076 CVCL_BK00 ND12282 transformed cell line human CVCL_BK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138077 CVCL_BK03 ND12286 transformed cell line human CVCL_BK03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138078 CVCL_BK02 ND12284 transformed cell line human CVCL_BK02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138079 CVCL_9Q82 GM02629 finite cell line human CVCL_9Q82 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138080 CVCL_9Q81 GM02528 finite cell line human CVCL_9Q81 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19815695) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21138081 CVCL_9Q84 GM03265 finite cell line human CVCL_9Q84 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with oculocerebrorenal syndrome but has a 50% risk; Derived from sampling site: Cell type=Fibroblast. Male 21138082 CVCL_9Q83 GM01676 finite cell line human CVCL_9Q83 CL:0000010 Sequence variation: Mutation; HGNC; 8108; OCRL; Simple; p.Arg844Ter (c.2530C>T) (R827X, c.2479C>T); ClinVar=VCV000010857; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138083 CVCL_9Q80 GM02527 finite cell line human CVCL_9Q80 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Homozygous (PubMed=11013137) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21138084 CVCL_BK16 ND12314 transformed cell line human CVCL_BK16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138085 CVCL_9Q89 GM01590 finite cell line human CVCL_9Q89 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138086 CVCL_BK15 ND12310 transformed cell line human CVCL_BK15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138087 CVCL_BK18 ND12317 transformed cell line human CVCL_BK18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138088 CVCL_BK17 ND12316 transformed cell line human CVCL_BK17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138089 CVCL_9Q86 GM00081 finite cell line human CVCL_9Q86 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Thr284Leufs*5 (c.850delA) (1012delA); ClinVar=VCV000038434; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138090 CVCL_9Q85 GM00080 finite cell line human CVCL_9Q85 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Cys528Valfs*19 (c.1581delC) (1744delC); ClinVar=VCV000038414; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138091 CVCL_BK19 ND12318 transformed cell line human CVCL_BK19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138092 CVCL_9Q88 GM01589 finite cell line human CVCL_9Q88 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138093 CVCL_9Q87 GM01586 finite cell line human CVCL_9Q87 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Homozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138094 CVCL_BK10 ND12295 transformed cell line human CVCL_BK10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138095 CVCL_BK12 ND12298 transformed cell line human CVCL_BK12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138096 CVCL_BK11 ND12296 transformed cell line human CVCL_BK11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138097 CVCL_BK14 ND12309 transformed cell line human CVCL_BK14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138098 CVCL_BK13 ND12307 transformed cell line human CVCL_BK13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138099 CVCL_9Q51 NHEK/SVTERT3-5 transformed cell line human CVCL_9Q51 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: STR profile from personal communication of Evercyte Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Doubling time: 48-60 hours (Evercyte) 21138100 CVCL_9Q50 NHEK/SV3 finite cell line human CVCL_9Q50 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: Evercyte; Catalog number CLT-011-0026 Female Senescence: SV40-transformed but with a finite life span (maximum PDL is 30); Doubling time: ~48 hours (Evercyte) 21138101 CVCL_9Q57 WILF 7C11 hybrid cell line CVCL_9Q57 CL:0000010 21138102 CVCL_9Q56 DT40-PRKDC(-/-)-XRCC6(-/-) cancer cell line CVCL_9Q56 CL:0000010 Knockout cell: Method=Targeted integration; PRKDC+XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21138103 CVCL_9Q59 RHF14 hybrid cell line CVCL_9Q59 CL:0000010 Discontinued: ATCC; CRL-2792; true. 21138104 CVCL_9Q58 WILF 7C9 hybrid cell line CVCL_9Q58 CL:0000010 Discontinued: ATCC; CRL-2790; true. 21138105 CVCL_9Q53 HUVEC/TERT2 telomerase immortalized cell line human CVCL_9Q53 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: 46,XX,add(14) (ATCC); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female Doubling time: ~2.5 days (ATCC=CRL-4053); 28 hours (Evercyte) 21138106 CVCL_9Q52 HBF/TERT88 telomerase immortalized cell line human CVCL_9Q52 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain Cell type=Fibroblast.. Discontinued: Evercyte; Catalog number HBF/TERT88 Female 21138107 CVCL_9Q55 HDF/TERT1 telomerase immortalized cell line human CVCL_9Q55 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Evercyte; Catalog number CHT-008-0012 Female Doubling time: 72-96 hours (Evercyte) 21138108 CVCL_9Q49 HSR-1 transformed cell line CVCL_9Q49 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0973; true Unspecified Group: Non-human primate cell line 21138109 CVCL_9Q60 RHF407 hybrid cell line CVCL_9Q60 CL:0000010 Discontinued: ATCC; CRL-2791; true. 21138110 CVCL_9Q62 MML-1 [Human leukemia] cancer cell line human CVCL_9Q62 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. 21138111 CVCL_9Q61 hMC somatic stem cell human CVCL_9Q61 CL:0000010 Miscellaneous: Cell line name from personal communication of Trapecar M Derived from sampling site: Semitendinosus tendon. Male 21138112 CVCL_9Q68 GM05952 transformed cell line human CVCL_9Q68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138113 CVCL_9Q67 GM05951 transformed cell line human CVCL_9Q67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138114 CVCL_9Q69 GM05953 transformed cell line human CVCL_9Q69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138115 CVCL_9Q64 GM05948 finite cell line human CVCL_9Q64 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138116 CVCL_9Q63 GM00148 transformed cell line human CVCL_9Q63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00148; probable Male 21138117 CVCL_9Q66 GM05950 finite cell line human CVCL_9Q66 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138118 CVCL_9Q65 GM05949 finite cell line human CVCL_9Q65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138119 CVCL_KE66 PCRP-FOSB-1C9 hybridoma house mouse CVCL_KE66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P53539; Human FOSB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138120 CVCL_KE65 PCRP-FOS-1A7 hybridoma house mouse CVCL_KE65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01100; Human FOS. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138121 CVCL_KE68 PCRP-FOSL1-1E3 hybridoma house mouse CVCL_KE68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15407; Human FOSL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138122 CVCL_KE67 PCRP-FOSB-1D8 hybridoma house mouse CVCL_KE67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P53539; Human FOSB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138123 CVCL_KE62 PCRP-FEZF2-1A7 hybridoma house mouse CVCL_KE62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TBJ5; Human FEZF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138124 CVCL_KE61 PCRP-EZH2-1B3 hybridoma house mouse CVCL_KE61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15910; Human EZH2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138125 CVCL_KE64 PCRP-FLI1-4H6 hybridoma house mouse CVCL_KE64 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01543; Human FLI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138126 CVCL_KE63 PCRP-FEZF2-1B1 hybridoma house mouse CVCL_KE63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TBJ5; Human FEZF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138127 CVCL_KE60 PCRP-ETV7-1A6 hybridoma house mouse CVCL_KE60 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y603; Human ETV7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138128 CVCL_KE59 PCRP-ETV7-1A1 hybridoma house mouse CVCL_KE59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y603; Human ETV7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138129 CVCL_KE58 PCRP-ETV6-1A9 hybridoma house mouse CVCL_KE58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P41212; Human ETV6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138130 CVCL_KE77 PCRP-FOXI1-1F8 hybridoma house mouse CVCL_KE77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q12951; Human FOXI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138131 CVCL_KE76 PCRP-FOXI1-1C4 hybridoma house mouse CVCL_KE76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q12951; Human FOXI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138132 CVCL_KE79 PCRP-FOXJ2-1D3 hybridoma house mouse CVCL_KE79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9P0K8; Human FOXJ2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138133 CVCL_KE78 PCRP-FOXI1-1G11 hybridoma house mouse CVCL_KE78 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q12951; Human FOXI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138134 CVCL_KE73 PCRP-FOXB2-2B2 hybridoma house mouse CVCL_KE73 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q5VYV0; Human FOXB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138135 CVCL_KE72 PCRP-FOXA3-2A9 hybridoma house mouse CVCL_KE72 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P55318; Human FOXA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138136 CVCL_KE75 PCRP-FOXC2-1B6 hybridoma house mouse CVCL_KE75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99958; Human FOXC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138137 CVCL_KE74 PCRP-FOXC2-1B1 hybridoma house mouse CVCL_KE74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99958; Human FOXC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138138 CVCL_KE71 PCRP-FOXA2-3A2 hybridoma house mouse CVCL_KE71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y261; Human FOXA2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138139 CVCL_KE70 PCRP-FOSL2-1B1 hybridoma house mouse CVCL_KE70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15408; Human FOSL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138140 CVCL_KE69 PCRP-FOSL1-1G1 hybridoma house mouse CVCL_KE69 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15407; Human FOSL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138141 CVCL_KE44 PCRP-ELF2-5A5 hybridoma house mouse CVCL_KE44 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138142 CVCL_KE43 PCRP-ELF2-3H4 hybridoma house mouse CVCL_KE43 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138143 CVCL_KE46 PCRP-ELK1-1B9 hybridoma house mouse CVCL_KE46 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19419; Human ELK1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138144 CVCL_KE45 PCRP-ELF3-8F6 hybridoma house mouse CVCL_KE45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P78545; Human ELF3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138145 CVCL_KE40 PCRP-ELF2-1F1 hybridoma house mouse CVCL_KE40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138146 CVCL_KE42 PCRP-ELF2-3A9 hybridoma house mouse CVCL_KE42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138147 CVCL_KE41 PCRP-ELF2-1H10 hybridoma house mouse CVCL_KE41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138148 CVCL_KE37 PCRP-ELF1-1A3 hybridoma house mouse CVCL_KE37 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P32519; Human ELF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138149 CVCL_KE36 PCRP-EIF4E-1D3 hybridoma house mouse CVCL_KE36 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06730; Human EIF4E. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138150 CVCL_KE39 PCRP-ELF2-1B5 hybridoma house mouse CVCL_KE39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15723; Human ELF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138151 CVCL_KE38 PCRP-ELF1-1C9 hybridoma house mouse CVCL_KE38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P32519; Human ELF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138152 CVCL_KE55 PCRP-ETS1-1F1 hybridoma house mouse CVCL_KE55 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14921; Human ETS1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138153 CVCL_KE54 PCRP-ETS1-1C8 hybridoma house mouse CVCL_KE54 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P14921; Human ETS1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138154 CVCL_KE57 PCRP-ETV6-1A7 hybridoma house mouse CVCL_KE57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P41212; Human ETV6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138155 CVCL_KE56 PCRP-ETS2-1D9 hybridoma house mouse CVCL_KE56 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P15036; Human ETS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138156 CVCL_KE51 PCRP-ESRRA-1B10 hybridoma house mouse CVCL_KE51 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11474; Human ESRRA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138157 CVCL_KE50 PCRP-ESRP2-1D2 hybridoma house mouse CVCL_KE50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H6T0; Human ESRP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138158 CVCL_KE53 PCRP-ESRRG-3A6 hybridoma house mouse CVCL_KE53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P62508; Human ESRRG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138159 CVCL_KE52 PCRP-ESRRB-2A6 hybridoma house mouse CVCL_KE52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95718; Human ESRRB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138160 CVCL_KE48 PCRP-ERG-2C6 hybridoma house mouse CVCL_KE48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11308; Human ERG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138161 CVCL_KE47 PCRP-ELK1-1D9 hybridoma house mouse CVCL_KE47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P19419; Human ELK1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138162 CVCL_KE49 PCRP-ESR1-1A12 hybridoma house mouse CVCL_KE49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P03372; Human ESR1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138163 CVCL_KE22 PCRP-E2F8-1G6 hybridoma house mouse CVCL_KE22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0AVK6; Human E2F8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138164 CVCL_KE21 PCRP-E2F8-1A10 hybridoma house mouse CVCL_KE21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0AVK6; Human E2F8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138165 CVCL_KE24 PCRP-EBF1-1B1 hybridoma house mouse CVCL_KE24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UH73; Human EBF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138166 CVCL_KE23 PCRP-E4F1-2D1 hybridoma house mouse CVCL_KE23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q66K89; Human E4F1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138167 CVCL_KE20 PCRP-E2F6-1F8 hybridoma house mouse CVCL_KE20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75461; Human E2F6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138168 CVCL_BK85 ND12481 transformed cell line human CVCL_BK85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138169 CVCL_BK84 ND12480 transformed cell line human CVCL_BK84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138170 CVCL_BK87 ND12487 transformed cell line human CVCL_BK87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138171 CVCL_BK86 ND12484 transformed cell line human CVCL_BK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138172 CVCL_BK89 ND12491 transformed cell line human CVCL_BK89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138173 CVCL_BK88 ND12488 transformed cell line human CVCL_BK88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138174 CVCL_KE19 PCRP-E2F6-1F6 hybridoma house mouse CVCL_KE19 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75461; Human E2F6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138175 CVCL_KE18 PCRP-E2F4-3C9 hybridoma house mouse CVCL_KE18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16254; Human E2F4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138176 CVCL_BK81 ND12464 transformed cell line human CVCL_BK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138177 CVCL_KE15 PCRP-DVL3-3A9 hybridoma house mouse CVCL_KE15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138178 CVCL_BK80 ND12463 transformed cell line human CVCL_BK80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138179 CVCL_KE14 PCRP-DVL3-2E12 hybridoma house mouse CVCL_KE14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138180 CVCL_BK83 ND12479 transformed cell line human CVCL_BK83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138181 CVCL_KE17 PCRP-E2F4-2H10 hybridoma house mouse CVCL_KE17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16254; Human E2F4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138182 CVCL_BK82 ND12465 transformed cell line human CVCL_BK82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138183 CVCL_KE16 PCRP-DVL3-3D6 hybridoma house mouse CVCL_KE16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138184 CVCL_KE33 PCRP-EIF2S1-2A10 hybridoma house mouse CVCL_KE33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05198; Human EIF2S1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138185 CVCL_KE32 PCRP-EIF2S1-1E2 hybridoma house mouse CVCL_KE32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05198; Human EIF2S1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138186 CVCL_KE35 PCRP-EIF4A3-3A2 hybridoma house mouse CVCL_KE35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P38919; Human EIF4A3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138187 CVCL_KE34 PCRP-EIF4A2-2B5 hybridoma house mouse CVCL_KE34 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q14240; Human EIF4A2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138188 CVCL_KE31 PCRP-EIF2S1-1C11 hybridoma house mouse CVCL_KE31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05198; Human EIF2S1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138189 CVCL_KE30 PCRP-EHMT2-3D9 hybridoma house mouse CVCL_KE30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96KQ7; Human EHMT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138190 CVCL_BK96 ND12526 transformed cell line human CVCL_BK96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138191 CVCL_BK95 ND12525 transformed cell line human CVCL_BK95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138192 CVCL_BK98 ND12531 transformed cell line human CVCL_BK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138193 CVCL_BK97 ND12530 transformed cell line human CVCL_BK97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138194 CVCL_BK99 ND12533 transformed cell line human CVCL_BK99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138195 CVCL_KE29 PCRP-EEA1-2H11 hybridoma house mouse CVCL_KE29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15075; Human EEA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138196 CVCL_BK90 ND12492 transformed cell line human CVCL_BK90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138197 CVCL_BK92 ND12517 transformed cell line human CVCL_BK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138198 CVCL_KE26 PCRP-ECD-1D10 hybridoma house mouse CVCL_KE26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95905; Human ECD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138199 CVCL_BK91 ND12511 transformed cell line human CVCL_BK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138200 CVCL_KE25 PCRP-ECD-1C11 hybridoma house mouse CVCL_KE25 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O95905; Human ECD. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138201 CVCL_BK94 ND12521 transformed cell line human CVCL_BK94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138202 CVCL_KE28 PCRP-EEA1-1F8 hybridoma house mouse CVCL_KE28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15075; Human EEA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138203 CVCL_BK93 ND12520 transformed cell line human CVCL_BK93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138204 CVCL_KE27 PCRP-EDF1-1A3 hybridoma house mouse CVCL_KE27 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O60869; Human EDF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138205 CVCL_KE00 PCRP-DPRX-2F5 hybridoma house mouse CVCL_KE00 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A6NFQ7; Human DPRX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138206 CVCL_KE02 PCRP-DPRX-3C4 hybridoma house mouse CVCL_KE02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NFQ7; Human DPRX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138207 CVCL_KE01 PCRP-DPRX-3A1 hybridoma house mouse CVCL_KE01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A6NFQ7; Human DPRX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138208 CVCL_BK63 ND12427 transformed cell line human CVCL_BK63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138209 CVCL_BK62 ND12426 transformed cell line human CVCL_BK62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138210 CVCL_BK65 ND12429 transformed cell line human CVCL_BK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138211 CVCL_BK64 ND12428 transformed cell line human CVCL_BK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138212 CVCL_BK67 ND12432 transformed cell line human CVCL_BK67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138213 CVCL_BK66 ND12430 transformed cell line human CVCL_BK66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138214 CVCL_BK69 ND12435 transformed cell line human CVCL_BK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138215 CVCL_BK68 ND12434 transformed cell line human CVCL_BK68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138216 CVCL_BK61 ND12425 transformed cell line human CVCL_BK61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138217 CVCL_BK60 ND12423 transformed cell line human CVCL_BK60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138218 CVCL_KE11 PCRP-DVL3-1B1 hybridoma house mouse CVCL_KE11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138219 CVCL_KE10 PCRP-DVL3-1A11 hybridoma house mouse CVCL_KE10 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138220 CVCL_KE13 PCRP-DVL3-2D6 hybridoma house mouse CVCL_KE13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138221 CVCL_KE12 PCRP-DVL3-1B10 hybridoma house mouse CVCL_KE12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92997; Human DVL3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138222 CVCL_BK74 ND12450 transformed cell line human CVCL_BK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138223 CVCL_BK73 ND12449 transformed cell line human CVCL_BK73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138224 CVCL_BK76 ND12455 transformed cell line human CVCL_BK76 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138225 CVCL_BK75 ND12452 transformed cell line human CVCL_BK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138226 CVCL_BK78 ND12461 transformed cell line human CVCL_BK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138227 CVCL_BK77 ND12460 transformed cell line human CVCL_BK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138228 CVCL_BK79 ND12462 transformed cell line human CVCL_BK79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138229 CVCL_KE08 PCRP-DVL2-1A4 hybridoma house mouse CVCL_KE08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14641; Human DVL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138230 CVCL_KE07 PCRP-DRGX-3F1 hybridoma house mouse CVCL_KE07 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A6NNA5; Human DRGX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138231 CVCL_KE09 PCRP-DVL2-1C7 hybridoma house mouse CVCL_KE09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O14641; Human DVL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138232 CVCL_BK70 ND12438 transformed cell line human CVCL_BK70 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138233 CVCL_KE04 PCRP-DR1-1A12 hybridoma house mouse CVCL_KE04 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q01658; Human DR1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138234 CVCL_KE03 PCRP-DPRX-4A5 hybridoma house mouse CVCL_KE03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NFQ7; Human DPRX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138235 CVCL_BK72 ND12448 transformed cell line human CVCL_BK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138236 CVCL_KE06 PCRP-DRAP1-1A8 hybridoma house mouse CVCL_KE06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14919; Human DRAP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138237 CVCL_BK71 ND12447 transformed cell line human CVCL_BK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138238 CVCL_KE05 PCRP-DRAP1-1A12 hybridoma house mouse CVCL_KE05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14919; Human DRAP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138239 CVCL_0W18 GM18140 transformed cell line human CVCL_0W18 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138240 CVCL_1818 Granta-519 cancer cell line human CVCL_1818 HLA typing: A*02:05,02:05; B*07:02,50:01; C*06:02,07:02; DQA1*05:01,01:02; DQB1*06:02,03:01; DRB1*11:03,15:01 (PubMed=25960936); HLA typing: A*02,02; B*07,50; C*06,07 (PubMed=25688540); HLA typing: A*02:05,02:05; B*07:02,50:01; C*06:02,07:02 (PubMed=26589293); HLA typing: A*02:01:01,02:05:01; B*07:02:01,50:01:01; C*06:02:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,05:05:01; DQB1*03:01:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*11:03:01,15:01:01 (DSMZCellDive=ACC-342); Genome ancestry: African=1.28%; Native American=0%; East Asian, North=1.9%; East Asian, South=0%; South Asian=0%; European, North=66.14%; European, South=30.67% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16448697) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: ~48 hours (DSMZ=ACC-342); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138241 CVCL_0W17 GM18139 transformed cell line human CVCL_0W17 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138242 CVCL_1817 Granta-452 cancer cell line human CVCL_1817 CL:0000010 Omics: Array-based CGH. Male Doubling time: ~48 hours (DSMZ=ACC-713) 21138243 CVCL_0W19 GM18141 transformed cell line human CVCL_0W19 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138244 CVCL_1819 VAL cancer cell line human CVCL_1819 HLA typing: A*02:01:01,68:01:01; B*15:01:01,15:01:01; C*03:03:01,03:03:01; DPA1*02:02:02,02:01:02; DPB1*19:01,19:01; DQA1*01:03:01,01:03:01; DQB1*06:03:01,06:03:01; DRA*01:01:01,01:01:01; DRB1*13:01:01,13:01:01 (DSMZCellDive=ACC-586); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.47%; South Asian=2.83%; European, North=64.59%; European, South=32.11% (PubMed=30894373) CL:0000010 Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50-70 hours (DSMZ=ACC-586); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138245 CVCL_1810 CRO-AP3 cancer cell line human CVCL_1810 Genome ancestry: African=2.63%; Native American=0%; East Asian, North=0.61%; East Asian, South=1.52%; South Asian=1.46%; European, North=42.74%; European, South=51.05% (PubMed=30894373) CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Ascites. Omics: Deep exome analysis Male Virology: Contains 10 to 30 copies of the human herpesvirus 8 (HHV-8/KSHV) genome per cell Doubling time: ~50 hours (DSMZ=ACC-275) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138246 CVCL_0W10 GM18131 transformed cell line human CVCL_0W10 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138247 CVCL_1812 EFM-192A cancer cell line human CVCL_1812 HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03; DQB1*06:02,02:02; DRB1*15:01,09:10 (PubMed=25960936); HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293); Genome ancestry: African=0.34%; Native American=0%; East Asian, North=2.91%; East Asian, South=0%; South Asian=0.06%; European, North=67.61%; European, South=29.07% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271fs*1 (c.807_808insT); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~9 days (DSMZ=ACC-258); 80.21 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138248 CVCL_0W12 GM18133 transformed cell line human CVCL_0W12 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138249 CVCL_1811 CRO-AP6 cancer cell line human CVCL_1811 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Male Doubling time: 40-50 hours (PubMed=10914556); ~48 hours (DSMZ=ACC-650) 21138250 CVCL_0W11 GM18132 transformed cell line human CVCL_0W11 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138251 CVCL_1814 EFM-192C cancer cell line human CVCL_1814 HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03; DQB1*06:13,06:13; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~4 days (DSMZ=ACC-311); 40.64 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138252 CVCL_0W14 GM18135 transformed cell line human CVCL_0W14 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138253 CVCL_1813 EFM-192B cancer cell line human CVCL_1813 HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03; DQB1*06:02,02:02; DRB1*15:01,09:10 (PubMed=25960936); HLA typing: A*01:01,24:02; B*07:02,39:01; C*07:02,12:03 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~4-5 days (DSMZ=ACC-308); 68.47 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138254 CVCL_0W13 GM18134 transformed cell line human CVCL_0W13 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138255 CVCL_1816 Girardi Heart clone 7 cancer cell line human CVCL_1816 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: DSMZ; ACC-121; true Female Problematic cell line: Contaminated Parent cell line (Girardi Heart) has been shown to be a HeLa derivative (PubMed=20143388). 21138256 CVCL_0W16 GM18138 transformed cell line human CVCL_0W16 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138257 CVCL_1815 Girardi Heart clone 2 cancer cell line human CVCL_1815 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: DSMZ; ACC-116; true Female Problematic cell line: Contaminated Parent cell line (Girardi Heart) has been shown to be a HeLa derivative (PubMed=20143388). 21138258 CVCL_0W15 GM18136 transformed cell line human CVCL_0W15 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138259 CVCL_0W29 GM18152 transformed cell line human CVCL_0W29 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138260 CVCL_1829 LA-N-2 cancer cell line human CVCL_1829 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis. Female Characteristics: Intermediate type (I-type) (PubMed=15720811) Doubling time: ~50-70 hours, but longer after recovery from liquid nitrogen freezing (DSMZ=ACC-671) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138261 CVCL_0W28 GM18151 transformed cell line human CVCL_0W28 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138262 CVCL_1828 LAN-188 finite cell line human CVCL_1828 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian. 21138263 CVCL_0W21 GM18144 transformed cell line human CVCL_0W21 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138264 CVCL_1821 Karpas-1106P cancer cell line human CVCL_1821 HLA typing: A*03:01,24:02; B*35:01,51:01; C*04:01,16:02; DQA1*03:02,05:01; DQB1*03:02,03:02; DRB1*03:17,03:17 (PubMed=26589293); Genome ancestry: African=1.68%; Native American=0.48%; East Asian, North=0.25%; East Asian, South=1.18%; South Asian=11.86%; European, North=19.43%; European, South=65.12% (PubMed=30894373) CL:0000010 Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-545; true Female Doubling time: ~60-100 hours (ECACC=06072607); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138265 CVCL_0W20 GM18143 transformed cell line human CVCL_0W20 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138266 CVCL_1820 HPB-ALL cancer cell line human CVCL_1820 HLA typing: A*24:02,24:02; B*15:07,52:01; C*03:03,12:02 (PubMed=26589293); HLA typing: A*24:02:01,24:02:01; B*15:07:01,52:01:01; C*03:03:01,12:02:02 (DSMZCellDive=ACC-483); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.04%; East Asian, South=20.81%; South Asian=1.14%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (PubMed=31160637); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Ala134Ser (c.400G>T); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (PubMed=16142349; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Unspecified (PubMed=22675565) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (DSMZ=ACC-483); Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21138267 CVCL_0W23 GM18146 transformed cell line human CVCL_0W23 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138268 CVCL_1823 Karpas-620 cancer cell line human CVCL_1823 HLA typing: A*02:01; B*44; C*05:01 (Direct_author_submission); HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*03:17,11:04 (PubMed=26589293); Genome ancestry: African=1.6%; Native American=0%; East Asian, North=2.67%; East Asian, South=0%; South Asian=0%; European, North=63.77%; European, South=31.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11157491; PubMed=21173094; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Homozygous (PubMed=21173094; Cosmic-CLP; DepMap) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-514; true Female Characteristics: Produces IgG kappa Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138269 CVCL_0W22 GM18145 transformed cell line human CVCL_0W22 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138270 CVCL_1822 Karpas-231 cancer cell line human CVCL_1822 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.09%; East Asian, South=0%; South Asian=0.51%; European, North=68.07%; European, South=30.33% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 9211; POU2AF1; Name(s)=POU2AF1-BCL6, BOB1-LAZ3 (PubMed=8574789; PubMed=8618432) Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia (ALL-L3) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Discontinued: DSMZ; ACC-562; true Female Doubling time: ~30-40 hours (DSMZ=ACC-562); ~60 hours (ECACC=06120601); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138271 CVCL_0W25 GM18148 transformed cell line human CVCL_0W25 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138272 CVCL_1825 KYAE-1 cancer cell line human CVCL_1825 Genome ancestry: African=0%; Native American=1.72%; East Asian, North=76.1%; East Asian, South=22.17%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Unspecified (PubMed=20075370) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~3-4 days (DSMZ=ACC-703); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138273 CVCL_0W24 GM18147 transformed cell line human CVCL_0W24 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138274 CVCL_1824 KG-1a cancer cell line human CVCL_1824 CL:0000010 Sequence variation: Gene fusion; HGNC; 3688; FGFR1 + HGNC; 23098; FGFR1OP2; Name(s)=FGFR1OP2-FGFR1 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Characteristics: Less differentiated subline of KG-1, composed of undifferentiated promyeloblasts Doubling time: ~45 hours (CLS); ~50 hours (DSMZ=ACC-421) 21138275 CVCL_0W27 GM18150 transformed cell line human CVCL_0W27 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138276 CVCL_1827 LA-N-1 cancer cell line human CVCL_1827 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18724359; PubMed=18923523) Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ICLC; HTL98005; true Male Doubling time: ~100 hours (DSMZ=ACC-655); ~2 days (ECACC=06041201) 21138277 CVCL_0W26 GM18149 transformed cell line human CVCL_0W26 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138278 CVCL_1826 LAMA-87 cancer cell line human CVCL_1826 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female Characteristics: Established after subcutaneous transplantation of parent cells into estrone-treated nude mice Doubling time: ~50-60 hours (DSMZ=ACC-270) 21138279 CVCL_1807 AP-1060 cancer cell line human CVCL_1807 CL:0000010 Sequence variation: Gene deletion; HGNC; 12796; WT1; Zygosity=Homozygous (PubMed=29119387); Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 8033; NTRK3; Name(s)=ETV6-NTRK3, TEL-TRKC (PubMed=29119387); Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=15116119); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Pro408Ser (c.1222C>T); Zygosity=Unspecified; Note=Equivalent to p.Pro900Ser in the PML-RARA fusion protein (PubMed=15116119) Derived from sampling site: Bone marrow. Omics: Array-based CGH Male Doubling time: ~48 hours (PubMed=15116119); ~80-100 hours (DSMZ=ACC-593) 21138280 CVCL_0W07 GM18128 transformed cell line human CVCL_0W07 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138281 CVCL_1806 AMO1 cancer cell line human CVCL_1806 HLA typing: A*26:03,33; B*44,54:01; C*01:02/03,14:02/03 (Direct_author_submission); HLA typing: A*26:03,33:03; B*44:03,54:01; C*14:03,14:03 (PubMed=26589293); Genome ancestry: African=1.35%; Native American=0%; East Asian, North=79.12%; East Asian, South=17.86%; South Asian=0%; European, North=0%; European, South=1.66% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5719; IGKJ1 + HGNC; 5743; IGKV1-8; Name(s)=IGKV1-8-IGKJ1 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5720; IGKJ2 + HGNC; 5817; IGKV3-20; Name(s)=IGKV3-20-IGKJ2 (CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 20893; BCOR; Simple; p.Gln312del (c.932_934AGC[1]) (c.935_937delAGC); ClinVar=VCV000418060; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Cys712Tyr (c.2135G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 25941; TET2; Simple; p.Gln1699Ter (c.5095C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Population: Japanese; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA kappa Doubling time: ~24 hours (PubMed=8426482); ~70-90 hours (DSMZ=ACC-538); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138282 CVCL_0W06 GM18127 transformed cell line human CVCL_0W06 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138283 CVCL_1809 CAL-78 cancer cell line human CVCL_1809 HLA typing: A*29:01,32:01; B*18:01,55:01; C*03:03,12:03 (PubMed=26589293); Genome ancestry: African=7.03%; Native American=0%; East Asian, North=6.11%; East Asian, South=0%; South Asian=3.86%; European, North=15.05%; European, South=67.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286_Glu287del (c.856_861delCTCTTC); Zygosity=Unspecified (DepMap) Derived from sampling site: Thigh; skeletal muscle. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 60 hours, at 15th passage (PubMed=21590123); ~240 hours (DSMZ=ACC-449); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138284 CVCL_0W09 GM18130 transformed cell line human CVCL_0W09 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138285 CVCL_1808 CAL-29 cancer cell line human CVCL_1808 HLA typing: A*03:01,23:01; B*49:01,49:01; C*07:01,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.1%; East Asian, North=2.83%; East Asian, South=0%; South Asian=0%; European, North=51.89%; European, South=45.18% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30 hours, at 18th passage (PubMed=11720483); ~50-60 hours (DSMZ=ACC-515); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21138286 CVCL_0W08 GM18129 transformed cell line human CVCL_0W08 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138287 CVCL_1801 AC-1M59 hybrid cell line human CVCL_1801 CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33096371). Characteristics: Fusion of the AC1-1 choriocarcinoma cell line with normal human trophoblast cells (from parent cell line) Doubling time: ~50 hours (DSMZ=ACC-455) 21138288 CVCL_0W01 GM18122 transformed cell line human CVCL_0W01 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138289 CVCL_1800 AC-1M46 hybrid cell line human CVCL_1800 CL:0000010 Characteristics: Fusion of the AC1-1 choriocarcinoma cell line with normal human trophoblast cells (from parent cell line) Doubling time: ~40-50 hours (DSMZ=ACC-454). 21138290 CVCL_0W00 GM18120 transformed cell line human CVCL_0W00 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138291 CVCL_1803 AC-1M88 hybrid cell line human CVCL_1803 CL:0000010 Doubling time: ~30-50 hours (DSMZ=ACC-457). 21138292 CVCL_0W03 GM18124 transformed cell line human CVCL_0W03 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138293 CVCL_1802 AC-1M81 hybrid cell line human CVCL_1802 CL:0000010 Doubling time: ~24 hours (DSMZ=ACC-456). 21138294 CVCL_0W02 GM18123 transformed cell line human CVCL_0W02 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138295 CVCL_1805 ALL-SIL cancer cell line human CVCL_1805 HLA typing: A*02:01,30:02; B*14:02,15:01; C*03:03,08:02; DQB1*06:07;06:07; DRB1*15:01;15:01 (PubMed=26589293); Genome ancestry: African=1.38%; Native American=0%; East Asian, North=1.27%; East Asian, South=1.49%; South Asian=5.24%; European, North=39.53%; European, South=51.09% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 32 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797; DSMZ); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2474fs*4 (c.7418_7419insGG); Zygosity=Heterozygous (PubMed=15472075) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 64 hours (PubMed=17117183); ~48 hours (DSMZ=ACC-511); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138296 CVCL_0W05 GM18126 transformed cell line human CVCL_0W05 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138297 CVCL_1804 ACH-1P hybrid cell line human CVCL_1804 CL:0000010 Characteristics: Fusion of the AC1-1 choriocarcinoma cell line with normal human trophoblast cells (PubMed=10616526) Doubling time: ~40-50 hours (DSMZ=ACC-481). 21138298 CVCL_0W04 GM18125 transformed cell line human CVCL_0W04 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138299 CVCL_KD89 PCRP-DMRTB1-1B3 hybridoma house mouse CVCL_KD89 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96MA1; Human DMRTB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138300 CVCL_KD88 PCRP-DMRT2-1B11 hybridoma house mouse CVCL_KD88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y5R5; Human DMRT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138301 CVCL_KD85 PCRP-DIS3-1A7 hybridoma house mouse CVCL_KD85 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2L1; Human DIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138302 CVCL_KD84 PCRP-DGCR8-1A1 hybridoma house mouse CVCL_KD84 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8WYQ5; Human DGCR8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138303 CVCL_KD87 PCRP-DLX3-2C4 hybridoma house mouse CVCL_KD87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60479; Human DLX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138304 CVCL_KD86 PCRP-DIS3-1D7 hybridoma house mouse CVCL_KD86 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2L1; Human DIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138305 CVCL_KD81 PCRP-DDX53-3B3 hybridoma house mouse CVCL_KD81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86TM3; Human DDX53. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138306 CVCL_KD80 PCRP-DDX43-1E7 hybridoma house mouse CVCL_KD80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NXZ2; Human DDX43. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138307 CVCL_KD83 PCRP-DEAF1-1A10 hybridoma house mouse CVCL_KD83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75398; Human DEAF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138308 CVCL_KD82 PCRP-DDX58-3D8 hybridoma house mouse CVCL_KD82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95786; Human RIGI. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138309 CVCL_KD99 PCRP-DPF1-1B6 hybridoma house mouse CVCL_KD99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92782; Human DPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138310 CVCL_KD96 PCRP-DPF1-1A4 hybridoma house mouse CVCL_KD96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92782; Human DPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138311 CVCL_KD95 PCRP-DNMT3L-1E3 hybridoma house mouse CVCL_KD95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJW3; Human DNMT3L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138312 CVCL_KD98 PCRP-DPF1-1B3 hybridoma house mouse CVCL_KD98 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92782; Human DPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138313 CVCL_KD97 PCRP-DPF1-1A9 hybridoma house mouse CVCL_KD97 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92782; Human DPF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138314 CVCL_KD92 PCRP-DMTF1-1B7 hybridoma house mouse CVCL_KD92 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y222; Human DMTF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138315 CVCL_KD91 PCRP-DMTF1-1A8 hybridoma house mouse CVCL_KD91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y222; Human DMTF1 Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138316 CVCL_KD94 PCRP-DNMT3L-1D5 hybridoma house mouse CVCL_KD94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UJW3; Human DNMT3L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138317 CVCL_KD93 PCRP-DNMT3A-1E2 hybridoma house mouse CVCL_KD93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y6K1; Human DNMT3A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138318 CVCL_KD90 PCRP-DMRTB1-1C10 hybridoma house mouse CVCL_KD90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96MA1; Human DMRTB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138319 CVCL_KD67 PCRP-DAXX-6E9 hybridoma house mouse CVCL_KD67 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138320 CVCL_KD66 PCRP-DAXX-6E11 hybridoma house mouse CVCL_KD66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138321 CVCL_KD69 PCRP-DAXX-8B7 hybridoma house mouse CVCL_KD69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138322 CVCL_KD68 PCRP-DAXX-8B5 hybridoma house mouse CVCL_KD68 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138323 CVCL_KD63 PCRP-DAXX-5H2 hybridoma house mouse CVCL_KD63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138324 CVCL_KD62 PCRP-DAXX-5G11 hybridoma house mouse CVCL_KD62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138325 CVCL_KD65 PCRP-DAXX-6A8 hybridoma house mouse CVCL_KD65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138326 CVCL_KD64 PCRP-DAXX-6A7 hybridoma house mouse CVCL_KD64 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138327 CVCL_KD61 PCRP-DAXX-5C12 hybridoma house mouse CVCL_KD61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138328 CVCL_KD60 PCRP-DAXX-2B3 hybridoma house mouse CVCL_KD60 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138329 CVCL_KD59 PCRP-DAXX-1F6 hybridoma house mouse CVCL_KD59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UER7; Human DAXX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138330 CVCL_KD78 PCRP-DDX41-1B4 hybridoma house mouse CVCL_KD78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UJV9; Human DDX41. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138331 CVCL_KD77 PCRP-DDX41-1A10 hybridoma house mouse CVCL_KD77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UJV9; Human DDX41. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138332 CVCL_KD79 PCRP-DDX43-1B1 hybridoma house mouse CVCL_KD79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NXZ2; Human DDX43. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138333 CVCL_KD74 PCRP-DCP2-1D6 hybridoma house mouse CVCL_KD74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IU60; Human DCP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138334 CVCL_KD73 PCRP-DBX2-2B7 hybridoma house mouse CVCL_KD73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6ZNG2; Human DBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138335 CVCL_KD76 PCRP-DDIT3-1D10 hybridoma house mouse CVCL_KD76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35638; Human DDIT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138336 CVCL_KD75 PCRP-DDIT3-1A10 hybridoma house mouse CVCL_KD75 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35638; Human DDIT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138337 CVCL_KD70 PCRP-DBX2-1D8 hybridoma house mouse CVCL_KD70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6ZNG2; Human DBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138338 CVCL_KD72 PCRP-DBX2-1E5 hybridoma house mouse CVCL_KD72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6ZNG2; Human DBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138339 CVCL_KD71 PCRP-DBX2-1E4 hybridoma house mouse CVCL_KD71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6ZNG2; Human DBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138340 CVCL_9Q35 DD3724 transformed cell line human CVCL_9Q35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138341 CVCL_9Q34 DD2935 transformed cell line human CVCL_9Q34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21138342 CVCL_9Q37 DD3726 transformed cell line human CVCL_9Q37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138343 CVCL_9Q36 DD2920 transformed cell line human CVCL_9Q36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous Part of: ECACC chromosomal abnormality collection 21138344 CVCL_9Q31 DD3714 transformed cell line human CVCL_9Q31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138345 CVCL_9Q30 DD3713 transformed cell line human CVCL_9Q30 CL:0000010 Karyotypic information: 46,XX,t(10,22)(q24.3;q13.31) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138346 CVCL_9Q33 DD2924 transformed cell line human CVCL_9Q33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138347 CVCL_9Q32 DD2000 transformed cell line human CVCL_9Q32 CL:0000010 Karyotypic information: 45,X0 (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138348 CVCL_0W90 GM18767 transformed cell line human CVCL_0W90 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138349 CVCL_1890 SU-DHL-16 cancer cell line human CVCL_1890 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0.78%; Native American=0.75%; East Asian, North=0%; East Asian, South=0%; South Asian=2.95%; European, North=66.22%; European, South=29.29% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (DSMZ=ACC-577); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138350 CVCL_0W92 GM18770 transformed cell line human CVCL_0W92 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138351 CVCL_1892 XTH-2 spontaneously immortalized cell line African clawed frog CVCL_1892 CL:0000010 Derived from sampling site: Heart Cell type=Cardiac endothelial cell.. Unspecified Doubling time: ~10-12 days (DSMZ=ACC-190) Group: Amphibian cell line 21138352 CVCL_0W91 GM18768 transformed cell line human CVCL_0W91 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138353 CVCL_1891 XC cancer cell line Norway rat CVCL_1891 CL:0000010 Transformant: Rous sarcoma virus (strain Prague C)(NCBI-Taxonomy; 11888); Breed/subspecies: White-Weston. Discontinued: ATCC; CRL-6603; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21138354 CVCL_9Q28 DD3697 finite cell line human CVCL_9Q28 CL:0000010 Karyotypic information: 46,XX,t(10;18)?(q21.2;q12.2); de novo (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138355 CVCL_0W94 GM18773 transformed cell line human CVCL_0W94 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138356 CVCL_1894 TMM transformed cell line human CVCL_1894 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: ~20-40 hours (DSMZ=ACC-95) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00279 Problematic cell line: Misclassified Originally thought to be a leukemia cell line from a patient with myelodysplastic syndrome but is a B-lymphoblastoid cell line (PubMed=10516762; PubMed=20143388). 21138357 CVCL_9Q27 DD3696 finite cell line human CVCL_9Q27 CL:0000010 Karyotypic information: 46,XY,del(9)(p23).ish(wcp9+34H2-) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21138358 CVCL_0W93 GM18772 transformed cell line human CVCL_0W93 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138359 CVCL_1893 Y-79 cancer cell line human CVCL_1893 HLA typing: A*02:01:01; B*40:01:02,51:01:01; C*03:04:01,12:03:01; DPB1*03:01,04:01; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01 (CLS=300382) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (PubMed=3413073; PubMed=25326674); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (PubMed=3413073; PubMed=25326674) Anecdotal: Named Y-79 because it was the result of the 79th attempt of a group at Yale to establish a retinoblastoma cell line Population: Caucasian; Derived from sampling site: Eye; globe. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; KURB2684; probable; Discontinued: RCB; RCB0427; true Female Doubling time: 52 hours (PubMed=4135597); 47 hours (PubMed=25326674); ~40 hours (DSMZ=ACC-246) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138360 CVCL_0W96 GM18775 transformed cell line human CVCL_0W96 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138361 CVCL_1896 U-2932 cancer cell line human CVCL_1896 HLA typing: A*01:01,03:01; B*08:01,15:01; C*03:04,07:01 (PubMed=26589293); HLA typing: A*01:01:01,03:01:01; B*08:01:01,15:01:01; C*03:04:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,03:01:01; DQA1*03:01:01,05:01:01; DQB1*02:01:01,03:02:01; DRA*01:01:01,01:02:02; DRB1*03:01:01,04:01:01 (DSMZCellDive=ACC-633) CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Ascites. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572) Doubling time: 48 hours (PubMed=12533045); ~50 hours (DSMZ=ACC-633) Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138362 CVCL_9Q29 DD3712 transformed cell line human CVCL_9Q29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138363 CVCL_0W95 GM18774 transformed cell line human CVCL_0W95 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138364 CVCL_1895 TOM-1 cancer cell line human CVCL_1895 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=3103721) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~60-70 hours (DSMZ=ACC-578) 21138365 CVCL_0W98 GM18778 transformed cell line human CVCL_0W98 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138366 CVCL_1898 U-2973 cancer cell line human CVCL_1898 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=18510704); Sequence variation: Gene fusion; HGNC; 6690; IRAG2 + HGNC; 7553; MYC; Name(s)=MYC-IRAG2, MYC-LRMP (PubMed=23171647) Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Doubling time: ~35 hours (DSMZ=ACC-642) 21138367 CVCL_0W97 GM18777 transformed cell line human CVCL_0W97 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138368 CVCL_1897 U-2940 cancer cell line human CVCL_1897 HLA typing: A*02:01:01,02:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*02:06,02:06; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-634) CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572) Doubling time: ~50 hours (DSMZ=ACC-634) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138369 CVCL_0W99 GM18779 transformed cell line human CVCL_0W99 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138370 CVCL_1899 UPCI-SCC-090 cancer cell line human CVCL_1899 Genome ancestry: African=0%; Native American=0%; East Asian, North=3.18%; East Asian, South=0%; South Asian=0%; European, North=67.02%; European, South=29.79% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains from 100 to 500 copies of the HPV16 genome (PubMed=24201445) Doubling time: 2.8 days (PubMed=29156801); ~120-150 hours (DSMZ=ACC-670); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21138371 CVCL_9Q40 DD3747 transformed cell line human CVCL_9Q40 CL:0000010 Karyotypic information: 46,XX,t(1;9)(q10;p21.2) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138372 CVCL_9Q46 DD3753 transformed cell line human CVCL_9Q46 CL:0000010 Karyotypic information: 47,XY,+mar (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138373 CVCL_9Q45 DD3752 transformed cell line human CVCL_9Q45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138374 CVCL_9Q48 8CB-1 transformed cell line CVCL_9Q48 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Spleen. Male Group: Non-human primate cell line 21138375 CVCL_9Q47 13CB-1 transformed cell line CVCL_9Q47 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Spleen. Male Group: Non-human primate cell line 21138376 CVCL_9Q42 DD3749 transformed cell line human CVCL_9Q42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138377 CVCL_9Q41 DD2940 transformed cell line human CVCL_9Q41 CL:0000010 Karyotypic information: 46,XY,add(2)(q37.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138378 CVCL_9Q44 DD3751 transformed cell line human CVCL_9Q44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138379 CVCL_9Q43 DD3750 transformed cell line human CVCL_9Q43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138380 CVCL_9Q39 DD3746 transformed cell line human CVCL_9Q39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138381 CVCL_9Q38 DD3727 transformed cell line human CVCL_9Q38 CL:0000010 Karyotypic information: 47,XX,+idic(15)(q13) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138382 CVCL_9Q13 DD3660 transformed cell line human CVCL_9Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138383 CVCL_9Q12 DD3655 finite cell line human CVCL_9Q12 CL:0000010 Karyotypic information: 46,XX t(5;13)(p15.1;q32.3)pat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138384 CVCL_9Q15 DD3662 finite cell line human CVCL_9Q15 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138385 CVCL_9Q14 DD3661 transformed cell line human CVCL_9Q14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138386 CVCL_9Q11 DD3650 transformed cell line human CVCL_9Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138387 CVCL_9Q10 DD3628 transformed cell line human CVCL_9Q10 CL:0000010 Karyotypic information: 46,X,del(X)(q21.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138388 CVCL_9Q09 DD3619 finite cell line human CVCL_9Q09 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21138389 CVCL_0W70 GM18704 transformed cell line human CVCL_0W70 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138390 CVCL_1870 MEC-1 cancer cell line human CVCL_1870 HLA typing: A*23:01:01,30:01:01; B*13:02:01;18:01:01; C*06:02:01;12:03:01; DPA1*01:03:01;01:03:01; DPB1*04:02:01;02:01:02; DQA1*01:02:01;05:05:01; DQB1*03:01:01;06:02:01; DRA*01:02:02;01:02:03; DRB1*12:01:01;15:01:01 (DSMZCellDive=ACC-497); Genome ancestry: African=1.9%; Native American=0%; East Asian, North=2.04%; East Asian, South=0%; South Asian=5.76%; European, North=26.14%; European, South=64.15% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 9476; HTRA1 + HGNC; 23512; R3HCC1L; Name(s)=R3HCC1L-HTRA1 (PubMed=31160637); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Profs*20 (c.949dupC) (c.949_950insC); Zygosity=Homozygous (DepMap) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (DSMZ; PubMed=10071128) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138391 CVCL_9Q06 DD3609 finite cell line human CVCL_9Q06 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21138392 CVCL_0W72 GM18707 transformed cell line human CVCL_0W72 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138393 CVCL_1872 Mino cancer cell line human CVCL_1872 HLA typing: A*11:01,68:01; B*35:01,39:01; C*04:01,12:03; DQA1*01:02,01:02; DQB1*05:01,06:03; DRB1*01:01,13:01 (PubMed=25960936); HLA typing: A*11,68; B*35,39; C*04,12 (PubMed=25688540); HLA typing: A*11:01:01,68:01:01; B*35:01:01,39:01:01; C*04:01:01,12:03:01; DPA1*01:03:01,02:01:01; DPB1*10:01:01,10:01:01; DQA1*01:03:01,01:01:01; DQB1*05:01:01,06:03:01; DRA*01:01:01,01:02:02; DRB1*01:01:01,13:01:01 (DSMZCellDive=ACC-687); Genome ancestry: African=0.85%; Native American=0%; East Asian, North=1.5%; East Asian, South=0%; South Asian=6.1%; European, North=39.56%; European, South=51.98% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.262G>A); ClinVar=VCV000821566; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Gly (c.440T>G); Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 72 hours (PubMed=25315077); ~50 hours (DSMZ=ACC-687) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project 21138394 CVCL_9Q05 DD3593 transformed cell line human CVCL_9Q05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,add(1)(p36.3) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138395 CVCL_0W71 GM18706 transformed cell line human CVCL_0W71 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138396 CVCL_1871 MEC-2 cancer cell line human CVCL_1871 Genome ancestry: African=1.35%; Native American=0%; East Asian, North=2.58%; East Asian, South=0%; South Asian=5.1%; European, North=25.37%; European, South=65.6% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 31 hours (PubMed=10071128); ~40-50 hours (DSMZ=ACC-500) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138397 CVCL_9Q08 DD3616 transformed cell line human CVCL_9Q08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138398 CVCL_0W74 GM18743 transformed cell line human CVCL_0W74 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138399 CVCL_1874 NC-NC transformed cell line human CVCL_1874 HLA typing: A*03:02:01,68:01:02; B*07:02:01,51:01:01; C*07:02:01,15:02:01; DPA1*01:03:01,02:01:01; DPB1*10:01:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:02:02,01:02:03; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-120) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Characteristics: Control cell line for toxicity or radiosensitivity assays Doubling time: ~50-60 hours (DSMZ=ACC-120) 21138400 CVCL_9Q07 DD3615 transformed cell line human CVCL_9Q07 CL:0000010 Karyotypic information: 46,XY,t(7;13)(q31.3;q21.3) de novo, inv(11)(p15.3;p15.5)pat (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138401 CVCL_0W73 GM18708 transformed cell line human CVCL_0W73 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138402 CVCL_1873 MUTZ-5 cancer cell line human CVCL_1873 HLA typing: A*30:01,30:01; B*13:02,13:02; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=16.18%; Native American=0.51%; East Asian, North=0%; East Asian, South=2.27%; South Asian=12.13%; European, North=13.74%; European, South=55.18% (PubMed=30894373) CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~70-100 hours (DOI=10.1007/978-3-642-59358-1_5; DSMZ) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138403 CVCL_0W76 GM18750 transformed cell line human CVCL_0W76 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138404 CVCL_1876 NU-DHL-1 cancer cell line human CVCL_1876 HLA typing: A*01:01,24:02; B*08:01,15:07; C*03:03,07:01 (PubMed=26589293); HLA typing: A*01:01:01,24:02:01; B*08:01:01,15:07:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,02:01:02; DQA1*03:01:01,05:01:01; DQB1*02:01:01,02:01:01; DRA*01:01:01,01:02:02; DRB1*03:01:01,04:04:01 (DSMZCellDive=ACC-583); Genome ancestry: African=2.04%; Native American=0.04%; East Asian, North=3.55%; East Asian, South=0%; South Asian=0%; European, North=56.54%; European, South=37.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Left inguinal lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~30-50 hours (DSMZ=ACC-583) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138405 CVCL_0W75 GM18744 transformed cell line human CVCL_0W75 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138406 CVCL_1875 NCEB-1 hybrid cell line CVCL_1875 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu221Lys (c.661G>A); ClinVar=VCV000184647; Zygosity=Unspecified (PubMed=16448697) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Doubling time: 72-96 hours (PubMed=2848599); 19 hours (PubMed=25315077); ~50-70 hours (DSMZ=ACC-721) Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project Caution: Established from a 57 year old male patient but contains some intact murine chromosomes (ATCC; PubMed=16448697) so should be considered as an hybrid cell line 21138407 CVCL_0W78 GM18752 transformed cell line human CVCL_0W78 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138408 CVCL_1878 OCI-Ly19 cancer cell line human CVCL_1878 HLA typing: B*44:02,44:02; C*05:01,08:02; DQA1*03:02,02:01; DQB1*03,03; DRB1*04,04 (PubMed=25960936); HLA typing: A*03:01,03:01; B*56:01,56:01; C*07:02,07:02 (PubMed=26589293); HLA typing: A*03:01:01,03:01:01; B*56:01:01,56:01:01; C*07:02:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*06:01,06:01; DQA1*01:01:01,01:01:01; DQB1*05:01:01,05:01:01; DRA*01:01:01,01:01:01; DRB1*01:01:01,01:01:01 (DSMZCellDive=ACC-528); Genome ancestry: African=2.55%; Native American=0%; East Asian, North=4.58%; East Asian, South=0%; South Asian=0%; European, North=53.54%; European, South=39.33% (PubMed=30894373) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: ~40 hours (DSMZ=ACC-528); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project Caution: While it was indicated to be EBV-positive (PubMed=20454443), this result has later been shown to be invalid (personal communication of Uphoff C.C.) 21138409 CVCL_0W77 GM18751 transformed cell line human CVCL_0W77 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138410 CVCL_1877 NU-DUL-1 cancer cell line human CVCL_1877 HLA typing: A*24:02,02:01; B*49:01,49:01; C*07:01,07:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*12:01,03:02 (PubMed=25960936); HLA typing: A*24:02,24:02; B*49:01,49:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.39%; East Asian, South=0.48%; South Asian=1.36%; European, North=63.99%; European, South=32.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp119Asn (c.355G>A); ClinVar=VCV000040460; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Met (c.427G>A); ClinVar=VCV000142657; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Cerebrospinal fluid. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~30-36 hours (DSMZ=ACC-579); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138411 CVCL_0W79 GM18753 transformed cell line human CVCL_0W79 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138412 CVCL_1879 OCI-Ly1 cancer cell line human CVCL_1879 HLA typing: A*02:01; C*05:01,05:01 (PubMed=25960936) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-60 hours (DSMZ=ACC-722) 21138413 CVCL_9Q24 DD3688 finite cell line human CVCL_9Q24 CL:0000010 Karyotypic information: 47,XX,t18 (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21138414 CVCL_9Q23 DD3686 transformed cell line human CVCL_9Q23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138415 CVCL_9Q26 DD3695 finite cell line human CVCL_9Q26 CL:0000010 Karyotypic information: 46,XY,t(6;10)(p23;q26.2)mat (ECACC); Derived from sampling site: Cell type=Fibroblast. Male Part of: ECACC chromosomal abnormality collection 21138416 CVCL_9Q25 DD3694 finite cell line human CVCL_9Q25 CL:0000010 Karyotypic information: 46,XY,t(1;8)(p3?1.2;p21.?1); de novo (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21138417 CVCL_9Q20 DD3675 transformed cell line human CVCL_9Q20 CL:0000010 Karyotypic information: 46,XY,+I(12p) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138418 CVCL_9Q22 DD3685 transformed cell line human CVCL_9Q22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138419 CVCL_9Q21 DD3681 finite cell line human CVCL_9Q21 CL:0000010 Karyotypic information: 47,XX,+I(18p); de novo (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138420 CVCL_0W81 GM18756 transformed cell line human CVCL_0W81 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138421 CVCL_1881 OCI-Ly7 cancer cell line human CVCL_1881 HLA typing: A*01:01; B*13; C*04:01; DQA1*05:02,05:02; DQB1*03:09,03:09; DRB1*13:03,07:01 (PubMed=25960936); HLA typing: A*01:01:01,01:01:01; B*35:02:01,35:02:01; C*04:01:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,17:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRA*01:02:02,01:02:02; DRB1*13:03:01,13:03:01 (DSMZCellDive=ACC-688); Genome ancestry: African=0.44%; Native American=0.13%; East Asian, North=0%; East Asian, South=0.31%; South Asian=1.19%; European, North=69.58%; European, South=28.35% (PubMed=30894373) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=31160637; DSMZ) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572) Doubling time: ~20-24 hours (DSMZ=ACC-688); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138422 CVCL_0W80 GM18755 transformed cell line human CVCL_0W80 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138423 CVCL_1880 OCI-Ly18 cancer cell line human CVCL_1880 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~30-40 hours (DSMZ=ACC-699) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138424 CVCL_9Q17 DD3665 transformed cell line human CVCL_9Q17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21138425 CVCL_0W83 GM18759 transformed cell line human CVCL_0W83 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138426 CVCL_1883 RC-K8 cancer cell line human CVCL_1883 HLA typing: A*24:02,26:01; B*51:01,54:15; C*01:02,01:02; DQA1*01:03,01:03; DQB1*06:01,06:01; DRB1*08:03,08:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.19%; East Asian, North=73.44%; East Asian, South=24.52%; South Asian=0.79%; European, North=0.06%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Peritoneal effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0537; true Male Doubling time: 48-60 hours (PubMed=3918906); ~36 hours (DSMZ=ACC-561); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: Was originally classified as originating from a histiocytic lymphoma 21138427 CVCL_9Q16 DD3664 finite cell line human CVCL_9Q16 CL:0000010 Karyotypic information: 46,XY,add(1)(p?36.2) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21138428 CVCL_0W82 GM18758 transformed cell line human CVCL_0W82 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138429 CVCL_1882 ONCO-DG-1 cancer cell line human CVCL_1882 HLA typing: A*02:01,29:02; B*07:02,58:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=4.26%; East Asian, South=0%; South Asian=0%; European, North=61.21%; European, South=34.52% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=14522906; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-507; true Female Doubling time: ~30 hours (DSMZ=ACC-507) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00338 Problematic cell line: Contaminated Shown to be a OVCAR-3 derivative (PubMed=20143388). Originally thought to originate from a 49 year old female patient with a thyroid gland papillary carcinoma. 21138430 CVCL_9Q19 DD3672 finite cell line human CVCL_9Q19 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138431 CVCL_0W85 GM18761 transformed cell line human CVCL_0W85 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138432 CVCL_1885 Ri-1 cancer cell line human CVCL_1885 HLA typing: A*02:01,03:01; B*44:02,47:01; C*05:01,06:02 (PubMed=26589293); HLA typing: A*02:01:01,02:01:01; B*44:02:01,47:01:01; C*05:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQB1*06:03:01,06:03:01; DRA*01:02:02,01:02:02 (DSMZCellDive=ACC-585); Genome ancestry: African=3.88%; Native American=0%; East Asian, North=3.34%; East Asian, South=0%; South Asian=0%; European, North=45.33%; European, South=47.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Heterozygous (DepMap) Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, lymphocytic type Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: ~48-72 hours (DSMZ=ACC-585) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21138433 CVCL_9Q18 DD3671 finite cell line human CVCL_9Q18 CL:0000010 Karyotypic information: 46,XY,t(1;4)?(q31;q28) (ECACC); Derived from sampling site: Amniotic fluid. Male Part of: ECACC chromosomal abnormality collection 21138434 CVCL_0W84 GM18760 transformed cell line human CVCL_0W84 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138435 CVCL_1884 REC-1 cancer cell line human CVCL_1884 HLA typing: A*26:01,36:04; B*35:01,57:01; C*04:01,06:02; DQA1*01:02,01:02; DRB1*04:03,04:03 (PubMed=25960936); HLA typing: A*01,03; B*35,57; C*04,06 (PubMed=25688540); HLA typing: A*01:01,24:02; B*35:01,57:01; C*04:01,06:02; DQA1*01:02,01:02; DQB1*03:02,03:02; DRB1*01:01,01:01 (PubMed=26589293); HLA typing: B*35:01:01,57:01:01; C*04:01:01,06:02:01 (DSMZCellDive=ACC-584); Genome ancestry: African=1.88%; Native American=0%; East Asian, North=2.34%; East Asian, South=0%; South Asian=0%; European, North=48.87%; European, South=46.91% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16448697); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 38 hours (PubMed=25315077); ~38 hours (ATCC=CRL-3004); ~20-40 hours (DSMZ=ACC-584) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel; Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project Caution: Wrongly indicated as originating from the lymph node of a 57 year old patient in ATCC 21138436 CVCL_0W87 GM18763 transformed cell line human CVCL_0W87 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138437 CVCL_1887 ROS-50 cancer cell line human CVCL_1887 Genome ancestry: African=0%; Native American=0.07%; East Asian, North=0.46%; East Asian, South=0%; South Asian=1.38%; European, North=66.51%; European, South=31.58% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~50 hours (DSMZ=ACC-557); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138438 CVCL_0W86 GM18762 transformed cell line human CVCL_0W86 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138439 CVCL_1886 RO transformed cell line human CVCL_1886 CL:0000010 Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Arg294Ter (c.880C>T); ClinVar=VCV001431893; Zygosity=Homozygous (PubMed=7744245); Sequence variation: Mutation; HGNC; 9986; RFX5; Simple; p.Pro409Arg (c.1226C>G); ClinVar=VCV000292612; Zygosity=Homozygous (PubMed=7744245) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~50-60 hours (DSMZ=ACC-452) 21138440 CVCL_0W89 GM18765 transformed cell line human CVCL_0W89 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138441 CVCL_1889 SU-DHL-10 cancer cell line human CVCL_1889 HLA typing: A*31:01,31:01; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=2.75%; Native American=0%; East Asian, North=4.02%; East Asian, South=0%; South Asian=0%; European, North=61.61%; European, South=31.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr68His (c.202T>C); ClinVar=VCV000189474; Zygosity=Homozygous (PubMed=9787181; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp162His (c.484G>C); Zygosity=Homozygous (PubMed=9787181; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.994-1G>A; ClinVar=VCV000142161; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~15-30 hours (DSMZ=ACC-576); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138442 CVCL_0W88 GM18764 transformed cell line human CVCL_0W88 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138443 CVCL_1888 Sc-1 cancer cell line human CVCL_1888 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*13:07,15:01 (PubMed=26589293); Genome ancestry: African=1.02%; Native American=0%; East Asian, North=1.9%; East Asian, South=0%; South Asian=0%; European, North=67.26%; European, South=29.81% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-002303; true Male Doubling time: ~30 hours (DSMZ=ACC-558); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138444 CVCL_0W50 GM18679 transformed cell line human CVCL_0W50 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138445 CVCL_1850 PaCaDD-137 cancer cell line human CVCL_1850 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (DepMap) Omics: Deep exome analysis. Female Doubling time: 24.24 hours (PubMed=21683373); ~2-3 days (DSMZ=ACC-711) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138446 CVCL_0W52 GM18683 transformed cell line human CVCL_0W52 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138447 CVCL_1852 Tanoue cancer cell line human CVCL_1852 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Heterozygous (PubMed=15901131; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Protein expression by reverse-phase protein arrays; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (PubMed=7538617); ~40 hours (DSMZ=ACC-399) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21138448 CVCL_0W51 GM18682 transformed cell line human CVCL_0W51 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138449 CVCL_1851 RCH-ACV cancer cell line human CVCL_1851 HLA typing: A*02:01,68:01; B*39:01,44:02; C*05:01,12:03 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0.59%; East Asian, North=1.16%; East Asian, South=0%; South Asian=2.04%; European, North=65.94%; European, South=30.22% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=11843816; PubMed=35354797); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg677Cys (c.2029C>T); ClinVar=VCV000950520; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Ala11Thr (c.31G>A); ClinVar=VCV000178860; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val14Ile (c.40G>A); ClinVar=VCV000012589; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36 hours (PubMed=3455845); ~30-50 hours (DSMZ=ACC-548); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138450 CVCL_0W54 GM18685 transformed cell line human CVCL_0W54 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138451 CVCL_1854 ULA cancer cell line human CVCL_1854 CL:0000010 Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray Male Doubling time: ~40-60 hours (DSMZ=ACC-627) 21138452 CVCL_0W53 GM18684 transformed cell line human CVCL_0W53 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138453 CVCL_1853 UCSD-AML1 cancer cell line human CVCL_1853 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: CSF1 or CSF2 or IL6 dependent Doubling time: 48-72 hours (PubMed=1698479); ~50-60 hours (DSMZ=ACC-691) 21138454 CVCL_1856 BC-2 cancer cell line human CVCL_1856 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~50-70 hours (DSMZ=ACC-678) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-2231 21138455 CVCL_0W56 GM18687 transformed cell line human CVCL_0W56 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138456 CVCL_0W55 GM18686 transformed cell line human CVCL_0W55 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138457 CVCL_1855 UPCI-SCC-029A cancer cell line human CVCL_1855 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Unspecified (PubMed=12872257). Population: Caucasian Male Doubling time: ~60 hours (DSMZ=ACC-659) 21138458 CVCL_1858 BT-B [Human HeLa contaminated cell line] cancer cell line human CVCL_1858 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: DSMZ; ACC-227; true Female Doubling time: ~43 hours (DSMZ=ACC-227) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00394 Problematic cell line: Contaminated Shown to be a HeLa derivative (DSMZ ACC-227). Originally thought to originate from the a 66 year old Caucasian man with a malignant urinary bladder carcinoma. 21138459 CVCL_0W58 GM18690 transformed cell line human CVCL_0W58 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138460 CVCL_1857 BD-215 transformed cell line human CVCL_1857 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Arg185Ter (c.553C>T); ClinVar=VCV000012044; Zygosity=Homozygous (PubMed=7689011) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~40-50 hours (DSMZ=ACC-398) 21138461 CVCL_0W57 GM18689 transformed cell line human CVCL_0W57 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138462 CVCL_1859 CCRF-HSB-2 cancer cell line human CVCL_1859 CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=2255914); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2144611) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: CLS; 300214; true; Discontinued: DepMap; ACH-001737; true Male Characteristics: Established by serial transplantation into newborn Syrian hamsters Doubling time: 40 hours (PubMed=17117183); ~25 hours (DSMZ=ACC-435); 24 hours (lot 042091) (JCRB); Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Partially contaminated The stock formerly distributed by CLS under catalog number 300214 was contaminated.; Compared to the STR values obtained by other distributors it differed from having: Amelogenin 21138463 CVCL_0W59 GM18691 transformed cell line human CVCL_0W59 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138464 CVCL_9Q02 DD3579 transformed cell line human CVCL_9Q02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138465 CVCL_9Q01 DD3575 finite cell line human CVCL_9Q01 CL:0000010 Karyotypic information: 47,XXX (ECACC); Derived from sampling site: Cell type=Fibroblast. Female Part of: ECACC chromosomal abnormality collection 21138466 CVCL_9Q04 DD3590 transformed cell line human CVCL_9Q04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC chromosomal abnormality collection 21138467 CVCL_9Q03 DD3585 finite cell line human CVCL_9Q03 CL:0000010 Karyotypic information: 46,XX,t(19;14)?(q31.2;q32.11)mat or ?(q22.33;q24.33)mat (ECACC); Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138468 CVCL_9Q00 DD3569 finite cell line human CVCL_9Q00 CL:0000010 Derived from sampling site: Amniotic fluid. Female Part of: ECACC chromosomal abnormality collection 21138469 CVCL_1861 Ci-1 cancer cell line human CVCL_1861 HLA typing: A*30:01,30:01; B*13:02,44:06; C*05:01,06:02 (PubMed=26589293); Genome ancestry: African=0.56%; Native American=0%; East Asian, North=0.29%; East Asian, South=1.5%; South Asian=8.65%; European, North=34.89%; European, South=54.11% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr211Ala (c.631A>G); ClinVar=VCV000406581; Zygosity=Heterozygous (DepMap) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: ~50 hours (DSMZ=ACC-570) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21138470 CVCL_0W61 GM18693 transformed cell line human CVCL_0W61 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138471 CVCL_1860 CCRF-SB cancer cell line human CVCL_1860 HLA typing: A*01:01,02:01; B*44:05,57:01; C*02:02,06:02 (PubMed=26589293) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21138472 CVCL_0W60 GM18692 transformed cell line human CVCL_0W60 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138473 CVCL_1863 COLO 720L transformed cell line human CVCL_1863 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: ~20-30 hours (DSMZ=ACC-206) 21138474 CVCL_0W63 GM18695 transformed cell line human CVCL_0W63 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138475 CVCL_1862 COLO 677 cancer cell line human CVCL_1862 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-248; true Male Characteristics: Produces IgG lambda (from parent cell line) Doubling time: ~40 hours (DSMZ=ACC-248) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00299 Problematic cell line: Contaminated Shown to be a RPMI-8226 derivative (PubMed=20143388). Originally thought to originate from the lymph nodes of a 50 year old male patient with a small cell lung carcinoma. 21138476 CVCL_0W62 GM18694 transformed cell line human CVCL_0W62 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138477 CVCL_0W65 GM18697 transformed cell line human CVCL_0W65 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138478 CVCL_1865 JeKo-1 cancer cell line human CVCL_1865 HLA typing: A*02:06,11:01; B*51:01,51:01; C*14:02,14:02; DQA1*03:02,03:02; DQB1*04:01,04:01; DRB1*04:05,14:103 (PubMed=25960936); HLA typing: A*02; B*51; C*14 (PubMed=25688540); HLA typing: A*02:06:01,02:06:01; B*51:01:01,51:01:01; C*14:02:01,14:02:01; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*03:03:01,03:03:01; DQB1*04:01:01,04:01:01; DRA*01:01:01,01:01:01; DRB1*04:05:01,04:05:01 (DSMZCellDive=ACC-553); Genome ancestry: African=2.41%; Native American=0%; East Asian, North=63.65%; East Asian, South=31.67%; South Asian=0%; European, North=0%; European, South=2.27% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=16448697); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=16448697); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro58Glnfs*65 (c.173delC); Zygosity=Heterozygous (PubMed=16448697) Population: Korean; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Doubling time: 33 hours (PubMed=9753063); 26 hours (PubMed=25315077); 26.1 +- 1.1 hours (PubMed=26439697); ~50 hours (DSMZ=ACC-553); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank); Part of: MD Anderson Cell Lines Project 21138479 CVCL_0W64 GM18696 transformed cell line human CVCL_0W64 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138480 CVCL_1864 May Roy finite cell line human CVCL_1864 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138481 CVCL_0W67 GM18699 transformed cell line human CVCL_0W67 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138482 CVCL_1867 L-591 cancer cell line human CVCL_1867 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays Female Virology: Contains a complete EBV genome (strain L591) which has been sequenced (PubMed=25787276) Doubling time: ~72 hours (DSMZ=ACC-602) Part of: MD Anderson Cell Lines Project 21138483 CVCL_0W66 GM18698 transformed cell line human CVCL_0W66 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138484 CVCL_1866 KOPN-8 cancer cell line human CVCL_1866 HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03 (PubMed=26589293); HLA typing: A*33:03:01,33:03:01; B*44:03:01,44:03:01; C*14:03,14:03; DPA1*01:03:01,02:02:02; DPB1*04:01:01,02:01:02; DQA1*01:02:01,01:02:01; DQB1*06:09:01,06:09:01; DRA*01:02:02,01:02:02; DRB1*13:02:01,13:02:01 (DSMZCellDive=ACC-552); Genome ancestry: African=3.7%; Native American=0%; East Asian, North=80.77%; East Asian, South=13.03%; South Asian=0%; European, North=0%; European, South=2.49% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7134; MLLT1; Name(s)=KMT2A-MLLT1, MLL-MLLT1; MLL-ENL (PubMed=31160637; PubMed=35354797; DSMZ); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours (DSMZ=ACC-552); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21138485 CVCL_0W69 GM18702 transformed cell line human CVCL_0W69 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138486 CVCL_1869 LCL-Wei transformed cell line human CVCL_1869 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Male Doubling time: ~30-40 hours (DSMZ=ACC-218) Caution: This cell line was reported to be isogenic with MEL-Wei (Cellosaurus=CVCL_3981) but it does not have the same STR profile (PubMed=10508494). 21138487 CVCL_0W68 GM18701 transformed cell line human CVCL_0W68 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138488 CVCL_1868 LCL-Ho transformed cell line human CVCL_1868 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Female Doubling time: ~30 hours (DSMZ=ACC-185) Caution: This cell line was reported to be isogenic with MEL-Ho (Cellosaurus=CVCL_1402) but it does not have the same STR profile (PubMed=10508494). 21138489 CVCL_0W39 GM18162 transformed cell line human CVCL_0W39 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138490 CVCL_1839 Namalwa.IPN/45 cancer cell line human CVCL_1839 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1; Virology: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443) Contains two partial SMRV copies integrated into the MYC gene locus and 10 further copies integrated at different sites of the genome. 21138491 CVCL_0W30 GM18153 transformed cell line human CVCL_0W30 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138492 CVCL_1830 LAZ-221 cancer cell line human CVCL_1830 HLA typing: A*01,24; B*22,35 (PubMed=2939141) From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,-9,-12,+t(9q;12q) (PubMed=205365); Derived from sampling site: Peripheral blood. Female Doubling time: >=4 days (PubMed=205365); ~50-80 hours (DSMZ=ACC-716); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21138493 CVCL_0W32 GM18155 transformed cell line human CVCL_0W32 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138494 CVCL_1832 MEG-A2 cancer cell line human CVCL_1832 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7869773; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~30 hours (PubMed=7869773); ~40 hours (DSMZ=ACC-718) 21138495 CVCL_0W31 GM18154 transformed cell line human CVCL_0W31 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138496 CVCL_1831 MAVER-1 cancer cell line human CVCL_1831 HLA typing: A*68:01,02:01; B*55:01,07:02; C*03:03,07:02; DQA1*05:01,02:01; DQB1*03:01,02:01; DRB1*11:01,07:01 (PubMed=25960936); HLA typing: A*24,26; B*38,44; C*05,12 (PubMed=25688540) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Hemizygous (PubMed=16434369) Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=25315077); ~48 hours (DSMZ=ACC-717) Part of: Lymphoma Research Foundation Mantle Cell Lymphoma cell bank (LRF MCL cell bank) 21138497 CVCL_0W34 GM18157 transformed cell line human CVCL_0W34 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138498 CVCL_1834 NALM-16 cancer cell line human CVCL_1834 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36.7 hours (PubMed=8847894); ~36 hours (DSMZ=ACC-680); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138499 CVCL_0W33 GM18156 transformed cell line human CVCL_0W33 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138500 CVCL_1833 MEGAL cancer cell line human CVCL_1833 HLA typing: A*11:01:01,11:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*02:01:02,02:01:02; DPB1*01:01:01,01:01:01; DQB1*06:02:01,06:02:01; DRA*01:02:03,01:02:03; DRB1*15:01:01,15:01:01 (DSMZCellDive=ACC-719) CL:0000010 Sequence variation: Gene fusion; HGNC; 8064; NUP214 + HGNC; 10760; SET; Name(s)=SET-NUP214 (PubMed=19166587) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: ~70 hours (DSMZ=ACC-719) Part of: LL-100 blood cancer cell line panel 21138501 CVCL_0W36 GM18159 transformed cell line human CVCL_0W36 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138502 CVCL_1836 NALM-20 cancer cell line human CVCL_1836 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1817649; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~72 hours (PubMed=1817649); ~60-80 hours (DSMZ=ACC-681) 21138503 CVCL_0W35 GM18158 transformed cell line human CVCL_0W35 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138504 CVCL_1835 NALM-19 cancer cell line human CVCL_1835 HLA typing: A*11:01,33:03; B*40:06,54:01; C*01:02,15:02 (PubMed=26589293); Genome ancestry: African=1.76%; Native American=0.1%; East Asian, North=79.97%; East Asian, South=14.34%; South Asian=0.01%; European, North=0%; European, South=3.83% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 29 hours (PubMed=1664237); ~50-70 hours (DSMZ=ACC-522) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138505 CVCL_0W38 GM18161 transformed cell line human CVCL_0W38 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138506 CVCL_1838 Namalwa.CSN/70 cancer cell line human CVCL_1838 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Protein expression by reverse-phase protein arrays. Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1; Virology: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443) Doubling time: ~40 hours (DSMZ=ACC-70) Part of: MD Anderson Cell Lines Project 21138507 CVCL_0W37 GM18160 transformed cell line human CVCL_0W37 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138508 CVCL_1837 NALM-21 cancer cell line human CVCL_1837 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (DSMZ=ACC-682) 21138509 CVCL_0W41 GM18164 transformed cell line human CVCL_0W41 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138510 CVCL_1841 Namalwa.PNT cancer cell line human CVCL_1841 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1; Virology: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443) 21138511 CVCL_0W40 GM18163 transformed cell line human CVCL_0W40 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138512 CVCL_1840 Namalwa.KN2 cancer cell line human CVCL_1840 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1; Virology: Infected by squirrel monkey retrovirus (SMRV) (PubMed=1339415; PubMed=20454443) 21138513 CVCL_0W43 GM18669 transformed cell line human CVCL_0W43 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138514 CVCL_1843 OACP4 C cancer cell line human CVCL_1843 Genome ancestry: African=0.19%; Native American=0.55%; East Asian, North=0%; East Asian, South=1.33%; South Asian=0.08%; European, North=66.1%; European, South=31.76% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: ~35-50 hours (DSMZ=ACC-704); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138515 CVCL_0W42 GM18166 transformed cell line human CVCL_0W42 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138516 CVCL_1842 OACM5.1 C cancer cell line human CVCL_1842 Genome ancestry: African=0%; Native American=0.02%; East Asian, North=0%; East Asian, South=0%; South Asian=1.6%; European, North=72.08%; European, South=26.29% (PubMed=30894373) CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Doubling time: ~48 hours (DSMZ=ACC-696); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138517 CVCL_0W45 GM18671 transformed cell line human CVCL_0W45 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138518 CVCL_1845 PaTu 8902 cancer cell line human CVCL_1845 HLA typing: A*02:01,02:01; B*51:01,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.21%; East Asian, North=1.73%; East Asian, South=0%; South Asian=0%; European, North=62.61%; European, South=35.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Ser1650Tyr (c.4949C>A); Zygosity=Heterozygous (PubMed=10700188; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Homozygous (PubMed=8194712; PubMed=10700188; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~25-40 hours (DSMZ=ACC-179); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI RAS program mutant KRAS cell line panel 21138519 CVCL_0W44 GM18670 transformed cell line human CVCL_0W44 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138520 CVCL_1844 OCI-AML-3 cancer cell line human CVCL_1844 HLA typing: A*02:01,23:01; B*44:02,53:01; C*04:01,05:01 (PubMed=26589293); HLA typing: A*02:01:01,23:01:01; B*44:02:01,53:01:01; C*04:01:01,05:01:01 (DSMZCellDive=ACC-582); Genome ancestry: African=0%; Native American=1.44%; East Asian, North=2.86%; East Asian, South=0%; South Asian=0.99%; European, North=55.94%; European, South=38.78% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882Cys (c.2644C>T); ClinVar=VCV000375882; Zygosity=Heterozygous (PubMed=26434589; PubMed=31160637; PubMed=31739141; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7910; NPM1; Simple; p.Trp288Cysfs*12 (c.860_863dupTCTG); ClinVar=VCV000013998; Zygosity=Heterozygous (PubMed=16079892) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 hours (PubMed=25984343); ~35-40 hours (DSMZ=ACC-582); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21138521 CVCL_0W47 GM18674 transformed cell line human CVCL_0W47 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138522 CVCL_1847 PaTu 8988t cancer cell line human CVCL_1847 HLA typing: A*31:01,32:01; B*27:05,35:01; C*02:02,04:01 (PubMed=26589293); Genome ancestry: African=0.4%; Native American=0%; East Asian, North=0.58%; East Asian, South=0.47%; South Asian=0%; European, North=61.7%; European, South=36.86% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=10408907); Sequence variation: Mutation; HGNC; 3373; EP300; Unexplicit; Ex17-19del (c.4342del448); Zygosity=Homozygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=10700188; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 4.7-5.2 days (PubMed=1348891); ~22-30 hours (DSMZ=ACC-162); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: MD Anderson Cell Lines Project 21138523 CVCL_0W46 GM18673 transformed cell line human CVCL_0W46 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138524 CVCL_1846 PaTu 8988s cancer cell line human CVCL_1846 HLA typing: A*31:01,32:01; B*27:05,35:01; C*02:02,04:01 (PubMed=26589293); Genome ancestry: African=1.16%; Native American=0%; East Asian, North=1.35%; East Asian, South=0%; South Asian=0%; European, North=59.03%; European, South=38.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2-2.6 days (PubMed=1348891); ~40-60 hours (DSMZ=ACC-204) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel Caution: TP53 mutation indicated incorrectly as being at p.Cys176Ser (c.451C>T) in PubMed=8194712 21138525 CVCL_0W49 GM18677 transformed cell line human CVCL_0W49 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138526 CVCL_1849 PaCaDD-135 cancer cell line human CVCL_1849 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=21683373; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249fs (c.746_750_delGGCCC); Zygosity=Unspecified (DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Doubling time: 43.83 hours (PubMed=21683373); ~72 hours (DSMZ=ACC-710) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138527 CVCL_0W48 GM18675 transformed cell line human CVCL_0W48 CL:0000010 Population: Chinese (from Denver); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138528 CVCL_1848 PaCaDD-119 cancer cell line human CVCL_1848 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=21683373; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis. Male Doubling time: 47.45 hours (PubMed=21683373); ~3-4 days (DSMZ=ACC-709) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138529 CVCL_KF01 PCRP-GBX1-2B3 hybridoma house mouse CVCL_KF01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14549; Human GBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138530 CVCL_KF00 PCRP-GATA4-1A7 hybridoma house mouse CVCL_KF00 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P43694; Human GATA4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138531 CVCL_BL69 ND12700 transformed cell line human CVCL_BL69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138532 CVCL_BL62 ND12684 transformed cell line human CVCL_BL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138533 CVCL_BL61 ND12683 transformed cell line human CVCL_BL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138534 CVCL_BL64 ND12692 transformed cell line human CVCL_BL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138535 CVCL_BL63 ND12686 transformed cell line human CVCL_BL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138536 CVCL_BL66 ND12694 transformed cell line human CVCL_BL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138537 CVCL_BL65 ND12693 transformed cell line human CVCL_BL65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138538 CVCL_BL68 ND12697 transformed cell line human CVCL_BL68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138539 CVCL_BL67 ND12695 transformed cell line human CVCL_BL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138540 CVCL_BL60 ND12682 transformed cell line human CVCL_BL60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138541 CVCL_KF10 PCRP-GRAMD4-1A10 hybridoma house mouse CVCL_KF10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6IC98; Human GRAMD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138542 CVCL_KF12 PCRP-GRHL1-1B6 hybridoma house mouse CVCL_KF12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZI5; Human GRHL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138543 CVCL_KF11 PCRP-GRAMD4-1A6 hybridoma house mouse CVCL_KF11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6IC98; Human GRAMD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138544 CVCL_BL73 ND12713 transformed cell line human CVCL_BL73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138545 CVCL_BL72 ND12711 transformed cell line human CVCL_BL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138546 CVCL_BL75 ND12720 transformed cell line human CVCL_BL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138547 CVCL_BL74 ND12714 transformed cell line human CVCL_BL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138548 CVCL_BL77 ND12736 transformed cell line human CVCL_BL77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138549 CVCL_BL76 ND12722 transformed cell line human CVCL_BL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138550 CVCL_BL79 ND12738 transformed cell line human CVCL_BL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138551 CVCL_BL78 ND12737 transformed cell line human CVCL_BL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138552 CVCL_KF07 PCRP-GLIS3-1D10 hybridoma house mouse CVCL_KF07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NEA6; Human GLIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138553 CVCL_KF06 PCRP-GLIS3-1B11 hybridoma house mouse CVCL_KF06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NEA6; Human GLIS3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138554 CVCL_KF09 PCRP-GMEB2-1C6 hybridoma house mouse CVCL_KF09 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UKD1; Human GMEB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138555 CVCL_KF08 PCRP-GMEB1-1C1 hybridoma house mouse CVCL_KF08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y692; Human GMEB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138556 CVCL_KF03 PCRP-GCM2-1B3 hybridoma house mouse CVCL_KF03 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75603; Human GCM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138557 CVCL_KF02 PCRP-GBX1-2F8 hybridoma house mouse CVCL_KF02 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14549; Human GBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138558 CVCL_BL71 ND12709 transformed cell line human CVCL_BL71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138559 CVCL_KF05 PCRP-GLI1-1E6 hybridoma house mouse CVCL_KF05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08151; Human GLI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138560 CVCL_BL70 ND12703 transformed cell line human CVCL_BL70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138561 CVCL_KF04 PCRP-GLI1-1A1 hybridoma house mouse CVCL_KF04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08151; Human GLI1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138562 CVCL_BL48 ND12663 transformed cell line human CVCL_BL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138563 CVCL_BL47 ND12659 transformed cell line human CVCL_BL47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138564 CVCL_BL49 ND12664 transformed cell line human CVCL_BL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138565 CVCL_BL40 ND12628 transformed cell line human CVCL_BL40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138566 CVCL_BL42 ND12630 transformed cell line human CVCL_BL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138567 CVCL_BL41 ND12629 transformed cell line human CVCL_BL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138568 CVCL_BL44 ND12643 transformed cell line human CVCL_BL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138569 CVCL_BL43 ND12642 transformed cell line human CVCL_BL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138570 CVCL_BL46 ND12645 transformed cell line human CVCL_BL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138571 CVCL_BL45 ND12644 transformed cell line human CVCL_BL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138572 CVCL_BL59 ND12681 transformed cell line human CVCL_BL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138573 CVCL_BL58 ND12680 transformed cell line human CVCL_BL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138574 CVCL_BL51 ND12667 transformed cell line human CVCL_BL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138575 CVCL_BL50 ND12666 transformed cell line human CVCL_BL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138576 CVCL_BL53 ND12669 transformed cell line human CVCL_BL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138577 CVCL_BL52 ND12668 transformed cell line human CVCL_BL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138578 CVCL_BL55 ND12671 transformed cell line human CVCL_BL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138579 CVCL_BL54 ND12670 transformed cell line human CVCL_BL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138580 CVCL_BL57 ND12673 transformed cell line human CVCL_BL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138581 CVCL_BL56 ND12672 transformed cell line human CVCL_BL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138582 CVCL_9R92 GM11406 transformed cell line human CVCL_9R92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138583 CVCL_9R91 GM11196 transformed cell line human CVCL_9R91 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Ser196_Leu197insTer (p.Leu197Terfs) (c.590_612del23); ClinVar=VCV000102745; Zygosity=Heterozygous (from familial inference of GM11195); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; c.912+1G>A (IVS8+1G>A); ClinVar=VCV000092752; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM11195) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138584 CVCL_9R94 GM11604 finite cell line human CVCL_9R94 CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Gly3Thrfs*24 (c.4_7dupACTG); Zygosity=Homozygous (PubMed=9054950) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138585 CVCL_9R93 GM11407 transformed cell line human CVCL_9R93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138586 CVCL_9R90 GM11195 transformed cell line human CVCL_9R90 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Ser196_Leu197insTer (p.Leu197Terfs) (c.590_612del23); ClinVar=VCV000102745; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; c.912+1G>A (IVS8+1G>A); ClinVar=VCV000092752; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138587 CVCL_BL26 ND12589 transformed cell line human CVCL_BL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138588 CVCL_9R99 CAMe002-A embryonic stem cell human CVCL_9R99 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC15-16. 21138589 CVCL_BL25 ND12588 transformed cell line human CVCL_BL25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138590 CVCL_BL28 ND12592 transformed cell line human CVCL_BL28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138591 CVCL_BL27 ND12591 transformed cell line human CVCL_BL27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138592 CVCL_9R96 GM13681 transformed cell line human CVCL_9R96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138593 CVCL_9R95 GM13307 finite cell line human CVCL_9R95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138594 CVCL_BL29 ND12594 transformed cell line human CVCL_BL29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138595 CVCL_9R98 CAMe001-A embryonic stem cell human CVCL_9R98 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC15-15. 21138596 CVCL_9R97 GM20136 finite cell line human CVCL_9R97 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu257Leu (c.771G>A) (G-A,EX7); ClinVar=VCV000002761; Zygosity=Homozygous; Note=Causes skipping of exon 7 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138597 CVCL_BL20 ND12576 transformed cell line human CVCL_BL20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138598 CVCL_BL22 ND12578 transformed cell line human CVCL_BL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138599 CVCL_BL21 ND12577 transformed cell line human CVCL_BL21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138600 CVCL_BL24 ND12587 transformed cell line human CVCL_BL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138601 CVCL_BL23 ND12586 transformed cell line human CVCL_BL23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138602 CVCL_BL37 ND12621 transformed cell line human CVCL_BL37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138603 CVCL_BL36 ND12620 transformed cell line human CVCL_BL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138604 CVCL_BL39 ND12626 transformed cell line human CVCL_BL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138605 CVCL_BL38 ND12625 transformed cell line human CVCL_BL38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138606 CVCL_BL31 ND12598 transformed cell line human CVCL_BL31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138607 CVCL_BL30 ND12596 transformed cell line human CVCL_BL30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138608 CVCL_BL33 ND12602 transformed cell line human CVCL_BL33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138609 CVCL_BL32 ND12600 transformed cell line human CVCL_BL32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138610 CVCL_BL35 ND12619 transformed cell line human CVCL_BL35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138611 CVCL_BL34 ND12618 transformed cell line human CVCL_BL34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138612 CVCL_9R70 GM02558 finite cell line human CVCL_9R70 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Gln278Ter (c.832C>T); ClinVar=VCV000038433; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; c.3335+6T>G (IVS17+6T>G); ClinVar=VCV000002773; Zygosity=Heterozygous (PubMed=16465621) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21138613 CVCL_9R72 GM02685 finite cell line human CVCL_9R72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138614 CVCL_9R71 GM02559 finite cell line human CVCL_9R71 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Gln278Ter (c.832C>T); ClinVar=VCV000038433; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; c.3335+6T>G (IVS17+6T>G); ClinVar=VCV000002773; Zygosity=Heterozygous (PubMed=16465621) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21138615 CVCL_9R78 GM03605 finite cell line human CVCL_9R78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138616 CVCL_BL04 ND12545 transformed cell line human CVCL_BL04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138617 CVCL_9R77 GM02923 finite cell line human CVCL_9R77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138618 CVCL_BL03 ND12544 transformed cell line human CVCL_BL03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138619 CVCL_BL06 ND12547 transformed cell line human CVCL_BL06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138620 CVCL_9R79 GM03685 finite cell line human CVCL_9R79 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; c.3335+6T>G (IVS17+6T>G); ClinVar=VCV000002773; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138621 CVCL_BL05 ND12546 transformed cell line human CVCL_BL05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138622 CVCL_9R74 GM02850 finite cell line human CVCL_9R74 CL:0000010 Population: Native North American; Derived from sampling site: Cell type=Fibroblast. Male 21138623 CVCL_BL08 ND12550 transformed cell line human CVCL_BL08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138624 CVCL_9R73 GM02837 finite cell line human CVCL_9R73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138625 CVCL_BL07 ND12548 transformed cell line human CVCL_BL07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138626 CVCL_9R76 GM02922 finite cell line human CVCL_9R76 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138627 CVCL_9R75 GM02921 finite cell line human CVCL_9R75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138628 CVCL_BL09 ND12551 transformed cell line human CVCL_BL09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138629 CVCL_BL00 ND12541 transformed cell line human CVCL_BL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138630 CVCL_BL02 ND12543 transformed cell line human CVCL_BL02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138631 CVCL_BL01 ND12542 transformed cell line human CVCL_BL01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138632 CVCL_9R81 GM04911 finite cell line human CVCL_9R81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138633 CVCL_9R80 GM04179 finite cell line human CVCL_9R80 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21138634 CVCL_9R83 GM07256 finite cell line human CVCL_9R83 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138635 CVCL_9R82 GM07255 finite cell line human CVCL_9R82 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Lys4Gln (c.10A>C); ClinVar=VCV000002774; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138636 CVCL_9R89 GM11111 finite cell line human CVCL_9R89 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21138637 CVCL_BL15 ND12564 transformed cell line human CVCL_BL15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138638 CVCL_9R88 GM11110 transformed cell line human CVCL_9R88 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Tyr414Cys (c.1241A>G); ClinVar=VCV000000593; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; c.1315+1G>A (IVS12+1G>A); ClinVar=VCV000000576; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138639 CVCL_BL14 ND12561 transformed cell line human CVCL_BL14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138640 CVCL_BL17 ND12569 transformed cell line human CVCL_BL17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138641 CVCL_BL16 ND12566 transformed cell line human CVCL_BL16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138642 CVCL_9R85 GM11085 finite cell line human CVCL_9R85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21138643 CVCL_BL19 ND12572 transformed cell line human CVCL_BL19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138644 CVCL_9R84 GM11083 finite cell line human CVCL_9R84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21138645 CVCL_BL18 ND12570 transformed cell line human CVCL_BL18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138646 CVCL_9R87 GM11109 transformed cell line human CVCL_9R87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138647 CVCL_9R86 GM11108 transformed cell line human CVCL_9R86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138648 CVCL_BL11 ND12553 transformed cell line human CVCL_BL11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138649 CVCL_BL10 ND12552 transformed cell line human CVCL_BL10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138650 CVCL_BL13 ND12558 transformed cell line human CVCL_BL13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138651 CVCL_BL12 ND12554 transformed cell line human CVCL_BL12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138652 CVCL_KF87 PCRP-HMGXB4-1B3 hybridoma house mouse CVCL_KF87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UGU5; Human HMGXB4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138653 CVCL_KF86 PCRP-HMGN5-2E6 hybridoma house mouse CVCL_KF86 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P82970; Human HMGN5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138654 CVCL_KF89 PCRP-HMX3-4C5 hybridoma house mouse CVCL_KF89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NHT5; Human HMX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138655 CVCL_KF88 PCRP-HMGXB4-3F4 hybridoma house mouse CVCL_KF88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UGU5; Human HMGXB4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138656 CVCL_KF83 PCRP-HMGB1-6E1 hybridoma house mouse CVCL_KF83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138657 CVCL_KF82 PCRP-HMGB1-6B7 hybridoma house mouse CVCL_KF82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138658 CVCL_KF85 PCRP-HMGN1-1G10 hybridoma house mouse CVCL_KF85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05114; Human HMGN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138659 CVCL_KF84 PCRP-HMGN1-1B2 hybridoma house mouse CVCL_KF84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05114; Human HMGN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138660 CVCL_KF81 PCRP-HMGB1-4F10 hybridoma house mouse CVCL_KF81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138661 CVCL_KF80 PCRP-HMGB1-4C10 hybridoma house mouse CVCL_KF80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138662 CVCL_KF79 PCRP-HMGB1-3B10 hybridoma house mouse CVCL_KF79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138663 CVCL_KF98 PCRP-HOXB5-1C3 hybridoma house mouse CVCL_KF98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09067; Human HOXB5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138664 CVCL_KF97 PCRP-HOXB2-1F2 hybridoma house mouse CVCL_KF97 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P14652; Human HOXB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138665 CVCL_KF99 PCRP-HOXB6-1A4 hybridoma house mouse CVCL_KF99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17509; Human HOXB6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138666 CVCL_KF94 PCRP-HOPX-1A1 hybridoma house mouse CVCL_KF94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BPY8; Human HOPX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138667 CVCL_KF93 PCRP-HOMEZ-1B5 hybridoma house mouse CVCL_KF93 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IX15; Human HOMEZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138668 CVCL_KF96 PCRP-HOXB2-1C9 hybridoma house mouse CVCL_KF96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P14652; Human HOXB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138669 CVCL_KF95 PCRP-HOPX-1A5 hybridoma house mouse CVCL_KF95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BPY8; Human HOPX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138670 CVCL_KF90 PCRP-HMX3-4E5 hybridoma house mouse CVCL_KF90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NHT5; Human HMX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138671 CVCL_KF92 PCRP-HOMEZ-1A5 hybridoma house mouse CVCL_KF92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IX15; Human HOMEZ. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138672 CVCL_KF91 PCRP-HNF4A-2A8 hybridoma house mouse CVCL_KF91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P41235; Human HNF4A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138673 CVCL_KF65 PCRP-HHEX-1D3 hybridoma house mouse CVCL_KF65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03014; Human HHEX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138674 CVCL_KF64 PCRP-HHEX-1C3 hybridoma house mouse CVCL_KF64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03014; Human HHEX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138675 CVCL_KF67 PCRP-HHEX-2B6 hybridoma house mouse CVCL_KF67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03014; Human HHEX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138676 CVCL_KF66 PCRP-HHEX-1H3 hybridoma house mouse CVCL_KF66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03014; Human HHEX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138677 CVCL_KF61 PCRP-HEY2-1H7 hybridoma house mouse CVCL_KF61 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UBP5; Human HEY2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138678 CVCL_KF60 PCRP-HEY2-1H10 hybridoma house mouse CVCL_KF60 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UBP5; Human HEY2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138679 CVCL_KF63 PCRP-HEYL-1G9 hybridoma house mouse CVCL_KF63 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NQ87; Human HEYL. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138680 CVCL_KF62 PCRP-HEY2-3A7 hybridoma house mouse CVCL_KF62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UBP5; Human HEY2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138681 CVCL_KF58 PCRP-HES3-1A10 hybridoma house mouse CVCL_KF58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5TGS1; Human HES3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138682 CVCL_KF57 PCRP-HES1-4A11 hybridoma house mouse CVCL_KF57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138683 CVCL_KF59 PCRP-HESX1-1A11 hybridoma house mouse CVCL_KF59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UBX0; Human HESX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138684 CVCL_KF76 PCRP-HMGB1-1E4 hybridoma house mouse CVCL_KF76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138685 CVCL_KF75 PCRP-HMGA1-1C3 hybridoma house mouse CVCL_KF75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17096; Human HMGA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138686 CVCL_KF78 PCRP-HMGB1-3A7 hybridoma house mouse CVCL_KF78 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138687 CVCL_KF77 PCRP-HMGB1-2G1 hybridoma house mouse CVCL_KF77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09429; Human HMGB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138688 CVCL_KF72 PCRP-HLF-1C5 hybridoma house mouse CVCL_KF72 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16534; Human HLF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138689 CVCL_KF71 PCRP-HINFP-1A1 hybridoma house mouse CVCL_KF71 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BQA5; Human HINFP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138690 CVCL_KF74 PCRP-HMGA1-1B6 hybridoma house mouse CVCL_KF74 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17096; Human HMGA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138691 CVCL_KF73 PCRP-HMG20B-1B5 hybridoma house mouse CVCL_KF73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0W2; Human HMG20B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138692 CVCL_KF70 PCRP-HIF3A-1C6 hybridoma house mouse CVCL_KF70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2N7; Human HIF3A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138693 CVCL_KF69 PCRP-HIC2-2F8 hybridoma house mouse CVCL_KF69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96JB3; Human HIC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138694 CVCL_KF68 PCRP-HIC2-1B1 hybridoma house mouse CVCL_KF68 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96JB3; Human HIC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138695 CVCL_KF43 PCRP-HDAC7-1C4 hybridoma house mouse CVCL_KF43 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8WUI4; Human HDAC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138696 CVCL_KF42 PCRP-HDAC7-1A3 hybridoma house mouse CVCL_KF42 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8WUI4; Human HDAC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138697 CVCL_KF45 PCRP-HDAC8-2C8 hybridoma house mouse CVCL_KF45 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BY41; Human HDAC8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138698 CVCL_KF44 PCRP-HDAC8-2A3 hybridoma house mouse CVCL_KF44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BY41; Human HDAC8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138699 CVCL_KF41 PCRP-HDAC6-1D9 hybridoma house mouse CVCL_KF41 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UBN7; Human HDAC6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138700 CVCL_KF40 PCRP-HDAC6-1A4 hybridoma house mouse CVCL_KF40 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UBN7; Human HDAC6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138701 CVCL_KF39 PCRP-HDAC3-3C9 hybridoma house mouse CVCL_KF39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15379; Human HDAC3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138702 CVCL_KF36 PCRP-HDAC10-1B2 hybridoma house mouse CVCL_KF36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q969S8; Human HDAC10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138703 CVCL_KF35 PCRP-HDAC1-2E12 hybridoma house mouse CVCL_KF35 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13547; Human HDAC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138704 CVCL_KF38 PCRP-HDAC3-2D4 hybridoma house mouse CVCL_KF38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15379; Human HDAC3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138705 CVCL_KF37 PCRP-HDAC11-1B7 hybridoma house mouse CVCL_KF37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96DB2; Human HDAC11. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138706 CVCL_KF54 PCRP-HES1-1B11 hybridoma house mouse CVCL_KF54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138707 CVCL_KF53 PCRP-HES1-1A3 hybridoma house mouse CVCL_KF53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138708 CVCL_KF56 PCRP-HES1-2E8 hybridoma house mouse CVCL_KF56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138709 CVCL_KF55 PCRP-HES1-2C1 hybridoma house mouse CVCL_KF55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138710 CVCL_KF50 PCRP-HDGFRP2-3D1 hybridoma house mouse CVCL_KF50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z4V5; Human HDGFRP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138711 CVCL_KF52 PCRP-HES1-1A10 hybridoma house mouse CVCL_KF52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14469; Human HES1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138712 CVCL_KF51 PCRP-HELLS-2A3 hybridoma house mouse CVCL_KF51 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NRZ9; Human HELLS. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138713 CVCL_KF47 PCRP-HDGF-1F2 hybridoma house mouse CVCL_KF47 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P51858; Human HDGF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138714 CVCL_KF46 PCRP-HDGF-1D1 hybridoma house mouse CVCL_KF46 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P51858; Human HDGF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138715 CVCL_KF49 PCRP-HDGFRP2-3C4 hybridoma house mouse CVCL_KF49 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q7Z4V5; Human HDGFRP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138716 CVCL_KF48 PCRP-HDGFL1-1A11 hybridoma house mouse CVCL_KF48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5TGJ6; Human HDGFL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138717 CVCL_KF21 PCRP-GTF2F2-1B3 hybridoma house mouse CVCL_KF21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13984; Human GTF2F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138718 CVCL_KF20 PCRP-GTF2F2-1A8 hybridoma house mouse CVCL_KF20 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13984; Human GTF2F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138719 CVCL_KF23 PCRP-GTF2H1-1A10 hybridoma house mouse CVCL_KF23 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P32780; Human GTF2H1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138720 CVCL_KF22 PCRP-GTF2F2-1B4 hybridoma house mouse CVCL_KF22 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13984; Human GTF2F2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138721 CVCL_BL84 ND12748 transformed cell line human CVCL_BL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138722 CVCL_BL83 ND12747 transformed cell line human CVCL_BL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138723 CVCL_BL86 ND12752 transformed cell line human CVCL_BL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138724 CVCL_BL85 ND12750 transformed cell line human CVCL_BL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138725 CVCL_BL88 ND12754 transformed cell line human CVCL_BL88 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138726 CVCL_BL87 ND12753 transformed cell line human CVCL_BL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138727 CVCL_BL89 ND12765 transformed cell line human CVCL_BL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138728 CVCL_KF18 PCRP-GTF2B-1H2 hybridoma house mouse CVCL_KF18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q00403; Human GTF2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138729 CVCL_KF17 PCRP-GTF2B-1D1 hybridoma house mouse CVCL_KF17 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q00403; Human GTF2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138730 CVCL_KF19 PCRP-GTF2E1-2C12 hybridoma house mouse CVCL_KF19 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P29083; Human GTF2E1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138731 CVCL_BL80 ND12739 transformed cell line human CVCL_BL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138732 CVCL_KF14 PCRP-GRHL1-1F9 hybridoma house mouse CVCL_KF14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZI5; Human GRHL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138733 CVCL_KF13 PCRP-GRHL1-1D11 hybridoma house mouse CVCL_KF13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZI5; Human GRHL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138734 CVCL_BL82 ND12745 transformed cell line human CVCL_BL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138735 CVCL_KF16 PCRP-GTF2A1-1F2 hybridoma house mouse CVCL_KF16 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52655; Human GTF2A1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138736 CVCL_BL81 ND12741 transformed cell line human CVCL_BL81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138737 CVCL_KF15 PCRP-GRHL2-1A6 hybridoma house mouse CVCL_KF15 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q6ISB3; Human GRHL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138738 CVCL_KF32 PCRP-HAND2-1C6 hybridoma house mouse CVCL_KF32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P61296; Human HAND2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138739 CVCL_KF31 PCRP-HAND1-2A9 hybridoma house mouse CVCL_KF31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O96004; Human HAND1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138740 CVCL_KF34 PCRP-HDAC1-2B9 hybridoma house mouse CVCL_KF34 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13547; Human HDAC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138741 CVCL_KF33 PCRP-HAT1-1G5 hybridoma house mouse CVCL_KF33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14929; Human HAT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138742 CVCL_KF30 PCRP-HAND1-1D5 hybridoma house mouse CVCL_KF30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O96004; Human HAND1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138743 CVCL_BL95 ND12776 transformed cell line human CVCL_BL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138744 CVCL_BL94 ND12774 transformed cell line human CVCL_BL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138745 CVCL_BL97 ND12779 transformed cell line human CVCL_BL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138746 CVCL_BL96 ND12778 transformed cell line human CVCL_BL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138747 CVCL_BL99 ND12781 transformed cell line human CVCL_BL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138748 CVCL_BL98 ND12780 transformed cell line human CVCL_BL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138749 CVCL_KF29 PCRP-GTF2IRD2-1B4 hybridoma house mouse CVCL_KF29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86UP8; Human GTF2IRD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138750 CVCL_KF28 PCRP-GTF2IRD2-1B12 hybridoma house mouse CVCL_KF28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86UP8; Human GTF2IRD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138751 CVCL_BL91 ND12770 transformed cell line human CVCL_BL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138752 CVCL_KF25 PCRP-GTF2H2C-2C9 hybridoma house mouse CVCL_KF25 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6P1K8; Human GTF2H2C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138753 CVCL_BL90 ND12767 transformed cell line human CVCL_BL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138754 CVCL_KF24 PCRP-GTF2H2-1B9 hybridoma house mouse CVCL_KF24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13888; Human GTF2H2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138755 CVCL_BL93 ND12773 transformed cell line human CVCL_BL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138756 CVCL_KF27 PCRP-GTF2I-1B10 hybridoma house mouse CVCL_KF27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P78347; Human GTF2I. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138757 CVCL_BL92 ND12772 transformed cell line human CVCL_BL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138758 CVCL_KF26 PCRP-GTF2I-1A7 hybridoma house mouse CVCL_KF26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P78347; Human GTF2I. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138759 CVCL_1939 A-2 spontaneously immortalized cell line CVCL_1939 CL:0000010 Breed/subspecies: YF1. Unspecified Doubling time: ~2-3 days (DSMZ=ACC-276) Group: Fish cell line 21138760 CVCL_0X39 GM19115 transformed cell line human CVCL_0X39 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138761 CVCL_1938 8709 cancer cell line house mouse CVCL_1938 From: Yoshida K.; National Institute of Radiological Sciences; Chiba-shi; Japan CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H. Doubling time: ~60-80 hours (DSMZ=ACC-588) 21138762 CVCL_0X38 GM19110 transformed cell line human CVCL_0X38 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138763 CVCL_1931 2E10-H2 hybridoma house mouse CVCL_1931 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine adenovirus serotype 1. 21138764 CVCL_0X31 GM19042 transformed cell line human CVCL_0X31 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138765 CVCL_1930 2A1 [Mouse hybridoma against chicken retinal antigen] hybridoma house mouse CVCL_1930 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chicken retinal membrane-associated cytoskeletal 2A1 antigen. Doubling time: ~25 hours (DSMZ=ACC-281) 21138766 CVCL_0X30 GM18935 transformed cell line human CVCL_0X30 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138767 CVCL_1933 2M6 hybridoma house mouse CVCL_1933 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q90634; Chicken TOPAP. Doubling time: ~35 hours (DSMZ=ACC-205) 21138768 CVCL_0X33 GM19097 transformed cell line human CVCL_0X33 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138769 CVCL_1932 2Hx-2 hybridoma house mouse CVCL_1932 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03277; Adenovirus 2 hexon protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8117 21138770 CVCL_0X32 GM19094 transformed cell line human CVCL_0X32 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138771 CVCL_1935 7-TD-1 hybridoma house mouse CVCL_1935 CL:0000010 Discontinued: ATCC; CRL-1851; true; Discontinued: ICLC; HYL96001; true. Doubling time: ~24-25 hours (DSMZ=ACC-23) Caution: Was reported to be IL6 dependent, but is not according to ATCC 21138772 CVCL_0X35 GM19103 transformed cell line human CVCL_0X35 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138773 CVCL_1934 4H1-A7 hybridoma house mouse CVCL_1934 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Canine adenovirus serotype 2. 21138774 CVCL_0X34 GM19100 transformed cell line human CVCL_0X34 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138775 CVCL_1937 7926 cancer cell line house mouse CVCL_1937 From: Yoshida K.; National Institute of Radiological Sciences; Chiba-shi; Japan CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H. Doubling time: ~50-80 hours (DSMZ=ACC-587) 21138776 CVCL_0X37 GM19109 transformed cell line human CVCL_0X37 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138777 CVCL_1936 72A1 hybridoma house mouse CVCL_1936 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03200; Epstein-Barr virus envelope glycoprotein GP350 (BLLF1). 21138778 CVCL_0X36 GM19104 transformed cell line human CVCL_0X36 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138779 CVCL_1949 A-S-30D cancer cell line Norway rat CVCL_1949 CL:0000010 Breed/subspecies: Sprague Dawley. Female Doubling time: ~26 hours (CLS=500116); ~29 hours (DSMZ=ACC-208) 21138780 CVCL_0X49 GM19139 transformed cell line human CVCL_0X49 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138781 CVCL_1940 A20 cancer cell line house mouse CVCL_1940 CL:0000010 Breed/subspecies: BALB/cAnN. Omics: Array-based CGH Unspecified Doubling time: 18 hours (PubMed=310843) Part of: ENCODE project mouse cell lines; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21138782 CVCL_0X40 GM19120 transformed cell line human CVCL_0X40 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138783 CVCL_1942 A2780cis cancer cell line human CVCL_1942 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (PubMed=25230021) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: OCCP ovarian cancer cell line panel 21138784 CVCL_0X42 GM19124 transformed cell line human CVCL_0X42 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138785 CVCL_1941 A2780ADR cancer cell line human CVCL_1941 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (PubMed=25230021) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: OCCP ovarian cancer cell line panel 21138786 CVCL_0X41 GM19123 transformed cell line human CVCL_0X41 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Triplication; Zygosity=Unspecified; Note=Has 2 copies on one chromosome and 1 on the other (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Homozygous (PubMed=33197628) Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138787 CVCL_1944 A4.1077 hybridoma house mouse CVCL_1944 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species). Doubling time: ~20-40 hours (DSMZ=ACC-297) 21138788 CVCL_0X44 GM19128 transformed cell line human CVCL_0X44 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138789 CVCL_1943 A4.1025 hybridoma house mouse CVCL_1943 CL:0000010 Discontinued: ATCC; CRL-2044; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species) Doubling time: ~40-50 hours (DSMZ=ACC-296) 21138790 CVCL_0X43 GM19125 transformed cell line human CVCL_0X43 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138791 CVCL_1946 A4.951 hybridoma house mouse CVCL_1946 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species). Doubling time: ~24 hours (DSMZ=ACC-214) 21138792 CVCL_0X46 GM19133 transformed cell line human CVCL_0X46 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138793 CVCL_1945 A4.840 hybridoma house mouse CVCL_1945 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human myosin heavy chains (Note=Also reacts with other species). Doubling time: ~25 hours (DSMZ=ACC-213) 21138794 CVCL_0X45 GM19132 transformed cell line human CVCL_0X45 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138795 CVCL_1948 AM-C6SC8 spontaneously immortalized cell line pig CVCL_1948 CL:0000010 Derived from sampling site: Kidney. Unspecified 21138796 CVCL_0X48 GM19136 transformed cell line human CVCL_0X48 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138797 CVCL_1947 ALC [Mouse ameloblast] spontaneously immortalized cell line house mouse CVCL_1947 CL:0000010 Derived from sampling site: Tooth bud; dental papilla; molar Cell type=Ameloblast.; Breed/subspecies: C57BL/6J. Unspecified 21138798 CVCL_0X47 GM19135 transformed cell line human CVCL_0X47 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138799 CVCL_1917 DAN cancer cell line dog CVCL_1917 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Lung; Breed/subspecies: Poodle. Female Group: Retrovirus packaging cell line 21138800 CVCL_0X17 GM18872 transformed cell line human CVCL_0X17 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138801 CVCL_1916 D-17 cancer cell line dog CVCL_1916 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Heterozygous (PubMed=31175136) Derived from metastatic site: Lung; Breed/subspecies: Poodle. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-6248; true; Discontinued: ECACC; 89090403; probable Female Doubling time: 22.2 hours (PubMed=22916246); 22 hours (PubMed=27257868) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Part of: FACC canine tumor cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8468 21138802 CVCL_0X16 GM18869 transformed cell line human CVCL_0X16 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138803 CVCL_1919 DSN cancer cell line dog CVCL_1919 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03360; Avian reticuloendotheliosis virus gag-pol; Transfected with: UniProtKB; P03399; Avian reticuloendotheliosis virus env; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung; Breed/subspecies: Poodle. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9939 21138804 CVCL_0X19 GM18876 transformed cell line human CVCL_0X19 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138805 CVCL_1918 DSDh cancer cell line dog CVCL_1918 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03360; Avian reticuloendotheliosis virus gag-pol; Transfected with: UniProtKB; P03399; Avian reticuloendotheliosis virus env; Transfected with: MGI; MGI:94890; Dhfr (with p.Leu23Arg; methotrexate-resistant) Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from metastatic site: Lung; Breed/subspecies: Poodle. Female Group: Retrovirus packaging cell line 21138806 CVCL_0X18 GM18875 transformed cell line human CVCL_0X18 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138807 CVCL_0X11 GM18857 transformed cell line human CVCL_0X11 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138808 CVCL_1911 UO-31 cancer cell line human CVCL_1911 HLA typing: A*01:01:01,03:01:01; B*07,14; C*07,08; DPB1*04:02,05:01; DQB1*06:02,06:09; DRB1*13:02:01,15:01:01 (PubMed=15748285); Genome ancestry: African=1.96%; Native American=0%; East Asian, North=3.55%; East Asian, South=0%; South Asian=0%; European, North=65.67%; European, South=28.82% (PubMed=30894373) CL:0000010 Derived from sampling site: Kidney. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Fluorescence phenotype profiling; Omics: lncRNA expression profiling; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-002203; true Female Doubling time: 41.7 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI-60 cancer cell line panel 21138809 CVCL_0X10 GM18854 transformed cell line human CVCL_0X10 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138810 CVCL_1910 MDA-N cancer cell line human CVCL_1910 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 22.5 hours (NCI-DTP); Microsatellite instability: Stable (MSS) (PubMed=12661003) Part of: NCI-60 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00236 Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative (PubMed=20143388). 21138811 CVCL_0X13 GM18863 transformed cell line human CVCL_0X13 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138812 CVCL_1913 Peer cancer cell line human CVCL_1913 HLA typing: A*23:01,24:02; B*35:02,44:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=3.73%; Native American=0.87%; East Asian, North=2.76%; East Asian, South=0.35%; South Asian=9.54%; European, North=10.64%; European, South=72.11% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 34 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797; DSMZ); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (PubMed=22675565); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Heterozygous (PubMed=10071127; PubMed=22675565) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50-60 hours (DSMZ=ACC-6); ~40-50 hours (lot 06202003), ~39 hours (lot 10012019) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138813 CVCL_0X12 GM18860 transformed cell line human CVCL_0X12 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138814 CVCL_1912 Vero-B4 spontaneously immortalized cell line green monkey CVCL_1912 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Virology: Susceptible to infection by Middle East respiratory syndrome-related coronavirus (MERS-CoV) (PubMed=25531820); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474) Doubling time: ~25 hours (DSMZ=ACC-33) Group: Non-human primate cell line; Group: Vaccine production cell line 21138815 CVCL_1915 BHK-21 clone 13 spontaneously immortalized cell line CVCL_1915 CL:0000010 Derived from sampling site: Kidney. Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: ~32-50 hours (DSMZ=ACC-61) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-10 21138816 CVCL_0X15 GM18865 transformed cell line human CVCL_0X15 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138817 CVCL_1914 BHK-21 spontaneously immortalized cell line CVCL_1914 CL:0000010 Miscellaneous: Not distributed parent cell line Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6281; true; Discontinued: ATCC; CRL-6282; true Male Doubling time: 12 hours (PubMed=14207308) Group: Space-flown cell line (cellonaut); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21138818 CVCL_0X14 GM18864 transformed cell line human CVCL_0X14 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138819 CVCL_1928 9L cancer cell line Norway rat CVCL_1928 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21138820 CVCL_0X28 GM18931 transformed cell line human CVCL_0X28 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138821 CVCL_0X27 GM18930 transformed cell line human CVCL_0X27 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138822 CVCL_1927 YNH-1 cancer cell line human CVCL_1927 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 4010; FUS; Name(s)=FUS-ERG, TLS-ERG (PubMed=9096702; PubMed=10354136); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Glu76Gly (c.227A>G); ClinVar=VCV000013338; Zygosity=Unspecified (PubMed=16518851) Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB1291; true Male Doubling time: 82 hours (PubMed=9096702); ~80 hours (DSMZ=ACC-692) 21138823 CVCL_1929 1G1 hybridoma house mouse CVCL_1929 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chicken dorsal retina cytoplasmic membranes (1G1 antigen). Doubling time: ~30 hours (DSMZ=ACC-424) 21138824 CVCL_0X29 GM18932 transformed cell line human CVCL_0X29 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138825 CVCL_0X20 GM18878 transformed cell line human CVCL_0X20 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138826 CVCL_1920 RTG-2 spontaneously immortalized cell line CVCL_1920 CL:0000010 Anecdotal: First fish cell line to have been established (in 1962) Derived from sampling site: Ovary Cell type=Fibroblast.. Female Doubling time: ~2 days, at 20 Celsius (PubMed=5167740; PubMed=3410806); ~3-7 days (DSMZ=ACC-352) Group: Fish cell line 21138827 CVCL_0X22 GM18906 transformed cell line human CVCL_0X22 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138828 CVCL_1922 HeLa Kyoto cancer cell line human CVCL_1922 From: Narumiya S.; Kyoto University; Kyoto; Japan CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Interactome by proteomics Female 21138829 CVCL_0X21 GM18879 transformed cell line human CVCL_0X21 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138830 CVCL_1921 RTG-P1 spontaneously immortalized cell line CVCL_1921 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary Cell type=Fibroblast.. Female Characteristics: Can be used as a reporter cell line to study interferon pathways; Characteristics: The expression of the luciferase reporter gene is under control of the trout Mx1 gene promoter Group: Fish cell line 21138831 CVCL_1924 EMT6/AR1 cancer cell line house mouse CVCL_1924 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: BALB/cCRGL. Female Doubling time: 12-15 hours (ECACC=96042327) 21138832 CVCL_0X24 GM18914 transformed cell line human CVCL_0X24 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138833 CVCL_1923 EMT6 cancer cell line house mouse CVCL_1923 CL:0000010 Breed/subspecies: BALB/cCRGL. Female 21138834 CVCL_0X23 GM18911 transformed cell line human CVCL_0X23 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138835 CVCL_0X26 GM18925 transformed cell line human CVCL_0X26 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138836 CVCL_1926 HEK293T/17 transformed cell line human CVCL_1926 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11268 21138837 CVCL_1925 EMT6/AR10.0 cancer cell line house mouse CVCL_1925 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: BALB/cCRGL. Female 21138838 CVCL_0X25 GM18921 transformed cell line human CVCL_0X25 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138839 CVCL_0X06 GM18792 transformed cell line human CVCL_0X06 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138840 CVCL_1906 HEp-2 cancer cell line human CVCL_1906 HLA typing: A*68:02,68:02; B*15:03,15:03; C*12:03,12:03 (PubMed=26589293) CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage); Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Ubiquitination analysis by proteomics Discontinued: BCRC; 60042; true Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Part of: KuDOS 95 cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00007 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from a 56 year old male patient with a laryngeal carcinoma. 21138841 CVCL_1905 FL cancer cell line human CVCL_1905 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage) Discontinued: JCRB; JCRB9016; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00046 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). Originally thought to originate from a normal amnion. 21138842 CVCL_0X05 GM18791 transformed cell line human CVCL_0X05 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138843 CVCL_0X08 GM18796 transformed cell line human CVCL_0X08 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138844 CVCL_1908 L-132 cancer cell line human CVCL_1908 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage) Discontinued: JCRB; NIHS0050; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00025 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to be a lung embryonic cell line. 21138845 CVCL_0X07 GM18795 transformed cell line human CVCL_0X07 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138846 CVCL_1907 Intestine 407 cancer cell line human CVCL_1907 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage) Discontinued: BCRC; 60022; true; Discontinued: RCB; RCB0553; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00008 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from embryonic intestinal cells (jejunum/ileum). 21138847 CVCL_0X09 GM18797 transformed cell line human CVCL_0X09 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM18797; probable Male 21138848 CVCL_1909 WISH cancer cell line human CVCL_1909 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage) Discontinued: ATCC; CRL-7727; true Female Virology: Used for differentiation of virulent and non virulent strains of measles virus (ECACC; IZSLER) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00013 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from cells of the amniotic sac of Susan Hayflick, the daughter of Leonard Hayflick. 21138849 CVCL_0X00 GM18780 transformed cell line human CVCL_0X00 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138850 CVCL_1900 WILL-1 cancer cell line human CVCL_1900 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: ~30-50 hours, 50-70 hours (after recovery from liquid nitrogen freezing) (DSMZ=ACC-651) 21138851 CVCL_0X02 GM18783 transformed cell line human CVCL_0X02 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138852 CVCL_1902 WSU-DLCL2 cancer cell line human CVCL_1902 HLA typing: A*24/29; C*12/15 (PubMed=25960936); HLA typing: A*02:01,29:02; B*27:07,44:03; C*15:02,15:02 (PubMed=26589293); HLA typing: A*02:01:01,29:02:01; B*27:07:01,44:03:01; C*15:02:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:02:01; DQA1*04:01:01,05:05:01; DQB1*03:01:01,04:02:01; DRA*01:01:01,01:02:02; DRB1*11:01:01,08:01:01 (DSMZCellDive=ACC-575); Genome ancestry: African=0.21%; Native American=0%; East Asian, North=2.12%; East Asian, South=0%; South Asian=0%; European, North=66.4%; European, South=31.27% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Phe (c.1937A>T) (Y641F); ClinVar=VCV000076768; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 18 hours (PubMed=9607591); ~50-70 hours (DSMZ=ACC-575); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11585 21138853 CVCL_0X01 GM18781 transformed cell line human CVCL_0X01 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138854 CVCL_1901 WILL-2 cancer cell line human CVCL_1901 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: ~36-48 hours (DSMZ=ACC-652) 21138855 CVCL_1904 AV3 cancer cell line human CVCL_1904 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced (low read coverage) Discontinued: KCLB; 10021; probable Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00001 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=1246601; PubMed=20143388). Originally thought to originate from a normal amnion. 21138856 CVCL_0X04 GM18789 transformed cell line human CVCL_0X04 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138857 CVCL_0X03 GM18784 transformed cell line human CVCL_0X03 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138858 CVCL_1903 WSU-FSCCL cancer cell line human CVCL_1903 HLA typing: A*02:01,02:01; B*27:05,44:02; C*01:02,05:01; DQA1*02:01,03:02; DQB1*03:02,03:02; DRB1*04:04,07:01 (PubMed=26589293) CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~26 hours (PubMed=8221615); ~20-30 hours (DSMZ=ACC-612) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21138859 CVCL_KE88 PCRP-FOXO3-1G5 hybridoma house mouse CVCL_KE88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43524; Human FOXO3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138860 CVCL_KE87 PCRP-FOXO3-1B7 hybridoma house mouse CVCL_KE87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O43524; Human FOXO3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138861 CVCL_KE89 PCRP-FOXP3-1B2 hybridoma house mouse CVCL_KE89 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BZS1; Human FOXP3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138862 CVCL_KE84 PCRP-FOXN1-2B8 hybridoma house mouse CVCL_KE84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15353; Human FOXN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138863 CVCL_KE83 PCRP-FOXM1-2E6 hybridoma house mouse CVCL_KE83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q08050; Human FOXM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138864 CVCL_KE86 PCRP-FOXN3-1A3 hybridoma house mouse CVCL_KE86 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O00409; Human FOXN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138865 CVCL_KE85 PCRP-FOXN1-2C1 hybridoma house mouse CVCL_KE85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15353; Human FOXN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138866 CVCL_KE80 PCRP-FOXL1-2B4 hybridoma house mouse CVCL_KE80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q12952; Human FOXL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138867 CVCL_KE82 PCRP-FOXM1-1H4 hybridoma house mouse CVCL_KE82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08050; Human FOXM1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138868 CVCL_KE81 PCRP-FOXL2-1B4 hybridoma house mouse CVCL_KE81 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P58012; Human FOXL2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138869 CVCL_KE99 PCRP-GABPB1-1A2 hybridoma house mouse CVCL_KE99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q06547; Human GABPB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138870 CVCL_KE98 PCRP-GABPA-2G3 hybridoma house mouse CVCL_KE98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q06546; Human GABPA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138871 CVCL_KE95 PCRP-FOXR1-1F8 hybridoma house mouse CVCL_KE95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6PIV2; Human FOXR1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138872 CVCL_KE94 PCRP-FOXQ1-2F10 hybridoma house mouse CVCL_KE94 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9C009; Human FOXQ1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138873 CVCL_KE97 PCRP-G3BP2-1C7 hybridoma house mouse CVCL_KE97 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UN86; Human G3BP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138874 CVCL_KE96 PCRP-G3BP1-2H8 hybridoma house mouse CVCL_KE96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13283; Human G3BP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138875 CVCL_KE91 PCRP-FOXP4-1D1 hybridoma house mouse CVCL_KE91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IVH2; Human FOXP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138876 CVCL_KE90 PCRP-FOXP4-1A10 hybridoma house mouse CVCL_KE90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IVH2; Human FOXP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138877 CVCL_KE93 PCRP-FOXQ1-2D2 hybridoma house mouse CVCL_KE93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9C009; Human FOXQ1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138878 CVCL_KE92 PCRP-FOXP4-1G7 hybridoma house mouse CVCL_KE92 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IVH2; Human FOXP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21138879 CVCL_9R50 GM07992 finite cell line human CVCL_9R50 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138880 CVCL_9R56 GM20202 transformed cell line human CVCL_9R56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138881 CVCL_9R55 GM14175 finite cell line human CVCL_9R55 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Male 21138882 CVCL_9R58 FSD1/F4 cancer cell line house mouse CVCL_9R58 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21138883 CVCL_9R57 GM21568 transformed cell line human CVCL_9R57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138884 CVCL_9R52 GM14080 transformed cell line human CVCL_9R52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138885 CVCL_9R51 GM10183 transformed cell line human CVCL_9R51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138886 CVCL_9R54 GM14174 transformed cell line human CVCL_9R54 CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138887 CVCL_9R53 GM14082 transformed cell line human CVCL_9R53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138888 CVCL_9R49 GM07149 finite cell line human CVCL_9R49 CL:0000010 Population: Caucasian; Karyotypic information: 45,X,dic(X;22)(p22.1;p11.2) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21138889 CVCL_9R48 GM06967 transformed cell line human CVCL_9R48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 21138890 CVCL_9R61 GM01494 finite cell line human CVCL_9R61 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Lys4Gln (c.10A>C); ClinVar=VCV000002774; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138891 CVCL_9R60 GM00113 finite cell line human CVCL_9R60 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Lys4Gln (c.10A>C); ClinVar=VCV000002774; Zygosity=Homozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138892 CVCL_9R67 GM01807 transformed cell line human CVCL_9R67 HLA typing: A*01,02; B*13,w35 (Coriell=GM01807) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138893 CVCL_9R66 GM01759 finite cell line human CVCL_9R66 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Asp190Val (c.569A>T) (733A>T) (p.Asp190fs*211); ClinVar=VCV000038431; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138894 CVCL_9R69 GM02425 finite cell line human CVCL_9R69 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Asp190Val (c.569A>T) (733A>T) (p.Asp190fs*211); ClinVar=VCV000038431; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138895 CVCL_9R68 GM02065 finite cell line human CVCL_9R68 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Ser685Lysfs*61 (c.2053_2057delACTCA) (2215_2219delACTCA); ClinVar=VCV000038417; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; c.3335+6T>G (IVS17+6T>G); ClinVar=VCV000002773; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138896 CVCL_9R63 GM01718 finite cell line human CVCL_9R63 CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Phe260Tyr (c.779T>A); ClinVar=VCV000002446; Zygosity=Heterozygous (PubMed=9054950); Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Leu363Pro (c.1088T>C); ClinVar=VCV000002447; Zygosity=Heterozygous (PubMed=9054950) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138897 CVCL_9R62 GM01565 transformed cell line human CVCL_9R62 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr67Ile (c.200C>T); ClinVar=VCV000002939; Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg252Gln (c.755G>A); ClinVar=VCV000102824; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; c.1315+1G>A (IVS12+1G>A); ClinVar=VCV000000576; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138898 CVCL_9R65 GM01720 finite cell line human CVCL_9R65 CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Phe260Tyr (c.779T>A); ClinVar=VCV000002446; Zygosity=Heterozygous (PubMed=9054950) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138899 CVCL_9R64 GM01719 finite cell line human CVCL_9R64 CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Leu363Pro (c.1088T>C); ClinVar=VCV000002447; Zygosity=Heterozygous (PubMed=9054950) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138900 CVCL_9R59 F4/B8 cancer cell line house mouse CVCL_9R59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21138901 CVCL_9R34 GM13497 transformed cell line human CVCL_9R34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138902 CVCL_9R33 GM13496 transformed cell line human CVCL_9R33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138903 CVCL_9R36 GM16512 finite cell line human CVCL_9R36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138904 CVCL_9R35 GM16510 finite cell line human CVCL_9R35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21138905 CVCL_9R30 GM11335 finite cell line human CVCL_9R30 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Arg98Trp (c.292C>T); ClinVar=VCV000002152; Zygosity=Homozygous (PubMed=12851857) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138906 CVCL_9R32 GM13298 finite cell line human CVCL_9R32 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138907 CVCL_9R31 GM13268 finite cell line human CVCL_9R31 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138908 CVCL_1991 COLO 685 cancer cell line human CVCL_1991 CL:0000010 Derived from sampling site: Endometrium. Omics: SNP array analysis Female 21138909 CVCL_0X91 GM19220 transformed cell line human CVCL_0X91 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138910 CVCL_1990 COLO 320DMF cancer cell line human CVCL_1990 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21138911 CVCL_0X90 GM19218 transformed cell line human CVCL_0X90 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138912 CVCL_1993 COLO 699N cancer cell line human CVCL_1993 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21138913 CVCL_9R27 GM07530 finite cell line human CVCL_9R27 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138914 CVCL_0X93 GM19228 transformed cell line human CVCL_0X93 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138915 CVCL_1992 COLO 699 cancer cell line human CVCL_1992 HLA typing: A*02:01,02:01; B*07:02,37:04; C*06:02,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-196; true Female Doubling time: ~38 hours (DSMZ=ACC-196) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138916 CVCL_9R26 GM04934 finite cell line human CVCL_9R26 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138917 CVCL_0X92 GM19221 transformed cell line human CVCL_0X92 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138918 CVCL_1995 COLO 720E cancer cell line human CVCL_1995 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala138Val (c.413C>T); ClinVar=VCV000184863; Zygosity=Heterozygous (PubMed=24023729); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1118delA; Zygosity=Heterozygous (PubMed=24023729) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00438 Problematic cell line: Partially contaminated Some stocks are contaminated by COLO 704 (Cellosaurus=CVCL_AV69). 21138919 CVCL_9R29 GM07675 finite cell line human CVCL_9R29 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Male 21138920 CVCL_0X95 GM19230 transformed cell line human CVCL_0X95 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138921 CVCL_1994 COLO 704 cancer cell line human CVCL_1994 HLA typing: A*02:01,11:01; B*07:02,45:01; C*04:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.08%; East Asian, North=1.33%; East Asian, South=0.27%; South Asian=0%; European, North=68.17%; European, South=30.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Heterozygous (PubMed=24023729) Population: Caucasian; Derived from metastatic site: Ascites (Note=From a colon metastasis). Omics: Deep exome analysis; Omics: Genome sequenced; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-198; true Female Doubling time: 26 hours (PubMed=25984343); ~30-40 hours (DSMZ=ACC-198); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: According to DSMZ from a 46 year old female and from ascite fluids while archive documents of Moore G.E indicate a 50 year old female and from a pleural effusion. 21138922 CVCL_9R28 GM07531 finite cell line human CVCL_9R28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138923 CVCL_0X94 GM19229 transformed cell line human CVCL_0X94 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138924 CVCL_1997 COLO 783 cancer cell line human CVCL_1997 HLA typing: A*24:02,24:02; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.51%; East Asian, North=1.36%; East Asian, South=0%; South Asian=0%; European, North=67.32%; European, South=30.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1785; CDKN1B; Simple; p.Glu14fs*109 (c.39_43delGGAGC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro48Leu (c.143C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro27Leu (c.80C>T); ClinVar=VCV000481176; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from metastatic site: Right axillary lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=25984343); ~5-7 days (DSMZ=ACC-257); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21138925 CVCL_0X97 GM19242 transformed cell line human CVCL_0X97 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138926 CVCL_1996 COLO 775 cancer cell line human CVCL_1996 Genome ancestry: African=73.36%; Native American=0%; East Asian, North=2.48%; East Asian, South=0%; South Asian=0%; European, North=7.83%; European, South=16.33% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Characteristics: Produces IgG lambda (from parent cell line) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00537 Problematic cell line: Contaminated Shown to be a RPMI-8226 derivative (ECACC). Originally thought to originate from the peripheral blood of a 57 year old female patient with chronic myelogenous leukemia. 21138927 CVCL_0X96 GM19237 transformed cell line human CVCL_0X96 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138928 CVCL_1999 COLO 829BL transformed cell line human CVCL_1999 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21138929 CVCL_0X99 GM19246 transformed cell line human CVCL_0X99 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138930 CVCL_1998 COLO 818 cancer cell line human CVCL_1998 HLA typing: A*02:01,29:02; B*44:02,44:03:01; C*05:01,16:01; DPB1*04:01,17:01; DQB1*03:01:01,02:01; DRB1*12:01,07:01 (PubMed=15592718); HLA typing: A*02:01,29:02; B*44:03,44:03; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.07%; South Asian=3.33%; European, North=39.88%; European, South=55.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (DepMap) Derived from metastatic site: Hypodermis. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 93052622; true Male Doubling time: ~60 hours (DSMZ=ACC-81) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00114 Problematic cell line: Contaminated Shown to be a COLO 800 derivative (PubMed=10508494; PubMed=20143388). 21138931 CVCL_0X98 GM19244 transformed cell line human CVCL_0X98 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138932 CVCL_9R45 GM18365 finite cell line human CVCL_9R45 CL:0000010 Sequence variation: Mutation; HGNC; 119; ACOX1; Unexplicit; Ex7del; Zygosity=Unspecified (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21138933 CVCL_9R44 GM18364 finite cell line human CVCL_9R44 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21138934 CVCL_9R47 GM06246 transformed cell line human CVCL_9R47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138935 CVCL_9R46 ZS-1 spontaneously immortalized cell line CVCL_9R46 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0.TVB*S1. Unspecified Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-121623 21138936 CVCL_9R41 GM18347 finite cell line human CVCL_9R41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138937 CVCL_9R40 GM18346 finite cell line human CVCL_9R40 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21138938 CVCL_9R43 GM18363 finite cell line human CVCL_9R43 CL:0000010 Population: Palestinian; Derived from sampling site: Cell type=Fibroblast. Male 21138939 CVCL_9R42 GM18362 transformed cell line human CVCL_9R42 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138940 CVCL_9R38 GM16523 finite cell line human CVCL_9R38 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21138941 CVCL_9R37 GM16521 finite cell line human CVCL_9R37 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21138942 CVCL_9R39 GM16524 finite cell line human CVCL_9R39 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21138943 CVCL_9R12 GM07505 finite cell line human CVCL_9R12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138944 CVCL_9R11 GM07504 finite cell line human CVCL_9R11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138945 CVCL_9R14 GM07507 finite cell line human CVCL_9R14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138946 CVCL_9R13 GM07506 finite cell line human CVCL_9R13 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138947 CVCL_9R10 GM09023 transformed cell line human CVCL_9R10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138948 CVCL_9R09 GM09018 transformed cell line human CVCL_9R09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138949 CVCL_9R08 GM09017 transformed cell line human CVCL_9R08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138950 CVCL_9R05 GM09013 transformed cell line human CVCL_9R05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138951 CVCL_0X71 GM19180 transformed cell line human CVCL_0X71 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21138952 CVCL_1971 IgG-C7 hybridoma house mouse CVCL_1971 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01131; Bovine LDLR (Note=Also reacts with human). 21138953 CVCL_1970 C6-BU-1 cancer cell line Norway rat CVCL_1970 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male Doubling time: ~30 hours (DSMZ=ACC-108) 21138954 CVCL_9R04 GM08939 transformed cell line human CVCL_9R04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138955 CVCL_0X70 GM19179 transformed cell line human CVCL_0X70 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21138956 CVCL_1973 CAT-13.1E10 hybridoma house mouse CVCL_1973 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. Doubling time: ~30-40 hours (DSMZ=ACC-473) 21138957 CVCL_9R07 GM09016 transformed cell line human CVCL_9R07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138958 CVCL_0X73 GM19182 transformed cell line human CVCL_0X73 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21138959 CVCL_1972 CAT-13.0B10 hybridoma house mouse CVCL_1972 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49961; Human ENTPD1/CD39. Doubling time: ~25 hours (DSMZ=ACC-472) 21138960 CVCL_9R06 GM09014 transformed cell line human CVCL_9R06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138961 CVCL_0X72 GM19181 transformed cell line human CVCL_0X72 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21138962 CVCL_1975 CF-10H5 hybridoma house mouse CVCL_1975 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Doubling time: ~30-45 hours (DSMZ=ACC-477) 21138963 CVCL_0X75 GM19186 transformed cell line human CVCL_0X75 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138964 CVCL_1974 CAT-13.9C1 hybridoma house mouse CVCL_1974 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06734; Human FCER2/CD23. Doubling time: ~48 hours (DSMZ=ACC-475) 21138965 CVCL_0X74 GM19183 transformed cell line human CVCL_0X74 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21138966 CVCL_1977 CHO-DXB11 spontaneously immortalized cell line CVCL_1977 CL:0000010 Derived from sampling site: Ovary. Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~20-24 hours (DSMZ=ACC-126) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9096 21138967 CVCL_0X77 GM19191 transformed cell line human CVCL_0X77 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138968 CVCL_1976 CF-1D12 hybridoma house mouse CVCL_1976 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P31358; Human CD52. Doubling time: ~30-35 hours (DSMZ=ACC-476) 21138969 CVCL_0X76 GM19187 transformed cell line human CVCL_0X76 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138970 CVCL_1979 CL-14 cancer cell line human CVCL_1979 HLA typing: A*02:01,11:01; B*07:02,51:01; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=3.68%; Native American=0%; East Asian, North=5.8%; East Asian, South=0%; South Asian=0%; European, North=50.95%; European, South=39.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Highly susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=15316659); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474) Doubling time: ~1 week (DSMZ=ACC-504); Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21138971 CVCL_0X79 GM19195 transformed cell line human CVCL_0X79 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138972 CVCL_1978 CL-11 cancer cell line human CVCL_1978 HLA typing: A*02:01,02:01; B*51:01,51:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0.97%; Native American=0%; East Asian, North=2.17%; East Asian, South=0%; South Asian=0%; European, North=62.27%; European, South=34.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val14Ile (c.40G>A); ClinVar=VCV000012589; Zygosity=Heterozygous (PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous (PubMed=28683746; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (PubMed=28683746; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~3-4 days (DSMZ=ACC-467); Microsatellite instability: Stable (MSS) (PubMed=25926053; PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138973 CVCL_0X78 GM19194 transformed cell line human CVCL_0X78 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male 21138974 CVCL_9R23 GM04903 finite cell line human CVCL_9R23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138975 CVCL_9R22 GM04674 transformed cell line human CVCL_9R22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21138976 CVCL_9R25 GM04933 finite cell line human CVCL_9R25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138977 CVCL_9R24 GM04904 finite cell line human CVCL_9R24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138978 CVCL_9R21 GM04673 transformed cell line human CVCL_9R21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21138979 CVCL_9R20 GM04496 finite cell line human CVCL_9R20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21138980 CVCL_9R19 GM02448 finite cell line human CVCL_9R19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138981 CVCL_1980 CL-34 cancer cell line human CVCL_1980 Genome ancestry: African=0.8%; Native American=0.86%; East Asian, North=2.45%; East Asian, South=0%; South Asian=0.51%; European, North=74%; European, South=21.37% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu418Ter (c.1252G>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg856Cys (c.2566C>T); ClinVar=VCV000469755; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556fs*3 (c.4660_4661insA) (E1554fs); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Pro (c.379T>C); ClinVar=VCV000934410; Zygosity=Unspecified (PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys382Asnfs*40 (c.1146delA); Zygosity=Unspecified (PubMed=28683746; DepMap) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~70 hours (DSMZ=ACC-520); Microsatellite instability: Instable (MSI) (PubMed=25926053; PubMed=28683746; PubMed=31068700); Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21138982 CVCL_0X80 GM19196 transformed cell line human CVCL_0X80 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138983 CVCL_1982 CL-40 cancer cell line human CVCL_1982 HLA typing: A*11:01,11:01; B*27:05,27:05; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.13%; East Asian, North=0%; East Asian, South=0.86%; South Asian=0%; European, North=71.2%; European, South=27.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=28683746; DepMap); Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Gly8Val (c.23G>T) (c.-57+99G>T); dbSNP=rs75603675; Zygosity=Heterozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Val197Met (c.589G>A) (p.Val160Met, c.478G>A); dbSNP=rs12329760; Zygosity=Heterozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=28683746) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=34339474) Doubling time: ~3-4 days (DSMZ=ACC-535); Microsatellite instability: Instable (MSI) (PubMed=25926053); Stable (MSS) (PubMed=28683746; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21138984 CVCL_9R16 GM01211 finite cell line human CVCL_9R16 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asp98His (c.292G>C); ClinVar=VCV000025149; Zygosity=Heterozygous (from familila inference of GM01209 and GM01210) Population: Latino or Hispanic; Dominican; Derived from sampling site: Cell type=Fibroblast. Male 21138985 CVCL_0X82 GM19202 transformed cell line human CVCL_0X82 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138986 CVCL_1981 CL-38 cancer cell line Norway rat CVCL_1981 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~30-40 hours (DSMZ=ACC-621) 21138987 CVCL_9R15 GM07508 finite cell line human CVCL_9R15 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21138988 CVCL_0X81 GM19199 transformed cell line human CVCL_0X81 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138989 CVCL_1984 CL-49IV cancer cell line Norway rat CVCL_1984 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~60-100 hours (DSMZ=ACC-628) 21138990 CVCL_9R18 GM00337 finite cell line human CVCL_9R18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138991 CVCL_0X84 GM19205 transformed cell line human CVCL_0X84 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138992 CVCL_1983 CL-44 cancer cell line Norway rat CVCL_1983 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~30-40 hours (DSMZ=ACC-622) 21138993 CVCL_9R17 GM00269 finite cell line human CVCL_9R17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21138994 CVCL_0X83 GM19203 transformed cell line human CVCL_0X83 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138995 CVCL_1986 CMT93 cancer cell line house mouse CVCL_1986 CL:0000010 Transformant: Methylazoxymethanol acetate (MAM acetate)(ChEBI; CHEBI:82341); Derived from sampling site: Rectum; Breed/subspecies: C57BL/ICRF. Omics: Array-based CGH Male 21138996 CVCL_0X86 GM19211 transformed cell line human CVCL_0X86 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138997 CVCL_1985 CL-50IIa cancer cell line Norway rat CVCL_1985 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~50-60 hours (DSMZ=ACC-623) 21138998 CVCL_0X85 GM19208 transformed cell line human CVCL_0X85 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21138999 CVCL_1988 COLO 206F cancer cell line human CVCL_1988 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293) CL:0000010 Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~2-3 days (DSMZ=ACC-21) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: MD Anderson Cell Lines Project 21139000 CVCL_0X88 GM19216 transformed cell line human CVCL_0X88 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139001 CVCL_1987 COLO 201 cancer cell line human CVCL_1987 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02 (PubMed=9023415); HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:06,07:06 (PubMed=26589293); Genome ancestry: African=13.18%; Native American=0%; East Asian, North=12.19%; East Asian, South=0%; South Asian=0%; European, North=27.33%; European, South=47.3% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20570890; PubMed=24755471; ATCC; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (PubMed=9294210) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21139002 CVCL_0X87 GM19215 transformed cell line human CVCL_0X87 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139003 CVCL_1989 COLO 320 cancer cell line human CVCL_1989 HLA typing: A*24:02; B*14:02; C*08:02 (PubMed=9023415); HLA typing: A*24:02,24:02; B*14:02,14:02; C*07:01,08:02 (PubMed=26589293); Genome ancestry: African=0.51%; Native American=2.1%; East Asian, North=3.77%; East Asian, South=0.13%; South Asian=9.18%; European, North=3.59%; European, South=80.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=9000147; PubMed=24042735; PubMed=28683746) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~38 hours (DSMZ=ACC-144); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=25926053; PubMed=28683746) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21139004 CVCL_0X89 GM19217 transformed cell line human CVCL_0X89 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139005 CVCL_1951 B35 cancer cell line Norway rat CVCL_1951 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21139006 CVCL_0X51 GM19145 transformed cell line human CVCL_0X51 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139007 CVCL_1950 B16V cancer cell line house mouse CVCL_1950 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: 15 +- 1.64 hours (PubMed=3730255); ~20 hours (DSMZ=ACC-370) 21139008 CVCL_0X50 GM19142 transformed cell line human CVCL_0X50 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139009 CVCL_1953 B95-8 transformed cell line CVCL_1953 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Discontinued: ATCC; CRL-1612; true; Discontinued: CLS; 305152; true; Discontinued: Coriell; GM07404; probable; Discontinued: KCLB; 21612; probable Female Characteristics: Was established by exposure extracts of the 883L cell line (Cellosaurus=CVCL_6A87); Virology: This cell line sheds the Epstein-Barr virus (EBV) strain B95-8 and is often used to transform human or other primates B lymphocytes Doubling time: ~41 hours (DSMZ=ACC-100) Group: Non-human primate cell line 21139010 CVCL_0X53 GM19151 transformed cell line human CVCL_0X53 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139011 CVCL_1952 B9 hybridoma house mouse CVCL_1952 CL:0000010 Discontinued: ATCC; CRL-2344; true; Discontinued: ECACC; 96080128; probable. Characteristics: IL6 dependent Doubling time: ~30-50 hours (DSMZ=ACC-211) 21139012 CVCL_0X52 GM19148 transformed cell line human CVCL_0X52 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139013 CVCL_1955 BA-F8 hybridoma house mouse CVCL_1955 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BE39; Bovine MYH7 (Note=Also recognizes other mammalian species, fish and Xenopus). Doubling time: ~30 hours (DSMZ=ACC-154) 21139014 CVCL_0X55 GM19156 transformed cell line human CVCL_0X55 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139015 CVCL_1954 BA-D5 hybridoma house mouse CVCL_1954 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q9BE39; Bovine MYH7 (Note=Also recognizes other mammalian species and fish). Doubling time: ~25 hours (DSMZ=ACC-75) 21139016 CVCL_0X54 GM19154 transformed cell line human CVCL_0X54 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139017 CVCL_1957 BAG-85D10 hybridoma house mouse CVCL_1957 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16284; Human PECAM1/CD31. Doubling time: ~72 hours (DSMZ=ACC-471) 21139018 CVCL_0X57 GM19155 transformed cell line human CVCL_0X57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21139019 CVCL_1956 BAG-12G2 hybridoma house mouse CVCL_1956 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. Doubling time: ~24 hours (DSMZ=ACC-470) 21139020 CVCL_0X56 GM19157 transformed cell line human CVCL_0X56 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139021 CVCL_1959 Ben-Men-1 telomerase immortalized cell line human CVCL_1959 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Leu214fs*6 (c.640delC); Zygosity=Hemizygous (PubMed=23151902; PubMed=28552950); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; falx cerebri. Omics: Deep exome analysis Female Doubling time: 25.6 hours (PubMed=15965488); ~40-50 hours (DSMZ=ACC-599) 21139022 CVCL_0X59 GM19162 transformed cell line human CVCL_0X59 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139023 CVCL_1958 BC-3C cancer cell line human CVCL_1958 Genome ancestry: African=1.78%; Native American=0.28%; East Asian, North=4.58%; East Asian, South=0%; South Asian=3.73%; European, North=37.13%; European, South=52.49% (PubMed=30894373) CL:0000010 Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~25-30 hours (DSMZ=ACC-450) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21139024 CVCL_0X58 GM19161 transformed cell line human CVCL_0X58 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139025 CVCL_9R01 GM08921 transformed cell line human CVCL_9R01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139026 CVCL_9R00 GM08831 transformed cell line human CVCL_9R00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139027 CVCL_9R03 GM08923 transformed cell line human CVCL_9R03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139028 CVCL_9R02 GM08922 transformed cell line human CVCL_9R02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139029 CVCL_1960 BF-32 hybridoma house mouse CVCL_1960 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q9BE41; Bovine MYH2 (Note=Also reacts with human, mouse, rat and sheep). Doubling time: ~34 hours (DSMZ=ACC-272) 21139030 CVCL_0X60 GM19163 transformed cell line human CVCL_0X60 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139031 CVCL_1962 BF-45 hybridoma house mouse CVCL_1962 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A6QPA6; Bovine MYH3 (Note=Also reacts with mouse and rat). Doubling time: ~45 hours (DSMZ=ACC-221) 21139032 CVCL_0X62 GM19167 transformed cell line human CVCL_0X62 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139033 CVCL_1961 BF-34 hybridoma house mouse CVCL_1961 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine neonatal myosin heavy chain. Doubling time: ~30-40 hours (DSMZ=ACC-156) 21139034 CVCL_0X61 GM19166 transformed cell line human CVCL_0X61 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139035 CVCL_1964 BF-G6 hybridoma house mouse CVCL_1964 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; A6QPA6; Bovine MYH3 (Note=Also reacts with human and mouse). Doubling time: ~30-40 hours (DSMZ=ACC-274) 21139036 CVCL_0X64 GM19170 transformed cell line human CVCL_0X64 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139037 CVCL_1963 BF-F3 hybridoma house mouse CVCL_1963 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; E1BP87; Bovine MYH4 (Note=Also reacts with mouse, pig, rat and sheep). Doubling time: 20-30 hours (DSMZ=ACC-212) 21139038 CVCL_0X63 GM19168 transformed cell line human CVCL_0X63 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139039 CVCL_1966 BL-2 cancer cell line human CVCL_1966 HLA typing: A*24:02,24:02; B*08:01,39:06; C*07:02,07:02; DQA1*01:01,05:01; DQB1*02:01,06:02; DRB1*03:01,14:01 (PubMed=25960936) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672) Population: Caucasian; French; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Virology: EBV-negative Doubling time: ~24 hours (DSMZ=ACC-625) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21139040 CVCL_0X66 GM19174 transformed cell line human CVCL_0X66 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139041 CVCL_1965 BL-100 cancer cell line human CVCL_1965 CL:0000010 Derived from sampling site: Bone marrow. Female Virology: EBV-negative Doubling time: ~50 hours (DSMZ=ACC-684) 21139042 CVCL_0X65 GM19173 transformed cell line human CVCL_0X65 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139043 CVCL_1968 BM-1604 cancer cell line human CVCL_1968 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Brain. Omics: SNP array analysis Discontinued: DSMZ; ACC-298; true Male Doubling time: 28 hours (PubMed=8054265); ~60 hours, highly variable (DSMZ=ACC-298) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00113 Problematic cell line: Contaminated Shown to be a DU145 derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a 67 year old man with a primary prostatic adenocarcinoma. 21139044 CVCL_0X68 GM19177 transformed cell line human CVCL_0X68 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139045 CVCL_1967 BLUE-1 cancer cell line human CVCL_1967 CL:0000010 Sequence variation: Gene fusion; HGNC; 14078; BACH2 + HGNC; 992; BCL2L1; Name(s)=BACH2-BCL2L1 (PubMed=21412927; DepMap); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=16697040); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays Male Virology: EBV-negative Doubling time: ~36-48 hours (PubMed=16697040); ~50 hours (DSMZ=ACC-594) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21139046 CVCL_0X67 GM19176 transformed cell line human CVCL_0X67 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21139047 CVCL_1969 C-433 cancer cell line human CVCL_1969 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; humerus. Discontinued: ATCC; CRL-2085; true; Discontinued: DSMZ; ACC-268; true Male Doubling time: ~25-30 hours (DSMZ=ACC-268) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00395 Problematic cell line: Contaminated Shown to be a RD-ES derivative (DSMZ ACC-268). Originally thought to originate from a 35 year old female patient with a benign giant cell tumor of the right distal tibia. 21139048 CVCL_0X69 GM19178 transformed cell line human CVCL_0X69 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21139049 CVCL_1C73 GM24170 transformed cell line human CVCL_1C73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139050 CVCL_1C72 GM24169 transformed cell line human CVCL_1C72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139051 CVCL_1C75 GM24172 transformed cell line human CVCL_1C75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139052 CVCL_1C74 GM24171 transformed cell line human CVCL_1C74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139053 CVCL_1C77 GM24176 transformed cell line human CVCL_1C77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139054 CVCL_1C76 GM24173 transformed cell line human CVCL_1C76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139055 CVCL_1C79 GM24594 transformed cell line human CVCL_1C79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139056 CVCL_1C78 GM24385 transformed cell line human CVCL_1C78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples; Registration: National Institute of Standards and Technology, Standard Reference Materials; HG002 21139057 CVCL_1C71 GM24168 transformed cell line human CVCL_1C71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139058 CVCL_1C70 GM24167 transformed cell line human CVCL_1C70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139059 CVCL_1C84 GM24602 transformed cell line human CVCL_1C84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139060 CVCL_1C83 GM24601 transformed cell line human CVCL_1C83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139061 CVCL_1C86 GM24604 transformed cell line human CVCL_1C86 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139062 CVCL_1C85 GM24603 transformed cell line human CVCL_1C85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139063 CVCL_1C88 GM24606 transformed cell line human CVCL_1C88 CL:0000010 Population: Asian and Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139064 CVCL_1C87 GM24605 transformed cell line human CVCL_1C87 CL:0000010 Population: Lebanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139065 CVCL_1C89 GM24607 transformed cell line human CVCL_1C89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139066 CVCL_1C80 GM24595 transformed cell line human CVCL_1C80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139067 CVCL_1C82 GM24599 transformed cell line human CVCL_1C82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139068 CVCL_1C81 GM24598 transformed cell line human CVCL_1C81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139069 CVCL_1C51 GM24146 transformed cell line human CVCL_1C51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139070 CVCL_1C50 GM24145 transformed cell line human CVCL_1C50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139071 CVCL_1C53 GM24148 transformed cell line human CVCL_1C53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139072 CVCL_1C52 GM24147 transformed cell line human CVCL_1C52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139073 CVCL_1C55 GM24150 transformed cell line human CVCL_1C55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139074 CVCL_1C54 GM24149 transformed cell line human CVCL_1C54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples; Registration: National Institute of Standards and Technology, Standard Reference Materials; HG003 21139075 CVCL_1C57 GM24152 transformed cell line human CVCL_1C57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Personal Genome Project (PGP) cell line collection 21139076 CVCL_1C56 GM24151 transformed cell line human CVCL_1C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139077 CVCL_1C59 GM24154 transformed cell line human CVCL_1C59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139078 CVCL_1C58 GM24153 transformed cell line human CVCL_1C58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139079 CVCL_1C62 GM24158 transformed cell line human CVCL_1C62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139080 CVCL_1C61 GM24157 transformed cell line human CVCL_1C61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139081 CVCL_1C64 GM24160 transformed cell line human CVCL_1C64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139082 CVCL_1C63 GM24159 transformed cell line human CVCL_1C63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139083 CVCL_1C66 GM24162 transformed cell line human CVCL_1C66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139084 CVCL_1C65 GM24161 transformed cell line human CVCL_1C65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139085 CVCL_1C68 GM24165 transformed cell line human CVCL_1C68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139086 CVCL_1C67 GM24164 transformed cell line human CVCL_1C67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139087 CVCL_1C69 GM24166 transformed cell line human CVCL_1C69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139088 CVCL_TI90 HAP1 RFWD3 (-) 2 cancer cell line human CVCL_TI90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25539; RFWD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139089 CVCL_TI92 HAP1 RFX5 (-) 2 cancer cell line human CVCL_TI92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9986; RFX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139090 CVCL_TI91 HAP1 RFX5 (-) 1 cancer cell line human CVCL_TI91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9986; RFX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139091 CVCL_TI94 HAP1 RFX5 (-) 4 cancer cell line human CVCL_TI94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9986; RFX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139092 CVCL_TI93 HAP1 RFX5 (-) 3 cancer cell line human CVCL_TI93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9986; RFX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139093 CVCL_TI96 HAP1 RHBDD2 (-) 2 cancer cell line human CVCL_TI96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23082; RHBDD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139094 CVCL_TI95 HAP1 RHBDD2 (-) 1 cancer cell line human CVCL_TI95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23082; RHBDD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139095 CVCL_TI98 HAP1 RHOD (-) 2 cancer cell line human CVCL_TI98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 670; RHOD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139096 CVCL_TI97 HAP1 RHOD (-) 1 cancer cell line human CVCL_TI97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 670; RHOD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139097 CVCL_TI99 HAP1 RICTOR (-) 1 cancer cell line human CVCL_TI99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28611; RICTOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139098 CVCL_1C60 GM24155 transformed cell line human CVCL_1C60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139099 CVCL_1C31 GM24122 transformed cell line human CVCL_1C31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139100 CVCL_1C30 GM24121 transformed cell line human CVCL_1C30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Personal Genome Project (PGP) cell line collection 21139101 CVCL_1C33 GM24124 transformed cell line human CVCL_1C33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139102 CVCL_1C32 GM24123 transformed cell line human CVCL_1C32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139103 CVCL_1C35 GM24126 transformed cell line human CVCL_1C35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139104 CVCL_1C34 GM24125 transformed cell line human CVCL_1C34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139105 CVCL_1C37 GM24130 transformed cell line human CVCL_1C37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139106 CVCL_1C36 GM24129 transformed cell line human CVCL_1C36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139107 CVCL_1C39 GM24132 transformed cell line human CVCL_1C39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139108 CVCL_1C38 GM24131 transformed cell line human CVCL_1C38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139109 CVCL_TI81 HAP1 RER1 (-) 2 cancer cell line human CVCL_TI81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30309; RER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139110 CVCL_TI80 HAP1 RER1 (-) 1 cancer cell line human CVCL_TI80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30309; RER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139111 CVCL_TI83 HAP1 REST (-) 1 cancer cell line human CVCL_TI83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139112 CVCL_TI82 HAP1 RERE (-) 1 cancer cell line human CVCL_TI82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9965; RERE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139113 CVCL_TI85 HAP1 REV1 (-) 1 cancer cell line human CVCL_TI85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14060; REV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139114 CVCL_TI84 HAP1 RET (-) cancer cell line human CVCL_TI84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9967; RET; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139115 CVCL_TI87 HAP1 REXO2 (-) cancer cell line human CVCL_TI87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17851; REXO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139116 CVCL_TI86 HAP1 REV1 (-) 2 cancer cell line human CVCL_TI86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14060; REV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139117 CVCL_TI89 HAP1 RFWD3 (-) 1 cancer cell line human CVCL_TI89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25539; RFWD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139118 CVCL_TI88 HAP1 REXO4 (-) 1 cancer cell line human CVCL_TI88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12820; REXO4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139119 CVCL_1C40 GM24133 transformed cell line human CVCL_1C40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139120 CVCL_1C42 GM24135 transformed cell line human CVCL_1C42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139121 CVCL_1C41 GM24134 transformed cell line human CVCL_1C41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139122 CVCL_1C44 GM24137 transformed cell line human CVCL_1C44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139123 CVCL_1C43 GM24136 transformed cell line human CVCL_1C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139124 CVCL_1C46 GM24141 transformed cell line human CVCL_1C46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139125 CVCL_1C45 GM24139 transformed cell line human CVCL_1C45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139126 CVCL_1C48 GM24143 transformed cell line human CVCL_1C48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples; Registration: National Institute of Standards and Technology, Standard Reference Materials; HG004 21139127 CVCL_1C47 GM24142 transformed cell line human CVCL_1C47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139128 CVCL_1C49 GM24144 transformed cell line human CVCL_1C49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139129 CVCL_TI70 HAP1 RECQL (-) 2 cancer cell line human CVCL_TI70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9948; RECQL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139130 CVCL_TI72 HAP1 RECQL4 (-) 2 cancer cell line human CVCL_TI72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9949; RECQL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139131 CVCL_TI71 HAP1 RECQL4 (-) 1 cancer cell line human CVCL_TI71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9949; RECQL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139132 CVCL_TI74 HAP1 REL (-) cancer cell line human CVCL_TI74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9954; REL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139133 CVCL_TI73 HAP1 RECQL4 (-) 3 cancer cell line human CVCL_TI73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9949; RECQL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139134 CVCL_TI76 HAP1 RELA (-) 2 cancer cell line human CVCL_TI76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139135 CVCL_TI75 HAP1 RELA (-) 1 cancer cell line human CVCL_TI75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139136 CVCL_TI78 HAP1 RELB (-) cancer cell line human CVCL_TI78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9956; RELB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139137 CVCL_TI77 HAP1 RELA (-) 3 cancer cell line human CVCL_TI77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9955; RELA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139138 CVCL_TI79 HAP1 RENBP (-) 1 cancer cell line human CVCL_TI79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9959; RENBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139139 CVCL_1C11 GM24101 transformed cell line human CVCL_1C11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139140 CVCL_1C10 GM24099 transformed cell line human CVCL_1C10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139141 CVCL_1C13 GM24103 transformed cell line human CVCL_1C13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139142 CVCL_1C12 GM24102 transformed cell line human CVCL_1C12 CL:0000010 Population: Caucasian; Dutch/Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139143 CVCL_1C15 GM24105 transformed cell line human CVCL_1C15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139144 CVCL_1C14 GM24104 transformed cell line human CVCL_1C14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139145 CVCL_1C17 GM24107 transformed cell line human CVCL_1C17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139146 CVCL_1C16 GM24106 transformed cell line human CVCL_1C16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139147 CVCL_1C19 GM24109 transformed cell line human CVCL_1C19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139148 CVCL_1C18 GM24108 transformed cell line human CVCL_1C18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139149 CVCL_TI61 HAP1 RBBP7 (-) 2 cancer cell line human CVCL_TI61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9890; RBBP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139150 CVCL_TI60 HAP1 RBBP7 (-) 1 cancer cell line human CVCL_TI60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9890; RBBP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139151 CVCL_TI63 HAP1 RBKS (-) 1 cancer cell line human CVCL_TI63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30325; RBKS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139152 CVCL_TI62 HAP1 RBBP7 (-) 3 cancer cell line human CVCL_TI62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9890; RBBP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139153 CVCL_TI65 HAP1 RCBTB2 (-) 1 cancer cell line human CVCL_TI65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1914; RCBTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139154 CVCL_TI64 HAP1 RCAN1 (-) cancer cell line human CVCL_TI64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3040; RCAN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139155 CVCL_TI67 HAP1 RCC2 (-) 2 cancer cell line human CVCL_TI67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30297; RCC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139156 CVCL_TI66 HAP1 RCC2 (-) 1 cancer cell line human CVCL_TI66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30297; RCC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139157 CVCL_TI69 HAP1 RECQL (-) 1 cancer cell line human CVCL_TI69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9948; RECQL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139158 CVCL_TI68 HAP1 RDH13 (-) 1 cancer cell line human CVCL_TI68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19978; RDH13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139159 CVCL_1C20 GM24110 transformed cell line human CVCL_1C20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139160 CVCL_1C22 GM24112 transformed cell line human CVCL_1C22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139161 CVCL_1C21 GM24111 transformed cell line human CVCL_1C21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139162 CVCL_1C24 GM24115 transformed cell line human CVCL_1C24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139163 CVCL_1C23 GM24114 transformed cell line human CVCL_1C23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139164 CVCL_1C26 GM24117 transformed cell line human CVCL_1C26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139165 CVCL_1C25 GM24116 transformed cell line human CVCL_1C25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139166 CVCL_1C28 GM24119 transformed cell line human CVCL_1C28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139167 CVCL_1C27 GM24118 transformed cell line human CVCL_1C27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139168 CVCL_1C29 GM24120 transformed cell line human CVCL_1C29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139169 CVCL_TI50 HAP1 RARG (-) 2 cancer cell line human CVCL_TI50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9866; RARG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139170 CVCL_TI52 HAP1 RASD1 (-) 2 cancer cell line human CVCL_TI52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15828; RASD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139171 CVCL_TI51 HAP1 RASD1 (-) 1 cancer cell line human CVCL_TI51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15828; RASD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139172 CVCL_TI54 HAP1 RASGRP1 (-) 2 cancer cell line human CVCL_TI54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9878; RASGRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139173 CVCL_TI53 HAP1 RASGRP1 (-) 1 cancer cell line human CVCL_TI53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9878; RASGRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139174 CVCL_TI56 HAP1 RB1 (-) 1 cancer cell line human CVCL_TI56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139175 CVCL_TI55 HAP1 RASSF5 (-) cancer cell line human CVCL_TI55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17609; RASSF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139176 CVCL_TI58 HAP1 RB1 (-) 3 cancer cell line human CVCL_TI58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139177 CVCL_TI57 HAP1 RB1 (-) 2 cancer cell line human CVCL_TI57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139178 CVCL_TI59 HAP1 RB1CC1 (-) cancer cell line human CVCL_TI59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15574; RB1CC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139179 CVCL_BV24 GM23259 transformed cell line human CVCL_BV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139180 CVCL_C724 SSMUe004-A embryonic stem cell human CVCL_C724 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Female Doubling time: 32 +- 2 hours (PubMed=15916726). 21139181 CVCL_BV23 GM23258 transformed cell line human CVCL_BV23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139182 CVCL_C723 SSMUe002-A embryonic stem cell human CVCL_C723 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Unspecified Doubling time: 37 hours (grown on EDF), 38 hours (grown on MEF) (PubMed=15955827). 21139183 CVCL_BV26 GM23265 transformed cell line human CVCL_BV26 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[60] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; English/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21139184 CVCL_C726 SSMUe005-A embryonic stem cell human CVCL_C726 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Female Doubling time: 30 +- 3 hours (PubMed=15916726). 21139185 CVCL_BV25 GM23260 transformed cell line human CVCL_BV25 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139186 CVCL_C725 SSMUe003-A embryonic stem cell human CVCL_C725 From: Shanghai Second Medical University; Shanghai; China. CL:0000010 Male 21139187 CVCL_BV28 GM23268 finite cell line human CVCL_BV28 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139188 CVCL_C728 SSMUe006-A-1 embryonic stem cell human CVCL_C728 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Female Doubling time: 33 hours (PubMed=15916726). 21139189 CVCL_BV27 GM23267 transformed cell line human CVCL_BV27 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139190 CVCL_C727 SSMUe006-A embryonic stem cell human CVCL_C727 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Female Doubling time: 36 +- 1 hours (PubMed=15916726). 21139191 CVCL_BV29 GM23275 transformed cell line human CVCL_BV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139192 CVCL_C729 SSMUe008-A embryonic stem cell human CVCL_C729 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Female Doubling time: 32 +- 3 hours (PubMed=15916726). 21139193 CVCL_C720 D551-RiPS-1.2 induced pluripotent stem cell human CVCL_C720 From: Harvard Medical School; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139194 CVCL_BV20 GM23252 transformed cell line human CVCL_BV20 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139195 CVCL_BV22 GM23256 transformed cell line human CVCL_BV22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139196 CVCL_C722 SSMUe001-A embryonic stem cell human CVCL_C722 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Unspecified Doubling time: 35 hours (grown on EDF), 33 hours (grown on MEF) (PubMed=15955827). 21139197 CVCL_C721 D551-RiPS-1.3 induced pluripotent stem cell human CVCL_C721 From: Harvard Medical School; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139198 CVCL_BV21 GM23253 finite cell line human CVCL_BV21 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139199 CVCL_BV35 GM23287 transformed cell line human CVCL_BV35 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139200 CVCL_C735 SHhES4 embryonic stem cell human CVCL_C735 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Unspecified 21139201 CVCL_BV34 GM23286 transformed cell line human CVCL_BV34 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139202 CVCL_C734 SHhES3 embryonic stem cell human CVCL_C734 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Unspecified 21139203 CVCL_BV37 GM23290 finite cell line human CVCL_BV37 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139204 CVCL_C737 SBDS-iPS2 induced pluripotent stem cell human CVCL_C737 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21139205 CVCL_BV36 GM23289 transformed cell line human CVCL_BV36 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139206 CVCL_C736 SBDS-iPS1 induced pluripotent stem cell human CVCL_C736 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21139207 CVCL_BV39 GM23297 transformed cell line human CVCL_BV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139208 CVCL_C739 SBDS-iPS8 induced pluripotent stem cell human CVCL_C739 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21139209 CVCL_BV38 GM23296 transformed cell line human CVCL_BV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139210 CVCL_C738 SBDS-iPS3 induced pluripotent stem cell human CVCL_C738 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21139211 CVCL_BV31 GM23283 transformed cell line human CVCL_BV31 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139212 CVCL_C731 SSMUe010-A embryonic stem cell human CVCL_C731 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Male Doubling time: 34 +- 2 hours (PubMed=15916726). 21139213 CVCL_BV30 GM23278 transformed cell line human CVCL_BV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139214 CVCL_C730 SSMUe009-A embryonic stem cell human CVCL_C730 From: Shanghai Second Medical University; Shanghai; China CL:0000010 Male Doubling time: 39 +- 3 hours (PubMed=15916726). 21139215 CVCL_BV33 GM23285 transformed cell line human CVCL_BV33 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139216 CVCL_C733 SHhES2 embryonic stem cell human CVCL_C733 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Male 21139217 CVCL_BV32 GM23284 finite cell line human CVCL_BV32 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139218 CVCL_C732 SHhES1 embryonic stem cell human CVCL_C732 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Female 21139219 CVCL_C702 dH1f-RiPS-1.5 induced pluripotent stem cell human CVCL_C702 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21139220 CVCL_BV02 GM22779 finite cell line human CVCL_BV02 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly939Asp (c.2816G>A); Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139221 CVCL_C701 dH1f-RiPS-1.3 induced pluripotent stem cell human CVCL_C701 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21139222 CVCL_BV01 GM22778 transformed cell line human CVCL_BV01 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly939Asp (c.2816G>A); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139223 CVCL_C704 dH1f-RiPS-1.7 induced pluripotent stem cell human CVCL_C704 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21139224 CVCL_BV04 GM22781 finite cell line human CVCL_BV04 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21139225 CVCL_C703 dH1f-RiPS-1.6 induced pluripotent stem cell human CVCL_C703 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21139226 CVCL_BV03 GM22780 transformed cell line human CVCL_BV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139227 CVCL_BV06 GM22784 transformed cell line human CVCL_BV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139228 CVCL_C706 W10-1A embryonic stem cell human CVCL_C706 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21139229 CVCL_BV05 GM22783 transformed cell line human CVCL_BV05 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg133Cys (c.397C>T) (p.Arg145Cys, c.433C>T); ClinVar=VCV000011809; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139230 CVCL_C705 W8-8A embryonic stem cell human CVCL_C705 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21139231 CVCL_BV08 GM22828 transformed cell line human CVCL_BV08 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; c.3892delT; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139232 CVCL_C708 W14-1A embryonic stem cell human CVCL_C708 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21139233 CVCL_BV07 GM22785 transformed cell line human CVCL_BV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139234 CVCL_C707 W13-1C embryonic stem cell human CVCL_C707 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21139235 CVCL_C700 dH1f-RiPS-1.2 induced pluripotent stem cell human CVCL_C700 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21139236 CVCL_BV00 GM22773 finite cell line human CVCL_BV00 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly762Asp (c.2285G>A); ClinVar=VCV000101377; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139237 CVCL_BV13 GM23057 transformed cell line human CVCL_BV13 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly222Val (c.665G>T) (G55V); ClinVar=VCV000101218; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139238 CVCL_C713 iPS-TIG120-4f1 induced pluripotent stem cell human CVCL_C713 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0616; true Female 21139239 CVCL_BV12 GM22920 transformed cell line human CVCL_BV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139240 CVCL_C712 iPS-TIG120-3f7 induced pluripotent stem cell human CVCL_C712 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0615; true Female 21139241 CVCL_BV15 GM23090 transformed cell line human CVCL_BV15 HLA typing: A*11:01:01,11:01:01; B*15:02:01,51:01:01; C*08:01:01,14:02:01; DPA1*01:03:01,02:02:02; DPB1*02:01:02,05:01:01; DQA1*03:02,03:03:01; DQB1*03:03:02,04:01:01; DRB1*04:05:01,09:01:02; DRB4*01:03:01,01:03:02 (PubMed=29959025) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21139242 CVCL_C715 ZHBTc4 embryonic stem cell house mouse CVCL_C715 CL:0000010 Breed/subspecies: 129P2/Ola. Discontinued: RCB; AES0136; probable Male Part of: ENCODE project mouse cell lines 21139243 CVCL_BV14 GM23058 transformed cell line human CVCL_BV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139244 CVCL_C714 ZHTc6 embryonic stem cell house mouse CVCL_C714 CL:0000010 Breed/subspecies: 129P2/Ola. Discontinued: RCB; AES0137; probable Male 21139245 CVCL_C717 CM-6 embryonic stem cell human CVCL_C717 From: Children's Memorial Hospital; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21139246 CVCL_BV17 GM23221 transformed cell line human CVCL_BV17 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Arg268Cys (c.802C>T) (R243C); ClinVar=VCV000289402; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Cys616_Val633del (c.1899+4_1899+7delAGTA) (1824IVS+3del4) (IVS21+3del4); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139247 CVCL_C716 CM-2 [Human ESC] embryonic stem cell human CVCL_C716 From: Children's Memorial Hospital; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21139248 CVCL_BV16 GM23093 transformed cell line human CVCL_BV16 HLA typing: A*11:01:01,11:01:01; B*15:02:01,15:02:01; C*08:01:01,08:01:01; DPA1*01:03:01,02:02:02; DPB1*05:01:01,21:01; DQA1*06:01:01,06:01:01; DQB1*03:01:01,03:01:01; DRB1*12:02:01,12:02:01; DRB3*03:01:03,03:01:03 (PubMed=29959025) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139249 CVCL_C719 D551-RiPS-1.1 induced pluripotent stem cell human CVCL_C719 From: Harvard Medical School; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139250 CVCL_BV19 GM23246 transformed cell line human CVCL_BV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139251 CVCL_C718 CM-7 embryonic stem cell human CVCL_C718 From: Children's Memorial Hospital; Chicago; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21139252 CVCL_BV11 GM22919 transformed cell line human CVCL_BV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139253 CVCL_C711 iPS-TIG114-4f1 induced pluripotent stem cell human CVCL_C711 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21139254 CVCL_BV10 GM22918 transformed cell line human CVCL_BV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139255 CVCL_C710 iPS-TIG103-4f4 induced pluripotent stem cell human CVCL_C710 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21139256 CVCL_BV09 GM22829 finite cell line human CVCL_BV09 CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple; c.3892delT; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21139257 CVCL_C709 iPS-TIG107-4f1 induced pluripotent stem cell human CVCL_C709 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0613; true Female 21139258 CVCL_1C95 GM24615 transformed cell line human CVCL_1C95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139259 CVCL_1C94 GM24614 transformed cell line human CVCL_1C94 CL:0000010 Population: Caucasian; Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139260 CVCL_1C97 GM24631 transformed cell line human CVCL_1C97 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples; Registration: National Institute of Standards and Technology, Standard Reference Materials; HG005 21139261 CVCL_1C96 GM24617 transformed cell line human CVCL_1C96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139262 CVCL_1C99 GM24695 transformed cell line human CVCL_1C99 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples 21139263 CVCL_1C98 GM24694 transformed cell line human CVCL_1C98 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection; Part of: Genome in a Bottle (GIAB) consortium samples 21139264 CVCL_1C91 GM24611 transformed cell line human CVCL_1C91 CL:0000010 Population: Caucasian and Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139265 CVCL_1C90 GM24608 transformed cell line human CVCL_1C90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139266 CVCL_1C93 GM24613 transformed cell line human CVCL_1C93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139267 CVCL_1C92 GM24612 transformed cell line human CVCL_1C92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139268 CVCL_BU83 GM22609 finite cell line human CVCL_BU83 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Ile256Tyrfs*7 (c.766delA); ClinVar=VCV000101146; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139269 CVCL_C683 INT-MEL-13 cancer cell line human CVCL_C683 CL:0000010 Derived from metastatic site: Lymph node. Male 21139270 CVCL_BU82 GM22608 transformed cell line human CVCL_BU82 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Ile256Tyrfs*7 (c.766delA); ClinVar=VCV000101146; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139271 CVCL_C682 INT-MEL-1 cancer cell line human CVCL_C682 CL:0000010 Female 21139272 CVCL_BU85 GM22704 transformed cell line human CVCL_BU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139273 CVCL_C685 INT-MEL-59/1 cancer cell line human CVCL_C685 CL:0000010 Derived from metastatic site: Lymph node. Female 21139274 CVCL_BU84 GM22703 transformed cell line human CVCL_BU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139275 CVCL_C684 Me9460 cancer cell line human CVCL_C684 CL:0000010 21139276 CVCL_BU87 GM22713 transformed cell line human CVCL_BU87 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg168Ter (c.502C>T) (p.Arg180Ter, c.538C>T); ClinVar=VCV000011828; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139277 CVCL_C687 LCL5810 transformed cell line human CVCL_C687 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139278 CVCL_BU86 GM22705 transformed cell line human CVCL_BU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139279 CVCL_C686 LCL9742 transformed cell line human CVCL_C686 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139280 CVCL_BU89 GM22715 transformed cell line human CVCL_BU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139281 CVCL_C689 LCL1811 transformed cell line human CVCL_C689 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21139282 CVCL_BU88 GM22714 transformed cell line human CVCL_BU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139283 CVCL_C688 LCL4405 transformed cell line human CVCL_C688 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139284 CVCL_L017 CHSE-sp spontaneously immortalized cell line CVCL_L017 CL:0000010 Unspecified Group: Fish cell line. 21139285 CVCL_L016 RTS34st spontaneously immortalized cell line CVCL_L016 CL:0000010 Miscellaneous: Equivalence of RTS34st with RTSp-W1 from personal communication of Lee L.E.J Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21139286 CVCL_L019 GFB3C-W1 spontaneously immortalized cell line CVCL_L019 CL:0000010 Derived from sampling site: Brain; cerebellum. Unspecified Group: Fish cell line 21139287 CVCL_L018 FHMT-W1 spontaneously immortalized cell line CVCL_L018 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21139288 CVCL_L013 RTP-91E spontaneously immortalized cell line CVCL_L013 CL:0000010 Derived from sampling site: Pituitary gland. Male Group: Fish cell line 21139289 CVCL_L012 RTP-2 spontaneously immortalized cell line CVCL_L012 CL:0000010 Derived from sampling site: Pituitary gland. Female Group: Fish cell line 21139290 CVCL_BU81 GM22607 finite cell line human CVCL_BU81 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Ile256Tyrfs*7 (c.766delA); ClinVar=VCV000101146; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139291 CVCL_C681 Me4855 cancer cell line human CVCL_C681 CL:0000010 21139292 CVCL_L015 RTS34 spontaneously immortalized cell line CVCL_L015 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21139293 CVCL_BU80 GM22606 transformed cell line human CVCL_BU80 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Ile256Tyrfs*7 (c.766delA); ClinVar=VCV000101146; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139294 CVCL_C680 INT-MEL-17 cancer cell line human CVCL_C680 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533). Female 21139295 CVCL_L014 RTP-91F spontaneously immortalized cell line CVCL_L014 CL:0000010 Derived from sampling site: Pituitary gland. Male Group: Fish cell line 21139296 CVCL_L011 RTL-W1 spontaneously immortalized cell line CVCL_L011 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.. Male Doubling time: 98.9 hours (PubMed=29268113) Group: Fish cell line 21139297 CVCL_L010 SSF-2 spontaneously immortalized cell line CVCL_L010 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21139298 CVCL_BU94 GM22752 transformed cell line human CVCL_BU94 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly177_Pro194del (c.582+5G>A) (IVS8+5G>A); ClinVar=VCV000101425; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139299 CVCL_C694 Mel 928 cancer cell line human CVCL_C694 HLA typing: A*11:01,24:02; B*53:01,57:01; C*04:01,06:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. 21139300 CVCL_BU93 GM22751 finite cell line human CVCL_BU93 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly177_Pro194del (c.582+5G>A) (IVS8+5G>A); ClinVar=VCV000101425; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21139301 CVCL_C693 Melb-a spontaneously immortalized cell line house mouse CVCL_C693 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Melanoblast.; Breed/subspecies: C57BL/6J. Unspecified 21139302 CVCL_BU96 GM22762 transformed cell line human CVCL_BU96 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139303 CVCL_C696 Lex-1 embryonic stem cell house mouse CVCL_C696 CL:0000010 Breed/subspecies: 129S5/SvEvBrd. Unspecified 21139304 CVCL_C695 1C9 embryonic stem cell house mouse CVCL_C695 CL:0000010 Breed/subspecies: 129S5/SvEvBrd. Unspecified 21139305 CVCL_BU95 GM22753 finite cell line human CVCL_BU95 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly177_Pro194del (c.582+5G>A) (IVS8+5G>A); ClinVar=VCV000101425; Zygosity=Unspecified (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139306 CVCL_C698 dH1f-RiPS-1.13 induced pluripotent stem cell human CVCL_C698 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21139307 CVCL_BU98 GM22764 finite cell line human CVCL_BU98 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139308 CVCL_C697 dH1f-RiPS-1.11 induced pluripotent stem cell human CVCL_C697 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21139309 CVCL_BU97 GM22763 transformed cell line human CVCL_BU97 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg159Cys (c.475C>T) (c.864C>T); ClinVar=VCV000280123; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139310 CVCL_C699 dH1f-RiPS-1.14 induced pluripotent stem cell human CVCL_C699 From: Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21139311 CVCL_BU99 GM22772 transformed cell line human CVCL_BU99 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly762Asp (c.2285G>A); ClinVar=VCV000101377; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139312 CVCL_L028 WM3208V cancer cell line human CVCL_L028 CL:0000010 Female Part of: Wistar Institute melanoma cell line collection. 21139313 CVCL_L027 WM1575 cancer cell line human CVCL_L027 CL:0000010 Male Part of: Wistar Institute melanoma cell line collection. 21139314 CVCL_L029 WM218 cancer cell line human CVCL_L029 CL:0000010 Female Part of: Wistar Institute melanoma cell line collection. 21139315 CVCL_L024 GM15844 transformed cell line human CVCL_L024 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139316 CVCL_BU90 GM22744 finite cell line human CVCL_BU90 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21139317 CVCL_C690 LCL10538 transformed cell line human CVCL_C690 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139318 CVCL_L023 AG04440 finite cell line human CVCL_L023 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh- (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG04440) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21139319 CVCL_L026 293B9 cancer cell line CVCL_L026 CL:0000010 Group: Bird cell line. 21139320 CVCL_BU92 GM22750 transformed cell line human CVCL_BU92 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly177_Pro194del (c.582+5G>A) (IVS8+5G>A); ClinVar=VCV000101425; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139321 CVCL_C692 Melan-a2 spontaneously immortalized cell line house mouse CVCL_C692 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Melanocyte.; Breed/subspecies: C57BL/6J. Unspecified 21139322 CVCL_L025 249L4 cancer cell line CVCL_L025 CL:0000010 Group: Bird cell line. 21139323 CVCL_C691 FR3T3 spontaneously immortalized cell line Norway rat CVCL_C691 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer. Unspecified 21139324 CVCL_BU91 GM22746 transformed cell line human CVCL_BU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139325 CVCL_L020 GFS spontaneously immortalized cell line CVCL_L020 CL:0000010 Derived from sampling site: Scale. Unspecified Group: Fish cell line 21139326 CVCL_L022 FHML2-6 spontaneously immortalized cell line CVCL_L022 CL:0000010 Derived from sampling site: Liver. Unspecified Doubling time: 2-3 days (DOI=10.1007/s11626-009-9201-x) Group: Fish cell line 21139327 CVCL_L021 GFSk-S1 spontaneously immortalized cell line CVCL_L021 CL:0000010 Derived from sampling site: Skin. Unspecified Characteristics: Produces collagen in response to ascorbic acid treatment (PubMed=9088943); Characteristics: Optimal growth temperature is 22 Celsius (PubMed=9088943) Group: Fish cell line 21139328 CVCL_BU69 GM22563 finite cell line human CVCL_BU69 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139329 CVCL_C669 Me1340 cancer cell line human CVCL_C669 CL:0000010 21139330 CVCL_BU68 GM22562 transformed cell line human CVCL_BU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139331 CVCL_C668 INT-MEL-20 cancer cell line human CVCL_C668 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=22383533); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=22383533). Male 21139332 CVCL_BU61 GM22550 finite cell line human CVCL_BU61 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139333 CVCL_C661 UKRV-Mel-22a cancer cell line human CVCL_C661 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21139334 CVCL_BU60 GM22549 transformed cell line human CVCL_BU60 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21139335 CVCL_C660 UKRV-Mel-12b cancer cell line human CVCL_C660 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Unspecified 21139336 CVCL_BU63 GM22553 transformed cell line human CVCL_BU63 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139337 CVCL_C663 MIH5(GIT) hybridoma CVCL_C663 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9EP73; Mouse Cd274. 21139338 CVCL_BU62 GM22551 transformed cell line human CVCL_BU62 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139339 CVCL_C662 UKRV-Mel-22b cancer cell line human CVCL_C662 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21139340 CVCL_BU65 GM22555 transformed cell line human CVCL_BU65 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; c.1209+2delT; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Asn536Asp (c.1606A>G); ClinVar=VCV000038881; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139341 CVCL_C665 Me43 cancer cell line human CVCL_C665 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 21139342 CVCL_BU64 GM22554 finite cell line human CVCL_BU64 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21139343 CVCL_C664 MIH5(RPMI) hybridoma CVCL_C664 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9EP73; Mouse Cd274. 21139344 CVCL_BU67 GM22557 transformed cell line human CVCL_BU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139345 CVCL_C667 Me665/1 cancer cell line human CVCL_C667 CL:0000010 Derived from metastatic site: Hypodermis. Female 21139346 CVCL_BU66 GM22556 transformed cell line human CVCL_BU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139347 CVCL_C666 ME [Human melanoma] cancer cell line human CVCL_C666 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Oral cavity; hard palate. Female Doubling time: 27.6 hours (PubMed=11287286) 21139348 CVCL_BU79 GM22600 finite cell line human CVCL_BU79 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139349 CVCL_C679 INT-MEL-52 cancer cell line human CVCL_C679 CL:0000010 Derived from metastatic site: Hypodermis. Female 21139350 CVCL_BU72 GM22574 transformed cell line human CVCL_BU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139351 CVCL_C672 INT-MEL-15/2 cancer cell line human CVCL_C672 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533). Male 21139352 CVCL_BU71 GM22565 finite cell line human CVCL_BU71 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139353 CVCL_C671 Me13924 cancer cell line human CVCL_C671 CL:0000010 21139354 CVCL_BU74 GM22580 transformed cell line human CVCL_BU74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139355 CVCL_C674 INT-MEL-39 cancer cell line human CVCL_C674 CL:0000010 Derived from metastatic site: Lymph node. Male 21139356 CVCL_BU73 GM22578 transformed cell line human CVCL_BU73 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139357 CVCL_C673 INT-MEL-19 cancer cell line human CVCL_C673 CL:0000010 Derived from metastatic site: Lymph node. Male 21139358 CVCL_BU76 GM22582 transformed cell line human CVCL_BU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139359 CVCL_C676 Me18732 cancer cell line human CVCL_C676 CL:0000010 Derived from metastatic site: Lymph node. 21139360 CVCL_BU75 GM22581 transformed cell line human CVCL_BU75 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.His140fs (c.418delC); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Leu532del (c.1593_1595delATT); ClinVar=VCV000554477; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139361 CVCL_C675 Me1811 cancer cell line human CVCL_C675 CL:0000010 Derived from metastatic site: Lymph node. 21139362 CVCL_L009 SSF-1 spontaneously immortalized cell line CVCL_L009 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 76 21139363 CVCL_BU78 GM22599 transformed cell line human CVCL_BU78 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139364 CVCL_C678 Me3068 cancer cell line human CVCL_C678 CL:0000010 Derived from metastatic site: Lymph node. 21139365 CVCL_BU77 GM22592 transformed cell line human CVCL_BU77 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139366 CVCL_C677 Me3046/2 cancer cell line human CVCL_C677 CL:0000010 Derived from metastatic site: Hypodermis. Male 21139367 CVCL_L006 UKTS9225 transformed cell line human CVCL_L006 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139368 CVCL_L005 UKTS9213 transformed cell line human CVCL_L005 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139369 CVCL_L008 UKTS9260 transformed cell line human CVCL_L008 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139370 CVCL_L007 UKTS9242 transformed cell line human CVCL_L007 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139371 CVCL_L002 UKTS9175 transformed cell line human CVCL_L002 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139372 CVCL_L001 UKTS9161 transformed cell line human CVCL_L001 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91032134; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139373 CVCL_BU70 GM22564 transformed cell line human CVCL_BU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139374 CVCL_C670 INT-MEL-23 cancer cell line human CVCL_C670 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21139375 CVCL_L004 UKTS9204 transformed cell line human CVCL_L004 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91070906; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139376 CVCL_L003 UKTS9201 transformed cell line human CVCL_L003 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139377 CVCL_L000 UKTS9160 transformed cell line human CVCL_L000 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 91032133; probable Unspecified Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139378 CVCL_BU47 GM22367 transformed cell line human CVCL_BU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139379 CVCL_C647 hESMK05 embryonic stem cell human CVCL_C647 From: Vavilov Institute of General Genetics; Moscow; Russia. CL:0000010 Female 21139380 CVCL_BU46 GM22366 transformed cell line human CVCL_BU46 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Glu248Lys (c.742G>A) (E233K); ClinVar=VCV000418400; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly477Val (c.1430G>T) (G452V); ClinVar=VCV000550273; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139381 CVCL_C646 hESM04 embryonic stem cell human CVCL_C646 From: Vavilov Institute of General Genetics; Moscow; Russia. CL:0000010 Female 21139382 CVCL_BU49 GM22369 finite cell line human CVCL_BU49 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21139383 CVCL_C649 HIPS #11 induced pluripotent stem cell human CVCL_C649 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139384 CVCL_BU48 GM22368 transformed cell line human CVCL_BU48 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139385 CVCL_C648 HIPS #1 induced pluripotent stem cell human CVCL_C648 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139386 CVCL_C641 D2-iPSC-1 induced pluripotent stem cell human CVCL_C641 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 2888; DISC1; Simple; p.Ile808Serfs*816 (c.2420_2423delTCAT); Zygosity=Heterozygous (PubMed=21339753) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139387 CVCL_BU41 GM22247 transformed cell line human CVCL_BU41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139388 CVCL_C640 D1-iPSC-1 induced pluripotent stem cell human CVCL_C640 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 2888; DISC1; Simple; p.Ile808Serfs*816 (c.2420_2423delTCAT); Zygosity=Heterozygous (PubMed=21339753) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139389 CVCL_BU40 GM22246 finite cell line human CVCL_BU40 CL:0000010 Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21139390 CVCL_BU43 GM22265 transformed cell line human CVCL_BU43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139391 CVCL_C643 hESM01 embryonic stem cell human CVCL_C643 From: Vavilov Institute of General Genetics; Moscow; Russia. CL:0000010 Female 21139392 CVCL_BU42 GM22248 finite cell line human CVCL_BU42 CL:0000010 Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139393 CVCL_C642 HFF-6 induced pluripotent stem cell human CVCL_C642 From: Boston University School of Medicine; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139394 CVCL_BU45 GM22272 transformed cell line human CVCL_BU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139395 CVCL_C645 hESM03 embryonic stem cell human CVCL_C645 From: Vavilov Institute of General Genetics; Moscow; Russia. CL:0000010 Female 21139396 CVCL_BU44 GM22270 transformed cell line human CVCL_BU44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139397 CVCL_C644 hESM02 embryonic stem cell human CVCL_C644 From: Vavilov Institute of General Genetics; Moscow; Russia. CL:0000010 Male 21139398 CVCL_BU58 GM22509 transformed cell line human CVCL_BU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139399 CVCL_C658 V9-7A embryonic stem cell human CVCL_C658 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Male 21139400 CVCL_BU57 GM22503 transformed cell line human CVCL_BU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139401 CVCL_C657 X-02 embryonic stem cell human CVCL_C657 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Male 21139402 CVCL_BU59 GM22510 transformed cell line human CVCL_BU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139403 CVCL_C659 UKRV-Mel-12a cancer cell line human CVCL_C659 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Unspecified 21139404 CVCL_BU50 GM22370 transformed cell line human CVCL_BU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139405 CVCL_C650 HIPS #14 induced pluripotent stem cell human CVCL_C650 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139406 CVCL_BU52 GM22376 transformed cell line human CVCL_BU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139407 CVCL_C652 HIPS #7 induced pluripotent stem cell human CVCL_C652 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139408 CVCL_BU51 GM22371 transformed cell line human CVCL_BU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139409 CVCL_C651 HIPS #3 induced pluripotent stem cell human CVCL_C651 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139410 CVCL_BU54 GM22496 transformed cell line human CVCL_BU54 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139411 CVCL_C654 HIPS #9 induced pluripotent stem cell human CVCL_C654 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139412 CVCL_BU53 GM22382 transformed cell line human CVCL_BU53 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Phe128Ser (c.383T>C); ClinVar=VCV000042259; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139413 CVCL_C653 HIPS #8 induced pluripotent stem cell human CVCL_C653 From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139414 CVCL_BU56 GM22498 transformed cell line human CVCL_BU56 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Heterozygous (By familial inference of GM22496) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139415 CVCL_C656 X-01 embryonic stem cell human CVCL_C656 From: Shanghai Institutes for Biological Sciences; Shanghai; China. CL:0000010 Female 21139416 CVCL_BU55 GM22497 transformed cell line human CVCL_BU55 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Heterozygous (By familial inference of GM22496) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139417 CVCL_C655 MISCES-01 embryonic stem cell human CVCL_C655 From: Monash University; Melbourne; Australia. CL:0000010 Female 21139418 CVCL_C625 B124-2 induced pluripotent stem cell human CVCL_C625 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139419 CVCL_BU25 GM22193 transformed cell line human CVCL_BU25 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Leu166Ter (c.498T>A); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139420 CVCL_C624 B124-1 induced pluripotent stem cell human CVCL_C624 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139421 CVCL_BU24 GM22192 transformed cell line human CVCL_BU24 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Arg94Cys (c.280C>T); ClinVar=VCV000202092; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139422 CVCL_C627 B124-13 induced pluripotent stem cell human CVCL_C627 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139423 CVCL_BU27 GM22208 transformed cell line human CVCL_BU27 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Lys298Arg (c.893A>G); ClinVar=VCV000449078; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8653; PCCA; Unexplicit; Ex13-20del; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139424 CVCL_C626 B124-10 induced pluripotent stem cell human CVCL_C626 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139425 CVCL_BU26 GM22194 transformed cell line human CVCL_BU26 CL:0000010 Sequence variation: Gene deletion; HGNC; 11577; TAFAZZIN; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139426 CVCL_C629 F12-3 induced pluripotent stem cell human CVCL_C629 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139427 CVCL_BU29 GM22212 finite cell line human CVCL_BU29 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139428 CVCL_C628 F12-1 induced pluripotent stem cell human CVCL_C628 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139429 CVCL_BU28 GM22211 transformed cell line human CVCL_BU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139430 CVCL_C621 B12-3 induced pluripotent stem cell human CVCL_C621 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139431 CVCL_BU21 GM22163 transformed cell line human CVCL_BU21 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Gly58Alafs*25 (c.171delA); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139432 CVCL_C620 B12-2 induced pluripotent stem cell human CVCL_C620 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139433 CVCL_BU20 GM22150 transformed cell line human CVCL_BU20 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Trp79Ter (c.236G>A); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139434 CVCL_C623 B12-11 induced pluripotent stem cell human CVCL_C623 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139435 CVCL_BU23 GM22165 transformed cell line human CVCL_BU23 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; c.110-2A>G (IVS1-2A>G); ClinVar=VCV000011109; Zygosity=Hemizygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139436 CVCL_C622 B12-6 induced pluripotent stem cell human CVCL_C622 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139437 CVCL_BU22 GM22164 transformed cell line human CVCL_BU22 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Gln233Ter (c.697C>T); ClinVar=VCV000662186; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139438 CVCL_C636 F124B-3 induced pluripotent stem cell human CVCL_C636 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139439 CVCL_BU36 GM22239 transformed cell line human CVCL_BU36 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21139440 CVCL_C635 F124-10 induced pluripotent stem cell human CVCL_C635 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139441 CVCL_BU35 GM22238 finite cell line human CVCL_BU35 CL:0000010 Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139442 CVCL_C638 CC1 [Human ESC] embryonic stem cell human CVCL_C638 From: University of Calgary; Calgary; Canada CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-01.. 21139443 CVCL_BU38 GM22244 transformed cell line human CVCL_BU38 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1067Thrfs*4 (c.3198delA); ClinVar=VCV002417452; Zygosity=Homozygous (Coriell) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139444 CVCL_C637 F124B-4 induced pluripotent stem cell human CVCL_C637 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139445 CVCL_BU37 GM22240 finite cell line human CVCL_BU37 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21139446 CVCL_C639 CC3 embryonic stem cell human CVCL_C639 From: University of Calgary; Calgary; Canada CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-01. 21139447 CVCL_BU39 GM22245 transformed cell line human CVCL_BU39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139448 CVCL_C630 F12-4 induced pluripotent stem cell human CVCL_C630 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139449 CVCL_BU30 GM22213 transformed cell line human CVCL_BU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139450 CVCL_C632 F12-6 induced pluripotent stem cell human CVCL_C632 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139451 CVCL_BU32 GM22215 transformed cell line human CVCL_BU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139452 CVCL_C631 F12-5 induced pluripotent stem cell human CVCL_C631 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139453 CVCL_BU31 GM22214 finite cell line human CVCL_BU31 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139454 CVCL_C634 F124-5 induced pluripotent stem cell human CVCL_C634 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139455 CVCL_BU34 GM22237 transformed cell line human CVCL_BU34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139456 CVCL_C633 F12-8 induced pluripotent stem cell human CVCL_C633 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139457 CVCL_BU33 GM22216 finite cell line human CVCL_BU33 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139458 CVCL_TI41 HAP1 RAF1 (-) 6 cancer cell line human CVCL_TI41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139459 CVCL_TI40 HAP1 RAF1 (-) 5 cancer cell line human CVCL_TI40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139460 CVCL_TI43 HAP1 RAMP1 (-) 1 cancer cell line human CVCL_TI43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9843; RAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139461 CVCL_TI42 HAP1 RAF1 (-) 7 cancer cell line human CVCL_TI42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139462 CVCL_TI45 HAP1 RAMP2 (-) 1 cancer cell line human CVCL_TI45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9844; RAMP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139463 CVCL_L097 OM3 hybridoma house mouse CVCL_L097 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HCN6; Human GP6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5940 21139464 CVCL_L096 CmA40 hybridoma house mouse CVCL_L096 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-11304 21139465 CVCL_TI44 HAP1 RAMP1 (-) 2 cancer cell line human CVCL_TI44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9843; RAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139466 CVCL_TI47 HAP1 RAP1GAP (-) 1 cancer cell line human CVCL_TI47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9858; RAP1GAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139467 CVCL_L099 OM2 hybridoma house mouse CVCL_L099 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HCN6; Human GP6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5939 21139468 CVCL_TI46 HAP1 RAMP2 (-) 2 cancer cell line human CVCL_TI46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9844; RAMP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139469 CVCL_L098 OM1 hybridoma house mouse CVCL_L098 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HCN6; Human GP6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5938 21139470 CVCL_TI49 HAP1 RARG (-) 1 cancer cell line human CVCL_TI49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9866; RARG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139471 CVCL_L093 ICBD-1 cancer cell line human CVCL_L093 CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male Doubling time: ~31.5 hours, at 30th passage (PubMed=9468580) 21139472 CVCL_TI48 HAP1 RARA (-) cancer cell line human CVCL_TI48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9864; RARA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139473 CVCL_L092 OCUCh-LM1-H1 cancer cell line human CVCL_L092 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male 21139474 CVCL_L095 KM20 cancer cell line human CVCL_L095 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Omics: Transcriptome analysis by microarray Discontinued: KCLB; 80017; probable. Female Microsatellite instability: Stable (MSS) (PubMed=25926053) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00513 Problematic cell line: Contaminated Shown to be a HT-29 derivative (ICLAC; an early sample of KM20 had been tested by the core facility where the cell line was established and the STR profile corresponds to that of HT-29). 21139475 CVCL_L094 Anti-My-10 clone 28/8/8/14/4 hybridoma house mouse CVCL_L094 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28906; Human CD34. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8483 21139476 CVCL_1C00 GM24087 transformed cell line human CVCL_1C00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139477 CVCL_1C02 GM24090 transformed cell line human CVCL_1C02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139478 CVCL_1C01 GM24088 transformed cell line human CVCL_1C01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139479 CVCL_1C04 GM24093 transformed cell line human CVCL_1C04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139480 CVCL_1C03 GM24091 transformed cell line human CVCL_1C03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139481 CVCL_1C06 GM24095 transformed cell line human CVCL_1C06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21139482 CVCL_1C05 GM24094 transformed cell line human CVCL_1C05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139483 CVCL_1C08 GM24097 transformed cell line human CVCL_1C08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139484 CVCL_1C07 GM24096 transformed cell line human CVCL_1C07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139485 CVCL_1C09 GM24098 transformed cell line human CVCL_1C09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21139486 CVCL_TI30 HAP1 RAB9A (-) cancer cell line human CVCL_TI30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9792; RAB9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139487 CVCL_TI32 HAP1 RABGAP1 (-) 2 cancer cell line human CVCL_TI32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17155; RABGAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139488 CVCL_TI31 HAP1 RABGAP1 (-) 1 cancer cell line human CVCL_TI31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17155; RABGAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139489 CVCL_TI34 HAP1 RAD51B (-) cancer cell line human CVCL_TI34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9822; RAD51B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139490 CVCL_TI33 HAP1 RAC1 (-) cancer cell line human CVCL_TI33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9801; RAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139491 CVCL_TI36 HAP1 RAF1 (-) 1 cancer cell line human CVCL_TI36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139492 CVCL_TI35 HAP1 RAD52 (-) cancer cell line human CVCL_TI35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9824; RAD52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139493 CVCL_TI38 HAP1 RAF1 (-) 3 cancer cell line human CVCL_TI38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139494 CVCL_TI37 HAP1 RAF1 (-) 2 cancer cell line human CVCL_TI37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139495 CVCL_TI39 HAP1 RAF1 (-) 4 cancer cell line human CVCL_TI39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9829; RAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139496 CVCL_TI19 HAP1 RAB4A (-) 2 cancer cell line human CVCL_TI19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9781; RAB4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139497 CVCL_L080 YD-9 cancer cell line human CVCL_L080 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16264262) Population: Korean; Derived from sampling site: Oral cavity; buccal mucosa. Male Doubling time: 33.4 hours (PubMed=16264262) 21139498 CVCL_L079 YD-8 cancer cell line human CVCL_L079 HLA typing: A*31:01,31:01; B*15:01,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.59%; East Asian, North=62.69%; East Asian, South=35.7%; South Asian=0%; European, North=0%; European, South=1.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly138Val (c.413G>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=16264262; DepMap) Population: Korean; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29.3 hours (PubMed=16264262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21139499 CVCL_L078 YD-15M cancer cell line human CVCL_L078 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Ala (c.773A>C); ClinVar=VCV000458563; Zygosity=Unspecified (PubMed=16264262) Population: Korean; Derived from metastatic site: Lymph node. Male Doubling time: 20.8 hours (PubMed=16264262) 21139500 CVCL_TI21 HAP1 RAB5A (-) 2 cancer cell line human CVCL_TI21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9783; RAB5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139501 CVCL_TI20 HAP1 RAB5A (-) 1 cancer cell line human CVCL_TI20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9783; RAB5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139502 CVCL_TI23 HAP1 RAB6A (-) 2 cancer cell line human CVCL_TI23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9786; RAB6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139503 CVCL_L075 MOLM-12 cancer cell line human CVCL_L075 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21139504 CVCL_L074 7.107 pRSV-T transformed cell line human CVCL_L074 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11136 21139505 CVCL_TI22 HAP1 RAB6A (-) 1 cancer cell line human CVCL_TI22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9786; RAB6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139506 CVCL_L077 B423 transformed cell line human CVCL_L077 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21139507 CVCL_TI25 HAP1 RAB7A (-) 2 cancer cell line human CVCL_TI25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9788; RAB7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139508 CVCL_L076 B422 transformed cell line human CVCL_L076 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21139509 CVCL_TI24 HAP1 RAB7A (-) 1 cancer cell line human CVCL_TI24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9788; RAB7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139510 CVCL_L071 F2408-No.3 spontaneously immortalized cell line Norway rat CVCL_L071 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21139511 CVCL_TI27 HAP1 RAB8A (-) 2 cancer cell line human CVCL_TI27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139512 CVCL_L070 F2408-No.20 spontaneously immortalized cell line Norway rat CVCL_L070 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21139513 CVCL_TI26 HAP1 RAB8A (-) 1 cancer cell line human CVCL_TI26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139514 CVCL_TI29 HAP1 RAB8A (-) 4 cancer cell line human CVCL_TI29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139515 CVCL_L073 WM98-1 cancer cell line human CVCL_L073 CL:0000010 Derived from sampling site: Skin. Male Part of: Wistar Institute melanoma cell line collection 21139516 CVCL_L072 F2408-No.7 spontaneously immortalized cell line Norway rat CVCL_L072 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21139517 CVCL_TI28 HAP1 RAB8A (-) 3 cancer cell line human CVCL_TI28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7007; RAB8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139518 CVCL_TI09 HAP1 RAB2A (-) 2 cancer cell line human CVCL_TI09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9763; RAB2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139519 CVCL_TI08 HAP1 RAB2A (-) 1 cancer cell line human CVCL_TI08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9763; RAB2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139520 CVCL_L091 OCUCh-LM1 cancer cell line human CVCL_L091 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 31 hours (PubMed=7880737) 21139521 CVCL_L090 HCC2373 cancer cell line human CVCL_L090 CL:0000010 Male 21139522 CVCL_L089 HCC1719 cancer cell line human CVCL_L089 CL:0000010 Male 21139523 CVCL_TI10 HAP1 RAB2A (-) 3 cancer cell line human CVCL_TI10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9763; RAB2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139524 CVCL_TI12 HAP1 RAB31 (-) 2 cancer cell line human CVCL_TI12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9771; RAB31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139526 CVCL_TI11 HAP1 RAB31 (-) 1 cancer cell line human CVCL_TI11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9771; RAB31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139527 CVCL_L085 SNU-1041 cancer cell line human CVCL_L085 HLA typing: A*02:01,02:01; B*15:01,27:05; C*01:02,04:01; DQA1*05:02,05:02; DQB1*05:01,05:01; DRB1*11:01,11:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Homozygous (DepMap) Population: Korean Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21139528 CVCL_TI14 HAP1 RAB32 (-) 2 cancer cell line human CVCL_TI14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9772; RAB32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139529 CVCL_L088 HCC1438 cancer cell line human CVCL_L088 HLA typing: A*29:02,29:02; B*44:03,44:03; C*16:01,16:01; DQA1*01:02,03:02; DQB1*05:03,06:04; DRB1*03:17,14:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139fs (c.415delG); Zygosity=Unspecified (PubMed=10353731) Population: African American; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 37 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21139530 CVCL_TI13 HAP1 RAB32 (-) 1 cancer cell line human CVCL_TI13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9772; RAB32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139531 CVCL_L087 HCC1313 cancer cell line human CVCL_L087 CL:0000010 Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21139532 CVCL_TI16 HAP1 RAB3A (-) 1 cancer cell line human CVCL_TI16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9777; RAB3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139533 CVCL_L082 YD-17M cancer cell line human CVCL_L082 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16264262) Population: Korean; Derived from metastatic site: Lymph node. Male Doubling time: 19.6 hours (PubMed=16264262) 21139534 CVCL_TI15 HAP1 RAB35 (-) 1 cancer cell line human CVCL_TI15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9774; RAB35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139535 CVCL_L081 YD-17 cancer cell line human CVCL_L081 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16264262) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 29.2 hours (PubMed=16264262) 21139536 CVCL_TI18 HAP1 RAB4A (-) 1 cancer cell line human CVCL_TI18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9781; RAB4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139537 CVCL_L084 SNU-620-ADR cancer cell line human CVCL_L084 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female Part of: Seoul National University (SNU) cell line collection 21139538 CVCL_TI17 HAP1 RAB3A (-) 2 cancer cell line human CVCL_TI17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9777; RAB3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139539 CVCL_L083 YD-38 cancer cell line human CVCL_L083 Genome ancestry: African=0%; Native American=0.56%; East Asian, North=61.56%; East Asian, South=37.62%; South Asian=0%; European, North=0%; European, South=0.26% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Ter (c.595G>T); ClinVar=VCV000634672; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Oral cavity; gingiva. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21.6 hours (PubMed=16264262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21139540 CVCL_L057 NALM-8 cancer cell line human CVCL_L057 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21139541 CVCL_L056 B240 transformed cell line human CVCL_L056 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139542 CVCL_L059 NALM-10 cancer cell line human CVCL_L059 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21139543 CVCL_L058 NALM-9 cancer cell line human CVCL_L058 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21139544 CVCL_TI01 HAP1 RAB20 (-) 1 cancer cell line human CVCL_TI01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18260; RAB20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139545 CVCL_L053 SNU-719-DOX cancer cell line human CVCL_L053 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro104Arg (c.311C>G); ClinVar=VCV001480334; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Stomach. Male Part of: Seoul National University (SNU) cell line collection 21139546 CVCL_TI00 HAP1 RAB1B (-) 2 cancer cell line human CVCL_TI00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18370; RAB1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139547 CVCL_L052 SNU-719-5FU cancer cell line human CVCL_L052 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro104Arg (c.311C>G); ClinVar=VCV001480334; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Stomach. Male Part of: Seoul National University (SNU) cell line collection 21139548 CVCL_L055 B239 transformed cell line human CVCL_L055 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139549 CVCL_TI03 HAP1 RAB20 (-) 3 cancer cell line human CVCL_TI03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18260; RAB20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139550 CVCL_L054 B250 transformed cell line human CVCL_L054 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 30-36 hours (PubMed=1817649) 21139551 CVCL_TI02 HAP1 RAB20 (-) 2 cancer cell line human CVCL_TI02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18260; RAB20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139552 CVCL_TI05 HAP1 RAB21 (-) 2 cancer cell line human CVCL_TI05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18263; RAB21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139553 CVCL_TI04 HAP1 RAB21 (-) 1 cancer cell line human CVCL_TI04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18263; RAB21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139554 CVCL_TI07 HAP1 RAB27A (-) 2 cancer cell line human CVCL_TI07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9766; RAB27A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139555 CVCL_L051 SNU-668-DOX cancer cell line human CVCL_L051 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21139556 CVCL_TI06 HAP1 RAB27A (-) 1 cancer cell line human CVCL_TI06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9766; RAB27A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139557 CVCL_L050 SNU-668-CIS cancer cell line human CVCL_L050 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21139558 CVCL_L068 MUTZ-6 cancer cell line human CVCL_L068 CL:0000010 Derived from sampling site: Peripheral blood. Male 21139559 CVCL_L067 JJN-2 cancer cell line human CVCL_L067 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgA1 kappa; Characteristics: IL6 dependent Doubling time: 3-4 days (PubMed=2495201) 21139560 CVCL_L069 MUTZ-7 cancer cell line human CVCL_L069 CL:0000010 Derived from sampling site: Peripheral blood. Male 21139561 CVCL_L064 HCC78 BL transformed cell line human CVCL_L064 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139562 CVCL_L063 HCC33 BL transformed cell line human CVCL_L063 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~48 hours (DSMZ=ACC-889) 21139563 CVCL_L066 JJN-1 cancer cell line human CVCL_L066 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgA1 kappa; Characteristics: IL6 dependent Doubling time: 10 days (PubMed=2495201) 21139564 CVCL_L065 HCC44 BL transformed cell line human CVCL_L065 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139565 CVCL_L060 NALM-11 cancer cell line human CVCL_L060 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21139566 CVCL_L062 HCC15 BL transformed cell line human CVCL_L062 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~40-45 hours (DSMZ=ACC-890) 21139567 CVCL_L061 NALM-13 cancer cell line human CVCL_L061 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21139568 CVCL_L039 CSOC 882 cancer cell line human CVCL_L039 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Ovary. Female Doubling time: 30.7 hours (PubMed=16956650) 21139569 CVCL_L038 NOMH-1 cancer cell line human CVCL_L038 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 273 hours (PubMed=23379414) 21139570 CVCL_L035 Vero 303 spontaneously immortalized cell line green monkey CVCL_L035 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Vaccine production cell line 21139571 CVCL_L034 WM28 cancer cell line human CVCL_L034 CL:0000010 Derived from metastatic site: Not specified. Unspecified Part of: Wistar Institute melanoma cell line collection 21139572 CVCL_L037 Vero/hSLAM spontaneously immortalized cell line green monkey CVCL_L037 CL:0000010 Transfected with: HGNC; 10903; SLAMF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Virology: Can be used to isolate measles virus from human clinical samples (ECACC); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 21139573 CVCL_L036 Vero F6 spontaneously immortalized cell line green monkey CVCL_L036 CL:0000010 Transfected with: UniProtKB; P08356; HHV-1 strain HFEM glycoprotein H (gH) Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21139574 CVCL_L031 WM3268 cancer cell line human CVCL_L031 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21139575 CVCL_L030 WM740V cancer cell line human CVCL_L030 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from sampling site: Skin. Female Part of: Wistar Institute melanoma cell line collection 21139576 CVCL_L033 WM165-1 cancer cell line human CVCL_L033 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (Wistar) Population: Caucasian; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21139577 CVCL_L032 WM4002 cancer cell line human CVCL_L032 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21139578 CVCL_L049 SNU-668-5FU cancer cell line human CVCL_L049 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21139579 CVCL_L046 SNU-620-DOX cancer cell line human CVCL_L046 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female Part of: Seoul National University (SNU) cell line collection 21139580 CVCL_L045 SNU-620-CIS cancer cell line human CVCL_L045 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female Part of: Seoul National University (SNU) cell line collection 21139581 CVCL_L048 SNU-638-CIS cancer cell line human CVCL_L048 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21139582 CVCL_L047 SNU-638-5FU cancer cell line human CVCL_L047 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21139583 CVCL_L042 SNU-1-DOX cancer cell line human CVCL_L042 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu1154fs*12 (c.3457_3458insT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6190; JAK1; Simple; p.Lys860Asnfs*16 (c.2580delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Male Part of: Seoul National University (SNU) cell line collection 21139584 CVCL_L041 HEY A4 cancer cell line human CVCL_L041 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Female 21139585 CVCL_L044 SNU-620-5FU cancer cell line human CVCL_L044 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Ascites. Female Part of: Seoul National University (SNU) cell line collection 21139586 CVCL_L043 SNU-16-DOX cancer cell line human CVCL_L043 CL:0000010 Sequence variation: Gene fusion; HGNC; 1681; CD44 + HGNC; 10940; SLC1A2; Name(s)=CD44-SLC1A2 (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4065_4066insTTGA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Phe (c.614A>T); ClinVar=VCV000376682; Zygosity=Homozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female Part of: Seoul National University (SNU) cell line collection 21139587 CVCL_L040 HEY AS1 cancer cell line human CVCL_L040 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Female 21139588 CVCL_1D94 HOS-CD4-CCR1 cancer cell line human CVCL_1D94 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1602; CCR1 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139589 CVCL_1D93 GM02044 finite cell line human CVCL_1D93 CL:0000010 Karyotypic information: 45,XY,-16,t(14;16)(16;18)(14qter->14p12::16p11->16pter;18qter->18p1::16q12->16qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21139590 CVCL_1D96 HOS-CD4-CCR3 cancer cell line human CVCL_1D96 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1604; CCR3 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139591 CVCL_1D95 HOS-CD4-CCR2b cancer cell line human CVCL_1D95 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1603; CCR2 (isoform B) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139592 CVCL_1D98 HOS-CD4-CCR5 cancer cell line human CVCL_1D98 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139593 CVCL_1D97 HOS-CD4-CCR4 cancer cell line human CVCL_1D97 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1605; CCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139594 CVCL_1D99 HOS-CD4-Fusin cancer cell line human CVCL_1D99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21139595 CVCL_1D90 MDA-MB-231-luc2-tdTomato cancer cell line human CVCL_1D90 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 125738; true Female Group: Triple negative breast cancer (TNBC) cell line 21139596 CVCL_1D92 MDA-MB-231-luc2-LN cancer cell line human CVCL_1D92 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21139597 CVCL_1D91 MDA-MB-231-tdTomato cancer cell line human CVCL_1D91 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 125737; true Female Group: Triple negative breast cancer (TNBC) cell line 21139598 CVCL_1D72 UOK262 cancer cell line human CVCL_1D72 CL:0000010 Sequence variation: Mutation; HGNC; 3700; FH; Simple; p.Gln439Pro (c.1316A>C); Zygosity=Hemizygous (PubMed=19963135) Derived from metastatic site: Kidney. Female 21139599 CVCL_1D71 Sf-9ET spontaneously immortalized cell line CVCL_1D71 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Ovary. Female Characteristics: The expression of the eGFP gene is under the control of the baculovirus polyhedrin promoter Doubling time: 28-32 hours (ATCC=CRL-3357) Group: Insect cell line; Group: Recombinant protein production insect cell line 21139600 CVCL_1D74 FNC-A6 finite cell line human CVCL_1D74 CL:0000010 Derived from sampling site: Fetal nose; nasal cavity; olfactory mucosa Cell type=Epithelial cell.. Male 21139601 CVCL_1D73 UOK268 cancer cell line human CVCL_1D73 CL:0000010 Sequence variation: Mutation; HGNC; 3700; FH; Simple; p.His235Asp (c.703C>G); ClinVar=VCV000393569; Zygosity=Hemizygous (PubMed=22867999). Female 21139602 CVCL_1D76 LS106 cancer cell line human CVCL_1D76 CL:0000010 21139603 CVCL_1D75 FNC-B4 finite cell line human CVCL_1D75 CL:0000010 Derived from sampling site: Fetal nose; nasal cavity; olfactory mucosa Cell type=Epithelial cell.. Male 21139604 CVCL_1D78 LS277 cancer cell line human CVCL_1D78 CL:0000010 Derived from metastatic site: Skin. 21139605 CVCL_1D77 LS111 cancer cell line human CVCL_1D77 CL:0000010 Derived from metastatic site: Cervical lymph node. 21139606 CVCL_1D79 LS112 cancer cell line human CVCL_1D79 CL:0000010 Derived from metastatic site: Skin. 21139607 CVCL_1D70 HGTC-8 embryonic stem cell house mouse CVCL_1D70 CL:0000010 Breed/subspecies: C57BL/6J. Male 21139608 CVCL_1D83 KB-C1-R1 cancer cell line human CVCL_1D83 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21139609 CVCL_1D82 KB-A1 cancer cell line human CVCL_1D82 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21139610 CVCL_1D85 293TT transformed cell line human CVCL_1D85 CL:0000010 Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Engineered to overexpress the SV40 large T antigen 21139611 CVCL_1D84 TB1A2 cancer cell line Norway rat CVCL_1D84 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. 21139612 CVCL_1D87 HeLa-T8+ cancer cell line human CVCL_1D87 CL:0000010 Transfected with: HGNC; 1706; CD8A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139613 CVCL_1D86 PE cancer cell line house mouse CVCL_1D86 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: SENCAR. 21139614 CVCL_1D89 MDA-MB-231-luc2-GFP cancer cell line human CVCL_1D89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 128442; true Female Group: Triple negative breast cancer (TNBC) cell line 21139615 CVCL_1D88 MDA-MB-231-luc-D3H1 cancer cell line human CVCL_1D88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 119261; true Female Group: Triple negative breast cancer (TNBC) cell line 21139616 CVCL_1D81 KB-C2.5 cancer cell line human CVCL_1D81 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21139617 CVCL_1D80 KB-C1.5 cancer cell line human CVCL_1D80 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21139618 CVCL_1D50 2C4 [Human fibrosarcoma] cancer cell line human CVCL_1D50 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1639; CD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Expression of CD2 is under the control of the IFITM1 promoter inducible by interferon gamma 21139619 CVCL_1D52 HMSC.AD somatic stem cell human CVCL_1D52 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Discontinued: CLS; 300641; true 21139620 CVCL_1D51 2C4 gamma1A/JAK2 cancer cell line human CVCL_1D51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5440; IFNGR2; Simple; p.Thr299Aspfs*16 (c.897dupT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1639; CD2; Transfected with: MGI; MGI:96629; Jak2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male 21139621 CVCL_1D54 HMSC.AM somatic stem cell human CVCL_1D54 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Mesenchymal stem cell.. 21139623 CVCL_1D56 HMSC.BM somatic stem cell human CVCL_1D56 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: CLS; 300661; true 21139625 CVCL_1D58 HMSC.WJ somatic stem cell human CVCL_1D58 CL:0000010 Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. 21139628 CVCL_1D61 HeLa Kyoto EGFP-EB3 cancer cell line human CVCL_1D61 CL:0000010 Transfected with: HGNC; 6892; MAPRE3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139629 CVCL_1D60 HeLa Kyoto EGFP-Cap-D2 cancer cell line human CVCL_1D60 CL:0000010 Transfected with: HGNC; 24305; NCAPD2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139630 CVCL_1D63 HeLa Kyoto EGFP-H2B cancer cell line human CVCL_1D63 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139631 CVCL_1D62 HeLa Kyoto EGFP-LaminA/H2B-mCherry cancer cell line human CVCL_1D62 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: HGNC; 6636; LMNA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139632 CVCL_1D65 HeLa Kyoto Mad2-LAP/H2B-mCherry cancer cell line human CVCL_1D65 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: MGI; MGI:1860374; Mad2l1; Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139633 CVCL_1D64 HeLa Kyoto EGFP-Kleisin-beta cancer cell line human CVCL_1D64 CL:0000010 Transfected with: HGNC; 25071; NCAPH2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21139634 CVCL_1D67 U-CH11 cancer cell line human CVCL_1D67 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: Transcriptome analysis by microarray Male Doubling time: 10 days (PubMed=26183925); 15 days (Chordoma_Foundation) 21139635 CVCL_1D66 U-CH10 cancer cell line human CVCL_1D66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: Transcriptome analysis by microarray Female Doubling time: 14 days (PubMed=26183925) 21139636 CVCL_1D69 UOK257-2 cancer cell line human CVCL_1D69 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.His429Profs*27 (c.1285dupC) (1733insC); ClinVar=VCV000003363; Zygosity=Hemizygous (from parent cell line); Transfected with: HGNC; 27310; FLCN Derived from sampling site: Kidney. Male Characteristics: Transfection of wildtype FLCN corrects the defects of this gene in the cell line 21139637 CVCL_1D68 UM-Chor1 cancer cell line human CVCL_1D68 HLA typing: A*02,03 (Chordoma_Foundation) CL:0000010 Derived from sampling site: Bone; cranium; clivus. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~5 days (PubMed=28430034); 5 days (Chordoma_Foundation) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21139638 CVCL_TJ91 HAP1 RYK (-) 1 cancer cell line human CVCL_TJ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10481; RYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139639 CVCL_TJ90 HAP1 RXRB (-) 2 cancer cell line human CVCL_TJ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10478; RXRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139640 CVCL_TJ93 HAP1 RYK (-) 3 cancer cell line human CVCL_TJ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10481; RYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139641 CVCL_TJ92 HAP1 RYK (-) 2 cancer cell line human CVCL_TJ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10481; RYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139642 CVCL_TJ95 HAP1 S100A10 (-) 1 cancer cell line human CVCL_TJ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10487; S100A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139643 CVCL_TJ94 HAP1 RYR2 (-) 1 cancer cell line human CVCL_TJ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10484; RYR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139644 CVCL_TJ97 HAP1 S1PR5 (-) 1 cancer cell line human CVCL_TJ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14299; S1PR5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139645 CVCL_TJ96 HAP1 S1PR1 (-) 1 cancer cell line human CVCL_TJ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3165; S1PR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139646 CVCL_TJ99 HAP1 SAMD9 (-) cancer cell line human CVCL_TJ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1348; SAMD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139647 CVCL_TJ98 HAP1 S1PR5 (-) 2 cancer cell line human CVCL_TJ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14299; S1PR5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139648 CVCL_1D30 GM01800 transformed cell line human CVCL_1D30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139649 CVCL_1D32 MCF7 AREc32 cancer cell line human CVCL_1D32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a construct containing 8 copies of the the rat glutathione-S-transferase (GST) antioxidant response element (ARE) linked to the luciferase reporter gene Induction of the ARE results in luciferase activity (PubMed=17108137). 21139650 CVCL_1D31 GM01801 transformed cell line human CVCL_1D31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139651 CVCL_1D34 T47D/182R-1 cancer cell line human CVCL_1D34 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139652 CVCL_1D33 DX3-puro/beta6 cancer cell line human CVCL_1D33 CL:0000010 Transfected with: HGNC; 6161; ITGB6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Hypodermis. Discontinued: Ximbio; 151625; probable Female 21139653 CVCL_1D36 T47D/TR-1 cancer cell line human CVCL_1D36 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21139654 CVCL_1D35 T47D/182R-2 cancer cell line human CVCL_1D35 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139655 CVCL_1D38 MCF-7/164R-5 cancer cell line human CVCL_1D38 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139656 CVCL_1D37 T47D/TR-2 cancer cell line human CVCL_1D37 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21139657 CVCL_1D39 MCF-7/164R-7 cancer cell line human CVCL_1D39 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139658 CVCL_TJ80 HAP1 RSAD1 (-) 1 cancer cell line human CVCL_TJ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25634; RSAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139659 CVCL_TJ82 HAP1 RTN4 (-) 2 cancer cell line human CVCL_TJ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14085; RTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139660 CVCL_TJ81 HAP1 RTN4 (-) 1 cancer cell line human CVCL_TJ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14085; RTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139661 CVCL_TJ84 HAP1 RTN4 (-) 4 cancer cell line human CVCL_TJ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14085; RTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139662 CVCL_TJ83 HAP1 RTN4 (-) 3 cancer cell line human CVCL_TJ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14085; RTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139663 CVCL_TJ86 HAP1 RUNX3 (-) 1 cancer cell line human CVCL_TJ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10473; RUNX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139664 CVCL_TJ85 HAP1 RUNX1 (-) cancer cell line human CVCL_TJ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10471; RUNX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139665 CVCL_TJ88 HAP1 RXRA (-) 2 cancer cell line human CVCL_TJ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10477; RXRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139666 CVCL_TJ87 HAP1 RXRA (-) 1 cancer cell line human CVCL_TJ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10477; RXRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139667 CVCL_TJ89 HAP1 RXRB (-) 1 cancer cell line human CVCL_TJ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10478; RXRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139668 CVCL_1D41 MCF-7/182R-7 cancer cell line human CVCL_1D41 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139669 CVCL_1D40 MCF-7/182R-1 cancer cell line human CVCL_1D40 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139670 CVCL_1D43 MCF-7/TAMR-7 cancer cell line human CVCL_1D43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21139671 CVCL_1D42 MCF-7/TAMR-4 cancer cell line human CVCL_1D42 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21139672 CVCL_1D45 T47D/S2 cancer cell line human CVCL_1D45 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21139673 CVCL_1D44 MCF-7/TAMR-8 cancer cell line human CVCL_1D44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21139674 CVCL_1D47 MCF-7/S0.5 cancer cell line human CVCL_1D47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21139675 CVCL_1D46 T47D/S5 cancer cell line human CVCL_1D46 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21139676 CVCL_1D49 MCF-7/164R-4 cancer cell line human CVCL_1D49 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139677 CVCL_1D48 MCF-7/164R-1 cancer cell line human CVCL_1D48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21139678 CVCL_TJ71 HAP1 RPS6KC1 (-) 1 cancer cell line human CVCL_TJ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10439; RPS6KC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139679 CVCL_TJ70 HAP1 RPS6KB2 (-) cancer cell line human CVCL_TJ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10437; RPS6KB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139680 CVCL_TJ73 HAP1 RPS6KL1 (-) 1 cancer cell line human CVCL_TJ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20222; RPS6KL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139681 CVCL_TJ72 HAP1 RPS6KC1 (-) 2 cancer cell line human CVCL_TJ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10439; RPS6KC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139682 CVCL_TJ75 HAP1 RPS6KL1 (-) 3 cancer cell line human CVCL_TJ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20222; RPS6KL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139683 CVCL_TJ74 HAP1 RPS6KL1 (-) 2 cancer cell line human CVCL_TJ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20222; RPS6KL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139684 CVCL_TJ77 HAP1 RRM2B (-) 1 cancer cell line human CVCL_TJ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17296; RRM2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139685 CVCL_TJ76 HAP1 RRAGA (-) 1 cancer cell line human CVCL_TJ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16963; RRAGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139686 CVCL_TJ79 HAP1 RRNAD1 (-) 1 cancer cell line human CVCL_TJ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24273; METTL25B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139687 CVCL_TJ78 HAP1 RRM2B (-) 2 cancer cell line human CVCL_TJ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17296; RRM2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21139688 CVCL_BW45 GM23976 finite cell line human CVCL_BW45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139689 CVCL_C845 MM472 cancer cell line human CVCL_C845 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro30Ile; Zygosity=Unspecified (PubMed=17363583) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis Unspecified 21139690 CVCL_BW44 GM23975 finite cell line human CVCL_BW44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139691 CVCL_C844 MM470 cancer cell line human CVCL_C844 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078). Unspecified 21139692 CVCL_BW47 GM23989 transformed cell line human CVCL_BW47 CL:0000010 Sequence variation: Mutation; HGNC; 10983; SLC25A13; Simple; c.615+5G>A; ClinVar=VCV000021517; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10983; SLC25A13; Simple; p.Ala554Glyfs*16 (c.1638_1660dup23); ClinVar=VCV000006003; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139693 CVCL_C847 MM540 cancer cell line human CVCL_C847 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified 21139694 CVCL_BW46 GM23986 transformed cell line human CVCL_BW46 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Met185Val (c.553A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139695 CVCL_C846 MM488 cancer cell line human CVCL_C846 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21139696 CVCL_BW49 GM25309 transformed cell line human CVCL_BW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139697 CVCL_C849 MM598 cancer cell line human CVCL_C849 CL:0000010 Unspecified 21139698 CVCL_BW48 GM25294 transformed cell line human CVCL_BW48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139699 CVCL_C848 MM548 cancer cell line human CVCL_C848 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg99del; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21139700 CVCL_BW41 GM23972 finite cell line human CVCL_BW41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139701 CVCL_C841 MM396 cancer cell line human CVCL_C841 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro81Leu (c.242C>T); ClinVar=VCV000833629; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21139702 CVCL_BW40 GM23971 finite cell line human CVCL_BW40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21139703 CVCL_C840 MM384 cancer cell line human CVCL_C840 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro48Leu (c.143C>T); Zygosity=Unspecified (PubMed=9354451; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21139704 CVCL_BW43 GM23974 finite cell line human CVCL_BW43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139705 CVCL_C843 MM418 cancer cell line human CVCL_C843 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified Characteristics: Highly pigmented 21139706 CVCL_BW42 GM23973 finite cell line human CVCL_BW42 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21139707 CVCL_C842 MM409 cancer cell line human CVCL_C842 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis Unspecified 21139708 CVCL_BW56 GM25393 finite cell line human CVCL_BW56 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; c.189+1G>T (IVS3+1G>T); Zygosity=Hemizygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139709 CVCL_C856 PV10 cancer cell line human CVCL_C856 CL:0000010 21139710 CVCL_BW55 GM25392 transformed cell line human CVCL_BW55 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; c.189+1G>T (IVS3+1G>T); Zygosity=Hemizygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139711 CVCL_C855 MCH-MN-1 cancer cell line human CVCL_C855 CL:0000010 Population: African American; Derived from sampling site: Kidney. Male Doubling time: <12.4 hours (PubMed=11441343) 21139712 CVCL_BW58 iHCE-NY1 transformed cell line human CVCL_BW58 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium. Biotechnology: Can be used to produce a reconstructed human corneal epithelium (RhCE) so as to test the eye irritation potential of chemicals (DOI=10.1089/aivt.2020.0003) 21139713 CVCL_C858 MUNIe005-A embryonic stem cell human CVCL_C858 From: Masaryk University; Brno; Czech Republic CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21139714 CVCL_C857 MUNIe004-A embryonic stem cell human CVCL_C857 From: Masaryk University; Brno; Czech Republic CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21139715 CVCL_BW57 NOK-SI spontaneously immortalized cell line human CVCL_BW57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=25275298) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Omics: Deep exome analysis Male Part of: OPC-22 oral and pharyngeal cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00589 Problematic cell line: Contaminated Shown to be a HaCaT derivative (ICLAC). Originally thought to originate from normal oral keratinocytes from a female donor. 21139716 CVCL_C859 MUNIe006-A embryonic stem cell human CVCL_C859 From: Masaryk University; Brno; Czech Republic. CL:0000010 Male 21139717 CVCL_BW59 X25-4 transformed cell line human CVCL_BW59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. 21139718 CVCL_BW50 GM25334 transformed cell line human CVCL_BW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139719 CVCL_C850 MM622 cancer cell line human CVCL_C850 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly67fs*53; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu139Ter (c.416T>A); Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21139720 CVCL_BW52 GM25383 finite cell line human CVCL_BW52 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139721 CVCL_C852 MM647 cancer cell line human CVCL_C852 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21139722 CVCL_BW51 GM25382 transformed cell line human CVCL_BW51 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139723 CVCL_C851 MM628 cancer cell line human CVCL_C851 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21139724 CVCL_BW54 GM25386 finite cell line human CVCL_BW54 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139725 CVCL_C854 MEL-STR transformed cell line human CVCL_C854 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21139726 CVCL_BW53 GM25385 transformed cell line human CVCL_BW53 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139727 CVCL_C853 WMP-1 transformed cell line house mouse CVCL_C853 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Lymph node and spleen; Breed/subspecies: WMP/PasDnJ. Female 21139728 CVCL_BW23 GM23893 finite cell line human CVCL_BW23 CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21139729 CVCL_C823 mSDU-hES6 embryonic stem cell human CVCL_C823 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Female 21139730 CVCL_BW22 GM23846 transformed cell line human CVCL_BW22 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Pro388Argfs*7 (c.1163_1188del26); Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139731 CVCL_C822 mSDU-hES5 embryonic stem cell human CVCL_C822 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Female 21139732 CVCL_BW25 GM11708 transformed cell line human CVCL_BW25 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139733 CVCL_C825 mSDU-hES8 embryonic stem cell human CVCL_C825 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Male 21139734 CVCL_BW24 GM23895 finite cell line human CVCL_BW24 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21139735 CVCL_C824 mSDU-hES7 embryonic stem cell human CVCL_C824 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Male 21139736 CVCL_BW27 GM23916 transformed cell line human CVCL_BW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139737 CVCL_C827 HGC-25 cancer cell line human CVCL_C827 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 15.6 hours (PubMed=851032) 21139738 CVCL_BW26 GM11709 finite cell line human CVCL_BW26 CL:0000010 Population: Ecuadorian; Derived from sampling site: Cell type=Fibroblast. Male 21139739 CVCL_C826 mSDU-hES9 embryonic stem cell human CVCL_C826 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Female 21139740 CVCL_BW29 GM23944 transformed cell line human CVCL_BW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139741 CVCL_C829 OCC1 cancer cell line human CVCL_C829 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 36 hours (at 10th passage), 38 hours (at 40th passage) (PubMed=2354825) Part of: MD Anderson Cell Lines Project 21139742 CVCL_BW28 GM23941 transformed cell line human CVCL_BW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139743 CVCL_C828 U266R cancer cell line human CVCL_C828 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21139744 CVCL_BW21 GM23841 transformed cell line human CVCL_BW21 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139745 CVCL_C821 mSDU-hES4 embryonic stem cell human CVCL_C821 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Male 21139746 CVCL_BW20 GM23837 finite cell line human CVCL_BW20 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Arg167Met (c.500G>T); Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139747 CVCL_C820 mSDU-hES3 embryonic stem cell human CVCL_C820 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Male 21139748 CVCL_BW19 GM23836 transformed cell line human CVCL_BW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139749 CVCL_C819 mSDU-hES2 embryonic stem cell human CVCL_C819 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Female 21139750 CVCL_BW34 GM23965 finite cell line human CVCL_BW34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139751 CVCL_C834 HTLA161 cancer cell line human CVCL_C834 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2233717; PubMed=2253237) Derived from sampling site: Bone; femur. Omics: Protein expression by reverse-phase protein arrays Unspecified Part of: MD Anderson Cell Lines Project 21139752 CVCL_C833 AF10 cancer cell line human CVCL_C833 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21139753 CVCL_BW33 GM23964 finite cell line human CVCL_BW33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139754 CVCL_BW36 GM23967 finite cell line human CVCL_BW36 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21139755 CVCL_C836 MM200 cancer cell line human CVCL_C836 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533; PubMed=23455323); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe56Ile (c.166T>A); ClinVar=VCV000811083; Zygosity=Unspecified (PubMed=17363583) Derived from sampling site: Skin. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21139756 CVCL_BW35 GM23966 finite cell line human CVCL_BW35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139757 CVCL_C835 MM455 cancer cell line human CVCL_C835 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=15048078) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified 21139758 CVCL_BW38 GM23969 finite cell line human CVCL_BW38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139759 CVCL_C838 MM329 cancer cell line human CVCL_C838 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21139760 CVCL_BW37 GM23968 finite cell line human CVCL_BW37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139761 CVCL_C837 MM229 cancer cell line human CVCL_C837 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=10070891) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21139762 CVCL_BW39 GM23970 finite cell line human CVCL_BW39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139763 CVCL_C839 MM369 cancer cell line human CVCL_C839 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. 21139764 CVCL_C830 AMOC-2 cancer cell line human CVCL_C830 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Characteristics: Established from a third generation xenograft established in BALB/c nu/nu mice Doubling time: 21.5-26.4 hours (PubMed=9433040) 21139765 CVCL_BW30 GM23958 transformed cell line human CVCL_BW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139766 CVCL_BW32 GM23963 finite cell line human CVCL_BW32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139767 CVCL_C832 RL male 1 cancer cell line house mouse CVCL_C832 CL:0000010 Breed/subspecies: BALB/c. Male 21139768 CVCL_BW31 GM23962 finite cell line human CVCL_BW31 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139769 CVCL_C831 Jurkat-TAg cancer cell line human CVCL_C831 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21139770 CVCL_BW01 GM23659 transformed cell line human CVCL_BW01 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg133Cys (c.397C>T) (p.Arg145Cys, c.433C>T); ClinVar=VCV000011809; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139771 CVCL_C801 IMHe002-A embryonic stem cell human CVCL_C801 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21139772 CVCL_BW00 GM23654 transformed cell line human CVCL_BW00 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139773 CVCL_C800 IMHe001-A embryonic stem cell human CVCL_C800 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Male 21139774 CVCL_BW03 GM23674 transformed cell line human CVCL_BW03 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Asn238Lysfs*63 (c.713dupA) (c.713_714insA); ClinVar=VCV000004494; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139775 CVCL_C803 IMHe004-A embryonic stem cell human CVCL_C803 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Male 21139776 CVCL_BW02 GM23663 transformed cell line human CVCL_BW02 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg133Cys (c.397C>T) (p.Arg145Cys, c.433C>T); ClinVar=VCV000011809; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139777 CVCL_C802 IMHe003-A embryonic stem cell human CVCL_C802 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21139778 CVCL_BW05 GM23682 transformed cell line human CVCL_BW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139779 CVCL_C805 IMHe006-A embryonic stem cell human CVCL_C805 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21139780 CVCL_BW04 GM23678 transformed cell line human CVCL_BW04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139781 CVCL_C804 IMHe005-A embryonic stem cell human CVCL_C804 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21139782 CVCL_BW07 GM23742 transformed cell line human CVCL_BW07 CL:0000010 Population: Caucasian and Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139783 CVCL_C807 NT-hESC embryonic stem cell human CVCL_C807 From: Department of Nephrology and Transplantation Medicine, Institute of Transplantation Sciences, Civil Hospital; Gujarat; India. CL:0000010 Male 21139784 CVCL_BW06 GM23714 transformed cell line human CVCL_BW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139785 CVCL_C806 IMHe012-A embryonic stem cell human CVCL_C806 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Male 21139786 CVCL_BW12 GM23751 transformed cell line human CVCL_BW12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139787 CVCL_C812 WAe009-A-2 embryonic stem cell human CVCL_C812 From: University of Wisconsin; Madison; USA CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0014. 21139788 CVCL_BW11 GM23750 transformed cell line human CVCL_BW11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139789 CVCL_C811 WAe009-A-1 embryonic stem cell human CVCL_C811 From: University of Wisconsin; Madison; USA. CL:0000010 Female 21139790 CVCL_BW14 GM23784 finite cell line human CVCL_BW14 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; c.532+5G>A (IVS7+5G>A); ClinVar=VCV000010056; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139791 CVCL_C814 LCA1-hiPSC1 induced pluripotent stem cell human CVCL_C814 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139792 CVCL_BW13 GM23771 transformed cell line human CVCL_BW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139793 CVCL_C813 H1.1 embryonic stem cell human CVCL_C813 From: University of Wisconsin; Madison; USA. CL:0000010 Male 21139794 CVCL_BW16 GM23814 finite cell line human CVCL_BW16 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Arg48His (c.143G>A); ClinVar=VCV000029985; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139795 CVCL_C816 LCA1-hiPSC3 induced pluripotent stem cell human CVCL_C816 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139796 CVCL_BW15 GM23785 finite cell line human CVCL_BW15 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; c.532+5G>A (IVS7+5G>A); ClinVar=VCV000010056; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139797 CVCL_C815 LCA1-hiPSC2 induced pluripotent stem cell human CVCL_C815 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139798 CVCL_BW18 GM23820 transformed cell line human CVCL_BW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139799 CVCL_C818 mSDU-hES1 embryonic stem cell human CVCL_C818 From: Provincial Hospital Affiliated to Shandong University; Jinan; China. CL:0000010 Male 21139800 CVCL_BW17 GM23815 finite cell line human CVCL_BW17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21139801 CVCL_C817 LCA1-hiPSC4 induced pluripotent stem cell human CVCL_C817 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21139802 CVCL_C810 CR2 embryonic stem cell human CVCL_C810 From: University of Texas Health Science Center at Houston; Houston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21139803 CVCL_BW10 GM23749 transformed cell line human CVCL_BW10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139804 CVCL_C809 CR1 embryonic stem cell human CVCL_C809 From: University of Texas Health Science Center at Houston; Houston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21139805 CVCL_BW09 GM23748 transformed cell line human CVCL_BW09 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous (PubMed=24508304) Population: Asian and Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139806 CVCL_BW08 GM23747 transformed cell line human CVCL_BW08 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139807 CVCL_C808 SYSUe003-A embryonic stem cell human CVCL_C808 From: Sun Yat-sen University; Guangzhou; China. CL:0000010 Female 21139808 CVCL_KP38 PCRP-ZNF239-2A10 hybridoma house mouse CVCL_KP38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16600; Human ZNF239. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139809 CVCL_L138 UM-SCC-75 cancer cell line human CVCL_L138 CL:0000010 Female 21139810 CVCL_KP37 PCRP-ZNF232-3F3 hybridoma house mouse CVCL_KP37 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139811 CVCL_L137 UM-SCC-72 cancer cell line human CVCL_L137 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=12884349). Male 21139812 CVCL_KP39 PCRP-ZNF239-2F6 hybridoma house mouse CVCL_KP39 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q16600; Human ZNF239. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139813 CVCL_L139 UM-SCC-76 cancer cell line human CVCL_L139 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Glu248Lys (c.742C>T); Zygosity=Unspecified (PubMed=31090975) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male 21139814 CVCL_KP34 PCRP-ZNF232-2B6 hybridoma house mouse CVCL_KP34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139815 CVCL_L134 UM-SCC-68A cancer cell line human CVCL_L134 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=12884349; PubMed=15287027). Male 21139816 CVCL_KP33 PCRP-ZNF232-2B3 hybridoma house mouse CVCL_KP33 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139817 CVCL_L133 UM-SCC-67 cancer cell line human CVCL_L133 CL:0000010 Male 21139818 CVCL_KP36 PCRP-ZNF232-2G7 hybridoma house mouse CVCL_KP36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139819 CVCL_L136 UM-SCC-71 cancer cell line human CVCL_L136 CL:0000010 Male 21139820 CVCL_KP35 PCRP-ZNF232-2C7 hybridoma house mouse CVCL_KP35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139821 CVCL_L135 UM-SCC-68B cancer cell line human CVCL_L135 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21139822 CVCL_KP30 PCRP-ZNF232-1B10 hybridoma house mouse CVCL_KP30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139823 CVCL_L130 UM-SCC-63 cancer cell line human CVCL_L130 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Unspecified (PubMed=1394225) Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585). Male 21139824 CVCL_KP32 PCRP-ZNF232-2A5 hybridoma house mouse CVCL_KP32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139825 CVCL_L132 UM-SCC-66 cancer cell line human CVCL_L132 CL:0000010 Male 21139826 CVCL_KP31 PCRP-ZNF232-1D5 hybridoma house mouse CVCL_KP31 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UNY5; Human ZNF232. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139827 CVCL_L131 UM-SCC-65 cancer cell line human CVCL_L131 CL:0000010 Male 21139828 CVCL_L149 CIPp cancer cell line dog CVCL_L149 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Shih Tzu. Female Doubling time: 23.17 hours (PubMed=33461558) 21139829 CVCL_KP49 PCRP-ZNF280A-1C4 hybridoma house mouse CVCL_KP49 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P59817; Human ZNF280A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139830 CVCL_L148 CIPm cancer cell line dog CVCL_L148 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Shih Tzu. Female Doubling time: 20.29 hours (PubMed=33461558) 21139831 CVCL_KP48 PCRP-ZNF277-1E10 hybridoma house mouse CVCL_KP48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NRM2; Human ZNF277. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139832 CVCL_L145 CHMp-5b cancer cell line dog CVCL_L145 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female 21139833 CVCL_KP45 PCRP-ZNF264-1H4 hybridoma house mouse CVCL_KP45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43296; Human ZNF264. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139834 CVCL_L144 CHMp-13a cancer cell line dog CVCL_L144 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female 21139835 CVCL_KP44 PCRP-ZNF264-1D5 hybridoma house mouse CVCL_KP44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43296; Human ZNF264. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139836 CVCL_L147 CHMp cancer cell line dog CVCL_L147 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female 21139837 CVCL_KP47 PCRP-ZNF277-1A2 hybridoma house mouse CVCL_KP47 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NRM2; Human ZNF277. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139838 CVCL_L146 CHMm cancer cell line dog CVCL_L146 CL:0000010 Derived from metastatic site: Pleural effusion; Breed/subspecies: Mixed breed. Female 21139839 CVCL_KP46 PCRP-ZNF276-1A5 hybridoma house mouse CVCL_KP46 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N554; Human ZNF276. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139840 CVCL_KP41 PCRP-ZNF24-1E12 hybridoma house mouse CVCL_KP41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17028; Human ZNF24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139841 CVCL_L141 UM-SCC-78A cancer cell line human CVCL_L141 CL:0000010 Male 21139842 CVCL_KP40 PCRP-ZNF239-3C2 hybridoma house mouse CVCL_KP40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16600; Human ZNF239. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139843 CVCL_L140 UM-SCC-77 cancer cell line human CVCL_L140 CL:0000010 Female 21139844 CVCL_KP43 PCRP-ZNF263-1C11 hybridoma house mouse CVCL_KP43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O14978; Human ZNF263. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139845 CVCL_L143 UM-SCC-21B cancer cell line human CVCL_L143 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21139846 CVCL_KP42 PCRP-ZNF24-1G5 hybridoma house mouse CVCL_KP42 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17028; Human ZNF24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139847 CVCL_L142 UM-SCC-78B cancer cell line human CVCL_L142 CL:0000010 Male 21139848 CVCL_BV89 GM23624 transformed cell line human CVCL_BV89 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg133Pro (c.398G>C) (p.Arg145Pro, c.434G>C); ClinVar=VCV001679147; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139849 CVCL_C789 RC-7 embryonic stem cell human CVCL_C789 HLA typing: A*02,24; B*27,40; C*01,02; DQB1*03,05; DRB1*01,11; DRB3*02 (PubMed=27346020). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC09-48. 21139850 CVCL_BV82 GM23601 transformed cell line human CVCL_BV82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139851 CVCL_C782 RC-11 embryonic stem cell human CVCL_C782 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-02. 21139852 CVCL_BV81 GM23599 transformed cell line human CVCL_BV81 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139853 CVCL_C781 RC-10 embryonic stem cell human CVCL_C781 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-11.. 21139854 CVCL_BV84 GM23605 transformed cell line human CVCL_BV84 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Tyr141Ter (c.423C>G) (p.Tyr153Ter, c.459C>G); ClinVar=VCV000011833; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139855 CVCL_C784 RC-2 embryonic stem cell human CVCL_C784 HLA typing: A*01,26; B*08,37; C*06,07; DQB1*02,05; DRB1*03,10; DRB3*02 (PubMed=27346014). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-09-008, Steering comm appl. SCSC08-31. 21139856 CVCL_BV83 GM23602 transformed cell line human CVCL_BV83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139857 CVCL_C783 RC-12 embryonic stem cell human CVCL_C783 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-05.. 21139858 CVCL_BV86 GM23607 transformed cell line human CVCL_BV86 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Glyfs*4 (c.1157_1200del44) (p.Leu398Glyfs*4, c.1193_1236del44); ClinVar=VCV000143372; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139859 CVCL_C786 RC-4 embryonic stem cell human CVCL_C786 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-09-017, Steering comm appl. SCSC08-33.. 21139860 CVCL_BV85 GM23606 transformed cell line human CVCL_BV85 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; c.27-8C>G (IVS2-8C>G); ClinVar=VCV000156049; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139861 CVCL_KP19 PCRP-ZNF212-1A3 hybridoma house mouse CVCL_KP19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UDV6; Human ZNF212. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139862 CVCL_C785 RC-3 embryonic stem cell human CVCL_C785 HLA typing: A*01; B*08,37; C*06,07; DQB1*02,05; DRB1*01,03; DRB3*01 (PubMed=27346192). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-09-009, Steering comm appl. SCSC08-32. 21139863 CVCL_L119 SNUhES33 embryonic stem cell human CVCL_L119 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011001. 21139864 CVCL_BV88 GM23618 transformed cell line human CVCL_BV88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139865 CVCL_C788 RC-6 embryonic stem cell human CVCL_C788 HLA typing: A*01,03; B*08,44; C*05,07; DQB1*02,03; DRB1*03,04; DRB3*01; DRB4*01 (PubMed=27346019). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-09-018, Steering comm appl. SCSC09-16. 21139866 CVCL_BV87 GM23617 transformed cell line human CVCL_BV87 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~750] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139867 CVCL_C787 RC-5 embryonic stem cell human CVCL_C787 HLA typing: A*01,32; B*40,57; C*02,06; DQB1*06; DRB1*13; DRB3*02 (PubMed=27346004). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-09-014, Steering comm appl. SCSC08-34. 21139868 CVCL_KP16 PCRP-ZNF207-1A6 hybridoma house mouse CVCL_KP16 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43670; Human ZNF207. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139869 CVCL_L116 SNUhES18 embryonic stem cell human CVCL_L116 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010025. 21139870 CVCL_L115 CMPII C2 cancer cell line human CVCL_L115 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00038 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). 21139871 CVCL_KP15 PCRP-ZNF202-3G1 hybridoma house mouse CVCL_KP15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95125; Human ZNF202. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139872 CVCL_KP18 PCRP-ZNF207-2D8 hybridoma house mouse CVCL_KP18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43670; Human ZNF207. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139873 CVCL_L118 SNUhES32 embryonic stem cell human CVCL_L118 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010051. 21139874 CVCL_KP17 PCRP-ZNF207-1A7 hybridoma house mouse CVCL_KP17 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43670; Human ZNF207. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139875 CVCL_L117 SNUhES31 embryonic stem cell human CVCL_L117 From: Seoul National University; Seoul; South Korea CL:0000010 Population: Korean Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010037 21139876 CVCL_L112 NB56 cancer cell line human CVCL_L112 CL:0000010 Male 21139877 CVCL_KP12 PCRP-ZNF202-1C2 hybridoma house mouse CVCL_KP12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95125; Human ZNF202. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139878 CVCL_L111 NB76 cancer cell line human CVCL_L111 CL:0000010 Male 21139879 CVCL_KP11 PCRP-ZNF200-1A7 hybridoma house mouse CVCL_KP11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P98182; Human ZNF200. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139880 CVCL_BV80 GM23598 transformed cell line human CVCL_BV80 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139881 CVCL_C780 LUMCe004-A embryonic stem cell human CVCL_C780 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Male 21139882 CVCL_L114 OCUB-1 cancer cell line human CVCL_L114 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21139883 CVCL_KP14 PCRP-ZNF202-3D3 hybridoma house mouse CVCL_KP14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95125; Human ZNF202. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139884 CVCL_L113 NJB cancer cell line human CVCL_L113 CL:0000010 Derived from metastatic site: Lymph node. Female 21139885 CVCL_KP13 PCRP-ZNF202-1C4 hybridoma house mouse CVCL_KP13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O95125; Human ZNF202. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139886 CVCL_KP10 PCRP-ZNF200-1A3 hybridoma house mouse CVCL_KP10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P98182; Human ZNF200. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139887 CVCL_L110 RAW 309 cancer cell line house mouse CVCL_L110 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21139888 CVCL_BV93 GM23635 transformed cell line human CVCL_BV93 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139889 CVCL_C793 LNSc-iPS1 induced pluripotent stem cell human CVCL_C793 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139890 CVCL_C792 ESi030-A induced pluripotent stem cell human CVCL_C792 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139891 CVCL_BV92 GM23634 transformed cell line human CVCL_BV92 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg133Cys (c.397C>T) (p.Arg145Cys, c.433C>T); ClinVar=VCV000011809; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139892 CVCL_C795 BJMUe003-A embryonic stem cell human CVCL_C795 From: Peking University Third Hospital; Beijing; China. CL:0000010 Female 21139893 CVCL_BV95 GM23645 transformed cell line human CVCL_BV95 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~333] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; German/Norwegian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139894 CVCL_BV94 GM23642 finite cell line human CVCL_BV94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139895 CVCL_C794 LNSc-iPS2 induced pluripotent stem cell human CVCL_C794 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21139896 CVCL_C797 CL02 embryonic stem cell human CVCL_C797 From: Universite Paris-Sud 11; Paris; France. CL:0000010 Female 21139897 CVCL_BV97 GM23647 transformed cell line human CVCL_BV97 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; c.378-3C>G (IVS3-3C>G); ClinVar=VCV000156068; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139898 CVCL_C796 BJMUe004-A embryonic stem cell human CVCL_C796 From: Peking University Third Hospital; Beijing; China. CL:0000010 Male 21139899 CVCL_BV96 GM23646 transformed cell line human CVCL_BV96 CL:0000010 Population: Caucasian; Norwegian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139900 CVCL_BV99 GM23649 transformed cell line human CVCL_BV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139901 CVCL_C799 IMHe013-A embryonic stem cell human CVCL_C799 From: Istanbul Memorial Hospital; Istanbul; Turkey. CL:0000010 Female 21139902 CVCL_C798 CL03 embryonic stem cell human CVCL_C798 From: Universite Paris-Sud 11; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE10-131-L1. 21139903 CVCL_BV98 GM23648 transformed cell line human CVCL_BV98 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex4del; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139904 CVCL_KP27 PCRP-ZNF230-3C11 hybridoma house mouse CVCL_KP27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UIE0; Human ZNF230. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139905 CVCL_L127 UM-SCC-82A cancer cell line human CVCL_L127 CL:0000010 Female 21139906 CVCL_L126 CHA-hESB3 embryonic stem cell human CVCL_L126 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010048. 21139907 CVCL_KP26 PCRP-ZNF230-1E1 hybridoma house mouse CVCL_KP26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UIE0; Human ZNF230. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139908 CVCL_KP29 PCRP-ZNF230-4D11 hybridoma house mouse CVCL_KP29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UIE0; Human ZNF230. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139909 CVCL_L129 UM-SCC-62 cancer cell line human CVCL_L129 CL:0000010 Male 21139910 CVCL_KP28 PCRP-ZNF230-4B6 hybridoma house mouse CVCL_KP28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UIE0; Human ZNF230. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139911 CVCL_L128 UM-SCC-82B cancer cell line human CVCL_L128 CL:0000010 Female 21139912 CVCL_KP23 PCRP-ZNF222-2C5 hybridoma house mouse CVCL_KP23 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UK12; Human ZNF222. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139913 CVCL_L123 SNUhES38 embryonic stem cell human CVCL_L123 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011005. 21139914 CVCL_KP22 PCRP-ZNF217-5H9 hybridoma house mouse CVCL_KP22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75362; Human ZNF217. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139915 CVCL_L122 SNUhES37 embryonic stem cell human CVCL_L122 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011004. 21139916 CVCL_L125 CHA-hESB2 embryonic stem cell human CVCL_L125 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010047. 21139917 CVCL_BV91 GM23626 transformed cell line human CVCL_BV91 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Pro152Arg (c.455C>G) (p.Pro164Arg, c.491C>G); ClinVar=VCV000143579; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139918 CVCL_KP25 PCRP-ZNF23-2A5 hybridoma house mouse CVCL_KP25 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17027; Human ZNF23. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139919 CVCL_C791 RC-9 embryonic stem cell human CVCL_C791 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Miscellaneous: Complete STR profile from personal communication of De Sousa P. Omics: CNV analysis; Omics: SNP array analysis Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-15. 21139920 CVCL_L124 CHA-hESB1 embryonic stem cell human CVCL_L124 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010046. 21139921 CVCL_BV90 GM23625 transformed cell line human CVCL_BV90 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139922 CVCL_KP24 PCRP-ZNF23-2A2 hybridoma house mouse CVCL_KP24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17027; Human ZNF23. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139923 CVCL_C790 RC-8 embryonic stem cell human CVCL_C790 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-14.. 21139924 CVCL_KP21 PCRP-ZNF217-3C3 hybridoma house mouse CVCL_KP21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75362; Human ZNF217. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139925 CVCL_L121 SNUhES35 embryonic stem cell human CVCL_L121 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011003. 21139926 CVCL_KP20 PCRP-ZNF217-1G2 hybridoma house mouse CVCL_KP20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75362; Human ZNF217. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139927 CVCL_L120 SNUhES34 embryonic stem cell human CVCL_L120 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011002. 21139928 CVCL_C768 ESe026-A embryonic stem cell human CVCL_C768 HLA typing: A*01,02; B*41,53; C*04,17; DQB1*03:06; DRB1*13,15 (Spanish_Stem_Cell_Bank) From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 3513; EXT2; Simple; p.Gln162Argfs*108 (c.484delC); Zygosity=Heterozygous (Spanish_Stem_Cell_Bank). Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139929 CVCL_BV68 GM23426 transformed cell line human CVCL_BV68 CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Ile113Thr (c.338T>C); ClinVar=VCV000283107; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Phe200_Leu204del (c.598_612del15); ClinVar=VCV000166786; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139930 CVCL_C767 ESe025-A embryonic stem cell human CVCL_C767 HLA typing: A*02,25; B*18,44; C*12,16; DQB1*02:05; DRB1*07:05 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139931 CVCL_BV67 GM23418 transformed cell line human CVCL_BV67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139932 CVCL_C769 ESe009-A embryonic stem cell human CVCL_C769 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DQB1*02:01,02:01; DRB1*03:01,03:01 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139933 CVCL_BV69 GM23443 transformed cell line human CVCL_BV69 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~160]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~947]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139934 CVCL_C760 COS-M5 transformed cell line CVCL_C760 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21139935 CVCL_BV60 GM23382 finite cell line human CVCL_BV60 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Pro (c.464G>C); ClinVar=VCV000008472; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21139936 CVCL_C762 FS-11 finite cell line human CVCL_C762 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139937 CVCL_BV62 GM23385 finite cell line human CVCL_BV62 CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Unexplicit; Large deletion; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21139938 CVCL_C761 FS-7 finite cell line human CVCL_C761 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21139939 CVCL_BV61 GM23384 transformed cell line human CVCL_BV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139940 CVCL_BV64 GM23406 transformed cell line human CVCL_BV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139941 CVCL_C764 HT29-12B cancer cell line human CVCL_C764 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21139942 CVCL_BV63 GM23405 transformed cell line human CVCL_BV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139943 CVCL_C763 HT29-16E cancer cell line human CVCL_C763 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Female 21139944 CVCL_BV66 GM23417 transformed cell line human CVCL_BV66 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly12Valfs*2 (c.35delG); ClinVar=VCV000017004; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Met34Thr (c.101T>C); ClinVar=VCV000017000; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Val10952Leu (c.32854G>C) (p.Val13520Leu, c.40558G>C); ClinVar=VCV000130666; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; c.39893-1G>A (IVS192-1G>A) (c.37112-1G>A, IVS191-1G>A); ClinVar=VCV000202368; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139945 CVCL_C766 HT29-18A cancer cell line human CVCL_C766 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21139946 CVCL_BV65 GM23415 transformed cell line human CVCL_BV65 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.1494-1G>A (c.1398-1G>A); ClinVar=VCV000094272; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Gln691Ter (c.2071C>T) (p.Gln709Ter, c.2125C>T); ClinVar=VCV000963357; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139947 CVCL_C765 HT29-13G cancer cell line human CVCL_C765 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21139948 CVCL_BV79 GM23510 transformed cell line human CVCL_BV79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139949 CVCL_C779 LUMCe003-A embryonic stem cell human CVCL_C779 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 21139950 CVCL_BV78 GM23503 transformed cell line human CVCL_BV78 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139951 CVCL_C778 LUMCe002-A embryonic stem cell human CVCL_C778 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 21139952 CVCL_C771 ESe014-A embryonic stem cell human CVCL_C771 HLA typing: A*02:01,32:01; B*14:02,44:02; C*05:01,08:02; DQB1*03:01,06:03; DRB1*13:01,13:03 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139953 CVCL_BV71 GM23445 transformed cell line human CVCL_BV71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139954 CVCL_C770 ESe010-A embryonic stem cell human CVCL_C770 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DQB1*02:01,02:01; DRB1*03:01,03:01 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139955 CVCL_BV70 GM23444 transformed cell line human CVCL_BV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139956 CVCL_C773 ESe015-A embryonic stem cell human CVCL_C773 HLA typing: A*01:01,24:02; B*15:01,27:02; C*02:02,03:03; DQB1*03:01,06:03; DRB1*11:01,13:01 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139957 CVCL_BV73 GM23461 transformed cell line human CVCL_BV73 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Pro152Arg (c.455C>G) (p.Pro164Arg, c.491C>G); ClinVar=VCV000143579; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139958 CVCL_C772 ESe016-A embryonic stem cell human CVCL_C772 HLA typing: A*03:01,24:02; B*27:02,49:01; C*02:02,07:01; DRB1*04:05,11:01 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139959 CVCL_BV72 GM23459 transformed cell line human CVCL_BV72 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; c.1226_1337del (Ex4del); Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139960 CVCL_L109 C0940 transformed cell line human CVCL_L109 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139961 CVCL_C775 ESe023-A embryonic stem cell human CVCL_C775 HLA typing: A*02; B*18,44; C*07,16; DQB1*02:04; DRB1*07:08 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139962 CVCL_BV75 GM23463 transformed cell line human CVCL_BV75 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Glu392Ter (c.1173_1207del); Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139963 CVCL_KP09 PCRP-ZNF2-1D2 hybridoma house mouse CVCL_KP09 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9BSG1; Human ZNF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139964 CVCL_L108 C0834 transformed cell line human CVCL_L108 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94090157; probable Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21139965 CVCL_C774 ESe022-A embryonic stem cell human CVCL_C774 HLA typing: A*03,11; B*35,47; C*04,06; DQB1*02:05; DRB1*01:07 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139966 CVCL_BV74 GM23462 transformed cell line human CVCL_BV74 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21139967 CVCL_KP08 PCRP-ZNF197-2D1 hybridoma house mouse CVCL_KP08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14709; Human ZNF197. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139968 CVCL_BV77 GM23497 transformed cell line human CVCL_BV77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139969 CVCL_C777 LUMCe001-A embryonic stem cell human CVCL_C777 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 Female 21139970 CVCL_C776 ESe024-A embryonic stem cell human CVCL_C776 HLA typing: A*02,33; B*14,51; C*08,14; DQB1*02:06; DRB1*03:15 (PubMed=20177997). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139971 CVCL_BV76 GM23485 transformed cell line human CVCL_BV76 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21139972 CVCL_L105 5G2 transformed cell line human CVCL_L105 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 6 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8797 21139973 CVCL_KP05 PCRP-ZNF18-4B5 hybridoma house mouse CVCL_KP05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17022; Human ZNF18. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139974 CVCL_L104 13C1 transformed cell line human CVCL_L104 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 5 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8796 21139975 CVCL_KP04 PCRP-ZNF18-3E5 hybridoma house mouse CVCL_KP04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17022; Human ZNF18. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139976 CVCL_KP07 PCRP-ZNF192-1F10 hybridoma house mouse CVCL_KP07 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15776; Human ZKSCAN8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139977 CVCL_L107 PH [Human] cancer cell line human CVCL_L107 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00527; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9851 Problematic cell line: Contaminated Shown to be a U-937 derivative. 21139978 CVCL_L106 6F11 transformed cell line human CVCL_L106 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 2 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8562 21139979 CVCL_KP06 PCRP-ZNF189-3C5 hybridoma house mouse CVCL_KP06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O75820; Human ZNF189. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139980 CVCL_L101 NEAmp-48.2 hybridoma house mouse CVCL_L101 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:132237; rac-3,4-methylenedioxy-N-ethylamphetamine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5295 21139981 CVCL_KP01 PCRP-ZNF169-1A4 hybridoma house mouse CVCL_KP01 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14929; Human ZNF169. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139982 CVCL_L100 OM4 hybridoma house mouse CVCL_L100 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9HCN6; Human GP6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5941 21139983 CVCL_KP00 PCRP-ZNF165-2F4 hybridoma house mouse CVCL_KP00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P49910; Human ZNF165. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139984 CVCL_L103 NE-GFP-4C spontaneously immortalized cell line house mouse CVCL_L103 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: C57BL/6 x 129/Sv-Trp53-/-. Discontinued: ATCC; CRL-2926; true Unspecified 21139985 CVCL_KP03 PCRP-ZNF175-1A2 hybridoma house mouse CVCL_KP03 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y473; Human ZNF175. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139986 CVCL_L102 NEAmp-62.1 hybridoma house mouse CVCL_L102 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:132237; rac-3,4-methylenedioxy-N-ethylamphetamine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5294 21139987 CVCL_KP02 PCRP-ZNF174-1D12 hybridoma house mouse CVCL_KP02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15697; Human ZNF174. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21139988 CVCL_C746 CBiPS6-2F-4 induced pluripotent stem cell human CVCL_C746 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139989 CVCL_BV46 GM23352 transformed cell line human CVCL_BV46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139990 CVCL_C745 ESi034-B induced pluripotent stem cell human CVCL_C745 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21139991 CVCL_BV45 GM23349 transformed cell line human CVCL_BV45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139992 CVCL_BV48 GM23357 transformed cell line human CVCL_BV48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139993 CVCL_C748 KMUe002-A embryonic stem cell human CVCL_C748 From: Kaohsiung Medical University; Kaohsiung; Taiwan. CL:0000010 Male 21139994 CVCL_BV47 GM23355 transformed cell line human CVCL_BV47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139995 CVCL_C747 KMUe001-A embryonic stem cell human CVCL_C747 From: Kaohsiung Medical University; Kaohsiung; Taiwan. CL:0000010 Female 21139996 CVCL_BV49 GM23358 transformed cell line human CVCL_BV49 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~800-900] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21139997 CVCL_C749 KMUe003-A embryonic stem cell human CVCL_C749 From: Kaohsiung Medical University; Kaohsiung; Taiwan. CL:0000010 Female 21139998 CVCL_C740 CLS1 embryonic stem cell human CVCL_C740 From: Aalborg University; Aalborg; Denmark. CL:0000010 Male 21139999 CVCL_BV40 GM23299 transformed cell line human CVCL_BV40 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[90-100] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch/English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140000 CVCL_C742 CLS3 embryonic stem cell human CVCL_C742 From: Aalborg University; Aalborg; Denmark. CL:0000010 Female 21140001 CVCL_BV42 GM23313 transformed cell line human CVCL_BV42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140002 CVCL_C741 CLS2 embryonic stem cell human CVCL_C741 From: Aalborg University; Aalborg; Denmark. CL:0000010 Male 21140003 CVCL_BV41 GM23300 transformed cell line human CVCL_BV41 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~150-160] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140004 CVCL_C744 ESi034-A induced pluripotent stem cell human CVCL_C744 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21140005 CVCL_BV44 GM23348 transformed cell line human CVCL_BV44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140006 CVCL_C743 CLS4 embryonic stem cell human CVCL_C743 From: Aalborg University; Aalborg; Denmark. CL:0000010 Male 21140007 CVCL_BV43 GM23337 transformed cell line human CVCL_BV43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21140008 CVCL_BV57 GM23376 transformed cell line human CVCL_BV57 CL:0000010 Population: Caucasian; Austrian/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140009 CVCL_C757 PCI-30 cancer cell line human CVCL_C757 Genome ancestry: African=0.38%; Native American=0%; East Asian, North=0.85%; East Asian, South=0.5%; South Asian=4.81%; European, North=42.64%; European, South=50.82% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21140010 CVCL_BV56 GM23375 transformed cell line human CVCL_BV56 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700-1800] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140011 CVCL_C756 PCI-15B cancer cell line human CVCL_C756 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21140012 CVCL_BV59 GM23378 transformed cell line human CVCL_BV59 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~80-90] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; French/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21140013 CVCL_C759 PCI-37B cancer cell line human CVCL_C759 CL:0000010 Derived from metastatic site: Lymph node. Male 21140014 CVCL_BV58 GM23377 finite cell line human CVCL_BV58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21140015 CVCL_C758 PCI-37A cancer cell line human CVCL_C758 CL:0000010 Derived from sampling site: Larynx. Male 21140016 CVCL_BV51 GM23366 transformed cell line human CVCL_BV51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140017 CVCL_C751 KMUe005-A embryonic stem cell human CVCL_C751 From: Kaohsiung Medical University; Kaohsiung; Taiwan. CL:0000010 Male 21140018 CVCL_BV50 GM23365 transformed cell line human CVCL_BV50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140019 CVCL_C750 KMUe004-A embryonic stem cell human CVCL_C750 From: Kaohsiung Medical University; Kaohsiung; Taiwan. CL:0000010 Male 21140020 CVCL_BV53 GM23370 transformed cell line human CVCL_BV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140021 CVCL_C753 TIFRe002-A embryonic stem cell human CVCL_C753 From: Tata Institute of Fundamental Research; Bangalore; India. CL:0000010 Unspecified 21140022 CVCL_BV52 GM23367 transformed cell line human CVCL_BV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140023 CVCL_C752 TIFRe001-A embryonic stem cell human CVCL_C752 From: Tata Institute of Fundamental Research; Bangalore; India. CL:0000010 Unspecified 21140024 CVCL_C755 ATC1 cancer cell line house mouse CVCL_C755 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). 21140025 CVCL_BV55 GM23374 transformed cell line human CVCL_BV55 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~130-140] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140026 CVCL_BV54 GM23372 transformed cell line human CVCL_BV54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140027 CVCL_C754 TIFRe003-A embryonic stem cell human CVCL_C754 From: Tata Institute of Fundamental Research; Bangalore; India. CL:0000010 Unspecified 21140028 CVCL_1D10 HROC103 T0 M1 cancer cell line human CVCL_1D10 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Rectum. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140029 CVCL_1D12 HROC126 cancer cell line human CVCL_1D12 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Rectum. Female Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140030 CVCL_1D11 HROC107 cT0 M2 cancer cell line human CVCL_1D11 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; sigmoid. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140031 CVCL_1D14 HROC147Met cancer cell line human CVCL_1D14 HLA typing: A*02:01,11:01; B*07:02,15:01; C*03:04,07:02; DQB1*03:02,06:02; DRB1*04:01,15:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Microsatellite instability: Instable (MSI-low) (Direct_author_submission) 21140032 CVCL_1D13 HROC131 T0 M3 cancer cell line human CVCL_1D13 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21140033 CVCL_1D16 HROC183 cancer cell line human CVCL_1D16 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Doubling time: 29 hours (CLS); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140034 CVCL_1D15 HROC173 cancer cell line human CVCL_1D15 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140035 CVCL_1D18 HROC334 cancer cell line human CVCL_1D18 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cecum. Female Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140036 CVCL_1D17 HROC183 T0 M2 cancer cell line human CVCL_1D17 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 29 hours (CLS) 21140037 CVCL_1D19 GM01696 finite cell line human CVCL_1D19 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;7)(q21;p22) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21140038 CVCL_TJ60 HAP1 RPS6KA1 (-) cancer cell line human CVCL_TJ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10430; RPS6KA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140039 CVCL_TJ62 HAP1 RPS6KA3 (-) cancer cell line human CVCL_TJ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10432; RPS6KA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140040 CVCL_TJ61 HAP1 RPS6KA2 (-) cancer cell line human CVCL_TJ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10431; RPS6KA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140041 CVCL_TJ64 HAP1 RPS6KA4 (-) 2 cancer cell line human CVCL_TJ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10433; RPS6KA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140042 CVCL_TJ63 HAP1 RPS6KA4 (-) 1 cancer cell line human CVCL_TJ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10433; RPS6KA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140043 CVCL_TJ66 HAP1 RPS6KA5 (-) 1 cancer cell line human CVCL_TJ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10434; RPS6KA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140044 CVCL_TJ65 HAP1 RPS6KA4 (-) 3 cancer cell line human CVCL_TJ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10433; RPS6KA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140045 CVCL_TJ68 HAP1 RPS6KA6 (-) cancer cell line human CVCL_TJ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10435; RPS6KA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140046 CVCL_TJ67 HAP1 RPS6KA5 (-) 2 cancer cell line human CVCL_TJ67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10434; RPS6KA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140047 CVCL_TJ69 HAP1 RPS6KB1 (-) cancer cell line human CVCL_TJ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10436; RPS6KB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140048 CVCL_1D21 HROC46 T0 M1 cancer cell line human CVCL_1D21 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Characteristics: Established from a patient-derived xenograft established in female NOD SCID mice Microsatellite instability: Stable (MSS) (PubMed=25926053) 21140049 CVCL_1D20 HROC43 cancer cell line human CVCL_1D20 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140050 CVCL_1D23 GM01610 finite cell line human CVCL_1D23 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Arg611His (c.1832G>A); ClinVar=VCV000045442; Zygosity=Heterozygous (PubMed=32521500); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp648Ter (c.1944G>A); ClinVar=VCV000004511; Zygosity=Heterozygous (PubMed=32521500); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Gly695Val (c.2084G>T); ClinVar=VCV000004510; Zygosity=Heterozygous (PubMed=32521500) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140051 CVCL_1D22 GM01700 finite cell line human CVCL_1D22 CL:0000010 Karyotypic information: 46,XY,t(21;22)(p12;2q11.2).arr(1-22)x2,(XY)x1 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21140052 CVCL_1D25 GM01701 finite cell line human CVCL_1D25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21140053 CVCL_1D24 GM01611 finite cell line human CVCL_1D24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21140054 CVCL_1D27 GM01796 transformed cell line human CVCL_1D27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140055 CVCL_1D26 GM01795 transformed cell line human CVCL_1D26 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Arg611His (c.1832G>A); ClinVar=VCV000045442; Zygosity=Heterozygous (from autologous cell line GM01610); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp648Ter (c.1944G>A); ClinVar=VCV000004511; Zygosity=Heterozygous (from autologous cell line GM01610); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Gly695Val (c.2084G>T); ClinVar=VCV000004510; Zygosity=Heterozygous (from autologous cell line GM01610) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140056 CVCL_1D29 GM01799 transformed cell line human CVCL_1D29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140057 CVCL_1D28 GM01797 transformed cell line human CVCL_1D28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140058 CVCL_TJ51 HAP1 ROCK2 (-) 2 cancer cell line human CVCL_TJ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140059 CVCL_TJ50 HAP1 ROCK2 (-) 1 cancer cell line human CVCL_TJ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140060 CVCL_TJ53 HAP1 ROR1 (-) 1 cancer cell line human CVCL_TJ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10256; ROR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140061 CVCL_TJ52 HAP1 ROCK2 (-) 3 cancer cell line human CVCL_TJ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140062 CVCL_TJ55 HAP1 ROR1 (-) 3 cancer cell line human CVCL_TJ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10256; ROR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140063 CVCL_TJ54 HAP1 ROR1 (-) 2 cancer cell line human CVCL_TJ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10256; ROR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140064 CVCL_TJ57 HAP1 ROR2 (-) 5 cancer cell line human CVCL_TJ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10257; ROR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140065 CVCL_TJ56 HAP1 ROR2 (-) 4 cancer cell line human CVCL_TJ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10257; ROR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140066 CVCL_TJ59 HAP1 RPS25 (-) 2 cancer cell line human CVCL_TJ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10413; RPS25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140067 CVCL_TJ58 HAP1 RPS25 (-) 1 cancer cell line human CVCL_TJ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10413; RPS25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140068 CVCL_TJ40 HAP1 RNF41 (-) 3 cancer cell line human CVCL_TJ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18401; RNF41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140069 CVCL_L199 Man-11 embryonic stem cell human CVCL_L199 From: University of Manchester; Manchester; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to Man-12 (Cellosaurus=CVCL_L200). Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-26. 21140070 CVCL_KP99 PCRP-ZNF483-1A1 hybridoma house mouse CVCL_KP99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TF39; Human ZNF483. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140071 CVCL_TJ42 HAP1 RNF43 (-) 1 cancer cell line human CVCL_TJ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18505; RNF43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140072 CVCL_TJ41 HAP1 RNF41 (-) 4 cancer cell line human CVCL_TJ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18401; RNF41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140073 CVCL_TJ44 HAP1 RNF43 (-) 3 cancer cell line human CVCL_TJ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18505; RNF43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140074 CVCL_L196 Man-8 embryonic stem cell human CVCL_L196 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-25.. 21140075 CVCL_KP96 PCRP-ZNF467-2H7 hybridoma house mouse CVCL_KP96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z7K2; Human ZNF467. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140076 CVCL_TJ43 HAP1 RNF43 (-) 2 cancer cell line human CVCL_TJ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18505; RNF43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140077 CVCL_L195 Man-7 embryonic stem cell human CVCL_L195 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-24.. 21140078 CVCL_KP95 PCRP-ZNF446-3C8 hybridoma house mouse CVCL_KP95 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NWS9; Human ZNF446. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140079 CVCL_TJ46 HAP1 ROBO1 (-) 1 cancer cell line human CVCL_TJ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10249; ROBO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140080 CVCL_L198 Man-10 embryonic stem cell human CVCL_L198 From: University of Manchester; Manchester; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-17.. 21140081 CVCL_KP98 PCRP-ZNF48-1B9 hybridoma house mouse CVCL_KP98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96MX3; Human ZNF48. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140082 CVCL_TJ45 HAP1 RNF8 (-) cancer cell line human CVCL_TJ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10071; RNF8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140083 CVCL_L197 Man-9 embryonic stem cell human CVCL_L197 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-16.. 21140084 CVCL_KP97 PCRP-ZNF48-1B3 hybridoma house mouse CVCL_KP97 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96MX3; Human ZNF48. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140085 CVCL_TJ48 HAP1 ROCK1 (-) 2 cancer cell line human CVCL_TJ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140086 CVCL_L192 Man-4 embryonic stem cell human CVCL_L192 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-21.. 21140087 CVCL_KP92 PCRP-ZNF444-1E11 hybridoma house mouse CVCL_KP92 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N0Y2; Human ZNF444. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140088 CVCL_TJ47 HAP1 ROCK1 (-) 1 cancer cell line human CVCL_TJ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140089 CVCL_L191 Man-3 embryonic stem cell human CVCL_L191 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-20.. 21140090 CVCL_KP91 PCRP-ZNF438-1H5 hybridoma house mouse CVCL_KP91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z4V0; Human ZNF438. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140091 CVCL_L194 Man-6 embryonic stem cell human CVCL_L194 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-23.. 21140092 CVCL_KP94 PCRP-ZNF446-2C7 hybridoma house mouse CVCL_KP94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NWS9; Human ZNF446. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140093 CVCL_TJ49 HAP1 ROCK1 (-) 3 cancer cell line human CVCL_TJ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140094 CVCL_L193 Man-5 embryonic stem cell human CVCL_L193 From: University of Manchester; Manchester; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-22.. 21140095 CVCL_KP93 PCRP-ZNF446-1B4 hybridoma house mouse CVCL_KP93 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NWS9; Human ZNF446. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140096 CVCL_TJ29 HAP1 RNF123 (-) 5 cancer cell line human CVCL_TJ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21148; RNF123; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140097 CVCL_1D01 Novikoff-Hepatoma cancer cell line Norway rat CVCL_1D01 CL:0000010 Breed/subspecies: Sprague Dawley. Male 21140098 CVCL_1D00 Zajdela-Hepatoma cancer cell line Norway rat CVCL_1D00 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Unspecified 21140099 CVCL_1D03 45.6.2.4 cancer cell line house mouse CVCL_1D03 CL:0000010 Breed/subspecies: BALB/c. Female 21140100 CVCL_1D02 45.6 cancer cell line house mouse CVCL_1D02 CL:0000010 Breed/subspecies: BALB/c. Female 21140101 CVCL_1D05 RY(ham) Yoshida Sarcoma cancer cell line Norway rat CVCL_1D05 CL:0000010 Derived from metastatic site: Ascites. 21140102 CVCL_1D04 45.6.3.1 cancer cell line house mouse CVCL_1D04 CL:0000010 Breed/subspecies: BALB/c. Female 21140103 CVCL_1D07 HROC32 T3 M1 cancer cell line human CVCL_1D07 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (CLS); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NOD SCID mice Doubling time: 33.8 +- 5.4 hours (PubMed=25574089) 21140104 CVCL_1D06 HROC32 cancer cell line human CVCL_1D06 HLA typing: A*01:01,02:01; B*08:01,03:01; C*07:01,14:02; DPB1*01:01,02:01; DQA1*01:02,05:01; DQB1*02:01,03:01; DRB1*03:01,11:01 (CLS=300818) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (CLS); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Doubling time: 32 +- 10.6 hours (PubMed=25574089); 30 hours (CLS); Microsatellite instability: Stable (MSS) (PubMed=25926053) 21140105 CVCL_1D09 HROBML03 cancer cell line human CVCL_1D09 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Discontinued: CLS; 300801; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00587 Problematic cell line: Contaminated The STR profile is identical to that of the NCI-H460 cell line. Contamination confirmed by personal communication of Linnebacher M. Originally thought to originate from the resection of the brain metastasis of a 47 year old female Caucasian patient with a non-small cell lung carcinoma. 21140106 CVCL_1D08 HROBMC01 cancer cell line human CVCL_1D08 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Female Doubling time: 30 hours (CLS); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21140107 CVCL_TJ31 HAP1 RNF2 (-) 2 cancer cell line human CVCL_TJ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140108 CVCL_TJ30 HAP1 RNF2 (-) 1 cancer cell line human CVCL_TJ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140109 CVCL_TJ33 HAP1 RNF2 (-) 4 cancer cell line human CVCL_TJ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140110 CVCL_TJ32 HAP1 RNF2 (-) 3 cancer cell line human CVCL_TJ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140111 CVCL_TJ35 HAP1 RNF216 (-) cancer cell line human CVCL_TJ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21698; RNF216; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140112 CVCL_TJ34 HAP1 RNF2 (-) 5 cancer cell line human CVCL_TJ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140113 CVCL_TJ37 HAP1 RNF31 (-) 2 cancer cell line human CVCL_TJ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16031; RNF31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140114 CVCL_TJ36 HAP1 RNF31 (-) 1 cancer cell line human CVCL_TJ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16031; RNF31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140115 CVCL_TJ39 HAP1 RNF41 (-) 2 cancer cell line human CVCL_TJ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18401; RNF41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140116 CVCL_TJ38 HAP1 RNF41 (-) 1 cancer cell line human CVCL_TJ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18401; RNF41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140117 CVCL_TJ19 HAP1 RNASEK (-) 3 cancer cell line human CVCL_TJ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33911; RNASEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140118 CVCL_TJ18 HAP1 RNASEK (-) 2 cancer cell line human CVCL_TJ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33911; RNASEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140119 CVCL_L178 LU-HNSCC-3 cancer cell line human CVCL_L178 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19216775). Unspecified Doubling time: 1.8 +- 0.4 days (PubMed=19216775) 21140120 CVCL_KP78 PCRP-ZNF398-1A8 hybridoma house mouse CVCL_KP78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TD17; Human ZNF398. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140121 CVCL_KP77 PCRP-ZNF398-1A1 hybridoma house mouse CVCL_KP77 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8TD17; Human ZNF398. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140122 CVCL_L177 TLBR-1 cancer cell line human CVCL_L177 CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Ser614Arg (c.1842C>G); Zygosity=Unspecified (PubMed=28356514) Derived from sampling site: Breast Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-3027; probable Female Doubling time: 55 hours (PubMed=21425149); ~30-40 hours (DSMZ=ACC-904) 21140123 CVCL_TJ20 HAP1 RNASEK (-) 4 cancer cell line human CVCL_TJ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33911; RNASEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140124 CVCL_L179 LU-HNSCC-4 cancer cell line human CVCL_L179 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (PubMed=19216775). Unspecified Doubling time: 1.1 +- 0.1 days (PubMed=19216775) 21140125 CVCL_KP79 PCRP-ZNF408-1E5 hybridoma house mouse CVCL_KP79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H9D4; Human ZNF408. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140126 CVCL_TJ22 HAP1 RNASEL (-) 2 cancer cell line human CVCL_TJ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10050; RNASEL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140127 CVCL_KP74 PCRP-ZNF394-1C1 hybridoma house mouse CVCL_KP74 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q53GI3; Human ZNF394. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140128 CVCL_L174 TMT-081MS cancer cell line Norway rat CVCL_L174 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21140129 CVCL_TJ21 HAP1 RNASEL (-) 1 cancer cell line human CVCL_TJ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10050; RNASEL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140130 CVCL_L173 MT-450TC cancer cell line Norway rat CVCL_L173 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar Furth. Female 21140131 CVCL_KP73 PCRP-ZNF385B-1B5 hybridoma house mouse CVCL_KP73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q569K4; Human ZNF385B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140132 CVCL_L176 B-23 cancer cell line Norway rat CVCL_L176 CL:0000010 Breed/subspecies: BDIX. 21140133 CVCL_TJ24 HAP1 RNF111 (-) 2 cancer cell line human CVCL_TJ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17384; RNF111; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140134 CVCL_KP76 PCRP-ZNF397-6B9 hybridoma house mouse CVCL_KP76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NF99; Human ZNF397. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140135 CVCL_TJ23 HAP1 RNF111 (-) 1 cancer cell line human CVCL_TJ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17384; RNF111; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140136 CVCL_KP75 PCRP-ZNF397-2F6 hybridoma house mouse CVCL_KP75 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8NF99; Human ZNF397. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140137 CVCL_L175 TMT-081NM cancer cell line Norway rat CVCL_L175 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21140138 CVCL_TJ26 HAP1 RNF123 (-) 2 cancer cell line human CVCL_TJ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21148; RNF123; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140139 CVCL_L170 MT-W9A cancer cell line Norway rat CVCL_L170 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar Furth. Discontinued: ATCC; CRL-6597; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21140140 CVCL_KP70 PCRP-ZNF384-1E8 hybridoma house mouse CVCL_KP70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TF68; Human ZNF384. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140141 CVCL_TJ25 HAP1 RNF123 (-) 1 cancer cell line human CVCL_TJ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21148; RNF123; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140142 CVCL_TJ28 HAP1 RNF123 (-) 4 cancer cell line human CVCL_TJ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21148; RNF123; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140143 CVCL_L172 MT-W9/PL2 cancer cell line Norway rat CVCL_L172 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar Furth. Female 21140144 CVCL_KP72 PCRP-ZNF385B-1A1 hybridoma house mouse CVCL_KP72 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q569K4; Human ZNF385B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140145 CVCL_TJ27 HAP1 RNF123 (-) 3 cancer cell line human CVCL_TJ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21148; RNF123; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140146 CVCL_L171 MT-W9/PL cancer cell line Norway rat CVCL_L171 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar Furth. Female 21140147 CVCL_KP71 PCRP-ZNF385A-1H9 hybridoma house mouse CVCL_KP71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96PM9; Human ZNF385A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140148 CVCL_TJ08 HAP1 RING1 (-) 3 cancer cell line human CVCL_TJ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140149 CVCL_TJ07 HAP1 RING1 (-) 2 cancer cell line human CVCL_TJ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140150 CVCL_L190 NCL12 embryonic stem cell human CVCL_L190 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-11-070, Steering comm appl. SCSC11-01.. 21140151 CVCL_KP90 PCRP-ZNF438-1A11 hybridoma house mouse CVCL_KP90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7Z4V0; Human ZNF438. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140152 CVCL_TJ09 HAP1 RIOK3 (-) cancer cell line human CVCL_TJ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11451; RIOK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140153 CVCL_L189 NCL11 embryonic stem cell human CVCL_L189 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-11-069, Steering comm appl. SCSC11-01.. 21140154 CVCL_KP89 PCRP-ZNF428-1D6 hybridoma house mouse CVCL_KP89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96B54; Human ZNF428. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140155 CVCL_L188 NCL10 embryonic stem cell human CVCL_L188 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-11-068, Steering comm appl. SCSC10-37.. 21140156 CVCL_KP88 PCRP-ZNF417-2B5 hybridoma house mouse CVCL_KP88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TAU3; Human ZNF417. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140157 CVCL_TJ11 HAP1 RIPK1 (-) 2 cancer cell line human CVCL_TJ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10019; RIPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140158 CVCL_L185 OxF2 embryonic stem cell human CVCL_L185 From: University of Oxford; Oxford; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-11-002, Steering comm appl. SCSC10-38.. 21140159 CVCL_KP85 PCRP-ZNF410-2B4 hybridoma house mouse CVCL_KP85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140160 CVCL_L184 CB660 somatic stem cell human CVCL_L184 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Fetal brain; forebrain Cell type=Neural stem cell.. Female Registration: UK Stem Cell Bank (UKSCB); R-08-035, Steering comm appl. SCSC08-25. 21140161 CVCL_TJ10 HAP1 RIPK1 (-) 1 cancer cell line human CVCL_TJ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10019; RIPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21140162 CVCL_KP84 PCRP-ZNF410-1H9 hybridoma house mouse CVCL_KP84 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140163 CVCL_TJ13 HAP1 RLIM (-) 1 cancer cell line human CVCL_TJ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13429; RLIM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140164 CVCL_L187 OxF4 embryonic stem cell human CVCL_L187 From: University of Oxford; Oxford; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-11-004, Steering comm appl. SCSC10-41.. 21140165 CVCL_KP87 PCRP-ZNF410-2C9 hybridoma house mouse CVCL_KP87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140166 CVCL_TJ12 HAP1 RIPK2 (-) cancer cell line human CVCL_TJ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10020; RIPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line 21140167 CVCL_L186 OxF3 embryonic stem cell human CVCL_L186 From: University of Oxford; Oxford; United Kingdom CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); R-11-003, Steering comm appl. SCSC10-39.. 21140168 CVCL_KP86 PCRP-ZNF410-2B7 hybridoma house mouse CVCL_KP86 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140169 CVCL_TJ15 HAP1 RNASEH2C (-) 1 cancer cell line human CVCL_TJ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24116; RNASEH2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140170 CVCL_L181 LU-HNSCC-6 cancer cell line human CVCL_L181 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19216775). Unspecified Doubling time: 1.3 +- 0.4 days (PubMed=19216775) 21140171 CVCL_KP81 PCRP-ZNF410-1A12 hybridoma house mouse CVCL_KP81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140172 CVCL_TJ14 HAP1 RLIM (-) 2 cancer cell line human CVCL_TJ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13429; RLIM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140173 CVCL_L180 LU-HNSCC-5 cancer cell line human CVCL_L180 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His168Pro (c.503A>C); Zygosity=Unspecified (PubMed=19216775). Unspecified Doubling time: 1.6 +- 0.2 days (PubMed=19216775) 21140174 CVCL_KP80 PCRP-ZNF408-1F6 hybridoma house mouse CVCL_KP80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H9D4; Human ZNF408. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140175 CVCL_TJ17 HAP1 RNASEK (-) 1 cancer cell line human CVCL_TJ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33911; RNASEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140176 CVCL_L183 LU-HNSCC-8 cancer cell line human CVCL_L183 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu252del (c.754_756delCTC); ClinVar=VCV000998484; Zygosity=Unspecified (PubMed=19216775). Unspecified Doubling time: 1.4 +- 0.3 days (PubMed=19216775) 21140177 CVCL_KP83 PCRP-ZNF410-1D7 hybridoma house mouse CVCL_KP83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140178 CVCL_TJ16 HAP1 RNASEH2C (-) 2 cancer cell line human CVCL_TJ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24116; RNASEH2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140179 CVCL_L182 LU-HNSCC-7 cancer cell line human CVCL_L182 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19216775). Unspecified Doubling time: 2.2 +- 0.2 days (PubMed=19216775) 21140180 CVCL_KP82 PCRP-ZNF410-1C7 hybridoma house mouse CVCL_KP82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VK4; Human ZNF410. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140181 CVCL_L159 PC-3M-Pro2 cancer cell line human CVCL_L159 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139fs*31 (c.413delC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140182 CVCL_KP59 PCRP-ZNF334-1B3 hybridoma house mouse CVCL_KP59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HCZ1; Human ZNF334. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140183 CVCL_L156 PC-3M-LN2 cancer cell line human CVCL_L156 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140184 CVCL_KP56 PCRP-ZNF326-3E7 hybridoma house mouse CVCL_KP56 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q5BKZ1; Human ZNF326. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140185 CVCL_L155 PC-3M-LN1 cancer cell line human CVCL_L155 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140186 CVCL_KP55 PCRP-ZNF324-1B9 hybridoma house mouse CVCL_KP55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75467; Human ZNF324. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140187 CVCL_L158 PC-3M-Pro1 cancer cell line human CVCL_L158 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140188 CVCL_KP58 PCRP-ZNF333-2A12 hybridoma house mouse CVCL_KP58 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96JL9; Human ZNF333. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140189 CVCL_L157 PC-3M-LN3 cancer cell line human CVCL_L157 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140190 CVCL_KP57 PCRP-ZNF333-1H4 hybridoma house mouse CVCL_KP57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96JL9; Human ZNF333. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140191 CVCL_L152 CNMm cancer cell line dog CVCL_L152 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Maltese. Male 21140192 CVCL_TJ00 HAP1 RICTOR (-) 2 cancer cell line human CVCL_TJ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28611; RICTOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140193 CVCL_KP52 PCRP-ZNF296-1D6 hybridoma house mouse CVCL_KP52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WUU4; Human ZNF296. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140194 CVCL_L151 CTBp cancer cell line dog CVCL_L151 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female 21140195 CVCL_KP51 PCRP-ZNF296-1B11 hybridoma house mouse CVCL_KP51 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8WUU4; Human ZNF296. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140196 CVCL_TJ02 HAP1 RIF1 (-) 2 cancer cell line human CVCL_TJ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23207; RIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140197 CVCL_L154 JHC7 cancer cell line human CVCL_L154 HLA typing: A*24 (Chordoma_Foundation) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Leu (c.638G>T); ClinVar=VCV000376650; Zygosity=Unspecified (DepMap) Anecdotal: Established in 2009 from a chordoma tumor sample originating from Susan L Garbett who wrote about her successful fight against cancer in an autobiographical book (CelloPub=CLPUB00390). Population: Caucasian; Derived from sampling site: Bone; sacrum. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~5 days (PubMed=21699479); 3.5-4 days (Chordoma_Foundation) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21140198 CVCL_KP54 PCRP-ZNF324-1B7 hybridoma house mouse CVCL_KP54 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75467; Human ZNF324. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140199 CVCL_L153 CNMp cancer cell line dog CVCL_L153 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Maltese. Male 21140200 CVCL_TJ01 HAP1 RIF1 (-) 1 cancer cell line human CVCL_TJ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23207; RIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140201 CVCL_KP53 PCRP-ZNF311-1A10 hybridoma house mouse CVCL_KP53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5JNZ3; Human ZNF311. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140202 CVCL_TJ04 HAP1 RIF1 (-) 4 cancer cell line human CVCL_TJ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23207; RIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140203 CVCL_TJ03 HAP1 RIF1 (-) 3 cancer cell line human CVCL_TJ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23207; RIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140204 CVCL_L150 CTBm cancer cell line dog CVCL_L150 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Mixed breed. Female 21140205 CVCL_TJ06 HAP1 RING1 (-) 1 cancer cell line human CVCL_TJ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140206 CVCL_KP50 PCRP-ZNF280D-1D11 hybridoma house mouse CVCL_KP50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6N043; Human ZNF280D. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140207 CVCL_TJ05 HAP1 RIF1 (-) 5 cancer cell line human CVCL_TJ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23207; RIF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140208 CVCL_L167 LNCaP-Pro4 cancer cell line human CVCL_L167 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140209 CVCL_KP67 PCRP-ZNF354B-1A8 hybridoma house mouse CVCL_KP67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96LW1; Human ZNF354B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140210 CVCL_L166 LNCaP-Pro3 cancer cell line human CVCL_L166 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140211 CVCL_KP66 PCRP-ZNF354B-1A6 hybridoma house mouse CVCL_KP66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96LW1; Human ZNF354B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140212 CVCL_L169 NCI-H1755A cancer cell line human CVCL_L169 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ala (c.1406G>C); ClinVar=VCV000013971; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Phe (c.725G>T); ClinVar=VCV000376578; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Liver. Female 21140213 CVCL_KP69 PCRP-ZNF384-1C11 hybridoma house mouse CVCL_KP69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TF68; Human ZNF384. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140214 CVCL_L168 LNCaP-Pro5 cancer cell line human CVCL_L168 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140215 CVCL_KP68 PCRP-ZNF358-1A6 hybridoma house mouse CVCL_KP68 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NW07; Human ZNF358. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140216 CVCL_L163 LNCaP-LN4 cancer cell line human CVCL_L163 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140217 CVCL_KP63 PCRP-ZNF354A-1B6 hybridoma house mouse CVCL_KP63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60765; Human ZNF354A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140218 CVCL_L162 LNCaP-LN3 cancer cell line human CVCL_L162 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140219 CVCL_KP62 PCRP-ZNF341-3B10 hybridoma house mouse CVCL_KP62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYN7; Human ZNF341. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140220 CVCL_L165 LNCaP-Pro2 cancer cell line human CVCL_L165 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140221 CVCL_KP65 PCRP-ZNF354B-1A2 hybridoma house mouse CVCL_KP65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96LW1; Human ZNF354B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140222 CVCL_L164 LNCaP-Pro1 cancer cell line human CVCL_L164 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140223 CVCL_KP64 PCRP-ZNF354A-1D7 hybridoma house mouse CVCL_KP64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60765; Human ZNF354A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140224 CVCL_L161 LNCaP-LN2 cancer cell line human CVCL_L161 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140225 CVCL_KP61 PCRP-ZNF341-2C5 hybridoma house mouse CVCL_KP61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BYN7; Human ZNF341. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140226 CVCL_L160 LNCaP-LN1 cancer cell line human CVCL_L160 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21140227 CVCL_KP60 PCRP-ZNF335-2C1 hybridoma house mouse CVCL_KP60 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9H4Z2; Human ZNF335. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140228 CVCL_1E93 SW213 cancer cell line human CVCL_1E93 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21140229 CVCL_1E92 Safi-1 cancer cell line human CVCL_1E92 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21140230 CVCL_1E95 SW419 cancer cell line human CVCL_1E95 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from metastatic site: Peritoneum. Female 21140231 CVCL_1E94 SW409 cancer cell line human CVCL_1E94 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Endometrium. Female 21140232 CVCL_1E97 U-489MG cancer cell line human CVCL_1E97 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21140233 CVCL_1E96 U-399MG cancer cell line human CVCL_1E96 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21140234 CVCL_1E99 U-539MG cancer cell line human CVCL_1E99 CL:0000010 Female 21140235 CVCL_1E98 U-495MG cancer cell line human CVCL_1E98 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21140236 CVCL_1E91 Casa-1 cancer cell line human CVCL_1E91 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; HTB-42; true Male 21140237 CVCL_1E90 Malme-3S cancer cell line human CVCL_1E90 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male 21140238 CVCL_1E71 NCRM-1 induced pluripotent stem cell human CVCL_1E71 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Genome sequenced Male 21140239 CVCL_1E70 ShiPS-miFF3 induced pluripotent stem cell human CVCL_1E70 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140240 CVCL_1E73 NCRM-3 induced pluripotent stem cell human CVCL_1E73 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21140241 CVCL_1E72 NCRM-2 induced pluripotent stem cell human CVCL_1E72 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21140242 CVCL_1E75 NCRM-5 induced pluripotent stem cell human CVCL_1E75 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Genome sequenced Male 21140243 CVCL_1E74 NCRM-4 induced pluripotent stem cell human CVCL_1E74 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21140244 CVCL_1E77 ND1.4 induced pluripotent stem cell human CVCL_1E77 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140245 CVCL_1E76 NCRM-6 induced pluripotent stem cell human CVCL_1E76 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21140246 CVCL_1E79 CY2 [Human iPSC] induced pluripotent stem cell human CVCL_1E79 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21140247 CVCL_1E78 ND2.0 induced pluripotent stem cell human CVCL_1E78 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140248 CVCL_1E82 NCRM5-AS1-iCAGcGFP induced pluripotent stem cell human CVCL_1E82 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21140249 CVCL_1E81 NCRM5-C13-iCLHN induced pluripotent stem cell human CVCL_1E81 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Umbilical cord blood. Male 21140250 CVCL_1E84 T21C5 induced pluripotent stem cell human CVCL_1E84 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Population: Caucasian; Karyotypic information: Lost the third copy of chromosome 21; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 21140251 CVCL_1E83 T21C1 induced pluripotent stem cell human CVCL_1E83 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 21140252 CVCL_1E86 UKBi006-A induced pluripotent stem cell human CVCL_1E86 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140253 CVCL_1E85 UKBi005-A induced pluripotent stem cell human CVCL_1E85 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140254 CVCL_1E88 MDA-MB-231-luc2-tdTomato-LN cancer cell line human CVCL_1E88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21140255 CVCL_1E87 GM01803 transformed cell line human CVCL_1E87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140256 CVCL_1E89 SW489 cancer cell line human CVCL_1E89 From: Scott and White Clinic; Temple; USA CL:0000010 Female Doubling time: 26 hours, at 10th passage (PubMed=994214). 21140257 CVCL_1E80 NCRM5-AS1-iCLHN induced pluripotent stem cell human CVCL_1E80 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Umbilical cord blood. Male 21140258 CVCL_1E51 SaOS-1 cancer cell line human CVCL_1E51 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Chest wall. Female 21140259 CVCL_1E50 SK-HD-1 cancer cell line human CVCL_1E50 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Pleural effusion. Female 21140260 CVCL_1E53 SW267 cancer cell line human CVCL_1E53 From: Scott and White Clinic; Temple; USA. CL:0000010 21140261 CVCL_1E52 SW161 cancer cell line human CVCL_1E52 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21140262 CVCL_1E55 SW451 cancer cell line human CVCL_1E55 From: Scott and White Clinic; Temple; USA. CL:0000010 Male 21140263 CVCL_1E54 SW47 cancer cell line human CVCL_1E54 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from metastatic site: Liver. Female 21140264 CVCL_1E57 SW594 cancer cell line human CVCL_1E57 From: Scott and White Clinic; Temple; USA. CL:0000010 Male 21140265 CVCL_1E56 SW534 cancer cell line human CVCL_1E56 From: Scott and White Clinic; Temple; USA. CL:0000010 21140266 CVCL_1E59 SW843 cancer cell line human CVCL_1E59 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21140267 CVCL_1E58 SW80 cancer cell line human CVCL_1E58 From: Scott and White Clinic; Temple; USA. CL:0000010 21140268 CVCL_1E60 SW897 cancer cell line human CVCL_1E60 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21140269 CVCL_1E62 Peri.4U finite cell line human CVCL_1E62 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Peripheral neuron. 21140270 CVCL_1E61 Dopa.4U finite cell line human CVCL_1E61 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Dopaminergic neuron. 21140271 CVCL_1E64 Endo.4M finite cell line house mouse CVCL_1E64 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Endothelial cell; Breed/subspecies: 129S2/SvPas. Characteristics: Expression of GFP is under the control of the endothelial cell-specific Flt1 promoter 21140272 CVCL_1E63 Cor.At-iPS-CL finite cell line house mouse CVCL_1E63 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Cardiomyocyte; Breed/subspecies: 129S2/SvPas. Male 21140273 CVCL_1E66 BIONi010-A induced pluripotent stem cell human CVCL_1E66 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21140274 CVCL_1E65 Smac.4M finite cell line house mouse CVCL_1E65 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Cell type=Smooth muscle cell; Breed/subspecies: 129S2/SvPas. 21140275 CVCL_1E68 BIONi010-C induced pluripotent stem cell human CVCL_1E68 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21140276 CVCL_1E67 BIONi010-B induced pluripotent stem cell human CVCL_1E67 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21140277 CVCL_1E69 ShiPS-miFF1 induced pluripotent stem cell human CVCL_1E69 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140278 CVCL_TK90 HAP1 SGK3 (-) cancer cell line human CVCL_TK90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10812; SGK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140279 CVCL_TK92 HAP1 SGK494 (-) 2 cancer cell line human CVCL_TK92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26314; RSKR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140280 CVCL_TK91 HAP1 SGK494 (-) 1 cancer cell line human CVCL_TK91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26314; RSKR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140281 CVCL_TK94 HAP1 SH3BP5 (-) 1 cancer cell line human CVCL_TK94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10827; SH3BP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140282 CVCL_TK93 HAP1 SGPL1 (-) 1 cancer cell line human CVCL_TK93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10817; SGPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140283 CVCL_TK96 HAP1 SH3GLB1 (-) 1 cancer cell line human CVCL_TK96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10833; SH3GLB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140284 CVCL_TK95 HAP1 SH3BP5L (-) 1 cancer cell line human CVCL_TK95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29360; SH3BP5L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140285 CVCL_TK98 HAP1 SHARPIN (-) 1 cancer cell line human CVCL_TK98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25321; SHARPIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140286 CVCL_TK97 HAP1 SH3GLB1 (-) 2 cancer cell line human CVCL_TK97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10833; SH3GLB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140287 CVCL_TK99 HAP1 SHC1 (-) 1 cancer cell line human CVCL_TK99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10840; SHC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140288 CVCL_C966 dH1f-iPS3-12 induced pluripotent stem cell human CVCL_C966 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21140289 CVCL_BX66 ND00127 transformed cell line human CVCL_BX66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140290 CVCL_C965 dH1cf32-iPS-4 induced pluripotent stem cell human CVCL_C965 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21140291 CVCL_BX65 ND00125 transformed cell line human CVCL_BX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140292 CVCL_C968 hFIB2-iPS2 induced pluripotent stem cell human CVCL_C968 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140293 CVCL_BX68 ND00129 transformed cell line human CVCL_BX68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140294 CVCL_C967 dH1f-iPS3-3 induced pluripotent stem cell human CVCL_C967 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21140295 CVCL_BX67 ND00128 transformed cell line human CVCL_BX67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140296 CVCL_C969 hFIB2-iPS4 induced pluripotent stem cell human CVCL_C969 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: ENCODE project common cell types; tier 3 21140297 CVCL_BX69 ND00130 transformed cell line human CVCL_BX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140298 CVCL_BX60 ND00094 transformed cell line human CVCL_BX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140299 CVCL_C960 p-hiPS02 induced pluripotent stem cell human CVCL_C960 From: Harvard Medical School; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140300 CVCL_C962 dH1cf16-iPS-1 induced pluripotent stem cell human CVCL_C962 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Deep exome analysis. Male 21140301 CVCL_BX62 ND00101 transformed cell line human CVCL_BX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140302 CVCL_C961 MSC-iPS1 induced pluripotent stem cell human CVCL_C961 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21140303 CVCL_BX61 ND00100 transformed cell line human CVCL_BX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140304 CVCL_C964 dH1cf32-iPS-2 induced pluripotent stem cell human CVCL_C964 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21140305 CVCL_BX64 ND00124 transformed cell line human CVCL_BX64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140306 CVCL_C963 dH1cf16-iPS-5 induced pluripotent stem cell human CVCL_C963 From: Children's Hospital Boston; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray. Male 21140307 CVCL_BX63 ND00123 transformed cell line human CVCL_BX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140308 CVCL_C977 MRC5-RiPS-1.2 induced pluripotent stem cell human CVCL_C977 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21140309 CVCL_BX77 ND00153 transformed cell line human CVCL_BX77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140310 CVCL_C976 MRC5-RiPS-1.11 induced pluripotent stem cell human CVCL_C976 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140311 CVCL_BX76 ND00149 transformed cell line human CVCL_BX76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140312 CVCL_C979 MRC5-RiPS-1.8 induced pluripotent stem cell human CVCL_C979 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140313 CVCL_BX79 ND00155 transformed cell line human CVCL_BX79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140314 CVCL_C978 MRC5-RiPS-1.3 induced pluripotent stem cell human CVCL_C978 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21140315 CVCL_BX78 ND00154 transformed cell line human CVCL_BX78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140316 CVCL_C971 hiPSC117 induced pluripotent stem cell human CVCL_C971 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21140317 CVCL_BX71 ND00134 transformed cell line human CVCL_BX71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140318 CVCL_C970 hFIB2-iPS5 induced pluripotent stem cell human CVCL_C970 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: ENCODE project common cell types; tier 3 21140319 CVCL_BX70 ND00132 transformed cell line human CVCL_BX70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140320 CVCL_L307 11028 cancer cell line dog CVCL_L307 CL:0000010 Derived from metastatic site: Cervical lymph node; Breed/subspecies: Saint Bernard. Male 21140321 CVCL_C973 hiPSC122 induced pluripotent stem cell human CVCL_C973 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21140322 CVCL_BX73 ND00143 transformed cell line human CVCL_BX73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140323 CVCL_KR07 PCRP-ZSCAN5A-1B7 hybridoma house mouse CVCL_KR07 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140324 CVCL_L306 GOT1 cancer cell line human CVCL_L306 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Heterozygous (PubMed=29444910) Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: SNP array analysis Female 21140325 CVCL_C972 hiPSC121 induced pluripotent stem cell human CVCL_C972 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21140326 CVCL_BX72 ND00136 transformed cell line human CVCL_BX72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140327 CVCL_KR06 PCRP-ZSCAN31-1B9 hybridoma house mouse CVCL_KR06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96LW9; Human ZSCAN31. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140328 CVCL_L309 Abrams cancer cell line dog CVCL_L309 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Cys267Phe (c.800G>T); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Rottweiler. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 27.2 hours (PubMed=22916246); 19 hours (PubMed=27257868); 18.72 hours (PubMed=31640712) Part of: FACC canine tumor cell line panel 21140329 CVCL_C975 MRC5-iPS12 induced pluripotent stem cell human CVCL_C975 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21140330 CVCL_BX75 ND00148 transformed cell line human CVCL_BX75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140331 CVCL_KR09 PCRP-ZSCAN5A-2B5 hybridoma house mouse CVCL_KR09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140332 CVCL_L308 11031 cancer cell line dog CVCL_L308 CL:0000010 Derived from metastatic site: Liver; Breed/subspecies: Saint Bernard. Male 21140333 CVCL_C974 MRC5-iPS17 induced pluripotent stem cell human CVCL_C974 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21140334 CVCL_BX74 ND00146 transformed cell line human CVCL_BX74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140335 CVCL_KR08 PCRP-ZSCAN5A-1G7 hybridoma house mouse CVCL_KR08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140336 CVCL_KR03 PCRP-ZSCAN25-1A6 hybridoma house mouse CVCL_KR03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6NSZ9; Human ZSCAN25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140337 CVCL_L303 R-3327-AT-2 cancer cell line Norway rat CVCL_L303 CL:0000010 Breed/subspecies: Copenhagen. Male 21140338 CVCL_KR02 PCRP-ZSCAN23-3G2 hybridoma house mouse CVCL_KR02 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q3MJ62; Human ZSCAN23. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140339 CVCL_L305 A204.1 cancer cell line human CVCL_L305 CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gln182Alafs*28 (c.543_544delTC); Zygosity=Heterozygous (from parent cell line). Population: Caucasian Female Part of: ENCODE project common cell types; tier 3 21140340 CVCL_KR05 PCRP-ZSCAN31-1B6 hybridoma house mouse CVCL_KR05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96LW9; Human ZSCAN31. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140341 CVCL_KR04 PCRP-ZSCAN26-1F12 hybridoma house mouse CVCL_KR04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q16670; Human ZSCAN26. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140342 CVCL_L301 PC-3M-Pro3 cancer cell line human CVCL_L301 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21140343 CVCL_KR01 PCRP-ZSCAN22-1C7 hybridoma house mouse CVCL_KR01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10073; Human ZSCAN22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140344 CVCL_L300 MEMO cancer cell line human CVCL_L300 CL:0000010 Population: Afro-Brazilian; Derived from sampling site: Oral cavity; hard palate. Male 21140345 CVCL_KR00 PCRP-ZSCAN22-1C12 hybridoma house mouse CVCL_KR00 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10073; Human ZSCAN22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140346 CVCL_C944 J713 embryonic stem cell human CVCL_C944 From: VistaGen Therapeutics, Inc.; South San Francisco; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21140347 CVCL_BX44 ND00059 transformed cell line human CVCL_BX44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140348 CVCL_C943 J618 embryonic stem cell human CVCL_C943 From: VistaGen Therapeutics, Inc.; South San Francisco; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21140349 CVCL_BX43 ND00058 transformed cell line human CVCL_BX43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140350 CVCL_C946 CD34 iPS1 induced pluripotent stem cell human CVCL_C946 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21140351 CVCL_BX46 ND00064 transformed cell line human CVCL_BX46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140352 CVCL_C945 K117 [Human ESC] embryonic stem cell human CVCL_C945 From: VistaGen Therapeutics, Inc.; South San Francisco; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; not approved. 21140353 CVCL_BX45 ND00060 transformed cell line human CVCL_BX45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140354 CVCL_C948 GD-iPS1 induced pluripotent stem cell human CVCL_C948 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu29Alafs*18 (c.84dupG) (c.84_85insG) (84GG); ClinVar=VCV000004302; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140355 CVCL_BX48 ND00070 transformed cell line human CVCL_BX48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140356 CVCL_C947 CD34 iPS2 induced pluripotent stem cell human CVCL_C947 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21140357 CVCL_BX47 ND00067 transformed cell line human CVCL_BX47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140358 CVCL_C949 GD-iPS3 induced pluripotent stem cell human CVCL_C949 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu29Alafs*18 (c.84dupG) (c.84_85insG) (84GG); ClinVar=VCV000004302; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140359 CVCL_BX49 ND00071 transformed cell line human CVCL_BX49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140360 CVCL_BX40 ND00054 transformed cell line human CVCL_BX40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140361 CVCL_C940 RC2 202 4 induced pluripotent stem cell human CVCL_C940 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140362 CVCL_BX42 ND00057 transformed cell line human CVCL_BX42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140363 CVCL_C942 UCLA 12 embryonic stem cell human CVCL_C942 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0186 21140364 CVCL_BX41 ND00055 transformed cell line human CVCL_BX41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140365 CVCL_C941 UCLA 11 embryonic stem cell human CVCL_C941 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0185 21140366 CVCL_C955 DiPS-H1.5 induced pluripotent stem cell human CVCL_C955 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140367 CVCL_BX55 ND00081 transformed cell line human CVCL_BX55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140368 CVCL_BX54 ND00080 transformed cell line human CVCL_BX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140369 CVCL_C954 PD-iPS5 induced pluripotent stem cell human CVCL_C954 From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140370 CVCL_C957 DiPS-H2.4 induced pluripotent stem cell human CVCL_C957 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: It seems not to be known which of DiPS-H2.1 or DiPS-H2.4 is NYSCF-DE-1005-1005-Skin-RV-IPSC1 (personal communication of Egli D.) 21140371 CVCL_BX57 ND00083 transformed cell line human CVCL_BX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140372 CVCL_C956 DiPS-H2.1 induced pluripotent stem cell human CVCL_C956 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: It seems not to be known which of DiPS-H2.1 or DiPS-H2.4 is NYSCF-DE-1005-1005-Skin-RV-IPSC1 (personal communication of Egli D.) 21140373 CVCL_BX56 ND00082 transformed cell line human CVCL_BX56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140374 CVCL_BX59 ND00088 transformed cell line human CVCL_BX59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140375 CVCL_C959 p-hiPS01 induced pluripotent stem cell human CVCL_C959 From: Harvard Medical School; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140376 CVCL_C958 iCB5 induced pluripotent stem cell human CVCL_C958 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21140377 CVCL_BX58 ND00087 transformed cell line human CVCL_BX58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140378 CVCL_BX51 ND00075 transformed cell line human CVCL_BX51 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140379 CVCL_C951 R5.5 embryonic stem cell human CVCL_C951 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Female 21140380 CVCL_BX50 ND00073 transformed cell line human CVCL_BX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140381 CVCL_C950 R5.3 embryonic stem cell human CVCL_C950 From: StemLifeLine, Inc.; San Carlos; USA. CL:0000010 Female 21140382 CVCL_BX53 ND00079 transformed cell line human CVCL_BX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140383 CVCL_C953 PD-iPS11 induced pluripotent stem cell human CVCL_C953 From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140384 CVCL_BX52 ND00076 transformed cell line human CVCL_BX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140385 CVCL_C952 PD-iPS1 [Human iPSC USA] induced pluripotent stem cell human CVCL_C952 From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140386 CVCL_C922 BJ-RiPS-1.1 induced pluripotent stem cell human CVCL_C922 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140387 CVCL_BX22 GM25330 transformed cell line human CVCL_BX22 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140388 CVCL_C921 BJ1-iPS1 induced pluripotent stem cell human CVCL_C921 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140389 CVCL_BX21 GM25285 transformed cell line human CVCL_BX21 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Heterozygous; Note=Factor V Leiden (Coriell); Sequence variation: Mutation; HGNC; 9479; LONP1; Simple; p.Arg721Gly (c.2161C>G); ClinVar=VCV000180657; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140390 CVCL_C924 BJ-RiPS-1.3 induced pluripotent stem cell human CVCL_C924 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140391 CVCL_BX24 GM25340 transformed cell line human CVCL_BX24 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln631Serfs*7 (c.1891delC); ClinVar=VCV000050961; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140392 CVCL_C923 BJ-RiPS-1.2 induced pluripotent stem cell human CVCL_C923 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21140393 CVCL_BX23 GM25331 transformed cell line human CVCL_BX23 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140394 CVCL_C926 BMD-iPS4 induced pluripotent stem cell human CVCL_C926 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21140395 CVCL_BX26 GM25342 transformed cell line human CVCL_BX26 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140396 CVCL_C925 BMD-iPS1 induced pluripotent stem cell human CVCL_C925 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21140397 CVCL_BX25 GM25341 transformed cell line human CVCL_BX25 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln631Serfs*7 (c.1891delC); ClinVar=VCV000050961; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140398 CVCL_C928 BMD2-iPS5 induced pluripotent stem cell human CVCL_C928 From: Children's Hospital Boston; Boston; USA. CL:0000010 21140399 CVCL_BX28 GM25344 finite cell line human CVCL_BX28 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140400 CVCL_C927 BMD2-iPS1 induced pluripotent stem cell human CVCL_C927 From: Children's Hospital Boston; Boston; USA. CL:0000010 21140401 CVCL_BX27 GM25343 finite cell line human CVCL_BX27 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140402 CVCL_C920 67 [Human iPSC] induced pluripotent stem cell human CVCL_C920 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21140403 CVCL_BX20 GM24588 finite cell line human CVCL_BX20 CL:0000010 Sequence variation: Mutation; HGNC; 17997; FKRP; Simple; p.Leu276Ile (c.826C>A); ClinVar=VCV000004221; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17997; FKRP; Simple; p.Lys291Argfs*137 (c.872delA); Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21140404 CVCL_C919 66 [Human iPSC] induced pluripotent stem cell human CVCL_C919 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21140405 CVCL_BX19 GM24529 finite cell line human CVCL_BX19 CL:0000010 Sequence variation: Mutation; HGNC; 20278; NUBPL; Simple; p.Leu104Pro (c.311T>C); ClinVar=VCV000209179; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 20278; NUBPL; Simple; c.815-27T>C; ClinVar=VCV000050317; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140406 CVCL_C918 61 induced pluripotent stem cell human CVCL_C918 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21140407 CVCL_BX18 GM24356 transformed cell line human CVCL_BX18 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Lys4534del (c.13597AAG[1]) (c.13600_13602delAAG); ClinVar=VCV000590434; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140408 CVCL_BX33 GM25391 transformed cell line human CVCL_BX33 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg458Lysfs*14 (c.1370dupG); ClinVar=VCV000126422; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140409 CVCL_C933 RC2 100 3 Cr-1 induced pluripotent stem cell human CVCL_C933 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140410 CVCL_BX32 GM25390 transformed cell line human CVCL_BX32 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg458Lysfs*14 (c.1370dupG); ClinVar=VCV000126422; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140411 CVCL_C932 RC2 100 3 induced pluripotent stem cell human CVCL_C932 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140412 CVCL_BX35 ND01930 transformed cell line human CVCL_BX35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140413 CVCL_C935 RC2 102 37 Cr-1 induced pluripotent stem cell human CVCL_C935 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140414 CVCL_BX34 ND01928 transformed cell line human CVCL_BX34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140415 CVCL_C934 RC2 100 3 Cr-6 induced pluripotent stem cell human CVCL_C934 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140416 CVCL_BX37 ND00046 transformed cell line human CVCL_BX37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140417 CVCL_C937 RC2 103 43 Cr-1 induced pluripotent stem cell human CVCL_C937 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140418 CVCL_BX36 ND00045 transformed cell line human CVCL_BX36 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140419 CVCL_C936 RC2 102 37 Cr-3 induced pluripotent stem cell human CVCL_C936 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140420 CVCL_BX39 ND00050 transformed cell line human CVCL_BX39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140421 CVCL_C939 RC2 202 2 induced pluripotent stem cell human CVCL_C939 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140422 CVCL_BX38 ND00048 transformed cell line human CVCL_BX38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140423 CVCL_C938 RC2 103 43 Cr-3 induced pluripotent stem cell human CVCL_C938 From: Boston University School of Medicine; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20715179) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140424 CVCL_BX31 GM25389 transformed cell line human CVCL_BX31 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg458Lysfs*14 (c.1370dupG); ClinVar=VCV000126422; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140425 CVCL_C931 MPS-MSC-iPS 2 induced pluripotent stem cell human CVCL_C931 From: University of Minnesota; Twin Cities; USA CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Homozygous (PubMed=21037085) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 21140426 CVCL_BX30 GM25348 transformed cell line human CVCL_BX30 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140427 CVCL_C930 MPS-KC-iPS 2 induced pluripotent stem cell human CVCL_C930 From: University of Minnesota; Twin Cities; USA CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Homozygous (PubMed=21037085) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21140428 CVCL_BX29 GM25347 transformed cell line human CVCL_BX29 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140429 CVCL_C929 MPS-KC-iPS 1 induced pluripotent stem cell human CVCL_C929 From: University of Minnesota; Twin Cities; USA CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Tyr167Ter (c.501C>G); ClinVar=VCV000092644; Zygosity=Heterozygous (PubMed=21037085); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (PubMed=21037085) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21140430 CVCL_BX00 GM14889 transformed cell line human CVCL_BX00 CL:0000010 Sequence variation: Mutation; HGNC; 8896; PGK1; Simple; p.Asp164Val (c.491A>T) (D163V); ClinVar=VCV000009954; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140431 CVCL_C900 R1-hiPSC8 induced pluripotent stem cell human CVCL_C900 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140432 CVCL_BX02 GM23421 transformed cell line human CVCL_BX02 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg249Gln (c.746G>A); ClinVar=VCV000066931; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140433 CVCL_C902 RP1-hiPSC1 induced pluripotent stem cell human CVCL_C902 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140434 CVCL_BX01 GM23321 transformed cell line human CVCL_BX01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140435 CVCL_C901 R1-hiPSC9 induced pluripotent stem cell human CVCL_C901 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140436 CVCL_BX04 GM23650 finite cell line human CVCL_BX04 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg401Cys (c.1201C>T); ClinVar=VCV000133029; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Pro2488Hisfs*39 (c.7463_7475delCAAAGATGTCAGC); ClinVar=VCV000197559; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140437 CVCL_C904 RP1-hiPSC11 induced pluripotent stem cell human CVCL_C904 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140438 CVCL_BX03 GM23630 transformed cell line human CVCL_BX03 CL:0000010 Sequence variation: Mutation; HGNC; 17997; FKRP; Simple; p.Leu276Ile (c.826C>A); ClinVar=VCV000004221; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140439 CVCL_C903 RP1-hiPSC10 induced pluripotent stem cell human CVCL_C903 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140440 CVCL_BX06 GM23733 transformed cell line human CVCL_BX06 CL:0000010 Sequence variation: Gene amplification; HGNC; 6990; MECP2; Duplication; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21140441 CVCL_C906 RP1-hiPSC2 induced pluripotent stem cell human CVCL_C906 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140442 CVCL_BX05 GM23652 finite cell line human CVCL_BX05 CL:0000010 Sequence variation: Mutation; HGNC; 6511; LARGE1; Simple; p.Glu509Lys (c.1525G>A); ClinVar=VCV000006216; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6511; LARGE1; Unexplicit; Large deletion; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140443 CVCL_C905 RP1-hiPSC12 induced pluripotent stem cell human CVCL_C905 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140444 CVCL_BX11 GM23817 transformed cell line human CVCL_BX11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140445 CVCL_C911 RP1-hiPSC7 induced pluripotent stem cell human CVCL_C911 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140446 CVCL_BX10 GM23780 finite cell line human CVCL_BX10 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Leu35Pro (c.104T>C); ClinVar=VCV000066765; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140447 CVCL_C910 RP1-hiPSC6 induced pluripotent stem cell human CVCL_C910 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140448 CVCL_BX13 GM23868 finite cell line human CVCL_BX13 CL:0000010 Sequence variation: Mutation; HGNC; 17997; FKRP; Simple; p.Leu276Ile (c.826C>A); ClinVar=VCV000004221; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140449 CVCL_C913 RP1-hiPSC9 induced pluripotent stem cell human CVCL_C913 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140450 CVCL_BX12 GM23824 finite cell line human CVCL_BX12 CL:0000010 Sequence variation: Mutation; HGNC; 19743; POMT2; Simple; p.Phe221Ile (c.661T>A); ClinVar=VCV000807153; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140451 CVCL_C912 RP1-hiPSC8 induced pluripotent stem cell human CVCL_C912 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140452 CVCL_BX15 GM23926 transformed cell line human CVCL_BX15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140453 CVCL_C915 RP2-hiPSC2 induced pluripotent stem cell human CVCL_C915 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140454 CVCL_BX14 GM23917 transformed cell line human CVCL_BX14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140455 CVCL_C914 RP2-hiPSC1 induced pluripotent stem cell human CVCL_C914 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140456 CVCL_C917 60 induced pluripotent stem cell human CVCL_C917 From: Samuel Lunenfeld Research Institute; Toronto; Canada CL:0000010 Derived from sampling site: Cell type=Fibroblast. 21140457 CVCL_BX17 GM24213 transformed cell line human CVCL_BX17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140458 CVCL_BX16 GM24202 transformed cell line human CVCL_BX16 CL:0000010 Sequence variation: Mutation; HGNC; 19139; POMGNT1; Simple; c.1895+1G>T; ClinVar=VCV000056593; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140459 CVCL_C916 RP2-hiPSC3 induced pluripotent stem cell human CVCL_C916 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140460 CVCL_BX08 GM23773 transformed cell line human CVCL_BX08 CL:0000010 Population: Caucasian; British/French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140461 CVCL_C908 RP1-hiPSC4 induced pluripotent stem cell human CVCL_C908 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140462 CVCL_BX07 GM23734 transformed cell line human CVCL_BX07 CL:0000010 Sequence variation: Gene amplification; HGNC; 6990; MECP2; Duplication; Zygosity=Hemizygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21140463 CVCL_C907 RP1-hiPSC3 induced pluripotent stem cell human CVCL_C907 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140464 CVCL_BX09 GM23774 transformed cell line human CVCL_BX09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140465 CVCL_C909 RP1-hiPSC5 induced pluripotent stem cell human CVCL_C909 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21140466 CVCL_L259 GM12867 transformed cell line human CVCL_L259 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145904 21140467 CVCL_KQ59 PCRP-ZNF746-1B7 hybridoma house mouse CVCL_KQ59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6NUN9; Human ZNF746. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140468 CVCL_L258 GM12866 transformed cell line human CVCL_L258 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145903 21140469 CVCL_KQ58 PCRP-ZNF704-3C10 hybridoma house mouse CVCL_KQ58 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q6ZNC4; Human ZNF704. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140470 CVCL_L255 GM12809 transformed cell line human CVCL_L255 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145409 21140471 CVCL_KQ55 PCRP-ZNF7-1B10 hybridoma house mouse CVCL_KQ55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17097; Human ZNF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140472 CVCL_L254 GM12808 transformed cell line human CVCL_L254 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145408 21140473 CVCL_KQ54 PCRP-ZNF697-1A8 hybridoma house mouse CVCL_KQ54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5TEC3; Human ZNF697. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140474 CVCL_L257 GM12865 transformed cell line human CVCL_L257 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (Coriell). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145902 21140475 CVCL_KQ57 PCRP-ZNF701-1C5 hybridoma house mouse CVCL_KQ57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NV72; Human ZNF701. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140476 CVCL_L256 GM12864 transformed cell line human CVCL_L256 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145901 21140477 CVCL_KQ56 PCRP-ZNF7-1C12 hybridoma house mouse CVCL_KQ56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17097; Human ZNF7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140478 CVCL_L251 GM12805 transformed cell line human CVCL_L251 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145405 21140479 CVCL_KQ51 PCRP-ZNF692-1G6 hybridoma house mouse CVCL_KQ51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BU19; Human ZNF692. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140480 CVCL_L250 GM12804 transformed cell line human CVCL_L250 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145404 21140481 CVCL_KQ50 PCRP-ZNF692-1D2 hybridoma house mouse CVCL_KQ50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BU19; Human ZNF692. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140482 CVCL_L253 GM12807 transformed cell line human CVCL_L253 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145407 21140483 CVCL_TK01 HAP1 SAMHD1 (-) 2 cancer cell line human CVCL_TK01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15925; SAMHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140484 CVCL_KQ53 PCRP-ZNF696-1D7 hybridoma house mouse CVCL_KQ53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H7X3; Human ZNF696. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140485 CVCL_L252 GM12806 transformed cell line human CVCL_L252 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145406 21140486 CVCL_TK00 HAP1 SAMHD1 (-) 1 cancer cell line human CVCL_TK00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15925; SAMHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140487 CVCL_KQ52 PCRP-ZNF692-2B10 hybridoma house mouse CVCL_KQ52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BU19; Human ZNF692. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140488 CVCL_TK03 HAP1 SAT2 (-) 1 cancer cell line human CVCL_TK03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23160; SAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140489 CVCL_TK02 HAP1 SAMHD1 (-) 3 cancer cell line human CVCL_TK02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15925; SAMHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140490 CVCL_TK05 HAP1 SATB2 (-) cancer cell line human CVCL_TK05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21637; SATB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140491 CVCL_TK04 HAP1 SATB1 (-) 1 cancer cell line human CVCL_TK04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10541; SATB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140492 CVCL_L269 G401.6 cancer cell line human CVCL_L269 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Part of: ENCODE project common cell types; tier 3 Problematic cell line: Misclassified Parent cell line (G-401) was originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line. 21140493 CVCL_KQ69 PCRP-ZNF783-2A8 hybridoma house mouse CVCL_KQ69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6ZMS7; Human ZNF783. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140494 CVCL_L266 GM13976 transformed cell line human CVCL_L266 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM13977 (Cellosaurus=CVCL_L267); Derived from sampling site: Peripheral blood. Female Part of: ENCODE project common cell types; tier 3 21140495 CVCL_KQ66 PCRP-ZNF774-3F7 hybridoma house mouse CVCL_KQ66 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q6NX45; Human ZNF774. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140496 CVCL_L265 GM12877 transformed cell line human CVCL_L265 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146301 21140497 CVCL_KQ65 PCRP-ZNF772-2B2 hybridoma house mouse CVCL_KQ65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q68DY9; Human ZNF772. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140498 CVCL_L268 Mel-2183 cancer cell line human CVCL_L268 CL:0000010 Derived from metastatic site: Hypodermis. Male Part of: ENCODE project common cell types; tier 3 21140499 CVCL_KQ68 PCRP-ZNF783-1B8 hybridoma house mouse CVCL_KQ68 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6ZMS7; Human ZNF783. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140500 CVCL_L267 GM13977 transformed cell line human CVCL_L267 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM13976 (Cellosaurus=CVCL_L266); Derived from sampling site: Peripheral blood. Female Part of: ENCODE project common cell types; tier 3 21140501 CVCL_KQ67 PCRP-ZNF783-1A1 hybridoma house mouse CVCL_KQ67 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6ZMS7; Human ZNF783. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140502 CVCL_L262 GM12870 transformed cell line human CVCL_L262 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145907 21140503 CVCL_KQ62 PCRP-ZNF75A-1E5 hybridoma house mouse CVCL_KQ62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96N20; Human ZNF75A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140504 CVCL_L261 GM12869 transformed cell line human CVCL_L261 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145906 21140505 CVCL_KQ61 PCRP-ZNF75A-1B6 hybridoma house mouse CVCL_KQ61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96N20; Human ZNF75A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140506 CVCL_L264 GM12876 transformed cell line human CVCL_L264 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145913 21140507 CVCL_KQ64 PCRP-ZNF772-2B11 hybridoma house mouse CVCL_KQ64 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q68DY9; Human ZNF772. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140508 CVCL_L263 GM12871 transformed cell line human CVCL_L263 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145908 21140509 CVCL_KQ63 PCRP-ZNF770-1D7 hybridoma house mouse CVCL_KQ63 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6IQ21; Human ZNF770. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140510 CVCL_L260 GM12868 transformed cell line human CVCL_L260 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Registration: CEPH Families Reference Panel; 145905 21140511 CVCL_KQ60 PCRP-ZNF746-1D7 hybridoma house mouse CVCL_KQ60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6NUN9; Human ZNF746. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140512 CVCL_KQ37 PCRP-ZNF639-1F10 hybridoma house mouse CVCL_KQ37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UID6; Human ZNF639. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140513 CVCL_L237 POE9n finite cell line human CVCL_L237 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=12077343) Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Male Senescence: Senesces at ~85 PDL (PubMed=10648628) 21140514 CVCL_L236 OKT4 finite cell line human CVCL_L236 CL:0000010 Derived from sampling site: Oral cavity; tongue Cell type=Keratinocyte.. Unspecified 21140515 CVCL_KQ36 PCRP-ZNF639-1E7 hybridoma house mouse CVCL_KQ36 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UID6; Human ZNF639. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140516 CVCL_L239 OKB3 finite cell line human CVCL_L239 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Unspecified 21140517 CVCL_KQ39 PCRP-ZNF639-2B2 hybridoma house mouse CVCL_KQ39 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UID6; Human ZNF639. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140518 CVCL_KQ38 PCRP-ZNF639-1F2 hybridoma house mouse CVCL_KQ38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UID6; Human ZNF639. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140519 CVCL_L238 POE9n/TERT telomerase immortalized cell line human CVCL_L238 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140520 CVCL_L233 OKP7/bmi1/TERT telomerase immortalized cell line human CVCL_L233 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; soft palate Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140521 CVCL_KQ33 PCRP-ZNF622-1C11 hybridoma house mouse CVCL_KQ33 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q969S3; Human ZNF622. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140522 CVCL_L232 OKP7 finite cell line human CVCL_L232 CL:0000010 Derived from sampling site: Oral cavity; soft palate Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140523 CVCL_KQ32 PCRP-ZNF608-1A10 hybridoma house mouse CVCL_KQ32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ULD9; Human ZNF608. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140524 CVCL_L235 OKP8 finite cell line human CVCL_L235 CL:0000010 Derived from sampling site: Oral cavity; soft palate Cell type=Keratinocyte.. Unspecified 21140525 CVCL_KQ35 PCRP-ZNF639-1D3 hybridoma house mouse CVCL_KQ35 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UID6; Human ZNF639. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140526 CVCL_L234 OFP8 finite cell line human CVCL_L234 CL:0000010 Derived from sampling site: Oral cavity; soft palate Cell type=Fibroblast.. Unspecified 21140527 CVCL_KQ34 PCRP-ZNF623-2C3 hybridoma house mouse CVCL_KQ34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75123; Human ZNF623. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140528 CVCL_L231 OKG12 finite cell line human CVCL_L231 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Male 21140529 CVCL_KQ31 PCRP-ZNF598-1A12 hybridoma house mouse CVCL_KQ31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86UK7; Human ZNF598. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140530 CVCL_L230 OKHP1 finite cell line human CVCL_L230 CL:0000010 Derived from sampling site: Oral cavity; hard palate Cell type=Keratinocyte.. Unspecified 21140531 CVCL_KQ30 PCRP-ZNF597-1C4 hybridoma house mouse CVCL_KQ30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96LX8; Human ZNF597. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140532 CVCL_L248 GM12802 transformed cell line human CVCL_L248 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145402 21140533 CVCL_KQ48 PCRP-ZNF689-1A4 hybridoma house mouse CVCL_KQ48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96CS4; Human ZNF689. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140534 CVCL_L247 GM12801 transformed cell line human CVCL_L247 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 145401 21140535 CVCL_KQ47 PCRP-ZNF683-1E4 hybridoma house mouse CVCL_KQ47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IZ20; Human ZNF683. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140536 CVCL_L249 GM12803 transformed cell line human CVCL_L249 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145403 21140537 CVCL_KQ49 PCRP-ZNF69-1H1 hybridoma house mouse CVCL_KQ49 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UC07; Human ZNF69. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140538 CVCL_L244 AG10803 finite cell line human CVCL_L244 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Part of: ENCODE project common cell types; tier 3 21140539 CVCL_KQ44 PCRP-ZNF654-1G11 hybridoma house mouse CVCL_KQ44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IZM8; Human ZNF654. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140540 CVCL_L243 AG09319 finite cell line human CVCL_L243 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: ENCODE project common cell types; tier 3 21140541 CVCL_KQ43 PCRP-ZNF654-1E4 hybridoma house mouse CVCL_KQ43 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IZM8; Human ZNF654. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140542 CVCL_L246 GM10266 transformed cell line human CVCL_L246 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: ENCODE project common cell types; tier 3 21140543 CVCL_KQ46 PCRP-ZNF654-4C3 hybridoma house mouse CVCL_KQ46 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IZM8; Human ZNF654. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140544 CVCL_L245 GM10248 transformed cell line human CVCL_L245 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ENCODE project common cell types; tier 3 21140545 CVCL_KQ45 PCRP-ZNF654-2E6 hybridoma house mouse CVCL_KQ45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IZM8; Human ZNF654. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140546 CVCL_L240 OKB4 finite cell line human CVCL_L240 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Unspecified 21140547 CVCL_KQ40 PCRP-ZNF648-1B3 hybridoma house mouse CVCL_KQ40 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q5T619; Human ZNF648. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140548 CVCL_L242 AG09309 finite cell line human CVCL_L242 CL:0000010 Population: Caucasian; Derived from sampling site: Toe; skin Cell type=Fibroblast.. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis Female Part of: ENCODE project common cell types; tier 3 21140549 CVCL_KQ42 PCRP-ZNF654-1C7 hybridoma house mouse CVCL_KQ42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IZM8; Human ZNF654. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140550 CVCL_L241 GingF12 finite cell line human CVCL_L241 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Male 21140551 CVCL_KQ41 PCRP-ZNF648-1C5 hybridoma house mouse CVCL_KQ41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5T619; Human ZNF648. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140552 CVCL_BW89 NCE-G 123T2 cancer cell line human CVCL_BW89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line). Male 21140553 CVCL_C889 R1-hiPSC10 induced pluripotent stem cell human CVCL_C889 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140554 CVCL_BW88 NCE-G 55T2 cancer cell line human CVCL_BW88 CL:0000010 Derived from sampling site: Brain; right occipital-parietal region. Male 21140555 CVCL_C888 R1-hiPSC1 induced pluripotent stem cell human CVCL_C888 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Male 21140556 CVCL_C881 LHON1-hiPSC2 induced pluripotent stem cell human CVCL_C881 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 7462; MT-ND6; Simple; p.Met64Val (m.14484T>C); ClinVar=VCV000009688; Zygosity=Unspecified (PubMed=22145677) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140557 CVCL_BW81 MasterShef8 embryonic stem cell human CVCL_BW81 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to MasterShef5 (Cellosaurus=CVCL_BW78). Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-09. 21140558 CVCL_C880 LHON1-hiPSC1 induced pluripotent stem cell human CVCL_C880 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 7462; MT-ND6; Simple; p.Met64Val (m.14484T>C); ClinVar=VCV000009688; Zygosity=Unspecified (PubMed=22145677) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140559 CVCL_BW80 MasterShef7 embryonic stem cell human CVCL_BW80 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-08. 21140560 CVCL_C883 LHON1-hiPSC5 induced pluripotent stem cell human CVCL_C883 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 7462; MT-ND6; Simple; p.Met64Val (m.14484T>C); ClinVar=VCV000009688; Zygosity=Unspecified (PubMed=22145677) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140561 CVCL_BW83 MasterShef11 embryonic stem cell human CVCL_BW83 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC13-06. 21140562 CVCL_C882 LHON1-hiPSC4 induced pluripotent stem cell human CVCL_C882 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 7462; MT-ND6; Simple; p.Met64Val (m.14484T>C); ClinVar=VCV000009688; Zygosity=Unspecified (PubMed=22145677) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140563 CVCL_BW82 MasterShef10 embryonic stem cell human CVCL_BW82 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC13-05. 21140564 CVCL_BW85 MasterShef13 embryonic stem cell human CVCL_BW85 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC13-08. 21140565 CVCL_C885 N206 cancer cell line human CVCL_C885 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18923523) Omics: Transcriptome analysis by microarray. 21140566 CVCL_L219 OKB2 finite cell line human CVCL_L219 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Male 21140567 CVCL_KQ19 PCRP-ZNF562-1A1 hybridoma house mouse CVCL_KQ19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6V9R5; Human ZNF562. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140568 CVCL_C884 BAL-KHs cancer cell line human CVCL_C884 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 32 hours (PubMed=2709874); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21140569 CVCL_BW84 MasterShef12 embryonic stem cell human CVCL_BW84 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC13-07. 21140570 CVCL_L218 PaTuO2 cancer cell line human CVCL_L218 CL:0000010 Miscellaneous: Only mentioned as a pancreatic adenocarcinoma cell line in PubMed=20709028. Unspecified 21140571 CVCL_KQ18 PCRP-ZNF556-1G1 hybridoma house mouse CVCL_KQ18 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9HAH1; Human ZNF556. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140572 CVCL_BW87 LRB21 embryonic stem cell human CVCL_BW87 From: University Hospital of Copenhagen; Copenhagen; Denmark CL:0000010 Unspecified Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-25.. 21140573 CVCL_C887 PaCa 5072 cancer cell line human CVCL_C887 CL:0000010 Miscellaneous: Doubling time from personal communication of Gungor C Derived from sampling site: Pancreas. Female Doubling time: 56-60 hours (Direct_author_submission) 21140574 CVCL_BW86 MasterShef14 embryonic stem cell human CVCL_BW86 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-65. 21140575 CVCL_C886 PaCa 5061 cancer cell line human CVCL_C886 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20553613); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20553613) Derived from sampling site: Pancreas. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 30-48 hours (PubMed=20553613) 21140576 CVCL_KQ15 PCRP-ZNF550-1B4 hybridoma house mouse CVCL_KQ15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z398; Human ZNF550. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140577 CVCL_L215 SW1083 cancer cell line human CVCL_L215 From: Scott and White Clinic; Temple; USA CL:0000010 Male Doubling time: 142 hours, at 6th passage (PubMed=1000501). 21140578 CVCL_KQ14 PCRP-ZNF549-2A2 hybridoma house mouse CVCL_KQ14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6P9A3; Human ZNF549. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140579 CVCL_L214 SW802 cancer cell line human CVCL_L214 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Colon. Female Doubling time: 58 hours, at 19th passage (PubMed=1000501) 21140580 CVCL_KQ17 PCRP-ZNF556-1C3 hybridoma house mouse CVCL_KQ17 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HAH1; Human ZNF556. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140581 CVCL_L217 YP-MEL cancer cell line human CVCL_L217 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Male Doubling time: 41 hours (PubMed=7520166) 21140582 CVCL_KQ16 PCRP-ZNF554-1B3 hybridoma house mouse CVCL_KQ16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86TJ5; Human ZNF554. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140583 CVCL_L216 YLC-KK1 cancer cell line human CVCL_L216 CL:0000010 Unspecified 21140584 CVCL_L211 1-LN cancer cell line human CVCL_L211 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=8510267) Population: Caucasian; Derived from metastatic site: Bone. Male 21140585 CVCL_KQ11 PCRP-ZNF526-2A4 hybridoma house mouse CVCL_KQ11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TF50; Human ZNF526. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140586 CVCL_KQ10 PCRP-ZNF526-1H7 hybridoma house mouse CVCL_KQ10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TF50; Human ZNF526. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140587 CVCL_L210 PR371 cancer cell line human CVCL_L210 CL:0000010 21140588 CVCL_L213 NECS-P cancer cell line human CVCL_L213 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Male Doubling time: 32.8 +- 2.1 hours (PubMed=11070410) 21140589 CVCL_KQ13 PCRP-ZNF548-1E11 hybridoma house mouse CVCL_KQ13 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NEK5; Human ZNF548. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140590 CVCL_L212 NECS-L cancer cell line human CVCL_L212 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 28.9 +- 4.2 hours (PubMed=11070410) 21140591 CVCL_KQ12 PCRP-ZNF543-1A8 hybridoma house mouse CVCL_KQ12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08ER8; Human ZNF543. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140592 CVCL_BW99 GM03728 finite cell line human CVCL_BW99 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; AG03728; probable Male 21140593 CVCL_C899 R1-hiPSC7 induced pluripotent stem cell human CVCL_C899 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140594 CVCL_BW92 ES-R1 CAG-S-hERRalpha embryonic stem cell house mouse CVCL_BW92 CL:0000010 Transfected with: HGNC; 3471; ESRRA Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140595 CVCL_C892 R1-hiPSC14 induced pluripotent stem cell human CVCL_C892 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140596 CVCL_BW91 ES-R1 CAG-S-hERalpha embryonic stem cell house mouse CVCL_BW91 CL:0000010 Transfected with: HGNC; 3467; ESR1 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140597 CVCL_C891 R1-hiPSC13 induced pluripotent stem cell human CVCL_C891 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140598 CVCL_BW94 ES-R1 CAG-S-hRXRalpha embryonic stem cell house mouse CVCL_BW94 CL:0000010 Transfected with: HGNC; 10477; RXRA Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140599 CVCL_C894 R1-hiPSC2 induced pluripotent stem cell human CVCL_C894 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140600 CVCL_BW93 ES-R1 CAG-S-hPPARgamma2 embryonic stem cell house mouse CVCL_BW93 CL:0000010 Transfected with: HGNC; 9236; PPARG Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140601 CVCL_C893 R1-hiPSC15 induced pluripotent stem cell human CVCL_C893 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140602 CVCL_BW96 ES-R1 CAG-S-hSRC-2 embryonic stem cell house mouse CVCL_BW96 CL:0000010 Transfected with: HGNC; 7669; NCOA2 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140603 CVCL_C896 R1-hiPSC4 induced pluripotent stem cell human CVCL_C896 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Male 21140604 CVCL_BW95 ES-R1 CAG-S-hSRC-1 embryonic stem cell house mouse CVCL_BW95 CL:0000010 Transfected with: HGNC; 7668; NCOA1 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140605 CVCL_L229 OKG4 finite cell line human CVCL_L229 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Unspecified 21140606 CVCL_KQ29 PCRP-ZNF597-1C12 hybridoma house mouse CVCL_KQ29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96LX8; Human ZNF597. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140607 CVCL_C895 R1-hiPSC3 induced pluripotent stem cell human CVCL_C895 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140608 CVCL_BW98 GM00743 finite cell line human CVCL_BW98 CL:0000010 Sequence variation: Mutation; HGNC; 8896; PGK1; Simple; p.Leu88Pro (c.263T>C); ClinVar=VCV000009946; Zygosity=Hemizygous; Note=PGK-Matsue (PubMed=2001457) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Male 21140609 CVCL_C898 R1-hiPSC6 induced pluripotent stem cell human CVCL_C898 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140610 CVCL_BW97 ES-R1 CAG-S-mPPARalpha embryonic stem cell house mouse CVCL_BW97 CL:0000010 Transfected with: MGI; MGI:104740; Ppara Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140611 CVCL_C897 R1-hiPSC5 induced pluripotent stem cell human CVCL_C897 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140612 CVCL_L226 OKF4/E6E7 transformed cell line human CVCL_L226 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140613 CVCL_KQ26 PCRP-ZNF584-1E10 hybridoma house mouse CVCL_KQ26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IVC4; Human ZNF584. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140614 CVCL_L225 OKF6/TERT-2 telomerase immortalized cell line human CVCL_L225 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140615 CVCL_KQ25 PCRP-ZNF583-1E5 hybridoma house mouse CVCL_KQ25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96ND8; Human ZNF583. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140616 CVCL_L228 OKB8 finite cell line human CVCL_L228 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Male 21140617 CVCL_KQ28 PCRP-ZNF585B-1D8 hybridoma house mouse CVCL_KQ28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q52M93; Human ZNF585B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140618 CVCL_L227 OKF4/TERT-1 telomerase immortalized cell line human CVCL_L227 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140619 CVCL_KQ27 PCRP-ZNF585B-1D2 hybridoma house mouse CVCL_KQ27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q52M93; Human ZNF585B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140620 CVCL_L222 OKF6 finite cell line human CVCL_L222 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Male Senescence: Senesces at ~45 PDL (PubMed=10648628) 21140621 CVCL_KQ22 PCRP-ZNF574-1G10 hybridoma house mouse CVCL_KQ22 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6ZN55; Human ZNF574. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140622 CVCL_L221 OKP4 finite cell line human CVCL_L221 CL:0000010 Derived from sampling site: Oral cavity; hard palate Cell type=Keratinocyte.. Male 21140623 CVCL_KQ21 PCRP-ZNF570-1B3 hybridoma house mouse CVCL_KQ21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96NI8; Human ZNF570. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140624 CVCL_BW90 ES-R1 CAG-S-hCOUP-TFI embryonic stem cell house mouse CVCL_BW90 CL:0000010 Transfected with: HGNC; 7975; NR2F1 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: The transfected construct consist of a ubiquitous CAGGS (hybrid chicken beta actin and cytomegalovirus) promoter, a loxP-STOP-loxP (LSL) cassette and the Myc-FLAG-tagged NR/CoR cDNA followed by a polyadenylation signal The contruct is silent and the transfected gene can be conditionally overexpressed after cre recombinase mediated activation. 21140625 CVCL_L224 OKF6/TERT-1 telomerase immortalized cell line human CVCL_L224 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Male 21140626 CVCL_KQ24 PCRP-ZNF581-1A12 hybridoma house mouse CVCL_KQ24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P0T4; Human ZNF581. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140627 CVCL_C890 R1-hiPSC11 induced pluripotent stem cell human CVCL_C890 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140628 CVCL_L223 OKF6/E6E7 transformed cell line human CVCL_L223 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21140629 CVCL_KQ23 PCRP-ZNF574-2A9 hybridoma house mouse CVCL_KQ23 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6ZN55; Human ZNF574. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140630 CVCL_L220 OKF4 finite cell line human CVCL_L220 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth Cell type=Keratinocyte.. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male Senescence: Senesces at ~32-37 PDL (PubMed=10648628; PubMed=12077343) 21140631 CVCL_KQ20 PCRP-ZNF562-1B12 hybridoma house mouse CVCL_KQ20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6V9R5; Human ZNF562. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140632 CVCL_C867 ASTC-a-1 cancer cell line human CVCL_C867 From: Department of Medicine; Jinan University; China CL:0000010 Population: Chinese. 21140633 CVCL_BW67 GM13265 finite cell line human CVCL_BW67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21140634 CVCL_BW66 GM13264 finite cell line human CVCL_BW66 CL:0000010 Sequence variation: Mutation; HGNC; 5213; HSD17B4; Simple; p.Lys142Valfs*23 (c.423_424delGA) (c.422_423delAG); ClinVar=VCV000007659; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21140635 CVCL_C866 HFF2/T telomerase immortalized cell line human CVCL_C866 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140636 CVCL_C869 HeLa/DDP cancer cell line human CVCL_C869 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000056) It was the sole source of information for this entry. Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140637 CVCL_BW69 Man-15 embryonic stem cell human CVCL_BW69 From: University of Manchester; Manchester; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-24.. 21140638 CVCL_C868 HHY41 spontaneously immortalized cell line human CVCL_C868 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Male Doubling time: 39 hours (at high density), 34 hours (at low density) (PubMed=7493648) 21140639 CVCL_BW68 Man-14 embryonic stem cell human CVCL_BW68 From: University of Manchester; Manchester; United Kingdom CL:0000010 Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-23.. 21140640 CVCL_C861 MUNIe001-A embryonic stem cell human CVCL_C861 From: Masaryk University; Brno; Czech Republic CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21140641 CVCL_BW61 X25-9 transformed cell line human CVCL_BW61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. 21140642 CVCL_C860 MUNIe007-A embryonic stem cell human CVCL_C860 From: Masaryk University; Brno; Czech Republic CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21140643 CVCL_BW60 X25-6 transformed cell line human CVCL_BW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. 21140644 CVCL_BW63 GM12601 finite cell line human CVCL_BW63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21140645 CVCL_C863 MUNIe003-A embryonic stem cell human CVCL_C863 From: Masaryk University; Brno; Czech Republic CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21140646 CVCL_C862 MUNIe002-A embryonic stem cell human CVCL_C862 From: Masaryk University; Brno; Czech Republic CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-14.. 21140647 CVCL_BW62 R-1-TC cancer cell line Norway rat CVCL_BW62 CL:0000010 Breed/subspecies: ACI/N. Male 21140648 CVCL_BW65 GM13263 finite cell line human CVCL_BW65 CL:0000010 Sequence variation: Mutation; HGNC; 5213; HSD17B4; Simple; p.Lys142Valfs*23 (c.423_424delGA) (c.422_423delAG); ClinVar=VCV000007659; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140649 CVCL_C865 v6.5 embryonic stem cell house mouse CVCL_C865 CL:0000010 Breed/subspecies: C57BL/6 x 129S4/SvJae. Omics: Transcriptome analysis by microarray Male 21140650 CVCL_C864 CL01 embryonic stem cell human CVCL_C864 From: Universite Paris-Sud 11; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE06-024-L1. 21140651 CVCL_BW64 GM13262 finite cell line human CVCL_BW64 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21140652 CVCL_C878 iPS-SMA-3.6 induced pluripotent stem cell human CVCL_C878 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=19098894) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male Problematic cell line: Misclassified Parent cell line originally thought to be a SMA type 1 (SMA1) cell line but shown to be from a SMA type 2 (SMA2). 21140653 CVCL_BW78 MasterShef5 embryonic stem cell human CVCL_BW78 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to MasterShef8 (Cellosaurus=CVCL_BW81). Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-06. 21140654 CVCL_C877 iPS-SMA-3.5 induced pluripotent stem cell human CVCL_C877 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=19098894) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Problematic cell line: Misclassified Parent cell line originally thought to be a SMA type 1 (SMA1) cell line but shown to be from a SMA type 2 (SMA2). 21140655 CVCL_BW77 MasterShef4 embryonic stem cell human CVCL_BW77 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-05. 21140656 CVCL_C879 iPS-WT 4.2 induced pluripotent stem cell human CVCL_C879 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM23241; probable Female 21140657 CVCL_BW79 MasterShef6 embryonic stem cell human CVCL_BW79 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-07.. 21140658 CVCL_C870 GSD1-hiPSC1 induced pluripotent stem cell human CVCL_C870 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140659 CVCL_BW70 Man-16 embryonic stem cell human CVCL_BW70 From: University of Manchester; Manchester; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-25.. 21140660 CVCL_C872 GSD1-hiPSC3 induced pluripotent stem cell human CVCL_C872 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140661 CVCL_BW72 Shef3.2 embryonic stem cell human CVCL_BW72 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-34. 21140662 CVCL_C871 GSD1-hiPSC2 induced pluripotent stem cell human CVCL_C871 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140663 CVCL_BW71 NCL14 embryonic stem cell human CVCL_BW71 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Unspecified Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); R-11-071, Steering comm appl. SCSC11-01/SCSC11-25.. 21140664 CVCL_C874 GSD1-hiPSC6 induced pluripotent stem cell human CVCL_C874 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140665 CVCL_BW74 MasterShef1 embryonic stem cell human CVCL_BW74 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-02.. 21140666 CVCL_KQ08 PCRP-ZNF524-2B4 hybridoma house mouse CVCL_KQ08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96C55; Human ZNF524. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140667 CVCL_L208 PLT-2 cancer cell line human CVCL_L208 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21140668 CVCL_L207 ECC18 cancer cell line human CVCL_L207 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 57 hours (PubMed=8392984) 21140669 CVCL_C873 GSD1-hiPSC5 induced pluripotent stem cell human CVCL_C873 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140670 CVCL_KQ07 PCRP-ZNF521-1A3 hybridoma house mouse CVCL_KQ07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96K83; Human ZNF521. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140671 CVCL_BW73 Shef6.1 embryonic stem cell human CVCL_BW73 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-35. 21140672 CVCL_C876 IPS-S induced pluripotent stem cell human CVCL_C876 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21140673 CVCL_BW76 MasterShef3 embryonic stem cell human CVCL_BW76 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-04. 21140674 CVCL_L209 A7573/HL-23V spontaneously immortalized cell line dog CVCL_L209 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Female 21140675 CVCL_C875 GSD1-hiPSC7 induced pluripotent stem cell human CVCL_C875 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 4061; SLC37A4; Simple; c.1124-2A>G; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21140676 CVCL_BW75 MasterShef2 embryonic stem cell human CVCL_BW75 From: University of Sheffield; Sheffield; United Kingdom CL:0000010 Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-03. 21140677 CVCL_KQ09 PCRP-ZNF526-1E5 hybridoma house mouse CVCL_KQ09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TF50; Human ZNF526. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140678 CVCL_KQ04 PCRP-ZNF496-1C1 hybridoma house mouse CVCL_KQ04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96IT1; Human ZNF496. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140679 CVCL_L204 RC-15 embryonic stem cell human CVCL_L204 HLA typing: A*01,02; B*08,56; C*01,07; DQB1*02,03; DRB1*03,04; DRB3*01; DRB4*01 (PubMed=27346200). From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-36. 21140680 CVCL_KQ03 PCRP-ZNF488-1B6 hybridoma house mouse CVCL_KQ03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96MN9; Human ZNF488. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140681 CVCL_L203 RC-14 embryonic stem cell human CVCL_L203 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-35.. 21140682 CVCL_KQ06 PCRP-ZNF503-AS2-1B7 hybridoma house mouse CVCL_KQ06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A6NEH8; Human ZNF503-AS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140683 CVCL_L206 RC-17 embryonic stem cell human CVCL_L206 HLA typing: A*01,03; B*07,08; C*07; DQB1*02,03; DRB1*03,11; DRB3*01 (PubMed=27558596) From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-38. 21140684 CVCL_KQ05 PCRP-ZNF496-1C5 hybridoma house mouse CVCL_KQ05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96IT1; Human ZNF496. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140685 CVCL_L205 RC-16 embryonic stem cell human CVCL_L205 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Female Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-37.. 21140686 CVCL_L200 Man-12 embryonic stem cell human CVCL_L200 From: University of Manchester; Manchester; United Kingdom CL:0000010 Donor information: Embryo is sibling to that giving rise to Man-11 (Cellosaurus=CVCL_L199). Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-27. 21140687 CVCL_KQ00 PCRP-ZNF483-1C11 hybridoma house mouse CVCL_KQ00 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TF39; Human ZNF483. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140688 CVCL_KQ02 PCRP-ZNF488-1A6 hybridoma house mouse CVCL_KQ02 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96MN9; Human ZNF488. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140689 CVCL_L202 RC-13 embryonic stem cell human CVCL_L202 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-04.. 21140690 CVCL_L201 Man-13 embryonic stem cell human CVCL_L201 From: University of Manchester; Manchester; United Kingdom CL:0000010 Male Group: Clinical grade hESC cell line; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-28.. 21140691 CVCL_KQ01 PCRP-ZNF485-1G1 hybridoma house mouse CVCL_KQ01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NCK3; Human ZNF485. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140692 CVCL_1E31 H-15 cancer cell line human CVCL_1E31 CL:0000010 Female 21140693 CVCL_1E30 SW1007 cancer cell line human CVCL_1E30 From: Scott and White Clinic; Temple; USA. CL:0000010 Male 21140694 CVCL_1E33 H-825 cancer cell line human CVCL_1E33 CL:0000010 Derived from metastatic site: Lung. Male 21140695 CVCL_1E32 H-22 cancer cell line human CVCL_1E32 CL:0000010 Male 21140696 CVCL_1E35 LeCa 26.5 cancer cell line human CVCL_1E35 CL:0000010 Male 21140697 CVCL_1E34 LeCa 19.4 cancer cell line human CVCL_1E34 CL:0000010 Male Characteristics: Highly pigmented Doubling time: 38 hours (PubMed=1127734). 21140698 CVCL_1E37 DBS-FRhL-1 finite cell line CVCL_1E37 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21140699 CVCL_1E36 FRhL-4 finite cell line CVCL_1E36 CL:0000010 Derived from sampling site: Fetal lung. Female Group: Non-human primate cell line 21140700 CVCL_1E39 BO #2 cancer cell line human CVCL_1E39 CL:0000010 Derived from metastatic site: Inguinal lymph node. Male Doubling time: 58 hours (at 5th passage), 72 hours (at 62th passage) (PubMed=994214) 21140701 CVCL_1E38 Led-130 finite cell line human CVCL_1E38 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified Senescence: Senesces at 50 PDL (PubMed=14207842) 21140702 CVCL_TK81 HAP1 SETX (-) 2 cancer cell line human CVCL_TK81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 445; SETX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140703 CVCL_TK80 HAP1 SETX (-) 1 cancer cell line human CVCL_TK80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 445; SETX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140704 CVCL_TK83 HAP1 SFXN3 (-) 1 cancer cell line human CVCL_TK83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16087; SFXN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140705 CVCL_TK82 HAP1 SFR1 (-) 1 cancer cell line human CVCL_TK82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29574; SFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140706 CVCL_TK85 HAP1 SGK1 (-) 2 cancer cell line human CVCL_TK85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10810; SGK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140707 CVCL_TK84 HAP1 SGK1 (-) 1 cancer cell line human CVCL_TK84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10810; SGK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140708 CVCL_TK87 HAP1 SGK223 (-) 1 cancer cell line human CVCL_TK87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25438; PRAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140709 CVCL_TK86 HAP1 SGK1 (-) 3 cancer cell line human CVCL_TK86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10810; SGK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140710 CVCL_TK89 HAP1 SGK223 (-) 3 cancer cell line human CVCL_TK89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25438; PRAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140711 CVCL_TK88 HAP1 SGK223 (-) 2 cancer cell line human CVCL_TK88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25438; PRAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140712 CVCL_1E40 CA #12 cancer cell line human CVCL_1E40 CL:0000010 Derived from metastatic site: Cervical lymph node. Male Doubling time: 17 hours, at 18th passage (PubMed=994214) 21140713 CVCL_1E42 HO #1 cancer cell line human CVCL_1E42 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female 21140714 CVCL_1E41 SK-OS-3B cancer cell line human CVCL_1E41 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21140715 CVCL_1E44 PA #2 cancer cell line human CVCL_1E44 CL:0000010 Derived from metastatic site: Colon. Male Doubling time: 106 hours, at 5th passage (PubMed=994214) 21140716 CVCL_1E43 MI #1 cancer cell line human CVCL_1E43 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female Doubling time: 48 hours, at 46th passage (PubMed=994214) 21140717 CVCL_1E46 Calu-2 cancer cell line human CVCL_1E46 CL:0000010 Male 21140718 CVCL_1E45 Sh #1 cancer cell line human CVCL_1E45 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 30 hours (at 41th passage), 31 hours (at 142th passage) (PubMed=994214) 21140719 CVCL_1E48 SK-SC-1 cancer cell line human CVCL_1E48 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Pleural effusion. Male 21140720 CVCL_1E47 SK-OS-10 cancer cell line human CVCL_1E47 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; HTB-90; true Male 21140721 CVCL_1E49 Nemo-1 cancer cell line human CVCL_1E49 CL:0000010 Unspecified 21140722 CVCL_TK70 HAP1 SETD8 (-) 1 cancer cell line human CVCL_TK70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29489; KMT5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140723 CVCL_TK72 HAP1 SETD9 (-) 2 cancer cell line human CVCL_TK72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28508; SETD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140724 CVCL_TK71 HAP1 SETD9 (-) 1 cancer cell line human CVCL_TK71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28508; SETD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140725 CVCL_TK74 HAP1 SETDB1 (-) 2 cancer cell line human CVCL_TK74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10761; SETDB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140726 CVCL_TK73 HAP1 SETDB1 (-) 1 cancer cell line human CVCL_TK73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10761; SETDB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140727 CVCL_TK76 HAP1 SETDB2 (-) 2 cancer cell line human CVCL_TK76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20263; SETDB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140728 CVCL_TK75 HAP1 SETDB2 (-) 1 cancer cell line human CVCL_TK75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20263; SETDB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140729 CVCL_TK78 HAP1 SETMAR (-) 1 cancer cell line human CVCL_TK78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10762; SETMAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140730 CVCL_TK77 HAP1 SETDB2 (-) 3 cancer cell line human CVCL_TK77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20263; SETDB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140731 CVCL_TK79 HAP1 SETMAR (-) 2 cancer cell line human CVCL_TK79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10762; SETMAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140732 CVCL_1E11 3T3.T4 transformed cell line house mouse CVCL_1E11 CL:0000010 Transfected with: HGNC; 1678; CD4 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140733 CVCL_1E10 GHOST(3).X4/R5 cancer cell line human CVCL_1E10 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140734 CVCL_1E13 3T3.T4.Bonzo transformed cell line house mouse CVCL_1E13 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 16647; CXCR6 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140735 CVCL_1E12 3T3.T4.BOB transformed cell line house mouse CVCL_1E12 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 4469; GPR15 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140736 CVCL_1E15 3T3.T4.CCR5 transformed cell line house mouse CVCL_1E15 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 1678; CD4 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140737 CVCL_1E14 3T3.T4.CCR3 transformed cell line house mouse CVCL_1E14 CL:0000010 Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 1678; CD4 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140738 CVCL_1E17 GHOST(3).Hi-5 cancer cell line human CVCL_1E17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140739 CVCL_1E16 3T3.T4.CXCR4 transformed cell line house mouse CVCL_1E16 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 2561; CXCR4 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21140740 CVCL_1E19 TZM-bl/FcgammaRIIa cancer cell line human CVCL_1E19 CL:0000010 Transfected with: HGNC; 3616; FCGR2A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140741 CVCL_1E18 TZM-bl/FcgammaRI cancer cell line human CVCL_1E18 CL:0000010 Transfected with: HGNC; 3613; FCGR1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140742 CVCL_1E09 GHOST(3).V28/CX3CR1 cancer cell line human CVCL_1E09 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 2558; CX3CR1 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140743 CVCL_TK61 HAP1 SENP5 (-) cancer cell line human CVCL_TK61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28407; SENP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140744 CVCL_TK60 HAP1 SENP3 (-) 2 cancer cell line human CVCL_TK60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17862; SENP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140745 CVCL_TK63 HAP1 SEPT6 (-) 2 cancer cell line human CVCL_TK63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15848; SEPTIN6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140746 CVCL_TK62 HAP1 SEPT6 (-) 1 cancer cell line human CVCL_TK62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15848; SEPTIN6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140747 CVCL_TK65 HAP1 SERPINF1 (-) 1 cancer cell line human CVCL_TK65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8824; SERPINF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140748 CVCL_TK64 HAP1 SEPT6 (-) 3 cancer cell line human CVCL_TK64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15848; SEPTIN6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140749 CVCL_TK67 HAP1 SETD2 (-) 1 cancer cell line human CVCL_TK67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140750 CVCL_TK66 HAP1 SERPINH1 (-) 1 cancer cell line human CVCL_TK66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1546; SERPINH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140751 CVCL_TK69 HAP1 SETD4 (-) 1 cancer cell line human CVCL_TK69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1258; SETD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140752 CVCL_TK68 HAP1 SETD2 (-) 2 cancer cell line human CVCL_TK68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140753 CVCL_1E20 TZM-bl/FcgammaRIIb cancer cell line human CVCL_1E20 CL:0000010 Transfected with: HGNC; 3618; FCGR2B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140754 CVCL_1E22 ADJ/PC6 cancer cell line house mouse CVCL_1E22 CL:0000010 Breed/subspecies: BALB/c. 21140755 CVCL_1E21 TZM-bl/FcgammaRIIIa cancer cell line human CVCL_1E21 CL:0000010 Transfected with: HGNC; 3619; FCGR3A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140756 CVCL_1E24 SW690 cancer cell line human CVCL_1E24 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from metastatic site: Brain. Male Doubling time: 34 hours, at 11th passage (PubMed=994214) 21140757 CVCL_1E23 SK-MEL-16 cancer cell line human CVCL_1E23 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21140758 CVCL_1E26 CGFR-BO-2 spontaneously immortalized cell line CVCL_1E26 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Holstein. Unspecified 21140759 CVCL_1E25 CGFR-BO-1 spontaneously immortalized cell line CVCL_1E25 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Holstein. Unspecified 21140760 CVCL_1E28 RPMI-5959 cancer cell line human CVCL_1E28 CL:0000010 Female 21140761 CVCL_1E27 C-33 B cancer cell line human CVCL_1E27 CL:0000010 Discontinued: ATCC; CRL-7716; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21140762 CVCL_1E29 SW1016 cancer cell line human CVCL_1E29 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21140763 CVCL_TK50 HAP1 SECISBP2L (-) 1 cancer cell line human CVCL_TK50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28997; SECISBP2L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140764 CVCL_TK52 HAP1 SELK (-) 1 cancer cell line human CVCL_TK52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30394; SELENOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140765 CVCL_TK51 HAP1 SECISBP2L (-) 2 cancer cell line human CVCL_TK51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28997; SECISBP2L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140766 CVCL_TK54 HAP1 SELK (-) 3 cancer cell line human CVCL_TK54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30394; SELENOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140767 CVCL_TK53 HAP1 SELK (-) 2 cancer cell line human CVCL_TK53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30394; SELENOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140768 CVCL_TK56 HAP1 SENP1 (-) cancer cell line human CVCL_TK56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17927; SENP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140769 CVCL_TK55 HAP1 SEMA7A (-) cancer cell line human CVCL_TK55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10741; SEMA7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140770 CVCL_TK58 HAP1 SENP2 (-) 2 cancer cell line human CVCL_TK58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23116; SENP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140771 CVCL_TK57 HAP1 SENP2 (-) 1 cancer cell line human CVCL_TK57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23116; SENP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140772 CVCL_TK59 HAP1 SENP3 (-) 1 cancer cell line human CVCL_TK59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17862; SENP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140773 CVCL_TK39 HAP1 SEC23B (-) 2 cancer cell line human CVCL_TK39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10702; SEC23B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140774 CVCL_KQ99 PCRP-ZSCAN22-1A12 hybridoma house mouse CVCL_KQ99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10073; Human ZSCAN22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140775 CVCL_L299 UM-SCC-79 cancer cell line human CVCL_L299 CL:0000010 Male 21140776 CVCL_L298 P-STS cancer cell line human CVCL_L298 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=29444910) Derived from sampling site: Small intestine; ileum. Omics: Array-based CGH; Omics: SNP array analysis Male Doubling time: ~4 days (PubMed=19528452); ~1 week (PubMed=28465562) 21140777 CVCL_KQ98 PCRP-ZSCAN21-1B2 hybridoma house mouse CVCL_KQ98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y5A6; Human ZSCAN21. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140778 CVCL_TK41 HAP1 SEC23IP (-) 1 cancer cell line human CVCL_TK41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17018; SEC23IP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140779 CVCL_TK40 HAP1 SEC23B (-) 3 cancer cell line human CVCL_TK40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10702; SEC23B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140780 CVCL_TK43 HAP1 SEC24A (-) 1 cancer cell line human CVCL_TK43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10703; SEC24A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140781 CVCL_L295 KRJ-II cancer cell line human CVCL_L295 CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Caution: The KRJ-I cell line established from the primary tumor of the same patient as KRJ-II was shown to be misidentified and to be an EBV-transformed lymphoblastoid cell line As KRJ-II does not seem to have ever been distributed its status is uncertain. 21140782 CVCL_KQ95 PCRP-ZSCAN2-2G2 hybridoma house mouse CVCL_KQ95 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140783 CVCL_L294 CNDT2.5 cancer cell line human CVCL_L294 CL:0000010 Omics: Transcriptome analysis by microarray. Female Problematic cell line: Possibly misidentified: Not certain if this a midgut carcinoid cell line (PubMed=20959409) 21140784 CVCL_TK42 HAP1 SEC23IP (-) 2 cancer cell line human CVCL_TK42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17018; SEC23IP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140785 CVCL_KQ94 PCRP-ZSCAN2-2D7 hybridoma house mouse CVCL_KQ94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140786 CVCL_TK45 HAP1 SEC24B (-) 1 cancer cell line human CVCL_TK45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10704; SEC24B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140787 CVCL_L297 L-STS transformed cell line human CVCL_L297 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Omics: SNP array analysis Male Doubling time: ~2 days (PubMed=19528452) Problematic cell line: Misclassified Originally thought to arise from a metastatic carcinoid of the terminal ileum but shown to be an EBV-transformed lymphoblastoid cell line (PubMed=29444910; PubMed=31548718). 21140788 CVCL_KQ97 PCRP-ZSCAN2-4B5 hybridoma house mouse CVCL_KQ97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140789 CVCL_L296 H-STS transformed cell line human CVCL_L296 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Liver. Omics: SNP array analysis Male Doubling time: ~3 days (PubMed=19528452) Problematic cell line: Misclassified Originally thought to arise from a metastatic carcinoid of the terminal ileum but shown to be an EBV-transformed lymphoblastoid cell line (PubMed=29444910; PubMed=31548718). Although misidentified, it has been argued that transcriptional regulation of the cells enough resemble gastroenteropancreatic neuroendocrine tumors to be used in studies (PubMed=31548719). 21140790 CVCL_TK44 HAP1 SEC24A (-) 2 cancer cell line human CVCL_TK44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10703; SEC24A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140791 CVCL_KQ96 PCRP-ZSCAN2-3A12 hybridoma house mouse CVCL_KQ96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140792 CVCL_L291 B16 melanoma/lacZ cancer cell line house mouse CVCL_L291 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21140793 CVCL_TK47 HAP1 SEC24C (-) cancer cell line human CVCL_TK47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10705; SEC24C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140794 CVCL_KQ91 PCRP-ZSCAN12-2F2 hybridoma house mouse CVCL_KQ91 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; O43309; Human ZSCAN12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140795 CVCL_L290 CCC-Ca761-03 cancer cell line house mouse CVCL_L290 CL:0000010 Breed/subspecies: 615. Female 21140796 CVCL_TK46 HAP1 SEC24B (-) 2 cancer cell line human CVCL_TK46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10704; SEC24B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140797 CVCL_KQ90 PCRP-ZSCAN12-2D1 hybridoma house mouse CVCL_KQ90 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43309; Human ZSCAN12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140798 CVCL_L293 CNDT2 cancer cell line human CVCL_L293 CL:0000010 Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00384. Problematic cell line: Possibly misidentified: Not certain if this a midgut carcinoid cell line (PubMed=20959409) 21140799 CVCL_TK49 HAP1 SECISBP2 (-) cancer cell line human CVCL_TK49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30972; SECISBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140800 CVCL_KQ93 PCRP-ZSCAN2-1G6 hybridoma house mouse CVCL_KQ93 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140801 CVCL_L292 B16F10/mGM cancer cell line house mouse CVCL_L292 CL:0000010 Transfected with: MGI; MGI:1339752; Csf2 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: 17.9 hours (PubMed=23890195) 21140802 CVCL_TK48 HAP1 SEC24D (-) cancer cell line human CVCL_TK48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10706; SEC24D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140803 CVCL_KQ92 PCRP-ZSCAN2-1F8 hybridoma house mouse CVCL_KQ92 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q7Z7L9; Human ZSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140804 CVCL_TK29 HAP1 SDCBP (-) 1 cancer cell line human CVCL_TK29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10662; SDCBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140805 CVCL_TK28 HAP1 SDC2 (-) 4 cancer cell line human CVCL_TK28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10659; SDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140806 CVCL_1E00 HOS-CD4-pBABE-puro cancer cell line human CVCL_1E00 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140807 CVCL_1E02 JLTRG-R5 cancer cell line human CVCL_1E02 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Reporter cell line that expresses eGFP as a direct and quantitative marker of HIV-1 infection The expression of eGFP is under the control of a HIV-1 LTR. Doubling time: 24-48 hours (HIVReagentProgram) 21140808 CVCL_1E01 JLTRG cancer cell line human CVCL_1E01 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Reporter cell line that expresses eGFP as a direct and quantitative marker of HIV-1 infection The expression of eGFP is under the control of a HIV-1 LTR. Doubling time: 24-48 hours (HIVReagentProgram) 21140809 CVCL_1E04 Rev-CEM cancer cell line human CVCL_1E04 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Transfected with a pNL-GFP-RRE(SA) construct that results in the expression of the GFP gene under the control of the HIV-1 LTR promoter in HIV-1 infected cells when Tat and Rev are present 21140810 CVCL_1E03 BC7 cancer cell line human CVCL_1E03 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: CD4 negative 21140811 CVCL_1E06 GHOST(3).CCR1 cancer cell line human CVCL_1E06 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1602; CCR1 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140812 CVCL_1E05 GHOST(3).BOB/GPR15 cancer cell line human CVCL_1E05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 4469; GPR15 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140813 CVCL_1E08 GHOST(3).R3/X4/R5 cancer cell line human CVCL_1E08 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140814 CVCL_1E07 GHOST(3).CCR2b cancer cell line human CVCL_1E07 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1603; CCR2 (isoform B) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21140815 CVCL_TK30 HAP1 SDR39U1 (-) cancer cell line human CVCL_TK30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20275; SDR39U1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140816 CVCL_TK32 HAP1 SEC22A (-) 2 cancer cell line human CVCL_TK32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20260; SEC22A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140817 CVCL_TK31 HAP1 SEC22A (-) 1 cancer cell line human CVCL_TK31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20260; SEC22A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140818 CVCL_TK34 HAP1 SEC22C (-) 1 cancer cell line human CVCL_TK34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16828; SEC22C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140819 CVCL_TK33 HAP1 SEC22A (-) 3 cancer cell line human CVCL_TK33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20260; SEC22A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140820 CVCL_TK36 HAP1 SEC23A (-) 1 cancer cell line human CVCL_TK36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10701; SEC23A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140821 CVCL_TK35 HAP1 SEC22C (-) 2 cancer cell line human CVCL_TK35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16828; SEC22C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140822 CVCL_TK38 HAP1 SEC23B (-) 1 cancer cell line human CVCL_TK38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10702; SEC23B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140823 CVCL_TK37 HAP1 SEC23A (-) 2 cancer cell line human CVCL_TK37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10701; SEC23A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140824 CVCL_TK18 HAP1 SCYL1 (-) 1 cancer cell line human CVCL_TK18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14372; SCYL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140825 CVCL_TK17 HAP1 SCNN1D (-) cancer cell line human CVCL_TK17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10601; SCNN1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140826 CVCL_TK19 HAP1 SCYL1 (-) 2 cancer cell line human CVCL_TK19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14372; SCYL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140827 CVCL_L277 AG08673 transformed cell line human CVCL_L277 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140828 CVCL_KQ77 PCRP-ZNF804A-1H8 hybridoma house mouse CVCL_KQ77 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7Z570; Human ZNF804A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140829 CVCL_L276 AG08672 transformed cell line human CVCL_L276 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140830 CVCL_KQ76 PCRP-ZNF800-2C12 hybridoma house mouse CVCL_KQ76 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q2TB10; Human ZNF800. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140831 CVCL_L279 COLO 232 cancer cell line human CVCL_L279 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Male Doubling time: 48 hours (PubMed=208962) 21140832 CVCL_KQ79 PCRP-ZNF81-2G2 hybridoma house mouse CVCL_KQ79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P51508; Human ZNF81. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140833 CVCL_L278 AG08916 transformed cell line human CVCL_L278 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140834 CVCL_KQ78 PCRP-ZNF81-2C7 hybridoma house mouse CVCL_KQ78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P51508; Human ZNF81. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140835 CVCL_L273 AG08467 finite cell line human CVCL_L273 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Female 21140836 CVCL_TK21 HAP1 SCYL2 (-) 2 cancer cell line human CVCL_TK21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19286; SCYL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140837 CVCL_KQ73 PCRP-ZNF8-1B7 hybridoma house mouse CVCL_KQ73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17098; Human ZNF8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140838 CVCL_L272 AG08466 finite cell line human CVCL_L272 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140839 CVCL_TK20 HAP1 SCYL2 (-) 1 cancer cell line human CVCL_TK20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19286; SCYL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140840 CVCL_KQ72 PCRP-ZNF792-2C6 hybridoma house mouse CVCL_KQ72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q3KQV3; Human ZNF792. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140841 CVCL_L275 AG08469 finite cell line human CVCL_L275 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140842 CVCL_TK23 HAP1 SCYL3 (-) 2 cancer cell line human CVCL_TK23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19285; SCYL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140843 CVCL_KQ75 PCRP-ZNF800-1C11 hybridoma house mouse CVCL_KQ75 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2TB10; Human ZNF800. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140844 CVCL_L274 AG08468 finite cell line human CVCL_L274 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21140845 CVCL_TK22 HAP1 SCYL3 (-) 1 cancer cell line human CVCL_TK22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19285; SCYL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140846 CVCL_KQ74 PCRP-ZNF8-1B8 hybridoma house mouse CVCL_KQ74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17098; Human ZNF8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140847 CVCL_TK25 HAP1 SDC2 (-) 1 cancer cell line human CVCL_TK25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10659; SDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140848 CVCL_TK24 HAP1 SDC1 (-) 1 cancer cell line human CVCL_TK24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10658; SDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140849 CVCL_L271 AG08671 transformed cell line human CVCL_L271 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140850 CVCL_TK27 HAP1 SDC2 (-) 3 cancer cell line human CVCL_TK27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10659; SDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140851 CVCL_KQ71 PCRP-ZNF784-1A7 hybridoma house mouse CVCL_KQ71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8NCA9; Human ZNF784. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140852 CVCL_L270 AG08470 finite cell line human CVCL_L270 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: H3K27me3 ChIP-seq epigenome analysis Female Part of: ENCODE project common cell types; tier 3 21140853 CVCL_TK26 HAP1 SDC2 (-) 2 cancer cell line human CVCL_TK26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10659; SDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140854 CVCL_KQ70 PCRP-ZNF784-1A4 hybridoma house mouse CVCL_KQ70 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8NCA9; Human ZNF784. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140855 CVCL_TK07 HAP1 SBK1 (-) 1 cancer cell line human CVCL_TK07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17699; SBK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140856 CVCL_TK06 HAP1 SAV1 (-) 1 cancer cell line human CVCL_TK06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17795; SAV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140857 CVCL_TK09 HAP1 SBK1 (-) 3 cancer cell line human CVCL_TK09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17699; SBK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140858 CVCL_TK08 HAP1 SBK1 (-) 2 cancer cell line human CVCL_TK08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17699; SBK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140859 CVCL_L288 KUSA-D somatic stem cell house mouse CVCL_L288 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21140860 CVCL_KQ88 PCRP-ZNFX1-1E6 hybridoma house mouse CVCL_KQ88 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9P2E3; Human ZNFX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140861 CVCL_L287 KUSA somatic stem cell house mouse CVCL_L287 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21140862 CVCL_KQ87 PCRP-ZNFX1-1D3 hybridoma house mouse CVCL_KQ87 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P2E3; Human ZNFX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140863 CVCL_L289 Ca761-03 cancer cell line house mouse CVCL_L289 CL:0000010 Breed/subspecies: 615. Female 21140864 CVCL_KQ89 PCRP-ZSCAN12-1A9 hybridoma house mouse CVCL_KQ89 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43309; Human ZSCAN12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140865 CVCL_TK10 HAP1 SCARB1 (-) 1 cancer cell line human CVCL_TK10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140866 CVCL_L284 M10 [Mouse leukemia] cancer cell line house mouse CVCL_L284 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21140867 CVCL_KQ84 PCRP-ZNF846-1F9 hybridoma house mouse CVCL_KQ84 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q147U1; Human ZNF846. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140868 CVCL_L283 LX827 cancer cell line house mouse CVCL_L283 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21140869 CVCL_KQ83 PCRP-ZNF846-1E12 hybridoma house mouse CVCL_KQ83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q147U1; Human ZNF846. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140870 CVCL_TK12 HAP1 SCFD2 (-) 1 cancer cell line human CVCL_TK12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30676; SCFD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140871 CVCL_L286 KUSA-MTAg transformed cell line house mouse CVCL_L286 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21140872 CVCL_KQ86 PCRP-ZNF98-1A11 hybridoma house mouse CVCL_KQ86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NK75; Human ZNF98. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140873 CVCL_TK11 HAP1 SCCPDH (-) 1 cancer cell line human CVCL_TK11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24275; SCCPDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140874 CVCL_L285 M10^(-) cancer cell line house mouse CVCL_L285 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21140875 CVCL_KQ85 PCRP-ZNF85-2A11 hybridoma house mouse CVCL_KQ85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q03923; Human ZNF85. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140876 CVCL_TK14 HAP1 SCML2 (-) 1 cancer cell line human CVCL_TK14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10581; SCML2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140877 CVCL_KQ80 PCRP-ZNF830-1B4 hybridoma house mouse CVCL_KQ80 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96NB3; Human ZNF830. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140878 CVCL_L280 SuSa cancer cell line human CVCL_L280 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 27.7 +- 1.3 hours (PubMed=2144165); ~48-72 hours (DSMZ=ACC-747) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21140879 CVCL_TK13 HAP1 SCFD2 (-) 2 cancer cell line human CVCL_TK13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30676; SCFD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140880 CVCL_TK16 HAP1 SCN1B (-) 2 cancer cell line human CVCL_TK16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10586; SCN1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140881 CVCL_L282 LX821 cancer cell line house mouse CVCL_L282 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21140882 CVCL_KQ82 PCRP-ZNF846-1D7 hybridoma house mouse CVCL_KQ82 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q147U1; Human ZNF846. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140883 CVCL_TK15 HAP1 SCN1B (-) 1 cancer cell line human CVCL_TK15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10586; SCN1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21140884 CVCL_KQ81 PCRP-ZNF830-1C5 hybridoma house mouse CVCL_KQ81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96NB3; Human ZNF830. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21140885 CVCL_L281 WI-38 CT-1 transformed cell line human CVCL_L281 CL:0000010 Population: Caucasian; Swedish; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~24 hours (PubMed=7418975) 21140886 CVCL_BY01 ND00197 transformed cell line human CVCL_BY01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140887 CVCL_BY00 ND00194 transformed cell line human CVCL_BY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140888 CVCL_BY03 ND00199 transformed cell line human CVCL_BY03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140889 CVCL_BY02 ND00198 transformed cell line human CVCL_BY02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140890 CVCL_BY05 ND00201 transformed cell line human CVCL_BY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140891 CVCL_BY04 ND00200 transformed cell line human CVCL_BY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140892 CVCL_BY10 ND00227 transformed cell line human CVCL_BY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140893 CVCL_BY12 ND00236 transformed cell line human CVCL_BY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140894 CVCL_BY11 ND00231 transformed cell line human CVCL_BY11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140895 CVCL_BY14 ND00248 transformed cell line human CVCL_BY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140896 CVCL_BY13 ND00241 transformed cell line human CVCL_BY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140897 CVCL_BY16 ND00258 transformed cell line human CVCL_BY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140898 CVCL_BY15 ND00257 transformed cell line human CVCL_BY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140899 CVCL_BY07 ND00216 transformed cell line human CVCL_BY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140900 CVCL_BY06 ND00212 transformed cell line human CVCL_BY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140901 CVCL_BY09 ND00223 transformed cell line human CVCL_BY09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140902 CVCL_BY08 ND00221 transformed cell line human CVCL_BY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140903 CVCL_1F92 CHO-hTRPV1 spontaneously immortalized cell line CVCL_1F92 CL:0000010 Transfected with: HGNC; 12716; TRPV1 Derived from sampling site: Ovary. Female 21140904 CVCL_1F91 CHO-hNCX1 spontaneously immortalized cell line CVCL_1F91 CL:0000010 Transfected with: HGNC; 11068; SLC8A1 Derived from sampling site: Ovary. Female 21140905 CVCL_1F94 Jurkat-HXBc2(4) cancer cell line human CVCL_1F94 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04578; HIV-1 isolate HXB2 env; Transfected with: UniProtKB; P04618; HIV-1 isolate HXB2 rev; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expresses HIV-1 Rev and Env when tetracycline is removed from the medium Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16. 21140906 CVCL_1F93 A2780-TC1 cancer cell line human CVCL_1F93 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Omics: Proteome analysis by 2D-DE/MS Female 21140907 CVCL_1F96 CHO-K1-Gln(-) spontaneously immortalized cell line CVCL_1F96 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line 21140908 CVCL_1F95 Jurkat-HXBc2(6) cancer cell line human CVCL_1F95 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04578; HIV-1 isolate HXB2 env; Transfected with: UniProtKB; P04618; HIV-1 isolate HXB2 rev; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: HIVReagentProgram; ARP-3953; true Male Characteristics: Expresses HIV-1 Rev and Env when tetracycline is removed from the medium Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16. 21140909 CVCL_1F98 GP-SMDCL finite cell line CVCL_1F98 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Skeletal muscle. Male Doubling time: ~33.8 hours (PubMed=26035009) Group: Endangered species/breed cell line 21140910 CVCL_1F97 GNE01.23B12.H8.A4 hybridoma Norway rat CVCL_1F97 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q969D9; Human TSLP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7951 21140911 CVCL_1F99 STF34 finite cell line CVCL_1F99 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Doubling time: 24 hours (PubMed=24845938) Group: Endangered species/breed cell line 21140912 CVCL_1F90 L0301/CDDP cancer cell line human CVCL_1F90 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Pleural effusion. Male 21140913 CVCL_1F70 XPH288BE finite cell line human CVCL_1F70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21140914 CVCL_1F72 GM16953 finite cell line human CVCL_1F72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21140915 CVCL_1F71 GM16952 transformed cell line human CVCL_1F71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140916 CVCL_1F74 GM17420 finite cell line human CVCL_1F74 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (from familial inference of XP86BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21140917 CVCL_1F73 GM17419 transformed cell line human CVCL_1F73 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (from familial inference of XP86BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140918 CVCL_1F76 GM17569 finite cell line human CVCL_1F76 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21140919 CVCL_1F75 GM17421 transformed cell line human CVCL_1F75 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of XP86BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140920 CVCL_1F78 GM17572 transformed cell line human CVCL_1F78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140921 CVCL_1F77 GM17570 transformed cell line human CVCL_1F77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140922 CVCL_1F79 XPH312BE LCL transformed cell line human CVCL_1F79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140923 CVCL_1F81 GM21149 transformed cell line human CVCL_1F81 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140924 CVCL_1F80 XPH311BE LCL transformed cell line human CVCL_1F80 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys692Ter (c.2074A>T); ClinVar=VCV000496267; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140925 CVCL_1F83 TZM-bl/FcalphaR cancer cell line human CVCL_1F83 CL:0000010 Transfected with: HGNC; 3608; FCAR; Transfected with: HGNC; 3611; FCER1G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21140926 CVCL_1F82 GM21150 transformed cell line human CVCL_1F82 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Arg425Ter (c.1273C>T); ClinVar=VCV000016585; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140927 CVCL_1F85 U373-MAGI-CCR5 cancer cell line human CVCL_1F85 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 21140928 CVCL_1F84 U373-MAGI cancer cell line human CVCL_1F84 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 21140929 CVCL_1F87 KAN-ES cancer cell line human CVCL_1F87 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 35.1 hours, at 55th passage (PubMed=10795747) 21140930 CVCL_1F86 U373-MAGI-CXCR4 cancer cell line human CVCL_1F86 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 21140931 CVCL_1F89 L0301 cancer cell line human CVCL_1F89 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 201 hours (DOI=10.2482/haigan.32.223) 21140932 CVCL_1F88 STC1/CDDP cancer cell line human CVCL_1F88 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Pleural effusion. Male 21140933 CVCL_BY87 ND00504 transformed cell line human CVCL_BY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140934 CVCL_BY86 ND00499 transformed cell line human CVCL_BY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140935 CVCL_BY89 ND00543 transformed cell line human CVCL_BY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140936 CVCL_BY88 ND00542 transformed cell line human CVCL_BY88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140937 CVCL_BY81 ND00457 transformed cell line human CVCL_BY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140938 CVCL_BY80 ND00453 transformed cell line human CVCL_BY80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140939 CVCL_KS17 CellSensor SBE-bla HEK 293T transformed cell line human CVCL_KS17 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of a Smad binding element (SBE) 21140940 CVCL_BY83 ND00486 transformed cell line human CVCL_BY83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140941 CVCL_KS16 CellSensor SBE-bla A375 cancer cell line human CVCL_KS16 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of a Smad binding element (SBE) 21140942 CVCL_BY82 ND00483 transformed cell line human CVCL_BY82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140943 CVCL_BY85 ND00498 transformed cell line human CVCL_BY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140944 CVCL_L419 SCCF1 cancer cell line CVCL_L419 CL:0000010 Derived from sampling site: Larynx. Female 21140945 CVCL_KS19 T-REx-293-MSR transformed cell line human CVCL_KS19 CL:0000010 Transfected with: HGNC; 7376; MSR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5079 21140946 CVCL_KS18 Flp-In-293-MSR transformed cell line human CVCL_KS18 CL:0000010 Transfected with: HGNC; 7376; MSR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5076 21140947 CVCL_BY84 ND00497 transformed cell line human CVCL_BY84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140948 CVCL_L418 RK9ML-1 cancer cell line dog CVCL_L418 CL:0000010 Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Peripheral blood; Breed/subspecies: Beagle. Unspecified Doubling time: 38-45 hours (PubMed=2796377) 21140949 CVCL_KS13 CellSensor DBE-bla MDA-MB-468 cancer cell line human CVCL_KS13 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Derived from metastatic site: Pleural effusion. Discontinued: Thermofisher/Invitrogen; Catalog number K1814 Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of a FOXO-responsive DBE response element (DBE) Group: Triple negative breast cancer (TNBC) cell line 21140950 CVCL_L413 POS [Dog osteosarcoma] cancer cell line dog CVCL_L413 CL:0000010 Derived from metastatic site: Bone; left femur; Breed/subspecies: Mixed breed. Omics: Cell surface proteome; Omics: Deep quantitative proteome analysis Male Doubling time: ~33 hours (PubMed=7696411) 21140951 CVCL_KS12 CellSensor ARE-bla Hep G2 cancer cell line human CVCL_KS12 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the antioxidant response element (ARE) 21140952 CVCL_L412 PL-14 cancer cell line human CVCL_L412 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 72 hours (PubMed=640319) 21140953 CVCL_KS15 CellSensor p53RE-bla HCT-116 cancer cell line human CVCL_KS15 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Colon. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the p53 response element (p53RE) 21140954 CVCL_L415 Rh3 cancer cell line human CVCL_L415 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7536457; PubMed=8275086) Derived from metastatic site: Axillary lymph node. Omics: Transcriptome analysis by microarray Male 21140955 CVCL_KS14 CellSensor Myc-bla HCT-116 cancer cell line human CVCL_KS14 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Colon. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of Myc binding sequences 21140956 CVCL_L414 PTCC cancer cell line dog CVCL_L414 From: Knapp D.; Purdue University College of Veterinary Medicine; WestLafayette; USA. CL:0000010 Female 21140957 CVCL_KS11 NM002-1 hybridoma house mouse CVCL_KS11 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: Human pancreatic cancer cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201173 21140958 CVCL_L411 P404 cancer cell line dog CVCL_L411 CL:0000010 Unspecified 21140959 CVCL_KS10 My-C-cC0C2-259-1A4 hybridoma house mouse CVCL_KS10 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14896; Human MYBPC3. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3224 21140960 CVCL_L410 P114 cancer cell line dog CVCL_L410 CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 26.9 hours (PubMed=20453304) 21140961 CVCL_BY98 ND00591 transformed cell line human CVCL_BY98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140962 CVCL_BY97 ND00590 transformed cell line human CVCL_BY97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140963 CVCL_BY99 ND00603 transformed cell line human CVCL_BY99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140964 CVCL_BY90 ND00544 transformed cell line human CVCL_BY90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140965 CVCL_BY92 ND00547 transformed cell line human CVCL_BY92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140966 CVCL_BY91 ND00545 transformed cell line human CVCL_BY91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140967 CVCL_KS28 CellSensor SIE-bla ME-180 cancer cell line human CVCL_KS28 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the Sis inducible element (SIE) 21140968 CVCL_L428 N-1A-103 cancer cell line house mouse CVCL_L428 CL:0000010 Breed/subspecies: A/J. Male 21140969 CVCL_BY94 ND00549 transformed cell line human CVCL_BY94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140970 CVCL_KS27 CellSensor SIE-bla HEK 293T transformed cell line human CVCL_KS27 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the Sis inducible element (SIE) 21140971 CVCL_BY93 ND00548 transformed cell line human CVCL_BY93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140972 CVCL_L427 NUTLC-5 cancer cell line human CVCL_L427 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female 21140973 CVCL_BY96 ND00589 transformed cell line human CVCL_BY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140974 CVCL_KS29 CellSensor SIE-bla THP-1 cancer cell line human CVCL_KS29 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the Sis inducible element (SIE) 21140975 CVCL_BY95 ND00556 transformed cell line human CVCL_BY95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140976 CVCL_L429 TBJ cancer cell line house mouse CVCL_L429 CL:0000010 Breed/subspecies: A/J. Male 21140977 CVCL_KS24 GeneBLAzer Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KS24 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21140978 CVCL_L424 NUTLC-2 cancer cell line human CVCL_L424 CL:0000010 Population: Japanese; Derived from metastatic site: Mediastinal lymph node. Male 21140979 CVCL_KS23 GeneBLAzer Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KS23 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21140980 CVCL_L423 NUTLC-1 cancer cell line human CVCL_L423 CL:0000010 Population: Japanese; Derived from metastatic site: Mediastinal lymph node. Male Doubling time: 19.1 hours (PubMed=8025020) 21140981 CVCL_KS26 GeneBLAzer ADRA2A-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KS26 CL:0000010 Transfected with: HGNC; 281; ADRA2A; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21140982 CVCL_L426 NUTLC-4 cancer cell line house mouse CVCL_L426 CL:0000010 Derived from sampling site: Lung. 21140983 CVCL_KS25 GeneBLAzer ADORA3-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_KS25 CL:0000010 Transfected with: HGNC; 268; ADORA3; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21140984 CVCL_L425 NUTLC-3 cancer cell line human CVCL_L425 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 32.5 hours (PubMed=8025020) 21140985 CVCL_KS20 MCF-7/AdVp3000 cancer cell line human CVCL_KS20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 74; ABCG2; Simple; p.Arg482Thr (c.1445G>C); Zygosity=Unspecified (PubMed=11559526); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female 21140986 CVCL_L420 SRT cancer cell line CVCL_L420 CL:0000010 Derived from sampling site: Paranasal sinus. Female Doubling time: ~18 hours (PubMed=2957013) 21140987 CVCL_KS22 MM2-3C6 hybridoma house mouse CVCL_KS22 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse melanoma cell line B16 antigen. 21140988 CVCL_L422 Vogel cancer cell line dog CVCL_L422 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; Simple; p.Val588Glu (c.1763T>A); Zygosity=Heterozygous (PubMed=27197945; PubMed=31175136); Sequence variation: Mutation; VGNC; 43120; MED12; Simple; p.Leu1349fs (c.4041_4044dupTATT); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Val162Leu (c.484G>T); Zygosity=Heterozygous (PubMed=31175136) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 35.9 hours (PubMed=22916246) Part of: FACC canine tumor cell line panel 21140989 CVCL_KS21 MM2-9B6 hybridoma house mouse CVCL_KS21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse melanoma-associated antigen (MAA). 21140990 CVCL_L421 UL-1 [Dog leukemia] cancer cell line dog CVCL_L421 CL:0000010 Derived from sampling site: Ascites; Breed/subspecies: Labrador Retriever mix. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 20.9 hours (PubMed=23196801) Caution: Was originally classified as originating from a T-cell lymphoma, but is reclassified as a T-cell acute lymphoblastic leukemia based on characteristic cytogenomic properties (PubMed=27639374) 21140991 CVCL_BY65 ND00401 transformed cell line human CVCL_BY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140992 CVCL_BY64 ND00393 transformed cell line human CVCL_BY64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140993 CVCL_BY67 ND00409 transformed cell line human CVCL_BY67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140994 CVCL_BY66 ND00406 transformed cell line human CVCL_BY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140995 CVCL_BY69 ND00413 transformed cell line human CVCL_BY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140996 CVCL_BY68 ND00410 transformed cell line human CVCL_BY68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140997 CVCL_BY61 ND00388 transformed cell line human CVCL_BY61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21140998 CVCL_BY60 ND00386 transformed cell line human CVCL_BY60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21140999 CVCL_BY63 ND00390 transformed cell line human CVCL_BY63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141000 CVCL_BY62 ND00389 transformed cell line human CVCL_BY62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141001 CVCL_BY76 ND00429 transformed cell line human CVCL_BY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141002 CVCL_BY75 ND00428 transformed cell line human CVCL_BY75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141003 CVCL_BY78 ND00449 transformed cell line human CVCL_BY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141004 CVCL_BY77 ND00447 transformed cell line human CVCL_BY77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141005 CVCL_BY79 ND00451 transformed cell line human CVCL_BY79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141006 CVCL_KS09 My-C-cC0C2-235-3H8 hybridoma house mouse CVCL_KS09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14896; Human MYBPC3. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3223 21141007 CVCL_L409 OSCA-99 cancer cell line dog CVCL_L409 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Labrador Retriever mix. Female 21141008 CVCL_BY70 ND00415 transformed cell line human CVCL_BY70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141009 CVCL_KS06 CellSensor HRE-bla HCT-116 cancer cell line human CVCL_KS06 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Colon. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the hypoxia response element (HRE) 21141010 CVCL_BY72 ND00417 transformed cell line human CVCL_BY72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141011 CVCL_L406 OSCA-84 cancer cell line dog CVCL_L406 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Female 21141012 CVCL_KS05 CellSensor ESRE-bla HeLa cancer cell line human CVCL_KS05 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of ER stress response element (ESRE) 21141013 CVCL_BY71 ND00416 transformed cell line human CVCL_BY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141014 CVCL_L405 OSCA-08 cancer cell line dog CVCL_L405 CL:0000010 Sequence variation: Mutation; VGNC; 54168; KDM6A; Simple; p.Thr986fs (c.2957delC); Zygosity=Homozygous (PubMed=31175136) Derived from sampling site: Bone; humerus; Breed/subspecies: Rottweiler. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 21 hours (PubMed=27257868); ~22 hours (Kerafast) Part of: FACC canine tumor cell line panel 21141015 CVCL_KS08 CellSensor HSE-bla HeLa cancer cell line human CVCL_KS08 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of a heat shock element (HSE) 21141016 CVCL_BY74 ND00424 transformed cell line human CVCL_BY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141017 CVCL_L408 OSCA-98 cancer cell line dog CVCL_L408 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Labrador Retriever. Male 21141018 CVCL_KS07 CellSensor HRE-bla ME-180 cancer cell line human CVCL_KS07 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the hypoxia response element (HRE) 21141019 CVCL_BY73 ND00422 transformed cell line human CVCL_BY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141020 CVCL_L407 OSCA-96 cancer cell line dog CVCL_L407 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Mastiff. Female 21141021 CVCL_KS02 CellSensor LEF/TCF-bla FreeStyle 293F transformed cell line human CVCL_KS02 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of beta-catenin/LEF/TCF binding elements 21141022 CVCL_L402 OSCA-75 cancer cell line dog CVCL_L402 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Female 21141023 CVCL_KS01 GeneBLAzer MC2R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_KS01 CL:0000010 Transfected with: HGNC; 6930; MC2R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21141024 CVCL_L401 OSCA-73 cancer cell line dog CVCL_L401 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Female 21141025 CVCL_KS04 CellSensor LEF/TCF-bla HCT-116 cancer cell line human CVCL_KS04 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Colon. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of beta-catenin/LEF/TCF binding elements 21141026 CVCL_L404 OSCA-78 cancer cell line dog CVCL_L404 CL:0000010 Derived from sampling site: Bone; femur; Breed/subspecies: German Shepherd. Male Doubling time: ~22 hours (Kerafast) 21141027 CVCL_KS03 CellSensor LEF/TCF-bla SW480 cancer cell line human CVCL_KS03 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Colon. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of beta-catenin/LEF/TCF binding elements 21141028 CVCL_L403 OSCA-77 cancer cell line dog CVCL_L403 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Belgian Malinois. Male 21141029 CVCL_KS00 GeneBLAzer HTR7-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_KS00 CL:0000010 Transfected with: HGNC; 5302; HTR7; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21141030 CVCL_L400 OSCA-71 cancer cell line dog CVCL_L400 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Female Doubling time: ~1 day (Kerafast) 21141031 CVCL_BY43 ND00325 transformed cell line human CVCL_BY43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141032 CVCL_BY42 ND00324 transformed cell line human CVCL_BY42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141033 CVCL_BY45 ND00331 transformed cell line human CVCL_BY45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141034 CVCL_BY44 ND00329 transformed cell line human CVCL_BY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141035 CVCL_BY47 ND00334 transformed cell line human CVCL_BY47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141036 CVCL_BY46 ND00333 transformed cell line human CVCL_BY46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141037 CVCL_BY49 ND00349 transformed cell line human CVCL_BY49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141038 CVCL_BY48 ND00348 transformed cell line human CVCL_BY48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141039 CVCL_BY41 ND00323 transformed cell line human CVCL_BY41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141040 CVCL_BY40 ND00320 transformed cell line human CVCL_BY40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141041 CVCL_BY39 ND00319 transformed cell line human CVCL_BY39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141042 CVCL_BY54 ND00359 transformed cell line human CVCL_BY54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141043 CVCL_BY53 ND00357 transformed cell line human CVCL_BY53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141044 CVCL_BY56 ND00365 transformed cell line human CVCL_BY56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141045 CVCL_BY55 ND00363 transformed cell line human CVCL_BY55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141046 CVCL_BY58 ND00379 transformed cell line human CVCL_BY58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141047 CVCL_BY57 ND00370 transformed cell line human CVCL_BY57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141048 CVCL_BY59 ND00384 transformed cell line human CVCL_BY59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141049 CVCL_BY50 ND00351 transformed cell line human CVCL_BY50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141050 CVCL_BY52 ND00355 transformed cell line human CVCL_BY52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141051 CVCL_BY51 ND00353 transformed cell line human CVCL_BY51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141052 CVCL_BY21 ND00267 transformed cell line human CVCL_BY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141053 CVCL_BY20 ND00266 transformed cell line human CVCL_BY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141054 CVCL_BY23 ND00275 transformed cell line human CVCL_BY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141055 CVCL_BY22 ND00273 transformed cell line human CVCL_BY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141056 CVCL_BY25 ND00280 transformed cell line human CVCL_BY25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141057 CVCL_BY24 ND00277 transformed cell line human CVCL_BY24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141058 CVCL_BY27 ND00285 transformed cell line human CVCL_BY27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141059 CVCL_BY26 ND00283 transformed cell line human CVCL_BY26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141060 CVCL_BY18 ND00264 transformed cell line human CVCL_BY18 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141061 CVCL_BY17 ND00260 transformed cell line human CVCL_BY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141062 CVCL_BY19 ND00265 transformed cell line human CVCL_BY19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141063 CVCL_BY32 ND00293 transformed cell line human CVCL_BY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141064 CVCL_BY31 ND00292 transformed cell line human CVCL_BY31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141065 CVCL_BY34 ND00305 transformed cell line human CVCL_BY34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141066 CVCL_BY33 ND00295 transformed cell line human CVCL_BY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141067 CVCL_BY36 ND00310 transformed cell line human CVCL_BY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141068 CVCL_BY35 ND00308 transformed cell line human CVCL_BY35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141069 CVCL_BY38 ND00318 transformed cell line human CVCL_BY38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141070 CVCL_BY37 ND00313 transformed cell line human CVCL_BY37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141071 CVCL_BY30 ND00289 transformed cell line human CVCL_BY30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141072 CVCL_BY29 ND00287 transformed cell line human CVCL_BY29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141073 CVCL_BY28 ND00286 transformed cell line human CVCL_BY28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141074 CVCL_TL17 HAP1 SIKE1 (-) 1 cancer cell line human CVCL_TL17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26119; SIKE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141075 CVCL_TL16 HAP1 SIK3 (-) 3 cancer cell line human CVCL_TL16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29165; SIK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141076 CVCL_TL19 HAP1 SIN3A (-) 1 cancer cell line human CVCL_TL19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19353; SIN3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141077 CVCL_TL18 HAP1 SIKE1 (-) 2 cancer cell line human CVCL_TL18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26119; SIKE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141078 CVCL_L379 OSCA-20 cancer cell line dog CVCL_L379 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Male 21141079 CVCL_KR79 YBC-122 hybridoma CVCL_KR79 CL:0000010 Monoclonal antibody isotype: IgM. 21141080 CVCL_KR76 M15 9F11.1 hybridoma house mouse CVCL_KR76 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-590 21141081 CVCL_L376 OSCA-16 cancer cell line dog CVCL_L376 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Rottweiler. Male 21141082 CVCL_KR75 M15 5A16.1 hybridoma house mouse CVCL_KR75 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-587 21141083 CVCL_L375 OSCA-12 cancer cell line dog CVCL_L375 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141084 CVCL_L378 OSCA-19 cancer cell line dog CVCL_L378 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141085 CVCL_KR78 YBC-058 hybridoma CVCL_KR78 CL:0000010 Monoclonal antibody isotype: IgM. 21141086 CVCL_L377 OSCA-17 cancer cell line dog CVCL_L377 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141087 CVCL_KR77 YBB-190 hybridoma CVCL_KR77 CL:0000010 Monoclonal antibody isotype: IgM. 21141088 CVCL_TL20 HAP1 SIN3A (-) 2 cancer cell line human CVCL_TL20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19353; SIN3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141089 CVCL_KR72 M15 1B4.1 hybridoma house mouse CVCL_KR72 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-588 21141090 CVCL_L372 OSCA-01 cancer cell line dog CVCL_L372 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Female 21141091 CVCL_KR71 M15 10F7.1 hybridoma house mouse CVCL_KR71 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-592 21141092 CVCL_L371 OS2.4/Doxo cancer cell line dog CVCL_L371 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: Golden Retriever. Male 21141093 CVCL_TL22 HAP1 SIRPA (-) 1 cancer cell line human CVCL_TL22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9662; SIRPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141094 CVCL_KR74 M15 3F7.3 hybridoma house mouse CVCL_KR74 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-593 21141095 CVCL_L374 OSCA-11M cancer cell line dog CVCL_L374 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Rottweiler. Female Caution: Indicated as originating from a female dog in PubMed=21621658 and a male dog in PubMed=23311495 21141096 CVCL_TL21 HAP1 SIN3A (-) 3 cancer cell line human CVCL_TL21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19353; SIN3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141097 CVCL_KR73 M15 203.1 hybridoma house mouse CVCL_KR73 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q01638; Human IL1RL1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-591 21141098 CVCL_L373 OSCA-109 cancer cell line dog CVCL_L373 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Irish Setter. Male 21141099 CVCL_TL24 HAP1 SIRT1 (-) 2 cancer cell line human CVCL_TL24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141100 CVCL_TL23 HAP1 SIRT1 (-) 1 cancer cell line human CVCL_TL23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141101 CVCL_KR70 6G2 hybridoma house mouse CVCL_KR70 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25311; Human AZGP1. 21141102 CVCL_TL26 HAP1 SIRT1 (-) 4 cancer cell line human CVCL_TL26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141103 CVCL_L370 OS2.4 cancer cell line dog CVCL_L370 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ile222Thr (c.665T>C); Zygosity=Homozygous (PubMed=31175136) Breed/subspecies: Golden Retriever. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: FACC canine tumor cell line panel 21141104 CVCL_TL25 HAP1 SIRT1 (-) 3 cancer cell line human CVCL_TL25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141105 CVCL_TL06 HAP1 SHOX2 (-) 4 cancer cell line human CVCL_TL06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10854; SHOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141106 CVCL_TL05 HAP1 SHOX2 (-) 3 cancer cell line human CVCL_TL05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10854; SHOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141107 CVCL_TL08 HAP1 SIAE (-) 2 cancer cell line human CVCL_TL08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18187; SIAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141108 CVCL_TL07 HAP1 SIAE (-) 1 cancer cell line human CVCL_TL07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18187; SIAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141109 CVCL_TL09 HAP1 SIAE (-) 3 cancer cell line human CVCL_TL09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18187; SIAE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141110 CVCL_KR87 137-26 hybridoma house mouse CVCL_KR87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01031; Human C5. 21141111 CVCL_L387 OSCA-33 cancer cell line dog CVCL_L387 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Female 21141112 CVCL_KR86 H15-B9-22 hybridoma house mouse CVCL_KR86 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03454; Influenza A virus isolate A/Wilson-Smith/1933 H1N1 hemagglutinin (HA). 21141113 CVCL_L386 OSCA-32 cancer cell line dog CVCL_L386 CL:0000010 Derived from sampling site: Bone; radius; Breed/subspecies: Pyrenean mountain dog. Female Doubling time: ~22 hours (Kerafast) 21141114 CVCL_KR89 14.G2a hybridoma house mouse CVCL_KR89 CL:0000010 Characteristics: Isotype switched derivative of 14.18; Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21141115 CVCL_L389 OSCA-40 cancer cell line dog CVCL_L389 CL:0000010 Derived from sampling site: Bone; femur; Breed/subspecies: Saint Bernard. Female Doubling time: ~22 hours (Kerafast) 21141116 CVCL_KR88 14.18 hybridoma house mouse CVCL_KR88 CL:0000010 Characteristics: Because it binds and kills neuroblastoma cells, was used to develop dinutuximab which is used in a clinical setting; Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21141117 CVCL_L388 OSCA-04 cancer cell line dog CVCL_L388 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male Caution: Indicated as originating from a male dog in PubMed=21621658 and a female dog in PubMed=23311495 21141118 CVCL_KR83 CT43 hybridoma house mouse CVCL_KR83 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human mucin epitope of unknown structure. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10217 21141119 CVCL_L383 OSCA-25 cancer cell line dog CVCL_L383 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Female 21141120 CVCL_L382 OSCA-23 cancer cell line dog CVCL_L382 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Male 21141121 CVCL_KR82 YBY-088 hybridoma CVCL_KR82 CL:0000010 Monoclonal antibody isotype: IgM. 21141122 CVCL_TL11 HAP1 SIGMAR1 (-) 2 cancer cell line human CVCL_TL11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8157; SIGMAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141123 CVCL_KR85 HS-7 hybridoma house mouse CVCL_KR85 CL:0000010 Monoclonal antibody isotype: IgM. 21141124 CVCL_L385 OSCA-30 cancer cell line dog CVCL_L385 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: German Shepherd. Male 21141125 CVCL_KR84 CT66 hybridoma house mouse CVCL_KR84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:62265; Beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc (Lewis A); Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10218 21141126 CVCL_TL10 HAP1 SIGMAR1 (-) 1 cancer cell line human CVCL_TL10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8157; SIGMAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141127 CVCL_L384 OSCA-29 cancer cell line dog CVCL_L384 CL:0000010 Derived from sampling site: Bone; humerus; Breed/subspecies: Rottweiler. Female Doubling time: ~1 day (Kerafast) 21141128 CVCL_TL13 HAP1 SIK2 (-) cancer cell line human CVCL_TL13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21680; SIK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141129 CVCL_TL12 HAP1 SIK1 (-) 1 cancer cell line human CVCL_TL12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11142; SIK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141130 CVCL_TL15 HAP1 SIK3 (-) 2 cancer cell line human CVCL_TL15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29165; SIK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141131 CVCL_L381 OSCA-22 cancer cell line dog CVCL_L381 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141132 CVCL_KR81 YBM-209 hybridoma CVCL_KR81 CL:0000010 Monoclonal antibody isotype: IgM. 21141133 CVCL_TL14 HAP1 SIK3 (-) 1 cancer cell line human CVCL_TL14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29165; SIK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141134 CVCL_L380 OSCA-21 cancer cell line dog CVCL_L380 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141135 CVCL_KR80 YBD-047 hybridoma CVCL_KR80 CL:0000010 Monoclonal antibody isotype: IgM. 21141136 CVCL_KR58 Anti-thaumatin clone 3 hybridoma house mouse CVCL_KR58 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02883; Thaumatococcus daniellii thaumatin-1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8922 21141137 CVCL_L358 Ingles cancer cell line dog CVCL_L358 CL:0000010 Unspecified 21141138 CVCL_KR57 Anti-thaumatin clone 21 hybridoma house mouse CVCL_KR57 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02883; Thaumatococcus daniellii thaumatin-1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8921 21141139 CVCL_L357 Hughes cancer cell line dog CVCL_L357 CL:0000010 Unspecified Doubling time: 17.9 hours (PubMed=22916246). 21141140 CVCL_KR59 263K 3F4 hybridoma house mouse CVCL_KR59 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04273; Mesocricetus auratus PRNP/CD230. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9222 21141141 CVCL_L359 Jarques cancer cell line dog CVCL_L359 CL:0000010 Unspecified 21141142 CVCL_KR54 CeSNB1 hybridoma house mouse CVCL_KR54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O02495; Caenorhabditis elegans snb-1. 21141143 CVCL_L354 Grey cancer cell line dog CVCL_L354 CL:0000010 Unspecified Doubling time: 18.1 hours (PubMed=22916246). 21141144 CVCL_KR53 CeSAX7 hybridoma house mouse CVCL_KR53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q53U87; Caenorhabditis elegans sax-7. 21141145 CVCL_L353 Gracie cancer cell line dog CVCL_L353 CL:0000010 Sequence variation: Mutation; VGNC; 46802; SRGAP3; Simple; p.Val850fs (c.2548dupG); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Golden Retriever. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 19.2 hours (PubMed=22916246); 19 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21141146 CVCL_KR56 CeTAC1 hybridoma house mouse CVCL_KR56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G5ECG0; Caenorhabditis elegans tac-1. 21141147 CVCL_L356 HOS [Dog osteosarcoma] cancer cell line dog CVCL_L356 CL:0000010 Derived from sampling site: Bone; scapula; Breed/subspecies: Mixed breed. Male Characteristics: Established from a nude mouse xenograft Doubling time: 42.0 +- 0.1 hours (PubMed=9673952) 21141148 CVCL_KR55 CeSQV8 hybridoma house mouse CVCL_KR55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q09363; Caenorhabditis elegans sqv-8. 21141149 CVCL_L355 HMPOS cancer cell line dog CVCL_L355 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg164His (c.491G>A); Zygosity=Homozygous (PubMed=31175136) Derived from metastatic site: Bone; left femur; Breed/subspecies: Mixed breed. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 20 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21141150 CVCL_KR50 CeRIM hybridoma house mouse CVCL_KR50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q22366; Caenorhabditis elegans unc-10. 21141151 CVCL_L350 Ema cancer cell line dog CVCL_L350 CL:0000010 Derived from sampling site: Pleural effusion; Breed/subspecies: English Springer Spaniel. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female Doubling time: 26.6 hours (PubMed=23196801) 21141152 CVCL_KR52 CeRME1 hybridoma house mouse CVCL_KR52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G5EFP1; Caenorhabditis elegans rme-1. 21141153 CVCL_L352 GL-1 [Dog leukemia] cancer cell line dog CVCL_L352 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: German Shepherd. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27.3 hours, at 33th passage (PubMed=8741612) 21141154 CVCL_TL00 HAP1 SHMT1 (-) 1 cancer cell line human CVCL_TL00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10850; SHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141155 CVCL_KR51 CeRIM2 hybridoma house mouse CVCL_KR51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q22366; Caenorhabditis elegans unc-10. 21141156 CVCL_L351 FUHS-1 cancer cell line human CVCL_L351 CL:0000010 Derived from sampling site: Skin. Female 21141157 CVCL_TL02 HAP1 SHMT2 (-) cancer cell line human CVCL_TL02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10852; SHMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141158 CVCL_TL01 HAP1 SHMT1 (-) 2 cancer cell line human CVCL_TL01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10850; SHMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141159 CVCL_TL04 HAP1 SHOX2 (-) 2 cancer cell line human CVCL_TL04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10854; SHOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141160 CVCL_TL03 HAP1 SHOX2 (-) 1 cancer cell line human CVCL_TL03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10854; SHOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141161 CVCL_KR69 1E2 [Mouse hybridoma against human AZGP1] hybridoma house mouse CVCL_KR69 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25311; Human AZGP1. 21141162 CVCL_L369 OOS [Dog osteosarcoma] cancer cell line dog CVCL_L369 CL:0000010 Derived from sampling site: Bone; jaw; mandible; Breed/subspecies: Maltese. Female Doubling time: 45.0 +- 0.5 hours (PubMed=9673952) 21141163 CVCL_KR68 1D4 [Mouse hybridoma against human AZGP1] hybridoma house mouse CVCL_KR68 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25311; Human AZGP1. 21141164 CVCL_L368 Nody-1 cancer cell line dog CVCL_L368 CL:0000010 Derived from sampling site: Ascites; Breed/subspecies: Shiba. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 21.5 hours (PubMed=23196801) 21141165 CVCL_KR65 IMM010.21.7 hybridoma house mouse CVCL_KR65 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21141166 CVCL_L365 MCM-B2 cancer cell line dog CVCL_L365 CL:0000010 Breed/subspecies: Pointer. Female Doubling time: 8 hours (PubMed=7659855) 21141167 CVCL_L364 MBSa1 cancer cell line dog CVCL_L364 CL:0000010 Breed/subspecies: German Shepherd. Male Doubling time: ~26 hours (PubMed=20974873) 21141168 CVCL_KR64 VPM 30 hybridoma house mouse CVCL_KR64 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Bovine antigen on B-cells. 21141169 CVCL_KR67 3F7 [Mouse hybridoma against HIV-1 antigens] hybridoma house mouse CVCL_KR67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 antigens. 21141170 CVCL_L367 MPT-1 cancer cell line dog CVCL_L367 CL:0000010 Unspecified Doubling time: 40.3 +- 3.1 hours (PubMed=18086553). 21141171 CVCL_L366 MCO-Y4 cancer cell line dog CVCL_L366 CL:0000010 Breed/subspecies: Mixed breed. Female Doubling time: 32.39 +- 4.66 hours, at 93th passage (PubMed=17085882) 21141172 CVCL_KR66 USCLS-1 cancer cell line human CVCL_KR66 CL:0000010 Derived from sampling site: Lung. Female 21141173 CVCL_KR61 H14-A2 hybridoma house mouse CVCL_KR61 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P03449; Influenza A virus isolate A/Memphis/1/1971 hemagglutinin (HA). 21141174 CVCL_L361 LMeC cancer cell line dog CVCL_L361 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468) Derived from metastatic site: Lymph node; Breed/subspecies: Beagle. Female Doubling time: 34.1 +- 5.61 hours (PubMed=15585963) 21141175 CVCL_KR60 2B8 [Mouse hybridoma against human MS4A1] hybridoma house mouse CVCL_KR60 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized rituximab (IDEC-C2B8) therapeutic antibody Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11388 21141176 CVCL_L360 KMeC cancer cell line dog CVCL_L360 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468) Derived from sampling site: Oral cavity; Breed/subspecies: Mixed breed. Male Doubling time: 37.1 +- 1.35 hours (PubMed=15585963) 21141177 CVCL_KR63 1.90.6 hybridoma house mouse CVCL_KR63 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella merozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8336 21141178 CVCL_L363 Marisco cancer cell line dog CVCL_L363 CL:0000010 Sequence variation: Mutation; VGNC; 43959; NRAS; Simple; p.Gln61His (c.183A>C); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 49609; RAC1; Simple; p.Pro29Thr (c.85C>A); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Greyhound. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Doubling time: 22.1 hours (PubMed=22916246); 22 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21141179 CVCL_L362 MacKinley cancer cell line dog CVCL_L362 CL:0000010 Sequence variation: Mutation; VGNC; 43120; MED12; Simple; p.Leu1938fs (c.5813delT); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 44864; PPM1D; Simple; p.Glu472Ter (c.1414G>T); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Newfoundland. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 27.6 hours (PubMed=22916246); 28 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21141180 CVCL_KR62 UCLAi090-A induced pluripotent stem cell CVCL_KR62 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Trunk; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21141181 CVCL_KR39 CeDLG1 hybridoma house mouse CVCL_KR39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G5ECY0; Caenorhabditis elegans dlg-1. 21141182 CVCL_L339 CMT-W2M cancer cell line dog CVCL_L339 CL:0000010 Derived from metastatic site: Lung. Omics: Transcriptome analysis by microarray Female 21141183 CVCL_KR36 CeCAV1 hybridoma house mouse CVCL_KR36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q94051; Caenorhabditis elegans cav-1. 21141184 CVCL_L336 CMT-W1 cancer cell line dog CVCL_L336 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21141185 CVCL_KR35 CeAPA2 hybridoma house mouse CVCL_KR35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q22601; Caenorhabditis elegans apa-2. 21141186 CVCL_L335 CMT-U27 cancer cell line dog CVCL_L335 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Omics: Transcriptome analysis by microarray Female Doubling time: ~48 hours (PubMed=1375928); 54.7 hours (PubMed=20453304) 21141187 CVCL_KR38 CeDAO5 hybridoma house mouse CVCL_KR38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9XVS4; Caenorhabditis elegans dao-5. 21141188 CVCL_L338 CMT-W2 cancer cell line dog CVCL_L338 CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 88.5 hours (PubMed=20453304) 21141189 CVCL_KR37 CeCYP33E1 hybridoma house mouse CVCL_KR37 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q27482; Caenorhabditis elegans cyp-33e1. 21141190 CVCL_L337 CMT-W1M cancer cell line dog CVCL_L337 CL:0000010 Derived from metastatic site: Lung. Omics: Transcriptome analysis by microarray Female 21141191 CVCL_KR32 5E10 [Mouse hybridoma against human THY1] hybridoma house mouse CVCL_KR32 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04216; Human THY1/CD90. 21141192 CVCL_L332 CMT-U131 cancer cell line dog CVCL_L332 CL:0000010 Breed/subspecies: German Shepherd. Female Doubling time: ~24 hours (PubMed=1375928) 21141193 CVCL_L331 CMT-U111 cancer cell line dog CVCL_L331 CL:0000010 Breed/subspecies: Poodle. Female Doubling time: ~12 hours (PubMed=1375928) 21141194 CVCL_KR31 RTS11-GFP spontaneously immortalized cell line CVCL_KR31 CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (pmaxGFP) Derived from sampling site: Spleen Cell type=Macrophage.. Unspecified Group: Fish cell line 21141195 CVCL_L334 CMT-U229 cancer cell line dog CVCL_L334 CL:0000010 Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Cys163Phe (c.488G>T); Zygosity=Hemizygous (PubMed=9042250) Derived from sampling site: Mammary gland; Breed/subspecies: German Shepherd. Female Doubling time: ~24 hours (PubMed=1375928) 21141196 CVCL_KR34 GV39M hybridoma house mouse CVCL_KR34 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P26617; Cavia porcellus VEGFA (Note=Also reacts with human and mouse). 21141197 CVCL_L333 CMT-U155 cancer cell line dog CVCL_L333 CL:0000010 Breed/subspecies: Borzoi. Female Doubling time: ~36 hours (PubMed=1375928) 21141198 CVCL_KR33 OSCC-1/KMC cancer cell line human CVCL_KR33 CL:0000010 Population: Chinese. Male 21141199 CVCL_L330 CMT25 cancer cell line dog CVCL_L330 CL:0000010 Female 21141200 CVCL_KR30 GML-5 spontaneously immortalized cell line CVCL_KR30 CL:0000010 Unspecified Doubling time: ~3 days (CelloPub=CLPUB00403). Group: Fish cell line 21141201 CVCL_KR47 CeLMP1 hybridoma house mouse CVCL_KR47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q11117; Caenorhabditis elegans lmp-1. 21141202 CVCL_L347 COS31/rCDDP cancer cell line dog CVCL_L347 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone; left distal radius; Breed/subspecies: Saint Bernard. Male 21141203 CVCL_KR46 CeLMN1 hybridoma house mouse CVCL_KR46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q21443; Caenorhabditis elegans lmn-1 Caution: Indicated as producing an IgG1 mAb in PubMed=20405020 and an IgM mAb in DSHB. 21141204 CVCL_L346 COS31 cancer cell line dog CVCL_L346 CL:0000010 Derived from metastatic site: Bone; left distal radius; Breed/subspecies: Saint Bernard. Omics: Transcriptome analysis by single cell RNAseq Male Doubling time: 28 hours (PubMed=9827352) 21141205 CVCL_KR49 CePAS7 hybridoma house mouse CVCL_KR49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q09583; Caenorhabditis elegans pas-7. 21141206 CVCL_L349 COSCA-Pr cancer cell line dog CVCL_L349 CL:0000010 Derived from metastatic site: Bone; right proximal humerus; Breed/subspecies: Boxer. Female Doubling time: 4 days (PubMed=9522958) 21141207 CVCL_KR48 CeORC2 hybridoma house mouse CVCL_KR48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q21037; Caenorhabditis elegans orc-2. 21141208 CVCL_L348 COSCA-T cancer cell line dog CVCL_L348 CL:0000010 Derived from metastatic site: Bone; left distal radius; Breed/subspecies: Mixed breed. Male Doubling time: 14 days (PubMed=9522958) 21141209 CVCL_KR43 CeHMR1 hybridoma house mouse CVCL_KR43 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q967F4; Caenorhabditis elegans hmr-1. 21141210 CVCL_L343 CO7 cancer cell line dog CVCL_L343 CL:0000010 Derived from sampling site: Bone; proximal humerus. Unspecified 21141211 CVCL_KR42 CeHCP4 hybridoma house mouse CVCL_KR42 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; G5EDA3; Caenorhabditis elegans hcp-4. 21141212 CVCL_L342 CO5 cancer cell line dog CVCL_L342 CL:0000010 Derived from sampling site: Bone; distal radius. Unspecified 21141213 CVCL_KR45 CeLET413 hybridoma house mouse CVCL_KR45 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O61967; Caenorhabditis elegans let-413. 21141214 CVCL_L345 CoMS cancer cell line dog CVCL_L345 CL:0000010 Breed/subspecies: Mixed breed. Male Doubling time: 27.0 +- 0.7 hours (PubMed=11642274) 21141215 CVCL_KR44 CeHSP60 hybridoma house mouse CVCL_KR44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P50140; Caenorhabditis elegans hsp-60. 21141216 CVCL_L344 CO8 cancer cell line dog CVCL_L344 CL:0000010 Derived from sampling site: Bone; proximal femur. Unspecified 21141217 CVCL_KR41 CeERM1 hybridoma house mouse CVCL_KR41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G5EES2; Caenorhabditis elegans erm-1. 21141218 CVCL_L341 CO3 cancer cell line dog CVCL_L341 CL:0000010 Derived from sampling site: Bone; distal radius. Unspecified 21141219 CVCL_KR40 CeDYN1 hybridoma house mouse CVCL_KR40 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P39055; Caenorhabditis elegans dyn-1. 21141220 CVCL_L340 CO2 [Dog osteosarcoma] cancer cell line dog CVCL_L340 CL:0000010 Derived from sampling site: Bone; distal femur. Unspecified 21141221 CVCL_C988 DMD-iPS (DYS-HAC)8 induced pluripotent stem cell human CVCL_C988 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141222 CVCL_BX88 ND00176 transformed cell line human CVCL_BX88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141223 CVCL_C987 DMD-iPS (DYS-HAC)7 induced pluripotent stem cell human CVCL_C987 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141224 CVCL_BX87 ND00175 transformed cell line human CVCL_BX87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141225 CVCL_C989 DMD-iPS (DYS-HAC)9 induced pluripotent stem cell human CVCL_C989 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141226 CVCL_BX89 ND00177 transformed cell line human CVCL_BX89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141227 CVCL_C980 MRC5-RiPS-1.9 induced pluripotent stem cell human CVCL_C980 From: Harvard Medical School; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21141228 CVCL_BX80 ND00164 transformed cell line human CVCL_BX80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141229 CVCL_C982 DMD-iPS (DYS-HAC)2 induced pluripotent stem cell human CVCL_C982 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141230 CVCL_BX82 ND00167 transformed cell line human CVCL_BX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141231 CVCL_C981 DMD-iPS (DYS-HAC)1 induced pluripotent stem cell human CVCL_C981 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141232 CVCL_BX81 ND00165 transformed cell line human CVCL_BX81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141233 CVCL_L318 CHS-5 cancer cell line dog CVCL_L318 CL:0000010 Derived from sampling site: Synovium; Breed/subspecies: Golden Retriever. Male 21141234 CVCL_C984 DMD-iPS (DYS-HAC)4 induced pluripotent stem cell human CVCL_C984 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141235 CVCL_BX84 ND00170 transformed cell line human CVCL_BX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141236 CVCL_KR18 PCRP-ZUFSP-1C12 hybridoma house mouse CVCL_KR18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96AP4; Human ZUFSP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141237 CVCL_L317 CHS-4 cancer cell line dog CVCL_L317 CL:0000010 Derived from sampling site: Synovium; Breed/subspecies: Flat-coated Retriever. Female 21141238 CVCL_C983 DMD-iPS (DYS-HAC)3 induced pluripotent stem cell human CVCL_C983 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141239 CVCL_BX83 ND00168 transformed cell line human CVCL_BX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141240 CVCL_KR17 PCRP-ZUFSP-1A2 hybridoma house mouse CVCL_KR17 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96AP4; Human ZUFSP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141241 CVCL_C986 DMD-iPS (DYS-HAC)6 induced pluripotent stem cell human CVCL_C986 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141242 CVCL_BX86 ND00173 transformed cell line human CVCL_BX86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141243 CVCL_L319 CHS-6 cancer cell line dog CVCL_L319 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Bernese mountain dog. Male 21141244 CVCL_C985 DMD-iPS (DYS-HAC)5 induced pluripotent stem cell human CVCL_C985 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141245 CVCL_BX85 ND00171 transformed cell line human CVCL_BX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141246 CVCL_KR19 PCRP-ZXDC-1H12 hybridoma house mouse CVCL_KR19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141247 CVCL_L314 CHS-1 cancer cell line dog CVCL_L314 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Maltese. Female 21141248 CVCL_KR14 PCRP-ZSCAN5A-4A9 hybridoma house mouse CVCL_KR14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141249 CVCL_L313 cHCC cancer cell line dog CVCL_L313 CL:0000010 Sequence variation: Mutation; VGNC; 43166; MET; Simple; p.Thr1344Ser (c.4030A>T); Zygosity=Unspecified (PubMed=15566568) Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Cairn Terrier. Female 21141250 CVCL_KR13 PCRP-ZSCAN5A-3F9 hybridoma house mouse CVCL_KR13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141251 CVCL_L316 CHS-3 cancer cell line dog CVCL_L316 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Bernese mountain dog. Male 21141252 CVCL_KR16 PCRP-ZSCAN9-2A6 hybridoma house mouse CVCL_KR16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15535; Human ZSCAN9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141253 CVCL_L315 CHS-2 cancer cell line dog CVCL_L315 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Shetland Sheepdog. Male 21141254 CVCL_KR15 PCRP-ZSCAN5A-4B5 hybridoma house mouse CVCL_KR15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141255 CVCL_L310 Ace-1 cancer cell line dog CVCL_L310 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Labrador Retriever. Male Characteristics: Orthotopic injection of Ace-1 in dogs results in prostatic tumors with metastases to lungs and lymph nodes (PubMed=23335024) 21141256 CVCL_KR10 PCRP-ZSCAN5A-2F11 hybridoma house mouse CVCL_KR10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141257 CVCL_L312 CCT [Dog] cancer cell line dog CVCL_L312 CL:0000010 Breed/subspecies: Borzoi. Male Doubling time: ~30 hours (PubMed=12867736) 21141258 CVCL_KR12 PCRP-ZSCAN5A-2H8 hybridoma house mouse CVCL_KR12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141259 CVCL_L311 BACA cancer cell line dog CVCL_L311 CL:0000010 Unspecified 21141260 CVCL_KR11 PCRP-ZSCAN5A-2H4 hybridoma house mouse CVCL_KR11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BUG6; Human ZSCAN5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141261 CVCL_C999 KiPS4F1 induced pluripotent stem cell human CVCL_C999 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21141262 CVCL_BX99 ND00192 transformed cell line human CVCL_BX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141263 CVCL_C998 KiPS4F-8 induced pluripotent stem cell human CVCL_C998 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21141264 CVCL_BX98 ND00190 transformed cell line human CVCL_BX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141265 CVCL_C991 DMD-iPS1 [Human iPSC Tottori] induced pluripotent stem cell human CVCL_C991 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141266 CVCL_BX91 ND00180 transformed cell line human CVCL_BX91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141267 CVCL_C990 DMD-iPS1 [Human iPSC Boston] induced pluripotent stem cell human CVCL_C990 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-53del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141268 CVCL_BX90 ND00179 transformed cell line human CVCL_BX90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141269 CVCL_C993 DMD-iPS2 [Human iPSC Tottori] induced pluripotent stem cell human CVCL_C993 From: Tottori University; Tottori; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141270 CVCL_BX93 ND00183 transformed cell line human CVCL_BX93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141271 CVCL_C992 DMD-iPS2 [Human iPSC Boston] induced pluripotent stem cell human CVCL_C992 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-53del; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141272 CVCL_BX92 ND00182 transformed cell line human CVCL_BX92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141273 CVCL_L329 CMT12 cancer cell line dog CVCL_L329 CL:0000010 Sequence variation: Mutation; VGNC; 42490; KMT2C; Simple; p.Arg1201fs (c.3600delGinsAA); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Val132Glu (c.395T>A); Zygosity=Homozygous (PubMed=31175136) Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~24 hours (PubMed=3462415); 19 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel Caution: CMT-2 was renamed CMT-12 in PubMed=11848473; Caution: On the basis of STR profile (PubMed=21908323; PubMed=27197945) CMT12 and CMT27 seem to originate from the same donor 21141274 CVCL_KR29 KFE-5 spontaneously immortalized cell line CVCL_KR29 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Doubling time: ~3 days (PubMed=24836542) Group: Fish cell line 21141275 CVCL_C995 KiPS3F1 induced pluripotent stem cell human CVCL_C995 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21141276 CVCL_BX95 ND00186 transformed cell line human CVCL_BX95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141277 CVCL_L328 CMS-C cancer cell line dog CVCL_L328 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Male Doubling time: 23 hours (PubMed=21519159) 21141278 CVCL_C994 KiPS3F-7 induced pluripotent stem cell human CVCL_C994 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21141279 CVCL_BX94 ND00185 transformed cell line human CVCL_BX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141280 CVCL_KR28 YPF-5 spontaneously immortalized cell line CVCL_KR28 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 21141281 CVCL_C997 KiPS4F-1 induced pluripotent stem cell human CVCL_C997 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21141282 CVCL_BX97 ND00189 transformed cell line human CVCL_BX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141283 CVCL_C996 KiPS3F2 induced pluripotent stem cell human CVCL_C996 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21141284 CVCL_BX96 ND00187 transformed cell line human CVCL_BX96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141285 CVCL_L325 CLK cancer cell line dog CVCL_L325 CL:0000010 Derived from sampling site: Ascites; Breed/subspecies: Pyrenean mountain dog. Female Doubling time: 36.2 hours (PubMed=23196801) 21141286 CVCL_KR25 PCRP-ZZZ3-1B11 hybridoma house mouse CVCL_KR25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IYH5; Human ZZZ3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141287 CVCL_L324 CLC [Dog lymphoma] cancer cell line dog CVCL_L324 CL:0000010 Derived from sampling site: Pleural effusion; Breed/subspecies: French Bulldog. Female Doubling time: 14.5 hours (PubMed=23196801) 21141288 CVCL_KR24 PCRP-ZXDC-4B9 hybridoma house mouse CVCL_KR24 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141289 CVCL_L327 CMeC-2 cancer cell line dog CVCL_L327 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Chow. Male Characteristics: Established from lung metastatic lesion obtained after subcutaneous injection of the parent cell line in nude mice (PubMed=15585963) Doubling time: 57.9 +- 3.28 hours (PubMed=15585963) 21141290 CVCL_L326 CMeC-1 cancer cell line dog CVCL_L326 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Chow. Male Doubling time: 37.7 +- 3.44 hours (PubMed=15585963) 21141291 CVCL_KR26 PCRP-ZZZ3-1B2 hybridoma house mouse CVCL_KR26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IYH5; Human ZZZ3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141292 CVCL_L321 CL-1 cancer cell line dog CVCL_L321 CL:0000010 Derived from sampling site: Pleural effusion; Breed/subspecies: Japanese Terrier. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21141293 CVCL_KR21 PCRP-ZXDC-3B6 hybridoma house mouse CVCL_KR21 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141294 CVCL_L320 CHS-7 cancer cell line dog CVCL_L320 CL:0000010 Derived from sampling site: Synovium; Breed/subspecies: Flat-coated Retriever. Male 21141295 CVCL_KR20 PCRP-ZXDC-2B5 hybridoma house mouse CVCL_KR20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141296 CVCL_L323 CLBL-1M cancer cell line dog CVCL_L323 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Bernese mountain dog. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a tumor in Rag-/- Gamma-c-/- mice injected subcutaneously with the parent cell line (PubMed=22761949) Doubling time: 26.4 hours (PubMed=22761949) 21141297 CVCL_KR23 PCRP-ZXDC-3D1 hybridoma house mouse CVCL_KR23 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141298 CVCL_L322 CLBL-1 cancer cell line dog CVCL_L322 CL:0000010 Sequence variation: Mutation; VGNC; 54284; CCND3; Simple; p.Arg358fs (c.1071_1075delCAGAG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ala127Val (c.380C>T); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Arg257His (c.770G>A); Zygosity=Heterozygous (PubMed=31175136) Derived from sampling site: Lymph node Cell type=B-cell.; Breed/subspecies: Bernese mountain dog. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 19 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel Caution: This cell line is owned by the University of Veterinary Medicine, Vienna who is the sole authorized distributor for both commercial and non-commercial research use 21141299 CVCL_KR22 PCRP-ZXDC-3C12 hybridoma house mouse CVCL_KR22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2QGD7; Human ZXDC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141300 CVCL_1F50 XP101TMA LCL transformed cell line human CVCL_1F50 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141301 CVCL_1F52 XPH102TMA LCL transformed cell line human CVCL_1F52 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141302 CVCL_1F51 XPH102TMA finite cell line human CVCL_1F51 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Heterozygous (PubMed=14662655) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141303 CVCL_1F54 XPH97TMA LCL transformed cell line human CVCL_1F54 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141304 CVCL_1F53 XPH97TMA finite cell line human CVCL_1F53 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (PubMed=11511294) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141305 CVCL_1F56 XPH103BE LCL transformed cell line human CVCL_1F56 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala874Thr (c.2620G>A) (G2817A); ClinVar=VCV000016577; Zygosity=Heterozygous (PubMed=12060391) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141306 CVCL_1F55 XP123TMA LCL transformed cell line human CVCL_1F55 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-24A>G (IVS3-24A>G); ClinVar=VCV000000261; Zygosity=Homozygous (PubMed=14662655) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141307 CVCL_1F58 XPH88BE finite cell line human CVCL_1F58 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys522Ter (c.1564A>T); ClinVar=VCV000549952; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141308 CVCL_1F57 XPH89BE finite cell line human CVCL_1F57 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu141Leufs*6 (c.420_423delTGAG) (p.Ser140fs*146) (525_528delTGAG); ClinVar=VCV000550638; Zygosity=Heterozygous (Coriell) Population: Jewish; Sephardic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141309 CVCL_1F59 XPH89BE LCL transformed cell line human CVCL_1F59 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu141Leufs*6 (c.420_423delTGAG) (p.Ser140fs*146) (525_528delTGAG); ClinVar=VCV000550638; Zygosity=Heterozygous (Coriell) Population: Jewish; Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16383; probable Female 21141310 CVCL_1F61 XPH90BE LCL transformed cell line human CVCL_1F61 CL:0000010 Population: Jewish; Ashkenazi/Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141311 CVCL_1F60 XPH88BE LCL transformed cell line human CVCL_1F60 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys522Ter (c.1564A>T); ClinVar=VCV000549952; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141312 CVCL_1F63 XPH106BE LCL transformed cell line human CVCL_1F63 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Heterozygous (PubMed=16081512) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141313 CVCL_1F62 XPH104BE LCL transformed cell line human CVCL_1F62 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gln136Ter (c.406C>T) (C603T); ClinVar=VCV000016578; Zygosity=Heterozygous (PubMed=12060391) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141314 CVCL_1F65 XPH133BE LCL transformed cell line human CVCL_1F65 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Honduran; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141315 CVCL_1F64 XPH107BE LCL transformed cell line human CVCL_1F64 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Heterozygous (PubMed=16081512) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141316 CVCL_1F67 GM16799 transformed cell line human CVCL_1F67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141317 CVCL_1F66 XPH133BE finite cell line human CVCL_1F66 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Honduran; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141318 CVCL_1F69 XPH288BE LCL transformed cell line human CVCL_1F69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141319 CVCL_1F68 GM16800 finite cell line human CVCL_1F68 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21141320 CVCL_TL91 HAP1 SLC20A2 (-) 1 cancer cell line human CVCL_TL91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141321 CVCL_TL90 HAP1 SLC20A1 (-) 2 cancer cell line human CVCL_TL90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10946; SLC20A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141322 CVCL_TL93 HAP1 SLC22A1 (-) 2 cancer cell line human CVCL_TL93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10963; SLC22A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141323 CVCL_TL92 HAP1 SLC22A1 (-) 1 cancer cell line human CVCL_TL92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10963; SLC22A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141324 CVCL_TL95 HAP1 SLC22A1 (-) 4 cancer cell line human CVCL_TL95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10963; SLC22A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141325 CVCL_TL94 HAP1 SLC22A1 (-) 3 cancer cell line human CVCL_TL94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10963; SLC22A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141326 CVCL_TL97 HAP1 SLC22A18 (-) 1 cancer cell line human CVCL_TL97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10964; SLC22A18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141327 CVCL_TL96 HAP1 SLC22A15 (-) 1 cancer cell line human CVCL_TL96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20301; SLC22A15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141328 CVCL_TL99 HAP1 SLC22A23 (-) 1 cancer cell line human CVCL_TL99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21106; SLC22A23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141329 CVCL_TL98 HAP1 SLC22A18 (-) 2 cancer cell line human CVCL_TL98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10964; SLC22A18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141330 CVCL_1F30 XPH137BE LCL transformed cell line human CVCL_1F30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141331 CVCL_1F32 XPH207BE LCL transformed cell line human CVCL_1F32 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>G (IVS5.1-2A>G); ClinVar=VCV000550100; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141332 CVCL_1F31 XPH136BE LCL transformed cell line human CVCL_1F31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141333 CVCL_1F34 XP68TMA finite cell line human CVCL_1F34 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Homozygous (PubMed=11511294) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141334 CVCL_1F33 XP67TMA finite cell line human CVCL_1F33 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Homozygous (PubMed=11511294; PubMed=18809580) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141335 CVCL_1F36 XP69TMA finite cell line human CVCL_1F36 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr430Ter (c.1290_1295delTAAAGA) (p.Tyr430_Glu432delinsTer) (1395_1400delTAAAGA); ClinVar=VCV000940041; Zygosity=Homozygous (Coriell) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141336 CVCL_1F35 XP69TMA LCL transformed cell line human CVCL_1F35 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr430Ter (c.1290_1295delTAAAGA) (p.Tyr430_Glu432delinsTer) (1395_1400delTAAAGA); ClinVar=VCV000940041; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141337 CVCL_1F38 XP72TMA finite cell line human CVCL_1F38 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-24A>G (IVS3-24A>G); ClinVar=VCV000000261; Zygosity=Homozygous (PubMed=14662655) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141338 CVCL_1F37 XP72TMA LCL transformed cell line human CVCL_1F37 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-24A>G (IVS3-24A>G); ClinVar=VCV000000261; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141339 CVCL_1F39 XP73TMA LCL transformed cell line human CVCL_1F39 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-24A>G (IVS3-24A>G); ClinVar=VCV000000261; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141340 CVCL_TL80 HAP1 SLC19A2 (-) 2 cancer cell line human CVCL_TL80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10938; SLC19A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141341 CVCL_TL82 HAP1 SLC1A1 (-) cancer cell line human CVCL_TL82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10939; SLC1A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141342 CVCL_TL81 HAP1 SLC19A3 (-) 1 cancer cell line human CVCL_TL81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16266; SLC19A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141343 CVCL_TL84 HAP1 SLC1A3 (-) 2 cancer cell line human CVCL_TL84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10941; SLC1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141344 CVCL_TL83 HAP1 SLC1A3 (-) 1 cancer cell line human CVCL_TL83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10941; SLC1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141345 CVCL_TL86 HAP1 SLC1A5 (-) 1 cancer cell line human CVCL_TL86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10943; SLC1A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141346 CVCL_TL85 HAP1 SLC1A4 (-) cancer cell line human CVCL_TL85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10942; SLC1A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141347 CVCL_TL88 HAP1 SLC1A5 (-) 3 cancer cell line human CVCL_TL88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10943; SLC1A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141348 CVCL_TL87 HAP1 SLC1A5 (-) 2 cancer cell line human CVCL_TL87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10943; SLC1A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141349 CVCL_TL89 HAP1 SLC20A1 (-) 1 cancer cell line human CVCL_TL89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10946; SLC20A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141350 CVCL_1F41 XPH93TMA LCL transformed cell line human CVCL_1F41 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr430Ter (c.1290_1295delTAAAGA) (p.Tyr430_Glu432delinsTer) (1395_1400delTAAAGA); ClinVar=VCV000940041; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141351 CVCL_1F40 XP73TMA finite cell line human CVCL_1F40 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-24A>G (IVS3-24A>G); ClinVar=VCV000000261; Zygosity=Homozygous (PubMed=14662655) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141352 CVCL_1F43 XPH96TMA finite cell line human CVCL_1F43 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (PubMed=11511294) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141353 CVCL_1F42 XPH94TMA LCL transformed cell line human CVCL_1F42 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr430Ter (c.1290_1295delTAAAGA) (p.Tyr430_Glu432delinsTer) (1395_1400delTAAAGA); ClinVar=VCV000940041; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141354 CVCL_1F45 XP100TMA finite cell line human CVCL_1F45 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Homozygous (PubMed=14662655; PubMed=16081512) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141355 CVCL_1F44 XPH96TMA LCL transformed cell line human CVCL_1F44 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Heterozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141356 CVCL_1F47 XP98TMA finite cell line human CVCL_1F47 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141357 CVCL_1F46 XP100TMA LCL transformed cell line human CVCL_1F46 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Homozygous (Coriell) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141358 CVCL_1F49 XP101TMA finite cell line human CVCL_1F49 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.413-9T>A (IVS3-9T>A); ClinVar=VCV000000260; Zygosity=Homozygous (PubMed=14662655) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141359 CVCL_1F48 XP98TMA LCL transformed cell line human CVCL_1F48 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (from autologous cell line XP98TMA) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141360 CVCL_TL71 HAP1 SLC17A5 (-) 1 cancer cell line human CVCL_TL71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10933; SLC17A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141361 CVCL_TL70 HAP1 SLC16A9 (-) 1 cancer cell line human CVCL_TL70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23520; SLC16A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141362 CVCL_TL73 HAP1 SLC17A9 (-) cancer cell line human CVCL_TL73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16192; SLC17A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141363 CVCL_TL72 HAP1 SLC17A5 (-) 2 cancer cell line human CVCL_TL72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10933; SLC17A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141364 CVCL_TL75 HAP1 SLC18A2 (-) 2 cancer cell line human CVCL_TL75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10935; SLC18A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141365 CVCL_TL74 HAP1 SLC18A2 (-) 1 cancer cell line human CVCL_TL74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10935; SLC18A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141366 CVCL_TL77 HAP1 SLC19A1 (-) 1 cancer cell line human CVCL_TL77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10937; SLC19A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141367 CVCL_TL76 HAP1 SLC18B1 (-) 1 cancer cell line human CVCL_TL76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21573; SLC18B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141368 CVCL_TL79 HAP1 SLC19A2 (-) 1 cancer cell line human CVCL_TL79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10938; SLC19A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141369 CVCL_TL78 HAP1 SLC19A1 (-) 2 cancer cell line human CVCL_TL78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10937; SLC19A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141370 CVCL_1F10 GM02523 finite cell line human CVCL_1F10 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Metabolome analysis Male 21141371 CVCL_1F12 GM03083 finite cell line human CVCL_1F12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141372 CVCL_1F11 GM03080 finite cell line human CVCL_1F11 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141373 CVCL_1F14 GM03390 finite cell line human CVCL_1F14 CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Metabolome analysis Male 21141374 CVCL_1F13 GM03388 finite cell line human CVCL_1F13 CL:0000010 Population: Iranian; Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Metabolome analysis Male 21141375 CVCL_1F16 XPH291BE LCL transformed cell line human CVCL_1F16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141376 CVCL_1F15 GM03614 finite cell line human CVCL_1F15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141377 CVCL_1F18 XPH310BE LCL transformed cell line human CVCL_1F18 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS11-1_IVS11-2delAG; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS11-6_IVS11-7insCC; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141378 CVCL_1F17 XPH292BE LCL transformed cell line human CVCL_1F17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141379 CVCL_1F09 GM01736 finite cell line human CVCL_1F09 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141380 CVCL_1F08 XPHM1WI finite cell line human CVCL_1F08 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141381 CVCL_TL60 HAP1 SLC15A4 (-) 2 cancer cell line human CVCL_TL60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23090; SLC15A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141382 CVCL_TL62 HAP1 SLC16A1 (-) 2 cancer cell line human CVCL_TL62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10922; SLC16A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141383 CVCL_TL61 HAP1 SLC16A1 (-) 1 cancer cell line human CVCL_TL61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10922; SLC16A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141384 CVCL_TL64 HAP1 SLC16A10 (-) 2 cancer cell line human CVCL_TL64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17027; SLC16A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141385 CVCL_TL63 HAP1 SLC16A10 (-) 1 cancer cell line human CVCL_TL63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17027; SLC16A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141386 CVCL_TL66 HAP1 SLC16A14 (-) cancer cell line human CVCL_TL66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26417; SLC16A14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141387 CVCL_TL65 HAP1 SLC16A13 (-) cancer cell line human CVCL_TL65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31037; SLC16A13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141388 CVCL_TL68 HAP1 SLC16A3 (-) 1 cancer cell line human CVCL_TL68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10924; SLC16A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141389 CVCL_TL67 HAP1 SLC16A2 (-) 1 cancer cell line human CVCL_TL67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10923; SLC16A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141390 CVCL_TL69 HAP1 SLC16A3 (-) 2 cancer cell line human CVCL_TL69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10924; SLC16A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141391 CVCL_TL49 HAP1 SLC12A2 (-) 6 cancer cell line human CVCL_TL49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10911; SLC12A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141392 CVCL_1F21 XPHM12BE finite cell line human CVCL_1F21 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-1G>T (IVS3-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141393 CVCL_1F20 XPHF12BE LCL transformed cell line human CVCL_1F20 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141394 CVCL_1F23 XPHM1WI LCL transformed cell line human CVCL_1F23 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141395 CVCL_1F22 XPHM12BE LCL transformed cell line human CVCL_1F22 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-1G>T (IVS3-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141396 CVCL_1F25 XPH130BE LCL transformed cell line human CVCL_1F25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141397 CVCL_1F24 GM09430 finite cell line human CVCL_1F24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141398 CVCL_1F27 XPH206BE LCL transformed cell line human CVCL_1F27 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg155Ter (c.463C>T); ClinVar=VCV000496268; Zygosity=Heterozygous (Coriell) Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141399 CVCL_1F26 XPH130BE finite cell line human CVCL_1F26 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141400 CVCL_1F29 XPCSH5BA finite cell line human CVCL_1F29 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141401 CVCL_1F28 XPCSH4BA finite cell line human CVCL_1F28 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (PubMed=16947863) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141402 CVCL_1F19 XPHF12BE finite cell line human CVCL_1F19 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141403 CVCL_TL51 HAP1 SLC12A4 (-) 2 cancer cell line human CVCL_TL51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10913; SLC12A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141404 CVCL_TL50 HAP1 SLC12A4 (-) 1 cancer cell line human CVCL_TL50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10913; SLC12A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141405 CVCL_TL53 HAP1 SLC12A5 (-) 2 cancer cell line human CVCL_TL53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13818; SLC12A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141406 CVCL_TL52 HAP1 SLC12A5 (-) 1 cancer cell line human CVCL_TL52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13818; SLC12A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141407 CVCL_TL55 HAP1 SLC12A7 (-) 1 cancer cell line human CVCL_TL55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10915; SLC12A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141408 CVCL_TL54 HAP1 SLC12A6 (-) cancer cell line human CVCL_TL54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10914; SLC12A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141409 CVCL_TL57 HAP1 SLC12A9 (-) 1 cancer cell line human CVCL_TL57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17435; SLC12A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141410 CVCL_TL56 HAP1 SLC12A7 (-) 2 cancer cell line human CVCL_TL56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10915; SLC12A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141411 CVCL_TL59 HAP1 SLC15A4 (-) 1 cancer cell line human CVCL_TL59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23090; SLC15A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141412 CVCL_TL58 HAP1 SLC12A9 (-) 2 cancer cell line human CVCL_TL58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17435; SLC12A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141413 CVCL_TL39 HAP1 SKP2 (-) 1 cancer cell line human CVCL_TL39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10901; SKP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141414 CVCL_TL38 HAP1 SKOR1 (-) 1 cancer cell line human CVCL_TL38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21326; SKOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141415 CVCL_KR98 GeneBLAzer GLP1R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_KR98 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21141416 CVCL_L398 OSCA-60 cancer cell line dog CVCL_L398 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Mastiff. Female 21141417 CVCL_KR97 CellSensor CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_KR97 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21141418 CVCL_L397 OSCA-06M cancer cell line dog CVCL_L397 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Rhodesian Ridgeback. Female 21141419 CVCL_TL40 HAP1 SKP2 (-) 2 cancer cell line human CVCL_TL40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10901; SKP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141420 CVCL_KR99 GeneBLAzer ADORA2A-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_KR99 CL:0000010 Transfected with: HGNC; 263; ADORA2A; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21141421 CVCL_L399 OSCA-67 cancer cell line dog CVCL_L399 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Mastiff. Female 21141422 CVCL_KR94 54-11-10 hybridoma house mouse CVCL_KR94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13231; Dictyostelium discoideum hatA. 21141423 CVCL_TL42 HAP1 SLC10A4 (-) 1 cancer cell line human CVCL_TL42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22980; SLC10A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141424 CVCL_L394 OSCA-56 cancer cell line dog CVCL_L394 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141425 CVCL_TL41 HAP1 SLC10A3 (-) cancer cell line human CVCL_TL41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22979; SLC10A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141426 CVCL_L393 OSCA-55 cancer cell line dog CVCL_L393 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Borzoi. Female 21141427 CVCL_KR93 SUK 5 hybridoma house mouse CVCL_KR93 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P35978; Strongylocentrotus purpuratus kinesin heavy chain. 21141428 CVCL_KR96 GeneBLAzer CMV-bla CHO-K1 spontaneously immortalized cell line CVCL_KR96 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Discontinued: Thermofisher/Invitrogen; Catalog number K1100 Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CMV promoter 21141429 CVCL_TL44 HAP1 SLC11A2 (-) 1 cancer cell line human CVCL_TL44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10908; SLC11A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141430 CVCL_L396 OSCA-59 cancer cell line dog CVCL_L396 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Female 21141431 CVCL_KR95 290.5C10 hybridoma house mouse CVCL_KR95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 21141432 CVCL_TL43 HAP1 SLC10A7 (-) 1 cancer cell line human CVCL_TL43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23088; SLC10A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141433 CVCL_L395 OSCA-57 cancer cell line dog CVCL_L395 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Golden Retriever. Male 21141434 CVCL_KR90 C17.9C6 hybridoma house mouse CVCL_KR90 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07207; Drosophila melanogaster Notch (N). 21141435 CVCL_TL46 HAP1 SLC11A2 (-) 3 cancer cell line human CVCL_TL46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10908; SLC11A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141436 CVCL_L390 OSCA-41 cancer cell line dog CVCL_L390 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Alaskan Malamute. Male 21141437 CVCL_TL45 HAP1 SLC11A2 (-) 2 cancer cell line human CVCL_TL45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10908; SLC11A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141438 CVCL_TL48 HAP1 SLC12A2 (-) 5 cancer cell line human CVCL_TL48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10911; SLC12A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141439 CVCL_L392 OSCA-50 cancer cell line dog CVCL_L392 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Rottweiler. Male 21141440 CVCL_KR92 SUK 4 hybridoma house mouse CVCL_KR92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35978; Strongylocentrotus purpuratus kinesin heavy chain. 21141441 CVCL_TL47 HAP1 SLC12A2 (-) 4 cancer cell line human CVCL_TL47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10911; SLC12A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141442 CVCL_L391 OSCA-45 cancer cell line dog CVCL_L391 CL:0000010 Derived from sampling site: Bone; leg; Breed/subspecies: Irish Setter. Female 21141443 CVCL_KR91 SUK 2 hybridoma house mouse CVCL_KR91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35978; Strongylocentrotus purpuratus kinesin heavy chain. 21141444 CVCL_TL28 HAP1 SIRT2 (-) 2 cancer cell line human CVCL_TL28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10886; SIRT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141445 CVCL_TL27 HAP1 SIRT2 (-) 1 cancer cell line human CVCL_TL27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10886; SIRT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141446 CVCL_TL29 HAP1 SIRT2 (-) 3 cancer cell line human CVCL_TL29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10886; SIRT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141447 CVCL_1F01 GM00111 finite cell line human CVCL_1F01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141448 CVCL_1F00 U-692MG cancer cell line human CVCL_1F00 CL:0000010 Male 21141449 CVCL_1F03 GM00241 finite cell line human CVCL_1F03 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141450 CVCL_1F02 GM00226 finite cell line human CVCL_1F02 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21141451 CVCL_1F05 GM00578 finite cell line human CVCL_1F05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21141452 CVCL_1F04 GM00573 finite cell line human CVCL_1F04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141453 CVCL_1F07 GM01509 finite cell line human CVCL_1F07 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141454 CVCL_1F06 GM01213 finite cell line human CVCL_1F06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141455 CVCL_TL31 HAP1 SIRT3 (-) 2 cancer cell line human CVCL_TL31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14931; SIRT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141456 CVCL_TL30 HAP1 SIRT3 (-) 1 cancer cell line human CVCL_TL30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14931; SIRT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141457 CVCL_TL33 HAP1 SIRT4 (-) 2 cancer cell line human CVCL_TL33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14932; SIRT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141458 CVCL_TL32 HAP1 SIRT4 (-) 1 cancer cell line human CVCL_TL32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14932; SIRT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141459 CVCL_TL35 HAP1 SIRT6 (-) 1 cancer cell line human CVCL_TL35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14934; SIRT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141460 CVCL_TL34 HAP1 SIRT5 (-) cancer cell line human CVCL_TL34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14933; SIRT5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141461 CVCL_TL37 HAP1 SIRT7 (-) cancer cell line human CVCL_TL37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14935; SIRT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141462 CVCL_TL36 HAP1 SIRT6 (-) 2 cancer cell line human CVCL_TL36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14934; SIRT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141463 CVCL_TE41 HAP1 PLCH1 (-) 2 cancer cell line human CVCL_TE41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29185; PLCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141464 CVCL_TE40 HAP1 PLCH1 (-) 1 cancer cell line human CVCL_TE40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29185; PLCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141465 CVCL_TE43 HAP1 PLD1 (-) 2 cancer cell line human CVCL_TE43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9067; PLD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141466 CVCL_TE42 HAP1 PLD1 (-) 1 cancer cell line human CVCL_TE42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9067; PLD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141467 CVCL_TE45 HAP1 PLD2 (-) 2 cancer cell line human CVCL_TE45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9068; PLD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141468 CVCL_TE44 HAP1 PLD2 (-) 1 cancer cell line human CVCL_TE44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9068; PLD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141469 CVCL_TE47 HAP1 PLD3 (-) 1 cancer cell line human CVCL_TE47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17158; PLD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141470 CVCL_TE46 HAP1 PLD2 (-) 3 cancer cell line human CVCL_TE46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9068; PLD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141471 CVCL_TE49 HAP1 PLD5 (-) 1 cancer cell line human CVCL_TE49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26879; PLD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141472 CVCL_TE48 HAP1 PLD3 (-) 2 cancer cell line human CVCL_TE48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17158; PLD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141473 CVCL_KK97 PCRP-SMAD4-2D1 hybridoma house mouse CVCL_KK97 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141474 CVCL_KK96 PCRP-SMAD4-2B3 hybridoma house mouse CVCL_KK96 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141475 CVCL_KK99 PCRP-SMAD9-2F4 hybridoma house mouse CVCL_KK99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15198; Human SMAD9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141476 CVCL_KK98 PCRP-SMAD7-1D7 hybridoma house mouse CVCL_KK98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15105; Human SMAD7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141477 CVCL_TE30 HAP1 PLCD3 (-) 3 cancer cell line human CVCL_TE30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9061; PLCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141478 CVCL_TE32 HAP1 PLCD4 (-) 2 cancer cell line human CVCL_TE32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9062; PLCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141479 CVCL_TE31 HAP1 PLCD4 (-) 1 cancer cell line human CVCL_TE31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9062; PLCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141480 CVCL_TE34 HAP1 PLCE1 (-) 2 cancer cell line human CVCL_TE34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17175; PLCE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141481 CVCL_TE33 HAP1 PLCE1 (-) 1 cancer cell line human CVCL_TE33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17175; PLCE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141482 CVCL_TE36 HAP1 PLCG1 (-) 1 cancer cell line human CVCL_TE36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141483 CVCL_TE35 HAP1 PLCE1 (-) 3 cancer cell line human CVCL_TE35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17175; PLCE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141484 CVCL_TE38 HAP1 PLCG2 (-) 1 cancer cell line human CVCL_TE38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9066; PLCG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141485 CVCL_TE37 HAP1 PLCG1 (-) 2 cancer cell line human CVCL_TE37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141486 CVCL_TE39 HAP1 PLCG2 (-) 2 cancer cell line human CVCL_TE39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9066; PLCG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141487 CVCL_KK82 PCRP-SLC25A24-3G2 hybridoma house mouse CVCL_KK82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6NUK1; Human SLC25A24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141488 CVCL_KK81 PCRP-SKIL-1D1 hybridoma house mouse CVCL_KK81 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P12757; Human SKIL. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141489 CVCL_KK84 PCRP-SMAD1-1B12 hybridoma house mouse CVCL_KK84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15797; Human SMAD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141490 CVCL_KK83 PCRP-SLC30A9-1C3 hybridoma house mouse CVCL_KK83 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6PML9; Human SLC30A9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141491 CVCL_KK80 PCRP-SIX5-2H4 hybridoma house mouse CVCL_KK80 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141492 CVCL_TE21 HAP1 PLCB1 (-) 2 cancer cell line human CVCL_TE21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15917; PLCB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141493 CVCL_TE20 HAP1 PLCB1 (-) 1 cancer cell line human CVCL_TE20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15917; PLCB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141494 CVCL_TE23 HAP1 PLCB3 (-) 2 cancer cell line human CVCL_TE23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141495 CVCL_TE22 HAP1 PLCB3 (-) 1 cancer cell line human CVCL_TE22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141496 CVCL_TE25 HAP1 PLCB4 (-) 2 cancer cell line human CVCL_TE25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9059; PLCB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141497 CVCL_TE24 HAP1 PLCB4 (-) 1 cancer cell line human CVCL_TE24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9059; PLCB4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141498 CVCL_TE27 HAP1 PLCD1 (-) 2 cancer cell line human CVCL_TE27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9060; PLCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141499 CVCL_KK79 PCRP-SIX5-2B11 hybridoma house mouse CVCL_KK79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N196; Human SIX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141500 CVCL_TE26 HAP1 PLCD1 (-) 1 cancer cell line human CVCL_TE26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9060; PLCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141501 CVCL_KK78 PCRP-SIRT6-1E2 hybridoma house mouse CVCL_KK78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N6T7; Human SIRT6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141502 CVCL_TE29 HAP1 PLCD3 (-) 2 cancer cell line human CVCL_TE29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9061; PLCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141503 CVCL_TE28 HAP1 PLCD3 (-) 1 cancer cell line human CVCL_TE28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9061; PLCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141504 CVCL_KK75 PCRP-SIRT2-1A8 hybridoma house mouse CVCL_KK75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IXJ6; Human SIRT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141505 CVCL_KK74 PCRP-SIRT2-1A2 hybridoma house mouse CVCL_KK74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IXJ6; Human SIRT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141506 CVCL_KK77 PCRP-SIRT5-1D4 hybridoma house mouse CVCL_KK77 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NXA8; Human SIRT5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141507 CVCL_KK76 PCRP-SIRT3-1C10 hybridoma house mouse CVCL_KK76 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9NTG7; Human SIRT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141508 CVCL_KK93 PCRP-SMAD4-1G12 hybridoma house mouse CVCL_KK93 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141509 CVCL_KK92 PCRP-SMAD4-1G11 hybridoma house mouse CVCL_KK92 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141510 CVCL_KK95 PCRP-SMAD4-2A5 hybridoma house mouse CVCL_KK95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141511 CVCL_KK94 PCRP-SMAD4-1H2 hybridoma house mouse CVCL_KK94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141512 CVCL_KK91 PCRP-SMAD4-1D3 hybridoma house mouse CVCL_KK91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141513 CVCL_KK90 PCRP-SMAD4-1D12 hybridoma house mouse CVCL_KK90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141514 CVCL_TE10 HAP1 PLA2G4A (-) 2 cancer cell line human CVCL_TE10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141515 CVCL_TE12 HAP1 PLA2G4B (-) 1 cancer cell line human CVCL_TE12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9036; PLA2G4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141516 CVCL_TE11 HAP1 PLA2G4A (-) 3 cancer cell line human CVCL_TE11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141517 CVCL_TE14 HAP1 PLA2G6 (-) 1 cancer cell line human CVCL_TE14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9039; PLA2G6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141518 CVCL_TE13 HAP1 PLA2G4B (-) 2 cancer cell line human CVCL_TE13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9036; PLA2G4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141519 CVCL_TE16 HAP1 PLAU (-) 1 cancer cell line human CVCL_TE16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9052; PLAU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141520 CVCL_TE15 HAP1 PLA2G6 (-) 2 cancer cell line human CVCL_TE15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9039; PLA2G6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141521 CVCL_KK89 PCRP-SMAD4-1C10 hybridoma house mouse CVCL_KK89 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13485; Human SMAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141522 CVCL_TE18 HAP1 PLAUR (-) 1 cancer cell line human CVCL_TE18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9053; PLAUR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141523 CVCL_TE17 HAP1 PLAU (-) 2 cancer cell line human CVCL_TE17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9052; PLAU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141524 CVCL_KK86 PCRP-SMAD2-1B10 hybridoma house mouse CVCL_KK86 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q15796; Human SMAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141525 CVCL_TE19 HAP1 PLAUR (-) 2 cancer cell line human CVCL_TE19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9053; PLAUR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141526 CVCL_KK85 PCRP-SMAD1-1B4 hybridoma house mouse CVCL_KK85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15797; Human SMAD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141527 CVCL_KK88 PCRP-SMAD3-1A2 hybridoma house mouse CVCL_KK88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P84022; Human SMAD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141528 CVCL_KK87 PCRP-SMAD2-1C12 hybridoma house mouse CVCL_KK87 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15796; Human SMAD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141529 CVCL_KK60 PCRP-SCXA-1D2 hybridoma house mouse CVCL_KK60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7RTU7; Human SCX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141530 CVCL_KK62 PCRP-SET-1C6 hybridoma house mouse CVCL_KK62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01105; Human SET. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141531 CVCL_KK61 PCRP-SCXA-2D11 hybridoma house mouse CVCL_KK61 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q7RTU7; Human SCX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141532 CVCL_TE01 HAP1 PKN1 (-) 2 cancer cell line human CVCL_TE01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9405; PKN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141533 CVCL_TE00 HAP1 PKN1 (-) 1 cancer cell line human CVCL_TE00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9405; PKN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141534 CVCL_TE03 HAP1 PKN3 (-) 1 cancer cell line human CVCL_TE03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17999; PKN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141535 CVCL_TE02 HAP1 PKN2 (-) cancer cell line human CVCL_TE02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9406; PKN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141536 CVCL_TE05 HAP1 PLA2G12A (-) 1 cancer cell line human CVCL_TE05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18554; PLA2G12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141537 CVCL_KK57 PCRP-SCML4-1F9 hybridoma house mouse CVCL_KK57 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N228; Human SCML4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141538 CVCL_TE04 HAP1 PKN3 (-) 2 cancer cell line human CVCL_TE04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17999; PKN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141539 CVCL_KK56 PCRP-SCML4-1D6 hybridoma house mouse CVCL_KK56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8N228; Human SCML4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141540 CVCL_TE07 HAP1 PLA2G15 (-) 1 cancer cell line human CVCL_TE07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17163; PLA2G15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141541 CVCL_KK59 PCRP-SCRT1-1B1 hybridoma house mouse CVCL_KK59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BWW7; Human SCRT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141542 CVCL_TE06 HAP1 PLA2G12A (-) 2 cancer cell line human CVCL_TE06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18554; PLA2G12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141543 CVCL_KK58 PCRP-SCRT1-1A11 hybridoma house mouse CVCL_KK58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BWW7; Human SCRT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141544 CVCL_TE09 HAP1 PLA2G4A (-) 1 cancer cell line human CVCL_TE09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141545 CVCL_KK53 PCRP-SCAND3-1C2 hybridoma house mouse CVCL_KK53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6R2W3; Human SCAND3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141546 CVCL_TE08 HAP1 PLA2G15 (-) 2 cancer cell line human CVCL_TE08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17163; PLA2G15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141547 CVCL_KK52 PCRP-SCAND3-1B7 hybridoma house mouse CVCL_KK52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6R2W3; Human SCAND3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141548 CVCL_KK55 PCRP-SCML2-1D12 hybridoma house mouse CVCL_KK55 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9UQR0; Human SCML2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141549 CVCL_KK54 PCRP-SCAND3-1D9 hybridoma house mouse CVCL_KK54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6R2W3; Human SCAND3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141550 CVCL_KK71 PCRP-SIN3B-1A9 hybridoma house mouse CVCL_KK71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75182; Human SIN3B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141551 CVCL_KK70 PCRP-SHOX-1A8 hybridoma house mouse CVCL_KK70 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15266; Human SHOX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141552 CVCL_KK73 PCRP-SIRT1-1F6 hybridoma house mouse CVCL_KK73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96EB6; Human SIRT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141553 CVCL_KK72 PCRP-SIRT1-1E11 hybridoma house mouse CVCL_KK72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96EB6; Human SIRT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141554 CVCL_KK68 PCRP-SHARPIN-1A5 hybridoma house mouse CVCL_KK68 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H0F6; Human SHARPIN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141555 CVCL_KK67 PCRP-SFMBT2-2E12 hybridoma house mouse CVCL_KK67 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q5VUG0; Human SFMBT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141556 CVCL_KK69 PCRP-SHARPIN-1A8 hybridoma house mouse CVCL_KK69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H0F6; Human SHARPIN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141557 CVCL_KK64 PCRP-SFMBT1-2C1 hybridoma house mouse CVCL_KK64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9UHJ3; Human SFMBT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141558 CVCL_KK63 PCRP-SETD6-1E8 hybridoma house mouse CVCL_KK63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TBK2; Human SETD6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141559 CVCL_KK66 PCRP-SFMBT2-2E1 hybridoma house mouse CVCL_KK66 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q5VUG0; Human SFMBT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141560 CVCL_KK65 PCRP-SFMBT2-1B7 hybridoma house mouse CVCL_KK65 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q5VUG0; Human SFMBT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141561 CVCL_KK40 PCRP-RXRG-5H4 hybridoma house mouse CVCL_KK40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P48443; Human RXRG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141562 CVCL_KK39 PCRP-RXRG-5G6 hybridoma house mouse CVCL_KK39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P48443; Human RXRG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141563 CVCL_KK38 PCRP-RXRG-5C9 hybridoma house mouse CVCL_KK38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P48443; Human RXRG. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141564 CVCL_KK35 PCRP-RUVBL1-1A1 hybridoma house mouse CVCL_KK35 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y265; Human RUVBL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141565 CVCL_KK34 PCRP-RUNX2-1B9 hybridoma house mouse CVCL_KK34 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q13950; Human RUNX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141566 CVCL_KK37 PCRP-RXRB-2B6 hybridoma house mouse CVCL_KK37 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P28702; Human RXRB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141567 CVCL_KK36 PCRP-RXRA-2A8 hybridoma house mouse CVCL_KK36 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19793; Human RXRA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141568 CVCL_KK31 PCRP-RPS6KA5-1F10 hybridoma house mouse CVCL_KK31 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75582; Human RPS6KA5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141569 CVCL_KK30 PCRP-RPS6KA5-1A8 hybridoma house mouse CVCL_KK30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75582; Human RPS6KA5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141570 CVCL_KK33 PCRP-RUNX2-1B7 hybridoma house mouse CVCL_KK33 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13950; Human RUNX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141571 CVCL_KK32 PCRP-RUNX1-3D7 hybridoma house mouse CVCL_KK32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q01196; Human RUNX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141572 CVCL_KK51 PCRP-SCAND1-3E7 hybridoma house mouse CVCL_KK51 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P57086; Human SCAND1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141573 CVCL_KK50 PCRP-SCAND1-3D11 hybridoma house mouse CVCL_KK50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P57086; Human SCAND1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141574 CVCL_KK49 PCRP-SCAND1-1D12 hybridoma house mouse CVCL_KK49 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P57086; Human SCAND1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141575 CVCL_KK46 PCRP-SATB1-3E9 hybridoma house mouse CVCL_KK46 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141576 CVCL_KK45 PCRP-SATB1-3C2 hybridoma house mouse CVCL_KK45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141577 CVCL_KK48 PCRP-SATB1-4H8 hybridoma house mouse CVCL_KK48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141578 CVCL_KK47 PCRP-SATB1-3H2 hybridoma house mouse CVCL_KK47 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141579 CVCL_KK42 PCRP-SAMD4B-2A6 hybridoma house mouse CVCL_KK42 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q5PRF9; Human SAMD4B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141580 CVCL_KK41 PCRP-SAMD4B-1H3 hybridoma house mouse CVCL_KK41 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q5PRF9; Human SAMD4B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141581 CVCL_KK44 PCRP-SATB1-3B6 hybridoma house mouse CVCL_KK44 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141582 CVCL_KK43 PCRP-SATB1-1D8 hybridoma house mouse CVCL_KK43 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01826; Human SATB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141583 CVCL_9X03 GM06329 finite cell line human CVCL_9X03 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141584 CVCL_9X02 GM06328 finite cell line human CVCL_9X02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141585 CVCL_9X05 GM07743 transformed cell line human CVCL_9X05 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141586 CVCL_9X04 GM07214 finite cell line human CVCL_9X04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141587 CVCL_9X01 GM06327 finite cell line human CVCL_9X01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141588 CVCL_9X00 GM12686 transformed cell line human CVCL_9X00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1708 21141589 CVCL_9X07 GM07841 transformed cell line human CVCL_9X07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141590 CVCL_9X06 GM07817 finite cell line human CVCL_9X06 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141591 CVCL_9X09 GM09292 transformed cell line human CVCL_9X09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141592 CVCL_9X08 GM09291 transformed cell line human CVCL_9X08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141593 CVCL_9X14 GM10082 transformed cell line human CVCL_9X14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141594 CVCL_9X13 GM09401 finite cell line human CVCL_9X13 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141595 CVCL_9X16 GM10277 finite cell line human CVCL_9X16 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Ala2Gly (c.5C>G); ClinVar=VCV000193063; Zygosity=Homozygous (PubMed=25059784) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141596 CVCL_9X15 GM10267 transformed cell line human CVCL_9X15 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Ala2Gly (c.5C>G); ClinVar=VCV000193063; Zygosity=Homozygous (from autologous cell line GM10277) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141597 CVCL_9X10 GM09293 transformed cell line human CVCL_9X10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141598 CVCL_9X12 GM09400 finite cell line human CVCL_9X12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141599 CVCL_9X11 GM09399 finite cell line human CVCL_9X11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141600 CVCL_9X18 GM11348 finite cell line human CVCL_9X18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141601 CVCL_9X17 GM11347 finite cell line human CVCL_9X17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141602 CVCL_9X19 GM11349 finite cell line human CVCL_9X19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141603 CVCL_TE90 HAP1 POLDIP2 (-) 1 cancer cell line human CVCL_TE90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23781; POLDIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141604 CVCL_TE92 HAP1 POLE (-) 1 cancer cell line human CVCL_TE92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9177; POLE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141605 CVCL_TE91 HAP1 POLDIP2 (-) 2 cancer cell line human CVCL_TE91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23781; POLDIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141606 CVCL_TE94 HAP1 POLE (-) 3 cancer cell line human CVCL_TE94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9177; POLE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141607 CVCL_TE93 HAP1 POLE (-) 2 cancer cell line human CVCL_TE93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9177; POLE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141608 CVCL_TE96 HAP1 POLH (-) 1 cancer cell line human CVCL_TE96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9181; POLH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141609 CVCL_TE95 HAP1 POLE4 (-) cancer cell line human CVCL_TE95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18755; POLE4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141610 CVCL_TE98 HAP1 POLI (-) 1 cancer cell line human CVCL_TE98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9182; POLI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141611 CVCL_TE97 HAP1 POLH (-) 2 cancer cell line human CVCL_TE97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9181; POLH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141612 CVCL_TE99 HAP1 POLI (-) 2 cancer cell line human CVCL_TE99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9182; POLI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141613 CVCL_TE81 HAP1 POGK (-) 1 cancer cell line human CVCL_TE81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18800; POGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141614 CVCL_TE80 HAP1 PODXL (-) 1 cancer cell line human CVCL_TE80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141615 CVCL_TE83 HAP1 POGK (-) 3 cancer cell line human CVCL_TE83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18800; POGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141616 CVCL_TE82 HAP1 POGK (-) 2 cancer cell line human CVCL_TE82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18800; POGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141617 CVCL_TE85 HAP1 POGZ (-) 1 cancer cell line human CVCL_TE85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18801; POGZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141618 CVCL_TE84 HAP1 POGK (-) 4 cancer cell line human CVCL_TE84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18800; POGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141619 CVCL_TE87 HAP1 POGZ (-) 3 cancer cell line human CVCL_TE87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18801; POGZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141620 CVCL_TE86 HAP1 POGZ (-) 2 cancer cell line human CVCL_TE86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18801; POGZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141621 CVCL_TE89 HAP1 POLB (-) 2 cancer cell line human CVCL_TE89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9174; POLB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141622 CVCL_TE88 HAP1 POLB (-) 1 cancer cell line human CVCL_TE88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9174; POLB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141623 CVCL_TE70 HAP1 PLP2 (-) 1 cancer cell line human CVCL_TE70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9087; PLP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141624 CVCL_TE72 HAP1 PMAIP1 (-) 1 cancer cell line human CVCL_TE72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9108; PMAIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141625 CVCL_TE71 HAP1 PLP2 (-) 2 cancer cell line human CVCL_TE71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9087; PLP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141626 CVCL_TE74 HAP1 PMS2 (-) cancer cell line human CVCL_TE74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9122; PMS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141627 CVCL_TE73 HAP1 PML (-) 1 cancer cell line human CVCL_TE73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141628 CVCL_TE76 HAP1 PNCK (-) 2 cancer cell line human CVCL_TE76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13415; PNCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141629 CVCL_TE75 HAP1 PNCK (-) 1 cancer cell line human CVCL_TE75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13415; PNCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141630 CVCL_TE78 HAP1 PNP (-) 2 cancer cell line human CVCL_TE78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7892; PNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141631 CVCL_TE77 HAP1 PNP (-) 1 cancer cell line human CVCL_TE77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7892; PNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141632 CVCL_TE79 HAP1 PNPLA2 (-) 1 cancer cell line human CVCL_TE79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30802; PNPLA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141633 CVCL_TE61 HAP1 PLIN3 (-) 3 cancer cell line human CVCL_TE61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16893; PLIN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141634 CVCL_TE60 HAP1 PLIN3 (-) 2 cancer cell line human CVCL_TE60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16893; PLIN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141635 CVCL_TE63 HAP1 PLK2 (-) 1 cancer cell line human CVCL_TE63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141636 CVCL_TE62 HAP1 PLK2 (-) cancer cell line human CVCL_TE62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141637 CVCL_TE65 HAP1 PLK2 (-) 3 cancer cell line human CVCL_TE65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141638 CVCL_TE64 HAP1 PLK2 (-) 2 cancer cell line human CVCL_TE64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141639 CVCL_TE67 HAP1 PLK3 (-) 1 cancer cell line human CVCL_TE67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2154; PLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141640 CVCL_TE66 HAP1 PLK2 (-) 4 cancer cell line human CVCL_TE66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19699; PLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141641 CVCL_TE69 HAP1 PLOD2 (-) 1 cancer cell line human CVCL_TE69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9082; PLOD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141642 CVCL_TE68 HAP1 PLK3 (-) 2 cancer cell line human CVCL_TE68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2154; PLK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141643 CVCL_TE50 HAP1 PLD5 (-) 2 cancer cell line human CVCL_TE50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26879; PLD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141644 CVCL_TE52 HAP1 PLEKHA1 (-) 1 cancer cell line human CVCL_TE52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14335; PLEKHA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141645 CVCL_TE51 HAP1 PLD6 (-) cancer cell line human CVCL_TE51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30447; PLD6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141646 CVCL_TE54 HAP1 PLEKHM2 (-) 1 cancer cell line human CVCL_TE54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29131; PLEKHM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141647 CVCL_TE53 HAP1 PLEKHA1 (-) 2 cancer cell line human CVCL_TE53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14335; PLEKHA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141648 CVCL_TE56 HAP1 PLGRKT (-) 1 cancer cell line human CVCL_TE56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23633; PLGRKT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141649 CVCL_TE55 HAP1 PLEKHM2 (-) 2 cancer cell line human CVCL_TE55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29131; PLEKHM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141650 CVCL_TE58 HAP1 PLIN2 (-) 1 cancer cell line human CVCL_TE58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 248; PLIN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141651 CVCL_TE57 HAP1 PLGRKT (-) 2 cancer cell line human CVCL_TE57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23633; PLGRKT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141652 CVCL_TE59 HAP1 PLIN3 (-) 1 cancer cell line human CVCL_TE59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16893; PLIN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141653 CVCL_C207 HS366 embryonic stem cell human CVCL_C207 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141654 CVCL_BQ07 ND13916 transformed cell line human CVCL_BQ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141655 CVCL_C206 HS364 embryonic stem cell human CVCL_C206 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141656 CVCL_BQ06 ND13913 transformed cell line human CVCL_BQ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141657 CVCL_C209 HS380 embryonic stem cell human CVCL_C209 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141658 CVCL_BQ09 ND13933 transformed cell line human CVCL_BQ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141659 CVCL_C208 HS368 embryonic stem cell human CVCL_C208 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141660 CVCL_BQ08 ND13932 transformed cell line human CVCL_BQ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141661 CVCL_9W73 GM00275 finite cell line human CVCL_9W73 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21141662 CVCL_9W72 PC14PE6/AS2 cancer cell line human CVCL_9W72 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male Problematic cell line: Contaminated Grand-parent cell line (PC-14) has been shown to be a PC-9 derivative. 21141663 CVCL_9W75 GM00538 finite cell line human CVCL_9W75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141664 CVCL_C201 HS356 embryonic stem cell human CVCL_C201 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Miscellaneous: Not distributed by the Karolinska Institutet Human Embryonic Stem Cell Bank. Unspecified 21141665 CVCL_BQ01 ND13866 transformed cell line human CVCL_BQ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141666 CVCL_9W74 GM00497 finite cell line human CVCL_9W74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM00497; probable Male 21141667 CVCL_C200 HS351 embryonic stem cell human CVCL_C200 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-20.. 21141668 CVCL_BQ00 ND13865 transformed cell line human CVCL_BQ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141669 CVCL_C203 HS361 embryonic stem cell human CVCL_C203 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141670 CVCL_BQ03 ND13882 transformed cell line human CVCL_BQ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141671 CVCL_C202 HS360 embryonic stem cell human CVCL_C202 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141672 CVCL_BQ02 ND13867 transformed cell line human CVCL_BQ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141673 CVCL_C205 HS363 embryonic stem cell human CVCL_C205 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141674 CVCL_BQ05 ND13890 transformed cell line human CVCL_BQ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141675 CVCL_9W71 PC14Br cancer cell line human CVCL_9W71 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male Problematic cell line: Contaminated Parent cell line (PC-14) has been shown to be a PC-9 derivative. 21141676 CVCL_C204 HS362 embryonic stem cell human CVCL_C204 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141677 CVCL_BQ04 ND13889 transformed cell line human CVCL_BQ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141678 CVCL_9W70 PC14PE6 cancer cell line human CVCL_9W70 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male Problematic cell line: Contaminated Parent cell line (PC-14) has been shown to be a PC-9 derivative.; Caution: PC-14-PM4 (Cellosaurus=CVCL_9W69) and PC14PE6 could be identical 21141679 CVCL_9W69 PC-14-PM4 cancer cell line human CVCL_9W69 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male Problematic cell line: Contaminated Parent cell line (PC-14) has been shown to be a PC-9 derivative.; Caution: PC-14-PM4 and PC14PE6 (Cellosaurus=CVCL_9W70) could be identical 21141680 CVCL_9W66 M4b transformed cell line house mouse CVCL_9W66 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic spinal cord; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141681 CVCL_9W65 HTk transformed cell line house mouse CVCL_9W65 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141682 CVCL_9W68 JN-DSRCT-1 cancer cell line human CVCL_9W68 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 12796; WT1; Name(s)=EWSR1-WT1, EWS-WT1; Note=EWSR1 Ex10-WT1 Ex8 fusion (PubMed=12218078; PubMed=34841430); Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Arg1443Alafs*11; Zygosity=Unspecified (PubMed=34841430); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Arg367Ter (c.1099C>T); ClinVar=VCV000016626; Zygosity=Unspecified (PubMed=34841430); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg621Ser (c.1861C>A); ClinVar=VCV000135120; Zygosity=Unspecified (PubMed=34841430) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: ~38 hours (PubMed=12218078); 22 hours (PubMed=34841430) 21141683 CVCL_9W67 MTh transformed cell line house mouse CVCL_9W67 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic spinal cord; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141684 CVCL_C218 HS429 embryonic stem cell human CVCL_C218 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0043. 21141685 CVCL_BQ18 ND13966 transformed cell line human CVCL_BQ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141686 CVCL_C217 HS426 embryonic stem cell human CVCL_C217 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Male Registration: Swiss research registry; BAG-hES-IMP-0042. 21141687 CVCL_BQ17 ND13964 transformed cell line human CVCL_BQ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141688 CVCL_C219 HS429A embryonic stem cell human CVCL_C219 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141689 CVCL_BQ19 ND13968 transformed cell line human CVCL_BQ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141690 CVCL_9W84 GM02455 finite cell line human CVCL_9W84 CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Trp273Leu (c.818G>T); ClinVar=VCV000000931; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Arg482His (c.1445G>A); ClinVar=VCV000000932; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21141691 CVCL_C210 HS382 embryonic stem cell human CVCL_C210 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Male 21141692 CVCL_BQ10 ND13938 transformed cell line human CVCL_BQ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141693 CVCL_9W83 GM01948 finite cell line human CVCL_9W83 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,15ps+ (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21141694 CVCL_9W86 GM02555 finite cell line human CVCL_9W86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21141695 CVCL_C212 HS401 embryonic stem cell human CVCL_C212 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0202; Registration: Swiss research registry; BAG-hES-IMP-0024; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-20. 21141696 CVCL_BQ12 ND13944 transformed cell line human CVCL_BQ12 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141697 CVCL_9W85 GM02456 finite cell line human CVCL_9W85 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21141698 CVCL_C211 HS400 embryonic stem cell human CVCL_C211 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141699 CVCL_BQ11 ND13939 transformed cell line human CVCL_BQ11 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141700 CVCL_9W80 GM01259 finite cell line human CVCL_9W80 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141701 CVCL_C214 HS415 embryonic stem cell human CVCL_C214 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0048; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC07-20.. 21141702 CVCL_BQ14 ND13957 transformed cell line human CVCL_BQ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141703 CVCL_C213 HS402 embryonic stem cell human CVCL_C213 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 21141704 CVCL_BQ13 ND13945 transformed cell line human CVCL_BQ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141705 CVCL_9W82 GM01602 finite cell line human CVCL_9W82 CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Trp273Leu (c.818G>T); ClinVar=VCV000000931; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Arg482His (c.1445G>A); ClinVar=VCV000000932; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141706 CVCL_C216 HS422 embryonic stem cell human CVCL_C216 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Male Registration: Swiss research registry; BAG-hES-IMP-0047. 21141707 CVCL_BQ16 ND13960 transformed cell line human CVCL_BQ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141708 CVCL_9W81 GM01361 finite cell line human CVCL_9W81 CL:0000010 Sequence variation: Mutation; HGNC; 4122; GALNS; Simple; p.Arg61Trp (c.181C>T); ClinVar=VCV000381663; Zygosity=Heterozygous (PubMed=30797135); Sequence variation: Mutation; HGNC; 4122; GALNS; Simple; p.Trp405_Thr406del (c.1207_1212TGGACC[1]) (c.1213_1218delTGGACC) (p.403_404WT[1]) (WT405del); ClinVar=VCV000566964; Zygosity=Heterozygous (PubMed=30797135) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141709 CVCL_C215 HS420 embryonic stem cell human CVCL_C215 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0203; Registration: Swiss research registry; BAG-hES-IMP-0046 21141710 CVCL_BQ15 ND13959 transformed cell line human CVCL_BQ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141711 CVCL_9W77 GM00740 finite cell line human CVCL_9W77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141712 CVCL_9W76 GM00593 finite cell line human CVCL_9W76 CL:0000010 Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Female 21141713 CVCL_9W79 GM00958 finite cell line human CVCL_9W79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141714 CVCL_9W78 GM00942 finite cell line human CVCL_9W78 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141715 CVCL_9W51 CHQC-MCQ3-5 cancer cell line CVCL_9W51 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Group: Bird cell line 21141716 CVCL_9W50 CHQC-MCQ1-4 cancer cell line CVCL_9W50 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Group: Bird cell line 21141717 CVCL_9W53 RCDMD transformed cell line human CVCL_9W53 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Skeletal muscle. Unspecified Doubling time: ~3 days (PubMed=7520531) 21141718 CVCL_9W52 RCMH transformed cell line human CVCL_9W52 CL:0000010 Miscellaneous: Sex assignment using analysis of proteomics identifications (Bairoch A.) Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Skeletal muscle. Omics: Deep proteome analysis Male Doubling time: ~24 hours (PubMed=1373077) 21141719 CVCL_9W48 RECC-(CLONE D1) transformed cell line CVCL_9W48 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141720 CVCL_9W47 RECC-(CLONE C3) transformed cell line CVCL_9W47 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141721 CVCL_9W49 RECC-RELB transformed cell line CVCL_9W49 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV)(NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn. Female Group: Bird cell line 21141722 CVCL_9W44 RECC-(CLONE B3) transformed cell line CVCL_9W44 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141723 CVCL_9W43 RECC-(CLONE A4) transformed cell line CVCL_9W43 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141724 CVCL_9W46 RECC-(CLONE C1) transformed cell line CVCL_9W46 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141725 CVCL_9W45 RECC-(CLONE B4) transformed cell line CVCL_9W45 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141726 CVCL_9W62 G4b transformed cell line house mouse CVCL_9W62 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic dorsal root ganglion; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141727 CVCL_9W61 CTb transformed cell line house mouse CVCL_9W61 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic brain; cerebral cortex; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141728 CVCL_9W64 H1b transformed cell line house mouse CVCL_9W64 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141729 CVCL_9W63 GTI transformed cell line house mouse CVCL_9W63 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic dorsal root ganglion; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141730 CVCL_9W60 CNh transformed cell line house mouse CVCL_9W60 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Embryonic brain; cerebral cortex; Breed/subspecies: C57BL/6 x Rb(16.17)32Lub/Rb(11.16)2H. Unspecified 21141731 CVCL_9W59 UCHCC1 transformed cell line Norway rat CVCL_9W59 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Brain; cerebellum; Breed/subspecies: Fischer 344. Female Doubling time: ~20 hours (PubMed=2418922) 21141732 CVCL_9W58 ND00205 transformed cell line human CVCL_9W58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141733 CVCL_9W55 PK-SV40 transformed cell line human CVCL_9W55 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle. Female Doubling time: 42 hours, at 38th passage (PubMed=6314331) 21141734 CVCL_9W54 KJ-SV40 transformed cell line human CVCL_9W54 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle. Male Doubling time: 48 hours, at 33th passage (PubMed=6314331) 21141735 CVCL_9W57 RCVC transformed cell line Norway rat CVCL_9W57 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Heart; ventricle; Breed/subspecies: Fischer 344. Male 21141736 CVCL_9W56 C127 ts cancer cell line house mouse CVCL_9W56 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21141737 CVCL_9W31 h1RPE116 transformed cell line human CVCL_9W31 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; retinal pigment epithelium. Female 21141738 CVCL_9W30 PATH.2 transformed cell line house mouse CVCL_9W30 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 x DBA/2 transgenic. Female 21141739 CVCL_9W26 OBL21 transformed cell line house mouse CVCL_9W26 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: CD-1. 21141740 CVCL_9W25 OBC13 transformed cell line house mouse CVCL_9W25 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: C57BL/6 x CD-1. 21141741 CVCL_9W28 OBL24 transformed cell line house mouse CVCL_9W28 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: CD-1. 21141742 CVCL_9W27 OBL21A transformed cell line house mouse CVCL_9W27 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: CD-1. 21141743 CVCL_9W22 BLS-1.DR4 transformed cell line human CVCL_9W22 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Unexplicit; 58-bp deletion that removes the last 23-bp and the splice donor site of exon 6; ClinVar=VCV000006598; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*04:01) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141744 CVCL_9W21 BLS-2 transformed cell line human CVCL_9W21 CL:0000010 Sequence variation: Mutation; HGNC; 7067; CIITA; Simple; c.2888+1G>A (c.72bpdel2932-3003) (IVS13DS,G-A,+1) (p.Thr940_Ala963del); ClinVar=VCV000501277; Zygosity=Homozygous (PubMed=8402893) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141745 CVCL_9W24 PandPush transformed cell line human CVCL_9W24 HLA typing: A*01:01,68:01:02; B*51:01:01,57:01; C*06:02,15:07 (IPD-IMGT/HLA=11279) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21141746 CVCL_9W23 BLS-1.DR5 transformed cell line human CVCL_9W23 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Unexplicit; 58-bp deletion that removes the last 23-bp and the splice donor site of exon 6; ClinVar=VCV000006598; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*11:01) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141747 CVCL_9W29 PATH.1 transformed cell line house mouse CVCL_9W29 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 x DBA/2 transgenic. Female 21141748 CVCL_9W40 RECC-CU66 transformed cell line CVCL_9W40 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: P2a. Female Group: Bird cell line Caution: Said to originate from RECC-CU60 in PubMed=18766641 21141749 CVCL_9W42 RECC-(CLONE 7) transformed cell line CVCL_9W42 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141750 CVCL_9W41 RECC-(CLONE 1) transformed cell line CVCL_9W41 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21141751 CVCL_9W37 RETC-RP21 transformed cell line CVCL_9W37 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: Nicholas. Group: Bird cell line 21141752 CVCL_9W36 143BTK- cancer cell line human CVCL_9W36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21141753 CVCL_9W39 RECC-CU64 transformed cell line CVCL_9W39 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: UCD-003. Female Group: Bird cell line 21141754 CVCL_9W38 RECC-CU60 transformed cell line CVCL_9W38 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Breed/subspecies: P2a. Female Group: Bird cell line 21141755 CVCL_9W33 HPCT-05-wt transformed cell line human CVCL_9W33 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal convoluted tubule. Male 21141756 CVCL_9W32 HPCT-03-ts transformed cell line human CVCL_9W32 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal convoluted tubule. Female 21141757 CVCL_9W35 UCHT1 cancer cell line Norway rat CVCL_9W35 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer 344. Male Doubling time: ~24 hours (PubMed=954652) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2535 21141758 CVCL_9W34 HPCT-06-wt transformed cell line human CVCL_9W34 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal convoluted tubule. Male 21141759 CVCL_9W04 Ac2F-CR4 spontaneously immortalized cell line Norway rat CVCL_9W04 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21141760 CVCL_9W03 Ac2F-CR10 spontaneously immortalized cell line Norway rat CVCL_9W03 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21141761 CVCL_9W06 EqS04b cancer cell line CVCL_9W06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Virology: Infected by bovine papillomavirus-1 (BPV-1) Doubling time: 26.7 hours (PubMed=18191170) 21141762 CVCL_9W05 EqS02a cancer cell line CVCL_9W05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Virology: Infected by bovine papillomavirus-1 (BPV-1) Doubling time: 32.2 hours (PubMed=18191170) 21141763 CVCL_9W00 MSPF-PI 31 finite cell line house mouse CVCL_9W00 CL:0000010 Derived from sampling site: Spleen Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified 21141764 CVCL_9W02 RAW-TT10 cancer cell line house mouse CVCL_9W02 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21141765 CVCL_9W01 HF2FF-PI 14 finite cell line human CVCL_9W01 CL:0000010 Derived from sampling site: Foreskin; skin. Male 21141766 CVCL_9W08 EqPalFS6-2 transformed cell line CVCL_9W08 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Bovine papillomavirus type 1 (BPV-1)(NCBI-Taxonomy; 10559); Derived from sampling site: Fetal oral cavity; palate Cell type=Fibroblast.. Unspecified Doubling time: 24 hours (PubMed=18191170) 21141767 CVCL_9W07 EqPalFS6-1 transformed cell line CVCL_9W07 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Bovine papillomavirus type 1 (BPV-1)(NCBI-Taxonomy; 10559); Derived from sampling site: Fetal oral cavity; palate Cell type=Fibroblast.. Unspecified Doubling time: 26.2 hours (PubMed=18191170) 21141768 CVCL_9W09 EqPalFS6-3 transformed cell line CVCL_9W09 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Bovine papillomavirus type 1 (BPV-1)(NCBI-Taxonomy; 10559); Derived from sampling site: Fetal oral cavity; palate Cell type=Fibroblast.. Unspecified Doubling time: 32.6 hours (PubMed=18191170) 21141769 CVCL_9W20 BLS-1 transformed cell line human CVCL_9W20 CL:0000010 Sequence variation: Mutation; HGNC; 9987; RFXANK; Unexplicit; 58-bp deletion that removes the last 23-bp and the splice donor site of exon 6; ClinVar=VCV000006598; Zygosity=Homozygous (PubMed=9806546) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141770 CVCL_9W15 T2.DR4 hybrid cell line human CVCL_9W15 CL:0000010 Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*04:01). 21141771 CVCL_9W14 MF1-PI 30 finite cell line house mouse CVCL_9W14 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21141772 CVCL_9W17 T2.DR3 hybrid cell line human CVCL_9W17 CL:0000010 Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*03:01). 21141773 CVCL_9W16 T2.DR4/DM hybrid cell line human CVCL_9W16 CL:0000010 Transfected with: HGNC; 4934; HLA-DMA; Transfected with: HGNC; 4935; HLA-DMB; Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*04:01). 21141774 CVCL_9W11 eCG 50.5 transformed cell line CVCL_9W11 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 21141775 CVCL_9W10 eCG 100.6 transformed cell line CVCL_9W10 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 21141776 CVCL_9W13 HFF-PI 34 finite cell line human CVCL_9W13 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21141777 CVCL_9W12 eCG 500.1 transformed cell line CVCL_9W12 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast Cell type=Chorionic girdle cell.. Unspecified 21141778 CVCL_9W19 Pala transformed cell line human CVCL_9W19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141779 CVCL_9W18 T2.DR3/DM hybrid cell line human CVCL_9W18 CL:0000010 Transfected with: HGNC; 4934; HLA-DMA; Transfected with: HGNC; 4935; HLA-DMB; Transfected with: HGNC; 4948; HLA-DRB1 (allele DRB1*03:01). 21141780 CVCL_C287 Ma-Mel-42b cancer cell line human CVCL_C287 CL:0000010 Female 21141781 CVCL_BQ87 ND14268 transformed cell line human CVCL_BQ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141782 CVCL_BQ86 ND14263 transformed cell line human CVCL_BQ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141783 CVCL_C286 WM873-3 cancer cell line human CVCL_C286 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from autologous cell lines WM740V, WM858 and WM873-1) Derived from metastatic site: Right axillary lymph node. Female Part of: Wistar Institute melanoma cell line collection 21141784 CVCL_C289 Ma-Mel-59b cancer cell line human CVCL_C289 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21141785 CVCL_BQ89 ND14289 transformed cell line human CVCL_BQ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141786 CVCL_C288 Ma-Mel-54b cancer cell line human CVCL_C288 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Gln959Pro (c.2876A>C); Zygosity=Homozygous (PubMed=28561041) Derived from metastatic site: Cutaneous. Omics: SNP array analysis Female 21141787 CVCL_BQ88 ND14277 transformed cell line human CVCL_BQ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141788 CVCL_BQ81 ND14252 transformed cell line human CVCL_BQ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141789 CVCL_C281 WM8 cancer cell line human CVCL_C281 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Unspecified (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D19S433 21141790 CVCL_BQ80 ND14250 transformed cell line human CVCL_BQ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141791 CVCL_C280 WM47 cancer cell line human CVCL_C280 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Discontinued: Rockland; 51398; True Male Part of: Wistar Institute melanoma cell line collection 21141792 CVCL_BQ83 ND14260 transformed cell line human CVCL_BQ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141793 CVCL_KK17 PCRP-RFX6-3D3 hybridoma house mouse CVCL_KK17 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8HWS3; Human RFX6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141794 CVCL_C283 WM858 cancer cell line human CVCL_C283 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; Wistar) Derived from metastatic site: Right axillary lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21141795 CVCL_BQ82 ND14253 transformed cell line human CVCL_BQ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141796 CVCL_KK16 PCRP-RFX6-1B12 hybridoma house mouse CVCL_KK16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8HWS3; Human RFX6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141797 CVCL_C282 WM853-2 cancer cell line human CVCL_C282 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from sampling site: Back; skin. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D8S1179 21141798 CVCL_BQ85 ND14262 transformed cell line human CVCL_BQ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141799 CVCL_KK19 PCRP-RGCC-2C4 hybridoma house mouse CVCL_KK19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H4X1; Human RGCC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141800 CVCL_C285 WM873-2 cancer cell line human CVCL_C285 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from autologous cell lines WM740V, WM858 and WM873-1) Derived from metastatic site: Right axillary lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21141801 CVCL_BQ84 ND14261 transformed cell line human CVCL_BQ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141802 CVCL_KK18 PCRP-RFXANK-1A9 hybridoma house mouse CVCL_KK18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14593; Human RFXANK. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141803 CVCL_C284 WM873-1 cancer cell line human CVCL_C284 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Right axillary lymph node. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21141804 CVCL_KK13 PCRP-RFX5-1C12 hybridoma house mouse CVCL_KK13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P48382; Human RFX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141805 CVCL_KK12 PCRP-RFX3-1D11 hybridoma house mouse CVCL_KK12 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P48380; Human RFX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141806 CVCL_KK15 PCRP-RFX5-1E5 hybridoma house mouse CVCL_KK15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P48382; Human RFX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141807 CVCL_KK14 PCRP-RFX5-1D11 hybridoma house mouse CVCL_KK14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P48382; Human RFX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141808 CVCL_KK11 PCRP-RFX2-1A11 hybridoma house mouse CVCL_KK11 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P48378; Human RFX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141809 CVCL_KK10 PCRP-RELB-1B4 hybridoma house mouse CVCL_KK10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01201; Human RELB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141810 CVCL_BQ98 ND14311 transformed cell line human CVCL_BQ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141811 CVCL_C298 UPMD-2 cancer cell line human CVCL_C298 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=22236444). Unspecified Doubling time: 150 hours (PubMed=19212147) 21141812 CVCL_BQ97 ND14310 transformed cell line human CVCL_BQ97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141813 CVCL_C297 UPMD-1 cancer cell line human CVCL_C297 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=22236444). Unspecified Doubling time: 100 hours (PubMed=19212147) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21141814 CVCL_BQ99 ND14332 transformed cell line human CVCL_BQ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141815 CVCL_C299 UPMM-1 cancer cell line human CVCL_C299 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Arg183Gln (c.548G>A); ClinVar=VCV000050853; Zygosity=Unspecified (PubMed=22236444). Karyotypic information: Monosomy of chromosome 3 (PubMed=16750193) Male Doubling time: 100-150 hours (PubMed=19212147) 21141816 CVCL_C290 Ma-Mel-59c cancer cell line human CVCL_C290 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21141817 CVCL_BQ90 ND14293 transformed cell line human CVCL_BQ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141818 CVCL_C292 Ma-Mel-61b cancer cell line human CVCL_C292 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Cutaneous. Omics: SNP array analysis Male 21141819 CVCL_BQ92 ND14295 transformed cell line human CVCL_BQ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141820 CVCL_C291 Ma-Mel-61a cancer cell line human CVCL_C291 CL:0000010 Sequence variation: Gene deletion; HGNC; 6190; JAK1; Zygosity=Heterozygous (PubMed=28561041); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=17311103; PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21141821 CVCL_BQ91 ND14294 transformed cell line human CVCL_BQ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141822 CVCL_BQ94 ND14305 transformed cell line human CVCL_BQ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141823 CVCL_KK28 PCRP-RPRD1A-1B2 hybridoma house mouse CVCL_KK28 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96P16; Human RPRD1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141824 CVCL_C294 UPMM-2 cancer cell line human CVCL_C294 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=22236444). Karyotypic information: Monosomy of chromosome 3 (PubMed=16750193) Unspecified Doubling time: 150 hours (PubMed=19212147) 21141825 CVCL_C293 Ma-Mel-63b cancer cell line human CVCL_C293 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21141826 CVCL_BQ93 ND14301 transformed cell line human CVCL_BQ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141827 CVCL_KK27 PCRP-RORA-2C2 hybridoma house mouse CVCL_KK27 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35398; Human RORA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141828 CVCL_BQ96 ND14308 transformed cell line human CVCL_BQ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141829 CVCL_C296 UPMM-4 cancer cell line human CVCL_C296 CL:0000010 Karyotypic information: Monosomy of chromosome 3 (PubMed=19212147). Male Doubling time: 300 hours (PubMed=19212147) 21141830 CVCL_BQ95 ND14306 transformed cell line human CVCL_BQ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141831 CVCL_KK29 PCRP-RPRD1A-1D9 hybridoma house mouse CVCL_KK29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96P16; Human RPRD1A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141832 CVCL_C295 UPMM-3 cancer cell line human CVCL_C295 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=22236444). Karyotypic information: Monosomy of chromosome 3 (PubMed=19212147) Male Doubling time: 100 hours (PubMed=19212147) 21141833 CVCL_KK24 PCRP-RNF17-1B9 hybridoma house mouse CVCL_KK24 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9BXT8; Human RNF17. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141834 CVCL_KK23 PCRP-RNF113B-3D10 hybridoma house mouse CVCL_KK23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IZP6; Human RNF113B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141835 CVCL_KK26 PCRP-RNF20-1D7 hybridoma house mouse CVCL_KK26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5VTR2; Human RNF20. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141836 CVCL_KK25 PCRP-RNF2-1D4 hybridoma house mouse CVCL_KK25 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99496; Human RNF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141837 CVCL_KK20 PCRP-RHOXF2-1C2 hybridoma house mouse CVCL_KK20 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BQY4; Human RHOXF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141838 CVCL_KK22 PCRP-RNF113B-2F4 hybridoma house mouse CVCL_KK22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IZP6; Human RNF113B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141839 CVCL_KK21 PCRP-RHOXF2-1D7 hybridoma house mouse CVCL_KK21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BQY4; Human RHOXF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141840 CVCL_BQ65 ND14177 transformed cell line human CVCL_BQ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141841 CVCL_C265 WM1193C cancer cell line human CVCL_C265 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection. 21141842 CVCL_BQ64 ND14172 transformed cell line human CVCL_BQ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141843 CVCL_C264 UCO-Mel-2 cancer cell line human CVCL_C264 CL:0000010 Derived from sampling site: Skin. Female 21141844 CVCL_BQ67 ND14182 transformed cell line human CVCL_BQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141845 CVCL_C267 WM1791A cancer cell line human CVCL_C267 HLA typing: A*02:01; B*07:02,44:02; C*07:02,05:01; DPB1*06:01,19:01; DQB1*06:02,03:01:01; DRB1*15:01,ND (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445) Derived from sampling site: Skin. Omics: Array-based CGH Male Part of: Wistar Institute melanoma cell line collection 21141846 CVCL_BQ66 ND14179 transformed cell line human CVCL_BQ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141847 CVCL_C266 WM139 cancer cell line human CVCL_C266 HLA typing: A*32:01,32:01; B*14:01,14:01; C*08:02,08:02; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Val82fs (c.243_244ins19) (p.Arg96fs, c.286_287ins19); Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Female Part of: Wistar Institute melanoma cell line collection 21141848 CVCL_BQ69 ND14185 transformed cell line human CVCL_BQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141849 CVCL_C269 WM209 cancer cell line human CVCL_C269 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000219097; Zygosity=Unspecified (Wistar) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21141850 CVCL_BQ68 ND14183 transformed cell line human CVCL_BQ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141851 CVCL_C268 WM1862 cancer cell line human CVCL_C268 HLA typing: A*32:01,68:01:02; B*14:01; C*08:01; DPB1*04:02,02:01:02; DQB1*02:01; DRB1*07:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=23851445; Wistar) Derived from sampling site: Skin. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Unspecified Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection 21141852 CVCL_C261 AB2.2 embryonic stem cell house mouse CVCL_C261 CL:0000010 Karyotypic information: Mosaic; 42,XY,+Y,+8; 41,XY,+Y; 40,XY (PubMed=23320952); Breed/subspecies: 129S7/SvEvBrd-Hprt. Omics: SNP array analysis Male 21141853 CVCL_BQ61 ND14151 transformed cell line human CVCL_BQ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141854 CVCL_C260 EDJ#22 embryonic stem cell house mouse CVCL_C260 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Male 21141855 CVCL_BQ60 ND14149 transformed cell line human CVCL_BQ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141856 CVCL_C263 IRNE cancer cell line human CVCL_C263 HLA typing: A*01:01,29:02; B*35:01,44:03:01; C*04:01:01; DPB1*04:02,02:01:02; DQB1*06:03,02:01; DRB1*11:03:01,07:01 (PubMed=15592718) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Lymph node. Discontinued: ESTDAB; ESTDAB-038; probable Female 21141857 CVCL_BQ63 ND14171 transformed cell line human CVCL_BQ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141858 CVCL_C262 Ma-Mel-45b cancer cell line human CVCL_C262 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.228_229CC>TT (-124/-125CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21141859 CVCL_BQ62 ND14154 transformed cell line human CVCL_BQ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141860 CVCL_BQ76 ND14210 transformed cell line human CVCL_BQ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141861 CVCL_C276 WM3681 cancer cell line human CVCL_C276 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection 21141862 CVCL_BQ75 ND14209 transformed cell line human CVCL_BQ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141863 CVCL_C275 WM3629 cancer cell line human CVCL_C275 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp594Gly (c.1781A>G); ClinVar=VCV000013972; Zygosity=Heterozygous (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Homozygous (Wistar) Derived from metastatic site: Lymph node. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00117; probable Unspecified Part of: MD Anderson Cell Lines Project; Part of: Wistar Institute melanoma cell line collection 21141864 CVCL_BQ78 ND14235 transformed cell line human CVCL_BQ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141865 CVCL_C278 WM3912 cancer cell line human CVCL_C278 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asn581Tyr (c.1741A>T); Zygosity=Unspecified (Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Leu213Phe; Zygosity=Unspecified (Wistar) Derived from metastatic site: Neck. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21141866 CVCL_BQ77 ND14226 transformed cell line human CVCL_BQ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141867 CVCL_C277 WM373 cancer cell line human CVCL_C277 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Wistar) Derived from metastatic site: Back; skin. Omics: Transcriptome analysis by microarray Male Characteristics: Pigmented Part of: Wistar Institute melanoma cell line collection 21141868 CVCL_BQ79 ND14241 transformed cell line human CVCL_BQ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141869 CVCL_C279 WM3918 cancer cell line human CVCL_C279 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D18S51 21141870 CVCL_KK09 PCRP-RELB-1B1 hybridoma house mouse CVCL_KK09 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q01201; Human RELB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141871 CVCL_BQ70 ND14186 transformed cell line human CVCL_BQ70 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141872 CVCL_C270 WM3066 cancer cell line human CVCL_C270 CL:0000010 Unspecified Part of: Wistar Institute melanoma cell line collection. 21141873 CVCL_BQ72 ND14188 transformed cell line human CVCL_BQ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141874 CVCL_KK06 PCRP-RELA-1E3 hybridoma house mouse CVCL_KK06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q04206; Human RELA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141875 CVCL_C272 WM3438 cancer cell line human CVCL_C272 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by microarray Female Part of: Wistar Institute melanoma cell line collection 21141876 CVCL_BQ71 ND14187 transformed cell line human CVCL_BQ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141877 CVCL_KK05 PCRP-RCOR3-1B6 hybridoma house mouse CVCL_KK05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P2K3; Human RCOR3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141878 CVCL_C271 WM3130 cancer cell line human CVCL_C271 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21141879 CVCL_BQ74 ND14208 transformed cell line human CVCL_BQ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141880 CVCL_KK08 PCRP-RELB-1A7 hybridoma house mouse CVCL_KK08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q01201; Human RELB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141881 CVCL_C274 WM3623 cancer cell line human CVCL_C274 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Derived from metastatic site: Right lymph node. Omics: Transcriptome analysis by microarray Male Part of: Wistar Institute melanoma cell line collection 21141882 CVCL_BQ73 ND14205 transformed cell line human CVCL_BQ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141883 CVCL_KK07 PCRP-RELA-2B6 hybridoma house mouse CVCL_KK07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04206; Human RELA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141884 CVCL_C273 WM3451 cancer cell line human CVCL_C273 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Wistar); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (Wistar) Omics: Transcriptome analysis by microarray Unspecified Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: D19S433. 21141885 CVCL_KK02 PCRP-RCOR2-1E10 hybridoma house mouse CVCL_KK02 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q8IZ40; Human RCOR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141886 CVCL_KK01 PCRP-RBMS2-1B6 hybridoma house mouse CVCL_KK01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15434; Human RBMS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141887 CVCL_KK04 PCRP-RCOR3-1B2 hybridoma house mouse CVCL_KK04 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P2K3; Human RCOR3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141888 CVCL_KK03 PCRP-RCOR2-3F4 hybridoma house mouse CVCL_KK03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IZ40; Human RCOR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141889 CVCL_KK00 PCRP-RBMS2-1B2 hybridoma house mouse CVCL_KK00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15434; Human RBMS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21141890 CVCL_C243 246G1 induced pluripotent stem cell human CVCL_C243 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21141891 CVCL_BQ43 ND14081 transformed cell line human CVCL_BQ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141892 CVCL_C242 246B6 induced pluripotent stem cell human CVCL_C242 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141893 CVCL_BQ42 ND14080 transformed cell line human CVCL_BQ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141894 CVCL_C245 246G4 induced pluripotent stem cell human CVCL_C245 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141895 CVCL_BQ45 ND14083 transformed cell line human CVCL_BQ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141896 CVCL_C244 246G3 induced pluripotent stem cell human CVCL_C244 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141897 CVCL_BQ44 ND14082 transformed cell line human CVCL_BQ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141898 CVCL_C247 246G6 induced pluripotent stem cell human CVCL_C247 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141899 CVCL_BQ47 ND14086 transformed cell line human CVCL_BQ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141900 CVCL_C246 246G5 induced pluripotent stem cell human CVCL_C246 From: Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141901 CVCL_BQ46 ND14084 transformed cell line human CVCL_BQ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141902 CVCL_BQ49 ND14091 transformed cell line human CVCL_BQ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141903 CVCL_C249 NU-AmB-1 cancer cell line human CVCL_C249 CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21141904 CVCL_C248 551-iPS8 induced pluripotent stem cell human CVCL_C248 From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141905 CVCL_BQ48 ND14088 transformed cell line human CVCL_BQ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141906 CVCL_C241 246B5 induced pluripotent stem cell human CVCL_C241 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141907 CVCL_BQ41 ND14077 transformed cell line human CVCL_BQ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141908 CVCL_C240 246B4 induced pluripotent stem cell human CVCL_C240 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141909 CVCL_BQ40 ND14076 transformed cell line human CVCL_BQ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141910 CVCL_C254 ATCC-DYR0530 induced pluripotent stem cell human CVCL_C254 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21141911 CVCL_BQ54 ND14126 transformed cell line human CVCL_BQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141912 CVCL_C253 ATCC-DYR0100 induced pluripotent stem cell human CVCL_C253 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141913 CVCL_BQ53 ND14123 transformed cell line human CVCL_BQ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141914 CVCL_C256 ATCC-HYR0103 induced pluripotent stem cell human CVCL_C256 CL:0000010 Population: Hispanic; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21141915 CVCL_BQ56 ND14136 transformed cell line human CVCL_BQ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141916 CVCL_C255 ATCC-DYS0530 induced pluripotent stem cell human CVCL_C255 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21141917 CVCL_BQ55 ND14135 transformed cell line human CVCL_BQ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141918 CVCL_C258 B6/BLU embryonic stem cell house mouse CVCL_C258 CL:0000010 Transfected with: HGNC; 4827; HBB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Breed/subspecies: C57BL/6Tac transgenic. Male Characteristics: The transgenic mice contains a HS-2-HBB-LacZ construct 21141919 CVCL_BQ58 ND14139 transformed cell line human CVCL_BQ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141920 CVCL_C257 ESF 158 embryonic stem cell house mouse CVCL_C257 CL:0000010 Unspecified 21141921 CVCL_BQ57 ND14137 transformed cell line human CVCL_BQ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141922 CVCL_BQ59 ND14141 transformed cell line human CVCL_BQ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141923 CVCL_C259 SCC#10 embryonic stem cell house mouse CVCL_C259 CL:0000010 Breed/subspecies: 129X1/SvJ. Male 21141924 CVCL_C250 ATCC-DYP0250 induced pluripotent stem cell human CVCL_C250 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21141925 CVCL_BQ50 ND14117 transformed cell line human CVCL_BQ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141926 CVCL_C252 ATCC-DYP0730 induced pluripotent stem cell human CVCL_C252 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21141927 CVCL_BQ52 ND14122 transformed cell line human CVCL_BQ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141928 CVCL_C251 ATCC-DYP0530 induced pluripotent stem cell human CVCL_C251 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21141929 CVCL_BQ51 ND14121 transformed cell line human CVCL_BQ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141930 CVCL_C229 HS181 embryonic stem cell human CVCL_C229 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: Swiss research registry; BAG-hES-IMP-0009; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-09. 21141931 CVCL_BQ29 ND13990 transformed cell line human CVCL_BQ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141932 CVCL_C228 HS799 embryonic stem cell human CVCL_C228 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0207. 21141933 CVCL_BQ28 ND13988 transformed cell line human CVCL_BQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141934 CVCL_9W95 GM03303 finite cell line human CVCL_9W95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21141935 CVCL_C221 HS429C embryonic stem cell human CVCL_C221 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141936 CVCL_BQ21 ND13972 transformed cell line human CVCL_BQ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141937 CVCL_9W94 GM03251 finite cell line human CVCL_9W94 CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Trp273Leu (c.818G>T); ClinVar=VCV000000931; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Trp509Cys (c.1527G>T); ClinVar=VCV000000933; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141938 CVCL_C220 HS429B embryonic stem cell human CVCL_C220 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141939 CVCL_BQ20 ND13970 transformed cell line human CVCL_BQ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141940 CVCL_9W97 GM04668 finite cell line human CVCL_9W97 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141941 CVCL_C223 HS475 embryonic stem cell human CVCL_C223 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Unspecified Registration: Swiss research registry; BAG-hES-IMP-0044. 21141942 CVCL_BQ23 ND13975 transformed cell line human CVCL_BQ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141943 CVCL_9W96 GM03726 finite cell line human CVCL_9W96 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21141944 CVCL_C222 HS429D embryonic stem cell human CVCL_C222 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Female 21141945 CVCL_BQ22 ND13974 transformed cell line human CVCL_BQ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141946 CVCL_9W91 GM02849 finite cell line human CVCL_9W91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141947 CVCL_C225 HS481 embryonic stem cell human CVCL_C225 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 21141948 CVCL_BQ25 ND13984 transformed cell line human CVCL_BQ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141949 CVCL_9W90 GM02674 finite cell line human CVCL_9W90 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [76]; 45,X [24] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21141950 CVCL_C224 HS480 embryonic stem cell human CVCL_C224 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Unspecified Registration: Swiss research registry; BAG-hES-IMP-0045. 21141951 CVCL_BQ24 ND13976 transformed cell line human CVCL_BQ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141952 CVCL_9W93 GM03234 finite cell line human CVCL_9W93 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21141953 CVCL_C227 HS539 embryonic stem cell human CVCL_C227 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 21141954 CVCL_BQ27 ND13987 transformed cell line human CVCL_BQ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141955 CVCL_9W92 GM03206 finite cell line human CVCL_9W92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141956 CVCL_C226 HS491 embryonic stem cell human CVCL_C226 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 21141957 CVCL_BQ26 ND13986 transformed cell line human CVCL_BQ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141958 CVCL_9W88 GM02623 finite cell line human CVCL_9W88 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21141959 CVCL_9W87 GM02572 finite cell line human CVCL_9W87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21141960 CVCL_9W89 GM02665 finite cell line human CVCL_9W89 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM02665; probable Female 21141961 CVCL_C239 246B3 induced pluripotent stem cell human CVCL_C239 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141962 CVCL_BQ39 ND14070 transformed cell line human CVCL_BQ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141963 CVCL_C232 HS237 embryonic stem cell human CVCL_C232 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0007; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18.. 21141964 CVCL_BQ32 ND14031 transformed cell line human CVCL_BQ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141965 CVCL_C231 HS235 embryonic stem cell human CVCL_C231 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: Swiss research registry; BAG-hES-IMP-0008; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-18.. 21141966 CVCL_BQ31 ND14030 transformed cell line human CVCL_BQ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141967 CVCL_BQ34 ND14045 transformed cell line human CVCL_BQ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141968 CVCL_C234 PP117 cancer cell line human CVCL_C234 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=19002021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leu (c.569C>T); ClinVar=VCV000418517; Zygosity=Unspecified (PubMed=19002021). Male Doubling time: 32.67 +- 0.71 hours (PubMed=19002021) 21141969 CVCL_BQ33 ND14034 transformed cell line human CVCL_BQ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141970 CVCL_C233 PP109 cancer cell line human CVCL_C233 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=19002021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val172Phe (c.514G>T); ClinVar=VCV000428909; Zygosity=Unspecified (PubMed=19002021). Female Doubling time: 28.46 +- 5.49 hours (PubMed=19002021) 21141971 CVCL_BQ36 ND14047 transformed cell line human CVCL_BQ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141972 CVCL_C236 PP78 cancer cell line human CVCL_C236 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (PubMed=19002021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281_Arg282delinsGlu; Zygosity=Unspecified (PubMed=19002021). Male Doubling time: 27.4 +- 2.49 hours (PubMed=19002021) 21141973 CVCL_BQ35 ND14046 transformed cell line human CVCL_BQ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141974 CVCL_C235 PP161 cancer cell line human CVCL_C235 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=19002021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Ter; Zygosity=Homozygous (PubMed=19002021). Female Doubling time: 31.37 +- 11.49 hours (PubMed=19002021) 21141975 CVCL_C238 246B2 induced pluripotent stem cell human CVCL_C238 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141976 CVCL_BQ38 ND14059 transformed cell line human CVCL_BQ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141977 CVCL_C237 246B1 induced pluripotent stem cell human CVCL_C237 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21141978 CVCL_BQ37 ND14058 transformed cell line human CVCL_BQ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21141979 CVCL_9W99 GM05241 finite cell line human CVCL_9W99 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Arg924Ter (c.2770C>T) (R897*); ClinVar=VCV000014686; Zygosity=Heterozygous (PubMed=25059784) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21141980 CVCL_9W98 GM04948 finite cell line human CVCL_9W98 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21141981 CVCL_C230 HS207 embryonic stem cell human CVCL_C230 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-21.. 21141982 CVCL_BQ30 ND14026 transformed cell line human CVCL_BQ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21141983 CVCL_TF60 HAP1 PPP1R13B (-) 1 cancer cell line human CVCL_TF60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14950; PPP1R13B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141984 CVCL_TF62 HAP1 PPP1R14A (-) cancer cell line human CVCL_TF62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14871; PPP1R14A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141985 CVCL_TF61 HAP1 PPP1R13B (-) 2 cancer cell line human CVCL_TF61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14950; PPP1R13B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141986 CVCL_TF64 HAP1 PPP1R14C (-) cancer cell line human CVCL_TF64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14952; PPP1R14C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141987 CVCL_TF63 HAP1 PPP1R14B (-) cancer cell line human CVCL_TF63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9057; PPP1R14B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141988 CVCL_TF66 HAP1 PPP1R16A (-) cancer cell line human CVCL_TF66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14941; PPP1R16A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141989 CVCL_TF65 HAP1 PPP1R15A (-) cancer cell line human CVCL_TF65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14375; PPP1R15A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141990 CVCL_TF68 HAP1 PPP1R18 (-) 1 cancer cell line human CVCL_TF68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29413; PPP1R18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141991 CVCL_TF67 HAP1 PPP1R16B (-) cancer cell line human CVCL_TF67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15850; PPP1R16B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141992 CVCL_TF69 HAP1 PPP1R18 (-) 2 cancer cell line human CVCL_TF69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29413; PPP1R18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141993 CVCL_TF51 HAP1 PPM1N (-) 1 cancer cell line human CVCL_TF51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26845; PPM1N; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141994 CVCL_TF50 HAP1 PPM1M (-) cancer cell line human CVCL_TF50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26506; PPM1M; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141995 CVCL_TF53 HAP1 PPOX (-) cancer cell line human CVCL_TF53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9280; PPOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141996 CVCL_TF52 HAP1 PPM1N (-) 2 cancer cell line human CVCL_TF52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26845; PPM1N; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141997 CVCL_TF55 HAP1 PPP1CA (-) 2 cancer cell line human CVCL_TF55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9281; PPP1CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141998 CVCL_TF54 HAP1 PPP1CA (-) 1 cancer cell line human CVCL_TF54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9281; PPP1CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21141999 CVCL_TF57 HAP1 PPP1R12C (-) 2 cancer cell line human CVCL_TF57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14947; PPP1R12C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142000 CVCL_TF56 HAP1 PPP1R12C (-) 1 cancer cell line human CVCL_TF56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14947; PPP1R12C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142001 CVCL_TF59 HAP1 PPP1R12C (-) 4 cancer cell line human CVCL_TF59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14947; PPP1R12C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142002 CVCL_TF58 HAP1 PPP1R12C (-) 3 cancer cell line human CVCL_TF58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14947; PPP1R12C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142003 CVCL_TF40 HAP1 PPM1F (-) 1 cancer cell line human CVCL_TF40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19388; PPM1F; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142004 CVCL_TF42 HAP1 PPM1G (-) cancer cell line human CVCL_TF42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9278; PPM1G; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142005 CVCL_TF41 HAP1 PPM1F (-) 2 cancer cell line human CVCL_TF41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19388; PPM1F; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142006 CVCL_TF44 HAP1 PPM1J (-) 1 cancer cell line human CVCL_TF44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20785; PPM1J; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142007 CVCL_TF43 HAP1 PPM1H (-) cancer cell line human CVCL_TF43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18583; PPM1H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142008 CVCL_TF46 HAP1 PPM1K (-) 1 cancer cell line human CVCL_TF46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25415; PPM1K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142009 CVCL_TF45 HAP1 PPM1J (-) 2 cancer cell line human CVCL_TF45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20785; PPM1J; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142010 CVCL_TF48 HAP1 PPM1L (-) 1 cancer cell line human CVCL_TF48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16381; PPM1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142011 CVCL_TF47 HAP1 PPM1K (-) 2 cancer cell line human CVCL_TF47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25415; PPM1K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142012 CVCL_KL99 PCRP-TCF24-1D6 hybridoma house mouse CVCL_KL99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7RTU0; Human TCF24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142013 CVCL_TF49 HAP1 PPM1L (-) 2 cancer cell line human CVCL_TF49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16381; PPM1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142014 CVCL_KL96 PCRP-TBX19-2B2 hybridoma house mouse CVCL_KL96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60806; Human TBX19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142015 CVCL_KL95 PCRP-TBX19-2A12 hybridoma house mouse CVCL_KL95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60806; Human TBX19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142016 CVCL_KL98 PCRP-TCEAL8-1C4 hybridoma house mouse CVCL_KL98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8IYN2; Human TCEAL8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142017 CVCL_KL97 PCRP-TBX4-1B11 hybridoma house mouse CVCL_KL97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P57082; Human TBX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142018 CVCL_TF31 HAP1 PPIF (-) 2 cancer cell line human CVCL_TF31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9259; PPIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142019 CVCL_TF30 HAP1 PPIF (-) 1 cancer cell line human CVCL_TF30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9259; PPIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142020 CVCL_TF33 HAP1 PPM1A (-) 1 cancer cell line human CVCL_TF33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9275; PPM1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142021 CVCL_TF32 HAP1 PPIL1 (-) 1 cancer cell line human CVCL_TF32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9260; PPIL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142022 CVCL_TF35 HAP1 PPM1B (-) cancer cell line human CVCL_TF35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9276; PPM1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142023 CVCL_TF34 HAP1 PPM1A (-) 2 cancer cell line human CVCL_TF34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9275; PPM1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142024 CVCL_TF37 HAP1 PPM1E (-) 1 cancer cell line human CVCL_TF37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19322; PPM1E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142025 CVCL_TF36 HAP1 PPM1D (-) cancer cell line human CVCL_TF36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9277; PPM1D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142026 CVCL_TF39 HAP1 PPM1E (-) 3 cancer cell line human CVCL_TF39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19322; PPM1E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142027 CVCL_TF38 HAP1 PPM1E (-) 2 cancer cell line human CVCL_TF38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19322; PPM1E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142028 CVCL_KL81 PCRP-T-1A5 hybridoma house mouse CVCL_KL81 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O15178; Human T. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142029 CVCL_KL80 PCRP-T-1A2 hybridoma house mouse CVCL_KL80 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O15178; Human T. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142030 CVCL_KL83 PCRP-TADA2A-3C4 hybridoma house mouse CVCL_KL83 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; O75478; Human TADA2A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142031 CVCL_KL82 PCRP-TADA1-1C9 hybridoma house mouse CVCL_KL82 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96BN2; Human TADA1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142032 CVCL_TF20 HAP1 POMT1 (-) 1 cancer cell line human CVCL_TF20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9202; POMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142033 CVCL_TF22 HAP1 POMT2 (-) 1 cancer cell line human CVCL_TF22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19743; POMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142034 CVCL_TF21 HAP1 POMT1 (-) 2 cancer cell line human CVCL_TF21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9202; POMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142035 CVCL_TF24 HAP1 POT1 (-) 1 cancer cell line human CVCL_TF24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17284; POT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142036 CVCL_TF23 HAP1 POMT2 (-) 2 cancer cell line human CVCL_TF23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19743; POMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142037 CVCL_TF26 HAP1 PPARD (-) 1 cancer cell line human CVCL_TF26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9235; PPARD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142038 CVCL_KL78 PCRP-STAT6-1C6 hybridoma house mouse CVCL_KL78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P42226; Human STAT6. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142039 CVCL_TF25 HAP1 PPARA (-) cancer cell line human CVCL_TF25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9232; PPARA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142040 CVCL_KL77 PCRP-STAT5B-3E9 hybridoma house mouse CVCL_KL77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51692; Human STAT5B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142041 CVCL_TF28 HAP1 PPEF1 (-) cancer cell line human CVCL_TF28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9243; PPEF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142042 CVCL_TF27 HAP1 PPARD (-) 2 cancer cell line human CVCL_TF27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9235; PPARD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142043 CVCL_KL79 PCRP-SYAP1-2B8 hybridoma house mouse CVCL_KL79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96A49; Human SYAP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142044 CVCL_KL74 PCRP-STAT5B-1B10 hybridoma house mouse CVCL_KL74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P51692; Human STAT5B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142045 CVCL_TF29 HAP1 PPIB (-) 1 cancer cell line human CVCL_TF29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9255; PPIB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142046 CVCL_KL73 PCRP-STAT5A-1A9 hybridoma house mouse CVCL_KL73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P42229; Human STAT5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142047 CVCL_KL76 PCRP-STAT5B-1H5 hybridoma house mouse CVCL_KL76 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P51692; Human STAT5B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142048 CVCL_KL75 PCRP-STAT5B-1B5 hybridoma house mouse CVCL_KL75 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P51692; Human STAT5B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142049 CVCL_KL92 PCRP-TBC1D23-2E4 hybridoma house mouse CVCL_KL92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NUY8; Human TBC1D23. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142050 CVCL_KL91 PCRP-TAX1BP1-1D8 hybridoma house mouse CVCL_KL91 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VP1; Human TAX1BP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142051 CVCL_KL94 PCRP-TBX19-1B5 hybridoma house mouse CVCL_KL94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60806; Human TBX19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142052 CVCL_KL93 PCRP-TBL1X-2C3 hybridoma house mouse CVCL_KL93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60907; Human TBL1X. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142053 CVCL_KL90 PCRP-TAX1BP1-1D4 hybridoma house mouse CVCL_KL90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86VP1; Human TAX1BP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142054 CVCL_TF11 HAP1 POLN (-) 3 cancer cell line human CVCL_TF11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18870; POLN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142055 CVCL_TF10 HAP1 POLN (-) 2 cancer cell line human CVCL_TF10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18870; POLN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142056 CVCL_TF13 HAP1 POLQ (-) 2 cancer cell line human CVCL_TF13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9186; POLQ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142057 CVCL_TF12 HAP1 POLQ (-) 1 cancer cell line human CVCL_TF12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9186; POLQ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142058 CVCL_TF15 HAP1 POMGNT1 (-) 2 cancer cell line human CVCL_TF15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19139; POMGNT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142059 CVCL_KL89 PCRP-TARBP2-1E5 hybridoma house mouse CVCL_KL89 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15633; Human TARBP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142060 CVCL_TF14 HAP1 POMGNT1 (-) 1 cancer cell line human CVCL_TF14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19139; POMGNT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142061 CVCL_KL88 PCRP-TARBP2-1B9 hybridoma house mouse CVCL_KL88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15633; Human TARBP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142062 CVCL_TF17 HAP1 POMGNT2 (-) 2 cancer cell line human CVCL_TF17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25902; POMGNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142063 CVCL_TF16 HAP1 POMGNT2 (-) 1 cancer cell line human CVCL_TF16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25902; POMGNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142064 CVCL_TF19 HAP1 POMK (-) 2 cancer cell line human CVCL_TF19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26267; POMK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142065 CVCL_KL85 PCRP-TADA3-1F3 hybridoma house mouse CVCL_KL85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75528; Human TADA3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142066 CVCL_TF18 HAP1 POMK (-) 1 cancer cell line human CVCL_TF18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26267; POMK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142067 CVCL_KL84 PCRP-TADA2B-1.1A3 hybridoma house mouse CVCL_KL84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86TJ2; Human TADA2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142068 CVCL_KL87 PCRP-TAF10-1A2 hybridoma house mouse CVCL_KL87 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q12962; Human TAF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142069 CVCL_KL86 PCRP-TAF10-1A10 hybridoma house mouse CVCL_KL86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q12962; Human TAF10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142070 CVCL_KL61 PCRP-STAT1-3D6 hybridoma house mouse CVCL_KL61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42224; Human STAT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142071 CVCL_KL60 PCRP-STAT1-1G5 hybridoma house mouse CVCL_KL60 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42224; Human STAT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142072 CVCL_TF00 HAP1 POLK (-) 1 cancer cell line human CVCL_TF00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9183; POLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142073 CVCL_KL59 PCRP-SSBP4-4G8 hybridoma house mouse CVCL_KL59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BWG4; Human SSBP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142074 CVCL_TF02 HAP1 POLK (-) 3 cancer cell line human CVCL_TF02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9183; POLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142075 CVCL_TF01 HAP1 POLK (-) 2 cancer cell line human CVCL_TF01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9183; POLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142076 CVCL_TF04 HAP1 POLL (-) 2 cancer cell line human CVCL_TF04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9184; POLL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142077 CVCL_KL56 PCRP-SRY-2C6 hybridoma house mouse CVCL_KL56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q05066; Human SRY. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142078 CVCL_TF03 HAP1 POLL (-) 1 cancer cell line human CVCL_TF03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9184; POLL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142079 CVCL_KL55 PCRP-SRY-1D7 hybridoma house mouse CVCL_KL55 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q05066; Human SRY. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142080 CVCL_TF06 HAP1 POLM (-) 1 cancer cell line human CVCL_TF06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9185; POLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142081 CVCL_KL58 PCRP-SSBP4-3D5 hybridoma house mouse CVCL_KL58 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BWG4; Human SSBP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142082 CVCL_TF05 HAP1 POLL (-) 3 cancer cell line human CVCL_TF05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9184; POLL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142083 CVCL_KL57 PCRP-SSBP4-3B5 hybridoma house mouse CVCL_KL57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BWG4; Human SSBP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142084 CVCL_TF08 HAP1 POLM (-) 3 cancer cell line human CVCL_TF08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9185; POLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142085 CVCL_KL52 PCRP-SRF-1F7 hybridoma house mouse CVCL_KL52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11831; Human SRF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142086 CVCL_TF07 HAP1 POLM (-) 2 cancer cell line human CVCL_TF07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9185; POLM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142087 CVCL_KL51 PCRP-SRF-1F1 hybridoma house mouse CVCL_KL51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11831; Human SRF. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142088 CVCL_KL54 PCRP-SRY-1D10 hybridoma house mouse CVCL_KL54 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q05066; Human SRY. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142089 CVCL_TF09 HAP1 POLN (-) 1 cancer cell line human CVCL_TF09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18870; POLN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142090 CVCL_KL53 PCRP-SRRT-1F5 hybridoma house mouse CVCL_KL53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BXP5; Human SRRT. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142091 CVCL_KL70 PCRP-STAT3-2F12 hybridoma house mouse CVCL_KL70 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P40763; Human STAT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142092 CVCL_KL72 PCRP-STAT5A-1A11 hybridoma house mouse CVCL_KL72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P42229; Human STAT5A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142093 CVCL_KL71 PCRP-STAT4-2A2 hybridoma house mouse CVCL_KL71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14765; Human STAT4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142094 CVCL_KL67 PCRP-STAT2-1H10 hybridoma house mouse CVCL_KL67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142095 CVCL_KL66 PCRP-STAT2-1G7 hybridoma house mouse CVCL_KL66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142096 CVCL_KL69 PCRP-STAT3-2E3 hybridoma house mouse CVCL_KL69 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P40763; Human STAT3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142097 CVCL_KL68 PCRP-STAT2-2B9 hybridoma house mouse CVCL_KL68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142098 CVCL_KL63 PCRP-STAT2-1B3 hybridoma house mouse CVCL_KL63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142099 CVCL_KL62 PCRP-STAT1-4H11 hybridoma house mouse CVCL_KL62 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42224; Human STAT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142100 CVCL_KL65 PCRP-STAT2-1E5 hybridoma house mouse CVCL_KL65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142101 CVCL_KL64 PCRP-STAT2-1B6 hybridoma house mouse CVCL_KL64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52630; Human STAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142102 CVCL_9Y24 GM13121 transformed cell line human CVCL_9Y24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88407 21142103 CVCL_9Y23 GM13120 transformed cell line human CVCL_9Y23 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88406 21142104 CVCL_9Y26 GM13123 transformed cell line human CVCL_9Y26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88409 21142105 CVCL_9Y25 GM13122 transformed cell line human CVCL_9Y25 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88408 21142106 CVCL_9Y20 GM13117 transformed cell line human CVCL_9Y20 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88403 21142107 CVCL_9Y22 GM13119 transformed cell line human CVCL_9Y22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88405 21142108 CVCL_9Y21 GM13118 transformed cell line human CVCL_9Y21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88404 21142109 CVCL_9Y28 GM13125 transformed cell line human CVCL_9Y28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88411 21142110 CVCL_9Y27 GM13124 transformed cell line human CVCL_9Y27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88410 21142111 CVCL_9Y29 GM13126 transformed cell line human CVCL_9Y29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88412 21142112 CVCL_9Y40 GM18473 transformed cell line human CVCL_9Y40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142113 CVCL_9Y35 GM16378 transformed cell line human CVCL_9Y35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142114 CVCL_9Y34 GM14442 transformed cell line human CVCL_9Y34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14441 (Cellosaurus=CVCL_F320); Derived from sampling site: Peripheral blood. Male 21142115 CVCL_9Y37 GM16728 finite cell line human CVCL_9Y37 CL:0000010 Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142116 CVCL_9Y36 GM16678 finite cell line human CVCL_9Y36 CL:0000010 Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142117 CVCL_9Y31 GM13128 transformed cell line human CVCL_9Y31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88414 21142118 CVCL_9Y30 GM13127 transformed cell line human CVCL_9Y30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88413 21142119 CVCL_9Y33 GM13239 finite cell line human CVCL_9Y33 CL:0000010 Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Female 21142120 CVCL_9Y32 GM13134 transformed cell line human CVCL_9Y32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 209 21142121 CVCL_9Y39 GM18456 transformed cell line human CVCL_9Y39 CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10560del4400; Zygosity=Heteroplasmic (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142122 CVCL_9Y38 GM16776 transformed cell line human CVCL_9Y38 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142123 CVCL_9Y02 GM12697 transformed cell line human CVCL_9Y02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2107 21142124 CVCL_9Y01 GM12696 transformed cell line human CVCL_9Y01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2106 21142125 CVCL_9Y04 GM12699 transformed cell line human CVCL_9Y04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4502 21142126 CVCL_9Y03 GM12698 transformed cell line human CVCL_9Y03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4501 21142127 CVCL_9Y00 GM12695 transformed cell line human CVCL_9Y00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2105 21142128 CVCL_9Y09 GM12704 transformed cell line human CVCL_9Y09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4508 21142129 CVCL_9Y06 GM12701 transformed cell line human CVCL_9Y06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4505 21142130 CVCL_9Y05 GM12700 transformed cell line human CVCL_9Y05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4503 21142131 CVCL_9Y08 GM12703 transformed cell line human CVCL_9Y08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4507 21142132 CVCL_9Y07 GM12702 transformed cell line human CVCL_9Y07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4506 21142133 CVCL_9Y13 GM12849 transformed cell line human CVCL_9Y13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4504 21142134 CVCL_9Y12 GM12779 transformed cell line human CVCL_9Y12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2108 21142135 CVCL_9Y15 GM13112 transformed cell line human CVCL_9Y15 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88416 21142136 CVCL_9Y14 GM13111 transformed cell line human CVCL_9Y14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88415 21142137 CVCL_9Y11 GM12706 transformed cell line human CVCL_9Y11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4510 21142138 CVCL_9Y10 GM12705 transformed cell line human CVCL_9Y10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 4509 21142139 CVCL_9Y17 GM13114 transformed cell line human CVCL_9Y17 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88402 21142140 CVCL_9Y16 GM13113 transformed cell line human CVCL_9Y16 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88401 21142141 CVCL_9Y19 GM13116 transformed cell line human CVCL_9Y19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88418 21142142 CVCL_9Y18 GM13115 transformed cell line human CVCL_9Y18 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Amish pedigree cell line collection; Registration: CEPH Families Reference Panel; 88417 21142143 CVCL_TF91 HAP1 PPP2CB (-) 2 cancer cell line human CVCL_TF91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9300; PPP2CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142144 CVCL_TF90 HAP1 PPP2CB (-) 1 cancer cell line human CVCL_TF90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9300; PPP2CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142145 CVCL_TF93 HAP1 PPP2R1B (-) 1 cancer cell line human CVCL_TF93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9303; PPP2R1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142146 CVCL_TF92 HAP1 PPP2CB (-) 3 cancer cell line human CVCL_TF92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9300; PPP2CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142147 CVCL_TF95 HAP1 PPP2R2B (-) 1 cancer cell line human CVCL_TF95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9305; PPP2R2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142148 CVCL_TF94 HAP1 PPP2R1B (-) 2 cancer cell line human CVCL_TF94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9303; PPP2R1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142149 CVCL_TF97 HAP1 PPP2R2C (-) cancer cell line human CVCL_TF97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9306; PPP2R2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142150 CVCL_TF96 HAP1 PPP2R2B (-) 2 cancer cell line human CVCL_TF96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9305; PPP2R2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142151 CVCL_TF99 HAP1 PPP2R2D (-) 2 cancer cell line human CVCL_TF99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23732; PPP2R2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142152 CVCL_TF98 HAP1 PPP2R2D (-) 1 cancer cell line human CVCL_TF98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23732; PPP2R2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142153 CVCL_TF80 HAP1 PPP1R3B (-) 1 cancer cell line human CVCL_TF80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14942; PPP1R3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142154 CVCL_TF82 HAP1 PPP1R3D (-) 1 cancer cell line human CVCL_TF82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9294; PPP1R3D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142155 CVCL_TF81 HAP1 PPP1R3B (-) 2 cancer cell line human CVCL_TF81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14942; PPP1R3B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142156 CVCL_TF84 HAP1 PPP1R3F (-) 1 cancer cell line human CVCL_TF84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14944; PPP1R3F; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142157 CVCL_TF83 HAP1 PPP1R3D (-) 2 cancer cell line human CVCL_TF83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9294; PPP1R3D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142158 CVCL_TF86 HAP1 PPP1R9A (-) 1 cancer cell line human CVCL_TF86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14946; PPP1R9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142159 CVCL_TF85 HAP1 PPP1R3F (-) 2 cancer cell line human CVCL_TF85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14944; PPP1R3F; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142160 CVCL_TF88 HAP1 PPP1R9B (-) 1 cancer cell line human CVCL_TF88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9298; PPP1R9B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142161 CVCL_TF87 HAP1 PPP1R9A (-) 2 cancer cell line human CVCL_TF87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14946; PPP1R9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142162 CVCL_TF89 HAP1 PPP1R9B (-) 2 cancer cell line human CVCL_TF89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9298; PPP1R9B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142163 CVCL_TF71 HAP1 PPP1R1A (-) 2 cancer cell line human CVCL_TF71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9286; PPP1R1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142164 CVCL_TF70 HAP1 PPP1R1A (-) 1 cancer cell line human CVCL_TF70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9286; PPP1R1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142165 CVCL_TF73 HAP1 PPP1R1A (-) 4 cancer cell line human CVCL_TF73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9286; PPP1R1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142166 CVCL_TF72 HAP1 PPP1R1A (-) 3 cancer cell line human CVCL_TF72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9286; PPP1R1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142167 CVCL_TF75 HAP1 PPP1R21 (-) 2 cancer cell line human CVCL_TF75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30595; PPP1R21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142168 CVCL_TF74 HAP1 PPP1R21 (-) 1 cancer cell line human CVCL_TF74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30595; PPP1R21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142169 CVCL_TF77 HAP1 PPP1R32 (-) cancer cell line human CVCL_TF77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28869; PPP1R32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142170 CVCL_TF76 HAP1 PPP1R26 (-) cancer cell line human CVCL_TF76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29089; PPP1R26; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142171 CVCL_TF79 HAP1 PPP1R37 (-) 2 cancer cell line human CVCL_TF79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27607; PPP1R37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142172 CVCL_TF78 HAP1 PPP1R37 (-) 1 cancer cell line human CVCL_TF78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27607; PPP1R37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142173 CVCL_C328 BD129mt-1 embryonic stem cell house mouse CVCL_C328 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x 129/Sv. Discontinued: RCB; RCB2174; true Male 21142174 CVCL_BR28 ND14417 transformed cell line human CVCL_BR28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142175 CVCL_C327 BD129fc-2 embryonic stem cell house mouse CVCL_C327 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x 129/Sv. Discontinued: RCB; RCB2177; true Female 21142176 CVCL_BR27 ND14416 transformed cell line human CVCL_BR27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142177 CVCL_C329 BD129mt-2 embryonic stem cell house mouse CVCL_C329 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x 129/Sv. Discontinued: RCB; RCB2175; true Male 21142178 CVCL_BR29 ND14429 transformed cell line human CVCL_BR29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142179 CVCL_C320 ES-E14 embryonic stem cell house mouse CVCL_C320 CL:0000010 Breed/subspecies: 129P2/Ola. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me2 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male Part of: ENCODE project mouse cell lines 21142180 CVCL_9X94 GM12687 transformed cell line human CVCL_9X94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1709 21142181 CVCL_BR20 ND14408 transformed cell line human CVCL_BR20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142182 CVCL_9X93 GM12685 transformed cell line human CVCL_9X93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1707 21142183 CVCL_C322 BCfc-2 embryonic stem cell house mouse CVCL_C322 CL:0000010 Breed/subspecies: C57BL/6 x C3H/He. Discontinued: RCB; RCB2173; true Female 21142184 CVCL_9X96 GM12691 transformed cell line human CVCL_9X96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2101 21142185 CVCL_BR22 ND14410 transformed cell line human CVCL_BR22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142186 CVCL_C321 BayGenomics ES cell line RST307 embryonic stem cell house mouse CVCL_C321 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917745; Atp6ap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21142187 CVCL_9X95 GM12688 transformed cell line human CVCL_9X95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1710 21142188 CVCL_BR21 ND14409 transformed cell line human CVCL_BR21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142189 CVCL_C324 BCmt-1 embryonic stem cell house mouse CVCL_C324 CL:0000010 Breed/subspecies: C57BL/6 x C3H/He. Discontinued: RCB; RCB2169; true Male 21142190 CVCL_9X90 GM12681 transformed cell line human CVCL_9X90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1703 21142191 CVCL_BR24 ND14413 transformed cell line human CVCL_BR24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142192 CVCL_C323 BCft-1 embryonic stem cell house mouse CVCL_C323 CL:0000010 Breed/subspecies: C57BL/6 x C3H/He. Discontinued: RCB; RCB2171; true Female 21142193 CVCL_BR23 ND14412 transformed cell line human CVCL_BR23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142194 CVCL_C326 BD129fc-1 embryonic stem cell house mouse CVCL_C326 CL:0000010 Breed/subspecies: (C57BL/6 x DBA/2) x 129/Sv. Discontinued: RCB; RCB2176; true Female 21142195 CVCL_9X92 GM12684 transformed cell line human CVCL_9X92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1706 21142196 CVCL_BR26 ND14415 transformed cell line human CVCL_BR26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142197 CVCL_C325 BCmt-2 embryonic stem cell house mouse CVCL_C325 CL:0000010 Breed/subspecies: C57BL/6 x C3H/He. Discontinued: RCB; RCB2170; true Male 21142198 CVCL_9X91 GM12682 transformed cell line human CVCL_9X91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1704 21142199 CVCL_BR25 ND14414 transformed cell line human CVCL_BR25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142200 CVCL_9X87 GM12678 transformed cell line human CVCL_9X87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 208 21142201 CVCL_9X86 GM12677 transformed cell line human CVCL_9X86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 207 21142202 CVCL_9X89 GM12680 transformed cell line human CVCL_9X89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1702 21142203 CVCL_9X88 GM12679 transformed cell line human CVCL_9X88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1701 21142204 CVCL_C339 MA50 embryonic stem cell human CVCL_C339 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Female 21142205 CVCL_BR39 ND14489 transformed cell line human CVCL_BR39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142206 CVCL_C338 MA42 embryonic stem cell human CVCL_C338 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Female 21142207 CVCL_BR38 ND14479 transformed cell line human CVCL_BR38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142208 CVCL_C331 BDft-1 embryonic stem cell house mouse CVCL_C331 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2166; true Female 21142209 CVCL_BR31 ND14441 transformed cell line human CVCL_BR31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142210 CVCL_C330 BDfc-1 embryonic stem cell house mouse CVCL_C330 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2167; true Female 21142211 CVCL_BR30 ND14434 transformed cell line human CVCL_BR30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142212 CVCL_C333 BDmt-2 embryonic stem cell house mouse CVCL_C333 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2165; true Male 21142213 CVCL_BR33 ND14453 transformed cell line human CVCL_BR33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142214 CVCL_C332 BDmt-1 embryonic stem cell house mouse CVCL_C332 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2164; true Male 21142215 CVCL_BR32 ND14442 transformed cell line human CVCL_BR32 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142216 CVCL_C335 J 3.2 embryonic stem cell human CVCL_C335 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Male 21142217 CVCL_BR35 ND14473 transformed cell line human CVCL_BR35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142218 CVCL_C334 J 3 embryonic stem cell human CVCL_C334 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Male 21142219 CVCL_BR34 ND14472 transformed cell line human CVCL_BR34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142220 CVCL_C337 MA40 embryonic stem cell human CVCL_C337 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Female 21142221 CVCL_BR37 ND14476 transformed cell line human CVCL_BR37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142222 CVCL_BR36 ND14474 transformed cell line human CVCL_BR36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142223 CVCL_9X98 GM12693 transformed cell line human CVCL_9X98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2103 21142224 CVCL_9X97 GM12692 transformed cell line human CVCL_9X97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2102 21142225 CVCL_9X99 GM12694 transformed cell line human CVCL_9X99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2104 21142226 CVCL_BR06 ND14364 transformed cell line human CVCL_BR06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142227 CVCL_C306 OMM2.3 cancer cell line human CVCL_C306 From: Ksander B.; Schepens Eye Research Institute; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=22236444) Derived from metastatic site: Liver. Male 21142228 CVCL_BR05 ND14339 transformed cell line human CVCL_BR05 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142229 CVCL_C305 OMM2.2 cancer cell line human CVCL_C305 From: Ksander B.; Schepens Eye Research Institute; Boston; USA CL:0000010 Derived from metastatic site: Liver. Male 21142230 CVCL_BR08 ND14379 transformed cell line human CVCL_BR08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142231 CVCL_C308 OMM2.6 cancer cell line human CVCL_C308 From: Ksander B.; Schepens Eye Research Institute; Boston; USA. CL:0000010 Male 21142232 CVCL_BR07 ND14365 transformed cell line human CVCL_BR07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142233 CVCL_C307 OMM2.5 cancer cell line human CVCL_C307 From: Ksander B.; Schepens Eye Research Institute; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=22236444) Derived from metastatic site: Liver. Male Doubling time: 50 hours (PubMed=24994677) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21142234 CVCL_C309 HP-1 cancer cell line human CVCL_C309 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21142235 CVCL_BR09 ND14382 transformed cell line human CVCL_BR09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142236 CVCL_9X72 GM12663 transformed cell line human CVCL_9X72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2301 21142237 CVCL_9X71 GM12642 transformed cell line human CVCL_9X71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2809 21142238 CVCL_C300 92-2 cancer cell line human CVCL_C300 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous (PubMed=22383533) Derived from sampling site: Eye; uvea. Female 21142239 CVCL_9X74 GM12665 transformed cell line human CVCL_9X74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2303 21142240 CVCL_BR00 ND14333 transformed cell line human CVCL_BR00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142241 CVCL_9X73 GM12664 transformed cell line human CVCL_9X73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2302 21142242 CVCL_C302 Mel270 cancer cell line human CVCL_C302 From: Ksander B.; Schepens Eye Research Institute; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Homozygous (PubMed=22236444; PubMed=22383533) Derived from sampling site: Eye; uvea. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21142243 CVCL_BR02 ND14335 transformed cell line human CVCL_BR02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142244 CVCL_C301 Mel202 cancer cell line human CVCL_C301 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu65Argfs*52 (c.194_201del) (p.Pro80fs, c.237_244del); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=22236444; PubMed=23851445; PubMed=28018010; DepMap); Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Arg210Lys (c.629G>A); Zygosity=Unspecified (PubMed=22236444; PubMed=23851445; PubMed=28018010; DepMap); Sequence variation: Mutation; HGNC; 10768; SF3B1; Simple; p.Arg625Gly (c.1793C>T); ClinVar=VCV000376536; Zygosity=Unspecified (PubMed=24994677) Derived from sampling site: Eye; uvea. Omics: Array-based CGH; Omics: Deep exome analysis Female Doubling time: 43 hours (PubMed=24994677) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21142245 CVCL_BR01 ND14334 transformed cell line human CVCL_BR01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142246 CVCL_9X70 GM12639 transformed cell line human CVCL_9X70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2806 21142247 CVCL_C304 Mel290 cancer cell line human CVCL_C304 From: Ksander B.; Schepens Eye Research Institute; Boston; USA. CL:0000010 Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21142248 CVCL_BR04 ND14338 transformed cell line human CVCL_BR04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142249 CVCL_C303 Mel285 cancer cell line human CVCL_C303 From: Ksander B.; Schepens Eye Research Institute; Boston; USA. CL:0000010 Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21142250 CVCL_BR03 ND14337 transformed cell line human CVCL_BR03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142251 CVCL_9X69 GM12638 transformed cell line human CVCL_9X69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2805 21142252 CVCL_9X68 GM12637 transformed cell line human CVCL_9X68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2804 21142253 CVCL_9X65 GM12634 transformed cell line human CVCL_9X65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2801 21142254 CVCL_9X64 GM12633 transformed cell line human CVCL_9X64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3709 21142255 CVCL_9X67 GM12636 transformed cell line human CVCL_9X67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2803 21142256 CVCL_9X66 GM12635 transformed cell line human CVCL_9X66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2802 21142257 CVCL_C317 KH2 embryonic stem cell house mouse CVCL_C317 CL:0000010 Breed/subspecies: C57BL/6 x 129/Sv. Unspecified 21142258 CVCL_BR17 ND14398 transformed cell line human CVCL_BR17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142259 CVCL_C316 CJ7 embryonic stem cell house mouse CVCL_C316 CL:0000010 Breed/subspecies: 129S1/SvImJ. Male Part of: ENCODE project mouse cell lines 21142260 CVCL_BR16 ND14392 transformed cell line human CVCL_BR16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142261 CVCL_BR19 ND14402 transformed cell line human CVCL_BR19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142262 CVCL_C319 PluriStem 129S6 embryonic stem cell house mouse CVCL_C319 CL:0000010 Breed/subspecies: 129S6/SvEv. Male 21142263 CVCL_BR18 ND14399 transformed cell line human CVCL_BR18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142264 CVCL_C318 TT2 embryonic stem cell house mouse CVCL_C318 CL:0000010 Breed/subspecies: C57BL/6 x CBA. Discontinued: RCB; RCB2077; true Male Part of: ENCODE project mouse cell lines 21142265 CVCL_9X83 GM12674 transformed cell line human CVCL_9X83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 204 21142266 CVCL_9X82 GM12673 transformed cell line human CVCL_9X82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 203 21142267 CVCL_9X85 GM12676 transformed cell line human CVCL_9X85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 206 21142268 CVCL_C311 HP-3 cancer cell line human CVCL_C311 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21142269 CVCL_BR11 ND14387 transformed cell line human CVCL_BR11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142270 CVCL_9X84 GM12675 transformed cell line human CVCL_9X84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 205 21142271 CVCL_C310 HP-2 cancer cell line human CVCL_C310 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21142272 CVCL_BR10 ND14386 transformed cell line human CVCL_BR10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142273 CVCL_C313 CCE embryonic stem cell house mouse CVCL_C313 CL:0000010 Anecdotal: CCE and ESC-ICR (Cellosaurus=CVCL_JA30) from Gail Martin are the first embryonic stem cell lines to have been established (in 1981) Breed/subspecies: 129S/SvEv-Gpi1. Male 21142274 CVCL_BR13 ND14389 transformed cell line human CVCL_BR13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142275 CVCL_C312 IST-Mes3 cancer cell line human CVCL_C312 CL:0000010 Derived from sampling site: Pleural effusion. Male 21142276 CVCL_BR12 ND14388 transformed cell line human CVCL_BR12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142277 CVCL_9X81 GM12672 transformed cell line human CVCL_9X81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 202 21142278 CVCL_C315 HM-1 ES embryonic stem cell house mouse CVCL_C315 CL:0000010 Breed/subspecies: 129P2/OlaHsd-Hprt. Male 21142279 CVCL_BR15 ND14391 transformed cell line human CVCL_BR15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142280 CVCL_9X80 GM12671 transformed cell line human CVCL_9X80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 201 21142281 CVCL_C314 MG1.19 embryonic stem cell house mouse CVCL_C314 CL:0000010 Breed/subspecies: 129S/SvEv-Gpi1. Male 21142282 CVCL_BR14 ND14390 transformed cell line human CVCL_BR14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142283 CVCL_9X79 GM12670 transformed cell line human CVCL_9X79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2308 21142284 CVCL_9X76 GM12667 transformed cell line human CVCL_9X76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2305 21142285 CVCL_9X75 GM12666 transformed cell line human CVCL_9X75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2304 21142286 CVCL_9X78 GM12669 transformed cell line human CVCL_9X78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2307 21142287 CVCL_9X77 GM12668 transformed cell line human CVCL_9X77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 2306 21142288 CVCL_9X50 GM12619 transformed cell line human CVCL_9X50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3505 21142289 CVCL_9X52 GM12621 transformed cell line human CVCL_9X52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3507 21142290 CVCL_9X51 GM12620 transformed cell line human CVCL_9X51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3506 21142291 CVCL_9X47 GM12616 transformed cell line human CVCL_9X47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3502 21142292 CVCL_9X46 GM12615 transformed cell line human CVCL_9X46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3501 21142293 CVCL_9X49 GM09887 transformed cell line human CVCL_9X49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142294 CVCL_9X48 GM12617 transformed cell line human CVCL_9X48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3503 21142295 CVCL_9X43 GM12570 transformed cell line human CVCL_9X43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1211 21142296 CVCL_9X42 GM12569 transformed cell line human CVCL_9X42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1210 21142297 CVCL_9X45 GM12572 transformed cell line human CVCL_9X45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1213 21142298 CVCL_9X44 GM12571 transformed cell line human CVCL_9X44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1212 21142299 CVCL_9X61 GM12630 transformed cell line human CVCL_9X61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3706 21142300 CVCL_9X60 GM12629 transformed cell line human CVCL_9X60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3705 21142301 CVCL_9X63 GM12632 transformed cell line human CVCL_9X63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3708 21142302 CVCL_9X62 GM12631 transformed cell line human CVCL_9X62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3707 21142303 CVCL_9X58 GM12627 transformed cell line human CVCL_9X58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3703 21142304 CVCL_9X57 GM12626 transformed cell line human CVCL_9X57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3702 21142305 CVCL_9X59 GM12628 transformed cell line human CVCL_9X59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3704 21142306 CVCL_9X54 GM12623 transformed cell line human CVCL_9X54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3509 21142307 CVCL_9X53 GM12622 transformed cell line human CVCL_9X53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3508 21142308 CVCL_9X56 GM12625 transformed cell line human CVCL_9X56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3701 21142309 CVCL_9X55 GM12624 transformed cell line human CVCL_9X55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3510 21142310 CVCL_9X30 GM12557 transformed cell line human CVCL_9X30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6611 21142311 CVCL_9X25 GM12552 transformed cell line human CVCL_9X25 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Triplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=33197628) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6606 21142312 CVCL_9X24 GM12551 transformed cell line human CVCL_9X24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6605 21142313 CVCL_9X27 GM12554 transformed cell line human CVCL_9X27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6608 21142314 CVCL_9X26 GM12553 transformed cell line human CVCL_9X26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6607 21142315 CVCL_9X21 GM12370 finite cell line human CVCL_9X21 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21142316 CVCL_9X20 GM11351 finite cell line human CVCL_9X20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142317 CVCL_9X23 GM12550 transformed cell line human CVCL_9X23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6604 21142318 CVCL_9X22 GM12549 transformed cell line human CVCL_9X22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6603 21142319 CVCL_9X29 GM12556 transformed cell line human CVCL_9X29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6610 21142320 CVCL_9X28 GM12555 transformed cell line human CVCL_9X28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6609 21142321 CVCL_9X41 GM12568 transformed cell line human CVCL_9X41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1209 21142322 CVCL_9X40 GM12567 transformed cell line human CVCL_9X40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1208 21142323 CVCL_9X36 GM12563 transformed cell line human CVCL_9X36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1204 21142324 CVCL_9X35 GM12562 transformed cell line human CVCL_9X35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1203 21142325 CVCL_9X38 GM12565 transformed cell line human CVCL_9X38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1206 21142326 CVCL_9X37 GM12564 transformed cell line human CVCL_9X37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1205 21142327 CVCL_9X32 GM12559 transformed cell line human CVCL_9X32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6613 21142328 CVCL_9X31 GM12558 transformed cell line human CVCL_9X31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 6612 21142329 CVCL_9X34 GM12561 transformed cell line human CVCL_9X34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1202 21142330 CVCL_9X33 GM12560 transformed cell line human CVCL_9X33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1201 21142331 CVCL_9X39 GM12566 transformed cell line human CVCL_9X39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 1207 21142332 CVCL_KL38 PCRP-SOX8-2D11 hybridoma house mouse CVCL_KL38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P57073; Human SOX8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142333 CVCL_KL37 PCRP-SOX8-2C6 hybridoma house mouse CVCL_KL37 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P57073; Human SOX8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142334 CVCL_KL39 PCRP-SOX9-1A2 hybridoma house mouse CVCL_KL39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P48436; Human SOX9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142335 CVCL_KL34 PCRP-SOX5-1C12 hybridoma house mouse CVCL_KL34 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P35711; Human SOX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142336 CVCL_KL33 PCRP-SOX4-3F12 hybridoma house mouse CVCL_KL33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q06945; Human SOX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142337 CVCL_KL36 PCRP-SOX8-2B9 hybridoma house mouse CVCL_KL36 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P57073; Human SOX8. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142338 CVCL_KL35 PCRP-SOX5-1E3 hybridoma house mouse CVCL_KL35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35711; Human SOX5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142339 CVCL_KL30 PCRP-SOX4-1D6 hybridoma house mouse CVCL_KL30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q06945; Human SOX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142340 CVCL_KL32 PCRP-SOX4-3B5 hybridoma house mouse CVCL_KL32 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q06945; Human SOX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142341 CVCL_KL31 PCRP-SOX4-1F1 hybridoma house mouse CVCL_KL31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q06945; Human SOX4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142342 CVCL_KL50 PCRP-SPIC-2C5 hybridoma house mouse CVCL_KL50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N5J4; Human SPIC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142343 CVCL_KL49 PCRP-SPIC-2C11 hybridoma house mouse CVCL_KL49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N5J4; Human SPIC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142344 CVCL_KL48 PCRP-SPIC-1F10 hybridoma house mouse CVCL_KL48 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N5J4; Human SPIC. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142345 CVCL_KL45 PCRP-SP140-3G1 hybridoma house mouse CVCL_KL45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13342; Human SP140. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142346 CVCL_KL44 PCRP-SP140-1G12 hybridoma house mouse CVCL_KL44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13342; Human SP140. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142347 CVCL_KL47 PCRP-SP5-2A5 hybridoma house mouse CVCL_KL47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6BEB4; Human SP5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142348 CVCL_KL46 PCRP-SP140L-2A10 hybridoma house mouse CVCL_KL46 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H930; Human SP140L. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142349 CVCL_KL41 PCRP-SP100-1B9 hybridoma house mouse CVCL_KL41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P23497; Human SP100. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142350 CVCL_KL40 PCRP-SOX9-1E5 hybridoma house mouse CVCL_KL40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P48436; Human SOX9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142351 CVCL_KL43 PCRP-SP110-1D9 hybridoma house mouse CVCL_KL43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HB58; Human SP110. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142352 CVCL_KL42 PCRP-SP110-1C5 hybridoma house mouse CVCL_KL42 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9HB58; Human SP110. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142353 CVCL_C386 MIHe005-A embryonic stem cell human CVCL_C386 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Female 21142354 CVCL_BR86 ND14675 transformed cell line human CVCL_BR86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142355 CVCL_C385 MIHe004-A embryonic stem cell human CVCL_C385 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Male 21142356 CVCL_BR85 ND14673 transformed cell line human CVCL_BR85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142357 CVCL_C388 MIHe007-A embryonic stem cell human CVCL_C388 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Male 21142358 CVCL_BR88 ND14681 transformed cell line human CVCL_BR88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142359 CVCL_C387 MIHe006-A embryonic stem cell human CVCL_C387 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Male 21142360 CVCL_BR87 ND14676 transformed cell line human CVCL_BR87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142361 CVCL_C389 MIHe008-A embryonic stem cell human CVCL_C389 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Female 21142362 CVCL_BR89 ND14682 transformed cell line human CVCL_BR89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142363 CVCL_KL19 PCRP-SNAPC4-3A7 hybridoma house mouse CVCL_KL19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5SXM2; Human SNAPC4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142364 CVCL_C380 I 6 embryonic stem cell human CVCL_C380 HLA typing: A*01:26; B*38,44; C*04,12; DQB1*02,03; DRB1*04,07 (PubMed=16919167) From: Technion - Israel Institute of Technology; Haifa; Israel CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0206; Registration: Swiss research registry; BAG-hES-IMP-0004 21142365 CVCL_BR80 ND14662 transformed cell line human CVCL_BR80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142366 CVCL_C382 MIHe001-A embryonic stem cell human CVCL_C382 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Male 21142367 CVCL_BR82 ND14664 transformed cell line human CVCL_BR82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142368 CVCL_KL16 PCRP-SNAI3-1G2 hybridoma house mouse CVCL_KL16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q3KNW1; Human SNAI3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142369 CVCL_C381 I 6.2 embryonic stem cell human CVCL_C381 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Male 21142370 CVCL_BR81 ND14663 transformed cell line human CVCL_BR81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142371 CVCL_KL15 PCRP-SMURF1-1E8 hybridoma house mouse CVCL_KL15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HCE7; Human SMURF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142372 CVCL_C384 MIHe003-A embryonic stem cell human CVCL_C384 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Female 21142373 CVCL_BR84 ND14672 transformed cell line human CVCL_BR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142374 CVCL_KL18 PCRP-SNAPC4-1G11 hybridoma house mouse CVCL_KL18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q5SXM2; Human SNAPC4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142375 CVCL_C383 MIHe002-A embryonic stem cell human CVCL_C383 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Female 21142376 CVCL_BR83 ND14667 transformed cell line human CVCL_BR83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142377 CVCL_KL17 PCRP-SNAI3-2D12 hybridoma house mouse CVCL_KL17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q3KNW1; Human SNAI3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142378 CVCL_KL12 PCRP-SMNDC1-1A9 hybridoma house mouse CVCL_KL12 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75940; Human SMNDC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142379 CVCL_KL11 PCRP-SMARCE1-2F1 hybridoma house mouse CVCL_KL11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q969G3; Human SMARCE1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142380 CVCL_KL14 PCRP-SMURF1-1A10 hybridoma house mouse CVCL_KL14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9HCE7; Human SMURF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142381 CVCL_KL13 PCRP-SMNDC1-2E7 hybridoma house mouse CVCL_KL13 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O75940; Human SMNDC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142382 CVCL_KL10 PCRP-SMARCE1-2E9 hybridoma house mouse CVCL_KL10 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q969G3; Human SMARCE1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142383 CVCL_BR97 ND14709 transformed cell line human CVCL_BR97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142384 CVCL_C397 UKRV-Mel-15b cancer cell line human CVCL_C397 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-149C>T (c.253C>T) (C253T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21142385 CVCL_BR96 ND14708 transformed cell line human CVCL_BR96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142386 CVCL_C396 OKM-4 embryonic stem cell house mouse CVCL_C396 CL:0000010 Breed/subspecies: ICR. Discontinued: RCB; RCB2199; true Male 21142387 CVCL_BR99 ND14712 transformed cell line human CVCL_BR99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142388 CVCL_C399 UKRV-Mel-19b cancer cell line human CVCL_C399 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Female 21142389 CVCL_BR98 ND14710 transformed cell line human CVCL_BR98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142390 CVCL_C398 UKRV-Mel-15c cancer cell line human CVCL_C398 CL:0000010 21142391 CVCL_BR91 ND14684 transformed cell line human CVCL_BR91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142392 CVCL_C391 UHOMe001-A embryonic stem cell human CVCL_C391 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE07-142-L1. 21142393 CVCL_C390 MIHe009-A embryonic stem cell human CVCL_C390 From: Maria Infertility Hospital; Seoul; South Korea. CL:0000010 Male 21142394 CVCL_BR90 ND14683 transformed cell line human CVCL_BR90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142395 CVCL_C393 Hair iPS2 induced pluripotent stem cell human CVCL_C393 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Female 21142396 CVCL_BR93 ND14686 transformed cell line human CVCL_BR93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142397 CVCL_KL27 PCRP-SOX13-1C4 hybridoma house mouse CVCL_KL27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UN79; Human SOX13. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142398 CVCL_C392 Hair iPS1 induced pluripotent stem cell human CVCL_C392 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Female 21142399 CVCL_BR92 ND14685 transformed cell line human CVCL_BR92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142400 CVCL_KL26 PCRP-SOX12-1E4 hybridoma house mouse CVCL_KL26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15370; Human SOX12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142401 CVCL_BR95 ND14707 transformed cell line human CVCL_BR95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142402 CVCL_C395 OCRG9 embryonic stem cell house mouse CVCL_C395 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 129P2/Ola. Male 21142403 CVCL_KL29 PCRP-SOX3-1A1 hybridoma house mouse CVCL_KL29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P41225; Human SOX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142404 CVCL_BR94 ND14706 transformed cell line human CVCL_BR94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142405 CVCL_KL28 PCRP-SOX2-1B3 hybridoma house mouse CVCL_KL28 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P48431; Human SOX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142406 CVCL_C394 SB247 cancer cell line human CVCL_C394 CL:0000010 Derived from metastatic site: Ascites. Female 21142407 CVCL_KL23 PCRP-SOHLH1-2D12 hybridoma house mouse CVCL_KL23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5JUK2; Human SOHLH1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142408 CVCL_KL22 PCRP-SOHLH1-2B1 hybridoma house mouse CVCL_KL22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5JUK2; Human SOHLH1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142409 CVCL_KL25 PCRP-SOX12-1C4 hybridoma house mouse CVCL_KL25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15370; Human SOX12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142410 CVCL_KL24 PCRP-SOX10-1D8 hybridoma house mouse CVCL_KL24 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P56693; Human SOX10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142411 CVCL_KL21 PCRP-SNW1-2A1 hybridoma house mouse CVCL_KL21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13573; Human SNW1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142412 CVCL_KL20 PCRP-SNW1-1C12 hybridoma house mouse CVCL_KL20 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13573; Human SNW1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142413 CVCL_BR64 ND14597 transformed cell line human CVCL_BR64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142414 CVCL_C364 TYR1-hiPSC4 induced pluripotent stem cell human CVCL_C364 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142415 CVCL_BR63 ND14596 transformed cell line human CVCL_BR63 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142416 CVCL_C363 TYR1-hiPSC3 induced pluripotent stem cell human CVCL_C363 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21142417 CVCL_BR66 ND14610 transformed cell line human CVCL_BR66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142418 CVCL_C366 TYR1-hiPSC6 induced pluripotent stem cell human CVCL_C366 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142419 CVCL_BR65 ND14609 transformed cell line human CVCL_BR65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142420 CVCL_C365 TYR1-hiPSC5 induced pluripotent stem cell human CVCL_C365 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142421 CVCL_BR68 ND14612 transformed cell line human CVCL_BR68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142422 CVCL_C368 USH1-hiPSC1 induced pluripotent stem cell human CVCL_C368 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142423 CVCL_BR67 ND14611 transformed cell line human CVCL_BR67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142424 CVCL_C367 TYR1-hiPSC7 induced pluripotent stem cell human CVCL_C367 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142425 CVCL_BR69 ND14617 transformed cell line human CVCL_BR69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142426 CVCL_C369 USH1-hiPSC2 induced pluripotent stem cell human CVCL_C369 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142427 CVCL_BR60 ND14587 transformed cell line human CVCL_BR60 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (Coriell) Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142428 CVCL_C360 RH7 embryonic stem cell human CVCL_C360 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-06-034, Steering comm appl. SCSC06-16(6).. 21142429 CVCL_BR62 ND14594 transformed cell line human CVCL_BR62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142430 CVCL_C362 TYR1-hiPSC2 induced pluripotent stem cell human CVCL_C362 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142431 CVCL_BR61 ND14588 transformed cell line human CVCL_BR61 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142432 CVCL_C361 TYR1-hiPSC1 induced pluripotent stem cell human CVCL_C361 From: Royan Institute; Theran; Iran CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Gln64His (c.192G>T); ClinVar=VCV000021054; Zygosity=Unspecified (PubMed=20821352) Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21142433 CVCL_BR75 ND14644 transformed cell line human CVCL_BR75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142434 CVCL_C375 USH1-hiPSC8 induced pluripotent stem cell human CVCL_C375 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142435 CVCL_BR74 ND14643 transformed cell line human CVCL_BR74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142436 CVCL_C374 USH1-hiPSC7 induced pluripotent stem cell human CVCL_C374 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142437 CVCL_C377 I 3.2 embryonic stem cell human CVCL_C377 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Female 21142438 CVCL_BR77 ND14649 transformed cell line human CVCL_BR77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142439 CVCL_C376 I 3 embryonic stem cell human CVCL_C376 From: Technion - Israel Institute of Technology; Haifa; Israel CL:0000010 Omics: Deep exome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0204; Registration: Swiss research registry; BAG-hES-IMP-0005 21142440 CVCL_BR76 ND14646 transformed cell line human CVCL_BR76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142441 CVCL_C379 I 4 embryonic stem cell human CVCL_C379 HLA typing: A*03:24; B*35:02,38; C*04,12; DQB1*01,06; DRB1*13,13; DRB3*01 (PubMed=16919167) From: Technion - Israel Institute of Technology; Haifa; Israel CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0205 21142442 CVCL_BR79 ND14653 transformed cell line human CVCL_BR79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142443 CVCL_C378 I 3.3 embryonic stem cell human CVCL_C378 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Female 21142444 CVCL_BR78 ND14652 transformed cell line human CVCL_BR78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142445 CVCL_KL09 PCRP-SMARCE1-1G7 hybridoma house mouse CVCL_KL09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q969G3; Human SMARCE1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142446 CVCL_KL08 PCRP-SMARCD1-2B5 hybridoma house mouse CVCL_KL08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q96GM5; Human SMARCD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142447 CVCL_BR71 ND14619 transformed cell line human CVCL_BR71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142448 CVCL_KL05 PCRP-SMARCC2-1A3 hybridoma house mouse CVCL_KL05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TAQ2; Human SMARCC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142449 CVCL_C371 USH1-hiPSC4 induced pluripotent stem cell human CVCL_C371 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142450 CVCL_BR70 ND14618 transformed cell line human CVCL_BR70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142451 CVCL_KL04 PCRP-SMARCC1-1F1 hybridoma house mouse CVCL_KL04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92922; Human SMARCC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142452 CVCL_C370 USH1-hiPSC3 induced pluripotent stem cell human CVCL_C370 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142453 CVCL_BR73 ND14623 transformed cell line human CVCL_BR73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142454 CVCL_KL07 PCRP-SMARCD1-2B3 hybridoma house mouse CVCL_KL07 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q96GM5; Human SMARCD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142455 CVCL_C373 USH1-hiPSC6 induced pluripotent stem cell human CVCL_C373 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142456 CVCL_BR72 ND14622 transformed cell line human CVCL_BR72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142457 CVCL_KL06 PCRP-SMARCC2-7B6 hybridoma house mouse CVCL_KL06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8TAQ2; Human SMARCC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142458 CVCL_C372 USH1-hiPSC5 induced pluripotent stem cell human CVCL_C372 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142459 CVCL_KL01 PCRP-SMARCAL1-1G2 hybridoma house mouse CVCL_KL01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZC9; Human SMARCAL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142460 CVCL_KL00 PCRP-SMARCAL1-1C4 hybridoma house mouse CVCL_KL00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZC9; Human SMARCAL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142461 CVCL_KL03 PCRP-SMARCB1-2C4 hybridoma house mouse CVCL_KL03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q12824; Human SMARCB1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142462 CVCL_KL02 PCRP-SMARCAL1-1G7 hybridoma house mouse CVCL_KL02 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZC9; Human SMARCAL1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142463 CVCL_BR49 ND14528 transformed cell line human CVCL_BR49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142464 CVCL_C349 UPSFRi005-A induced pluripotent stem cell human CVCL_C349 From: Universite Paris-Sud 11; Paris; France CL:0000010 Karyotypic information: 47,XY,+21 (hPSCreg); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142465 CVCL_C342 MA03 embryonic stem cell human CVCL_C342 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Female 21142466 CVCL_BR42 ND14497 transformed cell line human CVCL_BR42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142467 CVCL_C341 MA01 embryonic stem cell human CVCL_C341 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-38(1).. 21142468 CVCL_BR41 ND14496 transformed cell line human CVCL_BR41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142469 CVCL_C344 MA09 embryonic stem cell human CVCL_C344 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA. CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: NIH Human Embryonic Stem Cell Registry; pending review; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC06-38(2). 21142470 CVCL_BR44 ND14502 transformed cell line human CVCL_BR44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142471 CVCL_C343 MA04 embryonic stem cell human CVCL_C343 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Male 21142472 CVCL_BR43 ND14498 transformed cell line human CVCL_BR43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142473 CVCL_BR46 ND14504 transformed cell line human CVCL_BR46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142474 CVCL_C346 UPSFRi002-A induced pluripotent stem cell human CVCL_C346 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142475 CVCL_BR45 ND14503 transformed cell line human CVCL_BR45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142476 CVCL_C345 UPSFRi001-A induced pluripotent stem cell human CVCL_C345 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female 21142477 CVCL_BR48 ND14518 transformed cell line human CVCL_BR48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142478 CVCL_C348 UPSFRi004-A-1 induced pluripotent stem cell human CVCL_C348 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142479 CVCL_BR47 ND14507 transformed cell line human CVCL_BR47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142480 CVCL_C347 UPSFRi004-A induced pluripotent stem cell human CVCL_C347 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142481 CVCL_C340 MA99 embryonic stem cell human CVCL_C340 From: Ocata Therapeutics, Inc (Advanced Cell Technology, Inc.); Marlborough; USA.. CL:0000010 Female 21142482 CVCL_BR40 ND14495 transformed cell line human CVCL_BR40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142483 CVCL_BR53 ND14554 transformed cell line human CVCL_BR53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142484 CVCL_C353 UPSFRi008-A induced pluripotent stem cell human CVCL_C353 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142485 CVCL_BR52 ND14531 transformed cell line human CVCL_BR52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142486 CVCL_C352 UPSFRi007-A induced pluripotent stem cell human CVCL_C352 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142487 CVCL_BR55 ND14558 transformed cell line human CVCL_BR55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142488 CVCL_C355 RH1 [Human ESC] embryonic stem cell human CVCL_C355 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-06-029, Steering comm appl. SCSC06-16(1).. 21142489 CVCL_BR54 ND14556 transformed cell line human CVCL_BR54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142490 CVCL_C354 UPSFRi009-A induced pluripotent stem cell human CVCL_C354 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142491 CVCL_BR57 ND14569 transformed cell line human CVCL_BR57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142492 CVCL_C357 RH4 embryonic stem cell human CVCL_C357 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Male Registration: UK Stem Cell Bank (UKSCB); R-06-031, Steering comm appl. SCSC06-16(3).. 21142493 CVCL_BR56 ND14559 transformed cell line human CVCL_BR56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142494 CVCL_C356 RH3 embryonic stem cell human CVCL_C356 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-06-030, Steering comm appl. SCSC06-16(2).. 21142495 CVCL_BR59 ND14572 transformed cell line human CVCL_BR59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142496 CVCL_C359 RH6 embryonic stem cell human CVCL_C359 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); R-06-033, Steering comm appl. SCSC06-16(5).. 21142497 CVCL_BR58 ND14571 transformed cell line human CVCL_BR58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142498 CVCL_C358 RH5 embryonic stem cell human CVCL_C358 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Ambiguous Registration: UK Stem Cell Bank (UKSCB); R-06-032, Steering comm appl. SCSC06-16(4).. 21142499 CVCL_BR51 ND14530 transformed cell line human CVCL_BR51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142500 CVCL_C351 UPSFRi006-A induced pluripotent stem cell human CVCL_C351 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142501 CVCL_BR50 ND14529 transformed cell line human CVCL_BR50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142502 CVCL_C350 UPSFRi005-A-1 induced pluripotent stem cell human CVCL_C350 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21142503 CVCL_1A31 GM19554 transformed cell line human CVCL_1A31 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142504 CVCL_1A30 GM19553 transformed cell line human CVCL_1A30 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142505 CVCL_1A33 GM19560 transformed cell line human CVCL_1A33 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142506 CVCL_1A32 GM19555 transformed cell line human CVCL_1A32 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142507 CVCL_1A35 GM19565 transformed cell line human CVCL_1A35 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142508 CVCL_1A34 GM19561 transformed cell line human CVCL_1A34 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142509 CVCL_1A37 GM19572 transformed cell line human CVCL_1A37 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142510 CVCL_1A36 GM19568 transformed cell line human CVCL_1A36 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142511 CVCL_1A39 GM19650 transformed cell line human CVCL_1A39 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142512 CVCL_1A38 GM19574 transformed cell line human CVCL_1A38 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21142513 CVCL_TG81 HAP1 PRKCA (-) 2 cancer cell line human CVCL_TG81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9393; PRKCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142514 CVCL_TG80 HAP1 PRKCA (-) 1 cancer cell line human CVCL_TG80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9393; PRKCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142515 CVCL_TG83 HAP1 PRKCD (-) 2 cancer cell line human CVCL_TG83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9399; PRKCD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142516 CVCL_TG82 HAP1 PRKCD (-) 1 cancer cell line human CVCL_TG82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9399; PRKCD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142517 CVCL_TG85 HAP1 PRKCE (-) 2 cancer cell line human CVCL_TG85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9401; PRKCE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142518 CVCL_TG84 HAP1 PRKCE (-) 1 cancer cell line human CVCL_TG84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9401; PRKCE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142519 CVCL_TG87 HAP1 PRKCG (-) 1 cancer cell line human CVCL_TG87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9402; PRKCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142520 CVCL_TG86 HAP1 PRKCE (-) 3 cancer cell line human CVCL_TG86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9401; PRKCE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142521 CVCL_TG89 HAP1 PRKCG (-) 3 cancer cell line human CVCL_TG89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9402; PRKCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142522 CVCL_TG88 HAP1 PRKCG (-) 2 cancer cell line human CVCL_TG88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9402; PRKCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142523 CVCL_1A42 GM19659 transformed cell line human CVCL_1A42 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142524 CVCL_1A41 GM19656 transformed cell line human CVCL_1A41 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142525 CVCL_1A44 GM19665 transformed cell line human CVCL_1A44 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142526 CVCL_1A43 GM19662 transformed cell line human CVCL_1A43 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142527 CVCL_1A46 GM19674 transformed cell line human CVCL_1A46 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19674; probable Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142528 CVCL_1A45 GM19671 transformed cell line human CVCL_1A45 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142529 CVCL_1A48 GM19680 transformed cell line human CVCL_1A48 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142530 CVCL_1A47 GM19677 transformed cell line human CVCL_1A47 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142531 CVCL_1A49 GM19683 transformed cell line human CVCL_1A49 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142532 CVCL_TG70 HAP1 PRKACA (-) 1 cancer cell line human CVCL_TG70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9380; PRKACA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142533 CVCL_TG72 HAP1 PRKACB (-) 1 cancer cell line human CVCL_TG72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9381; PRKACB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142534 CVCL_TG71 HAP1 PRKACA (-) 2 cancer cell line human CVCL_TG71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9380; PRKACA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142535 CVCL_TG74 HAP1 PRKAG1 (-) 1 cancer cell line human CVCL_TG74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9385; PRKAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142536 CVCL_TG73 HAP1 PRKACB (-) 2 cancer cell line human CVCL_TG73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9381; PRKACB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142537 CVCL_TG76 HAP1 PRKAG1 (-) 3 cancer cell line human CVCL_TG76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9385; PRKAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142538 CVCL_TG75 HAP1 PRKAG1 (-) 2 cancer cell line human CVCL_TG75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9385; PRKAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142539 CVCL_TG78 HAP1 PRKAG2 (-) 1 cancer cell line human CVCL_TG78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9386; PRKAG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142540 CVCL_TG77 HAP1 PRKAG1 (-) 4 cancer cell line human CVCL_TG77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9385; PRKAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142541 CVCL_TG79 HAP1 PRKAG2 (-) 2 cancer cell line human CVCL_TG79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9386; PRKAG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142542 CVCL_1A40 GM19653 transformed cell line human CVCL_1A40 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142543 CVCL_1A11 GM21132 transformed cell line human CVCL_1A11 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142544 CVCL_1A10 GM21131 transformed cell line human CVCL_1A10 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142545 CVCL_1A13 GM21136 transformed cell line human CVCL_1A13 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 21142546 CVCL_1A12 GM21134 transformed cell line human CVCL_1A12 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142547 CVCL_1A15 GM20511 transformed cell line human CVCL_1A15 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142548 CVCL_1A14 GM21145 transformed cell line human CVCL_1A14 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142549 CVCL_1A17 GM19250 transformed cell line human CVCL_1A17 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142550 CVCL_1A16 GM19249 transformed cell line human CVCL_1A16 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142551 CVCL_1A19 GM19253 transformed cell line human CVCL_1A19 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142552 CVCL_1A18 GM19252 transformed cell line human CVCL_1A18 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142553 CVCL_TG61 HAP1 PRKAA1 (-) 2 cancer cell line human CVCL_TG61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9376; PRKAA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142554 CVCL_TG60 HAP1 PRKAA1 (-) 1 cancer cell line human CVCL_TG60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9376; PRKAA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142555 CVCL_TG63 HAP1 PRKAA2 (-) 2 cancer cell line human CVCL_TG63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9377; PRKAA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142556 CVCL_TG62 HAP1 PRKAA2 (-) 1 cancer cell line human CVCL_TG62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9377; PRKAA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142557 CVCL_TG65 HAP1 PRKAB1 (-) 2 cancer cell line human CVCL_TG65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9378; PRKAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142558 CVCL_TG64 HAP1 PRKAB1 (-) 1 cancer cell line human CVCL_TG64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9378; PRKAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142559 CVCL_TG67 HAP1 PRKAB1 (-) 4 cancer cell line human CVCL_TG67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9378; PRKAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142560 CVCL_TG66 HAP1 PRKAB1 (-) 3 cancer cell line human CVCL_TG66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9378; PRKAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142561 CVCL_TG69 HAP1 PRKAB2 (-) 2 cancer cell line human CVCL_TG69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9379; PRKAB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142562 CVCL_TG68 HAP1 PRKAB2 (-) 1 cancer cell line human CVCL_TG68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9379; PRKAB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142563 CVCL_1A20 GM19254 transformed cell line human CVCL_1A20 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142564 CVCL_1A22 GM19259 transformed cell line human CVCL_1A22 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142565 CVCL_1A21 GM19258 transformed cell line human CVCL_1A21 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142566 CVCL_1A24 GM19262 transformed cell line human CVCL_1A24 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142567 CVCL_1A23 GM19260 transformed cell line human CVCL_1A23 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142568 CVCL_1A26 GM19266 transformed cell line human CVCL_1A26 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142569 CVCL_1A25 GM19264 transformed cell line human CVCL_1A25 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142570 CVCL_1A28 GM19551 transformed cell line human CVCL_1A28 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142571 CVCL_1A27 GM19320 transformed cell line human CVCL_1A27 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142572 CVCL_1A29 GM19552 transformed cell line human CVCL_1A29 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142573 CVCL_TG50 HAP1 PRDX3 (-) 3 cancer cell line human CVCL_TG50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9354; PRDX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142574 CVCL_TG52 HAP1 PRDX3 (-) 5 cancer cell line human CVCL_TG52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9354; PRDX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142575 CVCL_TG51 HAP1 PRDX3 (-) 4 cancer cell line human CVCL_TG51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9354; PRDX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142576 CVCL_TG54 HAP1 PRDX5 (-) 2 cancer cell line human CVCL_TG54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9355; PRDX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142577 CVCL_TG53 HAP1 PRDX5 (-) 1 cancer cell line human CVCL_TG53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9355; PRDX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142578 CVCL_TG56 HAP1 PREP (-) 1 cancer cell line human CVCL_TG56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142579 CVCL_TG55 HAP1 PRDX6 (-) 1 cancer cell line human CVCL_TG55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16753; PRDX6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142580 CVCL_TG58 HAP1 PRIMPOL (-) 1 cancer cell line human CVCL_TG58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26575; PRIMPOL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142581 CVCL_TG57 HAP1 PREPL (-) 1 cancer cell line human CVCL_TG57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30228; PREPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142582 CVCL_TG59 HAP1 PRIMPOL (-) 2 cancer cell line human CVCL_TG59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26575; PRIMPOL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142583 CVCL_TG41 HAP1 PRDX1 (-) 5 cancer cell line human CVCL_TG41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142584 CVCL_TG40 HAP1 PRDX1 (-) 4 cancer cell line human CVCL_TG40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142585 CVCL_TG43 HAP1 PRDX1 (-) 7 cancer cell line human CVCL_TG43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142586 CVCL_TG42 HAP1 PRDX1 (-) 6 cancer cell line human CVCL_TG42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142587 CVCL_TG45 HAP1 PRDX2 (-) 2 cancer cell line human CVCL_TG45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9353; PRDX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142588 CVCL_TG44 HAP1 PRDX2 (-) 1 cancer cell line human CVCL_TG44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9353; PRDX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142589 CVCL_TG47 HAP1 PRDX2 (-) 4 cancer cell line human CVCL_TG47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9353; PRDX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142590 CVCL_KM99 PCRP-ZBTB16-1F2 hybridoma house mouse CVCL_KM99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q05516; Human ZBTB16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142591 CVCL_TG46 HAP1 PRDX2 (-) 3 cancer cell line human CVCL_TG46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9353; PRDX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142592 CVCL_KM98 PCRP-ZBTB16-1D6 hybridoma house mouse CVCL_KM98 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q05516; Human ZBTB16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142593 CVCL_TG49 HAP1 PRDX3 (-) 2 cancer cell line human CVCL_TG49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9354; PRDX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142594 CVCL_TG48 HAP1 PRDX3 (-) 1 cancer cell line human CVCL_TG48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9354; PRDX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142595 CVCL_KM95 PCRP-ZBED3-2D9 hybridoma house mouse CVCL_KM95 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q96IU2; Human ZBED3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142596 CVCL_KM94 PCRP-ZBED1-1E1 hybridoma house mouse CVCL_KM94 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O96006; Human ZBED1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142597 CVCL_KM97 PCRP-ZBTB16-1B7 hybridoma house mouse CVCL_KM97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q05516; Human ZBTB16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142598 CVCL_KM96 PCRP-ZBTB14-1B12 hybridoma house mouse CVCL_KM96 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O43829; Human ZBTB14. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142599 CVCL_1A00 GM21784 transformed cell line human CVCL_1A00 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21142600 CVCL_1A02 GM21786 transformed cell line human CVCL_1A02 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142601 CVCL_1A01 GM21785 transformed cell line human CVCL_1A01 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142602 CVCL_1A04 GM21826 transformed cell line human CVCL_1A04 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21142603 CVCL_1A03 GM21825 transformed cell line human CVCL_1A03 CL:0000010 Population: African; Maasai in Kinyawa, Kenya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21142604 CVCL_1A06 GM20829 transformed cell line human CVCL_1A06 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142605 CVCL_1A05 GM20825 transformed cell line human CVCL_1A05 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142606 CVCL_1A08 GM20907 transformed cell line human CVCL_1A08 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142607 CVCL_1A07 GM20879 transformed cell line human CVCL_1A07 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142608 CVCL_1A09 GM20909 transformed cell line human CVCL_1A09 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142609 CVCL_TG30 HAP1 PPP6R1 (-) 1 cancer cell line human CVCL_TG30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29195; PPP6R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142610 CVCL_TG32 HAP1 PPP6R2 (-) 1 cancer cell line human CVCL_TG32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19253; PPP6R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142611 CVCL_TG31 HAP1 PPP6R1 (-) 2 cancer cell line human CVCL_TG31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29195; PPP6R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142612 CVCL_TG34 HAP1 PPTC7 (-) cancer cell line human CVCL_TG34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30695; PPTC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142613 CVCL_TG33 HAP1 PPP6R2 (-) 2 cancer cell line human CVCL_TG33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19253; PPP6R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142614 CVCL_TG36 HAP1 PQLC2 (-) 1 cancer cell line human CVCL_TG36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26001; SLC66A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142615 CVCL_TG35 HAP1 PQLC1 (-) 1 cancer cell line human CVCL_TG35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26188; SLC66A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142616 CVCL_TG38 HAP1 PRDX1 (-) 2 cancer cell line human CVCL_TG38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142617 CVCL_TG37 HAP1 PRDX1 (-) 1 cancer cell line human CVCL_TG37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142618 CVCL_TG39 HAP1 PRDX1 (-) 3 cancer cell line human CVCL_TG39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142619 CVCL_KM80 PCRP-WTAP-1B11 hybridoma house mouse CVCL_KM80 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15007; Human WTAP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142620 CVCL_KM82 PCRP-YBX2-1C2 hybridoma house mouse CVCL_KM82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2T7; Human YBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142621 CVCL_KM81 PCRP-YBX1-1A8 hybridoma house mouse CVCL_KM81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P67809; Human YBX1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142622 CVCL_TG21 HAP1 PPP3R1 (-) 2 cancer cell line human CVCL_TG21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9317; PPP3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142623 CVCL_TG20 HAP1 PPP3R1 (-) 1 cancer cell line human CVCL_TG20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9317; PPP3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142624 CVCL_TG23 HAP1 PPP4R1 (-) 2 cancer cell line human CVCL_TG23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9320; PPP4R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142625 CVCL_TG22 HAP1 PPP4R1 (-) 1 cancer cell line human CVCL_TG22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9320; PPP4R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142626 CVCL_TG25 HAP1 PPP4R2 (-) 2 cancer cell line human CVCL_TG25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18296; PPP4R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142627 CVCL_KM77 PCRP-WHSC1-2A1 hybridoma house mouse CVCL_KM77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O96028; Human NSD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142628 CVCL_TG24 HAP1 PPP4R2 (-) 1 cancer cell line human CVCL_TG24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18296; PPP4R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142629 CVCL_KM76 PCRP-WDR5-1F5 hybridoma house mouse CVCL_KM76 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P61964; Human WDR5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142630 CVCL_TG27 HAP1 PPP4R4 (-) 2 cancer cell line human CVCL_TG27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23788; PPP4R4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142631 CVCL_KM79 PCRP-WTAP-1A4 hybridoma house mouse CVCL_KM79 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15007; Human WTAP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142632 CVCL_TG26 HAP1 PPP4R4 (-) 1 cancer cell line human CVCL_TG26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23788; PPP4R4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142633 CVCL_KM78 PCRP-WHSC1-2A11 hybridoma house mouse CVCL_KM78 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O96028; Human NSD2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142634 CVCL_TG29 HAP1 PPP5C (-) 2 cancer cell line human CVCL_TG29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9322; PPP5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142635 CVCL_KM73 PCRP-WDHD1-1B10 hybridoma house mouse CVCL_KM73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75717; Human WDHD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142636 CVCL_TG28 HAP1 PPP5C (-) 1 cancer cell line human CVCL_TG28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9322; PPP5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142637 CVCL_KM72 PCRP-WDHD1-1A5 hybridoma house mouse CVCL_KM72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75717; Human WDHD1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142638 CVCL_KM75 PCRP-WDR12-1C3 hybridoma house mouse CVCL_KM75 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9GZL7; Human WDR12. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142639 CVCL_KM74 PCRP-WDR11-1B3 hybridoma house mouse CVCL_KM74 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q9BZH6; Human WDR11. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142640 CVCL_KM91 PCRP-YY2-1A8 hybridoma house mouse CVCL_KM91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15391; Human YY2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142641 CVCL_KM90 PCRP-YY1-1B2 hybridoma house mouse CVCL_KM90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P25490; Human YY1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142642 CVCL_KM93 PCRP-ZBED1-1D4 hybridoma house mouse CVCL_KM93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O96006; Human ZBED1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142643 CVCL_KM92 PCRP-ZBED1-1C8 hybridoma house mouse CVCL_KM92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O96006; Human ZBED1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142644 CVCL_TG10 HAP1 PPP2R5C (-) 2 cancer cell line human CVCL_TG10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9311; PPP2R5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142645 CVCL_TG12 HAP1 PPP2R5E (-) 1 cancer cell line human CVCL_TG12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9313; PPP2R5E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142646 CVCL_TG11 HAP1 PPP2R5D (-) cancer cell line human CVCL_TG11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9312; PPP2R5D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142647 CVCL_TG14 HAP1 PPP3CA (-) 1 cancer cell line human CVCL_TG14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9314; PPP3CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142648 CVCL_KM88 PCRP-YEATS4-1D2 hybridoma house mouse CVCL_KM88 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95619; Human YEATS4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142649 CVCL_TG13 HAP1 PPP2R5E (-) 2 cancer cell line human CVCL_TG13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9313; PPP2R5E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142650 CVCL_KM87 PCRP-YEATS4-1C5 hybridoma house mouse CVCL_KM87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95619; Human YEATS4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142651 CVCL_TG16 HAP1 PPP3CB (-) 1 cancer cell line human CVCL_TG16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9315; PPP3CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142652 CVCL_TG15 HAP1 PPP3CA (-) 2 cancer cell line human CVCL_TG15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9314; PPP3CA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142653 CVCL_KM89 PCRP-YY1-1A5 hybridoma house mouse CVCL_KM89 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P25490; Human YY1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142654 CVCL_TG18 HAP1 PPP3CC (-) 1 cancer cell line human CVCL_TG18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9316; PPP3CC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142655 CVCL_KM84 PCRP-YBX3-1D8 hybridoma house mouse CVCL_KM84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16989; Human YBX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142656 CVCL_TG17 HAP1 PPP3CB (-) 2 cancer cell line human CVCL_TG17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9315; PPP3CB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142657 CVCL_KM83 PCRP-YBX2-1D8 hybridoma house mouse CVCL_KM83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y2T7; Human YBX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142658 CVCL_KM86 PCRP-YEATS2-1B3 hybridoma house mouse CVCL_KM86 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9ULM3; Human YEATS2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142659 CVCL_TG19 HAP1 PPP3CC (-) 2 cancer cell line human CVCL_TG19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9316; PPP3CC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142660 CVCL_KM85 PCRP-YBX3-2D12 hybridoma house mouse CVCL_KM85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16989; Human YBX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142661 CVCL_9Z50 GM16493 transformed cell line human CVCL_9Z50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142662 CVCL_9Z45 GM08771 finite cell line human CVCL_9Z45 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Met1Thr (c.2T>C); ClinVar=VCV000002156; Zygosity=Heterozygous (PubMed=12851857); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu45Pro (c.134T>C); ClinVar=VCV000002157; Zygosity=Heterozygous (PubMed=12851857) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21142663 CVCL_9Z44 GM08770 finite cell line human CVCL_9Z44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142664 CVCL_9Z47 GM13202 finite cell line human CVCL_9Z47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21142665 CVCL_9Z46 GM08772 finite cell line human CVCL_9Z46 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142666 CVCL_9Z41 GM03896 finite cell line human CVCL_9Z41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142667 CVCL_9Z40 GM11037 transformed cell line human CVCL_9Z40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10403 21142668 CVCL_9Z43 GM08769 finite cell line human CVCL_9Z43 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142669 CVCL_9Z42 GM03897 transformed cell line human CVCL_9Z42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142670 CVCL_9Z49 GM16492 finite cell line human CVCL_9Z49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142671 CVCL_9Z48 GM16491 finite cell line human CVCL_9Z48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142672 CVCL_9Z61 GM03420 transformed cell line human CVCL_9Z61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142673 CVCL_9Z60 GM01861 transformed cell line human CVCL_9Z60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142674 CVCL_9Z56 GM17400 finite cell line human CVCL_9Z56 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu44Pro (c.131T>C); Zygosity=Heterozygous (PubMed=16257970); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Arg98Trp (c.292C>T); ClinVar=VCV000002152; Zygosity=Heterozygous (PubMed=16257970) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21142675 CVCL_9Z55 GM17399 finite cell line human CVCL_9Z55 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu44Pro (c.131T>C); Zygosity=Heterozygous (PubMed=16257970); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Arg98Trp (c.292C>T); ClinVar=VCV000002152; Zygosity=Heterozygous (PubMed=16257970) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; GM17399; probable Female 21142676 CVCL_9Z58 GM01858 cancer cell line human CVCL_9Z58 CL:0000010 Population: Caucasian. Male 21142677 CVCL_9Z57 GM01634 transformed cell line human CVCL_9Z57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142678 CVCL_9Z52 GM16865 finite cell line human CVCL_9Z52 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Cys86Valfs*29 (c.254dupT); ClinVar=VCV000002158; Zygosity=Heterozygous (PubMed=12851857); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Arg98Trp (c.292C>T); ClinVar=VCV000002152; Zygosity=Heterozygous (PubMed=12851857) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21142679 CVCL_9Z51 GM16494 transformed cell line human CVCL_9Z51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142680 CVCL_9Z54 GM01633 finite cell line human CVCL_9Z54 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142681 CVCL_9Z53 GM17397 finite cell line human CVCL_9Z53 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Pro117Leu (c.350C>T); Zygosity=Heterozygous (PubMed=16257970); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu153Val (c.457G>C); Zygosity=Heterozygous (PubMed=16257970); Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Arg288fs (c.862delC) (c.861delC); dbSNP=rs267608192; Zygosity=Heterozygous (PubMed=16257970) Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM17397; probable Female 21142682 CVCL_9Z59 GM01859 finite cell line human CVCL_9Z59 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142683 CVCL_1A97 GM20288 transformed cell line human CVCL_1A97 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142684 CVCL_1A96 GM20285 transformed cell line human CVCL_1A96 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM20285; probable Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142685 CVCL_1A99 GM20292 transformed cell line human CVCL_1A99 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142686 CVCL_1A98 GM20290 transformed cell line human CVCL_1A98 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142687 CVCL_9Z23 LM00004 transformed cell line human CVCL_9Z23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00004; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142688 CVCL_9Z22 LM00002 transformed cell line human CVCL_9Z22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00002; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142689 CVCL_9Z25 LM00006 transformed cell line human CVCL_9Z25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00006; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142690 CVCL_9Z24 LM00005 transformed cell line human CVCL_9Z24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00005; probable. Male Part of: Leiomyosarcoma cell and DNA repository 21142691 CVCL_9Z21 LM00001 transformed cell line human CVCL_9Z21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00001; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142692 CVCL_9Z20 UtSMC-hTERT telomerase immortalized cell line human CVCL_9Z20 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Uterus; myometrium. Female 21142693 CVCL_1A91 GM20129 transformed cell line human CVCL_1A91 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142694 CVCL_1A90 GM20128 transformed cell line human CVCL_1A90 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142695 CVCL_1A93 GM20277 transformed cell line human CVCL_1A93 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142696 CVCL_9Z27 LM00008 transformed cell line human CVCL_9Z27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00008; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142697 CVCL_1A92 GM20274 transformed cell line human CVCL_1A92 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142698 CVCL_9Z26 LM00007 transformed cell line human CVCL_9Z26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00007; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142699 CVCL_1A95 GM20279 transformed cell line human CVCL_1A95 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142700 CVCL_9Z29 LM00011 transformed cell line human CVCL_9Z29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00011; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142701 CVCL_1A94 GM01813 finite cell line human CVCL_1A94 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;15)(Xqter->Xp11::15q13->15qter;15pter->15q13::Xp11->Xpter),t(1;21)(1pter->1q12::21q22->21qter;21pter->21q22::1q12->1qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21142702 CVCL_9Z28 LM00010 transformed cell line human CVCL_9Z28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00010; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142703 CVCL_9Z34 LM00020 transformed cell line human CVCL_9Z34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00020; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142704 CVCL_9Z33 LM00016 transformed cell line human CVCL_9Z33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00016; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142705 CVCL_9Z36 LM00023 transformed cell line human CVCL_9Z36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00023; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142706 CVCL_9Z35 LM00021 transformed cell line human CVCL_9Z35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00021; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142707 CVCL_9Z30 LM00013 transformed cell line human CVCL_9Z30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00013; probable. Male Part of: Leiomyosarcoma cell and DNA repository 21142708 CVCL_9Z32 LM00015 transformed cell line human CVCL_9Z32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00015; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142709 CVCL_9Z31 LM00014 transformed cell line human CVCL_9Z31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00014; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142710 CVCL_9Z38 LM00027 transformed cell line human CVCL_9Z38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00027; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142711 CVCL_9Z37 LM00024 transformed cell line human CVCL_9Z37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00024; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142712 CVCL_9Z39 LM00031 transformed cell line human CVCL_9Z39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Discontinued: Coriell; LM00031; probable. Female Part of: Leiomyosarcoma cell and DNA repository 21142713 CVCL_1A75 GM19787 transformed cell line human CVCL_1A75 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142714 CVCL_1A74 GM19784 transformed cell line human CVCL_1A74 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142715 CVCL_1A77 GM19796 transformed cell line human CVCL_1A77 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142716 CVCL_1A76 GM19790 transformed cell line human CVCL_1A76 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142717 CVCL_1A79 GM19798 transformed cell line human CVCL_1A79 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142718 CVCL_1A78 GM19797 transformed cell line human CVCL_1A78 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142719 CVCL_9Z01 HCC3498 cancer cell line human CVCL_9Z01 CL:0000010 21142720 CVCL_9Z00 HCC3440 cancer cell line human CVCL_9Z00 CL:0000010 21142721 CVCL_9Z03 HCC3531 cancer cell line human CVCL_9Z03 CL:0000010 21142722 CVCL_9Z02 HCC3524 cancer cell line human CVCL_9Z02 CL:0000010 21142723 CVCL_9Z09 HCC4005 cancer cell line human CVCL_9Z09 CL:0000010 21142724 CVCL_9Z08 HCC4004 cancer cell line human CVCL_9Z08 CL:0000010 21142725 CVCL_1A71 GM19775 transformed cell line human CVCL_1A71 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142726 CVCL_9Z05 HCC4001 cancer cell line human CVCL_9Z05 CL:0000010 21142727 CVCL_1A70 GM19772 transformed cell line human CVCL_1A70 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142728 CVCL_9Z04 HCC4000 cancer cell line human CVCL_9Z04 CL:0000010 21142729 CVCL_1A73 GM19781 transformed cell line human CVCL_1A73 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142730 CVCL_9Z07 HCC4003 cancer cell line human CVCL_9Z07 CL:0000010 21142731 CVCL_1A72 GM19778 transformed cell line human CVCL_1A72 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142732 CVCL_9Z06 HCC4002 cancer cell line human CVCL_9Z06 CL:0000010 21142733 CVCL_1A86 GM19918 transformed cell line human CVCL_1A86 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142734 CVCL_1A85 GM19915 transformed cell line human CVCL_1A85 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142735 CVCL_1A88 GM19924 transformed cell line human CVCL_1A88 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19924; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142736 CVCL_1A87 GM19919 transformed cell line human CVCL_1A87 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142737 CVCL_1A89 GM19983 transformed cell line human CVCL_1A89 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142738 CVCL_9Z12 HCC4037 cancer cell line human CVCL_9Z12 CL:0000010 21142739 CVCL_9Z11 HCC4034 cancer cell line human CVCL_9Z11 CL:0000010 21142740 CVCL_9Z14 HCC4047 cancer cell line human CVCL_9Z14 CL:0000010 21142741 CVCL_9Z13 HCC4038 cancer cell line human CVCL_9Z13 CL:0000010 21142742 CVCL_9Z10 HCC4021 cancer cell line human CVCL_9Z10 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21142743 CVCL_9Z19 UtLM-hTERT telomerase immortalized cell line human CVCL_9Z19 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Uterus; myometrium. Female 21142744 CVCL_1A80 GM19828 transformed cell line human CVCL_1A80 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142745 CVCL_1A82 GM19902 transformed cell line human CVCL_1A82 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142746 CVCL_9Z16 HCC4058 cancer cell line human CVCL_9Z16 CL:0000010 21142747 CVCL_1A81 GM19836 transformed cell line human CVCL_1A81 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142748 CVCL_9Z15 HCC4054 cancer cell line human CVCL_9Z15 CL:0000010 21142749 CVCL_1A84 GM19913 transformed cell line human CVCL_1A84 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142750 CVCL_9Z18 HCC4087 cancer cell line human CVCL_9Z18 CL:0000010 21142751 CVCL_1A83 GM19905 transformed cell line human CVCL_1A83 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19905; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142752 CVCL_9Z17 HCC4059 cancer cell line human CVCL_9Z17 CL:0000010 21142753 CVCL_1A53 GM19708 transformed cell line human CVCL_1A53 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142754 CVCL_1A52 GM19705 transformed cell line human CVCL_1A52 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142755 CVCL_1A55 GM19718 transformed cell line human CVCL_1A55 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142756 CVCL_1A54 GM19714 transformed cell line human CVCL_1A54 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142757 CVCL_1A57 GM19724 transformed cell line human CVCL_1A57 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142758 CVCL_1A56 GM19721 transformed cell line human CVCL_1A56 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142759 CVCL_1A59 GM19730 transformed cell line human CVCL_1A59 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142760 CVCL_1A58 GM19727 transformed cell line human CVCL_1A58 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142761 CVCL_1A51 GM19702 transformed cell line human CVCL_1A51 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142762 CVCL_1A50 GM19686 transformed cell line human CVCL_1A50 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142763 CVCL_1A64 GM19754 transformed cell line human CVCL_1A64 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19754; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142764 CVCL_1A63 GM19751 transformed cell line human CVCL_1A63 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142765 CVCL_1A66 GM19760 transformed cell line human CVCL_1A66 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142766 CVCL_1A65 GM19757 transformed cell line human CVCL_1A65 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142767 CVCL_1A68 GM19766 transformed cell line human CVCL_1A68 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19766; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142768 CVCL_1A67 GM19763 transformed cell line human CVCL_1A67 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142769 CVCL_1A69 GM19768 transformed cell line human CVCL_1A69 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142770 CVCL_TG90 HAP1 PRKCI (-) 1 cancer cell line human CVCL_TG90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9404; PRKCI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142771 CVCL_TG92 HAP1 PRKCQ (-) cancer cell line human CVCL_TG92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9410; PRKCQ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142772 CVCL_TG91 HAP1 PRKCI (-) 2 cancer cell line human CVCL_TG91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9404; PRKCI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142773 CVCL_TG94 HAP1 PRKCZ (-) 2 cancer cell line human CVCL_TG94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9412; PRKCZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142774 CVCL_TG93 HAP1 PRKCZ (-) 1 cancer cell line human CVCL_TG93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9412; PRKCZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142775 CVCL_TG96 HAP1 PRKD1 (-) 1 cancer cell line human CVCL_TG96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9407; PRKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142776 CVCL_TG95 HAP1 PRKCZ (-) 3 cancer cell line human CVCL_TG95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9412; PRKCZ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142777 CVCL_TG98 HAP1 PRKD2 (-) 1 cancer cell line human CVCL_TG98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17293; PRKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142778 CVCL_TG97 HAP1 PRKD1 (-) 2 cancer cell line human CVCL_TG97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9407; PRKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142779 CVCL_TG99 HAP1 PRKD2 (-) 2 cancer cell line human CVCL_TG99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17293; PRKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142780 CVCL_1A60 GM19733 transformed cell line human CVCL_1A60 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142781 CVCL_1A62 GM19748 transformed cell line human CVCL_1A62 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142782 CVCL_1A61 GM19742 transformed cell line human CVCL_1A61 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM19742; probable Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21142783 CVCL_C449 DS-5 hybridoma house mouse CVCL_C449 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06908; Dog SFTPA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8653 21142784 CVCL_BS49 ND14941 transformed cell line human CVCL_BS49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142785 CVCL_C448 DS-6 hybridoma house mouse CVCL_C448 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06908; Dog SFTPA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8652 21142786 CVCL_BS48 ND14928 transformed cell line human CVCL_BS48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142787 CVCL_C441 BOM1-hiPSC12 induced pluripotent stem cell human CVCL_C441 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21142788 CVCL_BS41 ND14866 transformed cell line human CVCL_BS41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142789 CVCL_C440 BOM1-hiPSC11 induced pluripotent stem cell human CVCL_C440 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21142790 CVCL_BS40 ND14865 transformed cell line human CVCL_BS40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142791 CVCL_C443 BOM1-hiPSC3 induced pluripotent stem cell human CVCL_C443 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142792 CVCL_BS43 ND14889 transformed cell line human CVCL_BS43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142793 CVCL_C442 BOM1-hiPSC13 induced pluripotent stem cell human CVCL_C442 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142794 CVCL_BS42 ND14874 transformed cell line human CVCL_BS42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142795 CVCL_C445 BOM1-hiPSC8 induced pluripotent stem cell human CVCL_C445 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142796 CVCL_BS45 ND14912 transformed cell line human CVCL_BS45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142797 CVCL_C444 BOM1-hiPSC4 induced pluripotent stem cell human CVCL_C444 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142798 CVCL_BS44 ND14911 transformed cell line human CVCL_BS44 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142799 CVCL_C447 hAFDC-iPS-6 induced pluripotent stem cell human CVCL_C447 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21142800 CVCL_BS47 ND14927 transformed cell line human CVCL_BS47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142801 CVCL_C446 BOM1-hiPSC9 induced pluripotent stem cell human CVCL_C446 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142802 CVCL_BS46 ND14913 transformed cell line human CVCL_BS46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142803 CVCL_C459 CuFi-4 transformed cell line human CVCL_C459 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Female 21142804 CVCL_BS59 ND14964 transformed cell line human CVCL_BS59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142805 CVCL_C452 CP-B telomerase immortalized cell line human CVCL_C452 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu97Gln (c.290T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male Doubling time: ~34 hours (ATCC=CRL-4028) 21142806 CVCL_BS52 ND14944 transformed cell line human CVCL_BS52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142807 CVCL_C451 CP-A telomerase immortalized cell line human CVCL_C451 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 21142808 CVCL_BS51 ND14943 transformed cell line human CVCL_BS51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142809 CVCL_C454 CP-D telomerase immortalized cell line human CVCL_C454 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser303Alafs*42 (c.906del); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Karyotypic information: Has lost chromosome Y; Derived from sampling site: Esophagus Cell type=Epithelial cell.. Omics: Genome sequenced Male Doubling time: ~39 hours (ATCC=CRL-4030) 21142810 CVCL_BS54 ND14946 transformed cell line human CVCL_BS54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142811 CVCL_C453 CP-C telomerase immortalized cell line human CVCL_C453 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male 21142812 CVCL_BS53 ND14945 transformed cell line human CVCL_BS53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142813 CVCL_BS56 ND14954 transformed cell line human CVCL_BS56 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (PubMed=22815561) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142814 CVCL_C456 NuLi-3 transformed cell line human CVCL_C456 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Discontinued: ATCC; CRL-4012; true Female 21142815 CVCL_BS55 ND14947 transformed cell line human CVCL_BS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142816 CVCL_C455 NuLi-1 transformed cell line human CVCL_C455 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21142817 CVCL_C458 CuFi-3 transformed cell line human CVCL_C458 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Discontinued: ATCC; CRL-4014; true Male 21142818 CVCL_BS58 ND14962 transformed cell line human CVCL_BS58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142819 CVCL_C457 CuFi-1 transformed cell line human CVCL_C457 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Female 21142820 CVCL_BS57 ND14955 transformed cell line human CVCL_BS57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142821 CVCL_C450 DS-3 hybridoma house mouse CVCL_C450 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06908; Dog SFTPA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8651 21142822 CVCL_BS50 ND14942 transformed cell line human CVCL_BS50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142823 CVCL_C427 HER1-hiPSC4 induced pluripotent stem cell human CVCL_C427 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142824 CVCL_BS27 ND14816 transformed cell line human CVCL_BS27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142825 CVCL_C426 HER1-hiPSC3 induced pluripotent stem cell human CVCL_C426 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142826 CVCL_BS26 ND14795 transformed cell line human CVCL_BS26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142827 CVCL_C429 HER1-hiPSC6 induced pluripotent stem cell human CVCL_C429 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142828 CVCL_BS29 ND14831 transformed cell line human CVCL_BS29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142829 CVCL_C428 HER1-hiPSC5 induced pluripotent stem cell human CVCL_C428 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142830 CVCL_BS28 ND14818 transformed cell line human CVCL_BS28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142831 CVCL_9Y93 HCC3321 cancer cell line human CVCL_9Y93 CL:0000010 21142832 CVCL_9Y92 HCC3270 cancer cell line human CVCL_9Y92 CL:0000010 21142833 CVCL_C421 FHC1-hiPSC7 induced pluripotent stem cell human CVCL_C421 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142834 CVCL_9Y95 HCC3350 cancer cell line human CVCL_9Y95 CL:0000010 21142835 CVCL_BS21 ND14768 transformed cell line human CVCL_BS21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142836 CVCL_C420 FHC1-hiPSC6 induced pluripotent stem cell human CVCL_C420 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142837 CVCL_9Y94 HCC3335 cancer cell line human CVCL_9Y94 CL:0000010 21142838 CVCL_BS20 ND14767 transformed cell line human CVCL_BS20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142839 CVCL_C423 FHC1-hiPSC9 induced pluripotent stem cell human CVCL_C423 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142840 CVCL_BS23 ND14791 transformed cell line human CVCL_BS23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142841 CVCL_C422 FHC1-hiPSC8 induced pluripotent stem cell human CVCL_C422 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142842 CVCL_BS22 ND14790 transformed cell line human CVCL_BS22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142843 CVCL_9Y91 HCC3172 cancer cell line human CVCL_9Y91 CL:0000010 21142844 CVCL_C425 HER1-hiPSC2 induced pluripotent stem cell human CVCL_C425 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142845 CVCL_BS25 ND14794 transformed cell line human CVCL_BS25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142846 CVCL_9Y90 HCC2974 cancer cell line human CVCL_9Y90 CL:0000010 21142847 CVCL_C424 HER1-hiPSC1 induced pluripotent stem cell human CVCL_C424 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142848 CVCL_BS24 ND14793 transformed cell line human CVCL_BS24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142849 CVCL_9Y89 HCC2962 cancer cell line human CVCL_9Y89 CL:0000010 21142850 CVCL_9Y86 HCC2036 cancer cell line human CVCL_9Y86 CL:0000010 21142851 CVCL_9Y85 HCC1637 cancer cell line human CVCL_9Y85 CL:0000010 21142852 CVCL_9Y88 HCC2879 cancer cell line human CVCL_9Y88 CL:0000010 21142853 CVCL_9Y87 HCC2858 cancer cell line human CVCL_9Y87 CL:0000010 21142854 CVCL_C438 BOM1-hiPSC1 induced pluripotent stem cell human CVCL_C438 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21142855 CVCL_BS38 ND14863 transformed cell line human CVCL_BS38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142856 CVCL_C437 IPS(IMR90)-4 induced pluripotent stem cell human CVCL_C437 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21142857 CVCL_BS37 ND14862 transformed cell line human CVCL_BS37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142858 CVCL_C439 BOM1-hiPSC10 induced pluripotent stem cell human CVCL_C439 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142859 CVCL_BS39 ND14864 transformed cell line human CVCL_BS39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142860 CVCL_C430 IPS(Foreskin)-1 induced pluripotent stem cell human CVCL_C430 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21142861 CVCL_BS30 ND14832 transformed cell line human CVCL_BS30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142862 CVCL_C432 IPS(Foreskin)-3 induced pluripotent stem cell human CVCL_C432 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21142863 CVCL_BS32 ND14834 transformed cell line human CVCL_BS32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142864 CVCL_C431 IPS(Foreskin)-2 induced pluripotent stem cell human CVCL_C431 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21142865 CVCL_BS31 ND14833 transformed cell line human CVCL_BS31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142866 CVCL_C434 IPS(IMR90)-1 induced pluripotent stem cell human CVCL_C434 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21142867 CVCL_BS34 ND14841 transformed cell line human CVCL_BS34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142868 CVCL_C433 IPS(Foreskin)-4 induced pluripotent stem cell human CVCL_C433 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21142869 CVCL_BS33 ND14840 transformed cell line human CVCL_BS33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142870 CVCL_C436 IPS(IMR90)-3 induced pluripotent stem cell human CVCL_C436 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21142871 CVCL_BS36 ND14860 transformed cell line human CVCL_BS36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142872 CVCL_C435 IPS(IMR90)-2 induced pluripotent stem cell human CVCL_C435 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21142873 CVCL_BS35 ND14843 transformed cell line human CVCL_BS35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142874 CVCL_9Y97 HCC3388 cancer cell line human CVCL_9Y97 CL:0000010 21142875 CVCL_9Y96 HCC3369 cancer cell line human CVCL_9Y96 CL:0000010 21142876 CVCL_9Y99 HCC3418 cancer cell line human CVCL_9Y99 CL:0000010 21142877 CVCL_9Y98 HCC3410 cancer cell line human CVCL_9Y98 CL:0000010 21142878 CVCL_BS05 ND14730 transformed cell line human CVCL_BS05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142879 CVCL_C405 UKRV-Mel-20h cancer cell line human CVCL_C405 CL:0000010 Male 21142880 CVCL_BS04 ND14729 transformed cell line human CVCL_BS04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142881 CVCL_C404 UKRV-Mel-20f cancer cell line human CVCL_C404 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21142882 CVCL_BS07 ND14732 transformed cell line human CVCL_BS07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142883 CVCL_C407 UKRV-Mel-30 cancer cell line human CVCL_C407 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21142884 CVCL_BS06 ND14731 transformed cell line human CVCL_BS06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142885 CVCL_C406 UKRV-Mel-25 cancer cell line human CVCL_C406 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21142886 CVCL_BS09 ND14735 transformed cell line human CVCL_BS09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142887 CVCL_C409 UKRV-Mel-14c cancer cell line human CVCL_C409 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Female 21142888 CVCL_BS08 ND14734 transformed cell line human CVCL_BS08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142889 CVCL_C408 UKRV-Mel-13 cancer cell line human CVCL_C408 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu97Pro (c.290T>C); ClinVar=VCV000962431; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.662_672+40del; Zygosity=Unspecified (PubMed=23851445). Unspecified 21142890 CVCL_9Y71 A5-BAG transformed cell line Norway rat CVCL_9Y71 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Salivary gland; submandibular gland; epithelium; Breed/subspecies: Fischer 344. Male 21142891 CVCL_9Y70 RSMT-A5 transformed cell line Norway rat CVCL_9Y70 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Salivary gland; submandibular gland; epithelium; Breed/subspecies: Fischer 344. Male 21142892 CVCL_9Y73 SMIE transformed cell line Norway rat CVCL_9Y73 CL:0000010 Miscellaneous: Assignment of SMIE to RSMG 2C-2 from personal communication of Tabak L.A Transformant: Adenovirus 12 [E1A](NCBI-Taxonomy; 28282); Derived from sampling site: Salivary gland; submandibular gland Cell type=Epithelial cell.; Breed/subspecies: Long-Evans. Unspecified 21142893 CVCL_9Y72 A5-DAP transformed cell line Norway rat CVCL_9Y72 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Salivary gland; submandibular gland; epithelium; Breed/subspecies: Fischer 344. Male 21142894 CVCL_BS01 ND14714 transformed cell line human CVCL_BS01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142895 CVCL_C401 UKRV-Mel-20b cancer cell line human CVCL_C401 CL:0000010 Male 21142896 CVCL_BS00 ND14713 transformed cell line human CVCL_BS00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142897 CVCL_C400 UKRV-Mel-19c cancer cell line human CVCL_C400 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503). Female 21142898 CVCL_BS03 ND14727 transformed cell line human CVCL_BS03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142899 CVCL_C403 UKRV-Mel-20e cancer cell line human CVCL_C403 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21142900 CVCL_BS02 ND14715 transformed cell line human CVCL_BS02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142901 CVCL_C402 UKRV-Mel-20c cancer cell line human CVCL_C402 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21142902 CVCL_9Y68 IOBA-NHC spontaneously immortalized cell line human CVCL_9Y68 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Epithelial cell.. Omics: Deep proteome analysis; Omics: Metabolome analysis; Omics: Transcriptome analysis by microarray Male 21142903 CVCL_9Y67 MK/T-1 telomerase immortalized cell line house mouse CVCL_9Y67 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; cornea; stroma Cell type=Fibroblast.; Breed/subspecies: C57BL/6. Unspecified 21142904 CVCL_9Y69 CHO HcD6 spontaneously immortalized cell line CVCL_9Y69 CL:0000010 Derived from sampling site: Ovary. Omics: Metabolome analysis Female 21142905 CVCL_9Y64 GM12618 transformed cell line human CVCL_9Y64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Registration: CEPH Families Reference Panel; 3504 21142906 CVCL_9Y63 Karpas-120 cancer cell line human CVCL_9Y63 CL:0000010 Male 21142907 CVCL_9Y66 Bb(ApMC1) spontaneously immortalized cell line CVCL_9Y66 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21142908 CVCL_9Y65 GM05294 finite cell line human CVCL_9Y65 CL:0000010 Population: African American; Karyotypic information: 46,XY [44]; 46,XY,t(3;11)(p21;q23) [6] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21142909 CVCL_C416 FHC1-hiPSC2 induced pluripotent stem cell human CVCL_C416 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142910 CVCL_BS16 ND14748 transformed cell line human CVCL_BS16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142911 CVCL_C415 FHC1-hiPSC1 induced pluripotent stem cell human CVCL_C415 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142912 CVCL_BS15 ND14743 transformed cell line human CVCL_BS15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142913 CVCL_C418 FHC1-hiPSC4 induced pluripotent stem cell human CVCL_C418 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142914 CVCL_BS18 ND14764 transformed cell line human CVCL_BS18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142915 CVCL_C417 FHC1-hiPSC3 induced pluripotent stem cell human CVCL_C417 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142916 CVCL_BS17 ND14753 transformed cell line human CVCL_BS17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142917 CVCL_C419 FHC1-hiPSC5 induced pluripotent stem cell human CVCL_C419 From: Royan Institute; Theran; Iran CL:0000010 Population: Iranian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21142918 CVCL_BS19 ND14766 transformed cell line human CVCL_BS19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142919 CVCL_9Y82 AGLCL [Human 1993] transformed cell line human CVCL_9Y82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142920 CVCL_9Y81 GM01501 transformed cell line human CVCL_9Y81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142921 CVCL_C410 ACT IV hybridoma house mouse CVCL_C410 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dictyostelium discoideum actins. 21142922 CVCL_9Y84 MLE-7 transformed cell line house mouse CVCL_9Y84 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: FVB/N-Tg(SFTPC-TAg)5.1Jaw transgenic. Unspecified Doubling time: 7-9 hours, at 7th passage (PubMed=8248207) 21142923 CVCL_BS10 ND14736 transformed cell line human CVCL_BS10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142924 CVCL_9Y83 LIMM-NBE1 telomerase immortalized cell line human CVCL_9Y83 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bronchus; epithelium. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Male 21142925 CVCL_BS12 ND14738 transformed cell line human CVCL_BS12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142926 CVCL_C412 TN-368 spontaneously immortalized cell line CVCL_C412 CL:0000010 Derived from sampling site: Ovary. Female Virology: Infected with alphanodavirus TnCLV (PubMed=29133148) Doubling time: 14.5 hours (PubMed=669727); ~24 hours (DSMZ=ACC-177) Group: Insect cell line; Group: Recombinant protein production insect cell line 21142927 CVCL_C411 IZD-MB-0503 spontaneously immortalized cell line CVCL_C411 CL:0000010 Discontinued: ECACC; 93090714; probable. Unspecified Doubling time: 12-14 hours (DOI=10.1111/j.1439-0418.1976.tb03417.x); 30 +- 2 hours (in static culture), 24 +- 1 hours (in suspension culture) (PubMed=10585188) Group: Insect cell line; Group: Recombinant protein production insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00603; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8003 Problematic cell line: Misidentified Originally thought to be of Mamestra brassicae origin but found to be from Trichoplusia ni (PubMed=8799737). Could be identical to TN-CL1 (Cellosaurus=CVCL_Z257). Originally thought to originate from larval hemocytes. 21142928 CVCL_BS11 ND14737 transformed cell line human CVCL_BS11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142929 CVCL_C414 CRO-AP1 cancer cell line human CVCL_C414 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21142930 CVCL_9Y80 GM04427 transformed cell line human CVCL_9Y80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142931 CVCL_BS14 ND14741 transformed cell line human CVCL_BS14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142932 CVCL_BS13 ND14739 transformed cell line human CVCL_BS13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142933 CVCL_C413 TN-368A spontaneously immortalized cell line CVCL_C413 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21142934 CVCL_9Y79 GM04426 transformed cell line human CVCL_9Y79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21142935 CVCL_9Y78 GM04425 transformed cell line human CVCL_9Y78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142936 CVCL_9Y75 Sb51 transformed cell line house mouse CVCL_9Y75 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9127 21142937 CVCL_9Y74 CHCC-NYU1 cancer cell line CVCL_9Y74 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Hy-Line SC. Group: Bird cell line 21142938 CVCL_9Y77 GM04411 transformed cell line human CVCL_9Y77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142939 CVCL_9Y76 LT1/41-H1 transformed cell line human CVCL_9Y76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9128 21142940 CVCL_9Y51 GM20033 finite cell line human CVCL_9Y51 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Ser350Leu (c.1049C>T) (S323L); Zygosity=Homozygous (Coriell) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142941 CVCL_9Y50 GM20032 finite cell line human CVCL_9Y50 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Leu120Gln (c.359T>A) (L93Q); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Tyr1149Ter (c.3447C>A) (Y1122*); Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142942 CVCL_9Y46 GM18479 transformed cell line human CVCL_9Y46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142943 CVCL_9Y45 GM18478 transformed cell line human CVCL_9Y45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142944 CVCL_9Y48 GM19813 finite cell line human CVCL_9Y48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21142945 CVCL_9Y47 GM19809 finite cell line human CVCL_9Y47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21142946 CVCL_9Y42 GM18475 transformed cell line human CVCL_9Y42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142947 CVCL_9Y41 GM18474 transformed cell line human CVCL_9Y41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142948 CVCL_9Y44 GM18477 transformed cell line human CVCL_9Y44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142949 CVCL_9Y43 GM18476 transformed cell line human CVCL_9Y43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142950 CVCL_9Y49 GM20031 finite cell line human CVCL_9Y49 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Asn458Asp (c.1372A>G) (N431D); ClinVar=VCV000014714; Zygosity=Homozygous (Coriell) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142951 CVCL_9Y60 RCAC transformed cell line Norway rat CVCL_9Y60 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Breed/subspecies: Fischer 344. 21142952 CVCL_9Y62 GM09402 finite cell line human CVCL_9Y62 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21142953 CVCL_9Y61 RCHT transformed cell line Norway rat CVCL_9Y61 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Brain; hypothalamus; Breed/subspecies: Fischer 344. Unspecified 21142954 CVCL_9Y57 LSQC-OK10QB5 transformed cell line CVCL_9Y57 CL:0000010 Transformant: Avian myelocytomatosis virus OK10(NCBI-Taxonomy; 11871); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Q/BCD. Unspecified Group: Bird cell line 21142955 CVCL_9Y56 GM50158 transformed cell line human CVCL_9Y56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21142956 CVCL_9Y59 RCPTH transformed cell line human CVCL_9Y59 CL:0000010 Transformant: Unknown product of UCHT1 (Cellosaurus=CVCL_9W35) conditioned media; Derived from sampling site: Parathyroid gland. Unspecified Doubling time: 30 hours (CelloPub=CLPUB00311) 21142957 CVCL_9Y58 NRCE spontaneously immortalized cell line CVCL_9Y58 CL:0000010 Derived from sampling site: Eye; cornea; endothelium; Breed/subspecies: New Zealand white. Female Doubling time: 40.32 hours, at 191th passage (PubMed=19503740) 21142958 CVCL_9Y53 GM20035 finite cell line human CVCL_9Y53 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Arg924Ter (c.2770C>T) (R897*); ClinVar=VCV000014686; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Arg1119Trp (c.3355C>T) (R1092W); Zygosity=Heterozygous (Coriell) Population: Kurdistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142959 CVCL_9Y52 GM20034 finite cell line human CVCL_9Y52 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Leu260Pro (c.779T>C) (L233P); ClinVar=VCV000014689; Zygosity=Homozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142960 CVCL_9Y55 GM20328 finite cell line human CVCL_9Y55 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Asn308del (c.922_924del) (N281del); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6091; INSR; Unexplicit; IVS13+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21142961 CVCL_9Y54 GM20327 finite cell line human CVCL_9Y54 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Glu151Ter (c.451G>T) (E124X); Zygosity=Homozygous (Coriell) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21142962 CVCL_KM60 PCRP-UBR2-1D12 hybridoma house mouse CVCL_KM60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IWV8; Human UBR2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142963 CVCL_KM59 PCRP-UBQLN2-1C7 hybridoma house mouse CVCL_KM59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UHD9; Human UBQLN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142964 CVCL_KM58 PCRP-UBP1-1G1 hybridoma house mouse CVCL_KM58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZI7; Human UBP1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142965 CVCL_TG01 HAP1 PPP2R3A (-) 1 cancer cell line human CVCL_TG01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9307; PPP2R3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142966 CVCL_TG00 HAP1 PPP2R2D (-) 3 cancer cell line human CVCL_TG00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23732; PPP2R2D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142967 CVCL_TG03 HAP1 PPP2R4 (-) 1 cancer cell line human CVCL_TG03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9308; PTPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142968 CVCL_KM55 PCRP-UBE2B-1C7 hybridoma house mouse CVCL_KM55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P63146; Human UBE2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142969 CVCL_TG02 HAP1 PPP2R3A (-) 2 cancer cell line human CVCL_TG02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9307; PPP2R3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142970 CVCL_KM54 PCRP-U2AF1-1A8 hybridoma house mouse CVCL_KM54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01081; Human U2AF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142971 CVCL_TG05 HAP1 PPP2R5A (-) 1 cancer cell line human CVCL_TG05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9309; PPP2R5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142972 CVCL_KM57 PCRP-UBE3A-1A2 hybridoma house mouse CVCL_KM57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q05086; Human UBE3A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142973 CVCL_TG04 HAP1 PPP2R4 (-) 2 cancer cell line human CVCL_TG04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9308; PTPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142974 CVCL_KM56 PCRP-UBE3A-1A10 hybridoma house mouse CVCL_KM56 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q05086; Human UBE3A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142975 CVCL_TG07 HAP1 PPP2R5B (-) 1 cancer cell line human CVCL_TG07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9310; PPP2R5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142976 CVCL_KM51 PCRP-TSC22D4-2B11 hybridoma house mouse CVCL_KM51 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y3Q8; Human TSC22D4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142977 CVCL_TG06 HAP1 PPP2R5A (-) 2 cancer cell line human CVCL_TG06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9309; PPP2R5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142978 CVCL_KM50 PCRP-TSC22D4-1C11 hybridoma house mouse CVCL_KM50 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y3Q8; Human TSC22D4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142979 CVCL_TG09 HAP1 PPP2R5C (-) 1 cancer cell line human CVCL_TG09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9311; PPP2R5C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142980 CVCL_KM53 PCRP-TSC22D4-4A4 hybridoma house mouse CVCL_KM53 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y3Q8; Human TSC22D4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142981 CVCL_TG08 HAP1 PPP2R5B (-) 2 cancer cell line human CVCL_TG08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9310; PPP2R5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21142982 CVCL_KM52 PCRP-TSC22D4-3E10 hybridoma house mouse CVCL_KM52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y3Q8; Human TSC22D4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142983 CVCL_KM71 PCRP-VENTX-2B9 hybridoma house mouse CVCL_KM71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95231; Human VENTX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142984 CVCL_KM70 PCRP-VENTX-2A9 hybridoma house mouse CVCL_KM70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95231; Human VENTX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142985 CVCL_KM69 PCRP-VDR-1F11 hybridoma house mouse CVCL_KM69 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11473; Human VDR. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142986 CVCL_KM66 PCRP-USP13-2H7 hybridoma house mouse CVCL_KM66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92995; Human USP13. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142987 CVCL_KM65 PCRP-USF2-1A7 hybridoma house mouse CVCL_KM65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15853; Human USF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142988 CVCL_KM68 PCRP-USP7-1B6 hybridoma house mouse CVCL_KM68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q93009; Human USP7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142989 CVCL_KM67 PCRP-USP16-1B2 hybridoma house mouse CVCL_KM67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9Y5T5; Human USP16. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142990 CVCL_KM62 PCRP-USF1-1C10 hybridoma house mouse CVCL_KM62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22415; Human USF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142991 CVCL_KM61 PCRP-USF1-1B8 hybridoma house mouse CVCL_KM61 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P22415; Human USF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142992 CVCL_KM64 PCRP-USF2-1A11 hybridoma house mouse CVCL_KM64 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q15853; Human USF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142993 CVCL_KM63 PCRP-USF2-1A1 hybridoma house mouse CVCL_KM63 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q15853; Human USF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142994 CVCL_KM37 PCRP-TOX3-1A6 hybridoma house mouse CVCL_KM37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15405; Human TOX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142995 CVCL_KM36 PCRP-TOX3-1A5 hybridoma house mouse CVCL_KM36 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15405; Human TOX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142996 CVCL_KM39 PCRP-TP53-1D9 hybridoma house mouse CVCL_KM39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04637; Human TP53. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142997 CVCL_KM38 PCRP-TOX3-1C7 hybridoma house mouse CVCL_KM38 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15405; Human TOX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142998 CVCL_KM33 PCRP-THAP9-2B3 hybridoma house mouse CVCL_KM33 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H5L6; Human THAP9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21142999 CVCL_KM32 PCRP-THAP9-1B7 hybridoma house mouse CVCL_KM32 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9H5L6; Human THAP9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143000 CVCL_KM35 PCRP-THRB-1A6 hybridoma house mouse CVCL_KM35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10828; Human THRB. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143001 CVCL_KM34 PCRP-THRA-1F10 hybridoma house mouse CVCL_KM34 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10827; Human THRA. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143002 CVCL_KM31 PCRP-THAP9-1A12 hybridoma house mouse CVCL_KM31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H5L6; Human THAP9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143003 CVCL_KM30 PCRP-THAP9-1A10 hybridoma house mouse CVCL_KM30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H5L6; Human THAP9. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143004 CVCL_KM48 PCRP-TSC22D1-1A2 hybridoma house mouse CVCL_KM48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15714; Human TSC22D1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143005 CVCL_KM47 PCRP-TRIM28-2G8 hybridoma house mouse CVCL_KM47 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13263; Human TRIM28. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143006 CVCL_KM49 PCRP-TSC22D3-1G10 hybridoma house mouse CVCL_KM49 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q99576; Human TSC22D3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143007 CVCL_KM44 PCRP-TRIM24-1B12 hybridoma house mouse CVCL_KM44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O15164; Human TRIM24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143008 CVCL_KM43 PCRP-TRDMT1-1E8 hybridoma house mouse CVCL_KM43 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O14717; Human TRDMT1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143009 CVCL_KM46 PCRP-TRIM28-2G5 hybridoma house mouse CVCL_KM46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13263; Human TRIM28. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143010 CVCL_KM45 PCRP-TRIM27-1B3 hybridoma house mouse CVCL_KM45 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P14373; Human TRIM27. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143011 CVCL_KM40 PCRP-TP53-1F7 hybridoma house mouse CVCL_KM40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04637; Human TP53. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143012 CVCL_KM42 PCRP-TP73-1A8 hybridoma house mouse CVCL_KM42 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15350; Human TP73. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143013 CVCL_KM41 PCRP-TP53-2A10 hybridoma house mouse CVCL_KM41 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04637; Human TP53. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143014 CVCL_C485 HP6014 hybridoma house mouse CVCL_C485 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG2 (Fd). 21143015 CVCL_BS85 RF-88l finite cell line CVCL_BS85 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21143016 CVCL_C484 HP6003 hybridoma house mouse CVCL_C484 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG3 (Fc). 21143017 CVCL_BS84 RF-88k finite cell line CVCL_BS84 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female 21143018 CVCL_C487 HP6017 hybridoma house mouse CVCL_C487 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IgG (Fc). 21143019 CVCL_BS87 S180-S1B11 cancer cell line house mouse CVCL_BS87 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21143020 CVCL_C486 HP6016 hybridoma house mouse CVCL_C486 CL:0000010 Monoclonal antibody isotype: IgG1. 21143021 CVCL_BS86 RF-88s finite cell line CVCL_BS86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143022 CVCL_C489 HP6023 hybridoma house mouse CVCL_C489 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human IgG4 (Fc). 21143023 CVCL_BS89 S180-S1H10 cancer cell line house mouse CVCL_BS89 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21143024 CVCL_C488 HP6020 hybridoma house mouse CVCL_C488 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IgG4 (Fab). 21143025 CVCL_BS88 S180-S1F11 cancer cell line house mouse CVCL_BS88 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21143026 CVCL_KM19 PCRP-TFAP2D-1A11 hybridoma house mouse CVCL_KM19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z6R9; Human TFAP2D. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143027 CVCL_KM18 PCRP-TFAP2C-1B9 hybridoma house mouse CVCL_KM18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92754; Human TFAP2C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143028 CVCL_BS81 CSAC spontaneously immortalized cell line CVCL_BS81 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21143029 CVCL_C481 HP6000 hybridoma house mouse CVCL_C481 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human IgG (Fc). 21143030 CVCL_KM15 PCRP-TFAP2B-2A4 hybridoma house mouse CVCL_KM15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q92481; Human TFAP2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143031 CVCL_C480 JFP-K2 hybridoma CVCL_C480 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42212; GFP. 21143032 CVCL_BS80 Mel-JD cancer cell line human CVCL_BS80 CL:0000010 Derived from metastatic site: Lymph node. 21143033 CVCL_KM14 PCRP-TFAP2A-2C2 hybridoma house mouse CVCL_KM14 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05549; Human TFAP2A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143034 CVCL_C483 HP6002 hybridoma house mouse CVCL_C483 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG2 (Fc). 21143035 CVCL_BS83 KCB 2012055S finite cell line CVCL_BS83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line; Group: Bird cell line 21143036 CVCL_KM17 PCRP-TFAP2C-1A7 hybridoma house mouse CVCL_KM17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92754; Human TFAP2C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143037 CVCL_C482 HP6001 hybridoma house mouse CVCL_C482 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human IgG1 (Fc). 21143038 CVCL_BS82 KCB 2012053S finite cell line CVCL_BS82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line; Group: Bird cell line 21143039 CVCL_KM16 PCRP-TFAP2B-2E1 hybridoma house mouse CVCL_KM16 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q92481; Human TFAP2B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143040 CVCL_KM11 PCRP-TERF2-1G5 hybridoma house mouse CVCL_KM11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15554; Human TERF2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143041 CVCL_KM10 PCRP-TERF1-1E5 hybridoma house mouse CVCL_KM10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P54274; Human TERF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143042 CVCL_KM13 PCRP-TFAP2A-1C6 hybridoma house mouse CVCL_KM13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05549; Human TFAP2A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143043 CVCL_KM12 PCRP-TERF2IP-1B6 hybridoma house mouse CVCL_KM12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NYB0; Human TERF2IP. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143044 CVCL_C496 HP6058 hybridoma house mouse CVCL_C496 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG (Fc). 21143045 CVCL_BS96 KM9304 transformed cell line human CVCL_BS96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21143046 CVCL_BS95 OAR-S1 finite cell line CVCL_BS95 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Diqing. Female 21143047 CVCL_C495 HP6054 hybridoma house mouse CVCL_C495 CL:0000010 Discontinued: ECACC; 93092704; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human Ig lambda light chains 21143048 CVCL_C498 GR-Mel-8 cancer cell line human CVCL_C498 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23851445). Male 21143049 CVCL_BS98 Myf5 Myod1 DKO MEF 2C5/7 finite cell line house mouse CVCL_BS98 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97252; Myf5; Knockout cell: Method=KO mouse; MGI; MGI:97275; Myod1 Derived from sampling site: Cell type=Fibroblast. Unspecified 21143050 CVCL_C497 GR-Mel-3 cancer cell line human CVCL_C497 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=23851445). Female 21143051 CVCL_BS97 RnKerTr-NYUSC-1 transformed cell line Norway rat CVCL_BS97 CL:0000010 Miscellaneous: Cell line has been lost; Miscellaneous: Cell line name, transformant, sex of donor and loss of cell line, from personal communication of Burns F.J Transformant: Iron-56 ion irradiation(NCIt; C129641); Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by microarray Male 21143052 CVCL_BS99 ACTK1 undefined cell line type African clawed frog CVCL_BS99 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Amphibian cell line 21143053 CVCL_C499 GR-Mel-9 cancer cell line human CVCL_C499 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Ser (c.404G>C); Zygosity=Unspecified (PubMed=23851445). Female 21143054 CVCL_KM29 PCRP-THAP7-3H4 hybridoma house mouse CVCL_KM29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BT49; Human THAP7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143055 CVCL_C490 HP6025 hybridoma house mouse CVCL_C490 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG4 (Fc). 21143056 CVCL_BS90 S180-S2D7 cancer cell line house mouse CVCL_BS90 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21143057 CVCL_C492 HP6047 hybridoma house mouse CVCL_C492 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG3 (hinge). 21143058 CVCL_BS92 KM9405 transformed cell line human CVCL_BS92 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143059 CVCL_KM26 PCRP-THAP4-1A7 hybridoma house mouse CVCL_KM26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8WY91; Human THAP4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143060 CVCL_C491 HP6045 hybridoma house mouse CVCL_C491 CL:0000010 Monoclonal antibody isotype: IgG2a. 21143061 CVCL_KM25 PCRP-THAP10-3A9 hybridoma house mouse CVCL_KM25 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P2Z0; Human THAP10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143062 CVCL_BS91 S180-S2D9 cancer cell line house mouse CVCL_BS91 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified 21143063 CVCL_BS94 DogL1 finite cell line dog CVCL_BS94 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21143064 CVCL_C494 HP6053 hybridoma house mouse CVCL_C494 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human Ig kappa light chains. 21143065 CVCL_KM28 PCRP-THAP5-2D4 hybridoma house mouse CVCL_KM28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z6K1; Human THAP5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143066 CVCL_BS93 CAM191 transformed cell line human CVCL_BS93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21143067 CVCL_C493 HP6050 hybridoma house mouse CVCL_C493 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgG3 (hinge). 21143068 CVCL_KM27 PCRP-THAP5-2B7 hybridoma house mouse CVCL_KM27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z6K1; Human THAP5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143069 CVCL_KM22 PCRP-TGIF1-2G6 hybridoma house mouse CVCL_KM22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15583; Human TGIF1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143070 CVCL_KM21 PCRP-TFCP2-3B1 hybridoma house mouse CVCL_KM21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q12800; Human TFCP2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143071 CVCL_KM24 PCRP-THAP10-2B9 hybridoma house mouse CVCL_KM24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P2Z0; Human THAP10. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143072 CVCL_KM23 PCRP-TGIF2LX-1H4 hybridoma house mouse CVCL_KM23 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IUE1; Human TGIF2LX. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143073 CVCL_KM20 PCRP-TFAP2D-1A12 hybridoma house mouse CVCL_KM20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7Z6R9; Human TFAP2D. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143074 CVCL_C463 CHON-002 telomerase immortalized cell line human CVCL_C463 HLA typing: B*58,81; C*06,08 (ATCC=CRL-2847) CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Female 21143075 CVCL_BS63 ND15904 transformed cell line human CVCL_BS63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143076 CVCL_C462 CHON-001 telomerase immortalized cell line human CVCL_C462 HLA typing: B*58,81; C*06,08 (ATCC=CRL-2846) CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal bone; long bone; cartilage Cell type=Chondrocyte.. Female 21143077 CVCL_BS62 ND15839 transformed cell line human CVCL_BS62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143078 CVCL_BS65 ND16061 transformed cell line human CVCL_BS65 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143079 CVCL_C465 NeHepLxHT telomerase immortalized cell line human CVCL_C465 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Hepatocyte.. Discontinued: ATCC; CRL-4020; probable Male Group: Patented cell line 21143080 CVCL_BS64 ND15971 transformed cell line human CVCL_BS64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143081 CVCL_C464 T HESCs telomerase immortalized cell line human CVCL_C464 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21143082 CVCL_C467 hTERT-HPNE E6/E7 transformed cell line human CVCL_C467 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 17.96 hours (PubMed=35454872) 21143083 CVCL_BS67 ND16183 transformed cell line human CVCL_BS67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143084 CVCL_C466 hTERT-HPNE telomerase immortalized cell line human CVCL_C466 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Transcriptome analysis by RNAseq Male Doubling time: ~26 hours (PBCF) 21143085 CVCL_BS66 ND16088 transformed cell line human CVCL_BS66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143086 CVCL_C469 hTERT-HPNE E6/E7/K-RasG12D transformed cell line human CVCL_C469 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 6407; KRAS (with p.Gly12Asp); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 19.03 hours (PubMed=35454872) 21143087 CVCL_BS69 ND16595 transformed cell line human CVCL_BS69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143088 CVCL_C468 hTERT-HPNE E6/E7/st transformed cell line human CVCL_C468 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Ductal cell.. Male 21143089 CVCL_BS68 ND16290 transformed cell line human CVCL_BS68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143090 CVCL_C461 CuFi-6 transformed cell line human CVCL_C461 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21143091 CVCL_BS61 ND15182 transformed cell line human CVCL_BS61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143092 CVCL_C460 CuFi-5 transformed cell line human CVCL_C460 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21143093 CVCL_BS60 ND14975 transformed cell line human CVCL_BS60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143094 CVCL_C474 HRC-17 hybridoma CVCL_C474 CL:0000010 Monoclonal antibody isotype: IgM. 21143095 CVCL_BS74 ND27188 transformed cell line human CVCL_BS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143096 CVCL_C473 HF10B4 hybridoma human CVCL_C473 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human lung cancer cell lines. 21143097 CVCL_BS73 ND26248 transformed cell line human CVCL_BS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143098 CVCL_C476 884F11 hybridoma house mouse CVCL_C476 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08226; Mouse Apoe. 21143099 CVCL_BS76 GM08885 transformed cell line human CVCL_BS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143100 CVCL_C475 802C11 hybridoma house mouse CVCL_C475 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q61490; Mouse Alcam/Cd166. 21143101 CVCL_BS75 ND28350 transformed cell line human CVCL_BS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143102 CVCL_BS78 GM08887 transformed cell line human CVCL_BS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143103 CVCL_C478 JFP-J1 hybridoma CVCL_C478 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42212; GFP. 21143104 CVCL_C477 859H5 hybridoma CVCL_C477 CL:0000010 Monoclonal antibody isotype: IgG2a. 21143105 CVCL_BS77 GM08886 transformed cell line human CVCL_BS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143106 CVCL_BS79 GM08888 transformed cell line human CVCL_BS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143107 CVCL_C479 JFP-J5 hybridoma CVCL_C479 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42212; GFP. 21143108 CVCL_KM08 PCRP-TEAD4-1G7 hybridoma house mouse CVCL_KM08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15561; Human TEAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143109 CVCL_KM07 PCRP-TEAD3-1A4 hybridoma house mouse CVCL_KM07 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q99594; Human TEAD3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143110 CVCL_KM09 PCRP-TEAD4-2F4 hybridoma house mouse CVCL_KM09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15561; Human TEAD4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143111 CVCL_C470 hTERT-HPNE E6/E7/K-RasG12D/st transformed cell line human CVCL_C470 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 6407; KRAS (with p.Gly12Asp); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Ductal cell.. Male 21143112 CVCL_BS70 ND19454 transformed cell line human CVCL_BS70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143113 CVCL_KM04 PCRP-TCF7L1-1A6 hybridoma house mouse CVCL_KM04 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q9HCS4; Human TCF7L1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143114 CVCL_KM03 PCRP-TCF25-1F12 hybridoma house mouse CVCL_KM03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BQ70; Human TCF25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143115 CVCL_C472 hTERT-1604 telomerase immortalized cell line human CVCL_C472 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21143116 CVCL_BS72 ND26210 transformed cell line human CVCL_BS72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143117 CVCL_KM06 PCRP-TDRKH-1H2 hybridoma house mouse CVCL_KM06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2W6; Human TDRKH. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143118 CVCL_BS71 ND21237 transformed cell line human CVCL_BS71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143119 CVCL_KM05 PCRP-TCF7L1-1A9 hybridoma house mouse CVCL_KM05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9HCS4; Human TCF7L1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143120 CVCL_C471 UMB1949 transformed cell line human CVCL_C471 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Val1362Leufs*50 (c.4083_4087delAGTCG); ClinVar=VCV000049741; Zygosity=Unspecified (PubMed=17592550); Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21143121 CVCL_KM00 PCRP-TCF24-2E11 hybridoma house mouse CVCL_KM00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q7RTU0; Human TCF24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143122 CVCL_KM02 PCRP-TCF25-1A9 hybridoma house mouse CVCL_KM02 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BQ70; Human TCF25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143123 CVCL_KM01 PCRP-TCF25-1A11 hybridoma house mouse CVCL_KM01 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BQ70; Human TCF25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143124 CVCL_1B52 EFM-55 cancer cell line human CVCL_1B52 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143125 CVCL_1B51 EFM-49 cancer cell line human CVCL_1B51 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143126 CVCL_1B54 EFM-61 cancer cell line human CVCL_1B54 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143127 CVCL_1B53 EFM-56 cancer cell line human CVCL_1B53 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143128 CVCL_1B56 S2-Mt-Msps-GFP spontaneously immortalized cell line fruit fly CVCL_1B56 CL:0000010 Transfected with: FlyBase_Gene; FBgn0027948; msps; Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Characteristics: Expresses a msps-GFP fusion under the control of a metallothionein promoter Group: Insect cell line 21143129 CVCL_1B55 EFM-76 cancer cell line human CVCL_1B55 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143130 CVCL_1B58 S2R+-Fucci spontaneously immortalized cell line fruit fly CVCL_1B58 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Oregon-R. Male Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with a Fucci like probe which consist of a nuclear eGFP fused to an E2F1 degron and unlocalized mRFP1 fused to a CycB degron Doubling time: ~35 hours (DGRC) Group: Insect cell line 21143131 CVCL_1B57 S2-Tub-wg spontaneously immortalized cell line fruit fly CVCL_1B57 CL:0000010 Transfected with: FlyBase_Gene; FBgn0004009; wg Breed/subspecies: Oregon-R. Male Doubling time: 39 hours (DGRC) Group: Insect cell line 21143132 CVCL_1B59 S2R+-Ubi-pHMA spontaneously immortalized cell line fruit fly CVCL_1B59 CL:0000010 Breed/subspecies: Oregon-R. Male Doubling time: 82 hours (DGRC) Group: Insect cell line 21143133 CVCL_1B50 EFM-40 cancer cell line human CVCL_1B50 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143134 CVCL_1B63 Pten 1A spontaneously immortalized cell line fruit fly CVCL_1B63 CL:0000010 Unspecified Group: Insect cell line. 21143135 CVCL_1B62 Pten 1 spontaneously immortalized cell line fruit fly CVCL_1B62 CL:0000010 Unspecified Group: Insect cell line. 21143136 CVCL_1B65 TRA-147 spontaneously immortalized cell line CVCL_1B65 CL:0000010 Unspecified Group: Insect cell line. 21143137 CVCL_1B64 Pten X spontaneously immortalized cell line fruit fly CVCL_1B64 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Doubling time: 3 days (DGRC) Group: Insect cell line 21143138 CVCL_1B67 TRA-293 spontaneously immortalized cell line CVCL_1B67 CL:0000010 Unspecified Group: Insect cell line. 21143139 CVCL_1B66 TRA-272 spontaneously immortalized cell line CVCL_1B66 CL:0000010 Unspecified Group: Insect cell line. 21143140 CVCL_1B69 GM00801 finite cell line human CVCL_1B69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21143141 CVCL_1B68 NAMRU2-CQ-01 spontaneously immortalized cell line CVCL_1B68 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution (Naval Medical Research Unit 2) and the species Derived from sampling site: Ovary. Female Group: Insect cell line 21143142 CVCL_TH91 HAP1 QPRT (-) 2 cancer cell line human CVCL_TH91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9755; QPRT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143143 CVCL_TH90 HAP1 QPRT (-) 1 cancer cell line human CVCL_TH90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9755; QPRT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143144 CVCL_TH93 HAP1 QSOX1 (-) 2 cancer cell line human CVCL_TH93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9756; QSOX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143145 CVCL_TH92 HAP1 QSOX1 (-) 1 cancer cell line human CVCL_TH92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9756; QSOX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143146 CVCL_TH95 HAP1 RAB12 (-) cancer cell line human CVCL_TH95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31332; RAB12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143147 CVCL_TH94 HAP1 RAB11B (-) 1 cancer cell line human CVCL_TH94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9761; RAB11B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143148 CVCL_TH97 HAP1 RAB13 (-) 2 cancer cell line human CVCL_TH97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9762; RAB13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143149 CVCL_TH96 HAP1 RAB13 (-) 1 cancer cell line human CVCL_TH96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9762; RAB13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143150 CVCL_TH99 HAP1 RAB1B (-) 1 cancer cell line human CVCL_TH99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18370; RAB1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143151 CVCL_TH98 HAP1 RAB14 (-) cancer cell line human CVCL_TH98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16524; RAB14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143152 CVCL_1B61 Ras[V12]-H7 spontaneously immortalized cell line fruit fly CVCL_1B61 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP Omics: Transcriptome analysis by RNAseq. Male Doubling time: 65 hours (DGRC) Group: Insect cell line 21143153 CVCL_1B60 Ras[V12]-H3 spontaneously immortalized cell line fruit fly CVCL_1B60 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP Omics: Transcriptome analysis by RNAseq. Male Doubling time: 45 hours (DGRC) Group: Insect cell line 21143154 CVCL_1B30 BALB/MK-1 factor-dependent cell line house mouse CVCL_1B30 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified Characteristics: EGF dependent 21143155 CVCL_1B32 GC3/M cancer cell line human CVCL_1B32 CL:0000010 Male 21143156 CVCL_1B31 CHO-hD3 spontaneously immortalized cell line CVCL_1B31 CL:0000010 Transfected with: HGNC; 3024; DRD3 Derived from sampling site: Ovary. Female 21143157 CVCL_1B34 GC3/Cl cancer cell line human CVCL_1B34 CL:0000010 Male 21143158 CVCL_1B33 GC3/M TK- cancer cell line human CVCL_1B33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. Male 21143159 CVCL_1B36 64CP cancer cell line human CVCL_1B36 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Abdomen. Male 21143160 CVCL_1B35 CEM/VM-1 cancer cell line human CVCL_1B35 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21143161 CVCL_1B38 P388/VCR-20 cancer cell line house mouse CVCL_1B38 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21143162 CVCL_1B37 KKLS cancer cell line human CVCL_1B37 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 25-30 hours (CelloPub=CLPUB00239) 21143163 CVCL_1B39 P388/DDP cancer cell line house mouse CVCL_1B39 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21143164 CVCL_TH80 HAP1 PXK (-) 1 cancer cell line human CVCL_TH80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23326; PXK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143165 CVCL_TH82 HAP1 PYCARD (-) 1 cancer cell line human CVCL_TH82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16608; PYCARD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143166 CVCL_TH81 HAP1 PXK (-) 2 cancer cell line human CVCL_TH81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23326; PXK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143167 CVCL_TH84 HAP1 PYCR1 (-) 1 cancer cell line human CVCL_TH84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9721; PYCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143168 CVCL_TH83 HAP1 PYCARD (-) 2 cancer cell line human CVCL_TH83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16608; PYCARD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143169 CVCL_TH86 HAP1 PYCR1 (-) 3 cancer cell line human CVCL_TH86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9721; PYCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143170 CVCL_TH85 HAP1 PYCR1 (-) 2 cancer cell line human CVCL_TH85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9721; PYCR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143171 CVCL_TH88 HAP1 PYURF (-) 2 cancer cell line human CVCL_TH88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 44317; PYURF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143172 CVCL_TH87 HAP1 PYURF (-) 1 cancer cell line human CVCL_TH87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 44317; PYURF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143173 CVCL_TH89 HAP1 QKI (-) 1 cancer cell line human CVCL_TH89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21100; QKI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143174 CVCL_1B41 SPC-A4 cancer cell line human CVCL_1B41 CL:0000010 21143175 CVCL_1B40 L1210/DDP cancer cell line house mouse CVCL_1B40 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21143176 CVCL_1B43 AIK-T8 transformed cell line human CVCL_1B43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: Contains an EBV genome in an episomal form (PubMed=8608235) 21143177 CVCL_1B42 AIK-T4 transformed cell line human CVCL_1B42 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Unexplicit; Ex18del; Zygosity=Heterozygous (PubMed=16827800) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: Contains an EBV genome in an episomal form (PubMed=8608235) 21143178 CVCL_1B45 fGS/OSS spontaneously immortalized cell line fruit fly CVCL_1B45 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Co-culture of ovarian germline stem cells (GSCs) and somatic sheath cells Doubling time: 2 days (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21143179 CVCL_1B44 H35R0.3 cancer cell line Norway rat CVCL_1B44 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21143180 CVCL_1B47 90-8 cancer cell line human CVCL_1B47 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.96+1G>A (IVS3+1G>A); ClinVar=VCV000860797; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=7522538). Female 21143181 CVCL_1B46 OSS spontaneously immortalized cell line fruit fly CVCL_1B46 CL:0000010 Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female Doubling time: 45 hours (DGRC) Group: Insect cell line; Part of: modENCODE project cell lines 21143182 CVCL_1B49 EFM-36 cancer cell line human CVCL_1B49 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143183 CVCL_1B48 EFM-30 cancer cell line human CVCL_1B48 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21143184 CVCL_TH71 HAP1 PTPRK (-) 4 cancer cell line human CVCL_TH71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143185 CVCL_TH70 HAP1 PTPRK (-) 3 cancer cell line human CVCL_TH70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143186 CVCL_TH73 HAP1 PTPRS (-) 2 cancer cell line human CVCL_TH73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9681; PTPRS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143187 CVCL_TH72 HAP1 PTPRS (-) 1 cancer cell line human CVCL_TH72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9681; PTPRS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143188 CVCL_TH75 HAP1 PUSL1 (-) 1 cancer cell line human CVCL_TH75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26914; PUSL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143189 CVCL_TH74 HAP1 PTPRS (-) 3 cancer cell line human CVCL_TH74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9681; PTPRS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143190 CVCL_TH77 HAP1 PVR (-) 2 cancer cell line human CVCL_TH77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9705; PVR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143191 CVCL_TH76 HAP1 PVR (-) 1 cancer cell line human CVCL_TH76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9705; PVR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143192 CVCL_TH79 HAP1 PWWP2B (-) 2 cancer cell line human CVCL_TH79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25150; PWWP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143193 CVCL_TH78 HAP1 PWWP2B (-) 1 cancer cell line human CVCL_TH78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25150; PWWP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143194 CVCL_1B10 GM20320 transformed cell line human CVCL_1B10 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143195 CVCL_1B12 GM20333 transformed cell line human CVCL_1B12 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143196 CVCL_1B11 GM20321 transformed cell line human CVCL_1B11 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143197 CVCL_1B14 GM20337 transformed cell line human CVCL_1B14 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143198 CVCL_1B13 GM20335 transformed cell line human CVCL_1B13 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143199 CVCL_1B16 GM20345 transformed cell line human CVCL_1B16 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143200 CVCL_1B15 GM20343 transformed cell line human CVCL_1B15 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143201 CVCL_1B18 GM20349 transformed cell line human CVCL_1B18 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143202 CVCL_1B17 GM20347 transformed cell line human CVCL_1B17 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143203 CVCL_1B19 GM20350 transformed cell line human CVCL_1B19 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143204 CVCL_TH60 HAP1 PTPN11 (-) 2 cancer cell line human CVCL_TH60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9644; PTPN11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143205 CVCL_TH62 HAP1 PTPN3 (-) 2 cancer cell line human CVCL_TH62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9655; PTPN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143206 CVCL_TH61 HAP1 PTPN3 (-) 1 cancer cell line human CVCL_TH61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9655; PTPN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143207 CVCL_TH64 HAP1 PTPRC (-) 2 cancer cell line human CVCL_TH64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9666; PTPRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143208 CVCL_TH63 HAP1 PTPRC (-) 1 cancer cell line human CVCL_TH63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9666; PTPRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143209 CVCL_TH66 HAP1 PTPRD (-) 1 cancer cell line human CVCL_TH66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9668; PTPRD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143210 CVCL_TH65 HAP1 PTPRC (-) 3 cancer cell line human CVCL_TH65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9666; PTPRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143211 CVCL_TH68 HAP1 PTPRK (-) 1 cancer cell line human CVCL_TH68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143212 CVCL_TH67 HAP1 PTPRJ (-) 1 cancer cell line human CVCL_TH67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9673; PTPRJ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143213 CVCL_TH69 HAP1 PTPRK (-) 2 cancer cell line human CVCL_TH69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9674; PTPRK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143214 CVCL_1B21 GM20358 transformed cell line human CVCL_1B21 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143215 CVCL_1B20 GM20355 transformed cell line human CVCL_1B20 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143216 CVCL_1B23 GM20361 transformed cell line human CVCL_1B23 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM20361; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143217 CVCL_1B22 GM20360 transformed cell line human CVCL_1B22 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143218 CVCL_1B25 GM20364 transformed cell line human CVCL_1B25 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143219 CVCL_1B24 GM20362 transformed cell line human CVCL_1B24 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143220 CVCL_1B27 GM20284 transformed cell line human CVCL_1B27 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143221 CVCL_1B26 GM20413 transformed cell line human CVCL_1B26 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM20413; probable Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143222 CVCL_1B29 BALB/MK factor-dependent cell line house mouse CVCL_1B29 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified Characteristics: EGF dependent 21143223 CVCL_1B28 C180-13S cancer cell line human CVCL_1B28 CL:0000010 Female 21143224 CVCL_TH51 HAP1 PTGER3 (-) 2 cancer cell line human CVCL_TH51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9595; PTGER3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143225 CVCL_TH50 HAP1 PTGER3 (-) 1 cancer cell line human CVCL_TH50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9595; PTGER3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143226 CVCL_TH53 HAP1 PTK2B (-) 1 cancer cell line human CVCL_TH53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9612; PTK2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143227 CVCL_TH52 HAP1 PTH1R (-) cancer cell line human CVCL_TH52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9608; PTH1R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143228 CVCL_TH55 HAP1 PTK7 (-) 1 cancer cell line human CVCL_TH55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9618; PTK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143229 CVCL_TH54 HAP1 PTK2B (-) 2 cancer cell line human CVCL_TH54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9612; PTK2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143230 CVCL_TH57 HAP1 PTPN1 (-) 1 cancer cell line human CVCL_TH57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9642; PTPN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143231 CVCL_TH56 HAP1 PTK7 (-) 2 cancer cell line human CVCL_TH56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9618; PTK7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143232 CVCL_TH59 HAP1 PTPN11 (-) 1 cancer cell line human CVCL_TH59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9644; PTPN11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143233 CVCL_TH58 HAP1 PTPN1 (-) 2 cancer cell line human CVCL_TH58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9642; PTPN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143234 CVCL_TH40 HAP1 PTAR1 (-) 2 cancer cell line human CVCL_TH40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30449; PTAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143235 CVCL_TH42 HAP1 PTCH1 (-) 1 cancer cell line human CVCL_TH42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143236 CVCL_TH41 HAP1 PTBP1 (-) cancer cell line human CVCL_TH41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9583; PTBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143237 CVCL_TH44 HAP1 PTCHD4 (-) 1 cancer cell line human CVCL_TH44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21345; PTCHD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143238 CVCL_TH43 HAP1 PTCH1 (-) 2 cancer cell line human CVCL_TH43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9585; PTCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143239 CVCL_TH46 HAP1 PTEN (-) 1 cancer cell line human CVCL_TH46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143240 CVCL_KN98 PCRP-ZNF157-1A8 hybridoma house mouse CVCL_KN98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51786; Human ZNF157. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143241 CVCL_TH45 HAP1 PTCHD4 (-) 2 cancer cell line human CVCL_TH45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21345; PTCHD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143242 CVCL_KN97 PCRP-ZNF157-1A6 hybridoma house mouse CVCL_KN97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51786; Human ZNF157. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143243 CVCL_TH48 HAP1 PTEN (-) 3 cancer cell line human CVCL_TH48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143244 CVCL_TH47 HAP1 PTEN (-) 2 cancer cell line human CVCL_TH47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143245 CVCL_KN99 PCRP-ZNF165-2D3 hybridoma house mouse CVCL_KN99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P49910; Human ZNF165. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143246 CVCL_KN94 PCRP-ZNF140-5C1 hybridoma house mouse CVCL_KN94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P52738; Human ZNF140. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143247 CVCL_TH49 HAP1 PTEN (-) 4 cancer cell line human CVCL_TH49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9588; PTEN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143248 CVCL_KN93 PCRP-ZNF140-2D1 hybridoma house mouse CVCL_KN93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P52738; Human ZNF140. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143249 CVCL_KN96 PCRP-ZNF155-1A5 hybridoma house mouse CVCL_KN96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q12901; Human ZNF155. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143250 CVCL_KN95 PCRP-ZNF143-1A10 hybridoma house mouse CVCL_KN95 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P52747; Human ZNF143. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143251 CVCL_1B01 GM20297 transformed cell line human CVCL_1B01 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143252 CVCL_1B00 GM20295 transformed cell line human CVCL_1B00 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143253 CVCL_1B03 GM20301 transformed cell line human CVCL_1B03 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143254 CVCL_1B02 GM20300 transformed cell line human CVCL_1B02 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143255 CVCL_1B05 GM20312 transformed cell line human CVCL_1B05 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Discontinued: Coriell; GM20312; probable Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143256 CVCL_1B04 GM20302 transformed cell line human CVCL_1B04 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143257 CVCL_1B07 GM20316 transformed cell line human CVCL_1B07 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143258 CVCL_1B06 GM20313 transformed cell line human CVCL_1B06 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143259 CVCL_1B09 GM20319 transformed cell line human CVCL_1B09 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143260 CVCL_1B08 GM20318 transformed cell line human CVCL_1B08 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21143261 CVCL_TH31 HAP1 PSMB8 (-) 2 cancer cell line human CVCL_TH31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9545; PSMB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143262 CVCL_TH30 HAP1 PSMB8 (-) 1 cancer cell line human CVCL_TH30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9545; PSMB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143263 CVCL_TH33 HAP1 PSMB9 (-) 1 cancer cell line human CVCL_TH33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143264 CVCL_TH32 HAP1 PSMB8 (-) 3 cancer cell line human CVCL_TH32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9545; PSMB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143265 CVCL_TH35 HAP1 PSMB9 (-) 3 cancer cell line human CVCL_TH35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143266 CVCL_TH34 HAP1 PSMB9 (-) 2 cancer cell line human CVCL_TH34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143267 CVCL_TH37 HAP1 PSMF1 (-) 2 cancer cell line human CVCL_TH37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9571; PSMF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143268 CVCL_TH36 HAP1 PSMF1 (-) 1 cancer cell line human CVCL_TH36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9571; PSMF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143269 CVCL_TH39 HAP1 PTAR1 (-) 1 cancer cell line human CVCL_TH39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30449; PTAR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143270 CVCL_TH38 HAP1 PSPC1 (-) 1 cancer cell line human CVCL_TH38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20320; PSPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143271 CVCL_C603 FM74 cancer cell line human CVCL_C603 HLA typing: A*31:01:02,24:02; B*15:01:01:01,35:01; C*03:03,04:01:01; DPB1*04:01; DQB1*03:02,05:01; DRB1*01:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Male 21143272 CVCL_BU03 GM22111 transformed cell line human CVCL_BU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143273 CVCL_C602 FM72 cancer cell line human CVCL_C602 HLA typing: A*02:01; B*07:02,18:01; C*05:01,07:02; DPB1*04:01,03:01; DQB1*06:02,02:01; DRB1*03:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Unspecified 21143274 CVCL_BU02 GM22110 transformed cell line human CVCL_BU02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143275 CVCL_C605 FM77 cancer cell line human CVCL_C605 CL:0000010 Unspecified 21143276 CVCL_BU05 GM22113 transformed cell line human CVCL_BU05 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143277 CVCL_BU04 GM22112 transformed cell line human CVCL_BU04 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143278 CVCL_C604 Me15392 cancer cell line human CVCL_C604 HLA typing: A*11:01,03:01; B*40:01,14:01; DPB1*10:01,13:01; DQB1*05:01; DRB1*01:01,10:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Lymph node. 21143279 CVCL_C607 FM79 cancer cell line human CVCL_C607 HLA typing: A*32:01,25:01; B*18:01,44:02; C*12:03,05:01; DPB1*04:02,02:01:02; DQB1*06:02,03:01:01; DRB1*15:01,12:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. 21143280 CVCL_BU07 GM22115 finite cell line human CVCL_BU07 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21143281 CVCL_C606 FM78 cancer cell line human CVCL_C606 HLA typing: A*31:01:02,03:01; B*15:01:01:01,27:04; C*02:02:02,03:03; DPB1*04:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Gly (c.815T>G); ClinVar=VCV000233323; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. 21143282 CVCL_BU06 GM22114 transformed cell line human CVCL_BU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143283 CVCL_C609 FM82 cancer cell line human CVCL_C609 HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*03:04,07:04; DPB1*04:01,03:01; DQB1*03:02,03:01:01; DRB1*04:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH; Omics: HLA class I peptidome analysis by proteomics. Female 21143284 CVCL_BU09 GM22124 transformed cell line human CVCL_BU09 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Arg113Ter (c.377C>T); ClinVar=VCV000265422; Zygosity=Heterozygous (By familial inference of GM22123); Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Phe391Ser (c.1172T>C); ClinVar=VCV001942487; Zygosity=Heterozygous (By familial inference of GM22123) Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143285 CVCL_BU08 GM22123 transformed cell line human CVCL_BU08 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Arg113Ter (c.377C>T); ClinVar=VCV000265422; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Phe391Ser (c.1172T>C); ClinVar=VCV001942487; Zygosity=Heterozygous (Coriell) Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143286 CVCL_C601 FM70 cancer cell line human CVCL_C601 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9288767; PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Female 21143287 CVCL_BU01 GM22103 finite cell line human CVCL_BU01 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143288 CVCL_C600 FM69 cancer cell line human CVCL_C600 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21143289 CVCL_BU00 GM22102 finite cell line human CVCL_BU00 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21143290 CVCL_C614 FM91 cancer cell line human CVCL_C614 CL:0000010 Unspecified 21143291 CVCL_BU14 GM22130 transformed cell line human CVCL_BU14 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.His69Gln (c.207C>G); ClinVar=VCV000559335; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143292 CVCL_C613 FM89 cancer cell line human CVCL_C613 CL:0000010 Unspecified 21143293 CVCL_BU13 GM22129 transformed cell line human CVCL_BU13 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; c.109+5G>A (IVS1+5G>A); ClinVar=VCV001073013; Zygosity=Hemizygous; Note=Splicing mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143294 CVCL_BU16 GM22138 finite cell line human CVCL_BU16 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143295 CVCL_C616 Mel 1241 cancer cell line human CVCL_C616 CL:0000010 21143296 CVCL_C615 FM92 cancer cell line human CVCL_C615 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Male 21143297 CVCL_BU15 GM22137 transformed cell line human CVCL_BU15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143298 CVCL_C618 FM95 cancer cell line human CVCL_C618 HLA typing: A*03:01,33:01; B*07:02,51:01:01; C*07:02,14:02:01; DPB1*04:01,10:01; DQB1*03:01:01,05:03:01; DRB1*12:01,14:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Skin. Omics: Array-based CGH Discontinued: ESTDAB; ESTDAB-034; probable Male 21143299 CVCL_BU18 GM22148 transformed cell line human CVCL_BU18 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Leu42Ter (c.124delC); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143300 CVCL_C617 FM93/2 cancer cell line human CVCL_C617 HLA typing: A*02:01,26:01; B*40:01,44:02; C*03:04,05:01; DPB1*04:02,03:01:01; DQB1*03:01:01,05:01; DRB1*14:01:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.795_796GG>AA); Zygosity=Unspecified (PubMed=23851445) Omics: HLA class I peptidome analysis by proteomics. Unspecified 21143301 CVCL_BU17 GM22147 transformed cell line human CVCL_BU17 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Lys37Ser_Tyr38ins18 (c.109+5G>C) (IVS1+5G>C); ClinVar=VCV000011106; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143302 CVCL_BU19 GM22149 transformed cell line human CVCL_BU19 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Arg123Ter (c.367C>T); ClinVar=VCV000560626; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143303 CVCL_C619 MZ-MEL-9 cancer cell line human CVCL_C619 CL:0000010 Unspecified 21143304 CVCL_C610 FM86 cancer cell line human CVCL_C610 HLA typing: A*02:01; B*15:01:01:01,44:02; C*03:04,05:01; DPB1*04:01; DQB1*03:02,03:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.171_172CC>TT) (p.Pro72Leu, c.214_215CC>TT); Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=23851445) Omics: Array-based CGH. Female 21143305 CVCL_BU10 GM22125 transformed cell line human CVCL_BU10 CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143306 CVCL_C612 888A2 mel cancer cell line human CVCL_C612 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*02) Derived from metastatic site: Oral cavity; soft palate; hypodermis. Female 21143307 CVCL_BU12 GM22128 transformed cell line human CVCL_BU12 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Leu212Pro (c.635T>C); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143308 CVCL_C611 FM87 cancer cell line human CVCL_C611 CL:0000010 Unspecified 21143309 CVCL_BU11 GM22126 transformed cell line human CVCL_BU11 CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143310 CVCL_1B96 GM24083 transformed cell line human CVCL_1B96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143311 CVCL_1B95 GM24081 transformed cell line human CVCL_1B95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143312 CVCL_1B98 GM24085 transformed cell line human CVCL_1B98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143313 CVCL_1B97 GM24084 transformed cell line human CVCL_1B97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143314 CVCL_1B99 GM24086 transformed cell line human CVCL_1B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143315 CVCL_1B90 GM24076 transformed cell line human CVCL_1B90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143316 CVCL_1B92 GM24078 transformed cell line human CVCL_1B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143317 CVCL_1B91 GM24077 transformed cell line human CVCL_1B91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143318 CVCL_1B94 GM24080 transformed cell line human CVCL_1B94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143319 CVCL_1B93 GM24079 transformed cell line human CVCL_1B93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143320 CVCL_1B74 ATC-310 spontaneously immortalized cell line CVCL_1B74 CL:0000010 Miscellaneous: Cell line probably no longer available; no published report since 1976 (personal communication of Bell-Sakyi L.). Unspecified Group: Tick cell line 21143321 CVCL_1B73 NAMRU2-CT-01 spontaneously immortalized cell line CVCL_1B73 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the institution (Naval Medical Research Unit 2) and the species Derived from sampling site: Ovary. Female Group: Insect cell line 21143322 CVCL_1B76 GM21730 transformed cell line human CVCL_1B76 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143323 CVCL_1B75 GM21660 transformed cell line human CVCL_1B75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143324 CVCL_1B78 GM21781 transformed cell line human CVCL_1B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143325 CVCL_1B77 GM21731 transformed cell line human CVCL_1B77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143326 CVCL_1B79 GM23843 transformed cell line human CVCL_1B79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143327 CVCL_1B70 GM00802 finite cell line human CVCL_1B70 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21143328 CVCL_1B72 GM11291 finite cell line human CVCL_1B72 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Female 21143329 CVCL_1B71 GM01214 finite cell line human CVCL_1B71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21143330 CVCL_1B85 GM24071 transformed cell line human CVCL_1B85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143331 CVCL_1B84 GM24070 transformed cell line human CVCL_1B84 CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143332 CVCL_1B87 GM24073 transformed cell line human CVCL_1B87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143333 CVCL_1B86 GM24072 transformed cell line human CVCL_1B86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143334 CVCL_1B89 GM24075 transformed cell line human CVCL_1B89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143335 CVCL_1B88 GM24074 transformed cell line human CVCL_1B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143336 CVCL_1B81 GM24050 transformed cell line human CVCL_1B81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143337 CVCL_1B80 GM24049 transformed cell line human CVCL_1B80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143338 CVCL_1B83 GM24068 transformed cell line human CVCL_1B83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 21143339 CVCL_1B82 GM24067 transformed cell line human CVCL_1B82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21143340 CVCL_BT69 GM22016 transformed cell line human CVCL_BT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143341 CVCL_C569 L6A4 transformed cell line Norway rat CVCL_C569 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143342 CVCL_BT62 GM21920 transformed cell line human CVCL_BT62 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex4del; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143343 CVCL_C562 T-Ag-MOSE transformed cell line house mouse CVCL_C562 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: C3H/He. Discontinued: JCRB; NIHS0214; true Female 21143344 CVCL_BT61 GM21916 transformed cell line human CVCL_BT61 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143345 CVCL_C561 Sp2/mIL-6 cancer cell line house mouse CVCL_C561 CL:0000010 Transfected with: MGI; MGI:96559; Il6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21143346 CVCL_C564 FM3A FSthy21 cancer cell line house mouse CVCL_C564 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Thymidylate synthase defective 21143347 CVCL_BT64 GM22011 transformed cell line human CVCL_BT64 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly241Valfs*19 (c.722delG) (G216fs); ClinVar=VCV000551231; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143348 CVCL_BT63 GM22010 transformed cell line human CVCL_BT63 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly241Valfs*19 (c.722delG) (G216fs); ClinVar=VCV000551231; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143349 CVCL_C563 p53-def-MOSE spontaneously immortalized cell line house mouse CVCL_C563 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Discontinued: JCRB; NIHS0215; true Female 21143350 CVCL_BT66 GM22013 transformed cell line human CVCL_BT66 CL:0000010 Population: Caucasian; German/Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143351 CVCL_C566 L6TG Cap transformed cell line Norway rat CVCL_C566 CL:0000010 Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143352 CVCL_BT65 GM22012 transformed cell line human CVCL_BT65 CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly241Valfs*19 (c.722delG) (G216fs); ClinVar=VCV000551231; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143353 CVCL_C565 L6TG transformed cell line Norway rat CVCL_C565 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143354 CVCL_BT68 GM22015 transformed cell line human CVCL_BT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143355 CVCL_C568 ts3b2 transformed cell line Norway rat CVCL_C568 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143356 CVCL_BT67 GM22014 transformed cell line human CVCL_BT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143357 CVCL_C567 ts485 transformed cell line Norway rat CVCL_C567 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143358 CVCL_C560 4G12 [Mouse hybridoma against human 65 kDa glycoprotein] hybridoma CVCL_C560 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human 65 kDa glycoprotein on cancer cells surface. Doubling time: 1.2 days (lot 06232004) (JCRB) 21143359 CVCL_BT60 GM21913 transformed cell line human CVCL_BT60 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143360 CVCL_BT73 GM22020 transformed cell line human CVCL_BT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143361 CVCL_C573 SV7tert PDGFtu1 transformed cell line human CVCL_C573 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Female 21143362 CVCL_BT72 GM22019 transformed cell line human CVCL_BT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143363 CVCL_C572 Ma-Mel-42a cancer cell line human CVCL_C572 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21143364 CVCL_C575 CHW spontaneously immortalized cell line CVCL_C575 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 12 hours (PubMed=4462979) 21143365 CVCL_BT75 GM22022 transformed cell line human CVCL_BT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143366 CVCL_C574 CHW-1102 transformed cell line CVCL_C574 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: HPRT deficient Doubling time: 13 hours (PubMed=4462979) 21143367 CVCL_BT74 GM22021 transformed cell line human CVCL_BT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143368 CVCL_BT77 GM22028 transformed cell line human CVCL_BT77 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143369 CVCL_C577 RE-25-HOM cancer cell line human CVCL_C577 HLA typing: A*30:01,25:01; B*18:01,44:03:01; C*12:03,16:01; DQB1*03:01:01,02:01; DRB1*11:03:01,07:01 (PubMed=15592718). CL:0000010 Male 21143370 CVCL_C576 FM2 cancer cell line human CVCL_C576 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21143371 CVCL_BT76 GM22025 transformed cell line human CVCL_BT76 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly112Asp (c.335G>A); ClinVar=VCV000038883; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Ala402Hisfs*41 (c.1204delG); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143372 CVCL_C579 FM3.26 cancer cell line human CVCL_C579 HLA typing: A*02:01,03:01; B*07:02,44:02; C*07:02,05:01; DPB1*04:01,13:01; DQB1*06:02,03:01:01; DRB1*04:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Right inguinal lymph node. Female 21143373 CVCL_BT79 GM22030 transformed cell line human CVCL_BT79 CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Phe391Cysfs*2 (c.1172_1173delTT); ClinVar=VCV000659170; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143374 CVCL_C578 FM3.13 cancer cell line human CVCL_C578 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Right inguinal lymph node. Female 21143375 CVCL_BT78 GM22029 finite cell line human CVCL_BT78 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143376 CVCL_KN07 PCRP-ZBTB25-1D12 hybridoma house mouse CVCL_KN07 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P24278; Human ZBTB25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143377 CVCL_KN06 PCRP-ZBTB25-1B10 hybridoma house mouse CVCL_KN06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P24278; Human ZBTB25. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143378 CVCL_KN09 PCRP-ZBTB3-2E10 hybridoma house mouse CVCL_KN09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H5J0; Human ZBTB3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143379 CVCL_KN08 PCRP-ZBTB3-2B2 hybridoma house mouse CVCL_KN08 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H5J0; Human ZBTB3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143380 CVCL_KN03 PCRP-ZBTB22-1A2 hybridoma house mouse CVCL_KN03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15209; Human ZBTB22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143381 CVCL_KN02 PCRP-ZBTB2-46F2 hybridoma house mouse CVCL_KN02 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N680; Human ZBTB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143382 CVCL_BT71 GM22018 transformed cell line human CVCL_BT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143383 CVCL_C571 L84 spontaneously immortalized cell line Norway rat CVCL_C571 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Wistar. Unspecified Characteristics: Non-fusing variant Continue to proliferate until a very high cell density is reached, but do not fuse (PubMed=558123). 21143384 CVCL_KN05 PCRP-ZBTB24-1E9 hybridoma house mouse CVCL_KN05 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O43167; Human ZBTB24. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143385 CVCL_BT70 GM22017 transformed cell line human CVCL_BT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143386 CVCL_C570 L6C9 transformed cell line Norway rat CVCL_C570 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21143387 CVCL_KN04 PCRP-ZBTB22-1F7 hybridoma house mouse CVCL_KN04 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15209; Human ZBTB22. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143388 CVCL_KN01 PCRP-ZBTB18-1B2 hybridoma house mouse CVCL_KN01 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q99592; Human ZBTB18. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143389 CVCL_KN00 PCRP-ZBTB17-1D3 hybridoma house mouse CVCL_KN00 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; Q13105; Human ZBTB17. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143390 CVCL_C548 FR-M-204 cancer cell line human CVCL_C548 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Gly (c.653T>G); ClinVar=VCV000528249; Zygosity=Unspecified (PubMed=23851445). Female 21143391 CVCL_BT48 GM21567 finite cell line human CVCL_BT48 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Arg1024Ter (c.3070C>T); ClinVar=VCV000101174; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143392 CVCL_C547 FR-M-170 cancer cell line human CVCL_C547 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Unspecified (PubMed=23851445). Male 21143393 CVCL_BT47 GM21566 transformed cell line human CVCL_BT47 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Arg1024Ter (c.3070C>T); ClinVar=VCV000101174; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143394 CVCL_C549 ASH-S2 finite cell line CVCL_C549 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 21143395 CVCL_BT49 GM21762 transformed cell line human CVCL_BT49 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Arg1024Ter (c.3070C>T); ClinVar=VCV000101174; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143396 CVCL_BT40 GM20479 transformed cell line human CVCL_BT40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143397 CVCL_C540 RUCH-2 cancer cell line human CVCL_C540 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=12068308) Omics: Cell surface proteome; Omics: Transcriptome analysis by microarray. Female 21143398 CVCL_BT42 GM20481 transformed cell line human CVCL_BT42 CL:0000010 Sequence variation: Gene fusion; HGNC; 4827; HBB + HGNC; 4829; HBD; Name(s)=HBD-HBB, HBD50/HBB86, Hb Lepore-Baltimore; ClinVar=VCV000015060 (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143399 CVCL_C542 RPMI-8322 cancer cell line human CVCL_C542 HLA typing: A*02,09; B*07,w05 (PubMed=77569) CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 38 hours (PubMed=1127734) 21143400 CVCL_BT41 GM20480 transformed cell line human CVCL_BT41 CL:0000010 Sequence variation: Gene fusion; HGNC; 4827; HBB + HGNC; 4829; HBD; Name(s)=HBD-HBB, HBD50/HBB86, Hb Lepore-Baltimore; ClinVar=VCV000015060 (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143401 CVCL_C541 RUCH-3 cancer cell line human CVCL_C541 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21143402 CVCL_C544 FR-M-101 cancer cell line human CVCL_C544 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=23851445). Female 21143403 CVCL_BT44 GM20483 transformed cell line human CVCL_BT44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143404 CVCL_BT43 GM20482 transformed cell line human CVCL_BT43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143405 CVCL_C543 RPMI8322/CDDP-300 cancer cell line human CVCL_C543 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lymph node. Male 21143406 CVCL_C546 FR-M-134 cancer cell line human CVCL_C546 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445). Female 21143407 CVCL_BT46 GM20576 transformed cell line human CVCL_BT46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143408 CVCL_C545 FR-M-119 cancer cell line human CVCL_C545 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Male 21143409 CVCL_BT45 GM20575 transformed cell line human CVCL_BT45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143410 CVCL_C559 B9-TY1 hybridoma house mouse CVCL_C559 CL:0000010 21143411 CVCL_BT59 GM21912 transformed cell line human CVCL_BT59 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143412 CVCL_C558 B9-11 hybridoma house mouse CVCL_C558 CL:0000010 21143413 CVCL_BT58 GM21911 transformed cell line human CVCL_BT58 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Glu137Aspfs*1 (c.411delG) (p.Glu149Aspfs*1, c.447delG) (L138X); ClinVar=VCV000143565; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143414 CVCL_BT51 GM21828 transformed cell line human CVCL_BT51 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143415 CVCL_C551 S6F1 hybridoma house mouse CVCL_C551 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20701; Human ITGAL/CD11a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9579 21143416 CVCL_C550 ASH-S3 finite cell line CVCL_C550 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female 21143417 CVCL_BT50 GM21827 transformed cell line human CVCL_BT50 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143418 CVCL_C553 9.4 hybridoma house mouse CVCL_C553 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10270; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10508 21143419 CVCL_BT53 GM21830 finite cell line human CVCL_BT53 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21143420 CVCL_C552 5F12 AD3 hybridoma house mouse CVCL_C552 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01588; Human EPO. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8209 21143421 CVCL_BT52 GM21829 finite cell line human CVCL_BT52 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21143422 CVCL_BT55 GM21851 finite cell line human CVCL_BT55 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21143423 CVCL_C555 J1-31 hybridoma house mouse CVCL_C555 CL:0000010 Monoclonal antibody isotype: IgM. 21143424 CVCL_C554 G-3-5 hybridoma house mouse CVCL_C554 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P35609; Human ACTN2. 21143425 CVCL_BT54 GM21850 transformed cell line human CVCL_BT54 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143426 CVCL_C557 B9-1-3 hybridoma house mouse CVCL_C557 CL:0000010 21143427 CVCL_BT57 GM21853 finite cell line human CVCL_BT57 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21143428 CVCL_BT56 GM21852 transformed cell line human CVCL_BT56 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143429 CVCL_C556 MY904 hybridoma house mouse CVCL_C556 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9510 21143430 CVCL_C526 1255O cancer cell line human CVCL_C526 CL:0000010 Male 21143431 CVCL_BT26 GM12023 transformed cell line human CVCL_BT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143432 CVCL_C525 1242B cancer cell line human CVCL_C525 CL:0000010 Male 21143433 CVCL_BT25 GM11947 transformed cell line human CVCL_BT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143434 CVCL_C528 5-8F hybrid cell line human CVCL_C528 CL:0000010 Sequence variation: Gene fusion; HGNC; 1490; CAPZA2 + HGNC; 7029; MET; Name(s)=CAPZA2-MET (CelloPub=CLPUB00484) Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00596 Problematic cell line: Contaminated On the basis of the STR profile (PubMed=26116706) it seems to be a hybrid of HeLa and of cell line of unknown origin. Originally thought to originate from SUNE1 which has also been shown to be contaminated. 21143435 CVCL_BT28 GM12129 transformed cell line human CVCL_BT28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143436 CVCL_C527 13-9B hybrid cell line human CVCL_C527 CL:0000010 Omics: Transcriptome analysis by microarray. Problematic cell line: Contaminated Parent cell line (SUNE1) has been shown to be an hybrid of HeLa and a cell line of unknown origin. 21143437 CVCL_BT27 GM12027 transformed cell line human CVCL_BT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143438 CVCL_C529 6-10B hybrid cell line human CVCL_C529 CL:0000010 Omics: Transcriptome analysis by microarray. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00597 Problematic cell line: Contaminated On the basis of the STR profile (PubMed=26116706) it seems to be a hybrid of HeLa and of cell line of unknown origin. Originally thought to originate from SUNE1 which has also been shown to be contaminated. 21143439 CVCL_BT29 GM12355 transformed cell line human CVCL_BT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143440 CVCL_9Z92 GM09651 transformed cell line human CVCL_9Z92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143441 CVCL_9Z91 GM09650 transformed cell line human CVCL_9Z91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143442 CVCL_C520 2044L cancer cell line human CVCL_C520 CL:0000010 Derived from metastatic site: Retroperitoneal space. Male 21143443 CVCL_BT20 GM07444 transformed cell line human CVCL_BT20 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.315+1G>A (IVS2,G>A,+1); ClinVar=VCV000015438; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143444 CVCL_9Z94 GM09688 transformed cell line human CVCL_9Z94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143445 CVCL_9Z93 GM09652 transformed cell line human CVCL_9Z93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143446 CVCL_C522 2102EP cancer cell line human CVCL_C522 CL:0000010 Derived from sampling site: Testis. Omics: Deep quantitative proteome analysis Male 21143447 CVCL_BT22 GM09153 transformed cell line human CVCL_BT22 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Gln40Ter (c.118C>T) (Q39*); ClinVar=VCV000015402; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143448 CVCL_C521 2061H cancer cell line human CVCL_C521 CL:0000010 Derived from metastatic site: Lung. Male 21143449 CVCL_BT21 GM07445 transformed cell line human CVCL_BT21 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Gln40Ter (c.118C>T) (Q39*); ClinVar=VCV000015402; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.315+1G>A (IVS2,G>A,+1); ClinVar=VCV000015438; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143450 CVCL_C524 1218E cancer cell line human CVCL_C524 CL:0000010 Male 21143451 CVCL_9Z90 GM09649 transformed cell line human CVCL_9Z90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143452 CVCL_BT24 GM11858 transformed cell line human CVCL_BT24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143453 CVCL_C523 2102ER cancer cell line human CVCL_C523 CL:0000010 Derived from sampling site: Retroperitoneal lymph node. Male 21143454 CVCL_BT23 GM11071 finite cell line human CVCL_BT23 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21143455 CVCL_9Z89 GM09642 transformed cell line human CVCL_9Z89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143456 CVCL_9Z88 GM09641 transformed cell line human CVCL_9Z88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143457 CVCL_9Z85 GM09638 transformed cell line human CVCL_9Z85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143458 CVCL_9Z84 GM09637 transformed cell line human CVCL_9Z84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143459 CVCL_9Z87 GM09640 transformed cell line human CVCL_9Z87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143460 CVCL_9Z86 GM09639 transformed cell line human CVCL_9Z86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143461 CVCL_BT37 GM16529 transformed cell line human CVCL_BT37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143462 CVCL_C537 Mel-NT9-00 cancer cell line human CVCL_C537 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Female 21143463 CVCL_BT36 GM16528 transformed cell line human CVCL_BT36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143464 CVCL_C536 Mel-NT8-00 cancer cell line human CVCL_C536 CL:0000010 21143465 CVCL_BT39 GM17726 transformed cell line human CVCL_BT39 CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Thr184Argfs*36 (c.550delA); ClinVar=VCV000017621; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Arg490Gln (c.1469G>A); ClinVar=VCV000017622; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143466 CVCL_C539 PA682 PB cancer cell line human CVCL_C539 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val166Leu (c.496G>C); ClinVar=VCV000639793; Zygosity=Unspecified (PubMed=9787181) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143467 CVCL_BT38 GM16643 transformed cell line human CVCL_BT38 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Heterozygous; Note=Factor V Leiden (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu102Asp (c.306G>C) (E101D); ClinVar=VCV000015317; Zygosity=Unspecified; Note=Hb Potomac (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143468 CVCL_C538 NW145/E7 cancer cell line human CVCL_C538 HLA typing: A*23:01,23:01; B*15:01:01:01,15:01:01:01; C*01:02,01:02; DPB1*04:02,04:02; DQB1*03:01:01,03:01:01; DRB1*11:01,11:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Male 21143469 CVCL_BT31 GM13531 transformed cell line human CVCL_BT31 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; None_reported; -; Zygosity=- (Coriell) Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143470 CVCL_C531 Mel-NT2-00 cancer cell line human CVCL_C531 HLA typing: A*02:01,03:01; B*14:02,44:02:01:01; C*05:01,08:02; DPB1*02:01:02,04:01; DQB1*03:01:01,04:02; DRB1*13:03,08:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Male 21143471 CVCL_BT30 GM12492 transformed cell line human CVCL_BT30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143472 CVCL_C530 Mel-NT1-00 cancer cell line human CVCL_C530 HLA typing: A*01:01,03:01; B*35:01,57:01; DPB1*04:01; DQB1*03:01:01,05:01; DRB1*01:01,11:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Val95_His97del (c.286_294del) (p.Gly110fs, c.329_337del); Zygosity=Unspecified (PubMed=23851445). Male 21143473 CVCL_BT33 GM16265 transformed cell line human CVCL_BT33 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143474 CVCL_C533 Mel-NT4-00 cancer cell line human CVCL_C533 CL:0000010 21143475 CVCL_BT32 GM14109 transformed cell line human CVCL_BT32 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; None_reported; -; Zygosity=- (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143476 CVCL_C532 Mel-NT3-00 cancer cell line human CVCL_C532 HLA typing: A*02:01,68:01:02; B*44:02:01:01,49:02; C*06:02,07:04; DPB1*04:02,04:01; DQB1*03:01:01,02:01; DRB1*11:01:01,03:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Male 21143477 CVCL_BT35 GM16527 transformed cell line human CVCL_BT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143478 CVCL_C535 Mel-NT6-00 cancer cell line human CVCL_C535 CL:0000010 21143479 CVCL_BT34 GM16267 transformed cell line human CVCL_BT34 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143480 CVCL_C534 Mel-NT5-00 cancer cell line human CVCL_C534 HLA typing: A*68:01:02,24:02; C*06:02,02:02:02; DPB1*03:01,13:01; DQB1*06:03,02:01; DRB1*13:01,03:01:01 (PubMed=15592718). CL:0000010 Female 21143481 CVCL_9Z99 GM09693 transformed cell line human CVCL_9Z99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143482 CVCL_9Z96 GM09690 transformed cell line human CVCL_9Z96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143483 CVCL_9Z95 GM09689 transformed cell line human CVCL_9Z95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143484 CVCL_9Z98 GM09692 transformed cell line human CVCL_9Z98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143485 CVCL_9Z97 GM09691 transformed cell line human CVCL_9Z97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143486 CVCL_BT04 MADB106 cancer cell line Norway rat CVCL_BT04 CL:0000010 Breed/subspecies: Fischer 344. Female 21143487 CVCL_C504 Mel-WL cancer cell line human CVCL_C504 HLA typing: A*11:01,01:01; B*35:01,51:01:01; C*04:01:01,12:03; DPB1*04:02,10:01; DQB1*03:01:01,05:01; DRB1*01:01,11:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro81Ser (c.241C>T) (p.Thr95Ile, c.284C>T); ClinVar=VCV000664812; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Unspecified (PubMed=23851445). 21143488 CVCL_BT03 HFLT spontaneously immortalized cell line human CVCL_BT03 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21143489 CVCL_C503 Mel-SOE cancer cell line human CVCL_C503 CL:0000010 Omics: Array-based CGH. Female 21143490 CVCL_C506 huFasM3 hybridoma house mouse CVCL_C506 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11726 21143491 CVCL_BT06 MFC-GFP cancer cell line house mouse CVCL_BT06 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Stomach; forestomach. 21143492 CVCL_BT05 293Ta transformed cell line human CVCL_BT05 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21143493 CVCL_C505 Ma-Mel-KNUD cancer cell line human CVCL_C505 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=16827748; PubMed=23348503; PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu247Ter (c.740T>G); ClinVar=VCV000428210; Zygosity=Unspecified (PubMed=23851445) Omics: Transcriptome analysis by microarray. Female 21143494 CVCL_C508 833K-LC transformed cell line human CVCL_C508 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143495 CVCL_BT08 LAZ-149 transformed cell line human CVCL_BT08 From: Lazarus H.; Dana-Farber Cancer Institute; Boston; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 4823; HBA1; Zygosity=Heterozygous (Coriell); Sequence variation: Gene deletion; HGNC; 4827; HBB; Zygosity=Homozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143496 CVCL_C507 M 368 hybridoma house mouse CVCL_C507 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human melanocytes cell surface antigen M-26. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8450 21143497 CVCL_BT07 YCR finite cell line CVCL_BT07 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21143498 CVCL_C509 577ML cancer cell line human CVCL_C509 CL:0000010 Derived from metastatic site: Lung. Male 21143499 CVCL_BT09 GP-H1 finite cell line CVCL_BT09 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male 21143500 CVCL_9Z70 GM09620 transformed cell line human CVCL_9Z70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143501 CVCL_9Z72 GM09622 transformed cell line human CVCL_9Z72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143502 CVCL_9Z71 GM09621 transformed cell line human CVCL_9Z71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143503 CVCL_BT00 H-bc cancer cell line human CVCL_BT00 CL:0000010 21143504 CVCL_C500 Mel-DO cancer cell line human CVCL_C500 CL:0000010 21143505 CVCL_BT02 2BS finite cell line human CVCL_BT02 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21143506 CVCL_C502 Mel-LG cancer cell line human CVCL_C502 CL:0000010 Female 21143507 CVCL_BT01 Mao transformed cell line human CVCL_BT01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143508 CVCL_C501 Mel-LE cancer cell line human CVCL_C501 HLA typing: A*68:01:01,31:01:02; B*27:09; C*02:02:02; DPB1*04:01,03:01; DQB1*03:01:01,02:01; DRB1*04:03,03:01:02 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Male 21143509 CVCL_9Z67 GM09616 transformed cell line human CVCL_9Z67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143510 CVCL_9Z66 GM09539 transformed cell line human CVCL_9Z66 CL:0000010 Population: Caucasian; English/Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143511 CVCL_9Z69 GM09619 transformed cell line human CVCL_9Z69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143512 CVCL_9Z68 GM09617 transformed cell line human CVCL_9Z68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143513 CVCL_9Z63 GM09534 transformed cell line human CVCL_9Z63 CL:0000010 Population: Caucasian; English/Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143514 CVCL_9Z62 GM03421 transformed cell line human CVCL_9Z62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143515 CVCL_9Z65 GM09536 transformed cell line human CVCL_9Z65 CL:0000010 Population: Caucasian; English/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143516 CVCL_9Z64 GM09535 transformed cell line human CVCL_9Z64 CL:0000010 Population: Caucasian; English/Irish/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143517 CVCL_BT15 GM02303 transformed cell line human CVCL_BT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143518 CVCL_C515 MM46 CEA1-2 cancer cell line house mouse CVCL_C515 CL:0000010 Transfected with: HGNC; 1814; CEACAM1 Female Caution: Not from strain C3H/He as originally assigned but from a NIH Swiss strain derivative (DOI=10.4051/ibc.2010.2.4.0014). 21143519 CVCL_BT14 GM02267 transformed cell line human CVCL_BT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143520 CVCL_C514 MM46-APR-MUC1 cl.1 cancer cell line house mouse CVCL_C514 CL:0000010 Transfected with: HGNC; 7508; MUC1 Female Caution: Not from strain C3H/He as originally assigned but from a NIH Swiss strain derivative (DOI=10.4051/ibc.2010.2.4.0014). 21143521 CVCL_BT17 GM07405 transformed cell line human CVCL_BT17 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143522 CVCL_C517 ISOS-1 cancer cell line house mouse CVCL_C517 CL:0000010 Breed/subspecies: C.B-17/Icr-SCID Jcl. Discontinued: JCRB; IFO50515; true; Discontinued: RCB; RCB3670; true Female Characteristics: While this is a mouse cell line, it was established from a tumor formed by transplantation of a human angiosarcoma (PubMed=9459120) 21143523 CVCL_BT16 GM04930 finite cell line human CVCL_BT16 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21143524 CVCL_C516 ISO-HAS cancer cell line human CVCL_C516 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser240Arg (c.720T>A); ClinVar=VCV001504304; Zygosity=Unspecified (PubMed=10188735) Population: Japanese; Derived from metastatic site: Ear; skin. Discontinued: JCRB; IFO50514; true; Discontinued: RCB; RCB3674; true Male Doubling time: 64 hours (PubMed=10188735) 21143525 CVCL_BT19 GM07425 transformed cell line human CVCL_BT19 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Gln40Ter (c.118C>T) (Q39*); ClinVar=VCV000015402; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143526 CVCL_C519 LO-22 hybridoma house mouse CVCL_C519 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Human alpha interferons. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8619 21143527 CVCL_BT18 GM07406 transformed cell line human CVCL_BT18 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.-137C>G (-87C>G); ClinVar=VCV000015464; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.93-21G>A (IVS1,G>A,+110); ClinVar=VCV000015454; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143528 CVCL_C518 ISO-HAS-1 cancer cell line human CVCL_C518 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser240Arg (c.720T>A); ClinVar=VCV001504304; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Ear; skin. Male 21143529 CVCL_9Z81 GM09634 transformed cell line human CVCL_9Z81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143530 CVCL_9Z80 GM09633 transformed cell line human CVCL_9Z80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143531 CVCL_9Z83 GM09636 transformed cell line human CVCL_9Z83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143532 CVCL_9Z82 GM09635 transformed cell line human CVCL_9Z82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143533 CVCL_BT11 GM23080 finite cell line human CVCL_BT11 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly588_Pro590delinsValSer (c.1763_1769delGTGCTCCinsTAAG); ClinVar=VCV000101208; Zygosity=Unspecified (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143534 CVCL_C511 L1210 TGR4 cancer cell line house mouse CVCL_C511 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21143535 CVCL_C510 577MR cancer cell line human CVCL_C510 CL:0000010 Derived from metastatic site: Retroperitoneal space. Male 21143536 CVCL_BT10 GM23709 transformed cell line human CVCL_BT10 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)51 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143537 CVCL_BT13 GM02266 transformed cell line human CVCL_BT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143538 CVCL_C513 L1210-5FU-R-TC cancer cell line house mouse CVCL_C513 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21143539 CVCL_BT12 GM02232 transformed cell line human CVCL_BT12 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143540 CVCL_9Z78 GM09631 transformed cell line human CVCL_9Z78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143541 CVCL_9Z77 GM09630 transformed cell line human CVCL_9Z77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143542 CVCL_9Z79 GM09632 transformed cell line human CVCL_9Z79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143543 CVCL_9Z74 GM09627 transformed cell line human CVCL_9Z74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143544 CVCL_9Z73 GM09625 transformed cell line human CVCL_9Z73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143545 CVCL_9Z76 GM09629 transformed cell line human CVCL_9Z76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143546 CVCL_9Z75 GM09628 transformed cell line human CVCL_9Z75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143547 CVCL_KN81 PCRP-ZKSCAN3-2E1 hybridoma house mouse CVCL_KN81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143548 CVCL_KN80 PCRP-ZKSCAN3-2A9 hybridoma house mouse CVCL_KN80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143549 CVCL_TH20 HAP1 PROS1 (-) 2 cancer cell line human CVCL_TH20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9456; PROS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143550 CVCL_KN79 PCRP-ZKSCAN3-2A4 hybridoma house mouse CVCL_KN79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143551 CVCL_TH22 HAP1 PRPF40B (-) 1 cancer cell line human CVCL_TH22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25031; PRPF40B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143552 CVCL_TH21 HAP1 PRPF39 (-) cancer cell line human CVCL_TH21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20314; PRPF39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143553 CVCL_TH24 HAP1 PRPS1 (-) 2 cancer cell line human CVCL_TH24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9462; PRPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143554 CVCL_KN76 PCRP-ZKSCAN3-1E8 hybridoma house mouse CVCL_KN76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143555 CVCL_TH23 HAP1 PRPS1 (-) 1 cancer cell line human CVCL_TH23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9462; PRPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143556 CVCL_KN75 PCRP-ZKSCAN3-1E12 hybridoma house mouse CVCL_KN75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143557 CVCL_TH26 HAP1 PSEN1 (-) 1 cancer cell line human CVCL_TH26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143558 CVCL_KN78 PCRP-ZKSCAN3-1F9 hybridoma house mouse CVCL_KN78 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143559 CVCL_TH25 HAP1 PSAT1 (-) 1 cancer cell line human CVCL_TH25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19129; PSAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143560 CVCL_KN77 PCRP-ZKSCAN3-1F4 hybridoma house mouse CVCL_KN77 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143561 CVCL_TH28 HAP1 PSMB10 (-) 1 cancer cell line human CVCL_TH28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9538; PSMB10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143562 CVCL_KN72 PCRP-ZKSCAN2-1G10 hybridoma house mouse CVCL_KN72 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q63HK3; Human ZKSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143563 CVCL_TH27 HAP1 PSKH1 (-) cancer cell line human CVCL_TH27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9529; PSKH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143564 CVCL_KN71 PCRP-ZKSCAN1-1F10 hybridoma house mouse CVCL_KN71 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P17029; Human ZKSCAN1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143565 CVCL_KN74 PCRP-ZKSCAN3-1D9 hybridoma house mouse CVCL_KN74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9BRR0; Human ZKSCAN3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143566 CVCL_TH29 HAP1 PSMB10 (-) 2 cancer cell line human CVCL_TH29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9538; PSMB10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143567 CVCL_KN73 PCRP-ZKSCAN2-2C6 hybridoma house mouse CVCL_KN73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q63HK3; Human ZKSCAN2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143568 CVCL_KN90 PCRP-ZMYM3-6D7 hybridoma house mouse CVCL_KN90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q14202; Human ZMYM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143569 CVCL_TH09 HAP1 PRKX (-) 2 cancer cell line human CVCL_TH09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9441; PRKX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143570 CVCL_KN92 PCRP-ZNF134-3E11 hybridoma house mouse CVCL_KN92 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52741; Human ZNF134. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143571 CVCL_KN91 PCRP-ZNF134-1A2 hybridoma house mouse CVCL_KN91 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P52741; Human ZNF134. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143572 CVCL_TH11 HAP1 PRLR (-) 2 cancer cell line human CVCL_TH11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9446; PRLR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143573 CVCL_TH10 HAP1 PRLR (-) 1 cancer cell line human CVCL_TH10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9446; PRLR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143574 CVCL_TH13 HAP1 PRMT3 (-) 2 cancer cell line human CVCL_TH13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30163; PRMT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143575 CVCL_KN87 PCRP-ZMYM3-1H3 hybridoma house mouse CVCL_KN87 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14202; Human ZMYM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143576 CVCL_TH12 HAP1 PRMT3 (-) 1 cancer cell line human CVCL_TH12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30163; PRMT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143577 CVCL_KN86 PCRP-ZMYM3-1C11 hybridoma house mouse CVCL_KN86 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14202; Human ZMYM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143578 CVCL_TH15 HAP1 PRNP (-) 1 cancer cell line human CVCL_TH15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9449; PRNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143579 CVCL_KN89 PCRP-ZMYM3-2C3 hybridoma house mouse CVCL_KN89 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q14202; Human ZMYM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143580 CVCL_TH14 HAP1 PRMT6 (-) 1 cancer cell line human CVCL_TH14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18241; PRMT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143581 CVCL_KN88 PCRP-ZMYM3-2B9 hybridoma house mouse CVCL_KN88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q14202; Human ZMYM3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143582 CVCL_TH17 HAP1 PROCR (-) cancer cell line human CVCL_TH17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9452; PROCR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143583 CVCL_KN83 PCRP-ZKSCAN7-2B10 hybridoma house mouse CVCL_KN83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P0L1; Human ZKSCAN7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143584 CVCL_TH16 HAP1 PRNP (-) 2 cancer cell line human CVCL_TH16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9449; PRNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143585 CVCL_KN82 PCRP-ZKSCAN7-1C4 hybridoma house mouse CVCL_KN82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9P0L1; Human ZKSCAN7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143586 CVCL_TH19 HAP1 PROS1 (-) 1 cancer cell line human CVCL_TH19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9456; PROS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143587 CVCL_KN85 PCRP-ZMAT4-1A6 hybridoma house mouse CVCL_KN85 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H898; Human ZMAT4. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143588 CVCL_TH18 HAP1 PRODH (-) 1 cancer cell line human CVCL_TH18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9453; PRODH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143589 CVCL_KN84 PCRP-ZMAT2-1E5 hybridoma house mouse CVCL_KN84 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96NC0; Human ZMAT2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143590 CVCL_KN58 PCRP-ZFYVE20-1C3 hybridoma house mouse CVCL_KN58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H1K0; Human RBSN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143591 CVCL_KN57 PCRP-ZFYVE19-3C5 hybridoma house mouse CVCL_KN57 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96K21; Human ZFYVE19. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143592 CVCL_TH00 HAP1 PRKD3 (-) cancer cell line human CVCL_TH00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9408; PRKD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143593 CVCL_KN59 PCRP-ZFYVE20-1E2 hybridoma house mouse CVCL_KN59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H1K0; Human RBSN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143594 CVCL_TH02 HAP1 PRKDC (-) 2 cancer cell line human CVCL_TH02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9413; PRKDC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143595 CVCL_KN54 PCRP-ZFP92-2A7 hybridoma house mouse CVCL_KN54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A6NM28; Human ZFP92. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143596 CVCL_TH01 HAP1 PRKDC (-) 1 cancer cell line human CVCL_TH01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9413; PRKDC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143597 CVCL_KN53 PCRP-ZFP90-1C5 hybridoma house mouse CVCL_KN53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TF47; Human ZFP90. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143598 CVCL_TH04 HAP1 PRKG2 (-) 2 cancer cell line human CVCL_TH04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9416; PRKG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143599 CVCL_KN56 PCRP-ZFPM2-2D5 hybridoma house mouse CVCL_KN56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WW38; Human ZFPM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143600 CVCL_TH03 HAP1 PRKG2 (-) 1 cancer cell line human CVCL_TH03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9416; PRKG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143601 CVCL_KN55 PCRP-ZFP92-2B9 hybridoma house mouse CVCL_KN55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A6NM28; Human ZFP92. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143602 CVCL_TH06 HAP1 PRKRA (-) 2 cancer cell line human CVCL_TH06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9438; PRKRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143603 CVCL_KN50 PCRP-ZFP41-1A1 hybridoma house mouse CVCL_KN50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N8Y5; Human ZFP41. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143604 CVCL_TH05 HAP1 PRKRA (-) 1 cancer cell line human CVCL_TH05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9438; PRKRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143605 CVCL_TH08 HAP1 PRKX (-) 1 cancer cell line human CVCL_TH08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9441; PRKX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143606 CVCL_KN52 PCRP-ZFP64-1H2 hybridoma house mouse CVCL_KN52 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NPA5; Human ZFP64. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143607 CVCL_TH07 HAP1 PRKRA (-) 3 cancer cell line human CVCL_TH07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9438; PRKRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143608 CVCL_KN51 PCRP-ZFP64-1A10 hybridoma house mouse CVCL_KN51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NPA5; Human ZFP64. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143609 CVCL_KN70 PCRP-ZIM2-1F10 hybridoma house mouse CVCL_KN70 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZV7; Human ZIM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143610 CVCL_KN69 PCRP-ZIM2-1D10 hybridoma house mouse CVCL_KN69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NZV7; Human ZIM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143611 CVCL_KN68 PCRP-ZIM2-1C2 hybridoma house mouse CVCL_KN68 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NZV7; Human ZIM2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143612 CVCL_KN65 PCRP-ZHX3-1G3 hybridoma house mouse CVCL_KN65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H4I2; Human ZHX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143613 CVCL_KN64 PCRP-ZHX3-1D11 hybridoma house mouse CVCL_KN64 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9H4I2; Human ZHX3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143614 CVCL_KN67 PCRP-ZIC2-2A2 hybridoma house mouse CVCL_KN67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O95409; Human ZIC2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143615 CVCL_KN66 PCRP-ZIC1-1E3 hybridoma house mouse CVCL_KN66 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15915; Human ZIC1. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143616 CVCL_KN61 PCRP-ZFYVE20-2B9 hybridoma house mouse CVCL_KN61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H1K0; Human RBSN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143617 CVCL_KN60 PCRP-ZFYVE20-1F6 hybridoma house mouse CVCL_KN60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H1K0; Human RBSN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143618 CVCL_KN63 PCRP-ZHX2-1B2 hybridoma house mouse CVCL_KN63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y6X8; Human ZHX2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143619 CVCL_KN62 PCRP-ZFYVE20-2E3 hybridoma house mouse CVCL_KN62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H1K0; Human RBSN. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143620 CVCL_KN39 PCRP-ZCCHC7-1H5 hybridoma house mouse CVCL_KN39 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143621 CVCL_KN36 PCRP-ZCCHC7-1D1 hybridoma house mouse CVCL_KN36 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143622 CVCL_KN35 PCRP-ZCCHC7-1C2 hybridoma house mouse CVCL_KN35 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143623 CVCL_KN38 PCRP-ZCCHC7-1F2 hybridoma house mouse CVCL_KN38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143624 CVCL_KN37 PCRP-ZCCHC7-1E3 hybridoma house mouse CVCL_KN37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143625 CVCL_KN32 PCRP-ZCCHC7-1A3 hybridoma house mouse CVCL_KN32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143626 CVCL_KN31 PCRP-ZCCHC7-1A2 hybridoma house mouse CVCL_KN31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143627 CVCL_KN34 PCRP-ZCCHC7-1C1 hybridoma house mouse CVCL_KN34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143628 CVCL_KN33 PCRP-ZCCHC7-1B4 hybridoma house mouse CVCL_KN33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143629 CVCL_KN30 PCRP-ZC3H7A-2G9 hybridoma house mouse CVCL_KN30 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8IWR0; Human ZC3H7A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143630 CVCL_KN47 PCRP-ZFP28-2B8 hybridoma house mouse CVCL_KN47 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q8NHY6; Human ZFP28. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143631 CVCL_KN46 PCRP-ZFAT-2D2 hybridoma house mouse CVCL_KN46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P243; Human ZFAT. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143632 CVCL_KN49 PCRP-ZFP3-1B3 hybridoma house mouse CVCL_KN49 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q96NJ6; Human ZFP3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143633 CVCL_KN48 PCRP-ZFP3-1A5 hybridoma house mouse CVCL_KN48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96NJ6; Human ZFP3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143634 CVCL_KN43 PCRP-ZEB2-1C6 hybridoma house mouse CVCL_KN43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O60315; Human ZEB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143635 CVCL_KN42 PCRP-ZCCHC7-2H8 hybridoma house mouse CVCL_KN42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143636 CVCL_KN45 PCRP-ZEB2-2A11 hybridoma house mouse CVCL_KN45 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60315; Human ZEB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143637 CVCL_KN44 PCRP-ZEB2-1E11 hybridoma house mouse CVCL_KN44 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O60315; Human ZEB2. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143638 CVCL_KN41 PCRP-ZCCHC7-2F4 hybridoma house mouse CVCL_KN41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143639 CVCL_KN40 PCRP-ZCCHC7-2E4 hybridoma house mouse CVCL_KN40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8N3Z6; Human ZCCHC7. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143640 CVCL_C584 FM37 cancer cell line human CVCL_C584 HLA typing: A*02,03; B*07,40; C*03 (PubMed=7656272) CL:0000010 Derived from metastatic site: Not specified. Unspecified 21143641 CVCL_BT84 GM22052 transformed cell line human CVCL_BT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143642 CVCL_C583 FM28 cancer cell line human CVCL_C583 HLA typing: A*01,02; B*08,15 (PubMed=7656272); HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*07:01:01,07:02; DPB1*04:01,01:01:01; DQB1*03:02,02:01; DRB1*04:01:01,03:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Pro (c.1637A>C); ClinVar=VCV000375898; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Skin. Omics: Array-based CGH Male 21143643 CVCL_BT83 GM22051 transformed cell line human CVCL_BT83 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly708Asp (c.2123G>A); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143644 CVCL_C586 624.28 Mel cancer cell line human CVCL_C586 HLA typing: A*11:01,03:01; B*07:02,14:02; C*08:02; DPB1*20:01,15:01; DQB1*03:01:01,02:01; DRB1*04:01:01,07:01 (PubMed=15592718) CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21143645 CVCL_BT86 GM22068 transformed cell line human CVCL_BT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143646 CVCL_BT85 GM22053 finite cell line human CVCL_BT85 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143647 CVCL_C585 SH-39-HOM cancer cell line human CVCL_C585 HLA typing: A*30:01,25:01; B*18:01,44:03:01; C*16:01,12:03; DPB1*03:01,16:01; DQB1*03:01:01,02:01; DRB1*11:03:01,07:01 (PubMed=15592718). CL:0000010 Male 21143648 CVCL_C588 624.38 Mel cancer cell line human CVCL_C588 HLA typing: A*03:01,03:02; B*14:01,07:02; DPB1*20:01,15:01; DQB1*03:01:01,02:01; DRB1*04:01,07:01 (PubMed=15592718) CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21143649 CVCL_BT88 GM22070 transformed cell line human CVCL_BT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143650 CVCL_C587 FM48 cancer cell line human CVCL_C587 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21143651 CVCL_BT87 GM22069 finite cell line human CVCL_BT87 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143652 CVCL_C589 FM55M1 cancer cell line human CVCL_C589 HLA typing: A*01,02; B*15,28; C*03 (PubMed=7656272); HLA typing: A*02:01,01:01; B*08:01,15:01:01:01; C*03:04,07:01:01; DPB1*04:01; DQB1*03:02,03:01:01; DRB1*04:01:01,11:03:01 (PubMed=15592718) CL:0000010 Derived from metastatic site: Hypodermis. Male 21143653 CVCL_BT89 GM22071 finite cell line human CVCL_BT89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143654 CVCL_KN18 PCRP-ZBTB48-3C4 hybridoma house mouse CVCL_KN18 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10074; Human ZBTB48. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143655 CVCL_KN17 PCRP-ZBTB46-2C1 hybridoma house mouse CVCL_KN17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86UZ6; Human ZBTB46. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143656 CVCL_KN19 PCRP-ZBTB48-3G1 hybridoma house mouse CVCL_KN19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10074; Human ZBTB48. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143657 CVCL_C580 FM3.29 cancer cell line human CVCL_C580 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Right inguinal lymph node. Female 21143658 CVCL_BT80 GM22034 transformed cell line human CVCL_BT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143659 CVCL_KN14 PCRP-ZBTB39-1A11 hybridoma house mouse CVCL_KN14 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15060; Human ZBTB39. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143660 CVCL_KN13 PCRP-ZBTB37-1G10 hybridoma house mouse CVCL_KN13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5TC79; Human ZBTB37. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143661 CVCL_C582 FM9 cancer cell line human CVCL_C582 HLA typing: A*01,03; B*08,35; C*04 (PubMed=7656272) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Gly (c.95A>G); ClinVar=VCV000017578; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000007827; Zygosity=Unspecified (PubMed=17260012) Derived from metastatic site: Not specified. Omics: Array-based CGH Female 21143662 CVCL_BT82 GM22041 finite cell line human CVCL_BT82 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21143663 CVCL_KN16 PCRP-ZBTB46-2B8 hybridoma house mouse CVCL_KN16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q86UZ6; Human ZBTB46. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143664 CVCL_C581 FM6 cancer cell line human CVCL_C581 HLA typing: A*01,02; B*07,08 (PubMed=7656272); HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01:01,07:02; DPB1*04:01,01:01:01; DQB1*06:02,02:01; DRB1*03:01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=17260012; PubMed=25728708) Derived from metastatic site: Not specified. Omics: Array-based CGH Male 21143665 CVCL_BT81 GM22040 transformed cell line human CVCL_BT81 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143666 CVCL_KN15 PCRP-ZBTB46-1D1 hybridoma house mouse CVCL_KN15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q86UZ6; Human ZBTB46. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143667 CVCL_KN10 PCRP-ZBTB3-2G4 hybridoma house mouse CVCL_KN10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9H5J0; Human ZBTB3. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143668 CVCL_KN12 PCRP-ZBTB32-2D2 hybridoma house mouse CVCL_KN12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9Y2Y4; Human ZBTB32. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143669 CVCL_KN11 PCRP-ZBTB32-2A7 hybridoma house mouse CVCL_KN11 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9Y2Y4; Human ZBTB32. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143670 CVCL_C595 FM58 cancer cell line human CVCL_C595 HLA typing: A*02:01; B*07:02,15:01:01:01; C*03:04,07:02; DPB1*02:01:02,04:01; DQB1*03:02,05:01; DRB1*10:01,04:01:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Skin. Omics: Array-based CGH Male 21143671 CVCL_BT95 GM22083 transformed cell line human CVCL_BT95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143672 CVCL_C594 FM57 cancer cell line human CVCL_C594 HLA typing: A*02:01; B*07:02,51:01:01; C*07:02,15:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. 21143673 CVCL_BT94 GM22082 transformed cell line human CVCL_BT94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143674 CVCL_C597 FM60 cancer cell line human CVCL_C597 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Unspecified (PubMed=9288767). Unspecified 21143675 CVCL_BT97 GM22085 finite cell line human CVCL_BT97 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21143676 CVCL_C596 FM59 cancer cell line human CVCL_C596 CL:0000010 Unspecified 21143677 CVCL_BT96 GM22084 transformed cell line human CVCL_BT96 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143678 CVCL_C599 FM66 cancer cell line human CVCL_C599 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21143679 CVCL_BT99 GM22101 finite cell line human CVCL_BT99 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143680 CVCL_BT98 GM22100 transformed cell line human CVCL_BT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143681 CVCL_C598 Me-116 cancer cell line human CVCL_C598 HLA typing: A*02:01,01:01; B*52:01:01,18:01; DPB1*03:01,13:01; DQB1*03:03:02,02:01; DRB1*03:01:01,07:01 (PubMed=15592718). CL:0000010 Male 21143682 CVCL_KN29 PCRP-ZC3H7A-1D6 hybridoma house mouse CVCL_KN29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8IWR0; Human ZC3H7A. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143683 CVCL_KN28 PCRP-ZC3H15-1D1 hybridoma house mouse CVCL_KN28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WU90; Human ZC3H15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143684 CVCL_C591 FM55p cancer cell line human CVCL_C591 HLA typing: A*01,02; B*15,28; C*03 (PubMed=7656272); HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*03:04,07:01:01; DPB1*04:01; DQB1*03:02,03:01:01; DRB1*04:02,04:01:01 (PubMed=15592718) CL:0000010 Derived from sampling site: Skin. Male 21143685 CVCL_BT91 GM22079 finite cell line human CVCL_BT91 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143686 CVCL_KN25 PCRP-ZBTB7C-4E10 hybridoma house mouse CVCL_KN25 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A1YPR0; Human ZBTB7C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143687 CVCL_C590 FM55M2 cancer cell line human CVCL_C590 HLA typing: A*01,02; B*15,28; C*03 (PubMed=7656272); HLA typing: A*01:01,02:01; B*08:01,15:01:01:01; C*07:01:01,03:04; DPB1*04:01,13:01; DQB1*03:02,03:01:01; DRB1*11:01,04:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu199Ter (c.596T>A); ClinVar=VCV000376329; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg455Ter (c.1363C>T); ClinVar=VCV000126837; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Hypodermis. Omics: Array-based CGH Male 21143688 CVCL_BT90 GM22078 transformed cell line human CVCL_BT90 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155His (c.464G>A); ClinVar=VCV000008468; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143689 CVCL_KN24 PCRP-ZBTB7C-2B11 hybridoma house mouse CVCL_KN24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; A1YPR0; Human ZBTB7C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143690 CVCL_C593 FM56 cancer cell line human CVCL_C593 HLA typing: A*31:01:02,68:01:02; B*27:05:02,44:02; C*07:01:01; DPB1*04:01; DQB1*03:02,03:01:01; DRB1*04:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=23851445) Omics: Array-based CGH. Unspecified 21143691 CVCL_BT93 GM22081 transformed cell line human CVCL_BT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143692 CVCL_KN27 PCRP-ZC3H15-1C12 hybridoma house mouse CVCL_KN27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WU90; Human ZC3H15. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143693 CVCL_C592 FM55p.R22.2 cancer cell line human CVCL_C592 CL:0000010 Derived from sampling site: Skin. Male 21143694 CVCL_BT92 GM22080 transformed cell line human CVCL_BT92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143695 CVCL_KN26 PCRP-ZBTB7C-4E12 hybridoma house mouse CVCL_KN26 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A1YPR0; Human ZBTB7C. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143696 CVCL_KN21 PCRP-ZBTB5-1C4 hybridoma house mouse CVCL_KN21 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15062; Human ZBTB5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143697 CVCL_KN20 PCRP-ZBTB5-1B3 hybridoma house mouse CVCL_KN20 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O15062; Human ZBTB5. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143698 CVCL_KN23 PCRP-ZBTB7B-1F7 hybridoma house mouse CVCL_KN23 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15156; Human ZBTB7B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143699 CVCL_KN22 PCRP-ZBTB7B-1B6 hybridoma house mouse CVCL_KN22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O15156; Human ZBTB7B. Part of: NIH Protein Capture Reagents Program (PCRP) hybridoma 21143700 CVCL_L939 GM00305 finite cell line human CVCL_L939 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00094; true Female 21143701 CVCL_KX39 PathHunter CHO-K1 GPR15 beta-arrestin spontaneously immortalized cell line CVCL_KX39 CL:0000010 Transfected with: HGNC; 4469; GPR15; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143702 CVCL_L937 GM00286 finite cell line human CVCL_L937 CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Val166Gly (c.497T>G) (553T>G); ClinVar=VCV000558415; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00058; true Male 21143703 CVCL_KX37 PathHunter CHO-K1 GPR148 beta-arrestin spontaneously immortalized cell line CVCL_KX37 CL:0000010 Transfected with: HGNC; 23623; GPR148; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143704 CVCL_L938 GM00288 finite cell line human CVCL_L938 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; GM00095; true Male 21143705 CVCL_KX38 PathHunter CHO-K1 GPR149 beta-arrestin spontaneously immortalized cell line CVCL_KX38 CL:0000010 Transfected with: HGNC; 23627; GPR149; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143706 CVCL_L935 GM00282 finite cell line human CVCL_L935 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00061; true Female 21143707 CVCL_KX35 PathHunter CHO-K1 GPR143 beta-arrestin spontaneously immortalized cell line CVCL_KX35 CL:0000010 Transfected with: HGNC; 20145; GPR143; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143708 CVCL_L936 GM00283 finite cell line human CVCL_L936 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00102; true Female 21143709 CVCL_KX36 PathHunter CHO-K1 GPR146 beta-arrestin spontaneously immortalized cell line CVCL_KX36 CL:0000010 Transfected with: HGNC; 21718; GPR146; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143710 CVCL_L933 XP40BE LCL transformed cell line human CVCL_L933 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143711 CVCL_KX33 PathHunter CHO-K1 GPR141 beta-arrestin spontaneously immortalized cell line CVCL_KX33 CL:0000010 Transfected with: HGNC; 19997; GPR141; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143712 CVCL_L934 GM00260 finite cell line human CVCL_L934 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00069; true Male 21143713 CVCL_KX34 PathHunter CHO-K1 GPR142 beta-arrestin spontaneously immortalized cell line CVCL_KX34 CL:0000010 Transfected with: HGNC; 20088; GPR142; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143714 CVCL_L931 GM13293 transformed cell line human CVCL_L931 HLA typing: A*24:CWFP,30:AUX; B*40:AZAY,42:01; C*03:04,17:MN; DRB1*03:02,04:04 (IPD-IMGT/HLA=17383) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21143715 CVCL_KX31 PathHunter CHO-K1 GPR137 beta-arrestin spontaneously immortalized cell line CVCL_KX31 CL:0000010 Transfected with: HGNC; 24300; GPR137; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143716 CVCL_L932 GM13294 transformed cell line human CVCL_L932 HLA typing: A*30:01,33:03; B*15:10,42:02; C*03:04,17:MN; DRB1*08:04,12:CVT (IPD-IMGT/HLA=15331) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21143717 CVCL_KX32 PathHunter CHO-K1 GPR139 beta-arrestin spontaneously immortalized cell line CVCL_KX32 CL:0000010 Transfected with: HGNC; 19995; GPR139; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143718 CVCL_L930 XP1PW finite cell line human CVCL_L930 CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143719 CVCL_KX30 PathHunter CHO-K1 GPR135 beta-arrestin spontaneously immortalized cell line CVCL_KX30 CL:0000010 Transfected with: HGNC; 19991; GPR135; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143720 CVCL_L948 GM03314 finite cell line human CVCL_L948 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143721 CVCL_KX48 PathHunter CHO-K1 GPR176 beta-arrestin spontaneously immortalized cell line CVCL_KX48 CL:0000010 Transfected with: HGNC; 32370; GPR176; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143722 CVCL_L949 GM03315 transformed cell line human CVCL_L949 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143723 CVCL_KX49 PathHunter CHO-K1 GPR18 beta-arrestin spontaneously immortalized cell line CVCL_KX49 CL:0000010 Transfected with: HGNC; 4472; GPR18; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143724 CVCL_L946 GM03948 finite cell line human CVCL_L946 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143725 CVCL_KX46 PathHunter CHO-K1 GPR171 beta-arrestin spontaneously immortalized cell line CVCL_KX46 CL:0000010 Transfected with: HGNC; 30057; GPR171; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143726 CVCL_L947 GM03949 transformed cell line human CVCL_L947 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143727 CVCL_KX47 PathHunter CHO-K1 GPR173 beta-arrestin spontaneously immortalized cell line CVCL_KX47 CL:0000010 Transfected with: HGNC; 18186; GPR173; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143728 CVCL_L944 GM00730 finite cell line human CVCL_L944 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM00238; true Female 21143729 CVCL_KX44 PathHunter CHO-K1 GPR161 beta-arrestin spontaneously immortalized cell line CVCL_KX44 CL:0000010 Transfected with: HGNC; 23694; GPR161; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143730 CVCL_L945 GM02355 finite cell line human CVCL_L945 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143731 CVCL_KX45 PathHunter CHO-K1 GPR162 beta-arrestin spontaneously immortalized cell line CVCL_KX45 CL:0000010 Transfected with: HGNC; 16693; GPR162; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143732 CVCL_L942 1411HRQmet cancer cell line human CVCL_L942 CL:0000010 Derived from metastatic site: Pelvis. Male 21143733 CVCL_KX42 PathHunter CHO-K1 GPR152 beta-arrestin spontaneously immortalized cell line CVCL_KX42 CL:0000010 Transfected with: HGNC; 23622; GPR152; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143734 CVCL_L943 46BR finite cell line human CVCL_L943 CL:0000010 Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Glu566Lys (c.1696G>A); ClinVar=VCV000016775; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Arg771Trp (c.2311C>T); ClinVar=VCV000016776; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143735 CVCL_KX43 PathHunter CHO-K1 GPR157 beta-arrestin spontaneously immortalized cell line CVCL_KX43 CL:0000010 Transfected with: HGNC; 23687; GPR157; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143736 CVCL_L940 GM00376 finite cell line human CVCL_L940 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00099; true Female 21143737 CVCL_KX40 PathHunter CHO-K1 GPR150 beta-arrestin spontaneously immortalized cell line CVCL_KX40 CL:0000010 Transfected with: HGNC; 23628; GPR150; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143738 CVCL_L941 GM00306 finite cell line human CVCL_L941 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00051; true Male 21143739 CVCL_KX41 PathHunter CHO-K1 GPR151 beta-arrestin spontaneously immortalized cell line CVCL_KX41 CL:0000010 Transfected with: HGNC; 23624; GPR151; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143740 CVCL_L919 ME17 [Human melanoma] cancer cell line human CVCL_L919 CL:0000010 Population: Japanese. 21143741 CVCL_KX19 PathHunter CHO-K1 GPR101 beta-arrestin spontaneously immortalized cell line CVCL_KX19 CL:0000010 Transfected with: HGNC; 14963; GPR101; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143742 CVCL_L917 ME10 cancer cell line human CVCL_L917 CL:0000010 Population: Japanese. 21143743 CVCL_KX17 PathHunter CHO-K1 GLP2R beta-arrestin spontaneously immortalized cell line CVCL_KX17 CL:0000010 Transfected with: HGNC; 4325; GLP2R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143744 CVCL_L918 ME16 cancer cell line human CVCL_L918 CL:0000010 Population: Japanese. 21143745 CVCL_KX18 PathHunter CHO-K1 GPR1 beta-arrestin spontaneously immortalized cell line CVCL_KX18 CL:0000010 Transfected with: HGNC; 4463; CMKLR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143746 CVCL_L915 ME8 cancer cell line human CVCL_L915 CL:0000010 Population: Japanese. 21143747 CVCL_KX15 PathHunter CHO-K1 GLP1R beta-arrestin spontaneously immortalized cell line CVCL_KX15 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143748 CVCL_L916 ME9 cancer cell line human CVCL_L916 CL:0000010 Population: Japanese. 21143749 CVCL_KX16 PathHunter CHO-K1 GLP1R beta-arrestin-1 spontaneously immortalized cell line CVCL_KX16 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143750 CVCL_L913 ME5 cancer cell line human CVCL_L913 CL:0000010 Population: Japanese. 21143751 CVCL_KX13 PathHunter CHO-K1 GHSR1b beta-arrestin spontaneously immortalized cell line CVCL_KX13 CL:0000010 Transfected with: HGNC; 4267; GHSR (isoform 1b); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143752 CVCL_L914 ME7 cancer cell line human CVCL_L914 CL:0000010 Population: Japanese. 21143753 CVCL_KX14 PathHunter CHO-K1 GIPR beta-arrestin spontaneously immortalized cell line CVCL_KX14 CL:0000010 Transfected with: HGNC; 4271; GIPR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143754 CVCL_L911 ME1 cancer cell line human CVCL_L911 CL:0000010 Population: Japanese. 21143755 CVCL_KX11 PathHunter CHO-K1 GCGR beta-arrestin spontaneously immortalized cell line CVCL_KX11 CL:0000010 Transfected with: HGNC; 4192; GCGR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143756 CVCL_L912 ME2 cancer cell line human CVCL_L912 CL:0000010 Population: Japanese. 21143757 CVCL_KX12 PathHunter CHO-K1 GCGR beta-arrestin-1 spontaneously immortalized cell line CVCL_KX12 CL:0000010 Transfected with: HGNC; 4192; GCGR; Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143758 CVCL_L910 NAKT-15 transformed cell line human CVCL_L910 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Secretes insulin in response to glucose stimulation and nonglucose secretagogues, and expresses proteins characteristic of beta-cells; Characteristics: Because it has been transduced by two constructs containing LoxP sites, transfection with the Cre recombinase eliminates both the SV40 T gene and TERT thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with two retroviral vectors: 1) SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by two loxP sites and 2) SSR#69 (MoMLV/LTR-LoxP-HygroR-HSV/TK-IRES-SV40T-LoxP-NeoR-MoMLV/LTR) expressing HygroR, HSV-1 TK and SV40 T-antigen flanked by two loxP sites 21143759 CVCL_KX10 PathHunter CHO-K1 GALR2 beta-arrestin spontaneously immortalized cell line CVCL_KX10 CL:0000010 Transfected with: HGNC; 4133; GALR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143760 CVCL_L928 B1A2A spontaneously immortalized cell line CVCL_L928 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Kidney. Male 21143761 CVCL_KX28 PathHunter CHO-K1 GPR123 beta-arrestin spontaneously immortalized cell line CVCL_KX28 CL:0000010 Transfected with: HGNC; 13838; ADGRA1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143762 CVCL_L929 B1A2A5 spontaneously immortalized cell line CVCL_L929 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Kidney. Male 21143763 CVCL_KX29 PathHunter CHO-K1 GPR132 beta-arrestin spontaneously immortalized cell line CVCL_KX29 CL:0000010 Transfected with: HGNC; 17482; GPR132; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143764 CVCL_L926 XPH1CH finite cell line human CVCL_L926 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Val125Ter (c.376C>T); Zygosity=Heterozygous (from familial inference of XP2CH) Population: Caucasian; Russian Armenian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143765 CVCL_KX26 PathHunter CHO-K1 GPR120S beta-arrestin spontaneously immortalized cell line CVCL_KX26 CL:0000010 Transfected with: HGNC; 19061; FFAR4 (isoform 2); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143766 CVCL_L927 BHK 21/13 subline B1 spontaneously immortalized cell line CVCL_L927 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Kidney. Male 21143767 CVCL_KX27 PathHunter CHO-K1 GPR120S beta-arrestin-1 spontaneously immortalized cell line CVCL_KX27 CL:0000010 Transfected with: HGNC; 19061; FFAR4 (isoform 2); Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143768 CVCL_L924 ME22 cancer cell line human CVCL_L924 CL:0000010 Population: Japanese. 21143769 CVCL_KX24 PathHunter CHO-K1 GPR12 beta-arrestin spontaneously immortalized cell line CVCL_KX24 CL:0000010 Transfected with: HGNC; 4466; GPR12; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143770 CVCL_L925 ME23 cancer cell line human CVCL_L925 CL:0000010 Population: Japanese. 21143771 CVCL_KX25 PathHunter CHO-K1 GPR120L beta-arrestin spontaneously immortalized cell line CVCL_KX25 CL:0000010 Transfected with: HGNC; 19061; FFAR4 (isoform 1); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143772 CVCL_L922 ME20 cancer cell line human CVCL_L922 CL:0000010 Population: Japanese. 21143773 CVCL_KX22 PathHunter CHO-K1 GPR109A beta-arrestin spontaneously immortalized cell line CVCL_KX22 CL:0000010 Transfected with: HGNC; 24827; HCAR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143774 CVCL_L923 ME21 cancer cell line human CVCL_L923 CL:0000010 Population: Japanese. 21143775 CVCL_KX23 PathHunter CHO-K1 GPR109B beta-arrestin spontaneously immortalized cell line CVCL_KX23 CL:0000010 Transfected with: HGNC; 16824; HCAR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143776 CVCL_L920 ME18 cancer cell line human CVCL_L920 CL:0000010 Population: Japanese. 21143777 CVCL_KX20 PathHunter CHO-K1 GPR103 beta-arrestin spontaneously immortalized cell line CVCL_KX20 CL:0000010 Transfected with: HGNC; 15565; QRFPR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143778 CVCL_L921 ME19 cancer cell line human CVCL_L921 CL:0000010 Population: Japanese. 21143779 CVCL_KX21 PathHunter CHO-K1 GPR107 beta-arrestin spontaneously immortalized cell line CVCL_KX21 CL:0000010 Transfected with: HGNC; 17830; GPR107; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143780 CVCL_L908 6.1.7 transformed cell line house mouse CVCL_L908 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143781 CVCL_KX08 PathHunter CHO-K1 FXR Protein Interaction spontaneously immortalized cell line CVCL_KX08 CL:0000010 Transfected with: HGNC; 7967; NR1H4; Transfected with: HGNC; 7669; NCOA2 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143782 CVCL_L909 EndoC-betaH1 transformed cell line human CVCL_L909 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Sex assignment derived from omics analysis Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me2 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by RNAseq Female Characteristics: Secretes insulin in response to glucose challenge; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=26901817) Doubling time: 5 days (PubMed=21865645) 21143783 CVCL_KX09 PathHunter CHO-K1 GALR1 beta-arrestin spontaneously immortalized cell line CVCL_KX09 CL:0000010 Transfected with: HGNC; 4132; GALR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143784 CVCL_L906 6.1.1 transformed cell line house mouse CVCL_L906 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143785 CVCL_KX06 PathHunter CHO-K1 FPRL1 beta-arrestin spontaneously immortalized cell line CVCL_KX06 CL:0000010 Transfected with: HGNC; 3827; FPR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143786 CVCL_L907 6.1.11 transformed cell line house mouse CVCL_L907 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143787 CVCL_KX07 PathHunter CHO-K1 FSHR beta-arrestin spontaneously immortalized cell line CVCL_KX07 CL:0000010 Transfected with: HGNC; 3969; FSHR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143788 CVCL_L904 427.1 transformed cell line house mouse CVCL_L904 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143789 CVCL_KX04 PathHunter CHO-K1 FFAR2 beta-arrestin spontaneously immortalized cell line CVCL_KX04 CL:0000010 Transfected with: HGNC; 4501; FFAR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143790 CVCL_L905 427.1.86 transformed cell line house mouse CVCL_L905 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143791 CVCL_KX05 PathHunter CHO-K1 FPR1 beta-arrestin spontaneously immortalized cell line CVCL_KX05 CL:0000010 Transfected with: HGNC; 3826; FPR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143792 CVCL_KX02 PathHunter CHO-K1 F2R beta-arrestin spontaneously immortalized cell line CVCL_KX02 CL:0000010 Transfected with: HGNC; 3537; F2R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143793 CVCL_L902 PC-1.2 cancer cell line CVCL_L902 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U7QTX5; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Unspecified (from parent cell line) Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Male 21143794 CVCL_L903 1308.1 transformed cell line house mouse CVCL_L903 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thymus Cell type=Stromal cell.; Breed/subspecies: (C57BL/6J x SJL/J) F2 transgenic. Unspecified 21143795 CVCL_KX03 PathHunter CHO-K1 F2RL3 beta-arrestin spontaneously immortalized cell line CVCL_KX03 CL:0000010 Transfected with: HGNC; 3540; F2RL3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143796 CVCL_KX00 PathHunter CHO-K1 EDNRB beta-arrestin spontaneously immortalized cell line CVCL_KX00 CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143797 CVCL_L900 PC-1 [Hamster] cancer cell line CVCL_L900 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U7QTX5; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Unspecified (PubMed=2173932) Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Male Doubling time: 38 hours (PubMed=2539915); 22 hours (PubMed=7728976) 21143798 CVCL_KX01 PathHunter CHO-K1 ERalpha Protein Interaction spontaneously immortalized cell line CVCL_KX01 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: HGNC; 9237; PPARGC1A Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143799 CVCL_L901 PC-1.0 cancer cell line CVCL_L901 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U7QTX5; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Unspecified (PubMed=2173932) Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Male 21143800 CVCL_TR56 HAP1 TAOK2 (-) 1 cancer cell line human CVCL_TR56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16835; TAOK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143801 CVCL_U356 mPitA-9 transformed cell line house mouse CVCL_U356 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143802 CVCL_TR57 HAP1 TAOK2 (-) 2 cancer cell line human CVCL_TR57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16835; TAOK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143803 CVCL_U357 mPitA-7 transformed cell line house mouse CVCL_U357 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143804 CVCL_TR54 HAP1 TAOK1 (-) 1 cancer cell line human CVCL_TR54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29259; TAOK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143805 CVCL_U354 LbetaT4 transformed cell line house mouse CVCL_U354 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6 x BALB/c transgenic. 21143806 CVCL_TR55 HAP1 TAOK1 (-) 2 cancer cell line human CVCL_TR55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29259; TAOK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143807 CVCL_U355 TalphaT1 transformed cell line house mouse CVCL_U355 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6 x BALB/c transgenic. Unspecified 21143808 CVCL_TR58 HAP1 TAOK3 (-) 1 cancer cell line human CVCL_TR58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18133; TAOK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143809 CVCL_U358 mPitA-17 transformed cell line house mouse CVCL_U358 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143810 CVCL_TR59 HAP1 TAOK3 (-) 2 cancer cell line human CVCL_TR59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18133; TAOK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143811 CVCL_U359 mPitA-18 transformed cell line house mouse CVCL_U359 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143812 CVCL_1L11 GM14552 transformed cell line human CVCL_1L11 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143813 CVCL_1L12 GM14574 transformed cell line human CVCL_1L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143814 CVCL_1L10 GM14551 transformed cell line human CVCL_1L10 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Thr737Asn (c.2210C>A); ClinVar=VCV000972796; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143815 CVCL_1L04 GM14463 transformed cell line human CVCL_1L04 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gln124Serfs*18 (c.366delT); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143816 CVCL_1L05 GM14484 transformed cell line human CVCL_1L05 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gln58Ter (c.172C>T); ClinVar=VCV000188903; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143817 CVCL_1L02 GM14434 transformed cell line human CVCL_1L02 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly293Arg (c.877G>A); ClinVar=VCV000004036; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143818 CVCL_1L03 GM14445 transformed cell line human CVCL_1L03 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly638Trp (c.1912G>T); ClinVar=VCV000280954; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143819 CVCL_1L08 GM14528 transformed cell line human CVCL_1L08 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Val939Leufs*78 (c.2815_2816delGT); ClinVar=VCV000371481; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143820 CVCL_1L09 GM14550 transformed cell line human CVCL_1L09 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Thr737Asn (c.2210C>A); ClinVar=VCV000972796; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143821 CVCL_1L06 GM14510 transformed cell line human CVCL_1L06 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asn87Glnfs*9 (c.258dupC) (c.251insC); ClinVar=VCV000282842; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1195-8G>A; ClinVar=VCV000570655; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143822 CVCL_1L07 GM14526 transformed cell line human CVCL_1L07 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Val939Leufs*78 (c.2815_2816delGT); ClinVar=VCV000371481; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143823 CVCL_TR60 HAP1 TARBP2 (-) 1 cancer cell line human CVCL_TR60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11569; TARBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143824 CVCL_U360 mPitA-13 transformed cell line house mouse CVCL_U360 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143825 CVCL_U363 235-1 cancer cell line Norway rat CVCL_U363 CL:0000010 Derived from sampling site: Pituitary gland. Unspecified 21143826 CVCL_TR63 HAP1 TARBP2 (-) 4 cancer cell line human CVCL_TR63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11569; TARBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143827 CVCL_U364 Alpha-TSH cancer cell line house mouse CVCL_U364 CL:0000010 Derived from sampling site: Pituitary gland. 21143828 CVCL_TR64 HAP1 TARDBP (-) 1 cancer cell line human CVCL_TR64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11571; TARDBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143829 CVCL_TR61 HAP1 TARBP2 (-) 2 cancer cell line human CVCL_TR61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11569; TARBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143830 CVCL_U361 mPitA-10 transformed cell line house mouse CVCL_U361 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143831 CVCL_TR62 HAP1 TARBP2 (-) 3 cancer cell line human CVCL_TR62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11569; TARBP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143832 CVCL_U362 mPitA-11 transformed cell line house mouse CVCL_U362 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21143833 CVCL_TR45 HAP1 TAB3 (-) cancer cell line human CVCL_TR45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30681; TAB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143834 CVCL_U345 M14P cancer cell line human CVCL_U345 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Male 21143835 CVCL_U346 CHO-Tax 5-6 spontaneously immortalized cell line CVCL_U346 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21143836 CVCL_TR46 HAP1 TAF15 (-) 1 cancer cell line human CVCL_TR46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11547; TAF15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143837 CVCL_TR43 HAP1 TAB2 (-) 1 cancer cell line human CVCL_TR43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17075; TAB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143838 CVCL_U343 M32K cancer cell line human CVCL_U343 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228). 21143839 CVCL_TR44 HAP1 TAB2 (-) 2 cancer cell line human CVCL_TR44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17075; TAB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143840 CVCL_U344 M15 [Human mesothelioma] cancer cell line human CVCL_U344 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Heterozygous (PubMed=1568228). Unspecified 21143841 CVCL_U349 C127 clone YP1N25 cancer cell line house mouse CVCL_U349 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21143842 CVCL_TR49 HAP1 TAF5L (-) 1 cancer cell line human CVCL_TR49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17304; TAF5L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143843 CVCL_TR47 HAP1 TAF15 (-) 2 cancer cell line human CVCL_TR47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11547; TAF15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143844 CVCL_U347 ST [Human leukemia] cancer cell line human CVCL_U347 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Thr (c.737T>C); ClinVar=VCV000428886; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21143845 CVCL_U348 C127 clone YP1N27 cancer cell line house mouse CVCL_U348 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21143846 CVCL_TR48 HAP1 TAF1L (-) cancer cell line human CVCL_TR48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18056; TAF1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143847 CVCL_1L22 GM20161 finite cell line human CVCL_1L22 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Cys647Trp (c.1941C>G); ClinVar=VCV000550327; Zygosity=Homozygous (Coriell) Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143848 CVCL_1L23 GM20310 finite cell line human CVCL_1L23 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex16-20del (IVS15>3' of exon 20 9-kb del); Zygosity=Homozygous (Coriell) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143849 CVCL_1L20 GM20122 finite cell line human CVCL_1L20 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143850 CVCL_1L21 GM20123 finite cell line human CVCL_1L21 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143851 CVCL_1L15 GM20088 finite cell line human CVCL_1L15 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.2646+2T>A (IVS18+2T>A); ClinVar=VCV000188924; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; IVS7-IVS15del; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143852 CVCL_1L16 GM20089 finite cell line human CVCL_1L16 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143853 CVCL_1L13 GM14603 transformed cell line human CVCL_1L13 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg224Trp (c.670C>T); ClinVar=VCV000189188; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly828_Asn882del (c.2481+102_2646+31del) (c.2482_2646del165); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143854 CVCL_1L14 GM14604 transformed cell line human CVCL_1L14 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg224Trp (c.670C>T); ClinVar=VCV000189188; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143855 CVCL_1L19 GM20092 finite cell line human CVCL_1L19 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Cys647Trp (c.1941C>G); ClinVar=VCV000550327; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Ala486Serfs*30 (c.1456_1468del); Zygosity=Heterozygous (Coriell) Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21143856 CVCL_1L17 GM20090 finite cell line human CVCL_1L17 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Asn (c.1933G>A); ClinVar=VCV000188728; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu748Glyfs*48 (c.2242dupG) (2243insG); ClinVar=VCV000370651; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143857 CVCL_1L18 GM20091 finite cell line human CVCL_1L18 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gln58Ter (c.172C>T); ClinVar=VCV000188903; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143858 CVCL_U352 CHO-Tax 11-3 spontaneously immortalized cell line CVCL_U352 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21143859 CVCL_TR52 HAP1 TANK (-) 1 cancer cell line human CVCL_TR52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143860 CVCL_U353 CHO-Tax 11-6 spontaneously immortalized cell line CVCL_U353 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21143861 CVCL_TR53 HAP1 TANK (-) 2 cancer cell line human CVCL_TR53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143862 CVCL_U350 CHO-Tax 2-3 spontaneously immortalized cell line CVCL_U350 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21143863 CVCL_TR50 HAP1 TAF5L (-) 2 cancer cell line human CVCL_TR50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17304; TAF5L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143864 CVCL_U351 CHO-Tax 2-4 spontaneously immortalized cell line CVCL_U351 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21143865 CVCL_TR51 HAP1 TAGLN2 (-) 1 cancer cell line human CVCL_TR51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11554; TAGLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143866 CVCL_TR34 HAP1 SYNJ1 (-) 2 cancer cell line human CVCL_TR34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11503; SYNJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143867 CVCL_U334 LE-II spontaneously immortalized cell line house mouse CVCL_U334 From: Curtis A.; University of Glasgow; Glasgow; United Kingdom CL:0000010 Derived from sampling site: Lung; capillary Cell type=Lung endothelial cell.; Breed/subspecies: AKR/J. 21143868 CVCL_U335 BC12 cancer cell line Norway rat CVCL_U335 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21143869 CVCL_TR35 HAP1 SYNJ2 (-) 1 cancer cell line human CVCL_TR35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11504; SYNJ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143870 CVCL_U332 C-386 cancer cell line human CVCL_U332 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; humerus. Discontinued: ATCC; CRL-2074; true Male Problematic cell line: Probably contaminated The STR profile is identical to that of the RD-ES cell line. Originally thought to originate from a giant cell tumor excised in 1986 from tumor tissue of a 41 year old female patient. 21143871 CVCL_TR32 HAP1 SYK (-) cancer cell line human CVCL_TR32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11491; SYK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143872 CVCL_U333 5E10 [Mouse hybridoma against human 110 kDa glycoprotein] hybridoma house mouse CVCL_U333 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human 110 kDa glycoprotein on prostate cell lines surface. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-865 21143873 CVCL_TR33 HAP1 SYNJ1 (-) 1 cancer cell line human CVCL_TR33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11503; SYNJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143874 CVCL_U338 BC50 cancer cell line Norway rat CVCL_U338 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21143875 CVCL_TR38 HAP1 SYT2 (-) 1 cancer cell line human CVCL_TR38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11510; SYT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143876 CVCL_TR39 HAP1 SYT2 (-) 2 cancer cell line human CVCL_TR39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11510; SYT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143877 CVCL_U339 HeLa CD4+ Clone1022 cancer cell line human CVCL_U339 CL:0000010 Transfected with: HGNC; 1678; CD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~38 hours (HIVReagentProgram) 21143878 CVCL_U336 BC35 cancer cell line Norway rat CVCL_U336 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21143879 CVCL_TR36 HAP1 SYNJ2 (-) 2 cancer cell line human CVCL_TR36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11504; SYNJ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143880 CVCL_U337 BC47 cancer cell line Norway rat CVCL_U337 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 21143881 CVCL_TR37 HAP1 SYNJ2 (-) 3 cancer cell line human CVCL_TR37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11504; SYNJ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143882 CVCL_L999 CRP-1 hybridoma house mouse CVCL_L999 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02741; Human CRP. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2873 21143883 CVCL_KX99 PathHunter CHO-K1 MC5R beta-arrestin spontaneously immortalized cell line CVCL_KX99 CL:0000010 Transfected with: HGNC; 6933; MC5R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143884 CVCL_L997 KOA-1 cancer cell line human CVCL_L997 CL:0000010 Population: Japanese. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4631 21143885 CVCL_KX97 PathHunter CHO-K1 mAGTRL1 beta-arrestin spontaneously immortalized cell line CVCL_KX97 CL:0000010 Transfected with: MGI; MGI:1346086; Aplnr; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143886 CVCL_L998 KOA-1L3 cancer cell line human CVCL_L998 CL:0000010 Population: Japanese Unspecified Characteristics: Established after 3 passages of the parent cell line into nude mice. 21143887 CVCL_KX98 PathHunter CHO-K1 mC5AR1 beta-arrestin spontaneously immortalized cell line CVCL_KX98 CL:0000010 Transfected with: MGI; MGI:88232; C5ar1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143888 CVCL_L995 NIH3T3/14-1 transformed cell line house mouse CVCL_L995 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21143889 CVCL_KX95 PathHunter CHO-K1 mADORA2B beta-arrestin spontaneously immortalized cell line CVCL_KX95 CL:0000010 Transfected with: MGI; MGI:99403; Adora2b; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143890 CVCL_L996 BALB/3T3 A31-1-13 spontaneously immortalized cell line house mouse CVCL_L996 CL:0000010 Breed/subspecies: Swiss albino. Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00529 Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (PubMed=27844419). Therefore this cell line is not a clone of BALB/3T3 clone A31 (Cellosaurus=CVCL_0184) as originally reported. 21143891 CVCL_KX96 PathHunter CHO-K1 mADORA3 beta-arrestin spontaneously immortalized cell line CVCL_KX96 CL:0000010 Transfected with: MGI; MGI:104847; Adora3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143892 CVCL_L993 NIH3T3-3-4 transformed cell line house mouse CVCL_L993 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21143893 CVCL_KX93 PathHunter CHO-K1 LXRbeta Protein Interaction spontaneously immortalized cell line CVCL_KX93 CL:0000010 Transfected with: HGNC; 7965; NR1H2; Transfected with: HGNC; 7671; NCOA4 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143894 CVCL_L994 NIH 3T3 p-7 cl-3 spontaneously immortalized cell line house mouse CVCL_L994 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Doubling time: ~1 day (lot 01252011) (JCRB) 21143895 CVCL_KX94 PathHunter CHO-K1 mADCYAP1R1 beta-arrestin spontaneously immortalized cell line CVCL_KX94 CL:0000010 Transfected with: MGI; MGI:108449; Adcyap1r1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143896 CVCL_L991 NIH-3T3-G185 spontaneously immortalized cell line house mouse CVCL_L991 CL:0000010 Transfected with: HGNC; 40; ABCB1 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21143897 CVCL_KX91 PathHunter CHO-K1 LTB4R beta-arrestin spontaneously immortalized cell line CVCL_KX91 CL:0000010 Transfected with: HGNC; 6713; LTB4R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143898 CVCL_L992 NIH3T3-3 transformed cell line house mouse CVCL_L992 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: RCB; RCB0150; true Male 21143899 CVCL_KX92 PathHunter CHO-K1 LXRalpha Protein Interaction spontaneously immortalized cell line CVCL_KX92 CL:0000010 Transfected with: HGNC; 7966; NR1H3; Transfected with: HGNC; 7669; NCOA2 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143900 CVCL_L990 NIH-3T3-A14 spontaneously immortalized cell line house mouse CVCL_L990 CL:0000010 Transfected with: HGNC; 6091; INSR Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21143901 CVCL_KX90 PathHunter CHO-K1 LHCGR beta-arrestin spontaneously immortalized cell line CVCL_KX90 CL:0000010 Transfected with: HGNC; 6585; LHCGR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143902 CVCL_U341 C127 clone 64 cancer cell line house mouse CVCL_U341 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21143903 CVCL_TR41 HAP1 TAB1 (-) 1 cancer cell line human CVCL_TR41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18157; TAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143904 CVCL_U342 C127 clone 76 cancer cell line house mouse CVCL_U342 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21143905 CVCL_TR42 HAP1 TAB1 (-) 2 cancer cell line human CVCL_TR42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18157; TAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143906 CVCL_TR40 HAP1 SZT2 (-) 3 cancer cell line human CVCL_TR40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29040; SZT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143907 CVCL_U340 HHUS cancer cell line human CVCL_U340 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 59 (HPV59)(NCBI-Taxonomy; 37115); Derived from sampling site: Uterus; cervix. Female Doubling time: 92 hours (at 10th passage), 67 hours (at 30th passage) (PubMed=15859161) 21143908 CVCL_TR23 HAP1 SUMO1 (-) 4 cancer cell line human CVCL_TR23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12502; SUMO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143909 CVCL_U323 Jurkat-99 cancer cell line human CVCL_U323 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8131 21143910 CVCL_TR24 HAP1 SUMO3 (-) 1 cancer cell line human CVCL_TR24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11124; SUMO3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143911 CVCL_U324 J-A1886 cancer cell line human CVCL_U324 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8130 21143912 CVCL_TR21 HAP1 SUMO1 (-) 2 cancer cell line human CVCL_TR21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12502; SUMO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143913 CVCL_U321 JDB1 hybridoma human CVCL_U321 CL:0000010 Monoclonal antibody isotype: IgG3+IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8143 21143914 CVCL_U322 1B2E12 hybridoma human CVCL_U322 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8144 21143915 CVCL_TR22 HAP1 SUMO1 (-) 3 cancer cell line human CVCL_TR22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12502; SUMO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143916 CVCL_U327 3G8 [Mouse hybridoma against HIV-1 antigens] hybridoma house mouse CVCL_U327 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: HIV-1 antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9114 21143917 CVCL_TR27 HAP1 SURF4 (-) 2 cancer cell line human CVCL_TR27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11476; SURF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143918 CVCL_U328 CCD-33Sk finite cell line human CVCL_U328 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1493; true Male 21143919 CVCL_TR28 HAP1 SUV39H1 (-) 1 cancer cell line human CVCL_TR28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143920 CVCL_TR25 HAP1 SUMO3 (-) 2 cancer cell line human CVCL_TR25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11124; SUMO3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143921 CVCL_U325 MRCC cancer cell line human CVCL_U325 CL:0000010 Population: Chinese; Derived from metastatic site: Bone; spine. Male Doubling time: 55.2 hours (PubMed=23442546) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200909 21143922 CVCL_TR26 HAP1 SURF4 (-) 1 cancer cell line human CVCL_TR26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11476; SURF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143923 CVCL_U326 Jurkat-111 cancer cell line human CVCL_U326 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Highly increased IL2 expression Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8129 21143924 CVCL_U329 CCD-14Sk finite cell line human CVCL_U329 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1454; true Female 21143925 CVCL_TR29 HAP1 SUV39H1 (-) 2 cancer cell line human CVCL_TR29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143926 CVCL_1L00 GM14423 transformed cell line human CVCL_1L00 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.His308Pro (c.923A>C); ClinVar=VCV001493530; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143927 CVCL_1L01 GM14428 transformed cell line human CVCL_1L01 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly638Trp (c.1912G>T); ClinVar=VCV000280954; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143928 CVCL_U330 CCD-41Sk finite cell line human CVCL_U330 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1505; true Male 21143929 CVCL_TR30 HAP1 SUZ12 (-) 1 cancer cell line human CVCL_TR30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143930 CVCL_U331 CCD-55Sk finite cell line human CVCL_U331 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1510; true Female 21143931 CVCL_TR31 HAP1 SUZ12 (-) 2 cancer cell line human CVCL_TR31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143932 CVCL_U312 AG05231 finite cell line human CVCL_U312 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG05231; probable Male 21143933 CVCL_TR12 HAP1 STX2 (-) 4 cancer cell line human CVCL_TR12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3403; STX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143934 CVCL_U313 AG07896 transformed cell line human CVCL_U313 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female 21143935 CVCL_TR13 HAP1 STX4 (-) 1 cancer cell line human CVCL_TR13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11439; STX4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143936 CVCL_U310 AG04103 transformed cell line human CVCL_U310 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143937 CVCL_TR10 HAP1 STX2 (-) 2 cancer cell line human CVCL_TR10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3403; STX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143938 CVCL_U311 AG04110 finite cell line human CVCL_U311 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu578Val (c.1733A>T); ClinVar=VCV000066863; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21143939 CVCL_TR11 HAP1 STX2 (-) 3 cancer cell line human CVCL_TR11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3403; STX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143940 CVCL_U316 AG12795 finite cell line human CVCL_U316 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21143941 CVCL_TR16 HAP1 STYK1 (-) 2 cancer cell line human CVCL_TR16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18889; STYK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143942 CVCL_U317 AG14424 transformed cell line human CVCL_U317 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg889Ter (c.2665C>T); ClinVar=VCV000404045; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12791; WRN; Unexplicit; Ex19-23del; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143943 CVCL_TR17 HAP1 STYK1 (-) 3 cancer cell line human CVCL_TR17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18889; STYK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143944 CVCL_U314 AG07897 transformed cell line human CVCL_U314 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143945 CVCL_TR14 HAP1 STX4 (-) 2 cancer cell line human CVCL_TR14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11439; STX4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143946 CVCL_U315 AG07898 transformed cell line human CVCL_U315 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143947 CVCL_TR15 HAP1 STYK1 (-) 1 cancer cell line human CVCL_TR15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18889; STYK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143948 CVCL_U318 AG14425 transformed cell line human CVCL_U318 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21143949 CVCL_TR18 HAP1 SUFU (-) 1 cancer cell line human CVCL_TR18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143950 CVCL_U319 AG14426 transformed cell line human CVCL_U319 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=10606667) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143951 CVCL_TR19 HAP1 SUFU (-) 2 cancer cell line human CVCL_TR19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16466; SUFU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143952 CVCL_L979 NA101 transformed cell line CVCL_L979 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Embryonic bone; tibia Cell type=Chondrocyte.; Breed/subspecies: White Leghorn. Unspecified Group: Bird cell line 21143953 CVCL_KX79 PathHunter CHO-K1 GPR97 beta-arrestin spontaneously immortalized cell line CVCL_KX79 CL:0000010 Transfected with: HGNC; 13728; ADGRG3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143954 CVCL_L977 GM02664 finite cell line human CVCL_L977 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02643; true Male 21143955 CVCL_KX77 PathHunter CHO-K1 GPR88 beta-arrestin spontaneously immortalized cell line CVCL_KX77 CL:0000010 Transfected with: HGNC; 4539; GPR88; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143956 CVCL_KX78 PathHunter CHO-K1 GPR92 beta-arrestin spontaneously immortalized cell line CVCL_KX78 CL:0000010 Transfected with: HGNC; 13307; LPAR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143957 CVCL_L978 RVP3 cancer cell line house mouse CVCL_L978 CL:0000010 Transformant: Rous sarcoma virus (strain Prague C)(NCBI-Taxonomy; 11888); Breed/subspecies: C57BL/6. 21143958 CVCL_L975 GM02431 transformed cell line human CVCL_L975 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02378; true Male 21143959 CVCL_KX75 PathHunter CHO-K1 GPR84 beta-arrestin spontaneously immortalized cell line CVCL_KX75 CL:0000010 Transfected with: HGNC; 4535; GPR84; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143960 CVCL_L976 GM02504 finite cell line human CVCL_L976 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00258; true Male 21143961 CVCL_KX76 PathHunter CHO-K1 GPR85 beta-arrestin spontaneously immortalized cell line CVCL_KX76 CL:0000010 Transfected with: HGNC; 4536; GPR85; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143962 CVCL_L973 GM00441 finite cell line human CVCL_L973 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21143963 CVCL_KX73 PathHunter CHO-K1 GPR79 beta-arrestin spontaneously immortalized cell line CVCL_KX73 CL:0000010 Transfected with: HGNC; 4529; GPR79; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143964 CVCL_L974 GM02429 transformed cell line human CVCL_L974 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02375; true Female 21143965 CVCL_KX74 PathHunter CHO-K1 GPR83 beta-arrestin spontaneously immortalized cell line CVCL_KX74 CL:0000010 Transfected with: HGNC; 4523; GPR83; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143966 CVCL_L971 XP221BE finite cell line human CVCL_L971 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21143967 CVCL_KX71 PathHunter CHO-K1 GPR75 beta-arrestin spontaneously immortalized cell line CVCL_KX71 CL:0000010 Transfected with: HGNC; 4526; GPR75; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143968 CVCL_L972 GM02412 transformed cell line human CVCL_L972 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01027; true Male 21143969 CVCL_KX72 PathHunter CHO-K1 GPR78 beta-arrestin spontaneously immortalized cell line CVCL_KX72 CL:0000010 Transfected with: HGNC; 4528; GPR78; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143970 CVCL_L970 XP221BE LCL transformed cell line human CVCL_L970 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143971 CVCL_KX70 PathHunter CHO-K1 GPR65 beta-arrestin spontaneously immortalized cell line CVCL_KX70 CL:0000010 Transfected with: HGNC; 4517; GPR65; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143972 CVCL_U320 AG19910 transformed cell line human CVCL_U320 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21143973 CVCL_TR20 HAP1 SUMO1 (-) 1 cancer cell line human CVCL_TR20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12502; SUMO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143974 CVCL_U301 GM20394 finite cell line human CVCL_U301 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex1del; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143975 CVCL_TR01 HAP1 STRADB (-) 2 cancer cell line human CVCL_TR01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13205; STRADB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143976 CVCL_U302 GM20393 finite cell line human CVCL_U302 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Glu47Gly (c.140A>G); Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143977 CVCL_TR02 HAP1 STRADB (-) 3 cancer cell line human CVCL_TR02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13205; STRADB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143978 CVCL_U300 GM20396 finite cell line human CVCL_U300 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Asp201Asn (c.601G>A); Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143979 CVCL_TR00 HAP1 STRADB (-) 1 cancer cell line human CVCL_TR00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13205; STRADB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143980 CVCL_U305 GM20392 finite cell line human CVCL_U305 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Val8Gly (c.23T>G); ClinVar=VCV001410753; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143981 CVCL_TR05 HAP1 STRN3 (-) 3 cancer cell line human CVCL_TR05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15720; STRN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143982 CVCL_U306 CCD-19Sk finite cell line human CVCL_U306 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1471; true Female 21143983 CVCL_TR06 HAP1 STRN3 (-) 4 cancer cell line human CVCL_TR06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15720; STRN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143984 CVCL_U303 GM20397 finite cell line human CVCL_U303 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Arg48His (c.143G>A); ClinVar=VCV000029985; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143985 CVCL_TR03 HAP1 STRN3 (-) 1 cancer cell line human CVCL_TR03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15720; STRN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143986 CVCL_U304 GM20398 finite cell line human CVCL_U304 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Asp194His (c.580G>C); ClinVar=VCV000284173; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21143987 CVCL_TR04 HAP1 STRN3 (-) 2 cancer cell line human CVCL_TR04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15720; STRN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143988 CVCL_U309 AG03364 transformed cell line human CVCL_U309 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male 21143989 CVCL_TR09 HAP1 STX2 (-) 1 cancer cell line human CVCL_TR09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3403; STX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143990 CVCL_U307 CCD-28Sk finite cell line human CVCL_U307 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1477; true Female 21143991 CVCL_TR07 HAP1 STS (-) cancer cell line human CVCL_TR07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11425; STS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143992 CVCL_U308 FF cancer cell line CVCL_U308 CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.. Discontinued: ATCC; CRL-1479; true Unspecified Characteristics: Pigmented 21143993 CVCL_TR08 HAP1 STX17 (-) 1 cancer cell line human CVCL_TR08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11432; STX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21143994 CVCL_L988 P19C6 cancer cell line house mouse CVCL_L988 CL:0000010 Breed/subspecies: C3H/He. Male 21143995 CVCL_KX88 PathHunter CHO-K1 LGR5 beta-arrestin spontaneously immortalized cell line CVCL_KX88 CL:0000010 Transfected with: HGNC; 4504; LGR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143996 CVCL_L989 A31-714 C4 spontaneously immortalized cell line house mouse CVCL_L989 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21143997 CVCL_KX89 PathHunter CHO-K1 LGR6 beta-arrestin spontaneously immortalized cell line CVCL_KX89 CL:0000010 Transfected with: HGNC; 19719; LGR6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143998 CVCL_KX86 PathHunter CHO-K1 HTR1A beta-arrestin spontaneously immortalized cell line CVCL_KX86 CL:0000010 Transfected with: HGNC; 5286; HTR1A; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21143999 CVCL_L986 SpR undefined cell line type CVCL_L986 CL:0000010 Anecdotal: Part of a set of 4 cell lines that were fraudulently stated to originate from Hodgkin lymphoma (PubMed=265539) Derived from sampling site: Kidney. Female Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00088 Problematic cell line: Misidentified/contaminated Originally thought to be of human origin but found to derive from Aotus trivirgatus OMK-210 (PubMed=7192801; PubMed=12592342; PubMed=20143388). 21144000 CVCL_L987 LLC-MK1 spontaneously immortalized cell line CVCL_L987 CL:0000010 Derived from sampling site: Kidney. Group: Non-human primate cell line 21144001 CVCL_KX87 PathHunter CHO-K1 LGR4 beta-arrestin spontaneously immortalized cell line CVCL_KX87 CL:0000010 Transfected with: HGNC; 13299; LGR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144002 CVCL_L984 FQ undefined cell line type CVCL_L984 CL:0000010 Anecdotal: Part of a set of 4 cell lines that were fraudulently stated to originate from Hodgkin lymphoma (PubMed=265539) Derived from sampling site: Kidney. Female Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00047 Problematic cell line: Misidentified Originally thought to be of human origin but found to derive from OMK-210 from owl monkey (PubMed=7192801; PubMed=12592342; PubMed=20143388). 21144003 CVCL_KX84 PathHunter CHO-K1 HRH2 beta-arrestin spontaneously immortalized cell line CVCL_KX84 CL:0000010 Transfected with: HGNC; 5183; HRH2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144004 CVCL_KX85 PathHunter CHO-K1 HRH3 beta-arrestin spontaneously immortalized cell line CVCL_KX85 CL:0000010 Transfected with: HGNC; 5184; HRH3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144005 CVCL_L985 RB [Aotus] undefined cell line type CVCL_L985 CL:0000010 Anecdotal: Part of a set of 4 cell lines that were fraudulently stated to originate from Hodgkin lymphoma (PubMed=265539) Derived from sampling site: Kidney. Female Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00083 Problematic cell line: Misidentified Originally thought to be of human origin but found to derive from OMK-210 from owl monkey (PubMed=7192801; PubMed=12592342; PubMed=20143388). 21144006 CVCL_L982 GM01707 finite cell line human CVCL_L982 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01008; true Female 21144007 CVCL_KX82 PathHunter CHO-K1 HCRTR2 beta-arrestin spontaneously immortalized cell line CVCL_KX82 CL:0000010 Transfected with: HGNC; 4849; HCRTR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144008 CVCL_L983 OMK-210 spontaneously immortalized cell line CVCL_L983 CL:0000010 Derived from sampling site: Kidney. Female Group: Non-human primate cell line 21144009 CVCL_KX83 PathHunter CHO-K1 HRH1 beta-arrestin spontaneously immortalized cell line CVCL_KX83 CL:0000010 Transfected with: HGNC; 5182; HRH1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144010 CVCL_L980 OKP-GS cancer cell line human CVCL_L980 CL:0000010 Derived from metastatic site: Hypodermis. Male 21144011 CVCL_KX80 PathHunter CHO-K1 GR Protein Interaction spontaneously immortalized cell line CVCL_KX80 CL:0000010 Transfected with: HGNC; 7978; NR3C1; Transfected with: HGNC; 9237; PPARGC1A Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144012 CVCL_L981 P19CL6 cancer cell line house mouse CVCL_L981 CL:0000010 Breed/subspecies: C3H/He. Male 21144013 CVCL_KX81 PathHunter CHO-K1 HCRTR1 beta-arrestin spontaneously immortalized cell line CVCL_KX81 CL:0000010 Transfected with: HGNC; 4848; HCRTR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144014 CVCL_L959 GM01708 finite cell line human CVCL_L959 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from familial inference of GM01014) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM01010; true Male 21144015 CVCL_KX59 PathHunter CHO-K1 GPR35 beta-arrestin spontaneously immortalized cell line CVCL_KX59 CL:0000010 Transfected with: HGNC; 4492; GPR35; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144016 CVCL_L957 GM01228 finite cell line human CVCL_L957 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00642; true Male 21144017 CVCL_KX57 PathHunter CHO-K1 GPR31 beta-arrestin spontaneously immortalized cell line CVCL_KX57 CL:0000010 Transfected with: HGNC; 4486; GPR31; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144018 CVCL_L958 GM00318 finite cell line human CVCL_L958 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00134; true Female 21144019 CVCL_KX58 PathHunter CHO-K1 GPR32 beta-arrestin spontaneously immortalized cell line CVCL_KX58 CL:0000010 Transfected with: HGNC; 4487; GPR32; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144020 CVCL_L955 GM00725 finite cell line human CVCL_L955 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21144021 CVCL_KX55 PathHunter CHO-K1 GPR3 beta-arrestin spontaneously immortalized cell line CVCL_KX55 CL:0000010 Transfected with: HGNC; 4484; GPR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144022 CVCL_L956 GM00978 finite cell line human CVCL_L956 CL:0000010 Derived from sampling site: Gonad Cell type=Fibroblast.. Discontinued: Coriell; GM00188; true Female 21144023 CVCL_KX56 PathHunter CHO-K1 GPR30 beta-arrestin spontaneously immortalized cell line CVCL_KX56 CL:0000010 Transfected with: HGNC; 4485; GPER1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144024 CVCL_L953 GM00721 finite cell line human CVCL_L953 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00547; true Female 21144025 CVCL_KX53 PathHunter CHO-K1 GPR26 beta-arrestin spontaneously immortalized cell line CVCL_KX53 CL:0000010 Transfected with: HGNC; 4481; GPR26; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144026 CVCL_L954 GM00722 finite cell line human CVCL_L954 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00548; true; Discontinued: Coriell; GM00722; probable Male 21144027 CVCL_KX54 PathHunter CHO-K1 GPR27 beta-arrestin spontaneously immortalized cell line CVCL_KX54 CL:0000010 Transfected with: HGNC; 4482; GPR27; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144028 CVCL_L951 BS1KA finite cell line human CVCL_L951 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (PubMed=17407155; Coriell); Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (Coriell) Population: Japanese; Donor information: From Bloom Syndrome Registry patient 86(NoKi) (BSR86); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: JCRB; KURB1861; probable Female Part of: Human variation panel 21144029 CVCL_KX51 PathHunter CHO-K1 GPR23 beta-arrestin spontaneously immortalized cell line CVCL_KX51 CL:0000010 Transfected with: HGNC; 4478; LPAR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144030 CVCL_L952 GM00509 finite cell line human CVCL_L952 CL:0000010 Population: African American; Karyotypic information: 46,XX,del(13)(pter->q14) (Coriell); Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00250; true Female 21144031 CVCL_KX52 PathHunter CHO-K1 GPR25 beta-arrestin spontaneously immortalized cell line CVCL_KX52 CL:0000010 Transfected with: HGNC; 4480; GPR25; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144032 CVCL_L950 46BRLigI transformed cell line human CVCL_L950 CL:0000010 Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Glu566Lys (c.1696G>A); ClinVar=VCV000016775; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Arg771Trp (c.2311C>T); ClinVar=VCV000016776; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144033 CVCL_KX50 PathHunter CHO-K1 GPR182 beta-arrestin spontaneously immortalized cell line CVCL_KX50 CL:0000010 Transfected with: HGNC; 13708; GPR182; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144034 CVCL_L968 GM02205 finite cell line human CVCL_L968 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM01515; true Male 21144035 CVCL_KX68 PathHunter CHO-K1 GPR6 beta-arrestin spontaneously immortalized cell line CVCL_KX68 CL:0000010 Transfected with: HGNC; 4515; GPR6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144036 CVCL_L969 GM02206 finite cell line human CVCL_L969 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis; Omics: SNP array analysis Discontinued: Coriell; GM01514; true Female 21144037 CVCL_KX69 PathHunter CHO-K1 GPR61 beta-arrestin spontaneously immortalized cell line CVCL_KX69 CL:0000010 Transfected with: HGNC; 13300; GPR61; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144038 CVCL_L966 GM01810 transformed cell line human CVCL_L966 HLA typing: A*01,10; B*07,13 (Coriell=GM01810) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01451; true Male 21144039 CVCL_KX66 PathHunter CHO-K1 GPR52 beta-arrestin spontaneously immortalized cell line CVCL_KX66 CL:0000010 Transfected with: HGNC; 4508; GPR52; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144040 CVCL_L967 GM01930 transformed cell line human CVCL_L967 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01802; true Female 21144041 CVCL_KX67 PathHunter CHO-K1 GPR55 beta-arrestin spontaneously immortalized cell line CVCL_KX67 CL:0000010 Transfected with: HGNC; 4511; GPR55; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144042 CVCL_L964 GM01769 transformed cell line human CVCL_L964 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01021; true Male 21144043 CVCL_KX64 PathHunter CHO-K1 GPR45 beta-arrestin spontaneously immortalized cell line CVCL_KX64 CL:0000010 Transfected with: HGNC; 4503; GPR45; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144044 CVCL_L965 GM01784 transformed cell line human CVCL_L965 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01462; true Male 21144045 CVCL_KX65 PathHunter CHO-K1 GPR50 beta-arrestin spontaneously immortalized cell line CVCL_KX65 CL:0000010 Transfected with: HGNC; 4506; GPR50; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144046 CVCL_L962 GM02110 transformed cell line human CVCL_L962 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01450; true Male 21144047 CVCL_KX62 PathHunter CHO-K1 GPR39 beta-arrestin spontaneously immortalized cell line CVCL_KX62 CL:0000010 Transfected with: HGNC; 4496; GPR39; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144048 CVCL_L963 GM01767 transformed cell line human CVCL_L963 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01452; true Female 21144049 CVCL_KX63 PathHunter CHO-K1 GPR4 beta-arrestin spontaneously immortalized cell line CVCL_KX63 CL:0000010 Transfected with: HGNC; 4497; GPR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144050 CVCL_L960 GM01763 finite cell line human CVCL_L960 CL:0000010 Sequence variation: Mutation; HGNC; 2330; CPT2; Simple; p.Ser113Leu (c.439C>T); ClinVar=VCV000008953; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00249; true Male 21144051 CVCL_KX60 PathHunter CHO-K1 GPR37 beta-arrestin spontaneously immortalized cell line CVCL_KX60 CL:0000010 Transfected with: HGNC; 4494; GPR37; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144052 CVCL_L961 GM01766 transformed cell line human CVCL_L961 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01449; true Female 21144053 CVCL_KX61 PathHunter CHO-K1 GPR37L1 beta-arrestin spontaneously immortalized cell line CVCL_KX61 CL:0000010 Transfected with: HGNC; 14923; GPR37L1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144054 CVCL_1K70 GM13291 transformed cell line human CVCL_1K70 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1195-8G>A; ClinVar=VCV000570655; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144055 CVCL_1K71 GM13305 transformed cell line human CVCL_1K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144056 CVCL_1K74 GM13352 finite cell line human CVCL_1K74 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu521Lys (c.1561G>A); ClinVar=VCV000004022; Zygosity=Homozygous (Coriell) Population: Indian; Derived from sampling site: Cell type=Fibroblast. Female 21144057 CVCL_1K75 GM13408 transformed cell line human CVCL_1K75 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-3C>A; ClinVar=VCV000371622; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144058 CVCL_1K72 GM13306 transformed cell line human CVCL_1K72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144059 CVCL_1K73 GM13331 transformed cell line human CVCL_1K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144060 CVCL_1K78 GM13450 transformed cell line human CVCL_1K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144061 CVCL_1K79 GM13522 finite cell line human CVCL_1K79 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg660His (c.1979G>A); ClinVar=VCV000189172; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21144062 CVCL_1K76 GM13409 transformed cell line human CVCL_1K76 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-3C>A; ClinVar=VCV000371622; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144063 CVCL_1K77 GM13449 transformed cell line human CVCL_1K77 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Tyr609Ter (c.1827delC) (p.Arg608_Tyr609insTer); ClinVar=VCV000188936; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144064 CVCL_1K69 GM12932 finite cell line human CVCL_1K69 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp481Arg (c.1441T>C); ClinVar=VCV000189007; Zygosity=Heterozygous (PubMed=10189220); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1326+1G>A (IVS8+1G>A); ClinVar=VCV000597944; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10189220) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144065 CVCL_1K81 GM13544 transformed cell line human CVCL_1K81 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp516Ter (c.1548G>A); ClinVar=VCV000189025; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asn520Ser (c.1559A>G); ClinVar=VCV000849167; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144066 CVCL_1K82 GM13561 transformed cell line human CVCL_1K82 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Pro482Arg (c.1445C>G); ClinVar=VCV001067574; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144067 CVCL_1K80 GM13527 transformed cell line human CVCL_1K80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144068 CVCL_1K85 GM13963 transformed cell line human CVCL_1K85 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144069 CVCL_1K86 GM14011 transformed cell line human CVCL_1K86 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asn87Glnfs*9 (c.258dupC) (c.251insC); ClinVar=VCV000282842; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1195-8G>A; ClinVar=VCV000570655; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144070 CVCL_1K83 GM13653 transformed cell line human CVCL_1K83 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly309Arg (c.925G>A); ClinVar=VCV000188797; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144071 CVCL_1K84 GM13793 transformed cell line human CVCL_1K84 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-2A>G; ClinVar=VCV000972817; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly293Arg (c.877G>A); ClinVar=VCV000004036; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144072 CVCL_1K89 GM14039 transformed cell line human CVCL_1K89 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg190His (c.569G>A); ClinVar=VCV000188809; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly828_Asn882del (c.2481+102_2646+31del) (c.2482_2646del165); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144073 CVCL_1K87 GM14015 transformed cell line human CVCL_1K87 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-2A>G; ClinVar=VCV000972817; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144074 CVCL_1K88 GM14016 transformed cell line human CVCL_1K88 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Tyr609Ter (c.1827delC) (p.Arg608_Tyr609insTer); ClinVar=VCV000188936; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144075 CVCL_U299 GM20395 finite cell line human CVCL_U299 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Met143Lys (c.428T>A); ClinVar=VCV000010062; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144076 CVCL_TQ99 HAP1 STRADA (-) 2 cancer cell line human CVCL_TQ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30172; STRADA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144077 CVCL_1K52 GM01568 transformed cell line human CVCL_1K52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144078 CVCL_1K53 GM01778 transformed cell line human CVCL_1K53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144079 CVCL_1K50 GM00577 finite cell line human CVCL_1K50 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144080 CVCL_1K51 GM01464 transformed cell line human CVCL_1K51 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144081 CVCL_1K56 GM05344 transformed cell line human CVCL_1K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144082 CVCL_1K57 GM07754 transformed cell line human CVCL_1K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144083 CVCL_1K54 GM01935 finite cell line human CVCL_1K54 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Asp645Glu (c.1935C>A); ClinVar=VCV000004029; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144084 CVCL_1K55 GM03329 finite cell line human CVCL_1K55 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met519Val (c.1555A>G); ClinVar=VCV001067893; Zygosity=Heterozygous (PubMed=10189220); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.1326+1G>A (IVS8+1G>A); ClinVar=VCV000597944; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10189220) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144085 CVCL_1K49 GM00572 finite cell line human CVCL_1K49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21144086 CVCL_1K47 GM00338 finite cell line human CVCL_1K47 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144087 CVCL_1K48 GM00443 finite cell line human CVCL_1K48 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144088 CVCL_U288 COLO/B cancer cell line human CVCL_U288 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Female 21144089 CVCL_TQ88 HAP1 STK32C (-) 1 cancer cell line human CVCL_TQ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21332; STK32C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144090 CVCL_U289 COLO/C cancer cell line human CVCL_U289 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Female 21144091 CVCL_TQ89 HAP1 STK32C (-) 2 cancer cell line human CVCL_TQ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21332; STK32C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144092 CVCL_1K60 GM08683 transformed cell line human CVCL_1K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144093 CVCL_1K63 GM11471 transformed cell line human CVCL_1K63 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (PubMed=19815695) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144094 CVCL_1K64 GM11603 finite cell line human CVCL_1K64 CL:0000010 Population: African American and Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144095 CVCL_1K61 GM09282 transformed cell line human CVCL_1K61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144096 CVCL_1K62 GM11470 transformed cell line human CVCL_1K62 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Arg83Cys (c.247C>T); ClinVar=VCV000011998; Zygosity=Heterozygous (PubMed=19815695) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21144097 CVCL_1K67 GM11849 finite cell line human CVCL_1K67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144098 CVCL_1K68 GM12131 finite cell line human CVCL_1K68 CL:0000010 Population: Caucasian; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21144099 CVCL_1K65 GM11706 finite cell line human CVCL_1K65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21144100 CVCL_1K66 GM11759 transformed cell line human CVCL_1K66 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Ser627Phe (c.1880C>T); ClinVar=VCV000597382; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144101 CVCL_1K58 GM08079 transformed cell line human CVCL_1K58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144102 CVCL_1K59 GM08443 transformed cell line human CVCL_1K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144103 CVCL_U290 COLO/D cancer cell line human CVCL_U290 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Female 21144104 CVCL_TQ90 HAP1 STK38 (-) cancer cell line human CVCL_TQ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17847; STK38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144105 CVCL_U293 6T-CEM20 cancer cell line human CVCL_U293 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8295 21144106 CVCL_TQ93 HAP1 STK39 (-) 2 cancer cell line human CVCL_TQ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17717; STK39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144107 CVCL_TQ94 HAP1 STK39 (-) 3 cancer cell line human CVCL_TQ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17717; STK39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144108 CVCL_U294 SL4c spontaneously immortalized cell line house mouse CVCL_U294 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: BALB/c. Male 21144109 CVCL_U291 COLO/DDP50 cancer cell line human CVCL_U291 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Female 21144110 CVCL_TQ91 HAP1 STK38L (-) cancer cell line human CVCL_TQ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17848; STK38L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144111 CVCL_U292 AG19912 transformed cell line human CVCL_U292 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144112 CVCL_TQ92 HAP1 STK39 (-) 1 cancer cell line human CVCL_TQ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17717; STK39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144113 CVCL_U297 CCD-48Sk finite cell line human CVCL_U297 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1507; true Male 21144114 CVCL_TQ97 HAP1 STK40 (-) cancer cell line human CVCL_TQ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21373; STK40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144115 CVCL_U298 CCD-50Sk finite cell line human CVCL_U298 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1508; true Male 21144116 CVCL_TQ98 HAP1 STRADA (-) 1 cancer cell line human CVCL_TQ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30172; STRADA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144117 CVCL_U295 CCD-974Sk finite cell line human CVCL_U295 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1906; true Female Senescence: Senesces at ~13 PDL (ATCC=CRL-1906) 21144118 CVCL_TQ95 HAP1 STK4 (-) 1 cancer cell line human CVCL_TQ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144119 CVCL_U296 CCD-45Sk finite cell line human CVCL_U296 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1506; true Female 21144120 CVCL_TQ96 HAP1 STK4 (-) 2 cancer cell line human CVCL_TQ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144121 CVCL_U279 1C11 [Mouse hybridoma against HIV-1 antigens] hybridoma house mouse CVCL_U279 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: HIV-1 antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9115 21144122 CVCL_TQ79 HAP1 STK19 (-) 2 cancer cell line human CVCL_TQ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11398; STK19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144123 CVCL_U277 3G12 [Mouse hybridoma against HIV-1 antigens] hybridoma house mouse CVCL_U277 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9102 21144124 CVCL_TQ77 HAP1 STK17B (-) 2 cancer cell line human CVCL_TQ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11396; STK17B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144125 CVCL_TQ78 HAP1 STK19 (-) 1 cancer cell line human CVCL_TQ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11398; STK19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144126 CVCL_U278 Rn2Nod undefined cell line type Norway rat CVCL_U278 CL:0000010 Discontinued: ATCC; CRL-6600; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21144127 CVCL_1K30 GM12214 transformed cell line human CVCL_1K30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144128 CVCL_1K31 MFF-8C1 spontaneously immortalized cell line CVCL_1K31 CL:0000010 Unspecified Group: Fish cell line; Group: Vaccine production cell line. 21144129 CVCL_1K34 GM23819 transformed cell line human CVCL_1K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144130 CVCL_1K35 GM03913 finite cell line human CVCL_1K35 CL:0000010 Population: Caucasian; French Canadian; Karyotypic information: 46,XY [46%]; 47,XY,+7 [54%] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21144131 CVCL_1K32 GM23490 transformed cell line human CVCL_1K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144132 CVCL_1K33 GM23491 transformed cell line human CVCL_1K33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144133 CVCL_1K27 GM05166 transformed cell line human CVCL_1K27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144134 CVCL_1K28 GM05167 finite cell line human CVCL_1K28 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144135 CVCL_1K25 GM05149 transformed cell line human CVCL_1K25 CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; c.448+64T>C (IVS3+64T>C); ClinVar=VCV000683189; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144136 CVCL_1K26 GM05165 finite cell line human CVCL_1K26 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144137 CVCL_1K29 GM05168 transformed cell line human CVCL_1K29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144138 CVCL_U282 AG00780 finite cell line human CVCL_U282 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM00780; probable Male 21144139 CVCL_TQ82 HAP1 STK25 (-) 3 cancer cell line human CVCL_TQ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11404; STK25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144140 CVCL_U283 AG19911 transformed cell line human CVCL_U283 CL:0000010 Population: Caucasian; Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female 21144141 CVCL_TQ83 HAP1 STK3 (-) 1 cancer cell line human CVCL_TQ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11406; STK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144142 CVCL_TQ80 HAP1 STK25 (-) 1 cancer cell line human CVCL_TQ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11404; STK25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144143 CVCL_U280 NRCC cancer cell line human CVCL_U280 CL:0000010 Population: Chinese Male Doubling time: 35.5 hours (PubMed=23442546). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200910 21144144 CVCL_U281 AG11395 transformed cell line human CVCL_U281 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (Coriell; PubMed=9230208) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21144145 CVCL_TQ81 HAP1 STK25 (-) 2 cancer cell line human CVCL_TQ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11404; STK25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144146 CVCL_U286 BC-009 cancer cell line human CVCL_U286 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000195) It was the sole source of information for this entry.. Population: Chinese Female 21144147 CVCL_TQ86 HAP1 STK32B (-) 1 cancer cell line human CVCL_TQ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14217; STK32B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144148 CVCL_U287 Anglne cancer cell line human CVCL_U287 CL:0000010 Female 21144149 CVCL_TQ87 HAP1 STK32B (-) 2 cancer cell line human CVCL_TQ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14217; STK32B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144150 CVCL_TQ84 HAP1 STK3 (-) 2 cancer cell line human CVCL_TQ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11406; STK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144151 CVCL_U284 RCC09HYF cancer cell line human CVCL_U284 CL:0000010 Population: Chinese; Han; Derived from sampling site: Kidney. Male Doubling time: 18 hours (Patent=US9386762) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201130 21144152 CVCL_U285 10G4 hybridoma house mouse CVCL_U285 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1); Monoclonal antibody target: ChEBI; CHEBI:48209; Aflatoxin B2 (AFB2); Monoclonal antibody target: ChEBI; CHEBI:80706; Aflatoxin G1 (AFG1); Monoclonal antibody target: ChEBI; CHEBI:80705; Aflatoxin G2 (AFG2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201016 21144153 CVCL_TQ85 HAP1 STK3 (-) 3 cancer cell line human CVCL_TQ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11406; STK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144154 CVCL_U268 CCD-1043Sk finite cell line human CVCL_U268 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-2056; true Male Senescence: Senesces after 70 PDL (ATCC=CRL-2056) 21144155 CVCL_TQ68 HAP1 STIP1 (-) 1 cancer cell line human CVCL_TQ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11387; STIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144156 CVCL_TQ69 HAP1 STK10 (-) 1 cancer cell line human CVCL_TQ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11388; STK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144157 CVCL_U269 NIT-3 transformed cell line house mouse CVCL_U269 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BLKS/J-Cpefat/1 x NOD/Lt-Tg(RIPTag)1Lt. Female 21144158 CVCL_U266 CCD-919Sk finite cell line human CVCL_U266 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1826; true Female 21144159 CVCL_TQ66 HAP1 STAT6 (-) 1 cancer cell line human CVCL_TQ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11368; STAT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144160 CVCL_U267 CCD-966Sk finite cell line human CVCL_U267 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1881; true Female 21144161 CVCL_1K41 GM22628 transformed cell line human CVCL_1K41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144162 CVCL_1K42 GM22629 transformed cell line human CVCL_1K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144163 CVCL_1K40 GM22627 transformed cell line human CVCL_1K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144164 CVCL_1K45 GM22632 transformed cell line human CVCL_1K45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144165 CVCL_1K46 GM00248 finite cell line human CVCL_1K46 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144166 CVCL_1K43 GM22630 transformed cell line human CVCL_1K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144167 CVCL_1K44 GM22631 transformed cell line human CVCL_1K44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144168 CVCL_1K38 GM22625 transformed cell line human CVCL_1K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144169 CVCL_1K39 GM22626 transformed cell line human CVCL_1K39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144170 CVCL_1K36 GM22623 transformed cell line human CVCL_1K36 CL:0000010 Karyotypic information: 46,XX,ins(13;11)(q14.1;p11.2p12).ish ins(13;11)(q14.1;p11.2p12)(wcp11+).arr(1-22,X)x2 (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144171 CVCL_1K37 GM22624 transformed cell line human CVCL_1K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144172 CVCL_TQ71 HAP1 STK11 (-) 1 cancer cell line human CVCL_TQ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144173 CVCL_U271 NK-92CI cancer cell line human CVCL_U271 CL:0000010 Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Discontinued: ATCC; CRL-2409; true Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6672 Caution: NantKwest exclusively owns, controls and distributes this cell line 21144174 CVCL_TQ72 HAP1 STK11 (-) 2 cancer cell line human CVCL_TQ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11389; STK11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144175 CVCL_U272 OLGA-PH-J/92 spontaneously immortalized cell line CVCL_U272 CL:0000010 Discontinued: ATCC; CRL-2576; true. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00378 Problematic cell line: Misidentified Shown not to originate from the crayfish Orconectes limosus. May have been derived from contaminating fresh water amoeba that could have been present in the neural tissue of the originating crayfish (PubMed=21938590). 21144176 CVCL_U270 CCD-1056Sk finite cell line human CVCL_U270 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-2068; true Female Senescence: Senesces at 37 PDL (ATCC=CRL-2068) 21144177 CVCL_TQ70 HAP1 STK10 (-) 2 cancer cell line human CVCL_TQ70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11388; STK10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144178 CVCL_U275 1E2 [Mouse hybridoma against HIV-1 antigens] hybridoma house mouse CVCL_U275 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: HIV-1 antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9100 21144179 CVCL_TQ75 HAP1 STK17A (-) cancer cell line human CVCL_TQ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11395; STK17A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144180 CVCL_U276 3D8 hybridoma house mouse CVCL_U276 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: HIV-1 antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9101 21144181 CVCL_TQ76 HAP1 STK17B (-) 1 cancer cell line human CVCL_TQ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11396; STK17B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144182 CVCL_U273 1A8 hybrid cell line house mouse CVCL_U273 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8090 21144183 CVCL_TQ73 HAP1 STK16 (-) 1 cancer cell line human CVCL_TQ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11394; STK16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144184 CVCL_U274 1A8C3C10 hybrid cell line house mouse CVCL_U274 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8089. 21144185 CVCL_TQ74 HAP1 STK16 (-) 2 cancer cell line human CVCL_TQ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11394; STK16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144186 CVCL_U257 BC-027 cancer cell line human CVCL_U257 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000203) It was the sole source of information for this entry.. Population: Chinese Female 21144187 CVCL_TQ57 HAP1 STAT1 (-) 1 cancer cell line human CVCL_TQ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144188 CVCL_U258 BC-028 cancer cell line human CVCL_U258 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000204) It was the sole source of information for this entry.. Population: Chinese Female 21144189 CVCL_TQ58 HAP1 STAT1 (-) 2 cancer cell line human CVCL_TQ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144190 CVCL_U255 BC-024 cancer cell line human CVCL_U255 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 39 hours, at 34th passage (PubMed=30662642) 21144191 CVCL_TQ55 HAP1 STAMBPL1 (-) 1 cancer cell line human CVCL_TQ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24105; STAMBPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144192 CVCL_U256 BC-025 cancer cell line human CVCL_U256 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000202) It was the sole source of information for this entry.. Population: Chinese Female 21144193 CVCL_TQ56 HAP1 STAMBPL1 (-) 2 cancer cell line human CVCL_TQ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24105; STAMBPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144194 CVCL_TQ59 HAP1 STAT1 (-) 3 cancer cell line human CVCL_TQ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144195 CVCL_U259 ROS 17/2.8-5 cancer cell line Norway rat CVCL_U259 CL:0000010 Breed/subspecies: ACI 9935. Discontinued: RCB; RCB0462; true 21144196 CVCL_1K12 9009B spontaneously immortalized cell line CVCL_1K12 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11302 Problematic cell line: Misidentified Parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21144197 CVCL_1K13 Vero/SF spontaneously immortalized cell line green monkey CVCL_1K13 CL:0000010 Derived from sampling site: Kidney; epithelium. Discontinued: ATCC; CCL-81.1; true Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21144198 CVCL_1K10 Pno cancer cell line human CVCL_1K10 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: 72 hours (PubMed=10910922) 21144199 CVCL_1K11 Vero-SF-ACF spontaneously immortalized cell line green monkey CVCL_1K11 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to serum-free and animal component-free medium Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21144200 CVCL_1K05 UHKT-944 cancer cell line human CVCL_1K05 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA1 kappa; Characteristics: IL6 dependent Doubling time: 65-77 hours (PubMed=23290585) 21144201 CVCL_1K06 BKP1 cancer cell line human CVCL_1K06 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 21144202 CVCL_1K03 CG-SH cancer cell line human CVCL_1K03 CL:0000010 Karyotypic information: Has a normal karyotype; Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48-52 hours (PubMed=19414191) 21144203 CVCL_1K04 GM08121 transformed cell line human CVCL_1K04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144204 CVCL_1K09 Cou-L cancer cell line human CVCL_1K09 CL:0000010 Miscellaneous: Sampling site and synonym from personal communication of Bensussan A Derived from sampling site: Peripheral blood. Male 21144205 CVCL_1K07 Cou-LS cancer cell line human CVCL_1K07 CL:0000010 Miscellaneous: Sampling site from personal communication of Bensussan A Derived from sampling site: Skin. Male 21144206 CVCL_1K08 Cou-L3 cancer cell line human CVCL_1K08 CL:0000010 Miscellaneous: Sampling site from personal communication of Bensussan A Derived from sampling site: Skin. Male 21144207 CVCL_U260 CEM/A5 cancer cell line human CVCL_U260 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21144208 CVCL_TQ60 HAP1 STAT1 (-) 4 cancer cell line human CVCL_TQ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11362; STAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144209 CVCL_U261 CEM/A7 cancer cell line human CVCL_U261 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21144210 CVCL_TQ61 HAP1 STAT2 (-) 1 cancer cell line human CVCL_TQ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144211 CVCL_TQ64 HAP1 STAT5B (-) 1 cancer cell line human CVCL_TQ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11367; STAT5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144212 CVCL_U264 RH9 cancer cell line human CVCL_U264 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12043 21144213 CVCL_TQ65 HAP1 STAT5B (-) 2 cancer cell line human CVCL_TQ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11367; STAT5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144214 CVCL_U265 RH9/CB cancer cell line human CVCL_U265 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11622 21144215 CVCL_U262 CB [Catla] spontaneously immortalized cell line CVCL_U262 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC020 21144216 CVCL_TQ62 HAP1 STAT3 (-) 1 cancer cell line human CVCL_TQ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144217 CVCL_TQ63 HAP1 STAT3 (-) 2 cancer cell line human CVCL_TQ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11364; STAT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144218 CVCL_U263 RE spontaneously immortalized cell line CVCL_U263 CL:0000010 Derived from sampling site: Eye. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC044 21144219 CVCL_TQ46 HAP1 SRPK1 (-) 1 cancer cell line human CVCL_TQ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144220 CVCL_U246 ITM-E6/E7-ST transformed cell line human CVCL_U246 CL:0000010 Transfected with: HGNC; 6840; MAP2K1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung. Female 21144221 CVCL_TQ47 HAP1 SRPK1 (-) 2 cancer cell line human CVCL_TQ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144222 CVCL_U247 ITM-ST transformed cell line human CVCL_U247 CL:0000010 Transfected with: HGNC; 6840; MAP2K1; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung. Female 21144223 CVCL_TQ44 HAP1 SREBF2 (-) 3 cancer cell line human CVCL_TQ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144224 CVCL_U244 ITM telomerase immortalized cell line human CVCL_U244 CL:0000010 Transfected with: HGNC; 6840; MAP2K1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal lung. Female 21144225 CVCL_TQ45 HAP1 SREBF2 (-) 4 cancer cell line human CVCL_TQ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144226 CVCL_U245 ITM-E6/E7 transformed cell line human CVCL_U245 CL:0000010 Transfected with: HGNC; 6840; MAP2K1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal lung. Female 21144227 CVCL_TQ48 HAP1 SRPK2 (-) cancer cell line human CVCL_TQ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11306; SRPK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144228 CVCL_U248 MG-22A cancer cell line house mouse CVCL_U248 CL:0000010 21144229 CVCL_TQ49 HAP1 SRPK3 (-) cancer cell line human CVCL_TQ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11402; SRPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144230 CVCL_U249 MMLAL cancer cell line human CVCL_U249 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=24330858) Population: Chinese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG lambda 21144231 CVCL_1K20 GM14717 transformed cell line human CVCL_1K20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144232 CVCL_1K23 GM05147 transformed cell line human CVCL_1K23 CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (from familial inference of GM05148 and GM05149) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144233 CVCL_1K24 GM05148 finite cell line human CVCL_1K24 CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; c.448+64T>C (IVS3+64T>C); ClinVar=VCV000683189; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144234 CVCL_1K21 GM17523 finite cell line human CVCL_1K21 CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Gly469Glu (c.1406G>A); ClinVar=VCV000007674; Zygosity=Heterozygous (PubMed=11779494); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg814Ter (c.2440C>T); ClinVar=VCV000007673; Zygosity=Heterozygous (PubMed=11779494) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21144235 CVCL_1K22 GM05146 finite cell line human CVCL_1K22 CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (from familial inference of GM05148 and GM05149) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144236 CVCL_1K16 PBS-1 transformed cell line CVCL_1K16 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line; Group: Vaccine production cell line 21144237 CVCL_1K17 PBS-12SF transformed cell line CVCL_1K17 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8565 21144238 CVCL_1K14 CHW-1103 transformed cell line CVCL_1K14 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: HPRT deficient 21144239 CVCL_1K15 911 transformed cell line human CVCL_1K15 CL:0000010 Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina Cell type=Retinoblast.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 95062101 21144240 CVCL_1K18 QOR/2E11 transformed cell line CVCL_1K18 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Bird cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21144241 CVCL_1K19 GM14081 transformed cell line human CVCL_1K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144242 CVCL_U250 BC-019 cancer cell line human CVCL_U250 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 36 hours (PubMed=19121212) 21144243 CVCL_TQ50 HAP1 SRXN1 (-) 1 cancer cell line human CVCL_TQ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16132; SRXN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144244 CVCL_U253 BC-022 cancer cell line human CVCL_U253 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000199) It was the sole source of information for this entry.. Population: Chinese Female 21144245 CVCL_TQ53 HAP1 ST3GAL5 (-) 2 cancer cell line human CVCL_TQ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10872; ST3GAL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144246 CVCL_U254 BC-023 cancer cell line human CVCL_U254 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 35 hours, at 23th passage (PubMed=30662642) 21144247 CVCL_TQ54 HAP1 STAMBP (-) cancer cell line human CVCL_TQ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16950; STAMBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144248 CVCL_U251 BC-020 cancer cell line human CVCL_U251 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 35 hours (PubMed=19121212) 21144249 CVCL_TQ51 HAP1 SSBP4 (-) 1 cancer cell line human CVCL_TQ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15676; SSBP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144250 CVCL_U252 BC-021 cancer cell line human CVCL_U252 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 48 hours (PubMed=19121212) 21144251 CVCL_TQ52 HAP1 ST3GAL5 (-) 1 cancer cell line human CVCL_TQ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10872; ST3GAL5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144252 CVCL_1K92 GM14047 transformed cell line human CVCL_1K92 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met318Thr (c.953T>C); ClinVar=VCV000004021; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144253 CVCL_1K93 GM14057 transformed cell line human CVCL_1K93 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-2A>G; ClinVar=VCV000972817; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Tyr609Ter (c.1827delC) (p.Arg608_Tyr609insTer); ClinVar=VCV000188936; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144254 CVCL_1K90 GM14045 transformed cell line human CVCL_1K90 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met318Thr (c.953T>C); ClinVar=VCV000004021; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp746Ser (c.2237G>C); ClinVar=VCV000188484; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144255 CVCL_1K91 GM14046 transformed cell line human CVCL_1K91 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp746Ser (c.2237G>C); ClinVar=VCV000188484; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144256 CVCL_1K96 GM14259 transformed cell line human CVCL_1K96 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg594Pro (c.1781G>C); ClinVar=VCV000289361; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly828_Asn882del (c.2481+102_2646+31del) (c.2482_2646del165); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144257 CVCL_1K97 GM14393 transformed cell line human CVCL_1K97 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly309Arg (c.925G>A); ClinVar=VCV000188797; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144258 CVCL_1K94 GM14108 transformed cell line human CVCL_1K94 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144259 CVCL_1K95 GM14242 transformed cell line human CVCL_1K95 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu176Argfs*45 (c.525delT); ClinVar=VCV000004033; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144260 CVCL_1K98 GM14407 transformed cell line human CVCL_1K98 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Leu291Phe (c.871C>T); ClinVar=VCV000956209; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp481Arg (c.1441T>C); ClinVar=VCV000189007; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144261 CVCL_1K99 GM14411 transformed cell line human CVCL_1K99 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; c.-32-13T>G (IVS1-13T>G); ClinVar=VCV000004027; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Gly309Arg (c.925G>A); ClinVar=VCV000188797; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144262 CVCL_KY58 PathHunter CHO-K1 mVIPR1 beta-arrestin spontaneously immortalized cell line CVCL_KY58 CL:0000010 Transfected with: MGI; MGI:109272; Vipr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144263 CVCL_KY59 PathHunter CHO-K1 NMBR beta-arrestin spontaneously immortalized cell line CVCL_KY59 CL:0000010 Transfected with: HGNC; 7843; NMBR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144264 CVCL_KY56 PathHunter CHO-K1 MTNR1B beta-arrestin spontaneously immortalized cell line CVCL_KY56 CL:0000010 Transfected with: HGNC; 7464; MTNR1B; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144265 CVCL_KY57 PathHunter CHO-K1 mUTR2 beta-arrestin spontaneously immortalized cell line CVCL_KY57 CL:0000010 Transfected with: MGI; MGI:2183450; Uts2r; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144266 CVCL_KY54 PathHunter CHO-K1 mSSTR5 beta-arrestin spontaneously immortalized cell line CVCL_KY54 CL:0000010 Transfected with: MGI; MGI:894282; Sstr5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144267 CVCL_KY55 PathHunter CHO-K1 MTNR1A beta-arrestin spontaneously immortalized cell line CVCL_KY55 CL:0000010 Transfected with: HGNC; 7463; MTNR1A; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144268 CVCL_KY52 PathHunter CHO-K1 mRXFP4 beta-arrestin spontaneously immortalized cell line CVCL_KY52 CL:0000010 Transfected with: MGI; MGI:2182926; Rxfp4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144269 CVCL_KY53 PathHunter CHO-K1 mSSTR2 beta-arrestin spontaneously immortalized cell line CVCL_KY53 CL:0000010 Transfected with: MGI; MGI:98328; Sstr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144270 CVCL_KY50 PathHunter CHO-K1 MRGPRX4 beta-arrestin spontaneously immortalized cell line CVCL_KY50 CL:0000010 Transfected with: HGNC; 17617; MRGPRX4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144271 CVCL_KY51 PathHunter CHO-K1 mRXFP3 beta-arrestin spontaneously immortalized cell line CVCL_KY51 CL:0000010 Transfected with: MGI; MGI:2441827; Rxfp3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144272 CVCL_KY69 PathHunter CHO-K1 OPRL1 beta-arrestin spontaneously immortalized cell line CVCL_KY69 CL:0000010 Transfected with: HGNC; 8155; OPRL1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144273 CVCL_KY67 PathHunter CHO-K1 OPN5 beta-arrestin spontaneously immortalized cell line CVCL_KY67 CL:0000010 Transfected with: HGNC; 19992; OPN5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144274 CVCL_KY68 PathHunter CHO-K1 OPRD1 beta-arrestin spontaneously immortalized cell line CVCL_KY68 CL:0000010 Transfected with: HGNC; 8153; OPRD1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144275 CVCL_KY65 PathHunter CHO-K1 NPY2R beta-arrestin spontaneously immortalized cell line CVCL_KY65 CL:0000010 Transfected with: HGNC; 7957; NPY2R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144276 CVCL_KY66 PathHunter CHO-K1 NTSR1 beta-arrestin spontaneously immortalized cell line CVCL_KY66 CL:0000010 Transfected with: HGNC; 8039; NTSR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144277 CVCL_KY63 PathHunter CHO-K1 NPR1 Functional Assay spontaneously immortalized cell line CVCL_KY63 CL:0000010 Transfected with: HGNC; 7943; NPR1 Derived from sampling site: Ovary. Female 21144278 CVCL_KY64 PathHunter CHO-K1 NPY1R beta-arrestin spontaneously immortalized cell line CVCL_KY64 CL:0000010 Transfected with: HGNC; 7956; NPY1R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144279 CVCL_KY61 PathHunter CHO-K1 NPBWR2 beta-arrestin spontaneously immortalized cell line CVCL_KY61 CL:0000010 Transfected with: HGNC; 4530; NPBWR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144280 CVCL_KY62 PathHunter CHO-K1 NPFFR1 beta-arrestin spontaneously immortalized cell line CVCL_KY62 CL:0000010 Transfected with: HGNC; 17425; NPFFR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144281 CVCL_KY60 PathHunter CHO-K1 NPBWR1 beta-arrestin spontaneously immortalized cell line CVCL_KY60 CL:0000010 Transfected with: HGNC; 4522; NPBWR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144282 CVCL_KY38 PathHunter CHO-K1 mOPRD1 beta-arrestin spontaneously immortalized cell line CVCL_KY38 CL:0000010 Transfected with: MGI; MGI:97438; Oprd1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144283 CVCL_KY39 PathHunter CHO-K1 mOPRK1 beta-arrestin spontaneously immortalized cell line CVCL_KY39 CL:0000010 Transfected with: MGI; MGI:97439; Oprk1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144284 CVCL_KY36 PathHunter CHO-K1 mMCHR1 beta-arrestin spontaneously immortalized cell line CVCL_KY36 CL:0000010 Transfected with: MGI; MGI:2180756; Mchr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144285 CVCL_KY37 PathHunter CHO-K1 mNPY2R beta-arrestin spontaneously immortalized cell line CVCL_KY37 CL:0000010 Transfected with: MGI; MGI:108418; Npy2r; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144286 CVCL_KY34 PathHunter CHO-K1 MLNR beta-arrestin spontaneously immortalized cell line CVCL_KY34 CL:0000010 Transfected with: HGNC; 4495; MLNR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144287 CVCL_KY35 PathHunter CHO-K1 mLTB4R1 beta-arrestin spontaneously immortalized cell line CVCL_KY35 CL:0000010 Transfected with: MGI; MGI:1309472; Ltb4r1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144288 CVCL_KY32 PathHunter CHO-K1 mGPR84 beta-arrestin spontaneously immortalized cell line CVCL_KY32 CL:0000010 Transfected with: MGI; MGI:1934129; Gpr84; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144289 CVCL_KY33 PathHunter CHO-K1 mHTR2A beta-arrestin spontaneously immortalized cell line CVCL_KY33 CL:0000010 Transfected with: MGI; MGI:109521; Htr2a; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144290 CVCL_KY30 PathHunter CHO-K1 mGLP1R beta-arrestin-1 spontaneously immortalized cell line CVCL_KY30 CL:0000010 Transfected with: MGI; MGI:99571; Glp1r; Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144291 CVCL_KY31 PathHunter CHO-K1 mGPR1 beta-arrestin spontaneously immortalized cell line CVCL_KY31 CL:0000010 Transfected with: MGI; MGI:2385324; Gpr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144292 CVCL_KY49 PathHunter CHO-K1 MRGPRX2 beta-arrestin spontaneously immortalized cell line CVCL_KY49 CL:0000010 Transfected with: HGNC; 17983; MRGPRX2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144293 CVCL_KY47 PathHunter CHO-K1 MRGPRF beta-arrestin spontaneously immortalized cell line CVCL_KY47 CL:0000010 Transfected with: HGNC; 24828; MRGPRF; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144294 CVCL_KY48 PathHunter CHO-K1 MRGPRX1 beta-arrestin spontaneously immortalized cell line CVCL_KY48 CL:0000010 Transfected with: HGNC; 17962; MRGPRX1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144295 CVCL_KY45 PathHunter CHO-K1 MRGPRD beta-arrestin spontaneously immortalized cell line CVCL_KY45 CL:0000010 Transfected with: HGNC; 29626; MRGPRD; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144296 CVCL_KY46 PathHunter CHO-K1 MRGPRE beta-arrestin spontaneously immortalized cell line CVCL_KY46 CL:0000010 Transfected with: HGNC; 30694; MRGPRE; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144297 CVCL_KY43 PathHunter CHO-K1 mPTAFR beta-arrestin spontaneously immortalized cell line CVCL_KY43 CL:0000010 Transfected with: MGI; MGI:106066; Ptafr; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144298 CVCL_KY44 PathHunter CHO-K1 MR Protein Interaction spontaneously immortalized cell line CVCL_KY44 CL:0000010 Transfected with: HGNC; 7979; NR3C2; Transfected with: HGNC; 9237; PPARGC1A Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144299 CVCL_KY41 PathHunter CHO-K1 mP2RY12 beta-arrestin spontaneously immortalized cell line CVCL_KY41 CL:0000010 Transfected with: MGI; MGI:1918089; P2ry12; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144300 CVCL_KY42 PathHunter CHO-K1 mPPYR1 beta-arrestin spontaneously immortalized cell line CVCL_KY42 CL:0000010 Transfected with: MGI; MGI:105374; Npy4r; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144301 CVCL_KY40 PathHunter CHO-K1 mOXTR beta-arrestin spontaneously immortalized cell line CVCL_KY40 CL:0000010 Transfected with: MGI; MGI:109147; Oxtr; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144302 CVCL_KY18 PathHunter CHO-K1 mEDG1 beta-arrestin spontaneously immortalized cell line CVCL_KY18 CL:0000010 Transfected with: MGI; MGI:1096355; S1pr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144303 CVCL_KY19 PathHunter CHO-K1 mEDG3 beta-arrestin spontaneously immortalized cell line CVCL_KY19 CL:0000010 Transfected with: MGI; MGI:1339365; S1pr3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144304 CVCL_KY16 PathHunter CHO-K1 mDRD5 beta-arrestin spontaneously immortalized cell line CVCL_KY16 CL:0000010 Transfected with: MGI; MGI:94927; Drd5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144305 CVCL_KY17 PathHunter CHO-K1 mEBI2 beta-arrestin spontaneously immortalized cell line CVCL_KY17 CL:0000010 Transfected with: MGI; MGI:2442034; Gpr183; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144306 CVCL_KY14 PathHunter CHO-K1 mCXCR5 beta-arrestin spontaneously immortalized cell line CVCL_KY14 CL:0000010 Transfected with: MGI; MGI:103567; Cxcr5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144307 CVCL_KY15 PathHunter CHO-K1 mCXCR6 beta-arrestin spontaneously immortalized cell line CVCL_KY15 CL:0000010 Transfected with: MGI; MGI:1934582; Cxcr6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144308 CVCL_KY12 PathHunter CHO-K1 mCXCR2 beta-arrestin spontaneously immortalized cell line CVCL_KY12 CL:0000010 Transfected with: MGI; MGI:105303; Cxcr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144309 CVCL_KY13 PathHunter CHO-K1 mCXCR3 beta-arrestin spontaneously immortalized cell line CVCL_KY13 CL:0000010 Transfected with: MGI; MGI:1277207; Cxcr3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144310 CVCL_KY10 PathHunter CHO-K1 mCRHR1 beta-arrestin spontaneously immortalized cell line CVCL_KY10 CL:0000010 Transfected with: MGI; MGI:88498; Crhr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144311 CVCL_KY11 PathHunter CHO-K1 mCRTH2 beta-arrestin spontaneously immortalized cell line CVCL_KY11 CL:0000010 Transfected with: MGI; MGI:1330275; Ptgdr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144312 CVCL_KY29 PathHunter CHO-K1 mGLP1R beta-arrestin spontaneously immortalized cell line CVCL_KY29 CL:0000010 Transfected with: MGI; MGI:99571; Glp1r; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144313 CVCL_KY27 PathHunter CHO-K1 mGCGR beta-arrestin-1 spontaneously immortalized cell line CVCL_KY27 CL:0000010 Transfected with: MGI; MGI:99572; Gcgr; Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144314 CVCL_KY28 PathHunter CHO-K1 mGHSR1a beta-arrestin spontaneously immortalized cell line CVCL_KY28 CL:0000010 Transfected with: MGI; MGI:2441906; Ghsr; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144315 CVCL_KY25 PathHunter CHO-K1 mGALR2 beta-arrestin spontaneously immortalized cell line CVCL_KY25 CL:0000010 Transfected with: MGI; MGI:1337018; Galr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144316 CVCL_KY26 PathHunter CHO-K1 mGCGR beta-arrestin spontaneously immortalized cell line CVCL_KY26 CL:0000010 Transfected with: MGI; MGI:99572; Gcgr; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144317 CVCL_KY23 PathHunter CHO-K1 mFPR1 beta-arrestin spontaneously immortalized cell line CVCL_KY23 CL:0000010 Transfected with: MGI; MGI:107443; Fpr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144318 CVCL_KY24 PathHunter CHO-K1 mFPR2 beta-arrestin spontaneously immortalized cell line CVCL_KY24 CL:0000010 Transfected with: MGI; MGI:1278319; Fpr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144319 CVCL_KY21 PathHunter CHO-K1 mEDNRA beta-arrestin spontaneously immortalized cell line CVCL_KY21 CL:0000010 Transfected with: MGI; MGI:105923; Ednra; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144320 CVCL_KY22 PathHunter CHO-K1 mEDNRB beta-arrestin spontaneously immortalized cell line CVCL_KY22 CL:0000010 Transfected with: MGI; MGI:102720; Ednrb; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144321 CVCL_KY20 PathHunter CHO-K1 mEDG5 beta-arrestin spontaneously immortalized cell line CVCL_KY20 CL:0000010 Transfected with: MGI; MGI:99569; S1pr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144322 CVCL_KY09 PathHunter CHO-K1 mCNR2 beta-arrestin spontaneously immortalized cell line CVCL_KY09 CL:0000010 Transfected with: MGI; MGI:104650; Cnr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144323 CVCL_KY07 PathHunter CHO-K1 mCMKLR1 beta-arrestin spontaneously immortalized cell line CVCL_KY07 CL:0000010 Transfected with: MGI; MGI:109603; Cmklr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144324 CVCL_KY08 PathHunter CHO-K1 mCNR1 beta-arrestin spontaneously immortalized cell line CVCL_KY08 CL:0000010 Transfected with: MGI; MGI:104615; Cnr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144325 CVCL_KY05 PathHunter CHO-K1 mCCR8 beta-arrestin spontaneously immortalized cell line CVCL_KY05 CL:0000010 Transfected with: MGI; MGI:1201402; Ccr8; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144326 CVCL_KY06 PathHunter CHO-K1 mCCR9 beta-arrestin spontaneously immortalized cell line CVCL_KY06 CL:0000010 Transfected with: MGI; MGI:1341902; Ccr9; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144327 CVCL_KY03 PathHunter CHO-K1 mCCR6 beta-arrestin spontaneously immortalized cell line CVCL_KY03 CL:0000010 Transfected with: MGI; MGI:1333797; Ccr6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144328 CVCL_KY04 PathHunter CHO-K1 mCCR7 beta-arrestin spontaneously immortalized cell line CVCL_KY04 CL:0000010 Transfected with: MGI; MGI:103011; Ccr7; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144329 CVCL_KY01 PathHunter CHO-K1 mCCR4 beta-arrestin spontaneously immortalized cell line CVCL_KY01 CL:0000010 Transfected with: MGI; MGI:107824; Ccr4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144330 CVCL_KY02 PathHunter CHO-K1 mCCR5 beta-arrestin spontaneously immortalized cell line CVCL_KY02 CL:0000010 Transfected with: MGI; MGI:107182; Ccr5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144331 CVCL_KY00 PathHunter CHO-K1 mCCR3 beta-arrestin spontaneously immortalized cell line CVCL_KY00 CL:0000010 Transfected with: MGI; MGI:104616; Ccr3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144332 CVCL_U477 GM08760 finite cell line human CVCL_U477 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (PubMed=30497978) Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Male 21144333 CVCL_TS77 HAP1 TMEM150A (-) 1 cancer cell line human CVCL_TS77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24677; TMEM150A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144334 CVCL_U478 GM00372 finite cell line human CVCL_U478 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu29Alafs*18 (c.84dupG) (c.84_85insG) (84GG); ClinVar=VCV000004302; Zygosity=Heterozygous (PubMed=30497978); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=30497978) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21144335 CVCL_TS78 HAP1 TMEM150A (-) 2 cancer cell line human CVCL_TS78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24677; TMEM150A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144336 CVCL_TS75 HAP1 TMEM106B (-) 1 cancer cell line human CVCL_TS75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22407; TMEM106B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144337 CVCL_U475 THK [Hamster] transformed cell line CVCL_U475 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified 21144338 CVCL_U476 GM08752 transformed cell line human CVCL_U476 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (from autologous cell line GM08760) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144339 CVCL_TS76 HAP1 TMEM126A (-) 1 cancer cell line human CVCL_TS76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25382; TMEM126A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144340 CVCL_U479 GM01019 transformed cell line human CVCL_U479 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144341 CVCL_TS79 HAP1 TMEM150C (-) 1 cancer cell line human CVCL_TS79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37263; TMEM150C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144342 CVCL_1M32 GM13984 transformed cell line human CVCL_1M32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144343 CVCL_1M33 GM13995 transformed cell line human CVCL_1M33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144344 CVCL_1M30 GM13972 transformed cell line human CVCL_1M30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144345 CVCL_1M31 GM13973 transformed cell line human CVCL_1M31 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp2959Glyfs*3 (c.8876_8879delACTG) (8876del4); ClinVar=VCV000189140; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144346 CVCL_1M25 GM13954 transformed cell line human CVCL_1M25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144347 CVCL_1M26 GM13957 transformed cell line human CVCL_1M26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144348 CVCL_1M23 GM13941 transformed cell line human CVCL_1M23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144349 CVCL_1M24 GM13942 transformed cell line human CVCL_1M24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144350 CVCL_1M29 GM13970 transformed cell line human CVCL_1M29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144351 CVCL_1M27 GM13961 transformed cell line human CVCL_1M27 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.7630-2A>C (IVS53-2A>C) (IVS51-2A>C) (L2544del53); ClinVar=VCV000127447; Zygosity=Heterozygous; Note=Causes in-frame skipping of exon 54 (Leu2544del53) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144352 CVCL_1M28 GM13969 transformed cell line human CVCL_1M28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144353 CVCL_U480 GM05081 finite cell line human CVCL_U480 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; None_reported; -; Zygosity=- (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144354 CVCL_TS80 HAP1 TMEM150C (-) 2 cancer cell line human CVCL_TS80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37263; TMEM150C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144355 CVCL_U481 GM05082 transformed cell line human CVCL_U481 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; None_reported; -; Zygosity=- (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144356 CVCL_TS81 HAP1 TMEM173 (-) 1 cancer cell line human CVCL_TS81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144357 CVCL_TS84 HAP1 TMEM173 (-) 4 cancer cell line human CVCL_TS84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144358 CVCL_U484 MCH047 finite cell line human CVCL_U484 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21144359 CVCL_TS85 HAP1 TMEM175 (-) 1 cancer cell line human CVCL_TS85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28709; TMEM175; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144360 CVCL_U485 MCH055 finite cell line human CVCL_U485 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144361 CVCL_U482 GM23127 transformed cell line human CVCL_U482 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex27-28dup; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144362 CVCL_TS82 HAP1 TMEM173 (-) 2 cancer cell line human CVCL_TS82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144363 CVCL_TS83 HAP1 TMEM173 (-) 3 cancer cell line human CVCL_TS83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144364 CVCL_U483 MCH045 finite cell line human CVCL_U483 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21144365 CVCL_TS66 HAP1 TMBIM6 (-) 3 cancer cell line human CVCL_TS66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11723; TMBIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144366 CVCL_U466 OLP6 conditionally immortalized cell line Norway rat CVCL_U466 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; suprachiasmatic nucleus Cell type=Oligodendrocyte.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21144367 CVCL_TS67 HAP1 TMBIM6 (-) 4 cancer cell line human CVCL_TS67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11723; TMBIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144368 CVCL_U467 tsBN2 spontaneously immortalized cell line CVCL_U467 CL:0000010 Derived from sampling site: Kidney. Male 21144369 CVCL_U464 42GPA9 transformed cell line house mouse CVCL_U464 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Tg(PyLT). Male 21144370 CVCL_TS64 HAP1 TMBIM6 (-) 1 cancer cell line human CVCL_TS64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11723; TMBIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144371 CVCL_TS65 HAP1 TMBIM6 (-) 2 cancer cell line human CVCL_TS65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11723; TMBIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144372 CVCL_U465 N14.5 conditionally immortalized cell line Norway rat CVCL_U465 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; suprachiasmatic nucleus; ventrolateral part Cell type=Neuron.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Unspecified 21144373 CVCL_TS68 HAP1 TMBIM6 (-) 5 cancer cell line human CVCL_TS68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11723; TMBIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144374 CVCL_U468 tsBN250 spontaneously immortalized cell line CVCL_U468 CL:0000010 Derived from sampling site: Kidney. Male 21144375 CVCL_TS69 HAP1 TMC1 (-) 1 cancer cell line human CVCL_TS69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16513; TMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144376 CVCL_U469 tsBN269 spontaneously immortalized cell line CVCL_U469 CL:0000010 Derived from sampling site: Kidney. Male 21144377 CVCL_1M40 GM14014 transformed cell line human CVCL_1M40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144378 CVCL_1M43 GM14051 transformed cell line human CVCL_1M43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144379 CVCL_1M44 GM14053 transformed cell line human CVCL_1M44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144380 CVCL_1M41 GM14031 transformed cell line human CVCL_1M41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144381 CVCL_1M42 GM14038 transformed cell line human CVCL_1M42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144382 CVCL_1M36 GM14000 transformed cell line human CVCL_1M36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144383 CVCL_1M37 GM14008 transformed cell line human CVCL_1M37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144384 CVCL_1M34 GM13996 transformed cell line human CVCL_1M34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144385 CVCL_1M35 GM13997 transformed cell line human CVCL_1M35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144386 CVCL_1M38 GM14010 transformed cell line human CVCL_1M38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144387 CVCL_1M39 GM14013 transformed cell line human CVCL_1M39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144388 CVCL_TS70 HAP1 TMC1 (-) 2 cancer cell line human CVCL_TS70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16513; TMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144389 CVCL_U470 tsBN462 spontaneously immortalized cell line CVCL_U470 CL:0000010 Derived from sampling site: Kidney. Male 21144390 CVCL_TS73 HAP1 TMED7 (-) 1 cancer cell line human CVCL_TS73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24253; TMED7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144391 CVCL_U473 tsBN7 spontaneously immortalized cell line CVCL_U473 CL:0000010 Derived from sampling site: Kidney. Male 21144392 CVCL_TS74 HAP1 TMED9 (-) 1 cancer cell line human CVCL_TS74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24878; TMED9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144393 CVCL_U474 tsBN75 spontaneously immortalized cell line CVCL_U474 CL:0000010 Derived from sampling site: Kidney. Male 21144394 CVCL_TS71 HAP1 TMCC3 (-) 1 cancer cell line human CVCL_TS71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29199; TMCC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144395 CVCL_U471 tsBN51 spontaneously immortalized cell line CVCL_U471 CL:0000010 Derived from sampling site: Kidney. Male 21144396 CVCL_TS72 HAP1 TMED5 (-) 1 cancer cell line human CVCL_TS72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24251; TMED5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144397 CVCL_U472 tsBN67 spontaneously immortalized cell line CVCL_U472 CL:0000010 Derived from sampling site: Kidney. Male 21144398 CVCL_U455 G5G2 transformed cell line house mouse CVCL_U455 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144399 CVCL_TS55 HAP1 TM6SF1 (-) 1 cancer cell line human CVCL_TS55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11860; TM6SF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144400 CVCL_TS56 HAP1 TM9SF1 (-) 1 cancer cell line human CVCL_TS56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11864; TM9SF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144401 CVCL_U456 J5 [Mouse Sertoli cells] transformed cell line house mouse CVCL_U456 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144402 CVCL_U453 G5B3 transformed cell line house mouse CVCL_U453 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144403 CVCL_TS53 HAP1 TLR2 (-) 1 cancer cell line human CVCL_TS53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144404 CVCL_U454 G5F2 transformed cell line house mouse CVCL_U454 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144405 CVCL_TS54 HAP1 TLR2 (-) 2 cancer cell line human CVCL_TS54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144406 CVCL_TS59 HAP1 TM9SF2 (-) 2 cancer cell line human CVCL_TS59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11865; TM9SF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144407 CVCL_U459 Huh-7-Lunet cancer cell line human CVCL_U459 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male 21144408 CVCL_TS57 HAP1 TM9SF1 (-) 2 cancer cell line human CVCL_TS57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11864; TM9SF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144409 CVCL_U457 SG5-1.13 transformed cell line house mouse CVCL_U457 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144410 CVCL_TS58 HAP1 TM9SF2 (-) 1 cancer cell line human CVCL_TS58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11865; TM9SF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144411 CVCL_U458 SG5-2 transformed cell line house mouse CVCL_U458 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144412 CVCL_1M10 GM13883 transformed cell line human CVCL_1M10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144413 CVCL_1M11 GM13898 transformed cell line human CVCL_1M11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144414 CVCL_1M03 GM13868 transformed cell line human CVCL_1M03 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1017Ter (c.3049C>T); ClinVar=VCV000181992; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144415 CVCL_1M04 GM13871 transformed cell line human CVCL_1M04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144416 CVCL_1M01 GM13866 transformed cell line human CVCL_1M01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144417 CVCL_1M02 GM13867 transformed cell line human CVCL_1M02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144418 CVCL_1M07 GM13878 transformed cell line human CVCL_1M07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144419 CVCL_1M08 GM13879 transformed cell line human CVCL_1M08 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8418+5_8418+8delGTGA (IVS59+5_IVS59+8delGTGA) (IVS59+1del4); ClinVar=VCV000181866; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144420 CVCL_1M05 GM13872 transformed cell line human CVCL_1M05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144421 CVCL_1M06 GM13873 transformed cell line human CVCL_1M06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21144422 CVCL_1M09 GM13882 transformed cell line human CVCL_1M09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144423 CVCL_TS62 HAP1 TM9SF4 (-) 1 cancer cell line human CVCL_TS62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30797; TM9SF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144424 CVCL_U462 HSY-EB cancer cell line human CVCL_U462 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HSY) has been shown to be a HeLa derivative. 21144425 CVCL_U463 AlphaT1-1 transformed cell line house mouse CVCL_U463 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6 x BALB/c transgenic. Unspecified 21144426 CVCL_TS63 HAP1 TM9SF4 (-) 2 cancer cell line human CVCL_TS63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30797; TM9SF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144427 CVCL_TS60 HAP1 TM9SF3 (-) 1 cancer cell line human CVCL_TS60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21529; TM9SF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144428 CVCL_U460 M14M cancer cell line human CVCL_U460 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Male 21144429 CVCL_U461 BFC012 transformed cell line house mouse CVCL_U461 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21144430 CVCL_TS61 HAP1 TM9SF3 (-) 2 cancer cell line human CVCL_TS61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21529; TM9SF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144431 CVCL_TS44 HAP1 TIRAP (-) 2 cancer cell line human CVCL_TS44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17192; TIRAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144432 CVCL_U444 MA-12 cancer cell line house mouse CVCL_U444 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: C57BL/6J. Male 21144433 CVCL_U445 BLT-1 transformed cell line house mouse CVCL_U445 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Leydig cell.. Male Doubling time: 36-48 hours (PubMed=8807633) 21144434 CVCL_TS45 HAP1 TJP1 (-) 1 cancer cell line human CVCL_TS45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11827; TJP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144435 CVCL_U442 B76/Huh7 cancer cell line human CVCL_U442 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21144436 CVCL_TS42 HAP1 TIPRL (-) cancer cell line human CVCL_TS42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30231; TIPRL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144437 CVCL_U443 B76.1/Huh7 cancer cell line human CVCL_U443 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21144438 CVCL_TS43 HAP1 TIRAP (-) 1 cancer cell line human CVCL_TS43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17192; TIRAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144439 CVCL_TS48 HAP1 TLE1 (-) 1 cancer cell line human CVCL_TS48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144440 CVCL_U448 TTE3 conditionally immortalized cell line house mouse CVCL_U448 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Male Characteristics: Proliferates at the permissive temperature (33 Celsius) Growth is signicantly prevented at the nonpermissive temperature (39 Celsius) (PubMed=11832784). 21144441 CVCL_TS49 HAP1 TLE1 (-) 2 cancer cell line human CVCL_TS49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144442 CVCL_U449 SMAT1 transformed cell line house mouse CVCL_U449 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: (B6.D2 x B6.CBA) F2 AMH-SV40 transgenic. Male 21144443 CVCL_TS46 HAP1 TK1 (-) 1 cancer cell line human CVCL_TS46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11830; TK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144444 CVCL_U446 MSC-1 transformed cell line house mouse CVCL_U446 CL:0000010 Transformant: Simian virus 40 (SV40) [ts1609](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: hMIS-SV40 transgenic. Male 21144445 CVCL_TS47 HAP1 TK1 (-) 2 cancer cell line human CVCL_TS47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11830; TK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144446 CVCL_U447 MSCFSHR-1 transformed cell line house mouse CVCL_U447 CL:0000010 Transfected with: RGD; 2632; Fshr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [ts1609](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.. Male 21144447 CVCL_1M21 GM13925 transformed cell line human CVCL_1M21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144448 CVCL_1M22 GM13935 transformed cell line human CVCL_1M22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144449 CVCL_1M20 GM13924 transformed cell line human CVCL_1M20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144450 CVCL_1M14 GM13907 transformed cell line human CVCL_1M14 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys750Lys (c.2250G>A); ClinVar=VCV000003044; Zygosity=Heterozygous; Note=Causes skipping of exon 14 (p.Ile709_Lys750del, c.2125_2250del) (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Unexplicit; IVS49-2A>G; Zygosity=Heterozygous; Note=Causes in-frame skipping of exon 50 (Met2315del38) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144451 CVCL_1M15 GM13909 transformed cell line human CVCL_1M15 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144452 CVCL_1M12 GM13899 transformed cell line human CVCL_1M12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144453 CVCL_1M13 GM13906 transformed cell line human CVCL_1M13 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1331His (c.3993G>C); ClinVar=VCV000221142; Zygosity=Heterozygous; Note=Causes in-frame skipping of exon 28 (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144454 CVCL_1M18 GM13921 transformed cell line human CVCL_1M18 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg1921Ter (IVS40+1126A>G); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144455 CVCL_1M19 GM13922 transformed cell line human CVCL_1M19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg1921Ter (IVS40+1126A>G); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144456 CVCL_1M16 GM13910 transformed cell line human CVCL_1M16 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144457 CVCL_1M17 GM13920 transformed cell line human CVCL_1M17 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp57Ter (c.170G>A); ClinVar=VCV000127341; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg1466Ter (c.4396C>T); ClinVar=VCV000236716; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144458 CVCL_U451 G5B1 transformed cell line house mouse CVCL_U451 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144459 CVCL_TS51 HAP1 TLE3 (-) 2 cancer cell line human CVCL_TS51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11839; TLE3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144460 CVCL_U452 G5B2 transformed cell line house mouse CVCL_U452 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144461 CVCL_TS52 HAP1 TLK1 (-) cancer cell line human CVCL_TS52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11841; TLK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144462 CVCL_U450 G5 transformed cell line house mouse CVCL_U450 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male 21144463 CVCL_TS50 HAP1 TLE3 (-) 1 cancer cell line human CVCL_TS50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11839; TLE3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144464 CVCL_U433 CHO CT60 spontaneously immortalized cell line CVCL_U433 CL:0000010 Derived from sampling site: Ovary. Female 21144465 CVCL_TS33 HAP1 TICAM1 (-) 2 cancer cell line human CVCL_TS33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18348; TICAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144466 CVCL_TS34 HAP1 TICAM2 (-) cancer cell line human CVCL_TS34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21354; TICAM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144467 CVCL_U434 RIN 1027-B2 cancer cell line Norway rat CVCL_U434 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Secretes somatostatin (PubMed=2879852) 21144468 CVCL_U431 CHO CT43 spontaneously immortalized cell line CVCL_U431 CL:0000010 Derived from sampling site: Ovary. Female 21144469 CVCL_TS31 HAP1 TIA1 (-) 3 cancer cell line human CVCL_TS31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11802; TIA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144470 CVCL_U432 CHO CT52 spontaneously immortalized cell line CVCL_U432 CL:0000010 Derived from sampling site: Ovary. Female 21144471 CVCL_TS32 HAP1 TICAM1 (-) 1 cancer cell line human CVCL_TS32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18348; TICAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144472 CVCL_U437 CCL16-B1 spontaneously immortalized cell line CVCL_U437 CL:0000010 Derived from sampling site: Lung. Male 21144473 CVCL_TS37 HAP1 TIMM8A (-) 1 cancer cell line human CVCL_TS37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11817; TIMM8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144474 CVCL_U438 CCL16-B10 spontaneously immortalized cell line CVCL_U438 CL:0000010 Derived from sampling site: Lung. Male 21144475 CVCL_TS38 HAP1 TIMP1 (-) 1 cancer cell line human CVCL_TS38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11820; TIMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144476 CVCL_TS35 HAP1 TIGIT (-) 1 cancer cell line human CVCL_TS35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26838; TIGIT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144477 CVCL_U435 RIN 1046-38 cancer cell line Norway rat CVCL_U435 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Secretes insulin (PubMed=1701127; PubMed=2879852); Characteristics: Loses glucose responsiveness as well as GLUT2 and glucokinase expression with time in culture (PubMed=1701127; PubMed=8157682) 21144478 CVCL_TS36 HAP1 TIGIT (-) 2 cancer cell line human CVCL_TS36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26838; TIGIT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144479 CVCL_U436 RIN 1056A cancer cell line Norway rat CVCL_U436 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Secretes glucagon, insulin and somatostatin (PubMed=2879852) 21144480 CVCL_U439 CCL16-B11 spontaneously immortalized cell line CVCL_U439 CL:0000010 Derived from sampling site: Lung. Male 21144481 CVCL_TS39 HAP1 TIMP2 (-) 1 cancer cell line human CVCL_TS39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11821; TIMP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144482 CVCL_KY98 PathHunter CHO-K1 rDRD2S beta-arrestin spontaneously immortalized cell line CVCL_KY98 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform short); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144483 CVCL_KY99 PathHunter CHO-K1 rEDG5 beta-arrestin spontaneously immortalized cell line CVCL_KY99 CL:0000010 Transfected with: RGD; 68334; S1pr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144484 CVCL_KY96 PathHunter CHO-K1 rDRD1 beta-arrestin spontaneously immortalized cell line CVCL_KY96 CL:0000010 Transfected with: RGD; 2518; Drd1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144485 CVCL_KY97 PathHunter CHO-K1 rDRD2L beta-arrestin spontaneously immortalized cell line CVCL_KY97 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform long); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144486 CVCL_KY94 PathHunter CHO-K1 rCHRM4 beta-arrestin spontaneously immortalized cell line CVCL_KY94 CL:0000010 Transfected with: RGD; 2344; Chrm4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144487 CVCL_KY95 PathHunter CHO-K1 rCRTH2 beta-arrestin spontaneously immortalized cell line CVCL_KY95 CL:0000010 Transfected with: RGD; 1311986; Ptgdr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144488 CVCL_KY92 PathHunter CHO-K1 RARalpha Protein Interaction spontaneously immortalized cell line CVCL_KY92 CL:0000010 Transfected with: HGNC; 9864; RARA; Transfected with: HGNC; 9234; MED1 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144489 CVCL_KY93 PathHunter CHO-K1 RARbeta Protein Interaction spontaneously immortalized cell line CVCL_KY93 CL:0000010 Transfected with: HGNC; 9865; RARB; Transfected with: HGNC; 7669; NCOA2 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144490 CVCL_KY90 PathHunter CHO-K1 PTHR1 beta-arrestin spontaneously immortalized cell line CVCL_KY90 CL:0000010 Transfected with: HGNC; 9608; PTH1R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144491 CVCL_KY91 PathHunter CHO-K1 PTHR2 beta-arrestin spontaneously immortalized cell line CVCL_KY91 CL:0000010 Transfected with: HGNC; 9609; PTH2R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144492 CVCL_U440 CCL16-B2 spontaneously immortalized cell line CVCL_U440 CL:0000010 Derived from sampling site: Lung. Male 21144493 CVCL_TS40 HAP1 TIPARP (-) 1 cancer cell line human CVCL_TS40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23696; TIPARP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144494 CVCL_U441 CCL16-B9 spontaneously immortalized cell line CVCL_U441 CL:0000010 Derived from sampling site: Lung. Male 21144495 CVCL_TS41 HAP1 TIPARP (-) 2 cancer cell line human CVCL_TS41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23696; TIPARP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144496 CVCL_U422 Flp-In-3T3 spontaneously immortalized cell line house mouse CVCL_U422 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21144497 CVCL_TS22 HAP1 TGFBR1 (-) 2 cancer cell line human CVCL_TS22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11772; TGFBR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144498 CVCL_U423 Flp-In-BHK spontaneously immortalized cell line CVCL_U423 CL:0000010 Derived from sampling site: Kidney. Male 21144499 CVCL_TS23 HAP1 TGFBR2 (-) 1 cancer cell line human CVCL_TS23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144500 CVCL_U420 CHO-TRVb spontaneously immortalized cell line CVCL_U420 CL:0000010 Transfected with: HGNC; 11763; TFRC Derived from sampling site: Ovary. Female 21144501 CVCL_TS20 HAP1 TFG (-) 1 cancer cell line human CVCL_TS20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11758; TFG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144502 CVCL_U421 Flp-In-293 transformed cell line human CVCL_U421 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21144503 CVCL_TS21 HAP1 TGFBR1 (-) 1 cancer cell line human CVCL_TS21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11772; TGFBR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144504 CVCL_U426 Flp-In-Jurkat cancer cell line human CVCL_U426 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21144505 CVCL_TS26 HAP1 TGOLN2 (-) cancer cell line human CVCL_TS26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15450; TGOLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144506 CVCL_U427 Flp-In-T-REx-293 transformed cell line human CVCL_U427 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Metabolome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Contains a single stably integrated FRT site at a transcriptionally active genomic locus (ThermoFisher) 21144507 CVCL_TS27 HAP1 THRB (-) 1 cancer cell line human CVCL_TS27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11799; THRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144508 CVCL_U424 Flp-In-CHO spontaneously immortalized cell line CVCL_U424 CL:0000010 Derived from sampling site: Ovary. Female 21144509 CVCL_TS24 HAP1 TGFBR2 (-) 2 cancer cell line human CVCL_TS24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144510 CVCL_U425 Flp-In-CV-1 transformed cell line CVCL_U425 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21144511 CVCL_TS25 HAP1 TGFBR2 (-) 3 cancer cell line human CVCL_TS25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144512 CVCL_U428 GripTite 293 MSR transformed cell line human CVCL_U428 CL:0000010 Transfected with: HGNC; 7376; MSR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: This cell line has a superior adherence compared to normal HEK293 cells These cells adhere to standard tissue culture treated plastic. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5078 21144513 CVCL_TS28 HAP1 THRB (-) 2 cancer cell line human CVCL_TS28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11799; THRB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144514 CVCL_U429 CHO 25-RA spontaneously immortalized cell line CVCL_U429 CL:0000010 Sequence variation: Mutation; UniProtKB; P97260; Scap; Simple; p.Asp443Asn (c.1327G>A); Zygosity=Heterozygous (PubMed=8898195) Derived from sampling site: Ovary. Female 21144515 CVCL_TS29 HAP1 TIA1 (-) 1 cancer cell line human CVCL_TS29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11802; TIA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144516 CVCL_1M00 GM13862 transformed cell line human CVCL_1M00 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Unexplicit; IVS19-21del3; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144517 CVCL_U430 CHO AC29 spontaneously immortalized cell line CVCL_U430 CL:0000010 Derived from sampling site: Ovary. Female 21144518 CVCL_TS30 HAP1 TIA1 (-) 2 cancer cell line human CVCL_TS30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11802; TIA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144519 CVCL_TS11 HAP1 TET3 (-) 2 cancer cell line human CVCL_TS11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28313; TET3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144520 CVCL_U411 MAEC spontaneously immortalized cell line house mouse CVCL_U411 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Aorta; endothelium Cell type=Vascular endothelial cell.. Female Doubling time: 23.2 hours (PubMed=17215585) 21144521 CVCL_TS12 HAP1 TET3 (-) 3 cancer cell line human CVCL_TS12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28313; TET3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144522 CVCL_U412 V79 Dtxr-1 spontaneously immortalized cell line CVCL_U412 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: UniProtKB; P00588; Corynephage beta diphtheria toxin; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144523 CVCL_TS10 HAP1 TET3 (-) 1 cancer cell line human CVCL_TS10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28313; TET3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144524 CVCL_U410 LSA-1 cancer cell line CVCL_U410 CL:0000010 Transformant: Feline sarcoma virus (strain Snyder-Theilen)(NCBI-Taxonomy; 11780); Derived from sampling site: Thymus. Unspecified Characteristics: Secretes interferon-alpha Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9462 21144525 CVCL_TS15 HAP1 TFAP2A (-) cancer cell line human CVCL_TS15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11742; TFAP2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144526 CVCL_U415 Paju cancer cell line human CVCL_U415 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21144527 CVCL_U416 CHU-2 cancer cell line human CVCL_U416 CL:0000010 Population: Japanese Female Doubling time: ~20 hours (PubMed=3487449). 21144528 CVCL_TS16 HAP1 TFE3 (-) 1 cancer cell line human CVCL_TS16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11752; TFE3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144529 CVCL_TS13 HAP1 TEX2 (-) 1 cancer cell line human CVCL_TS13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30884; TEX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144530 CVCL_U413 V79 Dtxr-2 spontaneously immortalized cell line CVCL_U413 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: UniProtKB; P00588; Corynephage beta diphtheria toxin; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144531 CVCL_TS14 HAP1 TEX2 (-) 2 cancer cell line human CVCL_TS14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30884; TEX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144532 CVCL_U414 V79 Dtxr-3 spontaneously immortalized cell line CVCL_U414 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: UniProtKB; P00588; Corynephage beta diphtheria toxin; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144533 CVCL_U419 DTG 1-5-4 spontaneously immortalized cell line CVCL_U419 CL:0000010 Derived from sampling site: Ovary. Female 21144534 CVCL_TS19 HAP1 TFEB (-) 2 cancer cell line human CVCL_TS19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11753; TFEB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144535 CVCL_U417 DTE 1-6-4 spontaneously immortalized cell line CVCL_U417 CL:0000010 Derived from sampling site: Ovary. Female 21144536 CVCL_TS17 HAP1 TFE3 (-) 2 cancer cell line human CVCL_TS17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11752; TFE3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144537 CVCL_U418 DTF 1-5-1 spontaneously immortalized cell line CVCL_U418 CL:0000010 Derived from sampling site: Ovary. Female 21144538 CVCL_TS18 HAP1 TFEB (-) 1 cancer cell line human CVCL_TS18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11753; TFEB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144539 CVCL_KY78 PathHunter CHO-K1 P2RY8 beta-arrestin spontaneously immortalized cell line CVCL_KY78 CL:0000010 Transfected with: HGNC; 15524; P2RY8; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144540 CVCL_KY79 PathHunter CHO-K1 PPARalpha Protein Interaction spontaneously immortalized cell line CVCL_KY79 CL:0000010 Transfected with: HGNC; 9232; PPARA; Transfected with: HGNC; 9234; MED1 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144541 CVCL_KY76 PathHunter CHO-K1 P2RY4 beta-arrestin spontaneously immortalized cell line CVCL_KY76 CL:0000010 Transfected with: HGNC; 8542; P2RY4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144542 CVCL_KY77 PathHunter CHO-K1 P2RY6 beta-arrestin spontaneously immortalized cell line CVCL_KY77 CL:0000010 Transfected with: HGNC; 8543; P2RY6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144543 CVCL_KY74 PathHunter CHO-K1 P2RY11 beta-arrestin spontaneously immortalized cell line CVCL_KY74 CL:0000010 Transfected with: HGNC; 8540; P2RY11; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144544 CVCL_KY75 PathHunter CHO-K1 P2RY12 beta-arrestin spontaneously immortalized cell line CVCL_KY75 CL:0000010 Transfected with: HGNC; 18124; P2RY12; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144545 CVCL_KY72 PathHunter CHO-K1 OXGR1 beta-arrestin spontaneously immortalized cell line CVCL_KY72 CL:0000010 Transfected with: HGNC; 4531; OXGR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144546 CVCL_KY73 PathHunter CHO-K1 OXTR beta-arrestin spontaneously immortalized cell line CVCL_KY73 CL:0000010 Transfected with: HGNC; 8529; OXTR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144547 CVCL_KY70 PathHunter CHO-K1 OPRM1 beta-arrestin spontaneously immortalized cell line CVCL_KY70 CL:0000010 Transfected with: HGNC; 8156; OPRM1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144548 CVCL_KY71 PathHunter CHO-K1 OXER1 beta-arrestin spontaneously immortalized cell line CVCL_KY71 CL:0000010 Transfected with: HGNC; 24884; OXER1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144549 CVCL_U400 GM12368 finite cell line human CVCL_U400 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21144550 CVCL_TS00 HAP1 TESK1 (-) 2 cancer cell line human CVCL_TS00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11731; TESK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144551 CVCL_U401 GM13204 finite cell line human CVCL_U401 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM13204; probable Female 21144552 CVCL_TS01 HAP1 TESK2 (-) 1 cancer cell line human CVCL_TS01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11732; TESK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144553 CVCL_U404 8HTEo- transformed cell line human CVCL_U404 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Male 21144554 CVCL_TS04 HAP1 TET1 (-) 2 cancer cell line human CVCL_TS04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29484; TET1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144555 CVCL_U405 9HTEo- transformed cell line human CVCL_U405 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Male Characteristics: Useful model for the study of epithelial ion transport, secretion and biochemistry and frequently used as a wild-type control for cystic fibrosis tracheobronchial epithelial cells (Millipore) 21144556 CVCL_TS05 HAP1 TET2 (-) 1 cancer cell line human CVCL_TS05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144557 CVCL_U402 2012 [Mouse liver] transformed cell line house mouse CVCL_U402 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma. Unspecified 21144558 CVCL_TS02 HAP1 TESK2 (-) 2 cancer cell line human CVCL_TS02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11732; TESK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144559 CVCL_U403 3HTEo- transformed cell line human CVCL_U403 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea. Male 21144560 CVCL_TS03 HAP1 TET1 (-) 1 cancer cell line human CVCL_TS03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29484; TET1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144561 CVCL_TS08 HAP1 TET2 (-) 4 cancer cell line human CVCL_TS08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144562 CVCL_U408 HRE-H9 transformed cell line CVCL_U408 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: New Zealand white. Female Characteristics: At the permissive temperature (33 Celsius) has a spindle shape morphology At the restrictive temperature (40 Celsius) has a round shape morphology. Doubling time: ~48 hours, at 33 Celsius (PubMed=2555129) 21144563 CVCL_TS09 HAP1 TET2 (-) 5 cancer cell line human CVCL_TS09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144564 CVCL_U409 NB324K transformed cell line human CVCL_U409 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified 21144565 CVCL_U406 CHO-glyA spontaneously immortalized cell line CVCL_U406 CL:0000010 Derived from sampling site: Ovary. Female 21144566 CVCL_TS06 HAP1 TET2 (-) 2 cancer cell line human CVCL_TS06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144567 CVCL_U407 CHO-glyB spontaneously immortalized cell line CVCL_U407 CL:0000010 Derived from sampling site: Ovary. Female 21144568 CVCL_TS07 HAP1 TET2 (-) 3 cancer cell line human CVCL_TS07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25941; TET2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144569 CVCL_KY89 PathHunter CHO-K1 PTGIR beta-arrestin spontaneously immortalized cell line CVCL_KY89 CL:0000010 Transfected with: HGNC; 9602; PTGIR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144570 CVCL_KY87 PathHunter CHO-K1 PTGER2 beta-arrestin spontaneously immortalized cell line CVCL_KY87 CL:0000010 Transfected with: HGNC; 9594; PTGER2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144571 CVCL_KY88 PathHunter CHO-K1 PTGER3 beta-arrestin spontaneously immortalized cell line CVCL_KY88 CL:0000010 Transfected with: HGNC; 9595; PTGER3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144572 CVCL_KY85 PathHunter CHO-K1 PROKR2 beta-arrestin spontaneously immortalized cell line CVCL_KY85 CL:0000010 Transfected with: HGNC; 15836; PROKR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144573 CVCL_KY86 PathHunter CHO-K1 PTAFR beta-arrestin spontaneously immortalized cell line CVCL_KY86 CL:0000010 Transfected with: HGNC; 9582; PTAFR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144574 CVCL_KY83 PathHunter CHO-K1 PRLHR beta-arrestin spontaneously immortalized cell line CVCL_KY83 CL:0000010 Transfected with: HGNC; 4464; PRLHR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144575 CVCL_KY84 PathHunter CHO-K1 PROKR1 beta-arrestin spontaneously immortalized cell line CVCL_KY84 CL:0000010 Transfected with: HGNC; 4524; PROKR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144576 CVCL_KY81 PathHunter CHO-K1 PPARgamma Protein Interaction spontaneously immortalized cell line CVCL_KY81 CL:0000010 Transfected with: HGNC; 9236; PPARG; Transfected with: HGNC; 9234; MED1 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144577 CVCL_KY82 PathHunter CHO-K1 PPYR1 beta-arrestin spontaneously immortalized cell line CVCL_KY82 CL:0000010 Transfected with: HGNC; 9329; NPY4R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144578 CVCL_KY80 PathHunter CHO-K1 PPARdelta Protein Interaction spontaneously immortalized cell line CVCL_KY80 CL:0000010 Transfected with: HGNC; 9235; PPARD; Transfected with: HGNC; 9234; MED1 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144579 CVCL_1L91 GM13812 transformed cell line human CVCL_1L91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144580 CVCL_1L92 GM13813 transformed cell line human CVCL_1L92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144581 CVCL_1L90 GM13811 transformed cell line human CVCL_1L90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144582 CVCL_1L95 GM13816 transformed cell line human CVCL_1L95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144583 CVCL_1L96 GM13819 transformed cell line human CVCL_1L96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144584 CVCL_1L93 GM13814 transformed cell line human CVCL_1L93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144585 CVCL_1L94 GM13815 transformed cell line human CVCL_1L94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144586 CVCL_1L99 GM13861 transformed cell line human CVCL_1L99 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8418+5_8418+8delGTGA (IVS59+5_IVS59+8delGTGA) (IVS59+1del4); ClinVar=VCV000181866; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144587 CVCL_1L97 GM13859 transformed cell line human CVCL_1L97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144588 CVCL_1L98 GM13860 transformed cell line human CVCL_1L98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144589 CVCL_1L70 AT34LA transformed cell line human CVCL_1L70 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8988-1G>C (IVS64-1G>C) (8988del13) (p.Ser2996Ter); ClinVar=VCV000181987; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144590 CVCL_1L73 GM13652 transformed cell line human CVCL_1L73 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp57Ter (c.170G>A); ClinVar=VCV000127341; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144591 CVCL_1L74 GM13661 transformed cell line human CVCL_1L74 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2993Ter (c.8977C>T); ClinVar=VCV000186330; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144592 CVCL_1L71 AT16LA transformed cell line human CVCL_1L71 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp393_Glu394delinsTer (c.1179_1180delGG) (p.Trp393Terfs); ClinVar=VCV000231937; Zygosity=Heterozygous (PubMed=8808599); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Heterozygous (PubMed=8808599) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144593 CVCL_1L72 AT13LA transformed cell line human CVCL_1L72 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg1921Ter (IVS40+1126A>G); Zygosity=Heterozygous (PubMed=8808599); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.7630-2A>C (IVS53-2A>C) (IVS51-2A>C) (L2544del53); ClinVar=VCV000127447; Zygosity=Heterozygous; Note=Causes in-frame skipping of exon 54 (Leu2544del53) (PubMed=8808599) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144594 CVCL_1L77 GM13692 transformed cell line human CVCL_1L77 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.901+1G>A (IVS9+1G>A); ClinVar=VCV000186761; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8988-2A>G (IVS64-2A>G); ClinVar=VCV000185326; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144595 CVCL_1L78 GM13762 transformed cell line human CVCL_1L78 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr2333Asnfs*40 (c.6997dupA) (6997insA); ClinVar=VCV000140818; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser2855_Val2856delinsArgIle (c.8565_8566delTGinsAA) (8565TG>AA); ClinVar=VCV000140897; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144596 CVCL_1L75 GM13683 transformed cell line human CVCL_1L75 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1267_Val1268insTer (c.3802delG) (p.Val1268Terfs); ClinVar=VCV000127374; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144597 CVCL_1L76 GM13691 transformed cell line human CVCL_1L76 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.901+1G>A (IVS9+1G>A); ClinVar=VCV000186761; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8988-2A>G (IVS64-2A>G); ClinVar=VCV000185326; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144598 CVCL_1L68 GM11264 transformed cell line human CVCL_1L68 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1839Ter (c.5515C>T); ClinVar=VCV000189177; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1905Ilefs*26 (c.5712dupA) (5712insA); ClinVar=VCV000141416; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144599 CVCL_1L69 AT31LA transformed cell line human CVCL_1L69 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1991Ter (c.5971G>T); ClinVar=VCV000453606; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Heterozygous (PubMed=8808599) Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144600 CVCL_1L80 GM13774 transformed cell line human CVCL_1L80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144601 CVCL_1L81 GM13785 transformed cell line human CVCL_1L81 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1839Ter (c.5515C>T); ClinVar=VCV000189177; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1905Ilefs*26 (c.5712dupA) (5712insA); ClinVar=VCV000141416; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144602 CVCL_1L84 GM13801 transformed cell line human CVCL_1L84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144603 CVCL_1L85 GM13802 transformed cell line human CVCL_1L85 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu762Valfs (c.2282_2283CT[1]) (c.2284_2285delCT); ClinVar=VCV000141325; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144604 CVCL_1L82 GM13791 transformed cell line human CVCL_1L82 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile1581Asnfs*5 (c.4741dupA) (4742insA); ClinVar=VCV000453535; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144605 CVCL_1L83 GM13792 transformed cell line human CVCL_1L83 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.3993+1G>A (IVS28+1G>A) (IVS26+1G>A); ClinVar=VCV000141447; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144606 CVCL_1L88 GM13805 transformed cell line human CVCL_1L88 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val410Ala (c.1229T>C); ClinVar=VCV000127332; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6736del20ins2; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144607 CVCL_1L89 GM13810 transformed cell line human CVCL_1L89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144608 CVCL_1L86 GM13803 transformed cell line human CVCL_1L86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144609 CVCL_1L87 GM13804 transformed cell line human CVCL_1L87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144610 CVCL_1L79 GM13765 transformed cell line human CVCL_1L79 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2136Ter (c.6404_6405insTT) (p.Leu2135_Arg2136insTer) (6404insTT); ClinVar=VCV000220763; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8786+1G>A (IVS62+1G>A) (c.8672del115) (G2891fsX); ClinVar=VCV000127463; Zygosity=Heterozygous; Note=Splice donor mutation Causes in-frame skipping of exon 62 (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144611 CVCL_U398 GM03773 transformed cell line human CVCL_U398 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from twin of GM03772 (Cellosaurus=CVCL_U397); Derived from sampling site: Peripheral blood. Male 21144612 CVCL_TR98 HAP1 TERT (-) 2 cancer cell line human CVCL_TR98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11730; TERT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144613 CVCL_U399 GM09787 transformed cell line human CVCL_U399 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1073+1G>A (IVS9+1G>A); ClinVar=VCV000003920; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144614 CVCL_TR99 HAP1 TESK1 (-) 1 cancer cell line human CVCL_TR99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11731; TESK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144615 CVCL_1L51 GM08929 transformed cell line human CVCL_1L51 CL:0000010 Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144616 CVCL_1L52 GM08931 transformed cell line human CVCL_1L52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144617 CVCL_1L50 GM08926 transformed cell line human CVCL_1L50 CL:0000010 Population: Caucasian; German/Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144618 CVCL_1L55 GM09252 finite cell line human CVCL_1L55 CL:0000010 Population: Caucasian; German/Swiss; Derived from sampling site: Cell type=Fibroblast. Female 21144619 CVCL_1L56 GM09254 finite cell line human CVCL_1L56 CL:0000010 Population: Caucasian; German/Swiss; Derived from sampling site: Cell type=Fibroblast. Male 21144620 CVCL_1L53 GM09246 finite cell line human CVCL_1L53 CL:0000010 Population: Caucasian; German/Swiss; Derived from sampling site: Cell type=Fibroblast. Female 21144621 CVCL_1L54 GM09247 finite cell line human CVCL_1L54 CL:0000010 Population: Caucasian; German/Swiss; Derived from sampling site: Cell type=Fibroblast. Male 21144622 CVCL_1L48 GM03399 finite cell line human CVCL_1L48 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144623 CVCL_1L49 AT1PX finite cell line human CVCL_1L49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144624 CVCL_1L46 KCEK spontaneously immortalized cell line CVCL_1L46 CL:0000010 Derived from sampling site: Embryonic kidney; Breed/subspecies: White Leghorn. Unspecified Group: Bird cell line 21144625 CVCL_1L47 KCEL spontaneously immortalized cell line CVCL_1L47 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: White Leghorn. Unspecified Group: Bird cell line 21144626 CVCL_U389 GM02968 finite cell line human CVCL_U389 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=3375249) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21144627 CVCL_TR89 HAP1 TECPR2 (-) 2 cancer cell line human CVCL_TR89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19957; TECPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144628 CVCL_U387 GM01675 finite cell line human CVCL_U387 CL:0000010 Sequence variation: Mutation; HGNC; 4367; GM2A; Simple; p.Cys138Arg (c.412T>C); ClinVar=VCV000000390; Zygosity=Homozygous (PubMed=1570834) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21144629 CVCL_TR87 HAP1 TEC (-) cancer cell line human CVCL_TR87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11719; TEC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144630 CVCL_U388 GM02366 transformed cell line human CVCL_U388 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02366; probable Male 21144631 CVCL_TR88 HAP1 TECPR2 (-) 1 cancer cell line human CVCL_TR88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19957; TECPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144632 CVCL_1L62 GM11238 transformed cell line human CVCL_1L62 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5395-12A>G (IVS32-12A>G); Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144633 CVCL_1L63 AT2LA transformed cell line human CVCL_1L63 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144634 CVCL_1L60 GM09583 transformed cell line human CVCL_1L60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144635 CVCL_1L61 GM09584 transformed cell line human CVCL_1L61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144636 CVCL_1L66 GM11258 transformed cell line human CVCL_1L66 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5497-2A>C (IVS38-2A>C) (c.5496_5556del61); ClinVar=VCV000449345; Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144637 CVCL_1L67 AT1LA transformed cell line human CVCL_1L67 CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144638 CVCL_1L64 AT6LA transformed cell line human CVCL_1L64 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2467del372 (Ex19-20del); Zygosity=Heterozygous (PubMed=16166284); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8786+1G>A (IVS62+1G>A) (c.8672del115) (G2891fsX); ClinVar=VCV000127463; Zygosity=Heterozygous; Note=Splice donor mutation Causes in-frame skipping of exon 62 (PubMed=16166284). Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144639 CVCL_1L65 AT14LA transformed cell line human CVCL_1L65 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu2007Argfs*11 (c.6015dupC) (6015insC); ClinVar=VCV000490638; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser2855_Val2856delinsArgIle (c.8565_8566delTGinsAA) (8565TG>AA); ClinVar=VCV000140897; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144640 CVCL_1L59 GM09581 transformed cell line human CVCL_1L59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144641 CVCL_1L57 GM09579 transformed cell line human CVCL_1L57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21144642 CVCL_1L58 GM09580 transformed cell line human CVCL_1L58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144643 CVCL_U392 GM03585 transformed cell line human CVCL_U392 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144644 CVCL_TR92 HAP1 TEK (-) 2 cancer cell line human CVCL_TR92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11724; TEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144645 CVCL_U393 GM03586 transformed cell line human CVCL_U393 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144646 CVCL_TR93 HAP1 TEK (-) 3 cancer cell line human CVCL_TR93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11724; TEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144647 CVCL_U390 GM03441 transformed cell line human CVCL_U390 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144648 CVCL_TR90 HAP1 TECPR2 (-) 3 cancer cell line human CVCL_TR90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19957; TECPR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144649 CVCL_U391 GM03461 transformed cell line human CVCL_U391 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144650 CVCL_TR91 HAP1 TEK (-) 1 cancer cell line human CVCL_TR91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11724; TEK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144651 CVCL_U396 GM03771 transformed cell line human CVCL_U396 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144652 CVCL_TR96 HAP1 TEP1 (-) 3 cancer cell line human CVCL_TR96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11726; TEP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144653 CVCL_U397 GM03772 transformed cell line human CVCL_U397 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from twin of GM03773 (Cellosaurus=CVCL_U398); Derived from sampling site: Peripheral blood. Male 21144654 CVCL_TR97 HAP1 TERT (-) 1 cancer cell line human CVCL_TR97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11730; TERT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144655 CVCL_U394 GM03691 transformed cell line human CVCL_U394 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144656 CVCL_TR94 HAP1 TEP1 (-) 1 cancer cell line human CVCL_TR94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11726; TEP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144657 CVCL_U395 GM03770 transformed cell line human CVCL_U395 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21144658 CVCL_TR95 HAP1 TEP1 (-) 2 cancer cell line human CVCL_TR95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11726; TEP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144659 CVCL_TR78 HAP1 TBX3 (-) 2 cancer cell line human CVCL_TR78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11602; TBX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144660 CVCL_U378 HT4 [Mouse neurons] transformed cell line house mouse CVCL_U378 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hippocampus Cell type=Neuron.. Characteristics: At the restrictive temperature (39 Celsius) the cells take on properties of differentiated neurons they express neuronal antigens, synthesize NGF mRNA and secrete biologically active NGF in vitro 21144661 CVCL_TR79 HAP1 TCERG1 (-) cancer cell line human CVCL_TR79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15630; TCERG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144662 CVCL_U379 NG125 transformed cell line human CVCL_U379 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified 21144663 CVCL_U376 A2774 cancer cell line human CVCL_U376 From: Benard J.; Institute Gustave Roussy; Villejuif; France. CL:0000010 Female 21144664 CVCL_TR76 HAP1 TBX21 (-) 1 cancer cell line human CVCL_TR76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11599; TBX21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144665 CVCL_TR77 HAP1 TBX3 (-) 1 cancer cell line human CVCL_TR77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11602; TBX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144666 CVCL_U377 OL-1 finite cell line Norway rat CVCL_U377 CL:0000010 Derived from sampling site: Brain Cell type=Oligodendrocyte precursor cell.. Unspecified 21144667 CVCL_1L30 GM09195 transformed cell line human CVCL_1L30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144668 CVCL_1L33 GM13667 finite cell line human CVCL_1L33 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Ile582fs (c.1748_1749delAG) (1893_1894delAG); Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144669 CVCL_1L34 GM13668 finite cell line human CVCL_1L34 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.His218fs (c.657_661delTATCT) (798_802delATCTT); Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144670 CVCL_1L31 GM09230 finite cell line human CVCL_1L31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144671 CVCL_1L32 GM09231 finite cell line human CVCL_1L32 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21144672 CVCL_1L26 GM23772 transformed cell line human CVCL_1L26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144673 CVCL_1L27 GM03659 finite cell line human CVCL_1L27 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21144674 CVCL_1L24 GM23505 transformed cell line human CVCL_1L24 CL:0000010 Sequence variation: Mutation; HGNC; 9726; PYGM; Simple; p.Arg50Ter (c.148C>T); ClinVar=VCV000002298; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144675 CVCL_1L25 GM23692 transformed cell line human CVCL_1L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144676 CVCL_1L28 GM04068 finite cell line human CVCL_1L28 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21144677 CVCL_1L29 GM09194 transformed cell line human CVCL_1L29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144678 CVCL_U381 GM00221 finite cell line human CVCL_U381 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144679 CVCL_TR81 HAP1 TCF7L2 (-) 1 cancer cell line human CVCL_TR81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11641; TCF7L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144680 CVCL_U382 GM00502 finite cell line human CVCL_U382 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21144681 CVCL_TR82 HAP1 TDG (-) 1 cancer cell line human CVCL_TR82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11700; TDG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144682 CVCL_U380 GM00077 finite cell line human CVCL_U380 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Val146Phefs*53 (c.436delG); ClinVar=VCV000371314; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21144683 CVCL_TR80 HAP1 TCF19 (-) 1 cancer cell line human CVCL_TR80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11629; TCF19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144684 CVCL_U385 GM00527 finite cell line human CVCL_U385 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp420Cys (c.1260G>C); ClinVar=VCV000003901; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1330+1G>A (IVS11+1G>A); ClinVar=VCV000371490; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144685 CVCL_TR85 HAP1 TDP1 (-) 3 cancer cell line human CVCL_TR85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18884; TDP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144686 CVCL_U386 GM01110 finite cell line human CVCL_U386 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Glu482Lys (c.1444G>A); ClinVar=VCV000003892; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144687 CVCL_TR86 HAP1 TEAD4 (-) 1 cancer cell line human CVCL_TR86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11717; TEAD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144688 CVCL_U383 GM00514 finite cell line human CVCL_U383 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp392Ter (c.1176G>A); ClinVar=VCV000003936; Zygosity=Heterozygous (from familial inference of GM00515); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (from familial inference of GM00515) Population: Jewish; Ashkenazi; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Female 21144689 CVCL_TR83 HAP1 TDP1 (-) 1 cancer cell line human CVCL_TR83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18884; TDP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144690 CVCL_U384 GM00515 finite cell line human CVCL_U384 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Trp392Ter (c.1176G>A); ClinVar=VCV000003936; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Heart; pericardium Cell type=Fibroblast.. Female 21144691 CVCL_TR84 HAP1 TDP1 (-) 2 cancer cell line human CVCL_TR84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18884; TDP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144692 CVCL_TR67 HAP1 TAZ (-) 1 cancer cell line human CVCL_TR67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144693 CVCL_U367 Pit1/0 transformed cell line house mouse CVCL_U367 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: CD-1 Pit-Tag+hGH/BAC transgenic. Unspecified 21144694 CVCL_TR68 HAP1 TAZ (-) 2 cancer cell line human CVCL_TR68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144695 CVCL_U368 Pit1/Prl transformed cell line house mouse CVCL_U368 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: CD-1 GH-Tag+hGH/BAC transgenic. Unspecified 21144696 CVCL_U365 FS/D1h spontaneously immortalized cell line Norway rat CVCL_U365 CL:0000010 Derived from sampling site: Pituitary gland Cell type=Folliculostellate cell.; Breed/subspecies: Sprague Dawley. Male 21144697 CVCL_TR65 HAP1 TARDBP (-) 2 cancer cell line human CVCL_TR65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11571; TARDBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144698 CVCL_U366 CHO-MCHR2 spontaneously immortalized cell line CVCL_U366 CL:0000010 Transfected with: HGNC; 20867; MCHR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21144699 CVCL_TR66 HAP1 TASP1 (-) 1 cancer cell line human CVCL_TR66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15859; TASP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144700 CVCL_TR69 HAP1 TBC1D24 (-) 1 cancer cell line human CVCL_TR69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29203; TBC1D24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144701 CVCL_U369 Pit1/Triple transformed cell line house mouse CVCL_U369 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: CD-1 Pit-Tag transgenic. Unspecified 21144702 CVCL_1L40 GM00647 finite cell line human CVCL_1L40 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144703 CVCL_1L41 GM01588 finite cell line human CVCL_1L41 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg35Ter (c.103C>T); ClinVar=VCV000003025; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144704 CVCL_1L44 GM02797 finite cell line human CVCL_1L44 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female 21144705 CVCL_1L45 GM03380 transformed cell line human CVCL_1L45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144706 CVCL_1L42 GM01829 finite cell line human CVCL_1L42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144707 CVCL_1L43 GM01841 finite cell line human CVCL_1L43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21144708 CVCL_1L37 GM13671 finite cell line human CVCL_1L37 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Arg645Ter (c.1933C>T); ClinVar=VCV000210404; Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144709 CVCL_1L38 GM13674 finite cell line human CVCL_1L38 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Gln167Ter (c.499C>T); Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144710 CVCL_1L35 GM13669 finite cell line human CVCL_1L35 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Unexplicit; IVS8DS+2,T>C; Zygosity=Hemizygous; Note=Exon skipping mutation (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144711 CVCL_1L36 GM13670 finite cell line human CVCL_1L36 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Gly727Arg (c.2179G>A); ClinVar=VCV000210418; Zygosity=Hemizygous (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144712 CVCL_1L39 GM13675 finite cell line human CVCL_1L39 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; c.4006-2A>G (IVS20AS-2,A>G); Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=7977350) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144713 CVCL_U370 GH3/GH-EYFP cancer cell line Norway rat CVCL_U370 CL:0000010 Transfected with: RGD; 2686; Gh1; Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231) Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21144714 CVCL_TR70 HAP1 TBC1D24 (-) 2 cancer cell line human CVCL_TR70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29203; TBC1D24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144715 CVCL_TR71 HAP1 TBCK (-) cancer cell line human CVCL_TR71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28261; TBCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144716 CVCL_U371 MtT/E-2 cancer cell line Norway rat CVCL_U371 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Fischer 344. Female 21144717 CVCL_U374 DB-7(fvb2) cancer cell line house mouse CVCL_U374 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTV-PyVmT) (Y315F/Y322F). Female 21144718 CVCL_TR74 HAP1 TBKBP1 (-) 1 cancer cell line human CVCL_TR74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30140; TBKBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144719 CVCL_TR75 HAP1 TBKBP1 (-) 2 cancer cell line human CVCL_TR75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30140; TBKBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144720 CVCL_U375 TER-3 cancer cell line human CVCL_U375 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: IL3 dependent 21144721 CVCL_TR72 HAP1 TBK1 (-) 1 cancer cell line human CVCL_TR72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144722 CVCL_U372 MHP36 conditionally immortalized cell line house mouse CVCL_U372 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; neuroepithelium; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21144723 CVCL_TR73 HAP1 TBK1 (-) 2 cancer cell line human CVCL_TR73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144724 CVCL_U373 Met-1(fvb2) cancer cell line house mouse CVCL_U373 CL:0000010 Breed/subspecies: FVB/N-Tg(MMTV-PyVmT). Female 21144725 CVCL_TT10 HAP1 TNFRSF1B (-) 1 cancer cell line human CVCL_TT10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11917; TNFRSF1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144726 CVCL_U510 MG87 spontaneously immortalized cell line house mouse CVCL_U510 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21144727 CVCL_TT11 HAP1 TNFRSF1B (-) 2 cancer cell line human CVCL_TT11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11917; TNFRSF1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144728 CVCL_U511 PAC1 spontaneously immortalized cell line Norway rat CVCL_U511 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Sprague Dawley. Male 21144729 CVCL_U514 GM01044 finite cell line human CVCL_U514 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144730 CVCL_TT14 HAP1 TNK1 (-) cancer cell line human CVCL_TT14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11940; TNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144731 CVCL_U515 GM01204 transformed cell line human CVCL_U515 HLA typing: A*02,28; B*12,35 (Coriell=GM01204) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144732 CVCL_TT15 HAP1 TNK2 (-) cancer cell line human CVCL_TT15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19297; TNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144733 CVCL_U512 GM01205 transformed cell line human CVCL_U512 HLA typing: A*01,28; B*13,35 (Coriell=GM01205) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144734 CVCL_TT12 HAP1 TNFSF9 (-) 1 cancer cell line human CVCL_TT12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11939; TNFSF9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144735 CVCL_TT13 HAP1 TNIK (-) 1 cancer cell line human CVCL_TT13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30765; TNIK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144736 CVCL_U518 GM01685 transformed cell line human CVCL_U518 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144737 CVCL_TT18 HAP1 TNPO1 (-) 1 cancer cell line human CVCL_TT18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6401; TNPO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144738 CVCL_U519 GM03056 finite cell line human CVCL_U519 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144739 CVCL_TT19 HAP1 TNPO1 (-) 2 cancer cell line human CVCL_TT19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6401; TNPO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144740 CVCL_U516 GM01679 finite cell line human CVCL_U516 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21144741 CVCL_TT16 HAP1 TNKS (-) cancer cell line human CVCL_TT16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11941; TNKS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144742 CVCL_KZ79 PathHunter U2OS BDKRB2 Activated GPCR Internalization cancer cell line human CVCL_KZ79 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144743 CVCL_U517 GM01684 finite cell line human CVCL_U517 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21144744 CVCL_TT17 HAP1 TNKS2 (-) 1 cancer cell line human CVCL_TT17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15677; TNKS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144745 CVCL_KZ77 PathHunter U2OS AVPR1B Activated GPCR Internalization cancer cell line human CVCL_KZ77 CL:0000010 Transfected with: HGNC; 896; AVPR1B; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144746 CVCL_KZ78 PathHunter U2OS AVPR2 Activated GPCR Internalization cancer cell line human CVCL_KZ78 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144747 CVCL_KZ75 PathHunter U2OS AVPR1A beta-arrestin cancer cell line human CVCL_KZ75 CL:0000010 Transfected with: HGNC; 895; AVPR1A; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144748 CVCL_KZ76 PathHunter U2OS AVPR1A Total GPCR Internalization cancer cell line human CVCL_KZ76 CL:0000010 Transfected with: HGNC; 895; AVPR1A Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144749 CVCL_KZ73 PathHunter U2OS AGTRL1 Activated GPCR Internalization cancer cell line human CVCL_KZ73 CL:0000010 Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144750 CVCL_KZ74 PathHunter U2OS AHR Protein Interaction cancer cell line human CVCL_KZ74 CL:0000010 Transfected with: HGNC; 348; AHR; Transfected with: HGNC; 700; ARNT (with del 1-155 and 271-789) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144751 CVCL_KZ71 PathHunter U2OS ADCYAP1R1 Total GPCR Internalization cancer cell line human CVCL_KZ71 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144752 CVCL_KZ72 PathHunter U2OS ADRA2C Total GPCR Internalization cancer cell line human CVCL_KZ72 CL:0000010 Transfected with: HGNC; 283; ADRA2C Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144753 CVCL_KZ70 PathHunter THP-1 IkappaB Degradation cancer cell line human CVCL_KZ70 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7797; NFKBIA Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144754 CVCL_U500 AS iPS del 2-0 induced pluripotent stem cell human CVCL_U500 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144755 CVCL_TT00 HAP1 TMEM5 (-) 5 cancer cell line human CVCL_TT00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144756 CVCL_TT03 HAP1 TMEM56 (-) 2 cancer cell line human CVCL_TT03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26477; TLCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144757 CVCL_U503 TIG-1 iPSC clone K2 induced pluripotent stem cell human CVCL_U503 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21144758 CVCL_TT04 HAP1 TMEM70 (-) 1 cancer cell line human CVCL_TT04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26050; TMEM70; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144759 CVCL_U504 TIG-1 iPSC clone K3 induced pluripotent stem cell human CVCL_U504 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21144760 CVCL_U501 AS iPS del 2-3 induced pluripotent stem cell human CVCL_U501 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21144761 CVCL_TT01 HAP1 TMEM5 (-) 6 cancer cell line human CVCL_TT01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144762 CVCL_TT02 HAP1 TMEM56 (-) 1 cancer cell line human CVCL_TT02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26477; TLCD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144763 CVCL_U502 TIG-1 iPSC clone K1 induced pluripotent stem cell human CVCL_U502 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21144764 CVCL_U507 GM02938 finite cell line human CVCL_U507 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Discontinued: Coriell; GM02938; probable Male 21144765 CVCL_TT07 HAP1 TNFRSF12A (-) 1 cancer cell line human CVCL_TT07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18152; TNFRSF12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144766 CVCL_TT08 HAP1 TNFRSF1A (-) 1 cancer cell line human CVCL_TT08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11916; TNFRSF1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144767 CVCL_U508 HMN-1 hybrid cell line house mouse CVCL_U508 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21144768 CVCL_TT05 HAP1 TMEM70 (-) 2 cancer cell line human CVCL_TT05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26050; TMEM70; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144769 CVCL_U505 TIG-1 iPSC clone K4 induced pluripotent stem cell human CVCL_U505 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21144770 CVCL_U506 GM00408 finite cell line human CVCL_U506 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM00408; probable Female 21144771 CVCL_TT06 HAP1 TNFRSF10B (-) cancer cell line human CVCL_TT06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11905; TNFRSF10B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144772 CVCL_KZ88 PathHunter U2OS CCKAR Activated GPCR Internalization cancer cell line human CVCL_KZ88 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144773 CVCL_KZ89 PathHunter U2OS CCKBR Activated GPCR Internalization cancer cell line human CVCL_KZ89 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144774 CVCL_TT09 HAP1 TNFRSF1A (-) 2 cancer cell line human CVCL_TT09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11916; TNFRSF1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144775 CVCL_U509 IMDF spontaneously immortalized cell line house mouse CVCL_U509 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: CD-1. Unspecified 21144776 CVCL_KZ86 PathHunter U2OS C5L2 Activated GPCR Internalization cancer cell line human CVCL_KZ86 CL:0000010 Transfected with: HGNC; 4527; C5AR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144777 CVCL_KZ87 PathHunter U2OS CALCR beta-arrestin cancer cell line human CVCL_KZ87 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144778 CVCL_KZ84 PathHunter U2OS C3AR1 beta-arrestin cancer cell line human CVCL_KZ84 CL:0000010 Transfected with: HGNC; 1319; C3AR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144779 CVCL_KZ85 PathHunter U2OS C5AR1 Activated GPCR Internalization cancer cell line human CVCL_KZ85 CL:0000010 Transfected with: HGNC; 1338; C5AR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144780 CVCL_KZ82 PathHunter U2OS beta-Catenin Nuclear Translocation cancer cell line human CVCL_KZ82 CL:0000010 Transfected with: HGNC; 2514; CTNNB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144781 CVCL_KZ83 PathHunter U2OS C3AR1 Activated GPCR Internalization cancer cell line human CVCL_KZ83 CL:0000010 Transfected with: HGNC; 1319; C3AR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144782 CVCL_KZ80 PathHunter U2OS beta-arrestin1-EA Parental cancer cell line human CVCL_KZ80 CL:0000010 Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21144783 CVCL_KZ81 PathHunter U2OS beta-arrestin2-EA Parental cancer cell line human CVCL_KZ81 CL:0000010 Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21144784 CVCL_KZ59 PathHunter HEK 293 LXRbeta-NCoR1 Protein Interaction transformed cell line human CVCL_KZ59 CL:0000010 Transfected with: HGNC; 7965; NR1H2; Transfected with: HGNC; 7672; NCOR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144785 CVCL_KZ57 PathHunter HEK 293 GRPR beta-arrestin transformed cell line human CVCL_KZ57 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144786 CVCL_KZ58 PathHunter HEK 293 IkappaB Degradation transformed cell line human CVCL_KZ58 CL:0000010 Transfected with: HGNC; 7797; NFKBIA Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144787 CVCL_KZ55 PathHunter HEK 293 GPR20 beta-arrestin transformed cell line human CVCL_KZ55 CL:0000010 Transfected with: HGNC; 4475; GPR20; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144788 CVCL_KZ56 PathHunter HEK 293 GPR45 beta-arrestin transformed cell line human CVCL_KZ56 CL:0000010 Transfected with: HGNC; 4503; GPR45; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144789 CVCL_KZ53 PathHunter HEK 293 GPR152 beta-arrestin transformed cell line human CVCL_KZ53 CL:0000010 Transfected with: HGNC; 23622; GPR152; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144790 CVCL_KZ54 PathHunter HEK 293 GPR173 beta-arrestin transformed cell line human CVCL_KZ54 CL:0000010 Transfected with: HGNC; 18186; GPR173; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144791 CVCL_KZ51 PathHunter HEK 293 GPR120L Total GPCR Internalization transformed cell line human CVCL_KZ51 CL:0000010 Transfected with: HGNC; 19061; FFAR4 (isoform 1) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144792 CVCL_KZ52 PathHunter HEK 293 GPR150 beta-arrestin transformed cell line human CVCL_KZ52 CL:0000010 Transfected with: HGNC; 23628; GPR150; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144793 CVCL_KZ50 PathHunter HEK 293 GPR119 beta-arrestin transformed cell line human CVCL_KZ50 CL:0000010 Transfected with: HGNC; 19060; GPR119; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144794 CVCL_KZ68 PathHunter Jurkat IkappaB Degradation cancer cell line human CVCL_KZ68 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7797; NFKBIA Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144795 CVCL_KZ69 PathHunter NCI-H460 CDC25A Degradation cancer cell line human CVCL_KZ69 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1725; CDC25A Derived from metastatic site: Pleural effusion. Male Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144796 CVCL_KZ66 PathHunter HEK 293 SCTR beta-arrestin transformed cell line human CVCL_KZ66 CL:0000010 Transfected with: HGNC; 10608; SCTR; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144797 CVCL_KZ67 PathHunter HEK 293 SSTR3 beta-arrestin transformed cell line human CVCL_KZ67 CL:0000010 Transfected with: HGNC; 11332; SSTR3; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144798 CVCL_KZ64 PathHunter HEK 293 PTGIR beta-arrestin transformed cell line human CVCL_KZ64 CL:0000010 Transfected with: HGNC; 9602; PTGIR; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144799 CVCL_KZ65 PathHunter HEK 293 RELA-IkappaB Nuclear Translocation transformed cell line human CVCL_KZ65 CL:0000010 Transfected with: HGNC; 9955; RELA; Transfected with: HGNC; 7797; NFKBIA Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21144800 CVCL_KZ62 PathHunter HEK 293 PTGER2 beta-arrestin transformed cell line human CVCL_KZ62 CL:0000010 Transfected with: HGNC; 9594; PTGER2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144801 CVCL_KZ63 PathHunter HEK 293 PTGER4 beta-arrestin transformed cell line human CVCL_KZ63 CL:0000010 Transfected with: HGNC; 9596; PTGER4; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144802 CVCL_KZ60 PathHunter HEK 293 mGPR120 beta-arrestin transformed cell line human CVCL_KZ60 CL:0000010 Transfected with: MGI; MGI:2147577; Ffar4; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144803 CVCL_KZ61 PathHunter HEK 293 P2RY4 beta-arrestin transformed cell line human CVCL_KZ61 CL:0000010 Transfected with: HGNC; 8542; P2RY4; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144804 CVCL_KZ39 PathHunter HEK 293 CCR7 beta-arrestin transformed cell line human CVCL_KZ39 CL:0000010 Transfected with: HGNC; 1608; CCR7; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144805 CVCL_KZ37 PathHunter HEK 293 CCKAR beta-arrestin transformed cell line human CVCL_KZ37 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144806 CVCL_KZ38 PathHunter HEK 293 CCR2 beta-arrestin transformed cell line human CVCL_KZ38 CL:0000010 Transfected with: HGNC; 1603; CCR2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144807 CVCL_KZ35 PathHunter HEK 293 beta-arrestin1-EA Parental transformed cell line human CVCL_KZ35 CL:0000010 Transfected with: HGNC; 711; ARRB1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21144808 CVCL_KZ36 PathHunter HEK 293 beta-arrestin2-EA Parental transformed cell line human CVCL_KZ36 CL:0000010 Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21144809 CVCL_KZ33 PathHunter HEK 293 AVPR2 beta-arrestin transformed cell line human CVCL_KZ33 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144810 CVCL_KZ34 PathHunter HEK 293 BDKRB2 beta-arrestin transformed cell line human CVCL_KZ34 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144811 CVCL_KZ31 PathHunter HEK 293 ADRA1D(82-572) beta-arrestin transformed cell line human CVCL_KZ31 CL:0000010 Transfected with: HGNC; 280; ADRA1D; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144812 CVCL_KZ32 PathHunter HEK 293 ADRB2 Total GPCR Internalization transformed cell line human CVCL_KZ32 CL:0000010 Transfected with: HGNC; 286; ADRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144813 CVCL_KZ30 PathHunter DLD1 MTNR1A Total GPCR Internalization cancer cell line human CVCL_KZ30 CL:0000010 Transfected with: HGNC; 7463; MTNR1A. Male Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144814 CVCL_CA98 ND01737 transformed cell line human CVCL_CA98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21144815 CVCL_CA99 ND01738 transformed cell line human CVCL_CA99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144816 CVCL_KZ48 PathHunter HEK 293 FFAR1 beta-arrestin-1 transformed cell line human CVCL_KZ48 CL:0000010 Transfected with: HGNC; 4498; FFAR1; Transfected with: HGNC; 711; ARRB1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144817 CVCL_KZ49 PathHunter HEK 293 GCGR Total GPCR Internalization transformed cell line human CVCL_KZ49 CL:0000010 Transfected with: HGNC; 4192; GCGR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144818 CVCL_KZ46 PathHunter HEK 293 EDG3 beta-arrestin transformed cell line human CVCL_KZ46 CL:0000010 Transfected with: HGNC; 3167; S1PR3; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144819 CVCL_KZ47 PathHunter HEK 293 F2RL1 beta-arrestin transformed cell line human CVCL_KZ47 CL:0000010 Transfected with: HGNC; 3538; F2RL1; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144820 CVCL_KZ44 PathHunter HEK 293 cyno CXCR2 beta-arrestin transformed cell line human CVCL_KZ44 CL:0000010 Transfected with: UniProtKB; G7PLE7; Macaca fascicularis CXCR2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144821 CVCL_KZ45 PathHunter HEK 293 EDG1 Total GPCR Internalization transformed cell line human CVCL_KZ45 CL:0000010 Transfected with: HGNC; 3165; S1PR1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144822 CVCL_KZ42 PathHunter HEK 293 CXCR6 beta-arrestin transformed cell line human CVCL_KZ42 CL:0000010 Transfected with: HGNC; 16647; CXCR6; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144823 CVCL_KZ43 PathHunter HEK 293 cyno CXCR1 beta-arrestin transformed cell line human CVCL_KZ43 CL:0000010 Transfected with: UniProtKB; G7PLE8; Macaca fascicularis CXCR1; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144824 CVCL_KZ40 PathHunter HEK 293 CNR2 beta-arrestin transformed cell line human CVCL_KZ40 CL:0000010 Transfected with: HGNC; 2160; CNR2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144825 CVCL_KZ41 PathHunter HEK 293 CXCR2 beta-arrestin transformed cell line human CVCL_KZ41 CL:0000010 Transfected with: HGNC; 6027; CXCR2; Transfected with: HGNC; 712; ARRB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144826 CVCL_CA81 ND01557 transformed cell line human CVCL_CA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144827 CVCL_CA82 ND01573 transformed cell line human CVCL_CA82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144828 CVCL_CA80 ND01555 transformed cell line human CVCL_CA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144829 CVCL_CA85 ND01607 transformed cell line human CVCL_CA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND01607; probable Male 21144830 CVCL_KZ19 PathHunter CHO-K1 TACR3 beta-arrestin spontaneously immortalized cell line CVCL_KZ19 CL:0000010 Transfected with: HGNC; 11528; TACR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144831 CVCL_CA86 ND01609 transformed cell line human CVCL_CA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144832 CVCL_CA83 ND01592 transformed cell line human CVCL_CA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144833 CVCL_KZ17 PathHunter CHO-K1 TACR1 beta-arrestin spontaneously immortalized cell line CVCL_KZ17 CL:0000010 Transfected with: HGNC; 11526; TACR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144834 CVCL_CA84 ND01593 transformed cell line human CVCL_CA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144835 CVCL_KZ18 PathHunter CHO-K1 TACR2 beta-arrestin spontaneously immortalized cell line CVCL_KZ18 CL:0000010 Transfected with: HGNC; 11527; TACR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144836 CVCL_KZ15 PathHunter CHO-K1 SSTR5 beta-arrestin spontaneously immortalized cell line CVCL_KZ15 CL:0000010 Transfected with: HGNC; 11334; SSTR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144837 CVCL_KZ16 PathHunter CHO-K1 TAAR5 beta-arrestin spontaneously immortalized cell line CVCL_KZ16 CL:0000010 Transfected with: HGNC; 30236; TAAR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144838 CVCL_KZ13 PathHunter CHO-K1 SSTR3 beta-arrestin spontaneously immortalized cell line CVCL_KZ13 CL:0000010 Transfected with: HGNC; 11332; SSTR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144839 CVCL_KZ14 PathHunter CHO-K1 SSTR4 beta-arrestin spontaneously immortalized cell line CVCL_KZ14 CL:0000010 Transfected with: HGNC; 11333; SSTR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144840 CVCL_KZ11 PathHunter CHO-K1 SSTR2 Activated GPCR Internalization spontaneously immortalized cell line CVCL_KZ11 CL:0000010 Transfected with: HGNC; 11331; SSTR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144841 CVCL_KZ12 PathHunter CHO-K1 SSTR2 beta-arrestin spontaneously immortalized cell line CVCL_KZ12 CL:0000010 Transfected with: HGNC; 11331; SSTR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144842 CVCL_KZ10 PathHunter CHO-K1 sEDG5 beta-arrestin spontaneously immortalized cell line CVCL_KZ10 CL:0000010 Transfected with: UniProtKB; F7HPM1; Macaca mulatta S1PR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144843 CVCL_CA78 ND01535 transformed cell line human CVCL_CA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144844 CVCL_CA79 ND01545 transformed cell line human CVCL_CA79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144845 CVCL_CA76 ND01533 transformed cell line human CVCL_CA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144846 CVCL_CA77 ND01534 transformed cell line human CVCL_CA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144847 CVCL_CA92 ND01650 transformed cell line human CVCL_CA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144848 CVCL_CA93 ND01651 transformed cell line human CVCL_CA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144849 CVCL_CA90 ND01628 transformed cell line human CVCL_CA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144850 CVCL_CA91 ND01629 transformed cell line human CVCL_CA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144851 CVCL_CA96 ND01707 transformed cell line human CVCL_CA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144852 CVCL_CA97 ND01735 transformed cell line human CVCL_CA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144853 CVCL_CA94 ND01683 transformed cell line human CVCL_CA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144854 CVCL_KZ28 PathHunter DLD1 HTR6 beta-arrestin cancer cell line human CVCL_KZ28 CL:0000010 Transfected with: HGNC; 5301; HTR6; Transfected with: HGNC; 712; ARRB2. Male Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144855 CVCL_CA95 ND01704 transformed cell line human CVCL_CA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144856 CVCL_KZ29 PathHunter DLD1 mPTGER4 beta-arrestin cancer cell line human CVCL_KZ29 CL:0000010 Transfected with: MGI; MGI:104311; Ptger4; Transfected with: HGNC; 712; ARRB2. Male Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144857 CVCL_KZ26 PathHunter CHO-K1 XCR1 beta-arrestin spontaneously immortalized cell line CVCL_KZ26 CL:0000010 Transfected with: HGNC; 1625; XCR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Discontinued: DiscoverX; 93-0958C2; true Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144858 CVCL_KZ27 PathHunter DLD1 FFAR1 beta-arrestin cancer cell line human CVCL_KZ27 CL:0000010 Transfected with: HGNC; 4498; FFAR1; Transfected with: HGNC; 712; ARRB2. Male Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144859 CVCL_KZ24 PathHunter CHO-K1 VIPR1 beta-arrestin spontaneously immortalized cell line CVCL_KZ24 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144860 CVCL_KZ25 PathHunter CHO-K1 VIPR2 beta-arrestin spontaneously immortalized cell line CVCL_KZ25 CL:0000010 Transfected with: HGNC; 12695; VIPR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144861 CVCL_KZ22 PathHunter CHO-K1 TRHR beta-arrestin spontaneously immortalized cell line CVCL_KZ22 CL:0000010 Transfected with: HGNC; 12299; TRHR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144862 CVCL_KZ23 PathHunter CHO-K1 UTR2 beta-arrestin spontaneously immortalized cell line CVCL_KZ23 CL:0000010 Transfected with: HGNC; 4468; UTS2R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144863 CVCL_KZ20 PathHunter CHO-K1 THRalpha Protein Interaction spontaneously immortalized cell line CVCL_KZ20 CL:0000010 Transfected with: HGNC; 11796; THRA; Transfected with: HGNC; 7669; NCOA2 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144864 CVCL_KZ21 PathHunter CHO-K1 THRbeta Protein Interaction spontaneously immortalized cell line CVCL_KZ21 CL:0000010 Transfected with: HGNC; 11799; THRB; Transfected with: HGNC; 9234; MED1 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21144865 CVCL_CA89 ND01618 transformed cell line human CVCL_CA89 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144866 CVCL_CA87 ND01610 transformed cell line human CVCL_CA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144867 CVCL_CA88 ND01612 transformed cell line human CVCL_CA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144868 CVCL_TT98 HAP1 TRIM26 (-) 1 cancer cell line human CVCL_TT98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12962; TRIM26; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144869 CVCL_U598 STSAR-84 cancer cell line human CVCL_U598 CL:0000010 Unspecified 21144870 CVCL_TT99 HAP1 TRIM26 (-) 2 cancer cell line human CVCL_TT99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12962; TRIM26; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144871 CVCL_U599 STSAR-88 cancer cell line human CVCL_U599 CL:0000010 Male 21144872 CVCL_TT96 HAP1 TRIM25 (-) 2 cancer cell line human CVCL_TT96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12932; TRIM25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144873 CVCL_U596 STSAR-75 cancer cell line human CVCL_U596 CL:0000010 Unspecified 21144874 CVCL_TT97 HAP1 TRIM25 (-) 3 cancer cell line human CVCL_TT97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12932; TRIM25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144875 CVCL_U597 STSAR-8 cancer cell line human CVCL_U597 CL:0000010 Unspecified 21144876 CVCL_1N50 UV40 transformed cell line CVCL_1N50 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144877 CVCL_1N53 irs3 spontaneously immortalized cell line CVCL_1N53 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144878 CVCL_1N54 Urd-A spontaneously immortalized cell line CVCL_1N54 CL:0000010 Derived from sampling site: Ovary. Female 21144879 CVCL_1N51 irs1 spontaneously immortalized cell line CVCL_1N51 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144880 CVCL_1N52 irs2 spontaneously immortalized cell line CVCL_1N52 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21144881 CVCL_1N46 UV47 transformed cell line CVCL_1N46 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144882 CVCL_1N47 UV57 transformed cell line CVCL_1N47 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144883 CVCL_1N44 UV152 transformed cell line CVCL_1N44 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144884 CVCL_1N45 UV46 transformed cell line CVCL_1N45 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144885 CVCL_1N48 UV78 transformed cell line CVCL_1N48 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144886 CVCL_1N49 MC5 spontaneously immortalized cell line CVCL_1N49 CL:0000010 Derived from sampling site: Ovary. Female 21144887 CVCL_TT87 HAP1 TRIM21 (-) 1 cancer cell line human CVCL_TT87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11312; TRIM21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144888 CVCL_U587 STSAR-34 cancer cell line human CVCL_U587 CL:0000010 Male 21144889 CVCL_TT88 HAP1 TRIM21 (-) 2 cancer cell line human CVCL_TT88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11312; TRIM21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144890 CVCL_U588 STSAR-35 cancer cell line human CVCL_U588 CL:0000010 Female 21144891 CVCL_TT85 HAP1 TRIM2 (-) 1 cancer cell line human CVCL_TT85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15974; TRIM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144892 CVCL_U585 STSAR-28 cancer cell line human CVCL_U585 CL:0000010 Donor information: Established from a patient originally treated by radiation therapy for a Hodgkin lymphoma (PubMed=2253180). Male 21144893 CVCL_TT86 HAP1 TRIM2 (-) 2 cancer cell line human CVCL_TT86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15974; TRIM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144894 CVCL_U586 STSAR-33 cancer cell line human CVCL_U586 CL:0000010 Male 21144895 CVCL_TT89 HAP1 TRIM22 (-) 1 cancer cell line human CVCL_TT89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16379; TRIM22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144896 CVCL_U589 STSAR-43 cancer cell line human CVCL_U589 CL:0000010 Female 21144897 CVCL_1N60 GM02068 finite cell line human CVCL_1N60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(6;7)(6pter->6q27::7q22->7qter;7pter->7q22::6q27->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21144898 CVCL_1N61 GM03005 finite cell line human CVCL_1N61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(11;16)(11pter->11q13::16p11->16pter;16qter->16p11::11q13->11qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21144899 CVCL_1N64 GM07941 transformed cell line human CVCL_1N64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144900 CVCL_1N65 GM08352 transformed cell line human CVCL_1N65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144901 CVCL_1N62 GM03884 finite cell line human CVCL_1N62 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;16)(q26;q24) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21144902 CVCL_1N63 GM04613 finite cell line human CVCL_1N63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(2;11)(2qter->2p11.2::11p13->11pter;11qter->11p13::2p11.2->2pter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21144903 CVCL_1N57 GM09528 transformed cell line human CVCL_1N57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144904 CVCL_1N58 CHO Q131-91A spontaneously immortalized cell line CVCL_1N58 CL:0000010 Derived from sampling site: Ovary. Female 21144905 CVCL_1N55 Urd-B spontaneously immortalized cell line CVCL_1N55 CL:0000010 Derived from sampling site: Ovary. Female 21144906 CVCL_1N56 Urd-C spontaneously immortalized cell line CVCL_1N56 CL:0000010 Derived from sampling site: Ovary. Female 21144907 CVCL_1N59 GM10062 transformed cell line human CVCL_1N59 CL:0000010 Karyotypic information: 46,X,t(X;21)(Xqter->Xp21::21p12->21pter;21qter->21p12::Xp21->Xpter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144908 CVCL_TT90 HAP1 TRIM22 (-) 2 cancer cell line human CVCL_TT90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16379; TRIM22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144909 CVCL_U590 STSAR-48 cancer cell line human CVCL_U590 CL:0000010 Unspecified 21144910 CVCL_TT91 HAP1 TRIM23 (-) 1 cancer cell line human CVCL_TT91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 660; TRIM23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144911 CVCL_U591 STSAR-49 cancer cell line human CVCL_U591 CL:0000010 Derived from sampling site: Left biceps brachis. Unspecified 21144912 CVCL_TT94 HAP1 TRIM24 (-) 2 cancer cell line human CVCL_TT94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11812; TRIM24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144913 CVCL_U594 STSAR-64 cancer cell line human CVCL_U594 CL:0000010 Male 21144914 CVCL_TT95 HAP1 TRIM25 (-) 1 cancer cell line human CVCL_TT95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12932; TRIM25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144915 CVCL_U595 STSAR-7 cancer cell line human CVCL_U595 CL:0000010 Male 21144916 CVCL_TT92 HAP1 TRIM23 (-) 2 cancer cell line human CVCL_TT92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 660; TRIM23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144917 CVCL_U592 STSAR-5 cancer cell line human CVCL_U592 CL:0000010 Donor information: Established from a patient originally treated by radiation therapy for a breast carcinoma (PubMed=2253180). Female 21144918 CVCL_TT93 HAP1 TRIM24 (-) 1 cancer cell line human CVCL_TT93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11812; TRIM24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144919 CVCL_U593 STSAR-6 cancer cell line human CVCL_U593 CL:0000010 Female 21144920 CVCL_TT76 HAP1 TRIB1 (-) 3 cancer cell line human CVCL_TT76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16891; TRIB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144921 CVCL_U576 STSAR-2 cancer cell line human CVCL_U576 CL:0000010 Female 21144922 CVCL_TT77 HAP1 TRIB2 (-) cancer cell line human CVCL_TT77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30809; TRIB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144923 CVCL_U577 STSAR-20 cancer cell line human CVCL_U577 CL:0000010 Male 21144924 CVCL_TT74 HAP1 TRIB1 (-) 1 cancer cell line human CVCL_TT74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16891; TRIB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144925 CVCL_U574 STSAR-19 cancer cell line human CVCL_U574 CL:0000010 Male 21144926 CVCL_TT75 HAP1 TRIB1 (-) 2 cancer cell line human CVCL_TT75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16891; TRIB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144927 CVCL_U575 STSAR-198 cancer cell line human CVCL_U575 CL:0000010 Unspecified 21144928 CVCL_TT78 HAP1 TRIB3 (-) 1 cancer cell line human CVCL_TT78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16228; TRIB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144929 CVCL_U578 STSAR-21 cancer cell line human CVCL_U578 CL:0000010 Female 21144930 CVCL_TT79 HAP1 TRIB3 (-) 2 cancer cell line human CVCL_TT79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16228; TRIB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144931 CVCL_U579 STSAR-210 cancer cell line human CVCL_U579 CL:0000010 Unspecified 21144932 CVCL_1N31 GM02860 finite cell line human CVCL_1N31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(3;16)(3pter->3q13.2::16q13->16qter;16pter->16q13::3q13.2->3qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21144933 CVCL_1N32 CHO Ade-A spontaneously immortalized cell line CVCL_1N32 CL:0000010 Derived from sampling site: Ovary. Female 21144934 CVCL_1N30 GM09963 transformed cell line human CVCL_1N30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144935 CVCL_1N24 GM19743 transformed cell line human CVCL_1N24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144936 CVCL_1N25 GM19744 transformed cell line human CVCL_1N25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144937 CVCL_1N22 GM19696 transformed cell line human CVCL_1N22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144938 CVCL_1N23 GM19698 finite cell line human CVCL_1N23 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21144939 CVCL_1N28 GM04025 transformed cell line human CVCL_1N28 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[645]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144940 CVCL_1N29 GM09425 transformed cell line human CVCL_1N29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144941 CVCL_1N26 GM19745 transformed cell line human CVCL_1N26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144942 CVCL_1N27 GM04024 finite cell line human CVCL_1N27 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[645]; ClinVar=VCV000009972; Zygosity=Hemizygous (from autologous cell line GM04025) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21144943 CVCL_TT80 HAP1 TRIB3 (-) 3 cancer cell line human CVCL_TT80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16228; TRIB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144944 CVCL_U580 STSAR-217 cancer cell line human CVCL_U580 CL:0000010 Derived from sampling site: Left thigh. Unspecified 21144945 CVCL_TT83 HAP1 TRIM14 (-) 2 cancer cell line human CVCL_TT83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16283; TRIM14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144946 CVCL_U583 STSAR-255 cancer cell line human CVCL_U583 CL:0000010 Unspecified 21144947 CVCL_TT84 HAP1 TRIM16 (-) cancer cell line human CVCL_TT84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17241; TRIM16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144948 CVCL_U584 STSAR-26 cancer cell line human CVCL_U584 CL:0000010 Derived from sampling site: Left triceps brachii. Unspecified 21144949 CVCL_TT81 HAP1 TRIM11 (-) cancer cell line human CVCL_TT81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16281; TRIM11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144950 CVCL_U581 STSAR-22 cancer cell line human CVCL_U581 CL:0000010 Male 21144951 CVCL_TT82 HAP1 TRIM14 (-) 1 cancer cell line human CVCL_TT82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16283; TRIM14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144952 CVCL_U582 STSAR-23 cancer cell line human CVCL_U582 CL:0000010 Female 21144953 CVCL_TT65 HAP1 TRAF7 (-) 1 cancer cell line human CVCL_TT65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20456; TRAF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144954 CVCL_U565 ORS [Human Ewing sarcoma] cancer cell line human CVCL_U565 From: Delattre O.; Institut Curie; Paris; France CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 4 fusion (Ex10/Ex5) (PubMed=11423975); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Asp625fs; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=25223734). 21144955 CVCL_TT66 HAP1 TRAF7 (-) 2 cancer cell line human CVCL_TT66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20456; TRAF7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144956 CVCL_U566 HIBCPP cancer cell line human CVCL_U566 CL:0000010 Population: Japanese; Derived from sampling site: Brain; right lateral ventricle. Female Doubling time: 69 hours (at 5th passage), 62 hours (at 20th passage), 53 hours (at 50th passage) (PubMed=16130902) 21144957 CVCL_TT63 HAP1 TRAF6 (-) 1 cancer cell line human CVCL_TT63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12036; TRAF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144958 CVCL_U563 RPE.40 spontaneously immortalized cell line CVCL_U563 CL:0000010 Selected for resistance to: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta); Derived from sampling site: Ovary. Female Characteristics: Deficient in furin 21144959 CVCL_U564 COH [Human Ewing sarcoma] cancer cell line human CVCL_U564 From: Delattre O.; Institut Curie; Paris; France CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=26428435) Derived from sampling site: Bone; femur. 21144960 CVCL_TT64 HAP1 TRAF6 (-) 2 cancer cell line human CVCL_TT64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12036; TRAF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144961 CVCL_TT69 HAP1 TRDMT1 (-) 2 cancer cell line human CVCL_TT69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2977; TRDMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144962 CVCL_U569 STSAR-104 cancer cell line human CVCL_U569 CL:0000010 Female 21144963 CVCL_TT67 HAP1 TRAK1 (-) 1 cancer cell line human CVCL_TT67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29947; TRAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144964 CVCL_U567 STSAR-10 cancer cell line human CVCL_U567 CL:0000010 Male 21144965 CVCL_TT68 HAP1 TRDMT1 (-) 1 cancer cell line human CVCL_TT68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2977; TRDMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144966 CVCL_U568 STSAR-100 cancer cell line human CVCL_U568 CL:0000010 Unspecified 21144967 CVCL_1N42 UV61 transformed cell line CVCL_1N42 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144968 CVCL_1N43 UVU1 transformed cell line CVCL_1N43 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21144969 CVCL_1N40 CHO Ade-I spontaneously immortalized cell line CVCL_1N40 CL:0000010 Derived from sampling site: Ovary. Female 21144970 CVCL_1N41 CHO Ade-PAB spontaneously immortalized cell line CVCL_1N41 CL:0000010 Derived from sampling site: Ovary. Female 21144971 CVCL_1N35 CHO Ade-D spontaneously immortalized cell line CVCL_1N35 CL:0000010 Derived from sampling site: Ovary. Female 21144972 CVCL_1N36 CHO Ade-E spontaneously immortalized cell line CVCL_1N36 CL:0000010 Derived from sampling site: Ovary. Female 21144973 CVCL_1N33 CHO Ade-B spontaneously immortalized cell line CVCL_1N33 CL:0000010 Derived from sampling site: Ovary. Female 21144974 CVCL_1N34 CHO Ade-C spontaneously immortalized cell line CVCL_1N34 CL:0000010 Derived from sampling site: Ovary. Female 21144975 CVCL_1N39 CHO Ade-H spontaneously immortalized cell line CVCL_1N39 CL:0000010 Derived from sampling site: Ovary. Female 21144976 CVCL_1N37 CHO Ade-F spontaneously immortalized cell line CVCL_1N37 CL:0000010 Derived from sampling site: Ovary. Female 21144977 CVCL_1N38 CHO Ade-G spontaneously immortalized cell line CVCL_1N38 CL:0000010 Derived from sampling site: Ovary. Female 21144978 CVCL_TT72 HAP1 TREX1 (-) 2 cancer cell line human CVCL_TT72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12269; TREX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144979 CVCL_U572 STSAR-14 cancer cell line human CVCL_U572 CL:0000010 Male 21144980 CVCL_TT73 HAP1 TREX1 (-) 3 cancer cell line human CVCL_TT73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12269; TREX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144981 CVCL_U573 STSAR-169 cancer cell line human CVCL_U573 CL:0000010 Unspecified 21144982 CVCL_TT70 HAP1 TRDMT1 (-) 3 cancer cell line human CVCL_TT70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2977; TRDMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144983 CVCL_U570 STSAR-11 cancer cell line human CVCL_U570 CL:0000010 Male 21144984 CVCL_TT71 HAP1 TREX1 (-) 1 cancer cell line human CVCL_TT71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12269; TREX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144985 CVCL_U571 STSAR-13 cancer cell line human CVCL_U571 CL:0000010 Unspecified 21144986 CVCL_U554 GM23863 transformed cell line human CVCL_U554 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144987 CVCL_TT54 HAP1 TRAF2 (-) 1 cancer cell line human CVCL_TT54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12032; TRAF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144988 CVCL_U555 GM23899 transformed cell line human CVCL_U555 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144989 CVCL_TT55 HAP1 TRAF2 (-) 2 cancer cell line human CVCL_TT55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12032; TRAF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144990 CVCL_U552 GM23857 transformed cell line human CVCL_U552 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21144991 CVCL_TT52 HAP1 TRA2A (-) 1 cancer cell line human CVCL_TT52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16645; TRA2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144992 CVCL_U553 GM23862 transformed cell line human CVCL_U553 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21144993 CVCL_TT53 HAP1 TRAF1 (-) cancer cell line human CVCL_TT53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12031; TRAF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144994 CVCL_U558 GM23988 transformed cell line human CVCL_U558 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21144995 CVCL_TT58 HAP1 TRAF3 (-) 3 cancer cell line human CVCL_TT58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12033; TRAF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144996 CVCL_U559 GM24065 transformed cell line human CVCL_U559 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144997 CVCL_TT59 HAP1 TRAF3IP2 (-) 1 cancer cell line human CVCL_TT59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1343; TRAF3IP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21144998 CVCL_U556 GM23943 transformed cell line human CVCL_U556 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21144999 CVCL_TT56 HAP1 TRAF3 (-) 1 cancer cell line human CVCL_TT56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12033; TRAF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145000 CVCL_U557 GM23977 transformed cell line human CVCL_U557 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145001 CVCL_TT57 HAP1 TRAF3 (-) 2 cancer cell line human CVCL_TT57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12033; TRAF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145002 CVCL_1N10 GM22757 finite cell line human CVCL_1N10 CL:0000010 Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21145003 CVCL_1N02 GM23611 finite cell line human CVCL_1N02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145004 CVCL_1N03 GM23620 transformed cell line human CVCL_1N03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145005 CVCL_1N00 GM23468 finite cell line human CVCL_1N00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145006 CVCL_1N01 GM23610 transformed cell line human CVCL_1N01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145007 CVCL_1N06 GM23623 finite cell line human CVCL_1N06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145008 CVCL_1N07 GM22660 transformed cell line human CVCL_1N07 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21145009 CVCL_1N04 GM23621 finite cell line human CVCL_1N04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145010 CVCL_1N05 GM23622 transformed cell line human CVCL_1N05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145011 CVCL_1N08 GM22661 finite cell line human CVCL_1N08 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Leu198Trp (c.593T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with myopathy but at significant risk for disease; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21145012 CVCL_1N09 GM22756 transformed cell line human CVCL_1N09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145013 CVCL_U561 GM24407 transformed cell line human CVCL_U561 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145014 CVCL_TT61 HAP1 TRAF3IP2 (-) 3 cancer cell line human CVCL_TT61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1343; TRAF3IP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145015 CVCL_U562 GM24482 transformed cell line human CVCL_U562 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145016 CVCL_TT62 HAP1 TRAF5 (-) cancer cell line human CVCL_TT62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12035; TRAF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145017 CVCL_U560 GM24341 transformed cell line human CVCL_U560 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145018 CVCL_TT60 HAP1 TRAF3IP2 (-) 2 cancer cell line human CVCL_TT60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1343; TRAF3IP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145019 CVCL_U543 GM21890 finite cell line human CVCL_U543 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21145020 CVCL_TT43 HAP1 TP53BP2 (-) 1 cancer cell line human CVCL_TT43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12000; TP53BP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145021 CVCL_U544 GM21891 transformed cell line human CVCL_U544 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145022 CVCL_TT44 HAP1 TP53BP2 (-) 2 cancer cell line human CVCL_TT44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12000; TP53BP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145023 CVCL_U541 GM20408 transformed cell line human CVCL_U541 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145024 CVCL_TT41 HAP1 TP53BP1 (-) 4 cancer cell line human CVCL_TT41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145025 CVCL_U542 GM21889 finite cell line human CVCL_U542 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21145026 CVCL_TT42 HAP1 TP53BP1 (-) 5 cancer cell line human CVCL_TT42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145027 CVCL_U547 GM23361 transformed cell line human CVCL_U547 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145028 CVCL_TT47 HAP1 TP53INP2 (-) 2 cancer cell line human CVCL_TT47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16104; TP53INP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145029 CVCL_U548 GM23425 transformed cell line human CVCL_U548 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145030 CVCL_TT48 HAP1 TP53INP2 (-) 3 cancer cell line human CVCL_TT48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16104; TP53INP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145031 CVCL_U545 GM23292 transformed cell line human CVCL_U545 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145032 CVCL_TT45 HAP1 TP53BP2 (-) 3 cancer cell line human CVCL_TT45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12000; TP53BP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145033 CVCL_U546 GM23336 transformed cell line human CVCL_U546 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145034 CVCL_TT46 HAP1 TP53INP2 (-) 1 cancer cell line human CVCL_TT46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16104; TP53INP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145035 CVCL_U549 GM23466 transformed cell line human CVCL_U549 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145036 CVCL_TT49 HAP1 TP73 (-) 1 cancer cell line human CVCL_TT49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145037 CVCL_1N20 GM19694 transformed cell line human CVCL_1N20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145038 CVCL_1N21 GM19695 finite cell line human CVCL_1N21 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21145039 CVCL_1N13 GM00575 finite cell line human CVCL_1N13 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21145040 CVCL_1N14 GM01702 finite cell line human CVCL_1N14 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21145041 CVCL_1N11 GM01936 finite cell line human CVCL_1N11 CL:0000010 Population: Jewish; Moroccan; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01936; probable Female 21145042 CVCL_1N12 GM01937 finite cell line human CVCL_1N12 CL:0000010 Population: Jewish; Moroccan; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01937; probable Female 21145043 CVCL_1N17 GM19687 transformed cell line human CVCL_1N17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145044 CVCL_1N18 GM19688 finite cell line human CVCL_1N18 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21145045 CVCL_1N15 GM19634 transformed cell line human CVCL_1N15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145046 CVCL_1N16 GM19647 finite cell line human CVCL_1N16 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21145047 CVCL_1N19 GM19693 finite cell line human CVCL_1N19 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21145048 CVCL_U550 GM23832 transformed cell line human CVCL_U550 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145049 CVCL_TT50 HAP1 TPMT (-) 1 cancer cell line human CVCL_TT50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12014; TPMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145050 CVCL_U551 GM23834 transformed cell line human CVCL_U551 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145051 CVCL_TT51 HAP1 TPMT (-) 2 cancer cell line human CVCL_TT51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12014; TPMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145052 CVCL_U532 GM11385 transformed cell line human CVCL_U532 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145053 CVCL_TT32 HAP1 TOP2B (-) 1 cancer cell line human CVCL_TT32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11990; TOP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145054 CVCL_U533 GM11388 transformed cell line human CVCL_U533 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145055 CVCL_TT33 HAP1 TOP2B (-) 2 cancer cell line human CVCL_TT33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11990; TOP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145056 CVCL_TT30 HAP1 TOP1MT (-) 1 cancer cell line human CVCL_TT30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29787; TOP1MT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145057 CVCL_U530 PWS iPS del 1-8 induced pluripotent stem cell human CVCL_U530 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145058 CVCL_TT31 HAP1 TOP1MT (-) 2 cancer cell line human CVCL_TT31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29787; TOP1MT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145059 CVCL_U531 PWS iPS del 1-9 induced pluripotent stem cell human CVCL_U531 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145060 CVCL_U536 GM12135 transformed cell line human CVCL_U536 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145061 CVCL_TT36 HAP1 TOX3 (-) 1 cancer cell line human CVCL_TT36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11972; TOX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145062 CVCL_U537 GM13553 transformed cell line human CVCL_U537 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145063 CVCL_TT37 HAP1 TOX3 (-) 2 cancer cell line human CVCL_TT37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11972; TOX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145064 CVCL_U534 GM11391 transformed cell line human CVCL_U534 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145065 CVCL_TT34 HAP1 TOX (-) 1 cancer cell line human CVCL_TT34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18988; TOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145066 CVCL_U535 GM12134 transformed cell line human CVCL_U535 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145067 CVCL_TT35 HAP1 TOX (-) 2 cancer cell line human CVCL_TT35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18988; TOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145068 CVCL_U538 GM13555 transformed cell line human CVCL_U538 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145069 CVCL_TT38 HAP1 TP53BP1 (-) 1 cancer cell line human CVCL_TT38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145070 CVCL_U539 GM13556 transformed cell line human CVCL_U539 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145071 CVCL_TT39 HAP1 TP53BP1 (-) 2 cancer cell line human CVCL_TT39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145072 CVCL_KZ99 PathHunter U2OS CDC25A Degradation cancer cell line human CVCL_KZ99 CL:0000010 Transfected with: HGNC; 1725; CDC25A Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21145073 CVCL_KZ97 PathHunter U2OS CCR6 Activated GPCR Internalization cancer cell line human CVCL_KZ97 CL:0000010 Transfected with: HGNC; 1607; CCR6; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145074 CVCL_KZ98 PathHunter U2OS CCR7 Activated GPCR Internalization cancer cell line human CVCL_KZ98 CL:0000010 Transfected with: HGNC; 1608; CCR7; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145075 CVCL_KZ95 PathHunter U2OS CCR4 Total GPCR Internalization cancer cell line human CVCL_KZ95 CL:0000010 Transfected with: HGNC; 1605; CCR4 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145076 CVCL_KZ96 PathHunter U2OS CCR5 Activated GPCR Internalization cancer cell line human CVCL_KZ96 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145077 CVCL_KZ93 PathHunter U2OS CCR10 beta-arrestin cancer cell line human CVCL_KZ93 CL:0000010 Transfected with: HGNC; 4474; CCR10; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145078 CVCL_KZ94 PathHunter U2OS CCR2 Total GPCR Internalization cancer cell line human CVCL_KZ94 CL:0000010 Transfected with: HGNC; 1603; CCR2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145079 CVCL_KZ91 PathHunter U2OS CCR1 beta-arrestin-1 cancer cell line human CVCL_KZ91 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145080 CVCL_KZ92 PathHunter U2OS CCR10 Activated GPCR Internalization cancer cell line human CVCL_KZ92 CL:0000010 Transfected with: HGNC; 4474; CCR10; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145081 CVCL_KZ90 PathHunter U2OS CCR1 Activated GPCR Internalization cancer cell line human CVCL_KZ90 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145082 CVCL_U540 GM20406 transformed cell line human CVCL_U540 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145083 CVCL_TT40 HAP1 TP53BP1 (-) 3 cancer cell line human CVCL_TT40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11999; TP53BP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145084 CVCL_U521 CMT-4 cancer cell line dog CVCL_U521 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: German Shepherd. Female Doubling time: ~30 hours (PubMed=3462415) 21145085 CVCL_TT21 HAP1 TNRC6A (-) 1 cancer cell line human CVCL_TT21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11969; TNRC6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145086 CVCL_U522 CMT9 cancer cell line dog CVCL_U522 CL:0000010 Derived from sampling site: Mammary gland. Female 21145087 CVCL_TT22 HAP1 TOM1 (-) 1 cancer cell line human CVCL_TT22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11982; TOM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145088 CVCL_U520 CMT-3 cancer cell line dog CVCL_U520 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Doberman Pinscher. Female Doubling time: ~40 hours (PubMed=3462415) 21145089 CVCL_TT20 HAP1 TNPO1 (-) 3 cancer cell line human CVCL_TT20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6401; TNPO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145090 CVCL_TT25 HAP1 TOM1 (-) 4 cancer cell line human CVCL_TT25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11982; TOM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145091 CVCL_U525 PWS iPS del 1-3 induced pluripotent stem cell human CVCL_U525 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145092 CVCL_TT26 HAP1 TOMM7 (-) 1 cancer cell line human CVCL_TT26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21648; TOMM7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145093 CVCL_U526 PWS iPS del 1-4 induced pluripotent stem cell human CVCL_U526 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145094 CVCL_TT23 HAP1 TOM1 (-) 2 cancer cell line human CVCL_TT23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11982; TOM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145095 CVCL_U523 PWS iPS del 1-1 induced pluripotent stem cell human CVCL_U523 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145096 CVCL_TT24 HAP1 TOM1 (-) 3 cancer cell line human CVCL_TT24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11982; TOM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145097 CVCL_U524 PWS iPS del 1-2 induced pluripotent stem cell human CVCL_U524 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145098 CVCL_TT29 HAP1 TOP1 (-) 2 cancer cell line human CVCL_TT29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11986; TOP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145099 CVCL_U529 PWS iPS del 1-7 induced pluripotent stem cell human CVCL_U529 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Kerafast; ECN002; true; Discontinued: Kerafast; ECN015; true Female 21145100 CVCL_TT27 HAP1 TOMM7 (-) 2 cancer cell line human CVCL_TT27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21648; TOMM7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145101 CVCL_U527 PWS iPS del 1-5 induced pluripotent stem cell human CVCL_U527 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145102 CVCL_TT28 HAP1 TOP1 (-) 1 cancer cell line human CVCL_TT28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11986; TOP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145103 CVCL_U528 PWS iPS del 1-6 induced pluripotent stem cell human CVCL_U528 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145104 CVCL_1M90 AG22145 finite cell line human CVCL_1M90 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21145105 CVCL_1M91 AG22146 finite cell line human CVCL_1M91 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21145106 CVCL_1M94 AG22284 finite cell line human CVCL_1M94 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21145107 CVCL_1M95 AG20457 transformed cell line human CVCL_1M95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145108 CVCL_1M92 AG22282 finite cell line human CVCL_1M92 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21145109 CVCL_1M93 AG22283 finite cell line human CVCL_1M93 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21145110 CVCL_1M98 GM20073 transformed cell line human CVCL_1M98 CL:0000010 Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Glu213Gly (c.638A>G); ClinVar=VCV000004336; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Glu304Ter (c.910G>T); ClinVar=VCV000977721; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145111 CVCL_1M99 GM20074 transformed cell line human CVCL_1M99 CL:0000010 Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Glu213Gly (c.638A>G); ClinVar=VCV000004336; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Glu304Ter (c.910G>T); ClinVar=VCV000977721; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145112 CVCL_1M96 AG22339 transformed cell line human CVCL_1M96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145113 CVCL_1M97 GM03719 finite cell line human CVCL_1M97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Metabolome analysis Male 21145114 CVCL_1M89 AG22144 finite cell line human CVCL_1M89 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21145115 CVCL_1M72 IWB transformed cell line human CVCL_1M72 HLA typing: A*23; B*07; C*w07 (Coriell=GM06825) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21145116 CVCL_1M73 MST1 transformed cell line human CVCL_1M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21145117 CVCL_1M70 BVR transformed cell line human CVCL_1M70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21145118 CVCL_1M71 HAR transformed cell line human CVCL_1M71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21145119 CVCL_1M76 THR transformed cell line human CVCL_1M76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21145120 CVCL_1M77 UCA transformed cell line human CVCL_1M77 HLA typing: A*09; B*35 (Coriell=GM08604) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21145121 CVCL_1M74 MWF transformed cell line human CVCL_1M74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21145122 CVCL_1M75 OOS [Human B-cell IHW] transformed cell line human CVCL_1M75 HLA typing: A*26; B*w56; C*w01 (Coriell=GM06827) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21145123 CVCL_1M69 GM02630 finite cell line human CVCL_1M69 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02630; probable 21145124 CVCL_1M67 GM01493 finite cell line human CVCL_1M67 CL:0000010 Donor information: From Bloom Syndrome Registry patient 57(AmEl) (BSR57); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM01493; probable Male 21145125 CVCL_1M68 GM01746 finite cell line human CVCL_1M68 CL:0000010 Population: Arab; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21145126 CVCL_1M80 AG15991 transformed cell line human CVCL_1M80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145127 CVCL_1M83 AG15829 transformed cell line human CVCL_1M83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145128 CVCL_1M84 AG15830 transformed cell line human CVCL_1M84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145129 CVCL_1M81 AG15995 transformed cell line human CVCL_1M81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145130 CVCL_1M82 AG15804 transformed cell line human CVCL_1M82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145131 CVCL_1M87 AG22118 finite cell line human CVCL_1M87 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21145132 CVCL_1M88 AG22119 finite cell line human CVCL_1M88 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21145133 CVCL_1M85 AG15831 transformed cell line human CVCL_1M85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145134 CVCL_1M86 AG22117 finite cell line human CVCL_1M86 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21145135 CVCL_1M78 AG15914 transformed cell line human CVCL_1M78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145136 CVCL_1M79 AG15803 transformed cell line human CVCL_1M79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21145137 CVCL_U499 AS iPS del 1-1 induced pluripotent stem cell human CVCL_U499 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21145138 CVCL_TS99 HAP1 TMEM5 (-) 4 cancer cell line human CVCL_TS99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145139 CVCL_TS97 HAP1 TMEM5 (-) 2 cancer cell line human CVCL_TS97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145140 CVCL_U497 MCH074 finite cell line human CVCL_U497 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145141 CVCL_U498 AS iPS del 1-0 induced pluripotent stem cell human CVCL_U498 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Kerafast; ECN001; true; Discontinued: Kerafast; ECN014; true Female 21145142 CVCL_TS98 HAP1 TMEM5 (-) 3 cancer cell line human CVCL_TS98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145143 CVCL_1M50 GM14085 transformed cell line human CVCL_1M50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145144 CVCL_1M51 GM14087 transformed cell line human CVCL_1M51 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys750Lys (c.2250G>A); ClinVar=VCV000003044; Zygosity=Heterozygous; Note=Causes skipping of exon 14 (p.Ile709_Lys750del, c.2125_2250del) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145145 CVCL_1M54 GM14134 transformed cell line human CVCL_1M54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145146 CVCL_1M55 GM14138 transformed cell line human CVCL_1M55 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1765Ter (c.5293C>T); ClinVar=VCV001073216; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145147 CVCL_1M52 GM14100 transformed cell line human CVCL_1M52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145148 CVCL_1M53 GM14101 transformed cell line human CVCL_1M53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145149 CVCL_1M47 GM14067 transformed cell line human CVCL_1M47 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1267_Val1268insTer (c.3802delG) (p.Val1268Terfs); ClinVar=VCV000127374; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145150 CVCL_1M48 GM14070 transformed cell line human CVCL_1M48 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1924Ter (c.5771C>A); ClinVar=VCV000429078; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp2625_Ala2626delinsGluPro (c.7875_7876delTGinsGC); ClinVar=VCV000003030; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145151 CVCL_1M45 GM14058 transformed cell line human CVCL_1M45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145152 CVCL_1M46 GM14066 transformed cell line human CVCL_1M46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145153 CVCL_1M49 GM14083 transformed cell line human CVCL_1M49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145154 CVCL_TS88 HAP1 TMEM2 (-) 1 cancer cell line human CVCL_TS88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11869; CEMIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145155 CVCL_U488 MCH060 finite cell line human CVCL_U488 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145156 CVCL_TS89 HAP1 TMEM205 (-) 1 cancer cell line human CVCL_TS89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29631; TMEM205; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145157 CVCL_U489 MCH064 finite cell line human CVCL_U489 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145158 CVCL_TS86 HAP1 TMEM177 (-) 1 cancer cell line human CVCL_TS86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28143; TMEM177; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145159 CVCL_U486 MCH058 finite cell line human CVCL_U486 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145160 CVCL_TS87 HAP1 TMEM177 (-) 2 cancer cell line human CVCL_TS87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28143; TMEM177; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145161 CVCL_U487 MCH059 finite cell line human CVCL_U487 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145162 CVCL_1M61 GM14451 transformed cell line human CVCL_1M61 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp2569Ter (c.7703_7704GA[1]) (c.7705_7706delGA) (p.Arg2568_Asp2569insTer); ClinVar=VCV000220550; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145163 CVCL_1M62 GM14471 transformed cell line human CVCL_1M62 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.7630-2A>C (IVS53-2A>C) (IVS51-2A>C) (L2544del53); ClinVar=VCV000127447; Zygosity=Heterozygous; Note=Splice acceptor mutation Causes in-frame skipping of exon 54 (Leu2544del53) (Coriell).; Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8786+1G>A (IVS62+1G>A) (c.8672del115) (G2891fsX); ClinVar=VCV000127463; Zygosity=Heterozygous; Note=Splice donor mutation Causes in-frame skipping of exon 62 (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145164 CVCL_1M60 GM14169 transformed cell line human CVCL_1M60 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr2333Asnfs*40 (c.6997dupA) (6997insA); ClinVar=VCV000140818; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8786+1G>A (IVS62+1G>A) (c.8672del115) (G2891fsX); ClinVar=VCV000127463; Zygosity=Heterozygous; Note=Splice donor mutation Causes in-frame skipping of exon 62 (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145165 CVCL_1M65 GM21849 transformed cell line human CVCL_1M65 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.His1082Leufs*14 (c.3245_3247delATCinsTGAT) (c.3245ATC>TGAT) (H1082X); ClinVar=VCV000003033; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145166 CVCL_1M66 GM22062 transformed cell line human CVCL_1M66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145167 CVCL_1M63 GM14472 transformed cell line human CVCL_1M63 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.7630-2A>C (IVS53-2A>C) (IVS51-2A>C) (L2544del53); ClinVar=VCV000127447; Zygosity=Heterozygous; Note=Splice acceptor mutation Causes in-frame skipping of exon 54 (Leu2544del53) (Coriell).; Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8786+1G>A (IVS62+1G>A) (c.8672del115) (G2891fsX); ClinVar=VCV000127463; Zygosity=Heterozygous; Note=Splice donor mutation Causes in-frame skipping of exon 62 (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145168 CVCL_1M64 GM21285 transformed cell line human CVCL_1M64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145169 CVCL_1M58 GM14153 transformed cell line human CVCL_1M58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145170 CVCL_1M59 GM14158 transformed cell line human CVCL_1M59 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1905Ilefs*26 (c.5712dupA) (5712insA); ClinVar=VCV000141416; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145171 CVCL_1M56 GM14142 transformed cell line human CVCL_1M56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145172 CVCL_1M57 GM14152 transformed cell line human CVCL_1M57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145173 CVCL_TS91 HAP1 TMEM209 (-) 2 cancer cell line human CVCL_TS91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21898; TMEM209; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145174 CVCL_U491 MCH068 finite cell line human CVCL_U491 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21145175 CVCL_TS92 HAP1 TMEM223 (-) 1 cancer cell line human CVCL_TS92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28464; TMEM223; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145176 CVCL_U492 MCH069 finite cell line human CVCL_U492 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145177 CVCL_TS90 HAP1 TMEM209 (-) 1 cancer cell line human CVCL_TS90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21898; TMEM209; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145178 CVCL_U490 MCH065 finite cell line human CVCL_U490 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145179 CVCL_TS95 HAP1 TMEM38B (-) 1 cancer cell line human CVCL_TS95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25535; TMEM38B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145180 CVCL_U495 MCH072 finite cell line human CVCL_U495 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145181 CVCL_TS96 HAP1 TMEM5 (-) 1 cancer cell line human CVCL_TS96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13530; RXYLT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145182 CVCL_U496 MCH073 finite cell line human CVCL_U496 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145183 CVCL_TS93 HAP1 TMEM223 (-) 2 cancer cell line human CVCL_TS93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28464; TMEM223; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145184 CVCL_U493 MCH070 finite cell line human CVCL_U493 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21145185 CVCL_TS94 HAP1 TMEM30A (-) 1 cancer cell line human CVCL_TS94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16667; TMEM30A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145186 CVCL_U494 MCH071 finite cell line human CVCL_U494 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145187 CVCL_CA60 ND01511 transformed cell line human CVCL_CA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145188 CVCL_CA63 ND01515 transformed cell line human CVCL_CA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145189 CVCL_CA64 ND01516 transformed cell line human CVCL_CA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145190 CVCL_CA61 ND01513 transformed cell line human CVCL_CA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145191 CVCL_CA62 ND01514 transformed cell line human CVCL_CA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145192 CVCL_CA56 ND01501 transformed cell line human CVCL_CA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145193 CVCL_CA57 ND01502 transformed cell line human CVCL_CA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145194 CVCL_CA54 ND01498 transformed cell line human CVCL_CA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145195 CVCL_CA55 ND01500 transformed cell line human CVCL_CA55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145196 CVCL_CA58 ND01506 transformed cell line human CVCL_CA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145197 CVCL_CA59 ND01510 transformed cell line human CVCL_CA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145198 CVCL_CA70 ND01524 transformed cell line human CVCL_CA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145199 CVCL_CA71 ND01526 transformed cell line human CVCL_CA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145200 CVCL_CA74 ND01531 transformed cell line human CVCL_CA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145201 CVCL_KZ08 PathHunter CHO-K1 RXRgamma Protein Interaction spontaneously immortalized cell line CVCL_KZ08 CL:0000010 Transfected with: HGNC; 10479; RXRG; Transfected with: HGNC; 7671; NCOA4 Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145202 CVCL_CA75 ND01532 transformed cell line human CVCL_CA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145203 CVCL_KZ09 PathHunter CHO-K1 SCTR beta-arrestin spontaneously immortalized cell line CVCL_KZ09 CL:0000010 Transfected with: HGNC; 10608; SCTR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145204 CVCL_CA72 ND01529 transformed cell line human CVCL_CA72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145205 CVCL_KZ06 PathHunter CHO-K1 RXFP3 beta-arrestin spontaneously immortalized cell line CVCL_KZ06 CL:0000010 Transfected with: HGNC; 24883; RXFP3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145206 CVCL_CA73 ND01530 transformed cell line human CVCL_CA73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145207 CVCL_KZ07 PathHunter CHO-K1 RXFP4 beta-arrestin spontaneously immortalized cell line CVCL_KZ07 CL:0000010 Transfected with: HGNC; 14666; RXFP4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145208 CVCL_KZ04 PathHunter CHO-K1 rPROKR2 beta-arrestin spontaneously immortalized cell line CVCL_KZ04 CL:0000010 Transfected with: RGD; 708445; Prokr2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145209 CVCL_KZ05 PathHunter CHO-K1 rVIPR1 beta-arrestin spontaneously immortalized cell line CVCL_KZ05 CL:0000010 Transfected with: RGD; 3961; Vipr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145210 CVCL_KZ02 PathHunter CHO-K1 rOPRM1 beta-arrestin spontaneously immortalized cell line CVCL_KZ02 CL:0000010 Transfected with: RGD; 3234; Oprm1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145211 CVCL_KZ03 PathHunter CHO-K1 rPROKR1 beta-arrestin spontaneously immortalized cell line CVCL_KZ03 CL:0000010 Transfected with: RGD; 708443; Prokr1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145212 CVCL_KZ00 PathHunter CHO-K1 rGPR120 beta-arrestin spontaneously immortalized cell line CVCL_KZ00 CL:0000010 Transfected with: RGD; 1308252; Ffar4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145213 CVCL_KZ01 PathHunter CHO-K1 rGPR35 beta-arrestin spontaneously immortalized cell line CVCL_KZ01 CL:0000010 Transfected with: RGD; 1309404; Gpr35; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21145214 CVCL_CA67 ND01520 transformed cell line human CVCL_CA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145215 CVCL_CA68 ND01521 transformed cell line human CVCL_CA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145216 CVCL_CA65 ND01517 transformed cell line human CVCL_CA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145217 CVCL_CA66 ND01518 transformed cell line human CVCL_CA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145218 CVCL_CA69 ND01522 transformed cell line human CVCL_CA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145219 CVCL_CA41 ND01409 transformed cell line human CVCL_CA41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145220 CVCL_CA42 ND01413 transformed cell line human CVCL_CA42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145221 CVCL_CA40 ND01408 transformed cell line human CVCL_CA40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145222 CVCL_CA34 ND01398 transformed cell line human CVCL_CA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145223 CVCL_CA35 ND01400 transformed cell line human CVCL_CA35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145224 CVCL_CA32 ND01396 transformed cell line human CVCL_CA32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145225 CVCL_CA33 ND01397 transformed cell line human CVCL_CA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145226 CVCL_CA38 ND01403 transformed cell line human CVCL_CA38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145227 CVCL_CA39 ND01404 transformed cell line human CVCL_CA39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145228 CVCL_CA36 ND01401 transformed cell line human CVCL_CA36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145229 CVCL_CA37 ND01402 transformed cell line human CVCL_CA37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145230 CVCL_CA52 ND01495 transformed cell line human CVCL_CA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145231 CVCL_CA53 ND01497 transformed cell line human CVCL_CA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145232 CVCL_CA50 ND01492 transformed cell line human CVCL_CA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145233 CVCL_CA51 ND01494 transformed cell line human CVCL_CA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145234 CVCL_CA45 ND01426 transformed cell line human CVCL_CA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145235 CVCL_CA46 ND01430 transformed cell line human CVCL_CA46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145236 CVCL_CA43 ND01423 transformed cell line human CVCL_CA43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145237 CVCL_CA44 ND01425 transformed cell line human CVCL_CA44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145238 CVCL_CA49 ND01470 transformed cell line human CVCL_CA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145239 CVCL_CA47 ND01434 transformed cell line human CVCL_CA47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145240 CVCL_CA48 ND01435 transformed cell line human CVCL_CA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145241 CVCL_CA20 ND01322 transformed cell line human CVCL_CA20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145242 CVCL_CA18 ND01318 transformed cell line human CVCL_CA18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145243 CVCL_CA19 ND01320 transformed cell line human CVCL_CA19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145244 CVCL_CA12 ND01272 transformed cell line human CVCL_CA12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145245 CVCL_CA13 ND01273 transformed cell line human CVCL_CA13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145246 CVCL_CA10 ND01249 transformed cell line human CVCL_CA10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145247 CVCL_CA11 ND01271 transformed cell line human CVCL_CA11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145248 CVCL_CA16 ND01314 transformed cell line human CVCL_CA16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145249 CVCL_CA17 ND01315 transformed cell line human CVCL_CA17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145250 CVCL_CA14 ND01275 transformed cell line human CVCL_CA14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145251 CVCL_CA15 ND01276 transformed cell line human CVCL_CA15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145252 CVCL_CA30 ND01370 transformed cell line human CVCL_CA30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145253 CVCL_CA31 ND01373 transformed cell line human CVCL_CA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145254 CVCL_CA29 ND01369 transformed cell line human CVCL_CA29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145255 CVCL_CA23 ND01345 transformed cell line human CVCL_CA23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145256 CVCL_CA24 ND01347 transformed cell line human CVCL_CA24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145257 CVCL_CA21 ND01332 transformed cell line human CVCL_CA21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145258 CVCL_CA22 ND01334 transformed cell line human CVCL_CA22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145259 CVCL_CA27 ND01358 transformed cell line human CVCL_CA27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145260 CVCL_CA28 ND01359 transformed cell line human CVCL_CA28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145261 CVCL_CA25 ND01353 transformed cell line human CVCL_CA25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145262 CVCL_CA26 ND01355 transformed cell line human CVCL_CA26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145263 CVCL_CA09 ND01248 transformed cell line human CVCL_CA09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145264 CVCL_CA07 ND01246 transformed cell line human CVCL_CA07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145265 CVCL_CA08 ND01247 transformed cell line human CVCL_CA08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145266 CVCL_CA01 ND01215 transformed cell line human CVCL_CA01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145267 CVCL_CA02 ND01216 transformed cell line human CVCL_CA02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145268 CVCL_CA00 ND01213 transformed cell line human CVCL_CA00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145269 CVCL_CA05 ND01243 transformed cell line human CVCL_CA05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145270 CVCL_CA06 ND01245 transformed cell line human CVCL_CA06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145271 CVCL_CA03 ND01218 transformed cell line human CVCL_CA03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145272 CVCL_CA04 ND01236 transformed cell line human CVCL_CA04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145273 CVCL_TU31 HAP1 TRIM47 (-) 2 cancer cell line human CVCL_TU31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19020; TRIM47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145274 CVCL_U631 U-937 GTB cancer cell line human CVCL_U631 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21145275 CVCL_U632 GM15812 transformed cell line human CVCL_U632 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145276 CVCL_TU32 HAP1 TRIM5 (-) 1 cancer cell line human CVCL_TU32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16276; TRIM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145277 CVCL_TU30 HAP1 TRIM47 (-) 1 cancer cell line human CVCL_TU30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19020; TRIM47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145278 CVCL_U630 WT SV40 MEF transformed cell line house mouse CVCL_U630 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145279 CVCL_U635 GM15819 transformed cell line human CVCL_U635 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145280 CVCL_TU35 HAP1 TRIM52 (-) 2 cancer cell line human CVCL_TU35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19024; TRIM52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145281 CVCL_U636 82-6 finite cell line human CVCL_U636 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21145282 CVCL_TU36 HAP1 TRIM54 (-) 1 cancer cell line human CVCL_TU36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16008; TRIM54; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145283 CVCL_U633 GM15814 transformed cell line human CVCL_U633 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145284 CVCL_TU33 HAP1 TRIM5 (-) 2 cancer cell line human CVCL_TU33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16276; TRIM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145285 CVCL_U634 GM15818 transformed cell line human CVCL_U634 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145286 CVCL_TU34 HAP1 TRIM52 (-) 1 cancer cell line human CVCL_TU34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19024; TRIM52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145287 CVCL_U639 Anti-FHA(1)1C6 hybridoma house mouse CVCL_U639 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12255; Bordetella pertussis filamentous hemagglutinin (fhaB). 21145288 CVCL_TU39 HAP1 TRIM58 (-) 1 cancer cell line human CVCL_TU39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24150; TRIM58; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145289 CVCL_U637 82-6pBlox telomerase immortalized cell line human CVCL_U637 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral vector containing a LTR-loxP-hTERT-SV40p-hisD-Pac-LTR construct When transfected with Cre recombinase the cells loose telomerase activity and histidinol sensitivity due to the excision of the hTERT and hisD genes. Simultaneously, the cells acquire puromycin resistance because the excision brings the Pac gene under the control of the retroviral promoter (LTR). 21145290 CVCL_TU37 HAP1 TRIM54 (-) 2 cancer cell line human CVCL_TU37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16008; TRIM54; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145291 CVCL_U638 7F9 hybridoma house mouse CVCL_U638 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; D4A9Q5; Rat Cpm. 21145292 CVCL_TU38 HAP1 TRIM56 (-) cancer cell line human CVCL_TU38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19028; TRIM56; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145293 CVCL_U620 BCL2 (S87A) Jurkat cancer cell line human CVCL_U620 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 990; BCL2 (with p.Ser87Ala) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21145294 CVCL_TU20 HAP1 TRIM39 (-) 2 cancer cell line human CVCL_TU20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10065; TRIM39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145295 CVCL_TU21 HAP1 TRIM4 (-) 1 cancer cell line human CVCL_TU21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16275; TRIM4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145296 CVCL_U621 Neo Jurkat cancer cell line human CVCL_U621 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21145297 CVCL_U624 Bad KO SV40 MEF transformed cell line house mouse CVCL_U624 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1096330; Bad Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145298 CVCL_TU24 HAP1 TRIM41 (-) 2 cancer cell line human CVCL_TU24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19013; TRIM41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145299 CVCL_U625 Bak KO SV40 MEF transformed cell line house mouse CVCL_U625 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1097161; Bak1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145300 CVCL_TU25 HAP1 TRIM44 (-) 1 cancer cell line human CVCL_TU25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19016; TRIM44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145301 CVCL_U622 BALB/MK-2 factor-dependent cell line house mouse CVCL_U622 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified Characteristics: EGF dependent 21145302 CVCL_TU22 HAP1 TRIM4 (-) 2 cancer cell line human CVCL_TU22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16275; TRIM4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145303 CVCL_U623 4DE4 cancer cell line house mouse CVCL_U623 From: Staudt L.M.; National Cancer Institute; Bethesda; USA. CL:0000010 21145304 CVCL_TU23 HAP1 TRIM41 (-) 1 cancer cell line human CVCL_TU23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19013; TRIM41; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145305 CVCL_U628 Bcl-2 KO SV40 MEF transformed cell line house mouse CVCL_U628 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88138; Bcl2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145306 CVCL_TU28 HAP1 TRIM45 (-) cancer cell line human CVCL_TU28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19018; TRIM45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145307 CVCL_U629 Bid KO SV40 MEF transformed cell line house mouse CVCL_U629 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108093; Bid Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145308 CVCL_TU29 HAP1 TRIM46 (-) cancer cell line human CVCL_TU29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19019; TRIM46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145309 CVCL_U626 Bax Bak DKO SV40 MEF transformed cell line house mouse CVCL_U626 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1097161; Bak1; Knockout cell: Method=KO mouse; MGI; MGI:99702; Bax Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145310 CVCL_TU26 HAP1 TRIM44 (-) 2 cancer cell line human CVCL_TU26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19016; TRIM44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145311 CVCL_U627 Bax KO SV40 MEF transformed cell line house mouse CVCL_U627 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99702; Bax Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21145312 CVCL_TU27 HAP1 TRIM44 (-) 3 cancer cell line human CVCL_TU27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19016; TRIM44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145313 CVCL_TU10 HAP1 TRIM33 (-) 2 cancer cell line human CVCL_TU10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16290; TRIM33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145314 CVCL_U610 S2G8 hybridoma house mouse CVCL_U610 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8405 21145315 CVCL_U613 94T778 cancer cell line human CVCL_U613 CL:0000010 Population: Caucasian; Derived from sampling site: Retroperitoneal space. Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145316 CVCL_TU13 HAP1 TRIM34 (-) 2 cancer cell line human CVCL_TU13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10063; TRIM34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145317 CVCL_U614 93T449 cancer cell line human CVCL_U614 CL:0000010 Population: Caucasian; Derived from sampling site: Retroperitoneal space. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145318 CVCL_TU14 HAP1 TRIM35 (-) cancer cell line human CVCL_TU14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16285; TRIM35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145319 CVCL_TU11 HAP1 TRIM33 (-) 3 cancer cell line human CVCL_TU11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16290; TRIM33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145320 CVCL_U611 S5B9 hybridoma house mouse CVCL_U611 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8402 21145321 CVCL_TU12 HAP1 TRIM34 (-) 1 cancer cell line human CVCL_TU12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10063; TRIM34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145322 CVCL_U612 S5E5 hybridoma house mouse CVCL_U612 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8403 21145323 CVCL_U617 BCL2 Jurkat cancer cell line human CVCL_U617 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 990; BCL2 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21145324 CVCL_TU17 HAP1 TRIM38 (-) 1 cancer cell line human CVCL_TU17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10059; TRIM38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145325 CVCL_U618 BCL2 (AAA) Jurkat cancer cell line human CVCL_U618 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 990; BCL2 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21145326 CVCL_TU18 HAP1 TRIM38 (-) 2 cancer cell line human CVCL_TU18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10059; TRIM38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145327 CVCL_TU15 HAP1 TRIM37 (-) 1 cancer cell line human CVCL_TU15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7523; TRIM37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145328 CVCL_U615 S635c15 cancer cell line Norway rat CVCL_U615 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Breed/subspecies: Fischer 344. Female 21145329 CVCL_U616 CHLA-03-AA cancer cell line human CVCL_U616 CL:0000010 Derived from sampling site: Brain; temporal lobe. Female 21145330 CVCL_TU16 HAP1 TRIM37 (-) 2 cancer cell line human CVCL_TU16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7523; TRIM37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145331 CVCL_U619 BCL2 (S70A) Jurkat cancer cell line human CVCL_U619 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 990; BCL2 (with p.Ser70Ala) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21145332 CVCL_TU19 HAP1 TRIM39 (-) 1 cancer cell line human CVCL_TU19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10065; TRIM39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145333 CVCL_U602 ASC52telo telomerase immortalized cell line human CVCL_U602 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female Doubling time: 36-48 hours (Evercyte) 21145334 CVCL_TU02 HAP1 TRIM28 (-) 1 cancer cell line human CVCL_TU02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16384; TRIM28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145335 CVCL_U603 ASC57telo telomerase immortalized cell line human CVCL_U603 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female Doubling time: ~40 hours (ATCC=SCRC-4001) 21145336 CVCL_TU03 HAP1 TRIM28 (-) 2 cancer cell line human CVCL_TU03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16384; TRIM28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145337 CVCL_TU00 HAP1 TRIM27 (-) 1 cancer cell line human CVCL_TU00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9975; TRIM27; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145338 CVCL_U600 STSAR-90 cancer cell line human CVCL_U600 CL:0000010 Male 21145339 CVCL_TU01 HAP1 TRIM27 (-) 3 cancer cell line human CVCL_TU01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9975; TRIM27; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145340 CVCL_U601 STSAR-91 cancer cell line human CVCL_U601 CL:0000010 Unspecified 21145341 CVCL_TU06 HAP1 TRIM32 (-) 1 cancer cell line human CVCL_TU06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16380; TRIM32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145342 CVCL_U606 TelCOFS02MA telomerase immortalized cell line human CVCL_U606 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys1239Glufs*1; Zygosity=Homozygous (PubMed=10739753); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145343 CVCL_TU07 HAP1 TRIM32 (-) 2 cancer cell line human CVCL_TU07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16380; TRIM32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145344 CVCL_U607 TelCOFS03MA telomerase immortalized cell line human CVCL_U607 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys1239Glufs*1; Zygosity=Homozygous (PubMed=10739753); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-4006; true Male 21145345 CVCL_U604 hAMSC76telo telomerase immortalized cell line human CVCL_U604 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Amnion Cell type=Mesenchymal stromal cell.. Discontinued: ATCC; CRL-4035; true Male 21145346 CVCL_TU04 HAP1 TRIM3 (-) 1 cancer cell line human CVCL_TU04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10064; TRIM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145347 CVCL_U605 hAMSC83telo telomerase immortalized cell line human CVCL_U605 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Amnion Cell type=Mesenchymal stromal cell.. Discontinued: ATCC; CRL-4033; probable 21145348 CVCL_TU05 HAP1 TRIM3 (-) 2 cancer cell line human CVCL_TU05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10064; TRIM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145349 CVCL_TU08 HAP1 TRIM32 (-) 3 cancer cell line human CVCL_TU08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16380; TRIM32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145350 CVCL_U608 S1C4 hybridoma house mouse CVCL_U608 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8333 21145351 CVCL_TU09 HAP1 TRIM33 (-) 1 cancer cell line human CVCL_TU09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16290; TRIM33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145352 CVCL_U609 s1A hybridoma house mouse CVCL_U609 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8404 21145353 CVCL_CB99 ND02578 transformed cell line human CVCL_CB99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145354 CVCL_CB97 ND02575 transformed cell line human CVCL_CB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145355 CVCL_CB98 ND02577 transformed cell line human CVCL_CB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145356 CVCL_2070 HKT-1097 cancer cell line CVCL_2070 CL:0000010 Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Kidney. Male Doubling time: 15 hours (PubMed=10476921); ~19 hours (DSMZ=ACC-445); 36 hours (ECACC=98061003) 21145357 CVCL_2071 HNT-34 cancer cell line human CVCL_2071 HLA typing: A*02:06,02:06; B*40:06,67:02; C*07:02,08:01 (PubMed=26589293); Genome ancestry: African=1.86%; Native American=0%; East Asian, North=80.82%; East Asian, South=13.41%; South Asian=0%; European, North=0%; European, South=3.91% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=25485619; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 26-27 hours (PubMed=9266939); 34 hours (PubMed=25984343); ~40 hours (DSMZ=ACC-600); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145358 CVCL_2074 Sf158 spontaneously immortalized cell line CVCL_2074 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~70 hours (DSMZ=ACC-292) Group: Insect cell line; Group: Recombinant protein production insect cell line 21145359 CVCL_2075 IGR-37 cancer cell line human CVCL_2075 HLA typing: A*01:01,01:01; B*39:01,39:01; C*12:03,12:03; DRB1*16:05,16:05 (PubMed=26589293); Genome ancestry: African=1.28%; Native American=0.29%; East Asian, North=1.79%; East Asian, South=0%; South Asian=0%; European, North=61.87%; European, South=34.77% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Inguinal lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48-72 hours (DSMZ=ACC-237); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145360 CVCL_2072 HPD-1NR cancer cell line CVCL_2072 CL:0000010 Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Female Doubling time: ~60-70 hours (DSMZ=ACC-314) 21145361 CVCL_2073 HPD-2NR cancer cell line CVCL_2073 CL:0000010 Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas. Female Doubling time: ~40 hours (DSMZ=ACC-293) 21145362 CVCL_2067 HDQ-P1 cancer cell line human CVCL_2067 Genome ancestry: African=1.07%; Native American=0%; East Asian, North=3.35%; East Asian, South=0%; South Asian=2.35%; European, North=51.89%; European, South=41.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12637; KDM6A; Simple; p.Arg165Ter (c.493C>T); ClinVar=VCV000692010; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11876; TMPRSS2; Simple; p.Gly8Val (c.23G>T) (c.-57+99G>T); dbSNP=rs75603675; Zygosity=Heterozygous (PubMed=34339474); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Breast. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 60 hours, at 88th passage (PubMed=10913678); ~72 hours (DSMZ=ACC-494); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145363 CVCL_2068 HH-16 cl.2/1 cancer cell line Norway rat CVCL_2068 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from metastatic site: Ascites; Breed/subspecies: Sprague Dawley. Female Doubling time: ~40 hours (DSMZ=ACC-485) 21145364 CVCL_2065 HCEC-B4G12 transformed cell line human CVCL_2065 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; endothelium. Female Doubling time: 62.26 +- 14.5 hours (PubMed=18196893); ~40-50 hours (DSMZ=ACC-647) 21145365 CVCL_2066 HCEC-H9C1 transformed cell line human CVCL_2066 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; endothelium. Female Doubling time: 44.05 +- 5.05 hours (PubMed=18196893); ~50-60 hours (DSMZ=ACC-649) 21145366 CVCL_2069 HH-16 cl.4 cancer cell line Norway rat CVCL_2069 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from metastatic site: Ascites; Breed/subspecies: Sprague Dawley. Female Doubling time: ~50-80 hours (DSMZ=ACC-358) 21145367 CVCL_2081 JMSU-1 cancer cell line human CVCL_2081 HLA typing: A*31:01,31:01; B*67:01,67:01; C*07:02,07:02; DQA1*03:02,04:01; DQB1*02:02,03:04; DRB1*04:08,04:08 (PubMed=26589293); Genome ancestry: African=1.12%; Native American=0.3%; East Asian, North=80.58%; East Asian, South=16.26%; South Asian=0%; European, North=0%; European, South=1.75% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (DepMap) Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32 hours (PubMed=7483139); ~30 hours (DSMZ=ACC-505) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145368 CVCL_2082 JOSK-I cancer cell line human CVCL_2082 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: DSMZ; ACC-155; true Male Doubling time: ~28-35 hours (DSMZ=ACC-155) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00135 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21145369 CVCL_2080 JL-1 cancer cell line human CVCL_2080 HLA typing: A*02:05,03:01; B*49:01,55:01; C*03:04,07:01; DQA1*05:02,05:02; DQB1*06:04,06:04; DRB1*04:05,11:30 (PubMed=26589293); Genome ancestry: African=0.03%; Native American=0%; East Asian, North=3.05%; East Asian, South=0%; South Asian=2.74%; European, North=56.74%; European, South=37.42% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47 hours (PubMed=23840376); ~70-80 hours (DSMZ=ACC-596) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21145370 CVCL_2085 JTC-27 cancer cell line Norway rat CVCL_2085 CL:0000010 Transformant: Ortho-aminoazotoluene(ChEBI; CHEBI:82285); Breed/subspecies: Donryu. Discontinued: JCRB; NIHS0227; true Female Doubling time: ~37 hours (DSMZ=ACC-330) 21145371 CVCL_2086 JURL-MK1 cancer cell line human CVCL_2086 Genome ancestry: African=3.4%; Native American=0%; East Asian, North=1.62%; East Asian, South=0%; South Asian=8.59%; European, North=29.18%; European, South=57.22% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9305612; PubMed=10071072; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Tyr1495Ter (c.4485C>A); ClinVar=VCV000521871; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=9305612); ~48 hours (DSMZ=ACC-532); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145372 CVCL_2083 JOSK-M cancer cell line human CVCL_2083 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: DSMZ; ACC-30; true Male Doubling time: ~30-40 hours (DSMZ=ACC-30) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00137 Problematic cell line: Contaminated Shown to be a U-937 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21145373 CVCL_2084 JTC-15 cancer cell line Norway rat CVCL_2084 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. Doubling time: ~30 hours (DSMZ=ACC-329) 21145374 CVCL_2078 JJN-3 cancer cell line human CVCL_2078 HLA typing: A*03,33; B*07,14:02/03; C*07,08:02 (Direct_author_submission); HLA typing: A*03:01,33:01; B*07:02,14:02; C*07:02,08:02; DQA1*01:02,01:02; DQB1*05:01,06:02; DRB1*01:02,15:01 (PubMed=26589293); Genome ancestry: African=0.8%; Native American=0%; East Asian, North=2.53%; East Asian, South=0%; South Asian=0%; European, North=64.14%; European, South=32.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA1 kappa; Characteristics: IL6 independent Doubling time: 24 hours (PubMed=25984343); ~20-35 hours (DSMZ=ACC-541); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145375 CVCL_2079 JK-1 cancer cell line human CVCL_2079 HLA typing: A*31:01,31:01; B*15:11,58:01; C*03:02,03:02; DQA1*02:01,05:02; DQB1*06:04,06:04; DRB1*13:02,14:05 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=74.72%; East Asian, South=25.28%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827; PubMed=20809971; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48 hours (PubMed=2169992); ~50 hours (DSMZ=ACC-347) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145376 CVCL_2076 IGR-39 cancer cell line human CVCL_2076 HLA typing: B*39:01:01,39:01:01; C*07:02,07:02; DPB1*31:01,09:01; DQB1*06:02; DRB1*16:02 (PubMed=15592718); Genome ancestry: African=1.8%; Native American=1.18%; East Asian, North=2.76%; East Asian, South=0%; South Asian=0%; European, North=58.99%; European, South=35.28% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23851445; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys229Tyrfs*10 (c.686_687delGT); ClinVar=VCV000863486; Zygosity=Unspecified (DepMap) Population: Caucasian; Derived from sampling site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ESTDAB; ESTDAB-037; probable Male Doubling time: 34 hours (PubMed=25984343); ~30 hours (DSMZ=ACC-239) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145377 CVCL_2077 JIMT-1 cancer cell line human CVCL_2077 HLA typing: A*03:01,68:01; B*08:01,35:08; C*03:04,07:06 (PubMed=25960936); HLA typing: A*03:01,68:01; B*08:01,40:01; C*03:04,07:06 (PubMed=26589293); Genome ancestry: African=3.6%; Native American=0.79%; East Asian, North=7.75%; East Asian, South=0%; South Asian=0%; European, North=71.27%; European, South=16.59% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (DepMap) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: ER-negative Has amplified ERBB2 and is insensitive to trastuzumab (Herceptin) (PubMed=15634652). Doubling time: ~30-40 hours (DSMZ=ACC-589); 35.39 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21145378 CVCL_U697 9L-7 cancer cell line Norway rat CVCL_U697 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3423; Carmustine (BCNU); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21145379 CVCL_TU97 HAP1 TSSC1 (-) 1 cancer cell line human CVCL_TU97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12383; EIPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145380 CVCL_U698 9L-8 cancer cell line Norway rat CVCL_U698 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3423; Carmustine (BCNU); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21145381 CVCL_TU98 HAP1 TSSC1 (-) 2 cancer cell line human CVCL_TU98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12383; EIPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145382 CVCL_TU95 HAP1 TSPO (-) 1 cancer cell line human CVCL_TU95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1158; TSPO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145383 CVCL_U695 XP4RO finite cell line human CVCL_U695 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000550020; Zygosity=Homozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1260; true Female 21145384 CVCL_U696 9L-2 cancer cell line Norway rat CVCL_U696 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3423; Carmustine (BCNU); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21145385 CVCL_TU96 HAP1 TSPO (-) 2 cancer cell line human CVCL_TU96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1158; TSPO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145386 CVCL_TU99 HAP1 TSSK2 (-) cancer cell line human CVCL_TU99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11401; TSSK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145387 CVCL_U699 Hu 126 finite cell line human CVCL_U699 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1246; true Female 21145388 CVCL_2053 H25B10 hybridoma house mouse CVCL_2053 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8017; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8017A 21145389 CVCL_2050 GOS-3 cancer cell line human CVCL_2050 HLA typing: A*02:01,03:01; B*07:02,47:01; C*06:02,07:02 (PubMed=26589293); Genome ancestry: African=1.06%; Native American=0%; East Asian, North=2.96%; East Asian, South=0%; South Asian=0%; European, North=75.07%; European, South=20.9% (PubMed=30894373) CL:0000010 Derived from sampling site: Brain; temporal lobe. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 hours (PubMed=9760066); ~50 hours (DSMZ=ACC-408) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00449 Problematic cell line: Contaminated Shown to be a U-343MGa derivative (PubMed=22570425). Originally thought to originate from the brain of a 55 year old patient with a mixed astro-oligodendroglioma (grade II/III). 21145390 CVCL_2051 GUMBUS cancer cell line human CVCL_2051 HLA typing: A*02:01,23:01; B*07:02,44:03; C*04:01,07:02; DQA1*01:01,02:01; DQB1*02:01,05:03; DRB1*14:01,07:01 (PubMed=25960936) CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Virology: EBV-negative Doubling time: ~48 hours (DSMZ=ACC-630) 21145391 CVCL_2045 FLO-1 cancer cell line human CVCL_2045 Genome ancestry: African=0.63%; Native American=0.21%; East Asian, North=0%; East Asian, South=0.68%; South Asian=0.12%; European, North=71.2%; European, South=27.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: ~40-50 hours (DSMZ=ACC-698); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145392 CVCL_2046 FM3 cancer cell line human CVCL_2046 HLA typing: A*02,03; B*07,44 (PubMed=7656272); HLA typing: A*02:01; B*07:02,44:02; C*05:01; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*04:01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012; PubMed=23851445) Derived from metastatic site: Right inguinal lymph node. Omics: Array-based CGH Female 21145393 CVCL_2043 FL-64 cancer cell line Norway rat CVCL_2043 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~60-100 hours (DSMZ=ACC-616) 21145394 CVCL_2044 FLK-BLV-044 transformed cell line CVCL_2044 CL:0000010 Transformant: Bovine leukemia virus (BLV) (isolate American FLK)(NCBI-Taxonomy; 11902); Derived from sampling site: Fetal kidney. Unspecified Doubling time: ~50 hours (DSMZ=ACC-153) 21145395 CVCL_2049 GM07373 transformed cell line CVCL_2049 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.. Male Characteristics: Grows in multilayers Doubling time: ~30-60 hours (DSMZ=ACC-109) 21145396 CVCL_2047 FU-OV-1 cancer cell line human CVCL_2047 HLA typing: A*24:02,24:02; B*51:01,52:01; C*12:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.66%; East Asian, North=78.56%; East Asian, South=18.72%; South Asian=0%; European, North=0%; European, South=2.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asp (c.535C>G); ClinVar=VCV000376610; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 25 hours (in serum-free medium), 21 hours (in FBS-supplemented medium) (PubMed=10337661); 71 hours (PubMed=25984343); ~120 hours (DSMZ=ACC-444); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145397 CVCL_2048 g/G spontaneously immortalized cell line house mouse CVCL_2048 CL:0000010 Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.; Breed/subspecies: C3H/E1. Female Doubling time: ~35-50 hours (DSMZ=ACC-224) 21145398 CVCL_TU86 HAP1 TROVE2 (-) 4 cancer cell line human CVCL_TU86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11313; RO60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145399 CVCL_U686 Se Red finite cell line human CVCL_U686 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1184; true Female 21145400 CVCL_U687 Dor Son finite cell line human CVCL_U687 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1126; true Male 21145401 CVCL_TU87 HAP1 TRPM7 (-) cancer cell line human CVCL_TU87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17994; TRPM7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145402 CVCL_TU84 HAP1 TROVE2 (-) 2 cancer cell line human CVCL_TU84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11313; RO60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145403 CVCL_U684 Pa Mer finite cell line human CVCL_U684 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1169; true Male 21145404 CVCL_U685 Be Cal finite cell line human CVCL_U685 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1171; true Female 21145405 CVCL_TU85 HAP1 TROVE2 (-) 3 cancer cell line human CVCL_TU85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11313; RO60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145406 CVCL_U688 El San finite cell line human CVCL_U688 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1222; true Male 21145407 CVCL_TU88 HAP1 TRPV6 (-) 1 cancer cell line human CVCL_TU88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14006; TRPV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145408 CVCL_TU89 HAP1 TSC1 (-) 1 cancer cell line human CVCL_TU89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12362; TSC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145409 CVCL_U689 XPKFSF finite cell line human CVCL_U689 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1206; true Female 21145410 CVCL_2060 HCC44 cancer cell line human CVCL_2060 HLA typing: A*24:02,24:02; B*35:03,35:03; C*04:01,04:01; DRB1*03:17,12:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=2.25%; East Asian, South=0%; South Asian=0%; European, North=61.76%; European, South=35.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>A (c.228C>A) (C228A); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser94Ter (c.281C>G); Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Leu (c.524G>T); ClinVar=VCV000182963; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29 hours (PubMed=25984343); 36.8 hours (PubMed=29681454); ~30 hours (DSMZ=ACC-534); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145411 CVCL_2063 HCC827 cancer cell line human CVCL_2063 HLA typing: A*11:01,11:01; B*51:01,52:01; C*12:02,12:02; DRB1*09:07,15:02 (PubMed=25960936); HLA typing: A*11:01,11:01; B*35:01,52:01; C*12:02,12:02; DQA1*03:02,05:01; DQB1*06:01,06:01; DRB1*01:01,15:01 (PubMed=26589293); Genome ancestry: African=1.62%; Native American=0.39%; East Asian, North=3.47%; East Asian, South=0%; South Asian=7.09%; European, North=19.48%; European, South=67.96% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Karyotypic information: Flat-moded hypotriploid karyotype with 6% polyploidy (DSMZ); Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 71 hours (PubMed=25984343); 44.5 hours (PubMed=29681454); 28 hours (ATCC=CRL-2868); ~50-60 hours (DSMZ=ACC-566); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145412 CVCL_2064 HCEC-12 transformed cell line human CVCL_2064 CL:0000010 Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; endothelium. Female Doubling time: ~40-50 hours (DSMZ=ACC-646) 21145413 CVCL_2061 HCC78 cancer cell line human CVCL_2061 HLA typing: A*02:05,02:05; B*13:02,15:03; C*06:02,12:03; DQA1*01:02;03:02; DQB1*06:02;06:02; DRB1*13:26;15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.1%; East Asian, North=0%; East Asian, South=0.13%; South Asian=2.41%; European, North=67.1%; European, South=30.25% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 10261; ROS1 + HGNC; 11020; SLC34A2; Name(s)=SLC34A2-ROS1 (PubMed=18083107; PubMed=25485619); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 38.7 hours (PubMed=29681454); ~60-70 hours (DSMZ=ACC-563); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145414 CVCL_2062 HCC202 cancer cell line human CVCL_2062 HLA typing: A*23:05,68:01; B*27:34,51:12; C*02:02,15:02; DQA1*05:02,01:02; DQB1*03:09,06:02; DRB1*11:01,03:17 (PubMed=25960936); HLA typing: A*32:01,32:01; B*27:07,27:07; C*15:02,15:02; DQA1*05:02,03:02; DQB1*03:04,03:04; DRB1*04:05,04:05 (PubMed=26589293); Genome ancestry: African=2.66%; Native American=0%; East Asian, North=3.54%; East Asian, South=0%; South Asian=0%; European, North=58.19%; European, South=35.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr284Argfs*21 (c.851_852delCA) (p.R283fs, c.849_850del2); Zygosity=Heterozygous (Cosmic-CLP; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Population: Caucasian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 212.49 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21145415 CVCL_2056 HCA2 cancer cell line human CVCL_2056 CL:0000010 Derived from sampling site: Colon; sigmoid. Discontinued: Ximbio; 152461; probable Female 21145416 CVCL_2057 HCC15 cancer cell line human CVCL_2057 HLA typing: A*30:02,30:02; B*15:17,15:17; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=76.99%; Native American=0%; East Asian, North=7.3%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=15.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Asnfs*3 (c.4408dupA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys652Ter (c.1954A>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Val (c.776A>T); ClinVar=VCV000485034; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Population: African American; Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 29.1 hours (PubMed=29681454); ~30-40 hours (DSMZ=ACC-496); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145417 CVCL_2054 HaP-T1 cancer cell line CVCL_2054 CL:0000010 Transformant: N,N-bis(2-hydroxypropyl)nitrosamine (Diisopropanolnitrosamine(ChEBI; CHEBI:131518); Derived from sampling site: Pancreas; Breed/subspecies: Inbred GN. Female Doubling time: 16.9 hours (PubMed=2838375); ~25-30 hours (DSMZ=ACC-222) 21145418 CVCL_2055 HB-894 cancer cell line Norway rat CVCL_2055 CL:0000010 Breed/subspecies: Wistar-AF/Han. Doubling time: ~3 days (DSMZ=ACC-631) 21145419 CVCL_2058 HCC33 cancer cell line human CVCL_2058 HLA typing: A*03:01,24:02; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=2.5%; Native American=0%; East Asian, North=2.1%; East Asian, South=0%; South Asian=0.21%; European, North=61.5%; European, South=33.69% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 32308; C1QTNF12 + HGNC; 10025; RLF; Name(s)=RLF-C1QTNF12, RLF-FAM132A (PubMed=23716474); Sequence variation: Gene fusion; HGNC; 10025; RLF + HGNC; 19268; UBE2J2; Name(s)=RLF-UBE2J2 (PubMed=23716474); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser402fs*8 (c.1202delT) (p.I401fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~40 hours (DSMZ=ACC-487); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145420 CVCL_2059 HCC366 cancer cell line human CVCL_2059 HLA typing: A*11:01,11:01; B*55:01,55:01; C*03:03,03:03; DQA1*03:02,03:02; DQB1*06:08,06:08; DRB1*03:02,13:01 (PubMed=26589293); Genome ancestry: African=1.18%; Native American=0.77%; East Asian, North=2.6%; East Asian, South=0%; South Asian=0%; European, North=62.65%; European, South=32.8% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro534Ala (c.1600C>G); Zygosity=Heterozygous (PubMed=27602502; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=20557307; Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~60-70 hours (DSMZ=ACC-492); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project Caution: KCLB seems to have two entries for HCC-366 one correctly indicated as such and the other as HCC-966 but with a STR profile identical to that of HCC-366 Furthermore there is no trace of a HCC-966 cell line in Gazdar's publications. 21145421 CVCL_TU90 HAP1 TSC1 (-) 2 cancer cell line human CVCL_TU90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12362; TSC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145422 CVCL_U690 XP11BE finite cell line human CVCL_U690 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe270Ter (c.807_808delTT); Zygosity=Heterozygous (from autologous cell line XP11BE LCL); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (from autologous cell line XP11BE LCL) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1199; probable Female 21145423 CVCL_TU93 HAP1 TSPAN13 (-) 1 cancer cell line human CVCL_TU93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21643; TSPAN13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145424 CVCL_U693 On Ser finite cell line human CVCL_U693 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1112; true Male 21145425 CVCL_U694 GM03509 finite cell line human CVCL_U694 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser595Ter (c.1784C>A); ClinVar=VCV000820081; Zygosity=Homozygous (from autologous cell line GM16375) Population: Caucasian; French Canadian; Donor information: From Bloom Syndrome Registry patient 81(MaGrou) (BSR81); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03509; probable Male 21145426 CVCL_TU94 HAP1 TSPAN13 (-) 2 cancer cell line human CVCL_TU94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21643; TSPAN13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145427 CVCL_U691 Eu Ken finite cell line human CVCL_U691 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1108; true Female 21145428 CVCL_TU91 HAP1 TSC2 (-) 1 cancer cell line human CVCL_TU91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12363; TSC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145429 CVCL_TU92 HAP1 TSC2 (-) 2 cancer cell line human CVCL_TU92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12363; TSC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145430 CVCL_U692 To Ser finite cell line human CVCL_U692 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1111; true Male 21145431 CVCL_TU75 HAP1 TRMT10B (-) 2 cancer cell line human CVCL_TU75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26454; TRMT10B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145432 CVCL_U675 Jo Cav finite cell line human CVCL_U675 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1387; true Male 21145433 CVCL_TU76 HAP1 TRMT2A (-) 1 cancer cell line human CVCL_TU76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145434 CVCL_U676 XP16BE finite cell line human CVCL_U676 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1307; true Male 21145435 CVCL_TU73 HAP1 TRMT10A (-) 4 cancer cell line human CVCL_TU73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28403; TRMT10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145436 CVCL_U673 XP15BE finite cell line human CVCL_U673 CL:0000010 Population: Pacific; Hawaiian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1279; true; Discontinued: BCRC; 60152; true Male Caution: From a male patient according to PubMed=4811796 and from a female patient according to ATCC CRL-1279 21145437 CVCL_TU74 HAP1 TRMT10B (-) 1 cancer cell line human CVCL_TU74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26454; TRMT10B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145438 CVCL_U674 XP1LO finite cell line human CVCL_U674 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1202; true Female 21145439 CVCL_U679 Eda Bel finite cell line human CVCL_U679 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1190; true Female 21145440 CVCL_TU79 HAP1 TRMT2A (-) 4 cancer cell line human CVCL_TU79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145441 CVCL_TU77 HAP1 TRMT2A (-) 2 cancer cell line human CVCL_TU77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145442 CVCL_U677 Me We finite cell line human CVCL_U677 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1194; true Female 21145443 CVCL_U678 Dor Bel finite cell line human CVCL_U678 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1188; true Female 21145444 CVCL_TU78 HAP1 TRMT2A (-) 3 cancer cell line human CVCL_TU78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145445 CVCL_2030 EJM cancer cell line human CVCL_2030 HLA typing: A*01:01,32:01; B*08:01,55:01; C*03:03,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.97%; East Asian, North=3.05%; East Asian, South=0%; South Asian=0%; European, North=63.97%; European, South=32.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=11157491); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>C); ClinVar=VCV000376624; Zygosity=Homozygous (PubMed=1373872; Cosmic-CLP; DepMap) Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda Doubling time: 40 hours (PubMed=25984343); ~50-60 hours (DSMZ=ACC-560); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145446 CVCL_2031 ELF-153 cancer cell line human CVCL_2031 HLA typing: A*01:01:01,02:01:01; B*08:01:01,35:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,02:01:01; DPB1*14:01:01,04:02:01; DQB1*03:01:01,03:01:01; DRA*01:01:01,01:01:01; DRB1*09:01:02,11:01:01 (DSMZCellDive=ACC-693) CL:0000010 Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: CSF2 dependent Doubling time: 36 hours (PubMed=7488550; PubMed=7519473); ~40-60 hours (DSMZ=ACC-693) Part of: LL-100 blood cancer cell line panel 21145447 CVCL_2023 DoGKiT cancer cell line human CVCL_2023 CL:0000010 Derived from sampling site: Peripheral blood. Male Virology: EBV-negative Doubling time: ~40-50 hours (DSMZ=ACC-629) 21145448 CVCL_2024 DOGUM cancer cell line human CVCL_2024 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, centroblastic-type Derived from sampling site: Pleural effusion. Female Virology: EBV-negative Doubling time: ~50 hours, ~100 hours (after recovery from liquid nitrogen freezing) (DSMZ=ACC-644) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145449 CVCL_2021 DND-39 cancer cell line human CVCL_2021 CL:0000010 Derived from sampling site: Pleural effusion. Male Virology: EBV-negative Doubling time: ~30-50 hours (DSMZ=ACC-648) 21145450 CVCL_2022 DND-41 cancer cell line human CVCL_2022 HLA typing: A*02:01:01,32:01:01; B*15:17:01,27:05:02; C*01:02:01,07:01:02 (DSMZCellDive=ACC-525); Genome ancestry: African=1.28%; Native American=0%; East Asian, North=1%; East Asian, South=0%; South Asian=4.99%; European, North=46.97%; European, South=45.76% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 13532; TLX3; Name(s)=TLX3-BCL11B, HOX11L2-BCL11B (PubMed=17308084; PubMed=31160637); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gln71Ter (c.211C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Ala279Thr (c.835G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593Pro (c.4778T>C); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp1609Val (c.4826A>T); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Val2443fs*35 (c.7327_7327G>TGT); Zygosity=Heterozygous (PubMed=15472075; PubMed=22675565); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8986; PIM1; Simple; p.Gln127Ter (c.379C>T); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Asp421Asn (c.1261G>A); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Ser1002Asn (c.3005G>A); ClinVar=VCV000241355; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg373Gly (c.1117A>G); Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=10071127; Cosmic-CLP) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H4K20me1 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~35 hours (DSMZ=ACC-525); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger); Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3; Part of: LL-100 blood cancer cell line panel 21145451 CVCL_2027 EB1 cancer cell line human CVCL_2027 HLA typing: A*29:02,31:04; B*47:03,57:03; C*07:01,07:01 (PubMed=26589293); HLA typing: A*29:02:01,31:04:01; B*47:03:01,57:03:01; C*07:01:02,07:18:01; DPB1*13:01:01G,30:01:01; DQA1*01:02:01,05:05:01; DQB1*03:01,06:04:01; DRB1*11:02:01,13:02:01 (CLS=300403); Genome ancestry: African=94.08%; Native American=0%; East Asian, North=1.53%; East Asian, South=0%; South Asian=1.12%; European, North=0%; European, South=3.27% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (DepMap) Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30-40 hours (DSMZ=ACC-80); ~2 days (CLS) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21145452 CVCL_2028 EBL spontaneously immortalized cell line CVCL_2028 CL:0000010 Derived from sampling site: Fetal lung. Unspecified Doubling time: ~70 hours (DSMZ=ACC-192) 21145453 CVCL_2025 DuCaP cancer cell line human CVCL_2025 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=14518029) Population: Caucasian; Derived from metastatic site: Brain; meningeal dura mater. Male Characteristics: Established from a xenograft produced by implantation of tumor cells in a SCID mouse Doubling time: 72-216 hours (PubMed=11317521) 21145454 CVCL_2029 ECV-304 cancer cell line human CVCL_2029 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0002000000074, 3142C0001000000023) They were one of the sources for the STR profile of this entry. Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Deep tyrosine phosphoproteome analysis Discontinued: ATCC; CRL-1998; true; Discontinued: BCRJ; 0283; probable; Discontinued: DSMZ; ACC-310; true; Discontinued: JCRB; NIHS0220; true Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 35 hours (PubMed=1817644); ~2 days (DSMZ=ACC-310) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00117 Problematic cell line: Contaminated Shown to be a T24 derivative (DOI=10.11418/jtca1981.18.4_329; PubMed=10508494; PubMed=10614862; PubMed=12197766; PubMed=20143388). Originally thought to originate from endothelial cells obtained from the umbilical vein of a healthy donor. 21145455 CVCL_TU82 HAP1 TRMT2B (-) 3 cancer cell line human CVCL_TU82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25748; TRMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145456 CVCL_U682 Se Mar finite cell line human CVCL_U682 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1134; true Female 21145457 CVCL_TU83 HAP1 TROVE2 (-) 1 cancer cell line human CVCL_TU83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11313; RO60; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145458 CVCL_TU80 HAP1 TRMT2B (-) 1 cancer cell line human CVCL_TU80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25748; TRMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145459 CVCL_U680 Par Bel finite cell line human CVCL_U680 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1191; true Male 21145460 CVCL_TU81 HAP1 TRMT2B (-) 2 cancer cell line human CVCL_TU81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25748; TRMT2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145461 CVCL_U681 Vin Dor finite cell line human CVCL_U681 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1097; true Male 21145462 CVCL_U664 XPHF1WI finite cell line human CVCL_U664 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145463 CVCL_TU64 HAP1 TRIP13 (-) 1 cancer cell line human CVCL_TU64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12307; TRIP13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145464 CVCL_U665 XPHF1WI LCL transformed cell line human CVCL_U665 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145465 CVCL_TU65 HAP1 TRIP4 (-) 1 cancer cell line human CVCL_TU65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12310; TRIP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145466 CVCL_U662 601 cancer cell line human CVCL_U662 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 21145467 CVCL_TU62 HAP1 TRIM9 (-) 2 cancer cell line human CVCL_TU62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16288; TRIM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145468 CVCL_U663 DA-3 [Mouse hybridoma against domoic acid] hybridoma house mouse CVCL_U663 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:34727; Domoic acid. 21145469 CVCL_TU63 HAP1 TRIO (-) cancer cell line human CVCL_TU63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12303; TRIO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145470 CVCL_TU68 HAP1 TRMT1 (-) 2 cancer cell line human CVCL_TU68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25980; TRMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145471 CVCL_U668 XP4BE finite cell line human CVCL_U668 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Phe18Serfs*12 (c.52_55delTTTG) (del 289-292); ClinVar=VCV000005885; Zygosity=Unspecified (PubMed=10385124) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1162; true Male 21145472 CVCL_TU69 HAP1 TRMT1 (-) 3 cancer cell line human CVCL_TU69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25980; TRMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145473 CVCL_U669 XP7BE finite cell line human CVCL_U669 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1200; probable; Discontinued: Coriell; GM02590; probable Female Senescence: Senesces at 26 PDL (PubMed=6492896) 21145474 CVCL_U666 XP10BE finite cell line human CVCL_U666 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1204; true Female 21145475 CVCL_TU66 HAP1 TRIT1 (-) cancer cell line human CVCL_TU66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20286; TRIT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145476 CVCL_U667 An Bay finite cell line human CVCL_U667 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1256; true Female 21145477 CVCL_TU67 HAP1 TRMT1 (-) 1 cancer cell line human CVCL_TU67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25980; TRMT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145478 CVCL_2041 FKH-1 cancer cell line human CVCL_2041 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 3495; ETV6; Name(s)=ETV6-ABL1; Note=In frame (PubMed=28751768); Sequence variation: Gene fusion; HGNC; 2768; DEK + HGNC; 8064; NUP214; Name(s)=DEK-NUP214; DEK-CAN (PubMed=9753053) Population: Japanese; Karyotypic information: 46,XY,t(6;9)(p23;q34) (PubMed=9753053); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB1428; probable Male Doubling time: ~54 hours (PubMed=9753053); ~60-100 hours (DSMZ=ACC-614); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21145479 CVCL_2042 FL-106 cancer cell line Norway rat CVCL_2042 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~2-3 days (DSMZ=ACC-620) 21145480 CVCL_2040 FDCP-Mix cl.A4 factor-dependent cell line house mouse CVCL_2040 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6 x DBA/2. Characteristics: IL3 dependent Doubling time: ~70-80 hours (DSMZ=ACC-401) 21145481 CVCL_2034 EN cancer cell line human CVCL_2034 HLA typing: A*24:02,26:01; B*35:01,54:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0.78%; Native American=0%; East Asian, North=80.75%; East Asian, South=16.89%; South Asian=0%; European, North=0.4%; European, South=1.18% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu186Valfs (c.556C>CG); Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Leu264Pro (c.791T>C); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Glnfs (c.817_818insA); Zygosity=Unspecified (PubMed=12581894) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24.4 hours (PubMed=12581894); ~50-80 hours (DSMZ=ACC-564); Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21145482 CVCL_2035 ESO-26 cancer cell line human CVCL_2035 Genome ancestry: African=3.22%; Native American=0%; East Asian, North=0%; East Asian, South=2.45%; South Asian=0.14%; European, North=50.67%; European, South=43.52% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=20075370) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: ~35-50 hours (DSMZ=ACC-708); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145483 CVCL_2032 ELM-I-1 cancer cell line house mouse CVCL_2032 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H/HeNSlc. Female Doubling time: ~20-40 hours (DSMZ=ACC-44) 21145484 CVCL_2033 EM-3 cancer cell line human CVCL_2033 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=15843827) Population: Caucasian; Derived from sampling site: Bone marrow. Female Doubling time: 2 days (CelloPub=CLPUB00038); ~40 hours (DSMZ=ACC-134) 21145485 CVCL_2038 F1-652 hybridoma house mouse CVCL_2038 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11055; Human MYH3. Doubling time: ~30-36 hours (DSMZ=ACC-309) 21145486 CVCL_2039 FDC-P1 factor-dependent cell line house mouse CVCL_2039 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. Characteristics: IL3 dependent Doubling time: ~30-40 hours (DSMZ=ACC-368) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12103 Caution: According to PubMed=6968334 originate from DBA/2 mice but in the original deposit document for DSMZ ACC-268 it is said to originate from C57BL/6 x DBA/2 (B6D2F1) (personal communication of MacLeod R.A.F.) 21145487 CVCL_2036 ESO-51 cancer cell line human CVCL_2036 Genome ancestry: African=3.22%; Native American=0.59%; East Asian, North=0%; East Asian, South=1.07%; South Asian=1.19%; European, North=50.02%; European, South=43.9% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=20075370) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21145488 CVCL_2037 F-36P cancer cell line human CVCL_2037 HLA typing: A*24:02,33:03; B*40:06,58:01; C*03:02,08:01 (PubMed=26589293); HLA typing: A*24:02:01,33:03:01; B*40:06:01,58:01:01; C*03:02:02,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*01:02:01,01:02:01; DQB1*04:02:01,06:09:01; DRA*01:02:02,01:02:02; DRB1*08:02:01,13:02:01 (DSMZCellDive=ACC-543); Genome ancestry: African=1.61%; Native American=0%; East Asian, North=78.68%; East Asian, South=18.21%; South Asian=0%; European, North=0%; European, South=1.5% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7132; KMT2A; Simple; p.Glu766Gln (c.2296G>C); Zygosity=Heterozygous (PubMed=27750403; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27750403; DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: CSF2 or IL3 dependent Doubling time: 55 hours (PubMed=25984343); ~24-36 hours (DSMZ=ACC-543) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21145489 CVCL_TU71 HAP1 TRMT10A (-) 2 cancer cell line human CVCL_TU71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28403; TRMT10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145490 CVCL_U671 XP14BE finite cell line human CVCL_U671 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS6-13_-21del9; Zygosity=Homozygous (CelloPub=CLPUB00565) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1311; true Male 21145491 CVCL_U672 Da Kam finite cell line human CVCL_U672 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1278; true Male 21145492 CVCL_TU72 HAP1 TRMT10A (-) 3 cancer cell line human CVCL_TU72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28403; TRMT10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145493 CVCL_TU70 HAP1 TRMT10A (-) 1 cancer cell line human CVCL_TU70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28403; TRMT10A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145494 CVCL_U670 XP13BE finite cell line human CVCL_U670 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1258; true Male 21145495 CVCL_U653 D2SC/1 transformed cell line house mouse CVCL_U653 CL:0000010 Transfected with: UniProtKB; P0C0N9; Avian retrovirus MH2 v-Myc Transformant: v-Myc; Derived from sampling site: Spleen Cell type=Dendritic cell.; Breed/subspecies: BALB/c. Group: Patented cell line 21145496 CVCL_TU53 HAP1 TRIM69 (-) 1 cancer cell line human CVCL_TU53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17857; TRIM69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145497 CVCL_U654 D2SC/1-CTLA4-Ig transformed cell line house mouse CVCL_U654 CL:0000010 Transfected with: MGI; MGI:88556; Ctla4; Transfected with: UniProtKB; P0C0N9; Avian retrovirus MH2 v-Myc Transformant: v-Myc; Derived from sampling site: Spleen Cell type=Dendritic cell.; Breed/subspecies: BALB/c. 21145498 CVCL_TU54 HAP1 TRIM69 (-) 2 cancer cell line human CVCL_TU54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17857; TRIM69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145499 CVCL_TU51 HAP1 TRIM68 (-) 1 cancer cell line human CVCL_TU51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21161; TRIM68; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145500 CVCL_U651 L12.9-2(1) transformed cell line human CVCL_U651 CL:0000010 Transformant: Unknown; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21145501 CVCL_U652 CB1 transformed cell line house mouse CVCL_U652 CL:0000010 Transfected with: UniProtKB; P0C0N9; Avian retrovirus MH2 v-Myc Transformant: v-Myc; Derived from sampling site: Spleen Cell type=Dendritic cell.; Breed/subspecies: DBA/2. Unspecified Group: Patented cell line 21145502 CVCL_TU52 HAP1 TRIM68 (-) 2 cancer cell line human CVCL_TU52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21161; TRIM68; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145503 CVCL_TU57 HAP1 TRIM72 (-) 1 cancer cell line human CVCL_TU57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32671; TRIM72; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145504 CVCL_U657 KE2a cancer cell line human CVCL_U657 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21145505 CVCL_U658 211A transformed cell line human CVCL_U658 CL:0000010 Transfected with: UniProtKB; P11818; Adenovirus 5 fiber protein Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Adenovirus packaging cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12194 21145506 CVCL_TU58 HAP1 TRIM72 (-) 2 cancer cell line human CVCL_TU58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32671; TRIM72; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145507 CVCL_TU55 HAP1 TRIM71 (-) 1 cancer cell line human CVCL_TU55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32669; TRIM71; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145508 CVCL_U655 Mf4/4 transformed cell line house mouse CVCL_U655 CL:0000010 Transformant: Recombinant retrovirus 3RV/VN-11; Derived from sampling site: Spleen Cell type=Macrophage.. Female 21145509 CVCL_U656 AE1-2a cancer cell line human CVCL_U656 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 21145510 CVCL_TU56 HAP1 TRIM71 (-) 2 cancer cell line human CVCL_TU56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32669; TRIM71; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145511 CVCL_U659 211B transformed cell line human CVCL_U659 CL:0000010 Transfected with: UniProtKB; P11818; Adenovirus 5 fiber protein Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Adenovirus packaging cell line 21145512 CVCL_TU59 HAP1 TRIM8 (-) 1 cancer cell line human CVCL_TU59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15579; TRIM8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145513 CVCL_2001 COLO 839 transformed cell line human CVCL_2001 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145514 CVCL_2002 COLO 849 cancer cell line human CVCL_2002 HLA typing: A*01:01,03:01; B*08:01,40:02; C*03:04,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.07%; East Asian, North=2.02%; East Asian, South=0%; South Asian=0%; European, North=73.1%; European, South=24.82% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-60 hours (DSMZ=ACC-216) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145515 CVCL_2000 COLO 832 cancer cell line human CVCL_2000 CL:0000010 Population: Caucasian Discontinued: ECACC; 93051124; probable. Male 21145516 CVCL_2005 COLO 858 cancer cell line human CVCL_2005 CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Omics: SNP array analysis Male 21145517 CVCL_2006 COR-L23/5010 cancer cell line human CVCL_2006 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male 21145518 CVCL_2003 COLO 853 cancer cell line human CVCL_2003 HLA typing: A*01:01,01:01; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21145519 CVCL_2004 COLO 857 cancer cell line human CVCL_2004 HLA typing: A*01:01,01:01; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21145520 CVCL_2009 COR-L23/R23- cancer cell line human CVCL_2009 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male 21145521 CVCL_2007 COR-L23/CPR cancer cell line human CVCL_2007 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Male 21145522 CVCL_2008 COR-L23/R cancer cell line human CVCL_2008 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male Doubling time: ~35-40 hours (DSMZ=ACC-883) 21145523 CVCL_U660 211R transformed cell line human CVCL_U660 CL:0000010 Transfected with: UniProtKB; P11818; Adenovirus 5 fiber protein Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Adenovirus packaging cell line 21145524 CVCL_TU60 HAP1 TRIM8 (-) 3 cancer cell line human CVCL_TU60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15579; TRIM8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145525 CVCL_TU61 HAP1 TRIM9 (-) 1 cancer cell line human CVCL_TU61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16288; TRIM9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145526 CVCL_U661 L23immo transformed cell line human CVCL_U661 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21145527 CVCL_U642 Anti-PT-S1-1B7 hybridoma house mouse CVCL_U642 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04977; Bordetella pertussis ptxA. 21145528 CVCL_TU42 HAP1 TRIM6 (-) 1 cancer cell line human CVCL_TU42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16277; TRIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145529 CVCL_U643 Anti-PT-S1-3F10 hybridoma house mouse CVCL_U643 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04977; Bordetella pertussis ptxA. 21145530 CVCL_TU43 HAP1 TRIM6 (-) 2 cancer cell line human CVCL_TU43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16277; TRIM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145531 CVCL_U640 Anti-FHA(2)2E9 hybridoma house mouse CVCL_U640 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12255; Bordetella pertussis filamentous hemagglutinin (fhaB). 21145532 CVCL_TU40 HAP1 TRIM58 (-) 2 cancer cell line human CVCL_TU40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24150; TRIM58; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145533 CVCL_U641 Anti-PT-S1-10D6 hybridoma house mouse CVCL_U641 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04977; Bordetella pertussis ptxA. 21145534 CVCL_TU41 HAP1 TRIM59 (-) cancer cell line human CVCL_TU41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30834; TRIM59; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145535 CVCL_U646 Anti-PT-S2-3A12 hybridoma house mouse CVCL_U646 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04978; Bordetella pertussis ptxB. 21145536 CVCL_TU46 HAP1 TRIM65 (-) 1 cancer cell line human CVCL_TU46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27316; TRIM65; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145537 CVCL_U647 Anti-PT-S2-9G8 hybridoma house mouse CVCL_U647 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04978; Bordetella pertussis ptxB. 21145538 CVCL_TU47 HAP1 TRIM65 (-) 2 cancer cell line human CVCL_TU47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27316; TRIM65; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145539 CVCL_U644 Anti-PT-S1-4D10 hybridoma house mouse CVCL_U644 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04977; Bordetella pertussis ptxA. 21145540 CVCL_TU44 HAP1 TRIM62 (-) 1 cancer cell line human CVCL_TU44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25574; TRIM62; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145541 CVCL_U645 Anti-PT-S1-8G4 hybridoma house mouse CVCL_U645 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04977; Bordetella pertussis ptxA. 21145542 CVCL_TU45 HAP1 TRIM62 (-) 2 cancer cell line human CVCL_TU45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25574; TRIM62; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145543 CVCL_U648 Anti-PT-S23-11E6 hybridoma house mouse CVCL_U648 CL:0000010 Monoclonal antibody isotype: IgG1. 21145544 CVCL_TU48 HAP1 TRIM65 (-) 3 cancer cell line human CVCL_TU48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27316; TRIM65; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145545 CVCL_U649 Anti-PT-S3-7E10 hybridoma house mouse CVCL_U649 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04979; Bordetella pertussis ptxC. 21145546 CVCL_TU49 HAP1 TRIM66 (-) 1 cancer cell line human CVCL_TU49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29005; TRIM66; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145547 CVCL_2020 DMBM-2 spontaneously immortalized cell line house mouse CVCL_2020 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Doubling time: 16-20 hours (PubMed=9103234); ~50 hours (DSMZ=ACC-269) 21145548 CVCL_2012 D-11 spontaneously immortalized cell line CVCL_2012 CL:0000010 Derived from sampling site: Liver Cell type=Fibroblast.. Discontinued: DSMZ; ACC-77; true Unspecified Doubling time: ~80 hours or more (DSMZ=ACC-77) Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00582 Problematic cell line: Misidentified Originally thought to be of Oncorhynchus mykiss (trout) origin but found to be from Oncorhynchus tshawytscha (DSMZ site). 21145549 CVCL_2013 D-36 factor-dependent cell line house mouse CVCL_2013 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: DBA/2. Unspecified Characteristics: IL10 dependent Doubling time: ~25 hours (DSMZ=ACC-184) 21145550 CVCL_2010 COV434 cancer cell line human CVCL_2010 HLA typing: A*02:05,31:01; B*44:02,50:01; C*06:02,15:02 (PubMed=26589293); Genome ancestry: African=1.5%; Native American=0.68%; East Asian, North=0.76%; East Asian, South=0%; South Asian=0%; European, North=60.55%; European, South=36.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; c.3952-1G>C; ClinVar=VCV000635379; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=33328126; DepMap) Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Because it conserved a number of properties of normal human granulosa cells, it is used in the investigation of such cell type Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Misclassified Originally thought to be an ovarian granulosa cell tumor but seems to be a small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) (PubMed=33328126). 21145551 CVCL_2011 CX-1 cancer cell line human CVCL_2011 HLA typing: A*01:01,24:03; B*44:02,58:01; C*04:01,04:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=7651727; PubMed=16418264) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: ~24 hours (CLS); ~30 hours (DSMZ=ACC-129); Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: MD Anderson Cell Lines Project 21145552 CVCL_2016 DERL-2 cancer cell line human CVCL_2016 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 72 hours (PubMed=11587224); ~60 hours (DSMZ=ACC-531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145553 CVCL_2017 DERL-7 cancer cell line human CVCL_2017 HLA typing: A*02:01:01,26:01:01; B*38:01:01,51:01:01; C*02:02:02,12:03:01 (DSMZCellDive=ACC-524) CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=11587224); ~30 hours (DSMZ=ACC-524) Part of: LL-100 blood cancer cell line panel 21145554 CVCL_2014 D3 [Mouse hybridoma against chicken NCAM1] hybridoma house mouse CVCL_2014 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13590; Chicken NCAM1 (Note=Also reacts with human, mouse and other species). Doubling time: ~22 hours (DSMZ=ACC-428) 21145555 CVCL_2015 DA-1 cancer cell line house mouse CVCL_2015 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: BALB/c. Characteristics: CSF2 and IL3 dependent 21145556 CVCL_2018 DH82 cancer cell line dog CVCL_2018 CL:0000010 Sequence variation: Mutation; VGNC; 45168; PTPN11; Simple; p.Gly503Val (c.1508G>T); Zygosity=Homozygous (PubMed=31175136) Breed/subspecies: Golden Retriever. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Can be infected by Trypanosoma cruzi which can then replicate and differentiate inside the cell; Characteristics: Susceptible to infection by Ehrlichia ruminantium (PubMed=11585095; PubMed=12234001); Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: 26 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10389 21145557 CVCL_2019 DM-3 cancer cell line human CVCL_2019 HLA typing: A*02:14,02:14; B*13:02,50:01; C*06:02,06:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.58%; East Asian, South=0.68%; South Asian=2.16%; European, North=58.64%; European, South=37.94% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg496Leu (c.1487G>T); Zygosity=Homozygous (DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 54 hours (PubMed=23840376); ~50-60 hours (DSMZ=ACC-595) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: May be misclassified While still annotated as a pleural sarcomatoid mesothelioma cell line, a variety of omics methods are classifying this cell line as a fibroblast (DOI=10.1101/166199; DepMap). 21145558 CVCL_U650 Anti-PT-S4-7F2 hybridoma house mouse CVCL_U650 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A3R5; Bordetella pertussis ptxD. 21145559 CVCL_TU50 HAP1 TRIM66 (-) 2 cancer cell line human CVCL_TU50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29005; TRIM66; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145560 CVCL_CB08 ND01767 transformed cell line human CVCL_CB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145561 CVCL_CB09 ND01777 transformed cell line human CVCL_CB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145562 CVCL_CB06 ND01759 transformed cell line human CVCL_CB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145563 CVCL_CB07 ND01761 transformed cell line human CVCL_CB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145564 CVCL_CB00 ND01749 transformed cell line human CVCL_CB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145565 CVCL_CB01 ND01750 transformed cell line human CVCL_CB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145566 CVCL_CB04 ND01755 transformed cell line human CVCL_CB04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145567 CVCL_CB05 ND01758 transformed cell line human CVCL_CB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145568 CVCL_CB02 ND01752 transformed cell line human CVCL_CB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145569 CVCL_CB03 ND01753 transformed cell line human CVCL_CB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145570 CVCL_1N90 GM24581 induced pluripotent stem cell human CVCL_1N90 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM24581; probable Female 21145571 CVCL_1N93 GM25267 induced pluripotent stem cell human CVCL_1N93 CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Asn406Lys (c.1218C>A); ClinVar=VCV000067648; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Latino or Hispanic; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Female 21145572 CVCL_1N94 GM25305 induced pluripotent stem cell human CVCL_1N94 CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Ala422Thr (c.1264G>A); ClinVar=VCV000067174; Zygosity=Heterozygous (Coriell) Population: Chinese; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Female 21145573 CVCL_1N91 UCSD233i-SAD2-2 induced pluripotent stem cell human CVCL_1N91 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145574 CVCL_1N92 UCSD241i-APP2-3 induced pluripotent stem cell human CVCL_1N92 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145575 CVCL_1N97 ND41864 induced pluripotent stem cell human CVCL_1N97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41864; true Male 21145576 CVCL_1N98 ND42765 induced pluripotent stem cell human CVCL_1N98 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42765; true; Discontinued: NHCDR; ND42765; true Female 21145577 CVCL_1N95 ND42223 induced pluripotent stem cell human CVCL_1N95 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42223; true; Discontinued: NHCDR; ND42223; true Female 21145578 CVCL_1N96 ND42228 induced pluripotent stem cell human CVCL_1N96 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42228; true; Discontinued: NHCDR; ND42228; true Female 21145579 CVCL_1N88 GM06102 finite cell line human CVCL_1N88 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg1743Gln (c.5528G>A); ClinVar=VCV000049960; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145580 CVCL_1N89 GM25318 induced pluripotent stem cell human CVCL_1N89 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg1743Gln (c.5528G>A); ClinVar=VCV000049960; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145581 CVCL_1N99 ND43208 induced pluripotent stem cell human CVCL_1N99 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND43208; true; Discontinued: NHCDR; ND43208; true Female 21145582 CVCL_1N71 B1 [Mouse embryonal carcinoma] cancer cell line house mouse CVCL_1N71 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: CBA. 21145583 CVCL_1N72 6B [Mouse embryonal carcinoma] cancer cell line house mouse CVCL_1N72 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: CBA. 21145584 CVCL_1N70 H6 cancer cell line house mouse CVCL_1N70 CL:0000010 Breed/subspecies: CBA. 21145585 CVCL_1N75 SFAT-3 cancer cell line house mouse CVCL_1N75 CL:0000010 Breed/subspecies: DDD. Male 21145586 CVCL_1N76 TSFAT-3 cancer cell line house mouse CVCL_1N76 CL:0000010 Breed/subspecies: DDD. Male 21145587 CVCL_1N73 B1(NG)C39D cancer cell line house mouse CVCL_1N73 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: CBA. 21145588 CVCL_1N74 6B(NG)C25 cancer cell line house mouse CVCL_1N74 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: CBA. 21145589 CVCL_1N68 GM11025 transformed cell line human CVCL_1N68 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;4)(Xqter->Xp21::4q35->4qter;4pter->4q35::Xp21->Xpter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145590 CVCL_1N69 C3A clone 2.5B1 cancer cell line human CVCL_1N69 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12461 21145591 CVCL_1N66 GM09542 transformed cell line human CVCL_1N66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145592 CVCL_1N67 GM11024 transformed cell line human CVCL_1N67 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;2)(Xqter->Xp21.2::2q37->2qter;2pter->2q37::Xp21.2->Xpter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145593 CVCL_1N82 GM08206 finite cell line human CVCL_1N82 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY.arr(1-22)x2,(XY)x1 (Coriell); Derived from sampling site: Liver Cell type=Fibroblast.. Omics: CNV analysis Male 21145594 CVCL_1N83 GM13415 transformed cell line human CVCL_1N83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21145595 CVCL_1N80 CHO-GAT spontaneously immortalized cell line CVCL_1N80 CL:0000010 Derived from sampling site: Ovary. Female 21145596 CVCL_1N81 GM00359 finite cell line human CVCL_1N81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21145597 CVCL_1N86 CV-hIPS-B induced pluripotent stem cell human CVCL_1N86 CL:0000010 Anecdotal: Established from Craig Venter fibroblasts Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21145598 CVCL_1N87 GM06101 transformed cell line human CVCL_1N87 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg1743Gln (c.5528G>A); ClinVar=VCV000049960; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145599 CVCL_1N84 GM13416 transformed cell line human CVCL_1N84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145600 CVCL_1N85 GM13419 transformed cell line human CVCL_1N85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21145601 CVCL_1N79 SEWA-CL-3 cancer cell line house mouse CVCL_1N79 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21145602 CVCL_1N77 GM03501 finite cell line human CVCL_1N77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21145603 CVCL_1N78 GM03876 finite cell line human CVCL_1N78 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;20)(1qter->1p13::20q13.3->20qter;20pter->20q13.3::1p13->1pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21145604 CVCL_CB80 ND02421 transformed cell line human CVCL_CB80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145605 CVCL_CB81 ND02425 transformed cell line human CVCL_CB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145606 CVCL_CB84 ND02454 transformed cell line human CVCL_CB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145607 CVCL_CB85 ND02471 transformed cell line human CVCL_CB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145608 CVCL_CB82 ND02426 transformed cell line human CVCL_CB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145609 CVCL_CB83 ND02453 transformed cell line human CVCL_CB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145610 CVCL_CB77 ND02387 transformed cell line human CVCL_CB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145611 CVCL_CB78 ND02395 transformed cell line human CVCL_CB78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145612 CVCL_CB75 ND02359 transformed cell line human CVCL_CB75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145613 CVCL_CB76 ND02385 transformed cell line human CVCL_CB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145614 CVCL_CB79 ND02404 transformed cell line human CVCL_CB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145615 CVCL_CB91 ND02527 transformed cell line human CVCL_CB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145616 CVCL_CB92 ND02530 transformed cell line human CVCL_CB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145617 CVCL_CB90 ND02512 transformed cell line human CVCL_CB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145618 CVCL_CB95 ND02554 transformed cell line human CVCL_CB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145619 CVCL_CB96 ND02556 transformed cell line human CVCL_CB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145620 CVCL_CB93 ND02533 transformed cell line human CVCL_CB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145621 CVCL_CB94 ND02552 transformed cell line human CVCL_CB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145622 CVCL_CB88 ND02506 transformed cell line human CVCL_CB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145623 CVCL_CB89 ND02509 transformed cell line human CVCL_CB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145624 CVCL_CB86 ND02503 transformed cell line human CVCL_CB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145625 CVCL_CB87 ND02504 transformed cell line human CVCL_CB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145626 CVCL_CB62 ND02309 transformed cell line human CVCL_CB62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145627 CVCL_CB63 ND02310 transformed cell line human CVCL_CB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145628 CVCL_CB60 ND02297 transformed cell line human CVCL_CB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145629 CVCL_CB61 ND02298 transformed cell line human CVCL_CB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145630 CVCL_CB55 ND02254 transformed cell line human CVCL_CB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145631 CVCL_CB56 ND02263 transformed cell line human CVCL_CB56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145632 CVCL_CB53 ND02227 transformed cell line human CVCL_CB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145633 CVCL_CB54 ND02253 transformed cell line human CVCL_CB54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145634 CVCL_CB59 ND02295 transformed cell line human CVCL_CB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145635 CVCL_CB57 ND02266 transformed cell line human CVCL_CB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145636 CVCL_CB58 ND02272 transformed cell line human CVCL_CB58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145637 CVCL_CB70 ND02327 transformed cell line human CVCL_CB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145638 CVCL_CB73 ND02356 transformed cell line human CVCL_CB73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145639 CVCL_CB74 ND02357 transformed cell line human CVCL_CB74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145640 CVCL_CB71 ND02354 transformed cell line human CVCL_CB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145641 CVCL_CB72 ND02355 transformed cell line human CVCL_CB72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145642 CVCL_CB66 ND02318 transformed cell line human CVCL_CB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145643 CVCL_CB67 ND02320 transformed cell line human CVCL_CB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145644 CVCL_CB64 ND02311 transformed cell line human CVCL_CB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145645 CVCL_CB65 ND02312 transformed cell line human CVCL_CB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145646 CVCL_CB68 ND02322 transformed cell line human CVCL_CB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145647 CVCL_CB69 ND02326 transformed cell line human CVCL_CB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145648 CVCL_CB40 ND02077 transformed cell line human CVCL_CB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145649 CVCL_CB41 ND02120 transformed cell line human CVCL_CB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145650 CVCL_CB39 ND02020 transformed cell line human CVCL_CB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145651 CVCL_CB33 ND01943 transformed cell line human CVCL_CB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145652 CVCL_CB34 ND01979 transformed cell line human CVCL_CB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145653 CVCL_CB31 ND01939 transformed cell line human CVCL_CB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145654 CVCL_CB32 ND01941 transformed cell line human CVCL_CB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145655 CVCL_CB37 ND01985 transformed cell line human CVCL_CB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145656 CVCL_CB38 ND02019 transformed cell line human CVCL_CB38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145657 CVCL_CB35 ND01981 transformed cell line human CVCL_CB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145658 CVCL_CB36 ND01982 transformed cell line human CVCL_CB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145659 CVCL_CB51 ND02215 transformed cell line human CVCL_CB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145660 CVCL_CB52 ND02217 transformed cell line human CVCL_CB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145661 CVCL_CB50 ND02213 transformed cell line human CVCL_CB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145662 CVCL_CB44 ND02142 transformed cell line human CVCL_CB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145663 CVCL_CB45 ND02144 transformed cell line human CVCL_CB45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145664 CVCL_CB42 ND02121 transformed cell line human CVCL_CB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145665 CVCL_CB43 ND02140 transformed cell line human CVCL_CB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145666 CVCL_CB48 ND02205 transformed cell line human CVCL_CB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145667 CVCL_CB49 ND02210 transformed cell line human CVCL_CB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145668 CVCL_CB46 ND02145 transformed cell line human CVCL_CB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145669 CVCL_CB47 ND02146 transformed cell line human CVCL_CB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145670 CVCL_CB19 ND01790 transformed cell line human CVCL_CB19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145671 CVCL_CB17 ND01786 transformed cell line human CVCL_CB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145672 CVCL_CB18 ND01788 transformed cell line human CVCL_CB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145673 CVCL_CB11 ND01779 transformed cell line human CVCL_CB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145674 CVCL_CB12 ND01780 transformed cell line human CVCL_CB12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145675 CVCL_CB10 ND01778 transformed cell line human CVCL_CB10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145676 CVCL_CB15 ND01784 transformed cell line human CVCL_CB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145677 CVCL_CB16 ND01785 transformed cell line human CVCL_CB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145678 CVCL_CB13 ND01781 transformed cell line human CVCL_CB13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145679 CVCL_CB14 ND01783 transformed cell line human CVCL_CB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145680 CVCL_CB30 ND01937 transformed cell line human CVCL_CB30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145681 CVCL_CB28 ND01933 transformed cell line human CVCL_CB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145682 CVCL_CB29 ND01935 transformed cell line human CVCL_CB29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145683 CVCL_CB22 ND01878 transformed cell line human CVCL_CB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145684 CVCL_CB23 ND01881 transformed cell line human CVCL_CB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145685 CVCL_CB20 ND01799 transformed cell line human CVCL_CB20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145686 CVCL_CB21 ND01877 transformed cell line human CVCL_CB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145687 CVCL_CB26 ND01927 transformed cell line human CVCL_CB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145688 CVCL_CB27 ND01931 transformed cell line human CVCL_CB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145689 CVCL_CB24 ND01883 transformed cell line human CVCL_CB24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145690 CVCL_CB25 ND01886 transformed cell line human CVCL_CB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145691 CVCL_BZ21 ND00705 transformed cell line human CVCL_BZ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145692 CVCL_BZ22 ND00708 transformed cell line human CVCL_BZ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145693 CVCL_BZ20 ND00703 transformed cell line human CVCL_BZ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145694 CVCL_BZ25 ND00715 transformed cell line human CVCL_BZ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145695 CVCL_BZ26 ND00720 transformed cell line human CVCL_BZ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145696 CVCL_BZ23 ND00712 transformed cell line human CVCL_BZ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145697 CVCL_BZ24 ND00713 transformed cell line human CVCL_BZ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145698 CVCL_BZ18 ND00699 transformed cell line human CVCL_BZ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145699 CVCL_BZ19 ND00701 transformed cell line human CVCL_BZ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145700 CVCL_BZ16 ND00693 transformed cell line human CVCL_BZ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145701 CVCL_BZ17 ND00695 transformed cell line human CVCL_BZ17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145702 CVCL_BZ32 ND00740 transformed cell line human CVCL_BZ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145703 CVCL_BZ33 ND00744 transformed cell line human CVCL_BZ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145704 CVCL_BZ30 ND00734 transformed cell line human CVCL_BZ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145705 CVCL_BZ31 ND00737 transformed cell line human CVCL_BZ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145706 CVCL_BZ36 ND00793 transformed cell line human CVCL_BZ36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145707 CVCL_BZ37 ND00816 transformed cell line human CVCL_BZ37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145708 CVCL_BZ34 ND00746 transformed cell line human CVCL_BZ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145709 CVCL_BZ35 ND00792 transformed cell line human CVCL_BZ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145710 CVCL_BZ29 ND00732 transformed cell line human CVCL_BZ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145711 CVCL_BZ27 ND00724 transformed cell line human CVCL_BZ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145712 CVCL_BZ28 ND00726 transformed cell line human CVCL_BZ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145713 CVCL_BZ00 ND00637 transformed cell line human CVCL_BZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145714 CVCL_BZ03 ND00666 transformed cell line human CVCL_BZ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145715 CVCL_BZ04 ND00668 transformed cell line human CVCL_BZ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145716 CVCL_BZ01 ND00647 transformed cell line human CVCL_BZ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145717 CVCL_BZ02 ND00664 transformed cell line human CVCL_BZ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145718 CVCL_BZ10 ND00683 transformed cell line human CVCL_BZ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145719 CVCL_BZ11 ND00686 transformed cell line human CVCL_BZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145720 CVCL_BZ14 ND00690 transformed cell line human CVCL_BZ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145721 CVCL_BZ15 ND00691 transformed cell line human CVCL_BZ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145722 CVCL_BZ12 ND00687 transformed cell line human CVCL_BZ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145723 CVCL_BZ13 ND00688 transformed cell line human CVCL_BZ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145724 CVCL_BZ07 ND00675 transformed cell line human CVCL_BZ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145725 CVCL_BZ08 ND00678 transformed cell line human CVCL_BZ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145726 CVCL_BZ05 ND00671 transformed cell line human CVCL_BZ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145727 CVCL_BZ06 ND00673 transformed cell line human CVCL_BZ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145728 CVCL_BZ09 ND00680 transformed cell line human CVCL_BZ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145729 CVCL_1G92 IGK spontaneously immortalized cell line CVCL_1G92 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC017 21145730 CVCL_1G93 PC1CpTr spontaneously immortalized cell line CVCL_1G93 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC035 21145731 CVCL_1G90 HC2SPEx spontaneously immortalized cell line CVCL_1G90 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC038 21145732 CVCL_1G91 ICG spontaneously immortalized cell line CVCL_1G91 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC021 21145733 CVCL_1G96 PCE spontaneously immortalized cell line CVCL_1G96 CL:0000010 Derived from sampling site: Eye. Unspecified Group: Fish cell line 21145734 CVCL_1G97 PDF spontaneously immortalized cell line CVCL_1G97 CL:0000010 Miscellaneous: Cell line is no longer avaible (NRFC) Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC009 21145735 CVCL_1G94 PC1F1Ex spontaneously immortalized cell line CVCL_1G94 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC036 21145736 CVCL_1G95 PC1L1Tr spontaneously immortalized cell line CVCL_1G95 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC037 21145737 CVCL_1G98 PDH spontaneously immortalized cell line CVCL_1G98 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21145738 CVCL_1G99 RC4H1Tr spontaneously immortalized cell line CVCL_1G99 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Heart. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC027 21145739 CVCL_KT39 HeLa SilenciX BCL2 cancer cell line human CVCL_KT39 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 990; BCL2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145740 CVCL_L539 My 43.51 hybridoma house mouse CVCL_L539 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12128 21145741 CVCL_KT37 HeLa SilenciX BAP1 cancer cell line human CVCL_KT37 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 950; BAP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145742 CVCL_L537 Mc 39-16 hybridoma CVCL_L537 CL:0000010 Monoclonal antibody isotype: IgG2a. 21145743 CVCL_KT38 HeLa SilenciX BAX cancer cell line human CVCL_KT38 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 959; BAX Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145744 CVCL_L538 MCP21 hybridoma house mouse CVCL_L538 CL:0000010 Monoclonal antibody isotype: IgG1. 21145745 CVCL_KT35 HeLa SilenciX ATP6AP2 cancer cell line human CVCL_KT35 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 18305; ATP6AP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145746 CVCL_L535 MT4/E4 hybridoma house mouse CVCL_L535 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01562; Human IFNA1; Monoclonal antibody target: UniProtKB; P01563; Human IFNA2. 21145747 CVCL_KT36 HeLa SilenciX ATR cancer cell line human CVCL_KT36 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 882; ATR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145748 CVCL_L536 MARC S5 hybridoma house mouse CVCL_L536 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:64637; O-polysaccharide (Escherichia coli O-antigen O157:H7). 21145749 CVCL_L533 A1H4 hybridoma house mouse CVCL_L533 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F1PAA9; Dog CDH1. 21145750 CVCL_KT33 HeLa SilenciX Artemis cancer cell line human CVCL_KT33 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 17642; DCLRE1C Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145751 CVCL_KT34 HeLa SilenciX ATM cancer cell line human CVCL_KT34 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 795; ATM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145752 CVCL_L534 MT3/B4 hybridoma house mouse CVCL_L534 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01563; Human IFNA2. 21145753 CVCL_KT31 HeLa SilenciX APE1 cancer cell line human CVCL_KT31 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 587; APEX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145754 CVCL_L531 Ig(5b)6.3 hybridoma house mouse CVCL_L531 CL:0000010 Monoclonal antibody isotype: IgG1. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21145755 CVCL_L532 8A12 [Mouse hybridoma against guinea pig MBP1] hybridoma house mouse CVCL_L532 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22032; Cavia porcellus MBP1. 21145756 CVCL_KT32 HeLa SilenciX Argonaute 2 cancer cell line human CVCL_KT32 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3263; AGO2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145757 CVCL_KT30 HeLa SilenciX AKT1 cancer cell line human CVCL_KT30 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 391; AKT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145758 CVCL_L530 Ig(5a)7.2 hybridoma house mouse CVCL_L530 CL:0000010 Discontinued: ATCC; TIB-97; true. Monoclonal antibody isotype: IgG2a Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21145759 CVCL_KT48 HeLa SilenciX COX2 cancer cell line human CVCL_KT48 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9605; PTGS2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145760 CVCL_L548 UD-SCC-5 cancer cell line human CVCL_L548 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=18487078). Male 21145761 CVCL_L549 DA6.147 hybridoma house mouse CVCL_L549 CL:0000010 Monoclonal antibody isotype: IgG1. 21145762 CVCL_KT49 HeLa SilenciX CTNNB1 cancer cell line human CVCL_KT49 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 2514; CTNNB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145763 CVCL_KT46 HeLa SilenciX Caspase 9 cancer cell line human CVCL_KT46 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1511; CASP9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145764 CVCL_L546 MARC 29F8 hybridoma house mouse CVCL_L546 CL:0000010 Monoclonal antibody isotype: IgM. 21145765 CVCL_KT47 HeLa SilenciX CDK2 cancer cell line human CVCL_KT47 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1771; CDK2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145766 CVCL_L547 MAC 2-48 hybridoma house mouse CVCL_L547 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q86VB7; Human CD163. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10714 21145767 CVCL_KT44 HeLa SilenciX BTG2 cancer cell line human CVCL_KT44 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1131; BTG2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145768 CVCL_L544 MARC 2B7 hybridoma house mouse CVCL_L544 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9K2Y6; Escherichia coli O157:H7 flagellin (fliC). 21145769 CVCL_KT45 HeLa SilenciX Caspase 3 cancer cell line human CVCL_KT45 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1504; CASP3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145770 CVCL_L545 MARC 46E9-9 hybridoma house mouse CVCL_L545 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9K2Y6; Escherichia coli O157:H7 flagellin (fliC). 21145771 CVCL_KT42 HeLa SilenciX BRCA1 cancer cell line human CVCL_KT42 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1100; BRCA1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145772 CVCL_L542 M195 hybridoma house mouse CVCL_L542 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20138; Human CD33. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10306 21145773 CVCL_KT43 HeLa SilenciX BRCA2 cancer cell line human CVCL_KT43 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1101; BRCA2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145774 CVCL_L543 IMM002.69.47.4 hybridoma house mouse CVCL_L543 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-450 21145775 CVCL_KT40 HeLa SilenciX BID cancer cell line human CVCL_KT40 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1050; BID Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145776 CVCL_L540 LS132.1D9 hybridoma house mouse CVCL_L540 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P41597; Human CCR2/CD192. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12549 21145777 CVCL_KT41 HeLa SilenciX BLM cancer cell line human CVCL_KT41 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1058; BLM Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145778 CVCL_L541 LS132.8G2 hybridoma house mouse CVCL_L541 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P41597; Human CCR2/CD192. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12550 21145779 CVCL_BZ87 ND01137 transformed cell line human CVCL_BZ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145780 CVCL_BZ88 ND01171 transformed cell line human CVCL_BZ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145781 CVCL_BZ85 ND01134 transformed cell line human CVCL_BZ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145782 CVCL_BZ86 ND01135 transformed cell line human CVCL_BZ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145783 CVCL_BZ89 ND01173 transformed cell line human CVCL_BZ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21145784 CVCL_BZ80 ND01122 transformed cell line human CVCL_BZ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145785 CVCL_KT19 AICD58.10 hybridoma house mouse CVCL_KT19 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145786 CVCL_L519 H21F8-1 hybridoma house mouse CVCL_L519 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Hepatitis B virus HBsAG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8018 21145787 CVCL_KT17 AICD58.8 hybridoma house mouse CVCL_KT17 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145788 CVCL_L517 H18/7 hybridoma house mouse CVCL_L517 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11684 21145789 CVCL_BZ83 ND01132 transformed cell line human CVCL_BZ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145790 CVCL_KT18 AICD58.9 hybridoma house mouse CVCL_KT18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145791 CVCL_L518 H2.8 hybridoma house mouse CVCL_L518 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q05996; Human ZP2. 21145792 CVCL_BZ84 ND01133 transformed cell line human CVCL_BZ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145793 CVCL_KT15 AICD58.6 hybridoma house mouse CVCL_KT15 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145794 CVCL_L515 G26.4.1C3/86 hybridoma house mouse CVCL_L515 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human red blood cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9893 21145795 CVCL_BZ81 ND01129 transformed cell line human CVCL_BZ81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145796 CVCL_KT16 AICD58.7 hybridoma house mouse CVCL_KT16 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145797 CVCL_L516 G28-5 hybridoma house mouse CVCL_L516 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25942; Human CD40. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9110 21145798 CVCL_BZ82 ND01131 transformed cell line human CVCL_BZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145799 CVCL_KT13 AICD58.4 hybridoma house mouse CVCL_KT13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145800 CVCL_L513 F45J hybridoma house mouse CVCL_L513 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02671; Human FGA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9740 21145801 CVCL_KT14 AICD58.5 hybridoma house mouse CVCL_KT14 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145802 CVCL_L514 F5-A-1/22.8.13 hybridoma house mouse CVCL_L514 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8051 21145803 CVCL_KT11 AICD58.2 hybridoma house mouse CVCL_KT11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145804 CVCL_L511 RMZ-RC5 cancer cell line human CVCL_L511 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Male 21145805 CVCL_KT12 AICD58.3 hybridoma house mouse CVCL_KT12 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145806 CVCL_L512 F32 VIII C4 hybridoma house mouse CVCL_L512 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; F1S379; Pig REN1. 21145807 CVCL_KT10 AICD58.1 hybridoma house mouse CVCL_KT10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 90082401 21145808 CVCL_L510 RMZ-RC2 cancer cell line human CVCL_L510 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Male Doubling time: ~38 hours (PubMed=3801282) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21145809 CVCL_BZ98 ND01209 transformed cell line human CVCL_BZ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145810 CVCL_BZ99 ND01211 transformed cell line human CVCL_BZ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145811 CVCL_BZ96 ND01204 transformed cell line human CVCL_BZ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145812 CVCL_BZ97 ND01208 transformed cell line human CVCL_BZ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145813 CVCL_BZ90 ND01175 transformed cell line human CVCL_BZ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145814 CVCL_BZ91 ND01177 transformed cell line human CVCL_BZ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145815 CVCL_KT28 HeLa SilenciX ABL1 cancer cell line human CVCL_KT28 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 76; ABL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145816 CVCL_L528 Ig(1a)8.3 hybridoma house mouse CVCL_L528 CL:0000010 Monoclonal antibody isotype: IgG2a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21145817 CVCL_BZ94 ND01181 transformed cell line human CVCL_BZ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145818 CVCL_KT29 HeLa SilenciX ADAM17 cancer cell line human CVCL_KT29 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 195; ADAM17 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21145819 CVCL_L529 Ig(4a)10.9 hybridoma house mouse CVCL_L529 CL:0000010 Monoclonal antibody isotype: IgG2a. 21145820 CVCL_BZ95 ND01183 transformed cell line human CVCL_BZ95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145821 CVCL_KT26 HEK-Blue IFN-alpha/beta transformed cell line human CVCL_KT26 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 6131; IRF9; Transfected with: HGNC; 11363; STAT2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human type I IFNs by monitoring the activation of the ISGF3 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the ISG54 promoter 21145822 CVCL_L526 Hybridoma 234 s.2a hybridoma house mouse CVCL_L526 CL:0000010 Characteristics: Isotype switched derivative of 234; Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9403 21145823 CVCL_BZ92 ND01179 transformed cell line human CVCL_BZ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145824 CVCL_KT27 HeLa SilenciX Control cancer cell line human CVCL_KT27 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Control cell line for the SilenciX series of knockdown cell lines Transfected with a control shRNA. 21145825 CVCL_L527 I(TL.m9) hybridoma house mouse CVCL_L527 CL:0000010 Monoclonal antibody isotype: IgG2a. 21145826 CVCL_BZ93 ND01180 transformed cell line human CVCL_BZ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145827 CVCL_KT24 AICD58.15 hybridoma house mouse CVCL_KT24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145828 CVCL_L524 Hybridoma 231 hybridoma house mouse CVCL_L524 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9401 21145829 CVCL_KT25 AICD58.16 hybridoma house mouse CVCL_KT25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145830 CVCL_L525 Hybridoma 234 hybridoma house mouse CVCL_L525 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9402 21145831 CVCL_KT22 AICD58.13 hybridoma house mouse CVCL_KT22 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145832 CVCL_L522 hCD40L-M90 hybridoma house mouse CVCL_L522 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29965; Human CD40LG/CD154. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12055 21145833 CVCL_KT23 AICD58.14 hybridoma house mouse CVCL_KT23 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145834 CVCL_L523 hCD40L-M91 hybridoma house mouse CVCL_L523 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29965; Human CD40LG/CD154. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12056 21145835 CVCL_KT20 AICD58.11 hybridoma house mouse CVCL_KT20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145836 CVCL_L520 H3.1 hybridoma house mouse CVCL_L520 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P21754; Human ZP3. 21145837 CVCL_KT21 AICD58.12 hybridoma house mouse CVCL_KT21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21145838 CVCL_L521 H4/18 hybridoma house mouse CVCL_L521 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16581; Human SELE/CD62E. 21145839 CVCL_BZ65 ND01075 transformed cell line human CVCL_BZ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145840 CVCL_BZ66 ND01076 transformed cell line human CVCL_BZ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145841 CVCL_BZ63 ND01060 transformed cell line human CVCL_BZ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145842 CVCL_BZ64 ND01074 transformed cell line human CVCL_BZ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145843 CVCL_BZ69 ND01079 transformed cell line human CVCL_BZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145844 CVCL_BZ67 ND01077 transformed cell line human CVCL_BZ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145845 CVCL_BZ68 ND01078 transformed cell line human CVCL_BZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145846 CVCL_BZ61 ND01044 transformed cell line human CVCL_BZ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145847 CVCL_BZ62 ND01058 transformed cell line human CVCL_BZ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145848 CVCL_BZ60 ND01041 transformed cell line human CVCL_BZ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145849 CVCL_BZ76 ND01116 transformed cell line human CVCL_BZ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145850 CVCL_BZ77 ND01119 transformed cell line human CVCL_BZ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145851 CVCL_BZ74 ND01091 transformed cell line human CVCL_BZ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145852 CVCL_BZ75 ND01101 transformed cell line human CVCL_BZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145853 CVCL_BZ78 ND01120 transformed cell line human CVCL_BZ78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145854 CVCL_BZ79 ND01121 transformed cell line human CVCL_BZ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145855 CVCL_L508 COLO 845 cancer cell line human CVCL_L508 CL:0000010 Population: Caucasian; Derived from metastatic site: Lymph node. Male 21145856 CVCL_KT08 GM2B4 hybridoma house mouse CVCL_KT08 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51124; Human GZMM. 21145857 CVCL_L509 COLO 848 cancer cell line human CVCL_L509 CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Male 21145858 CVCL_KT09 GM6C3 hybridoma house mouse CVCL_KT09 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa (Santa Cruz); IgG1 (Aldevron); Monoclonal antibody target: UniProtKB; P49863; Human GZMK. 21145859 CVCL_L506 COLO 835 cancer cell line human CVCL_L506 CL:0000010 Population: Caucasian; Derived from metastatic site: Left axillary lymph node. Male 21145860 CVCL_KT06 GM24C3 hybridoma house mouse CVCL_KT06 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P49863; Human GZMK (Note=Also reacts with mouse). 21145861 CVCL_BZ72 ND01088 transformed cell line human CVCL_BZ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145862 CVCL_L507 COLO 838 cancer cell line human CVCL_L507 CL:0000010 Population: Caucasian; Derived from metastatic site: Right axillary lymph node. Male 21145863 CVCL_KT07 GM26E7 hybridoma house mouse CVCL_KT07 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P49863; Human GZMK. 21145864 CVCL_BZ73 ND01089 transformed cell line human CVCL_BZ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145865 CVCL_KT04 AP-5 hybridoma house mouse CVCL_KT04 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 21145866 CVCL_L504 COLO 833 cancer cell line human CVCL_L504 CL:0000010 Population: Caucasian; Derived from metastatic site: Skin. Male 21145867 CVCL_BZ70 ND01085 transformed cell line human CVCL_BZ70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145868 CVCL_L505 COLO 834 cancer cell line human CVCL_L505 CL:0000010 Population: Caucasian; Derived from metastatic site: Skin. Male 21145869 CVCL_KT05 GM1H11 hybridoma house mouse CVCL_KT05 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P12544; Human GZMA. 21145870 CVCL_BZ71 ND01086 transformed cell line human CVCL_BZ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145871 CVCL_KT02 1321N1/FFAR1 cancer cell line human CVCL_KT02 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4498; FFAR1 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21145872 CVCL_L502 NUGC-3/5-FU/L cancer cell line human CVCL_L502 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Brachialis muscle. Omics: Transcriptome analysis by microarray Male Part of: JFCR45 cancer cell line panel 21145873 CVCL_KT03 CHO-K1 (+Galpha16) AequoScreen CXCR2 spontaneously immortalized cell line CVCL_KT03 CL:0000010 Transfected with: HGNC; 6027; CXCR2; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21145874 CVCL_L503 COLO 831 cancer cell line human CVCL_L503 CL:0000010 Population: Caucasian; Derived from metastatic site: Umbilicus. Male 21145875 CVCL_KT00 CHO-AA8-Luc Tet-Off spontaneously immortalized cell line CVCL_KT00 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16; Characteristics: The firefly luciferase reporter gene is under the control of a tetracycline-responsive promoter 21145878 CVCL_KT01 HepG2 Tet-On Advanced cancer cell line human CVCL_KT01 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with an advanced reverse tetracycline-controlled transactivator (rtTA2(S)-M2), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21145879 CVCL_BZ43 ND00832 transformed cell line human CVCL_BZ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145880 CVCL_BZ44 ND00896 transformed cell line human CVCL_BZ44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145881 CVCL_BZ41 ND00825 transformed cell line human CVCL_BZ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145882 CVCL_BZ42 ND00831 transformed cell line human CVCL_BZ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145883 CVCL_BZ47 ND00930 transformed cell line human CVCL_BZ47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145884 CVCL_BZ48 ND00931 transformed cell line human CVCL_BZ48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145885 CVCL_BZ45 ND00927 transformed cell line human CVCL_BZ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145886 CVCL_BZ46 ND00929 transformed cell line human CVCL_BZ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145887 CVCL_BZ40 ND00824 transformed cell line human CVCL_BZ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145888 CVCL_BZ38 ND00818 transformed cell line human CVCL_BZ38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145889 CVCL_BZ39 ND00819 transformed cell line human CVCL_BZ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145890 CVCL_BZ54 ND00968 transformed cell line human CVCL_BZ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145891 CVCL_BZ55 ND00977 transformed cell line human CVCL_BZ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145892 CVCL_BZ52 ND00942 transformed cell line human CVCL_BZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145893 CVCL_BZ53 ND00944 transformed cell line human CVCL_BZ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145894 CVCL_BZ58 ND00986 transformed cell line human CVCL_BZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145895 CVCL_BZ59 ND01005 transformed cell line human CVCL_BZ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145896 CVCL_BZ56 ND00978 transformed cell line human CVCL_BZ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145897 CVCL_BZ57 ND00982 transformed cell line human CVCL_BZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145898 CVCL_BZ50 ND00939 transformed cell line human CVCL_BZ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145899 CVCL_BZ51 ND00941 transformed cell line human CVCL_BZ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145900 CVCL_BZ49 ND00937 transformed cell line human CVCL_BZ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145901 CVCL_TM39 HAP1 SLC25A37 (-) 2 cancer cell line human CVCL_TM39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29786; SLC25A37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145902 CVCL_TM37 HAP1 SLC25A36 (-) cancer cell line human CVCL_TM37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25554; SLC25A36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145903 CVCL_TM38 HAP1 SLC25A37 (-) 1 cancer cell line human CVCL_TM38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29786; SLC25A37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145904 CVCL_L498 4-1st cancer cell line human CVCL_L498 CL:0000010 Omics: Transcriptome analysis by microarray. Female Part of: JFCR45 cancer cell line panel 21145905 CVCL_KS98 B436 hybridoma house mouse CVCL_KS98 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42 first 12 residues). Group: Patented cell line 21145906 CVCL_KS99 10/78 hybridoma house mouse CVCL_KS99 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P27471; Rat Klrb1a/Cd161a; Monoclonal antibody target: UniProtKB; A4KWA1; Rat Klrb1b/Cd161b. 21145907 CVCL_L499 GMK-2 cancer cell line human CVCL_L499 CL:0000010 Population: Japanese Omics: Transcriptome analysis by microarray. Male Part of: JFCR45 cancer cell line panel 21145908 CVCL_KS96 A387 hybridoma house mouse CVCL_KS96 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42). Group: Patented cell line 21145909 CVCL_L496 HBC-8 cancer cell line human CVCL_L496 CL:0000010 Population: Japanese. Female Part of: JFCR45 cancer cell line panel 21145910 CVCL_KS97 B113 hybridoma house mouse CVCL_KS97 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP40). 21145911 CVCL_L497 HBC-9 cancer cell line human CVCL_L497 CL:0000010 Population: Japanese. Female Part of: JFCR45 cancer cell line panel 21145912 CVCL_L494 GM12012 transformed cell line human CVCL_L494 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Gly40Glu (c.119G>A) (G39E); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145913 CVCL_TM42 HAP1 SLC25A39 (-) 2 cancer cell line human CVCL_TM42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24279; SLC25A39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145914 CVCL_KS94 Renca-lacZ/EGFR cancer cell line house mouse CVCL_KS94 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Breed/subspecies: BALB/c. Male 21145915 CVCL_L495 GM00082 finite cell line human CVCL_L495 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21145916 CVCL_TM43 HAP1 SLC25A39 (-) 3 cancer cell line human CVCL_TM43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24279; SLC25A39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145917 CVCL_KS95 Renca-lacZ/EGFRvIII cancer cell line house mouse CVCL_KS95 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Breed/subspecies: BALB/c. Male 21145918 CVCL_L492 GM12010 transformed cell line human CVCL_L492 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.Arg45Lys (c.134G>A); ClinVar=VCV000010048; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145919 CVCL_TM40 HAP1 SLC25A38 (-) cancer cell line human CVCL_TM40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26054; SLC25A38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145920 CVCL_KS92 Renca-lacZ cancer cell line house mouse CVCL_KS92 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Breed/subspecies: BALB/c. Male 21145921 CVCL_L493 GM12011 transformed cell line human CVCL_L493 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; p.His204Arg (c.611A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145922 CVCL_TM41 HAP1 SLC25A39 (-) 1 cancer cell line human CVCL_TM41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24279; SLC25A39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145923 CVCL_KS93 Renca-lacZ/ErbB2 cancer cell line house mouse CVCL_KS93 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Breed/subspecies: BALB/c. Male 21145924 CVCL_KS90 8-18C5 hybridoma house mouse CVCL_KS90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q63345; Rat Mog. 21145925 CVCL_L490 GM02852 finite cell line human CVCL_L490 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21145926 CVCL_TM46 HAP1 SLC25A40 (-) 1 cancer cell line human CVCL_TM46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29680; SLC25A40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145927 CVCL_L491 GM07093 transformed cell line human CVCL_L491 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21145928 CVCL_TM47 HAP1 SLC25A40 (-) 2 cancer cell line human CVCL_TM47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29680; SLC25A40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145929 CVCL_KS91 MEF/3T3 Tet-Off spontaneously immortalized cell line house mouse CVCL_KS91 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: Clontech; Catalog number 630914/631139 Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21145930 CVCL_TM44 HAP1 SLC25A4 (-) 1 cancer cell line human CVCL_TM44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10990; SLC25A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145931 CVCL_TM45 HAP1 SLC25A4 (-) 2 cancer cell line human CVCL_TM45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10990; SLC25A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145932 CVCL_TM28 HAP1 SLC25A28 (-) 1 cancer cell line human CVCL_TM28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23472; SLC25A28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145933 CVCL_TM29 HAP1 SLC25A29 (-) cancer cell line human CVCL_TM29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20116; SLC25A29; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145934 CVCL_TM26 HAP1 SLC25A25 (-) 1 cancer cell line human CVCL_TM26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20663; SLC25A25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145935 CVCL_TM27 HAP1 SLC25A25 (-) 2 cancer cell line human CVCL_TM27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20663; SLC25A25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145936 CVCL_1G01 HROC40 cancer cell line human CVCL_1G01 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; descending. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21145937 CVCL_1G02 HROC50 T1 M5 cancer cell line human CVCL_1G02 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NSG mice Doubling time: 25-40 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21145938 CVCL_1G00 BZR-T33 transformed cell line human CVCL_1G00 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male 21145939 CVCL_1G05 HROC60 cancer cell line human CVCL_1G05 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21145940 CVCL_1G06 HROC69 cancer cell line human CVCL_1G06 HLA typing: A*26:01,33:01; B*18:01,52:01; C*12:02,12:03; DQB1*03:01,06:01; DRB1*11:04,15:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu7Ter (c.19G>T); ClinVar=VCV000493079; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Ala382Val (c.1145C>T); dbSNP=rs779602560; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=27087592) Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21145941 CVCL_1G03 HROC57 cancer cell line human CVCL_1G03 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=30197480) Population: Caucasian; Derived from sampling site: Colon; ascending. Male Doubling time: 26.13 hours (PubMed=30197480); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21145942 CVCL_1G04 HROC59 T1 M1 cancer cell line human CVCL_1G04 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21145943 CVCL_TM31 HAP1 SLC25A3 (-) 2 cancer cell line human CVCL_TM31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10989; SLC25A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145944 CVCL_TM32 HAP1 SLC25A30 (-) cancer cell line human CVCL_TM32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27371; SLC25A30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145945 CVCL_TM30 HAP1 SLC25A3 (-) 1 cancer cell line human CVCL_TM30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10989; SLC25A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145946 CVCL_TM35 HAP1 SLC25A33 (-) 2 cancer cell line human CVCL_TM35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29681; SLC25A33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145947 CVCL_TM36 HAP1 SLC25A35 (-) cancer cell line human CVCL_TM36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31921; SLC25A35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145948 CVCL_TM33 HAP1 SLC25A32 (-) cancer cell line human CVCL_TM33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29683; SLC25A32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145949 CVCL_TM34 HAP1 SLC25A33 (-) 1 cancer cell line human CVCL_TM34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29681; SLC25A33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145950 CVCL_TM17 HAP1 SLC25A17 (-) 1 cancer cell line human CVCL_TM17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10987; SLC25A17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145951 CVCL_TM18 HAP1 SLC25A17 (-) 2 cancer cell line human CVCL_TM18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10987; SLC25A17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145952 CVCL_TM15 HAP1 SLC25A15 (-) 1 cancer cell line human CVCL_TM15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10985; SLC25A15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145953 CVCL_TM16 HAP1 SLC25A15 (-) 2 cancer cell line human CVCL_TM16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10985; SLC25A15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145954 CVCL_TM19 HAP1 SLC25A18 (-) 1 cancer cell line human CVCL_TM19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10988; SLC25A18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145955 CVCL_KS78 6F12 hybridoma house mouse CVCL_KS78 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q13751; Human LAMB3. 21145956 CVCL_L478 GM03467 finite cell line human CVCL_L478 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex7-9del; Zygosity=Hemizygous (PubMed=3296189; PubMed=6087154) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21145957 CVCL_L479 GM07092 transformed cell line human CVCL_L479 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; c.609+5G>A (Ex8del); ClinVar=VCV000010054; Zygosity=Hemizygous (Coriell) Population: Caucasian; Irish/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145958 CVCL_KS79 ME 311 hybridoma house mouse CVCL_KS79 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:61730; 9-O-acetyl-alpha-N-acetylneuraminosyl-(2->8)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-ceramide (9-O-Acetyl-GD3). 21145959 CVCL_KS76 CellSensor T-REx NICD-CSL-bla HeLa cancer cell line human CVCL_KS76 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Notch response element driving beta-lactamase reporter gene expression (CSL-bla) along with tetracycline repressor and tetracycline/doxycycline-inducible NICD (notch intracellular domain) constructs This cell line is a clonal population isolated by flow cytometry. 21145960 CVCL_L476 Chem-3 undefined cell line type house mouse CVCL_L476 CL:0000010 21145961 CVCL_KS77 CellSensor T-REx FOXO3-DBE-bla HeLa cancer cell line human CVCL_KS77 CL:0000010 Transfected with: HGNC; 3821; FOXO3; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a FOXO3 response element driving beta-lactamase reporter gene expression (DBE-bla) along with tetracycline repressor and tetracycline/doxycycline-inducible FOXO3 constructs 21145962 CVCL_L477 CSHM1BE LCL transformed cell line human CVCL_L477 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21145963 CVCL_KS74 CellSensor irf1-bla TF1 cancer cell line human CVCL_KS74 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the irf-1 response element; Characteristics: IL3 or CSF2 dependent 21145964 CVCL_L474 Chem-1 undefined cell line type Norway rat CVCL_L474 CL:0000010 21145965 CVCL_KS75 CellSensor MMTV-bla HeLa cancer cell line human CVCL_KS75 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Invitrogen; Catalog number K1279; Discontinued: Thermofisher/Invitrogen; Catalog number K1641B Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the MMTV response element 21145966 CVCL_L475 Chem-2 undefined cell line type human CVCL_L475 CL:0000010 Discontinued: Millipore; HTSCHEM-2; true. 21145967 CVCL_KS72 CellSensor irf1-bla HEL cancer cell line human CVCL_KS72 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the irf-1 response element 21145968 CVCL_L472 CS1AN-S3-G2 transformed cell line human CVCL_L472 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys337Ter (c.1009A>T) (A1088T); ClinVar=VCV000550722; Zygosity=Hemizygous (PubMed=1339317) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: JCRB; KURB1911; probable Female 21145969 CVCL_TM20 HAP1 SLC25A18 (-) 2 cancer cell line human CVCL_TM20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10988; SLC25A18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145970 CVCL_KS73 CellSensor irf1-bla Ba/F3 factor-dependent cell line house mouse CVCL_KS73 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the irf-1 response element; Characteristics: IL3 dependent Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21145971 CVCL_L473 CS1BE finite cell line human CVCL_L473 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg670Trp (c.2008C>T) (C2087T); ClinVar=VCV000190158; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Tyr1179Leufs*22 (c.3536delA) (3615delA); ClinVar=VCV000190167; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1918; probable Female 21145972 CVCL_TM21 HAP1 SLC25A20 (-) 1 cancer cell line human CVCL_TM21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1421; SLC25A20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145973 CVCL_KS70 CellSensor IL-1-bla ECV304 cancer cell line human CVCL_KS70 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene which has been randomly integrated in the genome of ECV-304 and which has been selected for IL1-responsiveness Problematic cell line: Contaminated Parent cell line (ECV-304) has been shown to be a T24 derivative. 21145974 CVCL_L470 GM02838 finite cell line human CVCL_L470 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21145975 CVCL_KS71 CellSensor irf1-bla CTLL-2 transformed cell line house mouse CVCL_KS71 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the irf-1 response element; Characteristics: IL2 dependent 21145976 CVCL_L471 CS1AN finite cell line human CVCL_L471 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys337Ter (c.1009A>T) (A1088T); ClinVar=VCV000550722; Zygosity=Heterozygous (PubMed=1339317); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg857Ter (c.2569C>T); ClinVar=VCV000553383; Zygosity=Heterozygous (PubMed=1339317) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 22 PDL (PubMed=6492896); Doubling time: 50 hours (PubMed=8609460) 21145977 CVCL_TM24 HAP1 SLC25A23 (-) 1 cancer cell line human CVCL_TM24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19375; SLC25A23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145978 CVCL_TM25 HAP1 SLC25A24 (-) 1 cancer cell line human CVCL_TM25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20662; SLC25A24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145979 CVCL_TM22 HAP1 SLC25A20 (-) 2 cancer cell line human CVCL_TM22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1421; SLC25A20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145980 CVCL_TM23 HAP1 SLC25A22 (-) cancer cell line human CVCL_TM23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19954; SLC25A22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145981 CVCL_TM06 HAP1 SLC25A10 (-) 1 cancer cell line human CVCL_TM06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10980; SLC25A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145982 CVCL_TM07 HAP1 SLC25A10 (-) 2 cancer cell line human CVCL_TM07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10980; SLC25A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145983 CVCL_TM04 HAP1 SLC25A1 (-) 2 cancer cell line human CVCL_TM04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10979; SLC25A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145984 CVCL_TM05 HAP1 SLC25A1 (-) 3 cancer cell line human CVCL_TM05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10979; SLC25A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145985 CVCL_TM08 HAP1 SLC25A11 (-) 1 cancer cell line human CVCL_TM08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10981; SLC25A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145986 CVCL_TM09 HAP1 SLC25A11 (-) 2 cancer cell line human CVCL_TM09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10981; SLC25A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21145987 CVCL_L489 GM02851 finite cell line human CVCL_L489 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21145988 CVCL_KS89 LM609 hybridoma house mouse CVCL_KS89 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9537 21145989 CVCL_KS87 AICD2.M2 hybridoma house mouse CVCL_KS87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2119 21145990 CVCL_L487 GM02227 finite cell line human CVCL_L487 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex6-9del/inv; Zygosity=Hemizygous (PubMed=3296189) Derived from sampling site: Cell type=Fibroblast. Male 21145991 CVCL_L488 GM02330 finite cell line human CVCL_L488 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21145992 CVCL_KS88 LM142 hybridoma house mouse CVCL_KS88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. 21145993 CVCL_KS85 Chem-9 GLP1R undefined cell line type Norway rat CVCL_KS85 CL:0000010 Transfected with: HGNC; 4324; GLP1R. 21145994 CVCL_L485 GM00537 finite cell line human CVCL_L485 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21145995 CVCL_KS86 AICD2.M1 hybridoma house mouse CVCL_KS86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2118 21145996 CVCL_L486 GM01362 finite cell line human CVCL_L486 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21145997 CVCL_KS83 Chem-5 DRD4 undefined cell line type Norway rat CVCL_KS83 CL:0000010 Transfected with: HGNC; 3025; DRD4. 21145998 CVCL_L483 GM00152 finite cell line human CVCL_L483 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21145999 CVCL_KS84 Chem-9 undefined cell line type Norway rat CVCL_KS84 CL:0000010 21146000 CVCL_L484 GM00159 finite cell line human CVCL_L484 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21146001 CVCL_TM10 HAP1 SLC25A12 (-) 1 cancer cell line human CVCL_TM10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10982; SLC25A12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146002 CVCL_L481 GM00377 finite cell line human CVCL_L481 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00029; true Male 21146003 CVCL_KS81 UJ181.4 hybridoma house mouse CVCL_KS81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P32004; Human L1CAM/CD171. 21146004 CVCL_KS82 Chem-4 CX3CR1 undefined cell line type Norway rat CVCL_KS82 CL:0000010 Transfected with: HGNC; 2558; CX3CR1 Discontinued: Eurofin; Catalog number HTS015C. 21146005 CVCL_L482 GM00068 finite cell line human CVCL_L482 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21146006 CVCL_TM13 HAP1 SLC25A14 (-) 1 cancer cell line human CVCL_TM13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10984; SLC25A14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146007 CVCL_L480 GM01900 transformed cell line human CVCL_L480 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; c.610-4_610-2delinsTTT (Ex9del partial); ClinVar=VCV000010055; Zygosity=Heterozygous (from familial inference of GM01899) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146008 CVCL_TM14 HAP1 SLC25A14 (-) 2 cancer cell line human CVCL_TM14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10984; SLC25A14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146009 CVCL_KS80 M340 hybridoma house mouse CVCL_KS80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen on neuroblastoma cells. 21146010 CVCL_TM11 HAP1 SLC25A12 (-) 2 cancer cell line human CVCL_TM11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10982; SLC25A12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146011 CVCL_TM12 HAP1 SLC25A13 (-) cancer cell line human CVCL_TM12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10983; SLC25A13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146012 CVCL_KS58 CellSensor CRE-bla Jurkat cancer cell line human CVCL_KS58 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21146013 CVCL_L458 CS2BE LCL transformed cell line human CVCL_L458 HLA typing: A*w32,10; B*w15,14 (Coriell=GM01712) CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Ser222Tyrfs*25 (c.665_723del59) (Ex10del); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Tyr1179Ilefs*22 (c.3535delT); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146014 CVCL_KS59 CellSensor AP1-bla A375 cancer cell line human CVCL_KS59 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the AP1 response element 21146015 CVCL_L459 GM01227 finite cell line human CVCL_L459 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146016 CVCL_KS56 CellSensor CRE-bla FreeStyle 293F transformed cell line human CVCL_KS56 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Thermofisher/Invitrogen; Catalog number K1130; Discontinued: Thermofisher/Invitrogen; Catalog number K1492 Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21146017 CVCL_L456 XP-CS2 LCL transformed cell line human CVCL_L456 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly602Asp (c.1805G>A); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146018 CVCL_L457 AT2KY TERT telomerase immortalized cell line human CVCL_L457 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146019 CVCL_KS57 CellSensor CRE-bla HEK 293T transformed cell line human CVCL_KS57 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21146020 CVCL_L454 AP7P(SVT) transformed cell line human CVCL_L454 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2152_2778del (Ex24-28del); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146021 CVCL_KS54 CellSensor Gli-bla NIH3T3 spontaneously immortalized cell line house mouse CVCL_KS54 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: Thermofisher/Invitrogen; Catalog number K1642B Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the Gli response element 21146022 CVCL_KS55 CellSensor STAT6-bla RA-1 cancer cell line human CVCL_KS55 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the STAT6 response element 21146023 CVCL_L455 XP-CS2 finite cell line human CVCL_L455 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly602Asp (c.1805G>A); Zygosity=Heterozygous (PubMed=7585650; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146024 CVCL_L452 BS1CH(SVT) transformed cell line human CVCL_L452 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146025 CVCL_KS52 CellSensor GAS-bla ME-180 cancer cell line human CVCL_KS52 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the gamma activated sequence (GAS) response element 21146026 CVCL_L453 BS2CH(SVT) transformed cell line human CVCL_L453 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146027 CVCL_KS53 CellSensor Gli-bla 22Rv1 cancer cell line human CVCL_KS53 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Prostate. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the Gli response element 21146028 CVCL_L450 EC-MZ-9 cancer cell line human CVCL_L450 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 2.5 weeks (PubMed=7681807) 21146029 CVCL_KS50 HEK293 p65-HaloTag transformed cell line human CVCL_KS50 CL:0000010 Transfected with: HGNC; 9955; RELA; Transfected with: UniProtKB; P0A3G2; Rhodococcus rhodochrous dhaA (mutated = Halo-Tag) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a p65(RELA)-Halo-Tag fusion protein 21146030 CVCL_L451 BS1CH finite cell line human CVCL_L451 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146031 CVCL_KS51 CellSensor CYP1A1-bla LS-180 cancer cell line human CVCL_KS51 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Colon. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CYP1A1 promoter 21146032 CVCL_TM02 HAP1 SLC24A1 (-) 1 cancer cell line human CVCL_TM02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10975; SLC24A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146033 CVCL_TM03 HAP1 SLC25A1 (-) 1 cancer cell line human CVCL_TM03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10979; SLC25A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146034 CVCL_TM00 HAP1 SLC22A5 (-) cancer cell line human CVCL_TM00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10969; SLC22A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146035 CVCL_TM01 HAP1 SLC23A2 (-) 1 cancer cell line human CVCL_TM01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10973; SLC23A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146036 CVCL_KS69 CellSensor dhfr(E2F)-bla NIH3T3 spontaneously immortalized cell line house mouse CVCL_KS69 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the E2F/DP1 binding sequence from the DHFR gene promoter 21146037 CVCL_L469 CS7SE finite cell line human CVCL_L469 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146038 CVCL_KS67 CellSensor c-fos-bla HEK 293T transformed cell line human CVCL_KS67 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the FOS promoter 21146039 CVCL_L467 XPH2AA finite cell line human CVCL_L467 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146040 CVCL_KS68 CellSensor c-fos-bla ME-180 cancer cell line human CVCL_KS68 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the FOS promoter 21146041 CVCL_L468 XP108LO finite cell line human CVCL_L468 CL:0000010 Derived from sampling site: Umbilical cord. Female Senescence: Senesces at 13 PDL (PubMed=6492896) 21146042 CVCL_KS65 CellSensor AP1-bla HEK 293T transformed cell line human CVCL_KS65 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the AP1 response element 21146043 CVCL_L465 GM03177 finite cell line human CVCL_L465 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146044 CVCL_KS66 CellSensor C/EBP-bla FreeStyle 293F transformed cell line human CVCL_KS66 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the C/EBP response element 21146045 CVCL_L466 XPH1AA finite cell line human CVCL_L466 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146046 CVCL_KS63 CellSensor ISRE-bla Jurkat cancer cell line human CVCL_KS63 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the interferon-stimulated response element (ISRE) 21146047 CVCL_L463 XPH135BE LCL transformed cell line human CVCL_L463 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe270Ter (c.807_808delTT); Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146048 CVCL_KS64 CellSensor ISRE-bla RA-1 cancer cell line human CVCL_KS64 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the interferon-stimulated response element (ISRE) 21146049 CVCL_L464 XP1AA finite cell line human CVCL_L464 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 21 PDL (PubMed=6492896) 21146050 CVCL_KS61 CellSensor NFkB-bla HEK 293T transformed cell line human CVCL_KS61 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NF-kappaB response element 21146051 CVCL_L461 XPH134BE finite cell line human CVCL_L461 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (from autologous cell line XPH134BE LCL) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146052 CVCL_KS62 CellSensor ISRE-bla HEK 293T transformed cell line human CVCL_KS62 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the interferon-stimulated response element (ISRE) 21146053 CVCL_L462 XPH134BE LCL transformed cell line human CVCL_L462 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146054 CVCL_KS60 CellSensor AP1-bla ME-180 cancer cell line human CVCL_KS60 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under the control of the AP1 response element 21146055 CVCL_L460 XP11BE LCL transformed cell line human CVCL_L460 HLA typing: A*w24,w32; B*12,w40 (Coriell=GM02252) CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe270Ter (c.807_808delTT); Zygosity=Heterozygous (PubMed=16947863); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146056 CVCL_KS38 CHO/CREB-luc spontaneously immortalized cell line CVCL_KS38 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Discontinued: Thermofisher/Panomics; Catalog number RC0008 Female Characteristics: The luciferase reporter gene is under the control of the CREB response element 21146057 CVCL_L438 M101 [Human melanoma] cancer cell line human CVCL_L438 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12271. 21146058 CVCL_KS39 HeLa/NFAT-luc cancer cell line human CVCL_KS39 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Panomics; Catalog number RC0005 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NFAT response element 21146059 CVCL_L439 MM14 spontaneously immortalized cell line house mouse CVCL_L439 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: BALB/c. Male 21146060 CVCL_KS36 A549/NFkB-luc cancer cell line human CVCL_KS36 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Discontinued: Thermofisher/Panomics; Catalog number RC0002 Male Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146061 CVCL_L436 SGS/4A cancer cell line Norway rat CVCL_L436 CL:0000010 Breed/subspecies: Galliera. 21146062 CVCL_KS37 C2C12/NFkB-luc spontaneously immortalized cell line house mouse CVCL_KS37 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Discontinued: Thermofisher/Panomics; Catalog number RC0016 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146063 CVCL_L437 FHCC-98 cancer cell line human CVCL_L437 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Doubling time: 21.4 hours (PubMed=15133854) 21146064 CVCL_KS34 293/NFkB-luc transformed cell line human CVCL_KS34 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Thermofisher/Panomics; Catalog number RC0014 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146065 CVCL_L434 P2UR/K-562 cancer cell line human CVCL_L434 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8541; P2RY2 Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21146066 CVCL_KS35 293T/NFkB-luc transformed cell line human CVCL_KS35 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Discontinued: Thermofisher/Panomics; Catalog number RC0001 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146067 CVCL_L435 RML-Yoshi finite cell line human CVCL_L435 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 22 PDL (PubMed=17395773) 21146068 CVCL_KS32 293/AP1-luc transformed cell line human CVCL_KS32 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Thermofisher/Panomics; Catalog number RC0006 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the AP-1 response element 21146069 CVCL_L432 Edom-iPS-2 induced pluripotent stem cell human CVCL_L432 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21146070 CVCL_KS33 293/CREB-luc transformed cell line human CVCL_KS33 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Thermofisher/Panomics; Catalog number RC0007 Female Characteristics: The luciferase reporter gene is under the control of the CREB response element 21146071 CVCL_L433 Edom-iPS-3 induced pluripotent stem cell human CVCL_L433 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21146072 CVCL_KS30 CellSensor TNFalpha-bla THP-1 cancer cell line human CVCL_KS30 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene which has been randomly integrated in the genome of THP-1 and which has been selected for TNFA-responsiveness 21146073 CVCL_L430 Edom22 somatic stem cell human CVCL_L430 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21146074 CVCL_L431 Edom-iPS-1 induced pluripotent stem cell human CVCL_L431 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Omics: DNA methylation analysis Female 21146075 CVCL_KS31 HEK 293 Tet-On transformed cell line human CVCL_KS31 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Clontech; Catalog number 630903 Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146076 CVCL_L449 EC-MZ-5 cancer cell line human CVCL_L449 CL:0000010 Derived from sampling site: Endometrium. Female Doubling time: 27 hours (PubMed=7681807) 21146077 CVCL_KS49 MultiScreen HEK293T mGluR4 transformed cell line human CVCL_KS49 CL:0000010 Transfected with: HGNC; 4596; GRM4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21146078 CVCL_L447 EC-MZ-2 cancer cell line human CVCL_L447 CL:0000010 Derived from sampling site: Endometrium. Female Doubling time: 72 hours (PubMed=7681807) 21146079 CVCL_KS47 Jurkat-Lucia NFAT cancer cell line human CVCL_KS47 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter fused to 6 NFAT consensus transcriptional response elements 21146080 CVCL_L448 EC-MZ-3 cancer cell line human CVCL_L448 CL:0000010 Derived from sampling site: Endometrium. Female Doubling time: 50 hours (PubMed=7681807) 21146081 CVCL_KS48 MultiScreen HEK293T mGluR2 transformed cell line human CVCL_KS48 CL:0000010 Transfected with: HGNC; 4594; GRM2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21146082 CVCL_L445 EC-MZ-1 cancer cell line human CVCL_L445 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 26 hours (PubMed=7681807) 21146083 CVCL_KS45 NIH3T3/NFkB-luc spontaneously immortalized cell line house mouse CVCL_KS45 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: Thermofisher/Panomics; Catalog number RC0015 Male Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146084 CVCL_KS46 CellSensor NFAT-bla RA-1 cancer cell line human CVCL_KS46 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21146085 CVCL_L446 EC-MZ-11 cancer cell line human CVCL_L446 CL:0000010 Derived from sampling site: Endometrium. Female Doubling time: 3 weeks (PubMed=7681807) 21146086 CVCL_KS43 HeLa/STAT3-luc cancer cell line human CVCL_KS43 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Panomics; Catalog number RC0003 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the STAT3 response element 21146087 CVCL_L443 HX156c cancer cell line human CVCL_L443 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: 30 hours, at 75th passage (PubMed=2441858) 21146088 CVCL_L444 HX160c cancer cell line human CVCL_L444 CL:0000010 Female Doubling time: 68 hours, at 50th passage (PubMed=2441858). 21146089 CVCL_KS44 K562/NFAT-luc cancer cell line human CVCL_KS44 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: Thermofisher/Panomics; Catalog number RC0009 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NFAT response element 21146090 CVCL_KS41 HeLa/STAT1-luc cancer cell line human CVCL_KS41 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Panomics; Catalog number RC0004 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the STAT1 response element 21146091 CVCL_L441 HX151c cancer cell line human CVCL_L441 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: 42 hours, at 70th passage (PubMed=2441858) 21146092 CVCL_KS42 HeLa/SRF-luc cancer cell line human CVCL_KS42 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Panomics; Catalog number RC0012 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the SRF response element 21146093 CVCL_L442 HX155c cancer cell line human CVCL_L442 CL:0000010 Female Doubling time: 48 hours, at 50th passage (PubMed=2441858). 21146094 CVCL_KS40 HeLa/NFkB-luc cancer cell line human CVCL_KS40 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Panomics; Catalog number RC0013 Female Characteristics: The luciferase reporter gene is under the control of multiple copies of the NF-kappaB response element 21146095 CVCL_L440 YCCEL1 cancer cell line human CVCL_L440 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Ascites. Male Virology: Contains a complete EBV genome (strain YCCEL1) which has been sequenced (PubMed=25787276; PubMed=26889033) 21146096 CVCL_1G70 AT4KY finite cell line human CVCL_1G70 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1637_Leu1668del32 (c.4910del96) (Ex35del); Zygosity=Homozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146097 CVCL_1G71 AT4KY TERT telomerase immortalized cell line human CVCL_1G71 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1637_Leu1668del32 (c.4910del96) (Ex35del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146098 CVCL_1G74 CFBR spontaneously immortalized cell line CVCL_1G74 CL:0000010 Miscellaneous: Cell line is no longer avaible (NRFC) Derived from sampling site: Brain. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC011 21146099 CVCL_1G75 CFCP1 spontaneously immortalized cell line CVCL_1G75 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC013 21146100 CVCL_1G72 TU-MM-1 cancer cell line human CVCL_1G72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26070481); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val1822Asp (c.5465T>A) (V1804D); ClinVar=VCV000021030; Zygosity=Unspecified (PubMed=26070481); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=26070481) Population: Japanese; Derived from sampling site: Peritoneum. Omics: Deep exome analysis; Omics: Genome sequenced Female Doubling time: 67.9 hours (PubMed=26070481) 21146101 CVCL_1G73 CCKF spontaneously immortalized cell line CVCL_1G73 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Koi. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC007 21146102 CVCL_1G78 CPG spontaneously immortalized cell line CVCL_1G78 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC049 21146103 CVCL_1G79 CSK [Channa] spontaneously immortalized cell line CVCL_1G79 CL:0000010 Derived from sampling site: Kidney. Unspecified Doubling time: ~29 hours (PubMed=23558109) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC045 21146104 CVCL_1G76 CFFN2 spontaneously immortalized cell line CVCL_1G76 CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC010 21146105 CVCL_1G77 CFSP spontaneously immortalized cell line CVCL_1G77 CL:0000010 Miscellaneous: Cell line is no longer avaible (NRFC) Derived from sampling site: Spleen. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC012 21146106 CVCL_1G81 DRM spontaneously immortalized cell line zebrafish CVCL_1G81 CL:0000010 Miscellaneous: Cell line is no longer avaible (NRFC) Derived from sampling site: Muscle. Male Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC050 21146107 CVCL_1G82 DT1CPEx spontaneously immortalized cell line CVCL_1G82 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC024 21146108 CVCL_1G80 CTM spontaneously immortalized cell line CVCL_1G80 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic macrophage.. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC028 21146109 CVCL_1G85 EM2HTr spontaneously immortalized cell line CVCL_1G85 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Heart. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC030 21146110 CVCL_1G86 EM2GEx a spontaneously immortalized cell line CVCL_1G86 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC031 21146111 CVCL_1G83 DT1CPTr spontaneously immortalized cell line CVCL_1G83 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC026 21146112 CVCL_1G84 DT1F4Ex spontaneously immortalized cell line CVCL_1G84 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC025 21146113 CVCL_1G89 HBF spontaneously immortalized cell line CVCL_1G89 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Endangered species/breed cell line; Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC008 21146114 CVCL_1G87 EM3GEx spontaneously immortalized cell line CVCL_1G87 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC032 21146115 CVCL_1G88 EM4SPEx spontaneously immortalized cell line CVCL_1G88 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC033 21146116 CVCL_1G52 TF228.1.16 cancer cell line human CVCL_1G52 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Derived from sampling site: Groin. Female Virology: EBV-negative 21146117 CVCL_1G53 CEM-GFP cancer cell line human CVCL_1G53 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: HIV-1 infection reporter cell line, the gene for GFP is under the control of a HIV-1 long terminal repeat 21146118 CVCL_1G50 Cf2Th-CCR5 spontaneously immortalized cell line dog CVCL_1G50 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Female 21146119 CVCL_1G51 Cf2Th-CXCR4 spontaneously immortalized cell line dog CVCL_1G51 CL:0000010 Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Female 21146120 CVCL_1G56 GSKC spontaneously immortalized cell line CVCL_1G56 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Amphibian cell line 21146121 CVCL_1G57 GSSC spontaneously immortalized cell line CVCL_1G57 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Amphibian cell line 21146122 CVCL_1G54 EGFP-CEM-NKr cancer cell line human CVCL_1G54 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21146123 CVCL_1G55 EGFP-K562 cancer cell line human CVCL_1G55 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21146124 CVCL_1G58 GSTC spontaneously immortalized cell line CVCL_1G58 CL:0000010 Derived from sampling site: Thymus. Unspecified Group: Amphibian cell line 21146125 CVCL_1G59 UCS spontaneously immortalized cell line CVCL_1G59 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 21146126 CVCL_1G60 RGS spontaneously immortalized cell line CVCL_1G60 CL:0000010 Derived from sampling site: Skin. Unspecified Group: Fish cell line 21146127 CVCL_1G63 AT7BI finite cell line human CVCL_1G63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146128 CVCL_1G64 AT5KY finite cell line human CVCL_1G64 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Incorrectly indicated as originating from a male patient in JCRB=KURB1791 21146129 CVCL_1G61 RLN-E7 finite cell line Norway rat CVCL_1G61 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: Donryu. Male 21146130 CVCL_1G62 PC-2 [Rat liver] finite cell line Norway rat CVCL_1G62 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21146131 CVCL_1G67 AT6KY TERT telomerase immortalized cell line human CVCL_1G67 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.332del165 (g.484C>T) (Ex7del); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146132 CVCL_1G68 AT7KY finite cell line human CVCL_1G68 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2125del126 (Ex16del); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146133 CVCL_1G65 AT5KY TERT telomerase immortalized cell line human CVCL_1G65 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Incorrectly indicated as originating from a male patient in JCRB=KURB1793 21146134 CVCL_1G66 AT6KY finite cell line human CVCL_1G66 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.332del165 (g.484C>T) (Ex7del); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146135 CVCL_1G69 AT3KY finite cell line human CVCL_1G69 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1637_Leu1668del32 (c.4910del96) (Ex35del); Zygosity=Homozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146136 CVCL_TM90 HAP1 SLC30A3 (-) 1 cancer cell line human CVCL_TM90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11014; SLC30A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146137 CVCL_TM93 HAP1 SLC30A6 (-) cancer cell line human CVCL_TM93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19305; SLC30A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146138 CVCL_TM94 HAP1 SLC30A7 (-) 1 cancer cell line human CVCL_TM94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19306; SLC30A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146139 CVCL_TM91 HAP1 SLC30A3 (-) 2 cancer cell line human CVCL_TM91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11014; SLC30A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146140 CVCL_TM92 HAP1 SLC30A5 (-) 1 cancer cell line human CVCL_TM92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19089; SLC30A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146141 CVCL_TM97 HAP1 SLC31A1 (-) cancer cell line human CVCL_TM97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11016; SLC31A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146142 CVCL_TM98 HAP1 SLC31A2 (-) 1 cancer cell line human CVCL_TM98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11017; SLC31A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146143 CVCL_TM95 HAP1 SLC30A7 (-) 2 cancer cell line human CVCL_TM95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19306; SLC30A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146144 CVCL_TM96 HAP1 SLC30A9 (-) cancer cell line human CVCL_TM96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1329; SLC30A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146145 CVCL_TM99 HAP1 SLC33A1 (-) 1 cancer cell line human CVCL_TM99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 95; SLC33A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146146 CVCL_1G30 C3647 induced pluripotent stem cell CVCL_1G30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21146147 CVCL_1G31 C3649 induced pluripotent stem cell CVCL_1G31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21146148 CVCL_1G34 C8861 induced pluripotent stem cell CVCL_1G34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21146149 CVCL_1G35 C40210 induced pluripotent stem cell CVCL_1G35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21146150 CVCL_1G32 C3651 induced pluripotent stem cell CVCL_1G32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21146151 CVCL_1G33 C4955 induced pluripotent stem cell CVCL_1G33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male Group: Non-human primate cell line 21146152 CVCL_1G38 AG05252 finite cell line CVCL_1G38 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05252; probable Male Group: Non-human primate cell line 21146153 CVCL_1G39 AtT-20ins4b/1 cancer cell line house mouse CVCL_1G39 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 21146154 CVCL_1G36 C40280 induced pluripotent stem cell CVCL_1G36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Group: Non-human primate cell line 21146155 CVCL_1G37 AG05253 finite cell line bonobo/pygmy chimpanzee CVCL_1G37 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05253; probable Male Group: Non-human primate cell line 21146156 CVCL_1G29 U251-TR3 cancer cell line human CVCL_1G29 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:72564; Temozolomide (TMZ); Derived from sampling site: Brain; parietal lobe. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00523 Problematic cell line: Misidentified Originally thought (PubMed=19584161) to be a A-172 (Cellosaurus=CVCL_0131) derivative but shown to be a U-251MG derivative (DOI=10.1158/1078-0432.CCR-13-1821). 21146157 CVCL_TM82 HAP1 SLC2A4RG (-) cancer cell line human CVCL_TM82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15930; SLC2A4RG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146158 CVCL_TM83 HAP1 SLC2A6 (-) 1 cancer cell line human CVCL_TM83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11011; SLC2A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146159 CVCL_TM80 HAP1 SLC29A4 (-) 3 cancer cell line human CVCL_TM80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23097; SLC29A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146160 CVCL_TM86 HAP1 SLC30A1 (-) cancer cell line human CVCL_TM86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11012; SLC30A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146161 CVCL_TM87 HAP1 SLC30A10 (-) 1 cancer cell line human CVCL_TM87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25355; SLC30A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146162 CVCL_TM84 HAP1 SLC2A8 (-) 1 cancer cell line human CVCL_TM84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13812; SLC2A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146163 CVCL_TM85 HAP1 SLC2A8 (-) 2 cancer cell line human CVCL_TM85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13812; SLC2A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146164 CVCL_TM88 HAP1 SLC30A10 (-) 2 cancer cell line human CVCL_TM88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25355; SLC30A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146165 CVCL_TM89 HAP1 SLC30A10 (-) 3 cancer cell line human CVCL_TM89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25355; SLC30A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146166 CVCL_1G41 J-Lat Tat-GFP Clone 82 cancer cell line human CVCL_1G41 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain The integrated HIV-1 genome is located in chromosome 10 (PubMed=28086908). 21146167 CVCL_1G42 J-Lat Tat-GFP Clone A1 cancer cell line human CVCL_1G42 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain The integrated HIV-1 genome is located in chromosome X (PubMed=28086908). 21146168 CVCL_1G40 AtT-20ins cancer cell line house mouse CVCL_1G40 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 21146169 CVCL_1G45 J-Lat Tat-GFP Clone H2 cancer cell line human CVCL_1G45 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain The integrated HIV-1 genome is located in gene SLC25A12 (PubMed=28086908). 21146170 CVCL_1G46 Jurkat-deltaKS cancer cell line human CVCL_1G46 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146171 CVCL_1G43 J-Lat Tat-GFP Clone A2 cancer cell line human CVCL_1G43 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain 21146172 CVCL_1G44 J-Lat Tat-GFP Clone A7 cancer cell line human CVCL_1G44 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain 21146173 CVCL_1G49 CHO NL4-3 gp160 spontaneously immortalized cell line CVCL_1G49 CL:0000010 Transfected with: UniProtKB; Q72502; HIV-1 isolate NL4-3 env (gp160); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21146174 CVCL_1G47 Jurkat-522 F/Y cancer cell line human CVCL_1G47 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146175 CVCL_1G48 Jurkat-7/3 STOP cancer cell line human CVCL_1G48 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146176 CVCL_TM71 HAP1 SLC27A5 (-) 1 cancer cell line human CVCL_TM71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10999; SLC27A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146177 CVCL_TM72 HAP1 SLC27A6 (-) 1 cancer cell line human CVCL_TM72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11000; SLC27A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146178 CVCL_TM70 HAP1 SLC27A4 (-) 2 cancer cell line human CVCL_TM70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10998; SLC27A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146179 CVCL_TM75 HAP1 SLC29A2 (-) 1 cancer cell line human CVCL_TM75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11004; SLC29A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146180 CVCL_TM76 HAP1 SLC29A3 (-) 1 cancer cell line human CVCL_TM76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23096; SLC29A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146181 CVCL_TM73 HAP1 SLC27A6 (-) 2 cancer cell line human CVCL_TM73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11000; SLC27A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146182 CVCL_TM74 HAP1 SLC29A1 (-) cancer cell line human CVCL_TM74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11003; SLC29A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146183 CVCL_TM79 HAP1 SLC29A4 (-) 2 cancer cell line human CVCL_TM79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23097; SLC29A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146184 CVCL_TM77 HAP1 SLC29A3 (-) 2 cancer cell line human CVCL_TM77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23096; SLC29A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146185 CVCL_TM78 HAP1 SLC29A4 (-) 1 cancer cell line human CVCL_TM78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23097; SLC29A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146186 CVCL_TM59 HAP1 SLC26A11 (-) cancer cell line human CVCL_TM59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14471; SLC26A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146187 CVCL_1G12 PA028 cancer cell line human CVCL_1G12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Val (c.797G>T); ClinVar=VCV000233303; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146188 CVCL_1G13 PA055 cancer cell line human CVCL_1G13 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser149fs; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146189 CVCL_1G10 UCVA-1 cancer cell line human CVCL_1G10 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Unspecified 21146190 CVCL_1G11 PA018 cancer cell line human CVCL_1G11 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146191 CVCL_1G16 PA107 cancer cell line human CVCL_1G16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 24659; EXOC8; Simple; p.Arg388Ter; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Ter (c.811G>T); ClinVar=VCV001174012; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146192 CVCL_1G17 PA122 cancer cell line human CVCL_1G17 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146193 CVCL_1G14 PA086 cancer cell line human CVCL_1G14 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146194 CVCL_1G15 PA090 cancer cell line human CVCL_1G15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146195 CVCL_1G09 HROC147 T0 M1 cancer cell line human CVCL_1G09 HLA typing: A*02:01,11:01; B*07:02,15:01; C*03:04,07:02; DQB1*03:02,06:02; DRB1*04:01,15:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; sigmoid. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Instable (MSI-low) (Direct_author_submission) 21146196 CVCL_1G07 HROC69 T0 M2 cancer cell line human CVCL_1G07 HLA typing: A*26:01,33:01; B*18:01,52:01; C*12:02,12:03; DQB1*03:01,06:01; DRB1*11:04,15:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu7Ter (c.19G>T); ClinVar=VCV000493079; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Ala382Val (c.1145C>T); dbSNP=rs779602560; Zygosity=Unspecified (PubMed=27087592); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=27087592) Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice 21146197 CVCL_1G08 HROC80 T1 M1 cancer cell line human CVCL_1G08 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 24 hours (CLS); Microsatellite instability: Stable (MSS) (PubMed=25926053) 21146198 CVCL_TM60 HAP1 SLC26A2 (-) 1 cancer cell line human CVCL_TM60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10994; SLC26A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146199 CVCL_TM61 HAP1 SLC26A2 (-) 2 cancer cell line human CVCL_TM61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10994; SLC26A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146200 CVCL_TM64 HAP1 SLC27A1 (-) 2 cancer cell line human CVCL_TM64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10995; SLC27A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146201 CVCL_TM65 HAP1 SLC27A2 (-) 1 cancer cell line human CVCL_TM65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10996; SLC27A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146202 CVCL_TM62 HAP1 SLC26A6 (-) cancer cell line human CVCL_TM62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14472; SLC26A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146203 CVCL_TM63 HAP1 SLC27A1 (-) 1 cancer cell line human CVCL_TM63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10995; SLC27A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146204 CVCL_TM68 HAP1 SLC27A3 (-) cancer cell line human CVCL_TM68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10997; SLC27A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146205 CVCL_TM69 HAP1 SLC27A4 (-) 1 cancer cell line human CVCL_TM69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10998; SLC27A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146206 CVCL_TM66 HAP1 SLC27A2 (-) 2 cancer cell line human CVCL_TM66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10996; SLC27A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146207 CVCL_TM67 HAP1 SLC27A2 (-) 3 cancer cell line human CVCL_TM67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10996; SLC27A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146208 CVCL_TM48 HAP1 SLC25A40 (-) 3 cancer cell line human CVCL_TM48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29680; SLC25A40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146209 CVCL_TM49 HAP1 SLC25A42 (-) 1 cancer cell line human CVCL_TM49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28380; SLC25A42; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146210 CVCL_1G20 PA195 cancer cell line human CVCL_1G20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.His92fs*2 (c.275delA); Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu330Arg (c.989T>G); ClinVar=VCV001510133; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146211 CVCL_1G23 PA254 cancer cell line human CVCL_1G23 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ala118Val (c.353C>T); ClinVar=VCV001691745; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146212 CVCL_1G24 PA285 cancer cell line human CVCL_1G24 CL:0000010 Sequence variation: Gene deletion; HGNC; 7127; MLH1; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337His (c.1010G>A); ClinVar=VCV000012379; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Instable (MSI-high) (PubMed=22156295) 21146213 CVCL_1G21 PA202 cancer cell line human CVCL_1G21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53fs; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146214 CVCL_1G22 PA215 cancer cell line human CVCL_1G22 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg135Ter (c.403C>T); ClinVar=VCV000024802; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146215 CVCL_1G27 M92-001 cancer cell line human CVCL_1G27 CL:0000010 Female 21146216 CVCL_1G28 UACC-2972 cancer cell line human CVCL_1G28 CL:0000010 21146217 CVCL_1G25 PA333 cancer cell line human CVCL_1G25 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ile435fs; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146218 CVCL_1G26 M91-054 cancer cell line human CVCL_1G26 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21146219 CVCL_1G18 PA167 cancer cell line human CVCL_1G18 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146220 CVCL_1G19 PA182 cancer cell line human CVCL_1G19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=22156295); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (PubMed=22156295); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys101Ter (c.301A>T); Zygosity=Unspecified (PubMed=22156295) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis Unspecified Microsatellite instability: Stable (MSS) (PubMed=22156295) 21146221 CVCL_TM50 HAP1 SLC25A43 (-) 1 cancer cell line human CVCL_TM50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30557; SLC25A43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146222 CVCL_TM53 HAP1 SLC25A46 (-) 1 cancer cell line human CVCL_TM53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25198; SLC25A46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146223 CVCL_TM54 HAP1 SLC25A46 (-) 2 cancer cell line human CVCL_TM54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25198; SLC25A46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146224 CVCL_TM51 HAP1 SLC25A44 (-) 1 cancer cell line human CVCL_TM51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29036; SLC25A44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146225 CVCL_TM52 HAP1 SLC25A45 (-) cancer cell line human CVCL_TM52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27442; SLC25A45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146226 CVCL_TM57 HAP1 SLC25A51 (-) 2 cancer cell line human CVCL_TM57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23323; SLC25A51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146227 CVCL_TM58 HAP1 SLC25A6 (-) cancer cell line human CVCL_TM58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10992; SLC25A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146228 CVCL_TM55 HAP1 SLC25A5 (-) cancer cell line human CVCL_TM55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10991; SLC25A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146229 CVCL_TM56 HAP1 SLC25A51 (-) 1 cancer cell line human CVCL_TM56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23323; SLC25A51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146230 CVCL_KU58 CHO-K1 GALR2 Gq spontaneously immortalized cell line CVCL_KU58 CL:0000010 Transfected with: HGNC; 4133; GALR2 Derived from sampling site: Ovary. Female 21146231 CVCL_L658 HGPS-iPSC#4 induced pluripotent stem cell human CVCL_L658 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146232 CVCL_KU59 CHO-K1 GNRHR Gq spontaneously immortalized cell line CVCL_KU59 CL:0000010 Transfected with: HGNC; 4421; GNRHR Derived from sampling site: Ovary. Female 21146233 CVCL_L659 HGPS-iPSC#5 induced pluripotent stem cell human CVCL_L659 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146234 CVCL_KU56 CHO-K1 FFAR1 Gq spontaneously immortalized cell line CVCL_KU56 CL:0000010 Transfected with: HGNC; 4498; FFAR1 Derived from sampling site: Ovary. Female 21146235 CVCL_L656 HGPS-iPSC#2 induced pluripotent stem cell human CVCL_L656 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146236 CVCL_KU57 CHO-K1 FFAR2 Gq spontaneously immortalized cell line CVCL_KU57 CL:0000010 Transfected with: HGNC; 4501; FFAR2 Derived from sampling site: Ovary. Female 21146237 CVCL_L657 HGPS-iPSC#3 induced pluripotent stem cell human CVCL_L657 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146238 CVCL_KU54 CHO-K1 EDG4 Gq spontaneously immortalized cell line CVCL_KU54 CL:0000010 Transfected with: HGNC; 3168; LPAR2 Derived from sampling site: Ovary. Female 21146239 CVCL_L654 FY-hES-35 embryonic stem cell human CVCL_L654 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21146240 CVCL_KU55 CHO-K1 F2RL1 Gq spontaneously immortalized cell line CVCL_KU55 CL:0000010 Transfected with: HGNC; 3538; F2RL1 Derived from sampling site: Ovary. Female 21146241 CVCL_L655 HGPS-iPSC#1 induced pluripotent stem cell human CVCL_L655 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146242 CVCL_KU52 CHO-K1 CYSLTR2 Gq spontaneously immortalized cell line CVCL_KU52 CL:0000010 Transfected with: HGNC; 18274; CYSLTR2 Derived from sampling site: Ovary. Female 21146243 CVCL_L652 FY-hES-33 embryonic stem cell human CVCL_L652 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Ambiguous 21146244 CVCL_KU53 CHO-K1 EDG3 Gq spontaneously immortalized cell line CVCL_KU53 CL:0000010 Transfected with: HGNC; 3167; S1PR3 Derived from sampling site: Ovary. Female 21146245 CVCL_L653 FY-hES-34 embryonic stem cell human CVCL_L653 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21146246 CVCL_KU50 CHO-K1 BDKRB1 Gq spontaneously immortalized cell line CVCL_KU50 CL:0000010 Transfected with: HGNC; 1029; BDKRB1 Derived from sampling site: Ovary. Female 21146247 CVCL_L650 FY-hES-31 embryonic stem cell human CVCL_L650 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21146248 CVCL_KU51 CHO-K1 BRS3 Gq spontaneously immortalized cell line CVCL_KU51 CL:0000010 Transfected with: HGNC; 1113; BRS3 Derived from sampling site: Ovary. Female 21146249 CVCL_L651 FY-hES-32 embryonic stem cell human CVCL_L651 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21146250 CVCL_U000 CHO-CNR1 spontaneously immortalized cell line CVCL_U000 CL:0000010 Transfected with: HGNC; 2159; CNR1 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21146251 CVCL_U001 CHO-NPY1R spontaneously immortalized cell line CVCL_U001 CL:0000010 Transfected with: HGNC; 7956; NPY1R Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21146252 CVCL_L669 PG2-iPS-2 induced pluripotent stem cell human CVCL_L669 From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21146253 CVCL_KU69 U2OS GRM5 Gq cancer cell line human CVCL_KU69 CL:0000010 Transfected with: HGNC; 4597; GRM5 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21146254 CVCL_L667 PG1-iPS-2 induced pluripotent stem cell human CVCL_L667 From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21146255 CVCL_KU67 U2OS GPR39 Gq cancer cell line human CVCL_KU67 CL:0000010 Transfected with: HGNC; 4496; GPR39 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21146256 CVCL_L668 PG2-iPS-1 induced pluripotent stem cell human CVCL_L668 From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21146257 CVCL_KU68 U2OS GRM1 Gq cancer cell line human CVCL_KU68 CL:0000010 Transfected with: HGNC; 4593; GRM1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21146258 CVCL_L665 PD-iPS2 induced pluripotent stem cell human CVCL_L665 HLA typing: A*11,31; B*35,67 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21146259 CVCL_KU65 RBL-2H3 MRGPRX1 Gq cancer cell line Norway rat CVCL_KU65 CL:0000010 Transfected with: HGNC; 17962; MRGPRX1 Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. 21146260 CVCL_L666 PG1-iPS-1 induced pluripotent stem cell human CVCL_L666 From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: African American; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21146261 CVCL_KU66 U2OS CASR Gq cancer cell line human CVCL_KU66 CL:0000010 Transfected with: HGNC; 1514; CASR Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21146262 CVCL_KU63 HEK 293 HTR2B Gq transformed cell line human CVCL_KU63 CL:0000010 Transfected with: HGNC; 5294; HTR2B Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21146263 CVCL_L663 OPCA-iPSC3 induced pluripotent stem cell human CVCL_L663 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[45] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Unspecified (PubMed=22301348) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21146264 CVCL_L664 PD-iPS1 [Human iPSC China] induced pluripotent stem cell human CVCL_L664 HLA typing: A*11,31; B*35,67 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21146265 CVCL_KU64 RBL-2H3 ADORA2A Gq cancer cell line Norway rat CVCL_KU64 CL:0000010 Transfected with: HGNC; 263; ADORA2A Derived from sampling site: Peripheral blood; Breed/subspecies: Wistar. 21146266 CVCL_KU61 CHO-K1 PTGER1 Gq spontaneously immortalized cell line CVCL_KU61 CL:0000010 Transfected with: HGNC; 9593; PTGER1 Derived from sampling site: Ovary. Female 21146267 CVCL_L661 OPCA-iPSC1 induced pluripotent stem cell human CVCL_L661 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[45] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Unspecified (PubMed=22301348) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21146268 CVCL_KU62 CHO-K1 PTGFR Gq spontaneously immortalized cell line CVCL_KU62 CL:0000010 Transfected with: HGNC; 9600; PTGFR Derived from sampling site: Ovary. Female 21146269 CVCL_L662 OPCA-iPSC2 induced pluripotent stem cell human CVCL_L662 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10560; ATXN7; Repeat_expansion; CAG[45] (g.53130CAG[(38_130)]); ClinVar=VCV000562100; Zygosity=Unspecified (PubMed=22301348) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21146270 CVCL_KU60 CHO-K1 GPR17 Gq spontaneously immortalized cell line CVCL_KU60 CL:0000010 Transfected with: HGNC; 4471; GPR17 Derived from sampling site: Ovary. Female 21146271 CVCL_L660 HGPS-iPSC#6 induced pluripotent stem cell human CVCL_L660 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21146272 CVCL_L638 dRLN-61 transformed cell line Norway rat CVCL_L638 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21146273 CVCL_KU38 Jurkat Tet-Off cancer cell line human CVCL_KU38 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: Clontech; Catalog number 630909/631135 Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21146274 CVCL_L639 3'-mRLN-30 transformed cell line Norway rat CVCL_L639 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21146275 CVCL_KU39 HEK 293 Tet-Off Advanced transformed cell line human CVCL_KU39 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an advanced tetracycline transactivator (tTA2(S)-M2) protein, a fusion of a mutated E.coli tetR with the activation domain of HSV-1 VP16 21146276 CVCL_L636 dRLa-74 transformed cell line Norway rat CVCL_L636 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21146277 CVCL_KU36 HepG2 Tet-Off Advanced cancer cell line human CVCL_KU36 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with an advanced tetracycline transactivator (tTA2(S)-M2) protein, a fusion of a mutated E.coli tetR with the activation domain of HSV-1 VP16 21146278 CVCL_L637 dRLN-60 transformed cell line Norway rat CVCL_L637 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21146279 CVCL_KU37 MCF7 Tet-Off advanced cancer cell line human CVCL_KU37 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with an advanced tetracycline transactivator (tTA2(S)-M2) protein, a fusion of a mutated E.coli tetR with the activation domain of HSV-1 VP16 21146280 CVCL_L634 AG13926 finite cell line human CVCL_L634 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(16;19)(p11;q13) [96%]; 46,XY,t(4;15)(q13;p11) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG13926) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146281 CVCL_KU34 Namalwa/21V cancer cell line human CVCL_KU34 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line). Population: African; Kenyan; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR) Female 21146282 CVCL_KU35 Jurkat Tet-On cancer cell line human CVCL_KU35 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: Clontech; Catalog number 630915/631140 Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146283 CVCL_L635 R15E6 hybridoma house mouse CVCL_L635 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P23467; Human PTPRB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7580 21146284 CVCL_L632 AG12788 finite cell line human CVCL_L632 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146285 CVCL_KU32 SU-DHL-4/12V cancer cell line human CVCL_KU32 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (from parent cell line); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr666Asn (c.1996T>A) (Y661N); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Peritoneal effusion. Male 21146286 CVCL_L633 AG11799 finite cell line human CVCL_L633 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG11799) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146287 CVCL_KU33 Namalwa/MDR1 cancer cell line human CVCL_KU33 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 40; ABCB1. Population: African; Kenyan Female 21146288 CVCL_L630 AG07135 finite cell line human CVCL_L630 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,13s+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146289 CVCL_KU30 Jurkat KZ142 clone #24 cancer cell line human CVCL_KU30 From: ZymoGenetics, Inc.; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 18153; TNFRSF13B; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expression of TNFRSF13B/TACI is control of the CMV promoter; Characteristics: Expression of luciferase is under the control of the NF-KappaB/AP-1 promoter 21146290 CVCL_L631 AG07143 finite cell line human CVCL_L631 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07143; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146291 CVCL_KU31 Raji/18V cancer cell line human CVCL_KU31 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21146292 CVCL_KU49 CHO-K1 ADRA1A Gq spontaneously immortalized cell line CVCL_KU49 CL:0000010 Transfected with: HGNC; 277; ADRA1A Derived from sampling site: Ovary. Female 21146293 CVCL_L649 FY-hES-30 embryonic stem cell human CVCL_L649 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Male 21146294 CVCL_L647 FY-hES-28 embryonic stem cell human CVCL_L647 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21146295 CVCL_KU47 Saos-2 Tet-Off cancer cell line human CVCL_KU47 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Bone. Discontinued: Clontech; Catalog number 630911/631136 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21146296 CVCL_KU48 1321N1 P2RY1 Gq cancer cell line human CVCL_KU48 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8539; P2RY1 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21146297 CVCL_L648 FY-hES-29 embryonic stem cell human CVCL_L648 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21146298 CVCL_L645 CSB-iPSC clone 3 induced pluripotent stem cell human CVCL_L645 From: University of California, San Diego; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (PubMed=22661500) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146299 CVCL_KU45 MCF7 Tet-On Advanced cancer cell line human CVCL_KU45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 632108/631153 Female Characteristics: Transfected with an advanced reverse tetracycline-controlled transactivator (rtTA2(S)-M2), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146300 CVCL_L646 FY-hES-27 embryonic stem cell human CVCL_L646 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China. CL:0000010 Female 21146301 CVCL_KU46 MEF-T7-SRp20 spontaneously immortalized cell line house mouse CVCL_KU46 CL:0000010 Transfected with: HGNC; 10785; SRSF3 (T7-tagged); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21146302 CVCL_L643 CSB-iPSC clone 1 induced pluripotent stem cell human CVCL_L643 From: University of California, San Diego; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (PubMed=22661500) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146303 CVCL_KU43 HEK 293 Tet-On Advanced transformed cell line human CVCL_KU43 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Clontech; Catalog number 630931/631149 Female Characteristics: Transfected with an advanced reverse tetracycline-controlled transactivator (rtTA2(S)-M2), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146304 CVCL_L644 CSB-iPSC clone 2 induced pluripotent stem cell human CVCL_L644 From: University of California, San Diego; San Diego; USA CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (PubMed=22661500) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146305 CVCL_KU44 HeLa S3 Tet-Off cancer cell line human CVCL_KU44 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Clontech; Catalog number 630902 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21146306 CVCL_L641 ALS-iPS1 induced pluripotent stem cell human CVCL_L641 HLA typing: A*02,31; B*75,48 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21146307 CVCL_KU41 HeLa Tet-On Advanced cancer cell line human CVCL_KU41 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Clontech; Catalog number 631555/632110 Female Characteristics: Transfected with an advanced reverse tetracycline-controlled transactivator (rtTA2(S)-M2), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146308 CVCL_L642 ALS-iPS2 induced pluripotent stem cell human CVCL_L642 HLA typing: A*02,31; B*75,48 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21146309 CVCL_KU42 CHO-K1 Tet-On spontaneously immortalized cell line CVCL_KU42 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Ovary. Discontinued: Clontech; Catalog number 630917/631142 Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21146310 CVCL_L640 3'-mRLN-31 transformed cell line Norway rat CVCL_L640 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21146311 CVCL_KU40 T-47D Tet-Off cancer cell line human CVCL_KU40 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 630924/631145 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21146312 CVCL_L618 AG03260 transformed cell line human CVCL_L618 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146313 CVCL_KU18 HeLa SilenciX USP19 cancer cell line human CVCL_KU18 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12617; USP19 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146314 CVCL_L619 AG03262 transformed cell line human CVCL_L619 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146315 CVCL_KU19 HeLa SilenciX USP7 cancer cell line human CVCL_KU19 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12630; USP7 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146316 CVCL_L616 AG03199 finite cell line human CVCL_L616 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from autologous cell line AG03259) Population: Caucasian; Derived from sampling site: Hip; skin Cell type=Fibroblast.. Female 21146317 CVCL_KU16 HeLa SilenciX USP11 cancer cell line human CVCL_KU16 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12609; USP11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146318 CVCL_L617 AG03259 transformed cell line human CVCL_L617 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146319 CVCL_KU17 HeLa SilenciX USP14 cancer cell line human CVCL_KU17 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12612; USP14 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146320 CVCL_L614 AG03198 finite cell line human CVCL_L614 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from autologous cell line AG03259) Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Female 21146321 CVCL_KU14 HeLa SilenciX TRIO cancer cell line human CVCL_KU14 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12303; TRIO Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146322 CVCL_L615 AG10750 finite cell line human CVCL_L615 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG10750; probable Male 21146323 CVCL_KU15 HeLa SilenciX TXNRD2 cancer cell line human CVCL_KU15 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 18155; TXNRD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146324 CVCL_L612 AG03508 transformed cell line human CVCL_L612 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146325 CVCL_KU12 HeLa SilenciX TP53BP1 cancer cell line human CVCL_KU12 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11999; TP53BP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146326 CVCL_L613 AG06917 finite cell line human CVCL_L613 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell; PubMed=12714972) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21146327 CVCL_KU13 HeLa SilenciX TRAILR2 cancer cell line human CVCL_KU13 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11905; TNFRSF10B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146328 CVCL_L610 AG03513 finite cell line human CVCL_L610 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (from autologous cell line AG03506) Population: Mexican; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21146329 CVCL_KU10 HeLa SilenciX TMSB4X cancer cell line human CVCL_KU10 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11881; TMSB4X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146330 CVCL_L611 AG03507 transformed cell line human CVCL_L611 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146331 CVCL_KU11 HeLa SilenciX TNFR1 cancer cell line human CVCL_KU11 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11916; TNFRSF1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146332 CVCL_L629 AG11488 finite cell line human CVCL_L629 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG11488) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146333 CVCL_KU29 HeLa SilenciX XRCC4 cancer cell line human CVCL_KU29 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12831; XRCC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146334 CVCL_L627 AG11556 finite cell line human CVCL_L627 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [80%]; 46,XY,t(1;3) [16%]; 46,XY,t(7;14) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 35 PDL (Coriell=AG11556) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146335 CVCL_KU27 HeLa SilenciX XPF cancer cell line human CVCL_KU27 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3436; ERCC4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146336 CVCL_L628 AG10548 finite cell line human CVCL_L628 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG10548; probable Male 21146337 CVCL_KU28 HeLa SilenciX XRCC1 cancer cell line human CVCL_KU28 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12828; XRCC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146338 CVCL_L625 AG08433 finite cell line human CVCL_L625 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 34 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146339 CVCL_KU25 HeLa SilenciX XPA cancer cell line human CVCL_KU25 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12814; XPA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146340 CVCL_L626 AG04462 finite cell line human CVCL_L626 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146341 CVCL_KU26 HeLa SilenciX XPC cancer cell line human CVCL_KU26 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12816; XPC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146342 CVCL_L623 AG04059 finite cell line human CVCL_L623 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146343 CVCL_KU23 HeLa SilenciX XIAP cancer cell line human CVCL_KU23 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 592; XIAP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146344 CVCL_L624 AG04064 finite cell line human CVCL_L624 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 40 PDL (PubMed=7307581); 32 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146345 CVCL_KU24 HeLa SilenciX XLF cancer cell line human CVCL_KU24 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 25737; NHEJ1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146346 CVCL_L621 AG03257 finite cell line human CVCL_L621 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21146347 CVCL_KU21 HeLa SilenciX WDR8 cancer cell line human CVCL_KU21 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12759; WRAP73 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146348 CVCL_L622 AG03258 finite cell line human CVCL_L622 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146349 CVCL_KU22 HeLa SilenciX WIP1 cancer cell line human CVCL_KU22 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9277; PPM1D Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146350 CVCL_L620 AG03263 transformed cell line human CVCL_L620 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146351 CVCL_KU20 HeLa SilenciX USP9X cancer cell line human CVCL_KU20 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 12632; USP9X Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146352 CVCL_L609 AG03506 transformed cell line human CVCL_L609 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146353 CVCL_KU09 HeLa SilenciX THTPA cancer cell line human CVCL_KU09 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 18987; THTPA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146354 CVCL_L607 AG09602 finite cell line human CVCL_L607 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 42-48 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146355 CVCL_KU07 HeLa SilenciX SSX2IP cancer cell line human CVCL_KU07 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 16509; SSX2IP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146356 CVCL_L608 AG03505 transformed cell line human CVCL_L608 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146357 CVCL_KU08 HeLa SilenciX STAT1 cancer cell line human CVCL_KU08 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11362; STAT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146358 CVCL_L605 AG05247 finite cell line human CVCL_L605 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [45]; 46,XX,t(2;6)(2pter->2q23::6q21->6qter;6pter->6q21::2q23->2qter) [3]; 46,XX,t(7;18)(7qter->7p22::18q21->18qter;18pter->18q21::7p22->7pter) [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 45 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146359 CVCL_KU05 HeLa SilenciX SOD2 cancer cell line human CVCL_KU05 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11180; SOD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146360 CVCL_L606 AG06299 finite cell line human CVCL_L606 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21146361 CVCL_KU06 HeLa SilenciX SORCIN cancer cell line human CVCL_KU06 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11292; SRI Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146362 CVCL_L603 AG03504 transformed cell line human CVCL_L603 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146363 CVCL_KU03 HeLa SilenciX SIRT1 cancer cell line human CVCL_KU03 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 14929; SIRT1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146364 CVCL_L604 AG03512 finite cell line human CVCL_L604 CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146365 CVCL_KU04 HeLa SilenciX SNAPIN cancer cell line human CVCL_KU04 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 17145; SNAPIN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146366 CVCL_L601 B407 transformed cell line human CVCL_L601 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~32 hours (PubMed=10848782) 21146367 CVCL_KU01 HeLa SilenciX RHOQ cancer cell line human CVCL_KU01 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 17736; RHOQ Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146368 CVCL_KU02 HeLa SilenciX Septin 9 cancer cell line human CVCL_KU02 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7323; SEPTIN9 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146369 CVCL_L602 MCHR2-SHG-44 cancer cell line human CVCL_L602 CL:0000010 Transfected with: HGNC; 20867; MCHR2 Population: Chinese; Derived from metastatic site: Lymph node. Female 21146370 CVCL_KU00 HeLa SilenciX RB cancer cell line human CVCL_KU00 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9884; RB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146371 CVCL_L600 LS129-3C3-E3-1 hybridoma house mouse CVCL_L600 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P51686; Human CCR9/CDw199. Doubling time: 18 hours (ATCC=HB-12653) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12653 21146372 CVCL_TN58 HAP1 SLC39A6 (-) cancer cell line human CVCL_TN58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18607; SLC39A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146373 CVCL_TN59 HAP1 SLC39A8 (-) 1 cancer cell line human CVCL_TN59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20862; SLC39A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146374 CVCL_1H11 K#1 50K transformed cell line human CVCL_1H11 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Has potent HIV-1-inhibitory activity Doubling time: 2 days (Patent=US6358511) 21146375 CVCL_1H12 Caf 10 transformed cell line human CVCL_1H12 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Donor information: Established from a HIV-1 infected child with rapid disease progression; Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Doubling time: 3 days (Patent=US6358511) 21146376 CVCL_1H10 3T3-msCD40L spontaneously immortalized cell line house mouse CVCL_1H10 CL:0000010 Transfected with: MGI; MGI:88337; Cd40lg Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21146377 CVCL_1H15 HeLa-env-IIIB cancer cell line human CVCL_1H15 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146378 CVCL_1H16 HeLa-env-Mal cancer cell line human CVCL_1H16 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146379 CVCL_1H13 HeLa-tat-III/LTR/d1EGFP cancer cell line human CVCL_1H13 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146380 CVCL_1H14 HeLa-env-Eli cancer cell line human CVCL_1H14 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146381 CVCL_1H08 J-Jhan cancer cell line human CVCL_1H08 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146382 CVCL_1H09 J-Jhan/U1102 cancer cell line human CVCL_1H09 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146383 CVCL_1H06 Clone HXBdeltaPdeltaEnv-T1RevEnv cancer cell line human CVCL_1H06 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Retrovirus packaging cell line 21146384 CVCL_1H07 M8166 transformed cell line human CVCL_1H07 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood. Male 21146385 CVCL_TN60 HAP1 SLC39A8 (-) 2 cancer cell line human CVCL_TN60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20862; SLC39A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146386 CVCL_TN63 HAP1 SLC39A9 (-) 2 cancer cell line human CVCL_TN63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20182; SLC39A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146387 CVCL_TN64 HAP1 SLC40A1 (-) 1 cancer cell line human CVCL_TN64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10909; SLC40A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146388 CVCL_TN61 HAP1 SLC39A8 (-) 3 cancer cell line human CVCL_TN61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20862; SLC39A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146389 CVCL_TN62 HAP1 SLC39A9 (-) 1 cancer cell line human CVCL_TN62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20182; SLC39A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146390 CVCL_TN67 HAP1 SLC41A2 (-) cancer cell line human CVCL_TN67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31045; SLC41A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146391 CVCL_TN68 HAP1 SLC41A3 (-) 1 cancer cell line human CVCL_TN68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31046; SLC41A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146392 CVCL_TN65 HAP1 SLC40A1 (-) 2 cancer cell line human CVCL_TN65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10909; SLC40A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146393 CVCL_TN66 HAP1 SLC41A1 (-) cancer cell line human CVCL_TN66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19429; SLC41A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146394 CVCL_TN49 HAP1 SLC38A9 (-) 2 cancer cell line human CVCL_TN49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26907; SLC38A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146395 CVCL_TN47 HAP1 SLC38A7 (-) cancer cell line human CVCL_TN47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25582; SLC38A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146396 CVCL_TN48 HAP1 SLC38A9 (-) 1 cancer cell line human CVCL_TN48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26907; SLC38A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146397 CVCL_1H22 BH24 transformed cell line CVCL_1H22 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood; Breed/subspecies: New Zealand white. Female Virology: HTLV-1 producing cell line 21146398 CVCL_1H23 PPIA-/- Jurkat cancer cell line human CVCL_1H23 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9253; PPIA; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21146399 CVCL_1H20 293T-CEP4SIVtat transformed cell line human CVCL_1H20 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21146400 CVCL_1H21 P4 MAGI CCR5+ cancer cell line human CVCL_1H21 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146401 CVCL_1H26 HeLa-tat-III/CMV/d1EGFP cancer cell line human CVCL_1H26 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146402 CVCL_1H27 CHO NL4-3 gp120 spontaneously immortalized cell line CVCL_1H27 CL:0000010 Transfected with: UniProtKB; Q72502; HIV-1 isolate NL4-3 env (gp120); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21146403 CVCL_1H24 C82/TK transformed cell line human CVCL_1H24 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Unspecified 21146404 CVCL_1H25 HeLa-tat-III cancer cell line human CVCL_1H25 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146405 CVCL_1H19 HOS-CCR5 cancer cell line human CVCL_1H19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21146406 CVCL_1H17 HOS-pBABE-puro cancer cell line human CVCL_1H17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21146407 CVCL_1H18 HOS-CXCR4 cancer cell line human CVCL_1H18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21146408 CVCL_TN52 HAP1 SLC39A11 (-) cancer cell line human CVCL_TN52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14463; SLC39A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146409 CVCL_TN53 HAP1 SLC39A13 (-) 1 cancer cell line human CVCL_TN53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20859; SLC39A13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146410 CVCL_TN50 HAP1 SLC39A1 (-) 1 cancer cell line human CVCL_TN50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12876; SLC39A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146411 CVCL_TN51 HAP1 SLC39A1 (-) 2 cancer cell line human CVCL_TN51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12876; SLC39A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146412 CVCL_TN56 HAP1 SLC39A3 (-) 1 cancer cell line human CVCL_TN56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17128; SLC39A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146413 CVCL_TN57 HAP1 SLC39A3 (-) 2 cancer cell line human CVCL_TN57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17128; SLC39A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146414 CVCL_TN54 HAP1 SLC39A14 (-) 1 cancer cell line human CVCL_TN54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20858; SLC39A14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146415 CVCL_TN55 HAP1 SLC39A14 (-) 2 cancer cell line human CVCL_TN55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20858; SLC39A14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146416 CVCL_TN38 HAP1 SLC37A4 (-) 2 cancer cell line human CVCL_TN38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4061; SLC37A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146417 CVCL_TN39 HAP1 SLC38A1 (-) cancer cell line human CVCL_TN39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13447; SLC38A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146418 CVCL_TN36 HAP1 SLC37A1 (-) 1 cancer cell line human CVCL_TN36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11024; SLC37A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146419 CVCL_TN37 HAP1 SLC37A4 (-) 1 cancer cell line human CVCL_TN37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4061; SLC37A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146420 CVCL_KT99 HeLa SilenciX Rad54B cancer cell line human CVCL_KT99 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 17228; RAD54B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146421 CVCL_L599 LS125-2D4-11-10-1 hybridoma house mouse CVCL_L599 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P32246; Human CCR1/CD191. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12644 21146422 CVCL_KT97 HeLa SilenciX Rad50 cancer cell line human CVCL_KT97 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9816; RAD50 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146423 CVCL_L597 IgG-11H4 hybridoma house mouse CVCL_L597 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q07954; Human LRP1. 21146424 CVCL_KT98 HeLa SilenciX Rad54A cancer cell line human CVCL_KT98 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9826; RAD54L Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146425 CVCL_L598 IgG-9D5 hybridoma house mouse CVCL_L598 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P97260; Cricetulus griseus Scap. 21146426 CVCL_KT95 HeLa SilenciX PRDX1 cancer cell line human CVCL_KT95 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9352; PRDX1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146427 CVCL_L595 Mab 96 hybridoma house mouse CVCL_L595 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9763 21146428 CVCL_KT96 HeLa SilenciX PRDX2 cancer cell line human CVCL_KT96 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9353; PRDX2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146429 CVCL_L596 mAb BB7 hybridoma house mouse CVCL_L596 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P26599; Human PTBP1. 21146430 CVCL_TN41 HAP1 SLC38A10 (-) 2 cancer cell line human CVCL_TN41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28237; SLC38A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146431 CVCL_KT93 HeLa SilenciX PKCalpha cancer cell line human CVCL_KT93 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9393; PRKCA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146432 CVCL_L593 Mab 543 hybridoma house mouse CVCL_L593 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P17927; Human CR1/CD35. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8592 21146433 CVCL_TN42 HAP1 SLC38A2 (-) 1 cancer cell line human CVCL_TN42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13448; SLC38A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146434 CVCL_KT94 HeLa SilenciX PolH cancer cell line human CVCL_KT94 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9181; POLH Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146435 CVCL_L594 MAb 951-5-1 hybridoma house mouse CVCL_L594 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12684 21146436 CVCL_KT91 HeLa SilenciX PCNA cancer cell line human CVCL_KT91 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 8729; PCNA Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146437 CVCL_L591 Mab 2B5 hybridoma house mouse CVCL_L591 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P18428; Human LBP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11491 21146438 CVCL_TN40 HAP1 SLC38A10 (-) 1 cancer cell line human CVCL_TN40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28237; SLC38A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146439 CVCL_KT92 HeLa SilenciX PIK3CD cancer cell line human CVCL_KT92 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 8977; PIK3CD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146440 CVCL_L592 MAb 5.2 hybridoma house mouse CVCL_L592 CL:0000010 Monoclonal antibody isotype: IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9148 21146441 CVCL_TN45 HAP1 SLC38A5 (-) 2 cancer cell line human CVCL_TN45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18070; SLC38A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146442 CVCL_TN46 HAP1 SLC38A6 (-) cancer cell line human CVCL_TN46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19863; SLC38A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146443 CVCL_KT90 HeLa SilenciX PARP2 cancer cell line human CVCL_KT90 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 272; PARP2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146444 CVCL_L590 MAb 26-7-5 hybridoma house mouse CVCL_L590 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12681 21146445 CVCL_TN43 HAP1 SLC38A2 (-) 2 cancer cell line human CVCL_TN43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13448; SLC38A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146446 CVCL_TN44 HAP1 SLC38A5 (-) 1 cancer cell line human CVCL_TN44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18070; SLC38A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146447 CVCL_TN27 HAP1 SLC35F2 (-) 1 cancer cell line human CVCL_TN27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23615; SLC35F2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146448 CVCL_TN28 HAP1 SLC35F2 (-) 2 cancer cell line human CVCL_TN28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23615; SLC35F2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146449 CVCL_TN25 HAP1 SLC35F1 (-) 1 cancer cell line human CVCL_TN25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21483; SLC35F1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146450 CVCL_TN26 HAP1 SLC35F1 (-) 2 cancer cell line human CVCL_TN26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21483; SLC35F1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146451 CVCL_TN29 HAP1 SLC35F5 (-) 1 cancer cell line human CVCL_TN29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23617; SLC35F5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146452 CVCL_1H00 WAF spontaneously immortalized cell line CVCL_1H00 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC005 21146453 CVCL_1H01 WAG spontaneously immortalized cell line CVCL_1H01 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC048 21146454 CVCL_1H04 LuSIV hybrid cell line human CVCL_1H04 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). 21146455 CVCL_1H05 Clone 69T1RevEnv cancer cell line human CVCL_1H05 CL:0000010 Transfected with: UniProtKB; P03377; HIV-1 isolate BRU/LAI env; Transfected with: UniProtKB; P04620; HIV-1 isolate BRU/LAI rev; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: HIV-1 Rev and Env proteins are induced by removing tetracycline from the culture medium 21146456 CVCL_1H02 WAM spontaneously immortalized cell line CVCL_1H02 CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC047 21146457 CVCL_1H03 CCF [Cyprinus fin India] spontaneously immortalized cell line CVCL_1H03 CL:0000010 Derived from sampling site: Fin Cell type=Epithelial cell.. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC004 21146458 CVCL_TN30 HAP1 SLC35G1 (-) cancer cell line human CVCL_TN30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26607; SLC35G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146459 CVCL_TN31 HAP1 SLC35G2 (-) cancer cell line human CVCL_TN31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28480; SLC35G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146460 CVCL_TN34 HAP1 SLC36A4 (-) 2 cancer cell line human CVCL_TN34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19660; SLC36A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146461 CVCL_TN35 HAP1 SLC36A4 (-) 3 cancer cell line human CVCL_TN35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19660; SLC36A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146462 CVCL_TN32 HAP1 SLC36A1 (-) 1 cancer cell line human CVCL_TN32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18761; SLC36A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146463 CVCL_TN33 HAP1 SLC36A4 (-) 1 cancer cell line human CVCL_TN33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19660; SLC36A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146464 CVCL_TN16 HAP1 SLC35D1 (-) 1 cancer cell line human CVCL_TN16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20800; SLC35D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146465 CVCL_TN17 HAP1 SLC35D1 (-) 2 cancer cell line human CVCL_TN17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20800; SLC35D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146466 CVCL_TN14 HAP1 SLC35C1 (-) 1 cancer cell line human CVCL_TN14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20197; SLC35C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146467 CVCL_TN15 HAP1 SLC35C2 (-) 1 cancer cell line human CVCL_TN15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17117; SLC35C2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146468 CVCL_TN18 HAP1 SLC35D2 (-) 1 cancer cell line human CVCL_TN18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20799; SLC35D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146469 CVCL_TN19 HAP1 SLC35E1 (-) 1 cancer cell line human CVCL_TN19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20803; SLC35E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146470 CVCL_KT79 HeLa SilenciX NBS1 cancer cell line human CVCL_KT79 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7652; NBN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146471 CVCL_L579 IL-A12 hybridoma house mouse CVCL_L579 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; I0J0K0; Bovine CD4. 21146472 CVCL_KT77 HeLa SilenciX MSH2 cancer cell line human CVCL_KT77 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7325; MSH2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146473 CVCL_L577 IL-A71 hybridoma house mouse CVCL_L577 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine IgA. 21146474 CVCL_KT78 HeLa SilenciX MTERFD2 cancer cell line human CVCL_KT78 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 28785; MTERF4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146475 CVCL_L578 IL-A88 hybridoma house mouse CVCL_L578 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine MHC class I. 21146476 CVCL_KT75 HeLa SilenciX MLH1 cancer cell line human CVCL_KT75 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7127; MLH1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146477 CVCL_L575 IL-A59 hybridoma house mouse CVCL_L575 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine Ig light chains. 21146478 CVCL_KT76 HeLa SilenciX MRE11 cancer cell line human CVCL_KT76 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7230; MRE11 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146479 CVCL_L576 IL-A60 hybridoma house mouse CVCL_L576 CL:0000010 Discontinued: ECACC; 91072529; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine IgG1 21146480 CVCL_KT73 HeLa SilenciX MAPK1 cancer cell line human CVCL_KT73 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 6871; MAPK1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146481 CVCL_L573 IL-A57 hybridoma house mouse CVCL_L573 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; F1MU15; Bovine CD6. 21146482 CVCL_KT74 HeLa SilenciX MCU cancer cell line human CVCL_KT74 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 23526; MCU Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146483 CVCL_L574 IL-A58 hybridoma house mouse CVCL_L574 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine Ig light chains. 21146484 CVCL_KT71 HeLa SilenciX LigIII cancer cell line human CVCL_KT71 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 6600; LIG3 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146485 CVCL_L571 IL-A46 hybridoma house mouse CVCL_L571 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Bovine myeloid cells. 21146486 CVCL_TN20 HAP1 SLC35E1 (-) 2 cancer cell line human CVCL_TN20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20803; SLC35E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146487 CVCL_KT72 HeLa SilenciX LigIV cancer cell line human CVCL_KT72 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 6601; LIG4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146488 CVCL_L572 IL-A50 hybridoma house mouse CVCL_L572 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine IgM (polymorphic determinant). 21146489 CVCL_KT70 HeLa SilenciX LigI cancer cell line human CVCL_KT70 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 6598; LIG1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146490 CVCL_L570 IL-A43 hybridoma house mouse CVCL_L570 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q148M9; Bovine CD2. 21146491 CVCL_TN23 HAP1 SLC35E3 (-) 1 cancer cell line human CVCL_TN23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20864; SLC35E3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146492 CVCL_TN24 HAP1 SLC35E4 (-) 1 cancer cell line human CVCL_TN24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17058; SLC35E4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146493 CVCL_TN21 HAP1 SLC35E2B (-) 1 cancer cell line human CVCL_TN21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33941; SLC35E2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146494 CVCL_TN22 HAP1 SLC35E2B (-) 2 cancer cell line human CVCL_TN22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33941; SLC35E2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146495 CVCL_TN05 HAP1 SLC35A3 (-) 1 cancer cell line human CVCL_TN05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11023; SLC35A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146496 CVCL_TN06 HAP1 SLC35A3 (-) 2 cancer cell line human CVCL_TN06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11023; SLC35A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146497 CVCL_TN03 HAP1 SLC35A1 (-) 1 cancer cell line human CVCL_TN03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11021; SLC35A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146498 CVCL_TN04 HAP1 SLC35A1 (-) 2 cancer cell line human CVCL_TN04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11021; SLC35A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146499 CVCL_TN09 HAP1 SLC35A5 (-) 2 cancer cell line human CVCL_TN09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20792; SLC35A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146500 CVCL_TN07 HAP1 SLC35A4 (-) 1 cancer cell line human CVCL_TN07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20753; SLC35A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146501 CVCL_TN08 HAP1 SLC35A5 (-) 1 cancer cell line human CVCL_TN08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20792; SLC35A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146502 CVCL_KT88 HeLa SilenciX PARG cancer cell line human CVCL_KT88 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 8605; PARG Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146503 CVCL_L588 mAb 24-1 hybridoma house mouse CVCL_L588 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P13569; Human CFTR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11947 21146504 CVCL_KT89 HeLa SilenciX PARP1 cancer cell line human CVCL_KT89 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 270; PARP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146505 CVCL_L589 mAb 24-2 hybridoma house mouse CVCL_L589 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13569; Human CFTR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11946 21146506 CVCL_KT86 HeLa SilenciX p21 cancer cell line human CVCL_KT86 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 1784; CDKN1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146507 CVCL_L586 MAb 1812-4-8 hybridoma house mouse CVCL_L586 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05177; Human CYP1A2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12683 21146508 CVCL_KT87 HeLa SilenciX p53 cancer cell line human CVCL_KT87 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 11998; TP53 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146509 CVCL_L587 Mab 1E8 hybridoma house mouse CVCL_L587 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18428; Human LBP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11490 21146510 CVCL_KT84 HeLa SilenciX NUDCD1 cancer cell line human CVCL_KT84 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 24306; NUDCD1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146511 CVCL_L584 mAb 13-2 hybridoma house mouse CVCL_L584 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13569; Human CFTR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10566 21146512 CVCL_KT85 HeLa SilenciX Ogg1 cancer cell line human CVCL_KT85 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 8125; OGG1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146513 CVCL_L585 MAb 151-45-4 hybridoma house mouse CVCL_L585 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11509; Human CYP2A6. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12682 21146514 CVCL_KT82 HeLa SilenciX NF1 cancer cell line human CVCL_KT82 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7765; NF1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146515 CVCL_L582 Mab 126 hybridoma house mouse CVCL_L582 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8568 21146516 CVCL_KT83 HeLa SilenciX NRF2 cancer cell line human CVCL_KT83 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7782; NFE2L2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146517 CVCL_L583 mAb 13-1 hybridoma house mouse CVCL_L583 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13569; Human CFTR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10565 21146518 CVCL_L580 anti-130-kDa Mesothelial-Ciliated Cells hybridoma house mouse CVCL_L580 CL:0000010 Monoclonal antibody isotype: IgM, kappa. 21146519 CVCL_KT80 HeLa SilenciX NCL cancer cell line human CVCL_KT80 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 7667; NCL Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146520 CVCL_KT81 HeLa SilenciX NEIL1 cancer cell line human CVCL_KT81 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 18448; NEIL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146521 CVCL_L581 Mab 108 hybridoma house mouse CVCL_L581 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9764 21146522 CVCL_TN12 HAP1 SLC35B4 (-) 1 cancer cell line human CVCL_TN12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20584; SLC35B4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146523 CVCL_TN13 HAP1 SLC35B4 (-) 2 cancer cell line human CVCL_TN13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20584; SLC35B4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146524 CVCL_TN10 HAP1 SLC35B2 (-) 1 cancer cell line human CVCL_TN10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16872; SLC35B2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146525 CVCL_TN11 HAP1 SLC35B3 (-) 1 cancer cell line human CVCL_TN11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21601; SLC35B3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146526 CVCL_L559 AW-EBV-LCL transformed cell line human CVCL_L559 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146527 CVCL_KT59 HeLa SilenciX GPS1 cancer cell line human CVCL_KT59 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4549; GPS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146528 CVCL_KT57 HeLa SilenciX FEN1 cancer cell line human CVCL_KT57 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3650; FEN1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146529 CVCL_L557 OTCD1TKB finite cell line human CVCL_L557 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146530 CVCL_L558 AT-PDH1TKB finite cell line human CVCL_L558 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146531 CVCL_KT58 HeLa SilenciX GNAQ cancer cell line human CVCL_KT58 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4390; GNAQ Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146532 CVCL_KT55 HeLa SilenciX FADD cancer cell line human CVCL_KT55 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3573; FADD Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146533 CVCL_L555 LY-A/hCERT spontaneously immortalized cell line CVCL_L555 CL:0000010 Transfected with: HGNC; 2205; CERT1 Derived from sampling site: Ovary. Female 21146534 CVCL_KT56 HeLa SilenciX FancD2 cancer cell line human CVCL_KT56 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3585; FANCD2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146535 CVCL_L556 PWS-Yamaguchi finite cell line human CVCL_L556 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 32 PDL (PubMed=17395773) 21146536 CVCL_KT53 HeLa SilenciX ERCC1 cancer cell line human CVCL_KT53 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3433; ERCC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146537 CVCL_L553 HyLDH-YK-2 hybridoma house mouse CVCL_L553 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13491; Rabbit LDHA. Group: Serum/protein free medium cell line 21146538 CVCL_KT54 HeLa SilenciX Exportin 5 cancer cell line human CVCL_KT54 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 17675; XPO5 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146539 CVCL_L554 HSNB cancer cell line human CVCL_L554 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Male Doubling time: ~50 hours (PubMed=2486666) 21146540 CVCL_KT51 HeLa SilenciX DIABLO cancer cell line human CVCL_KT51 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 21528; DIABLO Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146541 CVCL_L551 HyGPD-YK-1-1 hybridoma house mouse CVCL_L551 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P46406; Rabbit GAPDH. Group: Serum/protein free medium cell line 21146542 CVCL_KT52 HeLa SilenciX DNA-PKcs cancer cell line human CVCL_KT52 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9413; PRKDC Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146543 CVCL_L552 HyLDH-YK-1 hybridoma house mouse CVCL_L552 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13491; Rabbit LDHA. Group: Serum/protein free medium cell line 21146544 CVCL_L550 DA6.231 hybridoma house mouse CVCL_L550 CL:0000010 Monoclonal antibody isotype: IgG1. 21146545 CVCL_KT50 HeLa SilenciX DDB2 cancer cell line human CVCL_KT50 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 2718; DDB2 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146546 CVCL_TN01 HAP1 SLC34A2 (-) 1 cancer cell line human CVCL_TN01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11020; SLC34A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146547 CVCL_TN02 HAP1 SLC34A2 (-) 2 cancer cell line human CVCL_TN02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11020; SLC34A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146548 CVCL_TN00 HAP1 SLC33A1 (-) 2 cancer cell line human CVCL_TN00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 95; SLC33A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146549 CVCL_KT68 HeLa SilenciX HuR cancer cell line human CVCL_KT68 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3312; ELAVL1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146550 CVCL_L568 IL-A21 hybridoma house mouse CVCL_L568 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine MHC class II. 21146551 CVCL_KT69 HeLa SilenciX KIN17 cancer cell line human CVCL_KT69 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 6327; KIN Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146552 CVCL_L569 IL-A24 hybridoma house mouse CVCL_L569 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine myeloid cells. 21146553 CVCL_KT66 HeLa SilenciX HR23A cancer cell line human CVCL_KT66 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9812; RAD23A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146554 CVCL_L566 IL-A19 hybridoma house mouse CVCL_L566 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine MHC class I. 21146555 CVCL_KT67 HeLa SilenciX HR23B cancer cell line human CVCL_KT67 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 9813; RAD23B Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146556 CVCL_L567 IL-A2 hybridoma house mouse CVCL_L567 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine IgG. 21146557 CVCL_KT64 HeLa SilenciX HMG1L1 cancer cell line human CVCL_KT64 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4993; HMGB1P1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Because of the very high similarity between HMGB1 and HMGB1P1, both are knoched-down in this cell line 21146558 CVCL_L564 IL-A105 hybridoma house mouse CVCL_L564 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine CD8. 21146559 CVCL_KT65 HeLa SilenciX HMGB1 cancer cell line human CVCL_KT65 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4983; HMGB1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Because of the very high similarity between HMGB1 and HMGB1P1, both are knoched-down in this cell line 21146560 CVCL_L565 IL-A16 hybridoma house mouse CVCL_L565 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A1L5SMW6; Bovine ITGAX/CD11c. 21146561 CVCL_L562 CT9-B7 hybridoma house mouse CVCL_L562 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146562 CVCL_KT62 HeLa SilenciX HIF1A cancer cell line human CVCL_KT62 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4910; HIF1A Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146563 CVCL_KT63 HeLa SilenciX Hif2alpha cancer cell line human CVCL_KT63 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 3374; EPAS1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146564 CVCL_L563 MN4-91-6.E2 hybridoma house mouse CVCL_L563 CL:0000010 Monoclonal antibody isotype: IgG1. 21146565 CVCL_L560 CT14-B2 hybridoma house mouse CVCL_L560 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146566 CVCL_KT60 HeLa SilenciX GPX8 cancer cell line human CVCL_KT60 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 33100; GPX8 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146567 CVCL_L561 CT14-G4 hybridoma house mouse CVCL_L561 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146568 CVCL_KT61 HeLa SilenciX HDAC1 cancer cell line human CVCL_KT61 CL:0000010 Knockout cell: Method=EBV-based vector siRNA knockdown; HGNC; 4852; HDAC1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21146569 CVCL_1H91 GM04196 finite cell line human CVCL_1H91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146570 CVCL_1H92 GM04197 transformed cell line human CVCL_1H92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146571 CVCL_1H90 GM04195 transformed cell line human CVCL_1H90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146572 CVCL_1H95 GM04200 finite cell line human CVCL_1H95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146573 CVCL_1H96 GM04201 transformed cell line human CVCL_1H96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146574 CVCL_1H93 GM04198 finite cell line human CVCL_1H93 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146575 CVCL_1H94 GM04199 transformed cell line human CVCL_1H94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146576 CVCL_1H99 GM04207 transformed cell line human CVCL_1H99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Peripheral blood. Female 21146577 CVCL_1H97 GM04203 transformed cell line human CVCL_1H97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Peripheral blood. Female 21146578 CVCL_1H98 GM04206 finite cell line human CVCL_1H98 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146579 CVCL_1H70 GM03865 transformed cell line human CVCL_1H70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146580 CVCL_1H73 GM03868 finite cell line human CVCL_1H73 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146581 CVCL_1H74 GM03869 transformed cell line human CVCL_1H74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146582 CVCL_1H71 GM03866 finite cell line human CVCL_1H71 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146583 CVCL_1H72 GM03867 transformed cell line human CVCL_1H72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146584 CVCL_1H77 GM03872 finite cell line human CVCL_1H77 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146585 CVCL_1H78 GM03873 transformed cell line human CVCL_1H78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146586 CVCL_1H75 GM03870 finite cell line human CVCL_1H75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146587 CVCL_1H76 GM03871 transformed cell line human CVCL_1H76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146588 CVCL_1H79 GM04017 transformed cell line human CVCL_1H79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146589 CVCL_1H80 GM04021 transformed cell line human CVCL_1H80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Peripheral blood. Female 21146590 CVCL_1H81 GM04022 finite cell line human CVCL_1H81 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146591 CVCL_1H84 GM04189 transformed cell line human CVCL_1H84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146592 CVCL_1H85 GM04190 finite cell line human CVCL_1H85 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,1qh (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21146593 CVCL_1H82 GM04023 transformed cell line human CVCL_1H82 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM04022) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Peripheral blood. Female 21146594 CVCL_1H83 GM04188 finite cell line human CVCL_1H83 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(6;19)(6pter->6q13::19p13.3->19pter;19qter->19p13.3::6q13->6qter) [8]; 46,XX,t(7;22)(7qter->7p15::22q13->22qter;22pter->22q13::7p15>-7pter),del(qter->12)(p13) [4]; 46,XX [38] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21146595 CVCL_1H88 GM04193 transformed cell line human CVCL_1H88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146596 CVCL_1H89 GM04194 finite cell line human CVCL_1H89 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146597 CVCL_1H86 GM04191 transformed cell line human CVCL_1H86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146598 CVCL_1H87 GM04192 finite cell line human CVCL_1H87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146599 CVCL_1H51 GM02161 finite cell line human CVCL_1H51 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146600 CVCL_1H52 GM02162 transformed cell line human CVCL_1H52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146601 CVCL_1H50 GM02160 transformed cell line human CVCL_1H50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146602 CVCL_1H55 GM02171 finite cell line human CVCL_1H55 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21146603 CVCL_1H56 GM02178 transformed cell line human CVCL_1H56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146604 CVCL_1H53 GM02163 finite cell line human CVCL_1H53 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146605 CVCL_1H54 GM02170 transformed cell line human CVCL_1H54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146606 CVCL_1H59 GM02191 finite cell line human CVCL_1H59 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146607 CVCL_1H57 GM02180 transformed cell line human CVCL_1H57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146608 CVCL_1H58 GM02190 transformed cell line human CVCL_1H58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146609 CVCL_1H62 GM03747 transformed cell line human CVCL_1H62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146610 CVCL_1H63 GM03748 transformed cell line human CVCL_1H63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146611 CVCL_1H60 GM03745 transformed cell line human CVCL_1H60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146612 CVCL_1H61 GM03746 transformed cell line human CVCL_1H61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146613 CVCL_1H66 GM03861 transformed cell line human CVCL_1H66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146614 CVCL_1H67 GM03862 finite cell line human CVCL_1H67 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146615 CVCL_1H64 GM03790 transformed cell line human CVCL_1H64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146616 CVCL_1H65 GM03860 finite cell line human CVCL_1H65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146617 CVCL_1H68 GM03863 transformed cell line human CVCL_1H68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146618 CVCL_1H69 GM03864 finite cell line human CVCL_1H69 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146619 CVCL_TN92 HAP1 SLC4A3 (-) cancer cell line human CVCL_TN92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11029; SLC4A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146620 CVCL_TN93 HAP1 SLC4A8 (-) 1 cancer cell line human CVCL_TN93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11034; SLC4A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146621 CVCL_TN90 HAP1 SLC4A2 (-) 1 cancer cell line human CVCL_TN90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11028; SLC4A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146622 CVCL_TN91 HAP1 SLC4A2 (-) 2 cancer cell line human CVCL_TN91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11028; SLC4A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146623 CVCL_TN96 HAP1 SLC5A2 (-) 1 cancer cell line human CVCL_TN96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11037; SLC5A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146624 CVCL_TN97 HAP1 SLC5A2 (-) 2 cancer cell line human CVCL_TN97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11037; SLC5A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146625 CVCL_TN94 HAP1 SLC4A8 (-) 2 cancer cell line human CVCL_TN94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11034; SLC4A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146626 CVCL_TN95 HAP1 SLC50A1 (-) cancer cell line human CVCL_TN95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30657; SLC50A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146627 CVCL_TN98 HAP1 SLC5A3 (-) cancer cell line human CVCL_TN98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11038; SLC5A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146628 CVCL_TN99 HAP1 SLC5A4 (-) cancer cell line human CVCL_TN99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11039; SLC5A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146629 CVCL_1H30 T47D-Y cancer cell line human CVCL_1H30 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21146630 CVCL_1H33 hAGES embryonic stem cell human CVCL_1H33 From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China. CL:0000010 Female 21146631 CVCL_1H34 CMMT-CD4-LTR-beta-Gal cancer cell line CVCL_1H34 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Mason-Pfizer monkey virus (MPMV)(NCBI-Taxonomy; 11855); Derived from sampling site: Mammary gland. Female Characteristics: Stably transfected with a plasmid containing the HIV-1 LTR fused to the lacZ gene; Virology: Indicator cell line that allows rapid quantification of infectious SIV Group: Non-human primate cell line 21146632 CVCL_1H31 T47D-YA cancer cell line human CVCL_1H31 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21146633 CVCL_1H32 T47D-YB cancer cell line human CVCL_1H32 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female 21146634 CVCL_1H37 GM01168 finite cell line human CVCL_1H37 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146635 CVCL_1H38 GM01171 finite cell line human CVCL_1H38 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146636 CVCL_1H35 Sup-T1 Nef-ER 31 cancer cell line human CVCL_1H35 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: MGI; MGI:1352467; Esr1 (with p.Met1_Asp484del and p.Ile486_Ile599del); Transfected with: UniProtKB; Q90VU7; HIV-1 isolate NL4-3 nef; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: Expresses a chimeric Nef-estrogen receptor hormone-binding domain (Nef-ER) protein Nef-ER is kept in an inactive state due to steric hindrance, and addition of the membrane-permeable drug 4-hydroxytamoxifen (4-HT), which binds to the ER domain, leads to inducible activation of Nef-ER within cells (PubMed=11134296). 21146637 CVCL_1H36 HZ-293TS transformed cell line human CVCL_1H36 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10165 21146638 CVCL_1H28 J-Lat GFP Clone A72 cancer cell line human CVCL_1H28 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Latently infected with a GFP-tagged HIV-1 strain The integrated HIV-1 genome is located in gene KDM6A (PubMed=28086908). 21146639 CVCL_1H29 ICB-112 cancer cell line human CVCL_1H29 CL:0000010 Male 21146640 CVCL_TN81 HAP1 SLC46A1 (-) 1 cancer cell line human CVCL_TN81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30521; SLC46A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146641 CVCL_TN82 HAP1 SLC46A3 (-) 1 cancer cell line human CVCL_TN82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27501; SLC46A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146642 CVCL_TN80 HAP1 SLC45A3 (-) 2 cancer cell line human CVCL_TN80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8642; SLC45A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146643 CVCL_TN85 HAP1 SLC47A1 (-) cancer cell line human CVCL_TN85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25588; SLC47A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146644 CVCL_TN86 HAP1 SLC48A1 (-) cancer cell line human CVCL_TN86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26035; SLC48A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146645 CVCL_TN83 HAP1 SLC46A3 (-) 2 cancer cell line human CVCL_TN83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27501; SLC46A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146646 CVCL_TN84 HAP1 SLC46A3 (-) 3 cancer cell line human CVCL_TN84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27501; SLC46A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146647 CVCL_TN89 HAP1 SLC4A1AP (-) cancer cell line human CVCL_TN89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13813; SLC4A1AP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146648 CVCL_TN87 HAP1 SLC4A10 (-) cancer cell line human CVCL_TN87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13811; SLC4A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146649 CVCL_TN88 HAP1 SLC4A11 (-) cancer cell line human CVCL_TN88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16438; SLC4A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146650 CVCL_TN69 HAP1 SLC41A3 (-) 2 cancer cell line human CVCL_TN69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31046; SLC41A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146651 CVCL_1H40 GM02078 transformed cell line human CVCL_1H40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Peripheral blood. Female 21146652 CVCL_1H41 GM02079 finite cell line human CVCL_1H41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146653 CVCL_1H44 GM02154 transformed cell line human CVCL_1H44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146654 CVCL_1H45 GM02155 finite cell line human CVCL_1H45 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146655 CVCL_1H42 GM02080 transformed cell line human CVCL_1H42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146656 CVCL_1H43 GM02123 finite cell line human CVCL_1H43 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at 25% risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146657 CVCL_1H48 GM02158 transformed cell line human CVCL_1H48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146658 CVCL_1H49 GM02159 finite cell line human CVCL_1H49 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146659 CVCL_1H46 GM02156 transformed cell line human CVCL_1H46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146660 CVCL_1H47 GM02157 finite cell line human CVCL_1H47 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146661 CVCL_1H39 GM02077 finite cell line human CVCL_1H39 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at 50% risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146662 CVCL_TN70 HAP1 SLC43A1 (-) cancer cell line human CVCL_TN70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9225; SLC43A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146663 CVCL_TN71 HAP1 SLC43A2 (-) 1 cancer cell line human CVCL_TN71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23087; SLC43A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146664 CVCL_TN74 HAP1 SLC43A3 (-) 2 cancer cell line human CVCL_TN74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17466; SLC43A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146665 CVCL_TN75 HAP1 SLC44A1 (-) cancer cell line human CVCL_TN75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18798; SLC44A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146666 CVCL_TN72 HAP1 SLC43A2 (-) 2 cancer cell line human CVCL_TN72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23087; SLC43A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146667 CVCL_TN73 HAP1 SLC43A3 (-) 1 cancer cell line human CVCL_TN73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17466; SLC43A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146668 CVCL_TN78 HAP1 SLC44A3 (-) 1 cancer cell line human CVCL_TN78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28689; SLC44A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146669 CVCL_TN79 HAP1 SLC45A3 (-) 1 cancer cell line human CVCL_TN79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8642; SLC45A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146670 CVCL_TN76 HAP1 SLC44A2 (-) 1 cancer cell line human CVCL_TN76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17292; SLC44A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146671 CVCL_TN77 HAP1 SLC44A2 (-) 2 cancer cell line human CVCL_TN77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17292; SLC44A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146672 CVCL_KV08 cAMP Hunter CHO-K1 DRD2S Gi spontaneously immortalized cell line CVCL_KV08 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform short) Derived from sampling site: Ovary. Female 21146673 CVCL_L708 Myc1-9E10 hybridoma house mouse CVCL_L708 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146674 CVCL_KV09 cAMP Hunter CHO-K1 DRD4 Gi spontaneously immortalized cell line CVCL_KV09 CL:0000010 Transfected with: HGNC; 3025; DRD4 Derived from sampling site: Ovary. Female 21146675 CVCL_L709 tsJT16 transformed cell line Norway rat CVCL_L709 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0233.2; true Female Characteristics: Cell line grows at 34 Celsius but the growth is arrested at 40 Celsius (JCRB) 21146676 CVCL_KV06 cAMP Hunter CHO-K1 DRD1 Gs spontaneously immortalized cell line CVCL_KV06 CL:0000010 Transfected with: HGNC; 3020; DRD1 Derived from sampling site: Ovary. Female 21146677 CVCL_L706 Myc1-3C7 hybridoma house mouse CVCL_L706 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146678 CVCL_KV07 cAMP Hunter CHO-K1 DRD2L Gi spontaneously immortalized cell line CVCL_KV07 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform long) Derived from sampling site: Ovary. Female 21146679 CVCL_L707 Myc1-8F9 hybridoma house mouse CVCL_L707 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146680 CVCL_KV04 cAMP Hunter CHO-K1 CXCR5 Gi spontaneously immortalized cell line CVCL_KV04 CL:0000010 Transfected with: HGNC; 1060; CXCR5 Derived from sampling site: Ovary. Female 21146681 CVCL_L704 LDS 73/LW1 hybridoma house mouse CVCL_L704 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P46418; Rat Gsta5. 21146682 CVCL_KV05 cAMP Hunter CHO-K1 CXCR6 Gi spontaneously immortalized cell line CVCL_KV05 CL:0000010 Transfected with: HGNC; 16647; CXCR6 Derived from sampling site: Ovary. Female 21146683 CVCL_L705 M290 hybridoma CVCL_L705 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q60677; Mouse Itgae/Cd103. 21146684 CVCL_KV02 cAMP Hunter CHO-K1 CXCR3 Gi spontaneously immortalized cell line CVCL_KV02 CL:0000010 Transfected with: HGNC; 4540; CXCR3 Derived from sampling site: Ovary. Female 21146685 CVCL_L702 KOC-2S cancer cell line human CVCL_L702 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 29.0 hours, at 34th passage (PubMed=8428685) 21146686 CVCL_KV03 cAMP Hunter CHO-K1 CXCR4 Gi spontaneously immortalized cell line CVCL_KV03 CL:0000010 Transfected with: HGNC; 2561; CXCR4 Derived from sampling site: Ovary. Female 21146687 CVCL_L703 KOC-4C cancer cell line human CVCL_L703 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21146688 CVCL_KV00 cAMP Hunter CHO-K1 CXCR1 Gi spontaneously immortalized cell line CVCL_KV00 CL:0000010 Transfected with: HGNC; 6026; CXCR1 Derived from sampling site: Ovary. Female 21146689 CVCL_L700 TU-OC-1 cancer cell line human CVCL_L700 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=23430509) Population: Japanese; Derived from sampling site: Ovary. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 38.4 +- 3.5 hours (PubMed=23430509) Part of: MD Anderson Cell Lines Project 21146690 CVCL_KV01 cAMP Hunter CHO-K1 CXCR2 Gi spontaneously immortalized cell line CVCL_KV01 CL:0000010 Transfected with: HGNC; 6027; CXCR2 Derived from sampling site: Ovary. Female 21146691 CVCL_L701 KOC-1S cancer cell line human CVCL_L701 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 43.5 hours, at 102th passage (PubMed=8428685) 21146692 CVCL_TP14 HAP1 SLC7A5 (-) 1 cancer cell line human CVCL_TP14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11063; SLC7A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146693 CVCL_U114 Psi-CRE-MFGtsT transformed cell line house mouse CVCL_U114 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21146694 CVCL_TP15 HAP1 SLC7A6 (-) cancer cell line human CVCL_TP15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11064; SLC7A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146695 CVCL_U115 RPMI-8342 cancer cell line human CVCL_U115 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 38 hours (PubMed=1127734); 62 hours (PubMed=1161259) 21146696 CVCL_TP12 HAP1 SLC7A3 (-) 1 cancer cell line human CVCL_TP12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11061; SLC7A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146697 CVCL_U112 NB4.437r cancer cell line human CVCL_U112 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:88334; AHPN (6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalenecarboxylic acid; Derived from sampling site: Bone marrow. Female 21146698 CVCL_TP13 HAP1 SLC7A3 (-) 2 cancer cell line human CVCL_TP13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11061; SLC7A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146699 CVCL_U113 ND10734 transformed cell line human CVCL_U113 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (from autologous cell line ND39027) Population: Cape Verdian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146700 CVCL_TP18 HAP1 SLC9A1 (-) 1 cancer cell line human CVCL_TP18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11071; SLC9A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146701 CVCL_U118 SIL-6/1 factor-dependent cell line house mouse CVCL_U118 CL:0000010 Breed/subspecies: C3H/He. Male Characteristics: IL6 or KITLG dependent 21146702 CVCL_U119 Fvp^(r)B350 cancer cell line house mouse CVCL_U119 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21146703 CVCL_TP19 HAP1 SLC9A3 (-) cancer cell line human CVCL_TP19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11073; SLC9A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146704 CVCL_TP16 HAP1 SLC7A8 (-) 1 cancer cell line human CVCL_TP16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11066; SLC7A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146705 CVCL_U116 MDCC-AL2 cancer cell line CVCL_U116 CL:0000010 Breed/subspecies: N-line. Group: Bird cell line 21146706 CVCL_TP17 HAP1 SLC8B1 (-) 1 cancer cell line human CVCL_TP17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26175; SLC8B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146707 CVCL_U117 MDCC-AL3 cancer cell line CVCL_U117 CL:0000010 Breed/subspecies: N-line. Group: Bird cell line 21146708 CVCL_KV79 cAMP Hunter CHO-K1 RXFP4 Gi spontaneously immortalized cell line CVCL_KV79 CL:0000010 Transfected with: HGNC; 14666; RXFP4 Derived from sampling site: Ovary. Female 21146709 CVCL_L779 XP2CH finite cell line human CVCL_L779 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Val125Ter (c.376C>T); Zygosity=Homozygous (PubMed=10398605) Population: Caucasian; Russian Armenian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146710 CVCL_KV77 cAMP Hunter CHO-K1 RXFP2 Gs spontaneously immortalized cell line CVCL_KV77 CL:0000010 Transfected with: HGNC; 17318; RXFP2 Derived from sampling site: Ovary. Female 21146711 CVCL_L777 XP3KR finite cell line human CVCL_L777 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1372102; PubMed=7905727; PubMed=9671271); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Heterozygous (PubMed=1372102; PubMed=7905727; PubMed=9671271) Population: Japanese; Donor information: Established from monozygotic twin of XP4KR (Cellosaurus=CVCL_ZQ22); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1031; probable Female 21146712 CVCL_KV78 cAMP Hunter CHO-K1 RXFP3 Gi spontaneously immortalized cell line CVCL_KV78 CL:0000010 Transfected with: HGNC; 24883; RXFP3 Derived from sampling site: Ovary. Female 21146713 CVCL_L778 XP17BE LCL transformed cell line human CVCL_L778 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Asp681Asn (c.2041G>A); ClinVar=VCV000016787; Zygosity=Heterozygous (from autologous cell line XP17BE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP17BE) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146714 CVCL_KV75 cAMP Hunter CHO-K1 rTAAR1 Gs spontaneously immortalized cell line CVCL_KV75 CL:0000010 Transfected with: RGD; 621621; Taar1 Derived from sampling site: Ovary. Female 21146715 CVCL_L775 XPH4CA finite cell line human CVCL_L775 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21146716 CVCL_KV76 cAMP Hunter CHO-K1 RXFP1 Gs spontaneously immortalized cell line CVCL_KV76 CL:0000010 Transfected with: HGNC; 19718; RXFP1 Derived from sampling site: Ovary. Female 21146717 CVCL_L776 GM03112 finite cell line human CVCL_L776 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu730Lysfs*7 (c.2188delTinsAAA) (2352delTinsAAA); ClinVar=VCV000038418; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146718 CVCL_KV73 cAMP Hunter CHO-K1 rDRD2L Gi spontaneously immortalized cell line CVCL_KV73 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform long) Derived from sampling site: Ovary. Female 21146719 CVCL_L773 XP8CA finite cell line human CVCL_L773 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Homozygous (PubMed=15744458) Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146720 CVCL_KV74 cAMP Hunter CHO-K1 rDRD2S Gi spontaneously immortalized cell line CVCL_KV74 CL:0000010 Transfected with: RGD; 2520; Drd2 (isoform short) Derived from sampling site: Ovary. Female 21146721 CVCL_L774 XP7CA finite cell line human CVCL_L774 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (PubMed=6492896) 21146722 CVCL_KV71 cAMP Hunter CHO-K1 PTHR2 Gs/Gq spontaneously immortalized cell line CVCL_KV71 CL:0000010 Transfected with: HGNC; 9609; PTH2R Derived from sampling site: Ovary. Female 21146723 CVCL_L771 XP5CA finite cell line human CVCL_L771 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-2A>G (IVS3-2A>G); Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8595429) Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (PubMed=6492896) Part of: Human variation panel 21146724 CVCL_KV72 cAMP Hunter CHO-K1 rDRD1 Gs spontaneously immortalized cell line CVCL_KV72 CL:0000010 Transfected with: RGD; 2518; Drd1 Derived from sampling site: Ovary. Female 21146725 CVCL_L772 NM-M2 cancer cell line Norway rat CVCL_L772 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21146726 CVCL_KV70 cAMP Hunter CHO-K1 PTHR1 Gs/Gq spontaneously immortalized cell line CVCL_KV70 CL:0000010 Transfected with: HGNC; 9608; PTH1R Derived from sampling site: Ovary. Female 21146727 CVCL_L770 XP4CA finite cell line human CVCL_L770 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146728 CVCL_U121 B151K12 hybridoma house mouse CVCL_U121 CL:0000010 Characteristics: T-cell hybridoma Produces Il5.. 21146729 CVCL_TP21 HAP1 SLC9A3R1 (-) 2 cancer cell line human CVCL_TP21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11075; SLC9A3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146730 CVCL_U122 BBWV-22K3-9B hybridoma house mouse CVCL_U122 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; R4V130; Broad bean wilt virus 2 small capsid protein. 21146731 CVCL_TP22 HAP1 SLC9A3R2 (-) 1 cancer cell line human CVCL_TP22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11076; SLC9A3R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146732 CVCL_U120 BW5147-AZG(R),OU(R) cancer cell line house mouse CVCL_U120 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21146733 CVCL_TP20 HAP1 SLC9A3R1 (-) 1 cancer cell line human CVCL_TP20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11075; SLC9A3R1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146734 CVCL_U103 D611L cancer cell line human CVCL_U103 HLA typing: A*24:02; B*07:02; C*07:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146735 CVCL_TP03 HAP1 SLC5A7 (-) 2 cancer cell line human CVCL_TP03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14025; SLC5A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146736 CVCL_U104 E522L cancer cell line human CVCL_U104 HLA typing: A*02:07,24:02; B*40:06,59:01; C*01:02,08:01 (PubMed=12114371) CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Homozygous (PubMed=17725806) Population: Japanese; Derived from metastatic site: Pericardial effusion. Male 21146737 CVCL_TP04 HAP1 SLC6A6 (-) 1 cancer cell line human CVCL_TP04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11052; SLC6A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146738 CVCL_U101 C422L cancer cell line human CVCL_U101 HLA typing: A*26:01; B*46:01; C*01:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146739 CVCL_TP01 HAP1 SLC5A6 (-) 2 cancer cell line human CVCL_TP01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11041; SLC5A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146740 CVCL_U102 D1008L cancer cell line human CVCL_U102 HLA typing: A*24:02,26:01; B*40:02,51:01; C*03:04,14:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146741 CVCL_TP02 HAP1 SLC5A7 (-) 1 cancer cell line human CVCL_TP02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14025; SLC5A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146742 CVCL_U107 H1224L cancer cell line human CVCL_U107 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female 21146743 CVCL_TP07 HAP1 SLC6A9 (-) 1 cancer cell line human CVCL_TP07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11056; SLC6A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146744 CVCL_U108 G821L cancer cell line human CVCL_U108 HLA typing: A*26:02; B*51:01; C*14:02 (PubMed=17131342) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146745 CVCL_TP08 HAP1 SLC7A1 (-) 1 cancer cell line human CVCL_TP08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11057; SLC7A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146746 CVCL_TP05 HAP1 SLC6A8 (-) 1 cancer cell line human CVCL_TP05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11055; SLC6A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146747 CVCL_U105 Mehr-80 cancer cell line human CVCL_U105 CL:0000010 Population: Iranian; Derived from metastatic site: Ascites. Female Doubling time: 29 hours (PubMed=15619644) 21146748 CVCL_TP06 HAP1 SLC6A8 (-) 2 cancer cell line human CVCL_TP06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11055; SLC6A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146749 CVCL_U106 QU-DB cancer cell line human CVCL_U106 CL:0000010 Male Doubling time: 10-12 hours (PubMed=3719556). 21146750 CVCL_U109 H1215L cancer cell line human CVCL_U109 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146751 CVCL_TP09 HAP1 SLC7A1 (-) 2 cancer cell line human CVCL_TP09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11057; SLC7A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146752 CVCL_KV88 cAMP Hunter CHO-K1 VIPR1 Gs/Gq spontaneously immortalized cell line CVCL_KV88 CL:0000010 Transfected with: HGNC; 12694; VIPR1 Derived from sampling site: Ovary. Female 21146753 CVCL_L788 CPA-Yang3BM cancer cell line human CVCL_L788 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Female Characteristics: Bone metastatic phenotype Obtained after 3 serial passages of the parent cell line in nude mice. 21146754 CVCL_KV89 cAMP Hunter CHO-K1 VIPR2 Gs spontaneously immortalized cell line CVCL_KV89 CL:0000010 Transfected with: HGNC; 12695; VIPR2 Derived from sampling site: Ovary. Female 21146755 CVCL_L789 MM16 cancer cell line human CVCL_L789 CL:0000010 Population: Japanese Omics: CNV analysis; Omics: SNP array analysis. Male Doubling time: 12.4 +- 0.9 hours (PubMed=21205078) 21146756 CVCL_KV86 cAMP Hunter CHO-K1 TACR3 Gs/Gq spontaneously immortalized cell line CVCL_KV86 CL:0000010 Transfected with: HGNC; 11528; TACR3 Derived from sampling site: Ovary. Female 21146757 CVCL_L786 CSGC spontaneously immortalized cell line CVCL_L786 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21146758 CVCL_KV87 cAMP Hunter CHO-K1 TSHR(L) Gs spontaneously immortalized cell line CVCL_KV87 CL:0000010 Transfected with: HGNC; 12373; TSHR (isoform long) Derived from sampling site: Ovary. Female 21146759 CVCL_L787 CPA-Yang3 cancer cell line human CVCL_L787 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.3137 21146760 CVCL_KV84 cAMP Hunter CHO-K1 SSTR5 Gi spontaneously immortalized cell line CVCL_KV84 CL:0000010 Transfected with: HGNC; 11334; SSTR5 Derived from sampling site: Ovary. Female 21146761 CVCL_L784 ULT-1 finite cell line human CVCL_L784 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Senescence: Ultra long-lived cell line with a life span of 166 PDL (PubMed=22273270) 21146762 CVCL_KV85 cAMP Hunter CHO-K1 TAAR1 Gs spontaneously immortalized cell line CVCL_KV85 CL:0000010 Transfected with: HGNC; 17734; TAAR1 Derived from sampling site: Ovary. Female 21146763 CVCL_L785 IMT-1 telomerase immortalized cell line human CVCL_L785 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21146764 CVCL_L782 AG20447 transformed cell line human CVCL_L782 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146765 CVCL_KV82 cAMP Hunter CHO-K1 SSTR3 Gi spontaneously immortalized cell line CVCL_KV82 CL:0000010 Transfected with: HGNC; 11332; SSTR3 Derived from sampling site: Ovary. Female 21146766 CVCL_KV83 cAMP Hunter CHO-K1 SSTR4 Gi spontaneously immortalized cell line CVCL_KV83 CL:0000010 Transfected with: HGNC; 11333; SSTR4 Derived from sampling site: Ovary. Female 21146767 CVCL_L783 HIPEC-65 transformed cell line human CVCL_L783 CL:0000010 Transformant: Simian virus 40 (SV40) [HuVim [830]-T/t](NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast; cytotrophoblast. 21146768 CVCL_L780 AG05397 finite cell line human CVCL_L780 CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21146769 CVCL_KV80 cAMP Hunter CHO-K1 SCTR Gs spontaneously immortalized cell line CVCL_KV80 CL:0000010 Transfected with: HGNC; 10608; SCTR Derived from sampling site: Ovary. Female 21146770 CVCL_L781 AG20446 finite cell line human CVCL_L781 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146771 CVCL_KV81 cAMP Hunter CHO-K1 SSTR2 Gi spontaneously immortalized cell line CVCL_KV81 CL:0000010 Transfected with: HGNC; 11331; SSTR2 Derived from sampling site: Ovary. Female 21146772 CVCL_TP10 HAP1 SLC7A2 (-) 1 cancer cell line human CVCL_TP10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11060; SLC7A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146773 CVCL_U110 J206L cancer cell line human CVCL_U110 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146774 CVCL_U111 GM23764 induced pluripotent stem cell human CVCL_U111 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146775 CVCL_TP11 HAP1 SLC7A2 (-) 2 cancer cell line human CVCL_TP11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11060; SLC7A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146776 CVCL_KV59 cAMP Hunter CHO-K1 OPRD1 Gi spontaneously immortalized cell line CVCL_KV59 CL:0000010 Transfected with: HGNC; 8153; OPRD1 Derived from sampling site: Ovary. Female 21146777 CVCL_L759 XP2PD finite cell line human CVCL_L759 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys108Phe (c.323G>T); ClinVar=VCV000000993; Zygosity=Heterozygous (Coriell; PubMed=9671271); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Leu117Glufs*4 (c.349_353delCTTAT) (349del5); ClinVar=VCV000000994; Zygosity=Heterozygous (Coriell; PubMed=9671271) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146778 CVCL_KV57 cAMP Hunter CHO-K1 NPFFR1 Gi spontaneously immortalized cell line CVCL_KV57 CL:0000010 Transfected with: HGNC; 17425; NPFFR1 Derived from sampling site: Ovary. Female 21146779 CVCL_L757 XP4LO finite cell line human CVCL_L757 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.468_469delAA; Zygosity=Homozygous (PubMed=9671271; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (PubMed=6492896) 21146780 CVCL_KV58 cAMP Hunter CHO-K1 NPY2R Gi spontaneously immortalized cell line CVCL_KV58 CL:0000010 Transfected with: HGNC; 7957; NPY2R Derived from sampling site: Ovary. Female 21146781 CVCL_L758 XP1PD finite cell line human CVCL_L758 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys108Phe (c.323G>T); ClinVar=VCV000000993; Zygosity=Heterozygous (PubMed=9671271; PubMed=26184184); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Leu117Glufs*4 (c.349_353delCTTAT) (349del5); ClinVar=VCV000000994; Zygosity=Heterozygous (PubMed=9671271; PubMed=26184184) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146782 CVCL_KV55 cAMP Hunter CHO-K1 NPBWR1 Gi spontaneously immortalized cell line CVCL_KV55 CL:0000010 Transfected with: HGNC; 4522; NPBWR1 Derived from sampling site: Ovary. Female 21146783 CVCL_L755 GM02964 transformed cell line human CVCL_L755 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146784 CVCL_KV56 cAMP Hunter CHO-K1 NPBWR2 Gi spontaneously immortalized cell line CVCL_KV56 CL:0000010 Transfected with: HGNC; 4530; NPBWR2 Derived from sampling site: Ovary. Female 21146785 CVCL_L756 GM02965 finite cell line human CVCL_L756 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146786 CVCL_KV53 cAMP Hunter CHO-K1 MTNR1A Gi spontaneously immortalized cell line CVCL_KV53 CL:0000010 Transfected with: HGNC; 7463; MTNR1A Derived from sampling site: Ovary. Female 21146787 CVCL_L753 GM05170 transformed cell line human CVCL_L753 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21146788 CVCL_KV54 cAMP Hunter CHO-K1 MTNR1B Gi spontaneously immortalized cell line CVCL_KV54 CL:0000010 Transfected with: HGNC; 7464; MTNR1B Derived from sampling site: Ovary. Female 21146789 CVCL_L754 XP3NE finite cell line human CVCL_L754 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (from familial inference of XP2NE) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146790 CVCL_L751 AG12927 finite cell line human CVCL_L751 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [62%]; 47,XX,+7 [38%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (Coriell=AG12927) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146791 CVCL_KV51 cAMP Hunter CHO-K1 mRXFP1 Gs spontaneously immortalized cell line CVCL_KV51 CL:0000010 Transfected with: MGI; MGI:2682211; Rxfp1 Derived from sampling site: Ovary. Female 21146792 CVCL_KV52 cAMP Hunter CHO-K1 mTAAR1 Gs spontaneously immortalized cell line CVCL_KV52 CL:0000010 Transfected with: MGI; MGI:2148258; Taar1 Derived from sampling site: Ovary. Female 21146793 CVCL_L752 GM05169 finite cell line human CVCL_L752 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex4-43del; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21146794 CVCL_L750 AG07714 finite cell line human CVCL_L750 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [94%]; 46,XX,1p+,3p-,3q-,10q-,13p+,16q+ [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21146795 CVCL_KV50 cAMP Hunter CHO-K1 mGIPR Gs spontaneously immortalized cell line CVCL_KV50 CL:0000010 Transfected with: MGI; MGI:1352753; Gipr Derived from sampling site: Ovary. Female 21146796 CVCL_U100 C311L cancer cell line human CVCL_U100 HLA typing: A*24:02,31:012; B*51:01,52:01; C*12:02,14:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21146797 CVCL_TP00 HAP1 SLC5A6 (-) 1 cancer cell line human CVCL_TP00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11041; SLC5A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21146798 CVCL_KV68 cAMP Hunter CHO-K1 PTGER3 Gi spontaneously immortalized cell line CVCL_KV68 CL:0000010 Transfected with: HGNC; 9595; PTGER3 Derived from sampling site: Ovary. Female 21146799 CVCL_L768 XP2CA finite cell line human CVCL_L768 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Thr125Ilefs*15 (c.374delC); ClinVar=VCV000267186; Zygosity=Homozygous (Coriell; PubMed=9671271) Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146800 CVCL_KV69 cAMP Hunter CHO-K1 PTGIR Gs spontaneously immortalized cell line CVCL_KV69 CL:0000010 Transfected with: HGNC; 9602; PTGIR Derived from sampling site: Ovary. Female 21146801 CVCL_L769 XP3CA finite cell line human CVCL_L769 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146802 CVCL_KV66 cAMP Hunter CHO-K1 PTAFR Gi spontaneously immortalized cell line CVCL_KV66 CL:0000010 Transfected with: HGNC; 9582; PTAFR Derived from sampling site: Ovary. Female 21146803 CVCL_L766 GM02486 finite cell line human CVCL_L766 CL:0000010 Karyotypic information: 46,XX,dup(3)(pter->q27::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21146804 CVCL_KV67 cAMP Hunter CHO-K1 PTGDR Gs spontaneously immortalized cell line CVCL_KV67 CL:0000010 Transfected with: HGNC; 9591; PTGDR Derived from sampling site: Ovary. Female 21146805 CVCL_L767 XP1CA finite cell line human CVCL_L767 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Thr125Ilefs*15 (c.374delC); ClinVar=VCV000267186; Zygosity=Homozygous (Coriell; PubMed=9671271) Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21146806 CVCL_KV64 cAMP Hunter CHO-K1 PPYR1 Gi spontaneously immortalized cell line CVCL_KV64 CL:0000010 Transfected with: HGNC; 9329; NPY4R Derived from sampling site: Ovary. Female 21146807 CVCL_L764 XP4JO finite cell line human CVCL_L764 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg130Lys (c.389G>A); ClinVar=VCV000551153; Zygosity=Homozygous; Note=Affects splicing (Coriell; PubMed=9671271) Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (PubMed=6492896) Part of: Human variation panel 21146808 CVCL_KV65 cAMP Hunter CHO-K1 PROKR1 Gs spontaneously immortalized cell line CVCL_KV65 CL:0000010 Transfected with: HGNC; 4524; PROKR1 Derived from sampling site: Ovary. Female 21146809 CVCL_L765 XP5JO finite cell line human CVCL_L765 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg130Lys (c.389G>A); ClinVar=VCV000551153; Zygosity=Homozygous; Note=Affects splicing (PubMed=9671271) Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146810 CVCL_KV62 cAMP Hunter CHO-K1 OPRM1 Gi spontaneously immortalized cell line CVCL_KV62 CL:0000010 Transfected with: HGNC; 8156; OPRM1 Derived from sampling site: Ovary. Female 21146811 CVCL_L762 GM02047 finite cell line human CVCL_L762 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146812 CVCL_KV63 cAMP Hunter CHO-K1 OXER1 Gi spontaneously immortalized cell line CVCL_KV63 CL:0000010 Transfected with: HGNC; 24884; OXER1 Derived from sampling site: Ovary. Female 21146813 CVCL_L763 XP5PD finite cell line human CVCL_L763 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg211Ter (c.631C>T); ClinVar=VCV000551809; Zygosity=Heterozygous (Coriell; PubMed=9671271); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell; PubMed=9671271) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (PubMed=6492896) 21146814 CVCL_KV60 cAMP Hunter CHO-K1 OPRK1 Gi spontaneously immortalized cell line CVCL_KV60 CL:0000010 Transfected with: HGNC; 8154; OPRK1 Derived from sampling site: Ovary. Female 21146815 CVCL_L760 XP3JO finite cell line human CVCL_L760 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg130Lys (c.389G>A); ClinVar=VCV000551153; Zygosity=Homozygous; Note=Affects splicing (Coriell; PubMed=9671271) Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146816 CVCL_KV61 cAMP Hunter CHO-K1 OPRL1 Gi spontaneously immortalized cell line CVCL_KV61 CL:0000010 Transfected with: HGNC; 8155; OPRL1 Derived from sampling site: Ovary. Female 21146817 CVCL_L761 GM02046 finite cell line human CVCL_L761 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu730Lysfs*7 (c.2188delTinsAAA) (2352delTinsAAA); ClinVar=VCV000038418; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21146818 CVCL_L739 3Y1tsF121 transformed cell line Norway rat CVCL_L739 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146819 CVCL_KV39 cAMP Hunter CHO-K1 HTR1B Gi spontaneously immortalized cell line CVCL_KV39 CL:0000010 Transfected with: HGNC; 5287; HTR1B Derived from sampling site: Ovary. Female 21146820 CVCL_L737 3Y1tsD206 transformed cell line Norway rat CVCL_L737 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146821 CVCL_KV37 cAMP Hunter CHO-K1 HRH3 Gi spontaneously immortalized cell line CVCL_KV37 CL:0000010 Transfected with: HGNC; 5184; HRH3 Derived from sampling site: Ovary. Female 21146822 CVCL_L738 3Y1tsE204 transformed cell line Norway rat CVCL_L738 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146823 CVCL_KV38 cAMP Hunter CHO-K1 HTR1A Gi spontaneously immortalized cell line CVCL_KV38 CL:0000010 Transfected with: HGNC; 5286; HTR1A Derived from sampling site: Ovary. Female 21146824 CVCL_L735 3Y1tsD123 transformed cell line Norway rat CVCL_L735 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146825 CVCL_KV35 cAMP Hunter CHO-K1 GRM6 Gi spontaneously immortalized cell line CVCL_KV35 CL:0000010 Transfected with: HGNC; 4598; GRM6 Derived from sampling site: Ovary. Female 21146826 CVCL_L736 3Y1tsD124 transformed cell line Norway rat CVCL_L736 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146827 CVCL_KV36 cAMP Hunter CHO-K1 HRH2 Gs/Gq spontaneously immortalized cell line CVCL_KV36 CL:0000010 Transfected with: HGNC; 5183; HRH2 Derived from sampling site: Ovary. Female 21146828 CVCL_L733 3Y1tsC119 transformed cell line Norway rat CVCL_L733 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146829 CVCL_KV33 cAMP Hunter CHO-K1 GRM3 Gi spontaneously immortalized cell line CVCL_KV33 CL:0000010 Transfected with: HGNC; 4595; GRM3 Derived from sampling site: Ovary. Female 21146830 CVCL_L734 3Y1tsC205 transformed cell line Norway rat CVCL_L734 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146831 CVCL_KV34 cAMP Hunter CHO-K1 GRM4 Gi spontaneously immortalized cell line CVCL_KV34 CL:0000010 Transfected with: HGNC; 4596; GRM4 Derived from sampling site: Ovary. Female 21146832 CVCL_L731 3Y1tsC113 transformed cell line Norway rat CVCL_L731 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146833 CVCL_KV31 cAMP Hunter CHO-K1 GPR84 Gi spontaneously immortalized cell line CVCL_KV31 CL:0000010 Transfected with: HGNC; 4535; GPR84 Derived from sampling site: Ovary. Female 21146834 CVCL_L732 3Y1tsC116 transformed cell line Norway rat CVCL_L732 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146835 CVCL_KV32 cAMP Hunter CHO-K1 GRM2 Gi spontaneously immortalized cell line CVCL_KV32 CL:0000010 Transfected with: HGNC; 4594; GRM2 Derived from sampling site: Ovary. Female 21146836 CVCL_L730 3Y1tsC112 transformed cell line Norway rat CVCL_L730 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146837 CVCL_KV30 cAMP Hunter CHO-K1 GPR81 Gi spontaneously immortalized cell line CVCL_KV30 CL:0000010 Transfected with: HGNC; 4532; HCAR1 Derived from sampling site: Ovary. Female 21146838 CVCL_KV48 cAMP Hunter CHO-K1 MC5R Gs spontaneously immortalized cell line CVCL_KV48 CL:0000010 Transfected with: HGNC; 6933; MC5R Derived from sampling site: Ovary. Female 21146839 CVCL_L748 GM11425 transformed cell line human CVCL_L748 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Heterozygous; Note=MZ allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146840 CVCL_KV49 cAMP Hunter CHO-K1 MCHR1 Gi spontaneously immortalized cell line CVCL_KV49 CL:0000010 Transfected with: HGNC; 4479; MCHR1 Derived from sampling site: Ovary. Female 21146841 CVCL_L749 GM02340 finite cell line human CVCL_L749 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=18511599) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21146842 CVCL_KV46 cAMP Hunter CHO-K1 MC3R Gs spontaneously immortalized cell line CVCL_KV46 CL:0000010 Transfected with: HGNC; 6931; MC3R Derived from sampling site: Ovary. Female 21146843 CVCL_L746 GM11423 finite cell line human CVCL_L746 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (Coriell) Population: Caucasian; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21146844 CVCL_KV47 cAMP Hunter CHO-K1 MC4R Gs spontaneously immortalized cell line CVCL_KV47 CL:0000010 Transfected with: HGNC; 6932; MC4R Derived from sampling site: Ovary. Female 21146845 CVCL_L747 GM11424 transformed cell line human CVCL_L747 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Heterozygous; Note=MZ allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146846 CVCL_KV44 cAMP Hunter CHO-K1 LTB4R Gi spontaneously immortalized cell line CVCL_KV44 CL:0000010 Transfected with: HGNC; 6713; LTB4R Derived from sampling site: Ovary. Female 21146847 CVCL_L744 GM01012 finite cell line human CVCL_L744 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146848 CVCL_KV45 cAMP Hunter CHO-K1 MC1R Gs spontaneously immortalized cell line CVCL_KV45 CL:0000010 Transfected with: HGNC; 6929; MC1R Derived from sampling site: Ovary. Female 21146849 CVCL_L745 GM01011 finite cell line human CVCL_L745 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from familial inference of GM01012) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21146850 CVCL_L742 3Y1tsH203 transformed cell line Norway rat CVCL_L742 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146851 CVCL_KV42 cAMP Hunter CHO-K1 HTR7A Gs spontaneously immortalized cell line CVCL_KV42 CL:0000010 Transfected with: HGNC; 5302; HTR7 (isoform A) Derived from sampling site: Ovary. Female 21146852 CVCL_L743 BMR26 hybridoma house mouse CVCL_L743 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:61360; Globoside. 21146853 CVCL_KV43 cAMP Hunter CHO-K1 LHCGR Gs spontaneously immortalized cell line CVCL_KV43 CL:0000010 Transfected with: HGNC; 6585; LHCGR Derived from sampling site: Ovary. Female 21146854 CVCL_L740 3Y1tsF126 transformed cell line Norway rat CVCL_L740 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146855 CVCL_KV40 cAMP Hunter CHO-K1 HTR1F Gi spontaneously immortalized cell line CVCL_KV40 CL:0000010 Transfected with: HGNC; 5292; HTR1F Derived from sampling site: Ovary. Female 21146856 CVCL_L741 3Y1tsG125 transformed cell line Norway rat CVCL_L741 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146857 CVCL_KV41 cAMP Hunter CHO-K1 HTR5A Gi spontaneously immortalized cell line CVCL_KV41 CL:0000010 Transfected with: HGNC; 5300; HTR5A Derived from sampling site: Ovary. Female 21146858 CVCL_L719 3Y1ts-114 transformed cell line Norway rat CVCL_L719 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146859 CVCL_KV19 cAMP Hunter CHO-K1 GABBR1-GABBR2 Gi spontaneously immortalized cell line CVCL_KV19 CL:0000010 Transfected with: HGNC; 4070; GABBR1 Derived from sampling site: Ovary. Female 21146860 CVCL_L717 3Y1ts-109 transformed cell line Norway rat CVCL_L717 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146861 CVCL_KV17 cAMP Hunter CHO-K1 FPRL1 Gi spontaneously immortalized cell line CVCL_KV17 CL:0000010 Transfected with: HGNC; 3827; FPR2 Derived from sampling site: Ovary. Female 21146862 CVCL_L718 3Y1ts-111 transformed cell line Norway rat CVCL_L718 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146863 CVCL_KV18 cAMP Hunter CHO-K1 FSHR Gs spontaneously immortalized cell line CVCL_KV18 CL:0000010 Transfected with: HGNC; 3969; FSHR Derived from sampling site: Ovary. Female 21146864 CVCL_L715 3Y1ts-105 transformed cell line Norway rat CVCL_L715 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146865 CVCL_KV15 cAMP Hunter CHO-K1 FPR1 Gi spontaneously immortalized cell line CVCL_KV15 CL:0000010 Transfected with: HGNC; 3826; FPR1 Derived from sampling site: Ovary. Female 21146866 CVCL_L716 3Y1ts-108 transformed cell line Norway rat CVCL_L716 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146867 CVCL_KV16 cAMP Hunter CHO-K1 FPR3 Gi spontaneously immortalized cell line CVCL_KV16 CL:0000010 Transfected with: HGNC; 3828; FPR3 Derived from sampling site: Ovary. Female 21146868 CVCL_L713 3Y1ts-103 transformed cell line Norway rat CVCL_L713 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146869 CVCL_KV13 cAMP Hunter CHO-K1 EDG2 Gi spontaneously immortalized cell line CVCL_KV13 CL:0000010 Transfected with: HGNC; 3166; LPAR1 Derived from sampling site: Ovary. Female 21146870 CVCL_L714 3Y1ts-104 transformed cell line Norway rat CVCL_L714 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146871 CVCL_KV14 cAMP Hunter CHO-K1 FFAR3 Gi spontaneously immortalized cell line CVCL_KV14 CL:0000010 Transfected with: HGNC; 4499; FFAR3 Derived from sampling site: Ovary. Female 21146872 CVCL_KV11 cAMP Hunter CHO-K1 EBI2 Gi spontaneously immortalized cell line CVCL_KV11 CL:0000010 Transfected with: HGNC; 3128; GPR183 Derived from sampling site: Ovary. Female 21146873 CVCL_L711 tsJT663 transformed cell line Norway rat CVCL_L711 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0233.1; true Female Characteristics: Cell line grows at 34 Celsius but the growth is arrested at 40 Celsius (JCRB) 21146874 CVCL_L712 3Y1ts-101 transformed cell line Norway rat CVCL_L712 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146875 CVCL_KV12 cAMP Hunter CHO-K1 EDG1 Gi spontaneously immortalized cell line CVCL_KV12 CL:0000010 Transfected with: HGNC; 3165; S1PR1 Derived from sampling site: Ovary. Female 21146876 CVCL_KV10 cAMP Hunter CHO-K1 DRD5 Gs spontaneously immortalized cell line CVCL_KV10 CL:0000010 Transfected with: HGNC; 3026; DRD5 Derived from sampling site: Ovary. Female 21146877 CVCL_L710 tsJT60 transformed cell line Norway rat CVCL_L710 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0233.3; true Female Characteristics: Cell line grows at 34 Celsius but the growth is arrested at 40 Celsius (JCRB) 21146878 CVCL_L728 3Y1tsB107 transformed cell line Norway rat CVCL_L728 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146879 CVCL_KV28 cAMP Hunter CHO-K1 GPR109B Gi spontaneously immortalized cell line CVCL_KV28 CL:0000010 Transfected with: HGNC; 16824; HCAR3 Derived from sampling site: Ovary. Female 21146880 CVCL_L729 3Y1tsC102 transformed cell line Norway rat CVCL_L729 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146881 CVCL_KV29 cAMP Hunter CHO-K1 GPR35 Gi spontaneously immortalized cell line CVCL_KV29 CL:0000010 Transfected with: HGNC; 4492; GPR35 Derived from sampling site: Ovary. Female 21146882 CVCL_L726 3Y1ts-202 transformed cell line Norway rat CVCL_L726 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146883 CVCL_KV26 cAMP Hunter CHO-K1 GPBAR1 Gs spontaneously immortalized cell line CVCL_KV26 CL:0000010 Transfected with: HGNC; 19680; GPBAR1 Derived from sampling site: Ovary. Female 21146884 CVCL_L727 3Y1tsA106 transformed cell line Norway rat CVCL_L727 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146885 CVCL_KV27 cAMP Hunter CHO-K1 GPR109A Gi spontaneously immortalized cell line CVCL_KV27 CL:0000010 Transfected with: HGNC; 24827; HCAR2 Derived from sampling site: Ovary. Female 21146886 CVCL_L724 3Y1ts-122 transformed cell line Norway rat CVCL_L724 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146887 CVCL_KV24 cAMP Hunter CHO-K1 GLP1R Gs spontaneously immortalized cell line CVCL_KV24 CL:0000010 Transfected with: HGNC; 4324; GLP1R Derived from sampling site: Ovary. Female 21146888 CVCL_L725 3Y1ts-201 transformed cell line Norway rat CVCL_L725 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146889 CVCL_KV25 cAMP Hunter CHO-K1 GLP2R Gs spontaneously immortalized cell line CVCL_KV25 CL:0000010 Transfected with: HGNC; 4325; GLP2R Derived from sampling site: Ovary. Female 21146890 CVCL_L722 3Y1ts-118 transformed cell line Norway rat CVCL_L722 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146891 CVCL_KV22 cAMP Hunter CHO-K1 GHRHR Gs spontaneously immortalized cell line CVCL_KV22 CL:0000010 Transfected with: HGNC; 4266; GHRHR Derived from sampling site: Ovary. Female 21146892 CVCL_L723 3Y1ts-120 transformed cell line Norway rat CVCL_L723 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146893 CVCL_KV23 cAMP Hunter CHO-K1 GIPR Gs spontaneously immortalized cell line CVCL_KV23 CL:0000010 Transfected with: HGNC; 4271; GIPR Derived from sampling site: Ovary. Female 21146894 CVCL_L720 3Y1ts-115 transformed cell line Norway rat CVCL_L720 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146895 CVCL_KV20 cAMP Hunter CHO-K1 GALR1 Gi spontaneously immortalized cell line CVCL_KV20 CL:0000010 Transfected with: HGNC; 4132; GALR1 Derived from sampling site: Ovary. Female 21146896 CVCL_L721 3Y1ts-117 transformed cell line Norway rat CVCL_L721 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female Characteristics: Temperature sensitive for proliferation Defective at 38.5 Celsius (selection temperature) in undergoing the transition from quiescent to proliferating state. 21146897 CVCL_KV21 cAMP Hunter CHO-K1 GCGR Gs spontaneously immortalized cell line CVCL_KV21 CL:0000010 Transfected with: HGNC; 4192; GCGR Derived from sampling site: Ovary. Female 21146898 CVCL_U079 CAT-13.6E12 hybridoma house mouse CVCL_U079 CL:0000010 Discontinued: DSMZ; ACC-474; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 21146899 CVCL_1I32 GM04775 finite cell line human CVCL_1I32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146900 CVCL_1I33 GM04779 finite cell line human CVCL_1I33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146901 CVCL_1I30 GM04766 transformed cell line human CVCL_1I30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146902 CVCL_1I31 GM04767 finite cell line human CVCL_1I31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146903 CVCL_1I36 GM04786 transformed cell line human CVCL_1I36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146904 CVCL_1I37 GM04787 finite cell line human CVCL_1I37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146905 CVCL_1I34 GM04780 transformed cell line human CVCL_1I34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146906 CVCL_1I35 GM04781 finite cell line human CVCL_1I35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146907 CVCL_1I29 GM04745 finite cell line human CVCL_1I29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146908 CVCL_1I27 GM04711 finite cell line human CVCL_1I27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146909 CVCL_1I28 GM04734 transformed cell line human CVCL_1I28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146910 CVCL_U080 NB4-AsR cancer cell line human CVCL_U080 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Bone marrow. Female 21146911 CVCL_U081 NB4-LR2 cancer cell line human CVCL_U081 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21146912 CVCL_U084 NB4.306 cancer cell line human CVCL_U084 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21146913 CVCL_U085 NB4-DR1 cancer cell line human CVCL_U085 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21146914 CVCL_U082 NB4/As cancer cell line human CVCL_U082 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Bone marrow. Female 21146915 CVCL_U083 NB4.007/6 cancer cell line human CVCL_U083 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=12353268); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21146916 CVCL_U088 NB4-DR3 cancer cell line human CVCL_U088 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21146917 CVCL_U089 NHIK 3025 cancer cell line human CVCL_U089 CL:0000010 Derived from sampling site: Uterus; cervix. Female Doubling time: 18.9 hours (for exponentially growing cells), 20.3 hours (for synchronized cells) (PubMed=6879111) 21146918 CVCL_U086 NB4-S1 cancer cell line human CVCL_U086 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21146919 CVCL_U087 NB4-DR2 cancer cell line human CVCL_U087 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21146920 CVCL_U068 PNV35B hybridoma house mouse CVCL_U068 CL:0000010 Monoclonal antibody isotype: IgG+IgM. 21146921 CVCL_U069 10(AAT) Clone A hybridoma house mouse CVCL_U069 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01009; Human SERPINA1. 21146922 CVCL_1I40 GM04794 transformed cell line human CVCL_1I40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146923 CVCL_1I43 GM04801 finite cell line human CVCL_1I43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146924 CVCL_1I44 GM04808 transformed cell line human CVCL_1I44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146925 CVCL_1I41 GM04795 finite cell line human CVCL_1I41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146926 CVCL_1I42 GM04800 transformed cell line human CVCL_1I42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146927 CVCL_1I47 GM04820 transformed cell line human CVCL_1I47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146928 CVCL_1I48 GM04828 transformed cell line human CVCL_1I48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146929 CVCL_1I45 GM04809 finite cell line human CVCL_1I45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146930 CVCL_1I46 GM04819 finite cell line human CVCL_1I46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146931 CVCL_1I38 GM04792 transformed cell line human CVCL_1I38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146932 CVCL_1I39 GM04793 finite cell line human CVCL_1I39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146933 CVCL_U070 1D10(AAT) Clone 8D10 hybridoma house mouse CVCL_U070 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01009; Human SERPINA1. 21146934 CVCL_U073 2G2B(AAT) Clone 4D4 hybridoma house mouse CVCL_U073 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01009; Human SERPINA1. 21146935 CVCL_U074 4G5(PGM1) Clone B7 hybridoma house mouse CVCL_U074 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P36871; Human PGM1. 21146936 CVCL_U071 1E7(GC) Clone B hybridoma house mouse CVCL_U071 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02774; Human GC. 21146937 CVCL_U072 2A2(PGM1) Clone A6 hybridoma house mouse CVCL_U072 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P36871; Human PGM1. 21146938 CVCL_U077 6H7(PGM1) Clone D10 hybridoma house mouse CVCL_U077 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P36871; Human PGM1. 21146939 CVCL_U078 7E10(GC) Clone A hybridoma house mouse CVCL_U078 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02774; Human GC. 21146940 CVCL_U075 4H8(GC) Clone 4D4 hybridoma house mouse CVCL_U075 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02774; Human GC. 21146941 CVCL_U076 6G5(AAT) Clone 1C9 hybridoma house mouse CVCL_U076 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01009; Human SERPINA1. 21146942 CVCL_U059 PNMR OE hybridoma house mouse CVCL_U059 CL:0000010 Monoclonal antibody isotype: IgM. 21146943 CVCL_U057 PNMR 120E hybridoma house mouse CVCL_U057 CL:0000010 Monoclonal antibody isotype: IgM. 21146944 CVCL_U058 PNMR 160D hybridoma house mouse CVCL_U058 CL:0000010 Monoclonal antibody isotype: IgM. 21146945 CVCL_1I10 GM04225 transformed cell line human CVCL_1I10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146946 CVCL_1I11 GM04226 finite cell line human CVCL_1I11 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146947 CVCL_1I14 GM04230 finite cell line human CVCL_1I14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146948 CVCL_1I15 GM04231 transformed cell line human CVCL_1I15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146949 CVCL_1I12 GM04227 transformed cell line human CVCL_1I12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Peripheral blood. Male 21146950 CVCL_1I13 GM04229 transformed cell line human CVCL_1I13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21146951 CVCL_1I07 GM04221 transformed cell line human CVCL_1I07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21146952 CVCL_1I08 GM04222 finite cell line human CVCL_1I08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21146953 CVCL_1I05 GM04219 transformed cell line human CVCL_1I05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146954 CVCL_1I06 GM04220 finite cell line human CVCL_1I06 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21146955 CVCL_1I09 GM04223 transformed cell line human CVCL_1I09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21146956 CVCL_U062 CC101 hybridoma house mouse CVCL_U062 CL:0000010 Monoclonal antibody isotype: IgG2a. 21146957 CVCL_U063 CC171 hybridoma house mouse CVCL_U063 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; F1MJS9; Bovine PTPRC/CD45. 21146958 CVCL_U060 CC98 hybridoma house mouse CVCL_U060 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6WY07; Bovine LY75/CD205 (BoWC6). 21146959 CVCL_U061 CC62 hybridoma house mouse CVCL_U061 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P81425; Bovine DPP4/CD26. 21146960 CVCL_U066 Myc1-6E10 hybridoma house mouse CVCL_U066 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21146961 CVCL_U067 AFRC MAC 61.6 hybridoma Norway rat CVCL_U067 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: ChEBI; CHEBI:2365; (+)-abscisic acid. 21146962 CVCL_U064 C1 [Mouse hybridoma] hybridoma house mouse CVCL_U064 CL:0000010 Monoclonal antibody isotype: IgM. 21146963 CVCL_U065 LY9 hybridoma house mouse CVCL_U065 CL:0000010 Monoclonal antibody isotype: IgG3. 21146964 CVCL_U048 CLXXVI-3C11-F14 hybridoma house mouse CVCL_U048 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania venezuelensis. 21146965 CVCL_U049 XCIII-1F8-D7 hybridoma house mouse CVCL_U049 CL:0000010 Monoclonal antibody isotype: IgG1. 21146966 CVCL_U046 IX-5H9-C10 hybridoma house mouse CVCL_U046 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania amazonensis. 21146967 CVCL_U047 LXVIII-1D7-B8 hybridoma house mouse CVCL_U047 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania mexicana. 21146968 CVCL_1I21 GM04584 transformed cell line human CVCL_1I21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21146969 CVCL_1I22 GM04691 finite cell line human CVCL_1I22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146970 CVCL_1I20 GM04534 transformed cell line human CVCL_1I20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Peripheral blood. Male 21146971 CVCL_1I25 GM04707 finite cell line human CVCL_1I25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146972 CVCL_1I26 GM04708 transformed cell line human CVCL_1I26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146973 CVCL_1I23 GM04692 transformed cell line human CVCL_1I23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21146974 CVCL_1I24 GM04704 transformed cell line human CVCL_1I24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146975 CVCL_1I18 GM04290 transformed cell line human CVCL_1I18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146976 CVCL_1I19 GM04482 finite cell line human CVCL_1I19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21146977 CVCL_1I16 GM04232 finite cell line human CVCL_1I16 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21146978 CVCL_1I17 GM04233 transformed cell line human CVCL_1I17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at low risk for disease; Derived from sampling site: Peripheral blood. Male 21146979 CVCL_U051 XCIV-1H2-A8 hybridoma house mouse CVCL_U051 CL:0000010 Monoclonal antibody isotype: IgM. 21146980 CVCL_U052 LXXIX-1G12-G7 hybridoma house mouse CVCL_U052 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Leishmania donovani. 21146981 CVCL_U050 XCIII-3D8-D8 hybridoma house mouse CVCL_U050 CL:0000010 Monoclonal antibody isotype: IgG1. 21146982 CVCL_U055 R1 [Mouse hybridoma] hybridoma house mouse CVCL_U055 CL:0000010 Monoclonal antibody isotype: IgM. 21146983 CVCL_U056 W6/1 hybridoma house mouse CVCL_U056 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human group A erythrocytes. 21146984 CVCL_U053 JB1 [Mouse hybridoma against human HFE] hybridoma house mouse CVCL_U053 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21146985 CVCL_U054 16-23 hybridoma house mouse CVCL_U054 CL:0000010 Monoclonal antibody isotype: IgG3. 21146986 CVCL_U037 LXVIII-4D8-E3 hybridoma house mouse CVCL_U037 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Leishmania mexicana. 21146987 CVCL_U038 LXXVIII-2E5-A8 hybridoma house mouse CVCL_U038 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania chagasi. 21146988 CVCL_U035 IX-2H7-E10 hybridoma house mouse CVCL_U035 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Leishmania amazonensis. 21146989 CVCL_U036 LI-3H2-G6 hybridoma house mouse CVCL_U036 CL:0000010 Monoclonal antibody isotype: IgG2b. 21146990 CVCL_U039 VI-4D10-D12 hybridoma house mouse CVCL_U039 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania brazilensis and Leishmania panamensis. 21146991 CVCL_KU98 cAMP Hunter CHO-K1 CRHR2 Gs spontaneously immortalized cell line CVCL_KU98 CL:0000010 Transfected with: HGNC; 2358; CRHR2 Derived from sampling site: Ovary. Female 21146992 CVCL_L698 SK 8 hybridoma human CVCL_L698 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8585 21146993 CVCL_KU99 cAMP Hunter CHO-K1 CRTH2 Gi spontaneously immortalized cell line CVCL_KU99 CL:0000010 Transfected with: HGNC; 4502; PTGDR2 Derived from sampling site: Ovary. Female 21146994 CVCL_L699 KE 37.3.2 cancer cell line human CVCL_L699 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Male 21146995 CVCL_KU96 cAMP Hunter CHO-K1 CNR2 Gi spontaneously immortalized cell line CVCL_KU96 CL:0000010 Transfected with: HGNC; 2160; CNR2 Derived from sampling site: Ovary. Female 21146996 CVCL_L696 HM 1 hybridoma human CVCL_L696 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8586 21146997 CVCL_KU97 cAMP Hunter CHO-K1 CRHR1 Gs spontaneously immortalized cell line CVCL_KU97 CL:0000010 Transfected with: HGNC; 2357; CRHR1 Derived from sampling site: Ovary. Female 21146998 CVCL_L697 SK 7 hybridoma human CVCL_L697 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8584 21146999 CVCL_KU94 cAMP Hunter CHO-K1 CMKLR1 Gi spontaneously immortalized cell line CVCL_KU94 CL:0000010 Transfected with: HGNC; 2121; CMKLR1 Derived from sampling site: Ovary. Female 21147000 CVCL_L694 OPA1-null MEFs transformed cell line house mouse CVCL_L694 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1921393; Opa1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21147001 CVCL_KU95 cAMP Hunter CHO-K1 CNR1 Gi spontaneously immortalized cell line CVCL_KU95 CL:0000010 Transfected with: HGNC; 2159; CNR1 Derived from sampling site: Ovary. Female 21147002 CVCL_L695 HTUD1 spontaneously immortalized cell line CVCL_L695 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Female Group: Amphibian cell line 21147003 CVCL_KU92 cAMP Hunter CHO-K1 CHRM2 Gs spontaneously immortalized cell line CVCL_KU92 CL:0000010 Transfected with: HGNC; 1951; CHRM2 Derived from sampling site: Ovary. Female 21147004 CVCL_L692 Mfn1/Mfn2-null MEFs transformed cell line house mouse CVCL_L692 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1914664; Mfn1; Knockout cell: Method=KO mouse; MGI; MGI:2442230; Mfn2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21147005 CVCL_U040 VI-2A5-A4 hybridoma house mouse CVCL_U040 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania panamensis. 21147006 CVCL_KU93 cAMP Hunter CHO-K1 CHRM4 Gs spontaneously immortalized cell line CVCL_KU93 CL:0000010 Transfected with: HGNC; 1953; CHRM4 Derived from sampling site: Ovary. Female 21147007 CVCL_L693 Mfn2-null MEFs transformed cell line house mouse CVCL_L693 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2442230; Mfn2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21147008 CVCL_U041 VII-II-5G3-F3 hybridoma house mouse CVCL_U041 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania panamensis. 21147009 CVCL_KU90 cAMP Hunter CHO-K1 CCR6 Gi spontaneously immortalized cell line CVCL_KU90 CL:0000010 Transfected with: HGNC; 1607; CCR6 Derived from sampling site: Ovary. Female 21147010 CVCL_L690 Wt MEFs transformed cell line house mouse CVCL_L690 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21147011 CVCL_KU91 cAMP Hunter CHO-K1 CCR7 Gi spontaneously immortalized cell line CVCL_KU91 CL:0000010 Transfected with: HGNC; 1608; CCR7 Derived from sampling site: Ovary. Female 21147012 CVCL_L691 Mfn1-null MEFs transformed cell line house mouse CVCL_L691 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1914664; Mfn1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21147013 CVCL_U044 XIV-2A5-A10 hybridoma house mouse CVCL_U044 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania braziliensis braziliensis. 21147014 CVCL_U045 XLIV-5A2-B9 hybridoma house mouse CVCL_U045 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania guyanensis. 21147015 CVCL_U042 XIII-3H6-A12 hybridoma house mouse CVCL_U042 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania brazilensis and Leishmania panamensis. 21147016 CVCL_U043 XIII-3E6-B11 hybridoma house mouse CVCL_U043 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Leishmania braziliensis braziliensis. 21147017 CVCL_U026 OX-76 hybridoma house mouse CVCL_U026 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rat MHC class II. 21147018 CVCL_U027 OX-80 hybridoma Norway rat CVCL_U027 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q61451; Mouse Cd53. 21147019 CVCL_U024 OX-24 hybridoma house mouse CVCL_U024 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08603; Human CFH. 21147020 CVCL_U025 OX-46 hybridoma house mouse CVCL_U025 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10252; Rat Cd48. 21147021 CVCL_U028 OX-89 hybridoma CVCL_U028 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43488; Mouse Tnfsf4/Cd252. 21147022 CVCL_U029 OX-90 hybridoma CVCL_U029 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O54901; Mouse Cd200. 21147023 CVCL_1I00 GM04208 finite cell line human CVCL_1I00 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21147024 CVCL_1I03 GM04213 transformed cell line human CVCL_1I03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147025 CVCL_1I04 GM04217 transformed cell line human CVCL_1I04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147026 CVCL_1I01 GM04209 transformed cell line human CVCL_1I01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147027 CVCL_1I02 GM04212 finite cell line human CVCL_1I02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21147028 CVCL_U030 CLVIII-3A6-E3 hybridoma house mouse CVCL_U030 CL:0000010 Monoclonal antibody isotype: IgG2b. 21147029 CVCL_U033 utr-1 hybridoma house mouse CVCL_U033 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20333; Human TNFRSF1B/CD120b. 21147030 CVCL_U034 utr-4a hybridoma house mouse CVCL_U034 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P20333; Human TNFRSF1B/CD120b. 21147031 CVCL_U031 htr-20 hybridoma house mouse CVCL_U031 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P19438; Human TNFRSF1A/CD120a. 21147032 CVCL_U032 htr-9c hybridoma house mouse CVCL_U032 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19438; Human TNFRSF1A/CD120a. 21147033 CVCL_U015 SPARKY cancer cell line CVCL_U015 CL:0000010 Derived from metastatic site: Pleural effusion; Breed/subspecies: Persian. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2919 21147034 CVCL_U016 RN46A-B14 transformed cell line Norway rat CVCL_U016 CL:0000010 Transfected with: RGD; 2202; Bdnf; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; medullary raphe nucleus; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: 25 hours (ECACC=12061303) 21147035 CVCL_U013 T26J-1/09 spontaneously immortalized cell line CVCL_U013 CL:0000010 Transfected with: HGNC; 286; ADRB2 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147036 CVCL_U014 T35J-5/09 spontaneously immortalized cell line CVCL_U014 CL:0000010 Transfected with: HGNC; 4499; FFAR3 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147037 CVCL_U019 OX-104 hybridoma house mouse CVCL_U019 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P41217; Human CD200. 21147038 CVCL_U017 OX-101 hybridoma house mouse CVCL_U017 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P97829; Rat Cd47. 21147039 CVCL_U018 OX-102 hybridoma house mouse CVCL_U018 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9ES58; Rat Cd200r1. 21147040 CVCL_KU78 cAMP Hunter CHO-K1 ADRB1 Gs spontaneously immortalized cell line CVCL_KU78 CL:0000010 Transfected with: HGNC; 285; ADRB1 Derived from sampling site: Ovary. Female 21147041 CVCL_L678 QPN1 17G8 hybridoma house mouse CVCL_L678 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9504 21147042 CVCL_KU79 cAMP Hunter CHO-K1 ADRB2 Gs spontaneously immortalized cell line CVCL_KU79 CL:0000010 Transfected with: HGNC; 286; ADRB2 Derived from sampling site: Ovary. Female 21147043 CVCL_L679 QPN1 21G2 hybridoma house mouse CVCL_L679 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9507 21147044 CVCL_KU76 cAMP Hunter CHO-K1 ADRA2A Gi spontaneously immortalized cell line CVCL_KU76 CL:0000010 Transfected with: HGNC; 281; ADRA2A Derived from sampling site: Ovary. Female 21147045 CVCL_L676 FW14-14-18 hybridoma house mouse CVCL_L676 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P23229; Human ITGA6/CD49f. 21147046 CVCL_KU77 cAMP Hunter CHO-K1 ADRA2C Gi spontaneously immortalized cell line CVCL_KU77 CL:0000010 Transfected with: HGNC; 283; ADRA2C Derived from sampling site: Ovary. Female 21147047 CVCL_L677 QPN1 13E10 hybridoma house mouse CVCL_L677 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9503 21147048 CVCL_L674 Anti-SC35 hybridoma house mouse CVCL_L674 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q01130; Human SRSF2/SC35 21147049 CVCL_KU74 cAMP Hunter CHO-K1 ADORA2B Gs spontaneously immortalized cell line CVCL_KU74 CL:0000010 Transfected with: HGNC; 264; ADORA2B Derived from sampling site: Ovary. Female 21147050 CVCL_KU75 cAMP Hunter CHO-K1 ADORA3 Gi spontaneously immortalized cell line CVCL_KU75 CL:0000010 Transfected with: HGNC; 268; ADORA3 Derived from sampling site: Ovary. Female 21147051 CVCL_L675 FW3-47 hybridoma house mouse CVCL_L675 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B0FYY4; Sheep ITGB1/CD29. 21147052 CVCL_KU72 cAMP Hunter CHO-K1 ADCYAP1R1 Gs/Gq spontaneously immortalized cell line CVCL_KU72 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1 Derived from sampling site: Ovary. Female 21147053 CVCL_L672 MA2.1 hybridoma house mouse CVCL_L672 CL:0000010 Monoclonal antibody isotype: IgG1. 21147054 CVCL_L673 Antibody 2.06 hybridoma house mouse CVCL_L673 CL:0000010 Monoclonal antibody isotype: IgG1. 21147055 CVCL_KU73 cAMP Hunter CHO-K1 ADORA1 Gi spontaneously immortalized cell line CVCL_KU73 CL:0000010 Transfected with: HGNC; 262; ADORA1 Derived from sampling site: Ovary. Female 21147056 CVCL_L670 SMA-iPS1 induced pluripotent stem cell human CVCL_L670 HLA typing: A*24,26; B*60,55 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7del; Zygosity=Unspecified (PubMed=22673189) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21147057 CVCL_KU70 U2OS OXGR1 Gq cancer cell line human CVCL_KU70 CL:0000010 Transfected with: HGNC; 4531; OXGR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21147058 CVCL_KU71 cAMP Hunter 1321N1 CALCR-RAMP3 Gs cancer cell line human CVCL_KU71 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9845; RAMP3 Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21147059 CVCL_L671 SMA-iPS2 induced pluripotent stem cell human CVCL_L671 HLA typing: A*24,26; B*60,55 (PubMed=22673189) From: Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7del; Zygosity=Unspecified (PubMed=22673189) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21147060 CVCL_U022 OX-132 hybridoma Norway rat CVCL_U022 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6XJV6; Mouse Cd200r1l. 21147061 CVCL_U023 OX-23 hybridoma house mouse CVCL_U023 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08603; Human CFH. 21147062 CVCL_U020 OX-109 hybridoma house mouse CVCL_U020 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q8TD46; Human CD200R1. 21147063 CVCL_U021 OX-114 hybridoma Norway rat CVCL_U021 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18572; Mouse Bsg/Cd147. 21147064 CVCL_U004 CHO-CHRM5 spontaneously immortalized cell line CVCL_U004 CL:0000010 Transfected with: HGNC; 1954; CHRM5 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147065 CVCL_U005 CHO-FFAR2 spontaneously immortalized cell line CVCL_U005 CL:0000010 Transfected with: HGNC; 4501; FFAR2 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147066 CVCL_U002 CHO-CHRM1 spontaneously immortalized cell line CVCL_U002 CL:0000010 Transfected with: HGNC; 1950; CHRM1 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147067 CVCL_U003 CHO-CHRM2 spontaneously immortalized cell line CVCL_U003 CL:0000010 Transfected with: HGNC; 1951; CHRM2 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147068 CVCL_U008 CHO-OPRL1 spontaneously immortalized cell line CVCL_U008 CL:0000010 Transfected with: HGNC; 8155; OPRL1 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147069 CVCL_U009 CHO-SSTR1 spontaneously immortalized cell line CVCL_U009 CL:0000010 Transfected with: HGNC; 11330; SSTR1 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147070 CVCL_U006 Flp293A transformed cell line human CVCL_U006 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21147071 CVCL_U007 CHO-GPR120 spontaneously immortalized cell line CVCL_U007 CL:0000010 Transfected with: HGNC; 19061; FFAR4 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147072 CVCL_KU89 cAMP Hunter CHO-K1 CCR5 Gi spontaneously immortalized cell line CVCL_KU89 CL:0000010 Transfected with: HGNC; 1606; CCR5 Derived from sampling site: Ovary. Female 21147073 CVCL_L689 mAb 986.35 hybridoma house mouse CVCL_L689 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9284 21147074 CVCL_KU87 cAMP Hunter CHO-K1 CCR1 Gi spontaneously immortalized cell line CVCL_KU87 CL:0000010 Transfected with: HGNC; 1602; CCR1 Derived from sampling site: Ovary. Female 21147075 CVCL_L687 mAb 239 hybridoma house mouse CVCL_L687 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8288 21147076 CVCL_KU88 cAMP Hunter CHO-K1 CCR10 Gi spontaneously immortalized cell line CVCL_KU88 CL:0000010 Transfected with: HGNC; 4474; CCR10 Derived from sampling site: Ovary. Female 21147077 CVCL_L688 mAb 829 hybridoma house mouse CVCL_L688 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P40189; Human IL6ST/CD130/gp130. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8289 21147078 CVCL_KU85 cAMP Hunter CHO-K1 CALCRL-RAMP1 Gs spontaneously immortalized cell line CVCL_KU85 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9843; RAMP1 Derived from sampling site: Ovary. Female 21147079 CVCL_L685 P2 57G4 hybridoma house mouse CVCL_L685 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9505 21147080 CVCL_KU86 cAMP Hunter CHO-K1 CALCRL-RAMP3 Gs spontaneously immortalized cell line CVCL_KU86 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9845; RAMP3 Derived from sampling site: Ovary. Female 21147081 CVCL_L686 NPN 43C9 hybridoma house mouse CVCL_L686 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody that acts as an amidase; Monoclonal antibody isotype: IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9721 21147082 CVCL_KU83 cAMP Hunter CHO-K1 C5AR1 Gi spontaneously immortalized cell line CVCL_KU83 CL:0000010 Transfected with: HGNC; 1338; C5AR1 Derived from sampling site: Ovary. Female 21147083 CVCL_L683 P3 6D4 hybridoma house mouse CVCL_L683 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9168 21147084 CVCL_KU84 cAMP Hunter CHO-K1 CALCR Gs spontaneously immortalized cell line CVCL_KU84 CL:0000010 Transfected with: HGNC; 1440; CALCR Derived from sampling site: Ovary. Female 21147085 CVCL_L684 P2 50D8 hybridoma house mouse CVCL_L684 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9506 21147086 CVCL_KU81 cAMP Hunter CHO-K1 AVPR2 Gs spontaneously immortalized cell line CVCL_KU81 CL:0000010 Transfected with: HGNC; 897; AVPR2 Derived from sampling site: Ovary. Female 21147087 CVCL_L681 QPN1 44A2 hybridoma house mouse CVCL_L681 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9501 21147088 CVCL_KU82 cAMP Hunter CHO-K1 C3AR1 Gi spontaneously immortalized cell line CVCL_KU82 CL:0000010 Transfected with: HGNC; 1319; C3AR1 Derived from sampling site: Ovary. Female 21147089 CVCL_L682 QPN1 7E5 hybridoma house mouse CVCL_L682 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9502 21147090 CVCL_KU80 cAMP Hunter CHO-K1 AGTRL1 Gi spontaneously immortalized cell line CVCL_KU80 CL:0000010 Transfected with: HGNC; 339; APLNR Derived from sampling site: Ovary. Female 21147091 CVCL_L680 QPN1 37G2 hybridoma house mouse CVCL_L680 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9508 21147092 CVCL_U011 T02J-7/10 spontaneously immortalized cell line CVCL_U011 CL:0000010 Transfected with: HGNC; 1952; CHRM3 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147093 CVCL_U012 T02J-9/10 spontaneously immortalized cell line CVCL_U012 CL:0000010 Transfected with: HGNC; 5183; HRH2 Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147094 CVCL_U010 T02J-10/10 spontaneously immortalized cell line CVCL_U010 CL:0000010 Transfected with: HGNC; 4192; GCGR Derived from sampling site: Ovary. Female Characteristics: The target gene was transfected using the InSCREENeX SCREENflex system 21147095 CVCL_1I90 GM05528 transformed cell line human CVCL_1I90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147096 CVCL_1I91 GM05530 transformed cell line human CVCL_1I91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147097 CVCL_1I94 GM05538 transformed cell line human CVCL_1I94 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[97] (c.52CAG(97)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM05539) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147098 CVCL_1I95 GM05539 finite cell line human CVCL_1I95 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[97] (c.52CAG(97)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147099 CVCL_1I92 GM05534 transformed cell line human CVCL_1I92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147100 CVCL_1I93 GM05536 transformed cell line human CVCL_1I93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147101 CVCL_1I98 GM05546 transformed cell line human CVCL_1I98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147102 CVCL_1I99 GM05552 transformed cell line human CVCL_1I99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147103 CVCL_1I96 GM05542 transformed cell line human CVCL_1I96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147104 CVCL_1I97 GM05544 transformed cell line human CVCL_1I97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147105 CVCL_1I72 GM04868 transformed cell line human CVCL_1I72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147106 CVCL_1I73 GM04869 finite cell line human CVCL_1I73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147107 CVCL_1I70 GM04866 transformed cell line human CVCL_1I70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147108 CVCL_1I71 GM04867 finite cell line human CVCL_1I71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147109 CVCL_1I76 GM05030 finite cell line human CVCL_1I76 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21147110 CVCL_1I77 GM05031 finite cell line human CVCL_1I77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21147111 CVCL_1I74 GM04894 transformed cell line human CVCL_1I74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147112 CVCL_1I75 GM04915 transformed cell line human CVCL_1I75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147113 CVCL_1I78 GM05376 transformed cell line human CVCL_1I78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147114 CVCL_1I79 GM05428 transformed cell line human CVCL_1I79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147115 CVCL_1I80 GM05440 transformed cell line human CVCL_1I80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147116 CVCL_1I83 GM05452 transformed cell line human CVCL_1I83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147117 CVCL_1I84 GM05454 transformed cell line human CVCL_1I84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147118 CVCL_1I81 GM05442 transformed cell line human CVCL_1I81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147119 CVCL_1I82 GM05448 transformed cell line human CVCL_1I82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147120 CVCL_1I87 GM05506 transformed cell line human CVCL_1I87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147121 CVCL_1I88 GM05524 transformed cell line human CVCL_1I88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147122 CVCL_1I85 GM05486 transformed cell line human CVCL_1I85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147123 CVCL_1I86 GM05496 transformed cell line human CVCL_1I86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147124 CVCL_1I89 GM05526 transformed cell line human CVCL_1I89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147125 CVCL_1I50 GM04830 transformed cell line human CVCL_1I50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147126 CVCL_1I51 GM04831 finite cell line human CVCL_1I51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147127 CVCL_1I54 GM04845 finite cell line human CVCL_1I54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147128 CVCL_1I55 GM04846 transformed cell line human CVCL_1I55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147129 CVCL_1I52 GM04837 finite cell line human CVCL_1I52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147130 CVCL_1I53 GM04844 transformed cell line human CVCL_1I53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147131 CVCL_1I58 GM04852 transformed cell line human CVCL_1I58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147132 CVCL_1I59 GM04853 finite cell line human CVCL_1I59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147133 CVCL_1I56 GM04847 finite cell line human CVCL_1I56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147134 CVCL_1I57 GM04849 finite cell line human CVCL_1I57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147135 CVCL_1I49 GM04829 finite cell line human CVCL_1I49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147136 CVCL_1I61 GM04855 finite cell line human CVCL_1I61 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[48] (c.52CAG(48)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147137 CVCL_1I62 GM04856 transformed cell line human CVCL_1I62 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM04857); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM04857) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147138 CVCL_1I60 GM04854 transformed cell line human CVCL_1I60 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[48] (c.52CAG(48)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM04855) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147139 CVCL_1I65 GM04859 finite cell line human CVCL_1I65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147140 CVCL_1I66 GM04860 transformed cell line human CVCL_1I66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147141 CVCL_1I63 GM04857 finite cell line human CVCL_1I63 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147142 CVCL_1I64 GM04858 transformed cell line human CVCL_1I64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147143 CVCL_1I69 GM04865 finite cell line human CVCL_1I69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147144 CVCL_1I67 GM04861 finite cell line human CVCL_1I67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147145 CVCL_1I68 GM04864 transformed cell line human CVCL_1I68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147146 CVCL_U091 G603L cancer cell line human CVCL_U091 HLA typing: A*26:02,31:012; B*15:01,40:02; C*03:03,03:04 (PubMed=17131342) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=21498706) Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 23 hours (PubMed=15573370) 21147147 CVCL_U092 F1121L cancer cell line human CVCL_U092 HLA typing: A*24:02,02:01; B*15:07,40:06; C*03:03,08:01 (PubMed=17131342) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147148 CVCL_U090 G603AD cancer cell line human CVCL_U090 CL:0000010 Population: Japanese; Derived from metastatic site: Adrenal gland. Male Doubling time: 23 hours (PubMed=15573370) 21147149 CVCL_U095 A904L cancer cell line human CVCL_U095 HLA typing: A*24:02; B*07:02; C*07:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21147150 CVCL_U096 A925L cancer cell line human CVCL_U096 HLA typing: A*02:01,24:02; B*46:01,59:01; C*01:02,01:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21147151 CVCL_U093 A110L cancer cell line human CVCL_U093 HLA typing: A*24:02; B*52:01; C*12:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21147152 CVCL_U094 A129L cancer cell line human CVCL_U094 HLA typing: A*02:06; B*07:02; C*07:02 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21147153 CVCL_U099 C1026L cancer cell line human CVCL_U099 HLA typing: A*24:02,33:03; B*35:01,44:031; C*08:01,14:03 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147154 CVCL_U097 B203L cancer cell line human CVCL_U097 HLA typing: A*24:02,31:012; B*15:01,54:01; C*01:02,03:04 (PubMed=12114371) CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147155 CVCL_U098 B901L cancer cell line human CVCL_U098 HLA typing: A*02:06,26:01; B*39:01,40:06; C*07:02,08:01 (PubMed=12114371) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del; Zygosity=Unspecified (PubMed=21498706) Population: Japanese; Derived from sampling site: Lung. Female 21147156 CVCL_L818 AFRC 78A3 hybridoma house mouse CVCL_L818 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147157 CVCL_KW18 PathHunter C2C12 CXCR4 beta-arrestin spontaneously immortalized cell line house mouse CVCL_KW18 CL:0000010 Transfected with: HGNC; 2561; CXCR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147158 CVCL_L819 AFRC 84B4 hybridoma house mouse CVCL_L819 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147159 CVCL_KW19 PathHunter C2C12 CXCR5 beta-arrestin spontaneously immortalized cell line house mouse CVCL_KW19 CL:0000010 Transfected with: HGNC; 1060; CXCR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147160 CVCL_L816 AFRC 56D2 hybridoma house mouse CVCL_L816 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147161 CVCL_KW16 PathHunter A549 IkappaB Degradation cancer cell line human CVCL_KW16 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7797; NFKBIA Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21147162 CVCL_L817 AFRC 58D6 hybridoma house mouse CVCL_L817 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147163 CVCL_KW17 PathHunter BHK-21 rPTGER4 beta-arrestin spontaneously immortalized cell line CVCL_KW17 CL:0000010 Transfected with: RGD; 628641; Ptger4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Kidney. Male Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147164 CVCL_L814 B6 finite cell line human CVCL_L814 CL:0000010 Derived from sampling site: Trophoblast. Male Doubling time: 48 hours (PubMed=8671449) 21147165 CVCL_KW14 InCELL Hunter U2OS BCL2L1-BIM Protein Binding cancer cell line human CVCL_KW14 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 994; BCL2L11 (with del 1-121 and 182-198) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147166 CVCL_L815 AFRC 17D1 hybrid cell line house mouse CVCL_L815 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 21147167 CVCL_KW15 InCELL Hunter U2OS MCL1-BIM Protein Binding cancer cell line human CVCL_KW15 CL:0000010 Transfected with: HGNC; 6943; MCL1; Transfected with: HGNC; 994; BCL2L11 (with del 1-141 and 162-198) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147168 CVCL_KW12 InCELL Hunter U2OS BCL2-BIM Protein Binding cancer cell line human CVCL_KW12 CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: HGNC; 994; BCL2L11 (with del 1-141 and 162-198) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147169 CVCL_L812 Py-AL/N transformed cell line house mouse CVCL_L812 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Whole embryo; Breed/subspecies: AL/N. Unspecified 21147170 CVCL_KW13 InCELL Hunter U2OS BCL2L1-BAX Protein Binding cancer cell line human CVCL_KW13 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 959; BAX (with del 1-51 and 73-192) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147171 CVCL_L813 SV-AL/N transformed cell line house mouse CVCL_L813 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo; Breed/subspecies: AL/N. Unspecified 21147172 CVCL_KW10 InCELL Hunter HEK 293 TAF1L(2) Bromodomain transformed cell line human CVCL_KW10 CL:0000010 Transfected with: HGNC; 18056; TAF1L (with del 1-1522 and 1655-1826) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147173 CVCL_L810 NMS-2PC cancer cell line human CVCL_L810 CL:0000010 Population: Japanese; Derived from metastatic site: Retroperitoneal space. Male Doubling time: 44.7 hours (PubMed=9849858) 21147174 CVCL_L811 1E8 [Human leukemia] cancer cell line human CVCL_L811 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00169 Problematic cell line: Contaminated Parent cell line (BLIN-1) has been shown to be a NALM-6 derivative (PubMed=20143388). 21147175 CVCL_KW11 InCELL Hunter U2OS BCL2-BAX Protein Binding cancer cell line human CVCL_KW11 CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: HGNC; 959; BAX (with del 1-51 and 73-192) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147176 CVCL_L829 AFRC MAC 4 hybridoma Norway rat CVCL_L829 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21147177 CVCL_KW29 PathHunter CHO-K1 ADRB1 beta-arrestin spontaneously immortalized cell line CVCL_KW29 CL:0000010 Transfected with: HGNC; 285; ADRB1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147178 CVCL_L827 AFRC MAC 260 hybridoma CVCL_L827 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P13689; Maize auxin-binding protein 1 (ABP1). 21147179 CVCL_KW27 PathHunter CHO-K1 ADRA2B beta-arrestin spontaneously immortalized cell line CVCL_KW27 CL:0000010 Transfected with: HGNC; 282; ADRA2B; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147180 CVCL_L828 AFRC MAC 31 hybridoma Norway rat CVCL_L828 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21147181 CVCL_KW28 PathHunter CHO-K1 ADRA2C beta-arrestin spontaneously immortalized cell line CVCL_KW28 CL:0000010 Transfected with: HGNC; 283; ADRA2C; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147182 CVCL_L825 AFRC MAC 259 hybridoma Norway rat CVCL_L825 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13689; Maize auxin-binding protein 1 (ABP1). 21147183 CVCL_KW25 PathHunter CHO-K1 ADRA1B beta-arrestin spontaneously immortalized cell line CVCL_KW25 CL:0000010 Transfected with: HGNC; 278; ADRA1B; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147184 CVCL_L826 AFRC MAC 26 hybridoma Norway rat CVCL_L826 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17165; Rabbit APOB. 21147185 CVCL_KW26 PathHunter CHO-K1 ADRA2A beta-arrestin spontaneously immortalized cell line CVCL_KW26 CL:0000010 Transfected with: HGNC; 281; ADRA2A; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147186 CVCL_L823 AFRC 85D6 hybridoma house mouse CVCL_L823 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147187 CVCL_KW23 PathHunter CHO-K1 ADORA1 beta-arrestin spontaneously immortalized cell line CVCL_KW23 CL:0000010 Transfected with: HGNC; 262; ADORA1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147188 CVCL_L824 AFRC MAC 258 hybridoma Norway rat CVCL_L824 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13689; Maize auxin-binding protein 1 (ABP1). 21147189 CVCL_KW24 PathHunter CHO-K1 ADORA3 beta-arrestin spontaneously immortalized cell line CVCL_KW24 CL:0000010 Transfected with: HGNC; 268; ADORA3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147190 CVCL_L821 AFRC 85A2 hybridoma house mouse CVCL_L821 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147191 CVCL_KW21 PathHunter C2C12 TACR1 beta-arrestin spontaneously immortalized cell line house mouse CVCL_KW21 CL:0000010 Transfected with: HGNC; 11526; TACR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147192 CVCL_L822 AFRC 85B5 hybridoma house mouse CVCL_L822 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147193 CVCL_KW22 PathHunter CHO-K1 ADCYAP1R1 beta-arrestin spontaneously immortalized cell line CVCL_KW22 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147194 CVCL_L820 AFRC 84C6 hybridoma house mouse CVCL_L820 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; A0A023PW73; Influenza A virus isolate A/Equine/New Market/1979 H3N8 hemagglutinin (HA). 21147195 CVCL_KW20 PathHunter C2C12 KISS1R beta-arrestin spontaneously immortalized cell line house mouse CVCL_KW20 CL:0000010 Transfected with: HGNC; 4510; KISS1R; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147196 CVCL_KW09 InCELL Hunter HEK 293 SMARCA4 Bromodomain transformed cell line human CVCL_KW09 CL:0000010 Transfected with: HGNC; 11100; SMARCA4 (with del 1-1455 and 1567-1647) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147197 CVCL_L809 YaFuSS cancer cell line human CVCL_L809 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=15814652) Population: Japanese Omics: Transcriptome analysis by RNAseq. Male 21147198 CVCL_KW07 InCELL Hunter HEK 293 BRDT(1) Bromodomain transformed cell line human CVCL_KW07 CL:0000010 Transfected with: HGNC; 1105; BRDT (with del 1-27 and 131-947) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147199 CVCL_L807 MDS cancer cell line human CVCL_L807 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00237 Problematic cell line: Contaminated Shown to be a Jurkat derivative (PubMed=12592342; PubMed=19344951; PubMed=20143388). 21147200 CVCL_KW08 InCELL Hunter HEK 293 BRDT(1,2) Bromodomain transformed cell line human CVCL_KW08 CL:0000010 Transfected with: HGNC; 1105; BRDT (with del 1-27 and 377-947) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147201 CVCL_L808 RC-2A cancer cell line human CVCL_L808 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00259 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of an adult male patient with acute myelomonocytic leukemia. 21147202 CVCL_L805 HK cancer cell line human CVCL_L805 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 36 hours (PubMed=2827813) 21147203 CVCL_KW05 InCELL Hunter HEK 293 BRD3(1,2) Bromodomain transformed cell line human CVCL_KW05 CL:0000010 Transfected with: HGNC; 1104; BRD3 (with del 404-726) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147204 CVCL_KW06 InCELL Hunter HEK 293 BRD4(1) Bromodomain transformed cell line human CVCL_KW06 CL:0000010 Transfected with: HGNC; 13575; BRD4 (with del 1-43 and 167-1362) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147205 CVCL_L806 TI-1 [Human leukemia] cancer cell line human CVCL_L806 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00278 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=11871388; PubMed=12592342; PubMed=20143388). 21147206 CVCL_KW03 InCELL Hunter HEK 293 BRD2(1,2) Bromodomain transformed cell line human CVCL_KW03 CL:0000010 Transfected with: HGNC; 1103; BRD2 (with del 1-73 and 456-801) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147207 CVCL_L803 Reh 6 undefined cell line type house mouse CVCL_L803 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00261. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse (PubMed=12592342; PubMed=20143388). 21147208 CVCL_L804 EH cancer cell line human CVCL_L804 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 24 hours (PubMed=2827813) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00193 Problematic cell line: Contaminated Shown to be a HK derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a separate patient (68 year old female) than HK (male). 21147209 CVCL_KW04 InCELL Hunter HEK 293 BRD3(1) Bromodomain transformed cell line human CVCL_KW04 CL:0000010 Transfected with: HGNC; 1104; BRD3 (with del 144-726) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147210 CVCL_KW01 InCELL Hunter HEK 293 BAZ2A Bromodomain transformed cell line human CVCL_KW01 CL:0000010 Transfected with: HGNC; 962; BAZ2A (with del 1-1791) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147211 CVCL_L801 TALL-106 cancer cell line human CVCL_L801 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: IL3 dependent 21147212 CVCL_L802 HeLa Kyoto EGFP-alpha-tubulin/H2B-mCherry cancer cell line human CVCL_L802 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Genome sequenced Female 21147213 CVCL_KW02 InCELL Hunter HEK 293 BRD2(1) Bromodomain transformed cell line human CVCL_KW02 CL:0000010 Transfected with: HGNC; 1103; BRD2 (with del 1-73 and 189-801) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147214 CVCL_KW00 InCELL Hunter A549 PRMT3 Methyltransferase cancer cell line human CVCL_KW00 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 30163; PRMT3 (with del 1-210) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147215 CVCL_L800 TALL-105 cancer cell line human CVCL_L800 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Female 21147216 CVCL_TQ35 HAP1 SQSTM1 (-) 2 cancer cell line human CVCL_TQ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147217 CVCL_U235 IB-RS-2 clone 17 spontaneously immortalized cell line pig CVCL_U235 CL:0000010 Derived from sampling site: Kidney. Female Virology: Infected by classical swine fever virus (CSFV); Virology: Susceptible to infection by foot-and-mouth disease virus 21147218 CVCL_TQ36 HAP1 SRC (-) 1 cancer cell line human CVCL_TQ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147219 CVCL_U236 Psi-CRIP-GklacZ transformed cell line house mouse CVCL_U236 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: RCB; RCB1121; true Male 21147220 CVCL_TQ33 HAP1 SQRDL (-) cancer cell line human CVCL_TQ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20390; SQOR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147221 CVCL_U233 IT-79MTNC3 finite cell line house mouse CVCL_U233 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic nurse cell.; Breed/subspecies: BALB/c. Discontinued: BCRJ; 0120; probable Female 21147222 CVCL_TQ34 HAP1 SQSTM1 (-) 1 cancer cell line human CVCL_TQ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11280; SQSTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147223 CVCL_U234 MVPK-1 clone 7 spontaneously immortalized cell line pig CVCL_U234 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Virology: Susceptible to infection by foot-and-mouth disease virus Compared to the parent cell line, doe not loose its susceptibility to infectionat 37 Celsius (PubMed=192426). 21147224 CVCL_TQ39 HAP1 SRD5A1 (-) 1 cancer cell line human CVCL_TQ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11284; SRD5A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147225 CVCL_U239 L.R. finite cell line CVCL_U239 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6307; true Unspecified Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147226 CVCL_TQ37 HAP1 SRC (-) 2 cancer cell line human CVCL_TQ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147227 CVCL_U237 MDGK spontaneously immortalized cell line CVCL_U237 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6280; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147228 CVCL_TQ38 HAP1 SRC (-) 3 cancer cell line human CVCL_TQ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11283; SRC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147229 CVCL_U238 RhMK finite cell line CVCL_U238 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6317; true Unspecified Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147230 CVCL_L898 HT1080-luc2 cancer cell line human CVCL_L898 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Discontinued: PerkinElmer; 128092; true Male 21147231 CVCL_KW98 PathHunter CHO-K1 EDG7 beta-arrestin spontaneously immortalized cell line CVCL_KW98 CL:0000010 Transfected with: HGNC; 14298; LPAR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147232 CVCL_L899 4T1-luc2 [Caliper] cancer cell line house mouse CVCL_L899 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: PerkinElmer; 124087; true Female 21147233 CVCL_KW99 PathHunter CHO-K1 EDNRA beta-arrestin spontaneously immortalized cell line CVCL_KW99 CL:0000010 Transfected with: HGNC; 3179; EDNRA; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147234 CVCL_L896 ER-1 cancer cell line Norway rat CVCL_L896 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female Characteristics: Weakly tumorigenic and non-metastatic (PubMed=1618698) 21147235 CVCL_KW96 PathHunter CHO-K1 EDG5 beta-arrestin spontaneously immortalized cell line CVCL_KW96 CL:0000010 Transfected with: HGNC; 3169; S1PR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147236 CVCL_L897 ERpP cancer cell line Norway rat CVCL_L897 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Mammary gland; Breed/subspecies: Spontaneously hypertensive rat (SHR). Female 21147237 CVCL_KW97 PathHunter CHO-K1 EDG6 beta-arrestin spontaneously immortalized cell line CVCL_KW97 CL:0000010 Transfected with: HGNC; 3170; S1PR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147238 CVCL_L894 OSCC-3 cancer cell line human CVCL_L894 CL:0000010 Derived from sampling site: Oral cavity; tongue. Unspecified 21147239 CVCL_KW94 PathHunter CHO-K1 EDG3 beta-arrestin spontaneously immortalized cell line CVCL_KW94 CL:0000010 Transfected with: HGNC; 3167; S1PR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147240 CVCL_KW95 PathHunter CHO-K1 EDG4 beta-arrestin spontaneously immortalized cell line CVCL_KW95 CL:0000010 Transfected with: HGNC; 3168; LPAR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147241 CVCL_L895 VU-SCC-147 cancer cell line human CVCL_L895 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Asp108Tyr (c.322G>T); Zygosity=Unspecified (PubMed=31541927; PubMed=33802339); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu257Arg (c.770T>G); ClinVar=VCV000142134; Zygosity=Unspecified (PubMed=23613873; PubMed=25275298; PubMed=31541927; PubMed=33802339) Karyotypic information: Has lost chromosome Y; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; floor of mouth. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Doubling time: 2.2 days (PubMed=29156801) Part of: OPC-22 oral and pharyngeal cancer cell line panel 21147242 CVCL_L892 JSQ-3 cancer cell line human CVCL_L892 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1423286; PubMed=8339273) Derived from sampling site: Nose; nasal cavity; nasal vestibule. Unspecified Characteristics: Radioresistant (PubMed=2004949) 21147243 CVCL_KW92 PathHunter CHO-K1 EDG1 beta-arrestin spontaneously immortalized cell line CVCL_KW92 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147244 CVCL_L893 1Cc8 cancer cell line human CVCL_L893 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Oral cavity; floor of mouth. Male 21147245 CVCL_KW93 PathHunter CHO-K1 EDG2 beta-arrestin spontaneously immortalized cell line CVCL_KW93 CL:0000010 Transfected with: HGNC; 3166; LPAR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147246 CVCL_KW90 PathHunter CHO-K1 DRD5 beta-arrestin spontaneously immortalized cell line CVCL_KW90 CL:0000010 Transfected with: HGNC; 3026; DRD5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147247 CVCL_L890 UNC-10 cancer cell line human CVCL_L890 CL:0000010 Derived from metastatic site: Lymph node. 21147248 CVCL_KW91 PathHunter CHO-K1 EBI2 beta-arrestin spontaneously immortalized cell line CVCL_KW91 CL:0000010 Transfected with: HGNC; 3128; GPR183; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147249 CVCL_L891 UNC-7 cancer cell line human CVCL_L891 CL:0000010 Derived from metastatic site: Lymph node. 21147250 CVCL_TQ42 HAP1 SREBF2 (-) 1 cancer cell line human CVCL_TQ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147251 CVCL_U242 S4B6 hybridoma CVCL_U242 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04351; Mouse Il2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8794 21147252 CVCL_TQ43 HAP1 SREBF2 (-) 2 cancer cell line human CVCL_TQ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11290; SREBF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147253 CVCL_U243 ITV telomerase immortalized cell line human CVCL_U243 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21147254 CVCL_U240 B16-F10-Lr6 cancer cell line house mouse CVCL_U240 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Discontinued: ATCC; CRL-6324; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147255 CVCL_TQ40 HAP1 SRD5A1 (-) 2 cancer cell line human CVCL_TQ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11284; SRD5A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147256 CVCL_U241 CMMT 110/C1 cancer cell line CVCL_U241 CL:0000010 Transformant: Mason-Pfizer monkey virus (MPMV)(NCBI-Taxonomy; 11855); Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6300; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147257 CVCL_TQ41 HAP1 SREBF1 (-) cancer cell line human CVCL_TQ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11289; SREBF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147258 CVCL_U224 B-1-A-2 cancer cell line house mouse CVCL_U224 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/c. Male 21147259 CVCL_TQ24 HAP1 SPR (-) 2 cancer cell line human CVCL_TQ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11257; SPR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147260 CVCL_TQ25 HAP1 SPRED2 (-) 1 cancer cell line human CVCL_TQ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17722; SPRED2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147261 CVCL_U225 NISH spontaneously immortalized cell line CVCL_U225 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Booroola x Assaf. Female Doubling time: 20-24 hours (PubMed=9590506) 21147262 CVCL_TQ22 HAP1 SPP1 (-) 1 cancer cell line human CVCL_TQ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147263 CVCL_U222 PCC4 Type III hybrid cell line CVCL_U222 CL:0000010 21147264 CVCL_U223 A1 [Mouse brain] spontaneously immortalized cell line house mouse CVCL_U223 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Brain. Unspecified Doubling time: ~18 hours (lot 11132008), ~23 hours (lot 06142017) (JCRB) 21147265 CVCL_TQ23 HAP1 SPR (-) 1 cancer cell line human CVCL_TQ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11257; SPR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147266 CVCL_TQ28 HAP1 SPTLC1 (-) 1 cancer cell line human CVCL_TQ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11277; SPTLC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147267 CVCL_U228 PS-BME-L6 spontaneously immortalized cell line CVCL_U228 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21147268 CVCL_TQ29 HAP1 SPTLC1 (-) 2 cancer cell line human CVCL_TQ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11277; SPTLC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147269 CVCL_U229 PS-BME-L7 spontaneously immortalized cell line CVCL_U229 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21147270 CVCL_TQ26 HAP1 SPRED2 (-) 2 cancer cell line human CVCL_TQ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17722; SPRED2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147271 CVCL_U226 MAC-T transformed cell line CVCL_U226 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Anecdotal: Nexia, a former Canadian biotech company was orignally developed to make lactose-free free milk using MAC-T Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Omics: Transcriptome analysis by microarray Female Doubling time: ~17 hours (PubMed=1659986); 48 hours, in serum-free medium (PubMed=7540186) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10274 21147272 CVCL_TQ27 HAP1 SPRYD4 (-) 1 cancer cell line human CVCL_TQ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27468; SPRYD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147273 CVCL_U227 PS-BME-C1 spontaneously immortalized cell line CVCL_U227 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21147274 CVCL_1K01 GM13491 hybrid cell line human CVCL_1K01 CL:0000010 Group: Human/rodent somatic cell hybrid. 21147275 CVCL_1K02 GM13492 hybrid cell line human CVCL_1K02 CL:0000010 Group: Human/rodent somatic cell hybrid. 21147276 CVCL_1K00 GM12510 hybrid cell line human CVCL_1K00 CL:0000010 Group: Human/rodent somatic cell hybrid. 21147277 CVCL_TQ31 HAP1 SQLE (-) 1 cancer cell line human CVCL_TQ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11279; SQLE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147278 CVCL_U231 MAC-T CU-2 transformed cell line CVCL_U231 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Politis I.) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female Doubling time: 15 hours, 46 hours, in serum-free medium (PubMed=7540186) 21147279 CVCL_TQ32 HAP1 SQLE (-) 2 cancer cell line human CVCL_TQ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11279; SQLE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147280 CVCL_U232 MAC-T CU-3 transformed cell line CVCL_U232 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Politis I.) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female Doubling time: 14 hours, 80 hours, in serum-free medium (PubMed=7540186) 21147281 CVCL_TQ30 HAP1 SPTLC2 (-) 1 cancer cell line human CVCL_TQ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11278; SPTLC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147282 CVCL_U230 MAC-T CU-1 transformed cell line CVCL_U230 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line no longer available (personal communication of Politis I.) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female Doubling time: 16 hours, 78 hours, in serum-free medium (PubMed=7540186) 21147283 CVCL_TQ13 HAP1 SPARC (-) 1 cancer cell line human CVCL_TQ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11219; SPARC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147284 CVCL_U213 LYM-1.P3 cancer cell line Norway rat CVCL_U213 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from metastatic site: Lymph node; Breed/subspecies: JAR-2. Discontinued: JCRB; NIHS0225; true Female Group: Serum/protein free medium cell line 21147285 CVCL_TQ14 HAP1 SPATA20 (-) 1 cancer cell line human CVCL_TQ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26125; SPATA20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147286 CVCL_U214 LYM-1.P3B cancer cell line Norway rat CVCL_U214 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from metastatic site: Lymph node; Breed/subspecies: JAR-2. Discontinued: JCRB; NIHS0359; true Female Group: Serum/protein free medium cell line 21147287 CVCL_TQ11 HAP1 SP3 (-) 1 cancer cell line human CVCL_TQ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11208; SP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147288 CVCL_U211 OVISE-3 cancer cell line human CVCL_U211 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Pelvis; innominate bone. Female 21147289 CVCL_U212 bEnd.1 transformed cell line house mouse CVCL_U212 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Brain Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 21147290 CVCL_TQ12 HAP1 SP3 (-) 2 cancer cell line human CVCL_TQ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11208; SP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147291 CVCL_U217 CHO(pMAM-HSluc) spontaneously immortalized cell line CVCL_U217 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Discontinued: JCRB; NIHS0212.2; true Female 21147292 CVCL_TQ17 HAP1 SPEG (-) 3 cancer cell line human CVCL_TQ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16901; SPEG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147293 CVCL_U218 CHO(pMAM-luc) spontaneously immortalized cell line CVCL_U218 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Ovary. Discontinued: JCRB; NIHS0212.1; true Female 21147294 CVCL_TQ18 HAP1 SPG21 (-) cancer cell line human CVCL_TQ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20373; SPG21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147295 CVCL_TQ15 HAP1 SPEG (-) 1 cancer cell line human CVCL_TQ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16901; SPEG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147296 CVCL_U215 LYM-1.P3D cancer cell line Norway rat CVCL_U215 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from metastatic site: Lymph node; Breed/subspecies: JAR-2. Discontinued: JCRB; NIHS0360; true Female Group: Serum/protein free medium cell line 21147297 CVCL_U216 AH601.P3 cancer cell line Norway rat CVCL_U216 CL:0000010 Transformant: Ortho-aminoazotoluene(ChEBI; CHEBI:82285); Breed/subspecies: Donryu. Discontinued: JCRB; NIHS0211; true; Discontinued: JCRB; NIHS0357; true Female Group: Serum/protein free medium cell line 21147298 CVCL_TQ16 HAP1 SPEG (-) 2 cancer cell line human CVCL_TQ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16901; SPEG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147299 CVCL_TQ19 HAP1 SPIRE1 (-) 1 cancer cell line human CVCL_TQ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30622; SPIRE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147300 CVCL_U219 NCC16 transformed cell line human CVCL_U219 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: JCRB; JCRB0142; true; Discontinued: JCRB; NIHS0204; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00331 Problematic cell line: Contaminated Shown to be a PHK16-0b derivative (PubMed=20143388).; Caution: Replaced by NCC16-P11 21147301 CVCL_L878 GMK-AH-1 undefined cell line type CVCL_L878 CL:0000010 Derived from sampling site: Kidney. Group: Non-human primate cell line 21147302 CVCL_KW78 PathHunter CHO-K1 CXCR2 beta-arrestin spontaneously immortalized cell line CVCL_KW78 CL:0000010 Transfected with: HGNC; 6027; CXCR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147303 CVCL_L879 JF1 cancer cell line Norway rat CVCL_L879 CL:0000010 21147304 CVCL_KW79 PathHunter CHO-K1 CXCR3 beta-arrestin spontaneously immortalized cell line CVCL_KW79 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147305 CVCL_KW76 PathHunter CHO-K1 CRTH2 beta-arrestin spontaneously immortalized cell line CVCL_KW76 CL:0000010 Transfected with: HGNC; 4502; PTGDR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147306 CVCL_L876 TS/A clone F5 cancer cell line house mouse CVCL_L876 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: Low metastatic potential 21147307 CVCL_L877 FLC clone M2 cancer cell line house mouse CVCL_L877 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21147308 CVCL_KW77 PathHunter CHO-K1 CX3CR1 beta-arrestin spontaneously immortalized cell line CVCL_KW77 CL:0000010 Transfected with: HGNC; 2558; CX3CR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147309 CVCL_KW74 PathHunter CHO-K1 CRHR1 beta-arrestin spontaneously immortalized cell line CVCL_KW74 CL:0000010 Transfected with: HGNC; 2357; CRHR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147310 CVCL_L874 TS/A clone F1 cancer cell line house mouse CVCL_L874 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: Low metastatic potential 21147311 CVCL_KW75 PathHunter CHO-K1 CRHR2 beta-arrestin spontaneously immortalized cell line CVCL_KW75 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147312 CVCL_L875 TS/A clone F2 cancer cell line house mouse CVCL_L875 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: Low metastatic potential 21147313 CVCL_KW72 PathHunter CHO-K1 CNR1 beta-arrestin spontaneously immortalized cell line CVCL_KW72 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147314 CVCL_L872 TS/A clone E2 cancer cell line house mouse CVCL_L872 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: High metastatic potential 21147315 CVCL_KW73 PathHunter CHO-K1 CNR2 beta-arrestin spontaneously immortalized cell line CVCL_KW73 CL:0000010 Transfected with: HGNC; 2160; CNR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147316 CVCL_L873 TS/A clone E3 cancer cell line house mouse CVCL_L873 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: High metastatic potential 21147317 CVCL_L870 DSH4PV finite cell line human CVCL_L870 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147318 CVCL_KW70 PathHunter CHO-K1 CHRM5 beta-arrestin spontaneously immortalized cell line CVCL_KW70 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147319 CVCL_KW71 PathHunter CHO-K1 CMKLR1 beta-arrestin spontaneously immortalized cell line CVCL_KW71 CL:0000010 Transfected with: HGNC; 2121; CMKLR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147320 CVCL_L871 TS/A clone E1 cancer cell line house mouse CVCL_L871 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: High metastatic potential 21147321 CVCL_TQ20 HAP1 SPIRE1 (-) 2 cancer cell line human CVCL_TQ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30622; SPIRE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147322 CVCL_U220 P53LMACO1 spontaneously immortalized cell line house mouse CVCL_U220 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: C57BL/6 x 129Sv. Discontinued: JCRB; NIHS0213; true Unspecified Doubling time: ~1 day (lot 09232004) (JCRB) 21147323 CVCL_TQ21 HAP1 SPNS1 (-) 1 cancer cell line human CVCL_TQ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30621; SPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147324 CVCL_U221 PCC4 Type I hybrid cell line CVCL_U221 CL:0000010 Discontinued: JCRB; JCRB0204; true. 21147325 CVCL_U202 3Y1BU^(r-2) transformed cell line Norway rat CVCL_U202 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21147326 CVCL_TQ02 HAP1 SOX5 (-) 1 cancer cell line human CVCL_TQ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11201; SOX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147327 CVCL_U203 3Y1BU^(r-3) transformed cell line Norway rat CVCL_U203 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21147328 CVCL_TQ03 HAP1 SOX5 (-) 2 cancer cell line human CVCL_TQ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11201; SOX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147329 CVCL_U200 BP7(R80) cancer cell line Norway rat CVCL_U200 CL:0000010 Breed/subspecies: Wistar. Male 21147330 CVCL_TQ00 HAP1 SORT1 (-) 1 cancer cell line human CVCL_TQ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11186; SORT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147331 CVCL_U201 3Y1BU^(r-1) transformed cell line Norway rat CVCL_U201 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21147332 CVCL_TQ01 HAP1 SORT1 (-) 2 cancer cell line human CVCL_TQ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11186; SORT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147333 CVCL_TQ06 HAP1 SP100 (-) 2 cancer cell line human CVCL_TQ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11206; SP100; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147334 CVCL_U206 LLC-GA5 spontaneously immortalized cell line pig CVCL_U206 CL:0000010 Transfected with: HGNC; 40; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21147335 CVCL_TQ07 HAP1 SP110 (-) 1 cancer cell line human CVCL_TQ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5401; SP110; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147336 CVCL_U207 LLC-GA5-CoL150 spontaneously immortalized cell line pig CVCL_U207 CL:0000010 Transfected with: HGNC; 40; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21147337 CVCL_TQ04 HAP1 SP1 (-) cancer cell line human CVCL_TQ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11205; SP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147338 CVCL_TQ05 HAP1 SP100 (-) 1 cancer cell line human CVCL_TQ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11206; SP100; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147339 CVCL_TQ08 HAP1 SP110 (-) 2 cancer cell line human CVCL_TQ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5401; SP110; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147340 CVCL_U208 LLC-GA5-CoL300 spontaneously immortalized cell line pig CVCL_U208 CL:0000010 Transfected with: HGNC; 40; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21147341 CVCL_TQ09 HAP1 SP140 (-) 1 cancer cell line human CVCL_TQ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17133; SP140; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147342 CVCL_U209 HeLa S3 mer- cancer cell line human CVCL_U209 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147343 CVCL_L889 FCP-S6H finite cell line human CVCL_L889 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147344 CVCL_KW89 PathHunter CHO-K1 DRD4 beta-arrestin spontaneously immortalized cell line CVCL_KW89 CL:0000010 Transfected with: HGNC; 3025; DRD4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147345 CVCL_L887 FCP-S4H finite cell line human CVCL_L887 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147346 CVCL_KW87 PathHunter CHO-K1 DRD2S beta-arrestin spontaneously immortalized cell line CVCL_KW87 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform short); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147347 CVCL_L888 FCP-S5H finite cell line human CVCL_L888 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147348 CVCL_KW88 PathHunter CHO-K1 DRD3 beta-arrestin spontaneously immortalized cell line CVCL_KW88 CL:0000010 Transfected with: HGNC; 3024; DRD3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147349 CVCL_L885 FCP-S2H finite cell line human CVCL_L885 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147350 CVCL_KW85 PathHunter CHO-K1 DRD1 beta-arrestin spontaneously immortalized cell line CVCL_KW85 CL:0000010 Transfected with: HGNC; 3020; DRD1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147351 CVCL_L886 FCP-S3H finite cell line human CVCL_L886 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147352 CVCL_KW86 PathHunter CHO-K1 DRD2L beta-arrestin spontaneously immortalized cell line CVCL_KW86 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform long); Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147353 CVCL_L883 CL1 [Human ESC] embryonic stem cell human CVCL_L883 From: Technion - Israel Institute of Technology; Haifa; Israel. CL:0000010 Unspecified 21147354 CVCL_KW83 PathHunter CHO-K1 cyno GPR120 beta-arrestin spontaneously immortalized cell line CVCL_KW83 CL:0000010 Transfected with: UniProtKB; C8YUV0; Macaca fascicularis FFAR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147355 CVCL_L884 FCP-S1M finite cell line human CVCL_L884 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from familial colon polyposis; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147356 CVCL_KW84 PathHunter CHO-K1 DARC beta-arrestin spontaneously immortalized cell line CVCL_KW84 CL:0000010 Transfected with: HGNC; 4035; ACKR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147357 CVCL_L881 LI cancer cell line human CVCL_L881 CL:0000010 Anecdotal: Cell line name corresponds to the initials of the patient Derived from sampling site: Brain; fronto-temporal lobe. Male Doubling time: 24 hours (at 34th passage), 27 hours (at 86th passage) (PubMed=3225639) 21147358 CVCL_KW81 PathHunter CHO-K1 CXCR6 beta-arrestin spontaneously immortalized cell line CVCL_KW81 CL:0000010 Transfected with: HGNC; 16647; CXCR6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147359 CVCL_L882 mFS6 cancer cell line house mouse CVCL_L882 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865). 21147360 CVCL_KW82 PathHunter CHO-K1 CXCR7 beta-arrestin spontaneously immortalized cell line CVCL_KW82 CL:0000010 Transfected with: HGNC; 23692; ACKR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147361 CVCL_L880 JR1 cancer cell line human CVCL_L880 CL:0000010 Derived from metastatic site: Pre-tracheal region. Female 21147362 CVCL_KW80 PathHunter CHO-K1 CXCR5 beta-arrestin spontaneously immortalized cell line CVCL_KW80 CL:0000010 Transfected with: HGNC; 1060; CXCR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147363 CVCL_TQ10 HAP1 SP140 (-) 2 cancer cell line human CVCL_TQ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17133; SP140; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147364 CVCL_U210 MCAS-3 cancer cell line human CVCL_U210 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser504Arg (c.1512T>A); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Ovary. Female 21147365 CVCL_L858 B14-150 transformed cell line CVCL_L858 CL:0000010 Selected for resistance to: ChEBI; CHEBI:147675; 5-iodo-2'-deoxyuridine (IUdR); Derived from sampling site: Peritoneum Cell type=Fibroblast.. Discontinued: ATCC; CCL-14.1; true Female 21147366 CVCL_KW58 PathHunter CHO-K1 CCR4 beta-arrestin spontaneously immortalized cell line CVCL_KW58 CL:0000010 Transfected with: HGNC; 1605; CCR4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147367 CVCL_L859 BL20 cancer cell line CVCL_L859 CL:0000010 Breed/subspecies: Holstein Friesian. Omics: Transcriptome analysis by microarray Female 21147368 CVCL_KW59 PathHunter CHO-K1 CCR5 beta-arrestin spontaneously immortalized cell line CVCL_KW59 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147369 CVCL_KW56 PathHunter CHO-K1 CCR2 beta-arrestin spontaneously immortalized cell line CVCL_KW56 CL:0000010 Transfected with: HGNC; 1603; CCR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147370 CVCL_KW57 PathHunter CHO-K1 CCR3 beta-arrestin spontaneously immortalized cell line CVCL_KW57 CL:0000010 Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147371 CVCL_L857 U4SS cancer cell line human CVCL_L857 CL:0000010 Male 21147372 CVCL_L854 DG3 cancer cell line human CVCL_L854 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 60 hours (PubMed=22358579) 21147373 CVCL_KW54 PathHunter CHO-K1 CCKBR beta-arrestin spontaneously immortalized cell line CVCL_KW54 CL:0000010 Transfected with: HGNC; 1571; CCKBR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147374 CVCL_L855 Hep-G2/2.2.15 cancer cell line human CVCL_L855 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the D-genotype 21147375 CVCL_KW55 PathHunter CHO-K1 CCR1 beta-arrestin spontaneously immortalized cell line CVCL_KW55 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147376 CVCL_L852 DG1 cancer cell line human CVCL_L852 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 39 hours (PubMed=22358579) 21147377 CVCL_KW52 PathHunter CHO-K1 CALCR-RAMP3 beta-arrestin spontaneously immortalized cell line CVCL_KW52 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9845; RAMP3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147378 CVCL_L853 DG2 cancer cell line human CVCL_L853 CL:0000010 Derived from sampling site: Lung. Male Doubling time: 48 hours (PubMed=22358579) 21147379 CVCL_KW53 PathHunter CHO-K1 CCKAR beta-arrestin spontaneously immortalized cell line CVCL_KW53 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147380 CVCL_L850 AE2 cancer cell line human CVCL_L850 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 78 hours (PubMed=22358579) 21147381 CVCL_KW50 PathHunter CHO-K1 CALCRL-RAMP3 beta-arrestin spontaneously immortalized cell line CVCL_KW50 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9845; RAMP3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147382 CVCL_L851 AE3 [Human SCLC] cancer cell line human CVCL_L851 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 78 hours (PubMed=22358579) 21147383 CVCL_KW51 PathHunter CHO-K1 CALCR-RAMP2 beta-arrestin spontaneously immortalized cell line CVCL_KW51 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9844; RAMP2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147384 CVCL_L869 DSH3PV finite cell line human CVCL_L869 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147385 CVCL_KW69 PathHunter CHO-K1 CHRM4 beta-arrestin spontaneously immortalized cell line CVCL_KW69 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147386 CVCL_L867 DSH1PV finite cell line human CVCL_L867 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147387 CVCL_KW67 PathHunter CHO-K1 CHRM1 beta-arrestin spontaneously immortalized cell line CVCL_KW67 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Discontinued: DiscoverX; 93-0197C2; true Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147388 CVCL_L868 DSH2PV finite cell line human CVCL_L868 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147389 CVCL_KW68 PathHunter CHO-K1 CHRM2 beta-arrestin spontaneously immortalized cell line CVCL_KW68 CL:0000010 Transfected with: HGNC; 1951; CHRM2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147390 CVCL_L865 DM(cap) transformed cell line CVCL_L865 CL:0000010 Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21147391 CVCL_KW65 PathHunter CHO-K1 CCRL2 beta-arrestin spontaneously immortalized cell line CVCL_KW65 CL:0000010 Transfected with: HGNC; 1612; CCRL2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147392 CVCL_KW66 PathHunter CHO-K1 cEDG5 beta-arrestin spontaneously immortalized cell line CVCL_KW66 CL:0000010 Transfected with: UniProtKB; F1PB93; Dog S1PR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147393 CVCL_L863 DFK3 transformed cell line Norway rat CVCL_L863 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21147394 CVCL_KW63 PathHunter CHO-K1 CCR9 beta-arrestin spontaneously immortalized cell line CVCL_KW63 CL:0000010 Transfected with: HGNC; 1610; CCR9; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147395 CVCL_L864 DM-15 transformed cell line CVCL_L864 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female Doubling time: 20.15 +- 1.3 hours (PubMed=196977) 21147396 CVCL_KW64 PathHunter CHO-K1 CCRL1 beta-arrestin spontaneously immortalized cell line CVCL_KW64 CL:0000010 Transfected with: HGNC; 2558; CX3CR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147397 CVCL_L861 C57SV transformed cell line house mouse CVCL_L861 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21147398 CVCL_KW61 PathHunter CHO-K1 CCR7 beta-arrestin spontaneously immortalized cell line CVCL_KW61 CL:0000010 Transfected with: HGNC; 1608; CCR7; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147399 CVCL_L862 CS1PV finite cell line human CVCL_L862 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21147400 CVCL_KW62 PathHunter CHO-K1 CCR8 beta-arrestin spontaneously immortalized cell line CVCL_KW62 CL:0000010 Transfected with: HGNC; 1609; CCR8; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147401 CVCL_L860 BPE-1 spontaneously immortalized cell line CVCL_L860 CL:0000010 Derived from sampling site: Endoderm. Female Doubling time: ~96 hours (PubMed=16153145) 21147402 CVCL_KW60 PathHunter CHO-K1 CCR6 beta-arrestin spontaneously immortalized cell line CVCL_KW60 CL:0000010 Transfected with: HGNC; 1607; CCR6; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147403 CVCL_L838 H139-52 hybridoma CVCL_L838 CL:0000010 Discontinued: ECACC; 85103111; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mouse Ig kappa light chains 21147404 CVCL_KW38 PathHunter CHO-K1 BAI2 beta-arrestin spontaneously immortalized cell line CVCL_KW38 CL:0000010 Transfected with: HGNC; 944; ADGRB2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147405 CVCL_L839 H1a hybridoma house mouse CVCL_L839 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Gray seal IgM. 21147406 CVCL_KW39 PathHunter CHO-K1 BAI3 beta-arrestin spontaneously immortalized cell line CVCL_KW39 CL:0000010 Transfected with: HGNC; 945; ADGRB3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147407 CVCL_L836 H129-121.6.8 hybridoma CVCL_L836 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q62351; Mouse Tfrc/Cd71. 21147408 CVCL_KW36 PathHunter CHO-K1 AVPR2 beta-arrestin spontaneously immortalized cell line CVCL_KW36 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147409 CVCL_L837 H129-19.6.8 hybridoma CVCL_L837 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06332; Mouse Cd4. 21147410 CVCL_KW37 PathHunter CHO-K1 BAI1 beta-arrestin spontaneously immortalized cell line CVCL_KW37 CL:0000010 Transfected with: HGNC; 943; ADGRB1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147411 CVCL_L834 CAR-XP10 hybridoma house mouse CVCL_L834 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10599; Human TXN. 21147412 CVCL_KW34 PathHunter CHO-K1 AR Protein Interaction spontaneously immortalized cell line CVCL_KW34 CL:0000010 Transfected with: HGNC; 644; AR Derived from sampling site: Ovary. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147413 CVCL_L835 CIIC1 hybridoma house mouse CVCL_L835 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02460; Chicken COL2A1 (Note=Also reacts with mammalian, fish and Xenopus Recognizes the C1 epitope N-GARGLTGRPGDA-C).. 21147414 CVCL_KW35 PathHunter CHO-K1 AVPR1B beta-arrestin spontaneously immortalized cell line CVCL_KW35 CL:0000010 Transfected with: HGNC; 896; AVPR1B; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147415 CVCL_L832 B1D6 hybridoma house mouse CVCL_L832 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07355; Human ANXA2. 21147416 CVCL_KW32 PathHunter CHO-K1 AGTRL1 beta-arrestin spontaneously immortalized cell line CVCL_KW32 CL:0000010 Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147417 CVCL_L833 CAR-2/3F4 hybridoma house mouse CVCL_L833 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10599; Human TXN. 21147418 CVCL_KW33 PathHunter CHO-K1 AGTRL1 beta-arrestin-1 spontaneously immortalized cell line CVCL_KW33 CL:0000010 Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147419 CVCL_L830 AFRC MAC 48 hybridoma Norway rat CVCL_L830 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21147420 CVCL_KW30 PathHunter CHO-K1 ADRB2 beta-arrestin spontaneously immortalized cell line CVCL_KW30 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147421 CVCL_L831 AFRC MAC 49 hybridoma Norway rat CVCL_L831 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21147422 CVCL_KW31 PathHunter CHO-K1 AGTR1 beta-arrestin spontaneously immortalized cell line CVCL_KW31 CL:0000010 Transfected with: HGNC; 336; AGTR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147423 CVCL_L849 AE1 cancer cell line human CVCL_L849 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 72 hours (PubMed=22358579) 21147424 CVCL_KW49 PathHunter CHO-K1 CALCRL-RAMP2 beta-arrestin spontaneously immortalized cell line CVCL_KW49 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9844; RAMP2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147425 CVCL_L847 IC-08 hybridoma house mouse CVCL_L847 CL:0000010 Monoclonal antibody isotype: IgG. 21147426 CVCL_KW47 PathHunter CHO-K1 CALCR beta-arrestin spontaneously immortalized cell line CVCL_KW47 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147427 CVCL_L848 IC-09 hybridoma house mouse CVCL_L848 CL:0000010 Monoclonal antibody isotype: IgG3. 21147428 CVCL_KW48 PathHunter CHO-K1 CALCR-RAMP1 beta-arrestin spontaneously immortalized cell line CVCL_KW48 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: HGNC; 9843; RAMP1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147429 CVCL_L845 IC-01 hybridoma house mouse CVCL_L845 CL:0000010 Monoclonal antibody isotype: IgM. 21147430 CVCL_KW45 PathHunter CHO-K1 C5AR1 beta-arrestin spontaneously immortalized cell line CVCL_KW45 CL:0000010 Transfected with: HGNC; 1338; C5AR1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147431 CVCL_L846 IC-07 hybridoma house mouse CVCL_L846 CL:0000010 Monoclonal antibody isotype: IgG3. 21147432 CVCL_KW46 PathHunter CHO-K1 C5L2 beta-arrestin spontaneously immortalized cell line CVCL_KW46 CL:0000010 Transfected with: HGNC; 4527; C5AR2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147433 CVCL_L843 H81-208.22.6 hybridoma house mouse CVCL_L843 CL:0000010 Monoclonal antibody isotype: IgG2a. 21147434 CVCL_KW43 PathHunter CHO-K1 beta-arrestin2-EA Parental spontaneously immortalized cell line CVCL_KW43 CL:0000010 Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21147435 CVCL_L844 HA cl. 55 hybridoma house mouse CVCL_L844 CL:0000010 Monoclonal antibody isotype: IgG2b. 21147436 CVCL_KW44 PathHunter CHO-K1 BRS3 beta-arrestin spontaneously immortalized cell line CVCL_KW44 CL:0000010 Transfected with: HGNC; 1113; BRS3; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147437 CVCL_L841 H49a hybridoma house mouse CVCL_L841 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Gray seal IgG1. 21147438 CVCL_KW41 PathHunter CHO-K1 BDKRB2 beta-arrestin spontaneously immortalized cell line CVCL_KW41 CL:0000010 Transfected with: HGNC; 1030; BDKRB2; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147439 CVCL_L842 H6/31HL hybridoma house mouse CVCL_L842 CL:0000010 Monoclonal antibody isotype: IgM. 21147440 CVCL_KW42 PathHunter CHO-K1 beta-arrestin1-EA Parental spontaneously immortalized cell line CVCL_KW42 CL:0000010 Transfected with: HGNC; 711; ARRB1 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin parental cell lines express a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) They can be used to introduce a GPCR tagged with another beta-galactosidase fragment (ProLink=PK). 21147441 CVCL_L840 H24b hybridoma house mouse CVCL_L840 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Gray seal IgG. 21147442 CVCL_KW40 PathHunter CHO-K1 BDKRB1 beta-arrestin spontaneously immortalized cell line CVCL_KW40 CL:0000010 Transfected with: HGNC; 1029; BDKRB1; Transfected with: HGNC; 712; ARRB2 Derived from sampling site: Ovary. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147443 CVCL_1J50 GM06538 transformed cell line human CVCL_1J50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147444 CVCL_1J53 GM06585 transformed cell line human CVCL_1J53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147445 CVCL_1J54 GM06593 transformed cell line human CVCL_1J54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147446 CVCL_1J51 GM06566 transformed cell line human CVCL_1J51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147447 CVCL_1J52 GM06581 transformed cell line human CVCL_1J52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147448 CVCL_1J57 GM06629 transformed cell line human CVCL_1J57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147449 CVCL_1J58 GM06631 transformed cell line human CVCL_1J58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147450 CVCL_1J55 GM06595 transformed cell line human CVCL_1J55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147451 CVCL_1J56 GM06601 transformed cell line human CVCL_1J56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147452 CVCL_1J48 GM06530 transformed cell line human CVCL_1J48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147453 CVCL_1J49 GM06532 transformed cell line human CVCL_1J49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147454 CVCL_TP89 HAP1 SNX3 (-) 1 cancer cell line human CVCL_TP89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11174; SNX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147455 CVCL_U189 HH17-4 hybridoma house mouse CVCL_U189 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17931; Human LGALS3. 21147456 CVCL_1J60 GM06643 transformed cell line human CVCL_1J60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147457 CVCL_1J61 GM06651 transformed cell line human CVCL_1J61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147458 CVCL_1J64 GM06681 transformed cell line human CVCL_1J64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147459 CVCL_1J65 GM06685 transformed cell line human CVCL_1J65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147460 CVCL_1J62 GM06655 transformed cell line human CVCL_1J62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147461 CVCL_1J63 GM06677 transformed cell line human CVCL_1J63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147462 CVCL_1J68 GM06773 transformed cell line human CVCL_1J68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147463 CVCL_1J69 GM06777 transformed cell line human CVCL_1J69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147464 CVCL_1J66 GM06767 transformed cell line human CVCL_1J66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147465 CVCL_1J67 GM06769 transformed cell line human CVCL_1J67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147466 CVCL_1J59 GM06633 transformed cell line human CVCL_1J59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147467 CVCL_U190 BP11(R100) cancer cell line Norway rat CVCL_U190 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147468 CVCL_TP90 HAP1 SNX3 (-) 2 cancer cell line human CVCL_TP90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11174; SNX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147469 CVCL_U191 BP11(R2) cancer cell line Norway rat CVCL_U191 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147470 CVCL_TP91 HAP1 SNX9 (-) 1 cancer cell line human CVCL_TP91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14973; SNX9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147471 CVCL_U194 BP26(R2) cancer cell line Norway rat CVCL_U194 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147472 CVCL_TP94 HAP1 SOAT1 (-) 1 cancer cell line human CVCL_TP94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11177; SOAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147473 CVCL_U195 BP26(R80) cancer cell line Norway rat CVCL_U195 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147474 CVCL_TP95 HAP1 SOAT1 (-) 2 cancer cell line human CVCL_TP95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11177; SOAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147475 CVCL_U192 BP13(R100) cancer cell line Norway rat CVCL_U192 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147476 CVCL_TP92 HAP1 SNX9 (-) 2 cancer cell line human CVCL_TP92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14973; SNX9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147477 CVCL_U193 BP13(R2) cancer cell line Norway rat CVCL_U193 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147478 CVCL_TP93 HAP1 SNX9 (-) 3 cancer cell line human CVCL_TP93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14973; SNX9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147479 CVCL_U198 BP36B(R100) cancer cell line Norway rat CVCL_U198 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147480 CVCL_TP98 HAP1 SOD2 (-) cancer cell line human CVCL_TP98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11180; SOD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147481 CVCL_U199 BP36B(R2) cancer cell line Norway rat CVCL_U199 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147482 CVCL_TP99 HAP1 SORD (-) 1 cancer cell line human CVCL_TP99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11184; SORD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147483 CVCL_U196 BP30(R100) cancer cell line Norway rat CVCL_U196 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147484 CVCL_TP96 HAP1 SOAT1 (-) 3 cancer cell line human CVCL_TP96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11177; SOAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147485 CVCL_U197 BP30(R2) cancer cell line Norway rat CVCL_U197 CL:0000010 Transformant: N-ethyl-N-(2-hydroxyethyl)nitrosamine (EENA)(ChEBI; CHEBI:141568); Breed/subspecies: Wistar. Male 21147486 CVCL_TP97 HAP1 SOCS3 (-) 1 cancer cell line human CVCL_TP97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147487 CVCL_U178 GCCOT-1 cancer cell line human CVCL_U178 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761) Omics: Array-based CGH. Female Doubling time: 36.95 hours (PubMed=15010838) 21147488 CVCL_TP78 HAP1 SNAP23 (-) 3 cancer cell line human CVCL_TP78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11131; SNAP23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147489 CVCL_U179 GCCRK cancer cell line human CVCL_U179 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761) Omics: Array-based CGH. Female 21147490 CVCL_TP79 HAP1 SNAP23 (-) 4 cancer cell line human CVCL_TP79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11131; SNAP23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147491 CVCL_1J31 GM06364 transformed cell line human CVCL_1J31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147492 CVCL_1J32 GM06366 transformed cell line human CVCL_1J32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147493 CVCL_1J30 GM06348 transformed cell line human CVCL_1J30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147494 CVCL_1J35 GM06384 transformed cell line human CVCL_1J35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147495 CVCL_1J36 GM06421 transformed cell line human CVCL_1J36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147496 CVCL_1J33 GM06370 transformed cell line human CVCL_1J33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147497 CVCL_1J34 GM06376 transformed cell line human CVCL_1J34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147498 CVCL_1J28 GM05736 transformed cell line human CVCL_1J28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147499 CVCL_1J29 GM06273 finite cell line human CVCL_1J29 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21147500 CVCL_1J26 GM05724 transformed cell line human CVCL_1J26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147501 CVCL_1J27 GM05726 transformed cell line human CVCL_1J27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147502 CVCL_TP80 HAP1 SNAP23 (-) 5 cancer cell line human CVCL_TP80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11131; SNAP23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147503 CVCL_U180 MR1-3 cancer cell line human CVCL_U180 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147504 CVCL_TP83 HAP1 SNCA (-) 3 cancer cell line human CVCL_TP83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147505 CVCL_U183 MR6 cancer cell line human CVCL_U183 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147506 CVCL_TP84 HAP1 SNRK (-) cancer cell line human CVCL_TP84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30598; SNRK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147507 CVCL_U184 MR8 cancer cell line human CVCL_U184 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147508 CVCL_TP81 HAP1 SNCA (-) 1 cancer cell line human CVCL_TP81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147509 CVCL_U181 MR10-1 cancer cell line human CVCL_U181 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147510 CVCL_TP82 HAP1 SNCA (-) 2 cancer cell line human CVCL_TP82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147511 CVCL_U182 MR11 cancer cell line human CVCL_U182 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147512 CVCL_TP87 HAP1 SNX17 (-) 1 cancer cell line human CVCL_TP87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14979; SNX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147513 CVCL_U187 HeLa/Fucci2 cancer cell line human CVCL_U187 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci2 (Fluorescent Ubiquitination-based Cell Cycle Indicator 2) construct; Characteristics: Transfected with the Fucci2 probe which consist of the fusion of mCherry) to the ubiquitination domain of human CDT1 (aa 30-120) and of monomeric Venus (mVenus) to the ubiquitination domain of human geminin (aa 1-110) 21147514 CVCL_TP88 HAP1 SNX17 (-) 2 cancer cell line human CVCL_TP88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14979; SNX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147515 CVCL_U188 HH13-1 hybridoma house mouse CVCL_U188 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17931; Human LGALS3. 21147516 CVCL_U185 ACr41 cancer cell line human CVCL_U185 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:75270; Nimustine (ACNU); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147517 CVCL_TP85 HAP1 SNX10 (-) 1 cancer cell line human CVCL_TP85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14974; SNX10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147518 CVCL_U186 ACr42 cancer cell line human CVCL_U186 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:75270; Nimustine (ACNU); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21147519 CVCL_TP86 HAP1 SNX10 (-) 2 cancer cell line human CVCL_TP86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14974; SNX10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147520 CVCL_TP69 HAP1 SMPD1 (-) 1 cancer cell line human CVCL_TP69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11120; SMPD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147521 CVCL_U169 IISH6i-CML17 induced pluripotent stem cell human CVCL_U169 CL:0000010 Female 21147522 CVCL_TP67 HAP1 SMOX (-) 1 cancer cell line human CVCL_TP67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15862; SMOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147523 CVCL_U167 IISH2i-BM9 induced pluripotent stem cell human CVCL_U167 CL:0000010 Derived from sampling site: Bone marrow. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21147524 CVCL_TP68 HAP1 SMOX (-) 2 cancer cell line human CVCL_TP68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15862; SMOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147525 CVCL_U168 IISH3i-CB6 induced pluripotent stem cell human CVCL_U168 CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21147526 CVCL_1J42 GM06447 transformed cell line human CVCL_1J42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147527 CVCL_1J43 GM06449 transformed cell line human CVCL_1J43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147528 CVCL_1J40 GM06443 transformed cell line human CVCL_1J40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147529 CVCL_1J41 GM06445 transformed cell line human CVCL_1J41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147530 CVCL_1J46 GM06499 transformed cell line human CVCL_1J46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147531 CVCL_1J47 GM06528 transformed cell line human CVCL_1J47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147532 CVCL_1J44 GM06457 transformed cell line human CVCL_1J44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147533 CVCL_1J45 GM06481 transformed cell line human CVCL_1J45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147534 CVCL_1J39 GM06439 transformed cell line human CVCL_1J39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147535 CVCL_1J37 GM06423 transformed cell line human CVCL_1J37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147536 CVCL_1J38 GM06437 transformed cell line human CVCL_1J38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147537 CVCL_TP72 HAP1 SMTN (-) 1 cancer cell line human CVCL_TP72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11126; SMTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147538 CVCL_U172 MIRJT6i-mND1-4 induced pluripotent stem cell human CVCL_U172 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21147539 CVCL_TP73 HAP1 SMUG1 (-) cancer cell line human CVCL_TP73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17148; SMUG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147540 CVCL_U173 MIRJT7i-mND2-0 induced pluripotent stem cell human CVCL_U173 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21147541 CVCL_TP70 HAP1 SMPD1 (-) 2 cancer cell line human CVCL_TP70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11120; SMPD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147542 CVCL_U170 LT1e-OLIG2GFP embryonic stem cell human CVCL_U170 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: An EGFP cassette is inserted to the OLIG2 locus via homologous recombination 21147543 CVCL_TP71 HAP1 SMS (-) cancer cell line human CVCL_TP71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11123; SMS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147544 CVCL_U171 LT2e-H9CAGGFP embryonic stem cell human CVCL_U171 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female 21147545 CVCL_TP76 HAP1 SNAP23 (-) 1 cancer cell line human CVCL_TP76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11131; SNAP23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147546 CVCL_U176 NSC-H9 somatic stem cell human CVCL_U176 CL:0000010 Female 21147547 CVCL_TP77 HAP1 SNAP23 (-) 2 cancer cell line human CVCL_TP77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11131; SNAP23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147548 CVCL_U177 OS3 [Mouse brain] transformed cell line house mouse CVCL_U177 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [SV40-ori(-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Oligodendrocyte precursor cell.; Breed/subspecies: C3H/HeN. 21147549 CVCL_TP74 HAP1 SMYD3 (-) 1 cancer cell line human CVCL_TP74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15513; SMYD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147550 CVCL_U174 NSC-H14 somatic stem cell human CVCL_U174 CL:0000010 Male 21147551 CVCL_TP75 HAP1 SMYD5 (-) 1 cancer cell line human CVCL_TP75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16258; SMYD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147552 CVCL_U175 NSC-H14iPSZeng somatic stem cell human CVCL_U175 CL:0000010 Male 21147553 CVCL_TP58 HAP1 SMARCD1 (-) 1 cancer cell line human CVCL_TP58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11106; SMARCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147554 CVCL_U158 MovS6-4 transformed cell line house mouse CVCL_U158 CL:0000010 Transfected with: UniProtKB; P23907; Sheep PRNP (with p.Ala136Val and p.Arg171Gln = VRQ allele) Transformant: Simian virus 40 (SV40) [HuVim [830]-T/t](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Schwann cell.; Breed/subspecies: Transgenic tg301+/-. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3922 21147555 CVCL_U159 H1 Oct4-EGFP embryonic stem cell human CVCL_U159 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Characteristics: A eGFP-neo construct was added to the C-terminal of the POU5F1/OCT4 gene by homologous recombination 21147556 CVCL_TP59 HAP1 SMARCD1 (-) 2 cancer cell line human CVCL_TP59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11106; SMARCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147557 CVCL_TP56 HAP1 SMARCC1 (-) 2 cancer cell line human CVCL_TP56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147558 CVCL_U156 Rov9 spontaneously immortalized cell line CVCL_U156 CL:0000010 Transfected with: UniProtKB; P23907; Sheep PNRP (with p.Ala136Val and p.Arg171Gln = VRQ allele) Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21147559 CVCL_TP57 HAP1 SMARCC2 (-) 1 cancer cell line human CVCL_TP57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11105; SMARCC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147560 CVCL_U157 TSM1 transformed cell line house mouse CVCL_U157 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: v-Myc; Derived from sampling site: Embryonic brain; neocortex; Breed/subspecies: BALB/c. Unspecified 21147561 CVCL_1J10 GM05606 transformed cell line human CVCL_1J10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147562 CVCL_1J13 GM05626 transformed cell line human CVCL_1J13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147563 CVCL_1J14 GM05628 transformed cell line human CVCL_1J14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147564 CVCL_1J11 GM05608 transformed cell line human CVCL_1J11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147565 CVCL_1J12 GM05610 transformed cell line human CVCL_1J12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147566 CVCL_1J06 GM05590 transformed cell line human CVCL_1J06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147567 CVCL_1J07 GM05594 transformed cell line human CVCL_1J07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147568 CVCL_1J04 GM05580 transformed cell line human CVCL_1J04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147569 CVCL_1J05 GM05584 transformed cell line human CVCL_1J05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147570 CVCL_1J08 GM05600 transformed cell line human CVCL_1J08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147571 CVCL_1J09 GM05604 transformed cell line human CVCL_1J09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147572 CVCL_U161 H9 hNanog-pGZ embryonic stem cell human CVCL_U161 CL:0000010 Female 21147573 CVCL_TP61 HAP1 SMARCD2 (-) cancer cell line human CVCL_TP61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11107; SMARCD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147574 CVCL_U162 H9 hOct4-pGZ embryonic stem cell human CVCL_U162 CL:0000010 Female 21147575 CVCL_TP62 HAP1 SMARCD3 (-) 1 cancer cell line human CVCL_TP62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11108; SMARCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147576 CVCL_U160 H9 Cre-LoxP embryonic stem cell human CVCL_U160 CL:0000010 Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-06.. 21147577 CVCL_TP60 HAP1 SMARCD1 (-) 3 cancer cell line human CVCL_TP60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11106; SMARCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147578 CVCL_U165 H9-hTnnTZ-pGZ-D2 embryonic stem cell human CVCL_U165 CL:0000010 Female 21147579 CVCL_TP65 HAP1 SMO (-) 1 cancer cell line human CVCL_TP65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147580 CVCL_TP66 HAP1 SMO (-) 2 cancer cell line human CVCL_TP66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11119; SMO; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147581 CVCL_U166 IISH1i-BM1 induced pluripotent stem cell human CVCL_U166 CL:0000010 Derived from sampling site: Bone marrow. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21147582 CVCL_U163 H9 inGFPhES embryonic stem cell human CVCL_U163 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female 21147583 CVCL_TP63 HAP1 SMARCD3 (-) 2 cancer cell line human CVCL_TP63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11108; SMARCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147584 CVCL_U164 H9 Syn-GFP embryonic stem cell human CVCL_U164 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC11-12. 21147585 CVCL_TP64 HAP1 SMCR8 (-) cancer cell line human CVCL_TP64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17921; SMCR8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147586 CVCL_TP47 HAP1 SMAD4 (-) 1 cancer cell line human CVCL_TP47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147587 CVCL_U147 PC880 cancer cell line human CVCL_U147 CL:0000010 Derived from metastatic site: Ascites. Female 21147588 CVCL_U148 FU-MMT-3 cancer cell line human CVCL_U148 CL:0000010 Population: Japanese Female Doubling time: 29 hours, at 5th passage (PubMed=9368662). 21147589 CVCL_TP48 HAP1 SMARCA2 (-) 1 cancer cell line human CVCL_TP48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11098; SMARCA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147590 CVCL_U145 FU-MMT-2-C1 cancer cell line human CVCL_U145 CL:0000010 Population: Japanese. Female 21147591 CVCL_TP45 HAP1 SLX1B (-) 2 cancer cell line human CVCL_TP45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28748; SLX1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147592 CVCL_U146 FU-MMT-2-S1 cancer cell line human CVCL_U146 CL:0000010 Population: Japanese. Female 21147593 CVCL_TP46 HAP1 SLX4 (-) cancer cell line human CVCL_TP46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23845; SLX4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147594 CVCL_TP49 HAP1 SMARCA2 (-) 2 cancer cell line human CVCL_TP49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11098; SMARCA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147595 CVCL_U149 PC-9/f14 cancer cell line human CVCL_U149 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male 21147596 CVCL_1J20 GM05678 transformed cell line human CVCL_1J20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147597 CVCL_1J21 GM05682 transformed cell line human CVCL_1J21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147598 CVCL_1J24 GM05690 transformed cell line human CVCL_1J24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147599 CVCL_1J25 GM05700 transformed cell line human CVCL_1J25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147600 CVCL_1J22 GM05684 transformed cell line human CVCL_1J22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147601 CVCL_1J23 GM05688 transformed cell line human CVCL_1J23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147602 CVCL_1J17 GM05642 transformed cell line human CVCL_1J17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147603 CVCL_1J18 GM05660 transformed cell line human CVCL_1J18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147604 CVCL_1J15 GM05638 transformed cell line human CVCL_1J15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147605 CVCL_1J16 GM05640 transformed cell line human CVCL_1J16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147606 CVCL_1J19 GM05668 transformed cell line human CVCL_1J19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147607 CVCL_TP50 HAP1 SMARCA4 (-) 1 cancer cell line human CVCL_TP50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147608 CVCL_U150 PC-9/f9 cancer cell line human CVCL_U150 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Lymph node. Male 21147609 CVCL_U151 BN17 hybrid cell line CVCL_U151 CL:0000010 Transfected with: HGNC; 286; ADRB2. 21147610 CVCL_TP51 HAP1 SMARCA4 (-) 2 cancer cell line human CVCL_TP51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147611 CVCL_TP54 HAP1 SMARCA4 (-) 5 cancer cell line human CVCL_TP54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147612 CVCL_U154 MovS2 transformed cell line house mouse CVCL_U154 CL:0000010 Transfected with: UniProtKB; P23907; Sheep PRNP (with p.Ala136Val and p.Arg171Gln = VRQ allele) Transformant: Simian virus 40 (SV40) [HuVim [830]-T/t](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Schwann cell.; Breed/subspecies: tg301+/- transgenic. Unspecified 21147613 CVCL_TP55 HAP1 SMARCC1 (-) 1 cancer cell line human CVCL_TP55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11104; SMARCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147614 CVCL_U155 MovS6 transformed cell line house mouse CVCL_U155 CL:0000010 Transfected with: UniProtKB; P23907; Sheep PRNP (with p.Ala136Val and p.Arg171Gln = VRQ allele) Transformant: Simian virus 40 (SV40) [HuVim [830]-T/t](NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Schwann cell.; Breed/subspecies: Transgenic tg301+/-. Unspecified 21147615 CVCL_TP52 HAP1 SMARCA4 (-) 3 cancer cell line human CVCL_TP52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147616 CVCL_U152 Rat-1/BB16 transformed cell line Norway rat CVCL_U152 CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain Bratislava-77 (B77)](NCBI-Taxonomy; 11876); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21147617 CVCL_TP53 HAP1 SMARCA4 (-) 4 cancer cell line human CVCL_TP53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11100; SMARCA4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147618 CVCL_U153 Rat-1/tsLA29 transformed cell line Norway rat CVCL_U153 CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain tsLA29](NCBI-Taxonomy; 11876); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21147619 CVCL_TP36 HAP1 SLC9C1 (-) 2 cancer cell line human CVCL_TP36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31401; SLC9C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147620 CVCL_U136 OMB3 hybridoma house mouse CVCL_U136 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: N-linked neutral oligosaccharides of glycoproteins. 21147621 CVCL_TP37 HAP1 SLCO3A1 (-) 1 cancer cell line human CVCL_TP37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10952; SLCO3A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147622 CVCL_U137 OMB4 hybridoma house mouse CVCL_U137 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: N-linked neutral oligosaccharides of glycoproteins. 21147623 CVCL_TP34 HAP1 SLC9B2 (-) cancer cell line human CVCL_TP34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25143; SLC9B2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147624 CVCL_U134 MVP51 hybridoma house mouse CVCL_U134 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Medaka vitellogenin. 21147625 CVCL_TP35 HAP1 SLC9C1 (-) 1 cancer cell line human CVCL_TP35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31401; SLC9C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147626 CVCL_U135 NMuMG/Fucci2 spontaneously immortalized cell line house mouse CVCL_U135 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci2 (Fluorescent Ubiquitination-based Cell Cycle Indicator 2) construct; Characteristics: Transfected with the Fucci2 probe which consist of the fusion of mCherry) to the ubiquitination domain of human CDT1 (aa 30-120) and of monomeric Venus (mVenus) to the ubiquitination domain of human geminin (aa 1-110) 21147627 CVCL_TP38 HAP1 SLCO4A1 (-) 1 cancer cell line human CVCL_TP38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10953; SLCO4A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147628 CVCL_U138 OMR5 hybridoma house mouse CVCL_U138 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: F1-linked neutral oligosaccharides of glycoproteins. 21147629 CVCL_TP39 HAP1 SLCO5A1 (-) 1 cancer cell line human CVCL_TP39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19046; SLCO5A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147630 CVCL_U139 OMR6 hybridoma house mouse CVCL_U139 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: M1-linked neutral oligosaccharides of glycoproteins. 21147631 CVCL_KV99 InCELL Hunter A549 GLP Methyltransferase cancer cell line human CVCL_KV99 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 24650; EHMT1 (with del 1-1006 and 1283-1298) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147632 CVCL_L797 IMM010.37.14 hybridoma house mouse CVCL_L797 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human 200 kDa glycoprotein surface antigen of small cell lung cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2358 21147633 CVCL_KV97 InCELL Hunter A549 EP300 Bromodomain cancer cell line human CVCL_KV97 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3373; EP300 (with del 1-1039 and 1162-2414) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147634 CVCL_L798 IMM010.51.2 hybridoma house mouse CVCL_L798 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human 200 kDa glycoprotein surface antigen of small cell lung cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2360 21147635 CVCL_KV98 InCELL Hunter A549 G9a Methyltransferase cancer cell line human CVCL_KV98 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 14129; EHMT2 (with del 1-917 and 1194-1210) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: InCELL Hunter cell lines express a transfected target protein fragment tagged with a beta-galactosidase fragment (enhanced ProLabel=ePL) The technology measures compound binding to an intracellular target by detecting changes in protein stability. The amount of fusion is quantified through the addition of substrate and a second enzyme fragment (Enzyme acceptor=EA). 21147636 CVCL_KV95 cAMP Hunter U2OS mGLP1R Gs cancer cell line human CVCL_KV95 CL:0000010 Transfected with: MGI; MGI:99571; Glp1r Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21147637 CVCL_L795 IMM010.109.12 hybridoma house mouse CVCL_L795 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human 200 kDa glycoprotein surface antigen of small cell lung cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2357 21147638 CVCL_KV96 HCH-3 cancer cell line human CVCL_KV96 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DOI=10.4172/2157-2518.1000292); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (DOI=10.4172/2157-2518.1000292) Population: Japanese; Karyotypic information: Near tetraploid karyotype; Derived from sampling site: Ovary. Female Doubling time: 82 hours (DOI=10.4172/2157-2518.1000292) 21147639 CVCL_L796 IMM010.26.1 hybridoma house mouse CVCL_L796 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2359 21147640 CVCL_KV93 cAMP Hunter DLD1 PTGER2 Gs cancer cell line human CVCL_KV93 CL:0000010 Transfected with: HGNC; 9594; PTGER2. Male 21147641 CVCL_L793 MM46 [Human mesothelioma] cancer cell line human CVCL_L793 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 11.5 +- 0.5 hours (PubMed=21205078) 21147642 CVCL_KV94 cAMP Hunter U2OS HTR7B Gs cancer cell line human CVCL_KV94 CL:0000010 Transfected with: HGNC; 5302; HTR7 (isoform B) Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21147643 CVCL_L794 MM56 cancer cell line human CVCL_L794 CL:0000010 Population: Japanese Male Doubling time: 15.6 +- 1.8 hours (PubMed=21205078). 21147644 CVCL_KV91 cAMP Hunter DLD1 ADRB3 Gs cancer cell line human CVCL_KV91 CL:0000010 Transfected with: HGNC; 288; ADRB3. Male 21147645 CVCL_L791 MM26 cancer cell line human CVCL_L791 CL:0000010 Population: Japanese Omics: CNV analysis; Omics: SNP array analysis. Female Doubling time: 15.7 +- 1.3 hours (PubMed=21205078) 21147646 CVCL_KV92 cAMP Hunter DLD1 HTR7D Gs cancer cell line human CVCL_KV92 CL:0000010 Transfected with: HGNC; 5302; HTR7 (isoform D). Male 21147647 CVCL_TP40 HAP1 SLFN11 (-) 1 cancer cell line human CVCL_TP40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147648 CVCL_L792 MM35 cancer cell line human CVCL_L792 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 32.8 +- 2.5 hours (PubMed=21205078) 21147649 CVCL_U140 PC3.1 hybridoma house mouse CVCL_U140 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q64361; Rat Lxn. 21147650 CVCL_KV90 cAMP Hunter CHO-K1 XCR1 Gi spontaneously immortalized cell line CVCL_KV90 CL:0000010 Transfected with: HGNC; 1625; XCR1 Derived from sampling site: Ovary. Female 21147651 CVCL_L790 MM21 cancer cell line human CVCL_L790 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Omics: CNV analysis; Omics: SNP array analysis Male Doubling time: 13.9 +- 0.4 hours (PubMed=21205078) 21147652 CVCL_U143 FU-MMT-1 cancer cell line human CVCL_U143 CL:0000010 Population: Japanese Female Doubling time: 26 hours, at 5th passage (PubMed=1312893). 21147653 CVCL_TP43 HAP1 SLK (-) 2 cancer cell line human CVCL_TP43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11088; SLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147654 CVCL_U144 FU-MMT-2 cancer cell line human CVCL_U144 CL:0000010 Population: Japanese Female Doubling time: 30 hours, at 5th passage (PubMed=1312893). 21147655 CVCL_TP44 HAP1 SLX1B (-) 1 cancer cell line human CVCL_TP44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28748; SLX1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147656 CVCL_U141 FM3A ts T244 cancer cell line house mouse CVCL_U141 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Defective in DNA replication at the non-permissive temperature. 21147657 CVCL_TP41 HAP1 SLIT2 (-) 1 cancer cell line human CVCL_TP41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11086; SLIT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147658 CVCL_U142 CS-99 cancer cell line human CVCL_U142 CL:0000010 Derived from sampling site: Uterus. Female Doubling time: 27 hours (at 26th passage), 23 hours (at 66th passage) (PubMed=18334012) 21147659 CVCL_TP42 HAP1 SLK (-) 1 cancer cell line human CVCL_TP42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11088; SLK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147660 CVCL_U125 GT-13A hybridoma house mouse CVCL_U125 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:80769; Gonyautoxin 2. 21147661 CVCL_TP25 HAP1 SLC9A6 (-) 2 cancer cell line human CVCL_TP25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11079; SLC9A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147662 CVCL_U126 h1c hybridoma house mouse CVCL_U126 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Lygodium japonicum strain an-1 basal apparatus. 21147663 CVCL_TP26 HAP1 SLC9A6 (-) 3 cancer cell line human CVCL_TP26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11079; SLC9A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147664 CVCL_U123 BBWV-22K5-12A hybridoma house mouse CVCL_U123 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; R4V130; Broad bean wilt virus 2 small capsid protein. 21147665 CVCL_TP23 HAP1 SLC9A3R2 (-) 2 cancer cell line human CVCL_TP23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11076; SLC9A3R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147666 CVCL_U124 BBWV-22K6-2A hybridoma house mouse CVCL_U124 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; R4V130; Broad bean wilt virus 2 small capsid protein. 21147667 CVCL_TP24 HAP1 SLC9A6 (-) 1 cancer cell line human CVCL_TP24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11079; SLC9A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147668 CVCL_TP29 HAP1 SLC9A7 (-) 3 cancer cell line human CVCL_TP29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17123; SLC9A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147669 CVCL_U129 J#249.1-1 hybridoma house mouse CVCL_U129 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P97875; Mouse Jdp2. 21147670 CVCL_TP27 HAP1 SLC9A7 (-) 1 cancer cell line human CVCL_TP27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17123; SLC9A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147671 CVCL_U127 J#176-3.2 hybridoma house mouse CVCL_U127 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P97875; Mouse Jdp2. 21147672 CVCL_TP28 HAP1 SLC9A7 (-) 2 cancer cell line human CVCL_TP28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17123; SLC9A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147673 CVCL_U128 J#214.2-2 hybridoma house mouse CVCL_U128 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P97875; Mouse Jdp2. 21147674 CVCL_1J02 GM05560 transformed cell line human CVCL_1J02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21147675 CVCL_1J03 GM05572 transformed cell line human CVCL_1J03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147676 CVCL_1J00 GM05554 transformed cell line human CVCL_1J00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147677 CVCL_1J01 GM05558 transformed cell line human CVCL_1J01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21147678 CVCL_TP32 HAP1 SLC9A9 (-) 2 cancer cell line human CVCL_TP32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20653; SLC9A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147679 CVCL_U132 MVP47 hybridoma house mouse CVCL_U132 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Medaka vitellogenin. 21147680 CVCL_TP33 HAP1 SLC9A9 (-) 3 cancer cell line human CVCL_TP33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20653; SLC9A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147681 CVCL_U133 MVP49 hybridoma house mouse CVCL_U133 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Medaka vitellogenin. 21147682 CVCL_TP30 HAP1 SLC9A8 (-) 1 cancer cell line human CVCL_TP30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20728; SLC9A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147683 CVCL_U130 MVP1 hybridoma house mouse CVCL_U130 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Medaka vitellogenin. 21147684 CVCL_TP31 HAP1 SLC9A9 (-) 1 cancer cell line human CVCL_TP31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20653; SLC9A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21147685 CVCL_U131 MVP25 hybridoma house mouse CVCL_U131 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Medaka vitellogenin. 21147686 CVCL_1J90 BHK-SR19-T7 spontaneously immortalized cell line CVCL_1J90 CL:0000010 Derived from sampling site: Kidney. Male 21147687 CVCL_1J93 GM17505 finite cell line human CVCL_1J93 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21147688 CVCL_1J94 GM17506 transformed cell line human CVCL_1J94 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147689 CVCL_1J91 BHK-RR-B51E spontaneously immortalized cell line CVCL_1J91 CL:0000010 Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5257 21147690 CVCL_1J92 HLCZ01 cancer cell line human CVCL_1J92 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201309 21147691 CVCL_1J97 GM17586 finite cell line human CVCL_1J97 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147692 CVCL_1J98 GM17587 transformed cell line human CVCL_1J98 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147693 CVCL_1J95 GM17588 finite cell line human CVCL_1J95 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21147694 CVCL_1J96 GM17589 transformed cell line human CVCL_1J96 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147695 CVCL_1J99 HGUE-C-1 cancer cell line human CVCL_1J99 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=25885658); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (PubMed=25885658); Sequence variation: Mutation; HGNC; 8975; PIK3CA; None_reported; -; Zygosity=- (PubMed=25885658); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=25885658) Derived from metastatic site: Ascites. Male 21147696 CVCL_1J71 GM13504 transformed cell line human CVCL_1J71 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147697 CVCL_1J72 GM13505 transformed cell line human CVCL_1J72 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147698 CVCL_1J70 GM13503 transformed cell line human CVCL_1J70 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147699 CVCL_1J75 GM13508 transformed cell line human CVCL_1J75 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[58] (c.52CAG(58)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147700 CVCL_1J76 GM13509 transformed cell line human CVCL_1J76 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[70] (c.52CAG(70)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147701 CVCL_1J73 GM13506 transformed cell line human CVCL_1J73 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[48] (c.52CAG(48)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147702 CVCL_1J74 GM13507 transformed cell line human CVCL_1J74 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[55] (c.52CAG(55)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147703 CVCL_1J79 GM13512 transformed cell line human CVCL_1J79 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147704 CVCL_1J77 GM13510 transformed cell line human CVCL_1J77 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147705 CVCL_1J78 GM13511 transformed cell line human CVCL_1J78 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[47] (c.52CAG(47)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147706 CVCL_1J82 GM13515 transformed cell line human CVCL_1J82 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[66] (c.52CAG(66)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147707 CVCL_1J83 GM14044 transformed cell line human CVCL_1J83 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[750] (c.52CAG(750)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=32656337) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147708 CVCL_1J80 GM13513 transformed cell line human CVCL_1J80 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49] (c.52CAG(49)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147709 CVCL_1J81 GM13514 transformed cell line human CVCL_1J81 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[52] (c.52CAG(52)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147710 CVCL_1J86 32.3 embryonic stem cell house mouse CVCL_1J86 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:88335; Cd4 Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11114 21147711 CVCL_1J87 GP101 transformed cell line house mouse CVCL_1J87 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21147712 CVCL_1J84 GM21756 finite cell line human CVCL_1J84 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[70] (c.52CAG(70)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM13509) Derived from sampling site: Cell type=Fibroblast. Female 21147713 CVCL_1J85 GM21757 finite cell line human CVCL_1J85 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[66] (c.52CAG(66)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM13515) Derived from sampling site: Cell type=Fibroblast. Male 21147714 CVCL_1J88 RDF 21 transformed cell line house mouse CVCL_1J88 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4440 21147715 CVCL_1J89 HeLa-RR-B51S cancer cell line human CVCL_1J89 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5258 21147716 CVCL_2591 Mero-25 cancer cell line human CVCL_2591 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~48 hours (PubMed=2474517) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147717 CVCL_1T91 SK-MEL-457 cancer cell line human CVCL_1T91 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147718 CVCL_2592 Mero-41 cancer cell line human CVCL_2592 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147719 CVCL_1T92 SK-MEL-459 cancer cell line human CVCL_1T92 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147720 CVCL_2590 Mero-14 cancer cell line human CVCL_2590 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~24 hours (ECACC=09100101) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147721 CVCL_1T90 SK-MEL-455 cancer cell line human CVCL_1T90 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=24576830). 21147722 CVCL_2584 MCC14/2 cancer cell line human CVCL_2584 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Glu (c.815T>A); ClinVar=VCV000376673; Zygosity=Unspecified (PubMed=10732753; DepMap) Derived from metastatic site: Iliac lymph node. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147723 CVCL_1T84 SK-MEL-444 cancer cell line human CVCL_1T84 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147724 CVCL_2585 MCC26 cancer cell line human CVCL_2585 Genome ancestry: African=0%; Native American=0.82%; East Asian, North=1.72%; East Asian, South=0%; South Asian=0%; European, North=66.7%; European, South=30.75% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg556Ter (c.1666C>T); ClinVar=VCV000013090; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Karyotypic information: Hypotriploid karyotype Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21147725 CVCL_1T85 SK-MEL-445 cancer cell line human CVCL_1T85 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147726 CVCL_2582 LUDLU-1 cancer cell line human CVCL_2582 HLA typing: A*02:01,03:01; B*15:01,18:01; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=1.82%; Native American=0.66%; East Asian, North=3.82%; East Asian, South=0%; South Asian=0%; European, North=56.05%; European, South=37.65% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21147727 CVCL_1T82 SK-MEL-439 cancer cell line human CVCL_1T82 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147728 CVCL_2583 MCC13 cancer cell line human CVCL_2583 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=1.16%; South Asian=3.02%; European, North=64.74%; European, South=31.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Heterozygous (PubMed=10732753; PubMed=23563200); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Heterozygous (PubMed=10732753; PubMed=23563200) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis Female Doubling time: 1 day (PubMed=20444890) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21147729 CVCL_1T83 SK-MEL-441 cancer cell line human CVCL_1T83 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147730 CVCL_2588 MDST8 cancer cell line human CVCL_2588 HLA typing: A*02:01,24:02; B*07:02,27:05; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0.18%; Native American=0.98%; East Asian, North=1.64%; East Asian, South=0%; South Asian=1.57%; European, North=63.72%; European, South=31.91% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556fs*3 (c.4660_4661insA) (E1554fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp310Gly (c.929A>G); ClinVar=VCV000566673; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Microsatellite instability: Stable (MSS) (PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21147731 CVCL_1T88 SK-MEL-451 cancer cell line human CVCL_1T88 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147732 CVCL_2589 MDTC-RP19 cancer cell line CVCL_2589 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Nicholas. Male Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8135 21147733 CVCL_1T89 SK-MEL-452 cancer cell line human CVCL_1T89 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147734 CVCL_2586 MDCK.P3 spontaneously immortalized cell line dog CVCL_2586 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Serum/protein free medium cell line 21147735 CVCL_1T86 SK-MEL-446 cancer cell line human CVCL_1T86 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147736 CVCL_2587 MDOK spontaneously immortalized cell line CVCL_2587 CL:0000010 Derived from sampling site: Kidney. Discontinued: IZSLER; BS CL 65; probable Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) 21147737 CVCL_1T87 SK-MEL-447 cancer cell line human CVCL_1T87 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147738 CVCL_2595 Mero-83 cancer cell line human CVCL_2595 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~40 hours (ECACC=09100106) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147739 CVCL_1T95 SK-MEL-464B cancer cell line human CVCL_1T95 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147740 CVCL_2596 Mero-84 cancer cell line human CVCL_2596 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~48 hours (ECACC=09100107) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147741 CVCL_1T96 SK-MEL-479 cancer cell line human CVCL_1T96 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147742 CVCL_2593 Mero-48a cancer cell line human CVCL_2593 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~24 hours (ECACC=09100104) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147743 CVCL_1T93 SK-MEL-462 cancer cell line human CVCL_1T93 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147744 CVCL_2594 Mero-82 cancer cell line human CVCL_2594 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (DepMap) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Unspecified Doubling time: ~24 hours (PubMed=2474517) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147745 CVCL_1T94 SK-MEL-464A cancer cell line human CVCL_1T94 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147746 CVCL_2599 MES-SA/MX2 cancer cell line human CVCL_2599 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Uterus. Omics: SNP array analysis Female 21147747 CVCL_1T99 SK-MEL-495 cancer cell line human CVCL_1T99 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147748 CVCL_2597 Mero-95 cancer cell line human CVCL_2597 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: ~30 hours (ECACC=09100108) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147749 CVCL_1T97 SK-MEL-481 cancer cell line human CVCL_1T97 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147750 CVCL_2598 MES-SA/Dx5 cancer cell line human CVCL_2598 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Uterus. Omics: Protein expression by reverse-phase protein arrays; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis Discontinued: ATCC; CRL-1977; probable Female Doubling time: 30 hours (ECACC=95051031) Part of: MD Anderson Cell Lines Project 21147751 CVCL_1T98 SK-MEL-483 cancer cell line human CVCL_1T98 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147752 CVCL_2570 LB81 transformed cell line human CVCL_2570 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala792Val (c.2375C>T) (2572C>T); ClinVar=VCV000016567; Zygosity=Heterozygous (PubMed=7951246) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147753 CVCL_1T70 SK-MEL-411 cancer cell line human CVCL_1T70 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147754 CVCL_2562 TTD4BR LCL transformed cell line human CVCL_2562 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147755 CVCL_1T62 SK-MEL-391 cancer cell line human CVCL_1T62 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147756 CVCL_2563 AT6BR LCL transformed cell line human CVCL_2563 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5763-1050A>G (5762ins137); ClinVar=VCV000003021; Zygosity=Unspecified (from autologous cell line AT6BR) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147757 CVCL_1T63 SK-MEL-393 cancer cell line human CVCL_1T63 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147758 CVCL_2560 XP8BR LCL transformed cell line human CVCL_2560 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg669fs (c.2005delA); ClinVar=VCV000445466; Zygosity=Heterozygous (from autologous cell line XP8BR); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly675Arg (c.2023G>C); Zygosity=Heterozygous (from autologous cell line XP8BR) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147759 CVCL_1T60 SK-MEL-318 cancer cell line human CVCL_1T60 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147760 CVCL_2561 LB42 transformed cell line human CVCL_2561 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147761 CVCL_1T61 SK-MEL-332 cancer cell line human CVCL_1T61 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147762 CVCL_2566 LB7 transformed cell line human CVCL_2566 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147763 CVCL_1T66 SK-MEL-400 cancer cell line human CVCL_1T66 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147764 CVCL_2567 LB707 transformed cell line human CVCL_2567 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147765 CVCL_1T67 SK-MEL-406 cancer cell line human CVCL_1T67 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147766 CVCL_2564 AT2BR LCL transformed cell line human CVCL_2564 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Homozygous (from autologous cell line AT2BR) Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147767 CVCL_1T64 SK-MEL-394 cancer cell line human CVCL_1T64 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=24576830). 21147768 CVCL_2565 LB687 transformed cell line human CVCL_2565 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147769 CVCL_1T65 SK-MEL-398 cancer cell line human CVCL_1T65 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147770 CVCL_2568 LB708 transformed cell line human CVCL_2568 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147771 CVCL_1T68 SK-MEL-408 cancer cell line human CVCL_1T68 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147772 CVCL_2569 LB750 transformed cell line human CVCL_2569 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147773 CVCL_1T69 SK-MEL-410 cancer cell line human CVCL_1T69 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=24576830). 21147774 CVCL_2580 LMH cancer cell line CVCL_2580 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: White Leghorn L-M. Male Virology: Efficient cell line for duck hepatitis B virus (DHBV) DNA synthesis following transfection with viral constructs (PubMed=2352324) Group: Bird cell line 21147775 CVCL_1T80 SK-MEL-432 cancer cell line human CVCL_1T80 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147776 CVCL_2581 LO68 cancer cell line human CVCL_2581 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Exosome proteome analysis; Omics: Secretome proteome analysis; Omics: SNP array analysis Male 21147777 CVCL_1T81 SK-MEL-435 cancer cell line human CVCL_1T81 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147778 CVCL_2573 AF-2 clone 9B5 hybridoma house mouse CVCL_2573 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human AF-2 antigen. 21147779 CVCL_1T73 SK-MEL-423A cancer cell line human CVCL_1T73 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147780 CVCL_2574 LIM1215 cancer cell line human CVCL_2574 Genome ancestry: African=5.72%; Native American=0%; East Asian, North=3.18%; East Asian, South=0%; South Asian=6.91%; European, North=26.95%; European, South=57.24% (PubMed=30894373) From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (PubMed=24755471; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714) Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: N-glycan profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DepMap; ACH-001546; true Male Doubling time: 32 hours, at 8th passage (PubMed=3857372); 28 hours (PubMed=142798); Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21147781 CVCL_1T74 SK-MEL-423B cancer cell line human CVCL_1T74 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147782 CVCL_2571 LB823 transformed cell line human CVCL_2571 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147783 CVCL_1T71 SK-MEL-412Parotid cancer cell line human CVCL_1T71 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147784 CVCL_2572 XP125LO LCL transformed cell line human CVCL_2572 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala792Val (c.2375C>T) (2572C>T); ClinVar=VCV000016567; Zygosity=Heterozygous (PubMed=7951246); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu960Ter (c.2878G>T) (3075G>T); ClinVar=VCV000016566; Zygosity=Heterozygous (PubMed=7951246) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147785 CVCL_1T72 SK-MEL-413-2 cancer cell line human CVCL_1T72 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147786 CVCL_2577 LL47 (MaDo) finite cell line human CVCL_2577 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: KCLB; 10135; probable Male Senescence: Can undergo 15 PDL 21147787 CVCL_1T77 SK-MEL-428 cancer cell line human CVCL_1T77 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147788 CVCL_2578 LL86 (LeSa) finite cell line human CVCL_2578 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Can undergo 10 PDL 21147789 CVCL_1T78 SK-MEL-430 cancer cell line human CVCL_1T78 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147790 CVCL_2575 LL24 finite cell line human CVCL_2575 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Senescence: Can undergo 25 PDL 21147791 CVCL_1T75 SK-MEL-426 cancer cell line human CVCL_1T75 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21147792 CVCL_2576 LL29 (AnHa) finite cell line human CVCL_2576 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Senescence: Can undergo 9 PDL 21147793 CVCL_1T76 SK-MEL-427 cancer cell line human CVCL_1T76 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147794 CVCL_2579 LLC-RK1 spontaneously immortalized cell line CVCL_2579 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: New Zealand white. Unspecified 21147795 CVCL_1T79 SK-MEL-431 cancer cell line human CVCL_1T79 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147796 CVCL_TZ92 BIHi030-C induced pluripotent stem cell human CVCL_TZ92 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147797 CVCL_TZ93 BIHi006-A induced pluripotent stem cell human CVCL_TZ93 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147798 CVCL_TZ90 SL0006 cancer cell line human CVCL_TZ90 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P03255; Adenovirus 5 E1A protein (with p.Ile4_Glu25del and p.Ser111_Thr123del = dl01/07); Transfected with: UniProtKB; P03243; Adenovirus 5 E1B 55 kDa protein; Transfected with: UniProtKB; P03246; Adenovirus 5 E1B 19 kDa protein; Transfected with: UniProtKB; P04495; Adenovirus 5 DNA polymerase Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Useful for the production of E1-deleted adenovirus (rAd) vectors Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6663 21147799 CVCL_TZ91 BIHi001-A-1 induced pluripotent stem cell human CVCL_TZ91 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21147800 CVCL_TZ96 BIHi006-D induced pluripotent stem cell human CVCL_TZ96 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147801 CVCL_TZ97 BIHi007-A induced pluripotent stem cell human CVCL_TZ97 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147802 CVCL_TZ94 BIHi006-B induced pluripotent stem cell human CVCL_TZ94 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147803 CVCL_TZ95 BIHi006-C induced pluripotent stem cell human CVCL_TZ95 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147804 CVCL_TZ98 BIHi007-B induced pluripotent stem cell human CVCL_TZ98 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147805 CVCL_TZ99 BIHi007-C induced pluripotent stem cell human CVCL_TZ99 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21147806 CVCL_1T40 DT40-CARD11(-/-) cancer cell line CVCL_1T40 CL:0000010 Knockout cell: Method=Targeted integration; CARD11 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147807 CVCL_2540 Karpas-25 cancer cell line human CVCL_2540 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (ECACC=06072601; Ximbio=152420) 21147808 CVCL_1T41 DT40-LYN(-/-) cancer cell line CVCL_1T41 CL:0000010 Knockout cell: Method=Targeted integration; LYN Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147809 CVCL_2541 Karpas-384 cancer cell line human CVCL_2541 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (DepMap) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis Male Doubling time: ~60 hours (ECACC=06120602) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147810 CVCL_1T44 DT40-LIG4(-/-) cancer cell line CVCL_1T44 CL:0000010 Knockout cell: Method=Targeted integration; LIG4 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147811 CVCL_2544 KHOS-240S cancer cell line human CVCL_2544 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis Female Part of: MD Anderson Cell Lines Project 21147812 CVCL_1T45 DT40-BTK(-/-) cancer cell line CVCL_1T45 CL:0000010 Knockout cell: Method=Targeted integration; BTK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147813 CVCL_2545 KHOS-312H cancer cell line human CVCL_2545 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis Female Part of: MD Anderson Cell Lines Project 21147814 CVCL_1T42 DT40-PRKCB(-/-) cancer cell line CVCL_1T42 CL:0000010 Knockout cell: Method=Targeted integration; PRKCB Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147815 CVCL_2542 Karpas-417 cancer cell line human CVCL_2542 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (ECACC=06100302; Ximbio=152421) 21147816 CVCL_1T43 DT40-SYK(-/-) cancer cell line CVCL_1T43 CL:0000010 Knockout cell: Method=Targeted integration; SYK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147817 CVCL_2543 Karpas-929 cancer cell line human CVCL_2543 CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (ECACC=06072606; Ximbio=152422) 21147818 CVCL_1T48 Dnmt1-/-Dnmt3a-/-Dnmt3b-/- ES (clone19) embryonic stem cell house mouse CVCL_1T48 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:94912; Dnmt1; Knockout cell: Method=Homologous recombination; MGI; MGI:1261827; Dnmt3a; Knockout cell: Method=Homologous recombination; MGI; MGI:1261819; Dnmt3b Breed/subspecies: 129S4/SvJae. Discontinued: RCB; AES0146; probable Male 21147819 CVCL_2548 LA1-55n cancer cell line human CVCL_2548 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) Doubling time: ~2 days (ECACC=06041203) 21147820 CVCL_1T49 DT40-VAV3(-/-) cancer cell line CVCL_1T49 CL:0000010 Knockout cell: Method=Targeted integration; VAV3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147821 CVCL_2549 LA1-5s cancer cell line human CVCL_2549 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Male Characteristics: Substrate-adherent type (S-type) (PubMed=15720811) Doubling time: ~2 days (ECACC=06041204) 21147822 CVCL_1T46 DT40-CBL(-/-) cancer cell line CVCL_1T46 CL:0000010 Knockout cell: Method=Targeted integration; CBL Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147823 CVCL_2546 KHOS/NP cancer cell line human CVCL_2546 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Bone; right femur. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis Discontinued: ATCC; CRL-7723; true Female Characteristics: Tumorigenic Part of: MD Anderson Cell Lines Project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147824 CVCL_1T47 DT40-PLCG2(-/-) cancer cell line CVCL_1T47 CL:0000010 Knockout cell: Method=Targeted integration; PLCG2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147825 CVCL_2547 L2C cancer cell line CVCL_2547 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Strain 2. Female 21147826 CVCL_TZ81 L1023L cancer cell line human CVCL_TZ81 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147827 CVCL_TZ82 L619L cancer cell line human CVCL_TZ82 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147828 CVCL_TZ80 K420L cancer cell line human CVCL_TZ80 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21147829 CVCL_TZ85 A925LPE3 cancer cell line human CVCL_TZ85 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Established from parent cell line after 3 passages in the thoracic cavity of SCID mice 21147830 CVCL_TZ86 B514L cancer cell line human CVCL_TZ86 CL:0000010 Population: Japanese. Unspecified 21147831 CVCL_TZ83 H1224EBV-B transformed cell line human CVCL_TZ83 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147832 CVCL_TZ84 C831EBV-B transformed cell line human CVCL_TZ84 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147833 CVCL_TZ89 SL0003 cancer cell line human CVCL_TZ89 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P03255; Adenovirus 5 E1A protein (with p.Ile4_Glu25del and p.Ser111_Thr123del = dl01/07); Transfected with: UniProtKB; P03243; Adenovirus 5 E1B 55 kDa protein Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Useful for the production of E1-deleted adenovirus (rAd) vectors Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6231 21147834 CVCL_TZ87 803YT cancer cell line human CVCL_TZ87 CL:0000010 Population: Japanese. Unspecified 21147835 CVCL_TZ88 YM21 cancer cell line human CVCL_TZ88 CL:0000010 Population: Japanese. Unspecified 21147836 CVCL_1T51 DT40-REV3L(-/-) cancer cell line CVCL_1T51 CL:0000010 Knockout cell: Method=Targeted integration; REV3L Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147837 CVCL_2551 LB173 transformed cell line human CVCL_2551 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147838 CVCL_1T52 DT40-BLNK(-/-)-SYK(-/-) cancer cell line CVCL_1T52 CL:0000010 Knockout cell: Method=Targeted integration; BLNK+SYK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147839 CVCL_2552 LB182 transformed cell line human CVCL_2552 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147840 CVCL_1T50 DT40-MAP3K7(-/-) cancer cell line CVCL_1T50 CL:0000010 Knockout cell: Method=Targeted integration; MAP3K7 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147841 CVCL_2550 LADMAC transformed cell line house mouse CVCL_2550 CL:0000010 Breed/subspecies: C3H. Unspecified Characteristics: Secretes CSF1 21147842 CVCL_2555 TTD1BR LCL transformed cell line human CVCL_2555 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Leu21Pro (c.62T>C); ClinVar=VCV000002104; Zygosity=Heterozygous (from autologous cell line TTD1BR); Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Arg56Ter (c.166C>T); ClinVar=VCV000002103; Zygosity=Heterozygous (from autologous cell line TTD1BR) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147843 CVCL_1T55 MVh-Venns GS embryonic stem cell house mouse CVCL_1T55 CL:0000010 Breed/subspecies: C57BL/6J x DBA/2. Male Characteristics: Germ stem cell line 21147844 CVCL_2556 XP11BR LCL transformed cell line human CVCL_2556 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gly263Val (c.788G>T); dbSNP=rs1413703153; Zygosity=Homozygous (from autologous cell line XP11BR) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147845 CVCL_1T56 PCI-22A cancer cell line human CVCL_1T56 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00418. Problematic cell line: Misidentified/contaminated Supposed to be isogenic with PCI-22B (Cellosaurus=CVCL_1T57) but does not have the same STR profile and are therefore not originating from the same individual (PubMed=21868764). 21147846 CVCL_2553 LB185 transformed cell line human CVCL_2553 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147847 CVCL_1T53 mGS-DBA1 embryonic stem cell house mouse CVCL_1T53 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB2003; true Male Characteristics: Germ stem cell line 21147848 CVCL_2554 TTDHM1BR LCL transformed cell line human CVCL_2554 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147849 CVCL_1T54 Mili-KO GS embryonic stem cell house mouse CVCL_1T54 CL:0000010 Breed/subspecies: DBA/2. Male Characteristics: Germ stem cell line 21147850 CVCL_2559 LB277 transformed cell line human CVCL_2559 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147851 CVCL_1T59 SK-MEL-313 cancer cell line human CVCL_1T59 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21147852 CVCL_2557 CS4BR LCL transformed cell line human CVCL_2557 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Gln184Ter (c.550C>T) (C629T); ClinVar=VCV001459151; Zygosity=Heterozygous (from autologous cell line CS4BR); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg670Trp (c.2008C>T) (C2087T); ClinVar=VCV000190158; Zygosity=Heterozygous (from autologous cell line CS4BR) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147853 CVCL_1T57 PCI-22B cancer cell line human CVCL_1T57 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00419. Problematic cell line: Misidentified/contaminated Supposed to be isogenic with PCI-22A (Cellosaurus=CVCL_1T56) but does not have the same STR profile and are therefore not originating from the same individual (PubMed=21868764). 21147854 CVCL_2558 XP6BR LCL transformed cell line human CVCL_2558 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Thr808Valfs*48 (c.2421_2604del184); Zygosity=Heterozygous (from autologous cell line XP6BR) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147855 CVCL_1T58 OS-P2/HTLV-I transformed cell line human CVCL_1T58 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Virology: HTLV-1 producing cell line Doubling time: ~6 days (HIVReagentProgram) 21147856 CVCL_TZ70 EquiPSC clone I induced pluripotent stem cell CVCL_TZ70 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: LIF dependent 21147857 CVCL_TZ71 EquiPSC clone K induced pluripotent stem cell CVCL_TZ71 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: LIF dependent 21147858 CVCL_TZ74 NWR 6571 iPSC-c501 induced pluripotent stem cell CVCL_TZ74 CL:0000010 Anecdotal: Established from a rhinoceros named Dinka that lived in San Diego Zoo Safari Park and died in 1991 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21147859 CVCL_TZ75 NWR 8175 iPSC-c501 induced pluripotent stem cell CVCL_TZ75 CL:0000010 Anecdotal: Established from a rhinoceros named Nola that lived in San Diego Zoo Safari Park and died in 2015 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21147860 CVCL_TZ72 S2-DGRC spontaneously immortalized cell line fruit fly CVCL_TZ72 CL:0000010 Breed/subspecies: Oregon-R. Omics: Transcriptome analysis by RNAseq Male Doubling time: 23 hours (DGRC) Group: Insect cell line 21147861 CVCL_TZ73 NWR 5765 iPSC-c506 induced pluripotent stem cell CVCL_TZ73 CL:0000010 Anecdotal: Established from a rhinoceros named Suni that lived in Dvur Kralove zoo and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21147862 CVCL_TZ78 F1121EBV-B transformed cell line human CVCL_TZ78 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21147863 CVCL_TZ79 F1012L cancer cell line human CVCL_TZ79 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Unspecified 21147864 CVCL_TZ76 NWR 9947 iPSC-c501 induced pluripotent stem cell CVCL_TZ76 CL:0000010 Anecdotal: Established from a rhinoceros named Angalifu that lived in San Diego Zoo Safari Park and died in 2014 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21147865 CVCL_TZ77 G603EBV-B transformed cell line human CVCL_TZ77 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147866 CVCL_1T22 Atg3^(-/-)MEF transformed cell line house mouse CVCL_1T22 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1915091; Atg3 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21147867 CVCL_2522 HTK- cancer cell line human CVCL_2522 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=5.13%; South Asian=34.91%; European, North=0%; European, South=59.95% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Bone; right femur. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: Could be identical to 143B (Cellosaurus=CVCL_2270) 21147868 CVCL_1T23 DT40-ATM(-/-) cancer cell line CVCL_1T23 CL:0000010 Knockout cell: Method=Targeted integration; ATM Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147869 CVCL_2523 HtTA-1 cancer cell line human CVCL_2523 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21147870 CVCL_2520 HT115 cancer cell line human CVCL_2520 HLA typing: A*02:01,24:02; B*51:01,51:01; C*02:02,16:01 (PubMed=26589293); Genome ancestry: African=0.18%; Native American=0.04%; East Asian, North=1.25%; East Asian, South=0%; South Asian=0.21%; European, North=66.59%; European, South=31.73% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Microsatellite instability: Stable (MSS) (PubMed=25926053); Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21147871 CVCL_1T20 T404 cancer cell line human CVCL_1T20 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00425. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21147872 CVCL_1T21 Atg3^(+/+)MEF transformed cell line house mouse CVCL_1T21 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21147873 CVCL_2521 HT29/219 cancer cell line human CVCL_2521 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Omics: Protein expression by reverse-phase protein arrays. Female Part of: MD Anderson Cell Lines Project 21147874 CVCL_1T26 DT40-ORAI1(-/-) cancer cell line CVCL_1T26 CL:0000010 Knockout cell: Method=Targeted integration; ORAI1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147875 CVCL_2526 HuNS1 transformed cell line human CVCL_2526 Genome ancestry: African=0%; Native American=1.22%; East Asian, North=0%; East Asian, South=1.71%; South Asian=5.64%; European, North=56.19%; European, South=35.24% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Secretes IgG2 kappa Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8644 Problematic cell line: Misclassified Grand-parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21147876 CVCL_1T27 DT40-ORAI2(-/-) cancer cell line CVCL_1T27 CL:0000010 Knockout cell: Method=Targeted integration; ORAI2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147877 CVCL_2527 IMR-31 finite cell line CVCL_2527 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ATCC; CCL-40; true Female Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Senescence: Senesces at ~40 PDL (ATCC=CCL-40) 21147878 CVCL_1T24 DT40-ATM(-/-)-XRCC6(-/-) cancer cell line CVCL_1T24 CL:0000010 Knockout cell: Method=Targeted integration; ATM+XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147879 CVCL_2524 HUC-Fm finite cell line human CVCL_2524 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (PubMed=17395773) 21147880 CVCL_1T25 DT40-BLM(-/-) cancer cell line CVCL_1T25 CL:0000010 Knockout cell: Method=Targeted integration; BLM Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147881 CVCL_2525 huFasM38 hybridoma house mouse CVCL_2525 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11465 21147882 CVCL_1T28 DT40-STIM1(-/-) cancer cell line CVCL_1T28 CL:0000010 Knockout cell: Method=Targeted integration; STIM1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147883 CVCL_2528 IMR-33 cancer cell line CVCL_2528 CL:0000010 Male Doubling time: 36-38.5 hours (PubMed=5554453). 21147884 CVCL_1T29 DT40-STIM1(-/-)-STIM2(-/-) cancer cell line CVCL_1T29 CL:0000010 Knockout cell: Method=Targeted integration; STIM1+STIM2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147885 CVCL_2529 Ishikawa cancer cell line human CVCL_2529 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ser302fs*4 (c.906delC); Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from child cell line Ishikawa (Heraklio) 02 ER-); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (PubMed=15901131) Population: Japanese; Derived from sampling site: Endometrium. Omics: Array-based CGH; Omics: ATAC-seq; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 36 hours (at 9th passage), 29 hours (at 40th passage), 27 hours (at 50th passage) (DOI=10.1007/978-4-431-53981-0_2); 35.14 +- 2.68 hours (PubMed=23255909) Part of: ENCODE project common cell types; tier 3 21147886 CVCL_TZ60 NBE-4 finite cell line dog CVCL_TZ60 CL:0000010 Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6256; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147887 CVCL_TZ63 MS-E finite cell line CVCL_TZ63 CL:0000010 Derived from sampling site: Skin. Female Doubling time: 19 +- 1 hours (PubMed=9639098) Group: Endangered species/breed cell line 21147888 CVCL_TZ64 KDT3 spontaneously immortalized cell line house mouse CVCL_TZ64 CL:0000010 Derived from sampling site: Kidney; distal tubule. Unspecified 21147889 CVCL_TZ61 HepF cancer cell line human CVCL_TZ61 CL:0000010 Derived from metastatic site: Ascites. Discontinued: ATCC; CRL-7925; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147890 CVCL_TZ62 MS-D finite cell line CVCL_TZ62 CL:0000010 Derived from sampling site: Skin. Female Group: Endangered species/breed cell line 21147891 CVCL_TZ67 KPT2-TRPV4 spontaneously immortalized cell line house mouse CVCL_TZ67 CL:0000010 Transfected with: RGD; 69337; Trpv4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; proximal tubule. Discontinued: ABM; T6009; probable Unspecified 21147892 CVCL_TZ68 A2780-M cancer cell line human CVCL_TZ68 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Ovary. Female Characteristics: Compared to the parent cell line, has high invasiveness and motility 21147893 CVCL_TZ65 KPT1 spontaneously immortalized cell line house mouse CVCL_TZ65 CL:0000010 Derived from sampling site: Kidney; proximal tubule. Unspecified 21147894 CVCL_TZ66 KPT2 spontaneously immortalized cell line house mouse CVCL_TZ66 CL:0000010 Derived from sampling site: Kidney; proximal tubule. Discontinued: ABM; T0642; probable Unspecified 21147895 CVCL_TZ69 EquiPSC clone H induced pluripotent stem cell CVCL_TZ69 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: LIF dependent 21147896 CVCL_1T30 DT40-STIM2(-/-) cancer cell line CVCL_1T30 CL:0000010 Knockout cell: Method=Targeted integration; STIM2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147897 CVCL_2530 J45.01 cancer cell line human CVCL_2530 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: CD45-deficient 21147898 CVCL_1T33 DT40-NBN(-/-) cancer cell line CVCL_1T33 CL:0000010 Knockout cell: Method=Targeted integration; NBN Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147899 CVCL_2533 JIM3 cancer cell line human CVCL_2533 HLA typing: A*02; B*27,40; C*02,03 (PubMed=25688540) CL:0000010 Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5905; IGLV3-21; Name(s)=IGLV3-21-IGLJ3 (CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11157491; PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=21173094) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21147900 CVCL_1T34 DT40-RAD54L(-/-) cancer cell line CVCL_1T34 CL:0000010 Knockout cell: Method=Targeted integration; RAD54L Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147901 CVCL_2534 JLS-V5 spontaneously immortalized cell line house mouse CVCL_2534 CL:0000010 Derived from sampling site: Spleen and thymus; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6359; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147902 CVCL_1T31 DT40-XRCC6(-/-) cancer cell line CVCL_1T31 CL:0000010 Knockout cell: Method=Targeted integration; XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147903 CVCL_1T32 DT40-POLK(-/-) cancer cell line CVCL_1T32 CL:0000010 Knockout cell: Method=Targeted integration; POLK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147904 CVCL_2532 JIM1 cancer cell line human CVCL_2532 CL:0000010 Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5905; IGLV3-21; Name(s)=IGLV3-21-IGLJ3 (CelloPub=CLPUB00604) Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 21147905 CVCL_1T37 DT40-XRCC3(-/-) cancer cell line CVCL_1T37 CL:0000010 Knockout cell: Method=Targeted integration; XRCC3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147906 CVCL_2537 K1 cancer cell line human CVCL_2537 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244) Population: Caucasian; Italian; Derived from metastatic site: Thyroid gland. Omics: Transcriptome analysis by microarray Male Doubling time: 24 hours (PubMed=9054892) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00218 Problematic cell line: Contaminated Shown to be a GLAG-66 derivative (PubMed=19087340; PubMed=20143388). 21147907 CVCL_1T38 DT40-BLNK(-/-) cancer cell line CVCL_1T38 CL:0000010 Knockout cell: Method=Targeted integration; BLNK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147908 CVCL_2538 K6H6/B5 hybrid cell line CVCL_2538 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line 21147909 CVCL_1T35 DT40-WRN(-/-) cancer cell line CVCL_1T35 CL:0000010 Knockout cell: Method=Targeted integration; WRN Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147910 CVCL_2535 JLS-V9 spontaneously immortalized cell line house mouse CVCL_2535 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6360; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21147911 CVCL_1T36 DT40-XRCC2(-/-) cancer cell line CVCL_1T36 CL:0000010 Knockout cell: Method=Targeted integration; XRCC2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147912 CVCL_2536 JU77 cancer cell line human CVCL_2536 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Exosome proteome analysis; Omics: Secretome proteome analysis; Omics: SNP array analysis Male Doubling time: 25 hours (PubMed=1703129) 21147913 CVCL_1T39 DT40-PIK3AP1(-/-) cancer cell line CVCL_1T39 CL:0000010 Knockout cell: Method=Targeted integration; PIK3AP1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21147914 CVCL_2539 Karpas-1718 cancer cell line human CVCL_2539 CL:0000010 Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21147915 CVCL_CH35 ND06085 transformed cell line human CVCL_CH35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147916 CVCL_CH36 ND06086 transformed cell line human CVCL_CH36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147917 CVCL_CH33 ND06083 transformed cell line human CVCL_CH33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147918 CVCL_CH34 ND06084 transformed cell line human CVCL_CH34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147919 CVCL_CH39 ND06094 transformed cell line human CVCL_CH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147920 CVCL_CH37 ND06092 transformed cell line human CVCL_CH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147921 CVCL_CH38 ND06093 transformed cell line human CVCL_CH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147922 CVCL_CH31 ND06072 transformed cell line human CVCL_CH31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147923 CVCL_CH32 ND06078 transformed cell line human CVCL_CH32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147924 CVCL_CH30 ND06071 transformed cell line human CVCL_CH30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147925 CVCL_CH46 ND06142 transformed cell line human CVCL_CH46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147926 CVCL_CH47 ND06148 transformed cell line human CVCL_CH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147927 CVCL_CH44 ND06106 transformed cell line human CVCL_CH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147928 CVCL_CH45 ND06108 transformed cell line human CVCL_CH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147929 CVCL_CH48 ND06149 transformed cell line human CVCL_CH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147930 CVCL_CH49 ND06150 transformed cell line human CVCL_CH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147931 CVCL_CH42 ND06097 transformed cell line human CVCL_CH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147932 CVCL_CH43 ND06105 transformed cell line human CVCL_CH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147933 CVCL_CH40 ND06095 transformed cell line human CVCL_CH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147934 CVCL_CH41 ND06096 transformed cell line human CVCL_CH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147935 CVCL_CH19 ND06012 transformed cell line human CVCL_CH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147936 CVCL_CH13 ND05975 transformed cell line human CVCL_CH13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147937 CVCL_CH14 ND05976 transformed cell line human CVCL_CH14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147938 CVCL_CH11 ND05973 transformed cell line human CVCL_CH11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147939 CVCL_CH12 ND05974 transformed cell line human CVCL_CH12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147940 CVCL_CH17 ND05998 transformed cell line human CVCL_CH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147941 CVCL_CH18 ND06009 transformed cell line human CVCL_CH18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147942 CVCL_CH15 ND05994 transformed cell line human CVCL_CH15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147943 CVCL_CH16 ND05996 transformed cell line human CVCL_CH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147944 CVCL_CH10 ND05972 transformed cell line human CVCL_CH10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147945 CVCL_CH24 ND06025 transformed cell line human CVCL_CH24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147946 CVCL_CH25 ND06028 transformed cell line human CVCL_CH25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147947 CVCL_CH22 ND06015 transformed cell line human CVCL_CH22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147948 CVCL_CH23 ND06020 transformed cell line human CVCL_CH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147949 CVCL_CH28 ND06057 transformed cell line human CVCL_CH28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147950 CVCL_CH29 ND06070 transformed cell line human CVCL_CH29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147951 CVCL_CH26 ND06029 transformed cell line human CVCL_CH26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147952 CVCL_CH27 ND06030 transformed cell line human CVCL_CH27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147953 CVCL_CH20 ND06013 transformed cell line human CVCL_CH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147954 CVCL_CH21 ND06014 transformed cell line human CVCL_CH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147955 CVCL_CH08 ND05959 transformed cell line human CVCL_CH08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147956 CVCL_CH09 ND05971 transformed cell line human CVCL_CH09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147957 CVCL_CH02 ND05948 transformed cell line human CVCL_CH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147958 CVCL_CH03 ND05950 transformed cell line human CVCL_CH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147959 CVCL_CH00 ND05930 transformed cell line human CVCL_CH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147960 CVCL_CH01 ND05931 transformed cell line human CVCL_CH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147961 CVCL_CH06 ND05957 transformed cell line human CVCL_CH06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147962 CVCL_CH07 ND05958 transformed cell line human CVCL_CH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147963 CVCL_CH04 ND05952 transformed cell line human CVCL_CH04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147964 CVCL_CH05 ND05956 transformed cell line human CVCL_CH05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147965 CVCL_LA39 PathHunter U2OS GPR1 Total GPCR Internalization cancer cell line human CVCL_LA39 CL:0000010 Transfected with: HGNC; 4463; CMKLR2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147966 CVCL_LA37 PathHunter U2OS GLP2R Activated GPCR Internalization cancer cell line human CVCL_LA37 CL:0000010 Transfected with: HGNC; 4325; GLP2R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147967 CVCL_LA38 PathHunter U2OS GPBAR1 beta-arrestin cancer cell line human CVCL_LA38 CL:0000010 Transfected with: HGNC; 19680; GPBAR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147968 CVCL_LA35 PathHunter U2OS GLP1R Activated GPCR Internalization cancer cell line human CVCL_LA35 CL:0000010 Transfected with: HGNC; 4324; GLP1R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147969 CVCL_LA36 PathHunter U2OS GLP1R Total GPCR Internalization cancer cell line human CVCL_LA36 CL:0000010 Transfected with: HGNC; 4324; GLP1R Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147970 CVCL_LA33 PathHunter U2OS GALR1 Total GPCR Internalization cancer cell line human CVCL_LA33 CL:0000010 Transfected with: HGNC; 4132; GALR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147971 CVCL_LA34 PathHunter U2OS GHSR1a beta-arrestin-1 cancer cell line human CVCL_LA34 CL:0000010 Transfected with: HGNC; 4267; GHSR (isoform 1a); Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147972 CVCL_LA31 PathHunter U2OS FPR1 Total GPCR Internalization cancer cell line human CVCL_LA31 CL:0000010 Transfected with: HGNC; 3826; FPR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147973 CVCL_LA32 PathHunter U2OS FPRL1 Activated GPCR Internalization cancer cell line human CVCL_LA32 CL:0000010 Transfected with: HGNC; 3827; FPR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147974 CVCL_LA30 PathHunter U2OS FOXO3 Nuclear Translocation cancer cell line human CVCL_LA30 CL:0000010 Transfected with: HGNC; 3821; FOXO3 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21147975 CVCL_CG94 ND05921 transformed cell line human CVCL_CG94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147976 CVCL_CG95 ND05922 transformed cell line human CVCL_CG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147977 CVCL_CG92 ND05906 transformed cell line human CVCL_CG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147978 CVCL_CG93 ND05910 transformed cell line human CVCL_CG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147979 CVCL_CG98 ND05928 transformed cell line human CVCL_CG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147980 CVCL_CG99 ND05929 transformed cell line human CVCL_CG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147981 CVCL_CG96 ND05923 transformed cell line human CVCL_CG96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147982 CVCL_CG97 ND05924 transformed cell line human CVCL_CG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21147983 CVCL_LA48 PathHunter U2OS GRPR beta-arrestin cancer cell line human CVCL_LA48 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147984 CVCL_LA49 PathHunter U2OS HCRTR1 Total GPCR Internalization cancer cell line human CVCL_LA49 CL:0000010 Transfected with: HGNC; 4848; HCRTR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147985 CVCL_LA46 PathHunter U2OS GPR85 beta-arrestin cancer cell line human CVCL_LA46 CL:0000010 Transfected with: HGNC; 4536; GPR85; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147986 CVCL_LA47 PathHunter U2OS GRPR Activated GPCR Internalization cancer cell line human CVCL_LA47 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147987 CVCL_LA44 PathHunter U2OS GPR52 beta-arrestin cancer cell line human CVCL_LA44 CL:0000010 Transfected with: HGNC; 4508; GPR52; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147988 CVCL_LA45 PathHunter U2OS GPR6 beta-arrestin cancer cell line human CVCL_LA45 CL:0000010 Transfected with: HGNC; 4515; GPR6; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147989 CVCL_LA42 PathHunter U2OS GPR22 beta-arrestin cancer cell line human CVCL_LA42 CL:0000010 Transfected with: HGNC; 4477; GPR22; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147990 CVCL_LA43 PathHunter U2OS GPR35 Activated GPCR Internalization cancer cell line human CVCL_LA43 CL:0000010 Transfected with: HGNC; 4492; GPR35; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147991 CVCL_LA40 PathHunter U2OS GPR119 beta-arrestin cancer cell line human CVCL_LA40 CL:0000010 Transfected with: HGNC; 19060; GPR119; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147992 CVCL_LA41 PathHunter U2OS GPR17 beta-arrestin cancer cell line human CVCL_LA41 CL:0000010 Transfected with: HGNC; 4471; GPR17; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147993 CVCL_LA17 PathHunter U2OS CXCR6 Total GPCR Internalization cancer cell line human CVCL_LA17 CL:0000010 Transfected with: HGNC; 16647; CXCR6 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147994 CVCL_LA18 PathHunter U2OS CXCR7 Activated GPCR Internalization cancer cell line human CVCL_LA18 CL:0000010 Transfected with: HGNC; 23692; ACKR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147995 CVCL_LA15 PathHunter U2OS CXCR3 beta-arrestin cancer cell line human CVCL_LA15 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147996 CVCL_LA16 PathHunter U2OS CXCR4 Total GPCR Internalization cancer cell line human CVCL_LA16 CL:0000010 Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147997 CVCL_LA13 PathHunter U2OS CXCR2 Activated GPCR Internalization cancer cell line human CVCL_LA13 CL:0000010 Transfected with: HGNC; 6027; CXCR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21147998 CVCL_CG80 ND05843 transformed cell line human CVCL_CG80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21147999 CVCL_LA14 PathHunter U2OS CXCR3 Activated GPCR Internalization cancer cell line human CVCL_LA14 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148000 CVCL_LA11 PathHunter U2OS CXCR1 Activated GPCR Internalization cancer cell line human CVCL_LA11 CL:0000010 Transfected with: HGNC; 6026; CXCR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148001 CVCL_LA12 PathHunter U2OS CXCR1 beta-arrestin cancer cell line human CVCL_LA12 CL:0000010 Transfected with: HGNC; 6026; CXCR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148002 CVCL_LA10 PathHunter U2OS CRTH2 beta-arrestin cancer cell line human CVCL_LA10 CL:0000010 Transfected with: HGNC; 4502; PTGDR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148003 CVCL_CG78 ND05841 transformed cell line human CVCL_CG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148004 CVCL_CG79 ND05842 transformed cell line human CVCL_CG79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148005 CVCL_CG72 ND05820 transformed cell line human CVCL_CG72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148006 CVCL_CG73 ND05821 transformed cell line human CVCL_CG73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148007 CVCL_CG70 ND05803 transformed cell line human CVCL_CG70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148008 CVCL_CG71 ND05804 transformed cell line human CVCL_CG71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148009 CVCL_CG76 ND05824 transformed cell line human CVCL_CG76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148010 CVCL_CG77 ND05839 transformed cell line human CVCL_CG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148011 CVCL_CG74 ND05822 transformed cell line human CVCL_CG74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148012 CVCL_LA08 PathHunter U2OS CRHR1 Activated GPCR Internalization cancer cell line human CVCL_LA08 CL:0000010 Transfected with: HGNC; 2357; CRHR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148013 CVCL_CG75 ND05823 transformed cell line human CVCL_CG75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148014 CVCL_LA09 PathHunter U2OS CRHR2 Activated GPCR Internalization cancer cell line human CVCL_LA09 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148015 CVCL_LA28 PathHunter U2OS F2RL1 beta-arrestin cancer cell line human CVCL_LA28 CL:0000010 Transfected with: HGNC; 3538; F2RL1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148016 CVCL_LA29 PathHunter U2OS F2RL3 Activated GPCR Internalization cancer cell line human CVCL_LA29 CL:0000010 Transfected with: HGNC; 3540; F2RL3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148017 CVCL_LA26 PathHunter U2OS EDNRB Total GPCR Internalization cancer cell line human CVCL_LA26 CL:0000010 Transfected with: HGNC; 3180; EDNRB Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148018 CVCL_LA27 PathHunter U2OS F2RL1 Activated GPCR Internalization cancer cell line human CVCL_LA27 CL:0000010 Transfected with: HGNC; 3538; F2RL1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148019 CVCL_CG90 ND05901 transformed cell line human CVCL_CG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148020 CVCL_LA24 PathHunter U2OS EDG5 Activated GPCR Internalization cancer cell line human CVCL_LA24 CL:0000010 Transfected with: HGNC; 3169; S1PR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148021 CVCL_CG91 ND05904 transformed cell line human CVCL_CG91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148022 CVCL_LA25 PathHunter U2OS EDG7 Activated GPCR Internalization cancer cell line human CVCL_LA25 CL:0000010 Transfected with: HGNC; 14298; LPAR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148023 CVCL_LA22 PathHunter U2OS EDG2 Activated GPCR Internalization cancer cell line human CVCL_LA22 CL:0000010 Transfected with: HGNC; 3166; LPAR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148024 CVCL_LA23 PathHunter U2OS EDG3 Activated GPCR Internalization cancer cell line human CVCL_LA23 CL:0000010 Transfected with: HGNC; 3167; S1PR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148025 CVCL_LA20 PathHunter U2OS DRD3 beta-arrestin cancer cell line human CVCL_LA20 CL:0000010 Transfected with: HGNC; 3024; DRD3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148026 CVCL_LA21 PathHunter U2OS EBI2 Total GPCR Internalization cancer cell line human CVCL_LA21 CL:0000010 Transfected with: HGNC; 3128; GPR183 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148027 CVCL_CG89 ND05896 transformed cell line human CVCL_CG89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148028 CVCL_CG83 ND05865 transformed cell line human CVCL_CG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148029 CVCL_CG84 ND05872 transformed cell line human CVCL_CG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148030 CVCL_CG81 ND05849 transformed cell line human CVCL_CG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148031 CVCL_CG82 ND05850 transformed cell line human CVCL_CG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148032 CVCL_CG87 ND05888 transformed cell line human CVCL_CG87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148033 CVCL_CG88 ND05895 transformed cell line human CVCL_CG88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148034 CVCL_CG85 ND05878 transformed cell line human CVCL_CG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148035 CVCL_LA19 PathHunter U2OS DRD1 Total GPCR Internalization cancer cell line human CVCL_LA19 CL:0000010 Transfected with: HGNC; 3020; DRD1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148036 CVCL_CG86 ND05879 transformed cell line human CVCL_CG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148037 CVCL_CG58 ND05734 transformed cell line human CVCL_CG58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148038 CVCL_CG59 ND05745 transformed cell line human CVCL_CG59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148039 CVCL_CG56 ND05732 transformed cell line human CVCL_CG56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148040 CVCL_CG57 ND05733 transformed cell line human CVCL_CG57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148041 CVCL_CG50 ND05689 transformed cell line human CVCL_CG50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148042 CVCL_CG51 ND05690 transformed cell line human CVCL_CG51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148043 CVCL_CG54 ND05720 transformed cell line human CVCL_CG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148044 CVCL_CG55 ND05721 transformed cell line human CVCL_CG55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148045 CVCL_CG52 ND05692 transformed cell line human CVCL_CG52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148046 CVCL_CG53 ND05705 transformed cell line human CVCL_CG53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148047 CVCL_LA06 PathHunter U2OS CHRM5 Activated GPCR Internalization cancer cell line human CVCL_LA06 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148048 CVCL_LA07 PathHunter U2OS CMKLR1 Activated GPCR Internalization cancer cell line human CVCL_LA07 CL:0000010 Transfected with: HGNC; 2121; CMKLR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148049 CVCL_LA04 PathHunter U2OS CHRM3 Total GPCR Internalization cancer cell line human CVCL_LA04 CL:0000010 Transfected with: HGNC; 1952; CHRM3 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148050 CVCL_LA05 PathHunter U2OS CHRM4 Total GPCR Internalization cancer cell line human CVCL_LA05 CL:0000010 Transfected with: HGNC; 1953; CHRM4 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148051 CVCL_LA02 PathHunter U2OS CHRM2 Activated GPCR Internalization cancer cell line human CVCL_LA02 CL:0000010 Transfected with: HGNC; 1951; CHRM2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148052 CVCL_LA03 PathHunter U2OS CHRM3 beta-arrestin cancer cell line human CVCL_LA03 CL:0000010 Transfected with: HGNC; 1952; CHRM3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148053 CVCL_LA00 PathHunter U2OS CHRM1 Activated GPCR Internalization cancer cell line human CVCL_LA00 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148054 CVCL_LA01 PathHunter U2OS CHRM1 beta-arrestin cancer cell line human CVCL_LA01 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148055 CVCL_CG69 ND05790 transformed cell line human CVCL_CG69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148056 CVCL_CG67 ND05785 transformed cell line human CVCL_CG67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148057 CVCL_CG68 ND05786 transformed cell line human CVCL_CG68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148058 CVCL_CG61 ND05774 transformed cell line human CVCL_CG61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148059 CVCL_CG62 ND05776 transformed cell line human CVCL_CG62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148060 CVCL_CG60 ND05753 transformed cell line human CVCL_CG60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148061 CVCL_CG65 ND05783 transformed cell line human CVCL_CG65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148062 CVCL_CG66 ND05784 transformed cell line human CVCL_CG66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148063 CVCL_CG63 ND05778 transformed cell line human CVCL_CG63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148064 CVCL_CG64 ND05782 transformed cell line human CVCL_CG64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148065 CVCL_CG36 ND05643 transformed cell line human CVCL_CG36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148066 CVCL_CG37 ND05652 transformed cell line human CVCL_CG37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148067 CVCL_CG34 ND05641 transformed cell line human CVCL_CG34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148068 CVCL_CG35 ND05642 transformed cell line human CVCL_CG35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148069 CVCL_CG38 ND05654 transformed cell line human CVCL_CG38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148070 CVCL_CG39 ND05655 transformed cell line human CVCL_CG39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148071 CVCL_CG32 ND05623 transformed cell line human CVCL_CG32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148072 CVCL_CG33 ND05624 transformed cell line human CVCL_CG33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148073 CVCL_CG30 ND05615 transformed cell line human CVCL_CG30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148074 CVCL_CG31 ND05622 transformed cell line human CVCL_CG31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148075 CVCL_CG47 ND05677 transformed cell line human CVCL_CG47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148076 CVCL_CG48 ND05686 transformed cell line human CVCL_CG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148077 CVCL_CG45 ND05675 transformed cell line human CVCL_CG45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148078 CVCL_CG46 ND05676 transformed cell line human CVCL_CG46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148079 CVCL_CG49 ND05687 transformed cell line human CVCL_CG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148080 CVCL_CG40 ND05660 transformed cell line human CVCL_CG40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148081 CVCL_CG43 ND05673 transformed cell line human CVCL_CG43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148082 CVCL_CG44 ND05674 transformed cell line human CVCL_CG44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148083 CVCL_CG41 ND05661 transformed cell line human CVCL_CG41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148084 CVCL_CG42 ND05662 transformed cell line human CVCL_CG42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148085 CVCL_TZ52 HAP1 ZNF91 (-) 1 cancer cell line human CVCL_TZ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13166; ZNF91; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148086 CVCL_TZ53 HAP1 ZNF91 (-) 2 cancer cell line human CVCL_TZ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13166; ZNF91; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148087 CVCL_TZ50 HAP1 ZNF816 (-) 1 cancer cell line human CVCL_TZ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26995; ZNF816; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148088 CVCL_TZ51 HAP1 ZNF816 (-) 2 cancer cell line human CVCL_TZ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26995; ZNF816; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148089 CVCL_TZ56 HAP1 ZRANB1 (-) 1 cancer cell line human CVCL_TZ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18224; ZRANB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148090 CVCL_TZ57 HAP1 ZRANB1 (-) 2 cancer cell line human CVCL_TZ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18224; ZRANB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148091 CVCL_TZ54 HAP1 ZNF91 (-) 3 cancer cell line human CVCL_TZ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13166; ZNF91; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148092 CVCL_TZ55 HAP1 ZNRF3 (-) 1 cancer cell line human CVCL_TZ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18126; ZNRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148093 CVCL_TZ58 ND50066 induced pluripotent stem cell human CVCL_TZ58 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21148094 CVCL_TZ59 ND50075 induced pluripotent stem cell human CVCL_TZ59 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21148095 CVCL_2500 HMT-3522 S2 spontaneously immortalized cell line human CVCL_2500 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Unspecified (PubMed=7982476) Population: Caucasian; Donor information: Established from a nontumorigenic fibrocystic breast lesion (from parent cell line); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female Characteristics: Established from parent cell line by permanent ommission of EGF in culture medium 21148096 CVCL_1T00 HPS0337 induced pluripotent stem cell human CVCL_1T00 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21148097 CVCL_2501 HMT-3522 T4-2 spontaneously immortalized cell line human CVCL_2501 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Donor information: Established from a nontumorigenic fibrocystic breast lesion (from parent cell line); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 32.94 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel 21148098 CVCL_1T01 HPS0338 induced pluripotent stem cell human CVCL_1T01 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21148099 CVCL_2504 HO-22-1 hybridoma house mouse CVCL_2504 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.1). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21148100 CVCL_1T04 SJPL undefined cell line type CVCL_1T04 CL:0000010 Unspecified Group: Non-human primate cell line; Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00367; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3256. Problematic cell line: Misidentified Originally thought to be of pig origin but found to be from Chlorocebus aethiops (PubMed=20200241). 21148101 CVCL_2505 HR5 cancer cell line human CVCL_2505 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21148102 CVCL_1T05 LN 14832 spontaneously immortalized cell line CVCL_1T05 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Characteristics: In vitro infected by the NC-1 strain of Neospora caninum Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12231 Problematic cell line: Misidentified Grand-parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21148103 CVCL_2502 HO-13-4 hybridoma house mouse CVCL_2502 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.2). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21148104 CVCL_1T02 HPS0339 induced pluripotent stem cell human CVCL_1T02 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21148105 CVCL_1T03 Clone 1A spontaneously immortalized cell line CVCL_1T03 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00371 Problematic cell line: Misidentified/contaminated Originally thought to be of Oncorhynchus mykiss origin but found to be a Oncorhynchus tshawytscha CHSE-214 derivative (PubMed=19002917). 21148106 CVCL_2503 HO-2.2 hybridoma house mouse CVCL_2503 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21148107 CVCL_1T08 H7D7C cancer cell line human CVCL_1T08 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00205 Problematic cell line: Contaminated Shown to be a Hep-G2 derivative (PubMed=12619888; PubMed=20143388). Originally thought to originate from SV40-transformed normal liver cells. 21148108 CVCL_2508 HRA-19 cancer cell line human CVCL_2508 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (PubMed=8197130); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16418264; PubMed=24755471) Derived from sampling site: Rectum. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Ximbio; 152465; probable Male Part of: AstraZeneca Colorectal cell line (AZCL) panel 21148109 CVCL_1T09 H7D7D cancer cell line human CVCL_1T09 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00206 Problematic cell line: Contaminated Shown to be a Hep-G2 derivative (PubMed=12619888; PubMed=20143388). Originally thought to originate from SV40-transformed normal liver cells. 21148110 CVCL_2509 HRA-19a1.1 cancer cell line human CVCL_2509 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Rectum. Discontinued: Ximbio; 152466; probable Male 21148111 CVCL_1T06 H7D7A cancer cell line human CVCL_1T06 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00203 Problematic cell line: Contaminated Shown to be a Hep-G2 derivative (PubMed=12619888; PubMed=20143388). Originally thought to originate from SV40-transformed normal liver cells. 21148112 CVCL_2506 HR5-CL11 cancer cell line human CVCL_2506 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21148113 CVCL_1T07 H7D7B cancer cell line human CVCL_1T07 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00204 Problematic cell line: Contaminated Shown to be a Hep-G2 derivative (PubMed=12619888; PubMed=20143388). Originally thought to originate from SV40-transformed normal liver cells. 21148114 CVCL_2507 HRA-16 cancer cell line human CVCL_2507 CL:0000010 Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Discontinued: Ximbio; 152464; probable Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21148115 CVCL_TZ41 HAP1 ZNF589 (-) 2 cancer cell line human CVCL_TZ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16747; ZNF589; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148116 CVCL_TZ42 HAP1 ZNF646 (-) 1 cancer cell line human CVCL_TZ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29004; ZNF646; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148117 CVCL_TZ40 HAP1 ZNF589 (-) 1 cancer cell line human CVCL_TZ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16747; ZNF589; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148118 CVCL_TZ45 HAP1 ZNF746 (-) cancer cell line human CVCL_TZ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21948; ZNF746; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148119 CVCL_TZ46 HAP1 ZNF764 (-) 1 cancer cell line human CVCL_TZ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28200; ZNF764; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148120 CVCL_TZ43 HAP1 ZNF74 (-) 1 cancer cell line human CVCL_TZ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13144; ZNF74; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148121 CVCL_TZ44 HAP1 ZNF74 (-) 2 cancer cell line human CVCL_TZ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13144; ZNF74; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148122 CVCL_TZ49 HAP1 ZNF777 (-) 2 cancer cell line human CVCL_TZ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22213; ZNF777; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148123 CVCL_TZ47 HAP1 ZNF764 (-) 2 cancer cell line human CVCL_TZ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28200; ZNF764; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148124 CVCL_TZ48 HAP1 ZNF777 (-) 1 cancer cell line human CVCL_TZ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22213; ZNF777; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148125 CVCL_2511 HRA-19a1.1 Alpha2Alpha1 E cancer cell line human CVCL_2511 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6137; ITGA2 (chimeric extracellular and TM domain of ITGA2 and the cytoplasmic domain of ITGA1) Derived from sampling site: Rectum. Male 21148126 CVCL_1T11 JHPI-1 clone-16 undefined cell line type CVCL_1T11 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00037. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from hamster (PubMed=2903855; PubMed=20143388). Originally thought to originate from fetal pancreatic islets. 21148127 CVCL_2512 HRA-19a1.1 Alpha2 B cancer cell line human CVCL_2512 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6137; ITGA2 Derived from sampling site: Rectum. Discontinued: Ximbio; 152468; probable Male 21148128 CVCL_1T12 UPAM cancer cell line human CVCL_1T12 CL:0000010 Derived from sampling site: Brain. Unspecified 21148129 CVCL_1T10 H7D7BD5 cancer cell line human CVCL_1T10 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00560 Problematic cell line: Contaminated Parent cell line (H7D7B) has been shown to be a Hep-G2 derivative (PubMed=12619888). 21148130 CVCL_2510 HRA-19a1.1 Alpha2Alpha1 B cancer cell line human CVCL_2510 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6137; ITGA2 (chimeric extracellular and TM domain of ITGA2 and the cytoplasmic domain of ITGA1) Derived from sampling site: Rectum. Discontinued: Ximbio; 152467; probable Male 21148131 CVCL_1T15 222 cancer cell line human CVCL_1T15 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (PubMed=8557231) Derived from metastatic site: Ascites. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00454 Problematic cell line: Contaminated Shown to be a PA-1 derivative (PubMed=22710073). Originally thought to be an ovarian carcinoma. 21148132 CVCL_2515 HRT-18G cancer cell line human CVCL_2515 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line). Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11663 21148133 CVCL_1T16 222TR cancer cell line human CVCL_1T16 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (222) has been shown to be a PA-1 derivative. 21148134 CVCL_2516 HS-Sultan cancer cell line human CVCL_2516 HLA typing: A*03:01,74:01; B*53:01,58:01; C*04:01,04:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=6365856) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00214 Problematic cell line: Contaminated Shown to be a Jiyoye derivative (PubMed=10516762; PubMed=12592342; PubMed=20143388). Originally thought to originate from a plasma cell myeloma. 21148135 CVCL_2513 HRA-19a1.1 Alpha2 F cancer cell line human CVCL_2513 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg405Ter (c.1213C>T); ClinVar=VCV000127275; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.42_45delTCTT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6137; ITGA2 Derived from sampling site: Rectum. Discontinued: Ximbio; 152469; probable Male 21148136 CVCL_1T13 UPJM cancer cell line human CVCL_1T13 CL:0000010 Derived from sampling site: Brain. Male 21148137 CVCL_1T14 CaMa clone 15 hybrid cell line house mouse CVCL_1T14 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00034. Problematic cell line: Misidentified/contaminated Originally thought to be of human origin but found to be from both mouse and hamster (PubMed=6451928; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21148138 CVCL_2514 HRT-18 cancer cell line human CVCL_2514 Genome ancestry: African=0%; Native American=0.15%; East Asian, North=0.34%; East Asian, South=1.05%; South Asian=1.84%; European, North=63.7%; European, South=32.91% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=12068308; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis Male Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148139 CVCL_2519 HSP-250 transformed cell line CVCL_2519 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Female Characteristics: While not dependent on IL2 it will grow faster with addition of the cytokine in the growth medium (JCRB) Group: Non-human primate cell line 21148140 CVCL_1T19 T406 [Human HNSCC] cancer cell line human CVCL_1T19 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00426. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21148141 CVCL_2517 HSG cancer cell line human CVCL_2517 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Discontinued: JCRB; CHB0004; probable Female Doubling time: 29 hours (DOI=10.2330/joralbiosci1965.34.164) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00313 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388; PubMed=29923277; CelloPub=CLPUB00653). Originally thought to originate from a 54 year old male irradiated submandibular salivary gland. 21148142 CVCL_1T17 Tu 158LN cancer cell line human CVCL_1T17 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00429. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21148143 CVCL_2518 HSP-239 transformed cell line CVCL_2518 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Male Characteristics: While not dependent on IL2 it will grow faster with addition of the cytokine in the growth medium (JCRB) Group: Non-human primate cell line 21148144 CVCL_1T18 Tu 212LN cancer cell line human CVCL_1T18 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00434. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21148145 CVCL_TZ30 HAP1 ZMYND11 (-) 1 cancer cell line human CVCL_TZ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16966; ZMYND11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148146 CVCL_TZ31 HAP1 ZMYND11 (-) 2 cancer cell line human CVCL_TZ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16966; ZMYND11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148147 CVCL_LA99 PathHunter U2OS OPRL1 Total GPCR Internalization cancer cell line human CVCL_LA99 CL:0000010 Transfected with: HGNC; 8155; OPRL1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148148 CVCL_TZ34 HAP1 ZNF10 (-) cancer cell line human CVCL_TZ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12879; ZNF10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148149 CVCL_LA97 PathHunter U2OS OPRK1 beta-arrestin cancer cell line human CVCL_LA97 CL:0000010 Transfected with: HGNC; 8154; OPRK1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148150 CVCL_TZ35 HAP1 ZNF174 (-) 1 cancer cell line human CVCL_TZ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12963; ZNF174; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148151 CVCL_LA98 PathHunter U2OS OPRK1 Total GPCR Internalization cancer cell line human CVCL_LA98 CL:0000010 Transfected with: HGNC; 8154; OPRK1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148152 CVCL_TZ32 HAP1 ZMYND8 (-) 1 cancer cell line human CVCL_TZ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9397; ZMYND8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148153 CVCL_LA95 PathHunter U2OS OPRD1 beta-arrestin cancer cell line human CVCL_LA95 CL:0000010 Transfected with: HGNC; 8153; OPRD1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148154 CVCL_TZ33 HAP1 ZMYND8 (-) 2 cancer cell line human CVCL_TZ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9397; ZMYND8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148155 CVCL_LA96 PathHunter U2OS OPRD1 beta-arrestin-1 cancer cell line human CVCL_LA96 CL:0000010 Transfected with: HGNC; 8153; OPRD1; Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148156 CVCL_TZ38 HAP1 ZNF267 (-) 2 cancer cell line human CVCL_TZ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13060; ZNF267; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148157 CVCL_LA93 PathHunter U2OS NTSR1 Activated GPCR Internalization cancer cell line human CVCL_LA93 CL:0000010 Transfected with: HGNC; 8039; NTSR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148158 CVCL_TZ39 HAP1 ZNF367 (-) 1 cancer cell line human CVCL_TZ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18320; ZNF367; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148159 CVCL_LA94 PathHunter U2OS OPRD1 Activated GPCR Internalization cancer cell line human CVCL_LA94 CL:0000010 Transfected with: HGNC; 8153; OPRD1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148160 CVCL_TZ36 HAP1 ZNF174 (-) 2 cancer cell line human CVCL_TZ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12963; ZNF174; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148161 CVCL_LA91 PathHunter U2OS NPSR1 beta-arrestin cancer cell line human CVCL_LA91 CL:0000010 Transfected with: HGNC; 23631; NPSR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148162 CVCL_TZ37 HAP1 ZNF267 (-) 1 cancer cell line human CVCL_TZ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13060; ZNF267; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148163 CVCL_LA92 PathHunter U2OS NPY2R Activated GPCR Internalization cancer cell line human CVCL_LA92 CL:0000010 Transfected with: HGNC; 7957; NPY2R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148164 CVCL_LA90 PathHunter U2OS NMU1R Total GPCR Internalization cancer cell line human CVCL_LA90 CL:0000010 Transfected with: HGNC; 4518; NMUR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148165 CVCL_TZ20 HAP1 ZFYVE16 (-) 1 cancer cell line human CVCL_TZ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20756; ZFYVE16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148166 CVCL_TZ23 HAP1 ZMIZ2 (-) 2 cancer cell line human CVCL_TZ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22229; ZMIZ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148167 CVCL_TZ24 HAP1 ZMPSTE24 (-) 1 cancer cell line human CVCL_TZ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12877; ZMPSTE24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148168 CVCL_TZ21 HAP1 ZFYVE16 (-) 2 cancer cell line human CVCL_TZ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20756; ZFYVE16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148169 CVCL_TZ22 HAP1 ZMIZ2 (-) 1 cancer cell line human CVCL_TZ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22229; ZMIZ2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148170 CVCL_TZ27 HAP1 ZMYM3 (-) 2 cancer cell line human CVCL_TZ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13054; ZMYM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148171 CVCL_TZ28 HAP1 ZMYM3 (-) 3 cancer cell line human CVCL_TZ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13054; ZMYM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148172 CVCL_TZ25 HAP1 ZMPSTE24 (-) 2 cancer cell line human CVCL_TZ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12877; ZMPSTE24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148173 CVCL_TZ26 HAP1 ZMYM3 (-) 1 cancer cell line human CVCL_TZ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13054; ZMYM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148174 CVCL_TZ29 HAP1 ZMYM3 (-) 4 cancer cell line human CVCL_TZ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13054; ZMYM3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148175 CVCL_LA79 PathHunter U2OS mCXCR7 beta-arrestin cancer cell line human CVCL_LA79 CL:0000010 Transfected with: MGI; MGI:109562; Ackr3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148176 CVCL_LA77 PathHunter U2OS MCHR2 beta-arrestin cancer cell line human CVCL_LA77 CL:0000010 Transfected with: HGNC; 20867; MCHR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148177 CVCL_LA78 PathHunter U2OS mCXCR4 beta-arrestin cancer cell line human CVCL_LA78 CL:0000010 Transfected with: MGI; MGI:109563; Cxcr4; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148178 CVCL_TZ12 HAP1 ZEB2 (-) 1 cancer cell line human CVCL_TZ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148179 CVCL_LA75 PathHunter U2OS MCHR1 beta-arrestin-1 cancer cell line human CVCL_LA75 CL:0000010 Transfected with: HGNC; 4479; MCHR1; Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148180 CVCL_TZ13 HAP1 ZFP36 (-) 1 cancer cell line human CVCL_TZ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12862; ZFP36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148181 CVCL_LA76 PathHunter U2OS MCHR1 Total GPCR Internalization cancer cell line human CVCL_LA76 CL:0000010 Transfected with: HGNC; 4479; MCHR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148182 CVCL_TZ10 HAP1 ZDHHC9 (-) 2 cancer cell line human CVCL_TZ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18475; ZDHHC9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148183 CVCL_LA73 PathHunter U2OS mCCR2 beta-arrestin cancer cell line human CVCL_LA73 CL:0000010 Transfected with: MGI; MGI:106185; Ccr2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148184 CVCL_TZ11 HAP1 ZEB1 (-) 1 cancer cell line human CVCL_TZ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148185 CVCL_LA74 PathHunter U2OS MCHR1 beta-arrestin cancer cell line human CVCL_LA74 CL:0000010 Transfected with: HGNC; 4479; MCHR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148186 CVCL_TZ16 HAP1 ZFYVE1 (-) 2 cancer cell line human CVCL_TZ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13180; ZFYVE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148187 CVCL_LA71 PathHunter U2OS MC5R beta-arrestin cancer cell line human CVCL_LA71 CL:0000010 Transfected with: HGNC; 6933; MC5R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148188 CVCL_TZ17 HAP1 ZFYVE1 (-) 3 cancer cell line human CVCL_TZ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13180; ZFYVE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148189 CVCL_LA72 PathHunter U2OS mCCR1 beta-arrestin cancer cell line human CVCL_LA72 CL:0000010 Transfected with: MGI; MGI:104618; Ccr1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148190 CVCL_TZ14 HAP1 ZFP36 (-) 2 cancer cell line human CVCL_TZ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12862; ZFP36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148191 CVCL_TZ15 HAP1 ZFYVE1 (-) 1 cancer cell line human CVCL_TZ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13180; ZFYVE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148192 CVCL_LA70 PathHunter U2OS MC4R beta-arrestin cancer cell line human CVCL_LA70 CL:0000010 Transfected with: HGNC; 6932; MC4R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148193 CVCL_TZ18 HAP1 ZFYVE1 (-) 4 cancer cell line human CVCL_TZ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13180; ZFYVE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148194 CVCL_TZ19 HAP1 ZFYVE1 (-) 5 cancer cell line human CVCL_TZ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13180; ZFYVE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148195 CVCL_LA88 PathHunter U2OS NMBR Total GPCR Internalization cancer cell line human CVCL_LA88 CL:0000010 Transfected with: HGNC; 7843; NMBR Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148196 CVCL_LA89 PathHunter U2OS NMU1R beta-arrestin cancer cell line human CVCL_LA89 CL:0000010 Transfected with: HGNC; 4518; NMUR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148197 CVCL_TZ01 HAP1 ZDHHC5 (-) 2 cancer cell line human CVCL_TZ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18472; ZDHHC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148198 CVCL_LA86 PathHunter U2OS mP2RY12 beta-arrestin cancer cell line human CVCL_LA86 CL:0000010 Transfected with: MGI; MGI:1918089; P2ry12; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148199 CVCL_TZ02 HAP1 ZDHHC6 (-) 1 cancer cell line human CVCL_TZ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19160; ZDHHC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148200 CVCL_LA87 PathHunter U2OS MTNR1B Total GPCR Internalization cancer cell line human CVCL_LA87 CL:0000010 Transfected with: HGNC; 7464; MTNR1B Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148201 CVCL_LA84 PathHunter U2OS mNPY1R beta-arrestin cancer cell line human CVCL_LA84 CL:0000010 Transfected with: MGI; MGI:104963; Npy1r; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148202 CVCL_TZ00 HAP1 ZDHHC5 (-) 1 cancer cell line human CVCL_TZ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18472; ZDHHC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148203 CVCL_LA85 PathHunter U2OS mOPRM1 beta-arrestin cancer cell line human CVCL_LA85 CL:0000010 Transfected with: MGI; MGI:97441; Oprm1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148204 CVCL_TZ05 HAP1 ZDHHC7 (-) 2 cancer cell line human CVCL_TZ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18459; ZDHHC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148205 CVCL_LA82 PathHunter U2OS mHTR2C beta-arrestin cancer cell line human CVCL_LA82 CL:0000010 Transfected with: MGI; MGI:96281; Htr2c; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148206 CVCL_TZ06 HAP1 ZDHHC8 (-) 1 cancer cell line human CVCL_TZ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18474; ZDHHC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148207 CVCL_LA83 PathHunter U2OS MLNR Activated GPCR Internalization cancer cell line human CVCL_LA83 CL:0000010 Transfected with: HGNC; 4495; MLNR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148208 CVCL_TZ03 HAP1 ZDHHC6 (-) 2 cancer cell line human CVCL_TZ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19160; ZDHHC6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148209 CVCL_LA80 PathHunter U2OS mFFAR1 beta-arrestin cancer cell line human CVCL_LA80 CL:0000010 Transfected with: MGI; MGI:2684079; Ffar1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148210 CVCL_TZ04 HAP1 ZDHHC7 (-) 1 cancer cell line human CVCL_TZ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18459; ZDHHC7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148211 CVCL_LA81 PathHunter U2OS mGIPR beta-arrestin cancer cell line human CVCL_LA81 CL:0000010 Transfected with: MGI; MGI:1352753; Gipr; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148212 CVCL_TZ09 HAP1 ZDHHC9 (-) 1 cancer cell line human CVCL_TZ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18475; ZDHHC9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148213 CVCL_TZ07 HAP1 ZDHHC8 (-) 2 cancer cell line human CVCL_TZ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18474; ZDHHC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148214 CVCL_TZ08 HAP1 ZDHHC8 (-) 3 cancer cell line human CVCL_TZ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18474; ZDHHC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21148215 CVCL_LA59 PathHunter U2OS HTR2C(VGV) beta-arrestin cancer cell line human CVCL_LA59 CL:0000010 Transfected with: HGNC; 5295; HTR2C (with p.Ile156Val, p.Asn158Gly and p.Ile160Val); Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148216 CVCL_LA57 PathHunter U2OS HTR2C Activated GPCR Internalization cancer cell line human CVCL_LA57 CL:0000010 Transfected with: HGNC; 5295; HTR2C; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148217 CVCL_LA58 PathHunter U2OS HTR2C beta-arrestin cancer cell line human CVCL_LA58 CL:0000010 Transfected with: HGNC; 5295; HTR2C; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148218 CVCL_LA55 PathHunter U2OS HTR2A beta-arrestin cancer cell line human CVCL_LA55 CL:0000010 Transfected with: HGNC; 5293; HTR2A; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148219 CVCL_LA56 PathHunter U2OS HTR2A Total GPCR Internalization cancer cell line human CVCL_LA56 CL:0000010 Transfected with: HGNC; 5293; HTR2A Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148220 CVCL_LA53 PathHunter U2OS HTR1E beta-arrestin cancer cell line human CVCL_LA53 CL:0000010 Transfected with: HGNC; 5291; HTR1E; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148221 CVCL_LA54 PathHunter U2OS HTR1F beta-arrestin cancer cell line human CVCL_LA54 CL:0000010 Transfected with: HGNC; 5292; HTR1F; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148222 CVCL_LA51 PathHunter U2OS HRH4 beta-arrestin cancer cell line human CVCL_LA51 CL:0000010 Transfected with: HGNC; 17383; HRH4; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148223 CVCL_LA52 PathHunter U2OS HTR1B beta-arrestin cancer cell line human CVCL_LA52 CL:0000010 Transfected with: HGNC; 5287; HTR1B; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148224 CVCL_LA50 PathHunter U2OS HCRTR2 Total GPCR Internalization cancer cell line human CVCL_LA50 CL:0000010 Transfected with: HGNC; 4849; HCRTR2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148225 CVCL_LA68 PathHunter U2OS MC3R beta-arrestin cancer cell line human CVCL_LA68 CL:0000010 Transfected with: HGNC; 6931; MC3R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148226 CVCL_LA69 PathHunter U2OS MC3R Total GPCR Internalization cancer cell line human CVCL_LA69 CL:0000010 Transfected with: HGNC; 6931; MC3R Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148227 CVCL_LA66 PathHunter U2OS LTB4R Total GPCR Internalization cancer cell line human CVCL_LA66 CL:0000010 Transfected with: HGNC; 6713; LTB4R Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148228 CVCL_LA67 PathHunter U2OS MC1R beta-arrestin cancer cell line human CVCL_LA67 CL:0000010 Transfected with: HGNC; 6929; MC1R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148229 CVCL_LA64 PathHunter U2OS Keap1-NRF2 Nuclear Translocation cancer cell line human CVCL_LA64 CL:0000010 Transfected with: HGNC; 23177; KEAP1; Transfected with: HGNC; 7782; NFE2L2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148230 CVCL_LA65 PathHunter U2OS KISS1R beta-arrestin cancer cell line human CVCL_LA65 CL:0000010 Transfected with: HGNC; 4510; KISS1R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148231 CVCL_LA62 PathHunter U2OS HTR5A beta-arrestin cancer cell line human CVCL_LA62 CL:0000010 Transfected with: HGNC; 5300; HTR5A; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148232 CVCL_LA63 PathHunter U2OS IkappaB Degradation cancer cell line human CVCL_LA63 CL:0000010 Transfected with: HGNC; 7797; NFKBIA Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter degradation cell lines express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) Pathway activation results in the degradation of the target protein. The degraded protein is detected by adding to the cell lysis buffer another beta-galactosidase fragment (Enzyme Acceptor=EA). Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148233 CVCL_LA60 PathHunter U2OS HTR2C(VNV) beta-arrestin cancer cell line human CVCL_LA60 CL:0000010 Transfected with: HGNC; 5295; HTR2C (with p.Ile156Val and p.Ile160Val); Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148234 CVCL_LA61 PathHunter U2OS HTR2C(VSV) beta-arrestin cancer cell line human CVCL_LA61 CL:0000010 Transfected with: HGNC; 5295; HTR2C (with p.Ile156Val, p.Asn158Ser and p.Ile160Val); Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148235 CVCL_1U90 HROC278Met T2 M2 cancer cell line human CVCL_1U90 HLA typing: A*03:01,25:01; B*07:02,18:01; C*07:02,12:03; DQB1*03:02,03:02; DRB1*04:01,04:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Miscellaneous: STR profile from personal communication of Linnebacher M Population: Caucasian; Derived from metastatic site: Peritoneum. Female Characteristics: Established from a patient-derived xenograft established in mice Microsatellite instability: Instable (MSI-low) (Direct_author_submission) 21148236 CVCL_2690 PEO4 cancer cell line human CVCL_2690 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DRB1*11:01,04:05 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg160Trp (c.478A>T); ClinVar=VCV000412204; Zygosity=Homozygous (CelloPub=CLPUB00667; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Homozygous (CelloPub=CLPUB00667; PubMed=25230021; PubMed=28273451; DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 59 hours (PubMed=3583449); 36 hours (PubMed=3167863); 75.67 hours (CelloPub=CLPUB00667) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel 21148237 CVCL_1U91 HROC284Met cancer cell line human CVCL_1U91 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Female Doubling time: 29 hours (CLS); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148238 CVCL_2691 PEO6 cancer cell line human CVCL_2691 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Tyr (c.4965C>T) (5193C>T); ClinVar=VCV001657967; Zygosity=Hemizygous; Note=De novo mutation that cancels the c.4965C>G (5193C>G) mutation in the patient (PubMed=19654294); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (PubMed=28273451) Derived from metastatic site: Ascites. Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 77 hours (PubMed=3167863) 21148239 CVCL_1U83 HROC112Met T0 M2 cancer cell line human CVCL_1U83 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from metastatic site: Liver. Discontinued: CLS; 300846; true Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148240 CVCL_2683 PEA2 cancer cell line human CVCL_2683 CL:0000010 Sequence variation: Mutation; HGNC; 952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=25230021) Derived from metastatic site: Ascites. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 66 hours (PubMed=3167863) Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21148241 CVCL_1U84 HROC212 cancer cell line human CVCL_1U84 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cecum. Female Doubling time: 29 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21148242 CVCL_2684 PEA-10 spontaneously immortalized cell line house mouse CVCL_2684 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:96828; Lrp1 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x 129. Unspecified 21148243 CVCL_1U81 HROC39 cancer cell line human CVCL_1U81 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21148244 CVCL_2681 PE/CA-PJ49 cancer cell line human CVCL_2681 HLA typing: A*32:01,32:01; B*40:02,40:02; C*02:02,02:02; DQA1*01:02;05:02; DQB1*06:03;06:03; DRB1*03:17;13:01 (PubMed=26589293); Genome ancestry: African=2.94%; Native American=0%; East Asian, North=4.31%; East Asian, South=0%; South Asian=0%; European, North=59.12%; European, South=33.63% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel 21148245 CVCL_1U82 HROC39 T0 M2 cancer cell line human CVCL_1U82 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in female NOD SCID mice 21148246 CVCL_2682 PEA1 cancer cell line human CVCL_2682 CL:0000010 Sequence variation: Mutation; HGNC; 952; BARD1; Simple; p.Trp218Ter (c.653G>A); ClinVar=VCV000482781; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Unspecified (PubMed=25230021; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37 hours (PubMed=3167863) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel 21148247 CVCL_1U87 HROC277Met1 T0 M2 cancer cell line human CVCL_1U87 HLA typing: A*02:01,32:01; B*15:17,35:03; C*0:401,07:01; DQB1*03:01,06:04; DRB1*11:01,13:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Characteristics: Established from a patient-derived xenograft established in female NSG mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148248 CVCL_2687 PEO14 cancer cell line human CVCL_2687 HLA typing: A*11:01,11:01; B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01; DRB1*01:03,01:03 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451) Derived from metastatic site: Ascites. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 108 hours (PubMed=3167863) Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21148249 CVCL_1U88 HROC277Met2 cancer cell line human CVCL_1U88 HLA typing: A*02:01,32:01; B*15:17,35:03; C*0:401,07:01; DQB1*03:01,06:04; DRB1*11:01,13:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Doubling time: 29 hours (CLS); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148250 CVCL_2688 PEO16 cancer cell line human CVCL_2688 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 40 hours (PubMed=3167863); ~120 hours (ECACC=10032312) Part of: OCCP ovarian cancer cell line panel 21148251 CVCL_1U85 HROC212 T0 M1 cancer cell line human CVCL_1U85 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cecum. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice 21148252 CVCL_2685 PEA-13 spontaneously immortalized cell line house mouse CVCL_2685 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96828; Lrp1 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x 129. Unspecified 21148253 CVCL_1U86 HROC277 T0 M1 cancer cell line human CVCL_1U86 HLA typing: A*02:01,32:01; B*15:17,35:03; C*0:401,07:01; DQB1*03:01,06:04; DRB1*11:01,13:02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Miscellaneous: STR profile from personal communication of Linnebacher M Population: Caucasian; Derived from sampling site: Cecum. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148254 CVCL_2686 PEO1 cancer cell line human CVCL_2686 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DQB1*03:04,03:04 (PubMed=25960936); HLA typing: A*03:01,03:01; B*07:02,37:04; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.14%; East Asian, North=0.57%; East Asian, South=0%; South Asian=0%; European, North=70.43%; European, South=28.85% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Ter (c.4965C>G) (5193C>G); ClinVar=VCV000037936; Zygosity=Hemizygous (PubMed=19654294; PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (CelloPub=CLPUB00667; PubMed=25230021) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 53 hours (PubMed=3583449); 37 hours (PubMed=3167863); 44.92 hours (CelloPub=CLPUB00667); 37.48 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21148255 CVCL_1U89 HROC278 T0 M1 cancer cell line human CVCL_1U89 HLA typing: A*03:01,25:01; B*07:02,18:01; C*07:02,12:03; DQB1*03:02,03:02; DRB1*04:01,04:01 (Direct_author_submission); HLA typing: A*03:01:01,01:01:01; B*07:02:01,18:01:01; C*07:02:01,12:03:01; DPB1*02:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:01:01 (CLS=300835) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 43 hours (CLS); Microsatellite instability: Instable (MSI-low) (Direct_author_submission) 21148256 CVCL_2689 PEO23 cancer cell line human CVCL_2689 HLA typing: A*11:01,11:01; B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451) Derived from metastatic site: Ascites. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: 120 hours (PubMed=3167863) Part of: OCCP ovarian cancer cell line panel 21148257 CVCL_1U94 HHC6548 T1 M1 cancer cell line human CVCL_1U94 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 26 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21148258 CVCL_2694 PKS spontaneously immortalized cell line pig CVCL_2694 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by vaccinia virus (JCRB) 21148259 CVCL_1U95 HROC309 cancer cell line human CVCL_1U95 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; descending. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148260 CVCL_2695 Porthos spontaneously immortalized cell line pig CVCL_2695 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21148261 CVCL_1U92 HROC285 T0 M2 cancer cell line human CVCL_1U92 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; descending. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 29 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21148262 CVCL_2692 PKF spontaneously immortalized cell line pig CVCL_2692 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by vaccinia virus (JCRB) 21148263 CVCL_1U93 HROC239 T0 M1 cancer cell line human CVCL_1U93 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Rectum. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Doubling time: 29 hours (CLS) 21148264 CVCL_2693 PKR spontaneously immortalized cell line pig CVCL_2693 CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Susceptible to infection by vaccinia virus (JCRB) 21148265 CVCL_1U98 HROC313Met cancer cell line human CVCL_1U98 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21148266 CVCL_2698 Ra-1 transformed cell line CVCL_2698 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood; Breed/subspecies: Japanese white. Male Virology: HTLV-1 producing cell line 21148267 CVCL_1U99 HROC348Met cancer cell line human CVCL_1U99 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male 21148268 CVCL_2699 RAJI 'A' cancer cell line human CVCL_2699 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21148269 CVCL_1U96 HROC257 cancer cell line human CVCL_1U96 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Doubling time: 29 hours (CLS); Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21148270 CVCL_2696 PU5-1.8 cancer cell line house mouse CVCL_2696 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21148271 CVCL_1U97 HROC257 T0 M1 cancer cell line human CVCL_1U97 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice 21148272 CVCL_2697 PUTKO hybrid cell line human CVCL_2697 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21148273 CVCL_1U61 GM22319 transformed cell line human CVCL_1U61 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148274 CVCL_2661 OE21 cancer cell line human CVCL_2661 HLA typing: A*02:01,02:01; B*51:01,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.35%; East Asian, South=0.2%; South Asian=0%; European, North=64.63%; European, South=33.81% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: TCGA-110-CL cell line panel 21148275 CVCL_1U62 GM22320 transformed cell line human CVCL_1U62 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148276 CVCL_2662 OKT 1 hybridoma house mouse CVCL_2662 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06127; Human CD5. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8000 21148277 CVCL_1U60 GM22318 transformed cell line human CVCL_1U60 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148278 CVCL_2660 N-thy-ts.1 conditionally immortalized cell line human CVCL_2660 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Thyroid gland Cell type=Follicular cell.. Unspecified Characteristics: Grows at the permissive temperature (33 Celsius), but not at the restrictive temperature (40.5 Celsius) Doubling time: ~2 days, in 10% FCS (PubMed=1697930) 21148279 CVCL_1U65 GM22323 transformed cell line human CVCL_1U65 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148280 CVCL_2665 OKT 3 hybridoma house mouse CVCL_2665 CL:0000010 Anecdotal: OKT3 was the first monoclonal antibody to be approved for clinical use in humans. Biotechnology: The monoclonal antibody produced by this hybridoma was used as an immunosuppressant drug under the name Muromonab-CD3 (Orthoclone OKT3); Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized teplizumab (MGA031) therapeutic antibody Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P07766; Human CD3E Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8001 21148281 CVCL_1U66 GM22324 transformed cell line human CVCL_1U66 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148282 CVCL_2666 OKT 4 hybridoma house mouse CVCL_2666 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8002 21148283 CVCL_1U63 GM22321 transformed cell line human CVCL_1U63 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148284 CVCL_2663 OKT 10 hybridoma house mouse CVCL_2663 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28907; Human CD38. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8022 21148285 CVCL_1U64 GM22322 transformed cell line human CVCL_1U64 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148286 CVCL_2664 OKT 11 hybridoma house mouse CVCL_2664 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8027 21148287 CVCL_1U69 GM22327 transformed cell line human CVCL_1U69 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148288 CVCL_2669 OKT 8 hybridoma house mouse CVCL_2669 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01732; Human CD8A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8014 21148289 CVCL_1U67 GM22325 transformed cell line human CVCL_1U67 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148290 CVCL_2667 OKT 5 hybridoma house mouse CVCL_2667 CL:0000010 Monoclonal antibody isotype: IgG1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8013; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8016 Caution: mAb isotype is wrongly indicated as IgG2 in ECACC 88070705. 21148291 CVCL_1U68 GM22326 transformed cell line human CVCL_1U68 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148292 CVCL_2668 OKT 6 hybridoma house mouse CVCL_2668 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06126; Human CD1A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8020 21148293 CVCL_1U80 HROC24 T1 M1 cancer cell line human CVCL_1U80 HLA typing: A*02:01,30:02; B*18:01,38:01; C*05:01,12:03; DQB1*02:01,06:01; DRB1*03:01,13:01 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Male Characteristics: Established from a patient-derived xenograft established in female NOD SCID mice Doubling time: 20 hours (CLS) 21148294 CVCL_2680 PE/CA-PJ41 (clone D2) cancer cell line human CVCL_2680 Genome ancestry: African=2.91%; Native American=0%; East Asian, North=3.3%; East Asian, South=0%; South Asian=0%; European, North=62.2%; European, South=31.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920-2A>T (IVS8-2A>T); Zygosity=Homozygous; Note=Splice acceptor mutation (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel 21148295 CVCL_1U72 GM22330 transformed cell line human CVCL_1U72 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148296 CVCL_2672 OV17R cancer cell line human CVCL_2672 Genome ancestry: African=2.39%; Native American=0%; East Asian, North=1.99%; East Asian, South=0%; South Asian=0%; European, North=60.17%; European, South=35.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451; DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OCCP ovarian cancer cell line panel 21148297 CVCL_1U73 GM22332 transformed cell line human CVCL_1U73 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148298 CVCL_2673 OV56 cancer cell line human CVCL_2673 HLA typing: A*02:01,02:01; B*27:05,44:02; C*01:02,05:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.52%; South Asian=2.39%; European, North=69.8%; European, South=27.28% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asp2178Glyfs*47 (c.6527_6528insG); Zygosity=Heterozygous (PubMed=25230021; Cosmic-CLP); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=25230021; PubMed=28273451; Cosmic-CLP); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gly (c.388C>G); ClinVar=VCV000375958; Zygosity=Homozygous (PubMed=28273451; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys101_Thr102fs (c.303_304delAA); Zygosity=Heterozygous (PubMed=25230021; PubMed=28273451; Cosmic-CLP) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OCCP ovarian cancer cell line panel 21148299 CVCL_1U70 GM22328 transformed cell line human CVCL_1U70 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148300 CVCL_2670 OKT 9 hybridoma house mouse CVCL_2670 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8021 21148301 CVCL_1U71 GM22329 transformed cell line human CVCL_1U71 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148302 CVCL_2671 ONE58 cancer cell line human CVCL_2671 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Secretome proteome analysis; Omics: SNP array analysis Male 21148303 CVCL_1U76 GM22335 transformed cell line human CVCL_1U76 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148304 CVCL_2676 P3HR-1 cancer cell line human CVCL_2676 HLA typing: A*03:01,03:01; B*58:01,58:01; C*04:01,04:01 (PubMed=26589293); HLA typing: A*03:01:01,74:01:01; B*53:01:01,58:01:01; C*04:01:01; DPB1*01:01:01,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:19:01,06:02:01; DRB1*11:02:01,15:03:01 (CLS=302310); Genome ancestry: African=97.8%; Native American=0%; East Asian, North=0.68%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=1.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro72Ser (c.214C>T); ClinVar=VCV000012574; Zygosity=Unspecified (PubMed=8108117); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (PubMed=2052620; PubMed=8344493; PubMed=8402660) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 17 hours (PubMed=8402660) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: MYC genetic alteration cell panel (ATCC TCP-1035) 21148305 CVCL_1U77 GM22336 transformed cell line human CVCL_1U77 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148306 CVCL_2677 P4E6 transformed cell line human CVCL_2677 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148307 CVCL_1U74 GM22333 transformed cell line human CVCL_1U74 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148308 CVCL_2674 OV58 cancer cell line human CVCL_2674 CL:0000010 Derived from metastatic site: Ascites. Discontinued: ECACC; 96020760; probable Female 21148309 CVCL_1U75 GM22334 transformed cell line human CVCL_1U75 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148310 CVCL_2675 OV7 cancer cell line human CVCL_2675 HLA typing: A*01:01,02:01; B*35:01,38:01; C*04:01,12:03 (PubMed=26589293); Genome ancestry: African=1.94%; Native American=0%; East Asian, North=1.71%; East Asian, South=0%; South Asian=1.49%; European, North=63.24%; European, South=31.62% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=25230021; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu512Cysfs*10 (c.1534_1535delTT) (1533_1534del); Zygosity=Heterozygous (PubMed=25230021; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Ser (c.761T>G); ClinVar=VCV000659457; Zygosity=Homozygous (PubMed=25230021; Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 110 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OCCP ovarian cancer cell line panel 21148311 CVCL_1U78 GM22337 transformed cell line human CVCL_1U78 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148312 CVCL_2678 PE/CA-PJ15 cancer cell line human CVCL_2678 HLA typing: A*03:01,25:01; B*18:01,44:03; C*12:03,12:03 (PubMed=26589293); Genome ancestry: African=1.75%; Native American=0%; East Asian, North=3.5%; East Asian, South=0%; South Asian=0%; European, North=59.74%; European, South=35% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel 21148313 CVCL_1U79 GM22338 transformed cell line human CVCL_1U79 CL:0000010 Population: Jewish; Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148314 CVCL_2679 PE/CA-PJ34 (clone C12) cancer cell line human CVCL_2679 Genome ancestry: African=3.76%; Native American=0%; East Asian, North=3.52%; East Asian, South=0%; South Asian=0%; European, North=53.71%; European, South=39.01% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project 21148315 CVCL_1U40 DT40-RASGRP3(-/-) cancer cell line CVCL_1U40 CL:0000010 Knockout cell: Method=Targeted integration; RASGRP3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148316 CVCL_2640 NCI-BL1450 transformed cell line human CVCL_2640 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148317 CVCL_1U43 GM22301 transformed cell line human CVCL_1U43 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148318 CVCL_2643 NCI-BL1672 transformed cell line human CVCL_2643 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148319 CVCL_1U44 GM22302 transformed cell line human CVCL_1U44 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148320 CVCL_2644 NCI-BL1770 transformed cell line human CVCL_2644 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148321 CVCL_1U41 GM22299 transformed cell line human CVCL_1U41 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148322 CVCL_2641 NCI-BL1514 transformed cell line human CVCL_2641 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148323 CVCL_1U42 GM22300 transformed cell line human CVCL_1U42 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148324 CVCL_2642 NCI-BL1607 transformed cell line human CVCL_2642 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148325 CVCL_1U47 GM22305 transformed cell line human CVCL_1U47 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148326 CVCL_2647 NCI-BL2052 transformed cell line human CVCL_2647 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148327 CVCL_1U48 GM22306 transformed cell line human CVCL_1U48 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148328 CVCL_2648 NCI-BL2087 transformed cell line human CVCL_2648 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (PBCF) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148329 CVCL_1U45 GM22303 transformed cell line human CVCL_1U45 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148330 CVCL_2645 NCI-BL2009 transformed cell line human CVCL_2645 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148331 CVCL_1U46 GM22304 transformed cell line human CVCL_1U46 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148332 CVCL_2646 NCI-BL2028 transformed cell line human CVCL_2646 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148333 CVCL_1U49 GM22307 transformed cell line human CVCL_1U49 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148334 CVCL_2649 NCI-BL209 transformed cell line human CVCL_2649 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148335 CVCL_1U50 GM22308 transformed cell line human CVCL_1U50 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148336 CVCL_2650 NCI-BL2107 transformed cell line human CVCL_2650 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148337 CVCL_1U51 GM22309 transformed cell line human CVCL_1U51 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148338 CVCL_2651 NCI-BL2122 transformed cell line human CVCL_2651 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148339 CVCL_1U54 GM22312 transformed cell line human CVCL_1U54 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148340 CVCL_2654 NCI-BL2171 transformed cell line human CVCL_2654 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148341 CVCL_1U55 GM22313 transformed cell line human CVCL_1U55 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148342 CVCL_2655 NCI-BL2195 transformed cell line human CVCL_2655 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148343 CVCL_1U52 GM22310 transformed cell line human CVCL_1U52 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148344 CVCL_2652 NCI-BL2126 transformed cell line human CVCL_2652 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~66 hours (PBCF) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148345 CVCL_1U53 GM22311 transformed cell line human CVCL_1U53 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148346 CVCL_2653 NCI-BL2141 transformed cell line human CVCL_2653 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148347 CVCL_1U58 GM22316 transformed cell line human CVCL_1U58 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148348 CVCL_2658 NO36 cancer cell line human CVCL_2658 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Phe118Leufs*69 (c.354delC); Zygosity=Heterozygous (PubMed=21642991) Derived from sampling site: Pleural effusion. Male 21148349 CVCL_1U59 GM22317 transformed cell line human CVCL_1U59 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148350 CVCL_2659 Nthy-ori 3-1 transformed cell line human CVCL_2659 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Thyroid gland Cell type=Follicular cell.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21148351 CVCL_1U56 GM22314 transformed cell line human CVCL_1U56 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148352 CVCL_2656 NCI-BL2347 transformed cell line human CVCL_2656 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148353 CVCL_1U57 GM22315 transformed cell line human CVCL_1U57 CL:0000010 Population: Jewish; Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148354 CVCL_2657 NH17 cancer cell line human CVCL_2657 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21148355 CVCL_CI56 ND06796 transformed cell line human CVCL_CI56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148356 CVCL_CI57 ND06802 transformed cell line human CVCL_CI57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148357 CVCL_CI54 ND06773 transformed cell line human CVCL_CI54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148358 CVCL_CI55 ND06785 transformed cell line human CVCL_CI55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148359 CVCL_CI58 ND06804 transformed cell line human CVCL_CI58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148360 CVCL_CI59 ND06806 transformed cell line human CVCL_CI59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148361 CVCL_CI52 ND06771 transformed cell line human CVCL_CI52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148362 CVCL_CI53 ND06772 transformed cell line human CVCL_CI53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148363 CVCL_CI50 ND06740 transformed cell line human CVCL_CI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148364 CVCL_CI51 ND06764 transformed cell line human CVCL_CI51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148365 CVCL_LC04 11BD-2E11-2 hybridoma house mouse CVCL_LC04 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5643 21148366 CVCL_LC05 1A245.6 hybridoma house mouse CVCL_LC05 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4889 21148367 CVCL_LC02 PA1-3F10 hybridoma house mouse CVCL_LC02 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 1322CB 21148368 CVCL_LC03 GQPC2.27 hybridoma CVCL_LC03 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse cytoskeleton 51 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 93113040 21148369 CVCL_LC00 AR58A314.1 hybridoma house mouse CVCL_LC00 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human metastatic colon cancer cells. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 141205-02 21148370 CVCL_LC01 CHO-K1 h-GABA-b R1a/R2 spontaneously immortalized cell line CVCL_LC01 CL:0000010 Transfected with: HGNC; 4070; GABBR1 (isoform 1A); Transfected with: HGNC; 4507; GABBR2 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 6046CB 21148371 CVCL_CI67 ND06853 transformed cell line human CVCL_CI67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148372 CVCL_CI68 ND06854 transformed cell line human CVCL_CI68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148373 CVCL_CI65 ND06850 transformed cell line human CVCL_CI65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148374 CVCL_CI66 ND06852 transformed cell line human CVCL_CI66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148375 CVCL_CI69 ND06856 transformed cell line human CVCL_CI69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148376 CVCL_CI60 ND06811 transformed cell line human CVCL_CI60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148377 CVCL_CI63 ND06827 transformed cell line human CVCL_CI63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148378 CVCL_CI64 ND06844 transformed cell line human CVCL_CI64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148379 CVCL_CI61 ND06812 transformed cell line human CVCL_CI61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148380 CVCL_CI62 ND06813 transformed cell line human CVCL_CI62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148381 CVCL_CI34 ND06644 transformed cell line human CVCL_CI34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148382 CVCL_CI35 ND06646 transformed cell line human CVCL_CI35 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148383 CVCL_CI32 ND06642 transformed cell line human CVCL_CI32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148384 CVCL_CI33 ND06643 transformed cell line human CVCL_CI33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148385 CVCL_CI38 ND06710 transformed cell line human CVCL_CI38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148386 CVCL_CI39 ND06711 transformed cell line human CVCL_CI39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148387 CVCL_CI36 ND06670 transformed cell line human CVCL_CI36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148388 CVCL_CI37 ND06679 transformed cell line human CVCL_CI37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148389 CVCL_CI30 ND06639 transformed cell line human CVCL_CI30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148390 CVCL_CI31 ND06640 transformed cell line human CVCL_CI31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148391 CVCL_CI45 ND06729 transformed cell line human CVCL_CI45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148392 CVCL_CI46 ND06730 transformed cell line human CVCL_CI46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148393 CVCL_CI43 ND06727 transformed cell line human CVCL_CI43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148394 CVCL_CI44 ND06728 transformed cell line human CVCL_CI44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148395 CVCL_CI49 ND06733 transformed cell line human CVCL_CI49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148396 CVCL_CI47 ND06731 transformed cell line human CVCL_CI47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148397 CVCL_CI48 ND06732 transformed cell line human CVCL_CI48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148398 CVCL_CI41 ND06713 transformed cell line human CVCL_CI41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148399 CVCL_CI42 ND06726 transformed cell line human CVCL_CI42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148400 CVCL_CI40 ND06712 transformed cell line human CVCL_CI40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148401 CVCL_CI18 ND06589 transformed cell line human CVCL_CI18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148402 CVCL_CI19 ND06590 transformed cell line human CVCL_CI19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148403 CVCL_CI12 ND06550 transformed cell line human CVCL_CI12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148404 CVCL_CI13 ND06560 transformed cell line human CVCL_CI13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148405 CVCL_CI10 ND06538 transformed cell line human CVCL_CI10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148406 CVCL_CI11 ND06549 transformed cell line human CVCL_CI11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148407 CVCL_CI16 ND06587 transformed cell line human CVCL_CI16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148408 CVCL_CI17 ND06588 transformed cell line human CVCL_CI17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148409 CVCL_CI14 ND06568 transformed cell line human CVCL_CI14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148410 CVCL_CI15 ND06572 transformed cell line human CVCL_CI15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148411 CVCL_CI29 ND06637 transformed cell line human CVCL_CI29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148412 CVCL_CI23 ND06617 transformed cell line human CVCL_CI23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148413 CVCL_CI24 ND06618 transformed cell line human CVCL_CI24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148414 CVCL_CI21 ND06615 transformed cell line human CVCL_CI21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148415 CVCL_CI22 ND06616 transformed cell line human CVCL_CI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148416 CVCL_CI27 ND06635 transformed cell line human CVCL_CI27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148417 CVCL_CI28 ND06636 transformed cell line human CVCL_CI28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148418 CVCL_CI25 ND06619 transformed cell line human CVCL_CI25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148419 CVCL_CI26 ND06634 transformed cell line human CVCL_CI26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148420 CVCL_CI20 ND06596 transformed cell line human CVCL_CI20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148421 CVCL_CI09 ND06514 transformed cell line human CVCL_CI09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148422 CVCL_CI07 ND06503 transformed cell line human CVCL_CI07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148423 CVCL_CI08 ND06512 transformed cell line human CVCL_CI08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148424 CVCL_CI01 ND06476 transformed cell line human CVCL_CI01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148425 CVCL_CI02 ND06477 transformed cell line human CVCL_CI02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148426 CVCL_CI00 ND06474 transformed cell line human CVCL_CI00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148427 CVCL_CI05 ND06491 transformed cell line human CVCL_CI05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148428 CVCL_CI06 ND06502 transformed cell line human CVCL_CI06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148429 CVCL_CI03 ND06487 transformed cell line human CVCL_CI03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148430 CVCL_CI04 ND06488 transformed cell line human CVCL_CI04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148431 CVCL_LB58 GeneBLAzer NPSR1-B-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_LB58 CL:0000010 Transfected with: HGNC; 23631; NPSR1 (isoform B); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21148432 CVCL_LB59 GloResponse 9XGAL4UAS-luc2P HEK293 transformed cell line human CVCL_LB59 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The luciferase reporter gene is under the control of nine repeats of GAL4 Upstream Activator Sequence (UAS) The luciferase is expressed in response to binding of a fusion protein containing the Gal4 DNA Binding Domain when activated by a ligand. 21148433 CVCL_LB56 GeneBLAzer AVPR1a-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_LB56 CL:0000010 Transfected with: HGNC; 895; AVPR1A; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21148434 CVCL_LB57 GeneBLAzer HCRTR1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_LB57 CL:0000010 Transfected with: HGNC; 4848; HCRTR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21148435 CVCL_LB54 MCF-7 MX100 cancer cell line human CVCL_LB54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21148436 CVCL_LB55 WHIRC01 cancer cell line human CVCL_LB55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gly (c.742C>G); ClinVar=VCV000376652; Zygosity=Unspecified (PubMed=28251557) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Characteristics: Derived from a patient-derived mouse xenograft Doubling time: ~30 hours (PubMed=28251557) 21148437 CVCL_LB52 MCF-7 MX40 cancer cell line human CVCL_LB52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21148438 CVCL_LB53 MCF-7 MX80 cancer cell line human CVCL_LB53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21148439 CVCL_LB50 MCF-7 MX8 cancer cell line human CVCL_LB50 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21148440 CVCL_LB51 MCF-7 MX20 cancer cell line human CVCL_LB51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21148441 CVCL_LB69 BXP-21 hybridoma house mouse CVCL_LB69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9UNQ0; Human ABCG2/CD338. 21148442 CVCL_LB67 NCI-H460 MX10 cancer cell line human CVCL_LB67 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Male 21148443 CVCL_LB68 SF295 MX10 cancer cell line human CVCL_LB68 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Brain; left temporal lobe. Female 21148444 CVCL_LB65 A549 MX10 cancer cell line human CVCL_LB65 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Lung. Male 21148445 CVCL_LB66 KM12 MX10 cancer cell line human CVCL_LB66 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone Unspecified 21148446 CVCL_LB63 GloResponse NFAT-RE-luc2 Jurkat cancer cell line human CVCL_LB63 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: Promega; Catalog number CS176403 Male Characteristics: The luciferase reporter gene is under the control of a minimal TATA promoter with multiple copies of the NFAT response element 21148447 CVCL_LB64 425 hybridoma house mouse CVCL_LB64 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized matuzumab (EMD 72000) therapeutic antibody It was developed by Merck Serono for the treatment of a number of cancer types. It failed phase II clinical trials. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9629 21148448 CVCL_LB61 GloResponse NF-kappaB-RE-luc2P HEK293 transformed cell line human CVCL_LB61 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The luciferase reporter gene is under the control of a minimal TATA promoter with multiple copies of the NF-kappaB response element 21148449 CVCL_LB62 GloResponse NFAT-RE-luc2P HEK293 transformed cell line human CVCL_LB62 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The luciferase reporter gene is under the control of a minimal TATA promoter with multiple copies of the NFAT response element 21148450 CVCL_LB60 GloResponse CRE-luc2P HEK293 transformed cell line human CVCL_LB60 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The luciferase reporter gene is under the control of a minimal Herpes Simplex Virus thymidine kinase promoter with multiple cAMP response elements (CREs) 21148451 CVCL_LB38 PathHunter U2OS TBXA2R Activated GPCR Internalization cancer cell line human CVCL_LB38 CL:0000010 Transfected with: HGNC; 11608; TBXA2R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148452 CVCL_LB39 PathHunter U2OS TBXA2R beta-arrestin cancer cell line human CVCL_LB39 CL:0000010 Transfected with: HGNC; 11608; TBXA2R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148453 CVCL_LB36 PathHunter U2OS TACR2 Activated GPCR Internalization cancer cell line human CVCL_LB36 CL:0000010 Transfected with: HGNC; 11527; TACR2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148454 CVCL_LB37 PathHunter U2OS TACR3 Activated GPCR Internalization cancer cell line human CVCL_LB37 CL:0000010 Transfected with: HGNC; 11528; TACR3; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148455 CVCL_LB34 PathHunter U2OS SSTR5 beta-arrestin cancer cell line human CVCL_LB34 CL:0000010 Transfected with: HGNC; 11334; SSTR5; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148456 CVCL_LB35 PathHunter U2OS TACR1 Activated GPCR Internalization cancer cell line human CVCL_LB35 CL:0000010 Transfected with: HGNC; 11526; TACR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148457 CVCL_LB32 PathHunter U2OS SREBP2 Nuclear Translocation cancer cell line human CVCL_LB32 CL:0000010 Transfected with: HGNC; 11290; SREBF2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148458 CVCL_LB33 PathHunter U2OS SSTR1 beta-arrestin cancer cell line human CVCL_LB33 CL:0000010 Transfected with: HGNC; 11330; SSTR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148459 CVCL_LB30 PathHunter U2OS RXRalpha Protein Interaction cancer cell line human CVCL_LB30 CL:0000010 Transfected with: HGNC; 10477; RXRA; Transfected with: HGNC; 7669; NCOA2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148460 CVCL_LB31 PathHunter U2OS SCTR Activated GPCR Internalization cancer cell line human CVCL_LB31 CL:0000010 Transfected with: HGNC; 10608; SCTR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148461 CVCL_CH99 ND06466 transformed cell line human CVCL_CH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148462 CVCL_CH93 ND06415 transformed cell line human CVCL_CH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148463 CVCL_CH94 ND06416 transformed cell line human CVCL_CH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148464 CVCL_CH91 ND06399 transformed cell line human CVCL_CH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148465 CVCL_CH92 ND06408 transformed cell line human CVCL_CH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148466 CVCL_CH97 ND06448 transformed cell line human CVCL_CH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148467 CVCL_CH98 ND06449 transformed cell line human CVCL_CH98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21148468 CVCL_CH95 ND06446 transformed cell line human CVCL_CH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148469 CVCL_LB29 PathHunter U2OS RXFP3 Total GPCR Internalization cancer cell line human CVCL_LB29 CL:0000010 Transfected with: HGNC; 24883; RXFP3 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148470 CVCL_CH96 ND06447 transformed cell line human CVCL_CH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148471 CVCL_LB49 PathHunter U2OS XBP1 Nuclear Translocation cancer cell line human CVCL_LB49 CL:0000010 Transfected with: HGNC; 12801; XBP1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148472 CVCL_LB47 PathHunter U2OS VIPR1 Activated GPCR Internalization cancer cell line human CVCL_LB47 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148473 CVCL_LB48 PathHunter U2OS VIPR2 Total GPCR Internalization cancer cell line human CVCL_LB48 CL:0000010 Transfected with: HGNC; 12695; VIPR2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148474 CVCL_LB45 PathHunter U2OS TSHR(L) beta-arrestin-1 cancer cell line human CVCL_LB45 CL:0000010 Transfected with: HGNC; 12373; TSHR (isoform long); Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148475 CVCL_LB46 PathHunter U2OS UTR2 Total GPCR Internalization cancer cell line human CVCL_LB46 CL:0000010 Transfected with: HGNC; 4468; UTS2R Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148476 CVCL_LB43 PathHunter U2OS TRHR Total GPCR Internalization cancer cell line human CVCL_LB43 CL:0000010 Transfected with: HGNC; 12299; TRHR Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148477 CVCL_LB44 PathHunter U2OS TSHR(L) beta-arrestin cancer cell line human CVCL_LB44 CL:0000010 Transfected with: HGNC; 12373; TSHR (isoform long); Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148478 CVCL_LB41 PathHunter U2OS TORC2 Nuclear Translocation cancer cell line human CVCL_LB41 CL:0000010 Transfected with: HGNC; 27301; CRTC2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148479 CVCL_LB42 PathHunter U2OS TORC3 Nuclear Translocation cancer cell line human CVCL_LB42 CL:0000010 Transfected with: HGNC; 26148; CRTC3 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148480 CVCL_LB40 PathHunter U2OS TORC1 Nuclear Translocation cancer cell line human CVCL_LB40 CL:0000010 Transfected with: HGNC; 16062; CRTC1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148481 CVCL_LB16 PathHunter U2OS PROKR2 Total GPCR Internalization cancer cell line human CVCL_LB16 CL:0000010 Transfected with: HGNC; 15836; PROKR2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148482 CVCL_LB17 PathHunter U2OS PTAFR Activated GPCR Internalization cancer cell line human CVCL_LB17 CL:0000010 Transfected with: HGNC; 9582; PTAFR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148483 CVCL_LB14 PathHunter U2OS PRLHR Activated GPCR Internalization cancer cell line human CVCL_LB14 CL:0000010 Transfected with: HGNC; 4464; PRLHR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148484 CVCL_LB15 PathHunter U2OS PROKR1 Total GPCR Internalization cancer cell line human CVCL_LB15 CL:0000010 Transfected with: HGNC; 4524; PROKR1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148485 CVCL_LB12 PathHunter U2OS PRalpha Protein Interaction cancer cell line human CVCL_LB12 CL:0000010 Transfected with: HGNC; 8910; PGR (isoform A); Transfected with: HGNC; 7671; NCOA4 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148486 CVCL_LB13 PathHunter U2OS PRbeta Protein Interaction cancer cell line human CVCL_LB13 CL:0000010 Transfected with: HGNC; 8910; PGR (isoform B); Transfected with: HGNC; 7671; NCOA4 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter NHR protein interaction cell lines co-express a NHR tagged with a beta-galactosidase fragment (ProLink=PK) and a receptor co-activator tagged with another fragment (Enzyme Acceptor=EA) Activation of the NHR results in co-activator-EA recruitment thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148487 CVCL_LB10 PathHunter U2OS P2RY4 Activated GPCR Internalization cancer cell line human CVCL_LB10 CL:0000010 Transfected with: HGNC; 8542; P2RY4; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148488 CVCL_LB11 PathHunter U2OS p53 Nuclear Translocation cancer cell line human CVCL_LB11 CL:0000010 Transfected with: HGNC; 11998; TP53 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter nuclear translocation cell lines co-express a target protein tagged with a beta-galactosidase fragment (Enzyme Donor=ED) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the nucleus Complementation of the ED and EA enzyme fragments result into a catalytically active enzyme that generate a chemiluminescent signal. 21148489 CVCL_CH79 ND06332 transformed cell line human CVCL_CH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148490 CVCL_CH77 ND06328 transformed cell line human CVCL_CH77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148491 CVCL_CH78 ND06330 transformed cell line human CVCL_CH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148492 CVCL_CH71 ND06293 transformed cell line human CVCL_CH71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148493 CVCL_CH72 ND06295 transformed cell line human CVCL_CH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148494 CVCL_CH70 ND06292 transformed cell line human CVCL_CH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148495 CVCL_CH75 ND06310 transformed cell line human CVCL_CH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148496 CVCL_LB09 PathHunter U2OS P2RY2 beta-arrestin cancer cell line human CVCL_LB09 CL:0000010 Transfected with: HGNC; 8541; P2RY2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148497 CVCL_CH76 ND06311 transformed cell line human CVCL_CH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148498 CVCL_CH73 ND06296 transformed cell line human CVCL_CH73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148499 CVCL_LB07 PathHunter U2OS P2RY12 Total GPCR Internalization cancer cell line human CVCL_LB07 CL:0000010 Transfected with: HGNC; 18124; P2RY12 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148500 CVCL_CH74 ND06301 transformed cell line human CVCL_CH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148501 CVCL_LB08 PathHunter U2OS P2RY2 Activated GPCR Internalization cancer cell line human CVCL_LB08 CL:0000010 Transfected with: HGNC; 8541; P2RY2; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148502 CVCL_LB27 PathHunter U2OS rFFAR1 beta-arrestin cancer cell line human CVCL_LB27 CL:0000010 Transfected with: RGD; 628613; Ffar1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148503 CVCL_LB28 PathHunter U2OS rHTR2C beta-arrestin cancer cell line human CVCL_LB28 CL:0000010 Transfected with: RGD; 2848; Htr2c; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148504 CVCL_LB25 PathHunter U2OS PTHR2 Total GPCR Internalization cancer cell line human CVCL_LB25 CL:0000010 Transfected with: HGNC; 9609; PTH2R Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148505 CVCL_LB26 PathHunter U2OS RANK-IkappaB Functional Assay cancer cell line human CVCL_LB26 CL:0000010 Transfected with: HGNC; 11908; TNFRSF11A; Transfected with: HGNC; 7797; NFKBIA Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21148506 CVCL_LB23 PathHunter U2OS PTGIR Total GPCR Internalization cancer cell line human CVCL_LB23 CL:0000010 Transfected with: HGNC; 9602; PTGIR Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148507 CVCL_CH90 ND06394 transformed cell line human CVCL_CH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148508 CVCL_LB24 PathHunter U2OS PTHR1 Activated GPCR Internalization cancer cell line human CVCL_LB24 CL:0000010 Transfected with: HGNC; 9608; PTH1R; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148509 CVCL_LB21 PathHunter U2OS PTGFR beta-arrestin cancer cell line human CVCL_LB21 CL:0000010 Transfected with: HGNC; 9600; PTGFR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148510 CVCL_LB22 PathHunter U2OS PTGFR Total GPCR Internalization cancer cell line human CVCL_LB22 CL:0000010 Transfected with: HGNC; 9600; PTGFR Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148511 CVCL_LB20 PathHunter U2OS PTGER4 beta-arrestin cancer cell line human CVCL_LB20 CL:0000010 Transfected with: HGNC; 9596; PTGER4; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148512 CVCL_CH88 ND06391 transformed cell line human CVCL_CH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148513 CVCL_CH89 ND06392 transformed cell line human CVCL_CH89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148514 CVCL_CH82 ND06359 transformed cell line human CVCL_CH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148515 CVCL_CH83 ND06360 transformed cell line human CVCL_CH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148516 CVCL_CH80 ND06342 transformed cell line human CVCL_CH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148517 CVCL_CH81 ND06344 transformed cell line human CVCL_CH81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148518 CVCL_CH86 ND06371 transformed cell line human CVCL_CH86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148519 CVCL_CH87 ND06383 transformed cell line human CVCL_CH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148520 CVCL_CH84 ND06361 transformed cell line human CVCL_CH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148521 CVCL_LB18 PathHunter U2OS PTGER1 beta-arrestin cancer cell line human CVCL_LB18 CL:0000010 Transfected with: HGNC; 9593; PTGER1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148522 CVCL_CH85 ND06363 transformed cell line human CVCL_CH85 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148523 CVCL_LB19 PathHunter U2OS PTGER4 Activated GPCR Internalization cancer cell line human CVCL_LB19 CL:0000010 Transfected with: HGNC; 9596; PTGER4; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148524 CVCL_CH57 ND06200 transformed cell line human CVCL_CH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148525 CVCL_CH58 ND06217 transformed cell line human CVCL_CH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148526 CVCL_CH55 ND06165 transformed cell line human CVCL_CH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148527 CVCL_CH56 ND06199 transformed cell line human CVCL_CH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148528 CVCL_CH59 ND06243 transformed cell line human CVCL_CH59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148529 CVCL_CH50 ND06151 transformed cell line human CVCL_CH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148530 CVCL_CH53 ND06154 transformed cell line human CVCL_CH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148531 CVCL_CH54 ND06164 transformed cell line human CVCL_CH54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148532 CVCL_CH51 ND06152 transformed cell line human CVCL_CH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148533 CVCL_CH52 ND06153 transformed cell line human CVCL_CH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148534 CVCL_LB05 PathHunter U2OS P2RY1 Activated GPCR Internalization cancer cell line human CVCL_LB05 CL:0000010 Transfected with: HGNC; 8539; P2RY1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148535 CVCL_LB06 PathHunter U2OS P2RY1 beta-arrestin cancer cell line human CVCL_LB06 CL:0000010 Transfected with: HGNC; 8539; P2RY1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148536 CVCL_LB03 PathHunter U2OS OXER1 Total GPCR Internalization cancer cell line human CVCL_LB03 CL:0000010 Transfected with: HGNC; 24884; OXER1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148537 CVCL_LB04 PathHunter U2OS OXTR Activated GPCR Internalization cancer cell line human CVCL_LB04 CL:0000010 Transfected with: HGNC; 8529; OXTR; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter activated GPCR internalization cell lines co-express an untagged GPCR, a beta-arrestin tagged with a beta-galactosidase fragment (Enzyme Acceptor=EA) and a second beta-galactosidase fragment (ProLink=PK) localized to the endosomes Beta-arrestin recruitment is followed by internalization of the GPCR/arrestin-EA complex in PK-tagged endosomes and allowing complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148538 CVCL_LB01 PathHunter U2OS OPRM1 beta-arrestin-1 cancer cell line human CVCL_LB01 CL:0000010 Transfected with: HGNC; 8156; OPRM1; Transfected with: HGNC; 711; ARRB1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148539 CVCL_LB02 PathHunter U2OS OPRM1 Total GPCR Internalization cancer cell line human CVCL_LB02 CL:0000010 Transfected with: HGNC; 8156; OPRM1 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter total GPCR internalization cell lines co-express a tagged with a beta-galactosidase fragment (ProLink=PK) and a second beta-galactosidase fragment (Enzyme Acceptor=EA) localized to the endosomes Activation of the GPCR-PK induces internalization of the receptor in EA-tagged endosomes and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148540 CVCL_LB00 PathHunter U2OS OPRM1 beta-arrestin cancer cell line human CVCL_LB00 CL:0000010 Transfected with: HGNC; 8156; OPRM1; Transfected with: HGNC; 712; ARRB2 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: PathHunter beta-arrestin cell lines co-express a GPCR tagged with a beta-galactosidase fragment (ProLink=PK) and a beta-arrestin tagged with another fragment (Enzyme Acceptor=EA) Activation of the GPCR-PK induces beta-arrestin-EA recruitment and complementation of the PK and EA enzyme fragments thus resulting into a catalytically active enzyme that generate a chemiluminescent signal. 21148541 CVCL_CH68 ND06285 transformed cell line human CVCL_CH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148542 CVCL_CH69 ND06291 transformed cell line human CVCL_CH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148543 CVCL_CH66 ND06278 transformed cell line human CVCL_CH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148544 CVCL_CH67 ND06284 transformed cell line human CVCL_CH67 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (from autologous cell line ND30171); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (from autologous cell line ND30171) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148545 CVCL_CH60 ND06245 transformed cell line human CVCL_CH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148546 CVCL_CH61 ND06246 transformed cell line human CVCL_CH61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148547 CVCL_CH64 ND06276 transformed cell line human CVCL_CH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148548 CVCL_CH65 ND06277 transformed cell line human CVCL_CH65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148549 CVCL_CH62 ND06255 transformed cell line human CVCL_CH62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148550 CVCL_CH63 ND06275 transformed cell line human CVCL_CH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148551 CVCL_1U21 GM02304 finite cell line human CVCL_1U21 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21148552 CVCL_2621 MRC-5 pd13 finite cell line human CVCL_2621 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21148553 CVCL_1U22 GM02305 transformed cell line human CVCL_1U22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148554 CVCL_2622 MRC-5 pd19 finite cell line human CVCL_2622 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21148555 CVCL_1U20 GM02264 transformed cell line human CVCL_1U20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148556 CVCL_2620 MOR/CPR cancer cell line human CVCL_2620 Genome ancestry: African=1.26%; Native American=0%; East Asian, North=4.44%; East Asian, South=0%; South Asian=0%; European, North=61.77%; European, South=32.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (DepMap) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148557 CVCL_1U25 GM03221 finite cell line human CVCL_1U25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21148558 CVCL_2625 MRC-5 SV1 TG1 transformed cell line human CVCL_2625 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21148559 CVCL_1U26 GM22232 transformed cell line human CVCL_1U26 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM22232; probable Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148560 CVCL_2626 MRC-5 SV1 TG2 transformed cell line human CVCL_2626 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21148561 CVCL_1U23 GM02347 transformed cell line human CVCL_1U23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148562 CVCL_2623 MRC-5 pd25 finite cell line human CVCL_2623 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21148563 CVCL_1U24 GM03211 finite cell line human CVCL_1U24 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21148564 CVCL_2624 MRC-5 pd30 finite cell line human CVCL_2624 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ECACC; 84101801; true Male 21148565 CVCL_1U29 GM22235 transformed cell line human CVCL_1U29 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148566 CVCL_2629 MRC-9 finite cell line human CVCL_2629 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: SNP array analysis Discontinued: KCLB; 10212; probable Female Senescence: Can undergo at least 40 PDL (PubMed=113411) Senesces at 44 PDL (JCRB=IFO50072). 21148567 CVCL_1U27 GM22233 transformed cell line human CVCL_1U27 CL:0000010 Population: Jewish; Syrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM22233; probable Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148568 CVCL_2627 MRC-5V2 transformed cell line human CVCL_2627 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21148569 CVCL_1U28 GM22234 transformed cell line human CVCL_1U28 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148570 CVCL_2628 MRC-7 finite cell line human CVCL_2628 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 21148571 CVCL_1U32 DT40-GRB2(-/-) cancer cell line CVCL_1U32 CL:0000010 Knockout cell: Method=Targeted integration; GRB2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148572 CVCL_2632 MT-4 transformed cell line human CVCL_2632 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Discontinued: JCRB; NIHS0145; true; Discontinued: JCRB; NIHS0529; true Male Characteristics: Was established by co-cultivation of cells from a 50 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542); Virology: HTLV-1 producing cell line Expresses Tax. Is permissive for replication of an HIV-1 gp41 mutant lacking the cytoplasmic tail. Doubling time: ~30 hours (lot 102799) (JCRB) Problematic cell line: Partially contaminated Two different lots formerly distributed by NIH-ARP; 13 P7 3/9/92 and 150048; were shown not to be authentic MT-4 (PubMed=9261343; PubMed=31554688). 21148573 CVCL_1U33 DT40-GRAP(-/-) cancer cell line CVCL_1U33 CL:0000010 Knockout cell: Method=Targeted integration; GRAP Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148574 CVCL_2633 My-La CD4+ cancer cell line human CVCL_2633 CL:0000010 Male Characteristics: IL2 and IL4 dependent Doubling time: 50 hours (PubMed=1582990); 20-24 hours (ECACC=95051032). 21148575 CVCL_1U30 GM22236 transformed cell line human CVCL_1U30 CL:0000010 Population: Jewish; Lybian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 21148576 CVCL_2630 MRSS-1 hybridoma house mouse CVCL_2630 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:9160; Single-stranded DNA. 21148577 CVCL_1U31 DT40-RAD18(-/-) cancer cell line CVCL_1U31 CL:0000010 Knockout cell: Method=Targeted integration; RAD18 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148578 CVCL_2631 MT-2 transformed cell line human CVCL_2631 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=Regulatory T-cell.. Discontinued: ECACC; 93121518; probable; Discontinued: JCRB; NIHS0527; true Male Characteristics: Was established by co-cultivation of cells from a 45 year old female T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542); Virology: HTLV-1 producing cell line; Contains 11 integrated HTLV-1 proviruses: one complete proviral genome, six copies of a provirus with an internal deletion of 5.3 kb, one copy of a provirus with an internal deletion of 3.9 kb, one copy of a provirus with a 6.2 kB deletion from 5'LTR to position 6257 and two copies of a provirus composed of LTR only; Virology: Susceptible to infection by HCV (PubMed=7832798) 21148579 CVCL_1U36 DT40-SOS2(-/-) cancer cell line CVCL_1U36 CL:0000010 Knockout cell: Method=Targeted integration; SOS2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148580 CVCL_2636 NCI-BL128 transformed cell line human CVCL_2636 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148581 CVCL_1U37 DT40-SOS1(-/-)-SOS2(-/-) cancer cell line CVCL_1U37 CL:0000010 Knockout cell: Method=Targeted integration; SOS1+SOS2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148582 CVCL_2637 NCI-BL1339 transformed cell line human CVCL_2637 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148583 CVCL_1U34 DT40-SHC1(-/-) cancer cell line CVCL_1U34 CL:0000010 Knockout cell: Method=Targeted integration; SHC1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148584 CVCL_2634 My-La CD8+ cancer cell line human CVCL_2634 CL:0000010 Male Characteristics: IL2 dependent Doubling time: 20-24 hours (PubMed=1582990). 21148585 CVCL_1U35 DT40-SOS1(-/-) cancer cell line CVCL_1U35 CL:0000010 Knockout cell: Method=Targeted integration; SOS1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148586 CVCL_2635 NCI-BL1184 transformed cell line human CVCL_2635 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~44 hours (DSMZ=ACC-896) 21148587 CVCL_1U38 DT40-RASGRP1(-/-) cancer cell line CVCL_1U38 CL:0000010 Knockout cell: Method=Targeted integration; RASGRP1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148588 CVCL_2638 NCI-BL1395 transformed cell line human CVCL_2638 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148589 CVCL_1U39 DT40-RASGRP1(-/-)-RASGRP3(-/-) cancer cell line CVCL_1U39 CL:0000010 Knockout cell: Method=Targeted integration; RASGRP1+RASGRP3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21148590 CVCL_2639 NCI-BL1437 transformed cell line human CVCL_2639 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148591 CVCL_1U09 CaPa cancer cell line human CVCL_1U09 CL:0000010 Derived from metastatic site: Abdominal cavity. 21148592 CVCL_2609 MM426 cancer cell line human CVCL_2609 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Ter (c.262G>T); ClinVar=VCV000376305; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583; DepMap) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148593 CVCL_2600 MKL-1 cancer cell line human CVCL_2600 CL:0000010 Population: Caucasian; Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Left axillary lymph node. Omics: Array-based CGH; Omics: Deep quantitative proteome analysis Male Virology: Contains 3.5 copies of the genome of MCPyV per haploid cell (PubMed=23085629) Doubling time: ~120 hours (PubMed=3546933); 3 days (PubMed=20444890) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148594 CVCL_1U00 SK-MEL-498 cancer cell line human CVCL_1U00 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21148595 CVCL_2603 MM170 cancer cell line human CVCL_2603 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=22383533) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Discontinued: CBA; CBA-1346; true Male Problematic cell line: Contaminated Presence of a second cell line in earliest stock not picked up due to low level of contamination (CBA). 21148596 CVCL_1U03 SK-MEL-509 cancer cell line human CVCL_1U03 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21148597 CVCL_2604 MM253 cancer cell line human CVCL_2604 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148598 CVCL_1U04 SK-MEL-513 cancer cell line human CVCL_1U04 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21148599 CVCL_2601 MM127 cancer cell line human CVCL_2601 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Unspecified (PubMed=11930117); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533) Derived from metastatic site: Hypodermis. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Possibly misclassified It is not certain that this cell line originate from a metastatic melanoma.; Lacks the expression of three protein markers: S100, HMB-45 and Melan-A commonly found in melanoma cell lines (PubMed=27087056) Has a CTNNB1 mutation not seen in other melanoma cell lines (PubMed=11930117). 21148600 CVCL_1U01 SK-MEL-506 cancer cell line human CVCL_1U01 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21148601 CVCL_2602 MM138 cancer cell line human CVCL_2602 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis Female Doubling time: ~60 hours (ECACC=10092321) 21148602 CVCL_1U02 SK-MEL-507 cancer cell line human CVCL_1U02 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21148603 CVCL_2607 MM386 cancer cell line human CVCL_2607 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg290His (c.869G>A); ClinVar=VCV000127825; Zygosity=Unspecified (PubMed=10070891) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148604 CVCL_1U07 SK-MEL-534 cancer cell line human CVCL_1U07 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=24576830). 21148605 CVCL_2608 MM415 cancer cell line human CVCL_2608 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148606 CVCL_1U08 SK-MEL-538 cancer cell line human CVCL_1U08 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=24576830). 21148607 CVCL_2605 MM370 cancer cell line human CVCL_2605 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin. 21148608 CVCL_1U05 SK-MEL-524 cancer cell line human CVCL_1U05 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21148609 CVCL_2606 MM383 cancer cell line human CVCL_2606 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148610 CVCL_1U06 SK-MEL-529 cancer cell line human CVCL_1U06 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21148611 CVCL_2610 MM485 cancer cell line human CVCL_2610 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp100Ter; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583; DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; DepMap) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148612 CVCL_1U10 Panc03 cancer cell line house mouse CVCL_1U10 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6. Male 21148613 CVCL_2611 MM576 cancer cell line human CVCL_2611 CL:0000010 Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Unspecified 21148614 CVCL_1U11 UN-KC-6141 cancer cell line house mouse CVCL_1U11 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: B6.FVB-Tg(Pdx1-cre)6Tuv/J,LSL-Kras(G12D/+). 21148615 CVCL_2614 MOG-G-UVW cancer cell line human CVCL_2614 Genome ancestry: African=1.89%; Native American=0%; East Asian, North=2.75%; East Asian, South=0%; South Asian=0%; European, North=58.22%; European, South=37.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21148616 CVCL_2615 MOPC-31C cancer cell line house mouse CVCL_2615 CL:0000010 Breed/subspecies: BALB/cJ. 21148617 CVCL_1U15 T1 [Human contaminated neural stem cell] cancer cell line human CVCL_1U15 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00453 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=22949886). 21148618 CVCL_2612 MM603 cancer cell line human CVCL_2612 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21148619 CVCL_1U12 UN-KPC-960 cancer cell line house mouse CVCL_1U12 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: B6.FVB-Tg(Pdx1-cre)6Tuv/J,LSL-Kras(G12D/+),LSL-Trp53(R175H/+). 21148620 CVCL_2613 MOG-G-CCM cancer cell line human CVCL_2613 Genome ancestry: African=0.19%; Native American=0%; East Asian, North=0.2%; East Asian, South=0%; South Asian=0%; European, North=69.93%; European, South=29.68% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21148621 CVCL_1U13 UN-KPC-961 cancer cell line house mouse CVCL_1U13 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: B6.FVB-Tg(Pdx1-cre)6Tuv/J,LSL-Kras(G12D/+),LSL-Trp53(R175H/+). 21148622 CVCL_1U18 GM50323 transformed cell line human CVCL_1U18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21148623 CVCL_2618 MOR cancer cell line human CVCL_2618 HLA typing: A*02:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293) CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified 21148624 CVCL_1U19 GM02217 transformed cell line human CVCL_1U19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148625 CVCL_2619 MOR/0.4R cancer cell line human CVCL_2619 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Lung. Unspecified 21148626 CVCL_1U16 GM50124 transformed cell line human CVCL_1U16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21148627 CVCL_2616 MOPC-315 cancer cell line house mouse CVCL_2616 CL:0000010 Breed/subspecies: BALB/c. Monoclonal antibody isotype: IgA, lambda Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21148628 CVCL_1U17 GM50322 transformed cell line human CVCL_1U17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21148629 CVCL_2617 MOP-8 transformed cell line house mouse CVCL_2617 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21148630 CVCL_LB98 AR53A10.11 hybridoma house mouse CVCL_LB98 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Human ovarian cancer cells. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 141205-04 21148631 CVCL_LB99 AR58A258.8 hybridoma house mouse CVCL_LB99 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 290605-01 21148632 CVCL_LB96 14C12 hybridoma house mouse CVCL_LB96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody B02C11. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 5878CB 21148633 CVCL_LB97 AR40A603.13 hybridoma house mouse CVCL_LB97 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Human prostate cancer cells. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 280104-04 21148634 CVCL_LB94 6BD-25 hybridoma house mouse CVCL_LB94 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5691 21148635 CVCL_LB95 BO2C11 transformed cell line human CVCL_LB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Produces a monoclonal antibody that completely inhibits the procoagulant activity of native and activated factor VIII; Monoclonal antibody isotype: IgG4, kappa; Monoclonal antibody target: UniProtKB; P00451; Human F8 21148636 CVCL_LB92 TDC2 cancer cell line human CVCL_LB92 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Dendritic cell.. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3168 21148637 CVCL_LB93 5LAC-23 hybridoma house mouse CVCL_LB93 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P08865; Human RPSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5690 21148638 CVCL_LB90 HN0124 hybridoma house mouse CVCL_LB90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:138017; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694). 21148639 CVCL_LB91 NK0504 hybridoma house mouse CVCL_LB91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:138017; 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694). 21148640 CVCL_LB78 4906 cancer cell line CVCL_LB78 CL:0000010 Female Group: Marsupial cell line. 21148641 CVCL_LB79 C5065 cancer cell line CVCL_LB79 CL:0000010 Female Characteristics: Originates from DFT1 strain 3. Group: Marsupial cell line 21148642 CVCL_LB76 1426 cancer cell line CVCL_LB76 CL:0000010 Female Group: Marsupial cell line. 21148643 CVCL_LB77 2112 cancer cell line CVCL_LB77 CL:0000010 Female Characteristics: Originates from DFT1 strain 2. Group: Marsupial cell line 21148644 CVCL_LB74 TJ2 transformed cell line human CVCL_LB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P25189; Human MPZ 21148645 CVCL_LB75 1/2Pea cancer cell line CVCL_LB75 CL:0000010 Female Characteristics: Originates from DFT1 strain 2. Group: Marsupial cell line 21148646 CVCL_LB72 MSP-1 cancer cell line human CVCL_LB72 CL:0000010 Derived from sampling site: Bone marrow. Female 21148647 CVCL_LB73 TJ1 transformed cell line human CVCL_LB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P25189; Human MPZ 21148648 CVCL_LB70 BXP-34 hybridoma house mouse CVCL_LB70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9UNQ0; Human ABCG2/CD338. 21148649 CVCL_LB71 RLE-6T transformed cell line Norway rat CVCL_LB71 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21148650 CVCL_LB89 FA6 IIG5 hybridoma house mouse CVCL_LB89 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21184; Pseudomonas aeruginosa A-type flagellin (fliC). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9130 21148651 CVCL_LB87 NISK9 spontaneously immortalized cell line human CVCL_LB87 CL:0000010 Transfected with: HGNC; 59; ABCC8; Transfected with: HGNC; 6257; KCNJ11; Transfected with: HGNC; 6107; PDX1. Characteristics: Insulin secreting; Characteristics: Compared to the parent cell line, it has a repaired ATP-regulated potassium channel activity Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 09709106 21148652 CVCL_LB88 PaF4 IVE8 hybridoma house mouse CVCL_LB88 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P72151; Pseudomonas aeruginosa B-type flagellin (fliC). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9129 21148653 CVCL_LB85 A9G TG100 spontaneously immortalized cell line house mouse CVCL_LB85 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21148654 CVCL_LB86 NES2Y spontaneously immortalized cell line human CVCL_LB86 CL:0000010 Characteristics: Insulin secreting; Characteristics: Has a loss of function of ATP-regulated potassium channels. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 98081006 21148655 CVCL_LB83 BeWo b30 cancer cell line human CVCL_LB83 CL:0000010 Derived from metastatic site: Fetal brain. Male Characteristics: Compared to the parent cell line, forms confluent monolayers amenable to drug transport studies 21148656 CVCL_LB84 A9G TG40 spontaneously immortalized cell line house mouse CVCL_LB84 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21148657 CVCL_LB81 1C5 [Mouse hybridoma against human UBA1] hybridoma house mouse CVCL_LB81 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P22314; Human UBA1. 21148658 CVCL_LB82 BeWo b24 cancer cell line human CVCL_LB82 CL:0000010 Derived from metastatic site: Fetal brain. Male Characteristics: Compared to the parent cell line, forms confluent monolayers amenable to drug transport studies 21148659 CVCL_LB80 DFT2.RV cancer cell line CVCL_LB80 CL:0000010 Male Group: Marsupial cell line. 21148660 CVCL_CJ08 ND07170 transformed cell line human CVCL_CJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148661 CVCL_CJ09 ND07171 transformed cell line human CVCL_CJ09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148662 CVCL_CJ06 ND07131 transformed cell line human CVCL_CJ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148663 CVCL_CJ07 ND07132 transformed cell line human CVCL_CJ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148664 CVCL_CJ00 ND07088 transformed cell line human CVCL_CJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148665 CVCL_CJ01 ND07089 transformed cell line human CVCL_CJ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148666 CVCL_CJ04 ND07121 transformed cell line human CVCL_CJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148667 CVCL_CJ05 ND07122 transformed cell line human CVCL_CJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148668 CVCL_CJ02 ND07090 transformed cell line human CVCL_CJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148669 CVCL_CJ03 ND07104 transformed cell line human CVCL_CJ03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148670 CVCL_1V90 ND01630 transformed cell line human CVCL_1V90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148671 CVCL_2782 MOH (TOU II-3) transformed cell line human CVCL_2782 CL:0000010 Sequence variation: Gene deletion; HGNC; 5478; IGHA1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5523; IGHEP1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5525; IGHG1; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5526; IGHG2; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5528; IGHG4; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5529; IGHGP; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143) Population: Tunisian; Berber; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Heterozygous for deletion of IGH G1-EP1-A1-GP-G2-G4 and of EP1-A1-GP 21148672 CVCL_1V82 ND01574 transformed cell line human CVCL_1V82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148673 CVCL_1V83 ND01577 transformed cell line human CVCL_1V83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148674 CVCL_2783 Y0 hybrid cell line Norway rat CVCL_2783 CL:0000010 Group: Hybridoma fusion partner cell line. 21148675 CVCL_2780 CHSE-214 spontaneously immortalized cell line CVCL_2780 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Discontinued: ATCC; CRL-1681; true Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) (CelloPub=CLPUB00703) Group: Fish cell line 21148676 CVCL_1V80 ND01569 transformed cell line human CVCL_1V80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148677 CVCL_2781 EZZ (TOU II-4) transformed cell line human CVCL_2781 CL:0000010 Sequence variation: Gene deletion; HGNC; 5523; IGHEP1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5525; IGHG1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5526; IGHG2; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5528; IGHG4; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5529; IGHGP; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143) Population: Tunisian; Berber; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Homozygous for deletion of IGH G1-EP1-A1-GP-G2-G4 21148678 CVCL_1V81 ND01570 transformed cell line human CVCL_1V81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148679 CVCL_2786 JHH-2 cancer cell line human CVCL_2786 HLA typing: A*24:02,26:01; B*52:01,67:02; C*08:01,12:02; DQA1*03:02,03:02; DQB1*06:07,06:07; DRB1*11:09,15:02 (PubMed=26589293); Genome ancestry: African=0.15%; Native American=0.24%; East Asian, North=82.5%; East Asian, South=16.41%; South Asian=0%; European, North=0%; European, South=0.7% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (PubMed=31378681; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+2T>G (IVS4+2T>G); ClinVar=VCV000482210; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=31378681; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0058; true Male Doubling time: 150 hours (CelloPub=CLPUB00469); 60.12 hours (PubMed=31378681); 35-70 hours (lot 01222008), ~2 days (lot 11022010), ~33 hours (lot 09072011), ~59 hours (lot 05022018) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project 21148680 CVCL_1V86 ND01583 transformed cell line human CVCL_1V86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148681 CVCL_2787 JHH-4 cancer cell line human CVCL_2787 HLA typing: A*02:10,24:94; B*13:01,40:06; C*03:04,08:01; DQA1*02:01,03:02; DQB1*04:01,04:01; DRB1*04:05,04:05 (PubMed=26589293); Genome ancestry: African=0.12%; Native American=0%; East Asian, North=81.09%; East Asian, South=16.25%; South Asian=0%; European, North=0%; European, South=2.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Cys78Ter (c.234T>A); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0057; true. Male Doubling time: 55 hours (CelloPub=CLPUB00469); 32.99 hours (PubMed=31378681); ~40.5 hours (lot 04142005), ~32 hours (lot 01242022) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project Caution: FLC-4 (Cellosaurus=CVCL_D204) is often stated to be synonymous with JHH-4, but a FLC-4 patent reference (Patent=US5804441) seems to indicate that it is derived from JHH-4 and has a different karyotype 21148682 CVCL_1V87 ND01588 transformed cell line human CVCL_1V87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148683 CVCL_2784 HO-1-u-1 cancer cell line human CVCL_2784 Genome ancestry: African=1.54%; Native American=0%; East Asian, North=76.45%; East Asian, South=19.98%; South Asian=0.41%; European, North=1.61%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Salivary gland; sublingual gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Suitable for in vitro sublingual drug delivery screening involving passive diffusion (PubMed=17079100; PubMed=19071203) Doubling time: ~23 hours (DOI=10.5794/jjoms.31.1347); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21148684 CVCL_1V84 ND01580 transformed cell line human CVCL_1V84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148685 CVCL_2785 JHH-1 cancer cell line human CVCL_2785 HLA typing: A*02:07,02:07; B*15:01,46:01; C*01:02,01:02; DQA1*01:02,03:02; DQB1*03:02,03:02; DRB1*11:02,15:30 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=81.93%; East Asian, South=18.06%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB1062; probable; Discontinued: JCRB; NIHS0056; true; Discontinued: JCRB; NIHS0329; true. Unspecified Doubling time: 44-50 hours (CelloPub=CLPUB00469); 21.99 hours (PubMed=31378681); ~55 hours (lot 03262008), ~53 hours (lot 05262011) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00353 Problematic cell line: Partially contaminated Some JCRB stocks were found to be from mouse (PubMed=20143388). Stock bought in 2013 was shown to be human by exome sequencing (personal communication of Rebouissou S.). 21148686 CVCL_1V85 ND01582 transformed cell line human CVCL_1V85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148687 CVCL_2788 JHH-6 cancer cell line human CVCL_2788 Genome ancestry: African=0%; Native American=0.29%; East Asian, North=84.12%; East Asian, South=15.16%; South Asian=0%; European, North=0%; European, South=0.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Aspfs*7 (c.1008_1018delGCGCTTCGAGA); Zygosity=Heterozygous (PubMed=31378681; Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0280; true. Female Doubling time: 22.32 hours (PubMed=31378681); ~30 hours (lot 03282003), ~21 hours (lot 05182017) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project 21148688 CVCL_1V88 ND01611 transformed cell line human CVCL_1V88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148689 CVCL_2789 KOSC-3 cancer cell line human CVCL_2789 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=8314315) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Discontinued: JCRB; NIHS0166; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00324 Problematic cell line: Contaminated Shown to be a Ca9-22 derivative (PubMed=20143388). Originally thought to originate from a 72 year old female patient with a lower-gingiva squamous cell carcinoma. 21148690 CVCL_1V89 ND01613 transformed cell line human CVCL_1V89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148691 CVCL_1V93 ND01660 transformed cell line human CVCL_1V93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148692 CVCL_2793 SKG-I cancer cell line human CVCL_2793 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis Female Doubling time: 35-42 hours (PubMed=7196935) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148693 CVCL_1V94 ND01666 transformed cell line human CVCL_1V94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148694 CVCL_2794 SKG-II cancer cell line human CVCL_2794 HLA typing: A*24:02 (PubMed=9023415) CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (DepMap) Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; JCRB0171; true Female Doubling time: 31 hours (PubMed=10457904) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148695 CVCL_2791 MKN74 cancer cell line human CVCL_2791 HLA typing: A*31:01,31:01; B*51:01,51:01; C*03:04,03:04; DQB1*06:02,06:02; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*31:01,31:01; B*51:01,51:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=88.48%; East Asian, South=9.79%; South Asian=0.44%; European, North=0%; European, South=1.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (PubMed=1370612; PubMed=15900046) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42-46 hours (PubMed=3962675); 46-49 hours (CelloPub=CLPUB00584) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR39 cancer cell line panel; Part of: JFCR45 cancer cell line panel; Part of: MD Anderson Cell Lines Project 21148696 CVCL_1V91 ND01657 transformed cell line human CVCL_1V91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148697 CVCL_2792 MOLT-4F cancer cell line human CVCL_2792 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Male 21148698 CVCL_1V92 ND01659 transformed cell line human CVCL_1V92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148699 CVCL_1V97 ND01672 transformed cell line human CVCL_1V97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148700 CVCL_2797 V79-GalK1 transformed cell line CVCL_2797 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27411; 2-deoxy-D-galactose; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21148701 CVCL_2798 KNS-60 cancer cell line human CVCL_2798 HLA typing: A*24:02,24:02; B*52:01,54:01; C*01:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=80.41%; East Asian, South=18.86%; South Asian=0%; European, North=0%; European, South=0.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42 hours (CelloPub=CLPUB00152); 38 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148702 CVCL_1V98 ND01674 transformed cell line human CVCL_1V98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148703 CVCL_1V95 ND01670 transformed cell line human CVCL_1V95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148704 CVCL_2795 SKG-IIIb cancer cell line human CVCL_2795 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0026; true Female 21148705 CVCL_1V96 ND01671 transformed cell line human CVCL_1V96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148706 CVCL_2796 V79-4 spontaneously immortalized cell line CVCL_2796 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (PubMed=9023109); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (PubMed=9023109) Derived from sampling site: Lung Cell type=Fibroblast.. Male Characteristics: Widely used to study DNA damage induced by X-ray, UV radiation and oxidizing agents Doubling time: 12-14 hours (ECACC=93010723) Group: Space-flown cell line (cellonaut) 21148707 CVCL_2799 KNS-81 cancer cell line human CVCL_2799 Genome ancestry: African=0.61%; Native American=1.05%; East Asian, North=78.9%; East Asian, South=17.38%; South Asian=0%; European, North=0%; European, South=2.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (DepMap) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 54 hours (CelloPub=CLPUB00152); 110 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148708 CVCL_1V99 ND01675 transformed cell line human CVCL_1V99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148709 CVCL_1V60 ND01323 transformed cell line human CVCL_1V60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148710 CVCL_2760 WiDr cancer cell line human CVCL_2760 HLA typing: A*01:01,24:03; B*35:01,44:03; C*04:01,04:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20570890; PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (PubMed=24042735); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=24042735; PubMed=28683746) Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1908; true. Female Doubling time: 15 hours (PubMed=90012); 18 hours (PubMed=9488600); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=24042735; PubMed=25926053; PubMed=28683746) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00103 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=3472642; PubMed=20143388). Originally thought to originate from a 78 year old female patient with a primary adenocarcinoma of the rectosigmoid colon. 21148711 CVCL_1V61 ND01354 transformed cell line human CVCL_1V61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148712 CVCL_2761 WIL2 NS transformed cell line human CVCL_2761 HLA typing: DPA1*02:02:02 (IPD-IMGT/HLA=11561); Genome ancestry: African=0%; Native American=0.61%; East Asian, North=0%; East Asian, South=0%; South Asian=1.47%; European, North=69.86%; European, South=28.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (PubMed=33198927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (PubMed=7798274; PubMed=33198927) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB2285; true; Discontinued: TKG; TKG 0374; probable Male Characteristics: Does not secrete immunoglobulins Microsatellite instability: Stable (MSS) (Sanger) Group: Hybridoma fusion partner cell line; Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8155 21148713 CVCL_1V64 ND01493 transformed cell line human CVCL_1V64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148714 CVCL_2764 WKD cancer cell line human CVCL_2764 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00030 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). 21148715 CVCL_1V65 ND01496 transformed cell line human CVCL_1V65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148716 CVCL_2765 WM266-4 cancer cell line human CVCL_2765 HLA typing: A*02:01,29:02; B*13:02,44:03:01; C*06:02,16:01; DPB1*02:01:02,02:01:02; DQB1*02:01,02:01; DRB1*07:01,07:01 (PubMed=15592718); HLA typing: A*02:01,29:01; B*13:02,44:02; C*06:02,06:02; DQB1*06:04,06:04; DRB1*07:01,14:103 (PubMed=25960936); HLA typing: A*02:01,29:02; B*13:02,44:03; C*06:02,16:01 (PubMed=26589293); Genome ancestry: African=0.04%; Native American=0%; East Asian, North=0%; East Asian, South=0.62%; South Asian=0.32%; European, North=66.56%; European, South=32.46% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (Wistar); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (Wistar); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (PubMed=12068308; PubMed=19799798; PubMed=23851445; PubMed=29492214; ATCC; DepMap; Wistar); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Caucasian; Karyotypic information: Hypertriploid karyotype; Derived from metastatic site: Right thigh; skin. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-1676; probable; Discontinued: Coriell; WC00097; probable; Discontinued: ECACC; 91061233; probable Female Doubling time: ~30 hours (PBCF) Part of: BRAF genetic alteration cell panel (ATCC TCP-1032); Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: Wistar Institute melanoma cell line collection 21148717 CVCL_1V62 ND01424 transformed cell line human CVCL_1V62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148718 CVCL_2762 WIL2.NS.6TG transformed cell line human CVCL_2762 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line 21148719 CVCL_1V63 ND01491 transformed cell line human CVCL_1V63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148720 CVCL_2763 WILCL transformed cell line human CVCL_2763 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Unspecified 21148721 CVCL_1V68 ND01523 transformed cell line human CVCL_1V68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148722 CVCL_2768 X1/5 cancer cell line human CVCL_2768 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21148723 CVCL_2769 CCD-1112Sk finite cell line human CVCL_2769 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at ~44 PDL (ATCC=CRL-2429) 21148724 CVCL_1V69 ND01525 transformed cell line human CVCL_1V69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148725 CVCL_1V66 ND01504 transformed cell line human CVCL_1V66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148726 CVCL_2766 WS1 finite cell line human CVCL_2766 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: CLS; 300344; true Female Senescence: Senesces at 67 PDL (ATCC=CRL-1502) 21148727 CVCL_1V67 ND01519 transformed cell line human CVCL_1V67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148728 CVCL_2767 WSS-1 transformed cell line human CVCL_2767 CL:0000010 Transfected with: RGD; 61855; Gabra1; Transfected with: RGD; 61966; Gabrg2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21148729 CVCL_1V71 ND01528 transformed cell line human CVCL_1V71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148730 CVCL_2771 TALL-104 cancer cell line human CVCL_2771 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 8064; NUP214; Name(s)=NUP214-ABL1; Note=NUP214 exon 32 fused to ABL1 exon 2 (PubMed=15361874; PubMed=35354797) Miscellaneous: STR profile from personal communication of Leo I.R Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: AddexBio; C0003027; true Male Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11386 21148731 CVCL_1V72 ND01548 transformed cell line human CVCL_1V72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148732 CVCL_2772 TCMK-1 transformed cell line house mouse CVCL_2772 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C3H/Mai. Discontinued: ECACC; 90050802; probable Unspecified 21148733 CVCL_2770 gamma3-11.1 hybridoma house mouse CVCL_2770 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8700; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-243 21148734 CVCL_1V70 ND01527 transformed cell line human CVCL_1V70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148735 CVCL_1V75 ND01563 transformed cell line human CVCL_1V75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148736 CVCL_2775 TE 90.Sk finite cell line human CVCL_2775 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21148737 CVCL_1V76 ND01565 transformed cell line human CVCL_1V76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148738 CVCL_2776 Tera-1 cancer cell line human CVCL_2776 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lung. Male 21148739 CVCL_1V73 ND01552 transformed cell line human CVCL_1V73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148740 CVCL_2773 TE 91.Sk finite cell line human CVCL_2773 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7740; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21148741 CVCL_1V74 ND01562 transformed cell line human CVCL_1V74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148742 CVCL_2774 TE 98.T undefined cell line type human CVCL_2774 CL:0000010 Discontinued: ATCC; CRL-7741; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21148743 CVCL_2779 CHP 4 (W.W.) finite cell line human CVCL_2779 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Ser135Leu (c.404C>T); ClinVar=VCV000003618; Zygosity=Heterozygous (from autologous cell line GM02796); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Phe171Ser (c.512T>C); ClinVar=VCV000003616; Zygosity=Heterozygous (from autologous cell line GM02796) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00052; true Male 21148744 CVCL_1V79 ND01568 transformed cell line human CVCL_1V79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148745 CVCL_1V77 ND01566 transformed cell line human CVCL_1V77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148746 CVCL_2777 Tera-2 cancer cell line human CVCL_2777 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148747 CVCL_2778 CHP 3 (M.W.) finite cell line human CVCL_2778 CL:0000010 Derived from sampling site: Skin. Discontinued: ECACC; 90102536; probable Male 21148748 CVCL_1V78 ND01567 transformed cell line human CVCL_1V78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148749 CVCL_LD14 SW48 EGFR (S492R/+/+) cancer cell line human CVCL_LD14 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Ser492Arg (c.1476C>A); ClinVar=VCV000376341; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a EGFR mutation 21148750 CVCL_LD15 MCF-10A EGFR (L858R/+) spontaneously immortalized cell line human CVCL_LD15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a EGFR activating mutation 21148751 CVCL_LD12 SW48 EGFR (L65V/+/+) cancer cell line human CVCL_LD12 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu65Val; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a EGFR mutation 21148752 CVCL_LD13 SW48 EGFR (L858R/+/+) cancer cell line human CVCL_LD13 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a EGFR activating mutation 21148753 CVCL_LD10 RKO EGFR (T790M/+) cancer cell line human CVCL_LD10 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR mutation conferring drug resistance 21148754 CVCL_LD11 SW48 EGFR (I491M/+/+) cancer cell line human CVCL_LD11 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Ile491Met (c.1473A>G); ClinVar=VCV001404733; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a EGFR mutation 21148755 CVCL_CJ77 ND08141 transformed cell line human CVCL_CJ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148756 CVCL_CJ78 ND08142 transformed cell line human CVCL_CJ78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148757 CVCL_CJ75 ND08085 transformed cell line human CVCL_CJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148758 CVCL_CJ76 ND08107 transformed cell line human CVCL_CJ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148759 CVCL_CJ79 ND08151 transformed cell line human CVCL_CJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148760 CVCL_CJ70 ND08038 transformed cell line human CVCL_CJ70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148761 CVCL_LD09 RKO EGFR (S768I/+) cancer cell line human CVCL_LD09 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Ser768Ile (c.2303G>T); ClinVar=VCV000045251; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR mutation 21148762 CVCL_CJ73 ND08081 transformed cell line human CVCL_CJ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148763 CVCL_LD07 RKO EGFR (L858R/+) cancer cell line human CVCL_LD07 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR activating mutation 21148764 CVCL_CJ74 ND08082 transformed cell line human CVCL_CJ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148765 CVCL_LD08 RKO EGFR (L861Q/+) cancer cell line human CVCL_LD08 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu861Gln (c.2582T>A); ClinVar=VCV000163380; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR activating mutation 21148766 CVCL_LD05 NCI-H838 EGFR (L858R/+) cancer cell line human CVCL_LD05 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male Characteristics: Heterozygous knockin of a EGFR activating mutation 21148767 CVCL_CJ71 ND08039 transformed cell line human CVCL_CJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148768 CVCL_CJ72 ND08040 transformed cell line human CVCL_CJ72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148769 CVCL_LD06 RKO EGFR (C240Y/+) cancer cell line human CVCL_LD06 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Cys240Tyr (c.719G>A); Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR mutation 21148770 CVCL_LD25 UKKi018-A induced pluripotent stem cell human CVCL_LD25 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Glu58Gly (c.173A>G); ClinVar=VCV000067257; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21148771 CVCL_LD26 UKKi018-B induced pluripotent stem cell human CVCL_LD26 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Glu58Gly (c.173A>G); ClinVar=VCV000067257; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21148772 CVCL_LD23 UKKi017-B induced pluripotent stem cell human CVCL_LD23 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21148773 CVCL_LD24 UKKi017-C induced pluripotent stem cell human CVCL_LD24 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21148774 CVCL_LD21 UKKi020-D induced pluripotent stem cell human CVCL_LD21 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21148775 CVCL_LD22 UKKi017-A induced pluripotent stem cell human CVCL_LD22 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21148776 CVCL_LD20 UKKi020-C induced pluripotent stem cell human CVCL_LD20 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21148777 CVCL_CJ88 ND08187 transformed cell line human CVCL_CJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148778 CVCL_CJ89 ND08189 transformed cell line human CVCL_CJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148779 CVCL_CJ86 ND08164 transformed cell line human CVCL_CJ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148780 CVCL_CJ87 ND08181 transformed cell line human CVCL_CJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148781 CVCL_CJ80 ND08153 transformed cell line human CVCL_CJ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148782 CVCL_CJ81 ND08154 transformed cell line human CVCL_CJ81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148783 CVCL_CJ84 ND08162 transformed cell line human CVCL_CJ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148784 CVCL_LD18 UKKi020-A induced pluripotent stem cell human CVCL_LD18 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21148785 CVCL_CJ85 ND08163 transformed cell line human CVCL_CJ85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148786 CVCL_LD19 UKKi020-B induced pluripotent stem cell human CVCL_LD19 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21148787 CVCL_LD16 MCF-10A EGFR (L861Q/+) spontaneously immortalized cell line human CVCL_LD16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Leu861Gln (c.2582T>A); ClinVar=VCV000163380; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a EGFR activating mutation 21148788 CVCL_CJ82 ND08160 transformed cell line human CVCL_CJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148789 CVCL_LD17 MCF-10A EGFR (T790M/+) spontaneously immortalized cell line human CVCL_LD17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a EGFR mutation conferring drug resistance 21148790 CVCL_CJ83 ND08161 transformed cell line human CVCL_CJ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148791 CVCL_CJ55 ND07903 transformed cell line human CVCL_CJ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148792 CVCL_CJ56 ND07931 transformed cell line human CVCL_CJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148793 CVCL_CJ53 ND07827 transformed cell line human CVCL_CJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148794 CVCL_CJ54 ND07902 transformed cell line human CVCL_CJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148795 CVCL_CJ59 ND07942 transformed cell line human CVCL_CJ59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148796 CVCL_CJ57 ND07932 transformed cell line human CVCL_CJ57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148797 CVCL_CJ58 ND07941 transformed cell line human CVCL_CJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148798 CVCL_CJ51 ND07751 transformed cell line human CVCL_CJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148799 CVCL_CJ52 ND07752 transformed cell line human CVCL_CJ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148800 CVCL_CJ50 ND07691 transformed cell line human CVCL_CJ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148801 CVCL_LD03 SW48 NRAS (Q61K/+) cancer cell line human CVCL_LD03 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148802 CVCL_LD04 SW48 NRAS (Q61R/+) cancer cell line human CVCL_LD04 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148803 CVCL_LD01 SW48 NRAS (Q61H/+) cancer cell line human CVCL_LD01 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148804 CVCL_LD02 SW48 NRAS (Q61L/+) cancer cell line human CVCL_LD02 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148805 CVCL_LD00 SW48 NRAS (G12D/+) cancer cell line human CVCL_LD00 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148806 CVCL_CJ66 ND08007 transformed cell line human CVCL_CJ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148807 CVCL_CJ67 ND08011 transformed cell line human CVCL_CJ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148808 CVCL_CJ64 ND07975 transformed cell line human CVCL_CJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148809 CVCL_CJ65 ND08001 transformed cell line human CVCL_CJ65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148810 CVCL_CJ68 ND08012 transformed cell line human CVCL_CJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148811 CVCL_CJ69 ND08013 transformed cell line human CVCL_CJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148812 CVCL_CJ62 ND07946 transformed cell line human CVCL_CJ62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148813 CVCL_CJ63 ND07966 transformed cell line human CVCL_CJ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148814 CVCL_CJ60 ND07943 transformed cell line human CVCL_CJ60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148815 CVCL_CJ61 ND07945 transformed cell line human CVCL_CJ61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148816 CVCL_CJ39 ND07465 transformed cell line human CVCL_CJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148817 CVCL_CJ33 ND07419 transformed cell line human CVCL_CJ33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148818 CVCL_CJ34 ND07420 transformed cell line human CVCL_CJ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148819 CVCL_CJ31 ND07320 transformed cell line human CVCL_CJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148820 CVCL_CJ32 ND07406 transformed cell line human CVCL_CJ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148821 CVCL_CJ37 ND07463 transformed cell line human CVCL_CJ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148822 CVCL_CJ38 ND07464 transformed cell line human CVCL_CJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148823 CVCL_CJ35 ND07438 transformed cell line human CVCL_CJ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148824 CVCL_CJ36 ND07449 transformed cell line human CVCL_CJ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148825 CVCL_CJ30 ND07313 transformed cell line human CVCL_CJ30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148826 CVCL_CJ44 ND07520 transformed cell line human CVCL_CJ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148827 CVCL_CJ45 ND07530 transformed cell line human CVCL_CJ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148828 CVCL_CJ42 ND07514 transformed cell line human CVCL_CJ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148829 CVCL_CJ43 ND07515 transformed cell line human CVCL_CJ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148830 CVCL_CJ48 ND07663 transformed cell line human CVCL_CJ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148831 CVCL_CJ49 ND07690 transformed cell line human CVCL_CJ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148832 CVCL_CJ46 ND07603 transformed cell line human CVCL_CJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148833 CVCL_CJ47 ND07611 transformed cell line human CVCL_CJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148834 CVCL_CJ40 ND07486 transformed cell line human CVCL_CJ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148835 CVCL_CJ41 ND07495 transformed cell line human CVCL_CJ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148836 CVCL_CJ19 ND07254 transformed cell line human CVCL_CJ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148837 CVCL_CJ17 ND07240 transformed cell line human CVCL_CJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148838 CVCL_CJ18 ND07241 transformed cell line human CVCL_CJ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148839 CVCL_CJ11 ND07180 transformed cell line human CVCL_CJ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148840 CVCL_CJ12 ND07193 transformed cell line human CVCL_CJ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148841 CVCL_CJ10 ND07175 transformed cell line human CVCL_CJ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148842 CVCL_CJ15 ND07204 transformed cell line human CVCL_CJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148843 CVCL_CJ16 ND07224 transformed cell line human CVCL_CJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148844 CVCL_CJ13 ND07197 transformed cell line human CVCL_CJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148845 CVCL_CJ14 ND07202 transformed cell line human CVCL_CJ14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148846 CVCL_CJ28 ND07303 transformed cell line human CVCL_CJ28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148847 CVCL_CJ29 ND07312 transformed cell line human CVCL_CJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148848 CVCL_CJ22 ND07284 transformed cell line human CVCL_CJ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148849 CVCL_CJ23 ND07285 transformed cell line human CVCL_CJ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148850 CVCL_CJ20 ND07257 transformed cell line human CVCL_CJ20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148851 CVCL_CJ21 ND07262 transformed cell line human CVCL_CJ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148852 CVCL_CJ26 ND07288 transformed cell line human CVCL_CJ26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148853 CVCL_CJ27 ND07293 transformed cell line human CVCL_CJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148854 CVCL_CJ24 ND07286 transformed cell line human CVCL_CJ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148855 CVCL_CJ25 ND07287 transformed cell line human CVCL_CJ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148856 CVCL_LC79 LIM1215 KRAS (G12V/+) cancer cell line human CVCL_LC79 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148857 CVCL_LC77 LIM1215 KRAS (G12A/+) cancer cell line human CVCL_LC77 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148858 CVCL_LC78 LIM1215 KRAS (G12S/+) cancer cell line human CVCL_LC78 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148859 CVCL_LC75 HCC41 BL transformed cell line human CVCL_LC75 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148860 CVCL_LC76 LIM1215 KRAS (G12R/+) cancer cell line human CVCL_LC76 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148861 CVCL_LC73 PeTa cancer cell line human CVCL_LC73 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from sampling site: Skin. Omics: Array-based CGH; Omics: Deep quantitative proteome analysis Male Doubling time: 2-3 days (PubMed=30873613) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148862 CVCL_LC74 WoWe cancer cell line human CVCL_LC74 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Lower limb; skin. Omics: Array-based CGH; Omics: SNP array analysis Male Doubling time: 7 days (PubMed=30873613) 21148863 CVCL_LC71 AlDo cancer cell line human CVCL_LC71 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Back; skin. Omics: Array-based CGH; Omics: SNP array analysis Male Doubling time: 7 days (PubMed=30873613) 21148864 CVCL_LC72 KaRi cancer cell line human CVCL_LC72 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803). Unspecified 21148865 CVCL_LC70 293T-S transformed cell line human CVCL_LC70 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21148866 CVCL_LC88 SW48 KRAS (A146T/+) cancer cell line human CVCL_LC88 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21148867 CVCL_LC89 SW48 KRAS (A59T/+) cancer cell line human CVCL_LC89 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21148868 CVCL_LC86 A375 NRAS (Q61K/+/+) cancer cell line human CVCL_LC86 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21148869 CVCL_LC87 SW48 HRAS (G12V/+) cancer cell line human CVCL_LC87 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a HRAS activating mutation 21148870 CVCL_LC84 GeneBLAzer PAC1-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_LC84 CL:0000010 Transfected with: HGNC; 242; ADCYAP1R1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 21148871 CVCL_LC85 NCI-H1975 KRAS (G12D/+) cancer cell line human CVCL_LC85 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21148872 CVCL_LC82 LIM1215 KRAS (G13D/+) cancer cell line human CVCL_LC82 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148873 CVCL_LC83 EBC-1 KRAS (G12D/+/+/+) cancer cell line human CVCL_LC83 CL:0000010 Sequence variation: Mutation; HGNC; 2731; DDR2; Simple; p.Thr681Ile (c.2042C>T); ClinVar=VCV001435412; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Skin. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148874 CVCL_LC80 LIM1215 KRAS (G12D/+) cancer cell line human CVCL_LC80 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148875 CVCL_LC81 LIM1215 KRAS (G12C/+) cancer cell line human CVCL_LC81 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 21148876 CVCL_LC59 CRAM-13H33 hybridoma CVCL_LC59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9D8B7; Mouse Jam3. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2622 21148877 CVCL_LC57 343.11D1 hybridoma house mouse CVCL_LC57 From: Calbiochem-Behring Corp.; La Jolla; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18084; Human ITGB5. 21148878 CVCL_LC58 ValiScreen human CRTH2 spontaneously immortalized cell line CVCL_LC58 CL:0000010 Transfected with: HGNC; 4502; PTGDR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21148879 CVCL_LC55 32D G factor-dependent cell line house mouse CVCL_LC55 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: CSF3 dependent 21148880 CVCL_LC56 32D GM factor-dependent cell line house mouse CVCL_LC56 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: CSF2 dependent 21148881 CVCL_LC53 442.5C4 hybridoma house mouse CVCL_LC53 From: Calbiochem-Behring Corp.; La Jolla; USA CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P18564; Human ITGB6. 21148882 CVCL_LC54 32D Epo1 factor-dependent cell line house mouse CVCL_LC54 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 or EPO dependent 21148883 CVCL_LC51 BCLC-6 cancer cell line human CVCL_LC51 CL:0000010 Male Virology: Permissive for hepatitis C virus entry and replication. 21148884 CVCL_LC52 BCLC-10 cancer cell line human CVCL_LC52 CL:0000010 Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Virology: Permissive for hepatitis C virus entry and replication 21148885 CVCL_LC50 BCLC-5 cancer cell line human CVCL_LC50 CL:0000010 Female Virology: Permissive for hepatitis C virus entry and replication. 21148886 CVCL_LC68 PrecisION hNav1.6-HEK transformed cell line human CVCL_LC68 CL:0000010 Transfected with: HGNC; 10596; SCN8A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3010; true Female 21148887 CVCL_LC69 293T/pAPtag-4 transformed cell line human CVCL_LC69 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21148888 CVCL_LC66 PrecisION hNav1.2-CHO spontaneously immortalized cell line CVCL_LC66 CL:0000010 Transfected with: HGNC; 10588; SCN2A Derived from sampling site: Ovary. Discontinued: Millipore; CYL3023; true Female 21148889 CVCL_LC67 PrecisION hNav1.5-HEK transformed cell line human CVCL_LC67 CL:0000010 Transfected with: HGNC; 10593; SCN5A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3004; true Female 21148890 CVCL_LC64 PrecisION hKCNQ1/hminK-CHO spontaneously immortalized cell line CVCL_LC64 CL:0000010 Transfected with: HGNC; 6240; KCNE1; Transfected with: HGNC; 6294; KCNQ1 Derived from sampling site: Ovary. Discontinued: Millipore; CYL3007; true Female 21148891 CVCL_LC65 PrecisION hKv1.5-CHO spontaneously immortalized cell line CVCL_LC65 CL:0000010 Transfected with: HGNC; 6224; KCNA5 Derived from sampling site: Ovary. Discontinued: Millipore; CYL3018; true Female 21148892 CVCL_LC62 PrecisION hERG-HEK transformed cell line human CVCL_LC62 CL:0000010 Transfected with: HGNC; 6251; KCNH2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Millipore; CYL3039; true Female 21148893 CVCL_LC63 LTK-MOG transformed cell line house mouse CVCL_LC63 CL:0000010 Transfected with: HGNC; 7197; MOG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21148894 CVCL_LC60 CRAM-19H36 hybridoma CVCL_LC60 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9D8B7; Mouse Jam3 (Note=Also reacts with human). 21148895 CVCL_LC61 CRAM-18F26 hybridoma CVCL_LC61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9D8B7; Mouse Jam3 (Note=Also reacts with human). 21148896 CVCL_LC37 TYEK-1 cancer cell line human CVCL_LC37 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Unspecified (JCRB) Population: Japanese; Derived from sampling site: Pharynx. Male 21148897 CVCL_LC38 MK-19 finite cell line human CVCL_LC38 CL:0000010 Discontinued: JCRB; JCRB3047; probable. Unspecified 21148898 CVCL_LC35 FEPE1L-8 transformed cell line human CVCL_LC35 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21148899 CVCL_LC36 FEPE1L-9 transformed cell line human CVCL_LC36 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21148900 CVCL_LC33 FEP18-5 transformed cell line human CVCL_LC33 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21148901 CVCL_LC34 FEP18-11 transformed cell line human CVCL_LC34 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21148902 CVCL_LC31 FEAB10 transformed cell line human CVCL_LC31 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human herpesvirus 2 (HHV-2)(NCBI-Taxonomy; 10310); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21148903 CVCL_LC32 FEH18L transformed cell line human CVCL_LC32 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21148904 CVCL_LC30 FEAT transformed cell line human CVCL_LC30 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: 12-O-tetradecanoylphorbol-13-acetate (TPA)(ChEBI; CHEBI:37537); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21148905 CVCL_CI98 ND07084 transformed cell line human CVCL_CI98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148906 CVCL_CI99 ND07087 transformed cell line human CVCL_CI99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148907 CVCL_CI92 ND06967 transformed cell line human CVCL_CI92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148908 CVCL_CI93 ND06996 transformed cell line human CVCL_CI93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148909 CVCL_CI90 ND06965 transformed cell line human CVCL_CI90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148910 CVCL_CI91 ND06966 transformed cell line human CVCL_CI91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148911 CVCL_CI96 ND07030 transformed cell line human CVCL_CI96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148912 CVCL_CI97 ND07083 transformed cell line human CVCL_CI97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148913 CVCL_CI94 ND06997 transformed cell line human CVCL_CI94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148914 CVCL_LC28 UOK276 cancer cell line human CVCL_LC28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (PubMed=28736828); Sequence variation: Mutation; HGNC; 20456; TRAF7; Simple; p.Pro22_Thr25del; Zygosity=Homozygous; Note=Heterozygous mutation in germline of patient (PubMed=28736828) Miscellaneous: Doubling time from personal communication of Yang Y. Omics: Mitochondrial genome sequenced Male Doubling time: ~24 hours (Direct_author_submission) 21148915 CVCL_LC29 FE-A transformed cell line human CVCL_LC29 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21148916 CVCL_CI95 ND07029 transformed cell line human CVCL_CI95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148917 CVCL_LC48 BCLC-3 cancer cell line human CVCL_LC48 CL:0000010 Male Virology: Permissive for hepatitis C virus entry and replication. 21148918 CVCL_LC49 BCLC-4 cancer cell line human CVCL_LC49 CL:0000010 Female Virology: Permissive for hepatitis C virus entry and replication. 21148919 CVCL_LC46 BCLC-1 cancer cell line human CVCL_LC46 CL:0000010 Male Virology: Permissive for hepatitis C virus entry and replication. 21148920 CVCL_LC47 BCLC-2 cancer cell line human CVCL_LC47 CL:0000010 Male Virology: Permissive for hepatitis C virus entry and replication. 21148921 CVCL_LC44 MSN53 finite cell line human CVCL_LC44 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex16-18del (nsv1067857); ClinVar=VCV000003711; Zygosity=Heterozygous (PubMed=6272292) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21148922 CVCL_LC45 YS2 finite cell line human CVCL_LC45 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.1845+2T>C; ClinVar=VCV000252070; Zygosity=Homozygous; Note=Splice donor mutation (JCRB) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21148923 CVCL_LC42 AK28 finite cell line human CVCL_LC42 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.1845+2T>C; ClinVar=VCV000252070; Zygosity=Heterozygous; Note=Splice donor mutation (JCRB) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21148924 CVCL_LC43 KS32 finite cell line human CVCL_LC43 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.1845+2T>C; ClinVar=VCV000252070; Zygosity=Heterozygous; Note=Splice donor mutation (JCRB) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21148925 CVCL_LC40 MK-37c finite cell line human CVCL_LC40 CL:0000010 Derived from sampling site: Fallopian tube. Discontinued: JCRB; KURB2732; probable Ambiguous 21148926 CVCL_LC41 NCMDF finite cell line CVCL_LC41 CL:0000010 Derived from sampling site: Abdomen; skin; dermis Cell type=Fibroblast.. Male Group: Non-human primate cell line 21148927 CVCL_LC39 MK-2 finite cell line human CVCL_LC39 CL:0000010 Population: Japanese; Karyotypic information: 47,XY,+21 (JCRB) Discontinued: JCRB; KURB2766; probable. Female 21148928 CVCL_LC15 H460-16-2 hybridoma house mouse CVCL_LC15 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4621 21148929 CVCL_LC16 H460-22-1 hybridoma house mouse CVCL_LC16 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P08962; Human CD63. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4622 21148930 CVCL_LC13 7BD-33-11A hybridoma house mouse CVCL_LC13 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08962; Human CD63. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4890 21148931 CVCL_LC14 7BDI-60 hybridoma house mouse CVCL_LC14 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4623 21148932 CVCL_LC11 HLB transformed cell line human CVCL_LC11 CL:0000010 Female Virology: Infected by squirrel monkey retrovirus (SMRV). 21148933 CVCL_LC12 7BD-14 hybridoma house mouse CVCL_LC12 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2697 21148934 CVCL_LC10 5LAC-20 hybridoma house mouse CVCL_LC10 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2694 21148935 CVCL_CI78 ND06903 transformed cell line human CVCL_CI78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148936 CVCL_CI79 ND06910 transformed cell line human CVCL_CI79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148937 CVCL_CI76 ND06877 transformed cell line human CVCL_CI76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148938 CVCL_CI77 ND06879 transformed cell line human CVCL_CI77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148939 CVCL_CI70 ND06857 transformed cell line human CVCL_CI70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148940 CVCL_CI71 ND06858 transformed cell line human CVCL_CI71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148941 CVCL_LC08 3BD-27 hybridoma house mouse CVCL_LC08 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2698 21148942 CVCL_CI74 ND06875 transformed cell line human CVCL_CI74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148943 CVCL_LC09 3BD-8 hybridoma house mouse CVCL_LC09 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2696 21148944 CVCL_CI75 ND06876 transformed cell line human CVCL_CI75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148945 CVCL_LC06 1LN-8 hybridoma house mouse CVCL_LC06 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2693 21148946 CVCL_CI72 ND06860 transformed cell line human CVCL_CI72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148947 CVCL_LC07 3BD-26 hybridoma house mouse CVCL_LC07 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2695 21148948 CVCL_CI73 ND06861 transformed cell line human CVCL_CI73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148949 CVCL_LC26 NYSCFe001-A embryonic stem cell human CVCL_LC26 From: New York Stem Cell Foundation; New York; USA CL:0000010 Female Characteristics: Derived in feeder free and antibiotic free conditions. Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0389 21148950 CVCL_LC27 NYSCFe002-A embryonic stem cell human CVCL_LC27 From: New York Stem Cell Foundation; New York; USA CL:0000010 Female Characteristics: Derived in feeder free and antibiotic free conditions. Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0390 21148951 CVCL_LC24 Elf4 embryonic stem cell human CVCL_LC24 From: University of Washington; Seattle; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0398. 21148952 CVCL_LC25 Elm2 embryonic stem cell human CVCL_LC25 From: University of Washington; Seattle; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0396. 21148953 CVCL_LC22 1.1ASML hybridoma house mouse CVCL_LC22 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26051; Rat Cd44 (isoform V6). 21148954 CVCL_LC23 Elf3 embryonic stem cell human CVCL_LC23 From: University of Washington; Seattle; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-18-0397. 21148955 CVCL_LC20 HLB-B1 transformed cell line human CVCL_LC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified 21148956 CVCL_LC21 GKW.A3 hybridoma house mouse CVCL_LC21 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21148957 CVCL_CI89 ND06961 transformed cell line human CVCL_CI89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148958 CVCL_CI87 ND06944 transformed cell line human CVCL_CI87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148959 CVCL_CI88 ND06945 transformed cell line human CVCL_CI88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21148960 CVCL_CI81 ND06926 transformed cell line human CVCL_CI81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148961 CVCL_CI82 ND06930 transformed cell line human CVCL_CI82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148962 CVCL_CI80 ND06918 transformed cell line human CVCL_CI80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148963 CVCL_LC19 HLB-R1 transformed cell line human CVCL_LC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified 21148964 CVCL_CI85 ND06941 transformed cell line human CVCL_CI85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148965 CVCL_CI86 ND06943 transformed cell line human CVCL_CI86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148966 CVCL_LC17 H460-23 hybridoma house mouse CVCL_LC17 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2700 21148967 CVCL_CI83 ND06939 transformed cell line human CVCL_CI83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148968 CVCL_LC18 H460-27 hybridoma house mouse CVCL_LC18 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2699 21148969 CVCL_CI84 ND06940 transformed cell line human CVCL_CI84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21148970 CVCL_1V42 ND00707 transformed cell line human CVCL_1V42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148971 CVCL_2742 UM-RC-7 cancer cell line human CVCL_2742 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Pro61Alafs*61 (c.180_208del); Zygosity=Unspecified (PubMed=7915601). Male Doubling time: ~53 hours (PubMed=4038766) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148972 CVCL_1V43 ND00709 transformed cell line human CVCL_1V43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148973 CVCL_2743 UM-UC-1 cancer cell line human CVCL_2743 HLA typing: A*30:02,36:01; B*35:01,53:01; C*04:01,16:01 (PubMed=26589293); Genome ancestry: African=85.83%; Native American=0%; East Asian, North=2.25%; East Asian, South=0%; South Asian=0%; European, North=2.87%; European, South=9.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1102; BRD1; Simple; p.Gln340Ter (c.1018C>T); Zygosity=Heterozygous (PubMed=27270441) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26 hours (PubMed=3761468) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148974 CVCL_1V40 ND00702 transformed cell line human CVCL_1V40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148975 CVCL_2740 UM-RC-3 cancer cell line human CVCL_2740 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu89His (c.266T>A); ClinVar=VCV000376047; Zygosity=Unspecified (PubMed=7915601) Omics: GPI-anchored proteins analysis by proteomics. Unspecified Doubling time: ~29 hours (PubMed=4038766) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148976 CVCL_1V41 ND00706 transformed cell line human CVCL_1V41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148977 CVCL_2741 UM-RC-6 cancer cell line human CVCL_2741 Genome ancestry: African=81.78%; Native American=0.05%; East Asian, North=2.02%; East Asian, South=0%; South Asian=0%; European, North=4.24%; European, South=11.91% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser168Argfs*3 (c.504_511del); Zygosity=Unspecified (PubMed=7915601); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val170Argfs*29 (c.502_511del10); Zygosity=Unspecified (PubMed=8493574) Male Doubling time: ~43 hours (PubMed=4038766) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148978 CVCL_1V46 ND00727 transformed cell line human CVCL_1V46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148979 CVCL_2746 UM-UC-13 cancer cell line human CVCL_2746 CL:0000010 Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index 21148980 CVCL_1V47 ND00728 transformed cell line human CVCL_1V47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148981 CVCL_2747 UM-UC-14 cancer cell line human CVCL_2747 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Unspecified (DepMap) Derived from sampling site: Kidney; renal pelvis. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148982 CVCL_1V44 ND00714 transformed cell line human CVCL_1V44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148983 CVCL_2744 UM-UC-10 cancer cell line human CVCL_2744 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (DepMap) Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148984 CVCL_1V45 ND00723 transformed cell line human CVCL_1V45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148985 CVCL_2745 UM-UC-11 cancer cell line human CVCL_2745 CL:0000010 Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148986 CVCL_1V48 ND00745 transformed cell line human CVCL_1V48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148987 CVCL_2748 UM-UC-16 cancer cell line human CVCL_2748 CL:0000010 Derived from sampling site: Urinary bladder. Omics: Deep exome analysis Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148988 CVCL_1V49 ND00940 transformed cell line human CVCL_1V49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148989 CVCL_2749 UM-UC-4 cancer cell line human CVCL_2749 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Arg (c.389T>G); Zygosity=Unspecified (DepMap) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 32 hours (PubMed=3761468) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148990 CVCL_1V50 ND01042 transformed cell line human CVCL_1V50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21148991 CVCL_2750 UM-UC-5 cancer cell line human CVCL_2750 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (DepMap) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 19 hours (PubMed=3761468) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148992 CVCL_1V53 ND01205 transformed cell line human CVCL_1V53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148993 CVCL_2753 UM-UC-9 cancer cell line human CVCL_2753 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2888Thr (c.8663T>C); ClinVar=VCV000245842; Zygosity=Heterozygous (PubMed=27270441); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu348fs (c.1044delG); Zygosity=Unspecified (PubMed=27270441) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: UBC-40 urothelial bladder cancer cell line index Caution: PubMed=27270441 reports a STR profile (CSF1PO: 10; D13S317 21148994 CVCL_1V54 ND01207 transformed cell line human CVCL_1V54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148995 CVCL_2754 VP229 cancer cell line human CVCL_2754 CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Hemizygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=10700188; DepMap) Omics: Deep exome analysis; Omics: miRNA expression profiling. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21148996 CVCL_1V51 ND01096 transformed cell line human CVCL_1V51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148997 CVCL_2751 UM-UC-6 cancer cell line human CVCL_2751 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu198Ter (c.592G>T); ClinVar=VCV000634704; Zygosity=Homozygous (PubMed=27270441) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 38 hours (PubMed=3761468) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21148998 CVCL_1V52 ND01099 transformed cell line human CVCL_1V52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21148999 CVCL_2752 UM-UC-7 cancer cell line human CVCL_2752 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (DepMap) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 41 hours (PubMed=3761468) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: UBC-40 urothelial bladder cancer cell line index 21149000 CVCL_1V57 ND01220 transformed cell line human CVCL_1V57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149001 CVCL_1V58 ND01277 transformed cell line human CVCL_1V58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149002 CVCL_2758 WI-26 VA4 transformed cell line human CVCL_2758 CL:0000010 Population: Caucasian; Swedish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: SNP array analysis Male Doubling time: ~42 hours (lot 02102015) (JCRB) 21149003 CVCL_1V55 ND01212 transformed cell line human CVCL_1V55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149004 CVCL_2755 VP267 cancer cell line human CVCL_2755 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=29045385) Omics: Deep exome analysis. Female 21149005 CVCL_1V56 ND01217 transformed cell line human CVCL_1V56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149006 CVCL_2756 VP303 cancer cell line human CVCL_2756 CL:0000010 Female 21149007 CVCL_1V59 ND01317 transformed cell line human CVCL_1V59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149008 CVCL_2759 WI-38 VA13 subline 2RA transformed cell line human CVCL_2759 CL:0000010 Population: Caucasian; Swedish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21149009 CVCL_1V20 GM03495 finite cell line human CVCL_1V20 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03495; probable Male 21149010 CVCL_2720 SerBob cancer cell line human CVCL_2720 CL:0000010 Male Characteristics: Adapted to growth in a medium containing serum. 21149011 CVCL_1V21 GM00512 finite cell line human CVCL_1V21 CL:0000010 Population: Indian; Derived from sampling site: Cell type=Fibroblast. Female 21149012 CVCL_2721 Shh Light II spontaneously immortalized cell line house mouse CVCL_2721 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-2795; true; Discontinued: ATCC; JHU-68; true Male 21149013 CVCL_1V24 GM01255 finite cell line human CVCL_1V24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149014 CVCL_2724 SIRC spontaneously immortalized cell line CVCL_2724 CL:0000010 Derived from sampling site: Eye; cornea. Discontinued: ATCC; CRL-6595; true Unspecified Characteristics: Expresses a mix of epithelial and fibroblastic markers (PubMed=29653143); Virology: Can be used for isolation and growth of rubella virus; Virology: Not susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Doubling time: ~31 hours (lot 11132012), ~1.5 days (lot 10272017) (JCRB) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21149015 CVCL_1V25 GM02845 finite cell line human CVCL_1V25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149016 CVCL_2725 SWLA1 hybridoma house mouse CVCL_2725 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Streptococcus mutans cell surface lipooligosaccharide or lipopolysaccharide. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12559 21149017 CVCL_1V22 GM00963 finite cell line human CVCL_1V22 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149018 CVCL_2722 Shmac 4 transformed cell line human CVCL_2722 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149019 CVCL_1V23 GM01254 finite cell line human CVCL_1V23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149020 CVCL_2723 Shmac 5 transformed cell line human CVCL_2723 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149021 CVCL_1V28 GM11495 finite cell line human CVCL_1V28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149022 CVCL_2728 T24/83 cancer cell line human CVCL_2728 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female 21149023 CVCL_1V29 ND00412 transformed cell line human CVCL_1V29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149024 CVCL_2729 TAK3 transformed cell line human CVCL_2729 CL:0000010 Sequence variation: Gene deletion; HGNC; 5523; IGHEP1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5525; IGHG1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5526; IGHG2; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5528; IGHG4; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5529; IGHGP; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143) Population: Tunisian; Berber; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Characteristics: Homozygous for deletion of IGH G1-EP1-A1-GP-G2-G4 21149025 CVCL_1V26 GM02846 finite cell line human CVCL_1V26 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21149026 CVCL_2726 SWLA2 hybridoma house mouse CVCL_2726 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Streptococcus mutans cell surface lipooligosaccharide or lipopolysaccharide. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12560 21149027 CVCL_1V27 GM02847 finite cell line human CVCL_1V27 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21149028 CVCL_2727 SWLA3 hybridoma house mouse CVCL_2727 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Streptococcus mutans cell surface lipooligosaccharide or lipopolysaccharide. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12558 21149029 CVCL_1V31 ND00592 transformed cell line human CVCL_1V31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149030 CVCL_2731 TE 671 Subline No.2 cancer cell line human CVCL_2731 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Discontinued: BCRC; 60324; true; Discontinued: ECACC; 94052610; probable Female Doubling time: 27 hours (PubMed=2993532) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00347; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8805 Problematic cell line: Contaminated Parent cell line (TE 671) has been shown to be a RD derivative (PubMed=2739733; PubMed=20143388). 21149031 CVCL_1V32 ND00665 transformed cell line human CVCL_1V32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149032 CVCL_2732 TFTB1 hybridoma house mouse CVCL_2732 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (B chain). 21149033 CVCL_1V30 ND00528 transformed cell line human CVCL_1V30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149034 CVCL_2730 Tb 1 Lu finite cell line CVCL_2730 CL:0000010 Derived from sampling site: Lung Cell type=Epithelial cell.. Discontinued: ATCC; CRL-6564; true Female Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Bat cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21149035 CVCL_1V35 ND00677 transformed cell line human CVCL_1V35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149036 CVCL_2735 TOU (TOU I-2) transformed cell line human CVCL_2735 CL:0000010 Sequence variation: Gene deletion; HGNC; 5478; IGHA1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5523; IGHEP1; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5525; IGHG1; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5526; IGHG2; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5528; IGHG4; Zygosity=Heterozygous (PubMed=6438434; PubMed=6817143); Sequence variation: Gene deletion; HGNC; 5529; IGHGP; Zygosity=Homozygous (PubMed=6438434; PubMed=6817143) Population: Tunisian; Berber; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Characteristics: Heterozygous for deletion of IGH G1-EP1-A1-GP-G2-G4 and of EP1-A1-GP 21149037 CVCL_1V36 ND00679 transformed cell line human CVCL_1V36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149038 CVCL_2736 TR146 cancer cell line human CVCL_2736 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Female Doubling time: 22 hours (PubMed=2413234) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21149039 CVCL_1V33 ND00672 transformed cell line human CVCL_1V33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149040 CVCL_2733 TK6TGR transformed cell line human CVCL_2733 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Male 21149041 CVCL_1V34 ND00674 transformed cell line human CVCL_1V34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149042 CVCL_2734 TO14 cancer cell line human CVCL_2734 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (DepMap) Derived from metastatic site: Omentum. Omics: Deep exome analysis Female Doubling time: 130 hours (PubMed=3167863) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149043 CVCL_1V39 ND00700 transformed cell line human CVCL_1V39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149044 CVCL_2739 UM-RC-2 cancer cell line human CVCL_2739 Genome ancestry: African=5.05%; Native American=0.53%; East Asian, North=4.92%; East Asian, South=0%; South Asian=0%; European, North=55.48%; European, South=34.02% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Arg82Pro (c.245G>C); ClinVar=VCV000193118; Zygosity=Unspecified (PubMed=7915601) Unspecified Doubling time: ~24 hours (PubMed=4038766) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149045 CVCL_1V37 ND00689 transformed cell line human CVCL_1V37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149046 CVCL_2737 tsA201 transformed cell line human CVCL_2737 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21149047 CVCL_1V38 ND00694 transformed cell line human CVCL_1V38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149048 CVCL_2738 U-BLC1 cancer cell line human CVCL_2738 HLA typing: A*01:01,01:01; B*07:02,13:02; C*02:02,06:02; DQB1*05:02,06:02; DRB1*15:01,16:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His296Tyr (c.886C>T); ClinVar=VCV000132973; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149049 CVCL_1V08 GM02000 finite cell line human CVCL_1V08 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Glu408Lys (c.1222G>A) (E387K); ClinVar=VCV000036453; Zygosity=Homozygous (PubMed=29308438) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21149050 CVCL_2708 RFL-6 finite cell line Norway rat CVCL_2708 CL:0000010 Derived from sampling site: Embryonic lung Cell type=Fibroblast.; Breed/subspecies: Sprague Dawley. Unspecified Senescence: Capable of at least 45 PDL 21149051 CVCL_1V09 GM00799 finite cell line human CVCL_1V09 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (from familial inference of GM00798) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21149052 CVCL_2709 RL-33 spontaneously immortalized cell line CVCL_2709 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Japanese white. Discontinued: JCRB; NIHS0180; true Unspecified 21149053 CVCL_1V02 HROC296 cancer cell line human CVCL_1V02 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; ascending. Female Doubling time: 29 hours (CLS); Microsatellite instability: Stable (MSS) (Direct_author_submission) 21149054 CVCL_2702 Ramos-AW cancer cell line human CVCL_2702 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) 21149055 CVCL_1V03 LdlD spontaneously immortalized cell line CVCL_1V03 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Defective in UDP-Gal/UDP-GalNAc 4-epimerase 21149056 CVCL_2703 Ramos-EHRB cancer cell line human CVCL_2703 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from P3HR-1 cell line (Cellosaurus=CVCL_2676) 21149057 CVCL_1V00 HROC324 cancer cell line human CVCL_1V00 HLA typing: A*03:01:01; B*07:02:01; C*07:02:01; DPB1*02:01:02; DQA1*01:02:01; DQB1*06:04:01G; DRB1*13:02:01G (CLS=300838) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cecum. Female Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21149058 CVCL_2700 RAJI TK+ cancer cell line human CVCL_2700 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21149059 CVCL_1V01 HROC103Met cancer cell line human CVCL_1V01 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (Direct_author_submission) 21149060 CVCL_2701 RAJI TK- cancer cell line human CVCL_2701 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21149061 CVCL_1V06 ND14297 transformed cell line human CVCL_1V06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149062 CVCL_2706 RCC4/VHL cancer cell line human CVCL_2706 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Trp (c.194C>G); ClinVar=VCV000043597; Zygosity=Hemizygous (from parent cell line); Transfected with: HGNC; 12687; VHL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified 21149063 CVCL_1V07 ND14298 transformed cell line human CVCL_1V07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149064 CVCL_2707 REM 885 transformed cell line human CVCL_2707 CL:0000010 Sequence variation: Gene amplification; HGNC; 620; APP; Duplication; Zygosity=Unspecified (PubMed=16369530) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149065 CVCL_1V04 GM01108 finite cell line human CVCL_1V04 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Glu482Lys (c.1444G>A); ClinVar=VCV000003892; Zygosity=Heterozygous (By familial inference of GM01110) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21149066 CVCL_2704 RB247C cancer cell line human CVCL_2704 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Pro39Argfs*26 (c.116delC); Zygosity=Heterozygous (PubMed=30584916); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly617Argfs*36 (c.1848dup); Zygosity=Heterozygous (PubMed=30584916) Omics: Transcriptome analysis by microarray. Male 21149067 CVCL_1V05 GM01109 finite cell line human CVCL_1V05 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Glu482Lys (c.1444G>A); ClinVar=VCV000003892; Zygosity=Heterozygous (By familial inference of GM01110) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149068 CVCL_2705 RC-1 [Rabbit cornea] spontaneously immortalized cell line CVCL_2705 CL:0000010 Derived from sampling site: Eye; cornea; Breed/subspecies: Japanese white. Unspecified Doubling time: ~60 hours (lot 04142003) (JCRB) 21149069 CVCL_1V19 GM02594 finite cell line human CVCL_1V19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(6;9)(6pter->6q13::9p22->9pter;9qter->9p22::6q13->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21149070 CVCL_2719 SVCT-MI2 transformed cell line human CVCL_2719 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female Characteristics: Tumorigenic in nude mice (ECACC) 21149071 CVCL_1V10 GM00800 finite cell line human CVCL_1V10 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (from familial inference of GM00798) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149072 CVCL_2710 RPMI-1788 transformed cell line human CVCL_2710 HLA typing: A*02:01:01,33:01:01; B*07:06:01,14:01:01; C*08:02:01,15:05:02; DPA1*01:03:01,02:01:01; DPB1*45:01,124:01:NEW; DQA1*02:01:01,03:03:01; DQB1*02:02:01,03:02:01; DRB1*04:05:01,07:01:01; DRB4*01:01:01,01:03:01 (PubMed=29959025); HLA typing: A*02:01:01,09:01:01; B*07:06:01,14:01:01; C*08:02:01,15:05:02; DPB1*03:01:01G,21:01; DQA1*02:01:01,03:03:01; DQB1*02:02:01,03:02:01; DRB1*04:05:01,07:01:01 (CLS=300318) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: KCLB; 10156; probable Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21149073 CVCL_1V13 GM01391 finite cell line human CVCL_1V13 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21149074 CVCL_2713 RPMI-7932 cancer cell line human CVCL_2713 HLA typing: A*02,03; B*07,w40 (PubMed=77569) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Pleural effusion. Omics: CNV analysis; Omics: SNP array analysis Female Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma 21149075 CVCL_1V14 GM01392 finite cell line human CVCL_1V14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21149076 CVCL_2714 RT112/84 cancer cell line human CVCL_2714 Genome ancestry: African=2.22%; Native American=0%; East Asian, North=2.64%; East Asian, South=0%; South Asian=0%; European, North=59.02%; European, South=36.11% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149077 CVCL_1V11 GM01034 transformed cell line human CVCL_1V11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149078 CVCL_2711 RPMI-1846 cancer cell line CVCL_2711 CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.. Unspecified Doubling time: ~36 hours (PubMed=14071829) 21149079 CVCL_1V12 GM01867 transformed cell line human CVCL_1V12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM01867; probable Female 21149080 CVCL_2712 RPMI-7666 transformed cell line human CVCL_2712 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Discontinued: KCLB; 10114; probable Male 21149081 CVCL_1V17 GM01256 finite cell line human CVCL_1V17 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; c.590-7G>A (IVS5AS-7G>A); ClinVar=VCV000222996; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149082 CVCL_1V18 GM01323 finite cell line human CVCL_1V18 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; c.590-7G>A (IVS5AS-7G>A); ClinVar=VCV000222996; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149083 CVCL_2718 SVCT transformed cell line human CVCL_2718 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female 21149084 CVCL_1V15 GM01393 finite cell line human CVCL_1V15 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21149085 CVCL_2715 RT4/31 cancer cell line human CVCL_2715 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Leu557Cysfs*72 (c.1669delC); ClinVar=VCV000048811; Zygosity=Homozygous (from parent cell line). Male 21149086 CVCL_1V16 GM06214 finite cell line human CVCL_1V16 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149087 CVCL_2716 S1814.PB5 finite cell line human CVCL_2716 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21149088 CVCL_LC99 SW48 NRAS (K117N/+) cancer cell line human CVCL_LC99 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Lys117Asn (c.351G>T); Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21149089 CVCL_LC97 SW48 KRAS (Q61H/+) cancer cell line human CVCL_LC97 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149090 CVCL_LC98 SW48 NRAS (A59T/+) cancer cell line human CVCL_LC98 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Ala59Thr (c.175G>A); ClinVar=VCV000040473; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 21149091 CVCL_LC95 SW48 KRAS (G12V/+) cancer cell line human CVCL_LC95 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149092 CVCL_LC96 SW48 KRAS (G13D/+) cancer cell line human CVCL_LC96 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149093 CVCL_LC93 SW48 KRAS (G12S/+) cancer cell line human CVCL_LC93 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149094 CVCL_LC94 SW48 KRAS (G12R/+) cancer cell line human CVCL_LC94 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149095 CVCL_LC91 SW48 KRAS (G12C/+) cancer cell line human CVCL_LC91 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149096 CVCL_LC92 SW48 KRAS (G12D/+) cancer cell line human CVCL_LC92 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149097 CVCL_LC90 SW48 KRAS (G12A/+) cancer cell line human CVCL_LC90 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149098 CVCL_CK18 ND08381 transformed cell line human CVCL_CK18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149099 CVCL_CK19 ND08382 transformed cell line human CVCL_CK19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149100 CVCL_CK16 ND08346 transformed cell line human CVCL_CK16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149101 CVCL_CK17 ND08347 transformed cell line human CVCL_CK17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149102 CVCL_CK10 ND08299 transformed cell line human CVCL_CK10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149103 CVCL_CK11 ND08300 transformed cell line human CVCL_CK11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149104 CVCL_CK14 ND08312 transformed cell line human CVCL_CK14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149105 CVCL_CK15 ND08329 transformed cell line human CVCL_CK15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149106 CVCL_CK12 ND08301 transformed cell line human CVCL_CK12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149107 CVCL_CK13 ND08306 transformed cell line human CVCL_CK13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149108 CVCL_CK29 ND08571 transformed cell line human CVCL_CK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149109 CVCL_CK27 ND08568 transformed cell line human CVCL_CK27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149110 CVCL_CK28 ND08569 transformed cell line human CVCL_CK28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149111 CVCL_CK21 ND08405 transformed cell line human CVCL_CK21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149112 CVCL_CK22 ND08461 transformed cell line human CVCL_CK22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149113 CVCL_CK20 ND08388 transformed cell line human CVCL_CK20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149114 CVCL_CK25 ND08486 transformed cell line human CVCL_CK25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149115 CVCL_CK26 ND08528 transformed cell line human CVCL_CK26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149116 CVCL_CK23 ND08471 transformed cell line human CVCL_CK23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149117 CVCL_CK24 ND08472 transformed cell line human CVCL_CK24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149118 CVCL_CK07 ND08296 transformed cell line human CVCL_CK07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149119 CVCL_CK08 ND08297 transformed cell line human CVCL_CK08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149120 CVCL_CK05 ND08288 transformed cell line human CVCL_CK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149121 CVCL_CK06 ND08295 transformed cell line human CVCL_CK06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149122 CVCL_CK09 ND08298 transformed cell line human CVCL_CK09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149123 CVCL_CK00 ND08237 transformed cell line human CVCL_CK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149124 CVCL_CK03 ND08254 transformed cell line human CVCL_CK03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149125 CVCL_CK04 ND08268 transformed cell line human CVCL_CK04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149126 CVCL_CK01 ND08245 transformed cell line human CVCL_CK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149127 CVCL_CK02 ND08246 transformed cell line human CVCL_CK02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149128 CVCL_2881 CS2OS finite cell line human CVCL_2881 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (PubMed=12655141) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149129 CVCL_1W81 ND03633 transformed cell line human CVCL_1W81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149130 CVCL_2882 CS2OS(SVT) transformed cell line human CVCL_2882 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0305; true Male 21149131 CVCL_1W82 ND03660 transformed cell line human CVCL_1W82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149132 CVCL_2880 CS2AWTERT telomerase immortalized cell line human CVCL_2880 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0309; true Female 21149133 CVCL_1W80 ND03628 transformed cell line human CVCL_1W80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149134 CVCL_2885 De Gin finite cell line human CVCL_2885 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1133; true Female 21149135 CVCL_1W85 ND03663 transformed cell line human CVCL_1W85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149136 CVCL_2886 Dede spontaneously immortalized cell line CVCL_2886 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21149137 CVCL_1W86 ND03664 transformed cell line human CVCL_1W86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149138 CVCL_2883 D422T finite cell line human CVCL_2883 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen (Note=From a desmoid tumor) Cell type=Fibroblast.. Discontinued: ATCC; CRL-1659; true; Discontinued: JCRB; JCRB9112; true Male 21149139 CVCL_1W83 ND03661 transformed cell line human CVCL_1W83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149140 CVCL_2884 D98/AH2 Clone B cancer cell line human CVCL_2884 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:136532; 8-azahypoxanthine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00301 Problematic cell line: Contaminated Ancestral cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=20143388). 21149141 CVCL_1W84 ND03662 transformed cell line human CVCL_1W84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149142 CVCL_2889 DL-40 cancer cell line human CVCL_2889 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0542; true Female Doubling time: 72 hours (PubMed=1979248) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149143 CVCL_1W89 ND03710 transformed cell line human CVCL_1W89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149144 CVCL_2887 delta-47 cancer cell line human CVCL_2887 CL:0000010 Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ5 (CelloPub=CLPUB00604) Population: Japanese; Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0543; true Male Characteristics: Produces IgD lambda Doubling time: 40 hours (PubMed=1329502) 21149145 CVCL_1W87 ND03665 transformed cell line human CVCL_1W87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149146 CVCL_2888 Dempsey finite cell line human CVCL_2888 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; JCRB9088; true; Discontinued: KCLB; 10028; probable Male Senescence: Senesces at ~30 PDL (ATCC=CCL-28) 21149147 CVCL_1W88 ND03704 transformed cell line human CVCL_1W88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149148 CVCL_2892 Eos-HL-60 cancer cell line human CVCL_2892 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149149 CVCL_1W92 ND03713 transformed cell line human CVCL_1W92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149150 CVCL_2893 EJ-1 cancer cell line human CVCL_2893 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Discontinued: RCB; RCB2137; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00194 Problematic cell line: Contaminated Shown to be a T24 derivative (DOI=10.11418/jtca1981.18.4_329; PubMed=20143388). 21149151 CVCL_1W93 ND03715 transformed cell line human CVCL_1W93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149152 CVCL_2890 DSPT200 transformed cell line CVCL_2890 CL:0000010 Transformant: Unknown; Derived from sampling site: Cell type=Fibroblast. Unspecified 21149153 CVCL_1W90 ND03711 transformed cell line human CVCL_1W90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149154 CVCL_2891 EBC-1 cancer cell line human CVCL_2891 HLA typing: A*24:02,24:02; B*07:02,07:02; C*07:02,07:02; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:01,15:01 (PubMed=26589293); Genome ancestry: African=1.01%; Native American=0%; East Asian, North=85.35%; East Asian, South=10.91%; South Asian=0%; European, North=0%; European, South=2.73% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2731; DDR2; Simple; p.Thr681Ile (c.2042C>T); ClinVar=VCV001435412; Zygosity=Heterozygous (PubMed=28676216; Cosmic-CLP); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Skin. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42 hours (DOI=10.4044/joma1947.97.7-8_691); 38.7 hours (PubMed=8286010); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149155 CVCL_1W91 ND03712 transformed cell line human CVCL_1W91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149156 CVCL_2896 FA9JTO finite cell line human CVCL_2896 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149157 CVCL_1W96 ND03790 transformed cell line human CVCL_1W96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149158 CVCL_2897 FA9JTOTERT telomerase immortalized cell line human CVCL_2897 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0310; true Male 21149159 CVCL_1W97 ND03792 transformed cell line human CVCL_1W97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149160 CVCL_2894 Ep-16 hybridoma house mouse CVCL_2894 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human epithelial cells. 21149161 CVCL_1W94 ND03746 transformed cell line human CVCL_1W94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149162 CVCL_2895 FA18JTO finite cell line human CVCL_2895 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1811delT; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149163 CVCL_1W95 ND03770 transformed cell line human CVCL_1W95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149164 CVCL_2898 FBHE finite cell line CVCL_2898 CL:0000010 Derived from sampling site: Fetal heart Cell type=Cardiac endothelial cell.. Discontinued: ECACC; 87043002; probable; Discontinued: IZSLER; BS CL 113; probable Unspecified Characteristics: FGF dependent; Characteristics: Susceptible to infection by Ehrlichia ruminantium (CelloPub=CLPUB00632); Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21149165 CVCL_1W98 ND03830 transformed cell line human CVCL_1W98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149166 CVCL_2899 FHs 74 Int finite cell line human CVCL_2899 CL:0000010 Derived from sampling site: Fetal small intestine. Female Senescence: Can undergo 15 PDL; Doubling time: 6-7 days (PubMed=176412); 65 hours (with EGF), 168 hours (without EGF) (JCRB) Caution: Could be identical to Hs 74.Int (Cellosaurus=CVCL_S089) 21149167 CVCL_1W99 ND03833 transformed cell line human CVCL_1W99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149168 CVCL_LE35 UKBi012-A induced pluripotent stem cell human CVCL_LE35 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21149169 CVCL_LE36 UKBi013-A induced pluripotent stem cell human CVCL_LE36 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21149170 CVCL_LE33 BIONi035-A induced pluripotent stem cell human CVCL_LE33 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149171 CVCL_LE34 UKBi011-A induced pluripotent stem cell human CVCL_LE34 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=29753274) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149172 CVCL_LE31 BIONi033-A induced pluripotent stem cell human CVCL_LE31 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149173 CVCL_LE32 BIONi034-A induced pluripotent stem cell human CVCL_LE32 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149174 CVCL_LE30 BIONi032-A induced pluripotent stem cell human CVCL_LE30 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149175 CVCL_CK98 ND09460 transformed cell line human CVCL_CK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149176 CVCL_CK99 ND09470 transformed cell line human CVCL_CK99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149177 CVCL_CK96 ND09440 transformed cell line human CVCL_CK96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149178 CVCL_CK97 ND09448 transformed cell line human CVCL_CK97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149179 CVCL_CK90 ND09266 transformed cell line human CVCL_CK90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149180 CVCL_CK91 ND09336 transformed cell line human CVCL_CK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149181 CVCL_LE28 BIONi030-A induced pluripotent stem cell human CVCL_LE28 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149182 CVCL_CK94 ND09378 transformed cell line human CVCL_CK94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149183 CVCL_LE29 BIONi031-A induced pluripotent stem cell human CVCL_LE29 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149184 CVCL_CK95 ND09381 transformed cell line human CVCL_CK95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149185 CVCL_LE26 BIONi028-A induced pluripotent stem cell human CVCL_LE26 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149186 CVCL_CK92 ND09338 transformed cell line human CVCL_CK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149187 CVCL_LE27 BIONi029-A induced pluripotent stem cell human CVCL_LE27 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149188 CVCL_CK93 ND09352 transformed cell line human CVCL_CK93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149189 CVCL_LE46 UOXFi010-A induced pluripotent stem cell human CVCL_LE46 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi010-A; true Male 21149190 CVCL_LE47 UOXFi010-B induced pluripotent stem cell human CVCL_LE47 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Discontinued: EBiSC; UOXFi010-B; true Male 21149191 CVCL_LE44 UOXFi009-B induced pluripotent stem cell human CVCL_LE44 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi009-B; true Female 21149192 CVCL_LE45 UOXFi009-C induced pluripotent stem cell human CVCL_LE45 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi009-C; true Female 21149193 CVCL_LE42 UOXFi008-C induced pluripotent stem cell human CVCL_LE42 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi008-C; true Female 21149194 CVCL_LE43 UOXFi009-A induced pluripotent stem cell human CVCL_LE43 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Discontinued: EBiSC; UOXFi009-A; true Female 21149195 CVCL_LE40 UOXFi008-A induced pluripotent stem cell human CVCL_LE40 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi008-A; true Female 21149196 CVCL_LE41 UOXFi008-B induced pluripotent stem cell human CVCL_LE41 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21149197 CVCL_LE39 UOXFi007-C induced pluripotent stem cell human CVCL_LE39 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi007-C; true Female 21149198 CVCL_LE37 UOXFi007-A induced pluripotent stem cell human CVCL_LE37 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21149199 CVCL_LE38 UOXFi007-B induced pluripotent stem cell human CVCL_LE38 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; UOXFi007-B; true Female 21149200 CVCL_LE13 BIONi015-A induced pluripotent stem cell human CVCL_LE13 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149201 CVCL_LE14 BIONi016-A induced pluripotent stem cell human CVCL_LE14 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149202 CVCL_LE11 BIONi013-A induced pluripotent stem cell human CVCL_LE11 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149203 CVCL_LE12 BIONi014-A induced pluripotent stem cell human CVCL_LE12 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149204 CVCL_LE10 BIONi012-A induced pluripotent stem cell human CVCL_LE10 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Discontinued: EBiSC; BIONi012-A; true; Discontinued: ECACC; 66540263; true; Discontinued: hPSCreg; BIONi012-A; true. Male Problematic cell line: Misidentified/contaminated The STR profile matches the wrong donor (EBiSC). 21149205 CVCL_CK76 ND09181 transformed cell line human CVCL_CK76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149206 CVCL_CK77 ND09183 transformed cell line human CVCL_CK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149207 CVCL_CK74 ND09168 transformed cell line human CVCL_CK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149208 CVCL_CK75 ND09171 transformed cell line human CVCL_CK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149209 CVCL_CK78 ND09216 transformed cell line human CVCL_CK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149210 CVCL_CK79 ND09223 transformed cell line human CVCL_CK79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149211 CVCL_LE08 AG25370 induced pluripotent stem cell human CVCL_LE08 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21149212 CVCL_LE09 BIONi010-C-8 induced pluripotent stem cell human CVCL_LE09 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Thr66Met (c.197C>T); ClinVar=VCV000192242; Zygosity=Homozygous (EBiSC) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21149213 CVCL_CK72 ND09118 transformed cell line human CVCL_CK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149214 CVCL_LE06 PcBra3 cancer cell line human CVCL_LE06 CL:0000010 Derived from sampling site: Prostate. Male Doubling time: 48 hours (PubMed=19997870) 21149215 CVCL_LE07 AG25367 induced pluripotent stem cell human CVCL_LE07 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21149216 CVCL_CK73 ND09146 transformed cell line human CVCL_CK73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149217 CVCL_CK70 ND09110 transformed cell line human CVCL_CK70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149218 CVCL_LE04 PcBra1 cancer cell line human CVCL_LE04 CL:0000010 Derived from sampling site: Prostate. Male Doubling time: 50 hours (PubMed=19997870) 21149219 CVCL_CK71 ND09111 transformed cell line human CVCL_CK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149220 CVCL_LE05 PcBra2 cancer cell line human CVCL_LE05 CL:0000010 Derived from sampling site: Prostate. Male Doubling time: 35 hours (PubMed=19997870) 21149221 CVCL_LE24 BIONi026-A induced pluripotent stem cell human CVCL_LE24 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149222 CVCL_LE25 BIONi027-A induced pluripotent stem cell human CVCL_LE25 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149223 CVCL_LE22 BIONi024-A induced pluripotent stem cell human CVCL_LE22 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149224 CVCL_LE23 BIONi025-A induced pluripotent stem cell human CVCL_LE23 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149225 CVCL_LE20 BIONi022-A induced pluripotent stem cell human CVCL_LE20 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149226 CVCL_LE21 BIONi023-A induced pluripotent stem cell human CVCL_LE21 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149227 CVCL_CK87 ND09242 transformed cell line human CVCL_CK87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149228 CVCL_CK88 ND09244 transformed cell line human CVCL_CK88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149229 CVCL_CK85 ND09235 transformed cell line human CVCL_CK85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149230 CVCL_CK86 ND09236 transformed cell line human CVCL_CK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149231 CVCL_CK89 ND09249 transformed cell line human CVCL_CK89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149232 CVCL_CK80 ND09224 transformed cell line human CVCL_CK80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149233 CVCL_LE19 BIONi021-A induced pluripotent stem cell human CVCL_LE19 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149234 CVCL_LE17 BIONi019-A induced pluripotent stem cell human CVCL_LE17 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149235 CVCL_CK83 ND09231 transformed cell line human CVCL_CK83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149236 CVCL_LE18 BIONi020-A induced pluripotent stem cell human CVCL_LE18 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149237 CVCL_CK84 ND09234 transformed cell line human CVCL_CK84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149238 CVCL_LE15 BIONi017-A induced pluripotent stem cell human CVCL_LE15 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149239 CVCL_CK81 ND09227 transformed cell line human CVCL_CK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149240 CVCL_LE16 BIONi018-A induced pluripotent stem cell human CVCL_LE16 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21149241 CVCL_CK82 ND09228 transformed cell line human CVCL_CK82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149242 CVCL_CK54 ND08884 transformed cell line human CVCL_CK54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149243 CVCL_CK55 ND08906 transformed cell line human CVCL_CK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149244 CVCL_CK52 ND08882 transformed cell line human CVCL_CK52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149245 CVCL_CK53 ND08883 transformed cell line human CVCL_CK53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149246 CVCL_CK58 ND08945 transformed cell line human CVCL_CK58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149247 CVCL_CK59 ND08969 transformed cell line human CVCL_CK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149248 CVCL_CK56 ND08917 transformed cell line human CVCL_CK56 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Ala82Glu (c.245C>A); ClinVar=VCV000007038; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex5-6del; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149249 CVCL_CK57 ND08919 transformed cell line human CVCL_CK57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149250 CVCL_CK50 ND08880 transformed cell line human CVCL_CK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149251 CVCL_CK51 ND08881 transformed cell line human CVCL_CK51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149252 CVCL_LE02 NCI-H838 EGFR (delE746-A750/+) cancer cell line human CVCL_LE02 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Glu746_Ala750del; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male Characteristics: Heterozygous knockin of a EGFR activating mutation 21149253 CVCL_LE03 MCF-10A EGFR (delE746-A750/+) spontaneously immortalized cell line human CVCL_LE03 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Glu746_Ala750del; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a EGFR activating mutation 21149254 CVCL_LE00 HCT 116 PDGFRA (D842V/+) cancer cell line human CVCL_LE00 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple_edited; p.Asp842Val (c.2525A>T); ClinVar=VCV000013543; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a PDGFRA activating mutation 21149255 CVCL_LE01 RKO EGFR (delE746-A750/+) cancer cell line human CVCL_LE01 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Glu746_Ala750del; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified Characteristics: Heterozygous knockin of a EGFR activating mutation 21149256 CVCL_CK65 ND09021 transformed cell line human CVCL_CK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149257 CVCL_CK66 ND09042 transformed cell line human CVCL_CK66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149258 CVCL_CK63 ND09018 transformed cell line human CVCL_CK63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149259 CVCL_CK64 ND09019 transformed cell line human CVCL_CK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149260 CVCL_CK69 ND09085 transformed cell line human CVCL_CK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149261 CVCL_CK67 ND09064 transformed cell line human CVCL_CK67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149262 CVCL_CK68 ND09065 transformed cell line human CVCL_CK68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149263 CVCL_CK61 ND08973 transformed cell line human CVCL_CK61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149264 CVCL_CK62 ND08996 transformed cell line human CVCL_CK62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149265 CVCL_CK60 ND08972 transformed cell line human CVCL_CK60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149266 CVCL_CK38 ND08728 transformed cell line human CVCL_CK38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149267 CVCL_CK39 ND08729 transformed cell line human CVCL_CK39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149268 CVCL_CK32 ND08671 transformed cell line human CVCL_CK32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149269 CVCL_CK33 ND08680 transformed cell line human CVCL_CK33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149270 CVCL_CK30 ND08648 transformed cell line human CVCL_CK30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149271 CVCL_CK31 ND08665 transformed cell line human CVCL_CK31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149272 CVCL_CK36 ND08722 transformed cell line human CVCL_CK36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149273 CVCL_CK37 ND08723 transformed cell line human CVCL_CK37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149274 CVCL_CK34 ND08684 transformed cell line human CVCL_CK34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149275 CVCL_CK35 ND08693 transformed cell line human CVCL_CK35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149276 CVCL_CK49 ND08876 transformed cell line human CVCL_CK49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149277 CVCL_CK43 ND08782 transformed cell line human CVCL_CK43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149278 CVCL_CK44 ND08783 transformed cell line human CVCL_CK44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149279 CVCL_CK41 ND08780 transformed cell line human CVCL_CK41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149280 CVCL_CK42 ND08781 transformed cell line human CVCL_CK42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149281 CVCL_CK47 ND08824 transformed cell line human CVCL_CK47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149282 CVCL_CK48 ND08875 transformed cell line human CVCL_CK48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149283 CVCL_CK45 ND08792 transformed cell line human CVCL_CK45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149284 CVCL_CK46 ND08822 transformed cell line human CVCL_CK46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149285 CVCL_CK40 ND08754 transformed cell line human CVCL_CK40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149286 CVCL_LD98 HCT 116 NFE2L2 (E79K/+) cancer cell line human CVCL_LD98 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7782; NFE2L2; Simple_edited; p.Glu79Lys (c.235G>A); ClinVar=VCV000376466; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a NFE2L2 activating mutation 21149287 CVCL_LD99 HCT 116 NOTCH1 (L1601P/+) cancer cell line human CVCL_LD99 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple_edited; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a NOTCH1 activating mutation 21149288 CVCL_LD96 HCT 116 MET (Y1253D/+) cancer cell line human CVCL_LD96 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple_edited; p.Tyr1235Asp (c.3703T>G) (p.Tyr1253Asp, c.3757T>G); ClinVar=VCV000376200; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a MET activating mutation 21149289 CVCL_LD97 HCT 116 MTOR (S2035I/+) cancer cell line human CVCL_LD97 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3942; MTOR; Simple_edited; p.Ser2035Ile; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a MTOR rapamycin resistance mutation 21149290 CVCL_LD94 HCT 116 KIT (D816V/+) cancer cell line human CVCL_LD94 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple_edited; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a KIT activating mutation 21149291 CVCL_LD95 HCT 116 MAP2K1 (P124L/+) cancer cell line human CVCL_LD95 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple_edited; p.Pro124Leu (c.371C>T); ClinVar=VCV000040744; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a MAP2K1 activating mutation conferring drug resistance 21149292 CVCL_LD92 HCT 116 GNAQ (Q209L/+) cancer cell line human CVCL_LD92 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple_edited; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a GNAQ activating mutation 21149293 CVCL_LD93 HCT 116 JAK2 (V617F/+) cancer cell line human CVCL_LD93 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6192; JAK2; Simple_edited; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a JAK2 activating mutation 21149294 CVCL_LD90 HCT 116 FLT3 (D835Y/+) cancer cell line human CVCL_LD90 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple_edited; p.Asp835Tyr (c.2503G>T); ClinVar=VCV000016276; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a FLT3 activating mutation 21149295 CVCL_LD91 HCT 116 GNA11 (Q209L/+) cancer cell line human CVCL_LD91 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4379; GNA11; Simple_edited; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a GNA11 activating mutation 21149296 CVCL_LD78 SW48 GNAS (R201C/+) cancer cell line human CVCL_LD78 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4392; GNAS; Simple_edited; p.Arg201Cys (c.601C>T); ClinVar=VCV000015933; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a GNAS activating mutation 21149297 CVCL_LD79 SW48 JAK2 (V617F/+) cancer cell line human CVCL_LD79 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6192; JAK2; Simple_edited; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a JAK2 activating mutation 21149298 CVCL_LD76 MCF-10A RAC1 (Q61L/+) spontaneously immortalized cell line human CVCL_LD76 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple_edited; p.Gln61Leu; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a RAC1 mutation 21149299 CVCL_LD77 SW48 BRAF (V600E/+/+/+) cancer cell line human CVCL_LD77 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a BRAF activating mutation 21149300 CVCL_LD74 MCF-10A KRAS (G12V/+) spontaneously immortalized cell line human CVCL_LD74 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a KRAS activating mutation 21149301 CVCL_LD75 MCF-10A PIK3CA (E545K/+) spontaneously immortalized cell line human CVCL_LD75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a PIK3CA helix domain activating mutation 21149302 CVCL_LD72 MCF-10A BRAF (V600K/+) spontaneously immortalized cell line human CVCL_LD72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a BRAF activating mutation 21149303 CVCL_LD73 MCF-10A IDH1 (R132H/+) spontaneously immortalized cell line human CVCL_LD73 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple_edited; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a IDH1 dominant negative mutation 21149304 CVCL_LD70 HCT 116 IDH2 (R140Q/+) cancer cell line human CVCL_LD70 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5383; IDH2; Simple_edited; p.Arg140Gln (c.419G>A); ClinVar=VCV000014716; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a IDH2 altered metabolic activity mutation 21149305 CVCL_LD71 HCT 116 IDH2 (R172K/+) cancer cell line human CVCL_LD71 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5383; IDH2; Simple_edited; p.Arg172Lys (c.515G>A); ClinVar=VCV000375987; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a IDH2 altered metabolic activity mutation 21149306 CVCL_LD89 HCT 116 FGFR3 (S249C/+) cancer cell line human CVCL_LD89 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple_edited; p.Ser249Cys (c.746C>G); ClinVar=VCV000016339; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a FGFR3 activating mutation 21149307 CVCL_LD87 HCT 116 CDK2 (D145N/+) cancer cell line human CVCL_LD87 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1771; CDK2; Simple_edited; p.Asp145Asn; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a CDK2 dominant negative mutation 21149308 CVCL_LD88 HCT 116 FGFR2 (S252W/+/+) cancer cell line human CVCL_LD88 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3689; FGFR2; Simple_edited; p.Ser252Trp (c.755C>G); ClinVar=VCV000013272; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a FGFR2 activating mutation 21149309 CVCL_LD85 UKKi024-B induced pluripotent stem cell human CVCL_LD85 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149310 CVCL_LD86 UKKi024-C induced pluripotent stem cell human CVCL_LD86 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149311 CVCL_LD83 SW48 TP53 (R273H/+) cancer cell line human CVCL_LD83 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a TP53 mutation 21149312 CVCL_LD84 UKKi024-A induced pluripotent stem cell human CVCL_LD84 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149313 CVCL_LD81 SW48 PIK3CA (E545K/+) cancer cell line human CVCL_LD81 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a PIK3CA helix domain activating mutation 21149314 CVCL_LD82 SW48 RAC1 (Q61L/+/+) cancer cell line human CVCL_LD82 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple_edited; p.Gln61Leu; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a RAC1 mutation 21149315 CVCL_LD80 SW48 PIK3CA (E542K/+) cancer cell line human CVCL_LD80 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a PIK3CA helix domain activating mutation 21149316 CVCL_LD58 HROG15 cancer cell line human CVCL_LD58 HLA typing: A*02:01:01,03:01:01; B*15:01:01,11:03:01; C*03:03:01,04:01:01; DPB1*01:01:01,02:01:02; DQA1*01:03:01,05:01:01; DQB1*02:01:01,06:03:01; DRB1*03:01:01,13:01:01 (CLS=300937) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ser170Asn (c.509G>A); ClinVar=VCV000951765; Zygosity=Unspecified (CLS); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Brain; right parietal lobe. Male 21149317 CVCL_LD59 HROG16 cancer cell line human CVCL_LD59 From: Linnebacher M.; University of Rostock; Rostock; Germany. CL:0000010 Male 21149318 CVCL_LD56 SW48 PIK3CA (H1047R/+) cancer cell line human CVCL_LD56 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a PIK3CA kinase domain activating mutation 21149319 CVCL_LD57 VACO 432 PIK3CA (H1047R/+) cancer cell line human CVCL_LD57 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a PIK3CA kinase domain activating mutation 21149320 CVCL_LD54 HCT 116 PIK3CA (H1047R/-) cancer cell line human CVCL_LD54 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 8975; PIK3CA; Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Hemizygous; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21149321 CVCL_LD55 MCF-10A PIK3CA (H1047R/+) spontaneously immortalized cell line human CVCL_LD55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a PIK3CA kinase domain activating mutation 21149322 CVCL_LD52 UKKi028-B induced pluripotent stem cell human CVCL_LD52 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 21149323 CVCL_LD53 UKKi028-C induced pluripotent stem cell human CVCL_LD53 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 21149324 CVCL_LD50 UKKi027-C induced pluripotent stem cell human CVCL_LD50 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: African; Derived from sampling site: Peripheral blood. Female 21149325 CVCL_LD51 UKKi028-A induced pluripotent stem cell human CVCL_LD51 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 21149326 CVCL_LD49 UKKi027-B induced pluripotent stem cell human CVCL_LD49 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: African; Derived from sampling site: Peripheral blood. Female 21149327 CVCL_LD69 HCT 116 IDH1 (R132H/+) cancer cell line human CVCL_LD69 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple_edited; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a IDH1 dominant negative mutation 21149328 CVCL_LD67 HCT 116 GNAS (R201C/+) cancer cell line human CVCL_LD67 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4392; GNAS; Simple_edited; p.Arg201Cys (c.601C>T); ClinVar=VCV000015933; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a GNAS activating mutation 21149329 CVCL_LD68 HCT 116 IDH1 (R132C/+) cancer cell line human CVCL_LD68 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple_edited; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a IDH1 altered metabolic activity mutation 21149330 CVCL_LD65 HCT 116 BRAF (V600M/+) cancer cell line human CVCL_LD65 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Met (c.1798G>A); ClinVar=VCV000044815; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF mutation 21149331 CVCL_LD66 HCT 116 BRAF (V600R/+) cancer cell line human CVCL_LD66 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF activating mutation 21149332 CVCL_LD63 HCT 116 BRAF (V600G/+) cancer cell line human CVCL_LD63 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Gly (c.1799T>G); ClinVar=VCV000040389; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF mutation 21149333 CVCL_LD64 HCT 116 BRAF (V600K/+) cancer cell line human CVCL_LD64 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF activating mutation 21149334 CVCL_LD61 HCT 116 BRAF (V600A/+) cancer cell line human CVCL_LD61 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Ala (c.1799T>C); ClinVar=VCV000376288; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF mutation 21149335 CVCL_LD62 HCT 116 BRAF (V600E/+) cancer cell line human CVCL_LD62 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple_edited; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a BRAF activating mutation 21149336 CVCL_LD60 D122-96 cancer cell line house mouse CVCL_LD60 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: High metastatic potential Grows faster and is more metastatic than parental D122. 21149337 CVCL_LD36 UKKi022-D induced pluripotent stem cell human CVCL_LD36 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21149338 CVCL_LD37 UKKi023-A induced pluripotent stem cell human CVCL_LD37 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Arg531Trp (c.1591C>T); ClinVar=VCV000067218; Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149339 CVCL_LD34 UKKi022-B induced pluripotent stem cell human CVCL_LD34 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21149340 CVCL_LD35 UKKi022-C induced pluripotent stem cell human CVCL_LD35 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21149341 CVCL_LD32 UKKi021-B induced pluripotent stem cell human CVCL_LD32 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21149342 CVCL_LD33 UKKi022-A induced pluripotent stem cell human CVCL_LD33 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21149343 CVCL_LD30 UKKi019-C induced pluripotent stem cell human CVCL_LD30 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr427Cys (c.1280A>G); ClinVar=VCV000067179; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21149344 CVCL_LD31 UKKi021-A induced pluripotent stem cell human CVCL_LD31 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21149345 CVCL_CJ99 ND08219 transformed cell line human CVCL_CJ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149346 CVCL_CJ97 ND08213 transformed cell line human CVCL_CJ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149347 CVCL_CJ98 ND08218 transformed cell line human CVCL_CJ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149348 CVCL_CJ91 ND08191 transformed cell line human CVCL_CJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149349 CVCL_CJ92 ND08192 transformed cell line human CVCL_CJ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149350 CVCL_CJ90 ND08190 transformed cell line human CVCL_CJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149351 CVCL_CJ95 ND08210 transformed cell line human CVCL_CJ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149352 CVCL_LD29 UKKi019-B induced pluripotent stem cell human CVCL_LD29 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr427Cys (c.1280A>G); ClinVar=VCV000067179; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21149353 CVCL_CJ96 ND08212 transformed cell line human CVCL_CJ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149354 CVCL_CJ93 ND08193 transformed cell line human CVCL_CJ93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149355 CVCL_LD27 UKKi018-C induced pluripotent stem cell human CVCL_LD27 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Glu58Gly (c.173A>G); ClinVar=VCV000067257; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21149356 CVCL_CJ94 ND08209 transformed cell line human CVCL_CJ94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149357 CVCL_LD28 UKKi019-A induced pluripotent stem cell human CVCL_LD28 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr427Cys (c.1280A>G); ClinVar=VCV000067179; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21149358 CVCL_LD47 UKKi026-C induced pluripotent stem cell human CVCL_LD47 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 21149359 CVCL_LD48 UKKi027-A induced pluripotent stem cell human CVCL_LD48 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: African; Derived from sampling site: Peripheral blood. Female 21149360 CVCL_LD45 UKKi026-A induced pluripotent stem cell human CVCL_LD45 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 21149361 CVCL_LD46 UKKi026-B induced pluripotent stem cell human CVCL_LD46 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 21149362 CVCL_LD43 UKKi025-B induced pluripotent stem cell human CVCL_LD43 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg719Gly (c.2156G>A); Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21149363 CVCL_LD44 UKKi025-C induced pluripotent stem cell human CVCL_LD44 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg719Gly (c.2156G>A); Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21149364 CVCL_LD41 HCT 116 ALK (F1174L/+) cancer cell line human CVCL_LD41 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 427; ALK; Simple_edited; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a ALK activating mutation 21149365 CVCL_LD42 UKKi025-A induced pluripotent stem cell human CVCL_LD42 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg719Gly (c.2156G>A); Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21149366 CVCL_LD40 HCT 116 ABL1 (T315I/+) cancer cell line human CVCL_LD40 CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple_edited; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male Characteristics: Heterozygous knockin of a ABL1 drug resistance mutation 21149367 CVCL_LD38 UKKi023-B induced pluripotent stem cell human CVCL_LD38 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Arg531Trp (c.1591C>T); ClinVar=VCV000067218; Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149368 CVCL_LD39 UKKi023-C induced pluripotent stem cell human CVCL_LD39 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Arg531Trp (c.1591C>T); ClinVar=VCV000067218; Zygosity=Heterozygous (EBiSC) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21149369 CVCL_2860 AT1OS finite cell line human CVCL_2860 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21149370 CVCL_1W60 ND03229 transformed cell line human CVCL_1W60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149371 CVCL_2863 B104-R3 cancer cell line human CVCL_2863 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; JCRB0117.1; true Male 21149372 CVCL_1W63 ND03261 transformed cell line human CVCL_1W63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149373 CVCL_2864 B2-17 cancer cell line human CVCL_2864 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Brain; parietal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 48 hours (CelloPub=CLPUB00152) Caution: Was incorrectly reported to be a U-251MG contaminated cell line by ICLAC while it was specifically derived from U-251MG as described in the original publication (CelloPub=CLPUB00152) 21149374 CVCL_1W64 ND03355 transformed cell line human CVCL_1W64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149375 CVCL_2861 AT2KY finite cell line human CVCL_2861 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1550Argfs*13 (c.4649delA); Zygosity=Heterozygous (PubMed=9600235); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2629Serfs*24 (c.7881_7885TATTA[1]) (c.7883_7887delTTATA); ClinVar=VCV000230200; Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21149376 CVCL_1W61 ND03231 transformed cell line human CVCL_1W61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149377 CVCL_2862 AZ-521 cancer cell line human CVCL_2862 Genome ancestry: African=78.39%; Native American=0%; East Asian, North=1.7%; East Asian, South=0%; South Asian=0.23%; European, North=10.56%; European, South=9.12% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Phe (c.110C>T); ClinVar=VCV000017586; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1370612) Derived from sampling site: Small intestine; duodenum. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB2087; true Male Doubling time: ~30 hours (lot 11162006) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00369 Problematic cell line: Contaminated Shown to be a Hutu 80 derivative (see JCRB web site). 21149378 CVCL_1W62 ND03256 transformed cell line human CVCL_1W62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149379 CVCL_2867 BS2CH finite cell line human CVCL_2867 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21149380 CVCL_1W67 ND03401 transformed cell line human CVCL_1W67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149381 CVCL_2868 BS2CHTERT telomerase immortalized cell line human CVCL_2868 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0311; true Female 21149382 CVCL_1W68 ND03403 transformed cell line human CVCL_1W68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149383 CVCL_2865 BCE C/D-1b finite cell line CVCL_2865 CL:0000010 Derived from sampling site: Eye; cornea; endothelium. Male Doubling time: ~55 hours (at 70th passage), 30 hours (at 90th passage) (ATCC=CRL-2048) 21149384 CVCL_1W65 ND03356 transformed cell line human CVCL_1W65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149385 CVCL_2866 BCNS1KO finite cell line human CVCL_2866 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149386 CVCL_1W66 ND03357 transformed cell line human CVCL_1W66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149387 CVCL_2869 BSL2KA transformed cell line human CVCL_2869 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (from autologous cell line HG1626) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 93(YoYa) (BSR93); Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0306; true Male Doubling time: 60 hours (PubMed=1900268) 21149388 CVCL_1W69 ND03406 transformed cell line human CVCL_1W69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149389 CVCL_2870 CCD-14Br finite cell line human CVCL_2870 CL:0000010 Derived from sampling site: Bronchus Cell type=Fibroblast.. Discontinued: ATCC; CCL-203; true Female Senescence: Has been discontinued from ATCC because the cells senesced Problematic cell line: On the basis of the STR profile the cell line at ATCC (no longer available) and the one at JCRB are not the same 21149390 CVCL_1W70 ND03447 transformed cell line human CVCL_1W70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149391 CVCL_2871 CCD-841CoN finite cell line human CVCL_2871 CL:0000010 Derived from sampling site: Fetal colon. Discontinued: JCRB; IFO50482; true Female Senescence: Senesces at ~58 PDL (ATCC=CRL-1790) 21149392 CVCL_1W71 ND03463 transformed cell line human CVCL_1W71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149393 CVCL_2874 CCRF S-180 II cancer cell line house mouse CVCL_2874 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Discontinued: BCRJ; 0314; probable Unspecified 21149394 CVCL_1W74 ND03522 transformed cell line human CVCL_1W74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: Coriell; ND03522; probable 21149395 CVCL_2875 CHO(His9) hybrid cell line human CVCL_2875 CL:0000010 Transfected with: UniProtKB; P06988; Escherichia coli hisD. Characteristics: Contains human chromosome 9 Group: Human/rodent somatic cell hybrid 21149396 CVCL_1W75 ND03527 transformed cell line human CVCL_1W75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: Coriell; ND03527; probable 21149397 CVCL_2872 CCD-841CoTr transformed cell line human CVCL_2872 CL:0000010 Karyotypic information: Pentaploid The karyology is very different from that of the parental cell line (ATCC).; Transformant: Simian virus 40 (SV40) [ts](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal colon. Female Characteristics: Exhibits the transformed phenotype at the permissive temperature (33 Celsius) 21149398 CVCL_1W72 ND03465 transformed cell line human CVCL_1W72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149399 CVCL_2873 CCK-81 cancer cell line human CVCL_2873 Genome ancestry: African=0%; Native American=1.38%; East Asian, North=77.93%; East Asian, South=20.68%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278His (c.833C>A); ClinVar=VCV000376646; Zygosity=Heterozygous (PubMed=16418264; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45 hours (PubMed=7418977); ~40 hours (lot 03182016) (JCRB); Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149400 CVCL_1W73 ND03510 transformed cell line human CVCL_1W73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149401 CVCL_2878 CPT-K5 cancer cell line human CVCL_2878 CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (PubMed=29496689); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1583_Gln1584insProValGluLeuMetProProGlu (c.4750_4751insCCGTGGAGCTGATGCCGCCGGAGC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Asp533Gly (c.1598A>G); ClinVar=VCV000016773; Zygosity=Unspecified (PubMed=1849260); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Ser121Ter (c.362C>A); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH Female 21149402 CVCL_1W78 ND03587 transformed cell line human CVCL_1W78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149403 CVCL_2879 CS2AW finite cell line human CVCL_2879 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (PubMed=12655141) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21149404 CVCL_1W79 ND03627 transformed cell line human CVCL_1W79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149405 CVCL_2876 CPA finite cell line CVCL_2876 CL:0000010 Derived from sampling site: Lung; artery; endothelium Cell type=Endothelial cell.. Discontinued: ATCC; CCL-207; true; Discontinued: ECACC; 89050801; probable; Discontinued: JCRB; IFO50272; true Male Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Doubling time: 82 hours (lot 070298) (JCRB) Caution: Could be identical to CPA 47 (Cellosaurus=CVCL_3669) 21149406 CVCL_1W76 ND03532 transformed cell line human CVCL_1W76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149407 CVCL_2877 CPAE finite cell line CVCL_2877 CL:0000010 Derived from sampling site: Lung; artery; endothelium. Discontinued: JCRB; IFO50273; true Female Virology: Persistently infected by bovine viral diarrhea virus 2 (BVDV-2) (PubMed=7989438; PubMed=34737324) Senescence: Senesces at 24 PDL (JCRB); Doubling time: ~1.8 days (lot 12172003) (JCRB) 21149408 CVCL_1W77 ND03549 transformed cell line human CVCL_1W77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149409 CVCL_2841 A9(Neo16) hybrid cell line CVCL_2841 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 16 Group: Human/rodent somatic cell hybrid 21149410 CVCL_1W41 ND02422 transformed cell line human CVCL_1W41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149411 CVCL_2842 A9(Neo17) hybrid cell line CVCL_2842 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 17 Group: Human/rodent somatic cell hybrid 21149412 CVCL_1W42 ND02553 transformed cell line human CVCL_1W42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149413 CVCL_2840 A9(Neo15) hybrid cell line CVCL_2840 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 15 Group: Human/rodent somatic cell hybrid 21149414 CVCL_1W40 ND02405 transformed cell line human CVCL_1W40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149415 CVCL_2845 A9(Neo2) hybrid cell line CVCL_2845 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 2 Doubling time: ~1 day (lot 09192017) (JCRB) Group: Human/rodent somatic cell hybrid 21149416 CVCL_1W45 ND02652 transformed cell line human CVCL_1W45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149417 CVCL_2846 A9(Neo20) hybrid cell line CVCL_2846 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 20 Doubling time: ~21 hours (lot 12032018) (JCRB) Group: Human/rodent somatic cell hybrid 21149418 CVCL_1W46 ND02690 transformed cell line human CVCL_1W46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149419 CVCL_2843 A9(Neo18) hybrid cell line CVCL_2843 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 18 Group: Human/rodent somatic cell hybrid 21149420 CVCL_1W43 ND02633 transformed cell line human CVCL_1W43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149421 CVCL_2844 A9(Neo19) hybrid cell line CVCL_2844 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 19 Group: Human/rodent somatic cell hybrid 21149422 CVCL_1W44 ND02645 transformed cell line human CVCL_1W44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149423 CVCL_2849 A9(Neo5) hybrid cell line CVCL_2849 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 5 Group: Human/rodent somatic cell hybrid 21149424 CVCL_1W49 ND02862 transformed cell line human CVCL_1W49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149425 CVCL_2847 A9(Neo3) hybrid cell line CVCL_2847 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 3 Group: Human/rodent somatic cell hybrid 21149426 CVCL_1W47 ND02751 transformed cell line human CVCL_1W47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149427 CVCL_2848 A9(Neo4) hybrid cell line CVCL_2848 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 4 Group: Human/rodent somatic cell hybrid 21149428 CVCL_1W48 ND02760 transformed cell line human CVCL_1W48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149429 CVCL_2852 A9(Neo8) hybrid cell line CVCL_2852 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 8 Doubling time: 31-34 hours (lot 02012016) (JCRB) Group: Human/rodent somatic cell hybrid 21149430 CVCL_1W52 ND03071 transformed cell line human CVCL_1W52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149431 CVCL_2853 A9(NTI8)-2 hybrid cell line CVCL_2853 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Characteristics: Contains human chromosome 7 Group: Human/rodent somatic cell hybrid Caution: It is possible that A9(NTI8)-2 and A9(Neo7) (Cellosaurus=CVCL_2851) are the same cell line. 21149432 CVCL_1W53 ND03094 transformed cell line human CVCL_1W53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149433 CVCL_2850 A9(Neo6) hybrid cell line CVCL_2850 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 6 Doubling time: ~24 hours (lot 03052019) (JCRB) Group: Human/rodent somatic cell hybrid 21149434 CVCL_1W50 ND02864 transformed cell line human CVCL_1W50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149435 CVCL_2851 A9(Neo7) hybrid cell line CVCL_2851 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Characteristics: Contains human chromosome 7 Group: Human/rodent somatic cell hybrid Caution: It is possible that A9(Neo7) and A9(NTI8)-2 (Cellosaurus=CVCL_2853) are the same cell line. 21149436 CVCL_1W51 ND03047 transformed cell line human CVCL_1W51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149437 CVCL_2856 ASH-3 cancer cell line human CVCL_2856 Genome ancestry: African=0%; Native American=0.08%; East Asian, North=79.16%; East Asian, South=20.41%; South Asian=0.34%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23833040); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.181A>G); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe241fs (c.724dupG); Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Homozygous (PubMed=30737244; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0269; true Female Doubling time: 84 hours (PubMed=11686581); 43-47 hours (lot 12072015) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149438 CVCL_1W56 ND03110 transformed cell line human CVCL_1W56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149439 CVCL_2857 AT(L)5KY transformed cell line human CVCL_2857 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Caution: Incorrectly indicated as originating from a male patient in JCRB=KURB1795 21149440 CVCL_1W57 ND03123 transformed cell line human CVCL_1W57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149441 CVCL_2854 ASF-4-1 finite cell line human CVCL_2854 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Doubling time: 2-2.5 days (lot 07222002) (JCRB) 21149442 CVCL_1W54 ND03096 transformed cell line human CVCL_1W54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149443 CVCL_2855 ASF-4-2 finite cell line human CVCL_2855 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: The ASF-4 series of cell lines were established from the skin of the same donor at different ages Doubling time: ~60 hours (lot 08062002) (JCRB) 21149444 CVCL_1W55 ND03102 transformed cell line human CVCL_1W55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149445 CVCL_2858 AT(L)6KY transformed cell line human CVCL_2858 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.332del165 (g.484C>T) (Ex7del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149446 CVCL_1W58 ND03125 transformed cell line human CVCL_1W58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149447 CVCL_2859 AT(L)7KY transformed cell line human CVCL_2859 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2125del126 (Ex16del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: JCRB; KURB1806; probable Male Virology: Infected by human herpesvirus 7 (HHV-7) (PubMed=29892436) 21149448 CVCL_1W59 ND03227 transformed cell line human CVCL_1W59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149449 CVCL_2829 A9(GM7151)-3 hybrid cell line CVCL_2829 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149450 CVCL_1W29 ND01936 transformed cell line human CVCL_1W29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149451 CVCL_2820 3A(tPA-30-1) transformed cell line human CVCL_2820 CL:0000010 Transformant: Simian virus 40 (SV40) [ts30](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female Characteristics: Expresses the transformed phenotype at the permissive temperature (33 Celsius) and the non-transformed phenotype at the restrictive temperature (40 Celsius); Characteristics: Has a limited life expectancy of 15 to 18 passages before entering the crisis stage (ATCC) 21149452 CVCL_1W20 ND01754 transformed cell line human CVCL_1W20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149453 CVCL_1W23 ND01840 transformed cell line human CVCL_1W23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149454 CVCL_2823 Yub642p somatic stem cell human CVCL_2823 CL:0000010 Discontinued: JCRB; NIHS0478; true. Male 21149455 CVCL_1W24 ND01880 transformed cell line human CVCL_1W24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149456 CVCL_2824 Yub642b somatic stem cell human CVCL_2824 CL:0000010 Discontinued: JCRB; NIHS0479; true. Male 21149457 CVCL_2821 4-11 cancer cell line human CVCL_2821 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Stably expresses firefly luciferase under the control of the MMTV promoter Group: Patented cell line 21149458 CVCL_1W21 ND01757 transformed cell line human CVCL_1W21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149459 CVCL_2822 60H9(9)D10.E6 transformed cell line human CVCL_2822 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: HIVReagentProgram; ARP-8132; true Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1658-1711; Non-structural protein 4A) 21149460 CVCL_1W22 ND01801 transformed cell line human CVCL_1W22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149461 CVCL_2827 A9(GM3552)-2 hybrid cell line CVCL_2827 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149462 CVCL_1W27 ND01929 transformed cell line human CVCL_1W27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149463 CVCL_2828 A9(GM3884)-1 hybrid cell line CVCL_2828 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149464 CVCL_1W28 ND01934 transformed cell line human CVCL_1W28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149465 CVCL_2825 A9(GM0439)-1 hybrid cell line CVCL_2825 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149466 CVCL_1W25 ND01885 transformed cell line human CVCL_1W25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149467 CVCL_2826 A9(GM2621)-4 hybrid cell line CVCL_2826 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149468 CVCL_1W26 ND01887 transformed cell line human CVCL_1W26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149469 CVCL_2830 A9(An4)-2 hybrid cell line CVCL_2830 CL:0000010 Characteristics: Contains human chromosome 1. Group: Human/rodent somatic cell hybrid 21149470 CVCL_1W30 ND01938 transformed cell line human CVCL_1W30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149471 CVCL_2831 A9(Bsr10) hybrid cell line CVCL_2831 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr. Characteristics: Contains human chromosome 10 Group: Human/rodent somatic cell hybrid 21149472 CVCL_1W31 ND01940 transformed cell line human CVCL_1W31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149473 CVCL_2834 A9(Hygro14) hybrid cell line CVCL_2834 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Characteristics: Contains human chromosome 14 Doubling time: ~21 hours (lot 12142017) (JCRB) Group: Human/rodent somatic cell hybrid 21149474 CVCL_1W34 ND01983 transformed cell line human CVCL_1W34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149475 CVCL_2835 A9(Hygro21) hybrid cell line CVCL_2835 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Characteristics: Contains human chromosome 21 Doubling time: ~1 day (lot 04242006) (JCRB) Group: Human/rodent somatic cell hybrid 21149476 CVCL_1W35 ND02212 transformed cell line human CVCL_1W35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149477 CVCL_2832 A9(BsrX) hybrid cell line CVCL_2832 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr. Characteristics: Contains human chromosome X Group: Human/rodent somatic cell hybrid 21149478 CVCL_1W32 ND01942 transformed cell line human CVCL_1W32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149479 CVCL_2833 A9(Hygro13) hybrid cell line CVCL_2833 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Characteristics: Contains human chromosome 13 Doubling time: ~30 hours (lot 05202016) (JCRB) Group: Human/rodent somatic cell hybrid 21149480 CVCL_1W33 ND01944 transformed cell line human CVCL_1W33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149481 CVCL_2838 A9(Neo11) hybrid cell line CVCL_2838 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 11 Group: Human/rodent somatic cell hybrid 21149482 CVCL_1W38 ND02258 transformed cell line human CVCL_1W38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149483 CVCL_2839 A9(Neo12) hybrid cell line CVCL_2839 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 12 Group: Human/rodent somatic cell hybrid 21149484 CVCL_1W39 ND02296 transformed cell line human CVCL_1W39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149485 CVCL_2836 A9(Hygro22) hybrid cell line CVCL_2836 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Characteristics: Contains human chromosome 22 Doubling time: ~1 day (lot 04102006) (JCRB) Group: Human/rodent somatic cell hybrid 21149486 CVCL_1W36 ND02214 transformed cell line human CVCL_1W36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149487 CVCL_2837 A9(Neo1) hybrid cell line CVCL_2837 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains human chromosome 1 Doubling time: ~27 hours (lot 11192018) (JCRB) Group: Human/rodent somatic cell hybrid 21149488 CVCL_1W37 ND02256 transformed cell line human CVCL_1W37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149489 CVCL_1W09 ND01692 transformed cell line human CVCL_1W09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149490 CVCL_2809 U-251MG (KO) cancer cell line human CVCL_2809 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 21149491 CVCL_2807 HSC-1 cancer cell line human CVCL_2807 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Hand; skin. Omics: Deep exome analysis Discontinued: JCRB; NIHS0249; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149492 CVCL_1W07 ND01690 transformed cell line human CVCL_1W07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149493 CVCL_1W08 ND01691 transformed cell line human CVCL_1W08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149494 CVCL_2801 Lu-99B cancer cell line human CVCL_2801 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 18.2 hours (lot 062294) (JCRB) 21149495 CVCL_1W01 ND01678 transformed cell line human CVCL_1W01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149496 CVCL_2802 Lu-99C cancer cell line human CVCL_2802 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Male 21149497 CVCL_1W02 ND01679 transformed cell line human CVCL_1W02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149498 CVCL_2800 KNS-89 cancer cell line human CVCL_2800 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Discontinued: JCRB; IFO50360; true Male Doubling time: 42 hours (CelloPub=CLPUB00152) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00323 Problematic cell line: Contaminated Shown to be a U-251MG derivative (PubMed=20143388; PubMed=22570425). Originally thought to originate from a 66 year old male patient with a gliosarcoma. 21149499 CVCL_1W00 ND01676 transformed cell line human CVCL_1W00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149500 CVCL_2805 JHH-7 cancer cell line human CVCL_2805 HLA typing: A*24:02,31:01; B*51:01,67:02; C*14:02,14:02; DQB1*06:01,06:01; DRB1*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=86.04%; East Asian, South=12.59%; South Asian=1.36%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700; PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Pro (c.800G>C); ClinVar=VCV000428867; Zygosity=Unspecified (PubMed=31378681; DepMap) Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0281; true. Male Virology: Contains 2 copies of integrated incomplete hepatitis B virus (HBV) genomes Does not secrete hepatitis virus B surface antigen (HBsAg) (PubMed=1701409). Doubling time: 26.4 hours (PubMed=1707654); 17.1 hours (PubMed=31378681); 30 hours (lot 06252008), ~29 hours (lot 10312012), ~26 hours (lot 01182016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project 21149501 CVCL_1W05 ND01686 transformed cell line human CVCL_1W05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149502 CVCL_2806 KY821A3 cancer cell line human CVCL_2806 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Brain; meninges. Male 21149503 CVCL_1W06 ND01688 transformed cell line human CVCL_1W06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149504 CVCL_1W03 ND01682 transformed cell line human CVCL_1W03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149505 CVCL_2803 RMG-II cancer cell line human CVCL_2803 HLA typing: A*02:07,02:07; B*35:01,35:01; C*03:03,03:03; DQB1*02:02,02:02 (PubMed=25960936) CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Discontinued: JCRB; IFO50316; true; Discontinued: JCRB; FDSC0028; true Female Doubling time: ~58 hours (PubMed=1715339); 84 hours (lot 07132004), ~51 hours (lot 02032016) (JCRB) 21149506 CVCL_2804 CMK-86 cancer cell line human CVCL_2804 Genome ancestry: African=0%; Native American=0.34%; East Asian, North=91.48%; East Asian, South=8.18%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 4024; FXR2 + HGNC; 11998; TP53; Name(s)=TP53-FXR2 (PubMed=16778363); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149507 CVCL_1W04 ND01684 transformed cell line human CVCL_1W04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149508 CVCL_1W18 ND01708 transformed cell line human CVCL_1W18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149509 CVCL_2818 U-373MG Uppsala cancer cell line human CVCL_2818 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=19435942); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ile135_Ala137delinsThr (c.404_409delTATGTG); Zygosity=Unspecified (PubMed=10560660) Derived from sampling site: Brain; temporal lobe. Male Caution: This is the original U-373MG cell line established in 1973 at the University of Uppsala The cell line distributed by most cell collections is a different cell line. 21149510 CVCL_2819 11-4 cancer cell line human CVCL_2819 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a firefly luciferase reporter gene under the control of the HSV-thymidine kinase promoter; Characteristics: Used to evaluate the non-specific transcriptional activity of chemicals 21149511 CVCL_1W19 ND01751 transformed cell line human CVCL_1W19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149512 CVCL_1W12 ND01699 transformed cell line human CVCL_1W12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149513 CVCL_2812 WI-38-30 finite cell line human CVCL_2812 CL:0000010 Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: JCRB; JCRB0517; true Female 21149514 CVCL_1W13 ND01700 transformed cell line human CVCL_1W13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149515 CVCL_2813 WI-38-40 finite cell line human CVCL_2813 CL:0000010 Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~2 days (lot 04102007), 36-42 hours (lot 11022015) (JCRB) 21149516 CVCL_1W10 ND01693 transformed cell line human CVCL_1W10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149517 CVCL_2810 U-937 cl1-14 cancer cell line human CVCL_2810 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21149518 CVCL_1W11 ND01695 transformed cell line human CVCL_1W11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149519 CVCL_2811 U-937 cl1-22 cancer cell line human CVCL_2811 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21149520 CVCL_2816 Ha Fe finite cell line human CVCL_2816 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149521 CVCL_1W16 ND01703 transformed cell line human CVCL_1W16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149522 CVCL_2817 HEp-2 clone 2B cancer cell line human CVCL_2817 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=32994520) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00310 Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). 21149523 CVCL_1W17 ND01705 transformed cell line human CVCL_1W17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149524 CVCL_1W14 ND01701 transformed cell line human CVCL_1W14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21149525 CVCL_2814 YMB-1 cancer cell line human CVCL_2814 HLA typing: A*02:01,24:02; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=1.26%; Native American=0%; East Asian, North=3.7%; East Asian, South=0%; South Asian=0%; European, North=57.42%; European, South=37.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 44 hours (PubMed=6534930) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00391 Problematic cell line: Contaminated Shown to be a ZR-75-1 derivative (PubMed=23136038). Originally thought to originate from a 55 year old woman patient with a breast carcinoma. 21149526 CVCL_1W15 ND01702 transformed cell line human CVCL_1W15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21149527 CVCL_2815 YMB-1-E cancer cell line human CVCL_2815 HLA typing: A*24:18,24:18; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0.06%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=1.29%; European, North=66.59%; European, South=32.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>T); ClinVar=VCV000375964; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1964; true Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00392 Problematic cell line: Contaminated Parent cell line (YMB-1) has been shown to be a ZR-75-1 derivative (PubMed=23136038). 21149528 CVCL_U752 GM16243 transformed cell line human CVCL_U752 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~1170]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149529 CVCL_TV52 HAP1 UBE2C (-) 3 cancer cell line human CVCL_TV52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15937; UBE2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149530 CVCL_U753 GM16244 transformed cell line human CVCL_U753 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~550]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~920]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149531 CVCL_TV53 HAP1 UBE2D1 (-) 1 cancer cell line human CVCL_TV53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12474; UBE2D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149532 CVCL_U750 GM16238 transformed cell line human CVCL_U750 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~550]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149533 CVCL_TV50 HAP1 UBE2C (-) 1 cancer cell line human CVCL_TV50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15937; UBE2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149534 CVCL_U751 GM16242 transformed cell line human CVCL_U751 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~630]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~730]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149535 CVCL_TV51 HAP1 UBE2C (-) 2 cancer cell line human CVCL_TV51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15937; UBE2C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149536 CVCL_TV56 HAP1 UBE2D2 (-) 2 cancer cell line human CVCL_TV56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149537 CVCL_U756 TX3.833 hybridoma house mouse CVCL_U756 CL:0000010 Discontinued: ATCC; CRL-13013; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat 90 kDa protein expressed in lung caveolae Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-542 21149538 CVCL_TV57 HAP1 UBE2D2 (-) 3 cancer cell line human CVCL_TV57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149539 CVCL_U757 KD [Human abdomen rhabdoid tumor] cancer cell line human CVCL_U757 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from sampling site: Abdomen. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149540 CVCL_U754 GM16798 transformed cell line human CVCL_U754 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~750]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~1000]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149541 CVCL_TV54 HAP1 UBE2D1 (-) 2 cancer cell line human CVCL_TV54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12474; UBE2D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149542 CVCL_U755 GM21542 transformed cell line human CVCL_U755 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Simple; p.Gly130Val (c.389G>T); ClinVar=VCV000003982; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149543 CVCL_TV55 HAP1 UBE2D2 (-) 1 cancer cell line human CVCL_TV55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149544 CVCL_U758 1783 cancer cell line human CVCL_U758 CL:0000010 Derived from sampling site: Kidney. Male 21149545 CVCL_TV58 HAP1 UBE2D3 (-) 1 cancer cell line human CVCL_TV58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12476; UBE2D3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149546 CVCL_U759 2004 cancer cell line human CVCL_U759 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from sampling site: Kidney. Male 21149547 CVCL_TV59 HAP1 UBE2D3 (-) 2 cancer cell line human CVCL_TV59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12476; UBE2D3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149548 CVCL_2100 L138.8A factor-dependent cell line house mouse CVCL_2100 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: BALB/c. Female Characteristics: IL3 dependent Doubling time: ~30-40 hours (DSMZ=ACC-114) 21149549 CVCL_1P00 RAW264-TG3 cancer cell line house mouse CVCL_1P00 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21149550 CVCL_1P01 GM02621 finite cell line human CVCL_1P01 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;12)(q22;q24) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21149551 CVCL_2101 LAT spontaneously immortalized cell line CVCL_2101 CL:0000010 Derived from sampling site: Aorta. Male Doubling time: ~30-50 hours (DSMZ=ACC-349) 21149552 CVCL_1P04 A9(GM1533)-1 hybrid cell line CVCL_1P04 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149553 CVCL_2104 LOU-NH91 cancer cell line human CVCL_2104 HLA typing: A*02:01,02:01; B*15:01,15:01; C*03:03,03:03; DQA1*01:02,02:01; DQB1*06:11,06:11; DRB1*03:17,11:02 (PubMed=26589293); Genome ancestry: African=0.6%; Native American=0%; East Asian, North=3.36%; East Asian, South=0%; South Asian=0.43%; European, North=58.24%; European, South=37.36% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Pro257Argfs*39 (c.770del) (p.Phe256fs); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu726Lys (c.2176G>A); ClinVar=VCV000376476; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Met (c.427G>A); ClinVar=VCV000142657; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~80 hours (DSMZ=ACC-393); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149554 CVCL_1P05 A9(GM1695)-3 hybrid cell line CVCL_1P05 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149555 CVCL_2105 LS cancer cell line human CVCL_2105 CL:0000010 Omics: Deep exome analysis. Female Doubling time: ~45 hours (DSMZ=ACC-675) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149556 CVCL_1P02 A9(GM0097)-1 hybrid cell line CVCL_1P02 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149557 CVCL_2102 LCL 721 transformed cell line human CVCL_2102 HLA typing: A*01:01:01:01,02:01:01:01; B*08:01:01,51:01:01; C*07:01:01,01:02:01; DPA1*01:03,02:01:02; DPB1*02:01:02,04:01; DQB1*05:01:01; DRB1*01:01 (IPD-IMGT/HLA=10972) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21149558 CVCL_1P03 A9(GM0194)-3 hybrid cell line CVCL_1P03 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149559 CVCL_2103 LF-CL2A cancer cell line Norway rat CVCL_2103 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Wistar Commentry. Doubling time: ~20-25 hours (DSMZ=ACC-195) 21149560 CVCL_1P08 A9(GM2859)-3 hybrid cell line CVCL_1P08 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149561 CVCL_2108 M3E3/C3 spontaneously immortalized cell line CVCL_2108 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Female Doubling time: 11 hours (PubMed=6890064); ~40 hours (DSMZ=ACC-340) 21149562 CVCL_1P09 A9(GM2859)-4 hybrid cell line CVCL_1P09 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149563 CVCL_2109 MB-1 cancer cell line human CVCL_2109 CL:0000010 Population: Caucasian; Karyotypic information: Has lost chromosome Y (PubMed=18616678); Derived from sampling site: Thyroid gland. Omics: Deep exome analysis Male Doubling time: ~36 hours (PubMed=18616678); ~60-100 hours (DSMZ=ACC-638) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149564 CVCL_1P06 A9(GM1695)-4 hybrid cell line CVCL_1P06 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149565 CVCL_2106 M-07e cancer cell line human CVCL_2106 HLA typing: A*24:02:01,66:01:01; B*13:02:01,49:01:01; C*06:02:01;07:01:01 (DSMZCellDive=ACC-104); Genome ancestry: African=8.96%; Native American=0%; East Asian, North=0.92%; East Asian, South=0%; South Asian=3.01%; European, North=45.47%; European, South=41.63% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 31677; ANO7 + HGNC; 17887; DHDH; Name(s)=ANO7-DHDH (PubMed=31160637); Sequence variation: Gene fusion; HGNC; 1537; CBFA2T3 + HGNC; 29450; GLIS2; Name(s)=CBFA2T3-GLIS2, ETO2-GLIS2 (PubMed=28109323); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46 +- 12 hours (PubMed=9096695); ~40 hours (DSMZ=ACC-104) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21149566 CVCL_1P07 A9(GM1695)-5 hybrid cell line CVCL_1P07 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149567 CVCL_2107 M1 cancer cell line house mouse CVCL_2107 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: SL. Omics: SNP array analysis Doubling time: ~25-50 hours (DSMZ=ACC-331) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21149568 CVCL_U760 DL [Human lung rhabdoid tumor] cancer cell line human CVCL_U760 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307) Derived from sampling site: Lung. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149569 CVCL_TV60 HAP1 UBE2D4 (-) 1 cancer cell line human CVCL_TV60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21647; UBE2D4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149570 CVCL_U741 GM16211 transformed cell line human CVCL_U741 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149571 CVCL_TV41 HAP1 UBAC1 (-) 1 cancer cell line human CVCL_TV41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30221; UBAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149572 CVCL_U742 GM16214 transformed cell line human CVCL_U742 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~600]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~700]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149573 CVCL_TV42 HAP1 UBAC1 (-) 2 cancer cell line human CVCL_TV42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30221; UBAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149574 CVCL_U740 GM16210 transformed cell line human CVCL_U740 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~580]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149575 CVCL_TV40 HAP1 UBA7 (-) 3 cancer cell line human CVCL_TV40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12471; UBA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149576 CVCL_U745 GM16223 transformed cell line human CVCL_U745 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[400]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[630]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149577 CVCL_TV45 HAP1 UBAC2 (-) 2 cancer cell line human CVCL_TV45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20486; UBAC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149578 CVCL_U746 GM16227 transformed cell line human CVCL_U746 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[630]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149579 CVCL_TV46 HAP1 UBE2A (-) 1 cancer cell line human CVCL_TV46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12472; UBE2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149580 CVCL_U743 GM16216 transformed cell line human CVCL_U743 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~200]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~500]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149581 CVCL_TV43 HAP1 UBAC1 (-) 3 cancer cell line human CVCL_TV43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30221; UBAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149582 CVCL_U744 GM16220 transformed cell line human CVCL_U744 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~460]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149583 CVCL_TV44 HAP1 UBAC2 (-) 1 cancer cell line human CVCL_TV44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20486; UBAC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149584 CVCL_U749 GM16234 transformed cell line human CVCL_U749 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[580]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1030]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149585 CVCL_TV49 HAP1 UBE2B (-) 2 cancer cell line human CVCL_TV49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12473; UBE2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149586 CVCL_U747 GM16228 transformed cell line human CVCL_U747 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149587 CVCL_TV47 HAP1 UBE2A (-) 2 cancer cell line human CVCL_TV47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12472; UBE2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149588 CVCL_U748 GM16230 transformed cell line human CVCL_U748 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[380]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[950]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149589 CVCL_TV48 HAP1 UBE2B (-) 1 cancer cell line human CVCL_TV48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12473; UBE2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149590 CVCL_1P11 A9(GM3322)-2 hybrid cell line CVCL_1P11 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149591 CVCL_2111 MEL-745A cl. DS19 cancer cell line house mouse CVCL_2111 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K79me2 ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis Doubling time: ~20 hours (DSMZ=ACC-501) Part of: ENCODE project mouse cell lines 21149592 CVCL_1P12 A9(GM3884)-2 hybrid cell line CVCL_1P12 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149593 CVCL_2112 MFE-319 cancer cell line human CVCL_2112 HLA typing: A*01:01,01:01; B*07:02,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.63%; European, North=66.31%; European, South=31.06% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Trp902Ter (c.2706G>A); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~100 hours (DSMZ=ACC-423); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21149594 CVCL_1P10 A9(GM3322)-1 hybrid cell line CVCL_1P10 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149595 CVCL_2110 ME-1 [Human leukemia] cancer cell line human CVCL_2110 HLA typing: A*24:02,26:01; B*35:01,51:01; C*01:02,14:02; DQA1*01:03,01:03; DQB1*06:02,06:02; DRB1*08:02,15:01 (PubMed=26589293); HLA typing: A*24:02:01,26:01:01; B*35:01:01,51:01:01; C*01:02:01,14:02:01; DPA1*01:03:01,02:02:02; DPB1*05:01:01,02:02; DQB1*06:02:01,06:02:01; DRA*01:01:01,01:02:02; DRB1*08:02:01,15:01:01 (DSMZCellDive=ACC-537); Genome ancestry: African=0.67%; Native American=0.61%; East Asian, North=75.25%; East Asian, South=23.47%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (PubMed=15843827); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 4-5 days (PubMed=2070080); ~3-5 days (DSMZ=ACC-537); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: TCGA-110-CL cell line panel 21149596 CVCL_1P15 A9+12 hybrid cell line CVCL_1P15 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149597 CVCL_2115 MHEC5-T spontaneously immortalized cell line house mouse CVCL_2115 CL:0000010 Derived from sampling site: Heart; myocardium Cell type=Cardiac endothelial cell.; Breed/subspecies: NMRI. Unspecified Doubling time: ~30 hours (DSMZ=ACC-336) 21149598 CVCL_1P16 A9+15 hybrid cell line CVCL_1P16 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149599 CVCL_2116 MKPL-1 cancer cell line human CVCL_2116 HLA typing: A*24:02:01,31:01:02; B*07:02:01,56:01:01; C*04:01:01,07:02:01 (DSMZCellDive=ACC-697) CL:0000010 Sequence variation: Gene fusion; HGNC; 2433; CSF1R + HGNC; 9903; RBM6; Name(s)=RBM6-CSF1R (PubMed=17360941) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0536; true Male Doubling time: 30 hours (PubMed=1602796); ~50-60 hours (DSMZ=ACC-697) Part of: LL-100 blood cancer cell line panel 21149600 CVCL_1P13 A9(GM4618)-10 hybrid cell line CVCL_1P13 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149601 CVCL_2113 MH-7777A cancer cell line Norway rat CVCL_2113 CL:0000010 Transformant: N-2-fluorenylphthalamic acid (2-FPA)(ChEBI; CHEBI:189414); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Female Doubling time: ~48 hours (DSMZ=ACC-345) 21149602 CVCL_1P14 A9(GM4618)-2 hybrid cell line CVCL_1P14 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149603 CVCL_2114 MH1C1 cancer cell line Norway rat CVCL_2114 CL:0000010 Breed/subspecies: Buffalo. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 85112702; probable Doubling time: 1 week (PubMed=4177659); ~33-60 hours (DSMZ=ACC-106) 21149604 CVCL_1P19 A9+22 hybrid cell line CVCL_1P19 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149605 CVCL_2119 MOLM-13 cancer cell line human CVCL_2119 HLA typing: A*26:01:01,31:01:02; B*44:03:01,51:01:01; C*14:02:01,14:03 (DSMZCellDive=ACC-554); Genome ancestry: African=0%; Native American=1.24%; East Asian, North=76.64%; East Asian, South=22.12%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=9305600; PubMed=14671638; PubMed=15381384); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=10233379; PubMed=12529668; PubMed=27750403) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3-4 days (PubMed=9305600); 24 hours (PubMed=25984343); 41.1 hours (PubMed=28052028); ~50 hours (DSMZ=ACC-554); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21149606 CVCL_1P17 A9+2 hybrid cell line CVCL_1P17 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149607 CVCL_2117 MMQ cancer cell line Norway rat CVCL_2117 CL:0000010 Derived from sampling site: Pituitary gland. Unspecified Doubling time: ~48 hors (DSMZ=ACC-484) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10609 21149608 CVCL_1P18 A9+20 hybrid cell line CVCL_1P18 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149609 CVCL_2118 MOLM-1 cancer cell line human CVCL_2118 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1782185; PubMed=10071072); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Doubling time: ~43 hours (PubMed=1782185); ~60-70 hours (DSMZ=ACC-720); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149610 CVCL_TV30 HAP1 TYK2 (-) 1 cancer cell line human CVCL_TV30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149611 CVCL_U730 LS212-7F3-8-7 hybridoma house mouse CVCL_U730 CL:0000010 Discontinued: ATCC; CRL-13014; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00574; Human CXCR6/CD186/Bonzo Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-990 21149612 CVCL_TV31 HAP1 TYK2 (-) 2 cancer cell line human CVCL_TV31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149613 CVCL_U731 LS212-9G2-7-2 hybridoma house mouse CVCL_U731 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O00574; Human CXCR6/CD186/Bonzo. 21149614 CVCL_U734 GM15850 transformed cell line human CVCL_U734 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[650]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1030]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21149615 CVCL_TV34 HAP1 TYK2 (-) 5 cancer cell line human CVCL_TV34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149616 CVCL_U735 GM16197 transformed cell line human CVCL_U735 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[760]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149617 CVCL_TV35 HAP1 TYRO3 (-) 1 cancer cell line human CVCL_TV35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12446; TYRO3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149618 CVCL_U732 GM03665 finite cell line human CVCL_U732 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[816]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1400]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21149619 CVCL_TV32 HAP1 TYK2 (-) 3 cancer cell line human CVCL_TV32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149620 CVCL_U733 GM14518 transformed cell line human CVCL_U733 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~925]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~1122]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149621 CVCL_TV33 HAP1 TYK2 (-) 4 cancer cell line human CVCL_TV33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12440; TYK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149622 CVCL_U738 GM16207 transformed cell line human CVCL_U738 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[280]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149623 CVCL_TV38 HAP1 UBA7 (-) 1 cancer cell line human CVCL_TV38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12471; UBA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149624 CVCL_U739 GM16209 transformed cell line human CVCL_U739 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[~800]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149625 CVCL_TV39 HAP1 UBA7 (-) 2 cancer cell line human CVCL_TV39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12471; UBA7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149626 CVCL_U736 GM16203 transformed cell line human CVCL_U736 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149627 CVCL_TV36 HAP1 TYRO3 (-) 2 cancer cell line human CVCL_TV36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12446; TYRO3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149628 CVCL_U737 GM16206 transformed cell line human CVCL_U737 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[640]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[670]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149629 CVCL_TV37 HAP1 TYRO3 (-) 3 cancer cell line human CVCL_TV37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12446; TYRO3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149630 CVCL_U720 1A3.1.1 hybridoma house mouse CVCL_U720 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96PJ5; Human FCRL4/CD307d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6339 21149631 CVCL_TV20 HAP1 TUBB3 (-) 2 cancer cell line human CVCL_TV20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20772; TUBB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149632 CVCL_U723 2A10.1.1 hybridoma house mouse CVCL_U723 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA6; Human FCRL1/CD307a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6333 21149633 CVCL_TV23 HAP1 TUSC3 (-) 1 cancer cell line human CVCL_TV23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30242; TUSC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149634 CVCL_U724 6F2.1.1 hybridoma house mouse CVCL_U724 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96P31; Human FCRL3/CD307c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6337 21149635 CVCL_TV24 HAP1 TUSC3 (-) 2 cancer cell line human CVCL_TV24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30242; TUSC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149636 CVCL_U721 1D6.3.8 hybridoma house mouse CVCL_U721 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA6; Human FCRL1/CD307a; Monoclonal antibody target: UniProtKB; Q96LA5; Human FCRL2/CD307b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6334 21149637 CVCL_TV21 HAP1 TUBB4B (-) 1 cancer cell line human CVCL_TV21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20771; TUBB4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149638 CVCL_U722 1F9.1.1 hybridoma house mouse CVCL_U722 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA6; Human FCRL1/CD307a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6332 21149639 CVCL_TV22 HAP1 TUBB4B (-) 2 cancer cell line human CVCL_TV22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20771; TUBB4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149640 CVCL_U727 7E4.1.1 hybridoma house mouse CVCL_U727 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA6; Human FCRL1/CD307a; Monoclonal antibody target: UniProtKB; Q96LA5; Human FCRL2/CD307b; Monoclonal antibody target: UniProtKB; Q96P31; Human FCRL3/CD307c; Monoclonal antibody target: UniProtKB; Q96RD9; Human FCRL5/CD307e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6338 21149641 CVCL_TV27 HAP1 TWF2 (-) 2 cancer cell line human CVCL_TV27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9621; TWF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149642 CVCL_U728 7G7.7.8 hybridoma house mouse CVCL_U728 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA5; Human FCRL2/CD307b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6336 21149643 CVCL_TV28 HAP1 TWIST1 (-) cancer cell line human CVCL_TV28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12428; TWIST1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149644 CVCL_U725 7A2.4.1 hybridoma house mouse CVCL_U725 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96LA6; Human FCRL1/CD307a; Monoclonal antibody target: UniProtKB; Q96LA5; Human FCRL2/CD307b; Monoclonal antibody target: UniProtKB; Q96P31; Human FCRL3/CD307c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6335 21149645 CVCL_TV25 HAP1 TWF1 (-) cancer cell line human CVCL_TV25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9620; TWF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149646 CVCL_U726 7D11.1.1 hybridoma house mouse CVCL_U726 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q96RD9; Human FCRL5/CD307e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6340 21149647 CVCL_TV26 HAP1 TWF2 (-) 1 cancer cell line human CVCL_TV26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9621; TWF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149648 CVCL_TV29 HAP1 TXNIP (-) 1 cancer cell line human CVCL_TV29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16952; TXNIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149649 CVCL_U729 LS212-4A11-30-8 hybridoma house mouse CVCL_U729 CL:0000010 Discontinued: ATCC; CRL-13015; true. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; O00574; Human CXCR6/CD186/Bonzo Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-991 21149650 CVCL_U712 GM16883 finite cell line human CVCL_U712 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ala363fs (c.1088-2A>G) (IVS5-2A>G); Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=17407155; Coriell); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln672Arg (c.2015A>G) (2089A>G); ClinVar=VCV000188963; Zygosity=Heterozygous (PubMed=17407155; Coriell) Population: Caucasian; Belgian; Donor information: From Bloom Syndrome Registry patient 31(CaDe) (BSR31); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21149651 CVCL_TV12 HAP1 TUBA1C (-) 3 cancer cell line human CVCL_TV12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20768; TUBA1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149652 CVCL_U713 GM16886 finite cell line human CVCL_U713 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln700Ter (c.2098C>T); ClinVar=VCV000042067; Zygosity=Heterozygous (PubMed=17407155; Coriell) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 59(FrFi) (BSR59); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21149653 CVCL_TV13 HAP1 TUBA1C (-) 4 cancer cell line human CVCL_TV13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20768; TUBA1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149654 CVCL_U710 GM16881 finite cell line human CVCL_U710 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln975Lysfs*24 (c.2923delC); ClinVar=VCV000042076; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 6(DeSou) (BSR6); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21149655 CVCL_TV10 HAP1 TUBA1C (-) 1 cancer cell line human CVCL_TV10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20768; TUBA1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149656 CVCL_U711 GM16882 finite cell line human CVCL_U711 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155; Coriell); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe1087Leufs*11 (c.3261delT); Zygosity=Heterozygous (PubMed=17407155; Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 26(SaTi) (BSR26); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21149657 CVCL_TV11 HAP1 TUBA1C (-) 2 cancer cell line human CVCL_TV11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20768; TUBA1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149658 CVCL_U716 GM09494 finite cell line human CVCL_U716 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21149659 CVCL_TV16 HAP1 TUBB1 (-) 1 cancer cell line human CVCL_TV16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16257; TUBB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149660 CVCL_U717 GM10497 finite cell line human CVCL_U717 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21149661 CVCL_TV17 HAP1 TUBB1 (-) 2 cancer cell line human CVCL_TV17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16257; TUBB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149662 CVCL_U714 GM16890 finite cell line human CVCL_U714 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 133 (BSR133); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling Female 21149663 CVCL_TV14 HAP1 TUBA4A (-) 1 cancer cell line human CVCL_TV14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12407; TUBA4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149664 CVCL_U715 GM16891 finite cell line human CVCL_U715 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 169 (BSR169); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21149665 CVCL_TV15 HAP1 TUBA4A (-) 2 cancer cell line human CVCL_TV15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12407; TUBA4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149666 CVCL_TV18 HAP1 TUBB1 (-) 3 cancer cell line human CVCL_TV18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16257; TUBB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149667 CVCL_U718 HBME-1 transformed cell line human CVCL_U718 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pMT10D](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Endothelial cell.. Discontinued: ATCC; CRL-2767; true Male 21149668 CVCL_TV19 HAP1 TUBB3 (-) 1 cancer cell line human CVCL_TV19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20772; TUBB3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149669 CVCL_U719 LS212-7A2-32-1 hybridoma house mouse CVCL_U719 CL:0000010 Discontinued: ATCC; CRL-13016; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00574; Human CXCR6/CD186/Bonzo Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-992 21149670 CVCL_U701 AG01437 finite cell line human CVCL_U701 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: Coriell; AG01437; probable Male 21149671 CVCL_TV01 HAP1 TSSK4 (-) 1 cancer cell line human CVCL_TV01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19825; TSSK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149672 CVCL_U702 GM00811 finite cell line human CVCL_U702 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 3(HoCo) (BSR3); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling Discontinued: Coriell; GM00811; probable Male 21149673 CVCL_TV02 HAP1 TSSK4 (-) 2 cancer cell line human CVCL_TV02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19825; TSSK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149674 CVCL_TV00 HAP1 TSSK3 (-) cancer cell line human CVCL_TV00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15473; TSSK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149675 CVCL_U700 Ws-HMG finite cell line human CVCL_U700 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1253; true Female 21149676 CVCL_U705 GM02932 finite cell line human CVCL_U705 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 3(HoCo) (BSR3); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21149677 CVCL_TV05 HAP1 TTBK2 (-) 3 cancer cell line human CVCL_TV05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19141; TTBK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149678 CVCL_U706 GM09960 transformed cell line human CVCL_U706 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 27(LySe) (BSR27); Derived from sampling site: Peripheral blood. Female 21149679 CVCL_TV06 HAP1 TTC38 (-) 1 cancer cell line human CVCL_TV06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26082; TTC38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149680 CVCL_U703 GM02085 finite cell line human CVCL_U703 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 53(StAs) (BSR53); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21149681 CVCL_TV03 HAP1 TTBK2 (-) 1 cancer cell line human CVCL_TV03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19141; TTBK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149682 CVCL_U704 GM02520 finite cell line human CVCL_U704 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Val942fs (c.2824-1077_2999+310del1583); Zygosity=Heterozygous (PubMed=17407155; Coriell); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln975Lysfs*24 (c.2923delC); ClinVar=VCV000042076; Zygosity=Heterozygous (PubMed=17407155; Coriell) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 20(ViSh) (BSR20); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21149683 CVCL_TV04 HAP1 TTBK2 (-) 2 cancer cell line human CVCL_TV04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19141; TTBK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149684 CVCL_U709 GM16860 finite cell line human CVCL_U709 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Arg899Ter (c.2695C>T); ClinVar=VCV000127491; Zygosity=Homozygous (PubMed=17407155; Coriell) Donor information: From Bloom Syndrome Registry patient 191 (BSR191); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21149685 CVCL_TV09 HAP1 TUBA1A (-) 2 cancer cell line human CVCL_TV09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20766; TUBA1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149686 CVCL_U707 GM16377 transformed cell line human CVCL_U707 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155; Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 27(LySe) (BSR27); Derived from sampling site: Peripheral blood. Female 21149687 CVCL_TV07 HAP1 TTC7A (-) 1 cancer cell line human CVCL_TV07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19750; TTC7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149688 CVCL_U708 GM16859 finite cell line human CVCL_U708 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi/Sephardic; Donor information: From Bloom Syndrome Registry patient 107(MyAsa) (BSR107); Derived from sampling site: Uterus; cervix Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21149689 CVCL_TV08 HAP1 TUBA1A (-) 1 cancer cell line human CVCL_TV08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20766; TUBA1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149690 CVCL_1P91 GM22737 transformed cell line human CVCL_1P91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149691 CVCL_2191 SHI-1 cancer cell line human CVCL_2191 CL:0000010 Sequence variation: Gene fusion; HGNC; 7137; AFDN + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFDN, MLL-MLLT4, MLL-AF6 (PubMed=15921626; PubMed=15951289); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (DepMap) Population: Chinese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~36 hours (PubMed=15951289); ~60-70 hours (DSMZ=ACC-645) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149692 CVCL_1P92 GM22738 transformed cell line human CVCL_1P92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149693 CVCL_2192 YAR transformed cell line human CVCL_2192 HLA typing: A*26:01:01:01; B*38:01:01; C*12:03:01:01; DPA1*01:03; DPB1*04:01:01; DQA1*03:01; DQB1*03:02:01; DRA*01:01; DRB1*04:02:01; DRB4*01:01 (IPD-IMGT/HLA=11587) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21149694 CVCL_1P90 GM22735 transformed cell line human CVCL_1P90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149695 CVCL_2190 SH-2 [Human leukemia] cancer cell line human CVCL_2190 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192His (c.576G>T); ClinVar=VCV000922531; Zygosity=Hemizygous (PubMed=18715689; PubMed=19954598) Population: Chinese; Karyotypic information: Has lost chromosome Y (PubMed=18715689; PubMed=19954598); Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: ~80 hours (DSMZ=ACC-643) 21149696 CVCL_1P95 GM22633 transformed cell line human CVCL_1P95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21149697 CVCL_2195 SK-GT-4 cancer cell line human CVCL_2195 Genome ancestry: African=2.11%; Native American=1.08%; East Asian, North=1.62%; East Asian, South=0%; South Asian=7.99%; European, North=27.72%; European, South=59.48% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=27594985; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln100Ter (c.298C>T); ClinVar=VCV000634707; Zygosity=Homozygous (PubMed=20075370; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Esophagus; distal. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Doubling time: 39 hours (PubMed=8334620); ~30-35 hours (DSMZ=ACC-712); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Caution: TP53 mutation indicated incorrectly as being at p.Arg175His (c.524G>A) in PubMed=7665247 21149698 CVCL_1P96 GM06226 transformed cell line human CVCL_1P96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21149699 CVCL_2196 SKNO-1 cancer cell line human CVCL_2196 HLA typing: A*02:06:01,31:01:02; B*40:02:01,46:01:01; C*01:02:01,03:04:01; DRA*01:01:01,01:02:02; DRB1*14:02:01,14:02:01 (DSMZCellDive=ACC-690); Genome ancestry: African=1.83%; Native American=0%; East Asian, North=90.65%; East Asian, South=3.5%; South Asian=1.23%; European, North=0.2%; European, South=2.59% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1535; RUNX1T1; Name(s)=RUNX1-RUNX1T1, AML1-ETO (PubMed=11753612; PubMed=15843827); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asn822Lys (c.2466T>A) (N818K); ClinVar=VCV000375931; Zygosity=Homozygous (PubMed=18385756; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=7772516; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His368Arg (c.1103G>A); Zygosity=Homozygous (PubMed=7772516; DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by RNAseq Male Characteristics: CSF2 dependent Doubling time: 48-72 hours (PubMed=7772516); 24 hours (PubMed=25984343); ~35-50 hours (DSMZ=ACC-690); ~38 hours (lot 06112012), 52-57 hours (lot 02032016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21149700 CVCL_1P93 GM22739 transformed cell line human CVCL_1P93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149701 CVCL_2193 SiSo cancer cell line human CVCL_2193 Genome ancestry: African=3.91%; Native American=0.11%; East Asian, North=79.2%; East Asian, South=9.59%; South Asian=0%; European, North=0%; European, South=7.19% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser834Ter (c.2501C>G); ClinVar=VCV000428733; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 24 hours (PubMed=21556646); ~35 hours (DSMZ=ACC-327); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149702 CVCL_1P94 GM22741 transformed cell line human CVCL_1P94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149703 CVCL_2194 SK-GT-2 cancer cell line human CVCL_2194 Genome ancestry: African=20.34%; Native American=14.81%; East Asian, North=2.09%; East Asian, South=0%; South Asian=0%; European, North=30.94%; European, South=31.83% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=7665247; Cosmic-CLP; DepMap) Population: Hispanic; Derived from sampling site: Stomach; fundus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 44 hours (PubMed=8334620); ~48 hours (DSMZ=ACC-702); ~44 hours (ECACC=11012008); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149704 CVCL_1P88 GM22733 transformed cell line human CVCL_1P88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149705 CVCL_2188 SEWA cancer cell line house mouse CVCL_2188 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male Doubling time: ~28 hours (DSMZ=ACC-523) 21149706 CVCL_1P89 GM22734 transformed cell line human CVCL_1P89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149707 CVCL_2189 SGE-1 spontaneously immortalized cell line Norway rat CVCL_2189 CL:0000010 Derived from sampling site: Kidney; glomerulus Cell type=Epithelial cell.; Breed/subspecies: Wistar. Male Doubling time: 21.6 hours (PubMed=3242847); ~33 hours (DSMZ=ACC-343) 21149708 CVCL_1P86 GM22731 transformed cell line human CVCL_1P86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149709 CVCL_2186 SCLC-22H cancer cell line human CVCL_2186 HLA typing: A*01:01,32:01; B*35:86,27:05; C*02:02,02:02 (PubMed=25960936); HLA typing: A*01:01,32:01; B*27:05,35:86; C*02:02,02:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Arg (c.833C>G); ClinVar=VCV000376644; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from metastatic site: Pericardial effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 75-85 hours, depending on growth medium (PubMed=3029138); 75 hours (PubMed=2438285); ~48 hours (DSMZ=ACC-373) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149710 CVCL_1P87 GM22732 transformed cell line human CVCL_1P87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149711 CVCL_2187 SET-2 cancer cell line human CVCL_2187 HLA typing: A*02:01,33:03; B*40:02,44:03; C*03:03,14:03 (PubMed=26589293); HLA typing: A*02:01:01,33:03:01; B*40:02:01,44:03:01; C*03:03:01,14:03; DPA1*02:01:01,02:02:02; DPB1*09:01:01,05:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:09:01; DRA*01:01:01,01:02:02; DRB1*04:06:01,13:02:01 (DSMZCellDive=ACC-608); Genome ancestry: African=7.24%; Native American=0%; East Asian, North=78.39%; East Asian, South=9.7%; South Asian=0%; European, North=0%; European, South=4.67% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882His (c.2645G>A); ClinVar=VCV000375881; Zygosity=Heterozygous (PubMed=31739141; DepMap); Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=16408098; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+2T>A; ClinVar=VCV000635391; Zygosity=Heterozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~36 hours (PubMed=10637490); ~60-80 hours (DSMZ=ACC-608) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21149712 CVCL_1P99 CY3 hybrid cell line CVCL_1P99 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21149713 CVCL_2199 Sp2/0-Ag14 cancer cell line house mouse CVCL_2199 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Doubling time: ~30-40 hours (DSMZ=ACC-146) Group: Hybridoma fusion partner cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8287 21149714 CVCL_1P97 GM06227 transformed cell line human CVCL_1P97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149715 CVCL_2197 SKW-3 cancer cell line human CVCL_2197 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line). Population: Caucasian Male Doubling time: ~30-40 hours (DSMZ=ACC-53); ~30 hours (CLS) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00346 Problematic cell line: Contaminated Shown to be a KE-37 derivative (PubMed=20143388). Originally thought to originate from the peripheral blood of a 61 year old male patient with T cell chronic lymphocytic leukemia. 21149716 CVCL_1P98 CY2 [Human/mouse hybrid] hybrid cell line CVCL_1P98 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21149717 CVCL_2198 SOM-4D10 hybridoma house mouse CVCL_2198 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Doubling time: ~20-30 hours (DSMZ=ACC-480) 21149718 CVCL_1P70 GM22645 transformed cell line human CVCL_1P70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149719 CVCL_2170 RED-1 cancer cell line house mouse CVCL_2170 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: DBA/2. Female Doubling time: ~24 hours (DSMZ=ACC-407) 21149720 CVCL_1P73 GM22649 transformed cell line human CVCL_1P73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149721 CVCL_2173 RED-6 cancer cell line house mouse CVCL_2173 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: DBA/2. Female Doubling time: ~18 hours (DSMZ=ACC-466) 21149722 CVCL_1P74 GM22650 transformed cell line human CVCL_1P74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149723 CVCL_2174 RenCa cancer cell line house mouse CVCL_2174 CL:0000010 Breed/subspecies: BALB/c. Male 21149724 CVCL_1P71 GM22647 transformed cell line human CVCL_1P71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149725 CVCL_2171 RED-4 cancer cell line house mouse CVCL_2171 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: DBA/2. Female Doubling time: ~24 hours (DSMZ=ACC-425) 21149726 CVCL_1P72 GM22648 transformed cell line human CVCL_1P72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149727 CVCL_2172 RED-5 cancer cell line house mouse CVCL_2172 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: DBA/2. Female Doubling time: ~30 hours (DSMZ=ACC-451) 21149728 CVCL_1P66 GM22641 transformed cell line human CVCL_1P66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149729 CVCL_2166 PYS cancer cell line house mouse CVCL_2166 CL:0000010 Breed/subspecies: 129/Sv. Male Doubling time: ~24 hours (DSMZ=ACC-284) 21149730 CVCL_2167 ES-R1 embryonic stem cell house mouse CVCL_2167 CL:0000010 Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Omics: Cell surface proteome; Omics: Deep proteome analysis; Omics: SNP array analysis Male 21149731 CVCL_1P67 GM22642 transformed cell line human CVCL_1P67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149732 CVCL_1P64 GM22575 finite cell line human CVCL_1P64 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 30 PDL (Coriell=GM22575) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149733 CVCL_2164 PNT2 transformed cell line human CVCL_2164 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male Doubling time: 35.9 +- 1.56 hours (PubMed=21556542) 21149734 CVCL_1P65 GM22577 finite cell line human CVCL_1P65 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=GM22577) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149735 CVCL_2165 Psi-2 transformed cell line house mouse CVCL_2165 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Doubling time: ~34 hours (DSMZ=ACC-238) Group: Retrovirus packaging cell line 21149736 CVCL_1P68 GM22643 transformed cell line human CVCL_1P68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149737 CVCL_1P69 GM22644 transformed cell line human CVCL_1P69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149738 CVCL_2169 RD-ES cancer cell line human CVCL_2169 Genome ancestry: African=1.21%; Native American=0.02%; East Asian, North=3.1%; East Asian, South=0%; South Asian=0%; European, North=61.77%; European, South=33.89% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777; PubMed=19787792); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=8040301; PubMed=9738976; PubMed=11423975; PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8221663; PubMed=8378080; PubMed=19787792; PubMed=25010205; PubMed=25223734; DepMap) Population: Caucasian; Derived from sampling site: Bone; humerus. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (DSMZ=ACC-260) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21149739 CVCL_1P80 GM22675 transformed cell line human CVCL_1P80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149740 CVCL_2180 RMA-S cancer cell line house mouse CVCL_2180 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. Characteristics: Deficient in antigen processing 21149741 CVCL_1P81 GM22677 transformed cell line human CVCL_1P81 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX.arr(1-22,X)x2 (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149742 CVCL_2181 RMB-1 cancer cell line house mouse CVCL_2181 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938). Doubling time: ~30-35 hours (DSMZ=ACC-391) 21149743 CVCL_1P84 GM22680 transformed cell line human CVCL_1P84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149744 CVCL_2184 SC-71 hybridoma house mouse CVCL_2184 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BE41; Bovine MYH2 (Note=Also recognizes other mammalian species). Doubling time: ~20 hours (DSMZ=ACC-217) 21149745 CVCL_1P85 GM22681 transformed cell line human CVCL_1P85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149746 CVCL_2185 SC-75 hybridoma house mouse CVCL_2185 CL:0000010 Monoclonal antibody isotype: IgM. Doubling time: ~23 hours (DSMZ=ACC-232) 21149747 CVCL_1P82 GM22678 transformed cell line human CVCL_1P82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149748 CVCL_2182 RS-5 cancer cell line human CVCL_2182 HLA typing: A*02:01,11:01; B*35:01,44:02; C*04:01,07:04; DQA1*01:02,05:02; DQB1*05:01,05:01; DRB1*11:02,14:46 (PubMed=26589293) CL:0000010 Omics: Transcriptome analysis by RNAseq Male Doubling time: ~4 days (DSMZ=ACC-604) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: May be misclassified While still annotated as a pleural sarcomatoid mesothelioma cell line, a variety of omics methods are classifying this cell line as a fibroblast (DOI=10.1101/166199; DepMap).; Caution: Not directly described in the original publication (PubMed=15372243), but indirectly mentioned ('Three others cell lines progressed in tissue culture'). 21149749 CVCL_1P83 GM22679 transformed cell line human CVCL_1P83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149750 CVCL_2183 RV-C2 hybridoma house mouse CVCL_2183 CL:0000010 Monoclonal antibody isotype: IgG2b. Doubling time: ~32 hours (DSMZ=ACC-289) 21149751 CVCL_1P77 GM22672 transformed cell line human CVCL_1P77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149753 CVCL_1P78 GM22673 transformed cell line human CVCL_1P78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149754 CVCL_2178 RLC-18 spontaneously immortalized cell line Norway rat CVCL_2178 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: JAR-2. Unspecified Doubling time: ~35-40 hours (DSMZ=ACC-332) 21149755 CVCL_1P75 GM22651 transformed cell line human CVCL_1P75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149756 CVCL_2175 RGE transformed cell line Norway rat CVCL_2175 CL:0000010 Transformant: Adenovirus 31(NCBI-Taxonomy; 10529); Derived from sampling site: Kidney; glomerulus Cell type=Glomerular endothelial cell.; Breed/subspecies: Sprague Dawley. Female Doubling time: ~17 hours (DSMZ=ACC-262) 21149757 CVCL_1P76 GM22671 transformed cell line human CVCL_1P76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149758 CVCL_2176 Rh41 cancer cell line human CVCL_2176 HLA typing: A*68:01,68:01; B*14:02,40:01; C*01:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.24%; East Asian, South=0%; South Asian=0%; European, North=66.46%; European, South=32.3% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=17471488) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Exosome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 44 hours (PubMed=20922763); ~2-3 days (DSMZ=ACC-592); 60 hours (COG); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21149759 CVCL_1P79 GM22674 transformed cell line human CVCL_1P79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female Part of: NIGMS collection of multiple cell lines from the same individual; EBV-transformed lymphoblasts 21149760 CVCL_2179 RLD-1 [Mouse] cancer cell line house mouse CVCL_2179 CL:0000010 Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: DBA/2. Doubling time: ~20-30 hours (DSMZ=ACC-415) 21149761 CVCL_TV96 HAP1 UBE2Z (-) 2 cancer cell line human CVCL_TV96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25847; UBE2Z; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149762 CVCL_U796 NCC-RbC-30 cancer cell line human CVCL_U796 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Male Doubling time: >100 hours (PubMed=8263010) 21149763 CVCL_U797 CJM [Human melanoma] cancer cell line human CVCL_U797 HLA typing: A*02:01,02:01; B*40:02,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.43%; Native American=0.61%; East Asian, North=76.74%; East Asian, South=21.81%; South Asian=0%; European, North=0%; European, South=0.4% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Gly (c.838A>G); ClinVar=VCV000376658; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149764 CVCL_TV97 HAP1 UBE3A (-) 1 cancer cell line human CVCL_TV97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12496; UBE3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149765 CVCL_TV94 HAP1 UBE2W (-) 3 cancer cell line human CVCL_TV94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25616; UBE2W; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149766 CVCL_U794 To War finite cell line human CVCL_U794 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1244; true Male 21149767 CVCL_TV95 HAP1 UBE2Z (-) 1 cancer cell line human CVCL_TV95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25847; UBE2Z; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149768 CVCL_U795 NCC-RbC-58 cancer cell line human CVCL_U795 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Female 21149769 CVCL_TV98 HAP1 UBE4A (-) 1 cancer cell line human CVCL_TV98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12499; UBE4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149770 CVCL_U798 WW cancer cell line human CVCL_U798 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. 21149771 CVCL_TV99 HAP1 UBE4A (-) 2 cancer cell line human CVCL_TV99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12499; UBE4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149772 CVCL_U799 MW [Human melanoma] cancer cell line human CVCL_U799 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21149773 CVCL_1P51 GM22255 finite cell line human CVCL_1P51 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=GM22255) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149774 CVCL_2151 OMEGA-E spontaneously immortalized cell line house mouse CVCL_2151 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Doubling time: ~20-30 hours (DSMZ=ACC-253) Group: Retrovirus packaging cell line 21149775 CVCL_1P52 GM22258 finite cell line human CVCL_1P52 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 31 PDL (Coriell=GM22258) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149776 CVCL_2152 OTH-74D4 hybridoma house mouse CVCL_2152 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Doubling time: ~40-50 hours (DSMZ=ACC-478) 21149777 CVCL_1P50 GM22254 finite cell line human CVCL_1P50 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22254) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149778 CVCL_2150 OCI-M2 cancer cell line human CVCL_2150 HLA typing: A*02:01,02:01; B*08:01,44:02; C*05:01,07:06 (PubMed=26589293); HLA typing: A*02:01:01,02:01:01; B*08:01:01,44:02:01; C*05:01:01,07:01:01 (DSMZCellDive=ACC-619) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Gene fusion; HGNC; 10471; RUNX1 + HGNC; 1268; TSPEAR; Name(s)=RUNX1-TSPEAR (PubMed=31160637); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Asp (c.821T>A); ClinVar=VCV000376675; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: ~36 hours (DSMZ=ACC-619) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21149779 CVCL_1P44 GM22221 finite cell line human CVCL_1P44 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 41 PDL (Coriell=GM22221) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149780 CVCL_2144 NRK-49F spontaneously immortalized cell line Norway rat CVCL_2144 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. Doubling time: ~30-40 hours (DSMZ=ACC-172) 21149781 CVCL_1P45 GM22222 finite cell line human CVCL_1P45 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=GM22222) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149782 CVCL_2145 NT-92 cancer cell line Norway rat CVCL_2145 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~3-4 days (DSMZ=ACC-639) 21149783 CVCL_1P42 GM22204 finite cell line human CVCL_1P42 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 37 PDL (Coriell=GM22204) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149784 CVCL_2142 NK-92 cancer cell line human CVCL_2142 HLA typing: A*03:01:01,11:01:01; B*07:02:01,44:03:01; C*07:02:01,16:01:01; DPA1*01:03:01,01:03:01; DQB1*06:02:01,06:02:01 (DSMZCellDive=ACC-488) CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Unexplicit; Ex29-34del; Zygosity=Heterozygous (PubMed=16827800) Miscellaneous: Neukoplast is used as a trademark to refer to NK-92 cells that are available for non-human research applications while aNK is used as a trademark to refer to cells from the cGMP-grade NK-92 cell-line that is in use for therapeutic human testing Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: AddexBio; C0003026; true; Discontinued: BCRC; 60414; true Male Characteristics: Laboratory use as a standard cell line for antibody-dependent cell-mediated cytotoxicity (ADCC) testing Also being developed for cellular adoptive immunotherapy for cancers and viral infections.; Characteristics: IL2 dependent; Characteristics: Does not express FCGR3A/CD16 Doubling time: 35.6 +- 6.1 hours (PubMed=31126350); ~40-50 hours (DSMZ=ACC-488) Group: Patented cell line; Part of: LL-100 blood cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6670 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and noncommercial suppliers of NK-92 cells. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21149785 CVCL_1P43 GM22205 finite cell line human CVCL_1P43 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=GM22205) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149786 CVCL_2143 NMB cancer cell line human CVCL_2143 CL:0000010 Derived from metastatic site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~40-50 hours (DSMZ=ACC-657) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149787 CVCL_1P48 GM22252 finite cell line human CVCL_1P48 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149788 CVCL_2148 NW145 cancer cell line human CVCL_2148 HLA typing: A*23:01,23:01; B*15:01:01:01,15:01:01:01; C*01:02,01:02; DPB1*04:02; DQB1*06:04,03:01:01; DRB1*04:01,11:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Male 21149789 CVCL_1P49 GM22253 finite cell line human CVCL_1P49 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22253) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149790 CVCL_2149 OCI-M1 cancer cell line human CVCL_2149 HLA typing: A*02:01,03:01; B*14:02,15:03; C*02:02,08:02 (PubMed=26589293); Genome ancestry: African=3.87%; Native American=0%; East Asian, North=4.72%; East Asian, South=0%; South Asian=3.18%; European, North=27.28%; European, South=60.94% (PubMed=30894373). From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu145Arg (c.434T>G); ClinVar=VCV001027110; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: ~30 hours (DSMZ=ACC-529); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149791 CVCL_1P46 GM22250 finite cell line human CVCL_1P46 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149792 CVCL_2146 NUC-1 [Mouse urothelial] spontaneously immortalized cell line house mouse CVCL_2146 CL:0000010 Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.; Breed/subspecies: C3H/Law. Female Doubling time: ~24 hours (DSMZ=ACC-225) 21149793 CVCL_1P47 GM22251 finite cell line human CVCL_1P47 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149794 CVCL_2147 NUC-5 spontaneously immortalized cell line house mouse CVCL_2147 CL:0000010 Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.; Breed/subspecies: C3H/Law. Female Doubling time: ~60-75 hours (DSMZ=ACC-226) 21149795 CVCL_TV85 HAP1 UBE2Q1 (-) 2 cancer cell line human CVCL_TV85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15698; UBE2Q1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149796 CVCL_U785 Ma Tru finite cell line human CVCL_U785 CL:0000010 Derived from sampling site: Uterus Cell type=Fibroblast.. Discontinued: ATCC; CRL-1309; true Female 21149797 CVCL_TV86 HAP1 UBE2Q1 (-) 3 cancer cell line human CVCL_TV86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15698; UBE2Q1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149798 CVCL_U786 Me Lor finite cell line human CVCL_U786 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1368; true Male 21149799 CVCL_TV83 HAP1 UBE2O (-) 2 cancer cell line human CVCL_TV83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29554; UBE2O; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149800 CVCL_U783 Lu Gan finite cell line human CVCL_U783 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1264; true Female 21149801 CVCL_TV84 HAP1 UBE2Q1 (-) 1 cancer cell line human CVCL_TV84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15698; UBE2Q1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149802 CVCL_U784 Ma Not finite cell line human CVCL_U784 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1263; true Female 21149803 CVCL_TV89 HAP1 UBE2T (-) cancer cell line human CVCL_TV89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25009; UBE2T; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149804 CVCL_U789 Ne Col finite cell line human CVCL_U789 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1345; true Female 21149805 CVCL_TV87 HAP1 UBE2R2 (-) 1 cancer cell line human CVCL_TV87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19907; UBE2R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149806 CVCL_U787 Me Rey finite cell line human CVCL_U787 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1346; true Unspecified 21149807 CVCL_TV88 HAP1 UBE2R2 (-) 2 cancer cell line human CVCL_TV88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19907; UBE2R2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149808 CVCL_U788 Mor Man finite cell line human CVCL_U788 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1230; true Male 21149809 CVCL_1P62 GM22276 finite cell line human CVCL_1P62 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 44 PDL (Coriell=GM22276) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149810 CVCL_2162 PLB-985 cancer cell line human CVCL_2162 Genome ancestry: African=0.99%; Native American=0%; East Asian, North=1.35%; East Asian, South=0%; South Asian=0%; European, North=69.55%; European, South=28.11% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (DepMap) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 35 hours (PubMed=25984343); ~24 hours (DSMZ=ACC-139) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00258 Problematic cell line: Contaminated Shown to be a HL-60 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from a 38 year old female patient with acute nonlymphocytic leukemia. 21149811 CVCL_1P63 GM22277 finite cell line human CVCL_1P63 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=GM22277) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149812 CVCL_2163 PNT1A transformed cell line human CVCL_2163 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 29.93 +- 1.29 hours (PubMed=21556542) 21149813 CVCL_1P60 GM22268 finite cell line human CVCL_1P60 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 27 PDL (Coriell=GM22268) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149814 CVCL_2160 PK-15 spontaneously immortalized cell line pig CVCL_2160 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-6593; true Male Virology: PK-15 from ATCC was found to be infected with porcine circovirus type 1 (PCV1) (PubMed=2686830; PubMed=4151202) Doubling time: 12.1 +- 0.7 hours (PubMed=17889922); ~25 hours (DSMZ=ACC-640) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21149815 CVCL_1P61 GM22275 finite cell line human CVCL_1P61 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22275) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149816 CVCL_2161 PL-21 cancer cell line human CVCL_2161 HLA typing: A*24:02,26:01; B*13:01,40:06; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.5%; East Asian, North=78.62%; East Asian, South=18.83%; South Asian=0%; European, North=0%; European, South=1.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (PubMed=12529668); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Val (c.437C>T); ClinVar=VCV000375962; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro36fs*8 (c.107delC); Zygosity=Heterozygous (Cosmic-CLP) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48-64 hours (PubMed=6362749); ~40-50 hours (DSMZ=ACC-536); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149817 CVCL_1P55 GM22261 finite cell line human CVCL_1P55 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 25 PDL (Coriell=GM22261) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149818 CVCL_2155 P3/NS1/1-Ag4.1 cancer cell line house mouse CVCL_2155 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Doubling time: ~24 hours (DSMZ=ACC-145) Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C522 21149819 CVCL_1P56 GM22262 finite cell line human CVCL_1P56 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22262) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149820 CVCL_2156 PAb 100 hybridoma house mouse CVCL_2156 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21149821 CVCL_1P53 GM22259 finite cell line human CVCL_1P53 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 27 PDL (Coriell=GM22259) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149822 CVCL_2153 P19 cancer cell line house mouse CVCL_2153 CL:0000010 Breed/subspecies: C3H/He. Male Doubling time: ~2-3 days (DSMZ=ACC-316) Caution: There seem to be 3 distinct cell lines which were assigned NCBI_Iran catalog number C422 21149823 CVCL_1P54 GM22260 finite cell line human CVCL_1P54 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=GM22260) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149824 CVCL_2154 P815 cancer cell line house mouse CVCL_2154 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (PubMed=7513208; PubMed=10210327) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Omics: SNP array analysis Discontinued: JCRB; IFO50029; true Male Doubling time: ~18-22 hours (DSMZ=ACC-1) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21149825 CVCL_1P59 GM22267 finite cell line human CVCL_1P59 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 46 PDL (Coriell=GM22267) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149826 CVCL_2159 PB-1 [Mouse pre-B cell] factor-dependent cell line house mouse CVCL_2159 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: C57BL/6 x CBA. Unspecified Characteristics: IL7 dependent Doubling time: ~50 hours (DSMZ=ACC-241) 21149827 CVCL_1P57 GM22263 finite cell line human CVCL_1P57 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=GM22263) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149828 CVCL_2157 PAb 122 hybridoma house mouse CVCL_2157 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04637; Human TP53 (Note=Also reacts with other species). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21149829 CVCL_1P58 GM22266 finite cell line human CVCL_1P58 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 27 PDL (Coriell=GM22266) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149830 CVCL_2158 PAb 1620 hybridoma house mouse CVCL_2158 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04637; Human TP53 (Note=Also reacts with other species). Doubling time: ~24 hours (DSMZ=ACC-280) 21149831 CVCL_TV92 HAP1 UBE2W (-) 1 cancer cell line human CVCL_TV92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25616; UBE2W; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149832 CVCL_U792 Se Jac finite cell line human CVCL_U792 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1178; true Female 21149833 CVCL_TV93 HAP1 UBE2W (-) 2 cancer cell line human CVCL_TV93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25616; UBE2W; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149834 CVCL_U793 XPKABE finite cell line human CVCL_U793 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1275; true Female 21149835 CVCL_TV90 HAP1 UBE2V2 (-) 1 cancer cell line human CVCL_TV90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12495; UBE2V2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149836 CVCL_U790 Pa Coo finite cell line human CVCL_U790 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1293; true Male 21149837 CVCL_TV91 HAP1 UBE2V2 (-) 2 cancer cell line human CVCL_TV91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12495; UBE2V2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149838 CVCL_U791 Re Car finite cell line human CVCL_U791 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1175; true Male 21149839 CVCL_U774 En Son finite cell line human CVCL_U774 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1139; true Male 21149840 CVCL_TV74 HAP1 UBE2J1 (-) 1 cancer cell line human CVCL_TV74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17598; UBE2J1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149841 CVCL_U775 Es Ho finite cell line human CVCL_U775 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1274; true Female 21149842 CVCL_TV75 HAP1 UBE2J1 (-) 2 cancer cell line human CVCL_TV75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17598; UBE2J1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149843 CVCL_U772 Ce Rel finite cell line human CVCL_U772 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1196; true Female 21149844 CVCL_TV72 HAP1 UBE2H (-) 1 cancer cell line human CVCL_TV72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12484; UBE2H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149845 CVCL_U773 Ce Wo finite cell line human CVCL_U773 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1340; true Female 21149846 CVCL_TV73 HAP1 UBE2H (-) 2 cancer cell line human CVCL_TV73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12484; UBE2H; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149847 CVCL_TV78 HAP1 UBE2K (-) 1 cancer cell line human CVCL_TV78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4914; UBE2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149848 CVCL_U778 Ja Lin finite cell line human CVCL_U778 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1380; true Female 21149849 CVCL_TV79 HAP1 UBE2K (-) 2 cancer cell line human CVCL_TV79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4914; UBE2K; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149850 CVCL_U779 Jo Zan finite cell line human CVCL_U779 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1197; true Female 21149851 CVCL_U776 Fe Sin finite cell line human CVCL_U776 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1106; true Male 21149852 CVCL_TV76 HAP1 UBE2J2 (-) 1 cancer cell line human CVCL_TV76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19268; UBE2J2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149853 CVCL_TV77 HAP1 UBE2J2 (-) 2 cancer cell line human CVCL_TV77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19268; UBE2J2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149854 CVCL_U777 He Geg finite cell line human CVCL_U777 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1174; true Female 21149855 CVCL_1P30 GM22170 finite cell line human CVCL_1P30 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; GM22170; probable Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149856 CVCL_2130 MUTZ-8 cancer cell line human CVCL_2130 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (PubMed=16408098) Derived from sampling site: Peripheral blood. Female Doubling time: ~5 days (DOI=10.1007/978-3-642-59358-1_22); ~3-5 days (DSMZ=ACC-689) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149857 CVCL_1P22 GM09132 finite cell line human CVCL_1P22 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21149858 CVCL_2122 MOLM-6 cancer cell line human CVCL_2122 HLA typing: A*24:02,24:02; B*40:01,52:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.75%; East Asian, North=75.67%; East Asian, South=23.58%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~48-72 hours (DSMZ=ACC-611) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149859 CVCL_1P23 GM07147 finite cell line human CVCL_1P23 CL:0000010 Karyotypic information: 46,XX,t(13;16)(13pter->13q12.1::16p13.11->16pter;16qter->16p13.11::13q12.1->13qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21149860 CVCL_2123 MOLP-2 cancer cell line human CVCL_2123 HLA typing: A*02:01,31:01; B*07:02,56:01; C*04:01,07:02 (PubMed=26589293); Genome ancestry: African=3.42%; Native American=1.1%; East Asian, North=76.4%; East Asian, South=13.96%; South Asian=0%; European, North=0%; European, South=5.11% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgD lambda Doubling time: ~72 hours (PubMed=8148313); ~4 days (DSMZ=ACC-607) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149861 CVCL_1P20 A9+3 hybrid cell line CVCL_1P20 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149862 CVCL_2120 MOLM-16 cancer cell line human CVCL_2120 HLA typing: A*24:02,24:02; B*52:01,67:02; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=2.33%; Native American=0%; East Asian, North=81.24%; East Asian, South=12.89%; South Asian=0%; European, North=0%; European, South=3.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Ser (c.713G>C); ClinVar=VCV000376575; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50-80 hours (DSMZ=ACC-555); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149863 CVCL_1P21 A9+5 hybrid cell line CVCL_1P21 CL:0000010 Group: Human/rodent somatic cell hybrid. 21149864 CVCL_2121 MOLM-20 cancer cell line human CVCL_2121 HLA typing: A*26:02:01,26:03:01; B*15:01:01,40:06:01; C*03:03:01,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DRA*01:01:01,01:01:01; DRB1*09:01:02,09:01:02 (DSMZCellDive=ACC-591) CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 25589; SEPTIN11; Name(s)=KMT2A-SEPTIN11, KMT2A-SEPT11, MLL-SEPT11 (PubMed=31160637; DSMZ) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~70 hours (DSMZ=ACC-591) Part of: LL-100 blood cancer cell line panel 21149865 CVCL_1P26 GM22157 finite cell line human CVCL_1P26 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22157) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149866 CVCL_2126 MOR/0.2R cancer cell line human CVCL_2126 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Lung. Unspecified 21149867 CVCL_1P27 GM22159 finite cell line human CVCL_1P27 CL:0000010 Population: Asian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=GM22159) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149868 CVCL_2127 MOTN-1 cancer cell line human CVCL_2127 HLA typing: A*02:01:01,02:06:01; B*54:01:01,56:01:01; C*01:02:01,01:02:01; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*03:01:01,03:03:01; DQB1*03:02:01,04:01:01; DRA*01:01:01,01:02:02; DRB1*04:05:01,08:02:01 (DSMZCellDive=ACC-559); Genome ancestry: African=0.84%; Native American=0.4%; East Asian, North=73.72%; East Asian, South=24.39%; South Asian=0%; European, North=0%; European, South=0.64% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 29529; TBL1XR1 + HGNC; 15979; TP63; Name(s)=TBL1XR1-TP63 (PubMed=31160637); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.782+1G>A; ClinVar=VCV000634684; Zygosity=Homozygous; Note=Splice donor mutation (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: IL2 dependent Doubling time: 24 hours (PubMed=12127564); ~30-40 hours (DSMZ=ACC-559) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21149869 CVCL_1P24 GM22141 finite cell line human CVCL_1P24 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22141) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149870 CVCL_2124 MOLP-8 cancer cell line human CVCL_2124 HLA typing: A*03:02,24:02; B*13:02,52:01; C*06:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.26%; East Asian, North=74.81%; East Asian, South=24.35%; South Asian=0.12%; European, North=0.46%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgD lambda Doubling time: ~40 hours (DSMZ=ACC-569); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21149871 CVCL_1P25 GM22143 finite cell line human CVCL_1P25 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=GM22143) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149872 CVCL_2125 MOLT-17 cancer cell line human CVCL_2125 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1982; true Female Doubling time: ~50 hours (DSMZ=ACC-36) Problematic cell line: Partially contaminated The RCB/Riken RCB1982 stock was contaminated and was replaced by RCB4561 which originates from DSMZ ACC-36. On the basis of STR profile, the version at TKG (TKG 0385) seems to be identical or closely related to the RCB1962 contaminated stock. 21149873 CVCL_1P28 GM22167 finite cell line human CVCL_1P28 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; GM22167; probable Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149874 CVCL_2128 MS-5 [Mouse bone marrow] stromal cell line house mouse CVCL_2128 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. Male Doubling time: ~50 hours (DSMZ=ACC-441) 21149875 CVCL_1P29 GM22168 finite cell line human CVCL_1P29 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; GM22168; probable Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149876 CVCL_2129 MT-3 [Human contaminated breast cancer] cancer cell line human CVCL_2129 HLA typing: A*02:01,02:01; B*07:17,15:50; C*04:01,06:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: DSMZ; ACC-403; true Female Doubling time: 37.1 +- 8.1 hours (PubMed=9150904); ~30 hours (DSMZ=ACC-403); Microsatellite instability: Instable (MSI) (PubMed=12661003; PubMed=15677628) Part of: MD Anderson Cell Lines Project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00506 Problematic cell line: Contaminated Shown to be a LS174T derivative (PubMed=25877200; DSMZ). Originally thought to originate from a breast carcinoma. 21149877 CVCL_TV81 HAP1 UBE2L6 (-) 2 cancer cell line human CVCL_TV81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12490; UBE2L6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149878 CVCL_TV82 HAP1 UBE2O (-) 1 cancer cell line human CVCL_TV82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29554; UBE2O; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149879 CVCL_U782 Le Pat finite cell line human CVCL_U782 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1136; true Male 21149880 CVCL_TV80 HAP1 UBE2L6 (-) 1 cancer cell line human CVCL_TV80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12490; UBE2L6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149881 CVCL_U780 Ka Dan finite cell line human CVCL_U780 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1137; true Female 21149882 CVCL_TV63 HAP1 UBE2E1 (-) 2 cancer cell line human CVCL_TV63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12477; UBE2E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149883 CVCL_U763 XP1MI 1 finite cell line human CVCL_U763 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro334His (c.1001C>A); ClinVar=VCV000000253; Zygosity=Homozygous (from autologous cell line XP1MI 2) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1333; true Female 21149884 CVCL_TV64 HAP1 UBE2E2 (-) cancer cell line human CVCL_TV64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12478; UBE2E2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149885 CVCL_U764 XPKMSF finite cell line human CVCL_U764 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1203; probable Female 21149886 CVCL_TV61 HAP1 UBE2D4 (-) 2 cancer cell line human CVCL_TV61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21647; UBE2D4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149887 CVCL_U761 LP [Human kidney rhabdoid tumor] cancer cell line human CVCL_U761 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from sampling site: Kidney. Male 21149888 CVCL_TV62 HAP1 UBE2E1 (-) 1 cancer cell line human CVCL_TV62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12477; UBE2E1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149889 CVCL_U762 XP5BE finite cell line human CVCL_U762 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1160; probable Female 21149890 CVCL_U767 Ar Bo finite cell line human CVCL_U767 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1272; true Male 21149891 CVCL_TV67 HAP1 UBE2F (-) cancer cell line human CVCL_TV67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12480; UBE2F; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149892 CVCL_U768 Ar Mor finite cell line human CVCL_U768 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1221; true Male 21149893 CVCL_TV68 HAP1 UBE2G1 (-) 1 cancer cell line human CVCL_TV68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12482; UBE2G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149894 CVCL_U765 Am Tim finite cell line human CVCL_U765 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1270; true Male 21149895 CVCL_TV65 HAP1 UBE2E3 (-) 1 cancer cell line human CVCL_TV65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12479; UBE2E3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149896 CVCL_U766 An Na finite cell line human CVCL_U766 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1183; true Female 21149897 CVCL_TV66 HAP1 UBE2E3 (-) 2 cancer cell line human CVCL_TV66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12479; UBE2E3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149898 CVCL_U769 Be Jar finite cell line human CVCL_U769 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1143; true Male 21149899 CVCL_TV69 HAP1 UBE2G1 (-) 2 cancer cell line human CVCL_TV69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12482; UBE2G1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149900 CVCL_1P40 GM22202 finite cell line human CVCL_1P40 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=GM22202) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149901 CVCL_2140 NCI-H69/LX4 cancer cell line human CVCL_2140 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male 21149902 CVCL_1P41 GM22203 finite cell line human CVCL_1P41 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22203) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149903 CVCL_2141 NGP cancer cell line human CVCL_2141 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Trp (c.423C>G); ClinVar=VCV000376564; Zygosity=Unspecified (DepMap) Derived from metastatic site: Lung. Omics: Array-based CGH; Omics: ATAC-seq; Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50-70 hours (DSMZ=ACC-676) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149904 CVCL_1P33 GM22183 finite cell line human CVCL_1P33 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=GM22183) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149905 CVCL_2133 N2.261 hybridoma house mouse CVCL_2133 CL:0000010 Monoclonal antibody isotype: IgG1. Doubling time: ~20 hours (DSMZ=ACC-322) 21149906 CVCL_1P34 GM22185 finite cell line human CVCL_1P34 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 21 PDL (Coriell=GM22185) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149907 CVCL_2134 N3.36 hybridoma house mouse CVCL_2134 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P13535; Human MYH8. Doubling time: ~24 hours (DSMZ=ACC-318) 21149908 CVCL_1P31 GM22171 finite cell line human CVCL_1P31 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; GM22171; probable Male Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149909 CVCL_2131 MyEnd transformed cell line house mouse CVCL_2131 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; myocardium Cell type=Cardiac endothelial cell.. Unspecified 21149910 CVCL_1P32 GM22182 finite cell line human CVCL_1P32 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 25 PDL (Coriell=GM22182) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149911 CVCL_2132 N18TG2 cancer cell line house mouse CVCL_2132 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: A/J. Male Doubling time: ~40 hours (DSMZ=ACC-103) 21149912 CVCL_1P37 GM22191 finite cell line human CVCL_1P37 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=GM22191) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149913 CVCL_2137 NCI-H69/CPR cancer cell line human CVCL_2137 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21149914 CVCL_1P38 GM22200 finite cell line human CVCL_1P38 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22200) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149915 CVCL_2138 NCI-H69/LX10 cancer cell line human CVCL_2138 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male 21149916 CVCL_1P35 GM22186 finite cell line human CVCL_1P35 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 27 PDL (Coriell=GM22186) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149917 CVCL_2135 N4TG3 cancer cell line house mouse CVCL_2135 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: A/J. Male 21149918 CVCL_1P36 GM22189 finite cell line human CVCL_1P36 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22189) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149919 CVCL_2136 NBL-S cancer cell line human CVCL_2136 CL:0000010 Omics: Array-based CGH; Omics: ATAC-seq; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~36 hours (DSMZ=ACC-656) 21149920 CVCL_1P39 GM22201 finite cell line human CVCL_1P39 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 43 PDL (Coriell=GM22201) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21149921 CVCL_2139 NCI-H69/LX20 cancer cell line human CVCL_2139 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male 21149922 CVCL_U770 Ca Vel finite cell line human CVCL_U770 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1331; true Female 21149923 CVCL_TV70 HAP1 UBE2G2 (-) 1 cancer cell line human CVCL_TV70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12483; UBE2G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149924 CVCL_U771 Car Bur finite cell line human CVCL_U771 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1142; true Male 21149925 CVCL_TV71 HAP1 UBE2G2 (-) 2 cancer cell line human CVCL_TV71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12483; UBE2G2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21149926 CVCL_CC18 ND02691 transformed cell line human CVCL_CC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149927 CVCL_CC19 ND02693 transformed cell line human CVCL_CC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149928 CVCL_CC16 ND02661 transformed cell line human CVCL_CC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149929 CVCL_CC17 ND02689 transformed cell line human CVCL_CC17 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149930 CVCL_CC10 ND02631 transformed cell line human CVCL_CC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149931 CVCL_CC11 ND02632 transformed cell line human CVCL_CC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149932 CVCL_CC14 ND02644 transformed cell line human CVCL_CC14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149933 CVCL_CC15 ND02660 transformed cell line human CVCL_CC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149934 CVCL_CC12 ND02639 transformed cell line human CVCL_CC12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149935 CVCL_CC13 ND02641 transformed cell line human CVCL_CC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149936 CVCL_CC29 ND02755 transformed cell line human CVCL_CC29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149937 CVCL_CC27 ND02753 transformed cell line human CVCL_CC27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149938 CVCL_CC28 ND02754 transformed cell line human CVCL_CC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149939 CVCL_CC21 ND02710 transformed cell line human CVCL_CC21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149940 CVCL_CC22 ND02712 transformed cell line human CVCL_CC22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149941 CVCL_CC20 ND02708 transformed cell line human CVCL_CC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149942 CVCL_CC25 ND02750 transformed cell line human CVCL_CC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149943 CVCL_CC26 ND02752 transformed cell line human CVCL_CC26 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149944 CVCL_CC23 ND02714 transformed cell line human CVCL_CC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149945 CVCL_CC24 ND02744 transformed cell line human CVCL_CC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149946 CVCL_CC07 ND02625 transformed cell line human CVCL_CC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149947 CVCL_CC08 ND02629 transformed cell line human CVCL_CC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149948 CVCL_CC05 ND02595 transformed cell line human CVCL_CC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149949 CVCL_CC06 ND02624 transformed cell line human CVCL_CC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149950 CVCL_CC09 ND02630 transformed cell line human CVCL_CC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149951 CVCL_CC00 ND02579 transformed cell line human CVCL_CC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21149952 CVCL_CC03 ND02593 transformed cell line human CVCL_CC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149953 CVCL_CC04 ND02594 transformed cell line human CVCL_CC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149954 CVCL_CC01 ND02582 transformed cell line human CVCL_CC01 CL:0000010 Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21149955 CVCL_CC02 ND02587 transformed cell line human CVCL_CC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149956 CVCL_2092 Kelly cancer cell line human CVCL_2092 HLA typing: A*01:01,01:01; B*08:01,51:01; C*03:03,07:01; DQA1*03:02,03:02; DRB1*07:01,12:01 (PubMed=26589293); Genome ancestry: African=2.15%; Native American=0%; East Asian, North=2.95%; East Asian, South=0%; South Asian=0%; European, North=61.68%; European, South=33.22% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=18724359; PubMed=28350380; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro177Thr (c.529C>A); ClinVar=VCV000482220; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Brain. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by single cell RNAseq Discontinued: RCB; RCB0479; probable Female Characteristics: MYCN-amplified NBL cell line; Virology: Infected with a murine leukemia virus-related virus (PubMed=30629668) Doubling time: ~30-40 hours (DSMZ=ACC-355); ~30 hours (CLS); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21149957 CVCL_2093 Ki-JK cancer cell line human CVCL_2093 Genome ancestry: African=0.29%; Native American=0%; East Asian, North=78.51%; East Asian, South=20.22%; South Asian=0%; European, North=0%; European, South=0.97% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=15356658) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: JCRB; NIHS0222; true Male Doubling time: ~72 hours (PubMed=8169113); ~50-70 hours (DSMZ=ACC-695) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149958 CVCL_2090 KCI-MOH1 cancer cell line human CVCL_2090 HLA typing: A*03:01,03:01; B*14:02,14:02; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.11%; East Asian, North=2.33%; East Asian, South=0%; South Asian=0%; European, North=65.07%; European, South=32.5% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-MOH1; Discontinued: DSMZ; ACC-498; true Female Doubling time: ~70 hours (DSMZ=ACC-498) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00322 Problematic cell line: Contaminated Shown to be a HPAC derivative (PubMed=20143388). Originally thought to originate from a 74 year old male patient with a moderately differentiated adenocarcinoma of the head of the pancreas. 21149959 CVCL_2091 KCL-22 cancer cell line human CVCL_2091 HLA typing: A*24:02,26:03; B*15:01,40:06; C*03:03,03:03 (PubMed=26589293); HLA typing: A*24:02:01,26:03:01; B*15:01:01,40:06:01; C*03:03:01,03:03:01 (DSMZCellDive=ACC-519); Genome ancestry: African=0%; Native American=0.5%; East Asian, North=75.25%; East Asian, South=24.24%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; DepMap); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (PubMed=9510473); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (PubMed=9510473; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0534; true Female Doubling time: 24 hours (PubMed=6321612); 24-30 hours (ATCC=CRL-3349); ~24 hours (DSMZ=ACC-519); Microsatellite instability: Instable (MSI-high) (PubMed=9510473; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21149960 CVCL_2096 L-1236 cancer cell line human CVCL_2096 HLA typing: A*02:01,02:01; B*51:01,51:01; C*02:02,02:02 (PubMed=26589293); HLA typing: A*02:01:01,02:01:01; B*51:01:01,51:01:01; C*02:02:02,02:02:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,05:03:01; DRA*01:01:01,01:01:01; DRB1*14:54:01,14:54:01 (DSMZCellDive=ACC-530); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0.15%; European, North=70.78%; European, South=27.1% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Simple; p.Trp142Ter (c.425G>A) (G491A); Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Fusion of Ex9 wiith an Alu-element; Zygosity=Unspecified (PubMed=17065008) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE); Omics: Virome analysis using RNAseq Male Doubling time: ~48 hours (DSMZ=ACC-530); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21149961 CVCL_2097 L-5178-Y cancer cell line house mouse CVCL_2097 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Omics: Transcriptome analysis by microarray Female Doubling time: 11.3 hours (PubMed=6173370); ~20 hours (DSMZ=ACC-320); 10 hours (lot 07032005) (JCRB) 21149962 CVCL_2094 KPL-1 cancer cell line human CVCL_2094 HLA typing: A*02:01,02:01; B*18:01,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=2.04%; Native American=0%; East Asian, North=4.61%; East Asian, South=0%; South Asian=0%; European, North=53.32%; European, South=40.02% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=28889351) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~50 hours (DSMZ=ACC-317); Microsatellite instability: Stable (MSS) (PubMed=15677628) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00325 Problematic cell line: Contaminated Shown to be a MCF-7 derivative (PubMed=18304946; PubMed=20143388). 21149963 CVCL_2095 KYO-1 cancer cell line human CVCL_2095 HLA typing: A*24:02,24:02; B*54:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=3.73%; Native American=0%; East Asian, North=78.04%; East Asian, South=12.39%; South Asian=0%; European, North=0%; European, South=5.83% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3860700; PubMed=10071072; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~22 hours (PubMed=3860700); ~40-50 hours (DSMZ=ACC-601) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149964 CVCL_2089 KB-V1 cancer cell line human CVCL_2089 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~50 hours (DSMZ=ACC-149) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00373 Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21149965 CVCL_2087 JURL-MK2 cancer cell line human CVCL_2087 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9305612; PubMed=10071072) Derived from sampling site: Peripheral blood. Male Doubling time: 72 hours (PubMed=9305612); ~72 hours (DSMZ=ACC-533) 21149966 CVCL_2088 KB-3-1 cancer cell line human CVCL_2088 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~40 hours (DSMZ=ACC-158) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00372 Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21149967 CVCL_2098 L-82 cancer cell line human CVCL_2098 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=29899875) Derived from sampling site: Pleural effusion. Omics: CNV analysis; Omics: Deep exome analysis Female Doubling time: ~40 hours (DSMZ=ACC-597) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21149968 CVCL_2099 BC3 hybridoma house mouse CVCL_2099 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P07766; Human CD3E. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10166 21149969 CVCL_CC98 ND03581 transformed cell line human CVCL_CC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149970 CVCL_CC99 ND03582 transformed cell line human CVCL_CC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149971 CVCL_CC96 ND03534 transformed cell line human CVCL_CC96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149972 CVCL_CC97 ND03535 transformed cell line human CVCL_CC97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149973 CVCL_CC80 ND03375 transformed cell line human CVCL_CC80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149974 CVCL_CC83 ND03397 transformed cell line human CVCL_CC83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149975 CVCL_CC84 ND03431 transformed cell line human CVCL_CC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149976 CVCL_CC81 ND03377 transformed cell line human CVCL_CC81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149977 CVCL_CC82 ND03379 transformed cell line human CVCL_CC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149978 CVCL_CC76 ND03370 transformed cell line human CVCL_CC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149979 CVCL_CC77 ND03371 transformed cell line human CVCL_CC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149980 CVCL_CC74 ND03347 transformed cell line human CVCL_CC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149981 CVCL_CC75 ND03369 transformed cell line human CVCL_CC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149982 CVCL_CC78 ND03372 transformed cell line human CVCL_CC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149983 CVCL_CC79 ND03374 transformed cell line human CVCL_CC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149984 CVCL_CC90 ND03438 transformed cell line human CVCL_CC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149985 CVCL_CC91 ND03440 transformed cell line human CVCL_CC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149986 CVCL_CC94 ND03490 transformed cell line human CVCL_CC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149987 CVCL_CC95 ND03533 transformed cell line human CVCL_CC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149988 CVCL_CC92 ND03456 transformed cell line human CVCL_CC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149989 CVCL_CC93 ND03489 transformed cell line human CVCL_CC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149990 CVCL_CC87 ND03434 transformed cell line human CVCL_CC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149991 CVCL_CC88 ND03435 transformed cell line human CVCL_CC88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149992 CVCL_CC85 ND03432 transformed cell line human CVCL_CC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21149993 CVCL_CC86 ND03433 transformed cell line human CVCL_CC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149994 CVCL_CC89 ND03437 transformed cell line human CVCL_CC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149995 CVCL_CC61 ND03004 transformed cell line human CVCL_CC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149996 CVCL_CC62 ND03055 transformed cell line human CVCL_CC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21149997 CVCL_CC60 ND03003 transformed cell line human CVCL_CC60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149998 CVCL_CC54 ND02962 transformed cell line human CVCL_CC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21149999 CVCL_CC55 ND02964 transformed cell line human CVCL_CC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150000 CVCL_CC52 ND02958 transformed cell line human CVCL_CC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150001 CVCL_CC53 ND02960 transformed cell line human CVCL_CC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150002 CVCL_CC58 ND03000 transformed cell line human CVCL_CC58 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150003 CVCL_CC59 ND03001 transformed cell line human CVCL_CC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150004 CVCL_CC56 ND02978 transformed cell line human CVCL_CC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150005 CVCL_CC57 ND02979 transformed cell line human CVCL_CC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150006 CVCL_CC72 ND03333 transformed cell line human CVCL_CC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150007 CVCL_CC73 ND03334 transformed cell line human CVCL_CC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150008 CVCL_CC70 ND03281 transformed cell line human CVCL_CC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150009 CVCL_CC71 ND03282 transformed cell line human CVCL_CC71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150010 CVCL_CC65 ND03092 transformed cell line human CVCL_CC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150011 CVCL_CC66 ND03093 transformed cell line human CVCL_CC66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150012 CVCL_CC63 ND03072 transformed cell line human CVCL_CC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150013 CVCL_CC64 ND03090 transformed cell line human CVCL_CC64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150014 CVCL_CC69 ND03103 transformed cell line human CVCL_CC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150015 CVCL_CC67 ND03095 transformed cell line human CVCL_CC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150016 CVCL_CC68 ND03101 transformed cell line human CVCL_CC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150017 CVCL_CC40 ND02845 transformed cell line human CVCL_CC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150018 CVCL_CC38 ND02811 transformed cell line human CVCL_CC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150019 CVCL_CC39 ND02819 transformed cell line human CVCL_CC39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150020 CVCL_CC32 ND02761 transformed cell line human CVCL_CC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150021 CVCL_CC33 ND02762 transformed cell line human CVCL_CC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150022 CVCL_CC30 ND02757 transformed cell line human CVCL_CC30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150023 CVCL_CC31 ND02759 transformed cell line human CVCL_CC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150024 CVCL_CC36 ND02798 transformed cell line human CVCL_CC36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150025 CVCL_CC37 ND02809 transformed cell line human CVCL_CC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150026 CVCL_CC34 ND02771 transformed cell line human CVCL_CC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150027 CVCL_CC35 ND02797 transformed cell line human CVCL_CC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150028 CVCL_CC50 ND02916 transformed cell line human CVCL_CC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150029 CVCL_CC51 ND02918 transformed cell line human CVCL_CC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150030 CVCL_CC49 ND02893 transformed cell line human CVCL_CC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150031 CVCL_CC43 ND02854 transformed cell line human CVCL_CC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150032 CVCL_CC44 ND02856 transformed cell line human CVCL_CC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150033 CVCL_CC41 ND02849 transformed cell line human CVCL_CC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150034 CVCL_CC42 ND02852 transformed cell line human CVCL_CC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150035 CVCL_CC47 ND02863 transformed cell line human CVCL_CC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150036 CVCL_CC48 ND02892 transformed cell line human CVCL_CC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150037 CVCL_CC45 ND02858 transformed cell line human CVCL_CC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150038 CVCL_CC46 ND02861 transformed cell line human CVCL_CC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150039 CVCL_TW73 HAP1 USP20 (-) 2 cancer cell line human CVCL_TW73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12619; USP20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150040 CVCL_U873 Panc 09.06 cancer cell line human CVCL_U873 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=9612602) Discontinued: ATCC; CRL-2552; true. Female Doubling time: 34.3 hours (PubMed=9612602) 21150041 CVCL_U874 H5.46 hybridoma house mouse CVCL_U874 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P06935; West Nile virus envelope protein E. 21150042 CVCL_TW74 HAP1 USP21 (-) 1 cancer cell line human CVCL_TW74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12620; USP21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150043 CVCL_TW71 HAP1 USP2 (-) 2 cancer cell line human CVCL_TW71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12618; USP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150044 CVCL_U871 XP5SE finite cell line human CVCL_U871 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150045 CVCL_TW72 HAP1 USP20 (-) 1 cancer cell line human CVCL_TW72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12619; USP20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150046 CVCL_U872 Panc 04.14 cancer cell line human CVCL_U872 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female 21150047 CVCL_TW77 HAP1 USP22 (-) 2 cancer cell line human CVCL_TW77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12621; USP22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150048 CVCL_TW78 HAP1 USP24 (-) cancer cell line human CVCL_TW78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12623; USP24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150049 CVCL_U878 Ro cancer cell line human CVCL_U878 From: Scarpa A.; Universita di Verona; Verona; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=11169959) Derived from sampling site: Pancreas; ampulla of Vater. Female 21150050 CVCL_TW75 HAP1 USP21 (-) 2 cancer cell line human CVCL_TW75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12620; USP21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150051 CVCL_U875 Panc 02.02 cancer cell line human CVCL_U875 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21150052 CVCL_TW76 HAP1 USP22 (-) 1 cancer cell line human CVCL_TW76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12621; USP22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150053 CVCL_U879 GM08857 finite cell line human CVCL_U879 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150054 CVCL_TW79 HAP1 USP25 (-) cancer cell line human CVCL_TW79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12624; USP25; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150055 CVCL_1Q21 CY185 hybrid cell line CVCL_1Q21 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150056 CVCL_2221 UPCI-SCC-026 cancer cell line human CVCL_2221 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Female Doubling time: ~60 hours (DSMZ=ACC-658) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150057 CVCL_1Q22 CY192 hybrid cell line CVCL_1Q22 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150058 CVCL_2222 UPCI-SCC-040 cancer cell line human CVCL_2222 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male Doubling time: ~70-80 hours (DSMZ=ACC-660) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150059 CVCL_1Q20 CY170 hybrid cell line CVCL_1Q20 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150060 CVCL_2220 U-HO1 cancer cell line human CVCL_2220 CL:0000010 Sequence variation: Mutation; HGNC; 9642; PTPN1; Unexplicit; Ex2-8del; Zygosity=Unspecified (CelloPub=CLPUB00457); Sequence variation: Gene deletion; HGNC; 1787; 11896; TNFAIP3; Zygosity=Heterozygous (PubMed=19380639); Sequence variation: Mutation; HGNC; 11896; TNFAIP3; Simple; p.Met43fs (c.127-134del) (del 193-200); Zygosity=Heterozygous (PubMed=19380639) Anecdotal: Andreas Mader, the first author of the paper (PubMed=18253030) describing this cell line is the patient that donated the cell line As it is not frequent to see a patient 'acknowledged' by being an author this fact should be emphasized. Derived from sampling site: Pleural effusion. Omics: SNP array analysis Male Doubling time: ~4 days (PubMed=18253030); ~100 hours (DSMZ=ACC-626) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150061 CVCL_1Q25 GM05184 transformed cell line human CVCL_1Q25 CL:0000010 Population: Caucasian; Italian; Karyotypic information: 46,XY,t(6;7)(6pter->6q21::7q21.2->7qter;7pter->7q21.2::6q21->6qter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150062 CVCL_2225 UPCI-SCC-099 cancer cell line human CVCL_2225 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro177Arg (c.530C>G); ClinVar=VCV000458547; Zygosity=Unspecified (PubMed=12872257) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: ~50 hours (DSMZ=ACC-665) Caution: While the tumor has been shown to be HPV16 positive (PubMed=17112776), the cell line seems to be HPV16 negative (DSMZ) 21150063 CVCL_1Q26 HDm-15 hybrid cell line CVCL_1Q26 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150064 CVCL_2226 UPCI-SCC-111 cancer cell line human CVCL_2226 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Female Doubling time: ~40 hours (DSMZ=ACC-666) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150065 CVCL_1Q23 GM06326 transformed cell line human CVCL_1Q23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21150066 CVCL_2223 UPCI-SCC-072 cancer cell line human CVCL_2223 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; tonsil. Female Doubling time: ~120 hours (DSMZ=ACC-667) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150067 CVCL_1Q24 GM05183 finite cell line human CVCL_1Q24 CL:0000010 Population: Caucasian; Italian; Karyotypic information: 46,XY,t(6;7)(q21;q21.2) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21150068 CVCL_2224 UPCI-SCC-074 cancer cell line human CVCL_2224 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (DepMap) Population: Indian; Derived from sampling site: Oral cavity; alveolar ridge. Female Doubling time: ~60 hours (DSMZ=ACC-664) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150069 CVCL_1Q29 HDm-4 hybrid cell line CVCL_1Q29 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150070 CVCL_2229 UPCI-SCC-131 cancer cell line human CVCL_2229 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: ~50-60 hours (DSMZ=ACC-668) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150071 CVCL_1Q27 HDm-18 hybrid cell line CVCL_1Q27 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150072 CVCL_2227 UPCI-SCC-114 cancer cell line human CVCL_2227 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=12872257) Population: Caucasian; Derived from sampling site: Oral cavity; floor of mouth. Male Doubling time: ~60 hours (DSMZ=ACC-662) 21150073 CVCL_1Q28 HDm-20 hybrid cell line CVCL_1Q28 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150074 CVCL_2228 UPCI-SCC-116 cancer cell line human CVCL_2228 CL:0000010 Sequence variation: Mutation; HGNC; 667; RHOA; Simple; p.Gly17Val (c.50G>T); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=12872257; DepMap). Population: Caucasian Male Doubling time: ~80 hours (DSMZ=ACC-663) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150075 CVCL_U880 GM08858 finite cell line human CVCL_U880 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150076 CVCL_TW80 HAP1 USP27X (-) cancer cell line human CVCL_TW80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13486; USP27X; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150077 CVCL_U881 GM08859 finite cell line human CVCL_U881 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150078 CVCL_TW81 HAP1 USP28 (-) 1 cancer cell line human CVCL_TW81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12625; USP28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150079 CVCL_U862 CHO-LY-B/cLCB1 spontaneously immortalized cell line CVCL_U862 CL:0000010 Transfected with: UniProtKB; O54695; Cricetulus griseus Sptlc1 Derived from sampling site: Ovary. Female 21150080 CVCL_TW62 HAP1 USP16 (-) 2 cancer cell line human CVCL_TW62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150081 CVCL_TW63 HAP1 USP16 (-) 3 cancer cell line human CVCL_TW63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150082 CVCL_U863 NLS-6-5 spontaneously immortalized cell line CVCL_U863 CL:0000010 Derived from sampling site: Ovary. Female 21150083 CVCL_TW60 HAP1 USP15 (-) 3 cancer cell line human CVCL_TW60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12613; USP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150084 CVCL_U860 UV-P3U1-B8 hybridoma house mouse CVCL_U860 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:81145; Thymine dimer. 21150085 CVCL_U861 Anti-PT-S4-1H2 hybridoma house mouse CVCL_U861 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A3R5; Bordetella pertussis ptxD. 21150086 CVCL_TW61 HAP1 USP16 (-) 1 cancer cell line human CVCL_TW61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150087 CVCL_TW66 HAP1 USP18 (-) 1 cancer cell line human CVCL_TW66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12616; USP18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150088 CVCL_U866 XP18SE finite cell line human CVCL_U866 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150089 CVCL_TW67 HAP1 USP18 (-) 2 cancer cell line human CVCL_TW67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12616; USP18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150090 CVCL_U867 XP19SE finite cell line human CVCL_U867 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150091 CVCL_U864 CHO-K1 (SC) spontaneously immortalized cell line CVCL_U864 CL:0000010 Derived from sampling site: Ovary. Female 21150092 CVCL_TW64 HAP1 USP16 (-) 4 cancer cell line human CVCL_TW64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150093 CVCL_TW65 HAP1 USP16 (-) 5 cancer cell line human CVCL_TW65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12614; USP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150094 CVCL_U865 XP18SE LCL transformed cell line human CVCL_U865 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150095 CVCL_TW68 HAP1 USP19 (-) 1 cancer cell line human CVCL_TW68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12617; USP19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150096 CVCL_U868 NOD.ESA embryonic stem cell house mouse CVCL_U868 CL:0000010 Breed/subspecies: NOD. Discontinued: RCB; RCB2608; true Male 21150097 CVCL_TW69 HAP1 USP19 (-) 2 cancer cell line human CVCL_TW69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12617; USP19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150098 CVCL_U869 XP15SE finite cell line human CVCL_U869 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150099 CVCL_1Q40 BID7 hybrid cell line CVCL_1Q40 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150100 CVCL_2240 WM39 cancer cell line human CVCL_2240 HLA typing: A*02:01,02:05; B*07:02,15:03; C*07:02,15:05; DPB1*04:02,02:01:02; DQB1*05:01,02:01; DRB1*01:01,07:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=16827748; PubMed=18632627; PubMed=23851445; Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Unspecified (PubMed=23851445; Wistar); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45ins4aa (c.134ins12bp); Zygosity=Unspecified (PubMed=23851445) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2811; true; Discontinued: Coriell; WC00077; probable. Male Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21150101 CVCL_1Q32 GM07913 transformed cell line human CVCL_1Q32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21150102 CVCL_2232 UPCI-SCC-200 cancer cell line human CVCL_2232 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Male Doubling time: ~60-80 hours (DSMZ=ACC-672) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: While the tumor has been shown to be HPV16 positive (PubMed=17112776), the cell line seems to be HPV16 negative (DSMZ). 21150103 CVCL_1Q33 GM07912 transformed cell line human CVCL_1Q33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150104 CVCL_2233 UT-7 cancer cell line human CVCL_2233 HLA typing: A*02:01:01,11:01:01; B*55:02:01,55:02:01; C*01:02:01,01:02:01; DPA1*01:03:01,02:02:02; DPB1*03:01:01,03:01:01; DRA*01:01:01,01:02:02; DRB1*08:02:01,08:02:01 (DSMZCellDive=ACC-137); Genome ancestry: African=2.07%; Native American=0%; East Asian, North=82.57%; East Asian, South=12%; South Asian=0%; European, North=0%; European, South=3.36% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783_919del137; Zygosity=Unspecified (PubMed=1571549) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: CSF2 dependent Doubling time: ~36-48 hours (PubMed=1824823); ~70 hours (DSMZ=ACC-137); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21150105 CVCL_1Q30 HDm-5 hybrid cell line CVCL_1Q30 CL:0000010 Characteristics: Hybrid for chromosome 14 mapping Contains a complete copy of chromosome 14.. Group: Human/rodent somatic cell hybrid 21150106 CVCL_2230 UPCI-SCC-154 cancer cell line human CVCL_2230 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3.8 days (PubMed=29156801); ~50-60 hours (DSMZ=ACC-669) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21150107 CVCL_1Q31 HDm-9 hybrid cell line CVCL_1Q31 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150108 CVCL_2231 UPCI-SCC-172 cancer cell line human CVCL_2231 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Unspecified (PubMed=12872257). Population: Caucasian Male Doubling time: ~50 hours (DSMZ=ACC-661) 21150109 CVCL_1Q36 DC3F/MQ19 spontaneously immortalized cell line CVCL_1Q36 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21150110 CVCL_2236 VIP-VIIIC8 hybridoma house mouse CVCL_2236 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06729; Human CD2. Doubling time: ~40-50 hours (DSMZ=ACC-479) 21150111 CVCL_1Q37 Don/a3 spontaneously immortalized cell line CVCL_1Q37 CL:0000010 Derived from sampling site: Lung. Male 21150112 CVCL_2237 VLM transformed cell line house mouse CVCL_2237 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: BALB/c. Unspecified Doubling time: ~25 hours (DSMZ=ACC-429) 21150113 CVCL_1Q34 GM05878 transformed cell line human CVCL_1Q34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150114 CVCL_2234 V79 spontaneously immortalized cell line CVCL_2234 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from child cell line V79-4) (PubMed=9023109).; Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from child cell line V79-4) (PubMed=9023109). Derived from sampling site: Lung Cell type=Fibroblast.. Male Characteristics: Widely used to study DNA damage induced by X-ray, UV radiation and oxidizing agents Doubling time: ~16-20 hours (DSMZ=ACC-335) 21150115 CVCL_1Q35 DC3F/A3 spontaneously immortalized cell line CVCL_1Q35 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21150116 CVCL_2235 VCaP cancer cell line human CVCL_2235 Genome ancestry: African=0%; Native American=0.05%; East Asian, North=1.4%; East Asian, South=0%; South Asian=0.98%; European, North=69.8%; European, South=27.77% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (PubMed=23447416; PubMed=23615946); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (PubMed=23615946); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=14518029; PubMed=23615946; Cosmic-CLP; DepMap) Population: Caucasian; Derived from metastatic site: Bone; vertebra. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a xenograft produced by implantation of tumor cells in a SCID mouse; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104) Doubling time: 220 hours (PubMed=25984343); ~53 hours (ATCC=CRL-2876); ~51 hours (PBCF); 126.45 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21150117 CVCL_1Q38 GM07965 transformed cell line human CVCL_1Q38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21150118 CVCL_2238 WEHI-164S cancer cell line house mouse CVCL_2238 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Doubling time: ~30-50 hours (DSMZ=ACC-25) 21150119 CVCL_1Q39 NM87-26Xt hybrid cell line human CVCL_1Q39 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150120 CVCL_2239 WEHI-3B cancer cell line house mouse CVCL_2239 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male Characteristics: Constitutively produces interleukin-3 (IL3) Doubling time: 20 hours (PubMed=8343448); ~20-30 hours (DSMZ=ACC-26) 21150121 CVCL_TW70 HAP1 USP2 (-) 1 cancer cell line human CVCL_TW70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12618; USP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150122 CVCL_U870 XP12SE finite cell line human CVCL_U870 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150123 CVCL_U851 Anti-alpha(4)11D9G5 hybridoma house mouse CVCL_U851 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150124 CVCL_TW51 HAP1 USP11 (-) 3 cancer cell line human CVCL_TW51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12609; USP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150125 CVCL_U852 Anti-alpha(5)11D10B6 hybridoma house mouse CVCL_U852 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150126 CVCL_TW52 HAP1 USP11 (-) 4 cancer cell line human CVCL_TW52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12609; USP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150127 CVCL_U850 Anti-alpha(3)7E7C2 hybridoma house mouse CVCL_U850 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150128 CVCL_TW50 HAP1 USP11 (-) 2 cancer cell line human CVCL_TW50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12609; USP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150129 CVCL_U855 Anti-alpha(8)9F3A6 hybridoma house mouse CVCL_U855 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150130 CVCL_TW55 HAP1 USP13 (-) cancer cell line human CVCL_TW55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12611; USP13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150131 CVCL_U856 Anti-alpha(9)12G8B11 hybridoma house mouse CVCL_U856 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150132 CVCL_TW56 HAP1 USP14 (-) 1 cancer cell line human CVCL_TW56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12612; USP14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150133 CVCL_U853 Anti-alpha(6)11D10F7 hybridoma house mouse CVCL_U853 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150134 CVCL_TW53 HAP1 USP12 (-) 1 cancer cell line human CVCL_TW53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20485; USP12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150135 CVCL_U854 Anti-alpha(7)7C9A10 hybridoma house mouse CVCL_U854 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150136 CVCL_TW54 HAP1 USP12 (-) 2 cancer cell line human CVCL_TW54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20485; USP12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150137 CVCL_U859 AC1 [Mouse hybridoma against ganglioside GD1c] hybridoma house mouse CVCL_U859 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:87990; Ganglioside GD1c. 21150138 CVCL_TW59 HAP1 USP15 (-) 2 cancer cell line human CVCL_TW59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12613; USP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150139 CVCL_U857 Anti-theta(1)3H10 hybridoma house mouse CVCL_U857 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C2E9; Clostridium perfringens pfo. 21150140 CVCL_TW57 HAP1 USP14 (-) 2 cancer cell line human CVCL_TW57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12612; USP14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150141 CVCL_U858 AB1 [Mouse hybridoma against ganglioside GD1b] hybridoma house mouse CVCL_U858 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:28175; Ganglioside GD1b. 21150142 CVCL_TW58 HAP1 USP15 (-) 1 cancer cell line human CVCL_TW58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12613; USP15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150143 CVCL_1Q00 CY4 hybrid cell line CVCL_1Q00 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150144 CVCL_2200 SPI-801 cancer cell line human CVCL_2200 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: DSMZ; ACC-86; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00160 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21150145 CVCL_1Q03 CY7 hybrid cell line CVCL_1Q03 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150146 CVCL_1Q04 CY8 hybrid cell line CVCL_1Q04 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150147 CVCL_2204 ST [Pig testis] spontaneously immortalized cell line pig CVCL_2204 CL:0000010 Derived from sampling site: Fetal testis Cell type=Sertoli cell.. Male Virology: Useful for the propagation, assay and isolation of porcine parvovirus (PPV), transmissible gastroenteritis virus (TGEV) and swine enteroviruses (ATCC) Doubling time: ~30-40 hours (DSMZ=ACC-641) 21150148 CVCL_1Q01 CY5 hybrid cell line CVCL_1Q01 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150149 CVCL_2201 SPI-802 cancer cell line human CVCL_2201 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: DSMZ; ACC-92; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00161 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=10508494; PubMed=12592342; PubMed=20143388). 21150150 CVCL_1Q02 CY6 hybrid cell line CVCL_1Q02 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150151 CVCL_2202 SR-4987 stromal cell line house mouse CVCL_2202 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 x DBA/2. Female Doubling time: 14.7 hours (PubMed=1382506); ~24-36 hours (DSMZ=ACC-323) 21150152 CVCL_1Q07 CY13 hybrid cell line CVCL_1Q07 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150153 CVCL_2207 SU-DHL-8 cancer cell line human CVCL_2207 HLA typing: A*03:01,03:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293); Genome ancestry: African=0.67%; Native American=0%; East Asian, North=0.1%; East Asian, South=0%; South Asian=2.54%; European, North=64.1%; European, South=32.58% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Pro648Thrfs*2 (c.1940dupC) (c.1940_1941insC); ClinVar=VCV000432829; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asn (c.700T>A); ClinVar=VCV000376692; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~48-72 hours (DSMZ=ACC-573); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21150154 CVCL_1Q08 CY14 hybrid cell line CVCL_1Q08 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150155 CVCL_2208 SUP-HD1 cancer cell line human CVCL_2208 HLA typing: A*01:01:01,01:01:71; B*38:01:01,38:01:01; C*12:03:01,12:03:01; DPA1*02:02:02,02:02:02; DPB1*02:01:02,02:01:02; DQA1*01:03:01,01:03:01; DQB1*06:03:01,06:03:01; DRA*01:02:02,01:02:02; DRB1*13:01:01,13:01:01 (DSMZCellDive=ACC-574); Genome ancestry: African=5.43%; Native American=0%; East Asian, North=4.61%; East Asian, South=0%; South Asian=0.02%; European, North=49.35%; European, South=40.59% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 3-4 days (PubMed=2554995); ~40-80 hours (DSMZ=ACC-574); Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel 21150156 CVCL_1Q05 CY11 hybrid cell line CVCL_1Q05 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150157 CVCL_2205 ST2 stromal cell line house mouse CVCL_2205 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BC8. Unspecified Characteristics: Can differentiate into osteoblasts, adipocytes and hematopoietic supporting cells Doubling time: ~30-50 hours (DSMZ=ACC-333) 21150158 CVCL_1Q06 CY12 hybrid cell line CVCL_1Q06 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150159 CVCL_2206 SU-DHL-6 cancer cell line human CVCL_2206 HLA typing: A*11 (PubMed=25960936); HLA typing: A*02:01,23:01; B*15:01,49:01; C*03:03,07:06 (PubMed=26589293); HLA typing: A*02:01:01,23:01:01; B*15:01:01,49:01:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,05:02:01; DRA*01:01:01,01:01:02; DRB1*01:01:01,04:01:01 (DSMZCellDive=ACC-572); Genome ancestry: African=2.74%; Native American=0%; East Asian, North=1.8%; East Asian, South=0%; South Asian=0%; European, North=59.44%; European, South=36.02% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (DSMZ); Sequence variation: Mutation; HGNC; 3527; EZH2; Simple; p.Tyr646Ser (c.1937A>C) (Y641S); ClinVar=VCV000376218; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln211Ter (c.631C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu4712Ter (c.14134G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>C (IVS6-2A>C); ClinVar=VCV000635387; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Peritoneal effusion. Omics: Array-based CGH; Omics: Cell surface proteome; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: ~35-40 hours (DSMZ=ACC-572); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21150160 CVCL_1Q09 CY15 [Human/mouse hybrid] hybrid cell line CVCL_1Q09 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150161 CVCL_2209 SUP-M2 cancer cell line human CVCL_2209 HLA typing: A*02:01:01,02:01:01; B*44:03:01,50:01:01; C*06:02:01,16:01:01; DPA1*01:03:01,02:01:01; DPB1*11:01:01,04:01:01; DQA1*02:01:01,02:01:01; DQB1*02:01:01,02:02:01; DRA*01:01:01,01:02:02; DRB1*03:01:01,07:01:01 (DSMZCellDive=ACC-509); Genome ancestry: African=2.59%; Native American=1.22%; East Asian, North=2.73%; East Asian, South=0%; South Asian=0%; European, North=54.77%; European, South=38.68% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (PubMed=7824924; PubMed=9121481) Population: Caucasian; Derived from sampling site: Cerebrospinal fluid. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~40-50 hours (DSMZ=ACC-509); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: LL-100 blood cancer cell line panel; Part of: MD Anderson Cell Lines Project 21150162 CVCL_U840 GMR7 hybridoma house mouse CVCL_U840 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21150163 CVCL_TW40 HAP1 UNG (-) 3 cancer cell line human CVCL_TW40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12572; UNG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150164 CVCL_U841 GMR2 hybridoma house mouse CVCL_U841 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: O-acetylated-disialogangliosides. 21150165 CVCL_TW41 HAP1 UNG (-) 4 cancer cell line human CVCL_TW41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12572; UNG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150166 CVCL_U844 GMB28 hybridoma house mouse CVCL_U844 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2. 21150167 CVCL_TW44 HAP1 USP1 (-) 1 cancer cell line human CVCL_TW44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12607; USP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150168 CVCL_U845 AMR10 hybridoma house mouse CVCL_U845 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27499; Ganglioside GM4. 21150169 CVCL_TW45 HAP1 USP1 (-) 2 cancer cell line human CVCL_TW45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12607; USP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150170 CVCL_U842 GMR11 hybridoma house mouse CVCL_U842 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27691; Ganglioside GT1a. 21150171 CVCL_TW42 HAP1 USMG5 (-) 1 cancer cell line human CVCL_TW42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30889; ATP5MK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150172 CVCL_U843 GMR19 hybridoma house mouse CVCL_U843 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. 21150173 CVCL_TW43 HAP1 USMG5 (-) 2 cancer cell line human CVCL_TW43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30889; ATP5MK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150174 CVCL_U848 Anti-alpha(10)10E3B7 hybridoma house mouse CVCL_U848 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150175 CVCL_TW48 HAP1 USP10 (-) cancer cell line human CVCL_TW48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12608; USP10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150176 CVCL_U849 Anti-alpha(2)E2B5 hybridoma house mouse CVCL_U849 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150177 CVCL_TW49 HAP1 USP11 (-) 1 cancer cell line human CVCL_TW49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12609; USP11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150178 CVCL_U846 AGB43 hybridoma house mouse CVCL_U846 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:18318; Galactosylceramide sulfate (Sulfatide). 21150179 CVCL_TW46 HAP1 USP1 (-) 3 cancer cell line human CVCL_TW46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12607; USP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150180 CVCL_U847 Anti-alpha(1)1C6F4 hybridoma house mouse CVCL_U847 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0C216; Clostridium perfringens plc. 21150181 CVCL_TW47 HAP1 USP1 (-) 4 cancer cell line human CVCL_TW47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12607; USP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150182 CVCL_1Q10 CY18 hybrid cell line CVCL_1Q10 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping Contains a complete copy of chromosome 16.. Group: Human/rodent somatic cell hybrid 21150183 CVCL_2210 SUP-T11 cancer cell line human CVCL_2210 HLA typing: A*01:01,33:01; B*08:01,14:02; C*07:01,08:01 (PubMed=26589293); Genome ancestry: African=2.38%; Native American=0%; East Asian, North=3.57%; East Asian, South=0%; South Asian=0%; European, North=62.17%; European, South=31.87% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~35-45 hours (DSMZ=ACC-605) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150184 CVCL_1Q11 CY19 hybrid cell line CVCL_1Q11 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150185 CVCL_2211 T2 hybrid cell line human CVCL_2211 CL:0000010 Doubling time: ~40-60 hours (DSMZ=ACC-598). 21150186 CVCL_1Q14 CY120 hybrid cell line CVCL_1Q14 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150187 CVCL_2214 TFK-1 cancer cell line human CVCL_2214 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Bile duct. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~37 hours, at 40th passage (PubMed=8693487); ~40 hours (DSMZ=ACC-344) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150188 CVCL_1Q15 CY124 hybrid cell line CVCL_1Q15 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150189 CVCL_2215 THB-5 hybridoma house mouse CVCL_2215 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P20023; Human CR2/CD21. Doubling time: ~50 hours (DSMZ=ACC-88) 21150190 CVCL_1Q12 CY100 hybrid cell line CVCL_1Q12 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150191 CVCL_2212 TA-85B5 cancer cell line Norway rat CVCL_2212 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: Wistar-AF/Han. Doubling time: ~60-70 hours (DSMZ=ACC-624) 21150192 CVCL_1Q13 CY115 hybrid cell line CVCL_1Q13 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150193 CVCL_2213 TC-71 cancer cell line human CVCL_2213 HLA typing: A*02:01,68:01; B*15:07,44:02; C*03:03,05:01 (PubMed=26589293); Genome ancestry: African=0.1%; Native American=0.12%; East Asian, North=1.75%; East Asian, South=0%; South Asian=0.97%; European, North=65.4%; European, South=31.66% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18160777; PubMed=19787792; PubMed=25010205; PubMed=25223734); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=8040301; PubMed=11891184; PubMed=25010205; PubMed=25485619); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=24042735); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (PubMed=24042735); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=19787792; PubMed=25010205; PubMed=25223734; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=25010205) Derived from sampling site: Bone; humerus. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: scRNAseq analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 15 hours (PubMed=20922763); 21 hours (PubMed=24312454); 26 hours (PubMed=25984343); ~24 hours (DSMZ=ACC-516); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21150194 CVCL_1Q18 CY160 hybrid cell line CVCL_1Q18 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150195 CVCL_2218 TT2609-C02 cancer cell line human CVCL_2218 HLA typing: A*03:01,24:02; B*15:01,51:01; C*02:02,03:03 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=0.39%; East Asian, North=2.11%; East Asian, South=0%; South Asian=1.31%; European, North=62.71%; European, South=33.37% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Thr (c.761T>C); Zygosity=Heterozygous (DepMap) Population: Caucasian; Karyotypic information: Near tetraploid karyotype (PubMed=11716037); Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21 hours (PubMed=11716037); ~60-80 hours (DSMZ=ACC-510); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150196 CVCL_1Q19 CY165 hybrid cell line CVCL_1Q19 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150197 CVCL_2219 U-373MG ATCC cancer cell line human CVCL_2219 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=10416987; PubMed=14614447) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-17; true; Discontinued: ECACC; 89081403; true; Discontinued: JCRB; NIHS0295; true Male Doubling time: 40 hours (PubMed=9842975) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00295 Problematic cell line: Misidentified/contaminated Shown to be a U-251MG derivative. This cell line is not the original astrocytoma cell line established in 1973 at the University of Uppsala. See U-373MG Uppsala (Cellosaurus=CVCL_2818) for the original U-373MG cell line. 21150198 CVCL_1Q16 CY128 hybrid cell line CVCL_1Q16 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150199 CVCL_2216 TI-1 [Mouse hybridoma] hybridoma house mouse CVCL_2216 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P02646; Rabbit TNNI3. Doubling time: ~50 hours (DSMZ=ACC-285) 21150200 CVCL_1Q17 CY153 hybrid cell line CVCL_1Q17 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150201 CVCL_2217 TI-4 hybridoma house mouse CVCL_2217 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08057; Bovine TNNI3. 21150202 CVCL_U830 anti-alphaA-crystallin hybridoma house mouse CVCL_U830 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02504; Chicken CRYAA. 21150203 CVCL_TW30 HAP1 UIMC1 (-) 2 cancer cell line human CVCL_TW30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30298; UIMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150204 CVCL_U833 AMR38 hybridoma house mouse CVCL_U833 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:141641; Ganglioside GM1-lactone (GM1-L; Siagoside). 21150205 CVCL_TW33 HAP1 ULK2 (-) 2 cancer cell line human CVCL_TW33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13480; ULK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150206 CVCL_U834 AMR40 hybridoma house mouse CVCL_U834 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Ganglioside GD1a-lactone (GD1a-L). 21150207 CVCL_TW34 HAP1 ULK3 (-) 1 cancer cell line human CVCL_TW34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19703; ULK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150208 CVCL_U831 AMR19 hybridoma house mouse CVCL_U831 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Ganglioside GD3-lactone (GD3-L). 21150209 CVCL_TW31 HAP1 ULK1 (-) cancer cell line human CVCL_TW31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12558; ULK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150210 CVCL_U832 AMR20 hybridoma house mouse CVCL_U832 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:36498; Galactosylceramide (GalCer). 21150211 CVCL_TW32 HAP1 ULK2 (-) 1 cancer cell line human CVCL_TW32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13480; ULK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150212 CVCL_U837 GMR8 hybridoma house mouse CVCL_U837 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: N-glycolylneuraminic acid-containing gangliosides. 21150213 CVCL_TW37 HAP1 ULK4 (-) cancer cell line human CVCL_TW37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15784; ULK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150214 CVCL_TW38 HAP1 UNG (-) 1 cancer cell line human CVCL_TW38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12572; UNG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150215 CVCL_U838 NGR53 hybridoma house mouse CVCL_U838 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: IV6-NeuAcalpha-nLc4Cer gangliosides. 21150216 CVCL_U835 GMB7 hybridoma house mouse CVCL_U835 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21150217 CVCL_TW35 HAP1 ULK3 (-) 2 cancer cell line human CVCL_TW35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19703; ULK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150218 CVCL_U836 GMR3 hybridoma house mouse CVCL_U836 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: N-glycolylneuraminic acid-containing gangliosides. 21150219 CVCL_TW36 HAP1 ULK3 (-) 3 cancer cell line human CVCL_TW36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19703; ULK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150220 CVCL_U839 GMR6 hybridoma house mouse CVCL_U839 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:84118; Ganglioside GM3. 21150221 CVCL_TW39 HAP1 UNG (-) 2 cancer cell line human CVCL_TW39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12572; UNG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150222 CVCL_U822 1B2C6 finite cell line human CVCL_U822 CL:0000010 Population: Japanese; Derived from sampling site: Fetal pancreas. Unspecified 21150223 CVCL_TW22 HAP1 UFM1 (-) cancer cell line human CVCL_TW22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20597; UFM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150224 CVCL_U823 1C3D3 finite cell line human CVCL_U823 CL:0000010 Population: Japanese; Derived from sampling site: Fetal pancreas. Unspecified 21150225 CVCL_TW23 HAP1 UGCG (-) 1 cancer cell line human CVCL_TW23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12524; UGCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150226 CVCL_U820 D9 hybridoma house mouse CVCL_U820 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q16959; H.crassispina dynein intermediate chain 2, ciliary. 21150227 CVCL_TW20 HAP1 UFC1 (-) 1 cancer cell line human CVCL_TW20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26941; UFC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150228 CVCL_TW21 HAP1 UFC1 (-) 2 cancer cell line human CVCL_TW21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26941; UFC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150229 CVCL_U821 NAT-30 cancer cell line human CVCL_U821 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1 Group: Hybridoma fusion partner cell line 21150230 CVCL_U826 anti-beta5-crystallin hybridoma house mouse CVCL_U826 CL:0000010 Monoclonal antibody isotype: IgG. 21150231 CVCL_TW26 HAP1 UHMK1 (-) 1 cancer cell line human CVCL_TW26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19683; UHMK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150232 CVCL_U827 anti-beta6-crystallin hybridoma house mouse CVCL_U827 CL:0000010 Monoclonal antibody isotype: IgG. 21150233 CVCL_TW27 HAP1 UHMK1 (-) 2 cancer cell line human CVCL_TW27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19683; UHMK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150234 CVCL_U824 1C3IKEI finite cell line human CVCL_U824 CL:0000010 Population: Japanese; Derived from sampling site: Fetal pancreas. Unspecified 21150235 CVCL_TW24 HAP1 UGCG (-) 2 cancer cell line human CVCL_TW24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12524; UGCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150236 CVCL_U825 2C6 [Human fetal pancreas] finite cell line human CVCL_U825 CL:0000010 Population: Japanese; Derived from sampling site: Fetal pancreas. Unspecified 21150237 CVCL_TW25 HAP1 UGCG (-) 3 cancer cell line human CVCL_TW25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12524; UGCG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150238 CVCL_U828 anti-gamma1-crystallin hybridoma house mouse CVCL_U828 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q8QFU3; Cynops pyrrhogaster gamma-crystallin. 21150239 CVCL_TW28 HAP1 UHMK1 (-) 3 cancer cell line human CVCL_TW28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19683; UHMK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150240 CVCL_U829 anti-delta-crystallin hybridoma house mouse CVCL_U829 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02521; Chicken DLS1. 21150241 CVCL_TW29 HAP1 UIMC1 (-) 1 cancer cell line human CVCL_TW29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30298; UIMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150242 CVCL_U811 DMyc9-36 hybridoma house mouse CVCL_U811 CL:0000010 Transfected with: MGI; MGI:1913224; Hs1bp3. Characteristics: T-cell hybridoma expressing double Myc-tagged Hs1bp3 21150243 CVCL_TW11 HAP1 UCHL1 (-) 1 cancer cell line human CVCL_TW11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12513; UCHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150244 CVCL_TW12 HAP1 UCHL1 (-) 2 cancer cell line human CVCL_TW12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12513; UCHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150245 CVCL_U812 M4 [Mouse hybridoma against chicken IgM] hybridoma house mouse CVCL_U812 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chicken IgM. 21150246 CVCL_U810 DMyc3-45 hybridoma house mouse CVCL_U810 CL:0000010 Transfected with: MGI; MGI:1913224; Hs1bp3. Characteristics: T-cell hybridoma expressing double Myc-tagged Hs1bp3-C2 21150247 CVCL_TW10 HAP1 UBQLN2 (-) 2 cancer cell line human CVCL_TW10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12509; UBQLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150248 CVCL_U815 D16 [Mouse hybridoma against H.crassispina dynein IC3] hybridoma house mouse CVCL_U815 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16960; H.crassispina dynein intermediate chain 3, ciliary. 21150249 CVCL_TW15 HAP1 UCHL3 (-) 2 cancer cell line human CVCL_TW15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12515; UCHL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150250 CVCL_U816 D264 hybridoma house mouse CVCL_U816 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P46406; H.crassispina dynein beta. 21150251 CVCL_TW16 HAP1 UCP1 (-) 1 cancer cell line human CVCL_TW16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12517; UCP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150252 CVCL_U813 anti-alphaB-crystallin hybridoma house mouse CVCL_U813 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q05713; Chicken CRYAB. 21150253 CVCL_TW13 HAP1 UCHL1 (-) 3 cancer cell line human CVCL_TW13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12513; UCHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150254 CVCL_U814 D134 hybridoma house mouse CVCL_U814 CL:0000010 Monoclonal antibody isotype: IgM. 21150255 CVCL_TW14 HAP1 UCHL3 (-) 1 cancer cell line human CVCL_TW14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12515; UCHL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150256 CVCL_U819 D58 hybridoma house mouse CVCL_U819 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16959; H.crassispina dynein intermediate chain 2, ciliary. 21150257 CVCL_TW19 HAP1 UEVLD (-) 2 cancer cell line human CVCL_TW19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30866; UEVLD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150258 CVCL_U817 D308 hybridoma house mouse CVCL_U817 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P46406; H.crassispina dynein beta. 21150259 CVCL_TW17 HAP1 UCP1 (-) 2 cancer cell line human CVCL_TW17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12517; UCP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150260 CVCL_U818 D52 hybridoma house mouse CVCL_U818 CL:0000010 Monoclonal antibody isotype: IgM. 21150261 CVCL_TW18 HAP1 UEVLD (-) 1 cancer cell line human CVCL_TW18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30866; UEVLD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150262 CVCL_TW00 HAP1 UBE4B (-) 1 cancer cell line human CVCL_TW00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12500; UBE4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150263 CVCL_U800 Newton cancer cell line human CVCL_U800 CL:0000010 21150264 CVCL_U801 AF-6 cancer cell line human CVCL_U801 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21150265 CVCL_TW01 HAP1 UBE4B (-) 2 cancer cell line human CVCL_TW01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12500; UBE4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150266 CVCL_TW04 HAP1 UBL4A (-) cancer cell line human CVCL_TW04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12505; UBL4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150267 CVCL_U804 TtT/M-87 cancer cell line house mouse CVCL_U804 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6N x C3H/2N. 21150268 CVCL_U805 DHA3-1 hybridoma house mouse CVCL_U805 CL:0000010 Characteristics: T-cell hybridoma. 21150269 CVCL_TW05 HAP1 UBLCP1 (-) 1 cancer cell line human CVCL_TW05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28110; UBLCP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150270 CVCL_U802 BL cancer cell line human CVCL_U802 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=22383533); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Lys (c.262G>A); ClinVar=VCV000821566; Zygosity=Unspecified (PubMed=9354451) Omics: Transcriptome analysis by microarray. 21150271 CVCL_TW02 HAP1 UBL3 (-) 1 cancer cell line human CVCL_TW02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12504; UBL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150272 CVCL_U803 BA cancer cell line human CVCL_U803 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=9354451). 21150273 CVCL_TW03 HAP1 UBL3 (-) 2 cancer cell line human CVCL_TW03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12504; UBL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150274 CVCL_U808 DHA9-15 hybridoma house mouse CVCL_U808 CL:0000010 Characteristics: T-cell hybridoma. 21150275 CVCL_TW08 HAP1 UBQLN1 (-) 3 cancer cell line human CVCL_TW08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12508; UBQLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150276 CVCL_U809 DHA9-3 hybridoma house mouse CVCL_U809 CL:0000010 Characteristics: T-cell hybridoma. 21150277 CVCL_TW09 HAP1 UBQLN2 (-) 1 cancer cell line human CVCL_TW09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12509; UBQLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150278 CVCL_U806 DHA3-26 hybridoma house mouse CVCL_U806 CL:0000010 Characteristics: T-cell hybridoma. 21150279 CVCL_TW06 HAP1 UBLCP1 (-) 2 cancer cell line human CVCL_TW06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28110; UBLCP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150280 CVCL_U807 DHA9-13 hybridoma house mouse CVCL_U807 CL:0000010 Characteristics: T-cell hybridoma. 21150281 CVCL_TW07 HAP1 UBQLN1 (-) 2 cancer cell line human CVCL_TW07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12508; UBQLN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150282 CVCL_2290 577MF cancer cell line human CVCL_2290 CL:0000010 Derived from metastatic site: Forehead. Male 21150283 CVCL_1Q90 SEES2 embryonic stem cell human CVCL_1Q90 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan CL:0000010 Omics: Deep exome analysis. Female 21150284 CVCL_2291 59M cancer cell line human CVCL_2291 HLA typing: A*03:01,11:01; B*35:01,44:02; C*04:01,05:01 (PubMed=26589293); Genome ancestry: African=3.2%; Native American=0%; East Asian, North=4.18%; East Asian, South=0%; South Asian=0%; European, North=58.71%; European, South=33.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Lysfs*49 (c.577_592delCATCTTATCCGAGTGG); Zygosity=Heterozygous (DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours, at 6th passage (PubMed=2653399; PubMed=8795574); 66.24 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21150285 CVCL_1Q91 SEES3 embryonic stem cell human CVCL_1Q91 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan CL:0000010 Omics: Deep exome analysis. Male 21150286 CVCL_2294 A375-C5 cancer cell line human CVCL_2294 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 21150287 CVCL_1Q94 H414 cancer cell line human CVCL_1Q94 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150288 CVCL_2295 A375-C6 cancer cell line human CVCL_2295 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Omics: SNP array analysis Female 21150289 CVCL_1Q95 H414-LIG4(+/-) cancer cell line human CVCL_1Q95 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6601; LIG4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150290 CVCL_2292 833K-E cancer cell line human CVCL_2292 CL:0000010 Derived from metastatic site: Abdomen. Omics: CNV analysis Male 21150291 CVCL_1Q92 RY-PB cancer cell line Norway rat CVCL_1Q92 CL:0000010 Derived from sampling site: Endometrium; Breed/subspecies: Fischer 344/DuCrj. Female 21150292 CVCL_2293 84BR finite cell line human CVCL_2293 CL:0000010 Donor information: Established from the non-affected skin biopsy of a radiosensitive breast cancer patient; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 48 hours (PubMed=8609460) 21150293 CVCL_1Q93 RY-B-E3 cancer cell line Norway rat CVCL_1Q93 CL:0000010 Derived from sampling site: Endometrium; Breed/subspecies: Fischer 344/DuCrj. Female 21150294 CVCL_2287 3A sub E transformed cell line human CVCL_2287 CL:0000010 Transformant: Simian virus 40 (SV40) [ts30](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female Characteristics: Established from 3A(tPA-30-1) cells that had begun to senesce By passage 20 the cells had recovered and appeared capable of unlimited proliferation (ATCC=CRL-1584). 21150295 CVCL_2288 46BR.1G1 transformed cell line human CVCL_2288 CL:0000010 Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Glu566Lys (c.1696G>A); ClinVar=VCV000016775; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Arg771Trp (c.2311C>T); ClinVar=VCV000016776; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Proteome analysis by 2D-DE/MS Female 21150296 CVCL_1Q88 T409 cancer cell line human CVCL_1Q88 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Derived from sampling site: Oral cavity; floor of mouth. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00427 Problematic cell line: Contaminated Shown to be a UM-SCC-1 derivative (PubMed=21868764). 21150297 CVCL_2285 293 GTP-AC-free transformed cell line human CVCL_2285 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21150298 CVCL_1Q85 Tu167LN1 cancer cell line human CVCL_1Q85 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Characteristics: Anoikis-resistant (PubMed=12907203) Problematic cell line: Contaminated Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative. 21150299 CVCL_2286 293 N3S transformed cell line human CVCL_2286 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-2125; true Female Doubling time: 30 hours (ECACC=92052131) 21150300 CVCL_1Q86 JMAR cancer cell line human CVCL_1Q86 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Characteristics: Anoikis-resistant (PubMed=12907203) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00407 Problematic cell line: Contaminated Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative (PubMed=21868764). 21150301 CVCL_2289 46BR.1N transformed cell line human CVCL_2289 CL:0000010 Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Glu566Lys (c.1696G>A); ClinVar=VCV000016775; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6598; LIG1; Simple; p.Arg771Trp (c.2311C>T); ClinVar=VCV000016776; Zygosity=Heterozygous (Coriell); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150302 CVCL_1Q89 SEES1 embryonic stem cell human CVCL_1Q89 From: National Center for Child Health and Development (NCCHD); Tokyo; Japan CL:0000010 Omics: Deep exome analysis. Female 21150303 CVCL_2298 Athos spontaneously immortalized cell line pig CVCL_2298 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified Characteristics: Derived from parent cell line after withdrawal of thyroid stimulating hormone (TSH) (PubMed=7687180) 21150304 CVCL_1Q98 H414-RAD18(+/-) cancer cell line human CVCL_1Q98 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 18278; RAD18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150305 CVCL_2299 ATRFLOX cancer cell line human CVCL_2299 HLA typing: A*01:01,02:01; B*18:01,45:01; C*05:01,07:06 (PubMed=26589293) CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 882; ATR; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: One copy of the ATR gene has been disrupted while lox sites have been added flanking exon 2 of the 2nd allele thus making it susceptible to Cre-mediated deletion 21150306 CVCL_1Q99 H414-RAD18(-/-) cancer cell line human CVCL_1Q99 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 18278; RAD18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150307 CVCL_2296 AGLCL [Human 1989] transformed cell line human CVCL_2296 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=24244370) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 21150308 CVCL_1Q96 H414-MDC1(+/-) cancer cell line human CVCL_1Q96 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150309 CVCL_2297 ANGM-CSS cancer cell line human CVCL_2297 CL:0000010 Karyotypic information: Near tetraploid karyotype; Derived from sampling site: Brain; left temporo-occipital lobe. Omics: Deep exome analysis; Omics: SNP array analysis Male Doubling time: ~60 hours (PubMed=24366606) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150310 CVCL_1Q97 H414-MDC1(-/-) cancer cell line human CVCL_1Q97 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150311 CVCL_2272 153BR finite cell line human CVCL_2272 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150312 CVCL_1Q72 MT-R8 cancer cell line Norway rat CVCL_1Q72 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: Fischer 344/DuCrj. Male 21150313 CVCL_2273 155BR finite cell line human CVCL_2273 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150314 CVCL_1Q73 MT-R9 cancer cell line Norway rat CVCL_1Q73 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: Fischer 344/DuCrj. Male 21150315 CVCL_2270 143B cancer cell line human CVCL_2270 HLA typing: A*02:11,02:11; B*52:01,52:01; C*12:02,12:02; DQB1*05:02,05:02; DRB1*15:02,16:05 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=4.02%; South Asian=37%; European, North=0%; European, South=58.98% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (PubMed=19787792; DepMap) Population: Caucasian; Derived from sampling site: Bone; right femur. Omics: Deep exome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8303 Caution: Could be identical to HTK- (Cellosaurus=CVCL_2522) 21150316 CVCL_1Q70 MT-8L cancer cell line Norway rat CVCL_1Q70 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21150317 CVCL_2271 149BR finite cell line human CVCL_2271 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 46 hours (PubMed=8609460) 21150318 CVCL_1Q71 MT-9L cancer cell line Norway rat CVCL_1Q71 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21150319 CVCL_2265 1301 cancer cell line human CVCL_2265 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Has unusually long telomeres 21150320 CVCL_1Q65 HPS0171 induced pluripotent stem cell human CVCL_1Q65 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150321 CVCL_2266 1306 transformed cell line human CVCL_2266 CL:0000010 Population: Puerto Rican; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150322 CVCL_1Q66 HPS0317 induced pluripotent stem cell human CVCL_1Q66 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21150323 CVCL_2263 1184 transformed cell line human CVCL_2263 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21150324 CVCL_1Q63 HiPS-RIKEN-2F induced pluripotent stem cell human CVCL_1Q63 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21150325 CVCL_2264 1221 finite cell line human CVCL_2264 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21150326 CVCL_1Q64 HPS0145 induced pluripotent stem cell human CVCL_1Q64 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150327 CVCL_2269 142BR finite cell line human CVCL_2269 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150328 CVCL_1Q69 Etv2-Venus-KO embryonic stem cell house mouse CVCL_1Q69 CL:0000010 Transfected with: Venus, a bright yellow fluorescent protein derived from YFP. Male 21150329 CVCL_2267 104C1 transformed cell line CVCL_2267 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Breed/subspecies: Strain 2. Unspecified Virology: Susceptible to infection and early propagation by guinea pig adenovirus (GPAdV) (PubMed=32226606) 21150330 CVCL_1Q67 HPS0322 induced pluripotent stem cell human CVCL_1Q67 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21150331 CVCL_2268 1411H cancer cell line human CVCL_2268 CL:0000010 Derived from metastatic site: Abdomen. Male 21150332 CVCL_1Q68 Etv2-Venus-KI embryonic stem cell house mouse CVCL_1Q68 CL:0000010 Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Breed/subspecies: 129/Sv. Male 21150333 CVCL_2280 1BR.3.G transformed cell line human CVCL_2280 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150334 CVCL_1Q80 LY-PPB6 cancer cell line Norway rat CVCL_1Q80 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Female 21150335 CVCL_2283 293-Hektor transformed cell line human CVCL_2283 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Adapted to growth in the chemically defined protein- and peptide-free Hektor media from Cell Culture Technologies Group: Serum/protein free medium cell line 21150336 CVCL_1Q83 DM12 [Human OCSCC] cancer cell line human CVCL_1Q83 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00397 Problematic cell line: Contaminated Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative (PubMed=21868764). 21150337 CVCL_2284 293-PERV-PK-CIRCE transformed cell line human CVCL_2284 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21150338 CVCL_1Q84 DM14 [Human OCSCC] cancer cell line human CVCL_1Q84 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00398 Problematic cell line: Contaminated Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative (PubMed=21868764). 21150339 CVCL_2281 1BR.3.GN transformed cell line human CVCL_2281 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150340 CVCL_1Q81 PC-MDS cancer cell line human CVCL_1Q81 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00379 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=19344951). 21150341 CVCL_2282 1BR.3.N transformed cell line human CVCL_2282 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150342 CVCL_1Q82 M-TAT cancer cell line human CVCL_1Q82 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21150343 CVCL_2276 175BR finite cell line human CVCL_2276 CL:0000010 Donor information: Established from the non-affected skin biopsy from an individual with multiple tumours of independent histological origin (PubMed=23093295); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150344 CVCL_1Q76 KE-P cancer cell line Norway rat CVCL_1Q76 CL:0000010 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.; Breed/subspecies: Fischer 344/DuCrj. Male Doubling time: 20.9 hours (at 10th passage), 19.7 hours (at 20th passage), 20.5 hours (at 30th passage), 18.4 hours (at 50th passage) (PubMed=12811582) 21150345 CVCL_2277 1777N Rpmet cancer cell line human CVCL_2277 CL:0000010 Derived from sampling site: Retroperitoneal lymph node. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150346 CVCL_1Q77 KE-F11 cancer cell line Norway rat CVCL_1Q77 CL:0000010 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.; Breed/subspecies: Fischer 344/DuCrj. Male Doubling time: 20.0 hours (at 10th passage), 16.5 hours (at 20th passage), 19.0 hours (at 30th passage) (PubMed=12811582) 21150347 CVCL_2274 161BR finite cell line human CVCL_2274 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150348 CVCL_1Q74 KB-P cancer cell line Norway rat CVCL_1Q74 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male Doubling time: 20.3 hours (PubMed=12070602) 21150349 CVCL_2275 174BR finite cell line human CVCL_2275 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150350 CVCL_1Q75 KB-D8 cancer cell line Norway rat CVCL_1Q75 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male Doubling time: 19.1 hours (PubMed=12070602) 21150351 CVCL_2278 180BR finite cell line human CVCL_2278 CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg278His (c.833G>A); ClinVar=VCV000007675; Zygosity=Unspecified (PubMed=10395545) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: Radiosensitive cell line defective in DSB repair Doubling time: 57 hours (PubMed=8609460) 21150352 CVCL_1Q78 KJ-A cancer cell line Norway rat CVCL_1Q78 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21150353 CVCL_2279 1BR3 finite cell line human CVCL_2279 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 24 hours (PubMed=8609460) 21150354 CVCL_1Q79 LY-H12 cancer cell line Norway rat CVCL_1Q79 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Female 21150355 CVCL_TW95 HAP1 USP38 (-) 2 cancer cell line human CVCL_TW95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20067; USP38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150356 CVCL_U895 Hu5/E18 transformed cell line human CVCL_U895 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E7](NCBI-Taxonomy; 333760); Derived from sampling site: Abdomen; muscle. Discontinued: RCB; RCB2366; probable Female Doubling time: 34.7 +- 4.1 hours (PubMed=16919240) 21150357 CVCL_TW96 HAP1 USP4 (-) 1 cancer cell line human CVCL_TW96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12627; USP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150358 CVCL_U896 OLV2-1 embryonic stem cell house mouse CVCL_U896 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21150359 CVCL_U893 EBC-1/brain cancer cell line human CVCL_U893 CL:0000010 Sequence variation: Mutation; HGNC; 2731; DDR2; Simple; p.Thr681Ile (c.2042C>T); ClinVar=VCV001435412; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Skin. Male Characteristics: Brain metastatic Established from parent cell line in athymic mice after 5 cycles of in vivo serial passage of the cells in the mouse brain metastatic lesions. 21150360 CVCL_TW93 HAP1 USP35 (-) cancer cell line human CVCL_TW93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20061; USP35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150361 CVCL_TW94 HAP1 USP38 (-) 1 cancer cell line human CVCL_TW94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20067; USP38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150362 CVCL_U894 WA-mFib finite cell line house mouse CVCL_U894 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c(nu/nu). Unspecified 21150363 CVCL_TW99 HAP1 USP45 (-) 1 cancer cell line human CVCL_TW99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20080; USP45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150364 CVCL_U899 Tpit/E conditionally immortalized cell line house mouse CVCL_U899 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; adenohypophysis Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 28.6 hours (PubMed=24881870) 21150365 CVCL_TW97 HAP1 USP40 (-) 1 cancer cell line human CVCL_TW97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20069; USP40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150366 CVCL_U897 OLC2-1 embryonic stem cell house mouse CVCL_U897 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21150367 CVCL_TW98 HAP1 USP40 (-) 2 cancer cell line human CVCL_TW98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20069; USP40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150368 CVCL_U898 REF-RGB spontaneously immortalized cell line Norway rat CVCL_U898 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Wistar. Unspecified 21150369 CVCL_1Q50 PCG.G6 hybrid cell line CVCL_1Q50 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150370 CVCL_2250 SK-UT-1B cancer cell line human CVCL_2250 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1096Ter (c.3286C>T); ClinVar=VCV000156475; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg88Gln (c.263G>A); ClinVar=VCV000376049; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323fs*2 (c.968_969insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray. Female Part of: MD Anderson Cell Lines Project; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK2010-071 21150371 CVCL_1Q51 MCP6 hybrid cell line CVCL_1Q51 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150372 CVCL_2251 WEHI-164 cancer cell line house mouse CVCL_2251 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. 21150373 CVCL_1Q43 Agnes cancer cell line human CVCL_1Q43 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Female 21150374 CVCL_1Q44 Maku cancer cell line human CVCL_1Q44 CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Ser77Pro (c.229T>C); Zygosity=Unspecified (PubMed=8108117) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21150375 CVCL_2244 YAC-1 cancer cell line house mouse CVCL_2244 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: A/Sn. Doubling time: ~20 hours (DSMZ=ACC-96) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21150376 CVCL_1Q41 PEL16 hybrid cell line CVCL_1Q41 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150377 CVCL_2241 WMP-2 transformed cell line house mouse CVCL_2241 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Lymph node and spleen; Breed/subspecies: WMP/PasDnJ. Female Doubling time: ~30-40 hours (DSMZ=ACC-453) 21150378 CVCL_1Q42 PEL40 hybrid cell line CVCL_1Q42 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150379 CVCL_2242 WT49 transformed cell line human CVCL_2242 HLA typing: A*02:05:01; B*58:01:01; C*07:18; DPA1*01:03; DPB1*04:01; DQA1*05:01; DQB1*02:01:01; DRB1*03:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=11573) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21150380 CVCL_2247 HD-Mar-2 cancer cell line human CVCL_2247 CL:0000010 Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Doubling time: ~50 hours (DSMZ=ACC-685) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be a T lymphoblastic lymphoma (PubMed=29533902). 21150381 CVCL_1Q47 PCC4AO cancer cell line house mouse CVCL_1Q47 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Breed/subspecies: 129/Sv. Male 21150382 CVCL_1Q48 GEOC4 hybrid cell line CVCL_1Q48 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150383 CVCL_2248 WEHI-22.1 cancer cell line house mouse CVCL_2248 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Doubling time: ~12 hours (PubMed=4630643) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21150384 CVCL_1Q45 F-137 cancer cell line human CVCL_1Q45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Problematic cell line: Contaminated Shown to be a Jiyoye derivative (PubMed=4736620). Originally thought to originate from the lymph node of a male chronic lymphocytic leukemia patient. 21150385 CVCL_2245 IPEC-1 spontaneously immortalized cell line pig CVCL_2245 CL:0000010 Derived from sampling site: Small intestine; ileum and small intestine; jejunum. Omics: Transcriptome analysis by microarray Unspecified Doubling time: ~30 hours (DSMZ=ACC-705) 21150386 CVCL_1Q46 G3.32.2 cancer cell line human CVCL_1Q46 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Problematic cell line: Contaminated Parent cell line (F-137) has been shown to be a Jiyoye derivative. 21150387 CVCL_2246 IPEC-J2 spontaneously immortalized cell line pig CVCL_2246 CL:0000010 Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Unspecified Characteristics: Undergoes a process of spontaneous differentiation that leads to the formation of a polarized monolayer with low or high transepithelial electrical resistance (TEER), depending on the type of serum added to the culture medium, within 1-2 weeks (PubMed=29787056); Virology: Susceptible to infection by porcine circovirus type 2 (PCV2) (PubMed=25407967) Doubling time: ~40-60 hours (DSMZ=ACC-701) 21150388 CVCL_2249 OACM4.1 C cancer cell line human CVCL_2249 CL:0000010 Derived from metastatic site: Lymph node. Male 21150389 CVCL_1Q49 PC21A1 hybrid cell line CVCL_1Q49 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150390 CVCL_U884 GM12325 transformed cell line human CVCL_U884 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (from familial inference) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150391 CVCL_TW84 HAP1 USP30 (-) 1 cancer cell line human CVCL_TW84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20065; USP30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150392 CVCL_U885 GM12326 transformed cell line human CVCL_U885 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (from familial inference) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150393 CVCL_TW85 HAP1 USP30 (-) 2 cancer cell line human CVCL_TW85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20065; USP30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150394 CVCL_U882 GM11316 transformed cell line human CVCL_U882 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150395 CVCL_TW82 HAP1 USP28 (-) 2 cancer cell line human CVCL_TW82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12625; USP28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150396 CVCL_U883 GM11317 finite cell line human CVCL_U883 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21150397 CVCL_TW83 HAP1 USP3 (-) cancer cell line human CVCL_TW83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12626; USP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150398 CVCL_U888 CFK2 spontaneously immortalized cell line Norway rat CVCL_U888 CL:0000010 Derived from sampling site: Embryonic bone; calvaria; Breed/subspecies: Sprague Dawley. Unspecified 21150399 CVCL_TW88 HAP1 USP32 (-) 1 cancer cell line human CVCL_TW88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19143; USP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150400 CVCL_U889 GM16824 transformed cell line human CVCL_U889 CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg239Cys (c.729C>T); ClinVar=VCV000016167; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150401 CVCL_TW89 HAP1 USP32 (-) 2 cancer cell line human CVCL_TW89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19143; USP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150402 CVCL_TW86 HAP1 USP31 (-) 1 cancer cell line human CVCL_TW86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20060; USP31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150403 CVCL_U886 OBCK6 spontaneously immortalized cell line Norway rat CVCL_U886 CL:0000010 Derived from sampling site: Embryonic bone; calvaria; Breed/subspecies: Sprague Dawley. Unspecified 21150404 CVCL_U887 CFK1 spontaneously immortalized cell line Norway rat CVCL_U887 CL:0000010 Derived from sampling site: Embryonic bone; calvaria; Breed/subspecies: Sprague Dawley. Unspecified 21150405 CVCL_TW87 HAP1 USP31 (-) 2 cancer cell line human CVCL_TW87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20060; USP31; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150406 CVCL_2261 MTSV1-7 HB2 transformed cell line human CVCL_2261 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21150407 CVCL_1Q61 HiPS-RIKEN-11A induced pluripotent stem cell human CVCL_1Q61 CL:0000010 Population: Japanese; Derived from sampling site: Amniotic fluid. Male 21150408 CVCL_2262 1156QE/8 cancer cell line human CVCL_2262 CL:0000010 Omics: CNV analysis. Male 21150409 CVCL_1Q62 HiPS-RIKEN-13A induced pluripotent stem cell human CVCL_1Q62 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male 21150410 CVCL_2260 1-5c-4 cancer cell line human CVCL_2260 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00298 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=566722; PubMed=20143388). Originally thought to originate from the conjunctiva of a child. 21150411 CVCL_1Q60 Nur-1 cancer cell line human CVCL_1Q60 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 6.1 days (at 30th passage), 5.8 days (at 60th passage), 5.6 days (at 103th passage) (PubMed=25627346) 21150412 CVCL_2254 Girardi Heart cancer cell line human CVCL_2254 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-27; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00006 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=20143388). Originally thought to originate from normal heart cells. 21150413 CVCL_1Q54 GM10927 hybrid cell line human CVCL_1Q54 CL:0000010 Characteristics: Hybrid for chromosome 11 mapping Contains a complete copy of chromosome 11.. Group: Human/rodent somatic cell hybrid 21150414 CVCL_1Q55 GM11944 hybrid cell line human CVCL_1Q55 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150415 CVCL_2255 HLF-a undefined cell line type human CVCL_2255 Genome ancestry: African=90.86%; Native American=0%; East Asian, North=2.07%; East Asian, South=0%; South Asian=0%; European, North=1.99%; European, South=5.07% (PubMed=30894373) CL:0000010 Population: African American; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ECACC; 90112703; probable Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Misclassified Originally thought to be a lung squamous cell carcinoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21150416 CVCL_1Q52 78-5 hybrid cell line human CVCL_1Q52 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150417 CVCL_2252 bEnd.5 transformed cell line house mouse CVCL_2252 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Brain Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 21150418 CVCL_1Q53 78-5j1 hybrid cell line human CVCL_1Q53 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150419 CVCL_2253 C-4-I cancer cell line human CVCL_2253 HLA typing: A*01,03; B*07,w40 (PubMed=77569); Genome ancestry: African=0%; Native American=0.73%; East Asian, North=0%; East Asian, South=0%; South Asian=1.02%; European, North=72.49%; European, South=25.76% (PubMed=30894373) CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7396; true Female Virology: Contains a complete HPV18 genome Doubling time: 2 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21150420 CVCL_2258 1.2B4 hybrid cell line human CVCL_2258 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4071_4072insGATT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (from parent cell line). Characteristics: Insulin secreting; Characteristics: Produced by electrofusion of HuP-T3 with a primary culture of human pancreatic islets Doubling time: ~20 hours (ECACC=10070103) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3524 21150421 CVCL_1Q58 GM04125 finite cell line human CVCL_1Q58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(15;18)(15pter->15q15::18p11.3->18pter;18qter->18p11.3::15q15->15qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21150422 CVCL_2259 1.4E7 hybrid cell line human CVCL_2259 CL:0000010 Characteristics: Insulin secreting; Characteristics: Produced by electrofusion of PANC-1 with a primary culture of human pancreatic islets Doubling time: 26 +- 1.5 hours (PubMed=21515691); ~26 hours (ECACC=10070102). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3525 21150423 CVCL_1Q59 CY140 hybrid cell line CVCL_1Q59 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21150424 CVCL_1Q56 GM08210 finite cell line human CVCL_1Q56 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21150425 CVCL_2256 Hs 432.T cancer cell line human CVCL_2256 CL:0000010 Discontinued: ATCC; CRL-7299; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21150426 CVCL_2257 1.1E7 hybrid cell line CVCL_2257 CL:0000010 Discontinued: ECACC; 10070101; true. Characteristics: Insulin secreting Doubling time: 23 +- 1.9 hours (PubMed=21515691); ~23 hours (ECACC=10070101) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00600; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3523 Problematic cell line: Misidentified/contaminated Originally thought to be an hybrid cell line obtained by electrofusion of a primary culture of human pancreatic islets with the PANC-1 but found to contain rat DNA (ECACC). 21150427 CVCL_1Q57 GM05382 finite cell line human CVCL_1Q57 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(7;18)(7pter->7q36::18q12.2->18qter;18pter->18q12.2::7q36->7qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21150428 CVCL_U891 GM16826 transformed cell line human CVCL_U891 CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg79Cys (c.235C>T); ClinVar=VCV000016171; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150429 CVCL_TW91 HAP1 USP33 (-) 2 cancer cell line human CVCL_TW91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20059; USP33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150430 CVCL_U892 EBC-1/bone cancer cell line human CVCL_U892 CL:0000010 Sequence variation: Mutation; HGNC; 2731; DDR2; Simple; p.Thr681Ile (c.2042C>T); ClinVar=VCV001435412; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Skin. Male Characteristics: Bone metastatic Established from parent cell line in athymic mice after 5 cycles of in vivo serial passage of the cells in the mouse bone metastatic lesions. 21150431 CVCL_TW92 HAP1 USP34 (-) cancer cell line human CVCL_TW92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20066; USP34; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150432 CVCL_U890 GM16825 finite cell line human CVCL_U890 CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg239Cys (c.729C>T); ClinVar=VCV000016167; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150433 CVCL_TW90 HAP1 USP33 (-) 1 cancer cell line human CVCL_TW90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20059; USP33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150434 CVCL_CD39 ND03904 transformed cell line human CVCL_CD39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150435 CVCL_CD37 ND03901 transformed cell line human CVCL_CD37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150436 CVCL_CD38 ND03902 transformed cell line human CVCL_CD38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150437 CVCL_CD31 ND03874 transformed cell line human CVCL_CD31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150438 CVCL_CD32 ND03875 transformed cell line human CVCL_CD32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150439 CVCL_CD30 ND03872 transformed cell line human CVCL_CD30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150440 CVCL_CD35 ND03899 transformed cell line human CVCL_CD35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150441 CVCL_CD36 ND03900 transformed cell line human CVCL_CD36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150442 CVCL_CD33 ND03884 transformed cell line human CVCL_CD33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150443 CVCL_CD34 ND03896 transformed cell line human CVCL_CD34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150444 CVCL_CD50 ND04001 transformed cell line human CVCL_CD50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150445 CVCL_CD48 ND03982 transformed cell line human CVCL_CD48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150446 CVCL_CD49 ND03999 transformed cell line human CVCL_CD49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150447 CVCL_CD42 ND03944 transformed cell line human CVCL_CD42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150448 CVCL_CD43 ND03949 transformed cell line human CVCL_CD43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150449 CVCL_CD40 ND03926 transformed cell line human CVCL_CD40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150450 CVCL_CD41 ND03939 transformed cell line human CVCL_CD41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150451 CVCL_CD46 ND03964 transformed cell line human CVCL_CD46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150452 CVCL_CD47 ND03980 transformed cell line human CVCL_CD47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150453 CVCL_CD44 ND03951 transformed cell line human CVCL_CD44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150454 CVCL_CD45 ND03955 transformed cell line human CVCL_CD45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150455 CVCL_CD17 ND03766 transformed cell line human CVCL_CD17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150456 CVCL_CD18 ND03769 transformed cell line human CVCL_CD18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150457 CVCL_CD15 ND03722 transformed cell line human CVCL_CD15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150458 CVCL_CD16 ND03765 transformed cell line human CVCL_CD16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150459 CVCL_CD19 ND03795 transformed cell line human CVCL_CD19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150460 CVCL_CD10 ND03678 transformed cell line human CVCL_CD10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150461 CVCL_CD13 ND03684 transformed cell line human CVCL_CD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150462 CVCL_CD14 ND03705 transformed cell line human CVCL_CD14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150463 CVCL_CD11 ND03682 transformed cell line human CVCL_CD11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150464 CVCL_CD12 ND03683 transformed cell line human CVCL_CD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150465 CVCL_CD28 ND03866 transformed cell line human CVCL_CD28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150466 CVCL_CD29 ND03871 transformed cell line human CVCL_CD29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150467 CVCL_CD26 ND03864 transformed cell line human CVCL_CD26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150468 CVCL_CD27 ND03865 transformed cell line human CVCL_CD27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150469 CVCL_CD20 ND03796 transformed cell line human CVCL_CD20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150470 CVCL_CD21 ND03797 transformed cell line human CVCL_CD21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150471 CVCL_CD24 ND03831 transformed cell line human CVCL_CD24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150472 CVCL_CD25 ND03863 transformed cell line human CVCL_CD25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150473 CVCL_CD22 ND03798 transformed cell line human CVCL_CD22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150474 CVCL_CD23 ND03799 transformed cell line human CVCL_CD23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150475 CVCL_CD06 ND03658 transformed cell line human CVCL_CD06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150476 CVCL_CD07 ND03672 transformed cell line human CVCL_CD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150477 CVCL_CD04 ND03610 transformed cell line human CVCL_CD04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150478 CVCL_CD05 ND03611 transformed cell line human CVCL_CD05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150479 CVCL_CD08 ND03676 transformed cell line human CVCL_CD08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150480 CVCL_CD09 ND03677 transformed cell line human CVCL_CD09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150481 CVCL_CD02 ND03607 transformed cell line human CVCL_CD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150482 CVCL_CD03 ND03608 transformed cell line human CVCL_CD03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150483 CVCL_CD00 ND03583 transformed cell line human CVCL_CD00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150484 CVCL_CD01 ND03593 transformed cell line human CVCL_CD01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150485 CVCL_CD97 ND04341 transformed cell line human CVCL_CD97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150486 CVCL_CD98 ND04342 transformed cell line human CVCL_CD98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150487 CVCL_CD95 ND04334 transformed cell line human CVCL_CD95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150488 CVCL_CD96 ND04340 transformed cell line human CVCL_CD96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150489 CVCL_CD99 ND04344 transformed cell line human CVCL_CD99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150490 CVCL_CD82 ND04234 transformed cell line human CVCL_CD82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150491 CVCL_CD83 ND04235 transformed cell line human CVCL_CD83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150492 CVCL_CD80 ND04213 transformed cell line human CVCL_CD80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150493 CVCL_CD81 ND04228 transformed cell line human CVCL_CD81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150494 CVCL_CD75 ND04180 transformed cell line human CVCL_CD75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150495 CVCL_CD76 ND04181 transformed cell line human CVCL_CD76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150496 CVCL_CD73 ND04177 transformed cell line human CVCL_CD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150497 CVCL_CD74 ND04179 transformed cell line human CVCL_CD74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150498 CVCL_CD79 ND04207 transformed cell line human CVCL_CD79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150499 CVCL_CD77 ND04184 transformed cell line human CVCL_CD77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150500 CVCL_CD78 ND04206 transformed cell line human CVCL_CD78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150501 CVCL_CD90 ND04293 transformed cell line human CVCL_CD90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150502 CVCL_CD93 ND04303 transformed cell line human CVCL_CD93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150503 CVCL_CD94 ND04325 transformed cell line human CVCL_CD94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150504 CVCL_CD91 ND04294 transformed cell line human CVCL_CD91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150505 CVCL_CD92 ND04301 transformed cell line human CVCL_CD92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150506 CVCL_CD86 ND04263 transformed cell line human CVCL_CD86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150507 CVCL_CD87 ND04264 transformed cell line human CVCL_CD87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150508 CVCL_CD84 ND04248 transformed cell line human CVCL_CD84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150509 CVCL_CD85 ND04249 transformed cell line human CVCL_CD85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150510 CVCL_CD88 ND04265 transformed cell line human CVCL_CD88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150511 CVCL_CD89 ND04266 transformed cell line human CVCL_CD89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150512 CVCL_CD60 ND04093 transformed cell line human CVCL_CD60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150513 CVCL_CD61 ND04145 transformed cell line human CVCL_CD61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150514 CVCL_CD59 ND04091 transformed cell line human CVCL_CD59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150515 CVCL_CD53 ND04007 transformed cell line human CVCL_CD53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150516 CVCL_CD54 ND04018 transformed cell line human CVCL_CD54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150517 CVCL_CD51 ND04005 transformed cell line human CVCL_CD51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150518 CVCL_CD52 ND04006 transformed cell line human CVCL_CD52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150519 CVCL_CD57 ND04027 transformed cell line human CVCL_CD57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150520 CVCL_CD58 ND04038 transformed cell line human CVCL_CD58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150521 CVCL_CD55 ND04024 transformed cell line human CVCL_CD55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150522 CVCL_CD56 ND04026 transformed cell line human CVCL_CD56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150523 CVCL_CD71 ND04164 transformed cell line human CVCL_CD71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150524 CVCL_CD72 ND04176 transformed cell line human CVCL_CD72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150525 CVCL_CD70 ND04162 transformed cell line human CVCL_CD70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150526 CVCL_CD64 ND04151 transformed cell line human CVCL_CD64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150527 CVCL_CD65 ND04156 transformed cell line human CVCL_CD65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150528 CVCL_CD62 ND04147 transformed cell line human CVCL_CD62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150529 CVCL_CD63 ND04149 transformed cell line human CVCL_CD63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150530 CVCL_CD68 ND04159 transformed cell line human CVCL_CD68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150531 CVCL_CD69 ND04160 transformed cell line human CVCL_CD69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150532 CVCL_CD66 ND04157 transformed cell line human CVCL_CD66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150533 CVCL_CD67 ND04158 transformed cell line human CVCL_CD67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21150534 CVCL_TX94 HAP1 WDR76 (-) 2 cancer cell line human CVCL_TX94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25773; WDR76; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150535 CVCL_U994 NCI-H2722 cancer cell line human CVCL_U994 HLA typing: A*24:02,32:03; B*15:01,35:04; C*03:03,04:01 (PubMed=26589293); Genome ancestry: African=0.26%; Native American=1.83%; East Asian, North=0%; East Asian, South=0%; South Asian=2.81%; European, North=57.77%; European, South=37.33% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150536 CVCL_TX95 HAP1 WDR81 (-) cancer cell line human CVCL_TX95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26600; WDR81; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150537 CVCL_U995 NCI-H2731 cancer cell line human CVCL_U995 Genome ancestry: African=0%; Native American=0.84%; East Asian, North=1.33%; East Asian, South=0%; South Asian=1.88%; European, North=65.41%; European, South=30.53% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150538 CVCL_TX92 HAP1 WDR73 (-) cancer cell line human CVCL_TX92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25928; WDR73; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150539 CVCL_U992 L alpha spontaneously immortalized cell line house mouse CVCL_U992 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Discontinued: JCRB; NIHS0189; true Male 21150540 CVCL_U993 H4-C99 cancer cell line human CVCL_U993 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 620; APP (with p.Met1_Met671del = C99) Population: Caucasian; Derived from sampling site: Brain. Male 21150541 CVCL_TX93 HAP1 WDR76 (-) 1 cancer cell line human CVCL_TX93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25773; WDR76; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150542 CVCL_TX98 HAP1 WHAMM (-) 2 cancer cell line human CVCL_TX98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30493; WHAMM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150543 CVCL_U998 NCI-H2804 cancer cell line human CVCL_U998 HLA typing: A*02:01,03:01; B*35:01,51:01; C*04:01,14:02 (PubMed=26589293); Genome ancestry: African=1.05%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=0%; European, North=68.14%; European, South=28.74% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150544 CVCL_TX99 HAP1 WHAMM (-) 3 cancer cell line human CVCL_TX99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30493; WHAMM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150545 CVCL_U999 NCI-H2810 cancer cell line human CVCL_U999 HLA typing: A*02:05,24:02; B*35:02,50:01; C*04:01,06:02; DQB1*06:04,06:04 (PubMed=26589293); Genome ancestry: African=2.41%; Native American=0.47%; East Asian, North=2.44%; East Asian, South=0.76%; South Asian=5.17%; European, North=28.37%; European, South=60.38% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150546 CVCL_TX96 HAP1 WDR91 (-) 1 cancer cell line human CVCL_TX96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24997; WDR91; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150547 CVCL_U996 NCI-H2795 cancer cell line human CVCL_U996 HLA typing: A*24:02,68:01; B*35:01,40:01; C*03:04,04:01 (PubMed=26589293); Genome ancestry: African=1.04%; Native American=1.03%; East Asian, North=1.57%; East Asian, South=0%; South Asian=0.85%; European, North=65.63%; European, South=29.89% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150548 CVCL_TX97 HAP1 WHAMM (-) 1 cancer cell line human CVCL_TX97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30493; WHAMM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150549 CVCL_U997 NCI-H2803 cancer cell line human CVCL_U997 HLA typing: A*68:01,68:01; B*35:01,51:01; C*04:04,15:02 (PubMed=26589293); Genome ancestry: African=59.04%; Native American=0.46%; East Asian, North=1.75%; East Asian, South=0%; South Asian=0.55%; European, North=22.93%; European, South=15.28% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150550 CVCL_2350 CCD-1100Sk finite cell line human CVCL_2350 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~26 PDL (ATCC=CRL-2211) 21150551 CVCL_1R50 OS 187 cancer cell line human CVCL_1R50 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; c.68-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr30Ter (c.90C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg145Trp (c.433C>T); ClinVar=VCV000005592; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>C; ClinVar=VCV000635383; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line). Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00485 Problematic cell line: Contaminated Shown to be a HCT 15 derivative (PubMed=24046071). Originally thought to originate from an osteosarcoma. 21150552 CVCL_2342 CCD-1093Sk finite cell line human CVCL_2342 CL:0000010 Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~42 PDL (ATCC=CRL-2115) 21150553 CVCL_1R42 CMT28 cancer cell line dog CVCL_1R42 CL:0000010 Female 21150554 CVCL_1R43 C1 [Dog mastocytoma] cancer cell line dog CVCL_1R43 CL:0000010 Female Doubling time: 37.4 +- 18.7 hours (PubMed=2121170). 21150555 CVCL_2343 CCD-1094Sk finite cell line human CVCL_2343 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~41 PDL (ATCC=CRL-2120) 21150556 CVCL_2340 CCD-1090Sk finite cell line human CVCL_2340 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~37 PDL (ATCC=CRL-2106) 21150557 CVCL_1R40 UM-UC-3-GFP undefined cell line type human CVCL_1R40 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00282 Problematic cell line: Misidentified/contaminated Shown not to be derived from UM-UC-3, its origin is unknown (PubMed=19375735; PubMed=20143388). 21150558 CVCL_2341 CCD-1092Sk finite cell line human CVCL_2341 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~38 PDL (ATCC=CRL-2114) 21150559 CVCL_1R41 CMT27 cancer cell line dog CVCL_1R41 CL:0000010 Breed/subspecies: Poodle. Omics: Transcriptome analysis by microarray Female Doubling time: 18 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel Caution: On the basis of STR profile (PubMed=21908323; PubMed=27197945) CMT12 and CMT27 seem to originate from the same donor 21150560 CVCL_1R46 Ae-Aedve spontaneously immortalized cell line CVCL_1R46 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00015 Problematic cell line: Misidentified/contaminated Originally thought to be of Aedes vexans origin but found to be a Opodiphthera eucalypti Ae derivative (PubMed=4402510; PubMed=20143388). 21150561 CVCL_2346 CCD-1097Sk finite cell line human CVCL_2346 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 21150562 CVCL_1R47 Ae-Culin spontaneously immortalized cell line CVCL_1R47 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00018 Problematic cell line: Misidentified/contaminated Originally thought to be of Culiseta inornata origin but found to be a Opodiphthera eucalypti Ae derivative (PubMed=4402510; PubMed=20143388). 21150563 CVCL_2347 CCD-1098Sk finite cell line human CVCL_2347 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~23 PDL (ATCC=CRL-2127) 21150564 CVCL_1R44 C2 [Dog mastocytoma] cancer cell line dog CVCL_1R44 CL:0000010 Sequence variation: Mutation; VGNC; 54284; CCND3; Simple; p.Ala66_Ser67del (c.194_199delGCGCCA); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 42422; KIT; Unexplicit; Tandem duplication of a 48bp sequence; Zygosity=Unspecified (PubMed=10210327); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Val162Ala (c.485T>C); Zygosity=Homozygous (PubMed=31175136) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 49.3 +- 12.5 hours (PubMed=2121170); 21 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21150565 CVCL_2344 CCD-1095Sk finite cell line human CVCL_2344 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~36 PDL (ATCC=CRL-2122) 21150566 CVCL_2345 CCD-1096Sk finite cell line human CVCL_2345 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~43 PDL (ATCC=CRL-2129) 21150567 CVCL_1R45 CHB undefined cell line type Norway rat CVCL_1R45 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00017. Problematic cell line: Misidentified Originally thought to be of human origin (astrocytoma) but found to be from rat (PubMed=6451928; PubMed=20143388). 21150568 CVCL_1R48 Ae-Aedae spontaneously immortalized cell line CVCL_1R48 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00014 Problematic cell line: Misidentified/contaminated Originally thought to be of Aedes aegypti origin but found to be a Opodiphthera eucalypti Ae derivative (PubMed=4402510; PubMed=20143388). 21150569 CVCL_2348 CCD-1099Sk finite cell line human CVCL_2348 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~60 PDL (ATCC=CRL-2201) 21150570 CVCL_2349 CCD-11Lu finite cell line human CVCL_2349 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 94060302; probable Male 21150571 CVCL_1R49 LT-1 [Contaminated frog cell line] hybrid cell line CVCL_1R49 CL:0000010 Group: Fish cell line; Group: Reptilian cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00073. Problematic cell line: Misidentified/contaminated Originally thought to be of Lithobates pipiens (frog) origin but found to be a complex mixture of Pimephales promelas FHM and Terrapene carolina TH-1 (PubMed=304896; PubMed=6451928; PubMed=20143388). 21150572 CVCL_TX83 HAP1 WASL (-) 1 cancer cell line human CVCL_TX83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12735; WASL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150573 CVCL_U983 ZP127 transformed cell line CVCL_U983 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21150574 CVCL_U984 AILNCaP cancer cell line human CVCL_U984 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21150575 CVCL_TX84 HAP1 WASL (-) 2 cancer cell line human CVCL_TX84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12735; WASL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150576 CVCL_TX81 HAP1 WASF3 (-) 1 cancer cell line human CVCL_TX81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12734; WASF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150577 CVCL_U981 ZP124 transformed cell line CVCL_U981 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21150578 CVCL_TX82 HAP1 WASF3 (-) 2 cancer cell line human CVCL_TX82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12734; WASF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150579 CVCL_U982 ZP126 transformed cell line CVCL_U982 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21150580 CVCL_TX87 HAP1 WDR24 (-) 2 cancer cell line human CVCL_TX87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20852; WDR24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150581 CVCL_U987 TAOV cancer cell line human CVCL_U987 CL:0000010 Population: Japanese. Female 21150582 CVCL_TX88 HAP1 WDR37 (-) 1 cancer cell line human CVCL_TX88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31406; WDR37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150583 CVCL_U988 NCTC 3196 spontaneously immortalized cell line CVCL_U988 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21150584 CVCL_TX85 HAP1 WASL (-) 3 cancer cell line human CVCL_TX85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12735; WASL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150585 CVCL_U985 hCMEC/D3 transformed cell line human CVCL_U985 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; temporal lobe; blood microvessel Cell type=Endothelial cell.. Omics: Deep quantitative membrane proteome analysis; Omics: Secretome proteome analysis Female Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3308 21150586 CVCL_TX86 HAP1 WDR24 (-) 1 cancer cell line human CVCL_TX86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20852; WDR24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150587 CVCL_U986 HRA cancer cell line human CVCL_U986 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 15.6 hours (PubMed=3791243) 21150588 CVCL_TX89 HAP1 WDR37 (-) 2 cancer cell line human CVCL_TX89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31406; WDR37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150589 CVCL_U989 NCTC 1469 CB spontaneously immortalized cell line house mouse CVCL_U989 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3H/An. Male Characteristics: In contrat with the parent cell line, has reduced phagocytic activity 21150590 CVCL_2360 CCD-1122Sk finite cell line human CVCL_2360 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-2513; probable Female 21150591 CVCL_1R60 GM01672 finite cell line human CVCL_1R60 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21150592 CVCL_2361 CCD-1123Sk finite cell line human CVCL_2361 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~54 PDL (ATCC=CRL-2524) 21150593 CVCL_1R61 GM01730 finite cell line human CVCL_1R61 CL:0000010 Population: African American; Karyotypic information: 46,XX,der(21)(21qter->21p11::Xq11->Xqter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21150594 CVCL_2353 CCD-1109Sk finite cell line human CVCL_2353 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~20 PDL (ATCC=CRL-2361) 21150595 CVCL_1R53 IPRB undefined cell line type Norway rat CVCL_1R53 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00385. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=20951163). 21150596 CVCL_2354 CCD-1113Sk finite cell line human CVCL_2354 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~31 PDL (ATCC=CRL-2439) 21150597 CVCL_1R54 UPAB cancer cell line human CVCL_1R54 CL:0000010 Derived from sampling site: Brain. Male 21150598 CVCL_2351 CCD-1101Sk finite cell line human CVCL_2351 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~10 PDL (ATCC=CRL-2281) 21150599 CVCL_1R51 KM3 [Contaminated human melanoma] undefined cell line type Norway rat CVCL_1R51 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00227. Problematic cell line: Misidentified Originally thought to be of human origin (astrocytoma) but found to be from rat (PubMed=12740908; PubMed=20143388). Originally thought to originate from a woman patient lymph nodes metastases of a melanoma. 21150600 CVCL_2352 CCD-1108Sk finite cell line human CVCL_2352 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at ~32 PDL (ATCC=CRL-2352) 21150601 CVCL_1R52 Clom 15 undefined cell line type Norway rat CVCL_1R52 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00383. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=20951163). 21150602 CVCL_2357 CCD-1118Sk finite cell line human CVCL_2357 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~20 PDL (ATCC=CRL-2466) 21150603 CVCL_1R57 VC312R undefined cell line type Norway rat CVCL_1R57 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00390. Problematic cell line: Misidentified Originally thought to originate from a human 2 year old male patient with medullablastoma but found to be from rat (PubMed=20951163). 21150604 CVCL_2358 CCD-1120Sk finite cell line human CVCL_2358 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~36 PDL (ATCC=CRL-2510) 21150605 CVCL_1R58 HPS0332 induced pluripotent stem cell human CVCL_1R58 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female 21150606 CVCL_2355 CCD-1114Sk finite cell line human CVCL_2355 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~30 PDL (ATCC=CRL-2450) 21150607 CVCL_1R55 UPES/C undefined cell line type house mouse CVCL_1R55 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00388. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse (PubMed=20951163). 21150608 CVCL_2356 CCD-1117Sk finite cell line human CVCL_2356 CL:0000010 Derived from sampling site: Face; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~17 PDL (ATCC=CRL-2465) 21150609 CVCL_1R56 UPHHJA undefined cell line type Norway rat CVCL_1R56 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00389. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=20951163). 21150610 CVCL_2359 CCD-1121Sk finite cell line human CVCL_2359 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~24 PDL (ATCC=CRL-2511) 21150611 CVCL_1R59 HPS0333 induced pluripotent stem cell human CVCL_1R59 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female 21150612 CVCL_TX90 HAP1 WDR37 (-) 3 cancer cell line human CVCL_TX90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31406; WDR37; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150613 CVCL_U990 L.P3 spontaneously immortalized cell line house mouse CVCL_U990 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21150614 CVCL_TX91 HAP1 WDR6 (-) 1 cancer cell line human CVCL_TX91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12758; WDR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150615 CVCL_U991 L.P3(S) spontaneously immortalized cell line house mouse CVCL_U991 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21150616 CVCL_TX72 HAP1 VRK1 (-) 1 cancer cell line human CVCL_TX72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12718; VRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150617 CVCL_U972 RH-SLC-L12 cancer cell line human CVCL_U972 CL:0000010 Unspecified 21150618 CVCL_TX73 HAP1 VRK1 (-) 2 cancer cell line human CVCL_TX73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12718; VRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150619 CVCL_U973 RH-SLC-L13 cancer cell line human CVCL_U973 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21150620 CVCL_TX70 HAP1 VPS54 (-) 1 cancer cell line human CVCL_TX70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18652; VPS54; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150621 CVCL_U970 LLC-PK1-GR101 spontaneously immortalized cell line pig CVCL_U970 CL:0000010 Transfected with: RGD; 2741; Nr3c1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21150622 CVCL_TX71 HAP1 VPS54 (-) 2 cancer cell line human CVCL_TX71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18652; VPS54; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150623 CVCL_U971 VA13-TS4 transformed cell line human CVCL_U971 CL:0000010 Transfected with: HGNC; 220; ADAMTS4 Population: Caucasian; Swedish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21150624 CVCL_TX76 HAP1 VRK3 (-) cancer cell line human CVCL_TX76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18996; VRK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150625 CVCL_U976 OC/CDE 22 transformed cell line Norway rat CVCL_U976 CL:0000010 Transformant: DL-ethionine(ChEBI; CHEBI:68664); Derived from sampling site: Liver Cell type=Hepatic oval stem cell.; Breed/subspecies: Sprague Dawley. Male Doubling time: 45 hours (PubMed=7679995) 21150626 CVCL_TX77 HAP1 WAS (-) 1 cancer cell line human CVCL_TX77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12731; WAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150627 CVCL_U977 OC/CDE 6 transformed cell line Norway rat CVCL_U977 CL:0000010 Transformant: DL-ethionine(ChEBI; CHEBI:68664); Derived from sampling site: Liver Cell type=Hepatic oval stem cell.; Breed/subspecies: Sprague Dawley. Male Doubling time: 52 hours (PubMed=7679995) 21150628 CVCL_TX74 HAP1 VRK1 (-) 3 cancer cell line human CVCL_TX74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12718; VRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150629 CVCL_U974 RH-SCC-L10 cancer cell line human CVCL_U974 CL:0000010 Male Doubling time: ~55 hours (PubMed=6089998) 21150630 CVCL_TX75 HAP1 VRK2 (-) cancer cell line human CVCL_TX75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12719; VRK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150631 CVCL_U975 OC/CDE 14 transformed cell line Norway rat CVCL_U975 CL:0000010 Transformant: DL-ethionine(ChEBI; CHEBI:68664); Derived from sampling site: Liver Cell type=Hepatic oval stem cell.; Breed/subspecies: Sprague Dawley. Male Doubling time: 36 hours (PubMed=7679995) 21150632 CVCL_TX78 HAP1 WASF1 (-) 1 cancer cell line human CVCL_TX78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12732; WASF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150633 CVCL_U978 M22 transformed cell line Norway rat CVCL_U978 CL:0000010 Transformant: DL-ethionine(ChEBI; CHEBI:68664); Derived from sampling site: Liver Cell type=Hepatic oval stem cell.; Breed/subspecies: Sprague Dawley. Male 21150634 CVCL_U979 DPK-SKDF-H finite cell line human CVCL_U979 From: Dominion Pharmakine (which ceased operation); Bizkaia; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. 21150635 CVCL_TX79 HAP1 WASF1 (-) 2 cancer cell line human CVCL_TX79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12732; WASF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150636 CVCL_2320 HeLa BU-25 cancer cell line human CVCL_2320 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: SNP array analysis Female 21150637 CVCL_1R20 NP-2/CCR3 cancer cell line human CVCL_1R20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1604; CCR3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150638 CVCL_2321 BUD-8 finite cell line human CVCL_2321 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Highly sensitive to interferon and can be used in assays of interferon activity (ATCC) Senescence: Senesces at ~8 PDL (ATCC=CRL-1554) 21150639 CVCL_1R21 NP-2/CCR5 cancer cell line human CVCL_1R21 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150640 CVCL_2324 C32TG cancer cell line human CVCL_2324 HLA typing: A*02:01,25:01; B*18:01,44:02; C*05:01,12:03 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ter157Serext*13 (c.470G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Skin. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB1929; true; Discontinued: TKG; TKG 0190; probable Male Doubling time: 37 hours (lot 09262006), ~43 hours (lot 10302018) (JCRB) 21150641 CVCL_1R24 NP-2/GPR1 cancer cell line human CVCL_1R24 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4463; CMKLR2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150642 CVCL_2325 CCD-1037Sk finite cell line human CVCL_2325 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2054; true Female 21150643 CVCL_1R25 NP-2/CD4/APJ cancer cell line human CVCL_1R25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150644 CVCL_2322 C16 cancer cell line human CVCL_2322 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00296 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). Originally thought to be a clone of MRC-5. 21150645 CVCL_1R22 NP-2/CCR8 cancer cell line human CVCL_1R22 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1609; CCR8; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150646 CVCL_2323 C211 finite cell line human CVCL_2323 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 90112604; probable; Discontinued: KCLB; 10123; probable Male 21150647 CVCL_1R23 NP-2/CXCR4 cancer cell line human CVCL_1R23 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150648 CVCL_2328 CCD-1064Sk finite cell line human CVCL_2328 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~54 PDL (ATCC=CRL-2076) 21150649 CVCL_1R28 NP-2/CD4/CCR8 cancer cell line human CVCL_1R28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1609; CCR8; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150650 CVCL_2329 CCD-1065Sk finite cell line human CVCL_2329 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~33 PDL (ATCC=CRL-2077) 21150651 CVCL_1R29 NP-2/CD4/CXCR4 cancer cell line human CVCL_1R29 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150652 CVCL_2326 CCD-1058Sk finite cell line human CVCL_2326 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~34 PDL (ATCC=CRL-2071) 21150653 CVCL_1R26 NP-2/CD4/CCR3 cancer cell line human CVCL_1R26 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150654 CVCL_2327 CCD-1059Sk finite cell line human CVCL_2327 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Discontinued: BCRJ; 0061; probable Female Senescence: Senesces at ~35 PDL (ATCC=CRL-2072) 21150655 CVCL_1R27 NP-2/CD4/CCR5 cancer cell line human CVCL_1R27 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150656 CVCL_TX80 HAP1 WASF2 (-) cancer cell line human CVCL_TX80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12733; WASF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150657 CVCL_U980 ZP121 transformed cell line CVCL_U980 CL:0000010 Transfected with: RGD; 61814; Pex2 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Selected using the 9-(1'-pyrene)nonanol/ultraviolet (P9OH/UV) method P9OH acts as a photosensitizer. Normal cells which can incorporate the fluorescent fatty alcohol into lipids are killed by UV, but mutants who incorporate P9OH poorly are less susceptible to photosensitized killing. 21150658 CVCL_U961 Detroit 98/AH cancer cell line human CVCL_U961 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:136532; 8-azahypoxanthine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00115 Problematic cell line: Contaminated Ancestral cell line (Detroit 98) has been shown to be a HeLa derivative (PubMed=20143388). 21150659 CVCL_TX61 HAP1 VPS4A (-) 3 cancer cell line human CVCL_TX61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150660 CVCL_U962 G-11 cancer cell line human CVCL_U962 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00048 Problematic cell line: Contaminated Parent cell line (HBT-3) has been shown to be a HeLa derivative (PubMed=884688; PubMed=6451928; PubMed=20143388). 21150661 CVCL_TX62 HAP1 VPS4A (-) 4 cancer cell line human CVCL_TX62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150662 CVCL_TX60 HAP1 VPS4A (-) 2 cancer cell line human CVCL_TX60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150663 CVCL_U965 D-189 undefined cell line type human CVCL_U965 CL:0000010 Derived from sampling site: Foreskin; skin. Male 21150664 CVCL_TX65 HAP1 VPS4A (-) 7 cancer cell line human CVCL_TX65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150665 CVCL_TX66 HAP1 VPS4A (-) 8 cancer cell line human CVCL_TX66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150666 CVCL_U966 TgSVA transformed cell line house mouse CVCL_U966 CL:0000010 Transfected with: HGNC; 9705; PVR Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: ICR-PVRTg1 transgenic. Unspecified Virology: Highly susceptible to infection by poliovirus (PubMed=8389915) 21150667 CVCL_TX63 HAP1 VPS4A (-) 5 cancer cell line human CVCL_TX63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150668 CVCL_U963 MA-111 undefined cell line type CVCL_U963 CL:0000010 Unspecified Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00078. Problematic cell line: Misidentified Originally thought to be of rabbit origin but found to be from African Green monkey (PubMed=20143388). Originally thought to originate from kidney. Could be a VERO derivative. 21150669 CVCL_TX64 HAP1 VPS4A (-) 6 cancer cell line human CVCL_TX64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150670 CVCL_U964 RY undefined cell line type human CVCL_U964 CL:0000010 Anecdotal: Part of a set of 4 cell lines that were fraudulently stated to originate from Hodgkin lymphoma (PubMed=265539). Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00084 Problematic cell line: Misidentified Originally thought to be a Hodgkin lymphoma cell line but shown not be the case although the origin of this cell line is still not known (PubMed=7192801; PubMed=12592342; PubMed=20143388). 21150671 CVCL_TX69 HAP1 VPS52 (-) 2 cancer cell line human CVCL_TX69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10518; VPS52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150672 CVCL_U969 IMEC telomerase immortalized cell line human CVCL_U969 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21150673 CVCL_TX67 HAP1 VPS51 (-) cancer cell line human CVCL_TX67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1172; VPS51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150674 CVCL_U967 TgSVB transformed cell line house mouse CVCL_U967 CL:0000010 Transfected with: HGNC; 9705; PVR Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: ICR-PVRTg1 transgenic. Unspecified Virology: Highly susceptible to infection by poliovirus (PubMed=8389915) 21150675 CVCL_TX68 HAP1 VPS52 (-) 1 cancer cell line human CVCL_TX68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10518; VPS52; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150676 CVCL_U968 HML-Gb3 cancer cell line human CVCL_U968 CL:0000010 Transfected with: HGNC; 18149; A4GALT Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21150677 CVCL_2331 CCD-1069Sk finite cell line human CVCL_2331 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~23 PDL (ATCC=CRL-2089) 21150678 CVCL_1R31 GPS-M spontaneously immortalized cell line house mouse CVCL_1R31 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00049 Problematic cell line: Misidentified Originally thought to be of guinea pig origin but found to be from mouse (PubMed=4943055; PubMed=6451928; PubMed=20143388). 21150679 CVCL_2332 CCD-1070Sk finite cell line human CVCL_2332 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~36 PDL (ATCC=CRL-2091) 21150680 CVCL_1R32 GPS-PD spontaneously immortalized cell line house mouse CVCL_1R32 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00050 Problematic cell line: Misidentified Originally thought to be of guinea pig origin but found to be from mouse (PubMed=4943055; PubMed=6451928; PubMed=20143388). 21150681 CVCL_2330 CCD-1068Sk finite cell line human CVCL_2330 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~33 PDL (ATCC=CRL-2086) 21150682 CVCL_1R30 NP-2/CD4/GPR1 cancer cell line human CVCL_1R30 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 4463; CMKLR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150683 CVCL_2335 CCD-1076Sk finite cell line human CVCL_2335 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~46 PDL (ATCC=CRL-2096) 21150684 CVCL_1R35 K9TCC#1Lillie cancer cell line dog CVCL_1R35 CL:0000010 Derived from sampling site: Urethra; Breed/subspecies: Pointer. Female Doubling time: 47.4 hours (PubMed=24964787) 21150685 CVCL_2336 CCD-1077Sk finite cell line human CVCL_2336 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~40 PDL (ATCC=CRL-2094) 21150686 CVCL_1R36 K9TCC#2Dakota cancer cell line dog CVCL_1R36 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Bichon Fries. Female Doubling time: 31.96 hours (PubMed=24964787) 21150687 CVCL_2333 CCD-1072Sk finite cell line human CVCL_2333 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~35 PDL (ATCC=CRL-2088) 21150688 CVCL_1R33 DEN-HSA cancer cell line dog CVCL_1R33 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Golden Retriever. Omics: Deep exome analysis Male Doubling time: 16 hours (PubMed=27257868) 21150689 CVCL_2334 CCD-1074Sk finite cell line human CVCL_2334 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~26 PDL (ATCC=CRL-2090) 21150690 CVCL_1R34 Fitz-HSA cancer cell line dog CVCL_1R34 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male Part of: FACC canine tumor cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00400 Problematic cell line: Contaminated Shown to be a DEN-HSA derivative (PubMed=21908323). 21150691 CVCL_2339 CCD-1087Sk finite cell line human CVCL_2339 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~43 PDL (ATCC=CRL-2104) 21150692 CVCL_1R39 HEL-R66 undefined cell line type CVCL_1R39 CL:0000010 Unspecified Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00065. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from Chlorocebus aethiops (PubMed=6451928; PubMed=7236009; PubMed=20143388). 21150693 CVCL_2337 CCD-1079Sk finite cell line human CVCL_2337 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~56 PDL (ATCC=CRL-2097) 21150694 CVCL_1R37 K9TCC#4Molly cancer cell line dog CVCL_1R37 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Maltese. Female Doubling time: 44.69 hours (PubMed=24964787) 21150695 CVCL_2338 CCD-1086Sk finite cell line human CVCL_2338 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~57 PDL (ATCC=CRL-2103) 21150696 CVCL_1R38 K9TCC#5Lilly cancer cell line dog CVCL_1R38 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Mixed breed. Female Doubling time: 48.3 hours (PubMed=24964787) 21150697 CVCL_TX50 HAP1 VPS13C (-) cancer cell line human CVCL_TX50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23594; VPS13C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150698 CVCL_U950 IGF031/85 finite cell line human CVCL_U950 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150699 CVCL_TX51 HAP1 VPS26A (-) 1 cancer cell line human CVCL_TX51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12711; VPS26A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150700 CVCL_U951 UV female 2 transformed cell line house mouse CVCL_U951 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6 x BALB/c. Female 21150701 CVCL_U954 1255-B7 transformed cell line Norway rat CVCL_U954 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. Discontinued: ATCC; CRL-6604; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21150702 CVCL_TX54 HAP1 VPS35 (-) 2 cancer cell line human CVCL_TX54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13487; VPS35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150703 CVCL_TX55 HAP1 VPS35 (-) 3 cancer cell line human CVCL_TX55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13487; VPS35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150704 CVCL_U955 T 174 cancer cell line human CVCL_U955 CL:0000010 Discontinued: ATCC; CRL-7726; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21150705 CVCL_U952 EGFP-MBD-nls embryonic stem cell house mouse CVCL_U952 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 129P2/Ola. Discontinued: RCB; RCB2708; true Male 21150706 CVCL_TX52 HAP1 VPS26A (-) 2 cancer cell line human CVCL_TX52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12711; VPS26A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150707 CVCL_U953 EBRTcH3(serum) embryonic stem cell house mouse CVCL_U953 CL:0000010 Breed/subspecies: 129P2/Ola. Discontinued: RCB; RCB2659; true Male 21150708 CVCL_TX53 HAP1 VPS35 (-) 1 cancer cell line human CVCL_TX53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13487; VPS35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150709 CVCL_TX58 HAP1 VPS36 (-) cancer cell line human CVCL_TX58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20312; VPS36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150710 CVCL_U958 ThoCu cancer cell line human CVCL_U958 CL:0000010 Derived from sampling site: Lung. Male 21150711 CVCL_U959 FOC1.K finite cell line CVCL_U959 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6499; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21150712 CVCL_TX59 HAP1 VPS4A (-) 1 cancer cell line human CVCL_TX59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13488; VPS4A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150713 CVCL_TX56 HAP1 VPS35 (-) 4 cancer cell line human CVCL_TX56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13487; VPS35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150714 CVCL_U956 SaBa cancer cell line human CVCL_U956 CL:0000010 Male 21150715 CVCL_U957 AlAb cancer cell line human CVCL_U957 HLA typing: A*02,09; B*w15; C*w02,w06 (PubMed=77569) CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7715; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21150716 CVCL_TX57 HAP1 VPS35 (-) 5 cancer cell line human CVCL_TX57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13487; VPS35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150717 CVCL_1R02 HCT116-Ku70(+/-) cancer cell line human CVCL_1R02 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 4055; XRCC6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150718 CVCL_2302 Mo-B transformed cell line human CVCL_2302 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 90021503; probable Male Virology: HTLV-2 producing cell line 21150719 CVCL_2303 BHK-21 strain 31 spontaneously immortalized cell line CVCL_2303 CL:0000010 Derived from sampling site: Kidney. Male 21150720 CVCL_1R03 HCT116-LIG3(+/-) cancer cell line human CVCL_1R03 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6600; LIG3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150721 CVCL_2300 AtT-20 cancer cell line house mouse CVCL_2300 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Doubling time: ~3 days (lot 11152004) (JCRB) 21150722 CVCL_1R00 HCT116-53BPI(+/-) cancer cell line human CVCL_1R00 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11999; TP53BP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150723 CVCL_2301 B12.F8 transformed cell line human CVCL_2301 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgG1 21150724 CVCL_1R01 HCT116-DNAPKcs(+/-) cancer cell line human CVCL_1R01 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9413; PRKDC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150725 CVCL_2306 BHL-89 cancer cell line human CVCL_2306 CL:0000010 Female Doubling time: 48 hours (PubMed=7672713). 21150726 CVCL_1R06 HCT116-MDC1(-/-) cancer cell line human CVCL_1R06 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150727 CVCL_2307 BICR 10 cancer cell line human CVCL_2307 HLA typing: A*01:01,01:01; B*14:01,44:02; C*01:02,07:06 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0%; East Asian, North=0.01%; East Asian, South=0%; South Asian=0.82%; European, North=71.25%; European, South=27.87% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; buccal mucosa. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150728 CVCL_1R07 HCT116-POLM(+/-) cancer cell line human CVCL_1R07 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9185; POLM; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150729 CVCL_2304 BHK-21 strain 35 spontaneously immortalized cell line CVCL_2304 CL:0000010 Derived from sampling site: Kidney. Male 21150730 CVCL_1R04 HCT116-LIG4(+/-) cancer cell line human CVCL_1R04 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 6601; LIG4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150731 CVCL_2305 BHK-21 strain 38 spontaneously immortalized cell line CVCL_2305 CL:0000010 Derived from sampling site: Kidney. Male 21150732 CVCL_1R05 HCT116-MDC1(+/-) cancer cell line human CVCL_1R05 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 21163; MDC1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150733 CVCL_2308 BICR 16 cancer cell line human CVCL_2308 HLA typing: A*03:01,11:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.43%; Native American=0%; East Asian, North=3.56%; East Asian, South=0%; South Asian=0%; European, North=60.13%; European, South=35.88% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Unspecified (PubMed=8390283) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21150734 CVCL_1R08 HCT116-RAD18(+/-) cancer cell line human CVCL_1R08 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 18278; RAD18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150735 CVCL_2309 BICR 18 cancer cell line human CVCL_2309 Genome ancestry: African=6.55%; Native American=0%; East Asian, North=7.21%; East Asian, South=0%; South Asian=0%; European, North=48.15%; European, South=38.08% (PubMed=30894373) CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ICLC; HTL10003; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Partially contaminated The ICLC stock (now discontinued) was found to be contaminated, probably by U-251MG (Cellosaurus=CVCL_0021). 21150736 CVCL_1R09 HCT116-RAD18(-/-) cancer cell line human CVCL_1R09 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 18278; RAD18; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150737 CVCL_TX40 HAP1 VEGFA (-) 2 cancer cell line human CVCL_TX40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12680; VEGFA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150738 CVCL_U940 SK-MEL-163 cancer cell line human CVCL_U940 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150739 CVCL_TX43 HAP1 VIM (-) 1 cancer cell line human CVCL_TX43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12692; VIM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150740 CVCL_U943 TY09 conditionally immortalized cell line human CVCL_U943 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; microvascular endothelium. Unspecified Characteristics: Exhibits a robust proliferation at the permissive temperature of 33 Celsius Cell growth is arrested at 37 Celsius. Doubling time: ~2 days (DOI=10.1111/cen3.12001) 21150741 CVCL_U944 GM05759 finite cell line human CVCL_U944 CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Arg465Arg (c.1395G>T) (Chr20:g.10629709C>A); Zygosity=Heterozygous; Note=Splice site mutation (PubMed=34087995) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21150742 CVCL_TX44 HAP1 VIM (-) 2 cancer cell line human CVCL_TX44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12692; VIM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150743 CVCL_TX41 HAP1 VEGFB (-) 1 cancer cell line human CVCL_TX41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12681; VEGFB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150744 CVCL_U941 SK-MEL-168 cancer cell line human CVCL_U941 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150745 CVCL_TX42 HAP1 VEGFB (-) 2 cancer cell line human CVCL_TX42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12681; VEGFB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150746 CVCL_U942 SK-MEL-169 cancer cell line human CVCL_U942 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150747 CVCL_U947 GM12079 finite cell line human CVCL_U947 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21150748 CVCL_TX47 HAP1 VKORC1L1 (-) 1 cancer cell line human CVCL_TX47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21492; VKORC1L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150749 CVCL_U948 GM12254 finite cell line human CVCL_U948 CL:0000010 Derived from sampling site: Liver Cell type=Fibroblast.. Female 21150750 CVCL_TX48 HAP1 VKORC1L1 (-) 2 cancer cell line human CVCL_TX48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21492; VKORC1L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150751 CVCL_U945 GM11033 transformed cell line human CVCL_U945 CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Cys312Ter (c.936T>A); ClinVar=VCV001358138; Zygosity=Heterozygous (from autologous cell line GM11091) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150752 CVCL_TX45 HAP1 VKORC1 (-) 1 cancer cell line human CVCL_TX45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23663; VKORC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150753 CVCL_U946 GM11091 finite cell line human CVCL_U946 CL:0000010 Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Cys312Ter (c.936T>A); ClinVar=VCV001358138; Zygosity=Heterozygous (from child cell line TRNDi031-A) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150754 CVCL_TX46 HAP1 VKORC1 (-) 2 cancer cell line human CVCL_TX46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23663; VKORC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150755 CVCL_U949 GM02228 finite cell line human CVCL_U949 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21150756 CVCL_TX49 HAP1 VPS13A (-) 1 cancer cell line human CVCL_TX49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1908; VPS13A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150757 CVCL_2310 BICR 22 cancer cell line human CVCL_2310 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=9.32%; Native American=0%; East Asian, North=10.18%; East Asian, South=0%; South Asian=0%; European, North=36.79%; European, South=43.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920-1G>T (IVS8-1G>T); ClinVar=VCV000480765; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=25275298; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21150758 CVCL_1R10 HCT116-REV1(+/-) cancer cell line human CVCL_1R10 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 14060; REV1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150759 CVCL_2313 BICR 56 cancer cell line human CVCL_2313 HLA typing: A*02:01,24:02; B*07:02,50:01; C*06:02,07:02 (PubMed=26589293); Genome ancestry: African=0.75%; Native American=1.04%; East Asian, North=1.39%; East Asian, South=0%; South Asian=0.51%; European, North=67.74%; European, South=28.56% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8390283; DepMap) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150760 CVCL_1R13 SCC-TC cancer cell line human CVCL_1R13 CL:0000010 Discontinued: RCB; RCB2291; true. 21150761 CVCL_2314 BICR 6 cancer cell line human CVCL_2314 HLA typing: A*01:02,30:02; B*07:02,18:01; C*05:01,07:02 (PubMed=26589293); Genome ancestry: African=4.56%; Native American=0%; East Asian, North=5.39%; East Asian, South=0%; South Asian=0%; European, North=53.16%; European, South=36.88% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (PubMed=8390283; DepMap) Population: Caucasian; Derived from sampling site: Pharynx; hypopharynx. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150762 CVCL_1R14 Onda 9 cancer cell line human CVCL_1R14 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ile101del (c.301_303delATC); Zygosity=Unspecified (PubMed=10551321; DepMap) Population: Japanese; Derived from sampling site: Brain; left temporal lobe. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150763 CVCL_2311 BICR 3 cancer cell line human CVCL_2311 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Pro (c.845G>C); ClinVar=VCV000376659; Zygosity=Unspecified (PubMed=8390283) Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Female 21150764 CVCL_1R11 HCT116-REV1(-/-) cancer cell line human CVCL_1R11 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 14060; REV1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150765 CVCL_2312 BICR 31 cancer cell line human CVCL_2312 HLA typing: A*32:01,32:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.67%; Native American=0%; East Asian, North=1.96%; East Asian, South=0%; South Asian=0%; European, North=61.56%; European, South=34.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173_Arg174InsGly (c.518_520delTGA); Zygosity=Homozygous (PubMed=8390283; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21150766 CVCL_1R12 HCT116-REV3L(+/-) cancer cell line human CVCL_1R12 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9968; REV3L; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21150767 CVCL_2317 Bob cancer cell line human CVCL_2317 CL:0000010 Male Group: Serum/protein free medium cell line. 21150768 CVCL_1R17 NP-5 cancer cell line human CVCL_1R17 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Unspecified (PubMed=10551321; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8878451; DepMap) Population: Japanese; Derived from sampling site: Brain; right parietal lobe. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150769 CVCL_2318 Bristol 8 transformed cell line human CVCL_2318 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21150770 CVCL_1R18 NP-2/CD4 cancer cell line human CVCL_1R18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150771 CVCL_2315 BICR 78 cancer cell line human CVCL_2315 HLA typing: A*02:01,29:02; B*44:03,44:03; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=3.26%; Native American=1.14%; East Asian, North=2.29%; East Asian, South=0%; South Asian=0.91%; European, North=63.51%; European, South=28.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16051; PARD3; Unexplicit; Ex3-7del; Zygosity=Homozygous (PubMed=20215515); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln38Ter (c.112C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=9150362; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro177Leu (c.530C>T); ClinVar=VCV000406583; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Oral cavity; alveolar ridge. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21150772 CVCL_1R15 NP-2 cancer cell line human CVCL_1R15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (PubMed=8878451) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 36 hours, at 145th passage (CelloPub=CLPUB00260) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150773 CVCL_2316 BICR 82 cancer cell line human CVCL_2316 CL:0000010 Population: Caucasian; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 21150774 CVCL_1R16 NP-3 cancer cell line human CVCL_1R16 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Met199del (c.592_594ATG[1]) (c.595_597delATG); ClinVar=VCV000418437; Zygosity=Unspecified (PubMed=10551321) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 36 hours, at 129th passage (CelloPub=CLPUB00260) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21150775 CVCL_2319 BT-483 cancer cell line human CVCL_2319 HLA typing: A*24:02,24:02; B*08:01,15:01; C*03:03,07:01; DQB1*06:11,02:02; DRB1*03:05,03:05 (PubMed=25960936); HLA typing: A*24:02,24:02; B*08:01,15:01; C*03:03,07:01 (PubMed=26589293); Genome ancestry: African=3.96%; Native American=0%; East Asian, North=5.8%; East Asian, South=0%; South Asian=0%; European, North=48.37%; European, South=41.87% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>A); ClinVar=VCV000480961; Zygosity=Heterozygous (PubMed=16541312; DepMap) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 140.00 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Part of: PI3K genetic alteration cell panel (ATCC TCP-1028); Part of: TCGA-110-CL cell line panel 21150776 CVCL_1R19 NP-2/APJ cancer cell line human CVCL_1R19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 339; APLNR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male 21150777 CVCL_TX32 HAP1 VAV2 (-) 2 cancer cell line human CVCL_TX32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12658; VAV2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150778 CVCL_U932 SK-MEL-6 cancer cell line human CVCL_U932 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21150779 CVCL_TX33 HAP1 VAV2 (-) 3 cancer cell line human CVCL_TX33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12658; VAV2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150780 CVCL_U933 SK-MEL-18 cancer cell line human CVCL_U933 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150781 CVCL_TX30 HAP1 VAPB (-) 2 cancer cell line human CVCL_TX30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12649; VAPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150782 CVCL_U930 SK-MEL-47 cancer cell line human CVCL_U930 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150783 CVCL_TX31 HAP1 VAV2 (-) 1 cancer cell line human CVCL_TX31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12658; VAV2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150784 CVCL_U931 SK-MEL-48 cancer cell line human CVCL_U931 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150785 CVCL_TX36 HAP1 VCPIP1 (-) 2 cancer cell line human CVCL_TX36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30897; VCPIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150786 CVCL_U936 SK-MEL-114 cancer cell line human CVCL_U936 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150787 CVCL_TX37 HAP1 VDAC1 (-) 1 cancer cell line human CVCL_TX37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12669; VDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150788 CVCL_U937 MeWo-LC1 cancer cell line human CVCL_U937 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Male Doubling time: 42 +- 2 hours (PubMed=3000950) Group: Serum/protein free medium cell line 21150789 CVCL_TX34 HAP1 VAV2 (-) 4 cancer cell line human CVCL_TX34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12658; VAV2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150790 CVCL_U934 SK-MEL-9 cancer cell line human CVCL_U934 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150791 CVCL_TX35 HAP1 VCPIP1 (-) 1 cancer cell line human CVCL_TX35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30897; VCPIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150792 CVCL_U935 SK-MEL-50 cancer cell line human CVCL_U935 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150793 CVCL_TX38 HAP1 VDAC3 (-) 1 cancer cell line human CVCL_TX38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12674; VDAC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150794 CVCL_U938 SK-MEL-111 cancer cell line human CVCL_U938 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150795 CVCL_TX39 HAP1 VEGFA (-) 1 cancer cell line human CVCL_TX39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12680; VEGFA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150796 CVCL_U939 SK-MEL-96 cancer cell line human CVCL_U939 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150797 CVCL_TX21 HAP1 UTRN (-) 4 cancer cell line human CVCL_TX21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12635; UTRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150798 CVCL_U921 NIPBC-1 cancer cell line human CVCL_U921 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=24502646) Population: Indian; Karyotypic information: Near tetraploid karyotype with a modal number of 58 to 62 chromosomes; Derived from sampling site: Breast. Female Doubling time: 33.25 hours (PubMed=24502646) Group: Triple negative breast cancer (TNBC) cell line 21150799 CVCL_TX22 HAP1 UVSSA (-) cancer cell line human CVCL_TX22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29304; UVSSA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150800 CVCL_U922 NIPBC-2 cancer cell line human CVCL_U922 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=24502646) Population: Indian; Karyotypic information: Near tetraploid/pentaploid karyotype with a modal number of 107 to 110 chromosomes; Derived from sampling site: Breast. Female Doubling time: 31.56 hours (PubMed=24502646) Group: Triple negative breast cancer (TNBC) cell line 21150801 CVCL_TX20 HAP1 UTRN (-) 3 cancer cell line human CVCL_TX20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12635; UTRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150802 CVCL_U920 MMC-8 cancer cell line house mouse CVCL_U920 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: C57BL/6 x BALB/c. Unspecified 21150803 CVCL_TX25 HAP1 VAMP1 (-) 1 cancer cell line human CVCL_TX25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12642; VAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150804 CVCL_U925 SK-MEL-20 cancer cell line human CVCL_U925 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21150805 CVCL_TX26 HAP1 VAMP1 (-) 2 cancer cell line human CVCL_TX26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12642; VAMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150806 CVCL_U926 SK-MEL-38 cancer cell line human CVCL_U926 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150807 CVCL_U923 143B.206 cancer cell line human CVCL_U923 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Characteristics: Cell line devoid of mitochondrial DNA (rho0) 21150808 CVCL_TX23 HAP1 VAC14 (-) 1 cancer cell line human CVCL_TX23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25507; VAC14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150809 CVCL_TX24 HAP1 VAC14 (-) 2 cancer cell line human CVCL_TX24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25507; VAC14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150810 CVCL_U924 SH-SY5Y Rho0 64/5 cancer cell line human CVCL_U924 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Cell line devoid of mitochondrial DNA (rho0) 21150811 CVCL_TX29 HAP1 VAPB (-) 1 cancer cell line human CVCL_TX29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12649; VAPB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150812 CVCL_U929 SK-MEL-46 cancer cell line human CVCL_U929 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150813 CVCL_TX27 HAP1 VAPA (-) 1 cancer cell line human CVCL_TX27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12648; VAPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150814 CVCL_U927 SK-MEL-43 cancer cell line human CVCL_U927 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21150815 CVCL_TX28 HAP1 VAPA (-) 2 cancer cell line human CVCL_TX28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12648; VAPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150816 CVCL_U928 SK-MEL-45 cancer cell line human CVCL_U928 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21150817 CVCL_CF04 ND04884 transformed cell line human CVCL_CF04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150818 CVCL_CF05 ND04885 transformed cell line human CVCL_CF05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150819 CVCL_CF02 ND04875 transformed cell line human CVCL_CF02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150820 CVCL_CF03 ND04881 transformed cell line human CVCL_CF03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150821 CVCL_CF08 ND04893 transformed cell line human CVCL_CF08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150822 CVCL_CF09 ND04894 transformed cell line human CVCL_CF09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150823 CVCL_CF06 ND04886 transformed cell line human CVCL_CF06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150824 CVCL_CF07 ND04889 transformed cell line human CVCL_CF07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150825 CVCL_CF00 ND04859 transformed cell line human CVCL_CF00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150826 CVCL_CF01 ND04865 transformed cell line human CVCL_CF01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150827 CVCL_2390 CCD-33Lu finite cell line human CVCL_2390 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21150828 CVCL_1R90 GM10324 hybrid cell line CVCL_1R90 CL:0000010 Characteristics: Hybrid for chromosome X mapping Contains a complete copy of chromosome X.. Group: Human/rodent somatic cell hybrid 21150829 CVCL_2393 CCD-37Lu finite cell line human CVCL_2393 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-1496; true Female 21150830 CVCL_1R93 GM10498 hybrid cell line CVCL_1R93 CL:0000010 Characteristics: Hybrid for chromosome 17 mapping Contains a complete copy of chromosome 17.. Group: Human/rodent somatic cell hybrid 21150831 CVCL_2394 CCD-39Lu finite cell line human CVCL_2394 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21150832 CVCL_1R94 GM10500 hybrid cell line CVCL_1R94 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150833 CVCL_2391 CCD-34Lu finite cell line human CVCL_2391 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21150834 CVCL_1R91 GM10330 hybrid cell line human CVCL_1R91 CL:0000010 Characteristics: Hybrid for chromosome X mapping Contains a complete copy of chromosome X.. Group: Human/rodent somatic cell hybrid 21150835 CVCL_2392 CCD-34Sk finite cell line human CVCL_2392 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150836 CVCL_1R92 GM10482 hybrid cell line CVCL_1R92 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150837 CVCL_2386 CCD-29Lu finite cell line human CVCL_2386 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21150838 CVCL_1R86 GM10253 hybrid cell line human CVCL_1R86 CL:0000010 Characteristics: Hybrid for chromosome 3 mapping Contains a complete copy of chromosome 3.. Group: Human/rodent somatic cell hybrid 21150839 CVCL_2387 CCD-32Lu finite cell line human CVCL_2387 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-1485; true Male 21150840 CVCL_1R87 GM10321 hybrid cell line CVCL_1R87 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150841 CVCL_2384 CCD-25Sk finite cell line human CVCL_2384 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~8 PDL (ATCC=CRL-1474) 21150842 CVCL_1R84 GM10095 hybrid cell line human CVCL_1R84 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150843 CVCL_2385 CCD-27Sk finite cell line human CVCL_2385 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150844 CVCL_1R85 GM10157 hybrid cell line human CVCL_1R85 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150845 CVCL_2388 CCD-32Sk finite cell line human CVCL_2388 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150846 CVCL_1R88 GM10322 hybrid cell line CVCL_1R88 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150847 CVCL_2389 CCD-33Co finite cell line human CVCL_2389 CL:0000010 Derived from sampling site: Colon Cell type=Fibroblast.. Male 21150848 CVCL_1R89 GM10323 hybrid cell line CVCL_1R89 CL:0000010 Characteristics: Hybrid for chromosome 21 mapping Contains a complete copy of chromosome 21.. Group: Human/rodent somatic cell hybrid 21150849 CVCL_2397 CCD-43Sk finite cell line human CVCL_2397 CL:0000010 Donor information: Established from normal skin of a child that died of necrotizing enterocolitis; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150850 CVCL_1R97 GM10657 hybrid cell line CVCL_1R97 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150851 CVCL_2398 CCD-8Lu finite cell line human CVCL_2398 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 90112705; probable Male Senescence: Senesces at ~40-42 PDL (ATCC=CCL-201) 21150852 CVCL_1R98 GM10659 hybrid cell line CVCL_1R98 CL:0000010 Group: Human/rodent somatic cell hybrid 21150853 CVCL_2395 CCD-39Sk finite cell line human CVCL_2395 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21150854 CVCL_1R95 GM10501 hybrid cell line human CVCL_1R95 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150855 CVCL_2396 CCD-42Sk finite cell line human CVCL_2396 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150856 CVCL_1R96 GM10502 hybrid cell line CVCL_1R96 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150857 CVCL_2399 CCD-944Sk finite cell line human CVCL_2399 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 21150858 CVCL_1R99 GM10660 hybrid cell line CVCL_1R99 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150859 CVCL_2371 CCD-1136Sk finite cell line human CVCL_2371 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~42 PDL (ATCC=CRL-2697) 21150860 CVCL_1R71 TMA-16 embryonic stem cell house mouse CVCL_1R71 CL:0000010 Breed/subspecies: 129/Sv. Female 21150861 CVCL_2372 CCD-1137Sk finite cell line human CVCL_2372 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~60 PDL (ATCC=CRL-2703) 21150862 CVCL_1R72 TMA-29 embryonic stem cell house mouse CVCL_1R72 CL:0000010 Breed/subspecies: 129/Sv. Female 21150863 CVCL_2370 CCD-1135Sk finite cell line human CVCL_2370 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~46 PDL (ATCC=CRL-2691) 21150864 CVCL_1R70 TMA-2 embryonic stem cell house mouse CVCL_1R70 CL:0000010 Breed/subspecies: C3H/He x T37H. Discontinued: RCB; RCB2543; true Female 21150865 CVCL_2364 CCD-1127Sk finite cell line human CVCL_2364 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~40 PDL (ATCC=CRL-2565) 21150866 CVCL_1R64 GM03318 finite cell line human CVCL_1R64 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21150867 CVCL_2365 CCD-1128Sk finite cell line human CVCL_2365 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~30 PDL (ATCC=CRL-2566) 21150868 CVCL_1R65 HPS0334 induced pluripotent stem cell human CVCL_1R65 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21150869 CVCL_2362 CCD-1124Sk finite cell line human CVCL_2362 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~29 PDL (ATCC=CRL-2529) 21150870 CVCL_1R62 GM02365 finite cell line human CVCL_1R62 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21150871 CVCL_2363 CCD-1126Sk finite cell line human CVCL_2363 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~46 PDL (ATCC=CRL-2564) 21150872 CVCL_1R63 GM03317 transformed cell line human CVCL_1R63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150873 CVCL_2368 CCD-1132Sk finite cell line human CVCL_2368 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~56 PDL (ATCC=CRL-2368) 21150874 CVCL_1R68 MSH6-1-[ClX3.16]DT40 cancer cell line CVCL_1R68 CL:0000010 Knockout cell: Method=Cre/loxP; MSH6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21150875 CVCL_2369 CCD-1134Sk finite cell line human CVCL_2369 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~35 PDL (ATCC=CRL-2673) 21150876 CVCL_1R69 TMA-1 embryonic stem cell house mouse CVCL_1R69 CL:0000010 Breed/subspecies: 129/Sv. Discontinued: RCB; RCB2542; true Female 21150877 CVCL_2366 CCD-1129Sk finite cell line human CVCL_2366 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Omics: Deep proteome analysis Female Senescence: Senesces at ~36 PDL (ATCC=CRL-2575) 21150878 CVCL_1R66 HPS0335 induced pluripotent stem cell human CVCL_1R66 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21150879 CVCL_2367 CCD-1131Sk finite cell line human CVCL_2367 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female Senescence: Senesces at ~60 PDL (ATCC=CRL-2617) 21150880 CVCL_1R67 HPS0336 induced pluripotent stem cell human CVCL_1R67 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21150881 CVCL_2382 CCD-19Lu finite cell line human CVCL_2382 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 90112708; probable; Discontinued: KCLB; 10210; probable Female Senescence: Senesces at ~8-9 PDL (ATCC=CCL-210) 21150882 CVCL_1R82 GM10027 hybrid cell line human CVCL_1R82 CL:0000010 Characteristics: Hybrid for chromosome 22 mapping Contains a complete copy of chromosome 22.. Group: Human/rodent somatic cell hybrid 21150883 CVCL_2383 CCD-25Lu finite cell line human CVCL_2383 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: KCLB; 10215; probable Male Senescence: Senesces at ~9 PDL (ATCC=CCL-215) 21150884 CVCL_1R83 GM10063 hybrid cell line CVCL_1R83 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150885 CVCL_2380 CCD-18Lu finite cell line human CVCL_2380 CL:0000010 Population: African American; Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: KCLB; 10205; probable Female Senescence: Senesces at 60-70 PDL (ATCC=CCL-205) 21150886 CVCL_1R80 GM08854 hybrid cell line CVCL_1R80 CL:0000010 Characteristics: Hybrid for chromosome 21 mapping Contains a complete copy of chromosome 21.. Group: Human/rodent somatic cell hybrid 21150887 CVCL_2381 CCD-186Sk finite cell line human CVCL_2381 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (ATCC) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21150888 CVCL_1R81 GM09142 hybrid cell line CVCL_1R81 CL:0000010 Group: Human/rodent somatic cell hybrid. 21150889 CVCL_2375 CCD-1140Sk finite cell line human CVCL_2375 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~55 PDL (ATCC=CRL-2714) 21150890 CVCL_1R75 TMA-45 embryonic stem cell house mouse CVCL_1R75 CL:0000010 Breed/subspecies: 129/Sv x C3H/HeHa. Female 21150891 CVCL_2376 CCD-1141Sk finite cell line human CVCL_2376 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~50 PDL (ATCC=CRL-2796) 21150892 CVCL_1R76 TMA-46 embryonic stem cell house mouse CVCL_1R76 CL:0000010 Breed/subspecies: 129/Sv x C3H/HeHa. Female 21150893 CVCL_2373 CCD-1138Sk finite cell line human CVCL_2373 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~25 PDL (ATCC=CRL-2707) 21150894 CVCL_1R73 TMA-30 embryonic stem cell house mouse CVCL_1R73 CL:0000010 Breed/subspecies: 129/Sv. Female 21150895 CVCL_2374 CCD-1139Sk finite cell line human CVCL_2374 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at ~52 PDL (ATCC=CRL-2708) 21150896 CVCL_1R74 TMA-32 embryonic stem cell house mouse CVCL_1R74 CL:0000010 Breed/subspecies: 129/Sv. Female 21150897 CVCL_2379 CCD-18Co finite cell line human CVCL_2379 CL:0000010 Population: African American; Derived from sampling site: Colon Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Discontinued: ECACC; 90070503; probable Female Senescence: Senesces at ~42 PDL (ATCC=CRL-1459) 21150898 CVCL_1R79 GM06318 hybrid cell line human CVCL_1R79 CL:0000010 Characteristics: Hybrid for chromosome X mapping Contains a complete copy of chromosome X.. Group: Human/rodent somatic cell hybrid 21150899 CVCL_2377 CCD-13Lu finite cell line human CVCL_2377 CL:0000010 Population: African American; Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at ~20 PDL (ATCC=CCL-200) 21150900 CVCL_1R77 GM02963 finite cell line human CVCL_1R77 CL:0000010 Population: African American; Karyotypic information: 46,XY,t(3;17)(p21;q25).arr(1-22)x2,(XY)x1 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21150901 CVCL_2378 CCD-16Lu finite cell line human CVCL_2378 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at ~11 PDL (ATCC=CCL-204) 21150902 CVCL_1R78 GM06317 hybrid cell line human CVCL_1R78 CL:0000010 Characteristics: Hybrid for chromosome Y mapping Contains a complete copy of chromosome Y.. Group: Human/rodent somatic cell hybrid 21150903 CVCL_CE60 ND04676 transformed cell line human CVCL_CE60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150904 CVCL_CE58 ND04672 transformed cell line human CVCL_CE58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150905 CVCL_CE59 ND04674 transformed cell line human CVCL_CE59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150906 CVCL_CE52 ND04650 transformed cell line human CVCL_CE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150907 CVCL_CE53 ND04651 transformed cell line human CVCL_CE53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150908 CVCL_CE50 ND04648 transformed cell line human CVCL_CE50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150909 CVCL_CE51 ND04649 transformed cell line human CVCL_CE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150910 CVCL_CE56 ND04655 transformed cell line human CVCL_CE56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150911 CVCL_CE57 ND04670 transformed cell line human CVCL_CE57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150912 CVCL_CE54 ND04652 transformed cell line human CVCL_CE54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150913 CVCL_CE55 ND04653 transformed cell line human CVCL_CE55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150914 CVCL_CE70 ND04714 transformed cell line human CVCL_CE70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150915 CVCL_CE71 ND04724 transformed cell line human CVCL_CE71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150916 CVCL_CE69 ND04713 transformed cell line human CVCL_CE69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150917 CVCL_CE63 ND04694 transformed cell line human CVCL_CE63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150918 CVCL_CE64 ND04695 transformed cell line human CVCL_CE64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150919 CVCL_CE61 ND04677 transformed cell line human CVCL_CE61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150920 CVCL_CE62 ND04687 transformed cell line human CVCL_CE62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150921 CVCL_CE67 ND04698 transformed cell line human CVCL_CE67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150922 CVCL_CE68 ND04701 transformed cell line human CVCL_CE68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150923 CVCL_CE65 ND04696 transformed cell line human CVCL_CE65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150924 CVCL_CE66 ND04697 transformed cell line human CVCL_CE66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150925 CVCL_CE38 ND04564 transformed cell line human CVCL_CE38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150926 CVCL_CE39 ND04566 transformed cell line human CVCL_CE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150927 CVCL_CE36 ND04554 transformed cell line human CVCL_CE36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150928 CVCL_CE37 ND04555 transformed cell line human CVCL_CE37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150929 CVCL_CE30 ND04548 transformed cell line human CVCL_CE30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150930 CVCL_CE31 ND04549 transformed cell line human CVCL_CE31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150931 CVCL_CE34 ND04552 transformed cell line human CVCL_CE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150932 CVCL_CE35 ND04553 transformed cell line human CVCL_CE35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150933 CVCL_CE32 ND04550 transformed cell line human CVCL_CE32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150934 CVCL_CE33 ND04551 transformed cell line human CVCL_CE33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150935 CVCL_CE49 ND04636 transformed cell line human CVCL_CE49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150936 CVCL_CE47 ND04597 transformed cell line human CVCL_CE47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150937 CVCL_CE48 ND04598 transformed cell line human CVCL_CE48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150938 CVCL_CE41 ND04574 transformed cell line human CVCL_CE41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150939 CVCL_CE42 ND04581 transformed cell line human CVCL_CE42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150940 CVCL_CE40 ND04569 transformed cell line human CVCL_CE40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150941 CVCL_CE45 ND04587 transformed cell line human CVCL_CE45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150942 CVCL_CE46 ND04594 transformed cell line human CVCL_CE46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150943 CVCL_CE43 ND04582 transformed cell line human CVCL_CE43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150944 CVCL_CE44 ND04585 transformed cell line human CVCL_CE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150945 CVCL_CE16 ND04457 transformed cell line human CVCL_CE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150946 CVCL_CE17 ND04481 transformed cell line human CVCL_CE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150947 CVCL_CE14 ND04451 transformed cell line human CVCL_CE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150948 CVCL_CE15 ND04456 transformed cell line human CVCL_CE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150949 CVCL_CE18 ND04482 transformed cell line human CVCL_CE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150950 CVCL_CE19 ND04497 transformed cell line human CVCL_CE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150951 CVCL_CE12 ND04440 transformed cell line human CVCL_CE12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150952 CVCL_CE13 ND04450 transformed cell line human CVCL_CE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150953 CVCL_CE10 ND04424 transformed cell line human CVCL_CE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21150954 CVCL_CE11 ND04425 transformed cell line human CVCL_CE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150955 CVCL_CE27 ND04518 transformed cell line human CVCL_CE27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150956 CVCL_CE28 ND04543 transformed cell line human CVCL_CE28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150957 CVCL_CE25 ND04516 transformed cell line human CVCL_CE25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150958 CVCL_CE26 ND04517 transformed cell line human CVCL_CE26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150959 CVCL_CE29 ND04544 transformed cell line human CVCL_CE29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150960 CVCL_CE20 ND04503 transformed cell line human CVCL_CE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150961 CVCL_CE23 ND04513 transformed cell line human CVCL_CE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150962 CVCL_CE24 ND04514 transformed cell line human CVCL_CE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150963 CVCL_CE21 ND04504 transformed cell line human CVCL_CE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150964 CVCL_CE22 ND04512 transformed cell line human CVCL_CE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150965 CVCL_CE05 ND04399 transformed cell line human CVCL_CE05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150966 CVCL_CE06 ND04400 transformed cell line human CVCL_CE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150967 CVCL_CE03 ND04396 transformed cell line human CVCL_CE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150968 CVCL_CE04 ND04397 transformed cell line human CVCL_CE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150969 CVCL_CE09 ND04407 transformed cell line human CVCL_CE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150970 CVCL_CE07 ND04401 transformed cell line human CVCL_CE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150971 CVCL_CE08 ND04406 transformed cell line human CVCL_CE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150972 CVCL_CE01 ND04381 transformed cell line human CVCL_CE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21150973 CVCL_CE02 ND04383 transformed cell line human CVCL_CE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150974 CVCL_CE00 ND04375 transformed cell line human CVCL_CE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21150975 CVCL_U910 CMel 136 cancer cell line human CVCL_U910 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21150976 CVCL_TX10 HAP1 USP54 (-) cancer cell line human CVCL_TX10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23513; USP54; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150977 CVCL_TX11 HAP1 USP6 (-) 1 cancer cell line human CVCL_TX11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12629; USP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150978 CVCL_U911 SK-MEL-215-1 cancer cell line human CVCL_U911 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asn581Ser (c.1742A>G); ClinVar=VCV000177776; Zygosity=Unspecified (PubMed=24576830). 21150979 CVCL_TX14 HAP1 USP8 (-) 1 cancer cell line human CVCL_TX14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150980 CVCL_U914 SK-MEL-27-2 cancer cell line human CVCL_U914 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359). Female 21150981 CVCL_TX15 HAP1 USP8 (-) 2 cancer cell line human CVCL_TX15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12631; USP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150982 CVCL_U915 Mel 224 cancer cell line human CVCL_U915 From: Hansson J.; Karolinska Institutet; Stockholm; Sweden. CL:0000010 21150983 CVCL_TX12 HAP1 USP6 (-) 2 cancer cell line human CVCL_TX12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12629; USP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150984 CVCL_U912 SK-MEL-309B cancer cell line human CVCL_U912 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21150985 CVCL_TX13 HAP1 USP7 (-) cancer cell line human CVCL_TX13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12630; USP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150986 CVCL_U913 SK-MEL-27-1 cancer cell line human CVCL_U913 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359). Female 21150987 CVCL_TX18 HAP1 UTRN (-) 1 cancer cell line human CVCL_TX18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12635; UTRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150988 CVCL_U918 MMC-14 cancer cell line house mouse CVCL_U918 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Unspecified 21150989 CVCL_TX19 HAP1 UTRN (-) 2 cancer cell line human CVCL_TX19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12635; UTRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150990 CVCL_U919 MMC-34 cancer cell line house mouse CVCL_U919 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: CXBG. Unspecified 21150991 CVCL_TX16 HAP1 USP9X (-) 1 cancer cell line human CVCL_TX16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12632; USP9X; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150992 CVCL_U916 Mel 505 cancer cell line human CVCL_U916 From: Hansson J.; Karolinska Institutet; Stockholm; Sweden. CL:0000010 21150993 CVCL_TX17 HAP1 USP9X (-) 2 cancer cell line human CVCL_TX17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12632; USP9X; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150994 CVCL_U917 MMC-1 cancer cell line house mouse CVCL_U917 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: CXBI. Unspecified 21150995 CVCL_TX00 HAP1 USP45 (-) 2 cancer cell line human CVCL_TX00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20080; USP45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150996 CVCL_U900 MT-5 transformed cell line house mouse CVCL_U900 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21150997 CVCL_TX03 HAP1 USP47 (-) 2 cancer cell line human CVCL_TX03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20076; USP47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150998 CVCL_TX04 HAP1 USP48 (-) 1 cancer cell line human CVCL_TX04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18533; USP48; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21150999 CVCL_U901 Calu-5 cancer cell line human CVCL_U901 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lung. Unspecified 21151000 CVCL_TX01 HAP1 USP46 (-) cancer cell line human CVCL_TX01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20075; USP46; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151001 CVCL_TX02 HAP1 USP47 (-) 1 cancer cell line human CVCL_TX02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20076; USP47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151002 CVCL_TX07 HAP1 USP49 (-) 2 cancer cell line human CVCL_TX07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20078; USP49; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151003 CVCL_U907 SK-MEL-140 cancer cell line human CVCL_U907 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21151004 CVCL_TX08 HAP1 USP53 (-) 1 cancer cell line human CVCL_TX08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29255; USP53; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151005 CVCL_U908 SK-MEL-203 cancer cell line human CVCL_U908 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21151006 CVCL_TX05 HAP1 USP48 (-) 2 cancer cell line human CVCL_TX05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18533; USP48; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151007 CVCL_TX06 HAP1 USP49 (-) 1 cancer cell line human CVCL_TX06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20078; USP49; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151008 CVCL_TX09 HAP1 USP53 (-) 2 cancer cell line human CVCL_TX09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29255; USP53; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151009 CVCL_U909 SK-MEL-204 cancer cell line human CVCL_U909 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21151010 CVCL_CE96 ND04846 transformed cell line human CVCL_CE96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151011 CVCL_CE97 ND04847 transformed cell line human CVCL_CE97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151012 CVCL_CE94 ND04838 transformed cell line human CVCL_CE94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151013 CVCL_CE95 ND04841 transformed cell line human CVCL_CE95 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Gln34Arg (c.101A>G); ClinVar=VCV000468584; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151014 CVCL_CE98 ND04854 transformed cell line human CVCL_CE98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151015 CVCL_CE99 ND04858 transformed cell line human CVCL_CE99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151016 CVCL_CE81 ND04744 transformed cell line human CVCL_CE81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151017 CVCL_CE82 ND04754 transformed cell line human CVCL_CE82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151018 CVCL_CE80 ND04743 transformed cell line human CVCL_CE80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151019 CVCL_CE74 ND04727 transformed cell line human CVCL_CE74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151020 CVCL_CE75 ND04728 transformed cell line human CVCL_CE75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151021 CVCL_CE72 ND04725 transformed cell line human CVCL_CE72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151022 CVCL_CE73 ND04726 transformed cell line human CVCL_CE73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151023 CVCL_CE78 ND04741 transformed cell line human CVCL_CE78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151024 CVCL_CE79 ND04742 transformed cell line human CVCL_CE79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151025 CVCL_CE76 ND04729 transformed cell line human CVCL_CE76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151026 CVCL_CE77 ND04730 transformed cell line human CVCL_CE77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151027 CVCL_CE92 ND04832 transformed cell line human CVCL_CE92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151028 CVCL_CE93 ND04837 transformed cell line human CVCL_CE93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151029 CVCL_CE90 ND04773 transformed cell line human CVCL_CE90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151030 CVCL_CE91 ND04780 transformed cell line human CVCL_CE91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151031 CVCL_CE85 ND04759 transformed cell line human CVCL_CE85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151032 CVCL_CE86 ND04760 transformed cell line human CVCL_CE86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151033 CVCL_CE83 ND04755 transformed cell line human CVCL_CE83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151034 CVCL_CE84 ND04756 transformed cell line human CVCL_CE84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151035 CVCL_CE89 ND04772 transformed cell line human CVCL_CE89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151036 CVCL_CE87 ND04761 transformed cell line human CVCL_CE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151037 CVCL_CE88 ND04770 transformed cell line human CVCL_CE88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151038 CVCL_1S70 GM13341 hybrid cell line CVCL_1S70 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151039 CVCL_2470 HCA7 colony 11 cancer cell line human CVCL_2470 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152455; probable Female 21151040 CVCL_1S71 GM13342 hybrid cell line CVCL_1S71 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151041 CVCL_2471 HCA7 colony 24 cancer cell line human CVCL_2471 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152456; probable Female 21151042 CVCL_1S63 GM12511 hybrid cell line CVCL_1S63 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151043 CVCL_2463 H376 cancer cell line human CVCL_2463 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000954591; Zygosity=Homozygous (PubMed=7633286; DepMap) Derived from sampling site: Oral cavity; floor of mouth. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151044 CVCL_1S64 GM12513 hybrid cell line CVCL_1S64 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151045 CVCL_2464 H400 cancer cell line human CVCL_2464 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Gly (c.847C>G); ClinVar=VCV000580186; Zygosity=Homozygous (PubMed=7633286) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female 21151046 CVCL_1S61 GM12506 hybrid cell line CVCL_1S61 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151047 CVCL_2461 H33HJ-JA1 cancer cell line human CVCL_2461 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8163 21151048 CVCL_1S62 GM12508 hybrid cell line CVCL_1S62 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151049 CVCL_2462 H357 cancer cell line human CVCL_2462 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Ser (c.37G>A); ClinVar=VCV000376323; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Homozygous (PubMed=7633286) Derived from sampling site: Oral cavity; tongue. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151050 CVCL_1S67 GM13302 hybrid cell line human CVCL_1S67 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151051 CVCL_2467 HCA24 cancer cell line human CVCL_2467 CL:0000010 Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Discontinued: Ximbio; 152462; probable Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21151052 CVCL_1S68 GM13339 hybrid cell line CVCL_1S68 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151053 CVCL_2468 HCA46 cancer cell line human CVCL_2468 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala183Ser (c.547G>T); Zygosity=Heterozygous (PubMed=9294210); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Alafs*33 (c.815_816delTG); Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Colon; sigmoid. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Ximbio; 152463; probable Female Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21151054 CVCL_1S65 GM12515 hybrid cell line human CVCL_1S65 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151055 CVCL_2465 H413 cancer cell line human CVCL_2465 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu68Gly (c.203A>G); Zygosity=Heterozygous (PubMed=7633286) Derived from sampling site: Oral cavity; buccal mucosa. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151056 CVCL_1S66 GM12517 hybrid cell line CVCL_1S66 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151057 CVCL_2466 H69V cancer cell line human CVCL_2466 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Male Doubling time: 34.0 hours (PubMed=1662924) 21151058 CVCL_1S69 GM13340 hybrid cell line CVCL_1S69 CL:0000010 Discontinued: Coriell; GM13340; probable. Group: Human/rodent somatic cell hybrid 21151059 CVCL_2469 HCA7 colony 1 cancer cell line human CVCL_2469 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152452; probable Female 21151060 CVCL_1S81 GM13535 hybrid cell line human CVCL_1S81 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151061 CVCL_2481 HEL 92.1.7 cancer cell line human CVCL_2481 HLA typing: A*03,w32; B*w35 (CLS=300462); Genome ancestry: African=0%; Native American=2.04%; East Asian, North=1.78%; East Asian, South=0.21%; South Asian=6.68%; European, North=17.09%; European, South=72.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (DepMap) Population: Caucasian; Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21151062 CVCL_1S82 GM13546 hybrid cell line human CVCL_1S82 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151063 CVCL_2482 HeLa B cancer cell line human CVCL_2482 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21151064 CVCL_1S80 GM13534 hybrid cell line human CVCL_1S80 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151065 CVCL_2480 HEL 299 finite cell line human CVCL_2480 HLA typing: A*30:01; B*15:03,42:01; C*02:10 (IPD-IMGT/HLA=10725) CL:0000010 Derived from sampling site: Fetal lung. Male 21151066 CVCL_1S74 GM13445 hybrid cell line CVCL_1S74 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151067 CVCL_2474 HCA7 colony 29 cancer cell line human CVCL_2474 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152459; probable Female Characteristics: Useful for studying the role of PTGS2 (Cox-2) in cancer cell biology and the investigation of colorectal epithelial cell polarity 21151068 CVCL_1S75 GM13448 hybrid cell line CVCL_1S75 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151069 CVCL_2475 HCA7 colony 3 cancer cell line human CVCL_2475 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152453; probable Female 21151070 CVCL_1S72 GM13412 hybrid cell line human CVCL_1S72 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151071 CVCL_2472 HCA7 colony 26 cancer cell line human CVCL_2472 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152457; probable Female 21151072 CVCL_1S73 GM13413 hybrid cell line human CVCL_1S73 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151073 CVCL_2473 HCA7 colony 27 cancer cell line human CVCL_2473 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152458; probable Female 21151074 CVCL_1S78 GM13500 hybrid cell line human CVCL_1S78 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151075 CVCL_2478 HCT 8 cancer cell line human CVCL_2478 HLA typing: A*03,09; B*08 (PubMed=77569); HLA typing: A*02:01,24:02; B*08:01,35:01; C*04:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Val79Ile (c.235G>A); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Pro164fs*8 (c.490_491insA); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Val244Ile (c.730G>A); ClinVar=VCV000919044; Zygosity=Unspecified (PubMed=24755471) Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21151076 CVCL_1S79 GM13533 hybrid cell line human CVCL_1S79 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151077 CVCL_2479 HEL 12469 finite cell line human CVCL_2479 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21151078 CVCL_1S76 GM13498 hybrid cell line human CVCL_1S76 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151079 CVCL_2476 HCA7 colony 30 cancer cell line human CVCL_2476 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152460; probable Female 21151080 CVCL_1S77 GM13499 hybrid cell line human CVCL_1S77 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151081 CVCL_2477 HCA7 colony 6 cancer cell line human CVCL_2477 CL:0000010 Derived from sampling site: Colon. Discontinued: Ximbio; 152454; probable Female 21151082 CVCL_TY93 HAP1 ZDHHC24 (-) 2 cancer cell line human CVCL_TY93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27387; ZDHHC24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151083 CVCL_TY94 HAP1 ZDHHC3 (-) 1 cancer cell line human CVCL_TY94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18470; ZDHHC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151084 CVCL_TY91 HAP1 ZDHHC23 (-) 2 cancer cell line human CVCL_TY91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28654; ZDHHC23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151085 CVCL_TY92 HAP1 ZDHHC24 (-) 1 cancer cell line human CVCL_TY92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27387; ZDHHC24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151086 CVCL_TY97 HAP1 ZDHHC4 (-) 2 cancer cell line human CVCL_TY97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18471; ZDHHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151087 CVCL_TY98 HAP1 ZDHHC4 (-) 3 cancer cell line human CVCL_TY98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18471; ZDHHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151088 CVCL_TY95 HAP1 ZDHHC3 (-) 2 cancer cell line human CVCL_TY95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18470; ZDHHC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151089 CVCL_TY96 HAP1 ZDHHC4 (-) 1 cancer cell line human CVCL_TY96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18471; ZDHHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151090 CVCL_TY99 HAP1 ZDHHC4 (-) 4 cancer cell line human CVCL_TY99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18471; ZDHHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151091 CVCL_2441 E111 hybrid cell line CVCL_2441 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151092 CVCL_1S41 GM11766 hybrid cell line human CVCL_1S41 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151093 CVCL_2442 EBTr finite cell line CVCL_2442 CL:0000010 Derived from sampling site: Fetal trachea. Discontinued: ATCC; CRL-6565; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21151094 CVCL_1S42 GM11767 hybrid cell line human CVCL_1S42 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151095 CVCL_2440 E.H.IV transformed cell line human CVCL_2440 CL:0000010 Anecdotal: Established from Elaine Hutkin, a young technician in the Henles laboratory She caught infectious mononucleosis and her blood cells became positive for EBV thus allowing the link to be made between EBV and mononucleosis. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151096 CVCL_1S40 GM11754 hybrid cell line human CVCL_1S40 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151097 CVCL_2445 fR5 transformed cell line human CVCL_2445 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21151098 CVCL_1S45 GM11937 hybrid cell line human CVCL_1S45 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151099 CVCL_2446 FTC-236 cancer cell line human CVCL_2446 CL:0000010 Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=30737244) Derived from metastatic site: Cervical lymph node. Omics: Mitochondrial genome sequenced; Omics: Transcriptome analysis by microarray Male Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502) 21151100 CVCL_1S46 GM11939 hybrid cell line CVCL_1S46 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151101 CVCL_2443 Ej138 cancer cell line human CVCL_2443 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: SNP array analysis; Omics: Transcriptome analysis by ESTs sequencing; Omics: Transcriptome analysis by microarray Female Doubling time: 20 hours (PubMed=3708594) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00080; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00195 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=3708594; PubMed=6823318; PubMed=20143388). 21151102 CVCL_1S43 GM11908 hybrid cell line human CVCL_1S43 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151103 CVCL_2444 fR2 transformed cell line human CVCL_2444 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Female 21151104 CVCL_1S44 GM11936 hybrid cell line CVCL_1S44 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151105 CVCL_1S49 GM11979 hybrid cell line human CVCL_1S49 CL:0000010 21151106 CVCL_2449 GP-1 transformed cell line CVCL_2449 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood; Breed/subspecies: Hartley. Female 21151107 CVCL_2447 FTC-238 cancer cell line human CVCL_2447 HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.72%; Native American=2.05%; East Asian, North=2%; East Asian, South=0%; South Asian=0%; European, North=60.8%; European, South=33.42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (PubMed=30737244; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906; PubMed=30737244) Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Highly invasive; Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502) Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151108 CVCL_1S47 GM11943 hybrid cell line CVCL_1S47 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151109 CVCL_2448 GM01899 transformed cell line human CVCL_2448 HLA typing: A*02,11; B*18,35 (Coriell=GM01899) CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Simple; c.610-4_610-2delinsTTT (Ex9del partial); ClinVar=VCV000010055; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151110 CVCL_1S48 GM11978 hybrid cell line human CVCL_1S48 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151111 CVCL_TY82 HAP1 ZDHHC19 (-) 3 cancer cell line human CVCL_TY82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20713; ZDHHC19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151112 CVCL_TY83 HAP1 ZDHHC2 (-) 1 cancer cell line human CVCL_TY83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18469; ZDHHC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151113 CVCL_TY80 HAP1 ZDHHC19 (-) 1 cancer cell line human CVCL_TY80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20713; ZDHHC19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151114 CVCL_TY81 HAP1 ZDHHC19 (-) 2 cancer cell line human CVCL_TY81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20713; ZDHHC19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151115 CVCL_TY86 HAP1 ZDHHC20 (-) 2 cancer cell line human CVCL_TY86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20749; ZDHHC20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151116 CVCL_TY87 HAP1 ZDHHC21 (-) cancer cell line human CVCL_TY87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20750; ZDHHC21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151117 CVCL_TY84 HAP1 ZDHHC2 (-) 2 cancer cell line human CVCL_TY84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18469; ZDHHC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151118 CVCL_TY85 HAP1 ZDHHC20 (-) 1 cancer cell line human CVCL_TY85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20749; ZDHHC20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151119 CVCL_TY88 HAP1 ZDHHC22 (-) 1 cancer cell line human CVCL_TY88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20106; ZDHHC22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151120 CVCL_TY89 HAP1 ZDHHC22 (-) 2 cancer cell line human CVCL_TY89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20106; ZDHHC22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151121 CVCL_1S60 GM12449 hybrid cell line human CVCL_1S60 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151122 CVCL_2460 H314 cancer cell line human CVCL_2460 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Homozygous (PubMed=7633286); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys373Glu (c.1117A>G); Zygosity=Homozygous (PubMed=7633286). Male 21151123 CVCL_1S52 GM12083 hybrid cell line human CVCL_1S52 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151124 CVCL_2452 GS-109-IV-8 finite cell line human CVCL_2452 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151125 CVCL_1S53 GM12084 hybrid cell line human CVCL_1S53 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151126 CVCL_2453 GS-109-V-20 finite cell line human CVCL_2453 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151127 CVCL_1S50 GM11980 hybrid cell line human CVCL_1S50 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151128 CVCL_2450 GP2d cancer cell line human CVCL_2450 HLA typing: A*24:02,24:02; B*44:02,44:02; C*05:01,05:01; DQA1*03:02,05:02; DQB1*06:13,06:13; DRB1*04:05,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=0.09%; East Asian, South=0%; South Asian=0%; European, North=74.93%; European, South=24.97% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=25984343); Microsatellite instability: Instable (MSI) (PubMed=25926053; PubMed=31068700) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21151129 CVCL_1S51 GM12072 hybrid cell line human CVCL_1S51 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151130 CVCL_2451 GR-M cancer cell line human CVCL_2451 HLA typing: A*24:02,24:02; B*52:01:01,52:01:01; C*12:02,12:02; DPB1*09:01; DQB1*06:02,06:01:01; DRB1*15:01 (PubMed=15592718); HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=83.55%; East Asian, South=15.04%; South Asian=1.41%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Unspecified (PubMed=23851445; DepMap) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ESTDAB; ESTDAB-036; probable Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00538 Problematic cell line: Contaminated Shown to be a PSN1 derivative (PubMed=25877200). Originally thought to originate from the chest of a 36 year old male melanoma patient with skin metastases. 21151131 CVCL_1S56 GM12087 hybrid cell line human CVCL_1S56 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151132 CVCL_2456 GS-109-V-63 finite cell line human CVCL_2456 CL:0000010 Population: Caucasian; Karyotypic information: Diploid karyotype (ATCC); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151133 CVCL_1S57 GM12088 hybrid cell line human CVCL_1S57 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151134 CVCL_2457 H103 cancer cell line human CVCL_2457 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Homozygous (PubMed=7633286; DepMap) Karyotypic information: Has lost chromosome Y; Derived from sampling site: Oral cavity; tongue. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151135 CVCL_1S54 GM12085 hybrid cell line human CVCL_1S54 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151136 CVCL_2454 GS-109-V-21 finite cell line human CVCL_2454 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,-2,2q+ (ATCC); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151137 CVCL_1S55 GM12086 hybrid cell line human CVCL_1S55 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151138 CVCL_2455 GS-109-V-34 finite cell line human CVCL_2455 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151139 CVCL_1S58 GM12215 hybrid cell line human CVCL_1S58 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151140 CVCL_2458 H157 cancer cell line human CVCL_2458 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (PubMed=7633286; DepMap) Derived from sampling site: Oral cavity; buccal mucosa. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151141 CVCL_1S59 GM12448 hybrid cell line human CVCL_1S59 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151142 CVCL_2459 h1RPE7 transformed cell line human CVCL_2459 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Doubling time: ~24 hours (ECACC=09061602) 21151143 CVCL_TY90 HAP1 ZDHHC23 (-) 1 cancer cell line human CVCL_TY90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28654; ZDHHC23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151144 CVCL_TY71 HAP1 ZDHHC14 (-) 2 cancer cell line human CVCL_TY71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20341; ZDHHC14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151145 CVCL_TY72 HAP1 ZDHHC15 (-) cancer cell line human CVCL_TY72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20342; ZDHHC15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151146 CVCL_TY70 HAP1 ZDHHC14 (-) 1 cancer cell line human CVCL_TY70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20341; ZDHHC14; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151147 CVCL_TY75 HAP1 ZDHHC17 (-) 1 cancer cell line human CVCL_TY75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18412; ZDHHC17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151148 CVCL_TY76 HAP1 ZDHHC17 (-) 2 cancer cell line human CVCL_TY76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18412; ZDHHC17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151149 CVCL_TY73 HAP1 ZDHHC16 (-) 1 cancer cell line human CVCL_TY73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20714; ZDHHC16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151150 CVCL_TY74 HAP1 ZDHHC16 (-) 2 cancer cell line human CVCL_TY74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20714; ZDHHC16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151151 CVCL_TY79 HAP1 ZDHHC18 (-) 2 cancer cell line human CVCL_TY79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20712; ZDHHC18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151152 CVCL_TY77 HAP1 ZDHHC17 (-) 3 cancer cell line human CVCL_TY77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18412; ZDHHC17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151153 CVCL_TY78 HAP1 ZDHHC18 (-) 1 cancer cell line human CVCL_TY78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20712; ZDHHC18; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151154 CVCL_2420 COV362 cancer cell line human CVCL_2420 HLA typing: A*03:01,03:01; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=1.85%; Native American=0.2%; East Asian, North=3.12%; East Asian, South=0%; South Asian=0%; European, North=61.78%; European, South=33.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro871fs (c.2611_2612ins1); Zygosity=Homozygous (PubMed=25230021); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.4095+1G>T; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=25230021; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=25230021; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 91 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel; Part of: TCGA-110-CL cell line panel 21151155 CVCL_1S20 GM11222 hybrid cell line human CVCL_1S20 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151156 CVCL_2423 COV413B cancer cell line human CVCL_2423 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=25230021) Derived from metastatic site: Urinary bladder; bladder dome. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: OCCP ovarian cancer cell line panel 21151157 CVCL_1S23 GM11250 hybrid cell line CVCL_1S23 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151158 CVCL_2424 COV504 cancer cell line human CVCL_2424 HLA typing: A*11:01,11:01; B*35:01,35:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.33%; East Asian, North=1.96%; East Asian, South=0%; South Asian=1.71%; European, North=68.77%; European, South=27.23% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu323fs (c.966_967delAC); Zygosity=Unspecified (PubMed=25230021; PubMed=28273451; DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 50 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel 21151159 CVCL_1S24 GM11418 hybrid cell line human CVCL_1S24 CL:0000010 Characteristics: Hybrid for chromosome 15 mapping Contains a complete copy of chromosome 15.. Group: Human/rodent somatic cell hybrid 21151160 CVCL_2421 COV362.4 cancer cell line human CVCL_2421 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro871fs (c.2611_2612ins1); Zygosity=Homozygous (PubMed=25230021); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.4095+1G>T; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=25230021) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Part of: OCCP ovarian cancer cell line panel 21151161 CVCL_1S21 GM11223 hybrid cell line human CVCL_1S21 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151162 CVCL_2422 COV413A cancer cell line human CVCL_2422 HLA typing: A*02:01,02:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=25230021; DepMap) Derived from metastatic site: Colon; sigmoid. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel 21151163 CVCL_1S22 GM11224 hybrid cell line human CVCL_1S22 CL:0000010 Discontinued: Coriell; GM11224; probable. Group: Human/rodent somatic cell hybrid 21151164 CVCL_2427 Detroit 510 finite cell line human CVCL_2427 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~30 PDL 21151165 CVCL_1S27 GM11679 hybrid cell line CVCL_1S27 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151166 CVCL_2428 Detroit 525 finite cell line human CVCL_2428 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151167 CVCL_1S28 GM11685 hybrid cell line CVCL_1S28 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151168 CVCL_2425 COV644 cancer cell line human CVCL_2425 HLA typing: A*02:01,02:01; B*35:03,35:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=1.23%; Native American=0%; East Asian, North=3.96%; East Asian, South=0%; South Asian=21.27%; European, North=16.37%; European, South=57.17% (PubMed=30894373) CL:0000010 Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 188 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: OCCP ovarian cancer cell line panel 21151169 CVCL_1S25 GM11543 hybrid cell line human CVCL_1S25 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151170 CVCL_2426 CRFK spontaneously immortalized cell line CVCL_2426 CL:0000010 Derived from sampling site: Kidney. Biotechnology: Widely used to manufacture vaccines for parvoviruses such as feline panleukopenia virus (FPLV) and canine parvoviruses (CPVs) Discontinued: ATCC; CRL-6073; true Female Virology: Persistently infected by feline endogenous virus RD-114 Group: Vaccine production cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21151171 CVCL_1S26 GM11575 hybrid cell line human CVCL_1S26 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151172 CVCL_2429 Detroit 529 finite cell line human CVCL_2429 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 87021203; probable; Discontinued: JCRB; JCRB9043; true Female Senescence: Senesces at ~30 PDL (ATCC=CCL-66) 21151173 CVCL_1S29 GM11686 hybrid cell line CVCL_1S29 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains a neo-tagged human chromosome 2 Group: Human/rodent somatic cell hybrid 21151174 CVCL_TY60 HAP1 ZCCHC4 (-) 4 cancer cell line human CVCL_TY60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22917; ZCCHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151175 CVCL_TY61 HAP1 ZCCHC8 (-) cancer cell line human CVCL_TY61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25265; ZCCHC8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151176 CVCL_TY64 HAP1 ZDHHC11 (-) 2 cancer cell line human CVCL_TY64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19158; ZDHHC11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151177 CVCL_TY65 HAP1 ZDHHC12 (-) 1 cancer cell line human CVCL_TY65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19159; ZDHHC12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151178 CVCL_TY62 HAP1 ZDHHC1 (-) cancer cell line human CVCL_TY62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17916; ZDHHC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151179 CVCL_TY63 HAP1 ZDHHC11 (-) 1 cancer cell line human CVCL_TY63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19158; ZDHHC11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151180 CVCL_TY68 HAP1 ZDHHC13 (-) 1 cancer cell line human CVCL_TY68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18413; ZDHHC13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151181 CVCL_TY69 HAP1 ZDHHC13 (-) 2 cancer cell line human CVCL_TY69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18413; ZDHHC13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151182 CVCL_TY66 HAP1 ZDHHC12 (-) 2 cancer cell line human CVCL_TY66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19159; ZDHHC12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151183 CVCL_TY67 HAP1 ZDHHC12 (-) 3 cancer cell line human CVCL_TY67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19159; ZDHHC12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151184 CVCL_2430 Detroit 532 finite cell line human CVCL_2430 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21151185 CVCL_1S30 GM11687 hybrid cell line CVCL_1S30 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains a neo-tagged human chromosome 4 Group: Human/rodent somatic cell hybrid 21151186 CVCL_2431 Detroit 539 finite cell line human CVCL_2431 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151187 CVCL_1S31 GM11688 hybrid cell line CVCL_1S31 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains a neo-tagged human chromosome 10 Group: Human/rodent somatic cell hybrid 21151188 CVCL_2434 Detroit 551 finite cell line human CVCL_2434 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0302; probable Female Senescence: Senesces at ~25 PDL (ATCC=CCL-110) 21151189 CVCL_1S34 GM11692 hybrid cell line human CVCL_1S34 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151190 CVCL_2435 Detroit 573 finite cell line human CVCL_2435 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CCL-117; true Female 21151191 CVCL_1S35 GM11749 hybrid cell line human CVCL_1S35 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151192 CVCL_2432 Detroit 548 finite cell line human CVCL_2432 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151193 CVCL_1S32 GM11689 hybrid cell line CVCL_1S32 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Characteristics: Contains a neo-tagged human chromosome 13 Group: Human/rodent somatic cell hybrid 21151194 CVCL_2433 Detroit 550 finite cell line human CVCL_2433 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; CCL-109; probable Male 21151195 CVCL_1S33 GM11691 hybrid cell line human CVCL_1S33 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151196 CVCL_2438 DMS 454 cancer cell line human CVCL_2438 HLA typing: A*02:01,24:02; B*18:01,51:01; C*12:03,14:02 (PubMed=25960936); HLA typing: A*02:01,24:02; B*18:01,51:01; C*12:03,14:02 (PubMed=26589293); Genome ancestry: African=2.12%; Native American=0.07%; East Asian, North=2.95%; East Asian, South=0%; South Asian=0%; European, North=58.47%; European, South=36.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151197 CVCL_1S38 GM11752 hybrid cell line human CVCL_1S38 CL:0000010 Group: Human/rodent somatic cell hybrid 21151198 CVCL_2439 DMS 92 cancer cell line human CVCL_2439 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=1855224) Derived from metastatic site: Bone marrow. Omics: SNP array analysis Male Doubling time: 5.5 days (PubMed=6266631; PubMed=2986244) 21151199 CVCL_1S39 GM11753 hybrid cell line human CVCL_1S39 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151200 CVCL_2436 Detroit 6 cancer cell line human CVCL_2436 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-3; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00004 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=1246601; PubMed=20143388). Originally thought to originate from the bone marrow of a 58 year old male lung carcinoma patient. 21151201 CVCL_1S36 GM11750 hybrid cell line CVCL_1S36 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151202 CVCL_2437 Df hybrid cell line CVCL_2437 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151203 CVCL_1S37 GM11751 hybrid cell line human CVCL_1S37 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151204 CVCL_TY50 HAP1 ZAK (-) 2 cancer cell line human CVCL_TY50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17797; MAP3K20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151205 CVCL_TY53 HAP1 ZBTB24 (-) 3 cancer cell line human CVCL_TY53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21143; ZBTB24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151206 CVCL_TY54 HAP1 ZBTB33 (-) 1 cancer cell line human CVCL_TY54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16682; ZBTB33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151207 CVCL_TY51 HAP1 ZBTB24 (-) 1 cancer cell line human CVCL_TY51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21143; ZBTB24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151208 CVCL_TY52 HAP1 ZBTB24 (-) 2 cancer cell line human CVCL_TY52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21143; ZBTB24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151209 CVCL_TY57 HAP1 ZCCHC4 (-) 1 cancer cell line human CVCL_TY57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22917; ZCCHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151210 CVCL_TY58 HAP1 ZCCHC4 (-) 2 cancer cell line human CVCL_TY58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22917; ZCCHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151211 CVCL_TY55 HAP1 ZBTB33 (-) 2 cancer cell line human CVCL_TY55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16682; ZBTB33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151212 CVCL_TY56 HAP1 ZC3H12A (-) 1 cancer cell line human CVCL_TY56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26259; ZC3H12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151213 CVCL_TY59 HAP1 ZCCHC4 (-) 3 cancer cell line human CVCL_TY59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22917; ZCCHC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151214 CVCL_2401 Ch 1 Es spontaneously immortalized cell line CVCL_2401 CL:0000010 Derived from sampling site: Fetal esophagus. Discontinued: ATCC; CRL-6581; true; Discontinued: KCLB; 10073; probable Male Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21151215 CVCL_1S01 GM10663 hybrid cell line human CVCL_1S01 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151216 CVCL_2402 C1I hybrid cell line CVCL_2402 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151217 CVCL_1S02 GM10664 hybrid cell line human CVCL_1S02 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151218 CVCL_2400 CCD-986Sk finite cell line human CVCL_2400 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at ~36 PDL (ATCC=CRL-1947) 21151219 CVCL_1S00 GM10662 hybrid cell line human CVCL_1S00 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151220 CVCL_2405 CMT167 cancer cell line house mouse CVCL_2405 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Omics: Proteome analysis by 2D-DE/MS Female 21151221 CVCL_1S05 GM10826 hybrid cell line human CVCL_1S05 CL:0000010 Characteristics: Hybrid for chromosome 2 mapping Contains a complete copy of chromosome 2.. Group: Human/rodent somatic cell hybrid 21151222 CVCL_2406 CMT64 cancer cell line house mouse CVCL_2406 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Omics: Proteome analysis by 2D-DE/MS Female 21151223 CVCL_1S06 GM10880 hybrid cell line CVCL_1S06 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151224 CVCL_2403 CKT-1 spontaneously immortalized cell line CVCL_2403 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 6 days, at 105th passage (PubMed=4303468) 21151225 CVCL_1S03 GM10790 hybrid cell line human CVCL_1S03 CL:0000010 Discontinued: Coriell; GM10790; probable. Characteristics: Hybrid for chromosome 7 mapping Contains a complete copy of chromosome 7. Group: Human/rodent somatic cell hybrid 21151226 CVCL_2404 CM3.B6 transformed cell line human CVCL_2404 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Monoclonal antibody isotype: IgG1 21151227 CVCL_1S04 GM10791 hybrid cell line human CVCL_1S04 CL:0000010 Characteristics: Hybrid for chromosome 7 mapping Contains a complete copy of chromosome 7.. Group: Human/rodent somatic cell hybrid 21151228 CVCL_2409 COR-L24 cancer cell line human CVCL_2409 Genome ancestry: African=3.16%; Native American=0%; East Asian, North=4.31%; East Asian, South=0%; South Asian=0%; European, North=57.22%; European, South=35.31% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1554Ter (c.4660G>T); ClinVar=VCV000433664; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151229 CVCL_1S09 GM10890 hybrid cell line CVCL_1S09 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151230 CVCL_2407 COLO 738 cancer cell line human CVCL_2407 CL:0000010 Caution: Could be identical to RPMI-7932 (Cellosaurus=CVCL_2713). 21151231 CVCL_1S07 GM10888 hybrid cell line human CVCL_1S07 CL:0000010 Characteristics: Hybrid for chromosome 22 mapping Contains a complete copy of chromosome 22.. Group: Human/rodent somatic cell hybrid 21151232 CVCL_2408 COLO 794 cancer cell line human CVCL_2408 HLA typing: A*02:01,29:02; B*44:02,44:03:01; C*05:01,16:01; DPB1*04:01,17:01; DQB1*03:01:01,02:01; DRB1*12:01,07:01 (PubMed=15592718); HLA typing: A*02:01,29:02; B*44:03,44:03; C*05:01,16:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Arg (c.403T>C); ClinVar=VCV000376560; Zygosity=Heterozygous (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151233 CVCL_1S08 GM10889 hybrid cell line CVCL_1S08 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151234 CVCL_TY42 HAP1 YAP1 (-) 2 cancer cell line human CVCL_TY42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151235 CVCL_TY43 HAP1 YBEY (-) 1 cancer cell line human CVCL_TY43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1299; YBEY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151236 CVCL_TY40 HAP1 XRCC4 (-) cancer cell line human CVCL_TY40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12831; XRCC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151237 CVCL_TY41 HAP1 YAP1 (-) 1 cancer cell line human CVCL_TY41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151238 CVCL_TY46 HAP1 YES1 (-) 2 cancer cell line human CVCL_TY46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12841; YES1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151239 CVCL_TY47 HAP1 YTHDF2 (-) 1 cancer cell line human CVCL_TY47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31675; YTHDF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151240 CVCL_TY44 HAP1 YBEY (-) 2 cancer cell line human CVCL_TY44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1299; YBEY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151241 CVCL_TY45 HAP1 YES1 (-) 1 cancer cell line human CVCL_TY45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12841; YES1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151242 CVCL_TY48 HAP1 ZADH2 (-) 1 cancer cell line human CVCL_TY48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28697; PTGR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151243 CVCL_TY49 HAP1 ZAK (-) 1 cancer cell line human CVCL_TY49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17797; MAP3K20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151244 CVCL_2412 COR-L311 cancer cell line human CVCL_2412 Genome ancestry: African=1.93%; Native American=0%; East Asian, North=2.41%; East Asian, South=0%; South Asian=0%; European, North=61.29%; European, South=34.37% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser82Ter (c.245C>A); ClinVar=VCV000837710; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920-1G>A (IVS8-1G>A); ClinVar=VCV000141377; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21151245 CVCL_1S12 GM11022 hybrid cell line CVCL_1S12 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151246 CVCL_2413 COR-L32 cancer cell line human CVCL_2413 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.46%; East Asian, South=0%; South Asian=0%; European, North=70.96%; European, South=27.58% (PubMed=30894373) CL:0000010 Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21151247 CVCL_1S13 GM11023 hybrid cell line CVCL_1S13 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151248 CVCL_2410 COR-L26 cancer cell line human CVCL_2410 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293) CL:0000010 Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21151249 CVCL_1S10 GM10926 hybrid cell line human CVCL_1S10 CL:0000010 Characteristics: Hybrid for chromosome 10 mapping Contains a complete copy of chromosome 10.. Group: Human/rodent somatic cell hybrid 21151250 CVCL_2411 COR-L303 cancer cell line human CVCL_2411 Genome ancestry: African=1.07%; Native American=0.33%; East Asian, North=2.4%; East Asian, South=0%; South Asian=0%; European, North=68.04%; European, South=28.16% (PubMed=30894373). CL:0000010 Population: Caucasian Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~5 days (ECACC=96020722); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21151251 CVCL_1S11 GM11010 hybrid cell line human CVCL_1S11 CL:0000010 Characteristics: Hybrid for chromosome 18 mapping Contains a complete copy of chromosome 18.. Group: Human/rodent somatic cell hybrid 21151252 CVCL_2416 COR-L51 cancer cell line human CVCL_2416 Genome ancestry: African=3.99%; Native American=0%; East Asian, North=3.95%; East Asian, South=0%; South Asian=0%; European, North=54.28%; European, South=37.79% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe134Cys (c.401T>G); ClinVar=VCV000230477; Zygosity=Heterozygous (DepMap) Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151253 CVCL_1S16 GM11172 hybrid cell line human CVCL_1S16 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151254 CVCL_2417 COR-L64 cancer cell line human CVCL_2417 CL:0000010 Derived from metastatic site: Bone marrow. Male 21151255 CVCL_1S17 GM11173 hybrid cell line human CVCL_1S17 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151256 CVCL_2414 COR-L321 cancer cell line human CVCL_2414 Genome ancestry: African=0%; Native American=0%; East Asian, North=0.7%; East Asian, South=0%; South Asian=0%; European, North=67.03%; European, South=32.26% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21151257 CVCL_1S14 GM11087 hybrid cell line CVCL_1S14 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151258 CVCL_2415 COR-L47 cancer cell line human CVCL_2415 HLA typing: A*03:01,03:01; B*08:01,37:04; C*07:01,07:01 (PubMed=25960936); HLA typing: A*03:01,03:01; B*08:01,18:01; C*07:01,07:01 (PubMed=26589293); Genome ancestry: African=1.67%; Native American=0.43%; East Asian, North=2.28%; East Asian, South=0%; South Asian=1.16%; European, North=59.47%; European, South=34.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu18Ter (c.52G>T); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151259 CVCL_1S15 GM11130 hybrid cell line CVCL_1S15 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151260 CVCL_2418 COR-L95 cancer cell line human CVCL_2418 HLA typing: A*03:01,24:02; B*35:03,35:03; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0.63%; Native American=0%; East Asian, North=1.84%; East Asian, South=0%; South Asian=0%; European, North=66.43%; European, South=31.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265-1G>A; Zygosity=Homozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (Cosmic-CLP; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21151261 CVCL_1S18 GM11220 hybrid cell line human CVCL_1S18 CL:0000010 Discontinued: Coriell; GM11220; probable. Group: Human/rodent somatic cell hybrid 21151262 CVCL_2419 COV318 cancer cell line human CVCL_2419 HLA typing: A*02:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.46%; East Asian, South=0%; South Asian=0.55%; European, North=70.13%; European, South=27.85% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Phe (c.583A>T); ClinVar=VCV000376617; Zygosity=Unspecified (PubMed=25230021; PubMed=28273451) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 50 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21151263 CVCL_1S19 GM11221 hybrid cell line CVCL_1S19 CL:0000010 Discontinued: Coriell; GM11221; probable. Group: Human/rodent somatic cell hybrid 21151264 CVCL_CG14 ND05482 transformed cell line human CVCL_CG14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151265 CVCL_CG15 ND05498 transformed cell line human CVCL_CG15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151266 CVCL_CG12 ND05460 transformed cell line human CVCL_CG12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151267 CVCL_CG13 ND05462 transformed cell line human CVCL_CG13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151268 CVCL_CG18 ND05520 transformed cell line human CVCL_CG18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151269 CVCL_CG19 ND05535 transformed cell line human CVCL_CG19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151270 CVCL_CG16 ND05499 transformed cell line human CVCL_CG16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151271 CVCL_CG17 ND05502 transformed cell line human CVCL_CG17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151272 CVCL_CG10 ND05425 transformed cell line human CVCL_CG10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151273 CVCL_CG11 ND05426 transformed cell line human CVCL_CG11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151274 CVCL_CG25 ND05585 transformed cell line human CVCL_CG25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151275 CVCL_CG26 ND05598 transformed cell line human CVCL_CG26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151276 CVCL_CG23 ND05560 transformed cell line human CVCL_CG23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151277 CVCL_CG24 ND05583 transformed cell line human CVCL_CG24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151278 CVCL_CG29 ND05607 transformed cell line human CVCL_CG29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151279 CVCL_CG27 ND05602 transformed cell line human CVCL_CG27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151280 CVCL_CG28 ND05603 transformed cell line human CVCL_CG28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151281 CVCL_CG21 ND05556 transformed cell line human CVCL_CG21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151282 CVCL_CG22 ND05558 transformed cell line human CVCL_CG22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151283 CVCL_CG20 ND05545 transformed cell line human CVCL_CG20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151284 CVCL_CG09 ND05416 transformed cell line human CVCL_CG09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151285 CVCL_CG03 ND05387 transformed cell line human CVCL_CG03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151286 CVCL_CG04 ND05393 transformed cell line human CVCL_CG04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151287 CVCL_CG01 ND05385 transformed cell line human CVCL_CG01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151288 CVCL_CG02 ND05386 transformed cell line human CVCL_CG02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151289 CVCL_CG07 ND05404 transformed cell line human CVCL_CG07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151290 CVCL_CG08 ND05415 transformed cell line human CVCL_CG08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151291 CVCL_CG05 ND05394 transformed cell line human CVCL_CG05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151292 CVCL_CG06 ND05401 transformed cell line human CVCL_CG06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151293 CVCL_CG00 ND05375 transformed cell line human CVCL_CG00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151294 CVCL_1S92 GM15292 hybrid cell line CVCL_1S92 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151295 CVCL_2492 HL finite cell line human CVCL_2492 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21151296 CVCL_1S93 GM15296 hybrid cell line CVCL_1S93 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151297 CVCL_2493 HL-60 clone 15 cancer cell line human CVCL_2493 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21151298 CVCL_1S90 GM14855 hybrid cell line CVCL_1S90 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151299 CVCL_2490 HG-261 finite cell line human CVCL_2490 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00062; probable; Discontinued: ECACC; 90112603; probable; Discontinued: ECACC; 93120823; probable Male 21151300 CVCL_1S91 GM15113 hybrid cell line CVCL_1S91 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151301 CVCL_2491 HH-8 transformed cell line human CVCL_2491 CL:0000010 Transfected with: HGNC; 1390; CACNA1C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: ECACC; 99090226; probable Female 21151302 CVCL_1S85 GM14065 hybrid cell line human CVCL_1S85 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151303 CVCL_2485 HeLa9903 cancer cell line human CVCL_2485 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21151304 CVCL_1S86 GM14415 hybrid cell line human CVCL_1S86 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151305 CVCL_2486 HEPM finite cell line human CVCL_2486 CL:0000010 Derived from sampling site: Fetal oral cavity; palate Cell type=Mesenchymal cell.. Female Doubling time: 25-30 hours (PubMed=1282915) 21151306 CVCL_1S83 GM14050 hybrid cell line CVCL_1S83 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151307 CVCL_2483 HeLa DH cancer cell line human CVCL_2483 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21151308 CVCL_1S84 GM14064 hybrid cell line human CVCL_1S84 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151309 CVCL_2484 HeLa Ohio cancer cell line human CVCL_2484 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21151310 CVCL_1S89 JWR-22h hybrid cell line CVCL_1S89 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151311 CVCL_2489 HFFF2 finite cell line human CVCL_2489 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at ~16 PDL (ECACC=86031405) 21151312 CVCL_1S87 GM14849 hybrid cell line CVCL_1S87 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151313 CVCL_2487 HF19 finite cell line human CVCL_2487 CL:0000010 Derived from sampling site: Fetal lung. Female Senescence: Senesces at 16 PDL (PubMed=17395773); Doubling time: 24 hours (PubMed=8609460) 21151314 CVCL_1S88 GM14853 hybrid cell line CVCL_1S88 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151315 CVCL_2488 HF2x653 hybrid cell line CVCL_2488 CL:0000010 Group: Hybridoma fusion partner cell line. 21151316 CVCL_1S96 GM15302 hybrid cell line CVCL_1S96 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151317 CVCL_2496 HL60 Ast.4 cancer cell line human CVCL_2496 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Astatine-211 alpha radiation(NCIt; C129638); Derived from sampling site: Peripheral blood. Female 21151318 CVCL_1S97 GM15776 hybrid cell line human CVCL_1S97 CL:0000010 Discontinued: Coriell; GM15776; probable. Group: Human/rodent somatic cell hybrid 21151319 CVCL_2497 HL60 M2 cancer cell line human CVCL_2497 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21151320 CVCL_1S94 GM15297 hybrid cell line CVCL_1S94 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151321 CVCL_2494 HL-60 clone 15-12 cancer cell line human CVCL_2494 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21151322 CVCL_1S95 GM15301 hybrid cell line CVCL_1S95 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151323 CVCL_2495 HL60 Ast.3 cancer cell line human CVCL_2495 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Astatine-211 alpha radiation(NCIt; C129638); Derived from sampling site: Peripheral blood. Female 21151324 CVCL_1S98 GM16245 hybrid cell line human CVCL_1S98 CL:0000010 Group: Human/rodent somatic cell hybrid. 21151325 CVCL_2498 HL60 M4 cancer cell line human CVCL_2498 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21151326 CVCL_2499 HMT-3522 S1 spontaneously immortalized cell line human CVCL_2499 CL:0000010 Population: Caucasian; Donor information: Established from a nontumorigenic fibrocystic breast lesion (from parent cell line); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 40.14 hours (GrayJW panel) Part of: GrayJW breast cancer cell line panel 21151327 CVCL_1S99 UPMC cancer cell line human CVCL_1S99 CL:0000010 Derived from sampling site: Brain. Female 21151328 CVCL_CF80 ND05259 transformed cell line human CVCL_CF80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151329 CVCL_CF81 ND05270 transformed cell line human CVCL_CF81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151330 CVCL_CF79 ND05257 transformed cell line human CVCL_CF79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151331 CVCL_CF73 ND05221 transformed cell line human CVCL_CF73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151332 CVCL_CF74 ND05222 transformed cell line human CVCL_CF74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151333 CVCL_CF71 ND05215 transformed cell line human CVCL_CF71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151334 CVCL_CF72 ND05220 transformed cell line human CVCL_CF72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151335 CVCL_CF77 ND05254 transformed cell line human CVCL_CF77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151336 CVCL_CF78 ND05255 transformed cell line human CVCL_CF78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151337 CVCL_CF75 ND05223 transformed cell line human CVCL_CF75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151338 CVCL_CF76 ND05224 transformed cell line human CVCL_CF76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151339 CVCL_CF91 ND05322 transformed cell line human CVCL_CF91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151340 CVCL_CF92 ND05331 transformed cell line human CVCL_CF92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151341 CVCL_CF90 ND05304 transformed cell line human CVCL_CF90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151342 CVCL_CF84 ND05287 transformed cell line human CVCL_CF84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151343 CVCL_CF85 ND05293 transformed cell line human CVCL_CF85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151344 CVCL_CF82 ND05271 transformed cell line human CVCL_CF82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151345 CVCL_CF83 ND05272 transformed cell line human CVCL_CF83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151346 CVCL_CF88 ND05302 transformed cell line human CVCL_CF88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151347 CVCL_CF89 ND05303 transformed cell line human CVCL_CF89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151348 CVCL_CF86 ND05300 transformed cell line human CVCL_CF86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151349 CVCL_CF87 ND05301 transformed cell line human CVCL_CF87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151350 CVCL_CF59 ND05170 transformed cell line human CVCL_CF59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151351 CVCL_CF57 ND05164 transformed cell line human CVCL_CF57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151352 CVCL_CF58 ND05167 transformed cell line human CVCL_CF58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151353 CVCL_CF51 ND05113 transformed cell line human CVCL_CF51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151354 CVCL_CF52 ND05119 transformed cell line human CVCL_CF52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151355 CVCL_CF50 ND05112 transformed cell line human CVCL_CF50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151356 CVCL_CF55 ND05150 transformed cell line human CVCL_CF55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151357 CVCL_CF56 ND05163 transformed cell line human CVCL_CF56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151358 CVCL_CF53 ND05121 transformed cell line human CVCL_CF53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151359 CVCL_CF54 ND05122 transformed cell line human CVCL_CF54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151360 CVCL_CF70 ND05214 transformed cell line human CVCL_CF70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151361 CVCL_CF68 ND05193 transformed cell line human CVCL_CF68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151362 CVCL_CF69 ND05200 transformed cell line human CVCL_CF69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151363 CVCL_CF62 ND05181 transformed cell line human CVCL_CF62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151364 CVCL_CF63 ND05182 transformed cell line human CVCL_CF63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151365 CVCL_CF60 ND05171 transformed cell line human CVCL_CF60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151366 CVCL_CF61 ND05178 transformed cell line human CVCL_CF61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151367 CVCL_CF66 ND05191 transformed cell line human CVCL_CF66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151368 CVCL_CF67 ND05192 transformed cell line human CVCL_CF67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151369 CVCL_CF64 ND05189 transformed cell line human CVCL_CF64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151370 CVCL_CF65 ND05190 transformed cell line human CVCL_CF65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151371 CVCL_CF37 ND05064 transformed cell line human CVCL_CF37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151372 CVCL_CF38 ND05069 transformed cell line human CVCL_CF38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151373 CVCL_CF35 ND05055 transformed cell line human CVCL_CF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151374 CVCL_CF36 ND05056 transformed cell line human CVCL_CF36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151375 CVCL_CF39 ND05072 transformed cell line human CVCL_CF39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151376 CVCL_CF30 ND05019 transformed cell line human CVCL_CF30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151377 CVCL_CF33 ND05053 transformed cell line human CVCL_CF33 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151378 CVCL_CF34 ND05054 transformed cell line human CVCL_CF34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151379 CVCL_CF31 ND05030 transformed cell line human CVCL_CF31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151380 CVCL_CF32 ND05051 transformed cell line human CVCL_CF32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151381 CVCL_CF48 ND05106 transformed cell line human CVCL_CF48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151382 CVCL_CF49 ND05107 transformed cell line human CVCL_CF49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151383 CVCL_CF46 ND05101 transformed cell line human CVCL_CF46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151384 CVCL_CF47 ND05105 transformed cell line human CVCL_CF47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151385 CVCL_CF40 ND05076 transformed cell line human CVCL_CF40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151386 CVCL_CF41 ND05078 transformed cell line human CVCL_CF41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151387 CVCL_CF44 ND05081 transformed cell line human CVCL_CF44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151388 CVCL_CF45 ND05092 transformed cell line human CVCL_CF45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151389 CVCL_CF42 ND05079 transformed cell line human CVCL_CF42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151390 CVCL_CF43 ND05080 transformed cell line human CVCL_CF43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151391 CVCL_CF15 ND04956 transformed cell line human CVCL_CF15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151392 CVCL_CF16 ND04957 transformed cell line human CVCL_CF16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151393 CVCL_CF13 ND04933 transformed cell line human CVCL_CF13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151394 CVCL_CF14 ND04947 transformed cell line human CVCL_CF14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151395 CVCL_CF19 ND04972 transformed cell line human CVCL_CF19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151396 CVCL_CF17 ND04958 transformed cell line human CVCL_CF17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151397 CVCL_CF18 ND04959 transformed cell line human CVCL_CF18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151398 CVCL_CF11 ND04916 transformed cell line human CVCL_CF11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151399 CVCL_CF12 ND04932 transformed cell line human CVCL_CF12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151400 CVCL_CF10 ND04898 transformed cell line human CVCL_CF10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151401 CVCL_CF26 ND05012 transformed cell line human CVCL_CF26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151402 CVCL_CF27 ND05015 transformed cell line human CVCL_CF27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151403 CVCL_CF24 ND05009 transformed cell line human CVCL_CF24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151404 CVCL_CF25 ND05011 transformed cell line human CVCL_CF25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151405 CVCL_CF28 ND05017 transformed cell line human CVCL_CF28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151406 CVCL_CF29 ND05018 transformed cell line human CVCL_CF29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151407 CVCL_CF22 ND04983 transformed cell line human CVCL_CF22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151408 CVCL_CF23 ND04985 transformed cell line human CVCL_CF23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151409 CVCL_CF20 ND04975 transformed cell line human CVCL_CF20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151410 CVCL_CF21 ND04982 transformed cell line human CVCL_CF21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151411 CVCL_TY31 HAP1 XBP1 (-) 2 cancer cell line human CVCL_TY31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12801; XBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151412 CVCL_TY32 HAP1 XKR8 (-) 1 cancer cell line human CVCL_TY32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25508; XKR8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151413 CVCL_TY30 HAP1 XBP1 (-) 1 cancer cell line human CVCL_TY30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12801; XBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151414 CVCL_TY35 HAP1 XPC (-) 1 cancer cell line human CVCL_TY35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151415 CVCL_TY36 HAP1 XPC (-) 2 cancer cell line human CVCL_TY36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151416 CVCL_TY33 HAP1 XPA (-) 1 cancer cell line human CVCL_TY33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12814; XPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151417 CVCL_TY34 HAP1 XPA (-) 2 cancer cell line human CVCL_TY34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12814; XPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151418 CVCL_TY39 HAP1 XPR1 (-) 2 cancer cell line human CVCL_TY39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12827; XPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151419 CVCL_TY37 HAP1 XPC (-) 3 cancer cell line human CVCL_TY37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12816; XPC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151420 CVCL_TY38 HAP1 XPR1 (-) 1 cancer cell line human CVCL_TY38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12827; XPR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151421 CVCL_TY20 HAP1 WT1 (-) 1 cancer cell line human CVCL_TY20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12796; WT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151422 CVCL_TY21 HAP1 WT1 (-) 2 cancer cell line human CVCL_TY21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12796; WT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151423 CVCL_TY24 HAP1 WTAP (-) 2 cancer cell line human CVCL_TY24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16846; WTAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151424 CVCL_TY25 HAP1 WTAP (-) 3 cancer cell line human CVCL_TY25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16846; WTAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151425 CVCL_TY22 HAP1 WT1 (-) 3 cancer cell line human CVCL_TY22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12796; WT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151426 CVCL_TY23 HAP1 WTAP (-) 1 cancer cell line human CVCL_TY23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16846; WTAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151427 CVCL_TY28 HAP1 WWP1 (-) 2 cancer cell line human CVCL_TY28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17004; WWP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151428 CVCL_TY29 HAP1 WWTR1 (-) 1 cancer cell line human CVCL_TY29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151429 CVCL_TY26 HAP1 WWOX (-) 1 cancer cell line human CVCL_TY26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12799; WWOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151430 CVCL_TY27 HAP1 WWP1 (-) 1 cancer cell line human CVCL_TY27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17004; WWP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151431 CVCL_TY10 HAP1 WNK2 (-) 2 cancer cell line human CVCL_TY10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14542; WNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151432 CVCL_TY13 HAP1 WNK3 (-) 3 cancer cell line human CVCL_TY13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14543; WNK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151433 CVCL_TY14 HAP1 WNK3 (-) 4 cancer cell line human CVCL_TY14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14543; WNK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151434 CVCL_TY11 HAP1 WNK3 (-) 1 cancer cell line human CVCL_TY11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14543; WNK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151435 CVCL_TY12 HAP1 WNK3 (-) 2 cancer cell line human CVCL_TY12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14543; WNK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151436 CVCL_TY17 HAP1 WNK4 (-) 2 cancer cell line human CVCL_TY17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14544; WNK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151437 CVCL_TY18 HAP1 WRN (-) 1 cancer cell line human CVCL_TY18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12791; WRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151438 CVCL_TY15 HAP1 WNK3 (-) 5 cancer cell line human CVCL_TY15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14543; WNK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151439 CVCL_TY16 HAP1 WNK4 (-) 1 cancer cell line human CVCL_TY16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14544; WNK4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151440 CVCL_TY19 HAP1 WRN (-) 2 cancer cell line human CVCL_TY19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12791; WRN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151441 CVCL_TY02 HAP1 WHSC1L1 (-) 1 cancer cell line human CVCL_TY02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12767; NSD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151442 CVCL_TY03 HAP1 WHSC1L1 (-) 2 cancer cell line human CVCL_TY03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12767; NSD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151443 CVCL_TY00 HAP1 WHAMM (-) 4 cancer cell line human CVCL_TY00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30493; WHAMM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151444 CVCL_TY01 HAP1 WHSC1 (-) 1 cancer cell line human CVCL_TY01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151445 CVCL_TY06 HAP1 WNK1 (-) 2 cancer cell line human CVCL_TY06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14540; WNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151446 CVCL_TY07 HAP1 WNK1 (-) 3 cancer cell line human CVCL_TY07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14540; WNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151447 CVCL_TY04 HAP1 WIPI2 (-) 1 cancer cell line human CVCL_TY04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32225; WIPI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151448 CVCL_TY05 HAP1 WNK1 (-) 1 cancer cell line human CVCL_TY05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14540; WNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151449 CVCL_TY08 HAP1 WNK1 (-) 4 cancer cell line human CVCL_TY08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14540; WNK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151450 CVCL_TY09 HAP1 WNK2 (-) 1 cancer cell line human CVCL_TY09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14542; WNK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21151451 CVCL_CF95 ND05336 transformed cell line human CVCL_CF95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151452 CVCL_CF96 ND05337 transformed cell line human CVCL_CF96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151453 CVCL_CF93 ND05332 transformed cell line human CVCL_CF93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151454 CVCL_CF94 ND05333 transformed cell line human CVCL_CF94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151455 CVCL_CF99 ND05373 transformed cell line human CVCL_CF99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151456 CVCL_CF97 ND05364 transformed cell line human CVCL_CF97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151457 CVCL_CF98 ND05366 transformed cell line human CVCL_CF98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151458 CVCL_LJ52 tsET24 spontaneously immortalized cell line CVCL_LJ52 CL:0000010 Sequence variation: Mutation; UniProtKB; Q8K5D5; Ddx3x; Simple; p.Pro267Ser (c.799C>T); Zygosity=Unspecified (PubMed=12944373) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Kidney. Male Characteristics: Temperature sensitive At the non-permissive temperature of 39.5 Celsius, this cell line is arrested in the G1-phase and survives for more than 3 days. 21151459 CVCL_LJ53 BUG cancer cell line human CVCL_LJ53 CL:0000010 Unspecified Characteristics: Produces IgA lambda; Characteristics: IL6 dependent. 21151460 CVCL_LJ50 DEMF finite cell line pig CVCL_LJ50 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Duroc. Female Doubling time: ~26 hours (CelloPub=CLPUB00405) 21151461 CVCL_LJ51 1764EL spontaneously immortalized cell line Norway rat CVCL_LJ51 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21151462 CVCL_LJ49 QBC939/ADM cancer cell line human CVCL_LJ49 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Male Doubling time: 32.2 hours (PubMed=20111907) 21151463 CVCL_LJ47 HB1.F3.Ngn1 transformed cell line human CVCL_LJ47 CL:0000010 Transfected with: HGNC; 7764; NEUROG1; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Omics: Transcriptome analysis by microarray Female 21151464 CVCL_LJ48 HB1.F3.Ras transformed cell line human CVCL_LJ48 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Omics: Transcriptome analysis by microarray Female Characteristics: Tumorigenic, forms brain cancers when injected in mouse brains 21151465 CVCL_LJ45 HB1.F3.CD21 transformed cell line human CVCL_LJ45 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Female 21151466 CVCL_LJ46 HB1.F3.EGFRviii transformed cell line human CVCL_LJ46 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Female 21151467 CVCL_LJ43 HCC930599 cancer cell line dog CVCL_LJ43 CL:0000010 Breed/subspecies: Maltese. Female 21151468 CVCL_LJ44 HB1.F3 transformed cell line human CVCL_LJ44 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Fetal brain; telencephalon. Omics: Transcriptome analysis by microarray Female 21151469 CVCL_LJ63 BEAS-2B/S6 transformed cell line human CVCL_LJ63 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9867 21151470 CVCL_LJ64 BEAS-2B/c-myc transformed cell line human CVCL_LJ64 CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9869 21151471 CVCL_LJ61 BEAS-2B/EJ-ras transformed cell line human CVCL_LJ61 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9866 21151472 CVCL_LJ62 BEAS-2B/N-ras transformed cell line human CVCL_LJ62 CL:0000010 Transfected with: HGNC; 7989; NRAS (with p.Gly12Asp); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9870 21151473 CVCL_LJ60 BVK-Tll transformed cell line human CVCL_LJ60 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9871 21151474 CVCL_LJ58 SV2-61 hybridoma house mouse CVCL_LJ58 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. 21151475 CVCL_LJ59 SV2-61r hybridoma house mouse CVCL_LJ59 CL:0000010 Characteristics: Isotype switched derivative of SV2-61; Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. 21151476 CVCL_LJ56 HAE-3 hybridoma house mouse CVCL_LJ56 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q5SSG8; Human MUC21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9467 21151477 CVCL_LJ57 HAE-4 hybridoma house mouse CVCL_LJ57 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q5SSG8; Human MUC21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9468 21151478 CVCL_LJ54 NRCAN-Tb521 spontaneously immortalized cell line CVCL_LJ54 CL:0000010 Unspecified Doubling time: 255 hours, at 22th passage (PubMed=25952767). Group: Insect cell line 21151479 CVCL_LJ55 HAE-1 hybridoma house mouse CVCL_LJ55 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q5SSG8; Human MUC21. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9466 21151480 CVCL_LJ30 HT-29/B6 cancer cell line human CVCL_LJ30 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Derived from a glucose-free culture of HT-29 21151481 CVCL_LJ31 CHARGE1-11 induced pluripotent stem cell human CVCL_LJ31 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1391fs*13 (c.4171delC); Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151482 CVCL_D199 Ishikawa 3-H-12 cancer cell line human CVCL_D199 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 24.0 hours (PubMed=9183638) 21151483 CVCL_CP99 ND15845 transformed cell line human CVCL_CP99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151484 CVCL_CP93 ND15812 transformed cell line human CVCL_CP93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151485 CVCL_D193 S49.1TB4.1A cancer cell line house mouse CVCL_D193 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21151486 CVCL_CP94 ND15813 transformed cell line human CVCL_CP94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151487 CVCL_D194 S49.22R cancer cell line house mouse CVCL_D194 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21151488 CVCL_CP91 ND15808 transformed cell line human CVCL_CP91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151489 CVCL_D191 S49.13R cancer cell line house mouse CVCL_D191 CL:0000010 Breed/subspecies: BALB/c. 21151490 CVCL_CP92 ND15811 transformed cell line human CVCL_CP92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151491 CVCL_D192 S49.143R cancer cell line house mouse CVCL_D192 CL:0000010 Breed/subspecies: BALB/c. 21151492 CVCL_CP97 ND15835 transformed cell line human CVCL_CP97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151493 CVCL_D197 S49.A2 cancer cell line house mouse CVCL_D197 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21151494 CVCL_CP98 ND15838 transformed cell line human CVCL_CP98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151495 CVCL_D198 S49 Kin- cancer cell line house mouse CVCL_D198 CL:0000010 Breed/subspecies: BALB/c. 21151496 CVCL_LJ29 CW70161 induced pluripotent stem cell human CVCL_LJ29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70161; true Male 21151497 CVCL_CP95 ND15821 transformed cell line human CVCL_CP95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151498 CVCL_D195 S49.55R cancer cell line house mouse CVCL_D195 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21151499 CVCL_CP96 ND15822 transformed cell line human CVCL_CP96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151500 CVCL_D196 S49.75R cancer cell line house mouse CVCL_D196 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. 21151501 CVCL_LJ27 CW60421 induced pluripotent stem cell human CVCL_LJ27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60421; true Male 21151502 CVCL_LJ28 CW60503 induced pluripotent stem cell human CVCL_LJ28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60503; true Female 21151503 CVCL_LJ25 CW60288 induced pluripotent stem cell human CVCL_LJ25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60288; true Female 21151504 CVCL_LJ26 CW60296 induced pluripotent stem cell human CVCL_LJ26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60296; true Female 21151505 CVCL_LJ23 CW60267 induced pluripotent stem cell human CVCL_LJ23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60267; true Male 21151506 CVCL_LJ24 CW60281 induced pluripotent stem cell human CVCL_LJ24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60281; true Female 21151507 CVCL_CP90 ND15807 transformed cell line human CVCL_CP90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151508 CVCL_LJ21 CW60231 induced pluripotent stem cell human CVCL_LJ21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60231; true Male 21151509 CVCL_LJ22 CW60263 induced pluripotent stem cell human CVCL_LJ22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60263; true Male 21151510 CVCL_LJ41 WDT2 induced pluripotent stem cell human CVCL_LJ41 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21151511 CVCL_LJ42 LM-NSC008 somatic stem cell human CVCL_LJ42 CL:0000010 Transfected with: HGNC; 7555; MYCL; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Fetal brain Cell type=Neural stem cell.. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~30 hours (PubMed=27546534) 21151512 CVCL_LJ40 WA29 induced pluripotent stem cell human CVCL_LJ40 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21151513 CVCL_LJ38 1210B2 induced pluripotent stem cell human CVCL_LJ38 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21151514 CVCL_LJ39 1231A3 induced pluripotent stem cell human CVCL_LJ39 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21151515 CVCL_LJ36 692E1 induced pluripotent stem cell human CVCL_LJ36 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21151516 CVCL_LJ37 1201C1 induced pluripotent stem cell human CVCL_LJ37 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21151517 CVCL_LJ34 CHARGE2-16 induced pluripotent stem cell human CVCL_LJ34 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Arg1494Ter (c.4480C>T); ClinVar=VCV000158296; Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151518 CVCL_LJ35 CHARGE2-19 induced pluripotent stem cell human CVCL_LJ35 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Arg1494Ter (c.4480C>T); ClinVar=VCV000158296; Zygosity=Heterozygous (PubMed=29179815) Miscellaneous: Cell line information from personal communication of Okuno H Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151519 CVCL_LJ32 CHARGE1-7 induced pluripotent stem cell human CVCL_LJ32 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1391fs*13 (c.4171delC); Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151520 CVCL_LJ33 CHARGE2-1 induced pluripotent stem cell human CVCL_LJ33 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Arg1494Ter (c.4480C>T); ClinVar=VCV000158296; Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151521 CVCL_D179 iMPD183.C2 induced pluripotent stem cell human CVCL_D179 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151522 CVCL_CP79 ND15713 transformed cell line human CVCL_CP79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151523 CVCL_D177 CH1 [Human ESC] embryonic stem cell human CVCL_D177 From: Peking University; Beijing; China. CL:0000010 Female 21151524 CVCL_CP77 ND15708 transformed cell line human CVCL_CP77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151525 CVCL_D178 iMPD183.C1 induced pluripotent stem cell human CVCL_D178 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151526 CVCL_CP78 ND15710 transformed cell line human CVCL_CP78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151527 CVCL_D171 DA-3/sec cancer cell line house mouse CVCL_D171 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21151528 CVCL_CP71 ND15655 transformed cell line human CVCL_CP71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151529 CVCL_D172 DA-3/TM cancer cell line house mouse CVCL_D172 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21151530 CVCL_CP72 ND15665 transformed cell line human CVCL_CP72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151531 CVCL_CP70 ND15640 transformed cell line human CVCL_CP70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151532 CVCL_D170 OVXF 899L cancer cell line human CVCL_D170 CL:0000010 Female 21151533 CVCL_LJ09 CW60166 induced pluripotent stem cell human CVCL_LJ09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60166; true Male 21151534 CVCL_CP75 ND15685 transformed cell line human CVCL_CP75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151535 CVCL_D175 RW-7213 cancer cell line human CVCL_D175 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val1320fs*12 (c.3957_3958insT); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21151536 CVCL_CP76 ND15690 transformed cell line human CVCL_CP76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151537 CVCL_D176 RW-5928 cancer cell line human CVCL_D176 CL:0000010 Derived from sampling site: Cecum. Male 21151538 CVCL_LJ07 CW60157 induced pluripotent stem cell human CVCL_LJ07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60157; true Female 21151539 CVCL_D173 DA-3/neo cancer cell line house mouse CVCL_D173 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21151540 CVCL_CP73 ND15666 transformed cell line human CVCL_CP73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151541 CVCL_LJ08 CW60163 induced pluripotent stem cell human CVCL_LJ08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60163; true Female 21151542 CVCL_CP74 ND15679 transformed cell line human CVCL_CP74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151543 CVCL_D174 RW-2982 cancer cell line human CVCL_D174 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Ter (c.3925G>T); ClinVar=VCV000824390; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Cys363Tyr (c.1088G>A); ClinVar=VCV000233663; Zygosity=Unspecified (PubMed=24755471) Population: Caucasian; Derived from metastatic site: Omentum. Omics: Transcriptome analysis by RNAseq Male 21151544 CVCL_LJ05 CW60144 induced pluripotent stem cell human CVCL_LJ05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60144; true Female 21151545 CVCL_LJ06 CW60146 induced pluripotent stem cell human CVCL_LJ06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60146; true Male 21151546 CVCL_LJ03 CW60135 induced pluripotent stem cell human CVCL_LJ03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60135; true Male 21151547 CVCL_LJ04 CW60139 induced pluripotent stem cell human CVCL_LJ04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60139; true Female 21151548 CVCL_LJ01 CW60117 induced pluripotent stem cell human CVCL_LJ01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Native North American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60117; true Male 21151549 CVCL_LJ02 CW60124 induced pluripotent stem cell human CVCL_LJ02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60124; true Female 21151550 CVCL_LJ00 CW60107 induced pluripotent stem cell human CVCL_LJ00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60107; true Male 21151551 CVCL_LJ20 CW60227 induced pluripotent stem cell human CVCL_LJ20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60227; true Female 21151552 CVCL_D188 iMPD562.C3 induced pluripotent stem cell human CVCL_D188 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151553 CVCL_CP88 ND15801 transformed cell line human CVCL_CP88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151554 CVCL_D189 LXFA 629L cancer cell line human CVCL_D189 CL:0000010 21151555 CVCL_CP89 ND15802 transformed cell line human CVCL_CP89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151556 CVCL_D182 iMPD183.C6 induced pluripotent stem cell human CVCL_D182 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151557 CVCL_CP82 ND15745 transformed cell line human CVCL_CP82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151558 CVCL_D183 iMPD183.C7 induced pluripotent stem cell human CVCL_D183 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151559 CVCL_CP83 ND15752 transformed cell line human CVCL_CP83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151560 CVCL_D180 iMPD183.C3 induced pluripotent stem cell human CVCL_D180 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151561 CVCL_CP80 ND15718 transformed cell line human CVCL_CP80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151562 CVCL_D181 iMPD183.C5 induced pluripotent stem cell human CVCL_D181 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151563 CVCL_CP81 ND15735 transformed cell line human CVCL_CP81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151564 CVCL_D186 iMPD183.C11 induced pluripotent stem cell human CVCL_D186 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151565 CVCL_CP86 ND15798 transformed cell line human CVCL_CP86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151566 CVCL_D187 iMPD562.C2 induced pluripotent stem cell human CVCL_D187 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151567 CVCL_CP87 ND15799 transformed cell line human CVCL_CP87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151568 CVCL_LJ18 CW60213 induced pluripotent stem cell human CVCL_LJ18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60213; true Female 21151569 CVCL_D184 iMPD183.C8 induced pluripotent stem cell human CVCL_D184 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151570 CVCL_CP84 ND15755 transformed cell line human CVCL_CP84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151571 CVCL_LJ19 CW60218 induced pluripotent stem cell human CVCL_LJ19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60218; true Male 21151572 CVCL_D185 iMPD183.C10 induced pluripotent stem cell human CVCL_D185 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Heterozygous (PubMed=19797525) Derived from sampling site: Peripheral blood. Female 21151573 CVCL_CP85 ND15780 transformed cell line human CVCL_CP85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151574 CVCL_LJ16 CW60200 induced pluripotent stem cell human CVCL_LJ16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60200; true Female 21151575 CVCL_LJ17 CW60207 induced pluripotent stem cell human CVCL_LJ17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60207; true Male 21151576 CVCL_LJ14 CW60190 induced pluripotent stem cell human CVCL_LJ14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60190; true Female 21151577 CVCL_LJ15 CW60195 induced pluripotent stem cell human CVCL_LJ15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60195; true Female 21151578 CVCL_LJ12 CW60181 induced pluripotent stem cell human CVCL_LJ12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60181; true Female 21151579 CVCL_LJ13 CW60186 induced pluripotent stem cell human CVCL_LJ13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60186; true Female 21151580 CVCL_LJ10 CW60167 induced pluripotent stem cell human CVCL_LJ10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60167; true Male 21151581 CVCL_LJ11 CW60168 induced pluripotent stem cell human CVCL_LJ11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60168; true Female 21151582 CVCL_D157 A2780/ACRP cancer cell line human CVCL_D157 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21151583 CVCL_CP57 ND15426 transformed cell line human CVCL_CP57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151584 CVCL_CP58 ND15427 transformed cell line human CVCL_CP58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151585 CVCL_D158 SM5 cancer cell line house mouse CVCL_D158 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Breed/subspecies: C57BL/6J-Trp53tm1Tyj. Omics: Proteome analysis by 2D-DE/MS 21151586 CVCL_CP55 ND15392 transformed cell line human CVCL_CP55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151587 CVCL_D155 TRFK-5 hybridoma CVCL_D155 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. 21151588 CVCL_D156 A2780/ACR6 cancer cell line human CVCL_D156 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21151589 CVCL_CP56 ND15393 transformed cell line human CVCL_CP56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151590 CVCL_CP59 ND15444 transformed cell line human CVCL_CP59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151591 CVCL_D159 SM7 cancer cell line house mouse CVCL_D159 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Breed/subspecies: C57BL/6J-Trp53tm1Tyj. Omics: Proteome analysis by 2D-DE/MS 21151592 CVCL_D150 4C9 [Mouse hybridoma against rat B2m] hybridoma house mouse CVCL_D150 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07151; Rat B2m. 21151593 CVCL_CP50 ND15205 transformed cell line human CVCL_CP50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151594 CVCL_CP53 ND15314 transformed cell line human CVCL_CP53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151595 CVCL_D153 TRFK-2 hybridoma CVCL_D153 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. 21151596 CVCL_CP54 ND15329 transformed cell line human CVCL_CP54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151597 CVCL_D154 TRFK-4 hybridoma CVCL_D154 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. 21151598 CVCL_D151 A2E11 hybridoma house mouse CVCL_D151 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:27584; Aldosterone. 21151599 CVCL_CP51 ND15229 transformed cell line human CVCL_CP51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151600 CVCL_CP52 ND15265 transformed cell line human CVCL_CP52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151601 CVCL_D152 TRFK-1 hybridoma CVCL_D152 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04401; Mouse Il5. 21151602 CVCL_CP68 ND15618 transformed cell line human CVCL_CP68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151603 CVCL_D168 OVXF 1544 cancer cell line human CVCL_D168 CL:0000010 Female 21151604 CVCL_CP69 ND15634 transformed cell line human CVCL_CP69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151605 CVCL_D169 OVXF 1619L cancer cell line human CVCL_D169 CL:0000010 Female 21151606 CVCL_CP66 ND15588 transformed cell line human CVCL_CP66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151607 CVCL_D166 OVXF 1023 cancer cell line human CVCL_D166 CL:0000010 Female 21151608 CVCL_CP67 ND15605 transformed cell line human CVCL_CP67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151609 CVCL_D167 OVXF 1353 cancer cell line human CVCL_D167 CL:0000010 Female 21151610 CVCL_D160 CEC-32 spontaneously immortalized cell line CVCL_D160 CL:0000010 Group: Bird cell line Problematic cell line: Misidentified Originally thought to be of chicken origin but found to be from quail (PubMed=10954914).. 21151611 CVCL_CP60 ND15445 transformed cell line human CVCL_CP60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151612 CVCL_D161 LSCC-H32 spontaneously immortalized cell line CVCL_D161 CL:0000010 Group: Bird cell line Problematic cell line: Misidentified Originally thought to be of chicken origin but found to be from quail (PubMed=10954914).. 21151613 CVCL_CP61 ND15485 transformed cell line human CVCL_CP61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151614 CVCL_CP64 ND15561 transformed cell line human CVCL_CP64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151615 CVCL_D164 RIN-A12 cancer cell line Norway rat CVCL_D164 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 21151616 CVCL_CP65 ND15562 transformed cell line human CVCL_CP65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151617 CVCL_D165 RIN-A13 cancer cell line Norway rat CVCL_D165 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male 21151618 CVCL_D162 K562-Lucena 1 cancer cell line human CVCL_D162 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Pleural effusion. Female 21151619 CVCL_CP62 ND15495 transformed cell line human CVCL_CP62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151620 CVCL_CP63 ND15527 transformed cell line human CVCL_CP63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151621 CVCL_D163 RIN-r cancer cell line Norway rat CVCL_D163 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Established from the transplantable insulinoma RIN; Characteristics: Secretes insulin and somatostatin (PubMed=6106192) 21151622 CVCL_UD70 TVGH-iPSC-024-42 induced pluripotent stem cell human CVCL_UD70 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21151623 CVCL_UD73 RPMI-4098 transformed cell line human CVCL_UD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21151624 CVCL_UD74 OFEC17-FEN spontaneously immortalized cell line CVCL_UD74 CL:0000010 Unspecified Doubling time: 114.34 hours (PubMed=30324159). Group: Fish cell line 21151625 CVCL_UD71 Nalm-6-MSH+/TK+/- cancer cell line human CVCL_UD71 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21151626 CVCL_UD72 KG1 conditionally immortalized cell line house mouse CVCL_UD72 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: Gli1-CreERt2 x R26tdTomato/WT x H-2kbSV40tsA58/WT (Immortomouse) transgenic. Characteristics: Kidney Gli1-positive mesenchymal stem cell-like 21151627 CVCL_UD77 NEC-DUE3 cancer cell line human CVCL_UD77 CL:0000010 Derived from metastatic site: Left inguinal lymph node. Omics: Array-based CGH Female 21151628 CVCL_UD78 HT144A induced pluripotent stem cell human CVCL_UD78 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ala199Cysfs*13 (c.594dupT); ClinVar=VCV000000080; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000000078; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151629 CVCL_UD75 UP-ALL13 cancer cell line human CVCL_UD75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=30304769); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=30304769); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=30304769); Sequence variation: Mutation; HGNC; 2978; DNMT3A; Simple; p.Arg882His (c.2645G>A); ClinVar=VCV000375881; Zygosity=Heterozygous (PubMed=30304769) Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis Male Doubling time: 60-72 hours (PubMed=30304769) 21151630 CVCL_UD76 LREX' cancer cell line human CVCL_UD76 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68534; Enzalutamide (Xtandi; Derived from metastatic site: Left supraclavicular lymph node. Male 21151631 CVCL_UD79 HT144B induced pluripotent stem cell human CVCL_UD79 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ala199Cysfs*13 (c.594dupT); ClinVar=VCV000000080; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000000078; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151632 CVCL_UD62 WG0139 finite cell line human CVCL_UD62 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21151633 CVCL_UD63 WG0321 finite cell line human CVCL_UD63 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4137; GAN; Unexplicit; Ex10-11del; Zygosity=Unspecified (PubMed=17331252) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray 21151634 CVCL_UD60 TCC56 hybridoma house mouse CVCL_UD60 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; Q9H3R2; Human MUC13. 21151635 CVCL_UD61 MCH007 finite cell line human CVCL_UD61 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151636 CVCL_UD66 MCH030 finite cell line human CVCL_UD66 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Female 21151637 CVCL_UD67 IBMS-iPSC-036-01 induced pluripotent stem cell human CVCL_UD67 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Val37Ile (c.109G>A); ClinVar=VCV000017023; Zygosity=Heterozygous (PubMed=30316039) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21151638 CVCL_UD64 WG0791 finite cell line human CVCL_UD64 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4137; GAN; Simple; c.282+3A>C (Ex2del); ClinVar=VCV000637094; Zygosity=Heterozygous (PubMed=17331252); Sequence variation: Mutation; HGNC; 4137; GAN; Simple; p.Ile182Asn (c.545T>A); ClinVar=VCV000637093; Zygosity=Heterozygous (PubMed=17331252) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray 21151639 CVCL_UD65 MCH048 finite cell line human CVCL_UD65 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21151640 CVCL_UD68 HMS-4 cancer cell line human CVCL_UD68 CL:0000010 Female Characteristics: Established from a nude mouse xenograft (HMS-4X) of the original tumor. 21151641 CVCL_UD69 IBMS-iPSC-028-01 induced pluripotent stem cell human CVCL_UD69 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 2719; DDC; Simple; c.714+4A>T (IVS6+4A>T) (IVS6DS,A-T,+4); ClinVar=VCV000864024; Zygosity=Heterozygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21151642 CVCL_UD51 GRA cancer cell line human CVCL_UD51 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 48 hours (PubMed=3182331) 21151643 CVCL_UD52 OW-1 cancer cell line human CVCL_UD52 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 12 hours (PubMed=3182331) 21151644 CVCL_UD50 ATW cancer cell line human CVCL_UD50 CL:0000010 Female 21151645 CVCL_UD55 SKA cancer cell line human CVCL_UD55 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 48 hours (PubMed=3182331) 21151646 CVCL_UD56 HMS-1 cancer cell line human CVCL_UD56 CL:0000010 Derived from sampling site: Salivary gland; parotid gland; myoepithelium. Female Doubling time: 24-36 hours (PubMed=8946227) 21151647 CVCL_UD53 PEA cancer cell line human CVCL_UD53 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 72 hours (PubMed=3182331) 21151648 CVCL_UD54 SAU cancer cell line human CVCL_UD54 CL:0000010 Female Doubling time: 48 hours (PubMed=3182331). 21151649 CVCL_UD59 HMS-3 cancer cell line human CVCL_UD59 CL:0000010 Unspecified Characteristics: Established from a ninth generation nude mouse xenograft (HMS-3X) of the original tumor. 21151650 CVCL_UD57 HMS-XC cancer cell line human CVCL_UD57 CL:0000010 Derived from sampling site: Salivary gland; parotid gland; myoepithelium. Female Characteristics: Established from a fifth generation nude mouse xenograft (HMS-X) of the original tumor 21151651 CVCL_UD58 ZIPi015-K induced pluripotent stem cell human CVCL_UD58 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151652 CVCL_UD40 NS-SV-SC transformed cell line human CVCL_UD40 CL:0000010 Transformant: Simian virus 40 (SV40) [SV40-ori(-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland. Male 21151653 CVCL_UD41 UNC4 cancer cell line human CVCL_UD41 CL:0000010 Population: Caucasian; Derived from sampling site: Salivary gland; minor salivary gland. Female Doubling time: 25 hours (PubMed=8398066) 21151654 CVCL_UD44 HDE/LURF39 spontaneously immortalized cell line CVCL_UD44 CL:0000010 Unspecified Group: Tick cell line. 21151655 CVCL_UD45 HDE/PILS37 spontaneously immortalized cell line CVCL_UD45 CL:0000010 Unspecified Group: Tick cell line. 21151656 CVCL_UD42 ARE/LULS41 spontaneously immortalized cell line CVCL_UD42 CL:0000010 Unspecified Group: Tick cell line. 21151657 CVCL_UD43 BME/PIBB36 spontaneously immortalized cell line CVCL_UD43 CL:0000010 Unspecified Group: Tick cell line. 21151658 CVCL_UD48 REN/PIPA34 spontaneously immortalized cell line CVCL_UD48 CL:0000010 Unspecified Group: Tick cell line. 21151659 CVCL_UD49 LLE/LULS40 spontaneously immortalized cell line CVCL_UD49 CL:0000010 Breed/subspecies: Strain Campo Grande. Unspecified Group: Insect cell line 21151660 CVCL_UD46 HDE/PIPA33 spontaneously immortalized cell line CVCL_UD46 CL:0000010 Unspecified Group: Tick cell line. 21151661 CVCL_UD47 RAE/PIPM38 spontaneously immortalized cell line CVCL_UD47 CL:0000010 Unspecified Group: Tick cell line. 21151662 CVCL_LJ96 CW20299 induced pluripotent stem cell human CVCL_LJ96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20299; true Male 21151663 CVCL_LJ97 CW20300 induced pluripotent stem cell human CVCL_LJ97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20300; true Male 21151664 CVCL_LJ94 HA47T/VGH cancer cell line human CVCL_LJ94 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21151665 CVCL_LJ95 IBMS-iPSC-012-12 induced pluripotent stem cell human CVCL_LJ95 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Ala1458Profs*64 (c.4369_4370delTC) (p.Ser1457fs); Zygosity=Heterozygous (PubMed=29034881) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21151666 CVCL_LJ92 PLC/NUT/1 cancer cell line human CVCL_LJ92 CL:0000010 Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Female Characteristics: Tumorigenic When heterotransplanted subcutaneously into male athymic mice tumors develop at the site of inoculation.; Virology: Contains at least 3 copies of integrated hepatitis B virus (HBV) genomes 21151667 CVCL_LJ93 DELSH-5 cancer cell line human CVCL_LJ93 CL:0000010 Population: Indian; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Doubling time: 32-40 hours (PubMed=6257270) 21151668 CVCL_LJ90 HHS-25 cancer cell line human CVCL_LJ90 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21151669 CVCL_LJ91 HHS-85Nu cancer cell line human CVCL_LJ91 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified Characteristics: Established after one tumor passage of HHS-85 in nude mice 21151670 CVCL_UD30 S2R+-MT::Cas9 spontaneously immortalized cell line fruit fly CVCL_UD30 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21151671 CVCL_UD33 S2R+-IA2-KO spontaneously immortalized cell line fruit fly CVCL_UD33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0031294; IA-2 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21151672 CVCL_UD31 S2R+-Apc2-KO spontaneously immortalized cell line fruit fly CVCL_UD31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0026598; Apc2; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21151673 CVCL_UD37 NS-SV-AC transformed cell line human CVCL_UD37 CL:0000010 Transformant: Simian virus 40 (SV40) [SV40-ori(-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.. Male 21151674 CVCL_UD38 NS-SV-DC transformed cell line human CVCL_UD38 CL:0000010 Transformant: Simian virus 40 (SV40) [SV40-ori(-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland. Male 21151675 CVCL_UD35 S2R+-Znt63C-KO spontaneously immortalized cell line fruit fly CVCL_UD35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0035432; Znt63C Breed/subspecies: Oregon-R. Male Group: Insect cell line 21151676 CVCL_UD36 ACCAY cancer cell line human CVCL_UD36 CL:0000010 Population: Japanese Female Doubling time: 48-50 hours (PubMed=2570487). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2034 21151677 CVCL_UD39 NS-SV-MC transformed cell line human CVCL_UD39 CL:0000010 Transformant: Simian virus 40 (SV40) [SV40-ori(-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; submandibular gland. Male 21151678 CVCL_LJ89 UHi006-A-1 induced pluripotent stem cell human CVCL_LJ89 From: University of Helsinki; Helsinki; Finland CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Expresses bright nuclear located tDTomato upon SOX2 activation Heterozygous knockin of a T2A-NLS-tdTomato-F2A-Pac cassette at the C-terminus of the SOX2 gene by CRISPR/Cas9. 21151679 CVCL_LJ87 PLC/PRF/5 Luciferase/GFP cancer cell line human CVCL_LJ87 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21151680 CVCL_LJ88 UHi006-A-2 induced pluripotent stem cell human CVCL_LJ88 From: University of Helsinki; Helsinki; Finland CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Expresses bright nuclear located EmGFP upon POU5F1 activation Heterozygous knockin of a T2A-NLS-EmGFP-P2A-Pac cassette at the C-terminus of the POU5F1/OCT4 gene by CRISPR/Cas9. 21151681 CVCL_UD22 PR00087 finite cell line CVCL_UD22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00087; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151682 CVCL_UD23 PR00510 finite cell line CVCL_UD23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00510; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151683 CVCL_UD20 AG12256 finite cell line CVCL_UD20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG12256; probable Female Group: Non-human primate cell line 21151684 CVCL_UD21 PR00085 finite cell line CVCL_UD21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00085; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151685 CVCL_UD26 PR00431 finite cell line CVCL_UD26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00431; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151686 CVCL_UD27 PR00445 transformed cell line bonobo/pygmy chimpanzee CVCL_UD27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00445; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151687 CVCL_UD24 PR00534 finite cell line CVCL_UD24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00534; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151688 CVCL_UD25 PR00430 finite cell line CVCL_UD25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00430; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21151689 CVCL_UD28 A-375 MEK1 p.Q56P cancer cell line human CVCL_UD28 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple_edited; p.Gln56Pro (c.167A>C); ClinVar=VCV000375978; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Exhibits significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib, as well as the MAP2K1 inhibitor trametinib when compared to its parental cell line Displays increased sensitivity to combination MAP2K1/BRAF inhibitor treatments, making this line an ideal model system for the development of novel combination therapies targeting multiple points in the RAS-RAF-MEK-ERK-MAPK signaling pathway, as well as for the screening of new potential BRAF and MAP2K1 inhibitors (ATCC). Doubling time: ~19 hours (ATCC=CRL-1619IG-3) 21151690 CVCL_UD29 A-375 KRAS p.G13D cancer cell line human CVCL_UD29 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Exhibits significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC). Doubling time: ~21 hours (ATCC=CRL-1619IG-1) 21151691 CVCL_LJ98 CW30526 induced pluripotent stem cell human CVCL_LJ98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30526; true Female 21151692 CVCL_LJ99 CW30527 induced pluripotent stem cell human CVCL_LJ99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30527; true Male 21151693 CVCL_LJ74 NZOV4 cancer cell line human CVCL_LJ74 CL:0000010 Derived from metastatic site: Ovary. Female Characteristics: Indicated to be a metastatic ovarian adenocarcinoma with a probable gastrointestinal primary site 21151694 CVCL_LJ75 NZOV5 cancer cell line human CVCL_LJ75 CL:0000010 Derived from metastatic site: Ascites. Female 21151695 CVCL_LJ72 RL2 cancer cell line house mouse CVCL_LJ72 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: BALB/c. 21151696 CVCL_LJ73 NZOV9 cancer cell line human CVCL_LJ73 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Tyr1021Cys (c.3062A>G); ClinVar=VCV000376246; Zygosity=Unspecified (CBA; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gly (c.388C>G); ClinVar=VCV000375958; Zygosity=Unspecified (DepMap) Derived from sampling site: Ovary. Female Doubling time: 30 hours (CBA) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21151697 CVCL_LJ70 Bp53WT transformed cell line human CVCL_LJ70 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11168 21151698 CVCL_LJ71 Bp53MT143 transformed cell line human CVCL_LJ71 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11169 21151699 CVCL_UD11 GM16339 transformed cell line human CVCL_UD11 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Female 21151700 CVCL_UD12 GM16340 transformed cell line human CVCL_UD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151701 CVCL_UD10 GM16338 transformed cell line human CVCL_UD10 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151702 CVCL_UD15 WTC-mEGFP-MYL7-cl3 induced pluripotent stem cell human CVCL_UD15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 MYL7 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21151703 CVCL_UD16 WTC-mEGFP-TTN-cl39 induced pluripotent stem cell human CVCL_UD16 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 TTN has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21151704 CVCL_UD13 GM16341 transformed cell line human CVCL_UD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151705 CVCL_UD14 WTC-mEGFP-ATP2A2-cl51 induced pluripotent stem cell human CVCL_UD14 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 ATP2A2 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21151706 CVCL_UD19 AG05352 finite cell line CVCL_UD19 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05352; probable Male Group: Non-human primate cell line 21151707 CVCL_LJ69 BERB subclone 2 transformed cell line human CVCL_LJ69 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Weakly tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10634 21151708 CVCL_UD17 WTC-mEGFP-HIST1H2BJ-cl36 induced pluripotent stem cell human CVCL_UD17 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 HIST1H2BJhas been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21151709 CVCL_UD18 WTC-mEGFP-NUP153-cl88 induced pluripotent stem cell human CVCL_UD18 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 NUP153 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21151710 CVCL_LJ67 MeT-5A/EJ-ras transformed cell line human CVCL_LJ67 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Male Characteristics: Tumorigenic derivative of MeT-5A Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9865 21151711 CVCL_LJ68 BERB transformed cell line human CVCL_LJ68 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Weakly tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10635 21151712 CVCL_LJ65 BEAS-2B/c-raf-1 transformed cell line human CVCL_LJ65 CL:0000010 Transfected with: HGNC; 9829; RAF1 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9864 21151713 CVCL_LJ66 BEAS-2B/c-raf-1/c-myc transformed cell line human CVCL_LJ66 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 9829; RAF1 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9868 21151714 CVCL_LJ85 AE17-sOVA cancer cell line house mouse CVCL_LJ85 CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Female 21151716 CVCL_LJ83 AC31 cancer cell line house mouse CVCL_LJ83 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Omics: Deep exome analysis Female Doubling time: 22 hours (PubMed=1459729) 21151717 CVCL_LJ84 AC32 cancer cell line house mouse CVCL_LJ84 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Female Doubling time: 26 hours (PubMed=1459729) 21151718 CVCL_LJ81 AC16 [Mouse mesothelioma] cancer cell line house mouse CVCL_LJ81 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Omics: Deep exome analysis Female Doubling time: 14 hours (PubMed=1459729) 21151719 CVCL_LJ82 AC28 cancer cell line house mouse CVCL_LJ82 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Omics: Deep exome analysis Female Doubling time: 23 hours (PubMed=1459729) 21151720 CVCL_LJ80 AC14 cancer cell line house mouse CVCL_LJ80 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Female Doubling time: 22 hours (PubMed=1459729) 21151721 CVCL_UD00 GM16309 transformed cell line human CVCL_UD00 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151722 CVCL_UD01 GM16258 transformed cell line human CVCL_UD01 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151723 CVCL_UD04 GM16343 transformed cell line human CVCL_UD04 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151724 CVCL_UD05 GM16431 transformed cell line human CVCL_UD05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151725 CVCL_UD02 GM16100 transformed cell line human CVCL_UD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151726 CVCL_UD03 GM16342 transformed cell line human CVCL_UD03 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151727 CVCL_UD08 GM16336 transformed cell line human CVCL_UD08 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 5 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151728 CVCL_UD09 GM16337 transformed cell line human CVCL_UD09 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 5 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151729 CVCL_UD06 GM16334 transformed cell line human CVCL_UD06 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 5 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151730 CVCL_UD07 GM16335 transformed cell line human CVCL_UD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151731 CVCL_LJ78 AB13 cancer cell line house mouse CVCL_LJ78 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Omics: Deep exome analysis Female Doubling time: 16 hours (PubMed=1459729) 21151732 CVCL_LJ79 AB2 [Mouse mesothelioma] cancer cell line house mouse CVCL_LJ79 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Female Doubling time: 16 hours (PubMed=1459729) 21151733 CVCL_LJ76 NZOV7 cancer cell line human CVCL_LJ76 CL:0000010 Derived from metastatic site: Ovary. Female Characteristics: Indicated to be a metastatic mucinous carcinoma of ovary with a probable primary site from large bowel 21151734 CVCL_LJ77 NZOV13 cancer cell line human CVCL_LJ77 CL:0000010 Derived from metastatic site: Ascites. Female 21151735 CVCL_UC92 GM16301 transformed cell line human CVCL_UC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151736 CVCL_UC93 GM16302 transformed cell line human CVCL_UC93 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151737 CVCL_UC90 GM16299 transformed cell line human CVCL_UC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151738 CVCL_UC91 GM16300 transformed cell line human CVCL_UC91 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151739 CVCL_UC96 GM16305 transformed cell line human CVCL_UC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151740 CVCL_UC97 GM16306 transformed cell line human CVCL_UC97 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151741 CVCL_UC94 GM16303 transformed cell line human CVCL_UC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151742 CVCL_UC95 GM16304 transformed cell line human CVCL_UC95 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151743 CVCL_UC98 GM16307 transformed cell line human CVCL_UC98 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151744 CVCL_UC99 GM16308 transformed cell line human CVCL_UC99 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Male 21151745 CVCL_UC81 DIMF spontaneously immortalized cell line CVCL_UC81 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 48.43 hours, at 50th passage (PubMed=25721100) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013109 21151746 CVCL_UC82 TEMF spontaneously immortalized cell line CVCL_UC82 CL:0000010 Karyotypic information: Tetraploid karyotype; Derived from sampling site: Fin. Unspecified Doubling time: 41.45 hours, at 50th passage (PubMed=25721100) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013111 21151747 CVCL_UC80 ICO spontaneously immortalized cell line CVCL_UC80 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line; Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 66 21151748 CVCL_UC85 GM16253 transformed cell line human CVCL_UC85 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151749 CVCL_UC86 GM16257 transformed cell line human CVCL_UC86 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151750 CVCL_UC83 TRMF spontaneously immortalized cell line CVCL_UC83 CL:0000010 Karyotypic information: Triploid karyotype; Derived from sampling site: Fin. Unspecified Doubling time: 36.01 hours, at 50th passage (PubMed=25721100) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013110 21151751 CVCL_UC84 MECF-1 spontaneously immortalized cell line CVCL_UC84 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21151752 CVCL_UC89 GM16298 transformed cell line human CVCL_UC89 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151753 CVCL_UC87 GM16296 transformed cell line human CVCL_UC87 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151754 CVCL_UC88 GM16297 transformed cell line human CVCL_UC88 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151755 CVCL_UC70 LM-MEL-98 cancer cell line human CVCL_UC70 HLA typing: A*02,24; B*15,57; C*06,07 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Bone; spine. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151756 CVCL_UC71 LM-MEL-100 cancer cell line human CVCL_UC71 HLA typing: A*02,11; B*15,55; C*03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Glu (c.1801A>G); ClinVar=VCV000013966; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151757 CVCL_UC74 HuLa-PC transformed cell line human CVCL_UC74 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Larynx; glottis; posterior commissure Cell type=Epithelial cell.. Male Doubling time: 60-70 hours (ATCC=CRL-3342) 21151758 CVCL_UC75 OVPA8 cancer cell line human CVCL_UC75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1101; BRCA2; Zygosity=Heterozygous (PubMed=30018258); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Val1234Glnfs (c.3700_3704delGTAAA); Zygosity=Homozygous (PubMed=30018258); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=30018258) Population: Caucasian; Derived from metastatic site: Ascites. Female Doubling time: ~44 hours (PubMed=30018258); 50-60 hours (DSMZ=ACC-871); 40-44 hours (ECACC=19062601) 21151759 CVCL_UC72 LM-MEL-101 cancer cell line human CVCL_UC72 HLA typing: A*02,30; B*13,15; C*03,06 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Derived from metastatic site: Ascites. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151760 CVCL_UC73 GiCF spontaneously immortalized cell line CVCL_UC73 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Virology: Highly susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=30268797) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201856 21151761 CVCL_UC78 KGL-1 spontaneously immortalized cell line CVCL_UC78 CL:0000010 Derived from sampling site: Fin and scale. Unspecified Doubling time: ~2 days (DOI=10.1266/jjg.51.65) Group: Fish cell line 21151762 CVCL_UC79 SSO-1 spontaneously immortalized cell line CVCL_UC79 CL:0000010 Unspecified Group: Fish cell line. 21151763 CVCL_UC76 RyuF-2 spontaneously immortalized cell line CVCL_UC76 CL:0000010 Derived from sampling site: Fin; Breed/subspecies: Ryukin. Unspecified Virology: Highly susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=26290507) Group: Fish cell line 21151764 CVCL_UC77 KGC-1 spontaneously immortalized cell line CVCL_UC77 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21151765 CVCL_UC60 LM-MEL-62 cancer cell line human CVCL_UC60 HLA typing: A*02:01,31:01; B*07:02,60; C*03:04,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Glu (c.1406G>A) (p.Gly509Glu, c.1526G>A); ClinVar=VCV000013974; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~38 hours (ATCC=CRL-3339) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151766 CVCL_UC63 LM-MEL-70 cancer cell line human CVCL_UC63 HLA typing: A*01,11; B*15,27; C*01,03:03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151767 CVCL_UC64 LM-MEL-71 cancer cell line human CVCL_UC64 HLA typing: A*02:01; B*07:02,44:02; C*05:01,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain; right occipital lobe. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~45-50 hours (ATCC=CRL-3340) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151768 CVCL_UC61 LM-MEL-64 cancer cell line human CVCL_UC61 HLA typing: A*01:01,11:01; B*15:01,27:05; C*01:02,03:03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151769 CVCL_UC62 LM-MEL-69 cancer cell line human CVCL_UC62 HLA typing: A*02:01; B*39:01,60; C*03:04,12:03 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151770 CVCL_UC67 LM-MEL-77 cancer cell line human CVCL_UC67 HLA typing: A*01,02; B*08; C*07 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151771 CVCL_UC68 LM-MEL-82 cancer cell line human CVCL_UC68 HLA typing: A*01; B*08,40; C*03,07; DRB1*04,15 (Direct_author_submission) CL:0000010 Miscellaneous: Age/sex of donor, metastatic site, HLA typing and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Breast. Omics: miRNA expression profiling Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151772 CVCL_UC65 LM-MEL-73 cancer cell line human CVCL_UC65 HLA typing: A*02:01,03:01; B*27:05,44:02; C*02:02,05:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: PTK2B mutation, metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151773 CVCL_UC66 LM-MEL-75 cancer cell line human CVCL_UC66 HLA typing: A*24:02,29:02; B*38:01,44:03; C*12:03,16:01 (PubMed=23527996) CL:0000010 Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: 70 hours (ATCC=CRL-3341) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151774 CVCL_UC69 LM-MEL-97 cancer cell line human CVCL_UC69 HLA typing: A*02,11; B*15,35; C*03,04 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Leu576Pro (c.1727T>C); ClinVar=VCV000375919; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: KIT mutation, metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21151775 CVCL_D135 A-1165 cancer cell line human CVCL_D135 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=3945555). Unspecified 21151776 CVCL_CP35 ND14925 transformed cell line human CVCL_CP35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151777 CVCL_D136 A-1589 cancer cell line human CVCL_D136 CL:0000010 Unspecified 21151778 CVCL_CP36 ND14926 transformed cell line human CVCL_CP36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151779 CVCL_D133 BMS1 stromal cell line house mouse CVCL_D133 CL:0000010 21151780 CVCL_CP33 ND14881 transformed cell line human CVCL_CP33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151781 CVCL_D134 MS-1 [Mouse bone marrow] stromal cell line house mouse CVCL_D134 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. 21151782 CVCL_CP34 ND14907 transformed cell line human CVCL_CP34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151783 CVCL_D139 Hep293TT cancer cell line human CVCL_D139 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Val22_Leu139delinsVal (c.66_416del351); Zygosity=Heterozygous (PubMed=19637320) Population: Caucasian; Derived from sampling site: Liver. Omics: Array-based CGH Female 21151784 CVCL_CP39 ND14982 transformed cell line human CVCL_CP39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151785 CVCL_D137 A-1663 cancer cell line human CVCL_D137 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=3945555) Derived from sampling site: Urinary bladder. Unspecified 21151786 CVCL_CP37 ND14933 transformed cell line human CVCL_CP37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151787 CVCL_D138 A20/2J cancer cell line house mouse CVCL_D138 CL:0000010 Breed/subspecies: BALB/cAnN. Unspecified 21151788 CVCL_CP38 ND14967 transformed cell line human CVCL_CP38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151789 CVCL_D131 MAXF 401NL cancer cell line human CVCL_D131 CL:0000010 Derived from metastatic site: Lung. Female Characteristics: Developed from a breast tumor xenograft developed in athymic mice 21151790 CVCL_CP31 ND14870 transformed cell line human CVCL_CP31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151791 CVCL_D132 MEXF 276L cancer cell line human CVCL_D132 CL:0000010 21151792 CVCL_CP32 ND14879 transformed cell line human CVCL_CP32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151793 CVCL_CP30 ND14854 transformed cell line human CVCL_CP30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151794 CVCL_D130 VP185 cancer cell line human CVCL_D130 CL:0000010 Female 21151795 CVCL_D146 10C7 hybridoma house mouse CVCL_D146 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08560; Human cytomegalovirus glycoprotein UL18. 21151796 CVCL_CP46 ND15151 transformed cell line human CVCL_CP46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151797 CVCL_D147 15C6 [Mouse hybridoma against mouse cytomegalovirus m144] hybridoma house mouse CVCL_D147 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; D3XDW6; Mouse cytomegalovirus MHC class I-like protein m144. 21151798 CVCL_CP47 ND15161 transformed cell line human CVCL_CP47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151799 CVCL_CP44 ND15121 transformed cell line human CVCL_CP44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151800 CVCL_D145 HL-1 Friendly Myeloma-653 cancer cell line house mouse CVCL_D145 CL:0000010 Miscellaneous: Cell line probably no longer available; was distributed by Ventrex Bioventures Group which was later acquired by Hycor Biomedical Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21151801 CVCL_CP45 ND15129 transformed cell line human CVCL_CP45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151802 CVCL_D148 1C3 [Mouse hybridoma against human HFE] hybridoma house mouse CVCL_D148 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21151803 CVCL_CP48 ND15174 transformed cell line human CVCL_CP48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151804 CVCL_D149 1G3 [Mouse hybridoma against rat Fcgrt] hybridoma house mouse CVCL_D149 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13599; Rat Fcgrt. 21151805 CVCL_CP49 ND15189 transformed cell line human CVCL_CP49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151806 CVCL_D142 1F5 [Mouse hybridoma against human MS4A1] hybridoma house mouse CVCL_D142 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9645 21151807 CVCL_CP42 ND15039 transformed cell line human CVCL_CP42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151808 CVCL_D143 2A5 [Mouse hybridoma against human HFE] hybridoma house mouse CVCL_D143 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q30201; Human HFE. 21151809 CVCL_CP43 ND15062 transformed cell line human CVCL_CP43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151810 CVCL_CP40 ND15007 transformed cell line human CVCL_CP40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151811 CVCL_D140 TO [Salmo] spontaneously immortalized cell line CVCL_D140 CL:0000010 Derived from sampling site: Head kidney. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Group: Fish cell line 21151812 CVCL_D141 1E8 [Mouse hybridoma against chicken MPZ] hybridoma house mouse CVCL_D141 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P37301; Chicken MPZ. 21151813 CVCL_CP41 ND15036 transformed cell line human CVCL_CP41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151814 CVCL_CP19 ND14705 transformed cell line human CVCL_CP19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151815 CVCL_D119 SM-AP3 cancer cell line human CVCL_D119 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=19622142) Population: Japanese; Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: ~31 hours (PubMed=19622142) 21151816 CVCL_D113 Co84 cancer cell line human CVCL_D113 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Homozygous (PubMed=16959974) Derived from metastatic site: Lymph node. Male 21151817 CVCL_CP13 ND14638 transformed cell line human CVCL_CP13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151818 CVCL_D114 Co92 cancer cell line human CVCL_D114 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=16959974) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21151819 CVCL_CP14 ND14640 transformed cell line human CVCL_CP14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151820 CVCL_D111 Co79 cancer cell line human CVCL_D111 CL:0000010 Derived from metastatic site: Lymph node. Male 21151821 CVCL_CP11 ND14636 transformed cell line human CVCL_CP11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151822 CVCL_D112 Co82 cancer cell line human CVCL_D112 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (PubMed=16959974). Female 21151823 CVCL_CP12 ND14637 transformed cell line human CVCL_CP12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151824 CVCL_CP17 ND14660 transformed cell line human CVCL_CP17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151825 CVCL_D117 SM-AP1 cancer cell line human CVCL_D117 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=19622142) Population: Japanese; Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: ~31 hours (PubMed=19622142) 21151826 CVCL_CP18 ND14661 transformed cell line human CVCL_CP18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151827 CVCL_D118 SM-AP2 cancer cell line human CVCL_D118 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=19622142) Population: Japanese; Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: ~31 hours (PubMed=19622142) 21151828 CVCL_D115 Co94 cancer cell line human CVCL_D115 CL:0000010 Derived from metastatic site: Lymph node. Male 21151829 CVCL_CP15 ND14641 transformed cell line human CVCL_CP15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151830 CVCL_D116 Nagoya-78 cancer cell line human CVCL_D116 CL:0000010 Population: Japanese; Derived from sampling site: Salivary gland. Female Doubling time: ~24 hours (PubMed=5100402) 21151831 CVCL_CP16 ND14654 transformed cell line human CVCL_CP16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151832 CVCL_D110 Co74 cancer cell line human CVCL_D110 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe134Leu (c.402T>G); ClinVar=VCV001018290; Zygosity=Homozygous (PubMed=16959974) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21151833 CVCL_CP10 ND14635 transformed cell line human CVCL_CP10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151834 CVCL_D124 HEK-TERST transformed cell line human CVCL_D124 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. 21151835 CVCL_CP24 ND14777 transformed cell line human CVCL_CP24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151836 CVCL_D125 HEK-TERST110 transformed cell line human CVCL_D125 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. 21151837 CVCL_CP25 ND14815 transformed cell line human CVCL_CP25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151838 CVCL_D122 HEK-TERV transformed cell line human CVCL_D122 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. 21151839 CVCL_CP22 ND14758 transformed cell line human CVCL_CP22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151840 CVCL_D123 HEK-TERASB56gamma telomerase immortalized cell line human CVCL_D123 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal kidney. 21151841 CVCL_CP23 ND14771 transformed cell line human CVCL_CP23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151842 CVCL_D128 MEXF 462NL cancer cell line human CVCL_D128 CL:0000010 21151843 CVCL_CP28 ND14852 transformed cell line human CVCL_CP28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151844 CVCL_D129 MEXF 514L cancer cell line human CVCL_D129 CL:0000010 21151845 CVCL_CP29 ND14853 transformed cell line human CVCL_CP29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151846 CVCL_CP26 ND14823 transformed cell line human CVCL_CP26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151847 CVCL_D126 RXF 486L cancer cell line human CVCL_D126 CL:0000010 21151848 CVCL_CP27 ND14837 transformed cell line human CVCL_CP27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151849 CVCL_D127 RXF 944L cancer cell line human CVCL_D127 CL:0000010 21151850 CVCL_CP20 ND14716 transformed cell line human CVCL_CP20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151851 CVCL_D120 SM-AP4 cancer cell line human CVCL_D120 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=19622142) Population: Japanese; Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: ~31 hours (PubMed=19622142) 21151852 CVCL_CP21 ND14756 transformed cell line human CVCL_CP21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151853 CVCL_D121 SM-AP5 cancer cell line human CVCL_D121 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=19622142) Population: Japanese; Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: ~31 hours (PubMed=19622142) 21151854 CVCL_CP08 ND14631 transformed cell line human CVCL_CP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151855 CVCL_D108 SN12S1 cancer cell line human CVCL_D108 CL:0000010 Male 21151856 CVCL_D109 Co108 cancer cell line human CVCL_D109 CL:0000010 Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Female 21151857 CVCL_CP09 ND14634 transformed cell line human CVCL_CP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151858 CVCL_D102 Co-115 cancer cell line human CVCL_D102 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20570890; PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu157Glyfs*23 (c.469dupG) (c.469_470insG); ClinVar=VCV000655856; Zygosity=Unspecified (PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Unspecified (PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: N-glycan profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Established from a tumor implanted into a nude mice Doubling time: ~36 hours, at 26th passage (PubMed=975046); Microsatellite instability: Instable (MSI) (PubMed=9000147; PubMed=24042735; PubMed=25926053; PubMed=28683746) 21151859 CVCL_CP02 ND14613 transformed cell line human CVCL_CP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151860 CVCL_CP03 ND14614 transformed cell line human CVCL_CP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151861 CVCL_D103 YMB-S cancer cell line human CVCL_D103 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (YMB-1) has been shown to be a ZR-75-1 derivative. 21151862 CVCL_D100 CTL44 transformed cell line house mouse CVCL_D100 CL:0000010 Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: IL4 dependent 21151863 CVCL_CP00 ND14599 transformed cell line human CVCL_CP00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151864 CVCL_D101 AG-F cancer cell line human CVCL_D101 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: ATCC; CRL-2530; true Female Doubling time: ~8-9 hours (Patent=US5480825) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00171; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11391 Problematic cell line: Contaminated Shown to be a CCRF-CEM derivative (PubMed=12592342; PubMed=20143388). Originally thought to originates from the bone marrow of a patient suffering fron neuroblastoma that evolved into a Hodgkin lymphoma. 21151865 CVCL_CP01 ND14602 transformed cell line human CVCL_CP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151866 CVCL_CP06 ND14626 transformed cell line human CVCL_CP06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151867 CVCL_D106 SN12K1 cancer cell line human CVCL_D106 CL:0000010 Male 21151868 CVCL_CP07 ND14630 transformed cell line human CVCL_CP07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151869 CVCL_D107 SN12L1 cancer cell line human CVCL_D107 CL:0000010 Male 21151870 CVCL_D104 3'-mRLh-2 cancer cell line Norway rat CVCL_D104 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21151871 CVCL_CP04 ND14615 transformed cell line human CVCL_CP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151872 CVCL_CP05 ND14616 transformed cell line human CVCL_CP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151873 CVCL_D105 SN12A1 cancer cell line human CVCL_D105 CL:0000010 Male 21151874 CVCL_LK73 Kap 13 cancer cell line human CVCL_LK73 CL:0000010 Population: African; Ugandan. Male 21151875 CVCL_LK74 Kap 16 cancer cell line human CVCL_LK74 CL:0000010 Population: African; Ugandan. Male 21151876 CVCL_LK71 Cama-2 cancer cell line human CVCL_LK71 CL:0000010 Female 21151877 CVCL_LK72 Ast-1 cancer cell line human CVCL_LK72 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21151878 CVCL_LK70 RPMI-1720 cancer cell line human CVCL_LK70 CL:0000010 21151879 CVCL_UE10 TF-1 IDH2 p.R140Q cancer cell line human CVCL_UE10 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 5383; IDH2; Simple_edited; p.Arg140Gln (c.419G>A); ClinVar=VCV000014716; Zygosity=Homozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Compared to the parent cell line, has elevated intra- and extracellular D-2-hydroxyglutarate (D-2HG) levels (ATCC) Doubling time: ~24.8 hours (ATCC=CRL-2003IG) 21151880 CVCL_UE11 CHO INSR 1284 spontaneously immortalized cell line CVCL_UE11 CL:0000010 Transfected with: HGNC; 6091; INSR (long isoform); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Doubling time: ~30-40 hours (DSMZ=ACC-858) 21151881 CVCL_UE14 Rap1 F/F (#73493-6) transformed cell line house mouse CVCL_UE14 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 2nd coding exon of mouse Rap1 Rap1 knockout can be effected by transduction of Cre recombinase into the cell line. 21151882 CVCL_UE15 TPP1 F/F (#35027-1) transformed cell line house mouse CVCL_UE15 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on either side of the first-eighth coding exon of mouse Tpp1 Tpp1 knockout can be effected by transduction of Cre recombinase into the cell line. 21151883 CVCL_UE12 TRF1 F/F transformed cell line house mouse CVCL_UE12 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 1st coding exon of mouse Terf1 gene Terf1 knockout can be effected by transduction of Cre recombinase into the cell line. 21151884 CVCL_UE13 TRF2 F/- Rosa26-CreERT2 transformed cell line house mouse CVCL_UE13 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on either side of the first and second coding exon of mouse Terf2 Also expresses Cre-ERT2 from one Rosa26 locus. Terf2 knockout can be effected by transduction of Cre recombinase into the cell line. 21151885 CVCL_UE18 293T human CLDN18.2 transformed cell line human CVCL_UE18 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21151886 CVCL_UE19 293T human CD133 transformed cell line human CVCL_UE19 CL:0000010 Transfected with: HGNC; 9454; PROM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21151887 CVCL_LK68 SW1614 cancer cell line human CVCL_LK68 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21151888 CVCL_UE16 Tel2 F/- P53 -/- (#9136-1) spontaneously immortalized cell line house mouse CVCL_UE16 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Has loxP sites on both sides of the second coding exon of mouse Tel2 Tel2 knockout can be effected by transduction of Cre recombinase into the cell line. 21151889 CVCL_UE17 LASCPC-01 cancer cell line human CVCL_UE17 CL:0000010 Omics: SNP array analysis. Male Doubling time: ~18 hours (PubMed=27050099); ~24 hours (ATCC=CRL-3356) 21151890 CVCL_LK69 SK-OS-5 cancer cell line human CVCL_LK69 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Discontinued: ATCC; HTB-89; true. Male 21151891 CVCL_LK66 SW1494 cancer cell line human CVCL_LK66 From: Scott and White Clinic; Temple; USA CL:0000010 Discontinued: ATCC; HTB-116; true. Female 21151892 CVCL_LK67 SW1503 cancer cell line human CVCL_LK67 From: Scott and White Clinic; Temple; USA. CL:0000010 Male 21151893 CVCL_LK64 CCRC-1 finite cell line human CVCL_LK64 CL:0000010 Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. Virology: Susceptible to infection by a wide spectrum of viruses Doubling time: 30.8 +- 6.2 hours (at 10th passage), 36.5 +- 4.0 hours (at 15th passage), 42.8 +- 2.3 hours (at 20th passage), 41.8 +- 4.3 hours (at 25th passage), 42.4 +- 3.4 hours (at 30th passage) (DOI=10.1038/s41598-017-11997-1) Group: Vaccine production cell line 21151894 CVCL_LK65 6278 cancer cell line human CVCL_LK65 CL:0000010 Unspecified 21151895 CVCL_LK84 SK-L6 cancer cell line human CVCL_LK84 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21151896 CVCL_LK85 SK-L7 cancer cell line human CVCL_LK85 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21151897 CVCL_LK82 SK-L4 cancer cell line human CVCL_LK82 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21151898 CVCL_LK83 SK-L5 cancer cell line human CVCL_LK83 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21151899 CVCL_LK80 SK-L2 cancer cell line human CVCL_LK80 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: 23 hours (PubMed=5229525) 21151900 CVCL_LK81 SK-L3 cancer cell line human CVCL_LK81 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: 26 hours (PubMed=5229525) 21151901 CVCL_UE00 LOPRA-3 cancer cell line human CVCL_UE00 CL:0000010 Unspecified Characteristics: Produces IgG3 kappa. 21151902 CVCL_UE03 BNC1 transformed cell line human CVCL_UE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21151903 CVCL_UE04 CLF1 transformed cell line human CVCL_UE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21151904 CVCL_UE01 IB-4 transformed cell line human CVCL_UE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified Virology: Contains 4 to 5 copies of the EBV genome These are chromosomally integrated and do not exist in an episomal form (PubMed=1645805; PubMed=15681063). 21151905 CVCL_UE02 AND1 transformed cell line human CVCL_UE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21151906 CVCL_UE07 OAT1 HEK 293T/17 transformed cell line human CVCL_UE07 CL:0000010 Transfected with: HGNC; 10970; SLC22A6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21151907 CVCL_UE08 LAMA84-s cancer cell line human CVCL_UE08 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Derived from sampling site: Peripheral blood. Female 21151908 CVCL_LK79 NH-AR cancer cell line human CVCL_LK79 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from 'nodular histiocytic lymphoma'; Derived from sampling site: Cervical lymph node. Male Doubling time: 38.4 hours (PubMed=7002281) 21151909 CVCL_UE05 VLL1 transformed cell line human CVCL_UE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21151910 CVCL_UE06 RGN1 transformed cell line human CVCL_UE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Virology: Contains both episomal (~20 copies per cell) and chromosomally integrated (2 per cell) copies of the EBV genome (PubMed=1323719) 21151911 CVCL_LK77 Kap 9 cancer cell line human CVCL_LK77 CL:0000010 Population: African; Congolian. Male 21151912 CVCL_LK78 SK-BR-1 II cancer cell line human CVCL_LK78 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Pleural effusion. Female 21151913 CVCL_LK75 Kap 19 cancer cell line human CVCL_LK75 CL:0000010 Population: African; Ugandan. Male 21151914 CVCL_UE09 U-87MG ATCC IDH1 p.R132H cancer cell line human CVCL_UE09 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple_edited; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male Doubling time: 25.6 hours (ATCC=HTB-14IG) Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21151915 CVCL_LK76 Kap 22 cancer cell line human CVCL_LK76 CL:0000010 Population: African; Congolian. Male 21151916 CVCL_LK51 AML-004 cancer cell line human CVCL_LK51 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: ~15 hours (PubMed=28934678) 21151917 CVCL_LK52 TALL-1 [Human childhood T-ALL] cancer cell line human CVCL_LK52 CL:0000010 Derived from sampling site: Bone marrow or peripheral blood Cell type=T-cell.. Male 21151918 CVCL_LK50 AG21765 finite cell line CVCL_LK50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; AG21765; probable Male Group: Non-human primate cell line 21151919 CVCL_LK48 WG0576 finite cell line human CVCL_LK48 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151920 CVCL_LK49 WG0577 finite cell line human CVCL_LK49 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21151921 CVCL_LK46 WTC-mEGFP-ST6GAL1-cl1 induced pluripotent stem cell human CVCL_LK46 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 ST6GAL1 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21151922 CVCL_LK47 WG0575 finite cell line human CVCL_LK47 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21151923 CVCL_LK44 WTC-mTagRFPT-TUBA1B-cl35 induced pluripotent stem cell human CVCL_LK44 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 TUBA1B has been endogenously tagged in one allele at the N-terminus with mTagRFP-T Part of: Allen Cell Collection 21151924 CVCL_LK45 WTC-mTagRFPT-CETN2-cl19 induced pluripotent stem cell human CVCL_LK45 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 CETN2 has been endogenously tagged in one allele at the N-terminus with mTagRFP-T Part of: Allen Cell Collection 21151925 CVCL_LK42 WTC-mEGFP-LAMP1-cl37 induced pluripotent stem cell human CVCL_LK42 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 LAMP1 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21151926 CVCL_LK43 WTC-mEGFP-ST6GAL1-cl44 induced pluripotent stem cell human CVCL_LK43 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 ST6GAL1 has been endogenously tagged in both alleles at the C-terminus with mEGFP Part of: Allen Cell Collection 21151927 CVCL_LK62 Raji-GFP cancer cell line human CVCL_LK62 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21151928 CVCL_LK63 SW999 cancer cell line human CVCL_LK63 From: Scott and White Clinic; Temple; USA. CL:0000010 Unspecified 21151929 CVCL_LK60 WAe001-A-6 embryonic stem cell human CVCL_LK60 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 742; ASGR1. Male 21151930 CVCL_LK61 INCABRi001-A induced pluripotent stem cell human CVCL_LK61 From: Instituto Nacional de Cancer (INCA); Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 18318; ASXL1; Simple; p.Arg693Ter (c.2077C>T); ClinVar=VCV000620281; Zygosity=Unspecified (PubMed=29034885); Sequence variation: Mutation; HGNC; 1455; CALR; Simple; p.Leu367Thrfs*46 (c.1092_1143del52); ClinVar=VCV000097006; Zygosity=Unspecified (PubMed=29034885) Derived from sampling site: Peripheral blood. Female 21151931 CVCL_LK59 A4-15 transformed cell line house mouse CVCL_LK59 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with p.Val659Glu) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21151932 CVCL_LK57 WY090 transformed cell line human CVCL_LK57 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Part of: Sonoda-Tajima cell collection 21151933 CVCL_LK58 HEV0322 transformed cell line human CVCL_LK58 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21151934 CVCL_LK55 HGALBV471 transformed cell line human CVCL_LK55 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21151935 CVCL_LK56 NCC-LMS1-C1 cancer cell line human CVCL_LK56 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; rib. Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 88 hours (PubMed=29845452) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21151936 CVCL_LK53 DA02951 transformed cell line human CVCL_LK53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21151937 CVCL_LK54 DA03873 transformed cell line human CVCL_LK54 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 21151938 CVCL_LK30 CW60548 induced pluripotent stem cell human CVCL_LK30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60548; true Female 21151939 CVCL_D298 CBS [Human colon carcinoma] cancer cell line human CVCL_D298 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=9000147). Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147) 21151940 CVCL_CQ98 ND16503 transformed cell line human CVCL_CQ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151941 CVCL_D299 Asano cancer cell line human CVCL_D299 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248). Population: Japanese Female 21151942 CVCL_CQ99 ND16506 transformed cell line human CVCL_CQ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151943 CVCL_D292 3H5-1 hybridoma house mouse CVCL_D292 CL:0000010 Monoclonal antibody isotype: IgG1. 21151944 CVCL_CQ92 ND16483 transformed cell line human CVCL_CQ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151945 CVCL_D293 HNK-1 hybridoma house mouse CVCL_D293 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:60322; Beta-D-GlcA3S-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc (HNK-1). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21151946 CVCL_CQ93 ND16490 transformed cell line human CVCL_CQ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151947 CVCL_D290 15-5-5S hybridoma house mouse CVCL_D290 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21151948 CVCL_CQ90 ND16464 transformed cell line human CVCL_CQ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151949 CVCL_D291 3G5 [Mouse hybridoma against O-acetylated gangliosides] hybridoma house mouse CVCL_D291 CL:0000010 Discontinued: BCRJ; 0015; probable. Monoclonal antibody isotype: IgM; Monoclonal antibody target: O-acetylated gangliosides 21151950 CVCL_CQ91 ND16465 transformed cell line human CVCL_CQ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151951 CVCL_CQ96 ND16499 transformed cell line human CVCL_CQ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151952 CVCL_D296 SK-6 spontaneously immortalized cell line pig CVCL_D296 CL:0000010 Derived from sampling site: Kidney. Discontinued: BCRJ; 0225; probable Female Virology: Susceptible to infection by a wide variety of viruses including porcine adenoviruses, vaccinia and swinepox viruses (PubMed=4336054) 21151953 CVCL_D297 CMP [Human contaminated rectal cancer] cancer cell line human CVCL_D297 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00003 Problematic cell line: Contaminated; Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928: PubMed=20143388) Originally thought to originate from a rectal adenocarcinoma. 21151954 CVCL_CQ97 ND16502 transformed cell line human CVCL_CQ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151955 CVCL_LK28 CW60453 induced pluripotent stem cell human CVCL_LK28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60453; true Male 21151956 CVCL_D294 MAR 18.5 hybridoma house mouse CVCL_D294 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Rat Ig kappa light chains (allotypes allotype IgK-1a and IgK-1b). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21151957 CVCL_CQ94 ND16492 transformed cell line human CVCL_CQ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151958 CVCL_LK29 CW60470 induced pluripotent stem cell human CVCL_LK29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60470; true Male 21151959 CVCL_CQ95 ND16493 transformed cell line human CVCL_CQ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151960 CVCL_D295 R24 hybridoma house mouse CVCL_D295 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8445 21151961 CVCL_LK26 CW60427 induced pluripotent stem cell human CVCL_LK26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60427; true Male 21151962 CVCL_LK27 CW60450 induced pluripotent stem cell human CVCL_LK27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60450; true Female 21151963 CVCL_LK24 CW60405 induced pluripotent stem cell human CVCL_LK24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60405; true Female 21151964 CVCL_LK25 CW60417 induced pluripotent stem cell human CVCL_LK25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60417; true Male 21151965 CVCL_LK22 CW60389 induced pluripotent stem cell human CVCL_LK22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60389; true Female 21151966 CVCL_LK23 CW60391 induced pluripotent stem cell human CVCL_LK23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60391; true Female 21151967 CVCL_LK20 CW60305 induced pluripotent stem cell human CVCL_LK20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60305; true Male 21151968 CVCL_LK21 CW60350 induced pluripotent stem cell human CVCL_LK21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60350; true Female 21151969 CVCL_LK40 CW70373 induced pluripotent stem cell human CVCL_LK40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70373; true Male 21151970 CVCL_LK41 RL7 spontaneously immortalized cell line house mouse CVCL_LK41 CL:0000010 Transfected with: HGNC; 3430; ERBB2 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male 21151971 CVCL_LK39 CW70372 induced pluripotent stem cell human CVCL_LK39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70372; true Male 21151972 CVCL_LK37 CW70366 induced pluripotent stem cell human CVCL_LK37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70366; true Male 21151973 CVCL_LK38 CW70371 induced pluripotent stem cell human CVCL_LK38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70371; true Male 21151974 CVCL_LK35 CW70201 induced pluripotent stem cell human CVCL_LK35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70201; true Female 21151975 CVCL_LK36 CW70343 induced pluripotent stem cell human CVCL_LK36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70343; true Male 21151976 CVCL_LK33 CW70143 induced pluripotent stem cell human CVCL_LK33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70143; true Female 21151977 CVCL_LK34 CW70155 induced pluripotent stem cell human CVCL_LK34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70155; true Male 21151978 CVCL_LK31 CW70097 induced pluripotent stem cell human CVCL_LK31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70097; true Male 21151979 CVCL_LK32 CW70115 induced pluripotent stem cell human CVCL_LK32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70115; true Female 21151980 CVCL_D278 ML5 transformed cell line human CVCL_D278 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female Doubling time: 1.9 +- 0.2 days (PubMed=9441775) 21151981 CVCL_CQ78 ND16399 transformed cell line human CVCL_CQ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151982 CVCL_D279 DAPT cancer cell line human CVCL_D279 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00040 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4472134; PubMed=20143388). Originally thought to originate from a 41 year old patient with an astrocytoma. 21151983 CVCL_CQ79 ND16401 transformed cell line human CVCL_CQ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151984 CVCL_D276 G9T/VGH cancer cell line human CVCL_D276 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 21151985 CVCL_CQ76 ND16394 transformed cell line human CVCL_CQ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151986 CVCL_D277 A224 cancer cell line human CVCL_D277 From: De Greve J.; Oncologisch Centrum; Brussels; Belgium. CL:0000010 Female 21151987 CVCL_CQ77 ND16395 transformed cell line human CVCL_CQ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151988 CVCL_D270 LMM3 cancer cell line house mouse CVCL_D270 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established from the MM3 variant of the M3 transplantable tumor Doubling time: 19 +- 0.5 hours (PubMed=21528237) 21151989 CVCL_CQ70 ND16383 transformed cell line human CVCL_CQ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151990 CVCL_D271 LT12 cancer cell line Norway rat CVCL_D271 CL:0000010 Breed/subspecies: Brown Norway. Female 21151991 CVCL_CQ71 ND16384 transformed cell line human CVCL_CQ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21151992 CVCL_LK08 CW50166 induced pluripotent stem cell human CVCL_LK08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50166; true Female 21151993 CVCL_CQ74 ND16392 transformed cell line human CVCL_CQ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151994 CVCL_D274 STSA-1 cancer cell line dog CVCL_D274 CL:0000010 Sequence variation: Mutation; VGNC; 43761; NF1; Simple; p.Met877fs (c.2626dupT); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male Doubling time: 40 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21151995 CVCL_D275 B6G-2 embryonic stem cell house mouse CVCL_D275 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: C57BL/6J. Discontinued: RCB; RCB2001; true Male 21151996 CVCL_LK09 CW50168 induced pluripotent stem cell human CVCL_LK09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50168; true Female 21151997 CVCL_CQ75 ND16393 transformed cell line human CVCL_CQ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21151998 CVCL_LK06 CW50156 induced pluripotent stem cell human CVCL_LK06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50156; true Female 21151999 CVCL_D272 MDM2-RNB transformed cell line Norway rat CVCL_D272 CL:0000010 Transfected with: HGNC; 6973; MDM2 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: Wistar. Unspecified 21152000 CVCL_CQ72 ND16389 transformed cell line human CVCL_CQ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152001 CVCL_LK07 CW50157 induced pluripotent stem cell human CVCL_LK07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50157; true Male 21152002 CVCL_CQ73 ND16390 transformed cell line human CVCL_CQ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152003 CVCL_D273 RNB finite cell line Norway rat CVCL_D273 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: Wistar. Unspecified Doubling time: 20 hours (lot 09212010) (JCRB) 21152004 CVCL_LK04 CW50119 induced pluripotent stem cell human CVCL_LK04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50119; true Male 21152005 CVCL_LK05 CW50155 induced pluripotent stem cell human CVCL_LK05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50155; true Female 21152006 CVCL_LK02 CW40191 induced pluripotent stem cell human CVCL_LK02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40191; true Male 21152007 CVCL_LK03 CW40225 induced pluripotent stem cell human CVCL_LK03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40225; true Male 21152008 CVCL_LK00 CW30528 induced pluripotent stem cell human CVCL_LK00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30528; true Female 21152009 CVCL_LK01 CW30529 induced pluripotent stem cell human CVCL_LK01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30529; true Male 21152010 CVCL_D289 KOP-R finite cell line CVCL_D289 CL:0000010 Derived from sampling site: Pharynx; oropharynx. 21152011 CVCL_CQ89 ND16455 transformed cell line human CVCL_CQ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152012 CVCL_D287 CI80-13A cancer cell line human CVCL_D287 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21152013 CVCL_CQ87 ND16439 transformed cell line human CVCL_CQ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152014 CVCL_D288 CI81-1 cancer cell line human CVCL_D288 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21152015 CVCL_CQ88 ND16441 transformed cell line human CVCL_CQ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152016 CVCL_D281 HBT-3 cancer cell line human CVCL_D281 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00052 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4469665; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21152017 CVCL_CQ81 ND16409 transformed cell line human CVCL_CQ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152018 CVCL_CQ82 ND16410 transformed cell line human CVCL_CQ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152019 CVCL_D282 PH61-N cancer cell line human CVCL_D282 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pancreas. Discontinued: JCRB; JCRB1038; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00342 Problematic cell line: Contaminated Shown to be a MIA PaCa-2 derivative (PubMed=20143388). 21152020 CVCL_D280 BrCA 5 cancer cell line human CVCL_D280 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00016 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=557237; PubMed=6451928; PubMed=20143388). Originally thought to originate from a ductal breast carcinoma. 21152021 CVCL_CQ80 ND16406 transformed cell line human CVCL_CQ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152022 CVCL_D285 CI80-13S cancer cell line human CVCL_D285 CL:0000010 Population: Caucasian; Derived from metastatic site: Not specified. Female 21152023 CVCL_LK19 CW60291 induced pluripotent stem cell human CVCL_LK19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60291; true Male 21152024 CVCL_CQ85 ND16426 transformed cell line human CVCL_CQ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152025 CVCL_D286 CI79-36 cancer cell line human CVCL_D286 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21152026 CVCL_CQ86 ND16429 transformed cell line human CVCL_CQ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152027 CVCL_LK17 CW60058 induced pluripotent stem cell human CVCL_LK17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60058; true Female 21152028 CVCL_D283 KP-P1 cancer cell line human CVCL_D283 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00071 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from a prostate carcinoma. 21152029 CVCL_CQ83 ND16411 transformed cell line human CVCL_CQ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152030 CVCL_LK18 CW60228 induced pluripotent stem cell human CVCL_LK18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60228; true Female 21152031 CVCL_D284 KS-1 [Human Krukenberg tumour] cancer cell line human CVCL_D284 CL:0000010 Derived from metastatic site: Ovary. Female Doubling time: 28 +- 2 hours (in suspension), 36 +- 2 hours (in monolayer culture) (PubMed=2846312) 21152032 CVCL_CQ84 ND16413 transformed cell line human CVCL_CQ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152033 CVCL_LK15 CW50176 induced pluripotent stem cell human CVCL_LK15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50176; true Male 21152034 CVCL_LK16 CW50177 induced pluripotent stem cell human CVCL_LK16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50177; true Female 21152035 CVCL_LK13 CW50174 induced pluripotent stem cell human CVCL_LK13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50174; true Female 21152036 CVCL_LK14 CW50175 induced pluripotent stem cell human CVCL_LK14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50175; true Female 21152037 CVCL_LK11 CW50170 induced pluripotent stem cell human CVCL_LK11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50170; true Female 21152038 CVCL_LK12 CW50173 induced pluripotent stem cell human CVCL_LK12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50173; true Female 21152039 CVCL_LK10 CW50169 induced pluripotent stem cell human CVCL_LK10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50169; true Female 21152040 CVCL_UE90 Ba/F3 LMNA-NTRK1-G667C factor-dependent cell line house mouse CVCL_UE90 CL:0000010 Transfected with: HGNC; 6636; LMNA (LMNA-NTRK1 fusion); Transfected with: HGNC; 8031; NTRK1 (LMNA-NTRK1 fusion; with p.Gly667Cys); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152041 CVCL_UE91 Ba/F3 SLC34A2-ROS1 factor-dependent cell line house mouse CVCL_UE91 CL:0000010 Transfected with: HGNC; 11020; SLC34A2 (SLC34A2-ROS1 fusion); Transfected with: HGNC; 10261; ROS1 (SLC34A2-ROS1 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152042 CVCL_UE94 293T OS8 transformed cell line human CVCL_UE94 CL:0000010 Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains Doubling time: ~30 hours (KYinno) 21152043 CVCL_UE95 293T OS8-hB7H4 transformed cell line human CVCL_UE95 CL:0000010 Transfected with: HGNC; 28873; VTCN1; Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains Doubling time: ~30 hours (KYinno) 21152044 CVCL_UE92 Ba/F3 SLC34A2-ROS1-G2032R factor-dependent cell line house mouse CVCL_UE92 CL:0000010 Transfected with: HGNC; 11020; SLC34A2 (SLC34A2-ROS1 fusion); Transfected with: HGNC; 10261; ROS1 (SLC34A2-ROS1 fusion; with p.Gly2032Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152045 CVCL_UE93 293T human EGFR vIII transformed cell line human CVCL_UE93 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152046 CVCL_UE98 BCH-30 transformed cell line human CVCL_UE98 HLA typing: A*02:01; B*51:08,40:01; C*16:02,03 (PubMed=28446606) CL:0000010 Sequence variation: Mutation; HGNC; 18173; ERAP1; Simple; p.Met349Val (c.1045A>G); dbSNP=rs2287987; Zygosity=Homozygous; Note=Allele ERAP1*001/Hap10 (PubMed=28446606); Sequence variation: Mutation; HGNC; 18173; ERAP1; Simple; p.Lys528Arg (c.1583A>G); dbSNP=rs30187; Zygosity=Homozygous; Note=Allele ERAP1*001/Hap10 (PubMed=28446606); Sequence variation: Mutation; HGNC; 18173; ERAP1; Simple; p.Asp575Asn (c.1723G>A); dbSNP=rs10050860; Zygosity=Homozygous; Note=Allele ERAP1*001/Hap10 (PubMed=28446606); Sequence variation: Mutation; HGNC; 18173; ERAP1; Simple; p.Arg725Gln (c.2174G>A); dbSNP=rs17482078; Zygosity=Homozygous; Note=Allele ERAP1*001/Hap10 (PubMed=28446606); Sequence variation: Mutation; HGNC; 18173; ERAP1; Simple; p.Gln730Glu (c.2188C>G); dbSNP=rs27044; Zygosity=Homozygous; Note=Allele ERAP1*001/Hap10 (PubMed=28446606) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21152047 CVCL_UE99 NP-2/iGFP cancer cell line human CVCL_UE99 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Characteristics: GFP-inducible indicator cell line produced by transfection of the pHIV-LTR-GFP-NLS plasmid, containing HIV-1 long terminal repeat (LTR), eGFP, the nuclear localization signal (NLS) of HIV-1 Rev and pac 21152048 CVCL_UE96 293T OS8-hPDL1 transformed cell line human CVCL_UE96 CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: MGI; MGI:88346; Cd8a (with Met1_Tyr196del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the ScFV sequence of anti-human CD3 mAb OKT3 and a C-terminal domain of mouse CD8a which consists of the transmembrane and cytoplasmic domains Doubling time: ~30 hours (KYinno) 21152049 CVCL_UE97 SW193 cancer cell line human CVCL_UE97 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Endometrium. Female 21152050 CVCL_UE80 Ba/F3 FLT3-D835V factor-dependent cell line house mouse CVCL_UE80 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with p.Asp835Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152051 CVCL_UE83 Ba/F3 FLT3-ITD-D835V factor-dependent cell line house mouse CVCL_UE83 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152052 CVCL_UE84 Ba/F3 FLT3-ITD-D835Y factor-dependent cell line house mouse CVCL_UE84 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Asp835Tyr); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152053 CVCL_UE81 Ba/F3 FLT3-D835Y factor-dependent cell line house mouse CVCL_UE81 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with p.Asp835Tyr); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152054 CVCL_UE82 Ba/F3 FLT3-ITD factor-dependent cell line house mouse CVCL_UE82 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152055 CVCL_UE87 Ba/F3 LMNA-NTRK1 factor-dependent cell line house mouse CVCL_UE87 CL:0000010 Transfected with: HGNC; 6636; LMNA (LMNA-NTRK1 fusion); Transfected with: HGNC; 8031; NTRK1 (LMNA-NTRK1 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152056 CVCL_UE88 Ba/F3 LMNA-NTRK1-F589L factor-dependent cell line house mouse CVCL_UE88 CL:0000010 Transfected with: HGNC; 6636; LMNA (LMNA-NTRK1 fusion); Transfected with: HGNC; 8031; NTRK1 (LMNA-NTRK1 fusion; with p.Phe589Leu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152057 CVCL_UE85 Ba/F3 FLT3-ITD-F691L factor-dependent cell line house mouse CVCL_UE85 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD and p.Phe691Leu); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152058 CVCL_UE86 Ba/F3 KIF5B-RET factor-dependent cell line house mouse CVCL_UE86 CL:0000010 Transfected with: HGNC; 6324; KIF5B (KIF5B-RET fusion); Transfected with: HGNC; 9967; RET (KIF5B-RET fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152059 CVCL_UE89 Ba/F3 LMNA-NTRK1-G595R factor-dependent cell line house mouse CVCL_UE89 CL:0000010 Transfected with: HGNC; 6636; LMNA (LMNA-NTRK1 fusion); Transfected with: HGNC; 8031; NTRK1 (LMNA-NTRK1 fusion; with p.Gly595Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152060 CVCL_UE72 Ba/F3 EML4-ALK-L1196M factor-dependent cell line house mouse CVCL_UE72 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Leu1196Met); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152061 CVCL_UE73 Ba/F3 ERBB2-A775_G776insYVMA factor-dependent cell line house mouse CVCL_UE73 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with p.Ala775_Gly776insTyrValMetAla); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152062 CVCL_UE70 Ba/F3 EML4-ALK-F1174L factor-dependent cell line house mouse CVCL_UE70 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Phe1174Leu); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152063 CVCL_UE71 Ba/F3 EML4-ALK-G1202R factor-dependent cell line house mouse CVCL_UE71 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Gly1202Arg); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152064 CVCL_UE76 Ba/F3 ETV6-NTRK2-G639R factor-dependent cell line house mouse CVCL_UE76 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK2 fusion); Transfected with: HGNC; 8032; NTRK2 (ETV6-NTRK2 fusion; with p.Gly623Arg (G639R)); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152065 CVCL_UE77 Ba/F3 ETV6-NTRK3 factor-dependent cell line house mouse CVCL_UE77 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK3 fusion); Transfected with: HGNC; 8033; NTRK3 (ETV6-NTRK3 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152066 CVCL_UE74 Ba/F3 ETV6-NTRK2 factor-dependent cell line house mouse CVCL_UE74 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK2 fusion); Transfected with: HGNC; 8032; NTRK2 (ETV6-NTRK2 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152067 CVCL_UE75 Ba/F3 ETV6-NTRK2-G709C factor-dependent cell line house mouse CVCL_UE75 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK2 fusion); Transfected with: HGNC; 8032; NTRK2 (ETV6-NTRK2 fusion; with p.Gly693Cys (G709C)); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152068 CVCL_UE78 Ba/F3 ETV6-NTRK3-G623R factor-dependent cell line house mouse CVCL_UE78 CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-NTRK3 fusion); Transfected with: HGNC; 8033; NTRK3 (ETV6-NTRK3 fusion; with p.Gly623Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152069 CVCL_UE79 Ba/F3 FLT3 factor-dependent cell line house mouse CVCL_UE79 CL:0000010 Transfected with: HGNC; 3765; FLT3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152070 CVCL_UE61 293T mouse CLDN18.2 transformed cell line human CVCL_UE61 CL:0000010 Transfected with: MGI; MGI:1929209; Cldn18 (isoform A2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152071 CVCL_UE62 Ba/F3 AXL factor-dependent cell line house mouse CVCL_UE62 CL:0000010 Transfected with: HGNC; 905; AXL; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152072 CVCL_UE60 293T mouse CCR6 transformed cell line human CVCL_UE60 CL:0000010 Transfected with: MGI; MGI:1333797; Ccr6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152073 CVCL_UE65 Ba/F3 BTK C481S factor-dependent cell line house mouse CVCL_UE65 CL:0000010 Transfected with: HGNC; 1133; BTK (with p.Cys481Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152074 CVCL_UE66 Ba/F3 c-Kit D816V factor-dependent cell line house mouse CVCL_UE66 CL:0000010 Transfected with: HGNC; 6342; KIT (with p.Asp816Val); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152075 CVCL_UE63 Ba/F3 BCR-ABL factor-dependent cell line house mouse CVCL_UE63 CL:0000010 Transfected with: HGNC; 76; ABL1 (BCR-ABL1 fusion); Transfected with: HGNC; 1014; BCR (BCR-ABL1 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152076 CVCL_UE64 Ba/F3 BCR-ABL-T315I factor-dependent cell line house mouse CVCL_UE64 CL:0000010 Transfected with: HGNC; 76; ABL1 (BCR-ABL1 fusion; with p.Thr315Ile); Transfected with: HGNC; 1014; BCR (BCR-ABL1 fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152077 CVCL_UE69 Ba/F3 EML4-ALK-C1156Y factor-dependent cell line house mouse CVCL_UE69 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion; with p.Cys1156Tyr); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152078 CVCL_UE67 Ba/F3 CSF1R factor-dependent cell line house mouse CVCL_UE67 CL:0000010 Transfected with: HGNC; 2433; CSF1R; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152079 CVCL_UE68 Ba/F3 EML4-ALK factor-dependent cell line house mouse CVCL_UE68 CL:0000010 Transfected with: HGNC; 427; ALK (EML4-ALK fusion); Transfected with: HGNC; 1316; EML4 (EML4-ALK fusion); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21152080 CVCL_UE50 293T human TIGIT transformed cell line human CVCL_UE50 CL:0000010 Transfected with: HGNC; 26838; TIGIT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152081 CVCL_UE51 293T human TIM3 transformed cell line human CVCL_UE51 CL:0000010 Transfected with: HGNC; 18437; HAVCR2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152082 CVCL_UE54 293T cyno CCR6 transformed cell line human CVCL_UE54 CL:0000010 Transfected with: UniProtKB; A0A2K5WY45; Macaca fascicularis CCR6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152083 CVCL_UE55 293T cyno CD123 transformed cell line human CVCL_UE55 CL:0000010 Transfected with: UniProtKB; G8F3K3; Macaca fascicularis IL3RA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152084 CVCL_UE52 293T human TROP2 transformed cell line human CVCL_UE52 CL:0000010 Transfected with: HGNC; 11530; TACSTD2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152085 CVCL_UE53 293T cyno BCMA transformed cell line human CVCL_UE53 CL:0000010 Transfected with: UniProtKB; G7Q0I4; Macaca fascicularis TNFRSF17; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152086 CVCL_UE58 293T cyno DLL3 transformed cell line human CVCL_UE58 CL:0000010 Transfected with: UniProtKB; A0A2K5WSR4; Macaca fascicularis DLL3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152087 CVCL_UE59 293T cyno OX40 transformed cell line human CVCL_UE59 CL:0000010 Transfected with: UniProtKB; A0A2K5TJH8; Macaca fascicularis TNFRSF4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152088 CVCL_UE56 293T cyno CD137 transformed cell line human CVCL_UE56 CL:0000010 Transfected with: UniProtKB; A9YYE7; Macaca fascicularis TNFRSF9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152089 CVCL_UE57 293T cyno LAG3 transformed cell line human CVCL_UE57 CL:0000010 Transfected with: UniProtKB; A0A2K5V5Q3; Macaca fascicularis LAG3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152090 CVCL_UE40 293T human FOLH1 transformed cell line human CVCL_UE40 CL:0000010 Transfected with: HGNC; 3788; FOLH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152091 CVCL_UE43 293T human NRP1 transformed cell line human CVCL_UE43 CL:0000010 Transfected with: HGNC; 8004; NRP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152092 CVCL_UE44 293T human OX40 transformed cell line human CVCL_UE44 CL:0000010 Transfected with: HGNC; 11918; TNFRSF4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152093 CVCL_UE41 293T human GPC3 transformed cell line human CVCL_UE41 CL:0000010 Transfected with: HGNC; 4451; GPC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152094 CVCL_UE42 293T human LAG3 transformed cell line human CVCL_UE42 CL:0000010 Transfected with: HGNC; 6476; LAG3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152095 CVCL_UE47 293T human PDL1 transformed cell line human CVCL_UE47 CL:0000010 Transfected with: HGNC; 17635; CD274; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152096 CVCL_UE48 293T human PDL2 transformed cell line human CVCL_UE48 CL:0000010 Transfected with: HGNC; 18731; PDCD1LG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152097 CVCL_UE45 293T human OX40L transformed cell line human CVCL_UE45 CL:0000010 Transfected with: HGNC; 11934; TNFSF4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152098 CVCL_UE46 293T human PD-1 transformed cell line human CVCL_UE46 CL:0000010 Transfected with: HGNC; 8760; PDCD1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152099 CVCL_UE49 293T human ROR1 transformed cell line human CVCL_UE49 CL:0000010 Transfected with: HGNC; 10256; ROR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152100 CVCL_LK95 Calu-4 cancer cell line human CVCL_LK95 CL:0000010 Unspecified 21152101 CVCL_LK96 HPSI1014i-xiyh_3 induced pluripotent stem cell human CVCL_LK96 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152102 CVCL_LK93 SK-L9 cancer cell line human CVCL_LK93 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Spleen. Female 21152103 CVCL_LK94 SK-LN1 finite cell line human CVCL_LK94 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Lymph node. 21152104 CVCL_LK91 T-82 cancer cell line human CVCL_LK91 CL:0000010 Unspecified 21152105 CVCL_LK92 SK-L10 cancer cell line human CVCL_LK92 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. 21152106 CVCL_LK90 T-77 cancer cell line human CVCL_LK90 CL:0000010 Donor information: Established from a patient suffering from 'reticulum cell sarcoma'. Male 21152107 CVCL_UE32 HT1080 human GITR cancer cell line human CVCL_UE32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11914; TNFRSF18; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: ~48 hours (KYinno) 21152108 CVCL_UE33 OCI-AML-20 cancer cell line human CVCL_UE33 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=30352278) Karyotypic information: Monosomy of chromosome 7 (PubMed=30352278); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Doubling time: 57 hours (PubMed=30352278) 21152109 CVCL_UE30 NCI-H1975 EGFR T790M/C797S/L858R cancer cell line human CVCL_UE30 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple_edited; p.Cys797Ser (c.2389T>A); ClinVar=VCV000376342; Zygosity=Unspecified; Note=By CRISPR/Cas9 (KYinno); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). Female 21152110 CVCL_UE31 HT1080 human OX40 cancer cell line human CVCL_UE31 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11918; TNFRSF4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: ~48 hours (KYinno) 21152111 CVCL_UE36 293T human CCR6 transformed cell line human CVCL_UE36 CL:0000010 Transfected with: HGNC; 1607; CCR6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152112 CVCL_UE37 293T human CTLA4 transformed cell line human CVCL_UE37 CL:0000010 Transfected with: HGNC; 2505; CTLA4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152113 CVCL_UE34 293T human B7H4 transformed cell line human CVCL_UE34 CL:0000010 Transfected with: HGNC; 28873; VTCN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152114 CVCL_UE35 293T human BCMA transformed cell line human CVCL_UE35 CL:0000010 Transfected with: HGNC; 11913; TNFRSF17; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152115 CVCL_UE38 293T human DLL3 transformed cell line human CVCL_UE38 CL:0000010 Transfected with: HGNC; 2909; DLL3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152116 CVCL_UE39 293T human Epcam transformed cell line human CVCL_UE39 CL:0000010 Transfected with: HGNC; 11529; EPCAM; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152117 CVCL_LK88 SK-RCS1 cancer cell line human CVCL_LK88 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Donor information: Established from a patient suffering from 'reticulum cell sarcoma'; Derived from sampling site: Pleural effusion. Female Doubling time: 2-3 days (PubMed=4180348) 21152118 CVCL_LK89 AHE-1 cancer cell line human CVCL_LK89 CL:0000010 Unspecified 21152119 CVCL_LK86 LuKII transformed cell line human CVCL_LK86 CL:0000010 Derived from sampling site: Cell type=B-cell. Unspecified Characteristics: Produces TNF Problematic cell line: Misidentified Originally thought to derive from RPMI-8866 but, based on differences in phosphoglucomutase-1 isozyme fingerprints, was determined not to be originating from that cell line (PubMed=6160588). 21152120 CVCL_LK87 T1-18 hybridoma house mouse CVCL_LK87 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01375; Human TNF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8887 21152121 CVCL_UE21 293T human CD138 transformed cell line human CVCL_UE21 CL:0000010 Transfected with: HGNC; 10658; SDC1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152122 CVCL_UE22 293T human CD154(CD40L) transformed cell line human CVCL_UE22 CL:0000010 Transfected with: HGNC; 11935; CD40LG; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152123 CVCL_UE20 293T human CD137 transformed cell line human CVCL_UE20 CL:0000010 Transfected with: HGNC; 11924; TNFRSF9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152124 CVCL_UE25 293T human CD40 transformed cell line human CVCL_UE25 CL:0000010 Transfected with: HGNC; 11919; CD40; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152125 CVCL_UE26 CHO-K1 human CD47 spontaneously immortalized cell line CVCL_UE26 CL:0000010 Transfected with: HGNC; 1682; CD47; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21152126 CVCL_UE23 293T human CD22 transformed cell line human CVCL_UE23 CL:0000010 Transfected with: HGNC; 1643; CD22; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152127 CVCL_UE24 293T human CD33 transformed cell line human CVCL_UE24 CL:0000010 Transfected with: HGNC; 1659; CD33; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21152128 CVCL_UE29 CT26.WT human B7H4 cancer cell line house mouse CVCL_UE29 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gly12Asp (c.35G>A); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 28873; VTCN1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Colon; Breed/subspecies: BALB/c. Female 21152129 CVCL_UE27 CHO-K1 human INSR spontaneously immortalized cell line CVCL_UE27 CL:0000010 Transfected with: HGNC; 6091; INSR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21152130 CVCL_UE28 CHO-K1 human MSLN spontaneously immortalized cell line CVCL_UE28 CL:0000010 Transfected with: HGNC; 7371; MSLN; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female Doubling time: ~24 hours (KYinno) 21152131 CVCL_LK99 HPSI0115i-iuad_2 induced pluripotent stem cell human CVCL_LK99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152132 CVCL_LK97 HPSI0115i-bimq_4 induced pluripotent stem cell human CVCL_LK97 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152133 CVCL_LK98 HPSI0115i-boqx_2 induced pluripotent stem cell human CVCL_LK98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152134 CVCL_UD91 WAe001-A-20 embryonic stem cell human CVCL_UD91 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4319; GLI3. Male 21152135 CVCL_UD92 VRC-4 spontaneously immortalized cell line human CVCL_UD92 CL:0000010 Derived from sampling site: Amnion. Unspecified Caution: This is said to be a spontaneously immortalized amnion-derived cell line At the time this cell line was established other amnion-derived cell lines were thought to exist (AV3, FL, WISH), but all these cell lines were later shown to be HeLa contaminated. As there is no publication reporting the use and characterisation of VRC-4 except the original one, it is impossible to establish the real origin of this cell line. 21152136 CVCL_UD90 IMEDEAi004-B induced pluripotent stem cell human CVCL_UD90 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Arg245His (c.734G>A); ClinVar=VCV000005107; Zygosity=Heterozygous (PubMed=30269021); Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Glu447Lys (c.1339G>A); ClinVar=VCV000005114; Zygosity=Heterozygous (PubMed=30269021) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152137 CVCL_UD95 GM04912 iPSC induced pluripotent stem cell human CVCL_UD95 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp481Glyfs*39 (c.1441delT); ClinVar=VCV000972761; Zygosity=Heterozygous (PubMed=25488666); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp746Ter (c.2237G>A); ClinVar=VCV000280063; Zygosity=Heterozygous (PubMed=25488666) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152138 CVCL_UD96 Nalm-6-TK+/- cancer cell line human CVCL_UD96 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21152139 CVCL_UD93 GM20089 iPSC induced pluripotent stem cell human CVCL_UD93 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Homozygous (PubMed=25488666) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152140 CVCL_UD94 GM20123 iPSC induced pluripotent stem cell human CVCL_UD94 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Unexplicit; Ex18del; Zygosity=Heterozygous (PubMed=25488666) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152141 CVCL_UD99 SNU-3178S cancer cell line human CVCL_UD99 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: Seoul National University (SNU) cell line collection 21152142 CVCL_UD97 PM1015 cancer cell line human CVCL_UD97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=8557231) Derived from metastatic site: Pleural effusion. Female Doubling time: 48 hours (PubMed=7821846) 21152143 CVCL_UD98 SNU-2972-1 cancer cell line human CVCL_UD98 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Seoul National University (SNU) cell line collection 21152144 CVCL_UD80 HT149B induced pluripotent stem cell human CVCL_UD80 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152145 CVCL_UD81 HT149E induced pluripotent stem cell human CVCL_UD81 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152146 CVCL_UD84 CBTCi005-A induced pluripotent stem cell human CVCL_UD84 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=30296668) Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Female 21152147 CVCL_UD85 CBTCi006-A induced pluripotent stem cell human CVCL_UD85 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=30296668) Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Male 21152148 CVCL_UD82 ASUi005-A induced pluripotent stem cell human CVCL_UD82 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=30296667) Derived from sampling site: Peripheral blood. Male 21152149 CVCL_UD83 ASUi006-A induced pluripotent stem cell human CVCL_UD83 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=30296667) Derived from sampling site: Peripheral blood. Female 21152150 CVCL_UD88 HIHDNEi001-A induced pluripotent stem cell human CVCL_UD88 From: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Leu328Val (c.982T>G); Zygosity=Heterozygous (PubMed=30292882) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152151 CVCL_UD89 IMEDEAi004-A induced pluripotent stem cell human CVCL_UD89 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Arg245His (c.734G>A); ClinVar=VCV000005107; Zygosity=Heterozygous (PubMed=30269021); Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Glu447Lys (c.1339G>A); ClinVar=VCV000005114; Zygosity=Heterozygous (PubMed=30269021) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152152 CVCL_UD86 CBTCi007-A induced pluripotent stem cell human CVCL_UD86 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=30296668) Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Female 21152153 CVCL_UD87 CSi001-A induced pluripotent stem cell human CVCL_UD87 From: Changshu No.2 Hospital, Yangzhou University School of Medicine; Suchow; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21152154 CVCL_D256 GILM2 cancer cell line human CVCL_D256 CL:0000010 Derived from sampling site: Breast. Female Characteristics: Metastatic phenotype obtained by injection of parent cell line in nude mice and selection of cells from lung metastases Doubling time: 24 hours, in a medium with 10% serum (PubMed=14598885) 21152155 CVCL_CQ56 ND16285 transformed cell line human CVCL_CQ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152156 CVCL_D257 MDA-MB-231-luc-D3H2LN cancer cell line human CVCL_D257 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 119369; true Female Group: Triple negative breast cancer (TNBC) cell line 21152157 CVCL_CQ57 ND16296 transformed cell line human CVCL_CQ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152158 CVCL_D254 FA9JTO hTERT-1 telomerase immortalized cell line human CVCL_D254 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1463; probable Male 21152159 CVCL_CQ54 ND16272 transformed cell line human CVCL_CQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152160 CVCL_D255 GILM1 cancer cell line human CVCL_D255 CL:0000010 Derived from sampling site: Breast. Female Characteristics: Metastatic phenotype obtained by injection of parent cell line in nude mice and selection of cells from lung metastases 21152161 CVCL_CQ55 ND16274 transformed cell line human CVCL_CQ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152162 CVCL_CQ58 ND16297 transformed cell line human CVCL_CQ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152163 CVCL_D259 HeLa-MAGI cancer cell line human CVCL_D259 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21152164 CVCL_CQ59 ND16316 transformed cell line human CVCL_CQ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152165 CVCL_CQ52 ND16263 transformed cell line human CVCL_CQ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152166 CVCL_D252 UISO-BCA-4 cancer cell line human CVCL_D252 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21152167 CVCL_D253 FA18JTO hTERT telomerase immortalized cell line human CVCL_D253 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1811delT; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1389; probable Male 21152168 CVCL_CQ53 ND16264 transformed cell line human CVCL_CQ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152169 CVCL_CQ50 ND16250 transformed cell line human CVCL_CQ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152170 CVCL_D250 UISO-BCA-2 cancer cell line human CVCL_D250 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 56.0 +/- 5.0 hours (PubMed=1377894) 21152171 CVCL_CQ51 ND16262 transformed cell line human CVCL_CQ51 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152172 CVCL_D251 UISO-BCA-3 cancer cell line human CVCL_D251 CL:0000010 Female 21152173 CVCL_D267 KU-2 cancer cell line human CVCL_D267 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Characteristics: Established from a xenograft maintained in nude mice Doubling time: 26 hours (PubMed=661038) 21152174 CVCL_CQ67 ND16372 transformed cell line human CVCL_CQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152175 CVCL_D268 LDV/7 spontaneously immortalized cell line human CVCL_D268 CL:0000010 Derived from sampling site: Peripheral blood. Male Group: Patented cell line 21152176 CVCL_CQ68 ND16373 transformed cell line human CVCL_CQ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152177 CVCL_D265 CHO-CHRC4 spontaneously immortalized cell line CVCL_D265 CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female 21152178 CVCL_CQ65 ND16359 transformed cell line human CVCL_CQ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152179 CVCL_D266 CHO-CHRC5 spontaneously immortalized cell line CVCL_D266 CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female 21152180 CVCL_CQ66 ND16371 transformed cell line human CVCL_CQ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152181 CVCL_D269 LM3 cancer cell line house mouse CVCL_D269 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Characteristics: Established from the M3 transplantable tumor Doubling time: 19 +- 0.5 hours (PubMed=21528237) 21152182 CVCL_CQ69 ND16377 transformed cell line human CVCL_CQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152183 CVCL_D260 HeLa-MAGI-CCR5 cancer cell line human CVCL_D260 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21152184 CVCL_CQ60 ND16317 transformed cell line human CVCL_CQ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152185 CVCL_D263 AH125 cancer cell line human CVCL_D263 CL:0000010 21152186 CVCL_CQ63 ND16347 transformed cell line human CVCL_CQ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152187 CVCL_D264 CHO-AUXB1 spontaneously immortalized cell line CVCL_D264 CL:0000010 Derived from sampling site: Ovary. Female 21152188 CVCL_CQ64 ND16348 transformed cell line human CVCL_CQ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152189 CVCL_CQ61 ND16321 transformed cell line human CVCL_CQ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152190 CVCL_D261 RN46A transformed cell line Norway rat CVCL_D261 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; medullary raphe nucleus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: At the restrictive temperature (39 Celsius) the cells are capable of differentiating Doubling time: 19 hours (ECACC=12061302) 21152191 CVCL_D262 Ac2F spontaneously immortalized cell line Norway rat CVCL_D262 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 68.5 hours (PubMed=90011) 21152192 CVCL_CQ62 ND16334 transformed cell line human CVCL_CQ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152193 CVCL_D234 51B LiM-2 cancer cell line house mouse CVCL_D234 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152194 CVCL_CQ34 ND16062 transformed cell line human CVCL_CQ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152195 CVCL_D235 51B LiM-3 cancer cell line house mouse CVCL_D235 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152196 CVCL_CQ35 ND16063 transformed cell line human CVCL_CQ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152197 CVCL_D232 51B cancer cell line house mouse CVCL_D232 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152198 CVCL_CQ32 ND16045 transformed cell line human CVCL_CQ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152199 CVCL_D233 51B LiM-1 cancer cell line house mouse CVCL_D233 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152200 CVCL_CQ33 ND16052 transformed cell line human CVCL_CQ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152201 CVCL_D238 51B LiM-6 cancer cell line house mouse CVCL_D238 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152202 CVCL_CQ38 ND16072 transformed cell line human CVCL_CQ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152203 CVCL_D239 JAM cancer cell line human CVCL_D239 CL:0000010 Female 21152204 CVCL_CQ39 ND16075 transformed cell line human CVCL_CQ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152205 CVCL_D236 51B LiM-4 cancer cell line house mouse CVCL_D236 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152206 CVCL_CQ36 ND16064 transformed cell line human CVCL_CQ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152207 CVCL_D237 51B LiM-5 cancer cell line house mouse CVCL_D237 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: BALB/c. 21152208 CVCL_CQ37 ND16068 transformed cell line human CVCL_CQ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152209 CVCL_D230 Lc817 cancer cell line human CVCL_D230 CL:0000010 Unspecified 21152210 CVCL_CQ30 ND16037 transformed cell line human CVCL_CQ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152211 CVCL_D231 1-87 cancer cell line human CVCL_D231 HLA typing: A*02:07,11:01; B*46:01,54:01; C*01:02 (PubMed=9178645) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816). Population: Japanese Unspecified 21152212 CVCL_CQ31 ND16044 transformed cell line human CVCL_CQ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152213 CVCL_D245 MAXF 583 cancer cell line human CVCL_D245 CL:0000010 Derived from metastatic site: Lung. Female Characteristics: Developed from a breast tumor xenograft developed in athymic mice 21152214 CVCL_CQ45 ND16203 transformed cell line human CVCL_CQ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152215 CVCL_D246 MAXF 449 cancer cell line human CVCL_D246 CL:0000010 Female 21152216 CVCL_CQ46 ND16207 transformed cell line human CVCL_CQ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152217 CVCL_D243 GXF 251L cancer cell line human CVCL_D243 CL:0000010 21152218 CVCL_CQ43 ND16197 transformed cell line human CVCL_CQ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152219 CVCL_CQ44 ND16198 transformed cell line human CVCL_CQ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152220 CVCL_D244 OHSTMAM-4 cancer cell line human CVCL_D244 CL:0000010 Derived from metastatic site: Submandibular mass. Female Characteristics: Developed from a breast tumor xenograft developed in athymic mice 21152221 CVCL_CQ49 ND16249 transformed cell line human CVCL_CQ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152222 CVCL_D249 UISO-BCA-1 cancer cell line human CVCL_D249 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 31.2 +/- 9.6 hours (PubMed=1377894) 21152223 CVCL_D247 MAXF 713 cancer cell line human CVCL_D247 CL:0000010 Female 21152224 CVCL_CQ47 ND16233 transformed cell line human CVCL_CQ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152225 CVCL_D248 HAMT-1 cancer cell line human CVCL_D248 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 18-20 hours (PubMed=2625822; PubMed=21597716) Group: Serum/protein free medium cell line 21152226 CVCL_CQ48 ND16246 transformed cell line human CVCL_CQ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152227 CVCL_D241 Gro2C spontaneously immortalized cell line house mouse CVCL_D241 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21152228 CVCL_CQ41 ND16100 transformed cell line human CVCL_CQ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152229 CVCL_CQ42 ND16181 transformed cell line human CVCL_CQ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152230 CVCL_D242 Sog9 spontaneously immortalized cell line house mouse CVCL_D242 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21152231 CVCL_D240 LiM6 cancer cell line human CVCL_D240 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Has high liver-metastasizing ability during cecal growth, was established from parent cell line by serially selecting cells which metastasized from cecum to liver (PubMed=1999484) 21152232 CVCL_CQ40 ND16099 transformed cell line human CVCL_CQ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152233 CVCL_D218 HNO222 cancer cell line human CVCL_D218 CL:0000010 Derived from sampling site: Larynx. 21152234 CVCL_CQ18 ND15973 transformed cell line human CVCL_CQ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152235 CVCL_D219 HNO223 cancer cell line human CVCL_D219 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Female 21152236 CVCL_CQ19 ND15977 transformed cell line human CVCL_CQ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152237 CVCL_D212 HNO180 cancer cell line human CVCL_D212 CL:0000010 Derived from sampling site: Pharynx; oropharynx. Male Caution: From hypopharynx according to PubMed=12794754 but from oropharynx according to PubMed=20149059 21152238 CVCL_CQ12 ND15944 transformed cell line human CVCL_CQ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152239 CVCL_D213 HNO199 cancer cell line human CVCL_D213 CL:0000010 Derived from sampling site: Oral cavity. Female 21152240 CVCL_CQ13 ND15950 transformed cell line human CVCL_CQ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152241 CVCL_D210 HNO150 cancer cell line human CVCL_D210 CL:0000010 Derived from sampling site: Larynx. Female 21152242 CVCL_CQ10 ND15936 transformed cell line human CVCL_CQ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152243 CVCL_D211 HNO160 cancer cell line human CVCL_D211 CL:0000010 Derived from sampling site: Oral cavity. Female 21152244 CVCL_CQ11 ND15941 transformed cell line human CVCL_CQ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152245 CVCL_D216 HNO211 cancer cell line human CVCL_D216 CL:0000010 Derived from sampling site: Pharynx; oropharynx. Male 21152246 CVCL_CQ16 ND15958 transformed cell line human CVCL_CQ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152247 CVCL_D217 HNO212 cancer cell line human CVCL_D217 CL:0000010 Derived from sampling site: Oral cavity. Female 21152248 CVCL_CQ17 ND15972 transformed cell line human CVCL_CQ17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152249 CVCL_D214 HNO206 cancer cell line human CVCL_D214 CL:0000010 Derived from sampling site: Pharynx; oropharynx. Male 21152250 CVCL_CQ14 ND15951 transformed cell line human CVCL_CQ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152251 CVCL_D215 HNO210 cancer cell line human CVCL_D215 CL:0000010 Population: Caucasian; Derived from sampling site: Larynx. Male 21152252 CVCL_CQ15 ND15957 transformed cell line human CVCL_CQ15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152253 CVCL_D229 LNY1 cancer cell line human CVCL_D229 HLA typing: A*26,31; B*51,54; C*04,10 (PubMed=19818766). CL:0000010 Population: Japanese 21152254 CVCL_CQ29 ND16036 transformed cell line human CVCL_CQ29 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152255 CVCL_D223 HNO306 cancer cell line human CVCL_D223 CL:0000010 Derived from sampling site: Oral cavity. 21152256 CVCL_CQ23 ND16004 transformed cell line human CVCL_CQ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152257 CVCL_D224 HNO41 cancer cell line human CVCL_D224 CL:0000010 Population: Caucasian; Derived from sampling site: Pharynx; oropharynx. Male 21152258 CVCL_CQ24 ND16014 transformed cell line human CVCL_CQ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152259 CVCL_D221 HNO258 cancer cell line human CVCL_D221 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity. Male 21152260 CVCL_CQ21 ND15985 transformed cell line human CVCL_CQ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152261 CVCL_D222 HNO268 cancer cell line human CVCL_D222 CL:0000010 Derived from sampling site: Pharynx; oropharynx. 21152262 CVCL_CQ22 ND15989 transformed cell line human CVCL_CQ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152263 CVCL_D227 HNO97 cancer cell line human CVCL_D227 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue. Male 21152264 CVCL_CQ27 ND16027 transformed cell line human CVCL_CQ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152265 CVCL_D228 LHK2 cancer cell line human CVCL_D228 HLA typing: A*02:07,24:02; B*46:01,48:01; C*01:02 (PubMed=19818766) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21152266 CVCL_CQ28 ND16035 transformed cell line human CVCL_CQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152267 CVCL_D225 HNO89 cancer cell line human CVCL_D225 CL:0000010 Derived from sampling site: Larynx. Male 21152268 CVCL_CQ25 ND16019 transformed cell line human CVCL_CQ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152269 CVCL_D226 HNO91 cancer cell line human CVCL_D226 CL:0000010 Derived from sampling site: Oral cavity. Male 21152270 CVCL_CQ26 ND16022 transformed cell line human CVCL_CQ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152271 CVCL_D220 HNO237 cancer cell line human CVCL_D220 CL:0000010 21152272 CVCL_CQ20 ND15983 transformed cell line human CVCL_CQ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152273 CVCL_D209 HNO147 cancer cell line human CVCL_D209 CL:0000010 Derived from sampling site: Pharynx; hypopharynx. Male 21152274 CVCL_CQ09 ND15914 transformed cell line human CVCL_CQ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152275 CVCL_D207 HNO124 cancer cell line human CVCL_D207 CL:0000010 Derived from sampling site: Oral cavity. Male 21152276 CVCL_CQ07 ND15908 transformed cell line human CVCL_CQ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152277 CVCL_D208 HNO136 cancer cell line human CVCL_D208 CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus. Female 21152278 CVCL_CQ08 ND15909 transformed cell line human CVCL_CQ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152279 CVCL_D201 K562-IMR cancer cell line human CVCL_D201 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21152280 CVCL_CQ01 ND15871 transformed cell line human CVCL_CQ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152281 CVCL_D202 MYL cancer cell line human CVCL_D202 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=17432977) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Female 21152282 CVCL_CQ02 ND15890 transformed cell line human CVCL_CQ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152283 CVCL_D200 KT-1 [Human leukemia] cancer cell line human CVCL_D200 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9427720; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Sensitive to the antiproliferative and apoptosis-inducing effects of IFN-alpha Doubling time: 18-24 hours (PubMed=9427720) 21152284 CVCL_CQ00 ND15863 transformed cell line human CVCL_CQ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152285 CVCL_D205 K562/D1-9 cancer cell line human CVCL_D205 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Pleural effusion. Female 21152286 CVCL_CQ05 ND15906 transformed cell line human CVCL_CQ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152287 CVCL_CQ06 ND15907 transformed cell line human CVCL_CQ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152288 CVCL_D206 NWT-21 spontaneously immortalized cell line house mouse CVCL_D206 CL:0000010 Transfected with: HGNC; 5465; IGF1R Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21152289 CVCL_D203 MYL-R cancer cell line human CVCL_D203 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=17432977) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Female 21152290 CVCL_CQ03 ND15901 transformed cell line human CVCL_CQ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152291 CVCL_D204 FLC-4 cancer cell line human CVCL_D204 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Cys78Ter (c.234T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line) Population: Japanese Omics: Transcriptome analysis by microarray Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5165 Caution: FLC-4 is often stated to be synonymous with JHH-4 (Cellosaurus=CVCL_2787), but the patent reference (Patent=US5804441) seems to indicate that FLC-4 is derived from JHH-4 and has a different karyotype. 21152292 CVCL_CQ04 ND15905 transformed cell line human CVCL_CQ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152293 CVCL_LL94 HPSI1116i-vozo_3 induced pluripotent stem cell human CVCL_LL94 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152294 CVCL_LL95 HPSI1116i-wakr_3 induced pluripotent stem cell human CVCL_LL95 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152295 CVCL_LL92 HPSI1116i-mebq_7 induced pluripotent stem cell human CVCL_LL92 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152296 CVCL_LL93 HPSI1116i-vozo_2 induced pluripotent stem cell human CVCL_LL93 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152297 CVCL_LL90 HPSI1116i-eiyy_1 induced pluripotent stem cell human CVCL_LL90 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152298 CVCL_LL91 HPSI1116i-mebq_1 induced pluripotent stem cell human CVCL_LL91 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152299 CVCL_UF31 HEK-Blue IL-12 transformed cell line human CVCL_UF31 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5971; IL12RB1; Transfected with: HGNC; 5972; IL12RB2; Transfected with: HGNC; 6192; JAK2; Transfected with: HGNC; 11365; STAT4; Transfected with: HGNC; 12440; TYK2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and mouse IL12 by monitoring the activation of the STAT4 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT4 promoter 21152300 CVCL_UF32 HEK-Blue IL-17 transformed cell line human CVCL_UF32 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5985; IL17RA; Transfected with: HGNC; 18358; IL17RC; Transfected with: HGNC; 1343; TRAF3IP2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human and murine IL17A and IL17F by monitoring the activation of the NF-kappaB and AP-1 pathways (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the IFN-beta minimal promoter fused to five NF-kappaB and five AP-1 binding sites 21152301 CVCL_UF30 HEK-Blue IFN-gamma transformed cell line human CVCL_UF30 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11362; STAT1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human IFN-gamma by monitoring the activation of the JAK/STAT1 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the ISG54 promoter fused to four interferon-gamma-activated sites (GAS) 21152302 CVCL_UF35 IB-RS-2 clone 13 spontaneously immortalized cell line pig CVCL_UF35 CL:0000010 Derived from sampling site: Kidney. Female 21152303 CVCL_UF36 IB-RS-10-I spontaneously immortalized cell line pig CVCL_UF36 CL:0000010 Karyotypic information: Diploid karyotype; Derived from sampling site: Kidney; Breed/subspecies: Landrace x Yorkshire x Edelschwein. Female Virology: Susceptible to infection by foot-and-mouth disease virus Less susceptible than IB-RS-10-II. 21152304 CVCL_UF33 HEK-Blue IL-18 transformed cell line human CVCL_UF33 CL:0000010 Knockout cell: Method=Not specified; HGNC; 5993; IL1R1; Knockout cell: Method=Not specified; HGNC; 5995; IL1RAP; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5988; IL18R1; Transfected with: HGNC; 5989; IL18RAP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human IL18 (and to a lesser extent mouse IL18) by monitoring the activation of the NF-kappaB and AP-1 pathways In addition, the TNF-alpha and the IL-1beta responses have been blocked (InvivoGen).; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a promoter with NF-kappaB and AP-1-binding sites 21152305 CVCL_UF34 IB-RS-11 spontaneously immortalized cell line pig CVCL_UF34 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Landrace. Female 21152306 CVCL_UF39 CIBIOi002-A induced pluripotent stem cell human CVCL_UF39 From: CIBIO, University of Trento; Trento; Italy. CL:0000010 21152307 CVCL_LL89 HPSI1114i-zuuy_5 induced pluripotent stem cell human CVCL_LL89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152308 CVCL_UF37 IB-RS-10-II spontaneously immortalized cell line pig CVCL_UF37 CL:0000010 Karyotypic information: Tetraploid karyotype; Derived from sampling site: Kidney; Breed/subspecies: Landrace x Yorkshire x Edelschwein. Female Virology: Susceptible to infection by foot-and-mouth disease virus More susceptible than IB-RS-10-I. 21152309 CVCL_UF38 CIBIOi001-A induced pluripotent stem cell human CVCL_UF38 From: CIBIO, University of Trento; Trento; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6912; MATR3; Simple; p.Gln66Lys (c.196C>A); Zygosity=Heterozygous (PubMed=30366341) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21152310 CVCL_LL87 HPSI1114i-xiby_5 induced pluripotent stem cell human CVCL_LL87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152311 CVCL_LL88 HPSI1114i-zuuy_4 induced pluripotent stem cell human CVCL_LL88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152312 CVCL_LL85 HPSI0914i-yuvg_2 induced pluripotent stem cell human CVCL_LL85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152313 CVCL_LL86 HPSI1114i-xiby_4 induced pluripotent stem cell human CVCL_LL86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152314 CVCL_UF20 High5-ht35 spontaneously immortalized cell line CVCL_UF20 CL:0000010 Unspecified Characteristics: Adapted to growth at 35 Celsius Doubling time: 23 hours (PubMed=21667340). Group: Insect cell line; Group: Recombinant protein production insect cell line 21152315 CVCL_UF21 MG1-ht33 spontaneously immortalized cell line CVCL_UF21 CL:0000010 Derived from sampling site: Midgut. Unspecified Characteristics: Adapted to growth at 33 Celsius Doubling time: 20 hours (PubMed=21667340) Group: Insect cell line; Group: Recombinant protein production insect cell line 21152316 CVCL_UF24 sf9-ht35 spontaneously immortalized cell line CVCL_UF24 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Adapted to growth at 35 Celsius Doubling time: 23 hours (PubMed=21667340) Group: Insect cell line; Group: Recombinant protein production insect cell line 21152317 CVCL_UF25 HEK-Blue TNF-alpha transformed cell line human CVCL_UF25 CL:0000010 Knockout cell: Method=Not specified; HGNC; 7562; MYD88; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Allows the detection of bioactive human and murine TNF-alpha by monitoring the activation of the NF-kappaB pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21152318 CVCL_UF22 MG1-ht35 spontaneously immortalized cell line CVCL_UF22 CL:0000010 Derived from sampling site: Midgut. Unspecified Characteristics: Adapted to growth at 35 Celsius Doubling time: 19 hours (PubMed=21667340) Group: Insect cell line; Group: Recombinant protein production insect cell line 21152319 CVCL_UF23 sf9-ht33 spontaneously immortalized cell line CVCL_UF23 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Adapted to growth at 33 Celsius Doubling time: 26 hours (PubMed=21667340) Group: Insect cell line; Group: Recombinant protein production insect cell line 21152320 CVCL_UF28 HEK-Blue hTLR2-TLR1 transformed cell line human CVCL_UF28 CL:0000010 Knockout cell: Method=Not specified; HGNC; 11847; TLR1; Knockout cell: Method=Not specified; HGNC; 16711; TLR6; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11847; TLR1; Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21152321 CVCL_UF29 HEK-Blue hTLR2-TLR6 transformed cell line human CVCL_UF29 CL:0000010 Knockout cell: Method=Not specified; HGNC; 11847; TLR1; Knockout cell: Method=Not specified; HGNC; 16711; TLR6; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11848; TLR2; Transfected with: HGNC; 16711; TLR6; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21152322 CVCL_UF26 HEK-Blue IL-2 transformed cell line human CVCL_UF26 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 6008; IL2RA; Transfected with: HGNC; 6009; IL2RB; Transfected with: HGNC; 6010; IL2RG; Transfected with: HGNC; 6193; JAK3; Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to monitor the activation of the JAK-STAT pathway by both human and murine IL2 (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT5 promoter 21152323 CVCL_UF27 HEK-Blue hTLR2 KO-TLR1/6 transformed cell line human CVCL_UF27 CL:0000010 Knockout cell: Method=Not specified; HGNC; 11847; TLR1; Knockout cell: Method=Not specified; HGNC; 16711; TLR6; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21152324 CVCL_LL98 HPSI1116i-wiau_4 induced pluripotent stem cell human CVCL_LL98 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152325 CVCL_LL99 HPSI1116i-zies_2 induced pluripotent stem cell human CVCL_LL99 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152326 CVCL_LL96 HPSI1116i-wakr_6 induced pluripotent stem cell human CVCL_LL96 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152327 CVCL_LL97 HPSI1116i-wiau_1 induced pluripotent stem cell human CVCL_LL97 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152328 CVCL_LL72 HPSI0616i-giql_1 induced pluripotent stem cell human CVCL_LL72 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21152329 CVCL_LL73 HPSI0616i-giql_5 induced pluripotent stem cell human CVCL_LL73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21152330 CVCL_LL70 HPSI0616i-gayk_3 induced pluripotent stem cell human CVCL_LL70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21152331 CVCL_LL71 HPSI0616i-gayk_5 induced pluripotent stem cell human CVCL_LL71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21152332 CVCL_UF10 DIF2 cancer cell line human CVCL_UF10 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Moderately resistant to both the antiviral and antiproliferative actions of interferons 21152333 CVCL_UF13 DIF3REV5 cancer cell line human CVCL_UF13 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Interferon sensitive revertant of DIF3 21152334 CVCL_UF14 DIF8 cancer cell line human CVCL_UF14 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Resistant to both the antiviral and antiproliferative actions of interferons 21152335 CVCL_UF11 DIF3 cancer cell line human CVCL_UF11 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Strongly resistant to both the antiviral and antiproliferative actions of interferons 21152336 CVCL_UF12 DIF3-17 cancer cell line human CVCL_UF12 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Strongly resistant to both the antiviral and antiproliferative actions of interferons 21152337 CVCL_UF17 GM27172 transformed cell line human CVCL_UF17 CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg141Cys (c.421C>T); ClinVar=VCV000447846; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152338 CVCL_LL69 HPSI0616i-eomr_5 induced pluripotent stem cell human CVCL_LL69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21152339 CVCL_UF18 GM27200 transformed cell line human CVCL_UF18 CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg133Cys (c.397C>T); ClinVar=VCV000009225; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152340 CVCL_UF15 DIF9 cancer cell line human CVCL_UF15 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Resistant to both the antiviral and antiproliferative actions of interferons 21152341 CVCL_LL67 HPSI0614i-xubw_1 induced pluripotent stem cell human CVCL_LL67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152342 CVCL_LL68 HPSI0614i-xubw_3 induced pluripotent stem cell human CVCL_LL68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152343 CVCL_UF16 KC13-2 transformed cell line house mouse CVCL_UF16 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Kupffer cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Characteristics: Useful for the study of drug delivery, of phagocytosis of pathogens and apoptotic cells and of the role of Kupffer cells in transplantation (PubMed=19835055); Characteristics: Grows stably at 33 Celsius without gamma-interferon Also grows, more slowly, at 37 Celsius (PubMed=12832442). 21152344 CVCL_LL65 132P1 CD44+/CD90- cancer cell line human CVCL_LL65 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Oral cavity. Male Characteristics: Subpopulation of 132P1 derived according to the CD44/CD90 status using magnetic bead based separation Doubling time: 30 hours (PubMed=29029509) 21152345 CVCL_LL66 HPSI0614i-juzt_4 induced pluripotent stem cell human CVCL_LL66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152346 CVCL_LL63 132P1 cancer cell line human CVCL_LL63 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Oral cavity. Male Doubling time: 22 hours (PubMed=29029509) 21152347 CVCL_UF19 High5-ht33 spontaneously immortalized cell line CVCL_UF19 CL:0000010 Unspecified Characteristics: Adapted to growth at 33 Celsius Doubling time: 24 hours (PubMed=21667340). Group: Insect cell line; Group: Recombinant protein production insect cell line 21152348 CVCL_LL64 132P1 CD44+/CD90+ cancer cell line human CVCL_LL64 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Oral cavity. Male Characteristics: Subpopulation of 132P1 derived according to the CD44/CD90 status using magnetic bead based separation Doubling time: 30 hours (PubMed=29029509) 21152349 CVCL_LL83 HPSI0816i-xoga_12 induced pluripotent stem cell human CVCL_LL83 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152350 CVCL_LL84 HPSI0816i-xoga_7 induced pluripotent stem cell human CVCL_LL84 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152351 CVCL_LL81 HPSI0714i-oatm_2 induced pluripotent stem cell human CVCL_LL81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152352 CVCL_LL82 HPSI0816i-oemk_6 induced pluripotent stem cell human CVCL_LL82 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152353 CVCL_LL80 HPSI0714i-oatm_1 induced pluripotent stem cell human CVCL_LL80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152354 CVCL_UF02 NP-2/CD4/CCR5/iGFP cancer cell line human CVCL_UF02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Characteristics: GFP-inducible indicator cell line produced by transfection of the pHIV-LTR-GFP-NLS plasmid, containing HIV-1 long terminal repeat (LTR), eGFP, the nuclear localization signal (NLS) of HIV-1 Rev and pac 21152355 CVCL_UF03 Shs undefined cell line type pig CVCL_UF03 CL:0000010 Derived from sampling site: Fetal thyroid gland. Unspecified 21152356 CVCL_UF00 NP-2/CD4/iGFP cancer cell line human CVCL_UF00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Characteristics: GFP-inducible indicator cell line produced by transfection of the pHIV-LTR-GFP-NLS plasmid, containing HIV-1 long terminal repeat (LTR), eGFP, the nuclear localization signal (NLS) of HIV-1 Rev and pac 21152357 CVCL_UF01 NP-2/CCR5/iGFP cancer cell line human CVCL_UF01 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Brain; left frontal lobe. Male Characteristics: GFP-inducible indicator cell line produced by transfection of the pHIV-LTR-GFP-NLS plasmid, containing HIV-1 long terminal repeat (LTR), eGFP, the nuclear localization signal (NLS) of HIV-1 Rev and pac 21152358 CVCL_UF06 HCS1220 cancer cell line human CVCL_UF06 CL:0000010 Population: Chinese; Derived from metastatic site: Liver. Female 21152359 CVCL_UF07 43-9F hybridoma house mouse CVCL_UF07 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Beta-Gal(1->3)-[alpha-Fuc(1->4)]-beta-GlcNAc(1->3)-beta-Gal(1->4)[alpha-Fuc(1->3)]beta-GlcNAc(1->3)-R. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 85061402 21152360 CVCL_UF04 HEK293 CD63 CRISPR transformed cell line human CVCL_UF04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1692; CD63 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Deep proteome analysis Female 21152361 CVCL_LL78 HPSI0616i-vaqx_2 induced pluripotent stem cell human CVCL_LL78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152362 CVCL_UF05 HCT 116 NUF2mCherry/mCherry cancer cell line human CVCL_UF05 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Colon. Male Characteristics: Using CRISPR/Cas9 NUF2 has been endogenously tagged in both alleles at the C-terminus with mCherry 21152363 CVCL_LL79 HPSI0616i-vaqx_4 induced pluripotent stem cell human CVCL_LL79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152364 CVCL_LL76 HPSI0616i-kalo_6 induced pluripotent stem cell human CVCL_LL76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152365 CVCL_LL77 HPSI0616i-newl_6 induced pluripotent stem cell human CVCL_LL77 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21152366 CVCL_LL74 HPSI0616i-heba_11 induced pluripotent stem cell human CVCL_LL74 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152367 CVCL_UF08 PHF spontaneously immortalized cell line CVCL_UF08 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Can grow at temperatures ranging from 24 to 32 Celsius with an optimum temperature of 28 Celsius (PubMed=29545155) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC057 21152368 CVCL_UF09 DIF10 cancer cell line human CVCL_UF09 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Resistant to both the antiviral and antiproliferative actions of interferons 21152369 CVCL_LL75 HPSI0616i-heba_9 induced pluripotent stem cell human CVCL_LL75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152370 CVCL_LL50 ND22327 transformed cell line human CVCL_LL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152371 CVCL_LL51 ND38894 transformed cell line human CVCL_LL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152372 CVCL_LL49 ND20437 transformed cell line human CVCL_LL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152373 CVCL_LL47 ND20055 transformed cell line human CVCL_LL47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152374 CVCL_LL48 ND20120 transformed cell line human CVCL_LL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152375 CVCL_LL45 ND06266 transformed cell line human CVCL_LL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152376 CVCL_LL46 ND08749 transformed cell line human CVCL_LL46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152377 CVCL_LL43 ND43343 transformed cell line human CVCL_LL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152378 CVCL_LL44 ND43344 transformed cell line human CVCL_LL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152379 CVCL_LL41 SIGi001-A-12 induced pluripotent stem cell human CVCL_LL41 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female 21152380 CVCL_LL42 SIGi001-A-13 induced pluripotent stem cell human CVCL_LL42 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Heterozygous; Note=By method not specified (EBiSC); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Heterozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Female 21152381 CVCL_LL61 C-566 transformed cell line human CVCL_LL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21152382 CVCL_LL62 SK-HNF-5 cancer cell line human CVCL_LL62 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Lymph node. Male 21152383 CVCL_LL60 HEV0183 transformed cell line human CVCL_LL60 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21152384 CVCL_LL58 ND06832 transformed cell line human CVCL_LL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152385 CVCL_LL59 DA04177 transformed cell line human CVCL_LL59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 21152386 CVCL_LL56 ND40795 transformed cell line human CVCL_LL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152387 CVCL_LL57 ND41330 transformed cell line human CVCL_LL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152388 CVCL_LL54 ND39621 transformed cell line human CVCL_LL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152389 CVCL_LL55 ND39734 transformed cell line human CVCL_LL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152390 CVCL_LL52 HPSI0516i-kumr_11 induced pluripotent stem cell human CVCL_LL52 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152391 CVCL_LL53 ND39589 transformed cell line human CVCL_LL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152392 CVCL_D399 mHypoA-2/34 transformed cell line house mouse CVCL_D399 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU194 Male 21152393 CVCL_CR99 ND19934 transformed cell line human CVCL_CR99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152394 CVCL_D397 mHypoA-2/32 transformed cell line house mouse CVCL_D397 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152395 CVCL_CR97 ND19899 transformed cell line human CVCL_CR97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152396 CVCL_D398 mHypoA-2/33 transformed cell line house mouse CVCL_D398 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU193 Male 21152397 CVCL_CR98 ND19927 transformed cell line human CVCL_CR98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152398 CVCL_D391 mHypoA-2/26 transformed cell line house mouse CVCL_D391 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152399 CVCL_CR91 ND19825 transformed cell line human CVCL_CR91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152400 CVCL_D392 mHypoA-2/27 transformed cell line house mouse CVCL_D392 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152401 CVCL_CR92 ND19834 transformed cell line human CVCL_CR92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152402 CVCL_D390 mHypoA-2/25 transformed cell line house mouse CVCL_D390 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152403 CVCL_CR90 ND19823 transformed cell line human CVCL_CR90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152404 CVCL_LL29 HPSI0414i-voqc_2 induced pluripotent stem cell human CVCL_LL29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152405 CVCL_D395 mHypoA-2/30 transformed cell line house mouse CVCL_D395 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152406 CVCL_CR95 ND19871 transformed cell line human CVCL_CR95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152407 CVCL_D396 mHypoA-2/31 transformed cell line house mouse CVCL_D396 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152408 CVCL_CR96 ND19873 transformed cell line human CVCL_CR96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152409 CVCL_LL27 HPSI0414i-uugp_2 induced pluripotent stem cell human CVCL_LL27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152410 CVCL_D393 mHypoA-2/28 transformed cell line house mouse CVCL_D393 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152411 CVCL_CR93 ND19847 transformed cell line human CVCL_CR93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152412 CVCL_LL28 HPSI0414i-uugp_3 induced pluripotent stem cell human CVCL_LL28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152413 CVCL_D394 mHypoA-2/29 transformed cell line house mouse CVCL_D394 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152414 CVCL_CR94 ND19860 transformed cell line human CVCL_CR94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152415 CVCL_LL25 HPSI0316i-pecz_2 induced pluripotent stem cell human CVCL_LL25 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: African; Sudanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152416 CVCL_LL26 HPSI0316i-zuik_6 induced pluripotent stem cell human CVCL_LL26 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caribbean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152417 CVCL_LL23 HPSI0215i-uiao_2 induced pluripotent stem cell human CVCL_LL23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152418 CVCL_LL24 HPSI0314i-xagu_1 induced pluripotent stem cell human CVCL_LL24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152419 CVCL_LL21 HPSI0215i-romx_1 induced pluripotent stem cell human CVCL_LL21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152420 CVCL_LL22 HPSI0215i-uiao_1 induced pluripotent stem cell human CVCL_LL22 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152421 CVCL_LL20 HPSI0215i-qenw_5 induced pluripotent stem cell human CVCL_LL20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152422 CVCL_LL40 BIONi010-C-9 induced pluripotent stem cell human CVCL_LL40 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1659; CD33 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21152423 CVCL_LL38 FIB-MARFAN6 finite cell line human CVCL_LL38 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152424 CVCL_LL39 FIB-MOR1 finite cell line human CVCL_LL39 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152425 CVCL_LL36 HPSI0514i-yewo_4 induced pluripotent stem cell human CVCL_LL36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152426 CVCL_LL37 FIB-MARFAN5 finite cell line human CVCL_LL37 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152427 CVCL_LL34 HPSI0514i-suul_2 induced pluripotent stem cell human CVCL_LL34 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152428 CVCL_LL35 HPSI0514i-xufp_1 induced pluripotent stem cell human CVCL_LL35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152429 CVCL_LL32 HPSI0416i-ioys_6 induced pluripotent stem cell human CVCL_LL32 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152430 CVCL_LL33 HPSI0514i-suul_1 induced pluripotent stem cell human CVCL_LL33 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152431 CVCL_LL30 HPSI0414i-zabk_4 induced pluripotent stem cell human CVCL_LL30 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21152432 CVCL_LL31 HPSI0416i-ioys_5 induced pluripotent stem cell human CVCL_LL31 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152433 CVCL_UF90 sALS9 finite cell line human CVCL_UF90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152434 CVCL_UF94 RMS-1 cancer cell line human CVCL_UF94 CL:0000010 Derived from metastatic site: Ascites. Female 21152435 CVCL_UF91 MN20 finite cell line human CVCL_UF91 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex16-18del (nsv1067857); ClinVar=VCV000003711; Zygosity=Homozygous (PubMed=6272292) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152436 CVCL_UF92 SCMC-RM1 cancer cell line human CVCL_UF92 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0043; true. Male 21152437 CVCL_UF97 RMS-11 cancer cell line human CVCL_UF97 CL:0000010 Derived from metastatic site: Ascites. Female 21152439 CVCL_UF95 RMS-4 cancer cell line human CVCL_UF95 CL:0000010 Derived from metastatic site: Lymph node. Male 21152440 CVCL_UF96 RMS-5 cancer cell line human CVCL_UF96 CL:0000010 Derived from metastatic site: Bone marrow. Male 21152441 CVCL_UF99 RMS-14 cancer cell line human CVCL_UF99 CL:0000010 Derived from sampling site: Pharynx; nasopharynx. Male 21152442 CVCL_UF82 Ctrl 170 finite cell line human CVCL_UF82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152443 CVCL_UF83 ALS11 finite cell line human CVCL_UF83 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24379375) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152444 CVCL_UF80 SCMC-W2 cancer cell line human CVCL_UF80 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0047; true. Male 21152445 CVCL_UF81 Ctrl 155 finite cell line human CVCL_UF81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152446 CVCL_UF86 ALS201 finite cell line human CVCL_UF86 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified Miscellaneous: Cell line information from personal communication of Varcianna A Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152447 CVCL_UF87 fALS finite cell line human CVCL_UF87 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (PubMed=24379375) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152448 CVCL_UF84 ALS78 finite cell line human CVCL_UF84 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24379375) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152449 CVCL_UF85 ALS183 finite cell line human CVCL_UF85 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24379375) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152450 CVCL_UF88 sALS2 finite cell line human CVCL_UF88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152451 CVCL_UF89 sALS5 finite cell line human CVCL_UF89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152452 CVCL_UF71 KMOE-2/05 cancer cell line human CVCL_UF71 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0051; true Female 21152453 CVCL_UF72 HeLa P75 cancer cell line human CVCL_UF72 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; NIHS0038; true Female 21152454 CVCL_UF70 ND41181 induced pluripotent stem cell human CVCL_UF70 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41181; probable Female 21152455 CVCL_UF75 NGP-127 cancer cell line human CVCL_UF75 From: Brodeur G.; Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21152456 CVCL_UF76 SCMC-MM-1 cancer cell line human CVCL_UF76 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0045; true. Female Doubling time: 50 hours (PubMed=1313401) 21152457 CVCL_UF73 J-113 cancer cell line human CVCL_UF73 CL:0000010 Derived from sampling site: Peripheral blood. Male Caution: This cell line was derived in the same laboratory and at the same time as the J-111 and J-96 cell lines which have both later been shown to be contaminated by HeLa As this cell line was apparently never distributed it is not clear if it was a bona fide leukemia cell line. 21152458 CVCL_UF74 ARMS1 cancer cell line human CVCL_UF74 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=23665679) Omics: Transcriptome analysis by microarray. Unspecified 21152459 CVCL_UF79 SCMC-W1 cancer cell line human CVCL_UF79 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0046; true. Male 21152460 CVCL_UF77 SCMC-MM-1-19P cancer cell line human CVCL_UF77 CL:0000010 Population: Japanese Female Doubling time: 32 hours (PubMed=1313401). 21152461 CVCL_UF78 SCMC-MM-1-1T cancer cell line human CVCL_UF78 CL:0000010 Population: Japanese Female Doubling time: 72 hours (PubMed=1313401). 21152462 CVCL_UF60 HEK-Blue IL-6 transformed cell line human CVCL_UF60 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 6019; IL6R; Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive human IL6 by monitoring the activation of the STAT3 pathway (InvivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the STAT3 promoter 21152463 CVCL_UF61 ND40597 induced pluripotent stem cell human CVCL_UF61 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40597; probable Female 21152464 CVCL_UF64 ICGi016-A induced pluripotent stem cell human CVCL_UF64 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152465 CVCL_UF65 ICGi005-A induced pluripotent stem cell human CVCL_UF65 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=30660867) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152466 CVCL_UF62 ND40599 induced pluripotent stem cell human CVCL_UF62 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40599; probable Male 21152467 CVCL_UF63 ND40600 induced pluripotent stem cell human CVCL_UF63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40600; probable 21152468 CVCL_UF68 ICGi006-B induced pluripotent stem cell human CVCL_UF68 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=30660867); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=30660867) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152469 CVCL_UF69 ND41180 induced pluripotent stem cell human CVCL_UF69 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41180; probable Male 21152470 CVCL_UF66 ICGi005-B induced pluripotent stem cell human CVCL_UF66 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=30660867) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152471 CVCL_UF67 ICGi006-A induced pluripotent stem cell human CVCL_UF67 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=30660867); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=30660867) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152472 CVCL_UF50 TSRI51i-HDF509 induced pluripotent stem cell human CVCL_UF50 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21152473 CVCL_UF53 TSRIi-HEML506 induced pluripotent stem cell human CVCL_UF53 CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.. 21152474 CVCL_UF54 UCLA 21 embryonic stem cell human CVCL_UF54 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0405. 21152475 CVCL_UF51 TSRI68i-HDF505 induced pluripotent stem cell human CVCL_UF51 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21152476 CVCL_UF52 TSRIi-HEML503 induced pluripotent stem cell human CVCL_UF52 CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.. 21152477 CVCL_UF57 UM197-1 PGD embryonic stem cell human CVCL_UF57 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0399. 21152478 CVCL_UF58 UM202-1 PGS embryonic stem cell human CVCL_UF58 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0400. 21152479 CVCL_UF55 UCLA 22 embryonic stem cell human CVCL_UF55 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0406. 21152480 CVCL_UF56 UCLA 23 embryonic stem cell human CVCL_UF56 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0407. 21152481 CVCL_UF59 HEK-Blue IL-33 transformed cell line human CVCL_UF59 CL:0000010 Knockout cell: Method=Not specified; HGNC; 5993; IL1R1; Knockout cell: Method=Not specified; HGNC; 11916; TNFRSF1A; Knockout cell: Method=Not specified; HGNC; 11917; TNFRSF1B; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 5998; IL1RL1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Designed to detect bioactive IL33 by monitoring the activation of the NF-kappaB and AP-1 pathways In addition, the TNF-alpha and the IL-1beta responses have been blocked (InvivoGen).; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a promoter with NF-kappaB and AP-1-binding sites 21152482 CVCL_UF42 HDF-f finite cell line human CVCL_UF42 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female Senescence: Senesces at ~15 PDL (ScienCell) 21152483 CVCL_UF43 ZIPi013-A induced pluripotent stem cell human CVCL_UF43 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152484 CVCL_UF40 RCPFi007-A induced pluripotent stem cell human CVCL_UF40 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 359; AIPL1; Simple; p.Cys89Arg (c.265T>C); ClinVar=VCV000574505; Zygosity=Homozygous (PubMed=30366342) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21152485 CVCL_UF41 IM-MFS-1 cancer cell line human CVCL_UF41 CL:0000010 Omics: Array-based CGH. Male Doubling time: 72 hours (PubMed=30366467) 21152486 CVCL_UF46 ZIPi013-D induced pluripotent stem cell human CVCL_UF46 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152487 CVCL_UF47 ZIPi013-E induced pluripotent stem cell human CVCL_UF47 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152488 CVCL_UF44 ZIPi013-B induced pluripotent stem cell human CVCL_UF44 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152489 CVCL_UF45 ZIPi013-C induced pluripotent stem cell human CVCL_UF45 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152490 CVCL_UF48 TSRI51i-HDF1003 induced pluripotent stem cell human CVCL_UF48 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21152491 CVCL_UF49 TSRI51i-HDF11 induced pluripotent stem cell human CVCL_UF49 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21152492 CVCL_D308 CAVEOC-2 cancer cell line human CVCL_D308 CL:0000010 Miscellaneous: Cell line no longer available (personal communication of Merlin J.-L.). Female Doubling time: 33 hours (PubMed=8615606) 21152493 CVCL_CR08 ND16613 transformed cell line human CVCL_CR08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152494 CVCL_D309 EFO-3 cancer cell line human CVCL_D309 CL:0000010 Derived from sampling site: Ovary. Female 21152495 CVCL_CR09 ND16616 transformed cell line human CVCL_CR09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152496 CVCL_D306 AZ418 cancer cell line human CVCL_D306 CL:0000010 Derived from sampling site: Ovary. Female 21152497 CVCL_CR06 ND16594 transformed cell line human CVCL_CR06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152498 CVCL_D307 AZ419 cancer cell line human CVCL_D307 CL:0000010 Derived from metastatic site: Ascites. Female 21152499 CVCL_CR07 ND16612 transformed cell line human CVCL_CR07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152500 CVCL_D300 AZ303 cancer cell line human CVCL_D300 CL:0000010 Derived from metastatic site: Ascites. Female 21152501 CVCL_CR00 ND16546 transformed cell line human CVCL_CR00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152502 CVCL_D301 AZ382 cancer cell line human CVCL_D301 CL:0000010 Derived from metastatic site: Ascites. Female 21152503 CVCL_CR01 ND16547 transformed cell line human CVCL_CR01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152504 CVCL_D304 AZ402 cancer cell line human CVCL_D304 CL:0000010 Derived from metastatic site: Omentum. Female 21152505 CVCL_CR04 ND16567 transformed cell line human CVCL_CR04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152506 CVCL_D305 AZ403 cancer cell line human CVCL_D305 CL:0000010 Derived from sampling site: Ovary. Female 21152507 CVCL_CR05 ND16569 transformed cell line human CVCL_CR05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152508 CVCL_D302 AZ364 cancer cell line human CVCL_D302 CL:0000010 Derived from metastatic site: Ascites. Female 21152509 CVCL_CR02 ND16558 transformed cell line human CVCL_CR02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152510 CVCL_D303 AZ390 cancer cell line human CVCL_D303 CL:0000010 Derived from metastatic site: Ascites. Female 21152511 CVCL_CR03 ND16563 transformed cell line human CVCL_CR03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152512 CVCL_D377 mHippoE-2 transformed cell line house mouse CVCL_D377 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Swiss Webster. 21152513 CVCL_CR77 ND19620 transformed cell line human CVCL_CR77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152514 CVCL_D378 mHippoE-5 transformed cell line house mouse CVCL_D378 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Swiss Webster. 21152515 CVCL_CR78 ND19625 transformed cell line human CVCL_CR78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152516 CVCL_D375 mHippoE-14 transformed cell line house mouse CVCL_D375 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Swiss Webster. 21152517 CVCL_CR75 ND19618 transformed cell line human CVCL_CR75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152518 CVCL_D376 mHippoE-18 transformed cell line house mouse CVCL_D376 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Swiss Webster. 21152519 CVCL_CR76 ND19619 transformed cell line human CVCL_CR76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152520 CVCL_D379 mHypoA-1/1 transformed cell line house mouse CVCL_D379 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152521 CVCL_CR79 ND19633 transformed cell line human CVCL_CR79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152522 CVCL_D370 HITC6 finite cell line human CVCL_D370 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152523 CVCL_CR70 ND19566 transformed cell line human CVCL_CR70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152524 CVCL_LL09 HPSI0115i-roka_1 induced pluripotent stem cell human CVCL_LL09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152525 CVCL_D373 HITD5 finite cell line human CVCL_D373 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152526 CVCL_LL07 HPSI0115i-rakq_1 induced pluripotent stem cell human CVCL_LL07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152527 CVCL_CR73 ND19594 transformed cell line human CVCL_CR73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152528 CVCL_D374 HITD6 finite cell line human CVCL_D374 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152529 CVCL_LL08 HPSI0115i-rakq_3 induced pluripotent stem cell human CVCL_LL08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152530 CVCL_CR74 ND19596 transformed cell line human CVCL_CR74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152531 CVCL_D371 HITD1 finite cell line human CVCL_D371 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152532 CVCL_LL05 HPSI0115i-kozf_2 induced pluripotent stem cell human CVCL_LL05 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152533 CVCL_CR71 ND19574 transformed cell line human CVCL_CR71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152534 CVCL_D372 HITD4 finite cell line human CVCL_D372 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152535 CVCL_LL06 HPSI0115i-payf_1 induced pluripotent stem cell human CVCL_LL06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152536 CVCL_CR72 ND19586 transformed cell line human CVCL_CR72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152537 CVCL_LL03 HPSI0115i-jotn_4 induced pluripotent stem cell human CVCL_LL03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152538 CVCL_LL04 HPSI0115i-kozf_1 induced pluripotent stem cell human CVCL_LL04 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152539 CVCL_LL01 HPSI0115i-jakt_1 induced pluripotent stem cell human CVCL_LL01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152540 CVCL_LL02 HPSI0115i-jotn_2 induced pluripotent stem cell human CVCL_LL02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152541 CVCL_LL00 HPSI0115i-iuad_3 induced pluripotent stem cell human CVCL_LL00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152542 CVCL_D388 mHypoA-2/23 transformed cell line house mouse CVCL_D388 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152543 CVCL_CR88 ND19805 transformed cell line human CVCL_CR88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152544 CVCL_D389 mHypoA-2/24 transformed cell line house mouse CVCL_D389 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152545 CVCL_CR89 ND19819 transformed cell line human CVCL_CR89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152546 CVCL_D386 mHypoA-2/21 transformed cell line house mouse CVCL_D386 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152547 CVCL_CR86 ND19777 transformed cell line human CVCL_CR86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152548 CVCL_D387 mHypoA-2/22 transformed cell line house mouse CVCL_D387 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152549 CVCL_CR87 ND19802 transformed cell line human CVCL_CR87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152550 CVCL_D380 mHypoA-1/2 transformed cell line house mouse CVCL_D380 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152551 CVCL_CR80 ND19705 transformed cell line human CVCL_CR80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152552 CVCL_D381 mHypoA-1/3 transformed cell line house mouse CVCL_D381 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152553 CVCL_CR81 ND19707 transformed cell line human CVCL_CR81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152554 CVCL_LL18 HPSI0115i-zuer_4 induced pluripotent stem cell human CVCL_LL18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152555 CVCL_D384 mHypoA-2/10 transformed cell line house mouse CVCL_D384 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152556 CVCL_CR84 ND19746 transformed cell line human CVCL_CR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152557 CVCL_LL19 HPSI0215i-qenw_1 induced pluripotent stem cell human CVCL_LL19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152558 CVCL_D385 mHypoA-2/12 transformed cell line house mouse CVCL_D385 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152559 CVCL_CR85 ND19762 transformed cell line human CVCL_CR85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152560 CVCL_LL16 HPSI0115i-uupc_2 induced pluripotent stem cell human CVCL_LL16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152561 CVCL_D382 mHypoA-1/6 transformed cell line house mouse CVCL_D382 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152562 CVCL_CR82 ND19715 transformed cell line human CVCL_CR82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152563 CVCL_LL17 HPSI0115i-zuer_1 induced pluripotent stem cell human CVCL_LL17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152564 CVCL_D383 mHypoA-1/9 transformed cell line house mouse CVCL_D383 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21152565 CVCL_CR83 ND19719 transformed cell line human CVCL_CR83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152566 CVCL_LL14 HPSI0115i-tiku_3 induced pluripotent stem cell human CVCL_LL14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152567 CVCL_LL15 HPSI0115i-timk_4 induced pluripotent stem cell human CVCL_LL15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152568 CVCL_LL12 HPSI0115i-sehp_3 induced pluripotent stem cell human CVCL_LL12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152569 CVCL_LL13 HPSI0115i-tiku_1 induced pluripotent stem cell human CVCL_LL13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21152570 CVCL_LL10 HPSI0115i-roka_3 induced pluripotent stem cell human CVCL_LL10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152571 CVCL_LL11 HPSI0115i-sehp_2 induced pluripotent stem cell human CVCL_LL11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21152572 CVCL_D355 MCEC transformed cell line house mouse CVCL_D355 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Cardiac endothelial cell.; Breed/subspecies: FVB. Unspecified 21152573 CVCL_CR55 ND19439 transformed cell line human CVCL_CR55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152574 CVCL_CR56 ND19440 transformed cell line human CVCL_CR56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152575 CVCL_D356 NSC-34 hybrid cell line house mouse CVCL_D356 CL:0000010 Miscellaneous: STR profile from personal communication of Gemma R.-T. Omics: Deep proteome analysis Characteristics: Produced by the fusion of motor neuron enriched, embryonic 12-14 days mouse spinal cord cells with N18TG2 (PubMed=1467557) 21152576 CVCL_D353 H3774 cancer cell line human CVCL_D353 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21152577 CVCL_CR53 ND19426 transformed cell line human CVCL_CR53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152578 CVCL_D354 HOG cancer cell line human CVCL_D354 CL:0000010 Derived from sampling site: Brain Cell type=Oligodendrocyte.. Unspecified Characteristics: Useful model to study signal transduction pathways of oligodendrocyte metabolism and the role of oligodendrocytes in neurodegenerative diseases (Millipore) Doubling time: 2 days (PubMed=1329795); 18 hours (PubMed=8416742) 21152579 CVCL_CR54 ND19438 transformed cell line human CVCL_CR54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152580 CVCL_D359 HB1.1-EI cancer cell line house mouse CVCL_D359 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU145 21152581 CVCL_CR59 ND19476 transformed cell line human CVCL_CR59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152582 CVCL_D357 MO3.13 hybrid cell line human CVCL_D357 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine Omics: Deep proteome analysis. Characteristics: Produced by fusion of RD.TG6 with adult human oligodendrocytes (PubMed=7707048) 21152583 CVCL_CR57 ND19465 transformed cell line human CVCL_CR57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152584 CVCL_D358 HB1.1-ED cancer cell line house mouse CVCL_D358 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU143 Characteristics: EPO dependent 21152585 CVCL_CR58 ND19471 transformed cell line human CVCL_CR58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152586 CVCL_D351 H3639 cancer cell line human CVCL_D351 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21152587 CVCL_CR51 ND19392 transformed cell line human CVCL_CR51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152588 CVCL_D352 H3723 cancer cell line human CVCL_D352 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21152589 CVCL_CR52 ND19403 transformed cell line human CVCL_CR52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152590 CVCL_D350 H3477 cancer cell line human CVCL_D350 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21152591 CVCL_CR50 ND19372 transformed cell line human CVCL_CR50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152592 CVCL_D366 HITA5 finite cell line human CVCL_D366 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152593 CVCL_CR66 ND19547 transformed cell line human CVCL_CR66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152594 CVCL_D367 HITB2 finite cell line human CVCL_D367 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152595 CVCL_CR67 ND19548 transformed cell line human CVCL_CR67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152596 CVCL_D364 HITA2 finite cell line human CVCL_D364 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152597 CVCL_CR64 ND19530 transformed cell line human CVCL_CR64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152598 CVCL_D365 HITA4 finite cell line human CVCL_D365 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152599 CVCL_CR65 ND19534 transformed cell line human CVCL_CR65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152600 CVCL_D368 HITB5 finite cell line human CVCL_D368 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152601 CVCL_CR68 ND19556 transformed cell line human CVCL_CR68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152602 CVCL_D369 HITC1 finite cell line human CVCL_D369 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152603 CVCL_CR69 ND19558 transformed cell line human CVCL_CR69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152604 CVCL_D362 HB9.1-EI cancer cell line house mouse CVCL_D362 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU146 21152605 CVCL_CR62 ND19523 transformed cell line human CVCL_CR62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152606 CVCL_D363 HITA1 finite cell line human CVCL_D363 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Vascular associated smooth muscle cell.. Male 21152607 CVCL_CR63 ND19525 transformed cell line human CVCL_CR63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152608 CVCL_D360 HB60-5 cancer cell line house mouse CVCL_D360 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU142 Characteristics: Grows in the presence of EPO and KITLG, but undergo terminal differentiation when stimulated with EPO alone 21152609 CVCL_CR60 ND19509 transformed cell line human CVCL_CR60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152610 CVCL_D361 HB9.1-ED cancer cell line house mouse CVCL_D361 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU144 Characteristics: EPO dependent 21152611 CVCL_CR61 ND19512 transformed cell line human CVCL_CR61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152612 CVCL_D339 GM21873 finite cell line human CVCL_D339 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Lys253fs*12 (c.752delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; c.1132-7A>G (IVS6-7A>G) (p.I377_378insLX); ClinVar=VCV000021234; Zygosity=Heterozygous (Coriell) Derived from sampling site: Amniotic fluid. Female 21152613 CVCL_CR39 ND19278 transformed cell line human CVCL_CR39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152614 CVCL_D333 CL-21 cancer cell line human CVCL_D333 CL:0000010 Derived from sampling site: Colon; sigmoid. Unspecified 21152615 CVCL_CR33 ND19261 transformed cell line human CVCL_CR33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152616 CVCL_D334 CL-23 cancer cell line human CVCL_D334 CL:0000010 Derived from sampling site: Colon; sigmoid. Unspecified 21152617 CVCL_CR34 ND19269 transformed cell line human CVCL_CR34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152618 CVCL_D331 CL-11m cancer cell line human CVCL_D331 CL:0000010 Population: Caucasian; Derived from sampling site: Colon. Male 21152619 CVCL_CR31 ND19249 transformed cell line human CVCL_CR31 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152620 CVCL_D332 CL-19 [Human colon adenocarcinoma] cancer cell line human CVCL_D332 CL:0000010 Derived from sampling site: Colon. Unspecified 21152621 CVCL_CR32 ND19254 transformed cell line human CVCL_CR32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152622 CVCL_D337 CL-9 cancer cell line human CVCL_D337 CL:0000010 Derived from metastatic site: Liver. Unspecified 21152623 CVCL_CR37 ND19273 transformed cell line human CVCL_CR37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152624 CVCL_CR38 ND19277 transformed cell line human CVCL_CR38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152625 CVCL_D338 PJ-2 cancer cell line human CVCL_D338 CL:0000010 Derived from sampling site: Pleural effusion. 21152626 CVCL_D335 CL-30 cancer cell line human CVCL_D335 CL:0000010 Derived from metastatic site: Spleen. Unspecified 21152627 CVCL_CR35 ND19270 transformed cell line human CVCL_CR35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152628 CVCL_D336 CL-36 cancer cell line human CVCL_D336 CL:0000010 Derived from sampling site: Colon. Unspecified 21152629 CVCL_CR36 ND19271 transformed cell line human CVCL_CR36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152630 CVCL_D330 CARNAVAL cancer cell line human CVCL_D330 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified Doubling time: ~40-50 hours (DSMZ=ACC-724) 21152631 CVCL_CR30 ND19248 transformed cell line human CVCL_CR30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152632 CVCL_D344 GM01056 transformed cell line human CVCL_D344 HLA typing: A*24:02:01,29:02:01; B*15:01:01,44:03:01; C*03:03:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:01:01,06:02:01; DRB1*12:01:01G,15:01:01; DRB3*02:02:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21152633 CVCL_CR44 ND19335 transformed cell line human CVCL_CR44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152634 CVCL_D345 H2669 cancer cell line human CVCL_D345 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21152635 CVCL_CR45 ND19336 transformed cell line human CVCL_CR45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152636 CVCL_D342 GM00054 finite cell line human CVCL_D342 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Val44Met (c.130G>A); ClinVar=VCV000003611; Zygosity=Heterozygous (from autologous cell line GM02795); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Met142Lys (c.425T>A); ClinVar=VCV000003609; Zygosity=Heterozygous (from autologous cell line GM02795) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152637 CVCL_CR42 ND19326 transformed cell line human CVCL_CR42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152638 CVCL_D343 GM15836 transformed cell line human CVCL_D343 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152639 CVCL_CR43 ND19327 transformed cell line human CVCL_CR43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152640 CVCL_D348 H3396 cancer cell line human CVCL_D348 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA CL:0000010 Derived from metastatic site: Pleural effusion. Female 21152641 CVCL_CR48 ND19369 transformed cell line human CVCL_CR48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152642 CVCL_D349 H3464 cancer cell line human CVCL_D349 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21152643 CVCL_CR49 ND19371 transformed cell line human CVCL_CR49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152644 CVCL_D346 H2981 cancer cell line human CVCL_D346 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21152645 CVCL_CR46 ND19351 transformed cell line human CVCL_CR46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152646 CVCL_D347 H2987 cancer cell line human CVCL_D347 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21152647 CVCL_CR47 ND19368 transformed cell line human CVCL_CR47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152648 CVCL_D340 GM00042 finite cell line human CVCL_D340 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21152649 CVCL_CR40 ND19304 transformed cell line human CVCL_CR40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152650 CVCL_D341 GM00326 finite cell line human CVCL_D341 CL:0000010 Population: Caucasian; Sardinian; Karyotypic information: 49,XXXXY (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21152651 CVCL_CR41 ND19325 transformed cell line human CVCL_CR41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152652 CVCL_D319 B35M cancer cell line human CVCL_D319 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Male Doubling time: ~21 hours (PubMed=4166872) 21152653 CVCL_CR19 ND16714 transformed cell line human CVCL_CR19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152654 CVCL_D317 1181N1 cancer cell line human CVCL_D317 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Parent cell line (U-118MG) has been shown to be a U-138MG derivative. 21152655 CVCL_CR17 ND16682 transformed cell line human CVCL_CR17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152656 CVCL_CR18 ND16689 transformed cell line human CVCL_CR18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152657 CVCL_D318 Tu-2449 cancer cell line house mouse CVCL_D318 CL:0000010 21152658 CVCL_CR11 ND16653 transformed cell line human CVCL_CR11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152659 CVCL_D311 SPC111 cancer cell line human CVCL_D311 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 50 hours (PubMed=1373705) 21152660 CVCL_CR12 ND16654 transformed cell line human CVCL_CR12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152661 CVCL_D312 SPC212 cancer cell line human CVCL_D312 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Female Doubling time: 58 hours (PubMed=1373705). 21152662 CVCL_D310 EFO-47 cancer cell line human CVCL_D310 CL:0000010 Derived from metastatic site: Ascites. Female 21152663 CVCL_CR10 ND16634 transformed cell line human CVCL_CR10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152664 CVCL_D315 2fTGH-U5A cancer cell line human CVCL_D315 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21152665 CVCL_CR15 ND16679 transformed cell line human CVCL_CR15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152666 CVCL_D316 2fTGH-U6A cancer cell line human CVCL_D316 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Lacks expression of STAT2 Unresponsive to interferon-alpha. Normal response to IFN-gamma (ECACC).; Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21152667 CVCL_CR16 ND16680 transformed cell line human CVCL_CR16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152668 CVCL_CR13 ND16674 transformed cell line human CVCL_CR13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152669 CVCL_D313 SDM103T2 cancer cell line human CVCL_D313 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Established from a patient-derived xenograft 21152670 CVCL_D314 2fTGH-U4C cancer cell line human CVCL_D314 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21152671 CVCL_CR14 ND16678 transformed cell line human CVCL_CR14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152672 CVCL_D328 LCL 721.144 transformed cell line human CVCL_D328 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152673 CVCL_CR28 ND19214 transformed cell line human CVCL_CR28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152674 CVCL_D329 LCL 721.127 transformed cell line human CVCL_D329 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152675 CVCL_CR29 ND19226 transformed cell line human CVCL_CR29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152676 CVCL_CR22 ND16725 transformed cell line human CVCL_CR22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152677 CVCL_D322 TARS-1 transformed cell line Norway rat CVCL_D322 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Female Virology: HTLV-1 producing cell line 21152678 CVCL_CR23 ND16726 transformed cell line human CVCL_CR23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152679 CVCL_D323 TART-1 transformed cell line Norway rat CVCL_D323 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Thymus Cell type=T-cell.; Breed/subspecies: Wistar King Aptekman/Hok (WKA/Hok). Female 21152680 CVCL_D320 B46M cancer cell line human CVCL_D320 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21152681 CVCL_CR20 ND16719 transformed cell line human CVCL_CR20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152682 CVCL_D321 ABL-2 cancer cell line human CVCL_D321 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Virology: EBV-negative Doubling time: 32 hours (PubMed=3934897) 21152683 CVCL_CR21 ND16722 transformed cell line human CVCL_CR21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152684 CVCL_D326 LCL 721.114 transformed cell line human CVCL_D326 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152685 CVCL_CR26 ND19190 transformed cell line human CVCL_CR26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152686 CVCL_D327 LCL 721.184 transformed cell line human CVCL_D327 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Peripheral blood. Female 21152687 CVCL_CR27 ND19202 transformed cell line human CVCL_CR27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152688 CVCL_CR24 ND19184 transformed cell line human CVCL_CR24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152689 CVCL_D324 YTS cancer cell line human CVCL_D324 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion Cell type=Natural killer cell.. Omics: Transcriptome analysis by microarray Male 21152690 CVCL_D325 LCL 721.220 transformed cell line human CVCL_D325 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Peripheral blood. Female 21152691 CVCL_CR25 ND19186 transformed cell line human CVCL_CR25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152692 CVCL_2A00 PSALBV379 transformed cell line human CVCL_2A00 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+1G>A; ClinVar=VCV000066879; Zygosity=Heterozygous; Note=Splice donor mutation (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152693 CVCL_2A01 PSALBV341 transformed cell line human CVCL_2A01 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Homozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152694 CVCL_2A04 PSFLBV344 transformed cell line human CVCL_2A04 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152695 CVCL_2A05 PSALBV406 transformed cell line human CVCL_2A05 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Ser (c.1822G>A); ClinVar=VCV000014501; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152696 CVCL_2A02 PSALBV342 transformed cell line human CVCL_2A02 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Homozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152697 CVCL_2A03 PSMLBV343 transformed cell line human CVCL_2A03 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21152698 CVCL_2A08 HGADFN003 iPS1B induced pluripotent stem cell human CVCL_2A08 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152699 CVCL_2A09 HGADFN003 iPS1C induced pluripotent stem cell human CVCL_2A09 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152700 CVCL_2A06 PSALBV427 transformed cell line human CVCL_2A06 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Val607Val (c.1821G>A); ClinVar=VCV000014516; Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152701 CVCL_2A07 PSALBV432 transformed cell line human CVCL_2A07 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Leu (c.1580G>T); ClinVar=VCV000919926; Zygosity=Homozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152702 CVCL_UG52 iPSC DKC1 Del37 #2 induced pluripotent stem cell human CVCL_UG52 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Hemizygous (PubMed=25992652) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21152703 CVCL_UG53 iPSC DKC1 Q31E induced pluripotent stem cell human CVCL_UG53 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Gln31Glu (c.91C>G); ClinVar=VCV000038954; Zygosity=Hemizygous (PubMed=25992652) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21152704 CVCL_UG50 iPSC DKC1 A353V #2 induced pluripotent stem cell human CVCL_UG50 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Ala353Val (c.1058C>T); ClinVar=VCV000011587; Zygosity=Hemizygous (PubMed=25992652) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21152705 CVCL_UG51 iPSC DKC1 Del37 #1 induced pluripotent stem cell human CVCL_UG51 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Hemizygous (PubMed=25992652) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21152706 CVCL_UG56 Der(22)-iPS-C2 induced pluripotent stem cell human CVCL_UG56 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21152707 CVCL_UG57 Der(22)-iPS-C4 induced pluripotent stem cell human CVCL_UG57 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21152708 CVCL_UG54 TRI13-iPS-C1 induced pluripotent stem cell human CVCL_UG54 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152709 CVCL_UG55 TRI8-iPS-C12 induced pluripotent stem cell human CVCL_UG55 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152710 CVCL_UG58 TS2-iPS-C11 induced pluripotent stem cell human CVCL_UG58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152711 CVCL_UG59 TS2-iPS-C7 induced pluripotent stem cell human CVCL_UG59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152712 CVCL_2A11 HGADFN167 iPS1J induced pluripotent stem cell human CVCL_2A11 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152713 CVCL_2A12 HGADFN167 iPS1Q induced pluripotent stem cell human CVCL_2A12 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152714 CVCL_2A10 HGADFN003 iPS1D induced pluripotent stem cell human CVCL_2A10 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152715 CVCL_2A15 HGFDFN168 iPS1D2 induced pluripotent stem cell human CVCL_2A15 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152716 CVCL_2A16 HGFDFN168 iPS1P induced pluripotent stem cell human CVCL_2A16 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152717 CVCL_2A13 HGMDFN090 iPS1B induced pluripotent stem cell human CVCL_2A13 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21152718 CVCL_2A14 HGMDFN090 iPS1C induced pluripotent stem cell human CVCL_2A14 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21152719 CVCL_2A19 HGFLBV082 transformed cell line human CVCL_2A19 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152720 CVCL_2A17 HGFLBV050 transformed cell line human CVCL_2A17 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152721 CVCL_2A18 HGFLBV079 transformed cell line human CVCL_2A18 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152722 CVCL_UG41 ATCi-Ai6IslCre80 induced pluripotent stem cell house mouse CVCL_UG41 CL:0000010 Derived from metastatic site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: Ai6 x Isl1-Cre. Male 21152723 CVCL_UG42 UiPS-1 induced pluripotent stem cell human CVCL_UG42 CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Tyr2476Asp (c.7426T>G); Zygosity=Heterozygous (PubMed=30308486) Derived from sampling site: Urine Cell type=Epithelial cell.. Male Caution: The mutation indicated in PubMed=30308486 (c.7448T>G; p.L2483R) is incorrect and does not correspond to the sequence trace in Figure 2, we have therefore corrected it 21152724 CVCL_UG40 ATCi-Ai6IslCre74 induced pluripotent stem cell house mouse CVCL_UG40 CL:0000010 Derived from metastatic site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: Ai6 x Isl1-Cre. Male 21152725 CVCL_UG45 HeLa/GSTP1 cancer cell line human CVCL_UG45 CL:0000010 Transfected with: HGNC; 4638; GSTP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Has a reduced radiosensitivity compared to the parent cell line 21152726 CVCL_UG46 PMab-202 hybridoma house mouse CVCL_UG46 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; F6ZBL8; Horse PDPN. 21152727 CVCL_UG43 UiPS-2 induced pluripotent stem cell human CVCL_UG43 CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Tyr2476Asp (c.7426T>G); Zygosity=Heterozygous (PubMed=30308486) Derived from sampling site: Urine Cell type=Epithelial cell.. Male Caution: The mutation indicated in the paper (c.7448T>G; p.L2483R) is incorrect and does not correspond to the sequence trace in Figure 2, we have therefore corrected it 21152728 CVCL_UG44 IB-RS-10 spontaneously immortalized cell line pig CVCL_UG44 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Landrace x Yorkshire x Edelschwein. Female 21152729 CVCL_UG49 iPSC DKC1 A353V #1 induced pluripotent stem cell human CVCL_UG49 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Ala353Val (c.1058C>T); ClinVar=VCV000011587; Zygosity=Hemizygous (PubMed=25992652) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21152730 CVCL_UG47 TL-My transformed cell line human CVCL_UG47 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 independent 21152731 CVCL_UG48 LCL-Mor8 transformed cell line human CVCL_UG48 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Male 21152732 CVCL_LM93 B-C9921F finite cell line human CVCL_LM93 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21152733 CVCL_LM94 C-B9538F finite cell line human CVCL_LM94 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21152734 CVCL_LM91 A-A946F finite cell line human CVCL_LM91 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21152735 CVCL_LM92 B-R939F finite cell line human CVCL_LM92 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21152736 CVCL_LM90 PM9726F finite cell line human CVCL_LM90 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152737 CVCL_UG30 LUEi001-A induced pluripotent stem cell human CVCL_UG30 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152738 CVCL_UG31 LUEi002-A induced pluripotent stem cell human CVCL_UG31 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152739 CVCL_UG34 LUEi004-A induced pluripotent stem cell human CVCL_UG34 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Arg13His (c.38G>A); Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152740 CVCL_UG35 LUEi004-B induced pluripotent stem cell human CVCL_UG35 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Arg13His (c.38G>A); Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152741 CVCL_UG32 LUEi002-B induced pluripotent stem cell human CVCL_UG32 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21152742 CVCL_UG33 LUEi003-A induced pluripotent stem cell human CVCL_UG33 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152743 CVCL_UG38 ATCi-Ai6IslCre10 induced pluripotent stem cell house mouse CVCL_UG38 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.; Breed/subspecies: Ai6 x Isl1-Cre. Male 21152744 CVCL_UG39 ATCi-Ai6IslCre35 induced pluripotent stem cell house mouse CVCL_UG39 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.; Breed/subspecies: Ai6 x Isl1-Cre. Male 21152745 CVCL_LM88 DV9540M transformed cell line human CVCL_LM88 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152746 CVCL_UG36 LUEi005-A induced pluripotent stem cell human CVCL_UG36 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Arg13His (c.38G>A); Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152747 CVCL_LM89 GM9573M transformed cell line human CVCL_LM89 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152748 CVCL_UG37 LUEi005-B induced pluripotent stem cell human CVCL_UG37 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Arg13His (c.38G>A); Zygosity=Heterozygous (PubMed=30316041) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152749 CVCL_LM86 AM952F transformed cell line human CVCL_LM86 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152750 CVCL_LM87 BM95760M transformed cell line human CVCL_LM87 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152751 CVCL_LM84 MaPaC-HS-77 cancer cell line human CVCL_LM84 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=33087752); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Homozygous (PubMed=33087752) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Array-based CGH Male Doubling time: 71 hours (PubMed=33087752); ~2 days (DSMZ=ACC-814) 21152752 CVCL_LM85 MCC-60 cancer cell line human CVCL_LM85 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=33087752); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Heterozygous (PubMed=33087752); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (PubMed=33087752); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Heterozygous (PubMed=33087752); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Heterozygous (PubMed=33087752) Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Array-based CGH Male Doubling time: 42 hours (PubMed=33087752); ~70-80 hours (DSMZ=ACC-815) 21152753 CVCL_UG20 ESi064-A induced pluripotent stem cell human CVCL_UG20 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10519; SACS; Simple; p.Arg3792Ter (c.11374C>T); ClinVar=VCV000370283; Zygosity=Heterozygous (PubMed=30384130) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21152754 CVCL_UG23 MCCI0003i-HCM induced pluripotent stem cell human CVCL_UG23 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Arg502Trp (c.1504C>T); ClinVar=VCV000042540; Zygosity=Heterozygous (PubMed=30316040) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21152755 CVCL_UG24 TUSMi005-A induced pluripotent stem cell human CVCL_UG24 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21152756 CVCL_UG21 CDMLi002-A induced pluripotent stem cell human CVCL_UG21 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.1878+32_1878+55del24; Zygosity=Heterozygous; Note=Causes aberrant splicing (PubMed=30312871) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21152757 CVCL_UG22 KCi002-A induced pluripotent stem cell human CVCL_UG22 From: Kennedy Centret, Rigshospitalet; Glostrup; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 26291; BBS10; Simple; p.Cys91Leufs*5 (c.271dupT) (271insT); ClinVar=VCV000001328; Zygosity=Homozygous (PubMed=30312873) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152758 CVCL_UG27 UKWNLi002-A induced pluripotent stem cell human CVCL_UG27 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7808; NGF; Simple; p.Thr203Met (c.608C>T); Zygosity=Heterozygous (PubMed=30384131) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21152759 CVCL_UG28 WAe009-A-12 embryonic stem cell human CVCL_UG28 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu125Valfs*9 (c.374_380del); Zygosity=Homozygous (PubMed=30312872). Female 21152760 CVCL_LM99 GH [Human embryonal carcinoma] cancer cell line human CVCL_LM99 CL:0000010 Male Doubling time: ~50 hours (DSMZ=ACC-811). 21152761 CVCL_UG25 VUZUZLi001-A induced pluripotent stem cell human CVCL_UG25 From: Institut fur Virologie und Zellbiologie; Lubeck; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21152762 CVCL_UG26 CRMi001-A-1 induced pluripotent stem cell human CVCL_UG26 From: NIH Center for Regenerative Medicine (CRM); Bethesda; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Tyr66Trp, p.Ser72Ala, p.Asn146Phe, p.His148Asp, p.Met153Thr, p.Val163Ala, p.Ser175Gly, p.Ala206Lys and p.His231Leu = Turquoise2 (Tq2)); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 CTLA has been endogenously tagged in one allele at the C-terminus with a Tq2-P2A-pac construct 21152763 CVCL_LM97 MG-57 cancer cell line human CVCL_LM97 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone; right humerus. Male Doubling time: 48 hours (PubMed=218153) 21152764 CVCL_LM98 MG-72 cancer cell line human CVCL_LM98 CL:0000010 Population: Caucasian Male Doubling time: 91 hours (PubMed=218153). 21152765 CVCL_LM95 3AB-OS cancer cell line human CVCL_LM95 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:64042; 3-aminobenzamide (3AB); Derived from sampling site: Pelvis; muscle. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Discontinued: Millipore; SCC141; true Female Characteristics: Was thought to have cancer stem cell-like characteristics as it was thought to be produced by long term treatment of MG-63 with 3-aminobenzamide (3AB), an inhibitor of poly(ADP-ribose) polymerase Doubling time: ~22 hours (PubMed=19160414) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00545 Problematic cell line: Contaminated Shown to be a RD derivative (personal communication of Millipore). Originally thought to be a MG-63 derivative. 21152766 CVCL_UG29 WAe009-A-13 embryonic stem cell human CVCL_UG29 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu125Valfs*9 (c.374_380del); Zygosity=Heterozygous (PubMed=30312872). Female 21152767 CVCL_LM96 MG-34 cancer cell line human CVCL_LM96 CL:0000010 Doubling time: 39 hours (PubMed=1208022). 21152768 CVCL_LM71 132P1 CD44-/CD90- cancer cell line human CVCL_LM71 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Oral cavity. Male Characteristics: Subpopulation of 132P1 derived according to the CD44/CD90 status using magnetic bead based separation Doubling time: 34 hours (PubMed=29029509) 21152769 CVCL_LM72 CAV cancer cell line human CVCL_LM72 CL:0000010 Unspecified Characteristics: Established from a xenograft. 21152770 CVCL_LM70 132P1 CD44-/CD90+ cancer cell line human CVCL_LM70 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Oral cavity. Male Characteristics: Subpopulation of 132P1 derived according to the CD44/CD90 status using magnetic bead based separation Doubling time: 26 hours (PubMed=29029509) 21152771 CVCL_UG12 AH927 spontaneously immortalized cell line CVCL_UG12 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21152772 CVCL_UG13 AH927-FX4P spontaneously immortalized cell line CVCL_UG13 CL:0000010 Transfected with: VGNC; 61299; Cat CXCR4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Unspecified 21152773 CVCL_UG10 MCC cancer cell line CVCL_UG10 CL:0000010 Breed/subspecies: Domestic longhair. Male Doubling time: 39 hours (PubMed=2161827) 21152774 CVCL_UG11 CHOR16 spontaneously immortalized cell line CVCL_UG11 CL:0000010 Transfected with: HGNC; 10943; SLC1A5 Derived from sampling site: Ovary. Female 21152775 CVCL_LM68 UROtsa As#6-SPARC transformed cell line human CVCL_LM68 CL:0000010 Transfected with: HGNC; 11219; SPARC Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female 21152776 CVCL_UG16 Yu-1 spontaneously immortalized cell line CVCL_UG16 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent; Virology: Susceptible to infection by feline immunodeficiency virus (FIV) 21152777 CVCL_UG17 FEA spontaneously immortalized cell line CVCL_UG17 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified 21152778 CVCL_LM69 PaCa 5156 cancer cell line human CVCL_LM69 CL:0000010 Miscellaneous: Age/sex of donor and doubling time from personal communication of Gungor C Derived from sampling site: Pancreas. Male Doubling time: 32-45 hours (Direct_author_submission) 21152779 CVCL_UG14 AH927-FR5E spontaneously immortalized cell line CVCL_UG14 CL:0000010 Transfected with: UniProtKB; O97774; Cat CCR5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Cell type=Fibroblast. Unspecified 21152780 CVCL_LM66 UROtsa Cd#4-SPARC transformed cell line human CVCL_LM66 CL:0000010 Transfected with: HGNC; 11219; SPARC Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female 21152781 CVCL_UG15 3201-FIV cancer cell line CVCL_UG15 CL:0000010 Virology: Persistently infected by feline immunodeficiency virus (FIV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10909 21152782 CVCL_LM67 UROtsa As#3-SPARC transformed cell line human CVCL_LM67 CL:0000010 Transfected with: HGNC; 11219; SPARC Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female 21152783 CVCL_LM64 UROtsa As#6 transformed cell line human CVCL_LM64 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 21.6 +- 1.6 hours (PubMed=20186695) 21152784 CVCL_LM65 UROtsa Cd#1-SPARC transformed cell line human CVCL_LM65 CL:0000010 Transfected with: HGNC; 11219; SPARC Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Omics: Transcriptome analysis by microarray Female 21152785 CVCL_UG18 QN10S transformed cell line CVCL_UG18 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Cell type=Fibroblast. Unspecified 21152786 CVCL_LM62 UROtsa As#4 transformed cell line human CVCL_LM62 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 21.0 +- 0.9 hours (PubMed=20186695) 21152787 CVCL_UG19 CF927 spontaneously immortalized cell line CVCL_UG19 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21152788 CVCL_LM63 UROtsa As#5 transformed cell line human CVCL_LM63 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 16.4 +- 0.7 hours (PubMed=20186695) 21152789 CVCL_LM82 538-MG-BA cancer cell line human CVCL_LM82 CL:0000010 Derived from sampling site: Brain; temporal lobe. Omics: Array-based CGH Male Doubling time: 28 hours (PubMed=30509096); ~30-35 hours (DSMZ=ACC-805) 21152790 CVCL_LM83 CCC-5 cancer cell line human CVCL_LM83 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (CelloPub=CLPUB00408) Derived from metastatic site: Pleural effusion. Male Doubling time: 60.5 hours (CelloPub=CLPUB00408); 2-3 days (DSMZ=ACC-810) 21152791 CVCL_LM80 DV-90-GFP cancer cell line human CVCL_LM80 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Pleural effusion. Male 21152792 CVCL_LM81 170-MG-BA cancer cell line human CVCL_LM81 CL:0000010 Derived from sampling site: Brain; temporal lobe. Omics: Array-based CGH Female Doubling time: 24 hours (PubMed=30509096); ~40-60 hours (DSMZ=ACC-804) 21152793 CVCL_UG01 RMS-16 cancer cell line human CVCL_UG01 CL:0000010 Derived from sampling site: Thigh. Female 21152794 CVCL_UG02 RMS-17 cancer cell line human CVCL_UG02 CL:0000010 Derived from metastatic site: Bone marrow. Male 21152795 CVCL_UG00 RMS-15 cancer cell line human CVCL_UG00 CL:0000010 Derived from metastatic site: Bone marrow. Male 21152796 CVCL_UG05 RMS-20 cancer cell line human CVCL_UG05 CL:0000010 Derived from sampling site: Pelvis. Male 21152797 CVCL_LM79 TOMO cancer cell line human CVCL_LM79 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Female 21152798 CVCL_UG06 RMS-21 cancer cell line human CVCL_UG06 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21152799 CVCL_LM77 M93-007 cancer cell line human CVCL_LM77 CL:0000010 Female 21152800 CVCL_UG03 RMS-18 cancer cell line human CVCL_UG03 CL:0000010 Derived from metastatic site: Lymph node. Male 21152801 CVCL_UG04 RMS-19 cancer cell line human CVCL_UG04 CL:0000010 Male 21152802 CVCL_LM78 T-40 cancer cell line human CVCL_LM78 CL:0000010 Unspecified 21152803 CVCL_UG09 CT-1413-T cancer cell line CVCL_UG09 CL:0000010 Breed/subspecies: Domestic longhair. Unspecified 21152804 CVCL_LM75 U-1906E cancer cell line human CVCL_LM75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (PubMed=12820372) Derived from metastatic site: Brain. Male Doubling time: 56.0 +- 17.24 hours (PubMed=7655829) 21152805 CVCL_LM76 U-1906L cancer cell line human CVCL_LM76 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=12820372) Derived from metastatic site: Brain. Male Doubling time: 55.0 +- 17.36 hours (PubMed=7655829) 21152806 CVCL_LM73 BHK21/13/Ag clone 4 spontaneously immortalized cell line CVCL_LM73 CL:0000010 Derived from sampling site: Kidney. Male Characteristics: Grows in agar 21152807 CVCL_UG07 CT-1413-H cancer cell line CVCL_UG07 CL:0000010 Derived from metastatic site: Heart; Breed/subspecies: Domestic longhair. Unspecified 21152808 CVCL_LM74 BHK21/13/Py6 transformed cell line CVCL_LM74 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Kidney. Male 21152809 CVCL_UG08 CT-1413-L cancer cell line CVCL_UG08 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Domestic longhair. Omics: Proteome analysis by 2D-DE/MS Unspecified Characteristics: Trans-differentiates into neuronal cells after in vitro infection with feline endogenous retrovirus RD-114 (PubMed=6961415) Doubling time: 19.5 hours (PubMed=6850643) 21152810 CVCL_LM50 HPSI0916i-vajy_5 induced pluripotent stem cell human CVCL_LM50 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152811 CVCL_LM48 HPSI0916i-moyn_4 induced pluripotent stem cell human CVCL_LM48 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152812 CVCL_LM49 HPSI0916i-vajy_4 induced pluripotent stem cell human CVCL_LM49 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152813 CVCL_LM46 HPSI0916i-jejm_4 induced pluripotent stem cell human CVCL_LM46 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152814 CVCL_LM47 HPSI0916i-moyn_1 induced pluripotent stem cell human CVCL_LM47 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152815 CVCL_LM44 HPSI0916i-hikt_1 induced pluripotent stem cell human CVCL_LM44 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152816 CVCL_LM45 HPSI0916i-hikt_2 induced pluripotent stem cell human CVCL_LM45 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152817 CVCL_LM42 HPSI0916i-helh_1 induced pluripotent stem cell human CVCL_LM42 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caribbean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152818 CVCL_LM43 HPSI0916i-helh_6 induced pluripotent stem cell human CVCL_LM43 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caribbean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21152819 CVCL_LM40 HPSI0816i-hizl_3 induced pluripotent stem cell human CVCL_LM40 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152820 CVCL_LM41 HPSI0816i-hizl_4 induced pluripotent stem cell human CVCL_LM41 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152821 CVCL_LM60 UROtsa As#2 transformed cell line human CVCL_LM60 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 14.1 +- 0.9 hours (PubMed=20186695) 21152822 CVCL_LM61 UROtsa As#3 transformed cell line human CVCL_LM61 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 33.3 +- 1.4 hours (PubMed=20186695) 21152823 CVCL_LM59 UROtsa As#1 transformed cell line human CVCL_LM59 CL:0000010 Transformant: Sodium arsenite(ChEBI; CHEBI:29678); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Female Characteristics: Tumorigenic derivative of UROtsa Subcutaneous injection of this cell line in nude mice produces tumors. Doubling time: 26.4 +- 1.1 hours (PubMed=20186695) 21152824 CVCL_LM57 HPSI1016i-riwg_2 induced pluripotent stem cell human CVCL_LM57 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; Irish; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Female 21152825 CVCL_LM58 HPSI1016i-riwg_8 induced pluripotent stem cell human CVCL_LM58 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; Irish; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Female 21152826 CVCL_LM55 HPSI1016i-livl_2 induced pluripotent stem cell human CVCL_LM55 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Male 21152827 CVCL_LM56 HPSI1016i-livl_5 induced pluripotent stem cell human CVCL_LM56 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Male 21152828 CVCL_LM53 HPSI0916i-zipi_1 induced pluripotent stem cell human CVCL_LM53 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152829 CVCL_LM54 HPSI0916i-zipi_5 induced pluripotent stem cell human CVCL_LM54 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152830 CVCL_LM51 HPSI0916i-vorn_2 induced pluripotent stem cell human CVCL_LM51 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152831 CVCL_LM52 HPSI0916i-vorn_5 induced pluripotent stem cell human CVCL_LM52 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152832 CVCL_2A88 AG04446 finite cell line human CVCL_2A88 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 37 PDL (PubMed=9724752); 33 PDL (Coriell=AG04446); Doubling time: 2.2 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152833 CVCL_2A89 AG04447 finite cell line human CVCL_2A89 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [90%]; 46,XY,t(4;9)(4pter->4q33::9q12->9qter;9pter->9q12::4q33->4qter) [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG04447) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152834 CVCL_2A86 AG04444 finite cell line human CVCL_2A86 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG04444) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152835 CVCL_2A87 AG04445 finite cell line human CVCL_2A87 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG04445) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152836 CVCL_2A80 AG04387 finite cell line human CVCL_2A80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152837 CVCL_2A81 AG04438 finite cell line human CVCL_2A81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG04438) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152838 CVCL_2A84 AG04442 finite cell line human CVCL_2A84 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG04442) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152839 CVCL_2A85 AG04443 finite cell line human CVCL_2A85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG04443); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152840 CVCL_2A82 AG04439 finite cell line human CVCL_2A82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG04439) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152841 CVCL_2A83 AG04441 finite cell line human CVCL_2A83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37-38 PDL (PubMed=9724752); 47 PDL (Coriell=AG04441) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152842 CVCL_2A99 AG04551 finite cell line human CVCL_2A99 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG04551) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152843 CVCL_2A97 AG04460 finite cell line human CVCL_2A97 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG04460) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152844 CVCL_2A98 AG04461 finite cell line human CVCL_2A98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [54%]; 46,XY,2p-,5q+,22p+,Xp- [26%]; 46,XY,t(1;2)(q21;q37) [8%)]; 46,XY,16q+ [6%]; 46,XY,11p- [4%]; 46,XY,1p- [2%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152845 CVCL_2A91 AG04454 finite cell line human CVCL_2A91 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [11]; 46,XY,der(15)(15qter->15p11.2::17q21->17qter) [34]; 45,X [3]; 46,XY,t(2;10)(2qter->p23::10p13->10pter;10qter->10p13::2p23->2pter) [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG04454) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152846 CVCL_2A92 AG04455 finite cell line human CVCL_2A92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152847 CVCL_2A90 AG04453 finite cell line human CVCL_2A90 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (PubMed=7307581) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152848 CVCL_2A95 AG04458 finite cell line human CVCL_2A95 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG04458) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152849 CVCL_2A96 AG04459 finite cell line human CVCL_2A96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG04459; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152850 CVCL_2A93 AG04456 finite cell line human CVCL_2A93 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [8]; 46,XY,t(1;6)(1pter->1q25::6q13->6qter;6pter->6q13::1q25->1qter) [42] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152851 CVCL_2A94 AG04457 finite cell line human CVCL_2A94 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [23]; 46,XY,t(7;20)(7pter->7q11::20q11->20qter;20pter->20q11::7q11->7qter) [15]; 45,X [12] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152852 CVCL_2A66 AG04353 finite cell line human CVCL_2A66 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (PubMed=7307581) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152853 CVCL_2A67 AG04354 finite cell line human CVCL_2A67 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG04354) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152854 CVCL_2A64 AG04351 finite cell line human CVCL_2A64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 42 PDL (Coriell=AG04351) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152855 CVCL_2A65 AG04352 finite cell line human CVCL_2A65 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,t(1;8)(p22;q13) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG04352) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152856 CVCL_2A68 AG04355 finite cell line human CVCL_2A68 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG04355) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152857 CVCL_2A69 AG04356 finite cell line human CVCL_2A69 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG04356) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152858 CVCL_2A62 AG04349 finite cell line human CVCL_2A62 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [70%]; 47,XY,+mar [30%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 51 PDL (Coriell=AG04349) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152859 CVCL_2A63 AG04350 finite cell line human CVCL_2A63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [78%]; 46,XY,1q+ [22%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (PubMed=7307581); 40 PDL (Coriell=AG04350) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152860 CVCL_2A60 AG04153 finite cell line human CVCL_2A60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [43]; 46,XY,der(9)(9qter->9p23::7q11->7qter) [3]; 46,XY,der(13)(13qter->13p13::7q11->7qter) [2]; 46,XY,add(13)(?::p13->qter) [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152861 CVCL_2A61 AG04348 finite cell line human CVCL_2A61 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG04348) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152862 CVCL_2A77 AG04384 finite cell line human CVCL_2A77 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG04384) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152863 CVCL_2A78 AG04385 finite cell line human CVCL_2A78 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(1;21)(p12;p11.2),t(3;14)(q12;q11.2) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG04385) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152864 CVCL_2A75 AG04382 finite cell line human CVCL_2A75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152865 CVCL_2A76 AG04383 finite cell line human CVCL_2A76 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152866 CVCL_2A79 AG04386 finite cell line human CVCL_2A79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [70%]; 46,XY,8p-,22q+ [16%]; 46,XY,1p+,3p-,3q-,11p-,21q+ [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 27 PDL (Coriell=AG04386) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152867 CVCL_2A70 AG04357 finite cell line human CVCL_2A70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152868 CVCL_2A73 AG04380 finite cell line human CVCL_2A73 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [68%]; 46,XY,12p+ [32%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG04380) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152869 CVCL_2A74 AG04381 finite cell line human CVCL_2A74 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [40%]; 45,X [60%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG04381) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152870 CVCL_2A71 AG04378 finite cell line human CVCL_2A71 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152871 CVCL_2A72 AG04379 finite cell line human CVCL_2A72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG04379) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152872 CVCL_2A44 AG04057 finite cell line human CVCL_2A44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152873 CVCL_2A45 AG04060 finite cell line human CVCL_2A45 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(2;13)(2qter->2p13::13q32->13qter;13pter->13q32::2p13->2pter) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152874 CVCL_2A42 AG04055 finite cell line human CVCL_2A42 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152875 CVCL_2A43 AG04056 finite cell line human CVCL_2A43 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 45,X [4%]; 47,XY,+18 [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152876 CVCL_2A48 AG04063 finite cell line human CVCL_2A48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 45 PDL (Coriell=AG04063) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152877 CVCL_2A49 AG04065 finite cell line human CVCL_2A49 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [80%]; 46,XY,der(9)t(1;9)(q23;p24) [4%]; 46,XY,t(1;12;22)(p36;q13;q12),del(3)(q22;q25),der(10)t(10;15)(q26;q14),del(19)(?) [16%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152878 CVCL_2A46 AG04061 finite cell line human CVCL_2A46 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [80%]; 46,XY,t(8;18)(8pter->8q11::18q11->18qter;18pter->18q11::8q11->8qter) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 54 PDL (PubMed=7307581); 53 PDL (Coriell=AG04061) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152879 CVCL_2A47 AG04062 finite cell line human CVCL_2A47 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34-44 PDL (PubMed=9724752); 31 PDL (Coriell=AG04062) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152880 CVCL_UG92 HEK293 CYP2C8*3-V5 transformed cell line human CVCL_UG92 CL:0000010 Transfected with: HGNC; 2622; CYP2C8 (with p.Arg139Lys and p.Lys399Arg) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C8*3 with a C-terminal V5 tag 21152881 CVCL_UG93 HEK293 CYP2C8*4-V5 transformed cell line human CVCL_UG93 CL:0000010 Transfected with: HGNC; 2622; CYP2C8 (with p.Ile264Met) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C8*4 with a C-terminal V5 tag 21152882 CVCL_UG90 HEK293 CYP2C8*1-V5 transformed cell line human CVCL_UG90 CL:0000010 Transfected with: HGNC; 2622; CYP2C8 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C8*1 with a C-terminal V5 tag 21152883 CVCL_UG91 HEK293 CYP2C8*2-V5 transformed cell line human CVCL_UG91 CL:0000010 Transfected with: HGNC; 2622; CYP2C8 (with p.Ile269Phe) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C8*2 with a C-terminal V5 tag 21152884 CVCL_UG96 HEK293 CYP2C9*2-V5 transformed cell line human CVCL_UG96 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 (with p.Arg144Cys) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C9*2 with a C-terminal V5 tag 21152885 CVCL_UG97 HEK293 CYP2C9*3-V5 transformed cell line human CVCL_UG97 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 (with p.Ile359Leu) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C9*3 with a C-terminal V5 tag 21152886 CVCL_UG94 HEK293 CYP2C9*1 transformed cell line human CVCL_UG94 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152887 CVCL_UG95 HEK293 CYP2C9*1-V5 transformed cell line human CVCL_UG95 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C9*1 with a C-terminal V5 tag 21152888 CVCL_UG98 HEK293 CYP2C9*8-V5 transformed cell line human CVCL_UG98 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 (with p.Arg150His) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C9*8 with a C-terminal V5 tag 21152889 CVCL_UG99 HEK293 CYP2C9*9-V5 transformed cell line human CVCL_UG99 CL:0000010 Transfected with: HGNC; 2623; CYP2C9 (with p.His251Arg) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C9*9 with a C-terminal V5 tag 21152890 CVCL_2A40 Col-1 cancer cell line house mouse CVCL_2A40 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Col series of TS/A derived cell lines are obtained from repeated intravenous passage of lung colonies in BALB/c female mice 21152891 CVCL_2A41 AG04054 finite cell line human CVCL_2A41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152892 CVCL_2A55 AG04148 finite cell line human CVCL_2A55 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 55 PDL (PubMed=7307581) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152893 CVCL_2A56 AG04149 finite cell line human CVCL_2A56 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152894 CVCL_2A53 AG04146 finite cell line human CVCL_2A53 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152895 CVCL_2A54 AG04147 finite cell line human CVCL_2A54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 39 PDL (Coriell=AG04147) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152896 CVCL_2A59 AG04152 finite cell line human CVCL_2A59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152897 CVCL_2A57 AG04150 finite cell line human CVCL_2A57 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 54 PDL (PubMed=7307581); 45 PDL (Coriell=AG04150) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152898 CVCL_2A58 AG04151 finite cell line human CVCL_2A58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [60%]; 46,XY,t(2;18)(2pter->2q33::18q21->18qter;18pter->18q21::2q33->2qter) [40%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152899 CVCL_UG81 HEK293 CYP1A2*1A transformed cell line human CVCL_UG81 CL:0000010 Transfected with: HGNC; 2596; CYP1A2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152900 CVCL_UG82 HEK293 CYP1A2*1A-V5 transformed cell line human CVCL_UG82 CL:0000010 Transfected with: HGNC; 2596; CYP1A2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP1A2*1A with a C-terminal V5 tag 21152901 CVCL_UG80 HEK293 CYP1A1*1-V5 transformed cell line human CVCL_UG80 CL:0000010 Transfected with: HGNC; 2595; CYP1A1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP1A1*1 with a C-terminal V5 tag 21152902 CVCL_UG85 HEK293 CYP2A6*1A-V5 transformed cell line human CVCL_UG85 CL:0000010 Transfected with: HGNC; 2610; CYP2A6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2A6*1A with a C-terminal V5 tag 21152903 CVCL_UG86 HEK293 CYP2A13*1A transformed cell line human CVCL_UG86 CL:0000010 Transfected with: HGNC; 2608; CYP2A13 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152904 CVCL_UG83 HEK293 CYP1A2*21 transformed cell line human CVCL_UG83 CL:0000010 Transfected with: HGNC; 2596; CYP1A2 (with p.Ser298Arg) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152905 CVCL_UG84 HEK293 CYP2A6*1A transformed cell line human CVCL_UG84 CL:0000010 Transfected with: HGNC; 2610; CYP2A6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152906 CVCL_UG89 HEK293 CYP2B6*1-V5 transformed cell line human CVCL_UG89 CL:0000010 Transfected with: HGNC; 2615; CYP2B6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2B6*1 with a C-terminal V5 tag 21152907 CVCL_UG87 HEK293 CYP2A13*1A-V5 transformed cell line human CVCL_UG87 CL:0000010 Transfected with: HGNC; 2608; CYP2A13 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2A13*1A with a C-terminal V5 tag 21152908 CVCL_UG88 GM11772 transformed cell line human CVCL_UG88 CL:0000010 Anecdotal: Part of a set of 5 cell lines that were established from blood samples of members of the Huaorani (Waorani) indigenous people These samples were allegedly taken without the Ecuadorian government's permission during the early 1990s. Population: Native South American; Huaorani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11772; true Male 21152909 CVCL_2A51 AG04143 finite cell line human CVCL_2A51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [76%]; 45,X [10%]; 46,XY,t(1;5)(q24;p15) [14%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 32 PDL (Coriell=AG04143) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152910 CVCL_2A52 AG04145 finite cell line human CVCL_2A52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 56 PDL (PubMed=7307581) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152911 CVCL_2A50 AG04142 finite cell line human CVCL_2A50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG04142) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21152912 CVCL_2A22 HGMLBV078 transformed cell line human CVCL_2A22 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21152913 CVCL_2A23 HGMLBV081 transformed cell line human CVCL_2A23 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21152914 CVCL_2A20 HGMLBV013 transformed cell line human CVCL_2A20 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21152915 CVCL_2A21 HGMLBV058 transformed cell line human CVCL_2A21 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21152916 CVCL_2A26 HGADFN005 finite cell line human CVCL_2A26 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21152917 CVCL_2A27 HGADFN008 finite cell line human CVCL_2A27 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152918 CVCL_2A24 HGSLBV059 transformed cell line human CVCL_2A24 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21152919 CVCL_2A25 HGADFN001 finite cell line human CVCL_2A25 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21152920 CVCL_2A28 HGADFN014 finite cell line human CVCL_2A28 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152921 CVCL_2A29 AG06298 finite cell line human CVCL_2A29 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG06298; probable Male 21152922 CVCL_UG70 AMC-iPSC-C28 induced pluripotent stem cell human CVCL_UG70 CL:0000010 Derived from sampling site: Amnion Cell type=Mesenchymal cell.. Female 21152923 CVCL_UG71 UMC-iPS-C1 induced pluripotent stem cell human CVCL_UG71 CL:0000010 Derived from sampling site: Umbilical cord; Wharton's jelly. Female 21152924 CVCL_UG74 CMC-iPS-C28 induced pluripotent stem cell human CVCL_UG74 CL:0000010 Derived from sampling site: Placenta; chorion Cell type=Mesenchymal cell.. Omics: Transcriptome analysis by microarray Female 21152925 CVCL_UG75 CMC-iPS-C9 induced pluripotent stem cell human CVCL_UG75 CL:0000010 Derived from sampling site: Placenta; chorion Cell type=Mesenchymal cell.. Female 21152926 CVCL_UG72 UMC-iPS-C6 induced pluripotent stem cell human CVCL_UG72 CL:0000010 Derived from sampling site: Umbilical cord; Wharton's jelly. Female 21152927 CVCL_UG73 CMC-iPS-C1 induced pluripotent stem cell human CVCL_UG73 CL:0000010 Derived from sampling site: Placenta; chorion Cell type=Mesenchymal cell.. Omics: Transcriptome analysis by microarray Female 21152928 CVCL_UG78 FRTL-5 AG2 transformed cell line Norway rat CVCL_UG78 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 21152929 CVCL_UG79 HEK293 CYP1A1*1 transformed cell line human CVCL_UG79 CL:0000010 Transfected with: HGNC; 2595; CYP1A1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21152930 CVCL_UG76 GM10977 transformed cell line human CVCL_UG76 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10977; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21152931 CVCL_UG77 FRTL-5 AG1 transformed cell line Norway rat CVCL_UG77 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 21152932 CVCL_2A33 TUBO [Mouse mammary tumor] cancer cell line house mouse CVCL_2A33 CL:0000010 Breed/subspecies: BALB-neuT. Female 21152933 CVCL_2A34 TUBO-P2J cancer cell line house mouse CVCL_2A34 CL:0000010 Breed/subspecies: BALB-neuT. Female Characteristics: Metastatic phenotype Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00272 21152934 CVCL_2A31 AG03739 transformed cell line human CVCL_2A31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03739; probable Male 21152935 CVCL_2A32 HGADFN004 finite cell line human CVCL_2A32 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21152936 CVCL_2A37 MDCK 33016-PF spontaneously immortalized cell line dog CVCL_2A37 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Biotechnology: Used for the production of the influenza vaccine Optaflu Female Group: Vaccine production cell line 21152937 CVCL_2A38 SHEP-SF cancer cell line human CVCL_2A38 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21152938 CVCL_2A35 HGADFN136 finite cell line human CVCL_2A35 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21152939 CVCL_2A36 MDCK 33016 spontaneously immortalized cell line dog CVCL_2A36 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2219 21152940 CVCL_2A39 RYAS41 transformed cell line Norway rat CVCL_2A39 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic pancreas; islets of Langerhans; Breed/subspecies: Wistar. Unspecified Characteristics: Secretes insulin in response to glucose stimulation; Characteristics: Has been transduced with a recombinant lentivirus expressing the SV40 T antigen under the control of the insulin promoter 21152941 CVCL_UG60 TS3-iPS-C12 induced pluripotent stem cell human CVCL_UG60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152942 CVCL_UG63 Peri-iPS-C2 induced pluripotent stem cell human CVCL_UG63 CL:0000010 Derived from sampling site: Bone; periosteum. Omics: Transcriptome analysis by microarray Male 21152943 CVCL_UG64 TS1-iPS-C1 induced pluripotent stem cell human CVCL_UG64 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Omics: Transcriptome analysis by microarray Female 21152944 CVCL_UG61 TS3-iPS-C7 induced pluripotent stem cell human CVCL_UG61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21152945 CVCL_UG62 Peri-iPS-C1 induced pluripotent stem cell human CVCL_UG62 CL:0000010 Derived from sampling site: Bone; periosteum. Omics: Transcriptome analysis by microarray Male 21152946 CVCL_UG67 TS1-iPS-C5 induced pluripotent stem cell human CVCL_UG67 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Omics: Transcriptome analysis by microarray Female 21152947 CVCL_UG68 AMC-iPSC-C22 induced pluripotent stem cell human CVCL_UG68 CL:0000010 Derived from sampling site: Amnion Cell type=Mesenchymal cell.. Female 21152948 CVCL_UG65 TS1-iPS-C2 induced pluripotent stem cell human CVCL_UG65 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female 21152949 CVCL_UG66 TS1-iPS-C3 induced pluripotent stem cell human CVCL_UG66 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Omics: Transcriptome analysis by microarray Female 21152950 CVCL_UG69 AMC-iPSC-C27 induced pluripotent stem cell human CVCL_UG69 CL:0000010 Derived from sampling site: Amnion Cell type=Mesenchymal cell.. Female 21152951 CVCL_2A30 AG03342 transformed cell line human CVCL_2A30 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03342; probable Male 21152952 CVCL_D418 mHypoA-57 transformed cell line house mouse CVCL_D418 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152953 CVCL_CS18 ND20122 transformed cell line human CVCL_CS18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152954 CVCL_D419 mHypoA-58 transformed cell line house mouse CVCL_D419 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152955 CVCL_CS19 ND20125 transformed cell line human CVCL_CS19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152956 CVCL_D416 mHypoA-55 transformed cell line house mouse CVCL_D416 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152957 CVCL_CS16 ND20088 transformed cell line human CVCL_CS16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152958 CVCL_D417 mHypoA-56 transformed cell line house mouse CVCL_D417 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152959 CVCL_CS17 ND20093 transformed cell line human CVCL_CS17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152960 CVCL_D410 mHypoA-49 transformed cell line house mouse CVCL_D410 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152961 CVCL_CS10 ND20018 transformed cell line human CVCL_CS10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152962 CVCL_D411 mHypoA-50 transformed cell line house mouse CVCL_D411 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152963 CVCL_CS11 ND20022 transformed cell line human CVCL_CS11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152964 CVCL_D414 mHypoA-53 transformed cell line house mouse CVCL_D414 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152965 CVCL_CS14 ND20049 transformed cell line human CVCL_CS14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152966 CVCL_D415 mHypoA-54 transformed cell line house mouse CVCL_D415 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152967 CVCL_CS15 ND20061 transformed cell line human CVCL_CS15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152968 CVCL_D412 mHypoA-51 transformed cell line house mouse CVCL_D412 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152969 CVCL_CS12 ND20034 transformed cell line human CVCL_CS12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152970 CVCL_D413 mHypoA-52 transformed cell line house mouse CVCL_D413 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152971 CVCL_CS13 ND20044 transformed cell line human CVCL_CS13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152972 CVCL_D429 mHypoE-25/2 transformed cell line house mouse CVCL_D429 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21152973 CVCL_CS29 ND20210 transformed cell line human CVCL_CS29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152974 CVCL_D427 mHypoE-20/1 transformed cell line house mouse CVCL_D427 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21152975 CVCL_CS27 ND20200 transformed cell line human CVCL_CS27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152976 CVCL_D428 mHypoE-20/2 transformed cell line house mouse CVCL_D428 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21152977 CVCL_CS28 ND20205 transformed cell line human CVCL_CS28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152978 CVCL_D421 mHypoA-60 transformed cell line house mouse CVCL_D421 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152979 CVCL_CS21 ND20132 transformed cell line human CVCL_CS21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152980 CVCL_D422 mHypoA-61 transformed cell line house mouse CVCL_D422 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152981 CVCL_CS22 ND20144 transformed cell line human CVCL_CS22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152982 CVCL_D420 mHypoA-59 transformed cell line house mouse CVCL_D420 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152983 CVCL_CS20 ND20127 transformed cell line human CVCL_CS20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152984 CVCL_D425 mHypoE-1 transformed cell line house mouse CVCL_D425 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21152985 CVCL_CS25 ND20180 transformed cell line human CVCL_CS25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21152986 CVCL_D426 mHypoE-11 transformed cell line house mouse CVCL_D426 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21152987 CVCL_CS26 ND20182 transformed cell line human CVCL_CS26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152988 CVCL_D423 mHypoA-62 transformed cell line house mouse CVCL_D423 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152989 CVCL_CS23 ND20155 transformed cell line human CVCL_CS23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152990 CVCL_D424 mHypoA-63 transformed cell line house mouse CVCL_D424 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152991 CVCL_CS24 ND20159 transformed cell line human CVCL_CS24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152992 CVCL_D407 mHypoA-46 transformed cell line house mouse CVCL_D407 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152993 CVCL_CS07 ND19993 transformed cell line human CVCL_CS07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152994 CVCL_D408 mHypoA-47 transformed cell line house mouse CVCL_D408 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152995 CVCL_CS08 ND20013 transformed cell line human CVCL_CS08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152996 CVCL_D405 mHypoA-44 transformed cell line house mouse CVCL_D405 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152997 CVCL_CS05 ND19961 transformed cell line human CVCL_CS05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21152998 CVCL_D406 mHypoA-45 transformed cell line house mouse CVCL_D406 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21152999 CVCL_CS06 ND19966 transformed cell line human CVCL_CS06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153000 CVCL_D409 mHypoA-48 transformed cell line house mouse CVCL_D409 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21153001 CVCL_CS09 ND20014 transformed cell line human CVCL_CS09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153002 CVCL_D400 mHypoA-2/4 transformed cell line house mouse CVCL_D400 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21153003 CVCL_CS00 ND19937 transformed cell line human CVCL_CS00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153004 CVCL_D403 mHypoA-42 transformed cell line house mouse CVCL_D403 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21153005 CVCL_CS03 ND19957 transformed cell line human CVCL_CS03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153006 CVCL_D404 mHypoA-43 transformed cell line house mouse CVCL_D404 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21153007 CVCL_CS04 ND19958 transformed cell line human CVCL_CS04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153008 CVCL_D401 mHypoA-2/6 transformed cell line house mouse CVCL_D401 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Male 21153009 CVCL_CS01 ND19940 transformed cell line human CVCL_CS01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153010 CVCL_D402 mHypoA-41 transformed cell line house mouse CVCL_D402 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21153011 CVCL_CS02 ND19944 transformed cell line human CVCL_CS02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153012 CVCL_CS98 ND20765 transformed cell line human CVCL_CS98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153013 CVCL_D498 rHypoE-23 transformed cell line Norway rat CVCL_D498 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU214 Unspecified 21153014 CVCL_CS99 ND20766 transformed cell line human CVCL_CS99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153015 CVCL_D499 rHypoE-24 transformed cell line Norway rat CVCL_D499 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153016 CVCL_CS96 ND20752 transformed cell line human CVCL_CS96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153017 CVCL_D496 rHypoE-21 transformed cell line Norway rat CVCL_D496 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153018 CVCL_CS97 ND20764 transformed cell line human CVCL_CS97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153019 CVCL_D497 rHypoE-22 transformed cell line Norway rat CVCL_D497 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153020 CVCL_CS90 ND20699 transformed cell line human CVCL_CS90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153021 CVCL_D490 rHypoE-13 transformed cell line Norway rat CVCL_D490 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153022 CVCL_CS91 ND20709 transformed cell line human CVCL_CS91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153023 CVCL_D491 rHypoE-15 transformed cell line Norway rat CVCL_D491 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153024 CVCL_LM28 HPSI0616i-oajt_6 induced pluripotent stem cell human CVCL_LM28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153025 CVCL_CS94 ND20737 transformed cell line human CVCL_CS94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153026 CVCL_D494 rHypoE-19 transformed cell line Norway rat CVCL_D494 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153027 CVCL_LM29 HPSI0616i-rily_1 induced pluripotent stem cell human CVCL_LM29 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153028 CVCL_CS95 ND20738 transformed cell line human CVCL_CS95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153029 CVCL_D495 rHypoE-20 transformed cell line Norway rat CVCL_D495 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153030 CVCL_LM26 HPSI0616i-mifg_5 induced pluripotent stem cell human CVCL_LM26 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153031 CVCL_CS92 ND20729 transformed cell line human CVCL_CS92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153032 CVCL_D492 rHypoE-16 transformed cell line Norway rat CVCL_D492 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU208 Unspecified 21153033 CVCL_LM27 HPSI0616i-oajt_3 induced pluripotent stem cell human CVCL_LM27 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153034 CVCL_CS93 ND20730 transformed cell line human CVCL_CS93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153035 CVCL_D493 rHypoE-18 transformed cell line Norway rat CVCL_D493 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153036 CVCL_LM24 HPSI0616i-mesv_5 induced pluripotent stem cell human CVCL_LM24 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153037 CVCL_LM25 HPSI0616i-mifg_2 induced pluripotent stem cell human CVCL_LM25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153038 CVCL_LM22 HPSI0616i-kayf_6 induced pluripotent stem cell human CVCL_LM22 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153039 CVCL_LM23 HPSI0616i-mesv_4 induced pluripotent stem cell human CVCL_LM23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153040 CVCL_LM20 HPSI0616i-iuse_6 induced pluripotent stem cell human CVCL_LM20 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153041 CVCL_LM21 HPSI0616i-kayf_5 induced pluripotent stem cell human CVCL_LM21 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153042 CVCL_LM39 HPSI0816i-fuuy_3 induced pluripotent stem cell human CVCL_LM39 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153043 CVCL_LM37 HPSI0716i-yipp_2 induced pluripotent stem cell human CVCL_LM37 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153044 CVCL_LM38 HPSI0716i-yipp_6 induced pluripotent stem cell human CVCL_LM38 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153045 CVCL_LM35 HPSI0616i-xuvy_6 induced pluripotent stem cell human CVCL_LM35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153046 CVCL_LM36 HPSI0716i-toba_1 induced pluripotent stem cell human CVCL_LM36 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153047 CVCL_LM33 HPSI0616i-uofs_2 induced pluripotent stem cell human CVCL_LM33 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153048 CVCL_LM34 HPSI0616i-uofs_5 induced pluripotent stem cell human CVCL_LM34 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153049 CVCL_LM31 HPSI0616i-uegn_1 induced pluripotent stem cell human CVCL_LM31 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153050 CVCL_LM32 HPSI0616i-uegn_3 induced pluripotent stem cell human CVCL_LM32 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153051 CVCL_LM30 HPSI0616i-rily_3 induced pluripotent stem cell human CVCL_LM30 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153052 CVCL_D476 mPitA-14 transformed cell line house mouse CVCL_D476 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153053 CVCL_CS76 ND20583 transformed cell line human CVCL_CS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153054 CVCL_D477 mPitA-15 transformed cell line house mouse CVCL_D477 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153055 CVCL_CS77 ND20586 transformed cell line human CVCL_CS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153056 CVCL_D474 mPitA-12/5 transformed cell line house mouse CVCL_D474 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153057 CVCL_CS74 ND20579 transformed cell line human CVCL_CS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153058 CVCL_D475 mPitA-12/6 transformed cell line house mouse CVCL_D475 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153059 CVCL_CS75 ND20582 transformed cell line human CVCL_CS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153060 CVCL_D478 mPitA-16 transformed cell line house mouse CVCL_D478 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153061 CVCL_CS78 ND20598 transformed cell line human CVCL_CS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153062 CVCL_D479 mPitA-19 transformed cell line house mouse CVCL_D479 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153063 CVCL_CS79 ND20600 transformed cell line human CVCL_CS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153064 CVCL_LM08 HPSI0616i-baxr_5 induced pluripotent stem cell human CVCL_LM08 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153065 CVCL_LM09 HPSI0616i-baxr_6 induced pluripotent stem cell human CVCL_LM09 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153066 CVCL_LM06 HPSI0516i-peoo_1 induced pluripotent stem cell human CVCL_LM06 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153067 CVCL_D472 mPitA-12/3 transformed cell line house mouse CVCL_D472 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153068 CVCL_CS72 ND20570 transformed cell line human CVCL_CS72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153069 CVCL_LM07 HPSI0516i-peoo_2 induced pluripotent stem cell human CVCL_LM07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153070 CVCL_D473 mPitA-12/4 transformed cell line house mouse CVCL_D473 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153071 CVCL_CS73 ND20577 transformed cell line human CVCL_CS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153072 CVCL_D470 mPitA-1/8 transformed cell line house mouse CVCL_D470 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153073 CVCL_CS70 ND20552 transformed cell line human CVCL_CS70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153074 CVCL_LM04 ND39461 transformed cell line human CVCL_LM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153075 CVCL_D471 mPitA-12 transformed cell line house mouse CVCL_D471 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153076 CVCL_CS71 ND20563 transformed cell line human CVCL_CS71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153077 CVCL_LM05 ND39588 transformed cell line human CVCL_LM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153078 CVCL_LM02 FIB-MARFAN3 finite cell line human CVCL_LM02 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153079 CVCL_LM03 FIB-MARFAN4 finite cell line human CVCL_LM03 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153080 CVCL_LM00 HPSI1116i-zies_6 induced pluripotent stem cell human CVCL_LM00 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153081 CVCL_LM01 FIB-MARFAN1 finite cell line human CVCL_LM01 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153082 CVCL_D487 mPitA-6 transformed cell line house mouse CVCL_D487 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153083 CVCL_CS87 ND20684 transformed cell line human CVCL_CS87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153084 CVCL_D488 mPitA-8 transformed cell line house mouse CVCL_D488 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153085 CVCL_CS88 ND20696 transformed cell line human CVCL_CS88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153086 CVCL_D485 mPitA-4 transformed cell line house mouse CVCL_D485 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153087 CVCL_CS85 ND20659 transformed cell line human CVCL_CS85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153088 CVCL_D486 mPitA-5 transformed cell line house mouse CVCL_D486 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153089 CVCL_CS86 ND20660 transformed cell line human CVCL_CS86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153090 CVCL_CS89 ND20698 transformed cell line human CVCL_CS89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153091 CVCL_D489 rHypoE-11 transformed cell line Norway rat CVCL_D489 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21153092 CVCL_D480 mPitA-2 transformed cell line house mouse CVCL_D480 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153093 CVCL_CS80 ND20635 transformed cell line human CVCL_CS80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153094 CVCL_LM19 HPSI0616i-iuse_5 induced pluripotent stem cell human CVCL_LM19 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153095 CVCL_LM17 HPSI0616i-duve_6 induced pluripotent stem cell human CVCL_LM17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153096 CVCL_D483 mPitA-3/2 transformed cell line house mouse CVCL_D483 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153097 CVCL_CS83 ND20648 transformed cell line human CVCL_CS83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153098 CVCL_LM18 HPSI0616i-euia_7 induced pluripotent stem cell human CVCL_LM18 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153099 CVCL_D484 mPitA-3/3 transformed cell line house mouse CVCL_D484 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153100 CVCL_CS84 ND20650 transformed cell line human CVCL_CS84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153101 CVCL_LM15 HPSI0616i-bury_6 induced pluripotent stem cell human CVCL_LM15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153102 CVCL_D481 mPitA-3 transformed cell line house mouse CVCL_D481 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153103 CVCL_CS81 ND20646 transformed cell line human CVCL_CS81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153104 CVCL_LM16 HPSI0616i-duve_2 induced pluripotent stem cell human CVCL_LM16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153105 CVCL_D482 mPitA-3/1 transformed cell line house mouse CVCL_D482 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153106 CVCL_CS82 ND20647 transformed cell line human CVCL_CS82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153107 CVCL_LM13 HPSI0616i-biln_2 induced pluripotent stem cell human CVCL_LM13 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153108 CVCL_LM14 HPSI0616i-bury_5 induced pluripotent stem cell human CVCL_LM14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153109 CVCL_LM11 HPSI0616i-beyk_6 induced pluripotent stem cell human CVCL_LM11 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153110 CVCL_LM12 HPSI0616i-biln_1 induced pluripotent stem cell human CVCL_LM12 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153111 CVCL_LM10 HPSI0616i-beyk_2 induced pluripotent stem cell human CVCL_LM10 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153112 CVCL_D454 mHypoE-43/7 transformed cell line house mouse CVCL_D454 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153113 CVCL_CS54 ND20374 transformed cell line human CVCL_CS54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153114 CVCL_D455 mHypoE-43/8 transformed cell line house mouse CVCL_D455 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153115 CVCL_CS55 ND20393 transformed cell line human CVCL_CS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153116 CVCL_D452 mHypoE-43/5 transformed cell line house mouse CVCL_D452 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153117 CVCL_CS52 ND20368 transformed cell line human CVCL_CS52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153118 CVCL_D453 mHypoE-43/6 transformed cell line house mouse CVCL_D453 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153119 CVCL_CS53 ND20369 transformed cell line human CVCL_CS53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153120 CVCL_D458 mHypoE-45 transformed cell line house mouse CVCL_D458 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153121 CVCL_CS58 ND20443 transformed cell line human CVCL_CS58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153122 CVCL_D459 mHypoE-46 transformed cell line house mouse CVCL_D459 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153123 CVCL_CS59 ND20444 transformed cell line human CVCL_CS59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153124 CVCL_D456 mHypoE-43/9 transformed cell line house mouse CVCL_D456 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153125 CVCL_CS56 ND20412 transformed cell line human CVCL_CS56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153126 CVCL_D457 mHypoE-44 transformed cell line house mouse CVCL_D457 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153127 CVCL_CS57 ND20442 transformed cell line human CVCL_CS57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153128 CVCL_D450 mHypoE-43/3 transformed cell line house mouse CVCL_D450 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153129 CVCL_CS50 ND20365 transformed cell line human CVCL_CS50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153130 CVCL_D451 mHypoE-43/4 transformed cell line house mouse CVCL_D451 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153131 CVCL_CS51 ND20366 transformed cell line human CVCL_CS51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153132 CVCL_D465 mPitA-1/1 transformed cell line house mouse CVCL_D465 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153133 CVCL_CS65 ND20493 transformed cell line human CVCL_CS65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153134 CVCL_D466 mPitA-1/3 transformed cell line house mouse CVCL_D466 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153135 CVCL_CS66 ND20496 transformed cell line human CVCL_CS66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153136 CVCL_D463 mHypoE-8 transformed cell line house mouse CVCL_D463 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153137 CVCL_CS63 ND20477 transformed cell line human CVCL_CS63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153138 CVCL_D464 mPitA-1 transformed cell line house mouse CVCL_D464 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU401 Female 21153139 CVCL_CS64 ND20478 transformed cell line human CVCL_CS64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153140 CVCL_D469 mPitA-1/6 transformed cell line house mouse CVCL_D469 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153141 CVCL_CS69 ND20519 transformed cell line human CVCL_CS69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153142 CVCL_D467 mPitA-1/4 transformed cell line house mouse CVCL_D467 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153143 CVCL_CS67 ND20505 transformed cell line human CVCL_CS67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153144 CVCL_D468 mPitA-1/5 transformed cell line house mouse CVCL_D468 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6. Female 21153145 CVCL_CS68 ND20511 transformed cell line human CVCL_CS68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153146 CVCL_D461 mHypoE-6 transformed cell line house mouse CVCL_D461 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153147 CVCL_CS61 ND20470 transformed cell line human CVCL_CS61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153148 CVCL_D462 mHypoE-7 transformed cell line house mouse CVCL_D462 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153149 CVCL_CS62 ND20475 transformed cell line human CVCL_CS62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND20475; probable Male 21153150 CVCL_D460 mHypoE-47 transformed cell line house mouse CVCL_D460 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153151 CVCL_CS60 ND20465 transformed cell line human CVCL_CS60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153152 CVCL_D438 mHypoE-38 transformed cell line house mouse CVCL_D438 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153153 CVCL_CS38 ND20307 transformed cell line human CVCL_CS38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153154 CVCL_D439 mHypoE-39 transformed cell line house mouse CVCL_D439 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153155 CVCL_CS39 ND20315 transformed cell line human CVCL_CS39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153156 CVCL_D432 mHypoE-29/2 transformed cell line house mouse CVCL_D432 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153157 CVCL_CS32 ND20248 transformed cell line human CVCL_CS32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153158 CVCL_D433 mHypoE-29/3 transformed cell line house mouse CVCL_D433 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153159 CVCL_CS33 ND20271 transformed cell line human CVCL_CS33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153160 CVCL_D430 mHypoE-25/3 transformed cell line house mouse CVCL_D430 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153161 CVCL_CS30 ND20211 transformed cell line human CVCL_CS30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153162 CVCL_D431 mHypoE-29/1 transformed cell line house mouse CVCL_D431 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male Virology: Low susceptibility to infection by Zika virus (ZIKV) (PubMed=29468137) 21153163 CVCL_CS31 ND20227 transformed cell line human CVCL_CS31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153164 CVCL_D436 mHypoE-36/1 transformed cell line house mouse CVCL_D436 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153165 CVCL_CS36 ND20305 transformed cell line human CVCL_CS36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153166 CVCL_D437 mHypoE-37 transformed cell line house mouse CVCL_D437 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153167 CVCL_CS37 ND20306 transformed cell line human CVCL_CS37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153168 CVCL_D434 mHypoE-29/4 transformed cell line house mouse CVCL_D434 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153169 CVCL_CS34 ND20297 transformed cell line human CVCL_CS34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153170 CVCL_D435 mHypoE-3 transformed cell line house mouse CVCL_D435 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153171 CVCL_CS35 ND20298 transformed cell line human CVCL_CS35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153172 CVCL_D449 mHypoE-43/2 transformed cell line house mouse CVCL_D449 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153173 CVCL_CS49 ND20364 transformed cell line human CVCL_CS49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153174 CVCL_D443 mHypoE-42 transformed cell line house mouse CVCL_D443 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153175 CVCL_CS43 ND20331 transformed cell line human CVCL_CS43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153176 CVCL_D444 mHypoE-43/1 transformed cell line house mouse CVCL_D444 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153177 CVCL_CS44 ND20333 transformed cell line human CVCL_CS44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153178 CVCL_D441 mHypoE-40 transformed cell line house mouse CVCL_D441 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor from personal communication of Belsham D.D Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Male 21153179 CVCL_CS41 ND20322 transformed cell line human CVCL_CS41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153180 CVCL_D442 mHypoE-41 transformed cell line house mouse CVCL_D442 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153181 CVCL_CS42 ND20323 transformed cell line human CVCL_CS42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153182 CVCL_D447 mHypoE-43/14 transformed cell line house mouse CVCL_D447 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153183 CVCL_CS47 ND20339 transformed cell line human CVCL_CS47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153184 CVCL_D448 mHypoE-43/15 transformed cell line house mouse CVCL_D448 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153185 CVCL_CS48 ND20355 transformed cell line human CVCL_CS48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND00043; probable Female 21153186 CVCL_D445 mHypoE-43/10 transformed cell line house mouse CVCL_D445 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153187 CVCL_CS45 ND20335 transformed cell line human CVCL_CS45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153188 CVCL_D446 mHypoE-43/13 transformed cell line house mouse CVCL_D446 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Female 21153189 CVCL_CS46 ND20336 transformed cell line human CVCL_CS46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153190 CVCL_D440 mHypoE-4 transformed cell line house mouse CVCL_D440 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus. Unspecified 21153191 CVCL_CS40 ND20321 transformed cell line human CVCL_CS40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153192 CVCL_CL39 ND10194 transformed cell line human CVCL_CL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153193 CVCL_CL37 ND10176 transformed cell line human CVCL_CL37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153194 CVCL_CL38 ND10192 transformed cell line human CVCL_CL38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153195 CVCL_CL31 ND10061 transformed cell line human CVCL_CL31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153196 CVCL_CL32 ND10082 transformed cell line human CVCL_CL32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153197 CVCL_CL30 ND10030 transformed cell line human CVCL_CL30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153198 CVCL_CL35 ND10136 transformed cell line human CVCL_CL35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153199 CVCL_CL36 ND10152 transformed cell line human CVCL_CL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153200 CVCL_CL33 ND10089 transformed cell line human CVCL_CL33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153201 CVCL_CL34 ND10116 transformed cell line human CVCL_CL34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153202 CVCL_CL48 ND10504 transformed cell line human CVCL_CL48 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (Coriell) Population: Latino or Hispanic; Dominican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153203 CVCL_CL49 ND10519 transformed cell line human CVCL_CL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153204 CVCL_CL42 ND10432 transformed cell line human CVCL_CL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153205 CVCL_CL43 ND10433 transformed cell line human CVCL_CL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153206 CVCL_CL40 ND10262 transformed cell line human CVCL_CL40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153207 CVCL_CL41 ND10322 transformed cell line human CVCL_CL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153208 CVCL_CL46 ND10453 transformed cell line human CVCL_CL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153209 CVCL_CL47 ND10502 transformed cell line human CVCL_CL47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153210 CVCL_CL44 ND10434 transformed cell line human CVCL_CL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153211 CVCL_CL45 ND10435 transformed cell line human CVCL_CL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153212 CVCL_CL17 ND09817 transformed cell line human CVCL_CL17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153213 CVCL_CL18 ND09818 transformed cell line human CVCL_CL18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21153214 CVCL_CL15 ND09811 transformed cell line human CVCL_CL15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153215 CVCL_CL16 ND09816 transformed cell line human CVCL_CL16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153216 CVCL_CL19 ND09837 transformed cell line human CVCL_CL19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153217 CVCL_CL10 ND09587 transformed cell line human CVCL_CL10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153218 CVCL_CL13 ND09793 transformed cell line human CVCL_CL13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153219 CVCL_CL14 ND09810 transformed cell line human CVCL_CL14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153220 CVCL_CL11 ND09591 transformed cell line human CVCL_CL11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153221 CVCL_CL12 ND09656 transformed cell line human CVCL_CL12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153222 CVCL_CL28 ND09979 transformed cell line human CVCL_CL28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153223 CVCL_CL29 ND09984 transformed cell line human CVCL_CL29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153224 CVCL_CL26 ND09902 transformed cell line human CVCL_CL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153225 CVCL_CL27 ND09924 transformed cell line human CVCL_CL27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153226 CVCL_CL20 ND09838 transformed cell line human CVCL_CL20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153227 CVCL_CL21 ND09840 transformed cell line human CVCL_CL21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153228 CVCL_CL24 ND09900 transformed cell line human CVCL_CL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153229 CVCL_CL25 ND09901 transformed cell line human CVCL_CL25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153230 CVCL_CL22 ND09841 transformed cell line human CVCL_CL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153231 CVCL_CL23 ND09856 transformed cell line human CVCL_CL23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153232 CVCL_CL06 ND09530 transformed cell line human CVCL_CL06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153233 CVCL_CL07 ND09541 transformed cell line human CVCL_CL07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153234 CVCL_CL04 ND09528 transformed cell line human CVCL_CL04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153235 CVCL_CL05 ND09529 transformed cell line human CVCL_CL05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153236 CVCL_CL08 ND09560 transformed cell line human CVCL_CL08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153237 CVCL_CL09 ND09564 transformed cell line human CVCL_CL09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153238 CVCL_CL02 ND09478 transformed cell line human CVCL_CL02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153239 CVCL_CL03 ND09502 transformed cell line human CVCL_CL03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153240 CVCL_CL00 ND09471 transformed cell line human CVCL_CL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153241 CVCL_CL01 ND09477 transformed cell line human CVCL_CL01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153242 CVCL_LF56 GeneBLAzer TRbeta-UAS-bla HEK 293T transformed cell line human CVCL_LF56 CL:0000010 Transfected with: HGNC; 11799; THRB (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of THRB fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153243 CVCL_LF57 GeneBLAzer VDR-UAS-bla HEK 293T transformed cell line human CVCL_LF57 CL:0000010 Transfected with: HGNC; 12679; VDR (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of VDR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153244 CVCL_LF54 GeneBLAzer RXRbeta-UAS-bla HEK 293T transformed cell line human CVCL_LF54 CL:0000010 Transfected with: HGNC; 10478; RXRB (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of RXRB fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153245 CVCL_LF55 GeneBLAzer TRalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF55 CL:0000010 Transfected with: HGNC; 11796; THRA (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of THRA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153246 CVCL_LF52 GeneBLAzer RARgamma-UAS-bla HEK 293T transformed cell line human CVCL_LF52 CL:0000010 Transfected with: HGNC; 9866; RARG (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of RARG fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153247 CVCL_LF53 GeneBLAzer RXRalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF53 CL:0000010 Transfected with: HGNC; 10477; RXRA (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of RXRA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153248 CVCL_LF50 GeneBLAzer RARalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF50 CL:0000010 Transfected with: HGNC; 9864; RARA (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of RARA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153249 CVCL_LF51 GeneBLAzer RARbeta-UAS-bla HEK 293T transformed cell line human CVCL_LF51 CL:0000010 Transfected with: HGNC; 9865; RARB (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of RARB fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153250 CVCL_LF49 GeneBLAzer PR-UAS-bla HEK 293T transformed cell line human CVCL_LF49 CL:0000010 Transfected with: HGNC; 8910; PGR (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of PGR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153251 CVCL_LF47 GeneBLAzer MR-UAS-bla HEK 293T transformed cell line human CVCL_LF47 CL:0000010 Transfected with: HGNC; 7979; NR3C2 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of NR3C2/MR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153252 CVCL_LF48 GeneBLAzer PPARalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF48 CL:0000010 Transfected with: HGNC; 9232; PPARA (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of PPARA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153253 CVCL_LF67 COG-N-573 cancer cell line human CVCL_LF67 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153254 CVCL_LF68 NB-SD cancer cell line human CVCL_LF68 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Homozygous (PubMed=9802058) Derived from metastatic site: Bone marrow. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified 21153255 CVCL_LF65 COG-N-557nb cancer cell line human CVCL_LF65 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153256 CVCL_LF66 COG-N-561 cancer cell line human CVCL_LF66 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153257 CVCL_LF63 COG-N-534 cancer cell line human CVCL_LF63 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153258 CVCL_LF64 COG-N-549 cancer cell line human CVCL_LF64 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153259 CVCL_LF61 COG-N-496 cancer cell line human CVCL_LF61 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 85 hours (COG) 21153260 CVCL_LF62 COG-N-519 cancer cell line human CVCL_LF62 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153261 CVCL_LF60 COG-N-471nb cancer cell line human CVCL_LF60 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21153262 CVCL_LF58 COG-N-426 cancer cell line human CVCL_LF58 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1245Cys (c.3734T>G); ClinVar=VCV000217856; Zygosity=Unspecified (PubMed=28350380) Omics: Transcriptome analysis by RNAseq. Male 21153263 CVCL_LF59 COG-N-453 cancer cell line human CVCL_LF59 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (PubMed=28350380) Derived from metastatic site: Liver. Omics: ATAC-seq; Omics: Transcriptome analysis by RNAseq Male Doubling time: 71 hours (COG) 21153264 CVCL_LF34 HPSI0716i-yibs_3 induced pluripotent stem cell human CVCL_LF34 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153265 CVCL_LF35 HPSI1116i-aimh_3 induced pluripotent stem cell human CVCL_LF35 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153266 CVCL_LF32 HPSI0516i-zujs_5 induced pluripotent stem cell human CVCL_LF32 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153267 CVCL_LF33 HPSI0716i-yibs_1 induced pluripotent stem cell human CVCL_LF33 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153268 CVCL_LF30 HPSI0516i-quqp_4 induced pluripotent stem cell human CVCL_LF30 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153269 CVCL_LF31 HPSI0516i-quqp_6 induced pluripotent stem cell human CVCL_LF31 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153270 CVCL_CL97 ND11834 transformed cell line human CVCL_CL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153271 CVCL_CL98 ND11962 transformed cell line human CVCL_CL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153272 CVCL_CL95 ND11790 transformed cell line human CVCL_CL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153273 CVCL_CL96 ND11791 transformed cell line human CVCL_CL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153274 CVCL_CL99 ND11994 transformed cell line human CVCL_CL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153275 CVCL_CL90 ND11641 transformed cell line human CVCL_CL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153276 CVCL_LF29 HPSI0516i-menz_4 induced pluripotent stem cell human CVCL_LF29 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153277 CVCL_LF27 HPSI0516i-dewa_5 induced pluripotent stem cell human CVCL_LF27 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153278 CVCL_CL93 ND11649 transformed cell line human CVCL_CL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153279 CVCL_LF28 HPSI0516i-menz_3 induced pluripotent stem cell human CVCL_LF28 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153280 CVCL_CL94 ND11650 transformed cell line human CVCL_CL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153281 CVCL_LF25 HPSI0516i-aaun_6 induced pluripotent stem cell human CVCL_LF25 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Czechoslovakian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153282 CVCL_CL91 ND11642 transformed cell line human CVCL_CL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153283 CVCL_LF26 HPSI0516i-dewa_2 induced pluripotent stem cell human CVCL_LF26 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153284 CVCL_CL92 ND11646 transformed cell line human CVCL_CL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153285 CVCL_LF45 GeneBLAzer LXRalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF45 CL:0000010 Transfected with: HGNC; 7966; NR1H3 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of NR1H3/LXRA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153286 CVCL_LF46 GeneBLAzer LXRbeta-UAS-bla HEK 293T transformed cell line human CVCL_LF46 CL:0000010 Transfected with: HGNC; 7965; NR1H2 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of NR1H2/LXRB fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153287 CVCL_LF43 GeneBLAzer FXR-UAS-bla HEK 293T transformed cell line human CVCL_LF43 CL:0000010 Transfected with: HGNC; 7967; NR1H4 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of NR1H4/FXR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153288 CVCL_LF44 GeneBLAzer GR-UAS-bla HEK 293T transformed cell line human CVCL_LF44 CL:0000010 Transfected with: HGNC; 7978; NR3C1 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of NR3C1/GR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153289 CVCL_LF41 GeneBLAzer PPARdelta-UAS-bla HEK 293T transformed cell line human CVCL_LF41 CL:0000010 Transfected with: HGNC; 9235; PPARD (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of PPARD fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153290 CVCL_LF42 GeneBLAzer ERRalpha-UAS-bla HEK 293T transformed cell line human CVCL_LF42 CL:0000010 Transfected with: HGNC; 3471; ESRRA (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of ESRRA fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 21153291 CVCL_LF40 GeneBLAzer UAS-bla HEK 293T transformed cell line human CVCL_LF40 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS) 21153292 CVCL_LF38 HPSI1116i-rafd_1 induced pluripotent stem cell human CVCL_LF38 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153293 CVCL_LF39 HPSI1116i-rafd_4 induced pluripotent stem cell human CVCL_LF39 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153294 CVCL_LF36 HPSI1116i-aimh_5 induced pluripotent stem cell human CVCL_LF36 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153295 CVCL_LF37 HPSI1116i-naum_5 induced pluripotent stem cell human CVCL_LF37 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153296 CVCL_LF12 HPSI0316i-vats_4 induced pluripotent stem cell human CVCL_LF12 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153297 CVCL_LF13 HPSI0416i-mapx_1 induced pluripotent stem cell human CVCL_LF13 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Heterozygous (from autologous cell line HPSI0416i-mapx_5) Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153298 CVCL_LF10 HPSI0316i-circ_4 induced pluripotent stem cell human CVCL_LF10 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153299 CVCL_LF11 HPSI0316i-vats_2 induced pluripotent stem cell human CVCL_LF11 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153300 CVCL_CL75 ND11277 transformed cell line human CVCL_CL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153301 CVCL_CL76 ND11346 transformed cell line human CVCL_CL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153302 CVCL_CL73 ND11133 transformed cell line human CVCL_CL73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153303 CVCL_CL74 ND11257 transformed cell line human CVCL_CL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153304 CVCL_CL79 ND11391 transformed cell line human CVCL_CL79 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153305 CVCL_CL77 ND11347 transformed cell line human CVCL_CL77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153306 CVCL_CL78 ND11348 transformed cell line human CVCL_CL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153307 CVCL_LF09 HPSI0316i-circ_2 induced pluripotent stem cell human CVCL_LF09 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21153308 CVCL_LF07 HPSI0716i-bakv_4 induced pluripotent stem cell human CVCL_LF07 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 21153309 CVCL_LF08 HPSI0716i-bakv_6 induced pluripotent stem cell human CVCL_LF08 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male 21153310 CVCL_LF05 HPSI0516i-suqd_3 induced pluripotent stem cell human CVCL_LF05 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21153311 CVCL_CL71 ND11131 transformed cell line human CVCL_CL71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153312 CVCL_LF06 HPSI0516i-suqd_6 induced pluripotent stem cell human CVCL_LF06 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21153313 CVCL_CL72 ND11132 transformed cell line human CVCL_CL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153314 CVCL_LF03 HPSI0316i-ponl_2 induced pluripotent stem cell human CVCL_LF03 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153315 CVCL_LF04 HPSI0316i-ponl_4 induced pluripotent stem cell human CVCL_LF04 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153316 CVCL_CL70 ND11125 transformed cell line human CVCL_CL70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153317 CVCL_LF23 HPSI0816i-aorf_2 induced pluripotent stem cell human CVCL_LF23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153318 CVCL_LF24 HPSI0516i-aaun_5 induced pluripotent stem cell human CVCL_LF24 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Czechoslovakian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153319 CVCL_LF21 HPSI0216i-feht_1 induced pluripotent stem cell human CVCL_LF21 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153320 CVCL_LF22 HPSI0816i-aorf_1 induced pluripotent stem cell human CVCL_LF22 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153321 CVCL_LF20 CHO-K1 (GS Null) HD-BIOP3 spontaneously immortalized cell line CVCL_LF20 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; UniProtKB; P04773; Glul Derived from sampling site: Ovary. Omics: Genome sequenced Female Group: Serum/protein free medium cell line 21153322 CVCL_CL86 ND11492 transformed cell line human CVCL_CL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153323 CVCL_CL87 ND11521 transformed cell line human CVCL_CL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153324 CVCL_CL84 ND11468 transformed cell line human CVCL_CL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153325 CVCL_CL85 ND11469 transformed cell line human CVCL_CL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153326 CVCL_CL88 ND11595 transformed cell line human CVCL_CL88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153327 CVCL_CL89 ND11597 transformed cell line human CVCL_CL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153328 CVCL_LF18 HPSI0816i-neow_7 induced pluripotent stem cell human CVCL_LF18 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153329 CVCL_LF19 HCC122 BL transformed cell line human CVCL_LF19 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153330 CVCL_LF16 HPSI0516i-yist_3 induced pluripotent stem cell human CVCL_LF16 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2206; COL4A4; Simple; p.Pro1096Ser (c.3286C>T); Zygosity=Heterozygous (PubMed=35076391); Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Hemizygous (PubMed=35076391) Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153331 CVCL_CL82 ND11394 transformed cell line human CVCL_CL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153332 CVCL_LF17 HPSI0816i-neow_5 induced pluripotent stem cell human CVCL_LF17 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153333 CVCL_CL83 ND11467 transformed cell line human CVCL_CL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153334 CVCL_LF14 HPSI0416i-mapx_5 induced pluripotent stem cell human CVCL_LF14 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Heterozygous (PubMed=35076391) Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female 21153335 CVCL_CL80 ND11392 transformed cell line human CVCL_CL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153336 CVCL_LF15 HPSI0516i-yist_1 induced pluripotent stem cell human CVCL_LF15 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2206; COL4A4; Simple; p.Pro1096Ser (c.3286C>T); Zygosity=Heterozygous (from autologous cell line HPSI0516i-yist_3); Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1232Asp (c.3695G>A); Zygosity=Hemizygous (from autologous cell line HPSI0516i-yist_3) Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153337 CVCL_CL81 ND11393 transformed cell line human CVCL_CL81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153338 CVCL_CL59 ND10744 transformed cell line human CVCL_CL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153339 CVCL_CL53 ND10565 transformed cell line human CVCL_CL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153340 CVCL_CL54 ND10566 transformed cell line human CVCL_CL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153341 CVCL_CL51 ND10544 transformed cell line human CVCL_CL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153342 CVCL_CL52 ND10545 transformed cell line human CVCL_CL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153343 CVCL_CL57 ND10709 transformed cell line human CVCL_CL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153344 CVCL_CL58 ND10742 transformed cell line human CVCL_CL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153345 CVCL_CL55 ND10567 transformed cell line human CVCL_CL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153346 CVCL_CL56 ND10572 transformed cell line human CVCL_CL56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153347 CVCL_CL50 ND10520 transformed cell line human CVCL_CL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153348 CVCL_LF01 HPSI0316i-eoko_5 induced pluripotent stem cell human CVCL_LF01 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21153349 CVCL_LF02 HPSI0316i-miov_1 induced pluripotent stem cell human CVCL_LF02 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21153350 CVCL_LF00 HPSI0316i-eoko_3 induced pluripotent stem cell human CVCL_LF00 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21153351 CVCL_CL64 ND10752 transformed cell line human CVCL_CL64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153352 CVCL_CL65 ND10795 transformed cell line human CVCL_CL65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153353 CVCL_CL62 ND10748 transformed cell line human CVCL_CL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153354 CVCL_CL63 ND10749 transformed cell line human CVCL_CL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153355 CVCL_CL68 ND11104 transformed cell line human CVCL_CL68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153356 CVCL_CL69 ND11124 transformed cell line human CVCL_CL69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153357 CVCL_CL66 ND10994 transformed cell line human CVCL_CL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153358 CVCL_CL67 ND11099 transformed cell line human CVCL_CL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153359 CVCL_CL60 ND10746 transformed cell line human CVCL_CL60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153360 CVCL_CL61 ND10747 transformed cell line human CVCL_CL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153361 CVCL_2908 Fu97 cancer cell line human CVCL_2908 HLA typing: A*33:03,33:03; B*44:03,46:01; C*14:03,14:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=80.85%; East Asian, South=19.14%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Asp (c.658T>G); ClinVar=VCV000376689; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0332; true Female Characteristics: Produces high level of AFP Doubling time: ~72 hours (PubMed=10614861); 30 hours (lot 08072007), ~34 hours (lot 02022011), ~31 hours (lot 03132015) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21153362 CVCL_1X08 ND03970 transformed cell line human CVCL_1X08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153363 CVCL_2909 G-292 clone A141B1 cancer cell line human CVCL_2909 Genome ancestry: African=1.61%; Native American=0%; East Asian, North=5.38%; East Asian, South=0%; South Asian=0%; European, North=50.9%; European, South=42.1% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 2681; DAXX + HGNC; 6326; KIFC3; Name(s)=DAXX-KIFC3; Note=In frame (PubMed=30214690; PubMed=30872698) Population: Caucasian; Derived from sampling site: Bone. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21153364 CVCL_1X09 ND03971 transformed cell line human CVCL_1X09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153365 CVCL_2906 FPC5JTO finite cell line human CVCL_2906 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Virology: Infected with Human parvovirus B19 (PubMed=29892436) 21153366 CVCL_1X06 ND03938 transformed cell line human CVCL_1X06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153367 CVCL_2907 FS-1 [Human leukemia] cancer cell line human CVCL_2907 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: ~7 days (PubMed=8724543) 21153368 CVCL_1X07 ND03950 transformed cell line human CVCL_1X07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153369 CVCL_1X00 ND03834 transformed cell line human CVCL_1X00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153370 CVCL_2901 FLAM-76 cancer cell line human CVCL_2901 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0538; true Male Characteristics: Non-secretory; Characteristics: IL6 dependent 21153371 CVCL_1X01 ND03835 transformed cell line human CVCL_1X01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153372 CVCL_2904 Flow7000 finite cell line human CVCL_2904 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal brain Cell type=Fibroblast.. Female Doubling time: ~3 days (lot 04092004) (JCRB) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00306 Problematic cell line: Contaminated Shown to be a Flow3000 derivative. Originally thought to be a foresking fibroblast cell line. 21153373 CVCL_1X04 ND03885 transformed cell line human CVCL_1X04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153374 CVCL_2905 FPC15JTO finite cell line human CVCL_2905 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153375 CVCL_1X05 ND03903 transformed cell line human CVCL_1X05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153376 CVCL_2902 Flow2000 finite cell line human CVCL_2902 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: JCRB; JCRB0067; true Female 21153377 CVCL_1X02 ND03836 transformed cell line human CVCL_1X02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153378 CVCL_2903 Flow3000 finite cell line human CVCL_2903 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal brain Cell type=Fibroblast.. Female Caution: Indicated as originating from a male fetus but has a X,X karyotype 21153379 CVCL_1X03 ND03870 transformed cell line human CVCL_1X03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153380 CVCL_2919 HCSC-1 cancer cell line human CVCL_2919 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from metastatic site: Ascites. Female Doubling time: 24.3 hours (CelloPub=CLPUB00373) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153381 CVCL_1X19 ND04103 transformed cell line human CVCL_1X19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: Coriell; ND04103; probable 21153382 CVCL_2917 HCC-56 cancer cell line human CVCL_2917 HLA typing: A*24:02,33:03; B*44:03,51:01; C*03:04,14:03 (PubMed=26589293); Genome ancestry: African=3.92%; Native American=0%; East Asian, North=80.09%; East Asian, South=11.5%; South Asian=0%; European, North=0%; European, South=4.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Pro (c.587G>C); ClinVar=VCV000231165; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB1037; probable. Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21153383 CVCL_1X17 ND04045 transformed cell line human CVCL_1X17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153384 CVCL_2918 HCS-2 cancer cell line human CVCL_2918 HLA typing: A*24:02; B*52:01; C*12:02 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Discontinued: JCRB; NIHS0405; true Female Doubling time: ~65 hours, at 17th passage (PubMed=2979208); ~39 hours (lot 09092016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153385 CVCL_1X18 ND04069 transformed cell line human CVCL_1X18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153386 CVCL_2911 GOTO.P3 cancer cell line human CVCL_2911 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=12068308) Population: Japanese; Derived from sampling site: Adrenal gland. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0370; true Male Group: Serum/protein free medium cell line 21153387 CVCL_1X11 ND03974 transformed cell line human CVCL_1X11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153388 CVCL_2912 GS33JTO finite cell line human CVCL_2912 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153389 CVCL_1X12 ND03975 transformed cell line human CVCL_1X12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153390 CVCL_2910 GCH-nu-YS cancer cell line human CVCL_2910 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0409; true. Male Doubling time: ~35 hours (lot 04062012) (JCRB) Caution: Established from gestational carcinoma of a woman patient, but the cell line is from the male fetus 21153391 CVCL_1X10 ND03972 transformed cell line human CVCL_1X10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153392 CVCL_2915 HARA-B cancer cell line human CVCL_2915 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0352.1; true Male Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP) 21153393 CVCL_1X15 ND04017 transformed cell line human CVCL_1X15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153394 CVCL_2916 HCA1 cancer cell line human CVCL_2916 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0406; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153395 CVCL_1X16 ND04019 transformed cell line human CVCL_1X16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153396 CVCL_2913 GS70JTO finite cell line human CVCL_2913 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153397 CVCL_1X13 ND03976 transformed cell line human CVCL_1X13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153398 CVCL_2914 HARA [Human squamous cell lung carcinoma] cancer cell line human CVCL_2914 Genome ancestry: African=0.26%; Native American=0%; East Asian, North=78.38%; East Asian, South=20.35%; South Asian=0.8%; European, North=0%; European, South=0.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0352.0; true Male Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP) Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21153399 CVCL_1X14 ND04016 transformed cell line human CVCL_1X14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153400 CVCL_LE99 HCC90 BL transformed cell line human CVCL_LE99 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153401 CVCL_LE97 ZZUi004-A induced pluripotent stem cell human CVCL_LE97 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[76]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=29444500) Population: Chinese; Han; Derived from sampling site: Urine. Female 21153402 CVCL_LE98 ZZUi005-A induced pluripotent stem cell human CVCL_LE98 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 16499; RAB39B; Simple; p.Glu179fs*48 (c.536dupA); Zygosity=Hemizygous (PubMed=29128816) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153403 CVCL_LE95 HPSI0516i-iuoc_2 induced pluripotent stem cell human CVCL_LE95 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153404 CVCL_LE96 HPSI0516i-yibc_4 induced pluripotent stem cell human CVCL_LE96 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Czechoslovakian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153405 CVCL_LE93 HPSI0416i-xutl_2 induced pluripotent stem cell human CVCL_LE93 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153406 CVCL_LE94 HPSI0516i-iuoc_5 induced pluripotent stem cell human CVCL_LE94 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21153407 CVCL_LE91 CENSOi008-A induced pluripotent stem cell human CVCL_LE91 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21153408 CVCL_LE92 CENSOi010-A induced pluripotent stem cell human CVCL_LE92 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Discontinued: hPSCreg; CENSOi010-A; true. Female 21153409 CVCL_LE90 CENSOi007-A induced pluripotent stem cell human CVCL_LE90 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex52del; Zygosity=Hemizygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21153410 CVCL_LE79 EDi018-A induced pluripotent stem cell human CVCL_LE79 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Discontinued: EBiSC; EDi018-A; true Female 21153411 CVCL_LE77 EDi017-B induced pluripotent stem cell human CVCL_LE77 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi017-B; true Female 21153412 CVCL_LE78 EDi017-C induced pluripotent stem cell human CVCL_LE78 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi017-C; true Female 21153413 CVCL_LE75 EDi016-C induced pluripotent stem cell human CVCL_LE75 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi016-C; true Male 21153414 CVCL_LE76 EDi017-A induced pluripotent stem cell human CVCL_LE76 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi017-A; true Female 21153415 CVCL_LE73 EDi016-A induced pluripotent stem cell human CVCL_LE73 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi016-A; true Male 21153416 CVCL_LE74 EDi016-B induced pluripotent stem cell human CVCL_LE74 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; EDi016-B; true Male 21153417 CVCL_LE71 EDi015-B induced pluripotent stem cell human CVCL_LE71 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi015-B; true Male 21153418 CVCL_LE72 EDi015-C induced pluripotent stem cell human CVCL_LE72 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi015-C; true Male 21153419 CVCL_LE70 EDi015-A induced pluripotent stem cell human CVCL_LE70 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi015-A; true Male 21153420 CVCL_LE88 CENSOi003-B induced pluripotent stem cell human CVCL_LE88 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-52del; Zygosity=Hemizygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21153421 CVCL_LE89 CENSOi005-A induced pluripotent stem cell human CVCL_LE89 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-41dup; Zygosity=Hemizygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21153422 CVCL_LE86 CENSOi001-B induced pluripotent stem cell human CVCL_LE86 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21153423 CVCL_LE87 CENSOi002-B induced pluripotent stem cell human CVCL_LE87 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln3231Ter (c.9691C>T); ClinVar=VCV000523784; Zygosity=Hemizygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21153424 CVCL_LE84 EDi019-C induced pluripotent stem cell human CVCL_LE84 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153425 CVCL_LE85 HUBi001-A induced pluripotent stem cell human CVCL_LE85 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21153426 CVCL_LE82 EDi019-A induced pluripotent stem cell human CVCL_LE82 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153427 CVCL_LE83 EDi019-B induced pluripotent stem cell human CVCL_LE83 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153428 CVCL_LE80 EDi018-B induced pluripotent stem cell human CVCL_LE80 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Discontinued: EBiSC; EDi018-B; true Female 21153429 CVCL_LE81 EDi018-C induced pluripotent stem cell human CVCL_LE81 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Discontinued: EBiSC; EDi018-C; true Female 21153430 CVCL_LE57 EDi010-A induced pluripotent stem cell human CVCL_LE57 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153431 CVCL_LE58 EDi010-B induced pluripotent stem cell human CVCL_LE58 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153432 CVCL_LE55 EDi008-A induced pluripotent stem cell human CVCL_LE55 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Gly51Asp (c.152G>A); ClinVar=VCV000097000; Zygosity=Heterozygous (from autologous cell line EDi008-B) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; EDi008-A; true; Discontinued: hPSCreg; EDi008-A; true Female 21153433 CVCL_LE56 EDi008-B induced pluripotent stem cell human CVCL_LE56 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Gly51Asp (c.152G>A); ClinVar=VCV000097000; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21153434 CVCL_LE53 EDi001-A-3 induced pluripotent stem cell human CVCL_LE53 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 4 alleles); HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: The donor of the original cell line has 4 copies of SNCA This edited cell line clone has 1 of the 4 alleles KO by CRISPR/Cas9. 21153435 CVCL_LE54 EDi001-A-4 induced pluripotent stem cell human CVCL_LE54 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9 (2 of 4 alleles); HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; EDi001-A-4; true Female Characteristics: The donor of the original cell line has 4 copies of SNCA This edited cell line clone has 2 of the 4 alleles KO by CRISPR/Cas9. 21153436 CVCL_LE51 EDi001-A-1 induced pluripotent stem cell human CVCL_LE51 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=21863007) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21153437 CVCL_LE52 EDi001-A-2 induced pluripotent stem cell human CVCL_LE52 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 4 alleles); HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: The donor of the original cell line has 4 copies of SNCA This edited cell line clone has 1 of the 4 alleles KO by CRISPR/Cas9. 21153438 CVCL_LE50 SIGi001-A-11 induced pluripotent stem cell human CVCL_LE50 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Homozygous; Note=By method not specified (EBiSC); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21153439 CVCL_LE48 UOXFi010-C induced pluripotent stem cell human CVCL_LE48 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi010-C; true Male 21153440 CVCL_LE49 UOXFi010-D induced pluripotent stem cell human CVCL_LE49 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi010-D; true Male 21153441 CVCL_LE68 EDi014-A induced pluripotent stem cell human CVCL_LE68 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi014-A; true Male 21153442 CVCL_LE69 EDi014-B induced pluripotent stem cell human CVCL_LE69 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi014-B; true Male 21153443 CVCL_LE66 EDi013-B induced pluripotent stem cell human CVCL_LE66 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi013-B; true Male 21153444 CVCL_LE67 EDi013-C induced pluripotent stem cell human CVCL_LE67 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi013-C; true Male 21153445 CVCL_LE64 EDi012-C induced pluripotent stem cell human CVCL_LE64 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153446 CVCL_LE65 EDi013-A induced pluripotent stem cell human CVCL_LE65 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Discontinued: EBiSC; EDi013-A; true Male 21153447 CVCL_LE62 EDi012-A induced pluripotent stem cell human CVCL_LE62 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153448 CVCL_LE63 EDi012-B induced pluripotent stem cell human CVCL_LE63 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Female 21153449 CVCL_LE60 EDi011-B induced pluripotent stem cell human CVCL_LE60 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21153450 CVCL_LE61 EDi011-C induced pluripotent stem cell human CVCL_LE61 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21153451 CVCL_LE59 EDi011-A induced pluripotent stem cell human CVCL_LE59 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Genome sequenced Male 21153452 CVCL_2980 KMLS-1 cancer cell line human CVCL_2980 CL:0000010 Population: Japanese Omics: Deep exome analysis. Unspecified Doubling time: 88-175 hours (lot 04142008) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153453 CVCL_1X80 ND05155 transformed cell line human CVCL_1X80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153454 CVCL_2981 KMM-1 cancer cell line human CVCL_2981 HLA typing: A*02,24; B*40,52; C*03,12 (PubMed=25688540); HLA typing: A*02:01,24:02; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=81.62%; East Asian, South=17.61%; South Asian=0.77%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val9Ile (c.25G>A); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Homozygous (PubMed=11157491; PubMed=21173094; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (DepMap) Population: Japanese Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0481; true. Male Characteristics: Produces Ig lambda Doubling time: 29 hours (PubMed=2519219) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153455 CVCL_1X81 ND05156 transformed cell line human CVCL_1X81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153456 CVCL_2984 KMRC-2 cancer cell line human CVCL_2984 HLA typing: A*11:01,24:02; B*54:01,59:05; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.74%; East Asian, North=73.3%; East Asian, South=25.71%; South Asian=0.24%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0272; true Male Doubling time: 43 hours (lot 09262007), ~57 hours (lot 03182019) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153457 CVCL_1X84 ND05256 transformed cell line human CVCL_1X84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153458 CVCL_2985 KMRC-3 cancer cell line human CVCL_2985 HLA typing: A*11:01,24:02; B*51:01,55:02; C*03:03,14:02 (PubMed=26589293); Genome ancestry: African=1.13%; Native American=0%; East Asian, North=78.77%; East Asian, South=17.63%; South Asian=0%; European, North=0%; European, South=2.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.340+2T>C; ClinVar=VCV000635395; Zygosity=Homozygous; Note=Splice donor mutation (DepMap) Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0273; true Male Doubling time: ~7-8 days (lot 10222007), ~6 days (lot 07042016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21153459 CVCL_1X85 ND05283 transformed cell line human CVCL_1X85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153460 CVCL_2982 KMPC-3 cancer cell line human CVCL_2982 CL:0000010 Population: Japanese; Derived from sampling site: Kidney; renal pelvis. Unspecified Doubling time: ~40 hours (JCRB) 21153461 CVCL_1X82 ND05161 transformed cell line human CVCL_1X82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153462 CVCL_2983 KMRC-1 cancer cell line human CVCL_2983 HLA typing: A*02:19,24:02; B*54:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.41%; East Asian, North=74.54%; East Asian, South=25.05%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0271; true Male Doubling time: ~1.2 days (lot 04212005), ~29 hours (lot 06082018), ~41 hours (lot 04042022) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21153463 CVCL_1X83 ND05165 transformed cell line human CVCL_1X83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153464 CVCL_2988 KMRM-M1 cancer cell line human CVCL_2988 CL:0000010 Population: Japanese; Derived from metastatic site: Muscle. Male 21153465 CVCL_1X88 ND05299 transformed cell line human CVCL_1X88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153466 CVCL_2989 KMS-11 cancer cell line human CVCL_2989 HLA typing: A*24; B*51,54; C*01,14 (PubMed=25688540); HLA typing: A*24:02,24:02; B*51:01,54:01; C*01:02,14:02 (PubMed=26589293); Genome ancestry: African=4.44%; Native American=0.01%; East Asian, North=82.62%; East Asian, South=10.11%; South Asian=0%; European, North=0%; European, South=2.81% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (PubMed=11157491; CelloPub=CLPUB00604); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (PubMed=17692805) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0482; true Female Characteristics: Produces IgG kappa Doubling time: 36 hours (PubMed=2519219); 70 hours (PubMed=25984343); 50 hours (lot 03062008), ~2 days (lot 10142009), ~31 hours (lot 10072016), ~39 hours (lot 10222021) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21153467 CVCL_1X89 ND05368 transformed cell line human CVCL_1X89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153468 CVCL_2986 KMRC-20 cancer cell line human CVCL_2986 HLA typing: A*02:01,24:02; B*46:01,51:01; C*01:03,01:03 (PubMed=26589293); Genome ancestry: African=3.3%; Native American=0%; East Asian, North=77.74%; East Asian, South=14.66%; South Asian=0%; European, North=0%; European, South=4.3% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>T; ClinVar=VCV000630765; Zygosity=Homozygous; Note=Splice donor mutation (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: ~41 hours (lot 01202020) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: TCGA-110-CL cell line panel 21153469 CVCL_1X86 ND05296 transformed cell line human CVCL_1X86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153470 CVCL_2987 KMRC-5 cancer cell line human CVCL_2987 CL:0000010 Population: Japanese Discontinued: JCRB; JCRB1007; probable. Male 21153471 CVCL_1X87 ND05297 transformed cell line human CVCL_1X87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153472 CVCL_2991 KMS-21-BM undefined cell line type human CVCL_2991 HLA typing: A*24:02,24:02; B*40:01,40:01; C*01:02,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.63%; East Asian, South=21.2%; South Asian=0.16%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (DepMap) Population: Japanese Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0485; true. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00228 Problematic cell line: Misclassified Originally thought to be a myeloma cell line and to be a sister line to KMS-21-PE (Cellosaurus=CVCL_A445) but this does not seem to be the case (PubMed=12592342; PubMed=20143388). 21153473 CVCL_1X91 ND05370 transformed cell line human CVCL_1X91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153474 CVCL_2992 KMS-26 cancer cell line human CVCL_2992 HLA typing: A*02:01,31:01; B*40:02,51:01; C*03:04,14:02 (PubMed=26589293); Genome ancestry: African=1.51%; Native American=0%; East Asian, North=82.18%; East Asian, South=11.23%; South Asian=0%; European, North=0%; European, South=5.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0487; true Male Doubling time: 35 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153475 CVCL_1X92 ND05372 transformed cell line human CVCL_1X92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153476 CVCL_2990 KMS-20 cancer cell line human CVCL_2990 HLA typing: A*11:01,26:01; B*40:01,67:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.24%; East Asian, North=84.32%; East Asian, South=14.3%; South Asian=0.32%; European, North=0%; European, South=0.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0484; true Female Doubling time: 60 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153477 CVCL_1X90 ND05369 transformed cell line human CVCL_1X90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153478 CVCL_2995 KMS-28PE cancer cell line human CVCL_2995 HLA typing: A*24:02,24:02; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Arg (c.313G>C); ClinVar=VCV000406574; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0489; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153479 CVCL_1X95 ND05424 transformed cell line human CVCL_1X95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153480 CVCL_2996 KMS-34 cancer cell line human CVCL_2996 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.47%; East Asian, North=71.46%; East Asian, South=28.03%; South Asian=0%; European, North=0.05%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA kappa Doubling time: 100 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153481 CVCL_1X96 ND05461 transformed cell line human CVCL_1X96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153482 CVCL_2993 KMS-27 cancer cell line human CVCL_2993 HLA typing: A*02:01,26:01; B*40:03,40:03; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.28%; East Asian, North=76.27%; East Asian, South=23.45%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0488; true Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153483 CVCL_1X93 ND05421 transformed cell line human CVCL_1X93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153484 CVCL_2994 KMS-28BM cancer cell line human CVCL_2994 HLA typing: A*24:02,24:02; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293); Genome ancestry: African=2.75%; Native American=0%; East Asian, North=76.63%; East Asian, South=19.7%; South Asian=0%; European, North=0%; European, South=0.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Arg (c.313G>C); ClinVar=VCV000406574; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0490; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153485 CVCL_1X94 ND05422 transformed cell line human CVCL_1X94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153486 CVCL_2999 KMST-6/T transformed cell line human CVCL_2999 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: JCRB; JCRB0434; true Female Characteristics: Tumorigenic Established from 2nd-passage tumors obtained in nude mice by transplanting one of the primary tumors produced by subcutaneous inoculation of KMST-6 cells into nude mice. Doubling time: 37 +- 4.6 hours (in 10% FBS), 47 +- 2.9 hours (in 1% FBS) (PubMed=1537630) 21153487 CVCL_1X99 ND05523 transformed cell line human CVCL_1X99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153488 CVCL_2997 KMS-6 finite cell line human CVCL_2997 CL:0000010 Population: Japanese; Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21153489 CVCL_1X97 ND05484 transformed cell line human CVCL_1X97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153490 CVCL_2998 KMST-6 transformed cell line human CVCL_2998 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (PubMed=8790940) Population: Japanese; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) Doubling time: 38 +- 4.6 hours (in 10% FBS), 54 +- 2.9 hours (in 1% FBS) (PubMed=1537630); ~26 hours (lot 12242014) (JCRB) 21153491 CVCL_1X98 ND05500 transformed cell line human CVCL_1X98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153492 CVCL_2962 IM95m cancer cell line human CVCL_2962 HLA typing: A*26:03,26:03; B*15:40,67:02; C*12:02,12:02 (PubMed=26589293) CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0334; true Male Characteristics: Compared to the parent cell line, it produces higher level of HGF, IL8 and VEGFA Part of: MD Anderson Cell Lines Project 21153493 CVCL_1X62 ND04887 transformed cell line human CVCL_1X62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153494 CVCL_2963 IMR-90-40 finite cell line human CVCL_2963 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21153495 CVCL_1X63 ND04900 transformed cell line human CVCL_1X63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153496 CVCL_2960 IHH-4 cancer cell line human CVCL_2960 Genome ancestry: African=1.71%; Native American=0%; East Asian, North=73.08%; East Asian, South=21.44%; South Asian=0%; European, North=0.89%; European, South=2.88% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Trp592Ter (c.1776G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 14281; CRLF2; Simple; p.Trp255Ter (c.765G>A); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Arg1312Ter (c.3934C>T); ClinVar=VCV000545969; Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp11Glu (c.33C>G); Zygosity=Heterozygous (PubMed=30737244; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Population: Japanese; Derived from metastatic site: Left cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0270; true; Discontinued: JCRB; NIHS0270.1; true; Discontinued: JCRB; NIHS0271.1; true Male Doubling time: 42 hours (PubMed=11686581); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21153497 CVCL_1X60 ND04853 transformed cell line human CVCL_1X60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153498 CVCL_2961 IM95 cancer cell line human CVCL_2961 HLA typing: A*26:03,26:03; B*15:50,55:24; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=71.45%; East Asian, South=28.36%; South Asian=0.19%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0333; true Male Doubling time: 25 hours (PubMed=14609362); ~1.2 days (lot 11162005), ~46 hours (lot 10132009), ~35 hours (lot 09302016) (JCRB); Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21153499 CVCL_1X61 ND04880 transformed cell line human CVCL_1X61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153500 CVCL_2966 JKT-beta-del cancer cell line human CVCL_2966 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: JCRB; NIHS0224; true Male 21153501 CVCL_1X66 ND04980 transformed cell line human CVCL_1X66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153502 CVCL_2967 K562 AZQR cancer cell line human CVCL_2967 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90185; Diaziquone (AZQ); Derived from sampling site: Pleural effusion. Female 21153503 CVCL_1X67 ND04991 transformed cell line human CVCL_1X67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153504 CVCL_2964 IMR-90-50 finite cell line human CVCL_2964 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21153505 CVCL_1X64 ND04903 transformed cell line human CVCL_1X64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153506 CVCL_2965 J-111 cancer cell line human CVCL_2965 CL:0000010 Anecdotal: Have been flown in space on the ISS to study motility and cytoskeletal structures (PubMed=21246756); Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0002000000054) It was one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-24; true Female Group: Space-flown cell line (cellonaut); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00009 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=4864103; PubMed=5641128; PubMed=566722; PubMed=1246601; PubMed=12592342; PubMed=20143388). Originally thought to originate from a 25 year old female patient with acute monocytic leukemia. 21153507 CVCL_1X65 ND04946 transformed cell line human CVCL_1X65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153508 CVCL_2968 K562 cl.6 cancer cell line human CVCL_2968 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21153509 CVCL_1X68 ND04992 transformed cell line human CVCL_1X68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153510 CVCL_2969 KAI3 transformed cell line human CVCL_2969 CL:0000010 Population: Japanese; Karyotypic information: 46,XY,add(6)(p23),der(6)add(6)(p23)add(6)(q21) (PubMed=10193407); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a donor with severe hypersensitivity to mosquito bite (HMB) (PubMed=10193407); Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: IL2 dependent Doubling time: 3.5 days (lot 03082007), ~76 hours (lot 07312015) (JCRB) 21153511 CVCL_1X69 ND05016 transformed cell line human CVCL_1X69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153512 CVCL_2970 KD [Human lip fibroblast] finite cell line human CVCL_2970 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; lip Cell type=Fibroblast.. Discontinued: ATCC; CRL-1295; true Female Senescence: Senesces at 38-40 PDL (JCRB=JCRB9103); Doubling time: 51-70 hours (lot 06232003), ~27 hours (lot 11052009), ~36 hours (lot 12112017) (JCRB) 21153513 CVCL_1X70 ND05027 transformed cell line human CVCL_1X70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153514 CVCL_2973 KHM-10B cancer cell line human CVCL_2973 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Discontinued: JCRB; NIHS0195; true Male Virology: EBV-negative Doubling time: 24 hours (PubMed=8609722) 21153515 CVCL_1X73 ND05065 transformed cell line human CVCL_1X73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153516 CVCL_2974 KHM-3S cancer cell line human CVCL_2974 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Pleural effusion. Omics: SNP array analysis Discontinued: JCRB; NIHS0192; true Male Doubling time: ~2 days (lot 03052003) (JCRB) 21153517 CVCL_1X74 ND05067 transformed cell line human CVCL_1X74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153518 CVCL_2971 KG-1-C cancer cell line human CVCL_2971 Genome ancestry: African=8%; Native American=0%; East Asian, North=84.74%; East Asian, South=0.27%; South Asian=0%; European, North=0%; European, South=6.98% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15900046) Population: Japanese; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~41 hours (PubMed=222111); 5-6 days (lot 041698), 3.5 days (lot 03012016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153519 CVCL_1X71 ND05029 transformed cell line human CVCL_1X71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153520 CVCL_2972 KHM-1B cancer cell line human CVCL_2972 HLA typing: A*24:02,24:02; B*39:01,52:01; C*07:02,12:02 (PubMed=26589293); Genome ancestry: African=0.34%; Native American=0%; East Asian, North=77.81%; East Asian, South=17.18%; South Asian=0%; European, North=0%; European, South=4.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0190; true Male Characteristics: Produces IgA lambda Doubling time: ~2 days (PubMed=2458153) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153521 CVCL_1X72 ND05052 transformed cell line human CVCL_1X72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153522 CVCL_2977 KMBC-2 cancer cell line human CVCL_2977 HLA typing: A*24:02,24:02; B*07:02,07:02; C*07:02,07:02; DRB1*01:01;01:01 (PubMed=26589293); Genome ancestry: African=0.09%; Native American=0.61%; East Asian, North=77.27%; East Asian, South=21.21%; South Asian=0%; European, North=0%; European, South=0.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gly (c.388C>G); ClinVar=VCV000375958; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (DepMap) Population: Japanese Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0440; true. Unspecified Doubling time: ~68 hours (lot 02082017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21153523 CVCL_1X77 ND05124 transformed cell line human CVCL_1X77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153524 CVCL_1X78 ND05125 transformed cell line human CVCL_1X78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153525 CVCL_2975 KHM-5M cancer cell line human CVCL_2975 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=30737244) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0194; true Male Doubling time: 27 hours (lot 09272002) (JCRB) 21153526 CVCL_1X75 ND05071 transformed cell line human CVCL_1X75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153527 CVCL_2976 KHYG-1 cancer cell line human CVCL_2976 HLA typing: A*11:01:01,24:02:01; B*35:01:01,54:01:01; C*01:02:01,03:03:01; DPA1*02:01:01,02:01:01; DPB1*19:01,14:01:01; DQA1*01:03:01,01:03:01; DRA*01:01:01,01:02:02; DRB1*08:03:02,11:01:01 (DSMZCellDive=ACC-725) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10803526; DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0226; true Female Characteristics: IL2 dependent Doubling time: 24-48 hours (PubMed=10803526); ~30-40 hours (DSMZ=ACC-725); ~54 hours (lot 11012010), ~30 hours (lots 07242006 and 11202015), ~25 hours (lot 10182016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21153528 CVCL_1X76 ND05093 transformed cell line human CVCL_1X76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153529 CVCL_2979 KML-1 cancer cell line human CVCL_2979 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Discontinued: JCRB; NIHS0547; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153530 CVCL_1X79 ND05154 transformed cell line human CVCL_1X79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153531 CVCL_2940 HEp-2C cancer cell line human CVCL_2940 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00309 Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative (PubMed=20143388). 21153532 CVCL_1X40 ND04498 transformed cell line human CVCL_1X40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153533 CVCL_2941 HFb16d transformed cell line human CVCL_2941 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0241; true Male Doubling time: ~3 days (lot 12152003) (JCRB) 21153534 CVCL_1X41 ND04502 transformed cell line human CVCL_1X41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153535 CVCL_2944 HL60(S) cancer cell line human CVCL_2944 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0248; true Female 21153536 CVCL_1X44 ND04533 transformed cell line human CVCL_1X44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153537 CVCL_2945 HL60RG cancer cell line human CVCL_2945 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Doubling time: ~2 days (lot 12182006) (JCRB) 21153538 CVCL_1X45 ND04534 transformed cell line human CVCL_1X45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153539 CVCL_2942 HH [Bovine] finite cell line CVCL_2942 CL:0000010 Derived from sampling site: Carotid artery; endothelium. Unspecified Senescence: Can undergo 60-70 PDL (JCRB=JCRB0099) 21153540 CVCL_1X42 ND04531 transformed cell line human CVCL_1X42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153541 CVCL_2943 HKA-1 cancer cell line human CVCL_2943 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Skin. Omics: Deep exome analysis Discontinued: JCRB; NIHS0251; true Female Doubling time: ~34 hours, at 37th passage (CelloPub=CLPUB00048) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153542 CVCL_1X43 ND04532 transformed cell line human CVCL_1X43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153543 CVCL_2948 HM-1 [Hamster macrophage] cancer cell line CVCL_2948 CL:0000010 Derived from sampling site: Lymph node. Unspecified Doubling time: 114 hours (PubMed=657122) 21153544 CVCL_1X48 ND04575 transformed cell line human CVCL_1X48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153545 CVCL_2949 HMC-1-8 cancer cell line human CVCL_2949 HLA typing: A*24:02,31:01; B*07:13,35:08; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=83.08%; East Asian, South=16.92%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0048; true Female Doubling time: 26 hours (DOI=10.15114/tr.22.27) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153546 CVCL_1X49 ND04584 transformed cell line human CVCL_1X49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153547 CVCL_2946 HLCL-1 transformed cell line human CVCL_2946 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 4-5 days (lot 102497) (JCRB) 21153548 CVCL_1X46 ND04536 transformed cell line human CVCL_1X46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153549 CVCL_2947 HLF cancer cell line human CVCL_2947 HLA typing: A*02:06,24:02; B*15:01,15:01; C*01:02,03:03; DQB1*03:04,03:04; DRB1*04:05,11:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=85.67%; East Asian, South=14.33%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (PubMed=8389256; PubMed=31378681) Population: Japanese; Derived from sampling site: Liver Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 53 hours (PubMed=52570); 27 hours (PubMed=25984343); 22.98 hours (PubMed=31378681) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project 21153550 CVCL_1X47 ND04568 transformed cell line human CVCL_1X47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153551 CVCL_2951 HSGc-C5 cancer cell line human CVCL_2951 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; NIHS0331; true Female Doubling time: 23 hours (JCRB) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00316 Problematic cell line: Contaminated Parent cell line (HSG) has been shown to be a HeLa derivative (PubMed=20143388). 21153552 CVCL_1X51 ND04600 transformed cell line human CVCL_1X51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153553 CVCL_2952 HSR-5 transformed cell line CVCL_2952 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21153554 CVCL_1X52 ND04637 transformed cell line human CVCL_1X52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153555 CVCL_2950 HMY-1 cancer cell line human CVCL_2950 HLA typing: A*02:06,24:02; B*39:01,52:01; C*07:02,12:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from metastatic site: Left inguinal lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0252; true Male Doubling time: 37 hours (PubMed=6239887) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153556 CVCL_1X50 ND04586 transformed cell line human CVCL_1X50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153557 CVCL_2955 HuH-28 cancer cell line human CVCL_2955 Genome ancestry: African=3.05%; Native American=0%; East Asian, North=84.08%; East Asian, South=11.01%; South Asian=0%; European, North=0%; European, South=1.86% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~80 hours (PubMed=2852388); ~1 week (lot 09082006), ~88 hours (lot 01062011), 55-128 hours (lot 07222016), 5 days (lot 10022018) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153558 CVCL_1X55 ND04740 transformed cell line human CVCL_1X55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153559 CVCL_2956 HuH-1 cancer cell line human CVCL_2956 HLA typing: A*02:06,11:01; B*08:20,35:08; C*01:03,07:02 (PubMed=26589293); Genome ancestry: African=0.02%; Native American=0.87%; East Asian, North=80.09%; East Asian, South=18.1%; South Asian=0%; European, North=0%; European, South=0.92% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Asn302Profs*111 (c.904_907delAACC); Zygosity=Unspecified (PubMed=31395879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Homozygous (PubMed=31395879; Cosmic-CLP; DepMap) Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains multiple copies of integrated hepatitis B virus (HBV) genomes Doubling time: 28.23 hours (PubMed=31378681); ~36 hours (lot 02172003), ~31 hours (lot 07192012), ~39 hours (lot 08102017), ~35 hours (lot 04022021) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Liver Cancer Model Repository (LIMORE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21153560 CVCL_1X56 ND04771 transformed cell line human CVCL_1X56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153561 CVCL_2953 HT100 cancer cell line CVCL_2953 CL:0000010 Transformant: Cigarette tar; Derived from sampling site: Lung. Male 21153562 CVCL_1X53 ND04639 transformed cell line human CVCL_1X53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153563 CVCL_1X54 ND04675 transformed cell line human CVCL_1X54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153564 CVCL_2954 Yub642 somatic stem cell human CVCL_2954 CL:0000010 Discontinued: JCRB; NIHS0477; true. Male 21153565 CVCL_2959 HUVEC-C finite cell line human CVCL_2959 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Discontinued: IZSLER; BS CL 145; probable Female Virology: Contains a chromosomally integrated copy of human herpesvirus 6B (CI-HHV-6B) at the distal end of chromosome 9 (PubMed=28755030) Senescence: Life expectancy of 50 to 60 population doublings (ATCC=CRL-1730) 54 PDL (PubMed=28755030).; Doubling time: ~23.5 hours (between passages 18 and 30), ~67 hours (between passages 24 and 27), ~84 hours (between passages 27 and 30), ~100 hours (between passages 32 and 34) (PubMed=28755030) 21153566 CVCL_1X59 ND04845 transformed cell line human CVCL_1X59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153567 CVCL_2957 Huh-7D12 cancer cell line human CVCL_2957 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21153568 CVCL_1X57 ND04788 transformed cell line human CVCL_1X57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153569 CVCL_2958 HuO9N2 cancer cell line human CVCL_2958 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Female Characteristics: Established from a xenograft established in athymic nude mice after two passages Doubling time: ~5 days (lot 031297) (JCRB) 21153570 CVCL_1X58 ND04789 transformed cell line human CVCL_1X58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153571 CVCL_2928 HEC-265 cancer cell line human CVCL_2928 HLA typing: A*02:17,03:01; B*08:01,51:24; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=72.25%; East Asian, South=27.75%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Val (c.95A>T); ClinVar=VCV000376230; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0400; true Female Doubling time: 72 hours, at 7th passage (PubMed=15171304); 36 hours (DOI=10.1007/978-4-431-53981-0_1); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153572 CVCL_1X28 ND04291 transformed cell line human CVCL_1X28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153573 CVCL_2929 HEC-50B cancer cell line human CVCL_2929 HLA typing: A*02:07,02:07; B*08:01,15:39; C*01:02:01:02; DQB1*03:02,06:01; DRB1*01:01,11:09 (PubMed=26589293); Genome ancestry: African=0.78%; Native American=0%; East Asian, North=83.13%; East Asian, South=14.2%; South Asian=0%; European, North=0%; European, South=1.9% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0391; true Female Doubling time: 30.4 hours (PubMed=2064198) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153574 CVCL_1X29 ND04296 transformed cell line human CVCL_1X29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153575 CVCL_2922 HE-1 finite cell line human CVCL_2922 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21153576 CVCL_1X22 ND04178 transformed cell line human CVCL_1X22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153577 CVCL_2923 HEC-108 cancer cell line human CVCL_2923 HLA typing: A*24:20,26:01; B*40:01,52:01; C*12:02,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.21%; East Asian, South=21.79%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1446Ter (c.4336C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0394; true Female Doubling time: 26.5 hours, at 19th passage (DOI=10.5795/jjscc.26.433); ~42 hours (lot 07072012) (JCRB); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153578 CVCL_1X23 ND04214 transformed cell line human CVCL_1X23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153579 CVCL_2920 HCT-2 transformed cell line CVCL_2920 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Spleen. Female 21153580 CVCL_1X20 ND04104 transformed cell line human CVCL_1X20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153581 CVCL_2921 HD-70 cancer cell line human CVCL_2921 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0540; true Male Doubling time: 28 hours (PubMed=1735070; JCRB) 21153582 CVCL_1X21 ND04152 transformed cell line human CVCL_1X21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153583 CVCL_2926 HEC-155 cancer cell line human CVCL_2926 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; JCRB1127; true; Discontinued: JCRB; NIHS0397; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00307 Problematic cell line: Contaminated HEC-155 and HEC-180 have been shown to be identical (PubMed=20143388). Originally thought to originate from a 56 year old female patient with primary endometrial cancer. 21153584 CVCL_1X26 ND04275 transformed cell line human CVCL_1X26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153585 CVCL_2927 HEC-251 cancer cell line human CVCL_2927 HLA typing: A*24:08,24:08; B*54:01,54:01; C*01:02,01:02; DQA1*01:02,02:01; DQB1*05:01,06:08 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.73%; East Asian, North=78.55%; East Asian, South=20.72%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu299Ter (c.895G>T); ClinVar=VCV000428263; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg552Ter (c.1654C>T); ClinVar=VCV000126840; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Asp (c.461G>A); ClinVar=VCV000237950; Zygosity=Unspecified (PubMed=15053063); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Tyr (c.722C>A); ClinVar=VCV000376663; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36 hours, at 3rd passage (PubMed=15171304); 30 hours (DOI=10.1007/978-4-431-53981-0_1) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153586 CVCL_1X27 ND04276 transformed cell line human CVCL_1X27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153587 CVCL_2924 HEC-116 cancer cell line human CVCL_2924 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=15053063) Population: Japanese; Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Discontinued: JCRB; NIHS0395; true Female Doubling time: 27.2 hours (PubMed=2064198) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153588 CVCL_1X24 ND04240 transformed cell line human CVCL_1X24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153589 CVCL_2925 HEC-151 cancer cell line human CVCL_2925 HLA typing: A*24:02,31:01; B*51:01,52:01; C*12:02,14:02; DRB1*15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.66%; East Asian, North=76.07%; East Asian, South=23.27%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val31Ile (c.91G>A); ClinVar=VCV000127827; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0396; true Female Doubling time: 38 hours (PubMed=2064198); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21153590 CVCL_1X25 ND04274 transformed cell line human CVCL_1X25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153591 CVCL_2939 HeLa/MMTV-luc cancer cell line human CVCL_2939 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21153592 CVCL_1X39 ND04484 transformed cell line human CVCL_1X39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153593 CVCL_2930 HEC-59 cancer cell line human CVCL_2930 HLA typing: A*24:02,24:02; B*40:06,40:06; C*08:01,08:01; DQA1*02:01,02:01; DRB1*04:66,04:66 (PubMed=26589293); Genome ancestry: African=1.33%; Native American=0.09%; East Asian, North=79.33%; East Asian, South=17.72%; South Asian=0.28%; European, North=0%; European, South=1.25% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Val (c.437C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr46His (c.136T>C); ClinVar=VCV001701143; Zygosity=Heterozygous (PubMed=20944090; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro213Leufs (c.637_638insT) (c.637C>CT); Zygosity=Heterozygous (PubMed=20944090); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (PubMed=20944090; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=20944090; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser95Phe (c.284C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=15053063; DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0392; true Female Doubling time: 24.3 hours, at 152th passage (DOI=10.5795/jjscc.26.433); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153594 CVCL_1X30 ND04302 transformed cell line human CVCL_1X30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153595 CVCL_2933 HeLa AG cancer cell line human CVCL_2933 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21153596 CVCL_1X33 ND04343 transformed cell line human CVCL_1X33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153597 CVCL_2934 HeLa S3 (sc) cancer cell line human CVCL_2934 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21153598 CVCL_1X34 ND04350 transformed cell line human CVCL_1X34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153599 CVCL_2931 HEC-6 cancer cell line human CVCL_2931 HLA typing: A*24:02,24:02; B*59:01,59:01; C*01:02,01:02; DQA1*05:02,05:02; DQB1*04:01,04:01; DRB1*04:05,11:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=75.17%; East Asian, South=23.89%; South Asian=0%; European, North=0%; European, South=0.94% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Val (c.95A>T); ClinVar=VCV000376230; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg108His (c.323G>A); ClinVar=VCV000280875; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420_Pro421del (c.1258_1263delTGTCCA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Val160Ala (c.479T>C); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0390; true Female Doubling time: 52 hours (PubMed=862644); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21153600 CVCL_1X31 ND04305 transformed cell line human CVCL_1X31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153601 CVCL_2932 HEC-88nu cancer cell line human CVCL_2932 CL:0000010 Population: Japanese Omics: Protein expression by reverse-phase protein arrays Discontinued: JCRB; NIHS0393; true. Female Characteristics: Established from a tumor transplanted in nude mice Doubling time: 43.8 hours, at 58th passage (DOI=10.5795/jjscc.26.433); 48 hours (PubMed=2064198) Part of: MD Anderson Cell Lines Project 21153602 CVCL_1X32 ND04312 transformed cell line human CVCL_1X32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153603 CVCL_2937 HeLa.P3 cancer cell line human CVCL_2937 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: JCRB; JCRB0649.1; true; Discontinued: JCRB; NIHS0372; true Female Group: Serum/protein free medium cell line 21153604 CVCL_1X37 ND04404 transformed cell line human CVCL_1X37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153605 CVCL_2938 HeLa.P3(S) cancer cell line human CVCL_2938 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Serum/protein free medium cell line 21153606 CVCL_1X38 ND04431 transformed cell line human CVCL_1X38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153607 CVCL_2935 HeLa TG cancer cell line human CVCL_2935 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21153608 CVCL_1X35 ND04357 transformed cell line human CVCL_1X35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: Coriell; ND04357; probable 21153609 CVCL_2936 HeLa TG Cap cancer cell line human CVCL_2936 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21153610 CVCL_1X36 ND04361 transformed cell line human CVCL_1X36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153611 CVCL_CM58 ND13413 transformed cell line human CVCL_CM58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153612 CVCL_CM59 ND13414 transformed cell line human CVCL_CM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153613 CVCL_CM52 ND13368 transformed cell line human CVCL_CM52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153614 CVCL_CM53 ND13369 transformed cell line human CVCL_CM53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153615 CVCL_CM50 ND13351 transformed cell line human CVCL_CM50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153616 CVCL_CM51 ND13362 transformed cell line human CVCL_CM51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153617 CVCL_CM56 ND13394 transformed cell line human CVCL_CM56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153618 CVCL_CM57 ND13412 transformed cell line human CVCL_CM57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153619 CVCL_CM54 ND13370 transformed cell line human CVCL_CM54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153620 CVCL_CM55 ND13380 transformed cell line human CVCL_CM55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153621 CVCL_LG00 H3680B cancer cell line human CVCL_LG00 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21153622 CVCL_LG01 H3730 cancer cell line human CVCL_LG01 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21153623 CVCL_CM69 ND13601 transformed cell line human CVCL_CM69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153624 CVCL_CM63 ND13460 transformed cell line human CVCL_CM63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153625 CVCL_CM64 ND13476 transformed cell line human CVCL_CM64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153626 CVCL_CM61 ND13429 transformed cell line human CVCL_CM61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153627 CVCL_CM62 ND13448 transformed cell line human CVCL_CM62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153628 CVCL_CM67 ND13501 transformed cell line human CVCL_CM67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153629 CVCL_CM68 ND13530 transformed cell line human CVCL_CM68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153630 CVCL_CM65 ND13499 transformed cell line human CVCL_CM65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153631 CVCL_CM66 ND13500 transformed cell line human CVCL_CM66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153632 CVCL_CM60 ND13427 transformed cell line human CVCL_CM60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153633 CVCL_CM38 ND13017 transformed cell line human CVCL_CM38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153634 CVCL_CM39 ND13020 transformed cell line human CVCL_CM39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153635 CVCL_CM36 ND13015 transformed cell line human CVCL_CM36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153636 CVCL_CM37 ND13016 transformed cell line human CVCL_CM37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153637 CVCL_CM30 ND12901 transformed cell line human CVCL_CM30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153638 CVCL_CM31 ND12902 transformed cell line human CVCL_CM31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153639 CVCL_CM34 ND12993 transformed cell line human CVCL_CM34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153640 CVCL_CM35 ND13014 transformed cell line human CVCL_CM35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153641 CVCL_CM32 ND12960 transformed cell line human CVCL_CM32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153642 CVCL_CM33 ND12961 transformed cell line human CVCL_CM33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153643 CVCL_CM49 ND13350 transformed cell line human CVCL_CM49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153644 CVCL_CM47 ND13271 transformed cell line human CVCL_CM47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153645 CVCL_CM48 ND13272 transformed cell line human CVCL_CM48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153646 CVCL_CM41 ND13118 transformed cell line human CVCL_CM41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153647 CVCL_CM42 ND13127 transformed cell line human CVCL_CM42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153648 CVCL_CM40 ND13093 transformed cell line human CVCL_CM40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153649 CVCL_CM45 ND13178 transformed cell line human CVCL_CM45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153650 CVCL_CM46 ND13221 transformed cell line human CVCL_CM46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153651 CVCL_CM43 ND13169 transformed cell line human CVCL_CM43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153652 CVCL_CM44 ND13170 transformed cell line human CVCL_CM44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153653 CVCL_CM16 ND12302 transformed cell line human CVCL_CM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153654 CVCL_CM17 ND12303 transformed cell line human CVCL_CM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153655 CVCL_CM14 ND12229 transformed cell line human CVCL_CM14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153656 CVCL_CM15 ND12257 transformed cell line human CVCL_CM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153657 CVCL_CM18 ND12304 transformed cell line human CVCL_CM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153658 CVCL_CM19 ND12342 transformed cell line human CVCL_CM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153659 CVCL_CM12 ND12187 transformed cell line human CVCL_CM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153660 CVCL_CM13 ND12228 transformed cell line human CVCL_CM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153661 CVCL_CM10 ND12061 transformed cell line human CVCL_CM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153662 CVCL_CM11 ND12185 transformed cell line human CVCL_CM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153663 CVCL_CM27 ND12851 transformed cell line human CVCL_CM27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153664 CVCL_CM28 ND12854 transformed cell line human CVCL_CM28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153665 CVCL_CM25 ND12755 transformed cell line human CVCL_CM25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153666 CVCL_CM26 ND12756 transformed cell line human CVCL_CM26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153667 CVCL_CM29 ND12855 transformed cell line human CVCL_CM29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153668 CVCL_CM20 ND12473 transformed cell line human CVCL_CM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153669 CVCL_CM23 ND12656 transformed cell line human CVCL_CM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153670 CVCL_CM24 ND12725 transformed cell line human CVCL_CM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153671 CVCL_CM21 ND12646 transformed cell line human CVCL_CM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153672 CVCL_CM22 ND12648 transformed cell line human CVCL_CM22 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Thr2356Ile (c.7067C>T); ClinVar=VCV000039232; Zygosity=Heterozygous (PubMed=17622782) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153673 CVCL_CM05 ND12022 transformed cell line human CVCL_CM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153674 CVCL_CM06 ND12023 transformed cell line human CVCL_CM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153675 CVCL_CM03 ND11998 transformed cell line human CVCL_CM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153676 CVCL_CM04 ND11999 transformed cell line human CVCL_CM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153677 CVCL_CM09 ND12033 transformed cell line human CVCL_CM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153678 CVCL_CM07 ND12024 transformed cell line human CVCL_CM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153679 CVCL_CM08 ND12032 transformed cell line human CVCL_CM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153680 CVCL_CM01 ND11996 transformed cell line human CVCL_CM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153681 CVCL_CM02 ND11997 transformed cell line human CVCL_CM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153682 CVCL_CM00 ND11995 transformed cell line human CVCL_CM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153683 CVCL_LG77 CG1332 transformed cell line human CVCL_LG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153684 CVCL_LG78 CG1357 transformed cell line human CVCL_LG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153685 CVCL_LG75 CG1266 finite cell line human CVCL_LG75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21153686 CVCL_LG76 CG1297 finite cell line human CVCL_LG76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153687 CVCL_LG73 CG1254 transformed cell line human CVCL_LG73 CL:0000010 Sequence variation: Mutation; HGNC; 9752; QDPR; Simple; p.Thr233Pro (c.697A>C); Zygosity=Unspecified (BCRC) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153688 CVCL_LG74 CG1265 finite cell line human CVCL_LG74 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Unspecified 21153689 CVCL_LG71 CG1252 transformed cell line human CVCL_LG71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153690 CVCL_LG72 CG1253 transformed cell line human CVCL_LG72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153691 CVCL_LG70 CG1251 finite cell line human CVCL_LG70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153692 CVCL_UA10 Ba/F3 EGFR-Del19/T790M/C797S factor-dependent cell line house mouse CVCL_UA10 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del, p.Thr790Met and p.Cys797Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153693 CVCL_UA11 Ba/F3 EGFR-Del19/T790M/L858R factor-dependent cell line house mouse CVCL_UA11 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del, p.Thr790Met and p.Leu858Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153694 CVCL_UA14 Ba/F3 EGFR-H773-V774ins_NPH factor-dependent cell line house mouse CVCL_UA14 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.His773_Val774ins_AsnProHis); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153695 CVCL_UA15 Ba/F3 EGFR-L858R factor-dependent cell line house mouse CVCL_UA15 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Leu858Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153696 CVCL_UA12 Ba/F3 EGFR-G719S factor-dependent cell line house mouse CVCL_UA12 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Gly719Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153697 CVCL_UA13 Ba/F3 EGFR-T263P/G719S factor-dependent cell line house mouse CVCL_UA13 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr263Pro and p.Gly719Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153698 CVCL_UA18 Ba/F3 EGFR-L861Q factor-dependent cell line house mouse CVCL_UA18 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Leu861Gln); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153699 CVCL_UA19 Ba/F3 EGFR-T790M factor-dependent cell line house mouse CVCL_UA19 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr790Met); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153700 CVCL_UA16 Ba/F3 EGFR-C797S/L858R factor-dependent cell line house mouse CVCL_UA16 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Cys797Ser and p.Leu858Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153701 CVCL_UA17 Ba/F3 EGFR-T790M/L858R factor-dependent cell line house mouse CVCL_UA17 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr790Met and p.Leu858Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153702 CVCL_LG68 CG1152 finite cell line human CVCL_LG68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153703 CVCL_LG69 CG1164 transformed cell line human CVCL_LG69 CL:0000010 Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Asn52Ser (c.155A>G); ClinVar=VCV000000479; Zygosity=Heterozygous (BCRC); Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Pro87Ser (c.259C>T); ClinVar=VCV000000480; Zygosity=Heterozygous (BCRC) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153704 CVCL_LG88 CG1474 finite cell line human CVCL_LG88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153705 CVCL_LG89 CG1475 finite cell line human CVCL_LG89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153706 CVCL_LG86 CG1469 transformed cell line human CVCL_LG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153707 CVCL_LG87 CG1472 finite cell line human CVCL_LG87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153708 CVCL_LG84 CG1429 transformed cell line human CVCL_LG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153709 CVCL_LG85 CG1449 transformed cell line human CVCL_LG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153710 CVCL_LG82 CG1427 transformed cell line human CVCL_LG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153711 CVCL_LG83 CG1428 transformed cell line human CVCL_LG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153712 CVCL_LG80 CG1359 transformed cell line human CVCL_LG80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153713 CVCL_LG81 CG1360 transformed cell line human CVCL_LG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153714 CVCL_UA00 WG0987 finite cell line human CVCL_UA00 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (PubMed=11013137) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153715 CVCL_UA03 CaVa finite cell line human CVCL_UA03 CL:0000010 Karyotypic information: 46,X,t(X;22)(q22;q13) (PubMed=1056018). Female 21153716 CVCL_UA04 Ba/F3 EGFR factor-dependent cell line house mouse CVCL_UA04 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153717 CVCL_UA01 WG0988 finite cell line human CVCL_UA01 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11013137) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153718 CVCL_UA02 GM01006 finite cell line human CVCL_UA02 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; c.3435-1G>A (IVS19-1G>A); ClinVar=VCV000038427; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01006; probable 21153719 CVCL_UA07 Ba/F3 EGFR-Del19 factor-dependent cell line house mouse CVCL_UA07 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153720 CVCL_UA08 Ba/F3 EGFR-Del19/C797S factor-dependent cell line house mouse CVCL_UA08 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del and p.Cys797Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153721 CVCL_UA05 Ba/F3 EGFR-C797S factor-dependent cell line house mouse CVCL_UA05 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Cys797Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153722 CVCL_UA06 Ba/F3 EGFR-D770-N771ins_SVD factor-dependent cell line house mouse CVCL_UA06 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Asp770_Asn771insSerValAsp); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153723 CVCL_UA09 Ba/F3 EGFR-Del19/T790M factor-dependent cell line house mouse CVCL_UA09 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del and p.Thr790Met); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21153724 CVCL_LG79 CG1358 transformed cell line human CVCL_LG79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153725 CVCL_LG55 CG0290 transformed cell line human CVCL_LG55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153726 CVCL_LG56 CG0319 transformed cell line human CVCL_LG56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153727 CVCL_LG53 CG0284 transformed cell line human CVCL_LG53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153728 CVCL_LG54 CG0289 transformed cell line human CVCL_LG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153729 CVCL_LG51 CG0161 finite cell line human CVCL_LG51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153730 CVCL_LG52 CG0176 finite cell line human CVCL_LG52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153731 CVCL_LG50 CG0113 finite cell line human CVCL_LG50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153732 CVCL_LG48 CG0108 finite cell line human CVCL_LG48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153733 CVCL_LG49 CG0110 finite cell line human CVCL_LG49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153734 CVCL_LG46 CG0106 finite cell line human CVCL_LG46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153735 CVCL_LG47 CG0107 finite cell line human CVCL_LG47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153736 CVCL_LG66 CG1150 transformed cell line human CVCL_LG66 CL:0000010 Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Asn52Ser (c.155A>G); ClinVar=VCV000000479; Zygosity=Heterozygous (BCRC) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153737 CVCL_LG67 CG1151 transformed cell line human CVCL_LG67 CL:0000010 Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Pro87Ser (c.259C>T); ClinVar=VCV000000480; Zygosity=Heterozygous (BCRC) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153738 CVCL_LG64 CG1070 transformed cell line human CVCL_LG64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153739 CVCL_LG65 CG1149 transformed cell line human CVCL_LG65 CL:0000010 Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Asn52Ser (c.155A>G); ClinVar=VCV000000479; Zygosity=Heterozygous (BCRC); Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Pro87Ser (c.259C>T); ClinVar=VCV000000480; Zygosity=Heterozygous (BCRC) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153740 CVCL_LG62 CG1000 finite cell line human CVCL_LG62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153741 CVCL_LG63 CG1006 finite cell line human CVCL_LG63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153742 CVCL_LG60 CG0467 transformed cell line human CVCL_LG60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153743 CVCL_LG61 CG0999 finite cell line human CVCL_LG61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153744 CVCL_LG59 CG0446 finite cell line human CVCL_LG59 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Male 21153745 CVCL_LG57 CG0330 transformed cell line human CVCL_LG57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153746 CVCL_LG58 CG0396 transformed cell line human CVCL_LG58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153747 CVCL_LG33 IBMS-iPSC-004-02 induced pluripotent stem cell human CVCL_LG33 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21153748 CVCL_LG34 FIRDI-iPSC-002-30 induced pluripotent stem cell human CVCL_LG34 From: Food Industry Research and Development Institute; Hsinchu; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Homozygous; Note=Allele ALDH2*2 (PubMed=33592568) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21153749 CVCL_LG31 GUSS-3b cancer cell line human CVCL_LG31 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=23716114). Male 21153750 CVCL_LG32 IBMS-iPSC-003-06 induced pluripotent stem cell human CVCL_LG32 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21153751 CVCL_LG30 Rx 54-3 hybridoma CVCL_LG30 CL:0000010 Monoclonal antibody isotype: IgG. 21153752 CVCL_CM96 ND13801 transformed cell line human CVCL_CM96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153753 CVCL_CM97 ND13802 transformed cell line human CVCL_CM97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153754 CVCL_CM94 ND13795 transformed cell line human CVCL_CM94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153755 CVCL_CM95 ND13796 transformed cell line human CVCL_CM95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153756 CVCL_CM98 ND13805 transformed cell line human CVCL_CM98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153757 CVCL_CM99 ND13806 transformed cell line human CVCL_CM99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153758 CVCL_LG28 USC-HN1-GFP-G2 cancer cell line human CVCL_LG28 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray Female Characteristics: Transfected with an H2B-GFP fusion protein; Characteristics: Metastatic Parent cell line was injected into the tongues of SCID/nude mice. The metastatic cells were collected at lymph nodes, separated and cultured. 21153759 CVCL_LG29 W-18 VA 2 transformed cell line human CVCL_LG29 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa. Male 21153760 CVCL_CM92 ND13792 transformed cell line human CVCL_CM92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153761 CVCL_LG26 USC-HN1-GFP cancer cell line human CVCL_LG26 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray Female Characteristics: Transfected with an H2B-GFP fusion protein 21153762 CVCL_CM93 ND13793 transformed cell line human CVCL_CM93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153763 CVCL_LG27 USC-HN1-GFP-G1 cancer cell line human CVCL_LG27 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Omics: Transcriptome analysis by microarray Female Characteristics: Transfected with an H2B-GFP fusion protein; Characteristics: Metastatic Parent cell line was injected into the tongues of SCID/nude mice. The metastatic cells were collected at lymph nodes, separated and cultured. 21153764 CVCL_LG24 BR110 hybridoma house mouse CVCL_LG24 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11698 21153765 CVCL_CM90 ND13777 transformed cell line human CVCL_CM90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153766 CVCL_LG25 H3737 cancer cell line human CVCL_LG25 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153767 CVCL_CM91 ND13778 transformed cell line human CVCL_CM91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153768 CVCL_LG44 CG0101 finite cell line human CVCL_LG44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153769 CVCL_LG45 CG0103 finite cell line human CVCL_LG45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153770 CVCL_LG42 CG0099 finite cell line human CVCL_LG42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153771 CVCL_LG43 CG0100 finite cell line human CVCL_LG43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153772 CVCL_LG40 CG0035 finite cell line human CVCL_LG40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153773 CVCL_LG41 CG0097 finite cell line human CVCL_LG41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153774 CVCL_LG39 CG0028 finite cell line human CVCL_LG39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153775 CVCL_LG37 CG0008 finite cell line human CVCL_LG37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153776 CVCL_LG38 CG0020 finite cell line human CVCL_LG38 CL:0000010 Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Asn52Ser (c.155A>G); ClinVar=VCV000000479; Zygosity=Heterozygous (BCRC); Sequence variation: Mutation; HGNC; 9689; PTS; Simple; p.Pro87Ser (c.259C>T); ClinVar=VCV000000480; Zygosity=Heterozygous (BCRC) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153777 CVCL_LG35 mAbC7 hybridoma house mouse CVCL_LG35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13987; Human CD59 (Note=Glycated on Lys66). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6023 21153778 CVCL_LG36 CG0006 finite cell line human CVCL_LG36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153779 CVCL_LG11 H3600 cancer cell line human CVCL_LG11 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153780 CVCL_LG12 BR64 [Mouse hybridoma against human BRCA1] hybridoma house mouse CVCL_LG12 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. 21153781 CVCL_LG10 H2964 cancer cell line human CVCL_LG10 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153782 CVCL_CM74 ND13654 transformed cell line human CVCL_CM74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153783 CVCL_CM75 ND13655 transformed cell line human CVCL_CM75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153784 CVCL_CM72 ND13645 transformed cell line human CVCL_CM72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153785 CVCL_CM73 ND13646 transformed cell line human CVCL_CM73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153786 CVCL_CM78 ND13689 transformed cell line human CVCL_CM78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153787 CVCL_CM79 ND13690 transformed cell line human CVCL_CM79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153788 CVCL_CM76 ND13656 transformed cell line human CVCL_CM76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153789 CVCL_CM77 ND13688 transformed cell line human CVCL_CM77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153790 CVCL_LG08 H3802 cancer cell line human CVCL_LG08 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153791 CVCL_LG09 H3619 cancer cell line human CVCL_LG09 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153792 CVCL_LG06 H3650 cancer cell line human CVCL_LG06 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153793 CVCL_LG07 H3347 cancer cell line human CVCL_LG07 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153794 CVCL_LG04 H3614 cancer cell line human CVCL_LG04 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21153795 CVCL_CM70 ND13602 transformed cell line human CVCL_CM70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153796 CVCL_LG05 H3620 cancer cell line human CVCL_LG05 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153797 CVCL_CM71 ND13603 transformed cell line human CVCL_CM71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153798 CVCL_LG02 H3914 cancer cell line human CVCL_LG02 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21153799 CVCL_LG03 H3606 cancer cell line human CVCL_LG03 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 21153800 CVCL_LG22 HuH-7T1 cancer cell line human CVCL_LG22 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male Virology: Compared to the parent Huh-7 cell line, permits improved HCV production when infected with strain JFH-1 21153801 CVCL_LG23 H3719 cancer cell line human CVCL_LG23 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Unspecified 21153802 CVCL_LG20 HCC1954-LR cancer cell line human CVCL_LG20 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line) Population: East Indian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Female 21153803 CVCL_LG21 HCC1954-NR cancer cell line human CVCL_LG21 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line) Population: East Indian; Selected for resistance to: ChEBI; CHEBI:61397; Neratinib (Nerlynx; Derived from sampling site: Breast. Female 21153804 CVCL_CM85 ND13715 transformed cell line human CVCL_CM85 CL:0000010 Population: Caucasian; French/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153805 CVCL_CM86 ND13716 transformed cell line human CVCL_CM86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153806 CVCL_CM83 ND13707 transformed cell line human CVCL_CM83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153807 CVCL_CM84 ND13714 transformed cell line human CVCL_CM84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153808 CVCL_CM89 ND13775 transformed cell line human CVCL_CM89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153809 CVCL_CM87 ND13718 transformed cell line human CVCL_CM87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153810 CVCL_CM88 ND13752 transformed cell line human CVCL_CM88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153811 CVCL_LG19 SKBR3-TR cancer cell line human CVCL_LG19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from metastatic site: Pleural effusion. Female 21153812 CVCL_LG17 SKBR3-LR cancer cell line human CVCL_LG17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 21153813 CVCL_LG18 SKBR3-NR cancer cell line human CVCL_LG18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:61397; Neratinib (Nerlynx; Derived from metastatic site: Pleural effusion. Female 21153814 CVCL_LG15 BR96 hybridoma house mouse CVCL_LG15 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:59045; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc (Lewis Y). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10036 21153815 CVCL_CM81 ND13705 transformed cell line human CVCL_CM81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153816 CVCL_CM82 ND13706 transformed cell line human CVCL_CM82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153817 CVCL_LG16 NIH 3T3/HER2-3(400) spontaneously immortalized cell line house mouse CVCL_LG16 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with at least 55 copies of ERBB2 under the control of a SV40 promoter 21153818 CVCL_LG13 BR64 [Mouse hybridoma against Lewis Y] hybridoma house mouse CVCL_LG13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:59045; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc (Lewis Y). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9895 21153819 CVCL_LG14 BR64.60 hybridoma house mouse CVCL_LG14 CL:0000010 Characteristics: Isotype switched derivative of BR64; Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:59045; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc (Lewis Y). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10292 21153820 CVCL_CM80 ND13691 transformed cell line human CVCL_CM80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153821 CVCL_1Y29 GM01704 finite cell line human CVCL_1Y29 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153822 CVCL_1Y27 GM01419 finite cell line human CVCL_1Y27 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21153823 CVCL_1Y28 GM01703 finite cell line human CVCL_1Y28 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153824 CVCL_1Y21 GM00528 finite cell line human CVCL_1Y21 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21153825 CVCL_1Y22 GM00727 finite cell line human CVCL_1Y22 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21153826 CVCL_1Y20 GM00433 finite cell line human CVCL_1Y20 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Ser135Leu (c.404C>T); ClinVar=VCV000003618; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21153827 CVCL_1Y25 GM01417 finite cell line human CVCL_1Y25 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21153828 CVCL_1Y26 GM01418 finite cell line human CVCL_1Y26 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21153829 CVCL_1Y23 GM01209 finite cell line human CVCL_1Y23 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asp98His (c.292G>C); ClinVar=VCV000025149; Zygosity=Homozygous (from familial inference of GM01210) Population: Latino or Hispanic; Dominican; Donor information: Established from monozygotic twin of GM01210 (Cellosaurus=CVCL_1Y24); Derived from sampling site: Cell type=Fibroblast. Male 21153830 CVCL_1Y24 GM01210 finite cell line human CVCL_1Y24 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asp98His (c.292G>C); ClinVar=VCV000025149; Zygosity=Homozygous (Coriell) Population: Latino or Hispanic; Dominican; Donor information: Established from monozygotic twin of GM01209 (Cellosaurus=CVCL_1Y23); Derived from sampling site: Cell type=Fibroblast. Male 21153831 CVCL_1Y38 GM17435 transformed cell line human CVCL_1Y38 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asn314Asp (c.940A>G); ClinVar=VCV000003613; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153832 CVCL_1Y39 GM17436 transformed cell line human CVCL_1Y39 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Leu74Pro (c.221T>C); ClinVar=VCV000003615; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153833 CVCL_1Y32 GM11764 transformed cell line human CVCL_1Y32 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153834 CVCL_1Y33 GM17430 transformed cell line human CVCL_1Y33 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Arg333Trp (c.997C>T); ClinVar=VCV000003610; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153835 CVCL_1Y30 GM10402 transformed cell line human CVCL_1Y30 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Arg333Trp (c.997C>T); ClinVar=VCV000003610; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153836 CVCL_1Y31 GM11763 transformed cell line human CVCL_1Y31 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Arg333Trp (c.997C>T); ClinVar=VCV000003610; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153837 CVCL_1Y36 GM17433 transformed cell line human CVCL_1Y36 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Leu74Pro (c.221T>C); ClinVar=VCV000003615; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153838 CVCL_1Y37 GM17434 transformed cell line human CVCL_1Y37 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153839 CVCL_1Y34 GM17431 transformed cell line human CVCL_1Y34 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Leu195Pro (c.584T>C); ClinVar=VCV000025222; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153840 CVCL_1Y35 GM17432 transformed cell line human CVCL_1Y35 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153841 CVCL_1Y07 DT40-RAD54L(-/-)-RAD54B(-/-) cancer cell line CVCL_1Y07 CL:0000010 Knockout cell: Method=Targeted integration; RAD54L, RAD54B Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21153842 CVCL_1Y08 CHO PBj gp130 spontaneously immortalized cell line CVCL_1Y08 CL:0000010 Transfected with: UniProtKB; P19503; SIV isolate PBj env (gp130); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21153843 CVCL_1Y05 DLD-1/alpha-cat cell cancer cell line human CVCL_1Y05 CL:0000010 Transfected with: HGNC; 2509; CTNNA1. Male 21153844 CVCL_1Y06 DT40-PRKDC(-/-) cancer cell line CVCL_1Y06 CL:0000010 Knockout cell: Method=Targeted integration; PRKDC Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21153845 CVCL_1Y09 CHO MW959 gp140 (Clade A) spontaneously immortalized cell line CVCL_1Y09 CL:0000010 Transfected with: UniProtKB; Q6BBZ9; HIV-1 isolate 93MW959 env (gp140); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21153846 CVCL_1Y00 ND05536 transformed cell line human CVCL_1Y00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153847 CVCL_1Y03 ND05766 transformed cell line human CVCL_1Y03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153848 CVCL_1Y04 DLD-1/delta-alpha cancer cell line human CVCL_1Y04 CL:0000010 Male 21153849 CVCL_1Y01 ND05575 transformed cell line human CVCL_1Y01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male 21153850 CVCL_1Y02 ND05691 transformed cell line human CVCL_1Y02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21153851 CVCL_1Y18 S58-SF cancer cell line human CVCL_1Y18 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Female Doubling time: 35.7 hours (PubMed=26141632) Group: Serum/protein free medium cell line 21153852 CVCL_1Y19 GM00422 finite cell line human CVCL_1Y19 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln344Lys (c.1030C>A); ClinVar=VCV000025320; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21153853 CVCL_1Y16 AE-3 hybridoma house mouse CVCL_1Y16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. 21153854 CVCL_1Y17 SUIT-58 cancer cell line human CVCL_1Y17 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Female Doubling time: 32 hours (PubMed=26141632) 21153855 CVCL_1Y10 CHO JR-FL gp160 (Clone A19) spontaneously immortalized cell line CVCL_1Y10 CL:0000010 Transfected with: UniProtKB; Q72502; HIV-1 isolate JRFL env (gp160); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21153856 CVCL_1Y11 SP+ transformed cell line human CVCL_1Y11 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: HTLV-1 producing cell line 21153857 CVCL_1Y14 SIM.2 hybridoma house mouse CVCL_1Y14 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 21153858 CVCL_1Y15 SIM.4 hybridoma house mouse CVCL_1Y15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 21153859 CVCL_1Y12 HSB2/GS cancer cell line human CVCL_1Y12 CL:0000010 Sequence variation: Gene fusion; HGNC; 10879; STIL + HGNC; 11556; TAL1; Name(s)=STIL-TAL1, SIL-TAL1, SIL-SCL (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1175Arg (c.3524C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr226His (c.676T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Arg621His (c.1862G>A); ClinVar=VCV000016355; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Thr454Ile (c.1361C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Gln455Lys (c.1363C>A); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21153860 CVCL_1Y13 CHO 92UG21-9 gp120 (Clade D) spontaneously immortalized cell line CVCL_1Y13 CL:0000010 Transfected with: UniProtKB; Q6BBX2; HIV-1 isolate 92UG021 env (gp120); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21153861 CVCL_LF98 BRL-4143 cancer cell line human CVCL_LF98 CL:0000010 Unspecified 21153862 CVCL_LF99 H3630 cancer cell line human CVCL_LF99 From: Bristol-Myers Squibb Pharmaceutical Research Institute; Seattle; USA. CL:0000010 Female 21153863 CVCL_LF96 B77-A31 transformed cell line house mouse CVCL_LF96 From: Vogt P.K.; The Scripps Research Institute; La Jolla; USA CL:0000010 Transformant: Avian sarcoma virus (ASV) [Strain Bratislava-77 (B77)](NCBI-Taxonomy; 11876); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21153864 CVCL_LF97 MC5-5 transformed cell line house mouse CVCL_LF97 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21153865 CVCL_LF78 PS30 transformed cell line human CVCL_LF78 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21153866 CVCL_LF79 rUGM spontaneously immortalized cell line Norway rat CVCL_LF79 CL:0000010 Derived from sampling site: Urogenital sinus mesenchyme; Breed/subspecies: Nb. Male 21153867 CVCL_LF76 N263 transformed cell line house mouse CVCL_LF76 CL:0000010 Transfected with: HGNC; 6018; IL6; Transfected with: UniProtKB; P06740; Hylobates lar IL3; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21153868 CVCL_LF77 hTERT SMC PM151T telomerase immortalized cell line human CVCL_LF77 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male Doubling time: ~60 hours (ATCC=CRL-3291) 21153869 CVCL_LF74 RC-1 [Human renal cell carcinoma] cancer cell line human CVCL_LF74 CL:0000010 Derived from sampling site: Liver. Female Characteristics: Produces EPO Doubling time: 48 hours (at 37th passage), 29 hours (at 40th passage), 24 hours (at 53th passage) (PubMed=3455754) 21153870 CVCL_LF75 S2.13 conditionally immortalized cell line human CVCL_LF75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21153871 CVCL_LF72 HCC229 BL transformed cell line human CVCL_LF72 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153872 CVCL_LF73 Mfh-val2 cancer cell line human CVCL_LF73 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=28676915). Male Doubling time: 56 hours (PubMed=28676915) 21153873 CVCL_LF70 TUSMi001-A induced pluripotent stem cell human CVCL_LF70 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21153874 CVCL_LF71 TUSMi002-A induced pluripotent stem cell human CVCL_LF71 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21153875 CVCL_LF69 PiCa cancer cell line human CVCL_LF69 CL:0000010 Derived from sampling site: Larynx. 21153876 CVCL_LF85 C57MG/Wnt-1 spontaneously immortalized cell line house mouse CVCL_LF85 CL:0000010 Transfected with: MGI; MGI:98953; Wnt1 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by microarray Female 21153877 CVCL_LF86 C57MG/2-69-23 spontaneously immortalized cell line house mouse CVCL_LF86 CL:0000010 Transfected with: MGI; MGI:98953; Wnt1 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Characteristics: The expression of the Wnt1 gene is under the control of a tetracycline-repressible promoter Group: Patented cell line 21153878 CVCL_LF83 UGSM-2 spontaneously immortalized cell line house mouse CVCL_LF83 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a Derived from sampling site: Urogenital sinus mesenchyme; Breed/subspecies: Ink4a/Arf-/- transgenic. Male Doubling time: 13 hours (PubMed=16752376) 21153879 CVCL_LF84 TSEC transformed cell line house mouse CVCL_LF84 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Omics: Transcriptome analysis by microarray Unspecified 21153880 CVCL_LF81 U4F spontaneously immortalized cell line Norway rat CVCL_LF81 CL:0000010 Derived from sampling site: Urogenital sinus mesenchyme; Breed/subspecies: Harlan Sprague Dawley. Male 21153881 CVCL_LF82 U4F1 spontaneously immortalized cell line Norway rat CVCL_LF82 CL:0000010 Derived from sampling site: Urogenital sinus mesenchyme; Breed/subspecies: Harlan Sprague Dawley. Male 21153882 CVCL_LF80 simLSEC spontaneously immortalized cell line house mouse CVCL_LF80 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.; Breed/subspecies: Kunming White. Unspecified Doubling time: 4.01 days (at 20th passage), 3.50 days (at 21th passage) (PubMed=25585915) 21153883 CVCL_1Y80 Swiss3 spontaneously immortalized cell line house mouse CVCL_1Y80 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153884 CVCL_1Y83 Swiss5 spontaneously immortalized cell line house mouse CVCL_1Y83 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153885 CVCL_1Y84 Swiss8 spontaneously immortalized cell line house mouse CVCL_1Y84 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153886 CVCL_1Y81 Swiss30 spontaneously immortalized cell line house mouse CVCL_1Y81 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153887 CVCL_1Y82 Swiss38 spontaneously immortalized cell line house mouse CVCL_1Y82 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153888 CVCL_1Y87 HGADFN122 finite cell line human CVCL_1Y87 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153889 CVCL_1Y88 HGADFN127 finite cell line human CVCL_1Y88 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153890 CVCL_1Y85 Swiss9 spontaneously immortalized cell line house mouse CVCL_1Y85 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153891 CVCL_1Y86 HGADFN003 finite cell line human CVCL_1Y86 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF; PubMed=12714972) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21153892 CVCL_1Y89 HGADFN143 finite cell line human CVCL_1Y89 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Progeria Research Foundation cell lines 21153893 CVCL_1Y90 HGADFN155 finite cell line human CVCL_1Y90 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21153894 CVCL_1Y91 HGADFN164 finite cell line human CVCL_1Y91 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153895 CVCL_1Y94 HGMDFN090 finite cell line human CVCL_1Y94 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21153896 CVCL_1Y95 HGADFN169 finite cell line human CVCL_1Y95 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Progeria Research Foundation cell lines 21153897 CVCL_1Y92 HGADFN167 finite cell line human CVCL_1Y92 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Part of: ENCODE project common cell types; tier 3; Part of: Progeria Research Foundation cell lines 21153898 CVCL_1Y93 HGFDFN168 finite cell line human CVCL_1Y93 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: H3K27me3 ChIP-seq epigenome analysis Male Part of: Progeria Research Foundation cell lines 21153899 CVCL_1Y98 HGADFN271 finite cell line human CVCL_1Y98 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21153900 CVCL_1Y99 HGADFN367 finite cell line human CVCL_1Y99 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153901 CVCL_1Y96 HGADFN178 finite cell line human CVCL_1Y96 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153902 CVCL_1Y97 HGADFN188 finite cell line human CVCL_1Y97 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Progeria Research Foundation cell lines 21153903 CVCL_1Y61 LPC9p cancer cell line human CVCL_1Y61 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Tyr195fs*1 (c.585delC); Zygosity=Hemizygous (PubMed=9892110) Derived from sampling site: Pancreas. Female 21153904 CVCL_1Y62 LPC10m cancer cell line human CVCL_1Y62 CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH Female 21153905 CVCL_1Y60 LPC8p cancer cell line human CVCL_1Y60 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Female 21153906 CVCL_1Y65 LPC12m cancer cell line human CVCL_1Y65 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ala406Thr (c.1216G>A); ClinVar=VCV000193679; Zygosity=Hemizygous (PubMed=9892110) Derived from metastatic site: Not specified. Omics: Array-based CGH Male 21153907 CVCL_1Y66 LPC13p cancer cell line human CVCL_1Y66 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153908 CVCL_1Y63 LPC11m cancer cell line human CVCL_1Y63 CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH Male 21153909 CVCL_1Y64 LPC11p cancer cell line human CVCL_1Y64 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153910 CVCL_1Y69 NFS-1 cancer cell line human CVCL_1Y69 CL:0000010 21153911 CVCL_1Y67 LPC14p cancer cell line human CVCL_1Y67 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153912 CVCL_1Y68 LPC15p cancer cell line human CVCL_1Y68 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Female 21153913 CVCL_1Y72 HPAF1 spontaneously immortalized cell line human CVCL_1Y72 CL:0000010 Derived from sampling site: Salivary gland; parotid gland; epithelium. Female Doubling time: ~43 hours (PubMed=7713331) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11707 21153914 CVCL_1Y73 HPAM1 spontaneously immortalized cell line human CVCL_1Y73 CL:0000010 Derived from sampling site: Salivary gland; parotid gland; epithelium. Male Doubling time: ~41 hours (PubMed=7713331) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11706 21153915 CVCL_1Y70 S462 cancer cell line human CVCL_1Y70 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous (PubMed=15207265); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=15207265); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Tyr2285Ter (c.6792C>A); ClinVar=VCV000185082; Zygosity=Heterozygous (PubMed=15207265); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (PubMed=21084276) Derived from sampling site: Thigh. Female Doubling time: ~16 hours (PubMed=21084276) 21153916 CVCL_1Y71 1507.2 cancer cell line human CVCL_1Y71 CL:0000010 21153917 CVCL_1Y76 Swiss2 spontaneously immortalized cell line house mouse CVCL_1Y76 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153918 CVCL_1Y77 Swiss20 spontaneously immortalized cell line house mouse CVCL_1Y77 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153919 CVCL_1Y74 JinB8 cancer cell line human CVCL_1Y74 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: CD47-deficient 21153920 CVCL_1Y75 Swiss19 spontaneously immortalized cell line house mouse CVCL_1Y75 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153921 CVCL_1Y78 Swiss22 spontaneously immortalized cell line house mouse CVCL_1Y78 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153922 CVCL_1Y79 Swiss27 spontaneously immortalized cell line house mouse CVCL_1Y79 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21153923 CVCL_1Y49 GM11707 finite cell line human CVCL_1Y49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153924 CVCL_1Y40 GM00203 finite cell line human CVCL_1Y40 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153925 CVCL_1Y43 GM00317 finite cell line human CVCL_1Y43 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21153926 CVCL_1Y44 GM02094 finite cell line human CVCL_1Y44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153927 CVCL_1Y41 GM00204 finite cell line human CVCL_1Y41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21153928 CVCL_1Y42 GM00294 finite cell line human CVCL_1Y42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21153929 CVCL_1Y47 GM10720 transformed cell line human CVCL_1Y47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153930 CVCL_1Y48 GM11098 finite cell line human CVCL_1Y48 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21153931 CVCL_1Y45 GM10718 transformed cell line human CVCL_1Y45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153932 CVCL_1Y46 GM10719 transformed cell line human CVCL_1Y46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153933 CVCL_1Y50 AG08471 finite cell line human CVCL_1Y50 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Male 21153934 CVCL_1Y51 AG08498 finite cell line human CVCL_1Y51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21153935 CVCL_1Y54 LPC2p cancer cell line human CVCL_1Y54 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153936 CVCL_1Y55 LPC3p cancer cell line human CVCL_1Y55 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu43Ser (c.128T>C); Zygosity=Hemizygous (PubMed=9892110) Derived from sampling site: Pancreas. Omics: Array-based CGH Female 21153937 CVCL_1Y52 GM02144 finite cell line human CVCL_1Y52 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02144; probable Male 21153938 CVCL_1Y53 LPC1p cancer cell line human CVCL_1Y53 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=9892110) Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153939 CVCL_1Y58 LPC6p cancer cell line human CVCL_1Y58 CL:0000010 Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153940 CVCL_1Y59 LPC7m cancer cell line human CVCL_1Y59 CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH Female 21153941 CVCL_1Y56 LPC4p cancer cell line human CVCL_1Y56 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Tyr162fs*3; Zygosity=Hemizygous (PubMed=9892110) Derived from sampling site: Pancreas. Omics: Array-based CGH Male 21153942 CVCL_1Y57 LPC5m cancer cell line human CVCL_1Y57 CL:0000010 Derived from metastatic site: Not specified. Omics: Array-based CGH Female 21153943 CVCL_LH10 CG1634 finite cell line human CVCL_LH10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153944 CVCL_LH11 CG1635 finite cell line human CVCL_LH11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153945 CVCL_CN79 ND14514 transformed cell line human CVCL_CN79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153946 CVCL_CN73 ND14469 transformed cell line human CVCL_CN73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153947 CVCL_CN74 ND14470 transformed cell line human CVCL_CN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153948 CVCL_CN71 ND14466 transformed cell line human CVCL_CN71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153949 CVCL_CN72 ND14468 transformed cell line human CVCL_CN72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153950 CVCL_CN77 ND14505 transformed cell line human CVCL_CN77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153951 CVCL_CN78 ND14506 transformed cell line human CVCL_CN78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153952 CVCL_LH09 CG1633 finite cell line human CVCL_LH09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153953 CVCL_CN75 ND14471 transformed cell line human CVCL_CN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153954 CVCL_CN76 ND14493 transformed cell line human CVCL_CN76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153955 CVCL_LH07 CG1631 finite cell line human CVCL_LH07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153956 CVCL_LH08 CG1632 finite cell line human CVCL_LH08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153957 CVCL_LH05 CG1629 finite cell line human CVCL_LH05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21153958 CVCL_LH06 CG1630 finite cell line human CVCL_LH06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153959 CVCL_LH03 CG1609 transformed cell line human CVCL_LH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153960 CVCL_LH04 CG1610 transformed cell line human CVCL_LH04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153961 CVCL_CN70 ND14461 transformed cell line human CVCL_CN70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153962 CVCL_LH01 CG1576 transformed cell line human CVCL_LH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153963 CVCL_LH02 CG1599 transformed cell line human CVCL_LH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153964 CVCL_LH21 CG1680 transformed cell line human CVCL_LH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153965 CVCL_LH22 GM26075 transformed cell line human CVCL_LH22 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; c.1182_1197delAGGTGATGTTTGGGTC; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153966 CVCL_LH20 CG1672 transformed cell line human CVCL_LH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153967 CVCL_CN84 ND14535 transformed cell line human CVCL_CN84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153968 CVCL_CN85 ND14536 transformed cell line human CVCL_CN85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153969 CVCL_CN82 ND14521 transformed cell line human CVCL_CN82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153970 CVCL_CN83 ND14532 transformed cell line human CVCL_CN83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153971 CVCL_CN88 ND14552 transformed cell line human CVCL_CN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153972 CVCL_CN89 ND14553 transformed cell line human CVCL_CN89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153973 CVCL_CN86 ND14538 transformed cell line human CVCL_CN86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153974 CVCL_CN87 ND14551 transformed cell line human CVCL_CN87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153975 CVCL_LH18 CG1647 transformed cell line human CVCL_LH18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153976 CVCL_LH19 CG1669 transformed cell line human CVCL_LH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153977 CVCL_LH16 CG1645 transformed cell line human CVCL_LH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153978 CVCL_LH17 CG1646 transformed cell line human CVCL_LH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153979 CVCL_LH14 CG1639 finite cell line human CVCL_LH14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153980 CVCL_CN80 ND14515 transformed cell line human CVCL_CN80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153981 CVCL_LH15 CG1640 finite cell line human CVCL_LH15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153982 CVCL_CN81 ND14520 transformed cell line human CVCL_CN81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153983 CVCL_LH12 CG1637 finite cell line human CVCL_LH12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153984 CVCL_LH13 CG1638 finite cell line human CVCL_LH13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21153985 CVCL_CN59 ND14323 transformed cell line human CVCL_CN59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153986 CVCL_CN57 ND14317 transformed cell line human CVCL_CN57 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153987 CVCL_CN58 ND14322 transformed cell line human CVCL_CN58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153988 CVCL_CN51 ND14212 transformed cell line human CVCL_CN51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153989 CVCL_CN52 ND14227 transformed cell line human CVCL_CN52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153990 CVCL_CN50 ND14211 transformed cell line human CVCL_CN50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153991 CVCL_CN55 ND14287 transformed cell line human CVCL_CN55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153992 CVCL_CN56 ND14312 transformed cell line human CVCL_CN56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153993 CVCL_CN53 ND14234 transformed cell line human CVCL_CN53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153994 CVCL_CN54 ND14286 transformed cell line human CVCL_CN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153995 CVCL_LH00 CG1550 transformed cell line human CVCL_LH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21153996 CVCL_CN68 ND14457 transformed cell line human CVCL_CN68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153997 CVCL_CN69 ND14458 transformed cell line human CVCL_CN69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153998 CVCL_CN62 ND14330 transformed cell line human CVCL_CN62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21153999 CVCL_CN63 ND14362 transformed cell line human CVCL_CN63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154000 CVCL_CN60 ND14324 transformed cell line human CVCL_CN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154001 CVCL_CN61 ND14329 transformed cell line human CVCL_CN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154002 CVCL_CN66 ND14375 transformed cell line human CVCL_CN66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154003 CVCL_CN67 ND14421 transformed cell line human CVCL_CN67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154004 CVCL_CN64 ND14363 transformed cell line human CVCL_CN64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154005 CVCL_CN65 ND14374 transformed cell line human CVCL_CN65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154006 CVCL_CN37 ND14152 transformed cell line human CVCL_CN37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154007 CVCL_CN38 ND14153 transformed cell line human CVCL_CN38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154008 CVCL_CN35 ND14143 transformed cell line human CVCL_CN35 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154009 CVCL_CN36 ND14148 transformed cell line human CVCL_CN36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154010 CVCL_CN39 ND14155 transformed cell line human CVCL_CN39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154011 CVCL_CN30 ND14074 transformed cell line human CVCL_CN30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154012 CVCL_CN33 ND14114 transformed cell line human CVCL_CN33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154013 CVCL_CN34 ND14115 transformed cell line human CVCL_CN34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154014 CVCL_CN31 ND14092 transformed cell line human CVCL_CN31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154015 CVCL_CN32 ND14113 transformed cell line human CVCL_CN32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154016 CVCL_CN48 ND14206 transformed cell line human CVCL_CN48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154017 CVCL_CN49 ND14207 transformed cell line human CVCL_CN49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154018 CVCL_CN46 ND14170 transformed cell line human CVCL_CN46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154019 CVCL_CN47 ND14192 transformed cell line human CVCL_CN47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154020 CVCL_CN40 ND14162 transformed cell line human CVCL_CN40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154021 CVCL_CN41 ND14163 transformed cell line human CVCL_CN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154022 CVCL_CN44 ND14168 transformed cell line human CVCL_CN44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154023 CVCL_CN45 ND14169 transformed cell line human CVCL_CN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154024 CVCL_CN42 ND14166 transformed cell line human CVCL_CN42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154025 CVCL_CN43 ND14167 transformed cell line human CVCL_CN43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154026 CVCL_CN15 ND13948 transformed cell line human CVCL_CN15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154027 CVCL_CN16 ND13949 transformed cell line human CVCL_CN16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154028 CVCL_CN13 ND13946 transformed cell line human CVCL_CN13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154029 CVCL_CN14 ND13947 transformed cell line human CVCL_CN14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154030 CVCL_CN19 ND13989 transformed cell line human CVCL_CN19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154031 CVCL_CN17 ND13950 transformed cell line human CVCL_CN17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154032 CVCL_CN18 ND13983 transformed cell line human CVCL_CN18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154033 CVCL_CN11 ND13910 transformed cell line human CVCL_CN11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154034 CVCL_CN12 ND13911 transformed cell line human CVCL_CN12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154035 CVCL_CN10 ND13906 transformed cell line human CVCL_CN10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154036 CVCL_CN26 ND14044 transformed cell line human CVCL_CN26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154037 CVCL_CN27 ND14050 transformed cell line human CVCL_CN27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154038 CVCL_CN24 ND14038 transformed cell line human CVCL_CN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154039 CVCL_CN25 ND14043 transformed cell line human CVCL_CN25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154040 CVCL_CN28 ND14060 transformed cell line human CVCL_CN28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154041 CVCL_CN29 ND14066 transformed cell line human CVCL_CN29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154042 CVCL_CN22 ND13998 transformed cell line human CVCL_CN22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154043 CVCL_CN23 ND13999 transformed cell line human CVCL_CN23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154044 CVCL_CN20 ND13991 transformed cell line human CVCL_CN20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154045 CVCL_CN21 ND13997 transformed cell line human CVCL_CN21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154046 CVCL_LH98 RPMI-7841 transformed cell line human CVCL_LH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154047 CVCL_LH99 rBSCB-1 conditionally immortalized cell line Norway rat CVCL_LH99 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Spinal cord; microvascular endothelium; Breed/subspecies: Wistar. Male 21154048 CVCL_LH96 RPMI-7281 transformed cell line human CVCL_LH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154049 CVCL_LH97 RPMI-7881 transformed cell line human CVCL_LH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Peripheral blood. Male 21154050 CVCL_LH94 RPMI-7921 transformed cell line human CVCL_LH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from melanoma; Derived from sampling site: Peripheral blood. Male 21154051 CVCL_LH95 RPMI-7851 transformed cell line human CVCL_LH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from melanoma; Derived from sampling site: Peripheral blood. Male 21154052 CVCL_LH92 RPMI-7481 transformed cell line human CVCL_LH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154053 CVCL_LH93 RPMI-7491 transformed cell line human CVCL_LH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21154055 CVCL_LH91 RPMI-7711 transformed cell line human CVCL_LH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154056 CVCL_UB31 MCW081i-U7128 induced pluripotent stem cell human CVCL_UB31 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154057 CVCL_UB32 MCW082i-U2052 induced pluripotent stem cell human CVCL_UB32 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154058 CVCL_UB30 MCW080i-U2236 induced pluripotent stem cell human CVCL_UB30 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154059 CVCL_UB35 MCW085i-40002118 induced pluripotent stem cell human CVCL_UB35 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154060 CVCL_UB36 MCW086i-40000176 induced pluripotent stem cell human CVCL_UB36 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154061 CVCL_UB33 MCW083i-40000695 induced pluripotent stem cell human CVCL_UB33 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154062 CVCL_UB34 MCW084i-U2053 induced pluripotent stem cell human CVCL_UB34 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154063 CVCL_UB39 MCW090i-40000374 induced pluripotent stem cell human CVCL_UB39 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154064 CVCL_UB37 MCW088i-40000442 induced pluripotent stem cell human CVCL_UB37 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154065 CVCL_UB38 MCW089i-40000312 induced pluripotent stem cell human CVCL_UB38 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154066 CVCL_LH89 RPMI-M7041 cancer cell line human CVCL_LH89 CL:0000010 Male 21154067 CVCL_UB20 MCW069i-40000268 induced pluripotent stem cell human CVCL_UB20 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154068 CVCL_UB21 MCW070i-40002330 induced pluripotent stem cell human CVCL_UB21 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154069 CVCL_UB24 MCW073i-40000527 induced pluripotent stem cell human CVCL_UB24 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154070 CVCL_UB25 MCW074i-40002460 induced pluripotent stem cell human CVCL_UB25 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154071 CVCL_UB22 MCW071i-U2177 induced pluripotent stem cell human CVCL_UB22 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154072 CVCL_UB23 MCW072i-40001708 induced pluripotent stem cell human CVCL_UB23 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154073 CVCL_UB28 MCW077i-40001579 induced pluripotent stem cell human CVCL_UB28 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154074 CVCL_UB29 MCW078i-40000978 induced pluripotent stem cell human CVCL_UB29 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154075 CVCL_UB26 MCW075i-U2096 induced pluripotent stem cell human CVCL_UB26 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154076 CVCL_UB27 MCW076i-U2129 induced pluripotent stem cell human CVCL_UB27 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154077 CVCL_LH76 SPIBL-II cancer cell line human CVCL_LH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male 21154078 CVCL_LH77 SPIBL-III cancer cell line human CVCL_LH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male 21154079 CVCL_LH74 PBL-1 cancer cell line human CVCL_LH74 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Characteristics: IL6 dependent 21154080 CVCL_LH75 SPIBL-I cancer cell line human CVCL_LH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21154081 CVCL_LH72 CHO-K1 tsTM3 transformed cell line CVCL_LH72 CL:0000010 Sequence variation: Mutation; UniProtKB; G3IBG3; Uba1; Simple; p.Met256Ile (c.768G>A); Zygosity=Unspecified (PubMed=24805847) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature sensitive Exhibits chromosomal instability and cell-cycle arrest at S and G2 phases with decreased DNA synthesis at the non-permissive temperature of 39 Celsius. 21154082 CVCL_LH73 CHO-K1 tsTM13 transformed cell line CVCL_LH73 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female Characteristics: Temperature sensitive Exhibits a delayed cell cycle progression from metaphase to telophase at a non-permissive temperature of 39 Celsius and is finally arrested from anaphase to telophase. 21154083 CVCL_LH70 AR52A301.5 hybridoma house mouse CVCL_LH70 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 141205-03 21154084 CVCL_LH71 ts422E transformed cell line CVCL_LH71 CL:0000010 Transformant: 5-fluoro-2'-deoxyuridine (FUdR)(ChEBI; CHEBI:60761); Derived from sampling site: Kidney. Male Characteristics: Temperature sensitive Loses the ability to synthesize polyamines and 5.8s rRNA at the non-permissive temperature (39 Celsius). Doubling time: 16 hours, at 33 Celsius (PubMed=4515626) 21154085 CVCL_UB10 MCW059i-40001067 induced pluripotent stem cell human CVCL_UB10 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154086 CVCL_UB13 MCW062i-U2157 induced pluripotent stem cell human CVCL_UB13 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154087 CVCL_UB14 MCW063i-40000190 induced pluripotent stem cell human CVCL_UB14 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154088 CVCL_UB11 MCW060i-U2183 induced pluripotent stem cell human CVCL_UB11 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154089 CVCL_UB12 MCW061i-40000329 induced pluripotent stem cell human CVCL_UB12 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154090 CVCL_UB17 MCW066i-U2368 induced pluripotent stem cell human CVCL_UB17 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154091 CVCL_UB18 MCW067i-40001036 induced pluripotent stem cell human CVCL_UB18 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154092 CVCL_UB15 MCW064i-40001159 induced pluripotent stem cell human CVCL_UB15 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154093 CVCL_UB16 MCW065i-40001296 induced pluripotent stem cell human CVCL_UB16 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154094 CVCL_UB19 MCW068i-40002385 induced pluripotent stem cell human CVCL_UB19 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154095 CVCL_LH69 AR47A6.4.2 hybridoma house mouse CVCL_LH69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, IDA of Canada (IDAC); 141205-05 21154096 CVCL_LH67 2G10 [Mouse hybridoma against human TACSTD2] hybridoma house mouse CVCL_LH67 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 08020 21154097 CVCL_LH68 2EF hybridoma house mouse CVCL_LH68 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 08021 21154098 CVCL_LH87 RPMI-7821 cancer cell line human CVCL_LH87 CL:0000010 Male Doubling time: 42 hours (PubMed=1161259). 21154099 CVCL_LH88 RPMI-8312 cancer cell line human CVCL_LH88 CL:0000010 Unspecified Doubling time: 74 hours (PubMed=1161259). 21154100 CVCL_LH85 RPMI-7031 cancer cell line human CVCL_LH85 CL:0000010 Unspecified Doubling time: 64 hours (PubMed=1161259). 21154101 CVCL_LH86 RPMI-7449 cancer cell line human CVCL_LH86 CL:0000010 Unspecified Doubling time: 58 hours (PubMed=1161259). 21154102 CVCL_LH83 RPMI-6642 cancer cell line human CVCL_LH83 CL:0000010 Unspecified Doubling time: 56 hours (PubMed=1161259). 21154103 CVCL_LH84 RPMI-6738 cancer cell line human CVCL_LH84 CL:0000010 Unspecified Characteristics: Pigmented Doubling time: 120 hours (PubMed=1161259). 21154104 CVCL_LH81 RPMI-4767 cancer cell line human CVCL_LH81 CL:0000010 Unspecified Doubling time: 72 hours (PubMed=1161259). 21154105 CVCL_LH82 RPMI-5615 cancer cell line human CVCL_LH82 CL:0000010 Unspecified Doubling time: 76 hours (PubMed=1161259). 21154106 CVCL_LH80 KY-3 cancer cell line human CVCL_LH80 CL:0000010 Population: Japanese; Derived from sampling site: Cervical lymph node. Female Virology: EBV-negative 21154107 CVCL_UB02 MCW051i-40001166 induced pluripotent stem cell human CVCL_UB02 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154108 CVCL_UB03 MCW052i-40001760 induced pluripotent stem cell human CVCL_UB03 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154109 CVCL_UB00 MCW049i-40001630 induced pluripotent stem cell human CVCL_UB00 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154110 CVCL_UB01 MCW050i-40000626 induced pluripotent stem cell human CVCL_UB01 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154111 CVCL_UB06 MCW055i-U2054 induced pluripotent stem cell human CVCL_UB06 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154112 CVCL_UB07 MCW056i-U7076 induced pluripotent stem cell human CVCL_UB07 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154113 CVCL_UB04 MCW053i-U2213 induced pluripotent stem cell human CVCL_UB04 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154114 CVCL_UB05 MCW054i-U2073 induced pluripotent stem cell human CVCL_UB05 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154115 CVCL_UB08 MCW057i-A3286 induced pluripotent stem cell human CVCL_UB08 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154116 CVCL_UB09 MCW058i-U2082 induced pluripotent stem cell human CVCL_UB09 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154117 CVCL_LH78 KY-1 cancer cell line human CVCL_LH78 CL:0000010 Population: Japanese; Derived from sampling site: Cervical lymph node. Female Virology: EBV-negative 21154118 CVCL_LH79 KY-2 cancer cell line human CVCL_LH79 CL:0000010 Population: Japanese; Derived from sampling site: Cervical lymph node. Female Virology: EBV-negative 21154119 CVCL_LH54 DT40-ATM(-/-)-RAD5L(-/-) hRad54 cancer cell line CVCL_LH54 CL:0000010 Knockout cell: Method=Targeted integration; ATM+RAD54L; Transfected with: HGNC; 9826; RAD54L Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21154120 CVCL_LH55 CHO-hAANAT spontaneously immortalized cell line CVCL_LH55 CL:0000010 Transfected with: HGNC; 19; AANAT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21154121 CVCL_LH52 K-562-B1-V-2 p17 cancer cell line human CVCL_LH52 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21154122 CVCL_LH53 TSM15 conditionally immortalized cell line human CVCL_LH53 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Right biceps brachis Cell type=Microvascular endothelial cell.. Female Characteristics: Exhibits a robust proliferation at the permissive temperature of 33 Celsius One day after the temperature shift from 33 to 37 Celsius, the cell growth is arrested. Doubling time: ~4 days (PubMed=28063233) 21154123 CVCL_LH50 K-562-RH cancer cell line human CVCL_LH50 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21154124 CVCL_LH51 K-562-C-1 p365 cancer cell line human CVCL_LH51 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21154125 CVCL_LH49 Css-12 hybridoma house mouse CVCL_LH49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18998; Crotalus scutulatus scutulatus Mojave toxin acidic chain (Note=Also reacts with other Crotalus species); Monoclonal antibody target: UniProtKB; P62023; Crotalus scutulatus scutulatus Mojave toxin basic chain (Note=Also reacts with other Crotalus species). Group: Animal toxin research hybridoma; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9165 21154126 CVCL_LH47 Jurkat 1F2 cancer cell line human CVCL_LH47 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 6001; IL2; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: One of the two IL2 alleles was inactived by CRISPR/Cas9 and a luciferase reporter gene was inserted in the loci thus expressing the luciferase reporter gene under the control of endogenous IL2 promoter 21154127 CVCL_LH48 Jurkat 1F2-hGITR cancer cell line human CVCL_LH48 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 6001; IL2; Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11914; TNFRSF18; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: One of the two IL2 alleles was inactived by CRISPR/Cas9 and a luciferase reporter gene was inserted in the loci thus expressing the luciferase gene under the control of endogenous IL2 promoter 21154128 CVCL_LH45 12H4.11.3 hybridoma house mouse CVCL_LH45 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6034 21154129 CVCL_LH46 38B8 hybridoma house mouse CVCL_LH46 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16620; Human NTRK2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8766 21154130 CVCL_LH65 LK24 hybridoma house mouse CVCL_LH65 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human choriocarcinoma/breast tumor cell antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8769 21154131 CVCL_LH66 4F6 [Mouse hybridoma against human TACSTD2] hybridoma house mouse CVCL_LH66 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 08019 21154132 CVCL_LH63 SV19 hybridoma house mouse CVCL_LH63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human choriocarcinoma tumor cell 40 kDa glycoprotein antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8557 21154133 CVCL_LH64 K8 [Mouse hybridoma] hybridoma house mouse CVCL_LH64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human choriocarcinoma tumor cell 68 kDa glycoprotein antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8765 21154134 CVCL_LH61 MOv19 hybridoma house mouse CVCL_LH61 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 21154135 CVCL_LH62 LK26 hybridoma house mouse CVCL_LH62 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized MORAb-003 (Farletuzumab) therapeutic antibody Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8764 21154136 CVCL_LH60 MOv18 hybridoma house mouse CVCL_LH60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15328; Human FOLR1. 21154137 CVCL_LH58 COS-7 1E7 transformed cell line CVCL_LH58 CL:0000010 Transfected with: HGNC; 19; AANAT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21154138 CVCL_LH59 MOv16 hybridoma house mouse CVCL_LH59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. 21154139 CVCL_LH56 tsAF8 transformed cell line CVCL_LH56 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A1U8BM24; Polr2a; Simple; p.Ala315Asp (c.944C>A); Zygosity=Heterozygous (PubMed=11674999) Transformant: 5-fluoro-2'-deoxyuridine (FUdR)(ChEBI; CHEBI:60761); Derived from sampling site: Kidney. Male Characteristics: Temperature sensitive Arrests at the non-permissive temperature (40.6 Celsius) in the mid-G1 phase and is deficient in RNA polymerase II activity. Doubling time: ~18 hours, at 33 Celsius (PubMed=4373487) 21154140 CVCL_LH57 TY10 conditionally immortalized cell line human CVCL_LH57 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; microvascular endothelium. Unspecified 21154141 CVCL_LH32 GM26251 transformed cell line human CVCL_LH32 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154142 CVCL_LH33 GM26579 finite cell line human CVCL_LH33 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Flank; skin Cell type=Fibroblast.. Male 21154143 CVCL_LH30 GM26249 transformed cell line human CVCL_LH30 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154144 CVCL_LH31 GM26250 transformed cell line human CVCL_LH31 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154145 CVCL_CN95 ND14583 transformed cell line human CVCL_CN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154146 CVCL_CN96 ND14584 transformed cell line human CVCL_CN96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154147 CVCL_CN93 ND14581 transformed cell line human CVCL_CN93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154148 CVCL_CN94 ND14582 transformed cell line human CVCL_CN94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154149 CVCL_CN99 ND14598 transformed cell line human CVCL_CN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154150 CVCL_CN97 ND14585 transformed cell line human CVCL_CN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154151 CVCL_CN98 ND14586 transformed cell line human CVCL_CN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154152 CVCL_LH29 GM26100 transformed cell line human CVCL_LH29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154153 CVCL_LH27 GM26098 finite cell line human CVCL_LH27 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154154 CVCL_LH28 GM26099 transformed cell line human CVCL_LH28 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with inclusion myopathy but possess the mutation affecting his brother, mother and uncle; Derived from sampling site: Peripheral blood. Male 21154155 CVCL_LH25 GM26096 finite cell line human CVCL_LH25 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154156 CVCL_CN91 ND14579 transformed cell line human CVCL_CN91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154157 CVCL_LH26 GM26097 transformed cell line human CVCL_LH26 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154158 CVCL_CN92 ND14580 transformed cell line human CVCL_CN92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154159 CVCL_LH23 GM26076 transformed cell line human CVCL_LH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154160 CVCL_LH24 GM26095 transformed cell line human CVCL_LH24 CL:0000010 Sequence variation: Mutation; HGNC; 30171; HSPB8; Simple; p.Pro173Serfs*43 (c.515dupC); ClinVar=VCV000986227; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154161 CVCL_CN90 ND14578 transformed cell line human CVCL_CN90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154162 CVCL_LH43 9D6.11.15 hybridoma house mouse CVCL_LH43 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6032 21154163 CVCL_LH44 10G10.15.16 hybridoma house mouse CVCL_LH44 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6033 21154164 CVCL_LH41 5A8.11.6 hybridoma house mouse CVCL_LH41 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6030 21154165 CVCL_LH42 5F2.6.14 hybridoma house mouse CVCL_LH42 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6031 21154166 CVCL_LH40 4A9.12.12 hybridoma house mouse CVCL_LH40 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6029 21154167 CVCL_LH38 3F10.11.2 hybridoma house mouse CVCL_LH38 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6027 21154168 CVCL_LH39 3H1.4.8 hybridoma house mouse CVCL_LH39 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6028 21154169 CVCL_LH36 CG0468 transformed cell line human CVCL_LH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154170 CVCL_LH37 3E7.9.20 hybridoma house mouse CVCL_LH37 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8NFU4; Human FDCSP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6026 21154171 CVCL_LH34 GM26636 finite cell line human CVCL_LH34 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Homozygous (PubMed=35700637) Population: Jewish; Ashkenazi; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21154172 CVCL_LH35 GM15879 transformed cell line human CVCL_LH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154173 CVCL_1Z48 HGALBV074 transformed cell line human CVCL_1Z48 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154174 CVCL_1Z49 HGMLBV076 transformed cell line human CVCL_1Z49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154175 CVCL_UA90 MCW039i-40000473 induced pluripotent stem cell human CVCL_UA90 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154176 CVCL_UA91 MCW040i-40001098 induced pluripotent stem cell human CVCL_UA91 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154177 CVCL_UA94 MCW043i-U2326 induced pluripotent stem cell human CVCL_UA94 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154178 CVCL_UA95 MCW044i-U2448 induced pluripotent stem cell human CVCL_UA95 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154179 CVCL_UA92 MCW041i-U2104 induced pluripotent stem cell human CVCL_UA92 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154180 CVCL_UA93 MCW042i-40001401 induced pluripotent stem cell human CVCL_UA93 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154181 CVCL_UA98 MCW047i-U2234 induced pluripotent stem cell human CVCL_UA98 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154182 CVCL_UA99 MCW048i-40001845 induced pluripotent stem cell human CVCL_UA99 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154183 CVCL_UA96 MCW045i-U2033 induced pluripotent stem cell human CVCL_UA96 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154184 CVCL_UA97 MCW046i-U2346 induced pluripotent stem cell human CVCL_UA97 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154185 CVCL_1Z42 HGMLBV065 transformed cell line human CVCL_1Z42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154186 CVCL_1Z43 HGALBV057 transformed cell line human CVCL_1Z43 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF; PubMed=12714972) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154187 CVCL_1Z40 HGFLBV042 transformed cell line human CVCL_1Z40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154188 CVCL_1Z41 HGALBV055 transformed cell line human CVCL_1Z41 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154189 CVCL_1Z46 HGALBV071 transformed cell line human CVCL_1Z46 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF; PubMed=12714972) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154190 CVCL_1Z47 HGALBV073 transformed cell line human CVCL_1Z47 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154191 CVCL_1Z44 HGMLBV066 transformed cell line human CVCL_1Z44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154192 CVCL_1Z45 HGFLBV067 transformed cell line human CVCL_1Z45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154193 CVCL_1Z59 HGFLBV134 transformed cell line human CVCL_1Z59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154194 CVCL_UA80 MCW029i-A2757 induced pluripotent stem cell human CVCL_UA80 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154195 CVCL_UA83 MCW032i-A7214 induced pluripotent stem cell human CVCL_UA83 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154196 CVCL_UA84 MCW033i-A7195 induced pluripotent stem cell human CVCL_UA84 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154197 CVCL_UA81 MCW030i-A2688 induced pluripotent stem cell human CVCL_UA81 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154198 CVCL_UA82 MCW031i-A3202 induced pluripotent stem cell human CVCL_UA82 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154199 CVCL_UA87 MCW036i-A3170 induced pluripotent stem cell human CVCL_UA87 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154200 CVCL_UA88 MCW037i-50000777 induced pluripotent stem cell human CVCL_UA88 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154201 CVCL_UA85 MCW034i-A2780 induced pluripotent stem cell human CVCL_UA85 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154202 CVCL_UA86 MCW035i-A3267 induced pluripotent stem cell human CVCL_UA86 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154203 CVCL_UA89 MCW038i-40000503 induced pluripotent stem cell human CVCL_UA89 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154204 CVCL_1Z50 HGSLBV075 transformed cell line human CVCL_1Z50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154205 CVCL_1Z53 HGMLBV098 transformed cell line human CVCL_1Z53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154206 CVCL_1Z54 HGFLBV099 transformed cell line human CVCL_1Z54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154207 CVCL_1Z51 HGSLBV077 transformed cell line human CVCL_1Z51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154208 CVCL_1Z52 HGALBV097 transformed cell line human CVCL_1Z52 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154209 CVCL_1Z57 HGALBV132 transformed cell line human CVCL_1Z57 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154210 CVCL_1Z58 HGMLBV133 transformed cell line human CVCL_1Z58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154211 CVCL_1Z55 HGALBV110 transformed cell line human CVCL_1Z55 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154212 CVCL_1Z56 HGALBV113 transformed cell line human CVCL_1Z56 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154213 CVCL_1Z28 HGALBV009 transformed cell line human CVCL_1Z28 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF; PubMed=12714972) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154214 CVCL_1Z29 HGMLBV010 transformed cell line human CVCL_1Z29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154215 CVCL_1Z26 PSADFN414 finite cell line human CVCL_1Z26 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Cys588Arg (c.1762T>C); ClinVar=VCV000066865; Zygosity=Heterozygous (PRF) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154216 CVCL_1Z27 PSADFN425 finite cell line human CVCL_1Z27 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu111Lys (c.331G>A); Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154217 CVCL_UA72 MCW021i-50001743 induced pluripotent stem cell human CVCL_UA72 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154218 CVCL_UA73 MCW022i-A2965 induced pluripotent stem cell human CVCL_UA73 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154219 CVCL_UA70 MCW019i-A7230 induced pluripotent stem cell human CVCL_UA70 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154220 CVCL_UA71 MCW020i-A2023 induced pluripotent stem cell human CVCL_UA71 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154221 CVCL_UA76 MCW025i-A2566 induced pluripotent stem cell human CVCL_UA76 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154222 CVCL_UA77 MCW026i-50000685 induced pluripotent stem cell human CVCL_UA77 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154223 CVCL_UA74 MCW023i-A2121 induced pluripotent stem cell human CVCL_UA74 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154224 CVCL_UA75 MCW024i-A3263 induced pluripotent stem cell human CVCL_UA75 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154225 CVCL_UA78 MCW027i-50000784 induced pluripotent stem cell human CVCL_UA78 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154226 CVCL_UA79 MCW028i-A7312 induced pluripotent stem cell human CVCL_UA79 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154227 CVCL_1Z20 PSMDFN375 finite cell line human CVCL_1Z20 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154228 CVCL_1Z21 PSFDFN376 finite cell line human CVCL_1Z21 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154229 CVCL_1Z24 PSFDFN394 finite cell line human CVCL_1Z24 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154230 CVCL_1Z25 PSADFN412 finite cell line human CVCL_1Z25 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Cys588Arg (c.1762T>C); ClinVar=VCV000066865; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154231 CVCL_1Z22 PSADFN392 finite cell line human CVCL_1Z22 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+2T>C; ClinVar=VCV000162415; Zygosity=Unspecified; Note=Splice donor mutation (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154232 CVCL_1Z23 PSMDFN393 finite cell line human CVCL_1Z23 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154233 CVCL_1Z39 HGMLBV041 transformed cell line human CVCL_1Z39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154234 CVCL_1Z37 HGALBV039 transformed cell line human CVCL_1Z37 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154235 CVCL_1Z38 HGALBV040 transformed cell line human CVCL_1Z38 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154236 CVCL_UA61 MCW010i-40000756 induced pluripotent stem cell human CVCL_UA61 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154237 CVCL_UA62 MCW011i-40000664 induced pluripotent stem cell human CVCL_UA62 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154238 CVCL_UA60 MCW009i-40002262 induced pluripotent stem cell human CVCL_UA60 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154239 CVCL_UA65 MCW014i-50000395 induced pluripotent stem cell human CVCL_UA65 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154240 CVCL_UA66 MCW015i-A2196 induced pluripotent stem cell human CVCL_UA66 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154241 CVCL_UA63 MCW012i-A7156 induced pluripotent stem cell human CVCL_UA63 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154242 CVCL_UA64 MCW013i-A2767 induced pluripotent stem cell human CVCL_UA64 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154243 CVCL_UA69 MCW018i-A2868 induced pluripotent stem cell human CVCL_UA69 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154244 CVCL_UA67 MCW016i-A2159 induced pluripotent stem cell human CVCL_UA67 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154245 CVCL_UA68 MCW017i-A2106 induced pluripotent stem cell human CVCL_UA68 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154246 CVCL_1Z31 HGALBV011 transformed cell line human CVCL_1Z31 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF; PubMed=12714972) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154247 CVCL_1Z32 HGMLBV023 transformed cell line human CVCL_1Z32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154248 CVCL_1Z30 HGFLBV021 transformed cell line human CVCL_1Z30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154249 CVCL_1Z35 HGMLBV017 transformed cell line human CVCL_1Z35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154250 CVCL_1Z36 HGSLBV019 transformed cell line human CVCL_1Z36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154251 CVCL_1Z33 HGFLBV031 transformed cell line human CVCL_1Z33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154252 CVCL_1Z34 HGALBV016 transformed cell line human CVCL_1Z34 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154253 CVCL_1Z06 PSADFN257 finite cell line human CVCL_1Z06 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Met540Thr (c.1619T>C); ClinVar=VCV000066858; Zygosity=Homozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154254 CVCL_1Z07 PSADFN325 finite cell line human CVCL_1Z07 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+5G>C; ClinVar=VCV000162416; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154255 CVCL_1Z04 HGFDFN372 finite cell line human CVCL_1Z04 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154256 CVCL_1Z05 PSADFN086 finite cell line human CVCL_1Z05 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+1G>A; ClinVar=VCV000066879; Zygosity=Unspecified; Note=Splice donor mutation (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154257 CVCL_1Z08 PSMDFN326 finite cell line human CVCL_1Z08 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154258 CVCL_1Z09 PSFDFN327 finite cell line human CVCL_1Z09 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154259 CVCL_UA50 WC035i-SOD1-D90D induced pluripotent stem cell human CVCL_UA50 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple_corrected; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Heterozygous; Note=By TALEN (PubMed=24704493) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154260 CVCL_UA51 WC024i-FXS-Nluc1 induced pluripotent stem cell human CVCL_UA51 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>435]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27422057); Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: CRISPR/Cas9-mediated knock-in of a P2A-NanoLuc construct at the C-terminal end of FMR1; Characteristics: Reporter cell line to detect FMR1 gene reactivation in human neural cells and can be a valuable resource to identify novel compounds for FMR1 gene reactivation studies (WiCell) 21154261 CVCL_UA54 MCW003i-40001883 induced pluripotent stem cell human CVCL_UA54 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154262 CVCL_UA55 MCW004i-40002545 induced pluripotent stem cell human CVCL_UA55 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154263 CVCL_UA52 MCW001i-40001487 induced pluripotent stem cell human CVCL_UA52 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154264 CVCL_UA53 MCW002i-40001265 induced pluripotent stem cell human CVCL_UA53 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154265 CVCL_UA58 MCW007i-U2456 induced pluripotent stem cell human CVCL_UA58 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154266 CVCL_UA59 MCW008i-40000992 induced pluripotent stem cell human CVCL_UA59 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154267 CVCL_UA56 MCW005i-40002552 induced pluripotent stem cell human CVCL_UA56 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154268 CVCL_UA57 MCW006i-40000930 induced pluripotent stem cell human CVCL_UA57 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154269 CVCL_1Z02 HGADFN370 finite cell line human CVCL_1Z02 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154270 CVCL_1Z03 HGMDFN371 finite cell line human CVCL_1Z03 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154271 CVCL_1Z00 HGMDFN368 finite cell line human CVCL_1Z00 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154272 CVCL_1Z01 HGFDFN369 finite cell line human CVCL_1Z01 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154273 CVCL_1Z17 PSFDFN319 finite cell line human CVCL_1Z17 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154274 CVCL_1Z18 PSMDFN320 finite cell line human CVCL_1Z18 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154275 CVCL_1Z15 PSADFN317 finite cell line human CVCL_1Z15 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Pro248Leu (c.743C>T); ClinVar=VCV000004275; Zygosity=Heterozygous (PRF); Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Trp450Ter (c.1349G>A); ClinVar=VCV000030586; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154276 CVCL_1Z16 PSADFN318 finite cell line human CVCL_1Z16 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Pro248Leu (c.743C>T); ClinVar=VCV000004275; Zygosity=Heterozygous (PRF); Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Trp450Ter (c.1349G>A); ClinVar=VCV000030586; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154277 CVCL_1Z19 PSADFN373 finite cell line human CVCL_1Z19 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Homozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154278 CVCL_UA40 JFHZ4 induced pluripotent stem cell human CVCL_UA40 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154279 CVCL_UA43 JFMD6 induced pluripotent stem cell human CVCL_UA43 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Asp295Glyfs*45 (c.879_883dupGACAG); Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Unexplicit; Ex52del; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21154280 CVCL_UA44 JFNY2 induced pluripotent stem cell human CVCL_UA44 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser1173Phefs*2 (c.3517dupT) (p.Ser1191Phefs*2, c.3571dupT); ClinVar=VCV000370730; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154281 CVCL_UA41 JFHZ5 induced pluripotent stem cell human CVCL_UA41 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154282 CVCL_UA42 JFHZ6 induced pluripotent stem cell human CVCL_UA42 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154283 CVCL_UA47 JFRBi5 induced pluripotent stem cell human CVCL_UA47 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21154284 CVCL_UA48 JHU006i-1 induced pluripotent stem cell human CVCL_UA48 From: Becker L.; Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154285 CVCL_UA45 JFNY3 induced pluripotent stem cell human CVCL_UA45 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser1173Phefs*2 (c.3517dupT) (p.Ser1191Phefs*2, c.3571dupT); ClinVar=VCV000370730; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154286 CVCL_UA46 JFNY4 induced pluripotent stem cell human CVCL_UA46 From: Jain Foundation; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser1173Phefs*2 (c.3517dupT) (p.Ser1191Phefs*2, c.3571dupT); ClinVar=VCV000370730; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg1905Ter (c.5713C>T) (p.Arg1944Ter, c.5830C>T); ClinVar=VCV000006676; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male 21154287 CVCL_UA49 WC034i-SOD1-D90A induced pluripotent stem cell human CVCL_UA49 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Heterozygous (PubMed=24704493) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154288 CVCL_1Z10 PSADFN328 finite cell line human CVCL_1Z10 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Ser (c.1822G>A); ClinVar=VCV000014501; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154289 CVCL_1Z13 PSMDFN364 finite cell line human CVCL_1Z13 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154290 CVCL_1Z14 PSFDFN365 finite cell line human CVCL_1Z14 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154291 CVCL_1Z11 PSMDFN346 finite cell line human CVCL_1Z11 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21154292 CVCL_1Z12 PSADFN363 finite cell line human CVCL_1Z12 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Asp325Asn (c.973G>A); Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21154293 CVCL_LG99 CG1549 transformed cell line human CVCL_LG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154294 CVCL_LG97 CG1539 transformed cell line human CVCL_LG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154295 CVCL_LG98 CG1541 transformed cell line human CVCL_LG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154296 CVCL_LG95 CG1538 transformed cell line human CVCL_LG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154297 CVCL_LG96 CG1533 transformed cell line human CVCL_LG96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154298 CVCL_LG93 CG1486 transformed cell line human CVCL_LG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154299 CVCL_LG94 CG1519 finite cell line human CVCL_LG94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154300 CVCL_LG91 CG1483 transformed cell line human CVCL_LG91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154301 CVCL_LG92 CG1484 transformed cell line human CVCL_LG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154302 CVCL_LG90 CG1480 transformed cell line human CVCL_LG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154303 CVCL_UA32 GLS-1 transformed cell line CVCL_UA32 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Male Group: Reptilian cell line 21154304 CVCL_UA33 Bge 1 spontaneously immortalized cell line CVCL_UA33 CL:0000010 Unspecified Doubling time: 108 hours (PubMed=25907768). Group: Mollusk cell line 21154305 CVCL_UA30 PH-2 [Turtle] spontaneously immortalized cell line CVCL_UA30 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Reptilian cell line 21154306 CVCL_UA31 PH-6 spontaneously immortalized cell line CVCL_UA31 CL:0000010 Derived from sampling site: Heart. Male Group: Reptilian cell line 21154307 CVCL_UA36 Bge isolate UK spontaneously immortalized cell line CVCL_UA36 CL:0000010 Unspecified Doubling time: 40-56 hours (PubMed=25907768). Group: Mollusk cell line 21154308 CVCL_UA37 JFWT4 induced pluripotent stem cell human CVCL_UA37 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21154309 CVCL_UA34 Bge 2 spontaneously immortalized cell line CVCL_UA34 CL:0000010 Unspecified Doubling time: 157 hours (PubMed=25907768). Group: Mollusk cell line 21154310 CVCL_UA35 Bge 3 spontaneously immortalized cell line CVCL_UA35 CL:0000010 Omics: Genome sequenced Discontinued: ATCC; CRL-1494; true. Unspecified Group: Mollusk cell line 21154311 CVCL_UA38 JFWT5 induced pluripotent stem cell human CVCL_UA38 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21154312 CVCL_UA39 JFWT6 induced pluripotent stem cell human CVCL_UA39 From: Jain Foundation; Seattle; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21154313 CVCL_UA21 Ba/F3 EGFR-T790M/C797S/L858R factor-dependent cell line house mouse CVCL_UA21 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr790Met, p.Cys797Ser and p.Leu858Arg); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21154314 CVCL_UA22 Ba/F3 EGFR-T790M/L861Q factor-dependent cell line house mouse CVCL_UA22 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr790Met and p.Leu861Gln); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21154315 CVCL_UA20 Ba/F3 EGFR-T790M/C797S factor-dependent cell line house mouse CVCL_UA20 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Thr790Met and p.Cys797Ser); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21154316 CVCL_UA25 TH-4W spontaneously immortalized cell line CVCL_UA25 CL:0000010 Derived from sampling site: Heart. Female Group: Reptilian cell line 21154317 CVCL_UA26 TH-5 spontaneously immortalized cell line CVCL_UA26 CL:0000010 Derived from sampling site: Heart. Female Group: Reptilian cell line 21154318 CVCL_UA23 Ba/F3 EGFR vIII factor-dependent cell line house mouse CVCL_UA23 CL:0000010 Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del = EGFRvIII); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Doubling time: ~20 hours (KYinno) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 21154319 CVCL_UA24 TH-4 spontaneously immortalized cell line CVCL_UA24 CL:0000010 Derived from sampling site: Heart. Female Group: Reptilian cell line 21154320 CVCL_UA29 PH-1 spontaneously immortalized cell line CVCL_UA29 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Reptilian cell line 21154321 CVCL_UA27 TH-5W spontaneously immortalized cell line CVCL_UA27 CL:0000010 Derived from sampling site: Heart. Female Group: Reptilian cell line 21154322 CVCL_UA28 IgK-17 spontaneously immortalized cell line CVCL_UA28 CL:0000010 Derived from sampling site: Kidney. Group: Reptilian cell line 21154323 CVCL_CN04 ND13854 transformed cell line human CVCL_CN04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154324 CVCL_CN05 ND13855 transformed cell line human CVCL_CN05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154325 CVCL_CN02 ND13820 transformed cell line human CVCL_CN02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154326 CVCL_CN03 ND13853 transformed cell line human CVCL_CN03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154327 CVCL_CN08 ND13881 transformed cell line human CVCL_CN08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154328 CVCL_CN09 ND13905 transformed cell line human CVCL_CN09 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154329 CVCL_CN06 ND13879 transformed cell line human CVCL_CN06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154330 CVCL_CN07 ND13880 transformed cell line human CVCL_CN07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154331 CVCL_CN00 ND13818 transformed cell line human CVCL_CN00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154332 CVCL_CN01 ND13819 transformed cell line human CVCL_CN01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154333 CVCL_1Z82 HGALBV408 transformed cell line human CVCL_1Z82 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154334 CVCL_1Z83 HGALBV419 transformed cell line human CVCL_1Z83 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154335 CVCL_1Z80 HGALBV234 transformed cell line human CVCL_1Z80 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154336 CVCL_1Z81 HGALBV395 transformed cell line human CVCL_1Z81 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154337 CVCL_1Z86 HGALBV439 transformed cell line human CVCL_1Z86 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154338 CVCL_1Z87 PSALBV083 transformed cell line human CVCL_1Z87 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+1G>A; ClinVar=VCV000066879; Zygosity=Unspecified; Note=Splice donor mutation (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154339 CVCL_1Z84 HGALBV424 transformed cell line human CVCL_1Z84 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154340 CVCL_1Z85 HGALBV437 transformed cell line human CVCL_1Z85 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154341 CVCL_1Z88 PSFLBV084 transformed cell line human CVCL_1Z88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154342 CVCL_1Z89 PSMLBV085 transformed cell line human CVCL_1Z89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154343 CVCL_1Z90 PSALBV199 transformed cell line human CVCL_1Z90 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Thr623Ser (c.1868C>G); ClinVar=VCV000066869; Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154344 CVCL_1Z93 PSALBV245 transformed cell line human CVCL_1Z93 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Cys (c.1579C>T) (c.1791C>T); ClinVar=VCV000014487; Zygosity=Homozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154345 CVCL_1Z94 PSALBV339 transformed cell line human CVCL_1Z94 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Cys (c.1579C>T) (c.1791C>T); ClinVar=VCV000014487; Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154346 CVCL_1Z91 PSMLBV238 transformed cell line human CVCL_1Z91 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Cys (c.1579C>T) (c.1791C>T); ClinVar=VCV000014487; Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154347 CVCL_1Z92 PSFLBV239 transformed cell line human CVCL_1Z92 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Cys (c.1579C>T) (c.1791C>T); ClinVar=VCV000014487; Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154348 CVCL_1Z97 PSMLBV360 transformed cell line human CVCL_1Z97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154349 CVCL_1Z98 PSFLBV361 transformed cell line human CVCL_1Z98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154350 CVCL_1Z95 PSALBV229 transformed cell line human CVCL_1Z95 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Ser (c.1822G>A); ClinVar=VCV000014501; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154351 CVCL_1Z96 PSALBV295 transformed cell line human CVCL_1Z96 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu111Lys (c.331G>A); Zygosity=Heterozygous (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154352 CVCL_1Z99 PSALBV296 transformed cell line human CVCL_1Z99 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Ser (c.1822G>A); ClinVar=VCV000014501; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154353 CVCL_1Z60 HGALBV145 transformed cell line human CVCL_1Z60 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154354 CVCL_1Z61 HGALBV146 transformed cell line human CVCL_1Z61 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154355 CVCL_1Z64 HGALBV162 transformed cell line human CVCL_1Z64 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154356 CVCL_1Z65 HGALBV172 transformed cell line human CVCL_1Z65 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154357 CVCL_1Z62 HGALBV150 transformed cell line human CVCL_1Z62 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154358 CVCL_1Z63 HGALBV152 transformed cell line human CVCL_1Z63 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154359 CVCL_1Z68 HGALBV237 transformed cell line human CVCL_1Z68 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154360 CVCL_1Z69 HGALBV240 transformed cell line human CVCL_1Z69 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154361 CVCL_1Z66 HGALBV186 transformed cell line human CVCL_1Z66 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154362 CVCL_1Z67 HGALBV236 transformed cell line human CVCL_1Z67 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154363 CVCL_1Z71 HGALBV304 transformed cell line human CVCL_1Z71 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Miscellaneous: Cell line no longer available Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154364 CVCL_1Z72 HGALBV314 transformed cell line human CVCL_1Z72 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154365 CVCL_1Z70 HGALBV255 transformed cell line human CVCL_1Z70 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154366 CVCL_1Z75 HGALBV331 transformed cell line human CVCL_1Z75 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154367 CVCL_1Z76 HGALBV338 transformed cell line human CVCL_1Z76 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154368 CVCL_1Z73 HGSLBV353 transformed cell line human CVCL_1Z73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154369 CVCL_1Z74 HGSLBV359 transformed cell line human CVCL_1Z74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154370 CVCL_1Z79 HGALBV389 transformed cell line human CVCL_1Z79 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154371 CVCL_1Z77 HGALBV351 transformed cell line human CVCL_1Z77 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21154372 CVCL_1Z78 HGALBV378 transformed cell line human CVCL_1Z78 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21154373 CVCL_LI31 A-iPSC-19 induced pluripotent stem cell house mouse CVCL_LI31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154374 CVCL_LI32 A-iPSC-ZSCAN10-3 induced pluripotent stem cell house mouse CVCL_LI32 CL:0000010 Transfected with: HGNC; 12997; ZSCAN10 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154375 CVCL_LI30 A-iPSC-16 induced pluripotent stem cell house mouse CVCL_LI30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154376 CVCL_D094 HES-4 embryonic stem cell human CVCL_D094 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Male Registration: Swiss research registry; BAG-hES-IMP-0006; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21154377 CVCL_D095 HES-5 embryonic stem cell human CVCL_D095 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Omics: Transcriptome analysis by microarray. Male Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21154378 CVCL_D092 HES-1 embryonic stem cell human CVCL_D092 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA.; From: Monash University; Melbourne; Australia CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21154379 CVCL_D093 HES-2 embryonic stem cell human CVCL_D093 HLA typing: A*02:03,02; B*46,48; C*01,08; DQB1*04,06; DRB1*04,15; DRB5*01 (PubMed=16919167) From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA.; From: Monash University; Melbourne; Australia CL:0000010 Omics: Transcriptome analysis by microarray. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21154380 CVCL_D098 686LN-R30 cancer cell line human CVCL_D098 CL:0000010 Derived from metastatic site: Lymph node. Male 21154381 CVCL_D099 686LN-M3e cancer cell line human CVCL_D099 CL:0000010 Derived from metastatic site: Lymph node. Male 21154382 CVCL_D096 HES-6 embryonic stem cell human CVCL_D096 From: ESI BIO - BioTime, Inc (ES Cell International); Alameda; USA. CL:0000010 Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Female Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC03-02. 21154383 CVCL_D097 686LN-M4e cancer cell line human CVCL_D097 CL:0000010 Derived from metastatic site: Lymph node. Male 21154384 CVCL_LI28 Y-iPSC-12 induced pluripotent stem cell house mouse CVCL_LI28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154385 CVCL_LI29 Y-iPSC-4 induced pluripotent stem cell house mouse CVCL_LI29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154386 CVCL_LI26 EU-18 cancer cell line human CVCL_LI26 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=9823951) Derived from sampling site: Bone marrow. Male 21154387 CVCL_LI27 HBL-4 [Human AIDS-related non-Hodgkin lymphoma] cancer cell line human CVCL_LI27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. 21154388 CVCL_LI24 EU-10 cancer cell line human CVCL_LI24 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9823951) Derived from sampling site: Bone marrow. Male 21154389 CVCL_D090 iPS.C3a induced pluripotent stem cell human CVCL_D090 From: Medical College of Wisconsin; Milwaukee; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21154390 CVCL_LI25 EU-11 cancer cell line human CVCL_LI25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9823951) Derived from sampling site: Bone marrow. Female 21154391 CVCL_D091 iPS.C6a induced pluripotent stem cell human CVCL_D091 From: Medical College of Wisconsin; Milwaukee; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21154392 CVCL_LI22 DX3-LT5.1 cancer cell line human CVCL_LI22 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from metastatic site: Hypodermis. Omics: Proteome analysis by 2D-DE Female Characteristics: Highly metastatic in mice 21154393 CVCL_LI23 KT [Human leukemia] cancer cell line human CVCL_LI23 CL:0000010 Unspecified 21154394 CVCL_LI42 NKI-8 cancer cell line human CVCL_LI42 CL:0000010 21154395 CVCL_LI43 NKI-10 cancer cell line human CVCL_LI43 CL:0000010 21154396 CVCL_LI40 2A1-H7 hybridoma house mouse CVCL_LI40 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human laminin-binding protein complex. 21154397 CVCL_LI41 NKI-2 cancer cell line human CVCL_LI41 CL:0000010 21154398 CVCL_LI39 ZZUi003-A induced pluripotent stem cell human CVCL_LI39 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154399 CVCL_LI37 CWR-R1fb cancer cell line human CVCL_LI37 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Fibroblast derivative of CWR-R1 21154400 CVCL_LI38 CWR22Pc cancer cell line human CVCL_LI38 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (PubMed=18829484) Derived from sampling site: Prostate. Male Characteristics: Androgen-dependent Expresses full-length AR and PSA. 21154401 CVCL_LI35 A549 VIM RFP cancer cell line human CVCL_LI35 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Using CRISPR/Cas9 a red fluorescent protein (RFP) tag was added to the C-terminal of the VIM gene Allows to monitor the epithelial-to-mesenchymal transition (EMT) status of cells in vitro by monitoring RFP expression. 21154402 CVCL_LI36 CWR-R1ca cancer cell line human CVCL_LI36 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Fibroblast-free derivative of CWR-R1 21154403 CVCL_LI33 A-iPSC-ZSCAN10-7 induced pluripotent stem cell house mouse CVCL_LI33 CL:0000010 Transfected with: HGNC; 12997; ZSCAN10 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6 x CBA. Omics: Transcriptome analysis by microarray Male 21154404 CVCL_LI34 KOPN-40 cancer cell line human CVCL_LI34 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified 21154405 CVCL_LI10 LOHG-I cancer cell line human CVCL_LI10 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (PubMed=10375592). Male 21154406 CVCL_D078 HD-iPS1 induced pluripotent stem cell human CVCL_D078 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=18691744) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154407 CVCL_D079 HD-iPS11 induced pluripotent stem cell human CVCL_D079 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=18691744) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154408 CVCL_D072 SCC210011 cancer cell line human CVCL_D072 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male Doubling time: 42 hours (PubMed=21971914) 21154409 CVCL_D073 SCC211441 cancer cell line human CVCL_D073 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male Doubling time: 38 hours (PubMed=21971914) 21154410 CVCL_D070 Ma-19 cancer cell line human CVCL_D070 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 36.0 hours (PubMed=1650680) 21154411 CVCL_D071 Ma-20 cancer cell line human CVCL_D071 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 42.2 hours (PubMed=1650680) 21154412 CVCL_D076 U-2020 cancer cell line human CVCL_D076 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 2 days (PubMed=2990154) 21154413 CVCL_D077 U-2050 cancer cell line human CVCL_D077 CL:0000010 Derived from metastatic site: Pleural effusion. Male Doubling time: 3.5 days (PubMed=2990154) 21154414 CVCL_D074 ACC212102 cancer cell line human CVCL_D074 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male Doubling time: 25 hours (PubMed=21971914) 21154415 CVCL_LI08 CHLA-255/MYCN cancer cell line human CVCL_LI08 CL:0000010 Transfected with: HGNC; 7559; MYCN Derived from metastatic site: Brain. Unspecified 21154416 CVCL_LI09 LOHG-F finite cell line human CVCL_LI09 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (PubMed=10375592). Male Senescence: Senesces at 34 PDL (PubMed=15753990) 21154417 CVCL_D075 U-1906 cancer cell line human CVCL_D075 CL:0000010 Derived from metastatic site: Brain. Male Doubling time: 3 days (PubMed=2990154) 21154418 CVCL_LI06 OMC685 cancer cell line human CVCL_LI06 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a 33 year old female patient with ovarian mucinous cystadenocarcinoma. 21154419 CVCL_LI07 WAe001-A-12 embryonic stem cell human CVCL_LI07 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6257; KCNJ11. Male 21154420 CVCL_LI04 GHOST(3)-CXCR4 DRiP78 and NHERF1 knockdown cancer cell line human CVCL_LI04 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 24581; DNAJC14; Knockout cell: Method=shRNA knockdown; HGNC; 11075; SLC9A3R1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 2561; CXCR4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21154421 CVCL_LI05 PI 125/10 hybridoma house mouse CVCL_LI05 CL:0000010 Monoclonal antibody isotype: IgG2a. 21154422 CVCL_LI02 ciPTEC-OAT3 conditionally immortalized cell line human CVCL_LI02 CL:0000010 Transfected with: HGNC; 10972; SLC22A8; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female 21154423 CVCL_LI03 GHOST(3)-CCR5 DRiP78 and NHERF1 knockdown cancer cell line human CVCL_LI03 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 24581; DNAJC14; Knockout cell: Method=shRNA knockdown; HGNC; 11075; SLC9A3R1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP; Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21154424 CVCL_LI00 ZJUhES-1 embryonic stem cell human CVCL_LI00 From: College of Life Sciences, Zhejiang University; Hangzhou; China CL:0000010 Male Doubling time: 69 hours (PubMed=20973834). 21154425 CVCL_LI01 ciPTEC-OAT1 conditionally immortalized cell line human CVCL_LI01 CL:0000010 Transfected with: HGNC; 10970; SLC22A6; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female 21154426 CVCL_LI20 LN-1049 cancer cell line human CVCL_LI20 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=2989064) Population: Japanese; Derived from sampling site: Lymph node. Male Doubling time: 36 hours (PubMed=2989064) 21154427 CVCL_LI21 PB-1049 transformed cell line human CVCL_LI21 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 33.6 hours (PubMed=2989064) 21154428 CVCL_D089 iPSC-MHF2 c1 induced pluripotent stem cell human CVCL_D089 From: University of Washington; Seattle; USA CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154429 CVCL_D083 iPSC-2s induced pluripotent stem cell human CVCL_D083 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Unspecified 21154430 CVCL_D084 iPSC-3s induced pluripotent stem cell human CVCL_D084 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Unspecified 21154431 CVCL_D081 iPS.C2a induced pluripotent stem cell human CVCL_D081 From: Medical College of Wisconsin; Milwaukee; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21154432 CVCL_D082 iPSC-1s induced pluripotent stem cell human CVCL_D082 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Unspecified 21154433 CVCL_D087 iPSC2 induced pluripotent stem cell human CVCL_D087 From: University of California, San Diego; San Diego; USA CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon Cell type=Neural progenitor cell.. Omics: Transcriptome analysis by microarray Male 21154434 CVCL_D088 iPSC3 induced pluripotent stem cell human CVCL_D088 From: University of California, San Diego; San Diego; USA CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon Cell type=Neural progenitor cell.. Male 21154435 CVCL_D085 LXFL 529L cancer cell line human CVCL_D085 HLA typing: A*01:01,01:01; B*14:02,37:01; C*06:02,06:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq 21154436 CVCL_LI19 PAPLiGs cancer cell line human CVCL_LI19 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from metastatic site: Liver. Female 21154437 CVCL_D086 iPSC1 induced pluripotent stem cell human CVCL_D086 From: University of California, San Diego; San Diego; USA CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon Cell type=Neural progenitor cell.. Omics: Transcriptome analysis by microarray Male 21154438 CVCL_LI17 BI cancer cell line human CVCL_LI17 From: Andren-Sandberg A.; Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val197Leu (c.589G>T); ClinVar=VCV000216468; Zygosity=Unspecified (PubMed=11787853). 21154439 CVCL_LI18 BJ [Human pancreatic adenocarcinoma] cancer cell line human CVCL_LI18 From: Andren-Sandberg A.; Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=11787853). 21154440 CVCL_LI15 HABL transformed cell line human CVCL_LI15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8486778) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154441 CVCL_LI16 HATL cancer cell line human CVCL_LI16 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175Pro (c.524G>C); Zygosity=Heterozygous (PubMed=8486778) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21154442 CVCL_LI13 SV1-LOHG transformed cell line human CVCL_LI13 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male 21154443 CVCL_D080 HD-iPS4 induced pluripotent stem cell human CVCL_D080 From: Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=18691744) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154444 CVCL_LI14 T1-LOHG telomerase immortalized cell line human CVCL_LI14 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male 21154445 CVCL_LI11 LOHG-L finite cell line human CVCL_LI11 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (PubMed=10375592). Male 21154446 CVCL_LI12 LOHG-NSA finite cell line human CVCL_LI12 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr215Serfs*13 (c.643_646delACAG); ClinVar=VCV000200997; Zygosity=Unspecified (PubMed=10375592). Male 21154447 CVCL_D058 Ma-4 cancer cell line human CVCL_D058 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 49.1 hours (PubMed=1650680) 21154448 CVCL_D059 Ma-5 cancer cell line human CVCL_D059 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 61.0 hours (PubMed=1650680) 21154449 CVCL_D056 NCI-N179 cancer cell line human CVCL_D056 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Established from a mouse xenograft 21154450 CVCL_D057 NCI-N230 cancer cell line human CVCL_D057 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Established from a mouse xenograft 21154451 CVCL_D050 SCN2.2 transformed cell line Norway rat CVCL_D050 CL:0000010 Transformant: Psi2 defective retrovirus adenovirus E1A; Derived from sampling site: Embryonic brain; hypothalamus; suprachiasmatic nucleus; Breed/subspecies: Long-Evans. Omics: Transcriptome analysis by microarray Unspecified Characteristics: Capable to differentiate into different phenotypes Expresses the neuronal markers (NSE, PGP and MAP2), but absent of glial markers. Valuable tool for studies relating to the regulation of the central mammalian pacemaker function and the development of the suprachiasmatic nucleus (SCN) cell types (Kerafast). Doubling time: 28 hours (PubMed=10213449) 21154452 CVCL_D051 HVTs-SM1 conditionally immortalized cell line human CVCL_D051 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Saphenous vein; smooth muscle Cell type=Vascular associated smooth muscle cell.. Doubling time: 49 +- 9 hours (PubMed=10764661) 21154453 CVCL_D054 U-1810 cancer cell line human CVCL_D054 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val172Leufs*2 (c.514delG); Zygosity=Unspecified (PubMed=12820372) Derived from metastatic site: Pleural effusion. Male Doubling time: 1.5 days (PubMed=2990154) 21154454 CVCL_D055 U-1690 cancer cell line human CVCL_D055 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Val (c.776A>T); ClinVar=VCV000485034; Zygosity=Unspecified (PubMed=12820372) Derived from metastatic site: Pleural effusion. Male Doubling time: 5-8 days (PubMed=2990154) 21154455 CVCL_D052 HL1C cancer cell line Norway rat CVCL_D052 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21154456 CVCL_D053 HTC4 cancer cell line Norway rat CVCL_D053 CL:0000010 Derived from metastatic site: Ascites; Breed/subspecies: Buffalo. Male 21154457 CVCL_D069 Ma-18 cancer cell line human CVCL_D069 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 37.0 hours (PubMed=1650680) 21154458 CVCL_D067 Ma-15 cancer cell line human CVCL_D067 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 29.5 hours (PubMed=1650680) 21154459 CVCL_D068 Ma-16 cancer cell line human CVCL_D068 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 33.2 hours (PubMed=1650680) 21154460 CVCL_D061 Ma-7 cancer cell line human CVCL_D061 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 28.7 hours (PubMed=1650680) 21154461 CVCL_D062 Ma-8 cancer cell line human CVCL_D062 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 50.0 hours (PubMed=1650680) 21154462 CVCL_D060 Ma-6 cancer cell line human CVCL_D060 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21154463 CVCL_D065 Ma-13 cancer cell line human CVCL_D065 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 71.9 hours (PubMed=1650680) 21154464 CVCL_D066 Ma-14 cancer cell line human CVCL_D066 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 21.0 hours (PubMed=1650680) 21154465 CVCL_D063 Ma-9 cancer cell line human CVCL_D063 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 65.5 hours (PubMed=1650680) 21154466 CVCL_D064 Ma-11 cancer cell line human CVCL_D064 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 41.3 hours (PubMed=1650680) 21154467 CVCL_D036 TFTA1 hybridoma house mouse CVCL_D036 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02879; Ricinus communis ricin (A chain). 21154468 CVCL_D037 Sp2/5 cancer cell line house mouse CVCL_D037 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21154469 CVCL_D034 M6/B7 cancer cell line human CVCL_D034 HLA typing: A*01:01,23:01; B*07:02,49:01; C*07:01:01,07:02; DPB1*04:01,03:01; DQB1*06:02; DRB1*01:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Transfected with: HGNC; 1700; CD80 Derived from metastatic site: Lung. Omics: Array-based CGH Female 21154470 CVCL_D035 M88 cancer cell line human CVCL_D035 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. Male 21154471 CVCL_D038 THB-7 hybridoma house mouse CVCL_D038 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P28907; Human CD38. 21154472 CVCL_D039 UC 729-6 transformed cell line human CVCL_D039 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8061 21154473 CVCL_D032 M24 cancer cell line human CVCL_D032 HLA typing: A*02:01,68:01:01; B*40:01:01,40:02; C*03:04,02:02:02; DPB1*04:01; DQB1*03:01:01,05:02; DRB1*04:01:01,16:02 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445) Derived from metastatic site: Lymph node. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12270 21154474 CVCL_D030 M18/B7 cancer cell line human CVCL_D030 HLA typing: A*29:02:01,29:02:01; B*49:01,49:01; C*07:01:01,07:01:01; DPB1*02:01:02,03:01:01; DQB1*03:02,03:01:01; DRB1*04:05:01,04:07:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 1700; CD80. 21154475 CVCL_D031 M21 cancer cell line human CVCL_D031 HLA typing: A*03:01,02:01; B*07:02; C*07:02; DPB1*04:01; DQB1*06:02,03:01:01; DRB1*11:01,15:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24732172) Derived from metastatic site: Not specified. Female 21154476 CVCL_D047 G1E-ER4 embryonic stem cell house mouse CVCL_D047 CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: HGNC; 3467; ESR1 (ligand-binding domain); Transfected with: HGNC; 4170; GATA1 Breed/subspecies: 129S/SvEv-Gpi1. Male Characteristics: Transfected with a GATA-1-ER construct (GATA1 fused to the ligand-binding domains of ESR1) Part of: ENCODE project mouse cell lines 21154477 CVCL_D048 H0287 transformed cell line human CVCL_D048 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ENCODE project common cell types; tier 3 21154478 CVCL_D045 CM7/1 embryonic stem cell house mouse CVCL_D045 CL:0000010 Breed/subspecies: 129S4/SvJae. Male 21154479 CVCL_D046 G1E embryonic stem cell house mouse CVCL_D046 CL:0000010 Transfected with: HGNC; 990; BCL2 Breed/subspecies: 129S/SvEv-Gpi1. Male Characteristics: Proliferates continuously in culture as immature erythroblasts and undergo terminal maturation when GATA-1 function is restored; Characteristics: EPO and KITLG dependent Doubling time: ~12 hours (ENCODE) Part of: ENCODE project mouse cell lines 21154480 CVCL_D049 SCN1.4 transformed cell line Norway rat CVCL_D049 CL:0000010 Transformant: Psi2 defective retrovirus adenovirus E1A; Derived from sampling site: Embryonic brain; hypothalamus; suprachiasmatic nucleus; Breed/subspecies: Long-Evans. Unspecified Doubling time: 28 hours (PubMed=10213449) 21154481 CVCL_D040 OKP spontaneously immortalized cell line CVCL_D040 CL:0000010 Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female Group: Marsupial cell line 21154482 CVCL_D043 CS-OKB cancer cell line human CVCL_D043 CL:0000010 Population: Japanese; Derived from metastatic site: Left biceps femoris. Male Doubling time: 5 days (PubMed=9672194) 21154483 CVCL_D044 SK-N-SH-RA cancer cell line human CVCL_D044 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis Female Part of: ENCODE project common cell types; tier 3 21154484 CVCL_D041 OKB spontaneously immortalized cell line CVCL_D041 CL:0000010 Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female Group: Marsupial cell line 21154485 CVCL_D042 OKH spontaneously immortalized cell line CVCL_D042 CL:0000010 Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Group: Marsupial cell line 21154486 CVCL_UC52 LM-MEL-47 cancer cell line human CVCL_UC52 HLA typing: A*02:01; B*62; C*03:04 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154487 CVCL_UC53 LM-MEL-48 cancer cell line human CVCL_UC53 HLA typing: A*01,32; B*08,14; C*07,08 (PubMed=23527996) CL:0000010 Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154488 CVCL_UC50 LM-MEL-45 cancer cell line human CVCL_UC50 HLA typing: A*02:01,03:01; B*07:02,57:01; C*06:02,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain; right occipital lobe. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: ~40 hours (ATCC=CRL-3336) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154489 CVCL_UC51 LM-MEL-46 cancer cell line human CVCL_UC51 HLA typing: A*02:01,03:01; B*45:01,62; C*03:04,06:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Heart. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154490 CVCL_UC56 LM-MEL-53 cancer cell line human CVCL_UC56 HLA typing: A*02:01; B*60,44:02; C*03:04,05:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Soft tissue. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: ~40 hours (ATCC=CRL-3337) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154491 CVCL_UC57 LM-MEL-57 cancer cell line human CVCL_UC57 HLA typing: A*01:01,02:01; B*08:01,57:01; C*06:02,07:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Lung; right upper lobe. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154492 CVCL_UC54 LM-MEL-49 cancer cell line human CVCL_UC54 HLA typing: A*29,32; B*65,44; C*08,16 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154493 CVCL_UC55 LM-MEL-50 cancer cell line human CVCL_UC55 HLA typing: A*29:02,68:01; B*65,44:03; C*08:02,16:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Small intestine. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154494 CVCL_UC58 LM-MEL-59 cancer cell line human CVCL_UC58 HLA typing: A*11:01,24:02; B*18:01,52:01; C*07:01,12:02 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154495 CVCL_UC59 LM-MEL-60 cancer cell line human CVCL_UC59 HLA typing: A*24:02; B*08:01,35:03; C*07,04 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154496 CVCL_UC41 LM-MEL-34 cancer cell line human CVCL_UC41 HLA typing: A*02:01,26:01; B*27:03,56:01; C*01:02,03:03 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154497 CVCL_UC42 LM-MEL-35 cancer cell line human CVCL_UC42 HLA typing: A*01:01,26:01; B*08:01,27:05; C*01:02,07:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154498 CVCL_UC40 LM-MEL-33 cancer cell line human CVCL_UC40 HLA typing: A*02:01,03:01; B*60,47; C*03:04,06:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~55 hours (ATCC=CRL-3333) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154499 CVCL_UC45 LM-MEL-39 cancer cell line human CVCL_UC45 HLA typing: A*03:01,32:01; B*15:01,40:01; C*03:03,03.04 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Small intestine. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154500 CVCL_UC46 LM-MEL-40 cancer cell line human CVCL_UC46 HLA typing: A*32:01; B*08:01,51:01; C*07:01,14:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Glu (c.1406G>A) (p.Gly509Glu, c.1526G>A); ClinVar=VCV000013974; Zygosity=Unspecified (PubMed=23527996); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154501 CVCL_UC43 LM-MEL-36 cancer cell line human CVCL_UC43 HLA typing: A*24:02,25:01; B*39:01,39:06; C*07:02,12:03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154502 CVCL_UC44 LM-MEL-38a cancer cell line human CVCL_UC44 HLA typing: A*02:01,03:01; B*07:02,57.01; C*06,07 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154503 CVCL_UC49 LM-MEL-44 cancer cell line human CVCL_UC49 HLA typing: A*02:01; B*60,44:02; C*03:04,05:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154504 CVCL_UC47 LM-MEL-41 cancer cell line human CVCL_UC47 HLA typing: A*01:01,02:01; B*49:01,51:01; C*06:02,14:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Cervical lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154505 CVCL_UC48 LM-MEL-42 cancer cell line human CVCL_UC48 HLA typing: A*11:01,02:01; B*55,27; C*03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Spleen. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~38 hours (ATCC=CRL-3335) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154506 CVCL_LI97 CW60087 induced pluripotent stem cell human CVCL_LI97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60087; true Male 21154507 CVCL_LI98 CW60105 induced pluripotent stem cell human CVCL_LI98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60105; true Male 21154508 CVCL_LI95 CW60085 induced pluripotent stem cell human CVCL_LI95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60085; true Male 21154509 CVCL_LI96 CW60086 induced pluripotent stem cell human CVCL_LI96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60086; true Male 21154510 CVCL_LI93 CW60066 induced pluripotent stem cell human CVCL_LI93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60066; true Male 21154511 CVCL_LI94 CW60076 induced pluripotent stem cell human CVCL_LI94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60076; true Female 21154512 CVCL_LI91 CW60057 induced pluripotent stem cell human CVCL_LI91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60057; true Male 21154513 CVCL_LI92 CW60065 induced pluripotent stem cell human CVCL_LI92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60065; true Female 21154514 CVCL_LI90 CW60054 induced pluripotent stem cell human CVCL_LI90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60054; true Male 21154515 CVCL_UC30 LM-MEL-19 cancer cell line human CVCL_UC30 HLA typing: A*01:01,02:01; B*08:01,15:01; C*03:04,07:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: ~40 hours (ATCC=CRL-3328) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154516 CVCL_UC31 LM-MEL-20 cancer cell line human CVCL_UC31 HLA typing: A*02,32:01; B*44:02,62; C*03,05:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: KRAS mutation and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154517 CVCL_UC34 LM-MEL-26 cancer cell line human CVCL_UC34 HLA typing: A*02:01,24:02; B*07:02,27:05; C*01:02,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: MET mutation and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Cervical lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154518 CVCL_UC35 LM-MEL-27 cancer cell line human CVCL_UC35 HLA typing: A*11:01,33:01; B*08:01,35:01; C*04:01,07:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154519 CVCL_UC32 LM-MEL-24 cancer cell line human CVCL_UC32 HLA typing: A*01,02; B*08,44; C*05,07 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain; left parietal lobe. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154520 CVCL_UC33 LM-MEL-25 cancer cell line human CVCL_UC33 HLA typing: A*01:01,23:01; B*08:01,27:05; C*01:02,07:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Lung; left lower lobe. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Doubling time: >70 hours (ATCC=CRL-3330) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154521 CVCL_UC38 LM-MEL-30 cancer cell line human CVCL_UC38 HLA typing: A*01:01,31:01; B*51:01,35:03; C*04:01,12:03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154522 CVCL_UC39 LM-MEL-31 cancer cell line human CVCL_UC39 HLA typing: A*02:01,24:02; B*44:03,40:01; C*03:04,04:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154523 CVCL_UC36 LM-MEL-28 cancer cell line human CVCL_UC36 HLA typing: A*02:01; B*15:01,57:01; C*03:04,07:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: 45-55 hours (ATCC=CRL-3331) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154524 CVCL_UC37 LM-MEL-29 cancer cell line human CVCL_UC37 HLA typing: A*01:01; B*08:01; C*07:01 (PubMed=23527996) CL:0000010 Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Bone; femur. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154525 CVCL_LI88 CW60051 induced pluripotent stem cell human CVCL_LI88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60051; true Male 21154526 CVCL_LI89 CW60053 induced pluripotent stem cell human CVCL_LI89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60053; true Male 21154527 CVCL_UC20 LM-MEL-5a cancer cell line human CVCL_UC20 HLA typing: A*02:01,03:01; B*07:02,57:01; C*06:02,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor, metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154528 CVCL_UC23 LM-MEL-8 cancer cell line human CVCL_UC23 HLA typing: A*01:01,29:02; B*07:02,08:01; C*07:01,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154529 CVCL_UC24 LM-MEL-9 cancer cell line human CVCL_UC24 HLA typing: A*01:01,11:01; B*51:01,57:01; C*06:02,15:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor, metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154530 CVCL_UC21 LM-MEL-6 cancer cell line human CVCL_UC21 HLA typing: A*03:01,68:01; B*61,53:01; C*02:02,04:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154531 CVCL_UC22 LM-MEL-7 cancer cell line human CVCL_UC22 HLA typing: A*11,30; B*18,56; C*w01,w05; DRB1*02,03 (Direct_author_submission) CL:0000010 Miscellaneous: Metastatic site, HLA typing and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Brain. Omics: miRNA expression profiling Unspecified Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154532 CVCL_UC27 LM-MEL-15 cancer cell line human CVCL_UC27 HLA typing: A*26:01,68:01; B*44:02,51:01; C*05:01 (PubMed=23527996) CL:0000010 Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154533 CVCL_UC28 LM-MEL-16 cancer cell line human CVCL_UC28 HLA typing: A*01:01,03:01; B*65,57:01; C*05:01,06:11 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left axillary lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154534 CVCL_UC25 LM-MEL-12 cancer cell line human CVCL_UC25 HLA typing: A*01:01,33:03; B*08:01,35:03; C*04:01,07:01 (PubMed=23527996) CL:0000010 Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154535 CVCL_UC26 LM-MEL-14 cancer cell line human CVCL_UC26 HLA typing: A*23:01,24:02; B*15:01,44:03; C*03:03,04:01 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154536 CVCL_UC29 LM-MEL-17 cancer cell line human CVCL_UC29 HLA typing: A*01:01,02; B*44,15:01; C*03:04,05 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Age of donor and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154537 CVCL_LI99 CW60106 induced pluripotent stem cell human CVCL_LI99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60106; true Male 21154538 CVCL_LI75 CW40181 induced pluripotent stem cell human CVCL_LI75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40181; true Female 21154539 CVCL_LI76 CW40224 induced pluripotent stem cell human CVCL_LI76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40224; true Female 21154540 CVCL_LI73 CW40153 induced pluripotent stem cell human CVCL_LI73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40153; true Male 21154541 CVCL_LI74 CW40172 induced pluripotent stem cell human CVCL_LI74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40172; true Male 21154542 CVCL_LI71 CW40122 induced pluripotent stem cell human CVCL_LI71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40122; true Female 21154543 CVCL_LI72 CW40125 induced pluripotent stem cell human CVCL_LI72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40125; true Female 21154544 CVCL_LI70 CW40096 induced pluripotent stem cell human CVCL_LI70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40096; true Male 21154545 CVCL_UC12 iPSC #7_1 induced pluripotent stem cell pig CVCL_UC12 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154546 CVCL_UC13 AR230-s cancer cell line human CVCL_UC13 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Female Characteristics: Clone of AR230 used as a control cell line for studies using AR230-s which is resistant to imatinib Doubling time: ~30-48 hours (ATCC=CRL-3345) 21154547 CVCL_UC10 iPSC #5_1 induced pluripotent stem cell pig CVCL_UC10 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154548 CVCL_UC11 iPSC #5_2 induced pluripotent stem cell pig CVCL_UC11 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154549 CVCL_UC16 LM-MEL-1a cancer cell line human CVCL_UC16 HLA typing: A*02,24; B*07:02,70; C*07:04,12:03 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left thigh; hypodermis. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: ~40 hours (ATCC=CRL-3329) Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154550 CVCL_UC17 LM-MEL-2 cancer cell line human CVCL_UC17 HLA typing: A*02:01; B*51:01; C*14:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154551 CVCL_UC14 K562-r cancer cell line human CVCL_UC14 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female Doubling time: ~24-30 hours (ATCC=CRL-3344) 21154552 CVCL_UC15 K562-s cancer cell line human CVCL_UC15 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Clone of K-562 used as a control cell line for studies using K562-s which is resistant to imatinib Doubling time: ~24-30 hours (ATCC=CRL-3343) 21154553 CVCL_UC18 LM-MEL-3 cancer cell line human CVCL_UC18 HLA typing: A*01:01,24:02; B*07:02,08:01; C*07:01,07:02 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro124Leu (c.371C>T); ClinVar=VCV000040744; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: MAP2K1 mutation, metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Skin. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154554 CVCL_UC19 LM-MEL-4 cancer cell line human CVCL_UC19 HLA typing: A*68:01,11:01; B*07:02,08:01; C*07:02,07:04 (PubMed=23527996) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23527996) Miscellaneous: Metastatic site and STR profile from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Left inguinal lymph node. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21154555 CVCL_LI68 CW30387 induced pluripotent stem cell human CVCL_LI68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: East Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30387; true Female 21154556 CVCL_LI69 CW30494 induced pluripotent stem cell human CVCL_LI69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30494; true Female 21154557 CVCL_LI66 CW30374 induced pluripotent stem cell human CVCL_LI66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30374; true Male 21154558 CVCL_LI67 CW30382 induced pluripotent stem cell human CVCL_LI67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30382; true Male 21154559 CVCL_LI86 CW60017 induced pluripotent stem cell human CVCL_LI86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60017; true Male 21154560 CVCL_LI87 CW60031 induced pluripotent stem cell human CVCL_LI87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60031; true Female 21154561 CVCL_LI84 CW50123 induced pluripotent stem cell human CVCL_LI84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50123; true Female 21154562 CVCL_LI85 CW60011 induced pluripotent stem cell human CVCL_LI85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60011; true Female 21154563 CVCL_LI82 CW50093 induced pluripotent stem cell human CVCL_LI82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50093; true Male 21154564 CVCL_LI83 CW50096 induced pluripotent stem cell human CVCL_LI83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50096; true Female 21154565 CVCL_LI80 CW50039 induced pluripotent stem cell human CVCL_LI80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50039; true Female 21154566 CVCL_LI81 CW50041 induced pluripotent stem cell human CVCL_LI81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50041; true Male 21154567 CVCL_UC01 MPC960 cancer cell line human CVCL_UC01 CL:0000010 Female 21154568 CVCL_UC02 HROC357 T0 M1 cancer cell line human CVCL_UC02 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Female Characteristics: Established from a patient-derived xenograft established in female NSG mice 21154569 CVCL_UC00 MPC7105 cancer cell line human CVCL_UC00 CL:0000010 Female 21154570 CVCL_UC05 HK-2-KIM-1 transformed cell line human CVCL_UC05 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Kidney. Male Characteristics: CRISPR/Cas9-mediated knock-in of eGFP-T2A-luciferase construct at the C-terminal end of HAVCR1/KIM-1 21154571 CVCL_UC06 iPSC #2_1 induced pluripotent stem cell pig CVCL_UC06 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154572 CVCL_UC03 293T human CD123 transformed cell line human CVCL_UC03 CL:0000010 Transfected with: HGNC; 6012; IL3RA; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21154573 CVCL_UC04 293T human CLDN18.1 transformed cell line human CVCL_UC04 CL:0000010 Transfected with: HGNC; 2039; CLDN18 (isoform A1); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21154574 CVCL_UC09 iPSC #3_1.2 induced pluripotent stem cell pig CVCL_UC09 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154575 CVCL_UC07 iPSC #2_2 induced pluripotent stem cell pig CVCL_UC07 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154576 CVCL_UC08 iPSC #3_1.1 induced pluripotent stem cell pig CVCL_UC08 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified 21154577 CVCL_LI79 CW50032 induced pluripotent stem cell human CVCL_LI79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50032; true Male 21154578 CVCL_LI77 CW40250 induced pluripotent stem cell human CVCL_LI77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40250; true Male 21154579 CVCL_LI78 CW50023 induced pluripotent stem cell human CVCL_LI78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50023; true Male 21154580 CVCL_LI53 AP8 cancer cell line human CVCL_LI53 CL:0000010 Population: Korean; Derived from sampling site: Kidney; cortical collecting duct. Omics: Array-based CGH Female Doubling time: 29 hours (PubMed=19154479) 21154581 CVCL_LI54 LICR-HN2 R10.3 cancer cell line human CVCL_LI54 CL:0000010 Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Larynx. Male 21154582 CVCL_LI51 NKI-SC263 cancer cell line human CVCL_LI51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous; Note=Possible (Direct_author_submission); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.704_735del32; Zygosity=Unspecified (PubMed=25184754); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=25184754) Miscellaneous: Doubling time and CDKN2A status from personal communication of Dok R. Doubling time: 35-40 hours (Direct_author_submission) 21154583 CVCL_LI52 AP3 cancer cell line human CVCL_LI52 CL:0000010 Population: Korean; Derived from sampling site: Kidney; cortical collecting duct. Omics: Array-based CGH Male Doubling time: 72 hours (PubMed=19154479) 21154584 CVCL_LI50 NKI-SC179 cancer cell line human CVCL_LI50 CL:0000010 21154585 CVCL_LI48 NKI-6 cancer cell line human CVCL_LI48 CL:0000010 21154586 CVCL_LI49 NKI-SC173 cancer cell line human CVCL_LI49 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25184754). 21154587 CVCL_LI46 MC-1 [Human breast carcinoma] cancer cell line human CVCL_LI46 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21154588 CVCL_LI47 NKI-3 cancer cell line human CVCL_LI47 CL:0000010 21154589 CVCL_LI44 NKI-1 cancer cell line human CVCL_LI44 CL:0000010 21154590 CVCL_LI45 NKI-7 cancer cell line human CVCL_LI45 CL:0000010 21154591 CVCL_LI64 CW30200 induced pluripotent stem cell human CVCL_LI64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30200; true Male 21154592 CVCL_LI65 CW30275 induced pluripotent stem cell human CVCL_LI65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30275; true Female 21154593 CVCL_LI62 CW20284 induced pluripotent stem cell human CVCL_LI62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American and Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20284; true Male 21154594 CVCL_LI63 CW30174 induced pluripotent stem cell human CVCL_LI63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30174; true Male 21154595 CVCL_LI60 CW20104 induced pluripotent stem cell human CVCL_LI60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20104; true Female 21154596 CVCL_LI61 CW20170 induced pluripotent stem cell human CVCL_LI61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20170; true Female 21154597 CVCL_LI59 MB1.3.19 transformed cell line Norway rat CVCL_LI59 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Lys); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brown adipose tissue Cell type=Preadipocyte.; Breed/subspecies: Wistar. Unspecified 21154598 CVCL_LI57 OC125 hybridoma house mouse CVCL_LI57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. 21154599 CVCL_LI58 MB4.9.2 transformed cell line Norway rat CVCL_LI58 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brown adipose tissue Cell type=Preadipocyte.; Breed/subspecies: Wistar. Unspecified 21154600 CVCL_LI55 LICR-HN5 R9.1 cancer cell line human CVCL_LI55 CL:0000010 Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Oral cavity; tongue. Male 21154601 CVCL_LI56 SC263 R10.2 cancer cell line human CVCL_LI56 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.704_735del32; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (from parent cell line). Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux) 21154602 CVCL_UB90 UCSD-NDC5.20 induced pluripotent stem cell human CVCL_UB90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154603 CVCL_UB93 UCSD-SAD5.17 induced pluripotent stem cell human CVCL_UB93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154604 CVCL_UB94 UCSD-SAD6.9 induced pluripotent stem cell human CVCL_UB94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154605 CVCL_UB91 UCSD-SAD3.7 induced pluripotent stem cell human CVCL_UB91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154606 CVCL_UB92 UCSD-SAD4.43 induced pluripotent stem cell human CVCL_UB92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154607 CVCL_UB97 MBC647 cancer cell line human CVCL_UB97 HLA typing: A*24:02,01:02; B*14:02,49:01; C*02:02,07:01; DQA1*01:02,01:02; DQB1*06:13,05:01; DRB1*15:01,01:02 (PubMed=25960936) CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 21154608 CVCL_UB98 MPC298 cancer cell line human CVCL_UB98 CL:0000010 Female 21154609 CVCL_UB95 UCSD-SAD7D induced pluripotent stem cell human CVCL_UB95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154610 CVCL_UB96 Thomas cancer cell line human CVCL_UB96 HLA typing: A*02:11,25:01; B*52:01,18:01; C*15:02,12:03; DQA1*05:01,02:01; DQB1*03:01,02:01; DRB1*07:01,14:02 (PubMed=25960936) CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. 21154611 CVCL_UB99 MPC600 cancer cell line human CVCL_UB99 CL:0000010 Female 21154612 CVCL_UB82 WC013i-CMT2A-2.1 induced pluripotent stem cell human CVCL_UB82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154613 CVCL_UB83 WC014i-CMT2A-2.2 induced pluripotent stem cell human CVCL_UB83 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154614 CVCL_UB80 WC011i-CMT2A-1.2 induced pluripotent stem cell human CVCL_UB80 CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Unexplicit; Not described; Zygosity=Unspecified (WiCell) Derived from sampling site: Cell type=Fibroblast. Male 21154615 CVCL_UB81 WC012i-CMT2A-1.3 induced pluripotent stem cell human CVCL_UB81 CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Unexplicit; Not described; Zygosity=Unspecified (WiCell) Derived from sampling site: Cell type=Fibroblast. Male 21154616 CVCL_UB86 WC017i-CMT2A-3.2 induced pluripotent stem cell human CVCL_UB86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154617 CVCL_UB87 WC018i-CMT2A-3.3 induced pluripotent stem cell human CVCL_UB87 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154618 CVCL_UB84 WC015i-CMT2A-2.3 induced pluripotent stem cell human CVCL_UB84 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154619 CVCL_UB85 WC016i-CMT2A-3.1 induced pluripotent stem cell human CVCL_UB85 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21154620 CVCL_UB88 UCSD-NDC3.1 induced pluripotent stem cell human CVCL_UB88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154621 CVCL_UB89 UCSD-NDC4.43 induced pluripotent stem cell human CVCL_UB89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154622 CVCL_UB71 AI06e-SOX2YFP embryonic stem cell human CVCL_UB71 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a Flag-citrine-P2A-PuroR construct was introduced at the C-terminal end of one allele of SOX2 21154623 CVCL_UB72 AI07e-Timothy embryonic stem cell human CVCL_UB72 CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple_edited; p.Gly406Arg (c.1216G>A); ClinVar=VCV000017632; Zygosity=Homozygous; Note=By TALEN (WiCell). Male 21154624 CVCL_UB70 AI03e-DCXYFP embryonic stem cell human CVCL_UB70 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a FLAG-citrine-P2A-PuroR construct was introduced at the C-terminal end of the single copy DCX 21154625 CVCL_UB75 AI10e-KCTD13b embryonic stem cell human CVCL_UB75 CL:0000010 Knockout cell: Method=TALEN; HGNC; 22234; KCTD13. Male 21154626 CVCL_UB76 AI11e-OTX2YFP embryonic stem cell human CVCL_UB76 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a Flag-citrine-P2A-PuroR construct was introduced at the C-terminal end of one allele of OTX2 21154627 CVCL_UB73 AI08e-PAX6YFP embryonic stem cell human CVCL_UB73 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a Flag-citrine-P2A-PuroR construct was introduced at the C-terminal end of one allele of PAX6 21154628 CVCL_UB74 AI09e-KCTD13a embryonic stem cell human CVCL_UB74 CL:0000010 Knockout cell: Method=TALEN (1 of 2 alleles); HGNC; 22234; KCTD13. Male 21154629 CVCL_UB79 WC010i-CMT2A-1.1 induced pluripotent stem cell human CVCL_UB79 CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Unexplicit; Not described; Zygosity=Unspecified (WiCell) Derived from sampling site: Cell type=Fibroblast. Male 21154630 CVCL_UB77 AI12e-HOPX-CIT+/- embryonic stem cell human CVCL_UB77 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a Flag-citrine-P2A-PuroR construct was introduced at the C-terminal end of one allele of HOPX 21154631 CVCL_UB78 AI13e-HOPX-CIT+/+ embryonic stem cell human CVCL_UB78 CL:0000010 Transfected with: UniProtKB; P42212; Citrine (modified GFP at G-65, L-68, M-69, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a Flag-citrine-P2A-PuroR construct was introduced at the C-terminal end of both alleles of HOPX 21154632 CVCL_UB60 MCW113i-U7145 induced pluripotent stem cell human CVCL_UB60 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154633 CVCL_UB61 MCW114i-U2144 induced pluripotent stem cell human CVCL_UB61 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154634 CVCL_UB64 WC019i-SMA-GM13 induced pluripotent stem cell human CVCL_UB64 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=26190808) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Problematic cell line: Misclassified Parent cell line originally thought to be a SMA type 1 (SMA1) cell line but shown to be from a SMA type 2 (SMA2). 21154635 CVCL_UB65 WC020i-SMA-GM14 induced pluripotent stem cell human CVCL_UB65 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (PubMed=26190808) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21154636 CVCL_UB62 MCW115i-U2143 induced pluripotent stem cell human CVCL_UB62 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154637 CVCL_UB63 MCW116i-40001890 induced pluripotent stem cell human CVCL_UB63 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154638 CVCL_UB68 WC023i-SMA-GM232 induced pluripotent stem cell human CVCL_UB68 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=26190808) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154639 CVCL_UB69 WG0909 finite cell line human CVCL_UB69 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11013137); Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (PubMed=11013137) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154640 CVCL_UB66 WC021i-SMA-GM15 induced pluripotent stem cell human CVCL_UB66 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (PubMed=26190808) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21154641 CVCL_UB67 WC022i-SMA-GM77 induced pluripotent stem cell human CVCL_UB67 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (PubMed=26190808) Population: Caucasian; Derived from sampling site: Eye; ocular lens Cell type=Fibroblast.. Male 21154642 CVCL_UB50 MCW102i-UR117 induced pluripotent stem cell human CVCL_UB50 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154643 CVCL_UB53 MCW105i-U2130 induced pluripotent stem cell human CVCL_UB53 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154644 CVCL_UB54 MCW106i-U2120 induced pluripotent stem cell human CVCL_UB54 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154645 CVCL_UB51 MCW103i-40000237 induced pluripotent stem cell human CVCL_UB51 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154646 CVCL_UB52 MCW104i-U2175 induced pluripotent stem cell human CVCL_UB52 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154647 CVCL_UB57 MCW110i-U2170 induced pluripotent stem cell human CVCL_UB57 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154648 CVCL_UB58 MCW111i-40002422 induced pluripotent stem cell human CVCL_UB58 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154649 CVCL_UB55 MCW107i-40000886 induced pluripotent stem cell human CVCL_UB55 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154650 CVCL_UB56 MCW109i-40001470 induced pluripotent stem cell human CVCL_UB56 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154651 CVCL_UB59 MCW112i-40000893 induced pluripotent stem cell human CVCL_UB59 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154652 CVCL_UB42 MCW093i-40000435 induced pluripotent stem cell human CVCL_UB42 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154653 CVCL_UB43 MCW094i-U7120 induced pluripotent stem cell human CVCL_UB43 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154654 CVCL_UB40 MCW091i-U2202 induced pluripotent stem cell human CVCL_UB40 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154655 CVCL_UB41 MCW092i-U2390 induced pluripotent stem cell human CVCL_UB41 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154656 CVCL_UB46 MCW097i-40001654 induced pluripotent stem cell human CVCL_UB46 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154657 CVCL_UB47 MCW098i-40002583 induced pluripotent stem cell human CVCL_UB47 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154658 CVCL_UB44 MCW095i-U2311 induced pluripotent stem cell human CVCL_UB44 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154659 CVCL_UB45 MCW096i-40000169 induced pluripotent stem cell human CVCL_UB45 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154660 CVCL_UB48 MCW100i-U2341 induced pluripotent stem cell human CVCL_UB48 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154661 CVCL_UB49 MCW101i-40001005 induced pluripotent stem cell human CVCL_UB49 From: Broeckel U.; Medical College of Wisconsin; Milwaukee; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21154662 CVCL_D014 DS2-iPS10 induced pluripotent stem cell human CVCL_D014 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21154663 CVCL_D015 Hca-F cancer cell line house mouse CVCL_D015 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3HA. Omics: Mitochondrial genome sequenced (partial); Omics: Proteome analysis by 2D-DE/MS 21154664 CVCL_D012 DS1-iPS4 induced pluripotent stem cell human CVCL_D012 From: Children's Hospital Boston; Boston; USA CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21154665 CVCL_D013 DS2-iPS1 induced pluripotent stem cell human CVCL_D013 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21154666 CVCL_D018 P3NP cancer cell line house mouse CVCL_D018 CL:0000010 Group: Hybridoma fusion partner cell line. 21154667 CVCL_D019 HDN-16 cancer cell line human CVCL_D019 CL:0000010 21154668 CVCL_D016 Hca-P cancer cell line house mouse CVCL_D016 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3HA. Omics: Mitochondrial genome sequenced (partial); Omics: Proteome analysis by 2D-DE/MS 21154669 CVCL_D017 BHP 19-24 cancer cell line human CVCL_D017 CL:0000010 Unspecified 21154670 CVCL_D010 HSF8 embryonic stem cell human CVCL_D010 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Male 21154671 CVCL_D011 HSF9 embryonic stem cell human CVCL_D011 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Female 21154672 CVCL_D025 MC-MA1 cancer cell line human CVCL_D025 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female 21154673 CVCL_D026 MCCL-1 cancer cell line human CVCL_D026 CL:0000010 Derived from metastatic site: Cutaneous. Male 21154674 CVCL_D023 T1682 cancer cell line human CVCL_D023 CL:0000010 Derived from sampling site: Mediastinum. Omics: Array-based CGH Female 21154675 CVCL_D024 T1889 cancer cell line human CVCL_D024 CL:0000010 Omics: Array-based CGH. Male 21154676 CVCL_D029 M18 cancer cell line human CVCL_D029 HLA typing: A*29:02,29:02; B*49:01,49:01; C*07:01:01,07:01:01; DPB1*02:01:02,03:01; DQB1*03:02,06:01:01; DRB1*04:01,ND (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=17260012; PubMed=23851445) Omics: Array-based CGH. 21154677 CVCL_D027 MKL-2 cancer cell line human CVCL_D027 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803) Omics: Array-based CGH; Omics: Deep quantitative proteome analysis. Male Virology: Contains 1.7 copies of the genome of MCPyV per haploid cell (PubMed=23085629) Doubling time: 5 days (PubMed=20444890); 3 days (PubMed=30873613) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21154678 CVCL_D028 M-17 cancer cell line human CVCL_D028 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23851445). Female 21154679 CVCL_D021 MCC15 cancer cell line human CVCL_D021 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21154680 CVCL_D022 SP-49 cancer cell line human CVCL_D022 HLA typing: A*02:06,24:02; B*56:01,40:02; C*04:01,03:04; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*04:05,08:02 (PubMed=25960936) CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 60 hours (PubMed=3121553) 21154681 CVCL_D020 HDN-3 cancer cell line human CVCL_D020 CL:0000010 21154682 CVCL_D009 HSF7 embryonic stem cell human CVCL_D009 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Male 21154683 CVCL_D003 HSF-1 embryonic stem cell human CVCL_D003 From: University of California, San Francisco; San Francisco; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male 21154684 CVCL_D004 HSF-1-14 embryonic stem cell human CVCL_D004 From: University of California, San Francisco; San Francisco; USA. CL:0000010 Male 21154685 CVCL_D001 KiPS4F3 induced pluripotent stem cell human CVCL_D001 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21154686 CVCL_D002 KiPS4F4 induced pluripotent stem cell human CVCL_D002 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21154687 CVCL_D007 HSF12 embryonic stem cell human CVCL_D007 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Female 21154688 CVCL_D008 HSF13 embryonic stem cell human CVCL_D008 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Female 21154689 CVCL_D005 HSF-6 embryonic stem cell human CVCL_D005 From: University of California, San Francisco; San Francisco; USA CL:0000010 Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Female Registration: Swiss research registry; BAG-hES-IMP-0015; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC10-58. 21154690 CVCL_D006 HSF10 embryonic stem cell human CVCL_D006 From: Stanford University School of Medicine; Stanford; USA. CL:0000010 Female 21154691 CVCL_D000 KiPS4F2 induced pluripotent stem cell human CVCL_D000 From: The Salk Institute for Biological Studies; San Diego; USA CL:0000010 Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21154692 CVCL_2F83 AG13230 finite cell line human CVCL_2F83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (Coriell=AG13230) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154693 CVCL_2F84 AG13231 finite cell line human CVCL_2F84 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 7 PDL (Coriell=AG13231) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154694 CVCL_2F81 AG13228 finite cell line human CVCL_2F81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG13228) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154695 CVCL_2F82 AG13229 finite cell line human CVCL_2F82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG13229) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154696 CVCL_2F87 AG13235 finite cell line human CVCL_2F87 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154697 CVCL_2F88 AG13237 finite cell line human CVCL_2F88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [38%]; 46,XY,t(15;20)(p10;q10) [62%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 11 PDL (Coriell=AG13237) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154698 CVCL_2F85 AG13233 finite cell line human CVCL_2F85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG13233) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154699 CVCL_2F86 AG13234 finite cell line human CVCL_2F86 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; 46,XY,t(16;19); 46,XY,inv(1),t(7;14;15) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 9 PDL (Coriell=AG13234) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154700 CVCL_2F89 AG13244 finite cell line human CVCL_2F89 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,t(6;16)(p13;p21) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 28 PDL (Coriell=AG13244) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154701 CVCL_2F80 AG13227 finite cell line human CVCL_2F80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (Coriell=AG13227) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154702 CVCL_2F94 AG13297 finite cell line human CVCL_2F94 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 12 PDL (Coriell=AG13297) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154703 CVCL_2F95 AG05412 finite cell line human CVCL_2F95 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05412; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154704 CVCL_2F92 AG13285 finite cell line human CVCL_2F92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG13285) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154705 CVCL_2F93 AG13292 finite cell line human CVCL_2F93 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13292) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154706 CVCL_2F98 AG13308 finite cell line human CVCL_2F98 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 13 PDL (Coriell=AG13308) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154707 CVCL_2F99 AG13329 finite cell line human CVCL_2F99 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [52%]; 46,XY,t(8;12)(p21;p11) [34%]; 46,XY,add(8)(p23) [14%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13329) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154708 CVCL_2F96 AG13299 finite cell line human CVCL_2F96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 12 PDL (Coriell=AG13299) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154709 CVCL_2F97 AG13300 finite cell line human CVCL_2F97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [30%]; 46,XX,t(1;1)t(3;9) [34%]; 46,XX,t(2;10),del(13) [36%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (Coriell=AG13300) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154710 CVCL_2F90 AG13245 finite cell line human CVCL_2F90 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG13245) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154711 CVCL_2F91 AG13246 finite cell line human CVCL_2F91 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [78%]; 46,XX,t(1;15)(q1?;q4?),t(11;19)(q12;q12) [22%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 12 PDL (Coriell=AG13246) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154712 CVCL_2F61 AG13152 finite cell line human CVCL_2F61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (PubMed=9724752); 6 PDL (Coriell=AG13152) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154713 CVCL_2F62 AG13153 finite cell line human CVCL_2F62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 33 PDL (PubMed=9724752); Doubling time: 2.3 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154714 CVCL_2F60 AG13151 finite cell line human CVCL_2F60 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (Coriell=AG13151); Doubling time: 4.4 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154715 CVCL_2F65 AG13198 finite cell line human CVCL_2F65 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG13198) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154716 CVCL_2F66 AG13208 finite cell line human CVCL_2F66 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [90%]; 45,X [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 44 PDL (Coriell=AG13208) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154717 CVCL_2F63 AG13156 finite cell line human CVCL_2F63 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (PubMed=9724752); 37 PDL (Coriell=AG13156) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154718 CVCL_2F64 AG13197 finite cell line human CVCL_2F64 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 47,XY,+20,t(7;22)(p11;q13) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG13197) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154719 CVCL_2F69 AG13213 finite cell line human CVCL_2F69 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG13213) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154720 CVCL_2F67 AG13209 finite cell line human CVCL_2F67 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG13209) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154721 CVCL_2F68 AG13210 finite cell line human CVCL_2F68 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,add(15)(p13) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154722 CVCL_2F72 AG13218 finite cell line human CVCL_2F72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG13218) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154723 CVCL_2F73 AG13219 finite cell line human CVCL_2F73 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 54 PDL (Coriell=AG13219) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154724 CVCL_2F70 AG13216 finite cell line human CVCL_2F70 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 45,XY,-19 [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG13216) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154725 CVCL_2F71 AG13217 finite cell line human CVCL_2F71 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG13217) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154726 CVCL_2F76 AG13223 finite cell line human CVCL_2F76 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [24%]; 46,XY,t(12;18)(q13 or q14;q21) [76%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG13223) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154727 CVCL_2F77 AG13224 finite cell line human CVCL_2F77 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 19 PDL (Coriell=AG13224) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154728 CVCL_2F74 AG13220 finite cell line human CVCL_2F74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG13220) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154729 CVCL_2F75 AG13222 finite cell line human CVCL_2F75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG13222) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154730 CVCL_2F78 AG13225 finite cell line human CVCL_2F78 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 35 PDL (Coriell=AG13225) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154731 CVCL_2F79 AG13226 finite cell line human CVCL_2F79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [62%]; 46,XY,t(3;17)(p21;q21) [38%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG13226) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154732 CVCL_2F40 AG13093 finite cell line human CVCL_2F40 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG13093) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154733 CVCL_2F43 AG13096 finite cell line human CVCL_2F43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG13096) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154734 CVCL_2F44 AG13097 finite cell line human CVCL_2F44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG13097) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154735 CVCL_2F41 AG13094 finite cell line human CVCL_2F41 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 46,XY,der(15;17)(p10;q10),+17 [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG13094) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154736 CVCL_2F42 AG13095 finite cell line human CVCL_2F42 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG13095) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154737 CVCL_2F47 AG13100 finite cell line human CVCL_2F47 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG13100) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154738 CVCL_2F48 AG13101 finite cell line human CVCL_2F48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 21 PDL (Coriell=AG13101) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154739 CVCL_2F45 AG13098 finite cell line human CVCL_2F45 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [62%]; 46,XY,t(2;11)(p13;q23) [38%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG13098) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154740 CVCL_2F46 AG13099 finite cell line human CVCL_2F46 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 72 PDL (Coriell=AG13099) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154741 CVCL_2F49 AG13102 finite cell line human CVCL_2F49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 37 PDL (Coriell=AG13102) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154742 CVCL_UL91 CBTCi001-A induced pluripotent stem cell human CVCL_UL91 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21154743 CVCL_UL92 CBTCi002-A induced pluripotent stem cell human CVCL_UL92 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Female 21154744 CVCL_UL90 BIONi036-A induced pluripotent stem cell human CVCL_UL90 From: Bioneer A/S; Horsholm; Denmark. CL:0000010 21154745 CVCL_UL95 CIMHi002-A induced pluripotent stem cell human CVCL_UL95 From: Central Institute of Mental Health; Mannheim; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skeletal muscle Cell type=Fibroblast.. Male 21154746 CVCL_UL96 CIMHi003-A induced pluripotent stem cell human CVCL_UL96 From: Central Institute of Mental Health; Mannheim; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skeletal muscle Cell type=Fibroblast.. Male 21154747 CVCL_UL93 CDIi003-A induced pluripotent stem cell human CVCL_UL93 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 Male 21154748 CVCL_UL94 CIMHi001-A induced pluripotent stem cell human CVCL_UL94 From: Central Institute of Mental Health; Mannheim; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21154749 CVCL_UL99 DANi001-B induced pluripotent stem cell human CVCL_UL99 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21154750 CVCL_UL97 CRTDi003-A induced pluripotent stem cell human CVCL_UL97 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21154751 CVCL_UL98 DANi001-A induced pluripotent stem cell human CVCL_UL98 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21154752 CVCL_2F50 AG13103 finite cell line human CVCL_2F50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG13103); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154753 CVCL_2F51 AG13104 finite cell line human CVCL_2F51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [52%]; 46,XY,t(10;16) [48%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG13104) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154754 CVCL_2F54 AG13108 finite cell line human CVCL_2F54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (Coriell=AG13108) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154755 CVCL_2F55 AG13129 finite cell line human CVCL_2F55 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 41 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154756 CVCL_2F52 AG13105 finite cell line human CVCL_2F52 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(14;17) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG13105) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154757 CVCL_2F53 AG13106 finite cell line human CVCL_2F53 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 45,X [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG13106) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154758 CVCL_2F58 AG13146 finite cell line human CVCL_2F58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [89.4%]; 46,XY,t(1;3) [5.3%]; 46,XY,t(1;7) [5.3%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (Coriell=AG13146) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154759 CVCL_2F59 AG13150 finite cell line human CVCL_2F59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 43 PDL (Coriell=AG13150) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154760 CVCL_2F56 AG13144 finite cell line human CVCL_2F56 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 11 PDL (Coriell=AG13144); Doubling time: 2.8 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154761 CVCL_2F57 AG13145 finite cell line human CVCL_2F57 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21154762 CVCL_UL80 BIOMEDi001-A induced pluripotent stem cell human CVCL_UL80 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21154763 CVCL_UL81 BIOMEDi002-A induced pluripotent stem cell human CVCL_UL81 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21154764 CVCL_UL84 BIOMEDi005-A induced pluripotent stem cell human CVCL_UL84 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154765 CVCL_UL85 BIOMEDi006-A induced pluripotent stem cell human CVCL_UL85 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154766 CVCL_UL82 BIOMEDi003-A induced pluripotent stem cell human CVCL_UL82 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21154767 CVCL_UL83 BIOMEDi004-A induced pluripotent stem cell human CVCL_UL83 From: BioMedX Innovation Center; Heidelberg; Germany CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21154768 CVCL_UL88 AKOSi001-A induced pluripotent stem cell human CVCL_UL88 From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Glu20Ter (c.58G>T); ClinVar=VCV000008477; Zygosity=Heterozygous (PubMed=31669975); Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Cys47Phe (c.140G>T); ClinVar=VCV000549984; Zygosity=Heterozygous (PubMed=31669975) Derived from sampling site: Cell type=Fibroblast. Male 21154769 CVCL_UL89 BCRTi003-A induced pluripotent stem cell human CVCL_UL89 From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Discontinued: hPSCreg; BCRTi003-A; true. 21154770 CVCL_UL86 ZZUi012-A induced pluripotent stem cell human CVCL_UL86 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10947; SLC20A2; Simple; p.Val205Met (c.613G>A); Zygosity=Heterozygous (PubMed=30776674) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154771 CVCL_UL87 ZZUi013-A induced pluripotent stem cell human CVCL_UL87 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7014; MEOX2; Simple; p.His80del (c.228_230delCCA); Zygosity=Heterozygous (PubMed=30616143) Population: Chinese; Han; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 21154772 CVCL_CY56 GM06336 finite cell line human CVCL_CY56 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21154773 CVCL_CY57 GM09110 finite cell line human CVCL_CY57 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154774 CVCL_CY54 GM06330 finite cell line human CVCL_CY54 CL:0000010 Sequence variation: Mutation; HGNC; 8091; OAT; Simple; p.Ala226Val (c.677C>T); ClinVar=VCV000000181; Zygosity=Homozygous (Coriell) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21154775 CVCL_CY55 GM06335 finite cell line human CVCL_CY55 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21154776 CVCL_CY58 GM09112 finite cell line human CVCL_CY58 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154777 CVCL_CY59 GM09113 finite cell line human CVCL_CY59 CL:0000010 Sequence variation: Mutation; HGNC; 8091; OAT; Simple; p.Glu318Lys (c.952G>A); ClinVar=VCV000207045; Zygosity=Homozygous (PubMed=10617919) Population: Caucasian; Irish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154778 CVCL_CY52 IL-A55 hybridoma house mouse CVCL_CY52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bovine WC5 antigen (BoWC5). 21154779 CVCL_CY53 D11G10 hybridoma house mouse CVCL_CY53 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:27731; Asialo-GM2 ganglioside. 21154780 CVCL_CY50 MB15C11 hybridoma CVCL_CY50 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21154781 CVCL_CY51 IL-A54 hybridoma house mouse CVCL_CY51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine WC5 antigen (BoWC5). 21154782 CVCL_CY67 ND00501 transformed cell line human CVCL_CY67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154783 CVCL_CY68 ND00729 transformed cell line human CVCL_CY68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154784 CVCL_CY65 ND00084 transformed cell line human CVCL_CY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154785 CVCL_CY66 ND00376 transformed cell line human CVCL_CY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154786 CVCL_CY69 ND00730 transformed cell line human CVCL_CY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154787 CVCL_CY60 GM09115 finite cell line human CVCL_CY60 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154788 CVCL_CY63 GM09118 finite cell line human CVCL_CY63 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154789 CVCL_CY64 ND00042 transformed cell line human CVCL_CY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154790 CVCL_CY61 GM09116 finite cell line human CVCL_CY61 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154791 CVCL_CY62 GM09117 finite cell line human CVCL_CY62 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154792 CVCL_CY34 GM03943 transformed cell line human CVCL_CY34 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with familial adenomatous polyposis but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21154793 CVCL_CY35 GM03944 finite cell line human CVCL_CY35 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154794 CVCL_CY32 GM03941 transformed cell line human CVCL_CY32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with familial adenomatous polyposis but at risk for disease; Derived from sampling site: Peripheral blood. Male 21154795 CVCL_CY33 GM03942 finite cell line human CVCL_CY33 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with familial adenomatous polyposis but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154796 CVCL_CY38 GM03947 transformed cell line human CVCL_CY38 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154797 CVCL_CY39 GM03950 finite cell line human CVCL_CY39 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with familial adenomatous polyposis but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154798 CVCL_CY36 GM03945 transformed cell line human CVCL_CY36 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154799 CVCL_CY37 GM03946 finite cell line human CVCL_CY37 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154800 CVCL_CY30 GM03224 transformed cell line human CVCL_CY30 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154801 CVCL_CY31 GM03940 finite cell line human CVCL_CY31 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with familial adenomatous polyposis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154802 CVCL_CY29 GM03223 finite cell line human CVCL_CY29 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154803 CVCL_CY45 GM06888 finite cell line human CVCL_CY45 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06888; probable Male 21154804 CVCL_CY46 GM06964 finite cell line human CVCL_CY46 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154805 CVCL_CY43 GM03954 finite cell line human CVCL_CY43 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154806 CVCL_CY44 GM03955 transformed cell line human CVCL_CY44 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154807 CVCL_CY49 B13B hybridoma house mouse CVCL_CY49 CL:0000010 Discontinued: ATCC; CRL-2636; true. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q48245; Helicobacter pylori vacA 21154808 CVCL_CY47 GM07501 transformed cell line human CVCL_CY47 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154809 CVCL_CY48 GM07516 transformed cell line human CVCL_CY48 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154810 CVCL_CY41 GM03952 finite cell line human CVCL_CY41 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with familial adenomatous polyposis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154811 CVCL_CY42 GM03953 transformed cell line human CVCL_CY42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with familial adenomatous polyposis but at risk for disease; Derived from sampling site: Peripheral blood. Female 21154812 CVCL_CY40 GM03951 transformed cell line human CVCL_CY40 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with familial adenomatous polyposis but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21154813 CVCL_CY12 GM02675 transformed cell line human CVCL_CY12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154814 CVCL_CY13 GM02679 transformed cell line human CVCL_CY13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154815 CVCL_CY10 GM02640 finite cell line human CVCL_CY10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21154816 CVCL_CY11 GM02641 finite cell line human CVCL_CY11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21154817 CVCL_CY16 GM02709 transformed cell line human CVCL_CY16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154818 CVCL_CY17 GM02710 finite cell line human CVCL_CY17 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02710; probable Male 21154819 CVCL_CY14 GM02680 transformed cell line human CVCL_CY14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154820 CVCL_CY15 GM02708 finite cell line human CVCL_CY15 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Male 21154821 CVCL_CY09 GM02639 finite cell line human CVCL_CY09 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Male 21154822 CVCL_CY07 GM02616 finite cell line human CVCL_CY07 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21154823 CVCL_CY08 GM02617 finite cell line human CVCL_CY08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21154824 CVCL_CY23 GM02785 transformed cell line human CVCL_CY23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154825 CVCL_CY24 GM02812 transformed cell line human CVCL_CY24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154826 CVCL_CY21 GM02741 transformed cell line human CVCL_CY21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154827 CVCL_CY22 GM02766 transformed cell line human CVCL_CY22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154828 CVCL_CY27 GM03313 finite cell line human CVCL_CY27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03313; probable Male 21154829 CVCL_CY28 GM03355 transformed cell line human CVCL_CY28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03355; probable Female 21154830 CVCL_CY25 GM02866 transformed cell line human CVCL_CY25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154831 CVCL_CY26 GM02869 finite cell line human CVCL_CY26 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21154832 CVCL_CY20 GM02728 transformed cell line human CVCL_CY20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02728; probable Female 21154833 CVCL_CY18 GM02711 transformed cell line human CVCL_CY18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154834 CVCL_CY19 GM02714 transformed cell line human CVCL_CY19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154835 CVCL_CY01 ND20121 transformed cell line human CVCL_CY01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154836 CVCL_CY02 GM01874 finite cell line human CVCL_CY02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21154837 CVCL_CY00 ND00025 transformed cell line human CVCL_CY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154838 CVCL_CY05 GM01878 finite cell line human CVCL_CY05 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Female 21154839 CVCL_CY06 GM02615 finite cell line human CVCL_CY06 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21154840 CVCL_CY03 GM01875 finite cell line human CVCL_CY03 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21154841 CVCL_CY04 GM01876 finite cell line human CVCL_CY04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21154842 CVCL_LR49 BayGenomics ES cell line CSA032 embryonic stem cell house mouse CVCL_LR49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922832; Relch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154843 CVCL_M349 TC-1 [Human renal cell carcinoma] cancer cell line human CVCL_M349 CL:0000010 Population: Indian; Bengali; Derived from sampling site: Kidney. Male 21154844 CVCL_LR47 BayGenomics ES cell line CSA026 embryonic stem cell house mouse CVCL_LR47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913815; Zkscan8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154845 CVCL_M347 L-872 cancer cell line human CVCL_M347 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=16631476); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Unspecified (PubMed=26428435) Derived from sampling site: Bone; rib. Male 21154846 CVCL_LR48 BayGenomics ES cell line CSA029 embryonic stem cell house mouse CVCL_LR48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917689; Taf15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154847 CVCL_M348 L-1062 cancer cell line human CVCL_M348 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=16631476); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (PubMed=26428435) Derived from sampling site: Bone; tibia. Male 21154848 CVCL_LR45 BayGenomics ES cell line CSA024 embryonic stem cell house mouse CVCL_LR45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154849 CVCL_M345 HHS-89 cancer cell line human CVCL_M345 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154850 CVCL_LR46 BayGenomics ES cell line CSA025 embryonic stem cell house mouse CVCL_LR46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154851 CVCL_M346 QGY-8105 cancer cell line human CVCL_M346 CL:0000010 Population: Chinese. 21154852 CVCL_LR43 BayGenomics ES cell line CSA022 embryonic stem cell house mouse CVCL_LR43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922855; Kdm5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154853 CVCL_M343 HHS-56 cancer cell line human CVCL_M343 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154854 CVCL_LR44 BayGenomics ES cell line CSA023 embryonic stem cell house mouse CVCL_LR44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917140; Zfp219 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154855 CVCL_M344 HHS-85 cancer cell line human CVCL_M344 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154856 CVCL_LR41 BayGenomics ES cell line CSA019 embryonic stem cell house mouse CVCL_LR41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154857 CVCL_M341 HHS-20 cancer cell line human CVCL_M341 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154858 CVCL_LR42 BayGenomics ES cell line CSA021 embryonic stem cell house mouse CVCL_LR42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343297; Drg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154859 CVCL_M342 HHS-26 cancer cell line human CVCL_M342 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154860 CVCL_LR40 BayGenomics ES cell line CSA017 embryonic stem cell house mouse CVCL_LR40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154861 CVCL_M340 HHP-40 cancer cell line human CVCL_M340 CL:0000010 Population: Southeast Asian; Thai; Karyotypic information: Hypotetraploid; 76 chromosomes; Derived from sampling site: Liver. Male 21154862 CVCL_LR58 BayGenomics ES cell line CSA049 embryonic stem cell house mouse CVCL_LR58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354723; Pnpla6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154863 CVCL_M358 IBH-7 cancer cell line human CVCL_M358 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Female Characteristics: ER-alpha, ER-beta and PR-positive (PubMed=15095293) Doubling time: 49.63 hours (PubMed=15095293) 21154864 CVCL_LR59 BayGenomics ES cell line CSA050 embryonic stem cell house mouse CVCL_LR59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154865 CVCL_M359 HCC-S102 cancer cell line human CVCL_M359 CL:0000010 Population: Southeast Asian; Thai Omics: Secretome proteome analysis. 21154866 CVCL_LR56 BayGenomics ES cell line CSA047 embryonic stem cell house mouse CVCL_LR56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202880; Traf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154867 CVCL_M356 IBH-4 cancer cell line human CVCL_M356 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Female Characteristics: ER-alpha, ER-beta and PR-positive (PubMed=15095293) Doubling time: 43.47 hours (PubMed=15095293) 21154868 CVCL_LR57 BayGenomics ES cell line CSA048 embryonic stem cell house mouse CVCL_LR57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443858; Pcif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154869 CVCL_M357 IBH-6 cancer cell line human CVCL_M357 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Female Characteristics: ER-alpha, ER-beta and PR-positive (PubMed=15095293) Doubling time: 39.12 hours (PubMed=15095293) 21154870 CVCL_LR54 BayGenomics ES cell line CSA041 embryonic stem cell house mouse CVCL_LR54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109336; Etv6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154871 CVCL_M354 MDA-MB-231LLM cancer cell line human CVCL_M354 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21154872 CVCL_LR55 BayGenomics ES cell line CSA046 embryonic stem cell house mouse CVCL_LR55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924270; Atl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154873 CVCL_M355 MCF-7/Taxol cancer cell line human CVCL_M355 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female 21154874 CVCL_LR52 BayGenomics ES cell line CSA038 embryonic stem cell house mouse CVCL_LR52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448506; Pi4ka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154875 CVCL_M352 X63-omIL-3 cancer cell line house mouse CVCL_M352 CL:0000010 Transfected with: MGI; MGI:96552; Il3 Breed/subspecies: BALB/c. Female 21154876 CVCL_LR53 BayGenomics ES cell line CSA039 embryonic stem cell house mouse CVCL_LR53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154877 CVCL_M353 HCLO cancer cell line human CVCL_M353 CL:0000010 21154878 CVCL_LR50 BayGenomics ES cell line CSA035 embryonic stem cell house mouse CVCL_LR50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858415; Ddx20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154879 CVCL_M350 TC1 [Mouse ESC] embryonic stem cell house mouse CVCL_M350 CL:0000010 Breed/subspecies: 129S6/SvEvTacfBR. Omics: SNP array analysis Unspecified 21154880 CVCL_LR51 BayGenomics ES cell line CSA036 embryonic stem cell house mouse CVCL_LR51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154881 CVCL_M351 TB-6c spontaneously immortalized cell line CVCL_M351 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 21154882 CVCL_D999 MRC-iPS-81 induced pluripotent stem cell human CVCL_D999 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154883 CVCL_CX99 ND00024 transformed cell line human CVCL_CX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154884 CVCL_D993 MRC-iPS-76 induced pluripotent stem cell human CVCL_D993 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154885 CVCL_CX93 ND00001 transformed cell line human CVCL_CX93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154886 CVCL_D994 MRC-iPS-77 induced pluripotent stem cell human CVCL_D994 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000160; probable Male 21154887 CVCL_CX94 ND00005 transformed cell line human CVCL_CX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154888 CVCL_CX91 GM25445 finite cell line human CVCL_CX91 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1080Ilefs*18 (c.3234_3237_dupATTT); Zygosity=Heterozygous (Coriell) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154889 CVCL_D991 MRC-iPS-74 induced pluripotent stem cell human CVCL_D991 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154890 CVCL_CX92 GM25504 finite cell line human CVCL_CX92 CL:0000010 Sequence variation: Mutation; HGNC; 18127; TUBGCP6; Simple; p.Ter1820Glyext*16 (c.5458T>G); ClinVar=VCV000030809; Zygosity=Heterozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154891 CVCL_D992 MRC-iPS-75 induced pluripotent stem cell human CVCL_D992 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: DNA methylation analysis Discontinued: JCRB; NIHS0601; true; Discontinued: SKIP; SKIP000014; probable Male 21154892 CVCL_D997 MRC-iPS-8 induced pluripotent stem cell human CVCL_D997 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154893 CVCL_CX97 ND00016 transformed cell line human CVCL_CX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154894 CVCL_D998 MRC-iPS-80 induced pluripotent stem cell human CVCL_D998 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154895 CVCL_CX98 ND00022 transformed cell line human CVCL_CX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21154896 CVCL_LR29 BayGenomics ES cell line BGC522 embryonic stem cell house mouse CVCL_LR29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154897 CVCL_D995 MRC-iPS-78 induced pluripotent stem cell human CVCL_D995 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154898 CVCL_CX95 ND00009 transformed cell line human CVCL_CX95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154899 CVCL_M329 NT-hESC-11 embryonic stem cell human CVCL_M329 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154900 CVCL_D996 MRC-iPS-79 induced pluripotent stem cell human CVCL_D996 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154901 CVCL_CX96 ND00011 transformed cell line human CVCL_CX96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154902 CVCL_LR27 BayGenomics ES cell line BGC518 embryonic stem cell house mouse CVCL_LR27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154903 CVCL_M327 NT-hESC-1 embryonic stem cell human CVCL_M327 CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12016006. Problematic cell line: Retracted The paper reporting this cell line (PubMed=14963337) has been retracted due to fraud (see PubMed=16410485). 21154904 CVCL_LR28 BayGenomics ES cell line BGC520 embryonic stem cell house mouse CVCL_LR28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105926; Rab5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154905 CVCL_M328 NT-hESC-10 embryonic stem cell human CVCL_M328 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154906 CVCL_LR25 BayGenomics ES cell line BGC489 embryonic stem cell house mouse CVCL_LR25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154907 CVCL_M325 XP218BE LCL transformed cell line human CVCL_M325 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154908 CVCL_LR26 BayGenomics ES cell line BGC500 embryonic stem cell house mouse CVCL_LR26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154909 CVCL_M326 XP54BE transformed cell line human CVCL_M326 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys692Ter (c.2074A>T); ClinVar=VCV000496267; Zygosity=Heterozygous (PubMed=16081512) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154910 CVCL_LR23 BayGenomics ES cell line BGC485 embryonic stem cell house mouse CVCL_LR23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154911 CVCL_M323 XP35BE finite cell line human CVCL_M323 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile199Profs*52 (c.594_595insCCCCCCAG) (199insPP); Zygosity=Heterozygous (PubMed=18470933; PubMed=19934020); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=18470933; PubMed=19934020) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154912 CVCL_LR24 BayGenomics ES cell line BGC487 embryonic stem cell house mouse CVCL_LR24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159711; Usp33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154913 CVCL_M324 XP86BE LCL transformed cell line human CVCL_M324 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (from autologous cell line XP86BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154914 CVCL_CX90 GM25444 finite cell line human CVCL_CX90 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154915 CVCL_D990 MRC-iPS-73 induced pluripotent stem cell human CVCL_D990 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154916 CVCL_LR21 BayGenomics ES cell line BGC482 embryonic stem cell house mouse CVCL_LR21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914290; Ddx17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154917 CVCL_M321 XP34BE finite cell line human CVCL_M321 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile199Profs*52 (c.594_595insCCCCCCAG) (199insPP); Zygosity=Heterozygous (PubMed=18470933; PubMed=19934020); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=18470933; PubMed=19934020) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21154918 CVCL_LR22 BayGenomics ES cell line BGC483 embryonic stem cell house mouse CVCL_LR22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99173; Zfp26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154919 CVCL_M322 XP35BE LCL transformed cell line human CVCL_M322 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile199Profs*52 (c.594_595insCCCCCCAG) (199insPP); Zygosity=Heterozygous (from autologous cell line XP35BE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP35BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154920 CVCL_LR20 BayGenomics ES cell line BGC479 embryonic stem cell house mouse CVCL_LR20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154921 CVCL_M320 XP34BE LCL transformed cell line human CVCL_M320 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile199Profs*52 (c.594_595insCCCCCCAG) (199insPP); Zygosity=Heterozygous (from autologous cell line XP34BE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP34BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154922 CVCL_LR38 BayGenomics ES cell line CSA014 embryonic stem cell house mouse CVCL_LR38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154923 CVCL_M338 NT-hESC-9 embryonic stem cell human CVCL_M338 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154924 CVCL_LR39 BayGenomics ES cell line CSA015 embryonic stem cell house mouse CVCL_LR39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154925 CVCL_M339 HHP-16 cancer cell line human CVCL_M339 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver. Unspecified 21154926 CVCL_LR36 BayGenomics ES cell line CSA008 embryonic stem cell house mouse CVCL_LR36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154927 CVCL_M336 NT-hESC-7 embryonic stem cell human CVCL_M336 CL:0000010 Female Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154928 CVCL_LR37 BayGenomics ES cell line CSA012 embryonic stem cell house mouse CVCL_LR37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88031; Anxa7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154929 CVCL_M337 NT-hESC-8 embryonic stem cell human CVCL_M337 CL:0000010 Female Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154930 CVCL_LR34 BayGenomics ES cell line CSA006 embryonic stem cell house mouse CVCL_LR34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154931 CVCL_M334 NT-hESC-5 embryonic stem cell human CVCL_M334 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154932 CVCL_LR35 BayGenomics ES cell line CSA007 embryonic stem cell house mouse CVCL_LR35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154933 CVCL_M335 NT-hESC-6 embryonic stem cell human CVCL_M335 CL:0000010 Female Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154934 CVCL_LR32 BayGenomics ES cell line CSA004 embryonic stem cell house mouse CVCL_LR32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143886; Dot1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154935 CVCL_M332 NT-hESC-3 embryonic stem cell human CVCL_M332 CL:0000010 Female Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154936 CVCL_LR33 BayGenomics ES cell line CSA005 embryonic stem cell house mouse CVCL_LR33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97346; Nktr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154937 CVCL_M333 NT-hESC-4 embryonic stem cell human CVCL_M333 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154938 CVCL_LR30 BayGenomics ES cell line BGC532 embryonic stem cell house mouse CVCL_LR30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154939 CVCL_M330 NT-hESC-12 embryonic stem cell human CVCL_M330 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154940 CVCL_LR31 BayGenomics ES cell line CSA003 embryonic stem cell house mouse CVCL_LR31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154941 CVCL_M331 NT-hESC-2 embryonic stem cell human CVCL_M331 CL:0000010 Male Problematic cell line: Retracted The paper reporting this cell line (PubMed=15905366) has been retracted due to fraud (see PubMed=16410485).. 21154942 CVCL_CX79 GM23373 finite cell line human CVCL_CX79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154943 CVCL_D979 MRC-iPS-63 induced pluripotent stem cell human CVCL_D979 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154944 CVCL_CX77 GM23320 transformed cell line human CVCL_CX77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154945 CVCL_D977 MRC-iPS-61 induced pluripotent stem cell human CVCL_D977 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154946 CVCL_CX78 GM23328 transformed cell line human CVCL_CX78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154947 CVCL_D978 MRC-iPS-62 induced pluripotent stem cell human CVCL_D978 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154948 CVCL_CX71 GM22520 transformed cell line human CVCL_CX71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154949 CVCL_D971 MRC-iPS-56 induced pluripotent stem cell human CVCL_D971 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000163; probable Male 21154950 CVCL_CX72 GM22566 transformed cell line human CVCL_CX72 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154951 CVCL_D972 MRC-iPS-57 induced pluripotent stem cell human CVCL_D972 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154952 CVCL_CX70 GM22087 transformed cell line human CVCL_CX70 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154953 CVCL_D970 MRC-iPS-55 induced pluripotent stem cell human CVCL_D970 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154954 CVCL_LR09 BayGenomics ES cell line BGC424 embryonic stem cell house mouse CVCL_LR09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154955 CVCL_M309 XP22BE LCL transformed cell line human CVCL_M309 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2033+2T>G (IVS9+2T>G); ClinVar=VCV000000257; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21154956 CVCL_CX75 GM23151 finite cell line human CVCL_CX75 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21154957 CVCL_D975 MRC-iPS-6 induced pluripotent stem cell human CVCL_D975 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154958 CVCL_CX76 GM23152 finite cell line human CVCL_CX76 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21154959 CVCL_D976 MRC-iPS-60 induced pluripotent stem cell human CVCL_D976 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154960 CVCL_LR07 BayGenomics ES cell line BGC417 embryonic stem cell house mouse CVCL_LR07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154961 CVCL_M307 XP31BE LCL transformed cell line human CVCL_M307 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; c.764+1G>C; Zygosity=Hemizygous; Note=Splice donor mutation (from autologous cell line XP31BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154962 CVCL_CX73 GM22567 transformed cell line human CVCL_CX73 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154963 CVCL_D973 MRC-iPS-58 induced pluripotent stem cell human CVCL_D973 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154964 CVCL_LR08 BayGenomics ES cell line BGC420 embryonic stem cell house mouse CVCL_LR08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154965 CVCL_M308 XP31BE finite cell line human CVCL_M308 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; c.764+1G>C; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=18368133) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154966 CVCL_CX74 GM22568 transformed cell line human CVCL_CX74 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154967 CVCL_D974 MRC-iPS-59 induced pluripotent stem cell human CVCL_D974 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154968 CVCL_LR05 BayGenomics ES cell line BGC411 embryonic stem cell house mouse CVCL_LR05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154969 CVCL_M305 XP32BE LCL transformed cell line human CVCL_M305 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154970 CVCL_LR06 BayGenomics ES cell line BGC413 embryonic stem cell house mouse CVCL_LR06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154971 CVCL_M306 XP32BE finite cell line human CVCL_M306 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154972 CVCL_LR03 BayGenomics ES cell line BGC400 embryonic stem cell house mouse CVCL_LR03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915010; Slc38a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154973 CVCL_M303 XP33BE LCL transformed cell line human CVCL_M303 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154974 CVCL_LR04 BayGenomics ES cell line BGC410 embryonic stem cell house mouse CVCL_LR04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154975 CVCL_M304 XP33BE finite cell line human CVCL_M304 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154976 CVCL_LR01 BayGenomics ES cell line BGC393 embryonic stem cell house mouse CVCL_LR01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342005; Mthfd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154977 CVCL_M301 XP24BE LCL transformed cell line human CVCL_M301 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>G (IVS5.1-2A>G); ClinVar=VCV000550100; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=16081512); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg155Ter (c.463C>T); ClinVar=VCV000496268; Zygosity=Heterozygous (PubMed=16081512) Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154978 CVCL_LR02 BayGenomics ES cell line BGC397 embryonic stem cell house mouse CVCL_LR02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154979 CVCL_M302 XP24BE finite cell line human CVCL_M302 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>G (IVS5.1-2A>G); ClinVar=VCV000550100; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg155Ter (c.463C>T); ClinVar=VCV000496268; Zygosity=Heterozygous (Coriell) Population: Caucasian; Hungarian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154980 CVCL_LR00 BayGenomics ES cell line BGC390 embryonic stem cell house mouse CVCL_LR00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108087; Hars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154981 CVCL_M300 XP26BE finite cell line human CVCL_M300 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154982 CVCL_CX88 GM25441 finite cell line human CVCL_CX88 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154983 CVCL_D988 MRC-iPS-71 induced pluripotent stem cell human CVCL_D988 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154984 CVCL_CX89 GM25442 finite cell line human CVCL_CX89 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1080Ilefs*18 (c.3234_3237_dupATTT); Zygosity=Heterozygous (Coriell) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21154985 CVCL_D989 MRC-iPS-72 induced pluripotent stem cell human CVCL_D989 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154986 CVCL_CX82 GM23945 finite cell line human CVCL_CX82 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154987 CVCL_D982 MRC-iPS-66 induced pluripotent stem cell human CVCL_D982 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154988 CVCL_CX83 GM25247 transformed cell line human CVCL_CX83 CL:0000010 Sequence variation: Mutation; HGNC; 25928; WDR73; Simple; p.Phe296Leufs*26 (c.888delT); ClinVar=VCV000225244; Zygosity=Heterozygous (PubMed=26070982) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21154989 CVCL_D983 MRC-iPS-67 induced pluripotent stem cell human CVCL_D983 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154990 CVCL_CX80 GM23499 transformed cell line human CVCL_CX80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154991 CVCL_D980 MRC-iPS-64 induced pluripotent stem cell human CVCL_D980 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154992 CVCL_CX81 GM23633 transformed cell line human CVCL_CX81 CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly12Valfs*2 (c.35delG); ClinVar=VCV000017004; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21154993 CVCL_D981 MRC-iPS-65 induced pluripotent stem cell human CVCL_D981 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000165; probable Male 21154994 CVCL_CX86 GM25438 finite cell line human CVCL_CX86 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ser738Ter (c.2213C>A); Zygosity=Heterozygous (Coriell) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154995 CVCL_D986 MRC-iPS-7 induced pluripotent stem cell human CVCL_D986 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154996 CVCL_CX87 GM25440 finite cell line human CVCL_CX87 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21154997 CVCL_D987 MRC-iPS-70 induced pluripotent stem cell human CVCL_D987 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21154998 CVCL_LR18 BayGenomics ES cell line BGC468 embryonic stem cell house mouse CVCL_LR18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891925; Hnrnph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21154999 CVCL_M318 XP132BE LCL transformed cell line human CVCL_M318 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Honduran; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155000 CVCL_CX84 GM25248 finite cell line human CVCL_CX84 CL:0000010 Sequence variation: Mutation; HGNC; 25928; WDR73; Simple; p.Phe296Leufs*26 (c.888delT); ClinVar=VCV000225244; Zygosity=Heterozygous (PubMed=26070982) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21155001 CVCL_D984 MRC-iPS-68 induced pluripotent stem cell human CVCL_D984 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155002 CVCL_LR19 BayGenomics ES cell line BGC474 embryonic stem cell house mouse CVCL_LR19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155003 CVCL_M319 XP132BE finite cell line human CVCL_M319 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Honduran; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155004 CVCL_CX85 GM25249 transformed cell line human CVCL_CX85 CL:0000010 Sequence variation: Mutation; HGNC; 25928; WDR73; Simple; p.Phe296Leufs*26 (c.888delT); ClinVar=VCV000225244; Zygosity=Heterozygous (PubMed=26070982) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155005 CVCL_D985 MRC-iPS-69 induced pluripotent stem cell human CVCL_D985 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155006 CVCL_LR16 BayGenomics ES cell line BGC459 embryonic stem cell house mouse CVCL_LR16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155007 CVCL_M316 XP65BE finite cell line human CVCL_M316 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gln136Ter (c.406C>T) (C603T); ClinVar=VCV000016578; Zygosity=Heterozygous (PubMed=12060391); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala874Thr (c.2620G>A) (G2817A); ClinVar=VCV000016577; Zygosity=Heterozygous (PubMed=12060391) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155008 CVCL_LR17 BayGenomics ES cell line BGC464 embryonic stem cell house mouse CVCL_LR17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339795; Smc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155009 CVCL_M317 XP105BE transformed cell line human CVCL_M317 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Homozygous (PubMed=16081512) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155010 CVCL_LR14 BayGenomics ES cell line BGC456 embryonic stem cell house mouse CVCL_LR14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153049; Klf16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155011 CVCL_M314 XP87BE finite cell line human CVCL_M314 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu141Leufs*6 (c.420_423delTGAG) (p.Ser140fs*146) (525_528delTGAG); ClinVar=VCV000550638; Zygosity=Heterozygous (PubMed=16081512); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys522Ter (c.1564A>T); ClinVar=VCV000549952; Zygosity=Heterozygous (PubMed=16081512) Population: Jewish; Ashkenazi/Sephardic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155012 CVCL_LR15 BayGenomics ES cell line BGC458 embryonic stem cell house mouse CVCL_LR15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155013 CVCL_M315 XP87BE LCL transformed cell line human CVCL_M315 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu141Leufs*6 (c.420_423delTGAG) (p.Ser140fs*146) (525_528delTGAG); ClinVar=VCV000550638; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys522Ter (c.1564A>T); ClinVar=VCV000549952; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi/Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155014 CVCL_LR12 BayGenomics ES cell line BGC434 embryonic stem cell house mouse CVCL_LR12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155015 CVCL_M312 XP82DC finite cell line human CVCL_M312 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gln16Ter (c.46C>T); Zygosity=Heterozygous (PubMed=12060391); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Val869Glyfs*11 (c.2606_2607delTG) (c.2604_2605TG[1]) (2801delTG); ClinVar=VCV001065165; Zygosity=Heterozygous (PubMed=12060391) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155016 CVCL_LR13 BayGenomics ES cell line BGC435 embryonic stem cell house mouse CVCL_LR13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155017 CVCL_M313 XP86BE finite cell line human CVCL_M313 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (CelloPub=CLPUB00563) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155018 CVCL_LR10 BayGenomics ES cell line BGC425 embryonic stem cell house mouse CVCL_LR10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155019 CVCL_M310 XP65BE LCL transformed cell line human CVCL_M310 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gln136Ter (c.406C>T) (C603T); ClinVar=VCV000016578; Zygosity=Heterozygous (from autologous cell line XP65BE); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala874Thr (c.2620G>A) (G2817A); ClinVar=VCV000016577; Zygosity=Heterozygous (from autologous cell line XP65BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155020 CVCL_LR11 BayGenomics ES cell line BGC428 embryonic stem cell house mouse CVCL_LR11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155021 CVCL_M311 XP96TA finite cell line human CVCL_M311 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu308Serfs*12 (c.922_923delTC) (1116delTC); ClinVar=VCV000929130; Zygosity=Homozygous (PubMed=12060391; PubMed=26184184) Population: Palestinian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155022 CVCL_CX57 GM00695 finite cell line human CVCL_CX57 CL:0000010 Sequence variation: Mutation; HGNC; 18640; LDLRAP1; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV000004775; Zygosity=Heterozygous (Coriell) Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Male 21155023 CVCL_D957 MRC-iPS-43 induced pluripotent stem cell human CVCL_D957 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000166; probable Male 21155024 CVCL_CX58 CHO-EU-1 spontaneously immortalized cell line CVCL_CX58 CL:0000010 Derived from sampling site: Ovary. Female 21155025 CVCL_D958 MRC-iPS-44 induced pluripotent stem cell human CVCL_D958 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155026 CVCL_CX55 GM00641 finite cell line human CVCL_CX55 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00641; probable Male 21155027 CVCL_D955 MRC-iPS-41 induced pluripotent stem cell human CVCL_D955 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155028 CVCL_CX56 GM00644 finite cell line human CVCL_CX56 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00644; probable Female 21155029 CVCL_D956 MRC-iPS-42 induced pluripotent stem cell human CVCL_D956 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155030 CVCL_CX59 CHO-EU-2 spontaneously immortalized cell line CVCL_CX59 CL:0000010 Derived from sampling site: Ovary. Female 21155031 CVCL_D959 MRC-iPS-45 induced pluripotent stem cell human CVCL_D959 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155032 CVCL_CX50 GM00561 finite cell line human CVCL_CX50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00561; probable Female 21155033 CVCL_D950 MRC-iPS-37 induced pluripotent stem cell human CVCL_D950 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155034 CVCL_CX53 GM00915 finite cell line human CVCL_CX53 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00915; probable Male 21155035 CVCL_D953 MRC-iPS-4 induced pluripotent stem cell human CVCL_D953 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155036 CVCL_CX54 GM02407 finite cell line human CVCL_CX54 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02407; probable Female 21155037 CVCL_D954 MRC-iPS-40 induced pluripotent stem cell human CVCL_D954 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Glycosphingolipids analysis Discontinued: JCRB; NIHS0600; true; Discontinued: SKIP; SKIP000013; probable Male 21155038 CVCL_CX51 GM00754 finite cell line human CVCL_CX51 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00754; probable Female 21155039 CVCL_D951 MRC-iPS-38 induced pluripotent stem cell human CVCL_D951 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155040 CVCL_CX52 GM00133 finite cell line human CVCL_CX52 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00133; probable Male 21155041 CVCL_D952 MRC-iPS-39 induced pluripotent stem cell human CVCL_D952 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155042 CVCL_CX68 GM22005 transformed cell line human CVCL_CX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155043 CVCL_D968 MRC-iPS-53 induced pluripotent stem cell human CVCL_D968 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155044 CVCL_CX69 GM22086 transformed cell line human CVCL_CX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 21155045 CVCL_D969 MRC-iPS-54 induced pluripotent stem cell human CVCL_D969 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155046 CVCL_CX66 IMR-91S finite cell line human CVCL_CX66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; I91S-06; probable; Discontinued: Coriell; I91S-07; probable Male 21155047 CVCL_D966 MRC-iPS-51 induced pluripotent stem cell human CVCL_D966 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000162; probable Male 21155048 CVCL_CX67 GM22004 transformed cell line human CVCL_CX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155049 CVCL_D967 MRC-iPS-52 induced pluripotent stem cell human CVCL_D967 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155050 CVCL_CX60 CHO-UV-1 spontaneously immortalized cell line CVCL_CX60 CL:0000010 Derived from sampling site: Ovary. Female 21155051 CVCL_D960 MRC-iPS-46 induced pluripotent stem cell human CVCL_D960 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155052 CVCL_CX61 CHO AL hybrid cell line human CVCL_CX61 CL:0000010 Group: Human/rodent somatic cell hybrid. 21155053 CVCL_D961 MRC-iPS-47 induced pluripotent stem cell human CVCL_D961 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155054 CVCL_CX64 GM15780 hybrid cell line human CVCL_CX64 CL:0000010 Group: Human/rodent somatic cell hybrid. 21155055 CVCL_D964 MRC-iPS-5 induced pluripotent stem cell human CVCL_D964 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155056 CVCL_CX65 GM00898 finite cell line human CVCL_CX65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00898; probable Unspecified 21155057 CVCL_D965 MRC-iPS-50 induced pluripotent stem cell human CVCL_D965 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155058 CVCL_CX62 CHO ALC hybrid cell line human CVCL_CX62 CL:0000010 Group: Human/rodent somatic cell hybrid. 21155059 CVCL_D962 MRC-iPS-48 induced pluripotent stem cell human CVCL_D962 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155060 CVCL_CX63 CHO AL-AND6 hybrid cell line human CVCL_CX63 CL:0000010 Group: Human/rodent somatic cell hybrid. 21155061 CVCL_D963 MRC-iPS-49 induced pluripotent stem cell human CVCL_D963 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21155062 CVCL_2F21 AG13005 finite cell line human CVCL_2F21 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG13005) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155063 CVCL_2F22 AG13006 finite cell line human CVCL_2F22 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [75%]; 45,X [5%]; 46,X,t(Y;2) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 47 PDL (Coriell=AG13006) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155064 CVCL_2F20 AG13004 finite cell line human CVCL_2F20 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG13004) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155065 CVCL_2F25 AG13009 finite cell line human CVCL_2F25 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(p11;q13) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG13009) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155066 CVCL_2F26 AG13011 finite cell line human CVCL_2F26 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG13011) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155067 CVCL_2F23 AG13007 finite cell line human CVCL_2F23 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG13007) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155068 CVCL_2F24 AG13008 finite cell line human CVCL_2F24 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG13008) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155069 CVCL_2F29 AG13066 finite cell line human CVCL_2F29 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 39 PDL (Coriell=AG13066) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155070 CVCL_2F27 AG13018 finite cell line human CVCL_2F27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 38 PDL (Coriell=AG13018) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155071 CVCL_2F28 AG13065 finite cell line human CVCL_2F28 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [95%]; 46,XY,der(14;22)(q10;q10),+14 [5%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 13 PDL (Coriell=AG13065) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155072 CVCL_UL70 CHOPi003-A induced pluripotent stem cell human CVCL_UL70 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[43] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous (PubMed=30611021) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155073 CVCL_UL73 RAW 264.7 LRRK2 T1348N mut cancer cell line house mouse CVCL_UL73 CL:0000010 Sequence variation: Mutation; MGI; MGI:1913975; Lrrk2; Simple_edited; p.Thr1348Asn (c.4043A>C); Zygosity=Homozygous; Note=By ZFN (ATCC) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21155074 CVCL_UL74 INPERe001-A embryonic stem cell human CVCL_UL74 From: Instituto Nacional de Perinatologia; Mexico City; Mexico CL:0000010 Population: Mexican. Male 21155075 CVCL_UL71 RAW 264.7 LRRK2 parental cancer cell line house mouse CVCL_UL71 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Control cell line for RAW 264.7 LRRK2 KO and RAW 264.7 LRRK2 T1348N mut 21155076 CVCL_UL72 RAW 264.7 LRRK2 KO cancer cell line house mouse CVCL_UL72 CL:0000010 Knockout cell: Method=ZFN non-homologous recombination; MGI; MGI:1913975; Lrrk2 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21155077 CVCL_UL77 RCPFi003-A induced pluripotent stem cell human CVCL_UL77 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7027; MERTK; Simple; p.Ser331Cysfs*5 (c.992_993delCA); ClinVar=VCV000801735; Zygosity=Homozygous (PubMed=26263531) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155078 CVCL_UL78 RCPFi003-A-1 induced pluripotent stem cell human CVCL_UL78 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7027; MERTK; Simple; p.Ser331Cysfs*5 (c.992_993delCA); ClinVar=VCV000801735; Zygosity=Heterozygous (PubMed=30612079); Sequence variation: Mutation; HGNC; 7027; MERTK; Simple_corrected; p.Ser331Cysfs*5 (c.992_993delCA); ClinVar=VCV000801735; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30612079) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155079 CVCL_UL75 INPERe002-A embryonic stem cell human CVCL_UL75 From: Instituto Nacional de Perinatologia; Mexico City; Mexico CL:0000010 Population: Mexican. Female 21155080 CVCL_UL76 INPERe003-A embryonic stem cell human CVCL_UL76 From: Instituto Nacional de Perinatologia; Mexico City; Mexico. CL:0000010 Unspecified 21155081 CVCL_UL79 RCPFi003-A-2 induced pluripotent stem cell human CVCL_UL79 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7027; MERTK; Simple_corrected; p.Ser331Cysfs*5 (c.992_993delCA); ClinVar=VCV000801735; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=30612079) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155082 CVCL_2F32 AG13076 finite cell line human CVCL_2F32 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(7;14) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG13076) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155083 CVCL_2F33 AG13077 finite cell line human CVCL_2F33 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 47 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155084 CVCL_2F30 AG13067 finite cell line human CVCL_2F30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [74%]; 46,XY,t(5;12) [26%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 19 PDL (Coriell=AG13067) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155085 CVCL_2F31 AG13075 finite cell line human CVCL_2F31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [91%]; 46,XY,t(2;6) [9%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (Coriell=AG13075) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155086 CVCL_2F36 AG13089 finite cell line human CVCL_2F36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG13089) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155087 CVCL_2F37 AG13090 finite cell line human CVCL_2F37 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG13090) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155088 CVCL_2F34 AG13084 finite cell line human CVCL_2F34 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG13084) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155089 CVCL_2F35 AG13087 finite cell line human CVCL_2F35 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [64%]; 46,XY,t(2;15) [36%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG13087) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155090 CVCL_2F38 AG13091 finite cell line human CVCL_2F38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [81%]; 46,XY,t(3;13) [5%]; 46,XY,t(3;14) [7%]; 46,XY,t(9;13) [7%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG13091) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155091 CVCL_2F39 AG13092 finite cell line human CVCL_2F39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG13092) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155092 CVCL_UL62 RC-17 SNCA+/- clone 4-4 embryonic stem cell human CVCL_UL62 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 11138; SNCA. Female 21155093 CVCL_UL63 RC-17 SNCA+/- clone L5-4 embryonic stem cell human CVCL_UL63 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 11138; SNCA. Female 21155094 CVCL_UL60 HIHCNi004-A-1 induced pluripotent stem cell human CVCL_UL60 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11427; STUB1 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155095 CVCL_UL61 WAe001-A-22 embryonic stem cell human CVCL_UL61 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3157; EDA. Male 21155096 CVCL_UL66 UM-MCC19 cancer cell line human CVCL_UL66 CL:0000010 Omics: Transcriptome analysis by microarray. 21155097 CVCL_UL67 UM-MCC21 cancer cell line human CVCL_UL67 CL:0000010 Omics: Transcriptome analysis by microarray. 21155098 CVCL_UL64 RC-17 SNCA-/- clone L5-3 embryonic stem cell human CVCL_UL64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA. Female 21155099 CVCL_UL65 RC-17 SNCA-/- clone M1-4 embryonic stem cell human CVCL_UL65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA. Female 21155100 CVCL_UL68 FJMUi001-A induced pluripotent stem cell human CVCL_UL68 From: Fujian Medical University; Fuzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 1476; CAPN1; Simple; p.Pro498Leu (c.1493C>T); Zygosity=Heterozygous (PubMed=30611022); Sequence variation: Mutation; HGNC; 1476; CAPN1; Simple; p.Arg618Trp (c.1852C>T); Zygosity=Heterozygous (PubMed=30611022) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21155101 CVCL_UL69 CHOPi002-A induced pluripotent stem cell human CVCL_UL69 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[33] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous (PubMed=30611021) Population: Caucasian; French/Italian; Derived from sampling site: Peripheral blood. Male 21155102 CVCL_2F00 AG12954 finite cell line human CVCL_2F00 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p11::q13->p11::q13->qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 37 PDL (Coriell=AG12954) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155103 CVCL_2F03 AG12957 finite cell line human CVCL_2F03 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG12957) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155104 CVCL_2F04 AG12964 finite cell line human CVCL_2F04 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [50%]; 46,XY,t(1;2)(q12;q37) [50%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG12964) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155105 CVCL_2F01 AG12955 finite cell line human CVCL_2F01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [58%]; 45,X [6%]; 46,XY,inv(6)(p21.2;q12) [32%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 48 PDL (Coriell=AG12955) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155106 CVCL_2F02 AG12956 finite cell line human CVCL_2F02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155107 CVCL_2F07 AG12988 finite cell line human CVCL_2F07 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 26 PDL (Coriell=AG12988); Doubling time: 2.3 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155108 CVCL_2F08 AG12989 finite cell line human CVCL_2F08 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [4%]; 46,XY,t(2;19)(q23;q13.1) [96%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 15 PDL (Coriell=AG12989) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155109 CVCL_2F05 AG12965 finite cell line human CVCL_2F05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [54%]; 46,XY,t(1;13) [14%]; 46,XY,t(X;1;9;16;20) [28%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG12965) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155110 CVCL_2F06 AG12985 finite cell line human CVCL_2F06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [48%]; 46,XX,t(1;8) [46%]; 46,XX,t(1;19) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (Coriell=AG12985) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155111 CVCL_UL51 MUSIi007-A induced pluripotent stem cell human CVCL_UL51 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Male 21155112 CVCL_UL52 HIHRSi001-A induced pluripotent stem cell human CVCL_UL52 From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=30606667) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155113 CVCL_UL50 MUSIi008-A induced pluripotent stem cell human CVCL_UL50 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 6345; KLF1; Simple; p.Gly176Argfs*3 (c.519_525dupCGGCGCC) (c.525_526insCGGCGCC); ClinVar=VCV000100799; Zygosity=Heterozygous (PubMed=30605837); Sequence variation: Mutation; HGNC; 6345; KLF1; Simple; p.Ala298Pro (c.892G>C); ClinVar=VCV000056891; Zygosity=Heterozygous (PubMed=30605837) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21155114 CVCL_UL55 KIi002-A induced pluripotent stem cell human CVCL_UL55 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Heterozygous; Note=Germline (PubMed=30605844) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155115 CVCL_UL56 CIRAi004-A induced pluripotent stem cell human CVCL_UL56 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21155116 CVCL_UL53 HIHRSi002-A induced pluripotent stem cell human CVCL_UL53 From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Trp223Arg (c.667T>C) (W184R); ClinVar=VCV000093457; Zygosity=Heterozygous (PubMed=30606667); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=30606667) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155117 CVCL_UL54 KIi001-A induced pluripotent stem cell human CVCL_UL54 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Heterozygous; Note=Germline (PubMed=30605844) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155118 CVCL_UL59 HIHCNi004-A induced pluripotent stem cell human CVCL_UL59 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155119 CVCL_UL57 NCBSi001-A induced pluripotent stem cell human CVCL_UL57 From: Tata Institute of Fundamental Research, National Centre for Biological Sciences; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Trp165Cys (c.495G>C); ClinVar=VCV000098036; Zygosity=Heterozygous (PubMed=30605839) Population: Indian; Derived from sampling site: Peripheral blood. Female 21155120 CVCL_UL58 NCBSi002-A induced pluripotent stem cell human CVCL_UL58 From: Tata Institute of Fundamental Research, National Centre for Biological Sciences; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (PubMed=30605839); Sequence variation: Mutation; HGNC; 4140; GAP43; Simple; p.Ser41Gly (c.121A>G) (p.Ser77Gly, c.229A>G); Zygosity=Heterozygous (PubMed=30605839) Population: Indian; Derived from sampling site: Peripheral blood. Female 21155121 CVCL_UL39 ULBi001-A induced pluripotent stem cell human CVCL_UL39 From: Universite Libre de Bruxelles; Brussels; Belgium CL:0000010 Discontinued: hPSCreg; ULBi001-A; true. 21155122 CVCL_2F10 AG12993 finite cell line human CVCL_2F10 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG12993) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155123 CVCL_2F11 AG12995 finite cell line human CVCL_2F11 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 50 PDL (Coriell=AG12995) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155124 CVCL_2F14 AG12998 finite cell line human CVCL_2F14 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG12998) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155125 CVCL_2F15 AG12999 finite cell line human CVCL_2F15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [42%]; 46,XX,t(3;16) [58%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 37 PDL (Coriell=AG12999) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155126 CVCL_2F12 AG12996 finite cell line human CVCL_2F12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG12996) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155127 CVCL_2F13 AG12997 finite cell line human CVCL_2F13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [76%]; 45,X [24%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 19 PDL (Coriell=AG12997) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155128 CVCL_2F18 AG13002 finite cell line human CVCL_2F18 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG13002) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155129 CVCL_2F19 AG13003 finite cell line human CVCL_2F19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 47,XY,+18 [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 53 PDL (Coriell=AG13003) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155130 CVCL_2F16 AG13000 finite cell line human CVCL_2F16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 47,XY,+18 [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG13000) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155131 CVCL_2F17 AG13001 finite cell line human CVCL_2F17 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(Y;3;5) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13001) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155132 CVCL_2F09 AG12992 finite cell line human CVCL_2F09 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG12992); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155133 CVCL_UL40 UNIBSi004-A induced pluripotent stem cell human CVCL_UL40 From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155134 CVCL_UL41 USCi003-A induced pluripotent stem cell human CVCL_UL41 From: University of Southern California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 18145; PHF6; Simple; p.Cys45Tyr (c.134G>A); ClinVar=VCV000011066; Zygosity=Unspecified. 21155135 CVCL_UL44 USCi006-A induced pluripotent stem cell human CVCL_UL44 From: University of Southern California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21155136 CVCL_UL45 USCi001-A induced pluripotent stem cell human CVCL_UL45 From: University of Southern California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1701Ter (c.5101C>T); Zygosity=Unspecified Derived from sampling site: Cell type=Fibroblast. 21155137 CVCL_UL42 USCi004-A induced pluripotent stem cell human CVCL_UL42 From: University of Southern California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 18145; PHF6; Simple; p.Cys45Tyr (c.134G>A); ClinVar=VCV000011066; Zygosity=Unspecified. 21155138 CVCL_UL43 USCi005-A induced pluripotent stem cell human CVCL_UL43 From: University of Southern California, Los Angeles; Los Angeles; USA. CL:0000010 Female 21155139 CVCL_UL48 SFCi55-ZsGr induced pluripotent stem cell human CVCL_UL48 CL:0000010 Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using ZFN the fluorescent reporter gene ZsGreen has been inserted at the safe harbor locus (AAVS1) 21155140 CVCL_UL49 HEK293TN transformed cell line human CVCL_UL49 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21155141 CVCL_UL46 USCi002-A induced pluripotent stem cell human CVCL_UL46 From: University of Southern California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Arg1036Ter (c.3106C>T); ClinVar=VCV000488373; Zygosity=Unspecified Derived from sampling site: Cell type=Fibroblast. 21155142 CVCL_UL47 SFCi55 induced pluripotent stem cell human CVCL_UL47 CL:0000010 Female 21155143 CVCL_UL28 TRNDi008-A induced pluripotent stem cell human CVCL_UL28 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.His70Profs*29 (c.208dupC) (c.208insC); ClinVar=VCV000195037; Zygosity=Hemizygous (PubMed=31071499) Population: Caribbean; Haitian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155144 CVCL_UL29 UHi004-A induced pluripotent stem cell human CVCL_UL29 From: University of Helsinki; Helsinki; Finland. CL:0000010 Female 21155145 CVCL_LR89 BayGenomics ES cell line CSA122 embryonic stem cell house mouse CVCL_LR89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155146 CVCL_M389 MDA-MB-416 cancer cell line human CVCL_M389 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155147 CVCL_UL30 UHi004-B induced pluripotent stem cell human CVCL_UL30 From: University of Helsinki; Helsinki; Finland. CL:0000010 Female 21155148 CVCL_LR87 BayGenomics ES cell line CSA119 embryonic stem cell house mouse CVCL_LR87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155149 CVCL_M387 MDA-MB-390 cancer cell line human CVCL_M387 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155150 CVCL_LR88 BayGenomics ES cell line CSA121 embryonic stem cell house mouse CVCL_LR88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155151 CVCL_M388 MDA-MB-411 cancer cell line human CVCL_M388 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155152 CVCL_LR85 BayGenomics ES cell line CSA109 embryonic stem cell house mouse CVCL_LR85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146350; Scaf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155153 CVCL_UL33 HEL72.1 induced pluripotent stem cell human CVCL_UL33 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Lys392Arg (c.1175A>G); ClinVar=VCV000144030; Zygosity=Heterozygous (PubMed=28402852) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155154 CVCL_M385 MDA-MB-309 cancer cell line human CVCL_M385 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155155 CVCL_LR86 BayGenomics ES cell line CSA111 embryonic stem cell house mouse CVCL_LR86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450151; Cog3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155156 CVCL_UL34 HEL72A induced pluripotent stem cell human CVCL_UL34 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Lys392Arg (c.1175A>G); ClinVar=VCV000144030; Zygosity=Heterozygous (PubMed=28402852) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155157 CVCL_M386 MDA-MB-331 cancer cell line human CVCL_M386 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155158 CVCL_LR83 BayGenomics ES cell line CSA107 embryonic stem cell house mouse CVCL_LR83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103263; Mcf2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155159 CVCL_M383 SH-3 cancer cell line human CVCL_M383 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00087 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from the pleural effusion of a female patient with a breast carcinoma. 21155160 CVCL_UL31 UHi005-A induced pluripotent stem cell human CVCL_UL31 From: University of Helsinki; Helsinki; Finland. CL:0000010 Female 21155161 CVCL_LR84 BayGenomics ES cell line CSA108 embryonic stem cell house mouse CVCL_LR84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329038; Mllt10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155162 CVCL_M384 MDA-MB-253 cancer cell line human CVCL_M384 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155163 CVCL_UL32 UHi005-B induced pluripotent stem cell human CVCL_UL32 From: University of Helsinki; Helsinki; Finland. CL:0000010 Female 21155164 CVCL_LR81 BayGenomics ES cell line CSA105 embryonic stem cell house mouse CVCL_LR81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155165 CVCL_UL37 HEL46.11 induced pluripotent stem cell human CVCL_UL37 From: University of Helsinki; Helsinki; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21155166 CVCL_M381 VHB-1 cancer cell line human CVCL_M381 CL:0000010 Derived from sampling site: Breast. Female Doubling time: 37 hours (at 25th passage), 31 hours (at 87th passage) (PubMed=2824520) 21155167 CVCL_LR82 BayGenomics ES cell line CSA106 embryonic stem cell house mouse CVCL_LR82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444639; Fbxo38 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155168 CVCL_M382 Br-NHF-1 cancer cell line human CVCL_M382 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: ~100 hours, at 27th passage (PubMed=7327377) 21155169 CVCL_UL38 HEL122.2 induced pluripotent stem cell human CVCL_UL38 From: University of Helsinki; Helsinki; Finland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155170 CVCL_UL35 HEL72D induced pluripotent stem cell human CVCL_UL35 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Lys392Arg (c.1175A>G); ClinVar=VCV000144030; Zygosity=Heterozygous (PubMed=28402852) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155171 CVCL_LR80 BayGenomics ES cell line CSA101 embryonic stem cell house mouse CVCL_LR80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918972; Cic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155172 CVCL_M380 BC 1217 cancer cell line human CVCL_M380 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Female 21155173 CVCL_UL36 HEL115.6 induced pluripotent stem cell human CVCL_UL36 From: University of Helsinki; Helsinki; Finland CL:0000010 Derived from sampling site: Umbilical cord. Male 21155174 CVCL_UL19 TRNDi004-F induced pluripotent stem cell human CVCL_UL19 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155175 CVCL_UL17 TRNDi004-D induced pluripotent stem cell human CVCL_UL17 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155176 CVCL_UL18 TRNDi004-E induced pluripotent stem cell human CVCL_UL18 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155177 CVCL_LR98 BayGenomics ES cell line CSA143 embryonic stem cell house mouse CVCL_LR98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202301; Itch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155178 CVCL_M398 F16-4-4-11 hybridoma house mouse CVCL_M398 CL:0000010 Monoclonal antibody isotype: IgG1. 21155179 CVCL_LR99 BayGenomics ES cell line CSA145 embryonic stem cell house mouse CVCL_LR99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913208; Carm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155180 CVCL_M399 F17-23-2 hybridoma house mouse CVCL_M399 CL:0000010 Monoclonal antibody isotype: IgG1. 21155181 CVCL_LR96 BayGenomics ES cell line CSA141 embryonic stem cell house mouse CVCL_LR96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328328; Map7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155182 CVCL_M396 F10-89-4 hybridoma house mouse CVCL_M396 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21155183 CVCL_UL22 TRNDi004-I induced pluripotent stem cell human CVCL_UL22 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (PubMed=31009819) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155184 CVCL_LR97 BayGenomics ES cell line CSA142 embryonic stem cell house mouse CVCL_LR97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155185 CVCL_M397 F15-42-1-5 hybridoma house mouse CVCL_M397 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04216; Human THY1/CD90. 21155186 CVCL_UL23 TRNDi004-J induced pluripotent stem cell human CVCL_UL23 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155187 CVCL_LR94 BayGenomics ES cell line CSA131 embryonic stem cell house mouse CVCL_LR94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155188 CVCL_M394 F10-150 hybridoma house mouse CVCL_M394 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q4QWZ3; Sheep ITGAL/CD11a. 21155189 CVCL_UL20 TRNDi004-G induced pluripotent stem cell human CVCL_UL20 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155190 CVCL_LR95 BayGenomics ES cell line CSA140 embryonic stem cell house mouse CVCL_LR95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925953; Zfp972 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155191 CVCL_M395 F10-150.58 hybridoma house mouse CVCL_M395 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q4QWZ3; Sheep ITGAL/CD11a. 21155192 CVCL_UL21 TRNDi004-H induced pluripotent stem cell human CVCL_UL21 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155193 CVCL_LR92 BayGenomics ES cell line CSA128 embryonic stem cell house mouse CVCL_LR92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109602; Gphn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155194 CVCL_M392 MDA-MB-469 cancer cell line human CVCL_M392 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155195 CVCL_UL26 TRNDi007-A induced pluripotent stem cell human CVCL_UL26 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155196 CVCL_LR93 BayGenomics ES cell line CSA130 embryonic stem cell house mouse CVCL_LR93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155197 CVCL_M393 Clone 218 hybridoma house mouse CVCL_M393 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; W5Q5Y1; Sheep ITGA4/CD49d. 21155198 CVCL_UL27 TRNDi007-B induced pluripotent stem cell human CVCL_UL27 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Homozygous (PubMed=31026687) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155199 CVCL_LR90 BayGenomics ES cell line CSA124 embryonic stem cell house mouse CVCL_LR90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106281; Ilrun Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155200 CVCL_M390 MDA-MB-431 cancer cell line human CVCL_M390 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155201 CVCL_UL24 TRNDi005-A induced pluripotent stem cell human CVCL_UL24 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4122; GALNS; Simple; p.Arg61Trp (c.181C>T); ClinVar=VCV000381663; Zygosity=Heterozygous (PubMed=30797135); Sequence variation: Mutation; HGNC; 4122; GALNS; Simple; p.Trp405_Thr406del (c.1207_1212TGGACC[1]) (c.1213_1218delTGGACC) (p.403_404WT[1]) (WT405del); ClinVar=VCV000566964; Zygosity=Heterozygous (PubMed=30797135) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155202 CVCL_LR91 BayGenomics ES cell line CSA125 embryonic stem cell house mouse CVCL_LR91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109301; Papola Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155203 CVCL_M391 MDA-MB-461 cancer cell line human CVCL_M391 CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Female 21155204 CVCL_UL25 TRNDi006-A induced pluripotent stem cell human CVCL_UL25 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Glu153Lys (c.457G>A); ClinVar=VCV001067431; Zygosity=Homozygous (PubMed=30933722) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155205 CVCL_UL08 TRNDi002-A induced pluripotent stem cell human CVCL_UL08 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155206 CVCL_UL09 TRNDi002-B induced pluripotent stem cell human CVCL_UL09 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (PubMed=30612078); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (PubMed=30612078) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155207 CVCL_UL06 TRNDi001-C induced pluripotent stem cell human CVCL_UL06 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155208 CVCL_UL07 TRNDi001-D induced pluripotent stem cell human CVCL_UL07 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (PubMed=32114296) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155209 CVCL_LR69 BayGenomics ES cell line CSA075 embryonic stem cell house mouse CVCL_LR69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918049; Cep192 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155210 CVCL_M369 BRCA2-999del5-2T transformed cell line human CVCL_M369 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn257Lysfs*17 (c.771_775delTCAAA) (999del5); ClinVar=VCV000009326; Zygosity=Heterozygous (PubMed=16448223); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast. Female 21155211 CVCL_LR67 BayGenomics ES cell line CSA066 embryonic stem cell house mouse CVCL_LR67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88251; Calm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155212 CVCL_M367 MW1 [Human breast carcinoma] cancer cell line human CVCL_M367 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 79.7 hours (at 8th passage), 38.7 hours (at 65th passage) (PubMed=17273757) 21155213 CVCL_LR68 BayGenomics ES cell line CSA074 embryonic stem cell house mouse CVCL_LR68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105037; Ddx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155214 CVCL_M368 NABCA cancer cell line human CVCL_M368 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~66 hours (PubMed=17257375) 21155215 CVCL_LR65 BayGenomics ES cell line CSA060 embryonic stem cell house mouse CVCL_LR65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925123; Zbtb44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155216 CVCL_M365 BCa-15 cancer cell line human CVCL_M365 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=17959394) Population: Indian; Derived from sampling site: Breast. Female Doubling time: 60 hours (PubMed=17959394) 21155217 CVCL_LR66 BayGenomics ES cell line CSA064 embryonic stem cell house mouse CVCL_LR66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155218 CVCL_M366 BTIC cancer cell line human CVCL_M366 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: ~44 hours (PubMed=17645728) 21155219 CVCL_LR63 BayGenomics ES cell line CSA057 embryonic stem cell house mouse CVCL_LR63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443858; Pcif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155220 CVCL_M363 Hs578Ts(i)8 cancer cell line human CVCL_M363 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast. Female Characteristics: Invasive subclone of Hs 587T Doubling time: 22 hours (PubMed=18386134) 21155221 CVCL_UL11 TRNDi002-D induced pluripotent stem cell human CVCL_UL11 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155222 CVCL_LR64 BayGenomics ES cell line CSA058 embryonic stem cell house mouse CVCL_LR64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155223 CVCL_M364 BCa-11 cancer cell line human CVCL_M364 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=17959394) Population: Indian; Derived from sampling site: Breast. Female Doubling time: 96 hours (PubMed=17959394) 21155224 CVCL_UL12 TRNDi003-A induced pluripotent stem cell human CVCL_UL12 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gln510Pro (c.1529A>C); ClinVar=VCV000013344; Zygosity=Heterozygous (PubMed=30640061) Population: African; Somali; Derived from sampling site: Peripheral blood. Female 21155225 CVCL_M361 751-NA-15 undefined cell line type house mouse CVCL_M361 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10992; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12160. 21155226 CVCL_LR61 BayGenomics ES cell line CSA055 embryonic stem cell house mouse CVCL_LR61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88251; Calm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155227 CVCL_LR62 BayGenomics ES cell line CSA056 embryonic stem cell house mouse CVCL_LR62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918972; Cic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155228 CVCL_M362 SSILY cancer cell line human CVCL_M362 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Characteristics: ER-negative, PR-positive and ERBB2-positive Doubling time: ~20 hours (PubMed=19067762) 21155229 CVCL_UL10 TRNDi002-C induced pluripotent stem cell human CVCL_UL10 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155230 CVCL_UL15 TRNDi004-B induced pluripotent stem cell human CVCL_UL15 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155231 CVCL_LR60 BayGenomics ES cell line CSA051 embryonic stem cell house mouse CVCL_LR60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385621; Nup153 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155232 CVCL_M360 QGY/cDDP cancer cell line human CVCL_M360 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (QGY-7703) has been shown to be a HeLa derivative. 21155233 CVCL_UL16 TRNDi004-C induced pluripotent stem cell human CVCL_UL16 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155234 CVCL_UL13 TRNDi003-B induced pluripotent stem cell human CVCL_UL13 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gln510Pro (c.1529A>C); ClinVar=VCV000013344; Zygosity=Heterozygous (from autologous cell line TRNDi003-A) Population: African; Somali; Derived from sampling site: Peripheral blood. Female 21155235 CVCL_UL14 TRNDi004-A induced pluripotent stem cell human CVCL_UL14 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155236 CVCL_LR78 BayGenomics ES cell line CSA098 embryonic stem cell house mouse CVCL_LR78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346072; Psmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155237 CVCL_M378 HMA-1 cancer cell line human CVCL_M378 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 46 hours (PubMed=1750037) 21155238 CVCL_LR79 BayGenomics ES cell line CSA100 embryonic stem cell house mouse CVCL_LR79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144585; Slc16a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155239 CVCL_M379 KT [Human breast carcinoma] cancer cell line human CVCL_M379 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Female 21155240 CVCL_LR76 BayGenomics ES cell line CSA089 embryonic stem cell house mouse CVCL_LR76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155241 CVCL_M376 MaCa 2 cancer cell line human CVCL_M376 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21155242 CVCL_LR77 BayGenomics ES cell line CSA092 embryonic stem cell house mouse CVCL_LR77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98858; Psmd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155243 CVCL_M377 Clone 197 hybridoma house mouse CVCL_M377 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Sheep T19 antigen. 21155244 CVCL_LR74 BayGenomics ES cell line CSA085 embryonic stem cell house mouse CVCL_LR74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178598; Bloc1s5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155245 CVCL_M374 MAST cancer cell line human CVCL_M374 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Unspecified (PubMed=10841287) Derived from metastatic site: Ascites. Female Doubling time: ~68 hours (PubMed=8601577) 21155246 CVCL_UL00 TRDSi002-A induced pluripotent stem cell human CVCL_UL00 From: Technion Research and Development Foundation; Haifa; Israel CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155247 CVCL_LR75 BayGenomics ES cell line CSA086 embryonic stem cell house mouse CVCL_LR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155248 CVCL_M375 MaCa 1 cancer cell line human CVCL_M375 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21155249 CVCL_UL01 TRDSi002-A-1 induced pluripotent stem cell human CVCL_UL01 From: Technion Research and Development Foundation; Haifa; Israel CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155250 CVCL_LR72 BayGenomics ES cell line CSA080 embryonic stem cell house mouse CVCL_LR72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921802; Nipal3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155251 CVCL_M372 MDA-MB-468LN cancer cell line human CVCL_M372 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Derived from metastatic site: Pleural effusion. Omics: CNV analysis Female Group: Triple negative breast cancer (TNBC) cell line 21155252 CVCL_LR73 BayGenomics ES cell line CSA082 embryonic stem cell house mouse CVCL_LR73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103012; E2f4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155253 CVCL_M373 MCF3B cancer cell line human CVCL_M373 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: RGD; 69267; Slc5a5 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155254 CVCL_LR70 BayGenomics ES cell line CSA077 embryonic stem cell house mouse CVCL_LR70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2660884; Csnk1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155255 CVCL_M370 BRCA2-999del5-2N transformed cell line human CVCL_M370 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn257Lysfs*17 (c.771_775delTCAAA) (999del5); ClinVar=VCV000009326; Zygosity=Heterozygous (PubMed=16448223); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast. Female 21155256 CVCL_UL04 TRNDi001-A induced pluripotent stem cell human CVCL_UL04 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155257 CVCL_LR71 BayGenomics ES cell line CSA078 embryonic stem cell house mouse CVCL_LR71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2660884; Csnk1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155258 CVCL_M371 BRCA2-999del5-1N transformed cell line human CVCL_M371 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn257Lysfs*17 (c.771_775delTCAAA) (999del5); ClinVar=VCV000009326; Zygosity=Heterozygous (PubMed=16448223); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast. Female 21155259 CVCL_UL05 TRNDi001-B induced pluripotent stem cell human CVCL_UL05 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155260 CVCL_UL02 ULUNDi007-A induced pluripotent stem cell human CVCL_UL02 From: University of Lund; Lund; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg301Cys (c.901C>T) (R252C); ClinVar=VCV001303549; Zygosity=Heterozygous (PubMed=30640063) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155261 CVCL_UL03 TMOi001-A-1 induced pluripotent stem cell human CVCL_UL03 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Umbilical cord blood. Female Characteristics: CRISPR/Cas9-mediated knock-in of a IRES-GFP-NLS-PuroR construct at the 3'UTR of CD34 21155262 CVCL_CZ00 AFRC MAC 16 hybridoma Norway rat CVCL_CZ00 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Chlamydomonas reinhardii cell wall glycoprotein complex 2BII. 21155263 CVCL_CZ01 AFRC MAC 55 hybridoma Norway rat CVCL_CZ01 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21155264 CVCL_CZ04 GM02209 finite cell line human CVCL_CZ04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155265 CVCL_CZ05 GM02435 finite cell line human CVCL_CZ05 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155266 CVCL_CZ02 AFRC MAC 56 hybridoma Norway rat CVCL_CZ02 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06593; Avena sativa phytochrome A-3 (PHYA3) (probably also other PHYA). 21155267 CVCL_CZ03 GM01910 finite cell line human CVCL_CZ03 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155268 CVCL_2G82 TBL3 cancer cell line CVCL_2G82 CL:0000010 Breed/subspecies: Hereford. Male Characteristics: In vitro infected by Theileria annulata isolate Hissar 21155269 CVCL_2G83 TBL20 cancer cell line CVCL_2G83 CL:0000010 Breed/subspecies: Holstein Friesian. Omics: Transcriptome analysis by microarray Female Characteristics: In vitro infected by Theileria annulata isolate Hissar 21155270 CVCL_2G80 WU E-7 hybridoma house mouse CVCL_2G80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02649; Human APOE. 21155271 CVCL_2G81 Ainv18 embryonic stem cell house mouse CVCL_2G81 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: 129P2/Ola. Male 21155272 CVCL_2G86 GENEA101 embryonic stem cell human CVCL_2G86 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0377; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-59.. 21155273 CVCL_2G87 GENEA104 embryonic stem cell human CVCL_2G87 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0374. 21155274 CVCL_2G84 TaC12 transformed cell line CVCL_2G84 CL:0000010 Miscellaneous: The exact nature of this cell line is not clear, it could be derived from the TaA2 (Cellosaurus=CVCL_B6P0) cell line. Unspecified Characteristics: Infected by Theileria annulata 21155275 CVCL_2G85 GENEA100 embryonic stem cell human CVCL_2G85 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0376; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-59.. 21155276 CVCL_2G88 GENEA105 embryonic stem cell human CVCL_2G88 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0375. 21155277 CVCL_2G89 DT40-XRCC3(+/-) cancer cell line CVCL_2G89 CL:0000010 Knockout cell: Method=Targeted integration (1 of 2 alleles); XRCC3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155278 CVCL_2G93 DT40-INPP5D(-/-) cancer cell line CVCL_2G93 CL:0000010 Knockout cell: Method=Targeted integration; INPP5D Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155279 CVCL_2G94 CD4+ N#2 500 transformed cell line human CVCL_2G94 CL:0000010 Population: Caucasian; Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21155280 CVCL_2G91 DT40-PTPN6(-/-) cancer cell line CVCL_2G91 CL:0000010 Knockout cell: Method=Targeted integration; PTPN6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155281 CVCL_2G92 DT40-PTPN6(-/-)-PTPN11(-/-) cancer cell line CVCL_2G92 CL:0000010 Knockout cell: Method=Targeted integration; PTPN6+PTPN11 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155282 CVCL_2G97 GM00585 finite cell line human CVCL_2G97 HLA typing: A*03,15; B*15,27 (Coriell=GM00585) CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Arg224His (c.676G>A); Zygosity=Heterozygous (from autologous cell line GM01559) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155283 CVCL_2G98 GM00625 finite cell line human CVCL_2G98 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155284 CVCL_2G95 GM00423 finite cell line human CVCL_2G95 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21155285 CVCL_2G96 GM00584 finite cell line human CVCL_2G96 HLA typing: A*02,03; B*07,18 (Coriell=GM00584) CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Arg224His (c.676G>A); Zygosity=Unspecified (from familial inference of GM01559) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155286 CVCL_2G99 GM00720 finite cell line human CVCL_2G99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155287 CVCL_2G90 DT40-PTPN11(-/-) cancer cell line CVCL_2G90 CL:0000010 Knockout cell: Method=Targeted integration; PTPN11 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155288 CVCL_2G60 TIVE telomerase immortalized cell line human CVCL_2G60 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis Unspecified 21155289 CVCL_2G61 CMA-03/06 cancer cell line human CVCL_2G61 CL:0000010 Derived from sampling site: Peritoneal effusion. Omics: Transcriptome analysis by microarray Male Characteristics: Compared to the parent cell line, not IL6 dependent Doubling time: ~80 hours (PubMed=24327544) 21155290 CVCL_2G64 RTS3b transformed cell line human CVCL_2G64 CL:0000010 Derived from sampling site: Ear; skin; epidermis Cell type=Keratinocyte.. Unspecified 21155291 CVCL_2G65 GKP2 transformed cell line house mouse CVCL_2G65 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). 21155292 CVCL_2G62 mPAC L20 transformed cell line house mouse CVCL_2G62 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans. 21155293 CVCL_2G63 mPAC L4S2 transformed cell line house mouse CVCL_2G63 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Pancreas; islets of Langerhans. 21155294 CVCL_2G68 T80 telomerase immortalized cell line human CVCL_2G68 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155295 CVCL_2G69 T29H telomerase immortalized cell line human CVCL_2G69 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155296 CVCL_2G66 GKP4 transformed cell line house mouse CVCL_2G66 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). 21155297 CVCL_2G67 T29 telomerase immortalized cell line human CVCL_2G67 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155298 CVCL_2G71 NOF137 finite cell line human CVCL_2G71 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21155299 CVCL_2G72 NOF150 finite cell line human CVCL_2G72 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21155300 CVCL_2G70 T80H telomerase immortalized cell line human CVCL_2G70 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155301 CVCL_2G75 T80K telomerase immortalized cell line human CVCL_2G75 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155302 CVCL_2G76 NOF151-hTERT telomerase immortalized cell line human CVCL_2G76 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21155303 CVCL_2G73 NOF151 finite cell line human CVCL_2G73 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21155304 CVCL_2G74 T29K telomerase immortalized cell line human CVCL_2G74 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21155305 CVCL_2G79 INS-1 833/117 cancer cell line Norway rat CVCL_2G79 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21155306 CVCL_2G77 INS-1 834/40 cancer cell line Norway rat CVCL_2G77 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21155307 CVCL_2G78 INS-1 833/15 cancer cell line Norway rat CVCL_2G78 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21155308 CVCL_CZ77 GM20191 transformed cell line human CVCL_CZ77 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1183-1G>A (IVS3-1G>A) (p.Cys395fs*396); ClinVar=VCV000001195; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155309 CVCL_CZ78 GM20614 transformed cell line human CVCL_CZ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155310 CVCL_CZ75 GM17894 transformed cell line human CVCL_CZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155311 CVCL_CZ76 GM20173 transformed cell line human CVCL_CZ76 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+4_1331+7delAGTG (IVS4+2delTGAG) (p.Lys445fs*461); ClinVar=VCV000001196; Zygosity=Heterozygous (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155312 CVCL_CZ79 GM20615 transformed cell line human CVCL_CZ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155313 CVCL_CZ70 GM16786 transformed cell line human CVCL_CZ70 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155314 CVCL_LT09 BayGenomics ES cell line CSD116 embryonic stem cell house mouse CVCL_LT09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926048; Eml4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155315 CVCL_M509 Fravel cancer cell line human CVCL_M509 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa Doubling time: 62 hours (PubMed=6804081) 21155316 CVCL_LT07 BayGenomics ES cell line CSD108 embryonic stem cell house mouse CVCL_LT07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914093; Dolpp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155317 CVCL_CZ73 GM16791 transformed cell line human CVCL_CZ73 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155318 CVCL_M507 NCU-MM-2 cancer cell line human CVCL_M507 CL:0000010 Population: Japanese. 21155319 CVCL_LT08 BayGenomics ES cell line CSD115 embryonic stem cell house mouse CVCL_LT08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95728; Gli2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155320 CVCL_CZ74 GM17479 transformed cell line human CVCL_CZ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155321 CVCL_M508 NCU-MM-3 cancer cell line human CVCL_M508 CL:0000010 Population: Japanese. 21155322 CVCL_LT05 BayGenomics ES cell line CSD100 embryonic stem cell house mouse CVCL_LT05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155323 CVCL_M505 FR4 cancer cell line human CVCL_M505 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces IgA kappa Doubling time: 131 hours (PubMed=1697013) 21155324 CVCL_CZ71 GM16787 transformed cell line human CVCL_CZ71 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155325 CVCL_LT06 BayGenomics ES cell line CSD103 embryonic stem cell house mouse CVCL_LT06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155326 CVCL_CZ72 GM16790 transformed cell line human CVCL_CZ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155327 CVCL_M506 KIS-1 cancer cell line human CVCL_M506 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Doubling time: ~24 hours (PubMed=2852183) 21155328 CVCL_LT03 BayGenomics ES cell line CSD097 embryonic stem cell house mouse CVCL_LT03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921461; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155329 CVCL_M503 NOP-1 cancer cell line human CVCL_M503 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA kappa Doubling time: 36 hours (CelloPub=CLPUB00090) 21155330 CVCL_M504 AD3 [Human myeloma] cancer cell line human CVCL_M504 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Characteristics: Produces IgA kappa Doubling time: 16 hours (PubMed=1697013) 21155331 CVCL_LT04 BayGenomics ES cell line CSD099 embryonic stem cell house mouse CVCL_LT04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914144; Wwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155332 CVCL_LT01 BayGenomics ES cell line CSD093 embryonic stem cell house mouse CVCL_LT01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155333 CVCL_M501 SACHI cancer cell line human CVCL_M501 CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Omics: Array-based CGH Female 21155334 CVCL_LT02 BayGenomics ES cell line CSD096 embryonic stem cell house mouse CVCL_LT02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914339; Psmc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155335 CVCL_M502 NOP-2 cancer cell line human CVCL_M502 CL:0000010 Population: Japanese Male Characteristics: Produces Ig lambda. 21155336 CVCL_LT00 BayGenomics ES cell line CSD085 embryonic stem cell house mouse CVCL_LT00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914304; Paics Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155337 CVCL_M500 ILKM13 cancer cell line human CVCL_M500 CL:0000010 Population: Japanese. 21155338 CVCL_CZ88 ElFa cancer cell line human CVCL_CZ88 CL:0000010 Male 21155339 CVCL_CZ89 YPK-1 cancer cell line human CVCL_CZ89 HLA typing: A*02,24; B*01,46; C*03 (PubMed=18575732) CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male Doubling time: 49.3 hours (CelloPub=CLPUB00333) 21155340 CVCL_CZ86 MYP30-fDAF spontaneously immortalized cell line pig CVCL_CZ86 CL:0000010 Transfected with: UniProtKB; U6C7L4; Cat CD55 Derived from sampling site: Aorta; endothelium. Unspecified 21155341 CVCL_CZ87 DoSmi cancer cell line human CVCL_CZ87 CL:0000010 Female 21155342 CVCL_CZ80 GM20835 transformed cell line human CVCL_CZ80 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu288Val (c.863A>T); ClinVar=VCV000017969; Zygosity=Heterozygous (PubMed=19767587) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21155343 CVCL_CZ81 GM21656 transformed cell line human CVCL_CZ81 CL:0000010 Sequence variation: Mutation; HGNC; 30794; CEP57; Simple; p.Leu309Profs*9 (c.915_925dup11) (p.His317fs); ClinVar=VCV000030691; Zygosity=Heterozygous (PubMed=30804344) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155344 CVCL_LT18 BayGenomics ES cell line CSD158 embryonic stem cell house mouse CVCL_LT18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155345 CVCL_CZ84 GM02294 transformed cell line human CVCL_CZ84 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala215Thr (c.643G>A); ClinVar=VCV000001967; Zygosity=Homozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155346 CVCL_M518 MT-1 [Human leukemia] cancer cell line human CVCL_M518 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=19220422; PubMed=19710698) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: JCRB; JCRB0063; probable; Discontinued: JCRB; NIHS0526; true Male Characteristics: Was established by co-cultivation of cells from a 69 year old male T-cell leukemia patient with cord leukocytes from a female infant (CelloPub=CLPUB00542); Virology: HTLV-1 producing cell line Doubling time: 48-54 hours (PubMed=6966589) 21155347 CVCL_LT19 BayGenomics ES cell line CSD163 embryonic stem cell house mouse CVCL_LT19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155348 CVCL_CZ85 GM06091 transformed cell line human CVCL_CZ85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155349 CVCL_M519 MT-1 [Human mesothelioma] cancer cell line human CVCL_M519 CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 21 hours (CelloPub=CLPUB00383) 21155350 CVCL_LT16 BayGenomics ES cell line CSD156 embryonic stem cell house mouse CVCL_LT16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103561; Kpna2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155351 CVCL_CZ82 GM21657 transformed cell line human CVCL_CZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155352 CVCL_M516 MT3 cancer cell line human CVCL_M516 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgA kappa Doubling time: ~40-50 hours (PubMed=3114153) 21155353 CVCL_LT17 BayGenomics ES cell line CSD157 embryonic stem cell house mouse CVCL_LT17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924909; Slc25a36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155354 CVCL_CZ83 GM04307 finite cell line human CVCL_CZ83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155355 CVCL_M517 MT-3 [Human leukocyte] transformed cell line human CVCL_M517 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood. Discontinued: JCRB; NIHS0528; true Male Characteristics: Was established by co-cultivation of cells from a 36 year old male T-cell leukemia patient with cord leukocytes from a male infant (CelloPub=CLPUB00542); Virology: HTLV-1 producing cell line 21155356 CVCL_LT14 BayGenomics ES cell line CSD147 embryonic stem cell house mouse CVCL_LT14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155357 CVCL_M514 LB 84-1 cancer cell line human CVCL_M514 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgA kappa Doubling time: 34.2 hours (PubMed=2492835) 21155358 CVCL_LT15 BayGenomics ES cell line CSD148 embryonic stem cell house mouse CVCL_LT15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104884; Psmb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155359 CVCL_M515 MEF-1 [Human myeloma] cancer cell line human CVCL_M515 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255_Leu257delinsSer (c.763_768del6); Zygosity=Unspecified (PubMed=10223569) Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa Doubling time: ~36 hours (PubMed=10223569) 21155360 CVCL_LT12 BayGenomics ES cell line CSD143 embryonic stem cell house mouse CVCL_LT12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155361 CVCL_M512 HSM-2 cancer cell line human CVCL_M512 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgM kappa; Characteristics: IL6 dependent 21155362 CVCL_LT13 BayGenomics ES cell line CSD145 embryonic stem cell house mouse CVCL_LT13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155363 CVCL_M513 HSM-2.3 cancer cell line human CVCL_M513 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgM kappa; Characteristics: IL3 or IL6 dependent 21155364 CVCL_LT10 BayGenomics ES cell line CSD119 embryonic stem cell house mouse CVCL_LT10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155365 CVCL_M510 HL407 cancer cell line human CVCL_M510 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgA lambda 21155366 CVCL_LT11 BayGenomics ES cell line CSD141 embryonic stem cell house mouse CVCL_LT11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155367 CVCL_M511 HL461 cancer cell line human CVCL_M511 CL:0000010 Derived from sampling site: Bone marrow. Unspecified Characteristics: Produces IgG4 kappa Doubling time: 50 hours (PubMed=1700238) 21155368 CVCL_CZ55 GM15732 transformed cell line human CVCL_CZ55 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21155369 CVCL_CZ56 GM15733 transformed cell line human CVCL_CZ56 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21155370 CVCL_CZ53 GM15730 transformed cell line human CVCL_CZ53 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21155371 CVCL_CZ54 GM15731 transformed cell line human CVCL_CZ54 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21155372 CVCL_CZ59 GM16005 transformed cell line human CVCL_CZ59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155373 CVCL_CZ57 GM15909 transformed cell line human CVCL_CZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155374 CVCL_CZ58 GM15910 transformed cell line human CVCL_CZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155375 CVCL_CZ51 GM15728 transformed cell line human CVCL_CZ51 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21155376 CVCL_CZ52 GM15729 transformed cell line human CVCL_CZ52 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21155377 CVCL_CZ50 GM15727 transformed cell line human CVCL_CZ50 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21155378 CVCL_CZ66 GM16019 transformed cell line human CVCL_CZ66 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155379 CVCL_CZ67 GM16020 transformed cell line human CVCL_CZ67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155380 CVCL_CZ64 GM16010 transformed cell line human CVCL_CZ64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155381 CVCL_CZ65 GM16011 transformed cell line human CVCL_CZ65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155382 CVCL_CZ68 GM16151 transformed cell line human CVCL_CZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155383 CVCL_CZ69 GM16352 transformed cell line human CVCL_CZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155384 CVCL_CZ62 GM16008 transformed cell line human CVCL_CZ62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155385 CVCL_CZ63 GM16009 transformed cell line human CVCL_CZ63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155386 CVCL_CZ60 GM16006 transformed cell line human CVCL_CZ60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155387 CVCL_CZ61 GM16007 transformed cell line human CVCL_CZ61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155388 CVCL_CZ33 GM10271 finite cell line human CVCL_CZ33 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155389 CVCL_CZ34 GM10296 transformed cell line human CVCL_CZ34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155390 CVCL_CZ31 GM10261 finite cell line human CVCL_CZ31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155391 CVCL_CZ32 GM10270 finite cell line human CVCL_CZ32 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155392 CVCL_CZ37 GM10338 finite cell line human CVCL_CZ37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155393 CVCL_CZ38 GM10339 finite cell line human CVCL_CZ38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155394 CVCL_CZ35 GM10297 finite cell line human CVCL_CZ35 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155395 CVCL_CZ36 GM10320 finite cell line human CVCL_CZ36 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155396 CVCL_CZ30 GM10260 transformed cell line human CVCL_CZ30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155397 CVCL_CZ28 GM09496 finite cell line human CVCL_CZ28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155398 CVCL_CZ29 GM10258 finite cell line human CVCL_CZ29 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155399 CVCL_CZ44 GM14059 transformed cell line human CVCL_CZ44 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155400 CVCL_CZ45 GM14060 transformed cell line human CVCL_CZ45 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155401 CVCL_CZ42 GM14002 transformed cell line human CVCL_CZ42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155402 CVCL_CZ43 GM14003 transformed cell line human CVCL_CZ43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155403 CVCL_CZ48 GM15725 transformed cell line human CVCL_CZ48 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21155404 CVCL_CZ49 GM15726 transformed cell line human CVCL_CZ49 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21155405 CVCL_CZ46 GM14950 transformed cell line human CVCL_CZ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155406 CVCL_CZ47 GM15724 transformed cell line human CVCL_CZ47 CL:0000010 Population: Caucasian; Czechoslovakian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21155407 CVCL_CZ40 GM10351 transformed cell line human CVCL_CZ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155408 CVCL_CZ41 GM13780 transformed cell line human CVCL_CZ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155409 CVCL_CZ39 GM10349 transformed cell line human CVCL_CZ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155410 CVCL_CZ11 GM05049 transformed cell line human CVCL_CZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155411 CVCL_CZ12 GM01997 finite cell line human CVCL_CZ12 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala215Thr (c.643G>A); ClinVar=VCV000001967; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21155412 CVCL_CZ10 GM04306 finite cell line human CVCL_CZ10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155413 CVCL_CZ15 GM02472 transformed cell line human CVCL_CZ15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155414 CVCL_CZ16 GM06092 transformed cell line human CVCL_CZ16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155415 CVCL_CZ13 GM02028 finite cell line human CVCL_CZ13 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21155416 CVCL_CZ14 GM02433 finite cell line human CVCL_CZ14 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155417 CVCL_CZ08 GM02979 transformed cell line human CVCL_CZ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155418 CVCL_CZ09 GM03354 transformed cell line human CVCL_CZ09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155419 CVCL_CZ06 GM02580 finite cell line human CVCL_CZ06 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21155420 CVCL_CZ07 GM02581 transformed cell line human CVCL_CZ07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155421 CVCL_CZ22 GM07331 finite cell line human CVCL_CZ22 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21155422 CVCL_CZ23 GM07411 transformed cell line human CVCL_CZ23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155423 CVCL_CZ20 GM07329 finite cell line human CVCL_CZ20 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21155424 CVCL_CZ21 GM07330 transformed cell line human CVCL_CZ21 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155425 CVCL_CZ26 GM09325 finite cell line human CVCL_CZ26 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21155426 CVCL_CZ27 GM09495 finite cell line human CVCL_CZ27 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21155427 CVCL_CZ24 GM07413 finite cell line human CVCL_CZ24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM07413; probable Female 21155428 CVCL_CZ25 GM09324 finite cell line human CVCL_CZ25 CL:0000010 Karyotypic information: 46,XX,inv(7)(pter->p13::q22->p13::q22->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21155429 CVCL_CZ19 GM07328 transformed cell line human CVCL_CZ19 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155430 CVCL_CZ17 GM06140 transformed cell line human CVCL_CZ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155431 CVCL_CZ18 GM07326 transformed cell line human CVCL_CZ18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155432 CVCL_UM07 LEIi007-A induced pluripotent stem cell human CVCL_UM07 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Pro1380Leu (c.4139C>T); ClinVar=VCV000007904; Zygosity=Heterozygous (PubMed=30634128); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.5461-10T>C; ClinVar=VCV000092870; Zygosity=Heterozygous (PubMed=30634128) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21155433 CVCL_UM08 LSCTRi005-A induced pluripotent stem cell human CVCL_UM08 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21155434 CVCL_UM05 H237 C3 GC induced pluripotent stem cell human CVCL_UM05 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=27934586) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155435 CVCL_UM06 KthES11 embryonic stem cell human CVCL_UM06 From: Kyoto University; Kyoto; Japan. CL:0000010 Female Group: Clinical grade hESC cell line 21155436 CVCL_UM09 LSCTRi006-A induced pluripotent stem cell human CVCL_UM09 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Pro34Ser (c.100C>T); ClinVar=VCV000016893; Zygosity=Homozygous; Note=CYP2D6*10 allele (PubMed=36399926); Sequence variation: Mutation; HGNC; 2638; CYP3A5; Simple; c.219-237G>A; ClinVar=VCV000226021; Zygosity=Homozygous; Note=Aberrant splice site CYP3A5*3C allele (PubMed=36399926). Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155437 CVCL_LS68 BayGenomics ES cell line CSC182 embryonic stem cell house mouse CVCL_LS68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333855; Atox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155438 CVCL_M468 PaCaDD-183 cancer cell line human CVCL_M468 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (CelloPub=CLPUB00002) Derived from metastatic site: Ascites. Female Doubling time: 43.3 hours (CelloPub=CLPUB00002); ~2-3 days (DSMZ=ACC-751) 21155439 CVCL_LS69 BayGenomics ES cell line CSC183 embryonic stem cell house mouse CVCL_LS69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347095; Adgre5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155440 CVCL_M469 PaCaDD-188 cancer cell line human CVCL_M469 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (CelloPub=CLPUB00002; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu326fs; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis. Female Doubling time: 30.8 hours (CelloPub=CLPUB00002); ~2-4 days (DSMZ=ACC-753) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21155441 CVCL_LS66 BayGenomics ES cell line CSC175 embryonic stem cell house mouse CVCL_LS66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155442 CVCL_M466 PaCaDD-161 cancer cell line human CVCL_M466 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (CelloPub=CLPUB00002; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (DepMap) Derived from metastatic site: Liver. Omics: Deep exome analysis Female Doubling time: 20.6 hours (CelloPub=CLPUB00002); ~48 hours (DSMZ=ACC-746) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21155443 CVCL_LS67 BayGenomics ES cell line CSC180 embryonic stem cell house mouse CVCL_LS67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914869; Nob1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155444 CVCL_M467 PaCaDD-165 cancer cell line human CVCL_M467 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Unspecified (DepMap) Derived from metastatic site: Ascites. Omics: Deep exome analysis Male Doubling time: 26.2 hours (CelloPub=CLPUB00002); ~35-45 hours (DSMZ=ACC-750) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21155445 CVCL_LS64 BayGenomics ES cell line CSC171 embryonic stem cell house mouse CVCL_LS64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155446 CVCL_M464 PaCaDD-141 cancer cell line human CVCL_M464 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 33.7 hours (CelloPub=CLPUB00002) 21155447 CVCL_LS65 BayGenomics ES cell line CSC172 embryonic stem cell house mouse CVCL_LS65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155448 CVCL_M465 PaCaDD-159 cancer cell line human CVCL_M465 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (CelloPub=CLPUB00002; DepMap) Omics: Deep exome analysis. Male Doubling time: 41.3 hours (CelloPub=CLPUB00002); ~1 week (DSMZ=ACC-745) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21155449 CVCL_LS62 BayGenomics ES cell line CSC167 embryonic stem cell house mouse CVCL_LS62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2652875; Wnk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155450 CVCL_UM10 LSCTRi007-A induced pluripotent stem cell human CVCL_UM10 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (PubMed=36399926).; Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Pro34Ser (c.100C>T); ClinVar=VCV000016893; Zygosity=Homozygous; Note=CYP2D6*10 allele (PubMed=36399926) Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155451 CVCL_M462 NHI-6F cancer cell line Norway rat CVCL_M462 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from metastatic site: Liver; Breed/subspecies: NEDH. 21155452 CVCL_LS63 BayGenomics ES cell line CSC168 embryonic stem cell house mouse CVCL_LS63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3702875; Gm14325 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155453 CVCL_UM11 LSCTRi008-A induced pluripotent stem cell human CVCL_UM11 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21155454 CVCL_M463 NHI-6F-28 cancer cell line Norway rat CVCL_M463 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from metastatic site: Liver; Breed/subspecies: NEDH. 21155455 CVCL_LS60 BayGenomics ES cell line CSC160 embryonic stem cell house mouse CVCL_LS60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155456 CVCL_M460 MSL-G2-Tu6 cancer cell line Norway rat CVCL_M460 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from metastatic site: Liver; Breed/subspecies: NEDH. 21155457 CVCL_LS61 BayGenomics ES cell line CSC165 embryonic stem cell house mouse CVCL_LS61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88039; Apc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155458 CVCL_M461 NHI-5B cancer cell line Norway rat CVCL_M461 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from metastatic site: Liver; Breed/subspecies: NEDH. 21155459 CVCL_UM14 MICCNi001-B induced pluripotent stem cell human CVCL_UM14 From: Monash Institute of Cognitive and Clinical Neurosciences, Monash University; Victoria; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155460 CVCL_UM15 MICCNi002-A induced pluripotent stem cell human CVCL_UM15 From: Monash Institute of Cognitive and Clinical Neurosciences, Monash University; Victoria; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155461 CVCL_UM12 LSCTRi009-A induced pluripotent stem cell human CVCL_UM12 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21155462 CVCL_UM13 MICCNi001-A induced pluripotent stem cell human CVCL_UM13 From: Monash Institute of Cognitive and Clinical Neurosciences, Monash University; Victoria; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155463 CVCL_LS79 BayGenomics ES cell line CSD024 embryonic stem cell house mouse CVCL_LS79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98354; Sos1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155464 CVCL_M479 UIA-MM4 cancer cell line human CVCL_M479 CL:0000010 21155465 CVCL_LS77 BayGenomics ES cell line CSD021 embryonic stem cell house mouse CVCL_LS77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450166; Arhgap32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155466 CVCL_M477 UKF-NB-6rVCR10 cancer cell line human CVCL_M477 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21155467 CVCL_LS78 BayGenomics ES cell line CSD022 embryonic stem cell house mouse CVCL_LS78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155468 CVCL_M478 UKF-NB-3rCDDP1000 cancer cell line human CVCL_M478 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Female Part of: Resistant Cancer Cell Line (RCCL) collection 21155469 CVCL_LS75 BayGenomics ES cell line CSD019 embryonic stem cell house mouse CVCL_LS75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353593; Lcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155470 CVCL_M475 UKF-NB-6rCDDP1000 cancer cell line human CVCL_M475 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21155471 CVCL_LS76 BayGenomics ES cell line CSD020 embryonic stem cell house mouse CVCL_LS76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353593; Lcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155472 CVCL_M476 UKF-NB-6rDOX20 cancer cell line human CVCL_M476 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21155473 CVCL_LS73 BayGenomics ES cell line CSD016 embryonic stem cell house mouse CVCL_LS73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384589; Herc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155474 CVCL_M473 IMR-5/75 cancer cell line human CVCL_M473 CL:0000010 Population: Caucasian; Derived from metastatic site: Abdomen. Male 21155475 CVCL_LS74 BayGenomics ES cell line CSD018 embryonic stem cell house mouse CVCL_LS74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155476 CVCL_UM00 DANi001-C induced pluripotent stem cell human CVCL_UM00 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21155477 CVCL_M474 UKF-NB-6 cancer cell line human CVCL_M474 CL:0000010 Derived from metastatic site: Bone marrow. 21155478 CVCL_LS71 BayGenomics ES cell line CSD006 embryonic stem cell house mouse CVCL_LS71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155479 CVCL_M471 PCI-38 cancer cell line human CVCL_M471 Genome ancestry: African=3.33%; Native American=0%; East Asian, North=3.92%; East Asian, South=0%; South Asian=6.82%; European, North=30.5%; European, South=55.42% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21155480 CVCL_LS72 BayGenomics ES cell line CSD015 embryonic stem cell house mouse CVCL_LS72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100865; Rbm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155481 CVCL_M472 IMR-5/M-1 cancer cell line human CVCL_M472 CL:0000010 Population: Caucasian; Derived from metastatic site: Abdomen. Male 21155482 CVCL_UM03 DHMCi003-A induced pluripotent stem cell human CVCL_UM03 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 28908; DNAJC12; Simple; p.Arg72Pro (c.215G>C); ClinVar=VCV000393302; Zygosity=Homozygous (PubMed=30901742) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155483 CVCL_LS70 BayGenomics ES cell line CSD001 embryonic stem cell house mouse CVCL_LS70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045362; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155484 CVCL_UM04 DHMCi003-B induced pluripotent stem cell human CVCL_UM04 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 28908; DNAJC12; Simple; p.Arg72Pro (c.215G>C); ClinVar=VCV000393302; Zygosity=Homozygous (PubMed=30901742) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155485 CVCL_M470 PCI-50 cancer cell line human CVCL_M470 CL:0000010 Male 21155486 CVCL_UM01 DHMCi001-A induced pluripotent stem cell human CVCL_UM01 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11782; TH; Simple; p.Arg129Ter (c.385C>T) (p.Arg98Ter, c.292C>T); ClinVar=VCV000374732; Zygosity=Heterozygous (PubMed=27934587); Sequence variation: Mutation; HGNC; 11782; TH; Simple; p.Arg231Pro (c.692G>C); Zygosity=Heterozygous (PubMed=27934587) Derived from sampling site: Cell type=Fibroblast. Male 21155487 CVCL_UM02 DHMCi002-B induced pluripotent stem cell human CVCL_UM02 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4193; GCH1; Simple; p.Leu79_Ser80del (c.235_240del); Zygosity=Heterozygous (from autologous cell line DHMCi002-A) Derived from sampling site: Cell type=Fibroblast. Female 21155488 CVCL_LS48 BayGenomics ES cell line CSC119 embryonic stem cell house mouse CVCL_LS48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155489 CVCL_M448 UACC-1012 cancer cell line human CVCL_M448 CL:0000010 Derived from metastatic site: Neck. Male 21155490 CVCL_LS49 BayGenomics ES cell line CSC120 embryonic stem cell house mouse CVCL_LS49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155491 CVCL_M449 UACC-1097 cancer cell line human CVCL_M449 CL:0000010 Derived from metastatic site: Muscle. Male 21155492 CVCL_LS46 BayGenomics ES cell line CSC104 embryonic stem cell house mouse CVCL_LS46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913667; Mat2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155493 CVCL_M446 MSL-G2 cancer cell line Norway rat CVCL_M446 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from metastatic site: Liver; Breed/subspecies: NEDH. 21155494 CVCL_LS47 BayGenomics ES cell line CSC117 embryonic stem cell house mouse CVCL_LS47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914736; Polr3g Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155495 CVCL_M447 UACC-91 cancer cell line human CVCL_M447 CL:0000010 Derived from metastatic site: Not specified. Male 21155496 CVCL_LS44 BayGenomics ES cell line CSC099 embryonic stem cell house mouse CVCL_LS44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353593; Lcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155497 CVCL_M444 GIST-DR cancer cell line Norway rat CVCL_M444 CL:0000010 Breed/subspecies: Wistar. Male 21155498 CVCL_LS45 BayGenomics ES cell line CSC100 embryonic stem cell house mouse CVCL_LS45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353593; Lcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155499 CVCL_M445 BuMEC [Buffalo 2012] spontaneously immortalized cell line CVCL_M445 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Omics: Deep proteome analysis Female 21155500 CVCL_LS42 BayGenomics ES cell line CSC090 embryonic stem cell house mouse CVCL_LS42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99470; Dnajc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155501 CVCL_M442 GK1C cancer cell line human CVCL_M442 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys550_Lys558del (c.1648_1674del); ClinVar=VCV000013857; Zygosity=Unspecified (PubMed=23619463). Population: Japanese 21155502 CVCL_LS43 BayGenomics ES cell line CSC093 embryonic stem cell house mouse CVCL_LS43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109301; Papola Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155503 CVCL_M443 GK3C cancer cell line human CVCL_M443 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Phe590_Gly591del; Zygosity=Unspecified (PubMed=23619463). Population: Japanese 21155504 CVCL_LS40 BayGenomics ES cell line CSC085 embryonic stem cell house mouse CVCL_LS40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921802; Nipal3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155505 CVCL_M440 GIST-H1 cancer cell line human CVCL_M440 CL:0000010 Population: Chinese Unspecified Doubling time: 47.5 hours (PubMed=21131734). 21155506 CVCL_LS41 BayGenomics ES cell line CSC086 embryonic stem cell house mouse CVCL_LS41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155507 CVCL_M441 GIST48B cancer cell line human CVCL_M441 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Ala (c.2459A>C); ClinVar=VCV000953798; Zygosity=Heterozygous (PubMed=19706776); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Asp (c.1679T>A); ClinVar=VCV000375914; Zygosity=Homozygous (PubMed=19706776) Omics: ATAC-seq; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. Characteristics: Expresses KIT transcript and protein at essentially undetectable levels (PubMed=19706776) 21155508 CVCL_LS59 BayGenomics ES cell line CSC159 embryonic stem cell house mouse CVCL_LS59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155509 CVCL_M459 UACC-929 cancer cell line human CVCL_M459 CL:0000010 Male 21155510 CVCL_LS57 BayGenomics ES cell line CSC152 embryonic stem cell house mouse CVCL_LS57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921570; Wdr33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155511 CVCL_M457 UACC-375 cancer cell line human CVCL_M457 CL:0000010 21155512 CVCL_LS58 BayGenomics ES cell line CSC156 embryonic stem cell house mouse CVCL_LS58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155513 CVCL_M458 UACC-502 cancer cell line human CVCL_M458 CL:0000010 Derived from metastatic site: Cervical lymph node. Male 21155514 CVCL_LS55 BayGenomics ES cell line CSC132 embryonic stem cell house mouse CVCL_LS55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155515 CVCL_M455 UACC-3074 cancer cell line human CVCL_M455 CL:0000010 Unspecified 21155516 CVCL_LS56 BayGenomics ES cell line CSC146 embryonic stem cell house mouse CVCL_LS56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861942; Gtf2ird1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155517 CVCL_M456 UACC-3149 cancer cell line human CVCL_M456 CL:0000010 Female 21155518 CVCL_LS53 BayGenomics ES cell line CSC128 embryonic stem cell house mouse CVCL_LS53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890773; Actn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155519 CVCL_M453 UACC-2565 cancer cell line human CVCL_M453 CL:0000010 Derived from metastatic site: Lymph node. Male 21155520 CVCL_LS54 BayGenomics ES cell line CSC130 embryonic stem cell house mouse CVCL_LS54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155521 CVCL_M454 UACC-2973 cancer cell line human CVCL_M454 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21155522 CVCL_LS51 BayGenomics ES cell line CSC123 embryonic stem cell house mouse CVCL_LS51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155523 CVCL_M451 UACC-1529 cancer cell line human CVCL_M451 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21155524 CVCL_LS52 BayGenomics ES cell line CSC127 embryonic stem cell house mouse CVCL_LS52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97495; Pbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155525 CVCL_M452 UACC-2534 cancer cell line human CVCL_M452 CL:0000010 Derived from metastatic site: Abdomen. Male 21155526 CVCL_LS50 BayGenomics ES cell line CSC121 embryonic stem cell house mouse CVCL_LS50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139135; Anapc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155527 CVCL_M450 UACC-1256 cancer cell line human CVCL_M450 CL:0000010 Derived from metastatic site: Inguinal lymph node. Female 21155528 CVCL_CY98 ND15833 transformed cell line human CVCL_CY98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155529 CVCL_CY99 CLL-AAT cancer cell line human CVCL_CY99 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3920. 21155530 CVCL_CY92 ND06946 transformed cell line human CVCL_CY92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155531 CVCL_CY93 ND06947 transformed cell line human CVCL_CY93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155532 CVCL_CY90 ND05625 transformed cell line human CVCL_CY90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155533 CVCL_CY91 ND05840 transformed cell line human CVCL_CY91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155534 CVCL_CY96 ND09258 transformed cell line human CVCL_CY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155535 CVCL_CY97 ND09507 transformed cell line human CVCL_CY97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155536 CVCL_LS28 BayGenomics ES cell line CSC032 embryonic stem cell house mouse CVCL_LS28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351655; Shroom3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155537 CVCL_CY94 ND08074 transformed cell line human CVCL_CY94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND08075 (Cellosaurus=CVCL_CY95); Derived from sampling site: Peripheral blood. Female 21155538 CVCL_M428 SF4433-E6/E7-hTERT transformed cell line human CVCL_M428 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSP-puro-E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Brain; meninges. Unspecified 21155539 CVCL_LS29 BayGenomics ES cell line CSC038 embryonic stem cell house mouse CVCL_LS29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888697; Taf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155540 CVCL_M429 KT21-MG1 cancer cell line human CVCL_M429 CL:0000010 Population: Japanese; Derived from sampling site: Brain; falx cerebri. Female Characteristics: Established from a nude mouse xenograft Doubling time: ~24 hours, at 30th passage (PubMed=2804914) 21155541 CVCL_CY95 ND08075 transformed cell line human CVCL_CY95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND08074 (Cellosaurus=CVCL_CY94); Derived from sampling site: Peripheral blood. Female 21155542 CVCL_LS26 BayGenomics ES cell line CSC028 embryonic stem cell house mouse CVCL_LS26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136825; N4bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155543 CVCL_M426 SF3061-hTERT telomerase immortalized cell line human CVCL_M426 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain; meninges. Omics: Array-based CGH Unspecified 21155544 CVCL_LS27 BayGenomics ES cell line CSC031 embryonic stem cell house mouse CVCL_LS27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914345; Trak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155545 CVCL_M427 SF4068-E6/E7-hTERT transformed cell line human CVCL_M427 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSP-puro-E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Brain; meninges. Unspecified 21155546 CVCL_LS24 BayGenomics ES cell line CSC025 embryonic stem cell house mouse CVCL_LS24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684894; Nhs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155547 CVCL_M424 SISK spontaneously immortalized cell line CVCL_M424 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC014 21155548 CVCL_LS25 BayGenomics ES cell line CSC027 embryonic stem cell house mouse CVCL_LS25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643401; Gm8935 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155549 CVCL_M425 SF210 cancer cell line human CVCL_M425 CL:0000010 Derived from sampling site: Brain; left parietal lobe. Female 21155550 CVCL_LS22 BayGenomics ES cell line CSC018 embryonic stem cell house mouse CVCL_LS22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915512; Agpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155551 CVCL_M422 UC-302MG cancer cell line human CVCL_M422 CL:0000010 Male Doubling time: 43.7 +- 6.6 hours (PubMed=3007688). 21155552 CVCL_LS23 BayGenomics ES cell line CSC020 embryonic stem cell house mouse CVCL_LS23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155553 CVCL_M423 ICF spontaneously immortalized cell line CVCL_M423 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC022 21155554 CVCL_LS20 BayGenomics ES cell line CSC014 embryonic stem cell house mouse CVCL_LS20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155555 CVCL_M420 Tp 362-C cancer cell line human CVCL_M420 CL:0000010 Derived from metastatic site: Brain. Male 21155556 CVCL_LS21 BayGenomics ES cell line CSC017 embryonic stem cell house mouse CVCL_LS21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155557 CVCL_M421 UC-11MG cancer cell line human CVCL_M421 CL:0000010 Male Doubling time: 41.0 +- 6.4 hours (PubMed=3007688). 21155558 CVCL_LS39 BayGenomics ES cell line CSC076 embryonic stem cell house mouse CVCL_LS39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155559 CVCL_M439 MCF-7/E6 cancer cell line human CVCL_M439 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21155560 CVCL_LS37 BayGenomics ES cell line CSC064 embryonic stem cell house mouse CVCL_LS37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155561 CVCL_M437 MCF7/D40 cancer cell line human CVCL_M437 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female 21155562 CVCL_LS38 BayGenomics ES cell line CSC069 embryonic stem cell house mouse CVCL_LS38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441842; Serinc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155563 CVCL_M438 MCF7/Mitox cancer cell line human CVCL_M438 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21155564 CVCL_LS35 BayGenomics ES cell line CSC055 embryonic stem cell house mouse CVCL_LS35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933947; Rtn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155565 CVCL_M435 PDFS cancer cell line human CVCL_M435 CL:0000010 Derived from sampling site: Pituitary gland Cell type=Folliculostellate cell.. Male Doubling time: 23.8 hours (PubMed=10720059) 21155566 CVCL_LS36 BayGenomics ES cell line CSC063 embryonic stem cell house mouse CVCL_LS36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155567 CVCL_M436 MCF-7/TAMR-1 cancer cell line human CVCL_M436 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21155568 CVCL_LS33 BayGenomics ES cell line CSC049 embryonic stem cell house mouse CVCL_LS33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443304; Map1s Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155569 CVCL_M433 Tp378MG cancer cell line human CVCL_M433 CL:0000010 Unspecified 21155570 CVCL_LS34 BayGenomics ES cell line CSC051 embryonic stem cell house mouse CVCL_LS34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3051596; Znhit3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155571 CVCL_M434 Tp410N cancer cell line human CVCL_M434 CL:0000010 Unspecified 21155572 CVCL_LS31 BayGenomics ES cell line CSC044 embryonic stem cell house mouse CVCL_LS31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97874; Rb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155573 CVCL_M431 MENII-1 transformed cell line human CVCL_M431 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSP-puro-E6/E7](NCBI-Taxonomy; 333760). 21155574 CVCL_LS32 BayGenomics ES cell line CSC047 embryonic stem cell house mouse CVCL_LS32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916043; Rab3gap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155575 CVCL_M432 Tp242MG cancer cell line human CVCL_M432 CL:0000010 Unspecified 21155576 CVCL_LS30 BayGenomics ES cell line CSC043 embryonic stem cell house mouse CVCL_LS30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914869; Nob1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155577 CVCL_M430 LTAg2B transformed cell line human CVCL_M430 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-TEX](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Male Doubling time: ~24 hours (PubMed=1724784) 21155578 CVCL_CY78 ND02747 transformed cell line human CVCL_CY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155579 CVCL_CY79 ND02815 transformed cell line human CVCL_CY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155580 CVCL_CY76 ND02549 transformed cell line human CVCL_CY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155581 CVCL_CY77 ND02746 transformed cell line human CVCL_CY77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155582 CVCL_CY70 ND00731 transformed cell line human CVCL_CY70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155583 CVCL_CY71 ND02204 transformed cell line human CVCL_CY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155584 CVCL_LS08 BayGenomics ES cell line CSA169 embryonic stem cell house mouse CVCL_LS08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920977; Mcmbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155585 CVCL_M408 MZ-256 cancer cell line human CVCL_M408 CL:0000010 Unspecified 21155586 CVCL_CY74 ND02511 transformed cell line human CVCL_CY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155587 CVCL_LS09 BayGenomics ES cell line CSA170 embryonic stem cell house mouse CVCL_LS09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155588 CVCL_M409 MZ-257 cancer cell line human CVCL_M409 CL:0000010 Unspecified 21155589 CVCL_CY75 ND02548 transformed cell line human CVCL_CY75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155590 CVCL_LS06 BayGenomics ES cell line CSA164 embryonic stem cell house mouse CVCL_LS06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155591 CVCL_M406 MZ-54 cancer cell line human CVCL_M406 CL:0000010 Unspecified 21155592 CVCL_CY72 ND02211 transformed cell line human CVCL_CY72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155593 CVCL_LS07 BayGenomics ES cell line CSA168 embryonic stem cell house mouse CVCL_LS07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97856; Rara Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155594 CVCL_M407 MZ-159 cancer cell line human CVCL_M407 CL:0000010 Unspecified 21155595 CVCL_CY73 ND02313 transformed cell line human CVCL_CY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155596 CVCL_LS04 BayGenomics ES cell line CSA155 embryonic stem cell house mouse CVCL_LS04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155597 CVCL_M404 MZ-18 cancer cell line human CVCL_M404 CL:0000010 Unspecified 21155598 CVCL_LS05 BayGenomics ES cell line CSA161 embryonic stem cell house mouse CVCL_LS05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443226; Pde12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155599 CVCL_M405 MZ-51 cancer cell line human CVCL_M405 CL:0000010 Unspecified 21155600 CVCL_LS02 BayGenomics ES cell line CSA151 embryonic stem cell house mouse CVCL_LS02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2686934; Zfhx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155601 CVCL_M402 Mz21 cancer cell line human CVCL_M402 CL:0000010 Derived from metastatic site: Brain; left parietal lobe. Female 21155602 CVCL_LS03 BayGenomics ES cell line CSA153 embryonic stem cell house mouse CVCL_LS03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144724; Ttc7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155603 CVCL_M403 Mz35 cancer cell line human CVCL_M403 CL:0000010 Derived from metastatic site: Brain; left frontal lobe. Male 21155604 CVCL_LS00 BayGenomics ES cell line CSA146 embryonic stem cell house mouse CVCL_LS00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354946; Mapk6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155605 CVCL_M400 NCI-H929B cancer cell line human CVCL_M400 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgA kappa 21155606 CVCL_LS01 BayGenomics ES cell line CSA148 embryonic stem cell house mouse CVCL_LS01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155607 CVCL_M401 Mz18 cancer cell line human CVCL_M401 CL:0000010 Derived from sampling site: Brain; right occipital lobe. Male 21155608 CVCL_CY89 ND05070 transformed cell line human CVCL_CY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155609 CVCL_CY87 ND04212 transformed cell line human CVCL_CY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155610 CVCL_CY88 ND04403 transformed cell line human CVCL_CY88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155611 CVCL_CY81 ND02926 transformed cell line human CVCL_CY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155612 CVCL_CY82 ND03681 transformed cell line human CVCL_CY82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155613 CVCL_CY80 ND02925 transformed cell line human CVCL_CY80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155614 CVCL_LS19 BayGenomics ES cell line CSC012 embryonic stem cell house mouse CVCL_LS19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351455; Rpl13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155615 CVCL_CY85 ND03709 transformed cell line human CVCL_CY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21155616 CVCL_M419 Tp 242-C cancer cell line human CVCL_M419 CL:0000010 Derived from metastatic site: Brain. Male 21155617 CVCL_CY86 ND03862 transformed cell line human CVCL_CY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155618 CVCL_LS17 BayGenomics ES cell line CSC010 embryonic stem cell house mouse CVCL_LS17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155619 CVCL_M417 MyLa 2355 finite cell line human CVCL_M417 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21155620 CVCL_CY83 ND03703 transformed cell line human CVCL_CY83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155621 CVCL_LS18 BayGenomics ES cell line CSC011 embryonic stem cell house mouse CVCL_LS18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914309; Ola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155622 CVCL_M418 MyLa 3241 finite cell line human CVCL_M418 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 21155623 CVCL_CY84 ND03708 transformed cell line human CVCL_CY84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21155624 CVCL_LS15 BayGenomics ES cell line CSC006 embryonic stem cell house mouse CVCL_LS15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915512; Agpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155625 CVCL_M415 MyLa 1850 finite cell line human CVCL_M415 CL:0000010 Derived from sampling site: Skin Cell type=T-cell.. Unspecified 21155626 CVCL_LS16 BayGenomics ES cell line CSC007 embryonic stem cell house mouse CVCL_LS16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920997; Shld1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155627 CVCL_M416 MyLa 1928 finite cell line human CVCL_M416 CL:0000010 Derived from sampling site: Skin Cell type=T-cell.. Unspecified 21155628 CVCL_LS13 BayGenomics ES cell line CSC003 embryonic stem cell house mouse CVCL_LS13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107926; Rock2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155629 CVCL_M413 MZ-348 cancer cell line human CVCL_M413 CL:0000010 Unspecified 21155630 CVCL_LS14 BayGenomics ES cell line CSC004 embryonic stem cell house mouse CVCL_LS14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155631 CVCL_M414 MZ-373 cancer cell line human CVCL_M414 CL:0000010 Unspecified 21155632 CVCL_LS11 BayGenomics ES cell line CSB001 embryonic stem cell house mouse CVCL_LS11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155633 CVCL_M411 MZ-304 cancer cell line human CVCL_M411 CL:0000010 Unspecified 21155634 CVCL_LS12 BayGenomics ES cell line CSC002 embryonic stem cell house mouse CVCL_LS12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859026; Cnot4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155635 CVCL_M412 MZ-327 cancer cell line human CVCL_M412 CL:0000010 Unspecified 21155636 CVCL_LS10 BayGenomics ES cell line CSA171 embryonic stem cell house mouse CVCL_LS10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181074; Acbd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155637 CVCL_M410 MZ-294 cancer cell line human CVCL_M410 CL:0000010 Unspecified 21155638 CVCL_2G42 AG14422 finite cell line human CVCL_2G42 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 55 PDL (Coriell=AG14422) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155639 CVCL_2G43 AG14429 finite cell line human CVCL_2G43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG14429) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155640 CVCL_2G40 AG14298 finite cell line human CVCL_2G40 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 27 PDL (Coriell=AG14298) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155641 CVCL_2G41 AG14421 finite cell line human CVCL_2G41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 11 PDL (Coriell=AG14421) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155642 CVCL_2G46 AG16030 finite cell line human CVCL_2G46 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155643 CVCL_2G47 AG16086 finite cell line human CVCL_2G47 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155644 CVCL_2G44 AG14446 finite cell line human CVCL_2G44 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 24 PDL (Coriell=AG14446) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155645 CVCL_2G45 AG14642 finite cell line human CVCL_2G45 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 26 PDL (Coriell=AG14642) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155646 CVCL_2G48 AG16102 finite cell line human CVCL_2G48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155647 CVCL_2G49 AG16104 finite cell line human CVCL_2G49 CL:0000010 Population: African American; Karyotypic information: 46,XX,inv(9)(pter->p11::q13->p11::q13->qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155648 CVCL_UM90 518B cancer cell line human CVCL_UM90 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155649 CVCL_UM91 iPSC 09-89 induced pluripotent stem cell human CVCL_UM91 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1480; CAPN3; Simple; p.Arg788Serfs*14 (c.2362_2363delAGinsTCATCT); ClinVar=VCV000017618; Zygosity=Homozygous (PubMed=33862537) Derived from sampling site: Back; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155650 CVCL_UM94 IB PD-P2 induced pluripotent stem cell human CVCL_UM94 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; c.1488+1G>A; ClinVar=VCV000961640; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27975167) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155651 CVCL_UM95 IB PD-P3 induced pluripotent stem cell human CVCL_UM95 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; c.1252_1488del; Zygosity=Heterozygous (PubMed=27975167); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; c.1488+1G>A; ClinVar=VCV000961640; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27975167) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155652 CVCL_UM92 UAMi001-B induced pluripotent stem cell human CVCL_UM92 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Cys616_Val633del (c.1899+4_1899+7delAGTA) (1824IVS+3del4) (IVS21+3del4); Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 8653; PCCA; Simple; p.Gly477Glufs*9 (c.1430-?_1643+?del); Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155653 CVCL_UM93 IB PD-P1 induced pluripotent stem cell human CVCL_UM93 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; c.1252_1488del; Zygosity=Heterozygous (PubMed=27975167); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; c.1488+1G>A; ClinVar=VCV000961640; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27975167) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155654 CVCL_UM98 iPSC-HDFs-clone 30 induced pluripotent stem cell human CVCL_UM98 From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155655 CVCL_UM99 LVNC-FiPS-MIB1Ctrl-WTm6 induced pluripotent stem cell human CVCL_UM99 From: Centro Nacional de Investigaciones Cardiovasculares; Madrid; Spain CL:0000010 Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155656 CVCL_UM96 IB PD-R1 induced pluripotent stem cell human CVCL_UM96 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155657 CVCL_UM97 CQ4-iPSC clone 34 induced pluripotent stem cell human CVCL_UM97 From: Josep Carreras Leukemia Research Institute; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 19693; COQ4; Simple; p.Glu161Asp (c.483G>C); ClinVar=VCV000380493; Zygosity=Heterozygous (PubMed=28465093) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155658 CVCL_2G50 AG16146 finite cell line human CVCL_2G50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155659 CVCL_2G53 AG07311 finite cell line human CVCL_2G53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155660 CVCL_2G54 OKM5 hybridoma house mouse CVCL_2G54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16671; Human CD36. 21155661 CVCL_2G51 AG16358 finite cell line human CVCL_2G51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [33]; 46,XX,t(6;22)(p10;q10) [3]; 46,XX,t(8;18)(q21;p11) [14] (Coriell); Donor information: The donor has a history of radiation exposure at work (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155662 CVCL_2G52 AG16359 finite cell line human CVCL_2G52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155663 CVCL_2G57 OKM9 hybridoma house mouse CVCL_2G57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21155664 CVCL_2G58 OKM10 hybridoma house mouse CVCL_2G58 CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. 21155665 CVCL_2G55 OKM6 hybridoma house mouse CVCL_2G55 CL:0000010 Monoclonal antibody isotype: IgG1. 21155666 CVCL_2G56 OKM8 hybridoma house mouse CVCL_2G56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16671; Human CD36. 21155667 CVCL_2G59 F1-F spontaneously immortalized cell line house mouse CVCL_2G59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified 21155668 CVCL_UM80 610 cancer cell line human CVCL_UM80 CL:0000010 Unspecified 21155669 CVCL_UM83 9007 cancer cell line human CVCL_UM83 CL:0000010 Unspecified 21155670 CVCL_UM84 9304 cancer cell line human CVCL_UM84 CL:0000010 Unspecified 21155671 CVCL_UM81 634 cancer cell line human CVCL_UM81 CL:0000010 Unspecified 21155672 CVCL_UM82 8823 cancer cell line human CVCL_UM82 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn247Thr (c.740A>C); Zygosity=Unspecified (PubMed=10070891); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10070891). Unspecified 21155673 CVCL_UM87 453B cancer cell line human CVCL_UM87 CL:0000010 Unspecified 21155674 CVCL_UM88 X3C-5 cancer cell line human CVCL_UM88 CL:0000010 Derived from metastatic site: Not specified. Unspecified Characteristics: Derived from the third passage of a nude mouse xenograft 21155675 CVCL_UM85 528 [Human melanoma] cancer cell line human CVCL_UM85 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155676 CVCL_UM86 513E cancer cell line human CVCL_UM86 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155677 CVCL_UM89 518A1 cancer cell line human CVCL_UM89 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155678 CVCL_2G20 AG13927 finite cell line human CVCL_2G20 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [96%]; 46,XX,t(2;6)(p16;p21) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 10 PDL (Coriell=AG13927); Doubling time: 2.8 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155679 CVCL_2G21 AG13962 finite cell line human CVCL_2G21 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [74%]; 46,XY,t(2;9)(q14;q21) [14%]; 46,XY,t(1;4;5;14) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 25 PDL (Coriell=AG13962) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155680 CVCL_2G24 AG13975 finite cell line human CVCL_2G24 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [76%]; 46,XY,t(11;13)(q12;q21) [24%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 6 PDL (Coriell=AG13975) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155681 CVCL_2G25 AG13983 finite cell line human CVCL_2G25 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 8 PDL (Coriell=AG13983) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155682 CVCL_2G22 AG13967 finite cell line human CVCL_2G22 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 17 PDL (Coriell=AG13967) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155683 CVCL_2G23 AG13968 finite cell line human CVCL_2G23 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [96%]; 46,XX,add(13)(q34) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 13 PDL (Coriell=AG13968); Doubling time: 2.3 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155684 CVCL_2G28 AG13994 finite cell line human CVCL_2G28 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 9 PDL (Coriell=AG13994) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155685 CVCL_2G29 AG14036 finite cell line human CVCL_2G29 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [24%]; 46,XY,t(1;12)(p31;q21) [76%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG14036) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155686 CVCL_2G26 AG13990 finite cell line human CVCL_2G26 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [92%]; 46,XX,inv(4)(p16;q27) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 7 PDL (Coriell=AG13990) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155687 CVCL_2G27 AG13993 finite cell line human CVCL_2G27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 12 PDL (Coriell=AG13993) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155688 CVCL_2G19 AG13865 finite cell line human CVCL_2G19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [82%]; 46,XX,t(1;9),t(11;13) [6%]; 46,XX,t(4;6)(p16;p21),add(14)(qter)? [6%]; 47,XXX,t(1;4) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 32 PDL (Coriell=AG13865) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155689 CVCL_UM72 MM418-5 cancer cell line human CVCL_UM72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Unspecified 21155690 CVCL_UM73 MM446 cancer cell line human CVCL_UM73 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Leu (c.943_944delCCinsTT); Zygosity=Unspecified (PubMed=10070891) Derived from metastatic site: Not specified. Unspecified Caution: TP53 mutation indicated incorrectly as being in position Pro315 in PubMed=10070891 21155691 CVCL_UM70 MM253c1-3D cancer cell line human CVCL_UM70 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Lymph node. Male 21155692 CVCL_UM71 MM418-1 cancer cell line human CVCL_UM71 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line). Unspecified 21155693 CVCL_UM76 513D cancer cell line human CVCL_UM76 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155694 CVCL_UM77 518A2 cancer cell line human CVCL_UM77 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Unspecified (PubMed=10070891) Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified 21155695 CVCL_UM74 MM612 cancer cell line human CVCL_UM74 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155696 CVCL_UM75 453A0 cancer cell line human CVCL_UM75 CL:0000010 Unspecified 21155697 CVCL_UM78 603 cancer cell line human CVCL_UM78 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21155698 CVCL_UM79 607B cancer cell line human CVCL_UM79 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Unspecified (PubMed=10070891). Unspecified 21155699 CVCL_2G31 AG14099 finite cell line human CVCL_2G31 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG14099; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155700 CVCL_2G32 AG14135 finite cell line human CVCL_2G32 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (Coriell=AG14135) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155701 CVCL_2G30 AG14048 finite cell line human CVCL_2G30 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 13 PDL (Coriell=AG14048) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155702 CVCL_2G35 AG14245 finite cell line human CVCL_2G35 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [82%]; 46,XY,t(2;6)(q21;q21),t(11;16)(p11.2;q12.1) [18%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 51 PDL (Coriell=AG14245) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155703 CVCL_2G36 AG14251 finite cell line human CVCL_2G36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 36 PDL (Coriell=AG14251) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155704 CVCL_2G33 AG14181 finite cell line human CVCL_2G33 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [24%]; 46,XX,t(5;13)(q12;p13) [76%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 19 PDL (Coriell=AG14181) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155705 CVCL_2G34 AG14240 finite cell line human CVCL_2G34 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,t(1;2)(q42;q21) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 7 PDL (Coriell=AG14240) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155706 CVCL_2G39 AG14285 finite cell line human CVCL_2G39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG14285) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155707 CVCL_2G37 AG14252 finite cell line human CVCL_2G37 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [44%]; 46,XX,t(2;15;17) [56%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 49 PDL (Coriell=AG14252) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155708 CVCL_2G38 AG14284 finite cell line human CVCL_2G38 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 47 PDL (Coriell=AG14284) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155709 CVCL_UM61 MM392 cancer cell line human CVCL_UM61 CL:0000010 Unspecified 21155710 CVCL_UM62 MM408 cancer cell line human CVCL_UM62 CL:0000010 Unspecified 21155711 CVCL_UM60 MM387 cancer cell line human CVCL_UM60 CL:0000010 Unspecified 21155712 CVCL_UM65 MM253-3D cancer cell line human CVCL_UM65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Lymph node. Male 21155713 CVCL_UM66 MM253c1 cancer cell line human CVCL_UM66 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Male 21155714 CVCL_UM63 HeLa-2T cancer cell line human CVCL_UM63 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:72568; MTIC (5-(3-methyl-1-triazeno)imidazole-4-carboxamide); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21155715 CVCL_UM64 MM138-2T cancer cell line human CVCL_UM64 CL:0000010 Selected for resistance to: ChEBI; CHEBI:72568; MTIC (5-(3-methyl-1-triazeno)imidazole-4-carboxamide); Derived from metastatic site: Lymph node. Female 21155716 CVCL_UM69 MM253c1-1G cancer cell line human CVCL_UM69 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Derived from metastatic site: Lymph node. Male 21155717 CVCL_UM67 MM253c1-1T cancer cell line human CVCL_UM67 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:72568; MTIC (5-(3-methyl-1-triazeno)imidazole-4-carboxamide); Derived from metastatic site: Lymph node. Male 21155718 CVCL_UM68 MM253c1-4CG cancer cell line human CVCL_UM68 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Selected for resistance to: ChEBI; CHEBI:21759; N-methyl-N'-nitro-N-nitrosoguanidine (MNNG); Derived from metastatic site: Lymph node. Male 21155719 CVCL_UM49 EK [Anguilla] spontaneously immortalized cell line CVCL_UM49 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified Doubling time: 50.27 hours (PubMed=30429125) Group: Fish cell line 21155720 CVCL_2G02 AG13337 finite cell line human CVCL_2G02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13337) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155721 CVCL_2G03 AG13345 finite cell line human CVCL_2G03 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13345) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155722 CVCL_2G00 AG13333 finite cell line human CVCL_2G00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 11 PDL (Coriell=AG13333) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155723 CVCL_2G01 AG13334 finite cell line human CVCL_2G01 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG13334) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155724 CVCL_2G06 AG13353 finite cell line human CVCL_2G06 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG13353; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155725 CVCL_2G07 AG13354 finite cell line human CVCL_2G07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG13354) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155726 CVCL_2G04 AG13348 finite cell line human CVCL_2G04 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 12 PDL (Coriell=AG13348) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155727 CVCL_2G05 AG13349 finite cell line human CVCL_2G05 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155728 CVCL_UM50 Sui65 cancer cell line human CVCL_UM50 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from metastatic site: Peritoneum. Female Characteristics: Established from a SCID nude mouse xenograft Doubling time: 48.6 hours (PubMed=18691340) 21155729 CVCL_UM51 Sui66 cancer cell line human CVCL_UM51 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Male Characteristics: Established from a SCID nude mouse xenograft Doubling time: 41.2 hours (PubMed=18691340) 21155730 CVCL_UM54 Sui69 cancer cell line human CVCL_UM54 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Male Characteristics: Established from a SCID nude mouse xenograft Doubling time: 55.2 hours (PubMed=18691340) 21155731 CVCL_UM55 Sui70 cancer cell line human CVCL_UM55 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Male Characteristics: Established from a SCID nude mouse xenograft Doubling time: 20.8 hours (PubMed=18691340) 21155732 CVCL_UM52 Sui67 cancer cell line human CVCL_UM52 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Female Characteristics: Established from a SCID nude mouse xenograft Doubling time: 35.1 hours (PubMed=18691340) 21155733 CVCL_UM53 Sui68 cancer cell line human CVCL_UM53 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Male Characteristics: Established from a SCID nude mouse xenograft Doubling time: 43.3 hours (PubMed=18691340) 21155734 CVCL_UM58 Sui73 cancer cell line human CVCL_UM58 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Female Characteristics: Established from a SCID nude mouse xenograft Doubling time: 23.5 hours (PubMed=18691340) 21155735 CVCL_UM59 Sui74 cancer cell line human CVCL_UM59 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Female Characteristics: Established from a SCID nude mouse xenograft Doubling time: 47.5 hours (PubMed=18691340) 21155736 CVCL_UM56 Sui71 cancer cell line human CVCL_UM56 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=18691340); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr253Pro (c.757A>C); Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from metastatic site: Liver. Male Characteristics: Established from a SCID nude mouse xenograft Doubling time: 24.1 hours (PubMed=18691340) 21155737 CVCL_UM57 Sui72 cancer cell line human CVCL_UM57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Unspecified (PubMed=18691340) Population: Japanese; Derived from sampling site: Pancreas. Female Characteristics: Established from a SCID nude mouse xenograft Doubling time: 27.8 hours (PubMed=18691340) 21155738 CVCL_UM38 WAe009-A-14 embryonic stem cell human CVCL_UM38 From: The First Affiliated Hospital of Guangxi Medical University; Guangxi; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 812; ATP2A2 Discontinued: hPSCreg; WAe009-A-14; true. Female 21155739 CVCL_UM39 FRIMOi001-A induced pluripotent stem cell human CVCL_UM39 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8785; PDE6A; Simple; p.Arg102His (c.305G>A); ClinVar=VCV000971026; Zygosity=Heterozygous (PubMed=30685614); Sequence variation: Mutation; HGNC; 8785; PDE6A; Simple; p.Leu423Ter (c.1268delT); Zygosity=Heterozygous (PubMed=30685614) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155740 CVCL_2G10 AG13367 finite cell line human CVCL_2G10 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 10 PDL (Coriell=AG13367) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155741 CVCL_2G13 AG13414 finite cell line human CVCL_2G13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [42%]; 46,XY,t(1;2;3;16) [50%]; 46,Y,t(X;11;17) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (Coriell=AG13414) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155742 CVCL_2G14 AG13432 finite cell line human CVCL_2G14 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 46,XY,der(15)t(2;15)(q11.2;p12) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG13432) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155743 CVCL_2G11 AG13369 finite cell line human CVCL_2G11 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 28 PDL (Coriell=AG13369) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155744 CVCL_2G12 AG13407 finite cell line human CVCL_2G12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG13407) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155745 CVCL_2G17 AG13778 finite cell line human CVCL_2G17 CL:0000010 Karyotypic information: 46,XX [70%]; 46,XX,t(3;12) [10%] 46,XX,t(10;13) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 22 PDL (Coriell=AG13778) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155746 CVCL_2G18 AG13781 finite cell line human CVCL_2G18 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;18)(q32;q21) [94%]; 46,XX,t(1;9;18) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 8 PDL (Coriell=AG13781) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155747 CVCL_2G15 AG13442 finite cell line human CVCL_2G15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 46,XY,t(1;16)(q21;p13) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG13442) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155748 CVCL_2G16 AG13443 finite cell line human CVCL_2G16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,9qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 16 PDL (Coriell=AG13443) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155749 CVCL_2G08 AG13358 finite cell line human CVCL_2G08 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [66%]; 47,XXX [34%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 12 PDL (Coriell=AG13358) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155750 CVCL_2G09 AG13364 finite cell line human CVCL_2G09 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [90%]; 45,X [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 7 PDL (Coriell=AG13364) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21155751 CVCL_UM40 FRIMOi002-A induced pluripotent stem cell human CVCL_UM40 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Arg737Ter (c.2209C>T); ClinVar=VCV000002361; Zygosity=Heterozygous (PubMed=30685615); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr2898Ser (c.8693A>C); ClinVar=VCV000557316; Zygosity=Heterozygous (PubMed=30685615) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155752 CVCL_UM43 FDEENTi001-A induced pluripotent stem cell human CVCL_UM43 From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21155753 CVCL_UM44 BIHi002-A induced pluripotent stem cell human CVCL_UM44 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2025; CLCN7; Simple; p.Gly292Glu (c.875G>A); Zygosity=Heterozygous (PubMed=30763735); Sequence variation: Mutation; HGNC; 2025; CLCN7; Simple; p.Arg403Gln (c.1208G>A); ClinVar=VCV001687236; Zygosity=Heterozygous (PubMed=30763735) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155754 CVCL_UM41 FRIMOi003-A induced pluripotent stem cell human CVCL_UM41 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.4253+4C>T; ClinVar=VCV000099266; Zygosity=Heterozygous (PubMed=30798147); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Arg2030Gln (c.6089G>A); ClinVar=VCV000099428; Zygosity=Heterozygous (PubMed=30798147) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155755 CVCL_UM42 FRIMOi004-A induced pluripotent stem cell human CVCL_UM42 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Gly172Ser (c.514G>A); ClinVar=VCV000099347; Zygosity=Heterozygous (PubMed=30798147); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Val675Ile (c.2023G>A); ClinVar=VCV000288341; Zygosity=Heterozygous (PubMed=30798147); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Ser1071Cysfs*14 (c.3210_3211dupGT) (c.3211_3212insGT); ClinVar=VCV000372290; Zygosity=Heterozygous (PubMed=30798147); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Val2050Leu (c.6148G>C); ClinVar=VCV000007884; Zygosity=Heterozygous (PubMed=30798147) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155756 CVCL_UM47 HL-60 SCX3 cancer cell line human CVCL_UM47 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: The TP53 null parental cell line was transfected with a mutated TP53 sequence 21155757 CVCL_UM48 HL-60 SN3 cancer cell line human CVCL_UM48 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: The TP53 null parental cell line was transfected with a wild type TP53 sequence 21155758 CVCL_UM45 BIHi002-B induced pluripotent stem cell human CVCL_UM45 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2025; CLCN7; Simple; p.Gly292Glu (c.875G>A); Zygosity=Heterozygous (from autologous cell line BIHi002-A); Sequence variation: Mutation; HGNC; 2025; CLCN7; Simple; p.Arg403Gln (c.1208G>A); ClinVar=VCV001687236; Zygosity=Heterozygous (from autologous cell line BIHi002-A) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155759 CVCL_UM46 HL-60 248 cancer cell line human CVCL_UM46 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg248Trp); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: The TP53 null parental cell line was transfected with a mutated TP53 sequence 21155760 CVCL_UM29 SUSMi001-A induced pluripotent stem cell human CVCL_UM29 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 21155761 CVCL_UM27 UNEWi028-A induced pluripotent stem cell human CVCL_UM27 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21155762 CVCL_UM28 TUSMi008-A induced pluripotent stem cell human CVCL_UM28 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 8624; PAXIP1; Simple; p.Gln413_His414insGlnGln (c.1241_1242insGCAGCA); Zygosity=Heterozygous (PubMed=30831521) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21155763 CVCL_M488 ACB-1085 cancer cell line human CVCL_M488 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa 21155764 CVCL_LS88 BayGenomics ES cell line CSD043 embryonic stem cell house mouse CVCL_LS88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155765 CVCL_LS89 BayGenomics ES cell line CSD044 embryonic stem cell house mouse CVCL_LS89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155766 CVCL_M489 CZ-1 cancer cell line human CVCL_M489 CL:0000010 Population: Chinese Male Characteristics: Produces Ig lambda Doubling time: ~48 hours (PubMed=14733786) Caution: From the two papers we were not able to conclude whether two distinct cell lines were established (one from bone marrow the other from the peripheral blood) or only one. 21155767 CVCL_LS86 BayGenomics ES cell line CSD039 embryonic stem cell house mouse CVCL_LS86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922832; Relch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155768 CVCL_M486 CMA-03 cancer cell line human CVCL_M486 CL:0000010 Derived from sampling site: Peritoneal effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 80 hours (PubMed=16266902) 21155769 CVCL_M487 ACB-885 cancer cell line human CVCL_M487 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa Doubling time: ~30-35 hours (PubMed=3472643) 21155770 CVCL_LS87 BayGenomics ES cell line CSD041 embryonic stem cell house mouse CVCL_LS87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104683; Fnta Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155771 CVCL_LS84 BayGenomics ES cell line CSD032 embryonic stem cell house mouse CVCL_LS84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155772 CVCL_M484 CMA-01 cancer cell line human CVCL_M484 CL:0000010 Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgD lambda; Characteristics: IL6 dependent Doubling time: 90 hours (PubMed=16266902) 21155773 CVCL_UM32 GIBHe001-A embryonic stem cell human CVCL_UM32 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China. CL:0000010 Unspecified 21155774 CVCL_LS85 BayGenomics ES cell line CSD033 embryonic stem cell house mouse CVCL_LS85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155775 CVCL_M485 CMA-02 cancer cell line human CVCL_M485 CL:0000010 Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 110 hours (PubMed=16266902) 21155776 CVCL_UM33 GIBHe001-B embryonic stem cell human CVCL_UM33 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China. CL:0000010 Unspecified 21155777 CVCL_LS82 BayGenomics ES cell line CSD030 embryonic stem cell house mouse CVCL_LS82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155778 CVCL_M482 LOPRA-1/4 cancer cell line human CVCL_M482 CL:0000010 Derived from sampling site: Ascites. Female Characteristics: Produces IgA2 kappa 21155779 CVCL_UM30 SUSMi001-A-1 induced pluripotent stem cell human CVCL_UM30 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 21155780 CVCL_LS83 BayGenomics ES cell line CSD031 embryonic stem cell house mouse CVCL_LS83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155781 CVCL_M483 LOPRA-1/5 cancer cell line human CVCL_M483 CL:0000010 Derived from sampling site: Ascites. Female Characteristics: Produces IgA2 kappa Doubling time: ~5 days (DSMZ=ACC-778) Caution: On the basis of its characteristics it seems that LOPRA-1 from DSMZ correspond to the clone described as LOPRA-1/5 in the original publication (PubMed=3136791) 21155782 CVCL_UM31 SUSMi002-A induced pluripotent stem cell human CVCL_UM31 From: Stanford University School of Medicine; Stanford; USA CL:0000010 Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 21155783 CVCL_LS80 BayGenomics ES cell line CSD025 embryonic stem cell house mouse CVCL_LS80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140327; Phactr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155784 CVCL_M480 UIA-MM6 cancer cell line human CVCL_M480 CL:0000010 21155785 CVCL_UM36 WAe001-A-24 embryonic stem cell human CVCL_UM36 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS. Male 21155786 CVCL_LS81 BayGenomics ES cell line CSD029 embryonic stem cell house mouse CVCL_LS81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155787 CVCL_M481 LOPRA-1 cancer cell line human CVCL_M481 CL:0000010 Derived from sampling site: Ascites. Female Characteristics: Produces IgA2 kappa Caution: Not cloned cell line Two cloned cell lines were derived, LOPRA-1/4 (Cellosaurus=CVCL_M482) and LOPRA-1/5 (Cellosaurus=CVCL_M483), the later being most probably the cell line distributed by DSMZ as LOPRA-1. 21155788 CVCL_UM37 WAe009-A-11 embryonic stem cell human CVCL_UM37 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Heterozygous; Note=By TALEN (PubMed=30640060). Female 21155789 CVCL_UM34 WAe001-A-21 embryonic stem cell human CVCL_UM34 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2891; DKK1. Male 21155790 CVCL_UM35 WAe001-A-23 embryonic stem cell human CVCL_UM35 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3796; FOS. Male 21155791 CVCL_UM18 Wien 135 cancer cell line human CVCL_UM18 CL:0000010 Virology: EBV-negative. 21155792 CVCL_UM19 Karpas-111 transformed cell line human CVCL_UM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21155793 CVCL_UM16 MICCNi002-B induced pluripotent stem cell human CVCL_UM16 From: Monash Institute of Cognitive and Clinical Neurosciences, Monash University; Victoria; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21155794 CVCL_UM17 RPCi001-A induced pluripotent stem cell human CVCL_UM17 From: ReproCELL, Inc.; Yokohama; Japan. CL:0000010 Male 21155795 CVCL_LS99 BayGenomics ES cell line CSD077 embryonic stem cell house mouse CVCL_LS99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155796 CVCL_M499 ILKM12 cancer cell line human CVCL_M499 CL:0000010 Population: Japanese. 21155797 CVCL_LS97 BayGenomics ES cell line CSD073 embryonic stem cell house mouse CVCL_LS97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098280; Crebbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155798 CVCL_M497 ILKM8 cancer cell line human CVCL_M497 CL:0000010 Population: Japanese. 21155799 CVCL_M498 B104 [Human lymphoma] cancer cell line human CVCL_M498 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0144; true Male 21155800 CVCL_LS98 BayGenomics ES cell line CSD075 embryonic stem cell house mouse CVCL_LS98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914304; Paics Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155801 CVCL_LS95 BayGenomics ES cell line CSD071 embryonic stem cell house mouse CVCL_LS95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923864; Immt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155802 CVCL_UM21 Karpas-118 transformed cell line human CVCL_UM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21155803 CVCL_M495 U-1996 cancer cell line human CVCL_M495 CL:0000010 Derived from sampling site: Ascites. Female Characteristics: Produces Ig kappa Doubling time: 48 hours (PubMed=3580570) 21155804 CVCL_LS96 BayGenomics ES cell line CSD072 embryonic stem cell house mouse CVCL_LS96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155805 CVCL_M496 PCL4199 cancer cell line human CVCL_M496 CL:0000010 Unspecified 21155806 CVCL_UM22 UNIBSi002-A induced pluripotent stem cell human CVCL_UM22 From: University of Brescia; Brescia; Italy. CL:0000010 21155807 CVCL_LS93 BayGenomics ES cell line CSD060 embryonic stem cell house mouse CVCL_LS93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313288; Incenp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155808 CVCL_M493 U-1957 cancer cell line human CVCL_M493 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa Doubling time: 48 hours (PubMed=3580570) 21155809 CVCL_LS94 BayGenomics ES cell line CSD065 embryonic stem cell house mouse CVCL_LS94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155810 CVCL_UM20 Karpas-117 transformed cell line human CVCL_UM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21155811 CVCL_M494 U-1958 cancer cell line human CVCL_M494 CL:0000010 Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa Doubling time: 60 hours (PubMed=3580570) 21155812 CVCL_LS91 BayGenomics ES cell line CSD056 embryonic stem cell house mouse CVCL_LS91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155813 CVCL_M491 KMM-56 cancer cell line human CVCL_M491 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces Ig lambda 21155814 CVCL_UM25 UNEWi006-A induced pluripotent stem cell human CVCL_UM25 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21155815 CVCL_LS92 BayGenomics ES cell line CSD059 embryonic stem cell house mouse CVCL_LS92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102465; Tex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155816 CVCL_M492 NCU-MM-1 cancer cell line human CVCL_M492 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Characteristics: Produces IgG kappa Doubling time: ~48 hours (PubMed=10979215) 21155817 CVCL_UM26 UNEWi020-A induced pluripotent stem cell human CVCL_UM26 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21155818 CVCL_UM23 ULEIi002-A induced pluripotent stem cell human CVCL_UM23 From: Leipzig University Center for Biotechnology and Biomedicine; Leipzig; Germany. CL:0000010 21155819 CVCL_LS90 BayGenomics ES cell line CSD045 embryonic stem cell house mouse CVCL_LS90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155820 CVCL_M490 DOBIL-6 cancer cell line human CVCL_M490 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Non-secretory Doubling time: ~36 hours (PubMed=9674742) 21155821 CVCL_UM24 ULEIi003-A induced pluripotent stem cell human CVCL_UM24 From: Leipzig University Center for Biotechnology and Biomedicine; Leipzig; Germany. CL:0000010 21155822 CVCL_2H81 PRX-B6N #1 embryonic stem cell house mouse CVCL_2H81 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: C57BL/6N. Omics: SNP array analysis Male 21155823 CVCL_2H82 PRX-Balb/cJ #9 embryonic stem cell house mouse CVCL_2H82 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: BALB/c. Male 21155824 CVCL_2H80 PRX-B6-albino #1 embryonic stem cell house mouse CVCL_2H80 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: B6(Cg)-Tyrc-2J/J. Male 21155825 CVCL_2H85 C3Fe.SWV-Mbpshi/J Het PRX-#16 embryonic stem cell house mouse CVCL_2H85 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: C3Fe.SWV-Mbpshi/J. Male 21155826 CVCL_2H86 C3Fe.SWV-Mbpshi/J Hom PRX-#1003 embryonic stem cell house mouse CVCL_2H86 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: C3Fe.SWV-Mbpshi/J. Male 21155827 CVCL_2H83 PRX-C3H #2 embryonic stem cell house mouse CVCL_2H83 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: C3H/HeJ. Male 21155828 CVCL_2H84 BALB/cJ-line I embryonic stem cell house mouse CVCL_2H84 CL:0000010 Breed/subspecies: BALB/cJ. Male 21155829 CVCL_2H89 I11 embryonic stem cell house mouse CVCL_2H89 CL:0000010 Breed/subspecies: C57BL/6J-Chr 1A/J/NaJ. Male 21155830 CVCL_2H87 C3Fe.SWV-Mbpshi/J WT PRX-#1 embryonic stem cell house mouse CVCL_2H87 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: C3Fe.SWV-Mbpshi/J. Female 21155831 CVCL_2H88 JAG020 embryonic stem cell house mouse CVCL_2H88 CL:0000010 Breed/subspecies: NOD.CBALs-Tyr+/LtJ. Male 21155832 CVCL_2H92 I78 embryonic stem cell house mouse CVCL_2H92 CL:0000010 Breed/subspecies: C57BL/6J-Chr 6A/J/NaJ. Male 21155833 CVCL_2H93 AC175 embryonic stem cell house mouse CVCL_2H93 CL:0000010 Breed/subspecies: DBA/2J. Male 21155834 CVCL_2H90 I21 embryonic stem cell house mouse CVCL_2H90 CL:0000010 Breed/subspecies: C57BL/6J-Chr 2A/J/NaJ. Male 21155835 CVCL_2H91 I27 embryonic stem cell house mouse CVCL_2H91 CL:0000010 Breed/subspecies: C57BL/6J-Chr 3A/J/NaJ. Male 21155836 CVCL_2H96 DT40-BLM(-/-)-WRN(-/-) cancer cell line CVCL_2H96 CL:0000010 Knockout cell: Method=Targeted integration; BLM+WRN Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155837 CVCL_2H97 MLC-1-B stromal cell line house mouse CVCL_2H97 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/He. 21155838 CVCL_2H94 AC216 embryonic stem cell house mouse CVCL_2H94 CL:0000010 Breed/subspecies: DBA/2J. Male 21155839 CVCL_2H95 DT40-RAD52(-/-)-XRCC3(-/-) cancer cell line CVCL_2H95 CL:0000010 Knockout cell: Method=Targeted integration; RAD52+XRCC3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21155840 CVCL_2H98 MLC-2-4 stromal cell line house mouse CVCL_2H98 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/He. 21155841 CVCL_2H99 MLC-6 spontaneously immortalized cell line house mouse CVCL_2H99 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. 21155842 CVCL_LU28 BayGenomics ES cell line CSE107 embryonic stem cell house mouse CVCL_LU28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155843 CVCL_M628 RSp transformed cell line human CVCL_M628 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but is a B-lymphoblastoid cell line (PubMed=12592342). 21155844 CVCL_M629 2563 cancer cell line human CVCL_M629 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00032 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). Originally thought to originate from a male patient with a lung adenocarcinoma. The 2563 cell line is said to be derived from the MAC-21 cell line (Cellosaurus=CVCL_M627) which is also HeLa contaminated but which has never been tested for such a contamination. 21155845 CVCL_LU29 BayGenomics ES cell line CSE108 embryonic stem cell house mouse CVCL_LU29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890508; Zmpste24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155846 CVCL_LU26 BayGenomics ES cell line CSE097 embryonic stem cell house mouse CVCL_LU26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97791; Ptbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155847 CVCL_M626 BTT-T739 cancer cell line house mouse CVCL_M626 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: T739. Female 21155848 CVCL_LU27 BayGenomics ES cell line CSE105 embryonic stem cell house mouse CVCL_LU27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103575; Skp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155849 CVCL_M627 MAC-21 cancer cell line human CVCL_M627 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Shown to be a HeLa derivative. Originally thought to originate from a male patient with a lung adenocarcinoma. The original MAC-21 cell line was never tested for contamination. See the colorful description of the MAC-21 contamination story in the book from Michael Gold (CLPUB00262). 21155850 CVCL_LU24 BayGenomics ES cell line CSE080 embryonic stem cell house mouse CVCL_LU24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155851 CVCL_M624 HEK cancer cell line human CVCL_M624 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00063 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4469665; PubMed=4864103; PubMed=20143388). Originally thought to originate from an embryonic kidney.; Caution: Not to be confused with cell line HEK293 (Cellosaurus=CVCL_0045) 21155852 CVCL_LU25 BayGenomics ES cell line CSE087 embryonic stem cell house mouse CVCL_LU25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155853 CVCL_M625 HEK/HRV cancer cell line human CVCL_M625 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00064 Problematic cell line: Contaminated Parent cell line (HEK) has been shown to be a HeLa derivative (PubMed=1246601; PubMed=4469665; PubMed=20143388). 21155854 CVCL_LU22 BayGenomics ES cell line CSE076 embryonic stem cell house mouse CVCL_LU22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155855 CVCL_M622 SH-2 [Human contaminated breast cancer] cancer cell line human CVCL_M622 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00086 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=6451928; PubMed=20143388). Originally thought to originate from the pleural effusion of a female patient with a breast carcinoma. 21155856 CVCL_LU23 BayGenomics ES cell line CSE077 embryonic stem cell house mouse CVCL_LU23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202402; Pde7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155857 CVCL_M623 L132 clone G-38-7 cancer cell line human CVCL_M623 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (L-132) has been shown to be a HeLa derivative (PubMed=1246601). 21155858 CVCL_LU20 BayGenomics ES cell line CSE073 embryonic stem cell house mouse CVCL_LU20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155859 CVCL_M620 JHT cancer cell line human CVCL_M620 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00070 Problematic cell line: Contaminated Parent cell line (JHC) has been shown to be a HeLa derivative (PubMed=11178; PubMed=1246601; PubMed=20143388). 21155860 CVCL_LU21 BayGenomics ES cell line CSE075 embryonic stem cell house mouse CVCL_LU21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155861 CVCL_M621 OF cancer cell line human CVCL_M621 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00149 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=20143388). 21155862 CVCL_LU39 BayGenomics ES cell line CSF005 embryonic stem cell house mouse CVCL_LU39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155863 CVCL_M639 BL-21 cancer cell line human CVCL_M639 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=6441706; PubMed=6806672; PubMed=22120970) Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Cerebrospinal fluid. Male 21155864 CVCL_LU37 BayGenomics ES cell line CSE151 embryonic stem cell house mouse CVCL_LU37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145242; Arrdc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155865 CVCL_M637 DCH024 transformed cell line human CVCL_M637 HLA typing: B*46:01,57:01 (IPD-IMGT/HLA=12388) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155866 CVCL_LU38 BayGenomics ES cell line CSE513 embryonic stem cell house mouse CVCL_LU38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145242; Arrdc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155867 CVCL_M638 DCH032 transformed cell line human CVCL_M638 HLA typing: B*18:01,15:02 (IPD-IMGT/HLA=12386) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155868 CVCL_LU35 BayGenomics ES cell line CSE129 embryonic stem cell house mouse CVCL_LU35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155869 CVCL_M635 DCH020 transformed cell line human CVCL_M635 HLA typing: B*44:02,57:01 (IPD-IMGT/HLA=12417) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155870 CVCL_LU36 BayGenomics ES cell line CSE136 embryonic stem cell house mouse CVCL_LU36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155871 CVCL_M636 DCH021 transformed cell line human CVCL_M636 HLA typing: B*15:02,46:01 (IPD-IMGT/HLA=12382) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155872 CVCL_LU33 BayGenomics ES cell line CSE124 embryonic stem cell house mouse CVCL_LU33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155873 CVCL_M633 SZ-32 transformed cell line human CVCL_M633 HLA typing: A*02:07,31:01:02; B*46:01,55:02; C*01:02:01,03:61; DRB1*09:01,16:02 (IPD-IMGT/HLA=16475) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155874 CVCL_LU34 BayGenomics ES cell line CSE125 embryonic stem cell house mouse CVCL_LU34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155875 CVCL_M634 DCH019 transformed cell line human CVCL_M634 HLA typing: B*07,15:02 (IPD-IMGT/HLA=12387) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21155876 CVCL_LU31 BayGenomics ES cell line CSE119 embryonic stem cell house mouse CVCL_LU31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155877 CVCL_M631 LU cancer cell line human CVCL_M631 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00074 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). Originally thought to originate from fetal lung. 21155878 CVCL_LU32 BayGenomics ES cell line CSE120 embryonic stem cell house mouse CVCL_LU32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143362; Zfp809 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155879 CVCL_M632 QianhefenA26 transformed cell line human CVCL_M632 HLA typing: A*02:01,26:01:08; B*15:01,46:01; C*01:02,03:03; DQB1*03:03,06:02; DRB1*09:01,15:01 (IPD-IMGT/HLA=16442) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21155880 CVCL_LU30 BayGenomics ES cell line CSE115 embryonic stem cell house mouse CVCL_LU30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155881 CVCL_M630 HBC undefined cell line type Norway rat CVCL_M630 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00024. Problematic cell line: Misidentified Originally thought to be of human origin but found to be from rat (PubMed=557237; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21155882 CVCL_LU08 BayGenomics ES cell line CSE043 embryonic stem cell house mouse CVCL_LU08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155883 CVCL_M608 KC2H3 cancer cell line human CVCL_M608 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21155884 CVCL_M609 105AJ cancer cell line human CVCL_M609 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21155885 CVCL_LU09 BayGenomics ES cell line CSE046 embryonic stem cell house mouse CVCL_LU09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446634; Ago3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155886 CVCL_M606 AD [Human chondrosarcoma] cancer cell line human CVCL_M606 CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 24 hours (PubMed=16039953) 21155887 CVCL_LU06 BayGenomics ES cell line CSE040 embryonic stem cell house mouse CVCL_LU06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449307; Upf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155888 CVCL_LU07 BayGenomics ES cell line CSE042 embryonic stem cell house mouse CVCL_LU07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384931; Dhrs7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155889 CVCL_M607 SM [Human chondrosarcoma] cancer cell line human CVCL_M607 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 36 hours (PubMed=16039953) 21155890 CVCL_LU04 BayGenomics ES cell line CSE038 embryonic stem cell house mouse CVCL_LU04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155891 CVCL_M604 OSHU-1 cancer cell line human CVCL_M604 CL:0000010 Male Doubling time: 70-80 hours (PubMed=6931250). 21155892 CVCL_M605 105KC cancer cell line human CVCL_M605 CL:0000010 Miscellaneous: STR profile established at MicroSynth from personal communication of Muff R Derived from sampling site: Bone; distal femur. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=16039953) 21155893 CVCL_LU05 BayGenomics ES cell line CSE039 embryonic stem cell house mouse CVCL_LU05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155894 CVCL_LU02 BayGenomics ES cell line CSE033 embryonic stem cell house mouse CVCL_LU02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155895 CVCL_M602 Ch-1 cancer cell line human CVCL_M602 CL:0000010 Derived from sampling site: Bone; thoracic vertebra. Male Doubling time: 2 days (PubMed=9820274) 21155896 CVCL_LU03 BayGenomics ES cell line CSE034 embryonic stem cell house mouse CVCL_LU03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155897 CVCL_M603 HEEM cancer cell line human CVCL_M603 CL:0000010 Population: Caucasian; Dutch; Derived from metastatic site: Bone; left femur. Male Doubling time: 2 days (PubMed=857824) 21155898 CVCL_M600 Aramis finite cell line human CVCL_M600 CL:0000010 Derived from sampling site: Thyroid gland. Female Doubling time: ~2 weeks, in 5% FCS (PubMed=15320967) 21155899 CVCL_LU00 BayGenomics ES cell line CSE031 embryonic stem cell house mouse CVCL_LU00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109634; Terf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155900 CVCL_LU01 BayGenomics ES cell line CSE032 embryonic stem cell house mouse CVCL_LU01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449307; Upf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155901 CVCL_M601 ONSA-8 cancer cell line human CVCL_M601 CL:0000010 Population: Mexican Male Doubling time: ~13 hours (PubMed=4471180). 21155902 CVCL_LU19 BayGenomics ES cell line CSE072 embryonic stem cell house mouse CVCL_LU19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914457; Lsm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155903 CVCL_M619 HCE cancer cell line human CVCL_M619 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00055 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). 21155904 CVCL_LU17 BayGenomics ES cell line CSE069 embryonic stem cell house mouse CVCL_LU17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155905 CVCL_M617 SG cancer cell line human CVCL_M617 CL:0000010 Female 21155906 CVCL_LU18 BayGenomics ES cell line CSE070 embryonic stem cell house mouse CVCL_LU18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155907 CVCL_M618 Detroit 6 clone 12 cancer cell line human CVCL_M618 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ATCC; CCL-3.1; true Female Problematic cell line: Contaminated Parent cell line (Detroit 6) has been shown to be a HeLa derivative (PubMed=6451928; PubMed=1246601). 21155908 CVCL_LU15 BayGenomics ES cell line CSE064 embryonic stem cell house mouse CVCL_LU15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155909 CVCL_M615 OCUU-6 cancer cell line human CVCL_M615 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 26 hours (PubMed=15859154) 21155910 CVCL_LU16 BayGenomics ES cell line CSE068 embryonic stem cell house mouse CVCL_LU16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155911 CVCL_M616 FSCP-1 cancer cell line human CVCL_M616 CL:0000010 Male Doubling time: 36-48 hours (PubMed=15547702). 21155912 CVCL_M613 AQ cancer cell line human CVCL_M613 CL:0000010 21155913 CVCL_LU13 BayGenomics ES cell line CSE056 embryonic stem cell house mouse CVCL_LU13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155914 CVCL_M614 4BG cancer cell line human CVCL_M614 CL:0000010 Male 21155915 CVCL_LU14 BayGenomics ES cell line CSE062 embryonic stem cell house mouse CVCL_LU14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443272; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155916 CVCL_M611 105AJ3.1 cancer cell line human CVCL_M611 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21155917 CVCL_LU11 BayGenomics ES cell line CSE048 embryonic stem cell house mouse CVCL_LU11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155918 CVCL_M612 105AJ5.1 cancer cell line human CVCL_M612 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21155919 CVCL_LU12 BayGenomics ES cell line CSE052 embryonic stem cell house mouse CVCL_LU12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155920 CVCL_M610 105AJ1.1 cancer cell line human CVCL_M610 CL:0000010 Derived from sampling site: Bone; distal femur. Male 21155921 CVCL_LU10 BayGenomics ES cell line CSE047 embryonic stem cell house mouse CVCL_LU10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88474; Cox5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155922 CVCL_UN28 HPS0830 induced pluripotent stem cell human CVCL_UN28 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155923 CVCL_UN29 HPS0654 induced pluripotent stem cell human CVCL_UN29 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155924 CVCL_UN26 HPS0854 induced pluripotent stem cell human CVCL_UN26 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155925 CVCL_UN27 HPS0848 induced pluripotent stem cell human CVCL_UN27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21155926 CVCL_LT89 BayGenomics ES cell line CSE003 embryonic stem cell house mouse CVCL_LT89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155927 CVCL_M589 STHdhQ109 transformed cell line house mouse CVCL_M589 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; striatum Cell type=Neuron.. 21155928 CVCL_LT87 BayGenomics ES cell line CSD410 embryonic stem cell house mouse CVCL_LT87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155929 CVCL_M587 Nak-Pc2 cancer cell line human CVCL_M587 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155930 CVCL_LT88 BayGenomics ES cell line CSE001 embryonic stem cell house mouse CVCL_LT88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923012; Aftph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155931 CVCL_M588 ST14A conditionally immortalized cell line Norway rat CVCL_M588 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: At the permissive temperature (33 Celsius) proliferates At the restrictive temperature (39 Celsius) has reduced proliferation, decreased expression of nestin and differentiates into neuronal cells. 21155932 CVCL_LT85 BayGenomics ES cell line CSD404 embryonic stem cell house mouse CVCL_LT85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349423; Racgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155933 CVCL_M585 U-2031 transformed cell line human CVCL_M585 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Unspecified Doubling time: 24-48 hours (PubMed=3583453) 21155934 CVCL_LT86 BayGenomics ES cell line CSD407 embryonic stem cell house mouse CVCL_LT86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155935 CVCL_M586 UCLA # 1 cancer cell line human CVCL_M586 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified 21155936 CVCL_M583 AMU-ML1 cancer cell line human CVCL_M583 CL:0000010 Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 5477; IGH; Name(s)=IGH-BCL6 (DOI=10.1182/blood.V118.21.5210.5210); Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5853; IGL; Name(s)=IGL-BCL2 (DOI=10.1182/blood.V118.21.5210.5210); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (DOI=10.1182/blood.V118.21.5210.5210) Population: Japanese; Derived from sampling site: Pleural effusion. Male 21155937 CVCL_LT83 BayGenomics ES cell line CSD400 embryonic stem cell house mouse CVCL_LT83 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm2097 (MGI:3780264) which is no longer considered a gene by MGI 21155938 CVCL_UN31 HPS0549 induced pluripotent stem cell human CVCL_UN31 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155939 CVCL_M584 AMU-AML1 cancer cell line human CVCL_M584 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Omics: SNP array analysis Male Doubling time: ~96 hours (PubMed=21965128) 21155940 CVCL_LT84 BayGenomics ES cell line CSD402 embryonic stem cell house mouse CVCL_LT84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104582; Eps15l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155941 CVCL_UN32 HPS2478 induced pluripotent stem cell human CVCL_UN32 HLA typing: A*24:02:01:01,33:03:01; B*40:06:01:01,44:03:01:01New; C*08:01:01:01,14:03; DPB1*04:01:01:26,05:01:01:04; DQB1*03:03:02,06:04; DRB1*09:01:02,13:02:01:02 (RCB=HPS2478) CL:0000010 Derived from sampling site: Peripheral blood. Female 21155942 CVCL_LT81 BayGenomics ES cell line CSD385 embryonic stem cell house mouse CVCL_LT81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155943 CVCL_M581 U-2030 cancer cell line human CVCL_M581 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=10936422) Derived from sampling site: Pleural effusion. Unspecified Characteristics: Produces IgA lambda Doubling time: ~36 hours (PubMed=3583453) 21155944 CVCL_LT82 BayGenomics ES cell line CSD390 embryonic stem cell house mouse CVCL_LT82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155945 CVCL_UN30 HPS0660 induced pluripotent stem cell human CVCL_UN30 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Arg89Gln (c.266G>A); ClinVar=VCV000011922; Zygosity=Homozygous (PubMed=30849633) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21155946 CVCL_M582 U-2030 TG cancer cell line human CVCL_M582 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Pleural effusion. Unspecified Characteristics: Produces IgA lambda 21155947 CVCL_UN35 HPS3119 induced pluripotent stem cell human CVCL_UN35 HLA typing: A*24:02:01:01,24:02:01:01; B*40:02:01:01,54:01:01; C*01:02:01,03:04:01; DPB1*02:01:02,05:01:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,11:01:01:01New (RCB=HPS3119) CL:0000010 Derived from sampling site: Peripheral blood. Male 21155948 CVCL_LT80 BayGenomics ES cell line CSD378 embryonic stem cell house mouse CVCL_LT80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155949 CVCL_UN36 HPS3125 induced pluripotent stem cell human CVCL_UN36 HLA typing: A*02:01:01:01,24:02:01:01; B*54:01:01; C*01:02:01; DPB1*04:02:01,05:01:01; DQB1*04:01:01:01,06:02:01:01; DRB1*04:05:01:01,15:01:01 (RCB=HPS3135) CL:0000010 Derived from sampling site: Peripheral blood. Male 21155950 CVCL_M580 WSU-DLCL cancer cell line human CVCL_M580 CL:0000010 Derived from sampling site: Pleural effusion. Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-DLCL Female Doubling time: 20 hours (PubMed=1540884); ~48-72 hours (DSMZ=ACC-779) 21155951 CVCL_UN33 HPS0461 induced pluripotent stem cell human CVCL_UN33 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21155952 CVCL_UN34 HPS2508 induced pluripotent stem cell human CVCL_UN34 HLA typing: A*24:02:01:01,24:02:01:01; B*07:02:01:01,54:01:01; C*01:02:01,07:02:01; DPB1*05:01:01; DQB1*03:03:02,04:01:01:01; DRB1*04:05:01:01,09:01:02 (RCB=HPS2508) CL:0000010 Derived from sampling site: Peripheral blood. Female 21155953 CVCL_UN17 HPS1042 induced pluripotent stem cell human CVCL_UN17 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male 21155954 CVCL_UN18 HPS1043 induced pluripotent stem cell human CVCL_UN18 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155955 CVCL_UN15 6PNF_SiPSrv_PM_2 induced pluripotent stem cell human CVCL_UN15 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu983Ter (c.2946delT); Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155956 CVCL_UN16 7PNF_SiPSrv_PM_12 induced pluripotent stem cell human CVCL_UN16 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Ile679Aspfs*20 (c.2034_2035insC) (c.2034_2035dupC); ClinVar=VCV001048682; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155957 CVCL_UN19 HPS1046 induced pluripotent stem cell human CVCL_UN19 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male 21155958 CVCL_LT98 BayGenomics ES cell line CSE023 embryonic stem cell house mouse CVCL_LT98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913275; Rcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155959 CVCL_M598 CNE-3 cancer cell line human CVCL_M598 CL:0000010 Population: Chinese. Male 21155960 CVCL_LT99 BayGenomics ES cell line CSE025 embryonic stem cell house mouse CVCL_LT99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155961 CVCL_M599 Rh36 cancer cell line human CVCL_M599 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Unspecified (PubMed=12068308; DepMap) Omics: Deep exome analysis; Omics: Exosome proteome analysis; Omics: Protein expression by reverse-phase protein arrays. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21155962 CVCL_LT96 BayGenomics ES cell line CSE020 embryonic stem cell house mouse CVCL_LT96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155963 CVCL_M596 HONE-1/CPT30R cancer cell line human CVCL_M596 CL:0000010 Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu418Lys (c.1252G>A); ClinVar=VCV000016774; Zygosity=Unspecified (PubMed=12097280). Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT) Male Characteristics: Partial revertant of the CPT30 camptothecin-resistant subline Problematic cell line: Parent cell line (HONE-1) seems to bear part of the HeLa genomic sequence and may be a derivative of HeLa and another cell of unknown origin 21155964 CVCL_LT97 BayGenomics ES cell line CSE022 embryonic stem cell house mouse CVCL_LT97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155965 CVCL_M597 C666 cancer cell line human CVCL_M597 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Characteristics: Established from the athymic nude mouse xenograft xeno-666 21155966 CVCL_LT94 BayGenomics ES cell line CSE017 embryonic stem cell house mouse CVCL_LT94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155967 CVCL_M594 CRMM-2 cancer cell line human CVCL_M594 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=25722211). Male Doubling time: ~60 hours (PubMed=15993408) 21155968 CVCL_UN20 HPS1126 induced pluripotent stem cell human CVCL_UN20 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155969 CVCL_LT95 BayGenomics ES cell line CSE019 embryonic stem cell house mouse CVCL_LT95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145955; Prkaa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155970 CVCL_M595 HONE-1/CPT30 cancer cell line human CVCL_M595 CL:0000010 Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu418Lys (c.1252G>A); ClinVar=VCV000016774; Zygosity=Unspecified (PubMed=12097280). Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT) Male Problematic cell line: Parent cell line (HONE-1) seems to bear part of the HeLa genomic sequence and may be a derivative of HeLa and another cell of unknown origin 21155971 CVCL_UN21 HPS1127 induced pluripotent stem cell human CVCL_UN21 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155972 CVCL_LT92 BayGenomics ES cell line CSE011 embryonic stem cell house mouse CVCL_LT92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3779598; Gm6445 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155973 CVCL_M592 CM2005.1 cancer cell line human CVCL_M592 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25722211). Karyotypic information: Has lost chromosome Y Male Characteristics: Highly pigmented Doubling time: ~35 hours (PubMed=17947278) 21155974 CVCL_LT93 BayGenomics ES cell line CSE012 embryonic stem cell house mouse CVCL_LT93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109520; Pafah1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155975 CVCL_M593 CRMM-1 cancer cell line human CVCL_M593 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25722211). Unspecified Doubling time: ~60 hours (PubMed=15993408) 21155976 CVCL_LT90 BayGenomics ES cell line CSE006 embryonic stem cell house mouse CVCL_LT90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103296; Nfatc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155977 CVCL_UN24 HPS1133 induced pluripotent stem cell human CVCL_UN24 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155978 CVCL_M590 STHdhQ7 transformed cell line house mouse CVCL_M590 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; striatum Cell type=Neuron.. 21155979 CVCL_LT91 BayGenomics ES cell line CSE009 embryonic stem cell house mouse CVCL_LT91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201408; Srpk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155980 CVCL_UN25 HPS1134 induced pluripotent stem cell human CVCL_UN25 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155981 CVCL_M591 STHdhQ111 transformed cell line house mouse CVCL_M591 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum Cell type=Neuron.. 21155982 CVCL_UN22 HPS1128 induced pluripotent stem cell human CVCL_UN22 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21155983 CVCL_UN23 HPS1132 induced pluripotent stem cell human CVCL_UN23 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21155984 CVCL_UN06 ICCSICi014-A induced pluripotent stem cell human CVCL_UN06 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155985 CVCL_UN07 ICCSICi001-A induced pluripotent stem cell human CVCL_UN07 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=31203165) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155986 CVCL_UN04 ICCSICi012-A induced pluripotent stem cell human CVCL_UN04 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155987 CVCL_UN05 ICCSICi013-A induced pluripotent stem cell human CVCL_UN05 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155988 CVCL_UN08 ICCSICi002-A induced pluripotent stem cell human CVCL_UN08 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=31203165) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155989 CVCL_UN09 ICCSICi003-A induced pluripotent stem cell human CVCL_UN09 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31203165) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21155990 CVCL_LT69 BayGenomics ES cell line CSD339 embryonic stem cell house mouse CVCL_LT69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670178; Med13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155991 CVCL_M569 STKM-1 cancer cell line human CVCL_M569 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female Doubling time: 31.4 hours, at 30th passage (PubMed=1888706) 21155992 CVCL_LT67 BayGenomics ES cell line CSD333 embryonic stem cell house mouse CVCL_LT67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446143; Zfc3h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155993 CVCL_M567 BL-28 cancer cell line human CVCL_M567 HLA typing: A*01; B*08,16 (PubMed=3037521) From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672) Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21155994 CVCL_LT68 BayGenomics ES cell line CSD334 embryonic stem cell house mouse CVCL_LT68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384836; Nepro Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155995 CVCL_M568 BL-59 cancer cell line human CVCL_M568 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21155996 CVCL_LT65 BayGenomics ES cell line CSD329 embryonic stem cell house mouse CVCL_LT65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914737; Dhx40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155997 CVCL_M565 BL-43 cancer cell line human CVCL_M565 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21155998 CVCL_LT66 BayGenomics ES cell line CSD330 embryonic stem cell house mouse CVCL_LT66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21155999 CVCL_M566 BL-44 cancer cell line human CVCL_M566 CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21156000 CVCL_LT63 BayGenomics ES cell line CSD322 embryonic stem cell house mouse CVCL_LT63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651985; Zfp988 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156001 CVCL_M563 BL-5 cancer cell line human CVCL_M563 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian Male Virology: EBV-negative. 21156002 CVCL_LT64 BayGenomics ES cell line CSD327 embryonic stem cell house mouse CVCL_LT64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156003 CVCL_M564 BL-6 cancer cell line human CVCL_M564 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans north of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21156004 CVCL_LT61 BayGenomics ES cell line CSD309 embryonic stem cell house mouse CVCL_LT61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183747; Fgd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156005 CVCL_M561 BL-8 cancer cell line human CVCL_M561 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21156006 CVCL_LT62 BayGenomics ES cell line CSD314 embryonic stem cell house mouse CVCL_LT62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156007 CVCL_M562 BL-3 [Human Burkitt lymphoma] cancer cell line human CVCL_M562 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672). Population: Caucasian Male Virology: EBV-negative 21156008 CVCL_UN10 ICCSICi004-A induced pluripotent stem cell human CVCL_UN10 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31203165) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156009 CVCL_LT60 BayGenomics ES cell line CSD306 embryonic stem cell house mouse CVCL_LT60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156010 CVCL_M560 BL-69 cancer cell line human CVCL_M560 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21156011 CVCL_UN13 5PNF_TDiPSsv_MM_4 induced pluripotent stem cell human CVCL_UN13 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Ex16-35del; Zygosity=Unspecified (Spanish_Stem_Cell_Bank). Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156012 CVCL_UN14 5PNF_TDiPSsv_PM_6 induced pluripotent stem cell human CVCL_UN14 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Ex16-35del; Zygosity=Unspecified (Spanish_Stem_Cell_Bank). Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156013 CVCL_UN11 3PNF_FiPSsv_PM_2 induced pluripotent stem cell human CVCL_UN11 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln1315Ter (c.3943C>T); ClinVar=VCV000938573; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156014 CVCL_UN12 3PNF_SiPSsv_MM_11 induced pluripotent stem cell human CVCL_UN12 From: Institut d'Investigacio Germans Trias i Pujol (IGTP); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln1315Ter (c.3943C>T); ClinVar=VCV000938573; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156015 CVCL_LT78 BayGenomics ES cell line CSD369 embryonic stem cell house mouse CVCL_LT78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921677; Eaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156016 CVCL_M578 BCS-6 cancer cell line human CVCL_M578 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296). 21156017 CVCL_M579 B301 transformed cell line human CVCL_M579 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156018 CVCL_LT79 BayGenomics ES cell line CSD374 embryonic stem cell house mouse CVCL_LT79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914496; Resf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156019 CVCL_LT76 BayGenomics ES cell line CSD365 embryonic stem cell house mouse CVCL_LT76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156020 CVCL_M576 hmel11 cancer cell line human CVCL_M576 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Heterozygous (PubMed=23489693) Derived from sampling site: Skin. 21156021 CVCL_LT77 BayGenomics ES cell line CSD368 embryonic stem cell house mouse CVCL_LT77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156022 CVCL_M577 M35/01 cancer cell line human CVCL_M577 CL:0000010 Omics: Array-based CGH. Male 21156023 CVCL_LT74 BayGenomics ES cell line CSD355 embryonic stem cell house mouse CVCL_LT74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919318; Cnot2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156024 CVCL_M574 HBL-2 [Human AIDS-related non-Hodgkin lymphoma] cancer cell line human CVCL_M574 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asn (c.700T>A); ClinVar=VCV000376692; Zygosity=Unspecified (PubMed=8412324); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8412324) Derived from sampling site: Pleural effusion. Male 21156025 CVCL_LT75 BayGenomics ES cell line CSD359 embryonic stem cell house mouse CVCL_LT75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156026 CVCL_M575 HBL-3 [Human AIDS-related non-Hodgkin lymphoma] cancer cell line human CVCL_M575 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8412324) Derived from sampling site: Liver. Male 21156027 CVCL_LT72 BayGenomics ES cell line CSD351 embryonic stem cell house mouse CVCL_LT72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139369; Rtel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156028 CVCL_M572 HBL-1 [Human AIDS-related non-Hodgkin lymphoma] cancer cell line human CVCL_M572 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8412324) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Cell surface proteome Female 21156029 CVCL_LT73 BayGenomics ES cell line CSD352 embryonic stem cell house mouse CVCL_LT73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156030 CVCL_M573 HBL-2 [Human B-cell lymphoma] cancer cell line human CVCL_M573 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Arg (c.838A>C); ClinVar=VCV000926213; Zygosity=Unspecified (PubMed=8878455); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Unspecified (PubMed=8878455) Population: Chinese; Derived from sampling site: Peripheral blood. Male Doubling time: ~20 hours (PubMed=3899542) 21156031 CVCL_LT70 BayGenomics ES cell line CSD341 embryonic stem cell house mouse CVCL_LT70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107157; Sin3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156032 CVCL_M570 STKM-2 cancer cell line human CVCL_M570 From: Yanoma S.; School of Medicine, Yokohama City University; Yokohama; Japan CL:0000010 Population: Japanese. Unspecified 21156033 CVCL_LT71 BayGenomics ES cell line CSD349 embryonic stem cell house mouse CVCL_LT71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321398; F11r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156034 CVCL_M571 BKD cancer cell line CVCL_M571 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768); Breed/subspecies: Mixed breed. Female 21156035 CVCL_UN02 ICCSICi007-A induced pluripotent stem cell human CVCL_UN02 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=31698192) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156036 CVCL_UN03 ICCSICi006-A induced pluripotent stem cell human CVCL_UN03 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Gly206Asp (c.617G>A); ClinVar=VCV000807473; Zygosity=Heterozygous (PubMed=31627126) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156037 CVCL_UN00 LVNC-FiPS-MIB1STOP1 induced pluripotent stem cell human CVCL_UN00 From: Centro Nacional de Investigaciones Cardiovasculares; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 21086; MIB1; Simple; p.Arg530Ter (c.1588C>T); ClinVar=VCV000040092; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156038 CVCL_UN01 LVNC-FiPS-MIB1VF2 induced pluripotent stem cell human CVCL_UN01 From: Centro Nacional de Investigaciones Cardiovasculares; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 21086; MIB1; Simple; p.Val943Phe (c.2827G>T); ClinVar=VCV000040091; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21156039 CVCL_LT49 BayGenomics ES cell line CSD281 embryonic stem cell house mouse CVCL_LT49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156040 CVCL_M549 GAL-01 cancer cell line human CVCL_M549 CL:0000010 Derived from metastatic site: Ascites. Male Virology: EBV-negative 21156041 CVCL_LT47 BayGenomics ES cell line CSD273 embryonic stem cell house mouse CVCL_LT47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146350; Scaf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156042 CVCL_M547 MM-M1 cancer cell line human CVCL_M547 CL:0000010 Sequence variation: Gene fusion; HGNC; 1582; CCND1 + HGNC; 5477; IGH; Name(s)=IGH-CCND1 (PubMed=8695815) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq. Characteristics: Produces IgG kappa 21156043 CVCL_LT48 BayGenomics ES cell line CSD280 embryonic stem cell house mouse CVCL_LT48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914504; Bmerb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156044 CVCL_M548 UMJF-2 transformed cell line human CVCL_M548 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line (PubMed=10936422). 21156045 CVCL_LT45 BayGenomics ES cell line CSD262 embryonic stem cell house mouse CVCL_LT45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156046 CVCL_M545 VC5 cancer cell line human CVCL_M545 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgG lambda 21156047 CVCL_LT46 BayGenomics ES cell line CSD264 embryonic stem cell house mouse CVCL_LT46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931797; Ckap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156048 CVCL_M546 Sa5 cancer cell line human CVCL_M546 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces Ig kappa 21156049 CVCL_LT43 BayGenomics ES cell line CSD247 embryonic stem cell house mouse CVCL_LT43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039376; Dnph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156050 CVCL_M543 RPM-MC cancer cell line human CVCL_M543 CL:0000010 Discontinued: ATCC; CRL-2499; true. Unspecified 21156051 CVCL_LT44 BayGenomics ES cell line CSD256 embryonic stem cell house mouse CVCL_LT44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890212; Porcn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156052 CVCL_M544 ILKM10 cancer cell line human CVCL_M544 CL:0000010 Population: Japanese. 21156053 CVCL_LT41 BayGenomics ES cell line CSD244 embryonic stem cell house mouse CVCL_LT41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156054 CVCL_M541 MM-LH cancer cell line human CVCL_M541 CL:0000010 Derived from metastatic site: Omentum. Unspecified 21156055 CVCL_LT42 BayGenomics ES cell line CSD245 embryonic stem cell house mouse CVCL_LT42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917649; Wwtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156056 CVCL_M542 RPM-EP cancer cell line human CVCL_M542 CL:0000010 Unspecified 21156057 CVCL_LT40 BayGenomics ES cell line CSD243 embryonic stem cell house mouse CVCL_LT40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139764; Sec24b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156058 CVCL_M540 MM-BP cancer cell line human CVCL_M540 CL:0000010 Derived from metastatic site: Axillary lymph node. Unspecified 21156059 CVCL_LT58 BayGenomics ES cell line CSD301 embryonic stem cell house mouse CVCL_LT58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919891; Mob2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156060 CVCL_M558 BL-14 cancer cell line human CVCL_M558 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672) Population: Turkish; Derived from sampling site: Bone marrow. Female Virology: EBV-negative 21156061 CVCL_LT59 BayGenomics ES cell line CSD303 embryonic stem cell house mouse CVCL_LT59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88473; Cox4i1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156062 CVCL_M559 BL-46 cancer cell line human CVCL_M559 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21156063 CVCL_LT56 BayGenomics ES cell line CSD297 embryonic stem cell house mouse CVCL_LT56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108295; Pxn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156064 CVCL_M556 BL-61 cancer cell line human CVCL_M556 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Africans north of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21156065 CVCL_LT57 BayGenomics ES cell line CSD298 embryonic stem cell house mouse CVCL_LT57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924769; Zfp266 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156066 CVCL_M557 BL-33 cancer cell line human CVCL_M557 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672) Population: Caucasian; Derived from sampling site: Bone marrow. Male Virology: EBV-negative 21156067 CVCL_LT54 BayGenomics ES cell line CSD292 embryonic stem cell house mouse CVCL_LT54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156068 CVCL_M554 SUBL cancer cell line human CVCL_M554 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: ~48 hours (PubMed=7506636) 21156069 CVCL_LT55 BayGenomics ES cell line CSD296 embryonic stem cell house mouse CVCL_LT55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858222; Septin9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156070 CVCL_M555 BL-7 cancer cell line human CVCL_M555 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21156071 CVCL_LT52 BayGenomics ES cell line CSD288 embryonic stem cell house mouse CVCL_LT52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107889; Exosc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156072 CVCL_M552 WSU-BL cancer cell line human CVCL_M552 CL:0000010 Derived from sampling site: Ascites. Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-BL Male Virology: EBV-negative Doubling time: 19 hours (PubMed=2527086) 21156073 CVCL_LT53 BayGenomics ES cell line CSD290 embryonic stem cell house mouse CVCL_LT53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156074 CVCL_M553 OMA-BL-1 cancer cell line human CVCL_M553 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21156075 CVCL_LT50 BayGenomics ES cell line CSD282 embryonic stem cell house mouse CVCL_LT50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156076 CVCL_M550 GAL-02 cancer cell line human CVCL_M550 CL:0000010 Derived from metastatic site: Ascites. Male Virology: EBV-negative 21156077 CVCL_LT51 BayGenomics ES cell line CSD284 embryonic stem cell house mouse CVCL_LT51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338056; Klf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156078 CVCL_M551 Katata cancer cell line human CVCL_M551 CL:0000010 Population: Japanese; Transformant: Human herpesvirus 6B (HHV-6B)(NCBI-Taxonomy; 1592561). Female Virology: Contains a chromosomally integrated HHV-6B (CI-HHV-6B) Doubling time: 24 hours (PubMed=9242553) 21156079 CVCL_CZ99 OVCA429/T40 cancer cell line human CVCL_CZ99 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21156080 CVCL_CZ97 MES-OV/T40 cancer cell line human CVCL_CZ97 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21156081 CVCL_CZ98 OVCA429/TxT50 cancer cell line human CVCL_CZ98 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from sampling site: Ovary. Female 21156082 CVCL_CZ91 1CB4 hybridoma house mouse CVCL_CZ91 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Caenorhabditis elegans antigen on membranous organelles. 21156083 CVCL_CZ92 MES-OV cancer cell line human CVCL_CZ92 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: ~22 hours (ATCC=CRL-3272) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21156084 CVCL_CZ90 209/MDCT transformed cell line house mouse CVCL_CZ90 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; distal convoluted tubule; Breed/subspecies: CD-1. Male 21156085 CVCL_LT29 BayGenomics ES cell line CSD204 embryonic stem cell house mouse CVCL_LT29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107891; Nop2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156086 CVCL_CZ95 ES-2/TxT50 cancer cell line human CVCL_CZ95 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from sampling site: Ovary. Female Problematic cell line: Probably misclassified Parent cell line seems to originate from a Caucasian patient with an ovarian serous adenocarcinoma origin. 21156087 CVCL_M529 OPM-3 cancer cell line human CVCL_M529 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified Characteristics: Produces IgA kappa 21156088 CVCL_CZ96 MES-OV/TxT50 cancer cell line human CVCL_CZ96 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Ascites. Female 21156089 CVCL_CZ93 1A9/T80 cancer cell line human CVCL_CZ93 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21156090 CVCL_LT27 BayGenomics ES cell line CSD196 embryonic stem cell house mouse CVCL_LT27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156091 CVCL_M527 C463A cancer cell line house mouse CVCL_M527 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Patented cell line 21156092 CVCL_LT28 BayGenomics ES cell line CSD197 embryonic stem cell house mouse CVCL_LT28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914811; Wdr48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156093 CVCL_CZ94 ES-2/T80 cancer cell line human CVCL_CZ94 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female Problematic cell line: Probably misclassified Parent cell line seems to originate from a Caucasian patient with an ovarian serous adenocarcinoma origin. 21156094 CVCL_M528 TH [Human plasma cell myeloma] cancer cell line human CVCL_M528 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG3 kappa Doubling time: ~24 hours (PubMed=1958480) 21156095 CVCL_M525 ALMC-1 cancer cell line human CVCL_M525 CL:0000010 Donor information: Established from a patient suffering from primary systemic amyloidosis which relapsed with multiple myeloma; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda 21156096 CVCL_LT25 BayGenomics ES cell line CSD185 embryonic stem cell house mouse CVCL_LT25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156097 CVCL_M526 ALMC-2 cancer cell line human CVCL_M526 CL:0000010 Donor information: Established from a patient suffering from primary systemic amyloidosis which relapsed with multiple myeloma; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda 21156098 CVCL_LT26 BayGenomics ES cell line CSD188 embryonic stem cell house mouse CVCL_LT26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156099 CVCL_M523 ANBM-6 cancer cell line human CVCL_M523 CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21156100 CVCL_LT23 BayGenomics ES cell line CSD174 embryonic stem cell house mouse CVCL_LT23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156101 CVCL_LT24 BayGenomics ES cell line CSD178 embryonic stem cell house mouse CVCL_LT24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156102 CVCL_M524 KAS-6/2 cancer cell line human CVCL_M524 CL:0000010 Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent. 21156103 CVCL_LT21 BayGenomics ES cell line CSD169 embryonic stem cell house mouse CVCL_LT21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156104 CVCL_M521 MUM24 cancer cell line human CVCL_M521 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Unspecified (PubMed=23686003) Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa 21156105 CVCL_LT22 BayGenomics ES cell line CSD173 embryonic stem cell house mouse CVCL_LT22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156106 CVCL_M522 UHKT-893 cancer cell line human CVCL_M522 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 3.4-3.8 days (PubMed=23290585) 21156107 CVCL_LT20 BayGenomics ES cell line CSD164 embryonic stem cell house mouse CVCL_LT20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156108 CVCL_M520 MT-3 [Human mesothelioma] cancer cell line human CVCL_M520 From: Anderson T and Saxton R.; UCLA School of Medicine; Los Angeles; USA. CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228). 21156109 CVCL_LT38 BayGenomics ES cell line CSD237 embryonic stem cell house mouse CVCL_LT38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917599; Copb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156110 CVCL_M538 MM-S1 cancer cell line human CVCL_M538 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=11157491) Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent Doubling time: 24 hours (PubMed=2072743) 21156111 CVCL_LT39 BayGenomics ES cell line CSD241 embryonic stem cell house mouse CVCL_LT39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922542; Prkd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156112 CVCL_M539 MM-Y1 cancer cell line human CVCL_M539 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Doubling time: 49 hours (PubMed=2072743) 21156113 CVCL_LT36 BayGenomics ES cell line CSD232 embryonic stem cell house mouse CVCL_LT36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156114 CVCL_M536 MM-A1 cancer cell line human CVCL_M536 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG lambda; Characteristics: IL6 dependent Doubling time: 48 hours (PubMed=2072743) 21156115 CVCL_LT37 BayGenomics ES cell line CSD233 embryonic stem cell house mouse CVCL_LT37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156116 CVCL_M537 MM-C1 cancer cell line human CVCL_M537 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG lambda; Characteristics: IL6 dependent Doubling time: 96 hours (PubMed=2072743) 21156117 CVCL_LT34 BayGenomics ES cell line CSD228 embryonic stem cell house mouse CVCL_LT34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928753; Pfdn5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156118 CVCL_M534 JK-6 cancer cell line human CVCL_M534 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21156119 CVCL_LT35 BayGenomics ES cell line CSD230 embryonic stem cell house mouse CVCL_LT35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919563; Fryl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156120 CVCL_M535 ME-1 [Human myeloma] cancer cell line human CVCL_M535 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296). Unspecified 21156121 CVCL_LT32 BayGenomics ES cell line CSD225 embryonic stem cell house mouse CVCL_LT32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156122 CVCL_M532 KPC-32 cancer cell line human CVCL_M532 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21156123 CVCL_LT33 BayGenomics ES cell line CSD226 embryonic stem cell house mouse CVCL_LT33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384560; Aars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156124 CVCL_M533 LOPRA-2 cancer cell line human CVCL_M533 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Produces IgG1 lambda; Characteristics: Has a defect in the GPI-anchoring pathway 21156125 CVCL_LT30 BayGenomics ES cell line CSD220 embryonic stem cell house mouse CVCL_LT30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384782; Slc25a38 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156126 CVCL_M530 TU-1 cancer cell line human CVCL_M530 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (PubMed=9249875) Derived from sampling site: Bone marrow. Male 21156127 CVCL_LT31 BayGenomics ES cell line CSD224 embryonic stem cell house mouse CVCL_LT31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915345; Ociad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156128 CVCL_M531 LA-49 cancer cell line human CVCL_M531 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=10936422) Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgD lambda 21156129 CVCL_2H60 MPI-IV embryonic stem cell house mouse CVCL_2H60 CL:0000010 Breed/subspecies: 129S2/SvPas. Female 21156130 CVCL_2H63 91-1 embryonic stem cell house mouse CVCL_2H63 CL:0000010 Breed/subspecies: 129S2/SvPas. Female Characteristics: Contains 90% of human chromosome 21 21156131 CVCL_2H64 AC173 embryonic stem cell house mouse CVCL_2H64 CL:0000010 Breed/subspecies: DBA/2J. Male 21156132 CVCL_2H61 MPI-V embryonic stem cell house mouse CVCL_2H61 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21156133 CVCL_2H62 MPI-VI embryonic stem cell house mouse CVCL_2H62 CL:0000010 Breed/subspecies: 129S2/SvPas. Female 21156134 CVCL_2H67 AC386 embryonic stem cell house mouse CVCL_2H67 CL:0000010 Breed/subspecies: C3H/HeJ. Male 21156135 CVCL_2H68 AC401 embryonic stem cell house mouse CVCL_2H68 CL:0000010 Breed/subspecies: PWD/PhJ. Male 21156136 CVCL_2H65 AC203 embryonic stem cell house mouse CVCL_2H65 CL:0000010 Breed/subspecies: DBA/2J. Male 21156137 CVCL_2H66 AC383 embryonic stem cell house mouse CVCL_2H66 CL:0000010 Breed/subspecies: BALB/cByJ. Male 21156138 CVCL_2H69 AC429 embryonic stem cell house mouse CVCL_2H69 CL:0000010 Breed/subspecies: C57BL/6J-Chr 9A/J/NaJ. Male 21156139 CVCL_2H70 AC446 embryonic stem cell house mouse CVCL_2H70 CL:0000010 Breed/subspecies: C57BL/6J-Chr 10A/J/NaJ. Male 21156140 CVCL_2H71 AC453 embryonic stem cell house mouse CVCL_2H71 CL:0000010 Breed/subspecies: C57BL/6J-Chr 6A/J/NaJ. Male 21156141 CVCL_2H74 PB151.24 embryonic stem cell house mouse CVCL_2H74 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: C3H/HeJ. Male 21156142 CVCL_2H75 PB35.17 embryonic stem cell house mouse CVCL_2H75 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: NZW/LacJ. Male 21156143 CVCL_2H72 AC576 embryonic stem cell house mouse CVCL_2H72 CL:0000010 Breed/subspecies: NOD/ShiLtJ. Male 21156144 CVCL_2H73 PB150.18 embryonic stem cell house mouse CVCL_2H73 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: BALB/cByJ. Male 21156145 CVCL_2H78 PB84.3 embryonic stem cell house mouse CVCL_2H78 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: FVB/NJ. Male 21156146 CVCL_2H79 PRX-129X1/SvJ #1 embryonic stem cell house mouse CVCL_2H79 From: Primogenix, Inc.; Saint Louis; USA CL:0000010 Breed/subspecies: 129X1/SvJ. Male 21156147 CVCL_2H76 PB60.6 embryonic stem cell house mouse CVCL_2H76 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: BTBR T+ Itpr3tf/J. Male 21156148 CVCL_2H77 PB61.11 embryonic stem cell house mouse CVCL_2H77 From: Predictive Biology, Inc.; Carlsbad; USA CL:0000010 Breed/subspecies: MRL/MpJ. Male 21156149 CVCL_2H41 KCI-MENG1-LPSX-CL cancer cell line human CVCL_2H41 CL:0000010 Female 21156150 CVCL_2H42 KCI-MENG1-HP cancer cell line human CVCL_2H42 CL:0000010 Female 21156151 CVCL_2H40 KCI-MENG1-LP cancer cell line human CVCL_2H40 CL:0000010 Female 21156152 CVCL_2H45 XL-2 cancer cell line human CVCL_2H45 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Male 21156153 CVCL_2H46 XL-2sci cancer cell line human CVCL_2H46 CL:0000010 Population: Chinese; Derived from metastatic site: Ascites. Male 21156154 CVCL_2H43 KCI-MENG1-HPSX-CL cancer cell line human CVCL_2H43 CL:0000010 Female 21156155 CVCL_2H44 hTERT-CBECs telomerase immortalized cell line dog CVCL_2H44 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bronchus; epithelium; Breed/subspecies: Beagle. Male 21156156 CVCL_2H49 CHO/pS2P spontaneously immortalized cell line CVCL_2H49 CL:0000010 Transfected with: HGNC; 15455; MBTPS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21156157 CVCL_2H47 AmE-711 spontaneously immortalized cell line CVCL_2H47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Persistently infected with deformed wing virus (DWV) isolate DWV-AmE711 (PubMed=26923109) Doubling time: ~4 days (PubMed=23894551) Group: Insect cell line 21156158 CVCL_2H48 HEK1.1 transformed cell line human CVCL_2H48 CL:0000010 Transfected with: HGNC; 10585; SCN1A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156159 CVCL_UN90 HPS1776 induced pluripotent stem cell human CVCL_UN90 CL:0000010 Sequence variation: Mutation; HGNC; 7459; MT-ND4; Simple; p.Arg340His (m.11778G>A); ClinVar=VCV000009708; Zygosity=Unspecified (RCB) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156160 CVCL_UN93 HPS1936 induced pluripotent stem cell human CVCL_UN93 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156161 CVCL_UN94 HPS1988 induced pluripotent stem cell human CVCL_UN94 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156162 CVCL_UN91 HPS1900 induced pluripotent stem cell human CVCL_UN91 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156163 CVCL_UN92 HPS1906 induced pluripotent stem cell human CVCL_UN92 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156164 CVCL_UN97 HPS2096 induced pluripotent stem cell human CVCL_UN97 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21156165 CVCL_UN98 HPS2108 induced pluripotent stem cell human CVCL_UN98 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156166 CVCL_UN95 HPS2000 induced pluripotent stem cell human CVCL_UN95 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21156167 CVCL_UN96 HPS2084 induced pluripotent stem cell human CVCL_UN96 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156168 CVCL_UN99 HPS2114 induced pluripotent stem cell human CVCL_UN99 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156169 CVCL_2H52 SRD-13A spontaneously immortalized cell line CVCL_2H52 CL:0000010 Transfected with: HGNC; 15455; MBTPS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 21156170 CVCL_2H53 OX-CO-2 cancer cell line human CVCL_2H53 CL:0000010 Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21156171 CVCL_2H50 SRD-12A transformed cell line CVCL_2H50 CL:0000010 Transfected with: HGNC; 15455; MBTPS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Has a defect in the site 1 cleavage reaction 21156172 CVCL_2H51 SRD-12B transformed cell line CVCL_2H51 CL:0000010 Transfected with: HGNC; 15455; MBTPS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female Characteristics: Has a defect in the site 1 cleavage reaction 21156173 CVCL_2H56 CC22 cancer cell line human CVCL_2H56 CL:0000010 Unspecified 21156174 CVCL_2H57 MPI-I embryonic stem cell house mouse CVCL_2H57 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21156175 CVCL_2H54 CC20 [Human colon adenocarcinoma] cancer cell line human CVCL_2H54 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Unspecified (PubMed=16418264) Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray. Unspecified Part of: AstraZeneca Colorectal cell line (AZCL) panel 21156176 CVCL_2H55 CC21 [Human colon adenocarcinoma] cancer cell line human CVCL_2H55 CL:0000010 Unspecified 21156177 CVCL_2H58 MPI-II embryonic stem cell house mouse CVCL_2H58 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21156178 CVCL_2H59 MPI-III embryonic stem cell house mouse CVCL_2H59 CL:0000010 Breed/subspecies: 129S2/SvPas. Male 21156179 CVCL_UN82 HPS1466 induced pluripotent stem cell human CVCL_UN82 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156180 CVCL_UN83 HPS1472 induced pluripotent stem cell human CVCL_UN83 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156181 CVCL_UN80 HPS1454 induced pluripotent stem cell human CVCL_UN80 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156182 CVCL_UN81 HPS1460 induced pluripotent stem cell human CVCL_UN81 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21156183 CVCL_UN86 HPS1568 induced pluripotent stem cell human CVCL_UN86 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156184 CVCL_UN87 HPS1632 induced pluripotent stem cell human CVCL_UN87 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156185 CVCL_UN84 HPS1526 induced pluripotent stem cell human CVCL_UN84 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156186 CVCL_UN85 HPS1532 induced pluripotent stem cell human CVCL_UN85 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156187 CVCL_UN88 HPS1679 induced pluripotent stem cell human CVCL_UN88 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156188 CVCL_UN89 HPS0438 induced pluripotent stem cell human CVCL_UN89 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21156189 CVCL_2H20 GM01529 transformed cell line human CVCL_2H20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156190 CVCL_2H23 GM01559 transformed cell line human CVCL_2H23 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Arg224His (c.676G>A); Zygosity=Heterozygous (PubMed=8528202) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156191 CVCL_2H24 GM01560 transformed cell line human CVCL_2H24 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Arg224His (c.676G>A); Zygosity=Unspecified (from familial inference of GM01559) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156192 CVCL_2H21 GM01532 transformed cell line human CVCL_2H21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156193 CVCL_2H22 GM01558 transformed cell line human CVCL_2H22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156194 CVCL_2H27 OSCC-BD cancer cell line human CVCL_2H27 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu188_Pro191del (c.563_574del12); Zygosity=Unspecified (from parent cell line) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Oral cavity; tongue Cell type=Keratinocyte.. Omics: Proteome analysis Male 21156195 CVCL_2H28 SHG-139 cancer cell line human CVCL_2H28 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 21156196 CVCL_2H25 GM01808 transformed cell line human CVCL_2H25 HLA typing: A*02,10; B*12,27 (Coriell=GM01808) CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ile278Thr (c.833T>C); ClinVar=VCV000000120; Zygosity=Heterozygous (PubMed=8528202) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156197 CVCL_2H26 GM02690 transformed cell line human CVCL_2H26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156198 CVCL_2H18 GM01463 transformed cell line human CVCL_2H18 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ala331Val (c.992C>T); ClinVar=VCV000193793; Zygosity=Unspecified (PubMed=8528202) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156199 CVCL_2H19 GM01528 transformed cell line human CVCL_2H19 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; c.1149_1226del (Ex11del); Zygosity=Unspecified (PubMed=8528202) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156200 CVCL_UN71 HPS1343 induced pluripotent stem cell human CVCL_UN71 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21156201 CVCL_UN72 HPS1349 induced pluripotent stem cell human CVCL_UN72 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21156202 CVCL_UN70 HPS1337 induced pluripotent stem cell human CVCL_UN70 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21156203 CVCL_UN75 HPS1373 induced pluripotent stem cell human CVCL_UN75 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156204 CVCL_UN76 HPS1385 induced pluripotent stem cell human CVCL_UN76 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156205 CVCL_UN73 HPS1355 induced pluripotent stem cell human CVCL_UN73 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21156206 CVCL_UN74 HPS1367 induced pluripotent stem cell human CVCL_UN74 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21156207 CVCL_UN79 HPS1427 induced pluripotent stem cell human CVCL_UN79 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156208 CVCL_UN77 HPS1391 induced pluripotent stem cell human CVCL_UN77 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156209 CVCL_UN78 HPS1403 induced pluripotent stem cell human CVCL_UN78 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156210 CVCL_UN59 HPS1074 induced pluripotent stem cell human CVCL_UN59 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21156211 CVCL_2H30 IPC-clone 2 transformed cell line house mouse CVCL_2H30 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pituitary gland; Breed/subspecies: ICR. 21156212 CVCL_2H31 PeCa-UkHb-01 cancer cell line human CVCL_2H31 CL:0000010 Male Doubling time: 34.7 +- 3.8 hours (PubMed=26193922). 21156213 CVCL_2H34 3NB12.13 hybridoma house mouse CVCL_2H34 CL:0000010 Discontinued: ATCC; CRL-2354; true. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Caenorhabditis elegans antigen on pharyngeal cells 21156214 CVCL_2H35 22F.Li finite cell line CVCL_2H35 CL:0000010 Derived from sampling site: Liver. Discontinued: ATCC; CRL-6530; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21156215 CVCL_2H32 PCL12 transformed cell line human CVCL_2H32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~40-50 hours (DSMZ=ACC-794) 21156216 CVCL_2H33 DT40-LYN(-/-)-SYK(-/-) cancer cell line CVCL_2H33 CL:0000010 Knockout cell: Method=Targeted integration; LYN+SYK Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21156217 CVCL_2H38 HT168 cancer cell line human CVCL_2H38 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: Low metastatic potential 21156218 CVCL_2H39 HT168-M1 cancer cell line human CVCL_2H39 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: High metastatic potential 21156219 CVCL_2H36 S4B634 hybridoma CVCL_2H36 CL:0000010 Discontinued: BCRJ; 0216; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04351; Mouse Il2 21156220 CVCL_2H37 XMG1.2 hybridoma CVCL_2H37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01580; Mouse Ifng. 21156221 CVCL_2H29 IPC-clone 13 transformed cell line house mouse CVCL_2H29 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pituitary gland; Breed/subspecies: ICR. 21156222 CVCL_UN60 HPS1075 induced pluripotent stem cell human CVCL_UN60 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156223 CVCL_UN61 HPS1210 induced pluripotent stem cell human CVCL_UN61 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156224 CVCL_UN64 HPS1312 induced pluripotent stem cell human CVCL_UN64 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156225 CVCL_UN65 HPS1318 induced pluripotent stem cell human CVCL_UN65 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156226 CVCL_UN62 HPS1228 induced pluripotent stem cell human CVCL_UN62 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156227 CVCL_UN63 HPS1252 induced pluripotent stem cell human CVCL_UN63 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156228 CVCL_UN68 HPS1324 induced pluripotent stem cell human CVCL_UN68 CL:0000010 Derived from sampling site: Peripheral blood. Male 21156229 CVCL_UN69 HPS1325 induced pluripotent stem cell human CVCL_UN69 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156230 CVCL_UN66 HPS1319 induced pluripotent stem cell human CVCL_UN66 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156231 CVCL_UN67 HPS1320 induced pluripotent stem cell human CVCL_UN67 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156232 CVCL_UN48 G-1187GM cancer cell line human CVCL_UN48 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 11.74 days (in 0.5% FCS), 2.34 days (in 10% FCS) (PubMed=12894509) 21156233 CVCL_UN49 G-1265GM cancer cell line human CVCL_UN49 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Ser (c.313G>A); ClinVar=VCV000428884; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 5.45 days (in 0.5% FCS), 2.07 days (in 10% FCS) (PubMed=12894509) 21156234 CVCL_2H01 GM00751 finite cell line human CVCL_2H01 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ile278Thr (c.833T>C); ClinVar=VCV000000120; Zygosity=Unspecified (from familial inference of GM01808) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156235 CVCL_2H02 GM00752 finite cell line human CVCL_2H02 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ile278Thr (c.833T>C); ClinVar=VCV000000120; Zygosity=Unspecified (from familial inference of GM01808) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156236 CVCL_2H00 GM00724 finite cell line human CVCL_2H00 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156237 CVCL_2H05 GM00864 finite cell line human CVCL_2H05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21156238 CVCL_2H06 GM00866 finite cell line human CVCL_2H06 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21156239 CVCL_2H03 GM00753 finite cell line human CVCL_2H03 HLA typing: A*02,10; B*12,27 (Coriell=GM00753) CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ile278Thr (c.833T>C); ClinVar=VCV000000120; Zygosity=Heterozygous (from autologous cell line GM01808) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156240 CVCL_2H04 GM00813 finite cell line human CVCL_2H04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156241 CVCL_UN50 G-1301GM cancer cell line human CVCL_UN50 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ser (c.451C>T); ClinVar=VCV000012370; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 3.93 days (in 0.5% FCS), 2.32 days (in 10% FCS) (PubMed=12894509) 21156242 CVCL_UN53 NTUB1/P[9] cancer cell line human CVCL_UN53 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21156243 CVCL_UN54 HPS1032 induced pluripotent stem cell human CVCL_UN54 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156244 CVCL_UN51 G-1408GM cancer cell line human CVCL_UN51 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15035290). Unspecified Doubling time: 5.15 days (in 0.5% FCS), 1.73 days (in 10% FCS) (PubMed=12894509) 21156245 CVCL_UN52 NTUB1/P[3] cancer cell line human CVCL_UN52 CL:0000010 Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21156246 CVCL_UN57 HPS1066 induced pluripotent stem cell human CVCL_UN57 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156247 CVCL_UN58 HPS1071 induced pluripotent stem cell human CVCL_UN58 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156248 CVCL_UN55 HPS1033 induced pluripotent stem cell human CVCL_UN55 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156249 CVCL_UN56 HPS1052 induced pluripotent stem cell human CVCL_UN56 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156250 CVCL_UN39 HPS3344 induced pluripotent stem cell human CVCL_UN39 HLA typing: A*02:01:01:01; B*40:06:01:01,54:01:01; C*01:02:01:05,08:01:01:01; DPB1*02:01:02,05:01:01; DQB1*03:03:02,04:01:01:02; DRB1*04:05:01:01,09:01:02 (RCB=HPS3344) CL:0000010 Derived from sampling site: Peripheral blood. Male 21156251 CVCL_UN37 HPS3131 induced pluripotent stem cell human CVCL_UN37 HLA typing: A*02:01:01:01,24:20:01:01New; B*35:01:01:02,51:01:01; C*01:02:01,03:03:01; DPB1*02:01:02,05:01:01; DQB1*03:01:01,03:02:01; DRB1*08:02:01,12:01:01:03/12:10 (RCB=HPS3131) CL:0000010 Derived from sampling site: Peripheral blood. Female 21156252 CVCL_UN38 HPS3338 induced pluripotent stem cell human CVCL_UN38 HLA typing: A*02:06:01:04,24:02:01:01; B*40:02:01:01,48:01:01; C*03:04:01New,08:03:01; DPB1*05:01:0; DQB1*03:03:02,05:03:01New; DRB1*09:01:02,14:54:01:02New (RCB=HPS3338) CL:0000010 Derived from sampling site: Peripheral blood. Male 21156253 CVCL_2H12 GM01129 finite cell line human CVCL_2H12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156254 CVCL_2H13 GM01374 finite cell line human CVCL_2H13 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Val168Met (c.502G>A); ClinVar=VCV000000127; Zygosity=Unspecified (PubMed=8528202) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21156255 CVCL_2H10 GM01126 finite cell line human CVCL_2H10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156256 CVCL_2H11 GM01128 finite cell line human CVCL_2H11 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Gly307Ser (c.919G>A); ClinVar=VCV000000117; Zygosity=Heterozygous (PubMed=8528202); Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Val454Glu (c.1361T>A); Zygosity=Heterozygous (PubMed=8528202) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21156257 CVCL_2H16 GM01446 transformed cell line human CVCL_2H16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156258 CVCL_2H17 GM01447 transformed cell line human CVCL_2H17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156259 CVCL_2H14 GM01375 finite cell line human CVCL_2H14 HLA typing: A*02,11; B*22,27 (Coriell=GM01375) CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Caution: Indicated by Coriell to originate from mother of GM01374 but does not seem to contain any CBS mutation, therefore the pedigree relationship may be incorrect (PubMed=8528202) 21156260 CVCL_2H15 GM01376 finite cell line human CVCL_2H15 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Gly307Ser (c.919G>A); ClinVar=VCV000000117; Zygosity=Heterozygous (PubMed=8528202) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Caution: Indicated by Coriell to originate from father of GM01374 but does not contain the same CBS mutation, therefore the pedigree relationship may be incorrect (PubMed=8528202) 21156261 CVCL_2H09 GM00885 finite cell line human CVCL_2H09 CL:0000010 Sequence variation: Mutation; HGNC; 1550; CBS; Simple; p.Ile278Thr (c.833T>C); ClinVar=VCV000000120; Zygosity=Heterozygous (from familial inference of GM01808) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156262 CVCL_2H07 GM00867 finite cell line human CVCL_2H07 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21156263 CVCL_2H08 GM00883 finite cell line human CVCL_2H08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21156264 CVCL_UN42 HPS2214 induced pluripotent stem cell human CVCL_UN42 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156265 CVCL_UN43 G-210GM cancer cell line human CVCL_UN43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 2.94 days (in 0.5% FCS), 1.68 days (in 10% FCS) (PubMed=12894509) 21156266 CVCL_UN40 HPS3704 induced pluripotent stem cell human CVCL_UN40 HLA typing: A*11:01:01:01,31:01:02:01; B*51:01:01:01,67:01:01; C*07:02:01,14:02:01; DPB1*05:01:01; DRB1*04:05:01:01,15:01:01; DQB1*04:01:01:01,06:02:01:01 (RCB=HPS3704) CL:0000010 Derived from sampling site: Peripheral blood. Male 21156267 CVCL_UN41 HPS0818 induced pluripotent stem cell human CVCL_UN41 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156268 CVCL_UN46 G-750GM cancer cell line human CVCL_UN46 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 1.71 days (in 0.5% FCS), 1.20 days (in 10% FCS) (PubMed=12894509) 21156269 CVCL_UN47 G-1163GM cancer cell line human CVCL_UN47 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 4.44 days (in 0.5% FCS), 2.02 days (in 10% FCS) (PubMed=12894509) 21156270 CVCL_UN44 G-211GM cancer cell line human CVCL_UN44 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asp (c.535C>G); ClinVar=VCV000376610; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 5.13 days (in 0.5% FCS), 1.56 days (in 10% FCS) (PubMed=12894509) 21156271 CVCL_UN45 G-599GM cancer cell line human CVCL_UN45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Unspecified (PubMed=15035290). Unspecified Doubling time: 2.19 days (in 0.5% FCS), 2.04 days (in 10% FCS) (PubMed=12894509) 21156272 CVCL_LV49 BayGenomics ES cell line CSG197 embryonic stem cell house mouse CVCL_LV49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107940; Ezh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156273 CVCL_M749 TPS-2 spontaneously immortalized cell line CVCL_M749 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21156274 CVCL_LV47 BayGenomics ES cell line CSG195 embryonic stem cell house mouse CVCL_LV47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104517; Xrcc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156275 CVCL_M747 HCT-1 transformed cell line CVCL_M747 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Spleen. Male 21156276 CVCL_LV48 BayGenomics ES cell line CSG196 embryonic stem cell house mouse CVCL_LV48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156277 CVCL_M748 RTCC-1/KMC cancer cell line human CVCL_M748 CL:0000010 Population: Chinese; Derived from sampling site: Kidney; renal pelvis. Female Doubling time: 36 hours, at 3rd passage (PubMed=8774112) 21156278 CVCL_M745 50B11 transformed cell line Norway rat CVCL_M745 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Dorsal root ganglion Cell type=Neuron.. Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Differentiation into neurons with nociceptive properties can be accomplished by using forskolin (PubMed=17565537) 21156279 CVCL_LV45 BayGenomics ES cell line CSG193 embryonic stem cell house mouse CVCL_LV45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156280 CVCL_LV46 BayGenomics ES cell line CSG194 embryonic stem cell house mouse CVCL_LV46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144529; Cnot6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156281 CVCL_M746 HBT-E cancer cell line human CVCL_M746 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00054 Problematic cell line: Contaminated Parent cell line (HBT-3) has been shown to be a HeLa derivative (PubMed=1246601; PubMed=4469665; PubMed=20143388). 21156282 CVCL_LV43 BayGenomics ES cell line CSG191 embryonic stem cell house mouse CVCL_LV43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156283 CVCL_M743 PD-Mel cancer cell line human CVCL_M743 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy. CL:0000010 Unspecified 21156284 CVCL_LV44 BayGenomics ES cell line CSG192 embryonic stem cell house mouse CVCL_LV44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860513; Fnbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156285 CVCL_M744 PNM-Mel cancer cell line human CVCL_M744 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Trp (c.301G>T) (p.Arg115Leu, c.344G>T); ClinVar=VCV000009412; Zygosity=Unspecified (PubMed=29492214) Derived from metastatic site: Lymph node. Unspecified 21156286 CVCL_LV41 BayGenomics ES cell line CSG183 embryonic stem cell house mouse CVCL_LV41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156287 CVCL_M741 GL-Mel cancer cell line human CVCL_M741 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21156288 CVCL_LV42 BayGenomics ES cell line CSG190 embryonic stem cell house mouse CVCL_LV42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917317; Ermard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156289 CVCL_M742 LCM-Mel cancer cell line human CVCL_M742 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from metastatic site: Lymph node. Unspecified 21156290 CVCL_LV40 BayGenomics ES cell line CSG181 embryonic stem cell house mouse CVCL_LV40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289341; Sf3b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156291 CVCL_M740 GBC-SD/M3 cancer cell line human CVCL_M740 CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Male 21156292 CVCL_LV58 BayGenomics ES cell line CSG220 embryonic stem cell house mouse CVCL_LV58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446296; Sik3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156293 CVCL_M758 OLCAB-e3 spontaneously immortalized cell line CVCL_M758 CL:0000010 Breed/subspecies: CAB. Unspecified Doubling time: 50.2 hours (PubMed=29268113) Group: Fish cell line 21156294 CVCL_LV59 BayGenomics ES cell line CSG221 embryonic stem cell house mouse CVCL_LV59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913714; Taf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156295 CVCL_M759 OLHdrR-e3 spontaneously immortalized cell line CVCL_M759 CL:0000010 Breed/subspecies: HdrR. Unspecified Group: Fish cell line 21156296 CVCL_LV56 BayGenomics ES cell line CSG217 embryonic stem cell house mouse CVCL_LV56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147987; Pcyt1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156297 CVCL_M756 OLCAB-2 spontaneously immortalized cell line CVCL_M756 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: CAB. Unspecified Group: Fish cell line 21156298 CVCL_LV57 BayGenomics ES cell line CSG218 embryonic stem cell house mouse CVCL_LV57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385206; Pabpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156299 CVCL_M757 OLCAB-e31 spontaneously immortalized cell line CVCL_M757 CL:0000010 Breed/subspecies: CAB. Unspecified Group: Fish cell line 21156300 CVCL_LV54 BayGenomics ES cell line CSG206 embryonic stem cell house mouse CVCL_LV54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156301 CVCL_M754 OLHNI-1 spontaneously immortalized cell line CVCL_M754 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: HNI. Unspecified Group: Fish cell line 21156302 CVCL_LV55 BayGenomics ES cell line CSG209 embryonic stem cell house mouse CVCL_LV55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926045; Armc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156303 CVCL_M755 OL-32 spontaneously immortalized cell line CVCL_M755 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.; Breed/subspecies: HB32. Male Doubling time: 32 hours (DOI=10.1007/BF02628830) Group: Fish cell line 21156304 CVCL_LV52 BayGenomics ES cell line CSG203 embryonic stem cell house mouse CVCL_LV52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107931; Sqstm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156305 CVCL_M752 GSC spontaneously immortalized cell line CVCL_M752 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21156306 CVCL_LV53 BayGenomics ES cell line CSG204 embryonic stem cell house mouse CVCL_LV53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107931; Sqstm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156307 CVCL_M753 LJES1 embryonic stem cell CVCL_M753 CL:0000010 Unspecified Group: Fish cell line. 21156308 CVCL_LV50 BayGenomics ES cell line CSG199 embryonic stem cell house mouse CVCL_LV50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919654; Wdr44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156309 CVCL_M750 TSS spontaneously immortalized cell line CVCL_M750 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21156310 CVCL_LV51 BayGenomics ES cell line CSG201 embryonic stem cell house mouse CVCL_LV51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156311 CVCL_M751 LYCS-1 spontaneously immortalized cell line CVCL_M751 CL:0000010 Derived from sampling site: Spleen. Unspecified Doubling time: 48.7 hours (DOI=10.1007/s11802-011-1778-5) Group: Fish cell line 21156312 CVCL_LV29 BayGenomics ES cell line CSG158 embryonic stem cell house mouse CVCL_LV29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156313 CVCL_M729 CG-91 spontaneously immortalized cell line CVCL_M729 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 45 5 21156314 CVCL_LV27 BayGenomics ES cell line CSG156 embryonic stem cell house mouse CVCL_LV27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918580; Rcbtb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156315 CVCL_M727 DNRR51 spontaneously immortalized cell line CVCL_M727 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Ovary. Female 21156316 CVCL_LV28 BayGenomics ES cell line CSG157 embryonic stem cell house mouse CVCL_LV28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156317 CVCL_M728 DES-28 transformed cell line CVCL_M728 CL:0000010 Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Breed/subspecies: LSH/ssLAK. Male 21156318 CVCL_LV25 BayGenomics ES cell line CSG153 embryonic stem cell house mouse CVCL_LV25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679006; Zfp599 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156319 CVCL_M725 DNRR159 spontaneously immortalized cell line CVCL_M725 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Ovary. Female 21156320 CVCL_LV26 BayGenomics ES cell line CSG155 embryonic stem cell house mouse CVCL_LV26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156321 CVCL_M726 DNRR5 spontaneously immortalized cell line CVCL_M726 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Ovary. Female 21156322 CVCL_LV23 BayGenomics ES cell line CSG151 embryonic stem cell house mouse CVCL_LV23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156323 CVCL_M723 DNRR1 spontaneously immortalized cell line CVCL_M723 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Ovary. Female 21156324 CVCL_LV24 BayGenomics ES cell line CSG152 embryonic stem cell house mouse CVCL_LV24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156325 CVCL_M724 DNRR15 spontaneously immortalized cell line CVCL_M724 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Ovary. Female 21156326 CVCL_LV21 BayGenomics ES cell line CSG148 embryonic stem cell house mouse CVCL_LV21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917125; Ndufa11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156327 CVCL_M721 UROtsa/F35 cancer cell line human CVCL_M721 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=23691160). 21156328 CVCL_LV22 BayGenomics ES cell line CSG149 embryonic stem cell house mouse CVCL_LV22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156329 CVCL_M722 CHO-AUXE29 spontaneously immortalized cell line CVCL_M722 CL:0000010 Derived from sampling site: Ovary. Female 21156330 CVCL_LV20 BayGenomics ES cell line CSG146 embryonic stem cell house mouse CVCL_LV20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443419; Rps6kc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156331 CVCL_M720 TRT-HU1 telomerase immortalized cell line human CVCL_M720 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Male 21156332 CVCL_LV38 BayGenomics ES cell line CSG177 embryonic stem cell house mouse CVCL_LV38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442521; Cep295 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156333 CVCL_M738 GBC-SD/ATO cancer cell line human CVCL_M738 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Gallbladder. Male 21156334 CVCL_LV39 BayGenomics ES cell line CSG180 embryonic stem cell house mouse CVCL_LV39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442513; Eml5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156335 CVCL_M739 GBC-SD/HL cancer cell line human CVCL_M739 CL:0000010 Population: Chinese; Derived from sampling site: Gallbladder. Male 21156336 CVCL_LV36 BayGenomics ES cell line CSG174 embryonic stem cell house mouse CVCL_LV36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923959; Arpc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156337 CVCL_M736 GBK-1 cancer cell line human CVCL_M736 CL:0000010 Population: Japanese Female Doubling time: 43 hours (PubMed=3082828). 21156338 CVCL_LV37 BayGenomics ES cell line CSG176 embryonic stem cell house mouse CVCL_LV37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441773; Pcmtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156339 CVCL_M737 SGC-996 cancer cell line human CVCL_M737 CL:0000010 Population: Chinese Female Doubling time: ~48 hours (CelloPub=CLPUB00379). 21156340 CVCL_LV34 BayGenomics ES cell line CSG169 embryonic stem cell house mouse CVCL_LV34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156341 CVCL_M734 Wittier cancer cell line human CVCL_M734 CL:0000010 21156342 CVCL_LV35 BayGenomics ES cell line CSG173 embryonic stem cell house mouse CVCL_LV35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156343 CVCL_M735 KMG-C cancer cell line human CVCL_M735 CL:0000010 Population: Japanese Male Doubling time: 19 hours (PubMed=21544480). 21156344 CVCL_LV32 BayGenomics ES cell line CSG164 embryonic stem cell house mouse CVCL_LV32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156345 CVCL_M732 GB-CL-1 cancer cell line human CVCL_M732 CL:0000010 21156346 CVCL_LV33 BayGenomics ES cell line CSG166 embryonic stem cell house mouse CVCL_LV33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156347 CVCL_M733 CC-CL-1 cancer cell line human CVCL_M733 CL:0000010 Miscellaneous: Only mentioned as a cholangiocarcinoma cell line in PubMed=11802210 Unspecified 21156348 CVCL_LV30 BayGenomics ES cell line CSG162 embryonic stem cell house mouse CVCL_LV30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923959; Arpc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156349 CVCL_M730 RK 13/91 spontaneously immortalized cell line CVCL_M730 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Characteristics: Capable of multiplying both in a monolayer and in suspension on semi-synthetic nutrient media (Patent=RU2065496) Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 46 21156350 CVCL_LV31 BayGenomics ES cell line CSG163 embryonic stem cell house mouse CVCL_LV31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354165; Thop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156351 CVCL_M731 G5T/VGH cancer cell line human CVCL_M731 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 21156352 CVCL_LV09 BayGenomics ES cell line CSG128 embryonic stem cell house mouse CVCL_LV09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103306; Tiam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156353 CVCL_M709 GASH cancer cell line human CVCL_M709 CL:0000010 Male 21156354 CVCL_LV07 BayGenomics ES cell line CSG124 embryonic stem cell house mouse CVCL_LV07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448549; Cdk10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156355 CVCL_M707 BNBH-1 cancer cell line human CVCL_M707 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 51 hours (PubMed=3391709) 21156356 CVCL_LV08 BayGenomics ES cell line CSG125 embryonic stem cell house mouse CVCL_LV08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3648156; Slc38a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156357 CVCL_M708 CJ18 cancer cell line human CVCL_M708 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 3-4 days (PubMed=4081642) 21156358 CVCL_LV05 BayGenomics ES cell line CSG121 embryonic stem cell house mouse CVCL_LV05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270849; Rps6kb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156359 CVCL_M705 BEVA cancer cell line human CVCL_M705 CL:0000010 Derived from sampling site: Bone marrow. Omics: Array-based CGH Male Doubling time: ~72 hours (PubMed=9293903) 21156360 CVCL_LV06 BayGenomics ES cell line CSG123 embryonic stem cell house mouse CVCL_LV06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97856; Rara Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156361 CVCL_M706 JOK-1 [Human hairy cell leukemia] cancer cell line human CVCL_M706 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (PubMed=29989027); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (PubMed=29989027) Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21156362 CVCL_LV03 BayGenomics ES cell line CSG119 embryonic stem cell house mouse CVCL_LV03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156363 CVCL_M703 DEV [Human medulloblastoma] cancer cell line human CVCL_M703 CL:0000010 Derived from sampling site: Cerebrospinal fluid. Male 21156364 CVCL_LV04 BayGenomics ES cell line CSG120 embryonic stem cell house mouse CVCL_LV04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923749; Clasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156365 CVCL_M704 PL-29018 cancer cell line human CVCL_M704 CL:0000010 Omics: Array-based CGH. 21156366 CVCL_LV01 BayGenomics ES cell line CSG115 embryonic stem cell house mouse CVCL_LV01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97856; Rara Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156367 CVCL_M701 MCD-1 cancer cell line human CVCL_M701 CL:0000010 Derived from sampling site: Brain; cerebellum. Male Doubling time: 24 hours (PubMed=8971690) 21156368 CVCL_LV02 BayGenomics ES cell line CSG116 embryonic stem cell house mouse CVCL_LV02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139207; Sec16a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156369 CVCL_M702 ONS-81 cancer cell line human CVCL_M702 CL:0000010 Population: Japanese; Derived from sampling site: Brain; right frontal lobe. Female Doubling time: 19.2 hours (CelloPub=CLPUB00094; PubMed=2504489; PubMed=2818910) 21156370 CVCL_LV00 BayGenomics ES cell line CSG113 embryonic stem cell house mouse CVCL_LV00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384851; Slc39a14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156371 CVCL_M700 L-538 cancer cell line human CVCL_M700 CL:0000010 Derived from sampling site: Peripheral blood. Female 21156372 CVCL_LV18 BayGenomics ES cell line CSG141 embryonic stem cell house mouse CVCL_LV18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913714; Taf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156373 CVCL_M718 SYM-I cancer cell line human CVCL_M718 From: Sekiguchi M.; Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 21156374 CVCL_LV19 BayGenomics ES cell line CSG143 embryonic stem cell house mouse CVCL_LV19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156375 CVCL_M719 SYM-I clone K-104 cancer cell line human CVCL_M719 CL:0000010 Population: Japanese. Unspecified 21156376 CVCL_LV16 BayGenomics ES cell line CSG139 embryonic stem cell house mouse CVCL_LV16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156377 CVCL_M716 RMG-V cancer cell line human CVCL_M716 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 15.5 hours (PubMed=17022146) 21156378 CVCL_LV17 BayGenomics ES cell line CSG140 embryonic stem cell house mouse CVCL_LV17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98117; Rps15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156379 CVCL_M717 TAYA cancer cell line human CVCL_M717 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (PubMed=11914605) Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 50 hours (PubMed=11914605) 21156380 CVCL_LV14 BayGenomics ES cell line CSG135 embryonic stem cell house mouse CVCL_LV14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156381 CVCL_M714 KFrb cancer cell line human CVCL_M714 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21156382 CVCL_LV15 BayGenomics ES cell line CSG136 embryonic stem cell house mouse CVCL_LV15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919383; Trub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156383 CVCL_M715 ES-2R cancer cell line human CVCL_M715 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41576; 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin (Cyanomorpholinoadriamycin; Derived from sampling site: Ovary. Female Problematic cell line: Probably misclassified Parent cell line seems to originate from a Caucasian patient with an ovarian serous adenocarcinoma origin. 21156384 CVCL_LV12 BayGenomics ES cell line CSG132 embryonic stem cell house mouse CVCL_LV12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917125; Ndufa11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156385 CVCL_M712 JHOC-6 cancer cell line human CVCL_M712 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 70 hours (PubMed=10695020) 21156386 CVCL_LV13 BayGenomics ES cell line CSG133 embryonic stem cell house mouse CVCL_LV13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156387 CVCL_M713 KFra cancer cell line human CVCL_M713 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21156388 CVCL_LV10 BayGenomics ES cell line CSG129 embryonic stem cell house mouse CVCL_LV10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147162; Unc119b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156389 CVCL_M710 OZ [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_M710 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=9600110) 21156390 CVCL_LV11 BayGenomics ES cell line CSG131 embryonic stem cell house mouse CVCL_LV11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140998; Ube3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156391 CVCL_M711 CIPULLO cancer cell line human CVCL_M711 CL:0000010 Omics: Array-based CGH. Unspecified 21156392 CVCL_V049 GM07726 finite cell line human CVCL_V049 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21156393 CVCL_V047 GM00035 finite cell line human CVCL_V047 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156394 CVCL_V048 GM00036 finite cell line human CVCL_V048 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156395 CVCL_2I00 MLC-7 spontaneously immortalized cell line house mouse CVCL_2I00 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/He. 21156396 CVCL_2I01 DT40-TRPC1(-/-) cancer cell line CVCL_2I01 CL:0000010 Knockout cell: Method=Targeted integration; TRPC1 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21156397 CVCL_2I04 AG10202 spontaneously immortalized cell line CVCL_2I04 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156398 CVCL_2I05 AG10203 spontaneously immortalized cell line CVCL_2I05 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156399 CVCL_2I02 AG10187 spontaneously immortalized cell line CVCL_2I02 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156400 CVCL_2I03 AG10200 spontaneously immortalized cell line CVCL_2I03 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156401 CVCL_V052 GM10486 transformed cell line human CVCL_V052 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156402 CVCL_V053 GM10691 transformed cell line human CVCL_V053 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156403 CVCL_V050 GM07727 transformed cell line human CVCL_V050 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156404 CVCL_V051 GM10433 transformed cell line human CVCL_V051 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156405 CVCL_V056 DAP.3Ag7 spontaneously immortalized cell line house mouse CVCL_V056 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21156406 CVCL_V057 J27-sB7 spontaneously immortalized cell line house mouse CVCL_V057 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4932; HLA-B (allele B*07) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Discontinued: ATCC; CRL-2373; true Male 21156407 CVCL_V054 GM10748 transformed cell line human CVCL_V054 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156408 CVCL_V055 DAP.3 spontaneously immortalized cell line house mouse CVCL_V055 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21156409 CVCL_V038 GM01085 finite cell line human CVCL_V038 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156410 CVCL_V039 GM01169 finite cell line human CVCL_V039 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156411 CVCL_V036 GM01061 finite cell line human CVCL_V036 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156412 CVCL_V037 GM01083 finite cell line human CVCL_V037 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21156413 CVCL_2I11 AG10285 spontaneously immortalized cell line CVCL_2I11 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156414 CVCL_2I12 AG10286 spontaneously immortalized cell line CVCL_2I12 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156415 CVCL_2I10 AG10244 spontaneously immortalized cell line CVCL_2I10 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156416 CVCL_2I15 AG04676 finite cell line CVCL_2I15 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: New Zealand white. Female 21156417 CVCL_2I16 AG04677 finite cell line CVCL_2I16 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: New Zealand white. Female 21156418 CVCL_2I13 AG10328 spontaneously immortalized cell line CVCL_2I13 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156419 CVCL_2I14 AG04388 finite cell line CVCL_2I14 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle. Male Senescence: Senesces at 45 PDL (Coriell=AG04388) 21156420 CVCL_2I08 AG10240 spontaneously immortalized cell line CVCL_2I08 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156421 CVCL_2I09 AG10242 spontaneously immortalized cell line CVCL_2I09 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156422 CVCL_2I06 AG10218 spontaneously immortalized cell line CVCL_2I06 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156423 CVCL_2I07 AG10220 spontaneously immortalized cell line CVCL_2I07 CL:0000010 Derived from sampling site: Smooth muscle; trachealis; Breed/subspecies: New Zealand white. Male 21156424 CVCL_V041 GM02173 finite cell line human CVCL_V041 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis Female 21156425 CVCL_V042 GM03642 transformed cell line human CVCL_V042 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156426 CVCL_V040 GM02172 transformed cell line human CVCL_V040 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM02173) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156427 CVCL_V045 GM03645 transformed cell line human CVCL_V045 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156428 CVCL_V046 GM06274 finite cell line human CVCL_V046 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21156429 CVCL_V043 GM03643 transformed cell line human CVCL_V043 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156430 CVCL_V044 GM03644 transformed cell line human CVCL_V044 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156431 CVCL_V027 87HG31 cancer cell line human CVCL_V027 CL:0000010 Derived from metastatic site: Brain; left parietal lobe. Male 21156432 CVCL_V028 CaPA-4 cancer cell line human CVCL_V028 CL:0000010 21156433 CVCL_V025 Me2559/1 cancer cell line human CVCL_V025 CL:0000010 Derived from metastatic site: Lymph node. 21156434 CVCL_V026 87HG28 cancer cell line human CVCL_V026 CL:0000010 Derived from sampling site: Brain; right temporal lobe. Female 21156435 CVCL_V029 GM00954 finite cell line human CVCL_V029 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21156436 CVCL_LU88 BayGenomics ES cell line CSG087 embryonic stem cell house mouse CVCL_LU88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156437 CVCL_M688 IMa cancer cell line human CVCL_M688 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~48 hours (PubMed=6683709) 21156438 CVCL_LU89 BayGenomics ES cell line CSG089 embryonic stem cell house mouse CVCL_LU89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923864; Immt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156439 CVCL_M689 iC(3)-1 transformed cell line human CVCL_M689 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast. Unspecified 21156440 CVCL_LU86 BayGenomics ES cell line CSG084 embryonic stem cell house mouse CVCL_LU86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156441 CVCL_M686 HKRT-II cancer cell line human CVCL_M686 CL:0000010 Population: Japanese; Derived from metastatic site: Retroperitoneal space. Male Doubling time: 42 hours, at 50th passage (PubMed=10834109) 21156442 CVCL_LU87 BayGenomics ES cell line CSG085 embryonic stem cell house mouse CVCL_LU87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109520; Pafah1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156443 CVCL_M687 HCCM-5 cancer cell line human CVCL_M687 CL:0000010 Population: Japanese Female Doubling time: ~72 hours (PubMed=4039287). 21156444 CVCL_LU84 BayGenomics ES cell line CSG079 embryonic stem cell house mouse CVCL_LU84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156445 CVCL_M684 HOCC cancer cell line human CVCL_M684 CL:0000010 Population: Japanese Female Doubling time: ~32 hours (PubMed=15369135). 21156446 CVCL_LU85 BayGenomics ES cell line CSG082 embryonic stem cell house mouse CVCL_LU85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156447 CVCL_M685 NUC-1 [Human choriocarcinoma] cancer cell line human CVCL_M685 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu17Asp (c.51A>T); Zygosity=Unspecified (PubMed=7819056); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys24Asn (c.72A>T); Zygosity=Unspecified (PubMed=7819056). Population: Japanese Female Doubling time: 36 hours (PubMed=6579923) 21156448 CVCL_LU82 BayGenomics ES cell line CSG072 embryonic stem cell house mouse CVCL_LU82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925219; Trmt13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156449 CVCL_V030 GM02011 transformed cell line human CVCL_V030 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156450 CVCL_M682 NaUCC-3 cancer cell line human CVCL_M682 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Characteristics: Established from a xenograft established in a nude mice Doubling time: 14.9 hours, in vivo (PubMed=3171272) 21156451 CVCL_LU83 BayGenomics ES cell line CSG077 embryonic stem cell house mouse CVCL_LU83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156452 CVCL_V031 GM11634 transformed cell line human CVCL_V031 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156453 CVCL_M683 NaUCC-4 cancer cell line human CVCL_M683 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female 21156454 CVCL_LU80 BayGenomics ES cell line CSG056 embryonic stem cell house mouse CVCL_LU80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97175; Map2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156455 CVCL_M680 NaUCC-1 cancer cell line human CVCL_M680 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Female Characteristics: Established from a xenograft established in a nude mice Doubling time: 17.3 hours (in vivo), 20 hours (in vitro) (PubMed=3171272) 21156456 CVCL_LU81 BayGenomics ES cell line CSG067 embryonic stem cell house mouse CVCL_LU81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109601; Nck1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156457 CVCL_M681 NaUCC-2 cancer cell line human CVCL_M681 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Female Characteristics: Established from a xenograft established in a nude mice Doubling time: 20.6 hours, in vivo (PubMed=3171272) 21156458 CVCL_V034 GM23409 transformed cell line human CVCL_V034 CL:0000010 Sequence variation: Mutation; HGNC; 663; ARG1; Simple; p.Trp122Ter (c.365G>A); ClinVar=VCV000002390; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156459 CVCL_V035 GM23608 transformed cell line human CVCL_V035 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156460 CVCL_V032 GM16152 transformed cell line human CVCL_V032 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156461 CVCL_V033 GM23407 transformed cell line human CVCL_V033 CL:0000010 Sequence variation: Mutation; HGNC; 663; ARG1; Simple; p.Gly142Glu (c.425G>A); ClinVar=VCV000556022; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156462 CVCL_V016 FS-SC-3 cancer cell line CVCL_V016 CL:0000010 Breed/subspecies: European shorthair. Male 21156463 CVCL_V017 FS-SC-4 cancer cell line CVCL_V017 CL:0000010 Breed/subspecies: European shorthair. Male 21156464 CVCL_V014 FS-SC-1 cancer cell line CVCL_V014 CL:0000010 Breed/subspecies: European shorthair. Male 21156465 CVCL_V015 FS-SC-2 cancer cell line CVCL_V015 CL:0000010 Breed/subspecies: European shorthair. Male 21156466 CVCL_V018 FS-SC-5 cancer cell line CVCL_V018 CL:0000010 Breed/subspecies: Persian. Female 21156467 CVCL_V019 Me17697 cancer cell line human CVCL_V019 CL:0000010 Derived from metastatic site: Lymph node. 21156468 CVCL_LU99 BayGenomics ES cell line CSG112 embryonic stem cell house mouse CVCL_LU99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338026; Tom1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156469 CVCL_M699 L-439 cancer cell line human CVCL_M699 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=7216541; PubMed=6305805) Derived from sampling site: Pleural effusion. Male Doubling time: 48-72 hours (PubMed=7216541) 21156470 CVCL_LU97 BayGenomics ES cell line CSG108 embryonic stem cell house mouse CVCL_LU97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913875; Pnisr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156471 CVCL_M697 HDLM-3 cancer cell line human CVCL_M697 CL:0000010 Derived from sampling site: Pleural effusion. Male 21156472 CVCL_LU98 BayGenomics ES cell line CSG109 embryonic stem cell house mouse CVCL_LU98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916043; Rab3gap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156473 CVCL_M698 Ho cancer cell line human CVCL_M698 CL:0000010 Unspecified 21156474 CVCL_LU95 BayGenomics ES cell line CSG104 embryonic stem cell house mouse CVCL_LU95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109629; Atp6ap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156475 CVCL_M695 HDLM-1d cancer cell line human CVCL_M695 CL:0000010 Derived from sampling site: Pleural effusion. Male 21156476 CVCL_LU96 BayGenomics ES cell line CSG107 embryonic stem cell house mouse CVCL_LU96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921356; Dcaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156477 CVCL_M696 HDLM-2d cancer cell line human CVCL_M696 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Fusion with an Alu-element at the Ex7-Ex8 junction; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Pleural effusion. Male 21156478 CVCL_LU93 BayGenomics ES cell line CSG095 embryonic stem cell house mouse CVCL_LU93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156479 CVCL_M693 HDLM-1 cancer cell line human CVCL_M693 CL:0000010 Derived from sampling site: Pleural effusion. Male 21156480 CVCL_LU94 BayGenomics ES cell line CSG100 embryonic stem cell house mouse CVCL_LU94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156481 CVCL_V020 Me20842 cancer cell line human CVCL_V020 CL:0000010 21156482 CVCL_M694 ZO cancer cell line human CVCL_M694 CL:0000010 Derived from sampling site: Pericardial effusion. Female 21156483 CVCL_LU91 BayGenomics ES cell line CSG091 embryonic stem cell house mouse CVCL_LU91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104995; Gclm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156484 CVCL_M691 HX155cisR cancer cell line human CVCL_M691 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female 21156485 CVCL_LU92 BayGenomics ES cell line CSG092 embryonic stem cell house mouse CVCL_LU92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104995; Gclm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156486 CVCL_M692 SU/RH-HD-1 cancer cell line human CVCL_M692 CL:0000010 Derived from sampling site: Spleen. Male Doubling time: ~4-5 days (PubMed=6332936) 21156487 CVCL_V023 Me4024/2 cancer cell line human CVCL_V023 CL:0000010 Derived from metastatic site: Hypodermis. Female 21156488 CVCL_LU90 BayGenomics ES cell line CSG090 embryonic stem cell house mouse CVCL_LU90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156489 CVCL_M690 HX171c cancer cell line human CVCL_M690 CL:0000010 Female 21156490 CVCL_V024 Me17088/1 cancer cell line human CVCL_V024 CL:0000010 21156491 CVCL_V021 Me4023 cancer cell line human CVCL_V021 CL:0000010 Derived from metastatic site: Lymph node. 21156492 CVCL_V022 Me4024/1 cancer cell line human CVCL_V022 CL:0000010 Derived from metastatic site: Hypodermis. Female 21156493 CVCL_V005 KH88 B4D6 cancer cell line human CVCL_V005 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 20-26 hours (PubMed=8289484); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21156494 CVCL_V006 BE(2)-C/ADR(5) cancer cell line human CVCL_V006 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 21156495 CVCL_V003 GM12451 finite cell line human CVCL_V003 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21156496 CVCL_V004 GM17903 transformed cell line human CVCL_V004 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156497 CVCL_V009 BE(2)-C/CHCb cancer cell line human CVCL_V009 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 21156498 CVCL_V007 BE(2)-C/ACT(0.2) cancer cell line human CVCL_V007 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 21156499 CVCL_V008 BE(2)-C/CHC(1) cancer cell line human CVCL_V008 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 21156500 CVCL_LU68 BayGenomics ES cell line CSG029 embryonic stem cell house mouse CVCL_LU68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144529; Cnot6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156501 CVCL_M668 SCC-1CB cancer cell line human CVCL_M668 CL:0000010 Population: Japanese; Derived from sampling site: Skin. Male Doubling time: ~48 hours (PubMed=2585777) 21156502 CVCL_LU69 BayGenomics ES cell line CSG030 embryonic stem cell house mouse CVCL_LU69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891832; Patz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156503 CVCL_M669 HSC-1b cancer cell line human CVCL_M669 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (from autologous cell line HSC-1); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (from autologous cell line HSC-1) Population: Japanese; Derived from sampling site: Hand; skin. Male 21156504 CVCL_LU66 BayGenomics ES cell line CSG025 embryonic stem cell house mouse CVCL_LU66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156505 CVCL_M666 SCC-40 cancer cell line human CVCL_M666 CL:0000010 Female 21156506 CVCL_LU67 BayGenomics ES cell line CSG026 embryonic stem cell house mouse CVCL_LU67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156507 CVCL_M667 SCC-68 cancer cell line human CVCL_M667 CL:0000010 Male 21156508 CVCL_LU64 BayGenomics ES cell line CSG021 embryonic stem cell house mouse CVCL_LU64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345192; Psmd13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156509 CVCL_M664 HF-4.9 cancer cell line human CVCL_M664 CL:0000010 Derived from sampling site: Lymph node. Female 21156510 CVCL_LU65 BayGenomics ES cell line CSG024 embryonic stem cell house mouse CVCL_LU65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156511 CVCL_M665 MA-1 [Human contaminated lymphoma] cancer cell line human CVCL_M665 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1171Cys (c.3511C>T); ClinVar=VCV000133518; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00471 Problematic cell line: Contaminated Shown to be a Pfeiffer derivative (PubMed=23907998) and not a mucosa-associated lymphoid tissue (MALT) lymphoma cell line. This finding is disputed by the original authors (see PubMed=24285409). 21156512 CVCL_LU62 BayGenomics ES cell line CSG015 embryonic stem cell house mouse CVCL_LU62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95728; Gli2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156513 CVCL_M662 HF-1A3 cancer cell line human CVCL_M662 CL:0000010 Derived from sampling site: Lymph node. Female 21156514 CVCL_LU63 BayGenomics ES cell line CSG019 embryonic stem cell house mouse CVCL_LU63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156515 CVCL_M663 HF-28 cancer cell line human CVCL_M663 CL:0000010 Derived from sampling site: Lymph node. Unspecified 21156516 CVCL_LU60 BayGenomics ES cell line CSG013 embryonic stem cell house mouse CVCL_LU60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915248; Retreg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156517 CVCL_M660 HF-4a cancer cell line human CVCL_M660 CL:0000010 Derived from sampling site: Lymph node. Female 21156518 CVCL_LU61 BayGenomics ES cell line CSG014 embryonic stem cell house mouse CVCL_LU61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156519 CVCL_M661 HF-1.3.4 cancer cell line human CVCL_M661 CL:0000010 Derived from sampling site: Lymph node. Female 21156520 CVCL_V012 DLD-1 clone D cancer cell line human CVCL_V012 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=7651727). Male Doubling time: 20 hours (PubMed=427742) 21156521 CVCL_V013 Cocca-6A cancer cell line CVCL_V013 CL:0000010 Anecdotal: Cell line name is derived from the cat name 'Cocca' Breed/subspecies: Domestic Calico. Female Doubling time: ~27 hours (PubMed=22666387) 21156522 CVCL_V010 BE(2)-C/CHCg cancer cell line human CVCL_V010 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from metastatic site: Bone marrow. Male Characteristics: Intermediate type (I-type) (from parent cell line); Characteristics: MYCN-amplified NBL cell line (from parent cell line) 21156523 CVCL_V011 DLD-1 clone A cancer cell line human CVCL_V011 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=7651727). Male Doubling time: 22 hours (PubMed=427742) 21156524 CVCL_LU79 BayGenomics ES cell line CSG052 embryonic stem cell house mouse CVCL_LU79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103250; Calm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156525 CVCL_M679 HM [Human gestational choriocarcinoma] cancer cell line human CVCL_M679 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female Doubling time: ~48 hours (PubMed=6190712) 21156526 CVCL_LU77 BayGenomics ES cell line CSG050 embryonic stem cell house mouse CVCL_LU77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914499; Tbc1d19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156527 CVCL_M677 CS1AW finite cell line human CVCL_M677 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from familial inference) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156528 CVCL_LU78 BayGenomics ES cell line CSG051 embryonic stem cell house mouse CVCL_LU78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858195; Hnrnpu Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156529 CVCL_M678 CS1OS finite cell line human CVCL_M678 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156530 CVCL_LU75 BayGenomics ES cell line CSG044 embryonic stem cell house mouse CVCL_LU75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156531 CVCL_M675 SCC-12F.2b cancer cell line human CVCL_M675 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21156532 CVCL_LU76 BayGenomics ES cell line CSG045 embryonic stem cell house mouse CVCL_LU76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353423; Zfp292 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156533 CVCL_M676 SCC-12V cancer cell line human CVCL_M676 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21156534 CVCL_LU73 BayGenomics ES cell line CSG040 embryonic stem cell house mouse CVCL_LU73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354962; Copb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156535 CVCL_M673 SCC-12F.2 cancer cell line human CVCL_M673 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21156536 CVCL_LU74 BayGenomics ES cell line CSG043 embryonic stem cell house mouse CVCL_LU74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915755; Vps51 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156537 CVCL_M674 SCC-12F.2a cancer cell line human CVCL_M674 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21156538 CVCL_LU71 BayGenomics ES cell line CSG033 embryonic stem cell house mouse CVCL_LU71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920075; Mon1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156539 CVCL_M671 T87/rc cancer cell line human CVCL_M671 CL:0000010 Male Characteristics: Established from a xenograft maintained in nude mice. 21156540 CVCL_LU72 BayGenomics ES cell line CSG038 embryonic stem cell house mouse CVCL_LU72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915755; Vps51 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156541 CVCL_M672 SCC-12B.2 cancer cell line human CVCL_M672 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21156542 CVCL_LU70 BayGenomics ES cell line CSG031 embryonic stem cell house mouse CVCL_LU70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156543 CVCL_M670 R105 cancer cell line human CVCL_M670 CL:0000010 Male Characteristics: Established from a xenograft maintained in nude mice. 21156544 CVCL_V001 NCI-H2869 cancer cell line human CVCL_V001 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.6%; South Asian=0.96%; European, North=63.53%; European, South=34.91% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21156545 CVCL_V002 NCTC clone 1328 spontaneously immortalized cell line house mouse CVCL_V002 CL:0000010 Derived from sampling site: Adipose tissue; hypodermis; Breed/subspecies: C3H/HeN. Male 21156546 CVCL_V000 NCI-H2818 cancer cell line human CVCL_V000 Genome ancestry: African=0%; Native American=1.13%; East Asian, North=0%; East Asian, South=0.17%; South Asian=3.55%; European, North=76.08%; European, South=19.07% (PubMed=30894373). CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21156547 CVCL_LU48 BayGenomics ES cell line CSF039 embryonic stem cell house mouse CVCL_LU48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156548 CVCL_M648 QIMR-GOR cancer cell line human CVCL_M648 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible and bone; jaw; maxilla. Male 21156549 CVCL_LU49 BayGenomics ES cell line CSF040 embryonic stem cell house mouse CVCL_LU49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156550 CVCL_M649 QIMR-AMB/1 cancer cell line human CVCL_M649 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21156551 CVCL_LU46 BayGenomics ES cell line CSF033 embryonic stem cell house mouse CVCL_LU46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929091; Sinhcaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156552 CVCL_M646 Seraphina cancer cell line human CVCL_M646 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Array-based CGH. Female 21156553 CVCL_LU47 BayGenomics ES cell line CSF038 embryonic stem cell house mouse CVCL_LU47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889276; Dgke Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156554 CVCL_M647 KOPM-88 cancer cell line human CVCL_M647 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21156555 CVCL_LU44 BayGenomics ES cell line CSF026 embryonic stem cell house mouse CVCL_LU44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443272; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156556 CVCL_M644 BL-48 cancer cell line human CVCL_M644 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21156557 CVCL_LU45 BayGenomics ES cell line CSF027 embryonic stem cell house mouse CVCL_LU45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156558 CVCL_M645 BL-54 cancer cell line human CVCL_M645 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21156559 CVCL_LU42 BayGenomics ES cell line CSF019 embryonic stem cell house mouse CVCL_LU42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914290; Ddx17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156560 CVCL_M642 BL-45 cancer cell line human CVCL_M642 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Male Virology: EBV-negative 21156561 CVCL_LU43 BayGenomics ES cell line CSF022 embryonic stem cell house mouse CVCL_LU43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914290; Ddx17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156562 CVCL_M643 BL-47 cancer cell line human CVCL_M643 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Virology: EBV-negative 21156563 CVCL_LU40 BayGenomics ES cell line CSF008 embryonic stem cell house mouse CVCL_LU40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277120; Arfip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156564 CVCL_M640 BL-12 cancer cell line human CVCL_M640 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Ile (c.218C>T); ClinVar=VCV000376300; Zygosity=Unspecified (PubMed=8108117) Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Male Caution: Indicated as originating from a male patient in PubMed=3027441 and PubMed=3934070 and from a female patient in PubMed=6825067. 21156565 CVCL_LU41 BayGenomics ES cell line CSF010 embryonic stem cell house mouse CVCL_LU41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3712454; Zfp980 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156566 CVCL_M641 BL-42 cancer cell line human CVCL_M641 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Cerebrospinal fluid. Female 21156567 CVCL_LU59 BayGenomics ES cell line CSG011 embryonic stem cell house mouse CVCL_LU59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156568 CVCL_M659 Tree92 cancer cell line human CVCL_M659 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Virology: EBV-negative Doubling time: 35.4 hours (PubMed=8847894) Caution: Indicated as originating from a 3 year old female patient in text of PubMed=8847894 and from a 9 month old in table 1 of same paper 21156569 CVCL_LU57 BayGenomics ES cell line CSG009 embryonic stem cell house mouse CVCL_LU57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145578; Slain1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156570 CVCL_M657 HF-4b cancer cell line human CVCL_M657 CL:0000010 Miscellaneous: Originally assigned to be from a mantle cell lymphoma Derived from sampling site: Lymph node. Female 21156571 CVCL_M658 Bay91 cancer cell line human CVCL_M658 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21156572 CVCL_LU58 BayGenomics ES cell line CSG010 embryonic stem cell house mouse CVCL_LU58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156573 CVCL_LU55 BayGenomics ES cell line CSG007 embryonic stem cell house mouse CVCL_LU55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679003; Dcun1d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156574 CVCL_M655 SP-52EB transformed cell line human CVCL_M655 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156575 CVCL_LU56 BayGenomics ES cell line CSG008 embryonic stem cell house mouse CVCL_LU56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156576 CVCL_M656 HF-1 [Human follicular lymphoma] cancer cell line human CVCL_M656 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, centroblastic-type Derived from sampling site: Lymph node. Female 21156577 CVCL_LU53 BayGenomics ES cell line CSG002 embryonic stem cell house mouse CVCL_LU53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921584; Ranbp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156578 CVCL_M653 Elijah cancer cell line human CVCL_M653 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw. Omics: Array-based CGH Male 21156579 CVCL_LU54 BayGenomics ES cell line CSG006 embryonic stem cell house mouse CVCL_LU54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384939; Fam222b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156580 CVCL_M654 Wan-BL cancer cell line human CVCL_M654 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Male 21156581 CVCL_LU51 BayGenomics ES cell line CSF047 embryonic stem cell house mouse CVCL_LU51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926143; Cnot10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156582 CVCL_M651 QIMR-AMB cancer cell line human CVCL_M651 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21156583 CVCL_LU52 BayGenomics ES cell line CSG001 embryonic stem cell house mouse CVCL_LU52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919979; Cdc42se2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156584 CVCL_M652 Cheptage cancer cell line human CVCL_M652 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Female Virology: Contains a complete EBV genome (strain Cheptage) which has been sequenced (PubMed=25787276) 21156585 CVCL_LU50 BayGenomics ES cell line CSF046 embryonic stem cell house mouse CVCL_LU50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21156586 CVCL_M650 QIMR-AMB/2 cancer cell line human CVCL_M650 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21156587 CVCL_2I80 AG09391 transformed cell line human CVCL_2I80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156588 CVCL_2I81 AG09392 transformed cell line human CVCL_2I81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156589 CVCL_2I84 AG10103 transformed cell line human CVCL_2I84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156590 CVCL_2I85 AG10105 transformed cell line human CVCL_2I85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156591 CVCL_2I82 AG09393 transformed cell line human CVCL_2I82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156592 CVCL_2I83 AG10097 transformed cell line human CVCL_2I83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156593 CVCL_2I88 AG10673 transformed cell line human CVCL_2I88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156594 CVCL_2I89 AG10674 transformed cell line human CVCL_2I89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156595 CVCL_2I86 AG10107 transformed cell line human CVCL_2I86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156596 CVCL_2I87 AG10111 transformed cell line human CVCL_2I87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156597 CVCL_2I91 AG11340 transformed cell line human CVCL_2I91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156598 CVCL_2I92 AG11343 transformed cell line human CVCL_2I92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156599 CVCL_2I90 AG11339 transformed cell line human CVCL_2I90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156600 CVCL_2I95 AG11371 transformed cell line human CVCL_2I95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156601 CVCL_2I96 AG11372 transformed cell line human CVCL_2I96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156602 CVCL_2I93 AG11344 transformed cell line human CVCL_2I93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156603 CVCL_2I94 AG11354 transformed cell line human CVCL_2I94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156604 CVCL_2I99 AG11398 transformed cell line human CVCL_2I99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156605 CVCL_2I97 AG11378 transformed cell line human CVCL_2I97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156606 CVCL_2I98 AG11379 transformed cell line human CVCL_2I98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156607 CVCL_2I62 AG07953 finite cell line human CVCL_2I62 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156608 CVCL_2I63 AG07954 transformed cell line human CVCL_2I63 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156609 CVCL_2I60 AG07951 finite cell line human CVCL_2I60 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156610 CVCL_2I61 AG07952 transformed cell line human CVCL_2I61 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156611 CVCL_2I66 AG07957 finite cell line human CVCL_2I66 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21156612 CVCL_2I67 AG07958 transformed cell line human CVCL_2I67 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156613 CVCL_2I64 AG07955 finite cell line human CVCL_2I64 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156614 CVCL_2I65 AG07956 transformed cell line human CVCL_2I65 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156615 CVCL_2I68 AG07959 finite cell line human CVCL_2I68 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21156616 CVCL_2I69 AG07960 transformed cell line human CVCL_2I69 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156617 CVCL_2I70 AG07961 finite cell line human CVCL_2I70 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21156618 CVCL_2I73 AG08006 transformed cell line human CVCL_2I73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156619 CVCL_2I74 AG08606 finite cell line human CVCL_2I74 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21156620 CVCL_2I71 AG07962 transformed cell line human CVCL_2I71 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156621 CVCL_2I72 AG07963 finite cell line human CVCL_2I72 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21156622 CVCL_2I77 AG15898 finite cell line human CVCL_2I77 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21156623 CVCL_2I78 AG09389 transformed cell line human CVCL_2I78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156624 CVCL_2I75 AG08607 finite cell line human CVCL_2I75 CL:0000010 Derived from sampling site: Gonad Cell type=Fibroblast.. Female 21156625 CVCL_2I76 AG15881 finite cell line human CVCL_2I76 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21156626 CVCL_2I79 AG09390 transformed cell line human CVCL_2I79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156627 CVCL_2I40 AG07098 finite cell line CVCL_2I40 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156628 CVCL_2I41 AG07099 finite cell line CVCL_2I41 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07099; probable Female Group: Non-human primate cell line 21156629 CVCL_2I44 AG07102 finite cell line CVCL_2I44 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21156630 CVCL_2I45 AG07109 finite cell line CVCL_2I45 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156631 CVCL_2I42 AG07100 finite cell line CVCL_2I42 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07100; probable Female Group: Non-human primate cell line 21156632 CVCL_2I43 AG07101 finite cell line CVCL_2I43 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21156633 CVCL_2I48 AG08452 finite cell line CVCL_2I48 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156634 CVCL_2I49 AG08453 finite cell line CVCL_2I49 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156635 CVCL_2I46 AG07110 finite cell line CVCL_2I46 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156636 CVCL_2I47 AG07921 finite cell line CVCL_2I47 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21156637 CVCL_2I39 AG06209 finite cell line CVCL_2I39 CL:0000010 Derived from sampling site: Thoracolumbar junction; skin. Discontinued: Coriell; AG06209; probable Female Group: Non-human primate cell line 21156638 CVCL_V092 L-DR2-Dw12 spontaneously immortalized cell line house mouse CVCL_V092 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156639 CVCL_V093 L-DR4-Dw15 spontaneously immortalized cell line house mouse CVCL_V093 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156640 CVCL_V090 L-DQw1-Dw12 spontaneously immortalized cell line house mouse CVCL_V090 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156641 CVCL_V091 L-DQw4-Dw15 spontaneously immortalized cell line house mouse CVCL_V091 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156642 CVCL_V096 L/neo spontaneously immortalized cell line house mouse CVCL_V096 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156643 CVCL_V097 L105.1 spontaneously immortalized cell line house mouse CVCL_V097 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156644 CVCL_V094 L-DRw53-Dw15 spontaneously immortalized cell line house mouse CVCL_V094 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156645 CVCL_V095 L-HSO2 spontaneously immortalized cell line house mouse CVCL_V095 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156646 CVCL_V098 L11.3 spontaneously immortalized cell line house mouse CVCL_V098 CL:0000010 Transfected with: HGNC; 4940; HLA-DPB1 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156647 CVCL_V099 L12.2 spontaneously immortalized cell line house mouse CVCL_V099 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156648 CVCL_2I51 AG08611 finite cell line CVCL_2I51 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156649 CVCL_2I52 AG07107 finite cell line CVCL_2I52 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156650 CVCL_2I50 AG08610 finite cell line CVCL_2I50 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156651 CVCL_2I55 AG07128 finite cell line CVCL_2I55 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156652 CVCL_2I56 AG07180 finite cell line CVCL_2I56 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Lakeland (Lak:LVG). Discontinued: Coriell; AG07180; probable Female 21156653 CVCL_2I53 AG07108 finite cell line CVCL_2I53 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156654 CVCL_2I54 AG07127 finite cell line CVCL_2I54 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156655 CVCL_2I59 AG07950 transformed cell line human CVCL_2I59 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156656 CVCL_2I57 AG07184 finite cell line CVCL_2I57 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Lakeland (Lak:LVG). Female 21156657 CVCL_2I58 AG07388 finite cell line dog CVCL_2I58 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21156658 CVCL_V081 J26Cw3 spontaneously immortalized cell line house mouse CVCL_V081 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156659 CVCL_V082 J27.2 43R spontaneously immortalized cell line house mouse CVCL_V082 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156660 CVCL_V080 HII3 spontaneously immortalized cell line house mouse CVCL_V080 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156661 CVCL_V085 JF5 spontaneously immortalized cell line house mouse CVCL_V085 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*11) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156662 CVCL_V086 JII1 spontaneously immortalized cell line house mouse CVCL_V086 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156663 CVCL_V083 J27.2 Cw7neo spontaneously immortalized cell line house mouse CVCL_V083 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156664 CVCL_V084 J27.2 neoB7 spontaneously immortalized cell line house mouse CVCL_V084 CL:0000010 Transfected with: HGNC; 914; B2M Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156665 CVCL_V089 L-B7 spontaneously immortalized cell line house mouse CVCL_V089 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156666 CVCL_V087 JRO1-27 spontaneously immortalized cell line house mouse CVCL_V087 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156667 CVCL_V088 K2B-12H spontaneously immortalized cell line house mouse CVCL_V088 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*24) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156668 CVCL_V069 DAP.3-DR1 spontaneously immortalized cell line house mouse CVCL_V069 CL:0000010 Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4948; HLA-DRB1 (allele DR1) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156669 CVCL_2I22 BFAE-39 finite cell line CVCL_2I22 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male Senescence: Senesces at 86-95 PDL (PubMed=2981236) Caution: Indicated to be of female origin in PubMed=2981236, but karyotype from Coriell shows X,Y 21156670 CVCL_2I23 AG12077 finite cell line pig CVCL_2I23 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female Doubling time: Slow growth (Coriell) 21156671 CVCL_2I20 AG05055 finite cell line house mouse CVCL_2I20 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: CD-1. Male 21156672 CVCL_2I21 AG05056 finite cell line pig CVCL_2I21 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Female 21156673 CVCL_2I26 AG05308 finite cell line CVCL_2I26 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156674 CVCL_2I27 AG05311 finite cell line CVCL_2I27 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156675 CVCL_2I24 AG12119 finite cell line pig CVCL_2I24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21156676 CVCL_2I25 AG12120 finite cell line pig CVCL_2I25 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Female 21156677 CVCL_2I19 AG04907 finite cell line CVCL_2I19 CL:0000010 Derived from sampling site: Fetal lung Cell type=Mesothelial cell.; Breed/subspecies: Holstein. Female 21156678 CVCL_2I17 AG04762 finite cell line CVCL_2I17 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male 21156679 CVCL_2I18 AG04765 spontaneously immortalized cell line Norway rat CVCL_2I18 CL:0000010 Karyotypic information: 41,X [60%]; 41,X,11q+ [40%] (Coriell); Derived from sampling site: Lung Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Ambiguous 21156680 CVCL_V070 DAP.3-DR4 spontaneously immortalized cell line house mouse CVCL_V070 CL:0000010 Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4948; HLA-DRB1 (allele DR4) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156681 CVCL_V071 DAP-3DPw2 spontaneously immortalized cell line house mouse CVCL_V071 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156682 CVCL_V074 DAP-3DR2b spontaneously immortalized cell line house mouse CVCL_V074 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156683 CVCL_V075 DAP-3DRw52b spontaneously immortalized cell line house mouse CVCL_V075 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156684 CVCL_V072 DAP-3DQ1 spontaneously immortalized cell line house mouse CVCL_V072 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156685 CVCL_V073 DAP-3DR2a spontaneously immortalized cell line house mouse CVCL_V073 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156686 CVCL_V078 E1a spontaneously immortalized cell line house mouse CVCL_V078 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156687 CVCL_V079 E5ab2 spontaneously immortalized cell line house mouse CVCL_V079 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156688 CVCL_V076 DPW 5 spontaneously immortalized cell line house mouse CVCL_V076 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156689 CVCL_V077 DR 9 spontaneously immortalized cell line house mouse CVCL_V077 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156690 CVCL_V058 167.2 spontaneously immortalized cell line house mouse CVCL_V058 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156691 CVCL_V059 182.1 spontaneously immortalized cell line house mouse CVCL_V059 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156692 CVCL_2I30 AG06115 finite cell line CVCL_2I30 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21156693 CVCL_2I33 AG06252 finite cell line CVCL_2I33 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156694 CVCL_2I34 AG06253 finite cell line CVCL_2I34 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156695 CVCL_2I31 AG06116 finite cell line CVCL_2I31 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156696 CVCL_2I32 AG06249 finite cell line CVCL_2I32 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.; Breed/subspecies: Indian. Female Group: Non-human primate cell line 21156697 CVCL_2I37 MBHL-2 spontaneously immortalized cell line CVCL_2I37 CL:0000010 Unspecified Group: Insect cell line. 21156698 CVCL_2I38 MBHL-3 spontaneously immortalized cell line CVCL_2I38 CL:0000010 Unspecified Group: Insect cell line. 21156699 CVCL_2I35 AG06254 finite cell line CVCL_2I35 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156700 CVCL_2I36 BMC2 transformed cell line house mouse CVCL_2I36 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Unspecified 21156701 CVCL_2I28 AG05313 finite cell line CVCL_2I28 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156702 CVCL_2I29 AG05356 finite cell line CVCL_2I29 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21156703 CVCL_V060 19X14 spontaneously immortalized cell line house mouse CVCL_V060 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4931; HLA-A (allele A*26) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156704 CVCL_V063 A11 [Mouse IHW] spontaneously immortalized cell line house mouse CVCL_V063 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156705 CVCL_V064 A24 spontaneously immortalized cell line house mouse CVCL_V064 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156706 CVCL_V061 29.0.C.27 spontaneously immortalized cell line house mouse CVCL_V061 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156707 CVCL_V062 58D3C9 spontaneously immortalized cell line house mouse CVCL_V062 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156708 CVCL_V067 BL2-8G-E6 spontaneously immortalized cell line house mouse CVCL_V067 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*02) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156709 CVCL_V068 CII3 spontaneously immortalized cell line house mouse CVCL_V068 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156710 CVCL_V065 B18 spontaneously immortalized cell line house mouse CVCL_V065 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156711 CVCL_V066 B19 spontaneously immortalized cell line house mouse CVCL_V066 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21156712 CVCL_2B21 AG05099 finite cell line human CVCL_2B21 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG05099) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156713 CVCL_2B22 AG05100 finite cell line human CVCL_2B22 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [8]; 46,XY,t(17;19)(17qter->17p11.1::19q13.3->19qter;19pter->19q13.3::17p11.1->17pter) [42] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156714 CVCL_2B20 AG05098 finite cell line human CVCL_2B20 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(9)(pter>q22),t(19;19)(19pter->19q13.3::19q13.4->19qter;19pter->19q13.4::19q13.3->19qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG05098) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156715 CVCL_2B25 AG05103 finite cell line human CVCL_2B25 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,1qh+ [48]; 46,XY,1qh+,t(3;8)(3pter->3q29::8p12->8pter;8qter->8p12::3q29->3qter) [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156716 CVCL_2B26 AG05186 finite cell line human CVCL_2B26 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG05186) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156717 CVCL_2B23 AG05101 finite cell line human CVCL_2B23 CL:0000010 Population: Asian; Karyotypic information: 46,XY [52%]; 46,XY,inv(7)(q22;q32),t(9;17)(q34;q21.3) [32%]; 46,XY,t(9;17)(q34;q21.3) [16%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG05101) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156718 CVCL_2B24 AG05102 finite cell line human CVCL_2B24 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG05102) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156719 CVCL_2B29 AG05190 finite cell line human CVCL_2B29 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 45,X [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (Coriell=AG05190) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156720 CVCL_2B27 AG05188 finite cell line human CVCL_2B27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156721 CVCL_2B28 AG05189 finite cell line human CVCL_2B28 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [86%]; 46,XY,2q+ [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG05189) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156722 CVCL_UH70 WG0799 finite cell line human CVCL_UH70 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156723 CVCL_UH73 MCH018 finite cell line human CVCL_UH73 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21156724 CVCL_UH74 WG1078 finite cell line human CVCL_UH74 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156725 CVCL_UH71 WG0918 finite cell line human CVCL_UH71 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21156726 CVCL_UH72 MCH017 finite cell line human CVCL_UH72 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21156727 CVCL_UH77 WG1083 finite cell line human CVCL_UH77 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156728 CVCL_UH78 WG1194 finite cell line human CVCL_UH78 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Simple; p.Gly448Arg (c.1342G>A); ClinVar=VCV000000213; Zygosity=Homozygous (PubMed=8198124) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156729 CVCL_UH75 WG1079 finite cell line human CVCL_UH75 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156730 CVCL_UH76 WG1082 finite cell line human CVCL_UH76 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Simple; p.Glu453del (c.1356_1358GGA[1]) (c.1359_1361delGGA); ClinVar=VCV000000214; Zygosity=Heterozygous (PubMed=8198124) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156731 CVCL_UH79 WG1298 finite cell line human CVCL_UH79 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Unexplicit; Ex5del (IVS4-1G>C); Zygosity=Heterozygous (PubMed=8198124) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156732 CVCL_2B32 AG05245 finite cell line human CVCL_2B32 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156733 CVCL_2B33 AG05246 finite cell line human CVCL_2B33 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [88]; 46,XX,t(3;10)(3pter->3q25::10q22->10qter->10pter->10q22::3q25->3qter),t(11;19)(11pter->11q13::19q13.3->19qter;19pter->19q13.3::11q13->11qter) [12] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156734 CVCL_2B30 AG05191 finite cell line human CVCL_2B30 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG05191) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156735 CVCL_2B31 AG05244 finite cell line human CVCL_2B31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,22p+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156736 CVCL_2B36 AG05266 finite cell line human CVCL_2B36 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,15s+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (Coriell=AG05266) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156737 CVCL_2B37 AG05270 finite cell line human CVCL_2B37 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156738 CVCL_2B34 AG05248 finite cell line human CVCL_2B34 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156739 CVCL_2B35 AG05265 finite cell line human CVCL_2B35 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,21s+ [60%]; 46,XX,21s+,t(1;8)(p36 or p35;q23) [40%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156740 CVCL_2B38 AG05271 finite cell line human CVCL_2B38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [48]; 47,XY,+2,dup(11)(pter->q23::q23->q21::q23->qter) [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156741 CVCL_2B39 AG05274 finite cell line human CVCL_2B39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 38 PDL (PubMed=9724752); 52 PDL (Coriell=AG05274) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156742 CVCL_UH62 CBT026T cancer cell line human CVCL_UH62 CL:0000010 Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7742. 21156743 CVCL_UH63 NPC38 cancer cell line human CVCL_UH63 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Omics: Transcriptome analysis by RNAseq Female Caution: Shows histological features of squamous cell carcinoma, and no EBV infection Hence it may represent an independent primary squamous cell carcinoma induced by radiotherapy at the recurrent site of NPC (PubMed=30405107). 21156744 CVCL_UH60 hTERT FT240 telomerase immortalized cell line human CVCL_UH60 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female Doubling time: ~32 hours (ATCC=CRL-3447) 21156745 CVCL_UH61 FT246 telomerase immortalized cell line human CVCL_UH61 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis Female 21156746 CVCL_UH66 Ctrl 3050 finite cell line human CVCL_UH66 CL:0000010 Miscellaneous: Cell line information from personal communication of Varcianna A Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156747 CVCL_UH67 MCH049 finite cell line human CVCL_UH67 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21156748 CVCL_UH64 NPC43 cancer cell line human CVCL_UH64 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.158G>A); ClinVar=VCV000230285; Zygosity=Homozygous (PubMed=30405107) Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Omics: Transcriptome analysis by RNAseq Male Virology: Contains 15-20 copies per cell of EBV genome Doubling time: 8 days (at 22th passage), 4 days (at 90th passage), 2.5 days (at 200th passage) (PubMed=30405107) 21156749 CVCL_UH65 NPC53 cancer cell line human CVCL_UH65 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Omics: Transcriptome analysis by RNAseq Male Virology: Seems to have lost most of its episomal copies of EBV during its establishment as a cell culture 21156750 CVCL_UH68 WG0699 finite cell line human CVCL_UH68 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156751 CVCL_UH69 WG0738 finite cell line human CVCL_UH69 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156752 CVCL_2B00 AG04552 finite cell line human CVCL_2B00 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [66%]; 45,XY,t(13;21)(13qter->cen->21qter) [34%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156753 CVCL_2B03 AG04555 finite cell line human CVCL_2B03 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156754 CVCL_2B04 AG04556 finite cell line human CVCL_2B04 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,1qh+ [28%]; 46,Y,1qh+,t(X;1)(Xpter->Xq24::1q25->1qter;1pter->1q25::Xq24->Xqter) [72%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156755 CVCL_2B01 AG04553 finite cell line human CVCL_2B01 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG04553) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156756 CVCL_2B02 AG04554 finite cell line human CVCL_2B02 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [90%]; 46,XY,inv(1)(pter->p32::p11->p32::p11->qter) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG04554) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156757 CVCL_2B07 AG04559 finite cell line human CVCL_2B07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [46]; 45,XY,-9 [2]; 45,XY,der(7)(7qter->7p22::11q13->11qter),-9 [1]; 43,X,der(Y;13)(Yqter->Yq10;13q10->13qter),-3,der(7)(7qter->7p22::11q13->11qter),-11 [1] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156758 CVCL_2B08 AG04654 finite cell line human CVCL_2B08 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [49]; 46,XY,t(7;12)(7pter->7q22::12q13->12qter;12pter->12q13::7q22->7qter) [1] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156759 CVCL_2B05 AG04557 finite cell line human CVCL_2B05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(1)(q11;q21) [96%]; 46,XY,inv(1)(q11;q21),t(1;13)(1pter->1q25::13q12->13qter;13pter->13q12::1q25->1qter) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG04557) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156760 CVCL_2B06 AG04558 finite cell line human CVCL_2B06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(11)(11qter->11p15;14q11->14qter) [25]; 46,XY,add(11)(11qter->11p15:?) [11]; 46,XY,der(11)(11qter->11p15::3p14->3pter) [4]; 46,XY,inv(5)(pter->q22::q31->q22::q31->qter) [2]; 46,XY [8] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG04558) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156761 CVCL_2B09 AG04655 finite cell line human CVCL_2B09 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156762 CVCL_UH51 LM-MEL-103 cancer cell line human CVCL_UH51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Ascites. Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21156763 CVCL_UH52 LM-MEL-104 cancer cell line human CVCL_UH52 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Ascites. Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21156764 CVCL_UH50 LM-MEL-102 cancer cell line human CVCL_UH50 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Ascites. Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21156765 CVCL_UH56 NTU-h3 cancer cell line human CVCL_UH56 CL:0000010 Population: Chinese; Taiwan; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Unspecified Virology: Contains both episomal and chromosomal integrated forms of hepatitis B virus (HBV) 21156766 CVCL_UH53 LM-MEL-105 cancer cell line human CVCL_UH53 CL:0000010 Miscellaneous: Cell line information from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Ascites. Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21156767 CVCL_UH54 LM-MEL-51 cancer cell line human CVCL_UH54 CL:0000010 Miscellaneous: Cell line information from personal communication of Cardwell T., Olivia Newton-John Cancer Research Institute Derived from metastatic site: Right inguinal lymph node. Male Part of: Ludwig Institute for Cancer Research Melbourne melanoma cell line panel 21156768 CVCL_UH59 hTERT FT237 telomerase immortalized cell line human CVCL_UH59 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female Doubling time: ~32 hours (ATCC=CRL-3446) 21156769 CVCL_UH57 FT190 transformed cell line human CVCL_UH57 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 21156770 CVCL_UH58 FT194 transformed cell line human CVCL_UH58 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female 21156771 CVCL_2B10 AG04656 finite cell line human CVCL_2B10 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG04656) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156772 CVCL_2B11 AG04657 finite cell line human CVCL_2B11 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG04657) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156773 CVCL_2B14 AG04660 finite cell line human CVCL_2B14 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156774 CVCL_2B15 AG04661 finite cell line human CVCL_2B15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [16%]; 46,XY,inv(2),15q-,17p+ [84%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 39 PDL (Coriell=AG04661) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156775 CVCL_2B12 AG04658 finite cell line human CVCL_2B12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG04658) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156776 CVCL_2B13 AG04659 finite cell line human CVCL_2B13 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 29 PDL (Coriell=AG04659); Doubling time: 1.7 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156777 CVCL_2B18 AG05096 finite cell line human CVCL_2B18 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,add(14)(q32) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (PubMed=9724752); 29 PDL (Coriell=AG05096) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156778 CVCL_2B19 AG05097 finite cell line human CVCL_2B19 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156779 CVCL_2B16 AG04662 finite cell line human CVCL_2B16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [21]; 45,X [22]; 47,XY,+7 [7] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156780 CVCL_2B17 AG05095 finite cell line human CVCL_2B17 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG05095) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156781 CVCL_UH40 XP1TS finite cell line human CVCL_UH40 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Val605_Gly611del (c.1812_1832del); Zygosity=Homozygous or hemizygous (PubMed=9580660) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156782 CVCL_UH41 XP24KY finite cell line human CVCL_UH41 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg454Trp (c.1360A>T) (R443W); Zygosity=Heterozygous (PubMed=9580660); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Asn537Argfs*8 (c.1608_1617del); Zygosity=Heterozygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156783 CVCL_UH44 GM03093 finite cell line human CVCL_UH44 CL:0000010 Population: Caucasian; Donor information: Established from a patient suffering from an unknown defect in the pyruvate dehydrogenase complex; Derived from sampling site: Cell type=Fibroblast. Female 21156784 CVCL_UH45 GM11027 cancer cell line human CVCL_UH45 CL:0000010 Population: Caucasian; Karyotypic information: 47,X,-Y,+13,+19p+,9q-,11q-,19p+ (Coriell). Male Characteristics: Established from tumor tissue passaged in a nude mouse Doubling time: Slow growth (Coriell) 21156785 CVCL_UH42 GM13032 transformed cell line human CVCL_UH42 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile506Val (c.1516A>G); ClinVar=VCV000007131; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM13032; probable 21156786 CVCL_UH43 GM10156 hybrid cell line human CVCL_UH43 CL:0000010 Characteristics: Hybrid for chromosome 8 mapping Contains a complete copy of chromosome 8.. Group: Human/rodent somatic cell hybrid 21156787 CVCL_UH48 SK-L8 cancer cell line human CVCL_UH48 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21156788 CVCL_UH49 328/23 hybrid cell line house mouse CVCL_UH49 CL:0000010 21156789 CVCL_UH46 GM11028 cancer cell line human CVCL_UH46 CL:0000010 Population: Caucasian Male Characteristics: Established from tumor tissue passaged in a nude mouse. 21156790 CVCL_UH47 GM13818 transformed cell line human CVCL_UH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from an infant with primary hyperoxaluria and oxalosis; Derived from sampling site: Peripheral blood. Male 21156791 CVCL_LN92 GM25252 transformed cell line human CVCL_LN92 CL:0000010 Sequence variation: Mutation; HGNC; 17380; ANAPC7; Unexplicit; Ex4-6del (8054bp del); Zygosity=Homozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156792 CVCL_LN93 GM25253 transformed cell line human CVCL_LN93 CL:0000010 Sequence variation: Mutation; HGNC; 17380; ANAPC7; Unexplicit; Ex4-6del (8054bp del); Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156793 CVCL_LN90 GM16430 transformed cell line human CVCL_LN90 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Male 21156794 CVCL_LN91 GM16421 transformed cell line human CVCL_LN91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156795 CVCL_UH30 M23(CLB) finite cell line house mouse CVCL_UH30 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6365; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21156796 CVCL_UH33 Tp364MG cancer cell line human CVCL_UH33 CL:0000010 Unspecified 21156797 CVCL_UH34 Tp385MG cancer cell line human CVCL_UH34 CL:0000010 Unspecified 21156798 CVCL_UH31 Tp323MG cancer cell line human CVCL_UH31 CL:0000010 Unspecified 21156799 CVCL_UH32 Tp347MG cancer cell line human CVCL_UH32 CL:0000010 Unspecified 21156800 CVCL_LN89 GM16429 transformed cell line human CVCL_LN89 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Male 21156801 CVCL_UH37 XP101OS finite cell line human CVCL_UH37 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Ile225Met (c.675A>G) (I214M); Zygosity=Heterozygous (PubMed=9580660); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Gly513Arg (c.1537G>A) (G502R); Zygosity=Heterozygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156802 CVCL_UH38 XP7KA finite cell line human CVCL_UH38 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Glu502Lys (c.1504G>A) (E491K); Zygosity=Heterozygous (PubMed=9580660); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Ile529Thr (c.1586T>C) (I518T); Zygosity=Heterozygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156803 CVCL_LN87 GM16427 transformed cell line human CVCL_LN87 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156804 CVCL_UH35 Tp301MG cancer cell line human CVCL_UH35 CL:0000010 Unspecified 21156805 CVCL_LN88 GM16428 transformed cell line human CVCL_LN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156806 CVCL_UH36 XP82TO finite cell line human CVCL_UH36 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Lys244Glu (c.730A>G); ClinVar=VCV000008787; Zygosity=Homozygous (PubMed=8798680; PubMed=10777490) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156807 CVCL_LN85 GM16420 transformed cell line human CVCL_LN85 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156808 CVCL_LN86 GM16422 transformed cell line human CVCL_LN86 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156809 CVCL_LN83 GM16418 transformed cell line human CVCL_LN83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156810 CVCL_UH39 XP23OS finite cell line human CVCL_UH39 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Glu456Glyfs*8 (c.1364dupA); Zygosity=Homozygous or hemizygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (PubMed=6492896) 21156811 CVCL_LN84 GM16419 transformed cell line human CVCL_LN84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156812 CVCL_UH22 HEK293 CYP19A1*1 transformed cell line human CVCL_UH22 CL:0000010 Transfected with: HGNC; 2594; CYP19A1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156813 CVCL_UH23 HEK293 CYP19A1*3 transformed cell line human CVCL_UH23 CL:0000010 Transfected with: HGNC; 2594; CYP19A1 (with p.Thr201Met) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156814 CVCL_UH20 HEK293 CYP3A7*2-V5 transformed cell line human CVCL_UH20 CL:0000010 Transfected with: HGNC; 2640; CYP3A7 (with p.Thr409Arg) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP3A7*2 with a C-terminal V5 tag 21156815 CVCL_UH21 HEK293 CYP4A11*1-V5 transformed cell line human CVCL_UH21 CL:0000010 Transfected with: HGNC; 2642; CYP4A11 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP4A11*1 with a C-terminal V5 tag 21156816 CVCL_UH26 HMS001 cancer cell line human CVCL_UH26 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Male Virology: Contains from 1 to 2 copies of the HPV16 genome (PubMed=24201445) Doubling time: 5 days (PubMed=29156801) 21156817 CVCL_UH27 SME1.Lu undefined cell line type house mouse CVCL_UH27 CL:0000010 Derived from sampling site: Embryonic bronchus or embryonic lung; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6454; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21156818 CVCL_LN98 GM25579 transformed cell line human CVCL_LN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156819 CVCL_UH24 HEK293 CYP19A1*4 transformed cell line human CVCL_UH24 CL:0000010 Transfected with: HGNC; 2594; CYP19A1 (with p.Arg264Cys) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156820 CVCL_LN99 GM25580 transformed cell line human CVCL_LN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156821 CVCL_UH25 LCL-Ter50 transformed cell line human CVCL_UH25 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Male 21156822 CVCL_LN96 GM25577 transformed cell line human CVCL_LN96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156823 CVCL_LN97 GM25578 transformed cell line human CVCL_LN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156824 CVCL_LN94 GM25255 finite cell line human CVCL_LN94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156825 CVCL_UH28 SME2.Lu undefined cell line type house mouse CVCL_UH28 CL:0000010 Derived from sampling site: Embryonic bronchus or embryonic lung; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6455; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21156826 CVCL_LN95 GM25428 transformed cell line human CVCL_LN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156827 CVCL_UH29 SME3.Lu undefined cell line type house mouse CVCL_UH29 CL:0000010 Derived from sampling site: Embryonic bronchus or embryonic lung; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6456; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21156828 CVCL_LN70 GM16326 transformed cell line human CVCL_LN70 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156829 CVCL_LN71 GM16327 transformed cell line human CVCL_LN71 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156830 CVCL_UH11 HEK293 CYP2E1*1A transformed cell line human CVCL_UH11 CL:0000010 Transfected with: HGNC; 2631; CYP2E1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156831 CVCL_UH12 HEK293 CYP2E1*1A-V5 transformed cell line human CVCL_UH12 CL:0000010 Transfected with: HGNC; 2631; CYP2E1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2E1*1A with a C-terminal V5 tag 21156832 CVCL_LN69 GM16325 transformed cell line human CVCL_LN69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156833 CVCL_UH10 HEK293 CYP2D6*17-V5 transformed cell line human CVCL_UH10 CL:0000010 Transfected with: HGNC; 2625; CYP2D6 (with p.Thr107Ile, p.Arg296Cys and p.Ser486Thr) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2D6*17 with a C-terminal V5 tag 21156834 CVCL_LN67 GM16322 transformed cell line human CVCL_LN67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156835 CVCL_UH15 HEK293 CYP3A4*1A-V5 transformed cell line human CVCL_UH15 CL:0000010 Transfected with: HGNC; 2637; CYP3A4 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP3A4*1A with a C-terminal V5 tag 21156836 CVCL_LN68 GM16324 transformed cell line human CVCL_LN68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156837 CVCL_UH16 HEK293 CYP3A4*15-V5 transformed cell line human CVCL_UH16 CL:0000010 Transfected with: HGNC; 2637; CYP3A4 (with p.Arg162Gln) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP3A4*15 with a C-terminal V5 tag 21156838 CVCL_LN65 GM16320 transformed cell line human CVCL_LN65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156839 CVCL_UH13 HEK293 CYP2J2*1-V5 transformed cell line human CVCL_UH13 CL:0000010 Transfected with: HGNC; 2634; CYP2J2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2J2*1 with a C-terminal V5 tag 21156840 CVCL_UH14 GM11774 transformed cell line human CVCL_UH14 CL:0000010 Anecdotal: Part of a set of 5 cell lines that were established from blood samples of members of the Huaorani (Waorani) indigenous people These samples were allegedly taken without the Ecuadorian government's permission during the early 1990s. Population: Native South American; Huaorani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11774; true Female 21156841 CVCL_LN66 GM16321 transformed cell line human CVCL_LN66 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156842 CVCL_UH19 GM11777 transformed cell line human CVCL_UH19 CL:0000010 Anecdotal: Part of a set of 5 cell lines that were established from blood samples of members of the Huaorani (Waorani) indigenous people These samples were allegedly taken without the Ecuadorian government's permission during the early 1990s. Population: Native South American; Huaorani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11777; true Female 21156843 CVCL_LN63 GM16318 transformed cell line human CVCL_LN63 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156844 CVCL_LN64 GM16319 transformed cell line human CVCL_LN64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156845 CVCL_LN61 GM16316 transformed cell line human CVCL_LN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156846 CVCL_UH17 HEK293 CYP3A5*1 transformed cell line human CVCL_UH17 CL:0000010 Transfected with: HGNC; 2638; CYP3A5 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156847 CVCL_LN62 GM16317 transformed cell line human CVCL_LN62 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156848 CVCL_UH18 HEK293 CYP3A5*1-V5 transformed cell line human CVCL_UH18 CL:0000010 Transfected with: HGNC; 2638; CYP3A5 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP3A5*1 with a C-terminal V5 tag 21156849 CVCL_LN81 GM16416 transformed cell line human CVCL_LN81 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Male 21156850 CVCL_LN82 GM16417 transformed cell line human CVCL_LN82 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156851 CVCL_LN80 GM16415 transformed cell line human CVCL_LN80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156852 CVCL_UH00 HEK293 CYP2C18*1-V5 transformed cell line human CVCL_UH00 CL:0000010 Transfected with: HGNC; 2620; CYP2C18 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C18*1 with a C-terminal V5 tag 21156853 CVCL_UH04 GM11773 transformed cell line human CVCL_UH04 CL:0000010 Anecdotal: Part of a set of 5 cell lines that were established from blood samples of members of the Huaorani (Waorani) indigenous people These samples were allegedly taken without the Ecuadorian government's permission during the early 1990s. Population: Native South American; Huaorani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11773; true Female 21156854 CVCL_LN78 GM16413 transformed cell line human CVCL_LN78 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156855 CVCL_LN79 GM16414 transformed cell line human CVCL_LN79 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156856 CVCL_UH05 HEK293 CYP2C19-E92D-V5 transformed cell line human CVCL_UH05 CL:0000010 Transfected with: HGNC; 2621; CYP2C19 (with p.Glu92Asp) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C19 E92D with a C-terminal V5 tag 21156857 CVCL_LN76 GM16361 transformed cell line human CVCL_LN76 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156858 CVCL_UH02 HEK293 CYP2C19*1A-V5 transformed cell line human CVCL_UH02 CL:0000010 Transfected with: HGNC; 2621; CYP2C19 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C19*1A with a C-terminal V5 tag 21156859 CVCL_LN77 GM16412 transformed cell line human CVCL_LN77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156860 CVCL_UH03 HEK293 CYP2C19*1B-V5 transformed cell line human CVCL_UH03 CL:0000010 Transfected with: HGNC; 2621; CYP2C19 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2C19*1B with a C-terminal V5 tag 21156861 CVCL_LN74 GM16331 transformed cell line human CVCL_LN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156862 CVCL_UH08 HEK293 CYP2D6*2-V5 transformed cell line human CVCL_UH08 CL:0000010 Transfected with: HGNC; 2625; CYP2D6 (with p.Arg296Cys and p.Ser486Thr) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2D6*2 with a C-terminal V5 tag 21156863 CVCL_LN75 GM16332 transformed cell line human CVCL_LN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156864 CVCL_UH09 HEK293 CYP2D6*10 transformed cell line human CVCL_UH09 CL:0000010 Transfected with: HGNC; 2625; CYP2D6 (with p.Pro34Ser and p.Ser486Thr) Miscellaneous: Cell line has been lost Attempt to re-clone it are underway. Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21156865 CVCL_LN72 GM16328 transformed cell line human CVCL_LN72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156866 CVCL_LN73 GM16329 transformed cell line human CVCL_LN73 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to <=4 repeats) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156867 CVCL_UH07 HEK293 CYP2D6*1A-V5 transformed cell line human CVCL_UH07 CL:0000010 Transfected with: HGNC; 2625; CYP2D6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses CYP2D6*1A with a C-terminal V5 tag 21156868 CVCL_2B87 AG06291 finite cell line human CVCL_2B87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,del(5)(q14) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 19 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156869 CVCL_2B88 AG06292 finite cell line human CVCL_2B88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [70%]; 46,XY,t(14;19)(q11.2;q13.3) [18%]; 46,XY,t(5;6;8)(q13;p21;q22),t(10;14)(q22;q22) [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (Coriell=AG06292) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156870 CVCL_2B85 AG06289 finite cell line human CVCL_2B85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156871 CVCL_2B86 AG06290 finite cell line human CVCL_2B86 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 51 PDL (Coriell=AG06290) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156872 CVCL_2B89 AG06294 finite cell line human CVCL_2B89 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 49 PDL (Coriell=AG06294) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156873 CVCL_2B80 AG06283 finite cell line human CVCL_2B80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG06283) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156874 CVCL_2B83 AG06287 finite cell line human CVCL_2B83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156875 CVCL_2B84 AG06288 finite cell line human CVCL_2B84 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 45,X [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 48 PDL (Coriell=AG06288) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156876 CVCL_2B81 AG06284 finite cell line human CVCL_2B81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG06284) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156877 CVCL_2B82 AG06285 finite cell line human CVCL_2B82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26-29 PDL (PubMed=9724752); 51 PDL (Coriell=AG06285) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156878 CVCL_2B98 AG06310 finite cell line human CVCL_2B98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 38 PDL (Coriell=AG06310) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156879 CVCL_2B99 AG06877 finite cell line human CVCL_2B99 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG06877) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156880 CVCL_2B96 AG06307 finite cell line human CVCL_2B96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 47 PDL (Coriell=AG06307) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156881 CVCL_2B97 AG06308 finite cell line human CVCL_2B97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [64%]; 46,XY,t(13;15)(q14;q12) [36%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 47 PDL (Coriell=AG06308) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156882 CVCL_2B90 AG06295 finite cell line human CVCL_2B90 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [41]; 46,XY,inv(4)(pter->p14::q12->p14::q12->qter) [9] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156883 CVCL_2B91 AG06296 finite cell line human CVCL_2B91 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [44]; 46,XY,t(2;12)(2pter->2q14::12q23->12qter;12pter->12q23::2q14->2qter) [6] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156884 CVCL_2B94 AG06305 finite cell line human CVCL_2B94 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG06305) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156885 CVCL_2B95 AG06306 finite cell line human CVCL_2B95 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [36%]; 46,XY,t(1;9) [64%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 47 PDL (Coriell=AG06302) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156886 CVCL_2B92 AG06302 finite cell line human CVCL_2B92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG06302) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156887 CVCL_2B93 AG06304 finite cell line human CVCL_2B93 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG06304); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156888 CVCL_2B65 AG06010 finite cell line human CVCL_2B65 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156889 CVCL_2B66 AG06234 finite cell line human CVCL_2B66 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22-26 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156890 CVCL_2B63 AG05844 finite cell line human CVCL_2B63 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.1 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156891 CVCL_2B64 AG06009 finite cell line human CVCL_2B64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG06009) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156892 CVCL_2B69 AG06237 finite cell line human CVCL_2B69 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 32 PDL (Coriell=AG06237) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156893 CVCL_2B67 AG06235 finite cell line human CVCL_2B67 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.7 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156894 CVCL_2B68 AG06236 finite cell line human CVCL_2B68 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 46,XY,t(9;9)(9pter->9q13::9q34->9qter;9pter->9q34::9q13->9qter) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG06236) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156895 CVCL_2B61 AG05839 finite cell line human CVCL_2B61 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 40 PDL (Coriell=AG05839) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156896 CVCL_2B62 AG05840 finite cell line human CVCL_2B62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156897 CVCL_2B60 AG05838 finite cell line human CVCL_2B60 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,22p+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 54 PDL (Coriell=AG05838); Doubling time: 2.5 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156898 CVCL_2B76 AG06279 finite cell line human CVCL_2B76 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [82%]; 45,X [18%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 52 PDL (Coriell=AG06279) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156899 CVCL_2B77 AG06280 finite cell line human CVCL_2B77 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [66%]; 46,XY,t(3;17)(p23;p13),t(12;17)(q?;q?) [34%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156900 CVCL_2B74 AG06276 finite cell line human CVCL_2B74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 13 PDL (Coriell=AG06276) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156901 CVCL_2B75 AG06277 finite cell line human CVCL_2B75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG06277) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156902 CVCL_2B78 AG06281 finite cell line human CVCL_2B78 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (Coriell=AG06281) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156903 CVCL_2B79 AG06282 finite cell line human CVCL_2B79 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG06282) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156904 CVCL_2B72 AG06242 finite cell line human CVCL_2B72 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 46,XY,t(2;15)(2pter->2q33::15p11.1->15pter;15qter->15p11.1::2q33->2qter) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG06242) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156905 CVCL_2B73 AG06243 finite cell line human CVCL_2B73 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [38%]; 45,X [6%]; 46,XY,t(2;19)(q23;p13.1) [48%]; 46,XY,t(1;17)(q32;p11.2),t(2;13)(q31;p11.2),9q+,10q-,18q-,18q- [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG06243) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156906 CVCL_2B70 AG06239 finite cell line human CVCL_2B70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG06239) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156907 CVCL_2B71 AG06240 finite cell line human CVCL_2B71 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 52 PDL (Coriell=AG06240) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156908 CVCL_2B43 AG05283 finite cell line human CVCL_2B43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 49 PDL (Coriell=AG05283); Doubling time: 1.7 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156909 CVCL_2B44 AG05410 finite cell line human CVCL_2B44 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [47]; 46,XY,t(1;3)(1qter->1p32::3p21->3pter;3qter->3p21::1p32->1pter) [3] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156910 CVCL_2B41 AG05277 finite cell line human CVCL_2B41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156911 CVCL_2B42 AG05278 finite cell line human CVCL_2B42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [10%]; 45,X [90%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 22 PDL (Coriell=AG05278) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156912 CVCL_2B47 AG05414 finite cell line human CVCL_2B47 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.3 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156913 CVCL_2B48 AG05415 finite cell line human CVCL_2B48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05415; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156914 CVCL_2B45 AG05411 finite cell line human CVCL_2B45 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG05411) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156915 CVCL_2B46 AG05413 finite cell line human CVCL_2B46 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X,t(9;16)(9pter->9q34::16p11.2->16pter;16qter->16p11.2::9q34->9qter) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 41 PDL (Coriell=AG05413) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156916 CVCL_2B49 AG05416 finite cell line human CVCL_2B49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156917 CVCL_UH91 WG0448 finite cell line human CVCL_UH91 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156918 CVCL_UH92 WG0502 finite cell line human CVCL_UH92 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156919 CVCL_UH90 WG0433 finite cell line human CVCL_UH90 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156920 CVCL_UH95 MCH050 finite cell line human CVCL_UH95 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156921 CVCL_UH96 WG0358 finite cell line human CVCL_UH96 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156922 CVCL_UH93 WG1371 finite cell line human CVCL_UH93 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21156923 CVCL_UH94 WG2215 finite cell line human CVCL_UH94 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21156924 CVCL_UH99 MCH051 finite cell line human CVCL_UH99 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21156925 CVCL_UH97 WG0839 finite cell line human CVCL_UH97 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156926 CVCL_UH98 WG0840 finite cell line human CVCL_UH98 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156927 CVCL_2B40 AG05275 finite cell line human CVCL_2B40 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156928 CVCL_2B54 AG05806 finite cell line human CVCL_2B54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 51 PDL (Coriell=AG05806) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156929 CVCL_2B55 AG05807 finite cell line human CVCL_2B55 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156930 CVCL_2B52 AG05804 finite cell line human CVCL_2B52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156931 CVCL_2B53 AG05805 finite cell line human CVCL_2B53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG05805) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156932 CVCL_2B58 AG05836 finite cell line human CVCL_2B58 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 43 PDL (Coriell=AG05836) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156933 CVCL_2B59 AG05837 finite cell line human CVCL_2B59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (Coriell=AG05837) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156934 CVCL_2B56 AG05811 finite cell line human CVCL_2B56 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 53 PDL (Coriell=AG05811) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156935 CVCL_2B57 AG05813 finite cell line human CVCL_2B57 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,9qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156936 CVCL_UH80 WG1343 finite cell line human CVCL_UH80 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 8840; PEPD; Simple; p.Gly448Arg (c.1342G>A); ClinVar=VCV000000213; Zygosity=Heterozygous (PubMed=8198124) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156937 CVCL_UH81 WG1529 finite cell line human CVCL_UH81 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156938 CVCL_UH84 WG1528 finite cell line human CVCL_UH84 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156939 CVCL_UH85 MCH020 finite cell line human CVCL_UH85 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156940 CVCL_UH82 WG1530 finite cell line human CVCL_UH82 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21156941 CVCL_UH83 WG1531 finite cell line human CVCL_UH83 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156942 CVCL_UH88 WG0280 finite cell line human CVCL_UH88 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156943 CVCL_UH89 WG0348 finite cell line human CVCL_UH89 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21156944 CVCL_UH86 MCH031 finite cell line human CVCL_UH86 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156945 CVCL_UH87 MCH035 finite cell line human CVCL_UH87 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21156946 CVCL_2B50 AG05417 finite cell line human CVCL_2B50 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 45,XY,-22 [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156947 CVCL_2B51 AG05419 finite cell line human CVCL_2B51 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG05419) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21156948 CVCL_CT39 ND20997 transformed cell line human CVCL_CT39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156949 CVCL_D539 PG-49 cancer cell line human CVCL_D539 CL:0000010 Population: Chinese. 21156950 CVCL_D537 A2780/ADDP cancer cell line human CVCL_D537 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21156951 CVCL_CT37 ND20989 transformed cell line human CVCL_CT37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156952 CVCL_D538 B103 cancer cell line Norway rat CVCL_D538 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21156953 CVCL_CT38 ND20991 transformed cell line human CVCL_CT38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156954 CVCL_D531 HepLi4 conditionally immortalized cell line human CVCL_D531 CL:0000010 Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Characteristics: Reversible immortalized The cell line was obtained by transduction of a retrovirus containing SV40 LT flanked by a pair of LoxP recombination targets. The SV40 LT gene can be excised by Cre/Lox site-specific recombination. 21156955 CVCL_CT31 ND20952 transformed cell line human CVCL_CT31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156956 CVCL_D532 HepLi2 transformed cell line human CVCL_D532 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 21156957 CVCL_CT32 ND20955 transformed cell line human CVCL_CT32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156958 CVCL_D530 HepLi5 transformed cell line human CVCL_D530 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified Doubling time: 8 hours (PubMed=22930002) 21156959 CVCL_CT30 ND20951 transformed cell line human CVCL_CT30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156961 CVCL_CT35 ND20975 transformed cell line human CVCL_CT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156962 CVCL_D536 H938 cancer cell line human CVCL_D536 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21156963 CVCL_CT36 ND20988 transformed cell line human CVCL_CT36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156964 CVCL_D533 HepLi3 transformed cell line human CVCL_D533 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 21156965 CVCL_CT33 ND20957 transformed cell line human CVCL_CT33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156966 CVCL_D534 AG06848 finite cell line human CVCL_D534 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Heterozygous (PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21156967 CVCL_CT34 ND20972 transformed cell line human CVCL_CT34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156968 CVCL_D548 Mel-RM cancer cell line human CVCL_D548 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Lymph node. Unspecified 21156969 CVCL_CT48 ND21060 transformed cell line human CVCL_CT48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156970 CVCL_D549 MEL-AC cancer cell line human CVCL_D549 CL:0000010 21156971 CVCL_CT49 ND21061 transformed cell line human CVCL_CT49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156972 CVCL_D542 HXO-Rb44 cancer cell line human CVCL_D542 CL:0000010 Population: Chinese; Derived from sampling site: Eye socket. Male Doubling time: 44 hours (PubMed=8575599) 21156973 CVCL_CT42 ND21002 transformed cell line human CVCL_CT42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156974 CVCL_CT43 ND21022 transformed cell line human CVCL_CT43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156975 CVCL_D543 SO-Rb50 cancer cell line human CVCL_D543 CL:0000010 Population: Chinese Female Doubling time: 44.32 hours (CelloPub=CLPUB00236). 21156976 CVCL_CT40 ND20998 transformed cell line human CVCL_CT40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156977 CVCL_D540 TRSC-1 transformed cell line CVCL_D540 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen. Unspecified 21156978 CVCL_CT41 ND21000 transformed cell line human CVCL_CT41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156979 CVCL_D541 TRK-73 transformed cell line CVCL_D541 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified 21156980 CVCL_D546 CCRF/VCR1000 cancer cell line human CVCL_D546 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21156981 CVCL_CT46 ND21046 transformed cell line human CVCL_CT46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156982 CVCL_D547 Mel-FH cancer cell line human CVCL_D547 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078) Derived from metastatic site: Lymph node. 21156983 CVCL_CT47 ND21051 transformed cell line human CVCL_CT47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156984 CVCL_D544 CCRF/ADR5000 cancer cell line human CVCL_D544 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21156985 CVCL_CT44 ND21025 transformed cell line human CVCL_CT44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156986 CVCL_D545 CCRF/ACTD400 cancer cell line human CVCL_D545 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21156987 CVCL_CT45 ND21044 transformed cell line human CVCL_CT45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156988 CVCL_D517 CL1-1 cancer cell line human CVCL_D517 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male 21156989 CVCL_CT17 ND20873 transformed cell line human CVCL_CT17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156990 CVCL_D518 CL1-2 cancer cell line human CVCL_D518 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male 21156991 CVCL_CT18 ND20880 transformed cell line human CVCL_CT18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156992 CVCL_D515 GM01775 transformed cell line human CVCL_D515 CL:0000010 Sequence variation: Mutation; HGNC; 2890; DKC1; Simple; p.Leu37del (c.109_111delCTT); ClinVar=VCV000011583; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156993 CVCL_CT15 ND20863 transformed cell line human CVCL_CT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156994 CVCL_CT16 ND20865 transformed cell line human CVCL_CT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156995 CVCL_D519 CL1-3 cancer cell line human CVCL_D519 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male 21156996 CVCL_CT19 ND20883 transformed cell line human CVCL_CT19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21156997 CVCL_CT10 ND20816 transformed cell line human CVCL_CT10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21156998 CVCL_D510 rHypoE-9 transformed cell line Norway rat CVCL_D510 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21156999 CVCL_D513 GM01654 finite cell line human CVCL_D513 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Homozygous (from autologous cell line GM01655) Population: Caucasian; Mennonite; Derived from sampling site: Cell type=Fibroblast. Female 21157000 CVCL_CT13 ND20851 transformed cell line human CVCL_CT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157001 CVCL_D514 GM01655 transformed cell line human CVCL_D514 CL:0000010 Sequence variation: Mutation; HGNC; 986; BCKDHA; Simple; p.Tyr438Asn (c.1312T>A) (Y393N); ClinVar=VCV000100009; Zygosity=Homozygous (PubMed=2241958) Population: Caucasian; Mennonite; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157002 CVCL_CT14 ND20852 transformed cell line human CVCL_CT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157003 CVCL_D511 GM01583 finite cell line human CVCL_D511 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21157004 CVCL_CT11 ND20830 transformed cell line human CVCL_CT11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157005 CVCL_D512 GM01584 finite cell line human CVCL_D512 CL:0000010 Population: Caucasian; Derived from sampling site: Amniotic fluid. Male 21157006 CVCL_CT12 ND20832 transformed cell line human CVCL_CT12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157007 CVCL_D528 MPM2 cancer cell line human CVCL_D528 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 46 hours (PubMed=18383846) 21157008 CVCL_CT28 ND20922 transformed cell line human CVCL_CT28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157009 CVCL_D529 MPM3 cancer cell line human CVCL_D529 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female Doubling time: 43 hours (PubMed=18383846) 21157010 CVCL_CT29 ND20950 transformed cell line human CVCL_CT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157011 CVCL_D526 MIT cancer cell line human CVCL_D526 CL:0000010 Derived from sampling site: Bone marrow. Unspecified Characteristics: Produces IgG kappa 21157012 CVCL_CT26 ND20911 transformed cell line human CVCL_CT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157013 CVCL_D527 MPM1 cancer cell line human CVCL_D527 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 26 hours (PubMed=18383846) 21157014 CVCL_CT27 ND20921 transformed cell line human CVCL_CT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157015 CVCL_D520 CL1-4 cancer cell line human CVCL_D520 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male 21157016 CVCL_CT20 ND20886 transformed cell line human CVCL_CT20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157017 CVCL_D521 CL1-5 cancer cell line human CVCL_D521 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male 21157018 CVCL_CT21 ND20890 transformed cell line human CVCL_CT21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157019 CVCL_D524 LES cancer cell line human CVCL_D524 CL:0000010 Derived from sampling site: Bone marrow. Unspecified Characteristics: Produces IgG kappa 21157020 CVCL_CT24 ND20900 transformed cell line human CVCL_CT24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157021 CVCL_CT25 ND20908 transformed cell line human CVCL_CT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157022 CVCL_D525 SIK cancer cell line human CVCL_D525 CL:0000010 Derived from sampling site: Bone marrow. Unspecified Characteristics: Produces IgG kappa 21157023 CVCL_CT22 ND20892 transformed cell line human CVCL_CT22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157024 CVCL_D522 SHAC cancer cell line human CVCL_D522 CL:0000010 Male 21157025 CVCL_D523 ARP-1 cancer cell line human CVCL_D523 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgA kappa 21157026 CVCL_CT23 ND20895 transformed cell line human CVCL_CT23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157027 CVCL_CT06 ND20802 transformed cell line human CVCL_CT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157028 CVCL_D506 rHypoE-33 transformed cell line Norway rat CVCL_D506 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157029 CVCL_CT07 ND20803 transformed cell line human CVCL_CT07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157030 CVCL_D507 rHypoE-6 transformed cell line Norway rat CVCL_D507 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157031 CVCL_CT04 ND20796 transformed cell line human CVCL_CT04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157032 CVCL_D504 rHypoE-30 transformed cell line Norway rat CVCL_D504 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157033 CVCL_CT05 ND20801 transformed cell line human CVCL_CT05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157034 CVCL_D505 rHypoE-31 transformed cell line Norway rat CVCL_D505 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157035 CVCL_CT08 ND20805 transformed cell line human CVCL_CT08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157036 CVCL_D508 rHypoE-7 transformed cell line Norway rat CVCL_D508 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157037 CVCL_CT09 ND20811 transformed cell line human CVCL_CT09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157038 CVCL_D509 rHypoE-8 transformed cell line Norway rat CVCL_D509 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157039 CVCL_CT02 ND20784 transformed cell line human CVCL_CT02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157040 CVCL_D502 rHypoE-28 transformed cell line Norway rat CVCL_D502 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Discontinued: Cedarlane Cellutions Systems; Catalog number CLU218 Unspecified 21157041 CVCL_CT03 ND20795 transformed cell line human CVCL_CT03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157042 CVCL_D503 rHypoE-29 transformed cell line Norway rat CVCL_D503 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157043 CVCL_CT00 ND20775 transformed cell line human CVCL_CT00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157044 CVCL_D500 rHypoE-25 transformed cell line Norway rat CVCL_D500 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157045 CVCL_CT01 ND20776 transformed cell line human CVCL_CT01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157046 CVCL_D501 rHypoE-27 transformed cell line Norway rat CVCL_D501 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21157047 CVCL_LN49 GM16279 transformed cell line human CVCL_LN49 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157048 CVCL_LN47 GM16277 transformed cell line human CVCL_LN47 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157049 CVCL_LN48 GM16278 transformed cell line human CVCL_LN48 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157050 CVCL_LN45 GM16275 transformed cell line human CVCL_LN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157051 CVCL_LN46 GM16276 transformed cell line human CVCL_LN46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157052 CVCL_LN43 GM16250 transformed cell line human CVCL_LN43 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157053 CVCL_LN44 GM16251 transformed cell line human CVCL_LN44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157054 CVCL_LN41 PNL-P2 clone C1 cancer cell line pig CVCL_LN41 CL:0000010 Transformant: Strontium-90 beta radiation(NCIt; C141343); Breed/subspecies: Miniature pig. 21157055 CVCL_LN42 GM16130 transformed cell line human CVCL_LN42 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157056 CVCL_LN40 MPK [Mylopharyngodon] spontaneously immortalized cell line CVCL_LN40 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21157057 CVCL_LN60 GM16315 transformed cell line human CVCL_LN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157058 CVCL_LN58 GM16313 transformed cell line human CVCL_LN58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157059 CVCL_LN59 GM16314 transformed cell line human CVCL_LN59 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157060 CVCL_LN56 GM16311 transformed cell line human CVCL_LN56 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157061 CVCL_LN57 GM16312 transformed cell line human CVCL_LN57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157062 CVCL_LN54 GM16284 transformed cell line human CVCL_LN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157063 CVCL_LN55 GM16310 transformed cell line human CVCL_LN55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157064 CVCL_LN52 GM16282 transformed cell line human CVCL_LN52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157065 CVCL_LN53 GM16283 transformed cell line human CVCL_LN53 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157066 CVCL_LN50 GM16280 transformed cell line human CVCL_LN50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157067 CVCL_LN51 GM16281 transformed cell line human CVCL_LN51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157068 CVCL_D597 CEM/VLB10 cancer cell line human CVCL_D597 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21157069 CVCL_CT97 ND21609 transformed cell line human CVCL_CT97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157070 CVCL_D598 CEM-VBL16 cancer cell line human CVCL_D598 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21157071 CVCL_CT98 ND21611 transformed cell line human CVCL_CT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157072 CVCL_D595 A716 cancer cell line human CVCL_D595 From: Lerman M.; Center for Cancer Research, National Cancer Institute; Frederick; USA. CL:0000010 21157073 CVCL_CT95 ND21592 transformed cell line human CVCL_CT95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157074 CVCL_CT96 ND21595 transformed cell line human CVCL_CT96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157075 CVCL_D596 ZA cancer cell line human CVCL_D596 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=2654810); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly279Glu (c.836G>A); ClinVar=VCV000419454; Zygosity=Unspecified (PubMed=1570156) Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21157076 CVCL_D599 KBv200 cancer cell line human CVCL_D599 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21157077 CVCL_CT99 ND21623 transformed cell line human CVCL_CT99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157078 CVCL_CT90 ND21545 transformed cell line human CVCL_CT90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157079 CVCL_D590 SF-xL cancer cell line human CVCL_D590 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 992; BCL2L1 (isoform Bcl-xL) Derived from sampling site: Brain; frontal lobe. Male 21157080 CVCL_LN29 KRC-113 transformed cell line human CVCL_LN29 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157081 CVCL_LN27 KRC-104 transformed cell line human CVCL_LN27 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157082 CVCL_CT93 ND21579 transformed cell line human CVCL_CT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157083 CVCL_D593 SK-9 cancer cell line human CVCL_D593 CL:0000010 Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (PubMed=20471447) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: ~48 hours (PubMed=20471447) 21157084 CVCL_LN28 KRC-112 transformed cell line human CVCL_LN28 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157085 CVCL_CT94 ND21589 transformed cell line human CVCL_CT94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157087 CVCL_LN25 KRC-020 transformed cell line human CVCL_LN25 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157088 CVCL_CT91 ND21566 transformed cell line human CVCL_CT91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157089 CVCL_D591 RWLeu-4 cancer cell line human CVCL_D591 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Derived from sampling site: Peripheral blood. Unspecified Doubling time: 33 hours (CelloPub=CLPUB00106); 25-26 hours (PubMed=2159372) 21157090 CVCL_D592 JMRD3 cancer cell line human CVCL_D592 CL:0000010 Selected for resistance to: ChEBI; CHEBI:73558; Vitamin D3; Derived from sampling site: Peripheral blood. Unspecified 21157091 CVCL_LN26 KRC-083 transformed cell line human CVCL_LN26 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157092 CVCL_CT92 ND21569 transformed cell line human CVCL_CT92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157093 CVCL_LN23 GRC-192 transformed cell line human CVCL_LN23 CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157094 CVCL_LN24 KRC-006 transformed cell line human CVCL_LN24 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157095 CVCL_LN21 GRC-181 transformed cell line human CVCL_LN21 CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157096 CVCL_LN22 GRC-191 transformed cell line human CVCL_LN22 CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157097 CVCL_LN20 HAV-42 transformed cell line human CVCL_LN20 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157098 CVCL_LN38 MGH-U1/OCI cancer cell line human CVCL_LN38 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Parent cell line (Ej138) has been shown to be a T24 derivative. 21157099 CVCL_LN39 OCI-m/F1 cancer cell line human CVCL_LN39 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Grand-parent cell line (Ej138) has been shown to be a T24 derivative. 21157100 CVCL_LN36 EJ-30 clone B3 cancer cell line human CVCL_LN36 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Grand-parent cell line (Ej138) has been shown to be a T24 derivative. 21157101 CVCL_LN37 EJ-30 clone B3-WrnDN1 cancer cell line human CVCL_LN37 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12791; WRN (with p.Lys577Met); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Characteristics: Expresses WRN p.Lys577Met under the control of a tetracycline-inducible promoter Problematic cell line: Contaminated Ancestral cell line (Ej138) has been shown to be a T24 derivative. 21157102 CVCL_LN34 EJ-30 cancer cell line human CVCL_LN34 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Parent cell line (Ej138) has been shown to be a T24 derivative. 21157103 CVCL_LN35 EJ-30 clone A3 cancer cell line human CVCL_LN35 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Grand-parent cell line (Ej138) has been shown to be a T24 derivative. 21157104 CVCL_LN32 HEK293/hABCC6 transformed cell line human CVCL_LN32 CL:0000010 Transfected with: HGNC; 57; ABCC6; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Metabolome analysis Female 21157105 CVCL_LN33 HEK293/rABCC6 transformed cell line human CVCL_LN33 CL:0000010 Transfected with: RGD; 620268; Abcc6; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Metabolome analysis Female 21157106 CVCL_LN30 KIV-116 transformed cell line human CVCL_LN30 CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157107 CVCL_LN31 HN9.10e hybrid cell line house mouse CVCL_LN31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Somatic fusion product of hippocampal cells from embryonic day 18 C57BL/6 mice and N18TG2; Characteristics: Has morphological and cytoskeletal features similar to their neuronal precursors 21157108 CVCL_D575 LNGK9 cancer cell line human CVCL_D575 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21157109 CVCL_CT75 ND21428 transformed cell line human CVCL_CT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157110 CVCL_D576 HER14 spontaneously immortalized cell line house mouse CVCL_D576 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Expresses ~200000 EGFR (PubMed=1417788) 21157111 CVCL_CT76 ND21429 transformed cell line human CVCL_CT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157112 CVCL_D573 K562/R7 cancer cell line human CVCL_D573 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Pleural effusion. Female 21157113 CVCL_CT73 ND21425 transformed cell line human CVCL_CT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157114 CVCL_D574 EPYP-1 transformed cell line Norway rat CVCL_D574 CL:0000010 Transformant: Simian virus 40 (SV40) [pMT10D](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Copenhagen. Male Doubling time: 20 hours (PubMed=8900919) 21157115 CVCL_CT74 ND21426 transformed cell line human CVCL_CT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157116 CVCL_CT79 ND21458 transformed cell line human CVCL_CT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157117 CVCL_D579 PC-3M-Pro4 cancer cell line human CVCL_D579 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21157118 CVCL_CT77 ND21440 transformed cell line human CVCL_CT77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157119 CVCL_D577 PC-3M-luc-C6 cancer cell line human CVCL_D577 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; 119270; true Male 21157120 CVCL_CT78 ND21442 transformed cell line human CVCL_CT78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157121 CVCL_D578 PC-3M-LN4 cancer cell line human CVCL_D578 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21157122 CVCL_LN09 MET-1 cancer cell line human CVCL_LN09 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Hand; skin Cell type=Keratinocyte.. Male 21157123 CVCL_LN07 BA 68.1 spontaneously immortalized cell line CVCL_LN07 CL:0000010 Unspecified Doubling time: ~30 hours (DOI=10.1007/978-3-642-85791-1_7). Group: Amphibian cell line 21157124 CVCL_LN08 L-363 + EBV transformed cell line human CVCL_LN08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: 46-50 hours (PubMed=207377) 21157125 CVCL_LN05 A1-425 hybridoma house mouse CVCL_LN05 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21157126 CVCL_D571 HKESC-2 cancer cell line human CVCL_D571 CL:0000010 Population: Chinese Female Doubling time: 24 hours (PubMed=12127396). 21157127 CVCL_CT71 ND21351 transformed cell line human CVCL_CT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157128 CVCL_D572 HKESC-3 cancer cell line human CVCL_D572 CL:0000010 Population: Chinese Male Doubling time: 48 hours (PubMed=12127396). 21157129 CVCL_CT72 ND21367 transformed cell line human CVCL_CT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157130 CVCL_LN06 RPH 67.194 spontaneously immortalized cell line CVCL_LN06 CL:0000010 Unspecified Group: Amphibian cell line. 21157131 CVCL_LN03 A1-287 hybridoma house mouse CVCL_LN03 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21157132 CVCL_D570 243 cancer cell line human CVCL_D570 CL:0000010 Derived from sampling site: Bone marrow. Characteristics: Produces IgA lambda 21157133 CVCL_LN04 A1-410 hybridoma house mouse CVCL_LN04 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21157134 CVCL_CT70 ND21350 transformed cell line human CVCL_CT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157135 CVCL_LN01 A1-245 hybridoma house mouse CVCL_LN01 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. 21157136 CVCL_LN02 A1-267 hybridoma house mouse CVCL_LN02 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2; Monoclonal antibody target: ChEBI; CHEBI:89636; Ganglioside GD3. 21157137 CVCL_LN00 A1-201 hybridoma house mouse CVCL_LN00 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:89637; Ganglioside GD2. 21157138 CVCL_CT86 ND21522 transformed cell line human CVCL_CT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157139 CVCL_D586 T-REx-CHO spontaneously immortalized cell line CVCL_D586 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Ovary. Female 21157140 CVCL_CT87 ND21524 transformed cell line human CVCL_CT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157141 CVCL_D587 T-REx-HeLa cancer cell line human CVCL_D587 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21157142 CVCL_D584 N27 transformed cell line Norway rat CVCL_D584 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon. Unspecified Characteristics: Used as a dopaminergic neuron model for in vitro and in vivo studies (Millipore); Characteristics: During many passages over 20 years, the original cell line became a mixture of cell types with less than 5% TH-positive dopamine neurons (PubMed=27512998) Doubling time: 24 hours (PubMed=27512998) 21157143 CVCL_CT84 ND21517 transformed cell line human CVCL_CT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157144 CVCL_CT85 ND21521 transformed cell line human CVCL_CT85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157145 CVCL_D585 T-REx-293 transformed cell line human CVCL_D585 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used for the production of the AstraZeneca SARS-CoV-2 (COVID-19) vaccine (Trade name: Vaxzevria; also known as ChAdOx1-SARS-COV-2 or AZD1222) (DrugBank; DB15656) In the context of the vaccine production, the tetR repressor blocks the expression of the SARS-CoV-2 spike protein gene during production of the recombinant adenoviral vector, thereby optimising vector production. Female Group: Vaccine production cell line; Part of: ENCODE project common cell types; tier 3 21157146 CVCL_CT88 ND21531 transformed cell line human CVCL_CT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157147 CVCL_D588 T-REx-Jurkat cancer cell line human CVCL_D588 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21157148 CVCL_D589 GI-102 cancer cell line human CVCL_D589 CL:0000010 Female 21157149 CVCL_CT89 ND21538 transformed cell line human CVCL_CT89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157150 CVCL_LN18 HAV-280 transformed cell line human CVCL_LN18 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157151 CVCL_LN19 HAV-281 transformed cell line human CVCL_LN19 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157152 CVCL_LN16 HAV-102 transformed cell line human CVCL_LN16 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157153 CVCL_D582 MDA-MB-231-luc2 cancer cell line human CVCL_D582 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 124319; true Female Group: Triple negative breast cancer (TNBC) cell line 21157154 CVCL_CT82 ND21496 transformed cell line human CVCL_CT82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157155 CVCL_D583 CHO-CUR3 spontaneously immortalized cell line CVCL_D583 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29036; Copper(2+); Derived from sampling site: Ovary. Female 21157156 CVCL_LN17 HAV-256 transformed cell line human CVCL_LN17 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21157157 CVCL_CT83 ND21515 transformed cell line human CVCL_CT83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157158 CVCL_CT80 ND21479 transformed cell line human CVCL_CT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157159 CVCL_LN14 RPD 67.7 spontaneously immortalized cell line CVCL_LN14 CL:0000010 Unspecified Doubling time: ~60 hours (DOI=10.1007/978-3-642-85791-1_7). Group: Amphibian cell line 21157160 CVCL_D580 UMR-106-01 cancer cell line Norway rat CVCL_D580 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. 21157161 CVCL_LN15 HAV-1131 transformed cell line human CVCL_LN15 CL:0000010 Population: Native North American; Havasupai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21157162 CVCL_D581 MLE-15 transformed cell line house mouse CVCL_D581 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: FVB/N-Tg(SFTPC-TAg)5.1Jaw transgenic. Discontinued: ABM; T0495; probable Unspecified 21157163 CVCL_CT81 ND21480 transformed cell line human CVCL_CT81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157164 CVCL_LN12 MET-4 cancer cell line human CVCL_LN12 CL:0000010 Derived from metastatic site: Left axillary lymph node. Male 21157165 CVCL_LN13 PM-1 [Human oral dysplasia] transformed cell line human CVCL_LN13 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Asn86Ser (c.257A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly177Glu (c.530G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Lys (c.772G>A); ClinVar=VCV000012348; Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Forehead; skin Cell type=Keratinocyte.. Male 21157166 CVCL_LN10 MET-2 cancer cell line human CVCL_LN10 CL:0000010 Derived from sampling site: Hand; skin Cell type=Keratinocyte.. Male 21157167 CVCL_LN11 MET-3 cancer cell line human CVCL_LN11 CL:0000010 Derived from sampling site: Hand; skin Cell type=Keratinocyte.. Male 21157168 CVCL_CT59 ND21178 transformed cell line human CVCL_CT59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157169 CVCL_D559 NP31 transformed cell line Norway rat CVCL_D559 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Unspecified 21157170 CVCL_CT53 ND21150 transformed cell line human CVCL_CT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157171 CVCL_D554 H48N cancer cell line human CVCL_D554 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=21607521) Derived from sampling site: Pancreas. 21157172 CVCL_CT54 ND21152 transformed cell line human CVCL_CT54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157173 CVCL_D551 IU-TAB-1 cancer cell line human CVCL_D551 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=27117832) Derived from sampling site: Mediastinum. Omics: Transcriptome analysis by microarray Male Doubling time: 48 hours (PubMed=22926645) 21157174 CVCL_CT51 ND21109 transformed cell line human CVCL_CT51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157175 CVCL_CT52 ND21140 transformed cell line human CVCL_CT52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157176 CVCL_CT57 ND21170 transformed cell line human CVCL_CT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157177 CVCL_D557 NP11 transformed cell line Norway rat CVCL_D557 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Unspecified 21157178 CVCL_CT58 ND21176 transformed cell line human CVCL_CT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157179 CVCL_D558 NP26 transformed cell line Norway rat CVCL_D558 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Unspecified 21157180 CVCL_CT55 ND21165 transformed cell line human CVCL_CT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157181 CVCL_D555 WM1650 cancer cell line human CVCL_D555 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-2810; true Male Part of: Wistar Institute melanoma cell line collection 21157182 CVCL_CT56 ND21168 transformed cell line human CVCL_CT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157183 CVCL_D556 THX cancer cell line human CVCL_D556 CL:0000010 21157184 CVCL_D550 LC-06-JCK cancer cell line human CVCL_D550 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Population: Japanese 21157185 CVCL_CT50 ND21089 transformed cell line human CVCL_CT50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157186 CVCL_D564 DMBM-5 spontaneously immortalized cell line house mouse CVCL_D564 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: CBA/J. Female Doubling time: 18-22 hours (PubMed=9103234) 21157187 CVCL_CT64 ND21232 transformed cell line human CVCL_CT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157188 CVCL_D565 DMBM-6 spontaneously immortalized cell line house mouse CVCL_D565 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: CBA/J. Female Doubling time: 50-60 hours (PubMed=9103234) 21157189 CVCL_CT65 ND21254 transformed cell line human CVCL_CT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157190 CVCL_D562 DMBM-3 spontaneously immortalized cell line house mouse CVCL_D562 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Doubling time: 16-20 hours (PubMed=9103234) 21157191 CVCL_CT62 ND21215 transformed cell line human CVCL_CT62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157192 CVCL_D563 DMBM-4 spontaneously immortalized cell line house mouse CVCL_D563 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Doubling time: 30-40 hours (PubMed=9103234) 21157193 CVCL_CT63 ND21222 transformed cell line human CVCL_CT63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157194 CVCL_D568 HKESC-1 cancer cell line human CVCL_D568 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y. Male Doubling time: 46 hours (PubMed=10748291) 21157195 CVCL_CT68 ND21279 transformed cell line human CVCL_CT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157196 CVCL_D569 CAG cancer cell line human CVCL_D569 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604) Derived from sampling site: Bone marrow. Female 21157197 CVCL_CT69 ND21289 transformed cell line human CVCL_CT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157198 CVCL_D566 AT22IJE-T transformed cell line human CVCL_D566 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu762Valfs (c.2282_2283CT[1]) (c.2284_2285delCT); ClinVar=VCV000141325; Zygosity=Unspecified (PubMed=9244351) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21157199 CVCL_CT66 ND21256 transformed cell line human CVCL_CT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157200 CVCL_CT67 ND21277 transformed cell line human CVCL_CT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157201 CVCL_D567 OM10.1 cancer cell line human CVCL_D567 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Virology: In vitro infected by HIV-1 21157202 CVCL_CT60 ND21196 transformed cell line human CVCL_CT60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157203 CVCL_D560 NP32 transformed cell line Norway rat CVCL_D560 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Unspecified 21157204 CVCL_D561 DMBM-1 spontaneously immortalized cell line house mouse CVCL_D561 CL:0000010 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Doubling time: 18-22 hours (PubMed=9103234) 21157205 CVCL_CT61 ND21211 transformed cell line human CVCL_CT61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157206 CVCL_2C42 AG07720 finite cell line human CVCL_2C42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [92%]; 46,XX,add(14)(p12) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (PubMed=9724752); 36 PDL (Coriell=AG07720) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157207 CVCL_2C43 AG07722 finite cell line human CVCL_2C43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG07722) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157208 CVCL_2C40 AG07716 finite cell line human CVCL_2C40 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157209 CVCL_2C41 AG07719 finite cell line human CVCL_2C41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 34-37 PDL (PubMed=9724752); 36 PDL (Coriell=AG07719) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157210 CVCL_2C46 AG07725 finite cell line human CVCL_2C46 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157211 CVCL_2C47 AG07801 finite cell line human CVCL_2C47 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [82%]; 47,XY,+2 [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157212 CVCL_2C44 AG07723 finite cell line human CVCL_2C44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157213 CVCL_2C45 AG07724 finite cell line human CVCL_2C45 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 51 PDL (Coriell=AG07724) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157214 CVCL_2C48 AG07802 finite cell line human CVCL_2C48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157215 CVCL_2C49 AG07803 finite cell line human CVCL_2C49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157216 CVCL_UI90 IFAR-900/1 transformed cell line human CVCL_UI90 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn372His (c.1114A>C) (1342C>A); ClinVar=VCV000009329; Zygosity=Heterozygous (PubMed=15004464); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn863Lysfs*18 (c.2588dupA) (2816insA); ClinVar=VCV000037793; Zygosity=Heterozygous (PubMed=15004464) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21157217 CVCL_UI91 IFAR-632/2 transformed cell line human CVCL_UI91 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.631+1G>A (IVS7+1G>A); ClinVar=VCV000009348; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=15004464); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1894Ter (c.5682C>G) (5910C>G); ClinVar=VCV000037989; Zygosity=Heterozygous (PubMed=15004464) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21157218 CVCL_UI94 SB1690CB cancer cell line human CVCL_UI94 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.631+2T>G (IVS7+2T>G); ClinVar=VCV000009349; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=15645491); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (PubMed=15645491) Derived from sampling site: Peripheral blood. Male 21157219 CVCL_UI95 HNES2 embryonic stem cell human CVCL_UI95 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21157220 CVCL_UI92 AV036 transformed cell line human CVCL_UI92 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.631+2T>G (IVS7+2T>G); ClinVar=VCV000009349; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=15645491); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (PubMed=15645491) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21157221 CVCL_UI93 SB1685CB cancer cell line human CVCL_UI93 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.631+2T>G (IVS7+2T>G); ClinVar=VCV000009349; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=15645491); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (PubMed=15645491) Derived from sampling site: Bone marrow. Male 21157222 CVCL_UI98 FM cancer cell line human CVCL_UI98 CL:0000010 Male 21157223 CVCL_UI99 RT [Human] cancer cell line human CVCL_UI99 CL:0000010 Male 21157224 CVCL_UI96 HNES4 embryonic stem cell human CVCL_UI96 From: University of Cambridge; Cambridge; United Kingdom. CL:0000010 Male 21157225 CVCL_UI97 JT cancer cell line human CVCL_UI97 CL:0000010 Male 21157226 CVCL_2C53 AG07998 finite cell line human CVCL_2C53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG07998); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157227 CVCL_2C54 AG07999 finite cell line human CVCL_2C54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.5 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157228 CVCL_2C51 AG07996 finite cell line human CVCL_2C51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [2%]; 46,XY,inv(8)(p2?;q2?) [98%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG07996) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157229 CVCL_2C52 AG07997 finite cell line human CVCL_2C52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157230 CVCL_2C57 AG08046 finite cell line human CVCL_2C57 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 40 PDL (Coriell=AG08046) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157231 CVCL_2C58 AG08047 finite cell line human CVCL_2C58 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG08047) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157232 CVCL_2C55 AG08000 finite cell line human CVCL_2C55 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG08000) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157233 CVCL_2C56 AG08045 finite cell line human CVCL_2C56 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [86%]; 45,X [4%]; 46,XY,t(5;6)(p15;q23) [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157234 CVCL_2C59 AG08048 finite cell line human CVCL_2C59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157235 CVCL_UI80 PCi-ASI1 induced pluripotent stem cell human CVCL_UI80 From: Phenocell SAS; Grasse; France CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21157236 CVCL_UI83 CJ cancer cell line human CVCL_UI83 CL:0000010 Female 21157237 CVCL_UI84 HF cancer cell line human CVCL_UI84 CL:0000010 Derived from sampling site: Pleural effusion. Male 21157238 CVCL_UI81 PCi-CAU1 induced pluripotent stem cell human CVCL_UI81 From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21157239 CVCL_UI82 MDA-EJ-1 cancer cell line human CVCL_UI82 CL:0000010 Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: 24 hours (PubMed=12808126) 21157240 CVCL_UI87 OVCAR-5-CisR cancer cell line human CVCL_UI87 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Genome sequenced Female Problematic cell line: Possibly misclassified Parent cell line (OVCAR-5) was originally thought to be a high grade ovarian serous adenocarcinoma but suspected to have a upper gastrointestinal origin. 21157241 CVCL_UI88 SKOV3-CisR cancer cell line human CVCL_UI88 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female 21157242 CVCL_UI85 RR cancer cell line human CVCL_UI85 CL:0000010 Male 21157243 CVCL_UI86 hTERT A41hBAT-SVF telomerase immortalized cell line human CVCL_UI86 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brown adipose tissue. Male Doubling time: 48-72 hours (ATCC=CRL-3385) 21157244 CVCL_UI89 IFAR-772/1 transformed cell line human CVCL_UI89 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val220Ilefs*4 (c.658_659delGT) (886delGT); ClinVar=VCV000009342; Zygosity=Heterozygous (PubMed=15004464); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Leu2740Ter (c.8219T>A) (8447T>A); ClinVar=VCV000009343; Zygosity=Heterozygous (PubMed=15004464) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21157245 CVCL_2C50 AG07804 finite cell line human CVCL_2C50 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 45,X [4%]; 45,XY,-17 [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157246 CVCL_2C20 AG07136 finite cell line human CVCL_2C20 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG07136) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157247 CVCL_2C21 AG07137 finite cell line human CVCL_2C21 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [66%]; 46,XY,t(1;17)(p22;q12) [34%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG07137) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157248 CVCL_2C24 AG07141 finite cell line human CVCL_2C24 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 28 PDL (Coriell=AG07141) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157249 CVCL_2C25 AG07144 finite cell line human CVCL_2C25 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG07144) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157250 CVCL_2C22 AG07139 finite cell line human CVCL_2C22 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 34 PDL (Coriell=AG07139) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157251 CVCL_2C23 AG07140 finite cell line human CVCL_2C23 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [88%]; 46,XX,t(4;12)(4pter->4q21::12q13->12qter;12pter->12q13::4q21->4qter) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 32 PDL (Coriell=AG07140) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157252 CVCL_2C28 AG07306 finite cell line human CVCL_2C28 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157253 CVCL_2C29 AG07309 finite cell line human CVCL_2C29 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [33]; 46,XX,t(2;5)(2pter->2q35::5p11->5pter;5qter->5p11::2q35->2qter) [17] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157254 CVCL_2C26 AG07302 finite cell line human CVCL_2C26 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (Coriell=AG07302) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157255 CVCL_2C27 AG07303 finite cell line human CVCL_2C27 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [80%]; 46,XX,t(8;15)(q11;q15) [14%]; 46,XX,t(15;19)(q15;p13.3) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157256 CVCL_UI72 hTERT NF1 ipNF05.5 (Mixed clones) telomerase immortalized cell line human CVCL_UI72 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu1153Thrfs*42 (c.3456dupA) (3456_3457insA); ClinVar=VCV000656975; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Population: Caucasian; Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~59 hours (ATCC=CRL-3387) 21157257 CVCL_UI73 hTERT NF1 ipnNF09.4 telomerase immortalized cell line human CVCL_UI73 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu1153Thrfs*42 (c.3456dupA) (3456_3457insA); ClinVar=VCV000656975; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Caucasian Male 21157258 CVCL_UI70 hTERT NF1 ipNF95.6 telomerase immortalized cell line human CVCL_UI70 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg816Ter (c.2446C>T); ClinVar=VCV000280055; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg2258Ter (c.6772C>T) (R2237*); ClinVar=VCV000230389; Zygosity=Heterozygous; Note=Somatic (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~32.7 hours (ATCC=CRL-3389) 21157259 CVCL_UI71 hTERT NF1 ipNF05.5 telomerase immortalized cell line human CVCL_UI71 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu1153Thrfs*42 (c.3456dupA) (3456_3457insA); ClinVar=VCV000656975; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~59 hours (ATCC=CRL-3388) Caution: This cell line was also termed 'ipNF05.5 (single clone)', but this is a misnomer as this cell line is not clonal (personal communication Allaway R.J.) 21157260 CVCL_UI76 hTERT NF1 ipNF00.6 telomerase immortalized cell line human CVCL_UI76 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Female 21157261 CVCL_UI77 hTERT NF1 ipNF03.3 telomerase immortalized cell line human CVCL_UI77 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1423Lys (c.4269G>A); ClinVar=VCV000423536; Zygosity=Heterozygous; Note=Exon skipping mutation Germline (PubMed=27617404).; Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Male 21157262 CVCL_UI74 hTERT NF1 ipNF06.2A telomerase immortalized cell line human CVCL_UI74 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gly848Trp (c.2542G>T); Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21157263 CVCL_UI75 hTERT NF1 sipnNF95.12B telomerase immortalized cell line human CVCL_UI75 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu216Pro (c.647T>C); ClinVar=VCV000068360; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21157264 CVCL_UI78 hTERT NF1 ipNF04.4 telomerase immortalized cell line human CVCL_UI78 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg2258Ter (c.6772C>T) (R2237*); ClinVar=VCV000230389; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21157265 CVCL_UI79 PCi-AFR1 induced pluripotent stem cell human CVCL_UI79 From: Phenocell SAS; Grasse; France CL:0000010 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21157266 CVCL_2C31 AG07471 finite cell line human CVCL_2C31 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 44 PDL (PubMed=9724752); 42 PDL (Coriell=AG07471) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157267 CVCL_2C32 AG07472 finite cell line human CVCL_2C32 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [48%]; 46,XX,t(6;14)(6pter->6q22.2::14p11.2->14pter;14qter->14p11.2::6q22.2->6qter) [52%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 47 PDL (Coriell=AG07472) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157268 CVCL_2C30 AG07310 finite cell line human CVCL_2C30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,16qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 38 PDL (Coriell=AG07310) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157269 CVCL_2C35 AG07476 finite cell line human CVCL_2C35 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157270 CVCL_2C36 AG07477 finite cell line human CVCL_2C36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 33 PDL (Coriell=AG07477) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157271 CVCL_2C33 AG07473 finite cell line human CVCL_2C33 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 45 PDL (Coriell=AG07473) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157272 CVCL_2C34 AG07475 finite cell line human CVCL_2C34 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157273 CVCL_2C39 AG07715 finite cell line human CVCL_2C39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157274 CVCL_2C37 AG07478 finite cell line human CVCL_2C37 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 35 PDL (Coriell=AG07478) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157275 CVCL_2C38 AG07479 finite cell line human CVCL_2C38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,22s+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157276 CVCL_UI61 BET-3K transformed cell line human CVCL_UI61 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. 21157277 CVCL_UI62 BFT-3B transformed cell line human CVCL_UI62 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus Cell type=Fibroblast.. 21157278 CVCL_UI60 PCIi005-A induced pluripotent stem cell human CVCL_UI60 From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21157279 CVCL_UI65 hTERT SC ipn02.8 telomerase immortalized cell line human CVCL_UI65 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Female 21157280 CVCL_UI66 hTERT SC ipn97.4 telomerase immortalized cell line human CVCL_UI66 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21157281 CVCL_UI63 BFT-3K transformed cell line human CVCL_UI63 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus Cell type=Fibroblast.. 21157282 CVCL_UI64 hTERT SC ipn02.3 2lambda telomerase immortalized cell line human CVCL_UI64 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 38.8 hours (ATCC=CRL-3392) 21157283 CVCL_UI69 hTERT NF1 ipnNF95.11c telomerase immortalized cell line human CVCL_UI69 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Thr586Valfs*18 (c.1756_1759delACTA) (1756delACTA); ClinVar=VCV000186215; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~33.5 hours (ATCC=CRL-3391) 21157284 CVCL_UI67 hTERT NF1 ipNF95.11b C telomerase immortalized cell line human CVCL_UI67 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Thr586Valfs*18 (c.1756_1759delACTA) (1756delACTA); ClinVar=VCV000186215; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~32.7 hours (ATCC=CRL-3390) 21157285 CVCL_UI68 hTERT NF1 ipNF95.11b C/T telomerase immortalized cell line human CVCL_UI68 CL:0000010 Sequence variation: Gene deletion; HGNC; 7765; NF1; Zygosity=Heterozygous; Note=Somatic LOH (PubMed=27617404); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Thr586Valfs*18 (c.1756_1759delACTA) (1756delACTA); ClinVar=VCV000186215; Zygosity=Heterozygous; Note=Germline (PubMed=27617404); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male 21157286 CVCL_2C02 AG06880 finite cell line human CVCL_2C02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG06880) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157287 CVCL_2C03 AG06882 finite cell line human CVCL_2C03 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG06882) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157288 CVCL_2C00 AG06878 finite cell line human CVCL_2C00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 53 PDL (Coriell=AG06878) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157289 CVCL_2C01 AG06879 finite cell line human CVCL_2C01 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG06879) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157290 CVCL_2C06 AG06886 finite cell line human CVCL_2C06 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG06886) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157291 CVCL_2C07 AG06952 finite cell line human CVCL_2C07 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 40 PDL (PubMed=9724752); Doubling time: 2.4 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157292 CVCL_2C04 AG06883 finite cell line human CVCL_2C04 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [80%]; 46,XY,t(9;21)(q34;q21) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 51 PDL (Coriell=AG06883) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157293 CVCL_2C05 AG06885 finite cell line human CVCL_2C05 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG06885) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157294 CVCL_2C08 AG06953 finite cell line human CVCL_2C08 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG06953) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157295 CVCL_2C09 AG06956 finite cell line human CVCL_2C09 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 50 PDL (Coriell=AG06956) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157296 CVCL_UI50 SU-Ph2 cancer cell line human CVCL_UI50 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=18783828) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: 30-48 hours (PubMed=18783828) 21157297 CVCL_UI51 SU/SR cancer cell line human CVCL_UI51 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=18783828); Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (PubMed=18783828) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Bone marrow. Female 21157298 CVCL_UI54 L-KUM cancer cell line human CVCL_UI54 CL:0000010 Population: Japanese. 21157299 CVCL_UI55 L-MEG cancer cell line human CVCL_UI55 CL:0000010 Population: Japanese. 21157300 CVCL_UI52 L-HIRO cancer cell line human CVCL_UI52 CL:0000010 Population: Japanese. 21157301 CVCL_UI53 L-KAZ cancer cell line human CVCL_UI53 CL:0000010 Population: Japanese. 21157302 CVCL_UI58 PCIi003-A induced pluripotent stem cell human CVCL_UI58 From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21157303 CVCL_UI59 PCIi004-A induced pluripotent stem cell human CVCL_UI59 From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Male 21157304 CVCL_UI56 PCIi001-A induced pluripotent stem cell human CVCL_UI56 From: Phenocell SAS; Grasse; France CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21157305 CVCL_UI57 PCIi002-A induced pluripotent stem cell human CVCL_UI57 From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: hPSCreg; PCIi002-A; true Female 21157306 CVCL_2C10 AG06957 finite cell line human CVCL_2C10 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 45,X [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 50 PDL (Coriell=AG06957) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157307 CVCL_2C13 AG07118 finite cell line human CVCL_2C13 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157308 CVCL_2C14 AG07119 finite cell line human CVCL_2C14 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 23 PDL (Coriell=AG07119) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157309 CVCL_2C11 AG06959 finite cell line human CVCL_2C11 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG06959) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157310 CVCL_2C12 AG06962 finite cell line human CVCL_2C12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157311 CVCL_2C17 AG07122 finite cell line human CVCL_2C17 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [39]; 46,XX,add(14)(?::p13>qter) [11] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157312 CVCL_2C18 AG07123 finite cell line human CVCL_2C18 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,9qh+,16qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG07123) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157313 CVCL_2C15 AG07120 finite cell line human CVCL_2C15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,1qh-,16qh+ (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 42 PDL (Coriell=AG07120) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157314 CVCL_2C16 AG07121 finite cell line human CVCL_2C16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,9qh+ [49]; 46,XX,9qh+,del(10)(qter->p13) [1] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157315 CVCL_2C19 AG07124 finite cell line human CVCL_2C19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [78%]; 47,XX,+8; [12%]; 48,XX,+8,+20 [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157316 CVCL_UI40 U-HO1-PTPN1 cancer cell line human CVCL_UI40 CL:0000010 Sequence variation: Mutation; HGNC; 9642; PTPN1; Unexplicit; Ex2-8del; Zygosity=Unspecified (CelloPub=CLPUB00457); Transfected with: HGNC; 9642; PTPN1 Derived from sampling site: Pleural effusion. Male 21157317 CVCL_UI43 MGC-803/TA cancer cell line human CVCL_UI43 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol) Omics: Secretome proteome analysis by 2D-DE/MS. Male Problematic cell line: Possibly contaminated Parent cell lines (MGC-803) seems to be a derivative of HeLa and another cell of unknown origin. The STR profile of MGC-803 is highly similar to that of HeLa yet shows some specific differences that suggest a possible hybrid cell line. 21157318 CVCL_UI44 TSE.06 cancer cell line human CVCL_UI44 CL:0000010 Derived from sampling site: Breast. Female Characteristics: Adapted to glutamine deprivation 21157319 CVCL_UI41 MGC-803/5FU cancer cell line human CVCL_UI41 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Omics: Secretome proteome analysis by 2D-DE/MS. Male Problematic cell line: Possibly contaminated Parent cell lines (MGC-803) seems to be a derivative of HeLa and another cell of unknown origin. The STR profile of MGC-803 is highly similar to that of HeLa yet shows some specific differences that suggest a possible hybrid cell line. 21157320 CVCL_UI42 MGC-803/DDP cancer cell line human CVCL_UI42 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Omics: Secretome proteome analysis by 2D-DE/MS. Male Problematic cell line: Possibly contaminated Parent cell lines (MGC-803) seems to be a derivative of HeLa and another cell of unknown origin. The STR profile of MGC-803 is highly similar to that of HeLa yet shows some specific differences that suggest a possible hybrid cell line. 21157321 CVCL_UI47 BRG-H hybridoma human CVCL_UI47 CL:0000010 Monoclonal antibody isotype: IgM. 21157322 CVCL_UI48 AML10 cancer cell line human CVCL_UI48 CL:0000010 Sequence variation: Mutation; HGNC; 12440; TYK2; Simple; p.Arg243Trp (c.727C>T); ClinVar=VCV000890826; Zygosity=Unspecified (PubMed=22675565). 21157323 CVCL_UI45 MI 5G spontaneously immortalized cell line CVCL_UI45 CL:0000010 Female Doubling time: ~24 hours (DOI=10.1007/BF02624448). Group: Nematode cell line 21157324 CVCL_UI46 MI 8C spontaneously immortalized cell line CVCL_UI46 CL:0000010 Female Doubling time: ~96 hours (DOI=10.1007/BF02624448). Group: Nematode cell line 21157325 CVCL_UI49 CV-hIPS-B-control APP KO clone 151 induced pluripotent stem cell human CVCL_UI49 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: Control cell line for the APP KO cell line derived from CV-hIPS-B Have been transfected with CAS9 and guide RNA but have not been edited. 21157326 CVCL_M091 CaOV cancer cell line human CVCL_M091 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00035 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4472134; PubMed=20143388). 21157327 CVCL_M092 T-9 cancer cell line human CVCL_M092 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00096 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4472134; PubMed=20143388). Originally thought to be a derivative of WI-38. 21157328 CVCL_M090 SKOV-3/RFP cancer cell line human CVCL_M090 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: Cell_Biolabs; AKR-253; probable Female 21157329 CVCL_UI32 FM3.P cancer cell line human CVCL_UI32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Right inguinal lymph node. Female 21157330 CVCL_UI33 FM28.4 cancer cell line human CVCL_UI33 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Skin. Male 21157331 CVCL_UI30 FM97 cancer cell line human CVCL_UI30 CL:0000010 Unspecified 21157332 CVCL_UI31 FM3.D cancer cell line human CVCL_UI31 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Right inguinal lymph node. Female 21157333 CVCL_UI36 2nFC spontaneously immortalized cell line CVCL_UI36 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: 36.6 hours (PubMed=30017856) Group: Fish cell line 21157334 CVCL_M088 WM1 [Human Waldenstrom macroglobulinemia] cancer cell line human CVCL_M088 CL:0000010 Derived from sampling site: Peripheral blood. 21157335 CVCL_UI37 3nFC spontaneously immortalized cell line CVCL_UI37 CL:0000010 Karyotypic information: Triploid karyotype; Derived from sampling site: Caudal fin; Breed/subspecies: (Carassius auratus langsdorfii x Cyprinus carpio) x Carassius auratus langsdorfii. Unspecified Doubling time: 38.9 hours (PubMed=30017856) Group: Fish cell line 21157336 CVCL_M089 SKOV-3/Luc cancer cell line human CVCL_M089 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 21157337 CVCL_UI34 FM91.2 cancer cell line human CVCL_UI34 CL:0000010 Unspecified 21157338 CVCL_M086 MWCL-1 cancer cell line human CVCL_M086 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=23321251); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (PubMed=21415268) Derived from sampling site: Bone marrow. Omics: Array-based CGH Male 21157339 CVCL_UI35 FM91.5 cancer cell line human CVCL_UI35 CL:0000010 Unspecified 21157340 CVCL_M087 RPCI-WM1 cancer cell line human CVCL_M087 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=22812491) Derived from sampling site: Lymph node. Female Doubling time: ~34 hours (PubMed=22812491) 21157341 CVCL_M084 SV68c-IS transformed cell line house mouse CVCL_M084 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: ICR. Male 21157342 CVCL_M085 JX-G cancer cell line human CVCL_M085 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female 21157343 CVCL_UI38 4nFC spontaneously immortalized cell line CVCL_UI38 CL:0000010 Karyotypic information: Tetraploid karyotype; Derived from sampling site: Caudal fin; Breed/subspecies: Carassius auratus langsdorfii x Cyprinus carpio. Unspecified Doubling time: 41.3 hours (PubMed=30017856) Group: Fish cell line 21157344 CVCL_M082 MFBY2 spontaneously immortalized cell line Norway rat CVCL_M082 CL:0000010 Derived from sampling site: Liver Cell type=Myofibroblast.; Breed/subspecies: Wistar. Male 21157345 CVCL_M083 T-HSC/Cl-6 transformed cell line Norway rat CVCL_M083 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Sprague Dawley. Unspecified 21157346 CVCL_UI39 THK-72 cancer cell line human CVCL_UI39 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgG kappa Doubling time: ~40-80 hours (CelloPub=CLPUB00456) 21157347 CVCL_UI21 CV-hIPS-F induced pluripotent stem cell human CVCL_UI21 CL:0000010 Anecdotal: Established from Craig Venter fibroblasts Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21157348 CVCL_UI22 CV-hIPS-B-APP-KO clone 1B6 induced pluripotent stem cell human CVCL_UI22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21157349 CVCL_UI20 GM13720 transformed cell line human CVCL_UI20 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Unspecified (PubMed=16166284) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM13720; probable 21157350 CVCL_M099 BRC-230 cancer cell line human CVCL_M099 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000954591; Zygosity=Unspecified (PubMed=10841287). Female Doubling time: 30.5 hours (PubMed=8018954); Microsatellite instability: Stable (MSS) (PubMed=12661003) 21157351 CVCL_UI25 GT-1 telomerase immortalized cell line human CVCL_UI25 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 21157352 CVCL_UI26 PA-1 [Human dental papilla] transformed cell line human CVCL_UI26 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth bud; dental papilla. Unspecified 21157353 CVCL_M097 JHC-2 cancer cell line human CVCL_M097 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157354 CVCL_UI23 UCSD237i-APP1-2 APPnull induced pluripotent stem cell human CVCL_UI23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157355 CVCL_UI24 DP-1 transformed cell line human CVCL_UI24 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Tooth; dental pulp. Unspecified 21157356 CVCL_M098 MLO-Y4 transformed cell line house mouse CVCL_M098 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; long bone Cell type=Osteocyte.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 Bgla promoter T-Ag transgenic. Unspecified Characteristics: Useful to study effects of fluid flow and substrate stretching on activation of osteocyte-specific signaling pathways (Kerafast) Doubling time: 15.8 hours (CelloPub=CLPUB00625) Group: Patented cell line; Group: Space-flown cell line (cellonaut); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12161 21157357 CVCL_UI29 FM94 cancer cell line human CVCL_UI29 CL:0000010 Unspecified Characteristics: Very highly pigmented. 21157358 CVCL_M095 hTERT TIGKs telomerase immortalized cell line human CVCL_M095 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; gingiva Cell type=Keratinocyte.. Male Doubling time: 1 week (ATCC=CRL-3397) 21157359 CVCL_M096 KB-R cancer cell line human CVCL_M096 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21157360 CVCL_M093 JHC cancer cell line human CVCL_M093 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00069 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=11178; PubMed=6451928; PubMed=20143388). Originally thought to be a normal placenta cell line. 21157361 CVCL_UI27 PLT-1 transformed cell line human CVCL_UI27 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Tooth; periodontal ligament. Unspecified 21157362 CVCL_M094 M10T cancer cell line human CVCL_M094 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00076 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=20143388). 21157363 CVCL_UI28 RT7 transformed cell line human CVCL_UI28 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity Cell type=Keratinocyte.. Male 21157364 CVCL_D704 17-94 cancer cell line human CVCL_D704 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=22749038) Derived from sampling site: Kidney. Female Doubling time: ~1 week (DSMZ=ACC-741) 21157365 CVCL_CV04 ND23823 transformed cell line human CVCL_CV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157366 CVCL_D705 KMS-11R cancer cell line human CVCL_D705 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: AZ12908010; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa 21157367 CVCL_CV05 ND23829 transformed cell line human CVCL_CV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157368 CVCL_CV02 ND23799 transformed cell line human CVCL_CV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157369 CVCL_D702 SK-MEL-11 cancer cell line human CVCL_D702 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Male 21157370 CVCL_CV03 ND23802 transformed cell line human CVCL_CV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157371 CVCL_D703 OV-1847 cancer cell line human CVCL_D703 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00467 Problematic cell line: Contaminated Shown to be a OVCAR-8 derivative (PubMed=22710073). 21157372 CVCL_D708 L835 cancer cell line human CVCL_D708 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22928481); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (PubMed=22928481) Miscellaneous: STR profile from personal communication of Cleton-Jansen A.-M Derived from metastatic site: Bone; left distal radius. Omics: Array-based CGH Male 21157373 CVCL_CV08 ND23926 transformed cell line human CVCL_CV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157374 CVCL_D709 MD901 cancer cell line human CVCL_D709 CL:0000010 Miscellaneous: Originally assigned to be from a Burkitt lymphoma Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21157375 CVCL_CV09 ND24057 transformed cell line human CVCL_CV09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157376 CVCL_D706 L2975 cancer cell line human CVCL_D706 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22928481); Sequence variation: Mutation; HGNC; 5383; IDH2; Simple; p.Arg172Trp (c.514A>T); ClinVar=VCV000376438; Zygosity=Heterozygous (PubMed=22057234; PubMed=22928481) Miscellaneous: STR profile from personal communication of Cleton-Jansen A.-M Derived from metastatic site: Bone; spine. Omics: Array-based CGH Male 21157377 CVCL_CV06 ND23835 transformed cell line human CVCL_CV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157378 CVCL_D707 L3252 cancer cell line human CVCL_D707 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22928481) Miscellaneous: STR profile from personal communication of Cleton-Jansen A.-M Derived from sampling site: Bone; rib. Omics: Array-based CGH Female 21157379 CVCL_CV07 ND23873 transformed cell line human CVCL_CV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157380 CVCL_CV00 ND23777 transformed cell line human CVCL_CV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157381 CVCL_D700 FM3A SX9 cancer cell line house mouse CVCL_D700 CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Leu3191Pro (c.9572T>C); Zygosity=Unspecified (PubMed=9582343) Selected for resistance to: NCIt; C17262; X-Ray; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Radiation-sensitive The parent cell line was irradiated with 2 Gy and this clone was hypersensitive to X-ray killing (PubMed=2426230). Doubling time: 17.7 hours (PubMed=2426230); 20 hours (PubMed=7528891) 21157382 CVCL_CV01 ND23795 transformed cell line human CVCL_CV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157383 CVCL_D701 SK-MG-26 cancer cell line human CVCL_D701 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21157384 CVCL_2C86 AG09150 finite cell line human CVCL_2C86 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157385 CVCL_2C87 AG09156 finite cell line human CVCL_2C87 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 46 PDL (Coriell=AG09156) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157386 CVCL_2C84 AG09148 finite cell line human CVCL_2C84 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157387 CVCL_2C85 AG09149 finite cell line human CVCL_2C85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157388 CVCL_2C88 AG09157 finite cell line human CVCL_2C88 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 53 PDL (Coriell=AG09157) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157389 CVCL_2C89 AG09158 finite cell line human CVCL_2C89 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157390 CVCL_2C82 AG08908 finite cell line human CVCL_2C82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157391 CVCL_2C83 AG09147 finite cell line human CVCL_2C83 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [30%]; 46,XY,t(2;12)(p23;q21) [70%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG09147) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157392 CVCL_2C80 AG08905 finite cell line human CVCL_2C80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG08905) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157393 CVCL_2C81 AG08906 finite cell line human CVCL_2C81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG08906) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157394 CVCL_2C97 AG09268 finite cell line human CVCL_2C97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [82%]; 46,XY,t(4;19)(4pter->4q32::19q13->19qter;19pter->19q13::4q32->4qter) [18%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157395 CVCL_2C98 AG09269 finite cell line human CVCL_2C98 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG09269) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157396 CVCL_2C95 AG09266 finite cell line human CVCL_2C95 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [84%]; 46,XY,t(1;17)(q21;q21) [2%]; 46,XY,t(1;17)(q21;q21),t(11;16)(q13;q13) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157397 CVCL_2C96 AG09267 finite cell line human CVCL_2C96 CL:0000010 Population: Chinese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157398 CVCL_2C99 AG09270 finite cell line human CVCL_2C99 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [62%]; 45,X [38%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG09270) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157399 CVCL_2C90 AG09159 finite cell line human CVCL_2C90 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157400 CVCL_2C93 AG09224 finite cell line human CVCL_2C93 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(3;14)(3pter->3q23::14q13->14qter;14pter->14q13::3q23->3qter) [5]; 46,XX [45] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157401 CVCL_2C94 AG09225 finite cell line human CVCL_2C94 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 23 PDL (Coriell=AG09225) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157402 CVCL_2C91 AG09160 finite cell line human CVCL_2C91 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG09160) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157403 CVCL_2C92 AG09162 finite cell line human CVCL_2C92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 54 PDL (Coriell=AG09162) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157404 CVCL_2C64 AG08432 finite cell line human CVCL_2C64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157405 CVCL_2C65 AG08434 finite cell line human CVCL_2C65 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 51 PDL (Coriell=AG08434) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157406 CVCL_2C62 AG08430 finite cell line human CVCL_2C62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157407 CVCL_2C63 AG08431 finite cell line human CVCL_2C63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [8%]; 46,XY,t(1;10)(q12;q26),t(13;15)(q22;p13) [92%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157408 CVCL_2C68 AG08789 finite cell line human CVCL_2C68 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG08789) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157409 CVCL_2C69 AG08790 finite cell line human CVCL_2C69 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157410 CVCL_2C66 AG08442 finite cell line human CVCL_2C66 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157411 CVCL_2C67 AG08692 finite cell line human CVCL_2C67 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [80%]; 46,XX,t(4;7)(q31.3;q32),t(5;6)(p15.3;p21.3) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 35 PDL (Coriell=AG08692) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157412 CVCL_2C60 AG08049 finite cell line human CVCL_2C60 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157413 CVCL_2C61 AG08050 finite cell line human CVCL_2C61 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [83%]; 46,XX,t(7;20)(7pter->7q22::20p13->20pter;20qter->20p13::7q22->7qter) [17%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 30 PDL (Coriell=AG08050) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157414 CVCL_2C75 AG08818 finite cell line human CVCL_2C75 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(2;7)(p25;q31) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG08818) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157415 CVCL_2C76 AG08819 finite cell line human CVCL_2C76 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(6;12;22)(6pter->6q12::12q12->12q13::22q13.1->22qter::12pter->12q12::6q12->6qter;22pter->22q13.1::12q13->12qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG08819) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157416 CVCL_2C73 AG08815 finite cell line human CVCL_2C73 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG08815) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157417 CVCL_2C74 AG08816 finite cell line human CVCL_2C74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG08815) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157418 CVCL_2C79 AG08904 finite cell line human CVCL_2C79 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 43 PDL (Coriell=AG08904) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157419 CVCL_2C77 AG08902 finite cell line human CVCL_2C77 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG08902) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157420 CVCL_2C78 AG08903 finite cell line human CVCL_2C78 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [18%]; 45,X [82%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG08903) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157421 CVCL_2C71 AG08792 finite cell line human CVCL_2C71 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(1)(pter->p34::p31->p34::p31->qter) [47]; 46,XY [3] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157422 CVCL_2C72 AG08793 finite cell line human CVCL_2C72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG08793) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157423 CVCL_2C70 AG08791 finite cell line human CVCL_2C70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157424 CVCL_CU58 ND22772 transformed cell line human CVCL_CU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157425 CVCL_D658 NUTOS cancer cell line human CVCL_D658 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=20712710) Population: Japanese; Derived from sampling site: Oral cavity; tongue. Female Doubling time: 14.1 hours (PubMed=20712710) 21157426 CVCL_D659 20.6.5 hybridoma Norway rat CVCL_D659 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta 2. 21157427 CVCL_CU59 ND22773 transformed cell line human CVCL_CU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157428 CVCL_D652 AW 13516 cancer cell line human CVCL_D652 CL:0000010 Population: Indian Male Doubling time: 35.5 hours (PubMed=1691185). 21157429 CVCL_CU52 ND22624 transformed cell line human CVCL_CU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157430 CVCL_D653 AW 8507 cancer cell line human CVCL_D653 CL:0000010 Population: Indian Male Doubling time: 31.9 hours (PubMed=1691185). 21157431 CVCL_CU53 ND22625 transformed cell line human CVCL_CU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157432 CVCL_D650 N2aSW cancer cell line house mouse CVCL_D650 CL:0000010 Transfected with: HGNC; 620; APP (with p.Lys670Asn and p.Met671Leu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: A/J. Male 21157433 CVCL_CU50 ND22570 transformed cell line human CVCL_CU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157434 CVCL_D651 AW 10498 cancer cell line human CVCL_D651 CL:0000010 Population: Indian Female Doubling time: 52.2 hours (PubMed=1691185). 21157435 CVCL_CU51 ND22584 transformed cell line human CVCL_CU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157436 CVCL_CU56 ND22701 transformed cell line human CVCL_CU56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157437 CVCL_D656 USC-HN1 cancer cell line human CVCL_D656 CL:0000010 Discontinued: ATCC; CRL-3026; probable. Female Doubling time: 18 hours (PubMed=20175927) 21157438 CVCL_D657 KMS-4 cancer cell line human CVCL_D657 CL:0000010 Population: Japanese; Derived from metastatic site: Right supraclavicular lymph node. Female 21157439 CVCL_CU57 ND22749 transformed cell line human CVCL_CU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157440 CVCL_D654 AW 9803 cancer cell line human CVCL_D654 CL:0000010 Population: Indian; Derived from sampling site: Oral cavity; retromolar trigone. Male Doubling time: 66 hours (PubMed=1691185) 21157441 CVCL_CU54 ND22635 transformed cell line human CVCL_CU54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157442 CVCL_D655 BcaCD885 cancer cell line human CVCL_D655 CL:0000010 Population: Chinese. 21157443 CVCL_CU55 ND22647 transformed cell line human CVCL_CU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157444 CVCL_D669 KJ 23 hybridoma Norway rat CVCL_D669 CL:0000010 Discontinued: BCRJ; 0134; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-17 21157445 CVCL_CU69 ND23169 transformed cell line human CVCL_CU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157446 CVCL_D663 44-22-1 hybridoma Norway rat CVCL_D663 CL:0000010 Monoclonal antibody isotype: IgG2a. 21157447 CVCL_CU63 ND22843 transformed cell line human CVCL_CU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157448 CVCL_D664 AA4.1 hybridoma Norway rat CVCL_D664 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; O89103; Mouse Cd93. 21157449 CVCL_CU64 ND22976 transformed cell line human CVCL_CU64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157450 CVCL_D661 35 E 10 hybridoma Norway rat CVCL_D661 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01587; Mouse Csf2. 21157451 CVCL_CU61 ND22833 transformed cell line human CVCL_CU61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157452 CVCL_D662 3A10 [Rat hybridoma against mouse TcR gamma-delta] hybridoma Norway rat CVCL_D662 CL:0000010 Monoclonal antibody target: Mouse T cell receptor (TcR) gamma-delta. 21157453 CVCL_CU62 ND22841 transformed cell line human CVCL_CU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157454 CVCL_D667 H57 hybridoma Norway rat CVCL_D667 CL:0000010 Monoclonal antibody target: Mouse T cell receptor (TcR). Doubling time: ~24-30 hours (BCRJ) 21157455 CVCL_CU67 ND23153 transformed cell line human CVCL_CU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157456 CVCL_D668 KJ 16 hybridoma Norway rat CVCL_D668 CL:0000010 Discontinued: BCRJ; 0133; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-8.1/8.2 21157457 CVCL_CU68 ND23159 transformed cell line human CVCL_CU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157458 CVCL_D665 F23.1 hybridoma Norway rat CVCL_D665 CL:0000010 Discontinued: BCRJ; 0083; probable. Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-8 21157459 CVCL_CU65 ND22987 transformed cell line human CVCL_CU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157460 CVCL_D666 F23.2 hybridoma Norway rat CVCL_D666 CL:0000010 Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-8. 21157461 CVCL_CU66 ND22991 transformed cell line human CVCL_CU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157462 CVCL_D660 25-9-17S hybridoma house mouse CVCL_D660 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21157463 CVCL_CU60 ND22777 transformed cell line human CVCL_CU60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157464 CVCL_CU38 ND22107 transformed cell line human CVCL_CU38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157465 CVCL_D638 P388/CPT45 cancer cell line house mouse CVCL_D638 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21157466 CVCL_D639 DU145/RC1 cancer cell line human CVCL_D639 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg364His (c.1091G>A); Zygosity=Homozygous (PubMed=11280753); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90225; Rubitecan (Orathecin; Derived from metastatic site: Brain. Male 21157467 CVCL_CU39 ND22108 transformed cell line human CVCL_CU39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157468 CVCL_CU36 ND22102 transformed cell line human CVCL_CU36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157469 CVCL_D636 RzM6 cancer cell line human CVCL_D636 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21157470 CVCL_CU37 ND22105 transformed cell line human CVCL_CU37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157471 CVCL_D637 RzM6-LC cancer cell line human CVCL_D637 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21157472 CVCL_D630 M-07 cancer cell line human CVCL_D630 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: IL3 dependent 21157473 CVCL_CU30 ND22055 transformed cell line human CVCL_CU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157474 CVCL_D631 AO cancer cell line human CVCL_D631 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00033 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4472134; PubMed=20143388). 21157475 CVCL_CU31 ND22067 transformed cell line human CVCL_CU31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157476 CVCL_D634 mtop2beta-6 transformed cell line house mouse CVCL_D634 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:98791; Top2b Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21157477 CVCL_CU34 ND22099 transformed cell line human CVCL_CU34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157478 CVCL_D635 B6SUtA1 factor-dependent cell line house mouse CVCL_D635 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: B6.S. Characteristics: CSF2 and IL3 dependent 21157479 CVCL_CU35 ND22100 transformed cell line human CVCL_CU35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157480 CVCL_D632 mTOP2beta-4 transformed cell line house mouse CVCL_D632 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21157481 CVCL_CU32 ND22086 transformed cell line human CVCL_CU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157482 CVCL_D633 mtop2beta-5 transformed cell line house mouse CVCL_D633 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:98791; Top2b Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21157483 CVCL_CU33 ND22094 transformed cell line human CVCL_CU33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157484 CVCL_D649 N2aEGFP cancer cell line house mouse CVCL_D649 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: A/J. Male 21157485 CVCL_CU49 ND22532 transformed cell line human CVCL_CU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157486 CVCL_D647 15PC3 cancer cell line human CVCL_D647 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from sampling site: Prostate. Male 21157487 CVCL_CU47 ND22247 transformed cell line human CVCL_CU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157488 CVCL_D648 Mel120 cancer cell line human CVCL_D648 CL:0000010 21157489 CVCL_CU48 ND22499 transformed cell line human CVCL_CU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157490 CVCL_CU41 ND22136 transformed cell line human CVCL_CU41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157491 CVCL_D641 P388/amsacrine cancer cell line house mouse CVCL_D641 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21157492 CVCL_CU42 ND22138 transformed cell line human CVCL_CU42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157493 CVCL_D642 P388/A20 cancer cell line house mouse CVCL_D642 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21157494 CVCL_CU40 ND22126 transformed cell line human CVCL_CU40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157495 CVCL_D640 P388/S cancer cell line house mouse CVCL_D640 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21157496 CVCL_D645 Col 2 cancer cell line human CVCL_D645 CL:0000010 21157497 CVCL_CU45 ND22181 transformed cell line human CVCL_CU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157498 CVCL_CU46 ND22224 transformed cell line human CVCL_CU46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157499 CVCL_D646 UML-49 transformed cell line human CVCL_D646 CL:0000010 Miscellaneous: Only mentioned as a lymphoblastoid cell line in PubMed=20413351. Unspecified 21157500 CVCL_CU43 ND22162 transformed cell line human CVCL_CU43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157501 CVCL_D643 P388/WT20 cancer cell line house mouse CVCL_D643 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21157502 CVCL_D644 KBH5.0 cancer cell line human CVCL_D644 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:51232; 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole (Hoechst 33342; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21157503 CVCL_CU44 ND22172 transformed cell line human CVCL_CU44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157504 CVCL_D616 GI-103 cancer cell line human CVCL_D616 CL:0000010 Derived from metastatic site: Ascites. Unspecified 21157505 CVCL_CU16 ND21872 transformed cell line human CVCL_CU16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157506 CVCL_D617 GI-112 cancer cell line human CVCL_D617 CL:0000010 Female 21157507 CVCL_CU17 ND21890 transformed cell line human CVCL_CU17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157508 CVCL_D614 IAR 6-7 spontaneously immortalized cell line Norway rat CVCL_D614 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157509 CVCL_CU14 ND21856 transformed cell line human CVCL_CU14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157510 CVCL_D615 Expi293F transformed cell line human CVCL_D615 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21157511 CVCL_CU15 ND21871 transformed cell line human CVCL_CU15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157512 CVCL_D618 GI-117 cancer cell line human CVCL_D618 CL:0000010 Female 21157513 CVCL_CU18 ND21891 transformed cell line human CVCL_CU18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157514 CVCL_D619 A2780/CDDP cancer cell line human CVCL_D619 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21157515 CVCL_CU19 ND21892 transformed cell line human CVCL_CU19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157516 CVCL_D612 IAR 6 finite cell line Norway rat CVCL_D612 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157517 CVCL_CU12 ND21845 transformed cell line human CVCL_CU12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157518 CVCL_D613 IAR 6-1 transformed cell line Norway rat CVCL_D613 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157519 CVCL_CU13 ND21846 transformed cell line human CVCL_CU13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157520 CVCL_D610 IAR 27F spontaneously immortalized cell line Norway rat CVCL_D610 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157521 CVCL_CU10 ND21803 transformed cell line human CVCL_CU10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157522 CVCL_D611 IAR 2-28 transformed cell line Norway rat CVCL_D611 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157523 CVCL_CU11 ND21805 transformed cell line human CVCL_CU11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157524 CVCL_CU27 ND22035 transformed cell line human CVCL_CU27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157525 CVCL_D627 Panc02 cancer cell line house mouse CVCL_D627 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6. Male 21157526 CVCL_CU28 ND22037 transformed cell line human CVCL_CU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157527 CVCL_D628 Panc02-H7 cancer cell line house mouse CVCL_D628 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Pancreas; Breed/subspecies: C57BL/6. Male 21157528 CVCL_CU25 ND21957 transformed cell line human CVCL_CU25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157529 CVCL_D625 UAMS-33 spontaneously immortalized cell line house mouse CVCL_D625 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: SAMR1. Unspecified 21157530 CVCL_CU26 ND21982 transformed cell line human CVCL_CU26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157531 CVCL_D626 OB-6 spontaneously immortalized cell line house mouse CVCL_D626 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: SAMR1. Unspecified 21157532 CVCL_CU29 ND22051 transformed cell line human CVCL_CU29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157533 CVCL_D629 TTE1 conditionally immortalized cell line house mouse CVCL_D629 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Male Characteristics: Proliferates at the permissive temperature (33 Celsius) Growth is signicantly prevented at the nonpermissive temperature (39 Celsius) (PubMed=11789682). Doubling time: 24 hours (PubMed=11789682) 21157534 CVCL_D620 A2780/CBP cancer cell line human CVCL_D620 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from sampling site: Ovary. Female 21157535 CVCL_CU20 ND21898 transformed cell line human CVCL_CU20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157536 CVCL_CU23 ND21954 transformed cell line human CVCL_CU23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157537 CVCL_D623 XC-v cancer cell line Norway rat CVCL_D623 CL:0000010 Breed/subspecies: White-Weston. 21157538 CVCL_CU24 ND21955 transformed cell line human CVCL_CU24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157539 CVCL_D624 UAMS-32 spontaneously immortalized cell line house mouse CVCL_D624 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: SAMR1. Unspecified 21157540 CVCL_CU21 ND21914 transformed cell line human CVCL_CU21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157541 CVCL_D621 SK-OV-3/CBP cancer cell line human CVCL_D621 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Ascites. Female 21157542 CVCL_CU22 ND21915 transformed cell line human CVCL_CU22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157543 CVCL_D622 SK-OV-3/CDDP cancer cell line human CVCL_D622 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female 21157544 CVCL_D605 JJ012 cancer cell line human CVCL_D605 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,05:01 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19787792); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Gly (c.394C>G); ClinVar=VCV000375892; Zygosity=Heterozygous (PubMed=22057234; PubMed=26368816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Val (c.596G>T); ClinVar=VCV000451799; Zygosity=Unspecified (PubMed=19787792) Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 0.9 day (PubMed=12168675) 21157545 CVCL_CU05 ND21709 transformed cell line human CVCL_CU05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157546 CVCL_CU06 ND21718 transformed cell line human CVCL_CU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157547 CVCL_D603 FreeStyle 293-F transformed cell line human CVCL_D603 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5080 21157548 CVCL_CU03 ND21687 transformed cell line human CVCL_CU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157549 CVCL_D604 FreeStyle CHO-S spontaneously immortalized cell line CVCL_D604 CL:0000010 Derived from sampling site: Ovary. Female 21157550 CVCL_CU04 ND21688 transformed cell line human CVCL_CU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157551 CVCL_D609 IAR 27E spontaneously immortalized cell line Norway rat CVCL_D609 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157552 CVCL_CU09 ND21773 transformed cell line human CVCL_CU09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157553 CVCL_D607 COLO 16 cancer cell line human CVCL_D607 CL:0000010 Miscellaneous: STR profile from personal communication of Korch C Population: African American; Derived from metastatic site: Not specified. Female 21157554 CVCL_CU07 ND21747 transformed cell line human CVCL_CU07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157555 CVCL_D608 IAR 2-19 transformed cell line Norway rat CVCL_D608 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21157556 CVCL_CU08 ND21754 transformed cell line human CVCL_CU08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157557 CVCL_D601 H4-APP751 cancer cell line human CVCL_D601 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 620; APP Population: Caucasian; Derived from sampling site: Brain. Male 21157558 CVCL_CU01 ND21672 transformed cell line human CVCL_CU01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157559 CVCL_D602 36B10 cancer cell line Norway rat CVCL_D602 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995). 21157560 CVCL_CU02 ND21680 transformed cell line human CVCL_CU02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157561 CVCL_D600 KB-C2 cancer cell line human CVCL_D600 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21157562 CVCL_CU00 ND21624 transformed cell line human CVCL_CU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157563 CVCL_M070 2427T cancer cell line human CVCL_M070 CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Discontinued: CLS; 300167; true Female 21157564 CVCL_UI09 L6Cl5 transformed cell line Norway rat CVCL_UI09 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157565 CVCL_UI10 L6Cl6 transformed cell line Norway rat CVCL_UI10 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157566 CVCL_UI11 L6Cl1V20 transformed cell line Norway rat CVCL_UI11 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157567 CVCL_M068 2106LN cancer cell line human CVCL_M068 CL:0000010 Population: Caucasian; Derived from metastatic site: Lymph node. Discontinued: CLS; 300166; true Male 21157568 CVCL_M069 2106T cancer cell line human CVCL_M069 CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Male 21157569 CVCL_M066 H-59 [Mouse lung] cancer cell line house mouse CVCL_M066 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Metastatic primarily to the liver but also to the lung (PubMed=3697987) 21157570 CVCL_UI14 L6Cl6V1 transformed cell line Norway rat CVCL_UI14 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157571 CVCL_UI15 L6Cl6V3 transformed cell line Norway rat CVCL_UI15 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157572 CVCL_M067 MN9D hybrid cell line house mouse CVCL_M067 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Extensively used to model dopaminergic neurons and to test mechanisms and potential therapeutics relevant to the loss of DA neurons in Parkinson's disease (Millipore); Characteristics: Fusion of N18TG2 with rostral mesencephalic neurons from a 14-day-old C57BL/6J mouse embryo (PubMed=1913182) 21157573 CVCL_UI12 L6Cl2V1 transformed cell line Norway rat CVCL_UI12 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157574 CVCL_M064 M-3LL cancer cell line house mouse CVCL_M064 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Developed from a lung metastasis of the parent cell line Metastatic specifically to the lung (PubMed=3697987). 21157575 CVCL_UI13 L6Cl5V1 transformed cell line Norway rat CVCL_UI13 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157576 CVCL_M065 M-27 cancer cell line house mouse CVCL_M065 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Metastatic specifically to the lung (PubMed=3697987) 21157577 CVCL_M062 CC1 [Mouse hybridoma against bovine PTPRC] hybridoma house mouse CVCL_M062 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; F1MJS9; Bovine PTPRC/CD45. 21157578 CVCL_UI18 L6Cl6V6 transformed cell line Norway rat CVCL_UI18 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157579 CVCL_UI19 GM14260 transformed cell line human CVCL_UI19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM14260; probable 21157580 CVCL_M063 H-3LL cancer cell line house mouse CVCL_M063 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Developed from a spontaneous hepatic metastasis of the parent cell line Metastatic primarily to the liver (PubMed=3697987). 21157581 CVCL_UI16 L6Cl6V4 transformed cell line Norway rat CVCL_UI16 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157582 CVCL_M060 PC-3/nKR cancer cell line human CVCL_M060 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Omics: Secretome proteome analysis Male Characteristics: Compared to the parent cell line, has an increased cell migration capability and a higher number of invaded cell Established from nude mice that were implanted with the parent cell line without anti-NK treatment. 21157583 CVCL_M061 BT-20/nKR cancer cell line human CVCL_M061 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro539Arg (c.1616C>G); ClinVar=VCV000376243; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ile388Ser (c.1163T>G); ClinVar=VCV000665312; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Pro515Leu (c.1544C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Gln (c.394A>C); ClinVar=VCV000376628; Zygosity=Homozygous (from parent cell line). Population: Caucasian Female Group: Triple negative breast cancer (TNBC) cell line 21157584 CVCL_UI17 L6Cl6V5 transformed cell line Norway rat CVCL_UI17 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157585 CVCL_M080 V79-8HG- spontaneously immortalized cell line CVCL_M080 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21157586 CVCL_M081 T95-45D cancer cell line human CVCL_M081 From: Center for Medical Genetics; Ghent; Belgium. CL:0000010 21157587 CVCL_UI00 MCH075 finite cell line human CVCL_UI00 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21157588 CVCL_M079 V79-8 spontaneously immortalized cell line CVCL_M079 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21157589 CVCL_M077 HCC366 BL transformed cell line human CVCL_M077 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: ~15-24 hours (DSMZ=ACC-895) 21157590 CVCL_UI03 WG3354 finite cell line human CVCL_UI03 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Ser146Argfs*35 (c.435_436delAT); ClinVar=VCV001455466; Zygosity=Homozygous (PubMed=19447654) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21157591 CVCL_M078 AD94LEBV transformed cell line human CVCL_M078 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;17)(p11.2;p13.2)mat (CLDB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157592 CVCL_UI04 MCH057 finite cell line human CVCL_UI04 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157593 CVCL_M075 OCI-Ly5 cancer cell line human CVCL_M075 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Lymph node. 21157594 CVCL_UI01 WG1801 finite cell line human CVCL_UI01 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Arg73Ter (c.217C>T); ClinVar=VCV000203825; Zygosity=Homozygous (PubMed=19447654) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157595 CVCL_M076 OCI-Ly16 cancer cell line human CVCL_M076 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Miscellaneous: Cell line has been lost (PubMed=3567358) Derived from sampling site: Lymph node. 21157596 CVCL_UI02 WG2176 finite cell line human CVCL_UI02 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; c.1-234A>G; Zygosity=Heterozygous (PubMed=19447654); Sequence variation: Mutation; HGNC; 24525; MMACHC; Simple; p.Trp203Ter (c.609G>A); ClinVar=VCV000030800; Zygosity=Heterozygous (PubMed=19447654) Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157597 CVCL_UI07 L6Cl1 transformed cell line Norway rat CVCL_UI07 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157598 CVCL_M073 OCI-Ly14 cancer cell line human CVCL_M073 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Lymph node. 21157599 CVCL_UI08 L6Cl2 transformed cell line Norway rat CVCL_UI08 CL:0000010 Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21157600 CVCL_M074 OCI-Ly15 cancer cell line human CVCL_M074 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Bone marrow. 21157601 CVCL_M071 OCI-Ly11 cancer cell line human CVCL_M071 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Lymph node. 21157602 CVCL_UI05 WG0730 finite cell line human CVCL_UI05 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157603 CVCL_M072 OCI-Ly13.1 cancer cell line human CVCL_M072 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Derived from sampling site: Bone marrow. Female 21157604 CVCL_UI06 WG0729 finite cell line human CVCL_UI06 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157605 CVCL_M048 CC32 hybridoma house mouse CVCL_M048 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P98131; Bovine SELL/CD62L. 21157606 CVCL_M049 CC94 hybridoma house mouse CVCL_M049 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q24LN2; Bovine ITGAM/CD11b. 21157607 CVCL_M046 L180/1 hybridoma house mouse CVCL_M046 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5QG77; Sheep CD58. 21157608 CVCL_M047 CC104 hybridoma house mouse CVCL_M047 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q24LN2; Bovine ITGAM/CD11b. 21157609 CVCL_M044 ED4 hybridoma house mouse CVCL_M044 CL:0000010 Monoclonal antibody isotype: IgG1. 21157610 CVCL_M045 F12 hybridoma house mouse CVCL_M045 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q06304; Aeromonas sobria asa1 (aerolysin/hemolysin). 21157611 CVCL_M042 ED8 hybridoma house mouse CVCL_M042 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9JI30; Rat Itgam/Cd11b. 21157612 CVCL_M043 ED9 hybridoma house mouse CVCL_M043 CL:0000010 Monoclonal antibody isotype: IgG1. 21157613 CVCL_M040 ED17 hybridoma house mouse CVCL_M040 CL:0000010 Monoclonal antibody isotype: IgG1. 21157614 CVCL_M041 ED7 hybridoma house mouse CVCL_M041 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9JI30; Rat Itgam/Cd11b. 21157615 CVCL_M059 MTV/TM-011 hybrid cell line house mouse CVCL_M059 CL:0000010 21157616 CVCL_M057 MTV-L/BALB cancer cell line house mouse CVCL_M057 CL:0000010 Breed/subspecies: BALB/c. Female 21157617 CVCL_M058 MTV-L/BALB CL2 cancer cell line house mouse CVCL_M058 CL:0000010 Breed/subspecies: BALB/c. Discontinued: KCLB; 60056; probable Female 21157618 CVCL_M056 3J1 transformed cell line house mouse CVCL_M056 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21157619 CVCL_M053 NM-M2/TC cancer cell line Norway rat CVCL_M053 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21157620 CVCL_M051 FL.1 hybridoma house mouse CVCL_M051 CL:0000010 Monoclonal antibody isotype: IgG2b. 21157621 CVCL_M052 7C2 [Mouse hybridoma against sheep CD8A] hybridoma house mouse CVCL_M052 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; W5QHT2; Sheep CD8A. 21157622 CVCL_M050 CC76A hybridoma house mouse CVCL_M050 CL:0000010 Monoclonal antibody isotype: IgG1. 21157623 CVCL_CU96 ND23667 transformed cell line human CVCL_CU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157624 CVCL_D696 UV-2237M-ADMR cancer cell line house mouse CVCL_D696 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: C3H/HeN. Female 21157625 CVCL_D697 FEK finite cell line CVCL_D697 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: BCRJ; 0088; probable Unspecified 21157626 CVCL_CU97 ND23682 transformed cell line human CVCL_CU97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157627 CVCL_CU94 ND23651 transformed cell line human CVCL_CU94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157628 CVCL_D694 PALL-1 cancer cell line human CVCL_D694 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8428799; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Caution: Indicated as originating from a 23 year old male patient in PubMed=2732004 and from a 20 year old male patient in PubMed=8428799 21157629 CVCL_CU95 ND23666 transformed cell line human CVCL_CU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157630 CVCL_D695 Par-C5 transformed cell line Norway rat CVCL_D695 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; parotid gland; Breed/subspecies: Sprague Dawley. Male 21157631 CVCL_D698 LHY-821 cancer cell line human CVCL_D698 CL:0000010 Population: Chinese; Derived from sampling site: Endometrium. Female Doubling time: 44.6-47.7 hours (PubMed=22806968) 21157632 CVCL_CU98 ND23758 transformed cell line human CVCL_CU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157633 CVCL_D699 A99 cancer cell line human CVCL_D699 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Leu (c.34_35GG>CT) (c.34_35delinsCT); Zygosity=Homozygous (PubMed=21768923); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Thr (c.379T>A); ClinVar=VCV000824232; Zygosity=Homozygous (PubMed=21768923) Derived from metastatic site: Liver. Female Characteristics: Established from a nude mice xenograft Tumorigenic (PubMed=21768923). 21157634 CVCL_CU99 ND23766 transformed cell line human CVCL_CU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157635 CVCL_M028 347C2b/D4 hybridoma house mouse CVCL_M028 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18103; Escherichia coli K99 fanC. 21157636 CVCL_M029 7.4.C4 hybridoma house mouse CVCL_M029 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Cell surface components expressed on leukocytes, red blood cells and vascular endothelial cells of fish. 21157637 CVCL_M026 20.76 hybridoma house mouse CVCL_M026 CL:0000010 Monoclonal antibody isotype: IgG1. 21157638 CVCL_CU92 ND23580 transformed cell line human CVCL_CU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157639 CVCL_D692 PAE551 finite cell line human CVCL_D692 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21157640 CVCL_M027 347C2 hybridoma house mouse CVCL_M027 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P18103; Escherichia coli K99 fanC. 21157641 CVCL_CU93 ND23650 transformed cell line human CVCL_CU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157642 CVCL_D693 UtE1104 finite cell line human CVCL_D693 CL:0000010 Derived from sampling site: Endometrium. Omics: DNA methylation analysis; Omics: Glycosphingolipids analysis; Omics: Transcriptome analysis by microarray Female 21157643 CVCL_M024 CCL4 cancer cell line human CVCL_M024 CL:0000010 Problematic cell line: Misclassified Originally thought to be a chordoma cell line but is either contaminated or established from nonchordoma cells (PubMed=21253487).. 21157644 CVCL_D690 MRC-5V1 transformed cell line human CVCL_D690 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21157645 CVCL_CU90 ND23527 transformed cell line human CVCL_CU90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157646 CVCL_D691 AM936EP finite cell line human CVCL_D691 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21157647 CVCL_CU91 ND23528 transformed cell line human CVCL_CU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157648 CVCL_M025 NIH3T3/13C7 transformed cell line house mouse CVCL_M025 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21157649 CVCL_M022 CM-319 cancer cell line human CVCL_M022 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~33 hours (PubMed=12839683) Problematic cell line: Contaminated Shown to be a HeLa derivative (on the basis of the STR profile of PubMed=21253487). Originally thought to originate from a 42 year old male patient with chordoma. 21157650 CVCL_M023 CCL3 undefined cell line type house mouse CVCL_M023 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00381. Problematic cell line: Misidentified Originally thought to be a human chordoma cell line but found to originate from mouse (PubMed=21253487). 21157651 CVCL_M020 CH 8 cancer cell line human CVCL_M020 CL:0000010 Derived from sampling site: Bone; lumbar spine. Unspecified 21157652 CVCL_M021 GB60 cancer cell line human CVCL_M021 CL:0000010 Problematic cell line: Misclassified Originally thought to be a chordoma cell line but is either contaminated or established from nonchordoma cells (PubMed=21253487). 21157653 CVCL_M039 ED16 hybridoma house mouse CVCL_M039 CL:0000010 Monoclonal antibody isotype: IgG1. 21157654 CVCL_M037 ED2 hybridoma house mouse CVCL_M037 CL:0000010 Monoclonal antibody isotype: IgG1. 21157655 CVCL_M038 ED3 hybridoma house mouse CVCL_M038 CL:0000010 Monoclonal antibody isotype: IgG2a. 21157656 CVCL_M035 ALF [Human gastric carcinoma] cancer cell line human CVCL_M035 CL:0000010 Miscellaneous: Only mentioned as a stomach cancer cell line in PubMed=15767549. Unspecified Part of: JFCR45 cancer cell line panel 21157657 CVCL_M036 ED1 hybridoma house mouse CVCL_M036 CL:0000010 Monoclonal antibody isotype: IgG1. 21157658 CVCL_M033 T67 cancer cell line human CVCL_M033 CL:0000010 21157659 CVCL_M034 T70 cancer cell line human CVCL_M034 CL:0000010 21157660 CVCL_M031 NTU-G cancer cell line human CVCL_M031 CL:0000010 Population: Chinese; Derived from sampling site: Pituitary gland. Female Doubling time: 88 hours (in F12 medium), 132 hours (in MCDB 151 medium) (PubMed=8473267) 21157661 CVCL_M032 TM-1 [Human astrocytoma] cancer cell line human CVCL_M032 CL:0000010 Population: Japanese; Derived from sampling site: Brain; frontal lobe. Female Doubling time: ~36 hours (PubMed=1917778) 21157662 CVCL_M030 73B hybridoma house mouse CVCL_M030 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5Q2E5; Sheep PTPRC/CD45. 21157663 CVCL_D674 MR 9.4 hybridoma house mouse CVCL_D674 CL:0000010 Discontinued: BCRJ; 0179; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-5.1/5.2 21157664 CVCL_CU74 ND23312 transformed cell line human CVCL_CU74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157665 CVCL_CU75 ND23313 transformed cell line human CVCL_CU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157666 CVCL_D675 NIH 3T3-IL-7 spontaneously immortalized cell line house mouse CVCL_D675 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21157667 CVCL_D672 MR 10.2 hybridoma house mouse CVCL_D672 CL:0000010 Discontinued: BCRJ; 0177; probable. 21157668 CVCL_CU72 ND23246 transformed cell line human CVCL_CU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157669 CVCL_D673 MR 12.4 hybridoma house mouse CVCL_D673 CL:0000010 Discontinued: BCRJ; 0178; probable. 21157670 CVCL_CU73 ND23275 transformed cell line human CVCL_CU73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157671 CVCL_CU78 ND23373 transformed cell line human CVCL_CU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157672 CVCL_D678 ST/aut finite cell line CVCL_D678 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Unspecified 21157673 CVCL_CU79 ND23401 transformed cell line human CVCL_CU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157674 CVCL_D679 RA3-6B2 hybridoma CVCL_D679 CL:0000010 Discontinued: BCRJ; 0210; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45 21157675 CVCL_CU76 ND23348 transformed cell line human CVCL_CU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157676 CVCL_D676 OP42 stromal cell line house mouse CVCL_D676 CL:0000010 Derived from sampling site: Bone marrow; stroma. 21157677 CVCL_CU77 ND23363 transformed cell line human CVCL_CU77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157678 CVCL_D677 SXC1 hybridoma CVCL_D677 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P18893; Mouse Il10. 21157679 CVCL_M008 UCRU-BL-23 cancer cell line human CVCL_M008 CL:0000010 Female 21157680 CVCL_M009 UCSD-242L cancer cell line human CVCL_M009 HLA typing: A*02:02,32:01; B*40:02,40:02; C*02:02,03:04; DQA1*01:03,03:02; DQB1*03:02,06:11; DRB1*04:04,13:01 (PubMed=26589293) CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. 21157681 CVCL_M006 JMN-1B cancer cell line human CVCL_M006 CL:0000010 Derived from sampling site: Ascites. Omics: Transcriptome analysis by microarray Male 21157682 CVCL_M007 UCRU-BL-17 cancer cell line human CVCL_M007 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Unspecified (PubMed=9246190). Female 21157683 CVCL_M004 BCS-1 cancer cell line CVCL_M004 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. Male 21157684 CVCL_D670 KJ 25 hybridoma Norway rat CVCL_D670 CL:0000010 Discontinued: BCRJ; 0135; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mouse T cell receptor (TcR) V-beta-3 21157685 CVCL_CU70 ND23174 transformed cell line human CVCL_CU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157686 CVCL_M005 JMN cancer cell line human CVCL_M005 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=1568228) Derived from sampling site: Ascites. Omics: SNP array analysis Male 21157687 CVCL_CU71 ND23175 transformed cell line human CVCL_CU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157688 CVCL_M002 CRP-4 hybridoma house mouse CVCL_M002 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02741; Human CRP. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2876 21157689 CVCL_M003 BCM-1 cancer cell line CVCL_M003 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. Male 21157690 CVCL_M000 CRP-2 hybridoma house mouse CVCL_M000 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02741; Human CRP. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2874 21157691 CVCL_M001 CRP-3 hybridoma house mouse CVCL_M001 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02741; Human CRP. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2875 21157692 CVCL_CU85 ND23468 transformed cell line human CVCL_CU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157693 CVCL_D686 MIN6N8 transformed cell line house mouse CVCL_D686 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Unspecified 21157694 CVCL_CU86 ND23490 transformed cell line human CVCL_CU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157695 CVCL_D683 HTD114 cancer cell line human CVCL_D683 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 21157696 CVCL_CU83 ND23456 transformed cell line human CVCL_CU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157697 CVCL_D684 MSK-Leuk1 cancer cell line human CVCL_D684 CL:0000010 Derived from sampling site: Oral cavity; tongue Cell type=Keratinocyte.. Female 21157698 CVCL_CU84 ND23466 transformed cell line human CVCL_CU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157699 CVCL_CU89 ND23526 transformed cell line human CVCL_CU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157700 CVCL_D689 PC3B1 cancer cell line human CVCL_D689 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21157701 CVCL_D687 FM3A F28-7 cancer cell line house mouse CVCL_D687 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21157702 CVCL_CU87 ND23501 transformed cell line human CVCL_CU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157703 CVCL_D688 FM3A FUA169 cancer cell line house mouse CVCL_D688 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Compared to the parent cell line, shows a dramatic reduction in lactosylceramide (LacCer), the presence of a ganglioside GM3 and a high activity of CMP-sialic acid:LacCer 2,3-sialosyltransferase (PubMed=7678417) 21157704 CVCL_CU88 ND23524 transformed cell line human CVCL_CU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157705 CVCL_M019 2fTGH-U2A cancer cell line human CVCL_M019 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Unresponsive to alpha and beta interferons Partially defective in response to interferon-gamma (PubMed=1906577).; Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 21157706 CVCL_M017 MESC 21 embryonic stem cell house mouse CVCL_M017 CL:0000010 Breed/subspecies: 129P2/Olac. Female 21157707 CVCL_M018 MESC 23 embryonic stem cell house mouse CVCL_M018 CL:0000010 Breed/subspecies: 129P2/Olac. Female 21157708 CVCL_D681 KB 18 cancer cell line human CVCL_D681 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21157709 CVCL_M015 MESC 19 embryonic stem cell house mouse CVCL_M015 CL:0000010 Breed/subspecies: 129P2/Olac. Male 21157710 CVCL_CU81 ND23452 transformed cell line human CVCL_CU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157711 CVCL_M016 MESC 20 embryonic stem cell house mouse CVCL_M016 CL:0000010 Breed/subspecies: 129P2/Olac. Male 21157712 CVCL_CU82 ND23453 transformed cell line human CVCL_CU82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157713 CVCL_D682 SF 181 finite cell line human CVCL_D682 CL:0000010 Male 21157714 CVCL_M013 MESC 17 embryonic stem cell house mouse CVCL_M013 CL:0000010 Breed/subspecies: C57BL/6J. Female 21157715 CVCL_D680 KB 16 cancer cell line human CVCL_D680 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21157716 CVCL_M014 MESC 18 embryonic stem cell house mouse CVCL_M014 CL:0000010 Breed/subspecies: 129P2/Olac. Male 21157717 CVCL_CU80 ND23448 transformed cell line human CVCL_CU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157718 CVCL_M011 C106 [Human rectal adenocarcinoma] cancer cell line human CVCL_M011 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1237Glufs*2 (c.3709_3710delCA); ClinVar=VCV000433651; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.His1490fs*17 (c.4469delA); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Met (c.374C>T); ClinVar=VCV000183748; Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Rectum. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053) 21157719 CVCL_M012 MESC 16 embryonic stem cell house mouse CVCL_M012 CL:0000010 Breed/subspecies: 129P2/Olac. Unspecified 21157720 CVCL_M010 UCSD-354L cancer cell line human CVCL_M010 CL:0000010 21157721 CVCL_2D63 AG11073 finite cell line human CVCL_2D63 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG11073) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157722 CVCL_2D64 AG11075 finite cell line human CVCL_2D64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG11075) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157723 CVCL_2D61 AG11020 finite cell line human CVCL_2D61 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 67 PDL (PubMed=9724752); Doubling time: 2.3 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157724 CVCL_2D62 AG11072 finite cell line human CVCL_2D62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG11072) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157725 CVCL_2D67 AG11078 finite cell line human CVCL_2D67 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG11078) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157726 CVCL_2D68 AG11079 finite cell line human CVCL_2D68 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 9 PDL (Coriell=AG11079) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157727 CVCL_2D65 AG11076 finite cell line human CVCL_2D65 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 47,XYY [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG11076) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157728 CVCL_2D66 AG11077 finite cell line human CVCL_2D66 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG11077) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157729 CVCL_2D69 AG11080 finite cell line human CVCL_2D69 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [96%]; 45,XX,-3 [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 27 PDL (Coriell=AG11080) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157730 CVCL_2D60 AG11019 finite cell line human CVCL_2D60 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157731 CVCL_2D74 AG11157 finite cell line human CVCL_2D74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157732 CVCL_2D75 AG11158 finite cell line human CVCL_2D75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG11158) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157733 CVCL_2D72 AG11154 finite cell line human CVCL_2D72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 34 PDL (Coriell=AG11154) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157734 CVCL_2D73 AG11156 finite cell line human CVCL_2D73 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG11156) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157735 CVCL_2D78 AG11161 finite cell line human CVCL_2D78 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (Coriell=AG11161) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157736 CVCL_2D79 AG11162 finite cell line human CVCL_2D79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [78%]; 46,XY,t(3;6)(q26;q16) [22%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 25 PDL (Coriell=AG11162) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157737 CVCL_2D76 AG11159 finite cell line human CVCL_2D76 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG11159) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157738 CVCL_2D77 AG11160 finite cell line human CVCL_2D77 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (Coriell=AG11160) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157739 CVCL_2D70 AG11081 finite cell line human CVCL_2D70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 45 PDL (PubMed=9724752); 44 PDL (Coriell=AG11081) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157740 CVCL_2D71 AG11153 finite cell line human CVCL_2D71 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (Coriell=AG11153) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157741 CVCL_2D41 AG10882 finite cell line human CVCL_2D41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG10882) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157742 CVCL_2D42 AG10883 finite cell line human CVCL_2D42 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157743 CVCL_2D40 AG10055 finite cell line human CVCL_2D40 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(7)t(1;7)(7pter->7q36::1q21->1qter) [2]; 46,XY [48] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157744 CVCL_2D45 AG10938 finite cell line human CVCL_2D45 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157745 CVCL_2D46 AG10939 finite cell line human CVCL_2D46 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG10939) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157746 CVCL_2D43 AG10884 finite cell line human CVCL_2D43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 33 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157747 CVCL_2D44 AG10937 finite cell line human CVCL_2D44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 25 PDL (Coriell=AG10937) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157748 CVCL_2D49 AG10942 finite cell line human CVCL_2D49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 32 PDL (Coriell=AG10942); Doubling time: 2.6 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157749 CVCL_2D47 AG10940 finite cell line human CVCL_2D47 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (Coriell=AG10940) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157750 CVCL_2D48 AG10941 finite cell line human CVCL_2D48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 46 PDL (Coriell=AG10941) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157751 CVCL_UJ90 RPMI-6467 transformed cell line human CVCL_UJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21157752 CVCL_UJ93 NLF-TrkB, clone #6 cancer cell line human CVCL_UJ93 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8032; NTRK2. Male 21157753 CVCL_UJ94 SH-SY5Y-TrkA, clone P23A cancer cell line human CVCL_UJ94 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8031; NTRK1 Population: Caucasian; Derived from metastatic site: Bone marrow. Female Doubling time: 18-24 hours (Kerafast) 21157754 CVCL_UJ91 RPMI-8767 transformed cell line human CVCL_UJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21157755 CVCL_UJ92 NLF-TrkA, clone #2 cancer cell line human CVCL_UJ92 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 8031; NTRK1. Male 21157756 CVCL_UJ97 FLF92 finite cell line human CVCL_UJ97 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 21157757 CVCL_UJ98 R2J cancer cell line human CVCL_UJ98 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=30583471); Derived from metastatic site: Cerebrospinal fluid. Male Characteristics: Tumorigenic and possesses cancer stem cells (CSC) properties (PubMed=30583471) 21157758 CVCL_UJ95 SH-SY5Y-TrkB, clone BR6 cancer cell line human CVCL_UJ95 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 8032; NTRK2 Population: Caucasian; Derived from metastatic site: Bone marrow. Female Doubling time: 18-24 hours (Kerafast) 21157759 CVCL_UJ96 SH-SY5Y-pLNCX2 empty vector cancer cell line human CVCL_UJ96 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Doubling time: 18-24 hours (Kerafast) 21157760 CVCL_UJ99 HuWa-TERT telomerase immortalized cell line CVCL_UJ99 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 25 hours (PubMed=30627956) Group: Endangered species/breed cell line; Group: Cetacean cell line 21157761 CVCL_2D52 AG10992 finite cell line human CVCL_2D52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG10992) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157762 CVCL_2D53 AG10993 finite cell line human CVCL_2D53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG10993) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157763 CVCL_2D50 AG10943 finite cell line human CVCL_2D50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 20 PDL (Coriell=AG10943) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157764 CVCL_2D51 AG10944 finite cell line human CVCL_2D51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [76%]; 46,XY,t(2;4)(2pter->2q31::4q35->4qter;4pter->4q35::2q31->2qter) [22%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG10944) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157765 CVCL_2D56 AG11014 finite cell line human CVCL_2D56 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [62%]; 45,X [10%]; 46,XY,t(2;5),t(10;11) [28%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157766 CVCL_2D57 AG11016 finite cell line human CVCL_2D57 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 32 PDL (PubMed=9724752); 36 PDL (Coriell=AG11016) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157767 CVCL_2D54 AG11011 finite cell line human CVCL_2D54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG11011) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157768 CVCL_2D55 AG11013 finite cell line human CVCL_2D55 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG11013) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157769 CVCL_2D58 AG11017 finite cell line human CVCL_2D58 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 32 PDL (Coriell=AG11017) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157770 CVCL_2D59 AG11018 finite cell line human CVCL_2D59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157771 CVCL_UJ82 ICGi008-B induced pluripotent stem cell human CVCL_UJ82 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=30851551) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157772 CVCL_UJ83 RPMI-7437 cancer cell line human CVCL_UJ83 CL:0000010 Unspecified 21157773 CVCL_UJ80 ICGi007-A induced pluripotent stem cell human CVCL_UJ80 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[47] (c.52CAG(47)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=30658253) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk (from personal communication of Grigor'eva E.V to hPSCreg).; Derived from sampling site: Peripheral blood. Female 21157774 CVCL_UJ81 ICGi008-A induced pluripotent stem cell human CVCL_UJ81 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=30851551) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157775 CVCL_UJ86 RPMI-1358 cancer cell line human CVCL_UJ86 CL:0000010 Unspecified 21157776 CVCL_UJ87 RPMI-3157 transformed cell line human CVCL_UJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21157777 CVCL_UJ84 RPMI-8265 cancer cell line human CVCL_UJ84 CL:0000010 Unspecified 21157778 CVCL_UJ85 RPMI-8337 cancer cell line human CVCL_UJ85 CL:0000010 Unspecified 21157779 CVCL_UJ88 RPMI-3287 transformed cell line human CVCL_UJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21157780 CVCL_UJ89 RPMI-4467 transformed cell line human CVCL_UJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21157781 CVCL_2D20 AG09860 finite cell line human CVCL_2D20 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157782 CVCL_2D23 AG09876 finite cell line human CVCL_2D23 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG09876) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157783 CVCL_2D24 AG09877 finite cell line human CVCL_2D24 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 47 PDL (Coriell=AG09877) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157784 CVCL_2D21 AG09861 finite cell line human CVCL_2D21 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 47 PDL (Coriell=AG09861) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157785 CVCL_2D22 AG09875 finite cell line human CVCL_2D22 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [78%]; 45,X [2%]; 45,X,add(5)(q3?) [4%]; 46,XY,t(1;3)(p1?;p2?) [12%]; 46,XY,t(2;5)(q3?;q3?) [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG09875) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157786 CVCL_2D27 AG09969 finite cell line human CVCL_2D27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG09969) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157787 CVCL_2D28 AG09970 finite cell line human CVCL_2D28 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157788 CVCL_2D25 AG09879 finite cell line human CVCL_2D25 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 34 PDL (Coriell=AG09879) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157789 CVCL_2D26 AG09968 finite cell line human CVCL_2D26 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 48 PDL (Coriell=AG09968) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157790 CVCL_2D29 AG09971 finite cell line human CVCL_2D29 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG09971) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157791 CVCL_UJ71 ESi077-A induced pluripotent stem cell human CVCL_UJ71 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Leu55Leu (c.165G>A); Zygosity=Heterozygous (PubMed=30921587) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection Caution: The second allele of D7S820 is unreadable in the cell line documentation 21157792 CVCL_UJ72 CABi002-A induced pluripotent stem cell human CVCL_UJ72 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Sequence variation: Mutation; HGNC; 21555; EYS; Simple; p.Gly1190Aspfs*39 (c.3567delA); ClinVar=VCV001065732; Zygosity=Heterozygous (PubMed=30471616); Sequence variation: Mutation; HGNC; 21555; EYS; Simple; p.Ser1610Phefs*7 (c.4829_4832delCATT); ClinVar=VCV000289905; Zygosity=Heterozygous (PubMed=30471616) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21157793 CVCL_UJ70 SEIi001-A induced pluripotent stem cell human CVCL_UJ70 From: UCLA Stein Eye Institute; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 20145; GPR143; Simple; g.25288G>A; Zygosity=Hemizygous; Note=Creates an acceptor splice site (PubMed=30513407) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157794 CVCL_UJ75 INMi001-A induced pluripotent stem cell human CVCL_UJ75 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys759Phe (c.2276G>T); ClinVar=VCV000002356; Zygosity=Heterozygous (PubMed=30453153); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Glu767Serfs*21 (c.2299delG); ClinVar=VCV000002351; Zygosity=Heterozygous (PubMed=30453153) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis Female 21157795 CVCL_UJ76 INMi002-A induced pluripotent stem cell human CVCL_UJ76 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Glu767Serfs*21 (c.2299delG); ClinVar=VCV000002351; Zygosity=Homozygous (PubMed=30468996) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis Female 21157796 CVCL_UJ73 IMEDEAi005-A induced pluripotent stem cell human CVCL_UJ73 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Pro358Leu (c.1073C>T); ClinVar=VCV000631771; Zygosity=Homozygous (PubMed=30408744) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21157797 CVCL_UJ74 IMEDEAi005-B induced pluripotent stem cell human CVCL_UJ74 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple; p.Pro358Leu (c.1073C>T); ClinVar=VCV000631771; Zygosity=Homozygous (PubMed=30408744) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21157798 CVCL_UJ79 MLi003-A induced pluripotent stem cell human CVCL_UJ79 From: Faculty of Medicine, University of Ljubljana; Ljubljana; Slovenia CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21157799 CVCL_UJ77 IRFMNi002-B induced pluripotent stem cell human CVCL_UJ77 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8616; PAX2; Simple; p.Gly189Arg (c.565G>A); ClinVar=VCV000155928; Zygosity=Heterozygous (PubMed=30399566) Derived from sampling site: Peripheral blood. Female 21157800 CVCL_UJ78 MLi002-A induced pluripotent stem cell human CVCL_UJ78 From: Faculty of Medicine, University of Ljubljana; Ljubljana; Slovenia CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Glu475Gly (c.1424A>G); ClinVar=VCV000014638; Zygosity=Heterozygous (PubMed=30933721) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21157801 CVCL_2D30 AG09974 finite cell line human CVCL_2D30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 45,X [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG09974) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157802 CVCL_2D31 AG09975 finite cell line human CVCL_2D31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [66%]; 46,Y,t(X;3)(p22;q21) [34%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157803 CVCL_2D34 AG10047 finite cell line human CVCL_2D34 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG10047) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157804 CVCL_2D35 AG10048 finite cell line human CVCL_2D35 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 21 PDL (Coriell=AG10048) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157805 CVCL_2D32 AG09977 finite cell line human CVCL_2D32 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 40 PDL (Coriell=AG09977) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157806 CVCL_2D33 AG10046 finite cell line human CVCL_2D33 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157807 CVCL_2D38 AG10053 finite cell line human CVCL_2D38 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157808 CVCL_2D39 AG10054 finite cell line human CVCL_2D39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG10054) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157809 CVCL_2D36 AG10049 finite cell line human CVCL_2D36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 36 PDL (Coriell=AG10049) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157810 CVCL_2D37 AG10052 finite cell line human CVCL_2D37 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 44 PDL (Coriell=AG10052) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157811 CVCL_UJ60 86-7 cancer cell line human CVCL_UJ60 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 6.7 days (CelloPub=CLPUB00161; PubMed=7817386) 21157812 CVCL_UJ61 86-8 cancer cell line human CVCL_UJ61 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 5.8 days (CelloPub=CLPUB00161; PubMed=7817386) 21157813 CVCL_UJ64 XB694 spontaneously immortalized cell line CVCL_UJ64 CL:0000010 Unspecified Group: Amphibian cell line. 21157814 CVCL_UJ65 RPMI-4666 cancer cell line human CVCL_UJ65 CL:0000010 Unspecified Characteristics: Produces IgA kappa. 21157815 CVCL_UJ62 86-11 cancer cell line human CVCL_UJ62 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 1 day (CelloPub=CLPUB00161; PubMed=7817386) 21157816 CVCL_UJ63 86-14 cancer cell line human CVCL_UJ63 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 5 days (CelloPub=CLPUB00161; PubMed=7817386) 21157817 CVCL_UJ68 MCCI0004i-HCM induced pluripotent stem cell human CVCL_UJ68 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Arg403Gln (c.1208G>A); ClinVar=VCV000014087; Zygosity=Heterozygous (PubMed=30508693) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21157818 CVCL_UJ69 IMGTi003-A induced pluripotent stem cell human CVCL_UJ69 From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(13) [19]; 45,XY,-13 [2]; 46,XY,-13,+mar [1] (PubMed=30500678); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21157819 CVCL_UJ66 RPMI-5866 cancer cell line human CVCL_UJ66 CL:0000010 Unspecified 21157820 CVCL_UJ67 TUSMi007-A induced pluripotent stem cell human CVCL_UJ67 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21157821 CVCL_2D01 AG09272 finite cell line human CVCL_2D01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [22%]; 46,XY,inv(16)(pter->p13.1::q12.1->p13.1::q12.1->qter) [78%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG09272) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157822 CVCL_2D02 AG09274 finite cell line human CVCL_2D02 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [10]; 46,XX,der(15)t(7;15)(15qter->15p13::7q11.2->7qter) [37]; 45,XX,der(15)t(7;15)(p13;q11.2,tf(19;19)(qter->pter::pter->qter) [3] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157823 CVCL_2D00 AG09271 finite cell line human CVCL_2D00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157824 CVCL_2D05 AG09557 finite cell line human CVCL_2D05 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157825 CVCL_2D06 AG09559 finite cell line human CVCL_2D06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [78%]; 46,XY,add(5)(q?) [22%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 43 PDL (Coriell=AG09559) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157826 CVCL_2D03 AG09555 finite cell line human CVCL_2D03 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 24 PDL (Coriell=AG09555) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157827 CVCL_2D04 AG09556 finite cell line human CVCL_2D04 CL:0000010 Population: African American; Karyotypic information: 46,XY [90%]; 45,X [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG09556) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157828 CVCL_2D09 AG09601 finite cell line human CVCL_2D09 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [48]; 47,XX,t(9;15)(9pter->q11::15p11.2->15pter;15qter->15p11.2::9q11->9qter),+20 [2] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157829 CVCL_2D07 AG09599 finite cell line human CVCL_2D07 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157830 CVCL_2D08 AG09600 finite cell line human CVCL_2D08 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [64%]; 45,X [2%]; 45,X,inv(17)(q11.2;q23) [6%]; 46,XX,inv(17)(q11.2;q23) [28%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 29 PDL (Coriell=AG09600) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157831 CVCL_UJ50 NF-HFO-1 finite cell line human CVCL_UJ50 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 +- 5 PDL (DOI=10.1016/B978-0-12-427150-0.50063-2; PubMed=4570356) 21157832 CVCL_UJ53 87-1 cancer cell line human CVCL_UJ53 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 12.1 days (CelloPub=CLPUB00161; PubMed=7817386) 21157833 CVCL_UJ54 87-2 cancer cell line human CVCL_UJ54 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 5.4 days (CelloPub=CLPUB00161; PubMed=7817386) 21157834 CVCL_UJ51 NF-HFO-3 finite cell line human CVCL_UJ51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15-20 PDL (DOI=10.1016/B978-0-12-427150-0.50063-2; PubMed=4817727) 21157835 CVCL_UJ52 87-6 cancer cell line human CVCL_UJ52 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 6.7 days (CelloPub=CLPUB00161; PubMed=7817386) 21157836 CVCL_UJ57 86-4 cancer cell line human CVCL_UJ57 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Doubling time: 7 days (CelloPub=CLPUB00161; PubMed=7817386) 21157837 CVCL_UJ58 86-5 cancer cell line human CVCL_UJ58 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 10 days (CelloPub=CLPUB00161; PubMed=7817386) 21157838 CVCL_UJ55 87-3 cancer cell line human CVCL_UJ55 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 14 days (CelloPub=CLPUB00161; PubMed=7817386) 21157839 CVCL_UJ56 87-4 cancer cell line human CVCL_UJ56 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 9.2 days (CelloPub=CLPUB00161; PubMed=7817386) 21157840 CVCL_UJ59 86-6 cancer cell line human CVCL_UJ59 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 17.7 days (CelloPub=CLPUB00161; PubMed=7817386) 21157841 CVCL_2D12 AG09697 finite cell line human CVCL_2D12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 12 PDL (Coriell=AG09697) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157842 CVCL_2D13 AG09698 finite cell line human CVCL_2D13 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG09698) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157843 CVCL_2D10 AG09603 finite cell line human CVCL_2D10 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 52 PDL (PubMed=9724752); 18 PDL (Coriell=AG09603) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157844 CVCL_2D11 AG09605 finite cell line human CVCL_2D11 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [18%]; 46,XY,t(15;19)(p11.2;p13.1),t(15;19)(q26.3;q13.1) [68%]; 46,XY,t(4;6)(p12;q13),t(11;20)(q13;p13) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 40 PDL (Coriell=AG09605) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157845 CVCL_2D16 AG09843 finite cell line human CVCL_2D16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,-10,+der(10)t(9;10)(q12;q26) [72%]; 46,XY,-10,-10,+mar(10),+mar(10) [28%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 25 PDL (Coriell=AG09843) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157846 CVCL_2D17 AG09854 finite cell line human CVCL_2D17 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;2)(p36.1;p23),t(9;18)(q32;q21.3) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 50 PDL (Coriell=AG09854) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157847 CVCL_2D14 AG09699 finite cell line human CVCL_2D14 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 41 PDL (Coriell=AG09699) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157848 CVCL_2D15 AG09701 finite cell line human CVCL_2D15 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 37 PDL (Coriell=AG09701) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157849 CVCL_2D18 AG09857 finite cell line human CVCL_2D18 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 14 PDL (Coriell=AG09857) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157850 CVCL_2D19 AG09858 finite cell line human CVCL_2D19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [76%]; 46,XX,t(1;5)(q21?;q34?) [24%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 46 PDL (Coriell=AG09858) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157851 CVCL_UJ42 C-1300 clone 7 cancer cell line house mouse CVCL_UJ42 CL:0000010 Breed/subspecies: A/J. Male 21157852 CVCL_UJ43 C-1300 clone CR1 cancer cell line house mouse CVCL_UJ43 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50095; Bucladesine (dibutyryl 3',5'-cyclic AMP); Breed/subspecies: A/J. Male 21157853 CVCL_UJ40 HT9 transformed cell line house mouse CVCL_UJ40 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus. Unspecified 21157854 CVCL_UJ41 B16-F5 cancer cell line house mouse CVCL_UJ41 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Obtained from the pulmonary melanoma module of the 5th serial passage of the B16-F0 parent cell line in C57BL/6 mice 21157855 CVCL_UJ46 GH3C1 cancer cell line Norway rat CVCL_UJ46 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21157856 CVCL_UJ47 GH3C6 cancer cell line Norway rat CVCL_UJ47 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21157857 CVCL_UJ44 C-1300 clone TR1 cancer cell line house mouse CVCL_UJ44 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Temperature resistant, grows at 40 Celsius 21157858 CVCL_UJ45 GH1-2C1 cancer cell line Norway rat CVCL_UJ45 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female 21157859 CVCL_UJ48 NCTC 3959 cancer cell line house mouse CVCL_UJ48 CL:0000010 Breed/subspecies: DBA. Discontinued: ATCC; CCL-52; true Male 21157860 CVCL_UJ49 A549/SF cancer cell line human CVCL_UJ49 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Discontinued: ATCC; CCL-185.1; true Male Group: Serum/protein free medium cell line 21157861 CVCL_CW14 LCL-PI 158 transformed cell line human CVCL_CW14 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157862 CVCL_D814 NZOV10 cancer cell line human CVCL_D814 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Phe (c.659A>T); Zygosity=Unspecified (PubMed=21912889). Female 21157863 CVCL_CW15 FS 6 cancer cell line house mouse CVCL_CW15 CL:0000010 Breed/subspecies: BALB/c. 21157864 CVCL_D815 NZM001 cancer cell line human CVCL_D815 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Obturator lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 60 hours (PubMed=7718330); 70-80 hours (CBA) 21157865 CVCL_CW12 LCL-PI 145 transformed cell line human CVCL_CW12 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157866 CVCL_D812 NZOV2 cancer cell line human CVCL_D812 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Asp (c.658T>G); ClinVar=VCV000376689; Zygosity=Unspecified (PubMed=21912889) Derived from sampling site: Ovary. Female 21157867 CVCL_CW13 LCL-PI 147 transformed cell line human CVCL_CW13 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157868 CVCL_D813 NZOV8 cancer cell line human CVCL_D813 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Unspecified (PubMed=21912889) Derived from sampling site: Ovary. Female 21157869 CVCL_CW18 LCL-PI 173 transformed cell line human CVCL_CW18 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157870 CVCL_D818 NZM012 cancer cell line human CVCL_D818 HLA typing: A*02:01,32:01; B*44:02,44:02; C*01:02,05:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23755070; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Small intestine. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25.9 hours (CelloPub=CLPUB00227); 40-42 hours (CBA) 21157871 CVCL_CW19 LCL-PI 178 transformed cell line human CVCL_CW19 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157872 CVCL_D819 NZM013 cancer cell line human CVCL_D819 HLA typing: A*02:01,03:01; B*15:01,35:01; C*03:03,04:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (PubMed=32567790) Derived from metastatic site: Neck; hypodermis. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 76.8 hours (CelloPub=CLPUB00227) 21157873 CVCL_CW16 FR37-CMT cancer cell line dog CVCL_CW16 CL:0000010 Female Doubling time: 17 hours (PubMed=27140424). 21157874 CVCL_D816 NZM010 cancer cell line human CVCL_D816 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Lung. Male 21157875 CVCL_CW17 LCL-PI 172 transformed cell line human CVCL_CW17 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157876 CVCL_D817 NZM011 cancer cell line human CVCL_D817 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=32567790) Derived from metastatic site: Hypodermis. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 5-6 days (CBA) 21157877 CVCL_CW10 LCL-PI 140 transformed cell line human CVCL_CW10 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157878 CVCL_D810 NZOV11 cancer cell line human CVCL_D810 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=21912889) Derived from sampling site: Ovary. Female 21157879 CVCL_CW11 LCL-PI 141 transformed cell line human CVCL_CW11 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157880 CVCL_D811 NZOV1 cancer cell line human CVCL_D811 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His178Thr; Zygosity=Unspecified (PubMed=21912889) Derived from metastatic site: Ascites. Female Doubling time: 65 hours (PubMed=7718330) 21157881 CVCL_D809 IMO-3C6 conditionally immortalized cell line house mouse CVCL_D809 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21157882 CVCL_CW09 LCL-PI 135 transformed cell line human CVCL_CW09 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157883 CVCL_CW25 LCL-PI 199 transformed cell line human CVCL_CW25 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157884 CVCL_D825 NZM022 cancer cell line human CVCL_D825 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Ala (c.1397G>C); ClinVar=VCV000376295; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg1362Ter (c.4084C>T); ClinVar=VCV000000344; Zygosity=Unspecified (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Doubling time: 81.4 hours (CelloPub=CLPUB00227) 21157885 CVCL_CW26 LCL-PI 200 transformed cell line human CVCL_CW26 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157886 CVCL_D826 NZM023 cancer cell line human CVCL_D826 HLA typing: A*24:02,24:02; B*44:05,44:05; C*02:02,02:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. 21157887 CVCL_CW23 LCL-PI 187 transformed cell line human CVCL_CW23 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157888 CVCL_D823 NZM002 cancer cell line human CVCL_D823 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Iliac lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 43.2 hours (CelloPub=CLPUB00227); 70 hours (CBA) 21157889 CVCL_CW24 LCL-PI 188 transformed cell line human CVCL_CW24 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157890 CVCL_D824 NZM020 cancer cell line human CVCL_D824 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Male 21157891 CVCL_CW29 LCL-PI 203 transformed cell line human CVCL_CW29 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157892 CVCL_D829 NZM030 cancer cell line human CVCL_D829 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Doubling time: 29.6 hours (CelloPub=CLPUB00227); 80-90 hours (CBA) 21157893 CVCL_CW27 LCL-PI 207 transformed cell line human CVCL_CW27 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157894 CVCL_D827 NZM024 cancer cell line human CVCL_D827 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis. Doubling time: 39.4 hours (CelloPub=CLPUB00227) 21157895 CVCL_CW28 LCL-PI 210 transformed cell line human CVCL_CW28 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157896 CVCL_D828 NZM003 cancer cell line human CVCL_D828 HLA typing: A*01:01,02:01; B*08:01,27:05; C*02:02,07:01 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790; DepMap) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40.8 hours (CelloPub=CLPUB00227); 44-48 hours (CBA) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: The results of the Sequenom MassARRAY used in PubMed=32567790 contradicts the whole exome sequencing data for BRAF and indicates a p.Val600Lys (c.1798_1799delGTinsAA) variant 21157897 CVCL_D821 NZM015 cancer cell line human CVCL_D821 HLA typing: A*02:01,11:01; B*13:02,39:01; C*06:02,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Neck; hypodermis. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21157898 CVCL_CW21 OCUP-A2 cancer cell line human CVCL_CW21 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=27067801) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 20.6 +- 1.4 hours (PubMed=27067801) 21157899 CVCL_CW22 LCL-PI 185 transformed cell line human CVCL_CW22 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157900 CVCL_D822 NZM019 cancer cell line human CVCL_D822 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 63.1 hours (CelloPub=CLPUB00227) 21157901 CVCL_D820 NZM014 cancer cell line human CVCL_D820 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Thigh; skeletal muscle. Omics: Deep exome analysis Male 21157902 CVCL_CW20 OCUP-A1 cancer cell line human CVCL_CW20 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=27067801); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=27067801); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (PubMed=27067801) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 20.6 +- 1.2 hours (PubMed=27067801) 21157903 CVCL_CW03 LCL-CB-PI 49 transformed cell line human CVCL_CW03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: NCBI_Iran; C487; probable 21157904 CVCL_D803 MCPV-8 transformed cell line CVCL_D803 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ear; inner ear; cochlea; stria vascularis. Male Doubling time: ~34 hours (PubMed=9745959) 21157905 CVCL_CW04 LCL-PI 118 transformed cell line human CVCL_CW04 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157906 CVCL_D804 MESV transformed cell line CVCL_D804 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; middle ear Cell type=Epithelial cell.. Doubling time: 21 hours (PubMed=8382213) 21157907 CVCL_CW01 LCL-PI 106 transformed cell line human CVCL_CW01 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157908 CVCL_D801 OC-k3 conditionally immortalized cell line house mouse CVCL_D801 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21157909 CVCL_CW02 LCL-PI 116 transformed cell line human CVCL_CW02 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157910 CVCL_D802 OC-k4 conditionally immortalized cell line house mouse CVCL_D802 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21157911 CVCL_CW07 Fall-3 hybridoma CVCL_CW07 CL:0000010 Discontinued: ATCC; SCRC-1009; true. Monoclonal antibody isotype: IgM 21157912 CVCL_D807 UB/UE-1 conditionally immortalized cell line house mouse CVCL_D807 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; utricular macula Cell type=Epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21157913 CVCL_CW08 L-8A cancer cell line house mouse CVCL_CW08 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6363; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21157914 CVCL_D808 UEC-4 conditionally immortalized cell line Norway rat CVCL_D808 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; utricular macula Cell type=Epithelial cell.; Breed/subspecies: Wistar. Unspecified 21157915 CVCL_CW05 LCL-PI 120 transformed cell line human CVCL_CW05 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157916 CVCL_D805 SVK-1 conditionally immortalized cell line house mouse CVCL_D805 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; stria vascularis; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: At the permissive temperature (33 Celsius) capable of rapid proliferation in the presence of interferon gamma (IFNG) At the restrictive temperature (39 Celsius) have the potential to differentiate in the absence of IFNG. 21157917 CVCL_CW06 LCL-PI 122 transformed cell line human CVCL_CW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157918 CVCL_D806 SVK-2 conditionally immortalized cell line house mouse CVCL_D806 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; stria vascularis; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: At the permissive temperature (33 Celsius) capable of rapid proliferation in the presence of interferon gamma (IFNG) At the restrictive temperature (39 Celsius) have the potential to differentiate in the absence of IFNG. 21157919 CVCL_CW00 LCL-PI 105 transformed cell line human CVCL_CW00 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157920 CVCL_D800 OC-k2 conditionally immortalized cell line house mouse CVCL_D800 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21157921 CVCL_2D85 AG11245 finite cell line human CVCL_2D85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157922 CVCL_2D86 AG11246 finite cell line human CVCL_2D86 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 31 PDL (PubMed=9724752) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157923 CVCL_2D83 AG11243 finite cell line human CVCL_2D83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG11243) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157924 CVCL_2D84 AG11244 finite cell line human CVCL_2D84 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,t(2;19)(p23;p12) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (Coriell=AG11244) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157925 CVCL_2D89 AG11356 finite cell line human CVCL_2D89 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 48 PDL (Coriell=AG11356); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157926 CVCL_2D87 AG11248 finite cell line human CVCL_2D87 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (Coriell=AG11248) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157927 CVCL_2D88 AG11249 finite cell line human CVCL_2D88 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG11249) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157928 CVCL_2D81 AG11241 finite cell line human CVCL_2D81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG11241) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157929 CVCL_2D82 AG11242 finite cell line human CVCL_2D82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG11242); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157930 CVCL_2D80 AG11240 finite cell line human CVCL_2D80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 26 PDL (PubMed=9724752); 21 PDL (Coriell=AG11240); Doubling time: Slow growth (Coriell) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157931 CVCL_2D96 AG11365 finite cell line human CVCL_2D96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG11365) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157932 CVCL_2D97 AG11481 finite cell line human CVCL_2D97 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (Coriell=AG11481) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157933 CVCL_2D94 AG11363 finite cell line human CVCL_2D94 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157934 CVCL_2D95 AG11364 finite cell line human CVCL_2D95 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Senescence: Senesces at 45 PDL (Coriell=AG11364) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157935 CVCL_2D98 AG11482 finite cell line human CVCL_2D98 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG11482) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157936 CVCL_2D99 AG11483 finite cell line human CVCL_2D99 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 28 PDL (Coriell=AG11483) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157937 CVCL_2D92 AG11361 finite cell line human CVCL_2D92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG11361) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157938 CVCL_2D93 AG11362 finite cell line human CVCL_2D93 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 24 PDL (Coriell=AG11362); Doubling time: 2.1 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157939 CVCL_2D90 AG11357 finite cell line human CVCL_2D90 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [76%]; 46,XX,-14,+mar [24%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 35 PDL (Coriell=AG11357) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157940 CVCL_2D91 AG11358 finite cell line human CVCL_2D91 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21157941 CVCL_CV79 LCL-PI 71 transformed cell line human CVCL_CV79 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157942 CVCL_D779 MOLM-13-RES cancer cell line human CVCL_D779 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:90237; Tandutinib (MLN518; Derived from sampling site: Peripheral blood. Male 21157943 CVCL_CV73 LCL-PI 62 transformed cell line human CVCL_CV73 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157944 CVCL_D773 SNUCML-02 cancer cell line human CVCL_D773 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=20438801) Population: Korean; Derived from sampling site: Bone marrow. Female Doubling time: 24 hours (PubMed=20438801) 21157945 CVCL_CV74 LCL-PI 63 transformed cell line human CVCL_CV74 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157946 CVCL_D774 SQD9 cancer cell line human CVCL_D774 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (from parent cell line) Derived from sampling site: Larynx. Male Doubling time: ~36 hours (PubMed=7938462) 21157947 CVCL_CV71 LCL-PI 57 transformed cell line human CVCL_CV71 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157948 CVCL_D771 SK-MEL-321A cancer cell line human CVCL_D771 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21157949 CVCL_CV72 LCL-PI 61 transformed cell line human CVCL_CV72 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C427 21157950 CVCL_D772 SK-MEL-210-3 cancer cell line human CVCL_D772 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21157951 CVCL_D777 11-18-GEF20-1 cancer cell line human CVCL_D777 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Unspecified 21157952 CVCL_CV77 LCL-PI 68 transformed cell line human CVCL_CV77 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157953 CVCL_CV78 LCL-PI 70 transformed cell line human CVCL_CV78 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157954 CVCL_D778 PC-9/ER1 cancer cell line human CVCL_D778 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Lymph node. Male 21157955 CVCL_LP09 GM26077 induced pluripotent stem cell human CVCL_LP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Personal Genome Project (PGP) cell line collection 21157956 CVCL_M109 JW184/2/1 hybridoma CVCL_M109 CL:0000010 Monoclonal antibody isotype: IgG4; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21157957 CVCL_CV75 LCL-PI 66 transformed cell line human CVCL_CV75 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157958 CVCL_D775 SQG6 cancer cell line human CVCL_D775 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (from parent cell line) Derived from sampling site: Larynx. Male Doubling time: ~36 hours (PubMed=7938462) 21157959 CVCL_D776 11-18-GEF10-1 cancer cell line human CVCL_D776 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Unspecified 21157960 CVCL_CV76 LCL-PI 67 transformed cell line human CVCL_CV76 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157961 CVCL_LP07 GM25930 finite cell line human CVCL_LP07 CL:0000010 Population: Caucasian; Derived from sampling site: Esophagus Cell type=Fibroblast.. Male 21157962 CVCL_M107 H97-102.11.3 hybridoma house mouse CVCL_M107 CL:0000010 Monoclonal antibody isotype: IgG2a. 21157963 CVCL_LP08 GM25992 transformed cell line human CVCL_LP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157964 CVCL_M108 JW183/5/1 hybridoma CVCL_M108 CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21157965 CVCL_LP05 GM25591 transformed cell line human CVCL_LP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157966 CVCL_M105 H83-82.6.1 hybridoma house mouse CVCL_M105 CL:0000010 Discontinued: ECACC; 85062102; probable. 21157967 CVCL_LP06 GM25592 transformed cell line human CVCL_LP06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157968 CVCL_M106 H9-14.8 hybridoma house mouse CVCL_M106 CL:0000010 Monoclonal antibody isotype: IgG2a. 21157969 CVCL_LP03 GM25588 transformed cell line human CVCL_LP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157970 CVCL_M103 NFSC spontaneously immortalized cell line Norway rat CVCL_M103 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21157971 CVCL_M104 CFSC spontaneously immortalized cell line Norway rat CVCL_M104 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21157972 CVCL_LP04 GM25590 transformed cell line human CVCL_LP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157973 CVCL_CV70 LCL-PI 56 transformed cell line human CVCL_CV70 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157974 CVCL_D770 M375 cancer cell line human CVCL_D770 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21157975 CVCL_LP01 GM25584 transformed cell line human CVCL_LP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157976 CVCL_M101 HSC 180 undefined cell line type human CVCL_M101 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Unspecified 21157977 CVCL_LP02 GM25587 transformed cell line human CVCL_LP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157978 CVCL_M102 hTERT-HSC telomerase immortalized cell line human CVCL_M102 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Unspecified 21157979 CVCL_M100 BSMZ cancer cell line human CVCL_M100 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 27 hours, at 120th passage (PubMed=1356615) 21157980 CVCL_LP00 HROBMC01 T0 M4 cancer cell line human CVCL_LP00 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Female Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21157981 CVCL_D784 Hs 621.T cancer cell line human CVCL_D784 CL:0000010 Discontinued: ATCC; CRL-7384; true. Male Doubling time: 18-20 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21157982 CVCL_CV84 LCL-PI 81 transformed cell line human CVCL_CV84 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157983 CVCL_D785 JoN cancer cell line human CVCL_D785 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 33 hours (PubMed=2156601; PubMed=2903136) 21157984 CVCL_CV85 LCL-PI 82 transformed cell line human CVCL_CV85 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157985 CVCL_D782 Hs 456.T cancer cell line human CVCL_D782 CL:0000010 Discontinued: ATCC; CRL-7806; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21157986 CVCL_CV82 LCL-PI 76 transformed cell line human CVCL_CV82 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157987 CVCL_D783 Hs 467.T cancer cell line human CVCL_D783 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7809; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21157988 CVCL_CV83 LCL-PI 79 transformed cell line human CVCL_CV83 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21157989 CVCL_D788 HAL cancer cell line human CVCL_D788 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=19787792). Male 21157990 CVCL_CV88 LCL-PI 85 transformed cell line human CVCL_CV88 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157991 CVCL_CV89 LCL-PI 87 transformed cell line human CVCL_CV89 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157992 CVCL_D789 MA-10 cancer cell line house mouse CVCL_D789 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: C57BL/6J. Male 21157993 CVCL_D786 JoN HDF cancer cell line human CVCL_D786 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 26 hours (PubMed=2903136) 21157994 CVCL_CV86 LCL-PI 83 transformed cell line human CVCL_CV86 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21157995 CVCL_D787 JoN LDF cancer cell line human CVCL_D787 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 36 hours (PubMed=2903136) 21157996 CVCL_CV87 LCL-PI 84 transformed cell line human CVCL_CV87 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: There seem to be 3 distinct cell lines which were assigned NCBI_Iran catalog number C422 21157997 CVCL_LP18 Keck MirKO ES cell line Mir124-2 embryonic stem cell house mouse CVCL_LP18 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618700; Mir124a-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21157998 CVCL_M118 UD-SCC-7A cancer cell line human CVCL_M118 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=18487078). 21157999 CVCL_LP19 Keck MirKO ES cell line Mir124a-3 embryonic stem cell house mouse CVCL_LP19 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618704; Mir124a-3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158000 CVCL_M119 UD-SCC-7B cancer cell line human CVCL_M119 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=18487078). 21158001 CVCL_M116 BSC spontaneously immortalized cell line Norway rat CVCL_M116 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21158002 CVCL_LP16 Keck MirKO ES cell line Mir100 embryonic stem cell house mouse CVCL_LP16 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619057; Mir100 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158003 CVCL_M117 BSC-C10 spontaneously immortalized cell line Norway rat CVCL_M117 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male Doubling time: 40-48 hours (CelloPub=CLPUB00024) 21158004 CVCL_LP17 Keck MirKO ES cell line Mir10b embryonic stem cell house mouse CVCL_LP17 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676804; Mir10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158005 CVCL_LP14 GM26191 transformed cell line human CVCL_LP14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158006 CVCL_CV80 LCL-PI 73 transformed cell line human CVCL_CV80 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158007 CVCL_M114 M1-4HSC spontaneously immortalized cell line house mouse CVCL_M114 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Male 21158008 CVCL_D780 MOLM-13-RES-AC cancer cell line human CVCL_D780 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:90217; Quizartinib (AC220); Selected for resistance to: ChEBI; CHEBI:90237; Tandutinib (MLN518; Derived from sampling site: Peripheral blood. Male 21158009 CVCL_LP15 GM25144 transformed cell line human CVCL_LP15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158010 CVCL_M115 GRX spontaneously immortalized cell line house mouse CVCL_M115 CL:0000010 Derived from sampling site: Liver (Note=From a granulomatous inflammation) Cell type=Hepatic stellate cell.; Breed/subspecies: C3H/HeN. Unspecified Characteristics: Established from fibrotic granulomas induced in C3H/HeN mice liver by experimental infection with Schistosoma mansoni (PubMed=2126187) 21158011 CVCL_CV81 LCL-PI 74 transformed cell line human CVCL_CV81 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158012 CVCL_D781 MGH-mcc1 cancer cell line human CVCL_D781 CL:0000010 Male 21158013 CVCL_M112 FS6-14.13 Ag2.1 hybridoma house mouse CVCL_M112 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Characteristics: T-cell hybridoma Produces IL2 when stimulated by concanavalin A (ConA) (from parent cell line). Group: Hybridoma fusion partner cell line 21158014 CVCL_LP12 GM26107 induced pluripotent stem cell human CVCL_LP12 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Personal Genome Project (PGP) cell line collection 21158015 CVCL_M113 A7 [Mouse stellate] conditionally immortalized cell line house mouse CVCL_M113 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21158016 CVCL_LP13 GM26190 transformed cell line human CVCL_LP13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158017 CVCL_LP10 GM26267 transformed cell line human CVCL_LP10 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Glu95Aspfs*32 (c.285_286delGC); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Lys215Met (c.644A>T); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158018 CVCL_M110 JW393/A hybridoma CVCL_M110 CL:0000010 Monoclonal antibody isotype: IgA2; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21158019 CVCL_LP11 GM26105 induced pluripotent stem cell human CVCL_LP11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Personal Genome Project (PGP) cell line collection 21158020 CVCL_M111 JW8/5/13 hybridoma CVCL_M111 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: ChEBI; CHEBI:53793; (4-hydroxy-3-nitrophenyl)acetyl group (NP). 21158021 CVCL_CV59 LCL-PI 29 transformed cell line human CVCL_CV59 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158022 CVCL_D759 M263 cancer cell line human CVCL_D759 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=20406486); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 23.3 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158023 CVCL_CV57 LCL-PI 25 transformed cell line human CVCL_CV57 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C426 21158024 CVCL_D757 M257 cancer cell line human CVCL_D757 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Doubling time: 31.4 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158025 CVCL_CV58 LCL-PI 28 transformed cell line human CVCL_CV58 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158026 CVCL_D758 M262 cancer cell line human CVCL_D758 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=20406486) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 47.4 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158027 CVCL_CV51 LCL-PI 54 [From normal adult female] transformed cell line human CVCL_CV51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Caution: There seem to be two distinct cell lines which were assigned by NCBI_Iran the name LCL-PI 54 21158028 CVCL_D751 M238 cancer cell line human CVCL_D751 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965) Omics: Protein expression by reverse-phase protein arrays. Unspecified Doubling time: 28.1 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158029 CVCL_CV52 LCL-PI 9 transformed cell line human CVCL_CV52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158030 CVCL_D752 M243 cancer cell line human CVCL_D752 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Tyr (c.94G>T); ClinVar=VCV000017581; Zygosity=Unspecified (PubMed=25645078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Homozygous (PubMed=25645078); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu353Gly (c.1058A>G) (p.Glu156Gly, c.467A>G); ClinVar=VCV000237638; Zygosity=Heterozygous (PubMed=25645078). Unspecified 21158031 CVCL_D750 M233 cancer cell line human CVCL_D750 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20406486; PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 29.6 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158032 CVCL_CV55 LCL-PI 20 transformed cell line human CVCL_CV55 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158033 CVCL_D755 M249 cancer cell line human CVCL_D755 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=20406486; PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965) Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 21.2 hours (PubMed=20406486) 21158034 CVCL_CV56 LCL-PI 21 transformed cell line human CVCL_CV56 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158035 CVCL_D756 M255 cancer cell line human CVCL_D756 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486) Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 48.6 hours (PubMed=20406486) 21158036 CVCL_CV53 LCL-PI 14 transformed cell line human CVCL_CV53 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158037 CVCL_D753 M244 cancer cell line human CVCL_D753 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158038 CVCL_CV54 LCL-PI 18 transformed cell line human CVCL_CV54 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158039 CVCL_D754 M245 cancer cell line human CVCL_D754 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25645078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158040 CVCL_CV68 LCL-PI 52 transformed cell line human CVCL_CV68 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158041 CVCL_D768 M321 cancer cell line human CVCL_D768 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=20406486). Unspecified Doubling time: 34.1 hours (PubMed=20406486) 21158042 CVCL_CV69 LCL-PI 55 transformed cell line human CVCL_CV69 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158043 CVCL_D769 M368 cancer cell line human CVCL_D769 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Part of: MD Anderson Cell Lines Project 21158044 CVCL_CV62 LCL-PI 34 transformed cell line human CVCL_CV62 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158045 CVCL_D762 M288 cancer cell line human CVCL_D762 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158046 CVCL_CV63 LCL-PI 36 transformed cell line human CVCL_CV63 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158047 CVCL_D763 M296 cancer cell line human CVCL_D763 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158048 CVCL_CV60 LCL-PI 30 transformed cell line human CVCL_CV60 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158049 CVCL_D760 M275 cancer cell line human CVCL_D760 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158050 CVCL_CV61 LCL-PI 31 transformed cell line human CVCL_CV61 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158051 CVCL_D761 M285 cancer cell line human CVCL_D761 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158052 CVCL_CV66 LCL-PI 211 transformed cell line human CVCL_CV66 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: NCBI_Iran; C422; probable Male Caution: There seem to be 3 distinct cell lines which were assigned NCBI_Iran catalog number C422 21158053 CVCL_D766 M308 cancer cell line human CVCL_D766 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=20406486); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20406486) Omics: Protein expression by reverse-phase protein arrays. Unspecified Doubling time: 35.0 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158054 CVCL_CV67 LCL-PI 51 transformed cell line human CVCL_CV67 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158055 CVCL_D767 M318 cancer cell line human CVCL_D767 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25645078); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158056 CVCL_CV64 LCL-PI 37 transformed cell line human CVCL_CV64 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158057 CVCL_D764 M297 cancer cell line human CVCL_D764 CL:0000010 Unspecified 21158058 CVCL_CV65 LCL-PI 49 transformed cell line human CVCL_CV65 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158059 CVCL_D765 M299 cancer cell line human CVCL_D765 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930) Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158060 CVCL_D737 COR-L42 cancer cell line human CVCL_D737 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158061 CVCL_CV37 GM00229 finite cell line human CVCL_CV37 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158062 CVCL_D738 COR-L54 cancer cell line human CVCL_D738 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21158063 CVCL_CV38 GM00432 finite cell line human CVCL_CV38 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158064 CVCL_CV35 AG03511 finite cell line human CVCL_CV35 CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03511; probable Male 21158065 CVCL_D735 COR-L31 cancer cell line human CVCL_D735 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158066 CVCL_CV36 AG07721 finite cell line human CVCL_CV36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07721; probable Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158067 CVCL_D736 COR-L41 cancer cell line human CVCL_D736 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified 21158068 CVCL_D739 COR-L59 cancer cell line human CVCL_D739 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21158069 CVCL_CV39 GM00989 finite cell line human CVCL_CV39 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg644Cys (c.1930C>T); ClinVar=VCV000014527; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158070 CVCL_D730 MCC-1 cancer cell line human CVCL_D730 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 69 hours (PubMed=11319762) 21158071 CVCL_CV30 ND33000 transformed cell line human CVCL_CV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158072 CVCL_D733 COR-L27 cancer cell line human CVCL_D733 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158073 CVCL_CV33 SK [Scatophagus] spontaneously immortalized cell line CVCL_CV33 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21158074 CVCL_D734 COR-L30 cancer cell line human CVCL_D734 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158075 CVCL_CV34 SK-la spontaneously immortalized cell line CVCL_CV34 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21158076 CVCL_D731 SBcl1 cancer cell line human CVCL_D731 CL:0000010 Male 21158077 CVCL_CV31 XP40OS iPS induced pluripotent stem cell human CVCL_CV31 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21158078 CVCL_CV32 CIK spontaneously immortalized cell line CVCL_CV32 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21158079 CVCL_D732 SBcl2 cancer cell line human CVCL_D732 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=25645078; PubMed=29492214) Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21158080 CVCL_CV48 GM00172 finite cell line human CVCL_CV48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00172; probable 21158081 CVCL_D748 M229 cancer cell line human CVCL_D748 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=20406486; PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=20406486; PubMed=22194965) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 27.9 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158082 CVCL_D749 M230 cancer cell line human CVCL_D749 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Unspecified Part of: MD Anderson Cell Lines Project 21158083 CVCL_CV46 GM20255 transformed cell line human CVCL_CV46 CL:0000010 Sequence variation: Mutation; HGNC; 8918; PHEX; Simple; p.Leu650Arg (c.1949T>G); Zygosity=Hemizygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158084 CVCL_D746 M202 cancer cell line human CVCL_D746 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=20406486; PubMed=25645078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=20406486; PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Doubling time: 26.1 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158085 CVCL_CV47 GM20265 finite cell line human CVCL_CV47 CL:0000010 Sequence variation: Mutation; HGNC; 4803; HADHB; Simple; p.Arg61His (c.182G>A) (R28H); ClinVar=VCV000014845; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158086 CVCL_D747 M207 cancer cell line human CVCL_D747 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=20406486; PubMed=25645078); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu747_Pro753delinsSer (c.2240_2257del); ClinVar=VCV000016608; Zygosity=Unspecified (PubMed=25645078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=20406486; PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays. Unspecified Doubling time: 25.2 hours (PubMed=20406486) Part of: MD Anderson Cell Lines Project 21158087 CVCL_D740 COR-L65 cancer cell line human CVCL_D740 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158088 CVCL_CV40 GM01178 finite cell line human CVCL_CV40 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158089 CVCL_D741 COR-L71 cancer cell line human CVCL_D741 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158090 CVCL_CV41 GM04465 finite cell line human CVCL_CV41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158091 CVCL_D744 COR-L103 cancer cell line human CVCL_D744 CL:0000010 Discontinued: ECACC; 96020735; probable. Male 21158092 CVCL_CV44 GM17482 finite cell line human CVCL_CV44 CL:0000010 Sequence variation: Mutation; HGNC; 4803; HADHB; Simple; p.Arg61His (c.182G>A) (R28H); ClinVar=VCV000014845; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4803; HADHB; Simple; p.Arg247His (c.740G>A); ClinVar=VCV000014846; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158093 CVCL_D745 COR-L266 cancer cell line human CVCL_D745 CL:0000010 Unspecified 21158094 CVCL_CV45 GM20254 transformed cell line human CVCL_CV45 CL:0000010 Sequence variation: Mutation; HGNC; 8918; PHEX; Simple; p.Leu650Arg (c.1949T>G); Zygosity=Heterozygous (from familial inference) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158095 CVCL_D742 COR-L80 cancer cell line human CVCL_D742 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158096 CVCL_CV42 GM06074 finite cell line human CVCL_CV42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,rec(9)(pter->q22.1::q34.3->q34.1::q22.1->qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21158097 CVCL_D743 COR-L84 cancer cell line human CVCL_D743 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21158098 CVCL_CV43 GM16192 finite cell line human CVCL_CV43 CL:0000010 Sequence variation: Mutation; HGNC; 3622; FKTN; Simple; p.Ile129Ter (c.385delA) (p.Ile129fs*1); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3622; FKTN; Simple; p.Tyr392Ter (c.1176C>A); ClinVar=VCV000969988; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158099 CVCL_D715 Mel20-09-196 cancer cell line human CVCL_D715 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Heterozygous (PubMed=22515704). Unspecified 21158100 CVCL_CV15 ND24634 transformed cell line human CVCL_CV15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158101 CVCL_D716 ACI-158 cancer cell line human CVCL_D716 CL:0000010 Sequence variation: Mutation; HGNC; 9302; PPP2R1A; Simple; p.Pro179Arg (c.536C>G); ClinVar=VCV000376504; Zygosity=Unspecified (PubMed=21882256); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=21882256) Derived from sampling site: Endometrium. Omics: ATAC-seq Female 21158102 CVCL_CV16 ND24748 transformed cell line human CVCL_CV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158103 CVCL_CV13 ND24606 transformed cell line human CVCL_CV13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158104 CVCL_D713 PK-16 cancer cell line human CVCL_D713 CL:0000010 Population: Japanese Unspecified Characteristics: Established from a xenograft Doubling time: 60 hours (PubMed=3547771). 21158105 CVCL_D714 Mel20-08-128 cancer cell line human CVCL_D714 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Heterozygous (PubMed=22515704). Unspecified 21158106 CVCL_CV14 ND24627 transformed cell line human CVCL_CV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158107 CVCL_CV19 ND24927 transformed cell line human CVCL_CV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158108 CVCL_D719 PK-36 cancer cell line human CVCL_D719 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Male Doubling time: 51 hours (PubMed=7622937) 21158109 CVCL_D717 ACI-89 cancer cell line human CVCL_D717 CL:0000010 Sequence variation: Mutation; HGNC; 9302; PPP2R1A; Simple; p.Arg183Trp (c.547C>T); ClinVar=VCV000376505; Zygosity=Unspecified (PubMed=21882256). Female 21158110 CVCL_CV17 ND24821 transformed cell line human CVCL_CV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158111 CVCL_D718 BT142 cancer cell line human CVCL_D718 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous (PubMed=22166263) Population: Caucasian; Derived from sampling site: Brain; left frontal lobe. Male Group: Cancer stem cell line 21158112 CVCL_CV18 ND24925 transformed cell line human CVCL_CV18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158113 CVCL_CV11 ND24568 transformed cell line human CVCL_CV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158114 CVCL_D711 PK-12 cancer cell line human CVCL_D711 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Unspecified Characteristics: Established from a xenograft Doubling time: 82 hours (PubMed=3547771) 21158115 CVCL_CV12 ND24573 transformed cell line human CVCL_CV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158116 CVCL_D712 PK-14 cancer cell line human CVCL_D712 CL:0000010 Population: Japanese Unspecified Characteristics: Established from a xenograft Doubling time: 41.3 hours (PubMed=3547771). 21158117 CVCL_D710 MD903 cancer cell line human CVCL_D710 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell acute lymphoblastic leukemia (ALL-L3). Population: Japanese Omics: Array-based CGH; Omics: Genome sequenced Male 21158118 CVCL_CV10 ND24275 transformed cell line human CVCL_CV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158119 CVCL_CV26 ND25930 transformed cell line human CVCL_CV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158120 CVCL_D726 PC-9/ER3 cancer cell line human CVCL_D726 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Lymph node. Male 21158121 CVCL_CV27 ND26786 transformed cell line human CVCL_CV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158122 CVCL_D727 SGHPL-5 transformed cell line human CVCL_D727 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21158123 CVCL_D724 BC44 cancer cell line human CVCL_D724 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22669776) Derived from sampling site: Urinary bladder; urothelium. Omics: Array-based CGH Female 21158124 CVCL_CV24 ND25774 transformed cell line human CVCL_CV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158125 CVCL_D725 BC61 cancer cell line human CVCL_D725 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22669776); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly370Cys (c.1108G>T); ClinVar=VCV000016359; Zygosity=Unspecified (PubMed=22669776) Derived from sampling site: Urinary bladder; urothelium. Omics: Array-based CGH; Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: UBC-40 urothelial bladder cancer cell line index 21158126 CVCL_CV25 ND25795 transformed cell line human CVCL_CV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158127 CVCL_D728 HTR-8 finite cell line human CVCL_D728 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21158128 CVCL_CV28 ND27103 transformed cell line human CVCL_CV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158129 CVCL_D729 MCC1 [Human mucinous cystic carcinoma] cancer cell line human CVCL_D729 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=15688169); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=15688169); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Unspecified (PubMed=15688169). Female Doubling time: 72 +- 12 hours (PubMed=15688169) 21158130 CVCL_CV29 ND28130 transformed cell line human CVCL_CV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158131 CVCL_D722 hmel1 cancer cell line human CVCL_D722 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=21880213; PubMed=23489693); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Trp383Cys (c.1149G>T); Zygosity=Unspecified (PubMed=23489693) Population: Caucasian; Italian; Derived from metastatic site: Skin. Male 21158132 CVCL_CV22 ND25037 transformed cell line human CVCL_CV22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158133 CVCL_D723 hmel9 cancer cell line human CVCL_D723 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Arg (c.1798_1799delGTinsAG); ClinVar=VCV000375940; Zygosity=Homozygous (PubMed=21880213; PubMed=23489693) Population: Caucasian; Italian; Derived from sampling site: Skin. Male 21158134 CVCL_CV23 ND25055 transformed cell line human CVCL_CV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158135 CVCL_CV20 ND24930 transformed cell line human CVCL_CV20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158136 CVCL_D720 PK-47 cancer cell line human CVCL_D720 CL:0000010 Population: Japanese; Derived from sampling site: Pancreas. Female Doubling time: 47 hours (PubMed=7622937) 21158137 CVCL_CV21 ND24936 transformed cell line human CVCL_CV21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158138 CVCL_D721 PK-9 [Human] cancer cell line human CVCL_D721 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11115575; PubMed=22490663); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=11115575; PubMed=22490663) Population: Japanese; Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB2140; true Male Doubling time: 72 hours (PubMed=3547771; PubMed=7622937); 51.4 hours (PubMed=8872523) 21158139 CVCL_LP90 BayGenomics ES cell line BGA391 embryonic stem cell house mouse CVCL_LP90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270849; Rps6kb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158140 CVCL_M190 H2P cancer cell line human CVCL_M190 CL:0000010 Population: Chinese; Karyotypic information: Hypertriploid karyotype (PubMed=14697646); Derived from sampling site: Liver. Male 21158141 CVCL_LP91 BayGenomics ES cell line BGA395 embryonic stem cell house mouse CVCL_LP91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158142 CVCL_M191 TCPH-MM11 cancer cell line human CVCL_M191 CL:0000010 Derived from sampling site: Pleural effusion. Male 21158143 CVCL_UJ31 PF-6 cancer cell line human CVCL_UJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21158144 CVCL_UJ32 A549 ATGL-KO cancer cell line human CVCL_UJ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30802; PNPLA2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 21158145 CVCL_LP89 BayGenomics ES cell line BGA355 embryonic stem cell house mouse CVCL_LP89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917057; Trim32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158146 CVCL_M189 H2M cancer cell line human CVCL_M189 CL:0000010 Population: Chinese; Karyotypic information: Hypertetraploid karyotype (PubMed=14697646); Derived from metastatic site: Portal vein (Note=From a tumor thrombus). Male 21158147 CVCL_UJ30 PF-5 cancer cell line human CVCL_UJ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21158148 CVCL_LP87 BayGenomics ES cell line BGA341 embryonic stem cell house mouse CVCL_LP87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158149 CVCL_UJ35 CUTO-3.29 cancer cell line human CVCL_UJ35 CL:0000010 Sequence variation: Gene fusion; HGNC; 30321; MPRIP + HGNC; 8031; NTRK1; Name(s)=MPRIP-NTRK1 (PubMed=26216294). 21158150 CVCL_M187 HepG2/Adm cancer cell line human CVCL_M187 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Liver. Male 21158151 CVCL_LP88 BayGenomics ES cell line BGA350 embryonic stem cell house mouse CVCL_LP88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158153 CVCL_UJ36 HT9-C7 transformed cell line house mouse CVCL_UJ36 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus. Unspecified Characteristics: Secretes vasopressin and neurophysin Doubling time: ~24 hours (PubMed=1091196) 21158154 CVCL_LP85 BayGenomics ES cell line BGA332 embryonic stem cell house mouse CVCL_LP85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343135; Ndufs4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158155 CVCL_UJ33 HCC78-TR cancer cell line human CVCL_UJ33 CL:0000010 Sequence variation: Gene fusion; HGNC; 10261; ROS1 + HGNC; 11020; SLC34A2; Name(s)=SLC34A2-ROS1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:91338; 5-chloro-N2-[2-methoxy-4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]-N4-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine (TAE684); Derived from metastatic site: Pleural effusion. Male 21158156 CVCL_M185 HEPFT cancer cell line human CVCL_M185 CL:0000010 Population: Japanese; Derived from sampling site: Fallopian tube. Female Doubling time: 37 hours (PubMed=17949352) 21158157 CVCL_LP86 BayGenomics ES cell line BGA340 embryonic stem cell house mouse CVCL_LP86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923723; Supt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158158 CVCL_UJ34 CUTO-2 cancer cell line human CVCL_UJ34 CL:0000010 Sequence variation: Gene fusion; HGNC; 10261; ROS1 + HGNC; 11020; SLC34A2; Name(s)=SLC34A2-ROS1 (PubMed=24349229). 21158159 CVCL_M186 HepG2/mdr1 cancer cell line human CVCL_M186 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 40; ABCB1 Population: Caucasian; Derived from sampling site: Liver. Male 21158160 CVCL_UJ39 A2780AD cancer cell line human CVCL_UJ39 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21158161 CVCL_LP83 BayGenomics ES cell line BGA310 embryonic stem cell house mouse CVCL_LP83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328306; Orc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158162 CVCL_M183 CSQT-2 cancer cell line human CVCL_M183 CL:0000010 Population: Chinese; Derived from metastatic site: Portal vein. Male Doubling time: 36 hours (Patent=CN101955914B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200913 21158163 CVCL_LP84 BayGenomics ES cell line BGA318 embryonic stem cell house mouse CVCL_LP84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158164 CVCL_M184 BEL-7402/5'-DFUR cancer cell line human CVCL_M184 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31521; Doxifluridine (5'-deoxy-5-fluorouridine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (BEL-7402) has been shown to be a HeLa derivative. 21158165 CVCL_UJ37 3T3-L2 spontaneously immortalized cell line house mouse CVCL_UJ37 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21158166 CVCL_LP81 BayGenomics ES cell line BGA299 embryonic stem cell house mouse CVCL_LP81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158167 CVCL_M181 HLF-R4 cancer cell line human CVCL_M181 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver Cell type=Fibroblast.. Male 21158168 CVCL_UJ38 A2780ME cancer cell line human CVCL_UJ38 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from sampling site: Ovary. Female 21158169 CVCL_LP82 BayGenomics ES cell line BGA302 embryonic stem cell house mouse CVCL_LP82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158170 CVCL_M182 SK-Hep-1/CDDP cancer cell line human CVCL_M182 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells.; Caution: PubMed=20458768 describes SK-Hep-1/CDDP and does not cite PubMed=20109345 which describes SK-Hep1/DDP As the two papers are from the same authors and that the described cell lines have identical characteristics it is probable that they are identical. 21158171 CVCL_UJ19 53Bp1-/- MEF finite cell line house mouse CVCL_UJ19 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1351320; Trp53bp1 Derived from sampling site: Cell type=Fibroblast. Unspecified 21158172 CVCL_UJ20 ZR-75-1-Dox cancer cell line human CVCL_UJ20 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Omics: Poly-ADP-ribosylation by proteomics Female 21158173 CVCL_UJ21 MDA-MB-231-Dox cancer cell line human CVCL_UJ21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21158174 CVCL_LP98 BayGenomics ES cell line BGA465 embryonic stem cell house mouse CVCL_LP98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890494; Laptm4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158175 CVCL_M198 M19 cancer cell line human CVCL_M198 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228) Derived from sampling site: Pleural effusion. Male 21158176 CVCL_UJ24 TC620 1.3 cancer cell line human CVCL_UJ24 CL:0000010 Male 21158177 CVCL_LP99 BayGenomics ES cell line BGA474 embryonic stem cell house mouse CVCL_LP99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342005; Mthfd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158178 CVCL_UJ25 hTERT Lung Fibroblast telomerase immortalized cell line human CVCL_UJ25 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Female Doubling time: 22-24 hours (ATCC=CRL-4058) 21158179 CVCL_LP96 BayGenomics ES cell line BGA428 embryonic stem cell house mouse CVCL_LP96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88071; Arnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158180 CVCL_UJ22 BT-549-Dox cancer cell line human CVCL_UJ22 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Breast. Female Group: Triple negative breast cancer (TNBC) cell line 21158181 CVCL_M196 TCPH-MM14 cancer cell line human CVCL_M196 CL:0000010 Derived from sampling site: Pleural effusion. Male 21158182 CVCL_LP97 BayGenomics ES cell line BGA434 embryonic stem cell house mouse CVCL_LP97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158183 CVCL_M197 M22K cancer cell line human CVCL_M197 CL:0000010 Male 21158184 CVCL_UJ23 TC620 1.0 cancer cell line human CVCL_UJ23 CL:0000010 Male 21158185 CVCL_LP94 BayGenomics ES cell line BGA419 embryonic stem cell house mouse CVCL_LP94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158186 CVCL_UJ28 PF-3 cancer cell line human CVCL_UJ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21158187 CVCL_M194 TCPH-MM12 cancer cell line human CVCL_M194 CL:0000010 Derived from sampling site: Pleural effusion. Male 21158188 CVCL_LP95 BayGenomics ES cell line BGA423 embryonic stem cell house mouse CVCL_LP95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1195458; Abce1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158189 CVCL_UJ29 PF-4 cancer cell line human CVCL_UJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21158190 CVCL_M195 TCPH-MM13 cancer cell line human CVCL_M195 CL:0000010 Derived from sampling site: Pleural effusion. Male 21158191 CVCL_LP92 BayGenomics ES cell line BGA407 embryonic stem cell house mouse CVCL_LP92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921453; Eif4enif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158192 CVCL_UJ26 hTERT-DM telomerase immortalized cell line human CVCL_UJ26 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; dermis Cell type=Melanocyte.. Female Doubling time: 46 hours (ATCC=CRL-4059) 21158193 CVCL_M192 TCPH-MM04 cancer cell line human CVCL_M192 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Derived from sampling site: Pleural effusion. Omics: Genome sequenced Male 21158194 CVCL_LP93 BayGenomics ES cell line BGA418 embryonic stem cell house mouse CVCL_LP93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158195 CVCL_UJ27 PF-2 cancer cell line human CVCL_UJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21158196 CVCL_M193 TCPH-MM03 cancer cell line human CVCL_M193 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Derived from sampling site: Pleural effusion. Omics: Genome sequenced Male 21158197 CVCL_UJ08 N6-500 cancer cell line human CVCL_UJ08 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Peripheral blood. Male 21158198 CVCL_UJ09 HPB/ADR cancer cell line human CVCL_UJ09 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Problematic cell line: Contaminated Parent cell line (HPB-MLT) has been shown to be a HPB-ALL derivative. 21158199 CVCL_M169 HPC-36 cancer cell line human CVCL_M169 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=15643172). Male 21158200 CVCL_LP69 Keck MirKO ES cell line Mirc8 embryonic stem cell house mouse CVCL_LP69 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676793; ; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676796; Mirlet7d; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676798; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158201 CVCL_UJ10 HPB/VP-16 cancer cell line human CVCL_UJ10 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 29824; MYL11; Name(s)=CBFB-MYL11, CBFB-MYLPF (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1574Pro (c.4721T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp2442fs*39 (c.7326_7326insGGGCCGTGGACG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys124Ter (c.372C>A); ClinVar=VCV000458537; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Problematic cell line: Contaminated Parent cell line (HPB-MLT) has been shown to be a HPB-ALL derivative. 21158202 CVCL_LP67 Keck MirKO ES cell line Mirc35 embryonic stem cell house mouse CVCL_LP67 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619440; Mir96; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676846; Mir182; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676847; Mir183 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158203 CVCL_M167 SK-PN-AG cancer cell line human CVCL_M167 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21158204 CVCL_LP68 Keck MirKO ES cell line Mirc6 embryonic stem cell house mouse CVCL_LP68 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:5049944; Mirc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158205 CVCL_M168 SK-PN-WA cancer cell line human CVCL_M168 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21158206 CVCL_M165 COG-LL-356h cancer cell line human CVCL_M165 CL:0000010 Derived from sampling site: Bone marrow. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Hypoxic cell line grown at 5% O2 21158207 CVCL_LP65 Keck MirKO ES cell line Mirc30 embryonic stem cell house mouse CVCL_LP65 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676841; Mir15a; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676843; Mir16-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158208 CVCL_UJ13 TKPTS transformed cell line house mouse CVCL_UJ13 CL:0000010 Miscellaneous: Sex of donor and STR profile from personal communication of Gemma R.-T Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: C57BL/6J Tg(SV40E)Bri/7 transgenic. Male Doubling time: ~12 hours (ATCC=CRL-3361) 21158209 CVCL_M166 COG-LL-384h cancer cell line human CVCL_M166 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: Hypoxic cell line grown at 5% O2 21158210 CVCL_UJ14 JMP-1 cancer cell line human CVCL_UJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male 21158211 CVCL_LP66 Keck MirKO ES cell line Mirc31 embryonic stem cell house mouse CVCL_LP66 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676794; Mirlet7b; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619050; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158212 CVCL_M163 COG-LL-332h cancer cell line human CVCL_M163 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Hypoxic cell line grown at 5% O2 Doubling time: 30-34 hours (COG) 21158213 CVCL_LP63 Keck MirKO ES cell line Mirc28 embryonic stem cell house mouse CVCL_LP63 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619269; Mir296; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619321; Mir298 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158214 CVCL_UJ11 R/ADR cancer cell line human CVCL_UJ11 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21158215 CVCL_M164 COG-LL-355h cancer cell line human CVCL_M164 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (PubMed=35354797) Derived from sampling site: Bone marrow. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Hypoxic cell line grown at 5% O2 21158216 CVCL_LP64 Keck MirKO ES cell line Mirc29 embryonic stem cell house mouse CVCL_LP64 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619047; Mir29b-2; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676906; Mir29c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158217 CVCL_UJ12 R/VP-16 cancer cell line human CVCL_UJ12 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21158218 CVCL_UJ17 Brca1 delta11/delta11 MEF (S12) finite cell line house mouse CVCL_UJ17 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Established from mice homologous for Brca1 Ex11del 21158219 CVCL_M161 COG-LL-319h cancer cell line human CVCL_M161 CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (PubMed=35354797) Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Hypoxic cell line grown at 5% O2 Doubling time: 50-62 hours (COG) 21158220 CVCL_LP61 Keck MirKO ES cell line Mirc26 embryonic stem cell house mouse CVCL_LP61 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676908; Mir30b; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676910; Mir30d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158221 CVCL_UJ18 Brca1 delta11/delta11 53Bp1-/- MEF (S7) finite cell line house mouse CVCL_UJ18 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1351320; Trp53bp1 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Established from mice homologous for Brca1 Ex11del 21158222 CVCL_M162 COG-LL-329h cancer cell line human CVCL_M162 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: Hypoxic cell line grown at 5% O2 21158223 CVCL_LP62 Keck MirKO ES cell line Mirc27 embryonic stem cell house mouse CVCL_LP62 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676859; Mir195a; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3629886; Mir497 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158224 CVCL_UJ15 Ku80+/+ MEF transformed cell line house mouse CVCL_UJ15 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Control cell line for Ku80-/- 21158225 CVCL_M160 COG-LL-317h cancer cell line human CVCL_M160 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: Hypoxic cell line grown at 5% O2 Doubling time: 19-20 hours (COG) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158226 CVCL_LP60 Keck MirKO ES cell line Mirc25 embryonic stem cell house mouse CVCL_LP60 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618716; Mir130b; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3691602; Mir301b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158227 CVCL_UJ16 Ku80-/- MEF transformed cell line house mouse CVCL_UJ16 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104517; Xrcc5 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21158228 CVCL_LP80 BayGenomics ES cell line BGA287 embryonic stem cell house mouse CVCL_LP80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158229 CVCL_M180 HLF-R10 cancer cell line human CVCL_M180 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Liver Cell type=Fibroblast.. Male 21158230 CVCL_LP78 BayGenomics ES cell line BGA258 embryonic stem cell house mouse CVCL_LP78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890169; Erbin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158231 CVCL_M178 HepDE19 cancer cell line human CVCL_M178 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21158232 CVCL_LP79 BayGenomics ES cell line BGA276 embryonic stem cell house mouse CVCL_LP79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201670; Psmd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158233 CVCL_M179 HepDES19 cancer cell line human CVCL_M179 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male 21158234 CVCL_UJ02 AIP KO MEF transformed cell line house mouse CVCL_UJ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109622; Aip; Transfected with: MGI; MGI:98834; Trp53 (with p.Met1_Lys302del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast. Unspecified 21158235 CVCL_LP76 BayGenomics ES cell line BGA219 embryonic stem cell house mouse CVCL_LP76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158236 CVCL_M176 HUH6-eGFP cancer cell line human CVCL_M176 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Liver. Male 21158237 CVCL_UJ03 AIP WT MEF transformed cell line house mouse CVCL_UJ03 CL:0000010 Transfected with: MGI; MGI:98834; Trp53 (with p.Met1_Lys302del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast. Unspecified 21158238 CVCL_LP77 BayGenomics ES cell line BGA257 embryonic stem cell house mouse CVCL_LP77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96622; Itpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158239 CVCL_M177 HepAD38 cancer cell line human CVCL_M177 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Used in a bioassay that permits the large-scale screening of compound libraries for inhibitors of HBV replication Male Virology: Inducibly expresses a hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12077 21158240 CVCL_LP74 BayGenomics ES cell line BGA212 embryonic stem cell house mouse CVCL_LP74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914852; Necap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158241 CVCL_M174 HKCI-3 cancer cell line human CVCL_M174 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 21158242 CVCL_UJ00 POT1b F/- (#12436-2) transformed cell line house mouse CVCL_UJ00 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 3rd coding exon of one allele of mouse Pot1b The second allele is deleted. Pot1b knockout can be effected by transduction of Cre recombinase into the cell line. 21158243 CVCL_LP75 BayGenomics ES cell line BGA215 embryonic stem cell house mouse CVCL_LP75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158244 CVCL_M175 HKCI-4 cancer cell line human CVCL_M175 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Expresses chimeric hepatitis B virus (HBV)-human transcripts (PubMed=24582836) 21158245 CVCL_UJ01 POT1a F/F POT1b F/F (#20431-5) transformed cell line house mouse CVCL_UJ01 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/Ola x C57BL/6J. Unspecified Characteristics: Embryonic fibroblasts that have loxP sites on both sides of the 3rd coding exon of mouse Pot1a and Pot1b genes Pot1a anb Pot1b knockout can be effected by transduction of Cre recombinase into the cell line. 21158246 CVCL_LP72 BayGenomics ES cell line BGA188 embryonic stem cell house mouse CVCL_LP72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384822; Ap1ar Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158247 CVCL_M172 HC-AFW1 cancer cell line human CVCL_M172 CL:0000010 Sequence variation: Gene deletion; HGNC; 2625; CYP2D6; Zygosity=Heterozygous (PubMed=26310804); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Val22_Phe70del; Zygosity=Heterozygous (PubMed=22666492) Omics: CNV analysis. Male Doubling time: 40 hours (PubMed=22666492) 21158248 CVCL_UJ06 N6/ADR cancer cell line human CVCL_UJ06 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male 21158249 CVCL_LP73 BayGenomics ES cell line BGA206 embryonic stem cell house mouse CVCL_LP73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97791; Ptbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158250 CVCL_M173 HKCI-2 cancer cell line human CVCL_M173 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y Omics: Transcriptome analysis by microarray. Male 21158251 CVCL_UJ07 N6-1000 cancer cell line human CVCL_UJ07 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Peripheral blood. Male 21158252 CVCL_M170 HepU1 cancer cell line human CVCL_M170 CL:0000010 Derived from metastatic site: Ascites. Male Doubling time: ~10 days (PubMed=12704668) 21158253 CVCL_LP70 Keck MirKO ES cell line Mirlet7a-2 embryonic stem cell house mouse CVCL_LP70 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619049; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158254 CVCL_UJ04 PF-1 cancer cell line human CVCL_UJ04 CL:0000010 Sequence variation: Gene fusion; HGNC; 1582; CCND1 + HGNC; 5477; IGH; Name(s)=IGH-CCND1 (PubMed=24611650) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158255 CVCL_LP71 BayGenomics ES cell line BGA185 embryonic stem cell house mouse CVCL_LP71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104517; Xrcc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158256 CVCL_M171 HepU2 cancer cell line human CVCL_M171 CL:0000010 Derived from metastatic site: Ascites. Male Doubling time: ~10 days (PubMed=12704668) 21158257 CVCL_UJ05 NALM6, clone G5 cancer cell line human CVCL_UJ05 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158258 CVCL_M149 CHLA-266 cancer cell line human CVCL_M149 CL:0000010 Omics: Deep exome analysis. Female Doubling time: 40 hours (CelloPub=CLPUB00418); 45 hours (PubMed=22120608); 50 hours (PubMed=20922763) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158259 CVCL_LP49 Keck MirKO ES cell line Mir711 embryonic stem cell house mouse CVCL_LP49 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3629883; Mir711 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158260 CVCL_M147 CHLA-200 cancer cell line human CVCL_M147 CL:0000010 Male Doubling time: 54 hours (PubMed=22120608). 21158261 CVCL_LP47 Keck MirKO ES cell line Mir34a embryonic stem cell house mouse CVCL_LP47 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619363; Mir34a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158262 CVCL_M148 CHLA-259 cancer cell line human CVCL_M148 CL:0000010 Male Doubling time: 76 hours (PubMed=22120608). 21158263 CVCL_LP48 Keck MirKO ES cell line Mir688 embryonic stem cell house mouse CVCL_LP48 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3629926; Mir688 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158264 CVCL_LP45 Keck MirKO ES cell line Mir325 embryonic stem cell house mouse CVCL_LP45 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619336; Mir325 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158265 CVCL_M145 NCI-EWS-94 cancer cell line human CVCL_M145 CL:0000010 Unspecified 21158266 CVCL_LP46 Keck MirKO ES cell line Mir339 embryonic stem cell house mouse CVCL_LP46 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619354; Mir339 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158267 CVCL_M146 NCI-EWS-95 cancer cell line human CVCL_M146 CL:0000010 Unspecified 21158268 CVCL_LP43 Keck MirKO ES cell line Mir30e embryonic stem cell house mouse CVCL_LP43 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619329; Mir30e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158269 CVCL_M143 NCI-EWS-011 cancer cell line human CVCL_M143 CL:0000010 Unspecified 21158270 CVCL_LP44 Keck MirKO ES cell line Mir320 embryonic stem cell house mouse CVCL_LP44 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619332; Mir320 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158271 CVCL_M144 NCI-EWS-021 cancer cell line human CVCL_M144 CL:0000010 Unspecified 21158272 CVCL_LP41 Keck MirKO ES cell line Mir219-2 embryonic stem cell house mouse CVCL_LP41 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618754; Mir219a-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158273 CVCL_M141 SJ-GBM2 cancer cell line human CVCL_M141 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=9802058). Female Doubling time: 29 hours (PubMed=20922763) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158274 CVCL_M142 EWS-925 cancer cell line human CVCL_M142 CL:0000010 Unspecified 21158275 CVCL_LP42 Keck MirKO ES cell line Mir301 embryonic stem cell house mouse CVCL_LP42 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619324; Mir301 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158276 CVCL_M140 BO-101 cancer cell line human CVCL_M140 CL:0000010 Male Doubling time: 21.5 hours (PubMed=1862545). 21158277 CVCL_LP40 Keck MirKO ES cell line Mir219-1 embryonic stem cell house mouse CVCL_LP40 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618753; Mir219a-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158278 CVCL_LP58 Keck MirKO ES cell line Mirc22 embryonic stem cell house mouse CVCL_LP58 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676898; Mir23b; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676899; Mir24-1; Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676903; Mir27b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158279 CVCL_M158 LA-N-4 cancer cell line human CVCL_M158 CL:0000010 Unspecified Caution: Only mentioned as a neuroblastoma cell line in PubMed=6172518, could be a misspelling of LA-N-2. 21158280 CVCL_M159 COG-LL-317 cancer cell line human CVCL_M159 CL:0000010 Karyotypic information: 46,XY,t(8;14)(q24.1;q11.2) (COG); Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21 hours (PubMed=20922763); 30-40 hours (COG) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158281 CVCL_LP59 Keck MirKO ES cell line Mirc24 embryonic stem cell house mouse CVCL_LP59 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619333; Mir322; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619367; Mir351; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619428; Mir503 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158282 CVCL_M156 BT-16 cancer cell line human CVCL_M156 From: Biegel J.; Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Omics: Deep exome analysis. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158283 CVCL_LP56 Keck MirKO ES cell line Mirc13 embryonic stem cell house mouse CVCL_LP56 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676826; Mir141; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618750; Mir200c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158284 CVCL_M157 KCCF1 cancer cell line human CVCL_M157 CL:0000010 Derived from sampling site: Cerebrospinal fluid. Male 21158285 CVCL_LP57 Keck MirKO ES cell line Mirc17 embryonic stem cell house mouse CVCL_LP57 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676856; Mir192; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618738; Mir194-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158286 CVCL_M154 Atrt95 cancer cell line human CVCL_M154 CL:0000010 Female 21158287 CVCL_LP54 Keck MirKO ES cell line Mirc10 embryonic stem cell house mouse CVCL_LP54 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676842; Mir15b; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618690; Mir16-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158288 CVCL_M155 BT-12 cancer cell line human CVCL_M155 From: Biegel J.; Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Omics: Deep exome analysis. Female Doubling time: 27 hours (PubMed=20922763) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158289 CVCL_LP55 Keck MirKO ES cell line Mirc12 embryonic stem cell house mouse CVCL_LP55 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676829; Mir144; Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619412; Mir451a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158290 CVCL_M152 CHLA-25 cancer cell line human CVCL_M152 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Female Doubling time: 99 hours (PubMed=24312454) 21158291 CVCL_LP52 Keck MirKO ES cell line Mir9-1 embryonic stem cell house mouse CVCL_LP52 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676911; Mir9-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158292 CVCL_M153 COG-E-352 cancer cell line human CVCL_M153 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Leu791fs; Zygosity=Unspecified (PubMed=25010205; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=25010205; DepMap) Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28 hours (PubMed=24312454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21158293 CVCL_LP53 Keck MirKO ES cell line Mir9-2 embryonic stem cell house mouse CVCL_LP53 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619442; Mir9-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158294 CVCL_M150 CHLA-9 cancer cell line human CVCL_M150 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Val628insThrAspIle; Zygosity=Unspecified (PubMed=25010205) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: scRNAseq analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 20 hours (PubMed=20922763); 51 hours (PubMed=24312454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21158295 CVCL_LP50 Keck MirKO ES cell line Mir7-2 embryonic stem cell house mouse CVCL_LP50 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619437; Mir7-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158296 CVCL_M151 CHLA-32 cancer cell line human CVCL_M151 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=25010205; DepMap) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 26 hours (PubMed=24312454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158297 CVCL_LP51 Keck MirKO ES cell line Mir7b embryonic stem cell house mouse CVCL_LP51 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3619435; Mir7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158298 CVCL_D795 IMO-2D3 conditionally immortalized cell line house mouse CVCL_D795 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158299 CVCL_CV95 LCL-PI 99 transformed cell line human CVCL_CV95 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158300 CVCL_D796 IMO-3A1 conditionally immortalized cell line house mouse CVCL_D796 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158301 CVCL_CV96 LCL-PI 100 transformed cell line human CVCL_CV96 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158302 CVCL_D793 IMO-2B1 conditionally immortalized cell line house mouse CVCL_D793 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158303 CVCL_CV93 LCL-PI 97 transformed cell line human CVCL_CV93 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158304 CVCL_D794 IMO-2D2 conditionally immortalized cell line house mouse CVCL_D794 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158305 CVCL_CV94 LCL-PI 98 transformed cell line human CVCL_CV94 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158306 CVCL_CV99 LCL-PI 316 transformed cell line human CVCL_CV99 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: NCBI_Iran; C527; probable Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C527 21158307 CVCL_D799 OC-k1 conditionally immortalized cell line house mouse CVCL_D799 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158308 CVCL_D797 IMO-3C3 conditionally immortalized cell line house mouse CVCL_D797 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158309 CVCL_CV97 LCL-PI 311 transformed cell line human CVCL_CV97 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: NCBI_Iran; C522; probable Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C522 21158310 CVCL_D798 IMO-3D1 conditionally immortalized cell line house mouse CVCL_D798 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158311 CVCL_CV98 LCL-PI 103 transformed cell line human CVCL_CV98 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158312 CVCL_LP29 Keck MirKO ES cell line Mir146a embryonic stem cell house mouse CVCL_LP29 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676831; Mir146 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158313 CVCL_M129 LNCaP C-33 cancer cell line human CVCL_M129 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by microarray Male 21158314 CVCL_LP27 Keck MirKO ES cell line Mir138-1 embryonic stem cell house mouse CVCL_LP27 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676823; Mir138-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158315 CVCL_M127 LNCaP 104-R1 cancer cell line human CVCL_M127 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21158316 CVCL_LP28 Keck MirKO ES cell line Mir138-2 embryonic stem cell house mouse CVCL_LP28 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618733; Mir138-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158317 CVCL_M128 LNCaP 104-R2 cancer cell line human CVCL_M128 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21158318 CVCL_D791 CMEE-1 transformed cell line CVCL_D791 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Ear; middle ear Cell type=Epithelial cell.. Male 21158319 CVCL_M125 KB-ChR-8-5-11-24 cancer cell line human CVCL_M125 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21158320 CVCL_LP25 Keck MirKO ES cell line Mir135b embryonic stem cell house mouse CVCL_LP25 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618732; Mir135b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158321 CVCL_CV91 LCL-PI 94 transformed cell line human CVCL_CV91 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158322 CVCL_D792 IMO-1G1 conditionally immortalized cell line house mouse CVCL_D792 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21158323 CVCL_LP26 Keck MirKO ES cell line Mir137 embryonic stem cell house mouse CVCL_LP26 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676822; Mir137 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158324 CVCL_CV92 LCL-PI 95 transformed cell line human CVCL_CV92 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158325 CVCL_M126 LNCaP 104-S cancer cell line human CVCL_M126 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21158326 CVCL_M123 KCP-4 cancer cell line human CVCL_M123 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21158327 CVCL_LP23 Keck MirKO ES cell line Mir130a embryonic stem cell house mouse CVCL_LP23 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676816; Mir130a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158328 CVCL_LP24 Keck MirKO ES cell line Mir135a-1 embryonic stem cell house mouse CVCL_LP24 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676820; Mir135a-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158329 CVCL_CV90 LCL-PI 92 transformed cell line human CVCL_CV90 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158330 CVCL_M124 PC-5 [Human prostate carcinoma] cancer cell line human CVCL_M124 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone. Male 21158331 CVCL_D790 UB/OC-2 conditionally immortalized cell line house mouse CVCL_D790 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti. 21158332 CVCL_M121 HPaC-79 cancer cell line human CVCL_M121 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Unspecified 21158333 CVCL_LP21 Keck MirKO ES cell line Mir126 embryonic stem cell house mouse CVCL_LP21 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676811; Mir126a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158334 CVCL_M122 HSmC-78 cancer cell line human CVCL_M122 CL:0000010 Derived from metastatic site: Neck. Male 21158335 CVCL_LP22 Keck MirKO ES cell line Mir129-1 embryonic stem cell house mouse CVCL_LP22 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676815; Mir129-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158336 CVCL_LP20 Keck MirKO ES cell line Mir125b-2 embryonic stem cell house mouse CVCL_LP20 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:3618706; Mir125b-2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158337 CVCL_M120 UD-SCC-6 cancer cell line human CVCL_M120 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=18487078). Male 21158338 CVCL_LP38 Keck MirKO ES cell line Mir21 embryonic stem cell house mouse CVCL_LP38 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676885; Mir21a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158339 CVCL_M138 MED-MEB-8S cancer cell line human CVCL_M138 CL:0000010 Male 21158340 CVCL_LP39 Keck MirKO ES cell line Mir210 embryonic stem cell house mouse CVCL_LP39 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676886; Mir210 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158341 CVCL_M139 Madsen cancer cell line human CVCL_M139 From: Youle R.; National Institutes of Health; Bethesda; USA. CL:0000010 21158342 CVCL_M136 1580WU cancer cell line human CVCL_M136 CL:0000010 Female 21158343 CVCL_LP36 Keck MirKO ES cell line Mir199a-1 embryonic stem cell house mouse CVCL_LP36 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676863; Mir199a-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158344 CVCL_LP37 Keck MirKO ES cell line Mir205 embryonic stem cell house mouse CVCL_LP37 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676880; Mir205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158345 CVCL_M137 MED-MEB-8A cancer cell line human CVCL_M137 CL:0000010 Male 21158346 CVCL_LP34 Keck MirKO ES cell line Mir188 embryonic stem cell house mouse CVCL_LP34 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676852; Mir188 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158347 CVCL_M134 TsuGK27 cancer cell line human CVCL_M134 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Parent cell line (TSU-Pr1) has been shown to be a T24 derivative. 21158348 CVCL_LP35 Keck MirKO ES cell line Mir196a-1 embryonic stem cell house mouse CVCL_LP35 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676860; Mir196a-1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158349 CVCL_M135 UW443 cancer cell line human CVCL_M135 CL:0000010 Karyotypic information: Tetraploid karyotype (PubMed=8866661). Female Doubling time: 48.1 +- 1.6 hours (PubMed=8866661) 21158350 CVCL_LP32 Keck MirKO ES cell line Mir185 embryonic stem cell house mouse CVCL_LP32 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676849; Mir185 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158351 CVCL_M132 LNCaP C5 cancer cell line human CVCL_M132 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Derived from a tumor that developed in castrated nude mice injected with LNCaP cells 21158352 CVCL_LP33 Keck MirKO ES cell line Mir187 embryonic stem cell house mouse CVCL_LP33 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676851; Mir187 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158353 CVCL_M133 LNCaP M cancer cell line human CVCL_M133 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21158354 CVCL_LP30 Keck MirKO ES cell line Mir150 embryonic stem cell house mouse CVCL_LP30 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676835; Mir150 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158355 CVCL_M130 LNCaP C-51 cancer cell line human CVCL_M130 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21158356 CVCL_LP31 Keck MirKO ES cell line Mir155 embryonic stem cell house mouse CVCL_LP31 CL:0000010 Knockout cell: Method=Knockout-first conditional; MGI; MGI:2676840; Mir155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158357 CVCL_M131 LNCaP C-81 cancer cell line human CVCL_M131 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by microarray Male 21158358 CVCL_2E84 AG12938 finite cell line human CVCL_2E84 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [49%]; 46,XY,t(7;21)(p12;q21) [51%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG12938) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158359 CVCL_2E85 AG12939 finite cell line human CVCL_2E85 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 31 PDL (Coriell=AG12939) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158360 CVCL_2E82 AG12936 finite cell line human CVCL_2E82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG12936) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158361 CVCL_2E83 AG12937 finite cell line human CVCL_2E83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 52 PDL (Coriell=AG12937) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158362 CVCL_2E88 AG12942 finite cell line human CVCL_2E88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [86%]; 45,XY,der(9)t(9;15),-15 [8%]; 46,XY,add(8)(pter>q24::?) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG12942) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158363 CVCL_2E89 AG12943 finite cell line human CVCL_2E89 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG12943) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158364 CVCL_2E86 AG12940 finite cell line human CVCL_2E86 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 15 PDL (Coriell=AG12940) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158365 CVCL_2E87 AG12941 finite cell line human CVCL_2E87 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG12941) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158366 CVCL_2E80 AG12851 finite cell line human CVCL_2E80 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (PubMed=9724752); 18 PDL (Coriell=AG12851) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158367 CVCL_2E81 AG12934 finite cell line human CVCL_2E81 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG12934) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158368 CVCL_2E95 AG12949 finite cell line human CVCL_2E95 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG12949) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158369 CVCL_2E96 AG12950 finite cell line human CVCL_2E96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG12950) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158370 CVCL_2E93 AG12947 finite cell line human CVCL_2E93 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 23 PDL (Coriell=AG12947) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158371 CVCL_2E94 AG12948 finite cell line human CVCL_2E94 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [52%]; 46,XY,inv(3)(p11;q21) [48%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG12948) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158372 CVCL_2E99 AG12953 finite cell line human CVCL_2E99 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 42 PDL (Coriell=AG12953) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158373 CVCL_2E97 AG12951 finite cell line human CVCL_2E97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [84%]; 46,XY,t(1;2)(p10;q10) [16%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 41 PDL (Coriell=AG12951) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158374 CVCL_2E98 AG12952 finite cell line human CVCL_2E98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [88%]; 46,XY,add(9)(p23 or p24) [12%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 45 PDL (Coriell=AG12952) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158375 CVCL_2E91 AG12945 finite cell line human CVCL_2E91 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG12945) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158376 CVCL_2E92 AG12946 finite cell line human CVCL_2E92 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 43 PDL (Coriell=AG12946) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158377 CVCL_2E90 AG12944 finite cell line human CVCL_2E90 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG12944) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158378 CVCL_2E62 AG12428 finite cell line human CVCL_2E62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 29 PDL (Coriell=AG12428) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158379 CVCL_2E63 AG12429 finite cell line human CVCL_2E63 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG12429) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158380 CVCL_2E60 AG12361 finite cell line human CVCL_2E60 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG12361) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158381 CVCL_2E61 AG12427 finite cell line human CVCL_2E61 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158382 CVCL_2E66 AG12443 finite cell line human CVCL_2E66 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [94%]; 46,XY,t(9;20)(q21;p12) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 53 PDL (Coriell=AG12443) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158383 CVCL_2E67 AG12588 finite cell line human CVCL_2E67 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 34 PDL (Coriell=AG12588) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158384 CVCL_2E64 AG12430 finite cell line human CVCL_2E64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (Coriell=AG12430) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158385 CVCL_2E65 AG12438 finite cell line human CVCL_2E65 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [45]; 46,XY,t(1;11)(1pter->1q42::11q11.2->11pter;11qter->11p11.2::1q42->1qter) [5] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158386 CVCL_2E68 OKM3 hybridoma house mouse CVCL_2E68 CL:0000010 Monoclonal antibody isotype: IgM. 21158387 CVCL_2E69 AG12596 finite cell line human CVCL_2E69 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [86%]; 46,XX,t(3;10) [14%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 29 PDL (PubMed=9724752); 17 PDL (Coriell=AG12596) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158388 CVCL_2E73 AG12602 finite cell line human CVCL_2E73 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 44 PDL (Coriell=AG12602) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158389 CVCL_2E74 AG12605 finite cell line human CVCL_2E74 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=AG12605) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158390 CVCL_2E71 AG12598 finite cell line human CVCL_2E71 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [82%]; 46,X,-X,+mar(X) [12%]; 47,XXX [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 50 PDL (Coriell=AG12598) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158391 CVCL_2E72 AG12599 finite cell line human CVCL_2E72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 38 PDL (Coriell=AG12599) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158392 CVCL_2E77 AG12733 finite cell line human CVCL_2E77 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [92%]; 46,XY,t(15;17)(q23;q23) [8%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (Coriell=AG12733) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158393 CVCL_2E78 AG12786 finite cell line human CVCL_2E78 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 27 PDL (Coriell=AG12786) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158394 CVCL_2E75 AG12657 finite cell line human CVCL_2E75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158395 CVCL_2E76 AG12660 finite cell line human CVCL_2E76 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158396 CVCL_2E79 AG12850 finite cell line human CVCL_2E79 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 31 PDL (Coriell=AG12850) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158397 CVCL_2E70 AG12597 finite cell line human CVCL_2E70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 7 PDL (Coriell=AG12597) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158398 CVCL_2E40 AG11737 finite cell line human CVCL_2E40 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 21 PDL (Coriell=AG11737) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158399 CVCL_2E41 AG11740 finite cell line human CVCL_2E41 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 30 PDL (Coriell=AG11740) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158400 CVCL_2E44 AG11745 finite cell line human CVCL_2E44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 24 PDL (Coriell=AG11745); Doubling time: 1.8 days (PubMed=12840040) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158401 CVCL_2E45 AG11746 finite cell line human CVCL_2E45 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [82%]; 46,XY,t(10;15)(q24;p11) [18%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG11746) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158402 CVCL_2E42 AG11743 finite cell line human CVCL_2E42 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 43 PDL (Coriell=AG11743) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158403 CVCL_2E43 AG11744 finite cell line human CVCL_2E43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 30 PDL (Coriell=AG11744) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158404 CVCL_2E48 AG11786 finite cell line human CVCL_2E48 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158405 CVCL_2E49 AG11792 finite cell line human CVCL_2E49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 10 PDL (Coriell=AG11792) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158406 CVCL_2E46 AG11747 finite cell line human CVCL_2E46 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158407 CVCL_2E47 AG11748 finite cell line human CVCL_2E47 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [96%]; 47,XYY [4%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 47 PDL (Coriell=AG11748) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158408 CVCL_UK92 MUi025-A induced pluripotent stem cell human CVCL_UK92 From: Mahidol University; Bangkok; Thailand. CL:0000010 21158409 CVCL_UK93 NCCSi004-A induced pluripotent stem cell human CVCL_UK93 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Umbilical cord blood. Female 21158410 CVCL_UK90 MCRIi009-A induced pluripotent stem cell human CVCL_UK90 From: Murdoch Children's Research Institute; Melbourne; Australia. CL:0000010 21158411 CVCL_UK91 MCRIi010-A induced pluripotent stem cell human CVCL_UK91 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158412 CVCL_UK96 RCPCMi003-A induced pluripotent stem cell human CVCL_UK96 From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21158413 CVCL_UK97 RCTi001-A induced pluripotent stem cell human CVCL_UK97 From: Catalent GmbH (RheinCell Therapeutics GmbH); Langenfeld; Germany. CL:0000010 Female 21158414 CVCL_UK94 RCPCMi001-A induced pluripotent stem cell human CVCL_UK94 From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: hPSCreg; RCPCMi001-A; true Female 21158415 CVCL_UK95 RCPCMi002-A induced pluripotent stem cell human CVCL_UK95 From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158416 CVCL_UK98 SYSUi001-A induced pluripotent stem cell human CVCL_UK98 From: Sun Yat-sen University; Guangzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21158417 CVCL_UK99 SHEHi001-A induced pluripotent stem cell human CVCL_UK99 From: Shanghai East Hospital; Shanghai; China CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158418 CVCL_2E51 AG11795 finite cell line human CVCL_2E51 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (Coriell=AG11795) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158419 CVCL_2E52 AG11796 finite cell line human CVCL_2E52 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 34 PDL (Coriell=AG11796) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158420 CVCL_2E50 AG11793 finite cell line human CVCL_2E50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 18 PDL (Coriell=AG11793) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158421 CVCL_2E55 AG11802 finite cell line human CVCL_2E55 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [4%]; 46,XY,dup(1)(q12;q44) [96%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG11802) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158422 CVCL_2E56 AG11805 finite cell line human CVCL_2E56 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [54%]; 45,X [44%]; 47,XYY [2%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG11805) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158423 CVCL_2E53 AG11798 finite cell line human CVCL_2E53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 18 PDL (Coriell=AG11798) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158424 CVCL_2E54 AG11801 finite cell line human CVCL_2E54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (Coriell=AG11801) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158425 CVCL_2E59 AG12327 finite cell line human CVCL_2E59 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG12327) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158426 CVCL_2E57 AG11808 finite cell line human CVCL_2E57 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 14 PDL (Coriell=AG11808) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158427 CVCL_2E58 AG12322 finite cell line human CVCL_2E58 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [84%]; 47,XX,+18 [16%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 29 PDL (Coriell=AG12322) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158428 CVCL_UK81 NCC-ES1-C1 cancer cell line human CVCL_UK81 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=EWSR1 exon 7 fused to FLI1 exon 8 (PubMed=30324244) Population: Japanese; Derived from sampling site: Bone; left tibia. Male Doubling time: 33 hours (PubMed=30324244) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21158429 CVCL_UK82 MCRIi001-A induced pluripotent stem cell human CVCL_UK82 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158430 CVCL_UK80 LUMCi005-C induced pluripotent stem cell human CVCL_UK80 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693Gln (c.2077G>C); ClinVar=VCV000018087; Zygosity=Heterozygous (PubMed=30611017) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158431 CVCL_UK85 MCRIi004-A induced pluripotent stem cell human CVCL_UK85 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21158432 CVCL_UK86 MCRIi005-A induced pluripotent stem cell human CVCL_UK86 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21158433 CVCL_UK83 MCRIi002-A induced pluripotent stem cell human CVCL_UK83 From: Murdoch Children's Research Institute; Melbourne; Australia. CL:0000010 21158434 CVCL_UK84 MCRIi003-A induced pluripotent stem cell human CVCL_UK84 From: Murdoch Children's Research Institute; Melbourne; Australia. CL:0000010 21158435 CVCL_UK89 MCRIi008-A induced pluripotent stem cell human CVCL_UK89 From: Murdoch Children's Research Institute; Melbourne; Australia. CL:0000010 21158436 CVCL_UK87 MCRIi006-A induced pluripotent stem cell human CVCL_UK87 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158437 CVCL_UK88 MCRIi007-A induced pluripotent stem cell human CVCL_UK88 From: Murdoch Children's Research Institute; Melbourne; Australia. CL:0000010 21158438 CVCL_2E22 AG11697 finite cell line human CVCL_2E22 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [78%]; 45,X [16%]; 46,XY,add(1)(q43) [6%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG11697) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158439 CVCL_2E23 AG11698 finite cell line human CVCL_2E23 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [68%]; 46,XY,t(2;7)(q22;q31) [32%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 36 PDL (Coriell=AG11698) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158440 CVCL_2E20 AG11695 finite cell line human CVCL_2E20 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (Coriell=AG11695) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158441 CVCL_2E21 AG11696 finite cell line human CVCL_2E21 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 29 PDL (Coriell=AG11696) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158442 CVCL_2E26 AG11701 finite cell line human CVCL_2E26 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 29 PDL (Coriell=AG11701) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158443 CVCL_2E27 AG11702 finite cell line human CVCL_2E27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG11702) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158444 CVCL_2E24 AG11699 finite cell line human CVCL_2E24 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (Coriell=AG11699) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158445 CVCL_2E25 AG11700 finite cell line human CVCL_2E25 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 38 PDL (Coriell=AG11700) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158446 CVCL_2E28 AG11724 finite cell line human CVCL_2E28 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 35 PDL (Coriell=AG11724) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158447 CVCL_2E29 AG11725 finite cell line human CVCL_2E29 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158448 CVCL_UK70 BT085 cancer cell line human CVCL_UK70 CL:0000010 Male Group: Cancer stem cell line. 21158449 CVCL_UK71 BT090 cancer cell line human CVCL_UK71 CL:0000010 Male Group: Cancer stem cell line. 21158450 CVCL_UK74 BT189 cancer cell line human CVCL_UK74 CL:0000010 Omics: Transcriptome analysis by RNAseq. Group: Cancer stem cell line 21158451 CVCL_UK75 LUEi001-B induced pluripotent stem cell human CVCL_UK75 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (from autologous cell line LUEi001-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21158452 CVCL_UK72 BT094 cancer cell line human CVCL_UK72 CL:0000010 Derived from sampling site: Brain. Female Group: Cancer stem cell line 21158453 CVCL_UK73 BT121 cancer cell line human CVCL_UK73 CL:0000010 Male Group: Cancer stem cell line. 21158454 CVCL_UK78 LUMCi005-A induced pluripotent stem cell human CVCL_UK78 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693Gln (c.2077G>C); ClinVar=VCV000018087; Zygosity=Heterozygous (PubMed=30611017) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158455 CVCL_UK79 LUMCi005-B induced pluripotent stem cell human CVCL_UK79 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Glu693Gln (c.2077G>C); ClinVar=VCV000018087; Zygosity=Heterozygous (PubMed=30611017) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158456 CVCL_UK76 LUEi003-B induced pluripotent stem cell human CVCL_UK76 From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Lys158Asnfs*23 (c.474delA); ClinVar=VCV000001650; Zygosity=Heterozygous (from autologous cell line LUEi003-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21158457 CVCL_UK77 LUMCi004-A induced pluripotent stem cell human CVCL_UK77 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158458 CVCL_2E30 AG11726 finite cell line human CVCL_2E30 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Senescence: Senesces at 43 PDL (Coriell=AG11726) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158459 CVCL_2E33 AG11730 finite cell line human CVCL_2E33 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [2%]; 45,X [98%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158460 CVCL_2E34 AG11731 finite cell line human CVCL_2E34 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 28 PDL (Coriell=AG11731) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158461 CVCL_2E31 AG11727 finite cell line human CVCL_2E31 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 32 PDL (Coriell=AG11727) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158462 CVCL_2E32 AG11728 finite cell line human CVCL_2E32 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 46 PDL (Coriell=AG11728) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158463 CVCL_2E37 AG11734 finite cell line human CVCL_2E37 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158464 CVCL_2E38 AG11735 finite cell line human CVCL_2E38 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [93%]; 47,XX,+9 [7%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 18 PDL (Coriell=AG11735) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158465 CVCL_2E35 AG11732 finite cell line human CVCL_2E35 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158466 CVCL_2E36 AG11733 finite cell line human CVCL_2E36 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 21 PDL (Coriell=AG11733) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158467 CVCL_2E39 AG11736 finite cell line human CVCL_2E39 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;18)(q32;q21) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 66 PDL (Coriell=AG11736) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158468 CVCL_UK60 BT119 cancer cell line human CVCL_UK60 CL:0000010 Female Group: Cancer stem cell line. 21158469 CVCL_UK63 BT147 cancer cell line human CVCL_UK63 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21158470 CVCL_UK64 BT206 cancer cell line human CVCL_UK64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21158471 CVCL_UK61 BT124 cancer cell line human CVCL_UK61 CL:0000010 Unspecified Group: Cancer stem cell line. 21158472 CVCL_UK62 BT143 cancer cell line human CVCL_UK62 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Female Group: Cancer stem cell line 21158473 CVCL_UK67 BT134 cancer cell line human CVCL_UK67 CL:0000010 Omics: Transcriptome analysis by microarray. Group: Cancer stem cell line 21158474 CVCL_UK68 BT164 cancer cell line human CVCL_UK68 CL:0000010 Group: Cancer stem cell line. 21158475 CVCL_UK65 BT126 cancer cell line human CVCL_UK65 CL:0000010 Group: Cancer stem cell line. 21158476 CVCL_UK66 BT127 cancer cell line human CVCL_UK66 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Group: Cancer stem cell line 21158477 CVCL_UK69 BT084 cancer cell line human CVCL_UK69 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21158478 CVCL_CX35 GM00552 finite cell line human CVCL_CX35 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00552; probable Male 21158479 CVCL_D935 MRC-iPS-20 induced pluripotent stem cell human CVCL_D935 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158480 CVCL_CX36 GM00741 finite cell line human CVCL_CX36 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00741; probable Male 21158481 CVCL_D936 MRC-iPS-21 induced pluripotent stem cell human CVCL_D936 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158482 CVCL_CX33 GM00902 finite cell line human CVCL_CX33 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00902; probable Female 21158483 CVCL_D933 MRC-iPS-19 induced pluripotent stem cell human CVCL_D933 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: DNA methylation analysis Discontinued: SKIP; SKIP000168; probable Male 21158484 CVCL_CX34 GM00903 finite cell line human CVCL_CX34 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00903; probable Male 21158485 CVCL_D934 MRC-iPS-2 induced pluripotent stem cell human CVCL_D934 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000161; probable Male 21158486 CVCL_CX39 GM00904 finite cell line human CVCL_CX39 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00904; probable Female 21158487 CVCL_D939 MRC-iPS-26 induced pluripotent stem cell human CVCL_D939 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158488 CVCL_CX37 GM01068 finite cell line human CVCL_CX37 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01068; probable Male 21158489 CVCL_D937 MRC-iPS-23 induced pluripotent stem cell human CVCL_D937 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158490 CVCL_CX38 GM01070 finite cell line human CVCL_CX38 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01070; probable Female 21158491 CVCL_D938 MRC-iPS-24 induced pluripotent stem cell human CVCL_D938 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158492 CVCL_CX31 GM00002 finite cell line human CVCL_CX31 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00002; probable Male 21158493 CVCL_D931 MRC-iPS-16 induced pluripotent stem cell human CVCL_D931 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Glycosphingolipids analysis Discontinued: JCRB; NIHS0604; true; Discontinued: SKIP; SKIP000015; probable Male 21158494 CVCL_CX32 GM00901 finite cell line human CVCL_CX32 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00901; probable Male 21158495 CVCL_D932 MRC-iPS-17 induced pluripotent stem cell human CVCL_D932 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158496 CVCL_CX30 GM02274 finite cell line human CVCL_CX30 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158497 CVCL_D930 MRC-iPS-15 induced pluripotent stem cell human CVCL_D930 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158498 CVCL_CX46 GM01116 finite cell line human CVCL_CX46 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Glu408Lys (c.1222G>A) (E387K); ClinVar=VCV000036453; Zygosity=Homozygous (from autologous cell line GM02000) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01116; probable Female 21158499 CVCL_D946 MRC-iPS-33 induced pluripotent stem cell human CVCL_D946 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158500 CVCL_CX47 GM00853 finite cell line human CVCL_CX47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00853; probable Female 21158501 CVCL_D947 MRC-iPS-34 induced pluripotent stem cell human CVCL_D947 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000164; probable Male 21158502 CVCL_CX44 GM00918 finite cell line human CVCL_CX44 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21158503 CVCL_D944 MRC-iPS-31 induced pluripotent stem cell human CVCL_D944 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158504 CVCL_CX45 GM12369 finite cell line human CVCL_CX45 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21158505 CVCL_D945 MRC-iPS-32 induced pluripotent stem cell human CVCL_D945 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158506 CVCL_CX48 GM00854 finite cell line human CVCL_CX48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00854; probable Female 21158507 CVCL_D948 MRC-iPS-35 induced pluripotent stem cell human CVCL_D948 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158508 CVCL_CX49 GM00560 finite cell line human CVCL_CX49 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00560; probable Female 21158509 CVCL_D949 MRC-iPS-36 induced pluripotent stem cell human CVCL_D949 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158510 CVCL_CX42 GM00855 finite cell line human CVCL_CX42 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00855; probable Female 21158511 CVCL_D942 MRC-iPS-3 induced pluripotent stem cell human CVCL_D942 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158512 CVCL_CX43 GM00806 finite cell line human CVCL_CX43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00806; probable Female 21158513 CVCL_D943 MRC-iPS-30 induced pluripotent stem cell human CVCL_D943 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000167; probable Male 21158514 CVCL_CX40 GM00994 finite cell line human CVCL_CX40 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00994; probable Female 21158515 CVCL_D940 MRC-iPS-28 induced pluripotent stem cell human CVCL_D940 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158516 CVCL_CX41 GM00995 finite cell line human CVCL_CX41 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00995; probable Male 21158517 CVCL_D941 MRC-iPS-29 induced pluripotent stem cell human CVCL_D941 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158518 CVCL_D913 AM-iPS-19 induced pluripotent stem cell human CVCL_D913 CL:0000010 Derived from sampling site: Amnion. Female 21158519 CVCL_CX13 GM13440 finite cell line human CVCL_CX13 CL:0000010 Population: Jordanian; Derived from sampling site: Cell type=Fibroblast. Female 21158520 CVCL_D914 AM-iPS-2 induced pluripotent stem cell human CVCL_D914 CL:0000010 Derived from sampling site: Amnion. Female 21158521 CVCL_CX14 GM01159 finite cell line human CVCL_CX14 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01159; probable Male 21158522 CVCL_D911 AM-iPS-17 induced pluripotent stem cell human CVCL_D911 CL:0000010 Derived from sampling site: Amnion. Female 21158523 CVCL_CX11 GM10360 finite cell line human CVCL_CX11 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158524 CVCL_D912 AM-iPS-18 induced pluripotent stem cell human CVCL_D912 CL:0000010 Derived from sampling site: Amnion. Female 21158525 CVCL_CX12 GM13439 transformed cell line human CVCL_CX12 CL:0000010 Population: Jordanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158526 CVCL_D917 AM-iPS-4 induced pluripotent stem cell human CVCL_D917 CL:0000010 Derived from sampling site: Amnion. Female 21158527 CVCL_CX17 GM00218 finite cell line human CVCL_CX17 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00218; probable Male 21158528 CVCL_D918 AM-iPS-5 induced pluripotent stem cell human CVCL_D918 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21158529 CVCL_CX18 GM00888 finite cell line human CVCL_CX18 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00888; probable Male 21158530 CVCL_D915 AM-iPS-20 induced pluripotent stem cell human CVCL_D915 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21158531 CVCL_CX15 GM01557 finite cell line human CVCL_CX15 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01557; probable Male 21158532 CVCL_D916 AM-iPS-3 induced pluripotent stem cell human CVCL_D916 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21158533 CVCL_CX16 GM00264 finite cell line human CVCL_CX16 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00264; probable Male 21158534 CVCL_D910 AM-iPS-16 induced pluripotent stem cell human CVCL_D910 CL:0000010 Derived from sampling site: Amnion. Female 21158535 CVCL_CX10 GM01302 finite cell line human CVCL_CX10 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21158536 CVCL_D908 AM-iPS-13 induced pluripotent stem cell human CVCL_D908 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis Female 21158537 CVCL_CX08 GM01158 finite cell line human CVCL_CX08 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01158; probable Female 21158538 CVCL_D909 AM-iPS-15 induced pluripotent stem cell human CVCL_D909 CL:0000010 Derived from sampling site: Amnion. Female 21158539 CVCL_CX09 GM01301 finite cell line human CVCL_CX09 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158540 CVCL_CX24 GM00087 finite cell line human CVCL_CX24 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Thr284Leufs*5 (c.850delA) (1012delA); ClinVar=VCV000038434; Zygosity=Heterozygous (from familial inference of GM03066); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Cys528Valfs*19 (c.1581delC) (1744delC); ClinVar=VCV000038414; Zygosity=Heterozygous (from familial inference of GM03066) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00087; probable Male 21158541 CVCL_D924 MRC-iPS-10 induced pluripotent stem cell human CVCL_D924 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158542 CVCL_CX25 GM00521 finite cell line human CVCL_CX25 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Thr284Leufs*5 (c.850delA) (1012delA); ClinVar=VCV000038434; Zygosity=Heterozygous (from familial inference of GM03066); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Cys528Valfs*19 (c.1581delC) (1744delC); ClinVar=VCV000038414; Zygosity=Heterozygous (from familial inference of GM03066) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00521; probable Male 21158543 CVCL_D925 MRC-iPS-100 induced pluripotent stem cell human CVCL_D925 CL:0000010 Derived from sampling site: Fetal lung. Male 21158544 CVCL_D922 AM-iPS-9 induced pluripotent stem cell human CVCL_D922 CL:0000010 Derived from sampling site: Amnion. Female 21158545 CVCL_CX22 GM02224 finite cell line human CVCL_CX22 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02224; probable Female 21158546 CVCL_CX23 GM01851 finite cell line human CVCL_CX23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM01851; probable Male 21158547 CVCL_D923 MRC-iPS-1 induced pluripotent stem cell human CVCL_D923 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158548 CVCL_CX28 GM02045 finite cell line human CVCL_CX28 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02045; probable Male 21158549 CVCL_D928 MRC-iPS-13 induced pluripotent stem cell human CVCL_D928 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158550 CVCL_CX29 GM02145 finite cell line human CVCL_CX29 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02145; probable Male 21158551 CVCL_D929 MRC-iPS-14 induced pluripotent stem cell human CVCL_D929 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158552 CVCL_CX26 GM00164 finite cell line human CVCL_CX26 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00164; probable Male 21158553 CVCL_D926 MRC-iPS-101 induced pluripotent stem cell human CVCL_D926 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158554 CVCL_CX27 GM01742 finite cell line human CVCL_CX27 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01742; true Female 21158555 CVCL_D927 MRC-iPS-12 induced pluripotent stem cell human CVCL_D927 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21158556 CVCL_D920 AM-iPS-7 induced pluripotent stem cell human CVCL_D920 CL:0000010 Derived from sampling site: Amnion. Omics: Transcriptome analysis by microarray Female 21158557 CVCL_CX20 GM00683 finite cell line human CVCL_CX20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00683; probable Male 21158558 CVCL_D921 AM-iPS-8 induced pluripotent stem cell human CVCL_D921 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21158559 CVCL_CX21 GM00025 finite cell line human CVCL_CX21 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00025; probable Male 21158560 CVCL_D919 AM-iPS-6 induced pluripotent stem cell human CVCL_D919 CL:0000010 Derived from sampling site: Amnion. Omics: DNA methylation analysis Female 21158561 CVCL_CX19 GM00579 finite cell line human CVCL_CX19 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21158562 CVCL_D902 DB-1 [Human melanoma] cancer cell line human CVCL_D902 CL:0000010 Derived from metastatic site: Lymph node. Unspecified Doubling time: 48 hours (PubMed=12479222) 21158563 CVCL_CX02 GM00880 finite cell line human CVCL_CX02 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158564 CVCL_D903 DB-8 cancer cell line human CVCL_D903 CL:0000010 Derived from metastatic site: Lymph node. Unspecified Doubling time: 48 hours (PubMed=12479222) 21158565 CVCL_CX03 GM01140 finite cell line human CVCL_CX03 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158566 CVCL_CX00 GM00976 finite cell line human CVCL_CX00 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00976; probable Female 21158567 CVCL_D900 NEF spontaneously immortalized cell line house mouse CVCL_D900 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Expresses ~300000 EGFR (PubMed=1417788) 21158568 CVCL_CX01 GM00747 finite cell line human CVCL_CX01 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158569 CVCL_D901 JJ012-TS4 cancer cell line human CVCL_D901 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Gly (c.394C>G); ClinVar=VCV000375892; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Val (c.596G>T); ClinVar=VCV000451799; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 220; ADAMTS4. Male 21158570 CVCL_D906 AM-iPS-11 induced pluripotent stem cell human CVCL_D906 CL:0000010 Derived from sampling site: Amnion. Female 21158571 CVCL_CX06 GM00427 finite cell line human CVCL_CX06 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00427; probable Male 21158572 CVCL_D907 AM-iPS-12 induced pluripotent stem cell human CVCL_D907 CL:0000010 Derived from sampling site: Amnion. Female 21158573 CVCL_CX07 GM01000 finite cell line human CVCL_CX07 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01000; probable Female 21158574 CVCL_D904 AM-iPS-1 induced pluripotent stem cell human CVCL_D904 CL:0000010 Derived from sampling site: Amnion. Female 21158575 CVCL_CX04 GM01162 finite cell line human CVCL_CX04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158576 CVCL_D905 AM-iPS-10 induced pluripotent stem cell human CVCL_D905 CL:0000010 Derived from sampling site: Amnion. Female 21158577 CVCL_CX05 GM01297 finite cell line human CVCL_CX05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21158578 CVCL_CW94 GM50082 hybrid cell line human CVCL_CW94 CL:0000010 Group: Human/rodent somatic cell hybrid. 21158579 CVCL_D894 SRD-6A spontaneously immortalized cell line CVCL_D894 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2682; Amphotericin B; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21158580 CVCL_CW95 CHO-mB7 spontaneously immortalized cell line CVCL_CW95 CL:0000010 Transfected with: MGI; MGI:101775; Cd80 Derived from sampling site: Ovary. Female 21158581 CVCL_D895 SRD-6B transformed cell line CVCL_D895 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2682; Amphotericin B; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 21158582 CVCL_D892 MGL8 transformed cell line human CVCL_D892 CL:0000010 Derived from sampling site: Peripheral blood. Male 21158583 CVCL_CW92 N/TERT-1 telomerase immortalized cell line human CVCL_CW92 CL:0000010 Transfected with: HGNC; 11730; TERT Karyotypic information: 47,XY,+20 (PubMed=28928444); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21158584 CVCL_D893 CHO-7 spontaneously immortalized cell line CVCL_D893 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Were derived from parent cell line by adaptation to continuous growth in lipoprotein-deficient serum 21158585 CVCL_CW93 GGR51 hybridoma house mouse CVCL_CW93 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:90151; Ganglioside GM1b. 21158586 CVCL_D898 CHO-9 spontaneously immortalized cell line CVCL_D898 CL:0000010 Derived from sampling site: Ovary. Female 21158587 CVCL_CW98 GM00906 finite cell line human CVCL_CW98 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Trp138Ter (c.414G>A); ClinVar=VCV000004443; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158588 CVCL_CW99 GM00907 finite cell line human CVCL_CW99 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; c.970+2T>C (IVS11+2T>C); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158589 CVCL_D899 HEI-OC1 conditionally immortalized cell line house mouse CVCL_D899 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; inner ear; cochlea; organ of Corti; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Growth at the permissive (33 Celsius) temperature results in dedifferentiation of the cells and accelerated proliferation At the restrictive temperature (39 Celsius) cell proliferation halts in about 48h. 21158590 CVCL_CW96 GM00093 finite cell line human CVCL_CW96 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Discontinued: Coriell; GM00093; probable Male 21158591 CVCL_D896 SRD-6C transformed cell line CVCL_D896 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2682; Amphotericin B; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 21158592 CVCL_CW97 GM02066 finite cell line human CVCL_CW97 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Pro48Leufs*7 (c.225+5G>A); Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Gly339Arg (c.1015G>A); ClinVar=VCV000004455; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158593 CVCL_D897 SRD-6D transformed cell line CVCL_D897 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2682; Amphotericin B; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 21158594 CVCL_LQ28 BayGenomics ES cell line BGB038 embryonic stem cell house mouse CVCL_LQ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861942; Gtf2ird1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158595 CVCL_M228 MH2-FA transformed cell line human CVCL_M228 CL:0000010 Population: Arab; Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 69 hours (PubMed=3030788) 21158596 CVCL_LQ29 BayGenomics ES cell line BGB042 embryonic stem cell house mouse CVCL_LQ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644008; Ccdc85c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158597 CVCL_M229 MH3-XPD transformed cell line human CVCL_M229 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 32 hours (PubMed=3030788) 21158598 CVCL_LQ26 BayGenomics ES cell line BGB007 embryonic stem cell house mouse CVCL_LQ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341870; Stk11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158599 CVCL_M226 CW4-XPG transformed cell line human CVCL_M226 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Arg372Thrfs*5 (c.1115_1118delGGAA); ClinVar=VCV000016574; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu858Pro (c.2573T>C); ClinVar=VCV000016573; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 60 hours (PubMed=3030788) 21158600 CVCL_LQ27 BayGenomics ES cell line BGB015 embryonic stem cell house mouse CVCL_LQ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924039; Mzt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158601 CVCL_M227 MH1-BS transformed cell line human CVCL_M227 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln752Ter (c.2328C>T); Zygosity=Heterozygous (from parent cell line) Population: African American; Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Donor information: From Bloom Syndrome Registry patient 71(HaEn) (BSR71); Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 44 hours (PubMed=3030788) 21158602 CVCL_LQ24 BayGenomics ES cell line BGB003 embryonic stem cell house mouse CVCL_LQ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158603 CVCL_M224 CW12-XPC transformed cell line human CVCL_M224 CL:0000010 Population: Egyptian; Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158604 CVCL_D890 HPK-1A transformed cell line human CVCL_D890 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Virology: Contains 2 to 3 copies of the complete HPV16 genomes arranged in a head-to-tail fashion and integrated at a single chromosomal site 21158605 CVCL_CW90 TY25 hybridoma CVCL_CW90 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9WUL5; Mouse Pdcd1lg2/Cd273. 21158606 CVCL_LQ25 BayGenomics ES cell line BGB005 embryonic stem cell house mouse CVCL_LQ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158607 CVCL_M225 CW3-XPE transformed cell line human CVCL_M225 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000008788; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 15 hours (PubMed=3030788) 21158608 CVCL_D891 HPK-1A-ras transformed cell line human CVCL_D891 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Virology: Contains several complete HPV16 genomes arranged in a head-to-tail fashion and integrated at a single chromosomal site 21158609 CVCL_CW91 Huh-7-Lunet/Con1 cancer cell line human CVCL_CW91 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male 21158610 CVCL_M222 AG02804 transformed cell line human CVCL_M222 CL:0000010 Transformant: Simian virus 40 (SV40) [Rh911](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21158611 CVCL_LQ22 BayGenomics ES cell line BGB001 embryonic stem cell house mouse CVCL_LQ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922867; Rps25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158612 CVCL_LQ23 BayGenomics ES cell line BGB002 embryonic stem cell house mouse CVCL_LQ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158613 CVCL_M223 XP2BI finite cell line human CVCL_M223 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Arg372Thrfs*5 (c.1115_1118delGGAA); ClinVar=VCV000016574; Zygosity=Heterozygous (PubMed=11841555); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu858Pro (c.2573T>C); ClinVar=VCV000016573; Zygosity=Heterozygous (PubMed=11841555) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158614 CVCL_LQ20 BayGenomics ES cell line BGA626 embryonic stem cell house mouse CVCL_LQ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158615 CVCL_M220 TVMBO cancer cell line human CVCL_M220 CL:0000010 Unspecified 21158616 CVCL_LQ21 BayGenomics ES cell line BGA637 embryonic stem cell house mouse CVCL_LQ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919297; Ddx42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158617 CVCL_M221 XP44RO finite cell line human CVCL_M221 CL:0000010 Derived from sampling site: Testis. Male 21158618 CVCL_LQ39 BayGenomics ES cell line BGB113 embryonic stem cell house mouse CVCL_LQ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104889; Ubp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158619 CVCL_M239 GENEA088 embryonic stem cell human CVCL_M239 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0260; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50.. 21158620 CVCL_LQ37 BayGenomics ES cell line BGB088 embryonic stem cell house mouse CVCL_LQ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928277; Afg3l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158621 CVCL_M237 GENEA086 embryonic stem cell human CVCL_M237 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA087 (Cellosaurus=CVCL_M238). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0258; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21158622 CVCL_LQ38 BayGenomics ES cell line BGB112 embryonic stem cell house mouse CVCL_LQ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158623 CVCL_M238 GENEA087 embryonic stem cell human CVCL_M238 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA086 (Cellosaurus=CVCL_M237). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0259; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-50. 21158624 CVCL_LQ35 BayGenomics ES cell line BGB076 embryonic stem cell house mouse CVCL_LQ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158625 CVCL_M235 GENEA084 embryonic stem cell human CVCL_M235 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA083 (Cellosaurus=CVCL_M234). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0257; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-53. 21158626 CVCL_LQ36 BayGenomics ES cell line BGB085 embryonic stem cell house mouse CVCL_LQ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158627 CVCL_M236 GENEA085 embryonic stem cell human CVCL_M236 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0250; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-53.. 21158628 CVCL_LQ33 BayGenomics ES cell line BGB069 embryonic stem cell house mouse CVCL_LQ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97572; Phb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158629 CVCL_M233 XP6JO finite cell line human CVCL_M233 CL:0000010 Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21158630 CVCL_LQ34 BayGenomics ES cell line BGB070 embryonic stem cell house mouse CVCL_LQ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444453; Arhgef10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158631 CVCL_M234 GENEA083 embryonic stem cell human CVCL_M234 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA084 (Cellosaurus=CVCL_M235). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0256; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-52. 21158632 CVCL_LQ31 BayGenomics ES cell line BGB067 embryonic stem cell house mouse CVCL_LQ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914587; Cstf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158633 CVCL_M231 XP2NBi finite cell line human CVCL_M231 CL:0000010 Population: African; Kikuyu; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21158634 CVCL_LQ32 BayGenomics ES cell line BGB068 embryonic stem cell house mouse CVCL_LQ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158635 CVCL_M232 XP1NBi finite cell line human CVCL_M232 CL:0000010 Population: African; Kikuyu; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158636 CVCL_M230 AG03204 transformed cell line human CVCL_M230 CL:0000010 Transformant: Simian virus 40 (SV40) [Rh911](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21158637 CVCL_LQ30 BayGenomics ES cell line BGB066 embryonic stem cell house mouse CVCL_LQ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158638 CVCL_CW78 GM06973 transformed cell line human CVCL_CW78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158639 CVCL_D878 Troja 2 cancer cell line human CVCL_D878 CL:0000010 Derived from metastatic site: Liver. Unspecified 21158640 CVCL_D879 CCO7 cancer cell line human CVCL_D879 From: Bodmer W.F.; International Cancer Research Fund; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=16418264) Omics: Deep proteome analysis. 21158641 CVCL_CW79 GM07321 finite cell line human CVCL_CW79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158642 CVCL_D872 GM01366 transformed cell line human CVCL_D872 HLA typing: A*02,09; B*08,12 (Coriell=GM01366) CL:0000010 Sequence variation: Mutation; HGNC; 2698; DBT; Simple; p.Glu224Ter (c.670G>T) (E163X); ClinVar=VCV000094009; Zygosity=Homozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158643 CVCL_CW72 GM03073 finite cell line human CVCL_CW72 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21158644 CVCL_D873 GM01835 finite cell line human CVCL_D873 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21158645 CVCL_CW73 GM03074 finite cell line human CVCL_CW73 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Female 21158646 CVCL_D870 GM01500 transformed cell line human CVCL_D870 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Characteristics: Secretes IgG2 kappa Problematic cell line: Misclassified Originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21158647 CVCL_CW70 GM02075 finite cell line human CVCL_CW70 CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Ala40Glyfs*24 (c.118dupG) (c.118_119insG); ClinVar=VCV000003810; Zygosity=Heterozygous (PubMed=8896560) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158648 CVCL_D871 GM01364 finite cell line human CVCL_D871 CL:0000010 Sequence variation: Mutation; HGNC; 2698; DBT; Simple; p.Glu224Ter (c.670G>T) (E163X); ClinVar=VCV000094009; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21158649 CVCL_CW71 GM02870 finite cell line human CVCL_CW71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21158650 CVCL_CW76 GM03365 transformed cell line human CVCL_CW76 CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Arg1104Ter (c.3310C>T); ClinVar=VCV000003809; Zygosity=Homozygous (PubMed=8896560) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158651 CVCL_D876 NCM425 spontaneously immortalized cell line human CVCL_D876 CL:0000010 Population: Hispanic; Donor information: Established from the normal tissue of a patient suffering from a colone adenocarcinoma; Derived from sampling site: Colon; mucosa Cell type=Epithelial cell.. Male Doubling time: 34 hours (PubMed=7840378) 21158652 CVCL_CW77 GM06972 transformed cell line human CVCL_CW77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158653 CVCL_D877 Troja 1 cancer cell line human CVCL_D877 CL:0000010 Derived from metastatic site: Liver. Unspecified 21158654 CVCL_LQ08 BayGenomics ES cell line BGA536 embryonic stem cell house mouse CVCL_LQ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647820; Hectd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158655 CVCL_M208 EHMES-10 cancer cell line human CVCL_M208 CL:0000010 Population: Japanese Unspecified Doubling time: 36 hours (PubMed=16542214). 21158656 CVCL_D874 GM01836 transformed cell line human CVCL_D874 CL:0000010 Population: Jewish and Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158657 CVCL_CW74 GM03075 finite cell line human CVCL_CW74 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21158658 CVCL_LQ09 BayGenomics ES cell line BGA539 embryonic stem cell house mouse CVCL_LQ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158659 CVCL_CW75 GM03076 finite cell line human CVCL_CW75 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21158660 CVCL_D875 NCM356 spontaneously immortalized cell line human CVCL_D875 CL:0000010 Population: African American; Donor information: Established from the normal tissue of a patient suffering from a rectal adenocarcinoma; Derived from sampling site: Colon; mucosa Cell type=Epithelial cell.. Male Doubling time: 24 hours (PubMed=7840378); 32-35 hours (INCELL) 21158661 CVCL_M209 THLE-5B transformed cell line human CVCL_M209 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11113 21158662 CVCL_LQ06 BayGenomics ES cell line BGA526 embryonic stem cell house mouse CVCL_LQ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339639; Ogt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158663 CVCL_M206 Y-MESO-45 cancer cell line human CVCL_M206 CL:0000010 Population: Japanese. Female 21158664 CVCL_LQ07 BayGenomics ES cell line BGA534 embryonic stem cell house mouse CVCL_LQ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88568; Cux1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158665 CVCL_M207 EHMES-1 cancer cell line human CVCL_M207 CL:0000010 Population: Japanese. Unspecified 21158666 CVCL_LQ04 BayGenomics ES cell line BGA514 embryonic stem cell house mouse CVCL_LQ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97837; Qk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158667 CVCL_M204 Y-MESO-37 cancer cell line human CVCL_M204 CL:0000010 Population: Japanese. Male 21158668 CVCL_LQ05 BayGenomics ES cell line BGA523 embryonic stem cell house mouse CVCL_LQ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158669 CVCL_M205 Y-MESO-43 cancer cell line human CVCL_M205 CL:0000010 Population: Japanese. Male 21158670 CVCL_LQ02 BayGenomics ES cell line BGA510 embryonic stem cell house mouse CVCL_LQ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916976; Smyd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158671 CVCL_M202 REN cancer cell line human CVCL_M202 CL:0000010 21158672 CVCL_LQ03 BayGenomics ES cell line BGA513 embryonic stem cell house mouse CVCL_LQ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858330; Nxf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158673 CVCL_M203 Y-MESO-32 cancer cell line human CVCL_M203 CL:0000010 Population: Japanese. 21158674 CVCL_LQ00 BayGenomics ES cell line BGA493 embryonic stem cell house mouse CVCL_LQ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158675 CVCL_M200 I-45 cancer cell line human CVCL_M200 From: Testa J.; Fox Chase Cancer Center; Philadelphia; USA. CL:0000010 21158676 CVCL_LQ01 BayGenomics ES cell line BGA505 embryonic stem cell house mouse CVCL_LQ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88192; Smarca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158677 CVCL_M201 I-45-BTZ-R cancer cell line human CVCL_M201 CL:0000010 Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade). 21158678 CVCL_D889 KM20L2 cancer cell line human CVCL_D889 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00514 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=15703300; resulting in a decision not to include the cell line in the NCI60 panel). 21158679 CVCL_CW89 MIH6 hybridoma CVCL_CW89 CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; Q9EP73; Mouse Cd274. 21158680 CVCL_CW83 GM14624 transformed cell line human CVCL_CW83 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Leu1908Argfs*2 (c.5718_5719CT[2]) (c.5722_5723delCT); ClinVar=VCV000009320; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158681 CVCL_D883 KE-3 cancer cell line human CVCL_D883 HLA typing: A*02:24; B*07,61; C*07 (PubMed=7671230); HLA typing: A*02:06,24:02; C*04:01,15:02 (PubMed=9023415); HLA typing: A*02:06,24:02; B*07,61; C*01:02,03:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Unspecified 21158682 CVCL_CW84 GM14626 transformed cell line human CVCL_CW84 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158683 CVCL_D884 KE-4 cancer cell line human CVCL_D884 HLA typing: A*24:02,26:01; B*54,60; C*01,03 (PubMed=7671230); HLA typing: A*24:02,26:01; C*01:01,03:02 (PubMed=9023415); HLA typing: A*24:02,26:01; B*54,60; C*04:01,15:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Unspecified 21158684 CVCL_CW81 GM07843 finite cell line human CVCL_CW81 CL:0000010 Sequence variation: Mutation; HGNC; 4801; HADHA; Simple; p.Glu510Gln (c.1528G>C); ClinVar=VCV000100085; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158685 CVCL_D881 OS2000 cancer cell line human CVCL_D881 HLA typing: A*24:02; B*55:02,40:02; C*01:02 (PubMed=15289353); HLA typing: A*24; B*55,61; C*01 (PubMed=19818766) CL:0000010 Population: Japanese; Derived from sampling site: Bone; femur. Female 21158686 CVCL_CW82 GM14623 transformed cell line human CVCL_CW82 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr42Cys (c.125A>G); ClinVar=VCV000037734; Zygosity=Unspecified; Note=Predicted to be non-pathogenic (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158687 CVCL_D882 KMG-A cancer cell line human CVCL_D882 HLA typing: A*26:01; B*40:02; C*03:04 (PubMed=9023415). CL:0000010 Population: Japanese Male Doubling time: 28.5 hours (PubMed=2450224); 26 hours (PubMed=21544480) 21158688 CVCL_CW87 ND12315 transformed cell line human CVCL_CW87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158689 CVCL_D887 RMNE6 transformed cell line Norway rat CVCL_D887 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; ventral mesencephalon Cell type=Neuron.. Unspecified 21158690 CVCL_CW88 MIH5 hybridoma CVCL_CW88 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9EP73; Mouse Cd274. 21158691 CVCL_D888 NFL/T transformed cell line human CVCL_D888 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16-SV40(ori-)](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver. Female 21158692 CVCL_LQ19 BayGenomics ES cell line BGA613 embryonic stem cell house mouse CVCL_LQ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443878; Slc4a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158693 CVCL_CW85 GM14639 transformed cell line human CVCL_CW85 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2067Hisfs*10 (c.6198_6199delTT); ClinVar=VCV000052027; Zygosity=Unspecified (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158694 CVCL_M219 IPC-292 cancer cell line human CVCL_M219 CL:0000010 Female Doubling time: 133 hours (PubMed=8325707). 21158695 CVCL_D885 KiKu cancer cell line human CVCL_D885 HLA typing: A*02:06,24:02; B*40:06,52:01; C*08:01,12:02 (PubMed=15289353) CL:0000010 Population: Japanese; Derived from sampling site: Bone. Female 21158696 CVCL_CW86 GM23312 cancer cell line human CVCL_CW86 CL:0000010 Male 21158697 CVCL_D886 NT/T-S transformed cell line human CVCL_D886 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube. Female 21158698 CVCL_LQ17 BayGenomics ES cell line BGA578 embryonic stem cell house mouse CVCL_LQ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448542; Samd4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158699 CVCL_M217 IPC-227F cancer cell line human CVCL_M217 CL:0000010 Female Doubling time: 72 hours (PubMed=8325707) 21158700 CVCL_LQ18 BayGenomics ES cell line BGA585 embryonic stem cell house mouse CVCL_LQ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183441; Psat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158701 CVCL_M218 IPC-281 cancer cell line human CVCL_M218 CL:0000010 Male Doubling time: 432 hours (PubMed=8325707). 21158702 CVCL_LQ15 BayGenomics ES cell line BGA567 embryonic stem cell house mouse CVCL_LQ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158703 CVCL_M215 IPC-211 cancer cell line human CVCL_M215 CL:0000010 Male Doubling time: 86 hours (PubMed=8325707). 21158704 CVCL_LQ16 BayGenomics ES cell line BGA575 embryonic stem cell house mouse CVCL_LQ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158705 CVCL_M216 IPC-227E cancer cell line human CVCL_M216 CL:0000010 Female Doubling time: 336 hours (PubMed=8325707) 21158706 CVCL_LQ13 BayGenomics ES cell line BGA558 embryonic stem cell house mouse CVCL_LQ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915080; Rer1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158707 CVCL_M213 IPC-209 cancer cell line human CVCL_M213 CL:0000010 Female Doubling time: 168 hours (PubMed=8325707). 21158708 CVCL_LQ14 BayGenomics ES cell line BGA563 embryonic stem cell house mouse CVCL_LQ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920977; Mcmbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158709 CVCL_D880 Fuji cancer cell line human CVCL_D880 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=7539744) Population: Japanese Omics: Transcriptome analysis by RNAseq. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158710 CVCL_CW80 GM07398 finite cell line human CVCL_CW80 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158711 CVCL_M214 IPC-285 cancer cell line human CVCL_M214 CL:0000010 Female Doubling time: 92 hours (PubMed=8325707). 21158712 CVCL_LQ11 BayGenomics ES cell line BGA544 embryonic stem cell house mouse CVCL_LQ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158713 CVCL_M211 QM5 cancer cell line CVCL_M211 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line 21158714 CVCL_LQ12 BayGenomics ES cell line BGA556 embryonic stem cell house mouse CVCL_LQ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914838; Rnf41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158715 CVCL_M212 FRM [Human melanoma] cancer cell line human CVCL_M212 From: Zupi G.; Laboratory of Chemotherapy, Regina Elena Institute for Cancer Research; Rome; Italy. CL:0000010 21158716 CVCL_LQ10 BayGenomics ES cell line BGA543 embryonic stem cell house mouse CVCL_LQ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349767; Polk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158718 CVCL_D858 alphaTN4-1 transformed cell line house mouse CVCL_D858 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Cryaa-TAg transgenic. 21158719 CVCL_CW58 X19 hybridoma house mouse CVCL_CW58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q00610; Human CLTC. 21158720 CVCL_CW59 16D6-3 hybridoma CVCL_CW59 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02776; Human PF4/CXCL4. 21158721 CVCL_D859 OC3 cancer cell line human CVCL_D859 CL:0000010 Population: Chinese; Taiwan Omics: Transcriptome analysis by microarray. Male Doubling time: 16 hours, at 8th passage (PubMed=14720193) 21158722 CVCL_D856 11-18-ER1-7 cancer cell line human CVCL_D856 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Unspecified 21158723 CVCL_CW56 CB-16 hybridoma house mouse CVCL_CW56 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08637; Human FCGR3A/CD16. 21158724 CVCL_D857 11-18-ER2-1 cancer cell line human CVCL_D857 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Unspecified 21158725 CVCL_CW57 EP5 hybridoma house mouse CVCL_CW57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 21158726 CVCL_CW50 FR10B4 hybridoma house mouse CVCL_CW50 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20273; Human CD22. 21158727 CVCL_D850 HMY-2 cancer cell line human CVCL_D850 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=6239887) Population: Japanese; Derived from metastatic site: Right inguinal lymph node. Female 21158728 CVCL_D851 B-4 transformed cell line human CVCL_D851 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Unspecified 21158729 CVCL_CW51 WT-31 hybridoma house mouse CVCL_CW51 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21158730 CVCL_CW54 RIV9 hybridoma house mouse CVCL_CW54 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P07766; Human CD3E. 21158731 CVCL_D854 SK-MEL-7 cancer cell line human CVCL_D854 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Derived from metastatic site: Not specified. Male 21158732 CVCL_CW55 B-R18 hybridoma house mouse CVCL_CW55 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25445; Human FAS/CD95. 21158733 CVCL_D855 Swan 71 telomerase immortalized cell line human CVCL_D855 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Karyotypic information: Near pentaploid karyotype (PubMed=28454693); Derived from sampling site: Trophoblast. Female Doubling time: 14-24 hours (ABM) 21158734 CVCL_D852 MM96E cancer cell line human CVCL_D852 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Female Characteristics: Lightly pigmented 21158735 CVCL_CW52 RIV6 hybridoma house mouse CVCL_CW52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 21158736 CVCL_D853 MM96L cancer cell line human CVCL_D853 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Female 21158737 CVCL_CW53 RIV7 hybridoma house mouse CVCL_CW53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 21158738 CVCL_CW69 GM02039 finite cell line human CVCL_CW69 CL:0000010 Population: Caucasian; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21158739 CVCL_D869 GM02338 finite cell line human CVCL_D869 CL:0000010 Population: Caucasian; Derived from sampling site: Amniotic fluid. Male 21158740 CVCL_CW67 GM50086 hybrid cell line human CVCL_CW67 CL:0000010 Group: Human/rodent somatic cell hybrid. 21158741 CVCL_CW68 GM02038 finite cell line human CVCL_CW68 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158742 CVCL_D868 GM02292 transformed cell line human CVCL_D868 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158743 CVCL_D861 GM02606 transformed cell line human CVCL_D861 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg101Trp (c.301C>T); ClinVar=VCV000001955; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211His (c.632G>A); ClinVar=VCV000001957; Zygosity=Heterozygous (PubMed=1346349) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158744 CVCL_CW61 S148 hybridoma house mouse CVCL_CW61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O75683; Human SURF6 (Note=Also reacts with mouse). Group: Patented cell line 21158745 CVCL_D862 GM02446 finite cell line human CVCL_D862 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211His (c.632G>A); ClinVar=VCV000001957; Zygosity=Homozygous (Coriell) Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Female 21158746 CVCL_CW62 S79 hybridoma house mouse CVCL_CW62 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75683; Human SURF6. 21158747 CVCL_D860 GM02184 transformed cell line human CVCL_D860 HLA typing: A*24:02:01,30:02:01; B*18:01:01,49:01:01; C*05:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,02:02:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,11:04:01; DRB3*02:02:01,02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21158748 CVCL_CW60 SpG213Dc hybridoma CVCL_CW60 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; B2RUZ4; Human SMIM1. 21158749 CVCL_CW65 Cdelta2+ spontaneously immortalized cell line pig CVCL_CW65 CL:0000010 Miscellaneous: The '+' in the cell line name denotes the inclusion of LM929 supernatant in the culture medium Derived from sampling site: Peripheral blood Cell type=Macrophage.; Breed/subspecies: USMARC mixed breed. Female Characteristics: Bactericidal against Gram- (E.coli) and Gram+ (S.aureus) organisms 21158750 CVCL_D865 GM03043 transformed cell line human CVCL_D865 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Thr233Ile (c.698C>T); ClinVar=VCV000001980; Zygosity=Homozygous (Coriell) Population: African; !Kung; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21158751 CVCL_CW66 Cdelta2- spontaneously immortalized cell line pig CVCL_CW66 CL:0000010 Miscellaneous: The '-' in the cell line name denotes the absence of LM929 supernatant in the culture medium Derived from sampling site: Peripheral blood Cell type=Macrophage.; Breed/subspecies: USMARC mixed breed. Female Characteristics: Bactericidal against Gram- (E.coli) and Gram+ (S.aureus) organisms 21158752 CVCL_D866 GM03029 finite cell line human CVCL_D866 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Thr233Ile (c.698C>T); ClinVar=VCV000001980; Zygosity=Homozygous (Coriell) Population: African; !Kung; Derived from sampling site: Cell type=Fibroblast. Male 21158753 CVCL_D863 GM02607 finite cell line human CVCL_D863 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21158754 CVCL_CW63 SA12 hybridoma house mouse CVCL_CW63 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09428; Bovine IL1B (Note=Also reacts with human). 21158755 CVCL_CW64 GiCB spontaneously immortalized cell line CVCL_CW64 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Highly susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=25912023) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013179 21158756 CVCL_D864 GM02608 transformed cell line human CVCL_D864 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158757 CVCL_CW36 K4 [Mouse hybridoma] hybridoma house mouse CVCL_CW36 CL:0000010 Discontinued: ATCC; HB-8550; probable. Monoclonal antibody isotype: IgG1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8550 21158758 CVCL_D836 NZM046 cancer cell line human CVCL_D836 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=23658559); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by microarray. 21158759 CVCL_D837 NZM005 cancer cell line human CVCL_D837 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Axillary lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 30 hours (PubMed=7718330); 48 hours (CBA) 21158760 CVCL_CW37 P12 hybridoma house mouse CVCL_CW37 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8551 21158761 CVCL_CW34 F-3 hybridoma house mouse CVCL_CW34 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8217 21158762 CVCL_D834 NZM043 cancer cell line human CVCL_D834 HLA typing: A*03:01,24:02; B*07:02,52:01; C*07:02,12:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790) Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 5-6 days (CBA) 21158763 CVCL_CW35 K21 hybridoma house mouse CVCL_CW35 CL:0000010 Discontinued: ATCC; HB-8549; probable. Monoclonal antibody isotype: IgM Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8549 21158764 CVCL_D835 NZM045 cancer cell line human CVCL_D835 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Arg183Cys (c.547C>T); ClinVar=VCV000548668; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. 21158765 CVCL_CW38 9H7 hybridoma house mouse CVCL_CW38 CL:0000010 Monoclonal antibody isotype: IgG. 21158766 CVCL_D838 NZM052 cancer cell line human CVCL_D838 HLA typing: A*01:01,32:01; B*07:02,35:01; C*04:01,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. 21158767 CVCL_CW39 5C5 [Mouse hybridoma against L.donovani gp63] hybridoma house mouse CVCL_CW39 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P23223; Leishmania donovani gp63 (Note=Also reacts with other Leishmania species gp63). 21158768 CVCL_D839 NZM053 cancer cell line human CVCL_D839 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by microarray. 21158769 CVCL_CW32 CIRC-HLF-CI finite cell line human CVCL_CW32 CL:0000010 Donor information: Established from the lung biopsy of a victim of chemical weapons who sustained injury 23 years before the cell line was established; Derived from sampling site: Lung Cell type=Fibroblast.. Unspecified 21158770 CVCL_D832 NZM040 cancer cell line human CVCL_D832 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Homozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=23755070; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249_Thr253del; Zygosity=Unspecified (PubMed=23755070) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 38 hours (CBA) 21158771 CVCL_D833 NZM042 cancer cell line human CVCL_D833 HLA typing: A*03:01,11:01; B*07:02,45:01; C*06:02,07:02 (PubMed=32567790) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=32567790; CBA); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 70-80 hours (CBA) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158772 CVCL_CW33 S8 hybridoma house mouse CVCL_CW33 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9036 21158773 CVCL_CW30 CHOS cancer cell line human CVCL_CW30 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Bone; scapula. Male Doubling time: 36 hours (PubMed=27017908) 21158774 CVCL_D830 NZM034 cancer cell line human CVCL_D830 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790). Male Doubling time: 40.8 hours (CelloPub=CLPUB00227) 21158775 CVCL_CW31 CIRC-HLF finite cell line human CVCL_CW31 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21158776 CVCL_D831 NZM004 cancer cell line human CVCL_D831 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Unspecified (PubMed=11216673; PubMed=21912889) Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 29.8 hours (CelloPub=CLPUB00227); 48 hours (CBA) 21158777 CVCL_D847 NZM009 cancer cell line human CVCL_D847 CL:0000010 Derived from metastatic site: Axillary lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 45.6 hours (CelloPub=CLPUB00227) 21158778 CVCL_CW47 PS-iPS2 induced pluripotent stem cell human CVCL_CW47 CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10949del2501; Zygosity=Heteroplasmic (PubMed=23400930) Derived from sampling site: Bone marrow. Female 21158779 CVCL_D848 MM96 cancer cell line human CVCL_D848 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis Female 21158780 CVCL_CW48 PS-iPS3 induced pluripotent stem cell human CVCL_CW48 CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10949del2501; Zygosity=Heteroplasmic (PubMed=23400930) Derived from sampling site: Bone marrow. Female 21158781 CVCL_CW45 227-341-4 hybridoma house mouse CVCL_CW45 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P0CE94; Dictyostelium discoideum talA. 21158782 CVCL_D845 NZM007.4 cancer cell line human CVCL_D845 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11216673) Derived from metastatic site: Cervical lymph node. Omics: Transcriptome analysis by microarray Male 21158783 CVCL_D846 NZM008 cancer cell line human CVCL_D846 CL:0000010 Miscellaneous: Cell line has been lost. Male Doubling time: 100 hours (PubMed=7718330) 21158784 CVCL_CW46 PS-iPS1 induced pluripotent stem cell human CVCL_CW46 CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10949del2501; Zygosity=Heteroplasmic (PubMed=23400930) Derived from sampling site: Bone marrow. Female 21158785 CVCL_CW49 L6-20-4 hybridoma house mouse CVCL_CW49 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30408; Human TM4SF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8677 21158786 CVCL_D849 MM253-12M cancer cell line human CVCL_D849 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Lymph node. Male 21158787 CVCL_CW40 4C8 [Mouse hybridoma against L.donovani gp63] hybridoma house mouse CVCL_CW40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23223; Leishmania donovani gp63 (Note=Also reacts with other Leishmania species gp63). 21158788 CVCL_D840 NZM057 cancer cell line human CVCL_D840 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by microarray. 21158789 CVCL_CW43 BB7.8 hybridoma house mouse CVCL_CW43 CL:0000010 Monoclonal antibody isotype: IgG2b. 21158790 CVCL_D843 NZM007 cancer cell line human CVCL_D843 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Unspecified (PubMed=11216673; PubMed=21912889) Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 24 hours (PubMed=7718330); 49 hours (CBA) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158791 CVCL_D844 NZM007.2 cancer cell line human CVCL_D844 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Arg429Cys (c.1285C>T); dbSNP=rs201274282; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Pro (c.721T>C); ClinVar=VCV000376664; Zygosity=Unspecified (PubMed=11216673) Derived from metastatic site: Cervical lymph node. Omics: Transcriptome analysis by microarray Male 21158792 CVCL_CW44 OT145 hybridoma house mouse CVCL_CW44 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21158793 CVCL_CW41 BB7.3 hybridoma house mouse CVCL_CW41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21158794 CVCL_D841 NZM058 cancer cell line human CVCL_D841 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790) Omics: Transcriptome analysis by microarray. 21158795 CVCL_CW42 BB7.4 hybridoma house mouse CVCL_CW42 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21158796 CVCL_D842 NZM006 cancer cell line human CVCL_D842 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23658559; PubMed=32567790) Derived from metastatic site: Small intestine. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 34 hours (PubMed=7718330); 50 hours (CBA) 21158797 CVCL_2E00 AG11484 finite cell line human CVCL_2E00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 39 PDL (Coriell=AG11484) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158798 CVCL_2E01 AG11485 finite cell line human CVCL_2E01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [16%]; 46,XY,t(1;12)(q25;q13) [84%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG11485) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158799 CVCL_2E04 AG11489 finite cell line human CVCL_2E04 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 24 PDL (Coriell=AG11489) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158800 CVCL_2E05 AG11490 finite cell line human CVCL_2E05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [2%]; 46,XY,t(1;15;22) [98%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (Coriell=AG11490) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158801 CVCL_2E02 AG11486 finite cell line human CVCL_2E02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 52 PDL (Coriell=AG11486) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158802 CVCL_2E03 AG11487 finite cell line human CVCL_2E03 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 47 PDL (Coriell=AG11487) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158803 CVCL_2E08 AG11561 finite cell line human CVCL_2E08 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG11561) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158804 CVCL_2E09 AG11564 finite cell line human CVCL_2E09 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 37 PDL (Coriell=AG11564) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158805 CVCL_2E06 AG11555 finite cell line human CVCL_2E06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [42%]; 47,XY,+18 [58%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 13 PDL (Coriell=AG11555) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158806 CVCL_2E07 AG11557 finite cell line human CVCL_2E07 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 14 PDL (Coriell=AG11557) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158807 CVCL_UK52 BT068 cancer cell line human CVCL_UK52 CL:0000010 Male Group: Cancer stem cell line. 21158808 CVCL_UK53 BT071 cancer cell line human CVCL_UK53 CL:0000010 Male Group: Cancer stem cell line. 21158809 CVCL_UK50 BT033 cancer cell line human CVCL_UK50 CL:0000010 Male Group: Cancer stem cell line. 21158810 CVCL_UK51 BT034 cancer cell line human CVCL_UK51 CL:0000010 Female Group: Cancer stem cell line. 21158811 CVCL_UK56 BT075 cancer cell line human CVCL_UK56 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21158812 CVCL_UK57 BT092 cancer cell line human CVCL_UK57 CL:0000010 Male Group: Cancer stem cell line. 21158813 CVCL_UK54 BT073 cancer cell line human CVCL_UK54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Omics: Transcriptome analysis by RNAseq. Male Group: Cancer stem cell line 21158814 CVCL_UK55 BT074 cancer cell line human CVCL_UK55 CL:0000010 Male Group: Cancer stem cell line. 21158815 CVCL_UK58 BT100 cancer cell line human CVCL_UK58 CL:0000010 Male Group: Cancer stem cell line. 21158816 CVCL_UK59 BT108 cancer cell line human CVCL_UK59 CL:0000010 Male Group: Cancer stem cell line. 21158817 CVCL_2E11 AG11645 finite cell line human CVCL_2E11 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(p11;q12) [82%]; 46,XY,inv(9),t(8;10;14)(p21;p13;q24) [18%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG11645) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158818 CVCL_2E12 AG11646 finite cell line human CVCL_2E12 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27 PDL (Coriell=AG11646) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158819 CVCL_2E10 AG11643 finite cell line human CVCL_2E10 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG11643; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158820 CVCL_2E15 AG11649 finite cell line human CVCL_2E15 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [76%]; 46,XY,t(5;7) [24%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 25 PDL (Coriell=AG11649) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158821 CVCL_2E16 AG11650 finite cell line human CVCL_2E16 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (Coriell=AG11650) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158822 CVCL_2E13 AG11647 finite cell line human CVCL_2E13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [80%]; 46,XY,t(2;4)(q31;p16) [20%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26 PDL (Coriell=AG11647) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158823 CVCL_2E14 AG11648 finite cell line human CVCL_2E14 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=AG11648) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158824 CVCL_2E19 AG11693 finite cell line human CVCL_2E19 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [36%]; 46,XY,t(14;17)(q22;q12) [64%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 30 PDL (Coriell=AG11693) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158825 CVCL_2E17 AG11651 finite cell line human CVCL_2E17 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 40 PDL (Coriell=AG11651) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158826 CVCL_2E18 AG11652 finite cell line human CVCL_2E18 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (Coriell=AG11652) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21158827 CVCL_UK41 BT025 cancer cell line human CVCL_UK41 CL:0000010 Omics: Transcriptome analysis by microarray. Male Group: Cancer stem cell line 21158828 CVCL_UK42 BT042 cancer cell line human CVCL_UK42 CL:0000010 Group: Cancer stem cell line. 21158829 CVCL_UK40 BT089 cancer cell line human CVCL_UK40 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Female Group: Cancer stem cell line 21158830 CVCL_UK45 BT030 cancer cell line human CVCL_UK45 CL:0000010 Male Group: Cancer stem cell line. 21158831 CVCL_UK46 BT018 cancer cell line human CVCL_UK46 CL:0000010 Female Group: Cancer stem cell line. 21158832 CVCL_UK43 BT060 cancer cell line human CVCL_UK43 CL:0000010 Group: Cancer stem cell line. 21158833 CVCL_UK44 BT028 cancer cell line human CVCL_UK44 CL:0000010 Male Group: Cancer stem cell line. 21158834 CVCL_UK49 BT023 cancer cell line human CVCL_UK49 CL:0000010 Male Group: Cancer stem cell line. 21158835 CVCL_UK47 BT019 cancer cell line human CVCL_UK47 CL:0000010 Male Group: Cancer stem cell line. 21158836 CVCL_UK48 BT020 cancer cell line human CVCL_UK48 CL:0000010 Female Group: Cancer stem cell line. 21158837 CVCL_LQ90 BayGenomics ES cell line BGC171 embryonic stem cell house mouse CVCL_LQ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158838 CVCL_M290 XP2KA finite cell line human CVCL_M290 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1045; probable Female 21158839 CVCL_UK29 ChiPSC17 induced pluripotent stem cell human CVCL_UK29 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158840 CVCL_UK30 ChiPSC19 induced pluripotent stem cell human CVCL_UK30 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158841 CVCL_UK31 ChiPSC20 induced pluripotent stem cell human CVCL_UK31 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158842 CVCL_LQ88 BayGenomics ES cell line BGC165 embryonic stem cell house mouse CVCL_LQ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158843 CVCL_M288 XP25BE finite cell line human CVCL_M288 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2251-1_-2delAG (IVS11-1_IVS11-2delAG); Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS11-6_IVS11-7insCC; Zygosity=Homozygous (Coriell) Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21158844 CVCL_LQ89 BayGenomics ES cell line BGC167 embryonic stem cell house mouse CVCL_LQ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96952; Mdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158845 CVCL_M289 XP25BE LCL transformed cell line human CVCL_M289 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS11-1_IVS11-2delAG; Zygosity=Homozygous (PubMed=16081512); Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS11-6_IVS11-7insCC; Zygosity=Homozygous (PubMed=16081512) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158846 CVCL_LQ86 BayGenomics ES cell line BGC132 embryonic stem cell house mouse CVCL_LQ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158847 CVCL_UK34 ChiPSC6b induced pluripotent stem cell human CVCL_UK34 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: Takara/Clontech; Catalog number Y11032 Male 21158848 CVCL_M286 XP3BR finite cell line human CVCL_M286 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Asp499Ilefs*23 (c.1494delA); ClinVar=VCV000016575; Zygosity=Heterozygous (PubMed=11841555); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Lys917Asnfs*64 (c.2751delA); ClinVar=VCV000016576; Zygosity=Heterozygous (PubMed=11841555) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (PubMed=6492896) Caution: Could be identical to IMG-990 XP3Br2 (Cellosaurus=CVCL_IM57) 21158849 CVCL_LQ87 BayGenomics ES cell line BGC147 embryonic stem cell house mouse CVCL_LQ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925953; Zfp972 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158850 CVCL_UK35 ChiPSC8 induced pluripotent stem cell human CVCL_UK35 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158851 CVCL_M287 XP6DU finite cell line human CVCL_M287 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys70fs (c.207delG); ClinVar=VCV000005892; Zygosity=Heterozygous (PubMed=10398605; PubMed=11773631; PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=10398605; PubMed=11773631; PubMed=26884178) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158852 CVCL_LQ84 BayGenomics ES cell line BGC110 embryonic stem cell house mouse CVCL_LQ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144566; Tsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158853 CVCL_UK32 ChiPSC23 induced pluripotent stem cell human CVCL_UK32 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158854 CVCL_M284 XP3YO finite cell line human CVCL_M284 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg490Gln (c.1469G>A) (R479Q); Zygosity=Heterozygous (PubMed=9580660); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Leu608Pro (c.1823T>C) (L599P); Zygosity=Heterozygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1101; probable Male 21158855 CVCL_LQ85 BayGenomics ES cell line BGC125 embryonic stem cell house mouse CVCL_LQ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685387; Atp13a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158856 CVCL_UK33 ChiPSC24 induced pluripotent stem cell human CVCL_UK33 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158857 CVCL_M285 XP1BR finite cell line human CVCL_M285 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1068; probable Female Senescence: Senesces at 26 PDL (PubMed=6492896) 21158858 CVCL_LQ82 BayGenomics ES cell line BGC099 embryonic stem cell house mouse CVCL_LQ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385184; Ahcyl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158859 CVCL_UK38 BT050 cancer cell line human CVCL_UK38 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male Group: Cancer stem cell line 21158860 CVCL_M282 XP2JO skin finite cell line human CVCL_M282 CL:0000010 Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158861 CVCL_LQ83 BayGenomics ES cell line BGC102 embryonic stem cell house mouse CVCL_LQ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87860; Abl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158862 CVCL_UK39 BT067 cancer cell line human CVCL_UK39 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26095605) Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male Group: Cancer stem cell line 21158863 CVCL_M283 XP5MA finite cell line human CVCL_M283 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys220fs (c.661_764del); Zygosity=Homozygous (PubMed=10398605) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 19 PDL (PubMed=6492896) 21158864 CVCL_LQ80 BayGenomics ES cell line BGC020 embryonic stem cell house mouse CVCL_LQ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924203; Emsy Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158865 CVCL_UK36 ChiPSC9 induced pluripotent stem cell human CVCL_UK36 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158866 CVCL_M280 XP2JO tongue finite cell line human CVCL_M280 CL:0000010 Population: African; Zulu; Derived from sampling site: Oral cavity; tongue. Male 21158867 CVCL_LQ81 BayGenomics ES cell line BGC030 embryonic stem cell house mouse CVCL_LQ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158868 CVCL_UK37 BT069 cancer cell line human CVCL_UK37 CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 21158869 CVCL_M281 XPH2JO finite cell line human CVCL_M281 CL:0000010 Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158870 CVCL_UK18 HVRDi007-A induced pluripotent stem cell human CVCL_UK18 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158871 CVCL_UK19 IBMS-iPSC-042-01 induced pluripotent stem cell human CVCL_UK19 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile1371Val (c.4111A>G); ClinVar=VCV000039176; Zygosity=Heterozygous (PubMed=31029016) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21158872 CVCL_UK20 IBMS-iPSC-043-05 induced pluripotent stem cell human CVCL_UK20 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Asp331Tyr (c.991G>T); ClinVar=VCV000030371; Zygosity=Homozygous (PubMed=30978640) Population: Chinese; Derived from sampling site: Peripheral blood. Female 21158873 CVCL_LQ99 BayGenomics ES cell line BGC389 embryonic stem cell house mouse CVCL_LQ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158874 CVCL_M299 XP26BE LCL transformed cell line human CVCL_M299 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158875 CVCL_LQ97 BayGenomics ES cell line BGC386 embryonic stem cell house mouse CVCL_LQ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158876 CVCL_M297 XP29BE LCL transformed cell line human CVCL_M297 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gln452Ter (c.1354C>T); ClinVar=VCV001455083; Zygosity=Heterozygous (from autologous cell line XP29BE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP29BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158877 CVCL_UK23 LEIi008-A induced pluripotent stem cell human CVCL_UK23 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Ser402Ter (c.1205C>A); Zygosity=Heterozygous (PubMed=30611018) Population: Aboriginal Australian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21158878 CVCL_LQ98 BayGenomics ES cell line BGC388 embryonic stem cell house mouse CVCL_LQ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349722; Pabpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158879 CVCL_M298 XP29BE finite cell line human CVCL_M298 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gln452Ter (c.1354C>T); ClinVar=VCV001455083; Zygosity=Heterozygous (PubMed=19934020); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=19934020) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158880 CVCL_UK24 LEIi009-A induced pluripotent stem cell human CVCL_UK24 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Ser402Ter (c.1205C>A); Zygosity=Heterozygous (PubMed=30611018) Population: Aboriginal Australian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21158881 CVCL_LQ95 BayGenomics ES cell line BGC379 embryonic stem cell house mouse CVCL_LQ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158882 CVCL_M295 XP21BE LCL transformed cell line human CVCL_M295 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Met1Arg (c.2T>G); ClinVar=VCV001066146; Zygosity=Homozygous (PubMed=18955168) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21158883 CVCL_UK21 KCLi002-A induced pluripotent stem cell human CVCL_UK21 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 3748; FLG; Simple; p.Arg2447Ter (c.7339C>T); ClinVar=VCV000050932; Zygosity=Heterozygous (PubMed=31103941) Population: Caucasian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21158884 CVCL_LQ96 BayGenomics ES cell line BGC380 embryonic stem cell house mouse CVCL_LQ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158885 CVCL_M296 XP21BE finite cell line human CVCL_M296 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Met1Arg (c.2T>G); ClinVar=VCV001066146; Zygosity=Homozygous (PubMed=18955168) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158886 CVCL_UK22 KCLi003-A induced pluripotent stem cell human CVCL_UK22 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 3748; FLG; Simple; p.Arg501Ter (c.1501C>T); ClinVar=VCV000016319; Zygosity=Heterozygous (PubMed=31408836) Population: Caucasian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21158887 CVCL_LQ93 BayGenomics ES cell line BGC377 embryonic stem cell house mouse CVCL_LQ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914339; Psmc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158888 CVCL_UK27 ChiPSC11 induced pluripotent stem cell human CVCL_UK27 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158889 CVCL_M293 XP1SF finite cell line human CVCL_M293 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln23Ter (c.67C>T); Zygosity=Homozygous (PubMed=10398605) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21158890 CVCL_LQ94 BayGenomics ES cell line BGC378 embryonic stem cell house mouse CVCL_LQ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158891 CVCL_UK28 ChiPSC13 induced pluripotent stem cell human CVCL_UK28 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158892 CVCL_M294 XP20MA finite cell line human CVCL_M294 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158893 CVCL_LQ91 BayGenomics ES cell line BGC356 embryonic stem cell house mouse CVCL_LQ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158894 CVCL_UK25 ChiPSC15 induced pluripotent stem cell human CVCL_UK25 HLA typing: A*02,29; B*44,49; C*07,16; DQA1*02,03; DQB1*02,03; DRB1*04,07 (PubMed=29026098) From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158895 CVCL_M291 XP30BE LCL transformed cell line human CVCL_M291 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gln368Argfs*6 (c.1103_1104delAA) (delAA1208-1209); ClinVar=VCV000267279; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21158896 CVCL_LQ92 BayGenomics ES cell line BGC367 embryonic stem cell house mouse CVCL_LQ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158897 CVCL_UK26 ChiPSC10 induced pluripotent stem cell human CVCL_UK26 From: Takara Bio Europe AB (Cellartis); Goteborg; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21158898 CVCL_M292 XP30BE finite cell line human CVCL_M292 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gln368Argfs*6 (c.1103_1104delAA) (delAA1208-1209); ClinVar=VCV000267279; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21158899 CVCL_UK09 CS04iALS-SOD1H44Rn3 induced pluripotent stem cell human CVCL_UK09 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Heterozygous (CSMC) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158900 CVCL_UK07 FIBRNPC induced pluripotent stem cell human CVCL_UK07 CL:0000010 21158901 CVCL_UK08 CS00iCTR21-n2 induced pluripotent stem cell human CVCL_UK08 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 21158902 CVCL_LQ68 BayGenomics ES cell line BGB500 embryonic stem cell house mouse CVCL_LQ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158903 CVCL_M268 Cho-CK cancer cell line human CVCL_M268 CL:0000010 Population: Korean. Male 21158904 CVCL_LQ69 BayGenomics ES cell line BGB524 embryonic stem cell house mouse CVCL_LQ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158905 CVCL_M269 Choi-CK cancer cell line human CVCL_M269 CL:0000010 Population: Korean. Male 21158906 CVCL_LQ66 BayGenomics ES cell line BGB482 embryonic stem cell house mouse CVCL_LQ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158907 CVCL_M266 MMNK-1 telomerase immortalized cell line human CVCL_M266 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Cholangiocyte.. Unspecified Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the SV40 T gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8126 21158908 CVCL_LQ67 BayGenomics ES cell line BGB486 embryonic stem cell house mouse CVCL_LQ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158909 CVCL_M267 KMBC cancer cell line human CVCL_M267 CL:0000010 Population: Japanese; Derived from sampling site: Bile duct. Male Doubling time: 30 hours (PubMed=1312890); 67 hours (PubMed=9824643) 21158910 CVCL_LQ64 BayGenomics ES cell line BGB429 embryonic stem cell house mouse CVCL_LQ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158911 CVCL_UK12 CS22iALS-SOD1I114Tn2 induced pluripotent stem cell human CVCL_UK12 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (CSMC) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158912 CVCL_M264 KKU-213B cancer cell line human CVCL_M264 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB1556; probable Male Doubling time: 22.68 +- 2.20 hours (PubMed=25998688); 24.5 +- 0.2 hours (PubMed=32207095) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00592 Problematic cell line: Contaminated Shown to be a KKU-213A derivative (PubMed=32207095 and JCRB web site).; Caution: After JCRB found out that KKU-M156 and KKU-M214 were derived from KKU-M213, these three cell lines were renamed by the lab which established them: KKU-M213 became KKU-213A, KKU-M214 became KKU-M213B and KKU-M156 became KKU-M213C (PubMed=32207095) 21158913 CVCL_LQ65 BayGenomics ES cell line BGB472 embryonic stem cell house mouse CVCL_LQ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915031; Ilf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158914 CVCL_UK13 CS138isALS-Tn1 induced pluripotent stem cell human CVCL_UK13 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21158915 CVCL_M265 KKU-OCA17 cancer cell line human CVCL_M265 CL:0000010 Population: Southeast Asian; Thai. 21158916 CVCL_LQ62 BayGenomics ES cell line BGB340 embryonic stem cell house mouse CVCL_LQ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915486; Gtsf1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158917 CVCL_UK10 CS11iALS-SOD1I114Tn10 induced pluripotent stem cell human CVCL_UK10 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (CSMC) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158918 CVCL_M262 KKU-M213L0H cancer cell line human CVCL_M262 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Derived from sampling site: Liver. Male 21158919 CVCL_LQ63 BayGenomics ES cell line BGB424 embryonic stem cell house mouse CVCL_LQ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384560; Aars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158920 CVCL_UK11 CS14isALS-Tn16 induced pluripotent stem cell human CVCL_UK11 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158921 CVCL_M263 KKU-M213L5H cancer cell line human CVCL_M263 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Derived from sampling site: Liver. Male 21158922 CVCL_UK16 AGP01 PIWIL1 KO cancer cell line human CVCL_UK16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9007; PIWIL1 Derived from metastatic site: Ascites. Male 21158923 CVCL_LQ60 BayGenomics ES cell line BGB318 embryonic stem cell house mouse CVCL_LQ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3041235; Ska3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158924 CVCL_M260 KKU-213C cancer cell line human CVCL_M260 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (from parent cell line) Population: Southeast Asian; Thai; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Discontinued: JCRB; JCRB1561; probable Male Doubling time: 25.6 +- 0.2 hours (PubMed=32207095) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00591 Problematic cell line: Contaminated Shown to be a KKU-213A derivative (PubMed=32207095 and JCRB web site).; Caution: After JCRB found out that KKU-M156 and KKU-M214 were derived from KKU-M213, these three cell lines were renamed by the lab which established them: KKU-M213 became KKU-213A, KKU-M214 became KKU-M213B and KKU-M156 became KKU-M213C (PubMed=32207095) 21158925 CVCL_LQ61 BayGenomics ES cell line BGB338 embryonic stem cell house mouse CVCL_LQ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106381; Nopchap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158926 CVCL_UK17 HHUUKDi006-A induced pluripotent stem cell human CVCL_UK17 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (PubMed=30616142) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21158927 CVCL_M261 KKU-213A cancer cell line human CVCL_M261 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Unspecified (DepMap) Population: Southeast Asian; Thai; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 23.3 +- 0.8 hours (PubMed=32207095) 23.4 hours (PubMed=27461717). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: After JCRB found out that KKU-M156 and KKU-M214 were derived from KKU-M213, these three cell lines were renamed by the lab which established them: KKU-M213 became KKU-213A, KKU-M214 became KKU-M213B and KKU-M156 became KKU-M213C (PubMed=32207095) 21158928 CVCL_UK14 CS152isALS-Tn2 induced pluripotent stem cell human CVCL_UK14 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 21158929 CVCL_UK15 CS166isALS-Tn2 induced pluripotent stem cell human CVCL_UK15 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21158930 CVCL_LQ79 BayGenomics ES cell line BGC001 embryonic stem cell house mouse CVCL_LQ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158931 CVCL_M279 XP1JO finite cell line human CVCL_M279 CL:0000010 Population: African; Zulu; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158932 CVCL_LQ77 BayGenomics ES cell line BGB615 embryonic stem cell house mouse CVCL_LQ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202301; Itch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158933 CVCL_M277 XP1KC finite cell line human CVCL_M277 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158934 CVCL_LQ78 BayGenomics ES cell line BGB654 embryonic stem cell house mouse CVCL_LQ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443079; Klhl26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158935 CVCL_M278 XP1WA finite cell line human CVCL_M278 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21158936 CVCL_LQ75 BayGenomics ES cell line BGB581 embryonic stem cell house mouse CVCL_LQ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158937 CVCL_UK01 DPX2 cancer cell line human CVCL_UK01 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Used in cell-based assays for a parallel assessment of CYP3A4 induction, metabolism and inhibition at the cellular level Male Characteristics: The luciferase reporter gene is under the control of CYP3A4 response elements (proximal promoter and distal xenobiotic-responsive enhancer module) 21158938 CVCL_M275 RJK 853 transformed cell line human CVCL_M275 CL:0000010 Sequence variation: Gene deletion; HGNC; 5157; HPRT1; Zygosity=Hemizygous (PubMed=3296189; PubMed=6087154) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21158939 CVCL_LQ76 BayGenomics ES cell line BGB599 embryonic stem cell house mouse CVCL_LQ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106442; Vkorc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158940 CVCL_M276 XP21RO finite cell line human CVCL_M276 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000550020; Zygosity=Homozygous (from familial inference of XP4RO) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21158941 CVCL_UK02 WTC dual tagged SEC61B-mEGFP/LMNB1-mTagRFPT-cl36 induced pluripotent stem cell human CVCL_UK02 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 SEC61B has been endogenously tagged in one allele at the N-terminus with mEGFP and LMNB1 has been endogenously tagged in one allele at the N-terminus with mTagRFP-T Part of: Allen Cell Collection 21158942 CVCL_LQ73 BayGenomics ES cell line BGB551 embryonic stem cell house mouse CVCL_LQ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919847; Auts2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158943 CVCL_M273 HBDC cancer cell line human CVCL_M273 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 32.25 hours (PubMed=11180864) 21158944 CVCL_LQ74 BayGenomics ES cell line BGB561 embryonic stem cell house mouse CVCL_LQ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444008; Bptf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158945 CVCL_M274 CC-62 cancer cell line Norway rat CVCL_M274 CL:0000010 Breed/subspecies: Wistar. Male 21158946 CVCL_UK00 HuWaTERT2 telomerase immortalized cell line CVCL_UK00 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: 30 hours (CelloPub=CLPUB00462) Group: Endangered species/breed cell line; Group: Cetacean cell line 21158947 CVCL_LQ71 BayGenomics ES cell line BGB541 embryonic stem cell house mouse CVCL_LQ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923998; Pbrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158948 CVCL_M271 SCK cancer cell line human CVCL_M271 CL:0000010 Population: Korean. Male 21158949 CVCL_UK05 WTC-mEGFP-FUS-cl69 induced pluripotent stem cell human CVCL_UK05 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 FUS has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21158950 CVCL_LQ72 BayGenomics ES cell line BGB544 embryonic stem cell house mouse CVCL_LQ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889364; Akirin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158951 CVCL_M272 CHGS cancer cell line human CVCL_M272 CL:0000010 Population: Japanese Male Doubling time: 6.2 days (PubMed=2856440). 21158952 CVCL_UK06 V79-122D1 spontaneously immortalized cell line CVCL_UK06 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21158953 CVCL_UK03 WTC-mEGFP-MYL2-cl27 induced pluripotent stem cell human CVCL_UK03 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 MYL2 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21158954 CVCL_LQ70 BayGenomics ES cell line BGB533 embryonic stem cell house mouse CVCL_LQ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919837; Pan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158955 CVCL_M270 JCK cancer cell line human CVCL_M270 CL:0000010 Population: Korean. Male 21158956 CVCL_UK04 WTC-mEGFP-SMC1A-cl9 induced pluripotent stem cell human CVCL_UK04 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 SMC1A has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21158957 CVCL_LQ48 BayGenomics ES cell line BGB186 embryonic stem cell house mouse CVCL_LQ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924823; Vps33a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158958 CVCL_M248 POLZ KO cancer cell line human CVCL_M248 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9968; REV3L; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158959 CVCL_LQ49 BayGenomics ES cell line BGB191 embryonic stem cell house mouse CVCL_LQ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914552; Zc3h13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158960 CVCL_M249 POLZ KO MSH- cancer cell line human CVCL_M249 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9968; REV3L; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158961 CVCL_LQ46 BayGenomics ES cell line BGB160 embryonic stem cell house mouse CVCL_LQ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136841; Morc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158962 CVCL_M246 NYUES13 embryonic stem cell human CVCL_M246 From: New York University School of Medicine; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0237. 21158963 CVCL_LQ47 BayGenomics ES cell line BGB163 embryonic stem cell house mouse CVCL_LQ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158964 CVCL_M247 POLH KO MSH- cancer cell line human CVCL_M247 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9181; POLH; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158965 CVCL_LQ44 BayGenomics ES cell line BGB147 embryonic stem cell house mouse CVCL_LQ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888993; Api5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158966 CVCL_M244 GENEA097 embryonic stem cell human CVCL_M244 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA098 (Cellosaurus=CVCL_M245). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0248; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-47. 21158967 CVCL_LQ45 BayGenomics ES cell line BGB158 embryonic stem cell house mouse CVCL_LQ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929512; Litaf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158968 CVCL_M245 GENEA098 embryonic stem cell human CVCL_M245 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA097 (Cellosaurus=CVCL_M244). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0249; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-47. 21158969 CVCL_LQ42 BayGenomics ES cell line BGB123 embryonic stem cell house mouse CVCL_LQ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928744; Vapb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158970 CVCL_M242 GENEA091 embryonic stem cell human CVCL_M242 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Donor information: Embryo is sibling to those giving rise to GENEA089 (Cellosaurus=CVCL_M240) and GENEA090 (Cellosaurus=CVCL_M241). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0246; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-49. 21158971 CVCL_LQ43 BayGenomics ES cell line BGB135 embryonic stem cell house mouse CVCL_LQ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158972 CVCL_M243 GENEA096 embryonic stem cell human CVCL_M243 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0244; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-57.. 21158973 CVCL_LQ40 BayGenomics ES cell line BGB116 embryonic stem cell house mouse CVCL_LQ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158974 CVCL_M240 GENEA089 embryonic stem cell human CVCL_M240 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Donor information: Embryo is sibling to those giving rise to GENEA090 (Cellosaurus=CVCL_M241) and GENEA091 (Cellosaurus=CVCL_M242). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0247; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-47. 21158975 CVCL_LQ41 BayGenomics ES cell line BGB118 embryonic stem cell house mouse CVCL_LQ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343085; Spop Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158976 CVCL_M241 GENEA090 embryonic stem cell human CVCL_M241 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (Genea) Donor information: Embryo is sibling to those giving rise to GENEA089 (Cellosaurus=CVCL_M240) and GENEA091 (Cellosaurus=CVCL_M242). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0245; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-49. 21158977 CVCL_LQ59 BayGenomics ES cell line BGB312 embryonic stem cell house mouse CVCL_LQ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934031; Pi4k2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158978 CVCL_M259 KKU-M139 cancer cell line human CVCL_M259 CL:0000010 Population: Southeast Asian; Thai Doubling time: 17.36 +- 1.26 hours (PubMed=25998688). 21158979 CVCL_LQ57 BayGenomics ES cell line BGB306 embryonic stem cell house mouse CVCL_LQ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158980 CVCL_M257 RMCCA-1 cancer cell line human CVCL_M257 CL:0000010 Population: Southeast Asian; Thai Male Doubling time: 48 hours (PubMed=17072981). 21158981 CVCL_LQ58 BayGenomics ES cell line BGB307 embryonic stem cell house mouse CVCL_LQ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158982 CVCL_M258 KKU-M055 cancer cell line human CVCL_M258 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Liver; intrahepatic bile duct. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21158983 CVCL_LQ55 BayGenomics ES cell line BGB278 embryonic stem cell house mouse CVCL_LQ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916013; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158984 CVCL_M255 HuCC-A1 cancer cell line human CVCL_M255 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Omics: Secretome proteome analysis Male Doubling time: ~55 hours (PubMed=1666951) 21158985 CVCL_LQ56 BayGenomics ES cell line BGB287 embryonic stem cell house mouse CVCL_LQ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158986 CVCL_M256 HChol-Y1 cancer cell line human CVCL_M256 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Unspecified Doubling time: 52 hours (PubMed=2989602) Group: Serum/protein free medium cell line 21158987 CVCL_LQ53 BayGenomics ES cell line BGB202 embryonic stem cell house mouse CVCL_LQ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917678; Polr3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158988 CVCL_M253 Colon26-Luc cancer cell line house mouse CVCL_M253 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Discontinued: JCRB; NIHS0704; true Female 21158989 CVCL_LQ54 BayGenomics ES cell line BGB273 embryonic stem cell house mouse CVCL_LQ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158990 CVCL_M254 NCI-H441/CMV-Luc cancer cell line human CVCL_M254 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pericardial effusion Cell type=Club cell.. Discontinued: JCRB; NIHS0728; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21158991 CVCL_LQ51 BayGenomics ES cell line BGB200 embryonic stem cell house mouse CVCL_LQ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158992 CVCL_M251 KATO III/CMV-Luc cancer cell line human CVCL_M251 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS0713; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21158993 CVCL_LQ52 BayGenomics ES cell line BGB201 embryonic stem cell house mouse CVCL_LQ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158994 CVCL_M252 KYSE-3650 cancer cell line human CVCL_M252 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female 21158995 CVCL_LQ50 BayGenomics ES cell line BGB197 embryonic stem cell house mouse CVCL_LQ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384933; Wrap53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21158996 CVCL_M250 POLZ L2618M cancer cell line human CVCL_M250 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9968; REV3L; Simple_edited; p.Leu2618Met; Zygosity=Unspecified; Note=By homologous recombination (JCRB); Transfected with: HGNC; 7325; MSH2 (exons 9 to 16) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21158997 CVCL_UU00 CNIO AY cancer cell line human CVCL_UU00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Female Doubling time: 48 hours (PubMed=16888811) 21158998 CVCL_V600 HCC2389 cancer cell line human CVCL_V600 CL:0000010 Female 21158999 CVCL_UU03 CNIO BC cancer cell line human CVCL_UU03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Female Doubling time: 96 hours (PubMed=16888811) 21159000 CVCL_V603 HCC1944 cancer cell line human CVCL_V603 CL:0000010 Male 21159001 CVCL_UU04 CNIO BF cancer cell line human CVCL_UU04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16888811) Derived from sampling site: Bone. Male Doubling time: 24 hours (PubMed=16888811) 21159002 CVCL_V604 HCC1945 cancer cell line human CVCL_V604 CL:0000010 Female 21159003 CVCL_UU01 CNIO AZ cancer cell line human CVCL_UU01 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Female Doubling time: 96 hours (PubMed=16888811) 21159004 CVCL_V601 HCC2393 cancer cell line human CVCL_V601 CL:0000010 Unspecified 21159005 CVCL_UU02 CNIO BB cancer cell line human CVCL_UU02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Female Doubling time: 72 hours (PubMed=16888811) 21159006 CVCL_V602 HCC2414 cancer cell line human CVCL_V602 CL:0000010 Female 21159007 CVCL_UU07 CNIO BJ cancer cell line human CVCL_UU07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811) Derived from sampling site: Bone. Unspecified Doubling time: 96 hours (PubMed=16888811) 21159008 CVCL_V607 SLR21 cancer cell line human CVCL_V607 Genome ancestry: African=0.09%; Native American=0.64%; East Asian, North=0%; East Asian, South=0.43%; South Asian=1.26%; European, North=66.35%; European, South=31.24% (PubMed=30894373) CL:0000010 Miscellaneous: STR profile from personal communication of von Teichman A Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: shRNA library screening Doubling time: 60 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159009 CVCL_UU08 CNIO BK cancer cell line human CVCL_UU08 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Unspecified Doubling time: 96 hours (PubMed=16888811) 21159010 CVCL_V608 SLR22 cancer cell line human CVCL_V608 CL:0000010 Miscellaneous: STR profile from personal communication of von Teichman A. Male 21159011 CVCL_UU05 CNIO BG cancer cell line human CVCL_UU05 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=16888811). Male Doubling time: 24 hours (PubMed=16888811) 21159012 CVCL_V605 SK-RC-20 cancer cell line human CVCL_V605 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 55 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159013 CVCL_UU06 CNIO BI cancer cell line human CVCL_UU06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16888811). Male Doubling time: 24 hours (PubMed=16888811) 21159014 CVCL_V606 SLR20 cancer cell line human CVCL_V606 Genome ancestry: African=0%; Native American=0.52%; East Asian, North=2.35%; East Asian, South=0%; South Asian=0%; European, North=72.79%; European, South=24.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (DepMap) Miscellaneous: STR profile from personal communication of von Teichman A Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00573 Problematic cell line: Contaminated Shown to be a T24 derivative (ICLAC). Originally thought to originate from a clear cell renal cell carcinoma. 21159015 CVCL_UU09 CNIO BM cancer cell line human CVCL_UU09 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Unspecified Doubling time: 96 hours (PubMed=16888811) 21159016 CVCL_V609 SLR23 cancer cell line human CVCL_V609 Genome ancestry: African=0%; Native American=0.14%; East Asian, North=0.79%; East Asian, South=0%; South Asian=0%; European, North=67.65%; European, South=31.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Trp88Ter (c.264G>A); ClinVar=VCV000936684; Zygosity=Heterozygous (DepMap) Miscellaneous: STR profile from personal communication of von Teichman A Population: Caucasian; Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: shRNA library screening Unspecified Doubling time: 40 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159017 CVCL_DB92 GM16535 transformed cell line human CVCL_DB92 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro11_Ser12insAlaAlaGlySerSerMetGluPro (c.9_32dupGGCGGCGGGGAGCAGCATGGAGCC); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with cutaneous malignant melanoma 2 but at risk for disease (mutation in CDKN2A start site); Derived from sampling site: Peripheral blood. Female 21159018 CVCL_DB93 GM17515 finite cell line human CVCL_DB93 CL:0000010 Population: Pakistani; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21159019 CVCL_DB90 GM16350 transformed cell line human CVCL_DB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159020 CVCL_DB91 GM16407 transformed cell line human CVCL_DB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159021 CVCL_DB96 GM20188 transformed cell line human CVCL_DB96 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; p.Arg500Ter (c.1498C>T); ClinVar=VCV000001198; Zygosity=Heterozygous (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159022 CVCL_DB97 GM20192 transformed cell line human CVCL_DB97 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+2T>C (IVS4+2T>C) (p.Cys395fs*403); ClinVar=VCV000001197; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159023 CVCL_DB94 GM17516 finite cell line human CVCL_DB94 CL:0000010 Population: Pakistani; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21159024 CVCL_DB95 GM20184 transformed cell line human CVCL_DB95 CL:0000010 Sequence variation: Mutation; HGNC; 17009; TRIOBP; Simple; p.Arg788Ter (c.2362C>T); ClinVar=VCV000001493; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159025 CVCL_DB89 GM16349 transformed cell line human CVCL_DB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159026 CVCL_DB87 GM13808 transformed cell line human CVCL_DB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159027 CVCL_DB88 GM16347 transformed cell line human CVCL_DB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159028 CVCL_DB98 GM20196 transformed cell line human CVCL_DB98 CL:0000010 Sequence variation: Mutation; HGNC; 26401; MARVELD2; Simple; c.1331+2T>C (IVS4+2T>C) (p.Cys395fs*403); ClinVar=VCV000001197; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159029 CVCL_DB99 173TOR finite cell line human CVCL_DB99 CL:0000010 Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Phe231Leu (c.693C>G); ClinVar=VCV000016778; Zygosity=Heterozygous (PubMed=17273966) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21159030 CVCL_DB70 GM10225 transformed cell line human CVCL_DB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159031 CVCL_DB71 GM10227 transformed cell line human CVCL_DB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159032 CVCL_DB74 GM10250 transformed cell line human CVCL_DB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159033 CVCL_DB75 GM10275 transformed cell line human CVCL_DB75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159034 CVCL_DB72 GM10229 transformed cell line human CVCL_DB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159035 CVCL_DB73 GM10247 finite cell line human CVCL_DB73 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21159036 CVCL_DB67 GM09593 transformed cell line human CVCL_DB67 CL:0000010 Population: Belizean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159037 CVCL_DB68 GM09675 finite cell line human CVCL_DB68 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21159038 CVCL_DB65 GM09578 finite cell line human CVCL_DB65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21159039 CVCL_DB66 GM09592 finite cell line human CVCL_DB66 CL:0000010 Population: Belizean; Derived from sampling site: Cell type=Fibroblast. Female 21159040 CVCL_DB69 GM09814 transformed cell line human CVCL_DB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159041 CVCL_DB81 GM12220 transformed cell line human CVCL_DB81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159042 CVCL_DB82 GM12221 transformed cell line human CVCL_DB82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159043 CVCL_DB80 GM11413 transformed cell line human CVCL_DB80 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (PubMed=1680289) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159044 CVCL_DB85 GM13148 transformed cell line human CVCL_DB85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159045 CVCL_DB86 GM13693 transformed cell line human CVCL_DB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159046 CVCL_DB83 GM12894 transformed cell line human CVCL_DB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159047 CVCL_DB84 GM13147 transformed cell line human CVCL_DB84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159048 CVCL_DB78 GM10732 transformed cell line human CVCL_DB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159049 CVCL_DB79 GM11412 transformed cell line human CVCL_DB79 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (PubMed=1680289) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159050 CVCL_DB76 GM10648 transformed cell line human CVCL_DB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159051 CVCL_DB77 GM10712 transformed cell line human CVCL_DB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159052 CVCL_V687 HCC1266 cancer cell line human CVCL_V687 CL:0000010 Female 21159053 CVCL_UU87 MCF-7 M13 cancer cell line human CVCL_UU87 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2640; CYP3A7 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21159054 CVCL_V688 HCC1311 cancer cell line human CVCL_V688 CL:0000010 Female 21159055 CVCL_UU88 MCF-7 M21 cancer cell line human CVCL_UU88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2640; CYP3A7 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21159056 CVCL_UU85 CHL CNP-26 spontaneously immortalized cell line CVCL_UU85 CL:0000010 Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159057 CVCL_V685 HCC1261 cancer cell line human CVCL_V685 CL:0000010 Unspecified 21159058 CVCL_UU86 CHL CNP-40 spontaneously immortalized cell line CVCL_UU86 CL:0000010 Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159059 CVCL_V686 HCC1263 cancer cell line human CVCL_V686 HLA typing: A*01:01,23:01; B*07:02,50:01; C*06:02,07:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159060 CVCL_V689 HCC1426 cancer cell line human CVCL_V689 CL:0000010 Female 21159061 CVCL_UU89 MCF-7 M27 cancer cell line human CVCL_UU89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2640; CYP3A7 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21159062 CVCL_3042 NC-37 cancer cell line human CVCL_3042 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Omics: SNP array analysis Discontinued: ECACC; 89111414; true; Discontinued: KCLB; 10214; probable Male Doubling time: ~20 hours (HIVReagentProgram) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00330 Problematic cell line: Contaminated Shown to be a Raji derivative (PubMed=20143388). Originally thought to originate from the peripheral blood of a human donor not suffering from a disease. 21159063 CVCL_3043 NCO2 cancer cell line human CVCL_3043 HLA typing: A*24:02,24:02; B*15:01,52:01; C*01:21,01:21; DQA1*01:03,01:03; DQB1*06:01,06:01; DRB1*08:03,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=82.46%; East Asian, South=15.81%; South Asian=0%; European, North=0%; European, South=1.73% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.2 days (lot 01132005) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159064 CVCL_3040 184A1 transformed cell line human CVCL_3040 HLA typing: A*02:01,02:01; B*18:01,18:01; C*07:01,07:01 (PubMed=25960936) CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Omics: CNV analysis; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 58.07 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8798 21159065 CVCL_3041 NB(TU)1 cancer cell line human CVCL_3041 Genome ancestry: African=0.86%; Native American=0.24%; East Asian, North=77.99%; East Asian, South=19.62%; South Asian=1.28%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0179; true. Female Doubling time: 49 hours (PubMed=9378542); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159066 CVCL_3035 MY-M12 cancer cell line human CVCL_3035 Genome ancestry: African=0.94%; Native American=0.38%; East Asian, North=81.47%; East Asian, South=16.04%; South Asian=1.17%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis Discontinued: JCRB; NIHS0246.1; true Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159067 CVCL_3036 MY-M13 cancer cell line human CVCL_3036 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Discontinued: JCRB; NIHS0246.2; true Female 21159068 CVCL_3033 MTSV1-7 ce1 transformed cell line human CVCL_3033 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 21159069 CVCL_3034 MY cancer cell line human CVCL_3034 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Omics: SNP array analysis Discontinued: JCRB; NIHS0246; true Female Doubling time: ~48 hours (PubMed=9790503) 21159070 CVCL_3039 NALL-1 cancer cell line human CVCL_3039 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 8619; PAX5; Name(s)=PAX5-ETV6 (PubMed=35354797) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 88 hours (in RPMI 1640 + 20% HCS), 72 hours (in RPMI 1640 + 20% FCS) (PubMed=200333); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21159071 CVCL_3037 N2102Ep Clone 2/A6 cancer cell line human CVCL_3037 CL:0000010 Derived from sampling site: Testis. Male Characteristics: Established from a passage of 2102EP in nude mice 21159072 CVCL_3038 NAGL-1 cancer cell line human CVCL_3038 HLA typing: A*02,31; B*35,55; C*w01,w03 (PubMed=10071461) CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female 21159073 CVCL_UU90 CHL CR-119 spontaneously immortalized cell line CVCL_UU90 CL:0000010 Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159074 CVCL_V690 HCC985 cancer cell line human CVCL_V690 CL:0000010 Male 21159075 CVCL_UU91 CHL CRM2-18 spontaneously immortalized cell line CVCL_UU91 CL:0000010 Transfected with: MGI; MGI:88610; Cyp3a13; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159076 CVCL_V691 HCC880 cancer cell line human CVCL_V691 CL:0000010 Female 21159077 CVCL_UU94 CHL 4-3 spontaneously immortalized cell line CVCL_UU94 CL:0000010 Transfected with: HGNC; 2637; CYP3A4; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159078 CVCL_V694 HCC850 cancer cell line human CVCL_V694 CL:0000010 Female 21159079 CVCL_UU95 CHL 4-9 spontaneously immortalized cell line CVCL_UU95 CL:0000010 Transfected with: HGNC; 2637; CYP3A4; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159080 CVCL_V695 HCC853 cancer cell line human CVCL_V695 CL:0000010 Male 21159081 CVCL_UU92 CHL CRM2-28 spontaneously immortalized cell line CVCL_UU92 CL:0000010 Transfected with: MGI; MGI:88610; Cyp3a13; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159082 CVCL_V692 HCC889 cancer cell line human CVCL_V692 CL:0000010 Male 21159083 CVCL_UU93 CHL CRM2-63 spontaneously immortalized cell line CVCL_UU93 CL:0000010 Transfected with: MGI; MGI:88610; Cyp3a13; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159084 CVCL_V693 HCC845 cancer cell line human CVCL_V693 CL:0000010 Female 21159085 CVCL_UU76 CHL CNM-4 spontaneously immortalized cell line CVCL_UU76 CL:0000010 Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159086 CVCL_V676 HCC1033 cancer cell line human CVCL_V676 CL:0000010 Male 21159087 CVCL_UU77 CHL CNM-27 spontaneously immortalized cell line CVCL_UU77 CL:0000010 Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159088 CVCL_V677 HCC1042 cancer cell line human CVCL_V677 CL:0000010 Female 21159089 CVCL_UU74 CHL A2R-36 spontaneously immortalized cell line CVCL_UU74 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159090 CVCL_V674 HCC1010 cancer cell line human CVCL_V674 CL:0000010 Male 21159091 CVCL_UU75 CHL A2R-39 spontaneously immortalized cell line CVCL_UU75 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159092 CVCL_V675 HCC1011 cancer cell line human CVCL_V675 HLA typing: A*01:01,32:01; B*08:01,40:02; C*02:02,07:01 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159093 CVCL_UU78 CHL CNM-31 spontaneously immortalized cell line CVCL_UU78 CL:0000010 Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159094 CVCL_V678 HCC1054 cancer cell line human CVCL_V678 CL:0000010 Female 21159095 CVCL_UU79 CHL ANM-13 spontaneously immortalized cell line CVCL_UU79 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159096 CVCL_V679 HCC1057 cancer cell line human CVCL_V679 CL:0000010 Male 21159097 CVCL_3050 NCC-RbC-56 cancer cell line human CVCL_3050 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0498; true Male Doubling time: 50 hours (PubMed=8263010) 21159098 CVCL_3053 NCC-RbC-92 cancer cell line human CVCL_3053 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0504; true Female 21159099 CVCL_3054 NCC-RbC-T1 cancer cell line human CVCL_3054 CL:0000010 Population: Japanese; Derived from metastatic site: Cerebrospinal fluid. Male Doubling time: 78 hours (PubMed=8263010) 21159100 CVCL_3051 NCC-RbC-57 cancer cell line human CVCL_3051 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0499; true Female 21159101 CVCL_3052 NCC-RbC-67 cancer cell line human CVCL_3052 CL:0000010 Population: Japanese. Female 21159102 CVCL_3046 NCC-OvC-K119 cancer cell line human CVCL_3046 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Discontinued: JCRB; NIHS0507; true Female 21159103 CVCL_3047 NCC-RbC-39 cancer cell line human CVCL_3047 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0511; true Male Doubling time: 64 hours (CelloPub=CLPUB00087) 21159104 CVCL_3044 NCC16-P11 transformed cell line human CVCL_3044 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix Cell type=Endothelial cell.. Discontinued: JCRB; NIHS0259.0; true Female Caution: Original cell line NCC16 was contaminated and retired, it was replaced by NCC16-P11 21159105 CVCL_3045 NCC-IT-A3 cancer cell line human CVCL_3045 CL:0000010 Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (from parent cell line) Population: Japanese Discontinued: JCRB; FDSC0052; true. Male Doubling time: 27 hours (lot 01192004) (JCRB) 21159106 CVCL_3048 NCC-RbC-51 cancer cell line human CVCL_3048 CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Heterozygous (PubMed=31781967); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex24del; Zygosity=Heterozygous (PubMed=31781967) Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 85 hours (PubMed=8263010); 67 hours (PubMed=31781967) 21159107 CVCL_3049 NCC-RbC-54 cancer cell line human CVCL_3049 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0497; true Female Doubling time: 74 hours (PubMed=8263010) 21159108 CVCL_UU80 CHL ANM-35 spontaneously immortalized cell line CVCL_UU80 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159109 CVCL_V680 HCC1068 cancer cell line human CVCL_V680 CL:0000010 Male 21159110 CVCL_UU83 CHL ANP-38 spontaneously immortalized cell line CVCL_UU83 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159111 CVCL_V683 HCC1205 cancer cell line human CVCL_V683 CL:0000010 Female 21159112 CVCL_UU84 CHL CNP-16 spontaneously immortalized cell line CVCL_UU84 CL:0000010 Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159113 CVCL_V684 HCC1217 cancer cell line human CVCL_V684 CL:0000010 Male 21159114 CVCL_UU81 CHL ANP-19 spontaneously immortalized cell line CVCL_UU81 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159115 CVCL_V681 HCC1106 cancer cell line human CVCL_V681 CL:0000010 Female 21159116 CVCL_UU82 CHL ANP-25 spontaneously immortalized cell line CVCL_UU82 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159117 CVCL_V682 HCC1210 cancer cell line human CVCL_V682 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159118 CVCL_UU65 CHL A-15 spontaneously immortalized cell line CVCL_UU65 CL:0000010 Transfected with: UniProtKB; P33616; Macaca fascicularis CYP1A1 Derived from sampling site: Lung. Female 21159119 CVCL_V665 HCC1367 cancer cell line human CVCL_V665 CL:0000010 Unspecified 21159120 CVCL_UU66 CHL AR-10 spontaneously immortalized cell line CVCL_UU66 CL:0000010 Transfected with: UniProtKB; P33616; Macaca fascicularis CYP1A1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159121 CVCL_V666 HCC1375 cancer cell line human CVCL_V666 CL:0000010 Male 21159122 CVCL_V663 HCC1354 cancer cell line human CVCL_V663 CL:0000010 Derived from sampling site: Endometrium. Female 21159123 CVCL_UU63 MCL-1 transformed cell line human CVCL_UU63 CL:0000010 Transfected with: HGNC; 2610; CYP2A6; Transfected with: HGNC; 3401; EPHX1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9562 21159124 CVCL_V664 HCC1360 cancer cell line human CVCL_V664 CL:0000010 Male 21159125 CVCL_UU64 MCL-2 transformed cell line human CVCL_UU64 CL:0000010 Transfected with: HGNC; 2610; CYP2A6; Transfected with: HGNC; 3401; EPHX1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159126 CVCL_UU69 CHL AR-18 spontaneously immortalized cell line CVCL_UU69 CL:0000010 Transfected with: UniProtKB; P33616; Macaca fascicularis CYP1A1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159127 CVCL_V669 HCC2312 cancer cell line human CVCL_V669 CL:0000010 Female 21159128 CVCL_UU67 CHL AR-13 spontaneously immortalized cell line CVCL_UU67 CL:0000010 Transfected with: UniProtKB; P33616; Macaca fascicularis CYP1A1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159129 CVCL_V667 HCC1385 cancer cell line human CVCL_V667 CL:0000010 Female 21159130 CVCL_UU68 CHL AR-16 spontaneously immortalized cell line CVCL_UU68 CL:0000010 Transfected with: UniProtKB; P33616; Macaca fascicularis CYP1A1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159131 CVCL_V668 HCC1386 cancer cell line human CVCL_V668 CL:0000010 Female 21159132 CVCL_3020 MCAS cancer cell line human CVCL_3020 HLA typing: A*02:06,24:02; B*40:02,46:01; C*01:02,03:05 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.1%; East Asian, South=21.89%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=25846456; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=25846456; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser504Arg (c.1512T>A); Zygosity=Unspecified (PubMed=25846456) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=4056530); ~28 hours (lot 03262008), ~20 hours (lot 01202012), ~39 hours (lot 08162016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21159133 CVCL_3021 MDBK.P3 spontaneously immortalized cell line CVCL_3021 CL:0000010 Derived from sampling site: Kidney. Male Group: Serum/protein free medium cell line 21159134 CVCL_3013 Lu-65B cancer cell line human CVCL_3013 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser82Ter (c.245C>A); ClinVar=VCV000837710; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Omics: SNP array analysis Male 21159135 CVCL_3014 Lu-65C cancer cell line human CVCL_3014 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser82Ter (c.245C>A); ClinVar=VCV000837710; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Male 21159136 CVCL_3011 Lu Vin finite cell line human CVCL_3011 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159137 CVCL_3012 Lu-65A cancer cell line human CVCL_3012 HLA typing: A*11:01,24:02; B*40:02; C*03:04 (PubMed=9023415) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser82Ter (c.245C>A); ClinVar=VCV000837710; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Lung. Omics: SNP array analysis Male 21159138 CVCL_3017 Mar Ton finite cell line human CVCL_3017 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159139 CVCL_3018 Mar Vin finite cell line human CVCL_3018 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159140 CVCL_3015 Lu-99 cancer cell line human CVCL_3015 HLA typing: A*24:02,24:02; B*52:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.25%; Native American=0%; East Asian, North=84.63%; East Asian, South=13.5%; South Asian=0%; European, North=0%; European, South=1.62% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21.1 hours (lot 061891), ~25 hours (lot 10092014) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21159141 CVCL_3016 Mar Nol finite cell line human CVCL_3016 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159142 CVCL_3019 Marcus cancer cell line human CVCL_3019 CL:0000010 Discontinued: JCRB; IFO50290; probable. Female 21159143 CVCL_UU72 CHL CR-68 spontaneously immortalized cell line CVCL_UU72 CL:0000010 Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159144 CVCL_V672 HCC1323 cancer cell line human CVCL_V672 CL:0000010 Female 21159145 CVCL_UU73 CHL A2R-5 spontaneously immortalized cell line CVCL_UU73 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159146 CVCL_V673 HCC1347 cancer cell line human CVCL_V673 CL:0000010 Female 21159147 CVCL_UU70 CHL CR-50 spontaneously immortalized cell line CVCL_UU70 CL:0000010 Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159148 CVCL_V670 HCC1314 cancer cell line human CVCL_V670 CL:0000010 Male 21159149 CVCL_UU71 CHL CR-52 spontaneously immortalized cell line CVCL_UU71 CL:0000010 Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159150 CVCL_V671 HCC1319 cancer cell line human CVCL_V671 HLA typing: A*68:01,68:01; B*14:02,14:02; C*08:02,08:02; DQB1*05:01,05:01; DRB1*01:02,01:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159151 CVCL_UU54 CNIO CF cancer cell line human CVCL_UU54 CL:0000010 Unspecified 21159152 CVCL_V654 HCC1705 cancer cell line human CVCL_V654 CL:0000010 Unspecified 21159153 CVCL_UU55 CNIO CG cancer cell line human CVCL_UU55 CL:0000010 Unspecified 21159154 CVCL_V655 HCC1671 cancer cell line human CVCL_V655 CL:0000010 Male 21159155 CVCL_UU52 CNIO CC cancer cell line human CVCL_UU52 CL:0000010 Unspecified 21159156 CVCL_V652 HCC1820 cancer cell line human CVCL_V652 CL:0000010 Unspecified 21159157 CVCL_UU53 CNIO CD cancer cell line human CVCL_UU53 CL:0000010 Unspecified 21159158 CVCL_V653 HCC1772 cancer cell line human CVCL_V653 CL:0000010 Female 21159159 CVCL_UU58 CNIO CM telomerase immortalized cell line human CVCL_UU58 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast. Female 21159160 CVCL_V658 HCC1685 cancer cell line human CVCL_V658 CL:0000010 Female 21159161 CVCL_UU59 CNIO CP cancer cell line human CVCL_UU59 CL:0000010 Derived from sampling site: Ovary. Female 21159162 CVCL_V659 HCC1686 cancer cell line human CVCL_V659 CL:0000010 Female 21159163 CVCL_UU56 CNIO CJ telomerase immortalized cell line human CVCL_UU56 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast. Female 21159164 CVCL_V656 HCC1629 cancer cell line human CVCL_V656 CL:0000010 Male 21159165 CVCL_UU57 CNIO CL cancer cell line human CVCL_UU57 CL:0000010 Derived from sampling site: Breast. Female 21159166 CVCL_V657 HCC1623 cancer cell line human CVCL_V657 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (PubMed=29045385) Omics: Deep exome analysis. Female 21159167 CVCL_3032 MTA cancer cell line human CVCL_3032 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Doubling time: ~1.5 days (lot 03262004), ~69 hours (lot 02122015) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159168 CVCL_3030 MRC-9-30 finite cell line human CVCL_3030 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21159169 CVCL_3024 Mi Ten finite cell line human CVCL_3024 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1113; true Male 21159170 CVCL_3025 Miz-1 finite cell line human CVCL_3025 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; IFO50300; probable Unspecified 21159171 CVCL_3022 MEG-01s cancer cell line human CVCL_3022 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male 21159172 CVCL_3023 MEG-01SSF cancer cell line human CVCL_3023 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: ~20 hours (PubMed=1367286) Group: Serum/protein free medium cell line 21159173 CVCL_3028 MRC-5-40 finite cell line human CVCL_3028 CL:0000010 Derived from sampling site: Fetal lung. Male 21159174 CVCL_3029 MRC-5-50 finite cell line human CVCL_3029 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21159175 CVCL_3026 Mm2T spontaneously immortalized cell line CVCL_3026 CL:0000010 Derived from sampling site: Thymus. Discontinued: JCRB; JCRB0609; true Male Doubling time: 67.5 hours (CelloPub=CLPUB00082) 21159176 CVCL_3027 MRC-5-30 finite cell line human CVCL_3027 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Doubling time: ~40 hours (lot 05142008), ~26 hours (lot 09112017) (JCRB) 21159177 CVCL_UU61 AHH-1 TK+/- transformed cell line human CVCL_UU61 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=8841477) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159178 CVCL_V661 HCC1943 cancer cell line human CVCL_V661 CL:0000010 Male 21159179 CVCL_UU62 AHH-1 TK+/- L3 transformed cell line human CVCL_UU62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159180 CVCL_V662 HCC2308 cancer cell line human CVCL_V662 CL:0000010 Female 21159181 CVCL_UU60 CNIO CQ cancer cell line human CVCL_UU60 CL:0000010 Unspecified 21159182 CVCL_V660 HCC1688 cancer cell line human CVCL_V660 CL:0000010 Female 21159183 CVCL_V643 CHL-2 cancer cell line human CVCL_V643 CL:0000010 Sequence variation: Gene fusion; HGNC; 2352; CREM + HGNC; 3508; EWSR1; Name(s)=EWSR1-CREM (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Ile228Val (c.682A>G); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9051; PLAT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9451 21159184 CVCL_UU43 CNIO BR cancer cell line human CVCL_UU43 CL:0000010 Unspecified 21159185 CVCL_UU44 CNIO BT cancer cell line human CVCL_UU44 CL:0000010 Unspecified 21159186 CVCL_UU41 CNIO BO cancer cell line human CVCL_UU41 CL:0000010 Unspecified 21159187 CVCL_V641 HCC-M cancer cell line human CVCL_V641 CL:0000010 Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Proteome analysis by 2D-DE/MS Male Doubling time: 24 hours (PubMed=6307892) 21159188 CVCL_UU42 CNIO BQ cancer cell line human CVCL_UU42 CL:0000010 Unspecified 21159189 CVCL_V642 HCC-T cancer cell line human CVCL_V642 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 24 hours (PubMed=2474366) 21159190 CVCL_UU47 CNIO BW cancer cell line human CVCL_UU47 CL:0000010 Unspecified 21159191 CVCL_V647 PMO spontaneously immortalized cell line CVCL_V647 CL:0000010 Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200004. Problematic cell line: Misidentified Originally deposited as a shrimp (Penaeus mondodon) cell line, is in fact a Anguilla japonica cell line (PubMed=15994770). 21159192 CVCL_V648 293sars181A transformed cell line human CVCL_V648 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000170) It was the sole source of information for this entry. Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21159193 CVCL_UU48 CNIO BX cancer cell line human CVCL_UU48 CL:0000010 Unspecified 21159194 CVCL_UU45 CNIO BU cancer cell line human CVCL_UU45 CL:0000010 Unspecified 21159195 CVCL_V645 Koi-Fin spontaneously immortalized cell line CVCL_V645 CL:0000010 Derived from sampling site: Fin; Breed/subspecies: Koi. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201199 21159196 CVCL_V646 3G1 [Mouse hybridoma against aflatoxin B1] hybridoma house mouse CVCL_V646 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:2504; Aflatoxin B1 (AFB1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201014 21159197 CVCL_UU46 CNIO BV cancer cell line human CVCL_UU46 CL:0000010 Unspecified 21159198 CVCL_UU49 CNIO BY cancer cell line human CVCL_UU49 CL:0000010 Unspecified 21159199 CVCL_V649 L/1C2 hybridoma house mouse CVCL_V649 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9682 21159200 CVCL_UU50 CNIO BZ cancer cell line human CVCL_UU50 CL:0000010 Unspecified 21159201 CVCL_V650 CNLBC1 cancer cell line human CVCL_V650 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 25589; SEPTIN11; Name(s)=KMT2A-SEPTIN11, KMT2A-SEPT11, MLL-SEPT11 (PubMed=14999297) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 36 hours (PubMed=14999297) 21159202 CVCL_UU51 CNIO CB cancer cell line human CVCL_UU51 CL:0000010 Female 21159203 CVCL_V651 HCC1162 cancer cell line human CVCL_V651 HLA typing: A*30:02,33:01; B*37:01,57:03; C*06:02,18:02 (PubMed=26589293) CL:0000010 Derived from sampling site: Endometrium. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21159204 CVCL_UU32 CNIO AS cancer cell line human CVCL_UU32 CL:0000010 Female 21159205 CVCL_V632 LIXC012 cancer cell line human CVCL_V632 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 76.68 +- 4.16 hours (PubMed=24416385) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201114 21159206 CVCL_UU33 CNIO AT cancer cell line human CVCL_UU33 CL:0000010 Female 21159207 CVCL_V633 CPL0903 cancer cell line human CVCL_V633 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 46.81 +- 1.10 hours (PubMed=24416385) 21159208 CVCL_UU30 CNIO AQ cancer cell line human CVCL_UU30 CL:0000010 Female 21159209 CVCL_V630 LIXC006 cancer cell line human CVCL_V630 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 52.82 +- 0.93 hours (PubMed=24416385) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013182 21159210 CVCL_UU31 CNIO AR cancer cell line human CVCL_UU31 CL:0000010 Female 21159211 CVCL_V631 LIXC011 cancer cell line human CVCL_V631 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 110.6 +- 17.88 hours (PubMed=24416385) 21159212 CVCL_UU36 CNIO BA cancer cell line human CVCL_UU36 CL:0000010 Unspecified 21159213 CVCL_V636 HCC2302 cancer cell line human CVCL_V636 HLA typing: A*03:01,03:01; B*07:02,14:02; C*07:02,07:02; DQB1*06:02,06:02; DRB1*15:01,13:07 (PubMed=26589293) CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male 21159214 CVCL_UU37 CNIO BD cancer cell line human CVCL_UU37 CL:0000010 Unspecified 21159215 CVCL_V637 HCC2352 cancer cell line human CVCL_V637 CL:0000010 Population: African American Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159216 CVCL_UU34 CNIO AU cancer cell line human CVCL_UU34 CL:0000010 Female 21159217 CVCL_V634 JH-2/TPA cancer cell line human CVCL_V634 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 9051; PLAT Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200006 21159218 CVCL_UU35 CNIO AV cancer cell line human CVCL_UU35 CL:0000010 Female 21159219 CVCL_V635 HCC2270 cancer cell line human CVCL_V635 HLA typing: A*01:01,03:01; B*08:01,50:01; C*06:02,07:01 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159220 CVCL_UU38 CNIO BE cancer cell line human CVCL_UU38 CL:0000010 Unspecified 21159221 CVCL_V638 HCC2344 cancer cell line human CVCL_V638 CL:0000010 Population: African American Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159222 CVCL_UU39 CNIO BH cancer cell line human CVCL_UU39 CL:0000010 Unspecified 21159223 CVCL_V639 HCC1908 cancer cell line human CVCL_V639 CL:0000010 Female 21159224 CVCL_3010 Lu Rob finite cell line human CVCL_3010 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159225 CVCL_3002 KP-1N cancer cell line human CVCL_3002 Genome ancestry: African=0.39%; Native American=0.95%; East Asian, North=0%; East Asian, South=1.14%; South Asian=0.29%; European, North=65.14%; European, South=32.09% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=21607521; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=21607521; Cosmic-CLP; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0274.0; true Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00374 Problematic cell line: Contaminated Shown to be a PANC-1 derivative. 21159226 CVCL_3003 KP-1NL cancer cell line human CVCL_3003 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=21607521; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=21607521; DepMap) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0274.1; true Male Doubling time: 25 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Contaminated Parent cell line (KP-1N) has been shown to be a PANC-1 derivative. 21159227 CVCL_3000 KO51 cancer cell line human CVCL_3000 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: JCRB; NIHS0163; true; Discontinued: JCRB; NIHS0244; true Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00217 Problematic cell line: Contaminated Shown to be a K-562 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the bone marrow of 46 year old male patient with acute myeloid leukemia. 21159228 CVCL_3001 KON cancer cell line human CVCL_3001 Genome ancestry: African=0.36%; Native American=0.46%; East Asian, North=79.36%; East Asian, South=18.6%; South Asian=0.7%; European, North=0.27%; European, South=0.25% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 32.5 hours, at 28th passage (DOI=10.5794/jjoms.41.19); 43 hours (lot 01262007) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159229 CVCL_3006 KP-3L cancer cell line human CVCL_3006 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=21607521); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Glu538Ter (c.1612G>T); ClinVar=VCV000581974; Zygosity=Homozygous (PubMed=18380791); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Omics: Metabolome analysis Discontinued: JCRB; NIHS0275.1; true Male Characteristics: Established from parent cell line through a nude mice tumor 21159230 CVCL_3007 KYM-1 cancer cell line human CVCL_3007 HLA typing: A*11:01,26:01; B*35:01,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=74.54%; East Asian, South=24.94%; South Asian=0.51%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=11921280) Population: Japanese; Derived from sampling site: Neck. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~75 hours, at 30th passage (PubMed=3830265); ~41 hours (lot 030499), ~26 hours (lot 02142012) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project Problematic cell line: Possibly misclassified It is not certain that this cell line originate from a alveolar rhabdomyosarcoma (ARMS). It lacks the PAXA3-FOXO1 gene fusion characteristics of ARMS. Many papers classify it as an embryonal rhabdomyosarcoma (ERMS) and we accordingly describe it as such. 21159231 CVCL_3004 KP-2 cancer cell line human CVCL_3004 HLA typing: A*24:02,26:03; B*15:01,52:01; C*03:03,12:02 (PubMed=26589293); Genome ancestry: African=1.37%; Native American=0%; East Asian, North=79.94%; East Asian, South=16.44%; South Asian=0%; European, North=0%; European, South=2.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp415Glufs*20 (c.1245_1248delCAGA); ClinVar=VCV000142253; Zygosity=Heterozygous (PubMed=18380791; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Homozygous (PubMed=21607521; DepMap) Population: Japanese; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Metabolome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159232 CVCL_3005 KP-3 cancer cell line human CVCL_3005 HLA typing: A*24:02,24:02; B*35:01,35:01; C*08:01,08:01 (PubMed=26589293); Genome ancestry: African=0.33%; Native American=0.8%; East Asian, North=78.29%; East Asian, South=19.41%; South Asian=0.83%; European, North=0.07%; European, South=0.25% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (PubMed=21607521; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Glu538Ter (c.1612G>T); ClinVar=VCV000581974; Zygosity=Homozygous (PubMed=18380791; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0275.0; true Male Doubling time: ~28 hours (lot 12012006), ~38 hours (lot 10112019) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21159233 CVCL_3008 LC-1/sq cancer cell line human CVCL_3008 HLA typing: A*11,24:02; B*44:03:01; C*12:03,16:01 (PubMed=9023415); Genome ancestry: African=0.33%; Native American=0%; East Asian, North=91.84%; East Asian, South=7.55%; South Asian=0.28%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Arg1475Ter (c.4423C>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (PubMed=10536175; PubMed=20557307; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 64.6 hours (PubMed=1917142); ~75 hours (lot 11122004) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159234 CVCL_3009 LLC-MK2 spontaneously immortalized cell line CVCL_3009 CL:0000010 Derived from sampling site: Kidney. Unspecified Characteristics: Derived from the trypsinization of a pool of kidneys from 6 adult rhesus monkeys; Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-7; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-7.1 21159235 CVCL_UU40 CNIO BL cancer cell line human CVCL_UU40 CL:0000010 Unspecified 21159236 CVCL_V640 Tong/HCC cancer cell line human CVCL_V640 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; c.5125-1G>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31378681); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Leu148Ter (c.443T>A); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=31378681) Population: Caucasian; Italian; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~50 hours (PubMed=2445644); 26.71 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21159237 CVCL_UU21 CNIO AH cancer cell line human CVCL_UU21 CL:0000010 Unspecified 21159238 CVCL_V621 HCC827 GR2 cancer cell line human CVCL_V621 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21159239 CVCL_UU22 CNIO AI cancer cell line human CVCL_UU22 CL:0000010 Unspecified 21159240 CVCL_V622 HCC827 GR5 cancer cell line human CVCL_V622 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 48 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159241 CVCL_UU20 CNIO AG cancer cell line human CVCL_UU20 CL:0000010 Unspecified 21159242 CVCL_V620 HCC827 GR1 cancer cell line human CVCL_V620 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21159243 CVCL_UU25 CNIO AL cancer cell line human CVCL_UU25 CL:0000010 Unspecified 21159244 CVCL_V625 HCC827 GR8 cancer cell line human CVCL_V625 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21159245 CVCL_UU26 CNIO AM cancer cell line human CVCL_UU26 CL:0000010 Unspecified 21159246 CVCL_V626 PrEC LH transformed cell line human CVCL_V626 Genome ancestry: African=0.32%; Native American=0%; East Asian, North=0.26%; East Asian, South=0%; South Asian=1%; European, North=67.13%; European, South=31.28% (PubMed=30894373) CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159247 CVCL_UU23 CNIO AJ cancer cell line human CVCL_UU23 CL:0000010 Unspecified 21159248 CVCL_V623 HCC827 GR6 cancer cell line human CVCL_V623 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21159249 CVCL_UU24 CNIO AK cancer cell line human CVCL_UU24 CL:0000010 Unspecified 21159250 CVCL_V624 HCC827 GR7 cancer cell line human CVCL_V624 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Lung. Female 21159251 CVCL_UU29 CNIO AP cancer cell line human CVCL_UU29 CL:0000010 Female 21159252 CVCL_V629 LIXC004 cancer cell line human CVCL_V629 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Female Characteristics: Established from a patient-derived xenograft Doubling time: 36.02 +- 1.41 hours (PubMed=24416385) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201073 21159253 CVCL_UU27 CNIO AN cancer cell line human CVCL_UU27 CL:0000010 Female 21159254 CVCL_V627 LIXC002 cancer cell line human CVCL_V627 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 44.71 +- 0.38 hours (PubMed=24416385) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201072 21159255 CVCL_UU28 CNIO AO cancer cell line human CVCL_UU28 CL:0000010 Female 21159256 CVCL_V628 LIXC003 cancer cell line human CVCL_V628 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Characteristics: Established from a patient-derived xenograft Doubling time: 24.95 +- 0.43 hours (PubMed=24416385) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201112 21159257 CVCL_UU10 CNIO BN cancer cell line human CVCL_UU10 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Unspecified Doubling time: 72 hours (PubMed=16888811) 21159258 CVCL_V610 SLR24 cancer cell line human CVCL_V610 Genome ancestry: African=0.24%; Native American=0%; East Asian, North=2.8%; East Asian, South=0%; South Asian=0%; European, North=55.96%; European, South=41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Trp (c.194C>G); ClinVar=VCV000043597; Zygosity=Hemizygous (DepMap) Miscellaneous: STR profile from personal communication of von Teichman A. Omics: Deep exome analysis; Omics: shRNA library screening Unspecified Doubling time: 30 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00574 Problematic cell line: Contaminated Shown to be a RCC4 derivative (ICLAC). 21159259 CVCL_UU11 CNIO BP cancer cell line human CVCL_UU11 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=16888811) Derived from sampling site: Bone. Unspecified Doubling time: 48 hours (PubMed=16888811) 21159260 CVCL_V611 SLR25 cancer cell line human CVCL_V611 Genome ancestry: African=0.9%; Native American=0%; East Asian, North=3.02%; East Asian, South=0%; South Asian=0.26%; European, North=57.41%; European, South=38.41% (PubMed=30894373) CL:0000010 Miscellaneous: STR profile from personal communication of von Teichman A Population: Caucasian; Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: shRNA library screening Unspecified Doubling time: 80 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159261 CVCL_UU14 BY00466 transformed cell line human CVCL_UU14 HLA typing: A*02:DFKP,26:40; B*44:02,51:01; C*07:04,15:02; DQB1*03:01/16,03:03; DRB1*09:01,11:01 (IPD-IMGT/HLA=16465) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159262 CVCL_V614 HCC1963 cancer cell line human CVCL_V614 CL:0000010 Male 21159263 CVCL_UU15 CNIO AB cancer cell line human CVCL_UU15 CL:0000010 Unspecified 21159264 CVCL_V615 HCC1974 cancer cell line human CVCL_V615 CL:0000010 Unspecified 21159265 CVCL_UU12 CNIO CE cancer cell line human CVCL_UU12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Male Doubling time: 48 hours (PubMed=16888811) 21159266 CVCL_V612 SLR26 cancer cell line human CVCL_V612 Genome ancestry: African=1.17%; Native American=0%; East Asian, North=1.33%; East Asian, South=1.5%; South Asian=0%; European, North=65.36%; European, South=30.63% (PubMed=30894373) CL:0000010 Miscellaneous: STR profile from personal communication of von Teichman A. Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 55 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159267 CVCL_UU13 PC cancer cell line human CVCL_UU13 From: Andren-Sandberg A.; Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp355Gly (c.1064A>G); Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=11787853). 21159268 CVCL_V613 SF172 cancer cell line human CVCL_V613 Genome ancestry: African=75.55%; Native American=0.48%; East Asian, North=4.1%; East Asian, South=0%; South Asian=0%; European, North=7%; European, South=12.87% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Probably misidentified/contaminated Except of a loss of an allele of TH01 the STR profile of SF172 is identical to that of SF763. Furthermore we could not find in the literature any trace of the exact origin of SF172 and, according to a personal communication of Shai A. from the UCSF Biorepository, there is no record of SF172 in their system while SF763 is registered there. The TP53 mutation recorded for SF763 is also identical to the one in SF172. 21159269 CVCL_UU18 CNIO AE cancer cell line human CVCL_UU18 CL:0000010 Unspecified 21159271 CVCL_UU19 CNIO AF cancer cell line human CVCL_UU19 CL:0000010 Unspecified 21159272 CVCL_V619 HCC2041 cancer cell line human CVCL_V619 CL:0000010 Female 21159273 CVCL_UU16 CNIO AC cancer cell line human CVCL_UU16 CL:0000010 Unspecified 21159274 CVCL_V616 F5 cancer cell line human CVCL_V616 Genome ancestry: African=2.76%; Native American=0%; East Asian, North=3.58%; East Asian, South=0%; South Asian=0%; European, North=60.4%; European, South=33.25% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis Unspecified Doubling time: 46 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159275 CVCL_UU17 CNIO AD cancer cell line human CVCL_UU17 CL:0000010 Unspecified 21159276 CVCL_V617 TIG-3 TD telomerase immortalized cell line human CVCL_V617 Genome ancestry: African=0%; Native American=0.91%; East Asian, North=74.91%; East Asian, South=24.18%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159277 CVCL_2N80 AU10045 transformed cell line human CVCL_2N80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159278 CVCL_2N83 AU10049 transformed cell line human CVCL_2N83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159279 CVCL_2N84 AU10050 transformed cell line human CVCL_2N84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159280 CVCL_2N81 AU10047 transformed cell line human CVCL_2N81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159281 CVCL_2N82 AU10048 transformed cell line human CVCL_2N82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159282 CVCL_2N87 AU10053 transformed cell line human CVCL_2N87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159283 CVCL_2N88 AU10054 transformed cell line human CVCL_2N88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159284 CVCL_2N85 AU10051 transformed cell line human CVCL_2N85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159285 CVCL_2N86 AU10052 transformed cell line human CVCL_2N86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159286 CVCL_2N78 AU10043 transformed cell line human CVCL_2N78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159287 CVCL_2N79 AU10044 transformed cell line human CVCL_2N79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159288 CVCL_2N90 AU10056 transformed cell line human CVCL_2N90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159289 CVCL_2N91 AU10057 transformed cell line human CVCL_2N91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159290 CVCL_2N94 AU10060 transformed cell line human CVCL_2N94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159291 CVCL_2N95 AU10061 transformed cell line human CVCL_2N95 CL:0000010 Population: Caribbean; Trinidadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159292 CVCL_2N92 AU10058 transformed cell line human CVCL_2N92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159293 CVCL_2N93 AU10059 transformed cell line human CVCL_2N93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159294 CVCL_2N98 AU10064 transformed cell line human CVCL_2N98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159295 CVCL_2N99 AU10065 transformed cell line human CVCL_2N99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159296 CVCL_2N96 AU10062 transformed cell line human CVCL_2N96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159297 CVCL_2N97 AU10063 transformed cell line human CVCL_2N97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159298 CVCL_2N89 AU10055 transformed cell line human CVCL_2N89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159299 CVCL_2N61 AU10026 transformed cell line human CVCL_2N61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159300 CVCL_2N62 AU10027 transformed cell line human CVCL_2N62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159301 CVCL_2N60 AU10025 transformed cell line human CVCL_2N60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159302 CVCL_2N65 AU10030 transformed cell line human CVCL_2N65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10031 (Cellosaurus=CVCL_2N66); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159303 CVCL_2N66 AU10031 transformed cell line human CVCL_2N66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10030 (Cellosaurus=CVCL_2N65); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159304 CVCL_2N63 AU10028 transformed cell line human CVCL_2N63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159305 CVCL_2N64 AU10029 transformed cell line human CVCL_2N64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159306 CVCL_2N58 AU10023 transformed cell line human CVCL_2N58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159307 CVCL_2N59 AU10024 transformed cell line human CVCL_2N59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159308 CVCL_2N56 AU10021 transformed cell line human CVCL_2N56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159309 CVCL_2N57 AU10022 transformed cell line human CVCL_2N57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159310 CVCL_UT99 CNIO AX cancer cell line human CVCL_UT99 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16888811). Male Doubling time: 48 hours (PubMed=16888811) 21159311 CVCL_V599 HCC2433 cancer cell line human CVCL_V599 CL:0000010 Male 21159312 CVCL_UT97 CNIO AA cancer cell line human CVCL_UT97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16888811). Male Doubling time: 36 hours (PubMed=16888811) 21159313 CVCL_V597 HCC1576 cancer cell line human CVCL_V597 HLA typing: A*32:01,68:01; B*08:01,44:02; C*02:02,07:04 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159314 CVCL_UT98 CNIO AW cancer cell line human CVCL_UT98 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=16888811). Male Doubling time: 48 hours (PubMed=16888811) 21159315 CVCL_V598 HCC1581 cancer cell line human CVCL_V598 CL:0000010 Female 21159316 CVCL_2N72 AU10037 transformed cell line human CVCL_2N72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159317 CVCL_2N73 AU10038 transformed cell line human CVCL_2N73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159318 CVCL_2N70 AU10035 transformed cell line human CVCL_2N70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159319 CVCL_2N71 AU10036 transformed cell line human CVCL_2N71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159320 CVCL_2N76 AU10041 transformed cell line human CVCL_2N76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159321 CVCL_2N77 AU10042 transformed cell line human CVCL_2N77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159322 CVCL_2N74 AU10039 transformed cell line human CVCL_2N74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159323 CVCL_2N75 AU10040 transformed cell line human CVCL_2N75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159324 CVCL_2N69 AU10034 transformed cell line human CVCL_2N69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159325 CVCL_2N67 AU10032 transformed cell line human CVCL_2N67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159326 CVCL_2N68 AU10033 transformed cell line human CVCL_2N68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159327 CVCL_V588 HCC2885 cancer cell line human CVCL_V588 HLA typing: A*02:01,03:01; B*14:02,27:05; C*02:02,08:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159328 CVCL_UT88 HN-SCC-257 cancer cell line human CVCL_UT88 CL:0000010 Unspecified 21159329 CVCL_V589 HCC1445 cancer cell line human CVCL_V589 CL:0000010 Male 21159330 CVCL_UT89 HN-SCC-301B cancer cell line human CVCL_UT89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8339273). Unspecified 21159331 CVCL_UT86 GM27255 finite cell line human CVCL_UT86 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Tyr208Cys (c.623A>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21159332 CVCL_V586 HCC2814 cancer cell line human CVCL_V586 Genome ancestry: African=1.59%; Native American=0%; East Asian, North=5.79%; East Asian, South=0%; South Asian=0%; European, North=54.45%; European, South=38.17% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Trp (c.528C>G); ClinVar=VCV000376572; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Metfs*68 (c.535delC); Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21159333 CVCL_UT87 GM03094 transformed cell line human CVCL_UT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03094; probable Male 21159334 CVCL_V587 HCC2846 cancer cell line human CVCL_V587 CL:0000010 Female 21159335 CVCL_2N40 AU10005 transformed cell line human CVCL_2N40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159336 CVCL_2N43 AU10008 transformed cell line human CVCL_2N43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159337 CVCL_2N44 AU10009 transformed cell line human CVCL_2N44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159338 CVCL_2N41 AU10006 transformed cell line human CVCL_2N41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159339 CVCL_2N42 AU10007 transformed cell line human CVCL_2N42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159340 CVCL_2N36 AU10001 transformed cell line human CVCL_2N36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159341 CVCL_2N37 AU10002 transformed cell line human CVCL_2N37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159342 CVCL_2N34 GM16994 transformed cell line human CVCL_2N34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21159343 CVCL_2N35 AU10000 transformed cell line human CVCL_2N35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159344 CVCL_2N38 AU10003 transformed cell line human CVCL_2N38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10004 (Cellosaurus=CVCL_2N39); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159345 CVCL_2N39 AU10004 transformed cell line human CVCL_2N39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10003 (Cellosaurus=CVCL_2N38); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159346 CVCL_V591 HCC1482 cancer cell line human CVCL_V591 HLA typing: A*33:03,68:01; B*35:03,58:01; C*03:02,04:01 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159347 CVCL_UT91 ZC.Lu+ZC424 finite cell line CVCL_UT91 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6534; true Unspecified Virology: Infected with a virus isolated from a poxlike lesion on a young sea lion Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159348 CVCL_UT92 EJ1.Th finite cell line CVCL_UT92 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6532; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159349 CVCL_V592 HCC1493 cancer cell line human CVCL_V592 HLA typing: A*26:01,69:01; B*13:02,55:01; C*01:02,06:02 (PubMed=26589293) CL:0000010 Sequence variation: Gene fusion; HGNC; 1697; CD74 + HGNC; 10261; ROS1; Name(s)=CD74-ROS1 (PubMed=25485619) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159350 CVCL_V590 HCC1448 cancer cell line human CVCL_V590 CL:0000010 Female 21159351 CVCL_UT90 ZC.Lu finite cell line CVCL_UT90 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6533; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159352 CVCL_V595 HCC1534 cancer cell line human CVCL_V595 HLA typing: A*30:04,30:04; B*41:01,41:01; C*17:01,17:01; DQB1*03:03,03:03; DRB1*11:02,11:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Unspecified 21159353 CVCL_UT95 MSuD1 finite cell line human CVCL_UT95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21159354 CVCL_UT96 1455 cancer cell line human CVCL_UT96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16888811). Male Doubling time: 48 hours (PubMed=16888811) 21159355 CVCL_V596 HCC1561 cancer cell line human CVCL_V596 CL:0000010 Male 21159356 CVCL_UT93 EJ2.K finite cell line CVCL_UT93 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6531; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159357 CVCL_V593 HCC826 cancer cell line human CVCL_V593 CL:0000010 Female 21159358 CVCL_UT94 ALYaAK finite cell line human CVCL_UT94 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159359 CVCL_V594 HCC1501 cancer cell line human CVCL_V594 CL:0000010 Unspecified 21159360 CVCL_V577 XP20BE finite cell line human CVCL_V577 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu11Ter (c.31G>T); Zygosity=Heterozygous (from autologous cell line XP20BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159361 CVCL_UT77 GM16423 transformed cell line human CVCL_UT77 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159362 CVCL_UT78 GM16424 transformed cell line human CVCL_UT78 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 9 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Female 21159363 CVCL_V578 HCC1897 cancer cell line human CVCL_V578 Genome ancestry: African=77.47%; Native American=1.11%; East Asian, North=4.48%; East Asian, South=0%; South Asian=0%; European, North=1.19%; European, South=15.76% (PubMed=30894373). CL:0000010 Population: African American Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21159364 CVCL_V575 AT2SF finite cell line human CVCL_V575 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1774Lysfs*17 (c.5320_5326del) (c.5320del7); Zygosity=Heterozygous (PubMed=8845835); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2769Ter (c.8307G>A); ClinVar=VCV000189104; Zygosity=Heterozygous (PubMed=8845835) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159365 CVCL_UT75 GM16356 transformed cell line human CVCL_UT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159366 CVCL_V576 XP20BE LCL transformed cell line human CVCL_V576 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu11Ter (c.31G>T); Zygosity=Heterozygous (PubMed=9447232) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159367 CVCL_UT76 GM16357 transformed cell line human CVCL_UT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159368 CVCL_UT79 GM16425 transformed cell line human CVCL_UT79 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 9 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Female 21159369 CVCL_V579 HCC4017 cancer cell line human CVCL_V579 HLA typing: A*29:02,29:02; B*07:02,07:02; C*07:02,07:02; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*13:07,15:01 (PubMed=26589293) CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 46.3 hours (PubMed=29681454) Part of: MD Anderson Cell Lines Project 21159370 CVCL_2N50 AU10015 transformed cell line human CVCL_2N50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159371 CVCL_2N51 AU10016 transformed cell line human CVCL_2N51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159372 CVCL_2N54 AU10019 transformed cell line human CVCL_2N54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159373 CVCL_2N55 AU10020 transformed cell line human CVCL_2N55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159374 CVCL_2N52 AU10017 transformed cell line human CVCL_2N52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159375 CVCL_2N53 AU10018 transformed cell line human CVCL_2N53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159376 CVCL_2N47 AU10012 transformed cell line human CVCL_2N47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159377 CVCL_2N48 AU10013 transformed cell line human CVCL_2N48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159378 CVCL_2N45 AU10010 transformed cell line human CVCL_2N45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10011 (Cellosaurus=CVCL_2N46); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159379 CVCL_2N46 AU10011 transformed cell line human CVCL_2N46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of AU10010 (Cellosaurus=CVCL_2N45); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159380 CVCL_2N49 AU10014 transformed cell line human CVCL_2N49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159381 CVCL_UT80 GM16426 transformed cell line human CVCL_UT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159382 CVCL_V580 HCC4018 cancer cell line human CVCL_V580 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Part of: MD Anderson Cell Lines Project 21159383 CVCL_UT81 GM27190 finite cell line human CVCL_UT81 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Trp308Ter (c.924G>A); ClinVar=VCV000013871; Zygosity=Unspecified; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159384 CVCL_V581 HCC4019 cancer cell line human CVCL_V581 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 61.2 hours (PubMed=29681454) Part of: MD Anderson Cell Lines Project 21159385 CVCL_UT84 GM27246 finite cell line human CVCL_UT84 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln86Profs*35 (c.256dupC); ClinVar=VCV000189613; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159386 CVCL_V584 HCC2677 cancer cell line human CVCL_V584 CL:0000010 Female 21159387 CVCL_UT85 GM27248 transformed cell line human CVCL_UT85 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln86Profs*35 (c.256dupC); ClinVar=VCV000189613; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159388 CVCL_V585 HCC2783 cancer cell line human CVCL_V585 CL:0000010 Male 21159389 CVCL_UT82 GM27199 transformed cell line human CVCL_UT82 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; p.Gly281Arg (c.841G>A); ClinVar=VCV000017182; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159390 CVCL_V582 HCC3051 cancer cell line human CVCL_V582 CL:0000010 Population: African American Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project 21159391 CVCL_UT83 GM27241 transformed cell line human CVCL_UT83 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Arg230Cys (c.688C>T); ClinVar=VCV000803013; Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 6111; IQGAP2; Simple; p.Gln953Ter (c.2857C>T); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159392 CVCL_V583 HCC2771 cancer cell line human CVCL_V583 CL:0000010 Female 21159393 CVCL_DB52 HIL-12F3-20E11 hybridoma house mouse CVCL_DB52 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P29459; Human IL12A; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12448 21159394 CVCL_DB53 HIL-12F3-16G2 hybridoma house mouse CVCL_DB53 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P29459; Human IL12A; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12449 21159395 CVCL_DB50 HIL-12F3-5F2 hybridoma house mouse CVCL_DB50 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P29459; Human IL12A; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12446 21159396 CVCL_DB51 HIL-12F3-16F2 hybridoma house mouse CVCL_DB51 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P29459; Human IL12A; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12447 21159397 CVCL_DB45 FCK finite cell line CVCL_DB45 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6568; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159398 CVCL_DB46 18/20PAC2 hybridoma house mouse CVCL_DB46 CL:0000010 Discontinued: ATCC; HB-7; true. Monoclonal antibody isotype: IgG2a, kappa 21159399 CVCL_DB43 C5D5 transformed cell line human CVCL_DB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 4 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8754 21159400 CVCL_DB44 K6-2 hybridoma house mouse CVCL_DB44 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Escherichia coli J5 endotoxin core. 21159401 CVCL_DB49 R1B19 hybridoma house mouse CVCL_DB49 CL:0000010 Discontinued: ATCC; HB-83; true. Monoclonal antibody isotype: IgM 21159402 CVCL_DB47 B6YD10 hybridoma house mouse CVCL_DB47 CL:0000010 Discontinued: ATCC; HB-18; true. Monoclonal antibody isotype: IgG2 21159403 CVCL_DB48 B6YH4 hybridoma house mouse CVCL_DB48 CL:0000010 Discontinued: ATCC; HB-17; true. Monoclonal antibody isotype: IgG2 21159404 CVCL_DB60 GM04593 finite cell line human CVCL_DB60 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159405 CVCL_DB63 GM07210 transformed cell line human CVCL_DB63 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159406 CVCL_DB64 GM07211 finite cell line human CVCL_DB64 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21159407 CVCL_DB61 GM20935 transformed cell line human CVCL_DB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159408 CVCL_DB62 GM05237 transformed cell line human CVCL_DB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159409 CVCL_DB56 GM02582 finite cell line human CVCL_DB56 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21159410 CVCL_DB57 GM02583 transformed cell line human CVCL_DB57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159411 CVCL_DB54 1-1A4 hybridoma house mouse CVCL_DB54 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. 21159412 CVCL_DB55 1-1D5 hybridoma house mouse CVCL_DB55 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P29460; Human IL12B. 21159413 CVCL_DB58 GM02609 finite cell line human CVCL_DB58 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21159414 CVCL_DB59 GM02610 transformed cell line human CVCL_DB59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159415 CVCL_DB30 HFF-4 finite cell line human CVCL_DB30 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1044; probable Male 21159416 CVCL_DB31 FW14-14 hybridoma house mouse CVCL_DB31 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P23229; Human ITGA6/CD49f. 21159417 CVCL_DB29 HFF-3 finite cell line human CVCL_DB29 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1043; probable Male 21159418 CVCL_DB23 ND00062 transformed cell line human CVCL_DB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159419 CVCL_DB24 ND00063 transformed cell line human CVCL_DB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159420 CVCL_DB21 GM23162 finite cell line human CVCL_DB21 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Cys42Tyr (c.125G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asp948Asn (c.2842G>A); ClinVar=VCV000552987; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159421 CVCL_DB22 GM25439 finite cell line human CVCL_DB22 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ser738Ter (c.2213C>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1080Ilefs*18 (c.3234_3237_dupATTT); Zygosity=Heterozygous (Coriell) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159422 CVCL_DB27 ND00068 transformed cell line human CVCL_DB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159423 CVCL_DB28 ND00069 transformed cell line human CVCL_DB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159424 CVCL_DB25 ND00065 transformed cell line human CVCL_DB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159425 CVCL_DB26 ND00066 transformed cell line human CVCL_DB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159426 CVCL_DB41 2H6 hybridoma house mouse CVCL_DB41 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody that acts as a lipase; Monoclonal antibody isotype: IgG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9969 21159427 CVCL_DB42 21H3 hybridoma house mouse CVCL_DB42 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody that acts as a lipase; Monoclonal antibody isotype: IgG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9970 21159428 CVCL_DB40 QCRL-6 hybridoma house mouse CVCL_DB40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33527; Human ABCC1/MRP. 21159429 CVCL_DB34 LYK-4 hybridoma CVCL_DB34 CL:0000010 Discontinued: ATCC; HB-309; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21159430 CVCL_DB35 LYK-10 hybridoma CVCL_DB35 CL:0000010 Discontinued: ATCC; HB-314; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21159431 CVCL_DB32 FW14-14-15 hybridoma house mouse CVCL_DB32 CL:0000010 Discontinued: ATCC; HB-259; true. Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P23229; Human ITGA6/CD49f 21159432 CVCL_DB33 LYK-2 hybridoma CVCL_DB33 CL:0000010 Discontinued: ATCC; HB-307; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21159433 CVCL_DB38 QCRL-2 hybridoma house mouse CVCL_DB38 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P33527; Human ABCC1/MRP. 21159434 CVCL_DB39 QCRL-4 hybridoma house mouse CVCL_DB39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33527; Human ABCC1/MRP. 21159435 CVCL_DB36 LYK-11 hybridoma CVCL_DB36 CL:0000010 Discontinued: ATCC; HB-315; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21159436 CVCL_DB37 LYK-6 hybridoma CVCL_DB37 CL:0000010 Discontinued: ATCC; HB-320; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15379; Mouse Cd44 21159437 CVCL_DB09 GM20950 finite cell line human CVCL_DB09 CL:0000010 Sequence variation: Mutation; HGNC; 23056; ALG3; Simple; p.Arg171Gln (c.512G>A); ClinVar=VCV000002129; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159438 CVCL_DB07 GM20948 finite cell line human CVCL_DB07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159439 CVCL_DB08 GM20949 finite cell line human CVCL_DB08 CL:0000010 Sequence variation: Mutation; HGNC; 23157; ALG6; Simple; c.680+2T>G (IVS7+2T>G); ClinVar=VCV000030421; Zygosity=Heterozygous; Note=Causes skipping of exons 7-12 plus 22 bases of exon 13 (Coriell); Sequence variation: Mutation; HGNC; 23157; ALG6; Simple; p.Ile299del (c.897_899delAAT) (c.894_896AAT[1]); ClinVar=VCV000030420; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159440 CVCL_DB01 GM20746 transformed cell line human CVCL_DB01 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Glu429Ala (c.1286A>C) (1298A>C); ClinVar=VCV000003521; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159441 CVCL_DB02 GM20941 transformed cell line human CVCL_DB02 CL:0000010 Sequence variation: Mutation; HGNC; 2995; DPAGT1; Simple; p.Tyr170Cys (c.509A>G) (660A>G); ClinVar=VCV000012296; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159442 CVCL_DB00 GM20730 transformed cell line human CVCL_DB00 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Glu429Ala (c.1286A>C) (1298A>C); ClinVar=VCV000003521; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21159443 CVCL_DB05 GM20945 finite cell line human CVCL_DB05 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Leu32Arg (c.95_96delinsGC) (c.95TA>GC); ClinVar=VCV000092807; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe157Ser (c.470T>C); ClinVar=VCV000188763; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159444 CVCL_DB06 GM20947 finite cell line human CVCL_DB06 CL:0000010 Sequence variation: Mutation; HGNC; 23056; ALG3; Simple; p.Trp71Arg (c.211T>C); ClinVar=VCV000002130; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 23056; ALG3; Simple; p.Met157Lys (c.470T>A); ClinVar=VCV000002131; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159445 CVCL_DB03 GM20942 finite cell line human CVCL_DB03 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Phe119Leu (c.357C>A); ClinVar=VCV000007711; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159446 CVCL_DB04 GM20944 finite cell line human CVCL_DB04 CL:0000010 Sequence variation: Mutation; HGNC; 3005; DPM1; Simple; p.Arg92Gly (c.274C>G); ClinVar=VCV000006296; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159447 CVCL_DB20 GM23154 transformed cell line human CVCL_DB20 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[196]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg404Gln (c.1211G>A); ClinVar=VCV000188794; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1007Ala (c.3019C>G); ClinVar=VCV000002966; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159448 CVCL_DB18 GM22871 finite cell line human CVCL_DB18 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: Established from monozygotic twin of GM22227 (Cellosaurus=CVCL_DB13) and GM22871 (Cellosaurus=CVCL_DB17); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159449 CVCL_DB19 GM23150 transformed cell line human CVCL_DB19 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Unexplicit; IVS2+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159450 CVCL_DB12 GM20958 finite cell line human CVCL_DB12 CL:0000010 Sequence variation: Mutation; HGNC; 7207; MPDU1; Simple; p.Leu119Pro (c.356T>C); ClinVar=VCV000005868; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159451 CVCL_DB13 GM22227 transformed cell line human CVCL_DB13 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM22256 (Cellosaurus=CVCL_DB16) and GM22871 (Cellosaurus=CVCL_DB18); Derived from sampling site: Peripheral blood. Female 21159452 CVCL_DB10 GM20951 finite cell line human CVCL_DB10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159453 CVCL_DB11 GM20956 finite cell line human CVCL_DB11 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Pro113Thr (c.337C>A); ClinVar=VCV000420784; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159454 CVCL_DB16 GM22256 transformed cell line human CVCL_DB16 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM22227 (Cellosaurus=CVCL_DB13) and GM22871 (Cellosaurus=CVCL_DB17); Derived from sampling site: Peripheral blood. Female 21159455 CVCL_DB17 GM22870 finite cell line human CVCL_DB17 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; c.1554-1009G>A (IVS9-1009G>A); ClinVar=VCV000553804; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.His641Thrfs*2 (c.1920delG); ClinVar=VCV000281941; Zygosity=Heterozygous (Coriell) Population: Caucasian; Donor information: Established from monozygotic twin of GM22256 (Cellosaurus=CVCL_DB16) and GM22871 (Cellosaurus=CVCL_DB18); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159456 CVCL_DB14 GM22229 transformed cell line human CVCL_DB14 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg978Cys (c.2932C>T); ClinVar=VCV000002976; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Unexplicit; IVS21-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159457 CVCL_DB15 GM22230 transformed cell line human CVCL_DB15 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg978Cys (c.2932C>T); ClinVar=VCV000002976; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Unexplicit; IVS21-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159458 CVCL_V720 HCC19 cancer cell line human CVCL_V720 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Female Characteristics: Metastatic adenocarcinoma from unknown primary site 21159459 CVCL_UV20 MMPR-11 spontaneously immortalized cell line CVCL_UV20 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside). Unspecified Group: Insect cell line 21159460 CVCL_V721 HCC229 cancer cell line human CVCL_V721 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Female 21159461 CVCL_UV21 MMPR-12 spontaneously immortalized cell line CVCL_UV21 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside). Unspecified Group: Insect cell line 21159462 CVCL_UV24 B1C3 spontaneously immortalized cell line CVCL_UV24 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159463 CVCL_V724 HCC31 cancer cell line human CVCL_V724 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Male 21159464 CVCL_UV25 B1C4 spontaneously immortalized cell line CVCL_UV25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159465 CVCL_V725 HCC317 cancer cell line human CVCL_V725 CL:0000010 Male 21159466 CVCL_V722 HCC242 cancer cell line human CVCL_V722 CL:0000010 Male 21159467 CVCL_UV22 MMPR-21 spontaneously immortalized cell line CVCL_UV22 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside). Unspecified Group: Insect cell line 21159468 CVCL_UV23 AIS-C3 spontaneously immortalized cell line CVCL_UV23 CL:0000010 Unspecified Group: Insect cell line. 21159469 CVCL_V723 HCC267 cancer cell line human CVCL_V723 CL:0000010 Female 21159470 CVCL_UV28 alphaA3 spontaneously immortalized cell line CVCL_UV28 CL:0000010 Selected for resistance to: ChEBI; CHEBI:37415; Alpha-amanitin; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159471 CVCL_V728 HCC379 cancer cell line human CVCL_V728 CL:0000010 Female 21159472 CVCL_V729 HCC630 cancer cell line human CVCL_V729 HLA typing: A*11:01,24:02; B*18:01,37:01; C*07:04,07:04 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21159473 CVCL_UV29 Oua1 spontaneously immortalized cell line CVCL_UV29 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159474 CVCL_UV26 alphaA1 spontaneously immortalized cell line CVCL_UV26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:37415; Alpha-amanitin; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159475 CVCL_V726 HCC345 cancer cell line human CVCL_V726 CL:0000010 Male 21159476 CVCL_UV27 alphaA2 spontaneously immortalized cell line CVCL_UV27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:37415; Alpha-amanitin; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159477 CVCL_V727 HCC374 cancer cell line human CVCL_V727 CL:0000010 Female 21159478 CVCL_UV10 CHL 7M-126 spontaneously immortalized cell line CVCL_UV10 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159479 CVCL_V710 GM17513 finite cell line human CVCL_V710 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159480 CVCL_UV13 CHL ER-133 spontaneously immortalized cell line CVCL_UV13 CL:0000010 Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159481 CVCL_V713 GM17413 transformed cell line human CVCL_V713 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159482 CVCL_UV14 CHL ER-181 spontaneously immortalized cell line CVCL_UV14 CL:0000010 Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159483 CVCL_V714 GM17414 finite cell line human CVCL_V714 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159484 CVCL_UV11 CHL 7R-10 spontaneously immortalized cell line CVCL_UV11 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159485 CVCL_V711 GM17427 transformed cell line human CVCL_V711 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159486 CVCL_UV12 CHL 7R-54 spontaneously immortalized cell line CVCL_UV12 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159487 CVCL_V712 GM17428 finite cell line human CVCL_V712 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21159488 CVCL_UV17 CHL ER-269 spontaneously immortalized cell line CVCL_UV17 CL:0000010 Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159489 CVCL_V717 GM17426 finite cell line human CVCL_V717 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21159490 CVCL_UV18 CHL/IU KN63 spontaneously immortalized cell line CVCL_UV18 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female Characteristics: Designed to detect mutational events The target gene is E.coli gpt that is present in a shuttle vector that can be rescued from the host cells (PubMed=9393622). 21159491 CVCL_V718 GM17592 finite cell line human CVCL_V718 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159492 CVCL_UV15 CHL ER-235 spontaneously immortalized cell line CVCL_UV15 CL:0000010 Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159493 CVCL_V715 GM17410 finite cell line human CVCL_V715 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159494 CVCL_UV16 CHL ER-238 spontaneously immortalized cell line CVCL_UV16 CL:0000010 Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159495 CVCL_V716 GM17425 transformed cell line human CVCL_V716 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159496 CVCL_V719 HCC12 cancer cell line human CVCL_V719 HLA typing: A*03:01,03:01; B*40:15,47:01; C*06:02,06:02; DQB1*02:02,02:02 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159497 CVCL_UV19 MMPR-10 spontaneously immortalized cell line CVCL_UV19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44081; 6-methylthioinosine (6-methylmercaptopurine riboside). Unspecified Group: Insect cell line 21159498 CVCL_UV02 CHL 7P-142 spontaneously immortalized cell line CVCL_UV02 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159499 CVCL_V702 HCC149 cancer cell line human CVCL_V702 CL:0000010 Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F.. Population: African American Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21159500 CVCL_UV03 CHL 7P-145 spontaneously immortalized cell line CVCL_UV03 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159501 CVCL_V703 HCC128 cancer cell line human CVCL_V703 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Female 21159502 CVCL_UV00 CHL 7-40 spontaneously immortalized cell line CVCL_UV00 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159503 CVCL_V700 HCC590 cancer cell line human CVCL_V700 CL:0000010 Female 21159504 CVCL_UV01 CHL 7P-101 spontaneously immortalized cell line CVCL_UV01 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159505 CVCL_V701 HCC597 cancer cell line human CVCL_V701 CL:0000010 Derived from sampling site: Endometrium. Female 21159506 CVCL_UV06 CHL 7M-41 spontaneously immortalized cell line CVCL_UV06 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159507 CVCL_V706 HCC1498 cancer cell line human CVCL_V706 CL:0000010 Male 21159508 CVCL_UV07 CHL 7M-102 spontaneously immortalized cell line CVCL_UV07 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159509 CVCL_V707 HCC407 cancer cell line human CVCL_V707 CL:0000010 Male 21159510 CVCL_UV04 CHL 7P-217 spontaneously immortalized cell line CVCL_UV04 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159511 CVCL_V704 HCC122 cancer cell line human CVCL_V704 CL:0000010 Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F.. Population: African American Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21159512 CVCL_UV05 CHL 7P-219 spontaneously immortalized cell line CVCL_UV05 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159513 CVCL_V705 HCC103 cancer cell line human CVCL_V705 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Female 21159514 CVCL_UV08 CHL 7M-116 spontaneously immortalized cell line CVCL_UV08 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159515 CVCL_V708 HCC10 cancer cell line human CVCL_V708 CL:0000010 Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F.. Male 21159516 CVCL_UV09 CHL 7M-124 spontaneously immortalized cell line CVCL_UV09 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Lung. Female 21159517 CVCL_V709 HCC1192 cancer cell line human CVCL_V709 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21159518 CVCL_DC91 CTLL-R9 factor-dependent cell line house mouse CVCL_DC91 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8203 21159519 CVCL_DC92 CTLL-R11 factor-dependent cell line house mouse CVCL_DC92 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8204 21159520 CVCL_DC90 CTLL-R8 factor-dependent cell line house mouse CVCL_DC90 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8202 21159521 CVCL_DC95 N70-1.5e transformed cell line human CVCL_DC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a HIV-1 infected adult; Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: HIV-1 gp120 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10464 21159522 CVCL_DC96 N70-1.9b transformed cell line human CVCL_DC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a HIV-1 infected adult; Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: HIV-1 gp120 21159523 CVCL_DC93 CTLL-R12 factor-dependent cell line house mouse CVCL_DC93 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8205 21159524 CVCL_DC94 K24-3b transformed cell line human CVCL_DC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a HIV-1 infected adult; Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: HIV-1 gp120 21159525 CVCL_DC88 CTLL-R1 factor-dependent cell line house mouse CVCL_DC88 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent 21159526 CVCL_DC89 CTLL-R5 factor-dependent cell line house mouse CVCL_DC89 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent 21159527 CVCL_DC86 CTLL-A2 factor-dependent cell line house mouse CVCL_DC86 CL:0000010 Derived from sampling site: Peritoneal cavity Cell type=T-cell.; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21159528 CVCL_DC87 CTLL-A11 factor-dependent cell line house mouse CVCL_DC87 CL:0000010 Derived from sampling site: Peritoneal cavity Cell type=T-cell.; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21159529 CVCL_DC99 CHO 1beta9, 12.5, clone 36 spontaneously immortalized cell line CVCL_DC99 CL:0000010 Transfected with: HGNC; 11766; TGFB1 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9800 21159530 CVCL_DC97 N70-2.1H transformed cell line human CVCL_DC97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a HIV-1 infected adult; Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: Not specified; Monoclonal antibody target: HIV-1 gp120 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10758 21159531 CVCL_DC98 N70-2.3a transformed cell line human CVCL_DC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a HIV-1 infected adult; Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HIV-1 gp120 21159532 CVCL_2P60 AU10129 transformed cell line human CVCL_2P60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159533 CVCL_3160 SAT [Human HNSCC] cancer cell line human CVCL_3160 Genome ancestry: African=0.32%; Native American=1.29%; East Asian, North=77.72%; East Asian, South=18.87%; South Asian=0%; European, North=1.81%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0257; true. Characteristics: Established from a nude mouse xenograft Doubling time: 72 hours (PubMed=10601556); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159534 CVCL_2P63 AU10132 transformed cell line human CVCL_2P63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159535 CVCL_3163 SF-TY finite cell line human CVCL_3163 HLA typing: A*02,24; B*05,w22 (JCRB=JCRB0075) CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0016; true Male Doubling time: ~40 hours (lot 102198), ~1.5 days (lots 07092007 and 08082018), ~42 hours (lot 07162010), 34-54 hours (lot 10192015), ~52 hours (lot 03272017), ~41 hours (lot 12202021) (JCRB) 21159536 CVCL_2P64 AU10133 transformed cell line human CVCL_2P64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159537 CVCL_3164 SHOK spontaneously immortalized cell line CVCL_3164 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21159538 CVCL_2P61 AU10130 transformed cell line human CVCL_2P61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159539 CVCL_3161 SCCH-196 cancer cell line human CVCL_3161 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=7591257; PubMed=9738976) Population: Japanese Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~36 hours (PubMed=2513302); >5 days (lots 08032009 and 11302016) (JCRB) 21159540 CVCL_2P62 AU10131 transformed cell line human CVCL_2P62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159541 CVCL_3162 SEKI cancer cell line human CVCL_3162 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Leg; skin. Omics: Deep exome analysis Discontinued: JCRB; JCRB0620; probable; Discontinued: JCRB; NIHS0312; true Female Doubling time: 4-5 days (CelloPub=CLPUB00112) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159542 CVCL_2P56 AU10124 transformed cell line human CVCL_2P56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159543 CVCL_3156 RKN cancer cell line human CVCL_3156 HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03; DQB1*04:01,04:01; DRB1*03:42,03:42 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=77.67%; East Asian, South=22.19%; South Asian=0%; European, North=0%; European, South=0.14% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0033; true Female Doubling time: 65 hours (PubMed=25984343); 31.2 hours (JCRB=JCRB0176); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159544 CVCL_2P57 AU10125 transformed cell line human CVCL_2P57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159545 CVCL_3157 RMUG-L cancer cell line human CVCL_3157 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Discontinued: JCRB; IFO50319; true Female Doubling time: 53 hours (PubMed=2083224) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00421 Problematic cell line: Contaminated Shown to be a SNG-II derivative. Originally thought to originate from a 62 year old female patient with an ovarian mucinous cystadenocarcinoma. 21159546 CVCL_2P54 AU10120 transformed cell line human CVCL_2P54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159547 CVCL_3154 RERF-LC-OK cancer cell line human CVCL_3154 HLA typing: A*03:02,24:02; B*08:01,35:08; C*03:03,07:01; DRB1*04:22,04:22 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Unspecified (PubMed=10536175; PubMed=20557307) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; JCRB0811; true. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00344 Problematic cell line: Contaminated Shown to be a Marcus derivative (PubMed=20143388). Originally thought to originate from a lung adenocarcinoma. 21159548 CVCL_2P55 AU10121 transformed cell line human CVCL_2P55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159549 CVCL_3155 RK 13 spontaneously immortalized cell line CVCL_3155 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by herpes simplex virus, pseudorabies virus, vaccinia virus, rabbitpox virus, myxoma virus, simian adenoviruses, and rubella virus (ATCC); Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21159550 CVCL_2P58 AU10126 transformed cell line human CVCL_2P58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159551 CVCL_3158 RMUG-S cancer cell line human CVCL_3158 HLA typing: A*02:07,33:03; B*15:18,46:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0.94%; Native American=0.79%; East Asian, North=40.77%; East Asian, South=53.64%; South Asian=0%; European, North=0%; European, South=3.86% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala347Val (c.1040C>T); ClinVar=VCV000422725; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 43 hours (PubMed=2083224); 75 hours (PubMed=25984343); ~25 hours (lot 03162009), ~36 hours (lot 02242017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21159552 CVCL_2P59 AU10128 transformed cell line human CVCL_2P59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159553 CVCL_3159 Ron Har finite cell line human CVCL_3159 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159554 CVCL_V797 GM01091 finite cell line human CVCL_V797 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;10)(4pter->4q35::10q24->10qter;10pter->10q24::4q35->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159555 CVCL_UV97 NT01066 transformed cell line human CVCL_UV97 HLA typing: A*03:ANGK,68:PNP; B*50:01,57:25; C*06:AJB,06:REV; DRB1*07:01,11:03 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159556 CVCL_V798 GM01138 finite cell line human CVCL_V798 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159557 CVCL_UV98 NT01068 transformed cell line human CVCL_UV98 HLA typing: A*02:ANDA,25:01; B*40:AZAY,57:24; C*03:GFW,06:AJB; DRB1*07:APA,3:APWN (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159558 CVCL_V795 GM01029 transformed cell line human CVCL_V795 HLA typing: A*02,28; B*12,w35 (Coriell=GM01029) CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159559 CVCL_UV95 NT01062 transformed cell line human CVCL_UV95 HLA typing: A*02:05,33:24; B*50:01,58:01; C*03:BE,06:AJB; DRB1*07:APA,13:02 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159560 CVCL_V796 GM01064 finite cell line human CVCL_V796 CL:0000010 Population: Caucasian; Karyotypic information: 46;XY;t(2;4)(2qter->2p25::4q21->4qter;4pter->4q21::2p25->2pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01064; probable Male 21159561 CVCL_UV96 NT01063 transformed cell line human CVCL_UV96 HLA typing: A*01:ECAD,68:48; B*08:APTN,14:02; C*07:ANNG,08:02; DRB1*03:WZD,11:APNV (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159562 CVCL_V799 GM01202 transformed cell line human CVCL_V799 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21159563 CVCL_UV99 NT01069 transformed cell line human CVCL_UV99 HLA typing: A*11:ANRC,29:BKZA; B*15:01:11,58:VE; C*03:GEC,07:ANSJ; DRB1*03:01,04:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159564 CVCL_2P70 AU10139 transformed cell line human CVCL_2P70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159565 CVCL_3170 SNG-II cancer cell line human CVCL_3170 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Discontinued: JCRB; JCRB0175; true Female Doubling time: 62 hours, at 9th passage (PubMed=2478021); 30-41 hours (lot 09102015) (JCRB) Part of: MD Anderson Cell Lines Project 21159566 CVCL_2P71 AU10140 transformed cell line human CVCL_2P71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159567 CVCL_3171 STC 1 cancer cell line human CVCL_3171 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Omics: SNP array analysis Male Doubling time: 28 hours (DOI=10.2482/haigan.32.223); ~50 hours (lot 04212010), ~18 hours (lot 05202019) (JCRB) 21159568 CVCL_2P74 AU10143 transformed cell line human CVCL_2P74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159569 CVCL_3174 T.T cancer cell line human CVCL_3174 Genome ancestry: African=0.13%; Native American=0%; East Asian, North=82.54%; East Asian, South=14.89%; South Asian=0%; European, North=0%; European, South=2.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Unspecified (PubMed=9290701) Population: Japanese; Derived from metastatic site: Bone; jaw; mandible. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27 hours, at 50th passage (10.5794/jjoms.36.307); 40 hours (PubMed=25984343); ~1.2 days (lot 09262006), 28-38 hours (lot 10132015) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159570 CVCL_2P75 AU10144 transformed cell line human CVCL_2P75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159571 CVCL_3175 T.Tn cancer cell line human CVCL_3175 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Unspecified (PubMed=9290701) Population: Japanese; Derived from metastatic site: Bone; jaw; mandible. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Established from the original tumor through transplantation in nude mice Doubling time: 27 hours, at 52th passage (10.5794/jjoms.36.307); 32-35 hours (lot 01212003), ~28 hours (lot 01262015) (JCRB) 21159572 CVCL_2P72 AU10141 transformed cell line human CVCL_2P72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159573 CVCL_3172 SUIT-2 cancer cell line human CVCL_3172 HLA typing: A*02:06,24:02; B*07:02,59:01; C*01:02,07:02; DQA1*02:01,02:01; DQB1*06:13,06:13; DRB1*11:04,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.31%; East Asian, North=81.51%; East Asian, South=17.16%; South Asian=0.02%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853; PubMed=21607521); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853; PubMed=21607521) Population: Japanese; Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~38.2 hours (PubMed=3102439); 29.1 hours (PubMed=1391733); 15.64 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159574 CVCL_2P73 AU10142 transformed cell line human CVCL_2P73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159575 CVCL_3173 SVts8 transformed cell line human CVCL_3173 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: SNP array analysis Male 21159576 CVCL_2P67 AU10136 transformed cell line human CVCL_2P67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159577 CVCL_3167 SKN cancer cell line human CVCL_3167 Genome ancestry: African=0.3%; Native American=0%; East Asian, North=0%; East Asian, South=87.84%; South Asian=7.96%; European, North=0%; European, South=3.89% (PubMed=30894373) CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0031; true. Female Doubling time: 36 hours, at 29th passage (PubMed=556976); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159578 CVCL_2P68 AU10137 transformed cell line human CVCL_2P68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159579 CVCL_3168 SKN-3 cancer cell line human CVCL_3168 Genome ancestry: African=0%; Native American=0.03%; East Asian, North=76.9%; East Asian, South=21.66%; South Asian=0.86%; European, North=0.55%; European, South=0% (PubMed=30894373). CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Characteristics: Established from a xenograft established in nude mice Doubling time: ~40 hours (lot 09012008) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159580 CVCL_2P65 AU10134 transformed cell line human CVCL_2P65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159581 CVCL_3165 Si-1 transformed cell line CVCL_3165 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21159582 CVCL_2P66 AU10135 transformed cell line human CVCL_2P66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159583 CVCL_3166 Si-2 transformed cell line CVCL_3166 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21159584 CVCL_2P69 AU10138 transformed cell line human CVCL_2P69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159585 CVCL_3169 VL51 cancer cell line human CVCL_3169 Genome ancestry: African=0.61%; Native American=0.13%; East Asian, North=76.13%; East Asian, South=22.43%; South Asian=0.59%; European, North=0%; European, South=0.1% (PubMed=30894373) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0247; true Female Doubling time: 70-80 hours (PubMed=8551798); ~28 hours (lot 11252016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159586 CVCL_V786 GM00943 finite cell line human CVCL_V786 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159587 CVCL_UV86 NT01042 transformed cell line human CVCL_UV86 HLA typing: A*02:DFKP,31:CGAJ; B*07:CZZS,15:DFRA; C*03:04,07:72; DRB1*04:01:01,15:01:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159588 CVCL_V787 GM00959 finite cell line human CVCL_V787 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159589 CVCL_UV87 NT01044 transformed cell line human CVCL_UV87 HLA typing: A*02:22:02,02:DFKP; B*35:AEYZ,48:01; C*04:ZFD,08:CF; DRB1*04:AAHZ,04:ZX (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159590 CVCL_V784 GM00870 finite cell line human CVCL_V784 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21159591 CVCL_UV84 NT01040 transformed cell line human CVCL_UV84 HLA typing: A*29:02:01,33:BEKE; B*45:AH,53:01:01; C*04:40,06:02; DRB1*08:06,11:02:01 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159592 CVCL_V785 GM00935 finite cell line human CVCL_V785 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21159593 CVCL_UV85 NT01041 transformed cell line human CVCL_UV85 HLA typing: A*02:DFKP; B*08:XKT,40:AVGG; C*02:26:01,07:CVAG; DRB1*01:01:01,03:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159594 CVCL_V788 GM00982 finite cell line human CVCL_V788 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21159595 CVCL_UV88 NT01050 transformed cell line human CVCL_UV88 HLA typing: A*01:WUS,29:BKZA; B*08:AKNJ,44:AXJM; C*07:CVAG,14:10; DRB1*03:VHY,07:APA (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159596 CVCL_V789 GM00988 finite cell line human CVCL_V789 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM00988; probable Male 21159597 CVCL_UV89 NT01055 transformed cell line human CVCL_UV89 HLA typing: A*02:178,32:01; B*18:AERZ,38:AF; C*07:ANNG,12:NP; DRB1*11:ARKC,13:ARCR (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159598 CVCL_2P41 AU10107 transformed cell line human CVCL_2P41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159599 CVCL_3141 Pso-7 undefined cell line type human CVCL_3141 CL:0000010 Discontinued: JCRB; JCRB0647; true. 21159600 CVCL_2P42 AU10108 transformed cell line human CVCL_2P42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159601 CVCL_3142 PSV811 finite cell line human CVCL_3142 CL:0000010 Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: RCB; RCB0223; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00343 Problematic cell line: Contaminated Shown to be a WI-38 derivative (PubMed=20143388). Originally thought to originate from the skin fibroblasts of a 29 year old female patient with Werner syndrome. 21159602 CVCL_2P40 AU10106 transformed cell line human CVCL_2P40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159603 CVCL_3140 Pso-6 undefined cell line type human CVCL_3140 CL:0000010 Discontinued: JCRB; JCRB0646; true. 21159604 CVCL_2P34 AU10100 transformed cell line human CVCL_2P34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159605 CVCL_3134 PL532 somatic stem cell human CVCL_3134 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0516; true Male 21159606 CVCL_2P35 AU10101 transformed cell line human CVCL_2P35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159607 CVCL_3135 Pso-1 undefined cell line type human CVCL_3135 CL:0000010 Discontinued: JCRB; JCRB0641; true. 21159608 CVCL_2P32 AU10098 transformed cell line human CVCL_2P32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159609 CVCL_3132 PL516 somatic stem cell human CVCL_3132 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0569; true Female 21159610 CVCL_2P33 AU10099 transformed cell line human CVCL_2P33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159611 CVCL_3133 PL518 somatic stem cell human CVCL_3133 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0571; true Female 21159612 CVCL_2P38 AU10104 transformed cell line human CVCL_2P38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159613 CVCL_3138 Pso-4 undefined cell line type human CVCL_3138 CL:0000010 Discontinued: JCRB; JCRB0644; true. 21159614 CVCL_2P39 AU10105 transformed cell line human CVCL_2P39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159615 CVCL_3139 Pso-5 undefined cell line type human CVCL_3139 CL:0000010 Discontinued: JCRB; JCRB0645; true. 21159616 CVCL_2P36 AU10102 transformed cell line human CVCL_2P36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159617 CVCL_3136 Pso-2 undefined cell line type human CVCL_3136 CL:0000010 Discontinued: JCRB; JCRB0642; true. 21159618 CVCL_2P37 AU10103 transformed cell line human CVCL_2P37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159619 CVCL_3137 Pso-3 undefined cell line type human CVCL_3137 CL:0000010 Discontinued: JCRB; JCRB0643; true. 21159620 CVCL_V790 GM01022 transformed cell line human CVCL_V790 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159621 CVCL_UV90 NT01056 transformed cell line human CVCL_UV90 HLA typing: A*24:07,33:DWH; B*15:35,58:01; C*03:60,07:WCP; DRB1*03:WHX,15:AAXP (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159622 CVCL_V793 GM01025 transformed cell line human CVCL_V793 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (PubMed=8399358); Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (PubMed=8399358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159623 CVCL_UV93 NT01060 transformed cell line human CVCL_UV93 HLA typing: A*02:ANFV,30:YE; B*08:AVDM,18:ARVX; C*05:AC,07:73; DRB1*03:WHX,15:VYF (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159624 CVCL_V794 GM01026 transformed cell line human CVCL_V794 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (PubMed=8399358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159625 CVCL_UV94 NT01061 transformed cell line human CVCL_UV94 HLA typing: A*02:DFKP,24:07; B*15:35,40:AZAY; C*03:CD,08:26N; DRB1*11:01:01,15:02:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159626 CVCL_V791 GM01023 transformed cell line human CVCL_V791 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (PubMed=8399358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159627 CVCL_UV91 NT01058 transformed cell line human CVCL_UV91 HLA typing: A*23:ANJU,66:AD; B*07:AWCA,58:02; C*06:BK,15:22; DRB1*13:AFWJ,13:APRJ (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159628 CVCL_V792 GM01024 transformed cell line human CVCL_V792 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (PubMed=8399358); Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (PubMed=8399358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159629 CVCL_UV92 NT01059 transformed cell line human CVCL_UV92 HLA typing: A*02:CNEJ,68:AJCN; B*27:JNZ; C*01:28,02:02:02; DRB1*01:03,11:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159630 CVCL_V775 GM00519 finite cell line human CVCL_V775 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Female 21159631 CVCL_UV75 NT01030 transformed cell line human CVCL_UV75 HLA typing: A*02:DFKP,29:02:01; B*14:02:01,15:17; C*07:CVAG,08:23; DRB1*13:02:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159632 CVCL_V776 GM00520 finite cell line human CVCL_V776 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21159633 CVCL_UV76 NT01031 transformed cell line human CVCL_UV76 HLA typing: A*11:BDFZ,33:BEKE; B*13:01,44:03:02; C*04:03,07:69; DRB1*07:01:01,15:02:02 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159634 CVCL_V773 GM00479 finite cell line human CVCL_V773 CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,der(14;15)(14qter->q10::q10->15qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159635 CVCL_UV73 NT01028 transformed cell line human CVCL_UV73 HLA typing: A*02:DFKP,24:CWFP; B*15:160,15:DFRA; C*03:BPSK,04:CVAF; DRB1*12:CVT,13:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159636 CVCL_V774 GM00501 finite cell line human CVCL_V774 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159637 CVCL_UV74 NT01029 transformed cell line human CVCL_UV74 HLA typing: A*02:DFKP,31:CGAJ; B*27:50,40:AZAY; C*02:02:02,03:04; DRB1*04:04,07:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159638 CVCL_V779 GM00624 finite cell line human CVCL_V779 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;15)(4pter->4q11::15p11->15pter;15qter->15p11::4q11->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159639 CVCL_UV79 NT01034 transformed cell line human CVCL_UV79 HLA typing: A*02:DFKP,03:CVAB; B*18:RRG,35:BEZX; C*04:CVAF,07:70; DRB1*11:04:01,13:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159640 CVCL_V777 GM00589 finite cell line human CVCL_V777 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;14)(5qter->5p14::14q21->14qter;14pter->14q21::5p14->5pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159641 CVCL_UV77 NT01032 transformed cell line human CVCL_UV77 HLA typing: A*01:CNJK,02:DFKP; B*40:AZAY,44:WRJ; C*01:27,03:04; DRB1*08:01,09:01:02 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159642 CVCL_V778 GM00610 finite cell line human CVCL_V778 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(6;18)(6pter->6q21::18p11->18pter;18qter->18p11::6q21->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159643 CVCL_UV78 NT01033 transformed cell line human CVCL_UV78 HLA typing: A*02:DFKP; B*44:WRJ,57:01:01; C*05:AC,06:23; DRB1*01:01:01,04:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159644 CVCL_2P52 AU10118 transformed cell line human CVCL_2P52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159645 CVCL_3152 RERF-GC-1B cancer cell line human CVCL_3152 HLA typing: A*02:06,31:01; B*40:02,51:01; C*03:04,14:02 (PubMed=26589293); Genome ancestry: African=0.94%; Native American=0.65%; East Asian, North=82%; East Asian, South=14.34%; South Asian=0.5%; European, North=0%; European, South=1.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Pyloric lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~2 days (lot 10292008), 49 hours (lot 07192016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159646 CVCL_2P53 AU10119 transformed cell line human CVCL_2P53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159647 CVCL_3153 RERF-LC-MA cancer cell line human CVCL_3153 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Homozygous (PubMed=10536175) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Male Doubling time: ~1.5 days (lot 01252008) (JCRB) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00386 Problematic cell line: Contaminated Shown to be a SK-MES-1 derivative (PubMed=23136038). Originally thought to originate from a small cell lung carcinoma. 21159648 CVCL_2P50 AU10116 transformed cell line human CVCL_2P50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159649 CVCL_3150 RBL182T transformed cell line human CVCL_3150 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159650 CVCL_2P51 AU10117 transformed cell line human CVCL_2P51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159651 CVCL_3151 RBL221T transformed cell line human CVCL_3151 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159652 CVCL_2P45 AU10111 transformed cell line human CVCL_2P45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159653 CVCL_3145 Ran Nor finite cell line human CVCL_3145 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1135; true Male 21159654 CVCL_2P46 AU10112 transformed cell line human CVCL_2P46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159655 CVCL_3146 RB16KY finite cell line human CVCL_3146 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159656 CVCL_2P43 AU10109 transformed cell line human CVCL_2P43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159657 CVCL_3143 QGP-1 cancer cell line human CVCL_3143 HLA typing: A*24:02,24:02; B*15:11,67:02; C*01:21,12:03; DRB1*13:26,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=82.5%; East Asian, South=17.02%; South Asian=0.48%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Gln (c.6497G>A); ClinVar=VCV000230267; Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=21607521; PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leufs*25 (c.293delC); Zygosity=Heterozygous (PubMed=25612765; PubMed=29444910; Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Pancreas; islets of Langerhans Cell type=Delta cell.. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~3.5 days (PubMed=7227711); 61 hours (PubMed=25984343); 1.6 +- 0.3 days (PubMed=29330294); 40-50 hours (lot 04152003), ~2 days (lot 02162009), ~42 hours (lot 04112012), ~74 hours (lot 05312016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21159658 CVCL_2P44 AU10110 transformed cell line human CVCL_2P44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159659 CVCL_3144 Ran De finite cell line human CVCL_3144 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159660 CVCL_2P49 AU10115 transformed cell line human CVCL_2P49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159661 CVCL_3149 RBL162T transformed cell line human CVCL_3149 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159662 CVCL_2P47 AU10113 transformed cell line human CVCL_2P47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159663 CVCL_3147 RB24KY finite cell line human CVCL_3147 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159664 CVCL_2P48 AU10114 transformed cell line human CVCL_2P48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159665 CVCL_3148 RB28KY finite cell line human CVCL_3148 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 21159666 CVCL_V782 GM00845 finite cell line human CVCL_V782 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;8)(2pter->2q37::8q13->8qter;8pter->8q13::2q37->2qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159667 CVCL_UV82 NT01038 transformed cell line human CVCL_UV82 HLA typing: A*02:DFKP,24:CWFP; B*27:EKN,35:02:01; C*01:26,04:CVAF; DRB1*08:01,11:04:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159668 CVCL_V783 GM00846 finite cell line human CVCL_V783 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;8)(2pter->2q37::8q13->8qter;8pter->8q13::2q37->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159669 CVCL_UV83 NT01039 transformed cell line human CVCL_UV83 HLA typing: A*24:CWFP,68:CAKR; B*35:08:01,44:WRJ; C*04:CVAF,07:68; DRB1*03:01:01,11:01:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159670 CVCL_V780 GM00657 finite cell line human CVCL_V780 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159671 CVCL_UV80 NT01036 transformed cell line human CVCL_UV80 HLA typing: A*29:02:01,68:01; B*40:16,44:03; C*02:27,16:01:01; DRB1*07:01:01,13:03:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159672 CVCL_V781 GM00773 finite cell line human CVCL_V781 CL:0000010 Karyotypic information: 46,XX,t(4;7)(4qter->4p16::7q34->7qter;7pter->7q34::4p16->4pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159673 CVCL_UV81 NT01037 transformed cell line human CVCL_UV81 HLA typing: A*02:DFKP,02:DFKR; B*35:BEZX,44:WRJ; C*07:71,07:ET; DRB1*01:01:01,03:01:01 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159674 CVCL_V764 GM00292 finite cell line human CVCL_V764 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (from autologous cell line GM01025); Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (from autologous cell line GM01025) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21159675 CVCL_UV64 NT01015 transformed cell line human CVCL_UV64 HLA typing: A*03:51,23:DFKR; B*07:CZZS,35:BEZX; C*04:CVAF,07:WCP; DRB1*04:05:01,09:01:02 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159676 CVCL_V765 GM00327 finite cell line human CVCL_V765 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(2;8)(2pter->2q13::8q24->8qter;8pter->8q24::2q13->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159677 CVCL_UV65 NT01020 transformed cell line human CVCL_UV65 HLA typing: A*02:DFKP,26:38; B*07:CZZS,35:BEZX; C*04:CVAF,07:WCP; DRB1*07:01:01,16:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159678 CVCL_V762 GM00290 finite cell line human CVCL_V762 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (from autologous cell line GM01026) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21159679 CVCL_UV62 NT01013 transformed cell line human CVCL_UV62 HLA typing: A*02:CFKP,03:50; B*15:DFRA,44:WRJ; C*03:04,05:AC; DRB1*04:01:01,15:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159680 CVCL_V763 GM00291 finite cell line human CVCL_V763 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln82Ter (c.244C>T) (Q77*); ClinVar=VCV000000685; Zygosity=Heterozygous (from autologous cell line GM01024); Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (from autologous cell line GM01024) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159681 CVCL_UV63 NT01014 transformed cell line human CVCL_UV63 HLA typing: A*01:35,24:CWFP; B*35:08:01,51:CVAE; C*04:CVAF,14:02:01; DRB1*12:CVT,13:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159682 CVCL_V768 GM00380 finite cell line human CVCL_V768 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;11)(4pter->4q23::11q11->11qter;11pter->11q11::4q23->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159683 CVCL_UV68 NT01023 transformed cell line human CVCL_UV68 HLA typing: A*01:CNJK,24:CWFP; B*07:76,15:DFRA; C*03:BPSK,07:WCP; DRB1*04:01:01,15:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159684 CVCL_V769 GM00392 finite cell line human CVCL_V769 CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,der(13;22)(13qter->13q10::22q10->22qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159685 CVCL_UV69 NT01024 transformed cell line human CVCL_UV69 HLA typing: A*24:CWFP,33:BEKE; B*15:158,58:02; C*02:16,06:02; DRB1*13:01:01,13:03:01 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159686 CVCL_V766 GM00343 finite cell line human CVCL_V766 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159687 CVCL_UV66 NT01021 transformed cell line human CVCL_UV66 HLA typing: A*01:ECAD,11:42; B*15:CKN,58:VE; C*03:BPSK,07:CVAG; DRB1*03:01:01,12:02:01 (PubMed=20860585) CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159688 CVCL_V767 GM00344 finite cell line human CVCL_V767 CL:0000010 Population: Caucasian; Karyotypic information: 45,XY,der(5)(5qter->5p14::15q11->15qter),t(9;11)(9qter->9p24::11q23->11qter;11pter->11q23::9p24->9pter),-15 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159689 CVCL_UV67 NT01022 transformed cell line human CVCL_UV67 HLA typing: A*02:DFKP,23:21; B*41:02,42:01; C*17:MN; DRB1*03:02:01,13:02:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159690 CVCL_2P20 AU10086 transformed cell line human CVCL_2P20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159691 CVCL_3120 SK-RC-26B cancer cell line human CVCL_3120 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Lymph node. Male 21159692 CVCL_2P12 AU10078 transformed cell line human CVCL_2P12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159693 CVCL_3112 OVMIU cancer cell line human CVCL_3112 Genome ancestry: African=0.26%; Native American=0.2%; East Asian, North=75.07%; East Asian, South=23.44%; South Asian=1.02%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0302; true; Discontinued: JCRB; NIHS0344; true Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00341 Problematic cell line: Contaminated Shown to be a OVSAYO derivative (PubMed=20143388). Originally thought to originate from a 46 year old female patient with an ovarian adenocarcinoma. 21159694 CVCL_2P13 AU10079 transformed cell line human CVCL_2P13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159695 CVCL_3113 OVMIU-II cancer cell line human CVCL_3113 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Discontinued: JCRB; NIHS0303; true; Discontinued: JCRB; NIHS0345; true Female 21159696 CVCL_2P10 AU10076 transformed cell line human CVCL_2P10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159697 CVCL_3110 OVKATE cancer cell line human CVCL_3110 HLA typing: A*26:01,26:01; B*07:02,07:02; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=2.37%; Native American=0%; East Asian, North=79.04%; East Asian, South=17.87%; South Asian=0%; European, North=0%; European, South=0.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3942; MTOR; Simple; p.Thr1834_Thr1837delThrAlaAlaThr (c.5490_5501delGTGGTGGCGGCA); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (Cosmic-CLP; DepMap) Anecdotal: Dogs were trained to recognize the odor of this cell line so as to later detect ovarian cancer from blood samples (DOI=10.1016/j.jveb.2019.04.010) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0297; true; Discontinued: JCRB; NIHS0339; true Female Doubling time: 96 hours (PubMed=9328139; PubMed=11121861); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159698 CVCL_2P11 AU10077 transformed cell line human CVCL_2P11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159699 CVCL_3111 OVMANA cancer cell line human CVCL_3111 HLA typing: A*24:02,24:02; B*07:02,54:01; C*01:02,07:02; DQA1*03:02,03:02; DQB1*04:01,04:01; DRB1*15:01,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=79.88%; East Asian, South=19.76%; South Asian=0%; European, North=0.36%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Val (c.1634A>T); ClinVar=VCV000375897; Zygosity=Unspecified (PubMed=22705003) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: GPI-anchored proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0298; true; Discontinued: JCRB; NIHS0340; true Female Doubling time: 67 hours (PubMed=9328139; PubMed=11121861); 70 hours (PubMed=25984343); 50-60 hours (lot 02042008), ~55-60 hours (lot 09042012), ~38 hours (lot 05022017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21159700 CVCL_2P16 AU10082 transformed cell line human CVCL_2P16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159701 CVCL_3116 OVISE cancer cell line human CVCL_3116 HLA typing: A*26:01,31:01; B*40:02,51:01; C*03:04,14:02; DRB1*11:30,11:30 (PubMed=26589293); Genome ancestry: African=0.05%; Native American=0%; East Asian, North=80.54%; East Asian, South=17.28%; South Asian=0%; European, North=0%; European, South=2.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from metastatic site: Pelvis; innominate bone. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: GPI-anchored proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0296; true; Discontinued: JCRB; NIHS0338; true Female Doubling time: 60 hours (PubMed=7535723; PubMed=9328139; PubMed=11121861); 48 hours (PubMed=25984343); ~1.5 days (lots 04092007 and 06132011); ~49 hours (lot 05302016) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21159702 CVCL_2P17 AU10083 transformed cell line human CVCL_2P17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159703 CVCL_3117 OVTOKO cancer cell line human CVCL_3117 HLA typing: A*26:01,33:03; B*35:01,44:03; C*03:03,14:03; DQB1*06:04,06:04; DRB1*13:10,14:18 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=82.47%; East Asian, South=16.63%; South Asian=0%; European, North=0%; European, South=0.89% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Spleen. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0301; true; Discontinued: JCRB; NIHS0343; true Female Doubling time: 70 hours (PubMed=7535723; PubMed=9328139; PubMed=11121861); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21159704 CVCL_2P14 AU10080 transformed cell line human CVCL_2P14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159705 CVCL_3114 OVSAHO cancer cell line human CVCL_3114 HLA typing: A*26:01,26:01; B*39:01,39:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=83.52%; East Asian, South=14.27%; South Asian=0.06%; European, North=0%; European, South=2.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from metastatic site: Abdomen. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Genome sequenced; Omics: GPI-anchored proteins analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0299; true; Discontinued: JCRB; NIHS0341; true Female Doubling time: 56 hours (PubMed=9328139; PubMed=11121861); ~3 days (lot 09282010), ~43 hours (lots 04062015 and 12012017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21159706 CVCL_2P15 AU10081 transformed cell line human CVCL_2P15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159707 CVCL_3115 OVSAYO cancer cell line human CVCL_3115 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Met (c.746G>T); ClinVar=VCV000376653; Zygosity=Heterozygous (PubMed=24023729) Population: Japanese; Derived from sampling site: Ovary. Omics: GPI-anchored proteins analysis by proteomics; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0300; true; Discontinued: JCRB; NIHS0342; true Female Doubling time: 88 hours (PubMed=9328139; PubMed=11121861) Problematic cell line: Misclassified Originally thought to be an ovarian clear cell adenocarcinoma but shown to be a high grade ovarian serous adenocarcinoma (PubMed=24023729). 21159708 CVCL_2P18 AU10084 transformed cell line human CVCL_2P18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159709 CVCL_3118 OZ [Human cholangiocarcinoma] cancer cell line human CVCL_3118 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0282; true Male Doubling time: ~48 hours (CelloPub=CLPUB00469; PubMed=2889643) 21159710 CVCL_2P19 AU10085 transformed cell line human CVCL_2P19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159711 CVCL_3119 P32/ISH cancer cell line human CVCL_3119 Genome ancestry: African=0%; Native American=0%; East Asian, North=72.36%; East Asian, South=27.64%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~48 hours, at 30th passage (PubMed=6667834); ~1.3 days (lot 02122004) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159712 CVCL_V771 GM00439 finite cell line human CVCL_V771 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21159713 CVCL_UV71 NT01026 transformed cell line human CVCL_UV71 HLA typing: A*01:CNJK,02:DFKP; B*35:BEZX,44:69; C*04:CVAF,16:01:01; DRB1*01:01:01,07:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159714 CVCL_V772 GM00442 finite cell line human CVCL_V772 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21159715 CVCL_UV72 NT01027 transformed cell line human CVCL_UV72 HLA typing: A*02:177,11:BDFZ; B*18:RRG,40:90; C*05:AC,15:BJ; DRB1*03:01:01,16:02:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159716 CVCL_V770 GM00438 finite cell line human CVCL_V770 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21159717 CVCL_UV70 NT01025 transformed cell line human CVCL_UV70 HLA typing: A*02:DFKP,31:CGAJ; B*27:02,38:19; C*02:02:02,12:03; DRB1*01:01:01,13:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159718 CVCL_V753 GM00157 finite cell line human CVCL_V753 CL:0000010 Population: Caucasian; Karyotypic information: 49,XXXXY,t(4;11)(q35;q23).arr(X)x4,(Y)x1 (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21159719 CVCL_UV53 NT00781 transformed cell line human CVCL_UV53 HLA typing: A*02:CNDW; B*15:142,15:DKGD; C*03:AKZD,03:PWX; DRB1*13:APRJ,13:ARCR (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159720 CVCL_V754 GM00166 finite cell line human CVCL_V754 CL:0000010 Population: Caucasian; Karyotypic information: 45,XY,-9 [28]; 46,XY,r(9) [22] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159721 CVCL_UV54 NT00793 transformed cell line human CVCL_UV54 HLA typing: A*02:147,68:CSJM; B*15:ANPM,15:APFM; C*03:FJC,07:ET; DRB1*13:ARCR,15:VYF (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159722 CVCL_UV51 BY00605 transformed cell line human CVCL_UV51 HLA typing: A*01:TUS,24:CNFN; B*57:01:01,57:24; C*06:AJB,06:REV; DRB1*01:02,07:APA (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159723 CVCL_V751 GM00121 finite cell line human CVCL_V751 CL:0000010 Sequence variation: Mutation; HGNC; 4696; GUSB; Simple; p.Arg357Ter (c.1069C>T); ClinVar=VCV000000908; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4696; GUSB; Simple; p.Trp627Cys (c.1881G>T); ClinVar=VCV000000907; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21159724 CVCL_UV52 BY00620 transformed cell line human CVCL_UV52 HLA typing: A*34:BD,68:PNP; B*07:DHRB,78:01; C*15:22,16:01; DRB1*11:AET,13:ASGP (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159725 CVCL_V752 GM00126 finite cell line human CVCL_V752 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;15)(1qter->1p36.1::15q11.2->15qter;15pter->15q11.2::1p36.1->1pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159726 CVCL_V757 GM00216 finite cell line human CVCL_V757 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(10;17)(10pter->10q24::17p13->17pter;17qter->17p13::10q24->10qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159727 CVCL_UV57 NT01002 transformed cell line human CVCL_UV57 HLA typing: A*02:CNDW; B*08:AKNJ,14:01; C*07:60,08:02; DRB1*03:WHX,15:VYF (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159728 CVCL_V758 GM00217 finite cell line human CVCL_V758 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00217; probable Male 21159729 CVCL_UV58 NT01007 transformed cell line human CVCL_UV58 HLA typing: A*01:TUS,25:01; B*18:RRG,49:01:02; C*07:ANNG,12:NP; DRB1*15:AAXP,15:DWK (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159730 CVCL_V755 GM00213 finite cell line human CVCL_V755 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(8;12)(8qter->8p23::12p11->12pter;12qter->12p11::8p23->8pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159731 CVCL_UV55 NT00989 transformed cell line human CVCL_UV55 HLA typing: A*02:ANNS,29:BCHD; B*07:AWCA,44:AXJM; C*07:02,14:10; DRB1*01:03,03:02 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159732 CVCL_V756 GM00214 finite cell line human CVCL_V756 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159733 CVCL_UV56 NT00997 transformed cell line human CVCL_UV56 HLA typing: A*03:41,11:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159734 CVCL_V759 GM00257 finite cell line human CVCL_V759 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21159735 CVCL_UV59 NT01010 transformed cell line human CVCL_UV59 HLA typing: A*26:XX,31:01:02; B*40:AZAY,51:60; C*03:04,15:02; DRB1*01:AD,11:YM (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159736 CVCL_2P30 AU10096 transformed cell line human CVCL_2P30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159737 CVCL_3130 PL512 somatic stem cell human CVCL_3130 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0565; true Male 21159738 CVCL_2P31 AU10097 transformed cell line human CVCL_2P31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159739 CVCL_3131 PL514 somatic stem cell human CVCL_3131 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0566; true Female 21159740 CVCL_2P23 AU10089 transformed cell line human CVCL_2P23 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159741 CVCL_3123 PHK16-0b transformed cell line human CVCL_3123 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0203; true Male 21159742 CVCL_2P24 AU10090 transformed cell line human CVCL_2P24 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159743 CVCL_3124 PJS1JTO finite cell line human CVCL_3124 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21159744 CVCL_2P21 AU10087 transformed cell line human CVCL_2P21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159745 CVCL_3121 PA-1/6TG-r cancer cell line human CVCL_3121 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0328; true Female 21159746 CVCL_2P22 AU10088 transformed cell line human CVCL_2P22 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159747 CVCL_3122 PALL-2 cancer cell line human CVCL_3122 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8428799; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: JCRB; NIHS0546; true Male 21159748 CVCL_2P27 AU10093 transformed cell line human CVCL_2P27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159749 CVCL_3127 PL505 somatic stem cell human CVCL_3127 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0424; true Female 21159750 CVCL_2P28 AU10094 transformed cell line human CVCL_2P28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159751 CVCL_3128 PL507 somatic stem cell human CVCL_3128 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0426; true Female 21159752 CVCL_2P25 AU10091 transformed cell line human CVCL_2P25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159753 CVCL_3125 PJS5JTO finite cell line human CVCL_3125 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159754 CVCL_2P26 AU10092 transformed cell line human CVCL_2P26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159755 CVCL_3126 PL502 somatic stem cell human CVCL_3126 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0421; true Female 21159756 CVCL_2P29 AU10095 transformed cell line human CVCL_2P29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159757 CVCL_3129 PL508 somatic stem cell human CVCL_3129 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0429; true Female 21159758 CVCL_V760 GM00271 finite cell line human CVCL_V760 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21159759 CVCL_UV60 NT01011 transformed cell line human CVCL_UV60 HLA typing: DRB1*07:16,08:01:01/01:03 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159760 CVCL_V761 GM00289 finite cell line human CVCL_V761 CL:0000010 Sequence variation: Mutation; HGNC; 4006; FUCA1; Simple; p.Gln286Arg (c.857A>G) (Q281R); ClinVar=VCV000000691; Zygosity=Heterozygous (from autologous cell line GM01023) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21159761 CVCL_UV61 NT01012 transformed cell line human CVCL_UV61 HLA typing: A*01:CNJK,34:01:01; B*08:XKT,15:159; C*03:04,07:CVAG; DRB1*04:01:01,04:05:01 (PubMed=20860585) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159762 CVCL_UV42 BY00465 transformed cell line human CVCL_UV42 HLA typing: A*30:01,68:01; B*42:11,58:02; C*06:02,17:01; DRB1*03:02,12:CVT (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159763 CVCL_V742 Ogun cancer cell line human CVCL_V742 CL:0000010 Population: African; Nigerian Female Virology: EBV-negative Caution: Indicated in PubMed=4169243 to originate from a male patient, but has a female karyotype according to PubMed=6018567. 21159764 CVCL_UV43 BY00469 transformed cell line human CVCL_UV43 HLA typing: A*01:37,02:DFKP; B*07:02,08:01; C*07:01,07:02; DRB1*03:01,13:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159765 CVCL_V743 Kudi cancer cell line human CVCL_V743 CL:0000010 Population: African; Nigerian; Derived from sampling site: Bone; jaw. Female Virology: EBV-negative 21159766 CVCL_UV40 BY00463 transformed cell line human CVCL_UV40 HLA typing: A*04:01,24:02; B*08:01:04,15:01; C*07:02,07:02; DRB1*04:01:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159767 CVCL_V740 Gor cancer cell line human CVCL_V740 CL:0000010 21159768 CVCL_UV41 BY00464 transformed cell line human CVCL_UV41 HLA typing: A*30:01,34:02; B*35:01,52:01; C*16:01; DPB1*01:01:01,122:01; DQB1*02:02,04:02; DRB1*03:02,07:01 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159769 CVCL_V741 RPMI-2402 cancer cell line CVCL_V741 CL:0000010 Unspecified Doubling time: 33 hours (PubMed=14071829). 21159770 CVCL_UV46 BY00472 transformed cell line human CVCL_UV46 HLA typing: A*02:01,29:02; B*08:BYXK,44:03:04; C*07:01,16:01; DRB1*03:01,07:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159771 CVCL_V746 GM00072 finite cell line human CVCL_V746 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21159772 CVCL_UV47 BY00475 transformed cell line human CVCL_UV47 HLA typing: A*02:03,24:CNEY; B*38:XV,46:AB; C*01:BG,07:02; DRB1*12:20,16:02:01 (PubMed=20860585) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159773 CVCL_V747 GM00097 finite cell line human CVCL_V747 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;1)(q26;q21) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21159774 CVCL_UV44 BY00470 transformed cell line human CVCL_UV44 HLA typing: A*30:02,68:01; B*18:01,53:01; C*02:02:02,04:41; DRB1*10:01,11:04 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159775 CVCL_V744 M40 cancer cell line human CVCL_V744 CL:0000010 Female 21159776 CVCL_UV45 BY00471 transformed cell line human CVCL_UV45 HLA typing: A*02:179,26:GAX; B*35:08,78:01; C*04:01,16:01; DRB1*11:04,13:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159777 CVCL_V745 GM03115 finite cell line human CVCL_V745 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03115; probable Male 21159778 CVCL_UV48 BY00519 transformed cell line human CVCL_UV48 HLA typing: A*03:50,03:ECAM (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159779 CVCL_V748 GM00098 finite cell line human CVCL_V748 CL:0000010 Karyotypic information: 46,XY,der(21)(21qter->21p12::4p11->4pter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21159780 CVCL_UV49 BY00545 transformed cell line human CVCL_UV49 HLA typing: A*02:ANNS,30:01; B*15:31,48:01; DRB1*04:79,11:02:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159781 CVCL_V749 GM00118 finite cell line human CVCL_V749 CL:0000010 Population: Caucasian; Danish; Karyotypic information: 46,XX,der(15)(15qter->15p1::Yq11->Yqter)pat (Coriell); Derived from sampling site: Uterus; myometrium Cell type=Fibroblast.. Female 21159782 CVCL_UV50 BY00573 transformed cell line human CVCL_UV50 HLA typing: A*02:03,33:DWH; B*15:02,58:28; C*03:02,08:AJ; DRB1*08:APPA,15:AK (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159783 CVCL_V750 GM00119 finite cell line human CVCL_V750 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(17;22)(17qter->17p13::22q11->22qter;22pter->22q11::17p13->17pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159784 CVCL_V731 HCC89 cancer cell line human CVCL_V731 HLA typing: A*02:01,32:01; B*08:01,18:01; C*05:01,07:01 (PubMed=26589293) CL:0000010 Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F.. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21159785 CVCL_UV31 Oua3 spontaneously immortalized cell line CVCL_UV31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159786 CVCL_V732 HCC90 cancer cell line human CVCL_V732 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Male 21159787 CVCL_UV32 Oua4 spontaneously immortalized cell line CVCL_UV32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159788 CVCL_V730 HCC653 cancer cell line human CVCL_V730 CL:0000010 Male 21159789 CVCL_UV30 Oua2 spontaneously immortalized cell line CVCL_UV30 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159790 CVCL_UV35 BY00453 transformed cell line human CVCL_UV35 HLA typing: A*02:169,24:CWFP; B*44:03,52:01; DRB1*07:01,13:12 (PubMed=20860585) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159791 CVCL_V735 HCC435 cancer cell line human CVCL_V735 CL:0000010 Male 21159792 CVCL_UV36 BY00454 transformed cell line human CVCL_UV36 HLA typing: A*11:ANXJ,11:APCT; B*27:15,40:AZAY; DRB1*09:01:05,14:CFNU (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159793 CVCL_V736 HCC446 cancer cell line human CVCL_V736 CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21159794 CVCL_V733 HCC41 cancer cell line human CVCL_V733 CL:0000010 Miscellaneous: Cell line information from personal communication of Girard L and Gazdar A.F.. Female 21159795 CVCL_UV33 Oua5 spontaneously immortalized cell line CVCL_UV33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994). Unspecified Group: Insect cell line 21159796 CVCL_UV34 BY00450 transformed cell line human CVCL_UV34 HLA typing: A*02:DFKP,02:CGAE; B*35:05,40:AVGG; C*03:57,04:CVAF; DRB1*08:02:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159797 CVCL_V734 HCC420 cancer cell line human CVCL_V734 CL:0000010 Female 21159798 CVCL_UV39 BY00462 transformed cell line human CVCL_UV39 HLA typing: A*01:WUS,29:BKZA; B*07:EH,51:AFJY; C*14:12,15:05 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159799 CVCL_V739 HCC1972 cancer cell line human CVCL_V739 CL:0000010 Derived from sampling site: Endometrium. Female 21159800 CVCL_UV37 BY00460 transformed cell line human CVCL_UV37 HLA typing: A*02:01,03:01; B*27:05,44:02; C*02:02:08,05:AC; DRB1*04:01,12:CVT (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159801 CVCL_V737 GENEA099 embryonic stem cell human CVCL_V737 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0378; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-58.. 21159802 CVCL_UV38 BY00461 transformed cell line human CVCL_UV38 HLA typing: A*02:01,03:01; B*15:01,56:01; C*01:02,03:59; DRB1*04:01,07:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159803 CVCL_V738 HCC824 cancer cell line human CVCL_V738 CL:0000010 Female 21159804 CVCL_2P01 AU10067 transformed cell line human CVCL_2P01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159805 CVCL_3101 OUMS-36T-5F telomerase immortalized cell line human CVCL_3101 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.5S; true Female 21159806 CVCL_2P02 AU10068 transformed cell line human CVCL_2P02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159807 CVCL_3102 OUMS-36T-6 telomerase immortalized cell line human CVCL_3102 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.6; true Female 21159808 CVCL_2P00 AU10066 transformed cell line human CVCL_2P00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159809 CVCL_3100 OUMS-36T-5 telomerase immortalized cell line human CVCL_3100 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.5; true Female 21159810 CVCL_2P05 AU10071 transformed cell line human CVCL_2P05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159811 CVCL_3105 OUMS-36T-7F telomerase immortalized cell line human CVCL_3105 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.7S; true Female 21159812 CVCL_2P06 AU10072 transformed cell line human CVCL_2P06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159813 CVCL_3106 OUMS-36T-8 telomerase immortalized cell line human CVCL_3106 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.8; true Female 21159814 CVCL_2P03 AU10069 transformed cell line human CVCL_2P03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159815 CVCL_3103 OUMS-36T-6F telomerase immortalized cell line human CVCL_3103 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.6S; true Female 21159816 CVCL_2P04 AU10070 transformed cell line human CVCL_2P04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159817 CVCL_3104 OUMS-36T-7 telomerase immortalized cell line human CVCL_3104 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.7; true Female 21159818 CVCL_2P09 AU10075 transformed cell line human CVCL_2P09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159819 CVCL_3109 OVB-3 hybridoma house mouse CVCL_3109 CL:0000010 Monoclonal antibody isotype: IgG2a+IgG2b; Monoclonal antibody target: Human ovarian cancer cell lines (immunized against OVCAR-3 (Cellosaurus=CVCL_0465)). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9147 21159820 CVCL_2P07 AU10073 transformed cell line human CVCL_2P07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21159821 CVCL_3107 OUMS-36T-8F telomerase immortalized cell line human CVCL_3107 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.8S; true Female 21159822 CVCL_2P08 AU10074 transformed cell line human CVCL_2P08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21159823 CVCL_3108 OUS-11 finite cell line human CVCL_3108 CL:0000010 Population: Japanese; Donor information: Established from the normal tissue of a lung cancer patient; Derived from sampling site: Lung. Omics: SNP array analysis Discontinued: JCRB; NIHS0313; true Male Doubling time: ~23 hours (lot 11102015) (JCRB) 21159824 CVCL_3099 OUMS-36T-4F telomerase immortalized cell line human CVCL_3099 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.4S; true Female 21159825 CVCL_3082 NUGC-4 cancer cell line human CVCL_3082 HLA typing: A*02:01,24:02; B*46:01,51:02; C*01:02,15:02; DRB1*11:67,12:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.72%; East Asian, North=65.95%; East Asian, South=32.05%; South Asian=0%; European, North=0%; European, South=1.27% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1370612; PubMed=15900046) Population: Japanese; Derived from metastatic site: Paragastric lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 29.9 hours (PubMed=3172586); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159826 CVCL_3083 OCUG-1 cancer cell line human CVCL_3083 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from metastatic site: Peritoneal effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47.1 hours (PubMed=21533512) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159827 CVCL_3080 NTI-4 finite cell line human CVCL_3080 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female Doubling time: ~20 hours (lot 01112008) (JCRB) 21159828 CVCL_3081 NTI-5 finite cell line human CVCL_3081 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female Senescence: Senesces at 13 PDL (JCRB=JCRB0222) 21159829 CVCL_3086 OSC-19 cancer cell line human CVCL_3086 Genome ancestry: African=0.1%; Native American=0.32%; East Asian, North=72.98%; East Asian, South=24.24%; South Asian=0.65%; European, North=1.7%; European, South=0.01% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Ter (c.490A>T); ClinVar=VCV000935480; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; FDSC0050; true Male Doubling time: 33.4 hours (at 12th passage), 25.1 hours (at 28th passage), 16.7 hours (at 55th passage) (DOI=10.15114/tr.23.43); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21159830 CVCL_3087 OSC-20 cancer cell line human CVCL_3087 HLA typing: A*02,11; B*46,55; C*w01,w09 (PubMed=9119748); Genome ancestry: African=3.14%; Native American=0.23%; East Asian, North=75.72%; East Asian, South=16.66%; South Asian=0%; European, North=0%; European, South=4.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro81Leu (c.242C>T); ClinVar=VCV000833629; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1048Arg (c.3143A>G); ClinVar=VCV000450316; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Cervical lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0051; true Female Doubling time: 27.4 hours, at 35th passage (DOI=10.15114/tr.25.93); 65 hours (lot 02032003), ~49 hours (lot 11152011), ~35 hours (lot 07182019) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159831 CVCL_3084 OCUM-1 cancer cell line human CVCL_3084 HLA typing: A*24:02,31:01; B*07:02,52:01; C*07:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.6%; East Asian, North=77.58%; East Asian, South=21.82%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Gln56Pro (c.167A>C); ClinVar=VCV000375978; Zygosity=Hemizygous (PubMed=22327936) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 33.2 hours (PubMed=1961183); ~38 hours (lot 12222004), 49 hours (lot 09162009), ~64 hours (lot 11282012), ~26 hours (lot 08172016), ~34 hours (lot 06252018) (JCRB); Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159832 CVCL_3085 OKa-C-1 cancer cell line human CVCL_3085 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0544; true Male Doubling time: 95 hours (PubMed=8641981) 21159833 CVCL_3079 NOZ cancer cell line human CVCL_3079 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0283; true Female Doubling time: 40-48 hours (CelloPub=CLPUB00469); 30 hours (PubMed=32293552); 48 hours (PubMed=3154020); 30 hours (lot 09162008) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159834 CVCL_3077 NOMO-1/ADM cancer cell line human CVCL_3077 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.730-10T>C; dbSNP=rs201058616; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone marrow. Omics: SNP array analysis Female Doubling time: ~1.5 days (lot 10032003) (JCRB) 21159835 CVCL_3078 NOMO-1s cancer cell line human CVCL_3078 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.730-10T>C; dbSNP=rs201058616; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Alafs*5 (c.723delC) (p.S241fs); ClinVar=VCV001074338; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Female Group: Serum/protein free medium cell line 21159836 CVCL_3090 OUMS-27 cancer cell line human CVCL_3090 Genome ancestry: African=0.16%; Native American=0%; East Asian, North=79.69%; East Asian, South=17.75%; South Asian=0%; European, North=0%; European, South=2.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 5383; IDH2; None_reported; -; Zygosity=- (PubMed=22057234) Population: Japanese; Derived from metastatic site: Bone; left proximal humerus. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 41 hours (PubMed=9714054) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159837 CVCL_3093 OUMS-36T-1F telomerase immortalized cell line human CVCL_3093 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.1S; true Female 21159838 CVCL_3094 OUMS-36T-2 telomerase immortalized cell line human CVCL_3094 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.2; true Female 21159839 CVCL_3091 OUMS-36 finite cell line human CVCL_3091 CL:0000010 Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0291.0; true Female 21159840 CVCL_3092 OUMS-36T-1 telomerase immortalized cell line human CVCL_3092 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.1; true Female 21159841 CVCL_3097 OUMS-36T-3F telomerase immortalized cell line human CVCL_3097 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.3S; true Female 21159842 CVCL_3098 OUMS-36T-4 telomerase immortalized cell line human CVCL_3098 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.4; true Female 21159843 CVCL_3095 OUMS-36T-2F telomerase immortalized cell line human CVCL_3095 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.2S; true Female 21159844 CVCL_3096 OUMS-36T-3 telomerase immortalized cell line human CVCL_3096 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0291.3; true Female 21159845 CVCL_3088 OUMS-23 cancer cell line human CVCL_3088 HLA typing: A*02:06,24:02; B*52:01,67:02; C*03:03,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=82.03%; East Asian, South=16.25%; South Asian=0.32%; European, North=0%; European, South=1.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg657fs (c.1969_1970delAG); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556fs*3 (c.4660_4661insA) (E1554fs); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Pericardial effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0292; true Male Doubling time: 50.2 hours (in 1% FBS), 42.1 hours (in 10% FBS) (PubMed=8576285); ~40 hours (lot 01262009), ~41 hours (lot 10232015) (JCRB); Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159846 CVCL_3089 OUMS-24/P6X transformed cell line human CVCL_3089 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Cell type=Fibroblast. Discontinued: JCRB; NIHS0327; true Female 21159847 CVCL_3060 NCR-G2 cancer cell line human CVCL_3060 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; NIHS0443; true Male 21159848 CVCL_3061 NCR-G3 cancer cell line human CVCL_3061 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; NIHS0444; true Male 21159849 CVCL_3064 NCTC 4093 spontaneously immortalized cell line house mouse CVCL_3064 CL:0000010 Breed/subspecies: C57BL/KaLw. Unspecified 21159850 CVCL_3065 NCTC 4206 transformed cell line CVCL_3065 CL:0000010 Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female 21159851 CVCL_3062 NCR-G4 cancer cell line human CVCL_3062 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; NIHS0445; true Male 21159852 CVCL_3063 NCTC 3749 cancer cell line house mouse CVCL_3063 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Discontinued: ATCC; CRL-6441; true; Discontinued: ECACC; 90111912; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21159853 CVCL_3057 NCE16 transformed cell line human CVCL_3057 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0205; true Female 21159854 CVCL_3058 NCI-H69VCR/R cancer cell line human CVCL_3058 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Pleural effusion. Male 21159855 CVCL_3055 NCC-StC-K140 cancer cell line human CVCL_3055 Genome ancestry: African=1.19%; Native American=0%; East Asian, North=80.7%; East Asian, South=13.81%; South Asian=0%; European, North=0%; European, South=4.29% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~44 hours (lot 03222018) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21159856 CVCL_3056 NCE16-IIA transformed cell line human CVCL_3056 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Discontinued: JCRB; NIHS0265; true Female 21159857 CVCL_3059 NCR-G1 cancer cell line human CVCL_3059 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; NIHS0442; true Male 21159858 CVCL_UU98 CHL 7-33 spontaneously immortalized cell line CVCL_UU98 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159859 CVCL_V698 HCC711 cancer cell line human CVCL_V698 CL:0000010 Male 21159860 CVCL_UU99 CHL 7-38 spontaneously immortalized cell line CVCL_UU99 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159861 CVCL_V699 HCC815 cancer cell line human CVCL_V699 CL:0000010 Male 21159862 CVCL_UU96 CHL 4-10 spontaneously immortalized cell line CVCL_UU96 CL:0000010 Transfected with: HGNC; 2637; CYP3A4; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159863 CVCL_V696 HCC973 cancer cell line human CVCL_V696 CL:0000010 Male 21159864 CVCL_UU97 CHL 7-20 spontaneously immortalized cell line CVCL_UU97 CL:0000010 Transfected with: HGNC; 2640; CYP3A7; Transfected with: UniProtKB; P37039; Cavia porcellus Por; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung. Female 21159865 CVCL_V697 HCC954 cancer cell line human CVCL_V697 CL:0000010 Female 21159866 CVCL_3072 NIL-SF2 spontaneously immortalized cell line CVCL_3072 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Male Characteristics: Adapted to growth in serum-free culture conditions Group: Serum/protein free medium cell line 21159867 CVCL_3070 NEC14 cancer cell line human CVCL_3070 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; FDSC0006; true Male 21159868 CVCL_3075 Onda 10 cancer cell line human CVCL_3075 Genome ancestry: African=0.63%; Native American=0.27%; East Asian, North=79.08%; East Asian, South=19.61%; South Asian=0%; European, North=0.4%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8878451) Population: Japanese; Derived from sampling site: Brain; left parietal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159869 CVCL_3076 Onda 11 cancer cell line human CVCL_3076 Genome ancestry: African=1.72%; Native American=1.06%; East Asian, North=76.42%; East Asian, South=17.02%; South Asian=0%; European, North=1.56%; European, South=2.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln17del (c.49_51delCAA); Zygosity=Unspecified (PubMed=10551321); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=8878451) Population: Japanese; Derived from sampling site: Brain; right parietal lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21159870 CVCL_3073 NJG cancer cell line human CVCL_3073 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 80 hours (PubMed=3611867); 34 hours (lot 06132007) (JCRB) 21159871 CVCL_3074 NM-1 finite cell line CVCL_3074 CL:0000010 Derived from sampling site: Fetal artery; endothelium. Discontinued: JCRB; NIHS0232; true Unspecified Senescence: Estimated life-span is 110 PDL (JCRB=JCRB0155); Doubling time: 30 hours (lot 02142008) (JCRB) 21159872 CVCL_3068 NCTC 2555 spontaneously immortalized cell line house mouse CVCL_3068 CL:0000010 Derived from sampling site: Adipose tissue; hypodermis; Breed/subspecies: C3H/HeN. Discontinued: ECACC; 90102521; probable Male 21159873 CVCL_3069 NCTC 3526 spontaneously immortalized cell line CVCL_3069 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line 21159874 CVCL_3066 NCTC 1469 spontaneously immortalized cell line house mouse CVCL_3066 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3H/An. Male 21159875 CVCL_3067 NCTC 2472 cancer cell line house mouse CVCL_3067 CL:0000010 Derived from sampling site: Adipose tissue; hypodermis; Breed/subspecies: C3H/HeN. Discontinued: ECACC; 90111915; probable Male 21159876 CVCL_DC70 MCF-7.5C cancer cell line human CVCL_DC70 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Undergoes rapid and complete apoptosis in the presence of physiologic concentrations of 17-alpha-estradiol 21159877 CVCL_DC73 C418-59 transformed cell line human CVCL_DC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a gastric cancer; Derived from sampling site: Lymph node Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P05783; Human KRT18 Doubling time: 20 hours (PubMed=2470715) Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 85071031 21159878 CVCL_DC74 EC1 spontaneously immortalized cell line CVCL_DC74 CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Brain microvascular endothelial cell.. Female 21159879 CVCL_DC71 AS-1 transformed cell line human CVCL_DC71 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8118 21159880 CVCL_DC72 C1218-39 transformed cell line human CVCL_DC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a gastric cancer; Derived from sampling site: Lymph node Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P05783; Human KRT18 Doubling time: 18 hours (PubMed=2470715) 21159881 CVCL_DC66 Eph4 A6 transformed cell line house mouse CVCL_DC66 CL:0000010 Transfected with: RGD; 2561; Erbb2 (with p.Val661Glu) Transformant: Activated Erbb2/neu; Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21159882 CVCL_DC67 Dicer1-/- transformed cell line house mouse CVCL_DC67 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2177178; Dicer Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Dicer1tm1Bdh/J. Female 21159883 CVCL_DC64 CLL 36A/76 spontaneously immortalized cell line CVCL_DC64 CL:0000010 Derived from sampling site: Fetal pancreas; islets of Langerhans Cell type=Beta cell.. Unspecified Characteristics: Secretes insulin Doubling time: ~24 hours (Patent=US4477567) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-1407 21159884 CVCL_DC65 GL-V3 spontaneously immortalized cell line CVCL_DC65 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-1433; true Male Doubling time: ~90 hours (PubMed=4318075) Group: Non-human primate cell line 21159885 CVCL_DC68 Dicer1f/f transformed cell line house mouse CVCL_DC68 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: Dicer1tm1Bdh/J. Female 21159886 CVCL_DC69 T56/14 hybridoma house mouse CVCL_DC69 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8035 21159887 CVCL_DC80 T29/33 hybridoma house mouse CVCL_DC80 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8036 21159888 CVCL_DC81 CTLL-RP factor-dependent cell line house mouse CVCL_DC81 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8201 21159889 CVCL_DC84 CTLL-D5 factor-dependent cell line house mouse CVCL_DC84 CL:0000010 Derived from sampling site: Peritoneal cavity Cell type=T-cell.; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21159890 CVCL_DC85 CTLL-A1 factor-dependent cell line house mouse CVCL_DC85 CL:0000010 Derived from sampling site: Peritoneal cavity Cell type=T-cell.; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21159891 CVCL_DC82 CTLL-AP factor-dependent cell line house mouse CVCL_DC82 CL:0000010 Derived from sampling site: Peritoneal cavity Cell type=T-cell.; Breed/subspecies: C57BL/6. Characteristics: IL2 dependent 21159892 CVCL_DC83 CTLL-FP factor-dependent cell line house mouse CVCL_DC83 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: C57BL/6 x BALB/c. Characteristics: IL2 dependent 21159893 CVCL_DC77 49-15 hybridoma house mouse CVCL_DC77 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8011 21159894 CVCL_DC78 53-569 hybridoma house mouse CVCL_DC78 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: ChEBI; CHEBI:53018; 2,4-dinitrophenyl group (DNP). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8010 21159895 CVCL_DC75 I3/2 hybridoma CVCL_DC75 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P06800; Mouse Ptprc/Cd45. 21159896 CVCL_DC76 IgE-14-205 hybridoma house mouse CVCL_DC76 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: UniProtKB; P01012; Chicken ovalbumin (SERPINB14). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8009 21159897 CVCL_DC79 T101 [Mouse hybridoma against human CD5] hybridoma house mouse CVCL_DC79 CL:0000010 Anecdotal: The T101 mAb was one of the earliest mAbs to be tested in clinical trials against cutaneous T cell lymphoma (CTCL) and chronic lymphocytic leukemia (CLL). Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06127; Human CD5 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8023 21159898 CVCL_DC51 ND00112 transformed cell line human CVCL_DC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159899 CVCL_DC52 ND00113 transformed cell line human CVCL_DC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159900 CVCL_DC50 ND00111 transformed cell line human CVCL_DC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159901 CVCL_DC44 ND00105 transformed cell line human CVCL_DC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159902 CVCL_DC45 ND00106 transformed cell line human CVCL_DC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159903 CVCL_DC42 ND00103 transformed cell line human CVCL_DC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159904 CVCL_DC43 ND00104 transformed cell line human CVCL_DC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159905 CVCL_DC48 ND00109 transformed cell line human CVCL_DC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159906 CVCL_DC49 ND00110 transformed cell line human CVCL_DC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159907 CVCL_DC46 ND00107 transformed cell line human CVCL_DC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159908 CVCL_DC47 ND00108 transformed cell line human CVCL_DC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159909 CVCL_DC62 ND00126 transformed cell line human CVCL_DC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159910 CVCL_DC63 C3 transformed cell line house mouse CVCL_DC63 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Breed/subspecies: C57BL/6. Unspecified Virology: Probably contains a complete HPV16 genome 21159911 CVCL_DC60 ND00121 transformed cell line human CVCL_DC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159912 CVCL_DC61 ND00122 transformed cell line human CVCL_DC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159913 CVCL_DC55 ND00116 transformed cell line human CVCL_DC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159914 CVCL_DC56 ND00117 transformed cell line human CVCL_DC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159915 CVCL_DC53 ND00114 transformed cell line human CVCL_DC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159916 CVCL_DC54 ND00115 transformed cell line human CVCL_DC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159917 CVCL_DC59 ND00120 transformed cell line human CVCL_DC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159918 CVCL_DC57 ND00118 transformed cell line human CVCL_DC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159919 CVCL_DC58 ND00119 transformed cell line human CVCL_DC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159920 CVCL_DC30 HG2L6.1c1 cancer cell line human CVCL_DC30 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159921 CVCL_DC28 H4L7.5c2 cancer cell line Norway rat CVCL_DC28 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: AxC. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159922 CVCL_DC29 HG2L1.1c3 cancer cell line human CVCL_DC29 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159923 CVCL_DC22 H1L6.1c2 cancer cell line house mouse CVCL_DC22 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159924 CVCL_DC23 H1L6.1c3 cancer cell line house mouse CVCL_DC23 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists.; Biotechnology: Used in US Environmental Protection Agency (EPA) hazardous waste test method 4435 (SW-846) Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159925 CVCL_DC20 H1L1.1c2 cancer cell line house mouse CVCL_DC20 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12286 21159926 CVCL_DC21 H1L1.1c7 cancer cell line house mouse CVCL_DC21 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159927 CVCL_DC26 H4G1.1c2 cancer cell line Norway rat CVCL_DC26 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Liver; Breed/subspecies: AxC. Biotechnology: Cell line developed for CAFLUX (Chemically Activated FLUorescence eXpression) bioassay CAFLUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a EGFP gene under the control of dioxin-response elements (DREs) 21159928 CVCL_DC27 H4L1.1c4 cancer cell line Norway rat CVCL_DC27 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: AxC. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159929 CVCL_DC24 H1L7.5c1 cancer cell line house mouse CVCL_DC24 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159930 CVCL_DC25 H1L7.5c3 cancer cell line house mouse CVCL_DC25 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159931 CVCL_DC40 ND00098 transformed cell line human CVCL_DC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159932 CVCL_DC41 ND00099 transformed cell line human CVCL_DC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159933 CVCL_DC39 ND00097 transformed cell line human CVCL_DC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159934 CVCL_DC33 MLE/BV cancer cell line house mouse CVCL_DC33 From: Madhukar B.V.; Indiana University School of Medicine; Indianapolis; USA CL:0000010 Breed/subspecies: C3H/HeN. 21159935 CVCL_DC34 MLEL1.1c1 cancer cell line house mouse CVCL_DC34 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: C3H/HeN. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159936 CVCL_DC31 HG2L6.1c3 cancer cell line human CVCL_DC31 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159937 CVCL_DC32 HG2L7.5c1 cancer cell line human CVCL_DC32 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Male Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159938 CVCL_DC37 ND00095 transformed cell line human CVCL_DC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21159939 CVCL_DC38 ND00096 transformed cell line human CVCL_DC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21159940 CVCL_DC35 OMEGA-Z cancer cell line human CVCL_DC35 CL:0000010 Female 21159941 CVCL_DC36 SRD-3 transformed cell line CVCL_DC36 CL:0000010 Sequence variation: Mutation; UniProtKB; Q60429; Srebp2; Simple; p.Pro462_Ser1139del; Zygosity=Heterozygous (PubMed=7744865); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21159942 CVCL_DC08 DC3F/TG2 spontaneously immortalized cell line CVCL_DC08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9516; Thapsigargin; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21159943 CVCL_DC09 D2 [Mouse bone marrow] somatic stem cell house mouse CVCL_DC09 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12501 21159944 CVCL_DC06 DDT/TG500nM cancer cell line CVCL_DC06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9516; Thapsigargin; Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Vas deferens; smooth muscle. Male 21159945 CVCL_DC07 DDT/TG4muM cancer cell line CVCL_DC07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9516; Thapsigargin; Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Vas deferens; smooth muscle. Male 21159946 CVCL_DC00 REN/CTVM32 spontaneously immortalized cell line CVCL_DC00 CL:0000010 Unspecified Group: Tick cell line. 21159947 CVCL_DC01 GM09988 transformed cell line human CVCL_DC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM09988; probable Male 21159948 CVCL_DC04 UT-2 spontaneously immortalized cell line CVCL_DC04 CL:0000010 Derived from sampling site: Ovary. Female 21159949 CVCL_DC05 DDT1 cancer cell line CVCL_DC05 CL:0000010 Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Vas deferens; smooth muscle. Male 21159950 CVCL_DC02 LS141-1G1-65-15-1 hybridoma house mouse CVCL_DC02 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P51679; Human CCR4/CD194. Doubling time: 19 hours (ATCC=HB-12624) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12624 21159951 CVCL_DC03 LS185-2B10-4-1 hybridoma house mouse CVCL_DC03 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P51679; Human CCR4/CD194. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12625 21159952 CVCL_DC19 H1G1.1c3 cancer cell line house mouse CVCL_DC19 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Cell line developed for CAFLUX (Chemically Activated FLUorescence eXpression) bioassay CAFLUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a EGFP gene under the control of dioxin-response elements (DREs) 21159953 CVCL_DC17 G16L1.1c8 cancer cell line CVCL_DC17 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Colon. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159954 CVCL_DC18 G16L7.5c1 cancer cell line CVCL_DC18 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Colon. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21159955 CVCL_DC11 BuGR2 hybridoma house mouse CVCL_DC11 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06536; Rat Nr3c1/Grl. 21159956 CVCL_DC12 WCL2 spontaneously immortalized cell line CVCL_DC12 CL:0000010 Transfected with: MGI; MGI:95824; Nr3c1 Derived from sampling site: Ovary. Female 21159957 CVCL_DC10 BuGR1 hybridoma house mouse CVCL_DC10 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06536; Rat Nr3c1/Grl (Note=Also reacts with mouse). 21159958 CVCL_DC15 Hepa1c1c7-M4P2 cancer cell line house mouse CVCL_DC15 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Can be used for bioassays to detect dioxin/TCDD-like compounds Female Characteristics: Acts through the activation of a luciferase reporter gene which is under the control of dioxin-response elements (DREs) from mouse Cyp1a1 gene Group: Patented cell line; Registration: Bioresource Collection and Research Center (BCRC) of Taiwan; BCRC 960208; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6090 21159959 CVCL_DC16 PSF [Pelodiscus] spontaneously immortalized cell line CVCL_DC16 CL:0000010 Derived from sampling site: Heart. Female Doubling time: 51.1 hours (PubMed=27059326) Group: Reptilian cell line 21159960 CVCL_DC13 2B6 hybridoma CVCL_DC13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99665; Human IL12RB2. 21159961 CVCL_DC14 Hepa1c1c7-MP cancer cell line house mouse CVCL_DC14 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Can be used for bioassays to detect dioxin/TCDD-like compounds Female Characteristics: Acts through the activation of a luciferase reporter gene which is under the control of dioxin-response elements (DREs) from mouse Cyp1a1 gene Group: Patented cell line; Registration: Bioresource Collection and Research Center (BCRC) of Taiwan; BCRC 960207; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6089 21159962 CVCL_V841 S003629 transformed cell line CVCL_V841 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003629; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159963 CVCL_UW41 UK Pan-1 cancer cell line human CVCL_UW41 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=10813711); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=10813711). Male Doubling time: <24 hours (PubMed=10813711) 21159964 CVCL_UW42 Mes.Cl.-1 cancer cell line human CVCL_UW42 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Hemizygous (PubMed=1913660). Male 21159965 CVCL_V842 S003630 finite cell line CVCL_V842 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S003630; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159966 CVCL_V840 S003626 finite cell line CVCL_V840 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S003626; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159967 CVCL_UW40 SM5-1 hybridoma house mouse CVCL_UW40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12588 21159968 CVCL_UW45 Mes.Cl.-4 cancer cell line human CVCL_UW45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Hemizygous (PubMed=1913660). Male 21159969 CVCL_V845 S003642 finite cell line CVCL_V845 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S003642; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159970 CVCL_UW46 3808-1 transformed cell line human CVCL_UW46 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159971 CVCL_V846 S003646 transformed cell line CVCL_V846 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003646; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159972 CVCL_UW43 Mes.Cl.-2 cancer cell line human CVCL_UW43 CL:0000010 Male 21159973 CVCL_V843 S003639 transformed cell line CVCL_V843 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003639; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159974 CVCL_UW44 Mes.Cl.-3 cancer cell line human CVCL_UW44 CL:0000010 Female 21159975 CVCL_V844 S003641 transformed cell line CVCL_V844 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003641; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159976 CVCL_V849 S003649 finite cell line CVCL_V849 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003649; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159977 CVCL_UW49 SBC-9B cancer cell line human CVCL_UW49 CL:0000010 Population: Japanese. Unspecified 21159978 CVCL_UW47 6938-1 transformed cell line human CVCL_UW47 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21159979 CVCL_V847 S003647 finite cell line CVCL_V847 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003647; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159980 CVCL_V848 S003648 transformed cell line CVCL_V848 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003648; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159981 CVCL_UW48 SP-53 EBV-infected cancer cell line human CVCL_UW48 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: 73 hours (PubMed=11061568) 21159982 CVCL_UW30 BY00449 transformed cell line human CVCL_UW30 HLA typing: A*02:22/02:104,24:CWFP; B*35:43,35:99; C*01:02:01,03:05; DRB1*04:07:01,08:02:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21159983 CVCL_V830 GM01356 finite cell line human CVCL_V830 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;7)(1qter->1p34::7p13->7pter;7qter->7p13::1p34->1pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21159984 CVCL_UW31 Ocy454 conditionally immortalized cell line house mouse CVCL_UW31 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Gly, p.Ser72Ala, Lys79Arg, Thr203Tyr and His231Leu = Topaz) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; long bone Cell type=Osteocyte.; Breed/subspecies: C57BL/6-Tg(Dmp1-Topaz)1Ikal/J x (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Displays a dendritic morphology similar to other osteocytic cell lines; Characteristics: Expresses GFP Topaz under the control of the Dmp1 promoter 21159985 CVCL_V831 S003487 transformed cell line CVCL_V831 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003487; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159986 CVCL_UW34 ASA cancer cell line human CVCL_UW34 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Female 21159987 CVCL_V834 S003612 transformed cell line CVCL_V834 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: Coriell; S003612; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159988 CVCL_UW35 MINO cancer cell line human CVCL_UW35 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21159989 CVCL_V835 S003619 transformed cell line CVCL_V835 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003619; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159990 CVCL_UW32 A-1684 cancer cell line human CVCL_UW32 CL:0000010 Unspecified 21159991 CVCL_V832 S003489 transformed cell line CVCL_V832 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003489; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159992 CVCL_UW33 A-1723 cancer cell line human CVCL_UW33 CL:0000010 Unspecified 21159993 CVCL_V833 S003611 finite cell line CVCL_V833 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S003611; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159994 CVCL_V838 S003623 transformed cell line CVCL_V838 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003623; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159995 CVCL_UW38 SIRMu-1 spontaneously immortalized cell line Norway rat CVCL_UW38 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Displays key characteristics of primary Muller cells, including the expression of an array of well-characterized Muller cells marker proteins (PubMed=30677389) Doubling time: 36 hours (in 10% FBS), 30 hours (in 20% FBS) (PubMed=30677389) 21159996 CVCL_UW39 QMMuC-1 spontaneously immortalized cell line house mouse CVCL_UW39 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: C57BL/6J. Unspecified Characteristics: Morphology and phenotype are similar to those of primary Muller glial cultures (PubMed=29625493) Doubling time: 27.63 hours (PubMed=29625493) 21159997 CVCL_V839 S003624 finite cell line CVCL_V839 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S003624; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159998 CVCL_V836 S003621 transformed cell line CVCL_V836 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003621; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21159999 CVCL_UW36 TAKA cancer cell line human CVCL_UW36 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21160000 CVCL_V837 S003622 transformed cell line CVCL_V837 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Discontinued: Coriell; S003622; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160001 CVCL_UW37 TANI cancer cell line human CVCL_UW37 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21160002 CVCL_2Q00 AU10169 transformed cell line human CVCL_2Q00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160003 CVCL_3200 TIG-118 finite cell line human CVCL_3200 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~24 hours (lot 10182010), ~25 hours (lot 10182018) (JCRB) 21160004 CVCL_2Q01 AU10170 transformed cell line human CVCL_2Q01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160005 CVCL_3201 TIG-119 finite cell line human CVCL_3201 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 48 PDL (JCRB=JCRB0540); Doubling time: ~29 hours (lot 10162009), 53-65 hours (lot 06052013), ~23 hours (lot 09022016) (JCRB) 21160006 CVCL_2Q04 AU10173 transformed cell line human CVCL_2Q04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160007 CVCL_3204 TIG-2M-30 finite cell line human CVCL_3204 CL:0000010 Population: Japanese; Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Female Senescence: Senesces at 63 PDL (PubMed=7421303); Doubling time: ~43 hours (lot 10132009), ~3 days (lot 11022015) (JCRB) 21160008 CVCL_2Q05 AU10174 transformed cell line human CVCL_2Q05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160009 CVCL_3205 TIG-3-20 finite cell line human CVCL_3205 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: Senesces at 84 PDL (JCRB=JCRB0506); Doubling time: 1.5 days (lots 09122003 and 02192019), ~1 day (lot 06272008), ~52 hours (lot 11272014), ~30 hours (lot 07262017) (JCRB) 21160010 CVCL_2Q02 AU10171 transformed cell line human CVCL_2Q02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160011 CVCL_3202 TIG-120 finite cell line human CVCL_3202 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep proteome analysis Female Doubling time: ~45 hours (lot 08202010), ~2 days (lot 07122011), 26-48 hours (lot 04152013) (JCRB) 21160012 CVCL_2Q03 AU10172 transformed cell line human CVCL_2Q03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160013 CVCL_3203 TIG-121 finite cell line human CVCL_3203 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Doubling time: ~42 hours (lot 09272010) (JCRB) 21160014 CVCL_2Q08 AU10177 transformed cell line human CVCL_2Q08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160015 CVCL_3208 TIG-3-50 finite cell line human CVCL_3208 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160016 CVCL_2Q09 AU10178 transformed cell line human CVCL_2Q09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160017 CVCL_3209 TIG-3-60 finite cell line human CVCL_3209 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160018 CVCL_2Q06 AU10175 transformed cell line human CVCL_2Q06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160019 CVCL_3206 TIG-3-30 finite cell line human CVCL_3206 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160020 CVCL_2Q07 AU10176 transformed cell line human CVCL_2Q07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160021 CVCL_3207 TIG-3-40 finite cell line human CVCL_3207 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160022 CVCL_UW20 BIHi005-A-5 induced pluripotent stem cell human CVCL_UW20 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Knockout cell: Method=TALEN; HGNC; 11185; SORL1 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21160023 CVCL_V820 GM04126 finite cell line human CVCL_V820 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21160024 CVCL_UW23 BY00268 transformed cell line human CVCL_UW23 HLA typing: A*01:YAG,02:ANGR; B*07:ARKU,37:JTB; C*06:02:01:01,07:64; DRB1*10:01,15:AK (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160025 CVCL_V823 GM09216 transformed cell line human CVCL_V823 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21160026 CVCL_UW24 BY00342 transformed cell line human CVCL_UW24 HLA typing: A*02:BZNT,24:CNEX; B*18:ADSC,35:HNH; C*07:58,12:03:01:01; DRB1*11:ASZR,14:PRK (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160027 CVCL_V824 GM22601 transformed cell line human CVCL_V824 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21160028 CVCL_UW21 BIHi005-B induced pluripotent stem cell human CVCL_UW21 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Asian. Male 21160029 CVCL_V821 GM05358 transformed cell line human CVCL_V821 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160030 CVCL_UW22 BIHi005-C induced pluripotent stem cell human CVCL_UW22 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21160031 CVCL_V822 GM06056 finite cell line human CVCL_V822 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160032 CVCL_UW27 BY00445 transformed cell line human CVCL_UW27 HLA typing: A*33:BEKE,68:47; B*04:07:01,51:CVAE; C*15:02:01/15:13; DRB1*09:01:02 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160033 CVCL_V827 WI-25 finite cell line human CVCL_V827 CL:0000010 Anecdotal: The cell lines WI-1 to WI-25 derived by Hayflick were lost in 1961 when an electrical freezer failed at the Wistar Insitute (CelloPub=CLPUB00391) Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21160034 CVCL_UW28 BY00446 transformed cell line human CVCL_UW28 HLA typing: A*24:CWFP,25:01:01; B*18:RRG,35:99; C*03:05,12:03:01/12:03:06; DRB1*08:02:01,15:01:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160035 CVCL_V828 GM00361 finite cell line human CVCL_V828 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00361; probable; Discontinued: Coriell; GM00966; probable Female 21160036 CVCL_UW25 BY00343 transformed cell line human CVCL_UW25 HLA typing: A*03:APAD,25:MN; B*07:CZZS,18:30; C*07:BJ,12:NP; DRB1*10:01,15:AK (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160037 CVCL_V825 GM02025 finite cell line human CVCL_V825 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21160038 CVCL_UW26 BY00444 transformed cell line human CVCL_UW26 HLA typing: A*02:CNDW,03:58; B*09:01,40:XCG; C*07:02:01:01,35:BJJC; DRB1*15:AK (PubMed=20860585) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160039 CVCL_V826 WI-26 finite cell line human CVCL_V826 CL:0000010 Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CCL-95; true Male Senescence: Senesces at 36 PDL and are distributed at 27 PDL (ATCC=CCL-95) Group: Space-flown cell line (cellonaut) 21160040 CVCL_UW29 BY00447 transformed cell line human CVCL_UW29 HLA typing: A*02:G1,08:03:02; B*03:01:01,48:AF; C*07:CVAG,41:01; DRB1*08:02:01 (PubMed=20860585) CL:0000010 Population: Native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160041 CVCL_V829 GM00981 finite cell line human CVCL_V829 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21160042 CVCL_UW12 CHO-K1-XIAP spontaneously immortalized cell line CVCL_UW12 CL:0000010 Transfected with: HGNC; 592; XIAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21160043 CVCL_V812 GM01881 finite cell line human CVCL_V812 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Ser66Trp (c.197C>G); ClinVar=VCV000005111; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Val131Met (c.391G>A); ClinVar=VCV001372507; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160044 CVCL_UW13 CHO-K1-XIAP-GFP spontaneously immortalized cell line CVCL_UW13 CL:0000010 Transfected with: HGNC; 592; XIAP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe99Ser, p.Met153Thr and p.Val163Ala = cycle3) Derived from sampling site: Ovary. Female 21160045 CVCL_V813 GM01996 finite cell line human CVCL_V813 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asn314Asp (c.940A>G); ClinVar=VCV000003613; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160046 CVCL_V810 GM01663 finite cell line human CVCL_V810 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(17)(17qter->17p13::13q14->13qter)mat (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160047 CVCL_UW10 M17/4.2 hybridoma CVCL_UW10 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P24063; Mouse Itgal/Cd11a. 21160048 CVCL_V811 GM01695 finite cell line human CVCL_V811 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;11)(p21;q13) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21160049 CVCL_UW11 I-542 hybridoma house mouse CVCL_UW11 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P49064; Cat ALB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9498 21160050 CVCL_UW16 GM02451 transformed cell line human CVCL_UW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02451; probable Male 21160051 CVCL_V816 GM02598 finite cell line human CVCL_V816 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21160052 CVCL_V817 GM02808 finite cell line human CVCL_V817 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;17)(3qter->3p21::17p13->17pter;17qter->17p13::3p21->3pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21160053 CVCL_UW17 GM11374 transformed cell line human CVCL_UW17 CL:0000010 Population: Southeast Asian; Khmer Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11374; probable Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21160054 CVCL_V814 GM02018 finite cell line human CVCL_V814 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21160055 CVCL_UW14 Luc63.2.22 hybridoma house mouse CVCL_UW14 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized elotuzumab (HuLuc63; Empliciti) therapeutic antibody It was developed for the treatment of multiple myeloma. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9NQ25; Human SLAMF7/CD319. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5950 21160056 CVCL_V815 GM02492 finite cell line human CVCL_V815 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160057 CVCL_UW15 Luc90 hybridoma house mouse CVCL_UW15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q9NQ25; Human SLAMF7/CD319. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5091 21160058 CVCL_V818 GM02881 finite cell line human CVCL_V818 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male Senescence: Senesces at 24 PDL (PubMed=6492896) 21160059 CVCL_UW18 GM11375 transformed cell line human CVCL_UW18 CL:0000010 Population: Southeast Asian; Khmer Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11375; probable Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21160060 CVCL_V819 GM03196 finite cell line human CVCL_V819 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(5)(pter->p13::q13->p13::q13->qter),t(17;22)(17qter->17p13::22q11->22qter;22pter->22q11::17p13->17pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21160061 CVCL_UW19 Mel-NT7-00 cancer cell line human CVCL_UW19 HLA typing: A*03:02,03:02; B*51:01:01,51:01:01; C*01:02:01,01:02:01; DPB1*04:01,04:02; DQB1*03:01:01,05:01 (PubMed=15592718). CL:0000010 21160062 CVCL_V801 GM01224 finite cell line human CVCL_V801 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21160063 CVCL_UW01 NT01072 transformed cell line human CVCL_UW01 HLA typing: A*01:YAG,02:ANGR; B*08:XKT,44:02:08; C*05:ANJN,07:ANNG; DRB1*03:WKH,04:AFMT (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160064 CVCL_V802 GM01252 finite cell line human CVCL_V802 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21160065 CVCL_UW02 NT01073 transformed cell line human CVCL_UW02 HLA typing: A*02:BANP,23:ANJU; B*27:04:03,45:AH; C*06:AJB,12:02; DRB1*11:APKF,14:04 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160066 CVCL_V800 GM01220 finite cell line human CVCL_V800 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21160067 CVCL_UW00 NT01070 transformed cell line human CVCL_UW00 HLA typing: A*02:ANFV,31:AF; B*15:164,51:CVAE; C*03:FJC,12:NP; DRB1*03:WHX,15:VYF (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160068 CVCL_V805 GM01421 finite cell line human CVCL_V805 CL:0000010 Population: African American; Karyotypic information: 46,XY,t(1;6)(1pter->1q42::6q21->6qter;6pter->6q21::1q42->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21160069 CVCL_UW05 NT01107 transformed cell line human CVCL_UW05 HLA typing: B*07:CUCC,57:BC; C*07:ANHC,18:AB; DRB1*11:01:02,16:14 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160070 CVCL_V806 GM01533 finite cell line human CVCL_V806 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Karyotypic information: 46,X,t(X;3)(q26;p12) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21160071 CVCL_UW06 NT01108 transformed cell line human CVCL_UW06 HLA typing: A*01:ENWD,02:190; B*44:ANGD,57:VG; C*05:ARSE,06:ASCZ; DRB1*04:09,07:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160072 CVCL_V803 GM01253 finite cell line human CVCL_V803 CL:0000010 Population: African American; Karyotypic information: 46,XY,rec(3)(qter->p25::q25->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21160073 CVCL_UW03 NT01105 transformed cell line human CVCL_UW03 HLA typing: A*02:ANGN,03:ANGP; B*48:01,56:01; C*01:AEV,08:AJ; DRB1*04:79,11:04:01 (PubMed=20860585) CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160074 CVCL_V804 GM01396 finite cell line human CVCL_V804 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21160075 CVCL_UW04 NT01106 transformed cell line human CVCL_UW04 HLA typing: A*02:ANDC,11:XSH; B*27:02,55:XUB; C*03:PWX,07:AJB; DRB1*09:01:06,11:01:01 (PubMed=20860585) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160076 CVCL_V809 GM01570 finite cell line human CVCL_V809 CL:0000010 Karyotypic information: 6,XY,rec(13)(pter->q22::p11->pter)pat (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160077 CVCL_UW09 S2R+-Rab11-GFP-14 spontaneously immortalized cell line fruit fly CVCL_UW09 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Rab11 locus (FBgn0015790) Group: Insect cell line 21160078 CVCL_V807 GM01555 finite cell line human CVCL_V807 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21160079 CVCL_UW07 NT01114 transformed cell line human CVCL_UW07 HLA typing: A*23:NY; B*42:AB,53:01; C*04:01:11,17:MN; DRB1*08:BYC,13:02 (PubMed=20860585) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160080 CVCL_V808 GM01561 transformed cell line human CVCL_V808 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;11)(4pter->4q23::11q11->11qter;11pter->11q11::4q23->4qter) [8]; 45,X,t(4;11)(4pter->4q23::11q11->11qter;11pter->11q11::4q23->4qter),add(19)(?::p13.3->qter) [2] (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160081 CVCL_UW08 NT01121 transformed cell line human CVCL_UW08 HLA typing: A*02:ANGN,03:ANGP; C*03:FJC,06:32; DRB1*07:01,13:01 (PubMed=20860585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21160082 CVCL_2Q80 AG18181 transformed cell line human CVCL_2Q80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160083 CVCL_3280 HCC1739 BL transformed cell line human CVCL_3280 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160084 CVCL_2Q81 AG18182 transformed cell line human CVCL_2Q81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160085 CVCL_3281 HCC1937 BL transformed cell line human CVCL_3281 HLA typing: A*23:01,24:02; B*40:01,07:02; C*03:04,07:02; DQA1*04:01,01:02; DQB1*06:02,04:02; DRB1*08:01,15:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous; Note=The breast carcinoma cell line HCC1937 (Cellosaurus=CVCL_0290) is homozygous for the same mutation (PubMed=9699648; PubMed=22032724) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours (DSMZ=ACC-891) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160086 CVCL_2Q84 AG18185 transformed cell line human CVCL_2Q84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160087 CVCL_3284 HCN-2 finite cell line human CVCL_3284 CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.. Omics: Proteome analysis by 2D-DE/MS Female Senescence: Senesces at ~21 PDL (ATCC=CRL-10742); Doubling time: ~48 hours (PubMed=7700510) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10742 21160088 CVCL_2Q85 AG18186 transformed cell line human CVCL_2Q85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160089 CVCL_3285 HFF-1 finite cell line human CVCL_3285 CL:0000010 Donor information: Established from foreskin pooled from two individuals (ATCC); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21160090 CVCL_2Q82 AG18183 transformed cell line human CVCL_2Q82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160091 CVCL_3282 HCC1007 BL transformed cell line human CVCL_3282 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160092 CVCL_2Q83 AG18184 transformed cell line human CVCL_2Q83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160093 CVCL_3283 HCN-1A finite cell line human CVCL_3283 CL:0000010 Miscellaneous: Cell line no longer available due to depletion of the original seed stock Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.. Female Doubling time: ~72 hours (PubMed=1692158) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10442 21160094 CVCL_2Q77 AG22177 finite cell line human CVCL_2Q77 CL:0000010 Population: African American; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Female 21160095 CVCL_3277 Win Mec finite cell line human CVCL_3277 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160096 CVCL_2Q78 AG18170 transformed cell line human CVCL_2Q78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160097 CVCL_3278 WEHI-279 cancer cell line house mouse CVCL_3278 CL:0000010 Breed/subspecies: NZC. 21160098 CVCL_2Q75 AG20725 transformed cell line human CVCL_2Q75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160099 CVCL_3275 ZF4 spontaneously immortalized cell line zebrafish CVCL_3275 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Group: Fish cell line 21160100 CVCL_2Q76 AG21820 transformed cell line human CVCL_2Q76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160101 CVCL_3276 ZFL spontaneously immortalized cell line zebrafish CVCL_3276 CL:0000010 Donor information: According to PubMed=7994634 obtained from pooling the livers of three fish, while ATCC mentions 10 individuals; Derived from sampling site: Liver Cell type=Epithelial cell.. Unspecified Doubling time: 2.54 +- 0.28 days (in L-15-FBS), 6.6 +- 0.43 days (in UltraMEM-ITES) (PubMed=28587087); 72 hours (ATCC=CRL-2643) Group: Fish cell line 21160102 CVCL_2Q79 AG18171 transformed cell line human CVCL_2Q79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160103 CVCL_3279 Wa Fen finite cell line human CVCL_3279 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1271; true Male 21160104 CVCL_2Q91 AG18192 transformed cell line human CVCL_2Q91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160105 CVCL_3291 HIAE-78 finite cell line human CVCL_3291 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2475; true; Discontinued: Coriell; WC00100; probable Female Senescence: Capable of at least 36 PDL (ATCC=CRL-2475) Part of: Wistar Institute Special Collection vascular cell lines 21160106 CVCL_2Q92 AG18193 transformed cell line human CVCL_2Q92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160107 CVCL_3292 HIVE-26 finite cell line human CVCL_3292 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2603; true; Discontinued: Coriell; WC00110; probable Male Senescence: Capable of at least 67 PDL (ATCC=CRL-2603) Part of: Wistar Institute Special Collection vascular cell lines 21160108 CVCL_2Q90 AG18191 transformed cell line human CVCL_2Q90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160109 CVCL_3290 HIAE-65 finite cell line human CVCL_3290 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2606; true; Discontinued: Coriell; WC00114; probable Female Part of: Wistar Institute Special Collection vascular cell lines 21160110 CVCL_2Q95 AG18196 transformed cell line human CVCL_2Q95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160111 CVCL_3295 HIVE-78 finite cell line human CVCL_3295 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2476; true; Discontinued: Coriell; WC00101; probable Female Senescence: Capable of at least 27 PDL (ATCC=CRL-2476) Part of: Wistar Institute Special Collection vascular cell lines 21160112 CVCL_2Q96 AG18197 transformed cell line human CVCL_2Q96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160113 CVCL_3296 Cates-1B cancer cell line human CVCL_3296 CL:0000010 Derived from metastatic site: Lymph node. Male 21160114 CVCL_2Q93 AG18194 transformed cell line human CVCL_2Q93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160115 CVCL_3293 HIVE-55 finite cell line human CVCL_3293 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2609; true; Discontinued: Coriell; WC00113; probable Female Senescence: Capable of at least 24 PDL (ATCC=CRL-2609) Part of: Wistar Institute Special Collection vascular cell lines 21160116 CVCL_2Q94 AG18195 transformed cell line human CVCL_2Q94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160117 CVCL_3294 HIVE-65 finite cell line human CVCL_3294 CL:0000010 Derived from sampling site: Iliac vein; endothelium. Discontinued: ATCC; CRL-2605; true; Discontinued: Coriell; WC00111; probable Female Senescence: Capable of at least 39 PDL (ATCC=CRL-2605) Part of: Wistar Institute Special Collection vascular cell lines 21160118 CVCL_2Q88 AG18189 transformed cell line human CVCL_2Q88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160119 CVCL_3288 HIAE-38 finite cell line human CVCL_3288 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2599; true; Discontinued: Coriell; WC00108; probable Male Part of: Wistar Institute Special Collection vascular cell lines 21160120 CVCL_2Q89 AG18190 transformed cell line human CVCL_2Q89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160121 CVCL_3289 HIAE-55 finite cell line human CVCL_3289 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2608; true Female Senescence: Capable of at least 37 PDL (ATCC=CRL-2608) Part of: Wistar Institute Special Collection vascular cell lines 21160122 CVCL_2Q86 AG18187 transformed cell line human CVCL_2Q86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160123 CVCL_3286 HFF-2 finite cell line human CVCL_3286 CL:0000010 Donor information: Established from foreskin pooled from four individuals (ATCC); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1042; true Male 21160124 CVCL_2Q87 AG18188 transformed cell line human CVCL_2Q87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160125 CVCL_3287 HIAE-101 finite cell line human CVCL_3287 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: ATCC; CRL-2478; true Female Part of: Wistar Institute Special Collection vascular cell lines 21160126 CVCL_2Q62 AG12500 finite cell line human CVCL_2Q62 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: Coriell; AG12500; probable Female 21160127 CVCL_3262 Yub623 somatic stem cell human CVCL_3262 CL:0000010 Discontinued: JCRB; NIHS0419; true. Female Senescence: Senesces at 20 PDL (JCRB=JCRB1115) 21160128 CVCL_2Q63 AG12503 finite cell line human CVCL_2Q63 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: Coriell; AG12503; probable Female 21160129 CVCL_3263 Yub625 somatic stem cell human CVCL_3263 CL:0000010 Discontinued: JCRB; NIHS0461; true. Male 21160130 CVCL_2Q60 AG09130 transformed cell line human CVCL_2Q60 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male 21160131 CVCL_3260 Yub621c somatic stem cell human CVCL_3260 CL:0000010 Discontinued: JCRB; NIHS0415; true. Female Senescence: Senesces at 20 PDL (JCRB=JCRB1111) 21160132 CVCL_2Q61 AG09131 transformed cell line human CVCL_2Q61 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from familial inference) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160133 CVCL_3261 Yub622 somatic stem cell human CVCL_3261 CL:0000010 Discontinued: JCRB; NIHS0418; true. Female 21160134 CVCL_2Q55 AG17874 transformed cell line CVCL_2Q55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: Slow growth (Coriell) Group: Non-human primate cell line 21160135 CVCL_3255 XTK1 transformed cell line CVCL_3255 CL:0000010 Transformant: Human herpesvirus 2 (HHV-2)(NCBI-Taxonomy; 10310); Derived from sampling site: Skin. 21160136 CVCL_2Q56 AG21329 finite cell line CVCL_2Q56 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21160137 CVCL_3256 XTK2 transformed cell line CVCL_3256 CL:0000010 Transformant: Human herpesvirus 2 (HHV-2)(NCBI-Taxonomy; 10310); Derived from sampling site: Skin. 21160138 CVCL_2Q53 AG15897 spontaneously immortalized cell line house mouse CVCL_2Q53 CL:0000010 Karyotypic information: 63-64,XXXX,-2,+3,+5,-7,+10,+11,-13,-14,-16,+mar1,+mar2,+mar3,+mar4 cpk[9] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160139 CVCL_3253 XPL15OS transformed cell line human CVCL_3253 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160140 CVCL_2Q54 AG16273 spontaneously immortalized cell line CVCL_2Q54 CL:0000010 Karyotypic information: 22,XX [30]; 23,XX,+6 [20] (Coriell); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Female 21160141 CVCL_3254 XPL3KA transformed cell line human CVCL_3254 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160142 CVCL_2Q59 AG09129 transformed cell line human CVCL_2Q59 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21160143 CVCL_3259 Yub621BMC somatic stem cell human CVCL_3259 CL:0000010 Discontinued: JCRB; NIHS0417; true. Female Senescence: Senesces at 20 PDL (JCRB=JCRB1113) 21160144 CVCL_2Q57 AG09127 transformed cell line human CVCL_2Q57 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21160145 CVCL_3257 Yub 10F somatic stem cell human CVCL_3257 CL:0000010 Discontinued: JCRB; NIHS0420; true. Female Senescence: Senesces at 20 PDL (JCRB=JCRB1116) 21160146 CVCL_2Q58 AG09128 transformed cell line human CVCL_2Q58 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG09128; probable Female 21160147 CVCL_3258 Yub621b somatic stem cell human CVCL_3258 CL:0000010 Discontinued: JCRB; NIHS0416; true. Female Senescence: Senesces at 20 PDL (JCRB=JCRB1112) 21160148 CVCL_UW96 NH50181 finite cell line human CVCL_UW96 CL:0000010 Population: Southeast Asian; Filipino and Hispanic; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160149 CVCL_V896 S005228 transformed cell line CVCL_V896 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005228; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160150 CVCL_UW97 NH50144 finite cell line human CVCL_UW97 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160151 CVCL_V897 S005231 transformed cell line CVCL_V897 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005231; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160152 CVCL_UW94 NH50143 induced pluripotent stem cell human CVCL_UW94 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Non-edited control for NH50142 (Cellosaurus=CVCL_UW93) 21160153 CVCL_V894 S005216 transformed cell line CVCL_V894 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005216; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160154 CVCL_UW95 NH50180 finite cell line human CVCL_UW95 CL:0000010 Population: Pacific; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160155 CVCL_V895 S005224 transformed cell line CVCL_V895 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005224; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160156 CVCL_UW98 NH50145 finite cell line human CVCL_UW98 CL:0000010 Population: Pacific; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160157 CVCL_V898 S005233 transformed cell line CVCL_V898 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005233; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160158 CVCL_UW99 NH50147 finite cell line human CVCL_UW99 CL:0000010 Population: Pacific; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160159 CVCL_V899 S005235 transformed cell line CVCL_V899 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005235; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160160 CVCL_2Q70 AG16731 transformed cell line human CVCL_2Q70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG16731; probable Male Part of: National Institute on Aging (NIA) longevity collection 21160161 CVCL_3270 Yub637b somatic stem cell human CVCL_3270 CL:0000010 Discontinued: JCRB; NIHS0474; true. Male 21160162 CVCL_3273 68-1-2 hybridoma house mouse CVCL_3273 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P10443; Escherichia coli polC. 21160163 CVCL_2Q73 AG19642 finite cell line human CVCL_2Q73 CL:0000010 Population: African American; Derived from sampling site: Ischium; skin Cell type=Fibroblast.. Male 21160164 CVCL_2Q74 AG19644 finite cell line human CVCL_2Q74 CL:0000010 Population: African American; Derived from sampling site: Ischium; skin Cell type=Fibroblast.. Female 21160165 CVCL_3274 ZEM2S spontaneously immortalized cell line zebrafish CVCL_3274 CL:0000010 Unspecified Group: Fish cell line. 21160166 CVCL_2Q71 GM13166 transformed cell line human CVCL_2Q71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160167 CVCL_3271 XR-V15B spontaneously immortalized cell line CVCL_3271 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; Q60449; Xrcc5; Simple; p.Ala372_Glu417del46 (c.1114_1251del138); Zygosity=Unspecified (PubMed=8657125) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21160168 CVCL_3272 A8/D1 cancer cell line house mouse CVCL_3272 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Discontinued: ECACC; 94031011; probable 21160169 CVCL_2Q72 AG19641 finite cell line human CVCL_2Q72 CL:0000010 Population: African American; Derived from sampling site: Ischium; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) 21160170 CVCL_2Q66 AG19284 finite cell line human CVCL_2Q66 CL:0000010 Derived from sampling site: Leg; tendon Cell type=Fibroblast.. Male 21160171 CVCL_3266 Yub633 somatic stem cell human CVCL_3266 CL:0000010 Discontinued: JCRB; NIHS0464; true. Female 21160172 CVCL_2Q67 AG19285 finite cell line human CVCL_2Q67 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21160173 CVCL_3267 Yub634 somatic stem cell human CVCL_3267 CL:0000010 Discontinued: JCRB; NIHS0465; true. Male 21160174 CVCL_2Q64 AG17500 transformed cell line human CVCL_2Q64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160175 CVCL_3264 Yub631 somatic stem cell human CVCL_3264 CL:0000010 Discontinued: JCRB; NIHS0462; true. Male 21160176 CVCL_2Q65 AG19282 finite cell line human CVCL_2Q65 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21160177 CVCL_3265 Yub632 somatic stem cell human CVCL_3265 CL:0000010 Discontinued: JCRB; NIHS0463; true. Male 21160178 CVCL_2Q68 AG19289 finite cell line human CVCL_2Q68 CL:0000010 Derived from sampling site: Leg; skin Cell type=Fibroblast.. Female 21160179 CVCL_3268 Yub635 somatic stem cell human CVCL_3268 CL:0000010 Discontinued: JCRB; NIHS0473; true. Female 21160180 CVCL_2Q69 AG01440 finite cell line human CVCL_2Q69 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: Coriell; AG01440; probable Male 21160181 CVCL_3269 Yub636 somatic stem cell human CVCL_3269 CL:0000010 Discontinued: JCRB; NIHS0475; true. Male 21160182 CVCL_UW85 NH50141 induced pluripotent stem cell human CVCL_UW85 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Heterozygous (NHCDR) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Non-edited control for NH50140 (Cellosaurus=CVCL_UW84) 21160183 CVCL_V885 S005062 transformed cell line CVCL_V885 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005062; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160184 CVCL_UW86 NH50182 induced pluripotent stem cell human CVCL_UW86 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160185 CVCL_V886 S005082 transformed cell line CVCL_V886 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005082; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160186 CVCL_UW83 KoK spontaneously immortalized cell line CVCL_UW83 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Koi. Unspecified Group: Fish cell line 21160187 CVCL_V883 S005058 transformed cell line CVCL_V883 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005058; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160188 CVCL_UW84 NH50140 induced pluripotent stem cell human CVCL_UW84 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple_corrected; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160189 CVCL_V884 S005060 transformed cell line CVCL_V884 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005060; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160190 CVCL_UW89 NH50187 induced pluripotent stem cell human CVCL_UW89 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple_corrected; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160191 CVCL_V889 S005200 transformed cell line CVCL_V889 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005200; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160192 CVCL_UW87 NH50183 induced pluripotent stem cell human CVCL_UW87 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160193 CVCL_V887 S005083 transformed cell line CVCL_V887 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005083; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160194 CVCL_UW88 NH50186 induced pluripotent stem cell human CVCL_UW88 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple_corrected; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160195 CVCL_V888 S005192 transformed cell line CVCL_V888 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005192; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160196 CVCL_2Q40 AG12354 finite cell line pig CVCL_2Q40 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21160197 CVCL_3240 Yub637s somatic stem cell human CVCL_3240 CL:0000010 Discontinued: JCRB; NIHS0476; true. Male 21160198 CVCL_2Q41 AG12357 finite cell line pig CVCL_2Q41 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21160199 CVCL_3241 V79-6TG spontaneously immortalized cell line CVCL_3241 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21160200 CVCL_2Q33 AG20368 somatic stem cell human CVCL_2Q33 CL:0000010 Derived from sampling site: Abdomen; adipose tissue Cell type=Stromal cell.. Female 21160201 CVCL_3233 UE6E7-16 transformed cell line human CVCL_3233 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0457; true Female 21160202 CVCL_2Q34 AG20369 somatic stem cell human CVCL_2Q34 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Stromal cell.. Discontinued: Coriell; AG20369; probable Female Senescence: Senesces at 16 PDL (Coriell=AG20369) 21160203 CVCL_3234 UE6E7T-11 transformed cell line human CVCL_3234 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0453; true; Discontinued: RCB; RCB2159; probable Female 21160204 CVCL_2Q31 AG19304 somatic stem cell human CVCL_2Q31 CL:0000010 Derived from sampling site: Abdomen; skin; adipose tissue Cell type=Stromal cell.. Male 21160205 CVCL_3231 UCB408E6E7TERT-33 transformed cell line human CVCL_3231 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Discontinued: JCRB; NIHS0414; true; Discontinued: RCB; RCB2080; probable Male 21160206 CVCL_2Q32 AG20367 somatic stem cell human CVCL_2Q32 CL:0000010 Derived from sampling site: Thigh; adipose tissue Cell type=Stromal cell.. Female 21160207 CVCL_3232 UCBTERT-21 telomerase immortalized cell line human CVCL_3232 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Discontinued: JCRB; NIHS0411; true; Discontinued: RCB; RCB2079; probable Male 21160208 CVCL_2Q37 AG11721 finite cell line pig CVCL_2Q37 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Yorkshire. Female 21160209 CVCL_3237 UE6E7T-3 transformed cell line human CVCL_3237 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0448; true; Discontinued: RCB; RCB2154; probable Female Doubling time: 40 hours (PubMed=25978455) 21160210 CVCL_2Q38 AG12021 finite cell line pig CVCL_2Q38 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21160211 CVCL_3238 UE7T-13 transformed cell line human CVCL_3238 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0455; true; Discontinued: RCB; RCB2161; probable Female 21160212 CVCL_2Q35 AG20470 somatic stem cell human CVCL_2Q35 CL:0000010 Derived from sampling site: Skin; adipose tissue Cell type=Stromal cell.. Female 21160213 CVCL_3235 UE6E7T-12 transformed cell line human CVCL_3235 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0454; true; Discontinued: RCB; RCB2160; probable Female 21160214 CVCL_2Q36 AG20471 somatic stem cell human CVCL_2Q36 CL:0000010 Derived from sampling site: Abdomen; skin; adipose tissue Cell type=Stromal cell.. Male 21160215 CVCL_3236 UE6E7T-2 transformed cell line human CVCL_3236 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Omics: SNP array analysis Discontinued: JCRB; NIHS0447; true; Discontinued: RCB; RCB2153; probable Female 21160216 CVCL_2Q39 AG12071 finite cell line pig CVCL_2Q39 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Female 21160217 CVCL_3239 UE7T-9 transformed cell line human CVCL_3239 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0452; true; Discontinued: RCB; RCB2158; probable Female 21160218 CVCL_UW92 NH50190 induced pluripotent stem cell human CVCL_UW92 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Non-edited control for NH50189 (Cellosaurus=CVCL_UW91) 21160219 CVCL_V892 S005203 transformed cell line CVCL_V892 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005203; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160220 CVCL_UW93 NH50142 induced pluripotent stem cell human CVCL_UW93 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple_corrected; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160221 CVCL_V893 S005214 transformed cell line CVCL_V893 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005214; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160222 CVCL_UW90 NH50188 induced pluripotent stem cell human CVCL_UW90 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Non-edited control for NH50186 (Cellosaurus=CVCL_UW88) and NH50187 (Cellosaurus=CVCL_UW89) 21160223 CVCL_V890 S005201 transformed cell line CVCL_V890 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005201; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160224 CVCL_UW91 NH50189 induced pluripotent stem cell human CVCL_UW91 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160225 CVCL_V891 S005202 transformed cell line CVCL_V891 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005202; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160226 CVCL_UW74 Paesun spontaneously immortalized cell line human CVCL_UW74 CL:0000010 Anecdotal: Established in 1976 in the Democratic People's Republic of Korea and widely used there, but was not described in any publication before PubMed=30711449 Derived from sampling site: Fetal lung. Unspecified Virology: Used for the assessment of viral titers for vaccines 21160227 CVCL_V874 S005030 transformed cell line CVCL_V874 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005030; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160228 CVCL_UW75 Raf1 KI D486A transformed cell line house mouse CVCL_UW75 CL:0000010 Transfected with: MGI; MGI:97847; Raf1 (with p.Asp486Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: C57BL/6. Female 21160229 CVCL_V875 S005032 transformed cell line CVCL_V875 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005032; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160230 CVCL_UW72 FHS-1 cancer cell line CVCL_UW72 CL:0000010 Breed/subspecies: Domestic shorthair. Male 21160231 CVCL_V872 S004990 transformed cell line CVCL_V872 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004990; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160232 CVCL_UW73 MSCEK spontaneously immortalized cell line dog CVCL_UW73 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: Mixed breed. Female 21160233 CVCL_V873 S005028 transformed cell line CVCL_V873 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005028; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160234 CVCL_UW78 PL [Lateolabrax] spontaneously immortalized cell line CVCL_UW78 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21160235 CVCL_V878 S005043 transformed cell line CVCL_V878 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005043; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160236 CVCL_UW79 GK [Epinephelus amblycephalus] spontaneously immortalized cell line CVCL_UW79 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21160237 CVCL_V879 S005045 transformed cell line CVCL_V879 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005045; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160238 CVCL_UW76 H460R cancer cell line human CVCL_UW76 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Selected for resistance to: NCIt; C44386; Gamma radiation; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Characteristics: Established from parent cell line after 40 repetitive irradiation dose of 2 Gy each 21160239 CVCL_V876 S005034 transformed cell line CVCL_V876 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005034; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160240 CVCL_UW77 PH [Lateolabrax] spontaneously immortalized cell line CVCL_UW77 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21160241 CVCL_V877 S005041 transformed cell line CVCL_V877 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005041; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160242 CVCL_2Q51 AG15867 finite cell line CVCL_2Q51 CL:0000010 Derived from sampling site: Skin. Discontinued: Coriell; AG15867; probable Female Group: Endangered species/breed cell line; Group: Reptilian cell line 21160243 CVCL_3251 XP40OSTERT telomerase immortalized cell line human CVCL_3251 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0308; true Male 21160244 CVCL_2Q52 AG15868 finite cell line CVCL_2Q52 CL:0000010 Derived from sampling site: Skin. Discontinued: Coriell; AG15868; probable Female Group: Endangered species/breed cell line; Group: Reptilian cell line 21160245 CVCL_3252 XPEMB-1 finite cell line human CVCL_3252 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221; PubMed=27197874) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Unspecified 21160246 CVCL_2Q50 AG15866 finite cell line Norway rat CVCL_2Q50 CL:0000010 Derived from sampling site: Testis Cell type=Fibroblast.; Breed/subspecies: Sprague Dawley. Male 21160247 CVCL_3250 XP40OS finite cell line human CVCL_3250 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21160248 CVCL_2Q44 AG12364 finite cell line pig CVCL_2Q44 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Female 21160249 CVCL_3244 XP2YO(SV) transformed cell line human CVCL_3244 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Thr567Ala (c.1699A>G) (T556A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Val657Glufs*28 (c.1971delT); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160250 CVCL_2Q45 AG12372 finite cell line pig CVCL_2Q45 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Yorkshire. Female 21160251 CVCL_3245 XP3OS finite cell line human CVCL_3245 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221; PubMed=9671271; PubMed=27197874) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21160252 CVCL_2Q42 AG12362 finite cell line pig CVCL_2Q42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21160253 CVCL_3242 XP2OS(SV) transformed cell line human CVCL_3242 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Could be identical to GM04312 (Cellosaurus=CVCL_ZN80) 21160254 CVCL_2Q43 AG12363 finite cell line pig CVCL_2Q43 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Female 21160255 CVCL_3243 XP2SA finite cell line human CVCL_3243 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu306Ter (c.916G>T); ClinVar=VCV000005887; Zygosity=Unspecified (PubMed=10385124) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Virology: Infected with human parvovirus B19 (PubMed=29892436) Doubling time: 24 hours (JCRB) 21160256 CVCL_2Q48 AG15826 finite cell line CVCL_2Q48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160257 CVCL_3248 XP39OS finite cell line human CVCL_3248 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=1372102) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1013; probable Female 21160258 CVCL_2Q49 AG15865 finite cell line Norway rat CVCL_2Q49 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Fibroblast.; Breed/subspecies: Sprague Dawley. Male 21160259 CVCL_3249 XP39OSTERT telomerase immortalized cell line human CVCL_3249 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1015; probable; Discontinued: JCRB; NIHS0307; true Female 21160260 CVCL_2Q46 AG12417 finite cell line pig CVCL_2Q46 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Female 21160261 CVCL_3246 XP3OS(SVT) transformed cell line human CVCL_3246 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0304; true Female 21160262 CVCL_2Q47 AG13274 finite cell line CVCL_2Q47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Styan. Male Group: Endangered species/breed cell line 21160263 CVCL_3247 XP35OS finite cell line human CVCL_3247 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160264 CVCL_UW81 Fin-4 spontaneously immortalized cell line CVCL_UW81 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21160265 CVCL_V881 S005051 transformed cell line CVCL_V881 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005051; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160266 CVCL_UW82 Fr994 spontaneously immortalized cell line CVCL_UW82 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: INRA Sy. Female Virology: Susceptible to infection by infectious salmon anaemia virus (ISAV) Group: Fish cell line 21160267 CVCL_V882 S005052 transformed cell line CVCL_V882 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005052; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160268 CVCL_UW80 CHO-HPX spontaneously immortalized cell line CVCL_UW80 CL:0000010 Transfected with: HGNC; 5171; HPX; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21160269 CVCL_V880 S005049 transformed cell line CVCL_V880 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005049; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160270 CVCL_UW63 HFH(M) cancer cell line house mouse CVCL_UW63 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21160271 CVCL_V863 S004954 transformed cell line CVCL_V863 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004954; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160272 CVCL_UW64 NP133 cancer cell line house mouse CVCL_UW64 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Non-melanogenic 21160273 CVCL_V864 S004955 finite cell line CVCL_V864 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S004955; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160274 CVCL_UW61 HFH18-T2 cancer cell line house mouse CVCL_UW61 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Melanogenic 21160275 CVCL_V861 S004933 finite cell line CVCL_V861 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S004933; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160276 CVCL_UW62 HFH18/IL-6(+) cancer cell line house mouse CVCL_UW62 CL:0000010 Transfected with: MGI; MGI:96559; Il6 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21160277 CVCL_V862 S004934 transformed cell line CVCL_V862 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004934; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160278 CVCL_UW67 HMT-3909S13 clone G4 cancer cell line human CVCL_UW67 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (from parent cell line). Female Group: Triple negative breast cancer (TNBC) cell line 21160279 CVCL_V867 S004971 transformed cell line CVCL_V867 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004971; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160280 CVCL_UW68 HMT-3909S16 cancer cell line human CVCL_UW68 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (from parent cell line). Female Characteristics: Purified myoepithelial cell line Group: Triple negative breast cancer (TNBC) cell line 21160281 CVCL_V868 S004973 transformed cell line CVCL_V868 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S004973; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160282 CVCL_UW65 HMT-3909S13 cancer cell line human CVCL_UW65 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (from parent cell line). Female Characteristics: Appears to be a progenitor cell line Produces myoepithelial cells at the stromal-epithelial junction in tumors generated in nude mice. Group: Triple negative breast cancer (TNBC) cell line 21160283 CVCL_V865 S004960 transformed cell line CVCL_V865 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004960; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160284 CVCL_UW66 HMT-3909S13 clone A4 cancer cell line human CVCL_UW66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Unspecified (from parent cell line). Female Group: Triple negative breast cancer (TNBC) cell line 21160285 CVCL_V866 S004968 transformed cell line CVCL_V866 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004968; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160286 CVCL_UW69 HMEC-1330 finite cell line human CVCL_UW69 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160287 CVCL_V869 S004978 transformed cell line CVCL_V869 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004978; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160288 CVCL_2Q11 AU10180 transformed cell line human CVCL_2Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160289 CVCL_3211 TIG-7-20 finite cell line human CVCL_3211 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Doubling time: ~27 hours (lot 03162012) (JCRB) 21160290 CVCL_2Q12 AU10181 transformed cell line human CVCL_2Q12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160291 CVCL_3212 TIG-7-30 finite cell line human CVCL_3212 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160292 CVCL_2Q10 AU10179 transformed cell line human CVCL_2Q10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160293 CVCL_3210 TIG-3S finite cell line human CVCL_3210 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 67 PDL (JCRB=JCRB0544); Doubling time: ~35 hours (lot 11042010) (JCRB) 21160294 CVCL_2Q15 AU10184 transformed cell line human CVCL_2Q15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160295 CVCL_3215 TIG-7-60 finite cell line human CVCL_3215 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160296 CVCL_2Q16 AU10185 transformed cell line human CVCL_2Q16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160297 CVCL_3216 TK [Human B-cell lymphoma] cancer cell line human CVCL_3216 HLA typing: A*02:06,02:06; B*52:01,52:01; C*12:02,12:02; DQA1*01:01,01:01; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=26589293); Genome ancestry: African=0.67%; Native American=0%; East Asian, North=79.08%; East Asian, South=19.03%; South Asian=0.83%; European, North=0.39%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Asp (c.540G>T); ClinVar=VCV001521256; Zygosity=Unspecified (PubMed=10354143) Population: Japanese; Derived from sampling site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: JCRB; NIHS0245; true Female Doubling time: 5.3 days (PubMed=10354143); 30-40 hours (lot 08032007) (JCRB); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21160298 CVCL_2Q13 AU10182 transformed cell line human CVCL_2Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160299 CVCL_3213 TIG-7-40 finite cell line human CVCL_3213 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160300 CVCL_2Q14 AU10183 transformed cell line human CVCL_2Q14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160301 CVCL_3214 TIG-7-50 finite cell line human CVCL_3214 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160302 CVCL_2Q19 AG11131 finite cell line human CVCL_2Q19 CL:0000010 Derived from sampling site: Breast; epithelium. Male 21160303 CVCL_3219 TMH-1 cancer cell line human CVCL_3219 CL:0000010 Sequence variation: Mutation; HGNC; 391; AKT1; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000013983; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Trp592Ter (c.1776G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14281; CRLF2; Simple; p.Trp255Ter (c.765G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Arg1312Ter (c.3934C>T); ClinVar=VCV000545969; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp11Glu (c.33C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from metastatic site: Left cervical lymph node. Discontinued: JCRB; NIHS0267; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00349 Problematic cell line: Contaminated Shown to be a IHH-4 derivative (PubMed=20143388). Originally thought to originate from a 79 year old female patient with a thyroid gland anaplastic carcinoma. 21160304 CVCL_2Q17 HIAS-117C finite cell line human CVCL_2Q17 CL:0000010 Derived from sampling site: Iliac artery; smooth muscle. Male Part of: Wistar Institute Special Collection vascular cell lines 21160305 CVCL_3217 TK-1 [Mouse lymphoma] cancer cell line house mouse CVCL_3217 CL:0000010 Breed/subspecies: AKR/Cum. 21160306 CVCL_2Q18 HIVS-121T finite cell line human CVCL_2Q18 CL:0000010 Derived from sampling site: Iliac vein; smooth muscle. Male Part of: Wistar Institute Special Collection vascular cell lines 21160307 CVCL_3218 TMD5 cancer cell line human CVCL_3218 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=10071078; PubMed=35354797) Miscellaneous: STR profile from personal communication of Leo I.R Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 50 hours (PubMed=10071078) 21160308 CVCL_UW70 HOSE 96-9-98 transformed cell line human CVCL_UW70 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21160309 CVCL_V870 S004979 finite cell line CVCL_V870 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S004979; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160310 CVCL_UW71 HOSE 11-24-96 transformed cell line human CVCL_UW71 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21160311 CVCL_V871 S004988 transformed cell line CVCL_V871 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004988; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160312 CVCL_UW52 ABC-5 cancer cell line human CVCL_UW52 CL:0000010 Population: Japanese Unspecified Doubling time: 37.9 hours (PubMed=8286010). 21160313 CVCL_V852 S003654 transformed cell line CVCL_V852 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003654; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160314 CVCL_V853 S003656 transformed cell line CVCL_V853 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003656; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160315 CVCL_UW53 SBC-3/ADM100 cancer cell line human CVCL_UW53 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Male 21160316 CVCL_V850 S003650 transformed cell line CVCL_V850 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003650; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160317 CVCL_UW50 SBC-10 cancer cell line human CVCL_UW50 CL:0000010 Population: Japanese. Unspecified 21160318 CVCL_UW51 ABC-3 cancer cell line human CVCL_UW51 CL:0000010 Population: Japanese Unspecified Doubling time: 46.8 hours (PubMed=8286010). 21160319 CVCL_V851 S003651 finite cell line CVCL_V851 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003651; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160320 CVCL_UW56 MKN28-EGFP cancer cell line human CVCL_UW56 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from metastatic site: Liver. Male Problematic cell line: Contaminated Parent cell line (MKN28) has been shown to be a MKN74 derivative. 21160321 CVCL_V856 S003660 transformed cell line CVCL_V856 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003660; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160322 CVCL_UW57 MKN45-EGFP cancer cell line human CVCL_UW57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from metastatic site: Liver. Female 21160323 CVCL_V857 S004920 finite cell line CVCL_V857 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S004920; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160324 CVCL_UW54 p34 cancer cell line human CVCL_UW54 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 16 hours (PubMed=16141719) 21160325 CVCL_V854 S003657 transformed cell line CVCL_V854 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S003657; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160326 CVCL_UW55 GCIY-EGFP cancer cell line human CVCL_UW55 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Gln (c.537T>G); ClinVar=VCV000376607; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from metastatic site: Ascites. Female 21160327 CVCL_V855 S003659 transformed cell line CVCL_V855 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003659; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160328 CVCL_UW58 BG3C8 hybridoma house mouse CVCL_UW58 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human basal cells of stratified epithelia. 21160329 CVCL_V858 S004923 transformed cell line CVCL_V858 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004923; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160330 CVCL_UW59 KP8D4 hybridoma house mouse CVCL_UW59 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Macaca fuscata 84 kDa protein in basal cells of bronchial epithelia (Note=Also reacts with human and rabbit). 21160331 CVCL_V859 S004924 finite cell line CVCL_V859 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S004924; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160332 CVCL_2Q30 AG18928 somatic stem cell human CVCL_2Q30 CL:0000010 Derived from sampling site: Buttock; adipose tissue Cell type=Stromal cell.. Female 21160333 CVCL_3230 UCB408E7-32 transformed cell line human CVCL_3230 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Discontinued: JCRB; NIHS0413; true Male 21160334 CVCL_2Q22 AG11136 finite cell line human CVCL_2Q22 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160335 CVCL_3222 UBE6T-15 telomerase immortalized cell line human CVCL_3222 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0456; true; Discontinued: RCB; RCB2162; probable Female 21160336 CVCL_2Q23 AG11137 finite cell line human CVCL_2Q23 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160337 CVCL_3223 UBE6T-6 telomerase immortalized cell line human CVCL_3223 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0450; true; Discontinued: RCB; RCB2156; probable Female 21160338 CVCL_2Q20 AG11132 finite cell line human CVCL_2Q20 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160339 CVCL_3220 Ty-82 cancer cell line human CVCL_3220 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Genome sequenced Discontinued: JCRB; NIHS0541; true Female Doubling time: ~30 hours (lot 02152010), ~53 hours (lot 09082016) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160340 CVCL_2Q21 AG11134 finite cell line human CVCL_2Q21 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160341 CVCL_3221 TYK-nu.CP-r cancer cell line human CVCL_3221 HLA typing: A*02:01,26:03; B*35:08,58:05; C*03:03,07:02; DRB1*13:07,15:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female 21160342 CVCL_2Q26 AG17902 somatic stem cell human CVCL_2Q26 CL:0000010 Derived from sampling site: Arm; skin; adipose tissue Cell type=Stromal cell.. Female 21160343 CVCL_3226 UC702 finite cell line human CVCL_3226 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord. Discontinued: JCRB; NIHS0550; true Female 21160344 CVCL_2Q27 AG17907 somatic stem cell human CVCL_2Q27 CL:0000010 Derived from sampling site: Thigh; skin; adipose tissue Cell type=Stromal cell.. Female 21160345 CVCL_3227 UC704 finite cell line human CVCL_3227 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord. Discontinued: JCRB; NIHS0551; true Male 21160346 CVCL_2Q24 AG11138 finite cell line human CVCL_2Q24 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21160347 CVCL_3224 UBE6T-7 telomerase immortalized cell line human CVCL_3224 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Discontinued: JCRB; NIHS0451; true; Discontinued: RCB; RCB2157; probable Female 21160348 CVCL_2Q25 AG17870 somatic stem cell human CVCL_2Q25 CL:0000010 Derived from sampling site: Sacral area; skin; adipose tissue Cell type=Stromal cell.. Female 21160349 CVCL_3225 UC701 finite cell line human CVCL_3225 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord. Discontinued: JCRB; NIHS0549; true Male 21160350 CVCL_2Q28 AG17929 somatic stem cell human CVCL_2Q28 CL:0000010 Derived from sampling site: Abdomen; skin; adipose tissue Cell type=Stromal cell.. Female 21160351 CVCL_3228 UCB302MSCs somatic stem cell human CVCL_3228 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Discontinued: JCRB; NIHS0410; true Male 21160352 CVCL_2Q29 AG17930 somatic stem cell human CVCL_2Q29 CL:0000010 Derived from sampling site: Abdomen; skin; adipose tissue Cell type=Stromal cell.. Female 21160353 CVCL_3229 UCB408E6E7-31 transformed cell line human CVCL_3229 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Discontinued: JCRB; NIHS0412; true Male 21160354 CVCL_UW60 HFH18-15 cancer cell line house mouse CVCL_UW60 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Melanogenic 21160355 CVCL_V860 S004925 transformed cell line CVCL_V860 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S004925; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160356 CVCL_DD07 A10-2-4 spontaneously immortalized cell line CVCL_DD07 CL:0000010 Derived from sampling site: Ovary. Female 21160357 CVCL_DD05 HA-CHO clone 4J spontaneously immortalized cell line CVCL_DD05 CL:0000010 Transfected with: UniProtKB; P03451; Influenza A virus isolate A/Japan/305/1957 HA Derived from sampling site: Ovary. Female 21160358 CVCL_DD06 N211-1-8 spontaneously immortalized cell line CVCL_DD06 CL:0000010 Derived from sampling site: Ovary. Female 21160359 CVCL_DD09 CsR-1000 spontaneously immortalized cell line CVCL_DD09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27860; Castanospermine (Cs); Derived from sampling site: Ovary. Female 21160360 CVCL_DD00 CHO beta2(414)cl.32 spontaneously immortalized cell line CVCL_DD00 CL:0000010 Transfected with: HGNC; 11768; TGFB2 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10300 21160361 CVCL_DD03 HA-CHO spontaneously immortalized cell line CVCL_DD03 CL:0000010 Transfected with: UniProtKB; P03451; Influenza A virus isolate A/Japan/305/1957 HA Derived from sampling site: Ovary. Female 21160362 CVCL_DD04 HA-CHO clone 4B spontaneously immortalized cell line CVCL_DD04 CL:0000010 Transfected with: UniProtKB; P03451; Influenza A virus isolate A/Japan/305/1957 HA Derived from sampling site: Ovary. Female 21160363 CVCL_DD01 L-alpha-1c L-cells spontaneously immortalized cell line house mouse CVCL_DD01 CL:0000010 Transfected with: HGNC; 277; ADRA1A Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11140 21160364 CVCL_DD02 EA13.5 cancer cell line house mouse CVCL_DD02 CL:0000010 Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10934 21160365 CVCL_DD18 D(Mh11)1 hybrid cell line human CVCL_DD18 CL:0000010 Characteristics: Contains human chromosome 11. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11866 21160366 CVCL_DD19 CRIB-1 spontaneously immortalized cell line CVCL_DD19 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; SD-1831; probable Male Virology: Not susceptible to infection by bovine viral diarrhea virus (BVDV) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11883 21160367 CVCL_DD16 NS0bcl-2 cancer cell line house mouse CVCL_DD16 CL:0000010 Transfected with: HGNC; 990; BCL2 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11705 21160368 CVCL_DD17 NOV-31 finite cell line human CVCL_DD17 CL:0000010 Derived from sampling site: Ovary; epithelium. Omics: Transcriptome analysis by microarray Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11733 21160369 CVCL_DD10 SwR-100 spontaneously immortalized cell line CVCL_DD10 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9367; Swainsonine (Sw); Derived from sampling site: Ovary. Female 21160370 CVCL_DD11 PIR-P3 spontaneously immortalized cell line CVCL_DD11 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9367; Swainsonine (Sw); Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11378 21160371 CVCL_DD14 293LAP10 transformed cell line human CVCL_DD14 CL:0000010 Transfected with: UniProtKB; P03023; Escherichia coli lacI (modified version LAP348 with at the N-terminal a nuclear localization signal from SV40 T antigen and at the C-terminal the transactivator domain from HSV-1 VP16/Vmw65) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12586 21160372 CVCL_DD15 293LAP13 transformed cell line human CVCL_DD15 CL:0000010 Transfected with: UniProtKB; P03023; Escherichia coli lacI (modified version LAP348 with at the N-terminal a nuclear localization signal from SV40 T antigen and at the C-terminal the transactivator domain from HSV-1 VP16/Vmw65) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12587 21160373 CVCL_DD12 Lec9 spontaneously immortalized cell line CVCL_DD12 CL:0000010 Derived from sampling site: Ovary. Female 21160374 CVCL_DD13 BG1LucERbc9 cancer cell line human CVCL_DD13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3468; ESR2; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Developed to be used for identifying estrogen receptor agonists and antagonists; Characteristics: Acts through the activation of a luciferase reporter gene under the control of estrogen response elements (EREs) upstream of the mouse mammary tumor viral (MMTV) promoter Problematic cell line: Contaminated Parent cell line (VM7Luc4E2) shown to be a MCF-7 derivative. 21160375 CVCL_2P98 AU10167 transformed cell line human CVCL_2P98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160376 CVCL_3198 TIG-113 finite cell line human CVCL_3198 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 1.7 days (lot 04162008), ~41 hours (lot 01282013), ~45 hours (lot 11082018) (JCRB) 21160377 CVCL_2P99 AU10168 transformed cell line human CVCL_2P99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160378 CVCL_3199 TIG-114 finite cell line human CVCL_3199 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS0207; true Male Doubling time: 2.5-3.6 days (lot 12012010), ~56 hours (lot 10112012) (JCRB) 21160379 CVCL_2P81 AU10150 transformed cell line human CVCL_2P81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160380 CVCL_3181 TIG-1-20 finite cell line human CVCL_3181 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: RCB; RCB1983; true Female Senescence: Senesces at 67 PDL (JCRB=JCRB0501); Doubling time: ~1.5 days (lots 01202006 and 08172010), 32 hours (lot 01302008), ~21 hours (lot 01132009), ~1 day (lots 06142016, 05302017 and 07092018) (JCRB) 21160381 CVCL_2P82 AU10151 transformed cell line human CVCL_2P82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160382 CVCL_3182 TIG-1-30 finite cell line human CVCL_3182 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~1.5 days (lot 02072006) (JCRB) 21160383 CVCL_2P80 AU10149 transformed cell line human CVCL_2P80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160384 CVCL_3180 TGW.P3 cancer cell line human CVCL_3180 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Discontinued: JCRB; NIHS0371; true Male Group: Serum/protein free medium cell line 21160385 CVCL_2P85 AU10154 transformed cell line human CVCL_2P85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160386 CVCL_3185 TIG-1-60 finite cell line human CVCL_3185 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~4 days (lot 04102006), ~38 hours (lot 05262015) (JCRB) 21160387 CVCL_2P86 AU10155 transformed cell line human CVCL_2P86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160388 CVCL_3186 TIG-101 finite cell line human CVCL_3186 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~3-4 days (lot 06042007) (JCRB) 21160389 CVCL_2P83 AU10152 transformed cell line human CVCL_2P83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160390 CVCL_3183 TIG-1-40 finite cell line human CVCL_3183 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~1.9 days (lot 02172006), ~33 hours (lot 02062015) (JCRB) 21160391 CVCL_2P84 AU10153 transformed cell line human CVCL_2P84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160392 CVCL_3184 TIG-1-50 finite cell line human CVCL_3184 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Doubling time: ~1.5 days (lot 03082006), ~26 hours (lot 08222018) (JCRB) 21160393 CVCL_2P78 AU10147 transformed cell line human CVCL_2P78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160394 CVCL_3178 TCC-Pan2 cancer cell line human CVCL_3178 HLA typing: A*11:01,24:02; B*52:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=1.68%; Native American=0%; East Asian, North=89.24%; East Asian, South=5.56%; South Asian=0%; European, North=0%; European, South=3.52% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=30747829); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=30747829; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>A (IVS9+1G>A); ClinVar=VCV000528261; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30747829; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~26 hours (PubMed=30747829) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21160395 CVCL_2P79 AU10148 transformed cell line human CVCL_2P79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160396 CVCL_3179 TCO-1 [Human cervical carcinoma] cancer cell line human CVCL_3179 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Discontinued: RCB; RCB0640; true Female Doubling time: 48 hours (PubMed=1607768) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00272 Problematic cell line: Contaminated Shown to be a TCS derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from a 34 year old patient with an uterine cervical adenocarcinoma. 21160397 CVCL_2P76 AU10145 transformed cell line human CVCL_2P76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160398 CVCL_3176 Takigawa cancer cell line human CVCL_3176 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0182; true Male Characteristics: Produces high level of AFP Doubling time: 152 hours, at 58th passage (PubMed=8574330); ~2 weeks (lot 09022004), ~10 days (lot 06282011) (JCRB) 21160399 CVCL_2P77 AU10146 transformed cell line human CVCL_2P77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160400 CVCL_3177 TASK1 cancer cell line human CVCL_3177 Genome ancestry: African=1.94%; Native American=0.97%; East Asian, North=86.4%; East Asian, South=7.58%; South Asian=0.24%; European, North=0%; European, South=2.87% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=9661044) Population: Japanese; Derived from sampling site: Chest wall. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; NIHS0202; true Female Doubling time: 38 hours (PubMed=9661044); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21160401 CVCL_2P92 AU10161 transformed cell line human CVCL_2P92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160402 CVCL_3192 TIG-107 finite cell line human CVCL_3192 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 45 hours (lot 01182008), 29-63 hours (lot 11202015) (JCRB) 21160403 CVCL_2P93 AU10162 transformed cell line human CVCL_2P93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160404 CVCL_3193 TIG-108 finite cell line human CVCL_3193 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~51 hours (lot 10122010), ~31 hours (lot 10262015) (JCRB) 21160405 CVCL_2P90 AU10159 transformed cell line human CVCL_2P90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160406 CVCL_3190 TIG-105 finite cell line human CVCL_3190 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160407 CVCL_2P91 AU10160 transformed cell line human CVCL_2P91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160408 CVCL_3191 TIG-106 finite cell line human CVCL_3191 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160409 CVCL_2P96 AU10165 transformed cell line human CVCL_2P96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160410 CVCL_3196 TIG-111 finite cell line human CVCL_3196 CL:0000010 Population: Japanese; Derived from sampling site: Skin. Female Doubling time: ~31 hours (lot 08152014) (JCRB) 21160411 CVCL_2P97 AU10166 transformed cell line human CVCL_2P97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160412 CVCL_3197 TIG-112 finite cell line human CVCL_3197 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~58 hours (lot 08302010) (JCRB) 21160413 CVCL_2P94 AU10163 transformed cell line human CVCL_2P94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160414 CVCL_3194 TIG-109 finite cell line human CVCL_3194 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~42 hours (lot 02122010) (JCRB) 21160415 CVCL_2P95 AU10164 transformed cell line human CVCL_2P95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Autism Research Resource 21160416 CVCL_3195 TIG-110 finite cell line human CVCL_3195 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~45 hours (lot 12032015) (JCRB) 21160417 CVCL_2P89 AU10158 transformed cell line human CVCL_2P89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160418 CVCL_3189 TIG-104 finite cell line human CVCL_3189 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: Indicated to be from a female donor in PubMed=7556460 21160419 CVCL_2P87 AU10156 transformed cell line human CVCL_2P87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160420 CVCL_3187 TIG-102 finite cell line human CVCL_3187 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~70 hours (lot 05232007) (JCRB) 21160421 CVCL_2P88 AU10157 transformed cell line human CVCL_2P88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Autism Research Resource 21160422 CVCL_3188 TIG-103 finite cell line human CVCL_3188 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: ~2.6 days (lot 06262006) (JCRB) 21160423 CVCL_DD90 Hu44 hybridoma human CVCL_DD90 CL:0000010 Monoclonal antibody isotype: IgA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8576 21160424 CVCL_DD91 Ev248 hybridoma CVCL_DD91 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8565 21160425 CVCL_DD94 31BY4-1 transformed cell line Norway rat CVCL_DD94 CL:0000010 Transformant: Adenovirus 31 [BamHI-B fragment](NCBI-Taxonomy; 10529); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21160426 CVCL_DD95 31GY1-2 transformed cell line Norway rat CVCL_DD95 CL:0000010 Transformant: Adenovirus 31 [HindIII-G fragment](NCBI-Taxonomy; 10529); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21160427 CVCL_DD92 Ge1 hybridoma human CVCL_DD92 CL:0000010 Monoclonal antibody isotype: IgA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8574 21160428 CVCL_DD93 ROHA-9MC3 transformed cell line human CVCL_DD93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21160429 CVCL_DD87 GM11705 finite cell line human CVCL_DD87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160430 CVCL_DD88 GM11816 finite cell line human CVCL_DD88 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160431 CVCL_DD85 GM10625 finite cell line human CVCL_DD85 CL:0000010 Population: Jewish; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21160432 CVCL_DD86 GM11677 finite cell line human CVCL_DD86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160433 CVCL_DD89 Ch5 hybridoma CVCL_DD89 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8572 21160434 CVCL_DD98 Raji-TG cancer cell line human CVCL_DD98 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21160435 CVCL_DD99 1R [Mouse L cells] spontaneously immortalized cell line house mouse CVCL_DD99 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21160436 CVCL_DD96 31GY2-5 transformed cell line Norway rat CVCL_DD96 CL:0000010 Transformant: Adenovirus 31 [HindIII-G fragment](NCBI-Taxonomy; 10529); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21160437 CVCL_DD97 31GY3-4 transformed cell line Norway rat CVCL_DD97 CL:0000010 Transformant: Adenovirus 31 [HindIII-G fragment](NCBI-Taxonomy; 10529); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21160438 CVCL_DD72 GM02695 finite cell line human CVCL_DD72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160439 CVCL_DD73 GM02962 finite cell line human CVCL_DD73 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160440 CVCL_DD70 GM02573 finite cell line human CVCL_DD70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160441 CVCL_DD71 GM02645 finite cell line human CVCL_DD71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160442 CVCL_DD65 GM00744 finite cell line human CVCL_DD65 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160443 CVCL_DD66 GM01093 finite cell line human CVCL_DD66 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160444 CVCL_DD63 K25-iPSC induced pluripotent stem cell human CVCL_DD63 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160445 CVCL_DD64 A23-iPSC induced pluripotent stem cell human CVCL_DD64 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21160446 CVCL_DD69 GM02328 finite cell line human CVCL_DD69 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160447 CVCL_DD67 GM01436 finite cell line human CVCL_DD67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160448 CVCL_DD68 GM01789 finite cell line human CVCL_DD68 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160449 CVCL_DD80 GM05747 finite cell line human CVCL_DD80 CL:0000010 Population: Colombian; Derived from sampling site: Cell type=Fibroblast. Male 21160450 CVCL_DD83 GM10503 finite cell line human CVCL_DD83 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly997Asp (c.2990G>A); Zygosity=Heterozygous (PubMed=2914942) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160451 CVCL_DD84 GM10624 transformed cell line human CVCL_DD84 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160452 CVCL_DD81 GM06260 finite cell line human CVCL_DD81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160453 CVCL_DD82 GM08781 finite cell line human CVCL_DD82 CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Gly869Cys (c.2605G>T); ClinVar=VCV00001729; Zygosity=Heterozygous (PubMed=1953667) Population: Caucasian; Swiss; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 21160454 CVCL_DD76 GM03858 finite cell line human CVCL_DD76 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Male 21160455 CVCL_DD77 GM04178 finite cell line human CVCL_DD77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160456 CVCL_DD74 GM03138 finite cell line human CVCL_DD74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160457 CVCL_DD75 GM03857 transformed cell line human CVCL_DD75 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160458 CVCL_DD78 GM05181 finite cell line human CVCL_DD78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21160459 CVCL_DD79 GM05182 finite cell line human CVCL_DD79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21160460 CVCL_DD50 ND29802 finite cell line human CVCL_DD50 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29802; true Male 21160461 CVCL_DD51 ND29492 finite cell line human CVCL_DD51 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29492; true Male 21160462 CVCL_DD49 ND31618 finite cell line human CVCL_DD49 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31618; true Female 21160463 CVCL_DD43 JK-T1 cancer cell line human CVCL_DD43 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=T-cell.. Male Doubling time: ~36 hours (PubMed=1333881) 21160464 CVCL_DD44 LB2033-MEL cancer cell line human CVCL_DD44 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21160465 CVCL_DD41 37S2.8 transformed cell line human CVCL_DD41 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11971 21160466 CVCL_DD42 RPMI-M7021 cancer cell line human CVCL_DD42 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Female 21160467 CVCL_DD47 ND30171 finite cell line human CVCL_DD47 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (PubMed=25843045); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (PubMed=25843045) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30171; true Male 21160468 CVCL_DD48 ND29369 finite cell line human CVCL_DD48 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=22952635) Population: Latino or Hispanic; Dominican; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29369; true Female 21160469 CVCL_DD45 LB583-MEL cancer cell line human CVCL_DD45 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21160470 CVCL_DD46 C2.7 spontaneously immortalized cell line house mouse CVCL_DD46 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21160471 CVCL_DD61 T101-iPSC induced pluripotent stem cell human CVCL_DD61 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160472 CVCL_DD62 K20-iPSC induced pluripotent stem cell human CVCL_DD62 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160473 CVCL_DD60 I3-iPSC induced pluripotent stem cell human CVCL_DD60 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Asn52Metfs*29 (c.155delA) (255delA); ClinVar=VCV000536457; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160474 CVCL_DD54 ND29756 finite cell line human CVCL_DD54 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29756; probable Female 21160475 CVCL_DD55 ND34791 finite cell line human CVCL_DD55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34791; probable Female 21160476 CVCL_DD52 ND29542 finite cell line human CVCL_DD52 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29542; probable Male 21160477 CVCL_DD53 ND31630 finite cell line human CVCL_DD53 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31630; probable; Discontinued: NHCDR; ND31630; true Male 21160478 CVCL_DD58 S110-iPSC induced pluripotent stem cell human CVCL_DD58 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (PubMed=25843045) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160479 CVCL_DD59 A6-iPSC induced pluripotent stem cell human CVCL_DD59 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21160480 CVCL_DD56 Y9-iPSC induced pluripotent stem cell human CVCL_DD56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160481 CVCL_DD57 P1-iPSC induced pluripotent stem cell human CVCL_DD57 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (PubMed=25843045); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (PubMed=25843045) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160482 CVCL_DD29 ES5.2D8 hybridoma house mouse CVCL_DD29 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21926; Human CD9. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11374 21160483 CVCL_DD27 ER5.3D8 hybridoma house mouse CVCL_DD27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11641 21160484 CVCL_DD28 ER5.4D3 hybridoma house mouse CVCL_DD28 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11645 21160485 CVCL_DD21 MDBK clone 958-9 spontaneously immortalized cell line CVCL_DD21 CL:0000010 Derived from sampling site: Kidney. Male 21160486 CVCL_DD22 BHH2C hybrid cell line human CVCL_DD22 CL:0000010 21160487 CVCL_DD20 MDBK clone 955-1 spontaneously immortalized cell line CVCL_DD20 CL:0000010 Derived from sampling site: Kidney. Male 21160488 CVCL_DD25 M2B spontaneously immortalized cell line CVCL_DD25 CL:0000010 Transfected with: VGNC; 33356; Bovine PRNP Derived from sampling site: Kidney. Male Characteristics: Persistently infected with proteinase K resistant BSE (PrP(BSE)) 21160489 CVCL_DD26 BC8 [Mouse myeloma against human PTPRC] hybridoma house mouse CVCL_DD26 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10507 21160490 CVCL_DD23 BHH3 hybrid cell line human CVCL_DD23 CL:0000010 21160491 CVCL_DD24 BHH8 hybrid cell line human CVCL_DD24 CL:0000010 21160492 CVCL_DD40 35.32 transformed cell line human CVCL_DD40 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11972 21160493 CVCL_DD38 BTI-Tn-4A14 spontaneously immortalized cell line CVCL_DD38 CL:0000010 Unspecified Doubling time: 20 hours (DOI=10.1006/jipa.1997.4701). Group: Insect cell line; Group: Serum/protein free medium cell line 21160494 CVCL_DD39 BTI-Tn-4A22 spontaneously immortalized cell line CVCL_DD39 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21160495 CVCL_DD32 EX5.3D10 hybridoma house mouse CVCL_DD32 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10747; Human CD28. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11373 21160496 CVCL_DD33 BTI-Tn-4B spontaneously immortalized cell line CVCL_DD33 CL:0000010 Unspecified Doubling time: 28 hours (DOI=10.1006/jipa.1997.4701). Group: Insect cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11970 21160497 CVCL_DD30 ES5.3D6 hybridoma house mouse CVCL_DD30 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11644 21160498 CVCL_DD31 ES5.4E3 hybridoma house mouse CVCL_DD31 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11643 21160499 CVCL_DD36 BTI-Tn-4B44 spontaneously immortalized cell line CVCL_DD36 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21160500 CVCL_DD37 BTI-Tn-4A2 spontaneously immortalized cell line CVCL_DD37 CL:0000010 Unspecified Group: Insect cell line. 21160501 CVCL_DD34 BTI-Tn4-B31 spontaneously immortalized cell line CVCL_DD34 CL:0000010 Unspecified Doubling time: 26 hours (DOI=10.1006/jipa.1997.4701). Group: Insect cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11969 21160502 CVCL_DD35 BTI-Tn-4B42 spontaneously immortalized cell line CVCL_DD35 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21160503 CVCL_UX62 AG26783 transformed cell line human CVCL_UX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160504 CVCL_V962 S008919 finite cell line CVCL_V962 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008919; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160505 CVCL_UX63 AG26787 transformed cell line human CVCL_UX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160506 CVCL_V963 S008920 finite cell line CVCL_V963 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008920; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160507 CVCL_UX60 AG26779 transformed cell line human CVCL_UX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160508 CVCL_V960 S008894 finite cell line CVCL_V960 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008894; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160509 CVCL_UX61 AG26781 transformed cell line human CVCL_UX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160510 CVCL_V961 S008895 transformed cell line CVCL_V961 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008895; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160511 CVCL_UX66 AG26791 transformed cell line human CVCL_UX66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160512 CVCL_V966 S008939 transformed cell line CVCL_V966 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008939; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160513 CVCL_UX67 AG26805 transformed cell line human CVCL_UX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160514 CVCL_V967 S008956 finite cell line CVCL_V967 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008956; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160515 CVCL_UX64 AG26789 transformed cell line human CVCL_UX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160516 CVCL_V964 S008933 finite cell line CVCL_V964 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008933; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160517 CVCL_UX65 AG26790 transformed cell line human CVCL_UX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160518 CVCL_V965 S008938 finite cell line CVCL_V965 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008938; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160519 CVCL_UX68 AG26809 transformed cell line human CVCL_UX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160520 CVCL_V968 S008973 finite cell line CVCL_V968 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008973; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160521 CVCL_UX69 AG26812 transformed cell line human CVCL_UX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160522 CVCL_V969 S008974 transformed cell line CVCL_V969 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008974; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160523 CVCL_2R10 AG18216 transformed cell line human CVCL_2R10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160524 CVCL_3310 FoLu finite cell line CVCL_3310 CL:0000010 Derived from sampling site: Lung. Female 21160525 CVCL_2R11 AG18217 transformed cell line human CVCL_2R11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160526 CVCL_3311 Gam Per finite cell line human CVCL_3311 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160527 CVCL_2R14 AG18220 transformed cell line human CVCL_2R14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160528 CVCL_3314 Go Je finite cell line human CVCL_3314 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160529 CVCL_2R15 AG18221 transformed cell line human CVCL_2R15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160530 CVCL_3315 HaK spontaneously immortalized cell line CVCL_3315 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-42 (Spacelab IML-1) to study growth and metabolism in microgravity (PubMed=11541489) Derived from sampling site: Kidney. Male Group: Space-flown cell line (cellonaut) 21160531 CVCL_2R12 AG18218 transformed cell line human CVCL_2R12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160532 CVCL_3312 Gap Per finite cell line human CVCL_3312 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160533 CVCL_2R13 AG18219 transformed cell line human CVCL_2R13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160534 CVCL_3313 GeLu finite cell line CVCL_3313 CL:0000010 Derived from sampling site: Lung. Discontinued: ECACC; 90102534; probable Female 21160535 CVCL_2R18 AG18224 transformed cell line human CVCL_2R18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160536 CVCL_3318 HX cancer cell line human CVCL_3318 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12011 21160537 CVCL_2R19 AG18225 transformed cell line human CVCL_2R19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160538 CVCL_3319 Jay Sen finite cell line human CVCL_3319 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160539 CVCL_2R16 AG18222 transformed cell line human CVCL_2R16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160540 CVCL_3316 HCE-2 transformed cell line human CVCL_3316 CL:0000010 Population: African American; Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Eye; cornea; epithelium. Male Doubling time: ~30 hours (ATCC=CRL-11135) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11135 21160541 CVCL_2R17 AG18223 transformed cell line human CVCL_2R17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160542 CVCL_3317 HMCB cancer cell line human CVCL_3317 HLA typing: A*02:01,02:01; B*07:02,57:01; C*06:02,07:02 (PubMed=26589293); Genome ancestry: African=0.21%; Native American=0%; East Asian, North=1.87%; East Asian, South=0%; South Asian=0%; European, North=63.92%; European, South=33.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (DepMap) Anecdotal: The Bowes cell line is famous for its use in the identification and purification of tissue-type plasminogen activator (tPA) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9607 Caution: The exact relationship between HMCB (Cellosaurus=CVCL_3317) and RPMI-7262/7272/7932/7962/7972 is not clear: all are derived from patient 'Bowes' melanoma. 21160543 CVCL_UX70 AG26813 transformed cell line human CVCL_UX70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160544 CVCL_V970 S008975 finite cell line CVCL_V970 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008975; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160545 CVCL_UX51 AG26687 transformed cell line human CVCL_UX51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160546 CVCL_V951 S008885 transformed cell line CVCL_V951 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008885; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160547 CVCL_UX52 AG26701 transformed cell line human CVCL_UX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160548 CVCL_V952 S008886 finite cell line CVCL_V952 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008886; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160549 CVCL_UX50 AG26684 transformed cell line human CVCL_UX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160550 CVCL_V950 S008883 finite cell line CVCL_V950 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008883; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160551 CVCL_UX55 AG26712 transformed cell line human CVCL_UX55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160552 CVCL_V955 S008889 transformed cell line CVCL_V955 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008889; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160553 CVCL_UX56 AG26733 transformed cell line human CVCL_UX56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160554 CVCL_V956 S008890 finite cell line CVCL_V956 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008890; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160555 CVCL_UX53 AG26702 transformed cell line human CVCL_UX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160556 CVCL_V953 S008887 finite cell line CVCL_V953 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008887; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160557 CVCL_UX54 AG26710 transformed cell line human CVCL_UX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160558 CVCL_V954 S008888 finite cell line CVCL_V954 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008888; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160559 CVCL_UX59 AG26769 transformed cell line human CVCL_UX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160560 CVCL_V959 S008893 transformed cell line CVCL_V959 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008893; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160561 CVCL_UX57 AG26747 transformed cell line human CVCL_UX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160562 CVCL_V957 S008891 transformed cell line CVCL_V957 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008891; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160563 CVCL_UX58 AG26766 transformed cell line human CVCL_UX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160564 CVCL_V958 S008892 finite cell line CVCL_V958 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008892; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160565 CVCL_2R21 AG18227 transformed cell line human CVCL_2R21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160566 CVCL_3321 No Per finite cell line human CVCL_3321 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160567 CVCL_2R22 AG18228 transformed cell line human CVCL_2R22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160568 CVCL_3322 Or De finite cell line human CVCL_3322 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160569 CVCL_2R20 AG18226 transformed cell line human CVCL_2R20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160570 CVCL_3320 Jo Per finite cell line human CVCL_3320 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160571 CVCL_2R25 AG18232 transformed cell line human CVCL_2R25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160572 CVCL_3325 Pa Kel-2 finite cell line human CVCL_3325 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160573 CVCL_2R26 AG18233 transformed cell line human CVCL_2R26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160574 CVCL_3326 Pfeiffer cancer cell line human CVCL_3326 HLA typing: A*01:01,33:01; B*14:02,57:01; C*06:02,08:02; DQA1*01:01,05:01; DQB1*03:01,05:01; DRB1*01:02,13:05 (PubMed=26589293); Genome ancestry: African=1.72%; Native American=0.65%; East Asian, North=0%; East Asian, South=2.24%; South Asian=9.82%; European, North=22.11%; European, South=63.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1171Cys (c.3511C>T); ClinVar=VCV000133518; Zygosity=Heterozygous (DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Doubling time: 24-30 hours (ATCC=CRL-2632) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21160575 CVCL_2R23 AG18229 transformed cell line human CVCL_2R23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160576 CVCL_3323 Os Te finite cell line human CVCL_3323 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160577 CVCL_2R24 AG18230 transformed cell line human CVCL_2R24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160578 CVCL_3324 Pa Kel-1 finite cell line human CVCL_3324 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160579 CVCL_2R29 AG18236 transformed cell line human CVCL_2R29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160580 CVCL_3329 Be Ar finite cell line human CVCL_3329 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Heterozygous (from familial inference of XP8BE and XP9BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160581 CVCL_2R27 AG18234 transformed cell line human CVCL_2R27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160582 CVCL_3327 Per Sel finite cell line human CVCL_3327 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160583 CVCL_2R28 AG18235 transformed cell line human CVCL_2R28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160584 CVCL_3328 Tu To finite cell line human CVCL_3328 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160585 CVCL_UX40 NH50162 induced pluripotent stem cell human CVCL_UX40 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160586 CVCL_V940 S008397 finite cell line CVCL_V940 CL:0000010 Anecdotal: Established from Clint, the 'reference' genome chimpanzee Derived from sampling site: Cell type=Endothelial cell. Discontinued: Coriell; S008397; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160587 CVCL_UX41 NH50163 induced pluripotent stem cell human CVCL_UX41 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160588 CVCL_V941 S008829 finite cell line CVCL_V941 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008829; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160589 CVCL_UX44 NH50185 induced pluripotent stem cell human CVCL_UX44 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160590 CVCL_V944 S008844 finite cell line CVCL_V944 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008844; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160591 CVCL_UX45 NH50191 induced pluripotent stem cell human CVCL_UX45 CL:0000010 Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male 21160592 CVCL_V945 S008860 transformed cell line CVCL_V945 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008860; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160593 CVCL_UX42 NH50164 induced pluripotent stem cell human CVCL_UX42 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. 21160594 CVCL_V942 S008842 finite cell line CVCL_V942 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008842; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160595 CVCL_UX43 NH50184 induced pluripotent stem cell human CVCL_UX43 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160596 CVCL_V943 S008843 finite cell line CVCL_V943 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008843; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160597 CVCL_UX48 AG26671 transformed cell line human CVCL_UX48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160598 CVCL_V948 S008869 finite cell line CVCL_V948 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008869; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160599 CVCL_UX49 AG26672 transformed cell line human CVCL_UX49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160600 CVCL_V949 S008882 transformed cell line CVCL_V949 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008882; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160601 CVCL_UX46 NH50109 induced pluripotent stem cell human CVCL_UX46 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (NHCDR) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Discontinued: NHCDR; NH50109; true Unspecified 21160602 CVCL_V946 S008861 finite cell line CVCL_V946 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S008861; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160603 CVCL_UX47 AG27221 induced pluripotent stem cell human CVCL_UX47 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21160604 CVCL_V947 S008868 transformed cell line CVCL_V947 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008868; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160605 CVCL_UX30 NH50152 finite cell line human CVCL_UX30 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160606 CVCL_V930 S005825 transformed cell line CVCL_V930 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005825; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160607 CVCL_UX33 NH50155 induced pluripotent stem cell human CVCL_UX33 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[238] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160608 CVCL_V933 S006006 transformed cell line CVCL_V933 CL:0000010 Anecdotal: Established from Clint, the 'reference' genome chimpanzee Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome; Omics: Transcriptome analysis by microarray Discontinued: Coriell; S006006; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160609 CVCL_UX34 NH50156 induced pluripotent stem cell human CVCL_UX34 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160610 CVCL_V934 S006007 finite cell line CVCL_V934 CL:0000010 Anecdotal: Established from Clint, the 'reference' genome chimpanzee Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S006007; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160611 CVCL_UX31 NH50153 induced pluripotent stem cell human CVCL_UX31 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[238] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160612 CVCL_V931 S005837 transformed cell line CVCL_V931 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005837; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160613 CVCL_UX32 NH50154 induced pluripotent stem cell human CVCL_UX32 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[238] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160614 CVCL_V932 S006003 transformed cell line CVCL_V932 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S006003; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160615 CVCL_UX37 NH50159 induced pluripotent stem cell human CVCL_UX37 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160616 CVCL_V937 S007603 finite cell line CVCL_V937 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S007603; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160617 CVCL_UX38 NH50160 induced pluripotent stem cell human CVCL_UX38 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160618 CVCL_V938 S008395 finite cell line CVCL_V938 CL:0000010 Anecdotal: Established from Clint, the 'reference' genome chimpanzee Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Discontinued: Coriell; S008395; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160619 CVCL_UX35 NH50157 induced pluripotent stem cell human CVCL_UX35 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160620 CVCL_V935 S006008 transformed cell line CVCL_V935 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S006008; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160621 CVCL_UX36 NH50158 induced pluripotent stem cell human CVCL_UX36 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160622 CVCL_V936 S007602 transformed cell line CVCL_V936 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S007602; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160623 CVCL_UX39 NH50161 induced pluripotent stem cell human CVCL_UX39 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160624 CVCL_V939 S008396 somatic stem cell CVCL_V939 CL:0000010 Anecdotal: Established from Clint, the 'reference' genome chimpanzee Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S008396; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160625 CVCL_2R00 AG18201 transformed cell line human CVCL_2R00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160626 CVCL_3300 CCD-1106 KERTr transformed cell line human CVCL_3300 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21160627 CVCL_2R03 AG18208 transformed cell line human CVCL_2R03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160628 CVCL_3303 Fe Bos finite cell line human CVCL_3303 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160629 CVCL_2R04 AG18209 transformed cell line human CVCL_2R04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160630 CVCL_3304 Ja Bos finite cell line human CVCL_3304 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160631 CVCL_2R01 AG18202 transformed cell line human CVCL_2R01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160632 CVCL_3301 Citrullinemia finite cell line human CVCL_3301 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00063; probable; Discontinued: ECACC; 90102532; probable Female 21160633 CVCL_2R02 AG18203 transformed cell line human CVCL_2R02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160634 CVCL_3302 Farage cancer cell line human CVCL_3302 HLA typing: A*03:01,24:02; B*14:02,51:01; C*08:02,16:02 (PubMed=26589293); Genome ancestry: African=2.2%; Native American=0%; East Asian, North=0%; East Asian, South=1.9%; South Asian=11.86%; European, North=23.94%; European, South=60.11% (PubMed=30894373) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (DOI=10.3109/10428199209053591); Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21160635 CVCL_2R07 AG18212 transformed cell line human CVCL_2R07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160636 CVCL_3307 Am Ric finite cell line human CVCL_3307 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160637 CVCL_2R08 AG18213 transformed cell line human CVCL_2R08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160638 CVCL_3308 FHs 173We finite cell line human CVCL_3308 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Male 21160639 CVCL_2R05 AG18210 transformed cell line human CVCL_2R05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160640 CVCL_3305 Ja Coo finite cell line human CVCL_3305 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160641 CVCL_2R06 AG18211 transformed cell line human CVCL_2R06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160642 CVCL_3306 Am Coo finite cell line human CVCL_3306 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160643 CVCL_2R09 AG18215 transformed cell line human CVCL_2R09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160644 CVCL_3309 FHs 738Lu finite cell line human CVCL_3309 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21160645 CVCL_UX22 NH50114 induced pluripotent stem cell human CVCL_UX22 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160646 CVCL_V922 S005796 transformed cell line CVCL_V922 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005796; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160647 CVCL_UX23 NH50116 induced pluripotent stem cell human CVCL_UX23 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160648 CVCL_V923 S005801 transformed cell line CVCL_V923 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005801; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160649 CVCL_UX20 NH50112 induced pluripotent stem cell human CVCL_UX20 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160650 CVCL_V920 S005794 transformed cell line CVCL_V920 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005794; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160651 CVCL_UX21 NH50113 induced pluripotent stem cell human CVCL_UX21 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160652 CVCL_V921 S005795 finite cell line CVCL_V921 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S005795; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160653 CVCL_UX26 NH50148 finite cell line human CVCL_UX26 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160654 CVCL_V926 S005804 transformed cell line CVCL_V926 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005804; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160655 CVCL_UX27 NH50149 finite cell line human CVCL_UX27 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160656 CVCL_V927 S005807 transformed cell line CVCL_V927 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005807; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160657 CVCL_UX24 NH50117 induced pluripotent stem cell human CVCL_UX24 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160658 CVCL_V924 S005802 transformed cell line CVCL_V924 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005802; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160659 CVCL_UX25 NH50118 induced pluripotent stem cell human CVCL_UX25 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160660 CVCL_V925 S005803 transformed cell line CVCL_V925 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005803; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160661 CVCL_UX28 NH50150 finite cell line human CVCL_UX28 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21160662 CVCL_V928 S005823 transformed cell line CVCL_V928 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005823; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160663 CVCL_UX29 NH50151 finite cell line human CVCL_UX29 CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160664 CVCL_V929 S005824 transformed cell line CVCL_V929 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005824; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160665 CVCL_UX11 NH50168 induced pluripotent stem cell human CVCL_UX11 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Asn (c.914G>A) (S622N, c.1865G>A or S640N, c.1919G>A); ClinVar=VCV000014254; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160666 CVCL_V911 S005435 transformed cell line CVCL_V911 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005435; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160667 CVCL_UX12 NH50169 induced pluripotent stem cell human CVCL_UX12 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Asn (c.914G>A) (S622N, c.1865G>A or S640N, c.1919G>A); ClinVar=VCV000014254; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160668 CVCL_V912 S005436 transformed cell line CVCL_V912 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005436; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160669 CVCL_UX10 NH50173 induced pluripotent stem cell human CVCL_UX10 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160670 CVCL_V910 S005424 transformed cell line CVCL_V910 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005424; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160671 CVCL_UX15 NH50166 induced pluripotent stem cell human CVCL_UX15 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Ile (c.914G>T) (S622I, c.1865G>T or S640I, c.1919G>T); Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160672 CVCL_V915 S005549 transformed cell line CVCL_V915 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005549; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160673 CVCL_UX16 NH50167 induced pluripotent stem cell human CVCL_UX16 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Ile (c.914G>T) (S622I, c.1865G>T or S640I, c.1919G>T); Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160674 CVCL_V916 S005551 transformed cell line CVCL_V916 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005551; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160675 CVCL_UX13 NH50170 induced pluripotent stem cell human CVCL_UX13 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Asn (c.914G>A) (S622N, c.1865G>A or S640N, c.1919G>A); ClinVar=VCV000014254; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160676 CVCL_V913 S005438 transformed cell line CVCL_V913 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005438; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160677 CVCL_UX14 NH50115 induced pluripotent stem cell human CVCL_UX14 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Ser305Ile (c.914G>T) (S622I, c.1865G>T or S640I, c.1919G>T); Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160678 CVCL_V914 S005440 transformed cell line CVCL_V914 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005440; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160679 CVCL_UX19 NH50165 induced pluripotent stem cell human CVCL_UX19 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Gly389Arg (c.1165G>A) (G706R, c.2116G>A); ClinVar=VCV000014255; Zygosity=Unspecified (NHCDR) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160680 CVCL_V919 S005583 transformed cell line CVCL_V919 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005583; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160681 CVCL_UX17 NH50110 induced pluripotent stem cell human CVCL_UX17 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Gly389Arg (c.1165G>A) (G706R, c.2116G>A); ClinVar=VCV000014255; Zygosity=Unspecified (NHCDR) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160682 CVCL_V917 S005579 transformed cell line CVCL_V917 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005579; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160683 CVCL_UX18 NH50111 induced pluripotent stem cell human CVCL_UX18 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Gly389Arg (c.1165G>A) (G706R, c.2116G>A); ClinVar=VCV000014255; Zygosity=Unspecified (NHCDR) Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160684 CVCL_V918 S005581 transformed cell line CVCL_V918 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005581; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160685 CVCL_UX00 NH50178 induced pluripotent stem cell human CVCL_UX00 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160686 CVCL_V900 S005237 transformed cell line CVCL_V900 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005237; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160687 CVCL_UX01 NH50179 induced pluripotent stem cell human CVCL_UX01 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160688 CVCL_V901 S005239 transformed cell line CVCL_V901 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005239; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160689 CVCL_UX04 NH50177 induced pluripotent stem cell human CVCL_UX04 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160690 CVCL_V904 S005295 transformed cell line CVCL_V904 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005295; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160691 CVCL_UX05 NH50174 induced pluripotent stem cell human CVCL_UX05 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160692 CVCL_V905 S005297 transformed cell line CVCL_V905 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005297; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160693 CVCL_UX02 NH50119 induced pluripotent stem cell human CVCL_UX02 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160694 CVCL_V902 S005241 transformed cell line CVCL_V902 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005241; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160695 CVCL_UX03 NH50120 induced pluripotent stem cell human CVCL_UX03 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160696 CVCL_V903 S005293 transformed cell line CVCL_V903 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005293; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160697 CVCL_UX08 NH50171 induced pluripotent stem cell human CVCL_UX08 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160698 CVCL_V908 S005416 transformed cell line CVCL_V908 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005416; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160699 CVCL_UX09 NH50172 induced pluripotent stem cell human CVCL_UX09 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21160700 CVCL_V909 S005417 transformed cell line CVCL_V909 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005417; probable Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160701 CVCL_UX06 NH50175 induced pluripotent stem cell human CVCL_UX06 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160702 CVCL_V906 S005299 transformed cell line CVCL_V906 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005299; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160703 CVCL_UX07 NH50176 induced pluripotent stem cell human CVCL_UX07 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21160704 CVCL_V907 S005301 transformed cell line CVCL_V907 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005301; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160705 CVCL_2R98 AG19410 transformed cell line human CVCL_2R98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160706 CVCL_3398 MCF7-422 cancer cell line human CVCL_3398 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21160707 CVCL_2R99 AG19411 transformed cell line human CVCL_2R99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160708 CVCL_3399 MCF7-432 cancer cell line human CVCL_3399 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 (exon 4 defective) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21160709 CVCL_2R96 AG19408 transformed cell line human CVCL_2R96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160710 CVCL_3396 McA-RH8994 cancer cell line Norway rat CVCL_3396 CL:0000010 Transformant: 4'-(p-fluorophenyl)acetanilide (N-(4'-fluoro-4-biphenyl)acetamide(ChEBI; CHEBI:189411); Derived from sampling site: Liver; Breed/subspecies: Buffalo. Male 21160711 CVCL_2R97 AG19409 transformed cell line human CVCL_2R97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160712 CVCL_3397 MCF7-382 cancer cell line human CVCL_3397 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Control cell line for MCF7-422 (Cellosaurus=CVCL_3398) and MCF7-432 (Cellosaurus=CVCL_3399); transfected with emtpy vector pBact 21160713 CVCL_2R80 AG18294 transformed cell line human CVCL_2R80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160714 CVCL_3380 HeLa 422 cancer cell line human CVCL_3380 CL:0000010 Transfected with: HGNC; 3467; ESR1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21160715 CVCL_2R83 AG18297 transformed cell line human CVCL_2R83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160716 CVCL_3383 hTERT-HME1 telomerase immortalized cell line human CVCL_3383 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium. Omics: CNV analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48-64 hours (Evercyte); ~25 hours (PBCF) 21160717 CVCL_2R84 AG18298 transformed cell line human CVCL_2R84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160718 CVCL_3384 JM2 cancer cell line Norway rat CVCL_3384 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Breed/subspecies: Fischer 344. Male 21160719 CVCL_2R81 AG18295 transformed cell line human CVCL_2R81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160720 CVCL_3381 HeLa 432 cancer cell line human CVCL_3381 CL:0000010 Transfected with: HGNC; 3467; ESR1 (exon 4 defective) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21160721 CVCL_2R82 AG18296 transformed cell line human CVCL_2R82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160722 CVCL_3382 HTC cancer cell line Norway rat CVCL_3382 CL:0000010 Derived from metastatic site: Ascites; Breed/subspecies: Buffalo. Male 21160723 CVCL_2R76 AG18290 transformed cell line human CVCL_2R76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160724 CVCL_3376 HCC2688 cancer cell line human CVCL_3376 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DQB1*02:02,02:02; DRB1*03:01,03:01 (PubMed=26589293) CL:0000010 Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160725 CVCL_2R77 AG18291 transformed cell line human CVCL_2R77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160726 CVCL_3377 HCC3153 cancer cell line human CVCL_3377 HLA typing: A*34:02,34:02; B*08:01,15:03; C*07:01,02:02; DQB1*06:04,06:04 (PubMed=25960936) CL:0000010 Sequence variation: Gene fusion; HGNC; 290; GRK3 + HGNC; 29435; WWC1; Name(s)=WWC1-GRK3, WWC1-ADRBK2; Note=In frame (PubMed=22032724); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Thr276Alafs (c.815_824dupAGCCATGTGG); Zygosity=Unspecified (PubMed=22032724) Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 72.26 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21160727 CVCL_2R74 AG18288 transformed cell line human CVCL_2R74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160728 CVCL_3374 HCC1007 cancer cell line human CVCL_3374 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281His (c.841G>C); ClinVar=VCV000376588; Zygosity=Unspecified (PubMed=9865903) Population: African American; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2318; true Female Part of: GrayJW breast cancer cell line panel 21160729 CVCL_2R75 AG18289 transformed cell line human CVCL_2R75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160730 CVCL_3375 HCC2185 cancer cell line human CVCL_3375 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2342; true Female Characteristics: ER-negative, PR-negative and ERBB2-positive Doubling time: 163.56 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21160731 CVCL_2R78 AG18292 transformed cell line human CVCL_2R78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160732 CVCL_3378 HCC712 cancer cell line human CVCL_3378 CL:0000010 Population: Asian; Derived from sampling site: Breast. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2317; true Female 21160733 CVCL_2R79 AG18293 transformed cell line human CVCL_2R79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160734 CVCL_3379 HeLa 382 cancer cell line human CVCL_3379 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Control cell line for HeLa 422 (Cellosaurus=CVCL_3380) and HeLa 432 (Cellosaurus=CVCL_3381); transfected with emtpy vector pBact 21160735 CVCL_2R90 AG18304 transformed cell line human CVCL_2R90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160736 CVCL_3390 LB-B7 transformed cell line human CVCL_3390 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160737 CVCL_2R91 AG18305 transformed cell line human CVCL_2R91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160738 CVCL_3391 LB-F9 transformed cell line human CVCL_3391 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160739 CVCL_2R94 AG19406 transformed cell line human CVCL_2R94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160740 CVCL_3394 Mab 8A-PC hybridoma house mouse CVCL_3394 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human unidentified plasma cell-associated antigen. 21160741 CVCL_2R95 AG19407 transformed cell line human CVCL_2R95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160742 CVCL_3395 Mab 8F6-PC hybridoma house mouse CVCL_3395 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human unidentified plasma cell-associated antigen. 21160743 CVCL_2R92 AG18306 transformed cell line human CVCL_2R92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160744 CVCL_3392 LTK- transformed cell line house mouse CVCL_3392 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21160745 CVCL_2R93 AG18307 transformed cell line human CVCL_2R93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160746 CVCL_3393 Mab 62B1-PC hybridoma house mouse CVCL_3393 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human unidentified plasma cell-associated antigen. 21160747 CVCL_2R87 AG18301 transformed cell line human CVCL_2R87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160748 CVCL_3387 L6C5 transformed cell line Norway rat CVCL_3387 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21160749 CVCL_2R88 AG18302 transformed cell line human CVCL_2R88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160750 CVCL_3388 L6H2 transformed cell line Norway rat CVCL_3388 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21160751 CVCL_2R85 AG18299 transformed cell line human CVCL_2R85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160752 CVCL_3385 KE-39 cancer cell line human CVCL_3385 Genome ancestry: African=1.5%; Native American=0%; East Asian, North=89.52%; East Asian, South=4.53%; South Asian=0%; European, North=0%; European, South=4.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Asn (c.94G>A); ClinVar=VCV000376228; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~38.4 hours (PubMed=7599112) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160753 CVCL_2R86 AG18300 transformed cell line human CVCL_2R86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160754 CVCL_3386 KE-97 transformed cell line human CVCL_3386 Genome ancestry: African=0%; Native American=0%; East Asian, North=80.49%; East Asian, South=19.51%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Doubling time: ~28.8 hours (PubMed=7861622) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Misclassified Originally thought to be a mucinous gastric adenocarcinoma cell line from a 52 year old male patient but is a B-lymphoblastoid cell line (DSMZ; PubMed=30285677). 21160755 CVCL_2R89 AG18303 transformed cell line human CVCL_2R89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160756 CVCL_3389 LB4 transformed cell line human CVCL_3389 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160757 CVCL_2R61 AG18273 transformed cell line human CVCL_2R61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160758 CVCL_3361 C2-Rev 7 cancer cell line Norway rat CVCL_3361 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21160759 CVCL_2R62 AG18275 transformed cell line human CVCL_2R62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160760 CVCL_3362 CEINGE clone 3 transformed cell line Norway rat CVCL_3362 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Embryonic brain; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: ~24 hours (PubMed=8264960) 21160761 CVCL_2R60 AG18271 transformed cell line human CVCL_2R60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160762 CVCL_3360 BGC-823 cancer cell line human CVCL_3360 Genome ancestry: African=65.99%; Native American=0.77%; East Asian, North=2.9%; East Asian, South=0%; South Asian=0%; European, North=16.38%; European, South=13.96% (PubMed=30894373) CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000062, 3131C0001000700011) They were one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE; Omics: Transcriptome analysis by microarray Discontinued: ICLC; HTL98007; true Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00570 Problematic cell line: Contaminated Shown to be a HeLa derivative (CCRID; PubMed=26116706; PubMed=28851942). Originally thought to be a gastric adenocarcinoma. 21160763 CVCL_2R54 AG18265 transformed cell line human CVCL_2R54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160764 CVCL_3354 OMC-3 cancer cell line human CVCL_3354 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 98 hours, at 27th passage (PubMed=2010102) 21160765 CVCL_2R55 AG18266 transformed cell line human CVCL_2R55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160766 CVCL_3355 OMC-9 cancer cell line human CVCL_3355 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 36.6 hours, at 29th passage (PubMed=18397474) 21160767 CVCL_2R52 AG18263 transformed cell line human CVCL_2R52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160768 CVCL_3352 OCUB-F cancer cell line human CVCL_3352 CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Val17fs*1 (c.49_163del115); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala76Profs*70 (c.225delC); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ser (c.730G>A); ClinVar=VCV000376600; Zygosity=Unspecified (PubMed=16541312) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Instable (MSI) (PubMed=15677628) 21160769 CVCL_2R53 AG18264 transformed cell line human CVCL_2R53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160770 CVCL_3353 OMC-2 cancer cell line human CVCL_3353 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female Doubling time: 55-139 hours (PubMed=2624581) 21160771 CVCL_2R58 AG18269 transformed cell line human CVCL_2R58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160772 CVCL_3358 B3/AN cancer cell line house mouse CVCL_3358 CL:0000010 Discontinued: ECACC; 94031009; probable. 21160773 CVCL_2R59 AG18270 transformed cell line human CVCL_2R59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160774 CVCL_3359 BAE-1 finite cell line CVCL_3359 CL:0000010 Derived from sampling site: Aorta; endothelium; Breed/subspecies: Holstein Friesian. Unspecified 21160775 CVCL_3356 43L hybrid cell line house mouse CVCL_3356 CL:0000010 21160776 CVCL_2R56 AG18267 transformed cell line human CVCL_2R56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160777 CVCL_2R57 AG18268 transformed cell line human CVCL_2R57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160778 CVCL_3357 B1647 cancer cell line human CVCL_3357 CL:0000010 Derived from sampling site: Bone marrow. Male 21160779 CVCL_UX95 AG26916 transformed cell line human CVCL_UX95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160780 CVCL_V995 GM14119 transformed cell line human CVCL_V995 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160781 CVCL_UX96 AG26918 transformed cell line human CVCL_UX96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160782 CVCL_V996 GM14120 transformed cell line human CVCL_V996 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160783 CVCL_UX93 AG26913 transformed cell line human CVCL_UX93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160784 CVCL_V993 GM14117 transformed cell line human CVCL_V993 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21160785 CVCL_UX94 AG26915 transformed cell line human CVCL_UX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160786 CVCL_V994 GM14118 transformed cell line human CVCL_V994 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160787 CVCL_UX99 AG26931 transformed cell line human CVCL_UX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160788 CVCL_V999 GM14123 transformed cell line human CVCL_V999 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160789 CVCL_UX97 AG26924 transformed cell line human CVCL_UX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160790 CVCL_V997 GM14121 transformed cell line human CVCL_V997 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160791 CVCL_UX98 AG26925 transformed cell line human CVCL_UX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160792 CVCL_V998 GM14122 transformed cell line human CVCL_V998 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160793 CVCL_2R72 AG18286 transformed cell line human CVCL_2R72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160794 CVCL_2R73 AG18287 transformed cell line human CVCL_2R73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160795 CVCL_2R70 AG18283 transformed cell line human CVCL_2R70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160796 CVCL_3370 GI-LI-N cancer cell line human CVCL_3370 CL:0000010 Derived from metastatic site: Peripheral blood. Discontinued: ICLC; HTL96013; true Male 21160797 CVCL_2R71 AG18285 transformed cell line human CVCL_2R71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160798 CVCL_3371 GLC-82 cancer cell line human CVCL_3371 Genome ancestry: African=66.32%; Native American=1.23%; East Asian, North=2.62%; East Asian, South=0%; South Asian=0%; European, North=15.73%; European, South=14.1% (PubMed=30894373) CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000067) It was one of the sources for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: ICLC; HTL98006; true Female Doubling time: 48 hours (PubMed=4006684) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00572 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a 32 year old female patient with a lung adenocarcinoma. 21160799 CVCL_2R65 AG18278 transformed cell line human CVCL_2R65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160800 CVCL_3365 CHO-SSR2 spontaneously immortalized cell line CVCL_3365 CL:0000010 Transfected with: RGD; 3763; Sstr2 Derived from sampling site: Ovary. Female 21160801 CVCL_2R66 AG18279 transformed cell line human CVCL_2R66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160802 CVCL_3366 CM-S/un cancer cell line human CVCL_3366 CL:0000010 Derived from sampling site: Bone marrow. Male 21160803 CVCL_2R63 AG18276 transformed cell line human CVCL_2R63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160804 CVCL_3363 CF2.Th spontaneously immortalized cell line dog CVCL_3363 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6574; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21160805 CVCL_2R64 AG18277 transformed cell line human CVCL_2R64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160806 CVCL_3364 CHO-SSR1 spontaneously immortalized cell line CVCL_3364 CL:0000010 Transfected with: RGD; 3762; Sstr1 Derived from sampling site: Ovary. Female 21160807 CVCL_2R69 AG18282 transformed cell line human CVCL_2R69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160808 CVCL_3369 GI-CA-N cancer cell line human CVCL_3369 CL:0000010 Derived from metastatic site: Bone marrow. Discontinued: ICLC; HTL96025; true Male 21160809 CVCL_2R67 AG18280 transformed cell line human CVCL_2R67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160810 CVCL_3367 CM-S/Tum cancer cell line human CVCL_3367 CL:0000010 Derived from sampling site: Bone marrow. Male 21160811 CVCL_2R68 AG18281 transformed cell line human CVCL_2R68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160812 CVCL_3368 E. Derm finite cell line CVCL_3368 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.; Breed/subspecies: American Quarter Horse. Discontinued: ATCC; CRL-6288; true Female Senescence: Senesces at ~40 PDL (ATCC=CCL-57) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21160813 CVCL_V984 AG18357 transformed cell line CVCL_V984 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG18357; true Female Group: Non-human primate cell line 21160814 CVCL_UX84 AG26880 transformed cell line human CVCL_UX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160815 CVCL_V985 AG18358 transformed cell line CVCL_V985 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; AG18358; true Female Group: Non-human primate cell line 21160816 CVCL_UX85 AG26883 transformed cell line human CVCL_UX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160817 CVCL_V982 AG18355 transformed cell line CVCL_V982 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG18355; true Male Group: Non-human primate cell line 21160818 CVCL_UX82 AG26864 transformed cell line human CVCL_UX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160819 CVCL_V983 AG18356 transformed cell line CVCL_V983 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG18356; true Female Group: Non-human primate cell line 21160820 CVCL_UX83 AG26876 transformed cell line human CVCL_UX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160821 CVCL_UX88 AG26892 transformed cell line human CVCL_UX88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160822 CVCL_V988 S003628 finite cell line CVCL_V988 CL:0000010 Discontinued: Coriell; S003628; probable. Female Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160823 CVCL_UX89 AG26898 transformed cell line human CVCL_UX89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160824 CVCL_V989 HCC2429 BL transformed cell line human CVCL_V989 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160825 CVCL_V986 AG18359 transformed cell line CVCL_V986 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; AG18359; true Female Group: Non-human primate cell line 21160826 CVCL_UX86 AG26888 transformed cell line human CVCL_UX86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160827 CVCL_UX87 AG26891 transformed cell line human CVCL_UX87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160828 CVCL_V987 S003610 transformed cell line CVCL_V987 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: Coriell; S003610; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160829 CVCL_2R40 AG18248 transformed cell line human CVCL_2R40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160830 CVCL_3340 TGBC14TKB cancer cell line human CVCL_3340 CL:0000010 Population: Japanese. Female 21160831 CVCL_2R32 AG18239 transformed cell line human CVCL_2R32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160832 CVCL_3332 HL-60/MX1 cancer cell line human CVCL_3332 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21160833 CVCL_2R33 AG18240 transformed cell line human CVCL_2R33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160834 CVCL_3333 HL-60/MX2 cancer cell line human CVCL_3333 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Peripheral blood. Female Doubling time: 30 hours (ATCC=CRL-2257) 21160835 CVCL_2R30 AG18237 transformed cell line human CVCL_2R30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160836 CVCL_3330 Be Sal finite cell line human CVCL_3330 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1140; true Female 21160837 CVCL_2R31 AG18238 transformed cell line human CVCL_2R31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160838 CVCL_3331 Be Tim finite cell line human CVCL_3331 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1254; true Female 21160839 CVCL_2R36 AG18244 transformed cell line human CVCL_2R36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160840 CVCL_3336 TE-14 cancer cell line human CVCL_3336 HLA typing: A*11:01,11:01; B*07:02,48:01; C*08:01,08:01 (PubMed=26589293); Genome ancestry: African=3.44%; Native American=0%; East Asian, North=83.33%; East Asian, South=9.3%; South Asian=0%; European, North=0%; European, South=3.92% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160841 CVCL_2R37 AG18245 transformed cell line human CVCL_2R37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160842 CVCL_3337 TE-4 cancer cell line human CVCL_3337 HLA typing: A*02:07,11:01; B*46:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=2.46%; Native American=0%; East Asian, North=82.3%; East Asian, South=12.31%; South Asian=0%; European, North=0%; European, South=2.93% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ter404Leuext*8 (c.1211G>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21160843 CVCL_2R34 AG18242 transformed cell line human CVCL_2R34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160844 CVCL_3334 H1HeLa cancer cell line human CVCL_3334 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21160845 CVCL_2R35 AG18243 transformed cell line human CVCL_2R35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160846 CVCL_3335 Lu-140 cancer cell line human CVCL_3335 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Glnfs*3 (c.1025delG); Zygosity=Unspecified (PubMed=1312700; PubMed=10536175) Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 144 hours (PubMed=3022030) 21160847 CVCL_2R38 AG18246 transformed cell line human CVCL_2R38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160848 CVCL_3338 TGBC18TKB cancer cell line human CVCL_3338 CL:0000010 Population: Japanese. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21160849 CVCL_2R39 AG18247 transformed cell line human CVCL_2R39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160850 CVCL_3339 TGBC2TKB cancer cell line human CVCL_3339 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Female Doubling time: 37 hours (PubMed=32293552) 21160851 CVCL_UX91 AG26906 transformed cell line human CVCL_UX91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160852 CVCL_V991 GM14115 transformed cell line human CVCL_V991 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160853 CVCL_UX92 AG26908 transformed cell line human CVCL_UX92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160854 CVCL_V992 GM14116 transformed cell line human CVCL_V992 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21160855 CVCL_UX90 AG26899 transformed cell line human CVCL_UX90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160856 CVCL_V990 GM14114 transformed cell line human CVCL_V990 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21160857 CVCL_V973 AG05251 finite cell line CVCL_V973 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05251; probable Male Group: Non-human primate cell line 21160858 CVCL_UX73 AG26842 transformed cell line human CVCL_UX73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160859 CVCL_V974 AG20600 finite cell line CVCL_V974 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG20600; probable Female Group: Non-human primate cell line 21160860 CVCL_UX74 AG26844 transformed cell line human CVCL_UX74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160861 CVCL_UX71 AG26829 transformed cell line human CVCL_UX71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160862 CVCL_V971 S008976 transformed cell line CVCL_V971 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S008976; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160863 CVCL_UX72 AG26832 transformed cell line human CVCL_UX72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160864 CVCL_V972 S011081 finite cell line CVCL_V972 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; S011081; probable Unspecified Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21160865 CVCL_V977 AG16408 transformed cell line human CVCL_V977 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160866 CVCL_UX77 AG26848 transformed cell line human CVCL_UX77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160867 CVCL_V978 AG16409 finite cell line human CVCL_V978 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21160868 CVCL_UX78 AG26849 transformed cell line human CVCL_UX78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160869 CVCL_V975 AG06939 finite cell line CVCL_V975 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG06939; probable Male Group: Non-human primate cell line 21160870 CVCL_UX75 AG26845 transformed cell line human CVCL_UX75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160871 CVCL_V976 AG09429 finite cell line human CVCL_V976 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Female 21160872 CVCL_UX76 AG26847 transformed cell line human CVCL_UX76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160873 CVCL_V979 AG16410 finite cell line human CVCL_V979 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle. Discontinued: Coriell; AG16410; probable Male 21160874 CVCL_UX79 AG26856 transformed cell line human CVCL_UX79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160875 CVCL_2R50 AG18261 transformed cell line human CVCL_2R50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160876 CVCL_3350 Lu-138 cancer cell line human CVCL_3350 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175) Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 72 hours (PubMed=3022030) 21160877 CVCL_2R51 AG18262 transformed cell line human CVCL_2R51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160878 CVCL_3351 NOS-2 cancer cell line human CVCL_3351 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Male Characteristics: Established from a xenograft established in a nude mice Doubling time: 48.0 hours (PubMed=1449054) 21160879 CVCL_2R43 AG18251 transformed cell line human CVCL_2R43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160880 CVCL_3343 AKR/12B-2 cancer cell line house mouse CVCL_3343 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160881 CVCL_2R44 AG18252 transformed cell line human CVCL_2R44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160882 CVCL_3344 AKR/12B-3 cancer cell line house mouse CVCL_3344 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160883 CVCL_2R41 AG18249 transformed cell line human CVCL_2R41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160884 CVCL_3341 AKR/11D cancer cell line house mouse CVCL_3341 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160885 CVCL_2R42 AG18250 transformed cell line human CVCL_2R42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160886 CVCL_3342 AKR/12B-1 cancer cell line house mouse CVCL_3342 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160887 CVCL_2R47 AG18255 transformed cell line human CVCL_2R47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160888 CVCL_3347 Lu-141 cancer cell line human CVCL_3347 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175) Population: Japanese; Derived from metastatic site: Lymph node. Female 21160889 CVCL_2R48 AG18256 transformed cell line human CVCL_2R48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160890 CVCL_3348 Lu-143 cancer cell line human CVCL_3348 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.782+1G>T; ClinVar=VCV000496048; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=1312700) Population: Japanese; Derived from metastatic site: Lymph node. Male 21160891 CVCL_2R45 AG18253 transformed cell line human CVCL_2R45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160892 CVCL_3345 AKR/13B cancer cell line house mouse CVCL_3345 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160893 CVCL_2R46 AG18254 transformed cell line human CVCL_2R46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160894 CVCL_3346 AKR/14C cancer cell line house mouse CVCL_3346 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21160895 CVCL_2R49 AG18257 transformed cell line human CVCL_2R49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160896 CVCL_3349 Lu-24 cancer cell line human CVCL_3349 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1312700; PubMed=10536175; PubMed=20557307) Population: Japanese; Derived from sampling site: Lung. Omics: SNP array analysis Female Doubling time: 102 hours (PubMed=3022030) 21160897 CVCL_V980 AG16618 transformed cell line CVCL_V980 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG16618; true Male Group: Non-human primate cell line 21160898 CVCL_UX80 AG26859 transformed cell line human CVCL_UX80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21160899 CVCL_V981 AG18354 transformed cell line CVCL_V981 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG18354; true Male Group: Non-human primate cell line 21160900 CVCL_UX81 AG26863 transformed cell line human CVCL_UX81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21160901 CVCL_DE28 KM-105 transformed cell line human CVCL_DE28 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Male 21160902 CVCL_DE29 XP80TO finite cell line human CVCL_DE29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 21160903 CVCL_DE26 KM-103 transformed cell line human CVCL_DE26 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Male 21160904 CVCL_DE27 KM-104 transformed cell line human CVCL_DE27 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Male 21160905 CVCL_DE20 UVL-1 spontaneously immortalized cell line CVCL_DE20 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:77751; 8-azaadenine; Derived from sampling site: Ovary. Female 21160906 CVCL_DE21 UVL-10 spontaneously immortalized cell line CVCL_DE21 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:77751; 8-azaadenine; Derived from sampling site: Ovary. Female 21160907 CVCL_DE24 MZ-MEL-19/B-LCL transformed cell line human CVCL_DE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160908 CVCL_DE25 KM-101 transformed cell line human CVCL_DE25 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Male 21160909 CVCL_DE22 HepAD43 cancer cell line human CVCL_DE22 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Control cell line for the bioassay based on HepAD38 (Cellosaurus=CVCL_M177) or HepAD79 (Cellosaurus=CVCL_DE23) Male 21160910 CVCL_DE23 HepAD79 cancer cell line human CVCL_DE23 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Inducibly expresses a lamivudine-resistant hepatitis B virus (HBV) genome under the control of a tet operator/CMV promoter Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant. 21160911 CVCL_DE39 HHW890 hybrid cell line human CVCL_DE39 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160912 CVCL_DE37 HHW690 hybrid cell line human CVCL_DE37 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160913 CVCL_DE38 HHW805 hybrid cell line human CVCL_DE38 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160914 CVCL_DE31 GM01865 finite cell line human CVCL_DE31 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01865; probable Ambiguous 21160915 CVCL_DE32 2C3 [Mouse hybridoma against human VEGFA] hybridoma house mouse CVCL_DE32 CL:0000010 Discontinued: ATCC; CRL-13018; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P15692; Human VEGFA Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1595 21160916 CVCL_DE30 XP81TO finite cell line human CVCL_DE30 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 21160917 CVCL_DE35 AL-4-17 transformed cell line human CVCL_DE35 CL:0000010 Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Knee; articular cartilage. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 1.5-3 days (PubMed=20020445) 21160918 CVCL_DE36 HHW582 hybrid cell line human CVCL_DE36 CL:0000010 Characteristics: Hybrid for chromosome 4 mapping. Group: Human/rodent somatic cell hybrid 21160919 CVCL_DE33 B119-iPSC induced pluripotent stem cell human CVCL_DE33 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=25843045) Population: Latino or Hispanic; Dominican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21160920 CVCL_DE34 AL-3-11A transformed cell line human CVCL_DE34 CL:0000010 Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Knee; articular cartilage. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 1.5-3 days (PubMed=20020445) 21160921 CVCL_DE06 AD-S transformed cell line human CVCL_DE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21160922 CVCL_DE07 CV-S transformed cell line human CVCL_DE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21160923 CVCL_DE04 TSMK-1 transformed cell line house mouse CVCL_DE04 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: NIH Swiss. Unspecified 21160924 CVCL_DE05 CM-SM cancer cell line human CVCL_DE05 CL:0000010 Derived from sampling site: Bone marrow. Male 21160925 CVCL_DE08 H1.NPC-i1 induced pluripotent stem cell human CVCL_DE08 CL:0000010 Male 21160926 CVCL_DE09 H1.NPC-i2 induced pluripotent stem cell human CVCL_DE09 CL:0000010 Male 21160927 CVCL_DE02 THK [Tilapia] spontaneously immortalized cell line CVCL_DE02 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21160928 CVCL_DE03 ACL spontaneously immortalized cell line CVCL_DE03 CL:0000010 Unspecified Group: Fish cell line. 21160929 CVCL_DE00 THK-1 transformed cell line CVCL_DE00 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified 21160930 CVCL_DE01 TPK-1 transformed cell line pig CVCL_DE01 CL:0000010 Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Unspecified 21160931 CVCL_DE17 L-M(BU-25) spontaneously immortalized cell line house mouse CVCL_DE17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21160932 CVCL_DE18 TerC cancer cell line house mouse CVCL_DE18 CL:0000010 Breed/subspecies: 129/Sv. Male 21160933 CVCL_DE15 TSHC spontaneously immortalized cell line CVCL_DE15 CL:0000010 Derived from sampling site: Heart. Female Group: Fish cell line 21160934 CVCL_DE16 RTF spontaneously immortalized cell line CVCL_DE16 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21160935 CVCL_DE19 CHO-AT3-2 spontaneously immortalized cell line CVCL_DE19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:77751; 8-azaadenine; Derived from sampling site: Ovary. Female 21160936 CVCL_DE10 H1.NPC-i3 induced pluripotent stem cell human CVCL_DE10 CL:0000010 Male 21160937 CVCL_DE13 RTgutGC spontaneously immortalized cell line CVCL_DE13 CL:0000010 Derived from sampling site: Intestine Cell type=Epithelial cell.. Female Doubling time: 2.9 days (PubMed=34205481) Group: Fish cell line 21160938 CVCL_DE14 RTee spontaneously immortalized cell line CVCL_DE14 CL:0000010 Unspecified Group: Fish cell line. 21160939 CVCL_DE11 MUG-CC1-LCL transformed cell line human CVCL_DE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21160940 CVCL_DE12 HT-29/cl.f8 cancer cell line human CVCL_DE12 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Spontaneously polarizing cell line 21160941 CVCL_2Q99 AG18200 transformed cell line human CVCL_2Q99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160942 CVCL_3299 CCD-1105 KIDTr transformed cell line human CVCL_3299 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal kidney. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis Male Part of: MD Anderson Cell Lines Project 21160943 CVCL_2Q97 AG18198 transformed cell line human CVCL_2Q97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160944 CVCL_3297 CCD-1102 KERTr transformed cell line human CVCL_3297 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21160945 CVCL_2Q98 AG18199 transformed cell line human CVCL_2Q98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160946 CVCL_3298 CCD-1103 KIDTr transformed cell line human CVCL_3298 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal kidney. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis Male Part of: MD Anderson Cell Lines Project 21160947 CVCL_DE90 HEV0499 transformed cell line human CVCL_DE90 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160948 CVCL_DE93 CHO-K1.Cl-0204 spontaneously immortalized cell line CVCL_DE93 CL:0000010 Transfected with: HGNC; 3616; FCGR2A (with p.His167Arg) Derived from sampling site: Ovary. Female 21160949 CVCL_DE94 CHO-K1.Cl-0205 spontaneously immortalized cell line CVCL_DE94 CL:0000010 Transfected with: HGNC; 3616; FCGR2A Derived from sampling site: Ovary. Female 21160950 CVCL_DE91 CyN-1 spontaneously immortalized cell line CVCL_DE91 CL:0000010 Derived from sampling site: Caudal fin; muscle. Female Group: Fish cell line 21160951 CVCL_DE92 ND11265 transformed cell line human CVCL_DE92 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Unexplicit; IVS20+4delGTAA; Zygosity=Heterozygous; Note=Splicing mutation (PubMed=17622782) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21160952 CVCL_DE86 HEV0391 transformed cell line human CVCL_DE86 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160953 CVCL_DE87 HEV0425 transformed cell line human CVCL_DE87 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160954 CVCL_DE84 HEV0377 transformed cell line human CVCL_DE84 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160955 CVCL_DE85 HEV0390 transformed cell line human CVCL_DE85 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160956 CVCL_DE88 HEV0438 transformed cell line human CVCL_DE88 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160957 CVCL_DE89 HEV0466 transformed cell line human CVCL_DE89 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160958 CVCL_DE97 CHO-K1.Cl-0236 spontaneously immortalized cell line CVCL_DE97 CL:0000010 Transfected with: Cercocebus torquatus FCGR3A Derived from sampling site: Ovary. Female 21160959 CVCL_DE98 CHO-K1.Cl-0237 spontaneously immortalized cell line CVCL_DE98 CL:0000010 Transfected with: UniProtKB; A0A140HDP8; Macaca fascicularis FCGR3A Derived from sampling site: Ovary. Female 21160960 CVCL_DE95 CHO-K1.Cl-0206 spontaneously immortalized cell line CVCL_DE95 CL:0000010 Transfected with: HGNC; 3618; FCGR2B Derived from sampling site: Ovary. Female 21160961 CVCL_DE96 CHO-K1.Cl-0235 spontaneously immortalized cell line CVCL_DE96 CL:0000010 Transfected with: UniProtKB; H2RAL6; Pan troglodytes FCGR3A Derived from sampling site: Ovary. Female 21160962 CVCL_DE99 CHO-K1.Cl-0238 spontaneously immortalized cell line CVCL_DE99 CL:0000010 Transfected with: UniProtKB; A3RFZ7; Macaca mulatta FCGR3A Derived from sampling site: Ovary. Female 21160963 CVCL_DE71 HEV0250 transformed cell line human CVCL_DE71 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160964 CVCL_DE72 HEV0257 transformed cell line human CVCL_DE72 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160965 CVCL_DE70 HEV0209 transformed cell line human CVCL_DE70 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160966 CVCL_DE64 HEV0136 transformed cell line human CVCL_DE64 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160967 CVCL_DE65 HEV0146 transformed cell line human CVCL_DE65 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160968 CVCL_DE62 HEV0114 transformed cell line human CVCL_DE62 HLA typing: A*24:02; B*51:01,52:01; C*12:02,14:02; DPB1*02:01,09:01; DQB1*06:01,06:02; DRB1*15:01,15:02 (RCB=HEV0114) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21160969 CVCL_DE63 HEV0118 transformed cell line human CVCL_DE63 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160970 CVCL_DE68 HEV0196 transformed cell line human CVCL_DE68 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160971 CVCL_DE69 HEV0199 transformed cell line human CVCL_DE69 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160972 CVCL_DE66 HEV0153 transformed cell line human CVCL_DE66 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160973 CVCL_DE67 HEV0191 transformed cell line human CVCL_DE67 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160974 CVCL_DE82 HEV0352 transformed cell line human CVCL_DE82 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160975 CVCL_DE83 HEV0358 transformed cell line human CVCL_DE83 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160976 CVCL_DE80 HEV0338 transformed cell line human CVCL_DE80 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160977 CVCL_DE81 HEV0343 transformed cell line human CVCL_DE81 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160978 CVCL_DE75 HEV0290 transformed cell line human CVCL_DE75 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160979 CVCL_DE76 HEV0293 transformed cell line human CVCL_DE76 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160980 CVCL_DE73 HEV0261 transformed cell line human CVCL_DE73 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21160981 CVCL_DE74 HEV0283 transformed cell line human CVCL_DE74 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160982 CVCL_DE79 HEV0308 transformed cell line human CVCL_DE79 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160983 CVCL_DE77 HEV0299 transformed cell line human CVCL_DE77 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160984 CVCL_DE78 HEV0305 transformed cell line human CVCL_DE78 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160985 CVCL_DE50 GM12082 hybrid cell line human CVCL_DE50 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160986 CVCL_DE48 GM11623 hybrid cell line human CVCL_DE48 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160987 CVCL_DE49 GM11941 hybrid cell line CVCL_DE49 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160988 CVCL_DE42 HHW1124 hybrid cell line human CVCL_DE42 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160989 CVCL_DE43 HHW1138 hybrid cell line human CVCL_DE43 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160990 CVCL_DE40 HHW1107 hybrid cell line human CVCL_DE40 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160991 CVCL_DE41 HHW1113 hybrid cell line human CVCL_DE41 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160992 CVCL_DE46 GM11526 hybrid cell line CVCL_DE46 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160993 CVCL_DE47 GM11619 hybrid cell line human CVCL_DE47 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160994 CVCL_DE44 HHW1249 hybrid cell line human CVCL_DE44 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160995 CVCL_DE45 MHR14 hybrid cell line human CVCL_DE45 CL:0000010 Group: Human/rodent somatic cell hybrid. 21160996 CVCL_DE60 HEV0080 transformed cell line human CVCL_DE60 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160997 CVCL_DE61 HEV0097 transformed cell line human CVCL_DE61 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21160998 CVCL_DE59 HEV0069 transformed cell line human CVCL_DE59 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient; Derived from sampling site: Peripheral blood. Female 21160999 CVCL_DE53 GM13446 hybrid cell line human CVCL_DE53 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161000 CVCL_DE54 GM13501 hybrid cell line human CVCL_DE54 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161001 CVCL_DE51 GM13059 hybrid cell line human CVCL_DE51 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161002 CVCL_DE52 GM13175 hybrid cell line human CVCL_DE52 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161003 CVCL_DE57 HEV0445 transformed cell line human CVCL_DE57 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a vaginal cancer patient; Derived from sampling site: Peripheral blood. Female 21161004 CVCL_DE58 HEV0056 transformed cell line human CVCL_DE58 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a cervical cancer patient; Derived from sampling site: Peripheral blood. Female 21161005 CVCL_DE55 GM13502 hybrid cell line CVCL_DE55 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161006 CVCL_DE56 MDCK.5F1 spontaneously immortalized cell line dog CVCL_DE56 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12042 21161007 CVCL_V203 SP13.4 induced pluripotent stem cell human CVCL_V203 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22407749) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161008 CVCL_V204 GM00142 finite cell line human CVCL_V204 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21161009 CVCL_V201 SP02.1 induced pluripotent stem cell human CVCL_V201 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161010 CVCL_V202 SP08.1 induced pluripotent stem cell human CVCL_V202 From: Institut de Bioenginyeria de Catalunya (IBEC); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161011 CVCL_V207 GM00998 finite cell line human CVCL_V207 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21161012 CVCL_V208 GM00999 finite cell line human CVCL_V208 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe342Hisfs*28 (c.1019_1020TC[3]) (c.1021_1022dupTC) (1154insTC); ClinVar=VCV000007134; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21161013 CVCL_V205 GM00770 finite cell line human CVCL_V205 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161014 CVCL_V206 GM00997 finite cell line human CVCL_V206 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21161015 CVCL_V209 GM01013 finite cell line human CVCL_V209 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from familial inference of GM01014) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161016 CVCL_LW68 BayGenomics ES cell line CSH091 embryonic stem cell house mouse CVCL_LW68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161017 CVCL_M868 TuD-1-2 spontaneously immortalized cell line Norway rat CVCL_M868 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21161018 CVCL_LW69 BayGenomics ES cell line CSH092 embryonic stem cell house mouse CVCL_LW69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916555; Dcps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161019 CVCL_M869 TuD-1-7 spontaneously immortalized cell line Norway rat CVCL_M869 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21161020 CVCL_LW66 BayGenomics ES cell line CSH083 embryonic stem cell house mouse CVCL_LW66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98388; Sptbn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161021 CVCL_M866 TaD-1-6 cancer cell line Norway rat CVCL_M866 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21161022 CVCL_LW67 BayGenomics ES cell line CSH084 embryonic stem cell house mouse CVCL_LW67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387217; Ift52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161023 CVCL_M867 TaD-1-7 cancer cell line Norway rat CVCL_M867 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21161024 CVCL_LW64 BayGenomics ES cell line CSH066 embryonic stem cell house mouse CVCL_LW64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352483; Mga Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161025 CVCL_M864 TaD-1-4 cancer cell line Norway rat CVCL_M864 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21161026 CVCL_LW65 BayGenomics ES cell line CSH068 embryonic stem cell house mouse CVCL_LW65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103199; Mcm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161027 CVCL_M865 TaD-1-5 cancer cell line Norway rat CVCL_M865 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21161028 CVCL_LW62 BayGenomics ES cell line CSH059 embryonic stem cell house mouse CVCL_LW62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161029 CVCL_M862 TuD-1-1 spontaneously immortalized cell line Norway rat CVCL_M862 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21161030 CVCL_LW63 BayGenomics ES cell line CSH063 embryonic stem cell house mouse CVCL_LW63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161031 CVCL_M863 TaD-1-2 cancer cell line Norway rat CVCL_M863 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21161032 CVCL_LW60 BayGenomics ES cell line CSH053 embryonic stem cell house mouse CVCL_LW60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161033 CVCL_M860 HCu 57 cancer cell line human CVCL_M860 CL:0000010 21161034 CVCL_LW61 BayGenomics ES cell line CSH055 embryonic stem cell house mouse CVCL_LW61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914928; Lsm3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161035 CVCL_M861 Hut cancer cell line human CVCL_M861 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00067 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=6451928; PubMed=20143388). 21161036 CVCL_V210 GM01014 finite cell line human CVCL_V210 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161037 CVCL_V211 GM01348 finite cell line human CVCL_V211 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21161038 CVCL_LW79 BayGenomics ES cell line CSH118 embryonic stem cell house mouse CVCL_LW79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346870; Map2k6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161039 CVCL_M879 JTC-32 cancer cell line human CVCL_M879 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Female Doubling time: 86.7 hours (PubMed=6684098) 21161040 CVCL_LW77 BayGenomics ES cell line CSH114 embryonic stem cell house mouse CVCL_LW77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925836; Srbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161041 CVCL_M877 JTC-30 cancer cell line human CVCL_M877 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 69.2 hours (PubMed=6684098) 21161042 CVCL_LW78 BayGenomics ES cell line CSH117 embryonic stem cell house mouse CVCL_LW78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915392; Ino80 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161043 CVCL_M878 JTC-31 cancer cell line human CVCL_M878 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 59.4 hours (PubMed=6684098) 21161044 CVCL_LW75 BayGenomics ES cell line CSH112 embryonic stem cell house mouse CVCL_LW75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161045 CVCL_M875 HUB-41 cancer cell line human CVCL_M875 CL:0000010 Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Pro419His (c.1256C>A); Zygosity=Unspecified (PubMed=7474403). Population: Japanese 21161046 CVCL_LW76 BayGenomics ES cell line CSH113 embryonic stem cell house mouse CVCL_LW76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161047 CVCL_M876 JTC-29 cancer cell line human CVCL_M876 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 34.6 hours (PubMed=6684098) 21161048 CVCL_LW73 BayGenomics ES cell line CSH103 embryonic stem cell house mouse CVCL_LW73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445020; Exoc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161049 CVCL_M873 UCRU-BL-13 cancer cell line human CVCL_M873 CL:0000010 Male 21161050 CVCL_LW74 BayGenomics ES cell line CSH109 embryonic stem cell house mouse CVCL_LW74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917678; Polr3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161051 CVCL_M874 UCRU-BL-12 cancer cell line human CVCL_M874 CL:0000010 Male 21161052 CVCL_LW71 BayGenomics ES cell line CSH097 embryonic stem cell house mouse CVCL_LW71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161053 CVCL_M871 TuD-1-10 spontaneously immortalized cell line Norway rat CVCL_M871 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21161054 CVCL_LW72 BayGenomics ES cell line CSH100 embryonic stem cell house mouse CVCL_LW72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914345; Trak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161055 CVCL_M872 UC11 hybridoma house mouse CVCL_M872 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9756 21161056 CVCL_LW70 BayGenomics ES cell line CSH096 embryonic stem cell house mouse CVCL_LW70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161057 CVCL_M870 TuD-1-9 spontaneously immortalized cell line Norway rat CVCL_M870 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21161058 CVCL_V200 iPS-SCU-CD34+ #2 induced pluripotent stem cell human CVCL_V200 HLA typing: A*02:01,24:02; B*51:01,51:01; C*14:02,16:02; DQB1*06:02,06:03; DRB1*13:01,15:01 (Spanish_Stem_Cell_Bank) From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161059 CVCL_LW48 BayGenomics ES cell line CSH003 embryonic stem cell house mouse CVCL_LW48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679002; Prr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161060 CVCL_M848 SN cancer cell line human CVCL_M848 CL:0000010 Population: African; Zulu; Derived from sampling site: Esophagus. Male 21161061 CVCL_LW49 BayGenomics ES cell line CSH005 embryonic stem cell house mouse CVCL_LW49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161062 CVCL_M849 SN-T4 cancer cell line human CVCL_M849 CL:0000010 Population: African; Zulu; Derived from sampling site: Esophagus. Male Characteristics: Established after 4 tumor passages of parent cell line in nude mice 21161063 CVCL_LW46 BayGenomics ES cell line CSH001 embryonic stem cell house mouse CVCL_LW46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161064 CVCL_M846 MON cancer cell line human CVCL_M846 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=9671307) Derived from sampling site: Abdomen. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21161065 CVCL_LW47 BayGenomics ES cell line CSH002 embryonic stem cell house mouse CVCL_LW47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161066 CVCL_M847 Wa-2 cancer cell line human CVCL_M847 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Heterozygous (PubMed=9671307) Derived from metastatic site: Pleural effusion. Male Doubling time: 53 hours, at 50th passage (PubMed=2180563) 21161067 CVCL_LW44 BayGenomics ES cell line CSG525 embryonic stem cell house mouse CVCL_LW44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161068 CVCL_M844 WT-Pe.1 cancer cell line human CVCL_M844 CL:0000010 Derived from sampling site: Kidney. Female Doubling time: ~65 hours (PubMed=18558285) 21161069 CVCL_LW45 BayGenomics ES cell line CSG527 embryonic stem cell house mouse CVCL_LW45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161070 CVCL_M845 RM1 [Human Wilms tumor] cancer cell line human CVCL_M845 CL:0000010 Female 21161071 CVCL_LW42 BayGenomics ES cell line CSG515 embryonic stem cell house mouse CVCL_LW42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107403; Clk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161072 CVCL_M842 SBC-3/CDDP cancer cell line human CVCL_M842 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone marrow. Male Doubling time: 27.5 hours (PubMed=9615743; PubMed=10628341) 21161073 CVCL_LW43 BayGenomics ES cell line CSG521 embryonic stem cell house mouse CVCL_LW43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139746; Ankrd13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161074 CVCL_M843 SBC-3/DXCL1 cancer cell line human CVCL_M843 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:31587; Exatecan mesilate hydrate (DX-8951f); Derived from metastatic site: Bone marrow. Male Doubling time: 33.3 hours (PubMed=9914787) 21161075 CVCL_LW40 BayGenomics ES cell line CSG509 embryonic stem cell house mouse CVCL_LW40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685385; Kalrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161076 CVCL_M840 TCO-4 cancer cell line human CVCL_M840 CL:0000010 Population: Japanese. Unspecified 21161077 CVCL_LW41 BayGenomics ES cell line CSG512 embryonic stem cell house mouse CVCL_LW41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681523; Tnpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161078 CVCL_M841 SBC-3/ADM cancer cell line human CVCL_M841 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone marrow. Male Doubling time: 22 hours (PubMed=3012965); 45.9 hours (PubMed=10628341) 21161079 CVCL_LW59 BayGenomics ES cell line CSH052 embryonic stem cell house mouse CVCL_LW59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914346; Mmachc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161080 CVCL_M859 HCu 35 cancer cell line human CVCL_M859 CL:0000010 Male 21161081 CVCL_LW57 BayGenomics ES cell line CSH045 embryonic stem cell house mouse CVCL_LW57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161082 CVCL_M857 HCu 39 cancer cell line human CVCL_M857 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00062. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=3167823; PubMed=20143388). 21161083 CVCL_LW58 BayGenomics ES cell line CSH048 embryonic stem cell house mouse CVCL_LW58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161084 CVCL_M858 T-1 cancer cell line human CVCL_M858 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~22-24 hours (DOI=10.2172/4683311) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00095 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=7394535; PubMed=20143388). Originally thought to originate from the kidney of a 8 year old boy. 21161085 CVCL_LW55 BayGenomics ES cell line CSH029 embryonic stem cell house mouse CVCL_LW55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921331; Cep350 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161086 CVCL_M855 HCu 33 cancer cell line human CVCL_M855 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00060. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=3167823; PubMed=20143388). 21161087 CVCL_LW56 BayGenomics ES cell line CSH038 embryonic stem cell house mouse CVCL_LW56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161088 CVCL_M856 HCu 37 cancer cell line human CVCL_M856 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00061. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=3167823; PubMed=20143388). 21161089 CVCL_LW53 BayGenomics ES cell line CSH024 embryonic stem cell house mouse CVCL_LW53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106906; Eif4a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161090 CVCL_M853 HCu 22 cancer cell line human CVCL_M853 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00058. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=20143388). 21161091 CVCL_LW54 BayGenomics ES cell line CSH028 embryonic stem cell house mouse CVCL_LW54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161092 CVCL_M854 HCu 27 cancer cell line human CVCL_M854 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00059. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=20143388). 21161093 CVCL_LW51 BayGenomics ES cell line CSH014 embryonic stem cell house mouse CVCL_LW51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88251; Calm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161094 CVCL_M851 HCu 13 cancer cell line human CVCL_M851 CL:0000010 Derived from sampling site: Esophagus. Male 21161095 CVCL_LW52 BayGenomics ES cell line CSH020 embryonic stem cell house mouse CVCL_LW52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107788; Atp1b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161096 CVCL_M852 HCu 18 cancer cell line human CVCL_M852 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00057. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=3167823; PubMed=20143388). 21161097 CVCL_LW50 BayGenomics ES cell line CSH007 embryonic stem cell house mouse CVCL_LW50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276125; Utf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161098 CVCL_M850 HCu 10 cancer cell line human CVCL_M850 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00056. Problematic cell line: Contaminated Hcu 10, Hcu 18, Hcu 22, Hcu 27, Hcu 33, Hcu 37 and Hcu 39 have been shown to be identical (PubMed=3167823; PubMed=20143388). 21161099 CVCL_LW28 BayGenomics ES cell line CSG447 embryonic stem cell house mouse CVCL_LW28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161100 CVCL_M828 MMF-1 cancer cell line human CVCL_M828 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Doubling time: 72 hours (PubMed=7586821) 21161101 CVCL_LW29 BayGenomics ES cell line CSG449 embryonic stem cell house mouse CVCL_LW29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039624; Tstd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161102 CVCL_M829 MSUMFH cancer cell line human CVCL_M829 CL:0000010 Unspecified 21161103 CVCL_LW26 BayGenomics ES cell line CSG443 embryonic stem cell house mouse CVCL_LW26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3702045; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161104 CVCL_M826 MIPS-2 cancer cell line human CVCL_M826 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male Doubling time: ~48 hours (PubMed=15277221) 21161105 CVCL_LW27 BayGenomics ES cell line CSG446 embryonic stem cell house mouse CVCL_LW27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3026886; Cdin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161106 CVCL_M827 ML2308 cancer cell line human CVCL_M827 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21161107 CVCL_LW24 BayGenomics ES cell line CSG441 embryonic stem cell house mouse CVCL_LW24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161108 CVCL_M824 MFH-H cancer cell line human CVCL_M824 CL:0000010 Female Doubling time: 72 hours (PubMed=10470134). 21161109 CVCL_LW25 BayGenomics ES cell line CSG442 embryonic stem cell house mouse CVCL_LW25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161110 CVCL_M825 MFH-ToE cancer cell line human CVCL_M825 CL:0000010 Population: Japanese; Derived from sampling site: Right thigh. Female Doubling time: 37 hours, at 20th passage (PubMed=10536176) 21161111 CVCL_LW22 BayGenomics ES cell line CSG436 embryonic stem cell house mouse CVCL_LW22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161112 CVCL_M822 LMS148L cancer cell line human CVCL_M822 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21161113 CVCL_LW23 BayGenomics ES cell line CSG438 embryonic stem cell house mouse CVCL_LW23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916471; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161114 CVCL_M823 LPS141 cancer cell line human CVCL_M823 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21161115 CVCL_LW20 BayGenomics ES cell line CSG430 embryonic stem cell house mouse CVCL_LW20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161116 CVCL_M820 K-MFH-1 cancer cell line human CVCL_M820 CL:0000010 Population: Japanese. Female 21161117 CVCL_LW21 BayGenomics ES cell line CSG434 embryonic stem cell house mouse CVCL_LW21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929285; Orc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161118 CVCL_M821 LiSa-2 cancer cell line human CVCL_M821 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu348Ser (c.1043T>C); Zygosity=Unspecified (PubMed=26643872) Derived from metastatic site: Retroperitoneal space. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Can be differentiated into mature adipocytes 21161119 CVCL_LW39 BayGenomics ES cell line CSG508 embryonic stem cell house mouse CVCL_LW39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161120 CVCL_M839 TCO-1 [Human thyroid carcinoma] cancer cell line human CVCL_M839 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Tyr101Ter (c.303T>A); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=30737244) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: JCRB; FDSC0019; true Male Doubling time: ~26 hours (lot 11032003) (JCRB) 21161121 CVCL_LW37 BayGenomics ES cell line CSG494 embryonic stem cell house mouse CVCL_LW37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161122 CVCL_M837 NOS-1 [Human HNSCC] cancer cell line human CVCL_M837 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=11337272) Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 16.1 hours, at 100th passage (PubMed=11291288; PubMed=11337272) 21161123 CVCL_LW38 BayGenomics ES cell line CSG499 embryonic stem cell house mouse CVCL_LW38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915337; Dcakd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161124 CVCL_M838 HNOS undefined cell line type house mouse CVCL_M838 CL:0000010 Miscellaneous: A sample of HNOS was supplied to ICLAC for STR profiling by JCRB (Kohara A.) and tested by Labcorp Cell Line Testing (Ladd M.) Discontinued: JCRB; JCRB1023; true; Discontinued: JCRB; NIHS0256; true. Unspecified Doubling time: 20 hours (PubMed=10601556) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00580 Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse (ICLAC, JCRB). Originally thought to originate from a oral cavity squamous cell carcinoma. 21161125 CVCL_LW35 BayGenomics ES cell line CSG478 embryonic stem cell house mouse CVCL_LW35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924270; Atl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161126 CVCL_M835 RDD8107 cancer cell line human CVCL_M835 CL:0000010 Unspecified 21161127 CVCL_LW36 BayGenomics ES cell line CSG487 embryonic stem cell house mouse CVCL_LW36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97874; Rb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161128 CVCL_M836 TNMY1 cancer cell line human CVCL_M836 CL:0000010 Population: Japanese Female Doubling time: 62.7 hours (PubMed=11564213). 21161129 CVCL_LW33 BayGenomics ES cell line CSG466 embryonic stem cell house mouse CVCL_LW33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161130 CVCL_M833 OH931 cancer cell line human CVCL_M833 CL:0000010 Population: Caucasian. Female 21161131 CVCL_LW34 BayGenomics ES cell line CSG473 embryonic stem cell house mouse CVCL_LW34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161132 CVCL_M834 RC5397 cancer cell line human CVCL_M834 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21161133 CVCL_LW31 BayGenomics ES cell line CSG454 embryonic stem cell house mouse CVCL_LW31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920014; Csnk1g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161134 CVCL_M831 NDDLS-1 cancer cell line human CVCL_M831 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Characteristics: Produces CSF3 and IL6 Doubling time: 53.5 hours (at 20th passage), 37.9 hours (at 60th passage) (PubMed=21790860) 21161135 CVCL_LW32 BayGenomics ES cell line CSG464 embryonic stem cell house mouse CVCL_LW32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889585; Sall1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161136 CVCL_M832 NMSG 10 cancer cell line human CVCL_M832 CL:0000010 Population: Japanese; Derived from sampling site: Bone; tibia. Female Doubling time: 35 hours, at 40th passage (PubMed=8927571) 21161137 CVCL_LW30 BayGenomics ES cell line CSG452 embryonic stem cell house mouse CVCL_LW30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139083; Cep152 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161138 CVCL_M830 NATO cancer cell line human CVCL_M830 CL:0000010 Population: Japanese; Derived from sampling site: Bone; left femur. Male Doubling time: 84 hours (PubMed=7599108) 21161139 CVCL_LW08 BayGenomics ES cell line CSG376 embryonic stem cell house mouse CVCL_LW08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925860; Uvrag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161140 CVCL_M808 T778 cancer cell line human CVCL_M808 CL:0000010 Omics: SNP array analysis. Female 21161141 CVCL_LW09 BayGenomics ES cell line CSG380 embryonic stem cell house mouse CVCL_LW09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161142 CVCL_M809 T1000 cancer cell line human CVCL_M809 CL:0000010 Omics: SNP array analysis. Male 21161143 CVCL_LW06 BayGenomics ES cell line CSG367 embryonic stem cell house mouse CVCL_LW06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914210; Mindy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161144 CVCL_M806 NB-YK cancer cell line Norway rat CVCL_M806 CL:0000010 Breed/subspecies: Fischer 344. Female 21161145 CVCL_LW07 BayGenomics ES cell line CSG370 embryonic stem cell house mouse CVCL_LW07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105921; Zfp97 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161146 CVCL_M807 T449 cancer cell line human CVCL_M807 CL:0000010 Female 21161147 CVCL_LW04 BayGenomics ES cell line CSG362 embryonic stem cell house mouse CVCL_LW04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161148 CVCL_M804 MT-P cancer cell line Norway rat CVCL_M804 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21161149 CVCL_LW05 BayGenomics ES cell line CSG363 embryonic stem cell house mouse CVCL_LW05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109150; Mnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161150 CVCL_M805 MT-PR cancer cell line Norway rat CVCL_M805 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: Fischer 344/DuCrj. Male 21161151 CVCL_LW02 BayGenomics ES cell line CSG354 embryonic stem cell house mouse CVCL_LW02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161152 CVCL_M802 MT-10 cancer cell line Norway rat CVCL_M802 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21161153 CVCL_LW03 BayGenomics ES cell line CSG355 embryonic stem cell house mouse CVCL_LW03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444959; Kmt2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161154 CVCL_M803 MT-10R cancer cell line Norway rat CVCL_M803 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: Fischer 344/DuCrj. Male 21161155 CVCL_LW00 BayGenomics ES cell line CSG348 embryonic stem cell house mouse CVCL_LW00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924177; Tsacc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161156 CVCL_M800 MFH1NR cancer cell line Norway rat CVCL_M800 CL:0000010 Transformant: 4-(hydroxyamino)quinoline N-oxide (4-HAQO)(ChEBI; CHEBI:28469); Breed/subspecies: Fischer 344. Male 21161157 CVCL_LW01 BayGenomics ES cell line CSG349 embryonic stem cell house mouse CVCL_LW01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923264; Zc3h18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161158 CVCL_M801 MT-7 cancer cell line Norway rat CVCL_M801 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21161159 CVCL_LW19 BayGenomics ES cell line CSG429 embryonic stem cell house mouse CVCL_LW19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161160 CVCL_M819 GOT3 cancer cell line human CVCL_M819 CL:0000010 Derived from sampling site: Retroperitoneal space. Omics: Array-based CGH; Omics: SNP array analysis Female 21161161 CVCL_LW17 BayGenomics ES cell line CSG425 embryonic stem cell house mouse CVCL_LW17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144224; Dnaaf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161162 CVCL_M817 FU-MFH-2 cancer cell line human CVCL_M817 CL:0000010 Population: Japanese Male Doubling time: ~56 hours (PubMed=21092322). 21161163 CVCL_LW18 BayGenomics ES cell line CSG428 embryonic stem cell house mouse CVCL_LW18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88568; Cux1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161164 CVCL_M818 GBS-1 cancer cell line human CVCL_M818 CL:0000010 Population: Japanese Male Doubling time: ~30 hours (PubMed=11862471). 21161165 CVCL_LW15 BayGenomics ES cell line CSG413 embryonic stem cell house mouse CVCL_LW15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1195263; Lims1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161166 CVCL_M815 FU-DDLS-1 cancer cell line human CVCL_M815 CL:0000010 Population: Japanese Omics: SNP array analysis. Male Doubling time: ~52 hours (PubMed=12579306) 21161167 CVCL_LW16 BayGenomics ES cell line CSG418 embryonic stem cell house mouse CVCL_LW16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443049; Phaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161168 CVCL_M816 FU-MFH-1 cancer cell line human CVCL_M816 CL:0000010 Population: Japanese Female Doubling time: ~72 hours (PubMed=12810255). 21161169 CVCL_LW13 BayGenomics ES cell line CSG399 embryonic stem cell house mouse CVCL_LW13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105068; Rab7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161170 CVCL_M813 COMA cancer cell line human CVCL_M813 CL:0000010 Female 21161171 CVCL_LW14 BayGenomics ES cell line CSG400 embryonic stem cell house mouse CVCL_LW14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341890; Zfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161172 CVCL_M814 DDLS8817 cancer cell line human CVCL_M814 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21161173 CVCL_LW11 BayGenomics ES cell line CSG387 embryonic stem cell house mouse CVCL_LW11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144224; Dnaaf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161174 CVCL_M811 HSF-412 finite cell line human CVCL_M811 CL:0000010 Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21161175 CVCL_M812 AT4JTO finite cell line human CVCL_M812 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Heterozygous (PubMed=9600235) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1810; probable Female 21161176 CVCL_LW12 BayGenomics ES cell line CSG396 embryonic stem cell house mouse CVCL_LW12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161177 CVCL_LW10 BayGenomics ES cell line CSG383 embryonic stem cell house mouse CVCL_LW10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161178 CVCL_M810 KMST-6/RAS transformed cell line human CVCL_M810 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Population: Japanese; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21161179 CVCL_UP68 HPS0477 induced pluripotent stem cell human CVCL_UP68 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161180 CVCL_V168 HVR-3 embryonic stem cell human CVCL_V168 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161181 CVCL_V169 GRIP-1 transformed cell line Norway rat CVCL_V169 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Spinal cord neural tube Cell type=Tripotential glial-restricted precursor cell.; Breed/subspecies: Sprague Dawley. Discontinued: ATCC; CRL-2727; true Unspecified 21161182 CVCL_UP69 HPS0478 induced pluripotent stem cell human CVCL_UP69 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161183 CVCL_2J21 AG11769 transformed cell line human CVCL_2J21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161184 CVCL_2J22 AG12030 transformed cell line human CVCL_2J22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161185 CVCL_2J20 AG11719 transformed cell line human CVCL_2J20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161186 CVCL_2J25 AG12033 transformed cell line human CVCL_2J25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161187 CVCL_2J26 AG12034 transformed cell line human CVCL_2J26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161188 CVCL_2J23 AG12031 transformed cell line human CVCL_2J23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161189 CVCL_2J24 AG12032 transformed cell line human CVCL_2J24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161190 CVCL_2J18 AG11717 transformed cell line human CVCL_2J18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161191 CVCL_2J19 AG11718 transformed cell line human CVCL_2J19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161192 CVCL_2J16 AG11684 transformed cell line human CVCL_2J16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161193 CVCL_2J17 AG11716 transformed cell line human CVCL_2J17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161194 CVCL_V170 GRIP-1-GFP transformed cell line Norway rat CVCL_V170 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP Transformant: v-Myc; Derived from sampling site: Spinal cord neural tube Cell type=Tripotential glial-restricted precursor cell.; Breed/subspecies: Sprague Dawley. Discontinued: ATCC; CRL-2728; true Unspecified 21161195 CVCL_UP70 HPS0486 induced pluripotent stem cell human CVCL_UP70 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161196 CVCL_UP73 HPS0415 induced pluripotent stem cell human CVCL_UP73 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161197 CVCL_V173 L10BIOBR-MAPKK transformed cell line house mouse CVCL_V173 CL:0000010 Transfected with: MGI; MGI:1346866; Map2k1 (constitutively activated form); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: B10.BR. 21161198 CVCL_UP74 HPS0418 induced pluripotent stem cell human CVCL_UP74 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161199 CVCL_V174 VAL-11B embryonic stem cell human CVCL_V174 HLA typing: A*01:01,02:01; B*15:01,37:01; C*03:03,06:02; DPB1*04:01,05:02; DQA1*03:01,05:05; DQB1*03:02,03:01; DRB1*04:01,11:04 (Spanish_Stem_Cell_Bank). From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161200 CVCL_UP71 HPS0487 induced pluripotent stem cell human CVCL_UP71 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161201 CVCL_V171 L10BIOBR transformed cell line house mouse CVCL_V171 CL:0000010 Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: B10.BR. 21161202 CVCL_UP72 HPS0159 induced pluripotent stem cell human CVCL_UP72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161203 CVCL_V172 L10BIOBR-GFP transformed cell line house mouse CVCL_V172 CL:0000010 Transfected with: UniProtKB; P42212; GFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: B10.BR. 21161204 CVCL_V177 ESi038-B induced pluripotent stem cell human CVCL_V177 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161205 CVCL_UP77 HPS0434 induced pluripotent stem cell human CVCL_UP77 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161206 CVCL_V178 ESi038-C induced pluripotent stem cell human CVCL_V178 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161207 CVCL_UP78 HPS1067 induced pluripotent stem cell human CVCL_UP78 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161208 CVCL_V175 ESe028-A embryonic stem cell human CVCL_V175 HLA typing: A*11,26; B*35,38; C*04,12; DQB1*03,06; DRB1*08,13 (Spanish_Stem_Cell_Bank). From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161209 CVCL_UP75 HPS0492 induced pluripotent stem cell human CVCL_UP75 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161210 CVCL_UP76 HPS0493 induced pluripotent stem cell human CVCL_UP76 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161211 CVCL_V176 RiMi1 embryonic stem cell human CVCL_V176 From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain. CL:0000010 Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161212 CVCL_V159 AND-1 WASKO C1.2 embryonic stem cell human CVCL_V159 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Knockout cell: Method=ZFN; HGNC; 12731; WAS. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161213 CVCL_UP59 HPS0462 induced pluripotent stem cell human CVCL_UP59 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161214 CVCL_V157 ESi061-A induced pluripotent stem cell human CVCL_V157 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23075850) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161215 CVCL_UP57 HPS0459 induced pluripotent stem cell human CVCL_UP57 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161216 CVCL_V158 AND-1 WASKO C1.1 embryonic stem cell human CVCL_V158 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Knockout cell: Method=ZFN; HGNC; 12731; WAS. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161217 CVCL_UP58 HPS0460 induced pluripotent stem cell human CVCL_UP58 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161218 CVCL_2J32 AG12737 transformed cell line human CVCL_2J32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161219 CVCL_2J33 AG12738 transformed cell line human CVCL_2J33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161220 CVCL_2J30 AG12735 transformed cell line human CVCL_2J30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161221 CVCL_2J31 AG12736 transformed cell line human CVCL_2J31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161222 CVCL_2J36 AG14724 transformed cell line human CVCL_2J36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161223 CVCL_2J37 AG14725 transformed cell line human CVCL_2J37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161224 CVCL_2J34 AG14718 transformed cell line human CVCL_2J34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161225 CVCL_2J35 AG14719 transformed cell line human CVCL_2J35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161226 CVCL_2J29 AG12734 transformed cell line human CVCL_2J29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161227 CVCL_2J27 AG12257 transformed cell line human CVCL_2J27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161228 CVCL_2J28 AG12259 transformed cell line human CVCL_2J28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161229 CVCL_V162 AND-1 MLLAF4 embryonic stem cell human CVCL_V162 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 7135; AFF1 (KMT2-AFF1/MLL-AF4 fusion); Transfected with: HGNC; 7132; KMT2A (KMT2-AFF1/MLL-AF4 fusion); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Karyotypic information: 46,XY,+i(7)p(11),-7 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with a pRRL-EF1a-MLLAF4-PGK-Neo construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161230 CVCL_UP62 HPS0481 induced pluripotent stem cell human CVCL_UP62 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161231 CVCL_V163 AND-1 MLLAF4 FLT3 D835 embryonic stem cell human CVCL_V163 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 7135; AFF1 (KMT2-AFF1/MLL-AF4 fusion); Transfected with: HGNC; 7132; KMT2A (KMT2-AFF1/MLL-AF4 fusion); Transfected with: HGNC; 3765; FLT3 (with p.Asp835Xaa); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Karyotypic information: 46,XY,+i(7)p(11),-7 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with both a pRRL-EF1a-MLLAF4-PGK-Neo and a pRRL-EF1a-FLT3 D835-PGK-GFP constructs Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161232 CVCL_UP63 HPS0483 induced pluripotent stem cell human CVCL_UP63 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161233 CVCL_V160 AND-1 FLT3 ITD embryonic stem cell human CVCL_V160 From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Karyotypic information: 46,XY,+i(7)p(11),-7 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with a pRRL-EF1a-FLT3 ITD-PGK-GFP construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161234 CVCL_UP60 HPS0463 induced pluripotent stem cell human CVCL_UP60 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161235 CVCL_V161 AND-1 FLT3 D835 embryonic stem cell human CVCL_V161 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 3765; FLT3 (with p.Asp835Xaa); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Karyotypic information: 46,XY,+i(7)p(11),-7 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with a pRRL-EF1a-FLT3 D835-PGK-GFP construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161236 CVCL_UP61 HPS0480 induced pluripotent stem cell human CVCL_UP61 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161237 CVCL_UP66 HPS0474 induced pluripotent stem cell human CVCL_UP66 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161238 CVCL_V166 HVR-1 embryonic stem cell human CVCL_V166 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161239 CVCL_UP67 HPS0475 induced pluripotent stem cell human CVCL_UP67 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161240 CVCL_V167 HVR-2 embryonic stem cell human CVCL_V167 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain. CL:0000010 Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161241 CVCL_V164 AND-1 MLLAF4 FLT3 ITD embryonic stem cell human CVCL_V164 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 7135; AFF1 (KMT2-AFF1/MLL-AF4 fusion); Transfected with: HGNC; 7132; KMT2A (KMT2-AFF1/MLL-AF4 fusion); Transfected with: HGNC; 3765; FLT3 (with ITD); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Karyotypic information: 46,XY,+i(7)p(11),-7 (Spanish_Stem_Cell_Bank) Male Characteristics: Transduced with both a pRRL-EF1a-MLLAF4-PGK-Neo and a pRRL-EF1a-FLT3 ITD-PGK-GFP constructs Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161242 CVCL_UP64 HPS0420 induced pluripotent stem cell human CVCL_UP64 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161243 CVCL_UP65 HPS0421 induced pluripotent stem cell human CVCL_UP65 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161244 CVCL_V165 VAL-9-GFP embryonic stem cell human CVCL_V165 HLA typing: A*02:01,11:01; B*07:02,51:01; C*02:02,07:02; DPB1*04:01,05:01; DQA1*01:02,05:05; DQB1*03:01,06:02; DRB1*11:01,15:01; DRB3*02:02 (Spanish_Stem_Cell_Bank) From: Valencian Node of the Spanish Stem Cell Bank; Valencia; Spain CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161245 CVCL_UP48 1390C1 induced pluripotent stem cell human CVCL_UP48 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161246 CVCL_V148 AG07645 finite cell line human CVCL_V148 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from child cell line ESi035-A) Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21161247 CVCL_UP49 1390G3 induced pluripotent stem cell human CVCL_UP49 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161248 CVCL_V149 AG07646 transformed cell line human CVCL_V149 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG07645) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21161249 CVCL_UP46 1381B1 induced pluripotent stem cell human CVCL_UP46 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161250 CVCL_V146 PICM-19 spontaneously immortalized cell line pig CVCL_V146 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-126 to study growth and differentiation in microgravity (PubMed=20333478) Derived from sampling site: Fetal liver Cell type=Hepatocyte.. Unspecified Characteristics: Requires feeder cells Group: Space-flown cell line (cellonaut) 21161251 CVCL_UP47 1390B1 induced pluripotent stem cell human CVCL_UP47 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161252 CVCL_V147 ND00502 transformed cell line human CVCL_V147 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161253 CVCL_2J00 AG11399 transformed cell line human CVCL_2J00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161254 CVCL_2J03 AG11422 transformed cell line human CVCL_2J03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161255 CVCL_2J04 AG11426 transformed cell line human CVCL_2J04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161256 CVCL_2J01 AG11400 transformed cell line human CVCL_2J01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161257 CVCL_2J02 AG11421 transformed cell line human CVCL_2J02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161258 CVCL_V151 AG04160 transformed cell line human CVCL_V151 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG04159) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21161259 CVCL_UP51 HeLa GFP-LC3-RFP-LC3deltaG cancer cell line human CVCL_UP51 CL:0000010 Transfected with: RGD; 735183; Map1lc3a; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; A0A4V4ND72; mRFP1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Stably expresses EGFP-LC3-mRFP-LC3delta, an autophagic flux probe GFP-LC3 is fused to the N-terminus of RFP-LC3 whose C-terminal glycine is deleted. When expressed, the probe it is separated into EGFP-LC3 and mRFP-LC3deltaG by the action of endogenous ATG4 family proteases that cleave the peptide bond after the C-terminal glycine of LC3 in the cytosol producing equimolar amounts of EGFP-LC3 and mRFP-LC3deltaG. 21161260 CVCL_V152 ESi035-A induced pluripotent stem cell human CVCL_V152 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Spanish_Stem_Cell_Bank) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161261 CVCL_UP52 MEF GFP-LC3-RFP-LC3deltaG spontaneously immortalized cell line house mouse CVCL_UP52 CL:0000010 Transfected with: RGD; 735183; Map1lc3a; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; A0A4V4ND72; mRFP1 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified Characteristics: Stably expresses EGFP-LC3-mRFP-LC3delta, an autophagic flux probe GFP-LC3 is fused to the N-terminus of RFP-LC3 whose C-terminal glycine is deleted. When expressed, the probe it is separated into EGFP-LC3 and mRFP-LC3deltaG by the action of endogenous ATG4 family proteases that cleave the peptide bond after the C-terminal glycine of LC3 in the cytosol producing equimolar amounts of EGFP-LC3 and mRFP-LC3deltaG. 21161262 CVCL_UP50 585B1-868 induced pluripotent stem cell human CVCL_UP50 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Characteristics: Using TALEN a 2A-tdTomato construct was inserted at the C-terminal end of PRDM1 (BLIMP1) as well as 2A-EGFP construct at the C-terminal end of TFAP2C 21161263 CVCL_V150 AG04159 finite cell line human CVCL_V150 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21161264 CVCL_UP55 CiRA00003 induced pluripotent stem cell human CVCL_UP55 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161265 CVCL_V155 MSUH-001 induced pluripotent stem cell human CVCL_V155 HLA typing: A*23:01,30:02; B*53:01,58:01; C*04:01,07:01; DQB1*05:02,06:02; DRB1*15:03,16:02 (Spanish_Stem_Cell_Bank) From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161266 CVCL_V156 ESi004-A induced pluripotent stem cell human CVCL_V156 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Gly241Arg (c.721G>A) (G202R); ClinVar=VCV000093459; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161267 CVCL_UP56 HPS0439 induced pluripotent stem cell human CVCL_UP56 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161268 CVCL_V153 ESi036-A induced pluripotent stem cell human CVCL_V153 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Pro544Leu (c.1631C>T); ClinVar=VCV000065692; Zygosity=Hemizygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161269 CVCL_UP53 HPS3920 induced pluripotent stem cell human CVCL_UP53 CL:0000010 Population: Japanese; Donor information: Established from dizygotic twin of HPS3918 (Cellosaurus=CVCL_B0GQ); Derived from sampling site: Peripheral blood. Male 21161270 CVCL_UP54 CiRA00002 induced pluripotent stem cell human CVCL_UP54 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161271 CVCL_V154 ESi003-A induced pluripotent stem cell human CVCL_V154 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Gly466Arg (c.1396G>A); ClinVar=VCV000804101; Zygosity=Hemizygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Cell type=Fibroblast. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161272 CVCL_V137 GM13248 transformed cell line human CVCL_V137 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asn150Ilefs*9 (c.449delA); ClinVar=VCV000195093; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161273 CVCL_UP37 HPS2484 induced pluripotent stem cell human CVCL_UP37 HLA typing: A*24:02:01:01; B*40:02:01:01,59:01:01:01; C*01:02:01,03:04:01; DPB1*02:01:02; DQB1*03:02:01,05:03:01New; DRB1*08:02:01,14:54:01:02New (RCB=HPS2484) CL:0000010 Derived from sampling site: Peripheral blood. Male 21161274 CVCL_UP38 1383D2 induced pluripotent stem cell human CVCL_UP38 HLA typing: A*02:07,32:01; B*15:02,51:01; C*08:01;14:02; DQA1*03:03,06:01; DQB1*03:01,03:02; DRB1*04:05,12:01 (PubMed=30853558) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male 21161275 CVCL_V138 GM13249 transformed cell line human CVCL_V138 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161276 CVCL_V135 GM09256 finite cell line human CVCL_V135 CL:0000010 Population: Caucasian; English/German; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis Female 21161277 CVCL_UP35 HPS0510 induced pluripotent stem cell human CVCL_UP35 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161278 CVCL_V136 GM09257 finite cell line human CVCL_V136 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21161279 CVCL_UP36 HPS0515 induced pluripotent stem cell human CVCL_UP36 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161280 CVCL_UP39 1383D6 induced pluripotent stem cell human CVCL_UP39 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21161281 CVCL_V139 GM13250 transformed cell line human CVCL_V139 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161282 CVCL_2J10 AG11663 transformed cell line human CVCL_2J10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161283 CVCL_2J11 AG11664 transformed cell line human CVCL_2J11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161284 CVCL_2J14 AG11681 transformed cell line human CVCL_2J14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161285 CVCL_2J15 AG11682 transformed cell line human CVCL_2J15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161286 CVCL_2J12 AG11665 transformed cell line human CVCL_2J12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161287 CVCL_2J13 AG11680 transformed cell line human CVCL_2J13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161288 CVCL_2J07 AG11467 transformed cell line human CVCL_2J07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161289 CVCL_2J08 AG11506 transformed cell line human CVCL_2J08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161290 CVCL_2J05 AG11427 transformed cell line human CVCL_2J05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161291 CVCL_2J06 AG11466 transformed cell line human CVCL_2J06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161292 CVCL_2J09 AG11659 transformed cell line human CVCL_2J09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161293 CVCL_UP40 1020A12 induced pluripotent stem cell human CVCL_UP40 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Doubling time: 30.3 hours (PubMed=24399248) 21161294 CVCL_V140 GM13251 transformed cell line human CVCL_V140 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161295 CVCL_UP41 1020A3 induced pluripotent stem cell human CVCL_UP41 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. 21161296 CVCL_V141 GM13252 transformed cell line human CVCL_V141 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser168Cysfs*3 (c.501_502insTTGTCCGT) (8-nt insertion at nt 714); ClinVar=VCV000093329; Zygosity=Unspecified (PubMed=8493574) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161297 CVCL_UP44 1205A induced pluripotent stem cell human CVCL_UP44 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161298 CVCL_V144 GM13256 transformed cell line human CVCL_V144 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161299 CVCL_UP45 1205B induced pluripotent stem cell human CVCL_UP45 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Female 21161300 CVCL_V145 GM13257 transformed cell line human CVCL_V145 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161301 CVCL_UP42 1020A1 induced pluripotent stem cell human CVCL_UP42 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. 21161302 CVCL_V142 GM13254 transformed cell line human CVCL_V142 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161304 CVCL_V143 GM13255 transformed cell line human CVCL_V143 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161305 CVCL_UP26 HPS2912 induced pluripotent stem cell human CVCL_UP26 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161306 CVCL_V126 LR3.1/3 spontaneously immortalized cell line house mouse CVCL_V126 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161307 CVCL_UP27 HPS3006 induced pluripotent stem cell human CVCL_UP27 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161308 CVCL_V127 LR6.2/52a spontaneously immortalized cell line house mouse CVCL_V127 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161309 CVCL_UP24 HPS2894 induced pluripotent stem cell human CVCL_UP24 CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 21161310 CVCL_V124 LPP 3-6 spontaneously immortalized cell line house mouse CVCL_V124 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161311 CVCL_UP25 HPS2906 induced pluripotent stem cell human CVCL_UP25 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161312 CVCL_V125 LPRB3 112 spontaneously immortalized cell line house mouse CVCL_V125 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161313 CVCL_UP28 HPS3036 induced pluripotent stem cell human CVCL_UP28 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161314 CVCL_V128 LR6.3/52C spontaneously immortalized cell line house mouse CVCL_V128 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161315 CVCL_UP29 HPS3042 induced pluripotent stem cell human CVCL_UP29 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161316 CVCL_V129 PI1 spontaneously immortalized cell line house mouse CVCL_V129 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161317 CVCL_LV89 BayGenomics ES cell line CSG309 embryonic stem cell house mouse CVCL_LV89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444923; Rbm41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161318 CVCL_M789 Tat-1 cancer cell line human CVCL_M789 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Axillary lymph node. Female Doubling time: 72 hours (PubMed=11840295) 21161319 CVCL_LV87 BayGenomics ES cell line CSG298 embryonic stem cell house mouse CVCL_LV87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161320 CVCL_M787 RARE cancer cell line human CVCL_M787 CL:0000010 Derived from metastatic site: Lymph node. Female 21161321 CVCL_LV88 BayGenomics ES cell line CSG305 embryonic stem cell house mouse CVCL_LV88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858696; Copg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161322 CVCL_M788 FLK-1 cancer cell line human CVCL_M788 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Characteristics: Dependent on the FDC/HK (Cellosaurus=CVCL_IY38) cell line for its growth and survival 21161323 CVCL_LV85 BayGenomics ES cell line CSG282 embryonic stem cell house mouse CVCL_LV85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444959; Kmt2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161324 CVCL_M785 GRS-IV cancer cell line human CVCL_M785 CL:0000010 Derived from metastatic site: Lymph node. Male 21161325 CVCL_LV86 BayGenomics ES cell line CSG297 embryonic stem cell house mouse CVCL_LV86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351332; Azi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161326 CVCL_M786 GRS-V cancer cell line human CVCL_M786 CL:0000010 Derived from metastatic site: Lymph node. Male 21161327 CVCL_LV83 BayGenomics ES cell line CSG280 embryonic stem cell house mouse CVCL_LV83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915312; Btf3l4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161328 CVCL_M783 SINJ cancer cell line human CVCL_M783 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 3 days (PubMed=21573635) 21161329 CVCL_LV84 BayGenomics ES cell line CSG281 embryonic stem cell house mouse CVCL_LV84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161330 CVCL_M784 BOJO cancer cell line human CVCL_M784 CL:0000010 Derived from metastatic site: Lymph node. Male 21161331 CVCL_LV81 BayGenomics ES cell line CSG276 embryonic stem cell house mouse CVCL_LV81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914454; Eif2s2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161332 CVCL_M781 KJOS-II cancer cell line human CVCL_M781 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21161333 CVCL_LV82 BayGenomics ES cell line CSG279 embryonic stem cell house mouse CVCL_LV82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109404; Nup98 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161334 CVCL_UP30 HPS3048 induced pluripotent stem cell human CVCL_UP30 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161335 CVCL_V130 R/3.2-L spontaneously immortalized cell line house mouse CVCL_V130 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161336 CVCL_M782 SHER-I cancer cell line human CVCL_M782 CL:0000010 Derived from sampling site: Thyroid gland. Male 21161337 CVCL_LV80 BayGenomics ES cell line CSG274 embryonic stem cell house mouse CVCL_LV80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355299; Hnrnpdl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161338 CVCL_M780 GSJO cancer cell line human CVCL_M780 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Val804Met (c.2410G>A); ClinVar=VCV000037102; Zygosity=Unspecified (PubMed=15126569) Derived from sampling site: Thyroid gland. Unspecified 21161339 CVCL_UP33 HPS1090 induced pluripotent stem cell human CVCL_UP33 CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (PubMed=33901816) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161340 CVCL_V133 TR6.1/52b spontaneously immortalized cell line house mouse CVCL_V133 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161341 CVCL_V134 GM09255 finite cell line human CVCL_V134 CL:0000010 Population: Caucasian; English/German; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis Male 21161342 CVCL_UP34 HPS1096 induced pluripotent stem cell human CVCL_UP34 CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (PubMed=33901816) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161343 CVCL_UP31 HPS3143 induced pluripotent stem cell human CVCL_UP31 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161344 CVCL_V131 R/R1H-L spontaneously immortalized cell line house mouse CVCL_V131 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161345 CVCL_UP32 HPS3284 induced pluripotent stem cell human CVCL_UP32 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161346 CVCL_V132 S13ba3 spontaneously immortalized cell line house mouse CVCL_V132 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161347 CVCL_UP15 HPS2690 induced pluripotent stem cell human CVCL_UP15 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161348 CVCL_V115 LAQ 8251 spontaneously immortalized cell line house mouse CVCL_V115 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161349 CVCL_UP16 HPS2691 induced pluripotent stem cell human CVCL_UP16 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161350 CVCL_V116 LARB1 1212 spontaneously immortalized cell line house mouse CVCL_V116 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161351 CVCL_UP13 HPS2401 induced pluripotent stem cell human CVCL_UP13 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161352 CVCL_V113 LA3 beta2mHC2 spontaneously immortalized cell line house mouse CVCL_V113 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161353 CVCL_UP14 HPS2407 induced pluripotent stem cell human CVCL_UP14 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161354 CVCL_V114 LAP 4108-6 spontaneously immortalized cell line house mouse CVCL_V114 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161355 CVCL_UP19 HPS2828 induced pluripotent stem cell human CVCL_UP19 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161356 CVCL_V119 LDR2a spontaneously immortalized cell line house mouse CVCL_V119 CL:0000010 Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4953; HLA-DRB5 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161357 CVCL_UP17 HPS2692 induced pluripotent stem cell human CVCL_UP17 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161358 CVCL_V117 LB7alpha2mC25 spontaneously immortalized cell line house mouse CVCL_V117 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161359 CVCL_UP18 HPS2798 induced pluripotent stem cell human CVCL_UP18 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161360 CVCL_V118 LDR+25 spontaneously immortalized cell line house mouse CVCL_V118 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161361 CVCL_LV98 BayGenomics ES cell line CSG339 embryonic stem cell house mouse CVCL_LV98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916075; Mtmr14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161362 CVCL_M798 COS2NR cancer cell line Norway rat CVCL_M798 CL:0000010 Transformant: 4-(hydroxyamino)quinoline N-oxide (4-HAQO)(ChEBI; CHEBI:28469); Breed/subspecies: Fischer 344/Ns1c. Male 21161363 CVCL_LV99 BayGenomics ES cell line CSG341 embryonic stem cell house mouse CVCL_LV99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338803; Aire Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161364 CVCL_M799 COS4NR cancer cell line Norway rat CVCL_M799 CL:0000010 Transformant: 4-(hydroxyamino)quinoline N-oxide (4-HAQO)(ChEBI; CHEBI:28469); Breed/subspecies: Fischer 344/Ns1c. Male 21161365 CVCL_LV96 BayGenomics ES cell line CSG336 embryonic stem cell house mouse CVCL_LV96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95612; Gabpb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161366 CVCL_M796 GN-CL-2 cancer cell line human CVCL_M796 CL:0000010 Population: Japanese. Female 21161367 CVCL_LV97 BayGenomics ES cell line CSG338 embryonic stem cell house mouse CVCL_LV97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161368 CVCL_M797 COS1NR cancer cell line Norway rat CVCL_M797 CL:0000010 Transformant: 4-(hydroxyamino)quinoline N-oxide (4-HAQO)(ChEBI; CHEBI:28469); Breed/subspecies: Fischer 344/Ns1c. Male 21161369 CVCL_LV94 BayGenomics ES cell line CSG326 embryonic stem cell house mouse CVCL_LV94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161370 CVCL_M794 GN-3 cancer cell line human CVCL_M794 CL:0000010 Population: Japanese. Female 21161371 CVCL_LV95 BayGenomics ES cell line CSG330 embryonic stem cell house mouse CVCL_LV95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261437; Atp5c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161372 CVCL_M795 GN-CL-1 cancer cell line human CVCL_M795 CL:0000010 Population: Japanese. Female 21161373 CVCL_LV92 BayGenomics ES cell line CSG320 embryonic stem cell house mouse CVCL_LV92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685106; Mideas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161374 CVCL_M792 FPS-1 cancer cell line human CVCL_M792 CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y. Male Doubling time: ~36.5 hours (PubMed=17094458) 21161375 CVCL_LV93 BayGenomics ES cell line CSG324 embryonic stem cell house mouse CVCL_LV93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161376 CVCL_M793 GN-1 cancer cell line human CVCL_M793 CL:0000010 Population: Japanese Female Characteristics: Established from a 85th generation xenograft (MFH-R) established in nude BALB/cAJcl-nu mice. 21161377 CVCL_LV90 BayGenomics ES cell line CSG317 embryonic stem cell house mouse CVCL_LV90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443679; Sipa1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161378 CVCL_M790 MFH-I cancer cell line human CVCL_M790 CL:0000010 Female Doubling time: 1.1 days (PubMed=3025391). 21161379 CVCL_LV91 BayGenomics ES cell line CSG318 embryonic stem cell house mouse CVCL_LV91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103063; Stat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161380 CVCL_M791 MFH-II cancer cell line human CVCL_M791 CL:0000010 Male Doubling time: 1.4 days (PubMed=3025391). 21161381 CVCL_UP22 HPS2864 induced pluripotent stem cell human CVCL_UP22 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161382 CVCL_V122 LDR8 spontaneously immortalized cell line house mouse CVCL_V122 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161383 CVCL_UP23 HPS2870 induced pluripotent stem cell human CVCL_UP23 CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21161384 CVCL_V123 Line 14 spontaneously immortalized cell line house mouse CVCL_V123 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161385 CVCL_UP20 HPS2834 induced pluripotent stem cell human CVCL_UP20 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21161386 CVCL_V120 LDR2b spontaneously immortalized cell line house mouse CVCL_V120 CL:0000010 Transfected with: HGNC; 4947; HLA-DRA; Transfected with: HGNC; 4948; HLA-DRB1 (allele DR15) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161387 CVCL_UP21 HPS2846 induced pluripotent stem cell human CVCL_UP21 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161388 CVCL_V121 LDR7 spontaneously immortalized cell line house mouse CVCL_V121 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161389 CVCL_UP04 HPS2250 induced pluripotent stem cell human CVCL_UP04 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161390 CVCL_V104 L17.8 spontaneously immortalized cell line house mouse CVCL_V104 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161391 CVCL_UP05 HPS2274 induced pluripotent stem cell human CVCL_UP05 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161392 CVCL_V105 L201.15 spontaneously immortalized cell line house mouse CVCL_V105 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161393 CVCL_UP02 HPS2198 induced pluripotent stem cell human CVCL_UP02 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161394 CVCL_V102 L166.1 spontaneously immortalized cell line house mouse CVCL_V102 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161395 CVCL_UP03 HPS2226 induced pluripotent stem cell human CVCL_UP03 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161396 CVCL_V103 L168.2 spontaneously immortalized cell line house mouse CVCL_V103 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161397 CVCL_UP08 HPS2309 induced pluripotent stem cell human CVCL_UP08 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161398 CVCL_V108 L3.6.2 spontaneously immortalized cell line house mouse CVCL_V108 CL:0000010 Transfected with: HGNC; 4940; HLA-DPB1 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161399 CVCL_UP09 HPS2337 induced pluripotent stem cell human CVCL_UP09 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161400 CVCL_V109 L54.5 spontaneously immortalized cell line house mouse CVCL_V109 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161401 CVCL_UP06 HPS2307 induced pluripotent stem cell human CVCL_UP06 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161402 CVCL_V106 L21.3 spontaneously immortalized cell line house mouse CVCL_V106 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161403 CVCL_UP07 HPS2308 induced pluripotent stem cell human CVCL_UP07 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161404 CVCL_V107 L25.4 spontaneously immortalized cell line house mouse CVCL_V107 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161405 CVCL_LV69 BayGenomics ES cell line CSG247 embryonic stem cell house mouse CVCL_LV69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915385; Eif3h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161406 CVCL_M769 U1/HIV-1 cancer cell line human CVCL_M769 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Virology: Latently infected with HIV-1 isolate NY5 The two main sites of integrations are in chromosome 2 and chromosome X (PubMed=28086908). Doubling time: 36 hours (HIVReagentProgram) 21161407 CVCL_LV67 BayGenomics ES cell line CSG243 embryonic stem cell house mouse CVCL_LV67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161408 CVCL_M767 FL-4 spontaneously immortalized cell line CVCL_M767 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10772 21161409 CVCL_LV68 BayGenomics ES cell line CSG246 embryonic stem cell house mouse CVCL_LV68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913866; Snx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161410 CVCL_M768 FL-6 spontaneously immortalized cell line CVCL_M768 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10773 21161411 CVCL_LV65 BayGenomics ES cell line CSG236 embryonic stem cell house mouse CVCL_LV65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106248; Eif5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161412 CVCL_M765 FeT-1M spontaneously immortalized cell line CVCL_M765 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10775 21161413 CVCL_LV66 BayGenomics ES cell line CSG241 embryonic stem cell house mouse CVCL_LV66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161414 CVCL_M766 FeT-2D spontaneously immortalized cell line CVCL_M766 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10774 21161415 CVCL_LV63 BayGenomics ES cell line CSG234 embryonic stem cell house mouse CVCL_LV63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913435; Virma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161416 CVCL_M763 HeLa R19 cancer cell line human CVCL_M763 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21161417 CVCL_LV64 BayGenomics ES cell line CSG235 embryonic stem cell house mouse CVCL_LV64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99526; Ddx19a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161418 CVCL_M764 K028 cancer cell line human CVCL_M764 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23418523). 21161419 CVCL_LV61 BayGenomics ES cell line CSG224 embryonic stem cell house mouse CVCL_LV61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161420 CVCL_M761 OLSOK-e7 spontaneously immortalized cell line CVCL_M761 CL:0000010 Breed/subspecies: SOK. Unspecified Group: Fish cell line 21161421 CVCL_LV62 BayGenomics ES cell line CSG225 embryonic stem cell house mouse CVCL_LV62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913775; Timm50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161422 CVCL_M762 OL-17 spontaneously immortalized cell line CVCL_M762 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.; Breed/subspecies: Orange-red. Male Doubling time: 29 hours (DOI=10.1007/BF02628830) Group: Fish cell line 21161423 CVCL_LV60 BayGenomics ES cell line CSG223 embryonic stem cell house mouse CVCL_LV60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161424 CVCL_M760 OLKaga-e2 spontaneously immortalized cell line CVCL_M760 CL:0000010 Breed/subspecies: Kaga. Unspecified Group: Fish cell line 21161425 CVCL_UP11 HPS2377 induced pluripotent stem cell human CVCL_UP11 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161426 CVCL_V111 L89.2 spontaneously immortalized cell line house mouse CVCL_V111 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161427 CVCL_UP12 HPS2383 induced pluripotent stem cell human CVCL_UP12 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 21161428 CVCL_V112 L91.7 spontaneously immortalized cell line house mouse CVCL_V112 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161429 CVCL_UP10 HPS2359 induced pluripotent stem cell human CVCL_UP10 CL:0000010 Derived from sampling site: Peripheral blood. Male 21161430 CVCL_V110 L57.23 spontaneously immortalized cell line house mouse CVCL_V110 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161431 CVCL_LV78 BayGenomics ES cell line CSG272 embryonic stem cell house mouse CVCL_LV78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103097; Anapc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161432 CVCL_M778 SESX cancer cell line human CVCL_M778 CL:0000010 21161433 CVCL_LV79 BayGenomics ES cell line CSG273 embryonic stem cell house mouse CVCL_LV79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99211; Zfx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161434 CVCL_M779 RO-D81-1 cancer cell line human CVCL_M779 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00482 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=23472229). Originally thought to originate from a thyroid gland medullary carcinoma. 21161435 CVCL_LV76 BayGenomics ES cell line CSG268 embryonic stem cell house mouse CVCL_LV76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921445; Elp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161436 CVCL_M776 T/C28a4 transformed cell line human CVCL_M776 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Rib; costal cartilage Cell type=Chondrocyte.. Female 21161437 CVCL_LV77 BayGenomics ES cell line CSG271 embryonic stem cell house mouse CVCL_LV77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2155302; Sec63 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161438 CVCL_M777 BB132-MEL cancer cell line human CVCL_M777 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: CNV analysis. Unspecified 21161439 CVCL_LV74 BayGenomics ES cell line CSG260 embryonic stem cell house mouse CVCL_LV74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161440 CVCL_M774 MOLT-3/Z29 cancer cell line human CVCL_M774 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: HIVReagentProgram; ARP-12185; true Male Virology: Infected by human herpesvirus 6B (HHV-6B) strain Z29 Caution: Was discontinued from the HIVReagentProgram because the cell line seemed to have also been infected by HIV-1 (personal communication of Rashid S.) 21161441 CVCL_LV75 BayGenomics ES cell line CSG264 embryonic stem cell house mouse CVCL_LV75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919686; Tbcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161442 CVCL_M775 HEK293L transformed cell line human CVCL_M775 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21161443 CVCL_LV72 BayGenomics ES cell line CSG254 embryonic stem cell house mouse CVCL_LV72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161444 CVCL_M772 SUP-T1/Z29 cancer cell line human CVCL_M772 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Pleural effusion Cell type=T-cell.. Discontinued: HIVReagentProgram; ARP-12183; true Male Virology: Infected by human herpesvirus 6B (HHV-6B) strain Z29 Caution: Was discontinued from the HIVReagentProgram because the cell line seemed to have also been infected by HIV-1 (personal communication of Rashid S.) 21161445 CVCL_LV73 BayGenomics ES cell line CSG256 embryonic stem cell house mouse CVCL_LV73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3588201; Erich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161446 CVCL_M773 Sup-T1/JI cancer cell line human CVCL_M773 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Virology: Infected by human herpesvirus 7 (HHV-7) strain JI 21161447 CVCL_LV70 BayGenomics ES cell line CSG251 embryonic stem cell house mouse CVCL_LV70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95299; Eif2s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161448 CVCL_M770 U38 cancer cell line human CVCL_M770 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21161449 CVCL_LV71 BayGenomics ES cell line CSG253 embryonic stem cell house mouse CVCL_LV71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161450 CVCL_M771 M311 [Human leukemia] cancer cell line human CVCL_M771 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21161451 CVCL_UP00 HPS2150 induced pluripotent stem cell human CVCL_UP00 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161452 CVCL_V100 L164.11 spontaneously immortalized cell line house mouse CVCL_V100 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161453 CVCL_UP01 HPS2186 induced pluripotent stem cell human CVCL_UP01 CL:0000010 Derived from sampling site: Peripheral blood. Female 21161454 CVCL_V101 L165.6 spontaneously immortalized cell line house mouse CVCL_V101 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Part of: 11th International Histocompatibility Workshop (11IHW) cell line panel 21161455 CVCL_2J80 AG14843 transformed cell line human CVCL_2J80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161456 CVCL_2J83 AG14847 transformed cell line human CVCL_2J83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161457 CVCL_2J84 AG14848 transformed cell line human CVCL_2J84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161458 CVCL_2J81 AG14844 transformed cell line human CVCL_2J81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161459 CVCL_2J82 AG14846 transformed cell line human CVCL_2J82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161460 CVCL_2J87 AG14860 transformed cell line human CVCL_2J87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161461 CVCL_2J88 AG14884 transformed cell line human CVCL_2J88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161462 CVCL_2J85 AG14858 transformed cell line human CVCL_2J85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161463 CVCL_2J86 AG14859 transformed cell line human CVCL_2J86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161464 CVCL_2J89 AG14885 transformed cell line human CVCL_2J89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161465 CVCL_2J90 AG14886 transformed cell line human CVCL_2J90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161466 CVCL_2J91 AG14887 transformed cell line human CVCL_2J91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161467 CVCL_2J94 AG14948 transformed cell line human CVCL_2J94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161468 CVCL_2J95 AG14949 transformed cell line human CVCL_2J95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161469 CVCL_2J92 AG14888 transformed cell line human CVCL_2J92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161470 CVCL_2J93 AG14947 transformed cell line human CVCL_2J93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161471 CVCL_2J98 AG14980 transformed cell line human CVCL_2J98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161472 CVCL_2J99 AG14981 transformed cell line human CVCL_2J99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161473 CVCL_2J96 AG14953 transformed cell line human CVCL_2J96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161474 CVCL_2J97 AG14977 transformed cell line human CVCL_2J97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161475 CVCL_2J61 AG14803 transformed cell line human CVCL_2J61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161476 CVCL_2J62 AG14812 transformed cell line human CVCL_2J62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161477 CVCL_2J60 AG14802 transformed cell line human CVCL_2J60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161478 CVCL_2J65 AG14815 transformed cell line human CVCL_2J65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161479 CVCL_2J66 AG14816 transformed cell line human CVCL_2J66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161480 CVCL_2J63 AG14813 transformed cell line human CVCL_2J63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161481 CVCL_2J64 AG14814 transformed cell line human CVCL_2J64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161482 CVCL_2J69 AG14830 transformed cell line human CVCL_2J69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161483 CVCL_2J67 AG14828 transformed cell line human CVCL_2J67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161484 CVCL_2J68 AG14829 transformed cell line human CVCL_2J68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161485 CVCL_2J72 AG14833 transformed cell line human CVCL_2J72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161486 CVCL_2J73 AG14834 transformed cell line human CVCL_2J73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161487 CVCL_2J70 AG14831 transformed cell line human CVCL_2J70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161488 CVCL_2J71 AG14832 transformed cell line human CVCL_2J71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161489 CVCL_2J76 AG14839 transformed cell line human CVCL_2J76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161490 CVCL_2J77 AG14840 transformed cell line human CVCL_2J77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161491 CVCL_2J74 AG14835 transformed cell line human CVCL_2J74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161492 CVCL_2J75 AG14836 transformed cell line human CVCL_2J75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161493 CVCL_2J78 AG14841 transformed cell line human CVCL_2J78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161494 CVCL_2J79 AG14842 transformed cell line human CVCL_2J79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161495 CVCL_2J40 AG14748 transformed cell line human CVCL_2J40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161496 CVCL_2J43 AG14752 transformed cell line human CVCL_2J43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161497 CVCL_2J44 AG14756 transformed cell line human CVCL_2J44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161498 CVCL_2J41 AG14750 transformed cell line human CVCL_2J41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161499 CVCL_2J42 AG14751 transformed cell line human CVCL_2J42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161500 CVCL_2J47 AG14775 transformed cell line human CVCL_2J47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161501 CVCL_2J48 AG14776 transformed cell line human CVCL_2J48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161502 CVCL_2J45 AG14757 transformed cell line human CVCL_2J45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161503 CVCL_2J46 AG14774 transformed cell line human CVCL_2J46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161504 CVCL_2J38 AG14730 transformed cell line human CVCL_2J38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161505 CVCL_2J39 AG14731 transformed cell line human CVCL_2J39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161506 CVCL_V191 FiPS-3F-1 induced pluripotent stem cell human CVCL_V191 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161507 CVCL_UP91 HPS0540 induced pluripotent stem cell human CVCL_UP91 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161508 CVCL_V192 G15.AO induced pluripotent stem cell human CVCL_V192 From: Centro de Investigacion Medica Aplicada (CIMA); Pamplona; Spain CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161509 CVCL_UP92 HPS0541 induced pluripotent stem cell human CVCL_UP92 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161510 CVCL_V190 CBiPS1sv-4F-5 induced pluripotent stem cell human CVCL_V190 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161511 CVCL_UP90 HPS0396 induced pluripotent stem cell human CVCL_UP90 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161512 CVCL_V195 hiPS-drg9 induced pluripotent stem cell human CVCL_V195 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161513 CVCL_UP95 HPS0472 induced pluripotent stem cell human CVCL_UP95 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161514 CVCL_V196 hiPSC clone 1 induced pluripotent stem cell human CVCL_V196 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161515 CVCL_UP96 HPS1072 induced pluripotent stem cell human CVCL_UP96 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161516 CVCL_V193 G15.D induced pluripotent stem cell human CVCL_V193 From: Centro de Investigacion Medica Aplicada (CIMA); Pamplona; Spain CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161517 CVCL_UP93 HPS0542 induced pluripotent stem cell human CVCL_UP93 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161518 CVCL_V194 hiPS-drg13 induced pluripotent stem cell human CVCL_V194 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161519 CVCL_UP94 HPS0471 induced pluripotent stem cell human CVCL_UP94 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21161520 CVCL_UP99 HPS0528 induced pluripotent stem cell human CVCL_UP99 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161521 CVCL_V199 iPS-SCU-CD34+ #1 induced pluripotent stem cell human CVCL_V199 HLA typing: A*02:01,24:02; B*51:01,51:01; C*14:02,16:02; DQB1*06:02,06:03; DRB1*13:01,15:01 (Spanish_Stem_Cell_Bank) From: Andalusian Stem Cell Bank; Granada; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161522 CVCL_V197 hiPSC clone 4 induced pluripotent stem cell human CVCL_V197 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161523 CVCL_UP97 HPS0525 induced pluripotent stem cell human CVCL_UP97 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161524 CVCL_V198 ESi037-A induced pluripotent stem cell human CVCL_V198 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161525 CVCL_UP98 HPS0527 induced pluripotent stem cell human CVCL_UP98 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161526 CVCL_V179 CBiPS6-2F-1 induced pluripotent stem cell human CVCL_V179 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21161527 CVCL_UP79 HPS1068 induced pluripotent stem cell human CVCL_UP79 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161528 CVCL_2J50 AG14778 transformed cell line human CVCL_2J50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161529 CVCL_2J51 AG14784 transformed cell line human CVCL_2J51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161530 CVCL_2J54 AG14789 transformed cell line human CVCL_2J54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161531 CVCL_2J55 AG14790 transformed cell line human CVCL_2J55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161532 CVCL_2J52 AG14785 transformed cell line human CVCL_2J52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161533 CVCL_2J53 AG14786 transformed cell line human CVCL_2J53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161534 CVCL_2J58 AG14800 transformed cell line human CVCL_2J58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161535 CVCL_2J59 AG14801 transformed cell line human CVCL_2J59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161536 CVCL_2J56 AG14798 transformed cell line human CVCL_2J56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161537 CVCL_2J57 AG14799 transformed cell line human CVCL_2J57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161538 CVCL_2J49 AG14777 transformed cell line human CVCL_2J49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161539 CVCL_V180 ESi038-A induced pluripotent stem cell human CVCL_V180 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161540 CVCL_UP80 HPS1069 induced pluripotent stem cell human CVCL_UP80 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161541 CVCL_UP81 HPS1070 induced pluripotent stem cell human CVCL_UP81 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161542 CVCL_V181 iPSC-CGD1.1 induced pluripotent stem cell human CVCL_V181 CL:0000010 Sequence variation: Mutation; HGNC; 7660; NCF1; Simple; p.Tyr26Hisfs*26 (c.73_74GT[1]) (c.75_76delGT); ClinVar=VCV000002249; Zygosity=Homozygous (PubMed=22311747) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161543 CVCL_UP84 HPS0318 induced pluripotent stem cell human CVCL_UP84 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21161544 CVCL_V184 iPSC-CGD3 induced pluripotent stem cell human CVCL_V184 CL:0000010 Sequence variation: Mutation; HGNC; 2578; CYBB; Unexplicit; Ex1-3del; Zygosity=Hemizygous (PubMed=22311747) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161545 CVCL_UP85 HPS0320 induced pluripotent stem cell human CVCL_UP85 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21161546 CVCL_V185 iPSC-HDF induced pluripotent stem cell human CVCL_V185 CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 21161547 CVCL_UP82 HPS0315 induced pluripotent stem cell human CVCL_UP82 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (from autologous cell line HPS0312) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 21161548 CVCL_V182 iPSC-CGD1.2 induced pluripotent stem cell human CVCL_V182 CL:0000010 Sequence variation: Mutation; HGNC; 7660; NCF1; Simple; p.Tyr26Hisfs*26 (c.73_74GT[1]) (c.75_76delGT); ClinVar=VCV000002249; Zygosity=Homozygous (PubMed=22311747) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161549 CVCL_UP83 HPS0316 induced pluripotent stem cell human CVCL_UP83 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (from autologous cell line HPS0312) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 21161550 CVCL_V183 iPSC-CGD2 induced pluripotent stem cell human CVCL_V183 CL:0000010 Sequence variation: Mutation; HGNC; 2578; CYBB; Simple; c.46-11T>G (IVS1-11T>G); Zygosity=Hemizygous (PubMed=22311747) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161551 CVCL_UP88 HPS0325 induced pluripotent stem cell human CVCL_UP88 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21161552 CVCL_V188 Zh21 embryonic stem cell human CVCL_V188 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 Male 21161553 CVCL_V189 CBiPS1sv-4F-40 induced pluripotent stem cell human CVCL_V189 From: Inbiomed; Gipuzkoa; Spain CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21161554 CVCL_UP89 HPS0394 induced pluripotent stem cell human CVCL_UP89 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161555 CVCL_V186 CEM cl13 cancer cell line human CVCL_V186 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21161556 CVCL_UP86 HPS0321 induced pluripotent stem cell human CVCL_UP86 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21161557 CVCL_UP87 HPS0324 induced pluripotent stem cell human CVCL_UP87 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21161558 CVCL_V187 Zh1 embryonic stem cell human CVCL_V187 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 Female 21161559 CVCL_M909 9G2.1.3 hybridoma house mouse CVCL_M909 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11030 21161560 CVCL_LX09 BayGenomics ES cell line CSH180 embryonic stem cell house mouse CVCL_LX09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97346; Nktr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161561 CVCL_M907 293-VnR transformed cell line human CVCL_M907 CL:0000010 Transfected with: HGNC; 6150; ITGAV; Transfected with: HGNC; 6156; ITGB3 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21161562 CVCL_LX07 BayGenomics ES cell line CSH177 embryonic stem cell house mouse CVCL_LX07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914321; Rps6ka6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161563 CVCL_M908 9D4.9.1 hybridoma house mouse CVCL_M908 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11031 21161564 CVCL_LX08 BayGenomics ES cell line CSH178 embryonic stem cell house mouse CVCL_LX08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161565 CVCL_LX05 BayGenomics ES cell line CSH173 embryonic stem cell house mouse CVCL_LX05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161566 CVCL_M905 TSU-Pr1-B2 cancer cell line human CVCL_M905 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Grand-parent cell line (TSU-Pr1) has been shown to be a T24 derivative. 21161567 CVCL_LX06 BayGenomics ES cell line CSH175 embryonic stem cell house mouse CVCL_LX06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161568 CVCL_M906 M-NBT-II cancer cell line Norway rat CVCL_M906 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male 21161569 CVCL_LX03 BayGenomics ES cell line CSH169 embryonic stem cell house mouse CVCL_LX03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921571; Tipin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161570 CVCL_M903 Hs 237.T cancer cell line human CVCL_M903 CL:0000010 Discontinued: ATCC; CRL-7202; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161571 CVCL_LX04 BayGenomics ES cell line CSH170 embryonic stem cell house mouse CVCL_LX04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161572 CVCL_M904 TSU-Pr1-B1 cancer cell line human CVCL_M904 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Parent cell line (TSU-Pr1) has been shown to be a T24 derivative. 21161573 CVCL_LX01 BayGenomics ES cell line CSH164 embryonic stem cell house mouse CVCL_LX01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918764; Sfpq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161574 CVCL_M901 Hs 239.Pe cancer cell line human CVCL_M901 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7205; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161575 CVCL_LX02 BayGenomics ES cell line CSH165 embryonic stem cell house mouse CVCL_LX02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161576 CVCL_M902 Hs 240.Pe cancer cell line human CVCL_M902 CL:0000010 Derived from metastatic site: Pleural effusion. Discontinued: ATCC; CRL-7206; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161577 CVCL_LX00 BayGenomics ES cell line CSH161 embryonic stem cell house mouse CVCL_LX00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277172; Ddx56 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161578 CVCL_M900 Hs 243.T cancer cell line human CVCL_M900 CL:0000010 Discontinued: ATCC; CRL-7208; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161579 CVCL_LX18 BayGenomics ES cell line CSH195 embryonic stem cell house mouse CVCL_LX18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161580 CVCL_M918 GM23612 transformed cell line human CVCL_M918 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161581 CVCL_LX19 BayGenomics ES cell line CSH200 embryonic stem cell house mouse CVCL_LX19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161582 CVCL_M919 GM23613 finite cell line human CVCL_M919 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161583 CVCL_LX16 BayGenomics ES cell line CSH192 embryonic stem cell house mouse CVCL_LX16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914457; Lsm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161584 CVCL_M916 GM23721 transformed cell line human CVCL_M916 CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Ser140Thr (c.418T>A); ClinVar=VCV000447730; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161585 CVCL_LX17 BayGenomics ES cell line CSH194 embryonic stem cell house mouse CVCL_LX17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916478; Zfp746 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161586 CVCL_M917 GM23614 transformed cell line human CVCL_M917 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161587 CVCL_LX14 BayGenomics ES cell line CSH188 embryonic stem cell house mouse CVCL_LX14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161588 CVCL_M914 C3ABR transformed cell line human CVCL_M914 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161589 CVCL_LX15 BayGenomics ES cell line CSH189 embryonic stem cell house mouse CVCL_LX15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161590 CVCL_M915 L3 [Human A-T patient lymphoblastoid] transformed cell line human CVCL_M915 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21161591 CVCL_M912 AT3ABR transformed cell line human CVCL_M912 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys2756Ter (c.8266A>T); ClinVar=VCV000135780; Zygosity=Heterozygous (PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21161592 CVCL_LX12 BayGenomics ES cell line CSH185 embryonic stem cell house mouse CVCL_LX12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3578435; L1td1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161593 CVCL_M913 AT5ABR transformed cell line human CVCL_M913 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21161594 CVCL_LX13 BayGenomics ES cell line CSH187 embryonic stem cell house mouse CVCL_LX13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161595 CVCL_LX10 BayGenomics ES cell line CSH182 embryonic stem cell house mouse CVCL_LX10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916873; Zfp33b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161596 CVCL_M910 AT3LA LCL transformed cell line human CVCL_M910 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161597 CVCL_M911 AT1ABR transformed cell line human CVCL_M911 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Homozygous (PubMed=7792600; PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21161598 CVCL_LX11 BayGenomics ES cell line CSH184 embryonic stem cell house mouse CVCL_LX11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679002; Prr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161599 CVCL_V324 CCRF-CEM R3/7 cancer cell line human CVCL_V324 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21161600 CVCL_UR24 KU-SEPO-3 spontaneously immortalized cell line CVCL_UR24 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 59 hours (DOI=10.18178/joaat.5.4.281-288) Group: Insect cell line 21161601 CVCL_V325 CCRF-CEM R30dm cancer cell line human CVCL_V325 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21161602 CVCL_UR25 KU-SEPO-4 spontaneously immortalized cell line CVCL_UR25 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 55 hours (DOI=10.18178/joaat.5.4.281-288) Group: Insect cell line 21161603 CVCL_V322 CCR5 spontaneously immortalized cell line CVCL_V322 CL:0000010 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161604 CVCL_UR22 KU-SEPO-1 spontaneously immortalized cell line CVCL_UR22 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 57 hours (DOI=10.18178/joaat.5.4.281-288) Group: Insect cell line 21161605 CVCL_V323 CCRF-CEM R30/6 cancer cell line human CVCL_V323 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21161606 CVCL_UR23 KU-SEPO-2 spontaneously immortalized cell line CVCL_UR23 CL:0000010 Derived from sampling site: Ovary. Female Virology: Highly susceptible to infection by Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV) (DOI=10.18178/joaat.5.4.281-288) Doubling time: 46 hours (DOI=10.18178/joaat.5.4.281-288) Group: Insect cell line 21161607 CVCL_V328 CHO-91-22 spontaneously immortalized cell line CVCL_V328 CL:0000010 Transfected with: HGNC; 2577; CYBA; Transfected with: HGNC; 2578; CYBB Derived from sampling site: Ovary. Female 21161608 CVCL_UR28 HEK293 Cas9 transformed cell line human CVCL_UR28 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Using CRISPR/Cas9 a construct containing Cas9-2A-RFP-PA-Neo-PA was introduced in the AAVS1 safe harbor locus 21161609 CVCL_UR29 293/SF transformed cell line human CVCL_UR29 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-1573.1; true Female Group: Serum/protein free medium cell line 21161610 CVCL_V329 CHO-91-22-47-67 spontaneously immortalized cell line CVCL_V329 CL:0000010 Transfected with: HGNC; 2577; CYBA; Transfected with: HGNC; 2578; CYBB; Transfected with: HGNC; 7660; NCF1; Transfected with: HGNC; 7661; NCF2 Derived from sampling site: Ovary. Female 21161611 CVCL_UR26 BIONi010-C-37 induced pluripotent stem cell human CVCL_UR26 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30634129) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161612 CVCL_V326 CHO-22 spontaneously immortalized cell line CVCL_V326 CL:0000010 Transfected with: HGNC; 2577; CYBA Derived from sampling site: Ovary. Female 21161613 CVCL_UR27 BIONi010-C-38 induced pluripotent stem cell human CVCL_UR27 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Lys670_Met671delinsAsnLeu (c.2010_2011inv) (c.2010_2011delGAinsTC); ClinVar=VCV000018093; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30634129) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21161614 CVCL_V327 CHO-91 spontaneously immortalized cell line CVCL_V327 CL:0000010 Transfected with: HGNC; 2578; CYBB Derived from sampling site: Ovary. Female 21161615 CVCL_LX89 BayGenomics ES cell line CSH349 embryonic stem cell house mouse CVCL_LX89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917394; Lrch3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161616 CVCL_M989 GM01960 finite cell line human CVCL_M989 CL:0000010 Sequence variation: Mutation; HGNC; 12404; TTPA; Simple; p.Arg221Trp (c.661C>T); ClinVar=VCV000065597; Zygosity=Homozygous (Coriell) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21161617 CVCL_LX87 BayGenomics ES cell line CSH347 embryonic stem cell house mouse CVCL_LX87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161618 CVCL_M987 GM01840 finite cell line human CVCL_M987 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Discontinued: Coriell; AG01840; probable; Discontinued: Coriell; GM01840; probable; Discontinued: Coriell; GM17311; probable Female Part of: Human variation panel 21161619 CVCL_LX88 BayGenomics ES cell line CSH348 embryonic stem cell house mouse CVCL_LX88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161620 CVCL_M988 GM01850 finite cell line human CVCL_M988 HLA typing: A*24:CWFP,26:GAX; B*08:XKT,44:WRJ; C*01:02,03:04; DRB1*01:03,13:04 (IPD-IMGT/HLA=19227) CL:0000010 Sequence variation: Mutation; HGNC; 4696; GUSB; Simple; p.Trp627Cys (c.1881G>T); ClinVar=VCV000000907; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis Male Part of: Human variation panel 21161621 CVCL_LX85 BayGenomics ES cell line CSH345 embryonic stem cell house mouse CVCL_LX85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921728; Snx29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161622 CVCL_M985 GM01251 finite cell line human CVCL_M985 HLA typing: A*03:CVAB,29:02; B*58:02,81:MN; C*06:02,18:AB; DRB1*03:01,08:04 (IPD-IMGT/HLA=23055) CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis Male Part of: Human variation panel 21161623 CVCL_LX86 BayGenomics ES cell line CSH346 embryonic stem cell house mouse CVCL_LX86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161624 CVCL_M986 GM01536 finite cell line human CVCL_M986 HLA typing: A*33:01,74:AB; B*15:BKNX,53:01; C*02:10,04:CVAF; DRB1*08:04,13:02 (IPD-IMGT/HLA=16418) CL:0000010 Population: African American; Karyotypic information: 46,XX,t(5;12)(5pter->5q33::12q24->12qter;12pter->12q24::5q33->5qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis Female Part of: Human variation panel 21161625 CVCL_LX83 BayGenomics ES cell line CSH342 embryonic stem cell house mouse CVCL_LX83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161626 CVCL_M983 GM01212 finite cell line human CVCL_M983 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asp98His (c.292G>C); ClinVar=VCV000025149; Zygosity=Heterozygous (Coriell) Population: Latino or Hispanic; Dominican; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21161627 CVCL_LX84 BayGenomics ES cell line CSH344 embryonic stem cell house mouse CVCL_LX84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919686; Tbcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161628 CVCL_M984 GM01225 finite cell line human CVCL_M984 CL:0000010 Population: Indian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Human variation panel 21161629 CVCL_LX81 BayGenomics ES cell line CSH338 embryonic stem cell house mouse CVCL_LX81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925920; Plekhj1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161630 CVCL_M981 GM01032 transformed cell line human CVCL_M981 HLA typing: A*09:10; B*13 (Coriell=GM01032) CL:0000010 Population: Indo Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21161631 CVCL_LX82 BayGenomics ES cell line CSH341 embryonic stem cell house mouse CVCL_LX82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96622; Itpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161632 CVCL_M982 GM01208 finite cell line human CVCL_M982 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Asp98His (c.292G>C); ClinVar=VCV000025149; Zygosity=Heterozygous (from familila inference of GM01209 and GM01210) Population: Latino or Hispanic; Dominican; Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21161633 CVCL_LX80 BayGenomics ES cell line CSH337 embryonic stem cell house mouse CVCL_LX80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161634 CVCL_M980 GM01018 transformed cell line human CVCL_M980 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21161635 CVCL_UR31 A549-Luc2 cancer cell line human CVCL_UR31 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter 21161636 CVCL_V331 HepG2 Tet-On cancer cell line human CVCL_V331 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21161637 CVCL_UR32 A375-Luc2 cancer cell line human CVCL_UR32 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter 21161638 CVCL_V332 MCF7 Tet-On cancer cell line human CVCL_V332 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 630918 Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21161639 CVCL_V330 CHO-91-47-67 spontaneously immortalized cell line CVCL_V330 CL:0000010 Transfected with: HGNC; 2578; CYBB; Transfected with: HGNC; 7660; NCF1; Transfected with: HGNC; 7661; NCF2 Derived from sampling site: Ovary. Female 21161640 CVCL_UR30 hTERT A41hWAT-SVF telomerase immortalized cell line human CVCL_UR30 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: White adipose tissue. Male Doubling time: 48-72 hours (ATCC=CRL-3386) 21161641 CVCL_V313 HeLa K11A-HG-1 cancer cell line human CVCL_V313 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21161642 CVCL_UR13 HPS0954 induced pluripotent stem cell human CVCL_UR13 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161643 CVCL_UR14 HPS0287 induced pluripotent stem cell human CVCL_UR14 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161644 CVCL_V314 Shi/FeT-1C spontaneously immortalized cell line CVCL_V314 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent; Virology: Persistently infected by feline immunodeficiency virus (FIV) isolate Shi Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11976 21161645 CVCL_UR11 HPS0941 induced pluripotent stem cell human CVCL_UR11 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161646 CVCL_V311 NZP-53 finite cell line CVCL_V311 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1920; true Unspecified Senescence: Capable of at least 10 PDL (ATCC=CRL-1920) Group: Endangered species/breed cell line 21161647 CVCL_V312 HeLa K11 cancer cell line human CVCL_V312 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21161648 CVCL_UR12 HPS0953 induced pluripotent stem cell human CVCL_UR12 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161649 CVCL_UR17 HPS0398 induced pluripotent stem cell human CVCL_UR17 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161650 CVCL_V317 SV-Mm-11 transformed cell line CVCL_V317 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21161651 CVCL_UR18 HPS0399 induced pluripotent stem cell human CVCL_UR18 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161652 CVCL_V318 SV-Mm-12 transformed cell line CVCL_V318 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21161653 CVCL_V315 Bang/FeT-J spontaneously immortalized cell line CVCL_V315 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 independent; Virology: Persistently infected by feline immunodeficiency virus (FIV) isolate Bangston Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11975 21161654 CVCL_UR15 HPS0391 induced pluripotent stem cell human CVCL_UR15 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161655 CVCL_UR16 HPS0392 induced pluripotent stem cell human CVCL_UR16 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161656 CVCL_V316 Mm-2K finite cell line CVCL_V316 CL:0000010 Derived from sampling site: Kidney. Male 21161657 CVCL_UR19 HPS0409 induced pluripotent stem cell human CVCL_UR19 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161658 CVCL_V319 SV-Mm-12A transformed cell line CVCL_V319 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21161659 CVCL_LX98 BayGenomics ES cell line CSH364 embryonic stem cell house mouse CVCL_LX98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928380; B4galt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161660 CVCL_M998 GM02473 transformed cell line human CVCL_M998 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21161661 CVCL_LX99 BayGenomics ES cell line CSH368 embryonic stem cell house mouse CVCL_LX99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161662 CVCL_M999 XP15BE LCL transformed cell line human CVCL_M999 CL:0000010 Population: Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21161663 CVCL_LX96 BayGenomics ES cell line CSH361 embryonic stem cell house mouse CVCL_LX96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338026; Tom1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161664 CVCL_M996 GM02430 transformed cell line human CVCL_M996 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161665 CVCL_LX97 BayGenomics ES cell line CSH363 embryonic stem cell house mouse CVCL_LX97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108517; Denn2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161666 CVCL_M997 GM02432 transformed cell line human CVCL_M997 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21161667 CVCL_LX94 BayGenomics ES cell line CSH358 embryonic stem cell house mouse CVCL_LX94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161668 CVCL_M994 GM02064 transformed cell line human CVCL_M994 CL:0000010 Sequence variation: Gene deletion; HGNC; 4827; HBB; Zygosity=Homozygous (Coriell); Sequence variation: Gene deletion; HGNC; 4829; HBD; Zygosity=Homozygous (Coriell) Population: Africans south of the Sahara; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21161669 CVCL_LX95 BayGenomics ES cell line CSH360 embryonic stem cell house mouse CVCL_LX95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100851; Elavl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161670 CVCL_M995 GM02293 finite cell line human CVCL_M995 CL:0000010 Population: Cuban; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21161671 CVCL_LX92 BayGenomics ES cell line CSH354 embryonic stem cell house mouse CVCL_LX92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161672 CVCL_M992 GM02017 finite cell line human CVCL_M992 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Gly409Arg (c.1225G>C); ClinVar=VCV000092627; Zygosity=Heterozygous (PubMed=8328452); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Ter654Cysext*38 (c.1962A>T); ClinVar=VCV000242721; Zygosity=Heterozygous (PubMed=8328452) Population: Arab; Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21161673 CVCL_LX93 BayGenomics ES cell line CSH356 embryonic stem cell house mouse CVCL_LX93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444554; Mapkap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161674 CVCL_M993 GM02051 finite cell line human CVCL_M993 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.His72Leu (c.215A>T) (H71L); ClinVar=VCV000001684; Zygosity=Homozygous (Coriell) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21161675 CVCL_LX90 BayGenomics ES cell line CSH351 embryonic stem cell house mouse CVCL_LX90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161676 CVCL_M990 GM02014 finite cell line human CVCL_M990 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Tyr1079Leufs*3 (c.3231_3234dupCTAC) (3395_3398dupCTAC); ClinVar=VCV000038423; Zygosity=Heterozygous (PubMed=16465621) Population: Arab; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21161677 CVCL_LX91 BayGenomics ES cell line CSH352 embryonic stem cell house mouse CVCL_LX91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914289; Rbm25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161678 CVCL_M991 GM02016 finite cell line human CVCL_M991 HLA typing: A*02:01:01,30:02:01; B*53:01:01,58:01:01; C*04:01:01,07:18; DPA1*01:03:01,01:03:01; DPB1*02:01:02,03:01:01; DQA1*01:05:01,04:01:02; DQB1*04:02:01,05:01:01; DRB1*08:04:01,14:54:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Gly409Arg (c.1225G>C); ClinVar=VCV000092627; Zygosity=Heterozygous (PubMed=8328452); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Ter654Cysext*38 (c.1962A>T); ClinVar=VCV000242721; Zygosity=Heterozygous (PubMed=8328452) Population: Arab; Derived from sampling site: Cell type=Fibroblast. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21161679 CVCL_UR20 HPS0410 induced pluripotent stem cell human CVCL_UR20 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161680 CVCL_V320 SV-Mm-13 transformed cell line CVCL_V320 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21161681 CVCL_UR21 HPS0484 induced pluripotent stem cell human CVCL_UR21 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21161682 CVCL_V321 SV-Mm-21 transformed cell line CVCL_V321 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male 21161683 CVCL_UR02 HPS0947 induced pluripotent stem cell human CVCL_UR02 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161684 CVCL_V302 LM-100/SV40 transformed cell line human CVCL_V302 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161685 CVCL_UR03 HPS0948 induced pluripotent stem cell human CVCL_UR03 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161686 CVCL_V303 LM-30.1/SV40 transformed cell line human CVCL_V303 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161687 CVCL_UR00 HPS0945 induced pluripotent stem cell human CVCL_UR00 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161688 CVCL_V300 Li-538/SV40 transformed cell line human CVCL_V300 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. 21161689 CVCL_UR01 HPS0946 induced pluripotent stem cell human CVCL_UR01 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161690 CVCL_V301 LIS-3/SV40 transformed cell line human CVCL_V301 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male 21161691 CVCL_UR06 CiRA00169 induced pluripotent stem cell human CVCL_UR06 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161692 CVCL_V306 LM-605/SV40 transformed cell line human CVCL_V306 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161693 CVCL_UR07 CiRA00170 induced pluripotent stem cell human CVCL_UR07 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161694 CVCL_V307 LM-608/SV40 transformed cell line human CVCL_V307 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161695 CVCL_UR04 HPS0949 induced pluripotent stem cell human CVCL_UR04 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161696 CVCL_V304 LM-5.1/SV40 transformed cell line human CVCL_V304 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161697 CVCL_UR05 HPS0389 induced pluripotent stem cell human CVCL_UR05 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161698 CVCL_V305 LM-600/SV40 transformed cell line human CVCL_V305 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161699 CVCL_UR08 CiRA00171 induced pluripotent stem cell human CVCL_UR08 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161700 CVCL_V308 LM-609/SV40 transformed cell line human CVCL_V308 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161701 CVCL_UR09 HPS0939 induced pluripotent stem cell human CVCL_UR09 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161702 CVCL_V309 LM-65/SV40 transformed cell line human CVCL_V309 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21161703 CVCL_LX69 BayGenomics ES cell line CSH316 embryonic stem cell house mouse CVCL_LX69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161704 CVCL_M969 OLF4.6.2 transformed cell line house mouse CVCL_M969 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161705 CVCL_LX67 BayGenomics ES cell line CSH314 embryonic stem cell house mouse CVCL_LX67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926027; Tepsin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161706 CVCL_M967 OLF4.5.1 transformed cell line house mouse CVCL_M967 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161707 CVCL_LX68 BayGenomics ES cell line CSH315 embryonic stem cell house mouse CVCL_LX68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444737; Fem1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161708 CVCL_M968 OLF4.6.1 transformed cell line house mouse CVCL_M968 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161709 CVCL_LX65 BayGenomics ES cell line CSH310 embryonic stem cell house mouse CVCL_LX65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684864; Pfas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161710 CVCL_M965 OLF4.4.1 transformed cell line house mouse CVCL_M965 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161711 CVCL_LX66 BayGenomics ES cell line CSH312 embryonic stem cell house mouse CVCL_LX66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100856; Mras Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161712 CVCL_M966 OLF4.4.2 transformed cell line house mouse CVCL_M966 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161713 CVCL_LX63 BayGenomics ES cell line CSH307 embryonic stem cell house mouse CVCL_LX63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922083; Ciapin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161714 CVCL_M963 OLF4.1 transformed cell line house mouse CVCL_M963 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161715 CVCL_LX64 BayGenomics ES cell line CSH308 embryonic stem cell house mouse CVCL_LX64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918006; Dock4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161716 CVCL_M964 OLF4.3 transformed cell line house mouse CVCL_M964 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161717 CVCL_LX61 BayGenomics ES cell line CSH295 embryonic stem cell house mouse CVCL_LX61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105917; Fer Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161718 CVCL_M961 OLF3.3 transformed cell line house mouse CVCL_M961 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161719 CVCL_LX62 BayGenomics ES cell line CSH299 embryonic stem cell house mouse CVCL_LX62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161720 CVCL_M962 OLF3.6 transformed cell line house mouse CVCL_M962 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161721 CVCL_LX60 BayGenomics ES cell line CSH287 embryonic stem cell house mouse CVCL_LX60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161722 CVCL_M960 FNCB4-hTERT telomerase immortalized cell line human CVCL_M960 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Fetal nose; nasal cavity; olfactory mucosa Cell type=Epithelial cell.. Male 21161723 CVCL_UR10 HPS0940 induced pluripotent stem cell human CVCL_UR10 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161724 CVCL_V310 LIS-3/SV40/A9-B4 hybrid cell line CVCL_V310 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161725 CVCL_LX78 BayGenomics ES cell line CSH335 embryonic stem cell house mouse CVCL_LX78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161726 CVCL_M978 GM00627 finite cell line human CVCL_M978 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(13;22)(13pter->13q22::22q13->22qter;22pter->22q13::13q22->13qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis Female Part of: Human variation panel 21161727 CVCL_LX79 BayGenomics ES cell line CSH336 embryonic stem cell house mouse CVCL_LX79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161728 CVCL_M979 GM00726 finite cell line human CVCL_M979 CL:0000010 Population: Korean; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Part of: Human variation panel 21161729 CVCL_LX76 BayGenomics ES cell line CSH329 embryonic stem cell house mouse CVCL_LX76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384788; Sde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161730 CVCL_M976 T243 cancer cell line human CVCL_M976 CL:0000010 Sequence variation: Mutation; HGNC; 2681; DAXX; Simple; p.Arg318Ter (c.952C>T); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Pro723fs (c.2167delC); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11957; MED12; Simple; p.Arg282Ter (c.844C>T); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Gln130Valfs*2 (c.388_389delCA); ClinVar=VCV000091090; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg604Ter (c.1810C>T); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103Thrfs*20 (c.306delC) (p.Thr102fs); Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21161731 CVCL_LX77 BayGenomics ES cell line CSH331 embryonic stem cell house mouse CVCL_LX77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443446; Scfd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161732 CVCL_M977 T351 cancer cell line human CVCL_M977 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln28Ter (c.82C>T); ClinVar=VCV000429015; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn29Thrfs*15 (c.86delA); ClinVar=VCV000528243; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21161733 CVCL_M974 AT24 transformed cell line human CVCL_M974 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21161734 CVCL_LX74 BayGenomics ES cell line CSH326 embryonic stem cell house mouse CVCL_LX74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161735 CVCL_LX75 BayGenomics ES cell line CSH327 embryonic stem cell house mouse CVCL_LX75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145425; Depdc1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161736 CVCL_M975 T241 cancer cell line human CVCL_M975 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp252fs (c.756delT); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female 21161737 CVCL_M972 AT59 transformed cell line human CVCL_M972 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21161738 CVCL_LX72 BayGenomics ES cell line CSH324 embryonic stem cell house mouse CVCL_LX72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161739 CVCL_LX73 BayGenomics ES cell line CSH325 embryonic stem cell house mouse CVCL_LX73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161740 CVCL_M973 L40 transformed cell line human CVCL_M973 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21161741 CVCL_LX70 BayGenomics ES cell line CSH320 embryonic stem cell house mouse CVCL_LX70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161742 CVCL_M970 OLF4.6.3 transformed cell line house mouse CVCL_M970 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161743 CVCL_LX71 BayGenomics ES cell line CSH323 embryonic stem cell house mouse CVCL_LX71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161744 CVCL_M971 OLF4.7.8 transformed cell line house mouse CVCL_M971 CL:0000010 Transfected with: MGI; MGI:97357; Mycn; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; forebrain; olfactory bulb. Unspecified 21161745 CVCL_LX49 BayGenomics ES cell line CSH267 embryonic stem cell house mouse CVCL_LX49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161746 CVCL_M949 GM04205 transformed cell line human CVCL_M949 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21161747 CVCL_LX47 BayGenomics ES cell line CSH260 embryonic stem cell house mouse CVCL_LX47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924393; Trip11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161748 CVCL_M947 GM03957 transformed cell line human CVCL_M947 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21161749 CVCL_LX48 BayGenomics ES cell line CSH266 embryonic stem cell house mouse CVCL_LX48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161750 CVCL_M948 GM04204 finite cell line human CVCL_M948 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21161751 CVCL_LX45 BayGenomics ES cell line CSH256 embryonic stem cell house mouse CVCL_LX45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095403; Sf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161752 CVCL_M945 GM03759 finite cell line human CVCL_M945 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~2000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161753 CVCL_LX46 BayGenomics ES cell line CSH259 embryonic stem cell house mouse CVCL_LX46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333799; Xrcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161754 CVCL_M946 GM03956 finite cell line human CVCL_M946 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21161755 CVCL_LX43 BayGenomics ES cell line CSH250 embryonic stem cell house mouse CVCL_LX43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161756 CVCL_M943 GM03781 finite cell line human CVCL_M943 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-17del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Iberian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21161757 CVCL_LX44 BayGenomics ES cell line CSH253 embryonic stem cell house mouse CVCL_LX44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161758 CVCL_M944 GM03696 transformed cell line human CVCL_M944 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21161759 CVCL_LX41 BayGenomics ES cell line CSH244 embryonic stem cell house mouse CVCL_LX41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346340; Mta2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161760 CVCL_M941 GM03721 transformed cell line human CVCL_M941 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21161761 CVCL_LX42 BayGenomics ES cell line CSH247 embryonic stem cell house mouse CVCL_LX42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161762 CVCL_M942 GM03780 transformed cell line human CVCL_M942 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-17del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21161763 CVCL_LX40 BayGenomics ES cell line CSH239 embryonic stem cell house mouse CVCL_LX40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346340; Mta2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161764 CVCL_M940 GM03720 finite cell line human CVCL_M940 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21161765 CVCL_LX58 BayGenomics ES cell line CSH285 embryonic stem cell house mouse CVCL_LX58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107380; Spag7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161766 CVCL_M958 Boar88 cancer cell line human CVCL_M958 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=11572760). Population: Japanese Unspecified 21161767 CVCL_M959 3NA12 conditionally immortalized cell line house mouse CVCL_M959 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; olfactory epithelium Cell type=Olfactory sensory neuron.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Group: Patented cell line 21161768 CVCL_LX59 BayGenomics ES cell line CSH286 embryonic stem cell house mouse CVCL_LX59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352466; Nr2c2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161769 CVCL_LX56 BayGenomics ES cell line CSH278 embryonic stem cell house mouse CVCL_LX56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161770 CVCL_M956 IBE conditionally immortalized cell line house mouse CVCL_M956 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; capillary Cell type=Endothelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. 21161771 CVCL_LX57 BayGenomics ES cell line CSH281 embryonic stem cell house mouse CVCL_LX57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161772 CVCL_M957 AT4LA LCL transformed cell line human CVCL_M957 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161773 CVCL_LX54 BayGenomics ES cell line CSH275 embryonic stem cell house mouse CVCL_LX54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384798; Osgin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161774 CVCL_M954 GM04814 transformed cell line human CVCL_M954 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Venezuelan Huntington disease kindreds subcollection 21161775 CVCL_LX55 BayGenomics ES cell line CSH276 embryonic stem cell house mouse CVCL_LX55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161776 CVCL_M955 GM04815 finite cell line human CVCL_M955 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21161777 CVCL_LX52 BayGenomics ES cell line CSH272 embryonic stem cell house mouse CVCL_LX52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161778 CVCL_M952 GM04689 finite cell line human CVCL_M952 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21161779 CVCL_LX53 BayGenomics ES cell line CSH273 embryonic stem cell house mouse CVCL_LX53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141959; Alg8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161780 CVCL_M953 GM04690 transformed cell line human CVCL_M953 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Part of: Human variation panel; Part of: Venezuelan Huntington disease kindreds subcollection; Registration: CEPH Families Reference Panel; 10205/10402 21161781 CVCL_LX50 BayGenomics ES cell line CSH268 embryonic stem cell house mouse CVCL_LX50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140050; Ints3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161782 CVCL_M950 GM04634 finite cell line human CVCL_M950 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02343) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161783 CVCL_LX51 BayGenomics ES cell line CSH271 embryonic stem cell house mouse CVCL_LX51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161784 CVCL_M951 GM04635 transformed cell line human CVCL_M951 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM02343) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21161785 CVCL_LX29 BayGenomics ES cell line CSH217 embryonic stem cell house mouse CVCL_LX29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443926; Dmxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161786 CVCL_M929 GM02705 transformed cell line human CVCL_M929 HLA typing: A*01:01:01,02:01:01; B*08:01:01,35:01:01; C*07:01:01,15:02:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,04:01:01; DQA1*01:01:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*01:03:01,03:01:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21161787 CVCL_LX27 BayGenomics ES cell line CSH214 embryonic stem cell house mouse CVCL_LX27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346098; Nelfa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161788 CVCL_M927 GM02048 finite cell line human CVCL_M927 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (from autologous cell line GM02533); Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (from autologous cell line GM02533) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21161789 CVCL_LX28 BayGenomics ES cell line CSH215 embryonic stem cell house mouse CVCL_LX28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443926; Dmxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161790 CVCL_M928 GM02704 finite cell line human CVCL_M928 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21161791 CVCL_LX25 BayGenomics ES cell line CSH211 embryonic stem cell house mouse CVCL_LX25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336881; Mok Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161792 CVCL_M925 GM00940 finite cell line human CVCL_M925 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21161793 CVCL_LX26 BayGenomics ES cell line CSH212 embryonic stem cell house mouse CVCL_LX26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99204; Zfp57 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161794 CVCL_M926 GM02533 transformed cell line human CVCL_M926 CL:0000010 Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.406-2A>G (IVS3AS-2A>G); ClinVar=VCV000005131; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=11013137); Sequence variation: Mutation; HGNC; 13356; MCOLN1; Simple; c.511del6434 (Ex1-7del) (delta6432); Zygosity=Heterozygous (PubMed=11013137) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21161795 CVCL_LX23 BayGenomics ES cell line CSH205 embryonic stem cell house mouse CVCL_LX23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161796 CVCL_M923 GM00576 finite cell line human CVCL_M923 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21161797 CVCL_LX24 BayGenomics ES cell line CSH206 embryonic stem cell house mouse CVCL_LX24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182061; Usp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161798 CVCL_M924 GM02134 transformed cell line human CVCL_M924 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21161799 CVCL_LX21 BayGenomics ES cell line CSH202 embryonic stem cell house mouse CVCL_LX21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161800 CVCL_M921 GM00470 finite cell line human CVCL_M921 CL:0000010 Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21161801 CVCL_LX22 BayGenomics ES cell line CSH204 embryonic stem cell house mouse CVCL_LX22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145317; Brd9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161802 CVCL_M922 GM00546 transformed cell line human CVCL_M922 HLA typing: A*02:01:01,02:01:01; B*39:06:02,50:01:01; C*06:02:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*02:01:01,05:01:01; DQB1*02:01:01,02:02:01; DRB1*03:01:01,07:01:01; DRB3*02:02:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM00546; probable Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21161803 CVCL_LX20 BayGenomics ES cell line CSH201 embryonic stem cell house mouse CVCL_LX20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921404; Unkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161804 CVCL_M920 GM00244 finite cell line human CVCL_M920 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Met318Thr (c.953T>C); ClinVar=VCV000004021; Zygosity=Heterozygous (Coriell; PubMed=1652892); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg854Ter (c.2560C>T); ClinVar=VCV000004034; Zygosity=Heterozygous (Coriell; PubMed=1652892) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21161805 CVCL_LX38 BayGenomics ES cell line CSH230 embryonic stem cell house mouse CVCL_LX38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98884; U2af1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161806 CVCL_M938 GM03226 finite cell line human CVCL_M938 CL:0000010 Population: Caribbean; Trinidadian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Human variation panel 21161807 CVCL_LX39 BayGenomics ES cell line CSH232 embryonic stem cell house mouse CVCL_LX39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914760; Tvp23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161808 CVCL_M939 GM05067 transformed cell line human CVCL_M939 CL:0000010 Population: Caribbean; Trinidadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21161809 CVCL_LX36 BayGenomics ES cell line CSH228 embryonic stem cell house mouse CVCL_LX36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99181; Zfp37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161810 CVCL_M936 GM03071 finite cell line human CVCL_M936 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: SNP array analysis Male 21161811 CVCL_LX37 BayGenomics ES cell line CSH229 embryonic stem cell house mouse CVCL_LX37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99181; Zfp37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161812 CVCL_M937 GM03072 finite cell line human CVCL_M937 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21161813 CVCL_LX34 BayGenomics ES cell line CSH225 embryonic stem cell house mouse CVCL_LX34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161814 CVCL_M934 GM03037 finite cell line human CVCL_M934 CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Human variation panel 21161815 CVCL_LX35 BayGenomics ES cell line CSH227 embryonic stem cell house mouse CVCL_LX35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929648; Med20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161816 CVCL_M935 GM03038 finite cell line human CVCL_M935 CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21161817 CVCL_LX32 BayGenomics ES cell line CSH221 embryonic stem cell house mouse CVCL_LX32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670969; Nrde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161818 CVCL_M932 GM02859 finite cell line human CVCL_M932 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: South American (Brazil, Guyana, Venezuela); Karyotypic information: 46,X,t(X;11)(q11.1;p13) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Human variation panel 21161819 CVCL_LX33 BayGenomics ES cell line CSH222 embryonic stem cell house mouse CVCL_LX33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342294; Uri1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161820 CVCL_M933 GM03316 transformed cell line human CVCL_M933 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21161821 CVCL_LX30 BayGenomics ES cell line CSH219 embryonic stem cell house mouse CVCL_LX30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161822 CVCL_M930 GM02821 finite cell line human CVCL_M930 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(9;12)(9qter->9p13::12q24->12qter;12pter->12q24::9p13->9pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21161823 CVCL_LX31 BayGenomics ES cell line CSH220 embryonic stem cell house mouse CVCL_LX31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917140; Zfp219 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161824 CVCL_M931 GM02822 transformed cell line human CVCL_M931 HLA typing: A*03:CVAB,30:AUX; B*57:02,58:02; C*06:02,18:AB; DRB1*04:05,07:01 (IPD-IMGT/HLA=23056) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21161825 CVCL_V289 Ad-248/SV40 transformed cell line human CVCL_V289 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161826 CVCL_2K42 AG15782 transformed cell line human CVCL_2K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161827 CVCL_2K43 AG15783 transformed cell line human CVCL_2K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161828 CVCL_2K40 AG15767 transformed cell line human CVCL_2K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161829 CVCL_2K41 AG15781 transformed cell line human CVCL_2K41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161830 CVCL_2K46 AG15791 transformed cell line human CVCL_2K46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161831 CVCL_2K47 AG15792 transformed cell line human CVCL_2K47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161832 CVCL_2K44 AG15784 transformed cell line human CVCL_2K44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161833 CVCL_2K45 AG15787 transformed cell line human CVCL_2K45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161834 CVCL_2K39 AG15749 transformed cell line human CVCL_2K39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161835 CVCL_2K37 AG15449 transformed cell line human CVCL_2K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161836 CVCL_2K38 AG15450 transformed cell line human CVCL_2K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161837 CVCL_V290 Ad-263/SV40 transformed cell line human CVCL_V290 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161838 CVCL_V291 Ad-295/SV40 transformed cell line human CVCL_V291 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161839 CVCL_V294 Ad-366/SV40 transformed cell line human CVCL_V294 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161840 CVCL_V295 Li-136/SV40 transformed cell line human CVCL_V295 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. 21161841 CVCL_V292 Ad-302/SV40 transformed cell line human CVCL_V292 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161842 CVCL_V293 Ad-312/SV40 transformed cell line human CVCL_V293 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161843 CVCL_V298 Li-502/SV40 transformed cell line human CVCL_V298 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. 21161844 CVCL_V299 Li-506/SV40 transformed cell line human CVCL_V299 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. 21161845 CVCL_V296 Li-14/SV40 transformed cell line human CVCL_V296 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. Female 21161846 CVCL_V297 Li-501/SV40 transformed cell line human CVCL_V297 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Hypodermis. 21161847 CVCL_V278 MDA-584 cancer cell line human CVCL_V278 CL:0000010 Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21161848 CVCL_V279 HN-SCC-29 cancer cell line human CVCL_V279 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Asp (c.613T>G); ClinVar=VCV000376686; Zygosity=Unspecified (PubMed=8339273). Unspecified 21161849 CVCL_2K50 AG15798 transformed cell line human CVCL_2K50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161850 CVCL_2K53 AG15899 transformed cell line human CVCL_2K53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161851 CVCL_2K54 AG15982 transformed cell line human CVCL_2K54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161852 CVCL_2K51 AG15799 transformed cell line human CVCL_2K51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161853 CVCL_2K52 AG15801 transformed cell line human CVCL_2K52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161854 CVCL_2K57 AG16640 transformed cell line human CVCL_2K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161855 CVCL_2K58 AG16641 transformed cell line human CVCL_2K58 CL:0000010 Population: Caucasian; Dutch/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21161856 CVCL_2K55 AG15997 transformed cell line human CVCL_2K55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161857 CVCL_2K56 AG16639 transformed cell line human CVCL_2K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161858 CVCL_2K48 AG15793 transformed cell line human CVCL_2K48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161859 CVCL_2K49 AG15796 transformed cell line human CVCL_2K49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161860 CVCL_V280 HN-SCC-68 cancer cell line human CVCL_V280 CL:0000010 Unspecified 21161861 CVCL_V283 GM07890 transformed cell line human CVCL_V283 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21161862 CVCL_V284 PK-89-12 hybrid cell line human CVCL_V284 CL:0000010 Characteristics: Hybrid for chromosome 12 mapping Contains a complete copy of chromosome 12.. Group: Human/rodent somatic cell hybrid 21161863 CVCL_V281 JSQ-3B cancer cell line human CVCL_V281 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Nose; nasal cavity; nasal vestibule. Unspecified 21161864 CVCL_V282 SCC-61B cancer cell line human CVCL_V282 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Oral cavity; tongue. Male 21161865 CVCL_V287 PK-89-6A hybrid cell line human CVCL_V287 CL:0000010 Group: Human/rodent somatic cell hybrid. 21161866 CVCL_V288 Ad-211/SV40 transformed cell line human CVCL_V288 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21161867 CVCL_V285 PK-87-19 hybrid cell line human CVCL_V285 CL:0000010 Characteristics: Hybrid for chromosome 19 mapping Contains a complete copy of chromosome 19.. Group: Human/rodent somatic cell hybrid 21161868 CVCL_V286 PK-87-9 hybrid cell line human CVCL_V286 CL:0000010 Characteristics: Hybrid for chromosome 9 mapping Contains a complete copy of chromosome 9.. Group: Human/rodent somatic cell hybrid 21161869 CVCL_V269 GM16390 finite cell line human CVCL_V269 CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161870 CVCL_V267 XP23CA finite cell line human CVCL_V267 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (Coriell; PubMed=9671271) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21161871 CVCL_V268 AG06971 finite cell line human CVCL_V268 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Leu117Glufs*4 (c.349_353delCTTAT) (349del5); ClinVar=VCV000000994; Zygosity=Heterozygous (PubMed=9671271); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-12A>G; Zygosity=Heterozygous (PubMed=9671271) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21161872 CVCL_2K20 AG15044 transformed cell line human CVCL_2K20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161873 CVCL_2K21 AG15045 transformed cell line human CVCL_2K21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161874 CVCL_2K24 AG15058 transformed cell line human CVCL_2K24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161875 CVCL_2K25 AG15059 transformed cell line human CVCL_2K25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161876 CVCL_2K22 AG15046 transformed cell line human CVCL_2K22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161877 CVCL_2K23 AG15057 transformed cell line human CVCL_2K23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161878 CVCL_2K17 AG15023 transformed cell line human CVCL_2K17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161879 CVCL_2K18 AG15032 transformed cell line human CVCL_2K18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161880 CVCL_2K15 AG15018 transformed cell line human CVCL_2K15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161881 CVCL_2K16 AG15022 transformed cell line human CVCL_2K16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161882 CVCL_2K19 AG15033 transformed cell line human CVCL_2K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161883 CVCL_V272 XPCS2BA finite cell line human CVCL_V272 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (PubMed=16947863; PubMed=26184184); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (PubMed=16947863; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161884 CVCL_V273 XP33BR finite cell line human CVCL_V273 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (PubMed=16947863); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Arg425Ter (c.1273C>T); ClinVar=VCV000016585; Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161885 CVCL_V270 TTD1RO finite cell line human CVCL_V270 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg658Cys (c.1972C>T); ClinVar=VCV000016785; Zygosity=Heterozygous (PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly713Arg (c.2137G>C); ClinVar=VCV000016786; Zygosity=Heterozygous (PubMed=8571952) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161886 CVCL_V271 XPCS1BA finite cell line human CVCL_V271 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (PubMed=16947863; PubMed=26184184); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (PubMed=16947863; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161887 CVCL_V276 XP131MA finite cell line human CVCL_V276 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Asp474Glufs*2 (c.1421dupA); ClinVar=VCV000134130; Zygosity=Heterozygous (PubMed=16947863); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (PubMed=16947863) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161888 CVCL_V277 RPTC-1 cancer cell line human CVCL_V277 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00422 Problematic cell line: Contaminated Shown to be a TPC-1 derivative (PubMed=21868764). 21161889 CVCL_V274 XP183MA finite cell line human CVCL_V274 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln545Ter (c.1633C>T); ClinVar=VCV000016588; Zygosity=Heterozygous (PubMed=16947863); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Gln739fs*42 (c.2218-6C>A) (IVS14-6C>A); Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161890 CVCL_V275 XP33BR LCL transformed cell line human CVCL_V275 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Arg425Ter (c.1273C>T); ClinVar=VCV000016585; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161891 CVCL_V258 RC-77N/E transformed cell line human CVCL_V258 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21161892 CVCL_V259 RC-77T/E transformed cell line human CVCL_V259 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21161893 CVCL_V256 GM06034 finite cell line CVCL_V256 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Hereford. Male 21161894 CVCL_V257 GM06035 finite cell line CVCL_V257 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21161895 CVCL_2K31 AG15109 transformed cell line human CVCL_2K31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161896 CVCL_2K32 AG15110 transformed cell line human CVCL_2K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161897 CVCL_2K30 AG15108 transformed cell line human CVCL_2K30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161898 CVCL_2K35 AG15174 transformed cell line human CVCL_2K35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161899 CVCL_2K36 AG15448 transformed cell line human CVCL_2K36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161900 CVCL_2K33 AG15111 transformed cell line human CVCL_2K33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161901 CVCL_2K34 AG15173 transformed cell line human CVCL_2K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161902 CVCL_2K28 AG15091 transformed cell line human CVCL_2K28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161903 CVCL_2K29 AG15107 transformed cell line human CVCL_2K29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161904 CVCL_2K26 AG15060 transformed cell line human CVCL_2K26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161905 CVCL_2K27 AG15090 transformed cell line human CVCL_2K27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161906 CVCL_V261 GM22131 finite cell line human CVCL_V261 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22131) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21161907 CVCL_V262 GM22133 finite cell line human CVCL_V262 CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 33 PDL (Coriell=GM22133) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21161908 CVCL_V260 LNCaP-CS10 cancer cell line human CVCL_V260 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21161909 CVCL_V265 GM22136 finite cell line human CVCL_V265 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 29 PDL (Coriell=GM22136) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21161910 CVCL_V266 XP13CA finite cell line human CVCL_V266 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; GM03964; probable Male 21161911 CVCL_V263 GM22134 finite cell line human CVCL_V263 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male Senescence: Senesces at 26 PDL (Coriell=GM22134) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21161912 CVCL_V264 GM22135 finite cell line human CVCL_V264 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 38 PDL (Coriell=GM22135) Part of: NIGMS collection of multiple cell lines from the same individual; cell lines from neonatal foreskins 21161913 CVCL_V247 V-H1 transformed cell line CVCL_V247 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21161914 CVCL_V248 V-H4 transformed cell line CVCL_V248 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21161915 CVCL_V245 CHO-KK spontaneously immortalized cell line CVCL_V245 CL:0000010 Derived from sampling site: Ovary. Female 21161916 CVCL_V246 V-B11 transformed cell line CVCL_V246 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21161917 CVCL_V249 EM-C11 spontaneously immortalized cell line CVCL_V249 CL:0000010 Derived from sampling site: Ovary. Female 21161918 CVCL_2K02 AG14986 transformed cell line human CVCL_2K02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161919 CVCL_2K03 AG14987 transformed cell line human CVCL_2K03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161920 CVCL_2K00 AG14984 transformed cell line human CVCL_2K00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161921 CVCL_2K01 AG14985 transformed cell line human CVCL_2K01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161922 CVCL_V250 GM03655 finite cell line CVCL_V250 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21161923 CVCL_V251 GM05864 finite cell line CVCL_V251 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Limousin. Male 21161924 CVCL_V254 GM05867 finite cell line CVCL_V254 CL:0000010 Donor information: Cell line originating from a cow that was a carrier for bovine congenital erythropoietic porphyria; Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21161925 CVCL_V255 GM05868 finite cell line CVCL_V255 CL:0000010 Donor information: Cell line originating from a cow that was a carrier for bovine protoporphyria; Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Hereford x Limousin. Female 21161926 CVCL_V252 GM05865 finite cell line CVCL_V252 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Limousin x Hereford. Female 21161927 CVCL_V253 GM05866 finite cell line CVCL_V253 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Female 21161928 CVCL_V236 GM04272 finite cell line CVCL_V236 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM04272; probable Male Group: Non-human primate cell line 21161929 CVCL_V237 GM06207 finite cell line CVCL_V237 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21161930 CVCL_V234 MRC5-iPS2 induced pluripotent stem cell human CVCL_V234 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21161931 CVCL_V235 BJ1-iPS3 induced pluripotent stem cell human CVCL_V235 From: Children's Hospital Boston; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21161932 CVCL_V238 GM06206 finite cell line CVCL_V238 CL:0000010 Donor information: Cell line originating from a cat suffering from a Ehlers-Danlos like syndrome; Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Domestic shorthair. Male 21161933 CVCL_V239 GM03550 finite cell line CVCL_V239 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Southdown. Female Senescence: Senesces at 32 PDL (PubMed=15664728) 21161934 CVCL_2K10 AG15013 transformed cell line human CVCL_2K10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161935 CVCL_2K13 AG15016 transformed cell line human CVCL_2K13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161936 CVCL_2K14 AG15017 transformed cell line human CVCL_2K14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161937 CVCL_2K11 AG15014 transformed cell line human CVCL_2K11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161938 CVCL_2K12 AG15015 transformed cell line human CVCL_2K12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161939 CVCL_2K06 AG14995 transformed cell line human CVCL_2K06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161940 CVCL_2K07 AG15007 transformed cell line human CVCL_2K07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161941 CVCL_2K04 AG14988 transformed cell line human CVCL_2K04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161942 CVCL_2K05 AG14994 transformed cell line human CVCL_2K05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161943 CVCL_2K08 AG15008 transformed cell line human CVCL_2K08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161944 CVCL_2K09 AG15011 transformed cell line human CVCL_2K09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Intra-abdominal fat and risk of disease in adolescents study cell line collection 21161945 CVCL_V240 GM04053 finite cell line CVCL_V240 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21161946 CVCL_V243 GM11474 finite cell line dog CVCL_V243 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Portuguese water dog. Female 21161947 CVCL_V244 RJK88 spontaneously immortalized cell line CVCL_V244 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21161948 CVCL_V241 GM03978 finite cell line dog CVCL_V241 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mixed breed. Female 21161949 CVCL_V242 GM11473 finite cell line dog CVCL_V242 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Portuguese water dog. Female 21161950 CVCL_V225 GM11281 transformed cell line human CVCL_V225 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161951 CVCL_V226 GM11282 transformed cell line human CVCL_V226 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly85Glu (c.254G>A); ClinVar=VCV000007143; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161952 CVCL_V223 GM11279 transformed cell line human CVCL_V223 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161953 CVCL_V224 GM11280 transformed cell line human CVCL_V224 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.579+1G>T (711+1G>T); ClinVar=VCV000038494; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161954 CVCL_V229 GM11285 transformed cell line human CVCL_V229 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Tyr1092Ter (c.3276C>A); ClinVar=VCV000007211; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21161955 CVCL_V227 GM11283 transformed cell line human CVCL_V227 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ala455Glu (c.1364C>A); ClinVar=VCV000007111; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161956 CVCL_V228 GM11284 transformed cell line human CVCL_V228 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg560Thr (c.1679G>C); ClinVar=VCV000007113; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161957 CVCL_LW88 BayGenomics ES cell line CSH140 embryonic stem cell house mouse CVCL_LW88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161958 CVCL_M888 BFTC-905-compact cancer cell line human CVCL_M888 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Chinese; Taiwan; Derived from sampling site: Urinary bladder. Female 21161959 CVCL_LW89 BayGenomics ES cell line CSH141 embryonic stem cell house mouse CVCL_LW89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444773; Mavs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161960 CVCL_M889 BFTC-905-diffuse cancer cell line human CVCL_M889 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Chinese; Taiwan; Derived from sampling site: Urinary bladder. Female Characteristics: Differs from the BFTC-905-compact cell line by growing in a less organized, 'diffuse' manner, which involves colonies of cells exhibiting apparently normal cell-to-cell adhesion as well as individual cells outside of them (PubMed=18398596) 21161961 CVCL_LW86 BayGenomics ES cell line CSH135 embryonic stem cell house mouse CVCL_LW86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161962 CVCL_M886 JTC-25.P3 spontaneously immortalized cell line Norway rat CVCL_M886 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Group: Serum/protein free medium cell line 21161963 CVCL_LW87 BayGenomics ES cell line CSH136 embryonic stem cell house mouse CVCL_LW87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141291; Bud31 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161964 CVCL_M887 PV1.Pl cancer cell line CVCL_M887 CL:0000010 Derived from metastatic site: Pleural effusion. Discontinued: ATCC; CRL-6526; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161965 CVCL_LW84 BayGenomics ES cell line CSH133 embryonic stem cell house mouse CVCL_LW84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913516; Eapp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161966 CVCL_M884 JTC-1 cancer cell line Norway rat CVCL_M884 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21161967 CVCL_LW85 BayGenomics ES cell line CSH134 embryonic stem cell house mouse CVCL_LW85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917275; Acot7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161968 CVCL_M885 JTC-2 cancer cell line Norway rat CVCL_M885 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21161969 CVCL_LW82 BayGenomics ES cell line CSH129 embryonic stem cell house mouse CVCL_LW82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913501; Arfgap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161970 CVCL_M882 KATO II cancer cell line human CVCL_M882 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 74 hours (PubMed=209229) 21161971 CVCL_LW83 BayGenomics ES cell line CSH131 embryonic stem cell house mouse CVCL_LW83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161972 CVCL_M883 JTC-4 finite cell line Norway rat CVCL_M883 CL:0000010 Derived from sampling site: Heart; Breed/subspecies: Wistar. Unspecified 21161973 CVCL_LW80 BayGenomics ES cell line CSH123 embryonic stem cell house mouse CVCL_LW80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146156; Espl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161974 CVCL_M880 JTC-33 cancer cell line human CVCL_M880 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 43.2 hours (PubMed=6684098) 21161975 CVCL_LW81 BayGenomics ES cell line CSH124 embryonic stem cell house mouse CVCL_LW81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914179; Asf1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161976 CVCL_M881 JTC-34 cancer cell line human CVCL_M881 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 42.0 hours (PubMed=6684098) 21161977 CVCL_V232 GM11288 transformed cell line human CVCL_V232 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly178Arg (c.532G>A); ClinVar=VCV000048692; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21161978 CVCL_V233 GM11290 transformed cell line human CVCL_V233 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ala455Glu (c.1364C>A); ClinVar=VCV000007111; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161979 CVCL_V230 GM11286 transformed cell line human CVCL_V230 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161980 CVCL_V231 GM11287 transformed cell line human CVCL_V231 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Pro574His (c.1721C>A); ClinVar=VCV000007119; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21161981 CVCL_V214 GM01531 transformed cell line human CVCL_V214 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161982 CVCL_V215 GM07552 transformed cell line human CVCL_V215 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161983 CVCL_V212 GM01445 transformed cell line human CVCL_V212 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161984 CVCL_V213 GM01530 transformed cell line human CVCL_V213 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly542Ter (c.1624G>T); ClinVar=VCV000007115; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.His609Arg (c.1826A>G); ClinVar=VCV000053398; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161985 CVCL_V218 GM08345 transformed cell line human CVCL_V218 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161986 CVCL_V219 GM11274 transformed cell line human CVCL_V219 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161987 CVCL_V216 GM08338 transformed cell line human CVCL_V216 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21161988 CVCL_V217 GM08342 transformed cell line human CVCL_V217 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gly551Asp (c.1652G>A); ClinVar=VCV000007120; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21161989 CVCL_LW99 BayGenomics ES cell line CSH157 embryonic stem cell house mouse CVCL_LW99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161990 CVCL_M899 Hs 238.T cancer cell line human CVCL_M899 CL:0000010 Discontinued: ATCC; CRL-7204; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21161991 CVCL_LW97 BayGenomics ES cell line CSH155 embryonic stem cell house mouse CVCL_LW97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161992 CVCL_M897 T24T FL3 cancer cell line human CVCL_M897 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Exosome proteome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Forms metastasis in the lung of mice Produced by passage of the parent cell line through nude mice. Part of: BLA-40 bladder carcinoma cell line panel 21161993 CVCL_LW98 BayGenomics ES cell line CSH156 embryonic stem cell house mouse CVCL_LW98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161994 CVCL_M898 BC16.1 cancer cell line human CVCL_M898 CL:0000010 Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Part of: BLA-40 bladder carcinoma cell line panel Caution: Indicated (PubMed=8041746) to be established from normal human bladder epithelial tissue but used in many studies as a bladder cancer cell line 21161995 CVCL_LW95 BayGenomics ES cell line CSH150 embryonic stem cell house mouse CVCL_LW95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161996 CVCL_M895 T24T FL1 cancer cell line human CVCL_M895 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by passage of the parent cell line through nude mice 21161997 CVCL_LW96 BayGenomics ES cell line CSH154 embryonic stem cell house mouse CVCL_LW96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97502; Pcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21161998 CVCL_M896 T24T FL2 cancer cell line human CVCL_M896 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female Characteristics: Produced by passage of the parent cell line through nude mice 21161999 CVCL_LW93 BayGenomics ES cell line CSH148 embryonic stem cell house mouse CVCL_LW93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918677; Ibtk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162000 CVCL_M893 NEYS cancer cell line human CVCL_M893 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 59 hours (at 10th passage), 56 hours (at 30th passage) (PubMed=19624308) 21162001 CVCL_LW94 BayGenomics ES cell line CSH149 embryonic stem cell house mouse CVCL_LW94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162002 CVCL_M894 KU-7-luc2-GFP cancer cell line human CVCL_M894 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: PerkinElmer; 128091; true Female Problematic cell line: Contaminated Parent cell line (KU-7) has been shown to be a HeLa derivative. 21162003 CVCL_LW91 BayGenomics ES cell line CSH144 embryonic stem cell house mouse CVCL_LW91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162004 CVCL_M891 JON cancer cell line human CVCL_M891 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (PubMed=27270441); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=24035680); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=27270441) Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21162005 CVCL_LW92 BayGenomics ES cell line CSH147 embryonic stem cell house mouse CVCL_LW92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931123; Inpp4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162006 CVCL_M892 T24T cancer cell line human CVCL_M892 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Transcriptome analysis by microarray Female 21162007 CVCL_LW90 BayGenomics ES cell line CSH142 embryonic stem cell house mouse CVCL_LW90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920179; Dip2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162008 CVCL_M890 BFTC-905-diffuse M cancer cell line human CVCL_M890 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Chinese; Taiwan; Karyotypic information: Hypertetraploid karyotype (PubMed=18398596); Derived from sampling site: Urinary bladder. Female Characteristics: Differs from the BFTC-905-compact cell line by growing in a less organized, 'diffuse' manner, which involves colonies of cells exhibiting apparently normal cell-to-cell adhesion as well as individual cells outside of them (PubMed=18398596) 21162009 CVCL_V221 GM11277 transformed cell line human CVCL_V221 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162010 CVCL_V222 GM11278 transformed cell line human CVCL_V222 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln493Ter (c.1477C>T); ClinVar=VCV000007107; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162011 CVCL_V220 GM11275 transformed cell line human CVCL_V220 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=19359498); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Thr1220Lysfs*8 (c.3659delC); ClinVar=VCV000007124; Zygosity=Heterozygous (PubMed=19359498) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162012 CVCL_2K82 AG16858 transformed cell line human CVCL_2K82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162013 CVCL_2K83 AG16863 transformed cell line human CVCL_2K83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162014 CVCL_2K80 AG16821 transformed cell line human CVCL_2K80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162015 CVCL_2K81 AG16850 transformed cell line human CVCL_2K81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162016 CVCL_2K86 AG16894 transformed cell line human CVCL_2K86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162017 CVCL_2K87 AG16895 transformed cell line human CVCL_2K87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162018 CVCL_2K84 AG16892 transformed cell line human CVCL_2K84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162019 CVCL_2K85 AG16893 transformed cell line human CVCL_2K85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162020 CVCL_2K88 AG16896 transformed cell line human CVCL_2K88 CL:0000010 Population: Caucasian; Dutch/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162021 CVCL_2K89 AG16897 transformed cell line human CVCL_2K89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162022 CVCL_2K90 AG16898 transformed cell line human CVCL_2K90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162023 CVCL_2K93 AG16901 transformed cell line human CVCL_2K93 CL:0000010 Population: Caucasian; Dutch/Scottish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162024 CVCL_2K94 AG16903 transformed cell line human CVCL_2K94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162025 CVCL_2K91 AG16899 transformed cell line human CVCL_2K91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162026 CVCL_2K92 AG16900 transformed cell line human CVCL_2K92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162027 CVCL_2K97 AG16906 transformed cell line human CVCL_2K97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162028 CVCL_2K98 AG16907 transformed cell line human CVCL_2K98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162029 CVCL_2K95 AG16904 transformed cell line human CVCL_2K95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162030 CVCL_2K96 AG16905 transformed cell line human CVCL_2K96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162031 CVCL_2K99 AG16908 transformed cell line human CVCL_2K99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162032 CVCL_2K60 AG16644 transformed cell line human CVCL_2K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162033 CVCL_2K61 AG16655 transformed cell line human CVCL_2K61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162034 CVCL_2K64 AG16665 transformed cell line human CVCL_2K64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162035 CVCL_2K65 AG16698 transformed cell line human CVCL_2K65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162036 CVCL_2K62 AG16657 transformed cell line human CVCL_2K62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162037 CVCL_2K63 AG16662 transformed cell line human CVCL_2K63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162038 CVCL_2K68 AG16741 transformed cell line human CVCL_2K68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162039 CVCL_2K69 AG16742 transformed cell line human CVCL_2K69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162040 CVCL_2K66 AG16729 transformed cell line human CVCL_2K66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162041 CVCL_2K67 AG16730 transformed cell line human CVCL_2K67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162042 CVCL_2K59 AG16642 transformed cell line human CVCL_2K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162043 CVCL_2K71 AG16744 transformed cell line human CVCL_2K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162044 CVCL_2K72 AG16747 transformed cell line human CVCL_2K72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162045 CVCL_2K70 AG16743 transformed cell line human CVCL_2K70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162046 CVCL_2K75 AG16759 transformed cell line human CVCL_2K75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162047 CVCL_2K76 AG16803 transformed cell line human CVCL_2K76 CL:0000010 Population: Caucasian; Dutch/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162048 CVCL_2K73 AG16748 transformed cell line human CVCL_2K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162049 CVCL_2K74 AG16758 transformed cell line human CVCL_2K74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162050 CVCL_2K79 AG16820 transformed cell line human CVCL_2K79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162051 CVCL_2K77 AG16804 transformed cell line human CVCL_2K77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162052 CVCL_2K78 AG16819 transformed cell line human CVCL_2K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162053 CVCL_LY28 BayGenomics ES cell line CSH428 embryonic stem cell house mouse CVCL_LY28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162054 CVCL_LY29 BayGenomics ES cell line CSH429 embryonic stem cell house mouse CVCL_LY29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162055 CVCL_LY26 BayGenomics ES cell line CSH426 embryonic stem cell house mouse CVCL_LY26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162056 CVCL_LY27 BayGenomics ES cell line CSH427 embryonic stem cell house mouse CVCL_LY27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88431; Cnbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162057 CVCL_LY24 BayGenomics ES cell line CSH418 embryonic stem cell house mouse CVCL_LY24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388280; Polr2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162058 CVCL_LY25 BayGenomics ES cell line CSH424 embryonic stem cell house mouse CVCL_LY25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107788; Atp1b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162059 CVCL_LY22 BayGenomics ES cell line CSH415 embryonic stem cell house mouse CVCL_LY22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162060 CVCL_LY23 BayGenomics ES cell line CSH416 embryonic stem cell house mouse CVCL_LY23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162061 CVCL_LY20 BayGenomics ES cell line CSH411 embryonic stem cell house mouse CVCL_LY20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99135; Xpa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162062 CVCL_LY21 BayGenomics ES cell line CSH413 embryonic stem cell house mouse CVCL_LY21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385884; Ddx27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162063 CVCL_LY39 BayGenomics ES cell line CSH446 embryonic stem cell house mouse CVCL_LY39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162064 CVCL_LY37 BayGenomics ES cell line CSH442 embryonic stem cell house mouse CVCL_LY37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890165; Larp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162065 CVCL_LY38 BayGenomics ES cell line CSH444 embryonic stem cell house mouse CVCL_LY38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162066 CVCL_LY35 BayGenomics ES cell line CSH440 embryonic stem cell house mouse CVCL_LY35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196400; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162067 CVCL_LY36 BayGenomics ES cell line CSH441 embryonic stem cell house mouse CVCL_LY36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913667; Mat2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162068 CVCL_LY33 BayGenomics ES cell line CSH436 embryonic stem cell house mouse CVCL_LY33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141466; Bmt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162069 CVCL_LY34 BayGenomics ES cell line CSH438 embryonic stem cell house mouse CVCL_LY34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162070 CVCL_LY31 BayGenomics ES cell line CSH431 embryonic stem cell house mouse CVCL_LY31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921358; Parn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162071 CVCL_LY32 BayGenomics ES cell line CSH432 embryonic stem cell house mouse CVCL_LY32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2156528; Elovl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162072 CVCL_LY30 BayGenomics ES cell line CSH430 embryonic stem cell house mouse CVCL_LY30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162073 CVCL_LY08 BayGenomics ES cell line CSH392 embryonic stem cell house mouse CVCL_LY08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919782; Sap130 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162074 CVCL_LY09 BayGenomics ES cell line CSH394 embryonic stem cell house mouse CVCL_LY09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139764; Sec24b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162075 CVCL_LY06 BayGenomics ES cell line CSH389 embryonic stem cell house mouse CVCL_LY06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929494; Arhgap35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162076 CVCL_LY07 BayGenomics ES cell line CSH391 embryonic stem cell house mouse CVCL_LY07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933196; Rad54l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162077 CVCL_LY04 BayGenomics ES cell line CSH387 embryonic stem cell house mouse CVCL_LY04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919054; Mtfr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162078 CVCL_LY05 BayGenomics ES cell line CSH388 embryonic stem cell house mouse CVCL_LY05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162079 CVCL_LY02 BayGenomics ES cell line CSH383 embryonic stem cell house mouse CVCL_LY02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919607; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162080 CVCL_LY03 BayGenomics ES cell line CSH385 embryonic stem cell house mouse CVCL_LY03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443298; Tet2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162081 CVCL_LY00 BayGenomics ES cell line CSH376 embryonic stem cell house mouse CVCL_LY00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109404; Nup98 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162082 CVCL_LY01 BayGenomics ES cell line CSH382 embryonic stem cell house mouse CVCL_LY01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915955; Gtf2f2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162083 CVCL_LY19 BayGenomics ES cell line CSH410 embryonic stem cell house mouse CVCL_LY19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096570; Tex264 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162084 CVCL_LY17 BayGenomics ES cell line CSH408 embryonic stem cell house mouse CVCL_LY17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194497; Tgif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162085 CVCL_LY18 BayGenomics ES cell line CSH409 embryonic stem cell house mouse CVCL_LY18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162086 CVCL_LY15 BayGenomics ES cell line CSH404 embryonic stem cell house mouse CVCL_LY15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917294; Tut1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162087 CVCL_LY16 BayGenomics ES cell line CSH405 embryonic stem cell house mouse CVCL_LY16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162088 CVCL_LY13 BayGenomics ES cell line CSH402 embryonic stem cell house mouse CVCL_LY13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162089 CVCL_LY14 BayGenomics ES cell line CSH403 embryonic stem cell house mouse CVCL_LY14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162090 CVCL_LY11 BayGenomics ES cell line CSH399 embryonic stem cell house mouse CVCL_LY11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289332; Eipr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162091 CVCL_LY12 BayGenomics ES cell line CSH401 embryonic stem cell house mouse CVCL_LY12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162092 CVCL_LY10 BayGenomics ES cell line CSH398 embryonic stem cell house mouse CVCL_LY10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147437; Rrp12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162093 CVCL_US45 GM06553 finite cell line human CVCL_US45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06553; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162094 CVCL_V445 WT 9-9 transformed cell line human CVCL_V445 CL:0000010 Transformant: Ad-SV40 hybrid virus Discontinued: ATCC; CRL-2832; true. Female 21162095 CVCL_US46 GM06547 finite cell line human CVCL_US46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06547; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162096 CVCL_V446 GM10287 finite cell line human CVCL_V446 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162097 CVCL_US43 GM06551 finite cell line human CVCL_US43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06551; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162098 CVCL_V443 WT 10-7 transformed cell line human CVCL_V443 CL:0000010 Transformant: Ad-SV40 hybrid virus Discontinued: ATCC; CRL-2834; true. Female 21162099 CVCL_US44 GM06543 finite cell line human CVCL_US44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06543; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162100 CVCL_V444 TS 9-7 transformed cell line human CVCL_V444 CL:0000010 Transformant: Ad-SV40 hybrid virus Discontinued: ATCC; CRL-2831; true. Female 21162101 CVCL_US49 GM06620 finite cell line human CVCL_US49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06620; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162102 CVCL_V449 iPS ADPKD 1 induced pluripotent stem cell human CVCL_V449 CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Cys39Tyr (c.116G>A); ClinVar=VCV001310359; Zygosity=Unspecified (PubMed=24009235) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21162103 CVCL_US47 GM06545 finite cell line human CVCL_US47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06545; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162104 CVCL_V447 GM12607 finite cell line human CVCL_V447 CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Thr36Met (c.107C>T); ClinVar=VCV000004108; Zygosity=Unspecified (PubMed=24009235); Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Trp2736Gly (c.8206T>G); ClinVar=VCV000496527; Zygosity=Unspecified (PubMed=24009235) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162105 CVCL_US48 GM06546 finite cell line human CVCL_US48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06546; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162106 CVCL_V448 GM12609 finite cell line human CVCL_V448 CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Thr36Met (c.107C>T); ClinVar=VCV000004108; Zygosity=Unspecified (from autologous cell line GM12607); Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Trp2736Gly (c.8206T>G); ClinVar=VCV000496527; Zygosity=Unspecified (from autologous cell line GM12607) Derived from sampling site: Kidney Cell type=Fibroblast.. Female 21162107 CVCL_2M00 AG08076 finite cell line dog CVCL_2M00 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162108 CVCL_2M01 AG08080 finite cell line CVCL_2M01 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Male 21162109 CVCL_US52 GM06468 finite cell line human CVCL_US52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06468; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162110 CVCL_V452 iPS ARPKD 4 induced pluripotent stem cell human CVCL_V452 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162111 CVCL_US53 GM06472 finite cell line human CVCL_US53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06472; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162112 CVCL_V453 iPS ARPKD 5 induced pluripotent stem cell human CVCL_V453 CL:0000010 Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Thr36Met (c.107C>T); ClinVar=VCV000004108; Zygosity=Unspecified (PubMed=24009235); Sequence variation: Mutation; HGNC; 9016; PKHD1; Simple; p.Trp2736Gly (c.8206T>G); ClinVar=VCV000496527; Zygosity=Unspecified (PubMed=24009235) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162113 CVCL_US50 GM06461 finite cell line human CVCL_US50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06461; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162114 CVCL_V450 iPS ADPKD 2 induced pluripotent stem cell human CVCL_V450 CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Arg2051Pro (c.6152G>C); Zygosity=Unspecified (PubMed=24009235) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21162115 CVCL_US51 GM06467 finite cell line human CVCL_US51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06467; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162116 CVCL_V451 iPS ADPKD 3 induced pluripotent stem cell human CVCL_V451 CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Glu1929Ter (c.5785G>T); Zygosity=Unspecified (PubMed=24009235) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21162117 CVCL_V434 GENEA095 embryonic stem cell human CVCL_V434 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA094 (Cellosaurus=CVCL_V433). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0373; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-43. 21162118 CVCL_US34 GM05527 finite cell line human CVCL_US34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05527; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162119 CVCL_US35 GM06522 finite cell line human CVCL_US35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06522; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162120 CVCL_V435 GM16794 finite cell line human CVCL_V435 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21162121 CVCL_V432 GENEA093 embryonic stem cell human CVCL_V432 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0371; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-42.. 21162122 CVCL_US32 GM06521 finite cell line human CVCL_US32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06521; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162123 CVCL_V433 GENEA094 embryonic stem cell human CVCL_V433 From: Genea Biocells, Ltd; Sydney; Australia CL:0000010 Donor information: Embryo is sibling to that giving rise to GENEA095 (Cellosaurus=CVCL_V434). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0372; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC14-43. 21162124 CVCL_US33 GM05535 finite cell line human CVCL_US33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05535; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162125 CVCL_US38 GM06510 finite cell line human CVCL_US38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06510; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162126 CVCL_V438 GM16969 transformed cell line human CVCL_V438 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162127 CVCL_US39 GM06542 finite cell line human CVCL_US39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06542; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162128 CVCL_V439 GM16970 finite cell line human CVCL_V439 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21162129 CVCL_US36 GM06505 finite cell line human CVCL_US36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06505; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162130 CVCL_V436 GM16834 transformed cell line human CVCL_V436 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM16834; probable Female 21162131 CVCL_US37 GM06552 finite cell line human CVCL_US37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06552; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162132 CVCL_V437 GM16835 finite cell line human CVCL_V437 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21162133 CVCL_2M11 AG08158 finite cell line dog CVCL_2M11 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162134 CVCL_2M12 AG08160 finite cell line dog CVCL_2M12 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162135 CVCL_2M10 AG08157 finite cell line dog CVCL_2M10 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162136 CVCL_2M04 AG08103 finite cell line dog CVCL_2M04 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162137 CVCL_2M05 AG08117 finite cell line dog CVCL_2M05 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162138 CVCL_2M02 AG08082 finite cell line CVCL_2M02 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Male 21162139 CVCL_2M03 AG08102 finite cell line dog CVCL_2M03 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162140 CVCL_2M08 AG08152 finite cell line dog CVCL_2M08 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162141 CVCL_2M09 AG08153 finite cell line dog CVCL_2M09 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Female Doubling time: Slow growth (Coriell) 21162142 CVCL_2M06 AG08118 finite cell line dog CVCL_2M06 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162143 CVCL_2M07 AG08151 finite cell line dog CVCL_2M07 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162144 CVCL_US41 GM06549 finite cell line human CVCL_US41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06549; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162145 CVCL_V441 GM17720 finite cell line human CVCL_V441 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162146 CVCL_US42 GM06550 finite cell line human CVCL_US42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06550; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162147 CVCL_V442 TS 10-7 transformed cell line human CVCL_V442 CL:0000010 Transformant: Ad-SV40 hybrid virus Discontinued: ATCC; CRL-2835; true. Female 21162148 CVCL_US40 GM06548 finite cell line human CVCL_US40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06548; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162149 CVCL_V440 GM17719 transformed cell line human CVCL_V440 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162150 CVCL_US23 GM06523 finite cell line human CVCL_US23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06523; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162151 CVCL_V423 GM12225 transformed cell line human CVCL_V423 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162152 CVCL_US24 GM06411 finite cell line human CVCL_US24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06411; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162153 CVCL_V424 GM12226 transformed cell line human CVCL_V424 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162154 CVCL_V421 GM01236 finite cell line human CVCL_V421 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162155 CVCL_US21 GM06503 finite cell line human CVCL_US21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06503; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162156 CVCL_US22 GM06504 finite cell line human CVCL_US22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06504; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162157 CVCL_V422 GM10112 finite cell line human CVCL_V422 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162158 CVCL_V427 GM00158 finite cell line human CVCL_V427 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00158; probable Male 21162159 CVCL_US27 GM06695 finite cell line human CVCL_US27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06695; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162160 CVCL_V428 GM00407 finite cell line human CVCL_V428 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM00407; probable 21162161 CVCL_US28 GM06414 finite cell line human CVCL_US28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06414; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162162 CVCL_V425 GM01659 finite cell line human CVCL_V425 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex2-3dup; Zygosity=Heterozygous (from familial inference of GM01662 and GM06804) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162163 CVCL_US25 GM06406 finite cell line human CVCL_US25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06406; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162164 CVCL_V426 GM01660 finite cell line human CVCL_V426 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162165 CVCL_US26 GM06402 finite cell line human CVCL_US26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06402; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162166 CVCL_US29 GM06401 finite cell line human CVCL_US29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06401; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162167 CVCL_V429 NoGFP-CD16.NK92 cancer cell line human CVCL_V429 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val) Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6967 21162168 CVCL_LY88 BayGenomics ES cell line CSH550 embryonic stem cell house mouse CVCL_LY88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913986; Emc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162169 CVCL_LY89 BayGenomics ES cell line CSH552 embryonic stem cell house mouse CVCL_LY89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162170 CVCL_LY86 BayGenomics ES cell line CSH545 embryonic stem cell house mouse CVCL_LY86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924621; Sec24a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162171 CVCL_LY87 BayGenomics ES cell line CSH548 embryonic stem cell house mouse CVCL_LY87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919837; Pan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162172 CVCL_LY84 BayGenomics ES cell line CSH543 embryonic stem cell house mouse CVCL_LY84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162173 CVCL_LY85 BayGenomics ES cell line CSH544 embryonic stem cell house mouse CVCL_LY85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443878; Slc4a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162174 CVCL_LY82 BayGenomics ES cell line CSH540 embryonic stem cell house mouse CVCL_LY82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162175 CVCL_LY83 BayGenomics ES cell line CSH542 embryonic stem cell house mouse CVCL_LY83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651014; Zfp268 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162176 CVCL_LY80 BayGenomics ES cell line CSH530 embryonic stem cell house mouse CVCL_LY80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103197; Mcm5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162177 CVCL_LY81 BayGenomics ES cell line CSH532 embryonic stem cell house mouse CVCL_LY81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162178 CVCL_V430 GM00440 finite cell line human CVCL_V430 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21162179 CVCL_US30 GM06507 finite cell line human CVCL_US30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06507; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162180 CVCL_V431 GM01028 transformed cell line human CVCL_V431 HLA typing: A*01,02; B*12 (Coriell=GM01028) CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Gln188Arg (c.563A>G); ClinVar=VCV000003614; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162181 CVCL_US31 GM06500 finite cell line human CVCL_US31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06500; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162182 CVCL_US12 GM06470 finite cell line human CVCL_US12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06470; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162183 CVCL_V412 SCC7 cancer cell line house mouse CVCL_V412 CL:0000010 Breed/subspecies: C3H. 21162184 CVCL_US13 GM05691 finite cell line human CVCL_US13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05691; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162185 CVCL_V413 LP6 cancer cell line human CVCL_V413 CL:0000010 Omics: SNP array analysis. Male 21162186 CVCL_US10 GM06386 finite cell line human CVCL_US10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06386; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162187 CVCL_V410 LB2531-MEL-Z cancer cell line human CVCL_V410 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21162188 CVCL_US11 GM06403 finite cell line human CVCL_US11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06403; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162189 CVCL_V411 NUZ cancer cell line human CVCL_V411 CL:0000010 Population: Japanese. Female 21162190 CVCL_US16 GM06760 finite cell line human CVCL_US16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06760; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162191 CVCL_V416 LM-1 [Human osteosarcoma] cancer cell line human CVCL_V416 CL:0000010 Population: African American; Derived from sampling site: Bone; distal femur. Female 21162192 CVCL_US17 GM06749 finite cell line human CVCL_US17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06749; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162193 CVCL_V417 PPM-Phi cancer cell line human CVCL_V417 CL:0000010 21162194 CVCL_US14 GM06628 finite cell line human CVCL_US14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06628; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162195 CVCL_V414 LPS510 cancer cell line human CVCL_V414 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA. CL:0000010 Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21162196 CVCL_US15 GM06498 finite cell line human CVCL_US15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06498; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162197 CVCL_V415 LPS853 cancer cell line human CVCL_V415 From: Fletcher J.A.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School; Boston; USA. CL:0000010 Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21162198 CVCL_V418 Gard cancer cell line human CVCL_V418 CL:0000010 21162199 CVCL_US18 GM06757 finite cell line human CVCL_US18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06757; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162200 CVCL_US19 GM06753 finite cell line human CVCL_US19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06753; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162201 CVCL_V419 WCMC-7 embryonic stem cell human CVCL_V419 From: Weill Cornell Medical College; New York; USA. CL:0000010 Male 21162202 CVCL_LY99 BayGenomics ES cell line CSH571 embryonic stem cell house mouse CVCL_LY99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339970; Rtn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162203 CVCL_LY97 BayGenomics ES cell line CSH565 embryonic stem cell house mouse CVCL_LY97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162204 CVCL_LY98 BayGenomics ES cell line CSH568 embryonic stem cell house mouse CVCL_LY98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162205 CVCL_LY95 BayGenomics ES cell line CSH562 embryonic stem cell house mouse CVCL_LY95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919367; Naa50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162206 CVCL_LY96 BayGenomics ES cell line CSH563 embryonic stem cell house mouse CVCL_LY96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915955; Gtf2f2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162207 CVCL_LY93 BayGenomics ES cell line CSH559 embryonic stem cell house mouse CVCL_LY93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162208 CVCL_LY94 BayGenomics ES cell line CSH561 embryonic stem cell house mouse CVCL_LY94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915098; Ddx55 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162209 CVCL_LY91 BayGenomics ES cell line CSH556 embryonic stem cell house mouse CVCL_LY91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162210 CVCL_LY92 BayGenomics ES cell line CSH557 embryonic stem cell house mouse CVCL_LY92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162211 CVCL_LY90 BayGenomics ES cell line CSH553 embryonic stem cell house mouse CVCL_LY90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162212 CVCL_V420 GM00492 finite cell line human CVCL_V420 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21162213 CVCL_US20 GM06502 finite cell line human CVCL_US20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06502; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162214 CVCL_US01 GM06343 finite cell line human CVCL_US01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06343; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162215 CVCL_V401 HCT-116-MEK-R cancer cell line human CVCL_V401 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901); Derived from sampling site: Colon. Male 21162216 CVCL_US02 GM06390 finite cell line human CVCL_US02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06390; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162217 CVCL_V402 LoVo-MEK-R cancer cell line human CVCL_V402 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901); Derived from metastatic site: Left supraclavicular lymph node. Male 21162218 CVCL_V400 A-2233 cancer cell line human CVCL_V400 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Derived from sampling site: Colon. Unspecified 21162219 CVCL_US00 GM06680 finite cell line human CVCL_US00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06680; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162220 CVCL_US05 GM06394 finite cell line human CVCL_US05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06394; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162221 CVCL_V405 SUP-M2-CR03 cancer cell line human CVCL_V405 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori); Derived from sampling site: Cerebrospinal fluid. Female 21162222 CVCL_US06 GM06395 finite cell line human CVCL_US06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06395; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162223 CVCL_V406 HCC827CLR cancer cell line human CVCL_V406 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90180; CL-387785 (EKI-785); Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Selected for resistance to: ChEBI; CHEBI:90197; PHA-665752; Derived from sampling site: Lung. Female 21162224 CVCL_US03 GM06392 finite cell line human CVCL_US03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06392; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162225 CVCL_V403 MDA-MB-231-MEK-R cancer cell line human CVCL_V403 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:88249; 391210-10-9 (PD0325901); Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21162226 CVCL_US04 GM06393 finite cell line human CVCL_US04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06393; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162227 CVCL_V404 Karpas-299-CR06 cancer cell line human CVCL_V404 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 7910; NPM1; Name(s)=NPM1-ALK (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:64310; Crizotinib (Xalkori); Derived from sampling site: Peripheral blood. Male 21162228 CVCL_US09 GM06397 finite cell line human CVCL_US09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06397; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162229 CVCL_V409 K1-Mel cancer cell line human CVCL_V409 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714). 21162230 CVCL_US07 GM06391 finite cell line human CVCL_US07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06391; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162231 CVCL_V407 HCC827EPR cancer cell line human CVCL_V407 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Selected for resistance to: ChEBI; CHEBI:90197; PHA-665752; Derived from sampling site: Lung. Female 21162232 CVCL_US08 GM06396 finite cell line human CVCL_US08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06396; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162233 CVCL_V408 HCC827ER cancer cell line human CVCL_V408 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Female 21162234 CVCL_LY68 BayGenomics ES cell line CSH505 embryonic stem cell house mouse CVCL_LY68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162235 CVCL_LY69 BayGenomics ES cell line CSH507 embryonic stem cell house mouse CVCL_LY69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915955; Gtf2f2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162236 CVCL_LY66 BayGenomics ES cell line CSH499 embryonic stem cell house mouse CVCL_LY66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162237 CVCL_LY67 BayGenomics ES cell line CSH501 embryonic stem cell house mouse CVCL_LY67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88042; Apex1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162238 CVCL_LY64 BayGenomics ES cell line CSH493 embryonic stem cell house mouse CVCL_LY64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2663721; Zc3h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162239 CVCL_LY65 BayGenomics ES cell line CSH498 embryonic stem cell house mouse CVCL_LY65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162240 CVCL_LY62 BayGenomics ES cell line CSH488 embryonic stem cell house mouse CVCL_LY62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162241 CVCL_LY63 BayGenomics ES cell line CSH492 embryonic stem cell house mouse CVCL_LY63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162242 CVCL_LY60 BayGenomics ES cell line CSH480 embryonic stem cell house mouse CVCL_LY60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162243 CVCL_LY61 BayGenomics ES cell line CSH482 embryonic stem cell house mouse CVCL_LY61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88431; Cnbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162244 CVCL_LY79 BayGenomics ES cell line CSH528 embryonic stem cell house mouse CVCL_LY79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685335; Mctp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162245 CVCL_LY77 BayGenomics ES cell line CSH524 embryonic stem cell house mouse CVCL_LY77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915525; Rpa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162246 CVCL_LY78 BayGenomics ES cell line CSH527 embryonic stem cell house mouse CVCL_LY78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3527792; Zdhhc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162247 CVCL_LY75 BayGenomics ES cell line CSH520 embryonic stem cell house mouse CVCL_LY75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162248 CVCL_LY76 BayGenomics ES cell line CSH523 embryonic stem cell house mouse CVCL_LY76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916996; Znhit6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162249 CVCL_LY73 BayGenomics ES cell line CSH516 embryonic stem cell house mouse CVCL_LY73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88110; Atp2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162250 CVCL_LY74 BayGenomics ES cell line CSH518 embryonic stem cell house mouse CVCL_LY74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162251 CVCL_LY71 BayGenomics ES cell line CSH509 embryonic stem cell house mouse CVCL_LY71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925868; Acap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162252 CVCL_LY72 BayGenomics ES cell line CSH513 embryonic stem cell house mouse CVCL_LY72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108086; Hdac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162253 CVCL_LY70 BayGenomics ES cell line CSH508 embryonic stem cell house mouse CVCL_LY70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162254 CVCL_LY48 BayGenomics ES cell line CSH459 embryonic stem cell house mouse CVCL_LY48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162255 CVCL_LY49 BayGenomics ES cell line CSH461 embryonic stem cell house mouse CVCL_LY49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162256 CVCL_LY46 BayGenomics ES cell line CSH456 embryonic stem cell house mouse CVCL_LY46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162257 CVCL_LY47 BayGenomics ES cell line CSH458 embryonic stem cell house mouse CVCL_LY47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162258 CVCL_LY44 BayGenomics ES cell line CSH454 embryonic stem cell house mouse CVCL_LY44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920093; Prdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162259 CVCL_LY45 BayGenomics ES cell line CSH455 embryonic stem cell house mouse CVCL_LY45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162260 CVCL_LY42 BayGenomics ES cell line CSH452 embryonic stem cell house mouse CVCL_LY42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444951; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162261 CVCL_LY43 BayGenomics ES cell line CSH453 embryonic stem cell house mouse CVCL_LY43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098233; Impact Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162262 CVCL_LY40 BayGenomics ES cell line CSH447 embryonic stem cell house mouse CVCL_LY40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890156; Stx8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162263 CVCL_LY41 BayGenomics ES cell line CSH449 embryonic stem cell house mouse CVCL_LY41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2663721; Zc3h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162264 CVCL_LY59 BayGenomics ES cell line CSH479 embryonic stem cell house mouse CVCL_LY59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162265 CVCL_LY57 BayGenomics ES cell line CSH476 embryonic stem cell house mouse CVCL_LY57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162266 CVCL_LY58 BayGenomics ES cell line CSH478 embryonic stem cell house mouse CVCL_LY58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162267 CVCL_LY55 BayGenomics ES cell line CSH474 embryonic stem cell house mouse CVCL_LY55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162268 CVCL_LY56 BayGenomics ES cell line CSH475 embryonic stem cell house mouse CVCL_LY56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921728; Snx29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162269 CVCL_LY53 BayGenomics ES cell line CSH470 embryonic stem cell house mouse CVCL_LY53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3781595; Dynlt2a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162270 CVCL_LY54 BayGenomics ES cell line CSH473 embryonic stem cell house mouse CVCL_LY54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344381; Dnajb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162271 CVCL_LY51 BayGenomics ES cell line CSH465 embryonic stem cell house mouse CVCL_LY51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442988; Arfgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162272 CVCL_LY52 BayGenomics ES cell line CSH469 embryonic stem cell house mouse CVCL_LY52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162273 CVCL_LY50 BayGenomics ES cell line CSH464 embryonic stem cell house mouse CVCL_LY50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95739; Glul Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162274 CVCL_2L60 AG20452 transformed cell line human CVCL_2L60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162275 CVCL_2L63 AG20455 transformed cell line human CVCL_2L63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162276 CVCL_2L64 AG20606 transformed cell line human CVCL_2L64 CL:0000010 Anecdotal: This is currently the human cell line originating from the oldest donor Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162277 CVCL_2L61 AG20453 transformed cell line human CVCL_2L61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162278 CVCL_2L62 AG20454 transformed cell line human CVCL_2L62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162279 CVCL_2L67 AG20609 transformed cell line human CVCL_2L67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162280 CVCL_2L68 AG20610 transformed cell line human CVCL_2L68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162281 CVCL_2L65 AG20607 transformed cell line human CVCL_2L65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162282 CVCL_2L66 AG20608 transformed cell line human CVCL_2L66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162283 CVCL_2L58 AG20449 transformed cell line human CVCL_2L58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162284 CVCL_2L59 AG20450 transformed cell line human CVCL_2L59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162285 CVCL_V399 A-1698 cancer cell line human CVCL_V399 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Derived from sampling site: Urinary bladder. Unspecified 21162286 CVCL_UR99 GM06365 finite cell line human CVCL_UR99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06365; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162287 CVCL_2L70 AG20619 transformed cell line human CVCL_2L70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162288 CVCL_2L71 AG20620 transformed cell line human CVCL_2L71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162289 CVCL_2L74 AG20625 transformed cell line human CVCL_2L74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162290 CVCL_2L75 AG20626 transformed cell line human CVCL_2L75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162291 CVCL_2L72 AG20621 transformed cell line human CVCL_2L72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162292 CVCL_2L73 AG20623 transformed cell line human CVCL_2L73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162293 CVCL_2L78 AG07648 finite cell line dog CVCL_2L78 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162294 CVCL_2L79 BFAE-39b finite cell line CVCL_2L79 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male Senescence: Senesces at 87 PDL (PubMed=2981236) Caution: Indicated to be of female origin in PubMed=2981236, but karyotype from Coriell shows X,Y 21162295 CVCL_2L76 AG20627 transformed cell line human CVCL_2L76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162296 CVCL_2L77 AG20628 transformed cell line human CVCL_2L77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162297 CVCL_2L69 AG20618 transformed cell line human CVCL_2L69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162298 CVCL_UR88 GM06684 finite cell line human CVCL_UR88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06684; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162299 CVCL_V388 GM07254 transformed cell line human CVCL_V388 HLA typing: A*01; B*39; C*w07 (Coriell=GM07254) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a donor that was the offspring of consanguineous parents (brother/sister mating); Derived from sampling site: Peripheral blood. Male 21162300 CVCL_V389 GM00574 finite cell line human CVCL_V389 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gly222Arg (c.666G>C) (G743C); Zygosity=Heterozygous (PubMed=7814621); Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (PubMed=7814621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Metabolome analysis Male 21162301 CVCL_UR89 GM05583 finite cell line human CVCL_UR89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05583; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162302 CVCL_2L41 AG17666 transformed cell line human CVCL_2L41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162303 CVCL_2L42 AG17715 transformed cell line human CVCL_2L42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162304 CVCL_2L40 AG17665 transformed cell line human CVCL_2L40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162305 CVCL_2L45 AG17718 transformed cell line human CVCL_2L45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162306 CVCL_2L46 AG17727 transformed cell line human CVCL_2L46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162307 CVCL_2L43 AG17716 transformed cell line human CVCL_2L43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162308 CVCL_2L44 AG17717 transformed cell line human CVCL_2L44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162309 CVCL_2L38 AG16991 transformed cell line human CVCL_2L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162310 CVCL_2L39 AG17510 transformed cell line human CVCL_2L39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162311 CVCL_2L36 AG16989 transformed cell line human CVCL_2L36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162312 CVCL_2L37 AG16990 transformed cell line human CVCL_2L37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162313 CVCL_UR90 GM05589 finite cell line human CVCL_UR90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05589; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162314 CVCL_V390 GM11215 transformed cell line human CVCL_V390 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Homozygous (PubMed=19815695) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21162315 CVCL_UR93 GM05495 finite cell line human CVCL_UR93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05495; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162316 CVCL_V393 GM13073 transformed cell line human CVCL_V393 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162317 CVCL_UR94 GM06768 finite cell line human CVCL_UR94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06768; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162318 CVCL_V394 GM13243 transformed cell line human CVCL_V394 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162319 CVCL_UR91 GM06369 finite cell line human CVCL_UR91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06369; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162320 CVCL_V391 GM11416 transformed cell line human CVCL_V391 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162321 CVCL_UR92 GM06782 finite cell line human CVCL_UR92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06782; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162322 CVCL_V392 GM11468 transformed cell line human CVCL_V392 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Arg83Cys (c.247C>T); ClinVar=VCV000011998; Zygosity=Heterozygous (PubMed=19815695); Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (PubMed=19815695) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21162323 CVCL_UR97 GM05441 finite cell line human CVCL_UR97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05441; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162324 CVCL_V397 GM13290 transformed cell line human CVCL_V397 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162325 CVCL_V398 A-1604 cancer cell line human CVCL_V398 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 21162326 CVCL_UR98 GM05439 finite cell line human CVCL_UR98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05439; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162327 CVCL_UR95 GM06383 finite cell line human CVCL_UR95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06383; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162328 CVCL_V395 GM13247 transformed cell line human CVCL_V395 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162329 CVCL_UR96 GM05637 finite cell line human CVCL_UR96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05637; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162330 CVCL_V396 GM13289 transformed cell line human CVCL_V396 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162331 CVCL_UR79 GM03547 finite cell line human CVCL_UR79 CL:0000010 Population: Arab; Derived from sampling site: Cell type=Fibroblast. Ambiguous 21162332 CVCL_V379 NT00671 transformed cell line human CVCL_V379 HLA typing: A*02:02,74:MN; B*15:03,53:AD; C*02:16,04:01:01:01; DRB1*11:BK,11:NRV (IPD-IMGT/HLA=14453) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162333 CVCL_UR77 GM02447 finite cell line human CVCL_UR77 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02447; probable Male 21162334 CVCL_V377 NT00669 transformed cell line human CVCL_V377 HLA typing: A*03:BUVE,68:34; B*51:AFJH,58:BF; C*06:REV,18:AB; DRB1*12:GW,15:03 (IPD-IMGT/HLA=14456) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162335 CVCL_UR78 GM03081 finite cell line human CVCL_UR78 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03081; probable Female 21162336 CVCL_V378 NT00670 transformed cell line human CVCL_V378 HLA typing: A*02:BUWR,11:23; B*44:AJVH,57:GW; C*05:ANJN,07:02; DRB1*01:ANWV,04:AGCN (IPD-IMGT/HLA=14455) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162337 CVCL_2L52 AG20425 transformed cell line human CVCL_2L52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162338 CVCL_2L53 AG20426 transformed cell line human CVCL_2L53 CL:0000010 Population: Caucasian; Dutch/French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162339 CVCL_2L50 AG20423 transformed cell line human CVCL_2L50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162340 CVCL_2L51 AG20424 transformed cell line human CVCL_2L51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162341 CVCL_2L56 AG20429 transformed cell line human CVCL_2L56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162342 CVCL_2L57 AG20430 transformed cell line human CVCL_2L57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162343 CVCL_2L54 AG20427 transformed cell line human CVCL_2L54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162344 CVCL_2L55 AG20428 transformed cell line human CVCL_2L55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162345 CVCL_2L49 AG20422 transformed cell line human CVCL_2L49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162346 CVCL_2L47 AG17728 transformed cell line human CVCL_2L47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162347 CVCL_2L48 AG17862 transformed cell line human CVCL_2L48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162348 CVCL_UR82 GM09405 finite cell line human CVCL_UR82 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM09405; probable Female 21162349 CVCL_V382 STFO3416AN transformed cell line human CVCL_V382 HLA typing: A*01:RPH,03:BKS; B*07:XV,44:AMUT; C*05:ANJN,07:02; DQA1*01:03,03:MN; DQB1*03:AF,06:08:02; DRB1*04:01:01,13:01:01 (IPD-IMGT/HLA=14470) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162350 CVCL_UR83 GM03295 finite cell line human CVCL_UR83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03295; probable Male 21162351 CVCL_V383 TBC34836 transformed cell line human CVCL_V383 HLA typing: A*24:02; B*40:02,54:01; C*01:02,03:29; DRB1*04:05 (IPD-IMGT/HLA=14461) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162352 CVCL_UR80 GM10649 finite cell line human CVCL_UR80 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM10649; probable Female 21162353 CVCL_V380 NT00672 transformed cell line human CVCL_V380 HLA typing: A*01:TUS,24; B*40:SUF,57:MY; C*03:27,06:02; DRB1*04:VZB,16:01 (IPD-IMGT/HLA=14454) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162354 CVCL_UR81 GM10376 finite cell line human CVCL_UR81 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM10376; probable Female 21162355 CVCL_V381 NT00673 transformed cell line human CVCL_V381 HLA typing: A*01:TUS,11:ANXJ; B*35:ADSB,57:AG; C*04:15:02,06:02; DRB1*01:EW,07:APA (IPD-IMGT/HLA=14452) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162356 CVCL_UR86 GM05725 finite cell line human CVCL_UR86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05725; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162357 CVCL_V386 TZDR03 transformed cell line human CVCL_V386 HLA typing: A*02:07,11:01; B*40:01,58:01; C*03:02,04:01; DQB1*02:01,04:01; DRB1*04:03,03:31 (IPD-IMGT/HLA=14467) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162358 CVCL_UR87 GM05735 finite cell line human CVCL_UR87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05735; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162359 CVCL_V387 WF215-200 transformed cell line human CVCL_V387 HLA typing: DQA1*01:02,01:02; DQB1*05:02,06:04:03; DRB1*13:02,16:01 (IPD-IMGT/HLA=14463) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162360 CVCL_UR84 GM03959 transformed cell line human CVCL_UR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03959; probable Male 21162361 CVCL_V384 TBC60311 transformed cell line human CVCL_V384 HLA typing: A*24:02,26:01; B*40:01; C*03:28,04:01; DRB1*09:01,15:01 (IPD-IMGT/HLA=14460) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162362 CVCL_UR85 GM03791 finite cell line human CVCL_UR85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03791; probable Male 21162363 CVCL_V385 TMO-399 transformed cell line human CVCL_V385 HLA typing: A*02:01,02:11; B*07:02,40:68; C*03:04,07:02; DQB1*03:02,06:02; DRB1*04:07,15:01 (IPD-IMGT/HLA=14458) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162364 CVCL_V368 BY00117 transformed cell line human CVCL_V368 HLA typing: A*03:01:01,24:59 (IPD-IMGT/HLA=14474) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162365 CVCL_UR68 ESi073-A induced pluripotent stem cell human CVCL_UR68 From: Laboratorio de Neurociencia Elena Pessino Gornez del Campo; Madrid; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21162366 CVCL_V369 BY00119 transformed cell line human CVCL_V369 HLA typing: DRB1*12:02,03:27 (IPD-IMGT/HLA=14476) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162367 CVCL_UR69 RESC spontaneously immortalized cell line CVCL_UR69 CL:0000010 Unspecified Group: Fish cell line. 21162368 CVCL_V366 2681943 transformed cell line human CVCL_V366 HLA typing: A*02:01,03:01; B*18:01,44:03; C*04:01,07:40; DQB1*02:02,03:02; DRB1*04:05,07:01 (IPD-IMGT/HLA=14459) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162369 CVCL_UR66 SNU-2414B cancer cell line human CVCL_UR66 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1444Ter (c.4330C>T); Zygosity=Unspecified (PubMed=30114595) Population: Korean; Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 29 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162370 CVCL_V367 BY00116 transformed cell line human CVCL_V367 HLA typing: A*03:DDKG,33:08; C*04:01:01:01,07:01 (IPD-IMGT/HLA=14472) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162371 CVCL_UR67 ESi072-A induced pluripotent stem cell human CVCL_UR67 From: Laboratorio de Neurociencia Elena Pessino Gornez del Campo; Madrid; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21162372 CVCL_2L20 AG16941 transformed cell line human CVCL_2L20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162373 CVCL_2L23 AG16973 transformed cell line human CVCL_2L23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162374 CVCL_2L24 AG16974 transformed cell line human CVCL_2L24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162375 CVCL_2L21 AG16942 transformed cell line human CVCL_2L21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162376 CVCL_2L22 AG16943 transformed cell line human CVCL_2L22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162377 CVCL_2L16 AG16937 transformed cell line human CVCL_2L16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162378 CVCL_2L17 AG16938 transformed cell line human CVCL_2L17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162379 CVCL_2L14 AG16935 transformed cell line human CVCL_2L14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162380 CVCL_2L15 AG16936 transformed cell line human CVCL_2L15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162381 CVCL_2L18 AG16939 transformed cell line human CVCL_2L18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162382 CVCL_2L19 AG16940 transformed cell line human CVCL_2L19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162383 CVCL_V371 BY00121 transformed cell line human CVCL_V371 HLA typing: A*01:YAG,03:ANPZ; B*08:AKUY,51:AFJY; C*01:02:01/01:02:02,07:01:07; DRB1*03:WHX,11:ARAP (IPD-IMGT/HLA=14473) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162384 CVCL_UR71 GM03527 finite cell line human CVCL_UR71 CL:0000010 Population: Caucasian; Derived from sampling site: Penis; Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03527; probable Male 21162385 CVCL_V372 DN435.5 transformed cell line human CVCL_V372 HLA typing: A*68:02,25:05; B*14:02,18:01; C*08:02,12:03; DQB1*03:01,06:02; DRB1*13:03,15:01 (IPD-IMGT/HLA=14468) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162386 CVCL_UR72 GM06836 finite cell line human CVCL_UR72 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM06836; probable Female 21162387 CVCL_V370 BY00120 transformed cell line human CVCL_V370 HLA typing: A*31:01:02,24:66; C*04:01:01:01/04:01:01:02/04:09N,07:02 (IPD-IMGT/HLA=14477) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162388 CVCL_UR70 GM02270 finite cell line human CVCL_UR70 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; GM02270; probable Male 21162389 CVCL_UR75 GM03519 finite cell line human CVCL_UR75 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03519; probable Male 21162390 CVCL_V375 K107946 transformed cell line human CVCL_V375 HLA typing: A*03:01,29:02; B*40:01,44:03; C*03:04,16:01; DPB1*01:01,04:01; DQB1*02:02,06:04; DRB1*07:01:01,13:74; DRB3*03; DRB4*01:TMB (IPD-IMGT/HLA=14471) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162391 CVCL_UR76 GM09564 finite cell line human CVCL_UR76 HLA typing: A*01,02; B*51,w57 (PubMed=2916654) CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM09564; probable Male 21162392 CVCL_V376 MHHZ-00020533 transformed cell line human CVCL_V376 HLA typing: A*03:BUVE,24:ATEA; B*15:BKVK,35:BEZX; C*03:BPSK,04:KBG; DQB1*02:MS,05:01; DRB1*01:01,03:30 (IPD-IMGT/HLA=14464) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162393 CVCL_V373 FRFCB transformed cell line human CVCL_V373 HLA typing: A*11:01,24:13:02; B*35:02,44:02; C*04:01,05:01; DQB1*03:01; DRB1*04:01,11:01 (IPD-IMGT/HLA=14469) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162394 CVCL_UR73 GM11660 finite cell line human CVCL_UR73 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM11660; probable Female 21162395 CVCL_V374 GAGI8381AN transformed cell line human CVCL_V374 HLA typing: A*29:02:01,30:02; B*14:02,42:01; C*07:18,12:19; DPB1*01:VVY,04:BDVT; DQB1*05:03,03:AF; DRB1*11:17,08:04; DRB3*02 (IPD-IMGT/HLA=14466) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21162396 CVCL_UR74 GM01994 finite cell line human CVCL_UR74 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM01994; probable Male 21162397 CVCL_UR57 BEAS-2B/R1 transformed cell line human CVCL_UR57 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Partially resistant to retinoic acid 21162398 CVCL_V357 MCF7 Tet-Off cancer cell line human CVCL_V357 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 630907 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162399 CVCL_UR58 HB56B finite cell line human CVCL_UR58 CL:0000010 Population: African American; Derived from sampling site: Bronchus Cell type=Epithelial cell.. Female Senescence: Senesces at 125-200 PDL (PubMed=1712759); Doubling time: ~48 hours (at 3-10th passages), >90 hours (at 25-50th passages) (PubMed=1712759) 21162400 CVCL_V358 MCF7 tTS cancer cell line human CVCL_V358 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 630929/631148 Female 21162401 CVCL_UR55 Bar-1 finite cell line CVCL_UR55 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Unspecified Senescence: Senesces at 62 PDL (PubMed=15664728) 21162402 CVCL_V355 HT-1080 Tet-Off cancer cell line human CVCL_V355 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162403 CVCL_V356 Jurkat Tet-On 3G cancer cell line human CVCL_V356 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162404 CVCL_UR56 KPC-IL-6 KO cancer cell line house mouse CVCL_UR56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:96559; Il6 Miscellaneous: Cell line information from personal communication of Rupert J.E Breed/subspecies: LSL-KrasG12D:LSL-Trp53R172H:Pdx1-Cre (KPC). Male 21162405 CVCL_UR59 HB56B/5T transformed cell line human CVCL_UR59 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus Cell type=Epithelial cell.. Female 21162406 CVCL_V359 MDCK Tet-Off spontaneously immortalized cell line dog CVCL_V359 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Discontinued: Clontech; Catalog number 630913/631138 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162407 CVCL_2L30 AG16983 transformed cell line human CVCL_2L30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162408 CVCL_2L31 AG16984 transformed cell line human CVCL_2L31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162409 CVCL_2L34 AG16987 transformed cell line human CVCL_2L34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162410 CVCL_2L35 AG16988 transformed cell line human CVCL_2L35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162411 CVCL_2L32 AG16985 transformed cell line human CVCL_2L32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162412 CVCL_2L33 AG16986 transformed cell line human CVCL_2L33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162413 CVCL_2L27 AG16978 transformed cell line human CVCL_2L27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162414 CVCL_2L28 AG16981 transformed cell line human CVCL_2L28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162415 CVCL_2L25 AG16976 transformed cell line human CVCL_2L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162416 CVCL_2L26 AG16977 transformed cell line human CVCL_2L26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162417 CVCL_2L29 AG16982 transformed cell line human CVCL_2L29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162418 CVCL_V360 NIH/3T3 Tet-On 3G spontaneously immortalized cell line house mouse CVCL_V360 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162419 CVCL_UR60 SNU-2335A cancer cell line human CVCL_UR60 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg302Ter (c.904C>T) (R284*); ClinVar=VCV000000798; Zygosity=Unspecified (PubMed=30114595); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=30114595) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 45 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162420 CVCL_V361 PC12 Tet-Off cancer cell line Norway rat CVCL_V361 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162421 CVCL_UR61 SNU-2335D cancer cell line human CVCL_UR61 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg302Ter (c.904C>T) (R284*); ClinVar=VCV000000798; Zygosity=Unspecified (PubMed=30114595); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=30114595) Population: Korean; Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 48 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162422 CVCL_V364 2006042530 transformed cell line human CVCL_V364 HLA typing: A*24:02:01:01,33:03:01; B*15:07,58:13; C*03:02,03:03:01; DPA1*01:03:01,02:02:02; DPB1*02:01:02,05:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:09; DRB1*04:03:01,13:02:01; DRB3*03:01:01; DRB4*01:03:01 (IPD-IMGT/HLA=14457) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162423 CVCL_UR64 SNU-2404B cancer cell line human CVCL_UR64 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=30114595) Population: Korean; Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 67 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162424 CVCL_V365 264040 transformed cell line human CVCL_V365 HLA typing: B*08:30N,56:01; DQB1*03:02,05:02; DRB1*04:01,16:01 (IPD-IMGT/HLA=14451) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162425 CVCL_UR65 SNU-2414A cancer cell line human CVCL_UR65 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1444Ter (c.4330C>T); Zygosity=Unspecified (PubMed=30114595) Population: Korean Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: 45 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162426 CVCL_V362 051407cb transformed cell line human CVCL_V362 HLA typing: A*01:01,11:29; B*18:01,07:02; C*06:02,07:02; DQB1*03:01,06:02; DRB1*11:04,15:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=14462) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21162427 CVCL_UR62 SNU-2335E cancer cell line human CVCL_UR62 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Homozygous (PubMed=30114595) Population: Korean; Derived from metastatic site: Ovary. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 40 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162428 CVCL_V363 157748 transformed cell line human CVCL_V363 HLA typing: A*02,26; B*35,44; C*04,05; DQB1*03:01,03:02; DRB1*04:60,11:04:01; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=14465) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21162429 CVCL_UR63 SNU-2404A cancer cell line human CVCL_UR63 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg302Ter (c.904C>T) (R284*); ClinVar=VCV000000798; Zygosity=Unspecified (PubMed=30114595); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=30114595) Population: Korean Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: 55 hours (PubMed=30114595); Microsatellite instability: Stable (MSS) (PubMed=30114595) Part of: Seoul National University (SNU) cell line collection 21162430 CVCL_V346 GM13964 transformed cell line human CVCL_V346 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162431 CVCL_UR46 HK-CRISPR-mEGFP-CAP-H2 cancer cell line human CVCL_UR46 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NCAPH2 (CAP-H2) has been endogenously tagged in both alleles at the N-terminus with mEGFP 21162432 CVCL_V347 CHO-AA8 Tet-Off spontaneously immortalized cell line CVCL_V347 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Ovary. Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162433 CVCL_UR47 HK-ZFN-mEGFP-CAP-H cancer cell line human CVCL_UR47 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using ZFN NCAPH (CAP-H) has been endogenously tagged in both alleles at the N-terminus with mEGFP 21162434 CVCL_V344 GM10462 finite cell line human CVCL_V344 CL:0000010 Population: African American; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female 21162435 CVCL_UR44 HK-CRISPR-CAP-D3-mEGFP no.16 cancer cell line human CVCL_UR44 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NCAPD3 (CAP-D3) has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162436 CVCL_V345 GM10552 transformed cell line human CVCL_V345 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162437 CVCL_UR45 HK-CRISPR-CAP-H2-mEGFP no.67 cancer cell line human CVCL_UR45 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NCAPH2 (CAP-H2) has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162438 CVCL_V348 CHO Tet-On 3G spontaneously immortalized cell line CVCL_V348 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Ovary. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162439 CVCL_UR48 HK-ZFN-SMC4-mEGFP cancer cell line human CVCL_UR48 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using ZFN SMC4 has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162440 CVCL_V349 HEK 293 Tet-Off transformed cell line human CVCL_V349 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Clontech; Catalog number 630908 Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162441 CVCL_UR49 HK-CRISPR-NUP205-mEGFP no.81 cancer cell line human CVCL_UR49 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NUP205 has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162442 CVCL_2L01 AG16911 transformed cell line human CVCL_2L01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162443 CVCL_2L02 AG16912 transformed cell line human CVCL_2L02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162444 CVCL_2L00 AG16909 transformed cell line human CVCL_2L00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162445 CVCL_V350 HEK 293 Tet-On 3G transformed cell line human CVCL_V350 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162446 CVCL_UR50 HeLa R19 FlpIn TREx cancer cell line human CVCL_UR50 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21162447 CVCL_V353 HeLa Tet-On 3G cancer cell line human CVCL_V353 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162448 CVCL_UR53 NCC-DFSP1-C1 cancer cell line human CVCL_UR53 CL:0000010 Sequence variation: Gene fusion; HGNC; 2197; COL1A1 + HGNC; 8800; PDGFB; Name(s)=COL1A1-PDGFB (PubMed=30411273) Population: Japanese Omics: Deep proteome analysis. Male Doubling time: 48 hours (PubMed=30411273) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21162449 CVCL_V354 HeLa tTS cancer cell line human CVCL_V354 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Clontech; Catalog number 630928/631147 Female 21162450 CVCL_UR54 NCC-DFSP2-C1 cancer cell line human CVCL_UR54 CL:0000010 Sequence variation: Gene fusion; HGNC; 2197; COL1A1 + HGNC; 8800; PDGFB; Name(s)=COL1A1-PDGFB (PubMed=30411273) Population: Japanese; Derived from sampling site: Breast. Omics: Deep proteome analysis Female Doubling time: 44 hours (PubMed=30411273) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21162451 CVCL_V351 HEK 293 tTS transformed cell line human CVCL_V351 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Clontech; Catalog number 630927/631146 Female 21162452 CVCL_UR51 HeLa R19 FlpIn TREx H2B-Cherry/NS3-CMPK-hLBR1TM-mEGFP cancer cell line human CVCL_UR51 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with both H2B-mCherry and a DOX inducible NS3-CMPK-hLBR1TM-mEGFP construct 21162453 CVCL_V352 HeLa Tet-Off cancer cell line human CVCL_V352 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21162454 CVCL_UR52 imHC telomerase immortalized cell line human CVCL_UR52 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell derived hepatocyte.. Characteristics: Supports Plasmodium vivax liver-stage development (PubMed=29370800) 21162455 CVCL_UR35 U-87MG ATCC IDH1 p.R132H-Luc2 cancer cell line human CVCL_UR35 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple_edited; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression). Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21162456 CVCL_V335 U2-OS Tet-On cancer cell line human CVCL_V335 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162457 CVCL_UR36 13F3 hybridoma house mouse CVCL_UR36 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9D659; Mouse Vsir. 21162458 CVCL_V336 U2-OS-Luc Tet-On cancer cell line human CVCL_V336 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16; Characteristics: The firefly luciferase reporter gene is under the control of a tetracycline-responsive promoter 21162459 CVCL_V333 PC12 Tet-On cancer cell line Norway rat CVCL_V333 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: Clontech; Catalog number 630912/631137 Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162460 CVCL_UR33 U-87 MG-Luc2 cancer cell line human CVCL_UR33 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression). Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21162461 CVCL_UR34 A-375 KRAS p.G13D-Luc2 cancer cell line human CVCL_UR34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Exhibits significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC).; Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter 21162462 CVCL_V334 T-47D Tet-On cancer cell line human CVCL_V334 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Derived from metastatic site: Pleural effusion. Discontinued: Clontech; Catalog number 630923/631144 Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21162463 CVCL_V339 GM04476 finite cell line human CVCL_V339 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21162464 CVCL_UR39 K-562-luc2 cancer cell line human CVCL_UR39 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: 18 +- 2 hours (ATCC=CCL-243-LUC2) 21162465 CVCL_UR37 BHK21-human GCGR spontaneously immortalized cell line CVCL_UR37 CL:0000010 Transfected with: HGNC; 4192; GCGR Derived from sampling site: Kidney. Male 21162466 CVCL_V337 PC-9/ZD cancer cell line human CVCL_V337 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21162467 CVCL_UR38 C2C12 Scrambled spontaneously immortalized cell line house mouse CVCL_UR38 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: Control cell line for C2C12 Clone 5 DYS shRNA Transfected with a scrambled DYS shRNA. 21162468 CVCL_V338 ND10735 transformed cell line human CVCL_V338 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (from familial inference of ND10734) Population: Cape Verdian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162469 CVCL_2L12 AG16932 transformed cell line human CVCL_2L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162470 CVCL_2L13 AG16933 transformed cell line human CVCL_2L13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162471 CVCL_2L10 AG16930 transformed cell line human CVCL_2L10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162472 CVCL_2L11 AG16931 transformed cell line human CVCL_2L11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162473 CVCL_2L05 AG16915 transformed cell line human CVCL_2L05 CL:0000010 Population: Caucasian; Dutch/French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162474 CVCL_2L06 AG16926 transformed cell line human CVCL_2L06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162475 CVCL_2L03 AG16913 transformed cell line human CVCL_2L03 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162476 CVCL_2L04 AG16914 transformed cell line human CVCL_2L04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162477 CVCL_2L09 AG16929 transformed cell line human CVCL_2L09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Institute on Aging (NIA) longevity collection 21162478 CVCL_2L07 AG16927 transformed cell line human CVCL_2L07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162479 CVCL_2L08 AG16928 transformed cell line human CVCL_2L08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Institute on Aging (NIA) longevity collection 21162480 CVCL_V342 GM07983 transformed cell line human CVCL_V342 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (Coriell) Population: Caucasian; Austrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162481 CVCL_UR42 HK-2xCRISPR-CAP-D2-mEGFP no.272-78 cancer cell line human CVCL_UR42 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NCAPD2 (CAP-D2) has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162482 CVCL_V343 GM10461 finite cell line human CVCL_V343 CL:0000010 Population: African American; Derived from sampling site: Placenta Cell type=Fibroblast.. Female 21162483 CVCL_UR43 HK-CRISPR-CAP-H-mEGFP no.86 cancer cell line human CVCL_UR43 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9D10A NCAPH (CAP-H) has been endogenously tagged in both alleles at the C-terminus with mEGFP 21162484 CVCL_V340 GM04477 transformed cell line human CVCL_V340 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21162485 CVCL_UR40 HCT116 VIM RFP cancer cell line human CVCL_UR40 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Derived from sampling site: Colon. Male Characteristics: Useful in vitro cell model for dissecting the molecular switches underlying epithelial to mesenchymal transition (EMT) and for identifying compounds that target EMT in colorectal cancer (ATCC); Characteristics: Using CRISPR/Cas9 a RFP reporter gene was integrated at the C-terminal of VIM (ATCC) Doubling time: 22 hours (ATCC=CCL-247EMT) 21162486 CVCL_V341 GM07982 finite cell line human CVCL_V341 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (PubMed=11738860) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162487 CVCL_UR41 HeLa Kyoto EGFP-LaminB1/H2B-mCherry cancer cell line human CVCL_UR41 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: HGNC; 6637; LMNB1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21162488 CVCL_2L81 BFAE-39k finite cell line CVCL_2L81 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male 21162489 CVCL_2L82 BFAE-45 finite cell line CVCL_2L82 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Female 21162490 CVCL_2L80 BFAE-39e spontaneously immortalized cell line CVCL_2L80 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male Senescence: Senesces at 54 PDL (PubMed=2981236) But said to be immortal (PubMed=6715012). Caution: Indicated to be of female origin in PubMed=2981236, but karyotype from Coriell shows X,Y 21162491 CVCL_2L85 AG07915 finite cell line CVCL_2L85 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162492 CVCL_2L86 AG07923 finite cell line CVCL_2L86 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162493 CVCL_2L83 AG07906 finite cell line CVCL_2L83 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Female 21162494 CVCL_2L84 AG07937 finite cell line CVCL_2L84 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Female 21162495 CVCL_2L89 AG08029 finite cell line CVCL_2L89 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Female 21162496 CVCL_2L87 AG07980 finite cell line CVCL_2L87 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Male 21162497 CVCL_2L88 AG07984 finite cell line CVCL_2L88 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Male 21162498 CVCL_2L92 AG08032 finite cell line CVCL_2L92 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Female 21162499 CVCL_2L93 AG08033 finite cell line CVCL_2L93 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Thoroughbred. Female 21162500 CVCL_2L90 AG08030 finite cell line CVCL_2L90 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Thoroughbred. Female 21162501 CVCL_2L91 AG08031 finite cell line CVCL_2L91 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Female 21162502 CVCL_2L96 AG08053 finite cell line dog CVCL_2L96 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162503 CVCL_2L97 AG08056 finite cell line dog CVCL_2L97 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162504 CVCL_2L94 AG08034 finite cell line CVCL_2L94 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Female 21162505 CVCL_2L95 AG08052 finite cell line dog CVCL_2L95 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162506 CVCL_2L98 AG08057 finite cell line dog CVCL_2L98 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162507 CVCL_2L99 AG08075 finite cell line dog CVCL_2L99 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162508 CVCL_LZ49 BayGenomics ES cell line CSH664 embryonic stem cell house mouse CVCL_LZ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162509 CVCL_LZ47 BayGenomics ES cell line CSH659 embryonic stem cell house mouse CVCL_LZ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162510 CVCL_LZ48 BayGenomics ES cell line CSH663 embryonic stem cell house mouse CVCL_LZ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162511 CVCL_LZ45 BayGenomics ES cell line CSH657 embryonic stem cell house mouse CVCL_LZ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162512 CVCL_LZ46 BayGenomics ES cell line CSH658 embryonic stem cell house mouse CVCL_LZ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99433; Arf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162513 CVCL_LZ43 BayGenomics ES cell line CSH651 embryonic stem cell house mouse CVCL_LZ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162514 CVCL_LZ44 BayGenomics ES cell line CSH653 embryonic stem cell house mouse CVCL_LZ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162515 CVCL_LZ41 BayGenomics ES cell line CSH649 embryonic stem cell house mouse CVCL_LZ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95485; Fasn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162516 CVCL_LZ42 BayGenomics ES cell line CSH650 embryonic stem cell house mouse CVCL_LZ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330839; Lin7c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162517 CVCL_LZ40 BayGenomics ES cell line CSH645 embryonic stem cell house mouse CVCL_LZ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162518 CVCL_LZ58 BayGenomics ES cell line CSH681 embryonic stem cell house mouse CVCL_LZ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162519 CVCL_LZ59 BayGenomics ES cell line CSH682 embryonic stem cell house mouse CVCL_LZ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2674092; Zfp609 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162520 CVCL_LZ56 BayGenomics ES cell line CSH678 embryonic stem cell house mouse CVCL_LZ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913894; Uba6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162521 CVCL_LZ57 BayGenomics ES cell line CSH680 embryonic stem cell house mouse CVCL_LZ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332234; Zfp148 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162522 CVCL_LZ54 BayGenomics ES cell line CSH674 embryonic stem cell house mouse CVCL_LZ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927489; Pdlim5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162523 CVCL_LZ55 BayGenomics ES cell line CSH675 embryonic stem cell house mouse CVCL_LZ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162524 CVCL_LZ52 BayGenomics ES cell line CSH669 embryonic stem cell house mouse CVCL_LZ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104913; Abi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162525 CVCL_LZ53 BayGenomics ES cell line CSH673 embryonic stem cell house mouse CVCL_LZ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162526 CVCL_LZ50 BayGenomics ES cell line CSH665 embryonic stem cell house mouse CVCL_LZ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140248; Zbtb48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162527 CVCL_LZ51 BayGenomics ES cell line CSH667 embryonic stem cell house mouse CVCL_LZ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162528 CVCL_DA93 GM20381 transformed cell line human CVCL_DA93 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2074; CLN3; Unexplicit; IVS11+6G>A; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162529 CVCL_DA94 GM20382 transformed cell line human CVCL_DA94 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; p.Val142Leufs*39 (c.424delG); ClinVar=VCV000056269; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162530 CVCL_DA91 GM20379 transformed cell line human CVCL_DA91 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Gly42Glu (c.125G>A); ClinVar=VCV000056179; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg122Trp (c.364A>T); ClinVar=VCV000008899; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162531 CVCL_DA92 GM20380 transformed cell line human CVCL_DA92 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Val181Met (c.541G>A); ClinVar=VCV000188857; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162532 CVCL_DA97 GM20385 transformed cell line human CVCL_DA97 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>A (IVS5-1G>A); ClinVar=VCV000207574; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162533 CVCL_DA98 GM20387 transformed cell line human CVCL_DA98 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162534 CVCL_LZ29 BayGenomics ES cell line CSH628 embryonic stem cell house mouse CVCL_LZ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162535 CVCL_DA95 GM20383 transformed cell line human CVCL_DA95 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; p.Glu295Lys (c.883G>A); ClinVar=VCV000003556; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162536 CVCL_DA96 GM20384 transformed cell line human CVCL_DA96 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.1198-1G>T (IVS14-1G>T); ClinVar=VCV000056251; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162537 CVCL_LZ27 BayGenomics ES cell line CSH624 embryonic stem cell house mouse CVCL_LZ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162538 CVCL_LZ28 BayGenomics ES cell line CSH627 embryonic stem cell house mouse CVCL_LZ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894678; Aurka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162539 CVCL_LZ25 BayGenomics ES cell line CSH616 embryonic stem cell house mouse CVCL_LZ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926956; Zfp296 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162540 CVCL_LZ26 BayGenomics ES cell line CSH622 embryonic stem cell house mouse CVCL_LZ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330299; Dyrk1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162541 CVCL_LZ23 BayGenomics ES cell line CSH612 embryonic stem cell house mouse CVCL_LZ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109150; Mnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162542 CVCL_LZ24 BayGenomics ES cell line CSH615 embryonic stem cell house mouse CVCL_LZ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894678; Aurka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162543 CVCL_DA90 GM20378 transformed cell line human CVCL_DA90 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>A (IVS5-1G>A); ClinVar=VCV000207574; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.887-10A>G (IVS7-10A>G); ClinVar=VCV000002649; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162544 CVCL_LZ21 BayGenomics ES cell line CSH610 embryonic stem cell house mouse CVCL_LZ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915246; Srsf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162545 CVCL_LZ22 BayGenomics ES cell line CSH611 embryonic stem cell house mouse CVCL_LZ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914917; Alkbh8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162546 CVCL_LZ20 BayGenomics ES cell line CSH609 embryonic stem cell house mouse CVCL_LZ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162547 CVCL_DA88 GM20218 transformed cell line human CVCL_DA88 CL:0000010 Sequence variation: Gene deletion; HGNC; 10853; SHOX; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162548 CVCL_DA89 GM20377 transformed cell line human CVCL_DA89 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Gly473Arg (c.1417G>A); ClinVar=VCV000068740; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162549 CVCL_LZ38 BayGenomics ES cell line CSH643 embryonic stem cell house mouse CVCL_LZ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141207; Kctd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162550 CVCL_LZ39 BayGenomics ES cell line CSH644 embryonic stem cell house mouse CVCL_LZ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444479; Thumpd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162551 CVCL_LZ36 BayGenomics ES cell line CSH641 embryonic stem cell house mouse CVCL_LZ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162552 CVCL_LZ37 BayGenomics ES cell line CSH642 embryonic stem cell house mouse CVCL_LZ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162553 CVCL_LZ34 BayGenomics ES cell line CSH639 embryonic stem cell house mouse CVCL_LZ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891995; Mapre1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162554 CVCL_LZ35 BayGenomics ES cell line CSH640 embryonic stem cell house mouse CVCL_LZ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162555 CVCL_LZ32 BayGenomics ES cell line CSH635 embryonic stem cell house mouse CVCL_LZ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162556 CVCL_LZ33 BayGenomics ES cell line CSH638 embryonic stem cell house mouse CVCL_LZ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333818; Rps7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162557 CVCL_LZ30 BayGenomics ES cell line CSH629 embryonic stem cell house mouse CVCL_LZ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162558 CVCL_LZ31 BayGenomics ES cell line CSH633 embryonic stem cell house mouse CVCL_LZ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917338; Meaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162559 CVCL_DA99 GM20389 finite cell line human CVCL_DA99 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000056193; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Tyr247His (c.739T>C); ClinVar=VCV000056214; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162560 CVCL_DA71 GM18414 finite cell line human CVCL_DA71 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Thr1036Met (c.3107C>T); ClinVar=VCV000002958; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162561 CVCL_DA72 GM18415 finite cell line human CVCL_DA72 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Cys74Tyr (c.221G>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162562 CVCL_DA70 GM18411 finite cell line human CVCL_DA70 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Trp833Ter (c.2498G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162563 CVCL_LZ09 BayGenomics ES cell line CSH587 embryonic stem cell house mouse CVCL_LZ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859162; Rnf10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162564 CVCL_DA75 GM18422 finite cell line human CVCL_DA75 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile271del (c.810_812CAT[1]) (c.813_815delCAT); ClinVar=VCV000449503; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asp874Val (c.2621A>T); ClinVar=VCV000194810; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162565 CVCL_DA76 GM18424 finite cell line human CVCL_DA76 CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Val30Met (c.88G>A); ClinVar=VCV000183281; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162566 CVCL_LZ07 BayGenomics ES cell line CSH585 embryonic stem cell house mouse CVCL_LZ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3697726; Arhgap23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162567 CVCL_DA73 GM18417 finite cell line human CVCL_DA73 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162568 CVCL_LZ08 BayGenomics ES cell line CSH586 embryonic stem cell house mouse CVCL_LZ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914473; Rrp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162569 CVCL_DA74 GM18420 finite cell line human CVCL_DA74 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1007Ala (c.3019C>G); ClinVar=VCV000002966; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Unexplicit; IVS23+4delA; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162570 CVCL_LZ05 BayGenomics ES cell line CSH583 embryonic stem cell house mouse CVCL_LZ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926140; Trmt44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162571 CVCL_LZ06 BayGenomics ES cell line CSH584 embryonic stem cell house mouse CVCL_LZ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162572 CVCL_LZ03 BayGenomics ES cell line CSH578 embryonic stem cell house mouse CVCL_LZ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162573 CVCL_LZ04 BayGenomics ES cell line CSH580 embryonic stem cell house mouse CVCL_LZ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162574 CVCL_LZ01 BayGenomics ES cell line CSH573 embryonic stem cell house mouse CVCL_LZ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162575 CVCL_LZ02 BayGenomics ES cell line CSH575 embryonic stem cell house mouse CVCL_LZ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109547; Dnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162576 CVCL_LZ00 BayGenomics ES cell line CSH572 embryonic stem cell house mouse CVCL_LZ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162577 CVCL_DA68 GM18402 finite cell line human CVCL_DA68 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asp700Asn (c.2098G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Phe1221Serfs*21 (c.3662delT); ClinVar=VCV000002977; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162578 CVCL_DA69 GM18407 finite cell line human CVCL_DA69 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg404Gln (c.1211G>A); ClinVar=VCV000188794; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Met1142Thr (c.3425T>C); ClinVar=VCV000372435; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162579 CVCL_DA66 GM18397 finite cell line human CVCL_DA66 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asn1156Ser (c.3467A>G); ClinVar=VCV000002959; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg1186His (c.3557G>A); ClinVar=VCV000189174; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162580 CVCL_DA67 GM18398 finite cell line human CVCL_DA67 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Gly673Val (c.2018G>T); ClinVar=VCV000554148; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162581 CVCL_DA82 GM20212 transformed cell line human CVCL_DA82 CL:0000010 Sequence variation: Gene deletion; HGNC; 10853; SHOX; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162582 CVCL_DA83 GM20213 transformed cell line human CVCL_DA83 CL:0000010 Sequence variation: Gene deletion; HGNC; 10853; SHOX; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162583 CVCL_DA80 GM20100 finite cell line human CVCL_DA80 CL:0000010 Sequence variation: Mutation; HGNC; 19358; ALG12; Simple; p.Tyr230Asp (c.688T>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 19358; ALG12; Simple; p.Arg311Cys (c.931C>T); ClinVar=VCV000377465; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162584 CVCL_DA81 GM20101 finite cell line human CVCL_DA81 CL:0000010 Sequence variation: Mutation; HGNC; 19358; ALG12; Simple; p.Leu12Serfs*8 (c.29delG); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 19358; ALG12; Simple; p.Ser275Asn (c.824G>A); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162585 CVCL_DA86 GM20216 transformed cell line human CVCL_DA86 CL:0000010 Sequence variation: Gene deletion; HGNC; 10853; SHOX; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10853; SHOX; Simple; p.Arg119Alafs*10 (c.350_351AG[3]) (c.352_353dupAG) (ins350AG); ClinVar=VCV000009881; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162586 CVCL_DA87 GM20217 transformed cell line human CVCL_DA87 CL:0000010 Sequence variation: Gene deletion; HGNC; 10853; SHOX; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162587 CVCL_LZ18 BayGenomics ES cell line CSH607 embryonic stem cell house mouse CVCL_LZ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685179; Zfp407 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162588 CVCL_DA84 GM20214 transformed cell line human CVCL_DA84 CL:0000010 Sequence variation: Mutation; HGNC; 10853; SHOX; Simple; p.Arg153Cys (c.457C>T); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10853; SHOX; Simple; p.Val163Phe (c.487G>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162589 CVCL_LZ19 BayGenomics ES cell line CSH608 embryonic stem cell house mouse CVCL_LZ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162590 CVCL_DA85 GM20215 transformed cell line human CVCL_DA85 CL:0000010 Sequence variation: Mutation; HGNC; 10853; SHOX; Simple; p.Pro244Alafs*147 (c.728dupC) (ins723C); ClinVar=VCV000009880; Zygosity=Hemizygous or homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162591 CVCL_LZ16 BayGenomics ES cell line CSH603 embryonic stem cell house mouse CVCL_LZ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162592 CVCL_LZ17 BayGenomics ES cell line CSH606 embryonic stem cell house mouse CVCL_LZ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098280; Crebbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162593 CVCL_LZ14 BayGenomics ES cell line CSH598 embryonic stem cell house mouse CVCL_LZ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162594 CVCL_LZ15 BayGenomics ES cell line CSH600 embryonic stem cell house mouse CVCL_LZ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162595 CVCL_LZ12 BayGenomics ES cell line CSH594 embryonic stem cell house mouse CVCL_LZ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915525; Rpa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162596 CVCL_LZ13 BayGenomics ES cell line CSH595 embryonic stem cell house mouse CVCL_LZ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147627; Yars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162597 CVCL_LZ10 BayGenomics ES cell line CSH589 embryonic stem cell house mouse CVCL_LZ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917378; Oxsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162598 CVCL_LZ11 BayGenomics ES cell line CSH591 embryonic stem cell house mouse CVCL_LZ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917294; Tut1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162599 CVCL_DA79 GM18455 finite cell line human CVCL_DA79 CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Glu20Ter (c.58G>T); ClinVar=VCV000008477; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Cys47Phe (c.140G>T); ClinVar=VCV000549984; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162600 CVCL_DA77 GM18429 finite cell line human CVCL_DA77 CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; c.82+2T>C (IVS1+2T>C); ClinVar=VCV000242903; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162601 CVCL_DA78 GM18453 finite cell line human CVCL_DA78 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162602 CVCL_DA50 GM17912 finite cell line human CVCL_DA50 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro1007Ala (c.3019C>G); ClinVar=VCV000002966; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Thr1036Met (c.3107C>T); ClinVar=VCV000002958; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162603 CVCL_DA53 GM17918 finite cell line human CVCL_DA53 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Thr137Met (c.410C>T); ClinVar=VCV000449504; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Val780Argfs*9 (c.2336dupT) (c.2336insT); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162604 CVCL_DA54 GM17919 finite cell line human CVCL_DA54 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg404Trp (c.1210C>T); ClinVar=VCV000499939; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162605 CVCL_DA51 GM17913 finite cell line human CVCL_DA51 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Val1165Met (c.3493G>A); ClinVar=VCV000195723; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162606 CVCL_DA52 GM17914 finite cell line human CVCL_DA52 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Lys142Argfs*80 (c.423_424dupGA) (c.424_425insGA); ClinVar=VCV000503633; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21162607 CVCL_DA46 GM16485 finite cell line human CVCL_DA46 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Ter (c.379C>T); ClinVar=VCV000207569; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (Coriell) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162608 CVCL_DA47 GM16486 finite cell line human CVCL_DA47 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Gln (c.380G>A); ClinVar=VCV000068746; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162609 CVCL_DA44 GM16109 transformed cell line human CVCL_DA44 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg164Ter (c.490C>T) (p.Arg61Ter, c.181C>T); ClinVar=VCV000056197; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Gln291Ter (c.871C>T); ClinVar=VCV000056217; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162610 CVCL_DA45 GM16193 transformed cell line human CVCL_DA45 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Arg498Leu (c.1493G>T) (R496L); ClinVar=VCV000002980; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Arg610del (c.1826_1828GCC[1]) (c.1829_1831delGCC) (R608del); ClinVar=VCV000198093; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21162611 CVCL_DA48 GM17910 finite cell line human CVCL_DA48 CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Cys93Phe (c.278G>T); dbSNP=rs143960270; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162612 CVCL_DA49 GM17911 finite cell line human CVCL_DA49 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Thr1036Met (c.3107C>T); ClinVar=VCV000002958; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162613 CVCL_DA60 GM17926 finite cell line human CVCL_DA60 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Tyr509Ser (c.1526A>C); ClinVar=VCV000554002; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162614 CVCL_DA61 GM18382 transformed cell line human CVCL_DA61 CL:0000010 Sequence variation: Mutation; HGNC; 10825; SH3BP2; Simple; p.Gly420Arg (c.1258G>C); ClinVar=VCV000007552; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162615 CVCL_DA64 GM18390 finite cell line human CVCL_DA64 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asp242His (c.724G>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ser940Leu (c.2819C>T); ClinVar=VCV000188716; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162616 CVCL_DA65 GM18393 finite cell line human CVCL_DA65 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Gly248Val (c.743G>T); ClinVar=VCV000995578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Met1142Thr (c.3425T>C); ClinVar=VCV000372435; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162617 CVCL_DA62 GM18387 finite cell line human CVCL_DA62 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Asp874Val (c.2621A>T); ClinVar=VCV000194810; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Tyr890Ter (c.2670C>G); ClinVar=VCV000495788; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162618 CVCL_DA63 GM18388 finite cell line human CVCL_DA63 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Arg404Gln (c.1211G>A); ClinVar=VCV000188794; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162619 CVCL_DA57 GM17922 finite cell line human CVCL_DA57 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Lys142Argfs*80 (c.423_424dupGA) (c.424_425insGA); ClinVar=VCV000503633; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Gln991Argfs*15 (c.2972_2973delAG); ClinVar=VCV000188932; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM17922; probable Male 21162620 CVCL_DA58 GM17923 finite cell line human CVCL_DA58 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro543Leu (c.1628C>T); ClinVar=VCV000181455; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21162621 CVCL_DA55 GM17920 finite cell line human CVCL_DA55 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro401Thr (c.1201C>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21162622 CVCL_DA56 GM17921 finite cell line human CVCL_DA56 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro433Leu (c.1298C>T); ClinVar=VCV000419321; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162623 CVCL_DA59 GM17924 finite cell line human CVCL_DA59 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ser151Phefs*18 (c.449_450AG[1]) (c.451_452delAG); ClinVar=VCV000558159; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Tyr825Cys (c.2474A>G); ClinVar=VCV000370184; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162624 CVCL_V566 GM04478 finite cell line human CVCL_V566 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162625 CVCL_UT66 ND08570 transformed cell line human CVCL_UT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162626 CVCL_V567 GM04479 transformed cell line human CVCL_V567 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162627 CVCL_UT67 GM06923 transformed cell line human CVCL_UT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient with diabetes; bone pain and metastatic breast carcinoma; Derived from sampling site: Peripheral blood. Female 21162628 CVCL_UT64 ND40783 transformed cell line human CVCL_UT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162629 CVCL_V564 RJK 849 transformed cell line human CVCL_V564 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex4-9del; Zygosity=Hemizygous (PubMed=3296189; PubMed=6087154) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21162630 CVCL_V565 GM04284 transformed cell line human CVCL_V565 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21162631 CVCL_UT65 ND41130 transformed cell line human CVCL_UT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162632 CVCL_V568 GM04717 finite cell line human CVCL_V568 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162633 CVCL_UT68 GM16154 transformed cell line human CVCL_UT68 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162634 CVCL_V569 GM04718 transformed cell line human CVCL_V569 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162635 CVCL_UT69 GM16254 transformed cell line human CVCL_UT69 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 9 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with facioscapulohumeral muscular dystrophy but at risk for disease; Derived from sampling site: Peripheral blood. Female 21162636 CVCL_2N21 AG10637 finite cell line CVCL_2N21 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162637 CVCL_2N22 GM00056 finite cell line human CVCL_2N22 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162638 CVCL_2N20 AG10631 finite cell line CVCL_2N20 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162639 CVCL_2N14 GM09825 finite cell line human CVCL_2N14 CL:0000010 Karyotypic information: 46,X,der(X)(Xpter->Xq21::Yq12->Yqter) (Coriell); Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21162640 CVCL_2N15 AG11607 finite cell line pig CVCL_2N15 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Yorkshire. Female 21162641 CVCL_2N12 GM07978 finite cell line human CVCL_2N12 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;6)(4pter->4q31.3::6p25->6pter;6qter->6p25::4q31.3->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21162642 CVCL_2N13 GM09824 finite cell line human CVCL_2N13 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Omics: CNV analysis Female 21162643 CVCL_2N18 AG10638 finite cell line CVCL_2N18 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162644 CVCL_2N19 AG10630 finite cell line CVCL_2N19 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162645 CVCL_2N16 AG10671 finite cell line CVCL_2N16 CL:0000010 Derived from sampling site: Carotid artery Cell type=Carotid artery smooth muscle cell.; Breed/subspecies: Holstein. Female Doubling time: Slow growth (Coriell) 21162646 CVCL_2N17 AG10632 finite cell line CVCL_2N17 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162647 CVCL_V570 GM04807 finite cell line human CVCL_V570 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21162648 CVCL_UT70 GM16259 transformed cell line human CVCL_UT70 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162649 CVCL_V573 GM04886 transformed cell line human CVCL_V573 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162650 CVCL_UT73 GM16354 transformed cell line human CVCL_UT73 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 9 repeats) (PubMed=28161093) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162651 CVCL_V574 GM04887 finite cell line human CVCL_V574 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162652 CVCL_UT74 GM16355 transformed cell line human CVCL_UT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162653 CVCL_V571 GM04876 transformed cell line human CVCL_V571 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162654 CVCL_UT71 GM16344 transformed cell line human CVCL_UT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162655 CVCL_V572 GM04877 finite cell line human CVCL_V572 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21162656 CVCL_UT72 GM16353 transformed cell line human CVCL_UT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162657 CVCL_UT55 ND35342 transformed cell line human CVCL_UT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162658 CVCL_UT56 ND42514 transformed cell line human CVCL_UT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162659 CVCL_V553 AG01947 finite cell line human CVCL_V553 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01947; probable Male 21162660 CVCL_UT53 GM09958 transformed cell line human CVCL_UT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient with type II urogenital sinus with second degree urinary tract obstruction, partial aniridia, mild left hemifacial microsomia, CHD (patent ductus arteriosus) and cerebral vasculitis; Derived from sampling site: Peripheral blood. Female 21162661 CVCL_V554 AG01979 finite cell line human CVCL_V554 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01979; probable Male 21162662 CVCL_UT54 ND34510 transformed cell line human CVCL_UT54 CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Ile149Thr (c.446T>C); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162663 CVCL_UT59 ND36638 transformed cell line human CVCL_UT59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162664 CVCL_V559 RB16KY hTERT telomerase immortalized cell line human CVCL_V559 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162665 CVCL_UT57 ND35825 transformed cell line human CVCL_UT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162666 CVCL_UT58 ND35931 transformed cell line human CVCL_UT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162667 CVCL_V558 RB1KO finite cell line human CVCL_V558 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162668 CVCL_2N32 GM20616 transformed cell line human CVCL_2N32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162669 CVCL_2N33 AG11694 finite cell line human CVCL_2N33 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG11694; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21162670 CVCL_2N30 GM02805 finite cell line human CVCL_2N30 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162671 CVCL_2N31 GM03590 finite cell line human CVCL_2N31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162672 CVCL_2N25 GM00403 finite cell line human CVCL_2N25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162673 CVCL_2N26 GM00405 finite cell line human CVCL_2N26 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162674 CVCL_2N23 GM00057 finite cell line human CVCL_2N23 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162675 CVCL_2N24 GM00371 finite cell line human CVCL_2N24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162676 CVCL_2N29 GM01300 finite cell line human CVCL_2N29 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21162677 CVCL_2N27 GM01298 finite cell line human CVCL_2N27 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21162678 CVCL_2N28 GM01299 finite cell line human CVCL_2N28 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21162679 CVCL_V562 CH03 cancer cell line human CVCL_V562 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr107Thrfs*15 (c.318delC); Zygosity=Unspecified (PubMed=23958880) Derived from sampling site: Bone; femur. Female 21162680 CVCL_UT62 ND38709 transformed cell line human CVCL_UT62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162681 CVCL_V563 CH56 cancer cell line human CVCL_V563 CL:0000010 Sequence variation: Mutation; HGNC; 5383; IDH2; Simple; p.Arg172Ser (c.516G>C); ClinVar=VCV000375985; Zygosity=Unspecified (PubMed=23958880) Derived from sampling site: Bone; humerus. Female 21162682 CVCL_UT63 ND39575 transformed cell line human CVCL_UT63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162683 CVCL_V560 AT2BE finite cell line human CVCL_V560 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1343; probable Female 21162684 CVCL_UT60 ND37626 transformed cell line human CVCL_UT60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162685 CVCL_UT61 ND38635 transformed cell line human CVCL_UT61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162686 CVCL_V544 AG01978 finite cell line human CVCL_V544 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01978; probable Male 21162687 CVCL_UT44 GM09914 transformed cell line human CVCL_UT44 HLA typing: A*02,02; B*35,51; C*w04 (Coriell=GM09914) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM09914; probable Male 21162688 CVCL_V545 AT3BI finite cell line human CVCL_V545 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162689 CVCL_UT45 GM09915 transformed cell line human CVCL_UT45 HLA typing: A*01,02; B*44,w57; C*w05,w06 (Coriell=GM09915) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM09915; probable Female 21162690 CVCL_UT42 Me32a finite cell line human CVCL_UT42 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Unexplicit; 4bp deletion within exon 6; Zygosity=Unspecified (PubMed=12385784). 21162691 CVCL_UT43 Me32a-T22/2L transformed cell line human CVCL_UT43 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Unexplicit; 4bp deletion within exon 6; Zygosity=Unspecified (PubMed=12385784) Transformant: Simian virus 40 (SV40) [pRSV-T22](NCBI-Taxonomy; 1891767). 21162692 CVCL_UT48 22B transformed cell line human CVCL_UT48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21162693 CVCL_V548 GM00729 finite cell line human CVCL_V548 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162694 CVCL_UT49 108Z transformed cell line human CVCL_UT49 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 21162695 CVCL_V549 GM02719 finite cell line human CVCL_V549 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Discontinued: Coriell; AG02719; probable Male 21162696 CVCL_V546 AT4BI finite cell line human CVCL_V546 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162697 CVCL_UT46 GM06856 finite cell line human CVCL_UT46 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM06856; probable Male 21162698 CVCL_V547 GM00084 finite cell line human CVCL_V547 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+der(22)(22pter->22q11::11q23->11qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21162699 CVCL_UT47 GM08391 finite cell line human CVCL_UT47 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1548Thrfs*14 (c.4638_4641GATA[1]) (c.4642_4645delGATA); ClinVar=VCV000232070; Zygosity=Heterozygous (from autologous cell line GM08436); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (from autologous cell line GM08436) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM08391; probable Male 21162700 CVCL_2N00 GM10040 transformed cell line human CVCL_2N00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162701 CVCL_UT51 22B-RFP transformed cell line human CVCL_UT51 CL:0000010 Transfected with: DsRed2, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21162702 CVCL_V551 AG00991 finite cell line human CVCL_V551 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG00991; probable; Discontinued: Coriell; GM00991; probable Male 21162703 CVCL_V552 AG01946 finite cell line human CVCL_V552 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01946; probable Male 21162704 CVCL_UT52 GM10077 transformed cell line human CVCL_UT52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10077; probable Male 21162705 CVCL_UT50 12Z-GFP transformed cell line human CVCL_UT50 CL:0000010 Transfected with: UniProtKB; Q9U6Y4; Zoanthus sp chromoprotein FP538 (modified and distributed as ZsGreen1).; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 21162706 CVCL_UT33 GM10745 transformed cell line human CVCL_UT33 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (from parent cell line) Population: Japanese; Transformant: Ad-SV40 hybrid virus; Donor information: From Bloom Syndrome Registry patient 86(NoKi) (BSR86); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM10745; probable Female 21162707 CVCL_V533 KF28 cancer cell line human CVCL_V533 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21162708 CVCL_UT34 GM03534 transformed cell line human CVCL_UT34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03534; probable Female 21162709 CVCL_V534 KFr13 cancer cell line human CVCL_V534 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female Doubling time: 24.8 hours (in presence of 0.5 mug cisplatin/ml), 27.2 hours (in presence of 1 mug cisplatin/ml) (PubMed=3467111) 21162710 CVCL_V531 GM01053 finite cell line human CVCL_V531 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21162711 CVCL_UT31 GM05882 finite cell line human CVCL_UT31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM05882; probable Female 21162712 CVCL_V532 GM01257 finite cell line human CVCL_V532 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21162713 CVCL_UT32 GM03133 finite cell line human CVCL_UT32 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03133; probable Female 21162714 CVCL_V537 VOA1072 cancer cell line human CVCL_V537 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=24023729). Female 21162715 CVCL_UT37 WG0285 finite cell line human CVCL_UT37 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21162716 CVCL_V538 VOA1312 cancer cell line human CVCL_V538 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=27822414) Derived from metastatic site: Ascites. Female 21162717 CVCL_UT38 WG0482 finite cell line human CVCL_UT38 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21162718 CVCL_UT35 GM03540 transformed cell line human CVCL_UT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03540; probable Female 21162719 CVCL_V535 KFr13Tx cancer cell line human CVCL_V535 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21162720 CVCL_V536 VOA1056 cancer cell line human CVCL_V536 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 6193; JAK3; Simple; p.Val722Ile (c.2164G>A); ClinVar=VCV000134573; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=27822414). Female 21162721 CVCL_UT36 WG0173 finite cell line human CVCL_UT36 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21162722 CVCL_V539 VOA1400 cancer cell line human CVCL_V539 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu198Ter (c.592G>T); ClinVar=VCV000634704; Zygosity=Heterozygous (PubMed=24023729). Female 21162723 CVCL_UT39 WG1099 finite cell line human CVCL_UT39 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21162724 CVCL_2N10 GM06944 finite cell line human CVCL_2N10 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(21;22)(21qter->21p12::22q11.1->22qter;22pter->22q11.1::21p12->21pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Female 21162725 CVCL_2N11 GM07938 transformed cell line human CVCL_2N11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162726 CVCL_2N03 WiDr/R cancer cell line human CVCL_2N03 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone Female Problematic cell line: Contaminated Parent cell line (WiDr) had been shown to be a HT-29 derivative. 21162727 CVCL_2N04 GM13323 transformed cell line human CVCL_2N04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM13324 (Cellosaurus=CVCL_2N05); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21162728 CVCL_2N01 GM10179 finite cell line human CVCL_2N01 CL:0000010 Population: African American; Karyotypic information: 45,X0 (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21162729 CVCL_2N02 GM13019 transformed cell line human CVCL_2N02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21162730 CVCL_2N07 GM02658 finite cell line human CVCL_2N07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;6)(2pter->2q11::6q15->6qter;6pter->6q15::2q11->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21162731 CVCL_2N08 GM02699 finite cell line human CVCL_2N08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02699; probable Female 21162732 CVCL_2N05 GM13324 transformed cell line human CVCL_2N05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM13323 (Cellosaurus=CVCL_2N04); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21162733 CVCL_2N06 GM20027 transformed cell line human CVCL_2N06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21162734 CVCL_2N09 GM06943 transformed cell line human CVCL_2N09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162735 CVCL_V540 VOA1416 cancer cell line human CVCL_V540 CL:0000010 Derived from metastatic site: Ascites. Female 21162736 CVCL_UT40 WG1102 finite cell line human CVCL_UT40 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21162737 CVCL_V541 AG01615 finite cell line human CVCL_V541 CL:0000010 Donor information: Established from the non-irradiated skin of a nephroblastoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01615; probable Male 21162738 CVCL_UT41 GM03727 transformed cell line human CVCL_UT41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03727; probable Female 21162739 CVCL_UT22 GM05447 finite cell line human CVCL_UT22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05447; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162740 CVCL_V522 WCMC-40 embryonic stem cell human CVCL_V522 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162741 CVCL_UT23 GM05451 finite cell line human CVCL_UT23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05451; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162742 CVCL_V523 WCMC-41 embryonic stem cell human CVCL_V523 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162743 CVCL_UT20 GM05485 finite cell line human CVCL_UT20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05485; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162744 CVCL_V520 WCMC-38 embryonic stem cell human CVCL_V520 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162745 CVCL_UT21 GM06582 finite cell line human CVCL_UT21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06582; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162746 CVCL_V521 WCMC-39 embryonic stem cell human CVCL_V521 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0363. 21162747 CVCL_V526 CI78-1 cancer cell line human CVCL_V526 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21162748 CVCL_UT26 GM06480 finite cell line human CVCL_UT26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06480; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162749 CVCL_V527 GM00034 finite cell line human CVCL_V527 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21162750 CVCL_UT27 GM06363 finite cell line human CVCL_UT27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06363; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162751 CVCL_UT24 GM05453 finite cell line human CVCL_UT24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05453; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162752 CVCL_V524 WCMC-42 embryonic stem cell human CVCL_V524 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162753 CVCL_UT25 GM06458 finite cell line human CVCL_UT25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06458; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162754 CVCL_V525 WCMC-43 embryonic stem cell human CVCL_V525 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162755 CVCL_V528 GM00798 finite cell line human CVCL_V528 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Trp402Ter (c.1205G>A); ClinVar=VCV000011908; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162756 CVCL_UT28 GM06440 finite cell line human CVCL_UT28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06440; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162757 CVCL_V529 GM00415 finite cell line human CVCL_V529 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162758 CVCL_UT29 GM06772 finite cell line human CVCL_UT29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06772; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162759 CVCL_LZ89 BayGenomics ES cell line CSH747 embryonic stem cell house mouse CVCL_LZ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162760 CVCL_LZ87 BayGenomics ES cell line CSH740 embryonic stem cell house mouse CVCL_LZ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349409; Cops3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162761 CVCL_LZ88 BayGenomics ES cell line CSH743 embryonic stem cell house mouse CVCL_LZ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346867; Map2k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162762 CVCL_LZ85 BayGenomics ES cell line CSH734 embryonic stem cell house mouse CVCL_LZ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444782; Fkbp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162763 CVCL_LZ86 BayGenomics ES cell line CSH737 embryonic stem cell house mouse CVCL_LZ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925255; Rrn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162764 CVCL_LZ83 BayGenomics ES cell line CSH729 embryonic stem cell house mouse CVCL_LZ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333801; Mrpl10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162765 CVCL_LZ84 BayGenomics ES cell line CSH733 embryonic stem cell house mouse CVCL_LZ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162766 CVCL_LZ81 BayGenomics ES cell line CSH727 embryonic stem cell house mouse CVCL_LZ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682334; Smg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162767 CVCL_LZ82 BayGenomics ES cell line CSH728 embryonic stem cell house mouse CVCL_LZ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920093; Prdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162768 CVCL_LZ80 BayGenomics ES cell line CSH725 embryonic stem cell house mouse CVCL_LZ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162769 CVCL_V530 GM00887 finite cell line human CVCL_V530 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21162770 CVCL_UT30 GM06676 finite cell line human CVCL_UT30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06676; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162771 CVCL_UT11 GM05427 finite cell line human CVCL_UT11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05427; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162772 CVCL_V511 WCMC-28 embryonic stem cell human CVCL_V511 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162773 CVCL_UT12 GM06586 finite cell line human CVCL_UT12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06586; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162774 CVCL_V512 WCMC-29 embryonic stem cell human CVCL_V512 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162775 CVCL_UT10 GM06594 finite cell line human CVCL_UT10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06594; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162776 CVCL_V510 WCMC-27 embryonic stem cell human CVCL_V510 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162777 CVCL_UT15 GM06450 finite cell line human CVCL_UT15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06450; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162778 CVCL_V515 WCMC-32 embryonic stem cell human CVCL_V515 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162779 CVCL_UT16 GM06446 finite cell line human CVCL_UT16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06446; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162780 CVCL_V516 WCMC-33 embryonic stem cell human CVCL_V516 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162781 CVCL_UT13 GM06567 finite cell line human CVCL_UT13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06567; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162782 CVCL_V513 WCMC-30 embryonic stem cell human CVCL_V513 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162783 CVCL_UT14 GM06448 finite cell line human CVCL_UT14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06448; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162784 CVCL_V514 WCMC-31 embryonic stem cell human CVCL_V514 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162785 CVCL_UT19 GM06644 finite cell line human CVCL_UT19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06644; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162786 CVCL_V519 WCMC-36 embryonic stem cell human CVCL_V519 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162787 CVCL_UT17 GM06424 finite cell line human CVCL_UT17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06424; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162788 CVCL_V517 WCMC-34 embryonic stem cell human CVCL_V517 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162789 CVCL_UT18 GM06602 finite cell line human CVCL_UT18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06602; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162790 CVCL_V518 WCMC-35 embryonic stem cell human CVCL_V518 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162791 CVCL_LZ98 BayGenomics ES cell line CSH775 embryonic stem cell house mouse CVCL_LZ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923038; Smurf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162792 CVCL_LZ99 BayGenomics ES cell line CSH779 embryonic stem cell house mouse CVCL_LZ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162793 CVCL_LZ96 BayGenomics ES cell line CSH769 embryonic stem cell house mouse CVCL_LZ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643580; Epp13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162794 CVCL_LZ97 BayGenomics ES cell line CSH772 embryonic stem cell house mouse CVCL_LZ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913470; Zdhhc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162795 CVCL_LZ94 BayGenomics ES cell line CSH764 embryonic stem cell house mouse CVCL_LZ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98728; Tgfbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162796 CVCL_LZ95 BayGenomics ES cell line CSH767 embryonic stem cell house mouse CVCL_LZ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103575; Skp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162797 CVCL_LZ92 BayGenomics ES cell line CSH759 embryonic stem cell house mouse CVCL_LZ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162798 CVCL_LZ93 BayGenomics ES cell line CSH761 embryonic stem cell house mouse CVCL_LZ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444661; Susd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162799 CVCL_LZ90 BayGenomics ES cell line CSH755 embryonic stem cell house mouse CVCL_LZ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442833; Bbs9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162800 CVCL_LZ91 BayGenomics ES cell line CSH756 embryonic stem cell house mouse CVCL_LZ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97537; Pecam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162801 CVCL_UT00 GM06780 finite cell line human CVCL_UT00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06780; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162802 CVCL_V500 WCMC-17 embryonic stem cell human CVCL_V500 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162803 CVCL_UT01 GM06596 finite cell line human CVCL_UT01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06596; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162804 CVCL_V501 WCMC-18 embryonic stem cell human CVCL_V501 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162805 CVCL_UT04 GM06634 finite cell line human CVCL_UT04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06634; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162806 CVCL_V504 WCMC-21 embryonic stem cell human CVCL_V504 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162807 CVCL_UT05 GM06656 finite cell line human CVCL_UT05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06656; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162808 CVCL_V505 WCMC-22 embryonic stem cell human CVCL_V505 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162809 CVCL_UT02 GM05559 finite cell line human CVCL_UT02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05559; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162810 CVCL_V502 WCMC-19 embryonic stem cell human CVCL_V502 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162811 CVCL_UT03 GM06776 finite cell line human CVCL_UT03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06776; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162812 CVCL_V503 WCMC-20 embryonic stem cell human CVCL_V503 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162813 CVCL_UT08 GM06652 finite cell line human CVCL_UT08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06652; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162814 CVCL_V508 WCMC-25 embryonic stem cell human CVCL_V508 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162815 CVCL_UT09 GM06632 finite cell line human CVCL_UT09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06632; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162816 CVCL_V509 WCMC-26 embryonic stem cell human CVCL_V509 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162817 CVCL_LZ69 BayGenomics ES cell line CSH703 embryonic stem cell house mouse CVCL_LZ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354165; Thop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162818 CVCL_UT06 GM06766 finite cell line human CVCL_UT06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06766; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162819 CVCL_V506 WCMC-23 embryonic stem cell human CVCL_V506 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0364. 21162820 CVCL_UT07 GM06615 finite cell line human CVCL_UT07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06615; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162821 CVCL_V507 WCMC-24 embryonic stem cell human CVCL_V507 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162822 CVCL_LZ67 BayGenomics ES cell line CSH700 embryonic stem cell house mouse CVCL_LZ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162823 CVCL_LZ68 BayGenomics ES cell line CSH702 embryonic stem cell house mouse CVCL_LZ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162824 CVCL_LZ65 BayGenomics ES cell line CSH696 embryonic stem cell house mouse CVCL_LZ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162825 CVCL_LZ66 BayGenomics ES cell line CSH699 embryonic stem cell house mouse CVCL_LZ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162826 CVCL_LZ63 BayGenomics ES cell line CSH692 embryonic stem cell house mouse CVCL_LZ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157980; Vac14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162827 CVCL_LZ64 BayGenomics ES cell line CSH695 embryonic stem cell house mouse CVCL_LZ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162828 CVCL_LZ61 BayGenomics ES cell line CSH688 embryonic stem cell house mouse CVCL_LZ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098808; Pex5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162829 CVCL_LZ62 BayGenomics ES cell line CSH689 embryonic stem cell house mouse CVCL_LZ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651014; Zfp268 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162830 CVCL_LZ60 BayGenomics ES cell line CSH685 embryonic stem cell house mouse CVCL_LZ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162831 CVCL_LZ78 BayGenomics ES cell line CSH717 embryonic stem cell house mouse CVCL_LZ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3582693; Tor1aip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162832 CVCL_LZ79 BayGenomics ES cell line CSH722 embryonic stem cell house mouse CVCL_LZ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162833 CVCL_LZ76 BayGenomics ES cell line CSH715 embryonic stem cell house mouse CVCL_LZ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162834 CVCL_LZ77 BayGenomics ES cell line CSH716 embryonic stem cell house mouse CVCL_LZ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915472; Tubb4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162835 CVCL_LZ74 BayGenomics ES cell line CSH712 embryonic stem cell house mouse CVCL_LZ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162836 CVCL_LZ75 BayGenomics ES cell line CSH713 embryonic stem cell house mouse CVCL_LZ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162837 CVCL_LZ72 BayGenomics ES cell line CSH708 embryonic stem cell house mouse CVCL_LZ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162838 CVCL_LZ73 BayGenomics ES cell line CSH710 embryonic stem cell house mouse CVCL_LZ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915264; Zwilch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162839 CVCL_LZ70 BayGenomics ES cell line CSH704 embryonic stem cell house mouse CVCL_LZ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919448; Mtrex Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162840 CVCL_LZ71 BayGenomics ES cell line CSH707 embryonic stem cell house mouse CVCL_LZ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922832; Relch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21162841 CVCL_2M80 AG08750 finite cell line CVCL_2M80 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162842 CVCL_2M81 AG08751 finite cell line CVCL_2M81 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162843 CVCL_2M84 AG10442 finite cell line CVCL_2M84 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Female 21162844 CVCL_2M85 AG10447 finite cell line CVCL_2M85 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162845 CVCL_2M82 AG10375 finite cell line CVCL_2M82 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162846 CVCL_2M83 AG10385 finite cell line CVCL_2M83 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162847 CVCL_2M88 AG10477 finite cell line CVCL_2M88 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162848 CVCL_2M89 AG10484 finite cell line CVCL_2M89 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162849 CVCL_2M86 AG10466 finite cell line CVCL_2M86 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162850 CVCL_2M87 AG10467 finite cell line CVCL_2M87 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162851 CVCL_2M79 AG08748 finite cell line CVCL_2M79 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162852 CVCL_2M91 AG11074 finite cell line human CVCL_2M91 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG11074; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21162853 CVCL_2M92 AG10553 finite cell line CVCL_2M92 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162854 CVCL_2M90 AG10602 finite cell line CVCL_2M90 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162855 CVCL_2M95 AG10696 finite cell line CVCL_2M95 CL:0000010 Derived from sampling site: Lung; artery; endothelium; Breed/subspecies: Holstein. Male 21162856 CVCL_2M96 AG10555 finite cell line CVCL_2M96 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162857 CVCL_2M93 AG10554 finite cell line CVCL_2M93 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Holstein. Male 21162858 CVCL_2M94 AG10604 finite cell line CVCL_2M94 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162859 CVCL_2M99 GM03774 finite cell line human CVCL_2M99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21162860 CVCL_2M97 AG10605 finite cell line CVCL_2M97 CL:0000010 Derived from sampling site: Lung; artery Cell type=Pulmonary artery smooth muscle cell.; Breed/subspecies: Holstein. Male 21162861 CVCL_2M98 AG10697 finite cell line CVCL_2M98 CL:0000010 Derived from sampling site: Lung; artery; endothelium; Breed/subspecies: Holstein. Male 21162862 CVCL_2M62 AG08504 finite cell line CVCL_2M62 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Angus. Male 21162863 CVCL_2M63 AG08573 finite cell line CVCL_2M63 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162864 CVCL_2M60 AG08501 finite cell line CVCL_2M60 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Hereford. Male 21162865 CVCL_2M61 AG08503 finite cell line CVCL_2M61 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Angus. Male 21162866 CVCL_2M66 AG08592 finite cell line CVCL_2M66 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Angus. Male 21162867 CVCL_2M67 AG08593 finite cell line CVCL_2M67 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Angus. Male 21162868 CVCL_2M64 AG08574 finite cell line CVCL_2M64 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162869 CVCL_2M65 AG08591 finite cell line CVCL_2M65 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Angus. Male 21162870 CVCL_2M59 AG08500 finite cell line CVCL_2M59 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Hereford. Male 21162871 CVCL_2M57 AG08494 finite cell line CVCL_2M57 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162872 CVCL_2M58 AG08495 finite cell line CVCL_2M58 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162873 CVCL_US98 GM05603 finite cell line human CVCL_US98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05603; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162874 CVCL_V498 WCMC-15 embryonic stem cell human CVCL_V498 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162875 CVCL_US99 GM05571 finite cell line human CVCL_US99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05571; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162876 CVCL_V499 WCMC-16 embryonic stem cell human CVCL_V499 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162877 CVCL_2M70 AG08608 finite cell line CVCL_2M70 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162878 CVCL_2M73 AG08615 finite cell line CVCL_2M73 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162879 CVCL_2M74 AG08624 finite cell line dog CVCL_2M74 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162880 CVCL_2M71 AG08609 finite cell line CVCL_2M71 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162881 CVCL_2M72 AG08614 finite cell line CVCL_2M72 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162882 CVCL_2M77 AG08742 finite cell line CVCL_2M77 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162883 CVCL_2M78 AG08743 finite cell line CVCL_2M78 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162884 CVCL_2M75 AG08625 finite cell line dog CVCL_2M75 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162885 CVCL_2M76 AG08733 finite cell line CVCL_2M76 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Holstein. Female 21162886 CVCL_2M68 AG08594 finite cell line CVCL_2M68 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Angus. Male 21162887 CVCL_2M69 AG08595 finite cell line CVCL_2M69 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Angus. Male 21162888 CVCL_US89 GM06682 finite cell line human CVCL_US89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06682; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162889 CVCL_V489 WCMC-3 embryonic stem cell human CVCL_V489 From: Weill Cornell Medical College; New York; USA. CL:0000010 Female 21162890 CVCL_US87 GM05639 finite cell line human CVCL_US87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05639; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162891 CVCL_V487 PWH-S1 cancer cell line human CVCL_V487 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: ~28 hours (PubMed=7788927) Caution: Said to originate from a female patient but karyotype in PubMed=7788927 shows a Y chromosome 21162892 CVCL_US88 GM05744 finite cell line human CVCL_US88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05744; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162893 CVCL_V488 WCMC-1 embryonic stem cell human CVCL_V488 From: Weill Cornell Medical College; New York; USA. CL:0000010 Male 21162894 CVCL_2M40 AG08462 finite cell line dog CVCL_2M40 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162895 CVCL_2M41 AG08463 finite cell line dog CVCL_2M41 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162896 CVCL_2M44 AG08473 finite cell line pig CVCL_2M44 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Large White. Female 21162897 CVCL_2M45 AG08475 finite cell line pig CVCL_2M45 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Large White. Female 21162898 CVCL_2M42 AG08465 finite cell line dog CVCL_2M42 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Male 21162899 CVCL_2M43 AG08472 finite cell line pig CVCL_2M43 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Large White. Female 21162900 CVCL_2M37 AG08457 finite cell line dog CVCL_2M37 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Male 21162901 CVCL_2M38 AG08458 finite cell line dog CVCL_2M38 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162902 CVCL_2M35 AG08454 finite cell line dog CVCL_2M35 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162903 CVCL_2M36 AG08455 finite cell line dog CVCL_2M36 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162904 CVCL_2M39 AG08459 finite cell line dog CVCL_2M39 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162905 CVCL_US92 GM05593 finite cell line human CVCL_US92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05593; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162906 CVCL_V492 WCMC-6 embryonic stem cell human CVCL_V492 From: Weill Cornell Medical College; New York; USA. CL:0000010 Male 21162907 CVCL_US93 GM05627 finite cell line human CVCL_US93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05627; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162908 CVCL_V493 WCMC-10 embryonic stem cell human CVCL_V493 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0367. 21162909 CVCL_US90 GM05579 finite cell line human CVCL_US90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05579; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162910 CVCL_V490 WCMC-4 embryonic stem cell human CVCL_V490 From: Weill Cornell Medical College; New York; USA. CL:0000010 Male 21162911 CVCL_US91 GM05607 finite cell line human CVCL_US91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05607; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162912 CVCL_V491 WCMC-5 embryonic stem cell human CVCL_V491 From: Weill Cornell Medical College; New York; USA. CL:0000010 Male 21162913 CVCL_US96 GM05689 finite cell line human CVCL_US96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05689; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162914 CVCL_V496 WCMC-13 embryonic stem cell human CVCL_V496 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0365. 21162915 CVCL_US97 GM06438 finite cell line human CVCL_US97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06438; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162916 CVCL_V497 WCMC-14 embryonic stem cell human CVCL_V497 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162917 CVCL_US94 GM05557 finite cell line human CVCL_US94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05557; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162918 CVCL_V494 WCMC-11 embryonic stem cell human CVCL_V494 From: Weill Cornell Medical College; New York; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0366. 21162919 CVCL_US95 GM05547 finite cell line human CVCL_US95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05547; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162920 CVCL_V495 WCMC-12 embryonic stem cell human CVCL_V495 From: Weill Cornell Medical College; New York; USA. CL:0000010 Unspecified 21162921 CVCL_V478 GM04928 finite cell line human CVCL_V478 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21162922 CVCL_US78 GM05669 finite cell line human CVCL_US78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05669; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162923 CVCL_V479 GM04965 finite cell line human CVCL_V479 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21162924 CVCL_US79 GM06375 finite cell line human CVCL_US79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06375; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162925 CVCL_V476 GM04617 finite cell line human CVCL_V476 CL:0000010 Population: Puerto Rican; Karyotypic information: 47,XX,+21[25].arr(21)x3 (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162926 CVCL_US76 GM05683 finite cell line human CVCL_US76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05683; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162927 CVCL_V477 GM04927 transformed cell line human CVCL_V477 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162928 CVCL_US77 GM05661 finite cell line human CVCL_US77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05661; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162929 CVCL_2M51 AG08483 finite cell line CVCL_2M51 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162930 CVCL_2M52 AG08486 finite cell line CVCL_2M52 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Group: Non-human primate cell line 21162931 CVCL_2M50 AG08482 finite cell line CVCL_2M50 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162932 CVCL_2M55 AG08491 finite cell line CVCL_2M55 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162933 CVCL_2M56 AG08493 finite cell line CVCL_2M56 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162934 CVCL_2M53 AG08488 finite cell line CVCL_2M53 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162935 CVCL_2M54 AG08490 finite cell line CVCL_2M54 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162936 CVCL_2M48 AG08479 finite cell line dog CVCL_2M48 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162937 CVCL_2M49 AG08480 finite cell line dog CVCL_2M49 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Female 21162938 CVCL_2M46 AG08477 finite cell line pig CVCL_2M46 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Large White. Female 21162939 CVCL_2M47 AG08478 finite cell line dog CVCL_2M47 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Female 21162940 CVCL_V481 CL-39 cancer cell line human CVCL_V481 CL:0000010 Derived from sampling site: Colon; sigmoid. Unspecified 21162941 CVCL_US81 GM05625 finite cell line human CVCL_US81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05625; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162942 CVCL_US82 GM05555 finite cell line human CVCL_US82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05555; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162943 CVCL_V482 SNU-C5/5FU-R cancer cell line human CVCL_V482 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Leu (c.652G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Cecum. Female 21162944 CVCL_US80 GM05641 finite cell line human CVCL_US80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05641; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162945 CVCL_V480 GM13783 transformed cell line human CVCL_V480 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM13783; probable Female 21162946 CVCL_V485 COR-L96-LCL transformed cell line human CVCL_V485 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21162947 CVCL_US85 GM05723 finite cell line human CVCL_US85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05723; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162948 CVCL_US86 GM06444 finite cell line human CVCL_US86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06444; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162949 CVCL_V486 T201 cancer cell line human CVCL_V486 CL:0000010 Derived from sampling site: Larynx. Male Doubling time: 48 hours, at 35th passage (PubMed=11251167) 21162950 CVCL_US83 GM05605 finite cell line human CVCL_US83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05605; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162951 CVCL_V483 SNU-C5/IRT-R cancer cell line human CVCL_V483 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Leu (c.652G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from sampling site: Cecum. Female 21162952 CVCL_US84 GM05599 finite cell line human CVCL_US84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05599; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162953 CVCL_V484 SNU-C5/OXT-R cancer cell line human CVCL_V484 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Leu (c.652G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (from parent cell line) Population: Korean; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from sampling site: Cecum. Female 21162954 CVCL_V467 GM02067 finite cell line human CVCL_V467 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+21 [44]; 47,XY,t(1;16)(q21;p13.3],+21 [4]; 46,XY [2] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21162955 CVCL_US67 GM05551 finite cell line human CVCL_US67 CL:0000010 Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05551; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162956 CVCL_V468 GM02571 finite cell line human CVCL_V468 CL:0000010 Population: Caucasian; Karyotypic information: 48,XX,+21,+mar (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21162957 CVCL_US68 GM06630 finite cell line human CVCL_US68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06630; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162958 CVCL_V465 GM01921 transformed cell line human CVCL_V465 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21162959 CVCL_US65 GM06512 finite cell line human CVCL_US65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06512; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162960 CVCL_V466 GM02058 finite cell line human CVCL_V466 CL:0000010 Population: Jewish; Ashkenazi; Karyotypic information: 46,XX,i(21)(qter->q10::q10->qter) [13]; 46,XX [87] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21162961 CVCL_US66 GM06541 finite cell line human CVCL_US66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06541; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162962 CVCL_V469 GM02767 finite cell line human CVCL_V469 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21162963 CVCL_US69 GM06422 finite cell line human CVCL_US69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06422; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162964 CVCL_2M22 AG08324 finite cell line CVCL_2M22 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162965 CVCL_2M23 AG08326 finite cell line CVCL_2M23 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle. Female Group: Non-human primate cell line 21162966 CVCL_2M20 AG08320 finite cell line CVCL_2M20 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162967 CVCL_2M21 AG08323 finite cell line CVCL_2M21 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162968 CVCL_2M15 AG08250 finite cell line dog CVCL_2M15 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Beagle. Male 21162969 CVCL_2M16 AG08305 finite cell line CVCL_2M16 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162970 CVCL_2M13 AG08248 finite cell line dog CVCL_2M13 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162971 CVCL_2M14 AG08249 finite cell line dog CVCL_2M14 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Beagle. Male 21162972 CVCL_2M19 AG08319 finite cell line CVCL_2M19 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162973 CVCL_2M17 AG08308 finite cell line CVCL_2M17 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21162974 CVCL_2M18 AG08312 finite cell line CVCL_2M18 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21162975 CVCL_V470 GM03417 finite cell line human CVCL_V470 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(14;21)(14qter->14q10::21q10->21qter),+21 [34]; 45,XX,der(14;21)(14qter->14q10::21q10->21qter) [16] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21162976 CVCL_US70 GM06735 finite cell line human CVCL_US70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06735; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162977 CVCL_V471 GM03606 finite cell line human CVCL_V471 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21162978 CVCL_US71 GM05649 finite cell line human CVCL_US71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05649; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162979 CVCL_V474 GM04614 finite cell line human CVCL_V474 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM04614; probable Female 21162980 CVCL_US74 GM06456 finite cell line human CVCL_US74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06456; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162981 CVCL_V475 GM04616 finite cell line human CVCL_V475 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21162982 CVCL_US75 GM05685 finite cell line human CVCL_US75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05685; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162983 CVCL_V472 GM03716 transformed cell line human CVCL_V472 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162984 CVCL_US72 GM05679 finite cell line human CVCL_US72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05679; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162985 CVCL_V473 GM04592 finite cell line human CVCL_V473 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21162986 CVCL_US73 GM05609 finite cell line human CVCL_US73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05609; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162987 CVCL_US56 GM06407 finite cell line human CVCL_US56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06407; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162988 CVCL_V456 GM16634 hybrid cell line CVCL_V456 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male Group: Human/rodent somatic cell hybrid 21162989 CVCL_V457 AG09394 transformed cell line human CVCL_V457 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21162990 CVCL_US57 GM06405 finite cell line human CVCL_US57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06405; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162991 CVCL_US54 GM06404 finite cell line human CVCL_US54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06404; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162992 CVCL_V454 K7M2-pCI Neo cancer cell line house mouse CVCL_V454 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lung; Breed/subspecies: BALB/c. Female 21162993 CVCL_US55 GM06410 finite cell line human CVCL_US55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06410; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162994 CVCL_V455 K7M2-WT cancer cell line house mouse CVCL_V455 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: BALB/c. Omics: Transcriptome analysis by microarray Female 21162995 CVCL_V458 AG16777 transformed cell line human CVCL_V458 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21162996 CVCL_US58 GM06399 finite cell line human CVCL_US58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06399; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21162997 CVCL_V459 GM00144 finite cell line human CVCL_V459 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Female 21162998 CVCL_US59 GM06409 finite cell line human CVCL_US59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06409; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21162999 CVCL_2M30 AG08422 finite cell line CVCL_2M30 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle; Breed/subspecies: Thoroughbred. Female 21163000 CVCL_2M33 AG08426 finite cell line CVCL_2M33 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21163001 CVCL_2M34 AG08427 finite cell line CVCL_2M34 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21163002 CVCL_2M31 AG08423 finite cell line CVCL_2M31 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Angus. Female 21163003 CVCL_2M32 AG08424 finite cell line CVCL_2M32 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Angus. Female 21163004 CVCL_2M26 AG08351 finite cell line CVCL_2M26 CL:0000010 Derived from sampling site: Fetal thoracic aorta; smooth muscle. Male Group: Non-human primate cell line 21163005 CVCL_2M27 AG08419 finite cell line CVCL_2M27 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Female 21163006 CVCL_2M24 AG08346 finite cell line CVCL_2M24 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21163007 CVCL_2M25 AG08347 finite cell line CVCL_2M25 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21163008 CVCL_2M28 AG08420 finite cell line CVCL_2M28 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Thoroughbred. Female 21163009 CVCL_2M29 AG08421 finite cell line CVCL_2M29 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Thoroughbred. Female 21163010 CVCL_V460 GM00201 finite cell line human CVCL_V460 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21163011 CVCL_US60 GM06728 finite cell line human CVCL_US60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06728; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21163012 CVCL_V463 GM01413 finite cell line human CVCL_V463 CL:0000010 Population: African American; Karyotypic information: 46,XX,der(10)(10pter->10q26::21q21->21qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21163013 CVCL_US63 GM06531 finite cell line human CVCL_US63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06531; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21163014 CVCL_V464 GM01920 finite cell line human CVCL_V464 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,t(8;14)(8pter->8q13::14q13->14qter;14pter->14q13::8q13->8qter),inv(9)(p11q13),+21 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21163015 CVCL_US64 GM06529 finite cell line human CVCL_US64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06529; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21163016 CVCL_V461 GM00693 finite cell line human CVCL_V461 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;21)(2pter->2q37::21q21->21qter;21pter->21q21::2q37->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21163017 CVCL_US61 GM04289 transformed cell line human CVCL_US61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM04289; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21163018 CVCL_V462 GM01137 finite cell line human CVCL_V462 CL:0000010 Population: African American; Karyotypic information: 48,XXY,t(6;10)(6qter->6p25::10p11->10pter;10qter->10p11::6p25->6pter),+21 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21163019 CVCL_US62 GM06539 finite cell line human CVCL_US62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06539; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21163020 CVCL_DA31 GM09669 finite cell line human CVCL_DA31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21163021 CVCL_DA32 GM10570 finite cell line human CVCL_DA32 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Female 21163022 CVCL_DA30 GM09668 finite cell line human CVCL_DA30 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21163023 CVCL_DA24 GM02984 finite cell line human CVCL_DA24 CL:0000010 Population: Caucasian; French; Derived from sampling site: Cell type=Fibroblast. Male 21163024 CVCL_DA25 GM03393 finite cell line human CVCL_DA25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21163025 CVCL_DA22 GM02972 finite cell line human CVCL_DA22 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21163026 CVCL_DA23 GM02973 finite cell line human CVCL_DA23 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21163027 CVCL_DA28 GM08820 transformed cell line human CVCL_DA28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163028 CVCL_DA29 GM09404 finite cell line human CVCL_DA29 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Ile287Asn (c.860T>A); ClinVar=VCV000068750; Zygosity=Heterozygous (Coriell) Population: Asian; Derived from sampling site: Cell type=Fibroblast. Female 21163029 CVCL_DA26 GM08369 transformed cell line human CVCL_DA26 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163030 CVCL_DA27 GM08794 transformed cell line human CVCL_DA27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163031 CVCL_DA42 GM16107 transformed cell line human CVCL_DA42 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg164Ter (c.490C>T) (p.Arg61Ter, c.181C>T); ClinVar=VCV000056197; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163032 CVCL_DA43 GM16108 transformed cell line human CVCL_DA43 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000520610; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163033 CVCL_DA40 GM16085 transformed cell line human CVCL_DA40 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Thr75Pro (c.223A>C); ClinVar=VCV000008900; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163034 CVCL_DA41 GM16106 transformed cell line human CVCL_DA41 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Phe85del (c.255_257delCTT); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Gln177Glu (c.529C>G); ClinVar=VCV000056198; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163035 CVCL_DA35 GM16080 transformed cell line human CVCL_DA35 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Thr75Pro (c.223A>C); ClinVar=VCV000008900; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163036 CVCL_DA36 GM16081 transformed cell line human CVCL_DA36 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Asp79Gly (c.236A>G); ClinVar=VCV000008901; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163037 CVCL_DA33 GM10672 finite cell line human CVCL_DA33 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21163038 CVCL_DA34 GM11097 finite cell line human CVCL_DA34 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu43_Ala44del; Zygosity=Heterozygous (from child cell line TRNDi004-I) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21163039 CVCL_DA39 GM16084 transformed cell line human CVCL_DA39 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.His39Gln (c.117T>A); ClinVar=VCV000056175; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163040 CVCL_DA37 GM16082 transformed cell line human CVCL_DA37 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Gln177Glu (c.529C>G); ClinVar=VCV000056198; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Trp296Ter (c.888G>A); ClinVar=VCV000056219; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163041 CVCL_DA38 GM16083 transformed cell line human CVCL_DA38 CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Arg151Ter (c.451C>T); ClinVar=VCV000008904; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163042 CVCL_DA10 SRD-9 transformed cell line CVCL_DA10 CL:0000010 Sequence variation: Mutation; UniProtKB; P97260; Scap; Simple; p.Tyr298Cys (c.893A>G); Zygosity=Heterozygous (PubMed=9789003) Selected for resistance to: ChEBI; CHEBI:42977; 25-hydroxycholesterol; Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Ovary. Female 21163043 CVCL_DA08 D253-15-6 hybridoma CVCL_DA08 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8789 21163044 CVCL_DA09 SRD-4 transformed cell line CVCL_DA09 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Ovary. Female 21163045 CVCL_DA02 OVCAR-3/TxT5 cancer cell line human CVCL_DA02 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Ascites. Female 21163046 CVCL_DA03 OVCAR-3/T40 cancer cell line human CVCL_DA03 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21163047 CVCL_DA00 OVCA433/TxT50 cancer cell line human CVCL_DA00 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from sampling site: Ovary. Female 21163048 CVCL_DA01 OVCA433/T40 cancer cell line human CVCL_DA01 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21163049 CVCL_DA06 L-WRN spontaneously immortalized cell line house mouse CVCL_DA06 CL:0000010 Transfected with: MGI; MGI:104327; Nog; Transfected with: MGI; MGI:1920030; Rspo3; Transfected with: MGI; MGI:98956; Wnt3a Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21163050 CVCL_DA07 T4 clone 3 hybridoma house mouse CVCL_DA07 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:18332; L-thyroxine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8499 21163051 CVCL_DA04 Tau RD P301S FRET Biosensor transformed cell line human CVCL_DA04 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21163052 CVCL_DA05 L-WR spontaneously immortalized cell line house mouse CVCL_DA05 CL:0000010 Transfected with: MGI; MGI:1920030; Rspo3; Transfected with: MGI; MGI:98956; Wnt3a Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21163053 CVCL_DA20 AllSi-Liver finite cell line CVCL_DA20 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the species and the name of the tissue Derived from sampling site: Liver. Unspecified Doubling time: ~36 hours (DOI=10.1007/s11434-011-4622-9) Group: Endangered species/breed cell line; Group: Reptilian cell line 21163054 CVCL_DA21 AllSi-Muscle finite cell line CVCL_DA21 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the species and the name of the tissue Derived from sampling site: Muscle. Unspecified Doubling time: ~36 hours (DOI=10.1007/s11434-011-4622-9) Group: Endangered species/breed cell line; Group: Reptilian cell line 21163055 CVCL_DA19 AllSi-Heart finite cell line CVCL_DA19 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the species and the name of the tissue Derived from sampling site: Heart. Unspecified Doubling time: ~36 hours (DOI=10.1007/s11434-011-4622-9) Group: Endangered species/breed cell line; Group: Reptilian cell line 21163056 CVCL_DA13 KB10460 iPSC colony 1 induced pluripotent stem cell CVCL_DA13 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Group: Non-human primate cell line 21163057 CVCL_DA14 KB10460 iPSC colony 2 induced pluripotent stem cell CVCL_DA14 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Group: Non-human primate cell line 21163058 CVCL_DA11 Ace-1(CMV) cancer cell line dog CVCL_DA11 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Labrador Retriever. Male Characteristics: Control cell line for Ace-1(huGRPr) 21163059 CVCL_DA12 Ace-1(huGRPr) cancer cell line dog CVCL_DA12 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Labrador Retriever. Male 21163060 CVCL_DA17 KB10973 iPSC colony 2 induced pluripotent stem cell CVCL_DA17 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Group: Non-human primate cell line 21163061 CVCL_DA18 KB10973 iPSC colony 3 induced pluripotent stem cell CVCL_DA18 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Group: Non-human primate cell line 21163062 CVCL_DA15 KB10460 iPSC colony 3 induced pluripotent stem cell CVCL_DA15 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Group: Non-human primate cell line 21163063 CVCL_DA16 KB10973 iPSC colony 1 induced pluripotent stem cell CVCL_DA16 From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Group: Non-human primate cell line 21163064 CVCL_3893 A818-6 cancer cell line human CVCL_3893 CL:0000010 Derived from metastatic site: Ascites. Female 21163065 CVCL_2W93 PR00648 transformed cell line CVCL_2W93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00648; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163066 CVCL_3894 ATDC-5 cancer cell line house mouse CVCL_3894 CL:0000010 Breed/subspecies: 129. Male 21163067 CVCL_2W94 PR00650 transformed cell line CVCL_2W94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00650; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163068 CVCL_3891 A818-1 cancer cell line human CVCL_3891 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11169959); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959) Derived from metastatic site: Ascites. Female 21163069 CVCL_2W91 PR00636 finite cell line CVCL_2W91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00636; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163070 CVCL_3892 A818-4 cancer cell line human CVCL_3892 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=8426738; PubMed=11787853) Derived from metastatic site: Ascites. Female 21163071 CVCL_2W92 PR00644 finite cell line CVCL_2W92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00644; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163072 CVCL_3897 CGTH-W-2 cancer cell line human CVCL_3897 CL:0000010 Population: Chinese; Derived from metastatic site: Skull. Female Doubling time: ~20 hours (PubMed=8888804) 21163073 CVCL_2W97 PR00661 transformed cell line bonobo/pygmy chimpanzee CVCL_2W97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00661; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163074 CVCL_3898 CGTH-W-3 cancer cell line human CVCL_3898 CL:0000010 Population: Chinese; Derived from sampling site: Thyroid gland. Female 21163075 CVCL_2W98 PR00663 finite cell line CVCL_2W98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00663; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163076 CVCL_3895 BM-314 cancer cell line human CVCL_3895 CL:0000010 Population: Japanese. 21163077 CVCL_2W95 PR00652 transformed cell line CVCL_2W95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00652; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163078 CVCL_3896 BW5147 cancer cell line house mouse CVCL_3896 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Group: Hybridoma fusion partner cell line 21163079 CVCL_2W96 PR00657 transformed cell line CVCL_2W96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00657; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163080 CVCL_3899 CHCY-1 cancer cell line human CVCL_3899 CL:0000010 Population: Japanese. Unspecified 21163081 CVCL_2W99 PR00664 finite cell line CVCL_2W99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00664; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163082 CVCL_3871 CL1-0 cancer cell line human CVCL_3871 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Male Doubling time: 24 hours (PubMed=1497905) 21163083 CVCL_2W71 PR00592 transformed cell line CVCL_2W71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00592; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163084 CVCL_3872 LNCaP-CL1 cancer cell line human CVCL_3872 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep proteome analysis Male Characteristics: Androgen-independent Has highly locally invasive and metastatic properties. 21163085 CVCL_2W72 PR00594 transformed cell line CVCL_2W72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00594; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163086 CVCL_3870 7800C1 cancer cell line Norway rat CVCL_3870 CL:0000010 Breed/subspecies: Wistar. 21163087 CVCL_2W70 PR00586 finite cell line CVCL_2W70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00586; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163088 CVCL_2W75 PR00603 finite cell line CVCL_2W75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00603; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163089 CVCL_3875 SK-MEL-110 cancer cell line human CVCL_3875 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Glu63Lys (c.187G>A); Zygosity=Unspecified (PubMed=24576830). 21163090 CVCL_2W76 PR00604 finite cell line CVCL_2W76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00604; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163091 CVCL_3876 SK-MEL-147 cancer cell line human CVCL_3876 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830; PubMed=25728708) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq 21163092 CVCL_3873 Ehrlich-Lettre ascites strain E cancer cell line house mouse CVCL_3873 CL:0000010 Derived from sampling site: Ascites. Omics: SNP array analysis Female 21163093 CVCL_2W73 PR00597 finite cell line CVCL_2W73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00597; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163094 CVCL_3874 IDH4 transformed cell line human CVCL_3874 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21163095 CVCL_2W74 PR00598 transformed cell line CVCL_2W74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00598; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163096 CVCL_2W79 PR00609 finite cell line CVCL_2W79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00609; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163097 CVCL_2W77 PR00605 transformed cell line CVCL_2W77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00605; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163098 CVCL_3877 SK-MEL-21 cancer cell line human CVCL_3877 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Male Characteristics: Very highly pigmented 21163099 CVCL_2W78 PR00608 finite cell line CVCL_2W78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00608; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163100 CVCL_3878 SK-MEL-37 cancer cell line human CVCL_3878 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=9692547) Derived from metastatic site: Lymph node. Male 21163101 CVCL_3890 A818 cancer cell line human CVCL_3890 CL:0000010 Derived from metastatic site: Ascites. Female 21163102 CVCL_2W90 PR00634 finite cell line CVCL_2W90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00634; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163103 CVCL_3882 C127I cancer cell line house mouse CVCL_3882 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female 21163104 CVCL_2W82 PR00616 finite cell line CVCL_2W82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00616; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163105 CVCL_2W83 PR00622 finite cell line CVCL_2W83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00622; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163106 CVCL_3883 SW1736 cancer cell line human CVCL_3883 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 12373; TSHR; Simple; p.Ile486Phe (c.1456A>T); Zygosity=Heterozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Deep phosphoproteome analysis; Omics: Transcriptome analysis by microarray Female 21163107 CVCL_2W80 PR00612 finite cell line CVCL_2W80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00612; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163108 CVCL_3880 SK-MEL-94 cancer cell line human CVCL_3880 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21163109 CVCL_2W81 PR00615 finite cell line CVCL_2W81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00615; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163110 CVCL_3881 SU.86.86 cancer cell line human CVCL_3881 HLA typing: A*29:02,32:01; B*44:02,44:02; C*05:01,16:01 (PubMed=26589293); Genome ancestry: African=0.25%; Native American=1.63%; East Asian, North=1.94%; East Asian, South=0%; South Asian=0%; European, North=53.02%; European, South=43.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Hemizygous (PubMed=11115575); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=11115575) Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 77 hours (PubMed=3264833); 48 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel 21163111 CVCL_2W86 PR00627 finite cell line CVCL_2W86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00627; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163112 CVCL_3886 SW1222 cancer cell line human CVCL_3886 HLA typing: A*01 (PubMed=8464898) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1306Ter (c.3916G>T) (E1288*, c.3862G>T); ClinVar=VCV000376059; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Val (c.437C>T); ClinVar=VCV000375962; Zygosity=Unspecified (PubMed=20570890); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu540Arg (c.1619T>G); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex1 113 bp del; Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21163113 CVCL_3887 NALM-17 cancer cell line human CVCL_3887 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21163114 CVCL_2W87 PR00628 transformed cell line CVCL_2W87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00628; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163115 CVCL_2W84 PR00623 finite cell line CVCL_2W84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00623; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163116 CVCL_3884 SW742 cancer cell line human CVCL_3884 From: Scott and White Clinic; Temple; USA CL:0000010 Male Doubling time: 273 hours, at 2nd passage (PubMed=1000501). 21163117 CVCL_2W85 PR00626 finite cell line CVCL_2W85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00626; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163118 CVCL_3885 SW1398 cancer cell line human CVCL_3885 From: Scott and White Clinic; Temple; USA CL:0000010 Omics: Deep phosphoproteome analysis; Omics: N-glycan profiling. 21163119 CVCL_3888 NALM-24 cancer cell line human CVCL_3888 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1667895; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21163120 CVCL_2W88 PR00631 finite cell line CVCL_2W88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00631; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163121 CVCL_3889 NALM-26 cancer cell line human CVCL_3889 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 5 days (PubMed=7599111); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21163122 CVCL_2W89 PR00632 finite cell line CVCL_2W89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00632; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163123 CVCL_3850 MEL III cancer cell line CVCL_3850 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6308; true Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21163124 CVCL_2W50 PR00495 finite cell line CVCL_2W50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00495; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163125 CVCL_3853 Meta 7 cancer cell line house mouse CVCL_3853 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Meta series of TS/A derived cell lines are obtained from repeated subcutaneous passage of lung metastases in BALB/c female mice 21163126 CVCL_2W53 PR00519 finite cell line CVCL_2W53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00519; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163127 CVCL_3854 MH-22a cancer cell line house mouse CVCL_3854 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C3HA. 21163128 CVCL_2W54 PR00522 finite cell line CVCL_2W54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00522; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163129 CVCL_3851 Meta 10 cancer cell line house mouse CVCL_3851 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Meta series of TS/A derived cell lines are obtained from repeated subcutaneous passage of lung metastases in BALB/c female mice 21163130 CVCL_2W51 PR00496 transformed cell line CVCL_2W51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00496; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163131 CVCL_3852 Meta 15 cancer cell line house mouse CVCL_3852 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Meta series of TS/A derived cell lines are obtained from repeated subcutaneous passage of lung metastases in BALB/c female mice 21163132 CVCL_2W52 PR00503 finite cell line CVCL_2W52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00503; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163133 CVCL_3857 MPC-11 cancer cell line house mouse CVCL_3857 CL:0000010 Breed/subspecies: BALB/c. Female 21163134 CVCL_2W57 PR00527 finite cell line CVCL_2W57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00527; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163135 CVCL_3858 Mpf spontaneously immortalized cell line CVCL_3858 CL:0000010 Derived from sampling site: Brain. Discontinued: ECACC; 90062801; probable Unspecified Virology: Susceptible to infection by maedi visna virus (MVV) Synthesizes and released limited amounts of visna virus into the cultures' media for 80 day after infection (PubMed=6189779). Doubling time: 12.5-17.2 hours (PubMed=6185411); 12-13 hours (ATCC=CRL-1656) 21163136 CVCL_2W58 PR00530 finite cell line CVCL_2W58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00530; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163137 CVCL_3855 MH-S transformed cell line house mouse CVCL_3855 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: BALB/cJ. Male 21163138 CVCL_2W55 PR00524 finite cell line bonobo/pygmy chimpanzee CVCL_2W55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00524; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163139 CVCL_3856 MLA144 cancer cell line CVCL_3856 CL:0000010 Transformant: Gibbon ape leukemia virus (GALV)(NCBI-Taxonomy; 11840); Derived from sampling site: Lymph node. Discontinued: ATCC; TIB-201; true Doubling time: ~48 hours (PubMed=4501200) Group: Non-human primate cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981); Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8370 21163140 CVCL_2W56 PR00525 finite cell line CVCL_2W56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00525; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163141 CVCL_3859 MPK [Pig] spontaneously immortalized cell line pig CVCL_3859 CL:0000010 Derived from sampling site: Fetal kidney; Breed/subspecies: Miniature pig. Male Virology: Highly susceptible to infection by classical swine fever virus (CSFV) (PubMed=3173126); Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21163142 CVCL_2W59 PR00531 finite cell line CVCL_2W59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00531; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163143 CVCL_3860 Nb2-11 cancer cell line Norway rat CVCL_3860 CL:0000010 Breed/subspecies: Nb. Male Doubling time: 12 hours (ECACC=97041101) 21163144 CVCL_2W60 PR00548 transformed cell line CVCL_2W60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00548; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163145 CVCL_2W61 PR00550 finite cell line CVCL_2W61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00550; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163146 CVCL_3861 RLC-16 spontaneously immortalized cell line Norway rat CVCL_3861 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21163147 CVCL_2W64 PR00554 finite cell line CVCL_2W64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00554; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163148 CVCL_3864 Vx2 cancer cell line CVCL_3864 CL:0000010 Transformant: Rabbit fibroma virus (SFV)(NCBI-Taxonomy; 10271) Discontinued: ATCC; CRL-6503; true; Discontinued: CLS; 609374; true. Male Characteristics: Established from the VX2 (V2) transplantable tumor which was initiated in 1938 Doubling time: ~2-2.5 days (PubMed=6126038) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21163149 CVCL_3865 BW1J cancer cell line house mouse CVCL_3865 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L/J. 21163150 CVCL_2W65 PR00559 finite cell line CVCL_2W65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00559; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163151 CVCL_2W62 PR00551 finite cell line CVCL_2W62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00551; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163152 CVCL_3862 RLC-27 spontaneously immortalized cell line Norway rat CVCL_3862 CL:0000010 Derived from sampling site: Liver. Male 21163153 CVCL_2W63 PR00553 finite cell line CVCL_2W63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00553; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163154 CVCL_3863 Vero 317 spontaneously immortalized cell line green monkey CVCL_3863 CL:0000010 Derived from sampling site: Kidney; epithelium. Discontinued: ECACC; 89070502; probable Female Group: Non-human primate cell line; Group: Vaccine production cell line 21163155 CVCL_3868 HaCaT II-4 spontaneously immortalized cell line human CVCL_3868 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Tumorigenic 21163156 CVCL_2W68 PR00578 finite cell line CVCL_2W68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00578; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163157 CVCL_3869 FM3A cancer cell line house mouse CVCL_3869 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21163158 CVCL_2W69 PR00582 finite cell line CVCL_2W69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00582; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163159 CVCL_3866 HHUA cancer cell line human CVCL_3866 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala138Val (c.413C>T); ClinVar=VCV000184863; Zygosity=Unspecified (PubMed=8105795) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 34 hours (at 5th passage), 30 hours (at 15th passage) (PubMed=6706228); 30 hours (PubMed=6532401); 28 hours (PubMed=10457904) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163160 CVCL_2W66 PR00566 finite cell line CVCL_2W66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00566; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163161 CVCL_3867 HOUA-I cancer cell line human CVCL_3867 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=8105795); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=8105795) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: ~50 hours (CelloPub=CLPUB00051); 56 hours (PubMed=10457904) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163162 CVCL_2W67 PR00576 finite cell line CVCL_2W67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00576; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163163 CVCL_ME03 BayGenomics ES cell line CSI883 embryonic stem cell house mouse CVCL_ME03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163164 CVCL_ME04 BayGenomics ES cell line CSI884 embryonic stem cell house mouse CVCL_ME04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163165 CVCL_ME01 BayGenomics ES cell line CSI875 embryonic stem cell house mouse CVCL_ME01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140327; Phactr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163166 CVCL_ME02 BayGenomics ES cell line CSI882 embryonic stem cell house mouse CVCL_ME02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163167 CVCL_ME00 BayGenomics ES cell line CSI872 embryonic stem cell house mouse CVCL_ME00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917302; Prpf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163168 CVCL_DK66 CW50042 induced pluripotent stem cell human CVCL_DK66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50042; true Female 21163169 CVCL_DK67 CW50043 induced pluripotent stem cell human CVCL_DK67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50043; true Female 21163170 CVCL_DK64 CW50037 induced pluripotent stem cell human CVCL_DK64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50037; true Female 21163171 CVCL_DK65 CW50038 induced pluripotent stem cell human CVCL_DK65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50038; true Female 21163172 CVCL_DK68 CW50044 induced pluripotent stem cell human CVCL_DK68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50044; true Male 21163173 CVCL_DK69 CW50045 induced pluripotent stem cell human CVCL_DK69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50045; true Male 21163174 CVCL_DK62 CW50035 induced pluripotent stem cell human CVCL_DK62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50035; true Female 21163175 CVCL_DK63 CW50036 induced pluripotent stem cell human CVCL_DK63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50036; true Female 21163176 CVCL_DK60 CW50033 induced pluripotent stem cell human CVCL_DK60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50033; true Male 21163177 CVCL_DK61 CW50034 induced pluripotent stem cell human CVCL_DK61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50034; true Male 21163178 CVCL_ME14 BayGenomics ES cell line CSJ024 embryonic stem cell house mouse CVCL_ME14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163179 CVCL_ME15 BayGenomics ES cell line CSJ034 embryonic stem cell house mouse CVCL_ME15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163180 CVCL_ME12 BayGenomics ES cell line CSJ017 embryonic stem cell house mouse CVCL_ME12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163181 CVCL_ME13 BayGenomics ES cell line CSJ021 embryonic stem cell house mouse CVCL_ME13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923036; Ckap5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163182 CVCL_ME10 BayGenomics ES cell line CSJ014 embryonic stem cell house mouse CVCL_ME10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163183 CVCL_ME11 BayGenomics ES cell line CSJ015 embryonic stem cell house mouse CVCL_ME11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163184 CVCL_DK77 CW50056 induced pluripotent stem cell human CVCL_DK77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50056; true Female 21163185 CVCL_DK78 CW50057 induced pluripotent stem cell human CVCL_DK78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW50057; true; Discontinued: FCDI; CW50057; probable. Female 21163186 CVCL_DK75 CW50054 induced pluripotent stem cell human CVCL_DK75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50054; true Female 21163187 CVCL_DK76 CW50055 induced pluripotent stem cell human CVCL_DK76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50055; true Male 21163188 CVCL_DK79 CW50058 induced pluripotent stem cell human CVCL_DK79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50058; true Male 21163189 CVCL_DK70 CW50046 induced pluripotent stem cell human CVCL_DK70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50046; true Female 21163190 CVCL_ME09 BayGenomics ES cell line CSJ012 embryonic stem cell house mouse CVCL_ME09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891832; Patz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163191 CVCL_ME07 BayGenomics ES cell line CSJ004 embryonic stem cell house mouse CVCL_ME07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915770; Zfyve21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163192 CVCL_DK73 CW50051 induced pluripotent stem cell human CVCL_DK73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50051; true Female 21163193 CVCL_ME08 BayGenomics ES cell line CSJ006 embryonic stem cell house mouse CVCL_ME08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163194 CVCL_DK74 CW50052 induced pluripotent stem cell human CVCL_DK74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50052; true Male 21163195 CVCL_ME05 BayGenomics ES cell line CSI885 embryonic stem cell house mouse CVCL_ME05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387603; Ahsa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163196 CVCL_DK71 CW50047 induced pluripotent stem cell human CVCL_DK71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50047; true Female 21163197 CVCL_ME06 BayGenomics ES cell line CSI889 embryonic stem cell house mouse CVCL_ME06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138986; Qser1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163198 CVCL_DK72 CW50050 induced pluripotent stem cell human CVCL_DK72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50050; true Male 21163199 CVCL_DK44 CW40245 induced pluripotent stem cell human CVCL_DK44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40245; true Male 21163200 CVCL_DK45 CW40246 induced pluripotent stem cell human CVCL_DK45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40246; true Male 21163201 CVCL_DK42 CW40240 induced pluripotent stem cell human CVCL_DK42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40240; true. Male 21163202 CVCL_DK43 CW40244 induced pluripotent stem cell human CVCL_DK43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40244; true Female 21163203 CVCL_DK48 CW50009 induced pluripotent stem cell human CVCL_DK48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50009; true Female 21163204 CVCL_DK49 CW50015 induced pluripotent stem cell human CVCL_DK49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW50015; true; Discontinued: FCDI; CW50015; probable. Male 21163205 CVCL_DK46 CW40249 induced pluripotent stem cell human CVCL_DK46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40249; true Male 21163206 CVCL_DK47 CW40251 induced pluripotent stem cell human CVCL_DK47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40251; true Male 21163207 CVCL_DK40 CW40237 induced pluripotent stem cell human CVCL_DK40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40237; true Male 21163208 CVCL_DK41 CW40239 induced pluripotent stem cell human CVCL_DK41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40239; true Male 21163209 CVCL_DK55 CW50025 induced pluripotent stem cell human CVCL_DK55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50025; true Female 21163210 CVCL_DK56 CW50026 induced pluripotent stem cell human CVCL_DK56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50026; true Female 21163211 CVCL_DK53 CW50022 induced pluripotent stem cell human CVCL_DK53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50022; true Female 21163212 CVCL_DK54 CW50024 induced pluripotent stem cell human CVCL_DK54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50024; true Male 21163213 CVCL_DK59 CW50029 induced pluripotent stem cell human CVCL_DK59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50029; true Male 21163214 CVCL_DK57 CW50027 induced pluripotent stem cell human CVCL_DK57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50027; true Male 21163215 CVCL_DK58 CW50028 induced pluripotent stem cell human CVCL_DK58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50028; true Male 21163216 CVCL_DK51 CW50018 induced pluripotent stem cell human CVCL_DK51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50018; true Female 21163217 CVCL_DK52 CW50019 induced pluripotent stem cell human CVCL_DK52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50019; true Female 21163218 CVCL_DK50 CW50016 induced pluripotent stem cell human CVCL_DK50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50016; true Female 21163219 CVCL_DK28 CW40207 induced pluripotent stem cell human CVCL_DK28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40207; true Male 21163220 CVCL_DK29 CW40210 induced pluripotent stem cell human CVCL_DK29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40210; true. Male 21163221 CVCL_DK22 CW40195 induced pluripotent stem cell human CVCL_DK22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40195; true Male 21163222 CVCL_DK23 CW40196 induced pluripotent stem cell human CVCL_DK23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40196; true Male 21163223 CVCL_DK20 CW40187 induced pluripotent stem cell human CVCL_DK20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40187; true Female 21163224 CVCL_DK21 CW40194 induced pluripotent stem cell human CVCL_DK21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40194; true Female 21163225 CVCL_DK26 CW40199 induced pluripotent stem cell human CVCL_DK26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40199; true Female 21163226 CVCL_DK27 CW40200 induced pluripotent stem cell human CVCL_DK27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40200; true Female 21163227 CVCL_DK24 CW40197 induced pluripotent stem cell human CVCL_DK24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40197; true Male 21163228 CVCL_DK25 CW40198 induced pluripotent stem cell human CVCL_DK25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40198; true Male 21163229 CVCL_DK39 CW40236 induced pluripotent stem cell human CVCL_DK39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40236; true Male 21163230 CVCL_DK33 CW40222 induced pluripotent stem cell human CVCL_DK33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40222; true Male 21163231 CVCL_DK34 CW40226 induced pluripotent stem cell human CVCL_DK34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40226; true Male 21163232 CVCL_DK31 CW40220 induced pluripotent stem cell human CVCL_DK31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40220; true Female 21163233 CVCL_DK32 CW40221 induced pluripotent stem cell human CVCL_DK32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40221; true Female 21163234 CVCL_DK37 CW40232 induced pluripotent stem cell human CVCL_DK37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40232; true Male 21163235 CVCL_DK38 CW40233 induced pluripotent stem cell human CVCL_DK38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40233; true Male 21163236 CVCL_DK35 CW40227 induced pluripotent stem cell human CVCL_DK35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40227; true Male 21163237 CVCL_DK36 CW40231 induced pluripotent stem cell human CVCL_DK36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40231; true Male 21163238 CVCL_DK30 CW40219 induced pluripotent stem cell human CVCL_DK30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40219; true Male 21163239 CVCL_DK08 CW40021 induced pluripotent stem cell human CVCL_DK08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40021; true. Male 21163240 CVCL_DK09 CW40024 induced pluripotent stem cell human CVCL_DK09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40024; true. Male 21163241 CVCL_DK06 CW30446 induced pluripotent stem cell human CVCL_DK06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30446; true Male 21163242 CVCL_DK07 CW40005 induced pluripotent stem cell human CVCL_DK07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40005; true. Male 21163243 CVCL_DK00 CW30429 induced pluripotent stem cell human CVCL_DK00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30429; true Female 21163244 CVCL_DK01 CW30430 induced pluripotent stem cell human CVCL_DK01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30430; true Male 21163245 CVCL_DK04 CW30436 induced pluripotent stem cell human CVCL_DK04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30436; true Female 21163246 CVCL_DK05 CW30442 induced pluripotent stem cell human CVCL_DK05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30442; true Male 21163247 CVCL_DK02 CW30433 induced pluripotent stem cell human CVCL_DK02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30433; true Male 21163248 CVCL_DK03 CW30435 induced pluripotent stem cell human CVCL_DK03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30435; true Male 21163249 CVCL_DK19 CW40179 induced pluripotent stem cell human CVCL_DK19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40179; true; Discontinued: FCDI; CW40179; probable. Female 21163250 CVCL_DK17 CW40130 induced pluripotent stem cell human CVCL_DK17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40130; true; Discontinued: FCDI; CW40130; probable. Female 21163251 CVCL_DK18 CW40163 induced pluripotent stem cell human CVCL_DK18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40163; true Male 21163252 CVCL_DK11 CW40040 induced pluripotent stem cell human CVCL_DK11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40040; true. Male 21163253 CVCL_DK12 CW40064 induced pluripotent stem cell human CVCL_DK12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40064; true. Male 21163254 CVCL_DK10 CW40033 induced pluripotent stem cell human CVCL_DK10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40033; true. Male 21163255 CVCL_DK15 CW40088 induced pluripotent stem cell human CVCL_DK15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW40088; true. Male 21163256 CVCL_DK16 CW40107 induced pluripotent stem cell human CVCL_DK16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40107; true Male 21163257 CVCL_DK13 CW40074 induced pluripotent stem cell human CVCL_DK13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40074; true Female 21163258 CVCL_DK14 CW40078 induced pluripotent stem cell human CVCL_DK14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40078; true. Female 21163259 CVCL_MD68 BayGenomics ES cell line CSI772 embryonic stem cell house mouse CVCL_MD68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914436; Rplp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163260 CVCL_MD69 BayGenomics ES cell line CSI774 embryonic stem cell house mouse CVCL_MD69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346035; Farsb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163261 CVCL_MD66 BayGenomics ES cell line CSI770 embryonic stem cell house mouse CVCL_MD66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163262 CVCL_MD67 BayGenomics ES cell line CSI771 embryonic stem cell house mouse CVCL_MD67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163263 CVCL_MD64 BayGenomics ES cell line CSI763 embryonic stem cell house mouse CVCL_MD64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163264 CVCL_MD65 BayGenomics ES cell line CSI765 embryonic stem cell house mouse CVCL_MD65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914436; Rplp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163265 CVCL_MD62 BayGenomics ES cell line CSI760 embryonic stem cell house mouse CVCL_MD62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349457; Serinc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163266 CVCL_MD63 BayGenomics ES cell line CSI761 embryonic stem cell house mouse CVCL_MD63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163267 CVCL_MD60 BayGenomics ES cell line CSI754 embryonic stem cell house mouse CVCL_MD60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141291; Bud31 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163268 CVCL_MD61 BayGenomics ES cell line CSI758 embryonic stem cell house mouse CVCL_MD61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919837; Pan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163269 CVCL_MD79 BayGenomics ES cell line CSI802 embryonic stem cell house mouse CVCL_MD79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163270 CVCL_MD77 BayGenomics ES cell line CSI796 embryonic stem cell house mouse CVCL_MD77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448458; H2aw Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163271 CVCL_MD78 BayGenomics ES cell line CSI799 embryonic stem cell house mouse CVCL_MD78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349457; Serinc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163272 CVCL_MD75 BayGenomics ES cell line CSI786 embryonic stem cell house mouse CVCL_MD75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449311; Gemin5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163273 CVCL_MD76 BayGenomics ES cell line CSI788 embryonic stem cell house mouse CVCL_MD76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924621; Sec24a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163274 CVCL_MD73 BayGenomics ES cell line CSI784 embryonic stem cell house mouse CVCL_MD73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163275 CVCL_MD74 BayGenomics ES cell line CSI785 embryonic stem cell house mouse CVCL_MD74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449311; Gemin5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163276 CVCL_MD71 BayGenomics ES cell line CSI777 embryonic stem cell house mouse CVCL_MD71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3763743; Snhg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163277 CVCL_MD72 BayGenomics ES cell line CSI782 embryonic stem cell house mouse CVCL_MD72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163278 CVCL_MD70 BayGenomics ES cell line CSI776 embryonic stem cell house mouse CVCL_MD70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98285; Srsf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163279 CVCL_MD48 BayGenomics ES cell line CSI722 embryonic stem cell house mouse CVCL_MD48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920595; Timm21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163280 CVCL_MD49 BayGenomics ES cell line CSI724 embryonic stem cell house mouse CVCL_MD49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929095; Uso1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163281 CVCL_MD46 BayGenomics ES cell line CSI717 embryonic stem cell house mouse CVCL_MD46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163282 CVCL_MD47 BayGenomics ES cell line CSI721 embryonic stem cell house mouse CVCL_MD47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443731; Mat2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163283 CVCL_MD44 BayGenomics ES cell line CSI715 embryonic stem cell house mouse CVCL_MD44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443731; Mat2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163284 CVCL_MD45 BayGenomics ES cell line CSI716 embryonic stem cell house mouse CVCL_MD45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98351; Sod1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163285 CVCL_MD42 BayGenomics ES cell line CSI713 embryonic stem cell house mouse CVCL_MD42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163286 CVCL_MD43 BayGenomics ES cell line CSI714 embryonic stem cell house mouse CVCL_MD43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444412; Phf20l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163287 CVCL_MD40 BayGenomics ES cell line CSI707 embryonic stem cell house mouse CVCL_MD40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163288 CVCL_MD41 BayGenomics ES cell line CSI709 embryonic stem cell house mouse CVCL_MD41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353561; Vapa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163289 CVCL_MD39 BayGenomics ES cell line CSI702 embryonic stem cell house mouse CVCL_MD39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163290 CVCL_MD59 BayGenomics ES cell line CSI750 embryonic stem cell house mouse CVCL_MD59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163291 CVCL_MD57 BayGenomics ES cell line CSI743 embryonic stem cell house mouse CVCL_MD57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443731; Mat2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163292 CVCL_MD58 BayGenomics ES cell line CSI746 embryonic stem cell house mouse CVCL_MD58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163293 CVCL_MD55 BayGenomics ES cell line CSI740 embryonic stem cell house mouse CVCL_MD55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163294 CVCL_MD56 BayGenomics ES cell line CSI742 embryonic stem cell house mouse CVCL_MD56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163295 CVCL_MD53 BayGenomics ES cell line CSI738 embryonic stem cell house mouse CVCL_MD53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163296 CVCL_MD54 BayGenomics ES cell line CSI739 embryonic stem cell house mouse CVCL_MD54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163297 CVCL_MD51 BayGenomics ES cell line CSI731 embryonic stem cell house mouse CVCL_MD51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163298 CVCL_MD52 BayGenomics ES cell line CSI737 embryonic stem cell house mouse CVCL_MD52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163299 CVCL_MD50 BayGenomics ES cell line CSI726 embryonic stem cell house mouse CVCL_MD50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163300 CVCL_MD26 BayGenomics ES cell line CSI661 embryonic stem cell house mouse CVCL_MD26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163301 CVCL_MD27 BayGenomics ES cell line CSI662 embryonic stem cell house mouse CVCL_MD27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163302 CVCL_MD24 BayGenomics ES cell line CSI656 embryonic stem cell house mouse CVCL_MD24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338038; Aebp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163303 CVCL_MD25 BayGenomics ES cell line CSI657 embryonic stem cell house mouse CVCL_MD25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163304 CVCL_MD22 BayGenomics ES cell line CSI651 embryonic stem cell house mouse CVCL_MD22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921358; Parn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163305 CVCL_MD23 BayGenomics ES cell line CSI654 embryonic stem cell house mouse CVCL_MD23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98351; Sod1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163306 CVCL_MD20 BayGenomics ES cell line CSI647 embryonic stem cell house mouse CVCL_MD20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163307 CVCL_MD21 BayGenomics ES cell line CSI648 embryonic stem cell house mouse CVCL_MD21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860267; Set Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163308 CVCL_DJ89 CW30410 induced pluripotent stem cell human CVCL_DJ89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30410; true Male 21163309 CVCL_DJ87 CW30408 induced pluripotent stem cell human CVCL_DJ87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30408; true Male 21163310 CVCL_DJ88 CW30409 induced pluripotent stem cell human CVCL_DJ88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30409; true Male 21163311 CVCL_DJ81 CW30380 induced pluripotent stem cell human CVCL_DJ81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30380; true Female 21163312 CVCL_DJ82 CW30383 induced pluripotent stem cell human CVCL_DJ82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30383; true Male 21163313 CVCL_DJ80 CW30371 induced pluripotent stem cell human CVCL_DJ80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30371; true Male 21163314 CVCL_MD19 BayGenomics ES cell line CSI646 embryonic stem cell house mouse CVCL_MD19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163315 CVCL_DJ85 CW30401 induced pluripotent stem cell human CVCL_DJ85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30401; true Male 21163316 CVCL_DJ86 CW30404 induced pluripotent stem cell human CVCL_DJ86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30404; true Female 21163317 CVCL_MD17 BayGenomics ES cell line CSI644 embryonic stem cell house mouse CVCL_MD17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163318 CVCL_DJ83 CW30392 induced pluripotent stem cell human CVCL_DJ83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30392; true Female 21163319 CVCL_MD18 BayGenomics ES cell line CSI645 embryonic stem cell house mouse CVCL_MD18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163320 CVCL_DJ84 CW30393 induced pluripotent stem cell human CVCL_DJ84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30393; true Male 21163321 CVCL_MD37 BayGenomics ES cell line CSI700 embryonic stem cell house mouse CVCL_MD37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442524; Heatr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163322 CVCL_MD38 BayGenomics ES cell line CSI701 embryonic stem cell house mouse CVCL_MD38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163323 CVCL_MD35 BayGenomics ES cell line CSI695 embryonic stem cell house mouse CVCL_MD35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163324 CVCL_MD36 BayGenomics ES cell line CSI697 embryonic stem cell house mouse CVCL_MD36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144805; Vipas39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163325 CVCL_MD33 BayGenomics ES cell line CSI692 embryonic stem cell house mouse CVCL_MD33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933161; Trim23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163326 CVCL_MD34 BayGenomics ES cell line CSI694 embryonic stem cell house mouse CVCL_MD34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353472; Rpl7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163327 CVCL_MD31 BayGenomics ES cell line CSI685 embryonic stem cell house mouse CVCL_MD31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354702; Fbxl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163328 CVCL_MD32 BayGenomics ES cell line CSI690 embryonic stem cell house mouse CVCL_MD32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95393; Eno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163329 CVCL_MD30 BayGenomics ES cell line CSI670 embryonic stem cell house mouse CVCL_MD30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163330 CVCL_DJ98 CW30426 induced pluripotent stem cell human CVCL_DJ98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30426; true Male 21163331 CVCL_DJ99 CW30428 induced pluripotent stem cell human CVCL_DJ99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30428; true Male 21163332 CVCL_DJ92 CW30414 induced pluripotent stem cell human CVCL_DJ92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30414; true Male 21163333 CVCL_DJ93 CW30415 induced pluripotent stem cell human CVCL_DJ93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30415; true Female 21163334 CVCL_DJ90 CW30412 induced pluripotent stem cell human CVCL_DJ90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30412; true Male 21163335 CVCL_DJ91 CW30413 induced pluripotent stem cell human CVCL_DJ91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30413; true Male 21163336 CVCL_DJ96 CW30423 induced pluripotent stem cell human CVCL_DJ96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30423; true Male 21163337 CVCL_DJ97 CW30425 induced pluripotent stem cell human CVCL_DJ97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30425; true Male 21163338 CVCL_MD28 BayGenomics ES cell line CSI664 embryonic stem cell house mouse CVCL_MD28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163339 CVCL_DJ94 CW30419 induced pluripotent stem cell human CVCL_DJ94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30419; true Female 21163340 CVCL_MD29 BayGenomics ES cell line CSI668 embryonic stem cell house mouse CVCL_MD29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163341 CVCL_DJ95 CW30422 induced pluripotent stem cell human CVCL_DJ95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30422; true Male 21163342 CVCL_MD04 BayGenomics ES cell line CSI625 embryonic stem cell house mouse CVCL_MD04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355328; Nasp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163343 CVCL_MD05 BayGenomics ES cell line CSI626 embryonic stem cell house mouse CVCL_MD05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163344 CVCL_MD02 BayGenomics ES cell line CSI620 embryonic stem cell house mouse CVCL_MD02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163345 CVCL_MD03 BayGenomics ES cell line CSI622 embryonic stem cell house mouse CVCL_MD03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685031; Leo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163346 CVCL_MD00 BayGenomics ES cell line CSI617 embryonic stem cell house mouse CVCL_MD00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923036; Ckap5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163347 CVCL_MD01 BayGenomics ES cell line CSI619 embryonic stem cell house mouse CVCL_MD01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916175; Rpap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163348 CVCL_DJ67 CW30316 induced pluripotent stem cell human CVCL_DJ67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30316; true Male 21163349 CVCL_DJ68 CW30317 induced pluripotent stem cell human CVCL_DJ68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30317; true Female 21163350 CVCL_DJ65 CW30300 induced pluripotent stem cell human CVCL_DJ65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30300; true Male 21163351 CVCL_DJ66 CW30309 induced pluripotent stem cell human CVCL_DJ66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30309; true Female 21163352 CVCL_DJ69 CW30318 induced pluripotent stem cell human CVCL_DJ69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30318; true Female 21163353 CVCL_DJ60 CW30289 induced pluripotent stem cell human CVCL_DJ60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30289; true Female 21163354 CVCL_DJ63 CW30295 induced pluripotent stem cell human CVCL_DJ63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30295; true Male 21163355 CVCL_DJ64 CW30297 induced pluripotent stem cell human CVCL_DJ64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30297; true Male 21163356 CVCL_DJ61 CW30290 induced pluripotent stem cell human CVCL_DJ61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30290; true Female 21163357 CVCL_DJ62 CW30291 induced pluripotent stem cell human CVCL_DJ62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30291; true Female 21163358 CVCL_MD15 BayGenomics ES cell line CSI642 embryonic stem cell house mouse CVCL_MD15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163359 CVCL_MD16 BayGenomics ES cell line CSI643 embryonic stem cell house mouse CVCL_MD16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163360 CVCL_MD13 BayGenomics ES cell line CSI637 embryonic stem cell house mouse CVCL_MD13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157980; Vac14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163361 CVCL_MD14 BayGenomics ES cell line CSI641 embryonic stem cell house mouse CVCL_MD14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163362 CVCL_MD11 BayGenomics ES cell line CSI633 embryonic stem cell house mouse CVCL_MD11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163363 CVCL_MD12 BayGenomics ES cell line CSI636 embryonic stem cell house mouse CVCL_MD12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922847; Ndufaf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163364 CVCL_MD10 BayGenomics ES cell line CSI632 embryonic stem cell house mouse CVCL_MD10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163365 CVCL_DJ78 CW30369 induced pluripotent stem cell human CVCL_DJ78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30369; true Female 21163366 CVCL_DJ79 CW30370 induced pluripotent stem cell human CVCL_DJ79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30370; true Male 21163367 CVCL_DJ76 CW30329 induced pluripotent stem cell human CVCL_DJ76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30329; true Male 21163368 CVCL_DJ77 CW30334 induced pluripotent stem cell human CVCL_DJ77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30334; true Female 21163369 CVCL_DJ70 CW30319 induced pluripotent stem cell human CVCL_DJ70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30319; true Male 21163370 CVCL_DJ71 CW30322 induced pluripotent stem cell human CVCL_DJ71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30322; true Female 21163371 CVCL_MD08 BayGenomics ES cell line CSI630 embryonic stem cell house mouse CVCL_MD08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893579; Khdrbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163372 CVCL_DJ74 CW30326 induced pluripotent stem cell human CVCL_DJ74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30326; true Female 21163373 CVCL_MD09 BayGenomics ES cell line CSI631 embryonic stem cell house mouse CVCL_MD09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163374 CVCL_DJ75 CW30327 induced pluripotent stem cell human CVCL_DJ75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30327; true Male 21163375 CVCL_MD06 BayGenomics ES cell line CSI628 embryonic stem cell house mouse CVCL_MD06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163376 CVCL_DJ72 CW30323 induced pluripotent stem cell human CVCL_DJ72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30323; true Male 21163377 CVCL_MD07 BayGenomics ES cell line CSI629 embryonic stem cell house mouse CVCL_MD07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157980; Vac14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163378 CVCL_DJ73 CW30325 induced pluripotent stem cell human CVCL_DJ73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30325; true Female 21163379 CVCL_3831 L35 transformed cell line pig CVCL_3831 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163380 CVCL_2W31 PR00337 finite cell line CVCL_2W31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00337; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163381 CVCL_3832 L45 [Pig] transformed cell line pig CVCL_3832 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=T-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163382 CVCL_2W32 PR00338 finite cell line CVCL_2W32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00338; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163383 CVCL_3830 L231 transformed cell line pig CVCL_3830 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Discontinued: ECACC; 92040118; probable Male 21163384 CVCL_2W30 PR00336 finite cell line CVCL_2W30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00336; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163385 CVCL_3835 L6.C11 transformed cell line Norway rat CVCL_3835 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21163386 CVCL_2W35 PR00342 finite cell line CVCL_2W35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00342; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163387 CVCL_3836 L6.G8 transformed cell line Norway rat CVCL_3836 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21163388 CVCL_2W36 PR00344 finite cell line CVCL_2W36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00344; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163389 CVCL_3833 L52 transformed cell line pig CVCL_3833 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163390 CVCL_2W33 PR00340 finite cell line CVCL_2W33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00340; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163391 CVCL_3834 L6.C10 transformed cell line Norway rat CVCL_3834 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Discontinued: ECACC; 92102118; probable Male 21163392 CVCL_2W34 PR00341 finite cell line CVCL_2W34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00341; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163393 CVCL_3839 LBRM-33 clone 1A5 cancer cell line house mouse CVCL_3839 CL:0000010 Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: B10.BR. Discontinued: KCLB; 28079; probable Characteristics: Produces IL2 in response to IL1 and can be used to assay IL1 activity (ATCC) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8079 21163394 CVCL_2W39 PR00366 transformed cell line bonobo/pygmy chimpanzee CVCL_2W39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00366; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163395 CVCL_3837 L6.G8.C5 transformed cell line Norway rat CVCL_3837 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male 21163396 CVCL_2W37 PR00345 finite cell line CVCL_2W37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00345; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163397 CVCL_3838 LA7 cancer cell line Norway rat CVCL_3838 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Discontinued: ECACC; 96081411; probable Female 21163398 CVCL_2W38 PR00357 finite cell line CVCL_2W38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00357; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163399 CVCL_3842 M1WT2 spontaneously immortalized cell line CVCL_3842 CL:0000010 Transfected with: RGD; 2342; Chrm1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21163400 CVCL_2W42 PR00389 finite cell line CVCL_2W42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00389; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163401 CVCL_3843 M1WT3 spontaneously immortalized cell line CVCL_3843 CL:0000010 Transfected with: RGD; 2342; Chrm1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21163402 CVCL_2W43 PR00399 finite cell line CVCL_2W43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00399; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163403 CVCL_3840 Li-7 cancer cell line human CVCL_3840 Genome ancestry: African=0%; Native American=0.93%; East Asian, North=80.68%; East Asian, South=17.95%; South Asian=0%; European, North=0.44%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel; Part of: Liver Cancer Model Repository (LIMORE) 21163404 CVCL_2W40 PR00370 finite cell line CVCL_2W40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00370; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163405 CVCL_3841 M15 [Mouse] transformed cell line house mouse CVCL_3841 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Mesonephros; Breed/subspecies: C57BL/6 x DBA/2. Unspecified 21163406 CVCL_2W41 PR00381 transformed cell line CVCL_2W41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00381; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163407 CVCL_3846 MA-104 Clone 1 spontaneously immortalized cell line CVCL_3846 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Group: Non-human primate cell line Problematic cell line: Misidentified Parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21163408 CVCL_2W46 PR00474 finite cell line CVCL_2W46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00474; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163409 CVCL_3847 MAT-Lu cancer cell line Norway rat CVCL_3847 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-4; true Male 21163410 CVCL_2W47 PR00485 finite cell line CVCL_2W47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00485; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163411 CVCL_3844 M1WT5 spontaneously immortalized cell line CVCL_3844 CL:0000010 Transfected with: RGD; 2342; Chrm1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21163412 CVCL_2W44 PR00400 transformed cell line CVCL_2W44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00400; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163413 CVCL_3845 MA-104 spontaneously immortalized cell line CVCL_3845 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-2378; true Unspecified Virology: Susceptible to infection by many viruses (arboviruses, reoviruses, rotaviruses, etc.); Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00077 Problematic cell line: Misidentified Originally thought to be of Rhesus macaque origin but found to be from African Green monkey (PubMed=4043530; PubMed=20143388) and more precisely from Chlorocebus pygerythrus (PubMed=34737324). 21163414 CVCL_2W45 PR00418 finite cell line CVCL_2W45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00418; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163415 CVCL_3848 MAT-LyLu cancer cell line Norway rat CVCL_3848 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-5; true; Discontinued: ATCC; JHU-92; true Male Doubling time: ~15 hours (DSMZ=ACC-609) 21163416 CVCL_2W48 PR00486 finite cell line CVCL_2W48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00486; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163417 CVCL_3849 MAT-LyLu-B-2 cancer cell line Norway rat CVCL_3849 CL:0000010 Breed/subspecies: Copenhagen. Male 21163418 CVCL_2W49 PR00494 finite cell line CVCL_2W49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00494; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163419 CVCL_3819 EL4.BU.OU6 cancer cell line house mouse CVCL_3819 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21163420 CVCL_2W19 PR00319 finite cell line CVCL_2W19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00319; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163421 CVCL_2W10 PR00294 finite cell line CVCL_2W10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00294; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163422 CVCL_3810 WPE1-NA22 transformed cell line human CVCL_3810 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163423 CVCL_2W13 PR00301 finite cell line CVCL_2W13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00301; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163424 CVCL_3813 WPE1-NB26 transformed cell line human CVCL_3813 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male 21163425 CVCL_2W14 PR00302 finite cell line CVCL_2W14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00302; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163426 CVCL_3814 WPMY-1 transformed cell line human CVCL_3814 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21163427 CVCL_2W11 PR00295 finite cell line CVCL_2W11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00295; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163428 CVCL_3811 WPE1-NB11 transformed cell line human CVCL_3811 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male 21163429 CVCL_2W12 PR00296 finite cell line CVCL_2W12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00296; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163430 CVCL_3812 WPE1-NB14 transformed cell line human CVCL_3812 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male 21163431 CVCL_3817 EJG spontaneously immortalized cell line CVCL_3817 CL:0000010 Derived from sampling site: Adrenal gland Cell type=Endothelial cell.. Female Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Doubling time: 4.6 days (PubMed=3927288); 110 hours (ATCC=CRL-8659) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8659 21163432 CVCL_2W17 PR00306 finite cell line CVCL_2W17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00306; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163433 CVCL_3818 EL4.BU cancer cell line house mouse CVCL_3818 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21163434 CVCL_2W18 PR00316 finite cell line CVCL_2W18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00316; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163435 CVCL_2W15 PR00303 finite cell line CVCL_2W15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00303; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163436 CVCL_3815 XP17BE finite cell line human CVCL_3815 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Asp681Asn (c.2041G>A); ClinVar=VCV000016787; Zygosity=Heterozygous (PubMed=18470933); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=18470933) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21163437 CVCL_3816 EB176 (JC) transformed cell line CVCL_3816 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Male Group: Non-human primate cell line 21163438 CVCL_2W16 PR00304 finite cell line CVCL_2W16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00304; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163439 CVCL_3820 FHM spontaneously immortalized cell line CVCL_3820 CL:0000010 Derived from sampling site: Caudal peduncle. Unspecified Group: Fish cell line 21163440 CVCL_2W20 PR00320 finite cell line CVCL_2W20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00320; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163441 CVCL_3821 G-7 spontaneously immortalized cell line house mouse CVCL_3821 CL:0000010 Derived from sampling site: Embryonic skeletal muscle Cell type=Myoblast.; Breed/subspecies: Swiss Webster. Unspecified Doubling time: ~17-19 hours (ATCC=CRL-1447) 21163442 CVCL_2W21 PR00322 finite cell line CVCL_2W21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00322; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163443 CVCL_3824 HVS-SILVA 40 transformed cell line CVCL_3824 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1773; true; Discontinued: ECACC; 90020105; probable Male Group: Non-human primate cell line 21163444 CVCL_2W24 PR00326 finite cell line CVCL_2W24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00326; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163445 CVCL_3825 IPI-1 transformed cell line pig CVCL_3825 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163446 CVCL_2W25 PR00330 finite cell line CVCL_2W25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00330; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163447 CVCL_3822 G-8 spontaneously immortalized cell line house mouse CVCL_3822 CL:0000010 Derived from sampling site: Embryonic skeletal muscle Cell type=Myoblast.; Breed/subspecies: Swiss Webster. Unspecified Doubling time: 25-27 hours (ATCC=CRL-1456) 21163448 CVCL_2W22 PR00323 finite cell line CVCL_2W22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00323; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163449 CVCL_3823 GEEP hybrid cell line CVCL_3823 CL:0000010 21163450 CVCL_2W23 PR00324 finite cell line CVCL_2W23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00324; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163451 CVCL_3828 L14 [Pig] transformed cell line pig CVCL_3828 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163452 CVCL_2W28 PR00334 finite cell line CVCL_2W28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00334; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163453 CVCL_3829 L23 transformed cell line pig CVCL_3829 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163454 CVCL_2W29 PR00335 finite cell line CVCL_2W29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00335; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163455 CVCL_3826 IPI-2I transformed cell line pig CVCL_3826 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum; Breed/subspecies: Miniature boar (d/d haplotype). Male 21163456 CVCL_2W26 PR00331 finite cell line CVCL_2W26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00331; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163457 CVCL_3827 K562/Adr cancer cell line human CVCL_3827 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Pleural effusion. Omics: SNP array analysis Discontinued: JCRB; NIHS0053; true Female 21163458 CVCL_2W27 PR00333 finite cell line CVCL_2W27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00333; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163459 CVCL_2W08 PR00292 finite cell line CVCL_2W08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00292; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163460 CVCL_3808 Wgd5 transformed cell line house mouse CVCL_3808 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: ECACC; 95082908; probable Male 21163461 CVCL_2W09 PR00293 finite cell line CVCL_2W09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00293; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163462 CVCL_3809 WIL2 S transformed cell line human CVCL_3809 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8885 21163463 CVCL_2W02 PR00282 finite cell line CVCL_2W02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00282; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163464 CVCL_3802 Tep Be finite cell line human CVCL_3802 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21163465 CVCL_2W03 PR00285 finite cell line CVCL_2W03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00285; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163466 CVCL_3803 THLE-2 transformed cell line human CVCL_3803 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10149 21163467 CVCL_2W00 PR00280 finite cell line CVCL_2W00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00280; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163468 CVCL_3800 tao BpRc1 cancer cell line house mouse CVCL_3800 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Female Characteristics: Defective in aryl hydrocarbon receptor (AhR) function Doubling time: 12-24 hours (ATCC=CRL-2218) 21163469 CVCL_2W01 PR00281 finite cell line CVCL_2W01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00281; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163470 CVCL_3801 Te39 hybridoma CVCL_3801 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8577 21163471 CVCL_2W06 PR00290 finite cell line CVCL_2W06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00290; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163472 CVCL_3806 TO 175.T undefined cell line type human CVCL_3806 HLA typing: A*01:01,32:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.27%; East Asian, North=0.13%; East Asian, South=0%; South Asian=0%; European, North=71.49%; European, South=28.11% (PubMed=30894373) CL:0000010 Derived from sampling site: Trunk; skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21163473 CVCL_2W07 PR00291 finite cell line CVCL_2W07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00291; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163474 CVCL_3807 W162 transformed cell line green monkey CVCL_3807 CL:0000010 Transformant: Adenovirus 5 [E4](NCBI-Taxonomy; 28285); Derived from sampling site: Kidney; epithelium. Discontinued: ATCC; CRL-2783; true; Discontinued: ATCC; JHU-66; true Female Group: Non-human primate cell line 21163475 CVCL_2W04 PR00288 finite cell line CVCL_2W04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00288; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163476 CVCL_3804 THLE-3 transformed cell line human CVCL_3804 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Epithelial cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11233 21163477 CVCL_2W05 PR00289 finite cell line CVCL_2W05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00289; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163478 CVCL_3805 TO 166.M finite cell line human CVCL_3805 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21163479 CVCL_MD88 BayGenomics ES cell line CSI825 embryonic stem cell house mouse CVCL_MD88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163480 CVCL_MD89 BayGenomics ES cell line CSI827 embryonic stem cell house mouse CVCL_MD89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163481 CVCL_MD86 BayGenomics ES cell line CSI823 embryonic stem cell house mouse CVCL_MD86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916882; Arhgef12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163482 CVCL_MD87 BayGenomics ES cell line CSI824 embryonic stem cell house mouse CVCL_MD87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163483 CVCL_MD84 BayGenomics ES cell line CSI809 embryonic stem cell house mouse CVCL_MD84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685031; Leo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163484 CVCL_MD85 BayGenomics ES cell line CSI812 embryonic stem cell house mouse CVCL_MD85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163485 CVCL_MD82 BayGenomics ES cell line CSI807 embryonic stem cell house mouse CVCL_MD82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104708; Cct3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163486 CVCL_MD83 BayGenomics ES cell line CSI808 embryonic stem cell house mouse CVCL_MD83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163487 CVCL_MD80 BayGenomics ES cell line CSI803 embryonic stem cell house mouse CVCL_MD80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163488 CVCL_MD81 BayGenomics ES cell line CSI804 embryonic stem cell house mouse CVCL_MD81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101884; Ppard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163489 CVCL_MD99 BayGenomics ES cell line CSI870 embryonic stem cell house mouse CVCL_MD99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105071; Rab4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163490 CVCL_MD97 BayGenomics ES cell line CSI865 embryonic stem cell house mouse CVCL_MD97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101757; Cfl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163491 CVCL_MD98 BayGenomics ES cell line CSI867 embryonic stem cell house mouse CVCL_MD98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163492 CVCL_MD95 BayGenomics ES cell line CSI862 embryonic stem cell house mouse CVCL_MD95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163493 CVCL_MD96 BayGenomics ES cell line CSI864 embryonic stem cell house mouse CVCL_MD96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163494 CVCL_MD93 BayGenomics ES cell line CSI853 embryonic stem cell house mouse CVCL_MD93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673855; Bicral Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163495 CVCL_MD94 BayGenomics ES cell line CSI858 embryonic stem cell house mouse CVCL_MD94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163496 CVCL_MD91 BayGenomics ES cell line CSI843 embryonic stem cell house mouse CVCL_MD91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163497 CVCL_MD92 BayGenomics ES cell line CSI845 embryonic stem cell house mouse CVCL_MD92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163498 CVCL_MD90 BayGenomics ES cell line CSI829 embryonic stem cell house mouse CVCL_MD90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163499 CVCL_DL07 CW50120 induced pluripotent stem cell human CVCL_DL07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50120; true Male 21163500 CVCL_DL08 CW50121 induced pluripotent stem cell human CVCL_DL08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50121; true Male 21163501 CVCL_DL05 CW50114 induced pluripotent stem cell human CVCL_DL05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50114; true Female 21163502 CVCL_DL06 CW50118 induced pluripotent stem cell human CVCL_DL06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50118; true Female 21163503 CVCL_DL09 CW50122 induced pluripotent stem cell human CVCL_DL09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50122; true Male 21163504 CVCL_DL00 CW50104 induced pluripotent stem cell human CVCL_DL00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50104; true Male 21163505 CVCL_DL03 CW50109 induced pluripotent stem cell human CVCL_DL03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50109; true Male 21163506 CVCL_DL04 CW50111 induced pluripotent stem cell human CVCL_DL04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50111; true Male 21163507 CVCL_DL01 CW50106 induced pluripotent stem cell human CVCL_DL01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50106; true Female 21163508 CVCL_DL02 CW50107 induced pluripotent stem cell human CVCL_DL02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50107; true Male 21163509 CVCL_DL18 CW60029 induced pluripotent stem cell human CVCL_DL18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW60029; true. Female 21163510 CVCL_DL19 CW60034 induced pluripotent stem cell human CVCL_DL19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60034; true. Male 21163511 CVCL_DL16 CW60018 induced pluripotent stem cell human CVCL_DL16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60018; true Male 21163512 CVCL_DL17 CW60024 induced pluripotent stem cell human CVCL_DL17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60024; true Female 21163513 CVCL_DL10 CW50126 induced pluripotent stem cell human CVCL_DL10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Native North American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50126; true Male 21163514 CVCL_DL11 CW50127 induced pluripotent stem cell human CVCL_DL11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50127; true Female 21163515 CVCL_DL14 CW60013 induced pluripotent stem cell human CVCL_DL14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60013; true Female 21163516 CVCL_DL15 CW60014 induced pluripotent stem cell human CVCL_DL15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60014; true Male 21163517 CVCL_DL12 CW60001 induced pluripotent stem cell human CVCL_DL12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60001; true Female 21163518 CVCL_DL13 CW60002 induced pluripotent stem cell human CVCL_DL13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW60002; true. Female 21163519 CVCL_3992 KOCL-44 cancer cell line human CVCL_3992 CL:0000010 Population: Japanese. Female 21163520 CVCL_2X92 PR01168 finite cell line CVCL_2X92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01168; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163521 CVCL_3993 KOCL-45 cancer cell line human CVCL_3993 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Male 21163522 CVCL_2X93 PR01169 finite cell line CVCL_2X93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01169; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163523 CVCL_3990 J-96 cancer cell line human CVCL_3990 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00068 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=1246601; PubMed=4472134; PubMed=20143388). Originally thought to originate from a 29 year old male patient with subacute monocytic leukemia. 21163524 CVCL_2X90 PR01162 finite cell line CVCL_2X90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01162; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163525 CVCL_3991 KOCL-33 cancer cell line human CVCL_3991 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7134; MLLT1; Name(s)=KMT2A-MLLT1, MLL-MLLT1; MLL-ENL (PubMed=14671638; PubMed=15843827). Population: Japanese Female 21163526 CVCL_2X91 PR01163 finite cell line CVCL_2X91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01163; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163527 CVCL_3996 KKU-100 cancer cell line human CVCL_3996 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=29110582; DepMap) Population: Southeast Asian; Thai Omics: Deep exome analysis. Female Doubling time: ~72 hours (PubMed=15948244) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163528 CVCL_2X96 PR01182 finite cell line CVCL_2X96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01182; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163529 CVCL_3997 M5076 cancer cell line house mouse CVCL_3997 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: KCLB; 80019; probable Female 21163530 CVCL_2X97 PR01190 finite cell line CVCL_2X97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01190; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163531 CVCL_3994 KOCL-58 cancer cell line human CVCL_3994 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638). Population: Japanese Male 21163532 CVCL_2X94 PR01171 finite cell line CVCL_2X94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01171; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163533 CVCL_3995 KOCL-69 cancer cell line human CVCL_3995 CL:0000010 Sequence variation: Gene fusion; HGNC; 7135; AFF1 + HGNC; 7132; KMT2A; Name(s)=KMT2A-AFF1, MLL-AFF1, ALL-1/AF4 (PubMed=14671638); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Female 21163534 CVCL_2X95 PR01179 finite cell line CVCL_2X95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01179; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163535 CVCL_2X98 PR01193 finite cell line CVCL_2X98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01193; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163536 CVCL_3999 MM5MTC cancer cell line house mouse CVCL_3999 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/Crgl. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21163537 CVCL_2X99 PR01197 finite cell line CVCL_2X99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01197; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163538 CVCL_3970 NCI-H1264 cancer cell line human CVCL_3970 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from autologous cell line NCI-H157); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=1311061; PubMed=12068308); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (PubMed=1311061) Discontinued: ATCC; CRL-5860; true; Discontinued: KCLB; 91264; probable. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00410 Problematic cell line: Contaminated NCI-H157 and NCI-H1264 have been shown to be identical. 21163539 CVCL_2X70 PR01099 finite cell line CVCL_2X70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01099; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163540 CVCL_3971 NCI-H1334 cancer cell line human CVCL_3971 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Asp (c.672G>C); ClinVar=VCV001493447; Zygosity=Unspecified (PubMed=1311061) Derived from sampling site: Lung Cell type=Club cell.. Discontinued: ATCC; CRL-5863; true Male Problematic cell line: Probably contaminated The STR profile is identical to that of the NCI-H322 cell line. Originally thought to originate from a 56 year old male patient with a large cell lung carcinoma. 21163541 CVCL_2X71 PR01103 finite cell line CVCL_2X71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01103; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163542 CVCL_3974 Mel249 cancer cell line human CVCL_3974 CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asn62Argfs (c.184_185delAT); Zygosity=Unspecified (PubMed=16740750) Derived from metastatic site: Not specified. Unspecified 21163543 CVCL_2X74 PR01107 finite cell line CVCL_2X74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01107; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163544 CVCL_3975 Mel499 cancer cell line human CVCL_3975 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21163545 CVCL_2X75 PR01110 finite cell line CVCL_2X75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01110; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163546 CVCL_3972 NCI-H1684 cancer cell line human CVCL_3972 CL:0000010 Male 21163547 CVCL_2X72 PR01105 finite cell line CVCL_2X72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01105; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163548 CVCL_2X73 PR01106 finite cell line CVCL_2X73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01106; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163549 CVCL_3978 Mel Ei cancer cell line human CVCL_3978 CL:0000010 Derived from sampling site: Skin. Female 21163550 CVCL_2X78 PR01131 finite cell line CVCL_2X78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01131; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163551 CVCL_3979 Mel Ju cancer cell line human CVCL_3979 CL:0000010 Derived from metastatic site: Not specified. 21163552 CVCL_2X79 PR01134 finite cell line CVCL_2X79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01134; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163553 CVCL_3976 Mel505 cancer cell line human CVCL_3976 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Homozygous (PubMed=16740750) Derived from metastatic site: Not specified. Female 21163554 CVCL_2X76 PR01119 finite cell line CVCL_2X76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01119; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163555 CVCL_3977 Mel592 cancer cell line human CVCL_3977 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Homozygous (PubMed=16740750) Derived from metastatic site: Lymph node. Male 21163556 CVCL_2X77 PR01126 finite cell line CVCL_2X77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01126; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163557 CVCL_3981 Mel Wei cancer cell line human CVCL_3981 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00145 Problematic cell line: Misidentified/contaminated Shown to be identical to MEL-Ho. This cell line was reported to be isogenic with LCL-Wei (Cellosaurus=CVCL_1869) but it does not have the same STR profile (PubMed=10508494; PubMed=20143388). 21163558 CVCL_2X81 PR01143 finite cell line CVCL_2X81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01143; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163559 CVCL_3982 33B cancer cell line Norway rat CVCL_3982 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: Wistar Furth. 21163560 CVCL_2X82 PR01144 finite cell line CVCL_2X82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01144; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163561 CVCL_3980 Mel Im cancer cell line human CVCL_3980 CL:0000010 Derived from metastatic site: Not specified. 21163562 CVCL_2X80 PR01137 finite cell line CVCL_2X80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01137; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163563 CVCL_3985 BON-1 cancer cell line human CVCL_3985 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (PubMed=29444910); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (PubMed=29444910); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (PubMed=25612765; PubMed=29444910); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg1329His (c.3986G>A); ClinVar=VCV000041738; Zygosity=Unspecified (PubMed=25612765) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis Male Doubling time: 1.5 +- 0.4 days (PubMed=29330294); 46 +- 0.72 hours (PubMed=32884006) 21163564 CVCL_2X85 PR01152 finite cell line CVCL_2X85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01152; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163565 CVCL_3986 C108 [Mouse lung carcinoma] cancer cell line house mouse CVCL_3986 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. 21163566 CVCL_2X86 PR01154 finite cell line CVCL_2X86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01154; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163567 CVCL_3983 416B transformed cell line house mouse CVCL_3983 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6 x DBA/2. Discontinued: ECACC; 85061103; probable Female Part of: ENCODE project mouse cell lines 21163568 CVCL_2X83 PR01149 finite cell line CVCL_2X83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01149; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163569 CVCL_3984 A-9 spontaneously immortalized cell line house mouse CVCL_3984 CL:0000010 Miscellaneous: ECACC has two catalogue entries for A-9 which differ in that they were deposited by different groups: A9 (ECACC 85011426) and A9 (Hamprecht) (ECACC 08062526) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Doubling time: ~1 day (lot 07122006) (JCRB) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21163570 CVCL_2X84 PR01150 finite cell line CVCL_2X84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01150; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163571 CVCL_3989 HGF [Human gingival] finite cell line human CVCL_3989 CL:0000010 Derived from sampling site: Oral cavity; gingiva. 21163572 CVCL_2X89 PR01161 finite cell line CVCL_2X89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01161; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163573 CVCL_3987 CGR8 embryonic stem cell house mouse CVCL_3987 CL:0000010 Breed/subspecies: 129P2/Ola. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 95011018; probable Male 21163574 CVCL_2X87 PR01159 finite cell line CVCL_2X87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01159; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163575 CVCL_3988 FLC clone 745 cancer cell line house mouse CVCL_3988 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21163576 CVCL_2X88 PR01160 finite cell line CVCL_2X88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01160; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163577 CVCL_MF24 BayGenomics ES cell line CSJ270 embryonic stem cell house mouse CVCL_MF24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450166; Arhgap32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163578 CVCL_MF25 BayGenomics ES cell line CSJ274 embryonic stem cell house mouse CVCL_MF25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921417; Nudt9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163579 CVCL_MF22 BayGenomics ES cell line CSJ266 embryonic stem cell house mouse CVCL_MF22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163580 CVCL_MF23 BayGenomics ES cell line CSJ267 embryonic stem cell house mouse CVCL_MF23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384294; Rbm47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163581 CVCL_MF20 BayGenomics ES cell line CSJ259 embryonic stem cell house mouse CVCL_MF20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163582 CVCL_MF21 BayGenomics ES cell line CSJ260 embryonic stem cell house mouse CVCL_MF21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103306; Tiam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163583 CVCL_DL87 CW70098 induced pluripotent stem cell human CVCL_DL87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70098; true Male 21163584 CVCL_DL88 CW70102 induced pluripotent stem cell human CVCL_DL88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70102; true Female 21163585 CVCL_DL85 CW70084 induced pluripotent stem cell human CVCL_DL85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70084; true; Discontinued: FCDI; CW70084; probable. Female 21163586 CVCL_DL86 CW70085 induced pluripotent stem cell human CVCL_DL86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70085; true Male 21163587 CVCL_DL89 CW70105 induced pluripotent stem cell human CVCL_DL89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70105; true Female 21163588 CVCL_DL80 CW70059 induced pluripotent stem cell human CVCL_DL80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70059; true Female 21163589 CVCL_MF19 BayGenomics ES cell line CSJ257 embryonic stem cell house mouse CVCL_MF19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107940; Ezh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163590 CVCL_MF17 BayGenomics ES cell line CSJ251 embryonic stem cell house mouse CVCL_MF17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261856; Ankle2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163591 CVCL_DL83 CW70072 induced pluripotent stem cell human CVCL_DL83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70072; true Female 21163592 CVCL_MF18 BayGenomics ES cell line CSJ252 embryonic stem cell house mouse CVCL_MF18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261856; Ankle2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163593 CVCL_DL84 CW70083 induced pluripotent stem cell human CVCL_DL84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70083; true. Female 21163594 CVCL_MF15 BayGenomics ES cell line CSJ248 embryonic stem cell house mouse CVCL_MF15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926033; Brpf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163595 CVCL_DL81 CW70064 induced pluripotent stem cell human CVCL_DL81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70064; true Male 21163596 CVCL_MF16 BayGenomics ES cell line CSJ249 embryonic stem cell house mouse CVCL_MF16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914099; Ppp1r2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163597 CVCL_DL82 CW70066 induced pluripotent stem cell human CVCL_DL82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70066; true Female 21163598 CVCL_MF35 BayGenomics ES cell line CSJ300 embryonic stem cell house mouse CVCL_MF35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163599 CVCL_MF36 BayGenomics ES cell line CSJ301 embryonic stem cell house mouse CVCL_MF36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444114; Zcchc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163600 CVCL_MF33 BayGenomics ES cell line CSJ293 embryonic stem cell house mouse CVCL_MF33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163601 CVCL_MF34 BayGenomics ES cell line CSJ295 embryonic stem cell house mouse CVCL_MF34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163602 CVCL_MF31 BayGenomics ES cell line CSJ288 embryonic stem cell house mouse CVCL_MF31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163603 CVCL_MF32 BayGenomics ES cell line CSJ291 embryonic stem cell house mouse CVCL_MF32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163604 CVCL_MF30 BayGenomics ES cell line CSJ287 embryonic stem cell house mouse CVCL_MF30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336155; Lss Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163605 CVCL_DL98 CW70124 induced pluripotent stem cell human CVCL_DL98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70124; true Female 21163606 CVCL_DL99 CW70133 induced pluripotent stem cell human CVCL_DL99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70133; true Female 21163607 CVCL_DL96 CW70114 induced pluripotent stem cell human CVCL_DL96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70114; true Female 21163608 CVCL_DL97 CW70118 induced pluripotent stem cell human CVCL_DL97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70118; true Female 21163609 CVCL_DL90 CW70107 induced pluripotent stem cell human CVCL_DL90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70107; true Female 21163610 CVCL_DL91 CW70108 induced pluripotent stem cell human CVCL_DL91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70108; true Male 21163611 CVCL_MF28 BayGenomics ES cell line CSJ285 embryonic stem cell house mouse CVCL_MF28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88262; Cap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163612 CVCL_DL94 CW70111 induced pluripotent stem cell human CVCL_DL94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70111; true Female 21163613 CVCL_MF29 BayGenomics ES cell line CSJ286 embryonic stem cell house mouse CVCL_MF29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163614 CVCL_DL95 CW70112 induced pluripotent stem cell human CVCL_DL95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70112; true Male 21163615 CVCL_MF26 BayGenomics ES cell line CSJ276 embryonic stem cell house mouse CVCL_MF26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922816; Ing5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163616 CVCL_DL92 CW70109 induced pluripotent stem cell human CVCL_DL92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70109; true Female 21163617 CVCL_MF27 BayGenomics ES cell line CSJ279 embryonic stem cell house mouse CVCL_MF27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922246; Usp47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163618 CVCL_DL93 CW70110 induced pluripotent stem cell human CVCL_DL93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70110; true Female 21163619 CVCL_MF02 BayGenomics ES cell line CSJ219 embryonic stem cell house mouse CVCL_MF02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105047; Psmc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163620 CVCL_MF03 BayGenomics ES cell line CSJ220 embryonic stem cell house mouse CVCL_MF03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916334; Fam207a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163621 CVCL_MF00 BayGenomics ES cell line CSJ217 embryonic stem cell house mouse CVCL_MF00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385207; Gnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163622 CVCL_MF01 BayGenomics ES cell line CSJ218 embryonic stem cell house mouse CVCL_MF01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163623 CVCL_DL65 CW60272 induced pluripotent stem cell human CVCL_DL65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60272; true Female 21163624 CVCL_DL66 CW70009 induced pluripotent stem cell human CVCL_DL66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70009; true. Female 21163625 CVCL_DL63 CW60264 induced pluripotent stem cell human CVCL_DL63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60264; true Female 21163626 CVCL_DL64 CW60269 induced pluripotent stem cell human CVCL_DL64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60269; true Female 21163627 CVCL_DL69 CW70016 induced pluripotent stem cell human CVCL_DL69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70016; true. Female 21163628 CVCL_DL67 CW70010 induced pluripotent stem cell human CVCL_DL67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70010; true; Discontinued: FCDI; CW70010; probable. Female 21163629 CVCL_DL68 CW70011 induced pluripotent stem cell human CVCL_DL68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70011; true. Male 21163630 CVCL_DL61 CW60237 induced pluripotent stem cell human CVCL_DL61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60237; true Female 21163631 CVCL_DL62 CW60239 induced pluripotent stem cell human CVCL_DL62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60239; true Female 21163632 CVCL_DL60 CW60236 induced pluripotent stem cell human CVCL_DL60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60236; true Female 21163633 CVCL_MF13 BayGenomics ES cell line CSJ240 embryonic stem cell house mouse CVCL_MF13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930134; Ern1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163634 CVCL_MF14 BayGenomics ES cell line CSJ243 embryonic stem cell house mouse CVCL_MF14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927110; Tmem131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163635 CVCL_MF11 BayGenomics ES cell line CSJ235 embryonic stem cell house mouse CVCL_MF11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163636 CVCL_MF12 BayGenomics ES cell line CSJ238 embryonic stem cell house mouse CVCL_MF12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179381; Prpf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163637 CVCL_MF10 BayGenomics ES cell line CSJ233 embryonic stem cell house mouse CVCL_MF10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99204; Zfp57 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163638 CVCL_DL76 CW70032 induced pluripotent stem cell human CVCL_DL76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70032; true. Female 21163639 CVCL_DL77 CW70041 induced pluripotent stem cell human CVCL_DL77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70041; true Female 21163640 CVCL_DL74 CW70030 induced pluripotent stem cell human CVCL_DL74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70030; true. Male 21163641 CVCL_DL75 CW70031 induced pluripotent stem cell human CVCL_DL75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70031; true; Discontinued: FCDI; CW70031; probable. Male 21163642 CVCL_DL78 CW70047 induced pluripotent stem cell human CVCL_DL78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70047; true Female 21163643 CVCL_DL79 CW70057 induced pluripotent stem cell human CVCL_DL79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70057; true Female 21163644 CVCL_MF08 BayGenomics ES cell line CSJ231 embryonic stem cell house mouse CVCL_MF08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163645 CVCL_MF09 BayGenomics ES cell line CSJ232 embryonic stem cell house mouse CVCL_MF09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915127; Naa20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163646 CVCL_MF06 BayGenomics ES cell line CSJ226 embryonic stem cell house mouse CVCL_MF06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163647 CVCL_DL72 CW70028 induced pluripotent stem cell human CVCL_DL72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70028; true. Male 21163648 CVCL_MF07 BayGenomics ES cell line CSJ227 embryonic stem cell house mouse CVCL_MF07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336880; Eftud2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163649 CVCL_DL73 CW70029 induced pluripotent stem cell human CVCL_DL73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70029; true. Male 21163650 CVCL_MF04 BayGenomics ES cell line CSJ221 embryonic stem cell house mouse CVCL_MF04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923990; Efr3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163651 CVCL_DL70 CW70021 induced pluripotent stem cell human CVCL_DL70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70021; true. Male 21163652 CVCL_MF05 BayGenomics ES cell line CSJ222 embryonic stem cell house mouse CVCL_MF05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924550; Raph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163653 CVCL_DL71 CW70022 induced pluripotent stem cell human CVCL_DL71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic Discontinued: Coriell; CW70022; true. Female 21163654 CVCL_DL49 CW60187 induced pluripotent stem cell human CVCL_DL49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60187; true Male 21163655 CVCL_DL43 CW60136 induced pluripotent stem cell human CVCL_DL43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60136; true Male 21163656 CVCL_DL44 CW60141 induced pluripotent stem cell human CVCL_DL44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60141; true Male 21163657 CVCL_DL41 CW60133 induced pluripotent stem cell human CVCL_DL41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60133; true Female 21163658 CVCL_DL42 CW60134 induced pluripotent stem cell human CVCL_DL42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60134; true Female 21163659 CVCL_DL47 CW60164 induced pluripotent stem cell human CVCL_DL47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60164; true Female 21163660 CVCL_DL48 CW60171 induced pluripotent stem cell human CVCL_DL48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60171; true Male 21163661 CVCL_DL45 CW60142 induced pluripotent stem cell human CVCL_DL45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60142; true Male 21163662 CVCL_DL46 CW60161 induced pluripotent stem cell human CVCL_DL46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60161; true Male 21163663 CVCL_DL40 CW60132 induced pluripotent stem cell human CVCL_DL40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60132; true Female 21163664 CVCL_DL54 CW60221 induced pluripotent stem cell human CVCL_DL54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60221; true Female 21163665 CVCL_DL55 CW60222 induced pluripotent stem cell human CVCL_DL55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60222; true Female 21163666 CVCL_DL52 CW60219 induced pluripotent stem cell human CVCL_DL52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60219; true Male 21163667 CVCL_DL53 CW60220 induced pluripotent stem cell human CVCL_DL53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60220; true Male 21163668 CVCL_DL58 CW60232 induced pluripotent stem cell human CVCL_DL58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60232; true Male 21163669 CVCL_DL59 CW60234 induced pluripotent stem cell human CVCL_DL59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60234; true; Discontinued: FCDI; CW60234; probable Male 21163670 CVCL_DL56 CW60226 induced pluripotent stem cell human CVCL_DL56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60226; true Female 21163671 CVCL_DL57 CW60230 induced pluripotent stem cell human CVCL_DL57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60230; true Female 21163672 CVCL_DL50 CW60214 induced pluripotent stem cell human CVCL_DL50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60214; true Male 21163673 CVCL_DL51 CW60217 induced pluripotent stem cell human CVCL_DL51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60217; true Male 21163674 CVCL_DL29 CW60089 induced pluripotent stem cell human CVCL_DL29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60089; true. Female 21163675 CVCL_DL27 CW60060 induced pluripotent stem cell human CVCL_DL27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60060; true. Female 21163676 CVCL_DL28 CW60083 induced pluripotent stem cell human CVCL_DL28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60083; true Female 21163677 CVCL_DL21 CW60045 induced pluripotent stem cell human CVCL_DL21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60045; true Female 21163678 CVCL_DL22 CW60046 induced pluripotent stem cell human CVCL_DL22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60046; true; Discontinued: FCDI; CW60046; probable Female 21163679 CVCL_DL20 CW60040 induced pluripotent stem cell human CVCL_DL20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of CW60039 (Cellosaurus=CVCL_4S52) Discontinued: Coriell; CW60040; true. Male 21163680 CVCL_DL25 CW60055 induced pluripotent stem cell human CVCL_DL25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60055; true. Male 21163681 CVCL_DL26 CW60056 induced pluripotent stem cell human CVCL_DL26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60056; true Female 21163682 CVCL_DL23 CW60048 induced pluripotent stem cell human CVCL_DL23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60048; true Female 21163683 CVCL_DL24 CW60049 induced pluripotent stem cell human CVCL_DL24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60049; true Female 21163684 CVCL_DL38 CW60123 induced pluripotent stem cell human CVCL_DL38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60123; true Female 21163685 CVCL_DL39 CW60130 induced pluripotent stem cell human CVCL_DL39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60130; true Female 21163686 CVCL_DL32 CW60108 induced pluripotent stem cell human CVCL_DL32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60108; true Male 21163687 CVCL_DL33 CW60110 induced pluripotent stem cell human CVCL_DL33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60110; true Male 21163688 CVCL_DL30 CW60097 induced pluripotent stem cell human CVCL_DL30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60097; true. Female 21163689 CVCL_DL31 CW60098 induced pluripotent stem cell human CVCL_DL31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60098; true Male 21163690 CVCL_DL36 CW60119 induced pluripotent stem cell human CVCL_DL36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60119; true Male 21163691 CVCL_DL37 CW60122 induced pluripotent stem cell human CVCL_DL37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60122; true Male 21163692 CVCL_DL34 CW60111 induced pluripotent stem cell human CVCL_DL34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60111; true Male 21163693 CVCL_DL35 CW60118 induced pluripotent stem cell human CVCL_DL35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60118; true Male 21163694 CVCL_ME89 BayGenomics ES cell line CSJ197 embryonic stem cell house mouse CVCL_ME89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342283; Slc12a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163695 CVCL_ME87 BayGenomics ES cell line CSJ191 embryonic stem cell house mouse CVCL_ME87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163696 CVCL_ME88 BayGenomics ES cell line CSJ195 embryonic stem cell house mouse CVCL_ME88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924393; Trip11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163697 CVCL_ME85 BayGenomics ES cell line CSJ186 embryonic stem cell house mouse CVCL_ME85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924393; Trip11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163698 CVCL_ME86 BayGenomics ES cell line CSJ188 embryonic stem cell house mouse CVCL_ME86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780102; Gm9694 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163699 CVCL_ME83 BayGenomics ES cell line CSJ184 embryonic stem cell house mouse CVCL_ME83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163700 CVCL_ME84 BayGenomics ES cell line CSJ185 embryonic stem cell house mouse CVCL_ME84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354742; Synrg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163701 CVCL_ME81 BayGenomics ES cell line CSJ181 embryonic stem cell house mouse CVCL_ME81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913809; Metap1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163702 CVCL_ME82 BayGenomics ES cell line CSJ183 embryonic stem cell house mouse CVCL_ME82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916175; Rpap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163703 CVCL_ME80 BayGenomics ES cell line CSJ180 embryonic stem cell house mouse CVCL_ME80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163704 CVCL_ME98 BayGenomics ES cell line CSJ214 embryonic stem cell house mouse CVCL_ME98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163705 CVCL_ME99 BayGenomics ES cell line CSJ215 embryonic stem cell house mouse CVCL_ME99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101884; Ppard Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163706 CVCL_ME96 BayGenomics ES cell line CSJ211 embryonic stem cell house mouse CVCL_ME96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921285; Nol9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163707 CVCL_ME97 BayGenomics ES cell line CSJ213 embryonic stem cell house mouse CVCL_ME97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163708 CVCL_ME94 BayGenomics ES cell line CSJ208 embryonic stem cell house mouse CVCL_ME94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916960; Arap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163709 CVCL_ME95 BayGenomics ES cell line CSJ210 embryonic stem cell house mouse CVCL_ME95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915206; Kmt5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163710 CVCL_ME92 BayGenomics ES cell line CSJ202 embryonic stem cell house mouse CVCL_ME92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163711 CVCL_ME93 BayGenomics ES cell line CSJ204 embryonic stem cell house mouse CVCL_ME93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163712 CVCL_ME90 BayGenomics ES cell line CSJ200 embryonic stem cell house mouse CVCL_ME90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163713 CVCL_ME91 BayGenomics ES cell line CSJ201 embryonic stem cell house mouse CVCL_ME91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163714 CVCL_ME69 BayGenomics ES cell line CSJ160 embryonic stem cell house mouse CVCL_ME69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163715 CVCL_ME67 BayGenomics ES cell line CSJ156 embryonic stem cell house mouse CVCL_ME67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163716 CVCL_ME68 BayGenomics ES cell line CSJ158 embryonic stem cell house mouse CVCL_ME68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163717 CVCL_ME65 BayGenomics ES cell line CSJ152 embryonic stem cell house mouse CVCL_ME65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163718 CVCL_ME66 BayGenomics ES cell line CSJ153 embryonic stem cell house mouse CVCL_ME66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163719 CVCL_ME63 BayGenomics ES cell line CSJ150 embryonic stem cell house mouse CVCL_ME63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163720 CVCL_ME64 BayGenomics ES cell line CSJ151 embryonic stem cell house mouse CVCL_ME64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106505; Zmym6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163721 CVCL_ME61 BayGenomics ES cell line CSJ147 embryonic stem cell house mouse CVCL_ME61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98299; Shmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163722 CVCL_ME62 BayGenomics ES cell line CSJ148 embryonic stem cell house mouse CVCL_ME62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858683; Copg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163723 CVCL_ME60 BayGenomics ES cell line CSJ145 embryonic stem cell house mouse CVCL_ME60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163724 CVCL_ME78 BayGenomics ES cell line CSJ178 embryonic stem cell house mouse CVCL_ME78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934919; Rnf111 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163725 CVCL_ME79 BayGenomics ES cell line CSJ179 embryonic stem cell house mouse CVCL_ME79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096572; Zfand3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163726 CVCL_ME76 BayGenomics ES cell line CSJ176 embryonic stem cell house mouse CVCL_ME76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163727 CVCL_ME77 BayGenomics ES cell line CSJ177 embryonic stem cell house mouse CVCL_ME77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384993; Paip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163728 CVCL_ME74 BayGenomics ES cell line CSJ173 embryonic stem cell house mouse CVCL_ME74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342283; Slc12a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163729 CVCL_ME75 BayGenomics ES cell line CSJ174 embryonic stem cell house mouse CVCL_ME75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163730 CVCL_ME72 BayGenomics ES cell line CSJ166 embryonic stem cell house mouse CVCL_ME72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163731 CVCL_ME73 BayGenomics ES cell line CSJ167 embryonic stem cell house mouse CVCL_ME73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351638; Mkln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163732 CVCL_ME70 BayGenomics ES cell line CSJ163 embryonic stem cell house mouse CVCL_ME70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914304; Paics Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163733 CVCL_ME71 BayGenomics ES cell line CSJ165 embryonic stem cell house mouse CVCL_ME71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921455; Acsl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163734 CVCL_ME47 BayGenomics ES cell line CSJ108 embryonic stem cell house mouse CVCL_ME47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95659; Gas5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163735 CVCL_ME48 BayGenomics ES cell line CSJ114 embryonic stem cell house mouse CVCL_ME48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163736 CVCL_ME45 BayGenomics ES cell line CSJ102 embryonic stem cell house mouse CVCL_ME45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163737 CVCL_ME46 BayGenomics ES cell line CSJ106 embryonic stem cell house mouse CVCL_ME46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107637; Psmb7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163738 CVCL_ME43 BayGenomics ES cell line CSJ099 embryonic stem cell house mouse CVCL_ME43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100865; Rbm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163739 CVCL_ME44 BayGenomics ES cell line CSJ101 embryonic stem cell house mouse CVCL_ME44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163740 CVCL_ME41 BayGenomics ES cell line CSJ096 embryonic stem cell house mouse CVCL_ME41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643401; Gm8935 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163741 CVCL_ME42 BayGenomics ES cell line CSJ097 embryonic stem cell house mouse CVCL_ME42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163742 CVCL_ME40 BayGenomics ES cell line CSJ092 embryonic stem cell house mouse CVCL_ME40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917394; Lrch3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163743 CVCL_ME38 BayGenomics ES cell line CSJ088 embryonic stem cell house mouse CVCL_ME38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163744 CVCL_ME39 BayGenomics ES cell line CSJ090 embryonic stem cell house mouse CVCL_ME39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930751; Trpc4ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163745 CVCL_ME58 BayGenomics ES cell line CSJ140 embryonic stem cell house mouse CVCL_ME58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859637; Nphs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163746 CVCL_ME59 BayGenomics ES cell line CSJ144 embryonic stem cell house mouse CVCL_ME59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163747 CVCL_ME56 BayGenomics ES cell line CSJ137 embryonic stem cell house mouse CVCL_ME56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163748 CVCL_ME57 BayGenomics ES cell line CSJ139 embryonic stem cell house mouse CVCL_ME57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163749 CVCL_ME54 BayGenomics ES cell line CSJ134 embryonic stem cell house mouse CVCL_ME54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929760; Cdc42ep4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163750 CVCL_ME55 BayGenomics ES cell line CSJ136 embryonic stem cell house mouse CVCL_ME55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346877; Map3k7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163751 CVCL_ME52 BayGenomics ES cell line CSJ127 embryonic stem cell house mouse CVCL_ME52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916960; Arap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163752 CVCL_ME53 BayGenomics ES cell line CSJ130 embryonic stem cell house mouse CVCL_ME53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163753 CVCL_ME50 BayGenomics ES cell line CSJ117 embryonic stem cell house mouse CVCL_ME50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894676; Mast2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163754 CVCL_ME51 BayGenomics ES cell line CSJ126 embryonic stem cell house mouse CVCL_ME51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921358; Parn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163755 CVCL_ME49 BayGenomics ES cell line CSJ115 embryonic stem cell house mouse CVCL_ME49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163756 CVCL_ME25 BayGenomics ES cell line CSJ057 embryonic stem cell house mouse CVCL_ME25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682334; Smg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163757 CVCL_ME26 BayGenomics ES cell line CSJ060 embryonic stem cell house mouse CVCL_ME26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99961; Usf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163758 CVCL_ME23 BayGenomics ES cell line CSJ051 embryonic stem cell house mouse CVCL_ME23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163759 CVCL_ME24 BayGenomics ES cell line CSJ053 embryonic stem cell house mouse CVCL_ME24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163760 CVCL_ME21 BayGenomics ES cell line CSJ046 embryonic stem cell house mouse CVCL_ME21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923520; Cyrib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163761 CVCL_ME22 BayGenomics ES cell line CSJ048 embryonic stem cell house mouse CVCL_ME22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163762 CVCL_ME20 BayGenomics ES cell line CSJ043 embryonic stem cell house mouse CVCL_ME20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934811; Nucks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163763 CVCL_DK88 CW50067 induced pluripotent stem cell human CVCL_DK88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50067; true Male 21163764 CVCL_DK89 CW50069 induced pluripotent stem cell human CVCL_DK89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50069; true Female 21163765 CVCL_DK86 CW50065 induced pluripotent stem cell human CVCL_DK86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50065; true Female 21163766 CVCL_DK87 CW50066 induced pluripotent stem cell human CVCL_DK87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50066; true Male 21163767 CVCL_DK80 CW50059 induced pluripotent stem cell human CVCL_DK80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50059; true Female 21163768 CVCL_DK81 CW50060 induced pluripotent stem cell human CVCL_DK81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50060; true Male 21163769 CVCL_ME18 BayGenomics ES cell line CSJ041 embryonic stem cell house mouse CVCL_ME18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915202; Tomm20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163770 CVCL_DK84 CW50063 induced pluripotent stem cell human CVCL_DK84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50063; true Male 21163771 CVCL_ME19 BayGenomics ES cell line CSJ042 embryonic stem cell house mouse CVCL_ME19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88016; Ampd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163772 CVCL_DK85 CW50064 induced pluripotent stem cell human CVCL_DK85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50064; true Male 21163773 CVCL_ME16 BayGenomics ES cell line CSJ039 embryonic stem cell house mouse CVCL_ME16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163774 CVCL_DK82 CW50061 induced pluripotent stem cell human CVCL_DK82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50061; true Male 21163775 CVCL_ME17 BayGenomics ES cell line CSJ040 embryonic stem cell house mouse CVCL_ME17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036237; Rsbn1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163776 CVCL_DK83 CW50062 induced pluripotent stem cell human CVCL_DK83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50062; true Female 21163777 CVCL_ME36 BayGenomics ES cell line CSJ084 embryonic stem cell house mouse CVCL_ME36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163778 CVCL_ME37 BayGenomics ES cell line CSJ087 embryonic stem cell house mouse CVCL_ME37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859615; Otud5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163779 CVCL_ME34 BayGenomics ES cell line CSJ080 embryonic stem cell house mouse CVCL_ME34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163780 CVCL_ME35 BayGenomics ES cell line CSJ083 embryonic stem cell house mouse CVCL_ME35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386251; Eif3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163781 CVCL_ME32 BayGenomics ES cell line CSJ078 embryonic stem cell house mouse CVCL_ME32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336880; Eftud2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163782 CVCL_ME33 BayGenomics ES cell line CSJ079 embryonic stem cell house mouse CVCL_ME33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930134; Ern1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163783 CVCL_ME30 BayGenomics ES cell line CSJ075 embryonic stem cell house mouse CVCL_ME30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1335094; Septin7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163784 CVCL_ME31 BayGenomics ES cell line CSJ077 embryonic stem cell house mouse CVCL_ME31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919224; Prmt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163785 CVCL_DK99 CW50099 induced pluripotent stem cell human CVCL_DK99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50099; true Female 21163786 CVCL_DK97 CW50095 induced pluripotent stem cell human CVCL_DK97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50095; true Male 21163787 CVCL_DK98 CW50097 induced pluripotent stem cell human CVCL_DK98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50097; true Male 21163788 CVCL_DK91 CW50071 induced pluripotent stem cell human CVCL_DK91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50071; true Female 21163789 CVCL_DK92 CW50078 induced pluripotent stem cell human CVCL_DK92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50078; true Female 21163790 CVCL_DK90 CW50070 induced pluripotent stem cell human CVCL_DK90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50070; true Female 21163791 CVCL_ME29 BayGenomics ES cell line CSJ074 embryonic stem cell house mouse CVCL_ME29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921729; Snx11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163792 CVCL_DK95 CW50086 induced pluripotent stem cell human CVCL_DK95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50086; true Female 21163793 CVCL_DK96 CW50094 induced pluripotent stem cell human CVCL_DK96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50094; true Male 21163794 CVCL_ME27 BayGenomics ES cell line CSJ068 embryonic stem cell house mouse CVCL_ME27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163795 CVCL_DK93 CW50079 induced pluripotent stem cell human CVCL_DK93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50079; true Female 21163796 CVCL_ME28 BayGenomics ES cell line CSJ073 embryonic stem cell house mouse CVCL_ME28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347488; Foxk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163797 CVCL_DK94 CW50082 induced pluripotent stem cell human CVCL_DK94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50082; true Male 21163798 CVCL_2X52 PR01009 finite cell line CVCL_2X52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Schweinfurthii. Discontinued: Coriell; PR01009; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163799 CVCL_3953 NCI-H324 cancer cell line human CVCL_3953 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Unspecified (PubMed=1311061); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Val (c.776A>T); ClinVar=VCV000485034; Zygosity=Unspecified (PubMed=1311061) Population: African American; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47 hours (in RPMI 1640 + 10% FBS), 122 hours (in ACL-3 + BSA) (PubMed=3940644) Part of: MD Anderson Cell Lines Project 21163800 CVCL_2X53 PR01010 finite cell line CVCL_2X53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01010; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163801 CVCL_2X50 PR00996 finite cell line CVCL_2X50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00996; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163802 CVCL_3950 WEHI-7.2 cancer cell line house mouse CVCL_3950 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Characteristics: Treatment with dexamethasone, a synthetic glucocorticoid, causes the cells to undergo apoptosis (PubMed=17180014) Doubling time: 13.78 +- 0.38 hours (PubMed=11526450) 21163803 CVCL_2X51 PR01008 finite cell line CVCL_2X51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Schweinfurthii. Discontinued: Coriell; PR01008; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163804 CVCL_3951 RPMI-7931 cancer cell line human CVCL_3951 CL:0000010 Unspecified Doubling time: 46 hours (PubMed=1161259). 21163805 CVCL_3956 LN-382 cancer cell line human CVCL_3956 Genome ancestry: African=0.37%; Native American=0%; East Asian, North=1%; East Asian, South=0.55%; South Asian=0.62%; European, North=59.11%; European, South=38.35% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val197Leu (c.589G>T); ClinVar=VCV000216468; Zygosity=Homozygous (DepMap) Derived from sampling site: Brain; right fronto-parietal lobe. Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 52 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163806 CVCL_2X56 PR01023 finite cell line CVCL_2X56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01023; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163807 CVCL_3957 LN-235 cancer cell line human CVCL_3957 Genome ancestry: African=3.32%; Native American=0.31%; East Asian, North=4.46%; East Asian, South=0%; South Asian=3.28%; European, North=23.54%; European, South=65.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Unspecified (PubMed=10416987); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (DepMap) Derived from sampling site: Brain; right fronto-temporal lobe. Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 37 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163808 CVCL_2X57 PR01030 finite cell line CVCL_2X57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01030; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163809 CVCL_3954 LN-215 cancer cell line human CVCL_3954 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191_Gln192del; Zygosity=Heterozygous (PubMed=10416987; DepMap) Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray. Female Doubling time: 28 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163810 CVCL_2X54 PR01013 finite cell line CVCL_2X54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01013; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163811 CVCL_3955 LN-340 cancer cell line human CVCL_3955 Genome ancestry: African=0.66%; Native American=0%; East Asian, North=3.84%; East Asian, South=0%; South Asian=0%; European, North=54.01%; European, South=41.49% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Pro (c.542G>C); ClinVar=VCV000825729; Zygosity=Homozygous (PubMed=10416987; DepMap) Derived from metastatic site: Brain; right parietal lobe. Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: 30 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163812 CVCL_2X55 PR01017 finite cell line CVCL_2X55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01017; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163813 CVCL_3958 LN-319 cancer cell line human CVCL_3958 Genome ancestry: African=1.07%; Native American=0.71%; East Asian, North=1.65%; East Asian, South=0%; South Asian=1.15%; European, North=65.6%; European, South=29.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg15Ile (c.44G>T); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=7732013; PubMed=10416987; PubMed=14614447; DepMap) Derived from sampling site: Brain; right temporal lobe. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray Male Doubling time: 51 hours (PubMed=9842975); 45 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00450 Problematic cell line: Contaminated Shown to be a LN-992 derivative (PubMed=22570425). 21163814 CVCL_2X58 PR01034 finite cell line CVCL_2X58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01034; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163815 CVCL_3959 LN-428 cancer cell line human CVCL_3959 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9842975); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Heterozygous (PubMed=7732013; PubMed=10416987; PubMed=14614447; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=7732013; PubMed=10416987; PubMed=14614447; DepMap) Derived from sampling site: Brain; left temporal lobe. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: Transcriptome analysis by microarray Male Doubling time: 51 hours (PubMed=9842975); 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21163816 CVCL_2X59 PR01035 finite cell line CVCL_2X59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01035; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163817 CVCL_3960 LN-443 cancer cell line human CVCL_3960 Genome ancestry: African=3.39%; Native American=0%; East Asian, North=4.23%; East Asian, South=0%; South Asian=4.37%; European, North=27.1%; European, South=60.91% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Arg (c.641A>G); ClinVar=VCV000376615; Zygosity=Homozygous (DepMap) Derived from sampling site: Brain; left parietal lobe. Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 40 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00451 Problematic cell line: Contaminated Shown to be a LN-444 derivative (PubMed=22570425). Originally thought to originate from a 66 year old male patient with a glioblastoma at the right fronto-temporal lobe. 21163818 CVCL_2X60 PR01037 finite cell line CVCL_2X60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01037; probable Unspecified Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163819 CVCL_3963 LN-702 cancer cell line human CVCL_3963 CL:0000010 21163820 CVCL_2X63 PR01044 finite cell line CVCL_2X63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01044; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163821 CVCL_3964 LN-751 cancer cell line human CVCL_3964 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=10416987). Male 21163822 CVCL_2X64 PR01052 transformed cell line CVCL_2X64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01052; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163823 CVCL_3961 LN-444 cancer cell line human CVCL_3961 CL:0000010 Derived from sampling site: Brain; left parietal lobe. Omics: Transcriptome analysis by microarray Female 21163824 CVCL_2X61 PR01038 transformed cell line CVCL_2X61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01038; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163825 CVCL_3962 LN-464 cancer cell line human CVCL_3962 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn184fs*6 (c.545_546insA); Zygosity=Heterozygous (PubMed=10416987; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Ser (c.338T>C); ClinVar=VCV000823709; Zygosity=Homozygous (PubMed=10416987; DepMap) Population: Caucasian Omics: Deep exome analysis; Omics: shRNA library screening. Unspecified Doubling time: 35 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Contaminated The STR profile of ACN and LN-464 are identical. SNP analysis (DepMap) also shows identity of both cell lines. Personal communication from Hegi M. confirms the mismatch between the STR profile of this cell line and of the patient from which LN-464 was established. We believe this is a melanoma cell line based on the RNASeq expression profile of LN-464 (DepMap) which clusters with that of melanoma patient samples. The presence of the BRAF V600E while present at low frequency in gliomas is also a hallmark of melanomas. Originally thought to originate from the brain right parieto-occipital lobe of a 67 year old male patient with a glioblastoma. 21163826 CVCL_2X62 PR01040 finite cell line CVCL_2X62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01040; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163827 CVCL_3967 CWR22 cancer cell line human CVCL_3967 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous Miscellaneous: This is not a cell line but a xenograft, it is the parent tumor for many cell lines Derived from sampling site: Prostate. Male Microsatellite instability: Instable (MSI) (PubMed=23671654) 21163828 CVCL_2X67 PR01086 finite cell line bonobo/pygmy chimpanzee CVCL_2X67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01086; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163829 CVCL_3968 NCI-H125 cancer cell line human CVCL_3968 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238fs (c.714_715ins1); Zygosity=Unspecified (PubMed=1311061; PubMed=12820372); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Unspecified (PubMed=1311061) Population: African American; Derived from metastatic site: Hypodermis. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-5801; true; Discontinued: KCLB; 90125; probable Male Doubling time: 39 hours (in RPMI 1640 + 10% FBS), 39 hours (in ACL-3), 40 hours (in ACL-3 + BSA) (PubMed=3940644) Part of: MD Anderson Cell Lines Project 21163830 CVCL_2X68 PR01089 finite cell line CVCL_2X68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01089; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163831 CVCL_3965 LN-774 cancer cell line human CVCL_3965 CL:0000010 21163832 CVCL_2X65 PR01057 transformed cell line CVCL_2X65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01057; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163833 CVCL_3966 LN-784 cancer cell line human CVCL_3966 CL:0000010 21163834 CVCL_2X66 PR01084 finite cell line CVCL_2X66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01084; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163835 CVCL_3969 NCI-H460M cancer cell line human CVCL_3969 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male 21163836 CVCL_2X69 PR01094 transformed cell line CVCL_2X69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01094; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163837 CVCL_3930 CEM-CM3 cancer cell line human CVCL_3930 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21163838 CVCL_2X30 PR00794 finite cell line CVCL_2X30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00794; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163839 CVCL_3931 CEM-LAV-2 cancer cell line human CVCL_3931 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21163840 CVCL_2X31 PR00796 finite cell line CVCL_2X31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00796; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163841 CVCL_3934 COLO 38 cancer cell line human CVCL_3934 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24732172); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Discontinued: CLS; 300151; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00556 Problematic cell line: Contaminated Shown to be a M14 derivative (ICLAC). Originally thought to originate from a 67 year old female patient with a melanoma. 21163842 CVCL_2X34 PR00825 transformed cell line CVCL_2X34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00825; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163843 CVCL_3935 OVCA420 cancer cell line human CVCL_3935 HLA typing: A*30:01,30:01; B*42:01,48:17; C*04:01,17:01 (PubMed=26589293); Genome ancestry: African=82.47%; Native American=0%; East Asian, North=2.6%; East Asian, South=0%; South Asian=2.8%; European, North=3.32%; European, South=8.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=20204287; PubMed=28273451) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 47.62 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21163844 CVCL_2X35 PR00827 finite cell line CVCL_2X35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00827; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163845 CVCL_3932 CEM/VLB100 cancer cell line human CVCL_3932 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Caution: Seems to be interchangeably called VLB100 or VBL100 21163846 CVCL_2X32 PR00814 transformed cell line bonobo/pygmy chimpanzee CVCL_2X32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00814; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163847 CVCL_3933 CEM-VCR R cancer cell line human CVCL_3933 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21163848 CVCL_2X33 PR00818 finite cell line CVCL_2X33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00818; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163849 CVCL_3938 NG115-401L hybrid cell line CVCL_3938 CL:0000010 21163850 CVCL_2X38 PR00838 transformed cell line CVCL_2X38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00838; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163851 CVCL_3939 NOR-10 spontaneously immortalized cell line house mouse CVCL_3939 CL:0000010 Derived from sampling site: Abdomen; skeletal muscle Cell type=Fibroblast.; Breed/subspecies: C57BL/10. Unspecified Characteristics: Control cell line for BLO-11 21163852 CVCL_2X39 PR00839 finite cell line CVCL_2X39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00839; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163853 CVCL_3936 OVCA429 cancer cell line human CVCL_3936 HLA typing: A*26:01,26:01; B*39:01,39:01; C*12:03,12:03 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=20204287) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 34.58 hours (GrayJW panel) Part of: MD Anderson Cell Lines Project 21163854 CVCL_2X36 PR00833 finite cell line CVCL_2X36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00833; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163855 CVCL_3937 KOPN-1 cancer cell line human CVCL_3937 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7134; MLLT1; Name(s)=KMT2A-MLLT1, MLL-MLLT1; MLL-ENL (PubMed=14671638; PubMed=15843827); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20575032) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21163856 CVCL_2X37 PR00834 transformed cell line CVCL_2X37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00834; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163857 CVCL_3941 OVCAR-2 cancer cell line human CVCL_3941 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21163858 CVCL_2X41 PR00943 finite cell line CVCL_2X41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00943; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163859 CVCL_2X42 PR00949 finite cell line CVCL_2X42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00949; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163860 CVCL_3940 NS0 cancer cell line house mouse CVCL_3940 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Characteristics: Commonly employed for monoclonal antibody expression; Characteristics: Lacks endogenous glutamine synthetase (GS) activity Group: Hybridoma fusion partner cell line 21163861 CVCL_2X40 PR00871 finite cell line CVCL_2X40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00871; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163862 CVCL_2X45 PR00969 transformed cell line CVCL_2X45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00969; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163863 CVCL_3945 T-47 cancer cell line human CVCL_3945 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21163864 CVCL_2X46 PR00976 finite cell line CVCL_2X46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00976; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163865 CVCL_3946 SNU-216 cancer cell line human CVCL_3946 HLA typing: A*24:02,24:02; B*51:01,52:01; C*12:02,12:02; DRB1*15:02,15:02 (PubMed=25960936); HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=2.54%; Native American=0%; East Asian, North=69.93%; East Asian, South=26.25%; South Asian=0%; European, North=0%; European, South=1.27% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Homozygous (PubMed=9033653; DepMap) Population: Korean; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21163866 CVCL_3943 KOPN-41 cancer cell line human CVCL_3943 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21163867 CVCL_2X43 PR00950 finite cell line CVCL_2X43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00950; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163868 CVCL_3944 7316A cancer cell line Norway rat CVCL_3944 CL:0000010 21163869 CVCL_2X44 PR00951 finite cell line CVCL_2X44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00951; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163870 CVCL_3949 J558L cancer cell line house mouse CVCL_3949 CL:0000010 Derived from sampling site: Cell type=B-cell; Breed/subspecies: BALB/c. Group: Hybridoma fusion partner cell line 21163871 CVCL_2X49 PR00990 finite cell line CVCL_2X49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00990; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163872 CVCL_2X47 PR00978 finite cell line CVCL_2X47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00978; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163873 CVCL_3947 SNU-354 cancer cell line human CVCL_3947 CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Ala1090Cysfs*5 (c.3267dupT); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Gly1424Valfs*5 (c.4271delG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Lys515Ter (c.1543A>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Korean; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 34 hours (PubMed=7543080); 39.48 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21163874 CVCL_2X48 PR00980 finite cell line CVCL_2X48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00980; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163875 CVCL_3948 SNU-368 cancer cell line human CVCL_3948 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Leu1607Profs*41 (c.4817dupT); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gln184Ter (c.550C>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser106Arg (c.318C>G); ClinVar=VCV000492752; Zygosity=Unspecified (PubMed=8824565; PubMed=31378681) Population: Korean; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 41 hours (PubMed=7543080); 42.77 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21163876 CVCL_3918 MDA-Panc-3 cancer cell line human CVCL_3918 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853) Derived from metastatic site: Liver. Male Doubling time: ~50 hours (PubMed=1688394) 21163877 CVCL_2X18 PR00732 transformed cell line CVCL_2X18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00732; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163878 CVCL_3919 NKB-1 cancer cell line human CVCL_3919 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Female Doubling time: 45 hours (PubMed=9183630) 21163879 CVCL_2X19 PR00738 finite cell line CVCL_2X19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00738; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163880 CVCL_3912 IST-EBV-TW5B transformed cell line human CVCL_3912 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW5A (Cellosaurus=CVCL_3911); Derived from sampling site: Peripheral blood. Male 21163881 CVCL_2X12 PR00716 finite cell line CVCL_2X12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00716; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163882 CVCL_3913 IST-EBV-TW6A transformed cell line human CVCL_3913 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW6B (Cellosaurus=CVCL_3914); Derived from sampling site: Peripheral blood. Male 21163883 CVCL_2X13 PR00722 finite cell line CVCL_2X13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00722; probable Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163884 CVCL_3910 IST-EBV-TW4B transformed cell line human CVCL_3910 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of IST-EBV-TW4A (Cellosaurus=CVCL_3908); Derived from sampling site: Peripheral blood. Male 21163885 CVCL_2X10 PR00712 finite cell line CVCL_2X10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00712; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163886 CVCL_3911 IST-EBV-TW5A transformed cell line human CVCL_3911 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW5B (Cellosaurus=CVCL_3912); Derived from sampling site: Peripheral blood. Male 21163887 CVCL_2X11 PR00715 finite cell line CVCL_2X11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00715; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163888 CVCL_3916 M24met H1.11 cancer cell line human CVCL_3916 CL:0000010 Derived from metastatic site: Lymph node. Male 21163889 CVCL_2X16 PR00729 finite cell line CVCL_2X16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00729; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163890 CVCL_3917 MDA-Panc-28 cancer cell line human CVCL_3917 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=8656025). Female Doubling time: ~48 hours (PubMed=8656025) 21163891 CVCL_2X17 PR00730 transformed cell line CVCL_2X17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00730; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163892 CVCL_3914 IST-EBV-TW6B transformed cell line human CVCL_3914 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW6A (Cellosaurus=CVCL_3913); Derived from sampling site: Peripheral blood. Male 21163893 CVCL_2X14 PR00724 transformed cell line CVCL_2X14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00724; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163894 CVCL_3915 M24met cancer cell line human CVCL_3915 CL:0000010 Derived from metastatic site: Lymph node. Male Characteristics: Established from M24 cell line after a passage in nude mice 21163895 CVCL_2X15 PR00726 finite cell line CVCL_2X15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00726; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163896 CVCL_3929 NEC15 cancer cell line human CVCL_3929 CL:0000010 Population: Japanese; Derived from sampling site: Testis. Discontinued: JCRB; FDSC0007; true Male 21163897 CVCL_2X29 PR00793 finite cell line CVCL_2X29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00793; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163898 CVCL_3920 PA317 transformed cell line house mouse CVCL_3920 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9078 21163899 CVCL_2X20 PR00739 finite cell line CVCL_2X20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00739; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163900 CVCL_2X23 PR00748 transformed cell line bonobo/pygmy chimpanzee CVCL_2X23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00748; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163901 CVCL_3923 SNK-57 cancer cell line human CVCL_3923 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Female Doubling time: 24 hours (PubMed=9183630) Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21163902 CVCL_3924 Colon 26-L5 cancer cell line house mouse CVCL_3924 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21163903 CVCL_2X24 PR00762 finite cell line CVCL_2X24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00762; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163904 CVCL_3921 PANC3 cancer cell line human CVCL_3921 CL:0000010 21163905 CVCL_2X21 PR00741 finite cell line CVCL_2X21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00741; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163906 CVCL_2X22 PR00742 finite cell line CVCL_2X22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00742; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163907 CVCL_3922 T24T SLT4 cancer cell line human CVCL_3922 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Exosome proteome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Forms metastasis in the liver of mice Produced by passage of the parent cell line through nude mice. Part of: BLA-40 bladder carcinoma cell line panel 21163908 CVCL_3927 C26-A cancer cell line house mouse CVCL_3927 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21163909 CVCL_2X27 PR00788 finite cell line CVCL_2X27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00788; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163910 CVCL_3928 C26-G cancer cell line house mouse CVCL_3928 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21163911 CVCL_2X28 PR00789 finite cell line CVCL_2X28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00789; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163912 CVCL_3925 Colon C26-G cancer cell line house mouse CVCL_3925 CL:0000010 Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21163913 CVCL_2X25 PR00772 transformed cell line CVCL_2X25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00772; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163914 CVCL_3926 C26-10 cancer cell line house mouse CVCL_3926 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21163915 CVCL_2X26 PR00773 finite cell line CVCL_2X26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00773; probable Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163916 CVCL_3909 IST-EBV-TW4A transformed cell line human CVCL_3909 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of IST-EBV-TW4B (Cellosaurus=CVCL_3909); Derived from sampling site: Peripheral blood. Male 21163917 CVCL_2X09 PR00711 finite cell line CVCL_2X09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00711; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163918 CVCL_3907 IST-EBV-TW3.1 transformed cell line human CVCL_3907 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW3.2 (Cellosaurus=CVCL_3908); Derived from sampling site: Peripheral blood. Male 21163919 CVCL_2X07 PR00707 finite cell line CVCL_2X07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00707; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163920 CVCL_3908 IST-EBV-TW3.2 transformed cell line human CVCL_3908 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW3.1 (Cellosaurus=CVCL_3907); Derived from sampling site: Peripheral blood. Male 21163921 CVCL_2X08 PR00708 finite cell line CVCL_2X08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00708; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163922 CVCL_3901 EA.hy 926 hybrid cell line human CVCL_3901 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Anecdotal: Have been flown in space on Shijian-10 and on the ISS in 2016 to study growth and secretion in microgravity (PubMed=28199884; PubMed=30108515; PubMed=30977987) Omics: Transcriptome analysis by microarray Male Characteristics: Produced by the fusion of A549/8 with human umbilical vein endothelial cells Doubling time: 12 hours (PubMed=6407019) Group: Space-flown cell line (cellonaut) 21163923 CVCL_2X01 PR00671 finite cell line CVCL_2X01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00671; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163924 CVCL_3902 INC-2 spontaneously immortalized cell line house mouse CVCL_3902 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21163925 CVCL_2X02 PR00674 finite cell line CVCL_2X02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00674; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163926 CVCL_3900 COM-3 spontaneously immortalized cell line house mouse CVCL_3900 CL:0000010 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female 21163927 CVCL_2X00 PR00669 finite cell line CVCL_2X00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00669; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163928 CVCL_3905 IST-EBV-TW2.1 transformed cell line human CVCL_3905 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of IST-EBV-TW2.2 (Cellosaurus=CVCL_3906); Derived from sampling site: Peripheral blood. Male 21163929 CVCL_2X05 PR00679 finite cell line CVCL_2X05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00679; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163930 CVCL_3906 IST-EBV-TW2.2 transformed cell line human CVCL_3906 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of IST-EBV-TW2.1 (Cellosaurus=CVCL_3905); Derived from sampling site: Peripheral blood. Male 21163931 CVCL_2X06 PR00680 finite cell line CVCL_2X06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00680; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163932 CVCL_3903 IST-EBV-TW1.1 transformed cell line human CVCL_3903 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW1.2 (Cellosaurus=CVCL_3904); Derived from sampling site: Peripheral blood. Male 21163933 CVCL_2X03 PR00677 finite cell line CVCL_2X03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00677; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163934 CVCL_3904 IST-EBV-TW1.2 transformed cell line human CVCL_3904 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of IST-EBV-TW1.1 (Cellosaurus=CVCL_3903); Derived from sampling site: Peripheral blood. Male 21163935 CVCL_2X04 PR00678 finite cell line CVCL_2X04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00678; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21163936 CVCL_DM28 CW70191 induced pluripotent stem cell human CVCL_DM28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70191; true Female 21163937 CVCL_DM29 CW70193 induced pluripotent stem cell human CVCL_DM29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70193; true Female 21163938 CVCL_DM26 CW70189 induced pluripotent stem cell human CVCL_DM26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70189; true Male 21163939 CVCL_DM27 CW70190 induced pluripotent stem cell human CVCL_DM27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70190; true Male 21163940 CVCL_DM20 CW70180 induced pluripotent stem cell human CVCL_DM20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70180; true; Discontinued: FCDI; CW70180; probable. Male 21163941 CVCL_DM21 CW70182 induced pluripotent stem cell human CVCL_DM21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70182; true Male 21163942 CVCL_DM24 CW70186 induced pluripotent stem cell human CVCL_DM24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70186; true Female 21163943 CVCL_DM25 CW70188 induced pluripotent stem cell human CVCL_DM25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70188; true Female 21163944 CVCL_DM22 CW70184 induced pluripotent stem cell human CVCL_DM22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70184; true Female 21163945 CVCL_DM23 CW70185 induced pluripotent stem cell human CVCL_DM23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70185; true Female 21163946 CVCL_DM39 CW70212 induced pluripotent stem cell human CVCL_DM39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70212; true Female 21163947 CVCL_DM37 CW70210 induced pluripotent stem cell human CVCL_DM37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70210; true Male 21163948 CVCL_DM38 CW70211 induced pluripotent stem cell human CVCL_DM38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70211; true Female 21163949 CVCL_DM31 CW70195 induced pluripotent stem cell human CVCL_DM31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70195; true Female 21163950 CVCL_DM32 CW70196 induced pluripotent stem cell human CVCL_DM32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70196; true Female 21163951 CVCL_DM30 CW70194 induced pluripotent stem cell human CVCL_DM30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70194; true Female 21163952 CVCL_DM35 CW70207 induced pluripotent stem cell human CVCL_DM35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70207; true Male 21163953 CVCL_DM36 CW70208 induced pluripotent stem cell human CVCL_DM36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70208; true Female 21163954 CVCL_DM33 CW70198 induced pluripotent stem cell human CVCL_DM33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70198; true Male 21163955 CVCL_DM34 CW70205 induced pluripotent stem cell human CVCL_DM34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70205; true Female 21163956 CVCL_DM06 CW70158 induced pluripotent stem cell human CVCL_DM06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70158; true Female 21163957 CVCL_DM07 CW70159 induced pluripotent stem cell human CVCL_DM07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70159; true. Female 21163958 CVCL_DM04 CW70156 induced pluripotent stem cell human CVCL_DM04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70156; true Female 21163959 CVCL_DM05 CW70157 induced pluripotent stem cell human CVCL_DM05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70157; true. Female 21163960 CVCL_DM08 CW70160 induced pluripotent stem cell human CVCL_DM08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70160; true Male 21163961 CVCL_DM09 CW70163 induced pluripotent stem cell human CVCL_DM09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70163; true; Discontinued: FCDI; CW70163; probable. Male 21163962 CVCL_DM02 CW70151 induced pluripotent stem cell human CVCL_DM02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70151; true Female 21163963 CVCL_DM03 CW70152 induced pluripotent stem cell human CVCL_DM03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70152; true Female 21163964 CVCL_DM00 CW70139 induced pluripotent stem cell human CVCL_DM00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70139; true; Discontinued: FCDI; CW70139; probable. Male 21163965 CVCL_DM01 CW70144 induced pluripotent stem cell human CVCL_DM01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70144; true Male 21163966 CVCL_DM17 CW70175 induced pluripotent stem cell human CVCL_DM17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70175; true Male 21163967 CVCL_DM18 CW70176 induced pluripotent stem cell human CVCL_DM18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70176; true Male 21163968 CVCL_DM15 CW70173 induced pluripotent stem cell human CVCL_DM15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70173; true Male 21163969 CVCL_DM16 CW70174 induced pluripotent stem cell human CVCL_DM16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70174; true Male 21163970 CVCL_DM19 CW70179 induced pluripotent stem cell human CVCL_DM19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70179; true Female 21163971 CVCL_DM10 CW70164 induced pluripotent stem cell human CVCL_DM10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70164; true Female 21163972 CVCL_DM13 CW70168 induced pluripotent stem cell human CVCL_DM13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70168; true Male 21163973 CVCL_DM14 CW70170 induced pluripotent stem cell human CVCL_DM14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70170; true Female 21163974 CVCL_DM11 CW70165 induced pluripotent stem cell human CVCL_DM11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Native North American; Cherokee; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70165; true Male 21163975 CVCL_DM12 CW70166 induced pluripotent stem cell human CVCL_DM12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70166; true; Discontinued: FCDI; CW70166; probable. Male 21163976 CVCL_2Y91 GM08662 transformed cell line human CVCL_2Y91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163977 CVCL_2Y92 GM08663 transformed cell line human CVCL_2Y92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163978 CVCL_2Y90 GM08661 transformed cell line human CVCL_2Y90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163979 CVCL_2Y95 GM01598 finite cell line human CVCL_2Y95 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21163980 CVCL_2Y96 GM03479 finite cell line human CVCL_2Y96 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM03479; probable Male 21163981 CVCL_2Y93 GM08664 transformed cell line human CVCL_2Y93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21163982 CVCL_2Y94 GM08665 transformed cell line human CVCL_2Y94 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21163983 CVCL_2Y99 GM13325 finite cell line human CVCL_2Y99 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21163984 CVCL_2Y97 GM05876 finite cell line human CVCL_2Y97 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21163985 CVCL_2Y98 GM07215 finite cell line human CVCL_2Y98 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21163986 CVCL_MG45 BayGenomics ES cell line Ex312 embryonic stem cell house mouse CVCL_MG45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919279; Cnpy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163987 CVCL_MG46 BayGenomics ES cell line Ex316 embryonic stem cell house mouse CVCL_MG46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163988 CVCL_MG43 BayGenomics ES cell line Ex292 embryonic stem cell house mouse CVCL_MG43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298387; Fhl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163989 CVCL_MG44 BayGenomics ES cell line Ex297 embryonic stem cell house mouse CVCL_MG44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109520; Pafah1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163990 CVCL_MG41 BayGenomics ES cell line Ex283 embryonic stem cell house mouse CVCL_MG41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920930; Zbtb8a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163991 CVCL_MG42 BayGenomics ES cell line Ex284 embryonic stem cell house mouse CVCL_MG42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163992 CVCL_MG40 BayGenomics ES cell line Ex279 embryonic stem cell house mouse CVCL_MG40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163993 CVCL_MG38 BayGenomics ES cell line Ex269 embryonic stem cell house mouse CVCL_MG38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914635; Ubald2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163994 CVCL_MG39 BayGenomics ES cell line Ex273 embryonic stem cell house mouse CVCL_MG39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163995 CVCL_MG36 BayGenomics ES cell line Ex256 embryonic stem cell house mouse CVCL_MG36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916176; Ubap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163996 CVCL_MG37 BayGenomics ES cell line Ex260 embryonic stem cell house mouse CVCL_MG37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163997 CVCL_MG56 BayGenomics ES cell line Ex405 embryonic stem cell house mouse CVCL_MG56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922194; Qtrt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163998 CVCL_MG57 BayGenomics ES cell line Ex503 embryonic stem cell house mouse CVCL_MG57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921997; Ddit4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21163999 CVCL_MG54 BayGenomics ES cell line Ex388 embryonic stem cell house mouse CVCL_MG54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97298; Septin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164000 CVCL_MG55 BayGenomics ES cell line Ex400 embryonic stem cell house mouse CVCL_MG55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164001 CVCL_MG52 BayGenomics ES cell line Ex381 embryonic stem cell house mouse CVCL_MG52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914544; Elp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164002 CVCL_MG53 BayGenomics ES cell line Ex387 embryonic stem cell house mouse CVCL_MG53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164003 CVCL_MG50 BayGenomics ES cell line Ex335 embryonic stem cell house mouse CVCL_MG50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164004 CVCL_MG51 BayGenomics ES cell line Ex369 embryonic stem cell house mouse CVCL_MG51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164005 CVCL_MG49 BayGenomics ES cell line Ex332 embryonic stem cell house mouse CVCL_MG49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443487; Trmt61a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164006 CVCL_MG47 BayGenomics ES cell line Ex327 embryonic stem cell house mouse CVCL_MG47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164007 CVCL_MG48 BayGenomics ES cell line Ex331 embryonic stem cell house mouse CVCL_MG48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164008 CVCL_MG23 BayGenomics ES cell line EX187 embryonic stem cell house mouse CVCL_MG23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164009 CVCL_MG24 BayGenomics ES cell line Ex190 embryonic stem cell house mouse CVCL_MG24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164010 CVCL_MG21 BayGenomics ES cell line Ex184 embryonic stem cell house mouse CVCL_MG21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95794; Lrp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164011 CVCL_MG22 BayGenomics ES cell line Ex186 embryonic stem cell house mouse CVCL_MG22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164012 CVCL_MG20 BayGenomics ES cell line Ex183 embryonic stem cell house mouse CVCL_MG20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164013 CVCL_DM86 CW70296 induced pluripotent stem cell human CVCL_DM86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70296; true Female 21164014 CVCL_DM87 CW70297 induced pluripotent stem cell human CVCL_DM87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70297; true Female 21164015 CVCL_DM84 CW70289 induced pluripotent stem cell human CVCL_DM84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70289; true Female 21164016 CVCL_DM85 CW70292 induced pluripotent stem cell human CVCL_DM85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70292; true Male 21164017 CVCL_DM88 CW70298 induced pluripotent stem cell human CVCL_DM88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70298; true Male 21164018 CVCL_DM89 CW70299 induced pluripotent stem cell human CVCL_DM89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70299; true Female 21164019 CVCL_MG18 BayGenomics ES cell line Ex180 embryonic stem cell house mouse CVCL_MG18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164020 CVCL_MG19 BayGenomics ES cell line Ex182 embryonic stem cell house mouse CVCL_MG19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164021 CVCL_MG16 BayGenomics ES cell line Ex166 embryonic stem cell house mouse CVCL_MG16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164022 CVCL_DM82 CW70286 induced pluripotent stem cell human CVCL_DM82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70286; true Female 21164023 CVCL_MG17 BayGenomics ES cell line Ex173 embryonic stem cell house mouse CVCL_MG17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140592; Slc44a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164024 CVCL_DM83 CW70287 induced pluripotent stem cell human CVCL_DM83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70287; true Male 21164025 CVCL_MG14 BayGenomics ES cell line Ex158 embryonic stem cell house mouse CVCL_MG14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164026 CVCL_DM80 CW70282 induced pluripotent stem cell human CVCL_DM80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70282; true Male 21164027 CVCL_MG15 BayGenomics ES cell line Ex160 embryonic stem cell house mouse CVCL_MG15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106211; Cdc42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164028 CVCL_DM81 CW70284 induced pluripotent stem cell human CVCL_DM81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70284; true Male 21164029 CVCL_MG34 BayGenomics ES cell line Ex252 embryonic stem cell house mouse CVCL_MG34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164030 CVCL_MG35 BayGenomics ES cell line Ex255 embryonic stem cell house mouse CVCL_MG35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202296; Sorl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164031 CVCL_MG32 BayGenomics ES cell line Ex243 embryonic stem cell house mouse CVCL_MG32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95755; Slc2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164032 CVCL_MG33 BayGenomics ES cell line Ex245 embryonic stem cell house mouse CVCL_MG33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96392; Icam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164033 CVCL_MG30 BayGenomics ES cell line Ex208 embryonic stem cell house mouse CVCL_MG30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860139; Gabbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164034 CVCL_MG31 BayGenomics ES cell line Ex241 embryonic stem cell house mouse CVCL_MG31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278343; Nipsnap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164035 CVCL_DM97 CW70309 induced pluripotent stem cell human CVCL_DM97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70309; true Female 21164036 CVCL_DM98 CW70310 induced pluripotent stem cell human CVCL_DM98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Vietnamese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70310; true Female 21164037 CVCL_DM95 CW70307 induced pluripotent stem cell human CVCL_DM95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70307; true Female 21164038 CVCL_DM96 CW70308 induced pluripotent stem cell human CVCL_DM96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Japanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70308; true Male 21164039 CVCL_DM99 CW70313 induced pluripotent stem cell human CVCL_DM99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70313; true Male 21164040 CVCL_DM90 CW70301 induced pluripotent stem cell human CVCL_DM90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70301; true Female 21164041 CVCL_MG29 BayGenomics ES cell line Ex204 embryonic stem cell house mouse CVCL_MG29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164042 CVCL_MG27 BayGenomics ES cell line Ex197 embryonic stem cell house mouse CVCL_MG27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164043 CVCL_DM93 CW70305 induced pluripotent stem cell human CVCL_DM93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70305; true Female 21164044 CVCL_MG28 BayGenomics ES cell line Ex200 embryonic stem cell house mouse CVCL_MG28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921867; Scpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164045 CVCL_DM94 CW70306 induced pluripotent stem cell human CVCL_DM94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70306; true Female 21164046 CVCL_MG25 BayGenomics ES cell line Ex192 embryonic stem cell house mouse CVCL_MG25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87961; Agrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164047 CVCL_DM91 CW70303 induced pluripotent stem cell human CVCL_DM91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70303; true Male 21164048 CVCL_MG26 BayGenomics ES cell line Ex194 embryonic stem cell house mouse CVCL_MG26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104902; Gpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164049 CVCL_DM92 CW70304 induced pluripotent stem cell human CVCL_DM92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70304; true Male 21164050 CVCL_MG01 BayGenomics ES cell line DTM098 embryonic stem cell house mouse CVCL_MG01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916051; Elovl5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164051 CVCL_MG02 BayGenomics ES cell line DTM100 embryonic stem cell house mouse CVCL_MG02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164052 CVCL_MG00 BayGenomics ES cell line DTM096 embryonic stem cell house mouse CVCL_MG00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921642; Specc1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164053 CVCL_DM64 CW70260 induced pluripotent stem cell human CVCL_DM64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70260; true Female 21164054 CVCL_DM65 CW70262 induced pluripotent stem cell human CVCL_DM65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70262; true Male 21164055 CVCL_DM62 CW70256 induced pluripotent stem cell human CVCL_DM62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70256; true Female 21164056 CVCL_DM63 CW70257 induced pluripotent stem cell human CVCL_DM63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70257; true Male 21164057 CVCL_DM68 CW70266 induced pluripotent stem cell human CVCL_DM68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70266; true Female 21164058 CVCL_DM69 CW70267 induced pluripotent stem cell human CVCL_DM69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70267; true Female 21164059 CVCL_DM66 CW70263 induced pluripotent stem cell human CVCL_DM66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70263; true Female 21164060 CVCL_DM67 CW70264 induced pluripotent stem cell human CVCL_DM67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70264; true Female 21164061 CVCL_DM60 CW70253 induced pluripotent stem cell human CVCL_DM60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70253; true Female 21164062 CVCL_DM61 CW70254 induced pluripotent stem cell human CVCL_DM61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70254; true Female 21164063 CVCL_MG12 BayGenomics ES cell line Ex140 embryonic stem cell house mouse CVCL_MG12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164064 CVCL_MG13 BayGenomics ES cell line Ex153 embryonic stem cell house mouse CVCL_MG13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108077; Nptn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164065 CVCL_MG10 BayGenomics ES cell line Ex132 embryonic stem cell house mouse CVCL_MG10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143702; Enpp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164066 CVCL_MG11 BayGenomics ES cell line Ex136 embryonic stem cell house mouse CVCL_MG11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164067 CVCL_DM75 CW70276 induced pluripotent stem cell human CVCL_DM75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70276; true Female 21164068 CVCL_DM76 CW70278 induced pluripotent stem cell human CVCL_DM76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70278; true Female 21164069 CVCL_DM73 CW70274 induced pluripotent stem cell human CVCL_DM73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70274; true Female 21164070 CVCL_DM74 CW70275 induced pluripotent stem cell human CVCL_DM74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70275; true Male 21164071 CVCL_DM79 CW70281 induced pluripotent stem cell human CVCL_DM79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70281; true Male 21164072 CVCL_DM77 CW70279 induced pluripotent stem cell human CVCL_DM77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70279; true Female 21164073 CVCL_DM78 CW70280 induced pluripotent stem cell human CVCL_DM78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70280; true Male 21164074 CVCL_MG09 BayGenomics ES cell line Ex126 embryonic stem cell house mouse CVCL_MG09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164075 CVCL_MG07 BayGenomics ES cell line Ex124 embryonic stem cell house mouse CVCL_MG07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164076 CVCL_MG08 BayGenomics ES cell line Ex125 embryonic stem cell house mouse CVCL_MG08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164077 CVCL_MG05 BayGenomics ES cell line DTM103 embryonic stem cell house mouse CVCL_MG05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915689; Lrrc28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164078 CVCL_DM71 CW70272 induced pluripotent stem cell human CVCL_DM71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70272; true Male 21164079 CVCL_MG06 BayGenomics ES cell line DTM104 embryonic stem cell house mouse CVCL_MG06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894680; Bach1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164080 CVCL_DM72 CW70273 induced pluripotent stem cell human CVCL_DM72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70273; true Male 21164081 CVCL_MG03 BayGenomics ES cell line DTM101 embryonic stem cell house mouse CVCL_MG03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140729; Zfand2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164082 CVCL_MG04 BayGenomics ES cell line DTM102 embryonic stem cell house mouse CVCL_MG04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150016; Spred1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164083 CVCL_DM70 CW70269 induced pluripotent stem cell human CVCL_DM70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70269; true Male 21164084 CVCL_DM48 CW70235 induced pluripotent stem cell human CVCL_DM48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70235; true Female 21164085 CVCL_DM49 CW70239 induced pluripotent stem cell human CVCL_DM49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: East Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70239; true Female 21164086 CVCL_DM42 CW70217 induced pluripotent stem cell human CVCL_DM42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70217; true Female 21164087 CVCL_DM43 CW70221 induced pluripotent stem cell human CVCL_DM43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70221; true Female 21164088 CVCL_DM40 CW70215 induced pluripotent stem cell human CVCL_DM40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70215; true Female 21164089 CVCL_DM41 CW70216 induced pluripotent stem cell human CVCL_DM41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70216; true Female 21164090 CVCL_DM46 CW70227 induced pluripotent stem cell human CVCL_DM46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70227; true; Discontinued: FCDI; CW70227; probable. Female 21164091 CVCL_DM47 CW70229 induced pluripotent stem cell human CVCL_DM47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70229; true Female 21164092 CVCL_DM44 CW70225 induced pluripotent stem cell human CVCL_DM44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70225; true Female 21164093 CVCL_DM45 CW70226 induced pluripotent stem cell human CVCL_DM45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70226; true Female 21164094 CVCL_DM59 CW70252 induced pluripotent stem cell human CVCL_DM59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70252; true Female 21164095 CVCL_DM53 CW70245 induced pluripotent stem cell human CVCL_DM53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70245; true Female 21164096 CVCL_DM54 CW70246 induced pluripotent stem cell human CVCL_DM54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70246; true Male 21164097 CVCL_DM51 CW70241 induced pluripotent stem cell human CVCL_DM51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70241; true Female 21164098 CVCL_DM52 CW70244 induced pluripotent stem cell human CVCL_DM52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70244; true Male 21164099 CVCL_DM57 CW70250 induced pluripotent stem cell human CVCL_DM57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70250; true Female 21164100 CVCL_DM58 CW70251 induced pluripotent stem cell human CVCL_DM58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70251; true Male 21164101 CVCL_DM55 CW70247 induced pluripotent stem cell human CVCL_DM55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70247; true Female 21164102 CVCL_DM56 CW70249 induced pluripotent stem cell human CVCL_DM56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70249; true Male 21164103 CVCL_DM50 CW70240 induced pluripotent stem cell human CVCL_DM50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70240; true Female 21164104 CVCL_2Y08 PR01231 finite cell line CVCL_2Y08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01231; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164105 CVCL_2Y09 PR01238 finite cell line CVCL_2Y09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01238; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164106 CVCL_2Y06 PR01217 finite cell line CVCL_2Y06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01217; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164107 CVCL_2Y07 PR01218 finite cell line CVCL_2Y07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01218; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164108 CVCL_2Y00 PR01198 finite cell line CVCL_2Y00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01198; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164109 CVCL_2Y01 PR01205 transformed cell line CVCL_2Y01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01205; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164110 CVCL_2Y04 PR01215 finite cell line CVCL_2Y04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01215; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164111 CVCL_2Y05 PR01216 finite cell line CVCL_2Y05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01216; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164112 CVCL_2Y02 PR01209 finite cell line CVCL_2Y02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01209; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164113 CVCL_2Y03 PR01213 transformed cell line CVCL_2Y03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01213; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164114 CVCL_MF88 BayGenomics ES cell line DTM074 embryonic stem cell house mouse CVCL_MF88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894684; Pa2g4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164115 CVCL_MF89 BayGenomics ES cell line DTM076 embryonic stem cell house mouse CVCL_MF89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164116 CVCL_MF86 BayGenomics ES cell line DTM066 embryonic stem cell house mouse CVCL_MF86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446159; Itpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164117 CVCL_MF87 BayGenomics ES cell line DTM071 embryonic stem cell house mouse CVCL_MF87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159342; Pja2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164118 CVCL_MF84 BayGenomics ES cell line DTM062 embryonic stem cell house mouse CVCL_MF84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442555; Dis3l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164119 CVCL_MF85 BayGenomics ES cell line DTM065 embryonic stem cell house mouse CVCL_MF85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099804; Hip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164120 CVCL_MF82 BayGenomics ES cell line DTM060 embryonic stem cell house mouse CVCL_MF82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95299; Eif2s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164121 CVCL_MF83 BayGenomics ES cell line DTM061 embryonic stem cell house mouse CVCL_MF83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:91860; Dcaf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164122 CVCL_MF80 BayGenomics ES cell line DTM051 embryonic stem cell house mouse CVCL_MF80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3583954; Zfp961 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164123 CVCL_MF81 BayGenomics ES cell line DTM057 embryonic stem cell house mouse CVCL_MF81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927243; Rala Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164124 CVCL_MF99 BayGenomics ES cell line DTM093 embryonic stem cell house mouse CVCL_MF99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107629; Luzp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164125 CVCL_MF97 BayGenomics ES cell line DTM091 embryonic stem cell house mouse CVCL_MF97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164126 CVCL_MF98 BayGenomics ES cell line DTM092 embryonic stem cell house mouse CVCL_MF98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107180; Elf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164127 CVCL_MF95 BayGenomics ES cell line DTM088 embryonic stem cell house mouse CVCL_MF95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915371; Cep70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164128 CVCL_MF96 BayGenomics ES cell line DTM089 embryonic stem cell house mouse CVCL_MF96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164129 CVCL_MF93 BayGenomics ES cell line DTM084 embryonic stem cell house mouse CVCL_MF93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202402; Pde7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164130 CVCL_MF94 BayGenomics ES cell line DTM087 embryonic stem cell house mouse CVCL_MF94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443930; Lcor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164131 CVCL_MF91 BayGenomics ES cell line DTM078 embryonic stem cell house mouse CVCL_MF91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923549; Erp44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164132 CVCL_MF92 BayGenomics ES cell line DTM079 embryonic stem cell house mouse CVCL_MF92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108420; Nfe2l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164133 CVCL_MF90 BayGenomics ES cell line DTM077 embryonic stem cell house mouse CVCL_MF90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861601; Cpsf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164134 CVCL_MF68 BayGenomics ES cell line DTM030 embryonic stem cell house mouse CVCL_MF68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142716; Gpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164135 CVCL_MF69 BayGenomics ES cell line DTM033 embryonic stem cell house mouse CVCL_MF69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164136 CVCL_MF66 BayGenomics ES cell line DTM024 embryonic stem cell house mouse CVCL_MF66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916477; Selenot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164137 CVCL_MF67 BayGenomics ES cell line DTM026 embryonic stem cell house mouse CVCL_MF67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029632; Med13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164138 CVCL_MF64 BayGenomics ES cell line DTM021 embryonic stem cell house mouse CVCL_MF64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922665; Arhgap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164139 CVCL_MF65 BayGenomics ES cell line DTM023 embryonic stem cell house mouse CVCL_MF65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914490; Taok1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164140 CVCL_MF62 BayGenomics ES cell line DTM016 embryonic stem cell house mouse CVCL_MF62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443679; Sipa1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164141 CVCL_MF63 BayGenomics ES cell line DTM017 embryonic stem cell house mouse CVCL_MF63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164142 CVCL_MF60 BayGenomics ES cell line DTM013 embryonic stem cell house mouse CVCL_MF60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164143 CVCL_MF61 BayGenomics ES cell line DTM015 embryonic stem cell house mouse CVCL_MF61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88266; Capns1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164144 CVCL_MF59 BayGenomics ES cell line DTM012 embryonic stem cell house mouse CVCL_MF59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107628; Prdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164145 CVCL_MF79 BayGenomics ES cell line DTM049 embryonic stem cell house mouse CVCL_MF79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107423; Numb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164146 CVCL_MF77 BayGenomics ES cell line DTM043 embryonic stem cell house mouse CVCL_MF77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915393; Herpud2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164147 CVCL_MF78 BayGenomics ES cell line DTM044 embryonic stem cell house mouse CVCL_MF78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861601; Cpsf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164148 CVCL_MF75 BayGenomics ES cell line DTM040 embryonic stem cell house mouse CVCL_MF75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164149 CVCL_MF76 BayGenomics ES cell line DTM041 embryonic stem cell house mouse CVCL_MF76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164150 CVCL_MF73 BayGenomics ES cell line DTM037 embryonic stem cell house mouse CVCL_MF73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444951; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164151 CVCL_MF74 BayGenomics ES cell line DTM039 embryonic stem cell house mouse CVCL_MF74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920093; Prdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164152 CVCL_MF71 BayGenomics ES cell line DTM035 embryonic stem cell house mouse CVCL_MF71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858211; Zranb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164153 CVCL_MF72 BayGenomics ES cell line DTM036 embryonic stem cell house mouse CVCL_MF72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99638; Mark2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164154 CVCL_MF70 BayGenomics ES cell line DTM034 embryonic stem cell house mouse CVCL_MF70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146189; Topors Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164155 CVCL_MF46 BayGenomics ES cell line CSJ325 embryonic stem cell house mouse CVCL_MF46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164156 CVCL_MF47 BayGenomics ES cell line CSJ327 embryonic stem cell house mouse CVCL_MF47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347078; Grk6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164157 CVCL_MF44 BayGenomics ES cell line CSJ319 embryonic stem cell house mouse CVCL_MF44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164158 CVCL_MF45 BayGenomics ES cell line CSJ322 embryonic stem cell house mouse CVCL_MF45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100863; Kpna3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164159 CVCL_MF42 BayGenomics ES cell line CSJ315 embryonic stem cell house mouse CVCL_MF42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164160 CVCL_MF43 BayGenomics ES cell line CSJ317 embryonic stem cell house mouse CVCL_MF43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164161 CVCL_MF40 BayGenomics ES cell line CSJ311 embryonic stem cell house mouse CVCL_MF40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164162 CVCL_MF41 BayGenomics ES cell line CSJ313 embryonic stem cell house mouse CVCL_MF41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164163 CVCL_MF39 BayGenomics ES cell line CSJ309 embryonic stem cell house mouse CVCL_MF39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164164 CVCL_MF37 BayGenomics ES cell line CSJ303 embryonic stem cell house mouse CVCL_MF37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109150; Mnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164165 CVCL_MF38 BayGenomics ES cell line CSJ306 embryonic stem cell house mouse CVCL_MF38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164166 CVCL_MF57 BayGenomics ES cell line DTM010 embryonic stem cell house mouse CVCL_MF57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915119; Paip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164167 CVCL_MF58 BayGenomics ES cell line DTM011 embryonic stem cell house mouse CVCL_MF58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651986; Zfp985 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164168 CVCL_MF55 BayGenomics ES cell line DTM008 embryonic stem cell house mouse CVCL_MF55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913368; Sarnp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164169 CVCL_MF56 BayGenomics ES cell line DTM009 embryonic stem cell house mouse CVCL_MF56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921601; Ddx23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164170 CVCL_MF53 BayGenomics ES cell line DTM005 embryonic stem cell house mouse CVCL_MF53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861380; Sphk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164171 CVCL_MF54 BayGenomics ES cell line DTM007 embryonic stem cell house mouse CVCL_MF54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164172 CVCL_MF51 BayGenomics ES cell line CSJ336 embryonic stem cell house mouse CVCL_MF51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336155; Lss Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164173 CVCL_MF52 BayGenomics ES cell line DTM001 embryonic stem cell house mouse CVCL_MF52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917490; Ufsp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164174 CVCL_MF50 BayGenomics ES cell line CSJ332 embryonic stem cell house mouse CVCL_MF50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164175 CVCL_MF48 BayGenomics ES cell line CSJ328 embryonic stem cell house mouse CVCL_MF48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446634; Ago3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164176 CVCL_MF49 BayGenomics ES cell line CSJ330 embryonic stem cell house mouse CVCL_MF49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202305; Vps72 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164177 CVCL_2Y70 AG22173 finite cell line human CVCL_2Y70 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; AG22173; probable Male 21164178 CVCL_2Y73 AG22584 finite cell line human CVCL_2Y73 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164179 CVCL_2Y74 AG22586 finite cell line human CVCL_2Y74 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164180 CVCL_2Y71 AG22174 finite cell line human CVCL_2Y71 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; AG22174; probable Male 21164181 CVCL_2Y72 AG22175 finite cell line human CVCL_2Y72 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; AG22175; probable Male 21164182 CVCL_2Y77 AG22723 finite cell line human CVCL_2Y77 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 26 PDL (Coriell=AG22723) 21164183 CVCL_2Y78 AG22724 finite cell line human CVCL_2Y78 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164184 CVCL_2Y75 AG22716 finite cell line human CVCL_2Y75 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Senescence: Senesces at 28 PDL (Coriell=AG22716) 21164185 CVCL_2Y76 AG22717 finite cell line human CVCL_2Y76 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Senescence: Senesces at 27 PDL (Coriell=AG22717) 21164186 CVCL_2Y79 AG21156 transformed cell line human CVCL_2Y79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164187 CVCL_2Y80 AG21157 transformed cell line human CVCL_2Y80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164188 CVCL_2Y81 AG21158 finite cell line human CVCL_2Y81 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg176Cys (c.526C>T); ClinVar=VCV000017848; Zygosity=Heterozygous; Note=ApoE2 allele (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164189 CVCL_2Y84 AG14473 finite cell line human CVCL_2Y84 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21164190 CVCL_2Y85 AG06062 finite cell line human CVCL_2Y85 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164191 CVCL_2Y82 AG21159 transformed cell line human CVCL_2Y82 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg176Cys (c.526C>T); ClinVar=VCV000017848; Zygosity=Heterozygous; Note=ApoE2 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164192 CVCL_2Y83 AG14449 transformed cell line human CVCL_2Y83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21164193 CVCL_2Y88 GM03626 finite cell line human CVCL_2Y88 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male 21164194 CVCL_2Y89 GM08660 transformed cell line human CVCL_2Y89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164195 CVCL_2Y86 GM01671 finite cell line human CVCL_2Y86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21164196 CVCL_2Y87 GM03625 finite cell line human CVCL_2Y87 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female 21164197 CVCL_2Y51 AG21840 finite cell line human CVCL_2Y51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164198 CVCL_2Y52 AG21841 finite cell line human CVCL_2Y52 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164199 CVCL_2Y50 AG21834 finite cell line human CVCL_2Y50 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164200 CVCL_2Y55 AG21858 finite cell line human CVCL_2Y55 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164201 CVCL_2Y56 AG21859 finite cell line human CVCL_2Y56 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164202 CVCL_2Y53 AG21842 finite cell line human CVCL_2Y53 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164203 CVCL_2Y54 AG21857 finite cell line human CVCL_2Y54 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164204 CVCL_2Y59 AG21862 finite cell line human CVCL_2Y59 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164205 CVCL_2Y57 AG21860 finite cell line human CVCL_2Y57 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164206 CVCL_2Y58 AG21861 finite cell line human CVCL_2Y58 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164207 CVCL_2Y62 AG22009 finite cell line human CVCL_2Y62 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164208 CVCL_2Y63 AG22042 finite cell line human CVCL_2Y63 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164209 CVCL_2Y60 AG22007 finite cell line human CVCL_2Y60 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164210 CVCL_2Y61 AG22008 finite cell line human CVCL_2Y61 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164211 CVCL_2Y66 AG22055 finite cell line human CVCL_2Y66 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164212 CVCL_2Y67 AG22056 finite cell line human CVCL_2Y67 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164213 CVCL_2Y64 AG22050 finite cell line human CVCL_2Y64 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164214 CVCL_2Y65 AG22054 finite cell line human CVCL_2Y65 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164215 CVCL_2Y68 AG22057 finite cell line human CVCL_2Y68 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164216 CVCL_2Y69 AG22172 finite cell line human CVCL_2Y69 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: Coriell; AG22172; probable Male 21164217 CVCL_2Y39 AG21712 finite cell line human CVCL_2Y39 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164218 CVCL_2Y30 S004921 undefined cell line type CVCL_2Y30 CL:0000010 Discontinued: Coriell; S004921; probable. Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21164219 CVCL_2Y33 HQ00295 transformed cell line human CVCL_2Y33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00295; probable Male 21164220 CVCL_2Y31 S005226 transformed cell line CVCL_2Y31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005226; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21164221 CVCL_2Y32 S005808 transformed cell line CVCL_2Y32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; S005808; probable Male Group: Non-human primate cell line; Part of: Yerkes National Primate Research Center cell line collection 21164222 CVCL_2Y37 AG21704 finite cell line human CVCL_2Y37 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164223 CVCL_2Y38 AG21708 finite cell line human CVCL_2Y38 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164224 CVCL_2Y35 ND31009 finite cell line human CVCL_2Y35 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40-49] (c.52CAG(40-49)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31009; true Male 21164225 CVCL_2Y36 ND31008 finite cell line human CVCL_2Y36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31008; true Female 21164226 CVCL_2Y40 AG21753 finite cell line human CVCL_2Y40 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164227 CVCL_2Y41 AG21754 finite cell line human CVCL_2Y41 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164228 CVCL_2Y44 AG21803 finite cell line human CVCL_2Y44 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164229 CVCL_2Y45 AG21804 finite cell line human CVCL_2Y45 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164230 CVCL_2Y42 AG21801 finite cell line human CVCL_2Y42 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164231 CVCL_2Y43 AG21802 finite cell line human CVCL_2Y43 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164232 CVCL_2Y48 AG21822 finite cell line human CVCL_2Y48 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21164233 CVCL_2Y49 AG21823 finite cell line human CVCL_2Y49 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164234 CVCL_2Y46 AG21805 finite cell line human CVCL_2Y46 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21164235 CVCL_2Y47 AG21821 finite cell line human CVCL_2Y47 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21164236 CVCL_2Y19 PR01380 finite cell line CVCL_2Y19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01380; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164237 CVCL_2Y17 PR01378 finite cell line CVCL_2Y17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01378; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164238 CVCL_2Y18 PR01379 finite cell line CVCL_2Y18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01379; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164239 CVCL_2Y11 PR01240 finite cell line CVCL_2Y11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01240; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164240 CVCL_2Y12 PR01241 finite cell line CVCL_2Y12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01241; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164241 CVCL_2Y10 PR01239 finite cell line CVCL_2Y10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01239; probable Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164242 CVCL_2Y15 PR01375 finite cell line CVCL_2Y15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01375; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164243 CVCL_2Y16 PR01377 finite cell line CVCL_2Y16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01377; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164244 CVCL_2Y13 PR01257 finite cell line CVCL_2Y13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01257; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164245 CVCL_2Y14 PR01271 finite cell line CVCL_2Y14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01271; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164246 CVCL_2Y28 PR01411 finite cell line CVCL_2Y28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01411; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164247 CVCL_2Y29 PR01413 finite cell line CVCL_2Y29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01413; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164248 CVCL_2Y22 PR01393 finite cell line CVCL_2Y22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01393; probable Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164249 CVCL_2Y23 PR01396 finite cell line CVCL_2Y23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01396; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164250 CVCL_2Y20 PR01390 finite cell line CVCL_2Y20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01390; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164251 CVCL_2Y21 PR01391 finite cell line CVCL_2Y21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01391; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164252 CVCL_2Y26 PR01403 finite cell line CVCL_2Y26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01403; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164253 CVCL_2Y27 PR01410 finite cell line CVCL_2Y27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01410; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164254 CVCL_2Y24 PR01398 finite cell line CVCL_2Y24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01398; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164255 CVCL_2Y25 PR01402 finite cell line CVCL_2Y25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01402; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164256 CVCL_DN49 GM10981 finite cell line human CVCL_DN49 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21164257 CVCL_DN47 GM00697 finite cell line human CVCL_DN47 CL:0000010 Sequence variation: Mutation; HGNC; 18640; LDLRAP1; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV000004775; Zygosity=Homozygous (Coriell) Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Male 21164258 CVCL_DN48 GM10980 transformed cell line human CVCL_DN48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164259 CVCL_DN41 STHdhQ7/111 transformed cell line house mouse CVCL_DN41 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; striatum Cell type=Neuron.. 21164260 CVCL_DN42 ES[MC1R(20):tetTcea2] embryonic stem cell house mouse CVCL_DN42 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Male 21164261 CVCL_DN40 CW30265 induced pluripotent stem cell human CVCL_DN40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30265; true Female 21164262 CVCL_DN45 GM00694 finite cell line human CVCL_DN45 CL:0000010 Sequence variation: Mutation; HGNC; 18640; LDLRAP1; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV000004775; Zygosity=Homozygous (Coriell) Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Female 21164263 CVCL_DN46 GM00696 finite cell line human CVCL_DN46 CL:0000010 Sequence variation: Mutation; HGNC; 18640; LDLRAP1; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV000004775; Zygosity=Homozygous (Coriell) Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Female 21164264 CVCL_DN43 ES[MC1R(20):tetUtf1(7)] embryonic stem cell house mouse CVCL_DN43 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Male 21164265 CVCL_DN44 GM00667 finite cell line human CVCL_DN44 CL:0000010 Sequence variation: Mutation; HGNC; 18640; LDLRAP1; Simple; p.Gln136Ter (c.406C>T); ClinVar=VCV000004775; Zygosity=Homozygous (Coriell) Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Male 21164266 CVCL_DN58 CT1258-EGFP-HMGA2 cancer cell line dog CVCL_DN58 CL:0000010 Transfected with: UniProtKB; T2AX92; Dog HMGA2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Prostate; Breed/subspecies: Briard. Male 21164267 CVCL_DN59 DPC-1 cancer cell line dog CVCL_DN59 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Doberman Pinscher. Male Doubling time: 27 hours (PubMed=11170126) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2279 21164268 CVCL_DN52 GM22659 transformed cell line human CVCL_DN52 CL:0000010 Sequence variation: Mutation; HGNC; 2186; COL11A1; Simple; c.3816+1G>A (IVS50+1G>A); ClinVar=VCV000039776; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164269 CVCL_DN53 GM22786 finite cell line human CVCL_DN53 CL:0000010 Sequence variation: Mutation; HGNC; 2186; COL11A1; Simple; c.3816+1G>A (IVS50+1G>A); ClinVar=VCV000039776; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164270 CVCL_DN50 GM10982 transformed cell line human CVCL_DN50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164271 CVCL_DN51 GM10983 transformed cell line human CVCL_DN51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164272 CVCL_DN56 CPA-1 cancer cell line dog CVCL_DN56 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Doberman Pinscher. Male Doubling time: 40-45 hours (PubMed=3368402) 21164273 CVCL_DN57 CT1258-EGFP cancer cell line dog CVCL_DN57 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Prostate; Breed/subspecies: Briard. Male 21164274 CVCL_DN54 17G1 hybridoma house mouse CVCL_DN54 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. 21164275 CVCL_DN55 3F5.4G6 hybridoma house mouse CVCL_DN55 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12060 21164276 CVCL_DN27 Bliley cancer cell line dog CVCL_DN27 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; Simple; p.Val588Glu (c.1763T>A); Zygosity=Heterozygous (PubMed=27197945; PubMed=31175136) Derived from sampling site: Urinary bladder; Breed/subspecies: Shetland Sheepdog. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 20 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21164277 CVCL_DN28 Jones cancer cell line dog CVCL_DN28 CL:0000010 Sequence variation: Mutation; VGNC; 38196; ASXL1; Simple; p.Gly618fs (c.1850dupG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 43959; NRAS; Simple; p.Gln61Arg (c.182A>G); Zygosity=Heterozygous (PubMed=27197945; PubMed=31175136); Sequence variation: Mutation; VGNC; 44567; PTEN; Simple; p.Asp246fs (c.734dupA); Zygosity=Heterozygous (PubMed=31175136) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 14 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21164278 CVCL_DN25 K9TCC-PU-Pu cancer cell line dog CVCL_DN25 CL:0000010 Female Doubling time: 51.8 +- 1.0 hours (PubMed=18562222). 21164279 CVCL_DN26 K9TCC-PU-Sh cancer cell line dog CVCL_DN26 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Collie. Omics: Array-based CGH; Omics: CNV analysis Female Doubling time: 29.1 +- 3.4 hours (PubMed=18562222) 21164280 CVCL_DN29 MH/Nike cancer cell line dog CVCL_DN29 CL:0000010 Sequence variation: Mutation; VGNC; 43761; NF1; Simple; p.Ala2176fs (c.6525delG); Zygosity=Homozygous (PubMed=31175136) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 25 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21164281 CVCL_DN20 K9TCC-PU-AxA cancer cell line dog CVCL_DN20 CL:0000010 Derived from sampling site: Urinary bladder. Female Doubling time: 23.5 +- 1.9 hours (PubMed=18562222) 21164282 CVCL_DN23 K9TCC-PU-Mx cancer cell line dog CVCL_DN23 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: German Shepherd. Omics: Array-based CGH; Omics: CNV analysis Female Doubling time: 23.5 +- 1.3 hours (PubMed=18562222) 21164283 CVCL_DN24 K9TCC-PU-Nk cancer cell line dog CVCL_DN24 CL:0000010 Derived from sampling site: Urinary bladder. Female Doubling time: 58.4 +- 2.3 hours (PubMed=18562222) 21164284 CVCL_DN21 K9TCC-PU-AxC cancer cell line dog CVCL_DN21 CL:0000010 Derived from sampling site: Urinary bladder. Female Doubling time: 36.2 +- 2.9 hours (PubMed=18562222) 21164285 CVCL_DN22 K9TCC-PU-In cancer cell line dog CVCL_DN22 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: German Shepherd. Omics: Array-based CGH; Omics: CNV analysis Female Doubling time: 41.2 +- 12.2 hours (PubMed=18562222) 21164286 CVCL_DN38 GN7 transformed cell line Norway rat CVCL_DN38 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164287 CVCL_DN39 GP1 transformed cell line Norway rat CVCL_DN39 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164288 CVCL_DN36 GN2 transformed cell line Norway rat CVCL_DN36 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164289 CVCL_DN37 GN4 transformed cell line Norway rat CVCL_DN37 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164290 CVCL_DN30 Yamane cancer cell line dog CVCL_DN30 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Part of: FACC canine tumor cell line panel 21164291 CVCL_DN31 Talsky cancer cell line dog CVCL_DN31 CL:0000010 Unspecified 21164292 CVCL_DN34 GP8 [Rat liver transformed] transformed cell line Norway rat CVCL_DN34 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164293 CVCL_DN35 GN1 transformed cell line Norway rat CVCL_DN35 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164294 CVCL_DN32 Parks cancer cell line dog CVCL_DN32 CL:0000010 Sequence variation: Mutation; VGNC; 39068; CDKN1A; Simple; p.Asp33fs (c.97delG); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 54830; EIF1AX; Simple; p.Gly6Ser (c.16G>A); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 43120; MED12; Simple; p.Pro22Ser (c.64C>T); Zygosity=Homozygous (PubMed=31175136) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 30 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00444 Problematic cell line: Partially contaminated Some stocks of this cell line seemed to have been contaminated by a unknown human cell line (PubMed=21908323). 21164295 CVCL_DN33 WB-5-11 transformed cell line Norway rat CVCL_DN33 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male 21164296 CVCL_DN05 CW70321 induced pluripotent stem cell human CVCL_DN05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70321; true Female 21164297 CVCL_DN06 CW70322 induced pluripotent stem cell human CVCL_DN06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70322; true Male 21164298 CVCL_DN03 CW70319 induced pluripotent stem cell human CVCL_DN03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70319; true Female 21164299 CVCL_DN04 CW70320 induced pluripotent stem cell human CVCL_DN04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70320; true Male 21164300 CVCL_DN09 CW70325 induced pluripotent stem cell human CVCL_DN09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70325; true Male 21164301 CVCL_DN07 CW70323 induced pluripotent stem cell human CVCL_DN07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70323; true Male 21164302 CVCL_DN08 CW70324 induced pluripotent stem cell human CVCL_DN08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70324; true Male 21164303 CVCL_DN01 CW70316 induced pluripotent stem cell human CVCL_DN01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70316; true Male 21164304 CVCL_DN02 CW70318 induced pluripotent stem cell human CVCL_DN02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70318; true Male 21164305 CVCL_DN00 CW70315 induced pluripotent stem cell human CVCL_DN00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lebanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70315; true Male 21164306 CVCL_DN16 CW70345 induced pluripotent stem cell human CVCL_DN16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70345; true Female 21164307 CVCL_DN17 CW70347 induced pluripotent stem cell human CVCL_DN17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70347; true Female 21164308 CVCL_DN14 CW70342 induced pluripotent stem cell human CVCL_DN14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70342; true Male 21164309 CVCL_DN15 CW70344 induced pluripotent stem cell human CVCL_DN15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70344; true Male 21164310 CVCL_DN18 K9TCC cancer cell line dog CVCL_DN18 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Mixed breed. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 24.0 +- 0.7 hours (PubMed=18562222); 18 hours (PubMed=27257868) Caution: Was indicated to be part of the FACC canine tumor cell line panel in early version of PubMed=27197945, but was later removed 21164311 CVCL_DN19 K9TCC-PU-An cancer cell line dog CVCL_DN19 CL:0000010 Breed/subspecies: Scottish Terrier. Female 21164312 CVCL_DN12 CW70338 induced pluripotent stem cell human CVCL_DN12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70338; true Male 21164313 CVCL_DN13 CW70341 induced pluripotent stem cell human CVCL_DN13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70341; true Female 21164314 CVCL_DN10 CW70330 induced pluripotent stem cell human CVCL_DN10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70330; true Female 21164315 CVCL_DN11 CW70332 induced pluripotent stem cell human CVCL_DN11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70332; true Female 21164316 CVCL_MH66 BayGenomics ES cell line HMA310 embryonic stem cell house mouse CVCL_MH66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164317 CVCL_MH67 BayGenomics ES cell line HMA320 embryonic stem cell house mouse CVCL_MH67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039623; Thada Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164318 CVCL_MH64 BayGenomics ES cell line HMA300 embryonic stem cell house mouse CVCL_MH64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164319 CVCL_MH65 BayGenomics ES cell line HMA301 embryonic stem cell house mouse CVCL_MH65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201691; Rnf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164320 CVCL_MH62 BayGenomics ES cell line HMA274 embryonic stem cell house mouse CVCL_MH62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353633; Fus Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164321 CVCL_MH63 BayGenomics ES cell line HMA290 embryonic stem cell house mouse CVCL_MH63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95739; Glul Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164322 CVCL_MH60 BayGenomics ES cell line HMA257 embryonic stem cell house mouse CVCL_MH60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914345; Trak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164323 CVCL_MH61 BayGenomics ES cell line HMA263 embryonic stem cell house mouse CVCL_MH61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926157; Atf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164324 CVCL_VB00 LC0282 transformed cell line human CVCL_VB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164325 CVCL_VB03 LC0371 transformed cell line human CVCL_VB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164326 CVCL_VB04 LC0389 transformed cell line human CVCL_VB04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164327 CVCL_VB01 LC0291 transformed cell line human CVCL_VB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164328 CVCL_VB02 LC0293 transformed cell line human CVCL_VB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164329 CVCL_VB07 LC0579 transformed cell line human CVCL_VB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164330 CVCL_VB08 LC0658 transformed cell line human CVCL_VB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164331 CVCL_VB05 LC0404 transformed cell line human CVCL_VB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164332 CVCL_VB06 LC0501 transformed cell line human CVCL_VB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164333 CVCL_VB09 LC0696 transformed cell line human CVCL_VB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164334 CVCL_MH59 BayGenomics ES cell line HMA254 embryonic stem cell house mouse CVCL_MH59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289298; Knstrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164335 CVCL_MH57 BayGenomics ES cell line HMA252 embryonic stem cell house mouse CVCL_MH57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289298; Knstrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164336 CVCL_MH58 BayGenomics ES cell line HMA253 embryonic stem cell house mouse CVCL_MH58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101849; Rack1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164337 CVCL_MH77 BayGenomics ES cell line HMA346 embryonic stem cell house mouse CVCL_MH77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915699; Tbc1d10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164338 CVCL_MH78 BayGenomics ES cell line HMA348 embryonic stem cell house mouse CVCL_MH78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106281; Ilrun Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164339 CVCL_MH75 BayGenomics ES cell line HMA338 embryonic stem cell house mouse CVCL_MH75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888527; Apba3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164340 CVCL_MH76 BayGenomics ES cell line HMA339 embryonic stem cell house mouse CVCL_MH76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164341 CVCL_MH73 BayGenomics ES cell line HMA331 embryonic stem cell house mouse CVCL_MH73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164342 CVCL_MH74 BayGenomics ES cell line HMA333 embryonic stem cell house mouse CVCL_MH74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164343 CVCL_MH71 BayGenomics ES cell line HMA327 embryonic stem cell house mouse CVCL_MH71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164344 CVCL_MH72 BayGenomics ES cell line HMA329 embryonic stem cell house mouse CVCL_MH72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108295; Pxn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164345 CVCL_MH70 BayGenomics ES cell line HMA324 embryonic stem cell house mouse CVCL_MH70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921720; Cep72 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164346 CVCL_MH68 BayGenomics ES cell line HMA321 embryonic stem cell house mouse CVCL_MH68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443658; Prr14l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164347 CVCL_MH69 BayGenomics ES cell line HMA322 embryonic stem cell house mouse CVCL_MH69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915206; Kmt5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164348 CVCL_MH44 BayGenomics ES cell line HMA201 embryonic stem cell house mouse CVCL_MH44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914404; Mtdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164349 CVCL_MH45 BayGenomics ES cell line HMA204 embryonic stem cell house mouse CVCL_MH45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321393; Timeless Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164350 CVCL_MH42 BayGenomics ES cell line HMA185 embryonic stem cell house mouse CVCL_MH42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916969; Cad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164351 CVCL_MH43 BayGenomics ES cell line HMA192 embryonic stem cell house mouse CVCL_MH43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929455; Rpl23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164352 CVCL_MH40 BayGenomics ES cell line HMA175 embryonic stem cell house mouse CVCL_MH40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164353 CVCL_MH41 BayGenomics ES cell line HMA184 embryonic stem cell house mouse CVCL_MH41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915581; Stn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164354 CVCL_MH39 BayGenomics ES cell line HMA172 embryonic stem cell house mouse CVCL_MH39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915467; Prrc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164355 CVCL_MH37 BayGenomics ES cell line HMA164 embryonic stem cell house mouse CVCL_MH37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164356 CVCL_MH38 BayGenomics ES cell line HMA169 embryonic stem cell house mouse CVCL_MH38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354949; Dlc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164357 CVCL_MH35 BayGenomics ES cell line HMA153 embryonic stem cell house mouse CVCL_MH35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926037; Usp54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164358 CVCL_MH36 BayGenomics ES cell line HMA154 embryonic stem cell house mouse CVCL_MH36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164359 CVCL_MH55 BayGenomics ES cell line HMA247 embryonic stem cell house mouse CVCL_MH55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164360 CVCL_MH56 BayGenomics ES cell line HMA249 embryonic stem cell house mouse CVCL_MH56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145425; Depdc1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164361 CVCL_MH53 BayGenomics ES cell line HMA244 embryonic stem cell house mouse CVCL_MH53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164362 CVCL_MH54 BayGenomics ES cell line HMA245 embryonic stem cell house mouse CVCL_MH54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164363 CVCL_MH51 BayGenomics ES cell line HMA234 embryonic stem cell house mouse CVCL_MH51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923844; Dnajc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164364 CVCL_MH52 BayGenomics ES cell line HMA240 embryonic stem cell house mouse CVCL_MH52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164365 CVCL_MH50 BayGenomics ES cell line HMA221 embryonic stem cell house mouse CVCL_MH50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101839; Rpl28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164366 CVCL_MH48 BayGenomics ES cell line HMA210 embryonic stem cell house mouse CVCL_MH48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328362; Blm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164367 CVCL_MH49 BayGenomics ES cell line HMA218 embryonic stem cell house mouse CVCL_MH49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108390; Kif2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164368 CVCL_MH46 BayGenomics ES cell line HMA208 embryonic stem cell house mouse CVCL_MH46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164369 CVCL_MH47 BayGenomics ES cell line HMA209 embryonic stem cell house mouse CVCL_MH47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164370 CVCL_MH22 BayGenomics ES cell line HMA058 embryonic stem cell house mouse CVCL_MH22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164371 CVCL_MH23 BayGenomics ES cell line HMA065 embryonic stem cell house mouse CVCL_MH23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164372 CVCL_MH20 BayGenomics ES cell line HMA032 embryonic stem cell house mouse CVCL_MH20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164373 CVCL_MH21 BayGenomics ES cell line HMA043 embryonic stem cell house mouse CVCL_MH21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670969; Nrde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164374 CVCL_DN85 PR00655 transformed cell line CVCL_DN85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00655; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164375 CVCL_DN86 PR00660 transformed cell line CVCL_DN86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00660; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164376 CVCL_DN83 PR00573 finite cell line CVCL_DN83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00573; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164377 CVCL_DN84 PR00643 transformed cell line CVCL_DN84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00643; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164378 CVCL_DN89 PR00721 transformed cell line CVCL_DN89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00721; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164379 CVCL_DN87 PR00710 finite cell line CVCL_DN87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00710; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164380 CVCL_DN88 PR00718 transformed cell line CVCL_DN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00718; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164381 CVCL_MH19 BayGenomics ES cell line HMA013 embryonic stem cell house mouse CVCL_MH19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164382 CVCL_MH17 BayGenomics ES cell line HMA004 embryonic stem cell house mouse CVCL_MH17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107716; Myo10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164383 CVCL_MH18 BayGenomics ES cell line HMA010 embryonic stem cell house mouse CVCL_MH18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164384 CVCL_MH15 BayGenomics ES cell line GST193 embryonic stem cell house mouse CVCL_MH15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164385 CVCL_DN81 PR00488 transformed cell line CVCL_DN81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00488; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164386 CVCL_MH16 BayGenomics ES cell line GST203 embryonic stem cell house mouse CVCL_MH16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164387 CVCL_DN82 PR00512 finite cell line CVCL_DN82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00512; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164388 CVCL_MH13 BayGenomics ES cell line GST184 embryonic stem cell house mouse CVCL_MH13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164389 CVCL_MH14 BayGenomics ES cell line GST191 embryonic stem cell house mouse CVCL_MH14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96437; Igfbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164390 CVCL_DN80 PR00446 finite cell line bonobo/pygmy chimpanzee CVCL_DN80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00446; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164391 CVCL_MH33 BayGenomics ES cell line HMA136 embryonic stem cell house mouse CVCL_MH33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443114; Larp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164392 CVCL_MH34 BayGenomics ES cell line HMA140 embryonic stem cell house mouse CVCL_MH34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914144; Wwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164393 CVCL_MH31 BayGenomics ES cell line HMA134 embryonic stem cell house mouse CVCL_MH31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151233; Dph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164394 CVCL_MH32 BayGenomics ES cell line HMA135 embryonic stem cell house mouse CVCL_MH32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349399; Casp8ap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164395 CVCL_MH30 BayGenomics ES cell line HMA121 embryonic stem cell house mouse CVCL_MH30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164396 CVCL_DN96 PR00961 transformed cell line CVCL_DN96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00961; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164397 CVCL_DN97 PR00963 transformed cell line CVCL_DN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00963; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164398 CVCL_DN94 PR00953 transformed cell line CVCL_DN94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00953; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164399 CVCL_DN95 PR00960 transformed cell line CVCL_DN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00960; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164400 CVCL_DN98 PR00981 transformed cell line CVCL_DN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00981; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164401 CVCL_DN99 PR00983 transformed cell line CVCL_DN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00983; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164402 CVCL_MH28 BayGenomics ES cell line HMA103 embryonic stem cell house mouse CVCL_MH28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333825; Dgat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164403 CVCL_MH29 BayGenomics ES cell line HMA113 embryonic stem cell house mouse CVCL_MH29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164404 CVCL_MH26 BayGenomics ES cell line HMA095 embryonic stem cell house mouse CVCL_MH26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164405 CVCL_DN92 PR00807 transformed cell line CVCL_DN92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00807; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164406 CVCL_MH27 BayGenomics ES cell line HMA097 embryonic stem cell house mouse CVCL_MH27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925953; Zfp972 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164407 CVCL_DN93 PR00841 transformed cell line CVCL_DN93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00841; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164408 CVCL_MH24 BayGenomics ES cell line HMA073 embryonic stem cell house mouse CVCL_MH24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164409 CVCL_DN90 PR00744 finite cell line CVCL_DN90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00744; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164410 CVCL_MH25 BayGenomics ES cell line HMA086 embryonic stem cell house mouse CVCL_MH25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164411 CVCL_DN91 PR00786 undefined cell line type CVCL_DN91 CL:0000010 Discontinued: Coriell; PR00786; probable. Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164412 CVCL_MH00 BayGenomics ES cell line GST127 embryonic stem cell house mouse CVCL_MH00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105088; Ntn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164413 CVCL_MH01 BayGenomics ES cell line GST139 embryonic stem cell house mouse CVCL_MH01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164414 CVCL_DN69 ST14A HTT-Q120 High conditionally immortalized cell line Norway rat CVCL_DN69 CL:0000010 Transfected with: HGNC; 4851; HTT (1-548 region with 120-Q run); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum; Breed/subspecies: Sprague Dawley. Unspecified 21164415 CVCL_DN63 PC12 HTT-SW2-Q23-TagRFP clone 34 cancer cell line Norway rat CVCL_DN63 CL:0000010 Transfected with: HGNC; 4851; HTT (with 23-Q run); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain TagRFP) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164416 CVCL_DN64 PC12 HTT-SW2-Q73 clone 29 cancer cell line Norway rat CVCL_DN64 CL:0000010 Transfected with: HGNC; 4851; HTT (with 73-Q run) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164417 CVCL_DN61 PC12 HTT-SW2-Q145-TagRFP clone 5 cancer cell line Norway rat CVCL_DN61 CL:0000010 Transfected with: HGNC; 4851; HTT (with 145-Q run); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain TagRFP) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164418 CVCL_DN62 PC12 HTT-SW2-Q23 clone 28 cancer cell line Norway rat CVCL_DN62 CL:0000010 Transfected with: HGNC; 4851; HTT (with 23-Q run) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164419 CVCL_DN67 PSM-P12 hybridoma house mouse CVCL_DN67 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q04609; Human FOLH1/PSMA. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2280 21164420 CVCL_DN68 ST14A HTT-Q120 conditionally immortalized cell line Norway rat CVCL_DN68 CL:0000010 Transfected with: HGNC; 4851; HTT (1-548 region with 120-Q run); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum; Breed/subspecies: Sprague Dawley. Unspecified 21164421 CVCL_DN65 PC12 HTT-SW2-Q73-TagRFP clone 17 cancer cell line Norway rat CVCL_DN65 CL:0000010 Transfected with: HGNC; 4851; HTT (with 73-Q run); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain TagRFP) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164422 CVCL_DN66 Probasco cancer cell line dog CVCL_DN66 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Male Doubling time: ~18 hours (PubMed=25043424) 21164423 CVCL_DN60 PC12 HTT-SW2-Q145 clone 14 cancer cell line Norway rat CVCL_DN60 CL:0000010 Transfected with: HGNC; 4851; HTT (with 145-Q run) Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21164424 CVCL_MH11 BayGenomics ES cell line GST178 embryonic stem cell house mouse CVCL_MH11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108077; Nptn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164425 CVCL_MH12 BayGenomics ES cell line GST182 embryonic stem cell house mouse CVCL_MH12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96435; Igf2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164426 CVCL_MH10 BayGenomics ES cell line GST176 embryonic stem cell house mouse CVCL_MH10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109322; Kcnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164427 CVCL_DN74 PR00134 transformed cell line CVCL_DN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00134; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164428 CVCL_DN75 PR00265 transformed cell line CVCL_DN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00265; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164429 CVCL_DN72 PR00041 finite cell line CVCL_DN72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00041; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164430 CVCL_DN73 PR00111 finite cell line bonobo/pygmy chimpanzee CVCL_DN73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00111; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164431 CVCL_DN78 PR00398 transformed cell line CVCL_DN78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00398; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164432 CVCL_DN79 PR00408 transformed cell line CVCL_DN79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00408; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164433 CVCL_DN76 PR00276 transformed cell line CVCL_DN76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00276; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164434 CVCL_DN77 PR00367 transformed cell line bonobo/pygmy chimpanzee CVCL_DN77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00367; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21164435 CVCL_MH08 BayGenomics ES cell line GST166 embryonic stem cell house mouse CVCL_MH08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164436 CVCL_MH09 BayGenomics ES cell line GST171 embryonic stem cell house mouse CVCL_MH09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926157; Atf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164437 CVCL_MH06 BayGenomics ES cell line GST160 embryonic stem cell house mouse CVCL_MH06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924015; Mlec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164438 CVCL_MH07 BayGenomics ES cell line GST161 embryonic stem cell house mouse CVCL_MH07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98658; Tdgf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164439 CVCL_MH04 BayGenomics ES cell line GST158 embryonic stem cell house mouse CVCL_MH04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888921; P3h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164440 CVCL_DN70 ST14A HTT-Q15 conditionally immortalized cell line Norway rat CVCL_DN70 CL:0000010 Transfected with: HGNC; 4851; HTT (1-548 region with 15-Q run) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum; Breed/subspecies: Sprague Dawley. Unspecified 21164441 CVCL_MH05 BayGenomics ES cell line GST159 embryonic stem cell house mouse CVCL_MH05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164442 CVCL_DN71 ST14A HTT-Q15 High conditionally immortalized cell line Norway rat CVCL_DN71 CL:0000010 Transfected with: HGNC; 4851; HTT (1-548 region with 15-Q run); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; forebrain; striatum; Breed/subspecies: Sprague Dawley. Unspecified 21164443 CVCL_MH02 BayGenomics ES cell line GST142 embryonic stem cell house mouse CVCL_MH02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138856; Ldlrad3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164444 CVCL_MH03 BayGenomics ES cell line GST151 embryonic stem cell house mouse CVCL_MH03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95309; Eif5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164445 CVCL_2Z18 ID00031 transformed cell line human CVCL_2Z18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164446 CVCL_2Z19 ID00032 transformed cell line human CVCL_2Z19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164447 CVCL_2Z16 ID00028 transformed cell line human CVCL_2Z16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164448 CVCL_2Z17 ID00029 transformed cell line human CVCL_2Z17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164449 CVCL_VA62 BLi0204 transformed cell line human CVCL_VA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164450 CVCL_VA63 BLi0236 transformed cell line human CVCL_VA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164451 CVCL_VA60 BLi0083 transformed cell line human CVCL_VA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164452 CVCL_VA61 BLi0097 transformed cell line human CVCL_VA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164453 CVCL_VA66 BLi0251 transformed cell line human CVCL_VA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164454 CVCL_VA67 BLi0254 transformed cell line human CVCL_VA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164455 CVCL_VA64 BLi0246 transformed cell line human CVCL_VA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164456 CVCL_VA65 BLi0249 transformed cell line human CVCL_VA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164457 CVCL_VA68 BLi0265 transformed cell line human CVCL_VA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164458 CVCL_VA69 BOx0029 transformed cell line human CVCL_VA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164459 CVCL_2Z10 ID00016 transformed cell line human CVCL_2Z10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164460 CVCL_2Z11 ID00021 transformed cell line human CVCL_2Z11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164461 CVCL_2Z14 ID00025 transformed cell line human CVCL_2Z14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164462 CVCL_2Z15 ID00026 transformed cell line human CVCL_2Z15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164463 CVCL_2Z12 ID00022 transformed cell line human CVCL_2Z12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164464 CVCL_2Z13 ID00024 transformed cell line human CVCL_2Z13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164465 CVCL_2Z29 ID00078 transformed cell line human CVCL_2Z29 CL:0000010 Sequence variation: Mutation; HGNC; 9831; RAG1; Simple; p.Arg332Ter (c.994C>T); ClinVar=VCV000649706; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9831; RAG1; Simple; p.Arg561His (c.1682G>A); ClinVar=VCV000013143; Zygosity=Heterozygous (Coriell) Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164466 CVCL_2Z27 ID00063 transformed cell line human CVCL_2Z27 CL:0000010 Sequence variation: Mutation; HGNC; 11935; CD40LG; Simple; p.Ala187Leufs*4 (c.559delG) (580delG); ClinVar=VCV000521393; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164467 CVCL_2Z28 ID00064 transformed cell line human CVCL_2Z28 CL:0000010 Sequence variation: Mutation; HGNC; 11935; CD40LG; Simple; p.Ala187Leufs*4 (c.559delG) (580delG); ClinVar=VCV000521393; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164468 CVCL_VA51 BC6231 transformed cell line human CVCL_VA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164469 CVCL_VA52 BC6263 transformed cell line human CVCL_VA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164470 CVCL_VA50 BC6141 transformed cell line human CVCL_VA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164471 CVCL_VA55 BC6434 transformed cell line human CVCL_VA55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164472 CVCL_VA56 BC6448 transformed cell line human CVCL_VA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164473 CVCL_VA53 BC6309 transformed cell line human CVCL_VA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164474 CVCL_VA54 BC6325 transformed cell line human CVCL_VA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164475 CVCL_VA59 BLi0036 transformed cell line human CVCL_VA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164476 CVCL_VA57 BC6505 transformed cell line human CVCL_VA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164477 CVCL_VA58 BLi0001 transformed cell line human CVCL_VA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164478 CVCL_2Z21 ID00035 transformed cell line human CVCL_2Z21 CL:0000010 Sequence variation: Mutation; HGNC; 1133; BTK; Simple; c.361C>A; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164479 CVCL_2Z22 ID00044 transformed cell line human CVCL_2Z22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164480 CVCL_2Z20 ID00034 transformed cell line human CVCL_2Z20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164481 CVCL_2Z25 ID00051 transformed cell line human CVCL_2Z25 CL:0000010 Sequence variation: Mutation; HGNC; 10820; SH2D1A; Simple; c.577G>A; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164482 CVCL_2Z26 ID00052 transformed cell line human CVCL_2Z26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164483 CVCL_2Z23 ID00045 transformed cell line human CVCL_2Z23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164484 CVCL_2Z24 ID00050 transformed cell line human CVCL_2Z24 CL:0000010 Sequence variation: Mutation; HGNC; 10820; SH2D1A; Simple; p.Arg55Ter (c.163C>T); ClinVar=VCV000010898; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164485 CVCL_VA40 Y79-6 cancer cell line human CVCL_VA40 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Eye; globe. Female 21164486 CVCL_VA41 RB507 cancer cell line human CVCL_VA41 CL:0000010 21164487 CVCL_VA44 BC6046 transformed cell line human CVCL_VA44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164488 CVCL_VA45 BC6055 transformed cell line human CVCL_VA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164489 CVCL_VA42 BBr0015 transformed cell line human CVCL_VA42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164490 CVCL_VA43 BC6023 transformed cell line human CVCL_VA43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164491 CVCL_VA48 BC6073 transformed cell line human CVCL_VA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164492 CVCL_VA49 BC6125 transformed cell line human CVCL_VA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164493 CVCL_VA46 BC6062 transformed cell line human CVCL_VA46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164494 CVCL_VA47 BC6071 transformed cell line human CVCL_VA47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164495 CVCL_2Z07 ID00013 transformed cell line human CVCL_2Z07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164496 CVCL_2Z08 ID00014 transformed cell line human CVCL_2Z08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164497 CVCL_2Z05 ID00006 transformed cell line human CVCL_2Z05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164498 CVCL_2Z06 ID00011 transformed cell line human CVCL_2Z06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164499 CVCL_2Z09 ID00015 transformed cell line human CVCL_2Z09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21164500 CVCL_VA30 5f2-14 induced pluripotent stem cell CVCL_VA30 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164501 CVCL_VA33 Hep-G2 B-1 cancer cell line human CVCL_VA33 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the B-genotype 21164502 CVCL_VA34 Hep-G2 C-1 cancer cell line human CVCL_VA34 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the C-genotype 21164503 CVCL_VA31 5f2-18 induced pluripotent stem cell CVCL_VA31 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164504 CVCL_VA32 Hep-G2 A-1 cancer cell line human CVCL_VA32 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Contains 2 head to tails stably integrated hepatitis B virus (HBV) of the A-genotype 21164505 CVCL_VA37 ULUNDi001-A induced pluripotent stem cell human CVCL_VA37 From: University of Lund; Lund; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Gln456Ter (c.1366C>T); ClinVar=VCV000002415; Zygosity=Homozygous (PubMed=29331938) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21164506 CVCL_VA38 ULUNDi004-A induced pluripotent stem cell human CVCL_VA38 From: University of Lund; Lund; Sweden CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164507 CVCL_VA35 NIH3T3-47 spontaneously immortalized cell line house mouse CVCL_VA35 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: New England Biolabs; Catalog number C2001 Male 21164508 CVCL_VA36 CHO-R5 spontaneously immortalized cell line CVCL_VA36 CL:0000010 Derived from sampling site: Ovary. Discontinued: New England Biolabs; Catalog number C2005 Female 21164509 CVCL_VA39 SK-MEL-59 cancer cell line human CVCL_VA39 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21164510 CVCL_2Z00 GM17942 transformed cell line human CVCL_2Z00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21164511 CVCL_2Z03 ID00003 transformed cell line human CVCL_2Z03 CL:0000010 Sequence variation: Mutation; HGNC; 12731; WAS; Simple; p.Glu133Lys (c.397G>A); ClinVar=VCV000870492; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164512 CVCL_2Z04 ID00004 transformed cell line human CVCL_2Z04 CL:0000010 Sequence variation: Mutation; HGNC; 12731; WAS; Simple; p.Glu133Lys (c.397G>A); ClinVar=VCV000870492; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164513 CVCL_2Z01 ID00001 transformed cell line human CVCL_2Z01 CL:0000010 Sequence variation: Mutation; HGNC; 1133; BTK; Simple; p.Tyr361Cys (c.1082A>G); ClinVar=VCV000011346; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164514 CVCL_2Z02 ID00002 transformed cell line human CVCL_2Z02 CL:0000010 Sequence variation: Mutation; HGNC; 11935; CD40LG; Simple; p.Leu155Pro (c.464T>C); ClinVar=VCV000011160; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164515 CVCL_MG89 BayGenomics ES cell line GST090 embryonic stem cell house mouse CVCL_MG89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919711; Prcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164516 CVCL_MG87 BayGenomics ES cell line GST073 embryonic stem cell house mouse CVCL_MG87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164517 CVCL_MG88 BayGenomics ES cell line GST089 embryonic stem cell house mouse CVCL_MG88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95321; Emb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164518 CVCL_MG85 BayGenomics ES cell line GST070 embryonic stem cell house mouse CVCL_MG85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164519 CVCL_MG86 BayGenomics ES cell line GST071 embryonic stem cell house mouse CVCL_MG86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164520 CVCL_MG83 BayGenomics ES cell line GST066 embryonic stem cell house mouse CVCL_MG83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354756; Crim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164521 CVCL_MG84 BayGenomics ES cell line GST067 embryonic stem cell house mouse CVCL_MG84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164522 CVCL_MG81 BayGenomics ES cell line GST063 embryonic stem cell house mouse CVCL_MG81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105088; Ntn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164523 CVCL_MG82 BayGenomics ES cell line GST065 embryonic stem cell house mouse CVCL_MG82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104864; Pdia4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164524 CVCL_MG80 BayGenomics ES cell line GST062 embryonic stem cell house mouse CVCL_MG80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194891; Gpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164525 CVCL_VA22 ID8-B7H6 spontaneously immortalized cell line house mouse CVCL_VA22 CL:0000010 Transfected with: HGNC; 42400; NCR3LG1 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female 21164526 CVCL_VA23 RMA-B7H6 cancer cell line house mouse CVCL_VA23 CL:0000010 Transfected with: HGNC; 42400; NCR3LG1 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21164527 CVCL_VA20 HSCj-009 transformed cell line CVCL_VA20 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri) [Strain 488-77](NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21164528 CVCL_VA21 B16F10-B7H6 cancer cell line house mouse CVCL_VA21 CL:0000010 Transfected with: HGNC; 42400; NCR3LG1 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21164529 CVCL_VA26 4f1-1 induced pluripotent stem cell CVCL_VA26 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164530 CVCL_VA27 5f1-1 induced pluripotent stem cell CVCL_VA27 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164531 CVCL_VA24 SHSY5Y-B7H6 cancer cell line human CVCL_VA24 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 42400; NCR3LG1 Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21164532 CVCL_VA25 Snow leopard iPS induced pluripotent stem cell CVCL_VA25 CL:0000010 Derived from sampling site: Ear Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21164533 CVCL_VA28 5f2-7 induced pluripotent stem cell CVCL_VA28 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164534 CVCL_VA29 5f2-11 induced pluripotent stem cell CVCL_VA29 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21164535 CVCL_MG98 BayGenomics ES cell line GST111 embryonic stem cell house mouse CVCL_MG98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87904; Actb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164536 CVCL_MG99 BayGenomics ES cell line GST126 embryonic stem cell house mouse CVCL_MG99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164537 CVCL_MG96 BayGenomics ES cell line GST101 embryonic stem cell house mouse CVCL_MG96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1274781; Robo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164538 CVCL_MG97 BayGenomics ES cell line GST107 embryonic stem cell house mouse CVCL_MG97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107559; Sema4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164539 CVCL_MG94 BayGenomics ES cell line GST098 embryonic stem cell house mouse CVCL_MG94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97814; Ptprg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164540 CVCL_MG95 BayGenomics ES cell line GST100 embryonic stem cell house mouse CVCL_MG95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164541 CVCL_MG92 BayGenomics ES cell line GST093 embryonic stem cell house mouse CVCL_MG92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858901; Fut8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164542 CVCL_MG93 BayGenomics ES cell line GST094 embryonic stem cell house mouse CVCL_MG93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164543 CVCL_MG90 BayGenomics ES cell line GST091 embryonic stem cell house mouse CVCL_MG90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96433; Igf1r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164544 CVCL_MG91 BayGenomics ES cell line GST092 embryonic stem cell house mouse CVCL_MG91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164545 CVCL_VA11 BIHi025-A induced pluripotent stem cell human CVCL_VA11 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164546 CVCL_VA12 BIHi028-A induced pluripotent stem cell human CVCL_VA12 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: EBiSC; BIHi028-A; true Female 21164547 CVCL_VA10 BIHi024-A induced pluripotent stem cell human CVCL_VA10 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164548 CVCL_VA15 BIHi029-A induced pluripotent stem cell human CVCL_VA15 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164549 CVCL_VA16 BIHi029-B induced pluripotent stem cell human CVCL_VA16 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164550 CVCL_VA13 BIHi028-B induced pluripotent stem cell human CVCL_VA13 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164551 CVCL_VA14 BIHi028-C induced pluripotent stem cell human CVCL_VA14 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164552 CVCL_VA19 BIHi030-B induced pluripotent stem cell human CVCL_VA19 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164553 CVCL_VA17 BIHi029-C induced pluripotent stem cell human CVCL_VA17 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164554 CVCL_VA18 BIHi030-A induced pluripotent stem cell human CVCL_VA18 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164555 CVCL_MG67 BayGenomics ES cell line GST011 embryonic stem cell house mouse CVCL_MG67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298229; Nid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164556 CVCL_MG68 BayGenomics ES cell line GST012 embryonic stem cell house mouse CVCL_MG68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164557 CVCL_MG65 BayGenomics ES cell line GST008 embryonic stem cell house mouse CVCL_MG65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926157; Atf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164558 CVCL_MG66 BayGenomics ES cell line GST009 embryonic stem cell house mouse CVCL_MG66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164559 CVCL_MG63 BayGenomics ES cell line GST003 embryonic stem cell house mouse CVCL_MG63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139714; Adgrl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164560 CVCL_MG64 BayGenomics ES cell line GST004 embryonic stem cell house mouse CVCL_MG64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164561 CVCL_MG61 BayGenomics ES cell line GST001 embryonic stem cell house mouse CVCL_MG61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164562 CVCL_MG62 BayGenomics ES cell line GST002 embryonic stem cell house mouse CVCL_MG62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98277; Epha4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164563 CVCL_MG60 BayGenomics ES cell line GFP018 embryonic stem cell house mouse CVCL_MG60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109372; Cbx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164564 CVCL_VA00 BIHi009-A induced pluripotent stem cell human CVCL_VA00 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164565 CVCL_VA01 BIHi009-B induced pluripotent stem cell human CVCL_VA01 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164566 CVCL_VA04 BIHi012-A induced pluripotent stem cell human CVCL_VA04 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164567 CVCL_VA05 BIHi015-A induced pluripotent stem cell human CVCL_VA05 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164568 CVCL_VA02 BIHi010-A induced pluripotent stem cell human CVCL_VA02 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164569 CVCL_VA03 BIHi011-A induced pluripotent stem cell human CVCL_VA03 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164570 CVCL_VA08 BIHi018-A induced pluripotent stem cell human CVCL_VA08 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164571 CVCL_VA09 BIHi019-A induced pluripotent stem cell human CVCL_VA09 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164572 CVCL_VA06 BIHi016-A induced pluripotent stem cell human CVCL_VA06 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21164573 CVCL_VA07 BIHi017-A induced pluripotent stem cell human CVCL_VA07 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21164574 CVCL_MG58 BayGenomics ES cell line Ex504 embryonic stem cell house mouse CVCL_MG58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923549; Erp44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164575 CVCL_MG59 BayGenomics ES cell line Ex510 embryonic stem cell house mouse CVCL_MG59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164576 CVCL_MG78 BayGenomics ES cell line GST055 embryonic stem cell house mouse CVCL_MG78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443162; Uggt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164577 CVCL_MG79 BayGenomics ES cell line GST057 embryonic stem cell house mouse CVCL_MG79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164578 CVCL_MG76 BayGenomics ES cell line GST048 embryonic stem cell house mouse CVCL_MG76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926157; Atf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164579 CVCL_MG77 BayGenomics ES cell line GST050 embryonic stem cell house mouse CVCL_MG77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107476; Stim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164580 CVCL_MG74 BayGenomics ES cell line GST046 embryonic stem cell house mouse CVCL_MG74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164581 CVCL_MG75 BayGenomics ES cell line GST047 embryonic stem cell house mouse CVCL_MG75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104669; Man2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164582 CVCL_MG72 BayGenomics ES cell line GST039 embryonic stem cell house mouse CVCL_MG72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100492; Nrp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164583 CVCL_MG73 BayGenomics ES cell line GST042 embryonic stem cell house mouse CVCL_MG73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443955; Lrig3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164584 CVCL_MG70 BayGenomics ES cell line GST017 embryonic stem cell house mouse CVCL_MG70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164585 CVCL_MG71 BayGenomics ES cell line GST033 embryonic stem cell house mouse CVCL_MG71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164586 CVCL_MG69 BayGenomics ES cell line GST015 embryonic stem cell house mouse CVCL_MG69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21164587 CVCL_2Z90 CAMi002-A induced pluripotent stem cell human CVCL_2Z90 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21164588 CVCL_2Z91 CAMi002-B induced pluripotent stem cell human CVCL_2Z91 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21164589 CVCL_2Z94 UKKi007-A induced pluripotent stem cell human CVCL_2Z94 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Phe2483Ile (c.7447T>A); Zygosity=Heterozygous (PubMed=22178870) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Ximbio; 153331; probable Female 21164590 CVCL_2Z95 U937-DC-SIGN cancer cell line human CVCL_2Z95 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1641; CD209 Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21164591 CVCL_2Z92 CAMi002-C induced pluripotent stem cell human CVCL_2Z92 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21164592 CVCL_2Z93 CAMi004-A induced pluripotent stem cell human CVCL_2Z93 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Adipose tissue. Female 21164593 CVCL_2Z98 MCF-7D3Res cancer cell line human CVCL_2Z98 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27300; Vitamin D; Derived from metastatic site: Pleural effusion. Female 21164594 CVCL_2Z99 Shox2 finite cell line house mouse CVCL_2Z99 CL:0000010 Breed/subspecies: 129S1/SvImJ. Male 21164595 CVCL_2Z96 HEY-T30 cancer cell line human CVCL_2Z96 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol) Female 21164596 CVCL_2Z97 MCF-7/VD(R) cancer cell line human CVCL_2Z97 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27300; Vitamin D; Derived from metastatic site: Pleural effusion. Female 21164597 CVCL_2Z72 GM02098 finite cell line human CVCL_2Z72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male Characteristics: Hypersensitive to cell killing by ionizing radiation (Coriell) 21164598 CVCL_2Z73 GM02099 transformed cell line human CVCL_2Z73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164599 CVCL_2Z70 GM01725 finite cell line human CVCL_2Z70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164600 CVCL_2Z71 GM01726 transformed cell line human CVCL_2Z71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164601 CVCL_2Z76 GM03300 finite cell line human CVCL_2Z76 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164602 CVCL_2Z77 GM09833 transformed cell line human CVCL_2Z77 CL:0000010 Population: Caucasian; Irish; Karyotypic information: 46,XX,ins(5;15)(5pter->5q23.2::15q23->15q26.1::5q23.2->5qter;15pter->15q23::15q26.1->15qter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164603 CVCL_2Z74 GM02138 finite cell line human CVCL_2Z74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164604 CVCL_2Z75 GM02139 transformed cell line human CVCL_2Z75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164605 CVCL_2Z78 GM09834 finite cell line human CVCL_2Z78 CL:0000010 Population: Caucasian; Irish; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21164606 CVCL_2Z79 GM14155 transformed cell line human CVCL_2Z79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164607 CVCL_2Z80 Cj11 embryonic stem cell CVCL_2Z80 CL:0000010 Female Group: Non-human primate cell line. 21164608 CVCL_2Z83 PR00818-iPS induced pluripotent stem cell CVCL_2Z83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21164609 CVCL_2Z84 AG05253-iPS induced pluripotent stem cell bonobo/pygmy chimpanzee CVCL_2Z84 CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21164610 CVCL_2Z81 PR01086-iPS induced pluripotent stem cell bonobo/pygmy chimpanzee CVCL_2Z81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21164611 CVCL_2Z82 PR01209-iPS induced pluripotent stem cell CVCL_2Z82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21164612 CVCL_2Z87 Thy16 cancer cell line house mouse CVCL_2Z87 CL:0000010 Breed/subspecies: BALB/c. 21164613 CVCL_2Z88 HS980 embryonic stem cell human CVCL_2Z88 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female 21164614 CVCL_2Z85 Thy0517 cancer cell line human CVCL_2Z85 CL:0000010 Population: Chinese; Derived from sampling site: Thymus; anterior mediastinum. Male Doubling time: 37 hours (PubMed=26273358) 21164615 CVCL_2Z86 ThyL-6 cancer cell line human CVCL_2Z86 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 26.3 hours (PubMed=18691242) 21164616 CVCL_2Z89 CAMi001-A induced pluripotent stem cell human CVCL_2Z89 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21164617 CVCL_2Z50 GM04372 finite cell line human CVCL_2Z50 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21164618 CVCL_2Z51 GM04517 finite cell line human CVCL_2Z51 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164619 CVCL_2Z54 GM06805 transformed cell line human CVCL_2Z54 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164620 CVCL_2Z55 GM06806 finite cell line human CVCL_2Z55 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164621 CVCL_2Z52 GM04913 finite cell line human CVCL_2Z52 CL:0000010 Population: Caucasian; Greek; Derived from sampling site: Fetal spleen Cell type=Fibroblast.. Unspecified 21164622 CVCL_2Z53 GM04914 finite cell line human CVCL_2Z53 CL:0000010 Population: Caucasian; Greek; Derived from sampling site: Fetal brain Cell type=Fibroblast.. Unspecified 21164623 CVCL_2Z58 GM06809 transformed cell line human CVCL_2Z58 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164624 CVCL_2Z59 GM06810 finite cell line human CVCL_2Z59 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21164625 CVCL_2Z56 GM06807 transformed cell line human CVCL_2Z56 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164626 CVCL_2Z57 GM06808 finite cell line human CVCL_2Z57 CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Unexplicit; Ex11-17del (30-KB DEL,IVS10); ClinVar=VCV000003819; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164627 CVCL_VA91 BP6551 transformed cell line human CVCL_VA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164628 CVCL_VA92 LC0009 transformed cell line human CVCL_VA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164629 CVCL_VA90 BP6550 transformed cell line human CVCL_VA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164630 CVCL_VA95 LC0170 transformed cell line human CVCL_VA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164631 CVCL_VA96 LC0209 transformed cell line human CVCL_VA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164632 CVCL_VA93 LC0049 transformed cell line human CVCL_VA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164633 CVCL_VA94 LC0169 transformed cell line human CVCL_VA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164634 CVCL_VA99 LC0270 transformed cell line human CVCL_VA99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164635 CVCL_VA97 LC0216 transformed cell line human CVCL_VA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164636 CVCL_VA98 LC0226 transformed cell line human CVCL_VA98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164637 CVCL_2Z61 GM01552 finite cell line human CVCL_2Z61 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21164638 CVCL_2Z62 GM01553 transformed cell line human CVCL_2Z62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164639 CVCL_2Z60 GM08304 finite cell line human CVCL_2Z60 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164640 CVCL_2Z65 GM01577 finite cell line human CVCL_2Z65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21164641 CVCL_2Z66 GM01578 transformed cell line human CVCL_2Z66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164642 CVCL_2Z63 GM01575 finite cell line human CVCL_2Z63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164643 CVCL_2Z64 GM01576 transformed cell line human CVCL_2Z64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164644 CVCL_2Z69 GM01658 finite cell line human CVCL_2Z69 CL:0000010 Population: Caucasian; Derived from sampling site: Skin (Note=From a lesion) Cell type=Fibroblast.. Male 21164645 CVCL_2Z67 GM01656 transformed cell line human CVCL_2Z67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164646 CVCL_2Z68 GM01657 finite cell line human CVCL_2Z68 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164647 CVCL_2Z38 H36-4-5.2 hybridoma house mouse CVCL_2Z38 CL:0000010 Discontinued: Coriell; WC00005; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21164648 CVCL_2Z39 L39-17 hybridoma house mouse CVCL_2Z39 CL:0000010 Discontinued: Coriell; WC00006; probable. 21164649 CVCL_VA80 BP6334 transformed cell line human CVCL_VA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164650 CVCL_VA81 BP6391 transformed cell line human CVCL_VA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164651 CVCL_VA84 BP6494 transformed cell line human CVCL_VA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164652 CVCL_VA85 BP6502 transformed cell line human CVCL_VA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164653 CVCL_VA82 BP6447 transformed cell line human CVCL_VA82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164654 CVCL_VA83 BP6488 transformed cell line human CVCL_VA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164655 CVCL_VA88 BP6531 transformed cell line human CVCL_VA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164656 CVCL_VA89 BP6535 transformed cell line human CVCL_VA89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164657 CVCL_VA86 BP6504 transformed cell line human CVCL_VA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164658 CVCL_VA87 BP6508 transformed cell line human CVCL_VA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164659 CVCL_2Z32 ID00082 transformed cell line human CVCL_2Z32 CL:0000010 Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.71A>G (70A>G); ClinVar=VCV000014208; Zygosity=Homozygous (Coriell) Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Part of: US Immunodeficiency Network (USIDNET) cell repository 21164660 CVCL_2Z33 ID00083 transformed cell line human CVCL_2Z33 CL:0000010 Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.71A>G (70A>G); ClinVar=VCV000014208; Zygosity=Homozygous (Coriell) Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Part of: US Immunodeficiency Network (USIDNET) cell repository 21164661 CVCL_2Z30 ID00079 transformed cell line human CVCL_2Z30 CL:0000010 Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.71A>G (70A>G); ClinVar=VCV000014208; Zygosity=Homozygous (Coriell) Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Part of: US Immunodeficiency Network (USIDNET) cell repository 21164662 CVCL_2Z31 ID00081 transformed cell line human CVCL_2Z31 CL:0000010 Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.71A>G (70A>G); ClinVar=VCV000014208; Zygosity=Homozygous (Coriell) Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Part of: US Immunodeficiency Network (USIDNET) cell repository 21164663 CVCL_2Z36 M2-1 [Mouse hybridoma] hybridoma house mouse CVCL_2Z36 CL:0000010 Discontinued: Coriell; WC00001; probable. 21164664 CVCL_2Z37 Y8-10C2 hybridoma house mouse CVCL_2Z37 CL:0000010 Discontinued: Coriell; WC00004; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21164665 CVCL_2Z34 ID00084 transformed cell line human CVCL_2Z34 CL:0000010 Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.-24_-4dupACTACTCTGTGAAGCTGAGGA (n.-24_-4dup21) (g.-25_-5dup); ClinVar=VCV000632969; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10031; RMRP; Simple; n.147G>A (146G>A); ClinVar=VCV000379208; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164666 CVCL_2Z35 ID00085 transformed cell line human CVCL_2Z35 CL:0000010 Sequence variation: Mutation; HGNC; 6010; IL2RG; Simple; p.Val187Gly (c.574T>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21164667 CVCL_2Z49 GM03046 finite cell line human CVCL_2Z49 CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of GM03045 (Cellosaurus=CVCL_2Z48); Derived from sampling site: Cell type=Fibroblast. Female 21164668 CVCL_VA70 BP6054 transformed cell line human CVCL_VA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164669 CVCL_VA73 BP6072 transformed cell line human CVCL_VA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164670 CVCL_VA74 BP6074 transformed cell line human CVCL_VA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164671 CVCL_VA71 BP6061 transformed cell line human CVCL_VA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164672 CVCL_VA72 BP6063 transformed cell line human CVCL_VA72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164673 CVCL_VA77 BP6165 transformed cell line human CVCL_VA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164674 CVCL_VA78 BP6206 transformed cell line human CVCL_VA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164675 CVCL_VA75 BP6077 transformed cell line human CVCL_VA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21164676 CVCL_VA76 BP6124 transformed cell line human CVCL_VA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164677 CVCL_VA79 BP6308 transformed cell line human CVCL_VA79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21164678 CVCL_2Z40 CM1-1 hybridoma house mouse CVCL_2Z40 CL:0000010 Discontinued: Coriell; WC00009; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21164679 CVCL_2Z43 GM01737 finite cell line human CVCL_2Z43 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY; but phenotypically female (Coriell); Derived from sampling site: Gonad Cell type=Fibroblast.. Ambiguous 21164680 CVCL_2Z44 GM04329 finite cell line human CVCL_2Z44 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164681 CVCL_2Z41 NA-112-S2 hybridoma house mouse CVCL_2Z41 CL:0000010 Discontinued: Coriell; WC00008; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03466; Influenza A virus isolate A/Puerto Rico/8/1934 nucleoprotein (NP) 21164682 CVCL_2Z42 GM00364 finite cell line human CVCL_2Z42 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Cys410Tyr (c.1229G>A); ClinVar=VCV000018127; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21164683 CVCL_2Z47 GM01773 finite cell line human CVCL_2Z47 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21164684 CVCL_2Z48 GM03045 finite cell line human CVCL_2Z48 CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of GM03046 (Cellosaurus=CVCL_2Z49); Derived from sampling site: Cell type=Fibroblast. Female 21164685 CVCL_2Z45 GM00267 finite cell line human CVCL_2Z45 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21164686 CVCL_2Z46 GM00268 finite cell line human CVCL_2Z46 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21164687 CVCL_UY83 CaES-17 cancer cell line human CVCL_UY83 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00604 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from an esophageal squamous cell carcinoma. 21164688 CVCL_UY84 RAL-5 spontaneously immortalized cell line Norway rat CVCL_UY84 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21164689 CVCL_UY81 RCC4/empty vector cancer cell line human CVCL_UY81 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Trp (c.194C>G); ClinVar=VCV000043597; Zygosity=Hemizygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified 21164690 CVCL_UY82 RCC6/VHL cancer cell line human CVCL_UY82 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser111Gly (c.331A>G); ClinVar=VCV000633016; Zygosity=Hemizygous (from parent cell line); Transfected with: HGNC; 12687; VHL; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. 21164691 CVCL_UY87 Ac7E/LI spontaneously immortalized cell line Norway rat CVCL_UY87 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 12.6 hours (at 60th generation), 34.6 hours (at 36th generation) (PubMed=7319197) 21164692 CVCL_UY88 Ac7E/SI spontaneously immortalized cell line Norway rat CVCL_UY88 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 14.9 hours (at 126th generation), 36.9 hours (at 45th generation) (PubMed=7319197) 21164693 CVCL_UY85 RAL-7 spontaneously immortalized cell line Norway rat CVCL_UY85 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21164694 CVCL_UY86 Ac7E spontaneously immortalized cell line Norway rat CVCL_UY86 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 40.5 hours (PubMed=90011); 45.1 hours (PubMed=7319197) 21164695 CVCL_UY89 PAE-20 spontaneously immortalized cell line pig CVCL_UY89 CL:0000010 Derived from sampling site: Aorta; endothelium; Breed/subspecies: Miniature pig. Unspecified 21164696 CVCL_2S31 AG19520 transformed cell line human CVCL_2S31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164697 CVCL_3431 Wo Fel finite cell line human CVCL_3431 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164698 CVCL_2S32 AG19521 transformed cell line human CVCL_2S32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164699 CVCL_3432 Wo Jo finite cell line human CVCL_3432 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164700 CVCL_2S30 AG19519 transformed cell line human CVCL_2S30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164701 CVCL_3430 WEHI-3B/CPX cancer cell line house mouse CVCL_3430 CL:0000010 Selected for resistance to: ChEBI; CHEBI:100241; Ciprofloxacin (CIP); Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21164702 CVCL_2S35 AG19524 transformed cell line human CVCL_2S35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164703 CVCL_3435 SC-1 [Human Cetus] transformed cell line human CVCL_3435 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8756 21164704 CVCL_2S36 AG19525 transformed cell line human CVCL_2S36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164705 CVCL_3436 SC-1 [Mouse] spontaneously immortalized cell line house mouse CVCL_3436 CL:0000010 Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21164706 CVCL_2S33 AG19522 transformed cell line human CVCL_2S33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164707 CVCL_3433 WOP transformed cell line house mouse CVCL_3433 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21164708 CVCL_2S34 AG19523 transformed cell line human CVCL_2S34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164709 CVCL_3434 WX310 cancer cell line house mouse CVCL_3434 CL:0000010 21164710 CVCL_2S39 AG19530 transformed cell line human CVCL_2S39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164711 CVCL_3439 HIG-82 spontaneously immortalized cell line CVCL_3439 CL:0000010 Derived from sampling site: Knee joint; synovium Cell type=Synoviocyte.; Breed/subspecies: New Zealand white. Female Doubling time: ~24 hours (PubMed=2846503) 21164712 CVCL_2S37 AG19526 transformed cell line human CVCL_2S37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164713 CVCL_3437 HFAE-2 finite cell line human CVCL_3437 CL:0000010 Derived from sampling site: Femoral artery Cell type=Endothelial cell of artery.. Discontinued: ATCC; CRL-2474; true; Discontinued: Coriell; WC00099; probable Male Part of: Wistar Institute Special Collection vascular cell lines 21164714 CVCL_2S38 AG19529 transformed cell line human CVCL_2S38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164715 CVCL_3438 Le Ana finite cell line human CVCL_3438 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164716 CVCL_UY90 PAE-20cl-1 spontaneously immortalized cell line pig CVCL_UY90 CL:0000010 Derived from sampling site: Aorta; endothelium; Breed/subspecies: Miniature pig. Unspecified Group: Serum/protein free medium cell line 21164717 CVCL_UY91 t-HUE1 cancer cell line human CVCL_UY91 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Doubling time: 30 hours (PubMed=1817644) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (ECV-304) has been shown to be a T24 derivative. 21164718 CVCL_UY72 GM17934 transformed cell line human CVCL_UY72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164719 CVCL_UY73 GM13628 transformed cell line human CVCL_UY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Donor and sister have tubular adenomas; brother with lymphoma; mother with breast cancer; Derived from sampling site: Peripheral blood. Female 21164720 CVCL_UY70 GM07298 hybrid cell line human CVCL_UY70 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164721 CVCL_UY71 GM14006 transformed cell line human CVCL_UY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164722 CVCL_UY76 GM14566 hybrid cell line human CVCL_UY76 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164723 CVCL_UY77 GM14599 hybrid cell line human CVCL_UY77 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164724 CVCL_UY74 GM13629 transformed cell line human CVCL_UY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164725 CVCL_UY75 GM14416 hybrid cell line human CVCL_UY75 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164726 CVCL_UY78 GM15840 hybrid cell line house mouse CVCL_UY78 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164727 CVCL_UY79 CP50-EBV transformed cell line human CVCL_UY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21164728 CVCL_2S50 AG19581 transformed cell line human CVCL_2S50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164729 CVCL_3450 QM7 cancer cell line CVCL_3450 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line 21164730 CVCL_2S42 AG19534 transformed cell line human CVCL_2S42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164731 CVCL_3442 Lec2 spontaneously immortalized cell line CVCL_3442 CL:0000010 Derived from sampling site: Ovary. Female 21164732 CVCL_2S43 AG19535 transformed cell line human CVCL_2S43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164733 CVCL_3443 Lec8 spontaneously immortalized cell line CVCL_3443 CL:0000010 Derived from sampling site: Ovary. Female 21164734 CVCL_2S40 AG19532 transformed cell line human CVCL_2S40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164735 CVCL_3440 Lec1 spontaneously immortalized cell line CVCL_3440 CL:0000010 Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Gln339Arg; Zygosity=Unspecified (PubMed=8910379); Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Lys401Arg; Zygosity=Unspecified (PubMed=8910379) Derived from sampling site: Ovary. Female 21164736 CVCL_2S41 AG19533 transformed cell line human CVCL_2S41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164737 CVCL_3441 HK-PEG-1 hybridoma house mouse CVCL_3441 CL:0000010 Miscellaneous: STR profile from personal communication of Almeida J.L.; PubMed=23430347 has a different value for STR 6-4 (17,18) than that submitted (18,19,20) due to a change in the marker motif and stutter rules. Monoclonal antibody isotype: IgG1+IgG3; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21164738 CVCL_2S46 AG19539 transformed cell line human CVCL_2S46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164739 CVCL_3446 EW-2 cancer cell line human CVCL_3446 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8378080) Derived from metastatic site: Peripheral blood. Male 21164740 CVCL_2S47 AG19540 transformed cell line human CVCL_2S47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164741 CVCL_3447 MuM-2B cancer cell line human CVCL_3447 CL:0000010 Female 21164742 CVCL_2S44 AG19536 transformed cell line human CVCL_2S44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164743 CVCL_3444 Lei Cap finite cell line human CVCL_3444 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164744 CVCL_2S45 AG19538 transformed cell line human CVCL_2S45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164745 CVCL_3445 EW-17 cancer cell line human CVCL_3445 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975). Unspecified 21164746 CVCL_2S48 AG19579 transformed cell line human CVCL_2S48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164747 CVCL_3448 MuM-2C cancer cell line human CVCL_3448 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22236444); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000232) It was one of the sources for the STR profile of this entry. Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00501 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=28940260). Originally thought to originate from a female patient with metastatic uveal melanoma. 21164748 CVCL_2S49 AG19580 transformed cell line human CVCL_2S49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164749 CVCL_3449 __Parent_cell_line_of_DLD-1/HCT 8/HCT 15/HRT-18 cancer cell line human CVCL_3449 CL:0000010 Male 21164750 CVCL_UY80 SLR20.A2 cancer cell line human CVCL_UY80 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*02:01) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Problematic cell line: Contaminated Parent cell line (SLR20) has been shown to be a T24 derivative. 21164751 CVCL_UY61 GM02419 finite cell line human CVCL_UY61 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02419; probable Female 21164752 CVCL_UY62 GM03699 finite cell line human CVCL_UY62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03699; probable Female 21164753 CVCL_UY60 KPC-CRISPR/Cas9 empty plasmid cancer cell line house mouse CVCL_UY60 CL:0000010 Miscellaneous: Cell line information from personal communication of Rupert J.E Breed/subspecies: LSL-KrasG12D:LSL-Trp53R172H:Pdx1-Cre (KPC). Male Characteristics: Control cell line for KPC-IL-6 KO (Cellosaurus=CVCL_UR56) Transfected with a CRISPR/Cas9 empty plasmid. 21164754 CVCL_UY65 GM06213 finite cell line CVCL_UY65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM06213; probable Male Group: Non-human primate cell line 21164755 CVCL_UY66 GM07299 hybrid cell line human CVCL_UY66 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164756 CVCL_UY63 GM03983 finite cell line dog CVCL_UY63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Cocker Spaniel. Discontinued: Coriell; GM03983; probable Male 21164757 CVCL_UY64 GM03443 transformed cell line CVCL_UY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03443; probable Female Group: Non-human primate cell line 21164758 CVCL_UY69 GM07301 hybrid cell line human CVCL_UY69 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164759 CVCL_UY67 GM07297 hybrid cell line human CVCL_UY67 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164760 CVCL_UY68 GM07300 hybrid cell line human CVCL_UY68 CL:0000010 Group: Human/rodent somatic cell hybrid. 21164761 CVCL_2S10 AG19423 transformed cell line human CVCL_2S10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164762 CVCL_3410 P388D1 clone 3124 cancer cell line house mouse CVCL_3410 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21164763 CVCL_2S13 AG19494 transformed cell line human CVCL_2S13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164764 CVCL_3413 PG-4 (S+L-) transformed cell line CVCL_3413 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 21164765 CVCL_2S14 AG19495 transformed cell line human CVCL_2S14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164766 CVCL_3414 Rj2.2.5 cancer cell line human CVCL_3414 HLA typing: A*03:01:01; B*15:10:01; C*03:04:02,04:01:01; DPB1*01:01:01; DQA1*01:05:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*03:01:01,10:01:01 (CLS=300360) CL:0000010 Sequence variation: Gene deletion; HGNC; 7067; CIITA; Zygosity=Heterozygous (PubMed=8402893); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 7067; CIITA; Unexplicit; Major internal deletion; Zygosity=Heterozygous (PubMed=8402893); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Bone; jaw; maxilla. Omics: H3K27ac ChIP-seq epigenome analysis Male Characteristics: Deficient in expression of HLA class II antigens 21164767 CVCL_2S11 AG19424 transformed cell line human CVCL_2S11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164768 CVCL_3411 P3X63Ag8 cancer cell line house mouse CVCL_3411 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Doubling time: 16-26 hours (ECACC=85011401) Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164769 CVCL_2S12 AG19425 transformed cell line human CVCL_2S12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164770 CVCL_3412 P3X63Ag8U.1 cancer cell line house mouse CVCL_3412 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21164771 CVCL_2S17 AG19498 transformed cell line human CVCL_2S17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164772 CVCL_3417 RT 1 cancer cell line Norway rat CVCL_3417 CL:0000010 Transformant: Rous sarcoma virus [RSV-33](NCBI-Taxonomy; 11886); Breed/subspecies: Lewis. Unspecified 21164773 CVCL_2S18 AG19499 transformed cell line human CVCL_2S18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164774 CVCL_3418 S+L-CAT2 transformed cell line CVCL_3418 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801). 21164775 CVCL_2S15 AG19496 transformed cell line human CVCL_2S15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164776 CVCL_3415 ROV-S transformed cell line human CVCL_3415 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21164777 CVCL_2S16 AG19497 transformed cell line human CVCL_2S16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164778 CVCL_3416 RRAm1 finite cell line Norway rat CVCL_3416 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164779 CVCL_2S19 AG19500 transformed cell line human CVCL_2S19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164780 CVCL_3419 SHM-D33 hybrid cell line CVCL_3419 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine Discontinued: RCB; RCB0267; true. Group: Hybridoma fusion partner cell line 21164781 CVCL_UY50 NH50133 finite cell line human CVCL_UY50 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164782 CVCL_UY51 NH50134 finite cell line human CVCL_UY51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164783 CVCL_UY54 NH50137 finite cell line human CVCL_UY54 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164784 CVCL_UY55 NH50138 finite cell line human CVCL_UY55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164785 CVCL_UY52 NH50135 finite cell line human CVCL_UY52 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164786 CVCL_UY53 NH50136 finite cell line human CVCL_UY53 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Unspecified (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Unspecified (NHCDR) Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164787 CVCL_UY58 STP54 cancer cell line human CVCL_UY58 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Female Doubling time: 68 hours (PubMed=19419948) 21164788 CVCL_UY59 OvBH-1 cancer cell line human CVCL_UY59 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous; Note=2 out of 3 copies (PubMed=16364757) Population: Caucasian; Polish; Derived from metastatic site: Ascites. Female Characteristics: Shows temperature-sensitive growth characteristics Grows well at 37 Celsius and stop growing when shifted to 31 Celsius (PubMed=12359050). 21164789 CVCL_UY56 NH50139 finite cell line human CVCL_UY56 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with autosomal dominant torsion dystonia 1 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164790 CVCL_UY57 NDPEM 2/2 finite cell line CVCL_UY57 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Debao pony. Unspecified Group: Endangered species/breed cell line 21164791 CVCL_2S20 AG19503 transformed cell line human CVCL_2S20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164792 CVCL_3420 STO spontaneously immortalized cell line house mouse CVCL_3420 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Mixed 21164793 CVCL_2S21 AG19504 transformed cell line human CVCL_2S21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164794 CVCL_3421 SUM102PT cancer cell line human CVCL_3421 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 112.71 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21164795 CVCL_2S24 AG19507 transformed cell line human CVCL_2S24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164796 CVCL_3424 SUM44PE cancer cell line human CVCL_3424 HLA typing: B*14:02,56:29; C*08:04,08:04 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Phe423Leufs*8 (c.1269delT); Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu28fs*16 (c.82_84del3insCA); Zygosity=Unspecified (PubMed=16541312) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: ER-positive, PR-negative and ERBB2-negative Doubling time: 85.10 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21164797 CVCL_2S25 AG19508 transformed cell line human CVCL_2S25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164798 CVCL_3425 SUM52PE cancer cell line human CVCL_3425 HLA typing: A*32:01,32:01; B*07:02,15:01; C*03:03,07:02; DQB1*06:04,05:01; DRB1*15:01,15:01 (PubMed=25960936); HLA typing: A*32:01,32:01; B*07:02,15:01; C*03:03,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Val (c.203C>T); ClinVar=VCV000406701; Zygosity=Homozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=16541312; DepMap) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 55.21 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21164799 CVCL_2S22 AG19505 transformed cell line human CVCL_2S22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164800 CVCL_3422 SUM149PT cancer cell line human CVCL_3422 HLA typing: A*68:01,68:01; B*53:01,78:01; C*06:02,16:01 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (PubMed=16397213; PubMed=19593635; PubMed=22032724); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=16541312) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Characteristics: Derived from a mouse xenograft of a transplanted primary human invasive infiltrating ductal carcinoma metastatic nodule Doubling time: 33.95 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: KuDOS 95 cell line panel 21164801 CVCL_2S23 AG19506 transformed cell line human CVCL_2S23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164802 CVCL_3423 SUM190PT cancer cell line human CVCL_3423 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (PubMed=16541312) Omics: Array-based CGH; Omics: CNV analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Characteristics: ER-negative, PR-negative and ERBB2-positive Doubling time: 310.16 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21164803 CVCL_2S28 AG19517 transformed cell line human CVCL_2S28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164804 CVCL_3428 U87/DK cancer cell line human CVCL_3428 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val30_Arg297del and pLys745Met = EGFRvIII and dead kinase). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21164805 CVCL_2S29 AG19518 transformed cell line human CVCL_2S29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164806 CVCL_3429 U87/WT cancer cell line human CVCL_3429 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21164807 CVCL_2S26 AG19515 transformed cell line human CVCL_2S26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164808 CVCL_3426 THP-1h cancer cell line human CVCL_3426 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21164809 CVCL_2S27 AG19516 transformed cell line human CVCL_2S27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164810 CVCL_3427 THP-1l cancer cell line human CVCL_3427 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21164811 CVCL_UY40 NH50123 finite cell line human CVCL_UY40 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with torsion dystonia 6 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164812 CVCL_UY43 NH50126 finite cell line human CVCL_UY43 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164813 CVCL_UY44 NH50127 finite cell line human CVCL_UY44 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164814 CVCL_UY41 NH50124 finite cell line human CVCL_UY41 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164815 CVCL_UY42 NH50125 finite cell line human CVCL_UY42 CL:0000010 Sequence variation: Mutation; HGNC; 801; ATP1A3; Simple; p.Glu277Lys (c.829G>A); ClinVar=VCV000012911; Zygosity=Heterozygous; Note=De novo mutation (NHCDR) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164816 CVCL_UY47 NH50130 finite cell line human CVCL_UY47 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164817 CVCL_UY48 NH50131 finite cell line human CVCL_UY48 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164818 CVCL_UY45 NH50128 finite cell line human CVCL_UY45 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164819 CVCL_UY46 NH50129 finite cell line human CVCL_UY46 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164820 CVCL_UY49 NH50132 finite cell line human CVCL_UY49 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164821 CVCL_UY32 AG23117 finite cell line house mouse CVCL_UY32 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164822 CVCL_UY33 AG23121 finite cell line house mouse CVCL_UY33 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164823 CVCL_UY30 AG23109 finite cell line house mouse CVCL_UY30 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164824 CVCL_UY31 AG23113 finite cell line house mouse CVCL_UY31 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164825 CVCL_UY36 AG22799 finite cell line house mouse CVCL_UY36 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164826 CVCL_UY37 AG22820 finite cell line house mouse CVCL_UY37 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164827 CVCL_UY34 AG23129 finite cell line house mouse CVCL_UY34 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164828 CVCL_UY35 AG23133 finite cell line house mouse CVCL_UY35 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164829 CVCL_UY38 AG22886 finite cell line house mouse CVCL_UY38 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164830 CVCL_UY39 NH50122 finite cell line human CVCL_UY39 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164831 CVCL_2S02 AG19414 transformed cell line human CVCL_2S02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164832 CVCL_3402 MCF7-492X1 cancer cell line human CVCL_3402 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21164833 CVCL_2S03 AG19415 transformed cell line human CVCL_2S03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164834 CVCL_3403 MeCo 05 cancer cell line human CVCL_3403 CL:0000010 Derived from metastatic site: Lymph node. Male 21164835 CVCL_2S00 AG19412 transformed cell line human CVCL_2S00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164836 CVCL_3400 MCF7-488X1 cancer cell line human CVCL_3400 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 (exon 5 defective) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21164837 CVCL_2S01 AG19413 transformed cell line human CVCL_2S01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164838 CVCL_3401 MCF7-490X1 cancer cell line human CVCL_3401 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3467; ESR1 (exon 4 defective) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21164839 CVCL_2S06 AG19418 transformed cell line human CVCL_2S06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164840 CVCL_3406 MTP-GFP cancer cell line house mouse CVCL_3406 CL:0000010 Transfected with: RGD; 2561; Erbb2 (with p.Val661Glu); Transfected with: UniProtKB; P42212; GFP Transformant: Activated Erbb2/neu; Breed/subspecies: CD-1 transgenic MMTV-neu x CMV-GFP. Female 21164841 CVCL_2S07 AG19419 transformed cell line human CVCL_2S07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164842 CVCL_3407 NT2-D1 cancer cell line human CVCL_3407 Genome ancestry: African=1.78%; Native American=0%; East Asian, North=0.45%; East Asian, South=1.42%; South Asian=4.09%; European, North=53.03%; European, South=39.23% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: H3K9ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: ENCODE project common cell types; tier 3 21164843 CVCL_2S04 AG19416 transformed cell line human CVCL_2S04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164844 CVCL_3404 MG1361 cancer cell line house mouse CVCL_3404 CL:0000010 Transfected with: RGD; 2561; Erbb2 (with p.Val661Glu) Transformant: Activated Erbb2/neu; Breed/subspecies: (C57BL/6 x DBA)F1 x CD-1 MMTV-neu transgenic. Female 21164845 CVCL_2S05 AG19417 transformed cell line human CVCL_2S05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164846 CVCL_3405 MiCl1 (S+L-) transformed cell line CVCL_3405 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Mixed 21164847 CVCL_2S08 AG19420 transformed cell line human CVCL_2S08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164848 CVCL_3408 NULLI-SCC1 cancer cell line house mouse CVCL_3408 CL:0000010 Breed/subspecies: 129/Sv. Male 21164849 CVCL_2S09 AG19421 transformed cell line human CVCL_2S09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164850 CVCL_3409 OVNIS 6H spontaneously immortalized cell line CVCL_3409 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: ECACC; 93122324; probable Unspecified 21164851 CVCL_UY21 AG23041 finite cell line house mouse CVCL_UY21 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164852 CVCL_UY22 AG23045 finite cell line house mouse CVCL_UY22 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164853 CVCL_UY20 AG23037 finite cell line house mouse CVCL_UY20 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164854 CVCL_UY25 AG23063 finite cell line house mouse CVCL_UY25 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164855 CVCL_UY26 AG23067 finite cell line house mouse CVCL_UY26 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164856 CVCL_UY23 AG23049 finite cell line house mouse CVCL_UY23 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164857 CVCL_UY24 AG23059 finite cell line house mouse CVCL_UY24 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164858 CVCL_UY29 AG23105 finite cell line house mouse CVCL_UY29 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164859 CVCL_UY27 AG23071 finite cell line house mouse CVCL_UY27 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164860 CVCL_UY28 AG23075 finite cell line house mouse CVCL_UY28 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164861 CVCL_UY10 AG27045 transformed cell line human CVCL_UY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21164862 CVCL_UY11 AG27068 transformed cell line human CVCL_UY11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21164863 CVCL_UY14 AG27095 transformed cell line human CVCL_UY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21164864 CVCL_UY15 AG24465 transformed cell line human CVCL_UY15 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Leu528Cysfs*29 (c.1578delC); ClinVar=VCV000624320; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg741Ter (c.2221C>T); ClinVar=VCV000528094; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164865 CVCL_UY12 AG27076 transformed cell line human CVCL_UY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21164866 CVCL_UY13 AG27090 transformed cell line human CVCL_UY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21164867 CVCL_UY18 AG23029 finite cell line house mouse CVCL_UY18 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Heterozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164868 CVCL_UY19 AG23033 finite cell line house mouse CVCL_UY19 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Male Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164869 CVCL_UY16 AG24467 finite cell line human CVCL_UY16 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Asn1197Thrfs*2 (c.3590delA); ClinVar=VCV000038890; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21164870 CVCL_UY17 AG23013 finite cell line house mouse CVCL_UY17 CL:0000010 Sequence variation: Mutation; MGI; MGI:109330; Prop1; Simple; p.Ser83Pro (c.247T>C) (Prop1 df); Zygosity=Homozygous (Coriell) Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Ames dwarf. Female Part of: NIA Aging Cell Repository's Ames Dwarf Mouse Collection 21164871 CVCL_3497 CEM/C2 cancer cell line human CVCL_3497 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21164872 CVCL_2S97 GM03882 finite cell line human CVCL_2S97 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(3;10)(3pter->3q25::10p15->10pter;10qter->10p15::3q25->3qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164873 CVCL_3498 CFZT(A) cancer cell line house mouse CVCL_3498 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6338; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164874 CVCL_2S98 GM03886 finite cell line human CVCL_2S98 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;9)(4pter->4q33::9q12->9qter;9pter->9q12::4q33->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164875 CVCL_3495 CA-HPV-10 transformed cell line human CVCL_3495 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male Doubling time: 38.44 hours (GrayJW panel) 21164876 CVCL_2S95 GM03811 finite cell line human CVCL_2S95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164877 CVCL_3496 CEM/C1 cancer cell line human CVCL_3496 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=12068308); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Female 21164878 CVCL_2S96 GM03847 finite cell line human CVCL_2S96 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(11;22)(11pter->11q23::22q11.2->22qter;22pter->22q11.2::11q23->11qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164879 CVCL_3499 CFZT(B) cancer cell line house mouse CVCL_3499 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6339; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164880 CVCL_2S99 GM04012 finite cell line human CVCL_2S99 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;5)(2qter->2p25::5q33->5qter;5pter->5q33::2p25->2pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164881 CVCL_3482 2F7 cancer cell line human CVCL_3482 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10237. 21164882 CVCL_2S82 GM02426 finite cell line human CVCL_2S82 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;6)(5qter->5p15::6p21->6pter;6qter->6p21::5p15->5pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21164883 CVCL_3483 2PK-3 cancer cell line house mouse CVCL_3483 CL:0000010 Breed/subspecies: BALB/c. Omics: SNP array analysis Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164884 CVCL_2S83 GM02487 finite cell line human CVCL_2S83 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(5;15)(5qter->5p13::15p11->15pter;15qter->15p11::5p13->5pter) (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164885 CVCL_3480 1A2 transformed cell line human CVCL_3480 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Discontinued: ECACC; 93031502; probable Male Characteristics: Secretes IgG2 kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8119 Problematic cell line: Misclassified Parent cell line (GM01500) was originally thought to be a myeloma cell line but is a B-lymphoblastoid cell line. 21164886 CVCL_2S80 AG19623 transformed cell line human CVCL_2S80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164887 CVCL_3481 266-6 cancer cell line house mouse CVCL_3481 CL:0000010 Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.. Unspecified 21164888 CVCL_2S81 GM07069 finite cell line human CVCL_2S81 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(6;10)(6pter->6q25.3::10q26.1->10qter;10pter->10q26.1::6q25.3->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164889 CVCL_3475 13762 MAT B III cancer cell line Norway rat CVCL_3475 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from metastatic site: Ascites; Breed/subspecies: Fischer 344. Female 21164890 CVCL_2S75 AG19618 transformed cell line human CVCL_2S75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164891 CVCL_3476 143.98.2 cancer cell line human CVCL_3476 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11226 21164892 CVCL_2S76 AG19619 transformed cell line human CVCL_2S76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164893 CVCL_2S73 AG19616 transformed cell line human CVCL_2S73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164894 CVCL_3473 glomotel telomerase immortalized cell line human CVCL_3473 CL:0000010 Transfected with: HGNC; 11730; TERT Discontinued: ATCC; CRL-2597; true. Male 21164895 CVCL_2S74 AG19617 transformed cell line human CVCL_2S74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164896 CVCL_3479 182-PF SK finite cell line human CVCL_3479 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 10 PDL (ATCC=CRL-1532) 21164897 CVCL_2S79 AG19622 transformed cell line human CVCL_2S79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164898 CVCL_3477 143B pML BK TK cancer cell line human CVCL_3477 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8304 21164899 CVCL_2S77 AG19620 transformed cell line human CVCL_2S77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164900 CVCL_3478 166-ME SK finite cell line human CVCL_3478 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (ATCC=CRL-1533) 21164901 CVCL_2S78 AG19621 transformed cell line human CVCL_2S78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164902 CVCL_3490 BB88 cancer cell line house mouse CVCL_3490 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB.B. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164903 CVCL_2S90 GM03372 finite cell line human CVCL_2S90 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(11;22)(11pter->11q23::22q11->22qter;22pter->22q11::11q23->11qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164904 CVCL_3493 C1.18.4 cancer cell line house mouse CVCL_3493 CL:0000010 Breed/subspecies: C3H. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164905 CVCL_2S93 GM03494 finite cell line human CVCL_2S93 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;6)(q35;p22) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21164906 CVCL_3494 C1498 cancer cell line house mouse CVCL_3494 CL:0000010 Breed/subspecies: C57BL/6J. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164907 CVCL_2S94 GM03799 transformed cell line human CVCL_2S94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164908 CVCL_3491 BC16A cancer cell line house mouse CVCL_3491 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164909 CVCL_2S91 GM03404 finite cell line human CVCL_2S91 CL:0000010 Karyotypic information: 46,XX,t(6;12)(6pter->6q21::12p13->12pter;12qter->12p13::6q21->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164910 CVCL_3492 BpRc1 cancer cell line house mouse CVCL_3492 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L. Omics: Transcriptome analysis by microarray Female Characteristics: Defective in aryl hydrocarbon receptor nuclear translocator (Arnt) function Doubling time: 12-24 hours (ATCC=CRL-2217) 21164911 CVCL_2S92 GM03463 finite cell line human CVCL_2S92 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;14)(9qter->9p22::14q13->14qter;14pter->14q13::9p22->9pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164912 CVCL_2S86 GM03119 finite cell line human CVCL_2S86 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;17)(9qter->9p22::17p11->17pter;17qter->17p11::9p22->9pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164913 CVCL_3486 M2A7 cancer cell line human CVCL_3486 CL:0000010 Transfected with: HGNC; 3754; FLNA Omics: SNP array analysis. Unspecified 21164914 CVCL_3487 ABE-8.1/2 cancer cell line house mouse CVCL_3487 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21164915 CVCL_2S87 GM03256 finite cell line human CVCL_2S87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164916 CVCL_3484 8E5(CEM) cancer cell line human CVCL_3484 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: HIV-1 producing cell line Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8993 21164917 CVCL_2S84 GM02669 transformed cell line human CVCL_2S84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164918 CVCL_3485 A431NS cancer cell line human CVCL_3485 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female 21164919 CVCL_2S85 GM02927 transformed cell line human CVCL_2S85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164920 CVCL_3488 ARIP cancer cell line Norway rat CVCL_3488 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas; Breed/subspecies: Wistar. 21164921 CVCL_2S88 GM03305 finite cell line human CVCL_2S88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;9)(5pter->5q33::9p24->9pter;9qter->9p24::5q33->5qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21164922 CVCL_3489 AT3B-1 cancer cell line Norway rat CVCL_3489 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: Copenhagen. Male 21164923 CVCL_2S89 GM03370 finite cell line human CVCL_2S89 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;10)(1pter->1q44::10p11->10pter;10qter->10p11::1q44->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21164924 CVCL_2S60 AG19601 transformed cell line human CVCL_2S60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164925 CVCL_3460 De Te finite cell line human CVCL_3460 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164926 CVCL_2S61 AG19602 transformed cell line human CVCL_2S61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164927 CVCL_3461 DH82ECOK cancer cell line dog CVCL_3461 CL:0000010 Sequence variation: Mutation; VGNC; 45168; PTPN11; Simple; p.Gly503Val (c.1508G>T); Zygosity=Homozygous (from parent cell line) Breed/subspecies: Golden Retriever. Male Characteristics: In vitro infected by the intracellular pathogen Ehrlichia canis isolate Oklahoma Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10390 21164928 CVCL_3453 A-72 cancer cell line dog CVCL_3453 CL:0000010 Derived from sampling site: Left thigh Cell type=Fibroblast.; Breed/subspecies: Golden Retriever. Female Doubling time: ~27 hours, at 123th passage (PubMed=6254399); ~24 hours (CLS=602398) 21164929 CVCL_2S53 AG19584 transformed cell line human CVCL_2S53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164930 CVCL_2S54 AG19585 transformed cell line human CVCL_2S54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164931 CVCL_3454 BL-3 [Bovine leukemia] cancer cell line CVCL_3454 CL:0000010 Breed/subspecies: Hereford. Male Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8037 21164932 CVCL_2S51 AG19582 transformed cell line human CVCL_2S51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164933 CVCL_3451 QT6 cancer cell line CVCL_3451 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line 21164934 CVCL_3452 2FLB.Ln cancer cell line CVCL_3452 CL:0000010 Derived from sampling site: Fetal lymph node. Discontinued: ATCC; CRL-6045; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164935 CVCL_2S52 AG19583 transformed cell line human CVCL_2S52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164936 CVCL_2S57 AG19588 transformed cell line human CVCL_2S57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164937 CVCL_3457 CTPS cancer cell line CVCL_3457 CL:0000010 Transformant: Cottontail rabbit papillomavirus (Kappapapillomavirus 2)(NCBI-Taxonomy; 10623); Derived from sampling site: Skin. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164938 CVCL_2S58 AG19589 transformed cell line human CVCL_2S58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164939 CVCL_3458 D22 [Dog] cancer cell line dog CVCL_3458 CL:0000010 Derived from sampling site: Bone; Breed/subspecies: Border Collie. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-6250; probable Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164940 CVCL_2S55 AG19586 transformed cell line human CVCL_2S55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164941 CVCL_3455 BL3.1 cancer cell line CVCL_3455 CL:0000010 Breed/subspecies: Hereford. Male 21164942 CVCL_2S56 AG19587 transformed cell line human CVCL_2S56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164943 CVCL_3456 CMMT cancer cell line CVCL_3456 CL:0000010 Transformant: Mason-Pfizer monkey virus (MPMV)(NCBI-Taxonomy; 11855); Derived from sampling site: Mammary gland. Female Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164944 CVCL_2S59 AG19590 transformed cell line human CVCL_2S59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164945 CVCL_3459 DDT1-MF2 cancer cell line CVCL_3459 CL:0000010 Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Vas deferens; smooth muscle. Male Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12051 21164946 CVCL_UY94 OUR-23 cancer cell line human CVCL_UY94 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21164947 CVCL_UY95 RAL-2 spontaneously immortalized cell line Norway rat CVCL_UY95 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 21 hours (PubMed=126004) 21164948 CVCL_UY92 OUR-19 cancer cell line human CVCL_UY92 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21164949 CVCL_UY93 OUR-21 cancer cell line human CVCL_UY93 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21164950 CVCL_UY98 RAL-6 spontaneously immortalized cell line Norway rat CVCL_UY98 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 26 hours (PubMed=126004) 21164951 CVCL_UY99 Bs1A cancer cell line house mouse CVCL_UY99 CL:0000010 Transformant: JC polyomavirus (JCPyV)(NCBI-Taxonomy; 10632); Breed/subspecies: JCV T-Ag transgenic. 21164952 CVCL_UY96 RAL-3 spontaneously immortalized cell line Norway rat CVCL_UY96 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male Doubling time: 32 hours (PubMed=126004) 21164953 CVCL_UY97 RAL-4 spontaneously immortalized cell line Norway rat CVCL_UY97 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female Doubling time: 17 hours (PubMed=126004) 21164954 CVCL_2S71 AG19614 transformed cell line human CVCL_2S71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164955 CVCL_3471 WCH-17 cancer cell line CVCL_3471 From: Fernie B.; Georgetown University; Rockville; USA CL:0000010 Transformant: Woodchuck hepatitis virus(NCBI-Taxonomy; 35269); Derived from sampling site: Liver. Unspecified 21164956 CVCL_2S72 AG19615 transformed cell line human CVCL_2S72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164957 CVCL_3472 Don spontaneously immortalized cell line CVCL_3472 CL:0000010 Derived from sampling site: Lung. Male 21164958 CVCL_2S70 AG19613 transformed cell line human CVCL_2S70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164959 CVCL_3470 Vx7 cancer cell line CVCL_3470 CL:0000010 Transformant: Rabbit fibroma virus (SFV)(NCBI-Taxonomy; 10271); Breed/subspecies: New Zealand white. Discontinued: ATCC; CRL-6504; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21164960 CVCL_2S64 AG19605 transformed cell line human CVCL_2S64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164961 CVCL_3464 LCL 8664 cancer cell line CVCL_3464 CL:0000010 Transformant: Rhesus lymphocryptovirus (Macacine herpesvirus 4)(NCBI-Taxonomy; 45455); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21164962 CVCL_2S65 AG19606 transformed cell line human CVCL_2S65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164963 CVCL_3465 LMH/2A cancer cell line CVCL_3465 CL:0000010 Transfected with: UniProtKB; P06212; Chicken ESR1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: White Leghorn L-M. Male Group: Bird cell line 21164964 CVCL_2S62 AG19603 transformed cell line human CVCL_2S62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164965 CVCL_3462 DT95 cancer cell line CVCL_3462 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21164966 CVCL_2S63 AG19604 transformed cell line human CVCL_2S63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164967 CVCL_3463 GPC-16 cancer cell line CVCL_3463 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Colon. Female Virology: Susceptible to infection and early propagation by guinea pig adenovirus (GPAdV) (PubMed=32226606) 21164968 CVCL_2S68 AG19609 transformed cell line human CVCL_2S68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164969 CVCL_3468 TAC-1 cancer cell line CVCL_3468 CL:0000010 Derived from sampling site: Colon. Male Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10632 21164970 CVCL_2S69 AG19610 transformed cell line human CVCL_2S69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164971 CVCL_3469 Tal Jo finite cell line human CVCL_3469 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21164972 CVCL_2S66 AG19607 transformed cell line human CVCL_2S66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164973 CVCL_3466 PLHC-1 cancer cell line CVCL_3466 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032). Female Group: Fish cell line 21164974 CVCL_2S67 AG19608 transformed cell line human CVCL_2S67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164975 CVCL_3467 RTH-149 cancer cell line CVCL_3467 CL:0000010 Transformant: Aflatoxin B1 (AFB1)(ChEBI; CHEBI:2504); Derived from sampling site: Liver Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) (CelloPub=CLPUB00703) Group: Fish cell line 21164976 CVCL_DF49 Neuro-2a NucLight Green cancer cell line house mouse CVCL_DF49 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: A/J. Male Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label 21164977 CVCL_DF47 MDA-MB-231 NucLight Green cancer cell line human CVCL_DF47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Sartorius/Essen BioScience; Catalog number 4488 Female Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label Group: Triple negative breast cancer (TNBC) cell line 21164978 CVCL_DF48 MDA-MB-231 NucLight Red cancer cell line human CVCL_DF48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: Sartorius/Essen BioScience; Catalog number 4487 Female Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label Group: Triple negative breast cancer (TNBC) cell line 21164979 CVCL_DF41 HeLa NucLight Green cancer cell line human CVCL_DF41 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label 21164980 CVCL_DF42 HeLa NucLight Red cancer cell line human CVCL_DF42 CL:0000010 Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164981 CVCL_DF40 A549 NucLight Red cancer cell line human CVCL_DF40 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164982 CVCL_DF45 MCF7 NucLight Green cancer cell line human CVCL_DF45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label 21164983 CVCL_DF46 MCF7 NucLight Red cancer cell line human CVCL_DF46 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164984 CVCL_DF43 HT-1080 NucLight Green cancer cell line human CVCL_DF43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label 21164985 CVCL_DF44 HT-1080 NucLight Red cancer cell line human CVCL_DF44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164986 CVCL_DF60 AGE1.HN transformed cell line human CVCL_DF60 From: ProBioGen AG; Berlin; Germany CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285). 21164987 CVCL_DF58 GFP+LJES1 embryonic stem cell CVCL_DF58 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Unspecified Group: Fish cell line 21164988 CVCL_DF59 NGC-407 transformed cell line human CVCL_DF59 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon. Unspecified Characteristics: Neural progenitor cell line that can differentiate into neurons, astrocytes and dopaminergic neurons depending on the differentiation conditions Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2718 21164989 CVCL_DF52 THP-1 NucLight Red cancer cell line human CVCL_DF52 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164990 CVCL_DF53 GPS spontaneously immortalized cell line CVCL_DF53 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21164991 CVCL_DF50 Neuro-2a NucLight Red cancer cell line house mouse CVCL_DF50 CL:0000010 Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Breed/subspecies: A/J. Male Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164992 CVCL_DF51 Jurkat NucLight Red cancer cell line human CVCL_DF51 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Stably expresses a non-perturbing nuclear restricted red fluorescent label 21164993 CVCL_DF56 PD-L1.1 hybridoma house mouse CVCL_DF56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZQ7; Human CD274. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4080 21164994 CVCL_DF57 PD-L1.2 hybridoma house mouse CVCL_DF57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9NZQ7; Human CD274. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4081 21164995 CVCL_DF54 4NfinP9 spontaneously immortalized cell line CVCL_DF54 CL:0000010 Karyotypic information: Tetraploid karyotype Polyploidy induced by the JNK inhibitor SP600125.; Derived from sampling site: Fin. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.9155 21164996 CVCL_DF55 PD-1.3 hybridoma house mouse CVCL_DF55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4122 21164997 CVCL_DF27 GM07791 transformed cell line human CVCL_DF27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21164998 CVCL_DF28 GM08774 transformed cell line human CVCL_DF28 CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21164999 CVCL_DF25 GM05523 transformed cell line human CVCL_DF25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165000 CVCL_DF26 GM05751 transformed cell line human CVCL_DF26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165001 CVCL_DF29 GM08775 transformed cell line human CVCL_DF29 CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165002 CVCL_DF20 GM03640 transformed cell line human CVCL_DF20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03640; probable Female 21165003 CVCL_DF23 GM03785 finite cell line human CVCL_DF23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165004 CVCL_DF24 GM05425 finite cell line human CVCL_DF24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165005 CVCL_DF21 GM03641 transformed cell line human CVCL_DF21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03641; probable Female 21165006 CVCL_DF22 GM03784 transformed cell line human CVCL_DF22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165007 CVCL_DF38 B6MYC-CaP cancer cell line house mouse CVCL_DF38 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: B6MYC (FVB Hi-Myc x C57BL/6N). Male 21165008 CVCL_DF39 A549 NucLight Green cancer cell line human CVCL_DF39 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses a non-perturbing nuclear restricted green fluorescent label 21165009 CVCL_DF36 Drsub-H spontaneously immortalized cell line CVCL_DF36 CL:0000010 Unspecified Group: Insect cell line. 21165010 CVCL_DF37 Drsub-WT spontaneously immortalized cell line CVCL_DF37 CL:0000010 Unspecified Group: Insect cell line. 21165011 CVCL_DF30 GM08776 transformed cell line human CVCL_DF30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165012 CVCL_DF31 MDCK-chAbcb1 spontaneously immortalized cell line dog CVCL_DF31 CL:0000010 Transfected with: UniProtKB; F1NKW0; Chicken ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21165013 CVCL_DF34 imWilms10 conditionally immortalized cell line human CVCL_DF34 CL:0000010 Sequence variation: Gene deletion; HGNC; 12796; WT1; Zygosity=Homozygous; Note=Nested within a heterozygous 11p13 deletion (PubMed=27213811); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Homozygous (PubMed=27213811); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165014 CVCL_DF35 BmSG-SWU1 spontaneously immortalized cell line CVCL_DF35 CL:0000010 Derived from sampling site: Silk gland; Breed/subspecies: Xiafang x Qiubai. Unspecified Doubling time: ~62.8 hours (DOI=10.1603/AN13022) Group: Insect cell line 21165015 CVCL_DF32 HepBHAe82 cancer cell line human CVCL_DF32 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Biotechnology: Used for a bioassay to detect HBV covalently closed circular (ccc) DNA Male Characteristics: Transfected with an in-frame influenza hemagglutinin (HA) epitope tag into the precore domain of hepatitis B virus (HBV) e antigen (HBeAg) 21165016 CVCL_DF33 HepHA-HBe4 cancer cell line human CVCL_DF33 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Transfected with the HA-tagged HBeAg expression vector This cell line can be used as a counter-screen to cell line HepBHAe82 (Cellosaurus=CVCL_DF32). 21165017 CVCL_DF05 HCH-1 cancer cell line human CVCL_DF05 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 66.4 hours (at 6th passage), 48.7 hours (at 25th passage) (PubMed=27259990) 21165018 CVCL_DF06 RP-2 transformed cell line Norway rat CVCL_DF06 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.. Unspecified 21165019 CVCL_DF03 CHO-K1.Cl7 spontaneously immortalized cell line CVCL_DF03 CL:0000010 Transfected with: HGNC; 3619; FCGR3A Derived from sampling site: Ovary. Female 21165020 CVCL_DF04 HUES PGD 17 embryonic stem cell human CVCL_DF04 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-17-0379. 21165021 CVCL_DF09 SAM-K transformed cell line Norway rat CVCL_DF09 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Wistar. Male 21165022 CVCL_DF07 LTC-14 transformed cell line Norway rat CVCL_DF07 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Lewis LEW.1W. Male Doubling time: 20.6 +- 2.9 hours (PubMed=14977634) 21165023 CVCL_DF08 LTC-7 transformed cell line Norway rat CVCL_DF08 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Lewis LEW.1W. Male Doubling time: 15.4 +- 3.2 hours (PubMed=14977634) 21165024 CVCL_DF01 CHO-K1.Cl-0270 spontaneously immortalized cell line CVCL_DF01 CL:0000010 Transfected with: UniProtKB; G7MEA7; Macaca mulatta FCGR2B Derived from sampling site: Ovary. Female 21165025 CVCL_DF02 CHO-K1.Cl6 spontaneously immortalized cell line CVCL_DF02 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val) Derived from sampling site: Ovary. Female 21165026 CVCL_DF00 CHO-K1.Cl-0239 spontaneously immortalized cell line CVCL_DF00 CL:0000010 Transfected with: UniProtKB; A0A096MT85; Papio anubis FCGR3A Derived from sampling site: Ovary. Female 21165027 CVCL_DF16 GM01131 finite cell line human CVCL_DF16 CL:0000010 Population: African American; Donor information: Established from monozygotic twin of GM01123 (Cellosaurus=CVCL_DF14); Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01131; probable Female 21165028 CVCL_DF17 GM01408 finite cell line human CVCL_DF17 CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01408; probable Female 21165029 CVCL_DF14 GM01123 finite cell line human CVCL_DF14 CL:0000010 Population: African American; Donor information: Established from monozygotic twin of GM01131 (Cellosaurus=CVCL_DF16); Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01123; probable Female 21165030 CVCL_DF15 GM01125 finite cell line human CVCL_DF15 CL:0000010 Derived from sampling site: Eye; cornea. Female 21165031 CVCL_DF18 GM01879 finite cell line human CVCL_DF18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01879; probable Female 21165032 CVCL_DF19 GM01880 finite cell line human CVCL_DF19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01880; probable Female 21165033 CVCL_DF12 1670 cancer cell line CVCL_DF12 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381). Male Group: Non-human primate cell line 21165034 CVCL_DF13 HS-63 hybridoma house mouse CVCL_DF13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26436; Human ACRV1. 21165035 CVCL_DF10 SIPS spontaneously immortalized cell line Norway rat CVCL_DF10 CL:0000010 Derived from sampling site: Pancreas Cell type=Pancreatic stellate cell.; Breed/subspecies: Wistar. Male 21165036 CVCL_DF11 RC-IAL spontaneously immortalized cell line CVCL_DF11 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Albino. Unspecified Virology: Can be used for isolation and growth of rubella virus 21165037 CVCL_UY00 AG26939 transformed cell line human CVCL_UY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21165038 CVCL_UY03 AG26970 transformed cell line human CVCL_UY03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21165039 CVCL_UY04 AG26974 transformed cell line human CVCL_UY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21165040 CVCL_UY01 AG26950 transformed cell line human CVCL_UY01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21165041 CVCL_UY02 AG26959 transformed cell line human CVCL_UY02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21165042 CVCL_UY07 AG26988 transformed cell line human CVCL_UY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21165043 CVCL_UY08 AG26992 transformed cell line human CVCL_UY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21165044 CVCL_UY05 AG26978 transformed cell line human CVCL_UY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21165045 CVCL_UY06 AG26980 transformed cell line human CVCL_UY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21165046 CVCL_UY09 AG26997 transformed cell line human CVCL_UY09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21165047 CVCL_DF92 INT.Ov7 cancer cell line human CVCL_DF92 CL:0000010 Female 21165048 CVCL_DF93 INT.Ov8 cancer cell line human CVCL_DF93 CL:0000010 Female 21165049 CVCL_DF90 INT.Ov5 cancer cell line human CVCL_DF90 CL:0000010 Female 21165050 CVCL_DF91 INT.Ov6 cancer cell line human CVCL_DF91 CL:0000010 Derived from metastatic site: Ascites. Female 21165051 CVCL_DF85 HH-B2 cancer cell line human CVCL_DF85 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Omics: Array-based CGH 21165052 CVCL_DF86 INT.Ov1 cancer cell line human CVCL_DF86 CL:0000010 Female 21165053 CVCL_DF83 CC-11- cancer cell line human CVCL_DF83 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 67 (HPV67)(NCBI-Taxonomy; 37120); Derived from sampling site: Uterus; cervix. Female 21165054 CVCL_DF84 L56Br-C1 cancer cell line human CVCL_DF84 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln563Ter (c.1687C>T) (1806C>T); ClinVar=VCV000037426; Zygosity=Hemizygous (PubMed=12649339); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Unspecified (PubMed=12649339) Derived from metastatic site: Axillary lymph node. Omics: Array-based CGH Female Characteristics: Established from the xenograft L56Br-X1 (PubMed=12649339) 21165055 CVCL_DF89 INT.Ov4 cancer cell line human CVCL_DF89 CL:0000010 Female 21165056 CVCL_DF87 INT.Ov2 cancer cell line human CVCL_DF87 CL:0000010 Female 21165057 CVCL_DF88 INT.Ov3 cancer cell line human CVCL_DF88 CL:0000010 Derived from metastatic site: Ascites. Female 21165058 CVCL_DF96 MDS1r(17)-2 iPSC induced pluripotent stem cell human CVCL_DF96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165059 CVCL_DF97 MDS2-1 iPSC induced pluripotent stem cell human CVCL_DF97 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21165060 CVCL_DF94 INT.Ov9 cancer cell line human CVCL_DF94 CL:0000010 Female 21165061 CVCL_DF95 MDS1r(17)-1 iPSC induced pluripotent stem cell human CVCL_DF95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165062 CVCL_DF98 MDS2-2 iPSC induced pluripotent stem cell human CVCL_DF98 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21165063 CVCL_DF99 MDS3-1 iPSC induced pluripotent stem cell human CVCL_DF99 CL:0000010 Derived from sampling site: Fetal diaphragm; skeletal muscle Cell type=Fibroblast.. Male 21165064 CVCL_DF70 MDCK 9B9-1E4 spontaneously immortalized cell line dog CVCL_DF70 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Not tumorigenic Highly permissive to the live attenuated influenza vaccine (LAIV) components. Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7910 21165065 CVCL_DF71 HB 34-1 hybridoma house mouse CVCL_DF71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05231; Human IL6. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-813 21165066 CVCL_DF69 MDCK 9B9-1B1 spontaneously immortalized cell line dog CVCL_DF69 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7909 21165067 CVCL_DF63 BPEI-1 spontaneously immortalized cell line Norway rat CVCL_DF63 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: Long-Evans. Unspecified Doubling time: 18 hours (PubMed=7679997) 21165068 CVCL_DF64 tRPE spontaneously immortalized cell line CVCL_DF64 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Unspecified 21165069 CVCL_DF61 AGE1.HN.AAT transformed cell line human CVCL_DF61 From: ProBioGen AG; Berlin; Germany CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285). 21165070 CVCL_DF62 B6-RPE07 spontaneously immortalized cell line house mouse CVCL_DF62 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: C57BL/6. Female 21165071 CVCL_DF67 NGC-0301 spontaneously immortalized cell line human CVCL_DF67 CL:0000010 Transfected with: HGNC; 4232; GDNF Derived from sampling site: Eye; retina; retinal pigment epithelium. Biotechnology: Used in NsG0301, an encapsulated cell biodelivery device capable of local delivery of GDNF to the brain so at to treat Parkinson disease patients Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2732 21165072 CVCL_DF68 NGC-0363 spontaneously immortalized cell line human CVCL_DF68 CL:0000010 Transfected with: HGNC; 4232; GDNF Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2733 21165073 CVCL_DF65 NGC0211 spontaneously immortalized cell line human CVCL_DF65 CL:0000010 Transfected with: HGNC; 7808; NGF Derived from sampling site: Eye; retina; retinal pigment epithelium. Biotechnology: Used in NsG0202.1, an encapsulated cell biodelivery device capable of local delivery of NGF to the brain so at to treat the cognitive decline in Alzheimer disease patients Male Characteristics: Contains 4 integrated copies of the NGF gene 21165074 CVCL_DF66 NGC-0295 spontaneously immortalized cell line human CVCL_DF66 CL:0000010 Transfected with: HGNC; 7808; NGF Derived from sampling site: Eye; retina; retinal pigment epithelium. Biotechnology: Used in NsG0202, an encapsulated cell biodelivery device capable of local delivery of NGF to the brain so at to treat the cognitive decline in Alzheimer disease patients Male 21165075 CVCL_DF81 CC-11 cancer cell line human CVCL_DF81 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 67 (HPV67)(NCBI-Taxonomy; 37120); Derived from sampling site: Uterus; cervix. Female Doubling time: 62 +- 10 hours (PubMed=10554043) 21165076 CVCL_DF82 CC-11+ cancer cell line human CVCL_DF82 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 67 (HPV67)(NCBI-Taxonomy; 37120); Derived from sampling site: Uterus; cervix. Female 21165077 CVCL_DF80 CC-10B cancer cell line human CVCL_DF80 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 45 (HPV45)(NCBI-Taxonomy; 10593); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: SNP array analysis Female Doubling time: 31 +- 2 hours (PubMed=10554043) 21165078 CVCL_DF74 BMG-1 cancer cell line human CVCL_DF74 CL:0000010 21165079 CVCL_DF75 UTP-N-1 cancer cell line human CVCL_DF75 CL:0000010 Population: Japanese Omics: SNP array analysis. 21165080 CVCL_DF72 BLSC-KU-8 cancer cell line CVCL_DF72 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese black. Female 21165081 CVCL_DF73 EBLC-1 cancer cell line CVCL_DF73 CL:0000010 Breed/subspecies: Japanese black. Female 21165082 CVCL_DF78 CC-8 cancer cell line human CVCL_DF78 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 45 (HPV45)(NCBI-Taxonomy; 10593); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: SNP array analysis Female Doubling time: 55 +- 7 hours (PubMed=10554043) 21165083 CVCL_DF79 CC-10A cancer cell line human CVCL_DF79 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 45 (HPV45)(NCBI-Taxonomy; 10593); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: SNP array analysis Female Doubling time: 58 +- 1 hours (PubMed=10554043) 21165084 CVCL_DF76 CSCC-1 cancer cell line human CVCL_DF76 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: SNP array analysis Female Virology: Contains an episomal HPV16 genome Doubling time: 74 +- 5 hours (PubMed=10554043) 21165085 CVCL_DF77 CSCC-7 cancer cell line human CVCL_DF77 CL:0000010 Population: Surinamese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Omics: CNV analysis; Omics: SNP array analysis Female Doubling time: 50 +- 4 hours (PubMed=10554043) 21165086 CVCL_2T60 GM08828 transformed cell line human CVCL_2T60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165087 CVCL_3560 NFS-70 C-10 cancer cell line house mouse CVCL_3560 CL:0000010 Transformant: Murine leukemia virus [Isolate CAS-NS-7](NCBI-Taxonomy; 11786); Derived from sampling site: Peripheral blood; Breed/subspecies: NFS/N. Characteristics: Contains DJ rearrangements on both IgH alleles (PubMed=19363217) 21165088 CVCL_2T52 GM08254 transformed cell line human CVCL_2T52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165089 CVCL_3552 N1-S1 Fudr cancer cell line Norway rat CVCL_3552 CL:0000010 Selected for resistance to: ChEBI; CHEBI:60761; 5-fluoro-2'-deoxyuridine (FUdR); Breed/subspecies: Sprague Dawley. Male 21165090 CVCL_2T53 GM08263 finite cell line human CVCL_2T53 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165091 CVCL_3553 NB41A3 cancer cell line house mouse CVCL_3553 CL:0000010 Breed/subspecies: A/J. Discontinued: RCB; RCB2626; true Male 21165092 CVCL_2T50 GM08134 finite cell line human CVCL_2T50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165093 CVCL_3550 Mvi/It cancer cell line CVCL_3550 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6012; true Female Characteristics: From a skin tumor found in a bat from Frio Cave, Texas; Virology: Infected by bat gammaherpesvirus 8 (BGHV8) Group: Bat cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165094 CVCL_2T51 GM08135 finite cell line human CVCL_2T51 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;21)(q22.3;q11) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21165095 CVCL_3551 N1-S1 cancer cell line Norway rat CVCL_3551 CL:0000010 Breed/subspecies: Sprague Dawley. Male 21165096 CVCL_2T56 GM08586 transformed cell line human CVCL_2T56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165097 CVCL_3556 NF-1 cancer cell line house mouse CVCL_3556 CL:0000010 Breed/subspecies: BALB/c. Male 21165098 CVCL_2T57 GM08755 finite cell line human CVCL_2T57 CL:0000010 Derived from sampling site: Fetal Achilles tendon. Omics: CNV analysis Male 21165099 CVCL_3557 NFPE cancer cell line house mouse CVCL_3557 CL:0000010 Breed/subspecies: BALB/c. Male 21165100 CVCL_2T54 GM08386 finite cell line human CVCL_2T54 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165101 CVCL_3554 NE cancer cell line house mouse CVCL_3554 CL:0000010 Breed/subspecies: C3H/J. Unspecified 21165102 CVCL_2T55 GM08585 transformed cell line human CVCL_2T55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165103 CVCL_3555 Ne Loc finite cell line human CVCL_3555 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1205; true Female 21165104 CVCL_2T58 GM08773 transformed cell line human CVCL_2T58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165105 CVCL_3558 NFS-25 C-3 cancer cell line house mouse CVCL_3558 CL:0000010 Breed/subspecies: NFS.C58v1. 21165106 CVCL_2T59 GM08827 transformed cell line human CVCL_2T59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165107 CVCL_3559 NFS-5 C-1 cancer cell line house mouse CVCL_3559 CL:0000010 Breed/subspecies: NFS/N. 21165108 CVCL_UZ93 MBC02 cancer cell line human CVCL_UZ93 CL:0000010 Population: Indian; Derived from sampling site: Colon. Female Doubling time: ~24 hours (PubMed=30828563) 21165109 CVCL_UZ94 SCCTF TF-R cancer cell line human CVCL_UZ94 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:22907; Bleomycin; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 20.8 hours (PubMed=7536509) Problematic cell line: Contaminated Parent cell line (SCCTF) has been shown to be a SCCKN derivative. 21165110 CVCL_UZ91 CHO BLMR-3 spontaneously immortalized cell line CVCL_UZ91 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3139; Bleomycin A2; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21165111 CVCL_UZ92 CHO BLMR-4 spontaneously immortalized cell line CVCL_UZ92 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3139; Bleomycin A2; Derived from sampling site: Ovary. Female 21165112 CVCL_UZ97 Sl/Sl4-mSCF220 transformed cell line house mouse CVCL_UZ97 CL:0000010 Transfected with: MGI; MGI:96974; Kitl (isoform SCF220); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: WBB6 F1 Sl/Sl(d). Unspecified 21165113 CVCL_UZ98 UM-Chor5 cancer cell line human CVCL_UZ98 CL:0000010 Derived from sampling site: Bone; cranium; clivus. Male Doubling time: 96 hours (Chordoma_Foundation) 21165114 CVCL_UZ95 SCCTF TF-S cancer cell line human CVCL_UZ95 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 24.0 hours (PubMed=7536509) Problematic cell line: Contaminated Parent cell line (SCCTF) has been shown to be a SCCKN derivative. 21165115 CVCL_UZ96 KIK4 finite cell line human CVCL_UZ96 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; c.1845+2T>C; ClinVar=VCV000252070; Zygosity=Homozygous; Note=Splice donor mutation (JCRB) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21165116 CVCL_UZ99 HT-1080-Luc2 cancer cell line human CVCL_UZ99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~11 hours (ATCC=CCL-121-LUC2) 21165117 CVCL_2T70 GM10067 transformed cell line human CVCL_2T70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165118 CVCL_3570 R-3327-AT-3.1 cancer cell line Norway rat CVCL_3570 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-31; true Male 21165119 CVCL_2T71 GM10068 transformed cell line human CVCL_2T71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165120 CVCL_3571 R2C cancer cell line Norway rat CVCL_3571 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: Wistar Furth. Male 21165121 CVCL_2T63 GM09290 finite cell line human CVCL_2T63 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;6)(1pter->1q43::6q23->6qter;6pter->6q23::1q43->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165122 CVCL_3563 NMU cancer cell line Norway rat CVCL_3563 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102). Female 21165123 CVCL_2T64 GM09403 transformed cell line human CVCL_2T64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165124 CVCL_3564 P1.17 cancer cell line house mouse CVCL_3564 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165125 CVCL_2T61 GM09192 transformed cell line human CVCL_2T61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165126 CVCL_3561 NIT-1 transformed cell line house mouse CVCL_3561 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NOD/Lt-Tg(RIPTag)1Lt transgenic. Female Characteristics: Secretes insulin Doubling time: 49.1 hours, at 18th passage (PubMed=1647994) 21165127 CVCL_2T62 GM09285 finite cell line human CVCL_2T62 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165128 CVCL_3562 NIT-2 transformed cell line house mouse CVCL_3562 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BLKS/J-Cpefat/1 x NOD/Lt-Tg(RIPTag)1Lt. Male 21165129 CVCL_2T67 GM09623 finite cell line human CVCL_2T67 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165130 CVCL_3567 PL45 cancer cell line human CVCL_3567 HLA typing: A*01:01,31:01; B*40:01,49:01; C*03:04,07:01 (PubMed=26589293); Genome ancestry: African=1.25%; Native American=0%; East Asian, North=1.71%; East Asian, South=0%; South Asian=0%; European, North=62.06%; European, South=34.98% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Asn (c.764T>A); ClinVar=VCV000232289; Zygosity=Homozygous (from autologous cell line Panc 10.05) Population: Caucasian Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Metabolome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21165131 CVCL_2T68 GM09679 finite cell line human CVCL_2T68 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165132 CVCL_3568 R-3327-AT-1 cancer cell line Norway rat CVCL_3568 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-29; true Male 21165133 CVCL_2T65 GM09428 finite cell line human CVCL_2T65 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165134 CVCL_3565 P3.6.2.8.1 cancer cell line house mouse CVCL_3565 CL:0000010 Breed/subspecies: BALB/c. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165135 CVCL_2T66 GM09552 transformed cell line human CVCL_2T66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165136 CVCL_3566 PFHR-9 cancer cell line house mouse CVCL_3566 CL:0000010 Breed/subspecies: 129/Sv. Male Doubling time: 12 hours (ATCC=CRL-2423) 21165137 CVCL_2T69 GM10006 transformed cell line human CVCL_2T69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165138 CVCL_3569 R-3327-AT-2.1 cancer cell line Norway rat CVCL_3569 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-30; true Male 21165139 CVCL_UZ82 S2 RFP-Rhotekin+MRLC-EGFP spontaneously immortalized cell line fruit fly CVCL_UZ82 CL:0000010 Transfected with: MGI; MGI:107371; Rtkn; (with p.Met1_Arg6del and p.Arg90_Val551del = rGBD); Transfected with: FlyBase_Gene; FBgn0003514; sqh; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165140 CVCL_UZ83 S2 DmECT2-EGFP+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ83 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003041; pbl; Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165141 CVCL_UZ80 S2 EGFP-Rhotekin+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ80 CL:0000010 Transfected with: MGI; MGI:107371; Rtkn; (with p.Met1_Arg6del and p.Arg90_Val551del = rGBD); Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165142 CVCL_UZ81 S2 RFP-Rhotekin+DmMKLP1-EGFP spontaneously immortalized cell line fruit fly CVCL_UZ81 CL:0000010 Transfected with: MGI; MGI:107371; Rtkn; (with p.Met1_Arg6del and p.Arg90_Val551del = rGBD); Transfected with: FlyBase_Gene; FBgn0011692; pav; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165143 CVCL_UZ86 S2 EB1-DeltaPTIV-RacGAP50C-EGFP and TagRFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ86 CL:0000010 Transfected with: FlyBase_Gene; FBgn0027066; Eb1; Transfected with: FlyBase_Gene; FBgn0086356; tum (with p.Pro533_Val536del); Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165144 CVCL_UZ87 XTR-3 BSAgB hybrid cell line house mouse CVCL_UZ87 CL:0000010 Group: Human/rodent somatic cell hybrid. 21165145 CVCL_UZ84 S2 EB1-RacGAP50C-EGFP+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ84 CL:0000010 Transfected with: FlyBase_Gene; FBgn0027066; Eb1; Transfected with: FlyBase_Gene; FBgn0086356; tum; Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165146 CVCL_UZ85 S2 EB1-DeltaC-RacGAP50C-EGFP+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ85 CL:0000010 Transfected with: FlyBase_Gene; FBgn0027066; Eb1; Transfected with: FlyBase_Gene; FBgn0086356; tum (with p.Ile527_Lys625del); Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165147 CVCL_UZ88 L5178Y BLM-A2-R cancer cell line house mouse CVCL_UZ88 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the resistance phenotype Selected for resistance to: ChEBI; CHEBI:3139; Bleomycin A2; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female Doubling time: 14.7 hours (PubMed=6173370) 21165148 CVCL_UZ89 CHO BLMR-1 spontaneously immortalized cell line CVCL_UZ89 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3139; Bleomycin A2; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21165149 CVCL_2T30 GM07173 transformed cell line human CVCL_2T30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165150 CVCL_3530 JC cancer cell line house mouse CVCL_3530 CL:0000010 Karyotypic information: Hypo-tetraploid karyotype with 64-66 chromosomes (PubMed=33526060); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cRos. Omics: Array-based CGH Female Doubling time: 12-16 hours (ATCC=CRL-2116) 21165151 CVCL_2T31 GM07332 finite cell line human CVCL_2T31 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(11;22)(11pter->11q23::22q11.2->22qter;22pter->22q11.2::11q23->11qter)mat (Coriell); Derived from sampling site: Placenta Cell type=Fibroblast.. Male 21165152 CVCL_3531 Jensen sarcoma cancer cell line Norway rat CVCL_3531 CL:0000010 21165153 CVCL_2T34 GM07503 finite cell line human CVCL_2T34 CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165154 CVCL_3534 L2-RYC cancer cell line Norway rat CVCL_3534 CL:0000010 Breed/subspecies: Lewis. Unspecified 21165155 CVCL_2T35 GM07693 finite cell line human CVCL_2T35 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;10)(p11.2;q24.3) (PubMed=10377420); Derived from sampling site: Placenta Cell type=Fibroblast.. Omics: CNV analysis Female 21165156 CVCL_3535 LA-4 [Mouse lung adenoma] cancer cell line house mouse CVCL_3535 CL:0000010 Karyotypic information: 85 to 93 chromosomes; hyper-tetraploid karyotype (PubMed=34881029); Transformant: Urethane(ChEBI; CHEBI:17967); Derived from sampling site: Lung; Breed/subspecies: A/He. Omics: Array-based CGH Female 21165157 CVCL_2T32 GM07456 transformed cell line human CVCL_2T32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165158 CVCL_3532 JM-1 cancer cell line human CVCL_3532 HLA typing: A*01:01,01:01; B*07:02,51:01; C*07:02,16:01; DQA1*03:02,04:01; DQB1*03:03,04:02; DRB1*08:01,09:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=1.68%; East Asian, South=0%; South Asian=0%; European, North=66.6%; European, South=31.71% (PubMed=30894373) CL:0000010 Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10423 21165159 CVCL_2T33 GM07457 finite cell line human CVCL_2T33 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;21)(1pter->1q12::21q22.3->21qter;21pter->21q22.3::1q12->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165160 CVCL_3533 KLN205 cancer cell line house mouse CVCL_3533 CL:0000010 Karyotypic information: Tetraploid karyotype with 77-82 chromosomes per cell (DOI=10.20517/2394-4722.2021.59); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Lung; Breed/subspecies: DBA/2. Omics: Array-based CGH Male Characteristics: Tumorigenic Forms metastatic lesions in lungs after inoculation into mice (CLS). 21165161 CVCL_2T38 GM07908 finite cell line human CVCL_2T38 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21165162 CVCL_3538 LTPA cancer cell line house mouse CVCL_3538 CL:0000010 Breed/subspecies: LT/Sv. Omics: Mitochondrial genome sequenced Female Caution: The authors of PubMed=25492535 indicate that they have sequenced the mitochondrial genome of the 'rat' cell line LTPA Their submitted DNA sequence (KM820833.1) is indeed a rat sequence but is labelled as originating from 'rat isolate 671'. 21165163 CVCL_2T39 GM07964 transformed cell line human CVCL_2T39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165164 CVCL_3539 LNZTA3WT11 cancer cell line human CVCL_3539 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Brain; right parieto-occipital lobe. Male Characteristics: The expression of the luciferase reporter gene as well as the TP53 gene are under the control of a tetO operator; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11544 21165165 CVCL_2T36 GM07792 finite cell line human CVCL_2T36 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;20)(p10;q10) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165166 CVCL_3536 LC-540 cancer cell line Norway rat CVCL_3536 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: Fischer. Male 21165167 CVCL_2T37 GM07891 finite cell line human CVCL_2T37 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165168 CVCL_3537 LLC-WRC 256 cancer cell line Norway rat CVCL_3537 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Discontinued: CLS; 500375; true Female 21165169 CVCL_UZ90 CHO BLMR-2 spontaneously immortalized cell line CVCL_UZ90 CL:0000010 Selected for resistance to: ChEBI; CHEBI:3139; Bleomycin A2; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female 21165170 CVCL_UZ71 NV-8 spontaneously immortalized cell line CVCL_UZ71 CL:0000010 Unspecified Group: Insect cell line. 21165171 CVCL_UZ72 RD-5 spontaneously immortalized cell line CVCL_UZ72 CL:0000010 Unspecified Group: Insect cell line. 21165172 CVCL_UZ70 NV-5 spontaneously immortalized cell line CVCL_UZ70 CL:0000010 Unspecified Group: Insect cell line. 21165173 CVCL_UZ75 RD-8 spontaneously immortalized cell line CVCL_UZ75 CL:0000010 Unspecified Group: Insect cell line. 21165174 CVCL_UZ76 RD-9 spontaneously immortalized cell line CVCL_UZ76 CL:0000010 Unspecified Group: Insect cell line. 21165175 CVCL_UZ73 RD-6 spontaneously immortalized cell line CVCL_UZ73 CL:0000010 Unspecified Group: Insect cell line. 21165176 CVCL_UZ74 RD-7 spontaneously immortalized cell line CVCL_UZ74 CL:0000010 Unspecified Group: Insect cell line. 21165177 CVCL_UZ79 S2 Polo Kinase-EGFP spontaneously immortalized cell line fruit fly CVCL_UZ79 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003124; polo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165178 CVCL_UZ77 S2 DmMKLP1-EGFP+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ77 CL:0000010 Transfected with: FlyBase_Gene; FBgn0011692; pav; Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165179 CVCL_UZ78 S2 RacGAP50C-EGFP+Tag-RFP-alpha-tubulin spontaneously immortalized cell line fruit fly CVCL_UZ78 CL:0000010 Transfected with: FlyBase_Gene; FBgn0086356; tum; Transfected with: FlyBase_Gene; FBgn0003884; alphaTub84B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21165180 CVCL_2T41 GM07970 finite cell line human CVCL_2T41 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+der(9)(9pter->9q13::Yq12->Yqter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165181 CVCL_3541 Lo Ren finite cell line human CVCL_3541 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165182 CVCL_2T42 GM07971 finite cell line human CVCL_2T42 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(Y;9)(Ypter->Yq12::9q13->9qter;9pter->9q13::Yq12->Yqter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165183 CVCL_3542 Lo Wen finite cell line human CVCL_3542 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165184 CVCL_2T40 GM07966 finite cell line human CVCL_2T40 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21165185 CVCL_3540 LNZTA3WT4 cancer cell line human CVCL_3540 Genome ancestry: African=1.42%; Native American=1.36%; East Asian, North=1.52%; East Asian, South=0%; South Asian=1.65%; European, North=44.35%; European, South=49.7% (PubMed=30894373) CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Brain; right parieto-occipital lobe. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Characteristics: The expression of the luciferase reporter gene as well as the TP53 gene are under the control of a tetO operator; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11543 21165186 CVCL_2T45 GM08009 transformed cell line human CVCL_2T45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165187 CVCL_3545 MM2MT cancer cell line house mouse CVCL_3545 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165188 CVCL_2T46 GM08012 transformed cell line human CVCL_2T46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165189 CVCL_3546 MM2MTC cancer cell line house mouse CVCL_3546 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: ATCC; CRL-6374; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165190 CVCL_2T43 GM07987 finite cell line human CVCL_2T43 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165191 CVCL_3543 NFS-60 cancer cell line house mouse CVCL_3543 CL:0000010 Transformant: Cas-Br-E murine leukemia virus(NCBI-Taxonomy; 11792); Breed/subspecies: NFS x DBA/2. Characteristics: IL3 dependent 21165192 CVCL_2T44 GM07994 finite cell line human CVCL_2T44 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165193 CVCL_3544 MLTC-1 cancer cell line house mouse CVCL_3544 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: C57BL/6J. Male 21165194 CVCL_2T49 GM08123 finite cell line human CVCL_2T49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165195 CVCL_3549 Murphy cancer cell line human CVCL_3549 CL:0000010 Discontinued: ATCC; CRL-7722; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165196 CVCL_2T47 GM08070 transformed cell line human CVCL_2T47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165197 CVCL_3547 MM2SCT cancer cell line house mouse CVCL_3547 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6375; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165198 CVCL_2T48 GM08122 finite cell line human CVCL_2T48 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;11)(2pter->2q14.2::11q25->11qter;11pter->11q25::2q14.2->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165199 CVCL_3548 MTC-M cancer cell line house mouse CVCL_3548 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: BALB/c. Female Doubling time: ~4 days (PubMed=2875121); 96 hours (ATCC=CRL-1806) 21165200 CVCL_UZ60 N/bmi1/TERT telomerase immortalized cell line human CVCL_UZ60 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21165201 CVCL_UZ61 N/E6E7 transformed cell line human CVCL_UZ61 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21165202 CVCL_UZ64 OAL-1 cancer cell line human CVCL_UZ64 CL:0000010 Derived from sampling site: Cheek; skin. Female 21165203 CVCL_UZ65 OAL-2 cancer cell line human CVCL_UZ65 CL:0000010 Derived from sampling site: Cheek; skin. Male 21165204 CVCL_UZ62 N/TERT-2 telomerase immortalized cell line human CVCL_UZ62 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21165205 CVCL_UZ63 hESderK/E6E7 clK transformed cell line human CVCL_UZ63 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760). Female 21165206 CVCL_UZ68 NN-5 [Nephotettix] spontaneously immortalized cell line CVCL_UZ68 CL:0000010 Unspecified Group: Insect cell line. 21165207 CVCL_UZ69 NN-7 spontaneously immortalized cell line CVCL_UZ69 CL:0000010 Unspecified Group: Insect cell line. 21165208 CVCL_UZ66 MeGo cancer cell line human CVCL_UZ66 CL:0000010 Derived from metastatic site: Groin. 21165209 CVCL_UZ67 NN-2 spontaneously immortalized cell line CVCL_UZ67 CL:0000010 Unspecified Group: Insect cell line. 21165210 CVCL_2T12 GM05394 finite cell line human CVCL_2T12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165211 CVCL_3512 H4TG cancer cell line Norway rat CVCL_3512 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21165212 CVCL_2T13 GM05409 finite cell line human CVCL_2T13 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(5;17)(5pter->5q33::17p12->17pter;17qter->17p12::5q33->5qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165213 CVCL_3513 H69AR cancer cell line human CVCL_3513 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Group: Patented cell line; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11351 21165214 CVCL_3510 F98 cancer cell line Norway rat CVCL_3510 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; cerebellum; Breed/subspecies: Fischer 344. Female 21165215 CVCL_2T10 GM05235 finite cell line human CVCL_2T10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21165216 CVCL_3511 FAT 7 cancer cell line Norway rat CVCL_3511 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Simple; p.Arg271His (c.812G>A); Zygosity=Unspecified (PubMed=8148052) Transformant: Formaldehyde(ChEBI; CHEBI:16842); Derived from sampling site: Nose; nasal cavity; nasal vestibule; Breed/subspecies: Fischer 344. Male Doubling time: 24 hours (PubMed=8148052) 21165217 CVCL_2T11 GM05348 transformed cell line human CVCL_2T11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165218 CVCL_2T16 GM05654 transformed cell line human CVCL_2T16 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;11)(4pter->4q25::11p13->11pter;11qter->11p13::4q25->4qter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165219 CVCL_3516 HP75 transformed cell line human CVCL_3516 CL:0000010 Transformant: Simian virus 40 (SV40) [AD-SVR4](NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland. Discontinued: ATCC; CRL-2506; true Male Doubling time: ~2 days (DOI=10.1007/BF02782609) 21165220 CVCL_2T17 GM05656 finite cell line human CVCL_2T17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21165221 CVCL_3517 HPAC cancer cell line human CVCL_3517 HLA typing: A*03:01,03:01; B*14:02,14:02; C*08:02,08:02; DQA1*03:02,03:02 (PubMed=26589293); Genome ancestry: African=0.23%; Native American=0.7%; East Asian, North=2.44%; East Asian, South=0%; South Asian=0%; European, North=62.15%; European, South=34.47% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Unspecified (PubMed=15367885); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=15367885); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15367885) Population: Caucasian; Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Metabolome analysis; Omics: Proteome analysis by 2D-DE/MS; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a nude mouse xenograft (ATCC) Doubling time: 38 +- 6 hours (at 5th passage), 41 +- 2 hours (at 90th passage) (PubMed=25939163); 23 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21165222 CVCL_2T14 GM05519 finite cell line human CVCL_2T14 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(4;11)(4pter->4q25::11p13->11pter;11qter->11p13::4q25->4qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165223 CVCL_3514 H9/HTLV-IIIB cancer cell line human CVCL_3514 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: In vitro infected by HIV-1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8543 21165224 CVCL_2T15 GM05564 finite cell line human CVCL_2T15 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21165225 CVCL_3515 HOPC 1F/12 cancer cell line house mouse CVCL_3515 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165226 CVCL_2T18 GM06037 finite cell line human CVCL_2T18 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21165227 CVCL_3518 HSDM1C1 cancer cell line house mouse CVCL_3518 CL:0000010 Breed/subspecies: Swiss albino. 21165228 CVCL_2T19 GM06135 transformed cell line human CVCL_2T19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165229 CVCL_3519 Hs 207.T cancer cell line human CVCL_3519 CL:0000010 Discontinued: ATCC; CRL-7168; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165230 CVCL_UZ50 KYMM-1 cancer cell line human CVCL_UZ50 CL:0000010 Miscellaneous: STR profile from personal communication of Hata H Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa (PubMed=22766978); Characteristics: Has a very low expression of SDC1/CD138 (PubMed=22766978) 21165231 CVCL_UZ53 DrRPE spontaneously immortalized cell line zebrafish CVCL_UZ53 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Unspecified Characteristics: UV-B exposure results in morphological alterations Optimal growth at 28 Celsius (PubMed=25517103). Doubling time: ~40 hours, in L-15 medium + 10% FBS (PubMed=25517103) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC054 21165232 CVCL_UZ54 S2R+-polo-GFP-2 spontaneously immortalized cell line fruit fly CVCL_UZ54 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Polo locus (FBgn0003124) Group: Insect cell line 21165233 CVCL_UZ51 KYMM-2 cancer cell line human CVCL_UZ51 CL:0000010 Miscellaneous: STR profile from personal communication of Hata H Population: Japanese; Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa (PubMed=22766978); Characteristics: Compared to the autologous cell line KYMM-1, has a 5-fold higher expression of SDC1/CD138 (PubMed=22766978) 21165234 CVCL_UZ52 DrF spontaneously immortalized cell line zebrafish CVCL_UZ52 CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Doubling time: ~34 hours, in L-15 medium + 10% FBS (PubMed=30762877) Group: Fish cell line 21165235 CVCL_UZ57 N finite cell line human CVCL_UZ57 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male Senescence: Senesces at ~52-55 PDL (PubMed=10648628; PubMed=12077343) 21165236 CVCL_UZ58 LiF-EP finite cell line human CVCL_UZ58 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1delG (IVS9+1delG); ClinVar=VCV000428898; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10980596) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Senescence: Senesces at ~35 PDL (PubMed=10648628) 21165237 CVCL_UZ55 HCB-514 cancer cell line human CVCL_UZ55 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Trp2830Ter (c.8490G>A); ClinVar=VCV000155722; Zygosity=Heterozygous (PubMed=30760827); Sequence variation: Mutation; HGNC; 14359; IRX2; Simple; p.Tyr48Ter (c.144T>G); Zygosity=Heterozygous (PubMed=30760827); Sequence variation: Mutation; HGNC; 11772; TGFBR1; Simple; p.Ala202Val (c.605C>T); ClinVar=VCV000635251; Zygosity=Heterozygous (PubMed=30760827) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: Deep exome analysis. Female Virology: Contains HPV16 genomes integrated at two separate chromosomal locations (PubMed=30760827) Doubling time: 17 hours (in 10% FBS), 21 hours (in 5% FBS) (PubMed=30760827) 21165238 CVCL_UZ56 Huh7 IFITM2-/- cancer cell line human CVCL_UZ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5413; IFITM2; Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21165239 CVCL_UZ59 LiF-EP/TERT-1 telomerase immortalized cell line human CVCL_UZ59 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Heterozygous (PubMed=10648628); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1delG (IVS9+1delG); ClinVar=VCV000428898; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10980596); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21165240 CVCL_2T20 GM06228 transformed cell line human CVCL_2T20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165241 CVCL_3520 Hs 398.T cancer cell line human CVCL_3520 CL:0000010 Discontinued: ATCC; CRL-7273; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165242 CVCL_2T23 GM06563 finite cell line human CVCL_2T23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165243 CVCL_3523 HT-1417 cancer cell line human CVCL_3523 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21165244 CVCL_2T24 GM06832 transformed cell line human CVCL_2T24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165245 CVCL_3524 HT-728.T cancer cell line human CVCL_3524 CL:0000010 Omics: SNP array analysis Discontinued: ATCC; CRL-7783; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165246 CVCL_2T21 GM06321 finite cell line human CVCL_2T21 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21165247 CVCL_3521 Hs 51.T cancer cell line human CVCL_3521 CL:0000010 Discontinued: ATCC; CRL-7030; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165248 CVCL_2T22 GM06526 finite cell line human CVCL_2T22 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21165249 CVCL_3522 Hs 871.T cancer cell line human CVCL_3522 CL:0000010 Discontinued: ATCC; CRL-7609; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165250 CVCL_2T27 GaL23 cancer cell line human CVCL_2T27 CL:0000010 Female Doubling time: 36 hours (at 30th passage), 33 hours (at 50th passage), 29 hours (at 30th passage) (PubMed=9590507). 21165251 CVCL_3527 I-10 cancer cell line house mouse CVCL_3527 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/cJ. Male 21165252 CVCL_2T28 GaL23LZ cancer cell line human CVCL_2T28 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ. Female 21165253 CVCL_3528 IA-XsSBR cancer cell line Norway rat CVCL_3528 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Small intestine; Breed/subspecies: Holtzman Sprague Dawley. Male 21165254 CVCL_2T25 GM06924 transformed cell line human CVCL_2T25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165255 CVCL_3525 HT-762.T cancer cell line human CVCL_3525 CL:0000010 Discontinued: ATCC; CRL-7789; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165256 CVCL_2T26 GM07146 finite cell line human CVCL_2T26 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21165257 CVCL_3526 HuT 102 cancer cell line human CVCL_3526 HLA typing: A*66:02 (IPD-IMGT/HLA=10777); Genome ancestry: African=84.86%; Native American=0.23%; East Asian, North=1.93%; East Asian, South=0%; South Asian=0%; European, North=6.73%; European, South=6.25% (PubMed=30894373) CL:0000010 Anecdotal: This is the cell line that was used by Gallo's lab to isolate HTLV-1 (PubMed=26696625) Population: African American; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Lymph node Cell type=T-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Discontinued: ATCC; TIB-162; probable; Discontinued: KCLB; 90102; probable; Discontinued: RCB; RCB1979; true Male Doubling time: 38 hours (PubMed=6244013) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) Caution: Indicated as originating from a 28 year old at sampling in PubMed=6261256, 26 year old in PubMed=6244013 and 29 year old in PubMed=8806092 21165258 CVCL_2T29 GM07150 finite cell line human CVCL_2T29 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165259 CVCL_3529 J558 cancer cell line house mouse CVCL_3529 CL:0000010 Derived from sampling site: Cell type=B-cell; Breed/subspecies: BALB/c. Discontinued: BioSample; SAMN11397662; true Monoclonal antibody isotype: IgA, lambda; Monoclonal antibody target: ChEBI; CHEBI:52071; Dextran Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) Caution: A STR profile for this cell line was available in Cellosaurus releases 30 and 31 and originated from a BioSample entry created using NIST data As this data has been since removed because of possible misidentification/contamination we also have removed it. 21165260 CVCL_UZ42 HM-3/TERT telomerase immortalized cell line human CVCL_UZ42 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Peritoneal effusion. Female 21165261 CVCL_UZ43 TrBEp-1 finite cell line human CVCL_UZ43 CL:0000010 Derived from sampling site: Tracheobronchial epithelium. Unspecified 21165262 CVCL_UZ40 HM-3 [Human mesothelia] finite cell line human CVCL_UZ40 CL:0000010 Derived from sampling site: Peritoneal effusion. Female Senescence: Senesces at 43 PDL (PubMed=12077343) 21165263 CVCL_UZ41 HM-3/p53DD finite cell line human CVCL_UZ41 CL:0000010 Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD) Derived from sampling site: Peritoneal effusion. Female 21165264 CVCL_UZ46 KL-5/bmi1/TERT telomerase immortalized cell line human CVCL_UZ46 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Eye; cornea; epithelium Cell type=Keratinocyte.. Female 21165265 CVCL_UZ47 HBl-10U finite cell line human CVCL_UZ47 CL:0000010 Derived from sampling site: Fetal urinary bladder Cell type=Urothelial cell.. Unspecified 21165266 CVCL_UZ44 TrBEp-1/bmi1/TERT telomerase immortalized cell line human CVCL_UZ44 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Tracheobronchial epithelium. Unspecified 21165267 CVCL_UZ45 KL-5 finite cell line human CVCL_UZ45 CL:0000010 Derived from sampling site: Eye; cornea; epithelium Cell type=Keratinocyte.. Female Senescence: Senesces at 23 PDL (PubMed=19489101) 21165268 CVCL_UZ48 HBl-10U/bmi1/TERT telomerase immortalized cell line human CVCL_UZ48 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Fetal urinary bladder Cell type=Urothelial cell.. Unspecified 21165269 CVCL_UZ49 HBl-10U/E6E7 transformed cell line human CVCL_UZ49 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal urinary bladder Cell type=Urothelial cell.. Unspecified 21165270 CVCL_UZ31 HC0597 transformed cell line human CVCL_UZ31 CL:0000010 Anecdotal: Developed and patented by Gillette as a model to replace the Draize rabbit eye test for evaluation of the eye irritation potential of products Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.. Female Doubling time: 31.7 +- 0.5 hours (Patent=US6030789) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12658 21165271 CVCL_UZ32 HC0708 transformed cell line human CVCL_UZ32 CL:0000010 Anecdotal: Developed and patented by Gillette as a model to replace the Draize rabbit eye test for evaluation of the eye irritation potential of products Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.. Female Doubling time: 30.9 +- 0.4 hours (Patent=US6030789) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12659 21165272 CVCL_UZ30 CJ4.3C transformed cell line Norway rat CVCL_UZ30 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 23 +- 9 hours (PubMed=17123516) 21165273 CVCL_UZ35 R2F finite cell line human CVCL_UZ35 CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male Senescence: Senesces at 80 PDL (PubMed=12077343) 21165274 CVCL_UZ36 R2F/HTERT telomerase immortalized cell line human CVCL_UZ36 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 21165275 CVCL_UZ33 K107-Ep finite cell line human CVCL_UZ33 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Trp (c.301G>T) (p.Arg115Leu, c.344G>T); ClinVar=VCV000009412; Zygosity=Heterozygous (PubMed=12077343) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Senescence: Senesces at 55 PDL (PubMed=12077343) 21165276 CVCL_UZ34 K107-Ep/p53DD/TERT telomerase immortalized cell line human CVCL_UZ34 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Trp (c.301G>T) (p.Arg115Leu, c.344G>T); ClinVar=VCV000009412; Zygosity=Hemizygous (PubMed=12077343); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21165277 CVCL_UZ39 DOLA/bmi1/TERT telomerase immortalized cell line human CVCL_UZ39 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Axilla; skin Cell type=Myoepithelial cell.. Male 21165278 CVCL_UZ37 BRSO finite cell line human CVCL_UZ37 CL:0000010 Derived from sampling site: Axilla; skin Cell type=Myoepithelial cell.. Male Senescence: Senesces at 45-60 PDL (PubMed=10341211) 21165279 CVCL_UZ38 DOLA finite cell line human CVCL_UZ38 CL:0000010 Derived from sampling site: Axilla; skin Cell type=Myoepithelial cell.. Male Senescence: Senesces at 45-60 PDL (PubMed=10341211) 21165280 CVCL_3501 CMH1a cancer cell line house mouse CVCL_3501 CL:0000010 Transfected with: UniProtKB; P03139; Hepatitis B virus genotype D subtype adw HBsAg Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female Characteristics: Produces HBsAg under the control of a metallothionei promoter Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8399 21165281 CVCL_2T01 GM04139 finite cell line human CVCL_2T01 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;13)(2pter->2q31::13q32->13qter;13pter->13q32::2q31->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165282 CVCL_2T02 GM04240 finite cell line human CVCL_2T02 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;6)(4pter->4q25::6p25->6pter;6qter->6p25::4q25->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165283 CVCL_3502 Jurkat D1.1 cancer cell line human CVCL_3502 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10915 21165284 CVCL_3500 CL-S1 spontaneously immortalized cell line house mouse CVCL_3500 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Doubling time: ~24 hours (PubMed=232056) 21165285 CVCL_2T00 GM04088 finite cell line human CVCL_2T00 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;4)(1pter->1q32::4p16->4pter;4qter->4p16::1q32->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165286 CVCL_3505 E.G7-OVA cancer cell line house mouse CVCL_3505 CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21165287 CVCL_2T05 GM04500 finite cell line human CVCL_2T05 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(1;3)(1qter->1p36::3q13.3->3qter;3pter->3q13.3::1p36->1pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165288 CVCL_3506 EHS cancer cell line house mouse CVCL_3506 CL:0000010 Breed/subspecies: ST/Eh. Discontinued: ATCC; CRL-2108; true 21165289 CVCL_2T06 GM04628 finite cell line human CVCL_2T06 CL:0000010 Population: Caucasian; Swiss; Karyotypic information: 46,X,t(X;22)(q12;p11) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21165290 CVCL_3503 D1B cancer cell line house mouse CVCL_3503 CL:0000010 Breed/subspecies: DBA/2. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165291 CVCL_2T03 GM04403 finite cell line human CVCL_2T03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(11;22)(11pter->11q23::22q11->22qter;22pter->22q11::11q23->11qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165292 CVCL_3504 D2N cancer cell line house mouse CVCL_3504 CL:0000010 Breed/subspecies: DBA/2. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165293 CVCL_2T04 GM04410 finite cell line human CVCL_2T04 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(2;14)(2qter->2p23::14q32->14qter;14pter->14q32::2p23->2pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165294 CVCL_3509 ES-2 cancer cell line human CVCL_3509 HLA typing: A*03:01,68:02; B*14:02,41:01; C*07:01,08:02; DRB1*01:02,13:07 (PubMed=25960936); HLA typing: A*03:01,68:02; B*14:02,41:01; C*07:01,08:04; DQA1*04:01,04:01; DRB1*01:02,13:05' (PubMed=26589293); Genome ancestry: African=2.57%; Native American=0%; East Asian, North=3.68%; East Asian, South=0.75%; South Asian=7.03%; European, North=27.14%; European, South=58.83% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22705003; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Lys295_Met296insTer (c.886delA) (p.Met296Terfs); ClinVar=VCV000143979; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (PubMed=20204287; PubMed=24023729; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Secretome proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female Doubling time: 31.11 hours (GrayJW panel); 24 hours (ATCC=CRL-1978); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel Problematic cell line: Probably misclassified It is dubious that this cell line originates from an African American 47 year old patient diagnosed with an ovarian clear cell adenocarcinoma. Immunohistochemical and qPCR analysis as well as its mutational profile support an ovarian serous adenocarcinoma origin (PubMed=25049276; DOI=10.26502/ogr072). Furthermore its genome ancestry clearly shows a Caucasian/European decent (PubMed=30894373) which is confirmed by mtDNA haplotyping (DOI=10.26502/ogr072). 21165295 CVCL_2T09 GM04921 finite cell line human CVCL_2T09 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;8)(4qter->4p15::8p22->8pter;8qter->8p22::4p15->4pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165296 CVCL_3507 EOMA cancer cell line house mouse CVCL_3507 CL:0000010 Derived from sampling site: Blood vessel Cell type=Endothelial cell.; Breed/subspecies: 129. Discontinued: JCRB; NIHS0318; true Unspecified 21165297 CVCL_2T07 GM04862 finite cell line human CVCL_2T07 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(7;21)(7pter->7q36::21q21->21qter;21pter->21q21::7q36->7qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165298 CVCL_3508 EOMA-GFP cancer cell line house mouse CVCL_3508 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Blood vessel Cell type=Endothelial cell.; Breed/subspecies: 129. Unspecified 21165299 CVCL_2T08 GM04890 finite cell line human CVCL_2T08 CL:0000010 Population: Caucasian; Karyotypic information: 45,XX,dic(13;14)(13qter->13p11::14p11->14qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165300 CVCL_DH09 OCI-E1p cancer cell line human CVCL_DH09 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (PubMed=26080861) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165301 CVCL_DH03 OCI-C2p cancer cell line human CVCL_DH03 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Unspecified (PubMed=26080861) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165302 CVCL_DH04 OCI-C3x cancer cell line human CVCL_DH04 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165303 CVCL_DH01 FCI-P2p cancer cell line human CVCL_DH01 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=26080861) Derived from sampling site: Fallopian tube. Omics: Transcriptome analysis by microarray Female 21165304 CVCL_DH02 OCI-C1p cancer cell line human CVCL_DH02 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro539Arg (c.1616C>G); ClinVar=VCV000376243; Zygosity=Unspecified (PubMed=26080861); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Leu (c.1637A>T); ClinVar=VCV000375899; Zygosity=Unspecified (PubMed=26080861) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165305 CVCL_DH07 OCI-CSp cancer cell line human CVCL_DH07 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21165306 CVCL_DH08 OCI-D1p cancer cell line human CVCL_DH08 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165307 CVCL_DH05 OCI-C4p cancer cell line human CVCL_DH05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=26080861) Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21165308 CVCL_DH06 OCI-C5x cancer cell line human CVCL_DH06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21165309 CVCL_DH00 FCI-P1p cancer cell line human CVCL_DH00 CL:0000010 Derived from sampling site: Fallopian tube. Omics: Transcriptome analysis by microarray Female 21165310 CVCL_DH14 OCI-P1a cancer cell line human CVCL_DH14 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165311 CVCL_DH15 OCI-P2a cancer cell line human CVCL_DH15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Gly (c.799C>G); Zygosity=Unspecified (PubMed=26080861) Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165312 CVCL_DH12 OCI-EP1p cancer cell line human CVCL_DH12 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165313 CVCL_DH13 OCI-M1p cancer cell line human CVCL_DH13 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165314 CVCL_DH18 OCI-P5x cancer cell line human CVCL_DH18 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236Asn (c.706T>A); ClinVar=VCV000376694; Zygosity=Unspecified (PubMed=26080861; DepMap) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21165315 CVCL_DH19 OCI-P6p cancer cell line human CVCL_DH19 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21165316 CVCL_DH16 OCI-P3a cancer cell line human CVCL_DH16 CL:0000010 Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21165317 CVCL_DH17 OCI-P4p cancer cell line human CVCL_DH17 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165318 CVCL_DH10 OCI-E2p cancer cell line human CVCL_DH10 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21165319 CVCL_DH11 OCI-E3x cancer cell line human CVCL_DH11 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165320 CVCL_2T96 GM10960 transformed cell line human CVCL_2T96 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(1;11)(1pter->1q31.2::11q25->11qter;11pter->11q25::1q31.2->1qter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165321 CVCL_3596 Sal Mat finite cell line human CVCL_3596 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165322 CVCL_2T97 GM10961 finite cell line human CVCL_2T97 CL:0000010 Population: Southeast Asian; Cambodian; Derived from sampling site: Cell type=Fibroblast. Male 21165323 CVCL_3597 Sar Nis finite cell line human CVCL_3597 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165324 CVCL_2T94 GM10947 finite cell line human CVCL_2T94 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165325 CVCL_3594 Rn6T cancer cell line Norway rat CVCL_3594 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032) Discontinued: ATCC; CRL-6601; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165326 CVCL_2T95 GM10958 transformed cell line human CVCL_2T95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165327 CVCL_3595 SaI cancer cell line house mouse CVCL_3595 CL:0000010 Transformant: Dibenz[a,h]anthracene (DBA)(ChEBI; CHEBI:35299). 21165328 CVCL_2T98 GM10962 finite cell line human CVCL_2T98 CL:0000010 Population: African American; Karyotypic information: 46,XX,t(5;12)(5pter->5q33::12q24.3->12qter;12pter->12q24.3::5q33->5qter) (Coriell); Derived from sampling site: Amniotic fluid. Female 21165329 CVCL_3598 Sarcoma 180 cancer cell line house mouse CVCL_3598 CL:0000010 Breed/subspecies: Swiss Webster (CFW). Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165330 CVCL_2T99 GM10964 finite cell line human CVCL_2T99 CL:0000010 Derived from sampling site: Uterus; myometrium. Omics: CNV analysis Female 21165331 CVCL_3599 SCaBER cancer cell line human CVCL_3599 Genome ancestry: African=86.54%; Native American=1.69%; East Asian, North=2.11%; East Asian, South=0%; South Asian=0%; European, North=6%; European, South=3.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680; PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Homozygous (PubMed=9850064; Cosmic-CLP; DepMap) Population: African American; Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (Sanger) Part of: BLA-40 bladder carcinoma cell line panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: UBC-40 urothelial bladder cancer cell line index 21165332 CVCL_2T81 GM10329 finite cell line human CVCL_2T81 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165333 CVCL_3581 RG2 cancer cell line Norway rat CVCL_3581 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; cerebellum; Breed/subspecies: Fischer 344. Unspecified 21165334 CVCL_2T82 GM10374 finite cell line human CVCL_2T82 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165335 CVCL_3582 RIIIMT cancer cell line house mouse CVCL_3582 CL:0000010 Breed/subspecies: RIII. Discontinued: ATCC; CRL-6449; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165336 CVCL_2T80 GM10313 transformed cell line human CVCL_2T80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165337 CVCL_3580 RF-1 cancer cell line human CVCL_3580 CL:0000010 Discontinued: ATCC; CRL-1864; true. Male Problematic cell line: Misclassified From a B-cell lymphoma and not from a gastric cancer (PubMed=12226758). 21165338 CVCL_2T74 GM10177 finite cell line human CVCL_2T74 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;7)(Xpter->Xq28::7p11->7pter;7qter->7p11::Xq28->Xqter) (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165339 CVCL_3574 Ra Lot finite cell line human CVCL_3574 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165340 CVCL_2T75 GM10204 transformed cell line human CVCL_2T75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165341 CVCL_3575 RAG cancer cell line house mouse CVCL_3575 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Kidney; Breed/subspecies: BALB/c. 21165342 CVCL_2T72 GM10118 finite cell line human CVCL_2T72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21165343 CVCL_3572 R-3327-G cancer cell line Norway rat CVCL_3572 CL:0000010 Breed/subspecies: Copenhagen. Discontinued: ATCC; JHU-3; true Male 21165344 CVCL_2T73 GM10175 transformed cell line human CVCL_2T73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165345 CVCL_3573 Ra Bot finite cell line human CVCL_3573 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165346 CVCL_2T78 GM10276 transformed cell line human CVCL_2T78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165347 CVCL_3578 RAW 8.1 cancer cell line house mouse CVCL_3578 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165348 CVCL_2T79 GM10308 transformed cell line human CVCL_2T79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165349 CVCL_3579 RBA cancer cell line Norway rat CVCL_3579 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21165350 CVCL_2T76 GM10206 transformed cell line human CVCL_2T76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165351 CVCL_3576 RAW 309 Cr.1 cancer cell line house mouse CVCL_3576 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165352 CVCL_2T77 GM10239 transformed cell line human CVCL_2T77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165353 CVCL_3577 RAW 309F.1.1 cancer cell line house mouse CVCL_3577 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165354 CVCL_2T92 GM10806 finite cell line human CVCL_2T92 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(3)(3qter->3p26::2q36->2qter)mat (Coriell); Derived from sampling site: Fetal thymus Cell type=Fibroblast.. Female 21165355 CVCL_3592 Rn3T cancer cell line Norway rat CVCL_3592 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032) Discontinued: ATCC; CRL-6511; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165356 CVCL_2T93 GM10935 transformed cell line human CVCL_2T93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165357 CVCL_3593 Rn4T cancer cell line Norway rat CVCL_3593 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032) Discontinued: ATCC; CRL-6512; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165358 CVCL_2T90 GM10717 transformed cell line human CVCL_2T90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165359 CVCL_3590 Rn1T cancer cell line Norway rat CVCL_3590 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21165360 CVCL_2T91 GM10804 finite cell line human CVCL_2T91 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(3)(3qter->3p26::2q36->2qter)mat (Coriell); Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Female 21165361 CVCL_3591 Rn2T cancer cell line Norway rat CVCL_3591 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21165362 CVCL_2T85 GM10404 transformed cell line human CVCL_2T85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165363 CVCL_3585 Ro Bon finite cell line human CVCL_3585 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165364 CVCL_2T86 GM10607 transformed cell line human CVCL_2T86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165365 CVCL_3586 Ro Dow finite cell line human CVCL_3586 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165366 CVCL_2T83 GM10386 transformed cell line human CVCL_2T83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165367 CVCL_3583 RIN-14B cancer cell line Norway rat CVCL_3583 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Delta cell.; Breed/subspecies: NEDH. Male Characteristics: Produces somatostatin and aromatic-L-amino-acid decarboxylase (DDC) Secretes insulin but at lower level than the parent cell line (PubMed=6141566; PubMed=6295859). 21165368 CVCL_2T84 GM10393 transformed cell line human CVCL_2T84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165369 CVCL_3584 RIN-m cancer cell line Norway rat CVCL_3584 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Established from the transplantable insulinoma RIN; Characteristics: Secretes insulin and somatostatin (PubMed=6106192; PubMed=6141566) 21165370 CVCL_2T89 GM10716 transformed cell line human CVCL_2T89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165371 CVCL_3589 RR1022 cancer cell line Norway rat CVCL_3589 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Breed/subspecies: Amsterdam. 21165372 CVCL_2T87 GM10613 finite cell line human CVCL_2T87 CL:0000010 Karyotypic information: 46,XX,t(20;21)(20pter->20q11.2::21p11.2->21pter;21qter->21p11.2::20q11.2->20qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165373 CVCL_3587 Ro Shi finite cell line human CVCL_3587 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165374 CVCL_2T88 GM10635 finite cell line human CVCL_2T88 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(15;19)(15pter->15q13::19q13.3->19qter;19pter->19q13.3::15q13->15qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165375 CVCL_3588 Ro Vid finite cell line human CVCL_3588 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165376 CVCL_MA07 BayGenomics ES cell line CSH811 embryonic stem cell house mouse CVCL_MA07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354721; Slc25a13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165377 CVCL_MA08 BayGenomics ES cell line CSH812 embryonic stem cell house mouse CVCL_MA08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107628; Prdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165378 CVCL_MA05 BayGenomics ES cell line CSH808 embryonic stem cell house mouse CVCL_MA05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780541; Lncenc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165379 CVCL_MA06 BayGenomics ES cell line CSH809 embryonic stem cell house mouse CVCL_MA06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165380 CVCL_MA03 BayGenomics ES cell line CSH801 embryonic stem cell house mouse CVCL_MA03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165381 CVCL_MA04 BayGenomics ES cell line CSH802 embryonic stem cell house mouse CVCL_MA04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448541; Caprin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165382 CVCL_DG70 C135 cancer cell line human CVCL_DG70 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21165383 CVCL_MA01 BayGenomics ES cell line CSH790 embryonic stem cell house mouse CVCL_MA01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165384 CVCL_MA02 BayGenomics ES cell line CSH800 embryonic stem cell house mouse CVCL_MA02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914513; Zswim6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165385 CVCL_MA00 BayGenomics ES cell line CSH784 embryonic stem cell house mouse CVCL_MA00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135637; Park7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165386 CVCL_DG68 G174 cancer cell line human CVCL_DG68 CL:0000010 Male Group: Cancer stem cell line. 21165387 CVCL_DG69 G179 cancer cell line human CVCL_DG69 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Male Group: Cancer stem cell line 21165388 CVCL_DG62 GBM6 cancer cell line human CVCL_DG62 CL:0000010 Group: Cancer stem cell line. 21165389 CVCL_DG63 GBM7 cancer cell line human CVCL_DG63 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Male Group: Cancer stem cell line 21165390 CVCL_DG60 GBM4 cancer cell line human CVCL_DG60 CL:0000010 Group: Cancer stem cell line. 21165391 CVCL_DG61 GBM5 cancer cell line human CVCL_DG61 CL:0000010 Group: Cancer stem cell line. 21165392 CVCL_DG66 G166 cancer cell line human CVCL_DG66 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Female Group: Cancer stem cell line 21165393 CVCL_DG67 GliNS2 cancer cell line human CVCL_DG67 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Male Group: Cancer stem cell line 21165394 CVCL_DG64 G144 cancer cell line human CVCL_DG64 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Male Group: Cancer stem cell line 21165395 CVCL_DG65 G144ED cancer cell line human CVCL_DG65 CL:0000010 Male Group: Cancer stem cell line. 21165396 CVCL_MA18 BayGenomics ES cell line CSH857 embryonic stem cell house mouse CVCL_MA18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165397 CVCL_MA19 BayGenomics ES cell line CSH858 embryonic stem cell house mouse CVCL_MA19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165398 CVCL_MA16 BayGenomics ES cell line CSH840 embryonic stem cell house mouse CVCL_MA16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109382; Noct Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165399 CVCL_MA17 BayGenomics ES cell line CSH856 embryonic stem cell house mouse CVCL_MA17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137218; Mrpl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165400 CVCL_MA14 BayGenomics ES cell line CSH838 embryonic stem cell house mouse CVCL_MA14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921261; Slc25a27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165401 CVCL_DG80 SN12C-PM6-2 cancer cell line human CVCL_DG80 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Homozygous (from parent cell line) Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Male 21165402 CVCL_MA15 BayGenomics ES cell line CSH839 embryonic stem cell house mouse CVCL_MA15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165403 CVCL_DG81 ML38 transformed cell line human CVCL_DG81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21165404 CVCL_MA12 BayGenomics ES cell line CSH833 embryonic stem cell house mouse CVCL_MA12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165405 CVCL_MA13 BayGenomics ES cell line CSH834 embryonic stem cell house mouse CVCL_MA13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165406 CVCL_MA10 BayGenomics ES cell line CSH818 embryonic stem cell house mouse CVCL_MA10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914878; Anp32b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165407 CVCL_MA11 BayGenomics ES cell line CSH827 embryonic stem cell house mouse CVCL_MA11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102890; Ccng1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165408 CVCL_DG79 OVCAR-7 cancer cell line human CVCL_DG79 CL:0000010 Female 21165409 CVCL_DG73 NA-NR15 cancer cell line human CVCL_DG73 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male Virology: In vitro infected with EBV isolate Akata 21165410 CVCL_DG74 WM122 cancer cell line human CVCL_DG74 CL:0000010 Part of: Wistar Institute melanoma cell line collection 21165411 CVCL_DG71 NA-NP15 cancer cell line human CVCL_DG71 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male Virology: In vitro infected with EBV isolate Akata 21165412 CVCL_DG72 NA-NR1 cancer cell line human CVCL_DG72 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male Virology: In vitro infected with EBV isolate Akata 21165413 CVCL_DG77 OP-1 cancer cell line human CVCL_DG77 CL:0000010 Male 21165414 CVCL_DG78 UPN251 cancer cell line human CVCL_DG78 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Female Doubling time: 24.29 hours (GrayJW panel) Part of: MD Anderson Cell Lines Project 21165415 CVCL_MA09 BayGenomics ES cell line CSH813 embryonic stem cell house mouse CVCL_MA09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924767; Zfyve26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165416 CVCL_DG75 WM3004 cancer cell line human CVCL_DG75 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21165417 CVCL_DG76 WM3077 cancer cell line human CVCL_DG76 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21165418 CVCL_DG48 UACC-1118 cancer cell line human CVCL_DG48 CL:0000010 21165419 CVCL_DG49 STA-NB-10/dmin cancer cell line human CVCL_DG49 CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Male 21165420 CVCL_DG46 CHSE-EC spontaneously immortalized cell line CVCL_DG46 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (nuclear version; nCas9n) Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Fish cell line 21165421 CVCL_DG47 NKI-4 cancer cell line human CVCL_DG47 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=9354451). 21165422 CVCL_DG40 UACC-2837 cancer cell line human CVCL_DG40 CL:0000010 21165423 CVCL_DG41 UACC-558 cancer cell line human CVCL_DG41 CL:0000010 21165424 CVCL_DG44 ChaGo-C-5 cancer cell line human CVCL_DG44 CL:0000010 Derived from metastatic site: Hypodermis. Male 21165425 CVCL_DG45 CHSE-E spontaneously immortalized cell line CVCL_DG45 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Fish cell line 21165426 CVCL_DG42 TY-1 cancer cell line human CVCL_DG42 CL:0000010 Population: Japanese; Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pericardial effusion. Omics: Array-based CGH Male 21165427 CVCL_DG43 ChaGo cancer cell line human CVCL_DG43 CL:0000010 Derived from metastatic site: Hypodermis. Male Doubling time: 24-48 hours (PubMed=4708151) 21165428 CVCL_DG59 GBM3 cancer cell line human CVCL_DG59 CL:0000010 Group: Cancer stem cell line. 21165429 CVCL_DG57 GBM1 cancer cell line human CVCL_DG57 CL:0000010 Group: Cancer stem cell line. 21165430 CVCL_DG58 GBM2 cancer cell line human CVCL_DG58 CL:0000010 Omics: Array-based CGH; Omics: DNA methylation analysis. Male Group: Cancer stem cell line 21165431 CVCL_DG51 Mel1617 cancer cell line human CVCL_DG51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=21156289); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289) Omics: Array-based CGH. Male Part of: Wistar Institute melanoma cell line collection 21165432 CVCL_DG52 Mel1617-BR cancer cell line human CVCL_DG52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289). Selected for resistance to: ChEBI; CHEBI:131882; SB-590885 Male 21165433 CVCL_DG50 STA-NB-10/hsr cancer cell line human CVCL_DG50 CL:0000010 Omics: Array-based CGH; Omics: SNP array analysis. Male 21165434 CVCL_DG55 CHO-MOG spontaneously immortalized cell line CVCL_DG55 CL:0000010 Transfected with: HGNC; 7197; MOG Derived from sampling site: Ovary. Female 21165435 CVCL_DG56 HPCT-1E3 hybrid cell line Norway rat CVCL_DG56 CL:0000010 21165436 CVCL_DG53 Mel1617-MR cancer cell line human CVCL_DG53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist Omics: Array-based CGH. Male 21165437 CVCL_DG54 451Lu-MR cancer cell line human CVCL_DG54 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; Derived from metastatic site: Lymph node. Male 21165438 CVCL_DG26 HCC827/WR cancer cell line human CVCL_DG26 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from sampling site: Lung. Female 21165439 CVCL_DG27 PC-9/GR/WR cancer cell line human CVCL_DG27 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165440 CVCL_DG24 VACO 531 cancer cell line human CVCL_DG24 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=27004849). Male Microsatellite instability: Stable (MSS) (PubMed=27004849) 21165441 CVCL_DG25 H1975/WR cancer cell line human CVCL_DG25 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:61400; WZ4002 Female 21165442 CVCL_DG28 PC-9/ER/WR cancer cell line human CVCL_DG28 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165443 CVCL_DG29 PC-9/WR cancer cell line human CVCL_DG29 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165444 CVCL_DG22 SMMU-1 cancer cell line human CVCL_DG22 CL:0000010 Derived from sampling site: Skin. 21165445 CVCL_DG23 SMMU-2 cancer cell line human CVCL_DG23 CL:0000010 Derived from metastatic site: Lymph node. 21165446 CVCL_DG20 hFOB/ER9 conditionally immortalized cell line human CVCL_DG20 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal bone; limb Cell type=Osteoblast.. Female 21165447 CVCL_DG21 MDA231-LM2-4142 cancer cell line human CVCL_DG21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Established from MDA231-TGL cell line after 3 passage in nude mice Group: Triple negative breast cancer (TNBC) cell line 21165448 CVCL_DG37 D35 cancer cell line human CVCL_DG37 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21165449 CVCL_DG38 MM604 cancer cell line human CVCL_DG38 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165450 CVCL_DG35 LK0412 cancer cell line human CVCL_DG35 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=18452551) Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by microarray Female 21165451 CVCL_DG36 MEL1 cancer cell line human CVCL_DG36 CL:0000010 21165452 CVCL_DG39 UACC-1308 cancer cell line human CVCL_DG39 CL:0000010 21165453 CVCL_DG30 PC-9/WZR09 cancer cell line human CVCL_DG30 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165454 CVCL_DG33 PC-9/WZR12 cancer cell line human CVCL_DG33 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165455 CVCL_DG34 SVpgC2a transformed cell line human CVCL_DG34 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Female 21165456 CVCL_DG31 PC-9/WZR10 cancer cell line human CVCL_DG31 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165457 CVCL_DG32 PC-9/WZR11 cancer cell line human CVCL_DG32 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Selected for resistance to: ChEBI; CHEBI:61400; WZ4002; Derived from metastatic site: Lymph node. Male 21165458 CVCL_DG04 Res196 cancer cell line human CVCL_DG04 CL:0000010 Derived from sampling site: Brain. Male 21165459 CVCL_DG05 Res199 cancer cell line human CVCL_DG05 CL:0000010 Derived from sampling site: Brain. Female 21165460 CVCL_DG02 Rh18c cancer cell line human CVCL_DG02 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line). Female 21165461 CVCL_DG03 Res186 cancer cell line human CVCL_DG03 CL:0000010 Derived from sampling site: Brain. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46 hours (PubMed=19365568) 21165462 CVCL_DG08 Res254 cancer cell line human CVCL_DG08 CL:0000010 Derived from sampling site: Brain. Male 21165463 CVCL_DG09 Res256 cancer cell line human CVCL_DG09 CL:0000010 Derived from sampling site: Brain. Male 21165464 CVCL_DG06 Res251 cancer cell line human CVCL_DG06 CL:0000010 Derived from sampling site: Brain. Male 21165465 CVCL_DG07 Res253 cancer cell line human CVCL_DG07 CL:0000010 Derived from sampling site: Brain. Male 21165466 CVCL_DG00 MDS3-2 iPSC induced pluripotent stem cell human CVCL_DG00 CL:0000010 Derived from sampling site: Fetal diaphragm; skeletal muscle Cell type=Fibroblast.. Male 21165467 CVCL_DG01 LIM2045 cancer cell line human CVCL_DG01 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia. CL:0000010 21165468 CVCL_DG15 UW479 cancer cell line human CVCL_DG15 CL:0000010 Derived from sampling site: Brain. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 28 hours (PubMed=19365568) 21165469 CVCL_DG16 D-431 cancer cell line human CVCL_DG16 CL:0000010 Unspecified 21165470 CVCL_DG13 UW467 cancer cell line human CVCL_DG13 CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 21165471 CVCL_DG14 UW473 cancer cell line human CVCL_DG14 CL:0000010 Derived from sampling site: Brain. Male Doubling time: 25 +- 0.7 hours (PubMed=31346954) 21165472 CVCL_DG19 W-98 cancer cell line human CVCL_DG19 CL:0000010 Unspecified 21165473 CVCL_DG17 F-502 cancer cell line human CVCL_DG17 CL:0000010 Unspecified 21165474 CVCL_DG18 S-496 cancer cell line human CVCL_DG18 CL:0000010 Unspecified 21165475 CVCL_DG11 Res280 cancer cell line human CVCL_DG11 CL:0000010 Derived from sampling site: Brain. Female 21165476 CVCL_DG12 Res286 cancer cell line human CVCL_DG12 CL:0000010 Derived from sampling site: Brain. Omics: Transcriptome analysis by RNAseq Male 21165477 CVCL_DG10 Res259 cancer cell line human CVCL_DG10 CL:0000010 Derived from sampling site: Brain. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 24 hours (PubMed=19365568) 21165478 CVCL_UZ20 FMA cancer cell line house mouse CVCL_UZ20 CL:0000010 Breed/subspecies: LAF1. 21165479 CVCL_UZ21 NCC-dCS1-C1 cancer cell line human CVCL_UZ21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=30737713); Sequence variation: Gene deletion; HGNC; 2348; CREBBP; Zygosity=Homozygous (PubMed=30737713) Population: Japanese; Derived from sampling site: Bone; rib. Omics: Deep proteome analysis; Omics: SNP array analysis Female Doubling time: 29 hours (PubMed=30737713) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21165480 CVCL_MA89 BayGenomics ES cell line CSI072 embryonic stem cell house mouse CVCL_MA89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165481 CVCL_MA87 BayGenomics ES cell line CSI070 embryonic stem cell house mouse CVCL_MA87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165482 CVCL_UZ24 hTERT-BIEC telomerase immortalized cell line CVCL_UZ24 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Intestine; epithelium; Breed/subspecies: Holstein. Male Doubling time: 13.33 hours (PubMed=30600465) 21165483 CVCL_MA88 BayGenomics ES cell line CSI071 embryonic stem cell house mouse CVCL_MA88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165484 CVCL_UZ25 SV40-BIEC transformed cell line CVCL_UZ25 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Intestine; epithelium; Breed/subspecies: Holstein. Male Doubling time: 14.26 hours (PubMed=30600465) 21165485 CVCL_MA85 BayGenomics ES cell line CSI067 embryonic stem cell house mouse CVCL_MA85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165486 CVCL_UZ22 BIEC-c4 finite cell line CVCL_UZ22 CL:0000010 Derived from sampling site: Small intestine; ileum Cell type=Epithelial cell.; Breed/subspecies: Holstein. Male Doubling time: 14.16 hours (PubMed=30600465) 21165487 CVCL_MA86 BayGenomics ES cell line CSI069 embryonic stem cell house mouse CVCL_MA86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921285; Nol9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165488 CVCL_UZ23 HPV-BIEC transformed cell line CVCL_UZ23 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Intestine; epithelium; Breed/subspecies: Holstein. Male Doubling time: 13.26 hours (PubMed=30600465) 21165489 CVCL_MA83 BayGenomics ES cell line CSI064 embryonic stem cell house mouse CVCL_MA83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103185; Uimc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165490 CVCL_UZ28 HCLE telomerase immortalized cell line human CVCL_UZ28 CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Eye; cornea; limbus Cell type=Keratinocyte.. Male 21165491 CVCL_MA84 BayGenomics ES cell line CSI066 embryonic stem cell house mouse CVCL_MA84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165492 CVCL_UZ29 CJ4.1A transformed cell line Norway rat CVCL_UZ29 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; conjunctival epithelium Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 22 +- 7 hours (PubMed=17123516) 21165493 CVCL_MA81 BayGenomics ES cell line CSI062 embryonic stem cell house mouse CVCL_MA81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165494 CVCL_UZ26 HuCL-22 finite cell line human CVCL_UZ26 CL:0000010 Derived from sampling site: Eye; cornea; limbus Cell type=Keratinocyte.. Male Senescence: Senesces at 24 PDL (PubMed=12077343) 21165495 CVCL_MA82 BayGenomics ES cell line CSI063 embryonic stem cell house mouse CVCL_MA82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165496 CVCL_UZ27 ConjEp-1 finite cell line human CVCL_UZ27 CL:0000010 Derived from sampling site: Eye; conjunctival epithelium Cell type=Keratinocyte.. Male Senescence: Senesces at 18 PDL (PubMed=12077343) 21165497 CVCL_MA80 BayGenomics ES cell line CSI061 embryonic stem cell house mouse CVCL_MA80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681840; Rsl24d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165498 CVCL_UZ10 RLN-38 spontaneously immortalized cell line Norway rat CVCL_UZ10 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21165499 CVCL_UZ13 anti-Y 29/55 hybridoma house mouse CVCL_UZ13 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human malignant B-lymphocytes from patients with chronic lymphocytic leukemia. 21165500 CVCL_MA98 BayGenomics ES cell line CSI090 embryonic stem cell house mouse CVCL_MA98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351477; Cars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165501 CVCL_MA99 BayGenomics ES cell line CSI091 embryonic stem cell house mouse CVCL_MA99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165502 CVCL_UZ14 P21PZ telomerase immortalized cell line human CVCL_UZ14 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: SNP array analysis. Male 21165503 CVCL_MA96 BayGenomics ES cell line CSI087 embryonic stem cell house mouse CVCL_MA96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165504 CVCL_UZ11 RLN-39 spontaneously immortalized cell line Norway rat CVCL_UZ11 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21165505 CVCL_MA97 BayGenomics ES cell line CSI089 embryonic stem cell house mouse CVCL_MA97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165506 CVCL_UZ12 P3-Ag8-gamma1- cancer cell line house mouse CVCL_UZ12 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21165507 CVCL_MA94 BayGenomics ES cell line CSI079 embryonic stem cell house mouse CVCL_MA94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2658986; Wasf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165508 CVCL_UZ17 P21TZ 40 Gy (clone-a) telomerase immortalized cell line human CVCL_UZ17 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Gamma radiation(NCIt; C44386) Omics: SNP array analysis. Male Characteristics: The parent cell line was irradiated with 40 Gy 21165509 CVCL_MA95 BayGenomics ES cell line CSI080 embryonic stem cell house mouse CVCL_MA95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920454; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165510 CVCL_UZ18 CT/BCIRL-SfMG-0617-KZ spontaneously immortalized cell line CVCL_UZ18 CL:0000010 Derived from sampling site: Midgut. Unspecified Doubling time: 50.4 hours (PubMed=31792802) Group: Insect cell line 21165511 CVCL_MA92 BayGenomics ES cell line CSI076 embryonic stem cell house mouse CVCL_MA92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104517; Xrcc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165512 CVCL_UZ15 P21PZ (clone-a) telomerase immortalized cell line human CVCL_UZ15 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male 21165513 CVCL_MA93 BayGenomics ES cell line CSI077 embryonic stem cell house mouse CVCL_MA93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165514 CVCL_UZ16 P21TZ telomerase immortalized cell line human CVCL_UZ16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Omics: SNP array analysis. Male 21165515 CVCL_MA90 BayGenomics ES cell line CSI074 embryonic stem cell house mouse CVCL_MA90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859026; Cnot4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165516 CVCL_MA91 BayGenomics ES cell line CSI075 embryonic stem cell house mouse CVCL_MA91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915268; Cert1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165517 CVCL_UZ19 CT/BCIRL-SfMG1-0611-KZ spontaneously immortalized cell line CVCL_UZ19 CL:0000010 Derived from sampling site: Midgut. Unspecified Doubling time: 73.9 hours (PubMed=31792802) Group: Insect cell line 21165518 CVCL_MA69 BayGenomics ES cell line CSI040 embryonic stem cell house mouse CVCL_MA69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165519 CVCL_MA67 BayGenomics ES cell line CSI034 embryonic stem cell house mouse CVCL_MA67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914120; Serbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165520 CVCL_MA68 BayGenomics ES cell line CSI039 embryonic stem cell house mouse CVCL_MA68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109318; Myl6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165521 CVCL_MA65 BayGenomics ES cell line CSI028 embryonic stem cell house mouse CVCL_MA65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338056; Klf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165522 CVCL_UZ02 BsB13 cancer cell line house mouse CVCL_UZ02 CL:0000010 Transformant: JC polyomavirus (JCPyV)(NCBI-Taxonomy; 10632); Breed/subspecies: JCV T-Ag transgenic. 21165523 CVCL_MA66 BayGenomics ES cell line CSI032 embryonic stem cell house mouse CVCL_MA66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165524 CVCL_UZ03 BsB14 cancer cell line house mouse CVCL_UZ03 CL:0000010 Transformant: JC polyomavirus (JCPyV)(NCBI-Taxonomy; 10632); Breed/subspecies: JCV T-Ag transgenic. 21165525 CVCL_MA63 BayGenomics ES cell line CSI026 embryonic stem cell house mouse CVCL_MA63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165526 CVCL_UZ00 BsB7 cancer cell line house mouse CVCL_UZ00 CL:0000010 Transformant: JC polyomavirus (JCPyV)(NCBI-Taxonomy; 10632); Breed/subspecies: JCV T-Ag transgenic. 21165527 CVCL_MA64 BayGenomics ES cell line CSI027 embryonic stem cell house mouse CVCL_MA64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333754; Agfg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165528 CVCL_UZ01 BsB8 cancer cell line house mouse CVCL_UZ01 CL:0000010 Transformant: JC polyomavirus (JCPyV)(NCBI-Taxonomy; 10632); Breed/subspecies: JCV T-Ag transgenic. 21165529 CVCL_MA61 BayGenomics ES cell line CSI020 embryonic stem cell house mouse CVCL_MA61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165530 CVCL_UZ06 CHO SH-87 spontaneously immortalized cell line CVCL_UZ06 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Omics: Genome sequenced; Omics: Metabolome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfected with a tricistronic vector utilizing internal ribosome entry site (IRES) elements to express the light chain (LC), heavy chain (HC) and a neo selection marker from one transcript; Characteristics: Produces an anti-ERBB2 monoclonal antibody 21165531 CVCL_MA62 BayGenomics ES cell line CSI021 embryonic stem cell house mouse CVCL_MA62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926082; Cacul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165532 CVCL_UZ07 RLN-21 spontaneously immortalized cell line Norway rat CVCL_UZ07 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21165533 CVCL_UZ04 CHO Ade-PcG spontaneously immortalized cell line CVCL_UZ04 CL:0000010 Derived from sampling site: Ovary. Female 21165534 CVCL_MA60 BayGenomics ES cell line CSI018 embryonic stem cell house mouse CVCL_MA60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106913; Abi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165535 CVCL_UZ05 R21-1B hybrid cell line human CVCL_UZ05 CL:0000010 Group: Human/rodent somatic cell hybrid. 21165536 CVCL_UZ08 RLN-35 spontaneously immortalized cell line Norway rat CVCL_UZ08 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21165537 CVCL_UZ09 RLN-36 spontaneously immortalized cell line Norway rat CVCL_UZ09 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21165538 CVCL_MA78 BayGenomics ES cell line CSI056 embryonic stem cell house mouse CVCL_MA78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913875; Pnisr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165539 CVCL_MA79 BayGenomics ES cell line CSI057 embryonic stem cell house mouse CVCL_MA79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165540 CVCL_MA76 BayGenomics ES cell line CSI052 embryonic stem cell house mouse CVCL_MA76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343188; Ube2g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165541 CVCL_MA77 BayGenomics ES cell line CSI055 embryonic stem cell house mouse CVCL_MA77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141969; Efl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165542 CVCL_MA74 BayGenomics ES cell line CSI046 embryonic stem cell house mouse CVCL_MA74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165543 CVCL_MA75 BayGenomics ES cell line CSI049 embryonic stem cell house mouse CVCL_MA75 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm3811 (MGI:3781984) which is no longer considered a gene by MGI 21165544 CVCL_MA72 BayGenomics ES cell line CSI043 embryonic stem cell house mouse CVCL_MA72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914120; Serbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165545 CVCL_MA73 BayGenomics ES cell line CSI044 embryonic stem cell house mouse CVCL_MA73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165546 CVCL_MA70 BayGenomics ES cell line CSI041 embryonic stem cell house mouse CVCL_MA70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165547 CVCL_MA71 BayGenomics ES cell line CSI042 embryonic stem cell house mouse CVCL_MA71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165548 CVCL_MA49 BayGenomics ES cell line CSH960 embryonic stem cell house mouse CVCL_MA49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917476; Rbm3os Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165549 CVCL_MA47 BayGenomics ES cell line CSH949 embryonic stem cell house mouse CVCL_MA47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98230; Sar1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165550 CVCL_MA48 BayGenomics ES cell line CSH951 embryonic stem cell house mouse CVCL_MA48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165551 CVCL_MA45 BayGenomics ES cell line CSH947 embryonic stem cell house mouse CVCL_MA45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165552 CVCL_MA46 BayGenomics ES cell line CSH948 embryonic stem cell house mouse CVCL_MA46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670969; Nrde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165553 CVCL_MA43 BayGenomics ES cell line CSH945 embryonic stem cell house mouse CVCL_MA43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890651; Brwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165554 CVCL_MA44 BayGenomics ES cell line CSH946 embryonic stem cell house mouse CVCL_MA44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106582; Rfx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165555 CVCL_MA41 BayGenomics ES cell line CSH924 embryonic stem cell house mouse CVCL_MA41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923241; Slain2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165556 CVCL_MA42 BayGenomics ES cell line CSH934 embryonic stem cell house mouse CVCL_MA42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95917; H2-M5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165557 CVCL_MA40 BayGenomics ES cell line CSH914 embryonic stem cell house mouse CVCL_MA40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165558 CVCL_MA58 BayGenomics ES cell line CSI014 embryonic stem cell house mouse CVCL_MA58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351455; Rpl13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165559 CVCL_MA59 BayGenomics ES cell line CSI016 embryonic stem cell house mouse CVCL_MA59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914149; Fip1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165560 CVCL_MA56 BayGenomics ES cell line CSI008 embryonic stem cell house mouse CVCL_MA56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165561 CVCL_MA57 BayGenomics ES cell line CSI013 embryonic stem cell house mouse CVCL_MA57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353633; Fus Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165562 CVCL_MA54 BayGenomics ES cell line CSI004 embryonic stem cell house mouse CVCL_MA54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277166; Sp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165563 CVCL_MA55 BayGenomics ES cell line CSI005 embryonic stem cell house mouse CVCL_MA55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2678085; Sugp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165564 CVCL_MA52 BayGenomics ES cell line CSI001 embryonic stem cell house mouse CVCL_MA52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138893; Usp6nl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165565 CVCL_MA53 BayGenomics ES cell line CSI003 embryonic stem cell house mouse CVCL_MA53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914750; Ccar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165566 CVCL_MA50 BayGenomics ES cell line CSH961 embryonic stem cell house mouse CVCL_MA50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913339; Rmnd5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165567 CVCL_MA51 BayGenomics ES cell line CSH964 embryonic stem cell house mouse CVCL_MA51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354733; Dmrt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165568 CVCL_MA29 BayGenomics ES cell line CSH892 embryonic stem cell house mouse CVCL_MA29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921802; Nipal3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165569 CVCL_MA27 BayGenomics ES cell line CSH889 embryonic stem cell house mouse CVCL_MA27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924657; Rab35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165570 CVCL_MA28 BayGenomics ES cell line CSH891 embryonic stem cell house mouse CVCL_MA28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029586; Zfp870 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165571 CVCL_DG91 ACC-OV614 cancer cell line human CVCL_DG91 CL:0000010 Derived from metastatic site: Ascites. Female 21165572 CVCL_MA25 BayGenomics ES cell line CSH880 embryonic stem cell house mouse CVCL_MA25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165573 CVCL_DG92 ACC-OV616 cancer cell line human CVCL_DG92 CL:0000010 Derived from metastatic site: Ascites. Female 21165574 CVCL_MA26 BayGenomics ES cell line CSH881 embryonic stem cell house mouse CVCL_MA26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921802; Nipal3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165575 CVCL_MA23 BayGenomics ES cell line CSH873 embryonic stem cell house mouse CVCL_MA23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894316; Mknk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165576 CVCL_DG90 ACC-OV60 cancer cell line human CVCL_DG90 CL:0000010 Derived from metastatic site: Ascites. Female 21165577 CVCL_MA24 BayGenomics ES cell line CSH874 embryonic stem cell house mouse CVCL_MA24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448541; Caprin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165578 CVCL_MA21 BayGenomics ES cell line CSH864 embryonic stem cell house mouse CVCL_MA21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137218; Mrpl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165579 CVCL_MA22 BayGenomics ES cell line CSH870 embryonic stem cell house mouse CVCL_MA22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165580 CVCL_MA20 BayGenomics ES cell line CSH860 embryonic stem cell house mouse CVCL_MA20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914504; Bmerb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165581 CVCL_DG84 PHMLEB transformed cell line human CVCL_DG84 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21165582 CVCL_DG85 PHMLER transformed cell line human CVCL_DG85 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 21165583 CVCL_DG82 ML46 transformed cell line human CVCL_DG82 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female 21165584 CVCL_DG83 HIO180 transformed cell line human CVCL_DG83 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21165585 CVCL_DG88 ACC-OV551 cancer cell line human CVCL_DG88 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 36.7 +- 0.2 hours (PubMed=16759149) 21165586 CVCL_DG89 ACC-OV552 cancer cell line human CVCL_DG89 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 78.5 +- 2.6 hours (PubMed=16759149) 21165587 CVCL_DG86 ACC-OV7 cancer cell line human CVCL_DG86 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 24.5 +- 4.9 hours (PubMed=16759149) 21165588 CVCL_DG87 ACC-OV43 cancer cell line human CVCL_DG87 CL:0000010 Derived from sampling site: Ovary. Female 21165589 CVCL_MA38 BayGenomics ES cell line CSH912 embryonic stem cell house mouse CVCL_MA38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165590 CVCL_MA39 BayGenomics ES cell line CSH913 embryonic stem cell house mouse CVCL_MA39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891706; Spen Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165591 CVCL_MA36 BayGenomics ES cell line CSH906 embryonic stem cell house mouse CVCL_MA36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165592 CVCL_MA37 BayGenomics ES cell line CSH909 embryonic stem cell house mouse CVCL_MA37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165593 CVCL_MA34 BayGenomics ES cell line CSH903 embryonic stem cell house mouse CVCL_MA34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165594 CVCL_MA35 BayGenomics ES cell line CSH904 embryonic stem cell house mouse CVCL_MA35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165595 CVCL_MA32 BayGenomics ES cell line CSH900 embryonic stem cell house mouse CVCL_MA32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165596 CVCL_MA33 BayGenomics ES cell line CSH902 embryonic stem cell house mouse CVCL_MA33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914404; Mtdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165597 CVCL_MA30 BayGenomics ES cell line CSH894 embryonic stem cell house mouse CVCL_MA30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101920; Ap2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165598 CVCL_MA31 BayGenomics ES cell line CSH897 embryonic stem cell house mouse CVCL_MA31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931415; Mynn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165599 CVCL_DG95 ACC-OV684 cancer cell line human CVCL_DG95 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 26.9 +- 2.7 hours (PubMed=16759149) 21165600 CVCL_DG96 ACC-OV68A cancer cell line human CVCL_DG96 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 44.7 +- 5.7 hours (PubMed=16759149) 21165601 CVCL_DG93 ACC-OV62 cancer cell line human CVCL_DG93 CL:0000010 Derived from metastatic site: Ascites. Female 21165602 CVCL_DG94 ACC-OV682 cancer cell line human CVCL_DG94 CL:0000010 Derived from sampling site: Ovary. Female 21165603 CVCL_DG99 ACC-OV84 cancer cell line human CVCL_DG99 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21165604 CVCL_DG97 ACC-OV77 cancer cell line human CVCL_DG97 CL:0000010 Derived from metastatic site: Ascites. Female 21165605 CVCL_DG98 ACC-OV79 cancer cell line human CVCL_DG98 CL:0000010 Derived from sampling site: Ovary. Female 21165606 CVCL_2U80 Cj39 embryonic stem cell CVCL_2U80 CL:0000010 Female Group: Non-human primate cell line. 21165607 CVCL_3680 EL 1 cancer cell line human CVCL_3680 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00524; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9854 Problematic cell line: Contaminated On the basis of the STR profile seems to be a U-937 derivative. 21165608 CVCL_2U81 Cj62 embryonic stem cell CVCL_2U81 CL:0000010 Female Group: Non-human primate cell line. 21165609 CVCL_3681 El Don finite cell line human CVCL_3681 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165610 CVCL_3673 Da Hol finite cell line human CVCL_3673 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165611 CVCL_2U73 R278.5 embryonic stem cell CVCL_2U73 CL:0000010 Male Group: Non-human primate cell line. 21165612 CVCL_2U74 Cj11.2 embryonic stem cell CVCL_2U74 CL:0000010 Female Group: Non-human primate cell line. 21165613 CVCL_3674 Da Mo finite cell line human CVCL_3674 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165614 CVCL_3671 Da Bon finite cell line human CVCL_3671 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165615 CVCL_2U71 HROGas16 cancer cell line human CVCL_2U71 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from sampling site: Stomach. Female 21165616 CVCL_3672 Da Cav finite cell line human CVCL_3672 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165617 CVCL_2U72 HROHep03 cancer cell line human CVCL_2U72 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Liver. Female 21165618 CVCL_2U77 Cj33 embryonic stem cell CVCL_2U77 CL:0000010 Female Group: Non-human primate cell line. 21165619 CVCL_3677 DRS [Rabbit] finite cell line CVCL_3677 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165620 CVCL_2U78 Cj35 embryonic stem cell CVCL_2U78 CL:0000010 Female Group: Non-human primate cell line. 21165621 CVCL_3678 Dubca transformed cell line CVCL_3678 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165622 CVCL_2U75 Cj25.1 embryonic stem cell CVCL_2U75 CL:0000010 Female Group: Non-human primate cell line. 21165623 CVCL_3675 Dakiki transformed cell line human CVCL_3675 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165624 CVCL_2U76 Cj28 embryonic stem cell CVCL_2U76 CL:0000010 Male Group: Non-human primate cell line. 21165625 CVCL_3676 DNI.Tr finite cell line CVCL_3676 CL:0000010 Derived from sampling site: Trachea. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165626 CVCL_2U79 Cj36 embryonic stem cell CVCL_2U79 CL:0000010 Female Group: Non-human primate cell line. 21165627 CVCL_3679 Ect1/E6E7 transformed cell line human CVCL_3679 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; ectocervical epithelium Cell type=Epithelial cell.. Female 21165628 CVCL_3691 GSML transformed cell line CVCL_3691 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21165629 CVCL_2U91 ORMES-6 embryonic stem cell CVCL_2U91 CL:0000010 Female Group: Non-human primate cell line. 21165630 CVCL_3692 HAAE-1 finite cell line human CVCL_3692 CL:0000010 Derived from sampling site: Abdomen; aorta Cell type=Aortic endothelial cell.. Discontinued: ATCC; CRL-2472; true Male Part of: Wistar Institute Special Collection vascular cell lines 21165631 CVCL_2U92 ORMES-7 embryonic stem cell CVCL_2U92 CL:0000010 Male Group: Non-human primate cell line. 21165632 CVCL_3690 Gd1WE finite cell line CVCL_3690 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6181; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165633 CVCL_2U90 ORMES-5 embryonic stem cell CVCL_2U90 CL:0000010 Male Group: Non-human primate cell line. 21165634 CVCL_2U84 CMK7 embryonic stem cell CVCL_2U84 CL:0000010 Female Group: Non-human primate cell line. 21165635 CVCL_3684 End1/E6E7 transformed cell line human CVCL_3684 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix; endocervical epithelium Cell type=Epithelial cell.. Female 21165636 CVCL_2U85 CMK9 embryonic stem cell CVCL_2U85 CL:0000010 Female Group: Non-human primate cell line. 21165637 CVCL_3685 ESK-4 finite cell line pig CVCL_3685 CL:0000010 Derived from sampling site: Fetal kidney. Female Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-184 21165638 CVCL_2U82 CMK5 embryonic stem cell CVCL_2U82 CL:0000010 Male Group: Non-human primate cell line. 21165639 CVCL_3682 Em Ar finite cell line human CVCL_3682 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Heterozygous (from familial inference of XP8BE and XP9BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165640 CVCL_3683 CHO-EM9 spontaneously immortalized cell line CVCL_3683 CL:0000010 Derived from sampling site: Ovary. Female 21165641 CVCL_2U83 CMK6 embryonic stem cell CVCL_2U83 CL:0000010 Male Group: Non-human primate cell line. 21165642 CVCL_3688 FHC spontaneously immortalized cell line human CVCL_3688 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=20193843) Karyotypic information: Is hypotriploid, has >20 copies of the 8q23~8q24.3 region containing MYC; Derived from sampling site: Fetal colon Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male Characteristics: Forms solid tumors after transplantation into SCID mice Doubling time: ~62 hours (PubMed=6519668) 21165643 CVCL_2U88 ORMES-3 embryonic stem cell CVCL_2U88 CL:0000010 Male Group: Non-human primate cell line. 21165644 CVCL_3689 Ga Va finite cell line human CVCL_3689 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165645 CVCL_2U89 ORMES-4 embryonic stem cell CVCL_2U89 CL:0000010 Male Group: Non-human primate cell line. 21165646 CVCL_3686 FeT-1C spontaneously immortalized cell line CVCL_3686 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent; Virology: Susceptible to infection by feline immunodeficiency virus (FIV) (ATCC) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11968 21165647 CVCL_2U86 ORMES-1 embryonic stem cell CVCL_2U86 CL:0000010 Male Group: Non-human primate cell line. 21165648 CVCL_3687 FeT-J spontaneously immortalized cell line CVCL_3687 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 independent; Virology: Susceptible to infection by feline immunodeficiency virus (FIV) (ATCC) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11967 21165649 CVCL_2U87 ORMES-2 embryonic stem cell CVCL_2U87 CL:0000010 Male Group: Non-human primate cell line. 21165650 CVCL_3651 Bi Fin finite cell line human CVCL_3651 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165651 CVCL_2U51 GM18825 transformed cell line human CVCL_2U51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165652 CVCL_3652 Bing transformed cell line human CVCL_3652 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11554 21165653 CVCL_2U52 GM18826 transformed cell line human CVCL_2U52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165654 CVCL_3650 Ber Lin finite cell line human CVCL_3650 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1132; true Female 21165655 CVCL_2U50 GM17730 transformed cell line human CVCL_2U50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165656 CVCL_3655 BLn finite cell line CVCL_3655 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6017; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165657 CVCL_2U55 GM19344 transformed cell line human CVCL_2U55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165658 CVCL_3656 BSC40 spontaneously immortalized cell line CVCL_3656 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A7D5U6M6; MT-ND6; Simple; p.Tyr50fs*25 (c.147insG) (m.13952dupC); Zygosity=Heteroplasmic (from parent cell line) Derived from sampling site: Kidney. Unspecified Characteristics: Adapted to growth at 40 Celsius Group: Non-human primate cell line Problematic cell line: Misidentified Parent cell line (BS-C-1) was originally thought to be of Chlorocebus aethiops origin but originiate from Chlorocebus pygerythrus. 21165659 CVCL_2U56 GM19345 transformed cell line human CVCL_2U56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165660 CVCL_3653 BJ [Human fibroblast] finite cell line human CVCL_3653 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K36me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 72 PDL Has a long lifespan in comparison with other normal human fibroblast cell lines (ATCC=CRL-2522). Part of: ENCODE project common cell types; tier 3 21165661 CVCL_2U53 GM18827 transformed cell line human CVCL_2U53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165662 CVCL_2U54 GM18828 transformed cell line human CVCL_2U54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165663 CVCL_3659 C13589 transformed cell line human CVCL_3659 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[31]; Zygosity=Heterozygous (ATCC); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[59]; Zygosity=Heterozygous (ATCC) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165664 CVCL_2U59 GM20264 transformed cell line human CVCL_2U59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165665 CVCL_3657 BSp finite cell line CVCL_3657 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6019; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165666 CVCL_2U57 GM19814 finite cell line human CVCL_2U57 CL:0000010 Karyotypic information: 46,XY,t(4;9)(4qter->4p15.2::9p13->9pter;9qter->9p13::4p15.2->4pter) (Coriell); Derived from sampling site: Amniotic fluid Cell type=Fibroblast.. Male 21165667 CVCL_3658 BZR transformed cell line human CVCL_3658 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Characteristics: Highly tumorigenic derivative of BEAS-2B Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9483 21165668 CVCL_2U58 GM20263 transformed cell line human CVCL_2U58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165669 CVCL_3670 CTX TNA2 transformed cell line Norway rat CVCL_3670 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; frontal lobe Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21165670 CVCL_2U70 HROGas03 cancer cell line human CVCL_2U70 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Stomach. Female 21165671 CVCL_3662 Ce Wal finite cell line human CVCL_3662 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165672 CVCL_2U62 GM20572 transformed cell line human CVCL_2U62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165673 CVCL_3663 CLN cancer cell line dog CVCL_3663 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Dachshund. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165674 CVCL_2U63 GM21073 transformed cell line human CVCL_2U63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165675 CVCL_3660 Ce Ar finite cell line human CVCL_3660 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Heterozygous (from familial inference of XP8BE and XP9BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165676 CVCL_2U60 GM20311 transformed cell line human CVCL_2U60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165677 CVCL_3661 Ce Geg finite cell line human CVCL_3661 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1173; true Female 21165678 CVCL_2U61 GM20571 transformed cell line human CVCL_2U61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165679 CVCL_3666 Co88BV59-1 transformed cell line human CVCL_3666 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Human colon tumor associated antigen 16.88 (CTAA 16.88) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10624 21165680 CVCL_2U66 GM50128 transformed cell line human CVCL_2U66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165681 CVCL_3667 Co88BV59H21-2 hybrid cell line human CVCL_3667 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11538. 21165682 CVCL_2U67 GM50129 transformed cell line human CVCL_2U67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165683 CVCL_3664 CLNH11.4 hybridoma human CVCL_3664 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgG1, kappa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8307 21165684 CVCL_2U64 GM21078 transformed cell line human CVCL_2U64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165685 CVCL_3665 CLNH5.5 hybridoma human CVCL_3665 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human cervical squamous cell carcinoma (Note=Also reacts with lung, prostate, vulva and skin cancer cells) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8206 21165686 CVCL_2U65 GM21079 transformed cell line human CVCL_2U65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165687 CVCL_3668 Co88BV59H21-2V67-66 hybrid cell line human CVCL_3668 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11539. 21165688 CVCL_2U68 GM50291 transformed cell line human CVCL_2U68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165689 CVCL_3669 CPA 47 finite cell line CVCL_3669 CL:0000010 Derived from sampling site: Lung; artery; endothelium Cell type=Endothelial cell.. Unspecified Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Caution: Could be identical to CPA (Cellosaurus=CVCL_2876) 21165690 CVCL_2U69 HROBML01 cancer cell line human CVCL_2U69 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from metastatic site: Brain. Male 21165691 CVCL_2U30 GM13686 transformed cell line human CVCL_2U30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165692 CVCL_3630 TCO-2 cancer cell line human CVCL_3630 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Doubling time: 93 hours (PubMed=1607768) 21165693 CVCL_2U33 GM13689 transformed cell line human CVCL_2U33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165694 CVCL_3633 MCF-10F spontaneously immortalized cell line human CVCL_3633 HLA typing: A*01:01,33:01; B*40:01,55:01; C*07:02,03:03 (PubMed=25960936) CL:0000010 Derived from sampling site: Breast; epithelium. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 47.44 hours (GrayJW panel) Group: Patented cell line; Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10318 21165695 CVCL_3634 23 ScCr spontaneously immortalized cell line house mouse CVCL_3634 CL:0000010 Knockout cell: Method=Spontaneously KO; MGI; MGI:96824; Tlr4 Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/10ScN. Unspecified Characteristics: Not responsive to LPS signaling Maintains responsiveness to bacterial pathogen signaling through alternative TLRs, such as TLR2 (for example S. aureus LTA stimulation) (PubMed=12183533). 21165696 CVCL_2U34 GM13732 transformed cell line human CVCL_2U34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165697 CVCL_2U31 GM13687 transformed cell line human CVCL_2U31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165698 CVCL_3631 JTC-12 spontaneously immortalized cell line CVCL_3631 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-47 (Spacelab-J) to study growth in microgravity (DOI=10.2187/bss.6.147; PubMed=12101351) Derived from sampling site: Kidney. Female Group: Non-human primate cell line; Group: Space-flown cell line (cellonaut) 21165699 CVCL_2U32 GM13688 transformed cell line human CVCL_2U32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165700 CVCL_3632 JTC-19 spontaneously immortalized cell line Norway rat CVCL_3632 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: JAR-1. Female 21165701 CVCL_3637 5LBLN finite cell line CVCL_3637 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6049; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165702 CVCL_2U37 GM13743 transformed cell line human CVCL_2U37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165703 CVCL_3638 6LBLN finite cell line CVCL_3638 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6050; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165704 CVCL_2U38 GM13744 transformed cell line human CVCL_2U38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165705 CVCL_3635 2LBLN finite cell line CVCL_3635 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6047; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165706 CVCL_2U35 GM13733 transformed cell line human CVCL_2U35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165707 CVCL_3636 3LBLN finite cell line CVCL_3636 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6048; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165708 CVCL_2U36 GM13734 transformed cell line human CVCL_2U36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165709 CVCL_3639 Ad Hot finite cell line human CVCL_3639 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165710 CVCL_2U39 GM13992 transformed cell line human CVCL_2U39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165711 CVCL_3640 AHH-1 transformed cell line human CVCL_3640 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 16-19 hours (PubMed=8236284) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8146 21165712 CVCL_2U40 GM14236 transformed cell line human CVCL_2U40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165713 CVCL_3641 AK-D spontaneously immortalized cell line CVCL_3641 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by panleukopenia, feline herpes and feline picornaviruses (ECACC); Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21165714 CVCL_2U41 GM14239 transformed cell line human CVCL_2U41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165715 CVCL_3644 An Zan finite cell line human CVCL_3644 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165716 CVCL_2U44 GM14525 finite cell line human CVCL_2U44 CL:0000010 Karyotypic information: 46,XX,t(12;14)(q?14;q?24).arr(1-22,X)x2 (Coriell); Derived from sampling site: Uterus; myometrium. Omics: CNV analysis Female 21165717 CVCL_3645 Anjou 65 transformed cell line human CVCL_3645 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11269 21165718 CVCL_2U45 GM15232 transformed cell line human CVCL_2U45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165719 CVCL_3642 Al Ke finite cell line human CVCL_3642 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165720 CVCL_2U42 GM14523 finite cell line human CVCL_2U42 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165721 CVCL_3643 Amdur II finite cell line human CVCL_3643 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 90112605; true; Discontinued: KCLB; 10124; probable Male Senescence: Senesces at ~40 PDL (ATCC=CCL-124) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00289 Problematic cell line: Partially contaminated Some stocks were contaminated by pig LLC-PK1 (PubMed=14505435; PubMed=20143388). 21165722 CVCL_2U43 GM14524 finite cell line human CVCL_2U43 CL:0000010 Derived from sampling site: Uterus; myometrium. Female 21165723 CVCL_3648 B2.Sp finite cell line CVCL_3648 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6023; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165724 CVCL_2U48 GM16442 transformed cell line human CVCL_2U48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165725 CVCL_3649 B2.Sp/Thy finite cell line CVCL_3649 CL:0000010 Derived from sampling site: Spleen and thymus. Discontinued: ATCC; CRL-6024; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165726 CVCL_2U49 GM16717 transformed cell line human CVCL_2U49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165727 CVCL_3646 Ar Ke-2 finite cell line human CVCL_3646 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21165728 CVCL_2U46 GM15993 transformed cell line human CVCL_2U46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165729 CVCL_3647 B2.Ln finite cell line CVCL_3647 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6022; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165730 CVCL_2U47 GM16027 finite cell line human CVCL_2U47 CL:0000010 Karyotypic information: 46,XX,der(15)(15qter->15p11.1::7q11.2->7qter).ish der(15)(D7Z1-,D15Z+) (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21165731 CVCL_2U11 GM11553 transformed cell line human CVCL_2U11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165732 CVCL_3611 Toledo cancer cell line human CVCL_3611 HLA typing: A*24:02,30:02; B*18:01,41:01; C*12:03,17:01 (PubMed=26589293); Genome ancestry: African=7.85%; Native American=0%; East Asian, North=5.12%; East Asian, South=0%; South Asian=4.69%; European, North=17.53%; European, South=64.81% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu198fs (c.592_596del5); Zygosity=Unspecified (DepMap) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq; Omics: Virome analysis using RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21165733 CVCL_2U12 GM11597 finite cell line human CVCL_2U12 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(9)(9qter->9p22::6q23->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165734 CVCL_3612 TOV-112D cancer cell line human CVCL_3612 HLA typing: A*03:01,03:01; B*14:01,14:01; C*08:02,08:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.33%; East Asian, North=2.98%; East Asian, South=0%; South Asian=0.16%; European, North=53.45%; European, South=43.09% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser37Ala (c.109T>G); ClinVar=VCV000376235; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Leu639fs (c.1915delC); Zygosity=Homozygous (PubMed=33328126; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10949993; PubMed=18507860; PubMed=20204287; PubMed=22931248; PubMed=24023729; PubMed=25230021; PubMed=33328126; DepMap) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 0.8 day (PubMed=10949993); 1.0 +- 0.2 days (PubMed=18507860); 22 hours (PubMed=25984343); 1.49 days (PubMed=22931248); 29.13 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11371 21165735 CVCL_2U10 GM11520 transformed cell line human CVCL_2U10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165736 CVCL_3610 TO 203.T cancer cell line human CVCL_3610 CL:0000010 Derived from sampling site: Bone. Discontinued: ATCC; CRL-7780; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165737 CVCL_2U15 GM11960 transformed cell line human CVCL_2U15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165738 CVCL_3615 TRAMP-C2 cancer cell line house mouse CVCL_3615 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male Doubling time: 25.4 hours (PubMed=9269988) 21165739 CVCL_2U16 GM11961 transformed cell line human CVCL_2U16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165740 CVCL_3616 TRAMP-C3 cancer cell line house mouse CVCL_3616 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male Doubling time: 37.3 hours (PubMed=9269988) 21165741 CVCL_2U13 GM11678 transformed cell line human CVCL_2U13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165742 CVCL_3613 TOV-21G cancer cell line human CVCL_3613 HLA typing: A*11:01,26:01; B*40:02,46:01; C*02:02,04:01 (PubMed=25960936); HLA typing: A*11:01,26:01; B*40:02,40:02; C*02:02,04:01; DQA1*04:01,04:01; DQB1*05:01,06:01; DRB1*01:01,11:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.11%; East Asian, North=0.06%; East Asian, South=0%; South Asian=1.64%; European, North=59.77%; European, South=37.42% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Cys (c.37G>T); ClinVar=VCV000045123; Zygosity=Heterozygous (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Tyr (c.3139C>T); ClinVar=VCV000039705; Zygosity=Heterozygous (PubMed=22705003; PubMed=24224046; PubMed=25230021; PubMed=28273451; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (PubMed=25230021; Cosmic-CLP; DepMap) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: BCRJ; 0236; probable Female Doubling time: 1.5 days (PubMed=10949993); 27 hours (PubMed=25984343); 30.62 hours (GrayJW panel); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel; Part of: PTEN genetic alteration cell panel (ATCC TCP-1030); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11370 21165743 CVCL_2U14 GM11771 transformed cell line human CVCL_2U14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165744 CVCL_3614 TRAMP-C1 cancer cell line house mouse CVCL_3614 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; Breed/subspecies: C57BL/6-TgN(TRAMP)8247Ng. Male Doubling time: 24.4 hours (PubMed=9269988) 21165745 CVCL_2U19 GM12019 finite cell line human CVCL_2U19 CL:0000010 Derived from sampling site: Fetal diaphragm; skeletal muscle. Male 21165746 CVCL_3619 WEHI-13VAR cancer cell line house mouse CVCL_3619 CL:0000010 Breed/subspecies: BALB/c. Biotechnology: Used for a sensitive bioessay to detect and measure TNF-alpha in the presence of Actinomycin D 21165747 CVCL_2U17 GM11962 transformed cell line human CVCL_2U17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21165748 CVCL_3617 UMR-106 cancer cell line Norway rat CVCL_3617 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Characteristics: Established from a transplantable tumor; Characteristics: Responsive to PTH, prostaglandins and bone-resorbing steroids 21165749 CVCL_2U18 GM11966 transformed cell line human CVCL_2U18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165750 CVCL_3618 UMR-108 cancer cell line Norway rat CVCL_3618 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Characteristics: Established from a transplantable tumor 21165751 CVCL_2U22 GM12573 transformed cell line human CVCL_2U22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165752 CVCL_3622 WEHI-3 cancer cell line house mouse CVCL_3622 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Omics: SNP array analysis Male Doubling time: 18 hours, in 2% FCS (PubMed=3005406) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165753 CVCL_2U23 GM12592 finite cell line human CVCL_2U23 CL:0000010 Karyotypic information: 46,XX,t(3;7)(3qter->3p26::7p12->7pter;7qter->7p12::3p26->3pter) (Coriell); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21165754 CVCL_3623 WR21 cancer cell line house mouse CVCL_3623 CL:0000010 Breed/subspecies: (C57BL/6 x SJL)-Tg(Wap-HRAS)69Lln Chr YSJL/J. Male 21165755 CVCL_2U20 GM12446 transformed cell line human CVCL_2U20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165756 CVCL_3620 WEHI-265.1 cancer cell line house mouse CVCL_3620 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165757 CVCL_2U21 GM12514 transformed cell line human CVCL_2U21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21165758 CVCL_3621 WEHI-274.1 cancer cell line house mouse CVCL_3621 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. 21165759 CVCL_2U26 GM13330 finite cell line human CVCL_2U26 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle Cell type=Fibroblast.. Omics: CNV analysis Male 21165760 CVCL_3626 XS63 cancer cell line house mouse CVCL_3626 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165761 CVCL_3627 +/+ MGT cancer cell line house mouse CVCL_3627 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: HRS/J. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165762 CVCL_2U27 GM13410 transformed cell line human CVCL_2U27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Ambiguous 21165763 CVCL_2U24 GM13238 finite cell line human CVCL_2U24 CL:0000010 Karyotypic information: 46,XX,t(1;13)(1pter->1q25::13q22->13qter;13pter->13q22::1q25->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21165764 CVCL_3624 XB-2 cancer cell line house mouse CVCL_3624 CL:0000010 Breed/subspecies: CXBGB/By. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-177 21165765 CVCL_2U25 GM13284 finite cell line human CVCL_2U25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165766 CVCL_3625 XC1.5/51 cancer cell line house mouse CVCL_3625 CL:0000010 Breed/subspecies: C3H. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165767 CVCL_3628 +/+ SCT cancer cell line house mouse CVCL_3628 CL:0000010 Breed/subspecies: HRS/J. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165768 CVCL_2U28 GM13430 transformed cell line human CVCL_2U28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21165769 CVCL_2U29 GM13685 transformed cell line human CVCL_2U29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21165770 CVCL_3629 YSCCC cancer cell line human CVCL_3629 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21165771 CVCL_DI24 LAU-Me246.M1-LCL transformed cell line human CVCL_DI24 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female 21165772 CVCL_DI25 LAU-Me280.R.LN-LCL transformed cell line human CVCL_DI25 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21165773 CVCL_DI22 LAU-T50B cancer cell line human CVCL_DI22 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21165774 CVCL_DI23 LAU-T618A cancer cell line human CVCL_DI23 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Derived from metastatic site: Cutaneous. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21165775 CVCL_DI28 PC-9/GR1 cancer cell line human CVCL_DI28 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165776 CVCL_DI29 PC-9/GR2 cancer cell line human CVCL_DI29 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165778 CVCL_DI27 WM1942 cancer cell line human CVCL_DI27 CL:0000010 Part of: Wistar Institute melanoma cell line collection. 21165779 CVCL_DI20 LAU-Me280.R.LN cancer cell line human CVCL_DI20 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21165780 CVCL_DI21 LAU-T149D cancer cell line human CVCL_DI21 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Viscera. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21165781 CVCL_DI35 PC-9/DR3 cancer cell line human CVCL_DI35 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165782 CVCL_DI36 PC-9/DR4 cancer cell line human CVCL_DI36 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165783 CVCL_DI33 PC-9/DR1 cancer cell line human CVCL_DI33 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165784 CVCL_DI34 PC-9/DR2 cancer cell line human CVCL_DI34 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165785 CVCL_DI39 Hep3BLAP-I cancer cell line human CVCL_DI39 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1834; CEBPB (isoform LAP) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male 21165786 CVCL_DI37 PC-9/DR5 cancer cell line human CVCL_DI37 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165787 CVCL_DI38 PC-9/DR6 cancer cell line human CVCL_DI38 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165788 CVCL_DI31 PC-9/GR5 cancer cell line human CVCL_DI31 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165789 CVCL_DI32 PC-9/GR6 cancer cell line human CVCL_DI32 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165790 CVCL_DI30 PC-9/GR3 cancer cell line human CVCL_DI30 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165791 CVCL_DI08 OU-LC-ON cancer cell line human CVCL_DI08 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21165792 CVCL_DI09 OU-LC-KM cancer cell line human CVCL_DI09 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21165793 CVCL_DI02 OU-LC-A2 cancer cell line human CVCL_DI02 HLA typing: A*26:01; B*15:01; C*04:01; DQB1*03:02 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21165794 CVCL_DI03 OU-LC-A3 cancer cell line human CVCL_DI03 HLA typing: A*11:01,24:02; B*51:01,54:01; C*01:02,14:02; DQB1*04:01 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21165795 CVCL_DI00 EBC-2/R cancer cell line human CVCL_DI00 CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Male 21165796 CVCL_DI01 OU-LC-A1 cancer cell line human CVCL_DI01 HLA typing: A*24:02; B*40:02; C*03:03; DQB1*04:02 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21165797 CVCL_DI06 OU-LC-KI cancer cell line human CVCL_DI06 HLA typing: A*02:01,02:06; B*39:01,51:01; C*14:02,03:04; DQB1*03:32;04:02 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21165798 CVCL_DI07 OU-LC-OK cancer cell line human CVCL_DI07 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21165799 CVCL_DI04 OU-LC-A4 cancer cell line human CVCL_DI04 HLA typing: A*24:02,31:12; B*07:02,51:01; C*07:02,14:02; DQB1*03:02,04:01 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21165800 CVCL_DI05 OU-LC-AS1 cancer cell line human CVCL_DI05 HLA typing: A*11:01; B*55:02; C*01:02; DQB1*04:01 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Supraclavicular lymph node. Male 21165801 CVCL_DI13 1858-mel c cancer cell line human CVCL_DI13 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Right flank; hypodermis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21165802 CVCL_DI14 1936-mel cancer cell line human CVCL_DI14 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Right chest wall; hypodermis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21165803 CVCL_DI11 1858-mel a cancer cell line human CVCL_DI11 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Right flank; hypodermis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21165804 CVCL_DI12 1858-mel b cancer cell line human CVCL_DI12 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Right flank; hypodermis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21165805 CVCL_DI17 LAU-Me235 cancer cell line human CVCL_DI17 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Glu (c.1801A>G); ClinVar=VCV000013966; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male 21165806 CVCL_DI18 LAU-Me246.M1 cancer cell line human CVCL_DI18 From: Ludwig Institute for Cancer Research, Lausanne Branch; Lausanne; Switzerland CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20862285) Derived from metastatic site: Cutaneous. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 21165807 CVCL_DI15 1962-mel cancer cell line human CVCL_DI15 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Right breast; hypodermis. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female 21165808 CVCL_DI16 A2780-SCA cancer cell line human CVCL_DI16 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Ovary. Female 21165809 CVCL_DI10 OU-LC-SK cancer cell line human CVCL_DI10 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21165810 CVCL_3695 HBE135-E6E7 transformed cell line human CVCL_3695 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21165811 CVCL_2U95 ORMES-10 embryonic stem cell CVCL_2U95 CL:0000010 Female Group: Non-human primate cell line. 21165812 CVCL_3696 HBE4-E6/E7 transformed cell line human CVCL_3696 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Omics: SNP array analysis Male 21165813 CVCL_2U96 ORMES-11 embryonic stem cell CVCL_2U96 CL:0000010 Female Group: Non-human primate cell line. 21165814 CVCL_3693 HAAE-2 finite cell line human CVCL_3693 CL:0000010 Derived from sampling site: Abdomen; aorta Cell type=Aortic endothelial cell.. Discontinued: ATCC; CRL-2473; true Male Part of: Wistar Institute Special Collection vascular cell lines 21165815 CVCL_2U93 ORMES-8 embryonic stem cell CVCL_2U93 CL:0000010 Female Group: Non-human primate cell line. 21165816 CVCL_3694 HB [Human epidermolysis bullosa] finite cell line human CVCL_3694 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7729; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165817 CVCL_2U94 ORMES-9 embryonic stem cell CVCL_2U94 CL:0000010 Female Group: Non-human primate cell line. 21165818 CVCL_3699 HE-SK finite cell line human CVCL_3699 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7718; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165819 CVCL_2U99 ORMES-14 embryonic stem cell CVCL_2U99 CL:0000010 Male Group: Non-human primate cell line. 21165820 CVCL_3697 HBE4-E6/E7-C1 transformed cell line human CVCL_3697 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21165821 CVCL_2U97 ORMES-12 embryonic stem cell CVCL_2U97 CL:0000010 Male Group: Non-human primate cell line. 21165822 CVCL_3698 HE-LU (Rifkin) finite cell line human CVCL_3698 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CRL-7717; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165823 CVCL_2U98 ORMES-13 embryonic stem cell CVCL_2U98 CL:0000010 Female Group: Non-human primate cell line. 21165824 CVCL_MB28 BayGenomics ES cell line CSI165 embryonic stem cell house mouse CVCL_MB28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165825 CVCL_MB29 BayGenomics ES cell line CSI166 embryonic stem cell house mouse CVCL_MB29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99700; Cenpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165826 CVCL_MB26 BayGenomics ES cell line CSI163 embryonic stem cell house mouse CVCL_MB26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289325; Anapc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165827 CVCL_MB27 BayGenomics ES cell line CSI164 embryonic stem cell house mouse CVCL_MB27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106340; Rcor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165828 CVCL_MB24 BayGenomics ES cell line CSI156 embryonic stem cell house mouse CVCL_MB24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913401; Prr13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165829 CVCL_DH90 HT-29 BR300 cancer cell line human CVCL_DH90 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade) Female 21165830 CVCL_MB25 BayGenomics ES cell line CSI158 embryonic stem cell house mouse CVCL_MB25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914668; Ppil4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165831 CVCL_DH91 HBEC2-E transformed cell line human CVCL_DH91 CL:0000010 Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bronchus; epithelium. Male 21165832 CVCL_MB22 BayGenomics ES cell line CSI153 embryonic stem cell house mouse CVCL_MB22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100846; Med1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165833 CVCL_MB23 BayGenomics ES cell line CSI154 embryonic stem cell house mouse CVCL_MB23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100846; Med1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165834 CVCL_MB20 BayGenomics ES cell line CSI149 embryonic stem cell house mouse CVCL_MB20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922066; Tpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165835 CVCL_MB21 BayGenomics ES cell line CSI150 embryonic stem cell house mouse CVCL_MB21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165836 CVCL_DH89 HT-29 BR200 cancer cell line human CVCL_DH89 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade) Female 21165837 CVCL_DH83 MDA-MB-468GFP cancer cell line human CVCL_DH83 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+1G>T; ClinVar=VCV000189475; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_2787del2523; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Derived from metastatic site: Pleural effusion. Omics: CNV analysis Female Group: Triple negative breast cancer (TNBC) cell line 21165838 CVCL_DH84 USC-DHL-1 cancer cell line human CVCL_DH84 CL:0000010 Omics: Array-based CGH; Omics: CNV analysis; Omics: miRNA expression profiling. 21165839 CVCL_DH81 UW402 cancer cell line human CVCL_DH81 CL:0000010 Female Doubling time: 32 +- 0.5 hours (PubMed=31346954). 21165840 CVCL_DH82 UW426 cancer cell line human CVCL_DH82 CL:0000010 Female 21165841 CVCL_DH87 LS14 cancer cell line human CVCL_DH87 CL:0000010 Male Characteristics: Exhibits a gene expression pattern similar to that in primary preadipocytes and are capable of terminal differentiation Can be considered as partially-differentiated preadipocytes that can be induce to terminally differentiate and accumulate lipid droplets following incubation in serum-free medium which contains a combination of adipogenic-inducing compounds (PubMed=16195405). Doubling time: ~96 hours (PubMed=16195405). 21165842 CVCL_DH88 HT-29 BR100 cancer cell line human CVCL_DH88 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade) Female 21165843 CVCL_MB19 BayGenomics ES cell line CSI147 embryonic stem cell house mouse CVCL_MB19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145425; Depdc1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165844 CVCL_DH85 UTP-ES1 cancer cell line human CVCL_DH85 CL:0000010 Population: Japanese. 21165845 CVCL_DH86 E3GS2.4 cancer cell line human CVCL_DH86 CL:0000010 21165846 CVCL_MB39 BayGenomics ES cell line CSI180 embryonic stem cell house mouse CVCL_MB39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165847 CVCL_MB37 BayGenomics ES cell line CSI178 embryonic stem cell house mouse CVCL_MB37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682307; Ric8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165848 CVCL_MB38 BayGenomics ES cell line CSI179 embryonic stem cell house mouse CVCL_MB38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165849 CVCL_MB35 BayGenomics ES cell line CSI176 embryonic stem cell house mouse CVCL_MB35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384310; Rbm10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165850 CVCL_MB36 BayGenomics ES cell line CSI177 embryonic stem cell house mouse CVCL_MB36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107801; Atp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165851 CVCL_MB33 BayGenomics ES cell line CSI173 embryonic stem cell house mouse CVCL_MB33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919185; Cipc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165852 CVCL_MB34 BayGenomics ES cell line CSI174 embryonic stem cell house mouse CVCL_MB34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919185; Cipc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165853 CVCL_MB31 BayGenomics ES cell line CSI170 embryonic stem cell house mouse CVCL_MB31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95654; Gart Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165854 CVCL_MB32 BayGenomics ES cell line CSI171 embryonic stem cell house mouse CVCL_MB32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346858; Mapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165855 CVCL_MB30 BayGenomics ES cell line CSI167 embryonic stem cell house mouse CVCL_MB30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444233; Ythdf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165856 CVCL_DH94 HCC827 PFR4 cancer cell line human CVCL_DH94 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Derived from sampling site: Lung. Female 21165857 CVCL_DH95 HCC827 PFR5 cancer cell line human CVCL_DH95 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Derived from sampling site: Lung. Female 21165858 CVCL_DH92 HCC827 PFR1 cancer cell line human CVCL_DH92 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Derived from sampling site: Lung. Female 21165859 CVCL_DH93 HCC827 PFR3 cancer cell line human CVCL_DH93 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Derived from sampling site: Lung. Female 21165860 CVCL_DH98 SBC-9A cancer cell line human CVCL_DH98 CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Omics: SNP array analysis Unspecified 21165861 CVCL_DH99 EBC-2 cancer cell line human CVCL_DH99 HLA typing: A*31:12,33:03; B*35:01,44:31; C*03:03,14:03; DQB1*03:02;06:04 (PubMed=10213231) CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Male 21165862 CVCL_DH96 HCC827 PFR6 cancer cell line human CVCL_DH96 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Derived from sampling site: Lung. Female 21165863 CVCL_DH97 SBC-6 cancer cell line human CVCL_DH97 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Unspecified Doubling time: 26.2 hours (PubMed=8286010) 21165864 CVCL_MB06 BayGenomics ES cell line CSI117 embryonic stem cell house mouse CVCL_MB06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914923; Elob Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165865 CVCL_MB07 BayGenomics ES cell line CSI124 embryonic stem cell house mouse CVCL_MB07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150152; Ubqln4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165866 CVCL_MB04 BayGenomics ES cell line CSI103 embryonic stem cell house mouse CVCL_MB04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336214; Khsrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165867 CVCL_MB05 BayGenomics ES cell line CSI104 embryonic stem cell house mouse CVCL_MB05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344406; Ptpn21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165868 CVCL_MB02 BayGenomics ES cell line CSI100 embryonic stem cell house mouse CVCL_MB02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108466; Ralbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165869 CVCL_MB03 BayGenomics ES cell line CSI101 embryonic stem cell house mouse CVCL_MB03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165870 CVCL_MB00 BayGenomics ES cell line CSI092 embryonic stem cell house mouse CVCL_MB00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346036; Pin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165871 CVCL_MB01 BayGenomics ES cell line CSI095 embryonic stem cell house mouse CVCL_MB01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344347; Synj2bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165872 CVCL_DH69 D28 cancer cell line human CVCL_DH69 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533; PubMed=23890154); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=17363583); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro124Leu (c.371C>T); ClinVar=VCV000040744; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male 21165873 CVCL_DH67 D22 [Human melanoma] cancer cell line human CVCL_DH67 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro124Leu (c.371C>T); ClinVar=VCV000040744; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21165874 CVCL_DH68 D26 cancer cell line human CVCL_DH68 CL:0000010 Unspecified 21165875 CVCL_DH61 A13 cancer cell line human CVCL_DH61 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21165876 CVCL_DH62 D01 cancer cell line human CVCL_DH62 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=17363583; PubMed=22383533; PubMed=23890154) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female 21165877 CVCL_DH60 A12 cancer cell line human CVCL_DH60 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165878 CVCL_DH65 D54 [Human melanoma] cancer cell line human CVCL_DH65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165879 CVCL_DH66 D49 cancer cell line human CVCL_DH66 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165880 CVCL_DH63 D03 cancer cell line human CVCL_DH63 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165881 CVCL_DH64 D64 cancer cell line human CVCL_DH64 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165882 CVCL_MB17 BayGenomics ES cell line CSI141 embryonic stem cell house mouse CVCL_MB17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165883 CVCL_MB18 BayGenomics ES cell line CSI146 embryonic stem cell house mouse CVCL_MB18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165884 CVCL_MB15 BayGenomics ES cell line CSI138 embryonic stem cell house mouse CVCL_MB15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165885 CVCL_MB16 BayGenomics ES cell line CSI139 embryonic stem cell house mouse CVCL_MB16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146285; Nol12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165886 CVCL_MB13 BayGenomics ES cell line CSI133 embryonic stem cell house mouse CVCL_MB13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349448; Cenph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165887 CVCL_MB14 BayGenomics ES cell line CSI137 embryonic stem cell house mouse CVCL_MB14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165888 CVCL_DH80 OVCA-X cancer cell line human CVCL_DH80 CL:0000010 Female 21165889 CVCL_MB11 BayGenomics ES cell line CSI130 embryonic stem cell house mouse CVCL_MB11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107858; Arhgap39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165890 CVCL_MB12 BayGenomics ES cell line CSI132 embryonic stem cell house mouse CVCL_MB12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165891 CVCL_MB10 BayGenomics ES cell line CSI129 embryonic stem cell house mouse CVCL_MB10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165892 CVCL_DH78 OV-TRL-12B cancer cell line human CVCL_DH78 CL:0000010 Female 21165893 CVCL_DH79 OV-TRL-90T cancer cell line human CVCL_DH79 CL:0000010 Female 21165894 CVCL_DH72 D32 cancer cell line human CVCL_DH72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21165895 CVCL_DH73 D36 cancer cell line human CVCL_DH73 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21165896 CVCL_DH70 D29 cancer cell line human CVCL_DH70 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21165897 CVCL_DH71 D30 cancer cell line human CVCL_DH71 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165898 CVCL_DH76 D41 cancer cell line human CVCL_DH76 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21165899 CVCL_DH77 EN-TRL-67T cancer cell line human CVCL_DH77 CL:0000010 Derived from sampling site: Endometrium. Female 21165900 CVCL_MB08 BayGenomics ES cell line CSI125 embryonic stem cell house mouse CVCL_MB08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919449; Mms19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165901 CVCL_DH74 D38 [Human melanoma] cancer cell line human CVCL_DH74 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Omics: CNV analysis; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male 21165902 CVCL_MB09 BayGenomics ES cell line CSI127 embryonic stem cell house mouse CVCL_MB09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914750; Ccar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165903 CVCL_DH75 D40 cancer cell line human CVCL_DH75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 393; AKT3; Simple; p.Glu17Lys (c.49G>A); ClinVar=VCV000039816; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21165904 CVCL_DH47 MGH119 cancer cell line human CVCL_DH47 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Unspecified 21165905 CVCL_DH48 MGH119-R cancer cell line human CVCL_DH48 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839 Omics: Transcriptome analysis by microarray. Unspecified 21165906 CVCL_DH45 SUM149-Luc/MA1 cancer cell line human CVCL_DH45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase. Female Group: Triple negative breast cancer (TNBC) cell line 21165907 CVCL_DH46 SUM149-Luc/MA2 cancer cell line human CVCL_DH46 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase. Female Group: Triple negative breast cancer (TNBC) cell line 21165908 CVCL_DH49 MGH121 cancer cell line human CVCL_DH49 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Unspecified 21165909 CVCL_DH40 OVCAR3-533533-R6 cancer cell line human CVCL_DH40 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533; Derived from metastatic site: Ascites. Female 21165910 CVCL_DH43 PR1 [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_DH43 CL:0000010 Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Female 21165911 CVCL_DH44 SUM149-Luc cancer cell line human CVCL_DH44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Pro724Leufs*12 (c.2169delT) (p.Asn723fs*13) (2288delT); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4025+26_4025+30 (c.5224+28del3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase. Female Group: Triple negative breast cancer (TNBC) cell line 21165912 CVCL_DH41 OVCAR3-533533-R7 cancer cell line human CVCL_DH41 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533; Derived from metastatic site: Ascites. Female 21165913 CVCL_DH42 Granta-380 cancer cell line human CVCL_DH42 CL:0000010 Omics: Array-based CGH. Female 21165914 CVCL_DH58 MM636 cancer cell line human CVCL_DH58 CL:0000010 Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21165915 CVCL_DH59 MM266 cancer cell line human CVCL_DH59 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. 21165916 CVCL_DH56 MGH156 cancer cell line human CVCL_DH56 CL:0000010 Unspecified 21165917 CVCL_DH57 MGH157 cancer cell line human CVCL_DH57 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Unspecified 21165918 CVCL_DH50 MGH125 cancer cell line human CVCL_DH50 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=25758528) Derived from metastatic site: Pleural effusion. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165919 CVCL_DH51 MGH126 cancer cell line human CVCL_DH51 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Unspecified 21165920 CVCL_DH54 MGH134 cancer cell line human CVCL_DH54 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Unspecified 21165921 CVCL_DH55 MGH141 cancer cell line human CVCL_DH55 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Unspecified 21165922 CVCL_DH52 MGH131-1 cancer cell line human CVCL_DH52 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male 21165923 CVCL_DH53 MGH131-2 cancer cell line human CVCL_DH53 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Unexplicit; Ex19del; Zygosity=Unspecified (PubMed=25758528) Omics: Transcriptome analysis by microarray. Male 21165924 CVCL_DH25 SVpgC2a-FOXM1B transformed cell line human CVCL_DH25 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Female 21165925 CVCL_DH26 SVpgC2a-FOXM1B/SVFN1 transformed cell line human CVCL_DH26 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165926 CVCL_DH23 OCI-P9a2 cancer cell line human CVCL_DH23 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis Female 21165927 CVCL_DH24 OCI-U1a cancer cell line human CVCL_DH24 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Unspecified (PubMed=26080861) Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165928 CVCL_DH29 SVpgC2a-FOXM1B/SVFN4 transformed cell line human CVCL_DH29 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165929 CVCL_DH27 SVpgC2a-FOXM1B/SVFN2 transformed cell line human CVCL_DH27 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165930 CVCL_DH28 SVpgC2a-FOXM1B/SVFN3 transformed cell line human CVCL_DH28 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165931 CVCL_DH21 OCI-P8p cancer cell line human CVCL_DH21 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Unspecified (PubMed=26080861) Omics: Transcriptome analysis by microarray. Female 21165932 CVCL_DH22 OCI-P9a1 cancer cell line human CVCL_DH22 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165933 CVCL_DH20 OCI-P7a cancer cell line human CVCL_DH20 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21165934 CVCL_DH36 MCM1G cancer cell line human CVCL_DH36 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22570180) Derived from sampling site: Skin. Male 21165935 CVCL_DH37 OVCAR3-533533-R1 cancer cell line human CVCL_DH37 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533; Derived from metastatic site: Ascites. Female 21165936 CVCL_DH34 PC-9/GR4 cancer cell line human CVCL_DH34 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Male 21165937 CVCL_DH35 MCM1 cancer cell line human CVCL_DH35 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22570180) Derived from sampling site: Skin. Omics: SNP array analysis Male 21165938 CVCL_DH38 OVCAR3-533533-R3 cancer cell line human CVCL_DH38 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533; Derived from metastatic site: Ascites. Female 21165939 CVCL_DH39 OVCAR3-533533-R5 cancer cell line human CVCL_DH39 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533; Derived from metastatic site: Ascites. Female 21165940 CVCL_DH32 SVpgC2a-FOXM1B/SVFN7 transformed cell line human CVCL_DH32 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165941 CVCL_DH33 SVpgC2a-FOXM1B/SVFN8 transformed cell line human CVCL_DH33 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165942 CVCL_DH30 SVpgC2a-FOXM1B/SVFN5 transformed cell line human CVCL_DH30 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165943 CVCL_DH31 SVpgC2a-FOXM1B/SVFN6 transformed cell line human CVCL_DH31 CL:0000010 Transfected with: HGNC; 3818; FOXM1 (isoform FoxM1B) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Omics: SNP array analysis Female 21165944 CVCL_2U00 GM10995 finite cell line human CVCL_2U00 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165945 CVCL_2U01 GM11066 finite cell line human CVCL_2U01 CL:0000010 Karyotypic information: 46,XY,t(4;11)(4pter->4q33::11p13->11pter;11qter->11p13::4q33->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165946 CVCL_3601 SMT/2A LNM cancer cell line Norway rat CVCL_3601 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Wistar Furth. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21165947 CVCL_2U04 GM11327 finite cell line human CVCL_2U04 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21165948 CVCL_3604 SW839 cancer cell line human CVCL_3604 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; HTB-49; true; Discontinued: RCB; RCB2131; true; Discontinued: TKG; TKG 0582; true Female 21165949 CVCL_2U05 GM11329 finite cell line human CVCL_2U05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21165950 CVCL_3605 T1-73 undefined cell line type human CVCL_3605 HLA typing: A*01:01,01:01; B*08:01,44:05; C*02:02,07:06; DRB1*13:86,16:05 (PubMed=26589293); Genome ancestry: African=0.88%; Native American=0.25%; East Asian, North=0.51%; East Asian, South=0%; South Asian=3.27%; European, North=53.75%; European, South=41.34% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Bone Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Problematic cell line: Misclassified Originally thought to be a osteosarcoma cell line but using a variety of omics methods was shown to be a a fibroblastic cell line (DOI=10.1101/166199; DepMap). 21165951 CVCL_2U02 GM11219 finite cell line human CVCL_2U02 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21165952 CVCL_3602 SV7tert transformed cell line human CVCL_3602 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Female 21165953 CVCL_2U03 GM11251 finite cell line human CVCL_2U03 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(7;17)(7pter->7p10::17p13.3->17pter;17qter->17p13.3::7q10->7qter) (Coriell); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Male 21165954 CVCL_3603 SW579 cancer cell line human CVCL_3603 HLA typing: A*02:01,02:01; B*07:43,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=1.95%; East Asian, North=0.43%; East Asian, South=0%; South Asian=0.91%; European, North=63.94%; European, South=32.66% (PubMed=30894373) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Ser (c.764T>G); ClinVar=VCV000376622; Zygosity=Homozygous (PubMed=1516062; DepMap) Population: Caucasian; Derived from sampling site: Thyroid gland. Omics: Deep exome analysis; Omics: Mitochondrial genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel 21165955 CVCL_2U08 GM11459 finite cell line human CVCL_2U08 CL:0000010 Karyotypic information: 46,X,t(X;3)(p22.1;q23) (PubMed=10377420); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21165956 CVCL_3608 TF-1a cancer cell line human CVCL_3608 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Growth factor independent clone of TF-1 21165957 CVCL_2U09 GM11499 finite cell line human CVCL_2U09 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21165958 CVCL_3609 TIMI.4 cancer cell line house mouse CVCL_3609 CL:0000010 Transformant: Radiation murine leukemia virus(NCBI-Taxonomy; 11787); Breed/subspecies: C57BL/6. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165959 CVCL_2U06 GM11346 finite cell line human CVCL_2U06 CL:0000010 Population: Caucasian; Karyotypic information: 45,XY,der(14)(14qter->14p12::18q11->18qter),-18 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21165960 CVCL_3606 T27A cancer cell line house mouse CVCL_3606 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21165961 CVCL_2U07 GM11397 finite cell line human CVCL_2U07 CL:0000010 Karyotypic information: 46,XX,t(8;10)(8qter->8p11.2::10q24->10qter;10pter->10q24::8p11.2->8pter) (Coriell); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21165962 CVCL_3607 TF-1.CN5a.1 cancer cell line human CVCL_3607 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2170; CNTFR Population: Japanese; Derived from sampling site: Bone marrow. Male 21165963 CVCL_MB88 BayGenomics ES cell line CSI326 embryonic stem cell house mouse CVCL_MB88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165964 CVCL_MB89 BayGenomics ES cell line CSI327 embryonic stem cell house mouse CVCL_MB89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894687; Xrn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165965 CVCL_MB86 BayGenomics ES cell line CSI314 embryonic stem cell house mouse CVCL_MB86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165966 CVCL_MB87 BayGenomics ES cell line CSI323 embryonic stem cell house mouse CVCL_MB87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165967 CVCL_MB84 BayGenomics ES cell line CSI305 embryonic stem cell house mouse CVCL_MB84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353593; Lcmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165968 CVCL_MB85 BayGenomics ES cell line CSI307 embryonic stem cell house mouse CVCL_MB85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101949; Rad52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165969 CVCL_MB82 BayGenomics ES cell line CSI297 embryonic stem cell house mouse CVCL_MB82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916065; Btbd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165970 CVCL_MB83 BayGenomics ES cell line CSI303 embryonic stem cell house mouse CVCL_MB83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932339; Sf3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165971 CVCL_MB80 BayGenomics ES cell line CSI283 embryonic stem cell house mouse CVCL_MB80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106013; Slc16a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165972 CVCL_MB81 BayGenomics ES cell line CSI286 embryonic stem cell house mouse CVCL_MB81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3588234; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165973 CVCL_MB99 BayGenomics ES cell line CSI348 embryonic stem cell house mouse CVCL_MB99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165974 CVCL_MB97 BayGenomics ES cell line CSI346 embryonic stem cell house mouse CVCL_MB97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165975 CVCL_MB98 BayGenomics ES cell line CSI347 embryonic stem cell house mouse CVCL_MB98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105089; Hsd17b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165976 CVCL_MB95 BayGenomics ES cell line CSI344 embryonic stem cell house mouse CVCL_MB95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914132; Bzw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165977 CVCL_MB96 BayGenomics ES cell line CSI345 embryonic stem cell house mouse CVCL_MB96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107186; Cct2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165978 CVCL_MB93 BayGenomics ES cell line CSI340 embryonic stem cell house mouse CVCL_MB93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384876; Cdc73 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165979 CVCL_MB94 BayGenomics ES cell line CSI341 embryonic stem cell house mouse CVCL_MB94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919020; Ap2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165980 CVCL_MB91 BayGenomics ES cell line CSI334 embryonic stem cell house mouse CVCL_MB91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2663721; Zc3h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165981 CVCL_MB92 BayGenomics ES cell line CSI339 embryonic stem cell house mouse CVCL_MB92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165982 CVCL_MB90 BayGenomics ES cell line CSI328 embryonic stem cell house mouse CVCL_MB90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920997; Shld1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165983 CVCL_MB68 BayGenomics ES cell line CSI248 embryonic stem cell house mouse CVCL_MB68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165984 CVCL_MB69 BayGenomics ES cell line CSI249 embryonic stem cell house mouse CVCL_MB69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933184; Nop58 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165985 CVCL_MB66 BayGenomics ES cell line CSI236 embryonic stem cell house mouse CVCL_MB66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165986 CVCL_MB67 BayGenomics ES cell line CSI242 embryonic stem cell house mouse CVCL_MB67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921414; Nfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165987 CVCL_MB64 BayGenomics ES cell line CSI231 embryonic stem cell house mouse CVCL_MB64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165988 CVCL_MB65 BayGenomics ES cell line CSI234 embryonic stem cell house mouse CVCL_MB65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165989 CVCL_MB62 BayGenomics ES cell line CSI226 embryonic stem cell house mouse CVCL_MB62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919394; Slc37a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165990 CVCL_MB63 BayGenomics ES cell line CSI228 embryonic stem cell house mouse CVCL_MB63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165991 CVCL_MB60 BayGenomics ES cell line CSI222 embryonic stem cell house mouse CVCL_MB60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165992 CVCL_MB61 BayGenomics ES cell line CSI224 embryonic stem cell house mouse CVCL_MB61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165993 CVCL_MB79 BayGenomics ES cell line CSI281 embryonic stem cell house mouse CVCL_MB79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913840; Farsa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165994 CVCL_MB77 BayGenomics ES cell line CSI278 embryonic stem cell house mouse CVCL_MB77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165995 CVCL_MB78 BayGenomics ES cell line CSI280 embryonic stem cell house mouse CVCL_MB78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894687; Xrn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165996 CVCL_MB75 BayGenomics ES cell line CSI266 embryonic stem cell house mouse CVCL_MB75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95659; Gas5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165997 CVCL_MB76 BayGenomics ES cell line CSI275 embryonic stem cell house mouse CVCL_MB76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336196; Tsix Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165998 CVCL_MB73 BayGenomics ES cell line CSI258 embryonic stem cell house mouse CVCL_MB73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99240; Ddx39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21165999 CVCL_MB74 BayGenomics ES cell line CSI263 embryonic stem cell house mouse CVCL_MB74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166000 CVCL_MB71 BayGenomics ES cell line CSI253 embryonic stem cell house mouse CVCL_MB71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891692; Hnrnpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166001 CVCL_MB72 BayGenomics ES cell line CSI256 embryonic stem cell house mouse CVCL_MB72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166002 CVCL_MB70 BayGenomics ES cell line CSI252 embryonic stem cell house mouse CVCL_MB70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889205; Cpq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166003 CVCL_MB48 BayGenomics ES cell line CSI194 embryonic stem cell house mouse CVCL_MB48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913964; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166004 CVCL_MB49 BayGenomics ES cell line CSI197 embryonic stem cell house mouse CVCL_MB49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891295; Ube3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166005 CVCL_MB46 BayGenomics ES cell line CSI191 embryonic stem cell house mouse CVCL_MB46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166006 CVCL_MB47 BayGenomics ES cell line CSI193 embryonic stem cell house mouse CVCL_MB47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277977; Ubr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166007 CVCL_MB44 BayGenomics ES cell line CSI186 embryonic stem cell house mouse CVCL_MB44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914117; Hmg20a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166008 CVCL_MB45 BayGenomics ES cell line CSI189 embryonic stem cell house mouse CVCL_MB45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166009 CVCL_MB42 BayGenomics ES cell line CSI183 embryonic stem cell house mouse CVCL_MB42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166010 CVCL_MB43 BayGenomics ES cell line CSI184 embryonic stem cell house mouse CVCL_MB43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918885; Mast4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166011 CVCL_MB40 BayGenomics ES cell line CSI181 embryonic stem cell house mouse CVCL_MB40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443731; Mat2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166012 CVCL_MB41 BayGenomics ES cell line CSI182 embryonic stem cell house mouse CVCL_MB41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166013 CVCL_MB59 BayGenomics ES cell line CSI221 embryonic stem cell house mouse CVCL_MB59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932339; Sf3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166014 CVCL_MB57 BayGenomics ES cell line CSI212 embryonic stem cell house mouse CVCL_MB57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445003; Arhgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166015 CVCL_MB58 BayGenomics ES cell line CSI216 embryonic stem cell house mouse CVCL_MB58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166016 CVCL_MB55 BayGenomics ES cell line CSI208 embryonic stem cell house mouse CVCL_MB55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166017 CVCL_MB56 BayGenomics ES cell line CSI209 embryonic stem cell house mouse CVCL_MB56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351477; Cars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166018 CVCL_MB53 BayGenomics ES cell line CSI203 embryonic stem cell house mouse CVCL_MB53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166019 CVCL_MB54 BayGenomics ES cell line CSI207 embryonic stem cell house mouse CVCL_MB54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196294; Fubp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166020 CVCL_MB51 BayGenomics ES cell line CSI199 embryonic stem cell house mouse CVCL_MB51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914378; Ube2g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166021 CVCL_MB52 BayGenomics ES cell line CSI202 embryonic stem cell house mouse CVCL_MB52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166022 CVCL_MB50 BayGenomics ES cell line CSI198 embryonic stem cell house mouse CVCL_MB50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166023 CVCL_2V94 PR00268 finite cell line CVCL_2V94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00268; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166024 CVCL_3794 SBAC finite cell line CVCL_3794 CL:0000010 Derived from sampling site: Adrenal gland. Unspecified Characteristics: Responsive to ACTH and other steroidogenic agents (ATCC); Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Senescence: Capable of 60-70 PDL (ATCC=CRL-1796) 21166025 CVCL_2V95 PR00269 finite cell line CVCL_2V95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00269; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166026 CVCL_3795 Sf 1 Ep finite cell line CVCL_3795 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Epithelial cell.. Male Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166027 CVCL_2V92 PR00266 finite cell line CVCL_2V92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00266; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166028 CVCL_3792 RWPE-2 transformed cell line human CVCL_3792 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11610 21166029 CVCL_2V93 PR00267 finite cell line CVCL_2V93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00267; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166030 CVCL_3793 RWPE2-W99 transformed cell line human CVCL_3793 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21166031 CVCL_2V98 PR00275 finite cell line CVCL_2V98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00275; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166032 CVCL_3798 SV-HUC-1 transformed cell line human CVCL_3798 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Omics: Deep exome analysis Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9520 21166033 CVCL_2V99 PR00279 finite cell line CVCL_2V99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00279; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166034 CVCL_3799 SW527 cancer cell line human CVCL_3799 HLA typing: A*02:01,24:02; B*07:02,15:18; C*07:04,07:04; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:03,15:01 (PubMed=26589293) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00089 Problematic cell line: Contaminated Shown to be a SW480 derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 70 year old female patient with a metastatic breast carcinoma. 21166035 CVCL_2V96 PR00270 finite cell line CVCL_2V96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00270; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166036 CVCL_3796 SKW 6.4 transformed cell line human CVCL_3796 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly59_Thr125del (c.175_375del199); Zygosity=Heterozygous (PubMed=19220422) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Characteristics: Produces and secretes IgM Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00617 Problematic cell line: Contaminated Shown to be a WIL2-A3 derivative (ICLAC). Based on the STR profile. The exact WIL2 derivative has been arbitrarily chosen to be WIL2-A3 because this cell line was used in the lab where SKW 6.4 was derived (PubMed=305004). Originally thought to originate from the Daudi cell line. 21166037 CVCL_2V97 PR00273 finite cell line CVCL_2V97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00273; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166038 CVCL_3797 SVG p12 transformed cell line human CVCL_3797 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male Virology: Contaminated with BK polyomavirus strain UT (PubMed=24760884) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8621 21166039 CVCL_2V80 PR00245 finite cell line CVCL_2V80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00245; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166040 CVCL_3780 QNR/K2 transformed cell line CVCL_3780 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin) [tsNY68](NCBI-Taxonomy; 11889); Derived from sampling site: Embryonic eye; retina; neuroretina. Unspecified Group: Bird cell line 21166041 CVCL_3772 pEAK Rapid transformed cell line human CVCL_3772 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21166042 CVCL_2V72 PR00237 finite cell line bonobo/pygmy chimpanzee CVCL_2V72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00237; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166043 CVCL_3773 PMC2 finite cell line human CVCL_3773 CL:0000010 Derived from sampling site: Spleen. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9852 21166044 CVCL_2V73 PR00238 finite cell line CVCL_2V73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00238; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166045 CVCL_3770 OVK18 cancer cell line human CVCL_3770 HLA typing: A*24:02,24:02; B*15:01,54:01; C*01:02,04:01; DQA1*05:02,05:02; DRB1*13:07,15:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=78.65%; East Asian, South=21.35%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Leu437fs*1 (c.1305delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Gly (c.176C>G); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Tyr366fs*17 (c.1096delT); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Pro109fs*194 (c.322delC); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours (PubMed=6584390); Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21166046 CVCL_2V70 PR00235 finite cell line bonobo/pygmy chimpanzee CVCL_2V70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00235; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166047 CVCL_3771 Pl 1Ut finite cell line CVCL_3771 CL:0000010 Derived from sampling site: Uterus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6596; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166048 CVCL_2V71 PR00236 finite cell line bonobo/pygmy chimpanzee CVCL_2V71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00236; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166049 CVCL_2V76 PR00241 finite cell line CVCL_2V76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00241; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166050 CVCL_3776 PYS-2 cancer cell line house mouse CVCL_3776 CL:0000010 Breed/subspecies: 129/Sv. Male 21166051 CVCL_2V77 PR00242 finite cell line CVCL_2V77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00242; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166052 CVCL_3777 PZ-HPV-7 transformed cell line human CVCL_3777 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21166053 CVCL_2V74 PR00239 finite cell line CVCL_2V74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00239; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166054 CVCL_3774 PSP-36 spontaneously immortalized cell line CVCL_3774 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11171 Problematic cell line: Misidentified Parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21166055 CVCL_2V75 PR00240 finite cell line CVCL_2V75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00240; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166056 CVCL_3775 PWR-1E transformed cell line human CVCL_3775 Genome ancestry: African=2.52%; Native American=0%; East Asian, North=2.82%; East Asian, South=0%; South Asian=0%; European, North=64.08%; European, South=30.58% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11611 21166057 CVCL_2V78 PR00243 transformed cell line CVCL_2V78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00243; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166058 CVCL_3778 QG-U cancer cell line human CVCL_3778 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Doubling time: 48 hours (PubMed=6991350) 21166059 CVCL_2V79 PR00244 finite cell line CVCL_2V79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00244; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166060 CVCL_3779 QNR/D transformed cell line CVCL_3779 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin) [tsNY68](NCBI-Taxonomy; 11889); Derived from sampling site: Embryonic eye; retina; neuroretina. Unspecified Group: Bird cell line 21166061 CVCL_2V90 PR00261 finite cell line CVCL_2V90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00261; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166062 CVCL_3790 Ru Ra finite cell line human CVCL_3790 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166063 CVCL_2V91 PR00262 finite cell line CVCL_2V91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00262; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166064 CVCL_3791 RWPE-1 transformed cell line human CVCL_3791 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~22 hours (PBCF) Group: Patented cell line; Part of: ENCODE project common cell types; tier 3; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11609 21166065 CVCL_2V83 PR00253 transformed cell line CVCL_2V83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00253; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166066 CVCL_3783 RAB-9 finite cell line CVCL_3783 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: New Zealand white. Female Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Senescence: Can undergo 40 PDL 21166067 CVCL_2V84 PR00254 finite cell line CVCL_2V84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00254; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166068 CVCL_3784 Ray Hot finite cell line human CVCL_3784 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166069 CVCL_2V81 PR00247 finite cell line CVCL_2V81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00247; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166070 CVCL_3781 R2LBLN finite cell line CVCL_3781 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6070; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166071 CVCL_2V82 PR00251 transformed cell line bonobo/pygmy chimpanzee CVCL_2V82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00251; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166072 CVCL_3782 R9ab finite cell line CVCL_3782 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Senescence: Capable of at least 60 PDL (ATCC=CCL-193) 21166073 CVCL_2V87 PR00258 finite cell line CVCL_2V87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00258; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166074 CVCL_3787 RKO-E6 cancer cell line human CVCL_3787 HLA typing: A*03:01,03:01; B*18:01,37:04; C*07:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Unspecified 21166075 CVCL_2V88 PR00259 finite cell line CVCL_2V88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00259; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166076 CVCL_3788 RL-65 spontaneously immortalized cell line Norway rat CVCL_3788 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Sprague Dawley. Male Doubling time: 17 hours (Patent=US5364785; PubMed=2260675) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10354 21166077 CVCL_2V85 PR00255 finite cell line CVCL_2V85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00255; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166078 CVCL_3785 RC-4B/C cancer cell line Norway rat CVCL_3785 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: ACI x Fischer 344. Male 21166079 CVCL_2V86 PR00257 finite cell line CVCL_2V86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00257; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166080 CVCL_3786 RKO-AS45-1 cancer cell line human CVCL_3786 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4095; GADD45A Omics: Transcriptome analysis by microarray Unspecified 21166081 CVCL_2V89 PR00260 finite cell line CVCL_2V89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00260; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166082 CVCL_3789 RPE-J transformed cell line Norway rat CVCL_3789 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: Long-Evans. Unspecified Characteristics: At the restrictive temperature (40 Celsius) this cell line acquires a differentiated polarized RPE phenotype 21166083 CVCL_3750 MiF-6 cancer cell line house mouse CVCL_3750 CL:0000010 Breed/subspecies: C57BL/10. Male 21166084 CVCL_2V50 PR00128 finite cell line CVCL_2V50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00128; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166085 CVCL_3751 MLE-12 transformed cell line house mouse CVCL_3751 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: FVB/N-Tg(SFTPC-TAg)5.1Jaw transgenic. Female Doubling time: 7-9 hours, at 12th passage (PubMed=8248207) 21166086 CVCL_2V51 PR00129 finite cell line CVCL_2V51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00129; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166087 CVCL_3754 NCE-F161 transformed cell line CVCL_3754 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). Virology: Susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8727 21166088 CVCL_2V54 PR00132 finite cell line CVCL_2V54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00132; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166089 CVCL_3755 NK-92MI cancer cell line human CVCL_3755 Genome ancestry: African=1.91%; Native American=0.5%; East Asian, North=2.04%; East Asian, South=0%; South Asian=0%; European, North=62.71%; European, South=32.85% (PubMed=30894373) CL:0000010 Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis Discontinued: BCRC; 60438; true Male Characteristics: No longer dependent on IL2 Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6671 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers of NK-92MI. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21166090 CVCL_2V55 PR00133 finite cell line CVCL_2V55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00133; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166091 CVCL_3752 MN-11 cancer cell line house mouse CVCL_3752 CL:0000010 Breed/subspecies: C57BL/10. Male 21166092 CVCL_2V52 PR00130 finite cell line CVCL_2V52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00130; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166093 CVCL_3753 MYA-1 spontaneously immortalized cell line CVCL_3753 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent; Virology: Susceptible to infection by feline immunodeficiency virus (FIV) 21166094 CVCL_2V53 PR00131 finite cell line CVCL_2V53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00131; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166095 CVCL_3758 NRK spontaneously immortalized cell line Norway rat CVCL_3758 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21166096 CVCL_2V58 PR00198 finite cell line CVCL_2V58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00198; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166097 CVCL_3759 NZP-12 finite cell line CVCL_3759 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Unspecified Senescence: Capable of at least 13 PDL (ATCC=CRL-1921) 21166098 CVCL_2V59 PR00219 finite cell line CVCL_2V59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00219; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166099 CVCL_3756 NL20 transformed cell line human CVCL_3756 CL:0000010 Population: Caucasian; Karyotypic information: 43,X,-X,-5,-7,-15,del(4)(p14),del(6)(q21-q25),i(14q),18p+,21p+,+i(5q),+der(15)t(7p;15q) (PubMed=1522038); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: ~48 hours (PubMed=1522038); ~24 hours (PBCF) 21166100 CVCL_2V56 PR00174 finite cell line CVCL_2V56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00174; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166101 CVCL_3757 NL20T-A transformed cell line human CVCL_3757 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium Cell type=Epithelial cell.. Omics: SNP array analysis Female Characteristics: Tumorigenic Established from a subcutaneous tumor in an athymic nude mouse inoculated with the parent cell line (PubMed=8521416). 21166102 CVCL_2V57 PR00175 finite cell line CVCL_2V57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00175; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166103 CVCL_3761 NZP-36 finite cell line CVCL_3761 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified Senescence: Capable of at least 10 PDL (ATCC=CRL-1922) 21166104 CVCL_2V61 PR00221 finite cell line CVCL_2V61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00221; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166105 CVCL_3762 NZP-60 finite cell line CVCL_3762 CL:0000010 Derived from sampling site: Kidney. Unspecified Senescence: Capable of at least 12 PDL (ATCC=CRL-1924) Group: Non-human primate cell line 21166106 CVCL_2V62 PR00222 finite cell line CVCL_2V62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00222; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166107 CVCL_3760 NZP-29 finite cell line CVCL_3760 CL:0000010 Derived from sampling site: Lung. Unspecified Senescence: Capable of at least 12 PDL (ATCC=CRL-1925) 21166108 CVCL_2V60 PR00220 finite cell line CVCL_2V60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00220; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166109 CVCL_3765 OA4.Bm finite cell line CVCL_3765 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-6547; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166110 CVCL_2V65 PR00226 finite cell line CVCL_2V65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00226; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166111 CVCL_3766 OLF-136 spontaneously immortalized cell line CVCL_3766 CL:0000010 Derived from sampling site: Fin; Breed/subspecies: HB32C. Unspecified Doubling time: 43 hours (CelloPub=CLPUB00092) Group: Fish cell line 21166112 CVCL_2V66 PR00227 finite cell line CVCL_2V66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00227; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166113 CVCL_3763 OA1 finite cell line CVCL_3763 CL:0000010 Derived from sampling site: Brain. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166114 CVCL_2V63 PR00223 finite cell line CVCL_2V63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00223; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166115 CVCL_3764 OA3.Ts finite cell line CVCL_3764 CL:0000010 Derived from sampling site: Fetal testis. Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257); Virology: Persistently infected by bovine viral diarrhea virus 2 (BVDV-2) (PubMed=34737324) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166116 CVCL_2V64 PR00224 finite cell line CVCL_2V64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00224; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166117 CVCL_3769 OVCA432 cancer cell line human CVCL_3769 HLA typing: A*01:01,29:02; B*44:03,55:01; C*03:03,16:01; DQB1*02:02,03:02; DRB1*07:01,11:79 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys277Phe (c.830G>T); ClinVar=VCV000458567; Zygosity=Unspecified (PubMed=20204287; PubMed=28273451) Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 37.09 hours (GrayJW panel) 21166118 CVCL_2V69 PR00232 finite cell line CVCL_2V69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00232; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166119 CVCL_3767 OLME-104 cancer cell line CVCL_3767 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Breed/subspecies: HB32C. Unspecified Doubling time: 77 hours (CelloPub=CLPUB00092) Group: Fish cell line 21166120 CVCL_2V67 PR00228 finite cell line CVCL_2V67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00228; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166121 CVCL_3768 OV-90 cancer cell line human CVCL_3768 HLA typing: A*02:05,02:05; B*15:05,50:01; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=2.24%; Native American=0%; East Asian, North=2.36%; East Asian, South=0%; South Asian=5.06%; European, North=37.26%; European, South=53.08% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (PubMed=24675677); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (PubMed=10949993; PubMed=20204287; PubMed=24023729; PubMed=25230021; PubMed=28273451; DepMap) Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.5 days (PubMed=10949993); 40 hours (PubMed=25984343); 46.34 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (Sanger) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: KuDOS 95 cell line panel; Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11732 21166122 CVCL_2V68 PR00230 finite cell line CVCL_2V68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00230; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166123 CVCL_3732 KR-12 hybrid cell line human CVCL_3732 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8658 21166124 CVCL_2V32 PR00095 finite cell line CVCL_2V32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00095; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166125 CVCL_3733 L612 transformed cell line human CVCL_3733 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a breast carcinoma; Derived from sampling site: Lymph node Cell type=B-cell.. Female Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:84118; Ganglioside GM3; Monoclonal antibody target: ChEBI; CHEBI:27499; Ganglioside GM4 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10724 21166126 CVCL_2V33 PR00096 finite cell line CVCL_2V33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00096; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166127 CVCL_3730 KEL FIB finite cell line human CVCL_3730 CL:0000010 Population: African American; Derived from sampling site: Skin (Note=From a keloid) Cell type=Fibroblast.. Discontinued: BCRJ; 0279; probable Female Senescence: Senesces at ~10 PDL (ATCC=CRL-1762) 21166128 CVCL_2V30 PR00077 finite cell line CVCL_2V30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00077; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166129 CVCL_3731 KNRK transformed cell line Norway rat CVCL_3731 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV)(NCBI-Taxonomy; 11808); Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 21166130 CVCL_2V31 PR00092 transformed cell line bonobo/pygmy chimpanzee CVCL_2V31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00092; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166131 CVCL_3736 LL97A (AlMy) finite cell line human CVCL_3736 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21166132 CVCL_2V36 PR00101 finite cell line CVCL_2V36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00101; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166133 CVCL_3737 L53-10 undefined cell line type human CVCL_3737 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7720; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166134 CVCL_2V37 PR00103 finite cell line CVCL_2V37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00103; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166135 CVCL_3734 La Bel finite cell line human CVCL_3734 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166136 CVCL_2V34 PR00099 finite cell line CVCL_2V34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00099; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166137 CVCL_3735 La Bel II finite cell line human CVCL_3735 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1195; true Female 21166138 CVCL_2V35 PR00100 finite cell line CVCL_2V35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00100; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166139 CVCL_3738 Ltk-11 spontaneously immortalized cell line house mouse CVCL_3738 CL:0000010 Transfected with: HGNC; 5289; HTR1D Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10422 21166140 CVCL_2V38 PR00105 finite cell line CVCL_2V38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00105; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166141 CVCL_3739 Ma San finite cell line human CVCL_3739 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166142 CVCL_2V39 PR00107 finite cell line CVCL_2V39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00107; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166143 CVCL_2V40 PR00108 finite cell line CVCL_2V40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00108; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166144 CVCL_3743 MCF-10-2A spontaneously immortalized cell line human CVCL_3743 CL:0000010 Derived from sampling site: Breast; epithelium. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10781 21166145 CVCL_2V43 PR00119 finite cell line CVCL_2V43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00119; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166146 CVCL_3744 MCF-12A spontaneously immortalized cell line human CVCL_3744 HLA typing: A*66:01,02:01; B*41:02,18:01/35:08; C*07:01,17:01; DRB1*11:67,11:67 (PubMed=25960936) CL:0000010 Derived from sampling site: Breast; epithelium. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.42 hours (GrayJW panel) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10782 21166147 CVCL_2V44 PR00120 finite cell line CVCL_2V44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00120; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166148 CVCL_3741 MB III cancer cell line house mouse CVCL_3741 CL:0000010 Discontinued: ECACC; 90111914; probable. 21166149 CVCL_2V41 PR00112 finite cell line CVCL_2V41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00112; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166150 CVCL_3742 McCoy spontaneously immortalized cell line house mouse CVCL_3742 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00079 Problematic cell line: Misidentified Originally thought to be of human origin but found to be a mouse NCTC clone 929 derivative (PubMed=6451928; PubMed=20143388). Were thought to originate from the synovial fluid in the knee joint of a patient suffering from degenerative arthritis. 21166151 CVCL_2V42 PR00115 finite cell line CVCL_2V42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00115; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166152 CVCL_3747 Me Mon finite cell line human CVCL_3747 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166153 CVCL_2V47 PR00124 finite cell line CVCL_2V47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00124; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166154 CVCL_3748 Mel Neg finite cell line human CVCL_3748 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166155 CVCL_2V48 PR00126 finite cell line CVCL_2V48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00126; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166156 CVCL_3745 MCF-12F spontaneously immortalized cell line human CVCL_3745 CL:0000010 Derived from sampling site: Breast; epithelium. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10783 21166157 CVCL_2V45 PR00122 finite cell line CVCL_2V45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00122; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166158 CVCL_3746 Me Jon finite cell line human CVCL_3746 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166159 CVCL_2V46 PR00123 finite cell line CVCL_2V46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00123; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166160 CVCL_3749 MeT-5A transformed cell line human CVCL_3749 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Omics: Transcriptome analysis by microarray Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9444 21166161 CVCL_2V49 PR00127 finite cell line CVCL_2V49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00127; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166162 CVCL_DJ45 CW30094 induced pluripotent stem cell human CVCL_DJ45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30094; true Male 21166163 CVCL_DJ46 CW30146 induced pluripotent stem cell human CVCL_DJ46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30146; true Female 21166164 CVCL_DJ43 CW30056 induced pluripotent stem cell human CVCL_DJ43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30056; true Female 21166165 CVCL_DJ44 CW30090 induced pluripotent stem cell human CVCL_DJ44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30090; true Female 21166166 CVCL_DJ49 CW30175 induced pluripotent stem cell human CVCL_DJ49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30175; true Male 21166167 CVCL_DJ47 CW30164 induced pluripotent stem cell human CVCL_DJ47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30164; true Female 21166168 CVCL_DJ48 CW30168 induced pluripotent stem cell human CVCL_DJ48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30168; true Male 21166169 CVCL_DJ41 CW30020 induced pluripotent stem cell human CVCL_DJ41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30020; true. Female 21166170 CVCL_DJ42 CW30022 induced pluripotent stem cell human CVCL_DJ42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30022; true. Female 21166171 CVCL_DJ40 CW30006 induced pluripotent stem cell human CVCL_DJ40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30006; true. Female 21166172 CVCL_DJ56 CW30276 induced pluripotent stem cell human CVCL_DJ56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30276; true Male 21166173 CVCL_DJ57 CW30279 induced pluripotent stem cell human CVCL_DJ57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30279; true Male 21166174 CVCL_DJ54 CW30254 induced pluripotent stem cell human CVCL_DJ54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30254; true Female 21166175 CVCL_DJ55 CW30256 induced pluripotent stem cell human CVCL_DJ55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30256; true Male 21166176 CVCL_DJ58 CW30284 induced pluripotent stem cell human CVCL_DJ58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30284; true Male 21166177 CVCL_DJ59 CW30288 induced pluripotent stem cell human CVCL_DJ59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30288; true Female 21166178 CVCL_DJ52 CW30223 induced pluripotent stem cell human CVCL_DJ52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30223; true Female 21166179 CVCL_DJ53 CW30241 induced pluripotent stem cell human CVCL_DJ53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30241; true Male 21166180 CVCL_DJ50 CW30182 induced pluripotent stem cell human CVCL_DJ50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30182; true Female 21166181 CVCL_DJ51 CW30199 induced pluripotent stem cell human CVCL_DJ51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30199; true Female 21166182 CVCL_DJ29 CW20118 induced pluripotent stem cell human CVCL_DJ29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20118; true Female 21166183 CVCL_DJ23 CW20098 induced pluripotent stem cell human CVCL_DJ23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20098; true Male 21166184 CVCL_DJ24 CW20099 induced pluripotent stem cell human CVCL_DJ24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20099; true Female 21166185 CVCL_DJ21 CW20088 induced pluripotent stem cell human CVCL_DJ21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20088; true Female 21166186 CVCL_DJ22 CW20090 induced pluripotent stem cell human CVCL_DJ22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW20090; true; Discontinued: FCDI; CW20090; probable. Female 21166187 CVCL_DJ27 CW20110 induced pluripotent stem cell human CVCL_DJ27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20110; true Male 21166188 CVCL_DJ28 CW20115 induced pluripotent stem cell human CVCL_DJ28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20115; true Female 21166189 CVCL_DJ25 CW20106 induced pluripotent stem cell human CVCL_DJ25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20106; true Female 21166190 CVCL_DJ26 CW20109 induced pluripotent stem cell human CVCL_DJ26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20109; true Female 21166191 CVCL_DJ20 CW20085 induced pluripotent stem cell human CVCL_DJ20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20085; true Female 21166192 CVCL_DJ34 CW20137 induced pluripotent stem cell human CVCL_DJ34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20137; true Female 21166193 CVCL_DJ35 CW20142 induced pluripotent stem cell human CVCL_DJ35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20142; true Male 21166194 CVCL_DJ32 CW20132 induced pluripotent stem cell human CVCL_DJ32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20132; true Female 21166195 CVCL_DJ33 CW20135 induced pluripotent stem cell human CVCL_DJ33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20135; true Male 21166196 CVCL_DJ38 CW20151 induced pluripotent stem cell human CVCL_DJ38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20151; true Male 21166197 CVCL_DJ39 CW20237 induced pluripotent stem cell human CVCL_DJ39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20237; true Female 21166198 CVCL_DJ36 CW20146 induced pluripotent stem cell human CVCL_DJ36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20146; true Female 21166199 CVCL_DJ37 CW20149 induced pluripotent stem cell human CVCL_DJ37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20149; true Male 21166200 CVCL_DJ30 CW20122 induced pluripotent stem cell human CVCL_DJ30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20122; true Female 21166201 CVCL_DJ31 CW20128 induced pluripotent stem cell human CVCL_DJ31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20128; true Female 21166202 CVCL_DJ09 CW20068 induced pluripotent stem cell human CVCL_DJ09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20068; true Male 21166203 CVCL_DJ07 CW20062 induced pluripotent stem cell human CVCL_DJ07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20062; true Male 21166204 CVCL_DJ08 CW20065 induced pluripotent stem cell human CVCL_DJ08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20065; true Male 21166205 CVCL_DJ01 CW20049 induced pluripotent stem cell human CVCL_DJ01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20049; true Male 21166206 CVCL_DJ02 CW20052 induced pluripotent stem cell human CVCL_DJ02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20052; true Female 21166207 CVCL_DJ00 CW20048 induced pluripotent stem cell human CVCL_DJ00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20048; true Female 21166208 CVCL_DJ05 CW20057 induced pluripotent stem cell human CVCL_DJ05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20057; true Male 21166209 CVCL_DJ06 CW20058 induced pluripotent stem cell human CVCL_DJ06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20058; true Male 21166210 CVCL_DJ03 CW20055 induced pluripotent stem cell human CVCL_DJ03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20055; true Male 21166211 CVCL_DJ04 CW20056 induced pluripotent stem cell human CVCL_DJ04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20056; true Male 21166212 CVCL_DJ18 CW20083 induced pluripotent stem cell human CVCL_DJ18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20083; true Male 21166213 CVCL_DJ19 CW20084 induced pluripotent stem cell human CVCL_DJ19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20084; true Male 21166214 CVCL_DJ12 CW20075 induced pluripotent stem cell human CVCL_DJ12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20075; true Female 21166215 CVCL_DJ13 CW20076 induced pluripotent stem cell human CVCL_DJ13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20076; true Male 21166216 CVCL_DJ10 CW20072 induced pluripotent stem cell human CVCL_DJ10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW20072; true. Female 21166217 CVCL_DJ11 CW20074 induced pluripotent stem cell human CVCL_DJ11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20074; true Female 21166218 CVCL_DJ16 CW20080 induced pluripotent stem cell human CVCL_DJ16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20080; true Male 21166219 CVCL_DJ17 CW20081 induced pluripotent stem cell human CVCL_DJ17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20081; true Male 21166220 CVCL_DJ14 CW20077 induced pluripotent stem cell human CVCL_DJ14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20077; true Female 21166221 CVCL_DJ15 CW20078 induced pluripotent stem cell human CVCL_DJ15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Chinese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20078; true Male 21166222 CVCL_MC49 BayGenomics ES cell line CSI514 embryonic stem cell house mouse CVCL_MC49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166223 CVCL_MC47 BayGenomics ES cell line CSI510 embryonic stem cell house mouse CVCL_MC47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166224 CVCL_MC48 BayGenomics ES cell line CSI512 embryonic stem cell house mouse CVCL_MC48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166225 CVCL_MC45 BayGenomics ES cell line CSI499 embryonic stem cell house mouse CVCL_MC45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166226 CVCL_MC46 BayGenomics ES cell line CSI501 embryonic stem cell house mouse CVCL_MC46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107734; Ap3d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166227 CVCL_MC43 BayGenomics ES cell line CSI497 embryonic stem cell house mouse CVCL_MC43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346873; Map3k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166228 CVCL_MC44 BayGenomics ES cell line CSI498 embryonic stem cell house mouse CVCL_MC44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166229 CVCL_MC41 BayGenomics ES cell line CSI492 embryonic stem cell house mouse CVCL_MC41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144243; Clint1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166230 CVCL_MC42 BayGenomics ES cell line CSI494 embryonic stem cell house mouse CVCL_MC42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166231 CVCL_MC40 BayGenomics ES cell line CSI486 embryonic stem cell house mouse CVCL_MC40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166232 CVCL_MC58 BayGenomics ES cell line CSI538 embryonic stem cell house mouse CVCL_MC58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920924; Wdr75 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166233 CVCL_MC59 BayGenomics ES cell line CSI539 embryonic stem cell house mouse CVCL_MC59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144564; Fam117a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166234 CVCL_MC56 BayGenomics ES cell line CSI529 embryonic stem cell house mouse CVCL_MC56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166235 CVCL_MC57 BayGenomics ES cell line CSI533 embryonic stem cell house mouse CVCL_MC57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166236 CVCL_MC54 BayGenomics ES cell line CSI524 embryonic stem cell house mouse CVCL_MC54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931751; Pum2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166237 CVCL_MC55 BayGenomics ES cell line CSI527 embryonic stem cell house mouse CVCL_MC55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925678; Pym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166238 CVCL_MC52 BayGenomics ES cell line CSI521 embryonic stem cell house mouse CVCL_MC52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919782; Sap130 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166239 CVCL_MC53 BayGenomics ES cell line CSI522 embryonic stem cell house mouse CVCL_MC53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923749; Clasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166240 CVCL_MC50 BayGenomics ES cell line CSI516 embryonic stem cell house mouse CVCL_MC50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919283; Tsc22d2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166241 CVCL_MC51 BayGenomics ES cell line CSI520 embryonic stem cell house mouse CVCL_MC51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344353; Katna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166242 CVCL_MC27 BayGenomics ES cell line CSI438 embryonic stem cell house mouse CVCL_MC27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109547; Dnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166243 CVCL_MC28 BayGenomics ES cell line CSI442 embryonic stem cell house mouse CVCL_MC28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166244 CVCL_MC25 BayGenomics ES cell line CSI433 embryonic stem cell house mouse CVCL_MC25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929701; Metap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166245 CVCL_MC26 BayGenomics ES cell line CSI437 embryonic stem cell house mouse CVCL_MC26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329034; Ccne2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166246 CVCL_MC23 BayGenomics ES cell line CSI429 embryonic stem cell house mouse CVCL_MC23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196439; Cbx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166247 CVCL_MC24 BayGenomics ES cell line CSI430 embryonic stem cell house mouse CVCL_MC24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166248 CVCL_DI90 CW10175 induced pluripotent stem cell human CVCL_DI90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10175; true Male 21166249 CVCL_MC21 BayGenomics ES cell line CSI421 embryonic stem cell house mouse CVCL_MC21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166250 CVCL_MC22 BayGenomics ES cell line CSI423 embryonic stem cell house mouse CVCL_MC22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166251 CVCL_MC20 BayGenomics ES cell line CSI419 embryonic stem cell house mouse CVCL_MC20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98790; Top2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166252 CVCL_DI88 CW10167 induced pluripotent stem cell human CVCL_DI88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10167; true Male 21166253 CVCL_DI89 CW10171 induced pluripotent stem cell human CVCL_DI89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10171; true Female 21166254 CVCL_DI82 CW10130 induced pluripotent stem cell human CVCL_DI82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Nepali; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10130; true Male 21166255 CVCL_DI83 CW10149 induced pluripotent stem cell human CVCL_DI83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10149; true Male 21166256 CVCL_DI80 CW10118 induced pluripotent stem cell human CVCL_DI80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10118; true Male 21166257 CVCL_DI81 CW10128 induced pluripotent stem cell human CVCL_DI81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10128; true Male 21166258 CVCL_DI86 CW10152 induced pluripotent stem cell human CVCL_DI86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10152; true Male 21166259 CVCL_DI87 CW10154 induced pluripotent stem cell human CVCL_DI87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10154; true Male 21166260 CVCL_MC18 BayGenomics ES cell line CSI413 embryonic stem cell house mouse CVCL_MC18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166261 CVCL_DI84 CW10150 induced pluripotent stem cell human CVCL_DI84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10150; true Female 21166262 CVCL_MC19 BayGenomics ES cell line CSI416 embryonic stem cell house mouse CVCL_MC19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166263 CVCL_DI85 CW10151 induced pluripotent stem cell human CVCL_DI85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10151; true. Female 21166264 CVCL_MC38 BayGenomics ES cell line CSI483 embryonic stem cell house mouse CVCL_MC38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914238; Lap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166265 CVCL_MC39 BayGenomics ES cell line CSI484 embryonic stem cell house mouse CVCL_MC39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166266 CVCL_MC36 BayGenomics ES cell line CSI474 embryonic stem cell house mouse CVCL_MC36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166267 CVCL_MC37 BayGenomics ES cell line CSI475 embryonic stem cell house mouse CVCL_MC37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270841; Cry1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166268 CVCL_MC34 BayGenomics ES cell line CSI468 embryonic stem cell house mouse CVCL_MC34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166269 CVCL_MC35 BayGenomics ES cell line CSI471 embryonic stem cell house mouse CVCL_MC35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3763743; Snhg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166270 CVCL_MC32 BayGenomics ES cell line CSI450 embryonic stem cell house mouse CVCL_MC32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166271 CVCL_MC33 BayGenomics ES cell line CSI466 embryonic stem cell house mouse CVCL_MC33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934229; Setdb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166272 CVCL_MC30 BayGenomics ES cell line CSI444 embryonic stem cell house mouse CVCL_MC30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166273 CVCL_MC31 BayGenomics ES cell line CSI449 embryonic stem cell house mouse CVCL_MC31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166274 CVCL_DI99 CW20044 induced pluripotent stem cell human CVCL_DI99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20044; true Male 21166275 CVCL_DI93 CW20016 induced pluripotent stem cell human CVCL_DI93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20016; true Female 21166276 CVCL_DI94 CW20020 induced pluripotent stem cell human CVCL_DI94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20020; true Female 21166277 CVCL_DI91 CW10202 induced pluripotent stem cell human CVCL_DI91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10202; true Male 21166278 CVCL_DI92 CW20001 induced pluripotent stem cell human CVCL_DI92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20001; true Female 21166279 CVCL_DI97 CW20033 induced pluripotent stem cell human CVCL_DI97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20033; true Female 21166280 CVCL_DI98 CW20043 induced pluripotent stem cell human CVCL_DI98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20043; true Male 21166281 CVCL_MC29 BayGenomics ES cell line CSI443 embryonic stem cell house mouse CVCL_MC29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166282 CVCL_DI95 CW20026 induced pluripotent stem cell human CVCL_DI95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20026; true Male 21166283 CVCL_DI96 CW20030 induced pluripotent stem cell human CVCL_DI96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW20030; true. Male 21166284 CVCL_MC05 BayGenomics ES cell line CSI385 embryonic stem cell house mouse CVCL_MC05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166285 CVCL_MC06 BayGenomics ES cell line CSI387 embryonic stem cell house mouse CVCL_MC06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916882; Arhgef12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166286 CVCL_MC03 BayGenomics ES cell line CSI379 embryonic stem cell house mouse CVCL_MC03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109404; Nup98 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166287 CVCL_MC04 BayGenomics ES cell line CSI381 embryonic stem cell house mouse CVCL_MC04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166288 CVCL_MC01 BayGenomics ES cell line CSI362 embryonic stem cell house mouse CVCL_MC01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99670; Dmtn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166289 CVCL_MC02 BayGenomics ES cell line CSI367 embryonic stem cell house mouse CVCL_MC02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179432; Mycbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166290 CVCL_MC00 BayGenomics ES cell line CSI358 embryonic stem cell house mouse CVCL_MC00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166291 CVCL_DI68 CW10040 induced pluripotent stem cell human CVCL_DI68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10040; true. Male 21166292 CVCL_DI69 CW10042 induced pluripotent stem cell human CVCL_DI69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Chinese Discontinued: Coriell; CW10042; true. Female 21166293 CVCL_DI66 CW10015 induced pluripotent stem cell human CVCL_DI66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10015; true. Male 21166294 CVCL_DI67 CW10027 induced pluripotent stem cell human CVCL_DI67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10027; true. Female 21166295 CVCL_DI60 PER-VAS cancer cell line dog CVCL_DI60 CL:0000010 Derived from sampling site: Pericardial effusion; Breed/subspecies: Labrador Retriever. Male Doubling time: 16.5 hours (PubMed=26345430) 21166296 CVCL_DI61 CLL-1390 cancer cell line dog CVCL_DI61 CL:0000010 Sequence variation: Mutation; VGNC; 39069; CDKN1B; Simple; p.Ter199fs (c.596_597insCC); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 54168; KDM6A; Simple; p.Val1131fs (c.3390delCinsGGG); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47261; TET2; Simple; p.Gln965Ter (c.2893C>T); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Asp60fs (c.176_177insAAGGGAGCTTGAAGGTTTCT); Zygosity=Heterozygous (PubMed=31175136) Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 37 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21166297 CVCL_DI64 GM10180 transformed cell line human CVCL_DI64 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166298 CVCL_DI65 GM10182 transformed cell line human CVCL_DI65 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166299 CVCL_DI62 CLGL-90 cancer cell line dog CVCL_DI62 CL:0000010 Omics: Array-based CGH; Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Unspecified 21166300 CVCL_DI63 GM05365 transformed cell line human CVCL_DI63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166301 CVCL_MC16 BayGenomics ES cell line CSI408 embryonic stem cell house mouse CVCL_MC16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353418; Pmm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166302 CVCL_MC17 BayGenomics ES cell line CSI409 embryonic stem cell house mouse CVCL_MC17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891704; Hbs1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166303 CVCL_MC14 BayGenomics ES cell line CSI405 embryonic stem cell house mouse CVCL_MC14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166304 CVCL_MC15 BayGenomics ES cell line CSI406 embryonic stem cell house mouse CVCL_MC15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105047; Psmc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166305 CVCL_MC12 BayGenomics ES cell line CSI401 embryonic stem cell house mouse CVCL_MC12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166306 CVCL_MC13 BayGenomics ES cell line CSI404 embryonic stem cell house mouse CVCL_MC13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100836; Kpna6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166307 CVCL_MC10 BayGenomics ES cell line CSI398 embryonic stem cell house mouse CVCL_MC10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444629; Kctd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166308 CVCL_MC11 BayGenomics ES cell line CSI400 embryonic stem cell house mouse CVCL_MC11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166309 CVCL_DI79 CW10110 induced pluripotent stem cell human CVCL_DI79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10110; true Female 21166310 CVCL_DI77 CW10100 induced pluripotent stem cell human CVCL_DI77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10100; true Male 21166311 CVCL_DI78 CW10101 induced pluripotent stem cell human CVCL_DI78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10101; true Male 21166312 CVCL_DI71 CW10073 induced pluripotent stem cell human CVCL_DI71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10073; true Female 21166313 CVCL_DI72 CW10075 induced pluripotent stem cell human CVCL_DI72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10075; true Male 21166314 CVCL_DI70 CW10058 induced pluripotent stem cell human CVCL_DI70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10058; true Female 21166315 CVCL_MC09 BayGenomics ES cell line CSI397 embryonic stem cell house mouse CVCL_MC09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166316 CVCL_DI75 CW10096 induced pluripotent stem cell human CVCL_DI75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10096; true Male 21166317 CVCL_DI76 CW10098 induced pluripotent stem cell human CVCL_DI76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10098; true Male 21166318 CVCL_MC07 BayGenomics ES cell line CSI392 embryonic stem cell house mouse CVCL_MC07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166319 CVCL_DI73 CW10089 induced pluripotent stem cell human CVCL_DI73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10089; true Male 21166320 CVCL_MC08 BayGenomics ES cell line CSI393 embryonic stem cell house mouse CVCL_MC08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166321 CVCL_DI74 CW10095 induced pluripotent stem cell human CVCL_DI74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10095; true Male 21166322 CVCL_DI46 M950322 cancer cell line human CVCL_DI46 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21166323 CVCL_DI47 M950504 cancer cell line human CVCL_DI47 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Female 21166324 CVCL_DI44 M970131 cancer cell line human CVCL_DI44 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21166325 CVCL_DI45 M970805 cancer cell line human CVCL_DI45 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Female 21166326 CVCL_DI48 M961121 cancer cell line human CVCL_DI48 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor from personal communication of URPP Biobank. Male 21166327 CVCL_DI49 MFE-294 cancer cell line human CVCL_DI49 CL:0000010 Derived from sampling site: Endometrium. Female 21166328 CVCL_DI42 Hep3BLIP-II cancer cell line human CVCL_DI42 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1834; CEBPB (isoform LIP) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male 21166329 CVCL_DI43 M970109 cancer cell line human CVCL_DI43 From: URPP Biobank, University of Zurich; Zurich; Switzerland CL:0000010 Miscellaneous: Age/sex of donor and metastatic site from personal communication of URPP Biobank Derived from metastatic site: Brain. Female 21166330 CVCL_DI40 Hep3BLAP-II cancer cell line human CVCL_DI40 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1834; CEBPB (isoform LAP) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male 21166331 CVCL_DI41 Hep3BLIP-I cancer cell line human CVCL_DI41 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1834; CEBPB (isoform LIP) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male 21166332 CVCL_DI57 HSR-GBM1A cancer cell line human CVCL_DI57 CL:0000010 Group: Cancer stem cell line. 21166333 CVCL_DI58 HSR-GBM1B cancer cell line human CVCL_DI58 CL:0000010 Group: Cancer stem cell line. 21166334 CVCL_DI55 NCI-H3255GR cancer cell line human CVCL_DI55 CL:0000010 Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839. Female 21166335 CVCL_DI56 NCI-H3255DR cancer cell line human CVCL_DI56 CL:0000010 Selected for resistance to: ChEBI; CHEBI:132268; Dacomitinib (PF-00299804); Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839. Female 21166336 CVCL_DI59 1174 cancer cell line human CVCL_DI59 CL:0000010 Group: Cancer stem cell line. 21166337 CVCL_DI50 ML14 transformed cell line human CVCL_DI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166338 CVCL_DI53 MF14 finite cell line human CVCL_DI53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166339 CVCL_DI54 MF20 finite cell line human CVCL_DI54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21166340 CVCL_DI51 M20 [Human melanoma] cancer cell line human CVCL_DI51 CL:0000010 Unspecified 21166341 CVCL_DI52 M7 [Human melanoma UCLA] cancer cell line human CVCL_DI52 CL:0000010 Unspecified 21166342 CVCL_3710 HGF-1 finite cell line human CVCL_3710 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Discontinued: KCLB; 22014; probable Male Senescence: Senesces at ~22 PDL (ATCC=CRL-2014) 21166343 CVCL_2V10 PR00020 finite cell line CVCL_2V10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00020; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166344 CVCL_3711 HIIF-D spontaneously immortalized cell line CVCL_3711 CL:0000010 Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8200 21166345 CVCL_2V11 PR00024 finite cell line CVCL_2V11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00024; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166346 CVCL_3714 HMy2.C1R transformed cell line human CVCL_3714 HLA typing: A*02:01; B*35:03; C*04:01:01; DPB1*04:01,04:02 (IPD-IMGT/HLA=10372) CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166347 CVCL_2V14 PR00036 finite cell line CVCL_2V14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00036; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166348 CVCL_3715 HP cancer cell line human CVCL_3715 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12012 21166349 CVCL_2V15 PR00037 finite cell line CVCL_2V15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00037; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166350 CVCL_3712 HKB-11 hybrid cell line human CVCL_3712 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Doubling time: 41.0 +- 15.9 hours (in serum-containing medium), 57.6 hours (in FreeStyle medium), 48.1 hours (in CDM4 medium) (PubMed=25822314) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12568 21166351 CVCL_2V12 PR00030 finite cell line CVCL_2V12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00030; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166352 CVCL_3713 HM 2 hybridoma human CVCL_3713 CL:0000010 Characteristics: T-cell hybridoma. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8587 21166353 CVCL_2V13 PR00033 finite cell line CVCL_2V13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00033; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166354 CVCL_3718 HPVE-26 finite cell line human CVCL_3718 CL:0000010 Derived from sampling site: Lung; vein Cell type=Lung endothelial cell.. Discontinued: ATCC; CRL-2607; true Male Senescence: Capable of at least ~30 PDL (ATCC=CRL-2607) Part of: Wistar Institute Special Collection vascular cell lines 21166355 CVCL_2V18 PR00045 finite cell line CVCL_2V18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00045; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166356 CVCL_3719 HS-27A transformed cell line human CVCL_3719 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow; stroma. Male 21166357 CVCL_2V19 PR00048 finite cell line CVCL_2V19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00048; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166358 CVCL_3716 HPAE-26 finite cell line human CVCL_3716 CL:0000010 Derived from sampling site: Lung; artery; endothelium. Discontinued: ATCC; CRL-2598; true; Discontinued: Coriell; WC00107; probable Male Senescence: Capable of at least 29 PDL (ATCC=CRL-2598) Part of: Wistar Institute Special Collection vascular cell lines 21166359 CVCL_2V16 PR00039 finite cell line CVCL_2V16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00039; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166360 CVCL_3717 HPME finite cell line house mouse CVCL_3717 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6589; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166361 CVCL_2V17 PR00042 finite cell line CVCL_2V17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00042; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166362 CVCL_3721 HTZ17XP finite cell line human CVCL_3721 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166363 CVCL_2V21 PR00050 finite cell line CVCL_2V21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00050; probable Male Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166364 CVCL_3722 HUVE-12 finite cell line human CVCL_3722 CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Endothelial cell of umbilical vein.. Discontinued: ATCC; CRL-2480; true; Discontinued: Coriell; WC00103; probable Male Part of: Wistar Institute Special Collection vascular cell lines 21166365 CVCL_2V22 PR00051 finite cell line bonobo/pygmy chimpanzee CVCL_2V22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00051; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166366 CVCL_3720 HS-5 transformed cell line human CVCL_3720 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow; stroma. Omics: Deep quantitative proteome analysis Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11882 21166367 CVCL_2V20 PR00049 finite cell line CVCL_2V20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00049; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166368 CVCL_3725 I 9.2 cancer cell line human CVCL_3725 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21166369 CVCL_2V25 PR00054 finite cell line CVCL_2V25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00054; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166370 CVCL_3726 IC-21 transformed cell line house mouse CVCL_3726 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.; Breed/subspecies: C57BL/6. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21166371 CVCL_2V26 PR00055 finite cell line CVCL_2V26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00055; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166372 CVCL_3723 HUVS-112D finite cell line human CVCL_3723 CL:0000010 Derived from sampling site: Umbilical vein Cell type=Umbilical vein smooth muscle cell.. Discontinued: ATCC; CRL-2481; true; Discontinued: Coriell; WC00104; probable Male Part of: Wistar Institute Special Collection vascular cell lines 21166373 CVCL_2V23 PR00052 finite cell line CVCL_2V23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00052; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166374 CVCL_3724 I 2.1 cancer cell line human CVCL_3724 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21166375 CVCL_2V24 PR00053 finite cell line CVCL_2V24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00053; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166376 CVCL_3729 JHUS-nk1 cancer cell line human CVCL_3729 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female 21166377 CVCL_2V29 PR00075 finite cell line CVCL_2V29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00075; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166378 CVCL_3727 JAWSII spontaneously immortalized cell line house mouse CVCL_3727 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: C57BL/6 Trp53-/-. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11904 21166379 CVCL_2V27 PR00058 finite cell line CVCL_2V27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00058; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166380 CVCL_3728 JSC-1 cancer cell line human CVCL_3728 Genome ancestry: African=0.79%; Native American=0.09%; East Asian, North=0.94%; East Asian, South=0%; South Asian=1.9%; European, North=65.05%; European, South=31.24% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Ascites. Omics: Array-based CGH; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2769; true; Discontinued: ATCC; JHU-32; true Male Doubling time: 48 hours (PubMed=11024147); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21166381 CVCL_2V28 PR00062 finite cell line CVCL_2V28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00062; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166382 CVCL_3709 HFSKF-II finite cell line human CVCL_3709 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21166383 CVCL_2V09 PR00019 finite cell line CVCL_2V09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00019; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166384 CVCL_3700 HEK001 transformed cell line human CVCL_3700 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7 (p1321)](NCBI-Taxonomy; 333760); Derived from sampling site: Scalp; skin; epidermis Cell type=Keratinocyte.. Male 21166385 CVCL_2V00 ORMES-15 embryonic stem cell CVCL_2V00 CL:0000010 Female Group: Non-human primate cell line. 21166386 CVCL_3703 HF 282.Sp finite cell line human CVCL_3703 CL:0000010 Derived from sampling site: Fetal spleen. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166387 CVCL_2V03 ORMES-18 embryonic stem cell CVCL_2V03 CL:0000010 Male Group: Non-human primate cell line. 21166388 CVCL_3704 HF 322.Sk finite cell line human CVCL_3704 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7703; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166389 CVCL_2V04 PR00002 finite cell line CVCL_2V04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00002; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166390 CVCL_3701 Hep-G2/2.2.1 cancer cell line human CVCL_3701 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Liver. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11997 21166391 CVCL_2V01 ORMES-16 embryonic stem cell CVCL_2V01 CL:0000010 Female Group: Non-human primate cell line. 21166392 CVCL_3702 HET-1A transformed cell line human CVCL_3702 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Esophagus Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27.4 +- 3.6 hours (PubMed=21127259) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10209 Caution: Indicated as originating from a 25 year old male in ATCC, but said to be derived from autopsy specimen from a 74 year old male 21166393 CVCL_2V02 ORMES-17 embryonic stem cell CVCL_2V02 CL:0000010 Female Group: Non-human primate cell line. 21166394 CVCL_3707 HF 358.We finite cell line human CVCL_3707 CL:0000010 Derived from sampling site: Whole fetus. Discontinued: ATCC; CRL-7709; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166395 CVCL_2V07 PR00013 finite cell line CVCL_2V07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00013; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166396 CVCL_3708 hFOB 1.19 conditionally immortalized cell line human CVCL_3708 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Anecdotal: Have been flown in space on shuttle flight STS-80 to study growth in microgravity (PubMed=10719274) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal bone; limb Cell type=Osteoblast.. Discontinued: ABM; T0007; probable Female Doubling time: 36 hours, at permissive temperature of 33.5 Celsius (ATCC=CRL-11372) Group: Patented cell line; Group: Space-flown cell line (cellonaut); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11372 21166397 CVCL_2V08 PR00017 finite cell line CVCL_2V08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00017; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166398 CVCL_3705 HF 333.We finite cell line human CVCL_3705 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7706; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166399 CVCL_2V05 PR00003 finite cell line bonobo/pygmy chimpanzee CVCL_2V05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00003; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166400 CVCL_3706 HF 345.We finite cell line human CVCL_3706 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7708; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21166401 CVCL_2V06 PR00011 finite cell line CVCL_2V06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00011; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21166402 CVCL_MC89 BayGenomics ES cell line CSI595 embryonic stem cell house mouse CVCL_MC89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923998; Pbrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166403 CVCL_MC87 BayGenomics ES cell line CSI591 embryonic stem cell house mouse CVCL_MC87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166404 CVCL_MC88 BayGenomics ES cell line CSI593 embryonic stem cell house mouse CVCL_MC88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166405 CVCL_MC85 BayGenomics ES cell line CSI589 embryonic stem cell house mouse CVCL_MC85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166406 CVCL_MC86 BayGenomics ES cell line CSI590 embryonic stem cell house mouse CVCL_MC86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916526; Sec62 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166407 CVCL_MC83 BayGenomics ES cell line CSI584 embryonic stem cell house mouse CVCL_MC83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166408 CVCL_MC84 BayGenomics ES cell line CSI585 embryonic stem cell house mouse CVCL_MC84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098231; Kif11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166409 CVCL_MC81 BayGenomics ES cell line CSI582 embryonic stem cell house mouse CVCL_MC81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346870; Map2k6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166410 CVCL_MC82 BayGenomics ES cell line CSI583 embryonic stem cell house mouse CVCL_MC82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355315; Tmod3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166411 CVCL_MC80 BayGenomics ES cell line CSI580 embryonic stem cell house mouse CVCL_MC80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104816; Hnrnpl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166412 CVCL_MC98 BayGenomics ES cell line CSI613 embryonic stem cell house mouse CVCL_MC98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99206; Zfp59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166413 CVCL_MC99 BayGenomics ES cell line CSI614 embryonic stem cell house mouse CVCL_MC99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919369; Tpx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166414 CVCL_MC96 BayGenomics ES cell line CSI610 embryonic stem cell house mouse CVCL_MC96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183260; Luc7l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166415 CVCL_MC97 BayGenomics ES cell line CSI612 embryonic stem cell house mouse CVCL_MC97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97912; Rheb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166416 CVCL_MC94 BayGenomics ES cell line CSI608 embryonic stem cell house mouse CVCL_MC94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97912; Rheb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166417 CVCL_MC95 BayGenomics ES cell line CSI609 embryonic stem cell house mouse CVCL_MC95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97912; Rheb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166418 CVCL_MC92 BayGenomics ES cell line CSI602 embryonic stem cell house mouse CVCL_MC92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925678; Pym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166419 CVCL_MC93 BayGenomics ES cell line CSI604 embryonic stem cell house mouse CVCL_MC93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104816; Hnrnpl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166420 CVCL_MC90 BayGenomics ES cell line CSI596 embryonic stem cell house mouse CVCL_MC90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104816; Hnrnpl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166421 CVCL_MC91 BayGenomics ES cell line CSI601 embryonic stem cell house mouse CVCL_MC91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443157; Mib1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166422 CVCL_MC69 BayGenomics ES cell line CSI556 embryonic stem cell house mouse CVCL_MC69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166423 CVCL_MC67 BayGenomics ES cell line CSI552 embryonic stem cell house mouse CVCL_MC67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97286; Ncl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166424 CVCL_MC68 BayGenomics ES cell line CSI553 embryonic stem cell house mouse CVCL_MC68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166425 CVCL_MC65 BayGenomics ES cell line CSI548 embryonic stem cell house mouse CVCL_MC65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096570; Tex264 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166426 CVCL_MC66 BayGenomics ES cell line CSI549 embryonic stem cell house mouse CVCL_MC66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921428; Stk40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166427 CVCL_MC63 BayGenomics ES cell line CSI543 embryonic stem cell house mouse CVCL_MC63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166428 CVCL_MC64 BayGenomics ES cell line CSI545 embryonic stem cell house mouse CVCL_MC64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166429 CVCL_MC61 BayGenomics ES cell line CSI541 embryonic stem cell house mouse CVCL_MC61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277958; Pcm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166430 CVCL_MC62 BayGenomics ES cell line CSI542 embryonic stem cell house mouse CVCL_MC62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446632; Ago2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166431 CVCL_MC60 BayGenomics ES cell line CSI540 embryonic stem cell house mouse CVCL_MC60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104708; Cct3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166432 CVCL_MC78 BayGenomics ES cell line CSI577 embryonic stem cell house mouse CVCL_MC78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166433 CVCL_MC79 BayGenomics ES cell line CSI578 embryonic stem cell house mouse CVCL_MC79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919378; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166434 CVCL_MC76 BayGenomics ES cell line CSI574 embryonic stem cell house mouse CVCL_MC76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859652; Mtx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166435 CVCL_MC77 BayGenomics ES cell line CSI575 embryonic stem cell house mouse CVCL_MC77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919367; Naa50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166436 CVCL_MC74 BayGenomics ES cell line CSI570 embryonic stem cell house mouse CVCL_MC74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166437 CVCL_MC75 BayGenomics ES cell line CSI571 embryonic stem cell house mouse CVCL_MC75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914855; Akt1s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166438 CVCL_MC72 BayGenomics ES cell line CSI567 embryonic stem cell house mouse CVCL_MC72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166439 CVCL_MC73 BayGenomics ES cell line CSI568 embryonic stem cell house mouse CVCL_MC73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166440 CVCL_MC70 BayGenomics ES cell line CSI560 embryonic stem cell house mouse CVCL_MC70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166441 CVCL_MC71 BayGenomics ES cell line CSI566 embryonic stem cell house mouse CVCL_MC71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919378; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166442 CVCL_MM83 BayGenomics ES cell line RHA214 embryonic stem cell house mouse CVCL_MM83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166443 CVCL_MM84 BayGenomics ES cell line RHA215 embryonic stem cell house mouse CVCL_MM84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352502; Limd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166444 CVCL_MM81 BayGenomics ES cell line RHA211 embryonic stem cell house mouse CVCL_MM81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139369; Rtel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166445 CVCL_MM82 BayGenomics ES cell line RHA212 embryonic stem cell house mouse CVCL_MM82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917656; Vps26b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166446 CVCL_MM80 BayGenomics ES cell line RHA210 embryonic stem cell house mouse CVCL_MM80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913489; Rsrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166447 CVCL_VG20 7H10 [Human iPSC] induced pluripotent stem cell human CVCL_VG20 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166448 CVCL_VG21 7H5 induced pluripotent stem cell human CVCL_VG21 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166449 CVCL_VG24 7H9 induced pluripotent stem cell human CVCL_VG24 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166450 CVCL_VG25 09097C induced pluripotent stem cell human CVCL_VG25 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012602; Zygosity=Unspecified (PubMed=26740656) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166451 CVCL_VG22 7H2 induced pluripotent stem cell human CVCL_VG22 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166452 CVCL_VG23 7H8 induced pluripotent stem cell human CVCL_VG23 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166453 CVCL_VG28 C11011 induced pluripotent stem cell human CVCL_VG28 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012602; Zygosity=Unspecified (PubMed=26740656) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21166454 CVCL_VG29 09097B induced pluripotent stem cell human CVCL_VG29 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21166455 CVCL_VG26 110150C induced pluripotent stem cell human CVCL_VG26 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012602; Zygosity=Unspecified (PubMed=26740656) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166456 CVCL_MM78 BayGenomics ES cell line RHA203 embryonic stem cell house mouse CVCL_MM78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87989; Alas1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166457 CVCL_VG27 110131C induced pluripotent stem cell human CVCL_VG27 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012602; Zygosity=Unspecified (PubMed=26740656) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166458 CVCL_MM79 BayGenomics ES cell line RHA209 embryonic stem cell house mouse CVCL_MM79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166459 CVCL_MM76 BayGenomics ES cell line RHA200 embryonic stem cell house mouse CVCL_MM76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919060; Ranbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166460 CVCL_MM77 BayGenomics ES cell line RHA202 embryonic stem cell house mouse CVCL_MM77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338800; Bpnt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166461 CVCL_MM74 BayGenomics ES cell line RHA197 embryonic stem cell house mouse CVCL_MM74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166462 CVCL_MM75 BayGenomics ES cell line RHA199 embryonic stem cell house mouse CVCL_MM75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88192; Smarca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166463 CVCL_MM94 BayGenomics ES cell line RRA002 embryonic stem cell house mouse CVCL_MM94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343188; Ube2g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166464 CVCL_MM95 BayGenomics ES cell line RRA003 embryonic stem cell house mouse CVCL_MM95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916491; Polr2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166465 CVCL_MM92 BayGenomics ES cell line RHA230 embryonic stem cell house mouse CVCL_MM92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166466 CVCL_MM93 BayGenomics ES cell line RRA001 embryonic stem cell house mouse CVCL_MM93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166467 CVCL_MM90 BayGenomics ES cell line RHA226 embryonic stem cell house mouse CVCL_MM90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166468 CVCL_MM91 BayGenomics ES cell line RHA228 embryonic stem cell house mouse CVCL_MM91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444121; Tanc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166469 CVCL_VG10 MSnviPSNF1 induced pluripotent stem cell human CVCL_VG10 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166470 CVCL_VG13 MSnviPSNF5 induced pluripotent stem cell human CVCL_VG13 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166471 CVCL_VG14 MSnviPSNF6 induced pluripotent stem cell human CVCL_VG14 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166472 CVCL_VG11 MSnviPSNF2 induced pluripotent stem cell human CVCL_VG11 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166473 CVCL_VG12 MSnviPSNF3 induced pluripotent stem cell human CVCL_VG12 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166474 CVCL_VG17 7B1 induced pluripotent stem cell human CVCL_VG17 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166475 CVCL_VG18 7B6 induced pluripotent stem cell human CVCL_VG18 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166476 CVCL_VG15 4BJ1 induced pluripotent stem cell human CVCL_VG15 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166477 CVCL_MM89 BayGenomics ES cell line RHA225 embryonic stem cell house mouse CVCL_MM89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183747; Fgd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166478 CVCL_VG16 5B1 induced pluripotent stem cell human CVCL_VG16 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21166479 CVCL_MM87 BayGenomics ES cell line RHA221 embryonic stem cell house mouse CVCL_MM87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913944; Uqcrfs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166480 CVCL_MM88 BayGenomics ES cell line RHA224 embryonic stem cell house mouse CVCL_MM88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921778; Mgme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166481 CVCL_MM85 BayGenomics ES cell line RHA216 embryonic stem cell house mouse CVCL_MM85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444989; Spg11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166482 CVCL_VG19 XH1 [Human iPSC] induced pluripotent stem cell human CVCL_VG19 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166483 CVCL_MM86 BayGenomics ES cell line RHA218 embryonic stem cell house mouse CVCL_MM86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98759; Tjp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166484 CVCL_MM61 BayGenomics ES cell line RHA158 embryonic stem cell house mouse CVCL_MM61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166485 CVCL_MM62 BayGenomics ES cell line RHA161 embryonic stem cell house mouse CVCL_MM62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166486 CVCL_MM60 BayGenomics ES cell line RHA154 embryonic stem cell house mouse CVCL_MM60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385848; Bcas3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166487 CVCL_VG02 CSCRi005-A induced pluripotent stem cell human CVCL_VG02 From: Centre for Stem Cell Research, Christian Medical College; Vellore; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21166488 CVCL_VG03 OKM-3T cancer cell line human CVCL_VG03 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21166489 CVCL_VG00 Igaki cancer cell line human CVCL_VG00 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760). Virology: HPV16 in only detected in early passages 21166490 CVCL_VG01 OS-F cancer cell line human CVCL_VG01 CL:0000010 Population: Japanese. Female 21166491 CVCL_MM58 BayGenomics ES cell line RHA149 embryonic stem cell house mouse CVCL_MM58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166492 CVCL_VG06 HME348 cdk4 finite cell line human CVCL_VG06 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr2215Serfs*13 (c.6644_6647delACTC) (6872del4); ClinVar=VCV000038060; Zygosity=Heterozygous (PubMed=16541310); Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Breast; epithelium Cell type=Mammary gland epithelial cell.. Female 21166493 CVCL_MM59 BayGenomics ES cell line RHA152 embryonic stem cell house mouse CVCL_MM59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103267; Eif4ebp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166494 CVCL_VG07 HME348 hTERT telomerase immortalized cell line human CVCL_VG07 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr2215Serfs*13 (c.6644_6647delACTC) (6872del4); ClinVar=VCV000038060; Zygosity=Heterozygous (PubMed=16541310); Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium Cell type=Mammary gland epithelial cell.. Female 21166495 CVCL_MM56 BayGenomics ES cell line RHA122 embryonic stem cell house mouse CVCL_MM56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915770; Zfyve21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166496 CVCL_VG04 HCC40-CL cancer cell line human CVCL_VG04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Pro (c.311A>C); Zygosity=Unspecified (PubMed=27279800) Population: Chinese; Derived from sampling site: Liver. Male Doubling time: ~43 hours (PubMed=27279800) 21166497 CVCL_MM57 BayGenomics ES cell line RHA124 embryonic stem cell house mouse CVCL_MM57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166498 CVCL_VG05 HME348 finite cell line human CVCL_VG05 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr2215Serfs*13 (c.6644_6647delACTC) (6872del4); ClinVar=VCV000038060; Zygosity=Heterozygous (PubMed=16541310) Derived from sampling site: Breast; epithelium Cell type=Mammary gland epithelial cell.. Female Senescence: Senesces at 65 PDL 21166499 CVCL_MM54 BayGenomics ES cell line RHA110 embryonic stem cell house mouse CVCL_MM54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166500 CVCL_MM55 BayGenomics ES cell line RHA114 embryonic stem cell house mouse CVCL_MM55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166501 CVCL_MM52 BayGenomics ES cell line RHA107 embryonic stem cell house mouse CVCL_MM52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194490; Diaph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166502 CVCL_VG08 HME348 cdk4/hTERT telomerase immortalized cell line human CVCL_VG08 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr2215Serfs*13 (c.6644_6647delACTC) (6872del4); ClinVar=VCV000038060; Zygosity=Heterozygous (PubMed=16541310); Transfected with: MGI; MGI:88357; Cdk4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Breast; epithelium Cell type=Mammary gland epithelial cell.. Female 21166503 CVCL_MM53 BayGenomics ES cell line RHA109 embryonic stem cell house mouse CVCL_MM53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107688; Kif3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166504 CVCL_VG09 CHO-K1 cat FFAR4 spontaneously immortalized cell line CVCL_VG09 CL:0000010 Transfected with: VGNC; 62236; Cat FFAR4 Derived from sampling site: Ovary. Female 21166505 CVCL_MM72 BayGenomics ES cell line RHA185 embryonic stem cell house mouse CVCL_MM72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103257; Inpp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166506 CVCL_MM73 BayGenomics ES cell line RHA196 embryonic stem cell house mouse CVCL_MM73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442362; Zfp653 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166507 CVCL_MM70 BayGenomics ES cell line RHA181 embryonic stem cell house mouse CVCL_MM70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144243; Clint1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166508 CVCL_MM71 BayGenomics ES cell line RHA183 embryonic stem cell house mouse CVCL_MM71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166509 CVCL_MM69 BayGenomics ES cell line RHA179 embryonic stem cell house mouse CVCL_MM69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102467; Ptpn14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166510 CVCL_MM67 BayGenomics ES cell line RHA173 embryonic stem cell house mouse CVCL_MM67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109233; Kif22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166511 CVCL_MM68 BayGenomics ES cell line RHA175 embryonic stem cell house mouse CVCL_MM68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106581; Tsg101 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166512 CVCL_MM65 BayGenomics ES cell line RHA167 embryonic stem cell house mouse CVCL_MM65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101760; Sfswap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166513 CVCL_MM66 BayGenomics ES cell line RHA172 embryonic stem cell house mouse CVCL_MM66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922434; Camsap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166514 CVCL_MM63 BayGenomics ES cell line RHA162 embryonic stem cell house mouse CVCL_MM63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643133; Gm4924 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166515 CVCL_MM64 BayGenomics ES cell line RHA164 embryonic stem cell house mouse CVCL_MM64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99147; Yes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166516 CVCL_MM40 BayGenomics ES cell line RHA085 embryonic stem cell house mouse CVCL_MM40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166517 CVCL_MM38 BayGenomics ES cell line RHA082 embryonic stem cell house mouse CVCL_MM38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166518 CVCL_MM39 BayGenomics ES cell line RHA084 embryonic stem cell house mouse CVCL_MM39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166519 CVCL_MM36 BayGenomics ES cell line RHA079 embryonic stem cell house mouse CVCL_MM36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916435; Dtwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166520 CVCL_MM37 BayGenomics ES cell line RHA081 embryonic stem cell house mouse CVCL_MM37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913325; Chchd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166521 CVCL_MM34 BayGenomics ES cell line RHA071 embryonic stem cell house mouse CVCL_MM34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166522 CVCL_MM35 BayGenomics ES cell line RHA072 embryonic stem cell house mouse CVCL_MM35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166523 CVCL_MM32 BayGenomics ES cell line RHA069 embryonic stem cell house mouse CVCL_MM32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915149; Cmc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166524 CVCL_MM33 BayGenomics ES cell line RHA070 embryonic stem cell house mouse CVCL_MM33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166525 CVCL_MM30 BayGenomics ES cell line RHA066 embryonic stem cell house mouse CVCL_MM30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98886; U2af2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166526 CVCL_MM31 BayGenomics ES cell line RHA067 embryonic stem cell house mouse CVCL_MM31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916303; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166527 CVCL_MM50 BayGenomics ES cell line RHA105 embryonic stem cell house mouse CVCL_MM50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99954; Ighmbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166528 CVCL_MM51 BayGenomics ES cell line RHA106 embryonic stem cell house mouse CVCL_MM51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166529 CVCL_MM49 BayGenomics ES cell line RHA104 embryonic stem cell house mouse CVCL_MM49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684416; Arap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166530 CVCL_MM47 BayGenomics ES cell line RHA097 embryonic stem cell house mouse CVCL_MM47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330281; Cd2ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166531 CVCL_MM48 BayGenomics ES cell line RHA103 embryonic stem cell house mouse CVCL_MM48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929063; Copz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166532 CVCL_MM45 BayGenomics ES cell line RHA092 embryonic stem cell house mouse CVCL_MM45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343085; Spop Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166533 CVCL_MM46 BayGenomics ES cell line RHA093 embryonic stem cell house mouse CVCL_MM46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166534 CVCL_MM43 BayGenomics ES cell line RHA089 embryonic stem cell house mouse CVCL_MM43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166535 CVCL_MM44 BayGenomics ES cell line RHA090 embryonic stem cell house mouse CVCL_MM44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3029414; Brwd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166536 CVCL_MM41 BayGenomics ES cell line RHA086 embryonic stem cell house mouse CVCL_MM41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347053; Git2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166537 CVCL_MM42 BayGenomics ES cell line RHA088 embryonic stem cell house mouse CVCL_MM42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339975; Pak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166538 CVCL_E488 BM21 transformed cell line human CVCL_E488 HLA typing: A*01:01:01:01; B*41:01:01; C*17:01:01:05; DPA1*02:01; DPB1*10:01:01; DQA1*05:05; DQB1*03:01:01; DRA*01:01; DRB1*11:01:01; DRB3*02:02 (IPD-IMGT/HLA=10322) CL:0000010 Population: Caucasian; German/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166539 CVCL_DS88 GM15880 transformed cell line human CVCL_DS88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166540 CVCL_E489 BM9 transformed cell line human CVCL_E489 HLA typing: A*02:01:01:01; B*35:01:01:06; C*04:01:01:01; DPA1*01:03:01:01; DPB1*02:01:04; DQA1*04:01:01; DQB1*04:02:01; DRA*01:02; DRB1*08:01:01/08:77 (IPD-IMGT/HLA=11619) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166541 CVCL_DS89 GM16002 transformed cell line human CVCL_DS89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166542 CVCL_E486 BM15 transformed cell line human CVCL_E486 HLA typing: A*01:01:01:01; B*49:01:01:02; C*07:01:01:01; DPA1*01; DPB1*104:01; DQA1*05:05; DQB1*03:19:01; DRA*01:01; DRB1*11:02:01; DRB3*02:02:01 (IPD-IMGT/HLA=11621) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166543 CVCL_DS86 GM14389 transformed cell line human CVCL_DS86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166544 CVCL_E487 BM16 transformed cell line human CVCL_E487 HLA typing: A*02:01:01:01; B*18:01:01:02; C*07:01:01:01; DPA1*01:03; DPB1*02:01:02/02:01:19; DQA1*05:05:01:01; DQB1*03:01:01; DRA*01:02; DRB1*12:01:01/12:10; DRB3*02:02 (IPD-IMGT/HLA=10321) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166545 CVCL_DS87 GM14483 transformed cell line human CVCL_DS87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166546 CVCL_E480 BGE transformed cell line human CVCL_E480 HLA typing: A*01:01:01:01,02:01:01:01; B*52:01:01:01; C*12:02:02:01; DPB1*04:01:01; DQB1*06:01:01/06:01:15; DRB1*15:02:01; DRB5*01:02 (IPD-IMGT/HLA=10314) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166547 CVCL_DS80 GM14383 transformed cell line human CVCL_DS80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166548 CVCL_E481 BH transformed cell line human CVCL_E481 HLA typing: A*02:01:01:01; B*13:02:01; C*06:02:01:01; DPA1*01,02; DPB1*04:01:01,17:01; DQA1*02:01; DQB1*02:02:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11617) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166549 CVCL_DS81 GM14384 transformed cell line human CVCL_DS81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166550 CVCL_MM18 BayGenomics ES cell line RHA046 embryonic stem cell house mouse CVCL_MM18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109634; Terf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166551 CVCL_E484 BJO,PA transformed cell line human CVCL_E484 HLA typing: A*02; B*35,60; C*04:01; DPB1*03:01; DQA1*03,04:01; DQB1*03:01,04:02; DRB1*04:07,08:01; DRB4*01:01 (IPD-IMGT/HLA=11661) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166552 CVCL_DS84 GM14387 transformed cell line human CVCL_DS84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166553 CVCL_MM19 BayGenomics ES cell line RHA051 embryonic stem cell house mouse CVCL_MM19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99537; Rabggtb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166554 CVCL_E485 BM14 transformed cell line human CVCL_E485 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:01:01; DQA1*03; DQB1*03:02:01; DRA*01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11620) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166555 CVCL_DS85 GM14388 transformed cell line human CVCL_DS85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166556 CVCL_MM16 BayGenomics ES cell line RHA043 embryonic stem cell house mouse CVCL_MM16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99207; Zfp60 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166557 CVCL_E482 BIN40 transformed cell line human CVCL_E482 HLA typing: A*02:01:01,31:01:02; B*14:01,40:01:01; C*03:04:01/03:01,08:02; DPA1*01:03; DPB1*03:01:01,06:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:04 (IPD-IMGT/HLA=10316) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166558 CVCL_DS82 GM14385 transformed cell line human CVCL_DS82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166559 CVCL_MM17 BayGenomics ES cell line RHA044 embryonic stem cell house mouse CVCL_MM17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913446; Myo19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166560 CVCL_E483 BJ [Human B-cell] transformed cell line human CVCL_E483 HLA typing: A*69:01,30:01; B*42:01,35:08; C*17:01,12:03; DPB1*01:01:01,02:01:02 (IPD-IMGT/HLA=10317) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166561 CVCL_DS83 GM14386 transformed cell line human CVCL_DS83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166562 CVCL_MM14 BayGenomics ES cell line RHA040 embryonic stem cell house mouse CVCL_MM14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346869; Map2k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166563 CVCL_MM15 BayGenomics ES cell line RHA041 embryonic stem cell house mouse CVCL_MM15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926162; Sp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166564 CVCL_MM12 BayGenomics ES cell line RHA035 embryonic stem cell house mouse CVCL_MM12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135637; Park7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166565 CVCL_MM13 BayGenomics ES cell line RHA037 embryonic stem cell house mouse CVCL_MM13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166566 CVCL_MM10 BayGenomics ES cell line RHA031 embryonic stem cell house mouse CVCL_MM10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166567 CVCL_MM11 BayGenomics ES cell line RHA034 embryonic stem cell house mouse CVCL_MM11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922662; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166568 CVCL_E499 BRO,ML transformed cell line human CVCL_E499 HLA typing: A*01,29; B*44,58:01; C*07,16:01; DPB1*01:01:01,04:01; DQA1*05:01; DQB1*02:01,03:01; DRB1*03:01,13:03; DRB3*01:01 (IPD-IMGT/HLA=11742) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166569 CVCL_DS99 ND00204 transformed cell line human CVCL_DS99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166570 CVCL_E497 BRIP transformed cell line human CVCL_E497 HLA typing: A*24:02:01:01; B*51:01:01:01,15:17:01:01; C*07:01:02,15:04:01; DPB1*02:01:02/02:01:19,04:02:01; DQA1*05:01; DQB1*03:01:01; DRB1*11:01:01; DRB3*02:02 (IPD-IMGT/HLA=11623) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166571 CVCL_DS97 GM17493 finite cell line human CVCL_DS97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166572 CVCL_E498 BRO,LJ transformed cell line human CVCL_E498 HLA typing: A*02,29; B*44,50; C*06,16:01; DPB1*01:01:01,02:01:02; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*01:01 (IPD-IMGT/HLA=11712) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166573 CVCL_DS98 GM20613 finite cell line human CVCL_DS98 CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Fibroblast.. Male 21166574 CVCL_E491 BOB transformed cell line human CVCL_E491 HLA typing: A*24:03:01:01; B*51:01:01:01; C*15:02:01:01; DPA1*01; DPB1*04:02:01; DQA1*05:05; DQB1*03:01:01; DRA*01:01; DRB1*11:04:01; DRB3*02:02 (IPD-IMGT/HLA=11622) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166575 CVCL_DS91 GM16627 finite cell line human CVCL_DS91 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21166576 CVCL_E492 BOLETH transformed cell line human CVCL_E492 HLA typing: A*02:01:01:01; B*15:01:01:01; C*03:04:01:01; DPA1*01:03:01; DPB1*04:01:01; DQA1*03:01:01; DQB1*03:02:01; DRA*01:01; DRB1*04:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=10329) CL:0000010 Population: Caucasian; Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166577 CVCL_DS92 GM16784 transformed cell line human CVCL_DS92 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166578 CVCL_E490 BM92 transformed cell line human CVCL_E490 HLA typing: A*25:01:01; B*51:01:01:01; C*01:02:01; DPA1*01:03; DPB1*04:02:01; DQA1*03:01; DQB1*03:02:01; DRA*01:01; DRB1*04:04:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=10326) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166579 CVCL_DS90 GM16003 transformed cell line human CVCL_DS90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166580 CVCL_MM29 BayGenomics ES cell line RHA065 embryonic stem cell house mouse CVCL_MM29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104816; Hnrnpl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166581 CVCL_E495 BOW,MF transformed cell line human CVCL_E495 HLA typing: A*02; B*44,50; C*05; DPB1*04:01,04:02; DQA1*02:01,03; DQB1*03:01,02:01; DRB1*04:01,07; DRB4*01:01 (IPD-IMGT/HLA=11693) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166582 CVCL_DS95 GM16789 transformed cell line human CVCL_DS95 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166583 CVCL_E496 BPot transformed cell line human CVCL_E496 HLA typing: A*02:01:01:01; B*07:03,15:01:01:01; C*03:03:01,03:04:01:01; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*01:02:01:01,01:03:01:02; DQB1*06:02:01,06:03:01; DRB1*13:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (IPD-IMGT/HLA=10338) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21166584 CVCL_DS96 GM17488 finite cell line human CVCL_DS96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166585 CVCL_MM27 BayGenomics ES cell line RHA062 embryonic stem cell house mouse CVCL_MM27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922434; Camsap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166586 CVCL_E493 BON transformed cell line human CVCL_E493 HLA typing: A*01,03; B*44:03:01,35; C*16:01,04; DQA1*01:01; DRB1*01:03 (IPD-IMGT/HLA=10330) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166587 CVCL_DS93 GM16785 transformed cell line human CVCL_DS93 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166588 CVCL_MM28 BayGenomics ES cell line RHA064 embryonic stem cell house mouse CVCL_MM28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166589 CVCL_E494 BONA transformed cell line human CVCL_E494 HLA typing: A*02,03; B*51; DPB1*04:01,03:01; DQA1*05:01,01:02; DQB1*03:01,05:02; DRB1*11:01,16:04; DRB3*02; DRB5*02; DRB6*02:02 (IPD-IMGT/HLA=10331) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166590 CVCL_DS94 GM16788 transformed cell line human CVCL_DS94 CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166591 CVCL_MM25 BayGenomics ES cell line RHA059 embryonic stem cell house mouse CVCL_MM25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919563; Fryl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166592 CVCL_MM26 BayGenomics ES cell line RHA061 embryonic stem cell house mouse CVCL_MM26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95288; Eef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166593 CVCL_MM23 BayGenomics ES cell line RHA055 embryonic stem cell house mouse CVCL_MM23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893579; Khdrbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166594 CVCL_MM24 BayGenomics ES cell line RHA056 embryonic stem cell house mouse CVCL_MM24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928741; Ranbp9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166595 CVCL_MM21 BayGenomics ES cell line RHA053 embryonic stem cell house mouse CVCL_MM21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166596 CVCL_MM22 BayGenomics ES cell line RHA054 embryonic stem cell house mouse CVCL_MM22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166597 CVCL_MM20 BayGenomics ES cell line RHA052 embryonic stem cell house mouse CVCL_MM20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328362; Blm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166598 CVCL_3A56 HQ00057 transformed cell line human CVCL_3A56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166599 CVCL_3A57 HQ00058 transformed cell line human CVCL_3A57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166600 CVCL_3A54 HQ00055 transformed cell line human CVCL_3A54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00055; probable Male 21166601 CVCL_3A55 HQ00056 transformed cell line human CVCL_3A55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00056; probable Female 21166602 CVCL_3A58 HQ00059 transformed cell line human CVCL_3A58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00059; probable Male 21166603 CVCL_3A59 HQ00060 transformed cell line human CVCL_3A59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166604 CVCL_3A52 HQ00053 transformed cell line human CVCL_3A52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166605 CVCL_3A53 HQ00054 transformed cell line human CVCL_3A53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166606 CVCL_3A50 HQ00051 transformed cell line human CVCL_3A50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166607 CVCL_3A51 HQ00052 transformed cell line human CVCL_3A51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166608 CVCL_3A67 HQ00068 transformed cell line human CVCL_3A67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166609 CVCL_3A68 HQ00069 transformed cell line human CVCL_3A68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166610 CVCL_3A65 HQ00066 transformed cell line human CVCL_3A65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166611 CVCL_3A66 HQ00067 transformed cell line human CVCL_3A66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166612 CVCL_3A69 HQ00070 transformed cell line human CVCL_3A69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166613 CVCL_VG90 MM-1 [Mouse spleen] spontaneously immortalized cell line house mouse CVCL_VG90 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C3H. Unspecified 21166614 CVCL_VG93 HAL-24 cancer cell line human CVCL_VG93 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Non-metastatic 21166615 CVCL_VG94 HAL-33 cancer cell line human CVCL_VG94 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Low metastatic potential 21166616 CVCL_VG91 MM-2 spontaneously immortalized cell line house mouse CVCL_VG91 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C3H. Unspecified 21166617 CVCL_VG92 MM-3 spontaneously immortalized cell line house mouse CVCL_VG92 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C3H. Unspecified 21166618 CVCL_VG97 HAL-8Luc cancer cell line human CVCL_VG97 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Lung. Male Characteristics: High metastatic potential 21166619 CVCL_VG98 S194 cancer cell line house mouse CVCL_VG98 CL:0000010 Breed/subspecies: BALB/c. 21166620 CVCL_VG95 HAL-8 cancer cell line human CVCL_VG95 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Characteristics: High metastatic potential 21166621 CVCL_VG96 HAL-24Luc cancer cell line human CVCL_VG96 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Non-metastatic 21166622 CVCL_VG99 (L)PC6 cancer cell line human CVCL_VG99 CL:0000010 Derived from sampling site: Lung. Unspecified 21166623 CVCL_3A60 HQ00061 transformed cell line human CVCL_3A60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166624 CVCL_3A63 HQ00064 transformed cell line human CVCL_3A63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166625 CVCL_3A64 HQ00065 transformed cell line human CVCL_3A64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166626 CVCL_3A61 HQ00062 transformed cell line human CVCL_3A61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166627 CVCL_3A62 HQ00063 transformed cell line human CVCL_3A62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166628 CVCL_3A34 HQ00035 transformed cell line human CVCL_3A34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166629 CVCL_3A35 HQ00036 transformed cell line human CVCL_3A35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166630 CVCL_3A32 HQ00033 transformed cell line human CVCL_3A32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166631 CVCL_3A33 HQ00034 transformed cell line human CVCL_3A33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166632 CVCL_3A38 HQ00039 transformed cell line human CVCL_3A38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166633 CVCL_3A39 HQ00040 transformed cell line human CVCL_3A39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166634 CVCL_3A36 HQ00037 transformed cell line human CVCL_3A36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166635 CVCL_3A37 HQ00038 transformed cell line human CVCL_3A37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166636 CVCL_VG82 MRC-1 finite cell line human CVCL_VG82 CL:0000010 Derived from sampling site: Fetal lung. Unspecified Senescence: Senesces at 50 +- 10 PDL (PubMed=5956336) 21166637 CVCL_VG83 12C6 hybridoma house mouse CVCL_VG83 CL:0000010 Discontinued: ATCC; HB-173; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human endothelial cells 21166638 CVCL_VG80 NHBL2 cancer cell line human CVCL_VG80 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male Doubling time: 27 hours (PubMed=29435697) 21166639 CVCL_VG81 NT-3 cancer cell line human CVCL_VG81 CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Thr541Ala (c.1621A>G); ClinVar=VCV000134640; Zygosity=Homozygous; Note=Probable SNP (PubMed=29330294) Derived from metastatic site: Lymph node. Male Doubling time: 10.9 +- 0.7 days (PubMed=29330294) 21166640 CVCL_VG86 KKNS-1 cancer cell line human CVCL_VG86 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~35 hours (PubMed=3171271) 21166641 CVCL_VG87 KKNS-2 cancer cell line human CVCL_VG87 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~60 hours (PubMed=3171271) 21166642 CVCL_VG84 U-M cancer cell line human CVCL_VG84 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Characteristics: Obtained by treatment of parent cell line with TPA in eRDF medium 21166643 CVCL_VG85 HIHCNi001-A induced pluripotent stem cell human CVCL_VG85 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11427; STUB1; Simple; p.Arg119Ter (c.355C>T); Zygosity=Heterozygous (PubMed=29679845); Sequence variation: Mutation; HGNC; 11427; STUB1; Simple; p.Ile294Phe (c.880A>T); Zygosity=Heterozygous (PubMed=29679845) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166644 CVCL_VG88 KKNS-3 cancer cell line human CVCL_VG88 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~28 hours (PubMed=3171271) 21166645 CVCL_VG89 TAK-N cancer cell line human CVCL_VG89 CL:0000010 Population: Japanese. 21166646 CVCL_3A30 HQ00031 transformed cell line human CVCL_3A30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166647 CVCL_3A31 HQ00032 transformed cell line human CVCL_3A31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166648 CVCL_3A45 HQ00046 transformed cell line human CVCL_3A45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166649 CVCL_3A46 HQ00047 transformed cell line human CVCL_3A46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166650 CVCL_3A43 HQ00044 transformed cell line human CVCL_3A43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166651 CVCL_3A44 HQ00045 transformed cell line human CVCL_3A44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166652 CVCL_3A49 HQ00050 transformed cell line human CVCL_3A49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166653 CVCL_3A47 HQ00048 transformed cell line human CVCL_3A47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166654 CVCL_3A48 HQ00049 transformed cell line human CVCL_3A48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166655 CVCL_VG71 CGBC 01 cancer cell line human CVCL_VG71 CL:0000010 Population: Chinese; Han in Taiwan; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female Characteristics: ER/PR-positive and ERBB2-negative Doubling time: 30.68 hours (PubMed=29484537) 21166656 CVCL_VG72 CGBC 02 cancer cell line human CVCL_VG72 CL:0000010 Population: Chinese; Han in Taiwan; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female Characteristics: ER/PR-positive and ERBB2-negative Doubling time: 52.34 hours (PubMed=29484537) 21166657 CVCL_VG70 NCC-SS1-C1 cancer cell line human CVCL_VG70 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=29450702) Population: Japanese Omics: Deep proteome analysis. Female Doubling time: 41 hours (PubMed=29450702) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21166658 CVCL_VG75 ELGSN spontaneously immortalized cell line CVCL_VG75 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21166659 CVCL_VG76 ELGSNe spontaneously immortalized cell line CVCL_VG76 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21166660 CVCL_VG73 OnlB spontaneously immortalized cell line CVCL_VG73 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line 21166661 CVCL_VG74 OnlL spontaneously immortalized cell line CVCL_VG74 CL:0000010 Derived from sampling site: Liver. Unspecified Virology: Susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC052 21166662 CVCL_VG79 TOCF spontaneously immortalized cell line CVCL_VG79 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Virology: Susceptible to infection by Singapore grouper iridovirus (SGIV) (PubMed=29691845) Group: Fish cell line 21166663 CVCL_VG77 ELGSNf spontaneously immortalized cell line CVCL_VG77 CL:0000010 Derived from sampling site: Snout. Unspecified Group: Fish cell line 21166664 CVCL_VG78 PAM-pCD163 transformed cell line pig CVCL_VG78 CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus type 1 and type 2 (PRRSV-1/2) 21166665 CVCL_3A41 HQ00042 transformed cell line human CVCL_3A41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166666 CVCL_3A42 HQ00043 transformed cell line human CVCL_3A42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166667 CVCL_3A40 HQ00041 transformed cell line human CVCL_3A40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166668 CVCL_3A12 HQ00013 transformed cell line human CVCL_3A12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166669 CVCL_3A13 HQ00014 transformed cell line human CVCL_3A13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166670 CVCL_3A10 HQ00011 transformed cell line human CVCL_3A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166671 CVCL_3A11 HQ00012 transformed cell line human CVCL_3A11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166672 CVCL_3A16 HQ00017 transformed cell line human CVCL_3A16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166673 CVCL_3A17 HQ00018 transformed cell line human CVCL_3A17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166674 CVCL_3A14 HQ00015 transformed cell line human CVCL_3A14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166675 CVCL_3A15 HQ00016 transformed cell line human CVCL_3A15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166676 CVCL_3A18 HQ00019 transformed cell line human CVCL_3A18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166677 CVCL_3A19 HQ00020 transformed cell line human CVCL_3A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166678 CVCL_VG60 744 telomerase immortalized cell line human CVCL_VG60 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Arg959Trp (c.2875C>T) (p.Arg977Trp, c.2929C>T); ClinVar=VCV000284254; Zygosity=Heterozygous (Jain Foundation); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Trp1869Ter (c.5606G>A) (p.Trp1908Ter, c.5724G>A); ClinVar=VCV000571837; Zygosity=Heterozygous (Jain Foundation); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Triceps brachii Cell type=Myoblast.. Male 21166679 CVCL_VG61 AB320LGMD2B29Q telomerase immortalized cell line human CVCL_VG61 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.342-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (Jain Foundation); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Phe1172_Ser1173insTer (c.3516_3517delTT) (p.Ser1173Terfs) (p.Phe1190_Ser1191insTer, c.3570_3571del); ClinVar=VCV000217226; Zygosity=Heterozygous (Jain Foundation); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Quadriceps skeletal muscle Cell type=Myoblast.. Female 21166680 CVCL_VG64 MMF-2 cancer cell line human CVCL_VG64 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male 21166681 CVCL_VG65 MMF-3 cancer cell line human CVCL_VG65 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Male 21166682 CVCL_VG62 ER telomerase immortalized cell line human CVCL_VG62 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Gly1628Arg (c.4882G>A) (p.Gly1667Val, c.5000G>T); ClinVar=VCV000658470; Zygosity=Homozygous (Jain Foundation); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Quadriceps skeletal muscle Cell type=Myoblast.. Male 21166683 CVCL_VG63 RB [Human LGMD2B myoblast] telomerase immortalized cell line human CVCL_VG63 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Glu1833Ter (c.5497G>T) (p.Glu1872Ter, c.5614G>T); ClinVar=VCV000094339; Zygosity=Heterozygous (Jain Foundation); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.6063+1G>A (c.5946+1G>A); ClinVar=VCV000094349; Zygosity=Heterozygous; Note=Splice donor mutation (Jain Foundation); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Forearm; muscle Cell type=Myoblast.. Male 21166684 CVCL_VG68 hTERT-BMSC clone Y201 telomerase immortalized cell line human CVCL_VG68 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow Cell type=Stromal cell.. Omics: Transcriptome analysis by microarray Unspecified 21166685 CVCL_VG69 hTERT-BMSC clone Y202 telomerase immortalized cell line human CVCL_VG69 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow Cell type=Stromal cell.. Omics: Transcriptome analysis by microarray Unspecified 21166686 CVCL_VG66 hTERT-BMSC clone Y101 telomerase immortalized cell line human CVCL_VG66 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow Cell type=Stromal cell.. Omics: Transcriptome analysis by microarray Unspecified 21166687 CVCL_VG67 hTERT-BMSC clone Y102 telomerase immortalized cell line human CVCL_VG67 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Bone marrow Cell type=Stromal cell.. Omics: Transcriptome analysis by microarray Unspecified 21166688 CVCL_3A23 HQ00024 transformed cell line human CVCL_3A23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166689 CVCL_3A24 HQ00025 transformed cell line human CVCL_3A24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166690 CVCL_3A21 HQ00022 transformed cell line human CVCL_3A21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166691 CVCL_3A22 HQ00023 transformed cell line human CVCL_3A22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166692 CVCL_3A27 HQ00028 transformed cell line human CVCL_3A27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166693 CVCL_3A28 HQ00029 transformed cell line human CVCL_3A28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166694 CVCL_3A25 HQ00026 transformed cell line human CVCL_3A25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166695 CVCL_3A26 HQ00027 transformed cell line human CVCL_3A26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166696 CVCL_3A29 HQ00030 transformed cell line human CVCL_3A29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166697 CVCL_VG50 TUBA1A-iPS-A#1 induced pluripotent stem cell human CVCL_VG50 CL:0000010 Sequence variation: Mutation; HGNC; 20766; TUBA1A; Simple; p.Asn329Ser (c.986A>G); ClinVar=VCV000160167; Zygosity=Heterozygous (PubMed=27431206) Derived from sampling site: Umbilical cord Cell type=Stromal cell.. Male 21166698 CVCL_VG53 TUBA1A-iPS-B#2 induced pluripotent stem cell human CVCL_VG53 CL:0000010 Sequence variation: Mutation; HGNC; 20766; TUBA1A; Simple; p.Arg264Cys (c.790C>T); ClinVar=VCV000007070; Zygosity=Heterozygous (PubMed=27431206) Derived from sampling site: Peripheral blood. Male 21166699 CVCL_VG54 ONH-UCCiPS1#1 induced pluripotent stem cell human CVCL_VG54 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Stromal cell.. Male 21166700 CVCL_VG51 TUBA1A-iPS-A#3 induced pluripotent stem cell human CVCL_VG51 CL:0000010 Sequence variation: Mutation; HGNC; 20766; TUBA1A; Simple; p.Asn329Ser (c.986A>G); ClinVar=VCV000160167; Zygosity=Heterozygous (PubMed=27431206) Derived from sampling site: Umbilical cord Cell type=Stromal cell.. Male 21166701 CVCL_VG52 TUBA1A-iPS-B#1 induced pluripotent stem cell human CVCL_VG52 CL:0000010 Sequence variation: Mutation; HGNC; 20766; TUBA1A; Simple; p.Arg264Cys (c.790C>T); ClinVar=VCV000007070; Zygosity=Heterozygous (PubMed=27431206) Derived from sampling site: Peripheral blood. Male 21166702 CVCL_VG57 DYSF2 telomerase immortalized cell line human CVCL_VG57 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.951+1delG (c.855+1delG); ClinVar=VCV000006684; Zygosity=Heterozygous; Note=Causes mRNA decay (PubMed=22367358); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Gly299Arg (c.895G>A) (p.Gly331Arg, c.991G>A); ClinVar=VCV000006681; Zygosity=Heterozygous (PubMed=22367358); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Male 21166703 CVCL_VG58 DYSF3 telomerase immortalized cell line human CVCL_VG58 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.*107T>A; ClinVar=VCV000290170; Zygosity=Heterozygous; Note=3'UTR mutation (PubMed=22367358); Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Ser483Ter (c.1448C>A) (p.Ser515Ter, c.1544C>A); ClinVar=VCV000554057; Zygosity=Heterozygous (PubMed=22367358); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Female 21166704 CVCL_VG55 BIOi001-A induced pluripotent stem cell human CVCL_VG55 From: Beijing Institute of Ophthalmology; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Urine. Male 21166705 CVCL_VG56 DYSF1 telomerase immortalized cell line human CVCL_VG56 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; p.Leu1341Pro (c.4022T>C) (p.Leu1359Pro, c.4076T>C); ClinVar=VCV000555968; Zygosity=Homozygous (PubMed=22367358); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Unspecified 21166706 CVCL_VG59 DYSF4 telomerase immortalized cell line human CVCL_VG59 CL:0000010 Sequence variation: Mutation; HGNC; 3097; DYSF; Simple; c.2864+2T>A (c.2810+2T>A); ClinVar=VCV000498750; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=22367358); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT Derived from sampling site: Triceps brachii Cell type=Myoblast.. Female 21166707 CVCL_3A20 HQ00021 transformed cell line human CVCL_3A20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166708 CVCL_VG42 MGC-803/PTX cancer cell line human CVCL_VG42 CL:0000010 Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol). Male Doubling time: 24.55 hours (PubMed=29683800) Problematic cell line: Possibly contaminated Parent cell lines (MGC-803) seems to be a derivative of HeLa and another cell of unknown origin. The STR profile of MGC-803 is highly similar to that of HeLa yet shows some specific differences that suggest a possible hybrid cell line. 21166709 CVCL_VG43 YUMC44 cancer cell line human CVCL_VG43 CL:0000010 Population: Japanese. Male 21166710 CVCL_VG40 HMMA2.5 hybrid cell line CVCL_VG40 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line 21166711 CVCL_VG41 MARC-145 pig CD163 spontaneously immortalized cell line CVCL_VG41 CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163 Derived from sampling site: Fetal kidney. Unspecified Virology: Compared to the parent cell line, has increased susceptibility to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Non-human primate cell line Problematic cell line: Misidentified Grand-parent cell line (MA-104) has been shown to be from Chlorocebus pygerythrus instead of Rhesus macaque. 21166712 CVCL_VG46 YUMC8 cancer cell line human CVCL_VG46 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21166713 CVCL_VG47 T0033 transformed cell line human CVCL_VG47 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Male Doubling time: 30-40 hours (ABM) 21166714 CVCL_VG44 YUMC63 cancer cell line human CVCL_VG44 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21166715 CVCL_VG45 YUMC64 cancer cell line human CVCL_VG45 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21166716 CVCL_VG48 T0034 transformed cell line human CVCL_VG48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skeletal muscle. Male Doubling time: 30-40 hours (ABM) 21166717 CVCL_VG49 FRTL-5 Miami spontaneously immortalized cell line Norway rat CVCL_VG49 CL:0000010 Karyotypic information: Near tetraploid karyotype; Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Unspecified 21166718 CVCL_MM98 BayGenomics ES cell line RRA008 embryonic stem cell house mouse CVCL_MM98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166719 CVCL_MM99 BayGenomics ES cell line RRA010 embryonic stem cell house mouse CVCL_MM99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166720 CVCL_MM96 BayGenomics ES cell line RRA005 embryonic stem cell house mouse CVCL_MM96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915434; Denr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166721 CVCL_MM97 BayGenomics ES cell line RRA006 embryonic stem cell house mouse CVCL_MM97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914410; Eef1g Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166722 CVCL_3A01 HQ00002 transformed cell line human CVCL_3A01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166723 CVCL_3A02 HQ00003 transformed cell line human CVCL_3A02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166724 CVCL_3A00 HQ00001 transformed cell line human CVCL_3A00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166725 CVCL_3A05 HQ00006 transformed cell line human CVCL_3A05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166726 CVCL_3A06 HQ00007 transformed cell line human CVCL_3A06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166727 CVCL_3A03 HQ00004 transformed cell line human CVCL_3A03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166728 CVCL_3A04 HQ00005 transformed cell line human CVCL_3A04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166729 CVCL_3A09 HQ00010 transformed cell line human CVCL_3A09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166730 CVCL_3A07 HQ00008 transformed cell line human CVCL_3A07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166731 CVCL_3A08 HQ00009 transformed cell line human CVCL_3A08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166732 CVCL_VG31 0162D induced pluripotent stem cell human CVCL_VG31 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166733 CVCL_VG32 0165D induced pluripotent stem cell human CVCL_VG32 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21166734 CVCL_VG30 110119B induced pluripotent stem cell human CVCL_VG30 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21166735 CVCL_VG35 PETCAT 3 spontaneously immortalized cell line CVCL_VG35 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified Doubling time: 49 hours (CelloPub=CLPUB00429) 21166736 CVCL_VG36 PETCAT 4 spontaneously immortalized cell line CVCL_VG36 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Mixed breed. Male Doubling time: 33 hours (CelloPub=CLPUB00429) 21166737 CVCL_VG33 PETCAT 1 spontaneously immortalized cell line CVCL_VG33 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Persian. Female Doubling time: 34 hours (CelloPub=CLPUB00429) 21166738 CVCL_VG34 PETCAT 2 spontaneously immortalized cell line CVCL_VG34 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified Doubling time: 72 hours (CelloPub=CLPUB00429) 21166739 CVCL_VG39 HMMA2.11TG/0 hybrid cell line CVCL_VG39 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Group: Hybridoma fusion partner cell line 21166740 CVCL_VG37 ROMCAT spontaneously immortalized cell line CVCL_VG37 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 21166741 CVCL_VG38 SPYMEG hybrid cell line CVCL_VG38 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10761 21166742 CVCL_VF90 CNTL2 induced pluripotent stem cell human CVCL_VF90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166743 CVCL_VF91 CNTL3 induced pluripotent stem cell human CVCL_VF91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166744 CVCL_VF94 PCA-5 cancer cell line human CVCL_VF94 CL:0000010 Population: African; Ugandan; Derived from sampling site: Penis. Male 21166745 CVCL_VF95 Penl2 cancer cell line human CVCL_VF95 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ser1613Gly (c.4837A>G); ClinVar=VCV000041827; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Arg922Gln (c.2765G>A); ClinVar=VCV000410514; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=29880898) Population: Chinese; Derived from metastatic site: Lymph node. Omics: Genome sequenced Male Doubling time: 28.38 hours (PubMed=29880898) 21166746 CVCL_VF92 EGPE spontaneously immortalized cell line CVCL_VF92 CL:0000010 Unspecified 21166747 CVCL_VF93 Penl1 cancer cell line human CVCL_VF93 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=27351128; PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg283Pro (c.848G>C); ClinVar=VCV000486555; Zygosity=Unspecified (PubMed=27351128; PubMed=29880898) Population: Chinese; Derived from metastatic site: Lymph node. Omics: Genome sequenced Male Doubling time: ~27 hours (PubMed=27351128); 28.16 hours (PubMed=29880898) 21166748 CVCL_VF98 KKU-023 cancer cell line human CVCL_VF98 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=29110582) Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Female Doubling time: 34.8 hours (PubMed=29110582) 21166749 CVCL_VF99 KKU-452 cancer cell line human CVCL_VF99 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=29110582); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu349Ter (c.1045G>T); ClinVar=VCV000634695; Zygosity=Unspecified (PubMed=29110582) Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Female Doubling time: 17.9 hours (PubMed=29110582) 21166750 CVCL_VF96 149RCa cancer cell line human CVCL_VF96 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Ser25Ter (c.74C>G); Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Val (c.38G>T); ClinVar=VCV000180848; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=29880898) Population: Chinese; Derived from metastatic site: Penis. Omics: Genome sequenced Male Doubling time: 26.75 hours (PubMed=29880898) 21166751 CVCL_VF97 HCC21 cancer cell line human CVCL_VF97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Arg (c.796G>C); ClinVar=VCV000376605; Zygosity=Unspecified (PubMed=25349534) Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Female Doubling time: ~95 hours (PubMed=25349534) 21166752 CVCL_E466 AZH transformed cell line human CVCL_E466 HLA typing: A*24; B*56; C*01; DPB1*03:01; DQA1*01:02:01; DQB1*05:02:01; DRB1*16:01:01; DRB5*02:02 (IPD-IMGT/HLA=10278) CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166753 CVCL_DS66 GM14353 transformed cell line human CVCL_DS66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166754 CVCL_E467 BAI,FL transformed cell line human CVCL_E467 HLA typing: A*01,02; B*08,15; DPB1*02:01,04:01; DQA1*02:01,03; DQB1*02:01,03:01; DRB1*04:01,03:01; DRB4*01:01 (IPD-IMGT/HLA=11709) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082266; probable Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166755 CVCL_DS67 GM14354 transformed cell line human CVCL_DS67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166756 CVCL_E464 AVL transformed cell line human CVCL_E464 HLA typing: A*01; B*08; C*07 (PubMed=6417008); HLA typing: DRB1*03:01:01:01; DRB2*01:01; DRB3*01:01:02:01 (IPD-IMGT/HLA=10275) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel Caution: Indicated as originating from a female in Coriell and from a male in IPD-IMGT/HLA 21166757 CVCL_DS64 GM14351 transformed cell line human CVCL_DS64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166758 CVCL_E465 AWELLS transformed cell line human CVCL_E465 HLA typing: A*02:01:01:01; B*44:02:01:01; C*05:01:01:02; DPB1*04:01:01,14:01:01; DQA1*03; DQB1*03:01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11615) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166759 CVCL_DS65 GM14352 transformed cell line human CVCL_DS65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166760 CVCL_E468 BAI,JE transformed cell line human CVCL_E468 HLA typing: A*01,02; B*44:02; C*05,07; DPB1*03:01,04:01; DQA1*03; DQB1*03:01,03:02; DRB1*04:01; DRB4*01:01 (IPD-IMGT/HLA=11710) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166761 CVCL_DS68 GM14358 transformed cell line human CVCL_DS68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166762 CVCL_E469 BAI,NJ transformed cell line human CVCL_E469 HLA typing: A*01,02; B*08,15; C*03,07; DPB1*03:01,04:01; DQA1*03; DQB1*03:02; DRB1*04:01; DRB4*01:01 (IPD-IMGT/HLA=11711) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166763 CVCL_DS69 GM14359 transformed cell line human CVCL_DS69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166764 CVCL_E462 AT transformed cell line human CVCL_E462 HLA typing: A*02:06; B*59:01,51:01; C*01:02,14; DPB1*02:01:02 (IPD-IMGT/HLA=10268) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166765 CVCL_DS62 GM14349 transformed cell line human CVCL_DS62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166766 CVCL_E463 AVE,G transformed cell line human CVCL_E463 HLA typing: A*02,31; B*27:05,40:01; C*02:02; DPB1*02:01:02,11:01:01; DQA1*05:01,02:01; DQB1*02:01,03:01; DRB1*07,11:01:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=10274) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166767 CVCL_DS63 GM14350 transformed cell line human CVCL_DS63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166768 CVCL_E460 ARBO transformed cell line human CVCL_E460 HLA typing: A*03:01:01:01; B*58:02:01; C*06:02:01:01; DPB1*13:01:01/107:01,04:01:01; DQB1*02:02:01,05:03:01; DRB1*09:01:02/09:21 (IPD-IMGT/HLA=11614) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166769 CVCL_DS60 GM14347 transformed cell line human CVCL_DS60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166770 CVCL_E461 ARNT transformed cell line human CVCL_E461 HLA typing: A*02; B*38,39; DPA1*01:03; DPB1*02:01,20:01:01; DQA1*01:03; DRB1*13:01; DRB3*01:01 (IPD-IMGT/HLA=10264) CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166771 CVCL_DS61 GM14348 transformed cell line human CVCL_DS61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166772 CVCL_E477 BEL7MON transformed cell line human CVCL_E477 HLA typing: A*02:01:01:01; B*44:02:01:03,51:01:01:01; C*07:674; DPA1*01:03:01:03; DPB1*03:01:01; DQA1*03:03:01,05:05:01:01; DQB1*03:01:01:01,03:01:01:03; DRB1*11:09,04:07:01; DRB3*02:02:01:02; DRB4*01:03:01:01 (IPD-IMGT/HLA=10308) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166773 CVCL_DS77 GM14373 transformed cell line human CVCL_DS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166774 CVCL_E478 BEL8-CC transformed cell line human CVCL_E478 HLA typing: A*02; B*07,44; C*05,07; DPA1*01:03:01; DPB1*02:01:02,20:01:01; DQA1*01:01; DQB1*05:01; DRB1*01:01,01:03 (IPD-IMGT/HLA=10309) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166775 CVCL_DS78 GM14374 transformed cell line human CVCL_DS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166776 CVCL_E475 BEL5GB transformed cell line human CVCL_E475 HLA typing: A*02:01:01:01,29:02:01:01; B*44:02:01:01,44:03:01:01; C*05:01:01:02,16:01:01:01; DPB1*02:01:02/02:01:19,04:01:01; DQA1*02:01:01:02,03:03; DQB1*02:02:01,03:01:01; DRB1*04:16,07:01:01; DRB4*01:01:01:01,01:03:01:01 (IPD-IMGT/HLA=10306) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166777 CVCL_DS75 GM14371 transformed cell line human CVCL_DS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166778 CVCL_E476 BEL6KG transformed cell line human CVCL_E476 HLA typing: A*02; B*44,49; C*05,07; DRB1*11:07,04; DRB3*02:02 (IPD-IMGT/HLA=10307) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166779 CVCL_DS76 GM14372 transformed cell line human CVCL_DS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166780 CVCL_E479 BER transformed cell line human CVCL_E479 HLA typing: A*02:01:01:01,02:01:01:08; B*13:02:01; C*06:02:01:01; DPA1*01; DPB1*04:01:01,02:01:02/02:01:19; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11616) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166781 CVCL_DS79 GM14375 transformed cell line human CVCL_DS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166782 CVCL_E470 BAT,J transformed cell line human CVCL_E470 HLA typing: A*02:01:01:01,31:01:02; B*40:01,44:02:01:01; C*05:01; DPB1*01:01:01,03:01; DQA1*01:01,03; DQB1*03:02,05:03; DRB1*04:04,14:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11660) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166783 CVCL_DS70 GM14360 transformed cell line human CVCL_DS70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166784 CVCL_MM09 BayGenomics ES cell line RHA026 embryonic stem cell house mouse CVCL_MM09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685830; Nsl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166785 CVCL_MM07 BayGenomics ES cell line RHA015 embryonic stem cell house mouse CVCL_MM07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916366; Ubr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166786 CVCL_E473 BEA,PL transformed cell line human CVCL_E473 HLA typing: A*02,29; B*44:03; C*03; DPA1*01:03:01,02:01:01; DPB1*04:01,10:01; DQA1*03:01,02:01; DQB1*02:02,03:02; DRB1*04:01,07; DRB4*01:01 (IPD-IMGT/HLA=11681) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166787 CVCL_DS73 GM14363 transformed cell line human CVCL_DS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166788 CVCL_MM08 BayGenomics ES cell line RHA025 embryonic stem cell house mouse CVCL_MM08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914182; Rexo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166789 CVCL_E474 BEI transformed cell line human CVCL_E474 HLA typing: A*02; B*57; C*06; DPB1*05:01,04:01; DQA1*02:01; DQB1*02:01:01 (IPD-IMGT/HLA=10304) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166790 CVCL_DS74 GM14364 transformed cell line human CVCL_DS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166791 CVCL_E471 BAU transformed cell line human CVCL_E471 HLA typing: B*44:02:01:01 (IPD-IMGT/HLA=10297) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21166792 CVCL_MM05 BayGenomics ES cell line RHA011 embryonic stem cell house mouse CVCL_MM05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166793 CVCL_DS71 GM14361 transformed cell line human CVCL_DS71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166794 CVCL_MM06 BayGenomics ES cell line RHA012 embryonic stem cell house mouse CVCL_MM06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918625; Foxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166795 CVCL_E472 BCK transformed cell line human CVCL_E472 HLA typing: A*02:01:01,32:01; B*27:08,15:01:01:01; C*06:02,03:04:01; DPB1*02:01:02,04:02; DQA1*01:02,05:01; DQB1*05:02,03:01; DRB1*11:01,15:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=10300) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166796 CVCL_DS72 GM14362 transformed cell line human CVCL_DS72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166797 CVCL_MM03 BayGenomics ES cell line RHA007 embryonic stem cell house mouse CVCL_MM03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103040; Rsu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166798 CVCL_MM04 BayGenomics ES cell line RHA008 embryonic stem cell house mouse CVCL_MM04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166799 CVCL_MM01 BayGenomics ES cell line RHA005 embryonic stem cell house mouse CVCL_MM01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917262; Cep85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166800 CVCL_MM02 BayGenomics ES cell line RHA006 embryonic stem cell house mouse CVCL_MM02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103040; Rsu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166801 CVCL_MM00 BayGenomics ES cell line RHA004 embryonic stem cell house mouse CVCL_MM00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166802 CVCL_E444 31708 transformed cell line human CVCL_E444 HLA typing: A*23:01,68:02; B*15:03,35; C*02:02,04:01 (IPD-IMGT/HLA=10132) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166803 CVCL_DS44 GM14281 transformed cell line human CVCL_DS44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166804 CVCL_E445 32/32 transformed cell line human CVCL_E445 HLA typing: A*29:02,30:02; B*78:01,57:02; C*16:01,18:01; DPB1*02:01:02,13:01 (IPD-IMGT/HLA=10134) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166805 CVCL_DS45 GM14282 transformed cell line human CVCL_DS45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166806 CVCL_E442 280599 transformed cell line human CVCL_E442 HLA typing: A*24:02:01:01,26:04; B*38:02:01,39:01:03; C*07:02:01:01; DPA1*01:03:01:01,02:02:02; DPB1*02:01:02,05:01:01; DQA1*01:02:01:01,03:02; DQB1*03:03:02:02,06:02:01; DRB1*09:01:02,15:01:01:02; DRB4*01:03:02; DRB5*01:01 (IPD-IMGT/HLA=25979) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21166807 CVCL_DS42 GM14279 transformed cell line human CVCL_DS42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166808 CVCL_E443 31227ABO transformed cell line human CVCL_E443 HLA typing: A*02:01:01:01; B*18:01:01:02; C*07:01:01:01; DPA1*01; DPB1*04:01:01; DQA1*01:04:01; DQB1*05:03:01; DRB1*14:54:01; DRB3*02:02 (IPD-IMGT/HLA=10131) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166809 CVCL_DS43 GM14280 transformed cell line human CVCL_DS43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166810 CVCL_E448 32511 transformed cell line human CVCL_E448 HLA typing: A*80:01,02:06; B*18:JV,27:ENN; C*02:02:02; DPB1*01:01:01,05:01; DQA1*01:03,01:04; DQB1*05:03:01,06:03; DRB1*13:01:01,14:54; DRB3*01:01,02:02 (IPD-IMGT/HLA=10137) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166811 CVCL_DS48 GM14287 transformed cell line human CVCL_DS48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166812 CVCL_E449 35020 transformed cell line human CVCL_E449 HLA typing: A*80:01,30:01; B*57:02; C*04; DPB1*01:01:01 (IPD-IMGT/HLA=10145) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166813 CVCL_DS49 GM14288 transformed cell line human CVCL_DS49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166814 CVCL_E446 32/37 transformed cell line human CVCL_E446 HLA typing: A*24:02:01:01,30:02; B*27:05:01/27:13,57:02:01; C*02:02,04:01; DPB1*02:01:02,04:02 (IPD-IMGT/HLA=10135) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94022519; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166815 CVCL_DS46 GM14283 transformed cell line human CVCL_DS46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166816 CVCL_E447 32367 transformed cell line human CVCL_E447 HLA typing: A*33:03,74:01; B*56:01,14:01; C*01:02,07:01; DPB1*04:02,16:01 (IPD-IMGT/HLA=10136) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166817 CVCL_DS47 GM14286 transformed cell line human CVCL_DS47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166818 CVCL_E440 26931 transformed cell line human CVCL_E440 HLA typing: A*68; B*15:03; C*02 (IPD-IMGT/HLA=10116) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166819 CVCL_DS40 GM14277 transformed cell line human CVCL_DS40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166820 CVCL_E441 2708 transformed cell line human CVCL_E441 HLA typing: DQA1*02:01,01:05; DQB1*02:01; DRB1*13:03:01; DRB3*01:01 (IPD-IMGT/HLA=10119) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071406; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166821 CVCL_DS41 GM14278 transformed cell line human CVCL_DS41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166822 CVCL_E455 AMAI transformed cell line human CVCL_E455 HLA typing: A*68:02:01:01; B*53:01:01; C*04:01:01:01; DPA1*03:01; DPB1*105:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:01; DRB1*15:03:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=10246) CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166823 CVCL_DS55 GM14300 transformed cell line human CVCL_DS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166824 CVCL_E456 AMALA transformed cell line human CVCL_E456 HLA typing: A*02:17:02; B*15:01:01:01; C*03:03:01:01; DPA1*01:03:01; DPB1*04:02:01; DQA1*05:01:01,05:03; DQB1*03:01:01; DRA*01:02; DRB1*14:02:01; DRB3*01:01 (IPD-IMGT/HLA=10247) CL:0000010 Population: Native South American; Warao; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21166825 CVCL_DS56 GM14301 transformed cell line human CVCL_DS56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166826 CVCL_E453 AKIBA transformed cell line human CVCL_E453 HLA typing: A*24:02:01:01; B*52:01:01:02; C*12:02:02:01; DPA1*02:01:01:01; DPB1*09:01:01; DQA1*01:03; DQB1*06:01:01/06:01:15; DRB1*15:02:01; DRB5*01:02; DRB6*02 (IPD-IMGT/HLA=10239) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166827 CVCL_DS53 GM14294 transformed cell line human CVCL_DS53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166828 CVCL_E454 AM transformed cell line human CVCL_E454 HLA typing: A*02:05,32:01:01; B*49:01,40:01; C*07:01,03:04; DPB1*02:01:02,04:01 (IPD-IMGT/HLA=10244) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94022521; probable Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166829 CVCL_DS54 GM14299 transformed cell line human CVCL_DS54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166830 CVCL_E459 APD transformed cell line human CVCL_E459 HLA typing: A*01:01:01:01; B*40:01:02:01; C*06:02:01:01; DPA1*01:03; DPB1*04:02:01; DQA1*01:03; DQB1*06:03:01; DRB1*13:01:01 (IPD-IMGT/HLA=10258); HLA typing: A*01:01:01:01; B*40:01:02; C*06:02:01:01; DPA1*01:03:01:05; DPB1*04:02:01:01; DQA1*01:03:01; DQB1*06:03:01; DRB1*13:01:01; DRB3*02:02:01:02 (PubMed=30844424) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166831 CVCL_DS59 GM14304 transformed cell line human CVCL_DS59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166832 CVCL_E457 AP transformed cell line human CVCL_E457 HLA typing: A*02:07,33:01; B*46,58:01; C*01:02:01,03:02:01; DPB1*04:01 (IPD-IMGT/HLA=10251) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166833 CVCL_DS57 GM14302 transformed cell line human CVCL_DS57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166834 CVCL_E458 APA transformed cell line human CVCL_E458 HLA typing: A*11:01:01:07,24:03:01:01; B*15:02:01,55:02:01:01; C*08:01:01,12:03:01:01; DPA1*02:02:02; DPB1*05:01:01; DQA1*01:01:01,01:02:01; DQB1*05:03:01,06:01:01/06:01:15; DRB1*14:05:01,15:01:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=10257) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166835 CVCL_DS58 GM14303 transformed cell line human CVCL_DS58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166836 CVCL_E451 591 [Human B-cell 12IHW] transformed cell line human CVCL_E451 HLA typing: A*11:01,31:01; B*39:01:03,67:01:01; C*07:02; DPB1*05:01 (IPD-IMGT/HLA=10166) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166837 CVCL_DS51 GM14290 transformed cell line human CVCL_DS51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166838 CVCL_E452 ADL,HG transformed cell line human CVCL_E452 HLA typing: A*01:01:01,68:01:02; B*08:01,40:01:01; C*03; DPB1*01:01:01,03:01:01; DQA1*05:01,03; DQB1*02:01,03:01:01; DRB1*03:01:01,04:01:01; DRB3*01:01:02:01; DRB4*01:01 (IPD-IMGT/HLA=11687) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21166839 CVCL_DS52 GM14293 transformed cell line human CVCL_DS52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166840 CVCL_E450 35841 transformed cell line human CVCL_E450 HLA typing: A*80:01,68:01; B*58:02,18; C*02,06:02; DPB1*01:01:01,02:01:02 (IPD-IMGT/HLA=10146) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94050322; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166841 CVCL_DS50 GM14289 transformed cell line human CVCL_DS50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166842 CVCL_E428 1181 transformed cell line human CVCL_E428 HLA typing: DRB1*13:03:01 (IPD-IMGT/HLA=10035) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166843 CVCL_DS28 GM13643 transformed cell line human CVCL_DS28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166844 CVCL_E429 1183 transformed cell line human CVCL_E429 HLA typing: DQA1*01:05; DRB1*13:03:01 (IPD-IMGT/HLA=10036) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166845 CVCL_DS29 GM13767 transformed cell line human CVCL_DS29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166846 CVCL_E422 CB33 transformed cell line human CVCL_E422 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Unspecified 21166847 CVCL_DS22 GM10420 transformed cell line human CVCL_DS22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166848 CVCL_E423 DC3F/C-10 spontaneously immortalized cell line CVCL_E423 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27656; Camptothecin (CPT); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21166849 CVCL_DS23 GM11632 finite cell line human CVCL_DS23 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166850 CVCL_DS20 GM09885 finite cell line human CVCL_DS20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21166851 CVCL_E420 LCL 721.45 transformed cell line human CVCL_E420 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21166852 CVCL_E421 CB23 transformed cell line human CVCL_E421 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21166853 CVCL_DS21 GM10419 transformed cell line human CVCL_DS21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166854 CVCL_E426 1127 transformed cell line human CVCL_E426 HLA typing: DRB1*08:04:01 (IPD-IMGT/HLA=10033) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166855 CVCL_DS26 GM13557 transformed cell line human CVCL_DS26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166856 CVCL_E427 1180 transformed cell line human CVCL_E427 HLA typing: DQA1*01; DQB1*05; DRB1*11:01:02,12 (IPD-IMGT/HLA=10034) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166857 CVCL_DS27 GM13639 transformed cell line human CVCL_DS27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166858 CVCL_E424 1066 transformed cell line human CVCL_E424 HLA typing: DRB1*08:04:01 (IPD-IMGT/HLA=10022) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166859 CVCL_DS24 GM11633 finite cell line human CVCL_DS24 CL:0000010 Population: Caucasian; Derived from sampling site: Umbilical vein Cell type=Fibroblast.. Male 21166860 CVCL_E425 1125 transformed cell line human CVCL_E425 HLA typing: DQA1*05:01; DQB1*03:01; DRB1*13:04; DRB3*02 (IPD-IMGT/HLA=10032) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166861 CVCL_DS25 GM11850 finite cell line human CVCL_DS25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21166862 CVCL_E439 26/27 transformed cell line human CVCL_E439 HLA typing: A*02:01,24:02; B*51:02:01,48:01:01; C*08:01:01; DPB1*02:01:02,04:02; DQB1*03; DRB1*14; DRB3*01 (IPD-IMGT/HLA=10114); HLA typing: A*02:01:01:01,24:02:01:01; B*48:01:01,51:02:01; C*08:01:01; DPA1*01:03:01:01,01:03:01:05; DPB1*02:01:02(416:01),04:02:01:02(105:01); DQA1*05:03; DQB1*03:01:01:01; DRB1*14:02:01; DRB3*01:01:02 (PubMed=30844424) CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166863 CVCL_DS39 GM14275 transformed cell line human CVCL_DS39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166864 CVCL_E433 2012 [Human B-cell] transformed cell line human CVCL_E433 HLA typing: DQA1*01:03:01:01,01:04:01:01; DQB1*06:03:01; DRB1*13:01; DRB3*01:01 (IPD-IMGT/HLA=10095) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166865 CVCL_DS33 GM13806 transformed cell line human CVCL_DS33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166866 CVCL_E434 202002 transformed cell line human CVCL_E434 HLA typing: A*01:01:01,03:02; B*08:01; C*07; DRB1*04:08; DRB4*01:03:01:01 (IPD-IMGT/HLA=25999) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21166867 CVCL_DS34 GM13863 transformed cell line human CVCL_DS34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166868 CVCL_E431 1563 transformed cell line human CVCL_E431 HLA typing: DPB1*01:01:01,04:02; DRB1*03:02:01 (IPD-IMGT/HLA=10075) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071415; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166869 CVCL_DS31 GM13789 transformed cell line human CVCL_DS31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166870 CVCL_E432 1568 transformed cell line human CVCL_E432 HLA typing: A*30,34; B*42,71; DRB1*01:02:01 (IPD-IMGT/HLA=10077) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166871 CVCL_DS32 GM13790 transformed cell line human CVCL_DS32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166872 CVCL_E437 230699 transformed cell line human CVCL_E437 HLA typing: A*02:06,24:02:01:01; B*07:02:01,51:03; C*07:02,14:02:01; DPB1*04:02,05:01; DQA1*01:01,03; DQB1*04:01,05:01:01; DRB1*01:01:01,04:05:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=25981) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21166873 CVCL_DS37 GM13939 transformed cell line human CVCL_DS37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166874 CVCL_E438 25/1506 transformed cell line human CVCL_E438 HLA typing: A*02:01,66:01; B*07,35; DPB1*02:01:02,14:01 (IPD-IMGT/HLA=10112) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166875 CVCL_DS38 GM14274 transformed cell line human CVCL_DS38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166876 CVCL_E435 2041 transformed cell line human CVCL_E435 HLA typing: A*02,19; B*44,50; DQA1*04:01:01; DQB1*04:02:01,06:02:01; DRB1*03:02:01 (IPD-IMGT/HLA=10097) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166877 CVCL_DS35 GM13869 transformed cell line human CVCL_DS35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166878 CVCL_E436 2094 transformed cell line human CVCL_E436 HLA typing: DPB1*01:01:01,03:01; DQA1*01:02:01,03:02; DQB1*05:02,02:01; DRB1*11:04:02,09:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=10098) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166879 CVCL_DS36 GM13870 transformed cell line human CVCL_DS36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166880 CVCL_E430 1249 transformed cell line human CVCL_E430 HLA typing: DQA1*01:02,02:01; DQB1*05:01,02; DRB1*11:01:02,07:01; DRB3*02:02 (IPD-IMGT/HLA=10046) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21166881 CVCL_DS30 GM13786 transformed cell line human CVCL_DS30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166882 CVCL_E408 51 BLCL transformed cell line human CVCL_E408 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166883 CVCL_DS08 GM02600 finite cell line human CVCL_DS08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Ambiguous 21166884 CVCL_E409 63 BLCL transformed cell line human CVCL_E409 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166885 CVCL_DS09 GM02601 finite cell line human CVCL_DS09 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Ambiguous Doubling time: Slow growth (Coriell) 21166886 CVCL_E406 48 BLCL transformed cell line human CVCL_E406 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166887 CVCL_DS06 GM23386 transformed cell line human CVCL_DS06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166888 CVCL_E407 49 BLCL transformed cell line human CVCL_E407 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166889 CVCL_DS07 GM01628 finite cell line human CVCL_DS07 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Ambiguous 21166890 CVCL_E400 259 BLCL transformed cell line human CVCL_E400 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166891 CVCL_DS00 MCF-10A/Twist spontaneously immortalized cell line human CVCL_DS00 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12428; TWIST1 Derived from sampling site: Breast; epithelium. Female 21166892 CVCL_E401 36 BLCL transformed cell line human CVCL_E401 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166893 CVCL_DS01 Jurkat J77 cancer cell line human CVCL_DS01 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21166894 CVCL_E404 40 BLCL transformed cell line human CVCL_E404 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166895 CVCL_DS04 GM16401 transformed cell line human CVCL_DS04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166896 CVCL_E405 47 BLCL transformed cell line human CVCL_E405 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166897 CVCL_DS05 GM16402 transformed cell line human CVCL_DS05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166898 CVCL_E402 37 BLCL transformed cell line human CVCL_E402 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166899 CVCL_DS02 Jurkat J77 cl20 cancer cell line human CVCL_DS02 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21166900 CVCL_E403 39 BLCL transformed cell line human CVCL_E403 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166901 CVCL_DS03 GM07087 transformed cell line human CVCL_DS03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166902 CVCL_DS19 GM08497 finite cell line human CVCL_DS19 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Cell type=Fibroblast. Male 21166903 CVCL_E419 HAK-3 cancer cell line human CVCL_E419 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Female Doubling time: ~26 hours, at 52th passage (PubMed=10493947) 21166904 CVCL_E417 90 BLCL transformed cell line human CVCL_E417 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166905 CVCL_DS17 GM07065 finite cell line human CVCL_DS17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21166906 CVCL_E418 93 BLCL transformed cell line human CVCL_E418 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166907 CVCL_DS18 GM08496 finite cell line human CVCL_DS18 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Cell type=Fibroblast. Male 21166908 CVCL_E411 74 BLCL transformed cell line human CVCL_E411 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166909 CVCL_DS11 GM03368 finite cell line human CVCL_DS11 CL:0000010 Population: African American; Derived from sampling site: Gonad Cell type=Fibroblast.. Ambiguous 21166910 CVCL_E412 76 BLCL transformed cell line human CVCL_E412 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166911 CVCL_DS12 GM03368-A finite cell line human CVCL_DS12 CL:0000010 Population: African American; Derived from sampling site: Gonad Cell type=Fibroblast.. Discontinued: Coriell; GM03368-A; probable Ambiguous 21166912 CVCL_E410 71 BLCL transformed cell line human CVCL_E410 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166913 CVCL_DS10 GM03280 finite cell line human CVCL_DS10 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166914 CVCL_E415 86 BLCL transformed cell line human CVCL_E415 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166915 CVCL_DS15 GM05521 finite cell line human CVCL_DS15 CL:0000010 Population: Caucasian; Yugoslavian; Derived from sampling site: Cell type=Fibroblast. Female 21166916 CVCL_E416 88 BLCL transformed cell line human CVCL_E416 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166917 CVCL_DS16 GM05522 finite cell line human CVCL_DS16 CL:0000010 Population: Caucasian; Yugoslavian; Derived from sampling site: Cell type=Fibroblast. Male 21166918 CVCL_E413 78 BLCL transformed cell line human CVCL_E413 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166919 CVCL_DS13 GM05091 finite cell line human CVCL_DS13 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166920 CVCL_E414 84 BLCL transformed cell line human CVCL_E414 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166921 CVCL_DS14 GM05520 finite cell line human CVCL_DS14 CL:0000010 Population: Caucasian; Yugoslavian; Derived from sampling site: Cell type=Fibroblast. Female 21166922 CVCL_VH41 RD/19 cancer cell line human CVCL_VH41 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female 21166923 CVCL_VH42 C6/36-HT spontaneously immortalized cell line CVCL_VH42 CL:0000010 Unspecified Characteristics: Capable of growing at 34-35 Celsius. Group: Insect cell line 21166924 CVCL_VH40 RD/15 cancer cell line human CVCL_VH40 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female 21166925 CVCL_VH45 GM27177 induced pluripotent stem cell human CVCL_VH45 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>A (IVS5-1G>A); ClinVar=VCV000207574; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166926 CVCL_VH46 FIB-PSE1 finite cell line human CVCL_VH46 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166927 CVCL_VH43 GM27160 finite cell line human CVCL_VH43 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166928 CVCL_VH44 GM27162 induced pluripotent stem cell human CVCL_VH44 CL:0000010 Sequence variation: Mutation; HGNC; 10818; SGSH; Simple; p.Arg245His (c.734G>A); ClinVar=VCV000005107; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166929 CVCL_VH49 FIB-PSE12 finite cell line human CVCL_VH49 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21166930 CVCL_MN99 BayGenomics ES cell line RRB053 embryonic stem cell house mouse CVCL_MN99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166931 CVCL_VH47 FIB-PSE2 finite cell line human CVCL_VH47 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166932 CVCL_VH48 FIB-PSE3 finite cell line human CVCL_VH48 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21166933 CVCL_MN97 BayGenomics ES cell line RRB050 embryonic stem cell house mouse CVCL_MN97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166934 CVCL_MN98 BayGenomics ES cell line RRB051 embryonic stem cell house mouse CVCL_MN98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351652; Tbl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166935 CVCL_MN95 BayGenomics ES cell line RRB048 embryonic stem cell house mouse CVCL_MN95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137670; Ybx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166936 CVCL_MN96 BayGenomics ES cell line RRB049 embryonic stem cell house mouse CVCL_MN96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166937 CVCL_3B00 HQ00101 transformed cell line human CVCL_3B00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166938 CVCL_3B01 HQ00102 transformed cell line human CVCL_3B01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166939 CVCL_3B04 HQ00105 transformed cell line human CVCL_3B04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166940 CVCL_3B05 HQ00106 transformed cell line human CVCL_3B05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166941 CVCL_3B02 HQ00103 transformed cell line human CVCL_3B02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166942 CVCL_3B03 HQ00104 transformed cell line human CVCL_3B03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166943 CVCL_3B08 HQ00109 transformed cell line human CVCL_3B08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166944 CVCL_3B09 HQ00110 transformed cell line human CVCL_3B09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166945 CVCL_3B06 HQ00107 transformed cell line human CVCL_3B06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21166946 CVCL_3B07 HQ00108 transformed cell line human CVCL_3B07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21166947 CVCL_VH30 RGS-6 spontaneously immortalized cell line Norway rat CVCL_VH30 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21166948 CVCL_VH31 RGS-7A spontaneously immortalized cell line Norway rat CVCL_VH31 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified Doubling time: 50.4 hours (PubMed=599719) 21166949 CVCL_VH34 1135A1 induced pluripotent stem cell CVCL_VH34 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: Generated from an animal with an homozygous MHC haplotype (Mafa-HT4) Group: Non-human primate cell line 21166950 CVCL_VH35 MCF7-B7-TS cancer cell line human CVCL_VH35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 21166951 CVCL_VH32 RGS-9 spontaneously immortalized cell line Norway rat CVCL_VH32 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21166952 CVCL_VH33 GM04910 finite cell line human CVCL_VH33 CL:0000010 Population: Caucasian; French/German; Derived from sampling site: Cell type=Fibroblast. Female 21166953 CVCL_VH38 CLA-HT spontaneously immortalized cell line CVCL_VH38 CL:0000010 Unspecified Characteristics: Capable of growing at 33 Celsius. Group: Insect cell line 21166954 CVCL_VH39 RD/7 cancer cell line human CVCL_VH39 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Female 21166955 CVCL_VH36 MCF10A-JSB spontaneously immortalized cell line human CVCL_VH36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~16 hours (PBCF) 21166956 CVCL_VH37 CLA-1 spontaneously immortalized cell line CVCL_VH37 CL:0000010 Unspecified Group: Insect cell line. 21166957 CVCL_MN82 BayGenomics ES cell line RRB026 embryonic stem cell house mouse CVCL_MN82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919228; Ppp2r2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166958 CVCL_MN83 BayGenomics ES cell line RRB027 embryonic stem cell house mouse CVCL_MN83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166959 CVCL_MN80 BayGenomics ES cell line RRB024 embryonic stem cell house mouse CVCL_MN80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915835; Rtn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166960 CVCL_MN81 BayGenomics ES cell line RRB025 embryonic stem cell house mouse CVCL_MN81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104729; Akap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166961 CVCL_VH20 MDS-2.A3 induced pluripotent stem cell human CVCL_VH20 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166962 CVCL_VH23 N-2.A11 induced pluripotent stem cell human CVCL_VH23 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166963 CVCL_VH24 N-2.A2 induced pluripotent stem cell human CVCL_VH24 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166964 CVCL_VH21 N-2.12 induced pluripotent stem cell human CVCL_VH21 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Omics: Deep exome analysis Male 21166965 CVCL_VH22 N-2.8 induced pluripotent stem cell human CVCL_VH22 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166966 CVCL_MN79 BayGenomics ES cell line RRB023 embryonic stem cell house mouse CVCL_MN79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104885; Psma2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166967 CVCL_VH27 RGS-3A spontaneously immortalized cell line Norway rat CVCL_VH27 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21166968 CVCL_VH28 RGS-4A spontaneously immortalized cell line Norway rat CVCL_VH28 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified Doubling time: 25.9 hours (PubMed=599719) 21166969 CVCL_MN77 BayGenomics ES cell line RRB021 embryonic stem cell house mouse CVCL_MN77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860494; Ddx21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166970 CVCL_VH25 MDS-2.13C induced pluripotent stem cell human CVCL_VH25 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166971 CVCL_MN78 BayGenomics ES cell line RRB022 embryonic stem cell house mouse CVCL_MN78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166972 CVCL_VH26 MDS-2.A3C induced pluripotent stem cell human CVCL_VH26 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166973 CVCL_MN75 BayGenomics ES cell line RRB012 embryonic stem cell house mouse CVCL_MN75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166974 CVCL_MN76 BayGenomics ES cell line RRB015 embryonic stem cell house mouse CVCL_MN76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336880; Eftud2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166975 CVCL_MN73 BayGenomics ES cell line RRB008 embryonic stem cell house mouse CVCL_MN73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925678; Pym1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166976 CVCL_VH29 RGS-4B spontaneously immortalized cell line Norway rat CVCL_VH29 CL:0000010 Derived from sampling site: Fetal stomach; glandular region Cell type=Glandular cell of stomach.; Breed/subspecies: JAR-2. Unspecified 21166977 CVCL_MN74 BayGenomics ES cell line RRB011 embryonic stem cell house mouse CVCL_MN74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166978 CVCL_MN93 BayGenomics ES cell line RRB046 embryonic stem cell house mouse CVCL_MN93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166979 CVCL_MN94 BayGenomics ES cell line RRB047 embryonic stem cell house mouse CVCL_MN94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916966; Trip13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166980 CVCL_MN91 BayGenomics ES cell line RRB043 embryonic stem cell house mouse CVCL_MN91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166981 CVCL_MN92 BayGenomics ES cell line RRB044 embryonic stem cell house mouse CVCL_MN92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166982 CVCL_MN90 BayGenomics ES cell line RRB038 embryonic stem cell house mouse CVCL_MN90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894323; Ranbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166983 CVCL_VH12 PC12-D60 cancer cell line Norway rat CVCL_VH12 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Shows very low catecholamine reuptake 21166984 CVCL_VH13 PC12-1G2 cancer cell line Norway rat CVCL_VH13 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Releases very low levels of dopamine in response to high-K+ depolarization The origin of the deficiency is likely to involve defects in L-type Ca2+channels. 21166985 CVCL_VH10 PC12-2B3 cancer cell line Norway rat CVCL_VH10 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Not responsive to high-K(+)-induced depolarization and ionomycin 21166986 CVCL_VH11 PC12-C3 cancer cell line Norway rat CVCL_VH11 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Produces high level of acetylcholine 21166987 CVCL_VH16 MDS-3.4 induced pluripotent stem cell human CVCL_VH16 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166988 CVCL_VH17 MDS-3.5 induced pluripotent stem cell human CVCL_VH17 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166989 CVCL_MN88 BayGenomics ES cell line RRB035 embryonic stem cell house mouse CVCL_MN88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929492; Atl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166990 CVCL_VH14 Hept-2 hybridoma house mouse CVCL_VH14 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:34785; Heptachlor. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10623 21166991 CVCL_MN89 BayGenomics ES cell line RRB037 embryonic stem cell house mouse CVCL_MN89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349766; Brd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166992 CVCL_VH15 MDS-3.1 induced pluripotent stem cell human CVCL_VH15 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166993 CVCL_MN86 BayGenomics ES cell line RRB032 embryonic stem cell house mouse CVCL_MN86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166994 CVCL_MN87 BayGenomics ES cell line RRB034 embryonic stem cell house mouse CVCL_MN87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922858; Chmp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166995 CVCL_MN84 BayGenomics ES cell line RRB030 embryonic stem cell house mouse CVCL_MN84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387629; Tardbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166996 CVCL_VH18 N-3.10 induced pluripotent stem cell human CVCL_VH18 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Male 21166997 CVCL_MN85 BayGenomics ES cell line RRB031 embryonic stem cell house mouse CVCL_MN85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21166998 CVCL_VH19 MDS-2.13 induced pluripotent stem cell human CVCL_VH19 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mononuclear cell.. Omics: Deep exome analysis Male 21166999 CVCL_MN60 BayGenomics ES cell line RRA122 embryonic stem cell house mouse CVCL_MN60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917244; Ddi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167000 CVCL_MN61 BayGenomics ES cell line RRA123 embryonic stem cell house mouse CVCL_MN61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88350; Cdc25c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167001 CVCL_VH01 UM2 cancer cell line human CVCL_VH01 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Characteristics: Low metastatic potential Shows a firm cell-cell attachment and exhibits low motility. Negligible invasive activity on a collagen gel matrix. Doubling time: 19.18 hours (PubMed=10729767) 21167002 CVCL_VH02 JE-1 transformed cell line house mouse CVCL_VH02 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic oral cavity; gingiva; epithelium; Breed/subspecies: C57BL/6N-Tg(CAG-EGFP). Unspecified 21167003 CVCL_MN59 BayGenomics ES cell line RRA120 embryonic stem cell house mouse CVCL_MN59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916526; Sec62 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167004 CVCL_VH00 UM1 cancer cell line human CVCL_VH00 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Characteristics: Highly metastatic Has loose cell-cell adhesion and exhibits high motility. High invasive activity on a collagen gel matrix. Doubling time: 18.85 hours (PubMed=10729767) 21167005 CVCL_MN57 BayGenomics ES cell line RRA118 embryonic stem cell house mouse CVCL_MN57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926227; Nup160 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167006 CVCL_VH05 TH [Human esophageal squamous cell carcinoma] cancer cell line human CVCL_VH05 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~17 hours (DOI=10.1093/oxfordjournals.jjco.a038751) 21167007 CVCL_MN58 BayGenomics ES cell line RRA119 embryonic stem cell house mouse CVCL_MN58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892003; Tcof1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167008 CVCL_VH06 TS cancer cell line human CVCL_VH06 CL:0000010 Population: Japanese Male Doubling time: ~47 hours (DOI=10.1093/oxfordjournals.jjco.a038751). 21167009 CVCL_MN55 BayGenomics ES cell line RRA109 embryonic stem cell house mouse CVCL_MN55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444177; Cachd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167010 CVCL_VH03 JE-2 transformed cell line house mouse CVCL_VH03 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic oral cavity; gingiva; epithelium; Breed/subspecies: C57BL/6N-Tg(CAG-EGFP). Unspecified 21167011 CVCL_VH04 7A8 hybridoma house mouse CVCL_VH04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O88855; Mouse Ltb4r. 21167012 CVCL_MN56 BayGenomics ES cell line RRA117 embryonic stem cell house mouse CVCL_MN56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167013 CVCL_MN53 BayGenomics ES cell line RRA104 embryonic stem cell house mouse CVCL_MN53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892003; Tcof1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167014 CVCL_VH09 R-3 cancer cell line Norway rat CVCL_VH09 CL:0000010 Transformant: N-methyl-N-pentylnitrosamine (N-amyl-N-methylnitrosamine(ChEBI; CHEBI:140674); Derived from metastatic site: Lymph node; Breed/subspecies: Donryu. Male Doubling time: ~21 hours (DOI=10.1093/oxfordjournals.jjco.a038751) 21167015 CVCL_MN54 BayGenomics ES cell line RRA107 embryonic stem cell house mouse CVCL_MN54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920453; Zzz3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167016 CVCL_MN51 BayGenomics ES cell line RRA102 embryonic stem cell house mouse CVCL_MN51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445054; Senp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167017 CVCL_VH07 R-1 cancer cell line Norway rat CVCL_VH07 CL:0000010 Transformant: N-methyl-N-pentylnitrosamine (N-amyl-N-methylnitrosamine(ChEBI; CHEBI:140674); Breed/subspecies: Donryu. Unspecified Doubling time: ~15 hours (DOI=10.1093/oxfordjournals.jjco.a038751) 21167018 CVCL_MN52 BayGenomics ES cell line RRA103 embryonic stem cell house mouse CVCL_MN52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682307; Ric8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167019 CVCL_VH08 R-2 cancer cell line Norway rat CVCL_VH08 CL:0000010 Transformant: N-methyl-N-pentylnitrosamine (N-amyl-N-methylnitrosamine(ChEBI; CHEBI:140674); Breed/subspecies: Donryu. Unspecified Doubling time: ~16 hours (DOI=10.1093/oxfordjournals.jjco.a038751) 21167020 CVCL_MN71 BayGenomics ES cell line RRB004 embryonic stem cell house mouse CVCL_MN71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104653; Atp2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167021 CVCL_MN72 BayGenomics ES cell line RRB007 embryonic stem cell house mouse CVCL_MN72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930768; Arid3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167022 CVCL_MN70 BayGenomics ES cell line RRB003 embryonic stem cell house mouse CVCL_MN70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385884; Ddx27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167023 CVCL_MN68 BayGenomics ES cell line RRB001 embryonic stem cell house mouse CVCL_MN68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167024 CVCL_MN69 BayGenomics ES cell line RRB002 embryonic stem cell house mouse CVCL_MN69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138584; Gigyf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167025 CVCL_MN66 BayGenomics ES cell line RRA136 embryonic stem cell house mouse CVCL_MN66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140475; AU040320 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167026 CVCL_MN67 BayGenomics ES cell line RRA138 embryonic stem cell house mouse CVCL_MN67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915139; Rbm18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167027 CVCL_MN64 BayGenomics ES cell line RRA129 embryonic stem cell house mouse CVCL_MN64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103296; Nfatc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167028 CVCL_MN65 BayGenomics ES cell line RRA134 embryonic stem cell house mouse CVCL_MN65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167029 CVCL_MN62 BayGenomics ES cell line RRA124 embryonic stem cell house mouse CVCL_MN62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167030 CVCL_MN63 BayGenomics ES cell line RRA128 embryonic stem cell house mouse CVCL_MN63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442483; Usp37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167031 CVCL_MN39 BayGenomics ES cell line RRA081 embryonic stem cell house mouse CVCL_MN39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923957; Clasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167032 CVCL_MN37 BayGenomics ES cell line RRA075 embryonic stem cell house mouse CVCL_MN37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140327; Phactr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167033 CVCL_MN38 BayGenomics ES cell line RRA079 embryonic stem cell house mouse CVCL_MN38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167034 CVCL_MN35 BayGenomics ES cell line RRA071 embryonic stem cell house mouse CVCL_MN35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167035 CVCL_MN36 BayGenomics ES cell line RRA074 embryonic stem cell house mouse CVCL_MN36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442637; Thrap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167036 CVCL_MN33 BayGenomics ES cell line RRA064 embryonic stem cell house mouse CVCL_MN33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167037 CVCL_MN34 BayGenomics ES cell line RRA070 embryonic stem cell house mouse CVCL_MN34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167038 CVCL_MN31 BayGenomics ES cell line RRA058 embryonic stem cell house mouse CVCL_MN31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444639; Fbxo38 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167039 CVCL_MN32 BayGenomics ES cell line RRA060 embryonic stem cell house mouse CVCL_MN32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95728; Gli2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167040 CVCL_MN30 BayGenomics ES cell line RRA057 embryonic stem cell house mouse CVCL_MN30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333754; Agfg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167041 CVCL_MN50 BayGenomics ES cell line RRA101 embryonic stem cell house mouse CVCL_MN50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289294; Dop1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167042 CVCL_MN48 BayGenomics ES cell line RRA097 embryonic stem cell house mouse CVCL_MN48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167043 CVCL_MN49 BayGenomics ES cell line RRA098 embryonic stem cell house mouse CVCL_MN49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913563; Smurf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167044 CVCL_MN46 BayGenomics ES cell line RRA095 embryonic stem cell house mouse CVCL_MN46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167045 CVCL_MN47 BayGenomics ES cell line RRA096 embryonic stem cell house mouse CVCL_MN47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141503; Pot1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167046 CVCL_MN44 BayGenomics ES cell line RRA091 embryonic stem cell house mouse CVCL_MN44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919204; Suds3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167047 CVCL_MN45 BayGenomics ES cell line RRA094 embryonic stem cell house mouse CVCL_MN45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095419; Kdm6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167048 CVCL_MN42 BayGenomics ES cell line RRA086 embryonic stem cell house mouse CVCL_MN42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97858; Rarg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167049 CVCL_MN43 BayGenomics ES cell line RRA089 embryonic stem cell house mouse CVCL_MN43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096572; Zfand3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167050 CVCL_MN40 BayGenomics ES cell line RRA084 embryonic stem cell house mouse CVCL_MN40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167051 CVCL_MN41 BayGenomics ES cell line RRA085 embryonic stem cell house mouse CVCL_MN41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146110; Washc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167052 CVCL_3B77 HQ00181 transformed cell line human CVCL_3B77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167053 CVCL_3B78 HQ00182 transformed cell line human CVCL_3B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167054 CVCL_3B75 HQ00179 transformed cell line human CVCL_3B75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167055 CVCL_3B76 HQ00180 transformed cell line human CVCL_3B76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167056 CVCL_3B79 HQ00183 transformed cell line human CVCL_3B79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167057 CVCL_3B70 HQ00174 transformed cell line human CVCL_3B70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167058 CVCL_3B73 HQ00177 transformed cell line human CVCL_3B73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167059 CVCL_3B74 HQ00178 transformed cell line human CVCL_3B74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167060 CVCL_3B71 HQ00175 transformed cell line human CVCL_3B71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167061 CVCL_3B72 HQ00176 transformed cell line human CVCL_3B72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167062 CVCL_3B88 HQ00192 transformed cell line human CVCL_3B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167063 CVCL_3B89 HQ00193 transformed cell line human CVCL_3B89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167064 CVCL_3B86 HQ00190 transformed cell line human CVCL_3B86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167065 CVCL_3B87 HQ00191 transformed cell line human CVCL_3B87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167066 CVCL_3B80 HQ00184 transformed cell line human CVCL_3B80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167067 CVCL_3B81 HQ00185 transformed cell line human CVCL_3B81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167068 CVCL_3B84 HQ00188 transformed cell line human CVCL_3B84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167069 CVCL_3B85 HQ00189 transformed cell line human CVCL_3B85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167070 CVCL_3B82 HQ00186 transformed cell line human CVCL_3B82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167071 CVCL_3B83 HQ00187 transformed cell line human CVCL_3B83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167072 CVCL_3B55 HQ00159 transformed cell line human CVCL_3B55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167073 CVCL_3B56 HQ00160 transformed cell line human CVCL_3B56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167074 CVCL_3B53 HQ00157 transformed cell line human CVCL_3B53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167075 CVCL_3B54 HQ00158 transformed cell line human CVCL_3B54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167076 CVCL_3B59 HQ00163 transformed cell line human CVCL_3B59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167077 CVCL_3B57 HQ00161 transformed cell line human CVCL_3B57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167078 CVCL_3B58 HQ00162 transformed cell line human CVCL_3B58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167079 CVCL_3B51 HQ00155 transformed cell line human CVCL_3B51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167080 CVCL_3B52 HQ00156 transformed cell line human CVCL_3B52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167081 CVCL_3B50 HQ00154 transformed cell line human CVCL_3B50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167082 CVCL_3B66 HQ00170 transformed cell line human CVCL_3B66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167083 CVCL_3B67 HQ00171 transformed cell line human CVCL_3B67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167084 CVCL_3B64 HQ00168 transformed cell line human CVCL_3B64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167085 CVCL_3B65 HQ00169 transformed cell line human CVCL_3B65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167086 CVCL_3B68 HQ00172 transformed cell line human CVCL_3B68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167087 CVCL_3B69 HQ00173 transformed cell line human CVCL_3B69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167088 CVCL_VH92 FAL38P transformed cell line human CVCL_VH92 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Homozygous (from autologous cell line FA38P) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167089 CVCL_VH93 FA46P finite cell line human CVCL_VH93 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.3766_3828del (Ex38del); Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167090 CVCL_VH90 FA33P finite cell line human CVCL_VH90 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Met1Leu (c.1A>T); ClinVar=VCV000553965; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167091 CVCL_VH91 FA38P finite cell line human CVCL_VH91 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167092 CVCL_VH96 AP23P finite cell line human CVCL_VH96 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167093 CVCL_VH97 AP23P(SVT) transformed cell line human CVCL_VH97 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line AP23P) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167094 CVCL_VH94 AP22P finite cell line human CVCL_VH94 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4168-2A>G (IVS41-2A>G) (p.Gly1390_Glu1420del); ClinVar=VCV000864280; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167095 CVCL_VH95 AP22P(SVT) transformed cell line human CVCL_VH95 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4168-2A>G (IVS41-2A>G) (p.Gly1390_Glu1420del); ClinVar=VCV000864280; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167096 CVCL_VH98 AP35P finite cell line human CVCL_VH98 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4168-2A>G (IVS41-2A>G) (p.Gly1390_Glu1420del); ClinVar=VCV000864280; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167097 CVCL_VH99 AP35P(SVT) transformed cell line human CVCL_VH99 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4168-2A>G (IVS41-2A>G) (p.Gly1390_Glu1420del); ClinVar=VCV000864280; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167098 CVCL_3B62 HQ00166 transformed cell line human CVCL_3B62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167099 CVCL_3B63 HQ00167 transformed cell line human CVCL_3B63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167100 CVCL_3B60 HQ00164 transformed cell line human CVCL_3B60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167101 CVCL_3B61 HQ00165 transformed cell line human CVCL_3B61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167102 CVCL_3B33 HQ00135 transformed cell line human CVCL_3B33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167103 CVCL_3B34 HQ00136 transformed cell line human CVCL_3B34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167104 CVCL_3B31 HQ00133 transformed cell line human CVCL_3B31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167105 CVCL_3B32 HQ00134 transformed cell line human CVCL_3B32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167106 CVCL_3B37 HQ00139 transformed cell line human CVCL_3B37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167107 CVCL_3B38 HQ00140 transformed cell line human CVCL_3B38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167108 CVCL_3B35 HQ00137 transformed cell line human CVCL_3B35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167109 CVCL_3B36 HQ00138 transformed cell line human CVCL_3B36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167110 CVCL_3B39 HQ00141 transformed cell line human CVCL_3B39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167111 CVCL_VH81 FA29(SVT) transformed cell line human CVCL_VH81 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.1761-2A>G (IVS13-2A>G); Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167112 CVCL_VH82 FA31P finite cell line human CVCL_VH82 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167113 CVCL_VH80 FA29P finite cell line human CVCL_VH80 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.1761-2A>G (IVS13-2A>G); Zygosity=Homozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167114 CVCL_VH85 AP36P finite cell line human CVCL_VH85 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167115 CVCL_VH86 AP49P finite cell line human CVCL_VH86 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167116 CVCL_VH83 FA32P finite cell line human CVCL_VH83 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167117 CVCL_VH84 FA5P finite cell line human CVCL_VH84 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11); Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167118 CVCL_VH89 AP31P(SVT) transformed cell line human CVCL_VH89 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2504+134A>G (IVS26+134A>G); ClinVar=VCV000974137; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167119 CVCL_VH87 AP49P(SVT) transformed cell line human CVCL_VH87 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167120 CVCL_VH88 AP31P finite cell line human CVCL_VH88 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2504+134A>G (IVS26+134A>G); ClinVar=VCV000974137; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10090479); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.2606-2A>T (IVS27-2A>T) (p.Phe868_Gln869del); ClinVar=VCV000555572; Zygosity=Heterozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11; PubMed=10090479) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167121 CVCL_3B30 HQ00132 transformed cell line human CVCL_3B30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167122 CVCL_3B44 HQ00148 transformed cell line human CVCL_3B44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167123 CVCL_3B45 HQ00149 transformed cell line human CVCL_3B45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167124 CVCL_3B42 HQ00144 transformed cell line human CVCL_3B42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167125 CVCL_3B43 HQ00145 transformed cell line human CVCL_3B43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167126 CVCL_3B48 HQ00152 transformed cell line human CVCL_3B48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167127 CVCL_3B49 HQ00153 transformed cell line human CVCL_3B49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167128 CVCL_3B46 HQ00150 transformed cell line human CVCL_3B46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167129 CVCL_3B47 HQ00151 transformed cell line human CVCL_3B47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167130 CVCL_VH70 FA9JTO(SVT)-1 transformed cell line human CVCL_VH70 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167131 CVCL_VH71 FA9JTO(SVT)-2 transformed cell line human CVCL_VH71 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167132 CVCL_VH74 FA17P finite cell line human CVCL_VH74 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167133 CVCL_VH75 FA17P(SVT) transformed cell line human CVCL_VH75 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167134 CVCL_VH72 FA14P finite cell line human CVCL_VH72 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Homozygous (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167135 CVCL_VH73 FA14(SVT) transformed cell line human CVCL_VH73 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167136 CVCL_VH78 FA24P finite cell line human CVCL_VH78 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.1761-2A>G (IVS13-2A>G); Zygosity=Homozygous; Note=Splice acceptor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167137 CVCL_VH79 FA24(SVT) transformed cell line human CVCL_VH79 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.1761-2A>G (IVS13-2A>G); Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167138 CVCL_VH76 FA21P finite cell line human CVCL_VH76 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (DOI=10.1007/0-387-33776-8_11) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167139 CVCL_VH77 FA21P(SVT) transformed cell line human CVCL_VH77 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167140 CVCL_3B40 HQ00142 transformed cell line human CVCL_3B40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167141 CVCL_3B41 HQ00143 transformed cell line human CVCL_3B41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167142 CVCL_3B11 HQ00112 transformed cell line human CVCL_3B11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167143 CVCL_3B12 HQ00113 transformed cell line human CVCL_3B12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167144 CVCL_3B10 HQ00111 transformed cell line human CVCL_3B10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167145 CVCL_3B15 HQ00117 transformed cell line human CVCL_3B15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167146 CVCL_3B16 HQ00118 transformed cell line human CVCL_3B16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167147 CVCL_3B13 HQ00114 transformed cell line human CVCL_3B13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167148 CVCL_3B14 HQ00116 transformed cell line human CVCL_3B14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167149 CVCL_3B19 HQ00121 transformed cell line human CVCL_3B19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167150 CVCL_3B17 HQ00119 transformed cell line human CVCL_3B17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167151 CVCL_3B18 HQ00120 transformed cell line human CVCL_3B18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167152 CVCL_VH60 FIB-PSE43 finite cell line human CVCL_VH60 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167153 CVCL_VH63 FIB-PSE46 finite cell line human CVCL_VH63 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167154 CVCL_VH64 FIB-PSE47 finite cell line human CVCL_VH64 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167155 CVCL_VH61 FIB-PSE44 finite cell line human CVCL_VH61 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167156 CVCL_VH62 FIB-PSE45 finite cell line human CVCL_VH62 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167157 CVCL_VH67 FIB-PSE52 finite cell line human CVCL_VH67 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167158 CVCL_VH68 FIB-PSE53 finite cell line human CVCL_VH68 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167159 CVCL_VH65 FIB-PSE50 finite cell line human CVCL_VH65 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167160 CVCL_VH66 FIB-PSE51 finite cell line human CVCL_VH66 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167161 CVCL_VH69 FIB-PSE54 finite cell line human CVCL_VH69 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167162 CVCL_3B22 HQ00124 transformed cell line human CVCL_3B22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167163 CVCL_3B23 HQ00125 transformed cell line human CVCL_3B23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167164 CVCL_3B20 HQ00122 transformed cell line human CVCL_3B20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167165 CVCL_3B21 HQ00123 transformed cell line human CVCL_3B21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00123; probable Male 21167166 CVCL_3B26 HQ00128 transformed cell line human CVCL_3B26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00128; probable Female 21167167 CVCL_3B27 HQ00129 transformed cell line human CVCL_3B27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167168 CVCL_3B24 HQ00126 transformed cell line human CVCL_3B24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167169 CVCL_3B25 HQ00127 transformed cell line human CVCL_3B25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167170 CVCL_3B28 HQ00130 transformed cell line human CVCL_3B28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167171 CVCL_3B29 HQ00131 transformed cell line human CVCL_3B29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167172 CVCL_VH52 FIB-PSE15 finite cell line human CVCL_VH52 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167173 CVCL_VH53 FIB-PSE17 finite cell line human CVCL_VH53 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167174 CVCL_VH50 FIB-PSE13 finite cell line human CVCL_VH50 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167175 CVCL_VH51 FIB-PSE14 finite cell line human CVCL_VH51 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167176 CVCL_VH56 FIB-PSE34 finite cell line human CVCL_VH56 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167177 CVCL_VH57 FIB-PSE35 finite cell line human CVCL_VH57 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167178 CVCL_VH54 FIB-PSE26 finite cell line human CVCL_VH54 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167179 CVCL_VH55 FIB-PSE32 finite cell line human CVCL_VH55 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167180 CVCL_VH58 FIB-PSE39 finite cell line human CVCL_VH58 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167181 CVCL_VH59 FIB-PSE40 finite cell line human CVCL_VH59 From: Istituto di Patologia Generale, Universita degli Studi di Modena; Modena; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167182 CVCL_E507 BYD,A transformed cell line human CVCL_E507 HLA typing: A*02,03; B*35,50; C*04,06; DPB1*02:01:02,03:01; DQA1*05:01; DQB1*02:01,03:01; DRB1*03:01,11:04; DRB3*01:01,02:02 (IPD-IMGT/HLA=11743) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167183 CVCL_DT07 ND00229 transformed cell line human CVCL_DT07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167184 CVCL_E508 C.M.L. transformed cell line human CVCL_E508 HLA typing: DPB1*14:01,04:01; DQA1*05:01,03; DQB1*02:01,03:01; DRB1*03:01,04:01; DRB3*01:01; DRB4*01:02 (IPD-IMGT/HLA=10364) CL:0000010 Population: Caucasian; Belgian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167185 CVCL_DT08 ND00230 transformed cell line human CVCL_DT08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167186 CVCL_E505 BTB transformed cell line human CVCL_E505 HLA typing: A*02:01:01:01; B*27:05:02; C*01:02:01; DPA1*01; DPB1*04:01:01; DQA1*04:01; DQB1*04:02:01; DRA*01:02; DRB1*08:01:01/08:77 (IPD-IMGT/HLA=11625) CL:0000010 Population: Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Discontinued: ECACC; 88052067; probable Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167187 CVCL_DT05 ND00213 transformed cell line human CVCL_DT05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167188 CVCL_E506 BUR,E transformed cell line human CVCL_E506 HLA typing: A*02:01:01:01,24:02:01:01; B*56:01:01:02; C*01:02:01; DPA1*02:02:02; DPB1*05:01:01:01; DQA1*03:03:01:02,05:05:01; DQB1*04:02:01; DRB1*04:12,14:09; DRB3*01:01:02; DRB4*01:03:01:01 (IPD-IMGT/HLA=11663) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167189 CVCL_DT06 ND00228 transformed cell line human CVCL_DT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167190 CVCL_E509 C047 transformed cell line human CVCL_E509 HLA typing: A*01:01:01:01,24:02:01:01; B*51:01:01,15:01:01:01; C*15:04,07:04:01; DPA1*01:03:01:05,01:03:01:04; DPB1*04:01:01:01,04:02:01:01; DQA1*03:05:01:02; DQB1*03:01:01:03; DRB1*11:01:01,11:04:01; DRB3*02:02:01:02 (IPD-IMGT/HLA=10369); HLA typing: A*01:01:01:01,24:02:01:01; B*51:01:01:01,15:01:01:01; C*15:04:01,07:04:01:01; DPA1*01:03:01:04,01:03:01:05; DPB1*04:01:01:01(126:01),04:02:01:01(105:01); DQA1*05:05:01; DQB1*03:01:01:03; DRB1*11:01:01:01,11:04:01; DRB3*02:02:01:02 (PubMed=30844424) CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167191 CVCL_DT09 ND00234 transformed cell line human CVCL_DT09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167192 CVCL_E500 BRU transformed cell line human CVCL_E500 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21167193 CVCL_DT00 ND00206 transformed cell line human CVCL_DT00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167194 CVCL_E503 BSH017 transformed cell line human CVCL_E503 HLA typing: A*30; B*18; DPB1*02:01:02,02:02; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02:02 (IPD-IMGT/HLA=11722) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167195 CVCL_DT03 ND00210 transformed cell line human CVCL_DT03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167196 CVCL_E504 BSM transformed cell line human CVCL_E504 HLA typing: A*02:01:01:01; B*15:01:01:01; C*03:04:01:01; DPA1*01; DPB1*02:01:02/02:01:19; DQA1*03:01; DQB1*03:02:01; DRA*01:01; DRB1*04:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=11624) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167197 CVCL_DT04 ND00211 transformed cell line human CVCL_DT04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167198 CVCL_E501 BRUG transformed cell line human CVCL_E501 HLA typing: A*03:01:01:01,11:01:01:01; B*27:02:01,27:05:02; C*01:02:01,02:02:02:03; DPB1*04:01,14:01 (IPD-IMGT/HLA=10351) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167199 CVCL_DT01 ND00208 transformed cell line human CVCL_DT01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167200 CVCL_E502 BSH012 transformed cell line human CVCL_E502 HLA typing: A*01,26; B*08,38:01; C*07,12; DPB1*01:01:01,04:01; DQA1*05:01,03; DQB1*02:01,03:02; DRB1*03:01,04:02; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11721) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167201 CVCL_DT02 ND00209 transformed cell line human CVCL_DT02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167202 CVCL_E518 CB [Human B-cell] transformed cell line human CVCL_E518 HLA typing: A*02:01:01:01,03:01:01:01; B*07:02:01:01,39:08; C*07:02:01:03,07:02:01:01; DPA1*02:02:01; DPB1*04:01:01; DQB1*04:02:01,03:01:01; DRB1*04:10:01/04:10:03,13:03:01 (IPD-IMGT/HLA=10394) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167203 CVCL_DT18 ND00282 transformed cell line human CVCL_DT18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167204 CVCL_E519 CB6B transformed cell line human CVCL_E519 HLA typing: A*01:01:01:01; B*15:01:01:01; C*03:03:01:01; DPA1*02:02:01; DPB1*19:01; DQA1*01:03; DQB1*06:03:01; DRA*01:01; DRB1*13:01:01; DRB3*02:02 (IPD-IMGT/HLA=10397) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167205 CVCL_DT19 ND00288 transformed cell line human CVCL_DT19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167206 CVCL_E516 CAM020 transformed cell line human CVCL_E516 HLA typing: A*24:02; B*48,15:13; C*08; DPB1*05:01,14:01 (IPD-IMGT/HLA=10378) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167207 CVCL_DT16 ND00261 transformed cell line human CVCL_DT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167208 CVCL_E517 CAR,ML transformed cell line human CVCL_E517 HLA typing: A*02:01:01:01; B*35:01:01,55:01; C*03:03,04:01; DPB1*04:01,04:02; DQA1*01:01; DQB1*05:01; DRB1*01:01,14:01; DRB3*02:02 (IPD-IMGT/HLA=11653) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167209 CVCL_DT17 ND00262 transformed cell line human CVCL_DT17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167210 CVCL_E510 C073 transformed cell line human CVCL_E510 HLA typing: A*02:01,29:02; B*44:03:01,51:01; C*02:02,16:02; DPB1*02:01:02,04:01 (IPD-IMGT/HLA=10370) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167211 CVCL_DT10 ND00235 transformed cell line human CVCL_DT10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167212 CVCL_DT11 ND00249 transformed cell line human CVCL_DT11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167213 CVCL_E514 CAL transformed cell line human CVCL_E514 HLA typing: A*03:01,68:02; B*47:02,53:01; C*04:01,06:02; DPB1*04:01; DQA1*01:02,02:01; DQB1*06:04,02:02; DRB1*13:02,07:01; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=10376) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21167214 CVCL_DT14 ND00255 transformed cell line human CVCL_DT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167215 CVCL_E515 CALOGERO transformed cell line human CVCL_E515 HLA typing: A*02:01:01:01; B*40:02:01:01; C*02:02:02:01; DPB1*04:01:01; DQA1*01:02:02; DQB1*05:02:01; DRB1*16:01:01 (IPD-IMGT/HLA=10377) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167216 CVCL_DT15 ND00256 transformed cell line human CVCL_DT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167217 CVCL_E512 C212 transformed cell line human CVCL_E512 HLA typing: A*01,03; B*07,15; DPA1*01,02:01:01; DPB1*04:01,45:01; DQA1*01:03,01:01; DQB1*05:01,06:03; DRB1*01:01,13:01; DRB3*02:02 (IPD-IMGT/HLA=10374) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071424; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167218 CVCL_DT12 ND00250 transformed cell line human CVCL_DT12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167219 CVCL_E513 CAD,KR transformed cell line human CVCL_E513 HLA typing: A*02; B*07,41; C*07; DPB1*04:01,06:01; DQA1*03,01:02; DQB1*03:02,06:02; DRB1*04:05,15:01; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11655) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167220 CVCL_DT13 ND00251 transformed cell line human CVCL_DT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167221 CVCL_3A98 HQ00099 transformed cell line human CVCL_3A98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167222 CVCL_3A99 HQ00100 transformed cell line human CVCL_3A99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167223 CVCL_3A92 HQ00093 transformed cell line human CVCL_3A92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167224 CVCL_3A93 HQ00094 transformed cell line human CVCL_3A93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167225 CVCL_3A90 HQ00091 transformed cell line human CVCL_3A90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167226 CVCL_3A91 HQ00092 transformed cell line human CVCL_3A91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167227 CVCL_3A96 HQ00097 transformed cell line human CVCL_3A96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; HQ00097; probable Female 21167228 CVCL_3A97 HQ00098 transformed cell line human CVCL_3A97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167229 CVCL_3A94 HQ00095 transformed cell line human CVCL_3A94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167230 CVCL_3A95 HQ00096 transformed cell line human CVCL_3A95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167231 CVCL_3A78 HQ00079 transformed cell line human CVCL_3A78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167232 CVCL_3A79 HQ00080 transformed cell line human CVCL_3A79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167233 CVCL_3A76 HQ00077 transformed cell line human CVCL_3A76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167234 CVCL_3A77 HQ00078 transformed cell line human CVCL_3A77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167235 CVCL_3A70 HQ00071 transformed cell line human CVCL_3A70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167236 CVCL_3A71 HQ00072 transformed cell line human CVCL_3A71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167237 CVCL_3A74 HQ00075 transformed cell line human CVCL_3A74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167238 CVCL_3A75 HQ00076 transformed cell line human CVCL_3A75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167239 CVCL_3A72 HQ00073 transformed cell line human CVCL_3A72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167240 CVCL_3A73 HQ00074 transformed cell line human CVCL_3A73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167241 CVCL_3A89 HQ00090 transformed cell line human CVCL_3A89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167242 CVCL_3A87 HQ00088 transformed cell line human CVCL_3A87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167243 CVCL_3A88 HQ00089 transformed cell line human CVCL_3A88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167244 CVCL_3A81 HQ00082 transformed cell line human CVCL_3A81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167245 CVCL_3A82 HQ00083 transformed cell line human CVCL_3A82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167246 CVCL_3A80 HQ00081 transformed cell line human CVCL_3A80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167247 CVCL_3A85 HQ00086 transformed cell line human CVCL_3A85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167248 CVCL_3A86 HQ00087 transformed cell line human CVCL_3A86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167249 CVCL_3A83 HQ00084 transformed cell line human CVCL_3A83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167250 CVCL_3A84 HQ00085 transformed cell line human CVCL_3A84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167251 CVCL_E587 FH01 transformed cell line human CVCL_E587 HLA typing: A*02:05,68:02; B*14:02,58:01; C*07:01,08:02; DPA1*01:03; DPB1*04:02,104:01; DQA1*01:01,01:02; DQB1*05:01:01,06:09; DRB1*01:02:01,13:02:01; DRB3*03:01:01 (IPD-IMGT/HLA=13543) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167252 CVCL_DT87 ND00830 transformed cell line human CVCL_DT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167253 CVCL_E588 FH02 transformed cell line human CVCL_E588 HLA typing: A*02:01:01,34:02; B*40:01,44:02; C*03:04,05:01; DPB1*02:01:02; DQB1*06:03,06:04:01; DRB1*13:01,13:02; DRB3*01:01:02:01,03:01:01 (IPD-IMGT/HLA=25984) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167254 CVCL_DT88 ND00868 transformed cell line human CVCL_DT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167255 CVCL_E585 EVA,LW transformed cell line human CVCL_E585 HLA typing: A*11:01,29:02; B*18:01,44:03; C*07:01,16:01; DPB1*04:01,11:01:01; DQA1*05:01,02:01; DQB1*02:01,03:01; DRB1*07,11:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11664) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167256 CVCL_DT85 ND00828 transformed cell line human CVCL_DT85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167257 CVCL_E586 EVA,SP transformed cell line human CVCL_E586 HLA typing: A*02,19; B*18; C*05; DPB1*02:02,04:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02:02 (IPD-IMGT/HLA=11678) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082234; probable Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167258 CVCL_DT86 ND00829 transformed cell line human CVCL_DT86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167259 CVCL_E589 FH03 transformed cell line human CVCL_E589 HLA typing: A*31:01:02,33:01; B*14:02,35:02; C*04:01:01,08:02; DPA1*01:03:01,02:02:03; DPB1*04:01:01,05:01; DQA1*05:05; DQB1*03:01:01,03:01:01; DRB1*11:01:01,11:04:01; DRB3*02:02:01 (IPD-IMGT/HLA=25985) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167260 CVCL_DT89 ND00891 transformed cell line human CVCL_DT89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167261 CVCL_E580 EK [Human B-cell] transformed cell line human CVCL_E580 HLA typing: A*02:01:01:01; B*44:02:01:01; C*05:01:01:02; DPA1*01:03; DPB1*04:02:01; DQA1*01:04:01; DQB1*05:03:01; DRA*01:02; DRB1*14:54:01; DRB3*02:02 (IPD-IMGT/HLA=10557) CL:0000010 Population: Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167262 CVCL_DT80 ND00505 transformed cell line human CVCL_DT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167263 CVCL_MN19 BayGenomics ES cell line RRA039 embryonic stem cell house mouse CVCL_MN19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921407; Cmtr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167264 CVCL_MN17 BayGenomics ES cell line RRA037 embryonic stem cell house mouse CVCL_MN17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443472; Atf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167265 CVCL_E583 EMJ transformed cell line human CVCL_E583 HLA typing: A*02:01:01:01,03:01:01:01; B*40:01:02:01; C*03:04:01:01; DPA1*01; DPB1*03:01:01,04:01:01; DQA1*01:02:01; DQB1*06:04:01; DRA*01:02; DRB1*13:02:01; DRB3*03:01:01 (IPD-IMGT/HLA=10562) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167266 CVCL_DT83 ND00554 transformed cell line human CVCL_DT83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167267 CVCL_MN18 BayGenomics ES cell line RRA038 embryonic stem cell house mouse CVCL_MN18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167268 CVCL_E584 ENA transformed cell line human CVCL_E584 HLA typing: A*34:01:01; B*56:02; DPA1*01:03; DPB1*02:01:02 (IPD-IMGT/HLA=10564) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167269 CVCL_DT84 ND00634 transformed cell line human CVCL_DT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167270 CVCL_MN15 BayGenomics ES cell line RRA034 embryonic stem cell house mouse CVCL_MN15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917244; Ddi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167271 CVCL_E581 EK-TOK transformed cell line human CVCL_E581 HLA typing: A*26:02; B*35,46; C*01,09; DPA1*01:03; DPB1*04:02; DRB1*04:05,11:01 (IPD-IMGT/HLA=10558) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167272 CVCL_DT81 ND00506 transformed cell line human CVCL_DT81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167273 CVCL_MN16 BayGenomics ES cell line RRA035 embryonic stem cell house mouse CVCL_MN16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929701; Metap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167274 CVCL_E582 ELON transformed cell line human CVCL_E582 HLA typing: A*23:01,03:01; B*38:01:01,35; C*04:01,12:03; DPB1*04:01,04:02 (IPD-IMGT/HLA=10559) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167275 CVCL_DT82 ND00507 transformed cell line human CVCL_DT82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167276 CVCL_MN13 BayGenomics ES cell line RRA032 embryonic stem cell house mouse CVCL_MN13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444951; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167277 CVCL_MN14 BayGenomics ES cell line RRA033 embryonic stem cell house mouse CVCL_MN14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682305; Rsf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167278 CVCL_MN11 BayGenomics ES cell line RRA027 embryonic stem cell house mouse CVCL_MN11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167279 CVCL_MN12 BayGenomics ES cell line RRA029 embryonic stem cell house mouse CVCL_MN12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916229; Nol11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167280 CVCL_MN10 BayGenomics ES cell line RRA026 embryonic stem cell house mouse CVCL_MN10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167281 CVCL_E598 FH12 transformed cell line human CVCL_E598 HLA typing: A*02:01:01,11:01; B*27:05:02,44:02; C*02:02:02,05:01; DPB1*02:01:02,04:01; DQB1*03:01,03:02; DRB1*04:04,12:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=25995) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167282 CVCL_DT98 ND01140 transformed cell line human CVCL_DT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167283 CVCL_E599 FH13 transformed cell line human CVCL_E599 HLA typing: A*34:02:01,68:02:01:01; B*44:03:01:01,15:10:01; C*03:04:02,04:01:01:01; DPB1*02:01:02/02:01:19,133:01; DQB1*02:01:01,06:02:01; DRB1*15:03:01,03:01:01; DRB3*02:02:01; DRB5*01:01:01 (IPD-IMGT/HLA=13295) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167284 CVCL_DT99 ND01143 transformed cell line human CVCL_DT99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167285 CVCL_E596 FH10 transformed cell line human CVCL_E596 HLA typing: A*02:06,24:02; B*40:02,55:02; C*01:02,15:02; DRB1*09,14:08 (IPD-IMGT/HLA=25993) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167286 CVCL_DT96 ND01100 transformed cell line human CVCL_DT96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167287 CVCL_E597 FH11 transformed cell line human CVCL_E597 HLA typing: A*03:01:01,29:02; B*07:02:01,44:04; C*07:02,16:01; DPB1*02:01:02,11:01:01; DQB1*03:01,05:01; DRB1*01:01,11:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=25994) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167288 CVCL_DT97 ND01130 transformed cell line human CVCL_DT97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167289 CVCL_E590 FH04 transformed cell line human CVCL_E590 HLA typing: A*01:01:01; B*27:03,27:05:02; C*02:02:02; DPA1*01:03:01,02:01:01; DPB1*02:01:02,14:01; DQA1*01:02,02:01; DQB1*02:02,06:02; DRB1*07:01:01,11:01:02; DRB3*02:02:01; DRB4*01:01:01 (IPD-IMGT/HLA=13541) CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167290 CVCL_DT90 ND00997 transformed cell line human CVCL_DT90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167291 CVCL_E591 FH05 transformed cell line human CVCL_E591 HLA typing: A*02:01:01:01,29:02:01:01; B*27:09,44:03:01:01; C*01:02:01,16:01:01:01; DPA1*01:03:01,02:01:01; DPB1*11:01:01,04:01:01; DQA1*02:01,01:04; DQB1*02:02:01,05:03:01; DRB1*07:01:01,14:54:01; DRB3*02:02:01; DRB4*01:01:02 (IPD-IMGT/HLA=17341) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167292 CVCL_DT91 ND00998 transformed cell line human CVCL_DT91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167293 CVCL_MN28 BayGenomics ES cell line RRA055 embryonic stem cell house mouse CVCL_MN28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138893; Usp6nl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167294 CVCL_E594 FH08 transformed cell line human CVCL_E594 HLA typing: A*11:01:01:01,34:02:01; B*82:01,27:05:02; C*03:02:02:04,01:02:01; DPB1*04:02:01,01:01:01; DQB1*02:02:01,06:02:01; DRB1*07:01:01,15:03:01; DRB4*01:01:01 (IPD-IMGT/HLA=17342) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167295 CVCL_DT94 ND01045 transformed cell line human CVCL_DT94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167296 CVCL_MN29 BayGenomics ES cell line RRA056 embryonic stem cell house mouse CVCL_MN29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681271; Pigl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167297 CVCL_E595 FH09 transformed cell line human CVCL_E595 HLA typing: A*24:02,33:03; B*44:03:02,48:01; C*07:01,08:01; DRB1*04:10,07 (IPD-IMGT/HLA=25992) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167298 CVCL_DT95 ND01081 transformed cell line human CVCL_DT95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167299 CVCL_MN26 BayGenomics ES cell line RRA052 embryonic stem cell house mouse CVCL_MN26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913358; Ndufa9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167300 CVCL_E592 FH06 transformed cell line human CVCL_E592 HLA typing: A*24:02:01:01,29:01:01:01; B*07:05:01:01,27:02:01:04; C*02:02:02:01,15:05:02; DPA1*01:03; DPB1*02:01:02/02:01:19,04:01:01; DQA1*01:01:01,01:02:01; DQB1*05:02:01,05:01:01; DRB1*16:01:01,10:01:01; DRB5*02:02 (IPD-IMGT/HLA=17350) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167301 CVCL_DT92 ND01023 transformed cell line human CVCL_DT92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167302 CVCL_MN27 BayGenomics ES cell line RRA053 embryonic stem cell house mouse CVCL_MN27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167303 CVCL_E593 FH07 transformed cell line human CVCL_E593 HLA typing: A*02:06,30:02; B*18:01:01,39:08; C*05:01,07:02; DPA1*01:03; DPB1*02:02,04:02; DQA1*03:01,05:01:01; DQB1*02:01:01,03:02:01; DRB1*03:15,04:07:01; DRB3*02:02:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=14085) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167304 CVCL_DT93 ND01025 transformed cell line human CVCL_DT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167305 CVCL_MN24 BayGenomics ES cell line RRA048 embryonic stem cell house mouse CVCL_MN24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142572; Mtus1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167306 CVCL_MN25 BayGenomics ES cell line RRA049 embryonic stem cell house mouse CVCL_MN25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99700; Cenpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167307 CVCL_MN22 BayGenomics ES cell line RRA042 embryonic stem cell house mouse CVCL_MN22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352459; Nr6a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167308 CVCL_MN23 BayGenomics ES cell line RRA045 embryonic stem cell house mouse CVCL_MN23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923749; Clasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167309 CVCL_MN20 BayGenomics ES cell line RRA040 embryonic stem cell house mouse CVCL_MN20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167310 CVCL_MN21 BayGenomics ES cell line RRA041 embryonic stem cell house mouse CVCL_MN21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924315; Ints7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167311 CVCL_E565 DJU,S transformed cell line human CVCL_E565 HLA typing: A*02,24; B*15:02,15:13; C*08; DPB1*04:01,13:01; DQA1*06:01; DQB1*03:01; DRB1*12:02 (IPD-IMGT/HLA=11740) CL:0000010 Population: Indonesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167312 CVCL_DT65 ND00426 transformed cell line human CVCL_DT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167313 CVCL_E566 DK1 [Human B-cell] transformed cell line human CVCL_E566 HLA typing: A*02:03:01,33:01; B*44:03:01,40:01; C*03:04,14:03; DPB1*04:01,05:01; DQB1*01; DRB1*09,13 (IPD-IMGT/HLA=10501) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167314 CVCL_DT66 ND00427 transformed cell line human CVCL_DT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167315 CVCL_E563 DJA,N transformed cell line human CVCL_E563 HLA typing: A*02; B*15,46; C*01; DPB1*13:01,21:01; DQA1*01:02,06:01; DQB1*03:01,05:02; DRB1*12:02; DRB3*03:01 (IPD-IMGT/HLA=11668) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167316 CVCL_DT63 ND00423 transformed cell line human CVCL_DT63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167317 CVCL_E564 DJS transformed cell line human CVCL_E564 HLA typing: A*02:01,03:01; B*37:01,35:01; C*06:02:01:01,04:01; DPA1*01:03; DPB1*04:01,04:02; DQA1*01:02,01:01; DQB1*05:02,05:01; DRB1*16:01,01:01 (IPD-IMGT/HLA=10500) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167318 CVCL_DT64 ND00425 transformed cell line human CVCL_DT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167319 CVCL_E569 DOP-ND transformed cell line human CVCL_E569 HLA typing: A*02:01,33:03; B*44:03:01,15:16; C*04:01,14:02; DPB1*04:01,11:01:01 (IPD-IMGT/HLA=10517) CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167320 CVCL_DT69 ND00455 transformed cell line human CVCL_DT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167321 CVCL_E567 DKB transformed cell line human CVCL_E567 HLA typing: A*24:02:01:08; B*40:01:02:01; C*03:04:01:01; DPA1*01:03; DPB1*04:01:01; DQA1*03:02; DQB1*03:03:02; DRA*01:01; DRB1*09:01:02/09:21; DRB4*01:03:01:01 (IPD-IMGT/HLA=10503) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167322 CVCL_DT67 ND00430 transformed cell line human CVCL_DT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167323 CVCL_E568 DL [Human B-cell] transformed cell line human CVCL_E568 HLA typing: A*03,33; B*35:02:01,35:03; C*04; DPB1*04:01,30:01 (IPD-IMGT/HLA=10505) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94050328; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167324 CVCL_DT68 ND00454 transformed cell line human CVCL_DT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167325 CVCL_E561 DHIF transformed cell line human CVCL_E561 HLA typing: A*31:01:02:01; B*38:01:01; C*12:03:01:01; DPB1*04:01:01; DQB1*03:01:01; DRB1*11:01:01 (IPD-IMGT/HLA=10492) CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167326 CVCL_DT61 ND00419 transformed cell line human CVCL_DT61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167327 CVCL_E562 DHO transformed cell line human CVCL_E562 HLA typing: A*24; B*51; DPB1*09:01; DQB1*06:01; DRB1*15:02:01; DRB5*01:02 (IPD-IMGT/HLA=10494) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167328 CVCL_DT62 ND00420 transformed cell line human CVCL_DT62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167329 CVCL_E560 DEU transformed cell line human CVCL_E560 HLA typing: A*31:01:02:01; B*35:01:01:02; C*04:01:01:01; DPA1*01; DPB1*04:01:01:01; DQA1*03:02; DQB1*03:01:01:01; DRA*01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11628) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167330 CVCL_DT60 ND00418 transformed cell line human CVCL_DT60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167331 CVCL_E576 EAV,AC transformed cell line human CVCL_E576 HLA typing: A*19,02; B*21,37; DPB1*02:01,03:01; DQA1*01:05,02:01; DQB1*02:02:01,05:01:01/05:01:24; DRB1*07,10:01 (IPD-IMGT/HLA=11694) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167332 CVCL_DT76 ND00476 transformed cell line human CVCL_DT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167333 CVCL_E577 EC [Human B-cell] transformed cell line human CVCL_E577 HLA typing: A*02:01:01:01,68:02:01:01; B*14:02:01:01,40:04; C*08:02:01:01,03:04:01:02; DPB1*14:01:01,27:01; DQB1*02:01:01,03:02:01; DRB1*04:11:01,03:01:01 (IPD-IMGT/HLA=10550) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167334 CVCL_DT77 ND00477 transformed cell line human CVCL_DT77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167335 CVCL_E574 E4181324 transformed cell line human CVCL_E574 HLA typing: A*01:01:01:01; B*52:01:01:02; C*12:02:02:01; DPA1*01:03; DPB1*02:01:02/02:01:19,04:01:01; DQA1*01:03; DQB1*06:01:01/06:01:15; DRA*01:02; DRB1*15:02:01; DRB5*01:02; DRB6*02:01 (IPD-IMGT/HLA=10546) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167336 CVCL_DT74 ND00471 transformed cell line human CVCL_DT74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167337 CVCL_E575 EA transformed cell line human CVCL_E575 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02 (IPD-IMGT/HLA=11629) CL:0000010 Population: Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167338 CVCL_DT75 ND00473 transformed cell line human CVCL_DT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167339 CVCL_E578 EHM transformed cell line human CVCL_E578 HLA typing: A*03:01:01:01; B*35:01:01:02,35:03:01:01; C*04:01:01:01; DPA1*01; DPB1*04:01:01,04:02:01; DQA1*01:01; DQB1*05:01:01; DRA*01:01; DRB1*01:01:01; DRB6*01 (IPD-IMGT/HLA=11630) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167340 CVCL_DT78 ND00488 transformed cell line human CVCL_DT78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167341 CVCL_E579 EJ32B transformed cell line human CVCL_E579 HLA typing: A*30:02:01:01; B*18:01:01:01; C*05:01:01:01; DPB1*02:01:02/02:01:19,02:02; DQA1*05:01; DQB1*02:01:01; DRB1*03:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=11631) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167342 CVCL_DT79 ND00489 transformed cell line human CVCL_DT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167343 CVCL_MN08 BayGenomics ES cell line RRA019 embryonic stem cell house mouse CVCL_MN08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88141; Bcr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167344 CVCL_MN09 BayGenomics ES cell line RRA025 embryonic stem cell house mouse CVCL_MN09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167345 CVCL_MN06 BayGenomics ES cell line RRA017 embryonic stem cell house mouse CVCL_MN06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167346 CVCL_E572 DUG150 transformed cell line human CVCL_E572 HLA typing: A*02,68:01:01; B*45:01,58:02; C*06:02,16:01; DPA1*02:01:01; DPB1*01:01:02,85:01; DQA1*01:01:01,04:01:01; DQB1*03:01,05:01:01; DRB1*08:04,12:01; DRB3*02:02 (IPD-IMGT/HLA=26001) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167347 CVCL_DT72 ND00469 transformed cell line human CVCL_DT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167348 CVCL_MN07 BayGenomics ES cell line RRA018 embryonic stem cell house mouse CVCL_MN07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167349 CVCL_E573 E22758 transformed cell line human CVCL_E573 HLA typing: A*11:01,33:03; B*48:01,56:04; C*01:02,08:01 (IPD-IMGT/HLA=26003) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167350 CVCL_DT73 ND00470 transformed cell line human CVCL_DT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167351 CVCL_MN04 BayGenomics ES cell line RRA015 embryonic stem cell house mouse CVCL_MN04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446132; Bms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167352 CVCL_E570 DRI,SM transformed cell line human CVCL_E570 HLA typing: A*03; B*07; C*04:01; DPB1*04:01; DQA1*01:01,01:02; DQB1*05:01,06:02; DRB1*01:01,15:01; DRB5*01:01 (IPD-IMGT/HLA=11671) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167353 CVCL_DT70 ND00456 transformed cell line human CVCL_DT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167354 CVCL_MN05 BayGenomics ES cell line RRA016 embryonic stem cell house mouse CVCL_MN05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167355 CVCL_E571 DUCAF transformed cell line human CVCL_E571 HLA typing: A*30:02:01:01; B*18:01:01:01; C*05:01:01:01; DPA1*01:03; DPB1*02:02; DQA1*05:01:01; DQB1*02:01:01; DRA*01:01; DRB1*03:01:01; DRB3*02:02 (IPD-IMGT/HLA=10536) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167356 CVCL_DT71 ND00468 transformed cell line human CVCL_DT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167357 CVCL_MN02 BayGenomics ES cell line RRA013 embryonic stem cell house mouse CVCL_MN02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107750; Dync1i2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167358 CVCL_MN03 BayGenomics ES cell line RRA014 embryonic stem cell house mouse CVCL_MN03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351645; Prmt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167359 CVCL_MN00 BayGenomics ES cell line RRA011 embryonic stem cell house mouse CVCL_MN00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167360 CVCL_MN01 BayGenomics ES cell line RRA012 embryonic stem cell house mouse CVCL_MN01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21167361 CVCL_E549 #W7079 transformed cell line human CVCL_E549 HLA typing: A*02:01,02:06; B*40:01:02:01,67:01:01; C*03,07; DPB1*04:01,05:01 (IPD-IMGT/HLA=11548) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167362 CVCL_DT49 ND00383 transformed cell line human CVCL_DT49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167363 CVCL_E543 DAR,KR transformed cell line human CVCL_E543 HLA typing: A*02; B*15; C*03; DPB1*04:01; DQA1*03,05:01; DQB1*03:01,03:02; DRB1*04:01,12:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11690) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167364 CVCL_DT43 ND00342 transformed cell line human CVCL_DT43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167365 CVCL_E544 DBB transformed cell line human CVCL_E544 HLA typing: A*02:01:01:01; B*57:01:01; C*06:02:01:01; DPA1*01:03; DPB1*04:01:01; DQA1*02:01; DQB1*03:03:02; DRA*01:01; DRB1*07:01:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=10472) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167366 CVCL_DT44 ND00343 transformed cell line human CVCL_DT44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167367 CVCL_E541 DAN723 transformed cell line human CVCL_E541 HLA typing: A*31:01:02:01; B*15:08:01,40:02:01; C*01:02:01,03:04:01:02; DPA1*02:01:01,02:02:02; DPB1*05:01:01,14:01:01; DQA1*05:05:01:03,05:03; DQB1*03:01:01:01,03:03:02:02; DRB1*14:02:01,16:02; DRB3*01:01:02; DRB5*02:02 (IPD-IMGT/HLA=10468); HLA typing: A*31:01:02:01; B*15:08:01,40:02:01; C*01:02:01; C*03:04:01:02; DPA1*02:01:01:02,02:02:02; DPB1*05:01:01,14:01:01; DQA1*05:05:01,05:03; DQB1*03:01:01:01,03:03:02:04; DRB1*14:02:01,16:02:01:02; DRB3*01:01:02; DRB5*02:02 (PubMed=30844424) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167368 CVCL_DT41 ND00340 transformed cell line human CVCL_DT41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167369 CVCL_E542 DAR,E transformed cell line human CVCL_E542 HLA typing: A*02,29; B*15,44; C*03; DPB1*04:01,10:01; DQA1*05:01,02:01; DQB1*02:01,03:01; DRB1*07:01,12:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11691) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167370 CVCL_DT42 ND00341 transformed cell line human CVCL_DT42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167371 CVCL_E547 DCH002 transformed cell line human CVCL_E547 HLA typing: A*11,24; B*15:02,18; C*07,08; DPB1*13:01,21:01; DQA1*01:01,06:01; DQB1*03:01,05:01; DRB1*15:02,12:02; DRB3*03:01; DRB5*01:02 (IPD-IMGT/HLA=11724) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167372 CVCL_DT47 ND00381 transformed cell line human CVCL_DT47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167373 CVCL_E548 #15310-LN transformed cell line human CVCL_E548 HLA typing: A*03,25; B*37:01:01:01,47:01:01:03; C*06; DPA1*01; DPB1*04:01:01; DQA1*01:01:01:01,01:03:01; DQB1*05:01:01;06:03:01:02; DRB1*01:01:01,14:17; DRB3*01:01 (IPD-IMGT/HLA=10074) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167374 CVCL_DT48 ND00382 transformed cell line human CVCL_DT48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167375 CVCL_E545 DBUG transformed cell line human CVCL_E545 HLA typing: A*11:01,26:01; B*07:05:01,55:02:01; C*01:02:01,07:02:01:01; DPA1*01:03,02:02:02; DPB1*04:01:01,05:01; DQA1*01:01:01,02:01; DQB1*06:02,03:03:02; DRB1*11:05,07:01:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=10474) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167376 CVCL_DT45 ND00346 transformed cell line human CVCL_DT45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167377 CVCL_E546 DCH001 transformed cell line human CVCL_E546 HLA typing: A*11,24; B*75; C*08; DQA1*01:03,06:01; DQB1*03:01,06:03; DRB1*12:02,13:01; DRB3*01:01,03:01 (IPD-IMGT/HLA=11723) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167378 CVCL_DT46 ND00347 transformed cell line human CVCL_DT46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167379 CVCL_E540 DO208915 transformed cell line human CVCL_E540 HLA typing: A*25:01:01; B*18:01:01:02; C*12:03:01:01; DPA1*01:03:01; DPB1*02:01:02/02:01:19,23:01:01; DQA1*01:02:01,01:02:02; DQB1*06:02:01,06:03:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=10516) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167380 CVCL_DT40 ND00339 transformed cell line human CVCL_DT40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167381 CVCL_E554 DCH010 transformed cell line human CVCL_E554 HLA typing: A*24,11; B*46,15:02; C*08,12; DPB1*05:01; DQA1*01:03,03; DQB1*04:01,06:03; DRB1*13:01,04:05; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11727) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167382 CVCL_DT54 ND00398 transformed cell line human CVCL_DT54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167383 CVCL_E555 Lof(11-10) transformed cell line human CVCL_E555 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. 21167384 CVCL_DT55 ND00403 transformed cell line human CVCL_DT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167385 CVCL_E552 DCH008 transformed cell line human CVCL_E552 HLA typing: A*11,24; B*75,76; C*08,09; DPB1*03:01,41:01; DQA1*03:02,06:01; DQB1*03:01,03:03; DRB1*09,12:02; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=11726) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167386 CVCL_DT52 ND00396 transformed cell line human CVCL_DT52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167387 CVCL_E553 DCH009 transformed cell line human CVCL_E553 HLA typing: A*02,24:07; B*15:02,46; C*01,08; DPA1*02:02:02,04:01; DPB1*13:01,28:01; DQA1*01:02,03:02; DQB1*06:01,03:03; DRB1*09:01,15:01; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11731) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167388 CVCL_DT53 ND00397 transformed cell line human CVCL_DT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167389 CVCL_E558 DCH012 transformed cell line human CVCL_E558 HLA typing: A*28,33; B*08,46; C*01,07; DPB1*05:01,17:01; DQA1*05:01,03:02; DQB1*02:01,03:03; DRB1*03:01,09:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11729) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167390 CVCL_DT58 ND00407 transformed cell line human CVCL_DT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167391 CVCL_E559 DEM transformed cell line human CVCL_E559 HLA typing: A*02:01:01:01; B*57:01:01; C*06:02:01:01; DPA1*01; DPB1*03:01:01,04:01:01; DQA1*01:02:02,03:01; DQB1*05:02:01,03:02:01; DRA*01:01; DRB1*04:01:01,16:02:01; DRB4*01:01; DRB5*02; DRB6*02:02 (IPD-IMGT/HLA=11627) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167392 CVCL_DT59 ND00408 transformed cell line human CVCL_DT59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167393 CVCL_E556 DCH011 transformed cell line human CVCL_E556 HLA typing: A*11,24; B*15:02,46; C*03,08; DPB1*05:01; DQA1*01:03,03; DQB1*04:01,06:03; DRB1*13:01,04:05; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11728) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167394 CVCL_DT56 ND00404 transformed cell line human CVCL_DT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167395 CVCL_E557 00136 transformed cell line human CVCL_E557 HLA typing: A*02; B*40:05,48:01; C*03:04,08; DPB1*04:01,14:01; DQB1*03;04:02; DRB1*04:10,14:06; DRB3*01,01 (IPD-IMGT/HLA=10002) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167396 CVCL_DT57 ND00405 transformed cell line human CVCL_DT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167397 CVCL_E550 DCH006 transformed cell line human CVCL_E550 HLA typing: A*11,24; B*18,75; C*07,08; DPB1*04:01,05:01; DQA1*01:02,01:03; DQB1*06:01; DRB1*15:01,08:03; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11730) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167398 CVCL_DT50 ND00394 transformed cell line human CVCL_DT50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167399 CVCL_E551 DCH007 transformed cell line human CVCL_E551 HLA typing: A*11,24; B*75,76; C*08; DPB1*05:01; DQA1*06:01,01:01; DQB1*03:01,05:02; DRB1*15:02,12:02; DRB3*03:01; DRB5*01:02 (IPD-IMGT/HLA=11725) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167400 CVCL_DT51 ND00395 transformed cell line human CVCL_DT51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167401 CVCL_E529 CLA transformed cell line human CVCL_E529 HLA typing: A*02:06:01,24:02; B*08:01,35; C*07; DPB1*13:01,20:01:01 (IPD-IMGT/HLA=10422) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167402 CVCL_DT29 ND00315 transformed cell line human CVCL_DT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167403 CVCL_E527 CHR,KJ transformed cell line human CVCL_E527 HLA typing: A*01,02; B*08,57; DPB1*04:01,04:02; DQA1*05:01,02:01; DQB1*03:03,02:01; DRB1*03:01,07; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11744) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167404 CVCL_DT27 ND00304 transformed cell line human CVCL_DT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167405 CVCL_E528 CJO-A transformed cell line human CVCL_E528 HLA typing: A*11:01:01; B*35; C*04:01:01:01 (IPD-IMGT/HLA=10418) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167406 CVCL_DT28 ND00314 transformed cell line human CVCL_DT28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167407 CVCL_E521 CF996 transformed cell line human CVCL_E521 HLA typing: A*02:01:01:01,03:01:01:01; B*14:01:01; C*08:02:01:02; DPA1*01; DPB1*04:01:01,04:02:01; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11626) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167408 CVCL_DT21 ND00291 transformed cell line human CVCL_DT21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167409 CVCL_E522 CGP04 transformed cell line human CVCL_E522 HLA typing: A*02:01:01,29:02; B*35:01:01,44:03:01; C*04:01,16:01; DPB1*02:01:02,04:02; DQB1*05:01:01; DRB1*01:01:01 (IPD-IMGT/HLA=26028) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167410 CVCL_DT22 ND00298 transformed cell line human CVCL_DT22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167411 CVCL_E520 CC transformed cell line human CVCL_E520 HLA typing: A*43:01,74:01; B*44:03:01,15:03; C*02,08; DPB1*02:01:02,80:01; DRB1*15:03:01,13:02:01 (IPD-IMGT/HLA=10399) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167412 CVCL_DT20 ND00290 transformed cell line human CVCL_DT20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167413 CVCL_E525 CHI013 transformed cell line human CVCL_E525 HLA typing: A*02,11; B*07,27; C*03; DPB1*04:01; DQA1*06:01; DQB1*03:01; DRB1*12:02; DRB3*03:01 (IPD-IMGT/HLA=11665) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167414 CVCL_DT25 ND00302 transformed cell line human CVCL_DT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167415 CVCL_E526 CHI034 transformed cell line human CVCL_E526 HLA typing: A*11,19; B*07,40; DPA1*01:03:01; DPB1*02:01:02,32:01; DQA1*05:01,01:04; DQB1*05:01,03:01; DRB1*10:01,11; DRB3*02:02 (IPD-IMGT/HLA=11741) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167416 CVCL_DT26 ND00303 transformed cell line human CVCL_DT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167417 CVCL_E523 CHA,AJ transformed cell line human CVCL_E523 HLA typing: A*03:01:01:01,24:03:01; B*39:06:02,50:01; C*02; DPB1*04:01; DQA1*05:01,01:02; DQB1*05:02,02:01; DRB1*03:01,16:01; DRB3*02:02; DRB5*02 (IPD-IMGT/HLA=11657) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167418 CVCL_DT23 ND00299 transformed cell line human CVCL_DT23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167419 CVCL_E524 CHI007 transformed cell line human CVCL_E524 HLA typing: A*29:01:01:01,24:10:01; B*07:05:01:01,51:01:01:01; C*07:04:01,15:29; DPA1*01:03:01,04:01; DPB1*03:01:01,13:01; DQA1*01:05:01,03:03:01; DQB1*04:01:01,05:01:01; DRB1*04:05:01,10:01:01; DRB4*01:03:01 (IPD-IMGT/HLA=11733); HLA typing: A*29:01:01:01,24:10:01; B*07:05:01:01,51:01:01:01; C*15:29,07:04:01:01; DPA1*01:03:01:02,04:01; DPB1*13:01:01,104:01; DQA1*01:05:01,03:03:01:03; DQB1*04:01:01,05:01:01:02,04:05:01; DRB1*10:01:01:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167420 CVCL_DT24 ND00301 transformed cell line human CVCL_DT24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167421 CVCL_E538 CTM3953540 transformed cell line human CVCL_E538 HLA typing: A*80:01,03:01; B*08:01,55:01; C*03:03,07:01 (IPD-IMGT/HLA=10453) CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167422 CVCL_DT38 ND00337 transformed cell line human CVCL_DT38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167423 CVCL_E539 CTM4955926 transformed cell line human CVCL_E539 HLA typing: A*33:03:01,11:01; B*35; C*04:01 (IPD-IMGT/HLA=10456) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167424 CVCL_DT39 ND00338 transformed cell line human CVCL_DT39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167425 CVCL_E532 COL,S transformed cell line human CVCL_E532 HLA typing: A*03,24; B*07,40; C*07; DPB1*04:01,05:01; DQA1*01:02,01:04; DQB1*05:03,06; DRB1*15:01,14:05; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=11738) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167426 CVCL_DT32 ND00321 transformed cell line human CVCL_DT32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167427 CVCL_E533 COP,AH transformed cell line human CVCL_E533 HLA typing: A*02,03; B*44; C*05:01; DPB1*04:01,05:01; DQA1*01:02,03:01; DQB1*03:01,06:01; DRB1*04:01,13:02; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=11658) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082212; probable Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167428 CVCL_DT33 ND00322 transformed cell line human CVCL_DT33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167429 CVCL_E530 CODI transformed cell line human CVCL_E530 HLA typing: A*80:01; B*58,70; C*02 (IPD-IMGT/HLA=10427) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94071404; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167430 CVCL_DT30 ND00316 transformed cell line human CVCL_DT30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167431 CVCL_E531 COL,E transformed cell line human CVCL_E531 HLA typing: A*02; B*15; C*03; DPB1*04:01,13:01; DQA1*03; DQB1*03:02; DRB1*04:01; DRB4*01:01 (IPD-IMGT/HLA=11689) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167432 CVCL_DT31 ND00317 transformed cell line human CVCL_DT31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167433 CVCL_E536 CRIS transformed cell line human CVCL_E536 HLA typing: A*02,31; B*51,63; C*w03 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21167434 CVCL_DT36 ND00335 transformed cell line human CVCL_DT36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167435 CVCL_E537 CTM1953541 transformed cell line human CVCL_E537 HLA typing: A*80:01,30:02; B*08:01,27; C*02:02,07:01 (IPD-IMGT/HLA=10450) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167436 CVCL_DT37 ND00336 transformed cell line human CVCL_DT37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167437 CVCL_E534 COX transformed cell line human CVCL_E534 HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01:03:01:03; DPB1*03:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:02; DRB1*03:01:01; DRB3*01:01:02:01 (IPD-IMGT/HLA=10429); HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01:03:01:03; DPB1*03:01:01; DQA1*05:01:01:02; DQB1*02:01:01; DRB1*03:01:01; DRB3*01:01:02 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167438 CVCL_DT34 ND00327 transformed cell line human CVCL_DT34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167439 CVCL_E535 CRB transformed cell line human CVCL_E535 HLA typing: A*66:02,30:02:01; B*18:01,58:01; C*07:01; DPB1*01:01:02,02:01:02 (IPD-IMGT/HLA=10432) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167440 CVCL_DT35 ND00328 transformed cell line human CVCL_DT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167441 CVCL_3C10 HQ00214 transformed cell line human CVCL_3C10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167442 CVCL_3C11 HQ00215 transformed cell line human CVCL_3C11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167443 CVCL_3C14 HQ00218 transformed cell line human CVCL_3C14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167444 CVCL_3C15 HQ00219 transformed cell line human CVCL_3C15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167445 CVCL_3C12 HQ00216 transformed cell line human CVCL_3C12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167446 CVCL_3C13 HQ00217 transformed cell line human CVCL_3C13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167447 CVCL_3C18 HQ00222 transformed cell line human CVCL_3C18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167448 CVCL_3C19 HQ00224 transformed cell line human CVCL_3C19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167449 CVCL_3C16 HQ00220 transformed cell line human CVCL_3C16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167450 CVCL_3C17 HQ00221 transformed cell line human CVCL_3C17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167451 CVCL_VI62 SN48 hybrid cell line house mouse CVCL_VI62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Hybrid of septal neuronal cells from postnatal day 21 mice with the N18TG2 neuroblastoma 21167452 CVCL_VI63 FM3A tsFT20 cancer cell line house mouse CVCL_VI63 CL:0000010 Sequence variation: Mutation; MGI; MGI:99660; Pola1; Simple; p.Ser1180Phe (c.3539C>T); Zygosity=Unspecified (PubMed=8125989) Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Temperature sensitive phenotype Stop growing at 39 Celsius. Defective in DNA replication at the non-permissive temperature (PubMed=3856858). Doubling time: 16 hours (PubMed=3856858) 21167453 CVCL_VI60 9H11/53 hybridoma house mouse CVCL_VI60 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) merozoite surface protein 1 (MSP1) (19 kDa fragment). 21167454 CVCL_VI61 A31-714 spontaneously immortalized cell line house mouse CVCL_VI61 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21167455 CVCL_VI66 5TGM1 cancer cell line house mouse CVCL_VI66 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/KaLwRij. Characteristics: Produces IgG2b kappa 21167456 CVCL_VI67 MOPC315.4 cancer cell line house mouse CVCL_VI67 CL:0000010 Breed/subspecies: BALB/c. Monoclonal antibody isotype: IgA, lambda 21167457 CVCL_VI64 FM3A H-5 cancer cell line house mouse CVCL_VI64 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Doubling time: 15 hours (PubMed=1170081) 21167458 CVCL_VI65 FM3A EM6-TG cl.13 cancer cell line house mouse CVCL_VI65 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21167459 CVCL_VI68 MOPC315.BM cancer cell line house mouse CVCL_VI68 CL:0000010 Breed/subspecies: BALB/c. Monoclonal antibody isotype: IgA, lambda 21167460 CVCL_VI69 NMT-1 cancer cell line Norway rat CVCL_VI69 CL:0000010 Breed/subspecies: Wistar Mishima (WM/Ms). Unspecified Doubling time: 16.0 hours (PubMed=7507475; PubMed=8613682) 21167461 CVCL_3C21 HQ00226 transformed cell line human CVCL_3C21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167462 CVCL_3C22 HQ00227 transformed cell line human CVCL_3C22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167463 CVCL_3C20 HQ00225 transformed cell line human CVCL_3C20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167464 CVCL_3C25 HQ00230 transformed cell line human CVCL_3C25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167465 CVCL_3C26 HQ00231 transformed cell line human CVCL_3C26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167466 CVCL_3C23 HQ00228 transformed cell line human CVCL_3C23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167467 CVCL_3C24 HQ00229 transformed cell line human CVCL_3C24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167468 CVCL_3C29 HQ00234 transformed cell line human CVCL_3C29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167469 CVCL_3C27 HQ00232 transformed cell line human CVCL_3C27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167470 CVCL_3C28 HQ00233 transformed cell line human CVCL_3C28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167471 CVCL_VI51 3E10/18 hybridoma house mouse CVCL_VI51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium falciparum (isolate K1) rhoptry protein 3 (RhopH3). 21167472 CVCL_VI52 3E6/64 hybridoma house mouse CVCL_VI52 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Plasmodium falciparum rhoptry-associated protein 2 (RAP2). 21167473 CVCL_VI50 3B10/64 hybridoma house mouse CVCL_VI50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry-associated protein 1 (RAP1). 21167474 CVCL_VI55 5D5/47 hybridoma house mouse CVCL_VI55 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) merozoite surface protein 1 (MSP1). 21167475 CVCL_VI56 6F4/53 hybridoma house mouse CVCL_VI56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) high-molecular-mass rhoptry protein complex. 21167476 CVCL_VI53 3H7/64 hybridoma house mouse CVCL_VI53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry-associated protein 2 (RAP2). 21167477 CVCL_VI54 5D11/49 hybridoma house mouse CVCL_VI54 From: Saul A.; National Institute of Allergy and Infectious Diseases, National Institutes of Health; Rockville; USA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry protein 1 (RhopH1). 21167478 CVCL_VI59 8G10/48 hybridoma house mouse CVCL_VI59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) merozoite surface protein 2 (MSP2). 21167479 CVCL_VI57 7H8/50 hybridoma house mouse CVCL_VI57 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry-associated protein 1 (RAP1). 21167480 CVCL_VI58 8D12/49 hybridoma house mouse CVCL_VI58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry protein 3 (RhopH3). 21167481 CVCL_VI40 9G9 hybridoma house mouse CVCL_VI40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands median and distal lateral lobes. 21167482 CVCL_VI41 P5E2-2F7-1B3 hybridoma house mouse CVCL_VI41 CL:0000010 Discontinued: BEI_Resources; MRA-878; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P68874; Plasmodium falciparum (isolate 3D7) PFS230 21167483 CVCL_VI44 HEK-TLR4-YFP transformed cell line human CVCL_VI44 CL:0000010 Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with YFP fused in frame to the C-terminus of TLR4 21167484 CVCL_VI45 HEK-TLR4-YFP/MD-2 transformed cell line human CVCL_VI45 CL:0000010 Transfected with: HGNC; 17156; LY96; Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with YFP fused in frame to the C-terminus of TLR4 21167485 CVCL_VI42 P5E2-2F7-2B4 hybridoma house mouse CVCL_VI42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P68874; Plasmodium falciparum (isolate 3D7) PFS230. 21167486 CVCL_VI43 HEK-TLR2-YFP transformed cell line human CVCL_VI43 CL:0000010 Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with YFP fused in frame to the C-terminus of TLR2 21167487 CVCL_VI48 15E3/53 hybridoma house mouse CVCL_VI48 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) merozoite surface protein 1 (MSP1). 21167488 CVCL_VI49 3A9/48 hybridoma house mouse CVCL_VI49 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plasmodium falciparum (isolate FCQ27/PNG) rhoptry-associated protein 2 (RAP2). 21167489 CVCL_N098 GM09091 transformed cell line human CVCL_N098 HLA typing: A*01:01:01,32:01:01; B*15:01:01,27:05:02; C*01:02:01,02:02:02; DPA1*01:03:01,02:01:01; DPB1*03:01:01,10:01:01; DQA1*01:01:01,03:01:01; DQB1*03:02:01,05:01:01; DRB1*01:01:01,04:04:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167490 CVCL_VI46 HEK-TLR9-YFP transformed cell line human CVCL_VI46 CL:0000010 Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with YFP fused in frame to the C-terminus of TLR9 21167491 CVCL_VI47 4B7 [Mouse hybridoma against P.falciparum pfs25] hybridoma house mouse CVCL_VI47 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7KQL2; Plasmodium falciparum (isolate 3D7) 25 kDa ookinete surface antigen (pfs25). 21167492 CVCL_N099 GM09099 transformed cell line human CVCL_N099 HLA typing: A*02:01:01,03:01:01; B*14:02:01,45:01:01; C*06:02:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:02:01; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:09:01; DRB1*07:01:01,13:02:01; DRB3*03:01:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167493 CVCL_N096 GM09015 transformed cell line human CVCL_N096 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167494 CVCL_N097 GM09036 transformed cell line human CVCL_N097 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167495 CVCL_N094 GM08930 transformed cell line human CVCL_N094 CL:0000010 Population: Caucasian; Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167496 CVCL_N095 GM08932 transformed cell line human CVCL_N095 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167497 CVCL_3C00 HQ00204 transformed cell line human CVCL_3C00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167498 CVCL_3C03 HQ00207 transformed cell line human CVCL_3C03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167499 CVCL_3C04 HQ00208 transformed cell line human CVCL_3C04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167500 CVCL_3C01 HQ00205 transformed cell line human CVCL_3C01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167501 CVCL_3C02 HQ00206 transformed cell line human CVCL_3C02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167502 CVCL_3C07 HQ00211 transformed cell line human CVCL_3C07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167503 CVCL_3C08 HQ00212 transformed cell line human CVCL_3C08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167504 CVCL_3C05 HQ00209 transformed cell line human CVCL_3C05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167505 CVCL_3C06 HQ00210 transformed cell line human CVCL_3C06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167506 CVCL_3C09 HQ00213 transformed cell line human CVCL_3C09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167507 CVCL_VI30 17D4 hybridoma house mouse CVCL_VI30 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Anophele aegypti female and male salivary glands basal lamina, ovaries and midgut tissue. 21167508 CVCL_VI33 19A2 hybridoma house mouse CVCL_VI33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes (Note=Also reacts with Culex pipiens salivary glands). 21167509 CVCL_VI34 20B6 hybridoma house mouse CVCL_VI34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes (Note=Also reacts with Anopheles gambiae and Culex pipiens salivary glands). 21167510 CVCL_VI31 18D5 hybridoma house mouse CVCL_VI31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands, ovaries and midgut tissue (Note=Also reacts with Culex pipiens salivary glands). 21167511 CVCL_VI32 18E12 hybridoma house mouse CVCL_VI32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes and ovaries (Note=Also reacts with Culex pipiens salivary glands). 21167512 CVCL_VI37 6D12 hybridoma house mouse CVCL_VI37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes. 21167513 CVCL_VI38 6E9 hybridoma house mouse CVCL_VI38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands and midgut tissue. 21167514 CVCL_VI35 20G12 hybridoma house mouse CVCL_VI35 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands distal lateral lobes. 21167515 CVCL_VI36 20G8 hybridoma house mouse CVCL_VI36 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes and ovaries (Note=Also reacts with Culex pipiens salivary glands). 21167516 CVCL_VI39 7F8 hybridoma house mouse CVCL_VI39 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands median and distal lateral lobes. 21167517 CVCL_N081 GM08385 transformed cell line human CVCL_N081 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167518 CVCL_N082 GM08428 transformed cell line human CVCL_N082 HLA typing: A*01:01:01,24:02:01; B*15:01:01,55:01:01; C*03:03:01,03:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:03:01,05:05:01; DQB1*03:01:01,06:03:01; DRB1*12:01:01G,13:01:01; DRB3*01:01:02,02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167519 CVCL_N080 GM08384 transformed cell line human CVCL_N080 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167520 CVCL_VI22 ZM90633 transformed cell line human CVCL_VI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167521 CVCL_VI23 ZM90634 transformed cell line human CVCL_VI23 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=10606667) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167522 CVCL_VI20 TUR90060 transformed cell line human CVCL_VI20 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1165Ter (c.3493C>T); ClinVar=VCV000005445; Zygosity=Heterozygous (PubMed=10606667) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167523 CVCL_VI21 ZM90630 transformed cell line human CVCL_VI21 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys1046fs*14 (c.3139-1G>C) (IVS25-1G>C); ClinVar=VCV000005447; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=10606667) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167524 CVCL_VI26 12C9 hybridoma house mouse CVCL_VI26 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes. 21167525 CVCL_N078 GM08297 transformed cell line human CVCL_N078 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167526 CVCL_VI27 13B11 hybridoma house mouse CVCL_VI27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands median and distal lateral lobes and ovaries. 21167527 CVCL_N079 GM08371 transformed cell line human CVCL_N079 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167528 CVCL_VI24 1C10 [Mouse hybridoma against A.aegypti salivary glands] hybridoma house mouse CVCL_VI24 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female salivary glands median and distal lateral lobes. 21167529 CVCL_N076 GM08228 transformed cell line human CVCL_N076 HLA typing: A*01:01:01,02:01:01; B*08:01:01,40:02:01; C*02:02:02,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:04:01; DRB1*03:01:01,13:02:01; DRB3*01:01:02,03:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Lys281del (c.841_843delAAG) (2613_2615delAGA); ClinVar=VCV000039396; Zygosity=Heterozygous; Note=CYP2D6*9 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167530 CVCL_VI25 10C8 hybridoma house mouse CVCL_VI25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes. 21167531 CVCL_N077 GM08288 transformed cell line human CVCL_N077 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167532 CVCL_N074 GM07905 transformed cell line human CVCL_N074 HLA typing: A*01:CNJK,30:02; B*37:01,49:01; C*06:02,07:CVAG; DRB1*07:01,11:01 (IPD-IMGT/HLA=15809) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167533 CVCL_N075 GM08100 finite cell line human CVCL_N075 CL:0000010 Population: Egyptian; Derived from sampling site: Cell type=Fibroblast. Male 21167534 CVCL_VI28 13F10 hybridoma house mouse CVCL_VI28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands basal lamina. 21167535 CVCL_N072 GM07735 transformed cell line human CVCL_N072 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167536 CVCL_VI29 16B5 hybridoma house mouse CVCL_VI29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anophele aegypti female and male salivary glands distal lateral lobes. 21167537 CVCL_N073 GM07895 transformed cell line human CVCL_N073 CL:0000010 Population: Indo Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Human variation panel 21167538 CVCL_N092 GM08919 transformed cell line human CVCL_N092 HLA typing: A*02:05:01,23:01:01; B*35:02:01,51:08:01; C*04:01:01,16:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,104:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRB1*11:04:01,13:03:01; DRB3*01:01:02,02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167539 CVCL_N093 GM08927 transformed cell line human CVCL_N093 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167540 CVCL_N090 GM08787 transformed cell line human CVCL_N090 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167541 CVCL_N091 GM08873 transformed cell line human CVCL_N091 HLA typing: A*02:DFKP,34:02; B*08:XKT,51:CVAE; C*07:CVAG,16:01; DRB1*13:02,15:01 (IPD-IMGT/HLA=16403) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167542 CVCL_VI11 LGS90635 transformed cell line human CVCL_VI11 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=10606667) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167543 CVCL_VI12 OW90650 transformed cell line human CVCL_VI12 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=9230208) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167544 CVCL_VI10 LGS90625 transformed cell line human CVCL_VI10 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Heterozygous (PubMed=10606667) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167545 CVCL_N089 GM08786 transformed cell line human CVCL_N089 HLA typing: A*02:01:01,03:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRB1*15:01:01,15:01:01; DRB5*01:01:01,01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167546 CVCL_VI15 SYR10011 transformed cell line human CVCL_VI15 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1229fs*1246 (c.3688_3691delACAG); Zygosity=Homozygous (PubMed=10606667) Population: Syrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167547 CVCL_VI16 SY90575 transformed cell line human CVCL_VI16 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1165Ter (c.3493C>T); ClinVar=VCV000005445; Zygosity=Homozygous (PubMed=9230208) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167548 CVCL_N087 GM08753 transformed cell line human CVCL_N087 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167549 CVCL_VI13 SYR10009 transformed cell line human CVCL_VI13 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1229fs*1246 (c.3688_3691delACAG); Zygosity=Heterozygous (PubMed=10606667) Population: Syrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167550 CVCL_N088 GM08779 transformed cell line human CVCL_N088 HLA typing: A*01:CNJK,02:DFKP; B*07:CZZS,44:WRJ; C*05:AC,07:CVAG; DRB1*04:01,15:03 (IPD-IMGT/HLA=20687) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167551 CVCL_VI14 SYR10010 transformed cell line human CVCL_VI14 CL:0000010 Population: Syrian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167552 CVCL_N085 P25.91 hybridoma house mouse CVCL_N085 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9120 21167553 CVCL_VI19 TUR90050 transformed cell line human CVCL_VI19 CL:0000010 Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167554 CVCL_N086 GM08729 transformed cell line human CVCL_N086 HLA typing: A*03:01:01,11:01:01; B*35:03:01,56:01:01; C*01:02:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:03:01,02:01:01; DQB1*03:03:02,06:03:01; DRB1*07:01:01,13:01:01; DRB3*02:02:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167555 CVCL_N083 GM08587 transformed cell line human CVCL_N083 HLA typing: A*24:02:01,31:01:02; B*35:01:01,35:20:01; C*03:04:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:02:01G; DQA1*03:01:01,05:03; DQB1*03:01:01,03:02:01; DRB1*04:07:01,14:06:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167556 CVCL_VI17 SY90576 transformed cell line human CVCL_VI17 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1165Ter (c.3493C>T); ClinVar=VCV000005445; Zygosity=Heterozygous (from familial inference of SY90575) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21167557 CVCL_N084 P25.15 hybridoma house mouse CVCL_N084 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9140 21167558 CVCL_VI18 TUR90010 transformed cell line human CVCL_VI18 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1165Ter (c.3493C>T); ClinVar=VCV000005445; Zygosity=Homozygous (PubMed=10606667) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167559 CVCL_N060 GM07114 transformed cell line human CVCL_N060 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM07114; probable Female Part of: Human variation panel 21167560 CVCL_VI00 LN-V transformed cell line human CVCL_VI00 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167561 CVCL_VI01 HiPS-RIKEN-3A-TAL1 induced pluripotent stem cell human CVCL_VI01 CL:0000010 Transfected with: HGNC; 11556; TAL1. Population: Japanese Female 21167562 CVCL_N058 GM06940 finite cell line human CVCL_N058 CL:0000010 Population: South American (Andes); Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21167563 CVCL_N059 GM07104 transformed cell line human CVCL_N059 HLA typing: A*29:02,68:01; B*15:CWZY,35:BVYT; C*02:10,04:CVAF; DRB1*08:04,11:02 (IPD-IMGT/HLA=20693) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167564 CVCL_N056 GM06865 transformed cell line human CVCL_N056 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21167565 CVCL_VI04 HiDEP-2 transformed cell line human CVCL_VI04 CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Cell type=Erythroid progenitor cell. Female Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells 21167566 CVCL_N057 GM06904 transformed cell line human CVCL_N057 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; Zygosity=Heterozygous (PubMed=25776194); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[29]; Zygosity=Heterozygous (PubMed=25776194) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167567 CVCL_VI05 HUDEP-1 transformed cell line human CVCL_VI05 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord blood Cell type=Erythroid progenitor cell.. Unspecified Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells 21167568 CVCL_N054 GM06415 transformed cell line human CVCL_N054 CL:0000010 Population: Latino or Hispanic; Dominican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167569 CVCL_VI02 HiPS-RIKEN-4A-TAL1 induced pluripotent stem cell human CVCL_VI02 CL:0000010 Transfected with: HGNC; 11556; TAL1. Population: Japanese Female 21167570 CVCL_N055 GM06416 transformed cell line human CVCL_N055 CL:0000010 Population: Latino or Hispanic; Dominican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167571 CVCL_VI03 HiDEP-1 transformed cell line human CVCL_VI03 CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Cell type=Erythroid progenitor cell. Female Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells Expresses embryonic and fetal hemoglobin. 21167572 CVCL_VI08 AUS40010 transformed cell line human CVCL_VI08 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg389Glufs*4 (c.1165delA); ClinVar=VCV000238117; Zygosity=Heterozygous (PubMed=9230208) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167573 CVCL_N052 GM06331 finite cell line human CVCL_N052 CL:0000010 Sequence variation: Mutation; HGNC; 16002; MPLKIP; Simple; p.Gly46Glufs*13 (c.137_138delGG) (187_188delGG); ClinVar=VCV000001845; Zygosity=Homozygous (Coriell) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Human variation panel 21167574 CVCL_VI09 AUS40025 transformed cell line human CVCL_VI09 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg389Glufs*4 (c.1165delA); ClinVar=VCV000238117; Zygosity=Heterozygous (PubMed=9230208); Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln1153fs*1158 (c.3572+2T>A); Zygosity=Heterozygous (PubMed=9230208) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167575 CVCL_N053 GM06342 finite cell line human CVCL_N053 CL:0000010 Sequence variation: Gene fusion; HGNC; 4829; HBD + HGNC; 4831; HBG1; Name(s)=HBG1-HBD, Hb Kenya; Note=In frame fusion of AA 1-81 of HBG1 with AA 84-146 of HBD (Coriell) Population: African; Kenyan; Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21167576 CVCL_N050 GM06231 finite cell line human CVCL_N050 CL:0000010 Sequence variation: Mutation; HGNC; 8857; PEX16; Simple; p.Arg176Ter (c.526C>T); ClinVar=VCV000006466; Zygosity=Homozygous (PubMed=9922452) Population: Africans north of the Sahara; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167577 CVCL_VI06 HUDEP-2 transformed cell line human CVCL_VI06 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Miscellaneous: Please contact directly Dr Nakamura Y. for the use of this cell line (yukionak@brc.riken.jp). Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord blood Cell type=Erythroid progenitor cell.. Omics: ATAC-seq; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells Doubling time: 22.7 +- 5.0 hours (PubMed=31753923) 21167578 CVCL_N051 GM06325 finite cell line human CVCL_N051 CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167579 CVCL_VI07 HUDEP-3 transformed cell line human CVCL_VI07 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord blood Cell type=Erythroid progenitor cell.. Unspecified Characteristics: After in vitro induction of differentiation, will produce enucleated red blood cells 21167580 CVCL_N070 GM07711 finite cell line human CVCL_N070 CL:0000010 Population: Egyptian; Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21167581 CVCL_N071 GM07712 transformed cell line human CVCL_N071 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167582 CVCL_N069 GM07554 transformed cell line human CVCL_N069 HLA typing: A*02:DFKP,66:02; B*53:01,58:VE; C*04:CVAF,07:CVAG; DRB1*15:03 (IPD-IMGT/HLA=20688) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21167583 CVCL_N067 GM07527 transformed cell line human CVCL_N067 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167584 CVCL_N068 GM07546 transformed cell line human CVCL_N068 HLA typing: A*11:01:01,32:01:01; B*49:01:01,49:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,05:05:01; DQB1*03:01:01,06:02:01; DRB1*11:01:01,15:01:01; DRB3*02:02:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167585 CVCL_N065 GM07495 transformed cell line human CVCL_N065 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167586 CVCL_N066 GM07518 transformed cell line human CVCL_N066 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167587 CVCL_N063 GM07439 transformed cell line human CVCL_N063 HLA typing: A*29:02,68:02; B*42:02,53:01; C*04:CVAF,17:MN; DRB1*04:03,15:03 (IPD-IMGT/HLA=23057); HLA typing: A*29:02:01,68:02:01; B*42:02:01,53:01:01; C*04:01:01,17:01:01; DPA1*02:02:02,03:01; DPB1*01:01:01,105:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:02:01; DRB1*04:03:01,15:03:01; DRB4*01:03:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167588 CVCL_N064 GM07462 transformed cell line human CVCL_N064 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167589 CVCL_N061 GM07407 transformed cell line human CVCL_N061 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+1G>A (IVS1,G>A,+1); ClinVar=VCV000015436; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+6T>C (IVS1,T>C,+6) (IVS I-6 T>C); ClinVar=VCV000015450; Zygosity=Heterozygous (Coriell) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167590 CVCL_N062 GM07426 transformed cell line human CVCL_N062 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Ser73Lysfs*2 (c.217dupA) (c.216_217insA) (insA codons71/72); ClinVar=VCV000015419; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-197C>T (IVS2-654C>T); ClinVar=VCV000015458; Zygosity=Heterozygous (Coriell) Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167591 CVCL_3C98 HQ00305 transformed cell line human CVCL_3C98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167592 CVCL_3C99 HQ00306 transformed cell line human CVCL_3C99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167593 CVCL_3C96 HQ00303 transformed cell line human CVCL_3C96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167594 CVCL_3C97 HQ00304 transformed cell line human CVCL_3C97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167595 CVCL_3C90 HQ00297 transformed cell line human CVCL_3C90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167596 CVCL_3C91 HQ00298 transformed cell line human CVCL_3C91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167597 CVCL_3C94 HQ00301 transformed cell line human CVCL_3C94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167598 CVCL_3C95 HQ00302 transformed cell line human CVCL_3C95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167599 CVCL_3C92 HQ00299 transformed cell line human CVCL_3C92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167600 CVCL_3C93 HQ00300 transformed cell line human CVCL_3C93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167601 CVCL_3C76 HQ00282 transformed cell line human CVCL_3C76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167602 CVCL_3C77 HQ00283 transformed cell line human CVCL_3C77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167603 CVCL_3C74 HQ00280 transformed cell line human CVCL_3C74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167604 CVCL_3C75 HQ00281 transformed cell line human CVCL_3C75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167605 CVCL_3C78 HQ00284 transformed cell line human CVCL_3C78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167606 CVCL_3C79 HQ00285 transformed cell line human CVCL_3C79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167607 CVCL_3C72 HQ00278 transformed cell line human CVCL_3C72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167608 CVCL_3C73 HQ00279 transformed cell line human CVCL_3C73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167609 CVCL_3C70 HQ00276 transformed cell line human CVCL_3C70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167610 CVCL_3C71 HQ00277 transformed cell line human CVCL_3C71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167611 CVCL_3C87 HQ00293 transformed cell line human CVCL_3C87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167612 CVCL_3C88 HQ00294 transformed cell line human CVCL_3C88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167613 CVCL_3C85 HQ00291 transformed cell line human CVCL_3C85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167614 CVCL_3C86 HQ00292 transformed cell line human CVCL_3C86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167615 CVCL_3C89 HQ00296 transformed cell line human CVCL_3C89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167616 CVCL_3C80 HQ00286 transformed cell line human CVCL_3C80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167617 CVCL_3C83 HQ00289 transformed cell line human CVCL_3C83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167618 CVCL_3C84 HQ00290 transformed cell line human CVCL_3C84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167619 CVCL_3C81 HQ00287 transformed cell line human CVCL_3C81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167620 CVCL_3C82 HQ00288 transformed cell line human CVCL_3C82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167621 CVCL_3C54 HQ00260 transformed cell line human CVCL_3C54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167622 CVCL_3C55 HQ00261 transformed cell line human CVCL_3C55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167623 CVCL_3C52 HQ00258 transformed cell line human CVCL_3C52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167624 CVCL_3C53 HQ00259 transformed cell line human CVCL_3C53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167625 CVCL_3C58 HQ00264 transformed cell line human CVCL_3C58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167626 CVCL_3C59 HQ00265 transformed cell line human CVCL_3C59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167627 CVCL_3C56 HQ00262 transformed cell line human CVCL_3C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167628 CVCL_3C57 HQ00263 transformed cell line human CVCL_3C57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167629 CVCL_3C50 HQ00256 transformed cell line human CVCL_3C50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167630 CVCL_3C51 HQ00257 transformed cell line human CVCL_3C51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167631 CVCL_3C65 HQ00271 transformed cell line human CVCL_3C65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167632 CVCL_3C66 HQ00272 transformed cell line human CVCL_3C66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167633 CVCL_3C63 HQ00269 transformed cell line human CVCL_3C63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167634 CVCL_3C64 HQ00270 transformed cell line human CVCL_3C64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167635 CVCL_3C69 HQ00275 transformed cell line human CVCL_3C69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167636 CVCL_3C67 HQ00273 transformed cell line human CVCL_3C67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167637 CVCL_3C68 HQ00274 transformed cell line human CVCL_3C68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167638 CVCL_VI91 SKG-IIB cancer cell line human CVCL_VI91 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 28 hours, at 40th passage (CelloPub=CLPUB00434) 21167639 CVCL_VI92 MUSIi005-A induced pluripotent stem cell human CVCL_VI92 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Urine Cell type=Epithelial cell.. Female 21167640 CVCL_VI90 HCC36 cancer cell line human CVCL_VI90 CL:0000010 Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Virology: Contains integrated hepatitis B virus (HBV) genome DNA in at least 4 sites 21167641 CVCL_VI95 GM26580 finite cell line human CVCL_VI95 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg576Ter (c.1726C>T) (p.Arg572Ter, c.1714C>T); ClinVar=VCV000488988; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167642 CVCL_VI96 HM-1 [Human cervical carcinoma] cancer cell line human CVCL_VI96 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Female Doubling time: 35 hours (PubMed=28484083) 21167643 CVCL_VI93 GM27159 finite cell line human CVCL_VI93 CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21167644 CVCL_VI94 GM27161 finite cell line human CVCL_VI94 CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21167645 CVCL_VI99 WM3314 cancer cell line human CVCL_VI99 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Part of: Wistar Institute melanoma cell line collection 21167646 CVCL_VI97 GM25516 finite cell line human CVCL_VI97 CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg109Trp (c.325C>T); ClinVar=VCV000012988; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg2241Ter (c.6721C>T); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167647 CVCL_VI98 HT-1080/Arabidopsis hybrid chr15 hybrid cell line CVCL_VI98 CL:0000010 Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Hybrid human cell containing an Arabidopsis chromosome translocated on hum chr15; Characteristics: Arabidopsis cells were transformed using two constructs, one containing EGFP under the control of the CAG promoter and the other containing Bsd under the control of the human pGK promoter The CAG and pGK promoter have high activity only in human cells, resulting in the CC strong EGFP expression only after the plant chromosome carrying marker genes was transferred into human cells. 21167648 CVCL_3C61 HQ00267 transformed cell line human CVCL_3C61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167649 CVCL_3C62 HQ00268 transformed cell line human CVCL_3C62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167650 CVCL_3C60 HQ00266 transformed cell line human CVCL_3C60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167651 CVCL_3C32 HQ00238 transformed cell line human CVCL_3C32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167652 CVCL_3C33 HQ00239 transformed cell line human CVCL_3C33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167653 CVCL_3C30 HQ00235 transformed cell line human CVCL_3C30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167654 CVCL_3C31 HQ00237 transformed cell line human CVCL_3C31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167655 CVCL_3C36 HQ00242 transformed cell line human CVCL_3C36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167656 CVCL_3C37 HQ00243 transformed cell line human CVCL_3C37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167657 CVCL_3C34 HQ00240 transformed cell line human CVCL_3C34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167658 CVCL_3C35 HQ00241 transformed cell line human CVCL_3C35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167659 CVCL_3C38 HQ00244 transformed cell line human CVCL_3C38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167660 CVCL_3C39 HQ00245 transformed cell line human CVCL_3C39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167661 CVCL_VI80 NOBAH-2 transformed cell line Norway rat CVCL_VI80 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167662 CVCL_VI81 NOBAL-1 transformed cell line Norway rat CVCL_VI81 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167663 CVCL_VI84 NOBAL-4 transformed cell line Norway rat CVCL_VI84 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167664 CVCL_VI85 NOBAL-5 transformed cell line Norway rat CVCL_VI85 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167665 CVCL_VI82 NOBAL-2 transformed cell line Norway rat CVCL_VI82 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167666 CVCL_VI83 NOBAL-3 transformed cell line Norway rat CVCL_VI83 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167667 CVCL_VI88 PL16B transformed cell line human CVCL_VI88 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Female 21167668 CVCL_VI89 PL16T transformed cell line human CVCL_VI89 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Female 21167669 CVCL_VI86 NOBEC-1 transformed cell line Norway rat CVCL_VI86 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Olfactory ensheathing cell.; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: 68 hours (PubMed=8374779) 21167670 CVCL_VI87 GM26650 induced pluripotent stem cell human CVCL_VI87 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; c.189+1G>T (IVS3+1G>T); Zygosity=Hemizygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167671 CVCL_3C43 HQ00249 transformed cell line human CVCL_3C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167672 CVCL_3C44 HQ00250 transformed cell line human CVCL_3C44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167673 CVCL_3C41 HQ00247 transformed cell line human CVCL_3C41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167674 CVCL_3C42 HQ00248 transformed cell line human CVCL_3C42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167675 CVCL_3C47 HQ00253 transformed cell line human CVCL_3C47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167676 CVCL_3C48 HQ00254 transformed cell line human CVCL_3C48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167677 CVCL_3C45 HQ00251 transformed cell line human CVCL_3C45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167678 CVCL_3C46 HQ00252 transformed cell line human CVCL_3C46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167679 CVCL_3C49 HQ00255 transformed cell line human CVCL_3C49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167680 CVCL_VI70 NMT-1R cancer cell line Norway rat CVCL_VI70 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: Wistar Mishima (WM/Ms). Unspecified Characteristics: More radioresistant than parent cell line Its radiation sensitivity is 165 +- 3 cGy. Doubling time: 13.6 hours (PubMed=8613682) 21167681 CVCL_VI73 AOBA-3 transformed cell line Norway rat CVCL_VI73 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167682 CVCL_VI74 AOBA-4 transformed cell line Norway rat CVCL_VI74 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167683 CVCL_VI71 AOBA-1 transformed cell line Norway rat CVCL_VI71 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167684 CVCL_VI72 AOBA-2 transformed cell line Norway rat CVCL_VI72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167685 CVCL_VI77 AOBEC-3 transformed cell line Norway rat CVCL_VI77 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: Sprague Dawley. Unspecified 21167686 CVCL_VI78 AOBEC-4 transformed cell line Norway rat CVCL_VI78 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: Sprague Dawley. Unspecified 21167687 CVCL_VI75 AOBEC-1 transformed cell line Norway rat CVCL_VI75 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: Sprague Dawley. Unspecified 21167688 CVCL_VI76 AOBEC-2 transformed cell line Norway rat CVCL_VI76 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb; Breed/subspecies: Sprague Dawley. Unspecified 21167689 CVCL_VI79 NOBAH-1 transformed cell line Norway rat CVCL_VI79 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; olfactory bulb Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21167690 CVCL_3C40 HQ00246 transformed cell line human CVCL_3C40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167691 CVCL_E628 FH43 transformed cell line human CVCL_E628 HLA typing: A*30:01,33:01; B*53:01,81:01; C*04,08; DPB1*03:01:01,11:01:01; DQA1*02:01,03:03; DQB1*02:02,02:02; DRB1*07:01:01,11:08:02; DRB3*03:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=10782) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167692 CVCL_DU28 ND01591 transformed cell line human CVCL_DU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167693 CVCL_E629 FH44 transformed cell line human CVCL_E629 HLA typing: A*02:03:01,11:01:01:01; B*15:02:01:01,38:02:01; C*07:02:01:01,08:147; DPA1*02:02:02:01; DPB1*02:02,05:01:01; DQA1*01:03:01:05,03:03:01:03; DQB1*04:01:01:01; DRB1*04:05:01:01;08:14:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=10908) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167694 CVCL_DU29 ND01600 transformed cell line human CVCL_DU29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167695 CVCL_E626 FH41 transformed cell line human CVCL_E626 HLA typing: A*02:05,31:01; B*35:04,49:01; C*04:01/04:09N/04:30/04:82,07:01/07:06/07:18; DPB1*04:01:01,04:02; DQA1*03:03,04:01:01; DQB1*03:02:01,04:02; DRB1*04:05:01,08:07; DRB4*01:03 (IPD-IMGT/HLA=11285) CL:0000010 Population: Brazilian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167696 CVCL_DU26 ND01560 transformed cell line human CVCL_DU26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167697 CVCL_E627 FH42 transformed cell line human CVCL_E627 HLA typing: A*02,24; B*35,51; C*01:02,04:04; DPB1*04:02; DQA1*03:02,04:01; DQB1*03:03,04:02; DRB1*08:11,09:01; DRB4*01:03 (IPD-IMGT/HLA=10261) CL:0000010 Population: Native North American; Tlingit; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167698 CVCL_DU27 ND01572 transformed cell line human CVCL_DU27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167699 CVCL_E620 FH35 transformed cell line human CVCL_E620 HLA typing: A*34:01,34:01; B*15,15:02; C*03:03,04; DQB1*04:01,06:01; DRB1*04:05,08:03 (IPD-IMGT/HLA=26020) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167700 CVCL_DU20 ND01454 transformed cell line human CVCL_DU20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167701 CVCL_E621 FH36 transformed cell line human CVCL_E621 HLA typing: A*34:02,74:01; B*08:01,15:03; C*02:02:04,07:01; DPB1*01:01:01; DQB1*02,04:02; DRB1*03:01,03:02 (IPD-IMGT/HLA=26026) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167702 CVCL_DU21 ND01455 transformed cell line human CVCL_DU21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167703 CVCL_E624 FH39 transformed cell line human CVCL_E624 HLA typing: A*26:01,34:01; B*07:06,40:01:01; C*03:04,07:02; DPB1*05:01,135:01; DQA1*01:02:01,01:04:01; DQB1*05:02:01,06:02; DRB1*11:05,15:02:01; DRB3*02:02:01; DRB5*01:02,01:08N (IPD-IMGT/HLA=26029) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167704 CVCL_DU24 ND01536 transformed cell line human CVCL_DU24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167705 CVCL_E625 FH40 transformed cell line human CVCL_E625 HLA typing: A*02:01:01:01,29:02:01; B*18:01,44:03; C*07:01,16:01; DPB1*02:01,04:02; DQA1*02:01,05:05; DQB1*02:01,03:01; DRB1*07:01:01,11:08:01; DRB3*02:02:01; DRB4*01:01:01 (IPD-IMGT/HLA=10850) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167706 CVCL_DU25 ND01553 transformed cell line human CVCL_DU25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167707 CVCL_E622 FH37 transformed cell line human CVCL_E622 HLA typing: A*01:01:01,02:05; B*07:02,39:01; C*06:02:01:01,07:01:01; DQB1*04:02,06:02; DRB1*08:01,15:01 (IPD-IMGT/HLA=26027) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167708 CVCL_DU22 ND01466 transformed cell line human CVCL_DU22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167709 CVCL_E623 FH38 transformed cell line human CVCL_E623 HLA typing: A*03:01,23:08N; B*44:03:01,51:29; C*07; DPB1*02:01:02,04:01:01; DRB1*11:01,07; DRB3*02 (IPD-IMGT/HLA=12641) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167710 CVCL_DU23 ND01467 transformed cell line human CVCL_DU23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167711 CVCL_E639 FH54 transformed cell line human CVCL_E639 HLA typing: A*02:06,24:33; B*38:01,51:06; C*07:02,12:04; DQB1*05:02; DRB1*12:02,15:02 (IPD-IMGT/HLA=26041) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167712 CVCL_DU39 ND01762 transformed cell line human CVCL_DU39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167713 CVCL_E637 FH52 transformed cell line human CVCL_E637 HLA typing: A*11:01,24:33; B*51:06; C*12:04; DRB1*07,11 (IPD-IMGT/HLA=26039) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167714 CVCL_DU37 ND01734 transformed cell line human CVCL_DU37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167715 CVCL_E638 FH53 transformed cell line human CVCL_E638 HLA typing: A*24:03,24:07; B*35:05,51:06; C*04:01:01,12:04:02; DRB1*12,12:02 (IPD-IMGT/HLA=26040) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167716 CVCL_DU38 ND01748 transformed cell line human CVCL_DU38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167717 CVCL_E631 FH46 transformed cell line human CVCL_E631 HLA typing: A*11:01,24:33; B*27:22,51:06; C*03,12; DRB1*12:02,15:02 (IPD-IMGT/HLA=26035) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167718 CVCL_DU31 ND01623 transformed cell line human CVCL_DU31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167719 CVCL_E632 FH47 transformed cell line human CVCL_E632 HLA typing: A*03:01,26; B*35:02,38:01; C*04,12; DRB1*11:04 (IPD-IMGT/HLA=26036) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167720 CVCL_DU32 ND01624 transformed cell line human CVCL_DU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167721 CVCL_E630 FH45 transformed cell line human CVCL_E630 HLA typing: A*02,11:01; B*38:02,41:01; C*07:02,17; DQB1*03:01,05:02; DRB1*11:01,15:04 (IPD-IMGT/HLA=26034) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167722 CVCL_DU30 ND01601 transformed cell line human CVCL_DU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167723 CVCL_E635 FH50 transformed cell line human CVCL_E635 HLA typing: A*02:01,03:01; B*44:27,08:01; C*07,07; DQB1*02,03; DRB1*04:02,03:01 (IPD-IMGT/HLA=12967) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167724 CVCL_DU35 ND01627 transformed cell line human CVCL_DU35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167725 CVCL_E636 FH51 transformed cell line human CVCL_E636 HLA typing: A*23:01,24; B*40:02,44:03 (IPD-IMGT/HLA=26038) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167726 CVCL_DU36 ND01649 transformed cell line human CVCL_DU36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167727 CVCL_E633 FH48 transformed cell line human CVCL_E633 HLA typing: A*02:01,24:02; B*07:02,44:27; C*07:02,07:04; DQB1*06:04,06:02; DRB1*13:02,15:01 (IPD-IMGT/HLA=12966) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167728 CVCL_DU33 ND01625 transformed cell line human CVCL_DU33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167729 CVCL_E634 FH49 transformed cell line human CVCL_E634 HLA typing: A*01:01,02; B*07:02,39:01; C*07; DRB1*08:01,15:01 (IPD-IMGT/HLA=26037) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167730 CVCL_DU34 ND01626 transformed cell line human CVCL_DU34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167731 CVCL_E606 FH20 transformed cell line human CVCL_E606 HLA typing: A*01:01,02:01; B*44:02,44:05; C*02:02:02,16:04:01; DPB1*04:01; DQB1*03:01,05:01; DRB1*01:01,11:04 (IPD-IMGT/HLA=26006) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167732 CVCL_DU06 ND01269 transformed cell line human CVCL_DU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167733 CVCL_E607 FH21 transformed cell line human CVCL_E607 HLA typing: A*02:30,03:01:01:01; B*35:01:01:02,38:01:01; C*04:01:01,12:03:01:01; DPA1*01:03:01:03,01:03:01:04; DPB1*03:01:01,04:01:01:01; DQA1*01:01:01,01:03:01:02; DQB1*05:01:01:02,06:03:01; DRB1*01:01:01,13:01:01 (IPD-IMGT/HLA=26007); HLA typing: A*02:30:01,03:01:01:01; B*38:01:01,35:01:01:02; C*04:01:01:01,12:03:01:01; DPA1*01:03:01:03,01:03:01:04; DPB1*03:01:01(124:01),04:01:01:01(350:01); DQA1*01:03:01,01:01:01; DQB1*06:03:01,05:01:01:03; DRB1*13:01:01,01:01:01; DRB3*01:01:02 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167734 CVCL_DU07 ND01270 transformed cell line human CVCL_DU07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167735 CVCL_E604 FH18 transformed cell line human CVCL_E604 HLA typing: A*36:01,74:01; B*53:01,57:03; C*04:01,07:01; DPB1*03:01,11:01:01; DQB1*02:01,03:01; DRB1*08:04,13:03; DRB3*02:02:01 (IPD-IMGT/HLA=26002) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167736 CVCL_DU04 ND01261 transformed cell line human CVCL_DU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167737 CVCL_E605 FH19 transformed cell line human CVCL_E605 HLA typing: A*02:03,34:01; B*15,38:02; C*04,07; DQB1*05:01,06:01; DRB1*15:02 (IPD-IMGT/HLA=26004) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167738 CVCL_DU05 ND01268 transformed cell line human CVCL_DU05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167739 CVCL_E608 FH22 transformed cell line human CVCL_E608 HLA typing: A*02:01,02:01; B*08:01,51:09; C*07:01,16:02; DPA1*01:03:01; DPB1*02:01:02,51:01; DQA1*03,05; DQB1*02:01,03:02; DRB1*03:01,04:04 (IPD-IMGT/HLA=26008) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167740 CVCL_DU08 ND01280 transformed cell line human CVCL_DU08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167741 CVCL_E609 FH23 transformed cell line human CVCL_E609 HLA typing: A*03:01,31:01; B*07:02:01,27:07; C*07:02,15:02; DPB1*04:01,14:01; DQB1*03:01,06:02; DRB1*13:03,15:01 (IPD-IMGT/HLA=26009) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167742 CVCL_DU09 ND01281 transformed cell line human CVCL_DU09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167743 CVCL_E602 FH16 transformed cell line human CVCL_E602 HLA typing: A*01:01:01,02:01:01; B*08:01,27:09; C*01:02,07:01; DPB1*01:01:01,04:02; DQB1*02:01,05:03:01; DRB1*03:01,14:01; DRB3*01:01:02:01,02:02:01 (IPD-IMGT/HLA=25997) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167744 CVCL_DU02 ND01259 transformed cell line human CVCL_DU02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167745 CVCL_E603 FH17 transformed cell line human CVCL_E603 HLA typing: A*01:01,68:01; B*08:01,51:01:01; C*07:01,14:02; DPB1*04:01; DQB1*03:01:01,06:03; DRB1*11:01,13:01; DRB3*01:01:02:01,02:02:01 (IPD-IMGT/HLA=25998) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167746 CVCL_DU03 ND01260 transformed cell line human CVCL_DU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167747 CVCL_E600 FH14 transformed cell line human CVCL_E600 HLA typing: A*03:01:01,11:01:01; B*40:01:01; C*03:04:01; DPA1*01:03; DPB1*04:01,04:02; DQA1*03:01,03:02; DQB1*03:01,03:02; DRB1*04:01:01,04:04; DRB4*01:01:01,01:03:02 (IPD-IMGT/HLA=25996) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167748 CVCL_DU00 ND01187 transformed cell line human CVCL_DU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167749 CVCL_E601 FH15 transformed cell line human CVCL_E601 HLA typing: A*01:01:01:01,24:02:01:01; B*08:01:01:01,15:01:01:01; C*03:03:01:01,07:01:01:01; DPB1*04:01:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,11:03:01; DRB3*01:01:02:01,02:02:01 (IPD-IMGT/HLA=20677) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167750 CVCL_DU01 ND01237 transformed cell line human CVCL_DU01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167751 CVCL_E617 FH31 transformed cell line human CVCL_E617 HLA typing: A*29,32:01; B*27:08,44; DRB1*03,11 (IPD-IMGT/HLA=26017) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167752 CVCL_DU17 ND01407 transformed cell line human CVCL_DU17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167753 CVCL_E618 FH32 transformed cell line human CVCL_E618 HLA typing: A*01,32:01; B*08:01,27:08; C*06:02:01:01,07; DQB1*02,03:01; DRB1*03:01,11:01 (IPD-IMGT/HLA=26018) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167754 CVCL_DU18 ND01432 transformed cell line human CVCL_DU18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167755 CVCL_E615 FH29 transformed cell line human CVCL_E615 HLA typing: A*02:01,29:02; B*15:16,44:03:01; C*14:02,16:01; DPB1*04:01,11:01:01; DQB1*02:01,05:01; DRB1*01:02,07 (IPD-IMGT/HLA=26015) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167756 CVCL_DU15 ND01376 transformed cell line human CVCL_DU15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167757 CVCL_E616 FH30 transformed cell line human CVCL_E616 HLA typing: A*02:01,29:02; B*27,27:12; C*01,02:02; DQB1*06:02,06:03; DRB1*13:01,15:01 (IPD-IMGT/HLA=26016) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167758 CVCL_DU16 ND01406 transformed cell line human CVCL_DU16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167759 CVCL_E619 FH34 transformed cell line human CVCL_E619 HLA typing: A*34:01,34:01; B*15,15:21; C*04:03,07; DPA1*02:02; DPB1*01:01:01; DQB1*04:02,06:01:01; DRB1*04:05,08:03 (IPD-IMGT/HLA=26019) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167760 CVCL_DU19 ND01433 transformed cell line human CVCL_DU19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167761 CVCL_E610 FH24 transformed cell line human CVCL_E610 HLA typing: A*24:02,29:02; B*39:09,44:03:01; C*07:02,16:01; DPB1*04:02,14:01; DQB1*03:02,03:03; DRB1*04:04,13:01 (IPD-IMGT/HLA=26010) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167762 CVCL_DU10 ND01312 transformed cell line human CVCL_DU10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167763 CVCL_E613 FH27 transformed cell line human CVCL_E613 HLA typing: A*31:01:02,34:01; B*35:01:01,38:02:01; C*04:01,07:02; DPB1*01:01:01,04:02; DQB1*04:02,05:02; DRB1*08:11,15:02; DRB5*01:01 (IPD-IMGT/HLA=26013) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167764 CVCL_DU13 ND01364 transformed cell line human CVCL_DU13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167765 CVCL_E614 FH28 transformed cell line human CVCL_E614 HLA typing: A*01:01,11:01; B*08:01,27:04; C*07:01,08:01; DPB1*01:01:01,02:02; DQB1*02:01,03:03; DRB1*03:01,09 (IPD-IMGT/HLA=26014) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167766 CVCL_DU14 ND01375 transformed cell line human CVCL_DU14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167767 CVCL_E611 FH25 transformed cell line human CVCL_E611 HLA typing: A*02:05,26:01; B*07:02,39:03; C*07:02; DPB1*04:02,05:01; DQB1*05:01,06:02; DRB1*01:01,15:01 (IPD-IMGT/HLA=26011) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167768 CVCL_DU11 ND01351 transformed cell line human CVCL_DU11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167769 CVCL_E612 FH26 transformed cell line human CVCL_E612 HLA typing: A*02:06,26:01; B*35:01,48:03; C*03:03,08:01; DPB1*02:02,05:01; DQB1*03:01,03:02; DRB1*04:06,11:01 (IPD-IMGT/HLA=26012) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167770 CVCL_DU12 ND01363 transformed cell line human CVCL_DU12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167771 CVCL_3B99 HQ00203 transformed cell line human CVCL_3B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167772 CVCL_3B97 HQ00201 transformed cell line human CVCL_3B97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167773 CVCL_3B98 HQ00202 transformed cell line human CVCL_3B98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167774 CVCL_3B91 HQ00195 transformed cell line human CVCL_3B91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167775 CVCL_3B92 HQ00196 transformed cell line human CVCL_3B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167776 CVCL_3B90 HQ00194 transformed cell line human CVCL_3B90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167777 CVCL_3B95 HQ00199 transformed cell line human CVCL_3B95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167778 CVCL_3B96 HQ00200 transformed cell line human CVCL_3B96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167779 CVCL_3B93 HQ00197 transformed cell line human CVCL_3B93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167780 CVCL_3B94 HQ00198 transformed cell line human CVCL_3B94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167781 CVCL_N038 GM05567 transformed cell line human CVCL_N038 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167782 CVCL_N039 GM05652 finite cell line human CVCL_N039 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21167783 CVCL_N036 GM05052 transformed cell line human CVCL_N036 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167784 CVCL_N037 GM05566 finite cell line human CVCL_N037 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167785 CVCL_N034 GM04932 finite cell line human CVCL_N034 CL:0000010 Population: Pacific; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM04932; probable; Discontinued: Coriell; GM17386; probable Male Part of: Human variation panel 21167786 CVCL_N035 GM05045 transformed cell line human CVCL_N035 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167787 CVCL_N032 TLX5 cancer cell line house mouse CVCL_N032 CL:0000010 Breed/subspecies: CBA. 21167788 CVCL_N033 80-1 hybridoma CVCL_N033 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11871. 21167789 CVCL_N030 TSGH-8302 cancer cell line human CVCL_N030 CL:0000010 Female 21167790 CVCL_N031 MOVP-3 cancer cell line human CVCL_N031 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21167791 CVCL_N049 GM06201 transformed cell line human CVCL_N049 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg76Trp (c.226C>T); ClinVar=VCV000001962; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167792 CVCL_N047 GM06072 finite cell line human CVCL_N047 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21167793 CVCL_N048 GM06138 transformed cell line human CVCL_N048 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167794 CVCL_N045 GM06052 transformed cell line human CVCL_N045 HLA typing: A*23:DFKR,36:01; B*53:01,81:MN; C*04:CVAF,18:AB; DRB1*08:04,11:01 (IPD-IMGT/HLA=16419) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167795 CVCL_N046 GM06067 transformed cell line human CVCL_N046 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167796 CVCL_N043 GM05946 transformed cell line human CVCL_N043 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167797 CVCL_N044 GM08330 finite cell line human CVCL_N044 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21167798 CVCL_N041 GM05945 transformed cell line human CVCL_N041 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167799 CVCL_N042 GM08329 finite cell line human CVCL_N042 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21167800 CVCL_N040 GM05817 transformed cell line human CVCL_N040 HLA typing: A*36:01,80:01; B*50:01,53:01; C*04:CVAF,06:02; DRB1*03:01,16:02 (IPD-IMGT/HLA=15817) CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg76Trp (c.226C>T); ClinVar=VCV000001962; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21167801 CVCL_E686 HAM014 transformed cell line human CVCL_E686 HLA typing: A*01,02; B*08,58; C*06,07; DPB1*04:01; DQA1*05:01,02:01; DQB1*03:01,03:02; DRB1*12:01,07:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11719) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167802 CVCL_DU86 ND02199 transformed cell line human CVCL_DU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167803 CVCL_E687 HAR,G transformed cell line human CVCL_E687 HLA typing: A*01:01:01:01,32; B*08:01:01,14:01; C*07:01:01; DPB1*04:01:01,04:02; DQA1*02:01,05:01:01; DQB1*02:01:01; DRB1*03:01:01,07:01; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11692) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082249; probable Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167804 CVCL_DU87 ND02250 transformed cell line human CVCL_DU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167805 CVCL_E684 HAM008 transformed cell line human CVCL_E684 HLA typing: A*28; B*44,58; C*02,04 (IPD-IMGT/HLA=11718) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167806 CVCL_DU84 ND02173 transformed cell line human CVCL_DU84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167807 CVCL_E685 HAM013 transformed cell line human CVCL_E685 HLA typing: A*01; B*08; C*07; DPB1*04:01; DQA1*05:01; DQB1*03:01,02:01; DRB1*12:01,03:01; DRB3*02:02,01:01 (IPD-IMGT/HLA=11720) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167808 CVCL_DU85 ND02190 transformed cell line human CVCL_DU85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167809 CVCL_E688 HARA [Human B-cell] transformed cell line human CVCL_E688 HLA typing: A*24:02:01:01; B*52:01:01; C*12:02; DPB1*09:01; DQA1*01:03; DQB1*06:01; DRB1*15:02:01; DRB5*01:02 (IPD-IMGT/HLA=11685) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167810 CVCL_DU88 ND02251 transformed cell line human CVCL_DU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167811 CVCL_E689 HAS-15 transformed cell line human CVCL_E689 HLA typing: A*02; B*54:01,15; C*01:02,03:03; DPB1*05:01,19:01; DRB1*04:05 (IPD-IMGT/HLA=10710) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167812 CVCL_DU89 ND02252 transformed cell line human CVCL_DU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167813 CVCL_N018 GM04428 transformed cell line human CVCL_N018 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167814 CVCL_N019 GM04535 transformed cell line human CVCL_N019 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167815 CVCL_N016 GM04300 finite cell line human CVCL_N016 CL:0000010 Population: Indian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Human variation panel 21167816 CVCL_E682 HAM001 transformed cell line human CVCL_E682 HLA typing: A*01,34; B*17,58:02; C*02; DPB1*01:01:01,04:01; DQA1*05:01,03; DQB1*03:01,02:01; DRB1*11:01,07:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11717) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167817 CVCL_DU82 ND02162 transformed cell line human CVCL_DU82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167818 CVCL_N017 GM04340 finite cell line human CVCL_N017 CL:0000010 Population: Caucasian; Iberian; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167819 CVCL_E683 HAM006 transformed cell line human CVCL_E683 HLA typing: A*02,68; B*58:01,44; C*02,05; DPA1*01:03:01,03:01; DPB1*18:01,58:01; DQA1*03,02:01; DQB1*02:01,04:02; DRB1*04,07; DRB4*01:01 (IPD-IMGT/HLA=10709) CL:0000010 Population: African; Zulu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167820 CVCL_DU83 ND02171 transformed cell line human CVCL_DU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167821 CVCL_N014 GM04239 transformed cell line human CVCL_N014 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167822 CVCL_E680 GU373 transformed cell line human CVCL_E680 HLA typing: A*30:01; B*15:10,53:01; C*03:04,04:01; DPB1*04:02,17:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02:02 (IPD-IMGT/HLA=10694) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167823 CVCL_DU80 ND02154 transformed cell line human CVCL_DU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167824 CVCL_N015 GM04250 finite cell line human CVCL_N015 HLA typing: A*02:01:01,33:03:01; B*39:04,44:03:01; C*07:02:01,14:03; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:04:01; DRB1*04:03:01,13:02:01; DRB3*03:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Discontinued: Coriell; AG04250; probable Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167825 CVCL_E681 HAG transformed cell line human CVCL_E681 HLA typing: A*02:01:01; B*41:02; C*17:01; DPB1*02:01:02,03:01:01; DQA1*05:01; DQB1*03:01:01; DRB1*13:03:01; DRB3*01:01:02:01 (IPD-IMGT/HLA=10708) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167826 CVCL_DU81 ND02161 transformed cell line human CVCL_DU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167827 CVCL_N012 GM03786 finite cell line human CVCL_N012 CL:0000010 Population: Caucasian; Greek; Karyotypic information: 45,XX,dic(13;14)(13qter->13p11::14p11->14qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167828 CVCL_N013 GM03928 transformed cell line human CVCL_N013 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167829 CVCL_N010 GM03575 transformed cell line human CVCL_N010 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Gly269Ser (c.805G>A); ClinVar=VCV000003898; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167830 CVCL_N011 GM03579 transformed cell line human CVCL_N011 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Heterozygous; Note=MZ allele (PubMed=19767587) Population: Cuban; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167831 CVCL_E697 HIN,K transformed cell line human CVCL_E697 HLA typing: A*02,03; B*44:02; C*05,07; DPB1*02:02,17:01; DQA1*01:02,05:01; DQB1*02:01,06:04; DRB1*03:01,13:02; DRB3*02:02,03:01 (IPD-IMGT/HLA=11705) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167832 CVCL_DU97 ND02332 transformed cell line human CVCL_DU97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167833 CVCL_E698 HIN,R transformed cell line human CVCL_E698 HLA typing: A*01,03; B*07,08; C*07; DPB1*04:01,09:01; DQA1*01:02,05:01; DQB1*02:01,06:04; DRB1*03:01,13:02; DRB3*01:01,03:01 (IPD-IMGT/HLA=11707) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167834 CVCL_DU98 ND02333 transformed cell line human CVCL_DU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167835 CVCL_E695 HID transformed cell line human CVCL_E695 HLA typing: A*02:01:01:01,02:06:01:01; B*40:01:02:01,40:06:01:01; C*03:04:01:02,08:01:01; DPA1*01; DPB1*02:01:02/02:01:19,05:01:01; DQA1*03; DQB1*03:03:02; DRB1*09:01:02/09:21 (IPD-IMGT/HLA=11632) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167836 CVCL_DU95 ND02316 transformed cell line human CVCL_DU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167837 CVCL_E696 HIN,JP transformed cell line human CVCL_E696 HLA typing: A*01,02; B*08,51; C*07,14:02; DPB1*03:01,04:01; DQA1*06:01,05:01; DQB1*03:01,02:01; DRB1*03:01,08:03; DRB3*01:01 (IPD-IMGT/HLA=11706) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167838 CVCL_DU96 ND02317 transformed cell line human CVCL_DU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167839 CVCL_E699 HIN,S transformed cell line human CVCL_E699 HLA typing: A*02; B*44:02; C*01; DPB1*02:02,03:01; DQA1*05:01,06:01; DQB1*02:01,03:01; DRB1*03:01,08:03; DRB3*02:02 (IPD-IMGT/HLA=11708) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167840 CVCL_DU99 ND02336 transformed cell line human CVCL_DU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167841 CVCL_E690 HAU,ML transformed cell line human CVCL_E690 HLA typing: A*33; B*58:01; C*03:02; DPB1*05:01,13:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02 (IPD-IMGT/HLA=11700) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167842 CVCL_DU90 ND02259 transformed cell line human CVCL_DU90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167843 CVCL_N029 L1210/R71 cancer cell line house mouse CVCL_N029 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21167844 CVCL_N027 8H11 [Mouse hybridoma against human IL22RA1] hybridoma house mouse CVCL_N027 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8N6P7; Human IL22RA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7317 21167845 CVCL_E693 HERLUF transformed cell line human CVCL_E693 HLA typing: A*02:01:01:01; B*44:02:01:01,35:03:01:01; C*05:01:01:02,04:01:01:01; DPA1*01,02; DPB1*04:01:01; DQA1*05:01; DQB1*03:01:01; DRB1*12:01:01/12:10; DRB3*02:02 (IPD-IMGT/HLA=10728) CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167846 CVCL_DU93 ND02286 transformed cell line human CVCL_DU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167847 CVCL_E694 HHKB transformed cell line human CVCL_E694 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:01:01; DQA1*01:03; DQB1*06:03:01; DRA*01:02; DRB1*13:01:01; DRB3*01:01:02:01 (IPD-IMGT/HLA=10735) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167848 CVCL_N028 L1210/R81 cancer cell line house mouse CVCL_N028 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21167849 CVCL_DU94 ND02315 transformed cell line human CVCL_DU94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167850 CVCL_N025 8A12 [Mouse hybridoma against human IL22RA1] hybridoma house mouse CVCL_N025 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8N6P7; Human IL22RA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7318 21167851 CVCL_E691 HAY,BD transformed cell line human CVCL_E691 HLA typing: A*24:02:01:01; B*07:02:01,40:02:01; C*07:02:01:03,15:02:01:01; DPA1*01:03:01:02,02:02:02; DPB1*04:01:01:01,05:01:01; DQA1*01:04:01:04,01:02:01:01; DQB1*06:02:01,05:03:01; DRB1*14:07:01,15:01:01; DRB3*02:02:01,02:02:01:02; DRB5*01:01:01 (IPD-IMGT/HLA=11667) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167852 CVCL_DU91 ND02269 transformed cell line human CVCL_DU91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167853 CVCL_N026 8E11.9 hybridoma house mouse CVCL_N026 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9GZX6; Human IL22. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7319 21167854 CVCL_E692 HAY,KJ transformed cell line human CVCL_E692 HLA typing: A*02; B*15; DPB1*05:01,17:01; DQA1*01:03,05:01; DQB1*06:03,03:01; DRB1*13:01,14; DRB3*01:01 (IPD-IMGT/HLA=11737) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167855 CVCL_DU92 ND02271 transformed cell line human CVCL_DU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167856 CVCL_N023 3F11.3 hybridoma house mouse CVCL_N023 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9GZX6; Human IL22. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7312 21167857 CVCL_N024 7E9 hybridoma house mouse CVCL_N024 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q8N6P7; Human IL22RA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7313 21167858 CVCL_N021 Hs 853.T cancer cell line human CVCL_N021 CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7588; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21167859 CVCL_N022 11H4.4 hybridoma house mouse CVCL_N022 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9GZX6; Human IL22. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7315 21167860 CVCL_N020 Hs 862.T cancer cell line human CVCL_N020 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7597; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21167861 CVCL_E664 FJO transformed cell line human CVCL_E664 HLA typing: A*02,03; B*07,39; DPB1*04:01; DQB1*05:02:01; DRB1*16:01:01; DRB5*02:02 (IPD-IMGT/HLA=10582) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167862 CVCL_DU64 ND02043 transformed cell line human CVCL_DU64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167863 CVCL_E665 FMB transformed cell line human CVCL_E665 HLA typing: A*01:01,32:01; B*44:02:01:01,57; C*05:01,06:02; DPB1*02:01:02,04:01 (IPD-IMGT/HLA=10585) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94022529; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167864 CVCL_DU65 ND02051 transformed cell line human CVCL_DU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167865 CVCL_E662 FH78 transformed cell line human CVCL_E662 HLA typing: A*03:01,11:01; B*07:02,27; C*07:02,15; DQB1*03,05:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=26061) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167866 CVCL_DU62 ND02016 transformed cell line human CVCL_DU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167867 CVCL_E663 FIS,VJ transformed cell line human CVCL_E663 HLA typing: A*01; B*07,08; C*07; DPB1*02:01,04:02; DQA1*05:01,01:01; DQB1*05:01,02:01; DRB1*01:01,03:01; DRB3*01:01 (IPD-IMGT/HLA=11702) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167868 CVCL_DU63 ND02021 transformed cell line human CVCL_DU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167869 CVCL_E668 FPAF transformed cell line human CVCL_E668 HLA typing: A*01:01:01:01; B*35:02:01:01; C*04:01:01:01; DPA1*02:01:01; DPB1*02:01:02/02:01:19; DQA1*01:03; DQB1*06:03:01; DRB1*11:04:01; DRB3*02:02 (IPD-IMGT/HLA=10588) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21167870 CVCL_DU68 ND02066 transformed cell line human CVCL_DU68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167871 CVCL_E669 FUR,RE transformed cell line human CVCL_E669 HLA typing: A*01,02; B*17,60; C*03; DPB1*03:01,04:01; DQA1*01:02,02:01; DQB1*03:03,06:04; DRB1*07,13:02; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=11688) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167872 CVCL_DU69 ND02079 transformed cell line human CVCL_DU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167873 CVCL_E666 FO [Human B-cell] transformed cell line human CVCL_E666 HLA typing: A*11,31; B*39,51; C*07; DQA1*01:03,05:01; DQB1*06:01,03:01; DRB1*08:03:02,12:01:01; DRB3*01:01 (IPD-IMGT/HLA=10586) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167874 CVCL_DU66 ND02052 transformed cell line human CVCL_DU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167875 CVCL_E667 FORE transformed cell line human CVCL_E667 HLA typing: A*02:01:01:01,24:02:01:01; B*51:01:01,15:01:01:01; C*14:02:01,03:03:01; DPA1*01:03:01:03; DPB1*03:01:01,06:01; DQA1*03:01:01,01:02:02; DQB1*03:02:01,05:02:01; DRB1*04:04:01,16:04; DRB4*01:03:01:03; DRB5*02:02; DRB6*02:02 (IPD-IMGT/HLA=10587); HLA typing: A*02:01:01:01,24:02:01:01; B*51:01:01:01,15:01:01:01; C*14:02:01:01,03:03:01:01; DPA1*01:03:01:03; DPB1*03:01:01,06:01:01; DQA1*01:02:02,03:01:01; DQB1*03:02:01,05:02:01; DRB1*04:04:01,16:04; DRB4*01:03:01; DRB5*02:02 (PubMed=30844424) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167876 CVCL_DU67 ND02064 transformed cell line human CVCL_DU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167877 CVCL_E660 FH76 transformed cell line human CVCL_E660 HLA typing: A*24:02:01:02L; B*55:01,55:01; C*01:02 (IPD-IMGT/HLA=26059) CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167878 CVCL_DU60 ND02013 transformed cell line human CVCL_DU60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167879 CVCL_E661 FH77 transformed cell line human CVCL_E661 HLA typing: A*02,24; B*15:07,48:01; C*01:02,08:03; DQB1*03:01,04:02; DRB1*08:02,12 (IPD-IMGT/HLA=26060) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167880 CVCL_DU61 ND02014 transformed cell line human CVCL_DU61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167881 CVCL_E675 GRC-138 transformed cell line human CVCL_E675 HLA typing: A*02:01:01:01,02:11:01; B*15:04:01,40:03; C*03:03:01,03:04:01:02; DPA1*01:03:01:05; DPB1*04:02:01:02; DQA1*05:03,05:05:01:06; DQB1*03:01:01:01; DRB1*14:13,16:02:01; DRB3*01:01:02; DRB5*02:02 (IPD-IMGT/HLA=10682) CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167882 CVCL_DU75 ND02147 transformed cell line human CVCL_DU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167883 CVCL_E676 GRC-150 transformed cell line human CVCL_E676 HLA typing: A*02:01:01:01,31:01:02; B*51:04,15:04; C*03:03:01,15:03; DPA1*01:03; DPB1*04:01,04:02 (IPD-IMGT/HLA=10683) CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167884 CVCL_DU76 ND02148 transformed cell line human CVCL_DU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167885 CVCL_E673 GEV transformed cell line human CVCL_E673 HLA typing: A*03,26; B*55,62; C*w03 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21167886 CVCL_DU73 ND02127 transformed cell line human CVCL_DU73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167887 CVCL_E674 GN00218 transformed cell line human CVCL_E674 HLA typing: A*03:01:01,29:02; B*58:02,47:03; C*06:02,07; DPB1*13:01,30:01; DQB1*02,04:02; DRB1*07:01:01,08:04:01; DRB4*01:01:01 (IPD-IMGT/HLA=10658) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167888 CVCL_DU74 ND02138 transformed cell line human CVCL_DU74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167889 CVCL_E679 GRE,G transformed cell line human CVCL_E679 HLA typing: A*02,11; B*07:02,27:05; DPB1*04:01,04:02; DQA1*01:02,03; DQB1*03:01,06:02; DRB1*04:01,15:01; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11704) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21167890 CVCL_DU79 ND02153 transformed cell line human CVCL_DU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167891 CVCL_E677 GRC-187 transformed cell line human CVCL_E677 HLA typing: A*68:01:02,31:01:02; B*35:11,15:04; C*03:03:01,03:04:01; DPA1*01:03; DPB1*04:01,04:02 (IPD-IMGT/HLA=10684) CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167892 CVCL_DU77 ND02150 transformed cell line human CVCL_DU77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167893 CVCL_E678 GRC-212 transformed cell line human CVCL_E678 HLA typing: A*68:01:02:01,02:11:01; B*35:05:01:02,40:04; C*04:01:01:01,03:04:01:02; DPA1*02:01:01; DPB1*27:01; DQA1*03:01:01,03:02; DQB1*03:02:01,03:03:02; DRB1*04:11:01,09:01:02/09:21; DRB4*01:03:01:01,01:03:02 (IPD-IMGT/HLA=10685) CL:0000010 Population: Native South American; Guarani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167894 CVCL_DU78 ND02151 transformed cell line human CVCL_DU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167895 CVCL_N009 GM03552 finite cell line human CVCL_N009 CL:0000010 Population: Southeast Asian; Vietnamese; Karyotypic information: 46,X,t(X;11)(q26;q23) (PubMed=10377420); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21167896 CVCL_N007 GM03423 transformed cell line human CVCL_N007 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167897 CVCL_N008 GM03433 finite cell line human CVCL_N008 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Human variation panel 21167898 CVCL_E671 G088 transformed cell line human CVCL_E671 HLA typing: A*01,11; B*57,40; C*06:02:01:01,15:02:01; DPB1*04:01,14:01 (IPD-IMGT/HLA=10597) CL:0000010 Population: Caucasian; Gypsy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94050314; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167899 CVCL_N005 GM03321 finite cell line human CVCL_N005 CL:0000010 Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Human variation panel 21167900 CVCL_DU71 ND02122 transformed cell line human CVCL_DU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167901 CVCL_E672 GEE018 transformed cell line human CVCL_E672 HLA typing: A*02:03:01,29:01:01:01; B*07:05:01:01,15:19; C*04:03:01,15:05:02; DPB1*02:01:02/02:01:19,104:01; DQB1*05:01:01,05:02:01; DRB1*10:01:01,15:02:01 (IPD-IMGT/HLA=10608) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167902 CVCL_N006 GM03347 finite cell line human CVCL_N006 CL:0000010 Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167903 CVCL_DU72 ND02126 transformed cell line human CVCL_DU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167904 CVCL_N003 GM02743 transformed cell line human CVCL_N003 CL:0000010 Sequence variation: Mutation; HGNC; 1368; CA1; Simple; p.Arg247His (c.740G>A) (R246H); ClinVar=VCV000017606; Zygosity=Heterozygous (from familial inference) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21167905 CVCL_E670 G085 transformed cell line human CVCL_E670 HLA typing: A*01:01:01:01,29:01:01:01; B*40:06:01:02,52:01:01:02; C*12:02:02:01,15:02:01:01; DPA1*01:03:01; DPB1*02:01:02/02:01:19; DQA1*01:03,01:04; DQB1*05:03:01,06:01:01/06:01:15; DRB1*14:04:01,15:02:01; DRB3*02:02:01; DRB5*01:02 (IPD-IMGT/HLA=10596) CL:0000010 Population: Caucasian; Gypsy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21167906 CVCL_N004 GM03172 finite cell line human CVCL_N004 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Unspecified (Coriell) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21167907 CVCL_DU70 ND02081 transformed cell line human CVCL_DU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167908 CVCL_N001 GM02688 transformed cell line human CVCL_N001 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21167909 CVCL_N002 GM02742 transformed cell line human CVCL_N002 CL:0000010 Sequence variation: Mutation; HGNC; 1368; CA1; Simple; p.Arg247His (c.740G>A) (R246H); ClinVar=VCV000017606; Zygosity=Heterozygous (from familial inference) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21167910 CVCL_N000 GM02659 transformed cell line human CVCL_N000 HLA typing: A*02:01:01,02:01:01; B*27:05:02,44:02:01; C*01:02:01,05:01:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,10:01:01; DQA1*01:01:01,05:05:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,11:01:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg176Ter (c.526C>T); ClinVar=VCV000102723; Zygosity=Homozygous (Coriell) Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21167911 CVCL_E648 FH63 transformed cell line human CVCL_E648 HLA typing: A*24; B*15:01,44; C*05,15; DRB1*01:01,11:03 (IPD-IMGT/HLA=26048) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167912 CVCL_DU48 ND01874 transformed cell line human CVCL_DU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167913 CVCL_E649 FH64 transformed cell line human CVCL_E649 HLA typing: A*02,32:01; B*18:01,44; C*05,07; DRB1*04:01,11:04 (IPD-IMGT/HLA=26049) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167914 CVCL_DU49 ND01893 transformed cell line human CVCL_DU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167915 CVCL_E642 FH57 transformed cell line human CVCL_E642 HLA typing: A*02,24:02; B*39:01,44; C*05,07; DRB1*04,08:01 (IPD-IMGT/HLA=26044) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167916 CVCL_DU42 ND01792 transformed cell line human CVCL_DU42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167917 CVCL_E643 FH58 transformed cell line human CVCL_E643 HLA typing: A*02:01:01:01,02:20:02; B*40:01,44:02; C*03,05; DRB1*11:04,15:01 (IPD-IMGT/HLA=26045) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167918 CVCL_DU43 ND01793 transformed cell line human CVCL_DU43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167919 CVCL_E640 FH55 transformed cell line human CVCL_E640 HLA typing: A*02:01,24; B*15,40; C*02:02,03; DRB1*04:04,07 (IPD-IMGT/HLA=26042) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167920 CVCL_DU40 ND01768 transformed cell line human CVCL_DU40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167921 CVCL_E641 FH56 transformed cell line human CVCL_E641 HLA typing: A*02:05,03:01; B*41:02,49; C*04,07; DRB1*11:01,11:04 (IPD-IMGT/HLA=26043) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167922 CVCL_DU41 ND01772 transformed cell line human CVCL_DU41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167923 CVCL_E646 FH61 transformed cell line human CVCL_E646 HLA typing: A*02:01,26; B*38:01,40; C*03,12; DQB1*04,11; DRB1*04,11:04 (IPD-IMGT/HLA=26046) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167924 CVCL_DU46 ND01855 transformed cell line human CVCL_DU46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167925 CVCL_E647 FH62 transformed cell line human CVCL_E647 HLA typing: A*01:01,24; B*35,52:01; C*03,12:02; DRB1*13:02,15:02 (IPD-IMGT/HLA=26047) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167926 CVCL_DU47 ND01856 transformed cell line human CVCL_DU47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167927 CVCL_E644 FH59 transformed cell line human CVCL_E644 HLA typing: A*01:01,03:01; B*07:02,51:29; C*02:02,07; DQB1*03:01,06; DRB1*11:01,15:01; DRB3*03; DRB5*01:01 (IPD-IMGT/HLA=12743) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167928 CVCL_DU44 ND01804 transformed cell line human CVCL_DU44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167929 CVCL_E645 FH60 transformed cell line human CVCL_E645 HLA typing: A*01:01,02:17; B*15:72,35:03; C*04,07; DQB1*05:01; DRB1*01:01,01:02 (IPD-IMGT/HLA=12753) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167930 CVCL_DU45 ND01808 transformed cell line human CVCL_DU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167931 CVCL_E659 FH75 transformed cell line human CVCL_E659 HLA typing: A*02:01; B*07:02,27; C*01:02,07:10 (IPD-IMGT/HLA=26057) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167932 CVCL_DU59 ND01988 transformed cell line human CVCL_DU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167933 CVCL_E653 FH68 transformed cell line human CVCL_E653 HLA typing: A*02:01:01:01,30:01; B*18,41; C*06:02:01:01,07; DRB1*01:01,04:05 (IPD-IMGT/HLA=26051) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167934 CVCL_DU53 ND01918 transformed cell line human CVCL_DU53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167935 CVCL_E654 FH69 transformed cell line human CVCL_E654 HLA typing: A*02:03,11; B*52,58:01; C*03,12:03; DRB1*10,13:02 (IPD-IMGT/HLA=26052) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167936 CVCL_DU54 ND01923 transformed cell line human CVCL_DU54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167937 CVCL_E651 FH66 transformed cell line human CVCL_E651 HLA typing: A*02,03; B*15:71,40:01; C*03; DQB1*03:01,06:04; DRB1*11:01,13:02 (IPD-IMGT/HLA=12745) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167938 CVCL_DU51 ND01916 transformed cell line human CVCL_DU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167939 CVCL_E652 FH67 transformed cell line human CVCL_E652 HLA typing: A*02:01:01:01,03:01:01:01; B*15:71,40:01:02; C*03:03:01,03:04:01:01; DPA1*01:03:01:04; DPB1*02:01:02,04:01:01; DQA1*01:02:01:04,05:09; DQB1*03:01:01:03,06:04:01; DRB1*11:01:01,13:02:01; DRB3*02:02:01:01,03:01:01 (IPD-IMGT/HLA=12746) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167940 CVCL_DU52 ND01917 transformed cell line human CVCL_DU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167941 CVCL_E657 FH72 transformed cell line human CVCL_E657 HLA typing: A*01,68:02; B*44,44:05; C*01:02,02:02; DRB1*04:26 (IPD-IMGT/HLA=26055) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167942 CVCL_DU57 ND01984 transformed cell line human CVCL_DU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167943 CVCL_E658 FH74 transformed cell line human CVCL_E658 HLA typing: A*23,29; B*14:01,45:01; C*06:02:01:01,14; DQB1*02,06; DRB1*09:01,15:03 (IPD-IMGT/HLA=26056) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167944 CVCL_DU58 ND01987 transformed cell line human CVCL_DU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167945 CVCL_E655 FH70EY transformed cell line human CVCL_E655 HLA typing: A*30:02,68:02; B*08:01,53:01; C*04:01,07; DPB1*02:01:02; DQB1*02:01,03:01:01; DRB1*03:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=26053) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167946 CVCL_DU55 ND01945 transformed cell line human CVCL_DU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167947 CVCL_E656 FH71 transformed cell line human CVCL_E656 HLA typing: A*30:01,74:01; B*15:03,35:01; C*02:10,04:01; DQB1*06:05; DRB1*13:02,13:02; DRB3*03:01,03:01 (IPD-IMGT/HLA=20647) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167948 CVCL_DU56 ND01946 transformed cell line human CVCL_DU56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167949 CVCL_E650 FH65 transformed cell line human CVCL_E650 HLA typing: A*29,30; B*45:01,53:01; C*04,06:02; DRB1*07,13:02 (IPD-IMGT/HLA=26050) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21167950 CVCL_DU50 ND01915 transformed cell line human CVCL_DU50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167951 CVCL_3D31 HQ00338 transformed cell line human CVCL_3D31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167952 CVCL_3D32 HQ00339 transformed cell line human CVCL_3D32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167953 CVCL_3D30 HQ00337 transformed cell line human CVCL_3D30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167954 CVCL_3D35 HQ00342 transformed cell line human CVCL_3D35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167955 CVCL_3D36 HQ00343 transformed cell line human CVCL_3D36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167956 CVCL_3D33 HQ00340 transformed cell line human CVCL_3D33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167957 CVCL_3D34 HQ00341 transformed cell line human CVCL_3D34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167958 CVCL_3D39 HQ00346 transformed cell line human CVCL_3D39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167959 CVCL_3D37 HQ00344 transformed cell line human CVCL_3D37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167960 CVCL_3D38 HQ00345 transformed cell line human CVCL_3D38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167961 CVCL_VJ80 NO6-NS cancer cell line human CVCL_VJ80 CL:0000010 Unspecified 21167962 CVCL_VJ83 10CM cancer cell line human CVCL_VJ83 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val569Ala (c.1706T>C); Zygosity=Unspecified (PubMed=26744134); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg440Ter (c.1318C>T); ClinVar=VCV000230673; Zygosity=Unspecified (PubMed=26744134); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26744134). Unspecified 21167963 CVCL_VJ84 11CM cancer cell line human CVCL_VJ84 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26744134); Sequence variation: Mutation; HGNC; 7105; MITF; Simple; p.Leu117Phe (c.349C>T); Zygosity=Unspecified (PubMed=26744134). Unspecified 21167964 CVCL_VJ81 RET981 cancer cell line human CVCL_VJ81 CL:0000010 Female 21167966 CVCL_VJ87 MUG-Myx2a cancer cell line human CVCL_VJ87 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Phe386Leu (c.1158C>G); Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173His (c.518G>A); ClinVar=VCV000376032; Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Unspecified (PubMed=28304377). Female Doubling time: 20 hours (PubMed=28304377) 21167967 CVCL_VJ88 MUG-Myx2b cancer cell line human CVCL_VJ88 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Phe386Leu (c.1158C>G); Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Unspecified (PubMed=28304377); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Unspecified (PubMed=28304377). Female Doubling time: 22 hours (PubMed=28304377) 21167968 CVCL_VJ85 KSE-1 cancer cell line human CVCL_VJ85 CL:0000010 Population: Japanese; Derived from metastatic site: Axillary lymph node. Male Doubling time: ~19.5 hours (PubMed=3607755) 21167969 CVCL_VJ86 KSE-2 cancer cell line human CVCL_VJ86 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Female Doubling time: 13.2 hours (grown on confluent monolayers), 12.1 hours (grown on fixed-confluent monolayers), 21.9 hours (grown on plastic dishes) (PubMed=1863354) 21167970 CVCL_VJ89 MP57 cancer cell line human CVCL_VJ89 CL:0000010 Sequence variation: Mutation; HGNC; 8980; PIK3R2; Simple; p.Gly373Arg (c.1117G>C); Zygosity=Homozygous (PubMed=27117832); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro87Glnfs*36 (c.260delC); Zygosity=Homozygous (PubMed=27117832). Male Doubling time: ~24 hours (PubMed=27117832) 21167971 CVCL_3D42 HQ00349 transformed cell line human CVCL_3D42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167972 CVCL_3D43 HQ00350 transformed cell line human CVCL_3D43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167973 CVCL_3D40 HQ00347 transformed cell line human CVCL_3D40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167974 CVCL_3D41 HQ00348 transformed cell line human CVCL_3D41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167975 CVCL_3D46 HQ00353 transformed cell line human CVCL_3D46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167976 CVCL_3D47 HQ00354 transformed cell line human CVCL_3D47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167977 CVCL_3D44 HQ00351 transformed cell line human CVCL_3D44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167978 CVCL_3D45 HQ00352 transformed cell line human CVCL_3D45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167979 CVCL_3D48 HQ00355 transformed cell line human CVCL_3D48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167980 CVCL_3D49 HQ00356 transformed cell line human CVCL_3D49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167981 CVCL_VJ72 CV21-AC cancer cell line human CVCL_VJ72 CL:0000010 Unspecified 21167982 CVCL_VJ73 CV21-NS cancer cell line human CVCL_VJ73 CL:0000010 Unspecified 21167983 CVCL_VJ70 CV13-NS cancer cell line human CVCL_VJ70 CL:0000010 Unspecified 21167984 CVCL_VJ71 CV2-AC cancer cell line human CVCL_VJ71 CL:0000010 Unspecified 21167985 CVCL_VJ76 CV9-AC cancer cell line human CVCL_VJ76 CL:0000010 Unspecified 21167986 CVCL_VJ77 NO3-AC cancer cell line human CVCL_VJ77 CL:0000010 Unspecified 21167987 CVCL_VJ74 CV6-AC cancer cell line human CVCL_VJ74 CL:0000010 Unspecified 21167988 CVCL_VJ75 CV8-AC cancer cell line human CVCL_VJ75 CL:0000010 Unspecified 21167989 CVCL_VJ78 NO3-NS cancer cell line human CVCL_VJ78 CL:0000010 Unspecified 21167990 CVCL_VJ79 NO4-AC cancer cell line human CVCL_VJ79 CL:0000010 Unspecified 21167991 CVCL_3D10 HQ00317 transformed cell line human CVCL_3D10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167992 CVCL_3D13 HQ00320 transformed cell line human CVCL_3D13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167993 CVCL_3D14 HQ00321 transformed cell line human CVCL_3D14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167994 CVCL_3D11 HQ00318 transformed cell line human CVCL_3D11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167995 CVCL_3D12 HQ00319 transformed cell line human CVCL_3D12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167996 CVCL_3D17 HQ00324 transformed cell line human CVCL_3D17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167997 CVCL_3D18 HQ00325 transformed cell line human CVCL_3D18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21167998 CVCL_3D15 HQ00322 transformed cell line human CVCL_3D15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21167999 CVCL_3D16 HQ00323 transformed cell line human CVCL_3D16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168000 CVCL_3D19 HQ00326 transformed cell line human CVCL_3D19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168001 CVCL_VJ61 CTO15-AC cancer cell line human CVCL_VJ61 CL:0000010 Unspecified 21168002 CVCL_VJ62 CTO15-NS cancer cell line human CVCL_VJ62 CL:0000010 Unspecified 21168003 CVCL_VJ60 CTO12-NS cancer cell line human CVCL_VJ60 CL:0000010 Unspecified 21168004 CVCL_VJ65 CTO21-AC cancer cell line human CVCL_VJ65 CL:0000010 Unspecified 21168005 CVCL_VJ66 CTO22-NS cancer cell line human CVCL_VJ66 CL:0000010 Unspecified 21168006 CVCL_VJ63 CTO16-AC cancer cell line human CVCL_VJ63 CL:0000010 Unspecified 21168007 CVCL_VJ64 CTO20-AC cancer cell line human CVCL_VJ64 CL:0000010 Unspecified 21168008 CVCL_VJ69 CV10-AC cancer cell line human CVCL_VJ69 CL:0000010 Unspecified 21168009 CVCL_VJ67 CTO3-AC cancer cell line human CVCL_VJ67 CL:0000010 Unspecified 21168010 CVCL_VJ68 CTO3-NS cancer cell line human CVCL_VJ68 CL:0000010 Unspecified 21168011 CVCL_3D20 HQ00327 transformed cell line human CVCL_3D20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168012 CVCL_3D21 HQ00328 transformed cell line human CVCL_3D21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168013 CVCL_3D24 HQ00331 transformed cell line human CVCL_3D24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168014 CVCL_3D25 HQ00332 transformed cell line human CVCL_3D25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168015 CVCL_3D22 HQ00329 transformed cell line human CVCL_3D22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168016 CVCL_3D23 HQ00330 transformed cell line human CVCL_3D23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168017 CVCL_3D28 HQ00335 transformed cell line human CVCL_3D28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168018 CVCL_3D29 HQ00336 transformed cell line human CVCL_3D29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168019 CVCL_3D26 HQ00333 transformed cell line human CVCL_3D26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168020 CVCL_3D27 HQ00334 transformed cell line human CVCL_3D27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168021 CVCL_VJ50 SCCT9 cancer cell line human CVCL_VJ50 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro48Leu (c.143C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012604; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Asp107Gly (c.320A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; c.403+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys1089Tyr (c.3266G>A); Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Rigth hand; skin. Male 21168022 CVCL_VJ51 SCCIC15 cancer cell line human CVCL_VJ51 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Ser106Pro (c.316T>C); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln1534Ter (c.4600C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln1864Arg (c.5591A>G); Zygosity=Unspecified (PubMed=24662767). 21168023 CVCL_VJ54 SCCIC21 cancer cell line human CVCL_VJ54 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Val1867Ile (c.5599G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2405Pro (c.7214A>C); Zygosity=Unspecified (PubMed=24662767). 21168024 CVCL_VJ55 SCCIC4 cancer cell line human CVCL_VJ55 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Leu159Ter (c.476T>A); Zygosity=Unspecified (PubMed=24662767). 21168025 CVCL_VJ52 SCCIC18 cancer cell line human CVCL_VJ52 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly765Asp (c.2294G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Right ear; skin. Male 21168026 CVCL_VJ53 SCCIC19 cancer cell line human CVCL_VJ53 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys254Arg (c.760T>C); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Trp1843Ter (c.5528G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys315Ter (c.945T>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro64Leu (c.191C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Glu (c.596G>A); ClinVar=VCV000582257; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Scalp; skin. Male 21168027 CVCL_VJ58 SCCIC1Met cancer cell line human CVCL_VJ58 CL:0000010 Derived from metastatic site: Lymph node. Male 21168028 CVCL_VJ59 CTO11-NS cancer cell line human CVCL_VJ59 CL:0000010 Unspecified 21168029 CVCL_VJ56 SCCT10 cancer cell line human CVCL_VJ56 CL:0000010 Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Thr2295Ala (c.6883A>G); Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Left shin; skin. Male 21168030 CVCL_VJ57 SCCT11 cancer cell line human CVCL_VJ57 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Asp132Val (c.395A>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Lys170Arg (c.509A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Glu1117Val (c.3350A>T); Zygosity=Unspecified (PubMed=24662767) Derived from sampling site: Back; skin. Male 21168031 CVCL_VJ40 ORL-166 cancer cell line human CVCL_VJ40 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1532Serfs*2 (c.4593dupA); ClinVar=VCV000051681; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Malaysian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Female 21168032 CVCL_VJ43 ORL-195 cancer cell line human CVCL_VJ43 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met169Ilefs*4 (c.507delG); Zygosity=Unspecified (PubMed=24224046; PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Lys (c.710T>A); ClinVar=VCV000376636; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Omics: Transcriptome analysis by RNAseq Female 21168033 CVCL_VJ44 ORL-196 cancer cell line human CVCL_VJ44 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Leu398Phefs*6 (c.1193dup); Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys321Asnfs*24 (c.960delG); Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Omics: Transcriptome analysis by RNAseq Female 21168034 CVCL_VJ41 ORL-174 cancer cell line human CVCL_VJ41 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu88Ter (c.262G>T); ClinVar=VCV000376305; Zygosity=Heterozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Female 21168035 CVCL_VJ42 ORL-188 cancer cell line human CVCL_VJ42 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Heterozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204_Tyr205del (c.609_614del); Zygosity=Unspecified (PubMed=27050151) Population: Malaysian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male 21168036 CVCL_MP99 BayGenomics ES cell line RRC136 embryonic stem cell house mouse CVCL_MP99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168037 CVCL_N199 GM12930 transformed cell line human CVCL_N199 HLA typing: A*23:DFKR; B*07:CZZS,53:01; C*06:02,07:WCP; DRB1*13:02,15:03 (IPD-IMGT/HLA=20207) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21168038 CVCL_VJ47 ORL-214 cancer cell line human CVCL_VJ47 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1532Serfs*2 (c.4593dupA); ClinVar=VCV000051681; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Glu3654Ter (c.10960G>T); Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012613; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu1408Ter (c.4222G>T); ClinVar=VCV000523597; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Ser (c.460G>A); ClinVar=VCV000133284; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Unspecified (PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Omics: Transcriptome analysis by RNAseq Female 21168039 CVCL_VJ48 ORL-215 cancer cell line human CVCL_VJ48 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male 21168040 CVCL_MP97 BayGenomics ES cell line RRC134 embryonic stem cell house mouse CVCL_MP97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923206; Srrm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168041 CVCL_N197 GM12548 transformed cell line human CVCL_N197 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/French pedigree cell line collection; Part of: Human variation panel; Registration: CEPH Families Reference Panel; 6602 21168042 CVCL_VJ45 ORL-204 cancer cell line human CVCL_VJ45 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 3688; FGFR1; Simple; p.Asn224Lysfs*8 (c.671dup); Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Omics: Transcriptome analysis by RNAseq Male 21168043 CVCL_MP98 BayGenomics ES cell line RRC135 embryonic stem cell house mouse CVCL_MP98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925503; Map4k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168044 CVCL_N198 GM12928 transformed cell line human CVCL_N198 CL:0000010 Sequence variation: Mutation; HGNC; 5163; HPS1; Simple; p.His497Glnfs (c.1472_1487dup16); ClinVar=VCV000005277; Zygosity=Homozygous (PubMed=27345974) Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168045 CVCL_VJ46 ORL-207 cancer cell line human CVCL_VJ46 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Female 21168046 CVCL_MP95 BayGenomics ES cell line RRC130 embryonic stem cell house mouse CVCL_MP95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443162; Uggt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168047 CVCL_N195 GM12137 transformed cell line human CVCL_N195 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168048 CVCL_MP96 BayGenomics ES cell line RRC133 embryonic stem cell house mouse CVCL_MP96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168049 CVCL_N196 GM12547 transformed cell line human CVCL_N196 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/French pedigree cell line collection; Part of: Human variation panel; Registration: CEPH Families Reference Panel; 6601 21168050 CVCL_MP93 BayGenomics ES cell line RRC127 embryonic stem cell house mouse CVCL_MP93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98285; Srsf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168051 CVCL_N193 GM12081 transformed cell line human CVCL_N193 HLA typing: A*01:CNJK,29:02; B*08:XKT,35:BEZX; C*07:CVAG,07:19; DRB1*03:01,13:02 (IPD-IMGT/HLA=20694) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21168052 CVCL_VJ49 ORL-247 cancer cell line human CVCL_VJ49 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Glnfs*7 (c.642_643delTA); ClinVar=VCV000826394; Zygosity=Unspecified (PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male 21168053 CVCL_MP94 BayGenomics ES cell line RRC128 embryonic stem cell house mouse CVCL_MP94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168054 CVCL_N194 GM12136 transformed cell line human CVCL_N194 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168055 CVCL_3D02 HQ00309 transformed cell line human CVCL_3D02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168056 CVCL_3D03 HQ00310 transformed cell line human CVCL_3D03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168057 CVCL_3D00 HQ00307 transformed cell line human CVCL_3D00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168058 CVCL_3D01 HQ00308 transformed cell line human CVCL_3D01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168059 CVCL_3D06 HQ00313 transformed cell line human CVCL_3D06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168060 CVCL_3D07 HQ00314 transformed cell line human CVCL_3D07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168061 CVCL_3D04 HQ00311 transformed cell line human CVCL_3D04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168062 CVCL_3D05 HQ00312 transformed cell line human CVCL_3D05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168063 CVCL_3D08 HQ00315 transformed cell line human CVCL_3D08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168064 CVCL_3D09 HQ00316 transformed cell line human CVCL_3D09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168065 CVCL_VJ32 MWCL-1/IR cancer cell line human CVCL_VJ32 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:76612; Ibrutinib (Imbruvica); Derived from sampling site: Bone marrow. Male 21168066 CVCL_VJ33 RPCI-WM1/IR cancer cell line human CVCL_VJ33 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:76612; Ibrutinib (Imbruvica); Derived from sampling site: Lymph node. Female 21168067 CVCL_VJ30 BCWM.1/IR cancer cell line human CVCL_VJ30 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:76612; Ibrutinib (Imbruvica); Derived from sampling site: Bone marrow. Female 21168068 CVCL_VJ31 MWCL-1/BR cancer cell line human CVCL_VJ31 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Hemizygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Bone marrow. Male 21168069 CVCL_VJ36 U266/BR cancer cell line human CVCL_VJ36 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda 21168070 CVCL_VJ37 ORL-150 cancer cell line human CVCL_VJ37 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Unspecified (PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male 21168071 CVCL_VJ34 KMS-11/BR cancer cell line human CVCL_VJ34 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa 21168072 CVCL_VJ35 OPM-2/BR cancer cell line human CVCL_VJ35 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Female Characteristics: Produces Ig lambda 21168073 CVCL_VJ38 ORL-153 cancer cell line human CVCL_VJ38 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Tyr997Ter (c.2991T>G); Zygosity=Unspecified (PubMed=27050151) Population: Indian; Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by RNAseq Male 21168074 CVCL_VJ39 ORL-156 cancer cell line human CVCL_VJ39 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3033Asnfs*11 (c.9097dupA); ClinVar=VCV000038208; Zygosity=Unspecified (PubMed=27050151); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=27050151); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=24224046; PubMed=27050151) Population: Chinese; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by RNAseq Male 21168075 CVCL_MP80 BayGenomics ES cell line RRC083 embryonic stem cell house mouse CVCL_MP80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100851; Elavl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168076 CVCL_N180 GM11410 transformed cell line human CVCL_N180 HLA typing: A*30:04:01,68:02:01; B*44:03:02,57:03:01; C*07:01:02,07:06; DPA1*01:03:01,02:01:01; DPB1*01:01:02,18:01; DQA1*01:05:01,02:01:01; DQB1*02:02:01,05:01:01; DRB1*07:01:01,12:01:01G; DRB3*02:02:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala1050Glufs*6 (c.3149delC); ClinVar=VCV000183078; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168077 CVCL_MP81 BayGenomics ES cell line RRC086 embryonic stem cell house mouse CVCL_MP81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922816; Ing5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168078 CVCL_N181 GM11477 finite cell line human CVCL_N181 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala1050Glufs*6 (c.3149delC); ClinVar=VCV000183078; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (from autologous cell line GM11410) Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Male 21168079 CVCL_VJ21 GM25978 finite cell line human CVCL_VJ21 CL:0000010 Sequence variation: Mutation; HGNC; 2340; CRADD; Simple; p.Gly128Arg (c.382G>C); ClinVar=VCV000030360; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21168080 CVCL_VJ22 GM25979 finite cell line human CVCL_VJ22 CL:0000010 Sequence variation: Mutation; HGNC; 2340; CRADD; Simple; p.Gly128Arg (c.382G>C); ClinVar=VCV000030360; Zygosity=Heterozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21168081 CVCL_MP79 BayGenomics ES cell line RRC079 embryonic stem cell house mouse CVCL_MP79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647985; Rpl10l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168082 CVCL_N179 GM11409 transformed cell line human CVCL_N179 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Gly664Arg (c.1990G>A); ClinVar=VCV000013843; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168083 CVCL_VJ20 GM25977 finite cell line human CVCL_VJ20 CL:0000010 Sequence variation: Mutation; HGNC; 2340; CRADD; Simple; p.Gly128Arg (c.382G>C); ClinVar=VCV000030360; Zygosity=Heterozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21168084 CVCL_MP77 BayGenomics ES cell line RRC077 embryonic stem cell house mouse CVCL_MP77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108466; Ralbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168085 CVCL_N177 GM11377 transformed cell line human CVCL_N177 CL:0000010 Population: Southeast Asian; Khmer Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168086 CVCL_VJ25 UCP1:mCherry H1 hES embryonic stem cell human CVCL_VJ25 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Male Characteristics: The construct IRES-puro-P2A-mCherry was inserted at the stop codon of UCP1 using CRISPR-Cas9 21168087 CVCL_VJ26 154BR finite cell line human CVCL_VJ26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21168088 CVCL_MP78 BayGenomics ES cell line RRC078 embryonic stem cell house mouse CVCL_MP78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168089 CVCL_N178 GM11405 transformed cell line human CVCL_N178 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Human variation panel 21168090 CVCL_MP75 BayGenomics ES cell line RRC071 embryonic stem cell house mouse CVCL_MP75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920018; Topbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168091 CVCL_N175 GM11373 transformed cell line human CVCL_N175 CL:0000010 Population: Southeast Asian; Khmer Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168092 CVCL_VJ23 GM25980 finite cell line human CVCL_VJ23 CL:0000010 Sequence variation: Mutation; HGNC; 2340; CRADD; Simple; p.Gly128Arg (c.382G>C); ClinVar=VCV000030360; Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21168093 CVCL_MP76 BayGenomics ES cell line RRC076 embryonic stem cell house mouse CVCL_MP76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098687; Aak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168094 CVCL_N176 GM11376 transformed cell line human CVCL_N176 CL:0000010 Population: Southeast Asian; Khmer Cambodian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168095 CVCL_VJ24 GM25981 finite cell line human CVCL_VJ24 CL:0000010 Sequence variation: Mutation; HGNC; 2340; CRADD; Simple; p.Gly128Arg (c.382G>C); ClinVar=VCV000030360; Zygosity=Heterozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21168096 CVCL_MP73 BayGenomics ES cell line RRC067 embryonic stem cell house mouse CVCL_MP73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168097 CVCL_VJ29 BCWM.1/BR cancer cell line human CVCL_VJ29 CL:0000010 Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Bone marrow. Female 21168098 CVCL_N173 GM11324 transformed cell line human CVCL_N173 HLA typing: A*02:01:01,11:01:01; B*15:02:01,15:11:01; C*03:03:01,08:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,03:01:01; DQA1*03:02,06:01:01; DQB1*03:01:01,03:03:02; DRB1*09:01:02,12:02:01; DRB3*03:01:03; DRB4*01:03:02 (PubMed=29959025) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168099 CVCL_MP74 BayGenomics ES cell line RRC069 embryonic stem cell house mouse CVCL_MP74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930715; Ube2d2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168100 CVCL_N174 GM11325 transformed cell line human CVCL_N174 HLA typing: A*11:01:01,11:01:01; B*38:02:01,38:02:01; C*07:02:01,07:02:01; DPA1*02:02:02,02:10; DPB1*02:02:01,02:02:01; DQA1*01:03:01,06:01:01; DQB1*03:01:01,06:01:01; DRB1*08:03:02,12:02:01; DRB3*03:01:03 (PubMed=29959025) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168101 CVCL_MP71 BayGenomics ES cell line RRC064 embryonic stem cell house mouse CVCL_MP71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384585; Gatad2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168102 CVCL_N171 GM11322 transformed cell line human CVCL_N171 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168103 CVCL_VJ27 MUSCSDi001-A induced pluripotent stem cell human CVCL_VJ27 From: Medical University of South Carolina; Charleston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21168104 CVCL_MP72 BayGenomics ES cell line RRC065 embryonic stem cell house mouse CVCL_MP72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168105 CVCL_N172 GM11323 transformed cell line human CVCL_N172 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168106 CVCL_VJ28 HeLa-G63 cancer cell line human CVCL_VJ28 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21168107 CVCL_MP91 BayGenomics ES cell line RRC122 embryonic stem cell house mouse CVCL_MP91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098687; Aak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168108 CVCL_N191 GM11898 transformed cell line human CVCL_N191 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168109 CVCL_MP92 BayGenomics ES cell line RRC124 embryonic stem cell house mouse CVCL_MP92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914617; Paxbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168110 CVCL_N192 GM11970 transformed cell line human CVCL_N192 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Human variation panel 21168111 CVCL_VJ09 GM25195 transformed cell line human CVCL_VJ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168112 CVCL_MP90 BayGenomics ES cell line RRC120 embryonic stem cell house mouse CVCL_MP90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444989; Spg11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168113 CVCL_N190 GM11860 transformed cell line human CVCL_N190 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.3718-2477C>T (3849+10KB,C>T); ClinVar=VCV000007166; Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168114 CVCL_VJ10 GM25196 transformed cell line human CVCL_VJ10 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Asp198Gly (c.593A>G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168115 CVCL_VJ11 GM25198 transformed cell line human CVCL_VJ11 CL:0000010 Sequence variation: Mutation; HGNC; 4289; GK; Simple; p.Glu459Lys (c.1357G>A); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168116 CVCL_MP88 BayGenomics ES cell line RRC107 embryonic stem cell house mouse CVCL_MP88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919420; Chchd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168117 CVCL_N188 GM11811 transformed cell line human CVCL_N188 CL:0000010 Population: Saudi Arabian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168118 CVCL_VJ14 GM25582 transformed cell line human CVCL_VJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168119 CVCL_MP89 BayGenomics ES cell line RRC108 embryonic stem cell house mouse CVCL_MP89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168120 CVCL_N189 GM11814 transformed cell line human CVCL_N189 CL:0000010 Population: Caucasian; Northern European; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168121 CVCL_VJ15 GM25583 transformed cell line human CVCL_VJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168122 CVCL_MP86 BayGenomics ES cell line RRC100 embryonic stem cell house mouse CVCL_MP86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147627; Yars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168123 CVCL_N186 GM11589 transformed cell line human CVCL_N186 HLA typing: A*24:20,33:03:01; B*15:11:01,44:03:01; C*03:04:01,14:03; DPA1*02:02:02,02:02:02; DPB1*05:01:01,05:01:01; DQA1*01:02:01,03:02; DQB1*03:03:02,06:02:01; DRB1*09:01:02,15:01:01; DRB4*01:03:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Pro34Ser (c.100C>T); ClinVar=VCV000016893; Zygosity=Heterozygous; Note=CYP2D6*10 allele (Coriell) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168124 CVCL_VJ12 GM25401 transformed cell line human CVCL_VJ12 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Lys1753Ter (c.5257A>T); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168125 CVCL_MP87 BayGenomics ES cell line RRC102 embryonic stem cell house mouse CVCL_MP87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168126 CVCL_N187 GM11590 transformed cell line human CVCL_N187 HLA typing: A*24:02:01,26:01:01; B*13:01:01,40:01:02; C*03:04:01,08:03:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:02:01G; DQA1*03:03:01,06:01:01; DQB1*03:01:01,04:01:01; DRB1*04:05:01,12:02:01; DRB3*03:01:03; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168127 CVCL_VJ13 GM25581 transformed cell line human CVCL_VJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168128 CVCL_MP84 BayGenomics ES cell line RRC094 embryonic stem cell house mouse CVCL_MP84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168129 CVCL_N184 GM11532 transformed cell line human CVCL_N184 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Human variation panel 21168130 CVCL_VJ18 GM25931 transformed cell line human CVCL_VJ18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168131 CVCL_MP85 BayGenomics ES cell line RRC098 embryonic stem cell house mouse CVCL_MP85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109337; Brca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168132 CVCL_N185 GM11587 transformed cell line human CVCL_N185 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168133 CVCL_VJ19 GM25864 induced pluripotent stem cell human CVCL_VJ19 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21168134 CVCL_MP82 BayGenomics ES cell line RRC090 embryonic stem cell house mouse CVCL_MP82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168135 CVCL_N182 GM11419 transformed cell line human CVCL_N182 CL:0000010 Population: Indian (from Guyana); Karyotypic information: 49,XYYYY (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21168136 CVCL_VJ16 GM25589 transformed cell line human CVCL_VJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168137 CVCL_MP83 BayGenomics ES cell line RRC093 embryonic stem cell house mouse CVCL_MP83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168138 CVCL_N183 GM11420 finite cell line human CVCL_N183 CL:0000010 Population: Indian (from Guyana); Karyotypic information: 49,XYYYY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21168139 CVCL_VJ17 GM25595 transformed cell line human CVCL_VJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168140 CVCL_3D97 HQ00404 transformed cell line human CVCL_3D97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168141 CVCL_3D98 HQ00405 transformed cell line human CVCL_3D98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of HQ00406 (Cellosaurus=CVCL_3D99); Derived from sampling site: Peripheral blood. Female 21168142 CVCL_3D95 HQ00402 transformed cell line human CVCL_3D95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168143 CVCL_3D96 HQ00403 transformed cell line human CVCL_3D96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168144 CVCL_3D99 HQ00406 transformed cell line human CVCL_3D99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of HQ00405 (Cellosaurus=CVCL_3D98); Derived from sampling site: Peripheral blood. Female 21168145 CVCL_3D90 HQ00397 transformed cell line human CVCL_3D90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168146 CVCL_3D93 HQ00400 transformed cell line human CVCL_3D93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168147 CVCL_3D94 HQ00401 transformed cell line human CVCL_3D94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168148 CVCL_3D91 HQ00398 transformed cell line human CVCL_3D91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168149 CVCL_3D92 HQ00399 transformed cell line human CVCL_3D92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168150 CVCL_3D75 HQ00382 transformed cell line human CVCL_3D75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168151 CVCL_3D76 HQ00383 transformed cell line human CVCL_3D76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168152 CVCL_3D73 HQ00380 transformed cell line human CVCL_3D73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168153 CVCL_3D74 HQ00381 transformed cell line human CVCL_3D74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168154 CVCL_3D79 HQ00386 transformed cell line human CVCL_3D79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168155 CVCL_3D77 HQ00384 transformed cell line human CVCL_3D77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168156 CVCL_3D78 HQ00385 transformed cell line human CVCL_3D78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168157 CVCL_3D71 HQ00378 transformed cell line human CVCL_3D71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168158 CVCL_3D72 HQ00379 transformed cell line human CVCL_3D72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168159 CVCL_3D70 HQ00377 transformed cell line human CVCL_3D70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168160 CVCL_3D86 HQ00393 transformed cell line human CVCL_3D86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168161 CVCL_3D87 HQ00394 transformed cell line human CVCL_3D87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168162 CVCL_3D84 HQ00391 transformed cell line human CVCL_3D84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168163 CVCL_3D85 HQ00392 transformed cell line human CVCL_3D85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168164 CVCL_3D88 HQ00395 transformed cell line human CVCL_3D88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168165 CVCL_3D89 HQ00396 transformed cell line human CVCL_3D89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168166 CVCL_3D82 HQ00389 transformed cell line human CVCL_3D82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168167 CVCL_3D83 HQ00390 transformed cell line human CVCL_3D83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168168 CVCL_3D80 HQ00387 transformed cell line human CVCL_3D80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168169 CVCL_3D81 HQ00388 transformed cell line human CVCL_3D81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168170 CVCL_3D53 HQ00360 transformed cell line human CVCL_3D53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168171 CVCL_3D54 HQ00361 transformed cell line human CVCL_3D54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168172 CVCL_3D51 HQ00358 transformed cell line human CVCL_3D51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168173 CVCL_3D52 HQ00359 transformed cell line human CVCL_3D52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168174 CVCL_3D57 HQ00364 transformed cell line human CVCL_3D57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168175 CVCL_3D58 HQ00365 transformed cell line human CVCL_3D58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168176 CVCL_3D55 HQ00362 transformed cell line human CVCL_3D55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168177 CVCL_3D56 HQ00363 transformed cell line human CVCL_3D56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168178 CVCL_3D59 HQ00366 transformed cell line human CVCL_3D59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168179 CVCL_3D50 HQ00357 transformed cell line human CVCL_3D50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168180 CVCL_3D64 HQ00371 transformed cell line human CVCL_3D64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168181 CVCL_3D65 HQ00372 transformed cell line human CVCL_3D65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168182 CVCL_3D62 HQ00369 transformed cell line human CVCL_3D62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168183 CVCL_3D63 HQ00370 transformed cell line human CVCL_3D63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168184 CVCL_3D68 HQ00375 transformed cell line human CVCL_3D68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168185 CVCL_3D69 HQ00376 transformed cell line human CVCL_3D69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168186 CVCL_3D66 HQ00373 transformed cell line human CVCL_3D66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168187 CVCL_3D67 HQ00374 transformed cell line human CVCL_3D67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168188 CVCL_VJ90 NBLW cancer cell line human CVCL_VJ90 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Leu (c.3824G>T); ClinVar=VCV000376365; Zygosity=Heterozygous (PubMed=27888620) Derived from sampling site: Adrenal gland. Omics: Array-based CGH Male 21168189 CVCL_VJ91 NBLW-R cancer cell line human CVCL_VJ91 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (PubMed=27888620) Derived from metastatic site: Bone marrow. Omics: Array-based CGH Male 21168190 CVCL_VJ94 SB.07 cancer cell line human CVCL_VJ94 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=26962861) Derived from metastatic site: Ileal lymph node. Omics: Genome sequenced Female Doubling time: 50.3 hours (PubMed=26962861) 21168191 CVCL_VJ95 SB.12 cancer cell line human CVCL_VJ95 CL:0000010 Derived from metastatic site: Liver. Male Doubling time: 37.1 hours (PubMed=26962861) 21168192 CVCL_VJ92 SIAC1 cancer cell line human CVCL_VJ92 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=25478808) Population: Japanese; Derived from sampling site: Small intestine; jejunum. Female Microsatellite instability: Instable (MSI-high) (PubMed=25478808) 21168193 CVCL_VJ93 SB.06 cancer cell line human CVCL_VJ93 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=26962861); Sequence variation: Mutation; HGNC; 9099; PLXNA1; Simple; p.Asp863Asn (c.2587G>A); dbSNP=rs367569800; Zygosity=Unspecified (PubMed=26962861) Omics: Genome sequenced. Male Doubling time: 45.9 hours (PubMed=26962861) 21168194 CVCL_VJ98 UT33a cancer cell line human CVCL_VJ98 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Female 21168195 CVCL_VJ99 UT44 cancer cell line human CVCL_VJ99 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Male 21168196 CVCL_VJ96 UT14 cancer cell line human CVCL_VJ96 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Male 21168197 CVCL_VJ97 UT16 cancer cell line human CVCL_VJ97 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Female 21168198 CVCL_3D60 HQ00367 transformed cell line human CVCL_3D60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168199 CVCL_3D61 HQ00368 transformed cell line human CVCL_3D61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168200 CVCL_E749 LAM transformed cell line human CVCL_E749 HLA typing: A*29:02:01; B*44:03; C*16 (IPD-IMGT/HLA=10960) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94050345; probable Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168201 CVCL_DV49 ND02674 transformed cell line human CVCL_DV49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168202 CVCL_E747 LO081785 transformed cell line human CVCL_E747 HLA typing: A*03:01:01:01,24:02:01:01; B*18:01:01:01; C*05:01:01:01; DPA1*01; DPB1*03:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:01; DRB1*03:01:01; DRB3*02:02 (IPD-IMGT/HLA=11637) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168203 CVCL_DV47 ND02638 transformed cell line human CVCL_DV47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168204 CVCL_E748 LADA transformed cell line human CVCL_E748 HLA typing: A*02:01:01:01,80:01; B*07:02:01,57:03:01; C*07:02:01:01,08:02; DPA1*01:03:01,02:01:01; DPB1*03:01:01,17:01; DQA1*01:01:01,03:01:01; DQB1*02:02,05:01:01; DRB1*09:01:02,12:01:01; DRB3*02:02:01; DRB4*01:01:01 (IPD-IMGT/HLA=10959) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168205 CVCL_DV48 ND02669 transformed cell line human CVCL_DV48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168206 CVCL_E741 KT17 [Human B-cell] transformed cell line human CVCL_E741 HLA typing: A*02:06:01:01,11:01:01:01; B*15:01:01:01,35:01:01:02; C*04:01:01:01,03:03:01:01; DPA1*02:02:02; DPB1*05:01:01; DQA1*03:01; DQB1*03:02:01; DRB1*04:03:01,04:06:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=11002) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168207 CVCL_DV41 ND02589 transformed cell line human CVCL_DV41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168208 CVCL_E742 KT2 transformed cell line human CVCL_E742 HLA typing: A*02:01; B*51:01:01; C*14:02:01; DPB1*05:01; DQA1*03; DRB1*04:06:01; DRB4*01:03 (IPD-IMGT/HLA=11003) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94022538; probable Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168209 CVCL_DV42 ND02597 transformed cell line human CVCL_DV42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168210 CVCL_E740 KT14 [Human B-cell] transformed cell line human CVCL_E740 HLA typing: A*24:02:01:01,26:02:01; B*51:01:01:01,40:06:01:01; C*08:01:01,14:02:01:01; DPB1*02:01:02/02:01:19,19:01; DQA1*03; DQB1*03:03:02; DRB1*09:01:02/09:21; DRB4*01:03:02 (IPD-IMGT/HLA=11001) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168211 CVCL_DV40 ND02583 transformed cell line human CVCL_DV40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168212 CVCL_E745 KY [Human B-cell 09IHW] transformed cell line human CVCL_E745 HLA typing: A*31; B*60; C*w03; DQA1*03; DQB1*03:02 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168213 CVCL_DV45 ND02634 transformed cell line human CVCL_DV45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168214 CVCL_E746 KY [Human B-cell 12IHW] transformed cell line human CVCL_E746 HLA typing: A*02:06,24:02; B*59:01; C*01; DPB1*04:02,05:01 (IPD-IMGT/HLA=10949) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168215 CVCL_DV46 ND02637 transformed cell line human CVCL_DV46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168216 CVCL_E743 KT3 transformed cell line human CVCL_E743 HLA typing: A*24:02:01:01,24:02:43; B*54:01:01; C*01:02:01; DPA1*02:02:02; DPB1*05:01:01; DQA1*03:02; DQB1*04:01:01; DRA*01:01:01; DRB1*04:05:01; DRB4*01:02 (IPD-IMGT/HLA=11004) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168217 CVCL_DV43 ND02598 transformed cell line human CVCL_DV43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168218 CVCL_E744 KUROIWA transformed cell line human CVCL_E744 HLA typing: A*24; B*07; C*07; DPB1*04:01,04:02; DQA1*01:01; DQB1*05:01; DRB1*01:01 (IPD-IMGT/HLA=11674) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168219 CVCL_DV44 ND02609 transformed cell line human CVCL_DV44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168220 CVCL_E758 LO541265 transformed cell line human CVCL_E758 HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01,02:01; DPB1*01:01:01,04:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:02; DRB1*03:01:01; DRB3*01:01 (IPD-IMGT/HLA=11639) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168221 CVCL_DV58 ND02911 transformed cell line human CVCL_DV58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168222 CVCL_E759 LS40 transformed cell line human CVCL_E759 HLA typing: A*01,26; B*27:05,40:01; C*02:02,03:04; DPB1*02:01,03:01; DRB1*04:04; DRB4*01:03 (IPD-IMGT/HLA=11007) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168223 CVCL_DV59 ND02912 transformed cell line human CVCL_DV59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168224 CVCL_E752 LBF transformed cell line human CVCL_E752 HLA typing: A*30:01:01; B*13:02:01:01; C*06:02:01:01; DPA1*02:01:01; DPB1*17:01; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01:01 (IPD-IMGT/HLA=10969) CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Discontinued: ECACC; 88052096; probable Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168225 CVCL_DV52 ND02722 transformed cell line human CVCL_DV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168226 CVCL_E753 LCK transformed cell line human CVCL_E753 HLA typing: A*02:03,11:02; B*38:02:01,46:01; C*07:02,12:02; DPA1*02:02:02; DPB1*05:01; DQA1*03; DQB1*03:03:02,05:02:01; DRB1*09:01; DRB4*01:03:01:01,01:03:02 (IPD-IMGT/HLA=25978) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168227 CVCL_DV53 ND02782 transformed cell line human CVCL_DV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168228 CVCL_E750 LATIF transformed cell line human CVCL_E750 HLA typing: A*11:01:01:01,31:01:02:01; B*15:08:01,51:01:01; C*01:02:01,16:02:01; DPA1*01:03:01,02:02:02; DPB1*04:01:01:01,13:01; DQA1*02:01,03:02; DQB1*02:02:01:01,03:02:01; DRB1*07:01:01,09:01:02; DRB4*01:03:01,01:03:02 (IPD-IMGT/HLA=10961); HLA typing: A*11:01:01:01,31:01:02:01; B*15:08:01,51:01:01:01; C*01:02:01;16:02:01; DPA1*01:03:01:02,02:02:02; DPB1*04:01:01:01(350:01),13:01:01; DQA1*03:02,02:01:01; DQB1*03:02:01,02:02:01:01; DRB1*09:01:02,07:01:01; DRB4*01:03:01,01:03:02 (PubMed=30844424) CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168229 CVCL_DV50 ND02698 transformed cell line human CVCL_DV50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168230 CVCL_E751 LB transformed cell line human CVCL_E751 HLA typing: A*68:01:01:01; B*40:01:01; C*03:04; DPA1*01:03:01:01; DPB1*02:01:02:01,04:02; DQA1*01:02:01:01 (IPD-IMGT/HLA=10964) CL:0000010 Population: Caucasian; Swedish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168231 CVCL_DV51 ND02716 transformed cell line human CVCL_DV51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168232 CVCL_E756 LEW311 transformed cell line human CVCL_E756 HLA typing: A*02:01,74:01; B*18:01,40:16; C*08:02,15:05; DQB1*02:01; DRB1*07:01; DRB4*01:01 (IPD-IMGT/HLA=26000) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168233 CVCL_DV56 ND02792 transformed cell line human CVCL_DV56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168234 CVCL_E757 LK707 transformed cell line human CVCL_E757 HLA typing: A*02:01; B*52:01:01,73:01; C*07:01,15:05; DRB1*15:02/80N,04:05 (IPD-IMGT/HLA=10999) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168235 CVCL_DV57 ND02833 transformed cell line human CVCL_DV57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168236 CVCL_E754 LD2B transformed cell line human CVCL_E754 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=11638) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168237 CVCL_DV54 ND02783 transformed cell line human CVCL_DV54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168238 CVCL_E755 LE023 transformed cell line human CVCL_E755 HLA typing: A*66:01,32:01:01; B*51:01:01,73:01; C*01:02:01,15:05:01; DPA1*01:03:01:04; DPB1*04:01:01:01,30:01; DQA1*01:02:01:06,01:03:01:02; DQB1*06:03:01,06:04:01; DRB1*13:01:01,13:02:01; DRB3*01:01:02:01,03:01:01 (IPD-IMGT/HLA=10979); HLA typing: A*32:01:01,66:01:01; B*73:01,51:01:01:01; C*15:05:01,01:02:01; DPA1*01:03:01:01,01:03:01:04; DPB1*30:01,04:01:01:01; DQA1*01:02:01,01:03:01; DQB1*06:03:01(06:39),06:04:01(06:41); DRB1*13:01:01,13:02:01; DRB3*01:01:02,03:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168239 CVCL_DV55 ND02791 transformed cell line human CVCL_DV55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168240 CVCL_E727 KLO transformed cell line human CVCL_E727 HLA typing: A*02:08,01:01:01:01; B*50:01:01,08:01:01; C*07:01:01:01,06:02:01:02; DPA1*01:03:01:02,02:01:02; DPB1*01:01:01,104:01; DQA1*02:01,05:01:01:02; DQB1*02:01:01,02:02:01; DRB1*03:01:01:01,07:01:01:01; DRB3*01:01:02:01; DRB4*01:03:01 (IPD-IMGT/HLA=10919); HLA typing: A*01:01:01:01,02:08; B*08:01:01:01,50:01:01; C*06:02:01:02,07:01:01:01; DPA1*01:03:01:02,02:01:02; DPB1*01:01:01,104:01; DQA1*02:01:01,05:01:01:02; DQB1*02:01:01,02:02:01:01; DRB1*03:01:01,07:01:01; DRB3*01:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168241 CVCL_DV27 ND02476 transformed cell line human CVCL_DV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168242 CVCL_E728 KNE transformed cell line human CVCL_E728 HLA typing: A*02:07,01:01; C*07,12:02; DPB1*03:01 (IPD-IMGT/HLA=10923) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168243 CVCL_DV28 ND02483 transformed cell line human CVCL_DV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168244 CVCL_E725 KI transformed cell line human CVCL_E725 HLA typing: A*02; B*13,55; C*01,03; DRB1*12:02:01 (IPD-IMGT/HLA=10914) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168245 CVCL_DV25 ND02466 transformed cell line human CVCL_DV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168246 CVCL_E726 KIME transformed cell line human CVCL_E726 HLA typing: A*02:11:01,32:01:01:10; B*52:01,46:01; C*12:02:02:01,15:02:01:01; DPB1*04:01:01; DQB1*02:01:01,03:03:02:02; DRB1*03,07:01:01 (IPD-IMGT/HLA=10915) CL:0000010 Population: Southeast Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168247 CVCL_DV26 ND02475 transformed cell line human CVCL_DV26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168248 CVCL_E729 KOSE transformed cell line human CVCL_E729 HLA typing: A*02:01:01:01; B*35:03:01:01; C*12:03:01:01; DPA1*01:03:01,02:01:01; DPB1*02:01:02/02:01:19,13:01:01/107:01; DQA1*01:04:01,01:02:01; DQB1*05:03:01,06:04:01; DRA*01:01,01:02; DRB1*13:02:01,14:54:01; DRB3*03:01:01,02:02:01 (IPD-IMGT/HLA=10927) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168249 CVCL_DV29 ND02484 transformed cell line human CVCL_DV29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168250 CVCL_E720 KAS011 transformed cell line human CVCL_E720 HLA typing: A*01:01:01:01; B*37:01:01; C*06:02:01:01; DPA1*01:03:01,02:01:02; DPB1*04:01:01,14:01:01; DQA1*01:02:02; DQB1*05:02:01; DRA*01:01; DRB1*16:01:01; DRB5*02; DRB6*02:02 (IPD-IMGT/HLA=10901) CL:0000010 Population: Caucasian; Yugoslavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168251 CVCL_DV20 ND02447 transformed cell line human CVCL_DV20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168252 CVCL_E723 KGU transformed cell line human CVCL_E723 HLA typing: A*11; B*35; C*35; DPB1*04:01; DQA1*01:04:02; DRB1*14:04 (IPD-IMGT/HLA=10910) CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168253 CVCL_DV23 ND02452 transformed cell line human CVCL_DV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168254 CVCL_E724 KHAGNI transformed cell line human CVCL_E724 HLA typing: A*11:01:01:01,26:01:01:01; B*15:08:01,52:01:01:02; C*01:02:01,12:02:02:01; DPB1*04:01:01; DQB1*06:01:01/06:01:15,02:02:01; DRB1*15:02:01,07:01:01 (IPD-IMGT/HLA=10912) CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168255 CVCL_DV24 ND02457 transformed cell line human CVCL_DV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168256 CVCL_E721 KAS116 transformed cell line human CVCL_E721 HLA typing: A*24:02:01:01; B*51:01:01:03; C*12:03:01:01; DPA1*02:01; DPB1*13:01:01/107:01; DQA1*01:01:01; DQB1*05:01:01; DRA*01:01; DRB1*01:01:01; DRB6*01:01 (IPD-IMGT/HLA=10902) CL:0000010 Population: Caucasian; Yugoslavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168257 CVCL_DV21 ND02448 transformed cell line human CVCL_DV21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168258 CVCL_E722 KAWASAKI transformed cell line human CVCL_E722 HLA typing: A*24:02:01:01; B*52:01:01; DPB1*09:01; DQA1*01:03; DQB1*06:01:01; DRB1*15:02:01; DRB5*01:02 (IPD-IMGT/HLA=11686) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168259 CVCL_DV22 ND02451 transformed cell line human CVCL_DV22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168260 CVCL_E738 KT11 [Human B-cell] transformed cell line human CVCL_E738 HLA typing: A*33; B*44 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168261 CVCL_DV38 ND02544 transformed cell line human CVCL_DV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168262 CVCL_E739 KT12 [Human B-cell] transformed cell line human CVCL_E739 HLA typing: A*24:02:01:01,31:01:02:01; B*35:01:01:01,52:01:01:02; C*04:01:01:01,12:02:02:01; DPB1*04:02:01,05:01:01; DQB1*03:03:02; DRB1*09:01:02/09:21 (IPD-IMGT/HLA=11000) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168263 CVCL_DV39 ND02563 transformed cell line human CVCL_DV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168264 CVCL_E736 KRC-110 transformed cell line human CVCL_E736 HLA typing: A*31:01:02,24:02:01; B*51:01:01,15:20; C*03:04:01 (IPD-IMGT/HLA=10934) CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168265 CVCL_DV36 ND02542 transformed cell line human CVCL_DV36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168266 CVCL_E737 KRO3/4 transformed cell line human CVCL_E737 HLA typing: A*02; B*44:02; C*07:04:01; DPB1*02:01,04:01 (IPD-IMGT/HLA=10936) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168267 CVCL_DV37 ND02543 transformed cell line human CVCL_DV37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168268 CVCL_E730 KOZ transformed cell line human CVCL_E730 HLA typing: A*24,26; B*40,54:01; C*01; DPB1*02:01:02; DQA1*03; DQB1*03:03:02 (IPD-IMGT/HLA=10928) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168269 CVCL_DV30 ND02485 transformed cell line human CVCL_DV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168270 CVCL_E731 KPE transformed cell line human CVCL_E731 HLA typing: A*24:03:01,11:01; B*07,35; DPB1*04:01 (IPD-IMGT/HLA=10929) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168271 CVCL_DV31 ND02490 transformed cell line human CVCL_DV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168272 CVCL_E734 KRC-032 transformed cell line human CVCL_E734 HLA typing: A*24:02:01; B*35:05,35:06; C*04 (IPD-IMGT/HLA=10931) CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168273 CVCL_DV34 ND02521 transformed cell line human CVCL_DV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168274 CVCL_E735 KRC-103 transformed cell line human CVCL_E735 HLA typing: A*31:01:02; B*39:05,48:01:01; C*07:02,08:03; DPA1*01:03; DPB1*04:02 (IPD-IMGT/HLA=10933) CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168275 CVCL_DV35 ND02526 transformed cell line human CVCL_DV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168276 CVCL_E732 KRA transformed cell line human CVCL_E732 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168277 CVCL_DV32 ND02492 transformed cell line human CVCL_DV32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168278 CVCL_E733 KRC-005 transformed cell line human CVCL_E733 HLA typing: A*02:12; B*51:01:01; C*01:02:01; DPA1*01:03; DPB1*04:02 (IPD-IMGT/HLA=10930) CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168279 CVCL_DV33 ND02514 transformed cell line human CVCL_DV33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168280 CVCL_E705 HS-67 transformed cell line human CVCL_E705 HLA typing: A*24:02:01:01,11:01:01:01; B*48:01:01,67:01:01; C*07:02:01:01,08:03:01; DRB1*16,08 (IPD-IMGT/HLA=10764); HLA typing: A*11:01:01:01,24:02:01:01; B*48:01:01,67:01:01; C*07:02:01:01,08:03:01; DPA1*02:02:02; DPB1*05:01:01; DQA1*01:02:02,01:03:01; DQB1*05:02:01,06:01:01; DRB1*16:02:01:02,08:03:02; DRB5*02:02 (PubMed=30844424) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168281 CVCL_DV05 ND02363 transformed cell line human CVCL_DV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168282 CVCL_E706 IBW9 transformed cell line human CVCL_E706 HLA typing: A*33:01:01:01; B*14:02:01:01; C*08:02:01:01; DPA1*02; DPB1*01:01:02; DQA1*02:01; DQB1*02:02:01; DRB1*07:01:01 (IPD-IMGT/HLA=11634) CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Discontinued: Coriell; GM08065; probable Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168283 CVCL_DV06 ND02364 transformed cell line human CVCL_DV06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168284 CVCL_E703 HOR transformed cell line human CVCL_E703 HLA typing: A*33:03:01:01,33:03:01:02; B*44:03:01:01; C*14:03; DPB1*04:01:01; DQA1*01:02; DQB1*06:04:01; DRB1*13:02:01; DRB3*03:01:01 (IPD-IMGT/HLA=10757) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168285 CVCL_DV03 ND02360 transformed cell line human CVCL_DV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168286 CVCL_E704 HOSONUMA transformed cell line human CVCL_E704 HLA typing: A*24:02:01:01; B*07:02:01; C*07; DPB1*04:02; DQA1*01:01; DQB1*05:01:01; DRB1*01:01:01 (IPD-IMGT/HLA=11673) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168287 CVCL_DV04 ND02362 transformed cell line human CVCL_DV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168288 CVCL_E709 IHL,AD036 transformed cell line human CVCL_E709 HLA typing: A*02:01:01:01,34:01:01; B*40:02:01,56:02; C*01:02:01,15:02:01:01; DPB1*02:01:02,02:01:02; DQA1*01:03,01:04:01:02; DQB1*05:03:01,06:01:01; DRB1*08:03:02,14:14; DRB3*02:02 (IPD-IMGT/HLA=10797) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168289 CVCL_DV09 ND02402 transformed cell line human CVCL_DV09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168290 CVCL_E707 IDF transformed cell line human CVCL_E707 HLA typing: A*69:01,66:01:01; B*18:01:01:02,38:01:01; C*12:03:01:01; DPA1*01:03:01:05,01:03:01:02; DPB1*04:01:01:01,04:02:01:01; DQA1*05:05::01:01; DQB1*03:01:01:03; DRB1*11:01:01,11:04:01; DRB3*02:02:01:02 (IPD-IMGT/HLA=10795); HLA typing: A*66:01:01,69:01; B*38:01:01,18:01:01:02; C*12:03:01:01; DPA1*01:03:01:02,01:03:01:05; DPB1*04:01:01:01(126:01),04:02:01:01(105:01); DQA1*05:05:01; DQB1*03:01:01:03; DRB1*11:01:01:01,11:04:01; DRB3*02:02:01:02 (PubMed=30844424) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168291 CVCL_DV07 ND02388 transformed cell line human CVCL_DV07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168292 CVCL_E708 IHL,AD031 transformed cell line human CVCL_E708 HLA typing: A*02,31; B*27:05,40; C*02:02; DPB1*04:02,05:01; DQA1*03,01:03; DQB1*03:02,06:01; DRB1*04:01,08:03:02; DRB4*01:01 (IPD-IMGT/HLA=11662) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168293 CVCL_DV08 ND02389 transformed cell line human CVCL_DV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168294 CVCL_E701 HO301 transformed cell line human CVCL_E701 HLA typing: A*03:01:01:01; B*14:02:01:01; C*08:02:01:01; DPA1*02:01:01; DPB1*05:01:01; DQA1*01:02:01; DQB1*06:09:01; DRA*01:02; DRB1*13:02:01; DRB3*03:01 (IPD-IMGT/HLA=10751) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168295 CVCL_DV01 ND02341 transformed cell line human CVCL_DV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168296 CVCL_E702 HOKKAIDO transformed cell line human CVCL_E702 HLA typing: A*24; B*54; C*01; DPB1*05:01; DQA1*03; DQB1*04:01; DRB1*04:05; DRB4*01:01 (IPD-IMGT/HLA=11684) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168297 CVCL_DV02 ND02353 transformed cell line human CVCL_DV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168298 CVCL_E700 HO104 transformed cell line human CVCL_E700 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=11633) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168299 CVCL_DV00 ND02337 transformed cell line human CVCL_DV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168300 CVCL_E716 JESTHOM transformed cell line human CVCL_E716 HLA typing: A*02:01:01:01; B*27:05:02; C*01:02:01; DPA1*01; DPB1*04:01:01; DQA1*01:01; DQB1*05:01:01; DRA*01:01; DRB1*01:01:01; DRB6*01:01 (IPD-IMGT/HLA=11635) CL:0000010 Population: Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168301 CVCL_DV16 ND02434 transformed cell line human CVCL_DV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168302 CVCL_E717 JHAF transformed cell line human CVCL_E717 HLA typing: A*31:01:02:01; B*51:01:01:01; C*15:02:01:01; DPA1*01:03; DPB1*03:01:01; DQA1*03:01; DQB1*03:01:01; DRB1*04:07:01/04:92; DRB4*01:03:01:01 (IPD-IMGT/HLA=10845) CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168303 CVCL_DV17 ND02435 transformed cell line human CVCL_DV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168304 CVCL_E714 JAP-NF transformed cell line human CVCL_E714 HLA typing: A*02:01,26:01; B*15:17:01:01,38:01:01; C*07:01,12:03; DPB1*02:01:02,03:01 (IPD-IMGT/HLA=10819) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168305 CVCL_DV14 ND02413 transformed cell line human CVCL_DV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168306 CVCL_E715 JBUSH transformed cell line human CVCL_E715 HLA typing: A*32:01:01:01; B*38:01:01; C*12:03:01:01; DPB1*04:01:01; DQA1*05:05; DQB1*03:01:01; DRB1*11:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=10825) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168307 CVCL_DV15 ND02414 transformed cell line human CVCL_DV15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168308 CVCL_E718 JS transformed cell line human CVCL_E718 HLA typing: A*30:03,03:01:01:01; B*07:02:01,18:01:01:01; C*05:01:01:01,07:02:01:03; DPA1*01:03:01:05,01:03:01:01; DPB1*02:02,04:02:01:02; DQA1*01:02:01:01,05:01:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01:01,15:01:01; DRB3*02:02:01:01; DRB5*01:01:01 (IPD-IMGT/HLA=10872); HLA typing: A*03:01:01:01,30:03; B*07:02:01,18:01:01:01; C*05:01:01:01,07:02:01:03; DPA1*01:03:01:01,01:03:01:05; DPB1*02:02,04:02:01:02; DQA1*01:02:01,05:01:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01; DRB3*02:02:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168309 CVCL_DV18 ND02444 transformed cell line human CVCL_DV18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168310 CVCL_E719 JVM transformed cell line human CVCL_E719 HLA typing: A*02:01:01:01; B*18:01:01:01; C*05:01:01:01; DPA1*01; DPB1*02:01:02/02:01:19; DQA1*05:05; DQB1*03:01:01; DRA*01:01; DRB1*11:02:01; DRB3*02:02 (IPD-IMGT/HLA=10879) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel Caution: Erroneously indicated as being a B-cell leukemia cell line in Lonza=592 21168311 CVCL_DV19 ND02446 transformed cell line human CVCL_DV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168312 CVCL_E712 ISH5 transformed cell line human CVCL_E712 HLA typing: A*24:02:01:01; B*48:01,54:01; C*01:02,08:03; DPB1*05:01; DQB1*03:03:02,05:03:01; DRB1*09:01:02,14:05:01; DRB3*02:02:01; DRB4*01:03:02 (IPD-IMGT/HLA=25983) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168313 CVCL_DV12 ND02407 transformed cell line human CVCL_DV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168314 CVCL_E713 JO528239 transformed cell line human CVCL_E713 HLA typing: A*01:01:01:01; B*35:02:01:01; C*04:01:01:06; DPB1*04:02:01,11:01:01; DQA1*05:01; DQB1*03:01:01; DRB1*11:04:01; DRB3*02:02 (IPD-IMGT/HLA=11636) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168315 CVCL_DV13 ND02408 transformed cell line human CVCL_DV13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168316 CVCL_E710 ISH3 transformed cell line human CVCL_E710 HLA typing: A*24:02:01:01; B*15:26N; C*04:01:01:01; DPA1*02:02:02; DPB1*02:01:02; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:06:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=25980) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168317 CVCL_DV10 ND02403 transformed cell line human CVCL_DV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168318 CVCL_E711 ISH4 transformed cell line human CVCL_E711 HLA typing: A*02:18,11:01; B*15:01,46:01; C*01:02,04:01:01; DPB1*02:02,05:01; DQB1*03:02:01,06:01:01; DRB1*04:06,08:03:02; DRB4*01:03:01:01 (IPD-IMGT/HLA=10565) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168319 CVCL_DV11 ND02406 transformed cell line human CVCL_DV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168320 CVCL_MP59 BayGenomics ES cell line RRC044 embryonic stem cell house mouse CVCL_MP59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168321 CVCL_N159 GM10959 transformed cell line human CVCL_N159 HLA typing: A*02:01:01,03:01:01; B*07:02:01,07:02:01; C*07:02:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:02:01; DRB1*15:01:01,15:01:01; DRB5*01:01:01,01:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Arg296Cys (c.886C>T); ClinVar=VCV000242771; Zygosity=Heterozygous; Note=CYP2D6*2 allele (Coriell); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Ser486Thr (c.1457G>C); ClinVar=VCV000242701; Zygosity=Heterozygous; Note=CYP2D6*2 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168322 CVCL_VJ00 UM-1 [Human LCL] transformed cell line human CVCL_VJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168323 CVCL_MP57 BayGenomics ES cell line RRC040 embryonic stem cell house mouse CVCL_MP57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168324 CVCL_N157 GM10810 transformed cell line human CVCL_N157 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168325 CVCL_MP58 BayGenomics ES cell line RRC043 embryonic stem cell house mouse CVCL_MP58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102774; Aimp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168326 CVCL_N158 GM10873 transformed cell line human CVCL_N158 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168327 CVCL_MP55 BayGenomics ES cell line RRC036 embryonic stem cell house mouse CVCL_MP55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924093; Dtl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168328 CVCL_N155 GM10798 transformed cell line human CVCL_N155 HLA typing: A*11:01:01,80:01:01; B*38:02:02,40:02:01; C*04:01:01,07:02:01; DPA1*01:03:01,02:02:02; DPB1*01:01:01,04:01:01; DQA1*01:02:01,05:05:01; DQB1*03:01:01,05:02:01; DRB1*11:01:01,15:02:01G; DRB3*02:02:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168329 CVCL_VJ03 UM-21-6 transformed cell line human CVCL_VJ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168330 CVCL_MP56 BayGenomics ES cell line RRC037 embryonic stem cell house mouse CVCL_MP56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168331 CVCL_N156 GM10799 transformed cell line human CVCL_N156 CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168332 CVCL_VJ04 UM-43 transformed cell line human CVCL_VJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168333 CVCL_MP53 BayGenomics ES cell line RRC031 embryonic stem cell house mouse CVCL_MP53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105037; Ddx5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168334 CVCL_N153 GM10666 finite cell line human CVCL_N153 CL:0000010 Sequence variation: Mutation; HGNC; 10969; SLC22A5; Simple; p.Arg282Ter (c.844C>T); ClinVar=VCV000006416; Zygosity=Heterozygous (PubMed=10051646) Population: Indian; Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21168335 CVCL_VJ01 UM-1-6TGr transformed cell line human CVCL_VJ01 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168336 CVCL_MP54 BayGenomics ES cell line RRC032 embryonic stem cell house mouse CVCL_MP54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858303; Srrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168337 CVCL_N154 GM10667 finite cell line human CVCL_N154 CL:0000010 Sequence variation: Mutation; HGNC; 10969; SLC22A5; Simple; p.Arg282Ter (c.844C>T); ClinVar=VCV000006416; Zygosity=Heterozygous (PubMed=10051646) Population: Indian; Derived from sampling site: Cell type=Fibroblast. Male Part of: Human variation panel 21168338 CVCL_VJ02 UM-21-5 transformed cell line human CVCL_VJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168339 CVCL_MP51 BayGenomics ES cell line RRC028 embryonic stem cell house mouse CVCL_MP51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924093; Dtl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168340 CVCL_VJ07 ECN90 transformed cell line human CVCL_VJ07 HLA typing: A*02:01,03; B*40,49; C*03,07 (Patent=WO2017046335A1) CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas. Unspecified Group: Patented cell line 21168341 CVCL_N151 GM10641 finite cell line human CVCL_N151 CL:0000010 Sequence variation: Mutation; HGNC; 403; ALDH3A2; Simple; p.Ala314_Pro315delinsGlyAlaLysSerThrValGlyAla (c.941_943delCCCinsGGGCTAAAAGTACTGTTGGGG) (941-943delCCC+ins21bp); Zygosity=Homozygous (Coriell) Population: South American (Andes); Derived from sampling site: Cell type=Fibroblast. Female Part of: Human variation panel 21168342 CVCL_MP52 BayGenomics ES cell line RRC030 embryonic stem cell house mouse CVCL_MP52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914988; Ppid Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168343 CVCL_N152 GM10647 transformed cell line human CVCL_N152 HLA typing: A*01:01:01,24:02:01; B*08:01:01,15:01:01; C*03:03:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01G,23:01:01G; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168344 CVCL_VJ08 GM24411 transformed cell line human CVCL_VJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168345 CVCL_VJ05 UM-61 transformed cell line human CVCL_VJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168346 CVCL_MP50 BayGenomics ES cell line RRC027 embryonic stem cell house mouse CVCL_MP50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096340; E2f3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168347 CVCL_N150 GM10543 transformed cell line human CVCL_N150 CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168348 CVCL_VJ06 HLHL-1 hybrid cell line human CVCL_VJ06 CL:0000010 Karyotypic information: Tetraploid karyotype; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21168349 CVCL_MP70 BayGenomics ES cell line RRC063 embryonic stem cell house mouse CVCL_MP70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168350 CVCL_N170 GM11321 transformed cell line human CVCL_N170 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168351 CVCL_MP68 BayGenomics ES cell line RRC060 embryonic stem cell house mouse CVCL_MP68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168352 CVCL_N168 GM11235 transformed cell line human CVCL_N168 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168353 CVCL_MP69 BayGenomics ES cell line RRC062 embryonic stem cell house mouse CVCL_MP69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168354 CVCL_N169 GM11318 transformed cell line human CVCL_N169 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168355 CVCL_MP66 BayGenomics ES cell line RRC055 embryonic stem cell house mouse CVCL_MP66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918413; Zfp626 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168356 CVCL_N166 GM11200 transformed cell line human CVCL_N166 CL:0000010 Population: Native South American; Quechuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168357 CVCL_MP67 BayGenomics ES cell line RRC057 embryonic stem cell house mouse CVCL_MP67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889206; Skap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168358 CVCL_N167 GM11213 transformed cell line human CVCL_N167 CL:0000010 Population: Indo Pakistani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Human variation panel 21168359 CVCL_MP64 BayGenomics ES cell line RRC052 embryonic stem cell house mouse CVCL_MP64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168360 CVCL_N164 GM11198 transformed cell line human CVCL_N164 CL:0000010 Population: Native South American; Quechuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168361 CVCL_MP65 BayGenomics ES cell line RRC053 embryonic stem cell house mouse CVCL_MP65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105056; Cobl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168362 CVCL_N165 GM11199 transformed cell line human CVCL_N165 CL:0000010 Population: Native South American; Quechuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168363 CVCL_MP62 BayGenomics ES cell line RRC049 embryonic stem cell house mouse CVCL_MP62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102774; Aimp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168364 CVCL_N162 GM11032 transformed cell line human CVCL_N162 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168365 CVCL_MP63 BayGenomics ES cell line RRC051 embryonic stem cell house mouse CVCL_MP63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168366 CVCL_N163 GM11036 transformed cell line human CVCL_N163 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Part of: Human variation panel; Registration: CEPH Families Reference Panel; 10401 21168367 CVCL_MP60 BayGenomics ES cell line RRC045 embryonic stem cell house mouse CVCL_MP60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923957; Clasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168368 CVCL_N160 GM10989 transformed cell line human CVCL_N160 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21168369 CVCL_MP61 BayGenomics ES cell line RRC047 embryonic stem cell house mouse CVCL_MP61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918413; Zfp626 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168370 CVCL_N161 GM11012 transformed cell line human CVCL_N161 HLA typing: A*02:236,24:02:01; B*14:02:01,44:02:01; C*05:01:01,08:02:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,05:01:01; DQA1*01:02:01,01:02:01; DQB1*06:02:01,06:09:01; DRB1*13:02:01,15:01:01; DRB3*03:01:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168371 CVCL_MP39 BayGenomics ES cell line RRC004 embryonic stem cell house mouse CVCL_MP39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168372 CVCL_N139 GM10347 transformed cell line human CVCL_N139 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168373 CVCL_MP37 BayGenomics ES cell line RRB186 embryonic stem cell house mouse CVCL_MP37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442827; Tbc1d32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168374 CVCL_N137 GM10345 finite cell line human CVCL_N137 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis Female Part of: Human variation panel 21168375 CVCL_MP38 BayGenomics ES cell line RRC002 embryonic stem cell house mouse CVCL_MP38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108109; Ywhag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168376 CVCL_N138 GM10346 transformed cell line human CVCL_N138 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168377 CVCL_MP35 BayGenomics ES cell line RRB182 embryonic stem cell house mouse CVCL_MP35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168378 CVCL_N135 GM10262 transformed cell line human CVCL_N135 HLA typing: A*02:01:01,02:01:01; B*13:02:01,35:02:01; C*04:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*02:01:01,05:05:01; DQB1*02:02:01,03:01:01; DRB1*07:01:01,11:01:01; DRB3*02:02:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168379 CVCL_MP36 BayGenomics ES cell line RRB185 embryonic stem cell house mouse CVCL_MP36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336168; Cradd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168380 CVCL_N136 GM10263 finite cell line human CVCL_N136 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21168381 CVCL_MP33 BayGenomics ES cell line RRB172 embryonic stem cell house mouse CVCL_MP33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168382 CVCL_N133 GM10181 transformed cell line human CVCL_N133 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168383 CVCL_MP34 BayGenomics ES cell line RRB173 embryonic stem cell house mouse CVCL_MP34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168384 CVCL_N134 GM10251 transformed cell line human CVCL_N134 HLA typing: A*30:AUX,30:02; B*07:CZZS,35:BEZX; C*04:CVAF,07:WCP; DRB1*04:05,09:01 (IPD-IMGT/HLA=19228) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21168385 CVCL_MP31 BayGenomics ES cell line RRB168 embryonic stem cell house mouse CVCL_MP31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916527; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168386 CVCL_N131 GM10129 transformed cell line human CVCL_N131 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Retinitis Pigmentosa Foundation Collection 21168387 CVCL_MP32 BayGenomics ES cell line RRB169 embryonic stem cell house mouse CVCL_MP32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95543; Fkbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168388 CVCL_N132 GM10176 transformed cell line human CVCL_N132 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM17025; probable Male Part of: Human variation panel 21168389 CVCL_MP30 BayGenomics ES cell line RRB166 embryonic stem cell house mouse CVCL_MP30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914077; Ttc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168390 CVCL_N130 GM10072 transformed cell line human CVCL_N130 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168391 CVCL_MP48 BayGenomics ES cell line RRC023 embryonic stem cell house mouse CVCL_MP48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168392 CVCL_N148 GM10541 transformed cell line human CVCL_N148 CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168393 CVCL_MP49 BayGenomics ES cell line RRC024 embryonic stem cell house mouse CVCL_MP49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168394 CVCL_N149 GM10542 transformed cell line human CVCL_N149 CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168395 CVCL_MP46 BayGenomics ES cell line RRC019 embryonic stem cell house mouse CVCL_MP46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96957; Mea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168396 CVCL_N146 GM10490 transformed cell line human CVCL_N146 HLA typing: A*03:CVAB,34:02; B*07:CZZS,42:01; C*07:WCP,17:MN; DRB1*03:02,15:03 (IPD-IMGT/HLA=19225) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21168397 CVCL_MP47 BayGenomics ES cell line RRC020 embryonic stem cell house mouse CVCL_MP47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923036; Ckap5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168398 CVCL_N147 GM10539 transformed cell line human CVCL_N147 CL:0000010 Population: Pacific; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21168399 CVCL_MP44 BayGenomics ES cell line RRC014 embryonic stem cell house mouse CVCL_MP44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168400 CVCL_N144 GM10450 transformed cell line human CVCL_N144 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168401 CVCL_MP45 BayGenomics ES cell line RRC015 embryonic stem cell house mouse CVCL_MP45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104810; Plaa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168402 CVCL_N145 GM09964 finite cell line human CVCL_N145 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21168403 CVCL_MP42 BayGenomics ES cell line RRC010 embryonic stem cell house mouse CVCL_MP42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445220; Dcaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168404 CVCL_N142 GM10384 transformed cell line human CVCL_N142 HLA typing: A*02:01:01,29:02:01; B*07:02:01,44:02:01; C*05:01:01,07:02:01; DPA1*01:03:01,02:06; DPB1*03:01:01G,05:01:01G; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:02:01; DRB1*07:01:01,15:01:01; DRB4*01:01:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168405 CVCL_MP43 BayGenomics ES cell line RRC013 embryonic stem cell house mouse CVCL_MP43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929520; Eef1b2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168406 CVCL_N143 GM10432 transformed cell line human CVCL_N143 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21168407 CVCL_MP40 BayGenomics ES cell line RRC005 embryonic stem cell house mouse CVCL_MP40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99208; Zfp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168408 CVCL_N140 GM10356 transformed cell line human CVCL_N140 HLA typing: A*02:01:01,02:01:01; B*07:02:01,51:01:01; C*07:02:01,14:02:01; DPA1*01:03:01,02:01:01; DPB1*01:01:02,02:01:02; DQA1*05:05:01,06:01:01; DQB1*03:01:01,03:01:01; DRB1*08:03:02,11:01:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168409 CVCL_MP41 BayGenomics ES cell line RRC009 embryonic stem cell house mouse CVCL_MP41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889206; Skap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168410 CVCL_N141 GM10378 transformed cell line human CVCL_N141 HLA typing: A*01:CNJK,02:DFKP; B*08:XKT,49:01; C*07:CVAG; DRB1*03:01,11:01 (IPD-IMGT/HLA=16404) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21168411 CVCL_E785 MYE 2001 transformed cell line human CVCL_E785 HLA typing: A*01:04N,02:01:01:01; B*15:01:01:05,49:01:01; C*03:03:01,07:01:01; DPA1*01:03:01:05,01:03:01:04; DPB1*04:01:01,04:01:01:02; DQA1*02:01,05:05:01:01; DQB1*03:01:01:03,02:02:01:01; DRB1*07:01:01:01,11:01:01; DRB3*02:02:01:02; DRB4*01:01:01:01 (IPD-IMGT/HLA=26021); HLA typing: A*01:04N,02:01:01:01; B*15:01:01:05,49:01:01; C*03:03:01:01,07:01:01:01; DPA1*01:03:01:04,01:03:01:05; DPB1*04:01:01:01(126:01),04:02:01:02(105:01); DQA1*02:01:01,05:05:01; DQB1*02:02:01:01,03:01:01:03; DRB1*07:01:01,11:01:01:01; DRB3*02:02:01:02; DRB4*01:01:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168412 CVCL_DV85 ND03251 transformed cell line human CVCL_DV85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168413 CVCL_E786 MYE 2002 transformed cell line human CVCL_E786 HLA typing: A*03:01:01,68:11N; B*07:02:01,44:02:01:01; C*07:02; DPB1*02:01:02,05:01; DQB1*03:01:01,03:02:01; DRB1*04:05:01,11:01:01; DRB3*02:02:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=26022); HLA typing: A*03:01:01:01,68:11N; B*07:02:01,44:02:01:03; C*07:02:01:03,07:04:01:01; DPA1*01:03:01:01,02:02:02; DPB1*02:01:02,05:01:01; DQA1*03:03:01:01,05:05:01; DQB1*03:01:01:03,03:02:01; DRB1*11:01:01:01,04:05:01; DRB3*02:02:01:02; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168414 CVCL_DV86 ND03252 transformed cell line human CVCL_DV86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168415 CVCL_E783 MT14B transformed cell line human CVCL_E783 HLA typing: A*31:01:02:01; B*40:01:02:01; C*03:04:01:01; DPB1*04:02:01; DQA1*03; DQB1*03:02:01; DRB1*04:04:01; DRB4*01:01 (IPD-IMGT/HLA=11642) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168416 CVCL_DV83 ND03197 transformed cell line human CVCL_DV83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168417 CVCL_E784 MUL [Human B-cell IHW] transformed cell line human CVCL_E784 HLA typing: A*02:01,03:01; B*15:03,35:03; C*04:01,12:03; DPB1*02:01:02,04:02; DQA1*03:01,05:05; DQB1*03:01:01,03:02:01; DRB1*04:03:01,11:21; DRB3*02:02:01,02:02:01; DRB4*01:03:01:01,01:03:01:01 (IPD-IMGT/HLA=11112) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21168418 CVCL_DV84 ND03230 transformed cell line human CVCL_DV84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168419 CVCL_E789 MYE 2006 transformed cell line human CVCL_E789 HLA typing: A*24:09N,29:02; B*27:05:02,44:03:01; C*02:02:02,16:04:01; DPB1*02:01:02,04:01:01; DQB1*02:02,05:01:01; DRB1*01:01:01,07:01:01; DRB4*01:01:01 (IPD-IMGT/HLA=26025); HLA typing: A*24:09N,29:02:01:01; B*27:05:02,44:03:01:01; C*02:02:02:01,16:01:01:01; DPA1*01:03:01:01,01:03:01:04; DPB1*02:01:02,04:01:01:01; DQA1*01:01:01,02:01:01; DQB1*02:02:01:01,05:01:01:03; DRB1*01:01:01,07:01:01; DRB4*01:01:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168420 CVCL_DV89 ND03259 transformed cell line human CVCL_DV89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168421 CVCL_E787 MYE 2003 transformed cell line human CVCL_E787 HLA typing: A*24:02:01:04,68:11N; B*35:03,44:02:01:01; C*07,12:03; DPB1*02:01:02; DQB1*03:01:01,06:03; DRB1*11:01:01,13:01:01; DRB3*01:01:02:01,02:02:01 (IPD-IMGT/HLA=26023); HLA typing: A*24:02:01:04,68:11N; B*35:03:01,44:02:01:03; C*07:04:01:01,12:03:01:01; DPA1*01:03:01:01; DPB1*02:01:02; DQA1*05:05:01,01:03:01; DQB1*03:01:01:03,06:03:01; DRB1*11:01:01:01,13:01:01; DRB3*01:01:02,02:02:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168422 CVCL_DV87 ND03257 transformed cell line human CVCL_DV87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168423 CVCL_E788 MYE 2004 transformed cell line human CVCL_E788 HLA typing: A*29:02:01:01,68:18N; B*14:02:01,57:01:01; C*06:02:01:01,08:02:01:01; DPA1*01:03:01:03; DPB1*02:01:02,06:01; DQA1*02:01,05:05:01:02; DQB1*03:01:01:03,03:03:02:01; DRB1*07:01:01,13:03:01; DRB3*01:01:02:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=26024); HLA typing: A*29:02:01:01,68:18N; B*14:02:01:01,57:01:01; C*06:02:01:01,08:02:01:01; DPA1*01:03:01:01,01:03:01:03; DPB1*02:01:02,06:01:01; DQA1*02:01:01,05:05:01; DQB1*03:01:01:03,03:03:02:01; DRB1*07:01:01,13:03:01; DRB3*01:01:02; DRB4*01:03:01:02N (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168424 CVCL_DV88 ND03258 transformed cell line human CVCL_DV88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168425 CVCL_MP19 BayGenomics ES cell line RRB095 embryonic stem cell house mouse CVCL_MP19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168426 CVCL_N119 GM09771 transformed cell line human CVCL_N119 HLA typing: A*02:01:01,23:01:01; B*14:06:02,44:02:01; C*05:01:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:02,03:03:01; DQB1*03:01:01,05:01:01; DRB1*01:02:01,04:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Part of: Retinitis Pigmentosa Foundation Collection 21168427 CVCL_MP17 BayGenomics ES cell line RRB087 embryonic stem cell house mouse CVCL_MP17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168428 CVCL_N117 GM09737 finite cell line human CVCL_N117 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21168429 CVCL_MP18 BayGenomics ES cell line RRB094 embryonic stem cell house mouse CVCL_MP18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168430 CVCL_N118 GM09764 transformed cell line human CVCL_N118 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168431 CVCL_MP15 BayGenomics ES cell line RRB082 embryonic stem cell house mouse CVCL_MP15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104816; Hnrnpl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168432 CVCL_N115 GM09626 transformed cell line human CVCL_N115 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168433 CVCL_E781 MN-2 transformed cell line human CVCL_E781 HLA typing: A*02; B*07; C*07; DRB1*16:01:01; DRB5*02:02 (IPD-IMGT/HLA=11090) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168434 CVCL_DV81 ND03180 transformed cell line human CVCL_DV81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168435 CVCL_MP16 BayGenomics ES cell line RRB083 embryonic stem cell house mouse CVCL_MP16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168436 CVCL_N116 GM09736 transformed cell line human CVCL_N116 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168437 CVCL_E782 MOU transformed cell line human CVCL_E782 HLA typing: A*29:02:01:01; B*44:03:01:01; C*16:01:01:01; DPA1*01:03; DPB1*02:01:02,02:01:19; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01:01; DRB9*01:01:01:01 (IPD-IMGT/HLA=11096) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168438 CVCL_DV82 ND03196 transformed cell line human CVCL_DV82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168439 CVCL_MP13 BayGenomics ES cell line RRB079 embryonic stem cell house mouse CVCL_MP13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168440 CVCL_N113 GM09611 transformed cell line human CVCL_N113 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168441 CVCL_MP14 BayGenomics ES cell line RRB080 embryonic stem cell house mouse CVCL_MP14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168442 CVCL_N114 GM09618 transformed cell line human CVCL_N114 HLA typing: A*01:01:01,02:01:01; B*44:02:01,57:01:01; C*05:01:01,06:02:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,04:01:01; DQA1*02:01:01,05:01:01; DQB1*02:01:01,03:03:02; DRB1*03:01:01,07:01:01; DRB3*02:02:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168443 CVCL_E780 MMU transformed cell line human CVCL_E780 HLA typing: A*11:01:01; B*35,67; C*07,09; DPB1*03:01,13:01; DQB1*03:02,06:02; DRB1*04:07,15:01 (IPD-IMGT/HLA=11089) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168444 CVCL_DV80 ND03173 transformed cell line human CVCL_DV80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168445 CVCL_MP11 BayGenomics ES cell line RRB075 embryonic stem cell house mouse CVCL_MP11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915206; Kmt5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168446 CVCL_N111 GM09509 transformed cell line human CVCL_N111 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168447 CVCL_MP12 BayGenomics ES cell line RRB078 embryonic stem cell house mouse CVCL_MP12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168448 CVCL_N112 GM09567 transformed cell line human CVCL_N112 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168449 CVCL_MP10 BayGenomics ES cell line RRB074 embryonic stem cell house mouse CVCL_MP10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444737; Fem1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168450 CVCL_N110 GM09507 transformed cell line human CVCL_N110 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM09507; probable Male Part of: Human variation panel 21168451 CVCL_DV96 ND03297 transformed cell line human CVCL_DV96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168452 CVCL_E796 NP369 transformed cell line human CVCL_E796 HLA typing: A*02,11; B*57; C*06,07; DPB1*04:01,05:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02:02 (IPD-IMGT/HLA=11698) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168453 CVCL_DV97 ND03300 transformed cell line human CVCL_DV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168454 CVCL_E797 OLGA transformed cell line human CVCL_E797 HLA typing: A*31:01:02:01; B*15:01:01:01,15:20; C*01:02:30,03:04:01:02; DPA1*01:03:01:03,01:03:01:05; DPB1*03:01:01:01,04:02:01:02; DQA1*04:01:01/02/03; DQB1*04:02:01:04; DRA*01:02; DRB1*08:02:02,08:02:01:01 (IPD-IMGT/HLA=11212) CL:0000010 Population: Native South American; Warao; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168455 CVCL_E794 NAI031 transformed cell line human CVCL_E794 HLA typing: A*24; B*54,59; C*01; DPB1*02:01:02,04:02; DQA1*03,01:03; DQB1*04:01,06:01; DRB1*04:05,08:03; DRB4*01:01 (IPD-IMGT/HLA=11716) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168456 CVCL_DV94 ND03288 transformed cell line human CVCL_DV94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168457 CVCL_DV95 ND03289 transformed cell line human CVCL_DV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168458 CVCL_E795 NON,L transformed cell line human CVCL_E795 HLA typing: A*01,10; B*51,55; C*01; DPB1*02:01:02,05:01; DQA1*01:03,03; DQB1*06:01,03:02; DRB1*04:06,08:03; DRB4*01:03 (IPD-IMGT/HLA=11734) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168459 CVCL_DV98 ND03313 transformed cell line human CVCL_DV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168460 CVCL_E798 OMW transformed cell line human CVCL_E798 HLA typing: A*02:01:01:01; B*45:01:01; C*16:01:01:01; DPA1*02:01:08; DPB1*01:01:01; DQA1*01:03; DQB1*06:03:01; DRA*01:02; DRB1*13:01:01; DRB3*01:01 (IPD-IMGT/HLA=11215) CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168461 CVCL_DV99 ND03314 transformed cell line human CVCL_DV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168462 CVCL_E799 OZB transformed cell line human CVCL_E799 HLA typing: A*02:09,03:01:01; B*35:02,38:01; C*04:01:01,12:03:01; DPB1*04:02,10:01 (IPD-IMGT/HLA=11224) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168463 CVCL_MP28 BayGenomics ES cell line RRB120 embryonic stem cell house mouse CVCL_MP28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168464 CVCL_N128 GM04618 finite cell line human CVCL_N128 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21168465 CVCL_MP29 BayGenomics ES cell line RRB129 embryonic stem cell house mouse CVCL_MP29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448561; Ythdc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168466 CVCL_N129 GM10005 transformed cell line human CVCL_N129 HLA typing: A*02:01:01,33:03:01; B*15:03:01,44:02:01; C*02:10:01,05:01:01; DPA1*01:03:01,03:NEW-2; DPB1*04:01:01,350:01; DQA1*01:02:01,03:03:01; DQB1*03:01:01,06:02:01; DRB1*04:01:01,15:03:01; DRB4*01:03:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168467 CVCL_MP26 BayGenomics ES cell line RRB114 embryonic stem cell house mouse CVCL_MP26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168468 CVCL_N126 GM09947 transformed cell line human CVCL_N126 HLA typing: A*02:01:01,02:01:01; B*44:02:01,51:01:01; C*02:02:02,05:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:02:01G; DQA1*04:02,05:01:01; DQB1*02:01:01,04:02:01; DRB1*03:01:01,08:01:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Biotechnology: Used a source of control genomic and mitochondrial DNA for USA forensic testing; Omics: DNA methylation analysis; Omics: Mitochondrial genome sequenced Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2391b; Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2392 21168469 CVCL_E792 NAI006 transformed cell line human CVCL_E792 HLA typing: A*02,26:02; B*07,35; C*01:02,08; DPB1*02:01:02,04:02; DQA1*03,03:02; DQB1*03:03,04:01; DRB1*04:05,09:01; DRB4*01:01 (IPD-IMGT/HLA=11715) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168470 CVCL_DV92 ND03280 transformed cell line human CVCL_DV92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168471 CVCL_MP27 BayGenomics ES cell line RRB116 embryonic stem cell house mouse CVCL_MP27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107342; Zfp64 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168472 CVCL_N127 GM09948 transformed cell line human CVCL_N127 HLA typing: A*03:01:01,31:01:02; B*07:02:01,40:01:02; C*03:04:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:01,03:01:01; DQB1*03:02:01,06:02:01; DRB1*04:04:01,15:01:01; DRB4*01:03:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Biotechnology: Used a source of control genomic DNA for USA forensic testing; Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel; Registration: National Institute of Standards and Technology, Standard Reference Materials; SRM 2391b 21168473 CVCL_E793 NAI026 transformed cell line human CVCL_E793 HLA typing: A*24,26; B*35,59; C*01,03; DPB1*02:01:02,03:01; DQA1*03; DQB1*04:01; DRB1*04:05; DRB4*01:01 (IPD-IMGT/HLA=11714) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168474 CVCL_DV93 ND03287 transformed cell line human CVCL_DV93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168475 CVCL_MP24 BayGenomics ES cell line RRB106 embryonic stem cell house mouse CVCL_MP24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103097; Anapc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168476 CVCL_N124 GM09912 transformed cell line human CVCL_N124 HLA typing: A*01,02; B*07,35; C*w04,w07 (PubMed=2916654) CL:0000010 Population: Caucasian; Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168477 CVCL_E790 MZ070782 transformed cell line human CVCL_E790 HLA typing: A*24:02:01:01,24:02:01:12; B*14:02:01:01; C*02:02:02:03,08:02:01:01; DPA1*01; DPB1*04:01:01; DQA1*01:01:02; DQB1*05:01:01; DRA*01:01; DRB1*01:02:01; DRB6*01:01 (IPD-IMGT/HLA=11120) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168478 CVCL_DV90 ND03260 transformed cell line human CVCL_DV90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168479 CVCL_MP25 BayGenomics ES cell line RRB113 embryonic stem cell house mouse CVCL_MP25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108451; Acaca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168480 CVCL_N125 GM09916 transformed cell line human CVCL_N125 HLA typing: B*57:01 (Coriell=GM17290); HLA typing: A*01,02; B*51,w57 (PubMed=2916654); HLA typing: A*11:01:01,26:01:01; B*07:02:01,57:01:01; C*06:02:01,12:03:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:02:02,01:04:01; DQB1*05:02:01,05:03:01; DRB1*14:54:01,15:01:01; DRB3*02:02:01; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Discontinued: Coriell; GM09916; probable Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel Caution: Indicated as originating from a female child in Coriell, but seems to be from a male (PubMed=2916654) 21168481 CVCL_E791 NAI003 transformed cell line human CVCL_E791 HLA typing: A*02,26; B*35,59; C*01,09; DPB1*03:01,04:02; DQA1*03; DQB1*04:01; DRB1*04:05; DRB4*01:01 (IPD-IMGT/HLA=11713); HLA typing: A*68:01:02:01,02:11:01; B*35:05:01,40:04; C*04:01:01:01,03:04:01:02; DPA1*02:01:01:01; DPB1*27:01; DQA1*03:01:01,03:02; DQB1*03:02:01,03:03:02; DRB1*04:11:01,09:01:02; DRB4*01:03:01,01:03:02 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 94082270; probable Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168482 CVCL_DV91 ND03269 transformed cell line human CVCL_DV91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168483 CVCL_MP22 BayGenomics ES cell line RRB098 embryonic stem cell house mouse CVCL_MP22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168484 CVCL_N122 GM09899 transformed cell line human CVCL_N122 HLA typing: A*02:01:01,02:01:01; B*35:03:01,44:02:01; C*04:01:01,05:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:02,02:01:01; DQB1*03:03:02,05:01:01; DRB1*01:02:01,07:01:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168485 CVCL_MP23 BayGenomics ES cell line RRB102 embryonic stem cell house mouse CVCL_MP23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2652854; Smim13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168486 CVCL_N123 GM09901 transformed cell line human CVCL_N123 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168487 CVCL_MP20 BayGenomics ES cell line RRB096 embryonic stem cell house mouse CVCL_MP20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168488 CVCL_N120 GM09815 transformed cell line human CVCL_N120 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168489 CVCL_MP21 BayGenomics ES cell line RRB097 embryonic stem cell house mouse CVCL_MP21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168490 CVCL_N121 GM09871 transformed cell line human CVCL_N121 CL:0000010 Population: South American (Andes); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168491 CVCL_E769 MADURA transformed cell line human CVCL_E769 HLA typing: A*02:01:01:01; B*40:01:02:01; C*03:04:01:01; DPA1*01; DPB1*04:01:01; DQA1*04:01; DQB1*04:02:01; DRA*01:02; DRB1*08:01:01 (IPD-IMGT/HLA=11044) CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168492 CVCL_DV69 ND03049 transformed cell line human CVCL_DV69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168493 CVCL_E763 LZL transformed cell line human CVCL_E763 HLA typing: A*02:17:02; B*15:01:01:01; C*03:03:01:01; DPA1*01; DPB1*04:02:01; DQA1*05:03; DQB1*03:01:01; DRA*01:02; DRB1*14:02:01; DRB3*01:01 (IPD-IMGT/HLA=11014) CL:0000010 Population: Native South American; Warao; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168494 CVCL_DV63 ND02972 transformed cell line human CVCL_DV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168495 CVCL_E764 M.A. transformed cell line human CVCL_E764 HLA typing: DQA1*03:01:01,01:01; DQB1*03:05:01,05:01; DRB1*04:03,01 (IPD-IMGT/HLA=11015) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168496 CVCL_DV64 ND02984 transformed cell line human CVCL_DV64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168497 CVCL_E761 LUY transformed cell line human CVCL_E761 HLA typing: A*02:01:01:01; B*51:01:01:01; C*14:02:01:01; DPA1*01:03,02:01:02; DPB1*01:01:01,04:01:01; DQA1*04:01,06:01:01; DQB1*03:01:01; DRA*01:02; DRB1*08:03:02 (IPD-IMGT/HLA=11011) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168498 CVCL_DV61 ND02931 transformed cell line human CVCL_DV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168499 CVCL_E762 LWAGS transformed cell line human CVCL_E762 HLA typing: A*33:01:01:01; B*14:02:01:01; C*08:02:01:01; DPA1*01:03; DPB1*104:01,04:01:01; DQA1*01:01:02; DQB1*05:01:01; DRA*01:01; DRB1*01:02:01; DRB6*01 (IPD-IMGT/HLA=11013) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168500 CVCL_DV62 ND02938 transformed cell line human CVCL_DV62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168501 CVCL_E767 M7 [Human B-cell 12IHW] transformed cell line human CVCL_E767 HLA typing: A*02:02,03:01:01; B*35:01,53:01; C*04:01; DPB1*02:01:02,17:01; DQB1*02:01,02:02; DRB1*03:01:01,07:01:01; DRB3*02:02:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=11030) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168502 CVCL_DV67 ND02989 transformed cell line human CVCL_DV67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168503 CVCL_E768 MAD,MF transformed cell line human CVCL_E768 HLA typing: A*01:01:01,03:01:01; B*08:01,57:01:01; C*06,07; DPB1*03:01,04:01; DQA1*05:01,02:01; DQB1*02:01,03:03; DRB1*03:01:01,07; DRB3*01:01:02:01; DRB4*01:01 (IPD-IMGT/HLA=11676) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168504 CVCL_DV68 ND03012 transformed cell line human CVCL_DV68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168505 CVCL_E765 M.M. transformed cell line human CVCL_E765 HLA typing: DQA1*05:01,01:02; DQB1*03:04,05:02; DRB1*11,16:01 (IPD-IMGT/HLA=11020) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168506 CVCL_DV65 ND02985 transformed cell line human CVCL_DV65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168507 CVCL_E766 M.R. transformed cell line human CVCL_E766 HLA typing: DPB1*02:01,03:01; DQA1*03,05:01; DRB1*04:01,03:01:02; DRB3*02; DRB4*01:01 (IPD-IMGT/HLA=11022) CL:0000010 Population: Caucasian; Belgian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168508 CVCL_DV66 ND02988 transformed cell line human CVCL_DV66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168509 CVCL_E760 LUCE transformed cell line human CVCL_E760 HLA typing: A*11:01:01:01,02:01:01:01; B*35:03:01:01,27:02:01:01; C*12:03:01:01,02:02:02:03; DPB1*03:01:01,04:02:01; DQB1*05:02:01,03:01:01; DRB1*16:01:01,11:04:01 (IPD-IMGT/HLA=17343) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21168510 CVCL_DV60 ND02930 transformed cell line human CVCL_DV60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168511 CVCL_E774 MER,P transformed cell line human CVCL_E774 HLA typing: A*02:01:01; B*08:01,37:01; C*06:02; DPB1*02:01:02,04:01:01; DQA1*01:04,05:01; DQB1*05:01:01,02:01; DRB1*03:01:01,10:01:01; DRB3*01:01 (IPD-IMGT/HLA=11670) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168512 CVCL_DV74 ND03105 transformed cell line human CVCL_DV74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168513 CVCL_E775 MGAR transformed cell line human CVCL_E775 HLA typing: A*26:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01; DPB1*04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01:01; DRB6*02:01 (IPD-IMGT/HLA=11069) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168514 CVCL_DV75 ND03106 transformed cell line human CVCL_DV75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168515 CVCL_E772 MARMari transformed cell line human CVCL_E772 HLA typing: A*02; B*39,52; C*39,52; DPB1*04:01,02:01; DQA1*01:04,05:01; DQB1*03:01,03:01; DRB1*14:11,11:02; DRB3*02:02,02:02 (IPD-IMGT/HLA=11053) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168516 CVCL_DV72 ND03088 transformed cell line human CVCL_DV72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168517 CVCL_E773 MAY transformed cell line human CVCL_E773 HLA typing: A*26:01:01:01; B*38:01:01; C*12:03:01:01; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*03:01:01; DQB1*03:02:01; DRB1*04:02:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168518 CVCL_DV73 ND03089 transformed cell line human CVCL_DV73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168519 CVCL_E778 MLF transformed cell line human CVCL_E778 HLA typing: A*02:01:01:01; B*15:01:01:01; C*03:04:01:01; DPA1*01; DPB1*04:02:01; DQA1*03; DQB1*03:01:01; DRA*01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11641) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168520 CVCL_DV78 ND03167 transformed cell line human CVCL_DV78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168521 CVCL_E779 MMR transformed cell line human CVCL_E779 HLA typing: A*03,24; B*07; C*w07 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21168522 CVCL_DV79 ND03172 transformed cell line human CVCL_DV79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168523 CVCL_E776 MIKA transformed cell line human CVCL_E776 HLA typing: A*02:01,80:01; B*18,15:03; C*02:02; DPB1*03:01,01:01:02 (IPD-IMGT/HLA=11075) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168524 CVCL_DV76 ND03140 transformed cell line human CVCL_DV76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168525 CVCL_E777 MIN transformed cell line human CVCL_E777 HLA typing: A*02; B*15:13; C*01,03; DPA1*01:03:01; DPB1*04:01,21:01; DQA1*01:02,06:01; DQB1*03:01,05:02; DRB1*12:02; DRB3*03:01 (IPD-IMGT/HLA=11739) CL:0000010 Population: Indonesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21168526 CVCL_DV77 ND03142 transformed cell line human CVCL_DV77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168527 CVCL_MP08 BayGenomics ES cell line RRB070 embryonic stem cell house mouse CVCL_MP08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201685; Ctbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168528 CVCL_N108 GM09501 transformed cell line human CVCL_N108 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168529 CVCL_MP09 BayGenomics ES cell line RRB071 embryonic stem cell house mouse CVCL_MP09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3616079; Dnaaf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168530 CVCL_N109 GM09502 transformed cell line human CVCL_N109 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168531 CVCL_MP06 BayGenomics ES cell line RRB064 embryonic stem cell house mouse CVCL_MP06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108451; Acaca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168532 CVCL_N106 GM09426 transformed cell line human CVCL_N106 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168533 CVCL_MP07 BayGenomics ES cell line RRB066 embryonic stem cell house mouse CVCL_MP07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344347; Synj2bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168534 CVCL_N107 GM09427 transformed cell line human CVCL_N107 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168535 CVCL_MP04 BayGenomics ES cell line RRB062 embryonic stem cell house mouse CVCL_MP04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2651932; Lcorl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168536 CVCL_N104 GM09301 transformed cell line human CVCL_N104 HLA typing: A*23:01:01,30:01:01; B*13:02:01,49:01:01; C*06:02:01,07:01:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,17:01:01; DQA1*02:01:01,05:05:01; DQB1*02:02:01,03:01:01; DRB1*07:01:01,11:04:01; DRB3*02:02:01; DRB4*01:03:0 (PubMed=29959025) CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168537 CVCL_E770 MANIKA transformed cell line human CVCL_E770 HLA typing: A*03:01:01:01; B*50:01:01:01; C*06:02:01:02; DPA1*01,02:01; DPB1*04:01:01,13:01:01/107:01; DQA1*02:01; DQB1*02:02:01,03:03:02; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11640) CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21168538 CVCL_DV70 ND03077 transformed cell line human CVCL_DV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168539 CVCL_MP05 BayGenomics ES cell line RRB063 embryonic stem cell house mouse CVCL_MP05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168540 CVCL_N105 GM09306 transformed cell line human CVCL_N105 HLA typing: A*03:02:01,33:01:01; B*14:02:01,18:01:01; C*08:02:01,15:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,23:01:01; DQA1*01:01:02,02:01:01; DQB1*03:03:02,05:01:01; DRB1*01:02:01,07:01:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168541 CVCL_E771 MARMarg transformed cell line human CVCL_E771 HLA typing: A*01:01:01:01,02:01:01:01; B*35:01:01:01,52:01:01:01; C*04:01:01:01,12:02:02:01; DPB1*04:01:01,03:01:01; DQA1*01:01,01:04; DQB1*05:03:01,05:01:01; DRB1*01:01:01,14:11; DRB3*02:02 (IPD-IMGT/HLA=11052) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21168542 CVCL_DV71 ND03084 transformed cell line human CVCL_DV71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168543 CVCL_MP02 BayGenomics ES cell line RRB059 embryonic stem cell house mouse CVCL_MP02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168544 CVCL_N102 GM09283 transformed cell line human CVCL_N102 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21168545 CVCL_MP03 BayGenomics ES cell line RRB060 embryonic stem cell house mouse CVCL_MP03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444148; Phf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168546 CVCL_N103 GM09284 transformed cell line human CVCL_N103 CL:0000010 Population: Puerto Rican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21168547 CVCL_MP00 BayGenomics ES cell line RRB055 embryonic stem cell house mouse CVCL_MP00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168548 CVCL_N100 GM09196 transformed cell line human CVCL_N100 HLA typing: A*03:01:01,03:01:01; B*07:02:01,40:01:02; C*03:04:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:01:01G; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01; DRB3*03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21168549 CVCL_MP01 BayGenomics ES cell line RRB057 embryonic stem cell house mouse CVCL_MP01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88251; Calm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168550 CVCL_N101 GM09232 finite cell line human CVCL_N101 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21168551 CVCL_MI00 BayGenomics ES cell line HMA410 embryonic stem cell house mouse CVCL_MI00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685179; Zfp407 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168552 CVCL_E068 CH12F3-2A cancer cell line house mouse CVCL_E068 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21168553 CVCL_E069 NMuMG/Fucci spontaneously immortalized cell line house mouse CVCL_E069 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; Q60I24; Galaxea fascicularis monomeric Azami-Green; Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2) Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci probe which consist of the fusion of monomeric Kusabira-Orange 2 (mKO2) to the ubiquitination domain of human CDT1 (aa 30-120) and monomeric Azami-Green (mAG) to the ubiquitination domain of human geminin (aa 1-110) 21168554 CVCL_E062 LCAM1 cancer cell line human CVCL_E062 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 6.9 hours (PubMed=9142195) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21168555 CVCL_E063 TEN cancer cell line human CVCL_E063 Genome ancestry: African=0.21%; Native American=0%; East Asian, North=76.96%; East Asian, South=22.41%; South Asian=0.11%; European, North=0%; European, South=0.3% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Thr74Pro (c.220A>C); ClinVar=VCV000929160; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 47.1 hours (at 31th passage); 59.3 hours (at 22th passage) (PubMed=9436040) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21168556 CVCL_E060 HIRS-BM cancer cell line human CVCL_E060 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female Doubling time: 38.4 hours (at 30th passage), 35.2 hours (at 40th passage), 33.5 hours (at 60th passage) (PubMed=6328089); 35 hours (PubMed=3019754) 21168557 CVCL_E061 HIRS-PB cancer cell line human CVCL_E061 CL:0000010 Population: Japanese; Derived from metastatic site: Peripheral blood. Female Doubling time: 46.1 hours (at 28th passage), 45.8 hours (at 34th passage), 40.2 hours (at 60th passage) (PubMed=6328089) 21168558 CVCL_E066 633 cancer cell line human CVCL_E066 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 21168559 CVCL_E067 CH12F3 cancer cell line house mouse CVCL_E067 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 21168560 CVCL_E064 PCC3/A/1 cancer cell line house mouse CVCL_E064 CL:0000010 Breed/subspecies: 129/Sv. Male 21168561 CVCL_E065 HKb20 transformed cell line human CVCL_E065 CL:0000010 Transfected with: UniProtKB; Q9NDN4; Bombyx mori BtR175b Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21168562 CVCL_MI10 BayGenomics ES cell line HMA449 embryonic stem cell house mouse CVCL_MI10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445003; Arhgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168563 CVCL_MI11 BayGenomics ES cell line HMA450 embryonic stem cell house mouse CVCL_MI11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098802; Cdk12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168564 CVCL_E079 W-V transformed cell line human CVCL_E079 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Lys924fs*973 (c.2773delG); Zygosity=Unspecified (PubMed=9230208) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21168565 CVCL_E073 MDBK-NST spontaneously immortalized cell line CVCL_E073 CL:0000010 Derived from sampling site: Kidney. Male Group: Serum/protein free medium cell line 21168566 CVCL_E074 L8057 cancer cell line house mouse CVCL_E074 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H/He. Male Characteristics: Can be induced to differentiate along the megakaryocite/platelet lineage Doubling time: 24-27 hours (PubMed=7678813) 21168567 CVCL_E071 COS/Fucci transformed cell line CVCL_E071 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; Q60I24; Galaxea fascicularis monomeric Azami-Green; Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2) Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci probe which consist of the fusion of monomeric Kusabira-Orange 2 (mKO2) to the ubiquitination domain of human CDT1 (AA 30-120) and monomeric Azami-Green (mAG) to the ubiquitination domain of human geminin (AA 1-110) Group: Non-human primate cell line 21168568 CVCL_E072 293GP transformed cell line human CVCL_E072 CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21168569 CVCL_E077 JHTSK-col-L cancer cell line human CVCL_E077 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Male 21168570 CVCL_E078 G-201 embryonic stem cell house mouse CVCL_E078 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Breed/subspecies: 129S2/SvPas. Male 21168571 CVCL_MI09 BayGenomics ES cell line HMA445 embryonic stem cell house mouse CVCL_MI09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929869; Hic2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168572 CVCL_E075 JHCA-ov cancer cell line human CVCL_E075 CL:0000010 Population: Japanese; Derived from metastatic site: Ovary. Female 21168573 CVCL_E076 JHCOLOYI cancer cell line human CVCL_E076 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Male 21168574 CVCL_MI07 BayGenomics ES cell line HMA427 embryonic stem cell house mouse CVCL_MI07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168575 CVCL_MI08 BayGenomics ES cell line HMA430 embryonic stem cell house mouse CVCL_MI08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352755; Gtse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168576 CVCL_MI05 BayGenomics ES cell line HMA416 embryonic stem cell house mouse CVCL_MI05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443502; Cep95 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168577 CVCL_MI06 BayGenomics ES cell line HMA421 embryonic stem cell house mouse CVCL_MI06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168578 CVCL_MI03 BayGenomics ES cell line HMA413 embryonic stem cell house mouse CVCL_MI03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168579 CVCL_MI04 BayGenomics ES cell line HMA414 embryonic stem cell house mouse CVCL_MI04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385286; Pgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168580 CVCL_E070 HeLa/Fucci cancer cell line human CVCL_E070 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; Q60I24; Galaxea fascicularis monomeric Azami-Green; Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci probe which consist of the fusion of monomeric Kusabira-Orange 2 (mKO2) to the ubiquitination domain of human CDT1 (aa 30-120) and monomeric Azami-Green (mAG) to the ubiquitination domain of human geminin (aa 1-110) 21168581 CVCL_MI01 BayGenomics ES cell line HMA411 embryonic stem cell house mouse CVCL_MI01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168582 CVCL_MI02 BayGenomics ES cell line HMA412 embryonic stem cell house mouse CVCL_MI02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913628; Micos10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168583 CVCL_E048 RS11846 cancer cell line human CVCL_E048 CL:0000010 21168584 CVCL_E049 Huh-7.5.1 cancer cell line human CVCL_E049 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male Virology: Compared to the parent Huh-7 cell line, permits improved HCV production when infected with strain JFH-1 21168585 CVCL_E046 MZ1973RC cancer cell line human CVCL_E046 CL:0000010 Derived from sampling site: Kidney. Unspecified 21168586 CVCL_E047 MZ2865RC cancer cell line human CVCL_E047 CL:0000010 Derived from sampling site: Kidney. Unspecified 21168587 CVCL_E040 SRD-1 transformed cell line CVCL_E040 CL:0000010 Sequence variation: Gene fusion; UniProtKB; Q60429; Srebp2 + UniProtKB; G3IJJ1; Xrcc6; Name(s)=Srebp2-Xrcc6, Srebp-2/Ku p70; Note=Out of frame (PubMed=7744865) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Ovary. Female 21168588 CVCL_E041 SRD-2 transformed cell line CVCL_E041 CL:0000010 Sequence variation: Gene fusion; UniProtKB; Q60429; Srebp2 + UniProtKB; G3HX69; Lima1; Name(s)=Srebp2-Lima1; Note=In frame (PubMed=7744865) Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Ovary. Female 21168589 CVCL_E044 MZ1257RC cancer cell line human CVCL_E044 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Unspecified 21168590 CVCL_E045 MZ1851RC cancer cell line human CVCL_E045 CL:0000010 Derived from sampling site: Kidney. Unspecified 21168591 CVCL_E042 Muraoka cancer cell line human CVCL_E042 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 4 fusion (Ex10/Ex5) (PubMed=9738976) Anecdotal: Cell line name corresponds to the name of the patient Population: Japanese; Derived from sampling site: Right temporofacial region; hypodermis. Male Doubling time: 25 hours (PubMed=1357816) 21168592 CVCL_E043 RCCD1 transformed cell line Norway rat CVCL_E043 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: Sprague Dawley. Male 21168593 CVCL_E059 505-05-01 cancer cell line house mouse CVCL_E059 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C57BL/Ka x C3H/He. Female 21168594 CVCL_E057 RCC7 cancer cell line human CVCL_E057 HLA typing: A*02,29; B*44,51; C*w15,w16 (PubMed=12351398). CL:0000010 21168595 CVCL_E058 MC-NB-1 cancer cell line human CVCL_E058 CL:0000010 Population: Caucasian; Derived from metastatic site: Bone marrow. Male Doubling time: ~35 hours (PubMed=6616438) 21168596 CVCL_E051 SK-DHL2A cancer cell line human CVCL_E051 CL:0000010 Derived from sampling site: Peritoneal effusion. Male Doubling time: 17.9 +- 2.6 hours (PubMed=6608987) 21168597 CVCL_E052 SK-DHL2B cancer cell line human CVCL_E052 CL:0000010 Derived from sampling site: Peritoneal effusion. Male Doubling time: 17.1 +- 2.1 hours (PubMed=6608987) 21168598 CVCL_E050 HCC4977 cancer cell line human CVCL_E050 CL:0000010 Miscellaneous: Only mentioned as a hepatocellular carcinoma cell line in PubMed=22460906. 21168599 CVCL_E055 RCC5 cancer cell line human CVCL_E055 HLA typing: A*09,32; B*07,49; C*w07 (PubMed=12351398). CL:0000010 21168600 CVCL_E056 RCC6 cancer cell line human CVCL_E056 HLA typing: A*01,02; B*08,51; C*w07,w14 (PubMed=12351398) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser111Gly (c.331A>G); ClinVar=VCV000633016; Zygosity=Hemizygous (PubMed=21258414). 21168601 CVCL_E053 SKI-DLCL-1 cancer cell line human CVCL_E053 CL:0000010 Population: Caucasian; Derived from sampling site: Ascites. Omics: Deep exome analysis Male 21168602 CVCL_E054 LST-R1 cancer cell line human CVCL_E054 CL:0000010 Population: Chinese; Derived from sampling site: Rectum. Female Doubling time: 36 hours (PubMed=18300345) 21168603 CVCL_E026 PAE-iPS-5 induced pluripotent stem cell human CVCL_E026 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Omics: DNA methylation analysis Male 21168604 CVCL_E027 PAE-iPS-6 induced pluripotent stem cell human CVCL_E027 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168605 CVCL_E024 PAE-iPS-3 induced pluripotent stem cell human CVCL_E024 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168606 CVCL_E025 PAE-iPS-4 induced pluripotent stem cell human CVCL_E025 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Omics: DNA methylation analysis Male 21168607 CVCL_E028 PAE-iPS-7 induced pluripotent stem cell human CVCL_E028 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168608 CVCL_E029 PAE-iPS-8 induced pluripotent stem cell human CVCL_E029 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168609 CVCL_E022 PAE-iPS-12 induced pluripotent stem cell human CVCL_E022 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168610 CVCL_E023 PAE-iPS-2 induced pluripotent stem cell human CVCL_E023 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168611 CVCL_E020 PAE-iPS-10 induced pluripotent stem cell human CVCL_E020 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168612 CVCL_E021 PAE-iPS-11 induced pluripotent stem cell human CVCL_E021 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168613 CVCL_E037 UtE-iPS-5 induced pluripotent stem cell human CVCL_E037 CL:0000010 Derived from sampling site: Endometrium. Female 21168614 CVCL_E038 UtE-iPS-6 induced pluripotent stem cell human CVCL_E038 CL:0000010 Derived from sampling site: Endometrium. Omics: DNA methylation analysis Female 21168615 CVCL_E035 UtE-iPS-3 induced pluripotent stem cell human CVCL_E035 CL:0000010 Derived from sampling site: Endometrium. Female 21168616 CVCL_E036 UtE-iPS-4 induced pluripotent stem cell human CVCL_E036 CL:0000010 Derived from sampling site: Endometrium. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168617 CVCL_E039 UtE-iPS-7 induced pluripotent stem cell human CVCL_E039 CL:0000010 Derived from sampling site: Endometrium. Omics: DNA methylation analysis; Omics: Glycosphingolipids analysis Female 21168618 CVCL_E030 PAE-iPS-9 induced pluripotent stem cell human CVCL_E030 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Male 21168619 CVCL_E033 UtE-iPS-11 induced pluripotent stem cell human CVCL_E033 CL:0000010 Derived from sampling site: Endometrium. Omics: DNA methylation analysis; Omics: Glycosphingolipids analysis; Omics: Transcriptome analysis by microarray Female 21168620 CVCL_E034 UtE-iPS-2 induced pluripotent stem cell human CVCL_E034 CL:0000010 Derived from sampling site: Endometrium. Female 21168621 CVCL_E031 UtE-iPS-1 induced pluripotent stem cell human CVCL_E031 CL:0000010 Derived from sampling site: Endometrium. Female 21168622 CVCL_E032 UtE-iPS-10 induced pluripotent stem cell human CVCL_E032 CL:0000010 Derived from sampling site: Endometrium. Female 21168623 CVCL_E004 MRC-iPS-86 induced pluripotent stem cell human CVCL_E004 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168624 CVCL_E005 MRC-iPS-87 induced pluripotent stem cell human CVCL_E005 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168625 CVCL_E002 MRC-iPS-84 induced pluripotent stem cell human CVCL_E002 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168626 CVCL_E003 MRC-iPS-85 induced pluripotent stem cell human CVCL_E003 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000157; probable Male 21168627 CVCL_E008 MRC-iPS-9 induced pluripotent stem cell human CVCL_E008 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168628 CVCL_E009 MRC-iPS-90 induced pluripotent stem cell human CVCL_E009 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168629 CVCL_E006 MRC-iPS-88 induced pluripotent stem cell human CVCL_E006 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000158; probable Male 21168630 CVCL_E007 MRC-iPS-89 induced pluripotent stem cell human CVCL_E007 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: SKIP; SKIP000159; probable Male 21168631 CVCL_E000 MRC-iPS-82 induced pluripotent stem cell human CVCL_E000 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168632 CVCL_E001 MRC-iPS-83 induced pluripotent stem cell human CVCL_E001 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168633 CVCL_E015 MRC-iPS-96 induced pluripotent stem cell human CVCL_E015 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168634 CVCL_E016 MRC-iPS-97 induced pluripotent stem cell human CVCL_E016 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168635 CVCL_E013 MRC-iPS-94 induced pluripotent stem cell human CVCL_E013 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168636 CVCL_E014 MRC-iPS-95 induced pluripotent stem cell human CVCL_E014 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168637 CVCL_E019 PAE-iPS-1 induced pluripotent stem cell human CVCL_E019 CL:0000010 Derived from sampling site: Placenta; arterial endothelium. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168638 CVCL_E017 MRC-iPS-98 induced pluripotent stem cell human CVCL_E017 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168639 CVCL_E018 MRC-iPS-99 induced pluripotent stem cell human CVCL_E018 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168640 CVCL_E011 MRC-iPS-92 induced pluripotent stem cell human CVCL_E011 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168641 CVCL_E012 MRC-iPS-93 induced pluripotent stem cell human CVCL_E012 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21168642 CVCL_E010 MRC-iPS-91 induced pluripotent stem cell human CVCL_E010 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: DNA methylation analysis Discontinued: JCRB; NIHS0608; true; Discontinued: SKIP; SKIP000016; probable Male 21168643 CVCL_MI87 BayGenomics ES cell line KST254 embryonic stem cell house mouse CVCL_MI87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928380; B4galt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168644 CVCL_MI88 BayGenomics ES cell line KST256 embryonic stem cell house mouse CVCL_MI88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351618; Dnajb9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168645 CVCL_MI85 BayGenomics ES cell line KST252 embryonic stem cell house mouse CVCL_MI85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444465; Frem2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168646 CVCL_MI86 BayGenomics ES cell line KST253 embryonic stem cell house mouse CVCL_MI86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168647 CVCL_MI83 BayGenomics ES cell line KST246 embryonic stem cell house mouse CVCL_MI83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168648 CVCL_MI84 BayGenomics ES cell line KST249 embryonic stem cell house mouse CVCL_MI84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168649 CVCL_MI81 BayGenomics ES cell line KST243 embryonic stem cell house mouse CVCL_MI81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168650 CVCL_MI82 BayGenomics ES cell line KST245 embryonic stem cell house mouse CVCL_MI82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915720; Bpnt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168651 CVCL_MI80 BayGenomics ES cell line KST242 embryonic stem cell house mouse CVCL_MI80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98277; Epha4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168652 CVCL_VC20 SP3650 transformed cell line human CVCL_VC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168653 CVCL_VC21 SP3659 transformed cell line human CVCL_VC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168654 CVCL_VC24 SP3702 transformed cell line human CVCL_VC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168655 CVCL_VC25 SP3769 transformed cell line human CVCL_VC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168656 CVCL_VC22 SP3668 transformed cell line human CVCL_VC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168657 CVCL_VC23 SP3670 transformed cell line human CVCL_VC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168658 CVCL_VC28 SP3796 transformed cell line human CVCL_VC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168659 CVCL_VC29 SPr0026 transformed cell line human CVCL_VC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168660 CVCL_VC26 SP3779 transformed cell line human CVCL_VC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168661 CVCL_VC27 SP3783 transformed cell line human CVCL_VC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168662 CVCL_MI78 BayGenomics ES cell line KST237 embryonic stem cell house mouse CVCL_MI78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168663 CVCL_MI79 BayGenomics ES cell line KST240 embryonic stem cell house mouse CVCL_MI79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99682; Tmbim6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168664 CVCL_MI98 BayGenomics ES cell line KST271 embryonic stem cell house mouse CVCL_MI98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858907; Blcap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168665 CVCL_MI99 BayGenomics ES cell line KST272 embryonic stem cell house mouse CVCL_MI99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338031; Spint2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168666 CVCL_MI96 BayGenomics ES cell line KST269 embryonic stem cell house mouse CVCL_MI96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107685; Plxna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168667 CVCL_MI97 BayGenomics ES cell line KST270 embryonic stem cell house mouse CVCL_MI97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104652; Capzb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168668 CVCL_MI94 BayGenomics ES cell line KST265 embryonic stem cell house mouse CVCL_MI94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097159; Neo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168669 CVCL_MI95 BayGenomics ES cell line KST266 embryonic stem cell house mouse CVCL_MI95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924015; Mlec Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168670 CVCL_MI92 BayGenomics ES cell line KST263 embryonic stem cell house mouse CVCL_MI92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913355; Ube2d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168671 CVCL_MI93 BayGenomics ES cell line KST264 embryonic stem cell house mouse CVCL_MI93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354756; Crim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168672 CVCL_MI90 BayGenomics ES cell line KST258 embryonic stem cell house mouse CVCL_MI90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109553; Ctsc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168673 CVCL_MI91 BayGenomics ES cell line KST259 embryonic stem cell house mouse CVCL_MI91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168674 CVCL_VC10 SP3474 transformed cell line human CVCL_VC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168675 CVCL_VC13 SP3528 transformed cell line human CVCL_VC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168676 CVCL_VC14 SP3534 transformed cell line human CVCL_VC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168677 CVCL_VC11 SP3508 transformed cell line human CVCL_VC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168678 CVCL_VC12 SP3526 transformed cell line human CVCL_VC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168679 CVCL_VC17 SP3590 transformed cell line human CVCL_VC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168680 CVCL_VC18 SP3610 transformed cell line human CVCL_VC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168681 CVCL_VC15 SP3547 transformed cell line human CVCL_VC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168682 CVCL_VC16 SP3560 transformed cell line human CVCL_VC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168683 CVCL_VC19 SP3643 transformed cell line human CVCL_VC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168684 CVCL_MI89 BayGenomics ES cell line KST257 embryonic stem cell house mouse CVCL_MI89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102467; Ptpn14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168685 CVCL_MI65 BayGenomics ES cell line KST219 embryonic stem cell house mouse CVCL_MI65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146443; Xxylt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168686 CVCL_MI66 BayGenomics ES cell line KST222 embryonic stem cell house mouse CVCL_MI66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168687 CVCL_MI63 BayGenomics ES cell line KST214 embryonic stem cell house mouse CVCL_MI63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168688 CVCL_MI64 BayGenomics ES cell line KST216 embryonic stem cell house mouse CVCL_MI64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385850; Nomo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168689 CVCL_MI61 BayGenomics ES cell line KST212 embryonic stem cell house mouse CVCL_MI61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168690 CVCL_MI62 BayGenomics ES cell line KST213 embryonic stem cell house mouse CVCL_MI62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105088; Ntn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168691 CVCL_MI60 BayGenomics ES cell line KST211 embryonic stem cell house mouse CVCL_MI60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96392; Icam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168692 CVCL_VC02 SP3202 transformed cell line human CVCL_VC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168693 CVCL_VC03 SP3216 transformed cell line human CVCL_VC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168694 CVCL_VC00 SP3148 transformed cell line human CVCL_VC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168695 CVCL_VC01 SP3154 transformed cell line human CVCL_VC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168696 CVCL_VC06 SP3303 transformed cell line human CVCL_VC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168697 CVCL_VC07 SP3325 transformed cell line human CVCL_VC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168698 CVCL_VC04 SP3218 transformed cell line human CVCL_VC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168699 CVCL_VC05 SP3277 transformed cell line human CVCL_VC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168700 CVCL_VC08 SP3331 transformed cell line human CVCL_VC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168701 CVCL_VC09 SP3462 transformed cell line human CVCL_VC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168702 CVCL_MI58 BayGenomics ES cell line KST182 embryonic stem cell house mouse CVCL_MI58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168703 CVCL_MI59 BayGenomics ES cell line KST184 embryonic stem cell house mouse CVCL_MI59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103007; Epb41l4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168704 CVCL_MI56 BayGenomics ES cell line KST145 embryonic stem cell house mouse CVCL_MI56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168705 CVCL_MI57 BayGenomics ES cell line KST171 embryonic stem cell house mouse CVCL_MI57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168706 CVCL_MI76 BayGenomics ES cell line KST235 embryonic stem cell house mouse CVCL_MI76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321398; F11r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168707 CVCL_MI77 BayGenomics ES cell line KST236 embryonic stem cell house mouse CVCL_MI77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168708 CVCL_MI74 BayGenomics ES cell line KST232 embryonic stem cell house mouse CVCL_MI74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168709 CVCL_MI75 BayGenomics ES cell line KST233 embryonic stem cell house mouse CVCL_MI75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88613; Ccn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168710 CVCL_MI72 BayGenomics ES cell line KST229 embryonic stem cell house mouse CVCL_MI72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860139; Gabbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168711 CVCL_MI73 BayGenomics ES cell line KST231 embryonic stem cell house mouse CVCL_MI73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168712 CVCL_MI70 BayGenomics ES cell line KST227 embryonic stem cell house mouse CVCL_MI70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102768; Mfge8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168713 CVCL_MI71 BayGenomics ES cell line KST228 embryonic stem cell house mouse CVCL_MI71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168714 CVCL_MI69 BayGenomics ES cell line KST226 embryonic stem cell house mouse CVCL_MI69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444177; Cachd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168715 CVCL_MI67 BayGenomics ES cell line KST223 embryonic stem cell house mouse CVCL_MI67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159727; Il17rd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168716 CVCL_MI68 BayGenomics ES cell line KST224 embryonic stem cell house mouse CVCL_MI68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95794; Lrp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168717 CVCL_MI43 BayGenomics ES cell line KST045 embryonic stem cell house mouse CVCL_MI43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99256; Hdlbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168718 CVCL_MI44 BayGenomics ES cell line KST046 embryonic stem cell house mouse CVCL_MI44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926609; Trp53inp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168719 CVCL_MI41 BayGenomics ES cell line KST041 embryonic stem cell house mouse CVCL_MI41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99154; Zfp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168720 CVCL_MI42 BayGenomics ES cell line KST044 embryonic stem cell house mouse CVCL_MI42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168721 CVCL_MI40 BayGenomics ES cell line KST037 embryonic stem cell house mouse CVCL_MI40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914698; Plxdc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168722 CVCL_MI38 BayGenomics ES cell line KST027 embryonic stem cell house mouse CVCL_MI38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168723 CVCL_MI39 BayGenomics ES cell line KST030 embryonic stem cell house mouse CVCL_MI39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913522; Cox16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168724 CVCL_MI36 BayGenomics ES cell line KST012 embryonic stem cell house mouse CVCL_MI36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95392; Eng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168725 CVCL_MI37 BayGenomics ES cell line KST024 embryonic stem cell house mouse CVCL_MI37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168726 CVCL_MI34 BayGenomics ES cell line KST005 embryonic stem cell house mouse CVCL_MI34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168727 CVCL_MI35 BayGenomics ES cell line KST011 embryonic stem cell house mouse CVCL_MI35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914708; Ergic1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168728 CVCL_MI54 BayGenomics ES cell line KST109 embryonic stem cell house mouse CVCL_MI54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168729 CVCL_MI55 BayGenomics ES cell line KST113 embryonic stem cell house mouse CVCL_MI55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168730 CVCL_MI52 BayGenomics ES cell line KST067 embryonic stem cell house mouse CVCL_MI52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347007; Plod2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168731 CVCL_MI53 BayGenomics ES cell line KST085 embryonic stem cell house mouse CVCL_MI53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168732 CVCL_MI50 BayGenomics ES cell line KST064 embryonic stem cell house mouse CVCL_MI50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926609; Trp53inp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168733 CVCL_MI51 BayGenomics ES cell line KST065 embryonic stem cell house mouse CVCL_MI51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168734 CVCL_MI49 BayGenomics ES cell line KST063 embryonic stem cell house mouse CVCL_MI49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918917; Tmem248 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168735 CVCL_MI47 BayGenomics ES cell line KST059 embryonic stem cell house mouse CVCL_MI47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104669; Man2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168736 CVCL_MI48 BayGenomics ES cell line KST061 embryonic stem cell house mouse CVCL_MI48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168737 CVCL_MI45 BayGenomics ES cell line KST048 embryonic stem cell house mouse CVCL_MI45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168738 CVCL_MI46 BayGenomics ES cell line KST050 embryonic stem cell house mouse CVCL_MI46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138346; Suco Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168739 CVCL_MI21 BayGenomics ES cell line HMA497 embryonic stem cell house mouse CVCL_MI21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927170; Spata5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168740 CVCL_MI22 BayGenomics ES cell line HMA500 embryonic stem cell house mouse CVCL_MI22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342772; Klf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168741 CVCL_MI20 BayGenomics ES cell line HMA495 embryonic stem cell house mouse CVCL_MI20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97814; Ptprg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168742 CVCL_E084 HUES PGD 2 embryonic stem cell human CVCL_E084 From: Harvard University; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0195. 21168743 CVCL_E085 KCL042 embryonic stem cell human CVCL_E085 From: King's College London; London; United Kingdom CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0242; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-38.. 21168744 CVCL_E082 WA27 embryonic stem cell human CVCL_E082 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0198 21168745 CVCL_E083 CR4 [Human ESC] embryonic stem cell human CVCL_E083 From: University of Texas Health Science Center at Houston; Houston; USA CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0210. 21168746 CVCL_E088 UM57-1 PGD embryonic stem cell human CVCL_E088 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM57-3 PGD (Cellosaurus=CVCL_HF77). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0208 21168747 CVCL_E089 SK-MEL-321B cancer cell line human CVCL_E089 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21168748 CVCL_E086 KCL043 embryonic stem cell human CVCL_E086 From: King's College London; London; United Kingdom CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0243; Registration: UK Stem Cell Bank (UKSCB); Steering comm appl. SCSC12-38.. 21168749 CVCL_E087 UM22-2 embryonic stem cell human CVCL_E087 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-13-0209 21168750 CVCL_MI18 BayGenomics ES cell line HMA485 embryonic stem cell house mouse CVCL_MI18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919064; Mrps27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168751 CVCL_MI19 BayGenomics ES cell line HMA488 embryonic stem cell house mouse CVCL_MI19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914093; Dolpp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168752 CVCL_MI16 BayGenomics ES cell line HMA475 embryonic stem cell house mouse CVCL_MI16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917722; Atad2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168753 CVCL_MI17 BayGenomics ES cell line HMA483 embryonic stem cell house mouse CVCL_MI17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168754 CVCL_MI14 BayGenomics ES cell line HMA470 embryonic stem cell house mouse CVCL_MI14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168755 CVCL_E080 WA25 embryonic stem cell human CVCL_E080 From: University of Wisconsin; Madison; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0196 21168756 CVCL_MI15 BayGenomics ES cell line HMA471 embryonic stem cell house mouse CVCL_MI15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107637; Psmb7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168757 CVCL_E081 WA26 embryonic stem cell human CVCL_E081 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: Deep exome analysis; Omics: SNP array analysis. Female Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-12-0197 21168758 CVCL_MI12 BayGenomics ES cell line HMA455 embryonic stem cell house mouse CVCL_MI12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928896; Arpc1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168759 CVCL_MI13 BayGenomics ES cell line HMA469 embryonic stem cell house mouse CVCL_MI13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168760 CVCL_MI32 BayGenomics ES cell line HMA568 embryonic stem cell house mouse CVCL_MI32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88261; Canx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168761 CVCL_MI33 BayGenomics ES cell line HMA580 embryonic stem cell house mouse CVCL_MI33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98510; Tcf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168762 CVCL_MI30 BayGenomics ES cell line HMA563 embryonic stem cell house mouse CVCL_MI30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913325; Chchd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168763 CVCL_MI31 BayGenomics ES cell line HMA566 embryonic stem cell house mouse CVCL_MI31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106498; Rsrp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168764 CVCL_E095 NCI-BL289 transformed cell line human CVCL_E095 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168765 CVCL_E096 NCI-BL1474 transformed cell line human CVCL_E096 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168766 CVCL_E093 JB/MS cancer cell line house mouse CVCL_E093 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. Female 21168767 CVCL_E094 JB/RH cancer cell line house mouse CVCL_E094 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. Female 21168768 CVCL_E099 NCI-BL1819 transformed cell line human CVCL_E099 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21168769 CVCL_E097 NCI-BL1648 transformed cell line human CVCL_E097 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-5954; true Male 21168770 CVCL_E098 NCI-BL1688 transformed cell line human CVCL_E098 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21168771 CVCL_MI29 BayGenomics ES cell line HMA561 embryonic stem cell house mouse CVCL_MI29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168772 CVCL_MI27 BayGenomics ES cell line HMA542 embryonic stem cell house mouse CVCL_MI27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168773 CVCL_MI28 BayGenomics ES cell line HMA558 embryonic stem cell house mouse CVCL_MI28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168774 CVCL_MI25 BayGenomics ES cell line HMA527 embryonic stem cell house mouse CVCL_MI25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103250; Calm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168775 CVCL_E091 SK-MEL-315-03 cancer cell line human CVCL_E091 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21168776 CVCL_MI26 BayGenomics ES cell line HMA538 embryonic stem cell house mouse CVCL_MI26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289341; Sf3b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168777 CVCL_E092 SK-MEL-315-05 cancer cell line human CVCL_E092 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21168778 CVCL_MI23 BayGenomics ES cell line HMA502 embryonic stem cell house mouse CVCL_MI23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353499; Baz1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168779 CVCL_MI24 BayGenomics ES cell line HMA513 embryonic stem cell house mouse CVCL_MI24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168780 CVCL_E090 SK-MEL-315-02 cancer cell line human CVCL_E090 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21168781 CVCL_VB80 SMa0211 transformed cell line human CVCL_VB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168782 CVCL_VB83 SNc0041 transformed cell line human CVCL_VB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168783 CVCL_VB84 SNc0063 transformed cell line human CVCL_VB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168784 CVCL_VB81 SMa0232 transformed cell line human CVCL_VB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168785 CVCL_VB82 SNc0031 transformed cell line human CVCL_VB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168786 CVCL_VB87 SNc0125 transformed cell line human CVCL_VB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168787 CVCL_VB88 SNc0189 transformed cell line human CVCL_VB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168788 CVCL_VB85 SNc0080 transformed cell line human CVCL_VB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168789 CVCL_VB86 SNc0106 transformed cell line human CVCL_VB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168790 CVCL_VB89 SNc0202 transformed cell line human CVCL_VB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168791 CVCL_VB72 SC3780 transformed cell line human CVCL_VB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168792 CVCL_VB73 SC3784 transformed cell line human CVCL_VB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168793 CVCL_VB70 SC3690 transformed cell line human CVCL_VB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168794 CVCL_VB71 SC3709 transformed cell line human CVCL_VB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168795 CVCL_VB76 SMa0020 transformed cell line human CVCL_VB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168796 CVCL_VB77 SMa0031 transformed cell line human CVCL_VB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168797 CVCL_VB74 SMa0006 transformed cell line human CVCL_VB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168798 CVCL_VB75 SMa0008 transformed cell line human CVCL_VB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168799 CVCL_VB78 SMa0078 transformed cell line human CVCL_VB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168800 CVCL_VB79 SMa0166 transformed cell line human CVCL_VB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168801 CVCL_VB61 SC3345 transformed cell line human CVCL_VB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168802 CVCL_VB62 SC3406 transformed cell line human CVCL_VB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168803 CVCL_VB60 SC3336 transformed cell line human CVCL_VB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168804 CVCL_VB65 SC3509 transformed cell line human CVCL_VB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168805 CVCL_VB66 SC3521 transformed cell line human CVCL_VB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168806 CVCL_VB63 SC3490 transformed cell line human CVCL_VB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168807 CVCL_VB64 SC3504 transformed cell line human CVCL_VB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168808 CVCL_VB69 SC3611 transformed cell line human CVCL_VB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168809 CVCL_VB67 SC3535 transformed cell line human CVCL_VB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168810 CVCL_VB68 SC3602 transformed cell line human CVCL_VB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168811 CVCL_VB50 LP0682 transformed cell line human CVCL_VB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168812 CVCL_VB51 LPo0036 transformed cell line human CVCL_VB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168813 CVCL_VB54 LSh0038 transformed cell line human CVCL_VB54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168814 CVCL_VB55 SC3192 transformed cell line human CVCL_VB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168815 CVCL_VB52 LPy0018 transformed cell line human CVCL_VB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168816 CVCL_VB53 LRo0022 transformed cell line human CVCL_VB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168817 CVCL_VB58 SC3223 transformed cell line human CVCL_VB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168818 CVCL_VB59 SC3236 transformed cell line human CVCL_VB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168819 CVCL_VB56 SC3217 transformed cell line human CVCL_VB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168820 CVCL_VB57 SC3220 transformed cell line human CVCL_VB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168821 CVCL_VB40 LP0480 transformed cell line human CVCL_VB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168822 CVCL_VB43 LP0584 transformed cell line human CVCL_VB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168823 CVCL_VB44 LP0614 transformed cell line human CVCL_VB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168824 CVCL_VB41 LP0568 transformed cell line human CVCL_VB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168825 CVCL_VB42 LP0582 transformed cell line human CVCL_VB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168826 CVCL_VB47 LP0657 transformed cell line human CVCL_VB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168827 CVCL_VB48 LP0663 transformed cell line human CVCL_VB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168828 CVCL_VB45 LP0618 transformed cell line human CVCL_VB45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168829 CVCL_VB46 LP0637 transformed cell line human CVCL_VB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168830 CVCL_VB49 LP0665 transformed cell line human CVCL_VB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168831 CVCL_VB32 LP0303 transformed cell line human CVCL_VB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168832 CVCL_VB33 LP0305 transformed cell line human CVCL_VB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168833 CVCL_VB30 LP0168 transformed cell line human CVCL_VB30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168834 CVCL_VB31 LP0225 transformed cell line human CVCL_VB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168835 CVCL_VB36 LP0405 transformed cell line human CVCL_VB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168836 CVCL_VB37 LP0437 transformed cell line human CVCL_VB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168837 CVCL_VB34 LP0328 transformed cell line human CVCL_VB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168838 CVCL_VB35 LP0393 transformed cell line human CVCL_VB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168839 CVCL_VB38 LP0456 transformed cell line human CVCL_VB38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168840 CVCL_VB39 LP0475 transformed cell line human CVCL_VB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168841 CVCL_MH88 BayGenomics ES cell line HMA370 embryonic stem cell house mouse CVCL_MH88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443564; Ambra1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168842 CVCL_MH89 BayGenomics ES cell line HMA374 embryonic stem cell house mouse CVCL_MH89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919861; Zfp655 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168843 CVCL_MH86 BayGenomics ES cell line HMA368 embryonic stem cell house mouse CVCL_MH86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105968; Txlna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168844 CVCL_MH87 BayGenomics ES cell line HMA369 embryonic stem cell house mouse CVCL_MH87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168845 CVCL_MH84 BayGenomics ES cell line HMA365 embryonic stem cell house mouse CVCL_MH84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168846 CVCL_MH85 BayGenomics ES cell line HMA367 embryonic stem cell house mouse CVCL_MH85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168847 CVCL_MH82 BayGenomics ES cell line HMA362 embryonic stem cell house mouse CVCL_MH82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919806; Zfp566 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168848 CVCL_MH83 BayGenomics ES cell line HMA364 embryonic stem cell house mouse CVCL_MH83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168849 CVCL_MH80 BayGenomics ES cell line HMA353 embryonic stem cell house mouse CVCL_MH80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1335094; Septin7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168850 CVCL_MH81 BayGenomics ES cell line HMA355 embryonic stem cell house mouse CVCL_MH81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925920; Plekhj1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168851 CVCL_VB21 LP0048 transformed cell line human CVCL_VB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168852 CVCL_VB22 LP0051 transformed cell line human CVCL_VB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168853 CVCL_VB20 LP0013 transformed cell line human CVCL_VB20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168854 CVCL_VB25 LP0091 transformed cell line human CVCL_VB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168855 CVCL_VB26 LP0125 transformed cell line human CVCL_VB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168856 CVCL_VB23 LP0073 transformed cell line human CVCL_VB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168857 CVCL_VB24 LP0075 transformed cell line human CVCL_VB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168858 CVCL_VB29 LP0157 transformed cell line human CVCL_VB29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168859 CVCL_VB27 LP0137 transformed cell line human CVCL_VB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168860 CVCL_VB28 LP0148 transformed cell line human CVCL_VB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168861 CVCL_MH79 BayGenomics ES cell line HMA351 embryonic stem cell house mouse CVCL_MH79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104626; Strbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168862 CVCL_MH99 BayGenomics ES cell line HMA405 embryonic stem cell house mouse CVCL_MH99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168863 CVCL_MH97 BayGenomics ES cell line HMA399 embryonic stem cell house mouse CVCL_MH97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914963; Dnajc19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168864 CVCL_MH98 BayGenomics ES cell line HMA401 embryonic stem cell house mouse CVCL_MH98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168865 CVCL_MH95 BayGenomics ES cell line HMA394 embryonic stem cell house mouse CVCL_MH95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168866 CVCL_MH96 BayGenomics ES cell line HMA398 embryonic stem cell house mouse CVCL_MH96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917244; Ddi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168867 CVCL_MH93 BayGenomics ES cell line HMA390 embryonic stem cell house mouse CVCL_MH93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168868 CVCL_MH94 BayGenomics ES cell line HMA391 embryonic stem cell house mouse CVCL_MH94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168869 CVCL_MH91 BayGenomics ES cell line HMA379 embryonic stem cell house mouse CVCL_MH91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168870 CVCL_MH92 BayGenomics ES cell line HMA386 embryonic stem cell house mouse CVCL_MH92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913628; Micos10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168871 CVCL_MH90 BayGenomics ES cell line HMA377 embryonic stem cell house mouse CVCL_MH90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927167; Morf4l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168872 CVCL_VB10 LCa0020 transformed cell line human CVCL_VB10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168873 CVCL_VB11 LCa0026 transformed cell line human CVCL_VB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168874 CVCL_VB14 LNh0030 transformed cell line human CVCL_VB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168875 CVCL_VB15 LNh0050 transformed cell line human CVCL_VB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168876 CVCL_VB12 LCa0042 transformed cell line human CVCL_VB12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168877 CVCL_VB13 LCa0111 transformed cell line human CVCL_VB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168878 CVCL_VB18 LNh0108 transformed cell line human CVCL_VB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168879 CVCL_VB19 LP0008 transformed cell line human CVCL_VB19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168880 CVCL_VB16 LNh0072 transformed cell line human CVCL_VB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168881 CVCL_VB17 LNh0101 transformed cell line human CVCL_VB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168882 CVCL_VB90 SNc0204 transformed cell line human CVCL_VB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168883 CVCL_VB91 SNc0214 transformed cell line human CVCL_VB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168884 CVCL_VB94 SP3063 transformed cell line human CVCL_VB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168885 CVCL_VB95 SP3068 transformed cell line human CVCL_VB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168886 CVCL_VB92 SP3006 transformed cell line human CVCL_VB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168887 CVCL_VB93 SP3033 transformed cell line human CVCL_VB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168888 CVCL_VB98 SP3118 transformed cell line human CVCL_VB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168889 CVCL_VB99 SP3127 transformed cell line human CVCL_VB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168890 CVCL_VB96 SP3070 transformed cell line human CVCL_VB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21168891 CVCL_VB97 SP3089 transformed cell line human CVCL_VB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21168892 CVCL_MJ20 BayGenomics ES cell line KST315 embryonic stem cell house mouse CVCL_MJ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926810; Tmeff1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168893 CVCL_MJ21 BayGenomics ES cell line KST319 embryonic stem cell house mouse CVCL_MJ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277214; Septin11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168894 CVCL_E189 PHA00358IN transformed cell line CVCL_E189 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168895 CVCL_DP89 TkCBV4-2 induced pluripotent stem cell human CVCL_DP89 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168896 CVCL_DP83 iPS-DP31 3f-2 induced pluripotent stem cell human CVCL_DP83 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168897 CVCL_E183 MSY00353IN transformed cell line CVCL_E183 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168898 CVCL_DP84 iPS-DP31 3f-3 induced pluripotent stem cell human CVCL_DP84 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168899 CVCL_E184 MSY00354IN transformed cell line CVCL_E184 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168900 CVCL_DP81 iPS-DP75 4f-3 induced pluripotent stem cell human CVCL_DP81 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168901 CVCL_E181 MSY00351IN transformed cell line CVCL_E181 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168902 CVCL_DP82 iPS-DP31 3f-1 induced pluripotent stem cell human CVCL_DP82 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168903 CVCL_E182 MSY00352IN transformed cell line CVCL_E182 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168904 CVCL_DP87 iPS-DP31 4f-6 induced pluripotent stem cell human CVCL_DP87 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168905 CVCL_E187 PHA00356IN transformed cell line CVCL_E187 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168906 CVCL_E188 PHA00357IN transformed cell line CVCL_E188 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168907 CVCL_DP88 TkCB7-2 induced pluripotent stem cell human CVCL_DP88 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168908 CVCL_MJ19 BayGenomics ES cell line KST314 embryonic stem cell house mouse CVCL_MJ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351664; Ptdss2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168909 CVCL_DP85 iPS-DP31 4f-3 induced pluripotent stem cell human CVCL_DP85 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168910 CVCL_E185 PPA00322IN transformed cell line bonobo/pygmy chimpanzee CVCL_E185 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168911 CVCL_DP86 iPS-DP31 4f-5 induced pluripotent stem cell human CVCL_DP86 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168912 CVCL_E186 PPA00378IN transformed cell line bonobo/pygmy chimpanzee CVCL_E186 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168913 CVCL_MJ17 BayGenomics ES cell line KST310 embryonic stem cell house mouse CVCL_MJ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927167; Morf4l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168914 CVCL_MJ18 BayGenomics ES cell line KST311 embryonic stem cell house mouse CVCL_MJ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102551; Ccnf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168915 CVCL_MJ15 BayGenomics ES cell line KST307 embryonic stem cell house mouse CVCL_MJ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919849; Pdia5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168916 CVCL_MJ16 BayGenomics ES cell line KST308 embryonic stem cell house mouse CVCL_MJ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889505; B3gnt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168917 CVCL_MJ13 BayGenomics ES cell line KST303 embryonic stem cell house mouse CVCL_MJ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919213; Cdca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168918 CVCL_MJ14 BayGenomics ES cell line KST304 embryonic stem cell house mouse CVCL_MJ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168919 CVCL_DP80 iPS-DP75 4f-2 induced pluripotent stem cell human CVCL_DP80 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168920 CVCL_E180 MSY00350IN transformed cell line CVCL_E180 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168921 CVCL_MJ11 BayGenomics ES cell line KST301 embryonic stem cell house mouse CVCL_MJ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96743; Lamb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168922 CVCL_MJ12 BayGenomics ES cell line KST302 embryonic stem cell house mouse CVCL_MJ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919711; Prcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168923 CVCL_MJ31 BayGenomics ES cell line LRY020 embryonic stem cell house mouse CVCL_MJ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168924 CVCL_MJ32 BayGenomics ES cell line LRY025 embryonic stem cell house mouse CVCL_MJ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929264; Sae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168925 CVCL_MJ30 BayGenomics ES cell line LRY016 embryonic stem cell house mouse CVCL_MJ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168926 CVCL_DP94 421C1 induced pluripotent stem cell human CVCL_DP94 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21168927 CVCL_E194 PPY00331IN transformed cell line CVCL_E194 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168928 CVCL_DP95 426C2 induced pluripotent stem cell human CVCL_DP95 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21168929 CVCL_E195 PSP00359IN transformed cell line CVCL_E195 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168930 CVCL_DP92 404C2 induced pluripotent stem cell human CVCL_DP92 HLA typing: A*02:01; B*27:05,50:01; C*01:02;04:01; DQA1*01:01,05:01; DQB1*03:01,05:01; DRB1*01:01,13:03 (PubMed=30853558) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168931 CVCL_E192 PPY00329IN transformed cell line CVCL_E192 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168932 CVCL_DP93 418C1 induced pluripotent stem cell human CVCL_DP93 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21168933 CVCL_E193 PPY00330IN transformed cell line CVCL_E193 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168934 CVCL_DP98 451F3 induced pluripotent stem cell human CVCL_DP98 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168935 CVCL_E198 PSP00362IN transformed cell line CVCL_E198 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168936 CVCL_DP99 453F2 induced pluripotent stem cell human CVCL_DP99 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21168937 CVCL_E199 PTR00319IN transformed cell line CVCL_E199 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Schweinfurthii. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168938 CVCL_DP96 427D4 induced pluripotent stem cell human CVCL_DP96 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21168939 CVCL_E196 PSP00360IN transformed cell line CVCL_E196 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168940 CVCL_DP97 428C2 induced pluripotent stem cell human CVCL_DP97 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21168941 CVCL_E197 PSP00361IN transformed cell line CVCL_E197 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168942 CVCL_MJ28 BayGenomics ES cell line LRY014 embryonic stem cell house mouse CVCL_MJ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168943 CVCL_MJ29 BayGenomics ES cell line LRY015 embryonic stem cell house mouse CVCL_MJ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444629; Kctd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168944 CVCL_MJ26 BayGenomics ES cell line LRY011 embryonic stem cell house mouse CVCL_MJ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334462; Copa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168945 CVCL_MJ27 BayGenomics ES cell line LRY012 embryonic stem cell house mouse CVCL_MJ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168946 CVCL_MJ24 BayGenomics ES cell line LRY006 embryonic stem cell house mouse CVCL_MJ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168947 CVCL_E190 PPY00327IN transformed cell line CVCL_E190 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168948 CVCL_DP90 TkCBV5-6 induced pluripotent stem cell human CVCL_DP90 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168949 CVCL_DP91 225C7 induced pluripotent stem cell human CVCL_DP91 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168950 CVCL_MJ25 BayGenomics ES cell line LRY007 embryonic stem cell house mouse CVCL_MJ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917829; Zc3h11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168951 CVCL_E191 PPY00328IN transformed cell line CVCL_E191 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168952 CVCL_MJ22 BayGenomics ES cell line KST320 embryonic stem cell house mouse CVCL_MJ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168953 CVCL_MJ23 BayGenomics ES cell line LRY004 embryonic stem cell house mouse CVCL_MJ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3605986; Rad54b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168954 CVCL_DP69 1375-4f1 induced pluripotent stem cell human CVCL_DP69 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168955 CVCL_E169 MFA00338IN transformed cell line CVCL_E169 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168956 CVCL_DP67 HDF1554 finite cell line human CVCL_DP67 From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21168957 CVCL_E167 MFA00336IN transformed cell line CVCL_E167 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168958 CVCL_DP68 DP074 finite cell line human CVCL_DP68 HLA typing: A*24,24; B*52,52 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168959 CVCL_E168 MFA00337IN transformed cell line CVCL_E168 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168960 CVCL_E161 CMI00339IN transformed cell line CVCL_E161 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168961 CVCL_DP61 iPS-TIG108-4f3 induced pluripotent stem cell human CVCL_DP61 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168962 CVCL_E162 GGO00326IN transformed cell line CVCL_E162 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168963 CVCL_DP62 iPS-TIG109-4f1 induced pluripotent stem cell human CVCL_DP62 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168964 CVCL_DP60 414C2 induced pluripotent stem cell human CVCL_DP60 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168965 CVCL_E160 CJA00377IN transformed cell line CVCL_E160 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168966 CVCL_DP65 HDF1419 finite cell line human CVCL_DP65 From: Cell Applications, Inc.; San Diego; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep proteome analysis Female 21168967 CVCL_E165 MAR00334IN transformed cell line CVCL_E165 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168968 CVCL_DP66 HDF1437 finite cell line human CVCL_DP66 From: Cell Applications, Inc.; San Diego; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21168969 CVCL_E166 MFA00335IN transformed cell line CVCL_E166 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168970 CVCL_E163 HSP00332IN transformed cell line CVCL_E163 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168971 CVCL_DP63 iPS-TIG118-4f1 induced pluripotent stem cell human CVCL_DP63 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168972 CVCL_DP64 iPS-TIG121-4f4 induced pluripotent stem cell human CVCL_DP64 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168973 CVCL_E164 MAR00333IN transformed cell line CVCL_E164 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168974 CVCL_MJ10 BayGenomics ES cell line KST300 embryonic stem cell house mouse CVCL_MJ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448326; H3c6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168975 CVCL_DP78 iPS-DP75 3f-2 induced pluripotent stem cell human CVCL_DP78 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168976 CVCL_E178 MMU00348IN transformed cell line CVCL_E178 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168977 CVCL_DP79 iPS-DP75 4f-1 induced pluripotent stem cell human CVCL_DP79 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168978 CVCL_E179 MSY00349IN transformed cell line CVCL_E179 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168979 CVCL_DP72 1488-4f1 induced pluripotent stem cell human CVCL_DP72 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168980 CVCL_E172 MFA00342IN transformed cell line CVCL_E172 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168981 CVCL_DP73 297A1 induced pluripotent stem cell human CVCL_DP73 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168982 CVCL_E173 MMU00343IN transformed cell line CVCL_E173 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168983 CVCL_DP70 1377-4f1 induced pluripotent stem cell human CVCL_DP70 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168984 CVCL_E170 MFA00340IN transformed cell line CVCL_E170 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168985 CVCL_DP71 297F1 induced pluripotent stem cell human CVCL_DP71 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21168986 CVCL_E171 MFA00341IN transformed cell line CVCL_E171 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168987 CVCL_DP76 DP075 finite cell line human CVCL_DP76 HLA typing: A*02,24; B*51,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168988 CVCL_E176 MMU00346IN transformed cell line CVCL_E176 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168989 CVCL_DP77 iPS-DP75 3f-1 induced pluripotent stem cell human CVCL_DP77 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Male 21168990 CVCL_E177 MMU00347IN transformed cell line CVCL_E177 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168991 CVCL_DP74 1687-4f2 induced pluripotent stem cell human CVCL_DP74 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21168992 CVCL_MJ08 BayGenomics ES cell line KST290 embryonic stem cell house mouse CVCL_MJ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107685; Plxna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168993 CVCL_E174 MMU00344IN transformed cell line CVCL_E174 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168994 CVCL_MJ09 BayGenomics ES cell line KST296 embryonic stem cell house mouse CVCL_MJ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3603820; Tctn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168995 CVCL_DP75 DP031 finite cell line human CVCL_DP75 HLA typing: A*11,31; B*48,55 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: Transcriptome analysis by microarray Female 21168996 CVCL_E175 MMU00345IN transformed cell line CVCL_E175 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21168997 CVCL_MJ06 BayGenomics ES cell line KST286 embryonic stem cell house mouse CVCL_MJ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88261; Canx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168998 CVCL_MJ07 BayGenomics ES cell line KST288 embryonic stem cell house mouse CVCL_MJ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917329; Golm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21168999 CVCL_MJ04 BayGenomics ES cell line KST282 embryonic stem cell house mouse CVCL_MJ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353605; Tor1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169000 CVCL_MJ05 BayGenomics ES cell line KST285 embryonic stem cell house mouse CVCL_MJ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169001 CVCL_MJ02 BayGenomics ES cell line KST280 embryonic stem cell house mouse CVCL_MJ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169002 CVCL_MJ03 BayGenomics ES cell line KST281 embryonic stem cell house mouse CVCL_MJ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169003 CVCL_MJ00 BayGenomics ES cell line KST273 embryonic stem cell house mouse CVCL_MJ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917329; Golm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169004 CVCL_MJ01 BayGenomics ES cell line KST274 embryonic stem cell house mouse CVCL_MJ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095733; Pros1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169005 CVCL_E147 3Y1-B clone 1-6 spontaneously immortalized cell line Norway rat CVCL_E147 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: RCB; RCB0287; true Female Doubling time: ~1 day (lot 03172017) (JCRB) 21169006 CVCL_DP47 PC-9/IR cancer cell line human CVCL_DP47 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from metastatic site: Lymph node. Omics: Deep membrane proteome analysis; Omics: Deep phosphoproteome analysis Male 21169007 CVCL_E148 A7 [Rat optic nerve astrocyte] transformed cell line Norway rat CVCL_E148 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Optic nerve Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21169008 CVCL_DP48 MDA-BoM-1833 cancer cell line human CVCL_DP48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Proteome analysis by 2D-DE; Omics: Secretome proteome analysis Female Characteristics: Established from bone metastasis of nude mice inculated with the parent cell line Group: Triple negative breast cancer (TNBC) cell line 21169009 CVCL_DP45 HGFDFSV40T369 transformed cell line human CVCL_DP45 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169010 CVCL_E145 TGBC44TKB cancer cell line human CVCL_E145 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Discontinued: RCB; RCB1259; true Doubling time: 30 hours (PubMed=9824643) 21169011 CVCL_E146 3SB cancer cell line house mouse CVCL_E146 CL:0000010 Transformant: X-Ray(NCIt; C17262) Discontinued: RCB; RCB0681; true. 21169012 CVCL_DP46 PSFDFSV40T376 transformed cell line human CVCL_DP46 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169013 CVCL_E149 HEK293-A7 transformed cell line human CVCL_E149 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: New England Biolabs; Catalog number C2002 Female 21169014 CVCL_DP49 MCF7/MIII cancer cell line human CVCL_DP49 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21169015 CVCL_E140 MEDMC-BRC6 embryonic stem cell house mouse CVCL_E140 CL:0000010 Breed/subspecies: C57BL/6. Female 21169016 CVCL_DP40 PSMDFSV40T375 transformed cell line human CVCL_DP40 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Heterozygous (PRF) Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21169017 CVCL_DP43 HGADFSV40T367 transformed cell line human CVCL_DP43 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21169018 CVCL_E143 MEDEP-E14 clone 4 embryonic stem cell house mouse CVCL_E143 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21169019 CVCL_DP44 HGMDFSV40T368 transformed cell line human CVCL_DP44 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21169020 CVCL_E144 TGBC41TKB cancer cell line human CVCL_E144 CL:0000010 Population: Japanese Discontinued: RCB; RCB1254; true. 21169021 CVCL_DP41 HGMDFSV40T090 transformed cell line human CVCL_DP41 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21169022 CVCL_E141 MEDMC-NT2 embryonic stem cell house mouse CVCL_E141 CL:0000010 Breed/subspecies: 129. Unspecified 21169023 CVCL_DP42 HGFDFSV40T168 transformed cell line human CVCL_DP42 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169024 CVCL_E142 NTES-2 embryonic stem cell house mouse CVCL_E142 CL:0000010 Breed/subspecies: 129. Unspecified 21169025 CVCL_E158 CJA00375IN transformed cell line CVCL_E158 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169026 CVCL_DP58 KCL22-r cancer cell line human CVCL_DP58 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Omics: Proteome analysis by 2D-DE/MS Female Doubling time: 24-30 hours (ATCC=CRL-3350) 21169027 CVCL_E159 CJA00376IN transformed cell line CVCL_E159 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169028 CVCL_DP59 HDF1388 finite cell line human CVCL_DP59 From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169029 CVCL_DP56 AR230-r cancer cell line human CVCL_DP56 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Peripheral blood. Female Doubling time: ~30-48 hours (ATCC=CRL-3346) 21169030 CVCL_E156 CJA00373IN transformed cell line CVCL_E156 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169031 CVCL_E157 CJA00374IN transformed cell line CVCL_E157 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169032 CVCL_DP57 LAMA84-r cancer cell line human CVCL_DP57 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Peripheral blood. Female 21169033 CVCL_E150 A7 [Rat brain astrocyte] finite cell line Norway rat CVCL_E150 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.. Unspecified 21169034 CVCL_DP50 MCF7/LCC1 cancer cell line human CVCL_DP50 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21169035 CVCL_E151 594S transformed cell line CVCL_E151 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female Group: Non-human primate cell line 21169036 CVCL_DP51 MCF7/LCC2 cancer cell line human CVCL_DP51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44616; Afimoxifene (4-hydroxytamoxifen; Derived from metastatic site: Pleural effusion. Omics: Proteome analysis Female 21169037 CVCL_E154 CJA00371IN transformed cell line CVCL_E154 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169038 CVCL_DP54 LAMA84-rn cancer cell line human CVCL_DP54 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys319Ter (c.955A>T); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Derived from sampling site: Peripheral blood. Female 21169039 CVCL_E155 CJA00372IN transformed cell line CVCL_E155 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169040 CVCL_DP55 K562-rn cancer cell line human CVCL_DP55 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Derived from sampling site: Pleural effusion. Female 21169041 CVCL_E152 CJA00369IN transformed cell line CVCL_E152 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169042 CVCL_DP52 MCF7/LCC9 cancer cell line human CVCL_DP52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female 21169043 CVCL_DP53 AR230-rn cancer cell line human CVCL_DP53 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Derived from sampling site: Peripheral blood. Female 21169044 CVCL_E153 CJA00370IN transformed cell line CVCL_E153 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169045 CVCL_E125 GM19099 transformed cell line human CVCL_E125 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21169046 CVCL_DP25 TND-4 transformed cell line human CVCL_DP25 CL:0000010 Sequence variation: Mutation; HGNC; 43; TAP1; Simple; c.778delG; Zygosity=Heterozygous (from familial inference of TND-3) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169047 CVCL_E126 GM19193 transformed cell line human CVCL_E126 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3 21169048 CVCL_DP26 PR00283 finite cell line CVCL_DP26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00283; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169049 CVCL_E123 PrEC LHSR transformed cell line human CVCL_E123 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21169050 CVCL_DP23 TND-2 transformed cell line human CVCL_DP23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169051 CVCL_E124 GM18526 transformed cell line human CVCL_E124 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21169052 CVCL_DP24 TND-3 transformed cell line human CVCL_DP24 CL:0000010 Sequence variation: Mutation; HGNC; 43; TAP1; Simple; c.778delG; Zygosity=Homozygous (PubMed=10074495) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169053 CVCL_E129 GM08728 transformed cell line human CVCL_E129 CL:0000010 Sequence variation: Mutation; HGNC; 2979; DNMT3B; Simple; p.Ala603Thr (c.1807G>A); ClinVar=VCV000006740; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169054 CVCL_DP29 PR01097 transformed cell line CVCL_DP29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01097; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169055 CVCL_E127 GM20000 transformed cell line human CVCL_E127 CL:0000010 Sequence variation: Mutation; HGNC; 28862; NIPBL; Simple; p.Glu1908Ilefs*13 (c.5721_5725delTGAAA) (5721del5); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ENCODE project common cell types; tier 3 21169056 CVCL_DP27 PR00307 finite cell line CVCL_DP27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR00307; probable Female Group: Endangered species/breed cell line; Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169057 CVCL_E128 GM08714 transformed cell line human CVCL_E128 CL:0000010 Sequence variation: Mutation; HGNC; 2979; DNMT3B; Simple; p.Ala603Thr (c.1807G>A); ClinVar=VCV000006740; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2979; DNMT3B; Simple; c.2397-11G>A (IVS22AS,G>A,-11) (744ins3); ClinVar=VCV000006741; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ENCODE project common cell types; tier 3 21169058 CVCL_DP28 PR00782 transformed cell line CVCL_DP28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00782; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169059 CVCL_E121 LNC.4 factor-dependent cell line house mouse CVCL_E121 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: BALB/cAnN. Unspecified Characteristics: IL4 dependent 21169060 CVCL_DP21 ST-EMO transformed cell line human CVCL_DP21 CL:0000010 Sequence variation: Mutation; HGNC; 44; TAP2; Simple; p.Arg273Ter (c.817C>T) (R253*); ClinVar=VCV000013727; Zygosity=Homozygous (PubMed=7517574) Population: Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169061 CVCL_E122 KPL-3C cancer cell line human CVCL_E122 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: ~72 hours (PubMed=8688322) Part of: JFCR45 cancer cell line panel 21169062 CVCL_DP22 TND-1 transformed cell line human CVCL_DP22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169063 CVCL_E120 LNC.2 factor-dependent cell line house mouse CVCL_E120 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: BALB/cAnN. Unspecified Characteristics: IL2 dependent 21169064 CVCL_DP20 ST-EAH transformed cell line human CVCL_DP20 CL:0000010 Sequence variation: Mutation; HGNC; 44; TAP2; Simple; p.Arg273Ter (c.817C>T) (R253*); ClinVar=VCV000013727; Zygosity=Heterozygous (from familial inference of ST-EMO) Population: Moroccan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169065 CVCL_E136 MEDEP-BRC4-2 embryonic stem cell house mouse CVCL_E136 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2699; true Unspecified 21169066 CVCL_DP36 PSADFSV40T318 transformed cell line human CVCL_DP36 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169067 CVCL_E137 MEDEP-BRC5 embryonic stem cell house mouse CVCL_E137 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2609; true Male 21169068 CVCL_DP37 PSFDFSV40T319 transformed cell line human CVCL_DP37 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169069 CVCL_E134 GSM06 conditionally immortalized cell line house mouse CVCL_E134 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus; mucosa Cell type=Surface mucosal cell of stomach.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Discontinued: RCB; RCB1779; true Unspecified Characteristics: At the permissive temperature (33 Celsius) grow until confluent monolayer are formed (PubMed=8262157) 21169070 CVCL_DP34 HGALBV462 transformed cell line human CVCL_DP34 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21169071 CVCL_E135 GSM10 conditionally immortalized cell line house mouse CVCL_E135 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; fundus; mucosa Cell type=Surface mucosal cell of stomach.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Discontinued: RCB; RCB1780; true Unspecified Characteristics: At the permissive temperature (33 Celsius) grow until confluent monolayer are formed (PubMed=8262157) 21169072 CVCL_DP35 PSADFSV40T317 transformed cell line human CVCL_DP35 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Pro248Leu (c.743C>T); ClinVar=VCV000004275; Zygosity=Heterozygous (PRF); Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Trp450Ter (c.1349G>A); ClinVar=VCV000030586; Zygosity=Heterozygous (PRF) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169073 CVCL_E138 MEDEP-E14 embryonic stem cell house mouse CVCL_E138 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169074 CVCL_DP38 PSMDFSV40T320 transformed cell line human CVCL_DP38 CL:0000010 Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21169075 CVCL_E139 MEDEP-BRC4-1 embryonic stem cell house mouse CVCL_E139 CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21169076 CVCL_DP39 PSADFSV40T373 transformed cell line human CVCL_DP39 CL:0000010 Sequence variation: Mutation; HGNC; 12877; ZMPSTE24; Simple; p.Leu425Pro (c.1274T>C); Zygosity=Homozygous (PRF) Miscellaneous: Cell line no longer available Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21169077 CVCL_DP32 HGALBV451 transformed cell line human CVCL_DP32 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Progeria Research Foundation cell lines 21169078 CVCL_E132 NCU-F5 finite cell line human CVCL_E132 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: RCB; RCB0392; true Male Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin. 21169079 CVCL_E133 ABS-9 cancer cell line human CVCL_E133 CL:0000010 Discontinued: RCB; RCB1427; true. Male Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin. Originally thought to originate from an acute myelocytic leukemia (RCB). 21169080 CVCL_DP33 HGALBV452 transformed cell line human CVCL_DP33 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Progeria Research Foundation cell lines 21169081 CVCL_E130 GM08747 finite cell line human CVCL_E130 CL:0000010 Sequence variation: Mutation; HGNC; 2979; DNMT3B; Simple; p.Ala603Thr (c.1807G>A); ClinVar=VCV000006740; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2979; DNMT3B; Simple; c.2397-11G>A (IVS22AS,G>A,-11) (744ins3); ClinVar=VCV000006741; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21169082 CVCL_DP30 RD.TG6 cancer cell line human CVCL_DP30 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Pelvis; muscle. Female 21169083 CVCL_E131 KU-YS cancer cell line human CVCL_E131 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Discontinued: RCB; RCB1318; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00326 Problematic cell line: Contaminated Shown to be a KU-SN derivative (PubMed=20143388). 21169084 CVCL_DP31 mHypoA-GnRH/GFP transformed cell line house mouse CVCL_DP31 CL:0000010 Transfected with: UniProtKB; Q963I9; Renilla GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21169085 CVCL_VD41 ESi044-D induced pluripotent stem cell human CVCL_VD41 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169086 CVCL_VD42 ESi045-D induced pluripotent stem cell human CVCL_VD42 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Scrotum; skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169087 CVCL_VD40 ESi044-B induced pluripotent stem cell human CVCL_VD40 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169088 CVCL_VD45 ESi046-A induced pluripotent stem cell human CVCL_VD45 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169089 CVCL_VD46 ESi057-A induced pluripotent stem cell human CVCL_VD46 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169090 CVCL_VD43 ESi056-A induced pluripotent stem cell human CVCL_VD43 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1351Asp (c.4052G>A); Zygosity=Hemizygous (PubMed=29150092) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169091 CVCL_VD44 ESi054-A induced pluripotent stem cell human CVCL_VD44 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 2204; COL4A3; Simple; p.Pro116Leufs*37 (c.345delG); ClinVar=VCV000554004; Zygosity=Homozygous (PubMed=29246570) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169092 CVCL_VD49 ESi060-A induced pluripotent stem cell human CVCL_VD49 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169093 CVCL_VD47 ESi058-A induced pluripotent stem cell human CVCL_VD47 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169094 CVCL_VD48 ESi059-A induced pluripotent stem cell human CVCL_VD48 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169095 CVCL_MJ99 BayGenomics ES cell line LST103 embryonic stem cell house mouse CVCL_MJ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169096 CVCL_VD30 CSSi003-A induced pluripotent stem cell human CVCL_VD30 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Ser399Profs*40 (c.1194delC); Zygosity=Heterozygous (PubMed=29494847) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169097 CVCL_VD31 CSSi004-A induced pluripotent stem cell human CVCL_VD31 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=29486399) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169098 CVCL_VD34 EPFLi001-A induced pluripotent stem cell human CVCL_VD34 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169099 CVCL_VD35 EPFLi002-A induced pluripotent stem cell human CVCL_VD35 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169100 CVCL_VD32 CSSi005-A induced pluripotent stem cell human CVCL_VD32 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Gene amplification; HGNC; 1960; CHRNA7; Duplication; Zygosity=Unspecified; Note=15q13.3 interstitial duplication (PubMed=30218896) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169101 CVCL_VD33 CSSi006-A induced pluripotent stem cell human CVCL_VD33 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[65] (c.52CAG(65)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=29704769) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169102 CVCL_VD38 EPFLi005-A induced pluripotent stem cell human CVCL_VD38 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169103 CVCL_VD39 EPFLi006-A induced pluripotent stem cell human CVCL_VD39 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169104 CVCL_VD36 EPFLi003-A induced pluripotent stem cell human CVCL_VD36 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169105 CVCL_VD37 EPFLi004-A induced pluripotent stem cell human CVCL_VD37 From: Ecole Polytechnique Federale de Lausanne; Lausanne; Switzerland CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21169106 CVCL_MJ86 BayGenomics ES cell line LST083 embryonic stem cell house mouse CVCL_MJ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96677; Kit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169107 CVCL_MJ87 BayGenomics ES cell line LST086 embryonic stem cell house mouse CVCL_MJ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169108 CVCL_MJ84 BayGenomics ES cell line LST080 embryonic stem cell house mouse CVCL_MJ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96788; Lifr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169109 CVCL_MJ85 BayGenomics ES cell line LST081 embryonic stem cell house mouse CVCL_MJ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88356; Cdh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169110 CVCL_MJ82 BayGenomics ES cell line LST075 embryonic stem cell house mouse CVCL_MJ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96560; Il6st Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169111 CVCL_MJ83 BayGenomics ES cell line LST076 embryonic stem cell house mouse CVCL_MJ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169112 CVCL_MJ80 BayGenomics ES cell line LST067 embryonic stem cell house mouse CVCL_MJ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169113 CVCL_MJ81 BayGenomics ES cell line LST071 embryonic stem cell house mouse CVCL_MJ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169114 CVCL_VD20 CHDIi049-A induced pluripotent stem cell human CVCL_VD20 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169115 CVCL_VD23 CHDIi052-A induced pluripotent stem cell human CVCL_VD23 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi052-A; true; Discontinued: ECACC; 66541198; true 21169116 CVCL_VD24 CHDIi053-A induced pluripotent stem cell human CVCL_VD24 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi053-A; true; Discontinued: ECACC; 66541199; true 21169117 CVCL_VD21 CHDIi050-A induced pluripotent stem cell human CVCL_VD21 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21169118 CVCL_VD22 CHDIi051-A induced pluripotent stem cell human CVCL_VD22 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21169119 CVCL_VD27 CHDIi056-A induced pluripotent stem cell human CVCL_VD27 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21169120 CVCL_VD28 CHDIi057-A induced pluripotent stem cell human CVCL_VD28 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi057-A; true; Discontinued: ECACC; 66541203; true 21169121 CVCL_VD25 CHDIi054-A induced pluripotent stem cell human CVCL_VD25 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169122 CVCL_VD26 CHDIi055-A induced pluripotent stem cell human CVCL_VD26 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21169123 CVCL_VD29 CSSi001-A induced pluripotent stem cell human CVCL_VD29 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 21575; AHI1; Simple; p.His896Arg (c.2687A>G); ClinVar=VCV000217532; Zygosity=Homozygous (PubMed=29334628) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169124 CVCL_MJ79 BayGenomics ES cell line LST065 embryonic stem cell house mouse CVCL_MJ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169125 CVCL_MJ77 BayGenomics ES cell line LST061 embryonic stem cell house mouse CVCL_MJ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169126 CVCL_MJ78 BayGenomics ES cell line LST064 embryonic stem cell house mouse CVCL_MJ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169127 CVCL_MJ97 BayGenomics ES cell line LST100 embryonic stem cell house mouse CVCL_MJ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169128 CVCL_MJ98 BayGenomics ES cell line LST102 embryonic stem cell house mouse CVCL_MJ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169129 CVCL_MJ95 BayGenomics ES cell line LST096 embryonic stem cell house mouse CVCL_MJ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169130 CVCL_MJ96 BayGenomics ES cell line LST097 embryonic stem cell house mouse CVCL_MJ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919293; Sulf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169131 CVCL_MJ93 BayGenomics ES cell line LST093 embryonic stem cell house mouse CVCL_MJ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929270; Dstn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169132 CVCL_MJ94 BayGenomics ES cell line LST094 embryonic stem cell house mouse CVCL_MJ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443129; Golm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169133 CVCL_MJ91 BayGenomics ES cell line LST091 embryonic stem cell house mouse CVCL_MJ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95794; Lrp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169134 CVCL_MJ92 BayGenomics ES cell line LST092 embryonic stem cell house mouse CVCL_MJ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169135 CVCL_MJ90 BayGenomics ES cell line LST090 embryonic stem cell house mouse CVCL_MJ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169136 CVCL_VD12 CHDIi041-A induced pluripotent stem cell human CVCL_VD12 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169137 CVCL_VD13 CHDIi042-A induced pluripotent stem cell human CVCL_VD13 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169138 CVCL_VD10 CHDIi039-A induced pluripotent stem cell human CVCL_VD10 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi039-A; true; Discontinued: ECACC; 66541185; true 21169139 CVCL_VD11 CHDIi040-A induced pluripotent stem cell human CVCL_VD11 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169140 CVCL_VD16 CHDIi045-A induced pluripotent stem cell human CVCL_VD16 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169141 CVCL_VD17 CHDIi046-A induced pluripotent stem cell human CVCL_VD17 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169142 CVCL_VD14 CHDIi043-A induced pluripotent stem cell human CVCL_VD14 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169143 CVCL_VD15 CHDIi044-A induced pluripotent stem cell human CVCL_VD15 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169144 CVCL_VD18 CHDIi047-A induced pluripotent stem cell human CVCL_VD18 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169145 CVCL_VD19 CHDIi048-A induced pluripotent stem cell human CVCL_VD19 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[48] (c.52CAG(48)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21169146 CVCL_MJ88 BayGenomics ES cell line LST087 embryonic stem cell house mouse CVCL_MJ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914647; Erp29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169147 CVCL_MJ89 BayGenomics ES cell line LST089 embryonic stem cell house mouse CVCL_MJ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169148 CVCL_MJ64 BayGenomics ES cell line LST044 embryonic stem cell house mouse CVCL_MJ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169149 CVCL_MJ65 BayGenomics ES cell line LST045 embryonic stem cell house mouse CVCL_MJ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96605; Itga6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169150 CVCL_MJ62 BayGenomics ES cell line LST038 embryonic stem cell house mouse CVCL_MJ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915088; Dnajb11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169151 CVCL_MJ63 BayGenomics ES cell line LST041 embryonic stem cell house mouse CVCL_MJ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914217; Edem3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169152 CVCL_MJ60 BayGenomics ES cell line LST031 embryonic stem cell house mouse CVCL_MJ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169153 CVCL_MJ61 BayGenomics ES cell line LST032 embryonic stem cell house mouse CVCL_MJ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891468; Lgr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169154 CVCL_VD01 CHDIi030-A induced pluripotent stem cell human CVCL_VD01 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi030-A; true; Discontinued: ECACC; 66541159; true 21169155 CVCL_VD02 CHDIi031-A induced pluripotent stem cell human CVCL_VD02 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169156 CVCL_VD00 CHDIi029-A induced pluripotent stem cell human CVCL_VD00 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169157 CVCL_VD05 CHDIi034-A induced pluripotent stem cell human CVCL_VD05 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169158 CVCL_VD06 CHDIi035-A induced pluripotent stem cell human CVCL_VD06 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169159 CVCL_VD03 CHDIi032-A induced pluripotent stem cell human CVCL_VD03 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi032-A; true; Discontinued: ECACC; 66541160; true 21169160 CVCL_VD04 CHDIi033-A induced pluripotent stem cell human CVCL_VD04 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169161 CVCL_VD09 CHDIi038-A induced pluripotent stem cell human CVCL_VD09 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169162 CVCL_MJ59 BayGenomics ES cell line LST022 embryonic stem cell house mouse CVCL_MJ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97363; Notch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169163 CVCL_VD07 CHDIi036-A induced pluripotent stem cell human CVCL_VD07 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169164 CVCL_VD08 CHDIi037-A induced pluripotent stem cell human CVCL_VD08 From: CHDI Foundation; New York; USA CL:0000010 Discontinued: EBiSC; CHDIi037-A; true; Discontinued: ECACC; 66541184; true. 21169165 CVCL_MJ57 BayGenomics ES cell line LST018 embryonic stem cell house mouse CVCL_MJ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108077; Nptn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169166 CVCL_MJ58 BayGenomics ES cell line LST020 embryonic stem cell house mouse CVCL_MJ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891468; Lgr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169167 CVCL_MJ55 BayGenomics ES cell line LST015 embryonic stem cell house mouse CVCL_MJ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169168 CVCL_MJ56 BayGenomics ES cell line LST016 embryonic stem cell house mouse CVCL_MJ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443955; Lrig3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169169 CVCL_MJ75 BayGenomics ES cell line LST058 embryonic stem cell house mouse CVCL_MJ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169170 CVCL_MJ76 BayGenomics ES cell line LST059 embryonic stem cell house mouse CVCL_MJ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923937; Spcs3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169171 CVCL_MJ73 BayGenomics ES cell line LST056 embryonic stem cell house mouse CVCL_MJ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341628; Atrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169172 CVCL_MJ74 BayGenomics ES cell line LST057 embryonic stem cell house mouse CVCL_MJ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107892; Fam3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169173 CVCL_MJ71 BayGenomics ES cell line LST053 embryonic stem cell house mouse CVCL_MJ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169174 CVCL_MJ72 BayGenomics ES cell line LST055 embryonic stem cell house mouse CVCL_MJ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894663; Ext1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169175 CVCL_MJ70 BayGenomics ES cell line LST050 embryonic stem cell house mouse CVCL_MJ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443718; Lrig2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169176 CVCL_MJ68 BayGenomics ES cell line LST048 embryonic stem cell house mouse CVCL_MJ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169177 CVCL_MJ69 BayGenomics ES cell line LST049 embryonic stem cell house mouse CVCL_MJ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336172; Tbl1x Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169178 CVCL_MJ66 BayGenomics ES cell line LST046 embryonic stem cell house mouse CVCL_MJ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145316; Txndc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169179 CVCL_MJ67 BayGenomics ES cell line LST047 embryonic stem cell house mouse CVCL_MJ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354958; Hs6st1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169180 CVCL_MJ42 BayGenomics ES cell line LRY044 embryonic stem cell house mouse CVCL_MJ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3525053; Ppp1r13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169181 CVCL_MJ43 BayGenomics ES cell line LRY046 embryonic stem cell house mouse CVCL_MJ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338049; Itsn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169182 CVCL_MJ40 BayGenomics ES cell line LRY041 embryonic stem cell house mouse CVCL_MJ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169183 CVCL_MJ41 BayGenomics ES cell line LRY042 embryonic stem cell house mouse CVCL_MJ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88071; Arnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169184 CVCL_MJ39 BayGenomics ES cell line LRY039 embryonic stem cell house mouse CVCL_MJ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914179; Asf1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169185 CVCL_MJ37 BayGenomics ES cell line LRY036 embryonic stem cell house mouse CVCL_MJ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858961; Prc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169186 CVCL_MJ38 BayGenomics ES cell line LRY038 embryonic stem cell house mouse CVCL_MJ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169187 CVCL_MJ35 BayGenomics ES cell line LRY034 embryonic stem cell house mouse CVCL_MJ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169188 CVCL_MJ36 BayGenomics ES cell line LRY035 embryonic stem cell house mouse CVCL_MJ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891995; Mapre1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169189 CVCL_MJ33 BayGenomics ES cell line LRY026 embryonic stem cell house mouse CVCL_MJ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169190 CVCL_MJ34 BayGenomics ES cell line LRY027 embryonic stem cell house mouse CVCL_MJ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096572; Zfand3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169191 CVCL_MJ53 BayGenomics ES cell line LST011 embryonic stem cell house mouse CVCL_MJ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139054; Gpr107 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169192 CVCL_MJ54 BayGenomics ES cell line LST012 embryonic stem cell house mouse CVCL_MJ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99431; Arf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169193 CVCL_MJ51 BayGenomics ES cell line LST002 embryonic stem cell house mouse CVCL_MJ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442146; Dnajc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169194 CVCL_MJ52 BayGenomics ES cell line LST008 embryonic stem cell house mouse CVCL_MJ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169195 CVCL_MJ50 BayGenomics ES cell line LRY069 embryonic stem cell house mouse CVCL_MJ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328362; Blm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169196 CVCL_MJ48 BayGenomics ES cell line LRY052 embryonic stem cell house mouse CVCL_MJ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916974; Rnaseh2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169197 CVCL_MJ49 BayGenomics ES cell line LRY056 embryonic stem cell house mouse CVCL_MJ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169198 CVCL_MJ46 BayGenomics ES cell line LRY050 embryonic stem cell house mouse CVCL_MJ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913358; Ndufa9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169199 CVCL_MJ47 BayGenomics ES cell line LRY051 embryonic stem cell house mouse CVCL_MJ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103071; Rangap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169200 CVCL_MJ44 BayGenomics ES cell line LRY048 embryonic stem cell house mouse CVCL_MJ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169201 CVCL_MJ45 BayGenomics ES cell line LRY049 embryonic stem cell house mouse CVCL_MJ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107749; Tpd52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169202 CVCL_VC90 CHDIi019-A induced pluripotent stem cell human CVCL_VC90 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169203 CVCL_VC93 CHDIi022-A induced pluripotent stem cell human CVCL_VC93 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169204 CVCL_VC94 CHDIi023-A induced pluripotent stem cell human CVCL_VC94 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169205 CVCL_VC91 CHDIi020-A induced pluripotent stem cell human CVCL_VC91 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169206 CVCL_VC92 CHDIi021-A induced pluripotent stem cell human CVCL_VC92 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169207 CVCL_VC97 CHDIi026-A induced pluripotent stem cell human CVCL_VC97 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[47] (c.52CAG(47)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169208 CVCL_VC98 CHDIi027-A induced pluripotent stem cell human CVCL_VC98 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169209 CVCL_VC95 CHDIi024-A induced pluripotent stem cell human CVCL_VC95 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169210 CVCL_VC96 CHDIi025-A induced pluripotent stem cell human CVCL_VC96 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi025-A; true; Discontinued: ECACC; 66541157; true 21169211 CVCL_VC99 CHDIi028-A induced pluripotent stem cell human CVCL_VC99 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169212 CVCL_VC82 CHDIi011-A induced pluripotent stem cell human CVCL_VC82 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169213 CVCL_VC83 CHDIi012-A induced pluripotent stem cell human CVCL_VC83 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi012-A; true; Discontinued: ECACC; 66541153; true 21169214 CVCL_VC80 CHDIi009-A induced pluripotent stem cell human CVCL_VC80 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi009-A; true; Discontinued: ECACC; 66541167; true 21169215 CVCL_VC81 CHDIi010-A induced pluripotent stem cell human CVCL_VC81 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169216 CVCL_VC86 CHDIi015-A induced pluripotent stem cell human CVCL_VC86 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi015-A; true; Discontinued: ECACC; 66541170; true; Discontinued: hPSCreg; CHDIi015-A; true 21169217 CVCL_VC87 CHDIi016-A induced pluripotent stem cell human CVCL_VC87 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169218 CVCL_VC84 CHDIi013-A induced pluripotent stem cell human CVCL_VC84 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169219 CVCL_VC85 CHDIi014-A induced pluripotent stem cell human CVCL_VC85 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Array-based CGH Female 21169220 CVCL_VC88 CHDIi017-A induced pluripotent stem cell human CVCL_VC88 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169221 CVCL_VC89 CHDIi018-A induced pluripotent stem cell human CVCL_VC89 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Male 21169222 CVCL_VC71 CENSOi017-A induced pluripotent stem cell human CVCL_VC71 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21169223 CVCL_VC72 CHDIi001-A induced pluripotent stem cell human CVCL_VC72 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21169224 CVCL_VC70 CENSOi016-A induced pluripotent stem cell human CVCL_VC70 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Male 21169225 CVCL_VC75 CHDIi004-A induced pluripotent stem cell human CVCL_VC75 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21169226 CVCL_VC76 CHDIi005-A induced pluripotent stem cell human CVCL_VC76 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSc) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21169227 CVCL_VC73 CHDIi002-A induced pluripotent stem cell human CVCL_VC73 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169228 CVCL_VC74 CHDIi003-A induced pluripotent stem cell human CVCL_VC74 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Female 21169229 CVCL_VC79 CHDIi008-A induced pluripotent stem cell human CVCL_VC79 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169230 CVCL_VC77 CHDIi006-A induced pluripotent stem cell human CVCL_VC77 From: CHDI Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (EBiSC) Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Cell type=Fibroblast. Male 21169231 CVCL_VC78 CHDIi007-A induced pluripotent stem cell human CVCL_VC78 From: CHDI Foundation; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; CHDIi007-A; true; Discontinued: ECACC; 66541165; true 21169232 CVCL_VC60 BIONi011-B induced pluripotent stem cell human CVCL_VC60 From: Bioneer A/S; Horsholm; Denmark. CL:0000010 21169233 CVCL_VC61 BIONi011-C induced pluripotent stem cell human CVCL_VC61 From: Bioneer A/S; Horsholm; Denmark. CL:0000010 21169234 CVCL_VC64 CENSOi003-A induced pluripotent stem cell human CVCL_VC64 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-52del; Zygosity=Hemizygous (from autologous cell line CENSOi003-B) Derived from sampling site: Cell type=Fibroblast. Male 21169235 CVCL_VC65 CENSOi004-D induced pluripotent stem cell human CVCL_VC65 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Male 21169236 CVCL_VC62 CBIAi001-A induced pluripotent stem cell human CVCL_VC62 From: Centre for Biomedical Image Analysis; Brno; Czech Republic. CL:0000010 Female 21169237 CVCL_VC63 CDIi002-A induced pluripotent stem cell human CVCL_VC63 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21169238 CVCL_VC68 CENSOi014-A induced pluripotent stem cell human CVCL_VC68 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21169239 CVCL_VC69 CENSOi015-A induced pluripotent stem cell human CVCL_VC69 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Male 21169240 CVCL_VC66 CENSOi011-B induced pluripotent stem cell human CVCL_VC66 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21169241 CVCL_VC67 CENSOi013-A induced pluripotent stem cell human CVCL_VC67 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21169242 CVCL_VC50 BIHi031-B induced pluripotent stem cell human CVCL_VC50 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169243 CVCL_VC53 BIHi032-B induced pluripotent stem cell human CVCL_VC53 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169244 CVCL_VC54 BIHi032-C induced pluripotent stem cell human CVCL_VC54 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169245 CVCL_VC51 BIHi031-C induced pluripotent stem cell human CVCL_VC51 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169246 CVCL_VC52 BIHi032-A induced pluripotent stem cell human CVCL_VC52 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169247 CVCL_VC57 BIONi010-C-19 induced pluripotent stem cell human CVCL_VC57 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14552; IKBKE Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169248 CVCL_VC58 BIONi010-C-24 induced pluripotent stem cell human CVCL_VC58 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Transfected with: HGNC; 11138; SNCA Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: Using TALEN SNCA under the control of a doxycycline inducible promoter has been inserted at the safe harbor locus (AAVS1) 21169249 CVCL_VC55 BIHi038-A induced pluripotent stem cell human CVCL_VC55 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169250 CVCL_VC56 BIHi038-B induced pluripotent stem cell human CVCL_VC56 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169251 CVCL_VC59 BIONi010-C-25 induced pluripotent stem cell human CVCL_VC59 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 17761; TREM2 Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169252 CVCL_VC42 F121-9 embryonic stem cell house mouse CVCL_VC42 CL:0000010 Breed/subspecies: Castaneus x S129/SvJae. Female 21169253 CVCL_VC43 F123 embryonic stem cell house mouse CVCL_VC43 CL:0000010 Breed/subspecies: Castaneus x S129/SvJae. Male 21169254 CVCL_VC40 HFF-hTERT telomerase immortalized cell line human CVCL_VC40 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169255 CVCL_VC41 HFF-hTERT clone 6 telomerase immortalized cell line human CVCL_VC41 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169256 CVCL_VC46 DD1196 transformed cell line human CVCL_VC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93020808; true Female Part of: ECACC chromosomal abnormality collection 21169257 CVCL_VC47 DD1463 transformed cell line human CVCL_VC47 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-1 30kb del (CH-1 type CYP21A1P/CYP21A2 chimer); Zygosity=Heterozygous (PubMed=27896104); Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-7 30kb del (CH-7 type CYP21A1P/CYP21A2 chimer); Zygosity=Heterozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93082605; true Male Part of: ECACC chromosomal abnormality collection 21169258 CVCL_VC44 ES-E14 MLL3,MLL4 DKO embryonic stem cell house mouse CVCL_VC44 CL:0000010 Knockout cell: Method=Cre/loxP; MGI; MGI:109565; Kmt2b; Knockout cell: Method=Cre/loxP; MGI; MGI:2444959; Kmt2c Breed/subspecies: 129P2/Ola. Male 21169259 CVCL_VC45 H80HrPE-6 spontaneously immortalized cell line human CVCL_VC45 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Male 21169260 CVCL_VC48 DD1464 transformed cell line human CVCL_VC48 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-1 30kb del (CH-1 type CYP21A1P/CYP21A2 chimer); Zygosity=Heterozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ECACC; 93082606; true Female Part of: ECACC chromosomal abnormality collection 21169261 CVCL_VC49 BIHi031-A induced pluripotent stem cell human CVCL_VC49 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169262 CVCL_VC31 SPr0079 transformed cell line human CVCL_VC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21169263 CVCL_VC32 SPr0080 transformed cell line human CVCL_VC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21169264 CVCL_VC30 SPr0059 transformed cell line human CVCL_VC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21169265 CVCL_VC35 UFH-001 spontaneously immortalized cell line human CVCL_VC35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Transcriptome analysis by microarray Female Characteristics: Expresses CA9 21169266 CVCL_VC36 US/VOT-E36 conditionally immortalized cell line house mouse CVCL_VC36 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst Cell type=Epithelial cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Suitable for studies on inner ear development, gene expression and function of inner ear-specific genes, in vitro screening for gene activation and promoter analysis, ototoxicity and in vitro analysis of inherited deafness mutations and of ion channels, receptors and signalling pathways in vitro 21169267 CVCL_VC33 SPr0085 transformed cell line human CVCL_VC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Motor Neurone Disease (MND) collection 21169268 CVCL_VC34 SPr0086 transformed cell line human CVCL_VC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Motor Neurone Disease (MND) collection 21169269 CVCL_VC39 SSKWB cancer cell line human CVCL_VC39 CL:0000010 Derived from sampling site: Ascites. Unspecified Characteristics: Expresses both surface IgM and IgG1 21169270 CVCL_VC37 US/VOT-N33 conditionally immortalized cell line house mouse CVCL_VC37 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic ear; inner ear; otocyst Cell type=Neuroblast.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Neuroblast cell line suitable for studies on: inner ear development; gene expression and function of inner ear-specific genes; in vitro screening for gene activation and promoter analysis; ototoxicity; and in vitro analysis of inherited deafness mutations and of ion channels, receptors and signalling pathways in vitro 21169271 CVCL_VC38 BJAB/ADR cancer cell line human CVCL_VC38 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Groin. Female Virology: EBV-negative 21169272 CVCL_E109 LP-9 finite cell line human CVCL_E109 CL:0000010 Derived from sampling site: Ascites Cell type=Mesothelial cell.. Female Senescence: Senesces at ~50-60 PDL (PubMed=6192933; PubMed=10648628) 21169273 CVCL_DP09 PR01054 transformed cell line CVCL_DP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01054; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169274 CVCL_E103 NCI-BL2077 transformed cell line human CVCL_E103 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-5964; true Male 21169275 CVCL_DP03 PR00993 transformed cell line CVCL_DP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00993; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169276 CVCL_E104 NCI-H2115 cancer cell line human CVCL_E104 CL:0000010 Male 21169277 CVCL_DP04 PR00995 transformed cell line CVCL_DP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00995; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169278 CVCL_E101 NCI-BL1963 transformed cell line human CVCL_E101 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169279 CVCL_DP01 PR00987 transformed cell line CVCL_DP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00987; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169280 CVCL_E102 NCI-BL1993 transformed cell line human CVCL_E102 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21169281 CVCL_DP02 PR00991 transformed cell line CVCL_DP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00991; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169282 CVCL_DP07 PR01011 undefined cell line type CVCL_DP07 CL:0000010 Discontinued: Coriell; PR01011; probable. Unspecified Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169283 CVCL_E107 SNU-55 cancer cell line human CVCL_E107 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143fs (c.427delC); Zygosity=Unspecified (PubMed=1676761) Population: Korean; Derived from metastatic site: Not specified. Part of: Seoul National University (SNU) cell line collection 21169284 CVCL_E108 LP9/TERT-1 telomerase immortalized cell line human CVCL_E108 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Ascites Cell type=Mesothelial cell.. Omics: Transcriptome analysis by microarray Female 21169285 CVCL_DP08 PR01048 transformed cell line CVCL_DP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR01048; probable Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169286 CVCL_E105 NCI-H2973 cancer cell line human CVCL_E105 CL:0000010 21169287 CVCL_DP05 PR00997 transformed cell line CVCL_DP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00997; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169288 CVCL_DP06 PR01003 undefined cell line type CVCL_DP06 CL:0000010 Discontinued: Coriell; PR01003; probable. Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169289 CVCL_E100 NCI-BL1824 transformed cell line human CVCL_E100 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169290 CVCL_DP00 PR00985 transformed cell line CVCL_DP00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; PR00985; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169291 CVCL_DP14 Bre-70 finite cell line human CVCL_DP14 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21169292 CVCL_E114 CSML-0 cancer cell line house mouse CVCL_E114 CL:0000010 Breed/subspecies: A/Sn. Female 21169293 CVCL_DP15 B80-PT3 transformed cell line human CVCL_DP15 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female 21169294 CVCL_E115 EMTOKA cancer cell line human CVCL_E115 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 66 hours (PubMed=8431860) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21169295 CVCL_DP12 Bre-60 finite cell line human CVCL_DP12 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21169296 CVCL_E112 GE1 conditionally immortalized cell line house mouse CVCL_E112 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21169297 CVCL_DP13 Bre-40 finite cell line human CVCL_DP13 CL:0000010 Derived from sampling site: Breast; epithelium. Female 21169298 CVCL_E113 GE6 conditionally immortalized cell line house mouse CVCL_E113 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; gingiva Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Female 21169299 CVCL_DP18 B80-TERT3a telomerase immortalized cell line human CVCL_DP18 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21169300 CVCL_E118 KU-SS-1 cancer cell line human CVCL_E118 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=10961176). Population: Japanese Female Doubling time: 93.8 hours, at 40th passage (PubMed=10961176) 21169301 CVCL_DP19 B80-TERT3b telomerase immortalized cell line human CVCL_DP19 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21169302 CVCL_E119 F3II cancer cell line house mouse CVCL_E119 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Doubling time: 17.7 hours (PubMed=8691844); 22.80 hours (CelloPub=CLPUB00707) 21169303 CVCL_DP16 B80-TERT1 telomerase immortalized cell line human CVCL_DP16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21169304 CVCL_E116 UACC-2561 cancer cell line human CVCL_E116 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=8050085). Male Doubling time: 5 days (PubMed=8050085) 21169305 CVCL_DP17 B80-TERT2 telomerase immortalized cell line human CVCL_DP17 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21169306 CVCL_E117 OV-MZ-22 cancer cell line human CVCL_E117 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938). Female Doubling time: 42 hours (PubMed=11733966) 21169307 CVCL_E110 PPM-Mill cancer cell line human CVCL_E110 CL:0000010 21169308 CVCL_DP10 PR01121 finite cell line CVCL_DP10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; PR01121; probable Female Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169309 CVCL_E111 FAA-HTC1 cancer cell line Norway rat CVCL_E111 CL:0000010 Transformant: 2-acetamidofluorene (2AAF)(ChEBI; CHEBI:17356); Breed/subspecies: Fischer 344/DuCrj. Male 21169310 CVCL_DP11 PR00756 undefined cell line type CVCL_DP11 CL:0000010 Discontinued: Coriell; PR00756; probable. Male Group: Non-human primate cell line; Part of: Integrated Primate Biomaterials and Information Resource (IPBIR) 21169311 CVCL_MK41 BayGenomics ES cell line NPX208 embryonic stem cell house mouse CVCL_MK41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443590; Ddx11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169312 CVCL_MK42 BayGenomics ES cell line NPX210 embryonic stem cell house mouse CVCL_MK42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169313 CVCL_MK40 BayGenomics ES cell line NPX207 embryonic stem cell house mouse CVCL_MK40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385025; Alg12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169314 CVCL_MK38 BayGenomics ES cell line NPX146 embryonic stem cell house mouse CVCL_MK38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2149543; Ubap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169315 CVCL_MK39 BayGenomics ES cell line NPX206 embryonic stem cell house mouse CVCL_MK39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667663; Cep68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169316 CVCL_MK36 BayGenomics ES cell line NPX142 embryonic stem cell house mouse CVCL_MK36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914413; Ccdc47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169317 CVCL_MK37 BayGenomics ES cell line NPX145 embryonic stem cell house mouse CVCL_MK37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919675; Katnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169318 CVCL_MK34 BayGenomics ES cell line NPX139 embryonic stem cell house mouse CVCL_MK34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916740; Zfp524 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169319 CVCL_MK35 BayGenomics ES cell line NPX141 embryonic stem cell house mouse CVCL_MK35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919675; Katnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169320 CVCL_MK32 BayGenomics ES cell line NPX122 embryonic stem cell house mouse CVCL_MK32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95286; Eed Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169321 CVCL_MK33 BayGenomics ES cell line NPX129 embryonic stem cell house mouse CVCL_MK33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914629; Dedd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169322 CVCL_MK52 BayGenomics ES cell line NPX266 embryonic stem cell house mouse CVCL_MK52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919675; Katnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169323 CVCL_MK53 BayGenomics ES cell line NPX268 embryonic stem cell house mouse CVCL_MK53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88139; Bcl2l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169324 CVCL_MK50 BayGenomics ES cell line NPX242 embryonic stem cell house mouse CVCL_MK50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914418; Lpar6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169325 CVCL_MK51 BayGenomics ES cell line NPX246 embryonic stem cell house mouse CVCL_MK51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169326 CVCL_MK49 BayGenomics ES cell line NPX240 embryonic stem cell house mouse CVCL_MK49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169327 CVCL_MK47 BayGenomics ES cell line NPX236 embryonic stem cell house mouse CVCL_MK47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169328 CVCL_MK48 BayGenomics ES cell line NPX238 embryonic stem cell house mouse CVCL_MK48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169329 CVCL_MK45 BayGenomics ES cell line NPX232 embryonic stem cell house mouse CVCL_MK45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097667; Ganab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169330 CVCL_MK46 BayGenomics ES cell line NPX233 embryonic stem cell house mouse CVCL_MK46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169331 CVCL_MK43 BayGenomics ES cell line NPX230 embryonic stem cell house mouse CVCL_MK43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098230; Cenpe Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169332 CVCL_MK44 BayGenomics ES cell line NPX231 embryonic stem cell house mouse CVCL_MK44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922873; Tex30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169333 CVCL_MK20 BayGenomics ES cell line NPX083 embryonic stem cell house mouse CVCL_MK20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922873; Tex30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169334 CVCL_DQ88 CHOPHPS1 induced pluripotent stem cell human CVCL_DQ88 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 5163; HPS1; Simple; p.His497Glnfs (c.1472_1487dup16); ClinVar=VCV000005277; Zygosity=Homozygous (PubMed=27345974) Population: Puerto Rican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169335 CVCL_E288 PANC 253 cancer cell line human CVCL_E288 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169336 CVCL_DQ89 CHOPHPS2 induced pluripotent stem cell human CVCL_DQ89 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; p.Arg509Ter (c.1525C>T); ClinVar=VCV000006377; Zygosity=Heterozygous (PubMed=27345985); Sequence variation: Mutation; HGNC; 566; AP3B1; Simple; p.Glu659Ter (c.1975G>T); ClinVar=VCV000006378; Zygosity=Heterozygous (PubMed=27345985) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169337 CVCL_E289 PANC 480 cancer cell line human CVCL_E289 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169338 CVCL_E282 Panc 02.43 cancer cell line human CVCL_E282 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169339 CVCL_DQ82 GENYOi001-A-1 induced pluripotent stem cell human CVCL_DQ82 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169340 CVCL_E283 PANC 1002 cancer cell line human CVCL_E283 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169341 CVCL_DQ83 WAe009-A-6 embryonic stem cell human CVCL_DQ83 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 2910; DLL4. Female 21169342 CVCL_DQ80 BSS1-PBMC-iPS4F4 induced pluripotent stem cell human CVCL_DQ80 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4444; GP9; Simple; p.Trp87Arg (c.259T>C); ClinVar=VCV001691236; Zygosity=Homozygous (PubMed=27346198) Derived from sampling site: Peripheral blood. Female 21169343 CVCL_E280 JH029 cancer cell line human CVCL_E280 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169344 CVCL_E281 A61-5 cancer cell line human CVCL_E281 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Not specified. Male 21169345 CVCL_DQ81 GENYOi001-A-2 induced pluripotent stem cell human CVCL_DQ81 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 2910; DLL4 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169346 CVCL_DQ86 AHFiPS19 induced pluripotent stem cell house mouse CVCL_DQ86 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.; Breed/subspecies: Mef2c-AHF-Cre x Ai6(RCLZsGreen) transgenic. Male 21169347 CVCL_E286 PANC 215 cancer cell line human CVCL_E286 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169348 CVCL_DQ87 AHFiPS7 induced pluripotent stem cell house mouse CVCL_DQ87 CL:0000010 Derived from sampling site: Tail; tip Cell type=Fibroblast.; Breed/subspecies: Mef2c-AHF-Cre x Ai6(RCLZsGreen) transgenic. Male 21169349 CVCL_E287 PANC 247 cancer cell line human CVCL_E287 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169350 CVCL_MK18 BayGenomics ES cell line NPX071 embryonic stem cell house mouse CVCL_MK18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169351 CVCL_E284 PANC 185 cancer cell line human CVCL_E284 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169352 CVCL_DQ84 WAe009-A-5 embryonic stem cell human CVCL_DQ84 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female 21169353 CVCL_DQ85 A79V-hiPSC induced pluripotent stem cell human CVCL_DQ85 From: University of Copenhagen; Copenhagen; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala79Val (c.236C>T); ClinVar=VCV000018157; Zygosity=Heterozygous (PubMed=27345973) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169354 CVCL_MK19 BayGenomics ES cell line NPX078 embryonic stem cell house mouse CVCL_MK19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169355 CVCL_E285 PANC 198 cancer cell line human CVCL_E285 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169356 CVCL_MK16 BayGenomics ES cell line NPX058 embryonic stem cell house mouse CVCL_MK16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99256; Hdlbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169357 CVCL_MK17 BayGenomics ES cell line NPX067 embryonic stem cell house mouse CVCL_MK17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928373; Dnajc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169358 CVCL_MK14 BayGenomics ES cell line NPX055 embryonic stem cell house mouse CVCL_MK14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855695; Clasrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169359 CVCL_MK15 BayGenomics ES cell line NPX056 embryonic stem cell house mouse CVCL_MK15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169360 CVCL_MK12 BayGenomics ES cell line NPX044 embryonic stem cell house mouse CVCL_MK12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105369; Cbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169361 CVCL_MK13 BayGenomics ES cell line NPX053 embryonic stem cell house mouse CVCL_MK13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923055; Nln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169362 CVCL_MK10 BayGenomics ES cell line NPX039 embryonic stem cell house mouse CVCL_MK10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861380; Sphk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169363 CVCL_MK11 BayGenomics ES cell line NPX040 embryonic stem cell house mouse CVCL_MK11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169364 CVCL_MK30 BayGenomics ES cell line NPX116 embryonic stem cell house mouse CVCL_MK30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385025; Alg12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169365 CVCL_MK31 BayGenomics ES cell line NPX120 embryonic stem cell house mouse CVCL_MK31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169366 CVCL_E299 JD13D cancer cell line human CVCL_E299 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Lung. Male 21169367 CVCL_DQ99 SCA3.B11 induced pluripotent stem cell human CVCL_DQ99 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[78]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=27596958) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169368 CVCL_DQ93 iPSC-FH2.1 induced pluripotent stem cell human CVCL_DQ93 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169369 CVCL_E293 PANC 504 cancer cell line human CVCL_E293 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169370 CVCL_DQ94 LDS-iPSC8 induced pluripotent stem cell human CVCL_DQ94 From: Department of Dermatology, Jikei University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 3801; FOXC2; Simple; c.724_727delCGCAinsAG; Zygosity=Unspecified (PubMed=27346194) Population: Japanese; Derived from sampling site: Cell type=T-cell. Male 21169371 CVCL_E294 TS 0111 cancer cell line human CVCL_E294 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169372 CVCL_DQ91 DL-221 cancer cell line human CVCL_DQ91 CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=27270875); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=27270875); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Arg (c.374C>G); ClinVar=VCV000376667; Zygosity=Heterozygous (PubMed=27270875); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (PubMed=27270875) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 30 hours (PubMed=27270875) 21169373 CVCL_E291 PANC 502 cancer cell line human CVCL_E291 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169374 CVCL_DQ92 I2-12F induced pluripotent stem cell human CVCL_DQ92 From: Edith Nourse Rogers Memorial Veterans Hospital; Bedford; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21169375 CVCL_E292 PANC 503 cancer cell line human CVCL_E292 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169376 CVCL_E297 Panc 09.06.94 cancer cell line human CVCL_E297 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169377 CVCL_DQ97 RtCE-1 spontaneously immortalized cell line Norway rat CVCL_DQ97 CL:0000010 Derived from sampling site: Eye; cornea; epithelium; Breed/subspecies: WAG. Male 21169378 CVCL_E298 Panc 3.014 cancer cell line human CVCL_E298 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male 21169379 CVCL_DQ98 SCA3.A11 induced pluripotent stem cell human CVCL_DQ98 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[83]; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=27596958) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169380 CVCL_MK29 BayGenomics ES cell line NPX111 embryonic stem cell house mouse CVCL_MK29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108515; Cbx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169381 CVCL_DQ95 M146I-hiPSC induced pluripotent stem cell human CVCL_DQ95 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Ile (c.438G>A); ClinVar=VCV000018137; Zygosity=Heterozygous (PubMed=27345998) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169382 CVCL_E295 TS 0129 cancer cell line human CVCL_E295 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Female 21169383 CVCL_DQ96 Oex2054SV.4 induced pluripotent stem cell human CVCL_DQ96 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Gln621Ter (c.1861C>T); Zygosity=Heterozygous (PubMed=27346197) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169384 CVCL_E296 TS 0226 cancer cell line human CVCL_E296 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169385 CVCL_MK27 BayGenomics ES cell line NPX108 embryonic stem cell house mouse CVCL_MK27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169386 CVCL_MK28 BayGenomics ES cell line NPX109 embryonic stem cell house mouse CVCL_MK28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169387 CVCL_MK25 BayGenomics ES cell line NPX096 embryonic stem cell house mouse CVCL_MK25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922974; Ccdc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169388 CVCL_MK26 BayGenomics ES cell line NPX101 embryonic stem cell house mouse CVCL_MK26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101759; Rnf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169389 CVCL_MK23 BayGenomics ES cell line NPX088 embryonic stem cell house mouse CVCL_MK23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924825; Kmt2e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169390 CVCL_MK24 BayGenomics ES cell line NPX089 embryonic stem cell house mouse CVCL_MK24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169391 CVCL_DQ90 CHOPWT10 induced pluripotent stem cell human CVCL_DQ90 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 21169392 CVCL_E290 PANC 486 cancer cell line human CVCL_E290 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169393 CVCL_MK21 BayGenomics ES cell line NPX084 embryonic stem cell house mouse CVCL_MK21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169394 CVCL_MK22 BayGenomics ES cell line NPX086 embryonic stem cell house mouse CVCL_MK22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105125; Eif1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169395 CVCL_DQ68 BJNhem20-pCAG-tdTomato embryonic stem cell human CVCL_DQ68 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Population: Indian Female 21169396 CVCL_E268 GS-DG1 embryonic stem cell house mouse CVCL_E268 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB1968; true Male Characteristics: Germ stem cell line 21169397 CVCL_DQ69 BJNhem20-OCIAD1-CRISPR-39 embryonic stem cell human CVCL_DQ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 16074; OCIAD1. Population: Indian Female 21169398 CVCL_E269 SBOT-3.1 cancer cell line human CVCL_E269 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada. CL:0000010 Female 21169399 CVCL_E266 2TS22C embryonic stem cell house mouse CVCL_E266 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Discontinued: RCB; RCB2690; true Male 21169400 CVCL_DQ66 BJNhem20-OCIAD1-Tet-On embryonic stem cell human CVCL_DQ66 CL:0000010 Transfected with: HGNC; 16074; OCIAD1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Population: Indian Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21169401 CVCL_E267 B6-White embryonic stem cell house mouse CVCL_E267 CL:0000010 Breed/subspecies: C57BL/6 tyrc-2J. Male 21169402 CVCL_DQ67 BJNhem20-TetR embryonic stem cell human CVCL_DQ67 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR. Population: Indian Female 21169403 CVCL_E260 MRC-5 CV1 transformed cell line human CVCL_E260 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21169404 CVCL_DQ60 PH1-Fib-hiPSC4F1 induced pluripotent stem cell human CVCL_DQ60 From: Centro de Investigacion Medica Aplicada (CIMA); Pamplona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Homozygous (PubMed=27345794) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169405 CVCL_E261 HCS-2/8 cancer cell line human CVCL_E261 CL:0000010 Population: Japanese; Derived from sampling site: Bone; humerus. Omics: Transcriptome analysis by ESTs sequencing; Omics: Transcriptome analysis by microarray Male 21169406 CVCL_DQ61 PH1-PBMCs-hiPSC4F1 induced pluripotent stem cell human CVCL_DQ61 From: Centro de Investigacion Medica Aplicada (CIMA); Pamplona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 341; AGXT; Simple; p.Ile244Thr (c.731T>C); ClinVar=VCV000005646; Zygosity=Homozygous (PubMed=27345794) Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169407 CVCL_DQ64 H266 C10 GC induced pluripotent stem cell human CVCL_DQ64 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion_corrected; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The 44 CAG repeat in the ATXN2 gene of the donor has been replaced with a 22 CAG repeat by CRISPR/Cas9 (PubMed=27345815) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169408 CVCL_E264 TCC-MESO-2 cancer cell line human CVCL_E264 CL:0000010 Population: Japanese; Derived from metastatic site: Bone and hypodermis. Male Doubling time: 26.2 hours (PubMed=19876922) 21169409 CVCL_DQ65 H271 C1 GC induced pluripotent stem cell human CVCL_DQ65 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion_corrected; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The 44 CAG repeat in the ATXN2 gene of the donor has been replaced with a 22 CAG repeat by CRISPR/Cas9 (PubMed=27345809) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169410 CVCL_E265 TCC-MESO-3 cancer cell line human CVCL_E265 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 31.3 hours (PubMed=19876922) 21169411 CVCL_E262 HCS-2/A cancer cell line human CVCL_E262 CL:0000010 Population: Japanese; Derived from sampling site: Bone; humerus. Male 21169412 CVCL_DQ62 PG64SV.2 induced pluripotent stem cell human CVCL_DQ62 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9179; POLG; Simple; p.Trp748Ser (c.2243G>C); ClinVar=VCV000013507; Zygosity=Homozygous (PubMed=273457959) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169413 CVCL_DQ63 H196 C7 GC induced pluripotent stem cell human CVCL_DQ63 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion_corrected; p.Gln166[36] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The 36 CAG repeat in the ATXN2 gene of the donor has been replaced with a 22 CAG repeat by CRISPR/Cas9 (PubMed=27345804) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169414 CVCL_E263 TCC-MESO-1 cancer cell line human CVCL_E263 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: 24.5 hours (PubMed=19876922) 21169415 CVCL_E279 JH024 cancer cell line human CVCL_E279 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169416 CVCL_DQ79 V79-G7 spontaneously immortalized cell line CVCL_DQ79 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21169417 CVCL_DQ77 iPS-DP31 4f-1 induced pluripotent stem cell human CVCL_DQ77 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Miscellaneous: Although not directly described in PubMed=20554890, was established at the same time as the other DP31 iPSCs described in that paper (personal communication Koyanagi-Aoi M.) Population: Japanese; Derived from sampling site: Tooth; dental pulp. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169418 CVCL_E277 Panc 02.08 cancer cell line human CVCL_E277 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 Male 21169419 CVCL_DQ78 BVD2-5A2.4 hybridoma CVCL_DQ78 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04141; Human CSF2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9567 21169420 CVCL_E278 Panc 02.05 cancer cell line human CVCL_E278 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female 21169421 CVCL_DQ71 BJNhem20-Asrij embryonic stem cell human CVCL_DQ71 CL:0000010 Transfected with: MGI; MGI:1915345; Ociad1. Population: Indian Female 21169422 CVCL_E271 RCT-1 transformed cell line Norway rat CVCL_E271 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21169423 CVCL_E272 RCT-3 transformed cell line Norway rat CVCL_E272 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21169424 CVCL_DQ72 SV-HCEC transformed cell line human CVCL_DQ72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; temporal lobe; endothelium Cell type=Brain microvascular endothelial cell.. Unspecified 21169425 CVCL_DQ70 BJNhem20-pCAG-EGFP embryonic stem cell human CVCL_DQ70 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Population: Indian Female 21169426 CVCL_E270 IOSE-53 transformed cell line human CVCL_E270 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169427 CVCL_E275 A32-1 cancer cell line human CVCL_E275 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Peritoneum. Female 21169428 CVCL_MK09 BayGenomics ES cell line NPX025 embryonic stem cell house mouse CVCL_MK09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931797; Ckap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169429 CVCL_DQ75 LB129-SLCL cancer cell line human CVCL_DQ75 HLA typing: A*02:01; B*44:02; C*05:01:01,07:11 (IPD-IMGT/HLA=10966) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Mediastinal lymph node. Male 21169430 CVCL_E276 A38-5 cancer cell line human CVCL_E276 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Liver. Male 21169431 CVCL_DQ76 LB37-NSLCL cancer cell line human CVCL_DQ76 HLA typing: A*02,26; B*08,51; C*w02,w07 (PubMed=9872818) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Lymph node. Male 21169432 CVCL_MK07 BayGenomics ES cell line NPX004 embryonic stem cell house mouse CVCL_MK07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934030; Dleu2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169433 CVCL_DQ73 Kuna 14 transformed cell line human CVCL_DQ73 HLA typing: B*35:43,51:10 (IPD-IMGT/HLA=10945) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21169434 CVCL_E273 ROS 2/3 cancer cell line Norway rat CVCL_E273 CL:0000010 Breed/subspecies: ACI 9935. 21169435 CVCL_MK08 BayGenomics ES cell line NPX023 embryonic stem cell house mouse CVCL_MK08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919602; Zfyve27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169436 CVCL_E274 HIO80 transformed cell line human CVCL_E274 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169437 CVCL_DQ74 Kuna 20 transformed cell line human CVCL_DQ74 HLA typing: B*39:11 (IPD-IMGT/HLA=10946) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21169438 CVCL_MK05 BayGenomics ES cell line LST110 embryonic stem cell house mouse CVCL_MK05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169439 CVCL_MK06 BayGenomics ES cell line NPX002 embryonic stem cell house mouse CVCL_MK06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446175; Spryd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169440 CVCL_MK03 BayGenomics ES cell line LST107 embryonic stem cell house mouse CVCL_MK03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169441 CVCL_MK04 BayGenomics ES cell line LST109 embryonic stem cell house mouse CVCL_MK04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891396; Kirrel Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169442 CVCL_MK01 BayGenomics ES cell line LST105 embryonic stem cell house mouse CVCL_MK01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915213; Npc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169443 CVCL_MK02 BayGenomics ES cell line LST106 embryonic stem cell house mouse CVCL_MK02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169444 CVCL_MK00 BayGenomics ES cell line LST104 embryonic stem cell house mouse CVCL_MK00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169445 CVCL_DQ46 CiRA-PD26 induced pluripotent stem cell human CVCL_DQ46 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169446 CVCL_E246 HIO105 transformed cell line human CVCL_E246 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169447 CVCL_DQ47 CiRA-PD27 induced pluripotent stem cell human CVCL_DQ47 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169448 CVCL_E247 HIO107 transformed cell line human CVCL_E247 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (PubMed=11082050) 21169449 CVCL_DQ44 CiRA-PD24 induced pluripotent stem cell human CVCL_DQ44 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169450 CVCL_E244 HIO103 transformed cell line human CVCL_E244 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169451 CVCL_DQ45 CiRA-PD25 induced pluripotent stem cell human CVCL_DQ45 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169452 CVCL_E245 HIO104 transformed cell line human CVCL_E245 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169453 CVCL_DQ48 CiRA-PD28 induced pluripotent stem cell human CVCL_DQ48 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169454 CVCL_E248 HIO113 transformed cell line human CVCL_E248 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169455 CVCL_DQ49 CiRA-PD29 induced pluripotent stem cell human CVCL_DQ49 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169456 CVCL_E249 HIO114 transformed cell line human CVCL_E249 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169457 CVCL_DQ42 CiRA-PD22 induced pluripotent stem cell human CVCL_DQ42 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169458 CVCL_E242 SVOG-4o transformed cell line human CVCL_E242 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21169459 CVCL_DQ43 CiRA-PD23 induced pluripotent stem cell human CVCL_DQ43 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169460 CVCL_E243 HIO102 transformed cell line human CVCL_E243 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169461 CVCL_DQ40 821A1 induced pluripotent stem cell human CVCL_DQ40 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169462 CVCL_E240 IOSE-120 transformed cell line human CVCL_E240 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 45.9 hours (PubMed=10329039) 21169463 CVCL_DQ41 821B1 induced pluripotent stem cell human CVCL_DQ41 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169464 CVCL_E241 SVOG-4m transformed cell line human CVCL_E241 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21169465 CVCL_DQ57 H237 C3 induced pluripotent stem cell human CVCL_DQ57 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Heterozygous (PubMed=27345789) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169466 CVCL_E257 HIO108 transformed cell line human CVCL_E257 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169467 CVCL_DQ58 H236 C6 induced pluripotent stem cell human CVCL_DQ58 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Heterozygous (PubMed=27345791) Donor information: At sampling donor was pre-symptomatic for frontotemporal dementia; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169468 CVCL_E258 HIO115 transformed cell line human CVCL_E258 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169469 CVCL_E255 HIO3173-11 transformed cell line human CVCL_E255 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169470 CVCL_DQ55 vHFF1-iPS4 induced pluripotent stem cell human CVCL_DQ55 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169471 CVCL_DQ56 H251 C3 induced pluripotent stem cell human CVCL_DQ56 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous (PubMed=27345788) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169472 CVCL_E256 HIO106 transformed cell line human CVCL_E256 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169473 CVCL_DQ59 H234 C2 induced pluripotent stem cell human CVCL_DQ59 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu150Pro (c.449T>C); Zygosity=Heterozygous (PubMed=27345792) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169474 CVCL_E259 HIO120 transformed cell line human CVCL_E259 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169475 CVCL_DQ50 DP094 finite cell line human CVCL_DQ50 HLA typing: A*11,11; B*62,62 (PubMed=20554890) CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169476 CVCL_E250 HIO117 transformed cell line human CVCL_E250 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (PubMed=11082050) 21169477 CVCL_DQ53 32R6 induced pluripotent stem cell human CVCL_DQ53 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169478 CVCL_E253 HIO135 transformed cell line human CVCL_E253 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169479 CVCL_DQ54 epiHFF1-B1 induced pluripotent stem cell human CVCL_DQ54 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169480 CVCL_E254 HIO166 transformed cell line human CVCL_E254 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169481 CVCL_DQ51 32R1 induced pluripotent stem cell human CVCL_DQ51 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep proteome analysis Female 21169482 CVCL_E251 HIO118 transformed cell line human CVCL_E251 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (PubMed=11082050) 21169483 CVCL_DQ52 32R2 induced pluripotent stem cell human CVCL_DQ52 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169484 CVCL_E252 HIO121 transformed cell line human CVCL_E252 From: Fox Chase Cancer Center; Philadelphia; USA CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169485 CVCL_VE62 LEIi005-A induced pluripotent stem cell human CVCL_VE62 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Glu700Ter (c.2098G>T); Zygosity=Heterozygous (from autologous cell line LEIi005-B) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169486 CVCL_VE63 MUi015-A induced pluripotent stem cell human CVCL_VE63 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Heterozygous (PubMed=33550139) Population: Southeast Asian; Thai; Karyotypic information: 46,XY,del(13)(q13;q22) (PubMed=33550139); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 21169487 CVCL_VE60 MHHi005-A induced pluripotent stem cell human CVCL_VE60 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169488 CVCL_VE61 LEIi004-A induced pluripotent stem cell human CVCL_VE61 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000950856; Zygosity=Heterozygous (PubMed=29753273); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (PubMed=29753273) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169489 CVCL_VE66 PFIZi006-A induced pluripotent stem cell human CVCL_VE66 From: Pfizer, Inc.; New York; USA CL:0000010 Discontinued: EBiSC; PFIZi006-A; true; Discontinued: ECACC; 66540157; true. Unspecified 21169490 CVCL_VE67 PFIZi007-A induced pluripotent stem cell human CVCL_VE67 From: Pfizer, Inc.; New York; USA CL:0000010 Discontinued: EBiSC; PFIZi007-A; true; Discontinued: ECACC; 66540158; true. Unspecified 21169491 CVCL_VE64 chHES-442 embryonic stem cell human CVCL_VE64 From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 Unspecified 21169492 CVCL_VE65 PFIZi013-B induced pluripotent stem cell human CVCL_VE65 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; PFIZi013-B; true; Discontinued: ECACC; 66540498; true Female 21169493 CVCL_VE68 PFIZi008-A induced pluripotent stem cell human CVCL_VE68 From: Pfizer, Inc.; New York; USA CL:0000010 Discontinued: EBiSC; PFIZi008-A; true; Discontinued: ECACC; 66540160; true. Unspecified 21169494 CVCL_VE69 PFIZi010-A induced pluripotent stem cell human CVCL_VE69 From: Pfizer, Inc.; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21169495 CVCL_VE51 SPG11-22 induced pluripotent stem cell human CVCL_VE51 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Tyr1012Ter (c.3036C>A); ClinVar=VCV001344088; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Ala1933Valfs*18 (c.5798delC); ClinVar=VCV000041328; Zygosity=Heterozygous (PubMed=26971897) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169496 CVCL_VE52 SPG11-31 induced pluripotent stem cell human CVCL_VE52 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Trp89Ter (c.267G>A); ClinVar=VCV000041294; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; c.1457-2A>G; ClinVar=VCV000041272; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=26971897) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169497 CVCL_VE50 SPG11-21 induced pluripotent stem cell human CVCL_VE50 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Tyr1012Ter (c.3036C>A); ClinVar=VCV001344088; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Ala1933Valfs*18 (c.5798delC); ClinVar=VCV000041328; Zygosity=Heterozygous (PubMed=26971897) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169498 CVCL_VE55 SPG11-CTRL-13 induced pluripotent stem cell human CVCL_VE55 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169499 CVCL_VE56 SPG11-CTRL-21 induced pluripotent stem cell human CVCL_VE56 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169500 CVCL_VE53 SPG11-32 induced pluripotent stem cell human CVCL_VE53 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Trp89Ter (c.267G>A); ClinVar=VCV000041294; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; c.1457-2A>G; ClinVar=VCV000041272; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=26971897) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169501 CVCL_VE54 SPG11-CTRL-12 induced pluripotent stem cell human CVCL_VE54 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169502 CVCL_VE59 MHHi004-A induced pluripotent stem cell human CVCL_VE59 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169503 CVCL_VE57 SPG11-CTRL-22 induced pluripotent stem cell human CVCL_VE57 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169504 CVCL_VE58 MHHi003-A induced pluripotent stem cell human CVCL_VE58 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169505 CVCL_VE40 EURACi003-A induced pluripotent stem cell human CVCL_VE40 From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1529; CAV3; Simple; p.Thr78Lys (c.233C>A); ClinVar=VCV000132978; Zygosity=Heterozygous (PubMed=29304398) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21169506 CVCL_VE41 LUBi001-A induced pluripotent stem cell human CVCL_VE41 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; LUBi001-A; true; Discontinued: ECACC; 66540226; true Male 21169507 CVCL_VE44 LUMCi002-C induced pluripotent stem cell human CVCL_VE44 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[47]; Zygosity=Heterozygous; Note=The other allele has 29 repeats (PubMed=29656178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169508 CVCL_VE45 LUMCi003-A induced pluripotent stem cell human CVCL_VE45 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169509 CVCL_VE42 LUMCi002-A induced pluripotent stem cell human CVCL_VE42 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[46]; Zygosity=Heterozygous; Note=The other allele has 29 repeats (PubMed=29656178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169510 CVCL_VE43 LUMCi002-B induced pluripotent stem cell human CVCL_VE43 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[46]; Zygosity=Heterozygous; Note=The other allele has 29 repeats (PubMed=29656178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169511 CVCL_VE48 SPG11-11 induced pluripotent stem cell human CVCL_VE48 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Tyr1012Ter (c.3036C>A); ClinVar=VCV001344088; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Ala1933Valfs*18 (c.5798delC); ClinVar=VCV000041328; Zygosity=Heterozygous (PubMed=26971897) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169512 CVCL_VE49 SPG11-12 induced pluripotent stem cell human CVCL_VE49 CL:0000010 Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Tyr1012Ter (c.3036C>A); ClinVar=VCV001344088; Zygosity=Heterozygous (PubMed=26971897); Sequence variation: Mutation; HGNC; 11226; SPG11; Simple; p.Ala1933Valfs*18 (c.5798delC); ClinVar=VCV000041328; Zygosity=Heterozygous (PubMed=26971897) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169513 CVCL_VE46 LUMCi003-B induced pluripotent stem cell human CVCL_VE46 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169514 CVCL_VE47 SCA3.A8 induced pluripotent stem cell human CVCL_VE47 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[83]; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=27596958) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169515 CVCL_MK98 BayGenomics ES cell line NPX477 embryonic stem cell house mouse CVCL_MK98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919675; Katnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169516 CVCL_MK99 BayGenomics ES cell line NPX480 embryonic stem cell house mouse CVCL_MK99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098703; Sgta Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169517 CVCL_VE30 LSCTRi002-A induced pluripotent stem cell human CVCL_VE30 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2638; CYP3A5; Simple; c.219-237G>A; ClinVar=VCV000226021; Zygosity=Homozygous; Note=Aberrant splice site CYP3A5*3C allele (PubMed=30071395). Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169518 CVCL_VE33 WAe001-A-14 embryonic stem cell human CVCL_VE33 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 321; AGL. Male 21169519 CVCL_VE34 GZMU3Hi001-A induced pluripotent stem cell human CVCL_VE34 From: Guangzhou Medical University; Guangzhou; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Male 21169520 CVCL_VE31 LSCTRi003-A induced pluripotent stem cell human CVCL_VE31 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (PubMed=30071395). Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169521 CVCL_VE32 LSCTRi004-A induced pluripotent stem cell human CVCL_VE32 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169522 CVCL_VE37 WAe009-A-9 embryonic stem cell human CVCL_VE37 From: National Taiwan University; Taipei; Taiwan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3703; FHL2. Female 21169523 CVCL_VE38 EURACi001-A induced pluripotent stem cell human CVCL_VE38 From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1529; CAV3; Simple; p.Tyr62_Thr64del (c.184_192del); Zygosity=Heterozygous (PubMed=29304398) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21169524 CVCL_VE35 TUSMi003-A induced pluripotent stem cell human CVCL_VE35 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21169525 CVCL_VE36 WAe009-A-8 embryonic stem cell human CVCL_VE36 From: National Taiwan University; Taipei; Taiwan CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3703; FHL2. Female 21169526 CVCL_VE39 EURACi002-A induced pluripotent stem cell human CVCL_VE39 From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1529; CAV3; Simple; p.Trp101Cys (c.303G>C); ClinVar=VCV000265072; Zygosity=Heterozygous (PubMed=29304398) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21169527 CVCL_MK85 BayGenomics ES cell line NPX384 embryonic stem cell house mouse CVCL_MK85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914282; Snapc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169528 CVCL_MK86 BayGenomics ES cell line NPX389 embryonic stem cell house mouse CVCL_MK86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932915; Ndel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169529 CVCL_MK83 BayGenomics ES cell line NPX378 embryonic stem cell house mouse CVCL_MK83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140945; Pds5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169530 CVCL_MK84 BayGenomics ES cell line NPX381 embryonic stem cell house mouse CVCL_MK84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929869; Hic2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169531 CVCL_MK81 BayGenomics ES cell line NPX373 embryonic stem cell house mouse CVCL_MK81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928373; Dnajc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169532 CVCL_MK82 BayGenomics ES cell line NPX377 embryonic stem cell house mouse CVCL_MK82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169533 CVCL_MK80 BayGenomics ES cell line NPX372 embryonic stem cell house mouse CVCL_MK80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914629; Dedd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169534 CVCL_VE22 WAe009-A-4 embryonic stem cell human CVCL_VE22 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female 21169535 CVCL_VE23 WAe009-A-7 embryonic stem cell human CVCL_VE23 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: MGI; MGI:96180; Hoxa9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female 21169536 CVCL_VE20 ZZUi006-A induced pluripotent stem cell human CVCL_VE20 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169537 CVCL_VE21 ZZUi011-A induced pluripotent stem cell human CVCL_VE21 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 21169538 CVCL_VE26 NCCSi002-A induced pluripotent stem cell human CVCL_VE26 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Umbilical cord blood. Female 21169539 CVCL_VE27 NCCSi001-A induced pluripotent stem cell human CVCL_VE27 From: National Centre for Cell Science; Pune; India. CL:0000010 21169540 CVCL_VE24 KITi001-A induced pluripotent stem cell human CVCL_VE24 From: Korea Institute of Toxicology; Daejeon; South Korea CL:0000010 Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169541 CVCL_VE25 KITi001-A-35 induced pluripotent stem cell human CVCL_VE25 From: Korea Institute of Toxicology; Daejeon; South Korea CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Characteristics: CRISPR/Cas9-mediated knock-in of a mCherry-Poly A-PGK-neo construct at the C-terminal end of NR1I2/PXR 21169542 CVCL_VE28 SANi004-A induced pluripotent stem cell human CVCL_VE28 From: Sanquin; Amsterdam; Netherlands. CL:0000010 21169543 CVCL_VE29 LSCTRi001-A induced pluripotent stem cell human CVCL_VE29 From: Laboratory of Stem Cells and Tissue Regeneration, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Homozygous; Note=Cryptic splice acceptor activation CYP2C19*2 allele (PubMed=29310059).; Sequence variation: Mutation; HGNC; 2638; CYP3A5; Simple; c.219-237G>A; ClinVar=VCV000226021; Zygosity=Homozygous; Note=Aberrant splice site CYP3A5*3C allele (PubMed=29310059). Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169544 CVCL_MK78 BayGenomics ES cell line NPX366 embryonic stem cell house mouse CVCL_MK78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443590; Ddx11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169545 CVCL_MK79 BayGenomics ES cell line NPX367 embryonic stem cell house mouse CVCL_MK79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146423; Ccdc58 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169546 CVCL_MK76 BayGenomics ES cell line NPX362 embryonic stem cell house mouse CVCL_MK76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349473; Ppp2r5e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169547 CVCL_MK77 BayGenomics ES cell line NPX363 embryonic stem cell house mouse CVCL_MK77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106065; Ppm1g Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169548 CVCL_MK96 BayGenomics ES cell line NPX474 embryonic stem cell house mouse CVCL_MK96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891964; Xrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169549 CVCL_MK97 BayGenomics ES cell line NPX476 embryonic stem cell house mouse CVCL_MK97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321389; Vamp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169550 CVCL_MK94 BayGenomics ES cell line NPX472 embryonic stem cell house mouse CVCL_MK94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3040699; Wdcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169551 CVCL_MK95 BayGenomics ES cell line NPX473 embryonic stem cell house mouse CVCL_MK95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933169; Sacm1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169552 CVCL_MK92 BayGenomics ES cell line NPX451 embryonic stem cell house mouse CVCL_MK92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890645; Nek7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169553 CVCL_MK93 BayGenomics ES cell line NPX467 embryonic stem cell house mouse CVCL_MK93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679003; Dcun1d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169554 CVCL_MK90 BayGenomics ES cell line NPX442 embryonic stem cell house mouse CVCL_MK90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914418; Lpar6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169555 CVCL_MK91 BayGenomics ES cell line NPX444 embryonic stem cell house mouse CVCL_MK91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442579; Frmd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169556 CVCL_VE11 ESi055-A induced pluripotent stem cell human CVCL_VE11 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1241Asp (c.3722G>A); ClinVar=VCV000934057; Zygosity=Hemizygous (PubMed=29150092) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169557 CVCL_VE12 CDIi004-A induced pluripotent stem cell human CVCL_VE12 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21169558 CVCL_VE10 NYSCFe003-A embryonic stem cell human CVCL_VE10 From: New York Stem Cell Foundation; New York; USA CL:0000010 Male Characteristics: Derived in feeder free and antibiotic free conditions. 21169559 CVCL_VE15 WAe001-A-10 embryonic stem cell human CVCL_VE15 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu125Valfs*9 (c.374_380del); Zygosity=Heterozygous (PubMed=29246572). Male 21169560 CVCL_VE16 WAe001-A-11 embryonic stem cell human CVCL_VE16 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1; Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu125Valfs*9 (c.374_380del); Zygosity=Homozygous (PubMed=29246572). Male 21169561 CVCL_VE13 ASUi003-A induced pluripotent stem cell human CVCL_VE13 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=29246571) Derived from sampling site: Peripheral blood. Female 21169562 CVCL_VE14 ASUi004-A induced pluripotent stem cell human CVCL_VE14 From: Arizona State University; Tempe; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=29246571) Derived from sampling site: Peripheral blood. Male 21169563 CVCL_VE19 ZZUi002-A induced pluripotent stem cell human CVCL_VE19 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Problematic cell line: Probably misidentified This cell line is said to originate from the same individual as ZZUi001-A but the STR profiles of these two cell lines are completely different. 21169564 CVCL_VE17 EO771E2 cancer cell line house mouse CVCL_VE17 CL:0000010 Transfected with: HGNC; 3430; ERBB2 Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6. Female 21169565 CVCL_VE18 ZZUi001-A induced pluripotent stem cell human CVCL_VE18 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Problematic cell line: Probably misidentified This cell line is said to originate from the same individual as ZZUi002-A but the STR profiles of these two cell lines are completely different.; Caution: The STR value for D5S818 in PubMed=29246575 is incorrectly reported as 19,20 21169566 CVCL_MK89 BayGenomics ES cell line NPX427 embryonic stem cell house mouse CVCL_MK89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913495; Hspbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169567 CVCL_MK87 BayGenomics ES cell line NPX400 embryonic stem cell house mouse CVCL_MK87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344353; Katna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169568 CVCL_MK88 BayGenomics ES cell line NPX411 embryonic stem cell house mouse CVCL_MK88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385025; Alg12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169569 CVCL_MK63 BayGenomics ES cell line NPX317 embryonic stem cell house mouse CVCL_MK63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934029; Usp8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169570 CVCL_MK64 BayGenomics ES cell line NPX329 embryonic stem cell house mouse CVCL_MK64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344381; Dnajb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169571 CVCL_MK61 BayGenomics ES cell line NPX312 embryonic stem cell house mouse CVCL_MK61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928098; Tspan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169572 CVCL_MK62 BayGenomics ES cell line NPX316 embryonic stem cell house mouse CVCL_MK62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922974; Ccdc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169573 CVCL_MK60 BayGenomics ES cell line NPX305 embryonic stem cell house mouse CVCL_MK60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97803; Ptma Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169574 CVCL_VE00 BJAB HA-MS4A4A cancer cell line human CVCL_VE00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13371; MS4A4A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses the HA tag fused to the N-terminus of MS4A4A/CD20L1; Virology: EBV-negative 21169575 CVCL_VE01 BJAB HA-MS4A8B cancer cell line human CVCL_VE01 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13380; MS4A8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses the HA tag fused to the N-terminus of MS4A8; Virology: EBV-negative 21169576 CVCL_VE04 KSCBi003-A induced pluripotent stem cell human CVCL_VE04 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Omics: SNP array analysis Female 21169577 CVCL_VE05 IOZe001-A embryonic stem cell human CVCL_VE05 From: Institute of Zoology, Chinese Academy of Sciences; Beijing; China. CL:0000010 Female Group: Clinical grade hESC cell line 21169578 CVCL_VE02 DU145-AR cancer cell line human CVCL_VE02 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Brain. Male 21169579 CVCL_VE03 KLRMMEi001-A induced pluripotent stem cell human CVCL_VE03 From: Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Pro3043del (c.9127_9129delTCC); ClinVar=VCV000556050; Zygosity=Homozygous (PubMed=29660607) Population: Chinese; Derived from sampling site: Urine. Male 21169580 CVCL_VE08 NJMUi001-A induced pluripotent stem cell human CVCL_VE08 From: Obstetrics and Gynecology Hospital, Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg111Ter (c.331C>T); ClinVar=VCV000000581; Zygosity=Heterozygous (PubMed=29154227); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Tyr325Ter (c.975C>G); ClinVar=VCV000102921; Zygosity=Heterozygous (PubMed=29154227) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21169581 CVCL_VE09 CM-AS16 cancer cell line human CVCL_VE09 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=29653142) Population: Chinese; Han; Derived from metastatic site: Parotid lymph node. Omics: Deep exome analysis Male Doubling time: ~72 hours (PubMed=29653142) 21169582 CVCL_MK58 BayGenomics ES cell line NPX302 embryonic stem cell house mouse CVCL_MK58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95518; Fgf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169583 CVCL_VE06 IOZe002-A embryonic stem cell human CVCL_VE06 From: Institute of Zoology, Chinese Academy of Sciences; Beijing; China. CL:0000010 Female Group: Clinical grade hESC cell line 21169584 CVCL_MK59 BayGenomics ES cell line NPX304 embryonic stem cell house mouse CVCL_MK59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169585 CVCL_VE07 CCMi001-A induced pluripotent stem cell human CVCL_VE07 From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (PubMed=29127875) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169586 CVCL_MK56 BayGenomics ES cell line NPX274 embryonic stem cell house mouse CVCL_MK56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914462; Mrpl55 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169587 CVCL_MK57 BayGenomics ES cell line NPX275 embryonic stem cell house mouse CVCL_MK57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926465; Hnrnpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169588 CVCL_MK54 BayGenomics ES cell line NPX269 embryonic stem cell house mouse CVCL_MK54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169589 CVCL_MK55 BayGenomics ES cell line NPX272 embryonic stem cell house mouse CVCL_MK55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169590 CVCL_MK74 BayGenomics ES cell line NPX357 embryonic stem cell house mouse CVCL_MK74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861380; Sphk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169591 CVCL_MK75 BayGenomics ES cell line NPX358 embryonic stem cell house mouse CVCL_MK75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345964; Coro1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169592 CVCL_MK72 BayGenomics ES cell line NPX351 embryonic stem cell house mouse CVCL_MK72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384784; Eif4g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169593 CVCL_MK73 BayGenomics ES cell line NPX354 embryonic stem cell house mouse CVCL_MK73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349721; Tob1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169594 CVCL_MK70 BayGenomics ES cell line NPX349 embryonic stem cell house mouse CVCL_MK70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385025; Alg12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169595 CVCL_MK71 BayGenomics ES cell line NPX350 embryonic stem cell house mouse CVCL_MK71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140945; Pds5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169596 CVCL_MK69 BayGenomics ES cell line NPX347 embryonic stem cell house mouse CVCL_MK69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922873; Tex30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169597 CVCL_MK67 BayGenomics ES cell line NPX336 embryonic stem cell house mouse CVCL_MK67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919675; Katnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169598 CVCL_MK68 BayGenomics ES cell line NPX337 embryonic stem cell house mouse CVCL_MK68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144726; Tmem11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169599 CVCL_MK65 BayGenomics ES cell line NPX331 embryonic stem cell house mouse CVCL_MK65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169600 CVCL_MK66 BayGenomics ES cell line NPX332 embryonic stem cell house mouse CVCL_MK66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95606; Xrcc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169601 CVCL_VD92 BJAB GFP-CD20 cancer cell line human CVCL_VD92 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 7315; MS4A1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses GFP fused to the N-terminus of MS4A1/CD20; Virology: EBV-negative 21169602 CVCL_VD93 BJAB GFP-MS4A4A cancer cell line human CVCL_VD93 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13371; MS4A4A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses GFP fused to the N-terminus of MS4A4A/CD20L1; Virology: EBV-negative 21169603 CVCL_VD90 300-19 GFP-MS4A4A cancer cell line house mouse CVCL_VD90 CL:0000010 Transfected with: HGNC; 13371; MS4A4A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NIH Swiss. Characteristics: Expresses GFP fused to the N-terminus of MS4A4A/CD20L1 21169604 CVCL_VD91 300-19 GFP-MS4A8B cancer cell line house mouse CVCL_VD91 CL:0000010 Transfected with: HGNC; 13380; MS4A8; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NIH Swiss. Characteristics: Expresses GFP fused to the N-terminus of MS4A8 21169605 CVCL_VD96 BJAB GFP-MS4A8B cancer cell line human CVCL_VD96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13380; MS4A8; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses GFP fused to the N-terminus of MS4A8; Virology: EBV-negative 21169606 CVCL_VD97 3F2 [Mouse hybridoma against human MS4A4A] hybridoma house mouse CVCL_VD97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JQ5; Human MS4A4A/CD20L1. 21169607 CVCL_VD94 BJAB GFP-MS4A6A cancer cell line human CVCL_VD94 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13375; MS4A6A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses GFP fused to the N-terminus of MS4A6A/CD20L3; Virology: EBV-negative 21169608 CVCL_VD95 BJAB GFP-MS4A7 cancer cell line human CVCL_VD95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 13378; MS4A7; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Expresses GFP fused to the N-terminus of MS4A7/CD20L4; Virology: EBV-negative 21169609 CVCL_VD98 4H2 [Mouse hybridoma against human MS4A4A] hybridoma house mouse CVCL_VD98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JQ5; Human MS4A4A/CD20L1. 21169610 CVCL_VD99 5C12 [Mouse hybridoma against human MS4A4A] hybridoma house mouse CVCL_VD99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q96JQ5; Human MS4A4A/CD20L1. 21169611 CVCL_VD81 IMEDEAi002-B induced pluripotent stem cell human CVCL_VD81 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169612 CVCL_VD82 IMEDEAi003-A induced pluripotent stem cell human CVCL_VD82 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21169613 CVCL_VD80 IMEDEAi002-A induced pluripotent stem cell human CVCL_VD80 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169614 CVCL_VD85 GMP-iPSCs-2 induced pluripotent stem cell human CVCL_VD85 From: Institute of Zoology, Chinese Academy of Sciences; Beijing; China CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169615 CVCL_VD86 IRMBi001-A induced pluripotent stem cell human CVCL_VD86 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Gly217Asp (c.650G>A); ClinVar=VCV000098057; Zygosity=Heterozygous (PubMed=30677723) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169616 CVCL_VD83 INCABRi002-A induced pluripotent stem cell human CVCL_VD83 From: Instituto Nacional de Cancer (INCA); Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 1455; CALR; Simple; p.Lys385Asnfs*47 (c.1154_1155insTTGTC) (CALRins5); Zygosity=Heterozygous (PubMed=30343103); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.437G>A); ClinVar=VCV000634785; Zygosity=Homozygous (PubMed=30343103) Derived from sampling site: Peripheral blood. Male 21169617 CVCL_VD84 GMP-iPSCs-1 induced pluripotent stem cell human CVCL_VD84 From: Institute of Zoology, Chinese Academy of Sciences; Beijing; China CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169618 CVCL_VD89 MDBK DeltaGPI spontaneously immortalized cell line CVCL_VD89 CL:0000010 Transfected with: VGNC; 33356; Bovine PRNP (with p.Ser242_Gly264del) Derived from sampling site: Kidney. Male Characteristics: Expresses a GPI-anchorless prion protein 21169619 CVCL_VD87 IRMBi002-A induced pluripotent stem cell human CVCL_VD87 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Asp694Asn (c.2080G>A); ClinVar=VCV000018101; Zygosity=Heterozygous (PubMed=31004935) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Female 21169620 CVCL_VD88 H157R cancer cell line human CVCL_VD88 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 10540; SAT1; Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35fs*8 (c.102_103insT) (c.103_104insT); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Characteristics: Resistant to the polyamine analog N(1),N(12)-diethylspermine Problematic cell line: Contaminated Parent cell line (NCI-H157) has been shown to be identical to NCI-H1264. 21169621 CVCL_VD70 HUBi007-A induced pluripotent stem cell human CVCL_VD70 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi007-A; true; Discontinued: ECACC; 66540026; true. Male 21169622 CVCL_VD71 HUBi008-A induced pluripotent stem cell human CVCL_VD71 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi008-A; true; Discontinued: ECACC; 66540047; true. 21169623 CVCL_VD74 IMEDEAi001-B induced pluripotent stem cell human CVCL_VD74 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169624 CVCL_VD75 IMEDEAi001-C induced pluripotent stem cell human CVCL_VD75 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169625 CVCL_VD72 IITi001-A induced pluripotent stem cell human CVCL_VD72 From: Technion - Israel Institute of Technology; Haifa; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (PubMed=29653394) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169626 CVCL_VD73 IMEDEAi001-A induced pluripotent stem cell human CVCL_VD73 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21169627 CVCL_VD78 IMEDEAi001-F induced pluripotent stem cell human CVCL_VD78 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169628 CVCL_VD79 IMEDEAi001-G induced pluripotent stem cell human CVCL_VD79 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169629 CVCL_VD76 IMEDEAi001-D induced pluripotent stem cell human CVCL_VD76 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169630 CVCL_VD77 IMEDEAi001-E induced pluripotent stem cell human CVCL_VD77 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=29554588) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169631 CVCL_VD60 ESi057-B induced pluripotent stem cell human CVCL_VD60 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169632 CVCL_VD63 FAMRCi003-A induced pluripotent stem cell human CVCL_VD63 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 21169633 CVCL_VD64 FAMRCi003-B induced pluripotent stem cell human CVCL_VD64 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 21169634 CVCL_VD61 ESi065-A induced pluripotent stem cell human CVCL_VD61 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169635 CVCL_VD62 FAMRCi001-B induced pluripotent stem cell human CVCL_VD62 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Tyr119Metfs*23 (c.354delT); Zygosity=Heterozygous (from autologous cell line FAMRCi001-A); Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Lys859Arg (c.2576A>G); Zygosity=Heterozygous (from autologous cell line FAMRCi001-A) Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 21169636 CVCL_VD67 HUBi004-A induced pluripotent stem cell human CVCL_VD67 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi004-A; true; Discontinued: ECACC; 66540054; true. 21169637 CVCL_VD68 HUBi005-A induced pluripotent stem cell human CVCL_VD68 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi005-A; true; Discontinued: ECACC; 66540055; true. 21169638 CVCL_VD65 HUBi002-A induced pluripotent stem cell human CVCL_VD65 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi002-A; true; Discontinued: ECACC; 66540124; true. 21169639 CVCL_VD66 HUBi003-A induced pluripotent stem cell human CVCL_VD66 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Discontinued: EBiSC; HUBi003-A; true; Discontinued: ECACC; 66540053; true. Female 21169640 CVCL_VD69 HUBi006-A induced pluripotent stem cell human CVCL_VD69 From: The Hubrecht Institute; Utrecht; Netherlands. CL:0000010 21169641 CVCL_VD52 ESi058-B induced pluripotent stem cell human CVCL_VD52 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169642 CVCL_VD53 ESi047-A induced pluripotent stem cell human CVCL_VD53 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 2597; CYP1B1; Simple; p.Lys468_Ser476dup (c.1403_1429dupAGAAAGTTCTTCGCCAATGCACCGCCT); dbSNP=rs72549373; Zygosity=Homozygous (PubMed=29453128) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169643 CVCL_VD50 ESi060-B induced pluripotent stem cell human CVCL_VD50 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169644 CVCL_VD51 ESi059-B induced pluripotent stem cell human CVCL_VD51 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169645 CVCL_VD56 ESi050-A induced pluripotent stem cell human CVCL_VD56 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169646 CVCL_VD57 ESi051-A induced pluripotent stem cell human CVCL_VD57 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169647 CVCL_VD54 ESi048-A induced pluripotent stem cell human CVCL_VD54 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169648 CVCL_VD55 ESi049-A induced pluripotent stem cell human CVCL_VD55 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169649 CVCL_VD58 ESi052-A induced pluripotent stem cell human CVCL_VD58 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169650 CVCL_VD59 ESi053-A induced pluripotent stem cell human CVCL_VD59 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169651 CVCL_DQ24 711A6 induced pluripotent stem cell human CVCL_DQ24 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169652 CVCL_E224 KC02-44D telomerase immortalized cell line human CVCL_E224 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Population: Japanese; Derived from sampling site: Endometrium. Female 21169653 CVCL_DQ25 711C1 induced pluripotent stem cell human CVCL_DQ25 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169654 CVCL_E225 S10 spontaneously immortalized cell line house mouse CVCL_E225 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified 21169655 CVCL_DQ22 703B1 induced pluripotent stem cell human CVCL_DQ22 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169656 CVCL_E222 G4 [Mouse ESC] embryonic stem cell house mouse CVCL_E222 CL:0000010 Breed/subspecies: C57BL/6Ncr x 129S6/SvEvTac. Male 21169657 CVCL_DQ23 711A1 induced pluripotent stem cell human CVCL_DQ23 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169658 CVCL_E223 G4-2 embryonic stem cell house mouse CVCL_E223 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: 129P2/Ola. Male 21169659 CVCL_DQ28 751A3 induced pluripotent stem cell human CVCL_DQ28 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169660 CVCL_E228 IOSE-121 transformed cell line human CVCL_E228 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 35.3 hours (PubMed=10329039) 21169661 CVCL_DQ29 751B4 induced pluripotent stem cell human CVCL_DQ29 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169662 CVCL_E229 IOSE-385 transformed cell line human CVCL_E229 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169663 CVCL_DQ26 744A2 induced pluripotent stem cell human CVCL_DQ26 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169664 CVCL_E226 S17 spontaneously immortalized cell line house mouse CVCL_E226 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/cAn. Unspecified 21169665 CVCL_DQ27 744B9 induced pluripotent stem cell human CVCL_DQ27 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21169666 CVCL_E227 IOSE-7576 transformed cell line human CVCL_E227 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Deep proteome analysis Female 21169667 CVCL_DQ20 692D2 induced pluripotent stem cell human CVCL_DQ20 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21169668 CVCL_E220 DAc8 embryonic stem cell Norway rat CVCL_E220 CL:0000010 Breed/subspecies: Dark Agouti. Male 21169669 CVCL_DQ21 703A1 induced pluripotent stem cell human CVCL_DQ21 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169670 CVCL_E221 DAc2 embryonic stem cell Norway rat CVCL_E221 CL:0000010 Breed/subspecies: Dark Agouti. Female 21169671 CVCL_DQ35 346E2 induced pluripotent stem cell human CVCL_DQ35 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169672 CVCL_E235 Sld1 stromal cell line house mouse CVCL_E235 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (WC x C57BL/6)-Sl/Sld. Unspecified 21169673 CVCL_DQ36 346F1 induced pluripotent stem cell human CVCL_DQ36 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169674 CVCL_E236 Sld2 stromal cell line house mouse CVCL_E236 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (WC x C57BL/6)-Sl/Sld. Unspecified 21169675 CVCL_DQ33 346D1 induced pluripotent stem cell human CVCL_DQ33 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169676 CVCL_E233 OKT1 cancer cell line human CVCL_E233 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Doubling time: ~27 hours (PubMed=9826457) 21169677 CVCL_DQ34 346E1 induced pluripotent stem cell human CVCL_DQ34 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169678 CVCL_E234 IOSE-523 transformed cell line human CVCL_E234 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169679 CVCL_DQ39 798B2 induced pluripotent stem cell human CVCL_DQ39 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169680 CVCL_E239 IMCC5 transformed cell line human CVCL_E239 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 21169681 CVCL_DQ37 363G1 induced pluripotent stem cell human CVCL_DQ37 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21169682 CVCL_E237 Sld3 stromal cell line house mouse CVCL_E237 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: (WC x C57BL/6)-Sl/Sld. Unspecified 21169683 CVCL_DQ38 798A3 induced pluripotent stem cell human CVCL_DQ38 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169684 CVCL_E238 IMCC3 transformed cell line human CVCL_E238 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 21169685 CVCL_DQ31 427F1 induced pluripotent stem cell human CVCL_DQ31 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169686 CVCL_E231 ROS 25/1 cancer cell line Norway rat CVCL_E231 CL:0000010 Breed/subspecies: ACI 9935. 21169687 CVCL_DQ32 622C1 induced pluripotent stem cell human CVCL_DQ32 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21169688 CVCL_E232 HOSE1-E7/hTERT transformed cell line human CVCL_E232 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169689 CVCL_DQ30 648A1 induced pluripotent stem cell human CVCL_DQ30 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21169690 CVCL_E230 IOSE-386 transformed cell line human CVCL_E230 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21169691 CVCL_DQ08 604A1 induced pluripotent stem cell human CVCL_DQ08 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169692 CVCL_E208 SOE00365IN transformed cell line CVCL_E208 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169693 CVCL_DQ09 604A3 induced pluripotent stem cell human CVCL_DQ09 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169694 CVCL_E209 SOE00366IN transformed cell line CVCL_E209 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169695 CVCL_DQ02 454C2 induced pluripotent stem cell human CVCL_DQ02 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169696 CVCL_E202 PTR00323IN transformed cell line CVCL_E202 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Verus. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169697 CVCL_DQ03 454D1 induced pluripotent stem cell human CVCL_DQ03 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169698 CVCL_E203 PTR00324IN transformed cell line CVCL_E203 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Verus. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169699 CVCL_DQ00 BCC/P cancer cell line human CVCL_DQ00 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21169700 CVCL_E200 PTR00320IN transformed cell line CVCL_E200 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Schweinfurthii. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169701 CVCL_DQ01 454B1 induced pluripotent stem cell human CVCL_DQ01 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169702 CVCL_E201 PTR00321IN transformed cell line CVCL_E201 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169703 CVCL_DQ06 585A1 induced pluripotent stem cell human CVCL_DQ06 HLA typing: A*24:02; B*07:02,52:01; C*07:02,12:02; DRB1*01:01,15:01 (PubMed=30853558) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21169704 CVCL_E206 SOE00363IN transformed cell line CVCL_E206 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169705 CVCL_DQ07 585B1 induced pluripotent stem cell human CVCL_DQ07 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169706 CVCL_E207 SOE00364IN transformed cell line CVCL_E207 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169707 CVCL_DQ04 454F1 induced pluripotent stem cell human CVCL_DQ04 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169708 CVCL_E204 PTR00325IN transformed cell line CVCL_E204 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Verus. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169709 CVCL_DQ05 457C1 induced pluripotent stem cell human CVCL_DQ05 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21169710 CVCL_E205 PTR00355IN transformed cell line CVCL_E205 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood; Breed/subspecies: Verus. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169711 CVCL_DQ19 665A7 induced pluripotent stem cell human CVCL_DQ19 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169712 CVCL_E219 NAB-2 cancer cell line human CVCL_E219 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Array-based CGH. Female Virology: The single copy EBV genome is integrated on chromosome 2p13 between REL and BCL11A 21169713 CVCL_DQ13 610A2 induced pluripotent stem cell human CVCL_DQ13 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169714 CVCL_E213 MDAH087 cancer cell line human CVCL_E213 CL:0000010 Male 21169715 CVCL_DQ14 610B1 induced pluripotent stem cell human CVCL_DQ14 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169716 CVCL_E214 MDAH172 cancer cell line human CVCL_E214 CL:0000010 Female 21169717 CVCL_DQ11 606A1 induced pluripotent stem cell human CVCL_DQ11 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169718 CVCL_E211 SOE00368IN transformed cell line CVCL_E211 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169719 CVCL_DQ12 606B1 induced pluripotent stem cell human CVCL_DQ12 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21169720 CVCL_E212 MDAH041 cancer cell line human CVCL_E212 CL:0000010 Female 21169721 CVCL_DQ17 648B1 induced pluripotent stem cell human CVCL_DQ17 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21169722 CVCL_E217 NLF cancer cell line human CVCL_E217 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Met (c.1571G>T); Zygosity=Heterozygous (PubMed=16822308) Omics: Array-based CGH; Omics: N-glycan profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21169723 CVCL_DQ18 665A1 induced pluripotent stem cell human CVCL_DQ18 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169724 CVCL_E218 NB-EbC1 cancer cell line human CVCL_E218 CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=20922763) Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21169725 CVCL_DQ15 622E1 induced pluripotent stem cell human CVCL_DQ15 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169726 CVCL_E215 MDAH174 cancer cell line human CVCL_E215 CL:0000010 Female 21169727 CVCL_DQ16 622G1 induced pluripotent stem cell human CVCL_DQ16 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169728 CVCL_E216 NB-1771 cancer cell line human CVCL_E216 CL:0000010 Unspecified 21169729 CVCL_DQ10 604B1 induced pluripotent stem cell human CVCL_DQ10 HLA typing: A*01:01,24:02; B*07:02,37:01; C*06:02,07:02; DQA1*01:01,03:03; DQB1*03:03,05:01; DRB1*01:01 (PubMed=30853558) From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21169730 CVCL_E210 SOE00367IN transformed cell line CVCL_E210 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line; Part of: INPRIMAT consortium primate cell line collection 21169731 CVCL_ML62 BayGenomics ES cell line PST098 embryonic stem cell house mouse CVCL_ML62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169732 CVCL_ML63 BayGenomics ES cell line PST099 embryonic stem cell house mouse CVCL_ML63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169733 CVCL_ML60 BayGenomics ES cell line PST095 embryonic stem cell house mouse CVCL_ML60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169734 CVCL_ML61 BayGenomics ES cell line PST096 embryonic stem cell house mouse CVCL_ML61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169735 CVCL_VF00 STiPS-B004 induced pluripotent stem cell human CVCL_VF00 From: STEMCELL Technologies, Inc.; Vancouver; Canada. CL:0000010 21169736 CVCL_VF03 UAMi003-A induced pluripotent stem cell human CVCL_VF03 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Ile96Thr (c.287T>C); ClinVar=VCV000218323; Zygosity=Heterozygous (PubMed=29660608); Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Ser174Cysfs*23 (c.584G>A); Zygosity=Heterozygous (PubMed=29660608) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169737 CVCL_VF04 SMBCi001-A induced pluripotent stem cell human CVCL_VF04 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Derived from sampling site: Amniotic fluid. Male 21169738 CVCL_VF01 SCA3.B1 induced pluripotent stem cell human CVCL_VF01 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[78]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=27596958) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169739 CVCL_VF02 UAMi002-A induced pluripotent stem cell human CVCL_VF02 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Ile96Thr (c.287T>C); ClinVar=VCV000218323; Zygosity=Heterozygous (PubMed=29660608); Sequence variation: Mutation; HGNC; 19331; MMAB; Simple; p.Ser174Cysfs*23 (c.584G>A); Zygosity=Heterozygous (PubMed=29660608) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21169740 CVCL_ML59 BayGenomics ES cell line PST094 embryonic stem cell house mouse CVCL_ML59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298218; Lrp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169741 CVCL_VF07 TRDSi004-A induced pluripotent stem cell human CVCL_VF07 From: Technion Research and Development Foundation; Haifa; Israel CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169742 CVCL_VF08 TUMi001-A induced pluripotent stem cell human CVCL_VF08 From: Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169743 CVCL_ML57 BayGenomics ES cell line PST092 embryonic stem cell house mouse CVCL_ML57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169744 CVCL_VF05 TRDSi001-A induced pluripotent stem cell human CVCL_VF05 From: Technion Research and Development Foundation; Haifa; Israel CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169745 CVCL_ML58 BayGenomics ES cell line PST093 embryonic stem cell house mouse CVCL_ML58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169746 CVCL_VF06 TRDSi003-A induced pluripotent stem cell human CVCL_VF06 From: Technion Research and Development Foundation; Haifa; Israel. CL:0000010 Female 21169747 CVCL_ML55 BayGenomics ES cell line PST089 embryonic stem cell house mouse CVCL_ML55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929269; Tmed2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169748 CVCL_ML56 BayGenomics ES cell line PST090 embryonic stem cell house mouse CVCL_ML56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169749 CVCL_ML53 BayGenomics ES cell line PST087 embryonic stem cell house mouse CVCL_ML53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95835; Hspa5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169750 CVCL_VF09 RB182 finite cell line human CVCL_VF09 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169751 CVCL_ML54 BayGenomics ES cell line PST088 embryonic stem cell house mouse CVCL_ML54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169752 CVCL_ML73 BayGenomics ES cell line PST112 embryonic stem cell house mouse CVCL_ML73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341628; Atrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169753 CVCL_ML74 BayGenomics ES cell line PST113 embryonic stem cell house mouse CVCL_ML74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169754 CVCL_ML71 BayGenomics ES cell line PST108 embryonic stem cell house mouse CVCL_ML71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169755 CVCL_ML72 BayGenomics ES cell line PST111 embryonic stem cell house mouse CVCL_ML72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919293; Sulf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169756 CVCL_ML70 BayGenomics ES cell line PST107 embryonic stem cell house mouse CVCL_ML70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169757 CVCL_ML68 BayGenomics ES cell line PST105 embryonic stem cell house mouse CVCL_ML68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914262; Tm9sf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169758 CVCL_ML69 BayGenomics ES cell line PST106 embryonic stem cell house mouse CVCL_ML69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169759 CVCL_ML66 BayGenomics ES cell line PST103 embryonic stem cell house mouse CVCL_ML66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169760 CVCL_ML67 BayGenomics ES cell line PST104 embryonic stem cell house mouse CVCL_ML67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169761 CVCL_ML64 BayGenomics ES cell line PST100 embryonic stem cell house mouse CVCL_ML64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919293; Sulf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169762 CVCL_ML65 BayGenomics ES cell line PST102 embryonic stem cell house mouse CVCL_ML65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102493; mt-Rnr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169763 CVCL_ML40 BayGenomics ES cell line PST061 embryonic stem cell house mouse CVCL_ML40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169764 CVCL_ML41 BayGenomics ES cell line PST063 embryonic stem cell house mouse CVCL_ML41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169765 CVCL_ML39 BayGenomics ES cell line PST059 embryonic stem cell house mouse CVCL_ML39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169766 CVCL_ML37 BayGenomics ES cell line PST055 embryonic stem cell house mouse CVCL_ML37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349164; Sdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169767 CVCL_ML38 BayGenomics ES cell line PST058 embryonic stem cell house mouse CVCL_ML38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169768 CVCL_ML35 BayGenomics ES cell line PST043 embryonic stem cell house mouse CVCL_ML35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347007; Plod2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169769 CVCL_ML36 BayGenomics ES cell line PST046 embryonic stem cell house mouse CVCL_ML36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917611; Lman1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169770 CVCL_ML33 BayGenomics ES cell line PST038 embryonic stem cell house mouse CVCL_ML33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98277; Epha4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169771 CVCL_ML34 BayGenomics ES cell line PST040 embryonic stem cell house mouse CVCL_ML34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913863; Pigk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169772 CVCL_ML31 BayGenomics ES cell line PST036 embryonic stem cell house mouse CVCL_ML31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169773 CVCL_ML32 BayGenomics ES cell line PST037 embryonic stem cell house mouse CVCL_ML32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169774 CVCL_ML51 BayGenomics ES cell line PST084 embryonic stem cell house mouse CVCL_ML51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96743; Lamb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169775 CVCL_ML52 BayGenomics ES cell line PST086 embryonic stem cell house mouse CVCL_ML52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95566; Fn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169776 CVCL_ML50 BayGenomics ES cell line PST080 embryonic stem cell house mouse CVCL_ML50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96955; Slc3a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169777 CVCL_ML48 BayGenomics ES cell line PST078 embryonic stem cell house mouse CVCL_ML48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107373; Dnajc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169778 CVCL_ML49 BayGenomics ES cell line PST079 embryonic stem cell house mouse CVCL_ML49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169779 CVCL_ML46 BayGenomics ES cell line PST073 embryonic stem cell house mouse CVCL_ML46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196458; Scarb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169780 CVCL_ML47 BayGenomics ES cell line PST076 embryonic stem cell house mouse CVCL_ML47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97750; Ppib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169781 CVCL_ML44 BayGenomics ES cell line PST069 embryonic stem cell house mouse CVCL_ML44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169782 CVCL_ML45 BayGenomics ES cell line PST072 embryonic stem cell house mouse CVCL_ML45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169783 CVCL_ML42 BayGenomics ES cell line PST065 embryonic stem cell house mouse CVCL_ML42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97364; Notch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169784 CVCL_ML43 BayGenomics ES cell line PST066 embryonic stem cell house mouse CVCL_ML43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105377; Adam19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169785 CVCL_E389 233 BLCL transformed cell line human CVCL_E389 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21169786 CVCL_DR89 PaKiT03 transformed cell line CVCL_DR89 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by RNAseq Group: Bat cell line 21169787 CVCL_E387 227 BLCL transformed cell line human CVCL_E387 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169788 CVCL_DR87 PaKiT01 transformed cell line CVCL_DR87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21169789 CVCL_E388 230 BLCL transformed cell line human CVCL_E388 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169790 CVCL_DR88 PaKiT02 transformed cell line CVCL_DR88 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 21169791 CVCL_E381 219 BLCL transformed cell line human CVCL_E381 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169792 CVCL_DR81 PaFeT05 transformed cell line CVCL_DR81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169793 CVCL_E382 220 BLCL transformed cell line human CVCL_E382 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169794 CVCL_DR82 PaFeT06 transformed cell line CVCL_DR82 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169795 CVCL_E380 216 BLCL transformed cell line human CVCL_E380 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169796 CVCL_DR80 PaFeT04 transformed cell line CVCL_DR80 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169797 CVCL_E385 224 BLCL transformed cell line human CVCL_E385 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169798 CVCL_ML19 BayGenomics ES cell line PST005 embryonic stem cell house mouse CVCL_ML19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169799 CVCL_DR85 PaFeT09 transformed cell line CVCL_DR85 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169800 CVCL_E386 225 BLCL transformed cell line human CVCL_E386 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21169801 CVCL_DR86 PaFeT10 transformed cell line CVCL_DR86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169802 CVCL_E383 222 BLCL transformed cell line human CVCL_E383 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169803 CVCL_ML17 BayGenomics ES cell line PST002 embryonic stem cell house mouse CVCL_ML17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169804 CVCL_DR83 PaFeT07 transformed cell line CVCL_DR83 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169805 CVCL_E384 223 BLCL transformed cell line human CVCL_E384 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169806 CVCL_ML18 BayGenomics ES cell line PST004 embryonic stem cell house mouse CVCL_ML18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104556; Cdkn1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169807 CVCL_DR84 PaFeT08 transformed cell line CVCL_DR84 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169808 CVCL_ML15 BayGenomics ES cell line NST020 embryonic stem cell house mouse CVCL_ML15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169809 CVCL_ML16 BayGenomics ES cell line NST024 embryonic stem cell house mouse CVCL_ML16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104864; Pdia4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169810 CVCL_ML13 BayGenomics ES cell line NST003 embryonic stem cell house mouse CVCL_ML13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336175; Kcnk5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169811 CVCL_ML14 BayGenomics ES cell line NST005 embryonic stem cell house mouse CVCL_ML14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97004; Mme Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169812 CVCL_ML11 BayGenomics ES cell line NST001 embryonic stem cell house mouse CVCL_ML11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107658; Ifnar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169813 CVCL_ML12 BayGenomics ES cell line NST002 embryonic stem cell house mouse CVCL_ML12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96560; Il6st Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169814 CVCL_ML10 BayGenomics ES cell line NPX505 embryonic stem cell house mouse CVCL_ML10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914234; Med19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169815 CVCL_ML30 BayGenomics ES cell line PST035 embryonic stem cell house mouse CVCL_ML30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169816 CVCL_E398 256 BLCL transformed cell line human CVCL_E398 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169817 CVCL_DR98 CHO CAT-S spontaneously immortalized cell line CVCL_DR98 CL:0000010 Derived from sampling site: Ovary. Omics: Deep proteome analysis Female Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 10090201 21169818 CVCL_E399 257 BLCL transformed cell line human CVCL_E399 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169819 CVCL_DR99 MCF-7/Twist cancer cell line human CVCL_DR99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12428; TWIST1 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21169820 CVCL_E392 242 BLCL transformed cell line human CVCL_E392 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169821 CVCL_DR92 PaLuT03 transformed cell line CVCL_DR92 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21169822 CVCL_E393 245 BLCL transformed cell line human CVCL_E393 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169823 CVCL_DR93 PaLuT04 transformed cell line CVCL_DR93 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21169824 CVCL_E390 234 BLCL transformed cell line human CVCL_E390 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169825 CVCL_DR90 PaLuT01 transformed cell line CVCL_DR90 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21169826 CVCL_E391 239 BLCL transformed cell line human CVCL_E391 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169827 CVCL_DR91 PaLuT02 transformed cell line CVCL_DR91 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung. Group: Bat cell line 21169828 CVCL_E396 251 BLCL transformed cell line human CVCL_E396 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169829 CVCL_DR96 Potelligent CHOK1SV spontaneously immortalized cell line CVCL_DR96 CL:0000010 Knockout cell: Method=ZFN; UniProtKB; G3HCE4; Fut8 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21169830 CVCL_E397 252 BLCL transformed cell line human CVCL_E397 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169831 CVCL_DR97 CHOK1SV GS KO spontaneously immortalized cell line CVCL_DR97 CL:0000010 Knockout cell: Method=ZFN; UniProtKB; P04773; Glul Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21169832 CVCL_E394 246 BLCL transformed cell line human CVCL_E394 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169833 CVCL_DR94 293/ACE2 transformed cell line human CVCL_DR94 CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: Deep proteome analysis Female Group: SARS-CoV-2 research cell line 21169834 CVCL_ML28 BayGenomics ES cell line PST033 embryonic stem cell house mouse CVCL_ML28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99460; Notch3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169835 CVCL_E395 247 BLCL transformed cell line human CVCL_E395 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169836 CVCL_ML29 BayGenomics ES cell line PST034 embryonic stem cell house mouse CVCL_ML29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169837 CVCL_DR95 CHOK1SV spontaneously immortalized cell line CVCL_DR95 CL:0000010 Derived from sampling site: Ovary. Omics: Deep proteome analysis Female Characteristics: Compared to CHO-K1, this cell line is adapted to growth in suspension and protein-free medium Group: Serum/protein free medium cell line 21169838 CVCL_ML26 BayGenomics ES cell line PST026 embryonic stem cell house mouse CVCL_ML26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87961; Agrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169839 CVCL_ML27 BayGenomics ES cell line PST027 embryonic stem cell house mouse CVCL_ML27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169840 CVCL_ML24 BayGenomics ES cell line PST024 embryonic stem cell house mouse CVCL_ML24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169841 CVCL_ML25 BayGenomics ES cell line PST025 embryonic stem cell house mouse CVCL_ML25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914186; Asph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169842 CVCL_ML22 BayGenomics ES cell line PST009 embryonic stem cell house mouse CVCL_ML22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039616; Znrf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169843 CVCL_ML23 BayGenomics ES cell line PST019 embryonic stem cell house mouse CVCL_ML23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97513; Furin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169844 CVCL_ML20 BayGenomics ES cell line PST007 embryonic stem cell house mouse CVCL_ML20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384573; Ttc13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169845 CVCL_ML21 BayGenomics ES cell line PST008 embryonic stem cell house mouse CVCL_ML21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99892; Lama1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169846 CVCL_E367 196 BLCL transformed cell line human CVCL_E367 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169847 CVCL_DR67 PaBrH01 telomerase immortalized cell line CVCL_DR67 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169848 CVCL_E368 197 BLCL transformed cell line human CVCL_E368 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169849 CVCL_DR68 PaBrH02 telomerase immortalized cell line CVCL_DR68 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169850 CVCL_E365 193 BLCL transformed cell line human CVCL_E365 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169851 CVCL_DR65 SupB15RT cancer cell line human CVCL_DR65 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Bone marrow. Omics: HLA class I peptidome analysis by proteomics Male 21169852 CVCL_E366 194 BLCL transformed cell line human CVCL_E366 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169853 CVCL_DR66 CD114 transformed cell line human CVCL_DR66 HLA typing: DPB1*01:01,04:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*01:01 (PubMed=25502872) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: HLA class II peptidome analysis by proteomics. Unspecified 21169854 CVCL_E369 199 BLCL transformed cell line human CVCL_E369 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169855 CVCL_DR69 PaBrH03 telomerase immortalized cell line CVCL_DR69 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169856 CVCL_E360 166 BLCL transformed cell line human CVCL_E360 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169857 CVCL_DR60 GSC8-11 cancer cell line human CVCL_DR60 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21169858 CVCL_E363 170 BLCL transformed cell line human CVCL_E363 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169859 CVCL_DR63 M4T.6 transformed cell line house mouse CVCL_DR63 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: SJL/J. Male Doubling time: ~24 hours (PubMed=12948546) 21169860 CVCL_E364 183 BLCL transformed cell line human CVCL_E364 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169861 CVCL_DR64 PFV spontaneously immortalized cell line pig CVCL_DR64 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Gottingen minipig. Male Characteristics: Transfected with a construct that contains a Sleeping Beauty (SB) DNA transposon, a puromycin resistance gene, an EGFP reporter gene and an Flp recombinase site for locus-directed gene insertion 21169862 CVCL_E361 167 BLCL transformed cell line human CVCL_E361 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169863 CVCL_DR61 J.CaM2.5 cancer cell line human CVCL_DR61 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 18874; LAT; Simple; g.237C>T; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 18874; LAT; Simple; p.Thr56Met (c.167C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Cesium-137 gamma radiation(NCIt; C129643); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21169864 CVCL_E362 168 BLCL transformed cell line human CVCL_E362 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169865 CVCL_DR62 M4T.4 transformed cell line house mouse CVCL_DR62 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: SJL/J. Male Doubling time: ~24 hours (PubMed=12948546) 21169866 CVCL_E378 214 BLCL transformed cell line human CVCL_E378 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169867 CVCL_DR78 PaFeT02 transformed cell line CVCL_DR78 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169868 CVCL_E379 215 BLCL transformed cell line human CVCL_E379 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169869 CVCL_DR79 PaFeT03 transformed cell line CVCL_DR79 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169870 CVCL_E376 212 BLCL transformed cell line human CVCL_E376 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169871 CVCL_DR76 PaBrT03 transformed cell line CVCL_DR76 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21169872 CVCL_E377 213 BLCL transformed cell line human CVCL_E377 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169873 CVCL_DR77 PaFeT01 transformed cell line CVCL_DR77 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Unspecified Group: Bat cell line 21169874 CVCL_E370 200 BLCL transformed cell line human CVCL_E370 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169875 CVCL_DR70 PaBrH04 telomerase immortalized cell line CVCL_DR70 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169876 CVCL_E371 201 BLCL transformed cell line human CVCL_E371 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169877 CVCL_DR71 PaBrH05 telomerase immortalized cell line CVCL_DR71 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169878 CVCL_E374 205 BLCL transformed cell line human CVCL_E374 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169879 CVCL_ML08 BayGenomics ES cell line NPX499 embryonic stem cell house mouse CVCL_ML08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385142; Mettl8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169880 CVCL_DR74 PaBrT01 transformed cell line CVCL_DR74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21169881 CVCL_E375 211 BLCL transformed cell line human CVCL_E375 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169882 CVCL_ML09 BayGenomics ES cell line NPX503 embryonic stem cell house mouse CVCL_ML09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861746; Lmbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169883 CVCL_DR75 PaBrT02 transformed cell line CVCL_DR75 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Group: Bat cell line 21169884 CVCL_E372 202 BLCL transformed cell line human CVCL_E372 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169885 CVCL_ML06 BayGenomics ES cell line NPX496 embryonic stem cell house mouse CVCL_ML06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169886 CVCL_DR72 PaBrH06 telomerase immortalized cell line CVCL_DR72 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169887 CVCL_E373 203 BLCL transformed cell line human CVCL_E373 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21169888 CVCL_ML07 BayGenomics ES cell line NPX497 embryonic stem cell house mouse CVCL_ML07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922974; Ccdc18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169889 CVCL_DR73 PaBrH07 telomerase immortalized cell line CVCL_DR73 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Brain. Group: Bat cell line 21169890 CVCL_ML04 BayGenomics ES cell line NPX493 embryonic stem cell house mouse CVCL_ML04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3712454; Zfp980 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169891 CVCL_ML05 BayGenomics ES cell line NPX494 embryonic stem cell house mouse CVCL_ML05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913543; Snhg16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169892 CVCL_ML02 BayGenomics ES cell line NPX490 embryonic stem cell house mouse CVCL_ML02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915358; Snhg17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169893 CVCL_ML03 BayGenomics ES cell line NPX491 embryonic stem cell house mouse CVCL_ML03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444450; Fbxl18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169894 CVCL_ML00 BayGenomics ES cell line NPX481 embryonic stem cell house mouse CVCL_ML00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923055; Nln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169895 CVCL_ML01 BayGenomics ES cell line NPX487 embryonic stem cell house mouse CVCL_ML01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914282; Snapc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169896 CVCL_VF80 ESi062-A induced pluripotent stem cell human CVCL_VF80 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection Caution: Indicated as originating from a 4 year old boy in PubMed=29499498, but this cell line was derived from CCD-1112Sk which is from a newborn male 21169897 CVCL_VF83 NERCe003-A-1 embryonic stem cell human CVCL_VF83 CL:0000010 Male Characteristics: Unpon doxycycline-induction expresses CTNNB1. 21169898 CVCL_VF84 NERCe003-A-3 embryonic stem cell human CVCL_VF84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11998; TP53. Male 21169899 CVCL_VF81 NERCe002-A-3 embryonic stem cell human CVCL_VF81 CL:0000010 Transfected with: HGNC; 12855; YWHAZ. Male Characteristics: Unpon doxycycline-induction expresses YWHAZ (14-3-3 zeta) 21169900 CVCL_VF82 WAe001-A-19 embryonic stem cell human CVCL_VF82 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1. Male 21169901 CVCL_VF87 FUS2 corrected induced pluripotent stem cell human CVCL_VF87 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple_corrected; p.Arg495Glufs*34 (c.1483delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28082870) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169902 CVCL_VF88 FUS3 induced pluripotent stem cell human CVCL_VF88 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Asp502Thrfs*27 (c.1504delG); ClinVar=VCV000521661; Zygosity=Heterozygous (PubMed=28082870) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169903 CVCL_VF85 FUS1 induced pluripotent stem cell human CVCL_VF85 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Cys (c.1561C>T); ClinVar=VCV000016224; Zygosity=Heterozygous (PubMed=28082870) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169904 CVCL_VF86 FUS2 induced pluripotent stem cell human CVCL_VF86 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg495Glufs*34 (c.1483delC); Zygosity=Heterozygous (PubMed=28082870) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169905 CVCL_VF89 CNTL1 induced pluripotent stem cell human CVCL_VF89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169906 CVCL_VF72 RIRI-PaDe-3-C26 spontaneously immortalized cell line CVCL_VF72 CL:0000010 Unspecified Group: Insect cell line. 21169907 CVCL_VF73 RIRI-PaDe-3-C27 spontaneously immortalized cell line CVCL_VF73 CL:0000010 Unspecified Group: Insect cell line. 21169908 CVCL_VF70 NYSCF-DE-1111-1111-Skin-SV-iPSC1 induced pluripotent stem cell human CVCL_VF70 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169909 CVCL_VF71 RIRI-PaDe-3-C15 spontaneously immortalized cell line CVCL_VF71 CL:0000010 Unspecified Group: Insect cell line. 21169910 CVCL_VF76 RIRI-PaDe-3-C31 spontaneously immortalized cell line CVCL_VF76 CL:0000010 Unspecified Group: Insect cell line. 21169911 CVCL_VF77 RIRI-PaDe-3-C4 spontaneously immortalized cell line CVCL_VF77 CL:0000010 Unspecified Group: Insect cell line. 21169912 CVCL_VF74 RIRI-PaDe-3-C28 spontaneously immortalized cell line CVCL_VF74 CL:0000010 Unspecified Group: Insect cell line. 21169913 CVCL_VF75 RIRI-PaDe-3-C30 spontaneously immortalized cell line CVCL_VF75 CL:0000010 Unspecified Group: Insect cell line. 21169914 CVCL_VF78 RIRI-PaDe-3-C41 spontaneously immortalized cell line CVCL_VF78 CL:0000010 Unspecified Group: Insect cell line. 21169915 CVCL_VF79 RIRI-PaDe-3-C8 spontaneously immortalized cell line CVCL_VF79 CL:0000010 Unspecified Group: Insect cell line. 21169916 CVCL_VF61 WISCi010-B induced pluripotent stem cell human CVCL_VF61 From: University of Wisconsin; Madison; USA. CL:0000010 21169917 CVCL_VF62 WISCi010-C induced pluripotent stem cell human CVCL_VF62 From: University of Wisconsin; Madison; USA. CL:0000010 21169918 CVCL_VF60 WISCi010-A induced pluripotent stem cell human CVCL_VF60 From: University of Wisconsin; Madison; USA. CL:0000010 21169919 CVCL_VF65 MU-PH1 spontaneously immortalized cell line house mouse CVCL_VF65 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.; Breed/subspecies: C57BL/6. Female Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3187 21169920 CVCL_VF66 SDHCEC1 spontaneously immortalized cell line human CVCL_VF66 CL:0000010 Derived from sampling site: Eye; cornea; epithelium. Male Doubling time: 19.6 hours (PubMed=17223104) 21169921 CVCL_VF63 cCEpi spontaneously immortalized cell line dog CVCL_VF63 CL:0000010 Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Beagle. Unspecified Doubling time: 24.82 hours (at 30th passage), 18.41 hours (at 60th passage), 16.82 hours (at 100th passage) (PubMed=29522723) 21169922 CVCL_VF64 HMGEC telomerase immortalized cell line human CVCL_VF64 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Meibomian gland Cell type=Epithelial cell.. Male Doubling time: 27.39 hours (PubMed=20335607); ~3-7 days (ATCC=CRL-3472) 21169923 CVCL_VF69 NYSCF-DE-1110-1110-Skin-SV-iPSC1 induced pluripotent stem cell human CVCL_VF69 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169924 CVCL_VF67 NYSCF-DE-1017-1017-Skin-MR1 induced pluripotent stem cell human CVCL_VF67 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169925 CVCL_VF68 NYSCF-DE-1054-1054-Skin-MR-iPSC1 induced pluripotent stem cell human CVCL_VF68 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169926 CVCL_VF50 UKKi037-C induced pluripotent stem cell human CVCL_VF50 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169927 CVCL_VF51 USCBi001-A induced pluripotent stem cell human CVCL_VF51 From: National Institute for Biological Standards and Control - UK Stem Cell Bank; South Mimms Potters Bar; United Kingdom CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21169928 CVCL_VF54 WISCi007-C induced pluripotent stem cell human CVCL_VF54 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169929 CVCL_VF55 WISCi008-A induced pluripotent stem cell human CVCL_VF55 From: University of Wisconsin; Madison; USA CL:0000010 Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169930 CVCL_VF52 WISCi007-A induced pluripotent stem cell human CVCL_VF52 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169931 CVCL_VF53 WISCi007-B induced pluripotent stem cell human CVCL_VF53 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169932 CVCL_VF58 WISCi009-A induced pluripotent stem cell human CVCL_VF58 From: University of Wisconsin; Madison; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169933 CVCL_VF59 WISCi009-B induced pluripotent stem cell human CVCL_VF59 From: University of Wisconsin; Madison; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169934 CVCL_VF56 WISCi008-B induced pluripotent stem cell human CVCL_VF56 From: University of Wisconsin; Madison; USA CL:0000010 Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169935 CVCL_VF57 WISCi008-C induced pluripotent stem cell human CVCL_VF57 From: University of Wisconsin; Madison; USA CL:0000010 Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21169936 CVCL_VF40 UKKi034-B induced pluripotent stem cell human CVCL_VF40 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser277Leu (c.830C>T) (p.Ser150Leu, c.449C>T); ClinVar=VCV000053116; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21169937 CVCL_VF43 UKKi035-B induced pluripotent stem cell human CVCL_VF43 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Arg943Ter (c.2827C>T); ClinVar=VCV000037039; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169938 CVCL_VF44 UKKi035-C induced pluripotent stem cell human CVCL_VF44 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Arg943Ter (c.2827C>T); ClinVar=VCV000037039; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169939 CVCL_VF41 UKKi034-C induced pluripotent stem cell human CVCL_VF41 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser277Leu (c.830C>T) (p.Ser150Leu, c.449C>T); ClinVar=VCV000053116; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21169940 CVCL_VF42 UKKi035-A induced pluripotent stem cell human CVCL_VF42 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Arg943Ter (c.2827C>T); ClinVar=VCV000037039; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 21169941 CVCL_VF47 UKKi036-C induced pluripotent stem cell human CVCL_VF47 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169942 CVCL_VF48 UKKi037-A induced pluripotent stem cell human CVCL_VF48 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169943 CVCL_VF45 UKKi036-A induced pluripotent stem cell human CVCL_VF45 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169944 CVCL_VF46 UKKi036-B induced pluripotent stem cell human CVCL_VF46 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21169945 CVCL_VF49 UKKi037-B induced pluripotent stem cell human CVCL_VF49 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21169946 CVCL_ML99 BayGenomics ES cell line RHA003 embryonic stem cell house mouse CVCL_ML99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930780; Myh10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169947 CVCL_ML97 BayGenomics ES cell line PT326 embryonic stem cell house mouse CVCL_ML97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918518; Lrrfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169948 CVCL_ML98 BayGenomics ES cell line RHA002 embryonic stem cell house mouse CVCL_ML98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169949 CVCL_VF32 UNEWi011-A induced pluripotent stem cell human CVCL_VF32 From: University of Newcastle; Newcastle; United Kingdom CL:0000010 Miscellaneous: Cell line has been lost (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UNEWi011-A; true; Discontinued: ECACC; 66540041; true Male 21169950 CVCL_VF33 UKKi016-A induced pluripotent stem cell human CVCL_VF33 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg366Trp (c.1096C>T); ClinVar=VCV000052955; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21169951 CVCL_VF30 UOWi004-A induced pluripotent stem cell human CVCL_VF30 From: University of Wollongong; Wollongong; Australia. CL:0000010 21169952 CVCL_VF31 UOWi005-A induced pluripotent stem cell human CVCL_VF31 From: University of Wollongong; Wollongong; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1591; CCNF; Simple; p.Ser621Gly (c.1861A>G); ClinVar=VCV000992591; Zygosity=Unspecified (PubMed=31445393) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169953 CVCL_VF36 UKKi033-A induced pluripotent stem cell human CVCL_VF36 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Discontinued: EBiSC; UKKi033-A; true; Discontinued: ECACC; 66540889; true; Discontinued: hPSCreg; UKKi033-A; true. Male 21169954 CVCL_VF37 UKKi033-B induced pluripotent stem cell human CVCL_VF37 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Discontinued: EBiSC; UKKi033-B; true; Discontinued: ECACC; 66540890; true; Discontinued: hPSCreg; UKKi033-B; true. Male 21169955 CVCL_VF34 UKKi016-B induced pluripotent stem cell human CVCL_VF34 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg366Trp (c.1096C>T); ClinVar=VCV000052955; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21169956 CVCL_VF35 UKKi016-C induced pluripotent stem cell human CVCL_VF35 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg366Trp (c.1096C>T); ClinVar=VCV000052955; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21169957 CVCL_VF38 UKKi033-C induced pluripotent stem cell human CVCL_VF38 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Discontinued: EBiSC; UKKi033-C; true; Discontinued: ECACC; 66540891; true; Discontinued: hPSCreg; UKKi033-C; true. Male 21169958 CVCL_VF39 UKKi034-A induced pluripotent stem cell human CVCL_VF39 From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser277Leu (c.830C>T) (p.Ser150Leu, c.449C>T); ClinVar=VCV000053116; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21169959 CVCL_ML84 BayGenomics ES cell line PST129 embryonic stem cell house mouse CVCL_ML84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104903; Gpc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169960 CVCL_ML85 BayGenomics ES cell line PST131 embryonic stem cell house mouse CVCL_ML85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927471; Lsr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169961 CVCL_ML82 BayGenomics ES cell line PST127 embryonic stem cell house mouse CVCL_ML82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169962 CVCL_ML83 BayGenomics ES cell line PST128 embryonic stem cell house mouse CVCL_ML83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96257; Hspg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169963 CVCL_ML80 BayGenomics ES cell line PST124 embryonic stem cell house mouse CVCL_ML80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169964 CVCL_ML81 BayGenomics ES cell line PST126 embryonic stem cell house mouse CVCL_ML81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169965 CVCL_VF21 UHOMi001-A induced pluripotent stem cell human CVCL_VF21 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 26090; CCDC40; Simple; c.1116_1117delCT; Zygosity=Heterozygous (PubMed=30296669); Sequence variation: Mutation; HGNC; 26090; CCDC40; Simple; c.3180+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=30296669) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21169966 CVCL_VF22 UKERi002-A induced pluripotent stem cell human CVCL_VF22 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169967 CVCL_VF20 UFRJi004-A induced pluripotent stem cell human CVCL_VF20 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21169968 CVCL_VF25 UPSFRi013-A induced pluripotent stem cell human CVCL_VF25 From: Universite Paris-Sud 11; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Ser142Phe (c.425C>T); ClinVar=VCV001327620; Zygosity=Heterozygous (PubMed=29597128) Derived from sampling site: Peripheral blood. Female 21169969 CVCL_VF26 WAe001-A-15 embryonic stem cell human CVCL_VF26 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Transfected with: HGNC; 31501; MIR122; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Unpon doxycycline-induction expresses miR-122 Developed to study the role of miR-122 in embryonic development, organogenesis, steatosis and tumorigenesis.; Characteristics: Transfected with a PB-TRE-miR-122-EF1a-rtTA-2A-puroR-2A-EGFP construct 21169970 CVCL_VF23 UKERi003-A induced pluripotent stem cell human CVCL_VF23 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169971 CVCL_VF24 UNIPDi001-A induced pluripotent stem cell human CVCL_VF24 From: University of Padova; Padova; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial stem cell.. Female 21169972 CVCL_VF29 UOWi003-A induced pluripotent stem cell human CVCL_VF29 From: University of Wollongong; Wollongong; Australia CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Heterozygous (PubMed=30138848) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21169973 CVCL_ML79 BayGenomics ES cell line PST123 embryonic stem cell house mouse CVCL_ML79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169974 CVCL_VF27 UOWi001-A induced pluripotent stem cell human CVCL_VF27 From: University of Wollongong; Wollongong; Australia CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169975 CVCL_VF28 UOWi002-A induced pluripotent stem cell human CVCL_VF28 From: University of Wollongong; Wollongong; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21169976 CVCL_ML77 BayGenomics ES cell line PST118 embryonic stem cell house mouse CVCL_ML77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919293; Sulf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169977 CVCL_ML78 BayGenomics ES cell line PST120 embryonic stem cell house mouse CVCL_ML78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289273; Ppp1r10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169978 CVCL_ML75 BayGenomics ES cell line PST115 embryonic stem cell house mouse CVCL_ML75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927235; Mbtps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169979 CVCL_ML76 BayGenomics ES cell line PST116 embryonic stem cell house mouse CVCL_ML76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97815; Ptprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169980 CVCL_ML95 BayGenomics ES cell line PT175 embryonic stem cell house mouse CVCL_ML95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169981 CVCL_ML96 BayGenomics ES cell line PT193 embryonic stem cell house mouse CVCL_ML96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447762; Yeats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169982 CVCL_ML93 BayGenomics ES cell line PT138 embryonic stem cell house mouse CVCL_ML93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328337; Orc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169983 CVCL_ML94 BayGenomics ES cell line PT144 embryonic stem cell house mouse CVCL_ML94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448326; H3c6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169984 CVCL_ML91 BayGenomics ES cell line PT065 embryonic stem cell house mouse CVCL_ML91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933946; Ptov1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169985 CVCL_ML92 BayGenomics ES cell line PT084 embryonic stem cell house mouse CVCL_ML92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914750; Ccar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169986 CVCL_ML90 BayGenomics ES cell line PT058 embryonic stem cell house mouse CVCL_ML90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1340806; Parp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169987 CVCL_VF10 RB182(L) transformed cell line human CVCL_VF10 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21169988 CVCL_VF11 UCLi006-A induced pluripotent stem cell human CVCL_VF11 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Leu302Pro (c.905T>C); ClinVar=VCV000066953; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169989 CVCL_VF14 UCLi009-B induced pluripotent stem cell human CVCL_VF14 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (PubMed=28360103) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169990 CVCL_VF15 UCLi010-A induced pluripotent stem cell human CVCL_VF15 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Heterozygous (PubMed=28360103) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169991 CVCL_VF12 UCLi007-A induced pluripotent stem cell human CVCL_VF12 From: University College London; London; United Kingdom. CL:0000010 Male 21169992 CVCL_VF13 UCLi009-A induced pluripotent stem cell human CVCL_VF13 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg155Cys (c.463C>T); ClinVar=VCV000008469; Zygosity=Heterozygous (PubMed=28360103) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21169993 CVCL_VF18 UFRJi002-A induced pluripotent stem cell human CVCL_VF18 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Ser38Gly (c.112A>G); ClinVar=VCV000132651; Zygosity=Heterozygous (PubMed=30099333); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.1394-2A>G; ClinVar=VCV001500718; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=30099333) Derived from sampling site: Peripheral blood. Female 21169994 CVCL_VF19 UFRJi003-A induced pluripotent stem cell human CVCL_VF19 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Ser38Gly (c.112A>G); ClinVar=VCV000132651; Zygosity=Heterozygous (PubMed=30099333) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21169995 CVCL_VF16 UCLi010-B induced pluripotent stem cell human CVCL_VF16 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Heterozygous (PubMed=28360103) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21169996 CVCL_VF17 UFRJi001-A induced pluripotent stem cell human CVCL_VF17 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Ser38Gly (c.112A>G); ClinVar=VCV000132651; Zygosity=Heterozygous (PubMed=30099333); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.1394-2A>G; ClinVar=VCV001500718; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=30099333) Derived from sampling site: Peripheral blood. Male 21169997 CVCL_ML88 BayGenomics ES cell line PT032 embryonic stem cell house mouse CVCL_ML88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169998 CVCL_ML89 BayGenomics ES cell line PT036 embryonic stem cell house mouse CVCL_ML89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913799; Aggf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21169999 CVCL_ML86 BayGenomics ES cell line PST132 embryonic stem cell house mouse CVCL_ML86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104902; Gpc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170000 CVCL_ML87 BayGenomics ES cell line PT026 embryonic stem cell house mouse CVCL_ML87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170001 CVCL_VE91 SUSM-1/p53-1 transformed cell line human CVCL_VE91 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21170002 CVCL_VE92 SUSM-1/p53-6 transformed cell line human CVCL_VE92 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21170003 CVCL_VE90 OUMS-24/P6 finite cell line human CVCL_VE90 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female Senescence: Senesces at 79 PDL (PubMed=8985102; PubMed=9338145) 21170004 CVCL_VE95 SCSe001-A-1 embryonic stem cell human CVCL_VE95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16499; RAB39B. Male 21170005 CVCL_VE96 SCSe001-A-2 embryonic stem cell human CVCL_VE96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16499; RAB39B. Male 21170006 CVCL_VE93 WAe001-A-2 embryonic stem cell human CVCL_VE93 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using TALEN a 2A-GFP-PGK-Puro construct was integrated at the C-terminus of HBB (PubMed=32413789) 21170007 CVCL_VE94 LEIi004-A-1 induced pluripotent stem cell human CVCL_VE94 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple_corrected; p.Ala59Thr (c.175G>A); ClinVar=VCV000950856; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=29753273); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (PubMed=29753273) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21170008 CVCL_VE99 MUi010-A induced pluripotent stem cell human CVCL_VE99 From: Mahidol University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 7579; MYH9; Simple; p.Arg702Cys (c.2104C>T); ClinVar=VCV000014078; Zygosity=Heterozygous (PubMed=30798146) Population: Southeast Asian; Thai; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170009 CVCL_VE97 D551 iPSC induced pluripotent stem cell human CVCL_VE97 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21170010 CVCL_VE98 PSMi003-A induced pluripotent stem cell human CVCL_VE98 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly179Ser (c.535G>A); ClinVar=VCV000053063; Zygosity=Homozygous (PubMed=29684900) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170011 CVCL_VE80 PFIZi032-A induced pluripotent stem cell human CVCL_VE80 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Unexplicit; Not described; Zygosity=Unspecified (EBiSC) Derived from sampling site: Peripheral blood. Female 21170012 CVCL_VE81 PSMi002-A induced pluripotent stem cell human CVCL_VE81 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg190Trp (c.568C>T) (p.Arg63Trp, c.187C>T); ClinVar=VCV000053070; Zygosity=Heterozygous (PubMed=29677589); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg594Gln (c.1781G>A); ClinVar=VCV000053018; Zygosity=Heterozygous (PubMed=29677589) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170013 CVCL_VE84 NCC-SS2-C1 cancer cell line human CVCL_VE84 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=29626278) Population: Japanese Omics: Deep proteome analysis. Female Doubling time: 52 hours (PubMed=29626278) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21170014 CVCL_VE85 GM02439 GM1-iPSC clone 2 induced pluripotent stem cell human CVCL_VE85 CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Arg201Cys (c.601C>T); ClinVar=VCV000000925; Zygosity=Unspecified (PubMed=25925601) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170015 CVCL_VE82 VRFi001-A induced pluripotent stem cell human CVCL_VE82 From: Kamalnayan Bajaj Institute for Research in Vision and Ophthalmology, Vision Research Foundation; Chennai; India CL:0000010 Sequence variation: Gene deletion; HGNC; 9884; RB1; Zygosity=Heterozygous (PubMed=29579639) Population: Indian; Derived from sampling site: Eye socket Cell type=Adipose mesenchymal stem cell.. Male 21170016 CVCL_VE83 HHUUKDi003-A induced pluripotent stem cell human CVCL_VE83 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (PubMed=29602048) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170017 CVCL_VE88 OUMS-24/P1 finite cell line human CVCL_VE88 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female Senescence: Senesces at 88 PDL (PubMed=9338145) 21170018 CVCL_VE89 OUMS-24/P1N transformed cell line human CVCL_VE89 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Arg273His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Cell type=Fibroblast. Female 21170019 CVCL_VE86 GM02439 GM1-iPSC clone 3 induced pluripotent stem cell human CVCL_VE86 CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Arg201Cys (c.601C>T); ClinVar=VCV000000925; Zygosity=Unspecified (PubMed=25925601) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170020 CVCL_VE87 CON9 transformed cell line human CVCL_VE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170021 CVCL_VE70 PFIZi010-B induced pluripotent stem cell human CVCL_VE70 From: Pfizer, Inc.; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21170022 CVCL_VE73 PFIZi012-A induced pluripotent stem cell human CVCL_VE73 From: Pfizer, Inc.; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21170023 CVCL_VE74 PFIZi020-A induced pluripotent stem cell human CVCL_VE74 From: Pfizer, Inc.; New York; USA CL:0000010 Discontinued: EBiSC; PFIZi020-A; true; Discontinued: ECACC; 66540421; true. Female 21170024 CVCL_VE71 PFIZi010-C induced pluripotent stem cell human CVCL_VE71 From: Pfizer, Inc.; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21170025 CVCL_VE72 PFIZi011-A induced pluripotent stem cell human CVCL_VE72 From: Pfizer, Inc.; New York; USA CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21170026 CVCL_VE77 PFIZi029-A induced pluripotent stem cell human CVCL_VE77 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1917; CHD2; Simple; p.Arg1546Ter (c.4636C>T); ClinVar=VCV000423473; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Female 21170027 CVCL_VE78 PFIZi030-A induced pluripotent stem cell human CVCL_VE78 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7944; NPR2; Simple; p.Thr297Met (c.890C>T); Zygosity=Unspecified (EBiSC) Derived from sampling site: Peripheral blood. Female 21170028 CVCL_VE75 PFIZi023-A induced pluripotent stem cell human CVCL_VE75 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 4512; ADGRG1; Simple; p.Val316Leufs*8 (c.944_945dupTT); ClinVar=VCV000211096; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 4512; ADGRG1; Simple; p.Leu503Pro (c.1508T>C) (p.Leu497Pro, c.1490T>C); ClinVar=VCV000158620; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 21170029 CVCL_VE76 PFIZi028-A induced pluripotent stem cell human CVCL_VE76 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 29521; C12orf57; Simple; p.Gln62Ter (c.184C>T); ClinVar=VCV000155861; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 21170030 CVCL_VE79 PFIZi031-A induced pluripotent stem cell human CVCL_VE79 From: Pfizer, Inc.; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 10588; SCN2A; Simple; p.Lys1422Glu (c.4264A>G); ClinVar=VCV000206999; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Peripheral blood. Male 21170031 CVCL_E345 130 BLCL transformed cell line human CVCL_E345 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170032 CVCL_DR45 GM07248 finite cell line human CVCL_DR45 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21170033 CVCL_E346 131 BLCL transformed cell line human CVCL_E346 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170034 CVCL_DR46 GM07249 transformed cell line human CVCL_DR46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170035 CVCL_E343 127 BLCL transformed cell line human CVCL_E343 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170036 CVCL_DR43 ND14318 transformed cell line human CVCL_DR43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND12218 (Cellosaurus=CVCL_BJ79); Derived from sampling site: Peripheral blood. Male 21170037 CVCL_E344 129 BLCL transformed cell line human CVCL_E344 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170038 CVCL_DR44 GM07247 transformed cell line human CVCL_DR44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170039 CVCL_E349 147 BLCL transformed cell line human CVCL_E349 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170040 CVCL_DR49 GM15912 transformed cell line human CVCL_DR49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM15911 (Cellosaurus=CVCL_DR48); Derived from sampling site: Peripheral blood. Female 21170041 CVCL_E347 133 BLCL transformed cell line human CVCL_E347 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170042 CVCL_DR47 GM07250 finite cell line human CVCL_DR47 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170043 CVCL_E348 145 BLCL transformed cell line human CVCL_E348 HLA typing: A*03,30; B*07,13; C*06,07 (ECACC=94031627) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170044 CVCL_DR48 GM15911 transformed cell line human CVCL_DR48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM15912 (Cellosaurus=CVCL_DR49); Derived from sampling site: Peripheral blood. Female 21170045 CVCL_E341 111 BLCL transformed cell line human CVCL_E341 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170046 CVCL_DR41 ND03367 transformed cell line human CVCL_DR41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170047 CVCL_E342 126 BLCL transformed cell line human CVCL_E342 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170048 CVCL_DR42 ND12422 transformed cell line human CVCL_DR42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND12421 (Cellosaurus=CVCL_BK59); Derived from sampling site: Peripheral blood. Female 21170049 CVCL_E340 LUDLU-23 cancer cell line human CVCL_E340 CL:0000010 Population: Caucasian. Unspecified 21170050 CVCL_DR40 ND03366 transformed cell line human CVCL_DR40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170051 CVCL_E356 160 BLCL transformed cell line human CVCL_E356 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170052 CVCL_DR56 GSC13 cancer cell line human CVCL_DR56 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21170053 CVCL_E357 161 BLCL transformed cell line human CVCL_E357 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170054 CVCL_DR57 GSC17 cancer cell line human CVCL_DR57 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21170055 CVCL_E354 156 BLCL transformed cell line human CVCL_E354 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170056 CVCL_DR54 EU93-3 transformed cell line Norway rat CVCL_DR54 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. Unspecified 21170057 CVCL_E355 158 BLCL transformed cell line human CVCL_E355 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170058 CVCL_DR55 GSC11 cancer cell line human CVCL_DR55 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21170059 CVCL_E358 163 BLCL transformed cell line human CVCL_E358 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170060 CVCL_DR58 GSC2 cancer cell line human CVCL_DR58 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21170061 CVCL_E359 164 BLCL transformed cell line human CVCL_E359 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170062 CVCL_DR59 GSC23 cancer cell line human CVCL_DR59 CL:0000010 Omics: Deep proteome analysis. Group: Cancer stem cell line 21170063 CVCL_E352 150 BLCL transformed cell line human CVCL_E352 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170064 CVCL_DR52 GM20987 transformed cell line human CVCL_DR52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21170065 CVCL_E353 151 BLCL transformed cell line human CVCL_E353 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170066 CVCL_DR53 EU93-2 transformed cell line Norway rat CVCL_DR53 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. Unspecified 21170067 CVCL_E350 148 BLCL transformed cell line human CVCL_E350 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170068 CVCL_DR50 ND33438 transformed cell line human CVCL_DR50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND33439 (Cellosaurus=CVCL_DR51); Derived from sampling site: Peripheral blood. Male 21170069 CVCL_E351 149 BLCL transformed cell line human CVCL_E351 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170070 CVCL_DR51 ND33439 transformed cell line human CVCL_DR51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND33438 (Cellosaurus=CVCL_DR50); Derived from sampling site: Peripheral blood. Male 21170071 CVCL_DR29 GM20990 transformed cell line human CVCL_DR29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM20991 (Cellosaurus=CVCL_DR30); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21170072 CVCL_E329 HKGZ-CC cancer cell line human CVCL_E329 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (DepMap) Population: Chinese; Derived from sampling site: Liver. Male Doubling time: ~48 hours (PubMed=17914572) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21170073 CVCL_DR23 XGL spontaneously immortalized cell line CVCL_DR23 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Var singuonensis.. Unspecified Group: Fish cell line 21170074 CVCL_E323 YES-3 cancer cell line human CVCL_E323 HLA typing: A*04,24; B*01,15; C*01 (PubMed=18575732) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 61.0 hours (PubMed=1770930); 49.2 hours (DOI=10.5833/jjgs.27.1885) 21170075 CVCL_DR24 L749.1 induced pluripotent stem cell human CVCL_DR24 From: Instituto de Investigaciones Biomedicas Alberto Sols; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Unspecified (PubMed=27346203) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21170076 CVCL_E324 UD-SCC-1 cancer cell line human CVCL_E324 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu26Profs*10 (c.75delA); Zygosity=Unspecified (PubMed=10628319; PubMed=18487078) Derived from sampling site: Pharynx; oropharynx. Male Doubling time: 32.5 hours (PubMed=10628319) 21170077 CVCL_DR21 Rca-T cancer cell line Norway rat CVCL_DR21 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907). Unspecified Doubling time: 23.13 hours (at 21th passage), 22.94 hours (at 65th passage) (Patent=CN101469320A) 21170078 CVCL_E321 YES-1 cancer cell line human CVCL_E321 HLA typing: A*02,01; B*15,11; C*03 (PubMed=18575732) CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 35.2 hours (PubMed=1770930); 82.1 hours (DOI=10.5833/jjgs.27.1885) 21170079 CVCL_DR22 SEP-K1 finite cell line pig CVCL_DR22 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: Miniature pig. Female 21170080 CVCL_E322 YES-2 cancer cell line human CVCL_E322 HLA typing: A*24; B*01,40; C*03,07 (PubMed=18575732) CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 22.9 hours (PubMed=1770930); 67.2 hours (DOI=10.5833/jjgs.27.1885); 23.7 hours, at 102th passage (CelloPub=CLPUB00005) 21170081 CVCL_DR27 GM21220 transformed cell line human CVCL_DR27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21170082 CVCL_E327 UD-SCC-4 cancer cell line human CVCL_E327 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15495191; PubMed=18487078); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.449del13; Zygosity=Unspecified (PubMed=10628319; PubMed=18487078). Male Doubling time: 36 hours (PubMed=10628319) 21170083 CVCL_DR28 GM21791 transformed cell line human CVCL_DR28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21170084 CVCL_E328 NT-8e cancer cell line human CVCL_E328 CL:0000010 Population: Indian; Derived from sampling site: Pharynx; hypopharynx; pyriform sinus. Male Doubling time: 27 hours (PubMed=9310268) 21170085 CVCL_DR25 GM14544 transformed cell line human CVCL_DR25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21170086 CVCL_E325 UD-SCC-2 cancer cell line human CVCL_E325 Genome ancestry: African=3.2%; Native American=0%; East Asian, North=4%; East Asian, South=0%; South Asian=0%; European, North=57.49%; European, South=35.31% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg5154Gln (c.15461G>A); ClinVar=VCV000286834; Zygosity=Homozygous (PubMed=31541927) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Omics: CNV analysis; Omics: Deep exome analysis; Omics: Genome sequenced (low read coverage); Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Virology: Contains from 14 to 23 copies of the HPV16 genome (PubMed=24201445) Doubling time: 42 hours (PubMed=10628319); 4.1 days (PubMed=29156801) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21170087 CVCL_DR26 GM20988 transformed cell line human CVCL_DR26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21170088 CVCL_E326 UD-SCC-3 cancer cell line human CVCL_E326 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Ter (c.670G>T); Zygosity=Unspecified (PubMed=10628319) Derived from metastatic site: Lymph node. Male Doubling time: 31 hours (PubMed=10628319; PubMed=18487078) 21170089 CVCL_E320 Lscc-02 cancer cell line human CVCL_E320 CL:0000010 Population: Chinese; Derived from sampling site: Larynx. Characteristics: Established from tumor tissue after 2 passages in nude mice Doubling time: ~39.1 hours (PubMed=16383303) 21170090 CVCL_DR20 RS1 finite cell line Norway rat CVCL_DR20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21170091 CVCL_DR34 GM21787 transformed cell line human CVCL_DR34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170092 CVCL_E334 OCI-My4 cancer cell line human CVCL_E334 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Unspecified Characteristics: IL6 dependent Doubling time: 130 hours, 28 hours (with PHA-LCM in culture media) (PubMed=1912582). 21170093 CVCL_DR35 GM21745 transformed cell line human CVCL_DR35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170094 CVCL_E335 OCI-My6 cancer cell line human CVCL_E335 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Unspecified Doubling time: 45 hours (PubMed=1912582). 21170095 CVCL_DR32 GM21794 transformed cell line human CVCL_DR32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21170096 CVCL_E332 OCI-My5 cancer cell line human CVCL_E332 Genome ancestry: African=3.85%; Native American=0%; East Asian, North=4.08%; East Asian, South=0%; South Asian=1.28%; European, North=54.74%; European, South=36.05% (PubMed=30894373) From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Homozygous (DepMap) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Produces IgA lambda (PubMed=3137236) Doubling time: 8 hours (PubMed=1912582) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21170097 CVCL_DR33 GM21788 finite cell line human CVCL_DR33 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21170098 CVCL_E333 OCI-My7 cancer cell line human CVCL_E333 Genome ancestry: African=2.65%; Native American=0%; East Asian, North=2.7%; East Asian, South=1.34%; South Asian=7.94%; European, North=21.26%; European, South=64.1% (PubMed=30894373). From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 57 hours (PubMed=1912582) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21170099 CVCL_DR38 ND08243 transformed cell line human CVCL_DR38 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of ND08242 (Cellosaurus=CVCL_BA85); Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Peripheral blood. Male 21170100 CVCL_E338 OCI-My1 cancer cell line human CVCL_E338 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Sequence variation: Gene deletion; HGNC; 12033; TRAF3; Zygosity=Homozygous (PubMed=17692805) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Doubling time: 24 hours (PubMed=1912582) 21170101 CVCL_E339 HEK-CaSR transformed cell line human CVCL_E339 CL:0000010 Transfected with: HGNC; 1514; CASR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21170102 CVCL_DR39 ND03368 transformed cell line human CVCL_DR39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170103 CVCL_DR36 GM21746 finite cell line human CVCL_DR36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170104 CVCL_E336 OCI-My3 cancer cell line human CVCL_E336 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Unspecified Doubling time: 32 hours (PubMed=1912582). 21170105 CVCL_DR37 GM21747 transformed cell line human CVCL_DR37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170106 CVCL_E337 OCI-My2 cancer cell line human CVCL_E337 From: Ontario Cancer Institute (OCI); Toronto; Canada CL:0000010 Unspecified Doubling time: 24 hours (PubMed=1912582). 21170107 CVCL_DR30 GM20991 transformed cell line human CVCL_DR30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM20990 (Cellosaurus=CVCL_DR29); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21170108 CVCL_E330 KU-8 cancer cell line human CVCL_E330 CL:0000010 Population: Japanese; Derived from metastatic site: Inguinal lymph node. Male Doubling time: ~20 hours (PubMed=2585941) 21170109 CVCL_DR31 GM21793 transformed cell line human CVCL_DR31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21170110 CVCL_E331 HT93A cancer cell line human CVCL_E331 CL:0000010 Sequence variation: Gene fusion; HGNC; 77; ABL2 + HGNC; 3495; ETV6; Name(s)=ETV6-ABL2, ETV6-ARG (PubMed=10706884); Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=9472803) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~48 hours (PubMed=9472803); ~50 hours (DSMZ=ACC-735) 21170111 CVCL_DR09 CHOPWT2.2 induced pluripotent stem cell human CVCL_DR09 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170112 CVCL_E309 CSEC [Human] cancer cell line human CVCL_E309 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Female Doubling time: 39.6 hours, at 45th passage (PubMed=18477252) 21170113 CVCL_DR07 CHOPWT1.3 induced pluripotent stem cell human CVCL_DR07 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170114 CVCL_E307 EC9706 cancer cell line human CVCL_E307 CL:0000010 Derived from sampling site: Esophagus. Male Doubling time: 26 hours (PubMed=12476413) 21170115 CVCL_DR08 CHOPWT2.1 induced pluripotent stem cell human CVCL_DR08 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170116 CVCL_E308 HKCI-1 cancer cell line human CVCL_E308 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=10958934) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60 hours (PubMed=10958934) Caution: Indicated as originating from a 44 year old male in material methods of PubMed=10958934 and from a 58 year old male in table 1 of the same publication 21170117 CVCL_E301 A10.7 cancer cell line human CVCL_E301 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Liver. Male 21170118 CVCL_DR01 Zfp57+/- clone 6911 embryonic stem cell house mouse CVCL_DR01 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:99204; Zfp57. Unspecified 21170119 CVCL_E302 A6L cancer cell line human CVCL_E302 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Liver. Male 21170120 CVCL_DR02 Zfp57-/- clone 406 embryonic stem cell house mouse CVCL_DR02 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:99204; Zfp57. Unspecified 21170121 CVCL_E300 PANC 233 cancer cell line human CVCL_E300 From: Johns Hopkins University School of Medicine; Baltimore; USA. CL:0000010 21170122 CVCL_DR00 Zfp57+/- clone 6909 embryonic stem cell house mouse CVCL_DR00 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); MGI; MGI:99204; Zfp57. Unspecified 21170123 CVCL_DR05 CHOPWT1.1 induced pluripotent stem cell human CVCL_DR05 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [18]; 47,XX,+12 [2] (PubMed=27293150); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170124 CVCL_E305 SLMT-1 cancer cell line human CVCL_E305 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Esophagus. Male Characteristics: Established from a nude mouse xenograft Doubling time: ~31 hours (PubMed=11165320) 21170125 CVCL_DR06 CHOPWT1.2 induced pluripotent stem cell human CVCL_DR06 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170126 CVCL_E306 NE1-E6E7 transformed cell line human CVCL_E306 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Esophagus. Male 21170127 CVCL_E303 A2.1 cancer cell line human CVCL_E303 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from metastatic site: Liver. Male 21170128 CVCL_DR03 Zfp57-/- clone 631 embryonic stem cell house mouse CVCL_DR03 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:99204; Zfp57. Unspecified 21170129 CVCL_E304 HKESC-4 cancer cell line human CVCL_E304 CL:0000010 Population: Chinese Male Characteristics: Established from a xenograft produced in BALB/c nude mice Doubling time: 63 hours (PubMed=17889704). 21170130 CVCL_DR04 Zfp57-/- clone 634 embryonic stem cell house mouse CVCL_DR04 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:99204; Zfp57. Unspecified 21170131 CVCL_DR18 NRm finite cell line Norway rat CVCL_DR18 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21170132 CVCL_E318 T2/CUHK cancer cell line human CVCL_E318 CL:0000010 Population: Chinese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue. Unspecified Doubling time: 31 hours (PubMed=7788927) 21170133 CVCL_E319 CA cancer cell line human CVCL_E319 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Doubling time: 14.3 hours (PubMed=14751132) 21170134 CVCL_DR19 OCU-K3 finite cell line CVCL_DR19 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Female 21170135 CVCL_DR12 453C2 induced pluripotent stem cell human CVCL_DR12 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Tooth; dental pulp. Female 21170136 CVCL_E312 OSC-1 [Human esophageal squamous cell carcinoma] cancer cell line human CVCL_E312 CL:0000010 Derived from sampling site: Esophagus. Female Doubling time: 36 hours (PubMed=9216685) 21170137 CVCL_DR13 KEP1 induced pluripotent stem cell human CVCL_DR13 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21170138 CVCL_E313 OSC-2 [Human esophageal squamous cell carcinoma] cancer cell line human CVCL_E313 CL:0000010 Derived from sampling site: Esophagus. Unspecified Doubling time: 50 hours (PubMed=9216685) 21170139 CVCL_DR10 CHOPWT2.3 induced pluripotent stem cell human CVCL_DR10 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 21170140 CVCL_E310 ESC-410 cancer cell line human CVCL_E310 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Male Doubling time: ~53 hours (PubMed=20819098) 21170141 CVCL_DR11 711A5 induced pluripotent stem cell human CVCL_DR11 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21170142 CVCL_E311 FU-EPS-1 cancer cell line human CVCL_E311 CL:0000010 Population: Japanese; Derived from metastatic site: Right axillary lymph node. Male Doubling time: ~45 hours (PubMed=16010416) 21170143 CVCL_DR16 CiRA-PD82 induced pluripotent stem cell human CVCL_DR16 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21170144 CVCL_E316 HST-1 cancer cell line human CVCL_E316 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 21 hours (PubMed=2759736) 21170145 CVCL_DR17 CiRA-PD83 induced pluripotent stem cell human CVCL_DR17 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Peripheral blood. Male 21170146 CVCL_E317 T1/CUHK cancer cell line human CVCL_E317 CL:0000010 Population: Chinese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Oral cavity; tongue. Unspecified Doubling time: 26 hours (PubMed=7788927) 21170147 CVCL_E314 EC8712 cancer cell line human CVCL_E314 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Male 21170148 CVCL_DR14 KRV1 induced pluripotent stem cell human CVCL_DR14 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21170149 CVCL_DR15 7KE2 induced pluripotent stem cell human CVCL_DR15 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21170150 CVCL_E315 EC8733 cancer cell line human CVCL_E315 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Male 21170151 CVCL_3I92 HQ00904 transformed cell line human CVCL_3I92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170152 CVCL_3I93 HQ00905 transformed cell line human CVCL_3I93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170153 CVCL_3I90 HQ00902 transformed cell line human CVCL_3I90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170154 CVCL_3I91 HQ00903 transformed cell line human CVCL_3I91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170155 CVCL_3I96 HQ00908 transformed cell line human CVCL_3I96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170156 CVCL_3I97 HQ00909 transformed cell line human CVCL_3I97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170157 CVCL_3I94 HQ00906 transformed cell line human CVCL_3I94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170158 CVCL_3I95 HQ00907 transformed cell line human CVCL_3I95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170159 CVCL_3I98 HQ00910 transformed cell line human CVCL_3I98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170160 CVCL_3I99 HQ00911 transformed cell line human CVCL_3I99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170161 CVCL_3I70 HQ00882 transformed cell line human CVCL_3I70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170162 CVCL_3I71 HQ00883 transformed cell line human CVCL_3I71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170163 CVCL_3I74 HQ00886 transformed cell line human CVCL_3I74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170164 CVCL_3I75 HQ00887 transformed cell line human CVCL_3I75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170165 CVCL_3I72 HQ00884 transformed cell line human CVCL_3I72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170166 CVCL_3I73 HQ00885 transformed cell line human CVCL_3I73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170167 CVCL_3I78 HQ00890 transformed cell line human CVCL_3I78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170168 CVCL_3I79 HQ00891 transformed cell line human CVCL_3I79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170169 CVCL_3I76 HQ00888 transformed cell line human CVCL_3I76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170170 CVCL_3I77 HQ00889 transformed cell line human CVCL_3I77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170171 CVCL_3I81 HQ00893 transformed cell line human CVCL_3I81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170172 CVCL_3I82 HQ00894 transformed cell line human CVCL_3I82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170173 CVCL_3I80 HQ00892 transformed cell line human CVCL_3I80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170174 CVCL_3I85 HQ00897 transformed cell line human CVCL_3I85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170175 CVCL_3I86 HQ00898 transformed cell line human CVCL_3I86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170176 CVCL_3I83 HQ00895 transformed cell line human CVCL_3I83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170177 CVCL_3I84 HQ00896 transformed cell line human CVCL_3I84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170178 CVCL_3I89 HQ00901 transformed cell line human CVCL_3I89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170179 CVCL_3I87 HQ00899 transformed cell line human CVCL_3I87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170180 CVCL_3I88 HQ00900 transformed cell line human CVCL_3I88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170181 CVCL_MV19 BayGenomics ES cell line RRF395 embryonic stem cell house mouse CVCL_MV19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036254; Dennd2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170182 CVCL_N719 CM-3 [Human leukemia] cancer cell line human CVCL_N719 CL:0000010 Derived from sampling site: Bone marrow. Male 21170183 CVCL_MV17 BayGenomics ES cell line RRF390 embryonic stem cell house mouse CVCL_MV17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096327; Axin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170184 CVCL_N717 CCA cancer cell line human CVCL_N717 CL:0000010 Male Doubling time: ~90 hours (PubMed=2516717). 21170185 CVCL_MV18 BayGenomics ES cell line RRF391 embryonic stem cell house mouse CVCL_MV18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170186 CVCL_N718 CM-2 [Human leukemia] cancer cell line human CVCL_N718 CL:0000010 Derived from sampling site: Bone marrow. Male Doubling time: 20 hours (PubMed=7613515) 21170187 CVCL_N715 A924 cancer cell line human CVCL_N715 CL:0000010 Unspecified 21170188 CVCL_MV15 BayGenomics ES cell line RRF387 embryonic stem cell house mouse CVCL_MV15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347045; Psmb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170189 CVCL_N716 A964 cancer cell line human CVCL_N716 CL:0000010 Unspecified 21170190 CVCL_MV16 BayGenomics ES cell line RRF388 embryonic stem cell house mouse CVCL_MV16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109211; Pkn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170191 CVCL_MV13 BayGenomics ES cell line RRF381 embryonic stem cell house mouse CVCL_MV13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170192 CVCL_N713 TC 593 cancer cell line human CVCL_N713 CL:0000010 Male 21170193 CVCL_MV14 BayGenomics ES cell line RRF382 embryonic stem cell house mouse CVCL_MV14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923809; Atg2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170194 CVCL_N714 TC 620 cancer cell line human CVCL_N714 CL:0000010 Male Doubling time: 24 hours (PubMed=8416742). 21170195 CVCL_MV11 BayGenomics ES cell line RRF379 embryonic stem cell house mouse CVCL_MV11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108028; Atr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170196 CVCL_N711 TC 501 cancer cell line human CVCL_N711 CL:0000010 Male 21170197 CVCL_MV12 BayGenomics ES cell line RRF380 embryonic stem cell house mouse CVCL_MV12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921599; Fhip1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170198 CVCL_N712 TC 526 cancer cell line human CVCL_N712 CL:0000010 Male Characteristics: Established after a few passages of the original tumor in the anterior chamber of the eye of guinea pigs. 21170199 CVCL_MV10 BayGenomics ES cell line RRF375 embryonic stem cell house mouse CVCL_MV10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170200 CVCL_N710 TC 224 cancer cell line human CVCL_N710 CL:0000010 Derived from sampling site: Brain. Unspecified 21170201 CVCL_MV28 BayGenomics ES cell line RRF426 embryonic stem cell house mouse CVCL_MV28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145422; AW209491 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170202 CVCL_N728 NCE-G 55 cancer cell line human CVCL_N728 CL:0000010 Derived from sampling site: Brain; right occipital-parietal region. Male 21170203 CVCL_MV29 BayGenomics ES cell line RRF427 embryonic stem cell house mouse CVCL_MV29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1350328; Ofd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170204 CVCL_N729 NCE-G 59 cancer cell line human CVCL_N729 HLA typing: A*25:01,68:01; B*15:01,44:02; C*03:03,05:01 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 8598; PANK1; Zygosity=Homozygous (PubMed=36139163); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8253536) Derived from sampling site: Brain; left temporo-medial region. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170205 CVCL_MV26 BayGenomics ES cell line RRF410 embryonic stem cell house mouse CVCL_MV26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298366; Atf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170206 CVCL_N726 NCE-G 38 cancer cell line human CVCL_N726 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Female 21170207 CVCL_MV27 BayGenomics ES cell line RRF416 embryonic stem cell house mouse CVCL_MV27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170208 CVCL_N727 NCE-G 44 cancer cell line human CVCL_N727 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:06 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Ter (c.670G>T); Zygosity=Unspecified (PubMed=15816541) Derived from sampling site: Brain; left parietal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21170209 CVCL_MV24 BayGenomics ES cell line RRF403 embryonic stem cell house mouse CVCL_MV24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921728; Snx29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170210 CVCL_N724 NCE-G 28 cancer cell line human CVCL_N724 CL:0000010 Derived from sampling site: Brain; left parietal lobe. Male 21170211 CVCL_MV25 BayGenomics ES cell line RRF405 embryonic stem cell house mouse CVCL_MV25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98179; Rras Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170212 CVCL_N725 NCE-G 30 cancer cell line human CVCL_N725 CL:0000010 21170213 CVCL_MV22 BayGenomics ES cell line RRF401 embryonic stem cell house mouse CVCL_MV22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170214 CVCL_N722 MI-4 [Human glioblastoma] cancer cell line human CVCL_N722 CL:0000010 Derived from sampling site: Brain; parieto-temporal lobe. Omics: Array-based CGH Female 21170215 CVCL_MV23 BayGenomics ES cell line RRF402 embryonic stem cell house mouse CVCL_MV23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170216 CVCL_N723 NCE-G 22 cancer cell line human CVCL_N723 HLA typing: A*02:01,30:01; B*13:02,15:01; C*03:04,06:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Unspecified (PubMed=15816541); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=15816541) Derived from sampling site: Brain; occipito-medial region. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21170217 CVCL_MV20 BayGenomics ES cell line RRF397 embryonic stem cell house mouse CVCL_MV20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99197; Zbtb25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170218 CVCL_N720 CM-4 [Human leukemia] cancer cell line human CVCL_N720 CL:0000010 Derived from sampling site: Bone marrow. Male 21170219 CVCL_MV21 BayGenomics ES cell line RRF400 embryonic stem cell house mouse CVCL_MV21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921736; Osbpl10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170220 CVCL_N721 CM-5 [Human leukemia] cancer cell line human CVCL_N721 CL:0000010 Derived from sampling site: Bone marrow. Male 21170221 CVCL_MV08 BayGenomics ES cell line RRF373 embryonic stem cell house mouse CVCL_MV08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894659; Hbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170222 CVCL_N708 BT088 cancer cell line human CVCL_N708 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=20388696) Derived from sampling site: Brain. Male Group: Cancer stem cell line 21170223 CVCL_MV09 BayGenomics ES cell line RRF374 embryonic stem cell house mouse CVCL_MV09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107708; Ss18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170224 CVCL_N709 TC 178 cancer cell line human CVCL_N709 CL:0000010 Derived from sampling site: Brain. Male 21170225 CVCL_MV06 BayGenomics ES cell line RRF371 embryonic stem cell house mouse CVCL_MV06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917262; Cep85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170226 CVCL_N706 DFSP cancer cell line human CVCL_N706 CL:0000010 Population: Japanese; Derived from sampling site: Abdomen; skin. Female Doubling time: ~45 hours (PubMed=2600273) 21170227 CVCL_MV07 BayGenomics ES cell line RRF372 embryonic stem cell house mouse CVCL_MV07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170228 CVCL_N707 BT054 cancer cell line human CVCL_N707 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (PubMed=20388696) Derived from sampling site: Brain. Female Group: Cancer stem cell line 21170229 CVCL_MV04 BayGenomics ES cell line RRF367 embryonic stem cell house mouse CVCL_MV04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170230 CVCL_N704 KK124 cancer cell line human CVCL_N704 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8344493) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Caution: It is possible that KK124 and KK125 (Cellosaurus=CVCL_B495) are the same cell line 21170231 CVCL_MV05 BayGenomics ES cell line RRF370 embryonic stem cell house mouse CVCL_MV05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681124; Urb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170232 CVCL_N705 MS115 cancer cell line human CVCL_N705 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Unspecified 21170233 CVCL_MV02 BayGenomics ES cell line RRF362 embryonic stem cell house mouse CVCL_MV02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178836; Tubgcp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170234 CVCL_N702 DW6 cancer cell line human CVCL_N702 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Unspecified 21170235 CVCL_MV03 BayGenomics ES cell line RRF365 embryonic stem cell house mouse CVCL_MV03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141847; Phrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170236 CVCL_N703 JLP cancer cell line human CVCL_N703 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Unspecified 21170237 CVCL_MV00 BayGenomics ES cell line RRF358 embryonic stem cell house mouse CVCL_MV00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891692; Hnrnpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170238 CVCL_N700 HL-2 transformed cell line human CVCL_N700 CL:0000010 Transfected with: HGNC; 1390; CACNA1C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21170239 CVCL_N701 Abana cancer cell line human CVCL_N701 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8344493) Population: African; Ghanaian; Derived from sampling site: Ascites. Female Virology: Almost completely (>99%) EBV-negative (PubMed=6243721) 21170240 CVCL_MV01 BayGenomics ES cell line RRF360 embryonic stem cell house mouse CVCL_MV01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915512; Agpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170241 CVCL_W017 UCLA 17 embryonic stem cell human CVCL_W017 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0297 21170242 CVCL_W018 UCLA 18 embryonic stem cell human CVCL_W018 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0298 21170243 CVCL_W015 UCLA 15 embryonic stem cell human CVCL_W015 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0295 21170244 CVCL_W016 UCLA 16 embryonic stem cell human CVCL_W016 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0296 21170245 CVCL_W019 U-2149 cancer cell line human CVCL_W019 CL:0000010 Male 21170246 CVCL_MU78 BayGenomics ES cell line RRF296 embryonic stem cell house mouse CVCL_MU78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890430; Paxip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170247 CVCL_N678 MU9 undefined cell line type CVCL_N678 CL:0000010 Discontinued: ATCC; CRL-6480; true. Female Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170248 CVCL_MU79 BayGenomics ES cell line RRF299 embryonic stem cell house mouse CVCL_MU79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441717; Eno4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170249 CVCL_N679 MU8 [Melopsittacus] cancer cell line CVCL_N679 CL:0000010 Derived from sampling site: Testis. Discontinued: ATCC; CRL-6479; true Male Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170250 CVCL_MU76 BayGenomics ES cell line RRF294 embryonic stem cell house mouse CVCL_MU76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107440; Cep131 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170251 CVCL_N676 MU11 undefined cell line type CVCL_N676 CL:0000010 Discontinued: ATCC; CRL-6482; true. Female Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170252 CVCL_MU77 BayGenomics ES cell line RRF295 embryonic stem cell house mouse CVCL_MU77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170253 CVCL_N677 MU10 cancer cell line CVCL_N677 CL:0000010 Discontinued: ATCC; CRL-6481; true. Male Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170254 CVCL_MU74 BayGenomics ES cell line RRF284 embryonic stem cell house mouse CVCL_MU74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170255 CVCL_N674 MU13.T cancer cell line CVCL_N674 CL:0000010 Discontinued: ATCC; CRL-6484; true. Male Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170256 CVCL_MU75 BayGenomics ES cell line RRF291 embryonic stem cell house mouse CVCL_MU75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170257 CVCL_N675 MU12.T cancer cell line CVCL_N675 CL:0000010 Discontinued: ATCC; CRL-6483; true. Male Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170258 CVCL_MU72 BayGenomics ES cell line RRF280 embryonic stem cell house mouse CVCL_MU72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170259 CVCL_N672 MU26 cancer cell line CVCL_N672 CL:0000010 Discontinued: ATCC; CRL-6486; true. Female Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170260 CVCL_W020 U-410MG cancer cell line human CVCL_W020 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21170261 CVCL_MU73 BayGenomics ES cell line RRF282 embryonic stem cell house mouse CVCL_MU73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036247; Lmtk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170262 CVCL_N673 MU27 cancer cell line CVCL_N673 CL:0000010 Discontinued: ATCC; CRL-6487; true. Male Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170263 CVCL_W021 UACC-2648 cancer cell line human CVCL_W021 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21170264 CVCL_MU70 BayGenomics ES cell line RRF277 embryonic stem cell house mouse CVCL_MU70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107978; Klc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170265 CVCL_N670 FC83.Thy undefined cell line type CVCL_N670 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6112; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170266 CVCL_MU71 BayGenomics ES cell line RRF278 embryonic stem cell house mouse CVCL_MU71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107978; Klc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170267 CVCL_N671 Hs 910.T cancer cell line human CVCL_N671 CL:0000010 Discontinued: ATCC; CRL-7659; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170268 CVCL_W024 GM03589 finite cell line human CVCL_W024 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170269 CVCL_W025 GM05653 finite cell line human CVCL_W025 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Cell type=Fibroblast. Female 21170270 CVCL_W022 KMOE-1 cancer cell line human CVCL_W022 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: 48.3 hours (PubMed=6949905) 21170271 CVCL_W023 KMOE-3N cancer cell line human CVCL_W023 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Characteristics: Established after one tumor passage of KMOE-1 in nude mice Doubling time: 24.6 hours (PubMed=6949905) 21170272 CVCL_W006 GM14130 transformed cell line human CVCL_W006 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21170273 CVCL_W007 GM14131 transformed cell line human CVCL_W007 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21170274 CVCL_W004 GM14128 transformed cell line human CVCL_W004 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21170275 CVCL_W005 GM14129 transformed cell line human CVCL_W005 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21170276 CVCL_W008 GM03522 finite cell line human CVCL_W008 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170277 CVCL_W009 GM21068 transformed cell line human CVCL_W009 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170278 CVCL_MU89 BayGenomics ES cell line RRF328 embryonic stem cell house mouse CVCL_MU89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916340; Ascc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170279 CVCL_N689 Hs 412.Li finite cell line human CVCL_N689 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7284; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170280 CVCL_MU87 BayGenomics ES cell line RRF322 embryonic stem cell house mouse CVCL_MU87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448475; Fchsd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170281 CVCL_N687 Hs 407.Ov finite cell line human CVCL_N687 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-7280; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170282 CVCL_MU88 BayGenomics ES cell line RRF324 embryonic stem cell house mouse CVCL_MU88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919834; Cul4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170283 CVCL_N688 Hs 411.We finite cell line human CVCL_N688 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7283; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170284 CVCL_MU85 BayGenomics ES cell line RRF315 embryonic stem cell house mouse CVCL_MU85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919060; Ranbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170285 CVCL_N685 Hs 385.T cancer cell line human CVCL_N685 CL:0000010 Discontinued: ATCC; CRL-7261; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170286 CVCL_MU86 BayGenomics ES cell line RRF319 embryonic stem cell house mouse CVCL_MU86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99257; Eif3e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170287 CVCL_N686 Hs 386.Sk finite cell line human CVCL_N686 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7262; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170288 CVCL_MU83 BayGenomics ES cell line RRF309 embryonic stem cell house mouse CVCL_MU83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170289 CVCL_N683 Hs 382.T cancer cell line human CVCL_N683 CL:0000010 Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7259; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170290 CVCL_MU84 BayGenomics ES cell line RRF312 embryonic stem cell house mouse CVCL_MU84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107186; Cct2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170291 CVCL_W010 GM10309 finite cell line human CVCL_W010 CL:0000010 Sequence variation: Mutation; HGNC; 4976; HLCS; Simple; p.Val550Met (c.1648G>A); ClinVar=VCV000001911; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4976; HLCS; Simple; p.Arg565Ter (c.1693C>T); ClinVar=VCV000426486; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21170292 CVCL_N684 Hs 383.T cancer cell line human CVCL_N684 CL:0000010 Discontinued: ATCC; CRL-7260; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170293 CVCL_MU81 BayGenomics ES cell line RRF307 embryonic stem cell house mouse CVCL_MU81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915201; Tubb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170294 CVCL_N681 MU1 finite cell line CVCL_N681 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6477; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170295 CVCL_MU82 BayGenomics ES cell line RRF308 embryonic stem cell house mouse CVCL_MU82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147538; Btaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170296 CVCL_N682 MU9.Sp undefined cell line type CVCL_N682 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6592; true Female Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170297 CVCL_W013 UCLA 13 embryonic stem cell human CVCL_W013 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0293 21170298 CVCL_MU80 BayGenomics ES cell line RRF305 embryonic stem cell house mouse CVCL_MU80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444812; Camkk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170299 CVCL_N680 MU3 finite cell line CVCL_N680 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6478; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170300 CVCL_W014 UCLA 14 embryonic stem cell human CVCL_W014 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0294 21170301 CVCL_W011 GM10310 finite cell line human CVCL_W011 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21170302 CVCL_W012 GM10311 finite cell line human CVCL_W012 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21170303 CVCL_MU58 BayGenomics ES cell line RRF254 embryonic stem cell house mouse CVCL_MU58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170304 CVCL_N658 Hs 270.T finite cell line human CVCL_N658 CL:0000010 Discontinued: ATCC; CRL-7219; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170305 CVCL_MU59 BayGenomics ES cell line RRF255 embryonic stem cell house mouse CVCL_MU59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913732; Exoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170306 CVCL_N659 Hs 273.T undefined cell line type human CVCL_N659 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7221; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170307 CVCL_MU56 BayGenomics ES cell line RRF251 embryonic stem cell house mouse CVCL_MU56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683584; Ttc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170308 CVCL_N656 Hs 262.St finite cell line human CVCL_N656 CL:0000010 Derived from sampling site: Stomach. Discontinued: ATCC; CRL-7215; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170309 CVCL_MU57 BayGenomics ES cell line RRF253 embryonic stem cell house mouse CVCL_MU57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151013; Erc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170310 CVCL_N657 Hs 265.T cancer cell line human CVCL_N657 CL:0000010 Discontinued: ATCC; CRL-7216; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170311 CVCL_MU54 BayGenomics ES cell line RRF245 embryonic stem cell house mouse CVCL_MU54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337041; Serf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170312 CVCL_N654 Hs 234.Sp finite cell line human CVCL_N654 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7199; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170313 CVCL_MU55 BayGenomics ES cell line RRF248 embryonic stem cell house mouse CVCL_MU55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096342; Rhoa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170314 CVCL_N655 Hs 248.T cancer cell line human CVCL_N655 CL:0000010 Discontinued: ATCC; CRL-7210; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170315 CVCL_MU52 BayGenomics ES cell line RRF241 embryonic stem cell house mouse CVCL_MU52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170316 CVCL_N652 Hs 220.Th finite cell line human CVCL_N652 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7186; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170317 CVCL_MU53 BayGenomics ES cell line RRF242 embryonic stem cell house mouse CVCL_MU53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170318 CVCL_N653 Hs 224.T cancer cell line human CVCL_N653 CL:0000010 Discontinued: ATCC; CRL-7190; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170319 CVCL_MU50 BayGenomics ES cell line RRF235 embryonic stem cell house mouse CVCL_MU50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916618; Wdfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170320 CVCL_N650 Hs 218.Th finite cell line human CVCL_N650 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7183; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170321 CVCL_MU51 BayGenomics ES cell line RRF239 embryonic stem cell house mouse CVCL_MU51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170322 CVCL_N651 Hs 220.Sp finite cell line human CVCL_N651 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7185; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170323 CVCL_W002 GM14126 transformed cell line human CVCL_W002 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21170324 CVCL_W003 GM14127 transformed cell line human CVCL_W003 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21170325 CVCL_W000 GM14124 transformed cell line human CVCL_W000 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21170326 CVCL_W001 GM14125 transformed cell line human CVCL_W001 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170327 CVCL_MU69 BayGenomics ES cell line RRF276 embryonic stem cell house mouse CVCL_MU69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444777; Ncaph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170328 CVCL_N669 FC83.Bm finite cell line CVCL_N669 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6111; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170329 CVCL_MU67 BayGenomics ES cell line RRF269 embryonic stem cell house mouse CVCL_MU67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861601; Cpsf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170330 CVCL_N667 Hs 327.Fs finite cell line human CVCL_N667 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7241; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170331 CVCL_MU68 BayGenomics ES cell line RRF270 embryonic stem cell house mouse CVCL_MU68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170332 CVCL_N668 Hs 340.Sk finite cell line human CVCL_N668 CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7243; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170333 CVCL_MU65 BayGenomics ES cell line RRF267 embryonic stem cell house mouse CVCL_MU65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107634; Larp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170334 CVCL_N665 Hs 913(A).T cancer cell line human CVCL_N665 CL:0000010 Discontinued: ATCC; CRL-7663; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170335 CVCL_MU66 BayGenomics ES cell line RRF268 embryonic stem cell house mouse CVCL_MU66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913835; Snrnp40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170336 CVCL_N666 Hs 322.Sk finite cell line human CVCL_N666 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7238; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170337 CVCL_MU63 BayGenomics ES cell line RRF265 embryonic stem cell house mouse CVCL_MU63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170338 CVCL_N663 Hs 293.T cancer cell line human CVCL_N663 CL:0000010 Discontinued: ATCC; CRL-7231; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170339 CVCL_MU64 BayGenomics ES cell line RRF266 embryonic stem cell house mouse CVCL_MU64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2177178; Dicer1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170340 CVCL_N664 Hs 913(E).T cancer cell line human CVCL_N664 CL:0000010 Discontinued: ATCC; CRL-7667; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170341 CVCL_MU61 BayGenomics ES cell line RRF262 embryonic stem cell house mouse CVCL_MU61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170342 CVCL_N661 Hs 285.T cancer cell line human CVCL_N661 CL:0000010 Discontinued: ATCC; CRL-7229; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170343 CVCL_MU62 BayGenomics ES cell line RRF264 embryonic stem cell house mouse CVCL_MU62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442782; Baz2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170344 CVCL_N662 Hs 290.Ov finite cell line human CVCL_N662 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Discontinued: ATCC; CRL-7230; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170345 CVCL_MU60 BayGenomics ES cell line RRF256 embryonic stem cell house mouse CVCL_MU60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889008; Atp2c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170346 CVCL_N660 Hs 275.T finite cell line human CVCL_N660 CL:0000010 Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7224; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170347 CVCL_MU38 BayGenomics ES cell line RRF211 embryonic stem cell house mouse CVCL_MU38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170348 CVCL_N638 Hs 150.Bl finite cell line human CVCL_N638 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7096; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170349 CVCL_MU39 BayGenomics ES cell line RRF212 embryonic stem cell house mouse CVCL_MU39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913882; Dph6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170350 CVCL_N639 Hs 150.K finite cell line human CVCL_N639 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7097; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170351 CVCL_MU36 BayGenomics ES cell line RRF209 embryonic stem cell house mouse CVCL_MU36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170352 CVCL_N636 Hs 146.Fs finite cell line human CVCL_N636 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7094; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170353 CVCL_MU37 BayGenomics ES cell line RRF210 embryonic stem cell house mouse CVCL_MU37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170354 CVCL_N637 Hs 148.T cancer cell line human CVCL_N637 CL:0000010 Discontinued: ATCC; CRL-7095; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170355 CVCL_MU34 BayGenomics ES cell line RRF205 embryonic stem cell house mouse CVCL_MU34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103574; Amph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170356 CVCL_N634 Hs 139.Br finite cell line human CVCL_N634 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7088; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170357 CVCL_MU35 BayGenomics ES cell line RRF208 embryonic stem cell house mouse CVCL_MU35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347360; Cul3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170358 CVCL_N635 Hs 141.T cancer cell line human CVCL_N635 CL:0000010 Discontinued: ATCC; CRL-7089; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170359 CVCL_MU32 BayGenomics ES cell line RRF203 embryonic stem cell house mouse CVCL_MU32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333889; Bub1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170360 CVCL_N632 Hs 130.Br finite cell line human CVCL_N632 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7084; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170361 CVCL_MU33 BayGenomics ES cell line RRF204 embryonic stem cell house mouse CVCL_MU33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170362 CVCL_N633 Hs 133.Br finite cell line human CVCL_N633 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7086; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170363 CVCL_MU30 BayGenomics ES cell line RRF200 embryonic stem cell house mouse CVCL_MU30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109547; Dnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170364 CVCL_N630 Hs 128.Br finite cell line human CVCL_N630 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7082; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170365 CVCL_MU31 BayGenomics ES cell line RRF202 embryonic stem cell house mouse CVCL_MU31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915023; Kat8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170366 CVCL_N631 Hs 129.Br finite cell line human CVCL_N631 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7083; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170367 CVCL_MU49 BayGenomics ES cell line RRF233 embryonic stem cell house mouse CVCL_MU49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170368 CVCL_N649 Hs 218.Sp finite cell line human CVCL_N649 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-7182; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170369 CVCL_MU47 BayGenomics ES cell line RRF229 embryonic stem cell house mouse CVCL_MU47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098275; Gse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170370 CVCL_N647 Hs 214.T cancer cell line human CVCL_N647 CL:0000010 Discontinued: ATCC; CRL-7174; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170371 CVCL_MU48 BayGenomics ES cell line RRF231 embryonic stem cell house mouse CVCL_MU48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918419; Nbas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170372 CVCL_N648 Hs 218.Sk finite cell line human CVCL_N648 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7181; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170373 CVCL_MU45 BayGenomics ES cell line RRF222 embryonic stem cell house mouse CVCL_MU45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170374 CVCL_N645 Hs 199.Sk finite cell line human CVCL_N645 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7158; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170375 CVCL_MU46 BayGenomics ES cell line RRF228 embryonic stem cell house mouse CVCL_MU46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139220; Tm9sf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170376 CVCL_N646 Hs 201.Mu finite cell line human CVCL_N646 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7160; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170377 CVCL_MU43 BayGenomics ES cell line RRF218 embryonic stem cell house mouse CVCL_MU43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337994; Bcl10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170378 CVCL_N643 Hs 198.St finite cell line human CVCL_N643 CL:0000010 Derived from sampling site: Fetal stomach. Discontinued: ATCC; CRL-7155; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170379 CVCL_MU44 BayGenomics ES cell line RRF220 embryonic stem cell house mouse CVCL_MU44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344361; Arih2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170380 CVCL_N644 Hs 199.Ad finite cell line human CVCL_N644 CL:0000010 Derived from sampling site: Fetal adrenal gland. Discontinued: ATCC; CRL-7157; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170381 CVCL_MU41 BayGenomics ES cell line RRF215 embryonic stem cell house mouse CVCL_MU41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170382 CVCL_N641 Hs 198.Bm finite cell line human CVCL_N641 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-7153; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170383 CVCL_MU42 BayGenomics ES cell line RRF217 embryonic stem cell house mouse CVCL_MU42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170384 CVCL_N642 Hs 198.Li finite cell line human CVCL_N642 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7154; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170385 CVCL_MU40 BayGenomics ES cell line RRF214 embryonic stem cell house mouse CVCL_MU40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352465; Nr2c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170386 CVCL_N640 Hs 198.Bl finite cell line human CVCL_N640 CL:0000010 Derived from sampling site: Fetal urinary bladder Cell type=Fibroblast.. Discontinued: ATCC; CRL-7152; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170387 CVCL_MU18 BayGenomics ES cell line RRF175 embryonic stem cell house mouse CVCL_MU18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170388 CVCL_N618 Hs 242T cancer cell line human CVCL_N618 CL:0000010 Discontinued: ATCC; HTB-145; true. Male 21170389 CVCL_MU19 BayGenomics ES cell line RRF177 embryonic stem cell house mouse CVCL_MU19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913874; Spcs2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170390 CVCL_N619 Hs 44.Fs finite cell line human CVCL_N619 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7024; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170391 CVCL_MU16 BayGenomics ES cell line RRF173 embryonic stem cell house mouse CVCL_MU16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102774; Aimp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170392 CVCL_N616 Hs 417.Li finite cell line human CVCL_N616 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7290; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170393 CVCL_MU17 BayGenomics ES cell line RRF174 embryonic stem cell house mouse CVCL_MU17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860513; Fnbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170394 CVCL_N617 Hs 422.T cancer cell line human CVCL_N617 CL:0000010 Discontinued: ATCC; CRL-7293; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170395 CVCL_MU14 BayGenomics ES cell line RRF169 embryonic stem cell house mouse CVCL_MU14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170396 CVCL_N614 Hs 355.T cancer cell line human CVCL_N614 CL:0000010 Derived from sampling site: Gallbladder. Discontinued: ATCC; CRL-7251; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170397 CVCL_MU15 BayGenomics ES cell line RRF171 embryonic stem cell house mouse CVCL_MU15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170398 CVCL_N615 Hs 388.T cancer cell line human CVCL_N615 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7264; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170399 CVCL_MU12 BayGenomics ES cell line RRF166 embryonic stem cell house mouse CVCL_MU12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170400 CVCL_N612 Hs 352.Lu finite cell line human CVCL_N612 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7249; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170401 CVCL_MU13 BayGenomics ES cell line RRF167 embryonic stem cell house mouse CVCL_MU13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170402 CVCL_N613 Hs 352.Sk finite cell line human CVCL_N613 CL:0000010 Derived from sampling site: Fetal muscle and skin. Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-7250; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170403 CVCL_MU10 BayGenomics ES cell line RRF162 embryonic stem cell house mouse CVCL_MU10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170404 CVCL_N610 Hs 112.Tr finite cell line human CVCL_N610 CL:0000010 Derived from sampling site: Fetal trachea. Discontinued: ATCC; CRL-7076; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170405 CVCL_MU11 BayGenomics ES cell line RRF163 embryonic stem cell house mouse CVCL_MU11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682952; Prdm10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170406 CVCL_N611 Hs 347.T cancer cell line human CVCL_N611 CL:0000010 Discontinued: ATCC; CRL-7247; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170407 CVCL_MU29 BayGenomics ES cell line RRF197 embryonic stem cell house mouse CVCL_MU29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170408 CVCL_N629 Hs 74.Lu finite cell line human CVCL_N629 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7054; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170409 CVCL_MU27 BayGenomics ES cell line RRF190 embryonic stem cell house mouse CVCL_MU27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353654; Vps26a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170410 CVCL_N627 Hs 74.Hp finite cell line human CVCL_N627 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-7052; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170411 CVCL_MU28 BayGenomics ES cell line RRF194 embryonic stem cell house mouse CVCL_MU28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170412 CVCL_N628 Hs 74.Ht finite cell line human CVCL_N628 CL:0000010 Derived from sampling site: Fetal heart. Discontinued: ATCC; CRL-7053; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170413 CVCL_MU25 BayGenomics ES cell line RRF188 embryonic stem cell house mouse CVCL_MU25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918335; Arhgap19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170414 CVCL_N625 Hs 74.Ad finite cell line human CVCL_N625 CL:0000010 Derived from sampling site: Fetal adrenal gland. Discontinued: ATCC; CRL-7050; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170415 CVCL_MU26 BayGenomics ES cell line RRF189 embryonic stem cell house mouse CVCL_MU26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919353; Aplf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170416 CVCL_N626 Hs 74.Bm finite cell line human CVCL_N626 CL:0000010 Derived from sampling site: Fetal bone marrow Cell type=Fibroblast.. Discontinued: ATCC; CRL-7051; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170417 CVCL_MU23 BayGenomics ES cell line RRF186 embryonic stem cell house mouse CVCL_MU23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894292; Mtr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170418 CVCL_N623 Hs 66.Sk/Mu finite cell line human CVCL_N623 CL:0000010 Donor information: Obtained from a pool of tissues from twin fetuses; Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7045; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170419 CVCL_MU24 BayGenomics ES cell line RRF187 embryonic stem cell house mouse CVCL_MU24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643401; Gm8935 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170420 CVCL_N624 Hs 66.Th finite cell line human CVCL_N624 CL:0000010 Donor information: Obtained from twin A of the twin fetuses from which Hs 66.Sk/Mu (Cellosaurus=CVCL_N623) is derived; Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7046; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170421 CVCL_MU21 BayGenomics ES cell line RRF181 embryonic stem cell house mouse CVCL_MU21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1340806; Parp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170422 CVCL_N621 Hs 59.Fs finite cell line human CVCL_N621 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7039; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170423 CVCL_MU22 BayGenomics ES cell line RRF184 embryonic stem cell house mouse CVCL_MU22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153272; Trrap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170424 CVCL_N622 Hs 64.T cancer cell line human CVCL_N622 CL:0000010 Discontinued: ATCC; CRL-7044; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170425 CVCL_MU20 BayGenomics ES cell line RRF180 embryonic stem cell house mouse CVCL_MU20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928899; Tacc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170426 CVCL_N620 Hs 51.Mu finite cell line human CVCL_N620 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7029; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170427 CVCL_3I52 HQ00863 transformed cell line human CVCL_3I52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170428 CVCL_3I53 HQ00864 transformed cell line human CVCL_3I53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170429 CVCL_3I50 HQ00861 transformed cell line human CVCL_3I50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170430 CVCL_3I51 HQ00862 transformed cell line human CVCL_3I51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170431 CVCL_3I56 HQ00867 transformed cell line human CVCL_3I56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170432 CVCL_3I57 HQ00868 transformed cell line human CVCL_3I57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170433 CVCL_3I54 HQ00865 transformed cell line human CVCL_3I54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170434 CVCL_3I55 HQ00866 transformed cell line human CVCL_3I55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170435 CVCL_3I58 HQ00869 transformed cell line human CVCL_3I58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170436 CVCL_3I59 HQ00870 transformed cell line human CVCL_3I59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170437 CVCL_3I60 HQ00871 transformed cell line human CVCL_3I60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170438 CVCL_3I63 HQ00874 transformed cell line human CVCL_3I63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170439 CVCL_3I64 HQ00875 transformed cell line human CVCL_3I64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170440 CVCL_3I61 HQ00872 transformed cell line human CVCL_3I61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170441 CVCL_3I62 HQ00873 transformed cell line human CVCL_3I62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170442 CVCL_3I67 HQ00879 transformed cell line human CVCL_3I67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170443 CVCL_3I68 HQ00880 transformed cell line human CVCL_3I68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170444 CVCL_3I65 HQ00876 transformed cell line human CVCL_3I65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170445 CVCL_3I66 HQ00878 transformed cell line human CVCL_3I66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170446 CVCL_3I69 HQ00881 transformed cell line human CVCL_3I69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170447 CVCL_W090 CHES7 embryonic stem cell human CVCL_W090 From: University Hospital of Basel; Basel; Switzerland CL:0000010 Unspecified Registration: Swiss research registry; BAG-hES-GEW-0006. 21170448 CVCL_W093 BRIN-BG5 hybrid cell line Norway rat CVCL_W093 CL:0000010 Breed/subspecies: NEDH. Doubling time: ~28 hours (ECACC=10033001) 21170449 CVCL_W094 BRIN-BG7 hybrid cell line Norway rat CVCL_W094 CL:0000010 Breed/subspecies: NEDH. Doubling time: ~20 hours (ECACC=10020902) 21170450 CVCL_W091 UACC-3247 cancer cell line human CVCL_W091 CL:0000010 Discontinued: ATCC; CRL-3124; probable. Female 21170451 CVCL_W092 UACC-2996 cancer cell line human CVCL_W092 CL:0000010 Discontinued: ATCC; CRL-3123; probable. Female 21170452 CVCL_W097 KCF-1 spontaneously immortalized cell line CVCL_W097 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Koi. Unspecified Group: Fish cell line 21170453 CVCL_W098 NGF-2 spontaneously immortalized cell line CVCL_W098 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21170454 CVCL_W095 KF1 spontaneously immortalized cell line CVCL_W095 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.; Breed/subspecies: Koi. Unspecified Group: Fish cell line 21170455 CVCL_W096 CCB spontaneously immortalized cell line CVCL_W096 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Highly susceptible to infection by common carp paramyxovirus (CCPV) (PubMed=35934930); Virology: Susceptible to infection by cyprinid herpesvirus 3 (CyHV-3) Taiwan isolate (KHV-T) (PubMed=35934930); Virology: Not susceptible to infection by carp edema virus (CEV) (PubMed=35934930) Group: Fish cell line 21170456 CVCL_W099 NGF-3 spontaneously immortalized cell line CVCL_W099 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21170457 CVCL_3I30 HQ00841 transformed cell line human CVCL_3I30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170458 CVCL_3I31 HQ00842 transformed cell line human CVCL_3I31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170459 CVCL_3I34 HQ00845 transformed cell line human CVCL_3I34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170460 CVCL_3I35 HQ00846 transformed cell line human CVCL_3I35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170461 CVCL_3I32 HQ00843 transformed cell line human CVCL_3I32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170462 CVCL_3I33 HQ00844 transformed cell line human CVCL_3I33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170463 CVCL_3I38 HQ00849 transformed cell line human CVCL_3I38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170464 CVCL_3I39 HQ00850 transformed cell line human CVCL_3I39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170465 CVCL_3I36 HQ00847 transformed cell line human CVCL_3I36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170466 CVCL_3I37 HQ00848 transformed cell line human CVCL_3I37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170467 CVCL_3I29 HQ00840 transformed cell line human CVCL_3I29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170468 CVCL_W082 SU511 cancer cell line human CVCL_W082 CL:0000010 Omics: SNP array analysis. 21170469 CVCL_W083 O24B cancer cell line human CVCL_W083 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Gln322fs*9 (c.966_978del13); Zygosity=Homozygous (PubMed=21642991) Omics: SNP array analysis. 21170470 CVCL_W080 H10 transformed cell line Norway rat CVCL_W080 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Cardiomyocyte.; Breed/subspecies: Wistar. Unspecified 21170471 CVCL_W081 E6SM finite cell line human CVCL_W081 CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Unspecified 21170472 CVCL_W086 HO275 cancer cell line human CVCL_W086 CL:0000010 Omics: SNP array analysis 21170473 CVCL_W087 Twin-N-iPSCs line#8 induced pluripotent stem cell human CVCL_W087 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Karyotypic information: 45,X (PubMed=32739879); Donor information: Twin-DS-iPSC (Cellosaurus=CVCL_W088) and Twin-N-iPSC originate from monozygotic twins discordant for trisomy 21; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Female 21170474 CVCL_W084 VGE cancer cell line human CVCL_W084 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Phe118Leufs*69 (c.354delC); Zygosity=Heterozygous (PubMed=21642991) Omics: SNP array analysis. 21170475 CVCL_W085 MH [Human mesothelioma] cancer cell line human CVCL_W085 CL:0000010 Omics: SNP array analysis. 21170476 CVCL_W088 Twin-DS-iPSC induced pluripotent stem cell human CVCL_W088 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Donor information: Twin-DS-iPSC and Twin-N-iPSC (Cellosaurus=CVCL_B4L3 and CVCL_W087) originate from monozygotic twins discordant for trisomy 21; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21170477 CVCL_W089 CHES6 embryonic stem cell human CVCL_W089 From: University Hospital of Basel; Basel; Switzerland CL:0000010 Male Registration: Swiss research registry; BAG-hES-GEW-0005. 21170478 CVCL_3I41 HQ00852 transformed cell line human CVCL_3I41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170479 CVCL_3I42 HQ00853 transformed cell line human CVCL_3I42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170480 CVCL_3I40 HQ00851 transformed cell line human CVCL_3I40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170481 CVCL_3I45 HQ00856 transformed cell line human CVCL_3I45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170482 CVCL_3I46 HQ00857 transformed cell line human CVCL_3I46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170483 CVCL_3I43 HQ00854 transformed cell line human CVCL_3I43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170484 CVCL_3I44 HQ00855 transformed cell line human CVCL_3I44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170485 CVCL_3I49 HQ00860 transformed cell line human CVCL_3I49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170486 CVCL_3I47 HQ00858 transformed cell line human CVCL_3I47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170487 CVCL_3I48 HQ00859 transformed cell line human CVCL_3I48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170488 CVCL_W071 WR036 transformed cell line human CVCL_W071 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Heterozygous; Note=APRT*J allele (PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170489 CVCL_W072 WR063 transformed cell line human CVCL_W072 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170490 CVCL_W070 WR035 transformed cell line human CVCL_W070 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Heterozygous; Note=APRT*J allele (PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170491 CVCL_W075 WR077 transformed cell line human CVCL_W075 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170492 CVCL_W076 WR081 transformed cell line human CVCL_W076 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170493 CVCL_W073 WR064 transformed cell line human CVCL_W073 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Heterozygous; Note=APRT*J allele (PubMed=3343350) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170494 CVCL_W074 WR067 transformed cell line human CVCL_W074 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170495 CVCL_W079 Melan-a Hm spontaneously immortalized cell line house mouse CVCL_W079 CL:0000010 Transfected with: HGNC; 3236; EGFR (extracellular domain); Transfected with: UniProtKB; P13388; Xiphophorus maculatus xmrk (intracellular domain) Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Transfected with a chimeric tyrosine-protein kinase receptor composed of extracellular part of human EGFR and the intracellular part of Xmrk Stimulation of the chimera with EGF induces activation of the xmrk kinase domain. 21170496 CVCL_W077 WR083 transformed cell line human CVCL_W077 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170497 CVCL_W078 340-RPE-11tv telomerase immortalized cell line human CVCL_W078 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Eye; retina; retinal pigment epithelium. Discontinued: ATCC; CRL-4002; true Female 21170498 CVCL_W059 GM17819 finite cell line human CVCL_W059 CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Unexplicit; Ex8-10del; Zygosity=Hemizygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21170499 CVCL_3I12 HQ00823 transformed cell line human CVCL_3I12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170500 CVCL_3I13 HQ00824 transformed cell line human CVCL_3I13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170501 CVCL_3I10 HQ00821 transformed cell line human CVCL_3I10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170502 CVCL_3I11 HQ00822 transformed cell line human CVCL_3I11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170503 CVCL_3I16 HQ00827 transformed cell line human CVCL_3I16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170504 CVCL_3I17 HQ00828 transformed cell line human CVCL_3I17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170505 CVCL_3I14 HQ00825 transformed cell line human CVCL_3I14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170506 CVCL_3I15 HQ00826 transformed cell line human CVCL_3I15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170507 CVCL_3I09 HQ00820 transformed cell line human CVCL_3I09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170508 CVCL_3I07 HQ00816 transformed cell line human CVCL_3I07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170509 CVCL_3I08 HQ00819 transformed cell line human CVCL_3I08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170510 CVCL_W060 WR002 transformed cell line human CVCL_W060 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170511 CVCL_W061 WR004 transformed cell line human CVCL_W061 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170512 CVCL_W064 WR011 transformed cell line human CVCL_W064 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Lys88Profs*23 (c.258_261dupCCGA); ClinVar=VCV000018299; Zygosity=Homozygous; Note=APRT*Q0 allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170513 CVCL_W065 WR012 transformed cell line human CVCL_W065 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170514 CVCL_W062 WR005 transformed cell line human CVCL_W062 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170515 CVCL_W063 WR010 transformed cell line human CVCL_W063 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Lys88Profs*23 (c.258_261dupCCGA); ClinVar=VCV000018299; Zygosity=Heterozygous; Note=APRT*Q0 allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170516 CVCL_W068 WR017 transformed cell line human CVCL_W068 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Lys88Profs*23 (c.258_261dupCCGA); ClinVar=VCV000018299; Zygosity=Heterozygous; Note=APRT*Q0 allele (PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170517 CVCL_W069 WR020 transformed cell line human CVCL_W069 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3343350; PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170518 CVCL_W066 WR015 transformed cell line human CVCL_W066 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Lys88Profs*23 (c.258_261dupCCGA); ClinVar=VCV000018299; Zygosity=Homozygous; Note=APRT*Q0 allele (PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170519 CVCL_W067 WR016 transformed cell line human CVCL_W067 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Met136Thr (c.407T>C); ClinVar=VCV000018296; Zygosity=Homozygous; Note=APRT*J allele (PubMed=3488062) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21170520 CVCL_W048 GM06333 finite cell line human CVCL_W048 CL:0000010 Sequence variation: Mutation; HGNC; 16002; MPLKIP; Simple; p.Gly46Glufs*13 (c.137_138delGG) (187_188delGG); ClinVar=VCV000001845; Zygosity=Homozygous (Coriell) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170521 CVCL_W049 XP11BR finite cell line human CVCL_W049 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gly263Val (c.788G>T); dbSNP=rs1413703153; Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170522 CVCL_3I20 HQ00831 transformed cell line human CVCL_3I20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170523 CVCL_3I23 HQ00834 transformed cell line human CVCL_3I23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170524 CVCL_3I24 HQ00835 transformed cell line human CVCL_3I24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170525 CVCL_3I21 HQ00832 transformed cell line human CVCL_3I21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170526 CVCL_3I22 HQ00833 transformed cell line human CVCL_3I22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170527 CVCL_3I27 HQ00838 transformed cell line human CVCL_3I27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170528 CVCL_3I28 HQ00839 transformed cell line human CVCL_3I28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170529 CVCL_3I25 HQ00836 transformed cell line human CVCL_3I25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170530 CVCL_3I26 HQ00837 transformed cell line human CVCL_3I26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170531 CVCL_3I18 HQ00829 transformed cell line human CVCL_3I18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170532 CVCL_3I19 HQ00830 transformed cell line human CVCL_3I19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170533 CVCL_W050 CS4BR finite cell line human CVCL_W050 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Gln184Ter (c.550C>T) (C629T); ClinVar=VCV001459151; Zygosity=Heterozygous (PubMed=9443879); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg670Trp (c.2008C>T) (C2087T); ClinVar=VCV000190158; Zygosity=Heterozygous (PubMed=9443879) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170534 CVCL_W053 XP125LO finite cell line human CVCL_W053 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala792Val (c.2375C>T) (2572C>T); ClinVar=VCV000016567; Zygosity=Heterozygous (from autologous cell line XP125LO LCL); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu960Ter (c.2878G>T) (3075G>T); ClinVar=VCV000016566; Zygosity=Heterozygous (from autologous cell line XP125LO LCL) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170535 CVCL_W054 GM00110 finite cell line human CVCL_W054 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro237Ser (c.709C>T); ClinVar=VCV000021142; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Phe740_Ser741del (c.2217_2222delCTTTTC); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170536 CVCL_W051 XP8BR finite cell line human CVCL_W051 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg669fs (c.2005delA); ClinVar=VCV000445466; Zygosity=Heterozygous (PubMed=7825573); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly675Arg (c.2023G>C); Zygosity=Heterozygous (PubMed=7825573) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170537 CVCL_W052 TTD4BR finite cell line human CVCL_W052 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170538 CVCL_W057 GM00369 finite cell line human CVCL_W057 CL:0000010 Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 30.6 +- 0.8 hours (PubMed=1214005) 21170539 CVCL_W058 GM00370 finite cell line human CVCL_W058 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21170540 CVCL_W055 GM00367 finite cell line human CVCL_W055 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21170541 CVCL_W056 GM00368 finite cell line human CVCL_W056 CL:0000010 Population: African American; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male Doubling time: 30.7 +- 1.6 hours (PubMed=1214005) 21170542 CVCL_W039 GM09442 finite cell line human CVCL_W039 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21170543 CVCL_W037 GM09032 finite cell line human CVCL_W037 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gly334Asp (c.1001G>A) (G317D, 1177A); ClinVar=VCV000013672; Zygosity=Homozygous (PubMed=8675582) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21170544 CVCL_W038 GM09033 finite cell line human CVCL_W038 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gly334Asp (c.1001G>A) (G317D, 1177A); ClinVar=VCV000013672; Zygosity=Homozygous (PubMed=8675582) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170545 CVCL_MU98 BayGenomics ES cell line RRF355 embryonic stem cell house mouse CVCL_MU98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145890; Ano6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170546 CVCL_N698 Hs 507.T cancer cell line human CVCL_N698 CL:0000010 Discontinued: ATCC; CRL-7308; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170547 CVCL_MU99 BayGenomics ES cell line RRF357 embryonic stem cell house mouse CVCL_MU99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861601; Cpsf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170548 CVCL_N699 Hs 514.T undefined cell line type human CVCL_N699 CL:0000010 Discontinued: ATCC; CRL-7310; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170549 CVCL_MU96 BayGenomics ES cell line RRF351 embryonic stem cell house mouse CVCL_MU96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109602; Gphn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170550 CVCL_N696 Hs 503.Sk finite cell line human CVCL_N696 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7304; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170551 CVCL_MU97 BayGenomics ES cell line RRF352 embryonic stem cell house mouse CVCL_MU97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916412; Sec31a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170552 CVCL_N697 Hs 504.T cancer cell line human CVCL_N697 CL:0000010 Discontinued: ATCC; CRL-7305; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170553 CVCL_MU94 BayGenomics ES cell line RRF343 embryonic stem cell house mouse CVCL_MU94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151013; Erc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170554 CVCL_W042 BS2KA finite cell line human CVCL_W042 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (from autologous cell line HG1626) Population: Japanese; Donor information: From Bloom Syndrome Registry patient 93(YoYa) (BSR93); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1864; probable Male 21170555 CVCL_N694 Hs 428.Li finite cell line human CVCL_N694 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7297; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170556 CVCL_W043 AG03829 transformed cell line human CVCL_W043 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170557 CVCL_MU95 BayGenomics ES cell line RRF345 embryonic stem cell house mouse CVCL_MU95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346345; Map2k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170558 CVCL_N695 Hs 494 finite cell line human CVCL_N695 CL:0000010 Derived from sampling site: Peritoneum. Discontinued: ATCC; CRL-7301; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170559 CVCL_MU92 BayGenomics ES cell line RRF339 embryonic stem cell house mouse CVCL_MU92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919668; Thoc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170560 CVCL_W040 GM06168 finite cell line human CVCL_W040 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170561 CVCL_N692 Hs 426.T cancer cell line human CVCL_N692 CL:0000010 Discontinued: ATCC; CRL-7295; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170562 CVCL_MU93 BayGenomics ES cell line RRF342 embryonic stem cell house mouse CVCL_MU93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170563 CVCL_W041 GM06169 finite cell line human CVCL_W041 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21170564 CVCL_N693 Hs 427.Sp finite cell line human CVCL_N693 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-7296; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170565 CVCL_MU90 BayGenomics ES cell line RRF334 embryonic stem cell house mouse CVCL_MU90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170566 CVCL_N690 Hs 421 finite cell line human CVCL_N690 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7292; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170567 CVCL_W046 TTD1BR finite cell line human CVCL_W046 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Leu21Pro (c.62T>C); ClinVar=VCV000002104; Zygosity=Heterozygous (PubMed=15220921); Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Arg56Ter (c.166C>T); ClinVar=VCV000002103; Zygosity=Heterozygous (PubMed=15220921) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170568 CVCL_MU91 BayGenomics ES cell line RRF338 embryonic stem cell house mouse CVCL_MU91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915545; Aar2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170569 CVCL_W047 GM06332 finite cell line human CVCL_W047 CL:0000010 Sequence variation: Mutation; HGNC; 16002; MPLKIP; Simple; p.Gly46Glufs*13 (c.137_138delGG) (187_188delGG); ClinVar=VCV000001845; Zygosity=Homozygous (Coriell) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170570 CVCL_N691 Hs 425.T cancer cell line human CVCL_N691 CL:0000010 Discontinued: ATCC; CRL-7294; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170571 CVCL_W044 WPF22 finite cell line pig CVCL_W044 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Wuzhishan miniature pig. Male Doubling time: 30.2 hours (PubMed=24556363) Group: Endangered species/breed cell line 21170572 CVCL_W045 TTDHM1BR finite cell line human CVCL_W045 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170573 CVCL_W028 GM03859 finite cell line human CVCL_W028 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Arg71Pro (c.212G>C) (R54P, 388C); ClinVar=VCV000013665; Zygosity=Heterozygous (PubMed=1409720); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Gln207Pro (c.620A>C) (Q190P, 796C); ClinVar=VCV000013666; Zygosity=Heterozygous (PubMed=1409720) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21170574 CVCL_W029 GM04235 finite cell line human CVCL_W029 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Arg71Cys (c.211C>T) (R54C, 378T); ClinVar=VCV000013663; Zygosity=Heterozygous (PubMed=1409720); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Asp294Ala (c.881A>C) (D277A, 1057C); ClinVar=VCV000013664; Zygosity=Heterozygous (PubMed=1409720) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170575 CVCL_W026 GM10919 finite cell line human CVCL_W026 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170576 CVCL_W027 GM05335 finite cell line human CVCL_W027 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21170577 CVCL_3I01 HQ00810 transformed cell line human CVCL_3I01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170578 CVCL_3I02 HQ00811 transformed cell line human CVCL_3I02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170579 CVCL_3I00 HQ00809 transformed cell line human CVCL_3I00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170580 CVCL_3I05 HQ00814 transformed cell line human CVCL_3I05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170581 CVCL_3I06 HQ00815 transformed cell line human CVCL_3I06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170582 CVCL_3I03 HQ00812 transformed cell line human CVCL_3I03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170583 CVCL_3I04 HQ00813 transformed cell line human CVCL_3I04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170584 CVCL_W031 GM01571 finite cell line human CVCL_W031 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21170585 CVCL_W032 GM03459 finite cell line human CVCL_W032 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170586 CVCL_W030 GM00031 finite cell line human CVCL_W030 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21170587 CVCL_W035 GM08581 finite cell line human CVCL_W035 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21170588 CVCL_W036 GM08690 finite cell line human CVCL_W036 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Ala33Val (c.98C>T) (A16V, 274T); ClinVar=VCV000013667; Zygosity=Unspecified (PubMed=8675582) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21170589 CVCL_W033 GM08373 transformed cell line human CVCL_W033 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Ala33Val (c.98C>T) (A16V, 274T); ClinVar=VCV000013667; Zygosity=Unspecified (from autologous cell line GM08690) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170590 CVCL_W034 GM08435 finite cell line human CVCL_W034 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Ala33Val (c.98C>T) (A16V, 274T); ClinVar=VCV000013667; Zygosity=Unspecified (from autologous cell line GM08690) Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21170591 CVCL_3J91 HQ01004 transformed cell line human CVCL_3J91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170592 CVCL_3J92 HQ01005 transformed cell line human CVCL_3J92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170593 CVCL_3J90 HQ01003 transformed cell line human CVCL_3J90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170594 CVCL_3J95 HQ01008 transformed cell line human CVCL_3J95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170595 CVCL_3J96 HQ01009 transformed cell line human CVCL_3J96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170596 CVCL_3J93 HQ01006 transformed cell line human CVCL_3J93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170597 CVCL_3J94 HQ01007 transformed cell line human CVCL_3J94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170598 CVCL_3J99 HQ01012 transformed cell line human CVCL_3J99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170599 CVCL_3J97 HQ01010 transformed cell line human CVCL_3J97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170600 CVCL_3J98 HQ01011 transformed cell line human CVCL_3J98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170601 CVCL_N838 ACI-80 cancer cell line human CVCL_N838 CL:0000010 Derived from sampling site: Endometrium. Female 21170602 CVCL_MW38 BayGenomics ES cell line RRG221 embryonic stem cell house mouse CVCL_MW38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170603 CVCL_N839 ACI-98 cancer cell line human CVCL_N839 CL:0000010 Derived from sampling site: Endometrium. Female 21170604 CVCL_MW39 BayGenomics ES cell line RRG222 embryonic stem cell house mouse CVCL_MW39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924258; Ppp1r12c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170605 CVCL_N836 ACI-68 cancer cell line human CVCL_N836 CL:0000010 Derived from sampling site: Endometrium. Female 21170606 CVCL_MW36 BayGenomics ES cell line RRG217 embryonic stem cell house mouse CVCL_MW36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170607 CVCL_N837 ACI-70 cancer cell line human CVCL_N837 CL:0000010 Female 21170608 CVCL_MW37 BayGenomics ES cell line RRG220 embryonic stem cell house mouse CVCL_MW37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170609 CVCL_N834 ACI-52 cancer cell line human CVCL_N834 CL:0000010 Derived from sampling site: Endometrium. Female 21170610 CVCL_MW34 BayGenomics ES cell line RRG209 embryonic stem cell house mouse CVCL_MW34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170611 CVCL_N835 ACI-61 cancer cell line human CVCL_N835 CL:0000010 Derived from sampling site: Endometrium. Female 21170612 CVCL_MW35 BayGenomics ES cell line RRG216 embryonic stem cell house mouse CVCL_MW35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170613 CVCL_N832 ACI-54 cancer cell line human CVCL_N832 CL:0000010 Female 21170614 CVCL_MW32 BayGenomics ES cell line RRG205 embryonic stem cell house mouse CVCL_MW32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448541; Caprin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170615 CVCL_N833 ACI-45 cancer cell line human CVCL_N833 CL:0000010 Female 21170616 CVCL_MW33 BayGenomics ES cell line RRG207 embryonic stem cell house mouse CVCL_MW33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108498; Nbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170617 CVCL_N830 ACI-23 cancer cell line human CVCL_N830 CL:0000010 Female 21170618 CVCL_MW30 BayGenomics ES cell line RRG198 embryonic stem cell house mouse CVCL_MW30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921772; Morc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170619 CVCL_N831 ACI-27 cancer cell line human CVCL_N831 CL:0000010 Female 21170620 CVCL_MW31 BayGenomics ES cell line RRG204 embryonic stem cell house mouse CVCL_MW31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927197; Shoc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170621 CVCL_MW49 BayGenomics ES cell line RRG269 embryonic stem cell house mouse CVCL_MW49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891150; Styx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170622 CVCL_N849 HX165c cancer cell line human CVCL_N849 CL:0000010 Male Doubling time: 38 hours (PubMed=3179184). 21170623 CVCL_MW47 BayGenomics ES cell line RRG260 embryonic stem cell house mouse CVCL_MW47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170624 CVCL_N847 GRU-1B cancer cell line human CVCL_N847 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 16 hours (PubMed=7525493) 21170625 CVCL_MW48 BayGenomics ES cell line RRG262 embryonic stem cell house mouse CVCL_MW48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170626 CVCL_N848 GRU-1C cancer cell line human CVCL_N848 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 13 hours (PubMed=7525493) 21170627 CVCL_MW45 BayGenomics ES cell line RRG257 embryonic stem cell house mouse CVCL_MW45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170628 CVCL_N845 GRU-1 cancer cell line human CVCL_N845 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 29 hours (PubMed=1688830); 17 hours (PubMed=7525493) 21170629 CVCL_MW46 BayGenomics ES cell line RRG259 embryonic stem cell house mouse CVCL_MW46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170630 CVCL_N846 GRU-1A cancer cell line human CVCL_N846 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 19 hours (PubMed=7525493) 21170631 CVCL_MW43 BayGenomics ES cell line RRG252 embryonic stem cell house mouse CVCL_MW43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106014; Nudc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170632 CVCL_N843 Epi-544 cancer cell line human CVCL_N843 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=26365879) Omics: Transcriptome analysis by RNAseq. Female Doubling time: ~48 hours (PubMed=21357725) 21170633 CVCL_MW44 BayGenomics ES cell line RRG255 embryonic stem cell house mouse CVCL_MW44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170634 CVCL_N844 ES020488 cancer cell line human CVCL_N844 CL:0000010 Male Doubling time: ~60 hours (PubMed=7685133). 21170635 CVCL_MW41 BayGenomics ES cell line RRG248 embryonic stem cell house mouse CVCL_MW41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170636 CVCL_N841 NCI-EC1 cancer cell line human CVCL_N841 CL:0000010 Derived from sampling site: Endometrium. Female 21170637 CVCL_MW42 BayGenomics ES cell line RRG250 embryonic stem cell house mouse CVCL_MW42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924894; Steep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170638 CVCL_N842 NCI-EC2 cancer cell line human CVCL_N842 CL:0000010 Female 21170639 CVCL_MW40 BayGenomics ES cell line RRG223 embryonic stem cell house mouse CVCL_MW40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170640 CVCL_N840 Hs 692(C).Int finite cell line human CVCL_N840 CL:0000010 Derived from sampling site: Intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-7430; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170641 CVCL_MW18 BayGenomics ES cell line RRG169 embryonic stem cell house mouse CVCL_MW18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913929; Rae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170642 CVCL_N818 ROB [Human mesothelioma] cancer cell line human CVCL_N818 CL:0000010 Derived from sampling site: Ascites. Male 21170643 CVCL_MW19 BayGenomics ES cell line RRG171 embryonic stem cell house mouse CVCL_MW19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150019; Spred2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170644 CVCL_N819 YOU cancer cell line human CVCL_N819 CL:0000010 Derived from sampling site: Ascites. Male 21170645 CVCL_MW16 BayGenomics ES cell line RRG166 embryonic stem cell house mouse CVCL_MW16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170646 CVCL_N816 PET cancer cell line human CVCL_N816 CL:0000010 Derived from sampling site: Ascites. Female 21170647 CVCL_MW17 BayGenomics ES cell line RRG168 embryonic stem cell house mouse CVCL_MW17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170648 CVCL_N817 PRO cancer cell line human CVCL_N817 CL:0000010 Derived from sampling site: Ascites. Male 21170649 CVCL_MW14 BayGenomics ES cell line RRG159 embryonic stem cell house mouse CVCL_MW14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101877; Tcf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170650 CVCL_N814 HEC cancer cell line human CVCL_N814 CL:0000010 Derived from sampling site: Ascites. Male 21170651 CVCL_MW15 BayGenomics ES cell line RRG163 embryonic stem cell house mouse CVCL_MW15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2150019; Spred2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170652 CVCL_N815 ORT cancer cell line human CVCL_N815 CL:0000010 Derived from sampling site: Ascites. Female 21170653 CVCL_MW12 BayGenomics ES cell line RRG157 embryonic stem cell house mouse CVCL_MW12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914934; Luc7l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170654 CVCL_N812 Hs 322.Lu finite cell line human CVCL_N812 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7237; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170655 CVCL_MW13 BayGenomics ES cell line RRG158 embryonic stem cell house mouse CVCL_MW13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153608; Ube2j2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170656 CVCL_N813 HAY cancer cell line human CVCL_N813 CL:0000010 Derived from sampling site: Ascites. Male 21170657 CVCL_MW10 BayGenomics ES cell line RRG147 embryonic stem cell house mouse CVCL_MW10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109447; Ctcf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170658 CVCL_N810 Hs 377.T cancer cell line human CVCL_N810 CL:0000010 Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7258; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170659 CVCL_MW11 BayGenomics ES cell line RRG151 embryonic stem cell house mouse CVCL_MW11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643019; Gm6360 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170660 CVCL_N811 Hs 296.Thd finite cell line human CVCL_N811 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Fibroblast.. Discontinued: ATCC; CRL-7234; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170661 CVCL_N829 ACI-8 cancer cell line human CVCL_N829 CL:0000010 Female 21170662 CVCL_MW29 BayGenomics ES cell line RRG197 embryonic stem cell house mouse CVCL_MW29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443876; Zbtb11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170663 CVCL_N827 ACI-126 cancer cell line human CVCL_N827 CL:0000010 Derived from sampling site: Endometrium. Omics: ATAC-seq Female 21170664 CVCL_MW27 BayGenomics ES cell line RRG193 embryonic stem cell house mouse CVCL_MW27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921772; Morc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170665 CVCL_N828 ACI-181 cancer cell line human CVCL_N828 CL:0000010 Derived from sampling site: Endometrium. Female 21170666 CVCL_MW28 BayGenomics ES cell line RRG195 embryonic stem cell house mouse CVCL_MW28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923959; Arpc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170667 CVCL_MW25 BayGenomics ES cell line RRG185 embryonic stem cell house mouse CVCL_MW25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914705; Klhl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170668 CVCL_N825 CL83 cancer cell line human CVCL_N825 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Deep membrane proteome analysis Male 21170669 CVCL_MW26 BayGenomics ES cell line RRG188 embryonic stem cell house mouse CVCL_MW26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344336; Fiz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170670 CVCL_N826 CL97 cancer cell line human CVCL_N826 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly719Ala (c.2156G>C); ClinVar=VCV000045225; Zygosity=Unspecified (PubMed=23024022); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Unspecified (PubMed=23024022); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=23024022; PubMed=26202522) Derived from metastatic site: Pleural effusion. Omics: Deep membrane proteome analysis Male 21170671 CVCL_MW23 BayGenomics ES cell line RRG179 embryonic stem cell house mouse CVCL_MW23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170672 CVCL_N823 CL152 cancer cell line human CVCL_N823 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=23024022; PubMed=26202522) Derived from metastatic site: Pleural effusion. Omics: Deep membrane proteome analysis Male 21170673 CVCL_MW24 BayGenomics ES cell line RRG184 embryonic stem cell house mouse CVCL_MW24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344336; Fiz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170674 CVCL_N824 CL25 cancer cell line human CVCL_N824 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Tyr (c.404G>A); ClinVar=VCV000141762; Zygosity=Unspecified (PubMed=23024022; PubMed=26202522) Derived from metastatic site: Pleural effusion. Omics: Deep membrane proteome analysis Male 21170675 CVCL_MW21 BayGenomics ES cell line RRG176 embryonic stem cell house mouse CVCL_MW21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313302; Cenpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170676 CVCL_N821 CT-TC cancer cell line human CVCL_N821 From: Hosoi H.; Kyoto Prefectural University of Medicine; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Unspecified (PubMed=12068308). Population: Japanese Unspecified 21170677 CVCL_MW22 BayGenomics ES cell line RRG177 embryonic stem cell house mouse CVCL_MW22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159210; Tiparp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170678 CVCL_N822 CL141 cancer cell line human CVCL_N822 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=23024022; PubMed=26202522) Derived from metastatic site: Pleural effusion. Omics: Deep membrane proteome analysis Male 21170679 CVCL_MW20 BayGenomics ES cell line RRG173 embryonic stem cell house mouse CVCL_MW20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891217; Zfp423 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170680 CVCL_N820 CW9019 cancer cell line human CVCL_N820 From: Barr F.G.; School of Medicine, University of Pennsylvania; Philadelphia; USA CL:0000010 Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21170681 CVCL_MW09 BayGenomics ES cell line RRG143 embryonic stem cell house mouse CVCL_MW09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170682 CVCL_N809 UM89-1 PGD embryonic stem cell human CVCL_N809 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM89-2 PGD (Cellosaurus=CVCL_5H69), UM89-3 PGD (Cellosaurus=CVCL_5H70), UM89-4 PGD (Cellosaurus=CVCL_5H71) and UM89-5 PGD (Cellosaurus=CVCL_HF79). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0276 21170683 CVCL_MW07 BayGenomics ES cell line RRG140 embryonic stem cell house mouse CVCL_MW07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170684 CVCL_N807 Hs 341.T cancer cell line human CVCL_N807 CL:0000010 Discontinued: ATCC; CRL-7244; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170685 CVCL_MW08 BayGenomics ES cell line RRG142 embryonic stem cell house mouse CVCL_MW08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684063; Asxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170686 CVCL_N808 UM59-2 PGD embryonic stem cell human CVCL_N808 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM59-4 PGD (Cellosaurus=CVCL_5H78). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0275 21170687 CVCL_MW05 BayGenomics ES cell line RRG135 embryonic stem cell house mouse CVCL_MW05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147376; AW554918 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170688 CVCL_N805 MCF10A-Er-Src spontaneously immortalized cell line human CVCL_N805 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Female Part of: ENCODE project common cell types; tier 3 21170689 CVCL_MW06 BayGenomics ES cell line RRG138 embryonic stem cell house mouse CVCL_MW06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170690 CVCL_N806 WI-38/hTERT/GFP-RAF-ER telomerase immortalized cell line human CVCL_N806 CL:0000010 Transfected with: HGNC; 9829; RAF1 (catalytic domain with D-340 and D-341); Transfected with: HGNC; 3467; ESR1 (hormone-binding domain); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: H3K4me3 ChIP-seq epigenome analysis Female Characteristics: Transfected with a construct that is composed of EGFP at the N-terminus, the catalytic domain of RAF1 (with 340-DD-341) in the middle and the hormone-binding domain of ESR1 at the C-terminus Protein kinase activity is activated by estrogen or analogs such as 4-hydroxy-tamoxifen. Senescence: Cells can be senesced after exposure for 72 hours with 4-hydroxy-tamoxifen Part of: ENCODE project common cell types; tier 3 21170691 CVCL_MW03 BayGenomics ES cell line RRG133 embryonic stem cell house mouse CVCL_MW03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442456; Unk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170692 CVCL_N803 GM18505 transformed cell line human CVCL_N803 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21170693 CVCL_MW04 BayGenomics ES cell line RRG134 embryonic stem cell house mouse CVCL_MW04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170694 CVCL_N804 GM18951 transformed cell line human CVCL_N804 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines 21170695 CVCL_MW01 BayGenomics ES cell line RRG129 embryonic stem cell house mouse CVCL_MW01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170696 CVCL_N801 GM12878-XiMat clone 56 transformed cell line human CVCL_N801 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ENCODE project common cell types; tier 3 21170697 CVCL_MW02 BayGenomics ES cell line RRG131 embryonic stem cell house mouse CVCL_MW02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109447; Ctcf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170698 CVCL_N802 GM15510 transformed cell line human CVCL_N802 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: DNA polymorphism discovery resource collection; Part of: ENCODE project common cell types; tier 3 21170699 CVCL_MW00 BayGenomics ES cell line RRG127 embryonic stem cell house mouse CVCL_MW00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106463; Washc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170700 CVCL_N800 GM12878-XiMat clone 16 transformed cell line human CVCL_N800 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ENCODE project common cell types; tier 3 21170701 CVCL_VP38 BexBra1 cancer cell line human CVCL_VP38 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 58 hours (PubMed=19915932) 21170702 CVCL_W138 HeRo [Human glioblastoma] cancer cell line human CVCL_W138 CL:0000010 Derived from sampling site: Brain; left temporal lobe. Male 21170703 CVCL_VP39 BexBra2 cancer cell line human CVCL_VP39 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 96 hours (PubMed=19915932) 21170704 CVCL_W139 HeRo-SV cancer cell line human CVCL_W139 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; left temporal lobe. Male 21170705 CVCL_VP36 CFBE41o- 6.2 WT-CFTR transformed cell line human CVCL_VP36 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Unspecified; Note=In the 2 genomic alleles while the transfected copies are wildtype (PubMed=18769032); Transfected with: HGNC; 1884; CFTR; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified Caution: PubMed=18769032 describes two clones, CFBE41o- c7-6.2wt and CFBE41o- c10-6.2wt, but it is not possible to trace back which of the 2 clones is the one distributed as SCC160 (from personal communication of Millipore) 21170706 CVCL_W136 T508 cancer cell line human CVCL_W136 CL:0000010 Derived from sampling site: Brain. Female 21170707 CVCL_VP37 CFBE41o- 6.2 DeltaF508-CFTR transformed cell line human CVCL_VP37 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Unspecified; Note=In the 2 genomic alleles while the transfected copies are p.Phe508del (c.1522-1524delTTT) (PubMed=18769032); Transfected with: HGNC; 1884; CFTR (with p.Phe508del (c.1522-1524delTTT)); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified Caution: While not directly described in PubMed=18769032, that paper describes the process and constructs used to derive this cell line 21170708 CVCL_W137 T705 cancer cell line human CVCL_W137 CL:0000010 Derived from sampling site: Brain. Male 21170709 CVCL_MV99 BayGenomics ES cell line RRG126 embryonic stem cell house mouse CVCL_MV99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643019; Gm6360 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170710 CVCL_N799 GM10847 transformed cell line human CVCL_N799 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CAGE-seq analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: PU.1 ChIP-seq epigenome analysis; Omics: RPB2 ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: ENCODE project common cell types; tier 3; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 133402 21170711 CVCL_N797 AG20443 finite cell line human CVCL_N797 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: ENCODE project common cell types; tier 3 21170712 CVCL_MV97 BayGenomics ES cell line RRG118 embryonic stem cell house mouse CVCL_MV97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445040; Tyw3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170713 CVCL_N798 AG20444 transformed cell line human CVCL_N798 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170714 CVCL_MV98 BayGenomics ES cell line RRG124 embryonic stem cell house mouse CVCL_MV98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142048; Rnf40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170715 CVCL_N795 AG08395 finite cell line human CVCL_N795 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female Part of: ENCODE project common cell types; tier 3 21170716 CVCL_MV95 BayGenomics ES cell line RRG112 embryonic stem cell house mouse CVCL_MV95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97838; Eprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170717 CVCL_N796 AG08396 finite cell line human CVCL_N796 CL:0000010 Population: Caucasian; Derived from sampling site: Lung Cell type=Fibroblast.. Female Part of: ENCODE project common cell types; tier 3 21170718 CVCL_MV96 BayGenomics ES cell line RRG117 embryonic stem cell house mouse CVCL_MV96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170719 CVCL_MV93 BayGenomics ES cell line RRG074 embryonic stem cell house mouse CVCL_MV93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277113; Pacs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170720 CVCL_N793 HFF-2 MITC finite cell line human CVCL_N793 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1042.2; true Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21170721 CVCL_W141 K38 spontaneously immortalized cell line house mouse CVCL_W141 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. 21170722 CVCL_VP41 USM-BC-1 cancer cell line human CVCL_VP41 CL:0000010 Population: Malaysian; Derived from sampling site: Urinary bladder. Male Doubling time: 44.8 hours (CelloPub=CLPUB00438) 21170723 CVCL_MV94 BayGenomics ES cell line RRG100 embryonic stem cell house mouse CVCL_MV94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170724 CVCL_VP42 DD0719 transformed cell line human CVCL_VP42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21170725 CVCL_W142 GFP-KSC4 spontaneously immortalized cell line house mouse CVCL_W142 CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Skin Cell type=Keratinocyte stem cell.; Breed/subspecies: C57BL/6-Tg(CAG EGFP)1Osb/J transgenic. Unspecified Characteristics: Can be used for the generation of in vitro epidermal 'skin equivalents' to be used as screening tools to look at the activity of new chemical and/or biological entities of dermatological interest, and/or to screen for such entities in high throughput systems (ECACC) 21170726 CVCL_N794 VR09 cancer cell line human CVCL_N794 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: ~84 hours (PubMed=23285191) 21170727 CVCL_N791 AB1 [Mouse ESC] embryonic stem cell house mouse CVCL_N791 CL:0000010 Breed/subspecies: 129S7/SvEvBrd-Hprt<+>. Discontinued: ATCC; SCRC-1022; true Male 21170728 CVCL_MV91 BayGenomics ES cell line RRG071 embryonic stem cell house mouse CVCL_MV91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170729 CVCL_MV92 BayGenomics ES cell line RRG073 embryonic stem cell house mouse CVCL_MV92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170730 CVCL_VP40 BexBra4 cancer cell line human CVCL_VP40 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 43 hours (PubMed=19915932) 21170731 CVCL_N792 STO-SNL2 transformed cell line house mouse CVCL_N792 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Discontinued: ATCC; CRL-2225; true Mixed 21170732 CVCL_W140 Tol/F spontaneously immortalized cell line CVCL_W140 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21170733 CVCL_W145 CL3 [Human lung carcinoma] cancer cell line human CVCL_W145 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male Doubling time: 32 hours (PubMed=1497905) 21170734 CVCL_VP45 Mela11 cancer cell line human CVCL_VP45 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from metastatic site: Inguinal lymph node. Male Doubling time: 39 hours (Direct_author_submission) 21170735 CVCL_N790 11.9 embryonic stem cell house mouse CVCL_N790 CL:0000010 Discontinued: ATCC; CRL-2705; true. Unspecified 21170736 CVCL_MV90 BayGenomics ES cell line RRG070 embryonic stem cell house mouse CVCL_MV90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923164; Exoc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170737 CVCL_W146 GM00006 finite cell line human CVCL_W146 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Pro281Leu (c.842C>T); ClinVar=VCV000000589; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg408Gln (c.1223G>A); ClinVar=VCV000000612; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21170738 CVCL_VP46 Mela14 cancer cell line human CVCL_VP46 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from metastatic site: Small intestine; mesentery. Female Doubling time: 30 hours (Direct_author_submission) 21170739 CVCL_W143 A9423 cancer cell line human CVCL_W143 From: Triche T.J.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Derived from metastatic site: Lymph node. Female 21170740 CVCL_VP43 SKX cancer cell line human CVCL_VP43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (CelloPub=CLPUB00439; PubMed=11799138). Unspecified Characteristics: Established from a xenograft developed by serial transplantation of the original tumor in nude mice; Characteristics: Defective in double-strand break (DSB) DNA repair Highly radiosensitive, has a a TCD50 value of 19.8 Gy (PubMed=19038467). 21170741 CVCL_W144 CL2 [Human lung carcinoma] cancer cell line human CVCL_W144 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Lung. Male Doubling time: 30 hours (PubMed=1497905) 21170742 CVCL_VP44 FaDu(DD) cancer cell line human CVCL_VP44 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=11799138) Population: Indian; Derived from sampling site: Pharynx; hypopharynx. Omics: Transcriptome analysis by microarray Male 21170743 CVCL_VP27 J558L-OX40L cancer cell line house mouse CVCL_VP27 CL:0000010 Transfected with: MGI; MGI:104511; Tnfsf4; Transfected with: UniProtKB; P06988; Escherichia coli hisD Derived from sampling site: Cell type=B-cell; Breed/subspecies: BALB/c. 21170744 CVCL_W127 TU-OM-1 cancer cell line human CVCL_W127 CL:0000010 Population: Japanese. Female 21170745 CVCL_VP28 AGS NOD1 KO clone 41A8 cancer cell line human CVCL_VP28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16390; NOD1; Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female 21170746 CVCL_W128 SHIN-3/PTEN cancer cell line human CVCL_W128 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 9588; PTEN Population: Japanese; Derived from sampling site: Ovary. Female 21170747 CVCL_VP25 NHBEC BMI-1 6 finite cell line human CVCL_VP25 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Male Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170748 CVCL_W125 OAW42-A cancer cell line human CVCL_W125 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female 21170749 CVCL_VP26 HCT 116 BRCA2(-/-) clone 46 cancer cell line human CVCL_VP26 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 1101; BRCA2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21170750 CVCL_W126 MN-1 cancer cell line human CVCL_W126 CL:0000010 Population: Japanese Female Doubling time: 29.4 hours, at 47th passage (DOI=10.5795/jjscc.32.1). 21170751 CVCL_VP29 AGS NOD1 KO clone 41H8 cancer cell line human CVCL_VP29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16390; NOD1; Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female 21170752 CVCL_W129 OVI-P cancer cell line human CVCL_W129 CL:0000010 Female Microsatellite instability: Instable (MSI) (PubMed=15677628). 21170753 CVCL_3J00 HQ00912 transformed cell line human CVCL_3J00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170754 CVCL_3J01 HQ00913 transformed cell line human CVCL_3J01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170755 CVCL_3J04 HQ00916 transformed cell line human CVCL_3J04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170756 CVCL_3J05 HQ00917 transformed cell line human CVCL_3J05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170757 CVCL_3J02 HQ00914 transformed cell line human CVCL_3J02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170758 CVCL_3J03 HQ00915 transformed cell line human CVCL_3J03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170759 CVCL_W130 EC [Human ovarian yolk sac tumor] cancer cell line human CVCL_W130 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 36.1 hours (PubMed=21597681) 21170760 CVCL_VP30 SG01 transformed cell line human CVCL_VP30 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Larynx; subglottis. Male 21170761 CVCL_VP31 H9 CRX-GFP embryonic stem cell human CVCL_VP31 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Using ZFN CRX has been endogenously tagged at the 3'UTR with EGFP 21170762 CVCL_W131 LK1 [Human ovarian carcinoma] cancer cell line human CVCL_W131 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=12068308) Derived from metastatic site: Ascites. Female Microsatellite instability: Stable (MSS) (PubMed=15677628) 21170763 CVCL_VP34 CFBE41o- 4.7 WT-CFTR transformed cell line human CVCL_VP34 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Unspecified; Note=In the 2 genomic alleles while the transfected copies are wildtype (PubMed=18769032); Transfected with: HGNC; 1884; CFTR; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified Caution: While not directly described in PubMed=18769032, that paper describes the process and constructs used to derive this cell line 21170764 CVCL_W134 Ma44-3-GFP cancer cell line human CVCL_W134 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Population: Japanese 21170765 CVCL_VP35 CFBE41o- 4.7 DeltaF508-CFTR transformed cell line human CVCL_VP35 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Unspecified; Note=In the 2 genomic alleles while the transfected copies are p.Phe508del (c.1522-1524delTTT) (PubMed=18769032); Transfected with: HGNC; 1884; CFTR (with p.Phe508del (c.1522-1524delTTT)); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified 21170766 CVCL_W135 T567 cancer cell line human CVCL_W135 CL:0000010 Female 21170767 CVCL_VP32 hTERT-RPE1 FRT/TR telomerase immortalized cell line human CVCL_VP32 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Characteristics: Transfected with the pcDNA5/FRT/TO construct 21170768 CVCL_W132 LK2 cancer cell line human CVCL_W132 CL:0000010 Derived from metastatic site: Ascites. Female 21170769 CVCL_VP33 CFSMEo- transformed cell line human CVCL_VP33 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Gln2Ter (c.4C>T); ClinVar=VCV000053980; Zygosity=Heterozygous (PubMed=16037690); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=16037690) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; submucosal gland Cell type=Epithelial cell.. Unspecified 21170770 CVCL_W133 Ma44-3 cancer cell line human CVCL_W133 CL:0000010 Population: Japanese. 21170771 CVCL_VP16 LAD-III LCL family 2 sibling transformed cell line human CVCL_VP16 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Heterozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170772 CVCL_W116 VP223 cancer cell line human CVCL_W116 CL:0000010 Miscellaneous: Cell line has been lost. Female 21170773 CVCL_VP17 LAD-III LCL family 2 subject transformed cell line human CVCL_VP17 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Homozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170774 CVCL_W117 VP298 cancer cell line human CVCL_W117 CL:0000010 Female 21170775 CVCL_W114 GM11165 transformed cell line human CVCL_W114 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170776 CVCL_VP14 LAD-III LCL family 2 father transformed cell line human CVCL_VP14 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Heterozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170777 CVCL_VP15 LAD-III LCL family 2 mother transformed cell line human CVCL_VP15 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Heterozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170778 CVCL_W115 VP207 cancer cell line human CVCL_W115 CL:0000010 Female 21170779 CVCL_VP18 SVG-A Msh3-/- transformed cell line human CVCL_VP18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male 21170780 CVCL_W118 VP317 cancer cell line human CVCL_W118 CL:0000010 Female 21170781 CVCL_VP19 SVG-A Msh3 1.7X transformed cell line human CVCL_VP19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7326; MSH3; Transfected with: HGNC; 7326; MSH3 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male Characteristics: Compared to wild-type SVG-A, has a 1.7 times expression level of MSH3 21170782 CVCL_W119 VP331 cancer cell line human CVCL_W119 CL:0000010 Female 21170783 CVCL_N779 59B5 embryonic stem cell house mouse CVCL_N779 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96756; Lck Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11115 21170784 CVCL_MV79 BayGenomics ES cell line RRG033 embryonic stem cell house mouse CVCL_MV79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920136; Yju2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170785 CVCL_MV77 BayGenomics ES cell line RRG030 embryonic stem cell house mouse CVCL_MV77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170786 CVCL_N777 CF51.Mg/L3 cancer cell line dog CVCL_N777 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6243; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170787 CVCL_MV78 BayGenomics ES cell line RRG032 embryonic stem cell house mouse CVCL_MV78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170788 CVCL_N778 CSN undefined cell line type dog CVCL_N778 CL:0000010 Derived from sampling site: Stomach; Breed/subspecies: Dachshund. Discontinued: ATCC; CRL-6246; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170789 CVCL_MV75 BayGenomics ES cell line RRG027 embryonic stem cell house mouse CVCL_MV75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913787; Pomp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170790 CVCL_N775 CF45A.Mg cancer cell line dog CVCL_N775 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6236; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170791 CVCL_MV76 BayGenomics ES cell line RRG028 embryonic stem cell house mouse CVCL_MV76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313302; Cenpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170792 CVCL_N776 CF51.Mg/L1 cancer cell line dog CVCL_N776 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6242; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170793 CVCL_MV73 BayGenomics ES cell line RRG012 embryonic stem cell house mouse CVCL_MV73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442637; Thrap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170794 CVCL_N773 CF31A finite cell line dog CVCL_N773 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6226; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170795 CVCL_MV74 BayGenomics ES cell line RRG017 embryonic stem cell house mouse CVCL_MV74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170796 CVCL_N774 CF42.Mg undefined cell line type dog CVCL_N774 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6233; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170797 CVCL_MV71 BayGenomics ES cell line RRG008 embryonic stem cell house mouse CVCL_MV71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170798 CVCL_N771 Hs 608.Mg finite cell line human CVCL_N771 CL:0000010 Derived from sampling site: Breast Cell type=Fibroblast.. Discontinued: ATCC; CRL-7370; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170799 CVCL_MV72 BayGenomics ES cell line RRG011 embryonic stem cell house mouse CVCL_MV72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170800 CVCL_N772 Hs 608.T cancer cell line human CVCL_N772 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7371; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170801 CVCL_VP20 NHBEC BMI-1 1 finite cell line human CVCL_VP20 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Male Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170802 CVCL_W120 VP342 cancer cell line human CVCL_W120 CL:0000010 Female 21170803 CVCL_MV70 BayGenomics ES cell line RRG004 embryonic stem cell house mouse CVCL_MV70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170804 CVCL_N770 Hs 612.Bl finite cell line human CVCL_N770 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Fibroblast.. Discontinued: ATCC; CRL-7374; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170805 CVCL_W123 iPS CWRU1 induced pluripotent stem cell human CVCL_W123 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Male Part of: ENCODE project common cell types; tier 3 21170806 CVCL_VP23 NHBEC BMI-1 4 finite cell line human CVCL_VP23 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Male Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170807 CVCL_W124 KEN-3 cancer cell line human CVCL_W124 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 76.9 hours (PubMed=1351514) 21170808 CVCL_VP24 NHBEC BMI-1 5 finite cell line human CVCL_VP24 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Female Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170809 CVCL_W121 iPS NIHi11 induced pluripotent stem cell human CVCL_W121 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Part of: ENCODE project common cell types; tier 3 21170810 CVCL_VP21 NHBEC BMI-1 2 finite cell line human CVCL_VP21 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Male Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170811 CVCL_W122 iPS NIHi7 induced pluripotent stem cell human CVCL_W122 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: ENCODE project common cell types; tier 3 21170812 CVCL_VP22 NHBEC BMI-1 3 finite cell line human CVCL_VP22 CL:0000010 Transfected with: HGNC; 1066; BMI1 Derived from sampling site: Bronchus; epithelium. Male Characteristics: Has an extended lifespan compared to primary bronchial epithelial cells Retains both viability and differentiation potential of wild-type human bronchial epithelium. 21170813 CVCL_W105 Mero-72 cancer cell line human CVCL_W105 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21170814 CVCL_VP05 VUP-1 V+D9H cancer cell line human CVCL_VP05 CL:0000010 Discontinued: Ximbio; 153372; probable. Female Characteristics: Expresses ITGAV/ITGB1 at high level and does not express ITGAV/ITGB3 21170815 CVCL_VP06 HEK293-HM3 transformed cell line human CVCL_VP06 CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain); Transfected with: HGNC; 6855; MAP3K3 (kinase domain) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses the conditional kinase DeltaMEKK3:ER* which consist of the kinase domain of MAP3K3 fused in frame to a modified form of the hormone binding domain of the estrogen receptor (ESR1) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not beta-estradiol 21170816 CVCL_W106 Mero-91 cancer cell line human CVCL_W106 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21170817 CVCL_W103 Mero-48c cancer cell line human CVCL_W103 CL:0000010 Derived from metastatic site: Liver. Male 21170818 CVCL_VP03 VUP-1 V-C10 cancer cell line human CVCL_VP03 CL:0000010 Discontinued: Ximbio; 153373; probable. Female Characteristics: Expresses ITGAV/ITGB1 at low level and does not express ITGAV/ITGB3 21170819 CVCL_W104 Mero-48d cancer cell line human CVCL_W104 CL:0000010 Derived from metastatic site: Heart; pericardium. Male 21170820 CVCL_VP04 VUP-1 V+B2 cancer cell line human CVCL_VP04 CL:0000010 Discontinued: Ximbio; 153371; probable. Female Characteristics: Expresses ITGAV/ITGB1 at high level and does not express ITGAV/ITGB3 21170821 CVCL_W109 GM00045 finite cell line human CVCL_W109 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21170822 CVCL_VP09 LAD-III LCL family 1 mother transformed cell line human CVCL_VP09 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Unexplicit; IVS13AS,A-G,-2; ClinVar=VCV000002708; Zygosity=Heterozygous; Note=Frameshift mutation (PubMed=19234463) Population: Maltese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170823 CVCL_VP07 HEK293-HR1 transformed cell line human CVCL_VP07 CL:0000010 Transfected with: HGNC; 646; ARAF (kinase domain); Transfected with: HGNC; 3467; ESR1 (ligand-binding domain) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses the conditional kinase DeltaRaf-1:ER* which consist of the kinase domain of ARAF fused in frame to a modified form of the hormone binding domain of the estrogen receptor (ESR1) that can be de-repressed by 4-hydroxytamoxifen (4-HT) but not beta-estradiol 21170824 CVCL_W107 Mero-96 cancer cell line human CVCL_W107 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21170825 CVCL_W108 DF cancer cell line human CVCL_W108 CL:0000010 Anecdotal: Cell line name corresponds to the initials of the patient Derived from sampling site: Brain; right parasagittal parietal region. Male Doubling time: 48 hours (at 37th passage), 36 hours (at 77th passage) (PubMed=3225639) 21170826 CVCL_VP08 LAD-III LCL family 1 father transformed cell line human CVCL_VP08 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Unexplicit; IVS13AS,A-G,-2; ClinVar=VCV000002708; Zygosity=Heterozygous; Note=Frameshift mutation (PubMed=19234463) Population: Maltese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170827 CVCL_N788 41M-cisR cancer cell line human CVCL_N788 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Problematic cell line: Contaminated Parent cell line (41M) has been shown to be a OAW28 derivative. 21170828 CVCL_MV88 BayGenomics ES cell line RRG056 embryonic stem cell house mouse CVCL_MV88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353557; Schip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170829 CVCL_MV89 BayGenomics ES cell line RRG059 embryonic stem cell house mouse CVCL_MV89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170830 CVCL_N789 UKRV-Mel-01 cancer cell line human CVCL_N789 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21170831 CVCL_MV86 BayGenomics ES cell line RRG051 embryonic stem cell house mouse CVCL_MV86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384924; Ccm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170832 CVCL_N786 Ma-Mel-48b cancer cell line human CVCL_N786 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Heterozygous (PubMed=25294904); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis Male 21170833 CVCL_MV87 BayGenomics ES cell line RRG053 embryonic stem cell house mouse CVCL_MV87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329014; Stam Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170834 CVCL_N787 Ma-Mel-48c cancer cell line human CVCL_N787 CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Heterozygous (PubMed=25294904); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp96fs*4; Zygosity=Heterozygous (PubMed=25294904); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503) Derived from metastatic site: Lymph node. Omics: SNP array analysis Male 21170835 CVCL_MV84 BayGenomics ES cell line RRG042 embryonic stem cell house mouse CVCL_MV84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96163; Hmox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170836 CVCL_N784 Ma-Mel-24 cancer cell line human CVCL_N784 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Arg (c.1790T>G); ClinVar=VCV000013968; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). 21170837 CVCL_MV85 BayGenomics ES cell line RRG049 embryonic stem cell house mouse CVCL_MV85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151839; Mreg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170838 CVCL_N785 Ma-Mel-26b cancer cell line human CVCL_N785 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23348503); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Male 21170839 CVCL_MV82 BayGenomics ES cell line RRG038 embryonic stem cell house mouse CVCL_MV82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913929; Rae1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170840 CVCL_N782 WW1 embryonic stem cell house mouse CVCL_N782 CL:0000010 Male 21170841 CVCL_MV83 BayGenomics ES cell line RRG041 embryonic stem cell house mouse CVCL_MV83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298390; Swap70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170842 CVCL_N783 WW6 embryonic stem cell house mouse CVCL_N783 CL:0000010 Discontinued: ATCC; CRL-2239; true. Male Part of: ENCODE project mouse cell lines 21170843 CVCL_MV80 BayGenomics ES cell line RRG036 embryonic stem cell house mouse CVCL_MV80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170844 CVCL_N780 RW4-OPG#12 embryonic stem cell house mouse CVCL_N780 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:109587; Tnfrsf11b Breed/subspecies: 129X1/SvJ. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12418 21170845 CVCL_MV81 BayGenomics ES cell line RRG037 embryonic stem cell house mouse CVCL_MV81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917278; Dop1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170846 CVCL_N781 TM#1 embryonic stem cell house mouse CVCL_N781 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96590; Irf1 Breed/subspecies: 129S2/SvPas. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11380 21170847 CVCL_W112 GM11167 transformed cell line human CVCL_W112 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170848 CVCL_VP12 LAD-III LCL family 3 father transformed cell line human CVCL_VP12 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Heterozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170849 CVCL_W113 GM11168 transformed cell line human CVCL_W113 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170850 CVCL_VP13 LAD-III LCL family 3 subject transformed cell line human CVCL_VP13 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Simple; p.Arg513Ter (c.1537C>T) (R509*); ClinVar=VCV000002712; Zygosity=Homozygous (PubMed=19234463) Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170851 CVCL_W110 GM03478 finite cell line human CVCL_W110 CL:0000010 Population: Caucasian; Karyotypic information: 92,XXYY [12]; 46,XY [38] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21170852 CVCL_VP10 LAD-III LCL family 1 sibling transformed cell line human CVCL_VP10 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Unexplicit; IVS13AS,A-G,-2; ClinVar=VCV000002708; Zygosity=Heterozygous; Note=Frameshift mutation (PubMed=19234463) Population: Maltese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170853 CVCL_W111 GM11166 transformed cell line human CVCL_W111 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170854 CVCL_VP11 LAD-III LCL family 1 subject transformed cell line human CVCL_VP11 CL:0000010 Sequence variation: Mutation; HGNC; 23151; FERMT3; Unexplicit; IVS13AS,A-G,-2; ClinVar=VCV000002708; Zygosity=Homozygous; Note=Frameshift mutation (PubMed=19234463) Population: Maltese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170855 CVCL_MV59 BayGenomics ES cell line RRF529 embryonic stem cell house mouse CVCL_MV59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681523; Tnpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170856 CVCL_N759 Hs 562.Pl finite cell line human CVCL_N759 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7325; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170857 CVCL_MV57 BayGenomics ES cell line RRF517 embryonic stem cell house mouse CVCL_MV57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444777; Ncaph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170858 CVCL_N757 Hs 517.T cancer cell line human CVCL_N757 CL:0000010 Discontinued: ATCC; CRL-7312; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170859 CVCL_MV58 BayGenomics ES cell line RRF521 embryonic stem cell house mouse CVCL_MV58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921493; Slx4ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170860 CVCL_N758 Hs 561.Pl finite cell line human CVCL_N758 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Discontinued: ATCC; CRL-7324; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170861 CVCL_MV55 BayGenomics ES cell line RRF515 embryonic stem cell house mouse CVCL_MV55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107793; Crmp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170862 CVCL_N755 NCE-G 195 cancer cell line human CVCL_N755 CL:0000010 Male 21170863 CVCL_MV56 BayGenomics ES cell line RRF516 embryonic stem cell house mouse CVCL_MV56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98105; Rps12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170864 CVCL_N756 NCE-G 350 cancer cell line human CVCL_N756 CL:0000010 21170865 CVCL_MV53 BayGenomics ES cell line RRF511 embryonic stem cell house mouse CVCL_MV53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921831; Sbf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170866 CVCL_N753 NCE-G 168 cancer cell line human CVCL_N753 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536; PubMed=15816541). Male 21170867 CVCL_MV54 BayGenomics ES cell line RRF512 embryonic stem cell house mouse CVCL_MV54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170868 CVCL_N754 NCE-G 169 cancer cell line human CVCL_N754 CL:0000010 Female 21170869 CVCL_MV51 BayGenomics ES cell line RRF509 embryonic stem cell house mouse CVCL_MV51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170870 CVCL_N751 NCE-G 151 cancer cell line human CVCL_N751 CL:0000010 Derived from sampling site: Brain; left temporo-parietal lobe. Male 21170871 CVCL_MV52 BayGenomics ES cell line RRF510 embryonic stem cell house mouse CVCL_MV52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096397; Polr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170872 CVCL_N752 NCE-G 167 cancer cell line human CVCL_N752 CL:0000010 Male 21170873 CVCL_MV50 BayGenomics ES cell line RRF507 embryonic stem cell house mouse CVCL_MV50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445019; Pik3c3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170874 CVCL_N750 NCE-G 142 cancer cell line human CVCL_N750 HLA typing: A*11:01,24:02; B*35:03,51:01; C*03:03,12:03 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21170875 CVCL_W101 KoG spontaneously immortalized cell line CVCL_W101 CL:0000010 Derived from sampling site: Gill; Breed/subspecies: Koi. Unspecified Group: Fish cell line 21170876 CVCL_VP01 UACC-1460 cancer cell line human CVCL_VP01 CL:0000010 21170877 CVCL_W102 Mero-48b cancer cell line human CVCL_W102 CL:0000010 Derived from metastatic site: Omentum. Male 21170878 CVCL_VP02 UACC-612 cancer cell line human CVCL_VP02 CL:0000010 21170879 CVCL_W100 CaF-2 spontaneously immortalized cell line CVCL_W100 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21170880 CVCL_VP00 UACC-1065 cancer cell line human CVCL_VP00 CL:0000010 21170881 CVCL_MV68 BayGenomics ES cell line RRF562 embryonic stem cell house mouse CVCL_MV68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146565; Nsun3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170882 CVCL_N768 Hs 619.Int finite cell line human CVCL_N768 CL:0000010 Derived from sampling site: Colon Cell type=Fibroblast.. Discontinued: ATCC; CRL-7381; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170883 CVCL_MV69 BayGenomics ES cell line RRG003 embryonic stem cell house mouse CVCL_MV69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170884 CVCL_N769 Hs 619.T cancer cell line human CVCL_N769 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7382; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170885 CVCL_MV66 BayGenomics ES cell line RRF551 embryonic stem cell house mouse CVCL_MV66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914544; Elp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170886 CVCL_N766 Hs 572.Mg finite cell line human CVCL_N766 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7342; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170887 CVCL_MV67 BayGenomics ES cell line RRF552 embryonic stem cell house mouse CVCL_MV67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170888 CVCL_N767 Hs 615.T cancer cell line human CVCL_N767 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-7377; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170889 CVCL_MV64 BayGenomics ES cell line RRF547 embryonic stem cell house mouse CVCL_MV64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334460; Bop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170890 CVCL_N764 Hs 567(B).Mg finite cell line human CVCL_N764 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7339; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170891 CVCL_MV65 BayGenomics ES cell line RRF550 embryonic stem cell house mouse CVCL_MV65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100818; Crcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170892 CVCL_N765 Hs 570.T cancer cell line human CVCL_N765 CL:0000010 Discontinued: ATCC; CRL-7341; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170893 CVCL_MV62 BayGenomics ES cell line RRF537 embryonic stem cell house mouse CVCL_MV62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916177; Ptcd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170894 CVCL_N762 Hs 565(C).Mg finite cell line human CVCL_N762 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7332; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170895 CVCL_MV63 BayGenomics ES cell line RRF540 embryonic stem cell house mouse CVCL_MV63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918839; Slc38a9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170896 CVCL_N763 Hs 567(A).T cancer cell line human CVCL_N763 CL:0000010 Discontinued: ATCC; CRL-7338; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170897 CVCL_MV60 BayGenomics ES cell line RRF531 embryonic stem cell house mouse CVCL_MV60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170898 CVCL_N760 Hs 691.Thd finite cell line human CVCL_N760 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Fibroblast.. Discontinued: ATCC; CRL-7427; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170899 CVCL_MV61 BayGenomics ES cell line RRF532 embryonic stem cell house mouse CVCL_MV61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146189; Topors Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170900 CVCL_N761 Hs 565(B).Mg finite cell line human CVCL_N761 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7331; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21170901 CVCL_MV39 BayGenomics ES cell line RRF466 embryonic stem cell house mouse CVCL_MV39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170902 CVCL_N739 NCE-G 111 cancer cell line human CVCL_N739 HLA typing: A*02:01,03:01; B*15:01,35:01; C*03:03,04:01 (PubMed=26589293) CL:0000010 Derived from sampling site: Brain; left temporo-parietal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21170903 CVCL_MV37 BayGenomics ES cell line RRF463 embryonic stem cell house mouse CVCL_MV37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352757; Iqgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170904 CVCL_N737 NCE-G 98 cancer cell line human CVCL_N737 CL:0000010 21170905 CVCL_MV38 BayGenomics ES cell line RRF465 embryonic stem cell house mouse CVCL_MV38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170906 CVCL_N738 NCE-G 102 cancer cell line human CVCL_N738 CL:0000010 21170907 CVCL_MV35 BayGenomics ES cell line RRF459 embryonic stem cell house mouse CVCL_MV35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109490; Sms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170908 CVCL_N735 NCE-G 84 cancer cell line human CVCL_N735 HLA typing: A*03:01,30:01; B*08:01,51:01; C*07:01,15:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala79Val (c.236C>T); Zygosity=Unspecified (PubMed=15816541) Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female 21170909 CVCL_MV36 BayGenomics ES cell line RRF462 embryonic stem cell house mouse CVCL_MV36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442988; Arfgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170910 CVCL_N736 NCE-G 96 cancer cell line human CVCL_N736 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536) Derived from sampling site: Brain; left frontal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21170911 CVCL_MV33 BayGenomics ES cell line RRF440 embryonic stem cell house mouse CVCL_MV33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170912 CVCL_N733 NCE-G 63 cancer cell line human CVCL_N733 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536; PubMed=15816541) Derived from sampling site: Brain; right temporo-occipital lobe. Male 21170913 CVCL_MV34 BayGenomics ES cell line RRF444 embryonic stem cell house mouse CVCL_MV34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915512; Agpat4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170914 CVCL_N734 NCE-G 80 cancer cell line human CVCL_N734 CL:0000010 21170915 CVCL_MV31 BayGenomics ES cell line RRF432 embryonic stem cell house mouse CVCL_MV31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109352; Ung Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170916 CVCL_N731 NCE-G 61 cancer cell line human CVCL_N731 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536) Derived from sampling site: Brain; left temporo-occipital lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170917 CVCL_MV32 BayGenomics ES cell line RRF437 embryonic stem cell house mouse CVCL_MV32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447812; Dennd1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170918 CVCL_N732 NCE-G 62 cancer cell line human CVCL_N732 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49Tyr (c.145G>T); Zygosity=Unspecified (PubMed=15816541) Derived from sampling site: Brain; left temporo-parietal lobe. Female 21170919 CVCL_MV30 BayGenomics ES cell line RRF431 embryonic stem cell house mouse CVCL_MV30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442888; Uhrf1bp1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170920 CVCL_N730 NCE-G 60 cancer cell line human CVCL_N730 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536). Female 21170921 CVCL_MV48 BayGenomics ES cell line RRF492 embryonic stem cell house mouse CVCL_MV48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170922 CVCL_N748 NCE-G 140 cancer cell line human CVCL_N748 HLA typing: A*03:01,03:01; B*35:02,35:02; C*04:01,04:01; DRB1*14:76,14:76 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr211Ile (c.632C>T); ClinVar=VCV001503185; Zygosity=Unspecified (PubMed=8253536) Derived from sampling site: Brain; right occipital lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170923 CVCL_MV49 BayGenomics ES cell line RRF496 embryonic stem cell house mouse CVCL_MV49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106915; Vdac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170924 CVCL_N749 NCE-G 141 cancer cell line human CVCL_N749 HLA typing: A*24:02,24:02; B*51:01,51:01; C*03:03,03:03 (PubMed=26589293) CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21170925 CVCL_MV46 BayGenomics ES cell line RRF486 embryonic stem cell house mouse CVCL_MV46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891833; Pfkp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170926 CVCL_N746 NCE-G 124 cancer cell line human CVCL_N746 HLA typing: A*11:01,32:01; B*27:05,35:01; C*02:02,04:04 (PubMed=26589293) CL:0000010 Derived from sampling site: Brain; right temporal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170927 CVCL_MV47 BayGenomics ES cell line RRF489 embryonic stem cell house mouse CVCL_MV47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681523; Tnpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170928 CVCL_N747 NCE-G 130 cancer cell line human CVCL_N747 HLA typing: A*11:01,29:01; B*07:02,39:06; C*07:02,15:05 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=8253536; PubMed=15816541) Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21170929 CVCL_MV44 BayGenomics ES cell line RRF478 embryonic stem cell house mouse CVCL_MV44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170930 CVCL_N744 NCE-G 122 cancer cell line human CVCL_N744 HLA typing: A*01:01,02:01; B*08:01,15:01; C*03:03,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; 10bp deletion in intron4/exon5; Zygosity=Unspecified (PubMed=8253536) Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21170931 CVCL_MV45 BayGenomics ES cell line RRF480 embryonic stem cell house mouse CVCL_MV45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924234; Katnal2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170932 CVCL_N745 NCE-G 123 cancer cell line human CVCL_N745 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=15816541); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=15816541). Male 21170933 CVCL_MV42 BayGenomics ES cell line RRF471 embryonic stem cell house mouse CVCL_MV42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170934 CVCL_N742 NCE-G 120 cancer cell line human CVCL_N742 HLA typing: A*68:01,68:01; B*40:01,40:01; C*03:04,03:04; DRB1*03:01,03:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536; PubMed=15816541) Derived from sampling site: Brain; left temporo-parietal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170935 CVCL_MV43 BayGenomics ES cell line RRF474 embryonic stem cell house mouse CVCL_MV43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289341; Sf3b3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170936 CVCL_N743 NCE-G 121 cancer cell line human CVCL_N743 HLA typing: A*01:01,01:01; B*08:01,35:02; C*04:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536) Derived from sampling site: Brain; left occipital-parietal region. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Caution: Said to originate from a male patient according to PubMed=8289093 and PubMed=16696057, in contradiction with PubMed=8154317 21170937 CVCL_MV40 BayGenomics ES cell line RRF467 embryonic stem cell house mouse CVCL_MV40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921569; Mettl23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170938 CVCL_N740 NCE-G 112 cancer cell line human CVCL_N740 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8253536; PubMed=15816541) Derived from sampling site: Brain; right temporal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21170939 CVCL_MV41 BayGenomics ES cell line RRF470 embryonic stem cell house mouse CVCL_MV41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921565; Rnf145 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21170940 CVCL_N741 NCE-G 118 cancer cell line human CVCL_N741 HLA typing: A*24:02,24:02; B*51:01,51:01; C*03:03,03:03 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8253536) Derived from sampling site: Brain; right frontal lobe. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21170941 CVCL_3J70 HQ00983 transformed cell line human CVCL_3J70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170942 CVCL_3J73 HQ00986 transformed cell line human CVCL_3J73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170943 CVCL_3J74 HQ00987 transformed cell line human CVCL_3J74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170944 CVCL_3J71 HQ00984 transformed cell line human CVCL_3J71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170945 CVCL_3J72 HQ00985 transformed cell line human CVCL_3J72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170946 CVCL_3J77 HQ00990 transformed cell line human CVCL_3J77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170947 CVCL_3J78 HQ00991 transformed cell line human CVCL_3J78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170948 CVCL_3J75 HQ00988 transformed cell line human CVCL_3J75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170949 CVCL_3J76 HQ00989 transformed cell line human CVCL_3J76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170950 CVCL_3J79 HQ00992 transformed cell line human CVCL_3J79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170951 CVCL_3J80 HQ00993 transformed cell line human CVCL_3J80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170952 CVCL_3J81 HQ00994 transformed cell line human CVCL_3J81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170953 CVCL_3J84 HQ00997 transformed cell line human CVCL_3J84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170954 CVCL_3J85 HQ00998 transformed cell line human CVCL_3J85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170955 CVCL_3J82 HQ00995 transformed cell line human CVCL_3J82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170956 CVCL_3J83 HQ00996 transformed cell line human CVCL_3J83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170957 CVCL_3J88 HQ01001 transformed cell line human CVCL_3J88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170958 CVCL_3J89 HQ01002 transformed cell line human CVCL_3J89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170959 CVCL_3J86 HQ00999 transformed cell line human CVCL_3J86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170960 CVCL_3J87 HQ01000 transformed cell line human CVCL_3J87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170961 CVCL_3J51 HQ00964 transformed cell line human CVCL_3J51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170962 CVCL_3J52 HQ00965 transformed cell line human CVCL_3J52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170963 CVCL_3J50 HQ00963 transformed cell line human CVCL_3J50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170964 CVCL_3J55 HQ00968 transformed cell line human CVCL_3J55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170965 CVCL_3J56 HQ00969 transformed cell line human CVCL_3J56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170966 CVCL_3J53 HQ00966 transformed cell line human CVCL_3J53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170967 CVCL_3J54 HQ00967 transformed cell line human CVCL_3J54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170968 CVCL_3J59 HQ00972 transformed cell line human CVCL_3J59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170969 CVCL_3J57 HQ00970 transformed cell line human CVCL_3J57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170970 CVCL_3J58 HQ00971 transformed cell line human CVCL_3J58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170971 CVCL_3J62 HQ00975 transformed cell line human CVCL_3J62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170972 CVCL_3J63 HQ00976 transformed cell line human CVCL_3J63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170973 CVCL_3J60 HQ00973 transformed cell line human CVCL_3J60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170974 CVCL_3J61 HQ00974 transformed cell line human CVCL_3J61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170975 CVCL_3J66 HQ00979 transformed cell line human CVCL_3J66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170976 CVCL_3J67 HQ00980 transformed cell line human CVCL_3J67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170977 CVCL_3J64 HQ00977 transformed cell line human CVCL_3J64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170978 CVCL_3J65 HQ00978 transformed cell line human CVCL_3J65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21170979 CVCL_3J68 HQ00981 transformed cell line human CVCL_3J68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170980 CVCL_3J69 HQ00982 transformed cell line human CVCL_3J69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21170981 CVCL_W192 A549/TXL5 cancer cell line human CVCL_W192 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Lung. Male Doubling time: 74.7 hours (CelloPub=CLPUB00006) 21170982 CVCL_VP92 PES 43 cancer cell line human CVCL_VP92 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=29492214) Derived from metastatic site: Lung. Unspecified 21170983 CVCL_W193 Anip973/CDDP cancer cell line human CVCL_W193 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). 21170984 CVCL_VP93 PES 47 cancer cell line human CVCL_VP93 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=29492214) Derived from metastatic site: Hypodermis. Unspecified 21170985 CVCL_W190 A549/TXL10 cancer cell line human CVCL_W190 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Lung. Male Doubling time: 75.5 hours (CelloPub=CLPUB00006) 21170986 CVCL_VP90 Alo 40 cancer cell line human CVCL_VP90 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21170987 CVCL_W191 A549/TXL20 cancer cell line human CVCL_W191 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Lung. Male Doubling time: 77.3 hours (CelloPub=CLPUB00006) 21170988 CVCL_VP91 PES 41 cancer cell line human CVCL_VP91 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=29492214) Derived from metastatic site: Hypodermis. Unspecified 21170989 CVCL_VP96 BUMA 31 cancer cell line human CVCL_VP96 CL:0000010 21170990 CVCL_W196 WSU-HN3 cancer cell line human CVCL_W196 CL:0000010 Unspecified 21170991 CVCL_VP97 CIMA 62 cancer cell line human CVCL_VP97 CL:0000010 Derived from metastatic site: Not specified. 21170992 CVCL_W197 DSL-6B/C1 cancer cell line Norway rat CVCL_W197 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.; Breed/subspecies: Lewis. Male 21170993 CVCL_VP94 ANAD 63 cancer cell line human CVCL_VP94 CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu59_Ile66del; Zygosity=Unspecified (CelloPub=CLPUB00440). 21170994 CVCL_W194 Anip973/NVB cancer cell line human CVCL_W194 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine. 21170995 CVCL_VP95 COPA 159 cancer cell line human CVCL_VP95 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29492214) Derived from metastatic site: Lymph node. Unspecified 21170996 CVCL_W195 UTree-O2 cancer cell line human CVCL_W195 CL:0000010 Population: Japanese. Female 21170997 CVCL_W198 AT-MS-1 cancer cell line human CVCL_W198 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male Doubling time: ~43 hours (PubMed=3761063) 21170998 CVCL_VP98 CIMA 73 cancer cell line human CVCL_VP98 CL:0000010 Derived from metastatic site: Not specified. 21170999 CVCL_VP99 CIR 229 cancer cell line human CVCL_VP99 CL:0000010 21171000 CVCL_W199 UM-FSC-1 cancer cell line human CVCL_W199 CL:0000010 Derived from sampling site: Bone; jaw; maxilla. Male 21171001 CVCL_3J30 HQ00943 transformed cell line human CVCL_3J30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171002 CVCL_3J33 HQ00946 transformed cell line human CVCL_3J33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171003 CVCL_3J34 HQ00947 transformed cell line human CVCL_3J34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171004 CVCL_3J31 HQ00944 transformed cell line human CVCL_3J31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171005 CVCL_3J32 HQ00945 transformed cell line human CVCL_3J32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171006 CVCL_3J37 HQ00950 transformed cell line human CVCL_3J37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171007 CVCL_3J38 HQ00951 transformed cell line human CVCL_3J38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171008 CVCL_3J35 HQ00948 transformed cell line human CVCL_3J35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171009 CVCL_3J36 HQ00949 transformed cell line human CVCL_3J36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171010 CVCL_3J28 HQ00940 transformed cell line human CVCL_3J28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171011 CVCL_3J29 HQ00941 transformed cell line human CVCL_3J29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171012 CVCL_W181 GLL-19 cancer cell line human CVCL_W181 From: Blanquet S and Safi N.; Hopital Saint Andre; Bordeaux; France. CL:0000010 Population: Caucasian; Derived from sampling site: Eye. Female 21171013 CVCL_VP81 GM26045 finite cell line human CVCL_VP81 CL:0000010 Sequence variation: Mutation; HGNC; 21701; BRAT1; Simple; p.Val214Glyfs*189 (c.638dupA) (c.638_639insA); ClinVar=VCV000031199; Zygosity=Homozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21171014 CVCL_W182 B-29 cancer cell line house mouse CVCL_W182 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/Crgl. Discontinued: ATCC; CRL-6325; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21171015 CVCL_VP82 GM26046 finite cell line human CVCL_VP82 CL:0000010 Sequence variation: Mutation; HGNC; 21701; BRAT1; Simple; p.Val214Glyfs*189 (c.638dupA) (c.638_639insA); ClinVar=VCV000031199; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21171016 CVCL_VP80 GM27171 transformed cell line human CVCL_VP80 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Glu429Ala (c.1286A>C) (1298A>C); ClinVar=VCV000003521; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg141Cys (c.421C>T); ClinVar=VCV000447846; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171017 CVCL_W180 VP348 cancer cell line human CVCL_W180 CL:0000010 Female 21171018 CVCL_W185 CiGEnC conditionally immortalized cell line human CVCL_W185 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Glomerular endothelial cell.. Omics: Transcriptome analysis by microarray Unspecified 21171019 CVCL_VP85 UOWi007-A induced pluripotent stem cell human CVCL_VP85 From: University of Wollongong; Wollongong; Australia CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu101Gly (c.302A>G) (E100G); ClinVar=VCV000014761; Zygosity=Heterozygous (PubMed=32006803) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21171020 CVCL_W186 CIHP-1 conditionally immortalized cell line human CVCL_W186 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.. Omics: Transcriptome analysis by microarray Unspecified Doubling time: ~52 hours (PubMed=24349133) 21171021 CVCL_VP86 UOWi008-A induced pluripotent stem cell human CVCL_VP86 From: University of Wollongong; Wollongong; Australia CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=32887382) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171022 CVCL_W183 CCC3a subline 8C transformed cell line CVCL_W183 CL:0000010 Derived from sampling site: Kidney. Female 21171023 CVCL_VP83 ESi063-A induced pluripotent stem cell human CVCL_VP83 From: Principe Felipe Centro de Investigacion; Valencia; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10519; SACS; Simple; p.Gln3313Glyfs*11 (c.9938delC); Zygosity=Heterozygous (PubMed=30144656); Sequence variation: Mutation; HGNC; 10519; SACS; Simple; p.Arg3792Ter (c.11374C>T); ClinVar=VCV000370283; Zygosity=Heterozygous (PubMed=30144656) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21171024 CVCL_W184 ciPTEC conditionally immortalized cell line human CVCL_W184 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female 21171025 CVCL_VP84 UOWi006-A induced pluripotent stem cell human CVCL_VP84 From: University of Wollongong; Wollongong; Australia CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=32887382) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171026 CVCL_VP89 Alo 39 cancer cell line human CVCL_VP89 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21171027 CVCL_W189 P0318 cancer cell line human CVCL_W189 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray 21171028 CVCL_VP87 IHSTMi001-A induced pluripotent stem cell human CVCL_VP87 From: Institute of Health Service and Transfusion Medicine; Beijing; China CL:0000010 Derived from sampling site: Umbilical artery; endothelium. Female 21171029 CVCL_W187 Me665/R cancer cell line human CVCL_W187 CL:0000010 Derived from metastatic site: Hypodermis. Female 21171030 CVCL_W188 Am1010 cancer cell line human CVCL_W188 CL:0000010 Population: Chinese; Karyotypic information: Tetraploid karyotype; Derived from metastatic site: Upper arm; skeletal muscle. Omics: Transcriptome analysis by microarray Female Doubling time: 42.395 hours (PubMed=20418894) 21171031 CVCL_VP88 HVEC transformed cell line human CVCL_VP88 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Vagina Cell type=Epithelial cell.. Female 21171032 CVCL_VP69 B-LCL #1038-153 transformed cell line human CVCL_VP69 HLA typing: A*02:01,31:01; B*15:01,57:01; C*03:03,06:02; DRB1*15:01,13:01 (Cellero) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171033 CVCL_W169 NH-GEN1 transformed cell line CVCL_W169 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Endothelial cell.. Unspecified Doubling time: 32 hours, at 20th passage (PubMed=7933662) 21171034 CVCL_3J40 HQ00953 transformed cell line human CVCL_3J40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171035 CVCL_3J41 HQ00954 transformed cell line human CVCL_3J41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171036 CVCL_3J44 HQ00957 transformed cell line human CVCL_3J44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171037 CVCL_3J45 HQ00958 transformed cell line human CVCL_3J45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171038 CVCL_3J42 HQ00955 transformed cell line human CVCL_3J42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171039 CVCL_3J43 HQ00956 transformed cell line human CVCL_3J43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171040 CVCL_3J48 HQ00961 transformed cell line human CVCL_3J48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171041 CVCL_3J49 HQ00962 transformed cell line human CVCL_3J49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171042 CVCL_3J46 HQ00959 transformed cell line human CVCL_3J46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171043 CVCL_3J47 HQ00960 transformed cell line human CVCL_3J47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171044 CVCL_3J39 HQ00952 transformed cell line human CVCL_3J39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171045 CVCL_VP70 B-LCL #1038-287 transformed cell line human CVCL_VP70 HLA typing: A*03,68; B*15,44; C*03,07; DRB1*15,01 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171046 CVCL_W170 IRMC transformed cell line Norway rat CVCL_W170 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.; Breed/subspecies: Wistar. Male 21171047 CVCL_VP71 B-LCL #1038-358 transformed cell line human CVCL_VP71 HLA typing: A*02:01,02:01; B*44,15; C*03,05; DRB1*03,04:04 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171048 CVCL_W171 PAGS-6 transformed cell line Norway rat CVCL_W171 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21171049 CVCL_W174 6-3 factor-dependent cell line house mouse CVCL_W174 CL:0000010 Derived from sampling site: Brain; meninges Cell type=Microglial cell.; Breed/subspecies: C57BL/6J(H-2b). Unspecified Characteristics: CSF2 dependent 21171050 CVCL_VP74 TSt-4/N-DLL4 somatic stem cell house mouse CVCL_VP74 CL:0000010 Transfected with: HGNC; 7809; NGFR; Transfected with: MGI; MGI:1859388; Dll4 Derived from sampling site: Embryonic thymus Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Caution: Parent cell line is not from strain C57BL/6 as originally published but from strain BALB/c 21171051 CVCL_W175 GMI-R1 factor-dependent cell line Norway rat CVCL_W175 CL:0000010 Derived from sampling site: Brain; meninges Cell type=Microglial cell.; Breed/subspecies: Fischer. Unspecified Characteristics: CSF2 dependent Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7062 21171052 CVCL_VP75 PNUi002-A induced pluripotent stem cell human CVCL_VP75 From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21171053 CVCL_W172 5-2 factor-dependent cell line house mouse CVCL_W172 CL:0000010 Derived from sampling site: Brain; meninges Cell type=Microglial cell.; Breed/subspecies: C57BL/6J(H-2b). Unspecified Characteristics: CSF2 dependent 21171054 CVCL_VP72 B-LCL #1038-213 transformed cell line human CVCL_VP72 HLA typing: A*02,02; B*35,56; C*01,04; DRB1*11,01 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171055 CVCL_W173 6-1 factor-dependent cell line house mouse CVCL_W173 CL:0000010 Derived from sampling site: Brain; meninges Cell type=Microglial cell.; Breed/subspecies: C57BL/6J(H-2b). Unspecified Characteristics: CSF2 dependent 21171056 CVCL_VP73 B-LCL #1038-3 transformed cell line human CVCL_VP73 HLA typing: A*02:01,02:01; B*14,27:05; DRB1*15:01,14 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171057 CVCL_VP78 KCi001-A induced pluripotent stem cell human CVCL_VP78 From: Kennedy Centret, Rigshospitalet; Glostrup; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 966; BBS1; Simple; p.Gly379Arg (c.1135G>C); Zygosity=Heterozygous (PubMed=30142598); Sequence variation: Mutation; HGNC; 966; BBS1; Simple; p.Met390Arg (c.1169T>G); ClinVar=VCV000012143; Zygosity=Heterozygous (PubMed=30142598) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171058 CVCL_W178 ROB-C20 spontaneously immortalized cell line Norway rat CVCL_W178 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21171059 CVCL_VP79 GM27158 transformed cell line human CVCL_VP79 CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg141Cys (c.421C>T); ClinVar=VCV000447846; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171060 CVCL_W179 SBC-H20 hybrid cell line CVCL_W179 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8464 21171061 CVCL_VP76 PNUi002-B induced pluripotent stem cell human CVCL_VP76 From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21171062 CVCL_W176 ROB-C11 spontaneously immortalized cell line Norway rat CVCL_W176 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21171063 CVCL_VP77 PNUi002-C induced pluripotent stem cell human CVCL_VP77 From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21171064 CVCL_W177 ROB-C23 spontaneously immortalized cell line Norway rat CVCL_W177 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21171065 CVCL_W158 CO-MZ-2 cancer cell line human CVCL_W158 CL:0000010 Unspecified 21171066 CVCL_VP58 KHm-4 cancer cell line human CVCL_VP58 CL:0000010 Derived from sampling site: Skin. Unspecified 21171067 CVCL_VP59 CHO MGAT1- spontaneously immortalized cell line CVCL_VP59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q924C0; Mgat1 Derived from sampling site: Ovary. Female Characteristics: This cell line can only produce N-linked carbohydrates with early oligomannose glycans (Man5-9) 21171068 CVCL_W159 CO-MZ-4 cancer cell line human CVCL_W159 CL:0000010 Unspecified 21171069 CVCL_3J11 HQ00923 transformed cell line human CVCL_3J11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171070 CVCL_3J12 HQ00924 transformed cell line human CVCL_3J12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171071 CVCL_3J10 HQ00922 transformed cell line human CVCL_3J10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171072 CVCL_3J15 HQ00927 transformed cell line human CVCL_3J15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171073 CVCL_3J16 HQ00928 transformed cell line human CVCL_3J16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171074 CVCL_3J13 HQ00925 transformed cell line human CVCL_3J13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171075 CVCL_3J14 HQ00926 transformed cell line human CVCL_3J14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171076 CVCL_3J08 HQ00920 transformed cell line human CVCL_3J08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171077 CVCL_3J09 HQ00921 transformed cell line human CVCL_3J09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171078 CVCL_3J06 HQ00918 transformed cell line human CVCL_3J06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171079 CVCL_3J07 HQ00919 transformed cell line human CVCL_3J07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171080 CVCL_W160 H16-1.93 hybridoma house mouse CVCL_W160 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14638; Human ENPP3/CD203c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7449 21171081 CVCL_VP60 rESC 051A embryonic stem cell CVCL_VP60 CL:0000010 Donor information: Embryo is sibling to that giving rise to rESC 051B (Cellosaurus=CVCL_VP61). Female Group: Endangered species/breed cell line 21171082 CVCL_VP63 B-LCL #1038-222 transformed cell line human CVCL_VP63 HLA typing: A*02:01,02:01; B*15,27:05; C*02,03; DRB1*07:01,04:01 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171083 CVCL_W163 Ha16-1(1)11 hybridoma house mouse CVCL_W163 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14638; Human ENPP3/CD203c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7450 21171084 CVCL_VP64 B-LCL #1038-205 transformed cell line human CVCL_VP64 HLA typing: A*01,03; B*37,15; C*03,06; DRB1*13,07 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171085 CVCL_W164 ROB-C8a spontaneously immortalized cell line Norway rat CVCL_W164 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21171086 CVCL_W161 H16-9.69 hybridoma house mouse CVCL_W161 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14638; Human ENPP3/CD203c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7451 21171087 CVCL_VP61 rESC 051B embryonic stem cell CVCL_VP61 CL:0000010 Donor information: Embryo is sibling to that giving rise to rESC 051A (Cellosaurus=CVCL_VP60). Female Group: Endangered species/breed cell line 21171088 CVCL_VP62 B-LCL #1038-206 transformed cell line human CVCL_VP62 HLA typing: A*03,11; B*07,51; C*07,15; DRB1*04:04,04:01 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171089 CVCL_W162 Ha16-1(3,5)18 hybridoma house mouse CVCL_W162 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14638; Human ENPP3/CD203c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7452 21171090 CVCL_VP67 B-LCL #1038-224 transformed cell line human CVCL_VP67 HLA typing: A*02,02; B*07,15; C*03,07; DRB1*15,13 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171091 CVCL_W167 C2M15 transformed cell line human CVCL_W167 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.. Unspecified 21171092 CVCL_VP68 B-LCL #1038-333 transformed cell line human CVCL_VP68 HLA typing: A*03,34; B*35,40; C*04,15; DRB1*04,07 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171093 CVCL_W168 CIHGM-1 conditionally immortalized cell line human CVCL_W168 CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Cell line name and sex of donor from author direct submission Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.. Male 21171094 CVCL_VP65 B-LCL #1038-165 transformed cell line human CVCL_VP65 HLA typing: A*11,24; B*07,35; C*04,07; DRB1*15,11 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171095 CVCL_W165 ROB [Rat osteoblastic] spontaneously immortalized cell line Norway rat CVCL_W165 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: Sprague Dawley. Unspecified 21171096 CVCL_VP66 B-LCL #1038-228 transformed cell line human CVCL_VP66 HLA typing: A*02:01,30; B*18,44; C*05,05; DRB1*15,03 (Astarte) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171097 CVCL_W166 C2M12 transformed cell line human CVCL_W166 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.. Unspecified 21171098 CVCL_VP49 BCJ-4T cancer cell line human CVCL_VP49 CL:0000010 Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from sampling site: Urinary bladder; urothelium. Male Doubling time: 29.2 hours (Direct_author_submission) 21171099 CVCL_W149 GM02439 finite cell line human CVCL_W149 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 4298; GLB1; Simple; p.Arg201Cys (c.601C>T); ClinVar=VCV000000925; Zygosity=Unspecified (PubMed=25925601) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171100 CVCL_W147 GM00937 finite cell line human CVCL_W147 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Phe39Leu (c.117C>G); ClinVar=VCV000000605; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; c.1066-11G>A (IVS10-11G>A); ClinVar=VCV000000607; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171101 CVCL_VP47 Mela16 cancer cell line human CVCL_VP47 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from metastatic site: Axillary lymph node. Male Doubling time: 33 hours (Direct_author_submission) 21171102 CVCL_W148 GM02406 finite cell line human CVCL_W148 CL:0000010 Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Phe299Cys (c.896T>G); ClinVar=VCV000000613; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8582; PAH; Simple; p.Arg408Trp (c.1222C>T); ClinVar=VCV000000577; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171103 CVCL_VP48 Mela17 cancer cell line human CVCL_VP48 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000045115; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from metastatic site: Infraclavicular lymph node. Male Doubling time: 38 hours (Direct_author_submission) 21171104 CVCL_3J22 HQ00934 transformed cell line human CVCL_3J22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171105 CVCL_3J23 HQ00935 transformed cell line human CVCL_3J23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171106 CVCL_3J20 HQ00932 transformed cell line human CVCL_3J20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171107 CVCL_3J21 HQ00933 transformed cell line human CVCL_3J21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171108 CVCL_3J26 HQ00938 transformed cell line human CVCL_3J26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171109 CVCL_3J27 HQ00939 transformed cell line human CVCL_3J27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171110 CVCL_3J24 HQ00936 transformed cell line human CVCL_3J24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171111 CVCL_3J25 HQ00937 transformed cell line human CVCL_3J25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171112 CVCL_3J19 HQ00931 transformed cell line human CVCL_3J19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171113 CVCL_3J17 HQ00929 transformed cell line human CVCL_3J17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171114 CVCL_3J18 HQ00930 transformed cell line human CVCL_3J18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171115 CVCL_W152 GM18436 finite cell line human CVCL_W152 CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Pro543Argfs*20 (c.1628delC) (p.Phe542fs); ClinVar=VCV000556403; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Glu612Asp (c.1836A>C); ClinVar=VCV000555407; Zygosity=Heterozygous (Coriell) Population: Caucasian; Canadian/Italian; Derived from sampling site: Cell type=Fibroblast. Male 21171116 CVCL_VP52 XP12ROB4 transformed cell line human CVCL_VP52 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Homozygous (from parent cell line) Population: Palestinian; Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Combines defects in three DNA repair functions: MGMT, MMR and NER Does not express MSH2. 21171117 CVCL_VP53 APC-NT 2E7 hybridoma house mouse CVCL_VP53 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25054; Human APC (Note=Recognizes N-terminal region p.Met1_Ala61). 21171118 CVCL_W153 GM18445 finite cell line human CVCL_W153 CL:0000010 Sequence variation: Mutation; HGNC; 14537; NPC2; Simple; p.Val39Met (c.115G>A); ClinVar=VCV000008483; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21171119 CVCL_W150 AT9RM transformed cell line human CVCL_W150 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg3047Ter (c.9139C>T); ClinVar=VCV000003029; Zygosity=Homozygous (PubMed=9497252; PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171120 CVCL_VP50 XP12RO transformed cell line human CVCL_VP50 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Homozygous (PubMed=1372102; PubMed=8464385) Population: Palestinian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171121 CVCL_W151 GM15786 transformed cell line human CVCL_W151 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171122 CVCL_VP51 XP129 transformed cell line human CVCL_VP51 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Gly (c.619C>G); Zygosity=Unspecified (PubMed=8464385) Population: Palestinian; Selected for resistance to: NCIt; C17231; Ultraviolet radiation; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Revertant in term of the XP12RO phenotype 21171123 CVCL_VP56 APC-NT 8D9 hybridoma house mouse CVCL_VP56 CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: UniProtKB; P25054; Human APC (Note=Recognizes N-terminal region p.Met1_Ala61). 21171124 CVCL_W156 GM17418 finite cell line human CVCL_W156 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (from familial inference of XP86BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171125 CVCL_VP57 APC-NT 9G11 hybridoma house mouse CVCL_VP57 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25054; Human APC (Note=Recognizes N-terminal region p.Met1_Ala61). 21171126 CVCL_W157 CO-MZ-1 cancer cell line human CVCL_W157 CL:0000010 Unspecified 21171127 CVCL_VP54 APC-NT 6D12 hybridoma house mouse CVCL_VP54 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25054; Human APC (Note=Recognizes N-terminal region p.Met1_Ala61). 21171128 CVCL_W154 Y1-BS1 cancer cell line house mouse CVCL_W154 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21171129 CVCL_VP55 APC-NT 6G6 hybridoma house mouse CVCL_VP55 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P25054; Human APC (Note=Recognizes N-terminal region p.Met1_Ala61). 21171130 CVCL_W155 GM17417 transformed cell line human CVCL_W155 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS2+1G>A; Zygosity=Homozygous; Note=Splice donor mutation (from familial inference of XP86BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171131 CVCL_MX59 BayGenomics ES cell line RRH195 embryonic stem cell house mouse CVCL_MX59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171132 CVCL_N959 GM20896 transformed cell line human CVCL_N959 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171133 CVCL_MX57 BayGenomics ES cell line RRH189 embryonic stem cell house mouse CVCL_MX57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171134 CVCL_N957 GM20894 transformed cell line human CVCL_N957 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171135 CVCL_MX58 BayGenomics ES cell line RRH194 embryonic stem cell house mouse CVCL_MX58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171136 CVCL_N958 GM20895 transformed cell line human CVCL_N958 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171137 CVCL_MX55 BayGenomics ES cell line RRH187 embryonic stem cell house mouse CVCL_MX55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890222; Midn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171138 CVCL_N955 GM20892 transformed cell line human CVCL_N955 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171139 CVCL_MX56 BayGenomics ES cell line RRH188 embryonic stem cell house mouse CVCL_MX56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682307; Ric8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171140 CVCL_N956 GM20893 transformed cell line human CVCL_N956 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171141 CVCL_MX53 BayGenomics ES cell line RRH184 embryonic stem cell house mouse CVCL_MX53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921357; Cep55 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171142 CVCL_N953 GM20890 transformed cell line human CVCL_N953 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171143 CVCL_MX54 BayGenomics ES cell line RRH186 embryonic stem cell house mouse CVCL_MX54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171144 CVCL_N954 GM20891 transformed cell line human CVCL_N954 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171145 CVCL_MX51 BayGenomics ES cell line RRH173 embryonic stem cell house mouse CVCL_MX51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171146 CVCL_N951 GM20888 transformed cell line human CVCL_N951 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171147 CVCL_MX52 BayGenomics ES cell line RRH176 embryonic stem cell house mouse CVCL_MX52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916023; Zc3hc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171148 CVCL_N952 GM20889 transformed cell line human CVCL_N952 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171149 CVCL_MX50 BayGenomics ES cell line RRH166 embryonic stem cell house mouse CVCL_MX50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171150 CVCL_N950 GM20887 transformed cell line human CVCL_N950 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171151 CVCL_W300 GM09090 transformed cell line human CVCL_W300 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171152 CVCL_VR00 HROC383 T0 M2 cancer cell line human CVCL_VR00 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Female Characteristics: Established from a patient-derived xenograft established in female NSG mice 21171153 CVCL_MX68 BayGenomics ES cell line RRH213 embryonic stem cell house mouse CVCL_MX68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928899; Tacc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171154 CVCL_N968 GM20905 transformed cell line human CVCL_N968 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171155 CVCL_MX69 BayGenomics ES cell line RRH221 embryonic stem cell house mouse CVCL_MX69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171156 CVCL_N969 GM20906 transformed cell line human CVCL_N969 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171157 CVCL_MX66 BayGenomics ES cell line RRH209 embryonic stem cell house mouse CVCL_MX66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921850; Mrpl47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171158 CVCL_N966 GM20903 transformed cell line human CVCL_N966 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171159 CVCL_MX67 BayGenomics ES cell line RRH211 embryonic stem cell house mouse CVCL_MX67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890430; Paxip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171160 CVCL_N967 GM20904 transformed cell line human CVCL_N967 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171161 CVCL_MX64 BayGenomics ES cell line RRH207 embryonic stem cell house mouse CVCL_MX64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171162 CVCL_N964 GM20901 transformed cell line human CVCL_N964 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171163 CVCL_MX65 BayGenomics ES cell line RRH208 embryonic stem cell house mouse CVCL_MX65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135960; Slc12a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171164 CVCL_N965 GM20902 transformed cell line human CVCL_N965 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171165 CVCL_MX62 BayGenomics ES cell line RRH204 embryonic stem cell house mouse CVCL_MX62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675859; Wapl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171166 CVCL_N962 GM20899 transformed cell line human CVCL_N962 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171167 CVCL_MX63 BayGenomics ES cell line RRH205 embryonic stem cell house mouse CVCL_MX63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894646; Hlcs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171168 CVCL_N963 GM20900 transformed cell line human CVCL_N963 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171169 CVCL_MX60 BayGenomics ES cell line RRH199 embryonic stem cell house mouse CVCL_MX60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171170 CVCL_N960 GM20897 transformed cell line human CVCL_N960 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171171 CVCL_MX61 BayGenomics ES cell line RRH203 embryonic stem cell house mouse CVCL_MX61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2148019; Jade3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171172 CVCL_N961 GM20898 transformed cell line human CVCL_N961 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171173 CVCL_MX39 BayGenomics ES cell line RRH147 embryonic stem cell house mouse CVCL_MX39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171174 CVCL_N939 GM20874 transformed cell line human CVCL_N939 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171175 CVCL_MX37 BayGenomics ES cell line RRH145 embryonic stem cell house mouse CVCL_MX37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171176 CVCL_N937 GM20872 transformed cell line human CVCL_N937 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171177 CVCL_MX38 BayGenomics ES cell line RRH146 embryonic stem cell house mouse CVCL_MX38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171178 CVCL_N938 GM20873 transformed cell line human CVCL_N938 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171179 CVCL_MX35 BayGenomics ES cell line RRH141 embryonic stem cell house mouse CVCL_MX35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171180 CVCL_N935 GM20870 transformed cell line human CVCL_N935 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171181 CVCL_MX36 BayGenomics ES cell line RRH143 embryonic stem cell house mouse CVCL_MX36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3781595; Dynlt2a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171182 CVCL_N936 GM20871 transformed cell line human CVCL_N936 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171183 CVCL_MX33 BayGenomics ES cell line RRH136 embryonic stem cell house mouse CVCL_MX33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916658; Dnajc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171184 CVCL_N933 GM20868 transformed cell line human CVCL_N933 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171185 CVCL_MX34 BayGenomics ES cell line RRH138 embryonic stem cell house mouse CVCL_MX34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917822; Ipo5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171186 CVCL_N934 GM20869 transformed cell line human CVCL_N934 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171187 CVCL_MX31 BayGenomics ES cell line RRH128 embryonic stem cell house mouse CVCL_MX31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203522; Magi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171188 CVCL_N931 GM20866 transformed cell line human CVCL_N931 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171189 CVCL_MX32 BayGenomics ES cell line RRH131 embryonic stem cell house mouse CVCL_MX32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171190 CVCL_N932 GM20867 transformed cell line human CVCL_N932 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171191 CVCL_MX30 BayGenomics ES cell line RRH119 embryonic stem cell house mouse CVCL_MX30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106203; Skil Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171192 CVCL_N930 GM20864 transformed cell line human CVCL_N930 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171193 CVCL_MX48 BayGenomics ES cell line RRH162 embryonic stem cell house mouse CVCL_MX48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146430; Cblb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171194 CVCL_N948 GM20885 transformed cell line human CVCL_N948 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171195 CVCL_MX49 BayGenomics ES cell line RRH165 embryonic stem cell house mouse CVCL_MX49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171196 CVCL_N949 GM20886 transformed cell line human CVCL_N949 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171197 CVCL_MX46 BayGenomics ES cell line RRH159 embryonic stem cell house mouse CVCL_MX46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351613; Txnl4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171198 CVCL_N946 GM20883 transformed cell line human CVCL_N946 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171199 CVCL_MX47 BayGenomics ES cell line RRH161 embryonic stem cell house mouse CVCL_MX47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171200 CVCL_N947 GM20884 transformed cell line human CVCL_N947 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171201 CVCL_MX44 BayGenomics ES cell line RRH156 embryonic stem cell house mouse CVCL_MX44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3697726; Arhgap23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171202 CVCL_N944 GM20881 transformed cell line human CVCL_N944 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171203 CVCL_MX45 BayGenomics ES cell line RRH158 embryonic stem cell house mouse CVCL_MX45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855695; Clasrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171204 CVCL_N945 GM20882 transformed cell line human CVCL_N945 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171205 CVCL_MX42 BayGenomics ES cell line RRH152 embryonic stem cell house mouse CVCL_MX42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171206 CVCL_N942 GM20877 transformed cell line human CVCL_N942 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171207 CVCL_MX43 BayGenomics ES cell line RRH154 embryonic stem cell house mouse CVCL_MX43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171208 CVCL_N943 GM20878 transformed cell line human CVCL_N943 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171209 CVCL_MX40 BayGenomics ES cell line RRH148 embryonic stem cell house mouse CVCL_MX40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171210 CVCL_N940 GM20875 transformed cell line human CVCL_N940 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171211 CVCL_MX41 BayGenomics ES cell line RRH150 embryonic stem cell house mouse CVCL_MX41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171212 CVCL_N941 GM20876 transformed cell line human CVCL_N941 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171213 CVCL_MX19 BayGenomics ES cell line RRH063 embryonic stem cell house mouse CVCL_MX19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171214 CVCL_N919 GM20850 transformed cell line human CVCL_N919 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171215 CVCL_MX17 BayGenomics ES cell line RRH061 embryonic stem cell house mouse CVCL_MX17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105081; Tes Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171216 CVCL_N917 GM20847 transformed cell line human CVCL_N917 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171217 CVCL_MX18 BayGenomics ES cell line RRH062 embryonic stem cell house mouse CVCL_MX18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442153; Gak Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171218 CVCL_N918 GM20849 transformed cell line human CVCL_N918 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171219 CVCL_MX15 BayGenomics ES cell line RRH059 embryonic stem cell house mouse CVCL_MX15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933972; Tra2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171220 CVCL_N915 GM20845 transformed cell line human CVCL_N915 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171221 CVCL_MX16 BayGenomics ES cell line RRH060 embryonic stem cell house mouse CVCL_MX16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277960; Patj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171222 CVCL_N916 GM20846 transformed cell line human CVCL_N916 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171223 CVCL_MX13 BayGenomics ES cell line RRH054 embryonic stem cell house mouse CVCL_MX13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349473; Ppp2r5e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171224 CVCL_N913 GM20412 transformed cell line human CVCL_N913 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171225 CVCL_MX14 BayGenomics ES cell line RRH055 embryonic stem cell house mouse CVCL_MX14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99690; Pola2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171226 CVCL_N914 GM20414 transformed cell line human CVCL_N914 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171227 CVCL_MX11 BayGenomics ES cell line RRH050 embryonic stem cell house mouse CVCL_MX11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926045; Armc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171228 CVCL_N911 GM20359 transformed cell line human CVCL_N911 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171229 CVCL_MX12 BayGenomics ES cell line RRH053 embryonic stem cell house mouse CVCL_MX12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171230 CVCL_N912 GM20363 transformed cell line human CVCL_N912 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171231 CVCL_MX10 BayGenomics ES cell line RRH049 embryonic stem cell house mouse CVCL_MX10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914451; Glod4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171232 CVCL_N910 GM20357 transformed cell line human CVCL_N910 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171233 CVCL_MX28 BayGenomics ES cell line RRH099 embryonic stem cell house mouse CVCL_MX28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99463; Pigh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171234 CVCL_N928 GM20862 transformed cell line human CVCL_N928 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171235 CVCL_MX29 BayGenomics ES cell line RRH102 embryonic stem cell house mouse CVCL_MX29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171236 CVCL_N929 GM20863 transformed cell line human CVCL_N929 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171237 CVCL_MX26 BayGenomics ES cell line RRH082 embryonic stem cell house mouse CVCL_MX26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921493; Slx4ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171238 CVCL_N926 GM20859 transformed cell line human CVCL_N926 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171239 CVCL_MX27 BayGenomics ES cell line RRH084 embryonic stem cell house mouse CVCL_MX27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915670; Ankrd13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171240 CVCL_N927 GM20861 transformed cell line human CVCL_N927 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171241 CVCL_MX24 BayGenomics ES cell line RRH079 embryonic stem cell house mouse CVCL_MX24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914632; Brd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171242 CVCL_N924 GM20856 transformed cell line human CVCL_N924 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171243 CVCL_MX25 BayGenomics ES cell line RRH080 embryonic stem cell house mouse CVCL_MX25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171244 CVCL_N925 GM20858 transformed cell line human CVCL_N925 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171245 CVCL_MX22 BayGenomics ES cell line RRH069 embryonic stem cell house mouse CVCL_MX22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353557; Schip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171246 CVCL_N922 GM20853 transformed cell line human CVCL_N922 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171247 CVCL_MX23 BayGenomics ES cell line RRH070 embryonic stem cell house mouse CVCL_MX23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171248 CVCL_N923 GM20854 transformed cell line human CVCL_N923 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171249 CVCL_MX20 BayGenomics ES cell line RRH065 embryonic stem cell house mouse CVCL_MX20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914792; Cog6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171250 CVCL_N920 GM20851 transformed cell line human CVCL_N920 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171251 CVCL_MX21 BayGenomics ES cell line RRH068 embryonic stem cell house mouse CVCL_MX21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353557; Schip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171252 CVCL_N921 GM20852 transformed cell line human CVCL_N921 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171253 CVCL_MX08 BayGenomics ES cell line RRH047 embryonic stem cell house mouse CVCL_MX08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2148019; Jade3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171254 CVCL_N908 GM20351 transformed cell line human CVCL_N908 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171255 CVCL_MX09 BayGenomics ES cell line RRH048 embryonic stem cell house mouse CVCL_MX09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921642; Specc1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171256 CVCL_N909 GM20356 transformed cell line human CVCL_N909 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171257 CVCL_MX06 BayGenomics ES cell line RRH037 embryonic stem cell house mouse CVCL_MX06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137336; Baiap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171258 CVCL_N906 GM20346 transformed cell line human CVCL_N906 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171259 CVCL_MX07 BayGenomics ES cell line RRH040 embryonic stem cell house mouse CVCL_MX07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171260 CVCL_N907 GM20348 transformed cell line human CVCL_N907 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171261 CVCL_MX04 BayGenomics ES cell line RRH031 embryonic stem cell house mouse CVCL_MX04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261910; Pibf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171262 CVCL_N904 GM20342 transformed cell line human CVCL_N904 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171263 CVCL_MX05 BayGenomics ES cell line RRH032 embryonic stem cell house mouse CVCL_MX05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171264 CVCL_N905 GM20344 transformed cell line human CVCL_N905 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171265 CVCL_MX02 BayGenomics ES cell line RRH028 embryonic stem cell house mouse CVCL_MX02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685397; Rc3h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171266 CVCL_N902 GM20340 transformed cell line human CVCL_N902 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171267 CVCL_MX03 BayGenomics ES cell line RRH029 embryonic stem cell house mouse CVCL_MX03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098280; Crebbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171268 CVCL_N903 GM20341 transformed cell line human CVCL_N903 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171269 CVCL_MX00 BayGenomics ES cell line RRH025 embryonic stem cell house mouse CVCL_MX00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171270 CVCL_N900 GM20336 transformed cell line human CVCL_N900 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171271 CVCL_MX01 BayGenomics ES cell line RRH027 embryonic stem cell house mouse CVCL_MX01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95298; Eif1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171272 CVCL_N901 GM20339 transformed cell line human CVCL_N901 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171273 CVCL_W259 iPS.IV.1.1 induced pluripotent stem cell human CVCL_W259 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171274 CVCL_VQ59 M227 transformed cell line house mouse CVCL_VQ59 CL:0000010 Transformant: Kirsten murine sarcoma virus (Ki-MSV) [ts mutant](NCBI-Taxonomy; 11808); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified 21171275 CVCL_VQ57 BLaER1 cancer cell line human CVCL_VQ57 CL:0000010 Sequence variation: Gene fusion; HGNC; 8632; PBX1 + HGNC; 11633; TCF3; Name(s)=TCF3-PBX1; E2A-PBX1 (from parent cell line); Transfected with: HGNC; 1833; CEBPA; Transfected with: HGNC; 3467; ESR1 (ligand-binding domain); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Bone marrow. Female Characteristics: Can efficiently be convert into cells exhibiting increased adherent, phagocytic and quiescent properties with a transcriptome resembling normal macrophages; Characteristics: Transfected with the retrovirus vector C/EBPaER-GFP which consist of CEBPA fused with the estrogen receptor hormone binding domain and GFP Caution: Was originally (PubMed=23545498) described as originating from the Seraphina cell line (Cellosaurus=CVCL_M646) but was later (PubMed=28494875) shown to derive from RCH-ACV 21171276 CVCL_W257 iPS.III.7.3 induced pluripotent stem cell human CVCL_W257 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171277 CVCL_W258 iPS.III.7.4 induced pluripotent stem cell human CVCL_W258 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171278 CVCL_VQ58 TiHo-0906 cancer cell line CVCL_VQ58 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: British shorthair. Female Doubling time: 28.9 hours (at low passage), 27.4 hours (at high passage) (PubMed=30185896) 21171279 CVCL_3K10 HQ01023 transformed cell line human CVCL_3K10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171280 CVCL_3K11 HQ01024 transformed cell line human CVCL_3K11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171281 CVCL_3K14 HQ01027 transformed cell line human CVCL_3K14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171282 CVCL_3K15 HQ01028 transformed cell line human CVCL_3K15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171283 CVCL_3K12 HQ01025 transformed cell line human CVCL_3K12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171284 CVCL_3K13 HQ01026 transformed cell line human CVCL_3K13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171285 CVCL_3K07 HQ01020 transformed cell line human CVCL_3K07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171286 CVCL_3K08 HQ01021 transformed cell line human CVCL_3K08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171287 CVCL_3K05 HQ01018 transformed cell line human CVCL_3K05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171288 CVCL_3K06 HQ01019 transformed cell line human CVCL_3K06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171289 CVCL_3K09 HQ01022 transformed cell line human CVCL_3K09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171290 CVCL_VQ62 IN-IC transformed cell line Norway rat CVCL_VQ62 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; distal tubule Cell type=Renal intercalated cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21171291 CVCL_W262 iPS.IV.3.1 induced pluripotent stem cell human CVCL_W262 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171292 CVCL_W263 iPS.IV.3.2 induced pluripotent stem cell human CVCL_W263 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171293 CVCL_VQ63 TS/A-pc cancer cell line house mouse CVCL_VQ63 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Caution: Termed \"pc\" for \"parental cells\" not because it is supposed to be identical to TS/A but because it is the parent cell line for a number of transfectants 21171294 CVCL_VQ60 Atg7^(+/+)MEF transformed cell line house mouse CVCL_VQ60 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21171295 CVCL_W260 iPS.IV.1.2 induced pluripotent stem cell human CVCL_W260 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171296 CVCL_VQ61 Atg7^(-/-)MEF transformed cell line house mouse CVCL_VQ61 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1921494; Atg7 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21171297 CVCL_W261 iPS.IV.1.3 induced pluripotent stem cell human CVCL_W261 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171298 CVCL_VQ66 DKAT-SCGM cancer cell line human CVCL_VQ66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female Group: Serum/protein free medium cell line; Group: Triple negative breast cancer (TNBC) cell line 21171299 CVCL_W266 KOBK-130 cancer cell line human CVCL_W266 CL:0000010 Population: Japanese. 21171300 CVCL_W267 UTP-5 cancer cell line human CVCL_W267 CL:0000010 Population: Japanese. 21171301 CVCL_VQ67 ZZUi008-A induced pluripotent stem cell human CVCL_VQ67 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln1528Argfs*18 (c.4583delA); Zygosity=Hemizygous (PubMed=30172907) Population: Chinese; Han; Derived from sampling site: Chorionic villus. Male 21171302 CVCL_W264 iPS.IV.3.3 induced pluripotent stem cell human CVCL_W264 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171303 CVCL_VQ64 SCL215 transformed cell line human CVCL_VQ64 CL:0000010 Transfected with: RGD; 70513; Gnrhr; Transfected with: UniProtKB; O42329; Clarias gariepinus cfGnRH-R (with p.Met1_Phe328del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a rat GNRHR fused to a catfish GNRHR C-terminal cytoplasmic domain The fusion protein binds GNRH and analogs but this does not activate signaling. 21171304 CVCL_VQ65 DKAT cancer cell line human CVCL_VQ65 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (PubMed=23049838) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: Highly tumorigenic Only 10 DKAT cells are needed to form, in immunocompromised mice, xenograft tumors which display a range of epithelial and mesenchymal phenotypes (PubMed=23049838). Doubling time: ~24 hours (PubMed=23049838) Group: Patented cell line; Group: Triple negative breast cancer (TNBC) cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10322 21171305 CVCL_W265 KOBK-101 cancer cell line human CVCL_W265 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21171306 CVCL_VQ48 IARC-293 transformed cell line human CVCL_VQ48 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21171307 CVCL_W248 iPS.III.1.1 induced pluripotent stem cell human CVCL_W248 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171308 CVCL_VQ49 IARC-470 transformed cell line human CVCL_VQ49 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171309 CVCL_W249 iPS.III.1.2 induced pluripotent stem cell human CVCL_W249 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171310 CVCL_VQ46 IARC-305 transformed cell line human CVCL_VQ46 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171311 CVCL_W246 iPS.II.6.2 induced pluripotent stem cell human CVCL_W246 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171312 CVCL_VQ47 IARC-308 transformed cell line human CVCL_VQ47 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21171313 CVCL_W247 iPS.II.6.3 induced pluripotent stem cell human CVCL_W247 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171314 CVCL_3K21 HQ01034 transformed cell line human CVCL_3K21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171315 CVCL_3K22 HQ01035 transformed cell line human CVCL_3K22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171316 CVCL_3K20 HQ01033 transformed cell line human CVCL_3K20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171317 CVCL_3K25 HQ01038 transformed cell line human CVCL_3K25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171318 CVCL_3K26 HQ01039 transformed cell line human CVCL_3K26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171319 CVCL_3K23 HQ01036 transformed cell line human CVCL_3K23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171320 CVCL_3K24 HQ01037 transformed cell line human CVCL_3K24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171321 CVCL_3K18 HQ01031 transformed cell line human CVCL_3K18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171322 CVCL_3K19 HQ01032 transformed cell line human CVCL_3K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171323 CVCL_3K16 HQ01029 transformed cell line human CVCL_3K16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171324 CVCL_3K17 HQ01030 transformed cell line human CVCL_3K17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171325 CVCL_W251 iPS.III.3.2 induced pluripotent stem cell human CVCL_W251 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171326 CVCL_VQ51 VOA4881 cancer cell line human CVCL_VQ51 CL:0000010 Derived from metastatic site: Ascites. Female 21171327 CVCL_W252 iPS.III.3.3 induced pluripotent stem cell human CVCL_W252 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171328 CVCL_VQ52 VOA6406 cancer cell line human CVCL_VQ52 CL:0000010 Female 21171329 CVCL_VQ50 IARC-070 transformed cell line human CVCL_VQ50 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Turkish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171330 CVCL_W250 iPS.III.3.1 induced pluripotent stem cell human CVCL_W250 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171331 CVCL_VQ55 A6-KR spontaneously immortalized cell line African clawed frog CVCL_VQ55 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male Group: Amphibian cell line 21171332 CVCL_W255 iPS.III.7.1 induced pluripotent stem cell human CVCL_W255 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171333 CVCL_W256 iPS.III.7.2 induced pluripotent stem cell human CVCL_W256 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171334 CVCL_VQ56 XTC-GTX-11 spontaneously immortalized cell line African clawed frog CVCL_VQ56 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Amphibian cell line 21171335 CVCL_W253 iPS.III.4.1 induced pluripotent stem cell human CVCL_W253 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171336 CVCL_VQ53 VOA6800 cancer cell line human CVCL_VQ53 CL:0000010 Female 21171337 CVCL_VQ54 CB02 hybridoma house mouse CVCL_VQ54 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08637; Human FCGR3A/CD16. 21171338 CVCL_W254 iPS.III.4.2 induced pluripotent stem cell human CVCL_W254 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171339 CVCL_VQ37 BL-56 cancer cell line human CVCL_VQ37 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Female Virology: EBV-negative. 21171340 CVCL_W237 GM17886 finite cell line human CVCL_W237 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Thr7Phefs*7 (c.18_21delGACT); ClinVar=VCV000188834; Zygosity=Homozygous (PubMed=28649545) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171341 CVCL_W238 GM16266 transformed cell line human CVCL_W238 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Lys (c.19G>A) (E6K); ClinVar=VCV000015126; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171342 CVCL_VQ38 VOA4627 cancer cell line human CVCL_VQ38 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (PubMed=27822414) Derived from metastatic site: Ascites. Female 21171343 CVCL_VQ35 BL-66 cancer cell line human CVCL_VQ35 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Derived from sampling site: Pleural effusion. Male Virology: EBV-negative 21171344 CVCL_W235 GM00706 finite cell line human CVCL_W235 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Homozygous (PubMed=9792862) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21171345 CVCL_VQ36 BL-71 cancer cell line human CVCL_VQ36 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21171346 CVCL_W236 GM00760 finite cell line human CVCL_W236 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Trp138Ter (c.414G>A); ClinVar=VCV000004443; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21171347 CVCL_W239 GM16000 transformed cell line human CVCL_W239 CL:0000010 Sequence variation: Mutation; HGNC; 3535; F2; Simple; c.*97G>A (20210G>A); ClinVar=VCV000013310; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171348 CVCL_VQ39 VOA5646 cancer cell line human CVCL_VQ39 CL:0000010 Female 21171349 CVCL_MW98 BayGenomics ES cell line RRH017 embryonic stem cell house mouse CVCL_MW98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277162; Cdk6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171350 CVCL_N898 GM20332 transformed cell line human CVCL_N898 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171351 CVCL_MW99 BayGenomics ES cell line RRH021 embryonic stem cell house mouse CVCL_MW99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171352 CVCL_N899 GM20334 transformed cell line human CVCL_N899 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171353 CVCL_MW96 BayGenomics ES cell line RRH012 embryonic stem cell house mouse CVCL_MW96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338041; Tfg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171354 CVCL_N896 GM20317 transformed cell line human CVCL_N896 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171355 CVCL_MW97 BayGenomics ES cell line RRH013 embryonic stem cell house mouse CVCL_MW97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919815; Uaca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171356 CVCL_N897 GM20322 transformed cell line human CVCL_N897 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171357 CVCL_MW94 BayGenomics ES cell line RRH008 embryonic stem cell house mouse CVCL_MW94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152345; Taf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171358 CVCL_N894 GM20299 transformed cell line human CVCL_N894 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171359 CVCL_MW95 BayGenomics ES cell line RRH010 embryonic stem cell house mouse CVCL_MW95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914384; Nop56 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171360 CVCL_N895 GM20314 transformed cell line human CVCL_N895 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171361 CVCL_MW92 BayGenomics ES cell line RRG435 embryonic stem cell house mouse CVCL_MW92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103310; Ptprk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171362 CVCL_W240 GM14646 transformed cell line human CVCL_W240 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171363 CVCL_N892 GM20296 transformed cell line human CVCL_N892 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171364 CVCL_VQ40 VOA3448 cancer cell line human CVCL_VQ40 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Asn375Ser (c.1124A>G); ClinVar=VCV000041611; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414). Female 21171365 CVCL_MW93 BayGenomics ES cell line RRG454 embryonic stem cell house mouse CVCL_MW93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171366 CVCL_N893 GM20298 transformed cell line human CVCL_N893 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171367 CVCL_W241 iPS.II.1.1 induced pluripotent stem cell human CVCL_W241 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171368 CVCL_VQ41 VOA3723 cancer cell line human CVCL_VQ41 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Asn375Ser (c.1124A>G); ClinVar=VCV000041611; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414). Female 21171369 CVCL_MW90 BayGenomics ES cell line RRG427 embryonic stem cell house mouse CVCL_MW90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927617; Dhx38 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171370 CVCL_N890 GM20291 transformed cell line human CVCL_N890 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171371 CVCL_MW91 BayGenomics ES cell line RRG432 embryonic stem cell house mouse CVCL_MW91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922989; Mpp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171372 CVCL_N891 GM20294 transformed cell line human CVCL_N891 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171373 CVCL_VQ44 iOvCa241 cancer cell line human CVCL_VQ44 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=27822414) Derived from metastatic site: Ascites. Female 21171374 CVCL_W244 iPS.II.1.4 induced pluripotent stem cell human CVCL_W244 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171375 CVCL_VQ45 iOvCa250 cancer cell line human CVCL_VQ45 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Homozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414) Derived from metastatic site: Ascites. Female 21171376 CVCL_W245 iPS.II.6.1 induced pluripotent stem cell human CVCL_W245 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Heterozygous (PubMed=24319668) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171377 CVCL_W242 iPS.II.1.2 induced pluripotent stem cell human CVCL_W242 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171378 CVCL_VQ42 VOA3993 cancer cell line human CVCL_VQ42 CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Phe384Leu (c.1150T>C) (F386L); ClinVar=VCV000134404; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 6193; JAK3; Simple; p.Val722Ile (c.2164G>A); ClinVar=VCV000134573; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=27822414). Female 21171379 CVCL_W243 iPS.II.1.3 induced pluripotent stem cell human CVCL_W243 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171380 CVCL_VQ43 VOA4698 cancer cell line human CVCL_VQ43 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Met541Leu (c.1621A>C); ClinVar=VCV000041599; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ile391Met (c.1173A>G); ClinVar=VCV000135038; Zygosity=Heterozygous (PubMed=27822414); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (PubMed=27822414) Derived from metastatic site: Ascites. Female 21171381 CVCL_W226 GM02302 transformed cell line human CVCL_W226 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171382 CVCL_VQ26 IARC-208 transformed cell line human CVCL_VQ26 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171383 CVCL_W227 GM00008 finite cell line human CVCL_W227 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Homozygous (PubMed=9792862) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171384 CVCL_VQ27 WTC CRISPRi HOPX g1 induced pluripotent stem cell human CVCL_VQ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24961; HOPX; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry was introduced in the AAVS1 safe harbor locus 21171385 CVCL_W224 GM02135 transformed cell line human CVCL_W224 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg195Cys (c.583C>T); ClinVar=VCV000161251; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171386 CVCL_VQ24 IARC-464 transformed cell line human CVCL_VQ24 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21171387 CVCL_W225 GM00962 finite cell line human CVCL_W225 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171388 CVCL_VQ25 IARC-207 transformed cell line human CVCL_VQ25 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171389 CVCL_W228 GM00022 finite cell line human CVCL_W228 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21171390 CVCL_VQ28 WTC CRISPRi HOPX g4 induced pluripotent stem cell human CVCL_VQ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24961; HOPX; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry was introduced in the AAVS1 safe harbor locus 21171391 CVCL_W229 GM00242 finite cell line human CVCL_W229 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21171392 CVCL_VQ29 NOCS-1 cancer cell line human CVCL_VQ29 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Male Doubling time: 29 hours (at 12th passage), 26 hours (at 30th passage) (PubMed=30171458) 21171393 CVCL_3K00 HQ01013 transformed cell line human CVCL_3K00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171394 CVCL_3K03 HQ01016 transformed cell line human CVCL_3K03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171395 CVCL_3K04 HQ01017 transformed cell line human CVCL_3K04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171396 CVCL_3K01 HQ01014 transformed cell line human CVCL_3K01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171397 CVCL_3K02 HQ01015 transformed cell line human CVCL_3K02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171398 CVCL_VQ30 BL-55 cancer cell line human CVCL_VQ30 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow. Female Virology: EBV-negative 21171399 CVCL_W230 GM00296 finite cell line human CVCL_W230 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21171400 CVCL_VQ33 BL-52 cancer cell line human CVCL_VQ33 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21171401 CVCL_W233 GM00342 finite cell line human CVCL_W233 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171402 CVCL_VQ34 BL-68 cancer cell line human CVCL_VQ34 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Virology: EBV-negative 21171403 CVCL_W234 GM00046 finite cell line human CVCL_W234 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Ile69Argfs*5 (c.206_210delTCCTT); ClinVar=VCV000455787; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21171404 CVCL_W231 GM00297 finite cell line human CVCL_W231 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171405 CVCL_VQ31 IARC-205A transformed cell line human CVCL_VQ31 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171406 CVCL_VQ32 BL-39 cancer cell line human CVCL_VQ32 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21171407 CVCL_W232 GM00334 finite cell line human CVCL_W232 CL:0000010 Sequence variation: Mutation; HGNC; 4118; GALK1; Simple; p.Val32Met (c.94G>A); ClinVar=VCV000005628; Zygosity=Homozygous (PubMed=7670469) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171408 CVCL_VQ15 ATL-21C transformed cell line human CVCL_VQ15 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21171409 CVCL_W215 KN-41 cancer cell line human CVCL_W215 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 20.9 hours (PubMed=7154478) 21171410 CVCL_VQ16 ATL-48T cancer cell line human CVCL_VQ16 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21171411 CVCL_W216 KW-103 cancer cell line human CVCL_W216 CL:0000010 Population: Japanese Male Doubling time: 16.0 hours (PubMed=7154478). 21171412 CVCL_VQ13 IMGTi001-A induced pluripotent stem cell human CVCL_VQ13 From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: r(22),del22q13.32-q13.33,dup22q13.32,del3q13.31 (PubMed=30144655); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171413 CVCL_W213 KHm-6 cancer cell line human CVCL_W213 CL:0000010 Unspecified 21171414 CVCL_VQ14 IMGTi001-B induced pluripotent stem cell human CVCL_VQ14 From: Research Institute of Medical Genetics; Tomsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: r(22),del22q13.32-q13.33,dup22q13.32,del3q13.31 (PubMed=30144655); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171415 CVCL_W214 KH-39 cancer cell line human CVCL_W214 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 16.0 hours (PubMed=7154478) 21171416 CVCL_VQ19 IARC-099 transformed cell line human CVCL_VQ19 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Algerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171417 CVCL_W219 IBHK-4 spontaneously immortalized cell line CVCL_W219 CL:0000010 Derived from sampling site: Kidney. Male Group: Serum/protein free medium cell line 21171418 CVCL_VQ17 ATL-55T cancer cell line human CVCL_VQ17 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21171419 CVCL_W217 SPC-A1/DTX cancer cell line human CVCL_W217 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (SPC-A1) has been shown to be a HeLa derivative. 21171420 CVCL_W218 A549-Taxol cancer cell line human CVCL_W218 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Lung. Omics: Proteome analysis by 2D-DE/MS Male 21171421 CVCL_VQ18 IARC-113 transformed cell line human CVCL_VQ18 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21171422 CVCL_MW78 BayGenomics ES cell line RRG396 embryonic stem cell house mouse CVCL_MW78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352508; Stau2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171423 CVCL_N878 GM19923 transformed cell line human CVCL_N878 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171424 CVCL_MW79 BayGenomics ES cell line RRG397 embryonic stem cell house mouse CVCL_MW79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171425 CVCL_N879 GM19982 transformed cell line human CVCL_N879 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171426 CVCL_MW76 BayGenomics ES cell line RRG387 embryonic stem cell house mouse CVCL_MW76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923760; Trappc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171427 CVCL_N876 GM19921 transformed cell line human CVCL_N876 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171428 CVCL_MW77 BayGenomics ES cell line RRG392 embryonic stem cell house mouse CVCL_MW77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670983; BC025920 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171429 CVCL_N877 GM19922 transformed cell line human CVCL_N877 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171430 CVCL_MW74 BayGenomics ES cell line RRG371 embryonic stem cell house mouse CVCL_MW74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384864; BC002059 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171431 CVCL_N874 GM19917 transformed cell line human CVCL_N874 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171432 CVCL_MW75 BayGenomics ES cell line RRG381 embryonic stem cell house mouse CVCL_MW75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443623; Raver2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171433 CVCL_N875 GM19920 transformed cell line human CVCL_N875 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171434 CVCL_MW72 BayGenomics ES cell line RRG364 embryonic stem cell house mouse CVCL_MW72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684986; Asap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171435 CVCL_N872 GM19914 transformed cell line human CVCL_N872 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171436 CVCL_MW73 BayGenomics ES cell line RRG366 embryonic stem cell house mouse CVCL_MW73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194506; Serpini1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171437 CVCL_N873 GM19916 transformed cell line human CVCL_N873 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171438 CVCL_MW70 BayGenomics ES cell line RRG361 embryonic stem cell house mouse CVCL_MW70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313302; Cenpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171439 CVCL_N870 GM19908 transformed cell line human CVCL_N870 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171440 CVCL_MW71 BayGenomics ES cell line RRG363 embryonic stem cell house mouse CVCL_MW71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918954; Arhgef3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171441 CVCL_N871 GM19909 transformed cell line human CVCL_N871 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171442 CVCL_VQ22 IARC-303A transformed cell line human CVCL_VQ22 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21171443 CVCL_W222 STIP-3 spontaneously immortalized cell line CVCL_W222 CL:0000010 Derived from sampling site: Eye; iris. Unspecified Doubling time: 74.9 hours (Patent=US7217564) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8422 21171444 CVCL_W223 GM00939 finite cell line human CVCL_W223 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg195Cys (c.583C>T); ClinVar=VCV000161251; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: SNP array analysis Female 21171445 CVCL_VQ23 IARC-431 transformed cell line human CVCL_VQ23 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171446 CVCL_VQ20 IARC-373 transformed cell line human CVCL_VQ20 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 21171447 CVCL_W220 KM12-L4A cancer cell line human CVCL_W220 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Unspecified Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12496; Registration: Chiron Master Culture Collection; CMCC 11606 (CMCC #11606) 21171448 CVCL_VQ21 IARC-167 transformed cell line human CVCL_VQ21 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171449 CVCL_W221 STIP-1 spontaneously immortalized cell line CVCL_W221 CL:0000010 Derived from sampling site: Eye; iris. Unspecified Doubling time: 38.9 hours (Patent=US7217564) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8421 21171450 CVCL_W204 GM07819 finite cell line human CVCL_W204 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171451 CVCL_VQ04 NOCI 16 cancer cell line human CVCL_VQ04 CL:0000010 21171452 CVCL_W205 GM12720 finite cell line human CVCL_W205 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21171453 CVCL_VQ05 ROS 184 cancer cell line human CVCL_VQ05 CL:0000010 21171454 CVCL_VQ02 MARO 54 cancer cell line human CVCL_VQ02 CL:0000010 21171455 CVCL_W202 Waji cancer cell line human CVCL_W202 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21171456 CVCL_VQ03 MAVI 74 cancer cell line human CVCL_VQ03 CL:0000010 21171457 CVCL_W203 MC cancer cell line human CVCL_W203 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Female Doubling time: ~12 hours (PubMed=6986835) 21171458 CVCL_W208 GM07713 transformed cell line human CVCL_W208 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171459 CVCL_VQ08 PLF1 cancer cell line human CVCL_VQ08 CL:0000010 21171460 CVCL_W209 GM08589 finite cell line human CVCL_W209 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171461 CVCL_VQ09 PLF2 cancer cell line human CVCL_VQ09 CL:0000010 21171462 CVCL_W206 GM07157 transformed cell line human CVCL_W206 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Trp163Arg (c.487T>C) (W162R); ClinVar=VCV000011074; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171463 CVCL_VQ06 TOMA 70 cancer cell line human CVCL_VQ06 CL:0000010 21171464 CVCL_W207 GM07447 transformed cell line human CVCL_W207 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171465 CVCL_VQ07 TRAR 60 cancer cell line human CVCL_VQ07 CL:0000010 21171466 CVCL_MW89 BayGenomics ES cell line RRG422 embryonic stem cell house mouse CVCL_MW89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171467 CVCL_N889 GM20289 transformed cell line human CVCL_N889 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171468 CVCL_MW87 BayGenomics ES cell line RRG410 embryonic stem cell house mouse CVCL_MW87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643019; Gm6360 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171469 CVCL_N887 GM20282 transformed cell line human CVCL_N887 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171470 CVCL_MW88 BayGenomics ES cell line RRG412 embryonic stem cell house mouse CVCL_MW88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277143; Gtf2h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171471 CVCL_N888 GM20287 transformed cell line human CVCL_N888 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171472 CVCL_MW85 BayGenomics ES cell line RRG407 embryonic stem cell house mouse CVCL_MW85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351655; Shroom3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171473 CVCL_N885 GM20278 transformed cell line human CVCL_N885 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171474 CVCL_MW86 BayGenomics ES cell line RRG409 embryonic stem cell house mouse CVCL_MW86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171475 CVCL_N886 GM20281 transformed cell line human CVCL_N886 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171476 CVCL_MW83 BayGenomics ES cell line RRG405 embryonic stem cell house mouse CVCL_MW83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932286; Egln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171477 CVCL_N883 GM20127 transformed cell line human CVCL_N883 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171478 CVCL_MW84 BayGenomics ES cell line RRG406 embryonic stem cell house mouse CVCL_MW84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922250; Stk38l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171479 CVCL_N884 GM20276 transformed cell line human CVCL_N884 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171480 CVCL_MW81 BayGenomics ES cell line RRG399 embryonic stem cell house mouse CVCL_MW81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171481 CVCL_N881 GM19985 transformed cell line human CVCL_N881 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171482 CVCL_MW82 BayGenomics ES cell line RRG403 embryonic stem cell house mouse CVCL_MW82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171483 CVCL_N882 GM20126 transformed cell line human CVCL_N882 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171484 CVCL_MW80 BayGenomics ES cell line RRG398 embryonic stem cell house mouse CVCL_MW80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171485 CVCL_N880 GM19984 transformed cell line human CVCL_N880 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171486 CVCL_W211 KHm-3 cancer cell line human CVCL_W211 CL:0000010 Unspecified 21171487 CVCL_VQ11 MAR-Mel cancer cell line human CVCL_VQ11 CL:0000010 Derived from metastatic site: Lymph node. 21171488 CVCL_W212 KHm-5 cancer cell line human CVCL_W212 CL:0000010 Unspecified 21171489 CVCL_VQ12 Mel 3.0 cancer cell line human CVCL_VQ12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (PubMed=29492214); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=29492214). 21171490 CVCL_W210 KHm-1 cancer cell line human CVCL_W210 CL:0000010 Population: Caucasian; Derived from sampling site: Back; skin. Male Doubling time: 34 hours (PubMed=197244) 21171491 CVCL_VQ10 MNG-Mel cancer cell line human CVCL_VQ10 CL:0000010 Derived from sampling site: Skin. 21171492 CVCL_MW58 BayGenomics ES cell line RRG316 embryonic stem cell house mouse CVCL_MW58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171493 CVCL_N858 GM19704 transformed cell line human CVCL_N858 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171494 CVCL_MW59 BayGenomics ES cell line RRG319 embryonic stem cell house mouse CVCL_MW59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171495 CVCL_N859 GM19707 transformed cell line human CVCL_N859 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171496 CVCL_MW56 BayGenomics ES cell line RRG309 embryonic stem cell house mouse CVCL_MW56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442760; Katnip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171497 CVCL_N856 GM19701 transformed cell line human CVCL_N856 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171498 CVCL_MW57 BayGenomics ES cell line RRG314 embryonic stem cell house mouse CVCL_MW57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2148252; Zfp979 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171499 CVCL_N857 GM19703 transformed cell line human CVCL_N857 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171500 CVCL_MW54 BayGenomics ES cell line RRG306 embryonic stem cell house mouse CVCL_MW54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171501 CVCL_N854 GM19625 transformed cell line human CVCL_N854 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171502 CVCL_MW55 BayGenomics ES cell line RRG308 embryonic stem cell house mouse CVCL_MW55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171503 CVCL_N855 GM19700 transformed cell line human CVCL_N855 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171504 CVCL_MW52 BayGenomics ES cell line RRG292 embryonic stem cell house mouse CVCL_MW52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107470; Lyar Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171505 CVCL_N852 SARCCR2 cancer cell line human CVCL_N852 CL:0000010 Female Doubling time: 28 hours (PubMed=8099901). 21171506 CVCL_MW53 BayGenomics ES cell line RRG305 embryonic stem cell house mouse CVCL_MW53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141207; Kctd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171507 CVCL_N853 YCUS-5 cancer cell line human CVCL_N853 CL:0000010 Population: Japanese. Female 21171508 CVCL_MW50 BayGenomics ES cell line RRG284 embryonic stem cell house mouse CVCL_MW50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918817; Mcm9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171509 CVCL_N850 HX170c cancer cell line human CVCL_N850 CL:0000010 Male 21171510 CVCL_MW51 BayGenomics ES cell line RRG285 embryonic stem cell house mouse CVCL_MW51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388481; Ppp2r5d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171511 CVCL_N851 RM-HS1 cancer cell line human CVCL_N851 CL:0000010 Population: Caucasian. Male 21171512 CVCL_VQ00 CON 242 cancer cell line human CVCL_VQ00 CL:0000010 21171513 CVCL_W200 OzA cancer cell line human CVCL_W200 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21171514 CVCL_VQ01 LIMA 97 cancer cell line human CVCL_VQ01 CL:0000010 21171515 CVCL_W201 SU cancer cell line human CVCL_W201 CL:0000010 Population: Japanese; Derived from sampling site: Bone. Male 21171516 CVCL_MW69 BayGenomics ES cell line RRG360 embryonic stem cell house mouse CVCL_MW69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444121; Tanc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171517 CVCL_N869 GM19904 transformed cell line human CVCL_N869 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171518 CVCL_MW67 BayGenomics ES cell line RRG354 embryonic stem cell house mouse CVCL_MW67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099442; Atxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171519 CVCL_N867 GM19900 transformed cell line human CVCL_N867 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171520 CVCL_MW68 BayGenomics ES cell line RRG356 embryonic stem cell house mouse CVCL_MW68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171521 CVCL_N868 GM19901 transformed cell line human CVCL_N868 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171522 CVCL_MW65 BayGenomics ES cell line RRG348 embryonic stem cell house mouse CVCL_MW65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143994; Psme4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171523 CVCL_N865 GM19834 transformed cell line human CVCL_N865 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171524 CVCL_MW66 BayGenomics ES cell line RRG352 embryonic stem cell house mouse CVCL_MW66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171525 CVCL_N866 GM19835 transformed cell line human CVCL_N866 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171526 CVCL_MW63 BayGenomics ES cell line RRG337 embryonic stem cell house mouse CVCL_MW63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338871; Btrc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171527 CVCL_N863 GM19818 transformed cell line human CVCL_N863 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171528 CVCL_MW64 BayGenomics ES cell line RRG347 embryonic stem cell house mouse CVCL_MW64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344336; Fiz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171529 CVCL_N864 GM19819 transformed cell line human CVCL_N864 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171530 CVCL_MW61 BayGenomics ES cell line RRG329 embryonic stem cell house mouse CVCL_MW61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142048; Rnf40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171531 CVCL_N861 GM19712 transformed cell line human CVCL_N861 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171532 CVCL_MW62 BayGenomics ES cell line RRG332 embryonic stem cell house mouse CVCL_MW62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171533 CVCL_N862 GM19713 transformed cell line human CVCL_N862 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171534 CVCL_MW60 BayGenomics ES cell line RRG328 embryonic stem cell house mouse CVCL_MW60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151839; Mreg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171535 CVCL_N860 GM19711 transformed cell line human CVCL_N860 CL:0000010 Population: African ancestry in Southwest USA (ASW); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171536 CVCL_3K90 HQ01104 transformed cell line human CVCL_3K90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171537 CVCL_3K91 HQ01105 transformed cell line human CVCL_3K91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171538 CVCL_3K94 HQ01108 transformed cell line human CVCL_3K94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171539 CVCL_3K95 HQ01109 transformed cell line human CVCL_3K95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171540 CVCL_3K92 HQ01106 transformed cell line human CVCL_3K92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171541 CVCL_3K93 HQ01107 transformed cell line human CVCL_3K93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171542 CVCL_3K98 HQ01112 transformed cell line human CVCL_3K98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171543 CVCL_3K99 HQ01113 transformed cell line human CVCL_3K99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171544 CVCL_3K96 HQ01110 transformed cell line human CVCL_3K96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171545 CVCL_3K97 HQ01111 transformed cell line human CVCL_3K97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171546 CVCL_3K72 HQ01086 transformed cell line human CVCL_3K72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171547 CVCL_3K73 HQ01087 transformed cell line human CVCL_3K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171548 CVCL_3K70 HQ01084 transformed cell line human CVCL_3K70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171549 CVCL_3K71 HQ01085 transformed cell line human CVCL_3K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171550 CVCL_3K76 HQ01090 transformed cell line human CVCL_3K76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171551 CVCL_3K77 HQ01091 transformed cell line human CVCL_3K77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171552 CVCL_3K74 HQ01088 transformed cell line human CVCL_3K74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171553 CVCL_3K75 HQ01089 transformed cell line human CVCL_3K75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171554 CVCL_3K78 HQ01092 transformed cell line human CVCL_3K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171555 CVCL_3K79 HQ01093 transformed cell line human CVCL_3K79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171556 CVCL_3K80 HQ01094 transformed cell line human CVCL_3K80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171557 CVCL_3K83 HQ01097 transformed cell line human CVCL_3K83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171558 CVCL_3K84 HQ01098 transformed cell line human CVCL_3K84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171559 CVCL_3K81 HQ01095 transformed cell line human CVCL_3K81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171560 CVCL_3K82 HQ01096 transformed cell line human CVCL_3K82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171561 CVCL_3K87 HQ01101 transformed cell line human CVCL_3K87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171562 CVCL_3K88 HQ01102 transformed cell line human CVCL_3K88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171563 CVCL_3K85 HQ01099 transformed cell line human CVCL_3K85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171564 CVCL_3K86 HQ01100 transformed cell line human CVCL_3K86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171565 CVCL_3K89 HQ01103 transformed cell line human CVCL_3K89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171566 CVCL_3K50 HQ01064 transformed cell line human CVCL_3K50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171567 CVCL_3K51 HQ01065 transformed cell line human CVCL_3K51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171568 CVCL_3K54 HQ01068 transformed cell line human CVCL_3K54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171569 CVCL_3K55 HQ01069 transformed cell line human CVCL_3K55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171570 CVCL_3K52 HQ01066 transformed cell line human CVCL_3K52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171571 CVCL_3K53 HQ01067 transformed cell line human CVCL_3K53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171572 CVCL_3K58 HQ01072 transformed cell line human CVCL_3K58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171573 CVCL_3K59 HQ01073 transformed cell line human CVCL_3K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171574 CVCL_3K56 HQ01070 transformed cell line human CVCL_3K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171575 CVCL_3K57 HQ01071 transformed cell line human CVCL_3K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171576 CVCL_3K49 HQ01063 transformed cell line human CVCL_3K49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171577 CVCL_3K61 HQ01075 transformed cell line human CVCL_3K61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171578 CVCL_3K62 HQ01076 transformed cell line human CVCL_3K62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171579 CVCL_3K60 HQ01074 transformed cell line human CVCL_3K60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171580 CVCL_3K65 HQ01079 transformed cell line human CVCL_3K65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171581 CVCL_3K66 HQ01080 transformed cell line human CVCL_3K66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171582 CVCL_3K63 HQ01077 transformed cell line human CVCL_3K63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171583 CVCL_3K64 HQ01078 transformed cell line human CVCL_3K64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171584 CVCL_3K69 HQ01083 transformed cell line human CVCL_3K69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171585 CVCL_3K67 HQ01081 transformed cell line human CVCL_3K67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171586 CVCL_3K68 HQ01082 transformed cell line human CVCL_3K68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171587 CVCL_VQ91 HROC111Met1 T0 M2 cancer cell line human CVCL_VQ91 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from metastatic site: Brain. Male Characteristics: Established from a patient-derived xenograft established in male NSG mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171588 CVCL_W291 M2Ge cancer cell line human CVCL_W291 CL:0000010 Derived from metastatic site: Pleural effusion. Unspecified Characteristics: Non-pigmented (DOI=10.1007/BF01753729) 21171589 CVCL_VQ92 HROC217 T1 M2 cancer cell line human CVCL_VQ92 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from sampling site: Colon. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171590 CVCL_W292 OVT2 cancer cell line human CVCL_W292 CL:0000010 Female 21171591 CVCL_VQ90 HROC111 T4 M1 cancer cell line human CVCL_VQ90 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from sampling site: Colon. Male Characteristics: Established from a patient-derived xenograft established in female NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171592 CVCL_W290 M1Do cancer cell line human CVCL_W290 CL:0000010 Derived from metastatic site: Lymph node. Unspecified Characteristics: Non-pigmented (DOI=10.1007/BF01753729) 21171593 CVCL_VQ95 HROC300Met T3 M4 cancer cell line human CVCL_VQ95 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from metastatic site: Liver. Male Characteristics: Established from a patient-derived xenograft established in male NMRI nu/nu mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171594 CVCL_W295 KY-VCR cancer cell line human CVCL_W295 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Brain; meninges. Male 21171595 CVCL_VQ96 HROC370 cancer cell line human CVCL_VQ96 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian Female Microsatellite instability: Instable (MSI-high) (Direct_author_submission). 21171596 CVCL_W296 TWNT-4 telomerase immortalized cell line human CVCL_W296 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP Population: Japanese; Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Female Characteristics: Because it has been transduced by a construct containing LoxP sites, transfection with the Cre recombinase eliminates the TERT gene thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with a retroviral vector SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by a pair of loxP sites 21171597 CVCL_VQ93 HROC222 T1 M2 cancer cell line human CVCL_VQ93 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Male Characteristics: Established from a patient-derived xenograft established in male NSG mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171598 CVCL_W293 KY-MTX cancer cell line human CVCL_W293 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Brain; meninges. Male 21171599 CVCL_VQ94 HROC300 T2 M1 cancer cell line human CVCL_VQ94 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Rectum. Male Characteristics: Established from a patient-derived xenograft established in female NSG mice Microsatellite instability: Stable (MSS) (Direct_author_submission) 21171600 CVCL_W294 KY-Ra cancer cell line human CVCL_W294 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Brain; meninges. Male 21171601 CVCL_W299 GM09083 transformed cell line human CVCL_W299 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171602 CVCL_VQ99 HROC383 cancer cell line human CVCL_VQ99 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Female Microsatellite instability: Instable (MSI-high) (Direct_author_submission) 21171603 CVCL_W297 HN-15 cancer cell line human CVCL_W297 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Unspecified 21171604 CVCL_VQ97 HROC370 T0 M2 cancer cell line human CVCL_VQ97 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian Female Characteristics: Established from a patient-derived xenograft established in female NSG mice. 21171605 CVCL_W298 GM09063 transformed cell line human CVCL_W298 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171606 CVCL_VQ98 HROC374 cancer cell line human CVCL_VQ98 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Colon; sigmoid. Male 21171607 CVCL_W279 HDC-150 cancer cell line human CVCL_W279 CL:0000010 Female 21171608 CVCL_VQ79 pgsG-224 spontaneously immortalized cell line CVCL_VQ79 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in glucuronosyltransferase I (GlcAT-I) 21171609 CVCL_3K32 HQ01046 transformed cell line human CVCL_3K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171610 CVCL_3K33 HQ01047 transformed cell line human CVCL_3K33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171611 CVCL_3K30 HQ01044 transformed cell line human CVCL_3K30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171612 CVCL_3K31 HQ01045 transformed cell line human CVCL_3K31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171613 CVCL_3K36 HQ01050 transformed cell line human CVCL_3K36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171614 CVCL_3K37 HQ01051 transformed cell line human CVCL_3K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171615 CVCL_3K34 HQ01048 transformed cell line human CVCL_3K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171616 CVCL_3K35 HQ01049 transformed cell line human CVCL_3K35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171617 CVCL_3K29 HQ01043 transformed cell line human CVCL_3K29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171618 CVCL_3K27 HQ01040 transformed cell line human CVCL_3K27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171619 CVCL_3K28 HQ01042 transformed cell line human CVCL_3K28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171620 CVCL_VQ80 MLP-29 spontaneously immortalized cell line house mouse CVCL_VQ80 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified 21171621 CVCL_W280 MV3 cancer cell line human CVCL_W280 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: ~24 hours (PubMed=2019461) 21171622 CVCL_W281 136-2 cancer cell line human CVCL_W281 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Arg (c.737T>G); ClinVar=VCV000127822; Zygosity=Unspecified (PubMed=10070891) Derived from metastatic site: Not specified. Unspecified 21171623 CVCL_VQ81 HROP04 T0 M1 cancer cell line human CVCL_VQ81 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from sampling site: Pancreas; head. Female Characteristics: Established from a patient-derived xenograft established in mice 21171624 CVCL_W284 Mel-34 cancer cell line human CVCL_W284 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732). 21171625 CVCL_VQ84 Pten+/- Ctnnb1 ex3del CP1 cancer cell line house mouse CVCL_VQ84 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ctnnb1pc(ex3)delta/+ Ptenpcfl/+. Male Characteristics: Prostate cell line with Ctnnb1 gain of function mutation Established from a mouse prostate epithelium tumor in a mouse with probasin Cre driven exon 3 deletion of one Ctnnb1 allele and a Pten heterozygous deletion.; Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) and in immunocompetent mice (C57BL/6J- WT colony controls) as prostate orthografts Doubling time: ~13 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171626 CVCL_W285 553B-mel cancer cell line human CVCL_W285 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Unspecified 21171627 CVCL_VQ85 Pten+/- Ctnnb1 ex3del CP2 cancer cell line house mouse CVCL_VQ85 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ctnnb1pc(ex3)delta/+ Ptenpcfl/+. Male Characteristics: Prostate cell line with Ctnnb1 gain of function mutation Established from a mouse prostate epithelium tumor in a mouse with probasin Cre driven exon 3 deletion of one Ctnnb1 allele and a Pten heterozygous deletion.; Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) and in immunocompetent mice (C57BL/6J- WT colony controls) as prostate orthografts Doubling time: ~12 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171628 CVCL_W282 530 cancer cell line human CVCL_W282 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21171629 CVCL_VQ82 Pten-/- P1 cancer cell line house mouse CVCL_VQ82 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ptenpcfl/fl. Male Characteristics: From a primary prostate tumour from a Ptenpcfl/fl mice (probasin Cre driven Pten deletion in murine prostate epithelium); Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) as prostate orthografts Doubling time: ~19 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171630 CVCL_VQ83 Pten-/- P2 cancer cell line house mouse CVCL_VQ83 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ptenpcfl/fl. Male Characteristics: From a primary prostate tumour in a Ptenpcfl/fl mice (probasin Cre driven Pten deletion in murine prostate epithelium); Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) as prostate orthografts Doubling time: ~18.2 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171631 CVCL_W283 SM-MI-1 cancer cell line human CVCL_W283 CL:0000010 Population: Japanese Unspecified 21171632 CVCL_VQ88 11365 transformed cell line human CVCL_VQ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K14ac ChIP-seq epigenome analysis; Omics: H3K9ac ChIP-seq epigenome analysis Female 21171633 CVCL_W288 HMG cancer cell line human CVCL_W288 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 72 hours (PubMed=6807872) 21171634 CVCL_VQ89 SCL60 transformed cell line human CVCL_VQ89 CL:0000010 Transfected with: RGD; 70513; Gnrhr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Doubling time: 21.4 hours (PubMed=18676858) 21171635 CVCL_W289 SSM-1 cancer cell line human CVCL_W289 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Male Doubling time: 70 hours (DOI=10.5794/jjoms.42.51) 21171636 CVCL_W286 NM78-AM cancer cell line human CVCL_W286 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; buccal mucosa. Female 21171637 CVCL_VQ86 Pten-/- Spry2+/- SP1 cancer cell line house mouse CVCL_VQ86 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ptenpcfl/fl Spry2fl/+. Male Characteristics: From a primary prostate tumour from a Ptenpcfl/fl Spry2fl/+ mice (Probasin Cre driven Pten deletion and Spry2 heterozygous loss in murine prostate epithelium); Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) as prostate orthografts Doubling time: ~15 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171638 CVCL_W287 NM78-MM cancer cell line human CVCL_W287 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; buccal mucosa. Female Doubling time: 62 hours (at 5th passage), 55 hours (at 21th passage) (PubMed=20590915) 21171639 CVCL_VQ87 Pten-/- Spry2+/- SP2 cancer cell line house mouse CVCL_VQ87 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten Miscellaneous: Cell line information from personal communication of Patel R Derived from sampling site: Prostate; Breed/subspecies: C57BL/6J Ptenpcfl/fl Spry2fl/+. Male Characteristics: From a primary prostate tumour from a Ptenpcfl/fl Spry2fl/+ mice (Probasin Cre driven Pten deletion and Spry2 heterozygous loss in murine prostate epithelium); Characteristics: Tumorigenic in immunocompromised mice (CD-1 nudes) as prostate orthografts Doubling time: ~15.2 hours, in DMEM with glutamine + 10% FBS (Direct_author_submission) 21171640 CVCL_VQ68 RR-H460 cancer cell line human CVCL_VQ68 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu289_Lys292del; Zygosity=Unspecified; Note=Produces a truncated protein (PubMed=24558369) Selected for resistance to: NCIt; C17262; X-Ray; Derived from metastatic site: Pleural effusion. Male Characteristics: The parent cell line was irradiated with 20 Gy 21171641 CVCL_W268 UTP-6 cancer cell line human CVCL_W268 CL:0000010 Population: Japanese. 21171642 CVCL_W269 KOBK-96 cancer cell line human CVCL_W269 CL:0000010 Population: Japanese. 21171643 CVCL_VQ69 Panc-1-CTC cancer cell line human CVCL_VQ69 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Male Characteristics: Exhibits more profound migratory and invasive abilities than the parent cell line in vitro Has a higher tumor-forming ability than the parent cell line in vivo. 21171644 CVCL_3K40 HQ01054 transformed cell line human CVCL_3K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171645 CVCL_3K43 HQ01057 transformed cell line human CVCL_3K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171646 CVCL_3K44 HQ01058 transformed cell line human CVCL_3K44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171647 CVCL_3K41 HQ01055 transformed cell line human CVCL_3K41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171648 CVCL_3K42 HQ01056 transformed cell line human CVCL_3K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171649 CVCL_3K47 HQ01061 transformed cell line human CVCL_3K47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171650 CVCL_3K48 HQ01062 transformed cell line human CVCL_3K48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171651 CVCL_3K45 HQ01059 transformed cell line human CVCL_3K45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171652 CVCL_3K46 HQ01060 transformed cell line human CVCL_3K46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171653 CVCL_3K38 HQ01052 transformed cell line human CVCL_3K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171654 CVCL_3K39 HQ01053 transformed cell line human CVCL_3K39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171655 CVCL_W270 KOBK-134 cancer cell line human CVCL_W270 CL:0000010 Population: Japanese. 21171656 CVCL_VQ70 RCC-26 cancer cell line human CVCL_VQ70 HLA typing: A*02:01,33:03; B*41:01,51:01; C*15:02,17:01 (PubMed=11175312) CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. 21171657 CVCL_W273 KOPN-39 cancer cell line human CVCL_W273 CL:0000010 Population: Japanese. Unspecified 21171658 CVCL_VQ73 PBD018 finite cell line human CVCL_VQ73 CL:0000010 Sequence variation: Mutation; HGNC; 9719; PEX5; Simple; p.Asn526Lys (c.1578T>G) (N489K); ClinVar=VCV000009143; Zygosity=Homozygous (PubMed=7719337) Derived from sampling site: Skin Cell type=Fibroblast.. 21171659 CVCL_W274 KOPN-46 cancer cell line human CVCL_W274 CL:0000010 Population: Japanese. 21171660 CVCL_VQ74 PBD097 finite cell line human CVCL_VQ74 CL:0000010 Sequence variation: Mutation; HGNC; 8854; PEX12; Simple; p.Leu245Cysfs*19 (c.730_733dupGCCT) (c.733_734insGCCT); ClinVar=VCV000371737; Zygosity=Heterozygous (PubMed=9090384); Sequence variation: Mutation; HGNC; 8854; PEX12; Simple; p.Thr249Tyrfs*14 (c.744dupT) (c.744_745insT); ClinVar=VCV000553741; Zygosity=Heterozygous (PubMed=9090384) Derived from sampling site: Skin Cell type=Fibroblast.. 21171661 CVCL_W271 KOPN-83bi cancer cell line human CVCL_W271 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10360377). Population: Japanese Unspecified 21171662 CVCL_VQ71 PBD005 finite cell line human CVCL_VQ71 CL:0000010 Sequence variation: Mutation; HGNC; 9719; PEX5; Simple; p.Arg427Ter (c.1279C>T) (R390*); ClinVar=VCV000009144; Zygosity=Homozygous (PubMed=7719337) Derived from sampling site: Skin Cell type=Fibroblast.. 21171663 CVCL_VQ72 PBD009 finite cell line human CVCL_VQ72 CL:0000010 Sequence variation: Mutation; HGNC; 8850; PEX1; Simple; p.Gly843Asp (c.2528G>4); Zygosity=Heterozygous (PubMed=9398847); Sequence variation: Mutation; HGNC; 8850; PEX1; Simple; c.2926+1G>A; ClinVar=VCV000188729; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=9398847) Derived from sampling site: Skin Cell type=Fibroblast.. 21171664 CVCL_W272 YAMN-74 cancer cell line human CVCL_W272 CL:0000010 Population: Japanese. Unspecified 21171665 CVCL_W277 KOPB-38 cancer cell line human CVCL_W277 CL:0000010 Population: Japanese. 21171666 CVCL_VQ77 NS47 spontaneously immortalized cell line house mouse CVCL_VQ77 CL:0000010 Derived from sampling site: Trunk; skin; epidermis Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified 21171667 CVCL_W278 HDC-127 cancer cell line human CVCL_W278 CL:0000010 Male 21171668 CVCL_VQ78 pgsF-17 spontaneously immortalized cell line CVCL_VQ78 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in heparan sulfate hexuronic acid 2-o-sulfation 21171669 CVCL_VQ75 GM5756-T transformed cell line human CVCL_VQ75 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male Caution: Incorrectly stated in Lonza=1146 to originate from a 18 year old male patient with ataxia telangiectasia 21171670 CVCL_W275 KOPN-47 cancer cell line human CVCL_W275 CL:0000010 Population: Japanese. 21171671 CVCL_W276 KOPN-49 cancer cell line human CVCL_W276 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282fs (c.845delGinsCCC); Zygosity=Hemizygous (PubMed=8289498) Population: Japanese; Derived from sampling site: Peripheral blood. Unspecified 21171672 CVCL_VQ76 NS01 spontaneously immortalized cell line house mouse CVCL_VQ76 CL:0000010 Derived from sampling site: Trunk; skin; epidermis Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified 21171673 CVCL_MY09 BayGenomics ES cell line RRI017 embryonic stem cell house mouse CVCL_MY09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136980; Kdm5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171674 CVCL_MY07 BayGenomics ES cell line RRI014 embryonic stem cell house mouse CVCL_MY07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104560; Nsf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171675 CVCL_MY08 BayGenomics ES cell line RRI015 embryonic stem cell house mouse CVCL_MY08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144113; Tmem199 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171676 CVCL_MY05 BayGenomics ES cell line RRI002 embryonic stem cell house mouse CVCL_MY05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109622; Aip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171677 CVCL_MY06 BayGenomics ES cell line RRI004 embryonic stem cell house mouse CVCL_MY06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098749; Erc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171678 CVCL_MY03 BayGenomics ES cell line RRH351 embryonic stem cell house mouse CVCL_MY03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171679 CVCL_MY04 BayGenomics ES cell line RRI001 embryonic stem cell house mouse CVCL_MY04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146430; Cblb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171680 CVCL_MY01 BayGenomics ES cell line RRH342 embryonic stem cell house mouse CVCL_MY01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171681 CVCL_MY02 BayGenomics ES cell line RRH348 embryonic stem cell house mouse CVCL_MY02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171682 CVCL_MY00 BayGenomics ES cell line RRH336 embryonic stem cell house mouse CVCL_MY00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140779; Sdad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171683 CVCL_W413 GM13715 transformed cell line human CVCL_W413 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21171684 CVCL_VS13 SK-MEL-23-neoR cancer cell line human CVCL_VS13 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Very highly pigmented (from parent cell line) 21171685 CVCL_W414 GM14094 transformed cell line human CVCL_W414 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Leu392Glnfs (c.1175_1214del40); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171686 CVCL_VS14 Hmel-p16-1 finite cell line human CVCL_VS14 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala76Cysfs*64 (c.225_243del19) (p.Arg90Valfs*76, c.268_286del19) (p16-Leiden); ClinVar=VCV000182411; Zygosity=Homozygous (PubMed=12759390) Derived from sampling site: Skin Cell type=Melanocyte.. Male 21171687 CVCL_VS11 Hermes 3B telomerase immortalized cell line human CVCL_VS11 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171688 CVCL_W411 OK7A spontaneously immortalized cell line CVCL_W411 CL:0000010 Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Female Group: Marsupial cell line 21171689 CVCL_VS12 Hermes 3C transformed cell line human CVCL_VS12 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171690 CVCL_W412 U268 cancer cell line human CVCL_W412 CL:0000010 Derived from sampling site: Bone marrow. Male 21171691 CVCL_W417 GM14097 transformed cell line human CVCL_W417 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Cys61Gly (c.181T>G); ClinVar=VCV000017661; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171692 CVCL_VS17 Nohm-1 finite cell line human CVCL_VS17 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171693 CVCL_VS18 830-c finite cell line human CVCL_VS18 CL:0000010 Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Arg160Trp (c.478C>T); ClinVar=VCV000014310; Zygosity=Heterozygous (PubMed=12006619); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=12006619) Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171694 CVCL_W418 HPA [Human oral cavity adenoma] cancer cell line human CVCL_W418 CL:0000010 Population: Japanese; Derived from sampling site: Salivary gland; palatine gland. Male 21171695 CVCL_W415 GM14095 transformed cell line human CVCL_W415 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Val1713Terfs (c.5137delG) (p.Trp1712_Val1713insTer); ClinVar=VCV000055411; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171696 CVCL_VS15 Hmel-p16-2 finite cell line human CVCL_VS15 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390) Derived from sampling site: Skin Cell type=Melanocyte.. Female 21171697 CVCL_W416 GM14096 transformed cell line human CVCL_W416 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu1161Phefs*3 (c.3481_3491delGAAGATACTAG); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171698 CVCL_VS16 Q34 finite cell line human CVCL_VS16 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171699 CVCL_W419 AP2 finite cell line human CVCL_W419 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Male 21171700 CVCL_VS19 Hermes 4A telomerase immortalized cell line human CVCL_VS19 CL:0000010 Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Arg160Trp (c.478C>T); ClinVar=VCV000014310; Zygosity=Heterozygous (PubMed=16880792); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=16880792); Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171701 CVCL_MY78 BayGenomics ES cell line RRI189 embryonic stem cell house mouse CVCL_MY78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171702 CVCL_MY79 BayGenomics ES cell line RRI191 embryonic stem cell house mouse CVCL_MY79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171703 CVCL_MY76 BayGenomics ES cell line RRI179 embryonic stem cell house mouse CVCL_MY76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918335; Arhgap19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171704 CVCL_MY77 BayGenomics ES cell line RRI183 embryonic stem cell house mouse CVCL_MY77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385311; Dlat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171705 CVCL_MY74 BayGenomics ES cell line RRI172 embryonic stem cell house mouse CVCL_MY74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171706 CVCL_MY75 BayGenomics ES cell line RRI175 embryonic stem cell house mouse CVCL_MY75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171707 CVCL_MY72 BayGenomics ES cell line RRI164 embryonic stem cell house mouse CVCL_MY72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921375; Armc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171708 CVCL_MY73 BayGenomics ES cell line RRI166 embryonic stem cell house mouse CVCL_MY73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928899; Tacc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171709 CVCL_MY70 BayGenomics ES cell line RRI156 embryonic stem cell house mouse CVCL_MY70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171710 CVCL_MY71 BayGenomics ES cell line RRI162 embryonic stem cell house mouse CVCL_MY71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171711 CVCL_VS20 Hermes 4B telomerase immortalized cell line human CVCL_VS20 CL:0000010 Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Arg160Trp (c.478C>T); ClinVar=VCV000014310; Zygosity=Heterozygous (PubMed=16880792); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=16880792); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171712 CVCL_W420 Ishikawa 1-A-12 cancer cell line human CVCL_W420 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 40.8 hours (PubMed=9183638) 21171713 CVCL_VS21 Hermes 4C transformed cell line human CVCL_VS21 CL:0000010 Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Arg160Trp (c.478C>T); ClinVar=VCV000014310; Zygosity=Heterozygous (PubMed=16880792); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=16880792); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171714 CVCL_W421 Ishikawa 1-A-9 cancer cell line human CVCL_W421 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 34.3 hours (PubMed=9183638) 21171715 CVCL_W402 LB 84-5 cancer cell line human CVCL_W402 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21171716 CVCL_VS02 WISC011i-inGFPpuro induced pluripotent stem cell human CVCL_VS02 From: University of Wisconsin; Madison; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: The expression of the Clover GFP gene is under the control of the human EF-1 alpha promoter 21171717 CVCL_W403 LB 85-1 cancer cell line human CVCL_W403 CL:0000010 Unspecified 21171718 CVCL_VS03 WISC012i-SCA induced pluripotent stem cell human CVCL_VS03 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Unspecified (WiCell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171719 CVCL_VS00 DHMCi004-A induced pluripotent stem cell human CVCL_VS00 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 15625; NBAS; Simple; p.Leu903Arg (c.2708T>G); ClinVar=VCV000204582; Zygosity=Homozygous (PubMed=30772683) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21171720 CVCL_W400 LB 84-3 cancer cell line human CVCL_W400 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21171721 CVCL_VS01 23C27 induced pluripotent stem cell human CVCL_VS01 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Transfected with: HGNC; 633; AQP1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: AQP1-GFP reporter cell line 21171722 CVCL_W401 LB 84-4 cancer cell line human CVCL_W401 CL:0000010 Unspecified 21171723 CVCL_VS06 Hermes 1 telomerase immortalized cell line human CVCL_VS06 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala76Cysfs*64 (c.225_243del19) (p.Arg90Valfs*76, c.268_286del19) (p16-Leiden); ClinVar=VCV000182411; Zygosity=Homozygous (PubMed=12759390); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21171724 CVCL_W406 KM-4 [Human plasma cell myeloma] cancer cell line human CVCL_W406 CL:0000010 Population: Japanese Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21171725 CVCL_VS07 Hermes 2A telomerase immortalized cell line human CVCL_VS07 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.. Female 21171726 CVCL_W407 KM-5 cancer cell line human CVCL_W407 CL:0000010 Population: Japanese. Unspecified 21171727 CVCL_W404 Hs cancer cell line human CVCL_W404 CL:0000010 21171728 CVCL_VS04 WISC013i-SCID induced pluripotent stem cell human CVCL_VS04 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.33+1G>C (IVS1DS,G-C,+1); ClinVar=VCV000001976; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg101Gln (c.302G>A); ClinVar=VCV000001956; Zygosity=Heterozygous (from parent cell line) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171729 CVCL_W405 KM-1 cancer cell line human CVCL_W405 CL:0000010 Population: Japanese. Unspecified 21171730 CVCL_VS05 WISC014i-SC1 induced pluripotent stem cell human CVCL_VS05 From: University of Wisconsin; Madison; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1606; CCR5; Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: The expression of the Clover GFP gene is under the control of the human EF-1 alpha promoter 21171731 CVCL_VS08 Hermes 2B telomerase immortalized cell line human CVCL_VS08 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21171732 CVCL_W408 KM-6 cancer cell line human CVCL_W408 CL:0000010 Population: Japanese. Unspecified 21171733 CVCL_VS09 Hermes 2C telomerase immortalized cell line human CVCL_VS09 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met53Thr (c.158T>C); ClinVar=VCV001480737; Zygosity=Heterozygous (PubMed=12759390); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp108Asn (c.322G>A) (p.Arg122Gln, c.365G>A); ClinVar=VCV000216275; Zygosity=Heterozygous (PubMed=12759390); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Melanocyte.. Female 21171734 CVCL_W409 KM-7 cancer cell line human CVCL_W409 CL:0000010 Unspecified 21171735 CVCL_MY89 BayGenomics ES cell line RRI236 embryonic stem cell house mouse CVCL_MY89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442220; Zfp182 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171736 CVCL_MY87 BayGenomics ES cell line RRI232 embryonic stem cell house mouse CVCL_MY87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147870; Lrch2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171737 CVCL_MY88 BayGenomics ES cell line RRI234 embryonic stem cell house mouse CVCL_MY88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2673002; Arhgef17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171738 CVCL_MY85 BayGenomics ES cell line RRI224 embryonic stem cell house mouse CVCL_MY85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894676; Mast2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171739 CVCL_MY86 BayGenomics ES cell line RRI229 embryonic stem cell house mouse CVCL_MY86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860188; Snx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171740 CVCL_MY83 BayGenomics ES cell line RRI215 embryonic stem cell house mouse CVCL_MY83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930780; Myh10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171741 CVCL_MY84 BayGenomics ES cell line RRI222 embryonic stem cell house mouse CVCL_MY84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87867; Acadm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171742 CVCL_MY81 BayGenomics ES cell line RRI194 embryonic stem cell house mouse CVCL_MY81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922523; Pelp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171743 CVCL_MY82 BayGenomics ES cell line RRI203 embryonic stem cell house mouse CVCL_MY82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179381; Prpf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171744 CVCL_MY80 BayGenomics ES cell line RRI192 embryonic stem cell house mouse CVCL_MY80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171745 CVCL_VS10 Hermes 3A telomerase immortalized cell line human CVCL_VS10 CL:0000010 Transfected with: HGNC; 1773; CDK4; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21171746 CVCL_W410 KM-11 cancer cell line human CVCL_W410 CL:0000010 Population: Japanese. Unspecified 21171747 CVCL_MY58 BayGenomics ES cell line RRI118 embryonic stem cell house mouse CVCL_MY58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171748 CVCL_MY59 BayGenomics ES cell line RRI125 embryonic stem cell house mouse CVCL_MY59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151013; Erc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171749 CVCL_MY56 BayGenomics ES cell line RRI113 embryonic stem cell house mouse CVCL_MY56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915033; Ahctf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171750 CVCL_MY57 BayGenomics ES cell line RRI114 embryonic stem cell house mouse CVCL_MY57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171751 CVCL_MY54 BayGenomics ES cell line RRI109 embryonic stem cell house mouse CVCL_MY54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917822; Ipo5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171752 CVCL_MY55 BayGenomics ES cell line RRI110 embryonic stem cell house mouse CVCL_MY55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171753 CVCL_MY52 BayGenomics ES cell line RRI107 embryonic stem cell house mouse CVCL_MY52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171754 CVCL_MY53 BayGenomics ES cell line RRI108 embryonic stem cell house mouse CVCL_MY53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916976; Smyd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171755 CVCL_MY50 BayGenomics ES cell line RRI104 embryonic stem cell house mouse CVCL_MY50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334433; Pi4kb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171756 CVCL_MY51 BayGenomics ES cell line RRI105 embryonic stem cell house mouse CVCL_MY51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171757 CVCL_MY69 BayGenomics ES cell line RRI154 embryonic stem cell house mouse CVCL_MY69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136980; Kdm5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171758 CVCL_MY67 BayGenomics ES cell line RRI151 embryonic stem cell house mouse CVCL_MY67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270153; Zfp106 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171759 CVCL_MY68 BayGenomics ES cell line RRI153 embryonic stem cell house mouse CVCL_MY68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171760 CVCL_MY65 BayGenomics ES cell line RRI147 embryonic stem cell house mouse CVCL_MY65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443225; Gatad2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171761 CVCL_MY66 BayGenomics ES cell line RRI148 embryonic stem cell house mouse CVCL_MY66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171762 CVCL_MY63 BayGenomics ES cell line RRI143 embryonic stem cell house mouse CVCL_MY63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916706; Commd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171763 CVCL_MY64 BayGenomics ES cell line RRI144 embryonic stem cell house mouse CVCL_MY64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443895; Fry Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171764 CVCL_MY61 BayGenomics ES cell line RRI131 embryonic stem cell house mouse CVCL_MY61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443758; Akap17b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171765 CVCL_MY62 BayGenomics ES cell line RRI139 embryonic stem cell house mouse CVCL_MY62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913586; Cenpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171766 CVCL_MY60 BayGenomics ES cell line RRI130 embryonic stem cell house mouse CVCL_MY60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916891; Wdr20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171767 CVCL_MY38 BayGenomics ES cell line RRI077 embryonic stem cell house mouse CVCL_MY38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914125; Swt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171768 CVCL_MY39 BayGenomics ES cell line RRI083 embryonic stem cell house mouse CVCL_MY39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919205; Ist1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171769 CVCL_MY36 BayGenomics ES cell line RRI072 embryonic stem cell house mouse CVCL_MY36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915770; Zfyve21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171770 CVCL_MY37 BayGenomics ES cell line RRI073 embryonic stem cell house mouse CVCL_MY37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171771 CVCL_MY34 BayGenomics ES cell line RRI068 embryonic stem cell house mouse CVCL_MY34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270129; Dnaja1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171772 CVCL_MY35 BayGenomics ES cell line RRI069 embryonic stem cell house mouse CVCL_MY35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923401; Cep76 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171773 CVCL_MY32 BayGenomics ES cell line RRI064 embryonic stem cell house mouse CVCL_MY32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171774 CVCL_MY33 BayGenomics ES cell line RRI065 embryonic stem cell house mouse CVCL_MY33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171775 CVCL_MY30 BayGenomics ES cell line RRI061 embryonic stem cell house mouse CVCL_MY30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860512; Prpf40a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171776 CVCL_MY31 BayGenomics ES cell line RRI062 embryonic stem cell house mouse CVCL_MY31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926953; Ctdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171777 CVCL_MY49 BayGenomics ES cell line RRI103 embryonic stem cell house mouse CVCL_MY49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442415; Kat6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171778 CVCL_MY47 BayGenomics ES cell line RRI100 embryonic stem cell house mouse CVCL_MY47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913560; Dpy30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171779 CVCL_MY48 BayGenomics ES cell line RRI102 embryonic stem cell house mouse CVCL_MY48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171780 CVCL_MY45 BayGenomics ES cell line RRI096 embryonic stem cell house mouse CVCL_MY45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171781 CVCL_MY46 BayGenomics ES cell line RRI097 embryonic stem cell house mouse CVCL_MY46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171782 CVCL_MY43 BayGenomics ES cell line RRI092 embryonic stem cell house mouse CVCL_MY43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915467; Prrc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171783 CVCL_MY44 BayGenomics ES cell line RRI094 embryonic stem cell house mouse CVCL_MY44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915371; Cep70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171784 CVCL_MY41 BayGenomics ES cell line RRI087 embryonic stem cell house mouse CVCL_MY41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349439; Cops6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171785 CVCL_MY42 BayGenomics ES cell line RRI090 embryonic stem cell house mouse CVCL_MY42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921840; Ankrd10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171786 CVCL_MY40 BayGenomics ES cell line RRI085 embryonic stem cell house mouse CVCL_MY40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171787 CVCL_MY18 BayGenomics ES cell line RRI039 embryonic stem cell house mouse CVCL_MY18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171788 CVCL_MY19 BayGenomics ES cell line RRI040 embryonic stem cell house mouse CVCL_MY19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97499; Pcca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171789 CVCL_MY16 BayGenomics ES cell line RRI034 embryonic stem cell house mouse CVCL_MY16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171790 CVCL_MY17 BayGenomics ES cell line RRI037 embryonic stem cell house mouse CVCL_MY17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104913; Abi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171791 CVCL_MY14 BayGenomics ES cell line RRI032 embryonic stem cell house mouse CVCL_MY14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171792 CVCL_MY15 BayGenomics ES cell line RRI033 embryonic stem cell house mouse CVCL_MY15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355274; Uchl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171793 CVCL_MY12 BayGenomics ES cell line RRI030 embryonic stem cell house mouse CVCL_MY12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099452; Mtm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171794 CVCL_MY13 BayGenomics ES cell line RRI031 embryonic stem cell house mouse CVCL_MY13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105089; Hsd17b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171795 CVCL_MY10 BayGenomics ES cell line RRI018 embryonic stem cell house mouse CVCL_MY10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651978; Zfp984 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171796 CVCL_MY11 BayGenomics ES cell line RRI019 embryonic stem cell house mouse CVCL_MY11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96522; Rbpj Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171797 CVCL_MY29 BayGenomics ES cell line RRI060 embryonic stem cell house mouse CVCL_MY29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926952; Cyb5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171798 CVCL_MY27 BayGenomics ES cell line RRI058 embryonic stem cell house mouse CVCL_MY27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346518; Scamp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171799 CVCL_MY28 BayGenomics ES cell line RRI059 embryonic stem cell house mouse CVCL_MY28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351486; Trappc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171800 CVCL_MY25 BayGenomics ES cell line RRI056 embryonic stem cell house mouse CVCL_MY25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914722; Mtfr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171801 CVCL_MY26 BayGenomics ES cell line RRI057 embryonic stem cell house mouse CVCL_MY26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346834; Nr5a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171802 CVCL_MY23 BayGenomics ES cell line RRI051 embryonic stem cell house mouse CVCL_MY23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338069; Itsn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171803 CVCL_MY24 BayGenomics ES cell line RRI054 embryonic stem cell house mouse CVCL_MY24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930708; Zfp386 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171804 CVCL_MY21 BayGenomics ES cell line RRI045 embryonic stem cell house mouse CVCL_MY21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926879; Taf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171805 CVCL_MY22 BayGenomics ES cell line RRI047 embryonic stem cell house mouse CVCL_MY22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142048; Rnf40 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171806 CVCL_MY20 BayGenomics ES cell line RRI041 embryonic stem cell house mouse CVCL_MY20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171807 CVCL_W378 IGSK-2 cancer cell line human CVCL_W378 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~83 hours (PubMed=17547719) 21171808 CVCL_VR78 U2OS#18-RAD51B-8 cancer cell line human CVCL_VR78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9822; RAD51B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~50 hours (DSMZ=ACC-833) 21171809 CVCL_W379 HMMMF cancer cell line human CVCL_W379 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Doubling time: ~62 hours (PubMed=18667024) 21171810 CVCL_VR79 U2OS#18-RAD51B-8/B+ cancer cell line human CVCL_VR79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9822; RAD51B; Transfected with: HGNC; 9822; RAD51B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The parental RAD51B KO cell line is functionally reconstituted by retroviral transfection of RAD51B; Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~25-30 hours (DSMZ=ACC-838) 21171811 CVCL_3L31 HQ01145 transformed cell line human CVCL_3L31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171812 CVCL_3L32 HQ01146 transformed cell line human CVCL_3L32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171813 CVCL_3L30 HQ01144 transformed cell line human CVCL_3L30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171814 CVCL_3L35 HQ01149 transformed cell line human CVCL_3L35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171815 CVCL_3L36 HQ01150 transformed cell line human CVCL_3L36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171816 CVCL_3L33 HQ01147 transformed cell line human CVCL_3L33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171817 CVCL_3L34 HQ01148 transformed cell line human CVCL_3L34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171818 CVCL_3L28 HQ01142 transformed cell line human CVCL_3L28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171819 CVCL_3L29 HQ01143 transformed cell line human CVCL_3L29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171820 CVCL_3L26 HQ01140 transformed cell line human CVCL_3L26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171821 CVCL_3L27 HQ01141 transformed cell line human CVCL_3L27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171822 CVCL_W380 HES [Human endometrial carcinoma] cancer cell line human CVCL_W380 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=18667022) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: ~16 hours, at 113th passage (PubMed=18667022) 21171823 CVCL_VR80 U2OS#18-RAD51C-15 cancer cell line human CVCL_VR80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9820; RAD51C; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~50-60 hours (DSMZ=ACC-834) 21171824 CVCL_W383 HIUML cancer cell line human CVCL_W383 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: ~32 hours (PubMed=16130900) 21171825 CVCL_VR83 U2OS#18-RAD51D-4/D+ cancer cell line human CVCL_VR83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Transfected with: HGNC; 9823; RAD51D; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The parental RAD51D KO cell line is functionally reconstituted by retroviral transfection of RAD51D; Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~20-50 hours (DSMZ=ACC-840) 21171826 CVCL_W384 SPH-7(T) cancer cell line CVCL_W384 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747). Female Characteristics: IL2 dependent Group: Non-human primate cell line 21171827 CVCL_VR84 U2OS#18-XRCC2-5E cancer cell line human CVCL_VR84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12829; XRCC2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~4-6 days (DSMZ=ACC-836) 21171828 CVCL_W381 NOE cancer cell line human CVCL_W381 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: ~15.5 hours, at 10th passage (PubMed=17645726) 21171829 CVCL_VR81 U2OS#18-RAD51C-15/C+ cancer cell line human CVCL_VR81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9820; RAD51C; Transfected with: HGNC; 9820; RAD51C; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The parental RAD51C KO cell line is functionally reconstituted by retroviral transfection of RAD51C; Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~25-40 hours (DSMZ=ACC-839) 21171830 CVCL_W382 HYKSSPC cancer cell line human CVCL_W382 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 51.4 hours (PubMed=17257376) 21171831 CVCL_VR82 U2OS#18-RAD51D-4 cancer cell line human CVCL_VR82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~4-6 days (DSMZ=ACC-835) 21171832 CVCL_W387 Ham-1 cancer cell line CVCL_W387 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Transformant: Opisthorchis viverrini(NCBI-Taxonomy; 6198). Male Characteristics: Obtained by both Opisthorchis viverrini infection and N-nitrosodimethylamine treatment (PubMed=24516278) Doubling time: 36 hours (PubMed=24516278); 39.4 +- 2.6 hours (PubMed=34549357) 21171833 CVCL_VR87 U2OS#24 cancer cell line human CVCL_VR87 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids 21171834 CVCL_W388 HAM-1 finite cell line human CVCL_W388 CL:0000010 Population: Japanese; Derived from sampling site: Amnion. Female Doubling time: 24 hours (at 5th passage), 18 hours (at 30th passage) (PubMed=15859157) 21171835 CVCL_VR88 MS5-hDLL1 stromal cell line house mouse CVCL_VR88 CL:0000010 Transfected with: HGNC; 2908; DLL1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. Male 21171836 CVCL_W385 HTLS cancer cell line human CVCL_W385 CL:0000010 Population: Japanese; Derived from sampling site: Retroperitoneal space. Female Doubling time: 98 hours (at 5th passage), 89 hours (at 10th passage), 82 hours (at 30th passage) (PubMed=16130899) 21171837 CVCL_VR85 U2OS#18-XRCC2-5E/X2+ cancer cell line human CVCL_VR85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12829; XRCC2; Transfected with: HGNC; 12829; XRCC2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The parental XRCC2 KO cell line is functionally reconstituted by retroviral transfection of XRCC2; Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~24 hours (DSMZ=ACC-841) 21171838 CVCL_W386 TCC-S cancer cell line human CVCL_W386 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=16130897) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 27.96 +- 0.97 hours (PubMed=16130897) 21171839 CVCL_VR86 U2OS#18-XRCC3-6A cancer cell line human CVCL_VR86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12830; XRCC3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~50-60 hours (DSMZ=ACC-837) 21171840 CVCL_VR69 MDA-PATC53 cancer cell line human CVCL_VR69 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=25485535) Derived from metastatic site: Liver. Male Characteristics: Established from a xenograft established in NOD/SCID mice Doubling time: 51 hours (ATCC=CRL-3431; PubMed=25485535) 21171841 CVCL_W369 PSC-THP1-EPEP hybrid cell line human CVCL_W369 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06007. 21171842 CVCL_VR67 MDA-MB-231 VIM RFP cancer cell line human CVCL_VR67 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: A red fluorescent protein (RFP) tag was added to the C-terminal of the VIM gene by CRISPR/Cas9 Allows to monitor the epithelial-to-mesenchymal transition (EMT) status of cells in vitro by monitoring RFP expression. Group: Triple negative breast cancer (TNBC) cell line 21171843 CVCL_W367 PSC-THP1-EP cancer cell line human CVCL_W367 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06005 21171844 CVCL_W368 PSC-THP1-EP-FAST cancer cell line human CVCL_W368 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06008 21171845 CVCL_VR68 RPTEC/TERT1 OAT3 telomerase immortalized cell line human CVCL_VR68 CL:0000010 Transfected with: HGNC; 10972; SLC22A8; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Doubling time: ~70 hours (ATCC=CRL-4031-OAT3) 21171846 CVCL_3L42 HQ01156 transformed cell line human CVCL_3L42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171847 CVCL_3L43 HQ01157 transformed cell line human CVCL_3L43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171848 CVCL_3L40 HQ01154 transformed cell line human CVCL_3L40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171849 CVCL_3L41 HQ01155 transformed cell line human CVCL_3L41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171850 CVCL_3L46 HQ01160 transformed cell line human CVCL_3L46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171851 CVCL_3L47 HQ01161 transformed cell line human CVCL_3L47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171852 CVCL_3L44 HQ01158 transformed cell line human CVCL_3L44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171853 CVCL_3L45 HQ01159 transformed cell line human CVCL_3L45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171854 CVCL_3L39 HQ01153 transformed cell line human CVCL_3L39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171855 CVCL_3L37 HQ01151 transformed cell line human CVCL_3L37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171856 CVCL_3L38 HQ01152 transformed cell line human CVCL_3L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171857 CVCL_VR72 MDA-PATC66 cancer cell line human CVCL_VR72 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=25485535); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=25485535) Derived from sampling site: Pancreas. Female Characteristics: Established from a xenograft established in NOD/SCID mice Doubling time: 123 hours (ATCC=CRL-3432) 21171858 CVCL_W372 SDRL-1 finite cell line Norway rat CVCL_W372 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Spontaneous dwarf rat (SDR). Male Doubling time: ~96 hours (PubMed=21166888) 21171859 CVCL_VR73 A549 dCas9-KRAB cancer cell line human CVCL_VR73 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Using CRISPR/Cas9 a construct containing KRAB-dCas9-2A-Pac-2A-RFP-PA was introduced in the AAVS1 safe harbor locus 21171860 CVCL_W373 PX2 cancer cell line human CVCL_W373 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Problematic cell line: Contaminated Parent cell line (OV-2008) has been shown to be a ME-180 derivative. 21171861 CVCL_VR70 MDA-PATC43 cancer cell line human CVCL_VR70 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=25485535); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=25485535). Female Characteristics: Established from a xenograft established in NOD/SCID mice 21171862 CVCL_W370 PSC-THP1-HEP hybrid cell line human CVCL_W370 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 06006. 21171863 CVCL_W371 HepG2 hALR cancer cell line human CVCL_W371 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 4236; GFER Population: Caucasian; Derived from sampling site: Liver. Male 21171864 CVCL_VR71 MDA-PATC50 cancer cell line human CVCL_VR71 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=25485535); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=25485535) Derived from sampling site: Pancreas. Female Characteristics: Established from a xenograft established in NOD/SCID mice Doubling time: 99 hours (ATCC=CRL-3430; PubMed=25485535) 21171865 CVCL_VR76 ICCSICi008-A induced pluripotent stem cell human CVCL_VR76 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=31401456) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21171866 CVCL_W376 TMUU-08 cancer cell line human CVCL_W376 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~52 hours, at 10th passage (PubMed=19222609) 21171867 CVCL_VR77 ICCSICi011-A induced pluripotent stem cell human CVCL_VR77 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21171868 CVCL_W377 IGSK-3 cancer cell line human CVCL_W377 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Female Doubling time: ~43 hours (PubMed=18667025) 21171869 CVCL_VR74 CL-52b transformed cell line Norway rat CVCL_VR74 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~50 hours (DSMZ=ACC-843) 21171870 CVCL_W374 PX24 cancer cell line human CVCL_W374 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Transformant: Human papillomavirus type 68 (HPV68)(NCBI-Taxonomy; 45240); Derived from metastatic site: Omentum. Female Problematic cell line: Contaminated Parent cell line (OV-2008) has been shown to be a ME-180 derivative. 21171871 CVCL_W375 SS-1 cancer cell line human CVCL_W375 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female Doubling time: ~72 hours (PubMed=20712709) 21171872 CVCL_VR75 U2OS#18 cancer cell line human CVCL_VR75 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~50-60 hours (DSMZ=ACC-832) 21171873 CVCL_W358 cFA90-44-14 induced pluripotent stem cell human CVCL_W358 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171874 CVCL_VR58 KGUi002-A induced pluripotent stem cell human CVCL_VR58 From: Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt; Frankfurt Am Main; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 21171875 CVCL_W359 cFA90-44-20 induced pluripotent stem cell human CVCL_W359 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171876 CVCL_VR59 iNFF12 induced pluripotent stem cell human CVCL_VR59 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171877 CVCL_W356 cFA90-44-01 induced pluripotent stem cell human CVCL_W356 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171878 CVCL_VR56 TUSMi004-A induced pluripotent stem cell human CVCL_VR56 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21171879 CVCL_W357 cFA90-44-11 induced pluripotent stem cell human CVCL_W357 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171880 CVCL_VR57 KGUi001-A induced pluripotent stem cell human CVCL_VR57 From: Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt; Frankfurt Am Main; Germany CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Female 21171881 CVCL_3L10 HQ01124 transformed cell line human CVCL_3L10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171882 CVCL_3L13 HQ01127 transformed cell line human CVCL_3L13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171883 CVCL_3L14 HQ01128 transformed cell line human CVCL_3L14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171884 CVCL_3L11 HQ01125 transformed cell line human CVCL_3L11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171885 CVCL_3L12 HQ01126 transformed cell line human CVCL_3L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171886 CVCL_3L06 HQ01120 transformed cell line human CVCL_3L06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171887 CVCL_3L07 HQ01121 transformed cell line human CVCL_3L07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171888 CVCL_3L04 HQ01118 transformed cell line human CVCL_3L04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171889 CVCL_3L05 HQ01119 transformed cell line human CVCL_3L05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171890 CVCL_3L08 HQ01122 transformed cell line human CVCL_3L08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171891 CVCL_3L09 HQ01123 transformed cell line human CVCL_3L09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171892 CVCL_VR61 iDFF24 induced pluripotent stem cell human CVCL_VR61 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171893 CVCL_W361 IEE spontaneously immortalized cell line CVCL_W361 CL:0000010 Derived from sampling site: Eye. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC040 21171894 CVCL_VR62 iDFF9 induced pluripotent stem cell human CVCL_VR62 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171895 CVCL_W362 IEB spontaneously immortalized cell line CVCL_W362 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC043 21171896 CVCL_W360 cFA90-44-21 induced pluripotent stem cell human CVCL_W360 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21171897 CVCL_VR60 iNFF14 induced pluripotent stem cell human CVCL_VR60 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21171898 CVCL_VR65 A-375 NRAS p.Q61K-Luc2 cancer cell line human CVCL_VR65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Homozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Shows significant resistance to the BRAF inhibitors Dabrafineb and Vemurafenib when compared to its parental cell line in 2D and 3D culture systems Can be a useful model to study the RAS-RAF-MEK-ERK-MAP kinase signaling pathway and to screen potential BRAF inhibitors and anti-cancer compounds for drug discovery and development (ATCC).; Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter 21171899 CVCL_W365 MARC.OKF spontaneously immortalized cell line CVCL_W365 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.; Breed/subspecies: Texel. Discontinued: Coriell; AG19825; probable Male 21171900 CVCL_VR66 A549 EML4-ALK-Luc2 cancer cell line human CVCL_VR66 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~23 hours (ATCC=CCL-185IG-LUC2) 21171901 CVCL_W366 MARC.OVSM spontaneously immortalized cell line CVCL_W366 CL:0000010 Derived from sampling site: Aorta; smooth muscle; Breed/subspecies: Texel. Discontinued: Coriell; AG19826; probable Male 21171902 CVCL_VR63 iDFU8 induced pluripotent stem cell human CVCL_VR63 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin (Note=From an ulcer) Cell type=Fibroblast.. Female 21171903 CVCL_W363 IEK spontaneously immortalized cell line CVCL_W363 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC041 21171904 CVCL_VR64 iDFU25 induced pluripotent stem cell human CVCL_VR64 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Skin (Note=From an ulcer) Cell type=Fibroblast.. Female 21171905 CVCL_W364 IEG spontaneously immortalized cell line CVCL_W364 CL:0000010 Derived from sampling site: Gill. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC042 21171906 CVCL_W347 HEK293A/GFP-LC3 transformed cell line human CVCL_W347 CL:0000010 Transfected with: RGD; 735183; Map1lc3a; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21171907 CVCL_VR47 Pari-ICR cancer cell line human CVCL_VR47 CL:0000010 Population: Iranian; Derived from sampling site: Breast. Omics: Array-based CGH Female Doubling time: ~22 hours (PubMed=31244288) Group: Triple negative breast cancer (TNBC) cell line 21171908 CVCL_VR48 1E3 hybridoma house mouse CVCL_VR48 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human breast cancer cell line Pari-ICR. 21171909 CVCL_W348 MCF-7aro Let-R cancer cell line human CVCL_W348 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:6413; Letrozole; Derived from metastatic site: Pleural effusion. Female 21171910 CVCL_W345 E3 cancer cell line house mouse CVCL_W345 CL:0000010 Transfected with: HGNC; 7508; MUC1 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21171911 CVCL_VR45 U-CH17S cancer cell line human CVCL_VR45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous or homozygous (PubMed=29148152) Derived from metastatic site: Skin. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 3-17 days (PubMed=29148152); 5-7 days (Chordoma_Foundation); 8-10 days (ATCC=CRL-3401) 21171912 CVCL_W346 E3STn cancer cell line house mouse CVCL_W346 CL:0000010 Transfected with: HGNC; 7508; MUC1; Transfected with: MGI; MGI:1341826; St6galnac1 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21171913 CVCL_VR46 U-CH11R cancer cell line human CVCL_VR46 CL:0000010 Derived from sampling site: Bone; sacrum. Male Doubling time: 35 days (Chordoma_Foundation) 21171914 CVCL_VR49 Elf1-iCas9 embryonic stem cell human CVCL_VR49 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Cell line with robust Dox-inducible expression of Cas9 Can be used for rapid and highly efficient generation of biallelic knockout hPSCs for loss-of-function studies.; Characteristics: Using TALEN two constructs SA-2A-Puro-Cas9-TRE and SA-2A-Neo-M2rtTA were introduced in the AAVS1 locus, one in each allele 21171915 CVCL_W349 HEK293A mRFP-ATG9 transformed cell line human CVCL_W349 CL:0000010 Transfected with: HGNC; 22408; ATG9A; Transfected with: UniProtKB; A0A4V4ND72; mRFP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21171916 CVCL_3L20 HQ01134 transformed cell line human CVCL_3L20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171917 CVCL_3L21 HQ01135 transformed cell line human CVCL_3L21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171918 CVCL_3L24 HQ01138 transformed cell line human CVCL_3L24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171919 CVCL_3L25 HQ01139 transformed cell line human CVCL_3L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171920 CVCL_3L22 HQ01136 transformed cell line human CVCL_3L22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171921 CVCL_3L23 HQ01137 transformed cell line human CVCL_3L23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171922 CVCL_3L17 HQ01131 transformed cell line human CVCL_3L17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171923 CVCL_3L18 HQ01132 transformed cell line human CVCL_3L18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171924 CVCL_3L15 HQ01129 transformed cell line human CVCL_3L15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171925 CVCL_3L16 HQ01130 transformed cell line human CVCL_3L16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171926 CVCL_3L19 HQ01133 transformed cell line human CVCL_3L19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171927 CVCL_VR50 CV-hIPS-B-control APP edition clone B10 induced pluripotent stem cell human CVCL_VR50 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: Control cell line for the APP-edited cell lines derived from CV-hIPS-B Have been transfected with CAS9, guide RNA and APP repair oligo but have not been edited. 21171928 CVCL_W350 GATAGM-96 cancer cell line human CVCL_W350 CL:0000010 Population: Turkish; Derived from sampling site: Brain; left parieto-occipital lobe. Male Doubling time: 38-42 hours (PubMed=9595044) 21171929 CVCL_VR51 CV-hIPS-B-control APP edition clone B11 induced pluripotent stem cell human CVCL_VR51 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Characteristics: Control cell line for the APP-edited cell lines derived from CV-hIPS-B Have been transfected with CAS9, guide RNA and APP repair oligo but have not been edited. 21171930 CVCL_W351 GBM-HSF cancer cell line human CVCL_W351 CL:0000010 Population: Chinese; Derived from sampling site: Brain; left prefrontal lobe. Female Doubling time: ~51 hours (PubMed=24390806) 21171931 CVCL_VR54 CV-hIPS-B-APP-F691A/E693A clone D12 induced pluripotent stem cell human CVCL_VR54 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Phe691Ala (c.2071_2072TT>GC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=30686764); Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Glu693Ala (c.2078_2079AA>CC); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=30686764) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21171932 CVCL_W354 CHO-gmt4 spontaneously immortalized cell line CVCL_W354 CL:0000010 Sequence variation: Mutation; UniProtKB; Q924C0; Mgat1; Simple; p.Gln339Ter (c.1015C>T); Zygosity=Unspecified (PubMed=20346410) Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Ovary. Female Characteristics: Lacks N-acetylglucosaminyltransferase I activity Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9657 21171933 CVCL_VR55 EURACi004-A induced pluripotent stem cell human CVCL_VR55 From: EURAC Research Institute for Biomedicine; Bolzano; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; c.2569_2577+41del (c.2569_3018del50); ClinVar=VCV000406553; Zygosity=Heterozygous (PubMed=30219716) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21171934 CVCL_W355 PKSV-PR transformed cell line house mouse CVCL_W355 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal straight tubule; Breed/subspecies: L-PK/Tag1 transgenic. Male 21171935 CVCL_VR52 CV-hIPS-B-APP-E693A clone 2b2 induced pluripotent stem cell human CVCL_VR52 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Glu693Ala (c.2078_2079AA>CC); Zygosity=Homozygous; Note=By CRISPR/Cas9 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21171936 CVCL_W352 WJ1 cancer cell line human CVCL_W352 CL:0000010 Population: Chinese; Derived from sampling site: Brain; right temporo-parietal lobe. Male Doubling time: ~60 hours (PubMed=17703357) 21171937 CVCL_VR53 CV-hIPS-B-APP-E693A clone 3d9 induced pluripotent stem cell human CVCL_VR53 CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple_edited; p.Glu693Ala (c.2078_2079AA>CC); Zygosity=Homozygous; Note=By CRISPR/Cas9 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21171938 CVCL_W353 PTLC-1 cancer cell line human CVCL_W353 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male Doubling time: ~18.9 hours (PubMed=7829391) 21171939 CVCL_W336 D-PTC cancer cell line human CVCL_W336 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female 21171940 CVCL_VR36 MDA231-BrM2-831 cancer cell line human CVCL_VR36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from MDA231-TGL cell line after 2 passage in nude mice Group: Triple negative breast cancer (TNBC) cell line; Part of: Brain metastasis cell lines panel 21171941 CVCL_VR37 LL-iPSC-AECII telomerase immortalized cell line human CVCL_VR37 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Alveolar type 2 fibroblast.. Male Characteristics: This cell line was established in a three step process: 1) iPSCs were generated from the parent fibroblast cell line; 2) these iPSCs were differentiated into alveolar type II epithelial cells (AEC type II); 3) these AEC type II cells were immortalized by transfection with human BMI1 and TERT 21171942 CVCL_W337 UD-PTC cancer cell line human CVCL_W337 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female 21171943 CVCL_VR34 786-TGL cancer cell line human CVCL_VR34 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) 21171944 CVCL_W334 MRK-90 spontaneously immortalized cell line CVCL_W334 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line 21171945 CVCL_W335 A-PTC cancer cell line human CVCL_W335 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male 21171946 CVCL_VR35 MDA231-TGL cancer cell line human CVCL_VR35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Group: Triple negative breast cancer (TNBC) cell line Caution: In PubMed=28283064 and the associated GEO data sets MDA234-TGL is termed MDA234 Parental 21171947 CVCL_W338 293RC21 transformed cell line human CVCL_W338 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Adeno-associated virus packaging cell line 21171948 CVCL_VR38 gMDCKI spontaneously immortalized cell line dog CVCL_VR38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 37431; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21171949 CVCL_W339 AP-1 LUCPorter transformed cell line human CVCL_W339 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21171950 CVCL_VR39 gMDCKI-MDR1 spontaneously immortalized cell line dog CVCL_VR39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 37431; ABCB1; Transfected with: HGNC; 40; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21171951 CVCL_MX99 BayGenomics ES cell line RRH330 embryonic stem cell house mouse CVCL_MX99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915549; Vps53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171952 CVCL_N999 GM21113 transformed cell line human CVCL_N999 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171953 CVCL_MX97 BayGenomics ES cell line RRH325 embryonic stem cell house mouse CVCL_MX97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289325; Anapc16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171954 CVCL_N997 GM21111 transformed cell line human CVCL_N997 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171955 CVCL_MX98 BayGenomics ES cell line RRH327 embryonic stem cell house mouse CVCL_MX98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171956 CVCL_N998 GM21112 transformed cell line human CVCL_N998 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171957 CVCL_MX95 BayGenomics ES cell line RRH308 embryonic stem cell house mouse CVCL_MX95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915670; Ankrd13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171958 CVCL_N995 GM21109 transformed cell line human CVCL_N995 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171959 CVCL_MX96 BayGenomics ES cell line RRH309 embryonic stem cell house mouse CVCL_MX96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171960 CVCL_N996 GM21110 transformed cell line human CVCL_N996 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171961 CVCL_MX93 BayGenomics ES cell line RRH303 embryonic stem cell house mouse CVCL_MX93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441730; Tbl1xr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171962 CVCL_N993 GM21107 transformed cell line human CVCL_N993 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171963 CVCL_MX94 BayGenomics ES cell line RRH305 embryonic stem cell house mouse CVCL_MX94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914172; Rras2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171964 CVCL_N994 GM21108 transformed cell line human CVCL_N994 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171965 CVCL_MX91 BayGenomics ES cell line RRH298 embryonic stem cell house mouse CVCL_MX91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171966 CVCL_N991 GM21105 transformed cell line human CVCL_N991 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171967 CVCL_MX92 BayGenomics ES cell line RRH302 embryonic stem cell house mouse CVCL_MX92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441730; Tbl1xr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171968 CVCL_N992 GM21106 transformed cell line human CVCL_N992 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171969 CVCL_W340 K209 cancer cell line human CVCL_W340 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Group: Adeno-associated virus packaging cell line 21171970 CVCL_VR40 MDCKII-LE spontaneously immortalized cell line dog CVCL_VR40 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Compared to the parent cell line, has a lower expression of endogenous ABCB1/MDR1 21171971 CVCL_MX90 BayGenomics ES cell line RRH295 embryonic stem cell house mouse CVCL_MX90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21171972 CVCL_N990 GM21104 transformed cell line human CVCL_N990 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21171973 CVCL_W343 410.4 cancer cell line house mouse CVCL_W343 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21171974 CVCL_VR43 U-CH17M cancer cell line human CVCL_VR43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous or homozygous (PubMed=29148152) Derived from metastatic site: Soft tissue. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 3-10 days (PubMed=29148152); 6-8 days (Chordoma_Foundation) 21171975 CVCL_W344 410.4H cancer cell line house mouse CVCL_W344 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21171976 CVCL_VR44 U-CH17P cancer cell line human CVCL_VR44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous or homozygous (PubMed=29148152) Derived from sampling site: Bone; sacrum. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: 6-12 days (PubMed=29148152); 34 days (Chordoma_Foundation) 21171977 CVCL_VR41 CAF-SA spontaneously immortalized cell line human CVCL_VR41 CL:0000010 Population: Chinese. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201745 21171978 CVCL_W341 HeLa B-50 cancer cell line human CVCL_W341 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Adeno-associated virus packaging cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12401 21171979 CVCL_VR42 HEK293-SREBP1-T2A-luciferase-KI transformed cell line human CVCL_VR42 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Useful for studying transcriptional regulation of the SREBP1 gene and for screening drugs or chemical molecules that regulate SREBP1 gene expression (PubMed=30232659); Characteristics: CRISPR/Cas9-mediated knock-in of a T2A-luciferase-CMV-eGFP-T2A-Neomycin construct at the C-terminal end of SREBP1 21171980 CVCL_W342 HeLa C12 cancer cell line human CVCL_W342 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Adeno-associated virus packaging cell line 21171981 CVCL_VR25 HCC1954-LCC1 cancer cell line human CVCL_VR25 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: East Indian; Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Characteristics: After 3 months was recovered from the brain of healthy FOXN1nu mice that had been intracardially injected with the parent cell line Part of: Brain metastasis cell lines panel 21171982 CVCL_W325 SIHN-013/2 cancer cell line human CVCL_W325 CL:0000010 Derived from sampling site: Larynx. Male Doubling time: 76.3 +- 1.5 hours (PubMed=11497283) 21171983 CVCL_VR26 HCC1954-LCC2 cancer cell line human CVCL_VR26 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: East Indian; Derived from sampling site: Breast. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: After 3 months was recovered from the brain of healthy FOXN1nu mice that had been intracardially injected with the parent cell line Part of: Brain metastasis cell lines panel 21171984 CVCL_W326 SIHN-034B cancer cell line human CVCL_W326 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 57.5 +- 1.6 hours (PubMed=11497283) 21171985 CVCL_W323 SIHN-013 cancer cell line human CVCL_W323 CL:0000010 Derived from sampling site: Larynx. Male Doubling time: 40.6 +- 0.6 hours (PubMed=11497283) 21171986 CVCL_VR23 SK-RC-63 cancer cell line human CVCL_VR23 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility. Unspecified 21171987 CVCL_VR24 HCC1954-TGL cancer cell line human CVCL_VR24 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: East Indian; Derived from sampling site: Breast. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) and with PuroR/pac Caution: In PubMed=27015306, PubMed=28283064 and the associated GEO data sets HCC1954-TGL is termed HCC1954 Parental 21171988 CVCL_W324 SIHN-015B cancer cell line human CVCL_W324 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 47.6 +- 1.3 hours (PubMed=11497283) 21171989 CVCL_W329 BHK-HVJ spontaneously immortalized cell line CVCL_W329 CL:0000010 Derived from sampling site: Kidney. Male 21171990 CVCL_VR29 H2087-LCC1-2 cancer cell line human CVCL_VR29 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu848Gln (c.2542G>C); ClinVar=VCV001686474; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Val (c.1789C>G); ClinVar=VCV000013969; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Glu54Lys (c.160G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P33967; B.cereus Bsr Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from metastatic site: Lymph node. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: After 3 months was recovered from the kidney of healthy FOXN1nu mice that had been intracardially injected with the parent cell line 21171991 CVCL_VR27 H2087-TGL cancer cell line human CVCL_VR27 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu848Gln (c.2542G>C); ClinVar=VCV001686474; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Val (c.1789C>G); ClinVar=VCV000013969; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Glu54Lys (c.160G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P33967; B.cereus Bsr Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from metastatic site: Lymph node. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) and with bsr; parent cell line for the H2087-LCC1 and H2087-LCC2 Caution: In PubMed=27015306 and the associated GEO data sets H2087-TGL is termed H2087 Parental 21171992 CVCL_W327 USC-HN2 cancer cell line human CVCL_W327 CL:0000010 Donor information: Established from a patient with a 50-pack-year history of tobacco smoking and occasional alcohol consumption and a past medical history of recurrent left sided oral cancer (PubMed=21719345); Derived from sampling site: Oral cavity; buccal mucosa. Omics: Transcriptome analysis by microarray Female Doubling time: 22 hours (PubMed=21719345) 21171993 CVCL_VR28 H2087-LCC1-1 cancer cell line human CVCL_VR28 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu848Gln (c.2542G>C); ClinVar=VCV001686474; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Val (c.1789C>G); ClinVar=VCV000013969; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Glu54Lys (c.160G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P33967; B.cereus Bsr Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male Characteristics: After 3 months was recovered from the lung of healthy FOXN1nu mice that had been intracardially injected with the parent cell line 21171994 CVCL_W328 ICB-104 cancer cell line human CVCL_W328 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=11423975) Derived from sampling site: Knee. Unspecified 21171995 CVCL_3L02 HQ01116 transformed cell line human CVCL_3L02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171996 CVCL_3L03 HQ01117 transformed cell line human CVCL_3L03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21171997 CVCL_3L00 HQ01114 transformed cell line human CVCL_3L00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171998 CVCL_3L01 HQ01115 transformed cell line human CVCL_3L01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21171999 CVCL_VR32 786-M2A cancer cell line human CVCL_VR32 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Established from lung metastatis in NOD/SCID mice which were intravenous inoculated with the parental cell line 21172000 CVCL_W332 MISK81-5 cancer cell line human CVCL_W332 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Female Doubling time: 25 hours (PubMed=7531680) 21172001 CVCL_VR33 786-M2B cancer cell line human CVCL_VR33 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Established from lung metastatis in NOD/SCID mice which were intravenous inoculated with the parental cell line 21172002 CVCL_W333 sMISK cancer cell line human CVCL_W333 CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Female 21172003 CVCL_VR30 786-M1A cancer cell line human CVCL_VR30 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Established from lung metastatis in NOD/SCID mice which were intravenous inoculated with the parental cell line 21172004 CVCL_W330 Demel cancer cell line human CVCL_W330 CL:0000010 Derived from metastatic site: Lymph node. Male 21172005 CVCL_VR31 786-M1B cancer cell line human CVCL_VR31 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Characteristics: Established from lung metastatis in NOD/SCID mice which were intravenous inoculated with the parental cell line 21172006 CVCL_W331 HeLa JW36 cancer cell line human CVCL_W331 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21172007 CVCL_W314 HD-iPShom 4F-3 induced pluripotent stem cell human CVCL_W314 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[39-43] (c.52CAG(39-43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Homozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172008 CVCL_VR14 HEK293T GALE+GALK1 KO clone 12 transformed cell line human CVCL_VR14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4116; GALE; Knockout cell: Method=CRISPR/Cas9; HGNC; 4118; GALK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21172009 CVCL_W315 HD-iPShet 3F-1 induced pluripotent stem cell human CVCL_W315 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21172010 CVCL_VR15 HEK293T GALE+GALK2 KO clone 7 transformed cell line human CVCL_VR15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4116; GALE; Knockout cell: Method=CRISPR/Cas9; HGNC; 4119; GALK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Devoid of all O-glycosylation in all culture condition 21172011 CVCL_W312 HD-iPShom 4F-1 induced pluripotent stem cell human CVCL_W312 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42-44] (c.52CAG(42-44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Homozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172012 CVCL_VR12 HEK293T GALK1 KO clone 10 transformed cell line human CVCL_VR12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4118; GALK1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21172013 CVCL_W313 HD-iPShom 4F-2 induced pluripotent stem cell human CVCL_W313 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42-44] (c.52CAG(42-44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Homozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172014 CVCL_VR13 HEK293T GALK2 KO clone 7 transformed cell line human CVCL_VR13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4119; GALK2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21172015 CVCL_W318 SIHN-005A cancer cell line human CVCL_W318 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 38.0 +- 1.1 hours (PubMed=11497283) 21172016 CVCL_VR18 SK-RC-22 cancer cell line human CVCL_VR18 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21172017 CVCL_W319 SIHN-005B cancer cell line human CVCL_W319 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 45.9 +- 1.4 hours (PubMed=11497283) 21172018 CVCL_VR19 SK-RC-24 cancer cell line human CVCL_VR19 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21172019 CVCL_VR16 NCC-UPS1-X3-C1 cancer cell line human CVCL_VR16 CL:0000010 Population: Japanese Omics: Deep proteome analysis. Male Characteristics: Established from a third generation xenograft established by subcutaneous injection in female SCID mice Doubling time: ~40 hours (DOI=10.11418/jtca.37.133) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21172020 CVCL_W316 WT-iPS 3F-1 induced pluripotent stem cell human CVCL_W316 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172021 CVCL_VR17 PIG3V transformed cell line human CVCL_VR17 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin Cell type=Melanocyte.. Female Doubling time: 1.6 days (PubMed=10937834) 21172022 CVCL_W317 WT-iPS 4F-1 induced pluripotent stem cell human CVCL_W317 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21172023 CVCL_MX79 BayGenomics ES cell line RRH257 embryonic stem cell house mouse CVCL_MX79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138391; Pid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172024 CVCL_N979 GM21092 transformed cell line human CVCL_N979 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172025 CVCL_MX77 BayGenomics ES cell line RRH247 embryonic stem cell house mouse CVCL_MX77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925482; Trappc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172026 CVCL_N977 GM21090 transformed cell line human CVCL_N977 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172027 CVCL_MX78 BayGenomics ES cell line RRH252 embryonic stem cell house mouse CVCL_MX78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109349; Atf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172028 CVCL_N978 GM21091 transformed cell line human CVCL_N978 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172029 CVCL_MX75 BayGenomics ES cell line RRH243 embryonic stem cell house mouse CVCL_MX75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172030 CVCL_N975 GM21088 transformed cell line human CVCL_N975 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172031 CVCL_MX76 BayGenomics ES cell line RRH246 embryonic stem cell house mouse CVCL_MX76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172032 CVCL_N976 GM21089 transformed cell line human CVCL_N976 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172033 CVCL_MX73 BayGenomics ES cell line RRH236 embryonic stem cell house mouse CVCL_MX73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289155; Trmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172034 CVCL_N973 GM21086 transformed cell line human CVCL_N973 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172035 CVCL_MX74 BayGenomics ES cell line RRH237 embryonic stem cell house mouse CVCL_MX74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105921; Zfp97 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172036 CVCL_N974 GM21087 transformed cell line human CVCL_N974 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172037 CVCL_MX71 BayGenomics ES cell line RRH226 embryonic stem cell house mouse CVCL_MX71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922661; Ccdc191 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172038 CVCL_N971 GM20910 transformed cell line human CVCL_N971 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172039 CVCL_MX72 BayGenomics ES cell line RRH227 embryonic stem cell house mouse CVCL_MX72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921850; Mrpl47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172040 CVCL_N972 GM20911 transformed cell line human CVCL_N972 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172041 CVCL_MX70 BayGenomics ES cell line RRH224 embryonic stem cell house mouse CVCL_MX70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172042 CVCL_N970 GM20908 transformed cell line human CVCL_N970 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172043 CVCL_W321 SIHN-011A cancer cell line human CVCL_W321 CL:0000010 Derived from sampling site: Pharynx; hypopharynx; pyriform sinus. Male Doubling time: 40.1 +- 1.5 hours (PubMed=11497283) 21172044 CVCL_VR21 SK-RC-34 cancer cell line human CVCL_VR21 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21172045 CVCL_W322 SIHN-011B cancer cell line human CVCL_W322 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 36.8 +- 1.9 hours (PubMed=11497283) 21172046 CVCL_VR22 SK-RC-36 cancer cell line human CVCL_VR22 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, metastatic site and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Femoral neck; hypodermis. Male 21172047 CVCL_W320 SIHN-008 cancer cell line human CVCL_W320 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 31.1 +- 2.5 hours (PubMed=11497283) 21172048 CVCL_VR20 SK-RC-25 cancer cell line human CVCL_VR20 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and sex of donor from MSKCC antibody and bioresource core facility. Female 21172049 CVCL_W303 GM03889 finite cell line human CVCL_W303 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172050 CVCL_VR03 HUG-9 cancer cell line human CVCL_VR03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Heterozygous (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172051 CVCL_W304 GM03890 transformed cell line human CVCL_W304 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172052 CVCL_VR04 HUG-11 cancer cell line human CVCL_VR04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172053 CVCL_W301 GM09448 transformed cell line human CVCL_W301 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172054 CVCL_VR01 HROC385Met1 cancer cell line human CVCL_VR01 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Derived from metastatic site: Liver. Male 21172055 CVCL_W302 GM09449 transformed cell line human CVCL_W302 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172056 CVCL_VR02 HUG-2 cancer cell line human CVCL_VR02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172057 CVCL_W307 GM03853 transformed cell line human CVCL_W307 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172058 CVCL_VR07 HUG-31 cancer cell line human CVCL_VR07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Gly (c.482C>G); Zygosity=Heterozygous (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172059 CVCL_W308 GM03854 finite cell line human CVCL_W308 CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172060 CVCL_VR08 MCF7-h14 cancer cell line human CVCL_VR08 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4421; GNRHR Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21172061 CVCL_W305 GM03891 finite cell line human CVCL_W305 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172062 CVCL_VR05 HUG-15 cancer cell line human CVCL_VR05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Gly (c.518T>G); ClinVar=VCV000376016; Zygosity=Homozygous (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172063 CVCL_W306 GM03892 transformed cell line human CVCL_W306 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172064 CVCL_VR06 HUG-27 cancer cell line human CVCL_VR06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His115Tyr (c.343C>T); Zygosity=Heterozygous (PubMed=8707423) Population: Japanese; Derived from sampling site: Brain. Unspecified 21172065 CVCL_VR09 C2C12i spontaneously immortalized cell line house mouse CVCL_VR09 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: C3H. Female Characteristics: Transfected with the replication-defective retroviral vector containing Escherichia coli lacZ 21172066 CVCL_W309 GM09458 transformed cell line human CVCL_W309 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172067 CVCL_MX88 BayGenomics ES cell line RRH281 embryonic stem cell house mouse CVCL_MX88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172068 CVCL_N988 GM21102 transformed cell line human CVCL_N988 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172069 CVCL_MX89 BayGenomics ES cell line RRH290 embryonic stem cell house mouse CVCL_MX89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353557; Schip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172070 CVCL_N989 GM21103 transformed cell line human CVCL_N989 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172071 CVCL_MX86 BayGenomics ES cell line RRH274 embryonic stem cell house mouse CVCL_MX86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353598; Mapk8ip3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172072 CVCL_N986 GM21100 transformed cell line human CVCL_N986 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172073 CVCL_MX87 BayGenomics ES cell line RRH276 embryonic stem cell house mouse CVCL_MX87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918345; Kif24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172074 CVCL_N987 GM21101 transformed cell line human CVCL_N987 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172075 CVCL_MX84 BayGenomics ES cell line RRH270 embryonic stem cell house mouse CVCL_MX84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679002; Prr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172076 CVCL_N984 GM21098 transformed cell line human CVCL_N984 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172077 CVCL_MX85 BayGenomics ES cell line RRH272 embryonic stem cell house mouse CVCL_MX85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276533; Ncoa2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172078 CVCL_N985 GM21099 transformed cell line human CVCL_N985 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172079 CVCL_MX82 BayGenomics ES cell line RRH267 embryonic stem cell house mouse CVCL_MX82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172080 CVCL_N982 GM21095 transformed cell line human CVCL_N982 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172081 CVCL_MX83 BayGenomics ES cell line RRH268 embryonic stem cell house mouse CVCL_MX83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341070; Fkbp8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172082 CVCL_N983 GM21097 transformed cell line human CVCL_N983 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172083 CVCL_MX80 BayGenomics ES cell line RRH260 embryonic stem cell house mouse CVCL_MX80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105921; Zfp97 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172084 CVCL_N980 GM21093 transformed cell line human CVCL_N980 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172085 CVCL_MX81 BayGenomics ES cell line RRH262 embryonic stem cell house mouse CVCL_MX81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687282; Cep104 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172086 CVCL_N981 GM21094 transformed cell line human CVCL_N981 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21172087 CVCL_W310 HD-iPShom 3F-1 induced pluripotent stem cell human CVCL_W310 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42-44] (c.52CAG(42-44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Homozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172088 CVCL_VR10 HUES8 iCas9 embryonic stem cell human CVCL_VR10 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Cell line with robust Dox-inducible expression of Cas9 Can be used for rapid and highly efficient generation of biallelic knockout hPSCs for loss-of-function studies.; Characteristics: Using TALEN two constructs SA-2A-Puro-Cas9-TRE and SA-2A-Neo-M2rtTA were introduced in the AAVS1 locus, one in each allele 21172089 CVCL_W311 HD-iPShom 3F-2 induced pluripotent stem cell human CVCL_W311 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42-44] (c.52CAG(42-44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Homozygous (PubMed=22405424) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172090 CVCL_VR11 HEK293T GALE KO clone 4 transformed cell line human CVCL_VR11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4116; GALE; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Devoid of all O-glycosylation But with the addition of galactose and GalNAc to the culture media, salvage pathways are able to compensate for the lack of GALE enzymatic activity and restore O-linked glycosylation. 21172091 CVCL_3L90 HQ01204 transformed cell line human CVCL_3L90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172092 CVCL_3L93 HQ01207 transformed cell line human CVCL_3L93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172093 CVCL_3L94 HQ01208 transformed cell line human CVCL_3L94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172094 CVCL_3L91 HQ01205 transformed cell line human CVCL_3L91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172095 CVCL_3L92 HQ01206 transformed cell line human CVCL_3L92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172096 CVCL_3L97 HQ01211 transformed cell line human CVCL_3L97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172097 CVCL_3L98 HQ01212 transformed cell line human CVCL_3L98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172098 CVCL_3L95 HQ01209 transformed cell line human CVCL_3L95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172099 CVCL_3L96 HQ01210 transformed cell line human CVCL_3L96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172100 CVCL_3L99 HQ01213 transformed cell line human CVCL_3L99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172101 CVCL_3L71 HQ01185 transformed cell line human CVCL_3L71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172102 CVCL_3L72 HQ01186 transformed cell line human CVCL_3L72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172103 CVCL_3L70 HQ01184 transformed cell line human CVCL_3L70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172104 CVCL_3L75 HQ01189 transformed cell line human CVCL_3L75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172105 CVCL_3L76 HQ01190 transformed cell line human CVCL_3L76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172106 CVCL_3L73 HQ01187 transformed cell line human CVCL_3L73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172107 CVCL_3L74 HQ01188 transformed cell line human CVCL_3L74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172108 CVCL_3L79 HQ01193 transformed cell line human CVCL_3L79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172109 CVCL_3L77 HQ01191 transformed cell line human CVCL_3L77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172110 CVCL_3L78 HQ01192 transformed cell line human CVCL_3L78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172111 CVCL_3L82 HQ01196 transformed cell line human CVCL_3L82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172112 CVCL_3L83 HQ01197 transformed cell line human CVCL_3L83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172113 CVCL_3L80 HQ01194 transformed cell line human CVCL_3L80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172114 CVCL_3L81 HQ01195 transformed cell line human CVCL_3L81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172115 CVCL_3L86 HQ01200 transformed cell line human CVCL_3L86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172116 CVCL_3L87 HQ01201 transformed cell line human CVCL_3L87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172117 CVCL_3L84 HQ01198 transformed cell line human CVCL_3L84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172118 CVCL_3L85 HQ01199 transformed cell line human CVCL_3L85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172119 CVCL_3L88 HQ01202 transformed cell line human CVCL_3L88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172120 CVCL_3L89 HQ01203 transformed cell line human CVCL_3L89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172121 CVCL_3L50 HQ01164 transformed cell line human CVCL_3L50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172122 CVCL_3L53 HQ01167 transformed cell line human CVCL_3L53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172123 CVCL_3L54 HQ01168 transformed cell line human CVCL_3L54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172124 CVCL_3L51 HQ01165 transformed cell line human CVCL_3L51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172125 CVCL_3L52 HQ01166 transformed cell line human CVCL_3L52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172126 CVCL_3L57 HQ01171 transformed cell line human CVCL_3L57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172127 CVCL_3L58 HQ01172 transformed cell line human CVCL_3L58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172128 CVCL_3L55 HQ01169 transformed cell line human CVCL_3L55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172129 CVCL_3L56 HQ01170 transformed cell line human CVCL_3L56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172130 CVCL_3L48 HQ01162 transformed cell line human CVCL_3L48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172131 CVCL_3L49 HQ01163 transformed cell line human CVCL_3L49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172132 CVCL_VR89 AT-3 cancer cell line house mouse CVCL_VR89 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: B6.FVB-Tg(MMTV-PyVT)634Mul/LellJ (MTAG). Female 21172133 CVCL_W389 NC-HIMT cancer cell line human CVCL_W389 CL:0000010 Population: Japanese Female Doubling time: 94 hours (PubMed=15369138). 21172134 CVCL_3L60 HQ01174 transformed cell line human CVCL_3L60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172135 CVCL_3L61 HQ01175 transformed cell line human CVCL_3L61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172136 CVCL_3L64 HQ01178 transformed cell line human CVCL_3L64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172137 CVCL_3L65 HQ01179 transformed cell line human CVCL_3L65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172138 CVCL_3L62 HQ01176 transformed cell line human CVCL_3L62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172139 CVCL_3L63 HQ01177 transformed cell line human CVCL_3L63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172140 CVCL_3L68 HQ01182 transformed cell line human CVCL_3L68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172141 CVCL_3L69 HQ01183 transformed cell line human CVCL_3L69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172142 CVCL_3L66 HQ01180 transformed cell line human CVCL_3L66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172143 CVCL_3L67 HQ01181 transformed cell line human CVCL_3L67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172144 CVCL_3L59 HQ01173 transformed cell line human CVCL_3L59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172145 CVCL_W390 GHINK-1 cancer cell line human CVCL_W390 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Kidney. Male 21172146 CVCL_VR90 MCA-205 cancer cell line house mouse CVCL_VR90 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C57BL/6. Characteristics: Excellent model for studying the immune responses to tumor cells and for supporting the development of targeted cancer immunotherapies (Millipore) 21172147 CVCL_VR91 MS5-mDLL1 stromal cell line house mouse CVCL_VR91 CL:0000010 Transfected with: MGI; MGI:104659; Dll1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeNSlc. Male 21172148 CVCL_W391 TMG-L cancer cell line human CVCL_W391 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~48 hours, at 25th passage (PubMed=12971623) 21172149 CVCL_VR94 KOLT-2 hybridoma house mouse CVCL_VR94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10747; Human CD28. 21172150 CVCL_W394 UM-3 [Human plasma cell myeloma] cancer cell line human CVCL_W394 CL:0000010 Derived from sampling site: Bone marrow. Unspecified 21172151 CVCL_VR95 MHM6 hybridoma house mouse CVCL_VR95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06734; Human FCER2/CD23. 21172152 CVCL_W395 UM-6 cancer cell line human CVCL_W395 CL:0000010 Derived from sampling site: Bone marrow. Unspecified 21172153 CVCL_VR92 MEC1 spontaneously immortalized cell line house mouse CVCL_VR92 CL:0000010 Derived from sampling site: Embryonic heart; ventricular epicardium; Breed/subspecies: ICR(CD-1). Unspecified Characteristics: Useful model for cardiac developmental biology studies (Millipore) 21172154 CVCL_W392 UM-1 [Human plasma cell myeloma] cancer cell line human CVCL_W392 CL:0000010 Derived from sampling site: Bone marrow. Unspecified 21172155 CVCL_VR93 CHO-CH3S spontaneously immortalized cell line CVCL_VR93 CL:0000010 Derived from sampling site: Ovary. Female 21172156 CVCL_W393 UM-2 cancer cell line human CVCL_W393 CL:0000010 Derived from sampling site: Pericardial effusion. Unspecified 21172157 CVCL_W398 TRAMA cancer cell line human CVCL_W398 CL:0000010 Unspecified 21172158 CVCL_VR98 UKWNLi003-A induced pluripotent stem cell human CVCL_VR98 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Thr365Asn (c.1094C>A); dbSNP=rs754960592; Zygosity=Heterozygous (PubMed=30731422) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21172159 CVCL_W399 LB 84-2 cancer cell line human CVCL_W399 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21172160 CVCL_VR99 UKWNLi004-A induced pluripotent stem cell human CVCL_VR99 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Thr365Asn (c.1094C>A); dbSNP=rs754960592; Zygosity=Heterozygous (PubMed=30731422) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21172161 CVCL_W396 ARH-DR cancer cell line human CVCL_W396 CL:0000010 Unspecified 21172162 CVCL_VR96 BIONi010-C-29 induced pluripotent stem cell human CVCL_VR96 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu280Ala (c.839A>C); ClinVar=VCV000018131; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=30634129) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21172163 CVCL_VR97 BIONi010-C-30 induced pluripotent stem cell human CVCL_VR97 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu280Ala (c.839A>C); ClinVar=VCV000018131; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30634129) Population: African; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21172164 CVCL_W397 SMITH cancer cell line human CVCL_W397 CL:0000010 Unspecified 21172165 CVCL_3E52 HQ00459 transformed cell line human CVCL_3E52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172166 CVCL_3E53 HQ00460 transformed cell line human CVCL_3E53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172167 CVCL_3E50 HQ00457 transformed cell line human CVCL_3E50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172168 CVCL_3E51 HQ00458 transformed cell line human CVCL_3E51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172169 CVCL_3E56 HQ00463 transformed cell line human CVCL_3E56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172170 CVCL_3E57 HQ00464 transformed cell line human CVCL_3E57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172171 CVCL_3E54 HQ00461 transformed cell line human CVCL_3E54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172172 CVCL_3E55 HQ00462 transformed cell line human CVCL_3E55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172173 CVCL_3E58 HQ00465 transformed cell line human CVCL_3E58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172174 CVCL_3E59 HQ00466 transformed cell line human CVCL_3E59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172175 CVCL_3E63 HQ00470 transformed cell line human CVCL_3E63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172176 CVCL_3E64 HQ00471 transformed cell line human CVCL_3E64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172177 CVCL_3E61 HQ00468 transformed cell line human CVCL_3E61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172178 CVCL_3E62 HQ00469 transformed cell line human CVCL_3E62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172179 CVCL_3E67 HQ00474 transformed cell line human CVCL_3E67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172180 CVCL_3E68 HQ00475 transformed cell line human CVCL_3E68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172181 CVCL_3E65 HQ00472 transformed cell line human CVCL_3E65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172182 CVCL_3E66 HQ00473 transformed cell line human CVCL_3E66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172183 CVCL_3E69 HQ00476 transformed cell line human CVCL_3E69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172184 CVCL_VK90 ND12 hybrid cell line CVCL_VK90 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172185 CVCL_VK93 ND22 hybrid cell line CVCL_VK93 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172186 CVCL_VK94 ND23 hybrid cell line CVCL_VK94 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172187 CVCL_VK91 ND20 hybrid cell line CVCL_VK91 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172188 CVCL_VK92 ND21 hybrid cell line CVCL_VK92 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172189 CVCL_VK97 PH5T cancer cell line human CVCL_VK97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141fs (c.422delG); Zygosity=Unspecified (PubMed=8925135) Population: Japanese; Derived from sampling site: Liver. Male 21172190 CVCL_VK98 PH5CH1 transformed cell line human CVCL_VK98 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pRSV-TAg](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver. Male Characteristics: Supports HCV replication 21172191 CVCL_VK95 ND26 hybrid cell line CVCL_VK95 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172192 CVCL_VK96 PH5CH transformed cell line human CVCL_VK96 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pRSV-TAg](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21172193 CVCL_VK99 PH5CH7 transformed cell line human CVCL_VK99 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pRSV-TAg](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver. Male Characteristics: Supports HCV replication 21172194 CVCL_3E60 HQ00467 transformed cell line human CVCL_3E60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172195 CVCL_3E30 HQ00437 transformed cell line human CVCL_3E30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172196 CVCL_3E31 HQ00438 transformed cell line human CVCL_3E31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172197 CVCL_3E34 HQ00441 transformed cell line human CVCL_3E34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172198 CVCL_3E35 HQ00442 transformed cell line human CVCL_3E35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172199 CVCL_3E32 HQ00439 transformed cell line human CVCL_3E32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172200 CVCL_3E33 HQ00440 transformed cell line human CVCL_3E33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172201 CVCL_3E38 HQ00445 transformed cell line human CVCL_3E38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172202 CVCL_3E39 HQ00446 transformed cell line human CVCL_3E39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172203 CVCL_3E36 HQ00443 transformed cell line human CVCL_3E36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172204 CVCL_3E37 HQ00444 transformed cell line human CVCL_3E37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172205 CVCL_VK82 WTC-mEGFP-RAB5A-cl35 induced pluripotent stem cell human CVCL_VK82 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 RAB5A has been endogenously tagged in both alleles at the N-terminus with mEGFP Part of: Allen Cell Collection 21172206 CVCL_VK83 WTC-mEGFP-GJA1-cl16 induced pluripotent stem cell human CVCL_VK83 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 GJA1 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21172207 CVCL_VK80 WTC-mEGFP-TNNI1-cl172 induced pluripotent stem cell human CVCL_VK80 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 TNNI1 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21172208 CVCL_VK81 WTC-mEGFP-RAB5A-cl13 induced pluripotent stem cell human CVCL_VK81 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 RAB5A has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21172209 CVCL_VK86 WTC-mEGFP-CTNNB1-cl67 induced pluripotent stem cell human CVCL_VK86 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 CTNNB1 has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21172210 CVCL_VK87 ND7 hybrid cell line CVCL_VK87 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172211 CVCL_VK84 WTC-mTagRFPT-CAAX-Safe harbor locus (AAVS1)-cl91 induced pluripotent stem cell human CVCL_VK84 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 the CAAX domain of KRAS tagged with mTagRFP-T under the control of a CAG promoter was inserted at the AAVS1 safe harbor locus Part of: Allen Cell Collection 21172212 CVCL_VK85 WTC-mEGFP-NPM1-cl50 induced pluripotent stem cell human CVCL_VK85 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 NPM1 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21172213 CVCL_VK88 ND10 hybrid cell line CVCL_VK88 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172214 CVCL_VK89 ND11 hybrid cell line CVCL_VK89 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21172215 CVCL_3E41 HQ00448 transformed cell line human CVCL_3E41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172216 CVCL_3E42 HQ00449 transformed cell line human CVCL_3E42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172217 CVCL_3E40 HQ00447 transformed cell line human CVCL_3E40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172218 CVCL_3E45 HQ00452 transformed cell line human CVCL_3E45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172219 CVCL_3E46 HQ00453 transformed cell line human CVCL_3E46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172220 CVCL_3E43 HQ00450 transformed cell line human CVCL_3E43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172221 CVCL_3E44 HQ00451 transformed cell line human CVCL_3E44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172222 CVCL_3E49 HQ00456 transformed cell line human CVCL_3E49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172223 CVCL_3E47 HQ00454 transformed cell line human CVCL_3E47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172224 CVCL_3E48 HQ00455 transformed cell line human CVCL_3E48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172225 CVCL_VK71 F2N78 hybrid cell line human CVCL_VK71 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Characteristics: Developed for recombinant proteins production 21172226 CVCL_VK72 MEF (DR4) IRR finite cell line house mouse CVCL_VK72 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: DR4. Discontinued: ATCC; SCRC-1045.1; true Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 12000 rads; Characteristics: Expresses transgenes that make this cell line resistant to four different drugs: geneticin (G418), puromycin, hygromycin and 6-tioguanine 21172227 CVCL_VK70 TPP1-iPS 2B induced pluripotent stem cell human CVCL_VK70 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24271013); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172228 CVCL_VK75 UEFi001-A induced pluripotent stem cell human CVCL_VK75 From: University of Eastern Finland; Kuopio; Finland CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Ala673Thr (c.2017G>A); ClinVar=VCV000037145; Zygosity=Heterozygous (PubMed=29807259) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172229 CVCL_VK76 SB spontaneously immortalized cell line CVCL_VK76 CL:0000010 Unspecified Group: Fish cell line. 21172230 CVCL_VK73 PNUi001-A induced pluripotent stem cell human CVCL_VK73 From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Sequence variation: Gene deletion; HGNC; 17021; ASTN2; Zygosity=Heterozygous (from autologous cell line PNUi001-B) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21172231 CVCL_VK74 PNUi001-B induced pluripotent stem cell human CVCL_VK74 From: Department of Psychiatry, Nagoya University Graduate School of Medicine; Nagoya; Japan CL:0000010 Sequence variation: Gene deletion; HGNC; 17021; ASTN2; Zygosity=Heterozygous (PubMed=29803967) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21172232 CVCL_VK79 WTC-mEGFP-SLC25A17-cl115 induced pluripotent stem cell human CVCL_VK79 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 SLC25A17 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21172233 CVCL_VK77 CW60189 induced pluripotent stem cell human CVCL_VK77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Lybian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60189; true; Discontinued: FCDI; CW60189; probable Male 21172234 CVCL_VK78 WTC-mEGFP-MAP1LC3B-cl22 induced pluripotent stem cell human CVCL_VK78 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Deep exome analysis Male Characteristics: Using CRISPR/Cas9 MAP1LC3B has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21172235 CVCL_3E12 HQ00419 transformed cell line human CVCL_3E12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172236 CVCL_3E13 HQ00420 transformed cell line human CVCL_3E13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172237 CVCL_3E10 HQ00417 transformed cell line human CVCL_3E10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172238 CVCL_3E11 HQ00418 transformed cell line human CVCL_3E11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172239 CVCL_3E16 HQ00423 transformed cell line human CVCL_3E16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172240 CVCL_3E17 HQ00424 transformed cell line human CVCL_3E17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172241 CVCL_3E14 HQ00421 transformed cell line human CVCL_3E14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172242 CVCL_3E15 HQ00422 transformed cell line human CVCL_3E15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172243 CVCL_3E18 HQ00425 transformed cell line human CVCL_3E18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172244 CVCL_3E19 HQ00426 transformed cell line human CVCL_3E19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172245 CVCL_VK60 CLN3-iPS 2B induced pluripotent stem cell human CVCL_VK60 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.1056+3A>C; ClinVar=VCV000056247; Zygosity=Heterozygous (PubMed=24271013); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; p.Asp416Gly (c.1247A>G); ClinVar=VCV000056252; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172246 CVCL_VK61 CLN3-iPS 3A induced pluripotent stem cell human CVCL_VK61 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172247 CVCL_VK64 CLN3-iPS 4B induced pluripotent stem cell human CVCL_VK64 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172248 CVCL_VK65 CLN3-iPS 5A induced pluripotent stem cell human CVCL_VK65 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172249 CVCL_VK62 CLN3-iPS 3B induced pluripotent stem cell human CVCL_VK62 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172250 CVCL_VK63 CLN3-iPS 4A induced pluripotent stem cell human CVCL_VK63 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172251 CVCL_VK68 TPP1-iPS 1C induced pluripotent stem cell human CVCL_VK68 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24271013); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172252 CVCL_VK69 TPP1-iPS 2A induced pluripotent stem cell human CVCL_VK69 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24271013); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172253 CVCL_VK66 TPP1-iPS 1A induced pluripotent stem cell human CVCL_VK66 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24271013); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172254 CVCL_VK67 TPP1-iPS 1B induced pluripotent stem cell human CVCL_VK67 CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=24271013); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172255 CVCL_3E20 HQ00427 transformed cell line human CVCL_3E20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172256 CVCL_3E23 HQ00430 transformed cell line human CVCL_3E23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172257 CVCL_3E24 HQ00431 transformed cell line human CVCL_3E24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172258 CVCL_3E21 HQ00428 transformed cell line human CVCL_3E21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172259 CVCL_3E22 HQ00429 transformed cell line human CVCL_3E22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172260 CVCL_3E27 HQ00434 transformed cell line human CVCL_3E27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172261 CVCL_3E28 HQ00435 transformed cell line human CVCL_3E28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172262 CVCL_3E25 HQ00432 transformed cell line human CVCL_3E25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172263 CVCL_3E26 HQ00433 transformed cell line human CVCL_3E26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172264 CVCL_3E29 HQ00436 transformed cell line human CVCL_3E29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172265 CVCL_VK50 K-EW3 cancer cell line human CVCL_VK50 CL:0000010 Population: Japanese; Derived from sampling site: Bone; rib. Male 21172266 CVCL_VK53 SRT-1 cancer cell line CVCL_VK53 CL:0000010 Derived from sampling site: Paranasal sinus. Female 21172267 CVCL_VK54 UKRV-Mel-32 cancer cell line human CVCL_VK54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863); Sequence variation: Gene fusion; HGNC; 7413; MTAP + HGNC; 34341; CDKN2B-AS1; Name(s)=MTAP-ANRIL (PubMed=26909863); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503). Unspecified 21172268 CVCL_VK51 CT-1 [Mouse hybridoma against human TNF] hybridoma house mouse CVCL_VK51 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01375; Human TNF. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-472 21172269 CVCL_VK52 WM902B-BR cancer cell line human CVCL_VK52 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=21156289); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Leu (c.71G>T); ClinVar=VCV000376377; Zygosity=Unspecified (PubMed=21156289); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Lys1083Ter (c.3247A>T); Zygosity=Unspecified (PubMed=27500726) Selected for resistance to: ChEBI; CHEBI:131882; SB-590885; Derived from sampling site: Skin. Male Part of: Wistar Institute melanoma cell line collection 21172270 CVCL_VK57 CLN3-iPS 1A induced pluripotent stem cell human CVCL_VK57 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172271 CVCL_VK58 CLN3-iPS 1B induced pluripotent stem cell human CVCL_VK58 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.461-280_677+382del (1.02-kb del); ClinVar=VCV000003552; Zygosity=Homozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172272 CVCL_VK55 18T-iPSC induced pluripotent stem cell human CVCL_VK55 From: Key Laboratory for Rare Disease Research of Shandong Province; Jinan; China CL:0000010 Derived from sampling site: Amniotic fluid. Omics: Transcriptome analysis by RNAseq Male 21172273 CVCL_VK56 8330-iPS-8 induced pluripotent stem cell human CVCL_VK56 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172274 CVCL_VK59 CLN3-iPS 2A induced pluripotent stem cell human CVCL_VK59 CL:0000010 Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; c.1056+3A>C; ClinVar=VCV000056247; Zygosity=Heterozygous (PubMed=24271013); Sequence variation: Mutation; HGNC; 2074; CLN3; Simple; p.Asp416Gly (c.1247A>G); ClinVar=VCV000056252; Zygosity=Heterozygous (PubMed=24271013) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172275 CVCL_VK42 Ma-Mel-93I cancer cell line human CVCL_VK42 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (PubMed=23348503) Derived from metastatic site: Cutaneous/subcutaneous. Male 21172276 CVCL_VK43 HL-60 blast cancer cell line human CVCL_VK43 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10966170); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Subclone of HL-60 resistant to the growth and differentiation effects of various compounds 21172277 CVCL_VK40 SRT-2 cancer cell line CVCL_VK40 CL:0000010 Derived from sampling site: Paranasal sinus. Female 21172278 CVCL_VK41 CY194 hybrid cell line CVCL_VK41 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172279 CVCL_MQ98 BayGenomics ES cell line RRD082 embryonic stem cell house mouse CVCL_MQ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386741; Slc30a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172280 CVCL_N298 Hs 565(E) finite cell line human CVCL_N298 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7334; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172281 CVCL_VK46 KK-2 cancer cell line human CVCL_VK46 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=9738976) Population: Japanese; Derived from sampling site: Brain; occipital lobe. Discontinued: JCRB; IFO50494; true Female Doubling time: 96 hours (PubMed=1323907) 21172282 CVCL_MQ99 BayGenomics ES cell line RRD085 embryonic stem cell house mouse CVCL_MQ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354165; Thop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172283 CVCL_N299 Hs 564(A).T cancer cell line human CVCL_N299 CL:0000010 Discontinued: ATCC; CRL-7326; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172284 CVCL_VK47 PN-1 cancer cell line human CVCL_VK47 CL:0000010 21172285 CVCL_MQ96 BayGenomics ES cell line RRD080 embryonic stem cell house mouse CVCL_MQ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929871; Terf2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172286 CVCL_VK44 EW93 cancer cell line human CVCL_VK44 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=9738976). 21172287 CVCL_N296 IK-6 hybrid cell line CVCL_N296 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Endometrium. Discontinued: ATCC; CRL-7929; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172288 CVCL_MQ97 BayGenomics ES cell line RRD081 embryonic stem cell house mouse CVCL_MQ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915760; Ints1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172289 CVCL_N297 Hs 848.Sk finite cell line human CVCL_N297 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7581; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172290 CVCL_VK45 K-EW1 cancer cell line human CVCL_VK45 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=9738976) Population: Japanese; Derived from sampling site: Pelvic cavity. Male 21172291 CVCL_MQ94 BayGenomics ES cell line RRD073 embryonic stem cell house mouse CVCL_MQ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914172; Rras2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172292 CVCL_N294 Hs 566(A).T cancer cell line human CVCL_N294 CL:0000010 Discontinued: ATCC; CRL-7335; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172293 CVCL_MQ95 BayGenomics ES cell line RRD079 embryonic stem cell house mouse CVCL_MQ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928484; Nudt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172294 CVCL_N295 Hs 566(C).Mg finite cell line human CVCL_N295 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7337; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172295 CVCL_MQ92 BayGenomics ES cell line RRD071 embryonic stem cell house mouse CVCL_MQ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172296 CVCL_N292 Re-1 hybridoma house mouse CVCL_N292 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Salmonella minnesota Re glycolipid. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8482 21172297 CVCL_VK48 SYM-1 cancer cell line human CVCL_VK48 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=9738976). Population: Japanese 21172298 CVCL_MQ93 BayGenomics ES cell line RRD072 embryonic stem cell house mouse CVCL_MQ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97178; Map4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172299 CVCL_VK49 K-EW2 cancer cell line human CVCL_VK49 CL:0000010 Population: Japanese; Derived from sampling site: Bone; fibula. Male 21172300 CVCL_N293 Re-2 hybridoma house mouse CVCL_N293 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Salmonella minnesota Re glycolipid. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8481 21172301 CVCL_3E01 HQ00408 transformed cell line human CVCL_3E01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172302 CVCL_3E02 HQ00409 transformed cell line human CVCL_3E02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172303 CVCL_3E00 HQ00407 transformed cell line human CVCL_3E00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172304 CVCL_3E05 HQ00412 transformed cell line human CVCL_3E05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172305 CVCL_3E06 HQ00413 transformed cell line human CVCL_3E06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172306 CVCL_3E03 HQ00410 transformed cell line human CVCL_3E03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172307 CVCL_3E04 HQ00411 transformed cell line human CVCL_3E04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172308 CVCL_3E09 HQ00416 transformed cell line human CVCL_3E09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172309 CVCL_3E07 HQ00414 transformed cell line human CVCL_3E07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172310 CVCL_3E08 HQ00415 transformed cell line human CVCL_3E08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172311 CVCL_VK31 CY183 hybrid cell line CVCL_VK31 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172312 CVCL_VK32 CY190 hybrid cell line CVCL_VK32 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172313 CVCL_VK30 CY163 hybrid cell line CVCL_VK30 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172314 CVCL_VK35 CY125 hybrid cell line CVCL_VK35 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172315 CVCL_VK36 CY150 hybrid cell line CVCL_VK36 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172316 CVCL_VK33 CY198 hybrid cell line CVCL_VK33 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172317 CVCL_VK34 CY123 hybrid cell line CVCL_VK34 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172318 CVCL_VK39 MI-APY transformed cell line human CVCL_VK39 CL:0000010 Karyotypic information: 46,XY,t(1;16)(q12;p13.2) (PubMed=2095701); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172319 CVCL_VK37 CY177 hybrid cell line CVCL_VK37 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172320 CVCL_VK38 CY168 hybrid cell line CVCL_VK38 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172321 CVCL_E903 LB-831 cancer cell line human CVCL_E903 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp184Tyr (c.550G>T); Zygosity=Unspecified (PubMed=1373872) Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa Doubling time: 38.37 hours (PubMed=3927997) 21172322 CVCL_E904 LB-832 cancer cell line human CVCL_E904 CL:0000010 Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa Doubling time: ~48 hours (PubMed=3927997) 21172323 CVCL_E902 LB59Ly cancer cell line CVCL_E902 CL:0000010 Female 21172324 CVCL_E907 BB64-RCC cancer cell line human CVCL_E907 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21172325 CVCL_E908 LB1047-EBV transformed cell line human CVCL_E908 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172326 CVCL_E905 LB905-BLC cancer cell line human CVCL_E905 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21172327 CVCL_E906 LB796-BLC cancer cell line human CVCL_E906 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21172328 CVCL_E900 dRLN-53 transformed cell line Norway rat CVCL_E900 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21172329 CVCL_E914 LB2518-EBV transformed cell line human CVCL_E914 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172330 CVCL_E915 LB1610-MEL cancer cell line human CVCL_E915 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=28765120); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=28765120). Unspecified 21172331 CVCL_E912 LB996-EBV transformed cell line human CVCL_E912 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172332 CVCL_E913 LB831-EBV transformed cell line human CVCL_E913 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172333 CVCL_E918 LB373-MEL cancer cell line human CVCL_E918 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: CNV analysis. Female 21172334 CVCL_E919 WT100 transformed cell line human CVCL_E919 HLA typing: DRB1*01:01 (IPD-IMGT/HLA=13141) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21172335 CVCL_E916 LB951-MEL cancer cell line human CVCL_E916 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21172336 CVCL_E917 LB373-EBV transformed cell line human CVCL_E917 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172337 CVCL_E910 LE9211-EBV transformed cell line human CVCL_E910 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21172338 CVCL_E911 LE9211-RCC cancer cell line human CVCL_E911 HLA typing: A*03; B*07,35; C*04,07 (PubMed=8781117). CL:0000010 Unspecified 21172339 CVCL_E909 HA7-EBV transformed cell line human CVCL_E909 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172340 CVCL_3E96 HQ00504 transformed cell line human CVCL_3E96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172341 CVCL_3E97 HQ00505 transformed cell line human CVCL_3E97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172342 CVCL_3E94 HQ00502 transformed cell line human CVCL_3E94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172343 CVCL_3E95 HQ00503 transformed cell line human CVCL_3E95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172344 CVCL_3E98 HQ00506 transformed cell line human CVCL_3E98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172345 CVCL_3E99 HQ00507 transformed cell line human CVCL_3E99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172346 CVCL_3E92 HQ00499 transformed cell line human CVCL_3E92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172347 CVCL_3E93 HQ00501 transformed cell line human CVCL_3E93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172348 CVCL_3E90 HQ00497 transformed cell line human CVCL_3E90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172349 CVCL_3E91 HQ00498 transformed cell line human CVCL_3E91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172350 CVCL_3E74 HQ00481 transformed cell line human CVCL_3E74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172351 CVCL_3E75 HQ00482 transformed cell line human CVCL_3E75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172352 CVCL_3E72 HQ00479 transformed cell line human CVCL_3E72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172353 CVCL_3E73 HQ00480 transformed cell line human CVCL_3E73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172354 CVCL_3E78 HQ00485 transformed cell line human CVCL_3E78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172355 CVCL_3E79 HQ00486 transformed cell line human CVCL_3E79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172356 CVCL_3E76 HQ00483 transformed cell line human CVCL_3E76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172357 CVCL_3E77 HQ00484 transformed cell line human CVCL_3E77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172358 CVCL_3E70 HQ00477 transformed cell line human CVCL_3E70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172359 CVCL_3E71 HQ00478 transformed cell line human CVCL_3E71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172360 CVCL_3E85 HQ00492 transformed cell line human CVCL_3E85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172361 CVCL_3E86 HQ00493 transformed cell line human CVCL_3E86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172362 CVCL_3E83 HQ00490 transformed cell line human CVCL_3E83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172363 CVCL_3E84 HQ00491 transformed cell line human CVCL_3E84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172364 CVCL_3E89 HQ00496 transformed cell line human CVCL_3E89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172365 CVCL_3E87 HQ00494 transformed cell line human CVCL_3E87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172366 CVCL_3E88 HQ00495 transformed cell line human CVCL_3E88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172367 CVCL_3E81 HQ00488 transformed cell line human CVCL_3E81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172368 CVCL_3E82 HQ00489 transformed cell line human CVCL_3E82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172369 CVCL_3E80 HQ00487 transformed cell line human CVCL_3E80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172370 CVCL_DW68 ND04559 transformed cell line human CVCL_DW68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172371 CVCL_E868 WBD001088 transformed cell line human CVCL_E868 HLA typing: A*01,02; B*27,37; C*02,06; DPB1*04:01,04:02; DQA1*01:04,01:02; DQB1*05:01,05:02; DRB1*16:01,10:01; DRB5*02 (IPD-IMGT/HLA=11696) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172372 CVCL_DW69 ND04561 transformed cell line human CVCL_DW69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172373 CVCL_E869 WBD001816 transformed cell line human CVCL_E869 HLA typing: A*01; B*17; DPB1*01:01,04:01; DQA1*02:01; DQB1*03:03:02; DRB1*07; DRB4*01:01 (IPD-IMGT/HLA=11697) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172374 CVCL_DW62 ND04506 transformed cell line human CVCL_DW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172375 CVCL_E862 VBD234 transformed cell line human CVCL_E862 HLA typing: A*01; B*07,08; C*07; DPB1*04:01,04:02; DQA1*01:01,05:01; DQB1*05:01,02:01; DRB1*01:01,03:01; DRB3*01:01 (IPD-IMGT/HLA=11703) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172376 CVCL_DW63 ND04507 transformed cell line human CVCL_DW63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172377 CVCL_E863 VEN transformed cell line human CVCL_E863 HLA typing: A*03:01:01:01,31:01:02:01; B*55:01:01,18:01:01:01; C*05:01:01:01,03:03:01:01; DPA1*01:03:01:02; DPB1*104:01,04:01:01; DQA1*01:01:01:02,05:01:01:01; DQB1*02:01:01,05:01:01; DRB1*01:01:01,03:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=11525); HLA typing: A*03:01:01:01,31:01:02:01; B*18:01:01:01,55:01:01; C*05:01:01:01,03:03:01:01; DPA1*01:03:01:02; DPB1*04:01:01:01(350:01),104:01(124:01); DQA1*05:01:01:01,01:01:01; DQB1*02:01:01,05:01:01:03; DRB1*03:01:01,01:01:01; DRB3*02:02:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172378 CVCL_DW60 ND04460 transformed cell line human CVCL_DW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172379 CVCL_E860 V.E.C. transformed cell line human CVCL_E860 HLA typing: DPA1*01:03:01; DPB1*04:01,46:01; DQA1*01:02,03; DQB1*06:09,03:02; DRB1*13:02,04:01; DRB3*03:01; DRB4*01:01 (IPD-IMGT/HLA=11521) CL:0000010 Population: Caucasian; Belgian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172380 CVCL_DW61 ND04483 transformed cell line human CVCL_DW61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172381 CVCL_E861 VAVY transformed cell line human CVCL_E861 HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*02:01; DPB1*01:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:02; DRB1*03:01:01; DRB3*01:01 (IPD-IMGT/HLA=11522) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172382 CVCL_DW66 ND04537 transformed cell line human CVCL_DW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172383 CVCL_E866 WAL,FD transformed cell line human CVCL_E866 HLA typing: A*03; B*07; C*07; DPB1*04:01; DQA1*01:02; DQB1*06:02; DRB1*15:01; DRB5*01:01 (IPD-IMGT/HLA=11672) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172384 CVCL_DW67 ND04556 transformed cell line human CVCL_DW67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172385 CVCL_E867 WATANABE transformed cell line human CVCL_E867 HLA typing: A*02:01:01,02:07; B*46:01; C*01; DPB1*05:01; DQA1*01:03; DQB1*06:01; DRB1*08:03:02 (IPD-IMGT/HLA=11669) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172386 CVCL_DW64 ND04508 transformed cell line human CVCL_DW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172387 CVCL_E864 VOO transformed cell line human CVCL_E864 HLA typing: A*01:01:01:01,03:01:01:01; B*08:01:03,56:01; C*01:02:01,07:01:01; DPA1*01:03; DPB1*02:01:02,04:01:01; DQA1*01:01:01,05:01:01; DQB1*02:01:01,05:01:01; DRB1*01:01:01,03:01:01 (IPD-IMGT/HLA=11528) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172388 CVCL_DW65 ND04509 transformed cell line human CVCL_DW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172389 CVCL_E865 WAI,DL transformed cell line human CVCL_E865 HLA typing: A*02:01,03:01; B*07,21; DPB1*04:02,06:01; DQA1*05:01,03; DQB1*03:02,02:01; DRB1*03:01,04; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11745) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172390 CVCL_DW79 ND04622 transformed cell line human CVCL_DW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172391 CVCL_E879 WON,I transformed cell line human CVCL_E879 HLA typing: A*34:01; B*40:02,56:01; C*01:02,15:02:01; DPB1*02:01:02,05:01; DQA1*01:04,01:03; DQB1*05:03:01; DRB1*08:03:02,14:08; DRB3*02:02 (IPD-IMGT/HLA=11735) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172392 CVCL_DW73 ND04605 transformed cell line human CVCL_DW73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172393 CVCL_E873 WHO NP199 transformed cell line human CVCL_E873 HLA typing: A*02,30; B*13,46; C*06:02; DPB1*05:01; DQA1*02:01,03:02; DQB1*02:01,03:03; DRB1*07,09; DRB4*01:01 (IPD-IMGT/HLA=11677) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172394 CVCL_DW74 ND04606 transformed cell line human CVCL_DW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172395 CVCL_E874 WHO NP439 transformed cell line human CVCL_E874 HLA typing: A*02,24; B*46; C*01; DPB1*05:01; DQA1*03:02; DQB1*03:03:02; DRB1*09:01; DRB4*01:01 (IPD-IMGT/HLA=11682) CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172396 CVCL_DW71 ND04595 transformed cell line human CVCL_DW71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172397 CVCL_E871 WeWak1 transformed cell line human CVCL_E871 HLA typing: A*11:01,24:02; B*27:04:01,15:06; C*04:01,12:02; DPB1*01:01:01,03:01 (IPD-IMGT/HLA=11558) CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Pro72Thr (c.214C>A); Zygosity=Unspecified (PubMed=8108117) Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Virology: Contains a complete EBV genome (strain WeWak1) which has been sequenced (PubMed=25787276) Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel Caution: Could be identical to QIMR-WW1-LCL (Cellosaurus=CVCL_W930) 21172398 CVCL_DW72 ND04604 transformed cell line human CVCL_DW72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172399 CVCL_E872 WHO NP192 transformed cell line human CVCL_E872 HLA typing: A*02:07,11:01:01; B*46:01; C*01; DPB1*02:01:02,05:01; DQA1*03,03:02; DQB1*03:03:02,04:01; DRB1*04:05:01,09:01:02; DRB4*01:03:01:01 (IPD-IMGT/HLA=11683) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172400 CVCL_DW77 ND04619 transformed cell line human CVCL_DW77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172401 CVCL_E877 WJR076 transformed cell line human CVCL_E877 HLA typing: A*02:01:01:01; B*57:01:01; C*07:01:01:01; DPB1*02:01:02/02:01:19; DQA1*01:02:02; DQB1*05:02:01; DRB1*16:02:01 (IPD-IMGT/HLA=11567) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172402 CVCL_DW78 ND04620 transformed cell line human CVCL_DW78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172403 CVCL_E878 WON,C transformed cell line human CVCL_E878 HLA typing: A*19,26; B*15:25,40; C*04,07; DPB1*02:01:02,16:01; DQA1*01:03,05:01; DQB1*03:01,06:01; DRB1*12:01,08:03; DRB3*02:02 (IPD-IMGT/HLA=11736) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172404 CVCL_MQ09 BayGenomics ES cell line RRC161 embryonic stem cell house mouse CVCL_MQ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927542; Pitpnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172405 CVCL_N209 GM13649 transformed cell line human CVCL_N209 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172406 CVCL_DW75 ND04608 transformed cell line human CVCL_DW75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172407 CVCL_E875 WIL,M transformed cell line human CVCL_E875 HLA typing: A*29:02:01,02:02; B*15:03,41:01; C*02:02; DPB1*04:01,13:01; DQA1*05:01,03:01; DQB1*03:01,03:02; DRB1*04:03,11:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11659) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172408 CVCL_DW76 ND04618 transformed cell line human CVCL_DW76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172409 CVCL_E876 WIN transformed cell line human CVCL_E876 HLA typing: A*01:01:01:01; B*57:01:01; C*06:02:01:01; DPA1*01:03,02:01:02; DPB1*04:01:01,13:01:01/107:01; DQA1*02:01; DQB1*02:02:01,03:03:02; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11565) CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172410 CVCL_MQ07 BayGenomics ES cell line RRC152 embryonic stem cell house mouse CVCL_MQ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918867; Armh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172411 CVCL_N207 GM13321 transformed cell line human CVCL_N207 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis Male Part of: Human variation panel 21172412 CVCL_MQ08 BayGenomics ES cell line RRC160 embryonic stem cell house mouse CVCL_MQ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104897; Rest Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172413 CVCL_N208 GM13418 transformed cell line human CVCL_N208 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172414 CVCL_MQ05 BayGenomics ES cell line RRC147 embryonic stem cell house mouse CVCL_MQ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141969; Efl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172415 CVCL_N205 GM13203 finite cell line human CVCL_N205 CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.His70Profs*29 (c.208dupC) (c.208insC); ClinVar=VCV000195037; Zygosity=Hemizygous (Coriell) Population: Caribbean; Haitian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Human variation panel 21172416 CVCL_MQ06 BayGenomics ES cell line RRC150 embryonic stem cell house mouse CVCL_MQ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922387; Rprd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172417 CVCL_N206 GM13281 transformed cell line human CVCL_N206 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172418 CVCL_MQ03 BayGenomics ES cell line RRC144 embryonic stem cell house mouse CVCL_MQ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172419 CVCL_N203 GM13180 transformed cell line human CVCL_N203 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Part of: Human variation panel; Registration: CEPH Families Reference Panel; 10201/10415 21172420 CVCL_MQ04 BayGenomics ES cell line RRC146 embryonic stem cell house mouse CVCL_MQ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108451; Acaca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172421 CVCL_N204 GM13181 transformed cell line human CVCL_N204 CL:0000010 Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Part of: Human variation panel; Registration: CEPH Families Reference Panel; 10202/10416 21172422 CVCL_DW70 ND04562 transformed cell line human CVCL_DW70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172423 CVCL_E870 WDV transformed cell line human CVCL_E870 HLA typing: A*02:01:01:01; B*38:01:01; C*12:03:01:01; DPA1*01; DPB1*02:01:02/02:01:19,04:01:01; DQA1*01:03; DQB1*06:03:01; DRA*01:02; DRB1*13:01:01; DRB3*01:01 (IPD-IMGT/HLA=11555) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel; Part of: Human variation panel 21172424 CVCL_MQ01 BayGenomics ES cell line RRC139 embryonic stem cell house mouse CVCL_MQ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890218; Akap10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172425 CVCL_N201 GM13033 transformed cell line human CVCL_N201 HLA typing: A*03:01:01,11:01:01; B*07:02:01,08:01:01; C*07:01:01,07:02:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,04:01:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01; DRB3*01:01:02; DRB5*01:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508Cys (c.1523T>G); ClinVar=VCV000007126; Zygosity=Heterozygous; Note=Benign (PubMed=19359498) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21172426 CVCL_MQ02 BayGenomics ES cell line RRC142 embryonic stem cell house mouse CVCL_MQ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172427 CVCL_N202 GM13138 transformed cell line human CVCL_N202 CL:0000010 Population: Southeast Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172428 CVCL_MQ00 BayGenomics ES cell line RRC138 embryonic stem cell house mouse CVCL_MQ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915308; Chd1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172429 CVCL_N200 GM12931 transformed cell line human CVCL_N200 HLA typing: A*68:02; B*45:AH,78:01; C*16:01; DRB1*13:02,13:04 (IPD-IMGT/HLA=16405) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21172430 CVCL_DW48 ND04297 transformed cell line human CVCL_DW48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172431 CVCL_E848 THAI742 transformed cell line human CVCL_E848 HLA typing: A*24:03,33:03; B*46:01:01,15:12; C*01:02,03:03; DPB1*04:02,05:01; DQB1*03:01:01,03:02:01; DRB1*04:06,12:02:01; DRB3*03:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=11472) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172432 CVCL_DW49 ND04298 transformed cell line human CVCL_DW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172433 CVCL_E849 THO transformed cell line human CVCL_E849 HLA typing: A*02,03; B*60; C*w03 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21172434 CVCL_DW46 ND04204 transformed cell line human CVCL_DW46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172435 CVCL_E846 TER-ND transformed cell line human CVCL_E846 HLA typing: A*02,11; B*44:03:01,35; C*04,16:01; DPA1*01; DPB1*02:01,04:01; DQA1*01:01; DRB1*01:03 (IPD-IMGT/HLA=11449) CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172436 CVCL_DW47 ND04295 transformed cell line human CVCL_DW47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172437 CVCL_E847 THA transformed cell line human CVCL_E847 HLA typing: A*03:01:01:01,31:01:02:01; B*35:03,15:18:01:02; C*04:01:01:01,07:04:01; DPA1*01:03:01:04,01:03:01:02; DPB1*04:01:01; DQA1*01:03:01:01,01:04:01; DQB1*05:03:01,06:01:01; DRB1*13:08,15:02:02; DRB3*02:02:01; DRB5*01:02 (IPD-IMGT/HLA=11456) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172438 CVCL_DW40 ND04015 transformed cell line human CVCL_DW40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172439 CVCL_E840 T7526 transformed cell line human CVCL_E840 HLA typing: A*02:06:01:01,02:07:01; B*46:01:01; C*01:02:01,08:01:01; DPA1*04:01; DPB1*13:01:01/107:01; DQA1*03:02; DQB1*03:03:02; DRA*01:01; DRB1*09:01:02/09:21; DRB4*01:03:01:01 (IPD-IMGT/HLA=11420) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172440 CVCL_DW41 ND04046 transformed cell line human CVCL_DW41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172441 CVCL_E841 T7527 transformed cell line human CVCL_E841 HLA typing: A*02:07:01,02:01:01:27; B*46:01:01; C*01:02:01; DPB1*05:01:01,21:01; DQA1*03:01,06:01; DQB1*03:01:01,03:03:02; DRB1*09:01:02/09:21,12:02:01; DRB3*03:01:01; DRB4*01:03:01:01 (IPD-IMGT/HLA=11421) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172442 CVCL_DW44 ND04200 transformed cell line human CVCL_DW44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172443 CVCL_E844 TEM transformed cell line human CVCL_E844 HLA typing: A*66:01:01:01; B*38:01:01; C*12:03:01:01; DPA1*01; DPB1*04:01:01; DQA1*01:04; DQB1*05:03:01; DRA*01:01; DRB1*14:01:01; DRB3*02:01 (IPD-IMGT/HLA=11438) CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172444 CVCL_DW45 ND04201 transformed cell line human CVCL_DW45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172445 CVCL_E845 TER259 transformed cell line human CVCL_E845 HLA typing: A*32:01,68:02; B*08:01,44:02:01:01; C*01:02,07; DPB1*03:01:01,04:01:01; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:01,04:26; DRB3*01:01; DRB4*01:03 (IPD-IMGT/HLA=26005) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21172446 CVCL_DW42 ND04047 transformed cell line human CVCL_DW42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172447 CVCL_E842 TAB089 transformed cell line human CVCL_E842 HLA typing: A*02:07:01,02:01:01:01; B*46:01:01; C*01:02:01; DPA1*02:02:02; DPB1*02:02; DQA1*01:03; DQB1*06:01:01/06:01:15; DRA*01:02; DRB1*08:03:02 (IPD-IMGT/HLA=11424) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172448 CVCL_DW43 ND04105 transformed cell line human CVCL_DW43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172449 CVCL_E843 TAI034 transformed cell line human CVCL_E843 HLA typing: A*11:01:01,33:01; B*14:02,52:01:01; C*08:02; DPB1*04:01; DQA1*01:01,01:03; DQB1*05:01,06:01; DRB1*01:02,15:02; DRB5*01:02 (IPD-IMGT/HLA=11656) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172450 CVCL_DW59 ND04454 transformed cell line human CVCL_DW59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172451 CVCL_E859 UA-S2 transformed cell line human CVCL_E859 HLA typing: A*02,32; B*27,51; C*01; DPB1*04:01; DQA1*05:01; DQB1*03:01; DRB1*11:03,11:01; DRB3*02:02 (IPD-IMGT/HLA=11508) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172452 CVCL_DW57 ND04423 transformed cell line human CVCL_DW57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172453 CVCL_E857 TS10 transformed cell line human CVCL_E857 HLA typing: A*26; B*38 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21172454 CVCL_DW58 ND04453 transformed cell line human CVCL_DW58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172455 CVCL_E858 TUBO [Human B-cell 10IHW] transformed cell line human CVCL_E858 HLA typing: A*02:16,03:01:01:01; B*51:01:01:01; C*07:04:01:01,15:02:01:01; DPA1*01:03:01:05,01:03:01:01; DPB1*02:01:02/02:01:19,04:02:01; DQA1*05:05:01; DQB1*03:01:01; DRA*01:01,01:02; DRB1*11:04:01,12:01:01/12:10; DRB3*02:02:01:02 (IPD-IMGT/HLA=11502) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172456 CVCL_DW51 ND04329 transformed cell line human CVCL_DW51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172457 CVCL_E851 TISI transformed cell line human CVCL_E851 HLA typing: A*24:02:01:01; B*35:08:01; C*04:01:01:06; DPA1*01:03; DPB1*04:02:01; DQA1*05:05; DQB1*03:01:01; DRA*01:01; DRB1*11:03:01; DRB3*02:02 (IPD-IMGT/HLA=11649) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172458 CVCL_DW52 ND04349 transformed cell line human CVCL_DW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172459 CVCL_E852 TL [Human B-cell 12IHW] transformed cell line human CVCL_E852 HLA typing: A*02:01,24:02; B*35:08:01,13:02; C*04:01,06:02; DQA1*02:01,05:01; DQB1*02:01; DRB1*07:01,03:01 (IPD-IMGT/HLA=11481) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172460 CVCL_DW50 ND04299 transformed cell line human CVCL_DW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172461 CVCL_E850 THO,MA transformed cell line human CVCL_E850 HLA typing: A*02,11; B*07,27; C*02,07; DPB1*04:01; DQA1*01:02,03; DQB1*03:01,06:02; DRB1*04:01,15:01; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11701) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172462 CVCL_DW55 ND04364 transformed cell line human CVCL_DW55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172463 CVCL_E855 TOKUNAGA transformed cell line human CVCL_E855 HLA typing: A*24:02; B*52; DPA1*02; DPB1*09:01; DQA1*01:03; DQB1*06:01; DRB1*15:02; DRB5*01:02; DRB6*02 (IPD-IMGT/HLA=11493) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel; Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172464 CVCL_DW56 ND04380 transformed cell line human CVCL_DW56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172465 CVCL_E856 TRACHT transformed cell line human CVCL_E856 HLA typing: DPB1*03:01,02:01; DQA1*01:01,01:02; DQB1*05:01,06:09; DRB1*01:01,13:02 (IPD-IMGT/HLA=11494) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172466 CVCL_DW53 ND04362 transformed cell line human CVCL_DW53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172467 CVCL_E853 TM transformed cell line human CVCL_E853 HLA typing: A*26:03; B*62; C*09; DRB1*04:03,15:01 (IPD-IMGT/HLA=11415) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172468 CVCL_DW54 ND04363 transformed cell line human CVCL_DW54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172469 CVCL_E854 TO [Human B-cell] transformed cell line human CVCL_E854 HLA typing: A*68:02,30:01; B*13:02:01,51:01:01; C*06:02,15:02 (IPD-IMGT/HLA=11482) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172470 CVCL_DW26 ND03698 transformed cell line human CVCL_DW26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172471 CVCL_E826 SCL-116A transformed cell line human CVCL_E826 HLA typing: A*03:01,30:02; B*18:01,56:01; C*01:02,05; DQA1*01:02,01:03; DQB1*06:03,06:09; DRB1*03:07,13:01 (IPD-IMGT/HLA=26058) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21172472 CVCL_DW27 ND03714 transformed cell line human CVCL_DW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172473 CVCL_E827 SHJO transformed cell line human CVCL_E827 HLA typing: A*23:01:01,24:02:01:01; B*50:01:01,42:01:01; C*06:02:01:02,17:01:01:02; DPA1*01:03:01:02,03:01; DPB1*03:01,04:02; DQA1*02:01,03:03:01; DQB1*02:02:01:01; DRB1*07:01:01; DRB4*01:01:01:01,01:03:01 (IPD-IMGT/HLA=11384); HLA typing: A*23:01:01,24:02:01:01; B*50:01:01,42:01:01; C*06:02:01:02;17:01:01:02; DPA1*01:03:01:02,03:01; DPB1*104:01(124:01),105:01(463:01); DQA1*02:01:01,03:03:01:01; DQB1*02:02:01:01; DRB1*07:01:01; DRB4*01:01:01:01,01:03:01 (PubMed=30844424) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172474 CVCL_DW24 ND03631 transformed cell line human CVCL_DW24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172475 CVCL_E824 SCHU transformed cell line human CVCL_E824 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*04:02:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=11647) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172476 CVCL_DW25 ND03693 transformed cell line human CVCL_DW25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172477 CVCL_E825 SEC transformed cell line human CVCL_E825 HLA typing: A*31; B*62; C*w01 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21172478 CVCL_DW28 ND03745 transformed cell line human CVCL_DW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172479 CVCL_E828 SHY transformed cell line human CVCL_E828 HLA typing: A*29; B*41; C*02; DRB1*10 (IPD-IMGT/HLA=25988) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21172480 CVCL_DW29 ND03788 transformed cell line human CVCL_DW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172481 CVCL_E829 SLE005 transformed cell line human CVCL_E829 HLA typing: A*02:01:01:01; B*40:01:02:01; C*03:04:01:01; DPB1*03:01:01; DQA1*01:02; DQB1*06:04:01; DRB1*13:02:01; DRB3*03:01 (IPD-IMGT/HLA=11391) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172482 CVCL_DW22 ND03629 transformed cell line human CVCL_DW22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172483 CVCL_E822 SA transformed cell line human CVCL_E822 HLA typing: A*24:02:01:01; B*07:02:01:01; C*07:02:01:03; DPB1*04:02:01; DQA1*01:01; DQB1*05:01:01; DRB1*01:01:01 (IPD-IMGT/HLA=11356) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172484 CVCL_DW23 ND03630 transformed cell line human CVCL_DW23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172485 CVCL_E823 SAVC transformed cell line human CVCL_E823 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*02:01:01; DPB1*10:01:01; DQA1*03:01:01; DQB1*03:02:01; DRA*01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11368) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172486 CVCL_DW20 ND03550 transformed cell line human CVCL_DW20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172487 CVCL_E820 RSA-ND transformed cell line human CVCL_E820 HLA typing: A*02:01,34:01; B*15:13,38:02:01; C*07,08; DPB1*01:01:01 (IPD-IMGT/HLA=11339) CL:0000010 Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172488 CVCL_DW21 ND03557 transformed cell line human CVCL_DW21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172489 CVCL_E821 RSH transformed cell line human CVCL_E821 HLA typing: A*68:02:01:01,30:01:01; B*42:01:01; C*17:01:01:02; DPA1*03:01,02:02:02; DPB1*01:01:01,105:01; DQA1*04:01; DQB1*04:02:01; DRA*01:02; DRB1*03:02:01; DRB3*01:01:02:01 (IPD-IMGT/HLA=11340) CL:0000010 Population: African; Zulu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172490 CVCL_DW37 ND03977 transformed cell line human CVCL_DW37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172491 CVCL_E837 STEINLIN transformed cell line human CVCL_E837 HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01; DPB1*03:01:01,04:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:02; DRB1*03:01:01; DRB3*01:01 (IPD-IMGT/HLA=11648) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172492 CVCL_DW38 ND03978 transformed cell line human CVCL_DW38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172493 CVCL_E838 SWEIG007 transformed cell line human CVCL_E838 HLA typing: A*29:02:01:01; B*40:02:01:01; C*02:02:02:01; DPA1*01:03; DPB1*04:02:01; DQA1*05:05; DQB1*03:01:01; DRB1*11:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=11414) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172494 CVCL_DW35 ND03919 transformed cell line human CVCL_DW35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172495 CVCL_E835 SPO010 transformed cell line human CVCL_E835 HLA typing: A*02:01:01:01; B*44:02:01:01; C*05:01:01:02; DPA1*01; DPB1*02:01:02/02:01:19; DQA1*01:02:02; DQB1*05:02:01; DRA*01:01; DRB1*11:01:01; DRB3*02:02 (IPD-IMGT/HLA=11398) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172496 CVCL_DW36 ND03920 transformed cell line human CVCL_DW36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172497 CVCL_E836 SSTO transformed cell line human CVCL_E836 HLA typing: A*32:01:01:01; B*44:02:01:01; C*05:01:01:02; DPA1*01:03; DPB1*04:01:01; DQA1*03:01:01; DQB1*03:05:01; DRB1*04:03:01 (IPD-IMGT/HLA=11403); HLA typing: A*32:01:01; B*44:02:01:01; C*05:01:01:02; DPA1*01:03:01:04; DPB1*04:01:01:01; DQA1*03:01:01; DQB1*03:05:01; DRB1*04:03:01; DRB4*01:03:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172498 CVCL_DW39 ND03979 transformed cell line human CVCL_DW39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172499 CVCL_E839 T5-1 transformed cell line human CVCL_E839 HLA typing: A*02:01:01:01; B*08,27; DPA1*01:03:01 (IPD-IMGT/HLA=11419) CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172500 CVCL_DW30 ND03791 transformed cell line human CVCL_DW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172501 CVCL_E830 SM [Human B-cell] transformed cell line human CVCL_E830 HLA typing: A*02:01:01:01,26:03:01; B*39:01:01:03,51:01:01; C*07:02:01:01,03:04:01:02; DPA1*02:02:02; DPB1*05:01:01; DQA1*01:03:01:01,03:01:01; DQB1*03:02:01,06:01:01; DRB1*04:07:01,08:03:02; DRB4*01:03:01 (IPD-IMGT/HLA=11350) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172502 CVCL_DW33 ND03869 transformed cell line human CVCL_DW33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172503 CVCL_E833 SPACH transformed cell line human CVCL_E833 HLA typing: A*31:01:02:01; B*15:01:01:01; C*01:02:30; DPA1*01:03:01:15; DPB1*04:02:01:02; DQA1*04:01:01:07; DQB1*04:02:01:04; DRA*01:02:02; DRB1*08:02:01:01 (IPD-IMGT/HLA=11396) CL:0000010 Population: Native South American; Warao; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172504 CVCL_DW34 ND03918 transformed cell line human CVCL_DW34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172505 CVCL_E834 SPE,G transformed cell line human CVCL_E834 HLA typing: A*11:01:01,30:02; B*18:01:01,35:01:01; C*04,05; DPB1*02:02,04:01; DQA1*01:01,05:01; DQB1*05:01:01,02:01; DRB1*01:01:01,03:01; DRB3*02:02 (IPD-IMGT/HLA=11679) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172506 CVCL_DW31 ND03858 transformed cell line human CVCL_DW31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172507 CVCL_E831 SNA-BLL transformed cell line human CVCL_E831 HLA typing: A*03:01,68:02; B*78:01,07:02; C*16:01,07:02; DPB1*04:01 (IPD-IMGT/HLA=11394) CL:0000010 Population: Moroccan; Berber; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172508 CVCL_DW32 ND03868 transformed cell line human CVCL_DW32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172509 CVCL_E832 SOL,CA transformed cell line human CVCL_E832 HLA typing: A*11,33; B*50:01,55; C*03:03; DPB1*02:02,03:01; DQA1*05:01,02:01; DQB1*02:01; DRB1*03:01,07:01; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11695) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172510 CVCL_DW04 ND03405 transformed cell line human CVCL_DW04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172511 CVCL_E804 PF04015 transformed cell line human CVCL_E804 HLA typing: A*01:01:01:01; B*08:01:01:01; C*07:01:01:01; DPA1*01,02:01; DPB1*01:01:01,04:01:01; DQA1*05:01:01; DQB1*02:01:01; DRA*01:02; DRB1*03:01:01; DRB3*01:01 (IPD-IMGT/HLA=11645) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172512 CVCL_DW05 ND03407 transformed cell line human CVCL_DW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172513 CVCL_E805 PF97387 transformed cell line human CVCL_E805 HLA typing: A*29:02:01:01; B*44:03:01:01; C*16:01:01:01; DPA1*01:03; DPB1*04:01:01,04:02:01; DQA1*03; DQB1*03:01:01; DRB1*04:01:01 (IPD-IMGT/HLA=11644) CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172514 CVCL_DW02 ND03354 transformed cell line human CVCL_DW02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172515 CVCL_E802 PE117 transformed cell line human CVCL_E802 HLA typing: A*24:02:01:01,24:02:01:14; B*40:01:02:01,40:02:01:01; C*03:04:01:01,03:04:01:02; DPA1*01; DPB1*04:01:01; DQA1*03:01; DQB1*03:02:01; DRA*01:01; DRB1*04:04:01; DRB4*01:01 (IPD-IMGT/HLA=11643) CL:0000010 Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172516 CVCL_DW03 ND03360 transformed cell line human CVCL_DW03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172517 CVCL_E803 PETCH transformed cell line human CVCL_E803 HLA typing: A*24; B*18:02,15:13; C*07:04,08 (IPD-IMGT/HLA=11246) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172518 CVCL_DW08 ND03448 transformed cell line human CVCL_DW08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172519 CVCL_E808 PIN,LJ transformed cell line human CVCL_E808 HLA typing: A*01:01:01; B*08:01,57:01:01; C*06:02; DPB1*04:01; DQA1*01:01,02:01; DQB1*05:01,03:03; DRB1*01:03,07; DRB4*01:01 (IPD-IMGT/HLA=11654) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172520 CVCL_DW09 ND03449 transformed cell line human CVCL_DW09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172521 CVCL_E809 PITOUT transformed cell line human CVCL_E809 HLA typing: A*29:02:01:01; B*44:03:01:01; C*16:01:01:01; DPA1*01; DPB1*04:01:01; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11255) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172522 CVCL_DW06 ND03408 transformed cell line human CVCL_DW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172523 CVCL_E806 PGF transformed cell line human CVCL_E806 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01:03:01:02; DPB1*04:01:01; DQA1*01:02:01:05; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01; DRB6*02:01 (IPD-IMGT/HLA=11248); HLA typing: A*03:01:01:01; B*07:02:01; C*07:02:01:03; DPA1*01:03:01:02; DPB1*04:01:01:01; DQA1*01:02:01; DQB1*06:02:01; DRB1*15:01:01; DRB5*01:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172524 CVCL_DW07 ND03427 transformed cell line human CVCL_DW07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172525 CVCL_E807 PIL transformed cell line human CVCL_E807 HLA typing: A*03; B*07; C*w07 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21172526 CVCL_DW00 ND03318 transformed cell line human CVCL_DW00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172527 CVCL_E800 PA transformed cell line human CVCL_E800 HLA typing: A*68:02,26:01; B*38,14; C*08,12:03; DPB1*04:01,04:02 (IPD-IMGT/HLA=11226) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172528 CVCL_DW01 ND03353 transformed cell line human CVCL_DW01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172529 CVCL_E801 PAR transformed cell line human CVCL_E801 HLA typing: A*11:01:01,24:02; B*27:06,48:01; C*03:04:01,08:01; DPA1*02:02:02; DPB1*05:01,31:01; DQA1*01,05:01; DQB1*03:01,05:01:01; DRB1*11:01:01,15:02:01; DRB3*02:02:01 (IPD-IMGT/HLA=11231) CL:0000010 Population: Indonesian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172530 CVCL_DW15 ND03491 transformed cell line human CVCL_DW15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172531 CVCL_E815 RD-DJ transformed cell line human CVCL_E815 HLA typing: A*24:02:01:01,32:01:01; B*41:02:01,51:01:01; C*16:02:01,17:03; DPA1*01:03:01:04,02:02:01; DPB1*04:01:01:01,19:01; DQA1*01:02:01:07,01:03:01:02; DQB1*06:03:01,06:09:01; DRB1*13:01:01,13:36; DRB3*02:02:01:02,03:01:01 (IPD-IMGT/HLA=12446) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21172532 CVCL_DW16 ND03508 transformed cell line human CVCL_DW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172533 CVCL_E816 REE,GD transformed cell line human CVCL_E816 HLA typing: A*01,24; B*08; DPB1*01:01:01,02:01:02; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*01:01 (IPD-IMGT/HLA=11675) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172534 CVCL_DW13 ND03469 transformed cell line human CVCL_DW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172535 CVCL_E813 Priess transformed cell line human CVCL_E813 HLA typing: A*02; B*62; C*03; DPA1*01:03:01; DPB1*03:01:01,04:01:01; DQA1*03; DQB1*03:02:01; DRB1*04:01:01; DRB4*01:01:01 (IPD-IMGT/HLA=11277) CL:0000010 Population: Caucasian; Danish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172536 CVCL_DW14 ND03473 transformed cell line human CVCL_DW14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172537 CVCL_E814 QBL transformed cell line human CVCL_E814 HLA typing: A*26:01:01:01; B*18:01:01:01; C*05:01:01:01; DPA1*01:03; DPB1*02:02; DQA1*05:01:01; DQB1*02:01:01; DRA*01:01; DRB1*03:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=11282); HLA typing: A*26:01:01:01; B*18:01:01:01; C*05:01:01:01; DPA1*01:03:01:01; DPB1*02:02; DQA1*05:01:01:01; DQB1*02:01:01; DRB1*03:01:01; DRB3*02:02:01:01 (PubMed=30844424) CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172538 CVCL_DW19 ND03548 transformed cell line human CVCL_DW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172539 CVCL_E819 ROF-NL transformed cell line human CVCL_E819 HLA typing: A*03,32; B*07,55; C*03,07; DQA1*01:02:01; DQB1*06:02; DRB1*15:01:01; DRB5*01:01:01 (IPD-IMGT/HLA=11331) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172540 CVCL_DW17 ND03509 transformed cell line human CVCL_DW17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172541 CVCL_E817 RLO transformed cell line human CVCL_E817 HLA typing: A*03,26; B*38,41 (9IHW) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 9th International Histocompatibility Workshop (9IHW) cell line panel 21172542 CVCL_DW18 ND03511 transformed cell line human CVCL_DW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172543 CVCL_E818 RML transformed cell line human CVCL_E818 HLA typing: A*02:04; B*51:01:01:01; C*15:02:01:01; DPA1*01:03; DPB1*04:02:01; DQA1*05:05; DQB1*03:01:01; DRA*01:01; DRB1*16:02:01; DRB5*02:02; DRB6*02:02 (IPD-IMGT/HLA=11316) CL:0000010 Population: Native South American; Warao; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172544 CVCL_DW11 ND03451 transformed cell line human CVCL_DW11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172545 CVCL_E811 PMG075 transformed cell line human CVCL_E811 HLA typing: A*03:01:01:01,33:01:01:01; B*14:02:01:01; C*08:02:01:01; DPA1*01,02:01; DPB1*104:01,04:01:01; DQA1*01:01:02; DQB1*05:01:01; DRA*01:01; DRB1*01:02:01; DRB6*01:01 (IPD-IMGT/HLA=11646) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172546 CVCL_DW12 ND03468 transformed cell line human CVCL_DW12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172547 CVCL_E812 PMH161 transformed cell line human CVCL_E812 HLA typing: A*24,26; B*54,61; C*01,10; DQA1*03:01,05:01; DQB1*04:01,03:01; DRB1*04:05,11:06; DRB3*02:02; DRB4*01:01 (IPD-IMGT/HLA=11261) CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172548 CVCL_DW10 ND03450 transformed cell line human CVCL_DW10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172549 CVCL_E810 PLH transformed cell line human CVCL_E810 HLA typing: A*03:01:01:01,03:01:01:05; B*47:01:01:03; C*06:02:01:01; DPA1*01:03:01; DPB1*15:01:01; DQA1*02:01; DQB1*02:02:01; DRA*01:01; DRB1*07:01:01; DRB4*01:01 (IPD-IMGT/HLA=11258) CL:0000010 Population: Caucasian; Scandinavian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: HLA class II peptidome analysis by proteomics; Omics: MHC region genome Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172550 CVCL_N280 100-310 hybridoma house mouse CVCL_N280 CL:0000010 Monoclonal antibody isotype: IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11028 21172551 CVCL_MQ80 BayGenomics ES cell line RRD042 embryonic stem cell house mouse CVCL_MQ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926950; Zfp236 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172552 CVCL_VK19 CY197 hybrid cell line CVCL_VK19 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172553 CVCL_VK20 CY110 hybrid cell line CVCL_VK20 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172554 CVCL_VK21 CY116 hybrid cell line CVCL_VK21 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172555 CVCL_MQ78 BayGenomics ES cell line RRD037 embryonic stem cell house mouse CVCL_MQ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172556 CVCL_N278 IK-15 hybrid cell line CVCL_N278 CL:0000010 Discontinued: ATCC; CRL-7930; true. Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172557 CVCL_MQ79 BayGenomics ES cell line RRD038 embryonic stem cell house mouse CVCL_MQ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352757; Iqgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172558 CVCL_N279 TE 415.T cancer cell line human CVCL_N279 CL:0000010 Discontinued: ATCC; CRL-7764; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172559 CVCL_MQ76 BayGenomics ES cell line RRD035 embryonic stem cell house mouse CVCL_MQ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196294; Fubp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172560 CVCL_VK24 CY122 hybrid cell line CVCL_VK24 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172561 CVCL_N276 Ly91 cancer cell line human CVCL_N276 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=6441706; PubMed=6806672) Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21172562 CVCL_MQ77 BayGenomics ES cell line RRD036 embryonic stem cell house mouse CVCL_MQ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196294; Fubp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172563 CVCL_VK25 CY127 hybrid cell line CVCL_VK25 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172564 CVCL_N277 Hs 246.T cancer cell line human CVCL_N277 CL:0000010 Discontinued: ATCC; CRL-7209; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21172565 CVCL_MQ74 BayGenomics ES cell line RRD033 embryonic stem cell house mouse CVCL_MQ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172566 CVCL_VK22 CY117 hybrid cell line CVCL_VK22 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172567 CVCL_N274 Ly66 cancer cell line human CVCL_N274 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=3458667; PubMed=6441706; PubMed=6806672) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Male 21172568 CVCL_MQ75 BayGenomics ES cell line RRD034 embryonic stem cell house mouse CVCL_MQ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172569 CVCL_VK23 CY121 hybrid cell line CVCL_VK23 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172570 CVCL_N275 Ly67 cancer cell line human CVCL_N275 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672); Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Ser77Pro (c.229T>C); Zygosity=Unspecified (PubMed=8108117) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21172571 CVCL_MQ72 BayGenomics ES cell line RRD029 embryonic stem cell house mouse CVCL_MQ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444098; Heatr5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172572 CVCL_VK28 CY152 hybrid cell line CVCL_VK28 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172573 CVCL_N272 NUH2 hybridoma house mouse CVCL_N272 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Disialogangliosides with binary 2-3 sialosyllactosamine structure. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9762 21172574 CVCL_MQ73 BayGenomics ES cell line RRD031 embryonic stem cell house mouse CVCL_MQ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145118; Eif2b2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172575 CVCL_VK29 CY155 hybrid cell line CVCL_VK29 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172576 CVCL_N273 Ly47 cancer cell line human CVCL_N273 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=6806672) Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Part of: Human variation panel 21172577 CVCL_MQ70 BayGenomics ES cell line RRD017 embryonic stem cell house mouse CVCL_MQ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202722; Gtf2i Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172578 CVCL_VK26 CY138 hybrid cell line CVCL_VK26 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172579 CVCL_N270 GM16807 transformed cell line human CVCL_N270 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172580 CVCL_MQ71 BayGenomics ES cell line RRD027 embryonic stem cell house mouse CVCL_MQ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929261; Mtch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172581 CVCL_N271 BL-9 cancer cell line human CVCL_N271 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Ile (c.218C>T); ClinVar=VCV000376300; Zygosity=Unspecified (PubMed=8108117) Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21172582 CVCL_VK27 CY148 hybrid cell line CVCL_VK27 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172583 CVCL_MQ90 BayGenomics ES cell line RRD065 embryonic stem cell house mouse CVCL_MQ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929608; Aatf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172584 CVCL_N290 LA-4 [Mouse hybridoma against lipid A] hybridoma house mouse CVCL_N290 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:47040; Lipid A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8480 21172585 CVCL_MQ91 BayGenomics ES cell line RRD069 embryonic stem cell house mouse CVCL_MQ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172586 CVCL_N291 LA-5 hybridoma house mouse CVCL_N291 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:47040; Lipid A. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8479 21172587 CVCL_VK08 NCI-H226b cancer cell line human CVCL_VK08 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Pleural effusion. Male 21172588 CVCL_VK09 C055 cancer cell line human CVCL_VK09 CL:0000010 Derived from metastatic site: Not specified. Omics: Transcriptome analysis by RNAseq Unspecified 21172589 CVCL_VK10 VACO 8-2 cancer cell line human CVCL_VK10 CL:0000010 Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Asp522Asn (c.1564G>A); ClinVar=VCV000213936; Zygosity=Homozygous (PubMed=9927040); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leu (c.569C>T); ClinVar=VCV000418517; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Cecum. Male Microsatellite instability: Stable (MSS) (PubMed=9927040) 21172590 CVCL_MQ89 BayGenomics ES cell line RRD060 embryonic stem cell house mouse CVCL_MQ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916334; Fam207a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172591 CVCL_N289 C-2 hybridoma house mouse CVCL_N289 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8478 21172592 CVCL_N287 452F2 hybridoma house mouse CVCL_N287 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10811; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10082 21172593 CVCL_MQ87 BayGenomics ES cell line RRD058 embryonic stem cell house mouse CVCL_MQ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172594 CVCL_VK13 CY130 hybrid cell line CVCL_VK13 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172595 CVCL_N288 AT4ABR transformed cell line human CVCL_N288 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21172596 CVCL_MQ88 BayGenomics ES cell line RRD059 embryonic stem cell house mouse CVCL_MQ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309489; Cask Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172597 CVCL_VK14 CY135 hybrid cell line CVCL_VK14 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172598 CVCL_VK11 587X cancer cell line human CVCL_VK11 CL:0000010 Sequence variation: Mutation; HGNC; 9175; POLD1; Simple; p.Asp502Asn (c.1504G>A); ClinVar=VCV000414774; Zygosity=Heterozygous; Note=Not somatic (PubMed=7704014). Unspecified 21172599 CVCL_N285 A3026 hybridoma house mouse CVCL_N285 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9348 21172600 CVCL_MQ85 BayGenomics ES cell line RRD052 embryonic stem cell house mouse CVCL_MQ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172601 CVCL_N286 741F8 hybridoma house mouse CVCL_N286 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10807; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10078 21172602 CVCL_MQ86 BayGenomics ES cell line RRD057 embryonic stem cell house mouse CVCL_MQ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861733; Pcnx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172603 CVCL_VK12 Ins-1 cancer cell line human CVCL_VK12 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Male 21172604 CVCL_N283 A2106 hybridoma house mouse CVCL_N283 CL:0000010 Monoclonal antibody isotype: IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9350 21172605 CVCL_MQ83 BayGenomics ES cell line RRD048 embryonic stem cell house mouse CVCL_MQ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172606 CVCL_VK17 CY182 hybrid cell line CVCL_VK17 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172607 CVCL_N284 A2215 hybridoma house mouse CVCL_N284 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9349 21172608 CVCL_MQ84 BayGenomics ES cell line RRD051 embryonic stem cell house mouse CVCL_MQ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172609 CVCL_VK18 CY196 hybrid cell line CVCL_VK18 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172610 CVCL_N281 A1923 hybridoma house mouse CVCL_N281 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9352 21172611 CVCL_MQ81 BayGenomics ES cell line RRD043 embryonic stem cell house mouse CVCL_MQ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919204; Suds3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172612 CVCL_VK15 CY175 hybrid cell line CVCL_VK15 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172613 CVCL_N282 A1993 hybridoma house mouse CVCL_N282 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9351 21172614 CVCL_MQ82 BayGenomics ES cell line RRD046 embryonic stem cell house mouse CVCL_MQ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104729; Akap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172615 CVCL_VK16 CY180 hybrid cell line CVCL_VK16 CL:0000010 Characteristics: Hybrid for chromosome 16 mapping. Group: Human/rodent somatic cell hybrid 21172616 CVCL_MQ58 BayGenomics ES cell line RRC297 embryonic stem cell house mouse CVCL_MQ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172617 CVCL_N258 GM16200 transformed cell line human CVCL_N258 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172618 CVCL_MQ59 BayGenomics ES cell line RRC298 embryonic stem cell house mouse CVCL_MQ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349406; Ddx3y Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172619 CVCL_N259 GM16202 transformed cell line human CVCL_N259 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172620 CVCL_MQ56 BayGenomics ES cell line RRC295 embryonic stem cell house mouse CVCL_MQ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172621 CVCL_N256 GM16004 transformed cell line human CVCL_N256 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172622 CVCL_MQ57 BayGenomics ES cell line RRC296 embryonic stem cell house mouse CVCL_MQ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385066; Rprd1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172623 CVCL_N257 GM16198 transformed cell line human CVCL_N257 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172624 CVCL_MQ54 BayGenomics ES cell line RRC290 embryonic stem cell house mouse CVCL_MQ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88529; Cs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172625 CVCL_N254 GM15891 transformed cell line human CVCL_N254 CL:0000010 Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172626 CVCL_VK02 UT62a cancer cell line human CVCL_VK02 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Male 21172627 CVCL_MQ55 BayGenomics ES cell line RRC291 embryonic stem cell house mouse CVCL_MQ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443298; Tet2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172628 CVCL_N255 GM15892 transformed cell line human CVCL_N255 CL:0000010 Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172629 CVCL_VK03 UTE3 cancer cell line human CVCL_VK03 CL:0000010 Female 21172630 CVCL_MQ52 BayGenomics ES cell line RRC284 embryonic stem cell house mouse CVCL_MQ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172631 CVCL_N252 GM15889 transformed cell line human CVCL_N252 CL:0000010 Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172632 CVCL_VK00 UT48 cancer cell line human CVCL_VK00 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Male 21172633 CVCL_MQ53 BayGenomics ES cell line RRC285 embryonic stem cell house mouse CVCL_MQ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172634 CVCL_N253 GM15890 transformed cell line human CVCL_N253 CL:0000010 Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172635 CVCL_VK01 UT56 cancer cell line human CVCL_VK01 CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Male 21172636 CVCL_MQ50 BayGenomics ES cell line RRC281 embryonic stem cell house mouse CVCL_MQ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919318; Cnot2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172637 CVCL_N250 GM15869 finite cell line human CVCL_N250 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21172638 CVCL_VK06 VACC1430 cancer cell line human CVCL_VK06 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714). 21172639 CVCL_MQ51 BayGenomics ES cell line RRC282 embryonic stem cell house mouse CVCL_MQ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915308; Chd1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172640 CVCL_N251 GM15888 transformed cell line human CVCL_N251 CL:0000010 Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172641 CVCL_VK07 NCI-H358a cancer cell line human CVCL_VK07 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung Cell type=Club cell.. Male 21172642 CVCL_VK04 UTE4 cancer cell line human CVCL_VK04 CL:0000010 Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Ala957Val; Zygosity=Unspecified (PubMed=27894751). Female Microsatellite instability: Stable (MSS) (PubMed=27894751) 21172643 CVCL_VK05 Co53 cancer cell line human CVCL_VK05 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (PubMed=12615714). 21172644 CVCL_MQ69 BayGenomics ES cell line RRD013 embryonic stem cell house mouse CVCL_MQ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859026; Cnot4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172645 CVCL_N269 GM16775 transformed cell line human CVCL_N269 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172646 CVCL_MQ67 BayGenomics ES cell line RRD008 embryonic stem cell house mouse CVCL_MQ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172647 CVCL_N267 GM16734 transformed cell line human CVCL_N267 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172648 CVCL_MQ68 BayGenomics ES cell line RRD009 embryonic stem cell house mouse CVCL_MQ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172649 CVCL_N268 GM16774 transformed cell line human CVCL_N268 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172650 CVCL_MQ65 BayGenomics ES cell line RRD006 embryonic stem cell house mouse CVCL_MQ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446210; Kdm4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172651 CVCL_N265 GM16406 transformed cell line human CVCL_N265 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172652 CVCL_MQ66 BayGenomics ES cell line RRD007 embryonic stem cell house mouse CVCL_MQ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172653 CVCL_N266 GM16732 transformed cell line human CVCL_N266 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172654 CVCL_MQ63 BayGenomics ES cell line RRD004 embryonic stem cell house mouse CVCL_MQ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918779; Kazn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172655 CVCL_N263 GM16269 transformed cell line human CVCL_N263 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172656 CVCL_MQ64 BayGenomics ES cell line RRD005 embryonic stem cell house mouse CVCL_MQ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933786; Dnaja3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172657 CVCL_N264 GM16400 transformed cell line human CVCL_N264 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172658 CVCL_MQ61 BayGenomics ES cell line RRD002 embryonic stem cell house mouse CVCL_MQ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929601; Ndfip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172659 CVCL_N261 GM16213 transformed cell line human CVCL_N261 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[420]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172660 CVCL_MQ62 BayGenomics ES cell line RRD003 embryonic stem cell house mouse CVCL_MQ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891925; Hnrnph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172661 CVCL_N262 GM16215 transformed cell line human CVCL_N262 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[830]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172662 CVCL_MQ60 BayGenomics ES cell line RRD001 embryonic stem cell house mouse CVCL_MQ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172663 CVCL_N260 GM16212 transformed cell line human CVCL_N260 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[500]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172664 CVCL_MQ38 BayGenomics ES cell line RRC235 embryonic stem cell house mouse CVCL_MQ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443472; Atf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172665 CVCL_N238 GM14923 transformed cell line human CVCL_N238 HLA typing: A*29:02,66:01; B*58:02,78:01; C*06:02,16:01; DRB1*13:01,13:01 (IPD-IMGT/HLA=23054) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172666 CVCL_MQ39 BayGenomics ES cell line RRC236 embryonic stem cell house mouse CVCL_MQ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104670; Fkbp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172667 CVCL_N239 GM14924 transformed cell line human CVCL_N239 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172668 CVCL_MQ36 BayGenomics ES cell line RRC230 embryonic stem cell house mouse CVCL_MQ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929507; Arl6ip6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172669 CVCL_N236 GM14905 transformed cell line human CVCL_N236 HLA typing: A*02:DFKP,23:DFKR; B*15:BKNX,51:CVAE; C*02:10,16:01; DRB1*07:01,13:03 (IPD-IMGT/HLA=16401) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172670 CVCL_MQ37 BayGenomics ES cell line RRC231 embryonic stem cell house mouse CVCL_MQ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919904; Ccdc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172671 CVCL_N237 GM14922 transformed cell line human CVCL_N237 HLA typing: A*23:DFKR,32:01; B*07:CZZS,39:10; C*07:WCP,12:03; DRB1*03:02,1:401 (IPD-IMGT/HLA=20686) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172672 CVCL_MQ34 BayGenomics ES cell line RRC228 embryonic stem cell house mouse CVCL_MQ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3704127; Zfp808 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172673 CVCL_N234 GM14903 transformed cell line human CVCL_N234 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172674 CVCL_MQ35 BayGenomics ES cell line RRC229 embryonic stem cell house mouse CVCL_MQ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153272; Trrap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172675 CVCL_N235 GM14904 transformed cell line human CVCL_N235 HLA typing: A*29:02,74:AB; B*14:01,53:01; C*04:CVAF,14:03 (IPD-IMGT/HLA=15813) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172676 CVCL_MQ32 BayGenomics ES cell line RRC225 embryonic stem cell house mouse CVCL_MQ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328310; Zc3h7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172677 CVCL_N232 GM14900 transformed cell line human CVCL_N232 HLA typing: A*02:05,29:02; B*27:03,57:03; C*02:02,15:05; DRB1*07:01,08:04 (IPD-IMGT/HLA=20680) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172678 CVCL_MQ33 BayGenomics ES cell line RRC227 embryonic stem cell house mouse CVCL_MQ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915943; Hnrnpul2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172679 CVCL_N233 GM14901 transformed cell line human CVCL_N233 HLA typing: A*02:DFKP,29:02; B*51:CVAE,58:02; C*02:02,06:02; DRB1*13:01,13:02 (IPD-IMGT/HLA=23053) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172680 CVCL_MQ30 BayGenomics ES cell line RRC222 embryonic stem cell house mouse CVCL_MQ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448530; Vps13d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172681 CVCL_N230 GM14895 transformed cell line human CVCL_N230 HLA typing: A*34:02,34:02; B*35:BEZX,44:03; C*04:CVAF,04:CVAF; DRB1*13:01,15:03 (IPD-IMGT/HLA=23051) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172682 CVCL_MQ31 BayGenomics ES cell line RRC224 embryonic stem cell house mouse CVCL_MQ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923215; Zdhhc20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172683 CVCL_N231 GM14897 transformed cell line human CVCL_N231 HLA typing: A*32:01,68:02; B*53:01,81:MN; C*04:CVAF,08:02; DRB1*10:01,12:CVT (IPD-IMGT/HLA=17382) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172684 CVCL_MQ49 BayGenomics ES cell line RRC278 embryonic stem cell house mouse CVCL_MQ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172685 CVCL_N249 GM15860 transformed cell line human CVCL_N249 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172686 CVCL_MQ47 BayGenomics ES cell line RRC272 embryonic stem cell house mouse CVCL_MQ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922874; Metap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172687 CVCL_N247 GM15186 transformed cell line human CVCL_N247 HLA typing: A*03:02,31:CGAJ; B*14:02,57:03; C*07:CVAG,08:02; DRB1*15:01,15:03 (IPD-IMGT/HLA=15810) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21172688 CVCL_MQ48 BayGenomics ES cell line RRC273 embryonic stem cell house mouse CVCL_MQ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172689 CVCL_N248 GM15851 transformed cell line human CVCL_N248 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[<30]; ClinVar=VCV000561195; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Human variation panel 21172690 CVCL_MQ45 BayGenomics ES cell line RRC266 embryonic stem cell house mouse CVCL_MQ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289321; Mrpl48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172691 CVCL_N245 GM14936 transformed cell line human CVCL_N245 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172692 CVCL_MQ46 BayGenomics ES cell line RRC269 embryonic stem cell house mouse CVCL_MQ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172693 CVCL_N246 GM14941 transformed cell line human CVCL_N246 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Human variation panel 21172694 CVCL_MQ43 BayGenomics ES cell line RRC256 embryonic stem cell house mouse CVCL_MQ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172695 CVCL_N243 GM14934 transformed cell line human CVCL_N243 HLA typing: A*23:DFKR,02:02; B*15:16,53:01; C*04:CVAF,14:02 (IPD-IMGT/HLA=15808) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172696 CVCL_MQ44 BayGenomics ES cell line RRC263 embryonic stem cell house mouse CVCL_MQ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921736; Osbpl10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172697 CVCL_N244 GM14935 transformed cell line human CVCL_N244 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172698 CVCL_MQ41 BayGenomics ES cell line RRC251 embryonic stem cell house mouse CVCL_MQ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914265; Ccdc91 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172699 CVCL_N241 GM14932 transformed cell line human CVCL_N241 HLA typing: A*30:02,31:CGAJ; B*57:03,78:01; C*08:02,16:01; DRB1*13:02,13:03 (IPD-IMGT/HLA=19229) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172700 CVCL_MQ42 BayGenomics ES cell line RRC252 embryonic stem cell house mouse CVCL_MQ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932915; Ndel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172701 CVCL_N242 GM14933 transformed cell line human CVCL_N242 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172702 CVCL_MQ40 BayGenomics ES cell line RRC239 embryonic stem cell house mouse CVCL_MQ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172703 CVCL_N240 GM14925 transformed cell line human CVCL_N240 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172704 CVCL_DW84 ND04669 transformed cell line human CVCL_DW84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172705 CVCL_E884 WT24 transformed cell line human CVCL_E884 HLA typing: A*02:01:01:01; B*27:05:02; C*02:02:02:01; DPA1*01; DPB1*03:01:01; DQB1*05:02:01; DRB1*16:01:01 (IPD-IMGT/HLA=11651) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172706 CVCL_DW85 ND04681 transformed cell line human CVCL_DW85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172707 CVCL_E885 WT46 transformed cell line human CVCL_E885 HLA typing: A*32:01; B*44:02; C*05:01; DPB1*16:01:01; DQA1*01:02:01:01; DQB1*06:04; DRB1*13:02:01:01; DRB3*03:01:01 (IPD-IMGT/HLA=11571) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172708 CVCL_DW82 ND04625 transformed cell line human CVCL_DW82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172709 CVCL_E882 WOO,EM transformed cell line human CVCL_E882 HLA typing: A*03,24; B*07,40; C*07:02,02:02:02; DPB1*04:01,05:01; DQA1*01:04,01:02; DQB1*05:03,06:02; DRB1*15:01,14:EK; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=11666) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172710 CVCL_DW83 ND04626 transformed cell line human CVCL_DW83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172711 CVCL_E883 WT100BIS transformed cell line human CVCL_E883 HLA typing: A*11:01:01:01; B*35:01:01:02; C*04:01:01:01; DPA1*02:01:01; DPB1*01:01:01; DQA1*01:01; DQB1*05:01:01; DRA*01:01; DRB1*01:01:01; DRB6*01:01 (IPD-IMGT/HLA=11652) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172712 CVCL_DW88 ND04703 transformed cell line human CVCL_DW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172713 CVCL_E888 WT52 transformed cell line human CVCL_E888 HLA typing: A*11; B*55; C*22; DPB1*04:01; DQB1*05:03:01:01; DRB1*14:01; DRB3*01:01 (IPD-IMGT/HLA=11575) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172714 CVCL_DW89 ND04704 transformed cell line human CVCL_DW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172715 CVCL_E889 WT8 transformed cell line human CVCL_E889 HLA typing: A*03:01:01:01; B*07:02:01:01; C*07:02:01:03; DPA1*01; DPB1*02:01:02/02:01:19,04:01:01; DQA1*01:02:01; DQB1*06:02:01; DRA*01:02; DRB1*15:01:01; DRB5*01:01; DRB6*02:01 (IPD-IMGT/HLA=11650) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172716 CVCL_DW86 ND04685 transformed cell line human CVCL_DW86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172717 CVCL_E886 WT47 transformed cell line human CVCL_E886 HLA typing: A*32:01:01:01; B*44:02:01:01; C*05:01:01:02; DPA1*01; DPB1*16:01:01; DQA1*01:02:01; DQB1*06:04:01; DRA*01:02; DRB1*13:02:01; DRB3*03:01 (IPD-IMGT/HLA=11572) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172718 CVCL_DW87 ND04702 transformed cell line human CVCL_DW87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172719 CVCL_E887 WT51 transformed cell line human CVCL_E887 HLA typing: A*23:01:01:01; B*14:01:01; C*08:02:01:02; DPA1*01:03; DPB1*02:01:02/02:01:19; DQA1*03:01; DQB1*03:02:01; DRA*01:01; DRB1*04:01:01; DRB4*01:01 (IPD-IMGT/HLA=11574) CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: MHC region genome Male Part of: 10th International Histocompatibility Workshop (10IHW) cell line panel 21172720 CVCL_MQ18 BayGenomics ES cell line RRC195 embryonic stem cell house mouse CVCL_MQ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277977; Ubr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172721 CVCL_N218 GM14641 transformed cell line human CVCL_N218 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Heterozygous; Note=Factor V Leiden (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172722 CVCL_MQ19 BayGenomics ES cell line RRC199 embryonic stem cell house mouse CVCL_MQ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889206; Skap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172723 CVCL_N219 GM14654 transformed cell line human CVCL_N219 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172724 CVCL_MQ16 BayGenomics ES cell line RRC185 embryonic stem cell house mouse CVCL_MQ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921772; Morc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172725 CVCL_N216 GM14313 transformed cell line human CVCL_N216 CL:0000010 Population: Mexican Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository; Part of: Human variation panel 21172726 CVCL_MQ17 BayGenomics ES cell line RRC194 embryonic stem cell house mouse CVCL_MQ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172727 CVCL_N217 GM14590 transformed cell line human CVCL_N217 CL:0000010 Population: Peruvian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172728 CVCL_MQ14 BayGenomics ES cell line RRC175 embryonic stem cell house mouse CVCL_MQ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172729 CVCL_N214 GM14310 transformed cell line human CVCL_N214 CL:0000010 Population: Mexican Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository; Part of: Human variation panel 21172730 CVCL_DW80 ND04623 transformed cell line human CVCL_DW80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172731 CVCL_E880 WON,M transformed cell line human CVCL_E880 HLA typing: A*24:02,34:01; B*15:25,56; C*04,07; DPA1*01:03:01,02:02:02; DPB1*16:01,22:01; DQA1*01:03; DQB1*06:01; DRB1*08:03 (IPD-IMGT/HLA=11569) CL:0000010 Population: Aboriginal Australian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172732 CVCL_MQ15 BayGenomics ES cell line RRC183 embryonic stem cell house mouse CVCL_MQ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97757; Prim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172733 CVCL_N215 GM14311 transformed cell line human CVCL_N215 CL:0000010 Population: Mexican Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository; Part of: Human variation panel 21172734 CVCL_DW81 ND04624 transformed cell line human CVCL_DW81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172735 CVCL_E881 WON,PY transformed cell line human CVCL_E881 HLA typing: A*33; B*58:01; C*03:02; DPB1*04:01; DQA1*05:01; DQB1*02:01; DRB1*03:01; DRB3*02:02 (IPD-IMGT/HLA=11699) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172736 CVCL_MQ12 BayGenomics ES cell line RRC165 embryonic stem cell house mouse CVCL_MQ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333875; Babam2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172737 CVCL_N212 GM14308 transformed cell line human CVCL_N212 CL:0000010 Population: Mexican Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository; Part of: Human variation panel 21172738 CVCL_MQ13 BayGenomics ES cell line RRC166 embryonic stem cell house mouse CVCL_MQ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172739 CVCL_N213 GM14309 transformed cell line human CVCL_N213 CL:0000010 Population: Mexican Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository; Part of: Human variation panel 21172740 CVCL_MQ10 BayGenomics ES cell line RRC163 embryonic stem cell house mouse CVCL_MQ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98388; Sptbn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172741 CVCL_N210 GM13787 transformed cell line human CVCL_N210 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172742 CVCL_MQ11 BayGenomics ES cell line RRC164 embryonic stem cell house mouse CVCL_MQ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100846; Med1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172743 CVCL_N211 GM13989 transformed cell line human CVCL_N211 CL:0000010 Population: Middle Eastern; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Human variation panel 21172744 CVCL_DW95 ND04732 transformed cell line human CVCL_DW95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172745 CVCL_E895 YMU transformed cell line human CVCL_E895 HLA typing: A*11:01:01; B*48,62; C*04; DRB1*04:07,15:01 (IPD-IMGT/HLA=11592) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172746 CVCL_DW96 ND04733 transformed cell line human CVCL_DW96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172747 CVCL_E896 ZM transformed cell line human CVCL_E896 HLA typing: A*69:01,24:02; B*44:03,49; C*04,06:02; DPB1*04:01,04:02 (IPD-IMGT/HLA=11609) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172748 CVCL_DW93 ND04722 transformed cell line human CVCL_DW93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172749 CVCL_E893 YEO,AM transformed cell line human CVCL_E893 HLA typing: A*03; B*44:02; DPB1*04:01; DQA1*01:02,03; DQB1*03:01,06:02; DRB1*15:01,04:01; DRB4*01:01; DRB5*01:01 (IPD-IMGT/HLA=11680) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172750 CVCL_DW94 ND04723 transformed cell line human CVCL_DW94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172751 CVCL_E894 YGY 016 transformed cell line human CVCL_E894 HLA typing: A*02,33; B*35,61; C*03:03,04; DPB1*02:01:02,05:01; DQA1*01:04,05:01; DQB1*03:01,05:03; DRB1*12:01,14:01; DRB3*01:01,02:02 (IPD-IMGT/HLA=11732) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 4th Asia-Oceania Histocompatibility Workshop (4AOHW) cell line panel 21172752 CVCL_E899 C611B cancer cell line Norway rat CVCL_E899 CL:0000010 Breed/subspecies: Fischer 344. Male Doubling time: ~24 hours (PubMed=10590229) 21172753 CVCL_DW99 ND04866 transformed cell line human CVCL_DW99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172754 CVCL_DW97 ND04790 transformed cell line human CVCL_DW97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172755 CVCL_E897 ZM-FC transformed cell line human CVCL_E897 HLA typing: A*02; B*51; C*02:02; DPA1*01:03:01; DPB1*02:01:02,04:02; DQA1*03,05:01; DQB1*03:04,03:01; DRB1*04:03,11 (IPD-IMGT/HLA=11610) CL:0000010 Population: Caucasian; Sardinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172756 CVCL_E898 Li-10 finite cell line Norway rat CVCL_E898 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Sprague Dawley. Male 21172757 CVCL_DW98 ND04791 transformed cell line human CVCL_DW98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172758 CVCL_MQ29 BayGenomics ES cell line RRC221 embryonic stem cell house mouse CVCL_MQ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172759 CVCL_N229 GM14894 transformed cell line human CVCL_N229 HLA typing: A*68:02,74:AB; B*35:BEZX,44:03; C*04:CVAF; DRB1*09:01,13:02 (IPD-IMGT/HLA=15816) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172760 CVCL_MQ27 BayGenomics ES cell line RRC216 embryonic stem cell house mouse CVCL_MQ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172761 CVCL_N227 GM14892 transformed cell line human CVCL_N227 HLA typing: A*24:CWFP,30:02; B*07:CZZS,08:XKT; C*07:CVAG,07:WCP; DRB1*03:01,13:01 (IPD-IMGT/HLA=17388) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172762 CVCL_MQ28 BayGenomics ES cell line RRC218 embryonic stem cell house mouse CVCL_MQ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172763 CVCL_N228 GM14893 transformed cell line human CVCL_N228 HLA typing: A*30:02,33:BEKE; B*42:01,58:VE; C*03:02,04:CVAF; DRB1*03:01,04:02 (IPD-IMGT/HLA=20691) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21172764 CVCL_MQ25 BayGenomics ES cell line RRC212 embryonic stem cell house mouse CVCL_MQ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172765 CVCL_N225 GM14693 transformed cell line human CVCL_N225 HLA typing: A*01:01:01,24:03:01; B*44:03:01,57:01:01; C*04:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:01,05:05:01; DQB1*03:01:01,05:01:01; DRB1*01:01:01,13:05:01; DRB3*02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21172766 CVCL_DW91 ND04706 transformed cell line human CVCL_DW91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172767 CVCL_E891 XLI-ND transformed cell line human CVCL_E891 HLA typing: A*02:10,30:01; B*13:02,40:06:01:01; C*06:02,08:01; DPA1*02:01,02:02; DPB1*17:01,19:01; DQB1*02,03:03; DRB1*07:01:01,09:01:02; DRB4*01:03:01:01,01:03:02 (IPD-IMGT/HLA=11580) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172768 CVCL_MQ26 BayGenomics ES cell line RRC213 embryonic stem cell house mouse CVCL_MQ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172769 CVCL_N226 GM14694 transformed cell line human CVCL_N226 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21172770 CVCL_DW92 ND04707 transformed cell line human CVCL_DW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172771 CVCL_E892 Y.I. transformed cell line human CVCL_E892 HLA typing: A*24:02,26:02; B*40:02,52:01; C*03:03,12:02; DPB1*02:01,05:01; DQB1*03:03,05:03:01; DRB1*09:01,14:05 (IPD-IMGT/HLA=11583) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 12th International Histocompatibility Workshop (12IHW) cell line panel 21172772 CVCL_MQ23 BayGenomics ES cell line RRC205 embryonic stem cell house mouse CVCL_MQ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172773 CVCL_N223 GM14676 transformed cell line human CVCL_N223 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172774 CVCL_MQ24 BayGenomics ES cell line RRC209 embryonic stem cell house mouse CVCL_MQ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172775 CVCL_N224 GM14690 transformed cell line human CVCL_N224 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172776 CVCL_DW90 ND04705 transformed cell line human CVCL_DW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172777 CVCL_E890 WUZH1 transformed cell line human CVCL_E890 HLA typing: A*02:53N,11:01:01; B*37:01,58:01; C*03:02,06:02; DPB1*02:01:02,04:01:01; DQB1*02:01,05:01:01; DRB1*03:01:01,10:01:01; DRB3*02:02:01 (IPD-IMGT/HLA=26054) CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21172778 CVCL_MQ21 BayGenomics ES cell line RRC201 embryonic stem cell house mouse CVCL_MQ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172779 CVCL_N221 GM14671 transformed cell line human CVCL_N221 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21172780 CVCL_MQ22 BayGenomics ES cell line RRC203 embryonic stem cell house mouse CVCL_MQ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913762; Dera Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172781 CVCL_N222 GM14673 transformed cell line human CVCL_N222 HLA typing: A*24:02:01,25:01:01; B*08:01:01,18:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,02:01:02; DPB1*01:01:01,04:01:01; DQA1*01:03:01,05:01:01; DQB1*02:01:01,06:03:01; DRB1*03:01:01,13:01:01; DRB3*01:01:02,01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21172782 CVCL_MQ20 BayGenomics ES cell line RRC200 embryonic stem cell house mouse CVCL_MQ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384768; Hectd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172783 CVCL_N220 GM14655 transformed cell line human CVCL_N220 HLA typing: A*03:01:01,03:01:01; B*07:02:01,53:01:01; C*04:01:01,07:02:01; DPA1*01:03:01,02:01:01; DPB1*04:01:01,17:01:01; DQA1*02:01:01,03:01:01; DQB1*02:02:01,03:02:01; DRB1*04:04:01,07:01:01; DRB4*01:01:01,01:03:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Trp152Glyfs*2 (c.454delT) (1707delT) (1795delT); ClinVar=VCV000016891; Zygosity=Heterozygous; Note=CYP2D6*6 allele (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21172784 CVCL_3F73 HQ00582 transformed cell line human CVCL_3F73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172785 CVCL_3F74 HQ00583 transformed cell line human CVCL_3F74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172786 CVCL_3F71 HQ00580 transformed cell line human CVCL_3F71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172787 CVCL_3F72 HQ00581 transformed cell line human CVCL_3F72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172788 CVCL_3F77 HQ00586 transformed cell line human CVCL_3F77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172789 CVCL_3F78 HQ00587 transformed cell line human CVCL_3F78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172790 CVCL_3F75 HQ00584 transformed cell line human CVCL_3F75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172791 CVCL_3F76 HQ00585 transformed cell line human CVCL_3F76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172792 CVCL_3F79 HQ00588 transformed cell line human CVCL_3F79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172793 CVCL_3F70 HQ00579 transformed cell line human CVCL_3F70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172794 CVCL_3F84 HQ00593 transformed cell line human CVCL_3F84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172795 CVCL_3F85 HQ00594 transformed cell line human CVCL_3F85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172796 CVCL_3F82 HQ00591 transformed cell line human CVCL_3F82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172797 CVCL_3F83 HQ00592 transformed cell line human CVCL_3F83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172798 CVCL_3F88 HQ00597 transformed cell line human CVCL_3F88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172799 CVCL_3F89 HQ00598 transformed cell line human CVCL_3F89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172800 CVCL_3F86 HQ00595 transformed cell line human CVCL_3F86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172801 CVCL_3F87 HQ00596 transformed cell line human CVCL_3F87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172802 CVCL_3F80 HQ00589 transformed cell line human CVCL_3F80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172803 CVCL_3F81 HQ00590 transformed cell line human CVCL_3F81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172804 CVCL_3F51 HQ00560 transformed cell line human CVCL_3F51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172805 CVCL_3F52 HQ00561 transformed cell line human CVCL_3F52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172806 CVCL_3F50 HQ00559 transformed cell line human CVCL_3F50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172807 CVCL_3F55 HQ00564 transformed cell line human CVCL_3F55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172808 CVCL_3F56 HQ00565 transformed cell line human CVCL_3F56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172809 CVCL_3F53 HQ00562 transformed cell line human CVCL_3F53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172810 CVCL_3F54 HQ00563 transformed cell line human CVCL_3F54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172811 CVCL_3F59 HQ00568 transformed cell line human CVCL_3F59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172812 CVCL_3F57 HQ00566 transformed cell line human CVCL_3F57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172813 CVCL_3F58 HQ00567 transformed cell line human CVCL_3F58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172814 CVCL_3F62 HQ00571 transformed cell line human CVCL_3F62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172815 CVCL_3F63 HQ00572 transformed cell line human CVCL_3F63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172816 CVCL_3F60 HQ00569 transformed cell line human CVCL_3F60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172817 CVCL_3F61 HQ00570 transformed cell line human CVCL_3F61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172818 CVCL_3F66 HQ00575 transformed cell line human CVCL_3F66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172819 CVCL_3F67 HQ00576 transformed cell line human CVCL_3F67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172820 CVCL_3F64 HQ00573 transformed cell line human CVCL_3F64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172821 CVCL_3F65 HQ00574 transformed cell line human CVCL_3F65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172822 CVCL_3F68 HQ00577 transformed cell line human CVCL_3F68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172823 CVCL_3F69 HQ00578 transformed cell line human CVCL_3F69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172824 CVCL_VL92 WR001 finite cell line human CVCL_VL92 From: Nissley P.; National Cancer Institute; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172825 CVCL_VL93 AL639 finite cell line human CVCL_VL93 CL:0000010 Donor information: Established from a patient suffering from acute monomyelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21172826 CVCL_VL90 AL2673 finite cell line human CVCL_VL90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172827 CVCL_VL91 AL1899 finite cell line human CVCL_VL91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172828 CVCL_VL96 UM-MCC9 cancer cell line human CVCL_VL96 CL:0000010 Male 21172829 CVCL_VL97 UM-MCC13 cancer cell line human CVCL_VL97 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Leg. Omics: Transcriptome analysis by microarray Female 21172830 CVCL_VL94 GM02686 finite cell line human CVCL_VL94 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02686; probable 21172831 CVCL_VL95 CVG-1 cancer cell line human CVCL_VL95 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Cervical lymph node. Female Virology: Contains ~3.6 copies of the genome of MCPyV per haploid cell (PubMed=29696010) 21172832 CVCL_VL98 UM-MCC623 cancer cell line human CVCL_VL98 CL:0000010 Male Characteristics: Established from a mouse tumor xenograft in NOD/SCID/IL2RgammaNULL mice Doubling time: 34 hours (PubMed=24614157). 21172833 CVCL_VL99 UM-MCC624 cancer cell line human CVCL_VL99 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Characteristics: Established from a mouse tumor xenograft in NOD/SCID/IL2RgammaNULL mice Doubling time: 32 hours (PubMed=24614157) 21172834 CVCL_3F30 HQ00538 transformed cell line human CVCL_3F30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172835 CVCL_3F33 HQ00541 transformed cell line human CVCL_3F33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172836 CVCL_3F34 HQ00542 transformed cell line human CVCL_3F34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172837 CVCL_3F31 HQ00539 transformed cell line human CVCL_3F31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172838 CVCL_3F32 HQ00540 transformed cell line human CVCL_3F32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172839 CVCL_3F37 HQ00545 transformed cell line human CVCL_3F37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172840 CVCL_3F38 HQ00546 transformed cell line human CVCL_3F38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172841 CVCL_3F35 HQ00543 transformed cell line human CVCL_3F35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172842 CVCL_3F36 HQ00544 transformed cell line human CVCL_3F36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172843 CVCL_3F39 HQ00548 transformed cell line human CVCL_3F39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172844 CVCL_VL81 HuT11-5 cancer cell line human CVCL_VL81 CL:0000010 Derived from sampling site: Lymph node. Female 21172845 CVCL_VL82 HuT11-6 cancer cell line human CVCL_VL82 CL:0000010 Derived from sampling site: Lymph node. Female Doubling time: 13.6 +- 0.8 hours (PubMed=209894) 21172846 CVCL_VL80 HuT11-2 cancer cell line human CVCL_VL80 CL:0000010 Derived from sampling site: Lymph node. Female Doubling time: 12.1 +- 1.7 hours (PubMed=209894) 21172847 CVCL_VL85 AL2322 finite cell line human CVCL_VL85 CL:0000010 Donor information: Established from a patient suffering from acute lymphocytic leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172848 CVCL_VL86 AL2642 finite cell line human CVCL_VL86 CL:0000010 Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172849 CVCL_VL83 CEB001 cancer cell line human CVCL_VL83 CL:0000010 Male 21172850 CVCL_VL84 AL1665 finite cell line human CVCL_VL84 CL:0000010 Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172851 CVCL_VL89 AL377 finite cell line human CVCL_VL89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172852 CVCL_VL87 AL409 finite cell line human CVCL_VL87 CL:0000010 Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21172853 CVCL_VL88 AL1405 finite cell line human CVCL_VL88 CL:0000010 Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172854 CVCL_3F40 HQ00549 transformed cell line human CVCL_3F40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172855 CVCL_3F41 HQ00550 transformed cell line human CVCL_3F41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172856 CVCL_3F44 HQ00553 transformed cell line human CVCL_3F44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172857 CVCL_3F45 HQ00554 transformed cell line human CVCL_3F45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172858 CVCL_3F42 HQ00551 transformed cell line human CVCL_3F42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172859 CVCL_3F43 HQ00552 transformed cell line human CVCL_3F43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172860 CVCL_3F48 HQ00557 transformed cell line human CVCL_3F48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172861 CVCL_3F49 HQ00558 transformed cell line human CVCL_3F49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172862 CVCL_3F46 HQ00555 transformed cell line human CVCL_3F46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172863 CVCL_3F47 HQ00556 transformed cell line human CVCL_3F47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172864 CVCL_VL70 Qau-Se-E-2 spontaneously immortalized cell line CVCL_VL70 CL:0000010 Unspecified Virology: Highly susceptible to infection by Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV) Doubling time: 49.08 hours (PubMed=25999173). Group: Insect cell line 21172865 CVCL_VL71 Qau-Se-E-3 spontaneously immortalized cell line CVCL_VL71 CL:0000010 Unspecified Virology: Highly susceptible to infection by Spodoptera exigua multiple nucleopolyhedrovirus (SeMNPV) Doubling time: 49.91 hours (PubMed=25999173). Group: Insect cell line 21172866 CVCL_VL74 JPO2 spontaneously immortalized cell line CVCL_VL74 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Control cell line for JPO9 (Cellosaurus=CVCL_VL73) 21172867 CVCL_VL75 GES-1/miR-23a transformed cell line human CVCL_VL75 CL:0000010 Transfected with: HGNC; 31605; MIR23A Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal stomach; epithelium Cell type=Epithelial cell.. Unspecified 21172868 CVCL_VL72 Raji(A44) cancer cell line human CVCL_VL72 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Virology: Infected with human herpesvirus 1 (HHV-1) strain A44 21172869 CVCL_VL73 JPO9 spontaneously immortalized cell line CVCL_VL73 CL:0000010 Transfected with: HGNC; 12373; TSHR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21172870 CVCL_VL78 KDT transformed cell line human CVCL_VL78 CL:0000010 Population: Caucasian; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Oral cavity; lip Cell type=Fibroblast.. Female 21172871 CVCL_VL79 HuT11-1 cancer cell line human CVCL_VL79 CL:0000010 Derived from sampling site: Lymph node. Female 21172872 CVCL_VL76 Oli-neuM transformed cell line house mouse CVCL_VL76 CL:0000010 Transfected with: MGI; MGI:2684944; Myrf; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Activated EGFR-neu; Derived from sampling site: Embryonic brain Cell type=Oligodendrocyte.; Breed/subspecies: NMRI. Unspecified Characteristics: Expression of MRF/Myrf promotes the differentiation of this cell line up to the premyelination stage without the addition of chemical compounds (PubMed=26658258) 21172873 CVCL_VL77 FDOV1 cancer cell line human CVCL_VL77 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asn201fs (c.602_603delCT); Zygosity=Unspecified (PubMed=29986747); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Leu2106fs (c.6317_6318delG); Zygosity=Unspecified (PubMed=29986747); Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Glu1668Ter (c.5002G>T) (p.Glu1681Ter, c.5041G>T); Zygosity=Unspecified (PubMed=29986747); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=29986747); Sequence variation: Mutation; HGNC; 11254; SPOP; Simple; p.Asp82His (c.244G>C); ClinVar=VCV000694137; Zygosity=Unspecified (PubMed=29986747); Sequence variation: Mutation; HGNC; 13009; ZNF217; Simple; p.Thr985Ile (c.2954C>T); Zygosity=Unspecified (PubMed=29986747) Population: Chinese; Derived from sampling site: Ovary. Omics: Deep exome analysis Female Doubling time: 37.4 hours (PubMed=29986747) Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.13812 21172874 CVCL_3F11 HQ00519 transformed cell line human CVCL_3F11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172875 CVCL_3F12 HQ00520 transformed cell line human CVCL_3F12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172876 CVCL_3F10 HQ00518 transformed cell line human CVCL_3F10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172877 CVCL_3F15 HQ00523 transformed cell line human CVCL_3F15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172878 CVCL_3F16 HQ00524 transformed cell line human CVCL_3F16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172879 CVCL_3F13 HQ00521 transformed cell line human CVCL_3F13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172880 CVCL_3F14 HQ00522 transformed cell line human CVCL_3F14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172881 CVCL_3F19 HQ00527 transformed cell line human CVCL_3F19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172882 CVCL_3F17 HQ00525 transformed cell line human CVCL_3F17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172883 CVCL_3F18 HQ00526 transformed cell line human CVCL_3F18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172884 CVCL_VL60 T24M [Human bladder carcinoma] cancer cell line human CVCL_VL60 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Omics: Proteome analysis by 2D-DE/MS Female Characteristics: Established from T24 by cycles of subcutaneous injections into SCID mice 21172885 CVCL_VL63 Leslie transformed cell line CVCL_VL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21172886 CVCL_VL64 Simsim transformed cell line CVCL_VL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21172887 CVCL_VL61 MBT-2V cancer cell line house mouse CVCL_VL61 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from metastatic site: Urinary bladder; Breed/subspecies: C3H/He. Characteristics: High metastatic potential; Characteristics: Established from a lung metastasis nodule in C3H mice implanted with MBT-2 cells in the leg muscles 21172888 CVCL_VL62 MB49-I cancer cell line house mouse CVCL_VL62 CL:0000010 Karyotypic information: Has lost chromosome Y (PubMed=22559978); Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Urinary bladder; Breed/subspecies: C57BL/ICRF-a(t). Male Characteristics: Has an invasive and metastatic phenotype; Characteristics: Established after 13 consecutive passages of MB49 through subcutaneous injection in the left flank of C57BL/6J male mice 21172889 CVCL_VL67 Kichil transformed cell line CVCL_VL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21172890 CVCL_VL68 Molek transformed cell line CVCL_VL68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21172891 CVCL_VL65 Puddin transformed cell line CVCL_VL65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21172892 CVCL_VL66 Suzanna transformed cell line CVCL_VL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21172893 CVCL_VL69 Qau-Se-E-1 spontaneously immortalized cell line CVCL_VL69 CL:0000010 Unspecified Doubling time: 59.03 hours (PubMed=25999173). Group: Insect cell line 21172894 CVCL_3F22 HQ00530 transformed cell line human CVCL_3F22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172895 CVCL_3F23 HQ00531 transformed cell line human CVCL_3F23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172896 CVCL_3F20 HQ00528 transformed cell line human CVCL_3F20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172897 CVCL_3F21 HQ00529 transformed cell line human CVCL_3F21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172898 CVCL_3F26 HQ00534 transformed cell line human CVCL_3F26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172899 CVCL_3F27 HQ00535 transformed cell line human CVCL_3F27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172900 CVCL_3F24 HQ00532 transformed cell line human CVCL_3F24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172901 CVCL_3F25 HQ00533 transformed cell line human CVCL_3F25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172902 CVCL_3F28 HQ00536 transformed cell line human CVCL_3F28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172903 CVCL_3F29 HQ00537 transformed cell line human CVCL_3F29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172904 CVCL_VL52 PBMC2-iPS4F8 CBFA2T3-GLIS2 induced pluripotent stem cell human CVCL_VL52 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 1537; CBFA2T3 (CBFA2T3-GLIS2 fusion); Transfected with: HGNC; 29450; GLIS2 (CBFA2T3-GLIS2 fusion) Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21172905 CVCL_VL53 HSCR-iPSC 1 induced pluripotent stem cell human CVCL_VL53 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Glu61Argfs*163 (c.180delT); Zygosity=Heterozygous (PubMed=29965875) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21172906 CVCL_VL50 ZZUi007-A induced pluripotent stem cell human CVCL_VL50 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 21645; CHCHD2; Simple; p.Thr61Ile (c.182C>T); ClinVar=VCV000218882; Zygosity=Heterozygous (PubMed=30237140) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21172907 CVCL_VL51 PBMC2-iPS4F8 Neo induced pluripotent stem cell human CVCL_VL51 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood. Female 21172908 CVCL_VL56 UM-UC-3-Luc cancer cell line human CVCL_VL56 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder. Male 21172909 CVCL_VL57 UM-UC-3-LuL-1 cancer cell line human CVCL_VL57 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder. Male Characteristics: Produced after passage of UM-UC-3-Luc into nude mice 21172910 CVCL_VL54 HSCR-iPSC 2 induced pluripotent stem cell human CVCL_VL54 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Glu61Argfs*163 (c.180delT); Zygosity=Heterozygous (PubMed=29965875) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21172911 CVCL_VL55 HSCR-iPSC 3 induced pluripotent stem cell human CVCL_VL55 CL:0000010 Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Glu61Argfs*163 (c.180delT); Zygosity=Heterozygous (PubMed=29965875) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21172912 CVCL_VL58 UM-UC-3-LuL-2 cancer cell line human CVCL_VL58 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2800fs*6 (c.8400delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 14446; PARD3B; Unexplicit; Ex9-18del; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe113Cys (c.338T>G); ClinVar=VCV000634690; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Urinary bladder. Male Characteristics: Produced after passage of UM-UC-3-LuL-1 into nude mice 21172913 CVCL_VL59 1207 cancer cell line human CVCL_VL59 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified 21172914 CVCL_DY24 ND05068 transformed cell line human CVCL_DY24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172915 CVCL_DY25 ND05082 transformed cell line human CVCL_DY25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172916 CVCL_DY22 ND05032 transformed cell line human CVCL_DY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172917 CVCL_DY23 ND05033 transformed cell line human CVCL_DY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172918 CVCL_DY28 ND05111 transformed cell line human CVCL_DY28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172919 CVCL_DY29 ND05128 transformed cell line human CVCL_DY29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172920 CVCL_DY26 ND05083 transformed cell line human CVCL_DY26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172921 CVCL_DY27 ND05110 transformed cell line human CVCL_DY27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172922 CVCL_DY20 ND04989 transformed cell line human CVCL_DY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172923 CVCL_DY21 ND05026 transformed cell line human CVCL_DY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172924 CVCL_DY19 ND04988 transformed cell line human CVCL_DY19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172925 CVCL_DY35 ND05176 transformed cell line human CVCL_DY35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172926 CVCL_DY36 ND05184 transformed cell line human CVCL_DY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172927 CVCL_DY33 ND05158 transformed cell line human CVCL_DY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172928 CVCL_DY34 ND05162 transformed cell line human CVCL_DY34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172929 CVCL_DY39 ND05216 transformed cell line human CVCL_DY39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172930 CVCL_DY37 ND05209 transformed cell line human CVCL_DY37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172931 CVCL_DY38 ND05210 transformed cell line human CVCL_DY38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172932 CVCL_DY31 ND05142 transformed cell line human CVCL_DY31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172933 CVCL_DY32 ND05144 transformed cell line human CVCL_DY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172934 CVCL_DY30 ND05140 transformed cell line human CVCL_DY30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172935 CVCL_DY02 ND04871 transformed cell line human CVCL_DY02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172936 CVCL_DY03 ND04873 transformed cell line human CVCL_DY03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172937 CVCL_DY00 ND04867 transformed cell line human CVCL_DY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172938 CVCL_DY01 ND04869 transformed cell line human CVCL_DY01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172939 CVCL_DY06 ND04904 transformed cell line human CVCL_DY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172940 CVCL_DY07 ND04905 transformed cell line human CVCL_DY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172941 CVCL_DY04 ND04901 transformed cell line human CVCL_DY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172942 CVCL_DY05 ND04902 transformed cell line human CVCL_DY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172943 CVCL_DY13 ND04945 transformed cell line human CVCL_DY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172944 CVCL_DY14 ND04951 transformed cell line human CVCL_DY14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172945 CVCL_DY11 ND04922 transformed cell line human CVCL_DY11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172946 CVCL_DY12 ND04944 transformed cell line human CVCL_DY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172947 CVCL_DY17 ND04986 transformed cell line human CVCL_DY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172948 CVCL_DY18 ND04987 transformed cell line human CVCL_DY18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172949 CVCL_DY15 ND04962 transformed cell line human CVCL_DY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172950 CVCL_DY16 ND04976 transformed cell line human CVCL_DY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172951 CVCL_DY10 ND04921 transformed cell line human CVCL_DY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172952 CVCL_DY08 ND04906 transformed cell line human CVCL_DY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172953 CVCL_DY09 ND04907 transformed cell line human CVCL_DY09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172954 CVCL_3F95 HQ00604 transformed cell line human CVCL_3F95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172955 CVCL_3F96 HQ00605 transformed cell line human CVCL_3F96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172956 CVCL_3F93 HQ00602 transformed cell line human CVCL_3F93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172957 CVCL_3F94 HQ00603 transformed cell line human CVCL_3F94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172958 CVCL_3F99 HQ00608 transformed cell line human CVCL_3F99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172959 CVCL_3F97 HQ00606 transformed cell line human CVCL_3F97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172960 CVCL_3F98 HQ00607 transformed cell line human CVCL_3F98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172961 CVCL_3F91 HQ00600 transformed cell line human CVCL_3F91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172962 CVCL_3F92 HQ00601 transformed cell line human CVCL_3F92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172963 CVCL_3F90 HQ00599 transformed cell line human CVCL_3F90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172964 CVCL_E989 Y-3P hybridoma house mouse CVCL_E989 CL:0000010 Monoclonal antibody isotype: IgG2a. 21172965 CVCL_E983 Lp1 MAB 2 hybridoma house mouse CVCL_E983 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Legionella pneumophila serogroup 1. 21172966 CVCL_E984 Lp1 MAB 3 hybridoma house mouse CVCL_E984 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Legionella pneumophila serogroup 1. 21172967 CVCL_E981 L368 hybridoma house mouse CVCL_E981 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21172968 CVCL_E982 Lp1 MAB 1 hybridoma house mouse CVCL_E982 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Legionella pneumophila serogroup 1. 21172969 CVCL_E987 YI 328-18 hybridoma house mouse CVCL_E987 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:138018; Lactogangliotetraosylceramide (LcGg4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9306 21172970 CVCL_E988 YI 328-51 hybridoma house mouse CVCL_E988 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:138018; Lactogangliotetraosylceramide (LcGg4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9307 21172971 CVCL_N319 AT45LA transformed cell line human CVCL_N319 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg982fs (c.2945delT); Zygosity=Heterozygous (PubMed=9150358) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21172972 CVCL_MR19 BayGenomics ES cell line RRD128 embryonic stem cell house mouse CVCL_MR19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172973 CVCL_E985 Lym-1 hybridoma house mouse CVCL_E985 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human normal B cells and derived malignancies. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8612 21172974 CVCL_E986 Lym-2 hybridoma house mouse CVCL_E986 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human chronic lymphocytic leukemia cells. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8613 21172975 CVCL_MR17 BayGenomics ES cell line RRD120 embryonic stem cell house mouse CVCL_MR17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172976 CVCL_N317 GM09587 transformed cell line human CVCL_N317 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8269del150; Zygosity=Heterozygous (PubMed=8808599; PubMed=8845835); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg3008Cys (c.9022C>T); ClinVar=VCV000142187; Zygosity=Heterozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172977 CVCL_MR18 BayGenomics ES cell line RRD121 embryonic stem cell house mouse CVCL_MR18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442860; Eda2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172978 CVCL_N318 GM09588 transformed cell line human CVCL_N318 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21172979 CVCL_MR15 BayGenomics ES cell line RRD115 embryonic stem cell house mouse CVCL_MR15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915751; Nsmce2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172980 CVCL_N315 GM09585 transformed cell line human CVCL_N315 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172981 CVCL_MR16 BayGenomics ES cell line RRD119 embryonic stem cell house mouse CVCL_MR16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107566; Kifap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172982 CVCL_N316 GM09586 transformed cell line human CVCL_N316 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21172983 CVCL_MR13 BayGenomics ES cell line RRD112 embryonic stem cell house mouse CVCL_MR13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915760; Ints1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172984 CVCL_N313 H13.9G4 hybridoma house mouse CVCL_N313 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Mycoplasma pneumoniae antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8421 21172985 CVCL_MR14 BayGenomics ES cell line RRD113 embryonic stem cell house mouse CVCL_MR14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098687; Aak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172986 CVCL_N314 H17.8A5 hybridoma house mouse CVCL_N314 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycoplasma pneumoniae antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8423 21172987 CVCL_E980 HFN 7.1 hybridoma house mouse CVCL_E980 CL:0000010 Discontinued: ATCC; HB-39; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1 21172988 CVCL_MR11 BayGenomics ES cell line RRD110 embryonic stem cell house mouse CVCL_MR11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172989 CVCL_N311 H13.3B3 hybridoma house mouse CVCL_N311 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Mycoplasma pneumoniae lipid antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8972 21172990 CVCL_MR12 BayGenomics ES cell line RRD111 embryonic stem cell house mouse CVCL_MR12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914116; Nhlrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172991 CVCL_N312 H13.4F4 hybridoma house mouse CVCL_N312 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mycoplasma pneumoniae 32 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8974 21172992 CVCL_MR10 BayGenomics ES cell line RRD107 embryonic stem cell house mouse CVCL_MR10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181182; Nup155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21172993 CVCL_N310 H13.2G2 hybridoma house mouse CVCL_N310 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8424 21172994 CVCL_E994 DND-10B cancer cell line human CVCL_E994 CL:0000010 Derived from sampling site: Ascites. Male Doubling time: 48 hours (CelloPub=CLPUB00035) 21172995 CVCL_E995 MS-1 [Human Merkel cell carcinoma] cancer cell line human CVCL_E995 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251_Thr253del; Zygosity=Hemizygous (PubMed=23563200) Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Adrenal gland. Omics: Array-based CGH; Omics: Deep exome analysis Female Virology: Contains 2.1 copies of the genome of MCPyV per haploid cell (PubMed=23085629) Doubling time: 4 days (PubMed=20444890); 3 days (PubMed=30873613) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21172996 CVCL_E992 MS-2 [Human mesothelioma] cancer cell line human CVCL_E992 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified Doubling time: ~72 hours (PubMed=2457437) 21172997 CVCL_E993 MS-1 [Human mesothelioma] cancer cell line human CVCL_E993 CL:0000010 Derived from sampling site: Pleural effusion. Female Doubling time: ~46 hours (PubMed=2457437) 21172998 CVCL_E998 WaGa cancer cell line human CVCL_E998 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Ascites. Omics: Array-based CGH; Omics: Deep quantitative proteome analysis Male Doubling time: 4 days (PubMed=20444890); 2-3 days (PubMed=30873613) 21172999 CVCL_E999 MaTi cancer cell line human CVCL_E999 CL:0000010 Derived from metastatic site: Lymph node. Female Doubling time: 2.5 days (PubMed=20444890) 21173000 CVCL_E996 UISO-MCC-1 cancer cell line human CVCL_E996 CL:0000010 Derived from sampling site: Thigh; skin. Female Doubling time: 64.8 hours (PubMed=8227544); 1.5 days (PubMed=20444890) 21173001 CVCL_E997 BroLi cancer cell line human CVCL_E997 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis Male Doubling time: 5 days (PubMed=20444890); 4-5 days (PubMed=30873613) 21173002 CVCL_MR28 BayGenomics ES cell line RRD144 embryonic stem cell house mouse CVCL_MR28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892973; Gpr19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173003 CVCL_N328 Om5 hybridoma house mouse CVCL_N328 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen URO9 on bladder cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8270 21173004 CVCL_MR29 BayGenomics ES cell line RRD145 embryonic stem cell house mouse CVCL_MR29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3580376; Lemd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173005 CVCL_N329 S22 hybridoma house mouse CVCL_N329 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen URO7 on renal cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8542 21173006 CVCL_MR26 BayGenomics ES cell line RRD142 embryonic stem cell house mouse CVCL_MR26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173007 CVCL_N326 JP165 hybridoma house mouse CVCL_N326 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8280 21173008 CVCL_MR27 BayGenomics ES cell line RRD143 embryonic stem cell house mouse CVCL_MR27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859648; Ftsj1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173009 CVCL_N327 Om37 hybridoma house mouse CVCL_N327 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8233 21173010 CVCL_MR24 BayGenomics ES cell line RRD138 embryonic stem cell house mouse CVCL_MR24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173011 CVCL_N324 J143 hybridoma house mouse CVCL_N324 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8276 21173012 CVCL_E990 Y-3 hybridoma house mouse CVCL_E990 CL:0000010 Monoclonal antibody isotype: IgG2b. 21173013 CVCL_MR25 BayGenomics ES cell line RRD139 embryonic stem cell house mouse CVCL_MR25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102522; Cacnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173014 CVCL_N325 J233 hybridoma house mouse CVCL_N325 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8272 21173015 CVCL_E991 Y-17 hybridoma house mouse CVCL_E991 CL:0000010 Monoclonal antibody isotype: IgG2b. 21173016 CVCL_MR22 BayGenomics ES cell line RRD132 embryonic stem cell house mouse CVCL_MR22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173017 CVCL_N322 F23 hybridoma house mouse CVCL_N322 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen URO3 on renal cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8231 21173018 CVCL_MR23 BayGenomics ES cell line RRD136 embryonic stem cell house mouse CVCL_MR23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333833; Cbfa2t2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173019 CVCL_N323 F31 hybridoma house mouse CVCL_N323 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human antigen URO8 on renal cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8548 21173020 CVCL_N320 AT76LA transformed cell line human CVCL_N320 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21173021 CVCL_MR20 BayGenomics ES cell line RRD130 embryonic stem cell house mouse CVCL_MR20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914110; Tanc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173022 CVCL_N321 AJ8 hybridoma house mouse CVCL_N321 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8339 21173023 CVCL_MR21 BayGenomics ES cell line RRD131 embryonic stem cell house mouse CVCL_MR21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173024 CVCL_E969 147-67C6 hybridoma house mouse CVCL_E969 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9278 21173025 CVCL_E967 143-4-2 hybridoma house mouse CVCL_E967 CL:0000010 Monoclonal antibody isotype: IgG1. 21173026 CVCL_E968 146-03E04 hybridoma house mouse CVCL_E968 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8997 21173027 CVCL_E961 123-10 hybridoma house mouse CVCL_E961 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P10443; Escherichia coli polC. 21173028 CVCL_E962 123-28 hybridoma house mouse CVCL_E962 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06710; Escherichia coli dnaX. 21173029 CVCL_E960 121-19B10 hybridoma house mouse CVCL_E960 CL:0000010 Monoclonal antibody isotype: Not specified. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8955 21173030 CVCL_E965 133-10F6 hybridoma house mouse CVCL_E965 CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b, kappa; Monoclonal antibody target: UniProtKB; P10242; Human MYB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9077 21173031 CVCL_E966 142-24E5 hybridoma house mouse CVCL_E966 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8679 21173032 CVCL_E963 131-94H4 hybridoma house mouse CVCL_E963 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9003 21173033 CVCL_E964 132-1C8 hybridoma house mouse CVCL_E964 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10242; Human MYB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8927 21173034 CVCL_E978 FSHR-323 hybridoma house mouse CVCL_E978 CL:0000010 Discontinued: ATCC; CRL-2689; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P23945; Human FSHR 21173035 CVCL_E979 HFN 36.3 hybridoma house mouse CVCL_E979 CL:0000010 Discontinued: ATCC; HB-40; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1 21173036 CVCL_E972 172-12A4 hybridoma house mouse CVCL_E972 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9005 21173037 CVCL_E973 173-1C11 hybridoma house mouse CVCL_E973 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8894 21173038 CVCL_E970 16H3 hybridoma house mouse CVCL_E970 CL:0000010 Monoclonal antibody isotype: IgG1. 21173039 CVCL_E971 171-11B9 hybridoma house mouse CVCL_E971 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9117 21173040 CVCL_E976 IgG-9D9 hybridoma house mouse CVCL_E976 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01131; Bovine LDLR (Note=Also reacts with rabbit). 21173041 CVCL_E977 FSHR-18 hybridoma house mouse CVCL_E977 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P23945; Human FSHR. 21173042 CVCL_E974 240-13D10 hybridoma house mouse CVCL_E974 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9144 21173043 CVCL_MR08 BayGenomics ES cell line RRD100 embryonic stem cell house mouse CVCL_MR08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173044 CVCL_N308 H13.17D4 hybridoma house mouse CVCL_N308 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Mycoplasma pneumoniae lipid antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8973 21173045 CVCL_E975 2D12 [Mouse hybridoma against yellow fever virus envelope protein] hybridoma house mouse CVCL_E975 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03314; Yellow fever virus (strain 17D vaccine) envelope protein. 21173046 CVCL_MR09 BayGenomics ES cell line RRD101 embryonic stem cell house mouse CVCL_MR09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88110; Atp2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173047 CVCL_N309 H13.1D11 hybridoma house mouse CVCL_N309 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Mycoplasma pneumoniae 200 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8422 21173048 CVCL_MR06 BayGenomics ES cell line RRD093 embryonic stem cell house mouse CVCL_MR06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173049 CVCL_N306 Hs 854.T cancer cell line human CVCL_N306 CL:0000010 Derived from metastatic site: Skin. Discontinued: ATCC; CRL-7590; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173050 CVCL_MR07 BayGenomics ES cell line RRD099 embryonic stem cell house mouse CVCL_MR07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151152; Baz2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173051 CVCL_N307 H13.11F10 hybridoma house mouse CVCL_N307 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Mycoplasma pneumoniae lipid antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8425 21173052 CVCL_MR04 BayGenomics ES cell line RRD090 embryonic stem cell house mouse CVCL_MR04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921358; Parn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173053 CVCL_N304 Hs 249.T cancer cell line human CVCL_N304 CL:0000010 Discontinued: ATCC; CRL-7211; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173054 CVCL_MR05 BayGenomics ES cell line RRD092 embryonic stem cell house mouse CVCL_MR05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196463; Fndc3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173055 CVCL_N305 Hs 13.T cancer cell line human CVCL_N305 CL:0000010 Derived from sampling site: Bone. Discontinued: ATCC; CRL-7010; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173056 CVCL_MR02 BayGenomics ES cell line RRD088 embryonic stem cell house mouse CVCL_MR02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173057 CVCL_N302 Hs 559.Li finite cell line human CVCL_N302 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7322; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173058 CVCL_MR03 BayGenomics ES cell line RRD089 embryonic stem cell house mouse CVCL_MR03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681865; Zfat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173059 CVCL_N303 Hs 547.Sk finite cell line human CVCL_N303 CL:0000010 Population: Caucasian; Derived from sampling site: Trunk; skin. Discontinued: ATCC; CRL-7319; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173060 CVCL_MR00 BayGenomics ES cell line RRD086 embryonic stem cell house mouse CVCL_MR00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891925; Hnrnph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173061 CVCL_N300 Hs 564(B).Mg finite cell line human CVCL_N300 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7327; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173062 CVCL_MR01 BayGenomics ES cell line RRD087 embryonic stem cell house mouse CVCL_MR01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346035; Farsb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173063 CVCL_N301 Hs 564(C).Mg finite cell line human CVCL_N301 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7328; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173064 CVCL_E947 F2408 EBNA2 cl-24 transformed cell line Norway rat CVCL_E947 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.4; true Unspecified 21173065 CVCL_E948 F2408 EBNA2 cl-28 transformed cell line Norway rat CVCL_E948 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.7; true Unspecified 21173066 CVCL_E945 F2408 EBNA2 cl-18 transformed cell line Norway rat CVCL_E945 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.3; true Unspecified 21173067 CVCL_E946 F2408 EBNA2 cl-23 transformed cell line Norway rat CVCL_E946 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.6; true Unspecified 21173068 CVCL_E949 F2408 EBNA2 cl-9 transformed cell line Norway rat CVCL_E949 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.1; true Unspecified 21173069 CVCL_E940 TIG-7 finite cell line human CVCL_E940 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Senescence: Senesces at 73 +- 7 PDL (PubMed=1800129); 66-80 PDL (RCB=RCB4469); Doubling time: 23 hours (at 65th passage), 62 hours (at 75th passage) (PubMed=1800129) 21173070 CVCL_E943 F2408 EBNA2 cl-14 transformed cell line Norway rat CVCL_E943 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.5; true Unspecified 21173071 CVCL_E944 F2408 EBNA2 cl-16 transformed cell line Norway rat CVCL_E944 CL:0000010 Transfected with: UniProtKB; P12978; EBV EBNA2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.2; true Unspecified 21173072 CVCL_E941 TK [Human brain lymphoma] cancer cell line human CVCL_E941 CL:0000010 Anecdotal: Cell line name corresponds to the initials of the patient Population: Japanese; Derived from sampling site: Brain. Discontinued: JCRB; NIHS0524; true Male Doubling time: 34 hours (PubMed=7059907) 21173073 CVCL_E942 YSK-21 cancer cell line human CVCL_E942 CL:0000010 Sequence variation: Gene deletion; HGNC; 12003; TP73; Zygosity=Heterozygous (PubMed=11550287); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn288Tyr (c.862A>T); Zygosity=Hemizygous (PubMed=11550287) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: ~48 hours (PubMed=11550287) 21173074 CVCL_E958 11E10 hybridoma house mouse CVCL_E958 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09385; Bacteriophage 933W Shiga-like toxin 2 subunit A (stxA2). 21173075 CVCL_E959 11F11 hybridoma house mouse CVCL_E959 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P09385; Bacteriophage 933W Shiga-like toxin 2 subunit A (stxA2). 21173076 CVCL_E956 OV2944-LM-3 cancer cell line house mouse CVCL_E956 CL:0000010 Breed/subspecies: C57BL/6N x C3H/He. Female 21173077 CVCL_E957 HOUFXXX finite cell line human CVCL_E957 CL:0000010 Population: Japanese; Derived from sampling site: Vagina. Female 21173078 CVCL_E950 F2408 pZipNeo transformed cell line Norway rat CVCL_E950 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: JCRB; NIHS0223.0; true Unspecified 21173079 CVCL_E951 F2408-B812 spontaneously immortalized cell line Norway rat CVCL_E951 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21173080 CVCL_E954 OV2944-HM-1 cancer cell line house mouse CVCL_E954 CL:0000010 Breed/subspecies: C57BL/6N x C3H/He. Female 21173081 CVCL_E955 OV2944-LM-1 cancer cell line house mouse CVCL_E955 CL:0000010 Breed/subspecies: C57BL/6N x C3H/He. Female 21173082 CVCL_E952 F2408-B993 spontaneously immortalized cell line Norway rat CVCL_E952 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21173083 CVCL_E953 OV2944 cancer cell line house mouse CVCL_E953 CL:0000010 Breed/subspecies: C57BL/6N x C3H/He. Female 21173084 CVCL_E925 PluriStem C3H/HeN embryonic stem cell house mouse CVCL_E925 CL:0000010 Breed/subspecies: C3H/HeN. Male 21173085 CVCL_E926 PluriStem C57BL/6N embryonic stem cell house mouse CVCL_E926 CL:0000010 Breed/subspecies: C57BL/6N. Male 21173086 CVCL_E923 LT2 [Human immortalized pancreatic mesenchymal] transformed cell line human CVCL_E923 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal pancreas Cell type=Fibroblast.. Unspecified 21173087 CVCL_E924 PluriStem BALB/C embryonic stem cell house mouse CVCL_E924 CL:0000010 Breed/subspecies: BALB/c. Male 21173088 CVCL_E929 AGS-NSC somatic stem cell CVCL_E929 CL:0000010 Derived from sampling site: Brain; hippocampus Cell type=Neural stem cell.. Discontinued: Millipore; SCCE002; true Unspecified Characteristics: Can be used to screen drugs, genes and proteins for protective changes caused by oxygen and/or glucose deprivation 21173089 CVCL_E927 PluriStem DBA/2N embryonic stem cell house mouse CVCL_E927 CL:0000010 Breed/subspecies: DBA/2N. Male 21173090 CVCL_E928 PluriStem FVB/N embryonic stem cell house mouse CVCL_E928 CL:0000010 Breed/subspecies: FVB/N. Male 21173091 CVCL_E921 ReNcell VM transformed cell line human CVCL_E921 From: ReNeuron, Ltd; Pencoed; United Kingdom CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Fetal brain; ventral mesencephalon Cell type=Neural progenitor cell.. Omics: Deep proteome analysis Male Doubling time: 20-30 hours (Millipore) 21173092 CVCL_E922 ReNcell CX transformed cell line human CVCL_E922 From: ReNeuron, Ltd; Pencoed; United Kingdom CL:0000010 Transfected with: HGNC; 7553; MYC Derived from sampling site: Fetal brain; cerebral cortex Cell type=Neural progenitor cell.. Male Doubling time: 20-30 hours (Millipore) 21173093 CVCL_E920 SCED 461 embryonic stem cell human CVCL_E920 From: Cellectis; Paris; France. CL:0000010 Male 21173094 CVCL_E936 LB23-SAR cancer cell line human CVCL_E936 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21173095 CVCL_E937 LB45-MEL cancer cell line human CVCL_E937 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21173096 CVCL_E934 LB33-MELB cancer cell line human CVCL_E934 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Small intestine. Female 21173097 CVCL_E935 LB30-MEL cancer cell line human CVCL_E935 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21173098 CVCL_E938 SV transformed cell line house mouse CVCL_E938 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88151; Glb1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x CBA. Problematic cell line: Contaminated/misidentified Not from strain C57BL/6 as originally assigned but from a C57BL/6 x CBA cross (PubMed=27844419). 21173099 CVCL_E939 TIG-3 finite cell line human CVCL_E939 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Deep proteome analysis; Omics: Proteome analysis by 2D-DE Male Senescence: Senesces at 83.8 PDL (PubMed=7053395); Doubling time: 18-24 hours (PubMed=7053395) 21173100 CVCL_E932 LB24-MEL cancer cell line human CVCL_E932 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Skin. Female 21173101 CVCL_E933 LB33-MELA cancer cell line human CVCL_E933 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Hypodermis. Female 21173102 CVCL_E930 SqMkLu/68 finite cell line CVCL_E930 CL:0000010 Derived from sampling site: Lung. Group: Non-human primate cell line 21173103 CVCL_E931 7603830 finite cell line CVCL_E931 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Bolivian/Peruvian hybrid. Group: Non-human primate cell line 21173104 CVCL_VL41 HIHCNi002-A induced pluripotent stem cell human CVCL_VL41 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[73]; Zygosity=Heterozygous; Note=The other allele has 24 repeats (PubMed=29936336) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173105 CVCL_VL42 CDIi005-A induced pluripotent stem cell human CVCL_VL42 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 Female 21173106 CVCL_MR99 BayGenomics ES cell line RRE021 embryonic stem cell house mouse CVCL_MR99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173107 CVCL_N399 GM13614 transformed cell line human CVCL_N399 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173108 CVCL_VL40 HIHCNi003-A induced pluripotent stem cell human CVCL_VL40 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2433; CSF1R; Simple; p.Val838Leu (c.2512G>C); ClinVar=VCV000162121; Zygosity=Heterozygous (PubMed=29980109) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173109 CVCL_MR97 BayGenomics ES cell line RRE017 embryonic stem cell house mouse CVCL_MR97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173110 CVCL_N397 GM13612 transformed cell line human CVCL_N397 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173111 CVCL_VL45 IBPi002-A induced pluripotent stem cell human CVCL_VL45 From: Institute of Biophysics of the Czech Academy of Sciences; Brno; Czech Republic CL:0000010 Karyotypic information: Has lost chromosome Y; Derived from sampling site: Prostate Cell type=Fibroblast.. Male 21173112 CVCL_MR98 BayGenomics ES cell line RRE018 embryonic stem cell house mouse CVCL_MR98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919654; Wdr44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173113 CVCL_N398 GM13613 transformed cell line human CVCL_N398 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173114 CVCL_VL46 iMZ-9 induced pluripotent stem cell house mouse CVCL_VL46 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Pcdh21/Cre-Z/EG. Omics: Genome sequenced Male 21173115 CVCL_MR95 BayGenomics ES cell line RRE014 embryonic stem cell house mouse CVCL_MR95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173116 CVCL_N395 GM13610 transformed cell line human CVCL_N395 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173117 CVCL_VL43 IRFMNi002-A induced pluripotent stem cell human CVCL_VL43 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8616; PAX2; Simple; p.Gly189Arg (c.565G>A); ClinVar=VCV000155928; Zygosity=Heterozygous (PubMed=30399566) Derived from sampling site: Peripheral blood. Female 21173118 CVCL_MR96 BayGenomics ES cell line RRE016 embryonic stem cell house mouse CVCL_MR96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923206; Srrm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173119 CVCL_N396 GM13611 transformed cell line human CVCL_N396 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173120 CVCL_VL44 IBPi001-A induced pluripotent stem cell human CVCL_VL44 From: Institute of Biophysics of the Czech Academy of Sciences; Brno; Czech Republic CL:0000010 Derived from sampling site: Fetal prostate Cell type=Fibroblast.. Male 21173121 CVCL_MR93 BayGenomics ES cell line RRE012 embryonic stem cell house mouse CVCL_MR93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346861; Mapk8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173122 CVCL_N393 GM13608 transformed cell line human CVCL_N393 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173123 CVCL_VL49 iMZ-15 induced pluripotent stem cell house mouse CVCL_VL49 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Pcdh21/Cre-Z/EG. Unspecified 21173124 CVCL_MR94 BayGenomics ES cell line RRE013 embryonic stem cell house mouse CVCL_MR94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888594; Icmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173125 CVCL_N394 GM13609 transformed cell line human CVCL_N394 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173126 CVCL_MR91 BayGenomics ES cell line RRE007 embryonic stem cell house mouse CVCL_MR91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173127 CVCL_N391 GM13606 transformed cell line human CVCL_N391 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173128 CVCL_VL47 iMZ-21 induced pluripotent stem cell house mouse CVCL_VL47 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Pcdh21/Cre-Z/EG. Omics: Genome sequenced Male 21173129 CVCL_MR92 BayGenomics ES cell line RRE008 embryonic stem cell house mouse CVCL_MR92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103006; Epb41l5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173130 CVCL_N392 GM13607 transformed cell line human CVCL_N392 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173131 CVCL_VL48 iMZ-11 induced pluripotent stem cell house mouse CVCL_VL48 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Pcdh21/Cre-Z/EG. Omics: Genome sequenced Unspecified 21173132 CVCL_VL29 IBMS-iPSC-026-02 induced pluripotent stem cell human CVCL_VL29 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; c.640-801G>A (c.639+919G>A) (IVS4+919G>A); ClinVar=VCV000010768; Zygosity=Hemizygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21173133 CVCL_3F00 HQ00508 transformed cell line human CVCL_3F00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173134 CVCL_3F01 HQ00509 transformed cell line human CVCL_3F01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173135 CVCL_3F04 HQ00512 transformed cell line human CVCL_3F04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173136 CVCL_3F05 HQ00513 transformed cell line human CVCL_3F05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173137 CVCL_3F02 HQ00510 transformed cell line human CVCL_3F02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173138 CVCL_3F03 HQ00511 transformed cell line human CVCL_3F03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173139 CVCL_3F08 HQ00516 transformed cell line human CVCL_3F08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173140 CVCL_3F09 HQ00517 transformed cell line human CVCL_3F09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173141 CVCL_3F06 HQ00514 transformed cell line human CVCL_3F06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173142 CVCL_3F07 HQ00515 transformed cell line human CVCL_3F07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173143 CVCL_VL30 NHRI-iPSC-004-03 induced pluripotent stem cell human CVCL_VL30 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21173144 CVCL_VL31 NHRI-iPSC-007-01 induced pluripotent stem cell human CVCL_VL31 From: National Health Research Institutes (NHRI); Zhunan; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21173145 CVCL_VL34 TVGH-iPSC-017-08 induced pluripotent stem cell human CVCL_VL34 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21173146 CVCL_VL35 TVGH-iPSC-019-07 induced pluripotent stem cell human CVCL_VL35 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Male 21173147 CVCL_VL32 NTUH-iPSC-003-40 induced pluripotent stem cell human CVCL_VL32 From: National Taiwan University; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21173148 CVCL_VL33 NTUH-iPSC-009-07 induced pluripotent stem cell human CVCL_VL33 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21173149 CVCL_VL38 LM156 cancer cell line human CVCL_VL38 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=29880898) Population: Chinese; Derived from metastatic site: Lymph node. Omics: Genome sequenced Male Doubling time: 34.43 hours (PubMed=29880898) 21173150 CVCL_VL39 CCApin spontaneously immortalized cell line CVCL_VL39 CL:0000010 Derived from sampling site: Fin. Unspecified Virology: Highly susceptible to infection by common carp paramyxovirus (CCPV) (PubMed=35934930); Virology: Highly susceptible to infection by cyprinid herpesvirus 3 (CyHV-3) Taiwan isolate (KHV-T) (PubMed=29960082; PubMed=35934930); Virology: Not susceptible to infection by carp edema virus (CEV) (PubMed=35934930) Doubling time: ~44 hours (PubMed=29960082) Group: Fish cell line 21173151 CVCL_VL36 GM08582 transformed cell line human CVCL_VL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM08582; probable 21173152 CVCL_VL37 149RM cancer cell line human CVCL_VL37 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Val (c.38G>T); ClinVar=VCV000180848; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Unspecified (PubMed=29880898); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=29880898) Population: Chinese; Derived from metastatic site: Scrotum. Omics: Genome sequenced Male Doubling time: 26.39 hours (PubMed=29880898) 21173153 CVCL_VL18 MYCN-2 Tet-on cancer cell line human CVCL_VL18 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21173154 CVCL_VL19 MYCN-3 Tet-on cancer cell line human CVCL_VL19 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21173155 CVCL_MR79 BayGenomics ES cell line RRD284 embryonic stem cell house mouse CVCL_MR79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96623; Itpr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173156 CVCL_N379 GM11523 transformed cell line human CVCL_N379 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173157 CVCL_VL20 BPEG1 embryonic stem cell pig CVCL_VL20 CL:0000010 Breed/subspecies: Miniature pig. Female Characteristics: Germ stem cell line 21173158 CVCL_MR77 BayGenomics ES cell line RRD265 embryonic stem cell house mouse CVCL_MR77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173159 CVCL_N377 GM10979 transformed cell line human CVCL_N377 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173160 CVCL_MR78 BayGenomics ES cell line RRD280 embryonic stem cell house mouse CVCL_MR78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173161 CVCL_N378 GM11521 transformed cell line human CVCL_N378 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173162 CVCL_MR75 BayGenomics ES cell line RRD262 embryonic stem cell house mouse CVCL_MR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173163 CVCL_N375 GM10976 transformed cell line human CVCL_N375 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173164 CVCL_VL23 hD3-CHO spontaneously immortalized cell line CVCL_VL23 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform long) Derived from sampling site: Ovary. Female 21173165 CVCL_MR76 BayGenomics ES cell line RRD264 embryonic stem cell house mouse CVCL_MR76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173166 CVCL_N376 GM10978 transformed cell line human CVCL_N376 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173167 CVCL_VL24 GSS-Y218N-iPS induced pluripotent stem cell human CVCL_VL24 CL:0000010 Sequence variation: Mutation; HGNC; 9449; PRNP; Simple; p.Tyr218Asn (c.652T>A); Zygosity=Unspecified (PubMed=28466265) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21173168 CVCL_MR73 BayGenomics ES cell line RRD254 embryonic stem cell house mouse CVCL_MR73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914803; Gstcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173169 CVCL_VL21 BPEG2 embryonic stem cell pig CVCL_VL21 CL:0000010 Breed/subspecies: Miniature pig. Male Characteristics: Germ stem cell line 21173170 CVCL_N373 GM10974 transformed cell line human CVCL_N373 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10974; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173171 CVCL_MR74 BayGenomics ES cell line RRD257 embryonic stem cell house mouse CVCL_MR74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173172 CVCL_N374 GM10975 transformed cell line human CVCL_N374 CL:0000010 Population: Native South American; Mayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173173 CVCL_VL22 hD2L-CHO spontaneously immortalized cell line CVCL_VL22 CL:0000010 Transfected with: HGNC; 3023; DRD2 (isoform long) Derived from sampling site: Ovary. Female 21173174 CVCL_MR71 BayGenomics ES cell line RRD242 embryonic stem cell house mouse CVCL_MR71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173175 CVCL_VL27 C1-iPSC-2 induced pluripotent stem cell human CVCL_VL27 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21173176 CVCL_N371 GM10972 transformed cell line human CVCL_N371 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10972; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173177 CVCL_MR72 BayGenomics ES cell line RRD252 embryonic stem cell house mouse CVCL_MR72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104728; Caml Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173178 CVCL_N372 GM10973 transformed cell line human CVCL_N372 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10973; probable Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173179 CVCL_VL28 IBMS-iPSC-024-03 induced pluripotent stem cell human CVCL_VL28 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Glu398Aspfs*6 (c.1194delA); Zygosity=Hemizygous (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21173180 CVCL_VL25 D1-iPSC-2 induced pluripotent stem cell human CVCL_VL25 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 2888; DISC1; Simple; p.Ile808Serfs*816 (c.2420_2423delTCAT); Zygosity=Heterozygous (PubMed=21339753) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173181 CVCL_MR70 BayGenomics ES cell line RRD241 embryonic stem cell house mouse CVCL_MR70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173182 CVCL_VL26 D2-iPSC-2 induced pluripotent stem cell human CVCL_VL26 From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 2888; DISC1; Simple; p.Ile808Serfs*816 (c.2420_2423delTCAT); Zygosity=Heterozygous (PubMed=21339753) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173183 CVCL_N370 GM10971 transformed cell line human CVCL_N370 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10971; probable Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173184 CVCL_VL09 GM02052+hTERT telomerase immortalized cell line human CVCL_VL09 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg35Ter (c.103C>T); ClinVar=VCV000003025; Zygosity=Homozygous (from parent cell line) Population: Jewish; Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173185 CVCL_MR90 BayGenomics ES cell line RRE006 embryonic stem cell house mouse CVCL_MR90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096361; Jpt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173186 CVCL_N390 GM13605 transformed cell line human CVCL_N390 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173187 CVCL_VL07 AT25ABR transformed cell line human CVCL_VL07 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21173188 CVCL_VL08 F239hTert telomerase immortalized cell line human CVCL_VL08 CL:0000010 Sequence variation: Mutation; HGNC; 9816; RAD50; Simple; p.Arg1093Ter (c.3277C>T); ClinVar=VCV000005872; Zygosity=Heterozygous (PubMed=19409520); Sequence variation: Mutation; HGNC; 9816; RAD50; Simple; p.Ter1313Tyrext*66 (c.3939A>T); ClinVar=VCV000005873; Zygosity=Heterozygous (PubMed=19409520); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173189 CVCL_MR88 BayGenomics ES cell line RRD312 embryonic stem cell house mouse CVCL_MR88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136782; BC004004 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173190 CVCL_N388 GM13603 transformed cell line human CVCL_N388 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173191 CVCL_MR89 BayGenomics ES cell line RRE001 embryonic stem cell house mouse CVCL_MR89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329041; Rngtt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173192 CVCL_N389 GM13604 transformed cell line human CVCL_N389 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173193 CVCL_MR86 BayGenomics ES cell line RRD307 embryonic stem cell house mouse CVCL_MR86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173194 CVCL_N386 GM13601 transformed cell line human CVCL_N386 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173195 CVCL_VL12 HK-2xZFN-mEGFP-Nup107 cancer cell line human CVCL_VL12 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using ZFN NUP107 has been endogenously tagged in both alleles at the N-terminus with mEGFP 21173196 CVCL_MR87 BayGenomics ES cell line RRD310 embryonic stem cell house mouse CVCL_MR87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173197 CVCL_N387 GM13602 transformed cell line human CVCL_N387 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173198 CVCL_VL13 HK-ZFN-AURKB-mEGFP cancer cell line human CVCL_VL13 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Edited by ZFN at the AURKB locus to insert a mEGFP construct at the N-terminus of the gene 21173199 CVCL_MR84 BayGenomics ES cell line RRD303 embryonic stem cell house mouse CVCL_MR84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107769; Zfp65 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173200 CVCL_VL10 GM05823+hTERT telomerase immortalized cell line human CVCL_VL10 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2427_Arg2428del (c.7278_7283delCCTTAG); ClinVar=VCV000003020; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173201 CVCL_N384 GM13599 transformed cell line human CVCL_N384 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173202 CVCL_MR85 BayGenomics ES cell line RRD306 embryonic stem cell house mouse CVCL_MR85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173203 CVCL_N385 GM13600 transformed cell line human CVCL_N385 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173204 CVCL_VL11 TU-KATO-III cancer cell line human CVCL_VL11 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Characteristics: Has a high tumorigenic potential Established after seven tumor passages of KATO-III in nude mice. 21173205 CVCL_MR82 BayGenomics ES cell line RRD299 embryonic stem cell house mouse CVCL_MR82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173206 CVCL_N382 GM13597 transformed cell line human CVCL_N382 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173207 CVCL_VL16 U-87MG/DDP cancer cell line human CVCL_VL16 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21173208 CVCL_MR83 BayGenomics ES cell line RRD301 embryonic stem cell house mouse CVCL_MR83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922832; Relch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173209 CVCL_VL17 C19 MEL cancer cell line house mouse CVCL_VL17 CL:0000010 Breed/subspecies: DBA/2. Characteristics: Thymidine kinase negative 21173210 CVCL_N383 GM13598 transformed cell line human CVCL_N383 CL:0000010 Population: Chinese/Asian ethnic group: Atayal; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173211 CVCL_MR80 BayGenomics ES cell line RRD286 embryonic stem cell house mouse CVCL_MR80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173212 CVCL_N380 GM11524 transformed cell line human CVCL_N380 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173213 CVCL_VL14 HK-ZFN-AURKB-mEGFP/ZFN-INCENP-mCherry cancer cell line human CVCL_VL14 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Edited by ZFN at the AURKB locus to insert a mEGFP construct at the N-terminus of both alleles of the gene and at the INCENP locus to insert a mCherry construct at the N-terminus of one allele of the gene 21173214 CVCL_MR81 BayGenomics ES cell line RRD288 embryonic stem cell house mouse CVCL_MR81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97555; Pgk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173215 CVCL_N381 GM11525 transformed cell line human CVCL_N381 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173216 CVCL_VL15 TSCCa cancer cell line human CVCL_VL15 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00579 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706; PubMed=28107433). Originally thought to originate from a tongue squamous cell carcinoma. 21173217 CVCL_MR59 BayGenomics ES cell line RRD204 embryonic stem cell house mouse CVCL_MR59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921991; C2cd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173218 CVCL_N359 GM10473 transformed cell line human CVCL_N359 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173219 CVCL_MR57 BayGenomics ES cell line RRD197 embryonic stem cell house mouse CVCL_MR57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2686040; Mtx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173220 CVCL_N357 GM10471 transformed cell line human CVCL_N357 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173221 CVCL_MR58 BayGenomics ES cell line RRD201 embryonic stem cell house mouse CVCL_MR58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173222 CVCL_N358 GM10472 transformed cell line human CVCL_N358 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173223 CVCL_MR55 BayGenomics ES cell line RRD195 embryonic stem cell house mouse CVCL_MR55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921991; C2cd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173224 CVCL_N355 GM10469 transformed cell line human CVCL_N355 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173225 CVCL_MR56 BayGenomics ES cell line RRD196 embryonic stem cell house mouse CVCL_MR56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918413; Zfp626 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173226 CVCL_N356 GM10470 transformed cell line human CVCL_N356 CL:0000010 Population: African; Biaka pygmies; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173227 CVCL_MR53 BayGenomics ES cell line RRD190 embryonic stem cell house mouse CVCL_MR53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442555; Dis3l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173228 CVCL_VL01 BT474-LR cancer cell line human CVCL_VL01 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Female 21173229 CVCL_N353 GM10797 finite cell line human CVCL_N353 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Ambiguous 21173230 CVCL_VL02 AT-LD2 finite cell line human CVCL_VL02 CL:0000010 Sequence variation: Mutation; HGNC; 7230; MRE11; Simple; p.Arg633Ter (c.1897C>T); ClinVar=VCV000008782; Zygosity=Homozygous (PubMed=10612394) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173231 CVCL_MR54 BayGenomics ES cell line RRD192 embryonic stem cell house mouse CVCL_MR54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922387; Rprd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173232 CVCL_N354 GM22622 transformed cell line human CVCL_N354 CL:0000010 Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21173233 CVCL_MR51 BayGenomics ES cell line RRD188 embryonic stem cell house mouse CVCL_MR51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918764; Sfpq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173234 CVCL_N351 GM10381 finite cell line human CVCL_N351 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21173235 CVCL_MR52 BayGenomics ES cell line RRD189 embryonic stem cell house mouse CVCL_MR52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196365; Nus1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173236 CVCL_N352 GM10796 finite cell line human CVCL_N352 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21173237 CVCL_VL00 PH5CH8 transformed cell line human CVCL_VL00 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pRSV-TAg](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver. Male Characteristics: Supports HCV replication 21173238 CVCL_VL05 W1799 finite cell line human CVCL_VL05 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. 21173239 CVCL_MR50 BayGenomics ES cell line RRD187 embryonic stem cell house mouse CVCL_MR50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173240 CVCL_N350 GM10379 finite cell line human CVCL_N350 CL:0000010 Population: African American; Derived from sampling site: Axilla; skin Cell type=Fibroblast.. Male 21173241 CVCL_VL06 W1799-hTERT telomerase immortalized cell line human CVCL_VL06 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 21173242 CVCL_VL03 AT-LD2-hTERT telomerase immortalized cell line human CVCL_VL03 CL:0000010 Sequence variation: Mutation; HGNC; 7230; MRE11; Simple; p.Arg633Ter (c.1897C>T); ClinVar=VCV000008782; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173243 CVCL_VL04 GM02052A-hTERT telomerase immortalized cell line human CVCL_VL04 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg35Ter (c.103C>T); ClinVar=VCV000003025; Zygosity=Homozygous (from parent cell line) Population: Jewish; Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173244 CVCL_MR68 BayGenomics ES cell line RRD231 embryonic stem cell house mouse CVCL_MR68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108412; Plpp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173245 CVCL_N368 GM10969 transformed cell line human CVCL_N368 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10969; probable Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173246 CVCL_MR69 BayGenomics ES cell line RRD240 embryonic stem cell house mouse CVCL_MR69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173247 CVCL_N369 GM10970 transformed cell line human CVCL_N369 CL:0000010 Population: Native South American; Surui; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10970; probable Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173248 CVCL_MR66 BayGenomics ES cell line RRD223 embryonic stem cell house mouse CVCL_MR66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95772; Gnai2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173249 CVCL_N366 GM10967 transformed cell line human CVCL_N366 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10967; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173250 CVCL_MR67 BayGenomics ES cell line RRD228 embryonic stem cell house mouse CVCL_MR67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913762; Dera Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173251 CVCL_N367 GM10968 transformed cell line human CVCL_N367 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10968; probable Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173252 CVCL_MR64 BayGenomics ES cell line RRD221 embryonic stem cell house mouse CVCL_MR64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173253 CVCL_N364 GM10965 transformed cell line human CVCL_N364 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10965; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173254 CVCL_MR65 BayGenomics ES cell line RRD222 embryonic stem cell house mouse CVCL_MR65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173255 CVCL_N365 GM10966 transformed cell line human CVCL_N365 CL:0000010 Population: Native South American; Karitiana; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM10966; probable Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173256 CVCL_MR62 BayGenomics ES cell line RRD214 embryonic stem cell house mouse CVCL_MR62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173257 CVCL_N362 GM10495 transformed cell line human CVCL_N362 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173258 CVCL_MR63 BayGenomics ES cell line RRD220 embryonic stem cell house mouse CVCL_MR63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173259 CVCL_N363 GM10496 transformed cell line human CVCL_N363 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173260 CVCL_MR60 BayGenomics ES cell line RRD205 embryonic stem cell house mouse CVCL_MR60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108247; Tdg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173261 CVCL_N360 GM10493 transformed cell line human CVCL_N360 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173262 CVCL_MR61 BayGenomics ES cell line RRD212 embryonic stem cell house mouse CVCL_MR61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914302; Ndc80 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173263 CVCL_N361 GM10494 transformed cell line human CVCL_N361 CL:0000010 Population: African; Mbuti Pygmy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173264 CVCL_MR39 BayGenomics ES cell line RRD169 embryonic stem cell house mouse CVCL_MR39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448530; Vps13d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173265 CVCL_N339 T87 hybridoma house mouse CVCL_N339 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8274 21173266 CVCL_MR37 BayGenomics ES cell line RRD161 embryonic stem cell house mouse CVCL_MR37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173267 CVCL_N337 T23 hybridoma house mouse CVCL_N337 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8271 21173268 CVCL_MR38 BayGenomics ES cell line RRD163 embryonic stem cell house mouse CVCL_MR38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858965; Atf7ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173269 CVCL_N338 T43 hybridoma house mouse CVCL_N338 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen URO10 on bladder cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8275 21173270 CVCL_MR35 BayGenomics ES cell line RRD159 embryonic stem cell house mouse CVCL_MR35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173271 CVCL_N335 T138 hybridoma house mouse CVCL_N335 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8277 21173272 CVCL_MR36 BayGenomics ES cell line RRD160 embryonic stem cell house mouse CVCL_MR36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101772; Snta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173273 CVCL_N336 T16 hybridoma house mouse CVCL_N336 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09758; Human TACSTD2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8279 21173274 CVCL_MR33 BayGenomics ES cell line RRD156 embryonic stem cell house mouse CVCL_MR33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858683; Copg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173275 CVCL_N333 T101 [Mouse hybridoma against human bladder carcinomas] hybridoma house mouse CVCL_N333 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8273 21173276 CVCL_MR34 BayGenomics ES cell line RRD158 embryonic stem cell house mouse CVCL_MR34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700014; Sorbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173277 CVCL_N334 T110 [Mouse hybridoma] hybridoma house mouse CVCL_N334 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8278 21173278 CVCL_MR31 BayGenomics ES cell line RRD147 embryonic stem cell house mouse CVCL_MR31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173279 CVCL_N331 S27 hybridoma house mouse CVCL_N331 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human adenosine deaminase binding protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8428 21173280 CVCL_MR32 BayGenomics ES cell line RRD153 embryonic stem cell house mouse CVCL_MR32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923573; Zdhhc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173281 CVCL_N332 S4 [Mouse hybridoma against human URO2] hybridoma house mouse CVCL_N332 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human antigen URO2 on renal cancer cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8541 21173282 CVCL_MR30 BayGenomics ES cell line RRD146 embryonic stem cell house mouse CVCL_MR30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684789; Lrsam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173283 CVCL_N330 S23 hybridoma house mouse CVCL_N330 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human adenosine deaminase binding protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8540 21173284 CVCL_MR48 BayGenomics ES cell line RRD185 embryonic stem cell house mouse CVCL_MR48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173285 CVCL_N348 Hs 769.Bl finite cell line human CVCL_N348 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7881; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173286 CVCL_MR49 BayGenomics ES cell line RRD186 embryonic stem cell house mouse CVCL_MR49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923385; Prex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173287 CVCL_N349 Hs 805.Sk finite cell line human CVCL_N349 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Discontinued: ATCC; CRL-7536; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173288 CVCL_MR46 BayGenomics ES cell line RRD180 embryonic stem cell house mouse CVCL_MR46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345183; Tenm3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173289 CVCL_N346 Hs 755(A).T cancer cell line human CVCL_N346 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; leg. Discontinued: ATCC; CRL-7877; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173290 CVCL_MR47 BayGenomics ES cell line RRD181 embryonic stem cell house mouse CVCL_MR47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338822; Celf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173291 CVCL_N347 Hs 755.Mu finite cell line human CVCL_N347 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7876; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173292 CVCL_MR44 BayGenomics ES cell line RRD176 embryonic stem cell house mouse CVCL_MR44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643794; Eif1ad8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173293 CVCL_N344 GM01242 transformed cell line human CVCL_N344 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173294 CVCL_MR45 BayGenomics ES cell line RRD179 embryonic stem cell house mouse CVCL_MR45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917143; Coa7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173295 CVCL_N345 GM01435 finite cell line human CVCL_N345 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21173296 CVCL_MR42 BayGenomics ES cell line RRD172 embryonic stem cell house mouse CVCL_MR42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173297 CVCL_N342 Hs 717.T cancer cell line human CVCL_N342 CL:0000010 Discontinued: ATCC; CRL-7455; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173298 CVCL_MR43 BayGenomics ES cell line RRD175 embryonic stem cell house mouse CVCL_MR43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917042; Med6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173299 CVCL_N343 Hs 887.T cancer cell line human CVCL_N343 CL:0000010 Derived from metastatic site: Lung. Discontinued: ATCC; CRL-7621; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173300 CVCL_MR40 BayGenomics ES cell line RRD170 embryonic stem cell house mouse CVCL_MR40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892973; Gpr19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173301 CVCL_N340 F1-73 finite cell line human CVCL_N340 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7922; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173302 CVCL_MR41 BayGenomics ES cell line RRD171 embryonic stem cell house mouse CVCL_MR41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919055; Nup93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173303 CVCL_N341 HT-295.T cancer cell line human CVCL_N341 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7781; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173304 CVCL_3G94 HQ00703 transformed cell line human CVCL_3G94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173305 CVCL_3G95 HQ00704 transformed cell line human CVCL_3G95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173306 CVCL_3G92 HQ00701 transformed cell line human CVCL_3G92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173307 CVCL_3G93 HQ00702 transformed cell line human CVCL_3G93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173308 CVCL_3G98 HQ00707 transformed cell line human CVCL_3G98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173309 CVCL_3G99 HQ00708 transformed cell line human CVCL_3G99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173310 CVCL_3G96 HQ00705 transformed cell line human CVCL_3G96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173311 CVCL_3G97 HQ00706 transformed cell line human CVCL_3G97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173312 CVCL_3G90 HQ00699 transformed cell line human CVCL_3G90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173313 CVCL_3G91 HQ00700 transformed cell line human CVCL_3G91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173314 CVCL_3G72 HQ00681 transformed cell line human CVCL_3G72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173315 CVCL_3G73 HQ00682 transformed cell line human CVCL_3G73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173316 CVCL_3G70 HQ00679 transformed cell line human CVCL_3G70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173317 CVCL_3G71 HQ00680 transformed cell line human CVCL_3G71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173318 CVCL_3G76 HQ00685 transformed cell line human CVCL_3G76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173319 CVCL_3G77 HQ00686 transformed cell line human CVCL_3G77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173320 CVCL_3G74 HQ00683 transformed cell line human CVCL_3G74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173321 CVCL_3G75 HQ00684 transformed cell line human CVCL_3G75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173322 CVCL_3G78 HQ00687 transformed cell line human CVCL_3G78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173323 CVCL_3G79 HQ00688 transformed cell line human CVCL_3G79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173324 CVCL_3G83 HQ00692 transformed cell line human CVCL_3G83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173325 CVCL_3G84 HQ00693 transformed cell line human CVCL_3G84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173326 CVCL_3G81 HQ00690 transformed cell line human CVCL_3G81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173327 CVCL_3G82 HQ00691 transformed cell line human CVCL_3G82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173328 CVCL_3G87 HQ00696 transformed cell line human CVCL_3G87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173329 CVCL_3G88 HQ00697 transformed cell line human CVCL_3G88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173330 CVCL_3G85 HQ00694 transformed cell line human CVCL_3G85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173331 CVCL_3G86 HQ00695 transformed cell line human CVCL_3G86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173332 CVCL_3G89 HQ00698 transformed cell line human CVCL_3G89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173333 CVCL_3G80 HQ00689 transformed cell line human CVCL_3G80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173334 CVCL_3G50 HQ00659 transformed cell line human CVCL_3G50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173335 CVCL_3G51 HQ00660 transformed cell line human CVCL_3G51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173336 CVCL_3G54 HQ00663 transformed cell line human CVCL_3G54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173337 CVCL_3G55 HQ00664 transformed cell line human CVCL_3G55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173338 CVCL_3G52 HQ00661 transformed cell line human CVCL_3G52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173339 CVCL_3G53 HQ00662 transformed cell line human CVCL_3G53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173340 CVCL_3G58 HQ00667 transformed cell line human CVCL_3G58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173341 CVCL_3G59 HQ00668 transformed cell line human CVCL_3G59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173342 CVCL_3G56 HQ00665 transformed cell line human CVCL_3G56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173343 CVCL_3G57 HQ00666 transformed cell line human CVCL_3G57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173344 CVCL_3G61 HQ00670 transformed cell line human CVCL_3G61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173345 CVCL_3G62 HQ00671 transformed cell line human CVCL_3G62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173346 CVCL_3G60 HQ00669 transformed cell line human CVCL_3G60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173347 CVCL_3G65 HQ00674 transformed cell line human CVCL_3G65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173348 CVCL_3G66 HQ00675 transformed cell line human CVCL_3G66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173349 CVCL_3G63 HQ00672 transformed cell line human CVCL_3G63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173350 CVCL_3G64 HQ00673 transformed cell line human CVCL_3G64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173351 CVCL_3G69 HQ00678 transformed cell line human CVCL_3G69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173352 CVCL_3G67 HQ00676 transformed cell line human CVCL_3G67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173353 CVCL_3G68 HQ00677 transformed cell line human CVCL_3G68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173354 CVCL_VM91 HPS0408 induced pluripotent stem cell human CVCL_VM91 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173355 CVCL_VM92 HPS0417 induced pluripotent stem cell human CVCL_VM92 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173356 CVCL_VM90 HPS1010 induced pluripotent stem cell human CVCL_VM90 CL:0000010 Derived from sampling site: Peripheral blood. Male 21173357 CVCL_VM95 HPS0479 induced pluripotent stem cell human CVCL_VM95 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173358 CVCL_VM96 HPS0491 induced pluripotent stem cell human CVCL_VM96 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173359 CVCL_VM93 HPS0433 induced pluripotent stem cell human CVCL_VM93 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173360 CVCL_VM94 HPS0437 induced pluripotent stem cell human CVCL_VM94 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173361 CVCL_VM99 HeLa/Fucci(SCA)2 cancer cell line human CVCL_VM99 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Ser101_Leu546del and p.Arg68Ala, p.Arg69Ala and p.Leu70Ala); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci(SCA2) (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci(SCA)2 probe which consist of the fusion of mCherry) to the ubiquitination domain of human CDT1 (aa 1-100) and of monomeric Venus (mVenus) to the ubiquitination domain of human geminin (aa 1-110) 21173362 CVCL_VM97 HPS1011 induced pluripotent stem cell human CVCL_VM97 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173363 CVCL_VM98 HeLa/Fucci(CA)2 cancer cell line human CVCL_VM98 CL:0000010 Transfected with: HGNC; 24576; CDT1 (with p.Ser101_Leu546del and p.Arg68Ala, p.Arg69Ala and p.Leu70Ala); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: Venus, a bright yellow fluorescent protein derived from YFP Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Used for study of cell cycle progression thanks to the inclusion of a Fucci(CA2) (Fluorescent Ubiquitination-based Cell Cycle Indicator) construct; Characteristics: Transfected with the Fucci(CA)2 probe which consist of the fusion of mCherry to the ubiquitination domain of human CDT1 (aa 1-100) but with the Cy motif 68-RRL-70 replaced by AAA and of monomeric Venus (mVenus) to the ubiquitination domain of human geminin (aa 1-110) 21173364 CVCL_3G32 HQ00641 transformed cell line human CVCL_3G32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173365 CVCL_3G33 HQ00642 transformed cell line human CVCL_3G33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173366 CVCL_3G30 HQ00639 transformed cell line human CVCL_3G30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173367 CVCL_3G31 HQ00640 transformed cell line human CVCL_3G31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173368 CVCL_3G36 HQ00645 transformed cell line human CVCL_3G36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173369 CVCL_3G37 HQ00646 transformed cell line human CVCL_3G37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173370 CVCL_3G34 HQ00643 transformed cell line human CVCL_3G34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173371 CVCL_3G35 HQ00644 transformed cell line human CVCL_3G35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173372 CVCL_3G38 HQ00647 transformed cell line human CVCL_3G38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173373 CVCL_3G39 HQ00648 transformed cell line human CVCL_3G39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173374 CVCL_VM80 HPS1478 induced pluripotent stem cell human CVCL_VM80 CL:0000010 Derived from sampling site: Peripheral blood. Male 21173375 CVCL_VM81 HPS1725 induced pluripotent stem cell human CVCL_VM81 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173376 CVCL_VM84 HPS0388 induced pluripotent stem cell human CVCL_VM84 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173377 CVCL_VM85 HPS0390 induced pluripotent stem cell human CVCL_VM85 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173378 CVCL_VM82 HPS1728 induced pluripotent stem cell human CVCL_VM82 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173379 CVCL_VM83 HPS2220 induced pluripotent stem cell human CVCL_VM83 CL:0000010 Derived from sampling site: Peripheral blood. Female 21173380 CVCL_VM88 HPS0397 induced pluripotent stem cell human CVCL_VM88 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173381 CVCL_VM89 HPS0407 induced pluripotent stem cell human CVCL_VM89 CL:0000010 Derived from sampling site: Peripheral blood. Male 21173382 CVCL_VM86 HPS0393 induced pluripotent stem cell human CVCL_VM86 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173383 CVCL_VM87 HPS0395 induced pluripotent stem cell human CVCL_VM87 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173384 CVCL_3G40 HQ00649 transformed cell line human CVCL_3G40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173385 CVCL_3G43 HQ00652 transformed cell line human CVCL_3G43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173386 CVCL_3G44 HQ00653 transformed cell line human CVCL_3G44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173387 CVCL_3G41 HQ00650 transformed cell line human CVCL_3G41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173388 CVCL_3G42 HQ00651 transformed cell line human CVCL_3G42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173389 CVCL_3G47 HQ00656 transformed cell line human CVCL_3G47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173390 CVCL_3G48 HQ00657 transformed cell line human CVCL_3G48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173391 CVCL_3G45 HQ00654 transformed cell line human CVCL_3G45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173392 CVCL_3G46 HQ00655 transformed cell line human CVCL_3G46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173393 CVCL_3G49 HQ00658 transformed cell line human CVCL_3G49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173394 CVCL_VM70 HPS0485 induced pluripotent stem cell human CVCL_VM70 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173395 CVCL_VM73 CiRA00111-ES-H19 induced pluripotent stem cell human CVCL_VM73 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using TALEN a 18 bp deletion was introduced spanning the splicing acceptor site of DMD exon 45 thus restoring the reading frame 21173396 CVCL_VM74 CiRA00111-IF-D28 induced pluripotent stem cell human CVCL_VM74 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using TALEN a 1 bp deletion was introduced in DMD exon 45 thus restoring the reading frame 21173397 CVCL_VM71 CiRA00111 induced pluripotent stem cell human CVCL_VM71 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex44del; Zygosity=Hemizygous (PubMed=25434822) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173398 CVCL_VM72 CiRA00111-CKI-C2 induced pluripotent stem cell human CVCL_VM72 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 DMD exon 44 was knocked-in thus restoring the reading frame 21173399 CVCL_VM77 HPS0458 induced pluripotent stem cell human CVCL_VM77 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173400 CVCL_VM78 HPS0546 induced pluripotent stem cell human CVCL_VM78 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21173401 CVCL_VM75 CiRA00111-TKI-I15 induced pluripotent stem cell human CVCL_VM75 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using TALEN DMD exon 44 was knocked-in thus restoring the reading frame 21173402 CVCL_VM76 HPS0419 induced pluripotent stem cell human CVCL_VM76 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173403 CVCL_VM79 HPS0772 induced pluripotent stem cell human CVCL_VM79 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173404 CVCL_DZ45 ND07012 transformed cell line human CVCL_DZ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173405 CVCL_DZ46 ND07014 transformed cell line human CVCL_DZ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173406 CVCL_DZ43 ND06995 transformed cell line human CVCL_DZ43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173407 CVCL_DZ44 ND07005 transformed cell line human CVCL_DZ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173408 CVCL_DZ49 ND07046 transformed cell line human CVCL_DZ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173409 CVCL_DZ47 ND07016 transformed cell line human CVCL_DZ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173410 CVCL_DZ48 ND07035 transformed cell line human CVCL_DZ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173411 CVCL_DZ41 ND06970 transformed cell line human CVCL_DZ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173412 CVCL_DZ42 ND06994 transformed cell line human CVCL_DZ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173413 CVCL_DZ40 ND06969 transformed cell line human CVCL_DZ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173414 CVCL_DZ56 ND07115 transformed cell line human CVCL_DZ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173415 CVCL_DZ57 ND07116 transformed cell line human CVCL_DZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173416 CVCL_DZ54 ND07110 transformed cell line human CVCL_DZ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173417 CVCL_DZ55 ND07111 transformed cell line human CVCL_DZ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173418 CVCL_DZ58 ND07138 transformed cell line human CVCL_DZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173419 CVCL_DZ59 ND07139 transformed cell line human CVCL_DZ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173420 CVCL_DZ52 ND07108 transformed cell line human CVCL_DZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173421 CVCL_DZ53 ND07109 transformed cell line human CVCL_DZ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173422 CVCL_DZ50 ND07047 transformed cell line human CVCL_DZ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173423 CVCL_DZ51 ND07067 transformed cell line human CVCL_DZ51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173424 CVCL_DZ23 ND06760 transformed cell line human CVCL_DZ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173425 CVCL_DZ24 ND06761 transformed cell line human CVCL_DZ24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173426 CVCL_DZ21 ND06744 transformed cell line human CVCL_DZ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173427 CVCL_DZ22 ND06757 transformed cell line human CVCL_DZ22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173428 CVCL_DZ27 ND06791 transformed cell line human CVCL_DZ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173429 CVCL_DZ28 ND06793 transformed cell line human CVCL_DZ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173430 CVCL_DZ25 ND06788 transformed cell line human CVCL_DZ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173431 CVCL_DZ26 ND06790 transformed cell line human CVCL_DZ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173432 CVCL_DZ20 ND06565 transformed cell line human CVCL_DZ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173433 CVCL_DZ18 ND06539 transformed cell line human CVCL_DZ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173434 CVCL_DZ19 ND06559 transformed cell line human CVCL_DZ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173435 CVCL_DZ34 ND06883 transformed cell line human CVCL_DZ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173436 CVCL_DZ35 ND06919 transformed cell line human CVCL_DZ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173437 CVCL_DZ32 ND06841 transformed cell line human CVCL_DZ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173438 CVCL_DZ33 ND06882 transformed cell line human CVCL_DZ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173439 CVCL_DZ38 ND06925 transformed cell line human CVCL_DZ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173440 CVCL_DZ39 ND06968 transformed cell line human CVCL_DZ39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173441 CVCL_DZ36 ND06921 transformed cell line human CVCL_DZ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173442 CVCL_DZ37 ND06924 transformed cell line human CVCL_DZ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173443 CVCL_DZ30 ND06795 transformed cell line human CVCL_DZ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173444 CVCL_DZ29 ND06794 transformed cell line human CVCL_DZ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173445 CVCL_DZ01 ND06263 transformed cell line human CVCL_DZ01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173446 CVCL_DZ02 ND06265 transformed cell line human CVCL_DZ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173447 CVCL_DZ00 ND06257 transformed cell line human CVCL_DZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173448 CVCL_DZ05 ND06352 transformed cell line human CVCL_DZ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173449 CVCL_DZ06 ND06370 transformed cell line human CVCL_DZ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173450 CVCL_DZ04 ND06274 transformed cell line human CVCL_DZ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173451 CVCL_DZ12 ND06462 transformed cell line human CVCL_DZ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173452 CVCL_DZ13 ND06464 transformed cell line human CVCL_DZ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173453 CVCL_DZ10 ND06437 transformed cell line human CVCL_DZ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173454 CVCL_DZ11 ND06438 transformed cell line human CVCL_DZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173455 CVCL_DZ16 ND06493 transformed cell line human CVCL_DZ16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173456 CVCL_DZ17 ND06495 transformed cell line human CVCL_DZ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173457 CVCL_DZ14 ND06479 transformed cell line human CVCL_DZ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173458 CVCL_DZ15 ND06485 transformed cell line human CVCL_DZ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173459 CVCL_DZ09 ND06435 transformed cell line human CVCL_DZ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173460 CVCL_DZ07 ND06385 transformed cell line human CVCL_DZ07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173461 CVCL_DZ08 ND06419 transformed cell line human CVCL_DZ08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173462 CVCL_MS38 BayGenomics ES cell line RRE110 embryonic stem cell house mouse CVCL_MS38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346865; Mapk14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173463 CVCL_N438 GM13847 transformed cell line human CVCL_N438 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173464 CVCL_MS39 BayGenomics ES cell line RRE111 embryonic stem cell house mouse CVCL_MS39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173465 CVCL_N439 GM13848 transformed cell line human CVCL_N439 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173466 CVCL_MS36 BayGenomics ES cell line RRE101 embryonic stem cell house mouse CVCL_MS36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107745; Dctn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173467 CVCL_N436 GM13845 transformed cell line human CVCL_N436 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173468 CVCL_MS37 BayGenomics ES cell line RRE106 embryonic stem cell house mouse CVCL_MS37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096397; Polr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173469 CVCL_N437 GM13846 transformed cell line human CVCL_N437 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173470 CVCL_MS34 BayGenomics ES cell line RRE091 embryonic stem cell house mouse CVCL_MS34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930140; Wdr6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173471 CVCL_N434 GM13843 transformed cell line human CVCL_N434 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173472 CVCL_MS35 BayGenomics ES cell line RRE094 embryonic stem cell house mouse CVCL_MS35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173473 CVCL_N435 GM13844 transformed cell line human CVCL_N435 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173474 CVCL_MS32 BayGenomics ES cell line RRE088 embryonic stem cell house mouse CVCL_MS32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173475 CVCL_N432 GM13841 transformed cell line human CVCL_N432 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173476 CVCL_MS33 BayGenomics ES cell line RRE089 embryonic stem cell house mouse CVCL_MS33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914080; Nacc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173477 CVCL_N433 GM13842 transformed cell line human CVCL_N433 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173478 CVCL_MS30 BayGenomics ES cell line RRE083 embryonic stem cell house mouse CVCL_MS30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173479 CVCL_N430 GM13839 transformed cell line human CVCL_N430 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173480 CVCL_MS31 BayGenomics ES cell line RRE085 embryonic stem cell house mouse CVCL_MS31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173481 CVCL_N431 GM13840 transformed cell line human CVCL_N431 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173482 CVCL_MS49 BayGenomics ES cell line RRE133 embryonic stem cell house mouse CVCL_MS49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926135; Coro7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173483 CVCL_N449 GM13858 transformed cell line human CVCL_N449 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173484 CVCL_MS47 BayGenomics ES cell line RRE127 embryonic stem cell house mouse CVCL_MS47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159614; Mia2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173485 CVCL_N447 GM13856 transformed cell line human CVCL_N447 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173486 CVCL_MS48 BayGenomics ES cell line RRE131 embryonic stem cell house mouse CVCL_MS48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917933; Utp20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173487 CVCL_N448 GM13857 transformed cell line human CVCL_N448 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173488 CVCL_MS45 BayGenomics ES cell line RRE123 embryonic stem cell house mouse CVCL_MS45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328361; Bard1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173489 CVCL_N445 GM13854 transformed cell line human CVCL_N445 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173490 CVCL_MS46 BayGenomics ES cell line RRE125 embryonic stem cell house mouse CVCL_MS46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144564; Fam117a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173491 CVCL_N446 GM13855 transformed cell line human CVCL_N446 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173492 CVCL_MS43 BayGenomics ES cell line RRE120 embryonic stem cell house mouse CVCL_MS43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173493 CVCL_N443 GM13852 transformed cell line human CVCL_N443 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173494 CVCL_MS44 BayGenomics ES cell line RRE122 embryonic stem cell house mouse CVCL_MS44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3649996; Dnmt3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173495 CVCL_N444 GM13853 transformed cell line human CVCL_N444 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173496 CVCL_MS41 BayGenomics ES cell line RRE114 embryonic stem cell house mouse CVCL_MS41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916241; Ssu72 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173497 CVCL_N441 GM13850 transformed cell line human CVCL_N441 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173498 CVCL_MS42 BayGenomics ES cell line RRE117 embryonic stem cell house mouse CVCL_MS42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107180; Elf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173499 CVCL_N442 GM13851 transformed cell line human CVCL_N442 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173500 CVCL_MS40 BayGenomics ES cell line RRE112 embryonic stem cell house mouse CVCL_MS40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448759; Cdv3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173501 CVCL_N440 GM13849 transformed cell line human CVCL_N440 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173502 CVCL_DY88 ND05979 transformed cell line human CVCL_DY88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173503 CVCL_DY89 ND05980 transformed cell line human CVCL_DY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173504 CVCL_DY82 ND05806 transformed cell line human CVCL_DY82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173505 CVCL_DY83 ND05866 transformed cell line human CVCL_DY83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173506 CVCL_DY80 ND05757 transformed cell line human CVCL_DY80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173507 CVCL_DY81 ND05772 transformed cell line human CVCL_DY81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173508 CVCL_DY86 ND05898 transformed cell line human CVCL_DY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173509 CVCL_DY87 ND05978 transformed cell line human CVCL_DY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173510 CVCL_MS18 BayGenomics ES cell line RRE067 embryonic stem cell house mouse CVCL_MS18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173511 CVCL_N418 GM13827 transformed cell line human CVCL_N418 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173512 CVCL_DY84 ND05867 transformed cell line human CVCL_DY84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173513 CVCL_MS19 BayGenomics ES cell line RRE069 embryonic stem cell house mouse CVCL_MS19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337008; Ankfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173514 CVCL_N419 GM13828 transformed cell line human CVCL_N419 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173515 CVCL_DY85 ND05871 transformed cell line human CVCL_DY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173516 CVCL_MS16 BayGenomics ES cell line RRE061 embryonic stem cell house mouse CVCL_MS16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917890; Dcp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173517 CVCL_N416 GM13825 transformed cell line human CVCL_N416 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173518 CVCL_MS17 BayGenomics ES cell line RRE064 embryonic stem cell house mouse CVCL_MS17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173519 CVCL_N417 GM13826 transformed cell line human CVCL_N417 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173520 CVCL_MS14 BayGenomics ES cell line RRE057 embryonic stem cell house mouse CVCL_MS14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651986; Zfp985 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173521 CVCL_N414 GM13823 transformed cell line human CVCL_N414 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173522 CVCL_MS15 BayGenomics ES cell line RRE058 embryonic stem cell house mouse CVCL_MS15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914852; Necap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173523 CVCL_N415 GM13824 transformed cell line human CVCL_N415 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173524 CVCL_MS12 BayGenomics ES cell line RRE054 embryonic stem cell house mouse CVCL_MS12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173525 CVCL_N412 GM13821 transformed cell line human CVCL_N412 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173526 CVCL_MS13 BayGenomics ES cell line RRE056 embryonic stem cell house mouse CVCL_MS13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103199; Mcm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173527 CVCL_N413 GM13822 transformed cell line human CVCL_N413 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173528 CVCL_MS10 BayGenomics ES cell line RRE050 embryonic stem cell house mouse CVCL_MS10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99495; Brd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173529 CVCL_N410 GM13626 transformed cell line human CVCL_N410 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173530 CVCL_MS11 BayGenomics ES cell line RRE053 embryonic stem cell house mouse CVCL_MS11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173531 CVCL_N411 GM13820 transformed cell line human CVCL_N411 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173532 CVCL_DY99 ND06231 transformed cell line human CVCL_DY99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173533 CVCL_DY93 ND06024 transformed cell line human CVCL_DY93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173534 CVCL_DY94 ND06079 transformed cell line human CVCL_DY94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173535 CVCL_DY91 ND05983 transformed cell line human CVCL_DY91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173536 CVCL_DY92 ND06023 transformed cell line human CVCL_DY92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173537 CVCL_DY97 ND06227 transformed cell line human CVCL_DY97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173538 CVCL_DY98 ND06230 transformed cell line human CVCL_DY98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173539 CVCL_MS29 BayGenomics ES cell line RRE082 embryonic stem cell house mouse CVCL_MS29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173540 CVCL_N429 GM13838 transformed cell line human CVCL_N429 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173541 CVCL_DY95 ND06082 transformed cell line human CVCL_DY95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173542 CVCL_DY96 ND06144 transformed cell line human CVCL_DY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173543 CVCL_MS27 BayGenomics ES cell line RRE079 embryonic stem cell house mouse CVCL_MS27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173544 CVCL_N427 GM13836 transformed cell line human CVCL_N427 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173545 CVCL_MS28 BayGenomics ES cell line RRE080 embryonic stem cell house mouse CVCL_MS28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173546 CVCL_N428 GM13837 transformed cell line human CVCL_N428 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173547 CVCL_MS25 BayGenomics ES cell line RRE076 embryonic stem cell house mouse CVCL_MS25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890614; Dusp12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173548 CVCL_N425 GM13834 transformed cell line human CVCL_N425 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173549 CVCL_MS26 BayGenomics ES cell line RRE078 embryonic stem cell house mouse CVCL_MS26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916625; Btbd9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173550 CVCL_N426 GM13835 transformed cell line human CVCL_N426 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173551 CVCL_MS23 BayGenomics ES cell line RRE074 embryonic stem cell house mouse CVCL_MS23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173552 CVCL_N423 GM13832 transformed cell line human CVCL_N423 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173553 CVCL_MS24 BayGenomics ES cell line RRE075 embryonic stem cell house mouse CVCL_MS24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918419; Nbas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173554 CVCL_N424 GM13833 transformed cell line human CVCL_N424 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173555 CVCL_DY90 ND05982 transformed cell line human CVCL_DY90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173556 CVCL_MS21 BayGenomics ES cell line RRE071 embryonic stem cell house mouse CVCL_MS21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173557 CVCL_N421 GM13830 transformed cell line human CVCL_N421 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173558 CVCL_MS22 BayGenomics ES cell line RRE072 embryonic stem cell house mouse CVCL_MS22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446159; Itpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173559 CVCL_N422 GM13831 transformed cell line human CVCL_N422 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173560 CVCL_MS20 BayGenomics ES cell line RRE070 embryonic stem cell house mouse CVCL_MS20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918348; Cep170 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173561 CVCL_N420 GM13829 transformed cell line human CVCL_N420 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173562 CVCL_DY68 ND05574 transformed cell line human CVCL_DY68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173563 CVCL_DY69 ND05577 transformed cell line human CVCL_DY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173564 CVCL_DY66 ND05525 transformed cell line human CVCL_DY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173565 CVCL_DY67 ND05563 transformed cell line human CVCL_DY67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173566 CVCL_DY60 ND05479 transformed cell line human CVCL_DY60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173567 CVCL_DY61 ND05483 transformed cell line human CVCL_DY61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173568 CVCL_DY64 ND05522 transformed cell line human CVCL_DY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173569 CVCL_DY65 ND05524 transformed cell line human CVCL_DY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173570 CVCL_DY62 ND05485 transformed cell line human CVCL_DY62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173571 CVCL_DY63 ND05495 transformed cell line human CVCL_DY63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173572 CVCL_DY79 ND05742 transformed cell line human CVCL_DY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173573 CVCL_DY77 ND05651 transformed cell line human CVCL_DY77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173574 CVCL_DY78 ND05680 transformed cell line human CVCL_DY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173575 CVCL_DY71 ND05579 transformed cell line human CVCL_DY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173576 CVCL_DY72 ND05592 transformed cell line human CVCL_DY72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173577 CVCL_DY70 ND05578 transformed cell line human CVCL_DY70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173578 CVCL_MS09 BayGenomics ES cell line RRE045 embryonic stem cell house mouse CVCL_MS09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918052; Pwwp2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173579 CVCL_N409 GM13625 transformed cell line human CVCL_N409 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173580 CVCL_DY75 ND05649 transformed cell line human CVCL_DY75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173581 CVCL_DY76 ND05650 transformed cell line human CVCL_DY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173582 CVCL_MS07 BayGenomics ES cell line RRE042 embryonic stem cell house mouse CVCL_MS07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444584; Mysm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173583 CVCL_N407 GM13623 transformed cell line human CVCL_N407 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173584 CVCL_DY73 ND05593 transformed cell line human CVCL_DY73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173585 CVCL_MS08 BayGenomics ES cell line RRE043 embryonic stem cell house mouse CVCL_MS08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173586 CVCL_N408 GM13624 transformed cell line human CVCL_N408 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173587 CVCL_DY74 ND05606 transformed cell line human CVCL_DY74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173588 CVCL_MS05 BayGenomics ES cell line RRE038 embryonic stem cell house mouse CVCL_MS05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914915; Dctn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173589 CVCL_N405 GM13620 transformed cell line human CVCL_N405 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173590 CVCL_MS06 BayGenomics ES cell line RRE040 embryonic stem cell house mouse CVCL_MS06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448759; Cdv3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173591 CVCL_N406 GM13622 transformed cell line human CVCL_N406 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173592 CVCL_MS03 BayGenomics ES cell line RRE034 embryonic stem cell house mouse CVCL_MS03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917606; St13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173593 CVCL_N403 GM13618 transformed cell line human CVCL_N403 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173594 CVCL_MS04 BayGenomics ES cell line RRE035 embryonic stem cell house mouse CVCL_MS04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448759; Cdv3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173595 CVCL_N404 GM13619 transformed cell line human CVCL_N404 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173596 CVCL_MS01 BayGenomics ES cell line RRE024 embryonic stem cell house mouse CVCL_MS01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922066; Tpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173597 CVCL_N401 GM13616 transformed cell line human CVCL_N401 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173598 CVCL_MS02 BayGenomics ES cell line RRE025 embryonic stem cell house mouse CVCL_MS02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103288; Polr1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173599 CVCL_N402 GM13617 transformed cell line human CVCL_N402 CL:0000010 Population: Caucasian; Adyghean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173600 CVCL_MS00 BayGenomics ES cell line RRE023 embryonic stem cell house mouse CVCL_MS00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914051; Prkrip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173601 CVCL_N400 GM13615 transformed cell line human CVCL_N400 CL:0000010 Population: Chinese/Asian ethnic group: Ami; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173602 CVCL_DY46 ND05349 transformed cell line human CVCL_DY46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173603 CVCL_DY47 ND05351 transformed cell line human CVCL_DY47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173604 CVCL_DY44 ND05310 transformed cell line human CVCL_DY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173605 CVCL_DY45 ND05348 transformed cell line human CVCL_DY45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173606 CVCL_DY48 ND05352 transformed cell line human CVCL_DY48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173607 CVCL_DY49 ND05371 transformed cell line human CVCL_DY49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173608 CVCL_DY42 ND05294 transformed cell line human CVCL_DY42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173609 CVCL_DY43 ND05298 transformed cell line human CVCL_DY43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173610 CVCL_DY40 ND05240 transformed cell line human CVCL_DY40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173611 CVCL_DY41 ND05275 transformed cell line human CVCL_DY41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173612 CVCL_DY57 ND05446 transformed cell line human CVCL_DY57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173613 CVCL_DY58 ND05447 transformed cell line human CVCL_DY58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173614 CVCL_DY55 ND05423 transformed cell line human CVCL_DY55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173615 CVCL_DY56 ND05445 transformed cell line human CVCL_DY56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173616 CVCL_DY59 ND05450 transformed cell line human CVCL_DY59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173617 CVCL_DY50 ND05388 transformed cell line human CVCL_DY50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173618 CVCL_DY53 ND05391 transformed cell line human CVCL_DY53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173619 CVCL_DY54 ND05413 transformed cell line human CVCL_DY54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173620 CVCL_DY51 ND05389 transformed cell line human CVCL_DY51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173621 CVCL_DY52 ND05390 transformed cell line human CVCL_DY52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173622 CVCL_3G10 HQ00619 transformed cell line human CVCL_3G10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173623 CVCL_3G11 HQ00620 transformed cell line human CVCL_3G11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173624 CVCL_3G14 HQ00623 transformed cell line human CVCL_3G14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173625 CVCL_3G15 HQ00624 transformed cell line human CVCL_3G15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173626 CVCL_3G12 HQ00621 transformed cell line human CVCL_3G12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173627 CVCL_3G13 HQ00622 transformed cell line human CVCL_3G13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173628 CVCL_3G18 HQ00627 transformed cell line human CVCL_3G18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173629 CVCL_3G19 HQ00628 transformed cell line human CVCL_3G19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173630 CVCL_3G16 HQ00625 transformed cell line human CVCL_3G16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173631 CVCL_3G17 HQ00626 transformed cell line human CVCL_3G17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173632 CVCL_3G09 HQ00618 transformed cell line human CVCL_3G09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173633 CVCL_VM62 CUTC61 cancer cell line human CVCL_VM62 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000160364; Zygosity=Heterozygous (PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+1G>A; ClinVar=VCV000634702; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30733375; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 29 hours (PubMed=30733375) 21173634 CVCL_VM63 HPS0252 induced pluripotent stem cell human CVCL_VM63 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173635 CVCL_VM60 HPS0251 induced pluripotent stem cell human CVCL_VM60 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173636 CVCL_VM61 CUTC60 cancer cell line human CVCL_VM61 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Homozygous (PubMed=30733375; PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 22 hours (PubMed=30733375) 21173637 CVCL_VM66 HPS0288 induced pluripotent stem cell human CVCL_VM66 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173638 CVCL_VM67 HPS0473 induced pluripotent stem cell human CVCL_VM67 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173639 CVCL_VM64 HPS0253 induced pluripotent stem cell human CVCL_VM64 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173640 CVCL_VM65 HPS0258 induced pluripotent stem cell human CVCL_VM65 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173641 CVCL_VM68 HPS0476 induced pluripotent stem cell human CVCL_VM68 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173642 CVCL_VM69 HPS0482 induced pluripotent stem cell human CVCL_VM69 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173643 CVCL_3G21 HQ00630 transformed cell line human CVCL_3G21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173644 CVCL_3G22 HQ00631 transformed cell line human CVCL_3G22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173645 CVCL_3G20 HQ00629 transformed cell line human CVCL_3G20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173646 CVCL_3G25 HQ00634 transformed cell line human CVCL_3G25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173647 CVCL_3G26 HQ00635 transformed cell line human CVCL_3G26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173648 CVCL_3G23 HQ00632 transformed cell line human CVCL_3G23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173649 CVCL_3G24 HQ00633 transformed cell line human CVCL_3G24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173650 CVCL_3G29 HQ00638 transformed cell line human CVCL_3G29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173651 CVCL_3G27 HQ00636 transformed cell line human CVCL_3G27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173652 CVCL_3G28 HQ00637 transformed cell line human CVCL_3G28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173653 CVCL_VM51 HPS0812 induced pluripotent stem cell human CVCL_VM51 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173654 CVCL_VM52 HPS0144 induced pluripotent stem cell human CVCL_VM52 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173655 CVCL_VM50 HPS0323 induced pluripotent stem cell human CVCL_VM50 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21173656 CVCL_VM55 CiRA00455 induced pluripotent stem cell human CVCL_VM55 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173657 CVCL_VM56 HPS0267 induced pluripotent stem cell human CVCL_VM56 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male 21173658 CVCL_VM53 HPS0179 induced pluripotent stem cell human CVCL_VM53 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173659 CVCL_VM54 HPS0216 induced pluripotent stem cell human CVCL_VM54 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173660 CVCL_VM59 HPS0158 induced pluripotent stem cell human CVCL_VM59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173661 CVCL_VM57 HPS0313 induced pluripotent stem cell human CVCL_VM57 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (from autologous cell line HPS0312) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 21173662 CVCL_VM58 HPS0314 induced pluripotent stem cell human CVCL_VM58 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50dup; Zygosity=Hemizygous (from autologous cell line HPS0312) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Male 21173663 CVCL_VM39 CRISPRi Gen1C 6 induced pluripotent stem cell human CVCL_VM39 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry is introduced in the AAVS1 locus 21173664 CVCL_VM40 CRISPRi Gen2C 1 induced pluripotent stem cell human CVCL_VM40 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB is introduced in the AAVS1 locus 21173665 CVCL_VM41 CRISPRi Gen2C 2 induced pluripotent stem cell human CVCL_VM41 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB is introduced in the AAVS1 locus 21173666 CVCL_MS98 BayGenomics ES cell line RRE286 embryonic stem cell house mouse CVCL_MS98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109404; Nup98 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173667 CVCL_N498 Hs 124.Tg finite cell line human CVCL_N498 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-7079; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173668 CVCL_MS99 BayGenomics ES cell line RRE287 embryonic stem cell house mouse CVCL_MS99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197517; Limk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173669 CVCL_N499 Hs 126.T cancer cell line human CVCL_N499 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7080; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173670 CVCL_MS96 BayGenomics ES cell line RRE276 embryonic stem cell house mouse CVCL_MS96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927489; Pdlim5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173671 CVCL_N496 MM36T(B) cancer cell line house mouse CVCL_N496 CL:0000010 Derived from metastatic site: Hypodermis; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6412; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173672 CVCL_VM44 SGHPL-2 transformed cell line human CVCL_VM44 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21173673 CVCL_MS97 BayGenomics ES cell line RRE284 embryonic stem cell house mouse CVCL_MS97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173674 CVCL_N497 Hs 124.Sg finite cell line human CVCL_N497 CL:0000010 Derived from sampling site: Fetal salivary gland; sublingual gland. Discontinued: ATCC; CRL-7078; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173675 CVCL_VM45 SGHPL-3 transformed cell line human CVCL_VM45 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Female 21173676 CVCL_MS94 BayGenomics ES cell line RRE273 embryonic stem cell house mouse CVCL_MS94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173677 CVCL_VM42 CRISPRi Gen3C A3 induced pluripotent stem cell human CVCL_VM42 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with constitutive CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a CAG promoter and dCas9-KRAB is introduced in the AAVS1 locus 21173678 CVCL_N494 MM42.Ut finite cell line house mouse CVCL_N494 CL:0000010 Derived from sampling site: Uterus. Discontinued: ATCC; CRL-6417; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173679 CVCL_MS95 BayGenomics ES cell line RRE275 embryonic stem cell house mouse CVCL_MS95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173680 CVCL_VM43 CRISPRi Gen3C A4 induced pluripotent stem cell human CVCL_VM43 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with constitutive CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a CAG promoter and dCas9-KRAB is introduced in the AAVS1 locus 21173681 CVCL_N495 MM36T(A) cancer cell line house mouse CVCL_N495 CL:0000010 Derived from metastatic site: Hypodermis; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6410; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173682 CVCL_MS92 BayGenomics ES cell line RRE267 embryonic stem cell house mouse CVCL_MS92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3645613; Platr25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173683 CVCL_N492 Hs 104.Bl finite cell line human CVCL_N492 CL:0000010 Derived from sampling site: Fetal urinary bladder Cell type=Fibroblast.. Discontinued: ATCC; CRL-7069; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173684 CVCL_VM48 IARC-211 transformed cell line human CVCL_VM48 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173685 CVCL_MS93 BayGenomics ES cell line RRE271 embryonic stem cell house mouse CVCL_MS93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108515; Cbx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173686 CVCL_VM49 HPS0319 induced pluripotent stem cell human CVCL_VM49 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex42-43del; Zygosity=Heterozygous (PubMed=29127875) Population: Japanese; Derived from sampling site: Skeletal muscle Cell type=Fibroblast.. Female 21173687 CVCL_N493 Hs 112.Bl finite cell line human CVCL_N493 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7071; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173688 CVCL_MS90 BayGenomics ES cell line RRE264 embryonic stem cell house mouse CVCL_MS90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442733; Mical3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173689 CVCL_N490 Hs 887.Lu finite cell line human CVCL_N490 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-7619; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173690 CVCL_VM46 WTC11 HOPX-NLS-eGFP induced pluripotent stem cell human CVCL_VM46 CL:0000010 Transfected with: HGNC; 24961; HOPX; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21173691 CVCL_MS91 BayGenomics ES cell line RRE265 embryonic stem cell house mouse CVCL_MS91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448759; Cdv3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173692 CVCL_N491 Hs 674.T cancer cell line human CVCL_N491 CL:0000010 Derived from metastatic site: Liver. Discontinued: ATCC; CRL-7398; true Male Doubling time: 12-14 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173693 CVCL_VM47 WTC11 NLS-eGFP induced pluripotent stem cell human CVCL_VM47 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21173694 CVCL_VM28 RUES2 HOPX KO embryonic stem cell human CVCL_VM28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24961; HOPX. Female 21173695 CVCL_VM29 RUES2 HOPX-tdTomato embryonic stem cell human CVCL_VM29 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using CRISPR/Cas9 a tdTomato-pA-loxP-PGK-Puro-pA-loxP was inserted at the HOPX translational start site 21173696 CVCL_3G00 HQ00609 transformed cell line human CVCL_3G00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173697 CVCL_3G03 HQ00612 transformed cell line human CVCL_3G03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173698 CVCL_3G04 HQ00613 transformed cell line human CVCL_3G04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173699 CVCL_3G01 HQ00610 transformed cell line human CVCL_3G01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173700 CVCL_3G02 HQ00611 transformed cell line human CVCL_3G02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173701 CVCL_3G07 HQ00616 transformed cell line human CVCL_3G07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173702 CVCL_3G08 HQ00617 transformed cell line human CVCL_3G08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173703 CVCL_3G05 HQ00614 transformed cell line human CVCL_3G05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173704 CVCL_3G06 HQ00615 transformed cell line human CVCL_3G06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173705 CVCL_VM30 WTB6 induced pluripotent stem cell human CVCL_VM30 CL:0000010 Female 21173706 CVCL_VM33 CRISPRn Gen1C 19 induced pluripotent stem cell human CVCL_VM33 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9 is introduced in the AAVS1 locus 21173707 CVCL_VM34 CRISPRn Gen1C 22 induced pluripotent stem cell human CVCL_VM34 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9 is introduced in the AAVS1 locus 21173708 CVCL_VM31 CRISPRn Gen1B 1 induced pluripotent stem cell human CVCL_VM31 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9. Female Characteristics: Cell line with Dox-inducible CRISPR nuclease (CRISPRn); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9 is introduced in the AAVS1 locus 21173709 CVCL_VM32 CRISPRn Gen1B 3 induced pluripotent stem cell human CVCL_VM32 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9. Female Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9 is introduced in the AAVS1 locus 21173710 CVCL_VM37 GS-1 spontaneously immortalized cell line CVCL_VM37 CL:0000010 Derived from sampling site: Spleen. Unspecified Group: Fish cell line 21173711 CVCL_VM38 CRISPRi Gen1C 5 induced pluripotent stem cell human CVCL_VM38 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry is introduced in the AAVS1 locus 21173712 CVCL_VM35 CRISPRi Gen1B 1 induced pluripotent stem cell human CVCL_VM35 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry is introduced in the AAVS1 locus 21173713 CVCL_VM36 CRISPRi Gen1B 3 induced pluripotent stem cell human CVCL_VM36 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Characteristics: Cell line with Dox-inducible CRISPR interference (CRISPRi); Characteristics: Using TALEN a construct containing a rtTA+TRE3G promoter and dCas9-KRAB-P2A-mCherry is introduced in the AAVS1 locus 21173714 CVCL_VM19 TESPE cancer cell line human CVCL_VM19 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 21173715 CVCL_VM17 TES1 cancer cell line human CVCL_VM17 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21173716 CVCL_VM18 TES2b cancer cell line human CVCL_VM18 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21173717 CVCL_MS78 BayGenomics ES cell line RRE231 embryonic stem cell house mouse CVCL_MS78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109602; Gphn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173718 CVCL_N478 Hs 586.T cancer cell line human CVCL_N478 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7351; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173719 CVCL_MS79 BayGenomics ES cell line RRE232 embryonic stem cell house mouse CVCL_MS79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448759; Cdv3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173720 CVCL_N479 Hs 607.T cancer cell line human CVCL_N479 CL:0000010 Discontinued: ATCC; CRL-7369; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173721 CVCL_MS76 BayGenomics ES cell line RRE227 embryonic stem cell house mouse CVCL_MS76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858260; Gosr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173722 CVCL_N476 Hs 54.T cancer cell line human CVCL_N476 CL:0000010 Discontinued: ATCC; CRL-7034; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173723 CVCL_MS77 BayGenomics ES cell line RRE228 embryonic stem cell house mouse CVCL_MS77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173724 CVCL_N477 Hs 586.Int finite cell line human CVCL_N477 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7350; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173725 CVCL_MS74 BayGenomics ES cell line RRE220 embryonic stem cell house mouse CVCL_MS74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173726 CVCL_N474 Hs 272.Pe undefined cell line type human CVCL_N474 CL:0000010 Discontinued: ATCC; CRL-7220; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173727 CVCL_VM22 MODY1-iPS-B-5 induced pluripotent stem cell human CVCL_VM22 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173728 CVCL_MS75 BayGenomics ES cell line RRE226 embryonic stem cell house mouse CVCL_MS75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347359; Homer3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173729 CVCL_N475 Hs 402.T cancer cell line human CVCL_N475 CL:0000010 Discontinued: ATCC; CRL-7277; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173730 CVCL_VM23 MODY1-iPS-B-6 induced pluripotent stem cell human CVCL_VM23 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173731 CVCL_MS72 BayGenomics ES cell line RRE213 embryonic stem cell house mouse CVCL_MS72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346865; Mapk14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173732 CVCL_N472 Hs 252.T cancer cell line human CVCL_N472 CL:0000010 Discontinued: ATCC; CRL-7212; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173733 CVCL_VM20 MODY1-iPS-A-3 induced pluripotent stem cell human CVCL_VM20 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21173734 CVCL_MS73 BayGenomics ES cell line RRE217 embryonic stem cell house mouse CVCL_MS73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918850; Ythdf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173735 CVCL_N473 Hs 266.Pe undefined cell line type human CVCL_N473 CL:0000010 Derived from sampling site: Pleural effusion. Discontinued: ATCC; CRL-7217; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173736 CVCL_VM21 MODY1-iPS-B-1 induced pluripotent stem cell human CVCL_VM21 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173737 CVCL_MS70 BayGenomics ES cell line RRE205 embryonic stem cell house mouse CVCL_MS70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173738 CVCL_N470 Hs 227.T cancer cell line human CVCL_N470 CL:0000010 Discontinued: ATCC; CRL-7192; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173739 CVCL_VM26 MODY1-iPS-B-9 induced pluripotent stem cell human CVCL_VM26 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173740 CVCL_MS71 BayGenomics ES cell line RRE206 embryonic stem cell house mouse CVCL_MS71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97822; Nectin2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173741 CVCL_N471 Hs 241.T cancer cell line human CVCL_N471 CL:0000010 Discontinued: ATCC; CRL-7207; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173742 CVCL_VM27 MODY1-iPS-B-13 induced pluripotent stem cell human CVCL_VM27 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173743 CVCL_VM24 MODY1-iPS-B-7 induced pluripotent stem cell human CVCL_VM24 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173744 CVCL_VM25 MODY1-iPS-B-8 induced pluripotent stem cell human CVCL_VM25 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173745 CVCL_VM08 NCC-OS1-X2-C1 cancer cell line human CVCL_VM08 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His66Arg (c.197A>G) (p.Pro80Pro, c.240A>G); ClinVar=VCV000246117; Zygosity=Unspecified (DOI=10.2198/jelectroph.65.1) Population: Japanese; Derived from sampling site: Bone; distal femur. Omics: Deep proteome analysis Male Characteristics: Established from a second generation xenograft established by subcutaneous injection in female SCID mice Doubling time: 29 hours (PubMed=29943355) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21173746 CVCL_VM09 RIRI-PA1 spontaneously immortalized cell line CVCL_VM09 CL:0000010 Unspecified Virology: Susceptible to infection by Autographa californica nuclear polyhedrosis virus (AcMNPV) (PubMed=35460045) Doubling time: ~84.8 hours, at 40th passage (PubMed=29313222). Group: Insect cell line 21173747 CVCL_VM06 UM-MCC565 cancer cell line human CVCL_VM06 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803). Female Characteristics: Established from a mouse tumor xenograft in NOD/SCID/IL2RgammaNULL mice Doubling time: 36 hours (PubMed=24614157) 21173748 CVCL_VM07 NCC-LMS1-X3-C1 cancer cell line human CVCL_VM07 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; rib. Omics: Deep proteome analysis Female Characteristics: Established from a third generation xenograft established by subcutaneous injection in female SCID mice Doubling time: 57 hours (PubMed=29845452) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21173749 CVCL_MS89 BayGenomics ES cell line RRE262 embryonic stem cell house mouse CVCL_MS89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173750 CVCL_N489 Hs 844.T cancer cell line human CVCL_N489 CL:0000010 Discontinued: ATCC; CRL-7892; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173751 CVCL_MS87 BayGenomics ES cell line RRE255 embryonic stem cell house mouse CVCL_MS87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173752 CVCL_N487 Hs 785.T cancer cell line human CVCL_N487 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7884; true Male Doubling time: 8-10 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173753 CVCL_MS88 BayGenomics ES cell line RRE261 embryonic stem cell house mouse CVCL_MS88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333811; Mbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173754 CVCL_N488 Hs 703.T cancer cell line human CVCL_N488 CL:0000010 Derived from metastatic site: Colon. Discontinued: ATCC; CRL-7442; true Male Doubling time: 18-20 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173755 CVCL_MS85 BayGenomics ES cell line RRE249 embryonic stem cell house mouse CVCL_MS85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173756 CVCL_VM11 FUi002-A induced pluripotent stem cell human CVCL_VM11 From: Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University; Fukuoka; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg1525Ter (c.4573C>T); ClinVar=VCV000189911; Zygosity=Heterozygous (PubMed=29981888) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21173757 CVCL_N485 Hs 743.T cancer cell line human CVCL_N485 CL:0000010 Discontinued: ATCC; CRL-7484; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173758 CVCL_MS86 BayGenomics ES cell line RRE250 embryonic stem cell house mouse CVCL_MS86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173759 CVCL_N486 Hs 750.T cancer cell line human CVCL_N486 CL:0000010 Discontinued: ATCC; CRL-7873; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173760 CVCL_VM12 IAIi001-A induced pluripotent stem cell human CVCL_VM12 From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Lys1277Ter (c.3829A>T); Zygosity=Heterozygous (PubMed=29883886; PubMed=29944992) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21173761 CVCL_MS83 BayGenomics ES cell line RRE247 embryonic stem cell house mouse CVCL_MS83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918272; Ston2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173762 CVCL_N483 Hs 682.T cancer cell line human CVCL_N483 CL:0000010 Derived from sampling site: Colon. Discontinued: ATCC; CRL-7423; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173763 CVCL_MS84 BayGenomics ES cell line RRE248 embryonic stem cell house mouse CVCL_MS84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173764 CVCL_N484 Hs 715.K finite cell line human CVCL_N484 CL:0000010 Derived from sampling site: Kidney; renal pelvis. Discontinued: ATCC; CRL-7454; true Male Doubling time: 6-7 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173765 CVCL_VM10 RIRI-GG1 spontaneously immortalized cell line CVCL_VM10 CL:0000010 Unspecified Doubling time: ~122.1 hours (PubMed=21424241). Group: Insect cell line 21173766 CVCL_MS81 BayGenomics ES cell line RRE240 embryonic stem cell house mouse CVCL_MS81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859252; Fmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173767 CVCL_N481 Hs 631.T cancer cell line human CVCL_N481 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: ATCC; CRL-7853; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173768 CVCL_VM15 IAIi004-A induced pluripotent stem cell human CVCL_VM15 From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Trp1158Ter (c.3474G>A); Zygosity=Heterozygous (PubMed=29883886; PubMed=31491690) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 21173769 CVCL_MS82 BayGenomics ES cell line RRE241 embryonic stem cell house mouse CVCL_MS82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145219; Iars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173770 CVCL_VM16 DUTi001-A induced pluripotent stem cell human CVCL_VM16 From: Dell Pediatric Research Institute, University of Texas at Austin; Austin; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21173771 CVCL_N482 Hs 674.T/cc cancer cell line human CVCL_N482 CL:0000010 Discontinued: ATCC; CRL-7399; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173772 CVCL_VM13 IAIi002-A induced pluripotent stem cell human CVCL_VM13 From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Gly1479Ter (c.4435G>T); Zygosity=Heterozygous (PubMed=29883886) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 21173773 CVCL_MS80 BayGenomics ES cell line RRE233 embryonic stem cell house mouse CVCL_MS80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861099; Ubr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173774 CVCL_N480 Hs 614.T cancer cell line human CVCL_N480 CL:0000010 Derived from metastatic site: Urinary bladder. Discontinued: ATCC; CRL-7376; true Male Doubling time: 12-14 days (PubMed=176412) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173775 CVCL_VM14 IAIi003-A induced pluripotent stem cell human CVCL_VM14 From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Asp1543Tyr (c.4627G>T); Zygosity=Heterozygous (PubMed=29883886; PubMed=31491690) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 21173776 CVCL_MS58 BayGenomics ES cell line RRE161 embryonic stem cell house mouse CVCL_MS58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173777 CVCL_N458 GM13915 transformed cell line human CVCL_N458 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173778 CVCL_MS59 BayGenomics ES cell line RRE172 embryonic stem cell house mouse CVCL_MS59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173779 CVCL_N459 Hybridoma cell line 23 hybridoma house mouse CVCL_N459 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8630 21173780 CVCL_MS56 BayGenomics ES cell line RRE153 embryonic stem cell house mouse CVCL_MS56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173781 CVCL_N456 GM13913 transformed cell line human CVCL_N456 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173782 CVCL_MS57 BayGenomics ES cell line RRE156 embryonic stem cell house mouse CVCL_MS57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101357; Ece1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173783 CVCL_N457 GM13914 transformed cell line human CVCL_N457 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173784 CVCL_MS54 BayGenomics ES cell line RRE148 embryonic stem cell house mouse CVCL_MS54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88255; Anxa6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173785 CVCL_N454 GM13911 transformed cell line human CVCL_N454 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173786 CVCL_MS55 BayGenomics ES cell line RRE150 embryonic stem cell house mouse CVCL_MS55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913763; Tab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173787 CVCL_N455 GM13912 transformed cell line human CVCL_N455 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173788 CVCL_MS52 BayGenomics ES cell line RRE145 embryonic stem cell house mouse CVCL_MS52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173789 CVCL_N452 GM13876 transformed cell line human CVCL_N452 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173790 CVCL_VM00 UM-MCC29 cancer cell line human CVCL_VM00 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Inguinal lymph node. Male Doubling time: 27 hours (PubMed=24614157) 21173791 CVCL_MS53 BayGenomics ES cell line RRE146 embryonic stem cell house mouse CVCL_MS53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103006; Epb41l5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173792 CVCL_N453 GM13877 transformed cell line human CVCL_N453 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173793 CVCL_VM01 UM-MCC31 cancer cell line human CVCL_VM01 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 32 hours (PubMed=24614157) 21173794 CVCL_MS50 BayGenomics ES cell line RRE137 embryonic stem cell house mouse CVCL_MS50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173795 CVCL_N450 GM13874 transformed cell line human CVCL_N450 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173796 CVCL_MS51 BayGenomics ES cell line RRE142 embryonic stem cell house mouse CVCL_MS51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920977; Mcmbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173797 CVCL_N451 GM13875 transformed cell line human CVCL_N451 CL:0000010 Population: Caucasian/Russian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21173798 CVCL_VM04 UM-MCC34 cancer cell line human CVCL_VM04 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 28 hours (PubMed=24614157) 21173799 CVCL_VM05 UM-MCC40 cancer cell line human CVCL_VM05 CL:0000010 Derived from metastatic site: Inguinal lymph node. Male Doubling time: 33 hours (PubMed=24614157) 21173800 CVCL_VM02 UM-MCC32 cancer cell line human CVCL_VM02 CL:0000010 Female Doubling time: 35 hours (PubMed=24614157). 21173801 CVCL_VM03 UM-MCC35 cancer cell line human CVCL_VM03 CL:0000010 Derived from metastatic site: Mastoid lymph node. Female Doubling time: 29 hours (PubMed=24614157) 21173802 CVCL_MS69 BayGenomics ES cell line RRE196 embryonic stem cell house mouse CVCL_MS69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342248; Slc25a17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173803 CVCL_N469 Hs 217.T cancer cell line human CVCL_N469 CL:0000010 Derived from metastatic site: Colon. Discontinued: ATCC; CRL-7179; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173804 CVCL_MS67 BayGenomics ES cell line RRE190 embryonic stem cell house mouse CVCL_MS67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384876; Cdc73 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173805 CVCL_N467 Hs 187.T cancer cell line human CVCL_N467 CL:0000010 Derived from sampling site: Rectum. Discontinued: ATCC; CRL-7139; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173806 CVCL_MS68 BayGenomics ES cell line RRE192 embryonic stem cell house mouse CVCL_MS68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446632; Ago2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173807 CVCL_N468 Hs 210.T cancer cell line human CVCL_N468 CL:0000010 Discontinued: ATCC; CRL-7172; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173808 CVCL_MS65 BayGenomics ES cell line RRE187 embryonic stem cell house mouse CVCL_MS65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442789; Rc3h2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173809 CVCL_N465 HT-738.T cancer cell line human CVCL_N465 CL:0000010 Discontinued: ATCC; CRL-7784; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173810 CVCL_MS66 BayGenomics ES cell line RRE188 embryonic stem cell house mouse CVCL_MS66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173811 CVCL_N466 Hs 185.T cancer cell line human CVCL_N466 CL:0000010 Discontinued: ATCC; CRL-7135; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173812 CVCL_MS63 BayGenomics ES cell line RRE179 embryonic stem cell house mouse CVCL_MS63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923046; Cdyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173813 CVCL_N463 HT-758.Sk finite cell line human CVCL_N463 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7788; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173814 CVCL_MS64 BayGenomics ES cell line RRE185 embryonic stem cell house mouse CVCL_MS64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346870; Map2k6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173815 CVCL_N464 HT-824.Pe undefined cell line type human CVCL_N464 CL:0000010 Discontinued: ATCC; CRL-7796; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173816 CVCL_MS61 BayGenomics ES cell line RRE176 embryonic stem cell house mouse CVCL_MS61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173817 CVCL_N461 HT-756.Lu finite cell line human CVCL_N461 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-7786; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173818 CVCL_MS62 BayGenomics ES cell line RRE177 embryonic stem cell house mouse CVCL_MS62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933169; Sacm1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173819 CVCL_N462 HT-756.T cancer cell line human CVCL_N462 CL:0000010 Discontinued: ATCC; CRL-7787; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173820 CVCL_MS60 BayGenomics ES cell line RRE174 embryonic stem cell house mouse CVCL_MS60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106248; Eif5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173821 CVCL_N460 Hs 205.T cancer cell line human CVCL_N460 CL:0000010 Discontinued: ATCC; CRL-7167; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173822 CVCL_3H93 HQ00802 transformed cell line human CVCL_3H93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173823 CVCL_3H94 HQ00803 transformed cell line human CVCL_3H94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173824 CVCL_3H91 HQ00800 transformed cell line human CVCL_3H91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173825 CVCL_3H92 HQ00801 transformed cell line human CVCL_3H92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173826 CVCL_3H97 HQ00806 transformed cell line human CVCL_3H97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173827 CVCL_3H98 HQ00807 transformed cell line human CVCL_3H98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173828 CVCL_3H95 HQ00804 transformed cell line human CVCL_3H95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173829 CVCL_3H96 HQ00805 transformed cell line human CVCL_3H96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173830 CVCL_3H99 HQ00808 transformed cell line human CVCL_3H99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173831 CVCL_3H90 HQ00799 transformed cell line human CVCL_3H90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173832 CVCL_3H71 HQ00780 transformed cell line human CVCL_3H71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173833 CVCL_3H72 HQ00781 transformed cell line human CVCL_3H72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173834 CVCL_3H70 HQ00779 transformed cell line human CVCL_3H70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173835 CVCL_3H75 HQ00784 transformed cell line human CVCL_3H75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173836 CVCL_3H76 HQ00785 transformed cell line human CVCL_3H76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173837 CVCL_3H73 HQ00782 transformed cell line human CVCL_3H73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173838 CVCL_3H74 HQ00783 transformed cell line human CVCL_3H74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173839 CVCL_3H79 HQ00788 transformed cell line human CVCL_3H79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173840 CVCL_3H77 HQ00786 transformed cell line human CVCL_3H77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173841 CVCL_3H78 HQ00787 transformed cell line human CVCL_3H78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173842 CVCL_3H82 HQ00791 transformed cell line human CVCL_3H82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173843 CVCL_3H83 HQ00792 transformed cell line human CVCL_3H83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173844 CVCL_3H80 HQ00789 transformed cell line human CVCL_3H80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173845 CVCL_3H81 HQ00790 transformed cell line human CVCL_3H81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173846 CVCL_3H86 HQ00795 transformed cell line human CVCL_3H86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173847 CVCL_3H87 HQ00796 transformed cell line human CVCL_3H87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173848 CVCL_3H84 HQ00793 transformed cell line human CVCL_3H84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173849 CVCL_3H85 HQ00794 transformed cell line human CVCL_3H85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173850 CVCL_3H88 HQ00797 transformed cell line human CVCL_3H88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173851 CVCL_3H89 HQ00798 transformed cell line human CVCL_3H89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173852 CVCL_3H50 HQ00759 transformed cell line human CVCL_3H50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173853 CVCL_3H53 HQ00762 transformed cell line human CVCL_3H53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173854 CVCL_3H54 HQ00763 transformed cell line human CVCL_3H54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173855 CVCL_3H51 HQ00760 transformed cell line human CVCL_3H51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173856 CVCL_3H52 HQ00761 transformed cell line human CVCL_3H52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173857 CVCL_3H57 HQ00766 transformed cell line human CVCL_3H57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173858 CVCL_3H58 HQ00767 transformed cell line human CVCL_3H58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173859 CVCL_3H55 HQ00764 transformed cell line human CVCL_3H55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173860 CVCL_3H56 HQ00765 transformed cell line human CVCL_3H56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173861 CVCL_3H59 HQ00768 transformed cell line human CVCL_3H59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173862 CVCL_3H60 HQ00769 transformed cell line human CVCL_3H60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173863 CVCL_3H61 HQ00770 transformed cell line human CVCL_3H61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173864 CVCL_3H64 HQ00773 transformed cell line human CVCL_3H64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173865 CVCL_3H65 HQ00774 transformed cell line human CVCL_3H65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173866 CVCL_3H62 HQ00771 transformed cell line human CVCL_3H62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173867 CVCL_3H63 HQ00772 transformed cell line human CVCL_3H63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173868 CVCL_3H68 HQ00777 transformed cell line human CVCL_3H68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173869 CVCL_3H69 HQ00778 transformed cell line human CVCL_3H69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173870 CVCL_3H66 HQ00775 transformed cell line human CVCL_3H66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173871 CVCL_3H67 HQ00776 transformed cell line human CVCL_3H67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173872 CVCL_VN90 MK-44 finite cell line human CVCL_VN90 CL:0000010 Population: Japanese; Derived from sampling site: Amniotic fluid. Discontinued: JCRB; KURB2734; probable Male 21173873 CVCL_VN91 MK-50 finite cell line human CVCL_VN91 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21173874 CVCL_VN94 MK-46M finite cell line human CVCL_VN94 CL:0000010 Population: Japanese. Female 21173875 CVCL_VN95 MK-49 finite cell line human CVCL_VN95 CL:0000010 Unspecified 21173876 CVCL_VN92 MK-46 finite cell line human CVCL_VN92 CL:0000010 Population: Japanese; Karyotypic information: 46,XX,t(14;21) (JCRB). Female 21173877 CVCL_VN93 MK-46F finite cell line human CVCL_VN93 CL:0000010 Population: Japanese. Male 21173878 CVCL_VN98 AOF spontaneously immortalized cell line CVCL_VN98 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Capable of growing from 20 to 37 Celsius, the optimal growth temperature is 28 Celsius Group: Fish cell line 21173879 CVCL_VN99 VUP-1 V-D9 cancer cell line human CVCL_VN99 CL:0000010 Discontinued: Ximbio; 153374; probable. Female Characteristics: Expresses ITGAV/ITGB1 at low level and does not express ITGAV/ITGB4 21173880 CVCL_VN96 NUCOLL43 cancer cell line human CVCL_VN96 CL:0000010 Derived from metastatic site: Ascites. Omics: SNP array analysis Female Characteristics: Does not express TP53 Very high degree of loss of heterozygosity that affects 85% of the genome. Doubling time: 45 hours (at 13th passage), 42 hours (at 35th passage) (PubMed=30109783) 21173881 CVCL_VN97 MAC-T BLV transformed cell line CVCL_VN97 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Mammary alveolar epithelial cell.; Breed/subspecies: Holstein. Female Virology: Stably infected with bovine leukemia virus (BLV) 21173882 CVCL_MU09 BayGenomics ES cell line RRF156 embryonic stem cell house mouse CVCL_MU09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914105; Tcf25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173883 CVCL_N609 Hs 112.Tes finite cell line human CVCL_N609 CL:0000010 Derived from sampling site: Fetal testis. Discontinued: ATCC; CRL-7075; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173884 CVCL_MU07 BayGenomics ES cell line RRF154 embryonic stem cell house mouse CVCL_MU07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108076; Frrs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173885 CVCL_N607 Hs 112.K finite cell line human CVCL_N607 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7072; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173886 CVCL_MU08 BayGenomics ES cell line RRF155 embryonic stem cell house mouse CVCL_MU08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173887 CVCL_N608 Hs 112.Rt finite cell line human CVCL_N608 CL:0000010 Derived from sampling site: Fetal eye; retina. Discontinued: ATCC; CRL-7073; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173888 CVCL_MU05 BayGenomics ES cell line RRF146 embryonic stem cell house mouse CVCL_MU05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173889 CVCL_N605 Hs 101.K finite cell line human CVCL_N605 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7066; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173890 CVCL_MU06 BayGenomics ES cell line RRF152 embryonic stem cell house mouse CVCL_MU06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138391; Pid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173891 CVCL_N606 Hs 101.T cancer cell line human CVCL_N606 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-7067; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173892 CVCL_MU03 BayGenomics ES cell line RRF140 embryonic stem cell house mouse CVCL_MU03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342005; Mthfd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173893 CVCL_N603 TE 449.T cancer cell line human CVCL_N603 CL:0000010 Discontinued: ATCC; CRL-7948; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173894 CVCL_MU04 BayGenomics ES cell line RRF142 embryonic stem cell house mouse CVCL_MU04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646776; Gm4779 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173895 CVCL_N604 Hs 94.Mu finite cell line human CVCL_N604 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7063; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173896 CVCL_MU01 BayGenomics ES cell line RRF138 embryonic stem cell house mouse CVCL_MU01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173897 CVCL_N601 Hs 79.T cancer cell line human CVCL_N601 CL:0000010 Discontinued: ATCC; CRL-7057; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173898 CVCL_MU02 BayGenomics ES cell line RRF139 embryonic stem cell house mouse CVCL_MU02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173899 CVCL_N602 Hs 93.Mu finite cell line human CVCL_N602 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7061; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173900 CVCL_MU00 BayGenomics ES cell line RRF137 embryonic stem cell house mouse CVCL_MU00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919421; Shq1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173901 CVCL_N600 Hs 78.T cancer cell line human CVCL_N600 CL:0000010 Discontinued: ATCC; CRL-7056; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173902 CVCL_MT59 BayGenomics ES cell line RRF067 embryonic stem cell house mouse CVCL_MT59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173903 CVCL_N559 Hs 160.Tes finite cell line human CVCL_N559 CL:0000010 Derived from sampling site: Fetal testis. Discontinued: ATCC; CRL-7113; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173904 CVCL_MT57 BayGenomics ES cell line RRF061 embryonic stem cell house mouse CVCL_MT57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894689; Ywhae Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173905 CVCL_N557 Hs 160.K finite cell line human CVCL_N557 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7111; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173906 CVCL_MT58 BayGenomics ES cell line RRF064 embryonic stem cell house mouse CVCL_MT58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915545; Aar2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173907 CVCL_N558 Hs 160.Lu finite cell line human CVCL_N558 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-7112; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173908 CVCL_MT55 BayGenomics ES cell line RRF058 embryonic stem cell house mouse CVCL_MT55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920274; Emc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173909 CVCL_N555 Hs 159.Fs finite cell line human CVCL_N555 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7109; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173910 CVCL_MT56 BayGenomics ES cell line RRF060 embryonic stem cell house mouse CVCL_MT56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173911 CVCL_N556 Hs 160.Ht finite cell line human CVCL_N556 CL:0000010 Derived from sampling site: Fetal heart. Discontinued: ATCC; CRL-7110; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173912 CVCL_MT53 BayGenomics ES cell line RRF055 embryonic stem cell house mouse CVCL_MT53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442925; Atad5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173913 CVCL_N553 Hs 157.Tg finite cell line human CVCL_N553 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-7107; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173914 CVCL_MT54 BayGenomics ES cell line RRF056 embryonic stem cell house mouse CVCL_MT54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173915 CVCL_N554 Hs 158.Sk finite cell line human CVCL_N554 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7108; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173916 CVCL_MT51 BayGenomics ES cell line RRF052 embryonic stem cell house mouse CVCL_MT51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173917 CVCL_N551 Hs 157.K finite cell line human CVCL_N551 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7105; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173918 CVCL_MT52 BayGenomics ES cell line RRF053 embryonic stem cell house mouse CVCL_MT52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914552; Zc3h13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173919 CVCL_VN00 BLSC-KU-2 cancer cell line CVCL_VN00 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female 21173920 CVCL_N552 Hs 157.Li finite cell line human CVCL_N552 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7106; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173921 CVCL_MT50 BayGenomics ES cell line RRF051 embryonic stem cell house mouse CVCL_MT50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173922 CVCL_N550 Hs 157.Int finite cell line human CVCL_N550 CL:0000010 Derived from sampling site: Fetal intestine. Discontinued: ATCC; CRL-7104; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173923 CVCL_VN03 BLSC-KU-15 cancer cell line CVCL_VN03 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female 21173924 CVCL_VN04 BLSC-KU-16 cancer cell line CVCL_VN04 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female 21173925 CVCL_VN01 BLSC-KU-7 cancer cell line CVCL_VN01 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female 21173926 CVCL_VN02 BLSC-KU-18 cancer cell line CVCL_VN02 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female 21173927 CVCL_MT68 BayGenomics ES cell line RRF077 embryonic stem cell house mouse CVCL_MT68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173928 CVCL_N568 Hs 181.Bm finite cell line human CVCL_N568 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-7126; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173929 CVCL_MT69 BayGenomics ES cell line RRF083 embryonic stem cell house mouse CVCL_MT69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914832; Slc25a26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173930 CVCL_N569 Hs 181.Gb finite cell line human CVCL_N569 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal gallbladder. Discontinued: ATCC; CRL-7127; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173931 CVCL_MT66 BayGenomics ES cell line RRF075 embryonic stem cell house mouse CVCL_MT66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917544; Rnf126 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173932 CVCL_N566 Hs 167.Fs finite cell line human CVCL_N566 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7121; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173933 CVCL_MT67 BayGenomics ES cell line RRF076 embryonic stem cell house mouse CVCL_MT67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914713; Poc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173934 CVCL_N567 Hs 175.T cancer cell line human CVCL_N567 CL:0000010 Discontinued: ATCC; CRL-7125; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173935 CVCL_MT64 BayGenomics ES cell line RRF073 embryonic stem cell house mouse CVCL_MT64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332234; Zfp148 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173936 CVCL_N564 Hs 166.Bl finite cell line human CVCL_N564 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7119; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173937 CVCL_MT65 BayGenomics ES cell line RRF074 embryonic stem cell house mouse CVCL_MT65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173938 CVCL_N565 Hs 166.Li finite cell line human CVCL_N565 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7120; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173939 CVCL_MT62 BayGenomics ES cell line RRF071 embryonic stem cell house mouse CVCL_MT62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920428; Wasl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173940 CVCL_N562 Hs 161.Sk finite cell line human CVCL_N562 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7116; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173941 CVCL_MT63 BayGenomics ES cell line RRF072 embryonic stem cell house mouse CVCL_MT63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336214; Khsrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173942 CVCL_N563 Hs 161.Tg finite cell line human CVCL_N563 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-7117; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173943 CVCL_MT60 BayGenomics ES cell line RRF069 embryonic stem cell house mouse CVCL_MT60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386251; Eif3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173944 CVCL_N560 Hs 161.Cn finite cell line human CVCL_N560 CL:0000010 Derived from sampling site: Fetal eye; cornea. Discontinued: ATCC; CRL-7114; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173945 CVCL_MT61 BayGenomics ES cell line RRF070 embryonic stem cell house mouse CVCL_MT61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173946 CVCL_N561 Hs 161.Ht finite cell line human CVCL_N561 CL:0000010 Derived from sampling site: Fetal heart. Discontinued: ATCC; CRL-7115; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173947 CVCL_N539 10H-2 hybridoma house mouse CVCL_N539 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:61151; Poly-ADP-D-ribose (Poly(adenosine diphosphate ribose)). 21173948 CVCL_MT39 BayGenomics ES cell line RRF029 embryonic stem cell house mouse CVCL_MT39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173949 CVCL_MT37 BayGenomics ES cell line RRF025 embryonic stem cell house mouse CVCL_MT37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173950 CVCL_N537 Hs 812.Bm finite cell line human CVCL_N537 CL:0000010 Population: Pacific; Polynesian; Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7544; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173951 CVCL_N538 10H hybridoma house mouse CVCL_N538 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:61151; Poly-ADP-D-ribose (Poly(adenosine diphosphate ribose)). 21173952 CVCL_MT38 BayGenomics ES cell line RRF028 embryonic stem cell house mouse CVCL_MT38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261856; Ankle2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173953 CVCL_MT35 BayGenomics ES cell line RRF023 embryonic stem cell house mouse CVCL_MT35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173954 CVCL_N535 TE 89.T cancer cell line human CVCL_N535 CL:0000010 Discontinued: ATCC; CRL-7738; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173955 CVCL_MT36 BayGenomics ES cell line RRF024 embryonic stem cell house mouse CVCL_MT36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173956 CVCL_N536 Hs 818.T cancer cell line human CVCL_N536 CL:0000010 Discontinued: ATCC; CRL-7890; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173957 CVCL_MT33 BayGenomics ES cell line RRF021 embryonic stem cell house mouse CVCL_MT33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919367; Naa50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173958 CVCL_N533 TE 87.T cancer cell line human CVCL_N533 CL:0000010 Discontinued: ATCC; CRL-7737; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173959 CVCL_MT34 BayGenomics ES cell line RRF022 embryonic stem cell house mouse CVCL_MT34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173960 CVCL_N534 CHLA-01R-MED cancer cell line human CVCL_N534 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser1982Argfs*22 (c.5946delT) (6174delT); ClinVar=VCV000009325; Zygosity=Heterozygous (PubMed=26380221) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis Male 21173961 CVCL_MT31 BayGenomics ES cell line RRF018 embryonic stem cell house mouse CVCL_MT31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914295; Riok2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173962 CVCL_N531 TE 210.T cancer cell line human CVCL_N531 CL:0000010 Discontinued: ATCC; CRL-7759; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173963 CVCL_MT32 BayGenomics ES cell line RRF020 embryonic stem cell house mouse CVCL_MT32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443483; Pdzd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173964 CVCL_N532 TE 211.T cancer cell line human CVCL_N532 CL:0000010 Discontinued: ATCC; CRL-7760; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173965 CVCL_MT30 BayGenomics ES cell line RRF017 embryonic stem cell house mouse CVCL_MT30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891963; Ywhaq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173966 CVCL_N530 TO 167.T cancer cell line human CVCL_N530 CL:0000010 Discontinued: ATCC; CRL-7777; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173967 CVCL_MT48 BayGenomics ES cell line RRF047 embryonic stem cell house mouse CVCL_MT48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915268; Cert1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173968 CVCL_N548 Hs 155.Smg finite cell line human CVCL_N548 CL:0000010 Derived from sampling site: Fetal salivary gland; sublingual gland. Discontinued: ATCC; CRL-7101; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173969 CVCL_MT49 BayGenomics ES cell line RRF049 embryonic stem cell house mouse CVCL_MT49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96836; Lta4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173970 CVCL_N549 Hs 157.Br finite cell line human CVCL_N549 CL:0000010 Derived from sampling site: Fetal brain. Discontinued: ATCC; CRL-7103; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173971 CVCL_MT46 BayGenomics ES cell line RRF041 embryonic stem cell house mouse CVCL_MT46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892003; Tcof1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173972 CVCL_N546 Hs 155.Pan finite cell line human CVCL_N546 CL:0000010 Derived from sampling site: Fetal pancreas. Discontinued: ATCC; CRL-7099; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173973 CVCL_MT47 BayGenomics ES cell line RRF043 embryonic stem cell house mouse CVCL_MT47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147319; Svil Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173974 CVCL_N547 Hs 155.Pg finite cell line human CVCL_N547 CL:0000010 Derived from sampling site: Fetal salivary gland; parotid gland. Discontinued: ATCC; CRL-7100; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173975 CVCL_N544 4nH1 embryonic stem cell house mouse CVCL_N544 CL:0000010 Karyotypic information: Tetraploid karyotype; Breed/subspecies: C3H/He. Male 21173976 CVCL_MT44 BayGenomics ES cell line RRF037 embryonic stem cell house mouse CVCL_MT44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95286; Eed Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173977 CVCL_N545 A-6 factor-dependent cell line house mouse CVCL_N545 CL:0000010 Breed/subspecies: C3H/He. Male Characteristics: FGF2 or KITLG dependent 21173978 CVCL_MT45 BayGenomics ES cell line RRF038 embryonic stem cell house mouse CVCL_MT45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99511; Ptpn11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173979 CVCL_MT42 BayGenomics ES cell line RRF034 embryonic stem cell house mouse CVCL_MT42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98351; Sod1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173980 CVCL_N542 H-2 embryonic stem cell house mouse CVCL_N542 CL:0000010 Breed/subspecies: C3H/He. Female 21173981 CVCL_MT43 BayGenomics ES cell line RRF035 embryonic stem cell house mouse CVCL_MT43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173982 CVCL_N543 H-3 embryonic stem cell house mouse CVCL_N543 CL:0000010 Breed/subspecies: C3H/He. Female 21173983 CVCL_N540 16B hybridoma house mouse CVCL_N540 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:61151; Poly-ADP-D-ribose (Poly(adenosine diphosphate ribose)). 21173984 CVCL_MT40 BayGenomics ES cell line RRF031 embryonic stem cell house mouse CVCL_MT40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289172; Scyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173985 CVCL_MT41 BayGenomics ES cell line RRF033 embryonic stem cell house mouse CVCL_MT41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927133; Gmfb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173986 CVCL_N541 H-1 embryonic stem cell house mouse CVCL_N541 CL:0000010 Breed/subspecies: C3H/He. Discontinued: RCB; RCB1778; true Male 21173987 CVCL_DZ89 ND07619 transformed cell line human CVCL_DZ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173988 CVCL_DZ87 ND07614 transformed cell line human CVCL_DZ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173989 CVCL_DZ88 ND07618 transformed cell line human CVCL_DZ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173990 CVCL_DZ81 ND07496 transformed cell line human CVCL_DZ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173991 CVCL_DZ82 ND07509 transformed cell line human CVCL_DZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173992 CVCL_DZ80 ND07461 transformed cell line human CVCL_DZ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173993 CVCL_MT19 BayGenomics ES cell line RRE378 embryonic stem cell house mouse CVCL_MT19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173994 CVCL_N519 Hs 14.Mu finite cell line human CVCL_N519 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7012; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173995 CVCL_DZ85 ND07602 transformed cell line human CVCL_DZ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21173996 CVCL_DZ86 ND07608 transformed cell line human CVCL_DZ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21173997 CVCL_MT17 BayGenomics ES cell line RRE374 embryonic stem cell house mouse CVCL_MT17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349406; Ddx3y Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21173998 CVCL_N517 Hs 4.Li finite cell line human CVCL_N517 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7008; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21173999 CVCL_DZ83 ND07510 transformed cell line human CVCL_DZ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174000 CVCL_MT18 BayGenomics ES cell line RRE376 embryonic stem cell house mouse CVCL_MT18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682314; Zc3h4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174001 CVCL_N518 Hs 4.Bm finite cell line human CVCL_N518 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-7009; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174002 CVCL_DZ84 ND07582 transformed cell line human CVCL_DZ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174003 CVCL_MT15 BayGenomics ES cell line RRE370 embryonic stem cell house mouse CVCL_MT15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918779; Kazn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174004 CVCL_N515 Hs 2.Li finite cell line human CVCL_N515 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7004; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174005 CVCL_MT16 BayGenomics ES cell line RRE373 embryonic stem cell house mouse CVCL_MT16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174006 CVCL_N516 Hs 4.We finite cell line human CVCL_N516 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7007; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174007 CVCL_MT13 BayGenomics ES cell line RRE343 embryonic stem cell house mouse CVCL_MT13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174008 CVCL_N513 UCLA-P3 cancer cell line human CVCL_N513 CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Male 21174009 CVCL_MT14 BayGenomics ES cell line RRE346 embryonic stem cell house mouse CVCL_MT14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682314; Zc3h4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174010 CVCL_N514 COLO 357/FG-2 cancer cell line human CVCL_N514 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from metastatic site: Celiac axis lymph node. Female 21174011 CVCL_MT11 BayGenomics ES cell line RRE340 embryonic stem cell house mouse CVCL_MT11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138811; Cdc123 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174012 CVCL_N511 KOT-1 cancer cell line human CVCL_N511 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: ~72 hours (PubMed=9566709) 21174013 CVCL_MT12 BayGenomics ES cell line RRE342 embryonic stem cell house mouse CVCL_MT12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174014 CVCL_N512 KOT-2 cancer cell line human CVCL_N512 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: ~72 hours (PubMed=9566709) 21174015 CVCL_MT10 BayGenomics ES cell line RRE337 embryonic stem cell house mouse CVCL_MT10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174016 CVCL_N510 SCC 2/88 cancer cell line dog CVCL_N510 CL:0000010 Unspecified 21174017 CVCL_DZ98 ND07697 transformed cell line human CVCL_DZ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174018 CVCL_DZ99 ND07699 transformed cell line human CVCL_DZ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174019 CVCL_DZ92 ND07626 transformed cell line human CVCL_DZ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174020 CVCL_DZ93 ND07628 transformed cell line human CVCL_DZ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174021 CVCL_DZ90 ND07624 transformed cell line human CVCL_DZ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174022 CVCL_DZ91 ND07625 transformed cell line human CVCL_DZ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174023 CVCL_DZ96 ND07670 transformed cell line human CVCL_DZ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174024 CVCL_DZ97 ND07695 transformed cell line human CVCL_DZ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174025 CVCL_MT28 BayGenomics ES cell line RRF014 embryonic stem cell house mouse CVCL_MT28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174026 CVCL_DZ94 ND07653 transformed cell line human CVCL_DZ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174027 CVCL_N528 TO 165.T cancer cell line human CVCL_N528 CL:0000010 Discontinued: ATCC; CRL-7775; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174028 CVCL_MT29 BayGenomics ES cell line RRF015 embryonic stem cell house mouse CVCL_MT29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685541; Wdtc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174029 CVCL_DZ95 ND07654 transformed cell line human CVCL_DZ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174030 CVCL_N529 TO 173.T cancer cell line human CVCL_N529 CL:0000010 Discontinued: ATCC; CRL-7778; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174031 CVCL_MT26 BayGenomics ES cell line RRF011 embryonic stem cell house mouse CVCL_MT26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174032 CVCL_N526 Hs 36.T cancer cell line human CVCL_N526 CL:0000010 Discontinued: ATCC; CRL-7022; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174033 CVCL_MT27 BayGenomics ES cell line RRF013 embryonic stem cell house mouse CVCL_MT27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174034 CVCL_N527 FC25.T cancer cell line CVCL_N527 CL:0000010 Derived from sampling site: Bone Cell type=Fibroblast.. Discontinued: ATCC; CRL-6090; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174035 CVCL_MT24 BayGenomics ES cell line RRF008 embryonic stem cell house mouse CVCL_MT24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103071; Rangap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174036 CVCL_N524 Hs 31.Th finite cell line human CVCL_N524 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7020; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174037 CVCL_MT25 BayGenomics ES cell line RRF010 embryonic stem cell house mouse CVCL_MT25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445102; Dhx33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174038 CVCL_N525 Hs 35.T cancer cell line human CVCL_N525 CL:0000010 Discontinued: ATCC; CRL-7021; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174039 CVCL_MT22 BayGenomics ES cell line RRF004 embryonic stem cell house mouse CVCL_MT22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355315; Tmod3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174040 CVCL_N522 Hs 26.Mu finite cell line human CVCL_N522 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7018; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174041 CVCL_MT23 BayGenomics ES cell line RRF007 embryonic stem cell house mouse CVCL_MT23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97050; Mdh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174042 CVCL_N523 Hs 28.Fs finite cell line human CVCL_N523 CL:0000010 Derived from sampling site: Foreskin; skin. Discontinued: ATCC; CRL-7019; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174043 CVCL_MT20 BayGenomics ES cell line RRF002 embryonic stem cell house mouse CVCL_MT20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927224; Yeats4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174044 CVCL_N520 Hs 15.Mu finite cell line human CVCL_N520 CL:0000010 Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7013; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174045 CVCL_MT21 BayGenomics ES cell line RRF003 embryonic stem cell house mouse CVCL_MT21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891963; Ywhaq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174046 CVCL_N521 Hs 25.T cancer cell line human CVCL_N521 CL:0000010 Discontinued: ATCC; CRL-7017; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174047 CVCL_DZ67 ND07223 transformed cell line human CVCL_DZ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174048 CVCL_DZ68 ND07271 transformed cell line human CVCL_DZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174049 CVCL_DZ65 ND07188 transformed cell line human CVCL_DZ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174050 CVCL_DZ66 ND07222 transformed cell line human CVCL_DZ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174051 CVCL_DZ69 ND07275 transformed cell line human CVCL_DZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174052 CVCL_DZ60 ND07140 transformed cell line human CVCL_DZ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174053 CVCL_DZ63 ND07144 transformed cell line human CVCL_DZ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174054 CVCL_DZ64 ND07184 transformed cell line human CVCL_DZ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174055 CVCL_DZ61 ND07141 transformed cell line human CVCL_DZ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174056 CVCL_DZ62 ND07143 transformed cell line human CVCL_DZ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174057 CVCL_DZ78 ND07426 transformed cell line human CVCL_DZ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174058 CVCL_DZ79 ND07435 transformed cell line human CVCL_DZ79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174059 CVCL_DZ76 ND07422 transformed cell line human CVCL_DZ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174060 CVCL_DZ77 ND07425 transformed cell line human CVCL_DZ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174061 CVCL_DZ70 ND07276 transformed cell line human CVCL_DZ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174062 CVCL_DZ71 ND07299 transformed cell line human CVCL_DZ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174063 CVCL_MT08 BayGenomics ES cell line RRE322 embryonic stem cell house mouse CVCL_MT08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107733; Dctn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174064 CVCL_N508 HCT-116/VM46 cancer cell line human CVCL_N508 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from sampling site: Colon. Male 21174065 CVCL_DZ74 ND07311 transformed cell line human CVCL_DZ74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174066 CVCL_MT09 BayGenomics ES cell line RRE334 embryonic stem cell house mouse CVCL_MT09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174067 CVCL_N509 HCT-116/VP35 cancer cell line human CVCL_N509 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Colon. Male 21174068 CVCL_DZ75 ND07421 transformed cell line human CVCL_DZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174069 CVCL_MT06 BayGenomics ES cell line RRE314 embryonic stem cell house mouse CVCL_MT06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442789; Rc3h2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174070 CVCL_N506 MDTC-RP17 cancer cell line CVCL_N506 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Nicholas. Male Group: Bird cell line 21174071 CVCL_DZ72 ND07301 transformed cell line human CVCL_DZ72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174072 CVCL_MT07 BayGenomics ES cell line RRE320 embryonic stem cell house mouse CVCL_MT07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921807; Ppp6r3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174073 CVCL_N507 MDTC-RP18 cancer cell line CVCL_N507 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Nicholas. Male Doubling time: 8-11 hours (PubMed=6277804) Group: Bird cell line 21174074 CVCL_DZ73 ND07310 transformed cell line human CVCL_DZ73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174075 CVCL_N504 1B10 spontaneously immortalized cell line CVCL_N504 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Characteristics: Secretes IgM Group: Fish cell line 21174076 CVCL_MT04 BayGenomics ES cell line RRE311 embryonic stem cell house mouse CVCL_MT04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920995; Ubac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174077 CVCL_MT05 BayGenomics ES cell line RRE312 embryonic stem cell house mouse CVCL_MT05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387356; Ggnbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174078 CVCL_N505 MDTC-RP16 cancer cell line CVCL_N505 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain GA)(NCBI-Taxonomy; 10388); Breed/subspecies: Nicholas. Male Doubling time: 14-15 hours (PubMed=6277804) Group: Bird cell line 21174079 CVCL_MT02 BayGenomics ES cell line RRE309 embryonic stem cell house mouse CVCL_MT02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914105; Tcf25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174080 CVCL_N502 FB4.Bm finite cell line CVCL_N502 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-6040; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174081 CVCL_MT03 BayGenomics ES cell line RRE310 embryonic stem cell house mouse CVCL_MT03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349410; Triobp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174082 CVCL_N503 LB11.Bm finite cell line CVCL_N503 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: Hereford. Discontinued: ATCC; CRL-6065; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174083 CVCL_MT00 BayGenomics ES cell line RRE297 embryonic stem cell house mouse CVCL_MT00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349635; Sec23a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174084 CVCL_N500 FC105.We finite cell line CVCL_N500 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6153; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174085 CVCL_MT01 BayGenomics ES cell line RRE308 embryonic stem cell house mouse CVCL_MT01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344406; Ptpn21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174086 CVCL_N501 FB3.Bm finite cell line CVCL_N501 CL:0000010 Derived from sampling site: Fetal bone marrow. Discontinued: ATCC; CRL-6037; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174087 CVCL_3H31 HQ00740 transformed cell line human CVCL_3H31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174088 CVCL_3H32 HQ00741 transformed cell line human CVCL_3H32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174089 CVCL_3H30 HQ00739 transformed cell line human CVCL_3H30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174090 CVCL_3H35 HQ00744 transformed cell line human CVCL_3H35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174091 CVCL_3H36 HQ00745 transformed cell line human CVCL_3H36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174092 CVCL_3H33 HQ00742 transformed cell line human CVCL_3H33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174093 CVCL_3H34 HQ00743 transformed cell line human CVCL_3H34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174094 CVCL_3H39 HQ00748 transformed cell line human CVCL_3H39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174095 CVCL_3H37 HQ00746 transformed cell line human CVCL_3H37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174096 CVCL_3H38 HQ00747 transformed cell line human CVCL_3H38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174097 CVCL_VN80 TRA-284-SFG spontaneously immortalized cell line CVCL_VN80 CL:0000010 Unspecified Group: Insect cell line; Group: Serum/protein free medium cell line. 21174098 CVCL_VN83 HEK293 rLN10_hEcad transformed cell line human CVCL_VN83 CL:0000010 Transfected with: HGNC; 1748; CDH1; Transfected with: HGNC; 6485; LAMA5; Transfected with: HGNC; 6486; LAMB1; Transfected with: HGNC; 6492; LAMC1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21174099 CVCL_VN84 Vn-324 cancer cell line CVCL_VN84 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Brain; choroid plexus. 21174100 CVCL_VN81 YS-1 finite cell line human CVCL_VN81 CL:0000010 Derived from sampling site: Stomach Cell type=Fibroblast.. Male Characteristics: Tumor infiltrating fibroblasts Senescence: Senesces at ~45 PDL (JCRB=JCRB1522); Doubling time: 29 hours (JCRB) 21174101 CVCL_VN82 G-361/CMV-Luc#1(c-1) cancer cell line human CVCL_VN82 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS1039; true. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21174102 CVCL_VN87 Akata-EBV-P cancer cell line human CVCL_VN87 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21174103 CVCL_VN88 Akata-eGFP-EBV cancer cell line human CVCL_VN88 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative clone re-infected with a recombinant EBV in which eGFP was integrated in the BXLF1 gene 21174104 CVCL_VN85 293-M7 transformed cell line human CVCL_VN85 CL:0000010 Transfected with: HGNC; 6694; LRP2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: JCRB; JCRB1758; probable Female 21174105 CVCL_VN86 AR-EcoScreen GR KO M1 spontaneously immortalized cell line CVCL_VN86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7978; NR3C1; Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P27652; Renilla-type luciferase Derived from sampling site: Ovary. Female Characteristics: Used for rapid evaluation of in vitro androgen receptor transcriptional activation The NR3C1/GR knockout renders the AR-EcoScreen assay insensitive to glucocorticoid activation.; Characteristics: The luciferase reporter gene is under the control of a construct bearing four tandem repeats of a prostate C3 gene androgen-responsive element driven by a minimal heat shock protein promoter 21174106 CVCL_VN89 Akata-EBV-N cancer cell line human CVCL_VN89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative 21174107 CVCL_3H42 HQ00751 transformed cell line human CVCL_3H42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174108 CVCL_3H43 HQ00752 transformed cell line human CVCL_3H43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174109 CVCL_3H40 HQ00749 transformed cell line human CVCL_3H40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174110 CVCL_3H41 HQ00750 transformed cell line human CVCL_3H41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174111 CVCL_3H46 HQ00755 transformed cell line human CVCL_3H46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174112 CVCL_3H47 HQ00756 transformed cell line human CVCL_3H47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174113 CVCL_3H44 HQ00753 transformed cell line human CVCL_3H44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174114 CVCL_3H45 HQ00754 transformed cell line human CVCL_3H45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174115 CVCL_3H48 HQ00757 transformed cell line human CVCL_3H48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174116 CVCL_3H49 HQ00758 transformed cell line human CVCL_3H49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174117 CVCL_VN72 OARSAi007-A induced pluripotent stem cell human CVCL_VN72 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 21174118 CVCL_VN73 OARSAi008-A induced pluripotent stem cell human CVCL_VN73 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Male 21174119 CVCL_VN70 OARSAi005-A induced pluripotent stem cell human CVCL_VN70 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Caucasian; Non-hispanic white; Derived from sampling site: Umbilical cord blood. Male 21174120 CVCL_VN71 OARSAi006-A induced pluripotent stem cell human CVCL_VN71 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Caucasian; Non-hispanic white; Derived from sampling site: Umbilical cord blood. Male 21174121 CVCL_VN76 HPB-ATL-O cancer cell line human CVCL_VN76 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21174122 CVCL_VN77 HPB-ATL-T cancer cell line human CVCL_VN77 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21174123 CVCL_VN74 OARSAi009-A induced pluripotent stem cell human CVCL_VN74 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Caucasian; Non-hispanic white; Derived from sampling site: Umbilical cord blood. Male 21174124 CVCL_VN75 HLN-ATL-O cancer cell line human CVCL_VN75 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Lymph node Cell type=T-cell.. Male 21174125 CVCL_VN78 HPB-ATL-2 cancer cell line human CVCL_VN78 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21174126 CVCL_VN79 HPB-CTL-I cancer cell line human CVCL_VN79 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21174127 CVCL_3H10 HQ00719 transformed cell line human CVCL_3H10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174128 CVCL_3H13 HQ00722 transformed cell line human CVCL_3H13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174129 CVCL_3H14 HQ00723 transformed cell line human CVCL_3H14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174130 CVCL_3H11 HQ00720 transformed cell line human CVCL_3H11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174131 CVCL_3H12 HQ00721 transformed cell line human CVCL_3H12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174132 CVCL_3H17 HQ00726 transformed cell line human CVCL_3H17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174133 CVCL_3H18 HQ00727 transformed cell line human CVCL_3H18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174134 CVCL_3H15 HQ00724 transformed cell line human CVCL_3H15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174135 CVCL_3H16 HQ00725 transformed cell line human CVCL_3H16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174136 CVCL_3H08 HQ00717 transformed cell line human CVCL_3H08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174137 CVCL_3H09 HQ00718 transformed cell line human CVCL_3H09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174138 CVCL_VN61 IMFE1 telomerase immortalized cell line human CVCL_VN61 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000195028; Zygosity=Unspecified (PubMed=17644384); Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Microvascular endothelial cell.. Unspecified Doubling time: 33.6 hours (PubMed=17644384) 21174139 CVCL_VN62 UKWNLi001-A induced pluripotent stem cell human CVCL_VN62 From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Trp236Cys (c.708G>C); Zygosity=Heterozygous (PubMed=30130681) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21174140 CVCL_VN60 UEFi002-A induced pluripotent stem cell human CVCL_VN60 From: University of Eastern Finland; Kuopio; Finland CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Lys670_Met671delinsAsnLeu (c.2010_2011inv) (c.2010_2011delGAinsTC); ClinVar=VCV000018093; Zygosity=Heterozygous (PubMed=30099334) Population: Caucasian; Scandinavian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21174141 CVCL_VN65 IGIBi004-A induced pluripotent stem cell human CVCL_VN65 From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 9305; PPP2R2B; Repeat_expansion; CAG[65]; ClinVar=VCV000005614; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[17] (PubMed=30130680) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174142 CVCL_VN66 OARSAi001-A induced pluripotent stem cell human CVCL_VN66 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Caucasian; Non-hispanic white; Derived from sampling site: Umbilical cord blood. Male 21174143 CVCL_VN63 IGIBi002-A [2018] induced pluripotent stem cell human CVCL_VN63 From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 9305; PPP2R2B; Repeat_expansion; CAG[59]; ClinVar=VCV000005614; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[14] (PubMed=30130680) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Two different cell lines were established by CSIR-IGIB with the same IGIBi002-A designation 21174144 CVCL_VN64 IGIBi003-A induced pluripotent stem cell human CVCL_VN64 From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 9305; PPP2R2B; Repeat_expansion; CAG[67]; ClinVar=VCV000005614; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[10] (PubMed=30130680) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174145 CVCL_VN69 OARSAi004-A induced pluripotent stem cell human CVCL_VN69 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Black or African American; Derived from sampling site: Umbilical cord blood. Male 21174146 CVCL_VN67 OARSAi002-A induced pluripotent stem cell human CVCL_VN67 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Caucasian; Non-hispanic white; Derived from sampling site: Umbilical cord blood. Male 21174147 CVCL_VN68 OARSAi003-A induced pluripotent stem cell human CVCL_VN68 From: Office of Applied Research and Safety Assessment (OARSA), FDA; Laurel; USA CL:0000010 Population: Black or African American; Derived from sampling site: Umbilical cord blood. Male 21174148 CVCL_VN49 KOB cancer cell line human CVCL_VN49 CL:0000010 Sequence variation: Mutation; HGNC; 11920; FAS; Simple; p.Leu229Tyrfs (c.686_705delTGAGTAAATATATCACCACT); Zygosity=Heterozygous (PubMed=10190897); Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Arg48Trp (c.142C>T); Zygosity=Heterozygous (CelloPub=CLPUB00592); Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Met750Val (c.2248A>G); Zygosity=Heterozygous (CelloPub=CLPUB00592) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Ascites Cell type=T-cell.. Male 21174149 CVCL_3H20 HQ00729 transformed cell line human CVCL_3H20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174150 CVCL_3H21 HQ00730 transformed cell line human CVCL_3H21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174151 CVCL_3H24 HQ00733 transformed cell line human CVCL_3H24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174152 CVCL_3H25 HQ00734 transformed cell line human CVCL_3H25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174153 CVCL_3H22 HQ00731 transformed cell line human CVCL_3H22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174154 CVCL_3H23 HQ00732 transformed cell line human CVCL_3H23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174155 CVCL_3H28 HQ00737 transformed cell line human CVCL_3H28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174156 CVCL_3H29 HQ00738 transformed cell line human CVCL_3H29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174157 CVCL_3H26 HQ00735 transformed cell line human CVCL_3H26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174158 CVCL_3H27 HQ00736 transformed cell line human CVCL_3H27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174159 CVCL_3H19 HQ00728 transformed cell line human CVCL_3H19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174160 CVCL_VN50 LM-Y1 cancer cell line human CVCL_VN50 CL:0000010 Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Asn1171del (c.3512_3514delATT); Zygosity=Heterozygous (CelloPub=CLPUB00592); Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Arg1252Pro (c.3755G>C); Zygosity=Heterozygous (CelloPub=CLPUB00592) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 21174161 CVCL_VN51 LM-Y2 cancer cell line human CVCL_VN51 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 21174162 CVCL_VN54 laNK cancer cell line human CVCL_VN54 CL:0000010 Transfected with: HGNC; 3619; FCGR3A; Transfected with: HGNC; 6001; IL2 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: No longer dependent on IL2 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21174163 CVCL_VN55 laNK GFP cancer cell line human CVCL_VN55 CL:0000010 Transfected with: HGNC; 3619; FCGR3A; Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: No longer dependent on IL2 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21174164 CVCL_VN52 LMWT5 cancer cell line human CVCL_VN52 CL:0000010 Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Arg748His (c.2243G>A); Zygosity=Heterozygous (CelloPub=CLPUB00592); Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Ser520Phe (c.1559C>T); Zygosity=Heterozygous (CelloPub=CLPUB00592) Derived from sampling site: Peripheral blood Cell type=T-cell.. 21174165 CVCL_VN53 haNK GFP cancer cell line human CVCL_VN53 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val); Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: No longer dependent on IL2 Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21174166 CVCL_VN58 Mela15 cancer cell line human CVCL_VN58 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Marlow L.A Derived from metastatic site: Inguinal lymph node. Female Doubling time: 30 hours (Direct_author_submission) 21174167 CVCL_VN59 BWHGLi001 induced pluripotent stem cell naked mole-rat CVCL_VN59 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21174168 CVCL_VN56 NK-92 GFP cancer cell line human CVCL_VN56 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Caution: This cell line is exclusively owned and controlled by NantKwest, Inc NantKwest and its affiliate, Brink Biologics, Inc. are the sole authorized distributors for both commercial and non-commercial research requestors. There are no other authorized commercial and non-commercial suppliers for this cell line. Contact NantKwest and Brink Biologics for information concerning current inventory and cell line use and support. 21174169 CVCL_VN57 NK-92.26.5 cancer cell line human CVCL_VN57 CL:0000010 Transfected with: HGNC; 3619; FCGR3A Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male 21174170 CVCL_VN38 TVGHi006-A induced pluripotent stem cell human CVCL_VN38 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Heteroplasmic; Note=76% (PubMed=29960149) Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21174171 CVCL_VN39 KCLi001-A induced pluripotent stem cell human CVCL_VN39 From: King's College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 3748; FLG; Simple; p.Ser761Cysfs*36 (c.2278_2281CAGT[1]) (c.2282_2285delCAGT); ClinVar=VCV000016320; Zygosity=Heterozygous (PubMed=30075366) Population: Caucasian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21174172 CVCL_MT99 BayGenomics ES cell line RRF136 embryonic stem cell house mouse CVCL_MT99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174173 CVCL_N599 Hs 869.T cancer cell line human CVCL_N599 CL:0000010 Population: Caucasian; Derived from metastatic site: Brain. Discontinued: ATCC; CRL-7605; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174174 CVCL_VN40 TUSMi006-A induced pluripotent stem cell human CVCL_VN40 From: Tongji University School of Medicine; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 4586; GRIN2B; Simple; p.Arg712Lys (c.2135G>A); Zygosity=Unspecified (PubMed=30077089); Sequence variation: Mutation; HGNC; 11185; SORL1; Simple; p.Thr1483Ala (c.4447A>G); ClinVar=VCV000761546; Zygosity=Unspecified (PubMed=30077089) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21174175 CVCL_MT97 BayGenomics ES cell line RRF131 embryonic stem cell house mouse CVCL_MT97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152345; Taf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174176 CVCL_N597 Hs 879(A).T undefined cell line type human CVCL_N597 CL:0000010 Discontinued: ATCC; CRL-7614; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174177 CVCL_MT98 BayGenomics ES cell line RRF133 embryonic stem cell house mouse CVCL_MT98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109602; Gphn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174178 CVCL_N598 Hs 871.Bm finite cell line human CVCL_N598 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-7607; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174179 CVCL_MT95 BayGenomics ES cell line RRF127 embryonic stem cell house mouse CVCL_MT95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107940; Ezh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174180 CVCL_N595 LS274 cancer cell line human CVCL_N595 CL:0000010 Derived from metastatic site: Skin. 21174181 CVCL_VN43 NMSUNLi002-A induced pluripotent stem cell human CVCL_VN43 From: CEDOC, NOVA Medical School, Universidade Nova De Lisboa; Lisbon; Portugal CL:0000010 Population: Caucasian; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21174182 CVCL_MT96 BayGenomics ES cell line RRF130 embryonic stem cell house mouse CVCL_MT96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2148176; Snora65 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174183 CVCL_N596 LS310 cancer cell line human CVCL_N596 CL:0000010 Derived from metastatic site: Axillary lymph node. 21174184 CVCL_VN44 WAe001-A-17 embryonic stem cell human CVCL_VN44 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple_edited; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous; Note=By TALEN (PubMed=29730572). Male 21174185 CVCL_MT93 BayGenomics ES cell line RRF122 embryonic stem cell house mouse CVCL_MT93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443143; Wdr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174186 CVCL_VN41 LEIi006-A induced pluripotent stem cell human CVCL_VN41 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Tyr631Cys (c.1892A>G); ClinVar=VCV000636015; Zygosity=Heterozygous (PubMed=30092450); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Gly850Ser (c.2548G>A); ClinVar=VCV000565382; Zygosity=Heterozygous (PubMed=30092450) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21174187 CVCL_N593 PO spontaneously immortalized cell line CVCL_N593 CL:0000010 Derived from sampling site: Kidney. 21174188 CVCL_MT94 BayGenomics ES cell line RRF126 embryonic stem cell house mouse CVCL_MT94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332235; Nrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174189 CVCL_N594 FLK-N3 spontaneously immortalized cell line CVCL_N594 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21174190 CVCL_VN42 IISHDOi004-A induced pluripotent stem cell human CVCL_VN42 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys759Phe (c.2276G>T); ClinVar=VCV000002356; Zygosity=Homozygous (PubMed=30096711) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21174191 CVCL_MT91 BayGenomics ES cell line RRF117 embryonic stem cell house mouse CVCL_MT91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915208; U2surp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174192 CVCL_VN47 GE-2 spontaneously immortalized cell line CVCL_VN47 CL:0000010 Unspecified Group: Reptilian cell line. 21174193 CVCL_N591 GUSS-3 cancer cell line human CVCL_N591 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=23716114). Male 21174194 CVCL_MT92 BayGenomics ES cell line RRF118 embryonic stem cell house mouse CVCL_MT92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174195 CVCL_N592 HSS-84 cancer cell line human CVCL_N592 CL:0000010 Population: Chinese Female Doubling time: 65 hours (PubMed=2851424). 21174196 CVCL_VN48 SO-4 cancer cell line human CVCL_VN48 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223His (c.668C>A); Zygosity=Unspecified (PubMed=19710698; PubMed=19220422) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent Caution: It is uncertain if cell line SD-4 (Cellosaurus=CVCL_0G04) is not a misspelling of SO-4 21174197 CVCL_VN45 UKBi011-A-2 induced pluripotent stem cell human CVCL_VN45 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple_corrected; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33556820); Sequence variation: Mutation; HGNC; 613; APOE; Simple_edited; p.Arg176Cys (c.526C>T); ClinVar=VCV000017848; Zygosity=Homozygous; Note=ApoE2 allele By CRISPR/Cas9 (PubMed=33556820). Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21174198 CVCL_VN46 AT3' finite cell line human CVCL_VN46 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2935; probable Female 21174199 CVCL_MT90 BayGenomics ES cell line RRF116 embryonic stem cell house mouse CVCL_MT90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921373; Foxp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174200 CVCL_N590 GUSS-2 cancer cell line human CVCL_N590 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=23716114). Male 21174201 CVCL_VN29 ORL8 cancer cell line human CVCL_VN29 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Supports HCV replication; Characteristics: Transfected with ORN/C-5B/QR,KE,SR RNA, a construct containing renilla-type luciferase, neoR and genome-length HCV RNA from O strain (genotype 1b) 21174202 CVCL_VN27 Li-24 cancer cell line human CVCL_VN27 CL:0000010 Population: Japanese; Derived from sampling site: Liver. 21174203 CVCL_VN28 ORL11 cancer cell line human CVCL_VN28 CL:0000010 Transfected with: UniProtKB; P27652; Renilla-type luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Supports HCV replication; Characteristics: Transfected with ORN/C-5B/QR,KE,SR RNA, a construct containing renilla-type luciferase, neoR and genome-length HCV RNA from O strain (genotype 1b) 21174204 CVCL_3H02 HQ00711 transformed cell line human CVCL_3H02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174205 CVCL_3H03 HQ00712 transformed cell line human CVCL_3H03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174206 CVCL_3H00 HQ00709 transformed cell line human CVCL_3H00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174207 CVCL_3H01 HQ00710 transformed cell line human CVCL_3H01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174208 CVCL_3H06 HQ00715 transformed cell line human CVCL_3H06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174209 CVCL_3H07 HQ00716 transformed cell line human CVCL_3H07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174210 CVCL_3H04 HQ00713 transformed cell line human CVCL_3H04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174211 CVCL_3H05 HQ00714 transformed cell line human CVCL_3H05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174212 CVCL_VN32 MHHi007-A-1 induced pluripotent stem cell human CVCL_VN32 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: Venus, a bright yellow fluorescent protein derived from YFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Umbilical cord blood. Female Characteristics: Using TALEN a P2A-Venus(nucmem)-T2A-NeoR_PGK-Puro construct was integrated in front of the stop codon of CDX2 21174213 CVCL_VN33 MHHi006-A induced pluripotent stem cell human CVCL_VN33 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Umbilical cord blood. Omics: Transcriptome analysis by RNAseq Male 21174214 CVCL_VN30 OR6 [Human] cancer cell line human CVCL_VN30 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P27652; Renilla-type luciferase Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Supports HCV replication; Characteristics: Transfected with ORN/C-5B/KE RNA, a construct containing renilla-type luciferase, neoR and genome-length HCV RNA from O strain (genotype 1b) 21174215 CVCL_VN31 MHHi007-A induced pluripotent stem cell human CVCL_VN31 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21174216 CVCL_VN36 ADBSi002-A induced pluripotent stem cell human CVCL_VN36 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174217 CVCL_VN37 TVGHi005-A induced pluripotent stem cell human CVCL_VN37 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Heteroplasmic; Note=1% (PubMed=29960149) Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21174218 CVCL_VN34 KIOMi001-A induced pluripotent stem cell human CVCL_VN34 From: Korea Institute of Oriental Medicine; Daejeon; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple_corrected; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous; Note=By homologous recombination (PubMed=29906669) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21174219 CVCL_VN35 ADBSi001-A induced pluripotent stem cell human CVCL_VN35 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174220 CVCL_VN18 DOR-1 cancer cell line human CVCL_VN18 CL:0000010 Female Doubling time: 72-96 hours (PubMed=15390308). 21174221 CVCL_VN19 PRU-1 cancer cell line human CVCL_VN19 CL:0000010 Male 21174222 CVCL_VN16 HHUUKDi004-A induced pluripotent stem cell human CVCL_VN16 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (PubMed=29902745) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174223 CVCL_VN17 CHOPi001-A induced pluripotent stem cell human CVCL_VN17 From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 1541; CBL; Simple; p.Tyr371His (c.1111T>C); ClinVar=VCV000013811; Zygosity=Hemizygous (PubMed=30096712) Derived from sampling site: Bone marrow. Female 21174224 CVCL_MT79 BayGenomics ES cell line RRF096 embryonic stem cell house mouse CVCL_MT79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685106; Mideas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174225 CVCL_N579 Hs 191.T cancer cell line human CVCL_N579 CL:0000010 Derived from sampling site: Urinary bladder. Discontinued: ATCC; CRL-7146; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174226 CVCL_MT77 BayGenomics ES cell line RRF093 embryonic stem cell house mouse CVCL_MT77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174227 CVCL_N577 Hs 189.Tes finite cell line human CVCL_N577 CL:0000010 Derived from sampling site: Fetal testis. Discontinued: ATCC; CRL-7143; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174228 CVCL_MT78 BayGenomics ES cell line RRF094 embryonic stem cell house mouse CVCL_MT78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353653; Glrx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174229 CVCL_N578 Hs 189.Tg finite cell line human CVCL_N578 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-7144; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174230 CVCL_MT75 BayGenomics ES cell line RRF090 embryonic stem cell house mouse CVCL_MT75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918079; Ccdc93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174231 CVCL_N575 Hs 189.Bl finite cell line human CVCL_N575 CL:0000010 Derived from sampling site: Fetal urinary bladder. Discontinued: ATCC; CRL-7141; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174232 CVCL_MT76 BayGenomics ES cell line RRF091 embryonic stem cell house mouse CVCL_MT76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105968; Txlna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174233 CVCL_N576 Hs 189.K finite cell line human CVCL_N576 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-7142; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174234 CVCL_MT73 BayGenomics ES cell line RRF088 embryonic stem cell house mouse CVCL_MT73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3643133; Gm4924 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174235 CVCL_VN21 ELD-1 C-11 cancer cell line human CVCL_VN21 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Problematic cell line: Contaminated Ancestral cell line (MOBS-1) has been shown to be a U-937 derivative. 21174236 CVCL_N573 Hs 186.Int finite cell line human CVCL_N573 CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Discontinued: ATCC; CRL-7136; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174237 CVCL_MT74 BayGenomics ES cell line RRF089 embryonic stem cell house mouse CVCL_MT74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104580; Rapgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174238 CVCL_VN22 ELD-1 C-8 cancer cell line human CVCL_VN22 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Problematic cell line: Contaminated Ancestral cell line (MOBS-1) has been shown to be a U-937 derivative. 21174239 CVCL_N574 Hs 186.Li finite cell line human CVCL_N574 CL:0000010 Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7137; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174240 CVCL_MT71 BayGenomics ES cell line RRF085 embryonic stem cell house mouse CVCL_MT71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174241 CVCL_N571 Hs 181.St finite cell line human CVCL_N571 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal stomach. Discontinued: ATCC; CRL-7130; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174242 CVCL_MT72 BayGenomics ES cell line RRF086 embryonic stem cell house mouse CVCL_MT72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145310; Rnf44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174243 CVCL_VN20 ELD-1 cancer cell line human CVCL_VN20 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Problematic cell line: Contaminated Grand-parent cell line (MOBS-1) has been shown to be a U-937 derivative. 21174244 CVCL_N572 Hs 184.Mu finite cell line human CVCL_N572 CL:0000010 Population: Caucasian; Derived from sampling site: Muscle. Discontinued: ATCC; CRL-7132; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174245 CVCL_VN25 Li-22 cancer cell line human CVCL_VN25 CL:0000010 Population: Japanese; Derived from sampling site: Liver. 21174246 CVCL_MT70 BayGenomics ES cell line RRF084 embryonic stem cell house mouse CVCL_MT70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914120; Serbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174247 CVCL_N570 Hs 181.Li finite cell line human CVCL_N570 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal liver. Discontinued: ATCC; CRL-7128; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174248 CVCL_VN26 Li-23 cancer cell line human CVCL_VN26 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Supports HCV replication 21174249 CVCL_VN23 ELD-1 D-9 cancer cell line human CVCL_VN23 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Problematic cell line: Contaminated Ancestral cell line (MOBS-1) has been shown to be a U-937 derivative. 21174250 CVCL_VN24 Li-21 cancer cell line human CVCL_VN24 CL:0000010 Population: Japanese; Derived from sampling site: Liver. 21174251 CVCL_VN07 WTSIi227-A-1 induced pluripotent stem cell human CVCL_VN07 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6694; LRP2 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21174252 CVCL_VN08 HPS1012 induced pluripotent stem cell human CVCL_VN08 CL:0000010 Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Arg218His (c.653G>A); ClinVar=VCV000099736; Zygosity=Heterozygous (PubMed=32416576); Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Ala357Val (c.1070C>T); ClinVar=VCV000305125; Zygosity=Heterozygous (PubMed=32416576) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21174253 CVCL_VN05 BLSC-KU-11 cancer cell line CVCL_VN05 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese black. Female 21174254 CVCL_VN06 CHOExpress transformed cell line CVCL_VN06 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used for high yield production of therapeutic proteins and antibodies Female 21174255 CVCL_VN09 BLSC-KU-19 cancer cell line CVCL_VN09 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese black. Female 21174256 CVCL_N588 1273/99 cancer cell line human CVCL_N588 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=12097301; DepMap) Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21174257 CVCL_MT88 BayGenomics ES cell line RRF113 embryonic stem cell house mouse CVCL_MT88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919822; Spats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174258 CVCL_MT89 BayGenomics ES cell line RRF115 embryonic stem cell house mouse CVCL_MT89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917433; Dzip3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174259 CVCL_N589 GUSS-1 cancer cell line human CVCL_N589 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=23716114). Female 21174260 CVCL_MT86 BayGenomics ES cell line RRF111 embryonic stem cell house mouse CVCL_MT86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384761; Rapgef6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174261 CVCL_N586 CME-1 transformed cell line human CVCL_N586 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=7736791; DepMap) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Omics: Deep exome analysis. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21174262 CVCL_MT87 BayGenomics ES cell line RRF112 embryonic stem cell house mouse CVCL_MT87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2176740; Helq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174263 CVCL_N587 HS-SY-3 cancer cell line human CVCL_N587 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1; Note=Truncated (PubMed=10399965) Population: Japanese; Derived from sampling site: Popliteal fossa. Female Doubling time: 120 hours, at 18th passage (PubMed=10399965) 21174264 CVCL_MT84 BayGenomics ES cell line RRF106 embryonic stem cell house mouse CVCL_MT84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174265 CVCL_VN10 hTERT-PBEC telomerase immortalized cell line pig CVCL_VN10 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bronchus; epithelium; Breed/subspecies: Yorkshire. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201749 21174266 CVCL_N584 SN-SY-1 cancer cell line human CVCL_N584 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=9378564) Population: Japanese; Derived from metastatic site: Abdominal wall. Male Doubling time: ~167 hours (PubMed=9378564) 21174267 CVCL_MT85 BayGenomics ES cell line RRF108 embryonic stem cell house mouse CVCL_MT85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861099; Ubr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174268 CVCL_VN11 MUSIi004-A induced pluripotent stem cell human CVCL_VN11 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21174269 CVCL_N585 STS255 cancer cell line human CVCL_N585 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=2704557; PubMed=7539744) Derived from sampling site: Thigh; skeletal muscle. Female 21174270 CVCL_MT82 BayGenomics ES cell line RRF103 embryonic stem cell house mouse CVCL_MT82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384788; Sde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174271 CVCL_N582 Hs 197.T cancer cell line human CVCL_N582 CL:0000010 Discontinued: ATCC; CRL-7151; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174272 CVCL_MT83 BayGenomics ES cell line RRF104 embryonic stem cell house mouse CVCL_MT83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109634; Terf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174273 CVCL_N583 FU-SY-1 cancer cell line human CVCL_N583 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=12063544). Population: Japanese Female Doubling time: ~96 hours (PubMed=12063544) 21174274 CVCL_MT80 BayGenomics ES cell line RRF098 embryonic stem cell house mouse CVCL_MT80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914324; Mon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174275 CVCL_VN14 HHUUKDi008-A induced pluripotent stem cell human CVCL_VN14 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18590; PNPLA3; Simple; p.Ile148Met (c.444C>G); ClinVar=VCV000341932; Zygosity=Homozygous (PubMed=30071394) Derived from sampling site: Cell type=Fibroblast. Female 21174276 CVCL_N580 Hs 192.T cancer cell line human CVCL_N580 CL:0000010 Discontinued: ATCC; CRL-7147; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174277 CVCL_MT81 BayGenomics ES cell line RRF101 embryonic stem cell house mouse CVCL_MT81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915208; U2surp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21174278 CVCL_VN15 HHUUKDi007-A induced pluripotent stem cell human CVCL_VN15 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18590; PNPLA3; Simple; p.Ile148Met (c.444C>G); ClinVar=VCV000341932; Zygosity=Homozygous (PubMed=30081348) Derived from sampling site: Cell type=Fibroblast. Female 21174279 CVCL_N581 Hs 193.Th finite cell line human CVCL_N581 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-7149; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174280 CVCL_VN12 MUSIi006-A induced pluripotent stem cell human CVCL_VN12 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Hair follicle Cell type=Hair follicular keratinocyte.. Female 21174281 CVCL_VN13 MUSIe001-A embryonic stem cell human CVCL_VN13 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai. Male 21174282 CVCL_VX31 HePe-01 finite cell line CVCL_VX31 CL:0000010 Derived from sampling site: Tail Cell type=Fibroblast.. Female Doubling time: 24 +- 0.5 hours (PubMed=29948549) Group: Reptilian cell line 21174283 CVCL_W931 Oba-BL cancer cell line human CVCL_W931 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Male 21174284 CVCL_VX30 OCC-34 finite cell line human CVCL_VX30 CL:0000010 Male 21174285 CVCL_W930 QIMR-WW1-LCL transformed cell line human CVCL_W930 HLA typing: A*11,24; B*27,62 (PubMed=3037521) CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Could be identical to WeWak1 (Cellosaurus=CVCL_E871) 21174286 CVCL_VX35 OCC-15 finite cell line human CVCL_VX35 CL:0000010 Female 21174287 CVCL_W935 Odour cancer cell line human CVCL_W935 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 21174288 CVCL_W934 JI cancer cell line human CVCL_W934 CL:0000010 Sequence variation: Gene fusion; HGNC; 5715; IGK + HGNC; 7553; MYC; Name(s)=MYC-IGK (PubMed=3458667; PubMed=6806672) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Axillary lymph node. Female Virology: Contains 25 copies of the EBV genome (PubMed=6244869) 21174289 CVCL_VX34 OCC-06 finite cell line human CVCL_VX34 CL:0000010 Male 21174290 CVCL_W933 Akuba cancer cell line human CVCL_W933 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=8402660) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Unspecified Doubling time: 21 hours (PubMed=8402660) 21174291 CVCL_VX33 OCC-05 finite cell line human CVCL_VX33 CL:0000010 Female 21174292 CVCL_VX32 OCC-01 finite cell line human CVCL_VX32 CL:0000010 Female 21174293 CVCL_W932 QIMR-WW2-LCL transformed cell line human CVCL_W932 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174294 CVCL_W939 Liv-BL cancer cell line human CVCL_W939 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21174295 CVCL_VX39 OCC-26 finite cell line human CVCL_VX39 CL:0000010 Female 21174296 CVCL_W938 Kyu-BL cancer cell line human CVCL_W938 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21174297 CVCL_VX38 OCC-21 finite cell line human CVCL_VX38 CL:0000010 Male 21174298 CVCL_W937 Kie-BL cancer cell line human CVCL_W937 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21174299 CVCL_VX37 OCC-19 finite cell line human CVCL_VX37 CL:0000010 Female 21174300 CVCL_VX36 OCC-16 finite cell line human CVCL_VX36 CL:0000010 Male 21174301 CVCL_W936 Silfere cancer cell line human CVCL_W936 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Abdomen. Female 21174302 CVCL_VX20 GoBo-21 finite cell line CVCL_VX20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174303 CVCL_W920 THJ-16T cancer cell line human CVCL_W920 CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 7112; MKRN1; Name(s)=MKRN1-BRAF; Note=In frame (PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (PubMed=23833040; PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Ser799Phefs*5 (c.2396delC); Zygosity=Homozygous (PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 9967; RET; Simple; p.Glu90Lys (c.268G>A); Zygosity=Heterozygous (PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 27 hours (PubMed=20810568) 21174304 CVCL_VX24 GoBo-25 finite cell line CVCL_VX24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174305 CVCL_W924 OST 7 PT cancer cell line human CVCL_W924 CL:0000010 21174306 CVCL_VX23 GoBo-24 finite cell line CVCL_VX23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174307 CVCL_W923 OST 10 PT cancer cell line human CVCL_W923 CL:0000010 21174308 CVCL_VX22 GoBo-23 finite cell line CVCL_VX22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174309 CVCL_W922 THJ-29T cancer cell line human CVCL_W922 CL:0000010 Sequence variation: Gene fusion; HGNC; 3689; FGFR2 + HGNC; 8124; OGDH; Name(s)=FGFR2-OGDH; Note=In frame (PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gln70Serfs*102 (c.207delG) (G55fs); Zygosity=Homozygous (PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 18128; HDAC10; Simple; p.His134Thrfs*19 (c.399delG); Zygosity=Heterozygous (PubMed=26680454); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35 hours (PubMed=20810568) 21174310 CVCL_VX21 GoBo-22 finite cell line CVCL_VX21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174311 CVCL_W921 THJ-21T cancer cell line human CVCL_W921 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=23833040; PubMed=26680454; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 43 hours (PubMed=20810568) 21174312 CVCL_VX28 OCC-31 finite cell line human CVCL_VX28 CL:0000010 Male 21174313 CVCL_W928 SP-8.0 cancer cell line human CVCL_W928 CL:0000010 Derived from sampling site: Eye; uvea. Male 21174314 CVCL_W927 AVC1 cancer cell line human CVCL_W927 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=14677066) Derived from sampling site: Pancreas; ampulla of Vater. Omics: Deep proteome analysis Female Doubling time: 24 +- 1 hours (PubMed=14677066) 21174315 CVCL_VX27 OCC-25 finite cell line human CVCL_VX27 CL:0000010 Female 21174316 CVCL_W926 L27 cancer cell line human CVCL_W926 CL:0000010 Population: Japanese. 21174317 CVCL_VX26 OCC-22 finite cell line human CVCL_VX26 CL:0000010 Female 21174318 CVCL_VX25 GoBo-26 finite cell line CVCL_VX25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174319 CVCL_W925 OST 8 PT cancer cell line human CVCL_W925 CL:0000010 21174320 CVCL_VX29 OCC-32 finite cell line human CVCL_VX29 CL:0000010 Female 21174321 CVCL_VX13 GoBo-14 finite cell line CVCL_VX13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174322 CVCL_W913 MDA-T32 cancer cell line human CVCL_W913 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=25427145; PubMed=30737244); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Val (c.857A>T); ClinVar=VCV000376592; Zygosity=Heterozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male 21174323 CVCL_VX12 GoBo-13 finite cell line CVCL_VX12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174324 CVCL_W912 LAM1 cancer cell line human CVCL_W912 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Ile85Serfs*33 (c.249_252delGTCT) (p.Leu83fs); ClinVar=VCV000016693; Zygosity=Unspecified (PubMed=30737244); Sequence variation: Mutation; HGNC; 28958; NUP93; Simple; p.Gln15Ter (c.43C>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 9822; RAD51B; Simple; p.Gln270Ter (c.808C>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154del (c.460_462delGGC); Zygosity=Homozygous (PubMed=30737244) Derived from metastatic site: Left subcarinal lymph node. Omics: Transcriptome analysis by microarray Male 21174325 CVCL_VX11 GoBo-12 finite cell line CVCL_VX11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174326 CVCL_W911 KTC-3 cancer cell line human CVCL_W911 CL:0000010 Miscellaneous: STR profile from personal communication of Marlow L.A Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 24 hours (CelloPub=CLPUB00144) 21174327 CVCL_VX10 GoBo-11 finite cell line CVCL_VX10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174328 CVCL_W910 LGW01 cancer cell line human CVCL_W910 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified 21174329 CVCL_W917 CUTC48 cancer cell line human CVCL_W917 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30733375; PubMed=30737244) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 29 hours (PubMed=30733375) 21174330 CVCL_VX17 GoBo-18 finite cell line CVCL_VX17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174331 CVCL_W916 CUTC5 cancer cell line human CVCL_W916 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Glu1108Ter (c.3322G>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30733375; PubMed=30737244); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Leu (c.395G>T); ClinVar=VCV000375889; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Homozygous (PubMed=30733375; PubMed=30737244) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 29 hours (PubMed=30733375) 21174332 CVCL_VX16 GoBo-17 finite cell line CVCL_VX16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174333 CVCL_VX15 GoBo-16 finite cell line CVCL_VX15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174334 CVCL_W915 OCUT-2C cancer cell line human CVCL_W915 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23833040); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=23833040); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040) Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21174335 CVCL_VX14 GoBo-15 finite cell line CVCL_VX14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174336 CVCL_W914 MDA-T41 cancer cell line human CVCL_W914 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=25427145; PubMed=30737244); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ile831Phe (c.2491A>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe19fs (c.56_65delTTTCAGACCT); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Heterozygous (PubMed=30737244) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 21174337 CVCL_VX19 GoBo-20 finite cell line CVCL_VX19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174338 CVCL_W919 THJ-11T cancer cell line human CVCL_W919 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=20810568; PubMed=23833040); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040) Miscellaneous: STR profile and age of donor from personal communication of Marlow L.A Derived from sampling site: Thyroid gland. Male Doubling time: 30 hours (PubMed=20810568) Caution: Cell line wrongly indicated as being female in figure 2A of PubMed=20810568 21174339 CVCL_VX18 GoBo-19 finite cell line CVCL_VX18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174340 CVCL_W918 PTC032210 cancer cell line human CVCL_W918 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=23833040). 21174341 CVCL_VX02 GoBo-3 finite cell line CVCL_VX02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174342 CVCL_W902 SD cancer cell line human CVCL_W902 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680). Unspecified 21174343 CVCL_VX01 GoBo-2 finite cell line CVCL_VX01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174344 CVCL_W901 Mano cancer cell line human CVCL_W901 CL:0000010 21174345 CVCL_VX00 GoBo-1 finite cell line CVCL_VX00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174346 CVCL_W900 LUCC9 cancer cell line human CVCL_W900 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21174347 CVCL_W906 GM10711 transformed cell line human CVCL_W906 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174348 CVCL_VX06 GoBo-7 finite cell line CVCL_VX06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174349 CVCL_W905 GM10249 transformed cell line human CVCL_W905 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174350 CVCL_VX05 GoBo-6 finite cell line CVCL_VX05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174351 CVCL_W904 GM10231 transformed cell line human CVCL_W904 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174352 CVCL_VX04 GoBo-5 finite cell line CVCL_VX04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174353 CVCL_W903 GM10228 transformed cell line human CVCL_W903 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174354 CVCL_VX03 GoBo-4 finite cell line CVCL_VX03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174355 CVCL_W909 92-1 [Human bladder carcinoma] cancer cell line human CVCL_W909 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: UBC-40 urothelial bladder cancer cell line index 21174356 CVCL_VX09 GoBo-10 finite cell line CVCL_VX09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174357 CVCL_VX08 GoBo-9 finite cell line CVCL_VX08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Female Group: Endangered species/breed cell line 21174358 CVCL_W908 TRP3 telomerase immortalized cell line human CVCL_W908 CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple; p.Ile485Phe (c.1453A>T); Zygosity=Unspecified (PubMed=24853805); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Female 21174359 CVCL_W907 GM10715 transformed cell line human CVCL_W907 CL:0000010 Sequence variation: Mutation; HGNC; 3349; ENG; Simple; p.Arg437Arg (c.1311G>C) (G1311C); ClinVar=VCV000458335; Zygosity=Unspecified; Note=Splice site mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174360 CVCL_VX07 GoBo-8 finite cell line CVCL_VX07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Golpayegani cattle. Male Group: Endangered species/breed cell line 21174361 CVCL_EE99 HPSI0514i-naah_4 induced pluripotent stem cell human CVCL_EE99 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174362 CVCL_EE98 HPSI0514i-naah_2 induced pluripotent stem cell human CVCL_EE98 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174363 CVCL_EE97 HPSI0514i-mure_9 induced pluripotent stem cell human CVCL_EE97 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21174364 CVCL_EE96 HPSI0514i-mure_4 induced pluripotent stem cell human CVCL_EE96 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21174365 CVCL_3R70 HQ01695 transformed cell line human CVCL_3R70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174366 CVCL_4370 VSW spontaneously immortalized cell line CVCL_4370 CL:0000010 Derived from sampling site: Spleen. Female Virology: Infected by a C-type retrovirus Group: Reptilian cell line 21174367 CVCL_3R74 HQ01699 transformed cell line human CVCL_3R74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174368 CVCL_4374 RWP-2 cancer cell line human CVCL_4374 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=8026879) Derived from metastatic site: Liver. Female Doubling time: 46 hours (PubMed=7083162; PubMed=8026879) 21174369 CVCL_3R73 HQ01698 transformed cell line human CVCL_3R73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174370 CVCL_4373 RWP-1 cancer cell line human CVCL_4373 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879; PubMed=11169959; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853) Derived from metastatic site: Liver. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female Doubling time: 45 hours (PubMed=7083162; PubMed=8026879); 23.6 +- 0.54 hours (PubMed=27067801) 21174371 CVCL_3R72 HQ01697 transformed cell line human CVCL_3R72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174372 CVCL_4372 MIN6-m14 transformed cell line house mouse CVCL_4372 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Unspecified Characteristics: Glucose-unresponsive 21174373 CVCL_3R71 HQ01696 transformed cell line human CVCL_3R71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174374 CVCL_4371 MIN6-m9 transformed cell line house mouse CVCL_4371 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: C57BL/6 IT6 transgenic. Unspecified Characteristics: Glucose-responsive 21174375 CVCL_4367 AH130 cancer cell line Norway rat CVCL_4367 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21174376 CVCL_3R67 HQ01692 transformed cell line human CVCL_3R67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174377 CVCL_3R66 HQ01691 transformed cell line human CVCL_3R66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174378 CVCL_4366 OV-1063 cancer cell line human CVCL_4366 CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Glu40Ter (c.118G>T); Zygosity=Unspecified (PubMed=11565033); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Unspecified (PubMed=25846456); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Unspecified (PubMed=25846456) Miscellaneous: STR profile from personal communication of Granit A., Hadassah Medical Center, Jerusalem, Israel Derived from metastatic site: Ascites. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Discontinued: ATCC; CRL-2183; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00340 Problematic cell line: Partially misidentified The stock formerly distributed by ATCC and CCRID was misidentified and was actually DU145 (Cellosaurus=CVCL_0105). This is not the case of the original stock from Hadassah Medical Center. 21174379 CVCL_3R65 HQ01690 transformed cell line human CVCL_3R65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174380 CVCL_4365 NCI-H738 cancer cell line human CVCL_4365 CL:0000010 Discontinued: ATCC; CRL-5839; true. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00335 Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin. 21174381 CVCL_3R64 HQ01689 transformed cell line human CVCL_3R64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174382 CVCL_4364 NCI-H1622 cancer cell line human CVCL_4364 CL:0000010 Derived from metastatic site: Lymph node. Discontinued: ATCC; CRL-5880; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00332 Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (PubMed=20143388). In addition according to PubMed=8806092 it is supposed to be established from the same patient as NCI-H1618 (Cellosaurus=CVCL_1480) but the STR profile is different. 21174383 CVCL_3R69 HQ01694 transformed cell line human CVCL_3R69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174384 CVCL_4369 VH2 spontaneously immortalized cell line CVCL_4369 CL:0000010 Derived from sampling site: Heart. Female Group: Reptilian cell line 21174385 CVCL_4368 AH66-TC cancer cell line Norway rat CVCL_4368 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21174386 CVCL_3R68 HQ01693 transformed cell line human CVCL_3R68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174387 CVCL_3R81 HQ01706 transformed cell line human CVCL_3R81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174388 CVCL_4381 HuH-6 cancer cell line human CVCL_4381 Genome ancestry: African=0.79%; Native American=0.3%; East Asian, North=80.92%; East Asian, South=17.99%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (PubMed=9671767; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Asp (c.476C>A); ClinVar=VCV001026335; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239Asp (c.715A>G); ClinVar=VCV000234036; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel 21174389 CVCL_3R80 HQ01705 transformed cell line human CVCL_3R80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174390 CVCL_4380 SU-DHL-7 cancer cell line human CVCL_4380 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: ~50 hours (DSMZ=ACC-903) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00557 Caution: Was reported in the Cellosaurus and the ICLAC Register (from 2018 to early 2022) to be a SU-DHL-8 contaminated cell line but there seem to have been an issue with the sample tested DSMZ has obtained original stock from Epstein A.L. and SU-DHL-7 is a genuine non-problematic cell line. 21174391 CVCL_3R85 HQ01710 transformed cell line human CVCL_3R85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174392 CVCL_4385 TRK-43 transformed cell line CVCL_4385 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea Cell type=Keratocyte.. Unspecified 21174393 CVCL_3R84 HQ01709 transformed cell line human CVCL_3R84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174394 CVCL_4384 TMK-1 cancer cell line human CVCL_4384 Genome ancestry: African=0.05%; Native American=0.49%; East Asian, North=70.76%; East Asian, South=27.97%; South Asian=0%; European, North=0.73%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Unspecified (PubMed=1370612; PubMed=1933850; PubMed=11107048) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~34.9 hours (PubMed=3003017); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21174395 CVCL_4383 BNL CL.2 spontaneously immortalized cell line house mouse CVCL_4383 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21174396 CVCL_3R83 HQ01708 transformed cell line human CVCL_3R83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174397 CVCL_4382 CHO Pro-5 spontaneously immortalized cell line CVCL_4382 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Defective in purine biosynthesis 21174398 CVCL_3R82 HQ01707 transformed cell line human CVCL_3R82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174399 CVCL_4378 ES-D3 embryonic stem cell house mouse CVCL_4378 CL:0000010 Breed/subspecies: 129S2/SvPas. Omics: Cell surface proteome Male Part of: ENCODE project mouse cell lines; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11632 21174400 CVCL_3R78 HQ01703 transformed cell line human CVCL_3R78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174401 CVCL_3R77 HQ01702 transformed cell line human CVCL_3R77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174402 CVCL_4377 OVCAR-10 cancer cell line human CVCL_4377 CL:0000010 Omics: Transcriptome analysis by microarray. Female Doubling time: 32.31 hours (GrayJW panel) 21174403 CVCL_4376 HPDE finite cell line human CVCL_4376 CL:0000010 Derived from sampling site: Pancreas Cell type=Ductal cell.. Omics: Transcriptome analysis by microarray 21174404 CVCL_3R76 HQ01701 transformed cell line human CVCL_3R76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174405 CVCL_3R75 HQ01700 transformed cell line human CVCL_3R75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174406 CVCL_4375 OV-1946 cancer cell line human CVCL_4375 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=18507860; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.5 +- 0.9 days (PubMed=18507860) 21174407 CVCL_3R79 HQ01704 transformed cell line human CVCL_3R79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174408 CVCL_4379 SU-DHL-9 cancer cell line human CVCL_4379 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Pro648Thrfs*2 (c.1940dupC) (c.1940_1941insC); ClinVar=VCV000432829; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Asn (c.700T>A); ClinVar=VCV000376692; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: CNV analysis; Omics: Genome sequenced; Omics: miRNA expression profiling Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00558 Problematic cell line: Contaminated Shown to be a SU-DHL-8 derivative (ICLAC). Originally thought to originate from a 64 year old female patient with a diffuse large B-cell lymphoma. 21174409 CVCL_VX97 CpHi56 finite cell line CVCL_VX97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174410 CVCL_W997 Nara-F cancer cell line human CVCL_W997 CL:0000010 Population: Japanese Female Doubling time: 33.4 hours (PubMed=11408058). 21174411 CVCL_VX96 CpHi55 finite cell line CVCL_VX96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174412 CVCL_W996 GLL-1 cancer cell line human CVCL_W996 CL:0000010 Population: Japanese; Derived from metastatic site: Right axillary lymph node. Male Characteristics: Established from a 15th generation xenograft established in nude mice Doubling time: ~28 hours (PubMed=7600027) 21174413 CVCL_VX95 CpHi54 finite cell line CVCL_VX95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174414 CVCL_W995 Rat2 lambda/lacI spontaneously immortalized cell line Norway rat CVCL_W995 CL:0000010 Transfected with: UniProtKB; P03023; Escherichia coli lacI Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21174415 CVCL_VX94 CpHi53 finite cell line CVCL_VX94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174416 CVCL_W994 IREs-4 cancer cell line human CVCL_W994 CL:0000010 Derived from sampling site: Peripheral blood. Male 21174417 CVCL_W999 BM 2.2.1 cancer cell line human CVCL_W999 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Leu (c.536A>T); ClinVar=VCV000376608; Zygosity=Homozygous (PubMed=7658501; PubMed=10022320; PubMed=10952247) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Liver Cell type=Myofibroblast.. Male Doubling time: 52.8-55.2 hours, at 23th passage (PubMed=10952247) 21174418 CVCL_VX99 CpHi58 finite cell line CVCL_VX99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174419 CVCL_VX98 CpHi57 finite cell line CVCL_VX98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174420 CVCL_W998 Nara-H cancer cell line human CVCL_W998 CL:0000010 Population: Japanese Female Doubling time: 38.7 hours (PubMed=11408058). 21174421 CVCL_3R52 HQ01676 transformed cell line human CVCL_3R52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174422 CVCL_4352 NS20Y-BU-4 cancer cell line house mouse CVCL_4352 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21174423 CVCL_3R51 HQ01675 transformed cell line human CVCL_3R51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174424 CVCL_4351 NS20Y-BU-2 cancer cell line house mouse CVCL_4351 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21174425 CVCL_3R50 HQ01674 transformed cell line human CVCL_3R50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174426 CVCL_4350 K-BALB transformed cell line house mouse CVCL_4350 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21174427 CVCL_3R45 HQ01669 transformed cell line human CVCL_3R45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174428 CVCL_4345 ICR-2A spontaneously immortalized cell line CVCL_4345 CL:0000010 Unspecified Doubling time: ~40 hours (PubMed=5263768); 48 hours (PubMed=3500873). Group: Amphibian cell line; Group: Haploid karyotype cell line 21174429 CVCL_4344 F4N-S cancer cell line house mouse CVCL_4344 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21174430 CVCL_3R44 HQ01668 transformed cell line human CVCL_3R44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174431 CVCL_4343 C-1300 cancer cell line house mouse CVCL_4343 CL:0000010 Breed/subspecies: A/J. Male 21174432 CVCL_3R43 HQ01667 transformed cell line human CVCL_3R43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174433 CVCL_3R42 HQ01666 transformed cell line human CVCL_3R42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174434 CVCL_4342 Y3-Ag 1.2.3 cancer cell line Norway rat CVCL_4342 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: LOU/C. Group: Hybridoma fusion partner cell line 21174435 CVCL_3R49 HQ01673 transformed cell line human CVCL_3R49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174436 CVCL_4349 SCR5 transformed cell line CVCL_4349 CL:0000010 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 95071120; probable Male 21174437 CVCL_3R48 HQ01672 transformed cell line human CVCL_3R48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174438 CVCL_4348 IMT 9 transformed cell line CVCL_4348 CL:0000010 Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Transformant: N-nitroso-N-methylurethane (NNMU)(ChEBI; CHEBI:82373); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 95060901; probable Male 21174439 CVCL_3R47 HQ01671 transformed cell line human CVCL_3R47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174440 CVCL_4347 II b hybrid cell line CVCL_4347 CL:0000010 Group: Human/rodent somatic cell hybrid. 21174441 CVCL_3R46 HQ01670 transformed cell line human CVCL_3R46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174442 CVCL_4346 IgH-2 spontaneously immortalized cell line CVCL_4346 CL:0000010 Derived from sampling site: Heart. Male Group: Reptilian cell line 21174443 CVCL_VX86 CpHi45 finite cell line CVCL_VX86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174444 CVCL_W986 PER-490 cancer cell line human CVCL_W986 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 97 hours (PubMed=17117183); 72 hours (PubMed=27443263) 21174445 CVCL_VX85 CpHi44 finite cell line CVCL_VX85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174446 CVCL_W985 PER-487 cancer cell line human CVCL_W985 CL:0000010 Omics: Transcriptome analysis by microarray. Male Characteristics: IL2 dependent Doubling time: 363 hours (PubMed=17117183) 21174447 CVCL_VX84 CpHi43 finite cell line CVCL_VX84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174448 CVCL_W984 PER-485 cancer cell line human CVCL_W984 CL:0000010 Miscellaneous: Sampling site from personal communication of Kotecha R.S Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 53 hours (PubMed=17117183); 48 hours (PubMed=27443263) 21174449 CVCL_VX83 CpHi42 finite cell line CVCL_VX83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174450 CVCL_W983 PER-427 cancer cell line human CVCL_W983 CL:0000010 Omics: Transcriptome analysis by microarray. Female Characteristics: IL2 dependent Doubling time: 209 hours (PubMed=17117183) 21174451 CVCL_VX89 CpHi48 finite cell line CVCL_VX89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174452 CVCL_W989 PER-550 cancer cell line human CVCL_W989 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 252 hours (PubMed=17117183) 21174453 CVCL_VX88 CpHi47 finite cell line CVCL_VX88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174454 CVCL_W988 PER-537 cancer cell line human CVCL_W988 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 223 hours (PubMed=17117183) 21174455 CVCL_VX87 CpHi46 finite cell line CVCL_VX87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174456 CVCL_W987 PER-495 cancer cell line human CVCL_W987 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 53 hours (PubMed=17117183) 21174457 CVCL_3R63 HQ01688 transformed cell line human CVCL_3R63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174458 CVCL_4363 NCI-H1514 cancer cell line human CVCL_4363 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu68Ter (c.202G>T); ClinVar=VCV000224551; Zygosity=Unspecified (PubMed=1312696; PubMed=1565469) Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5873; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00242 Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (PubMed=20143388). 21174459 CVCL_4362 HBL-100 transformed cell line human CVCL_4362 HLA typing: A*01:01,02:01; B*08:01,40:01; C*03:04,07:01 (PubMed=26589293) CL:0000010 Karyotypic information: Near triploid with the modal number of 67 chromosomes (ATCC); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; HTB-124; true; Discontinued: RCB; RCB0460; true. Male Virology: Contains 2 copies of the SV40 genome, one complete the other incomplete tandemly integrated in the cell line genome Doubling time: 28 hours, at 10th passage (PubMed=6891286); 1.5 days (PubMed=9671407); ~40 hours (CLS); 30.21 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=12661003) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00207 Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (PubMed=16643607; PubMed=20143388). Originally thought to originate from a casein-producing breast cell line from a 27 year old Caucasian woman. In addition contains SV40 genomic sequence while the cell line was deemed to be spontaneously immortalized. 21174460 CVCL_3R62 HQ01687 transformed cell line human CVCL_3R62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174461 CVCL_4361 EPC spontaneously immortalized cell line CVCL_4361 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Doubling time: ~36 hours (ATCC=CRL-2872) Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00302 Problematic cell line: Misidentified Originally deposited as a carp (Cyprinus carpio) cell line, is in fact a fathead minnow (Pimephales promelas) cell line (PubMed=20497291). 21174462 CVCL_3R61 HQ01686 transformed cell line human CVCL_3R61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174463 CVCL_4360 Dami cancer cell line human CVCL_4360 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Doubling time: 24-30 hours (Patent=US5128245) Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00116; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9792 Problematic cell line: Contaminated Shown to be a HEL derivative (PubMed=9166871; PubMed=9326259; PubMed=9447816; PubMed=10508494; PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 57 year old male patient with megakaryoblastic leukemia. 21174464 CVCL_3R60 HQ01685 transformed cell line human CVCL_3R60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174465 CVCL_3R56 HQ01680 transformed cell line human CVCL_3R56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174466 CVCL_4356 NS20Y-TG cancer cell line house mouse CVCL_4356 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: A/J. Male 21174467 CVCL_3R55 HQ01679 transformed cell line human CVCL_3R55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174468 CVCL_4355 NS20Y-BU-7 cancer cell line house mouse CVCL_4355 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21174469 CVCL_3R54 HQ01678 transformed cell line human CVCL_3R54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174470 CVCL_4354 NS20Y-BU-6 cancer cell line house mouse CVCL_4354 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21174471 CVCL_3R53 HQ01677 transformed cell line human CVCL_3R53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174472 CVCL_4353 NS20Y-BU-5 cancer cell line house mouse CVCL_4353 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21174473 CVCL_4359 CHP-234 cancer cell line human CVCL_4359 CL:0000010 Discontinued: ATCC; CRL-2272; true. Male Characteristics: Neuroblastic type (N-type) (PubMed=15720811) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00297 Problematic cell line: Misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (PubMed=20143388). 21174474 CVCL_3R59 HQ01684 transformed cell line human CVCL_3R59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174475 CVCL_3R58 HQ01683 transformed cell line human CVCL_3R58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174476 CVCL_4358 LL/2 (LLC1) cancer cell line house mouse CVCL_4358 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Omics: HLA class I peptidome analysis by proteomics; Omics: Transcriptome analysis by microarray Doubling time: 21 hours (CLS) Caution: Could be identical to 3LL (Cellosaurus=CVCL_5653) 21174477 CVCL_3R57 HQ01681 transformed cell line human CVCL_3R57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174478 CVCL_4357 WEHI-3B D+ cancer cell line house mouse CVCL_4357 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21174479 CVCL_VX93 CpHi52 finite cell line CVCL_VX93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174480 CVCL_W993 PER-608 cancer cell line human CVCL_W993 CL:0000010 Male Doubling time: 260 hours (PubMed=17117183). 21174481 CVCL_VX92 CpHi51 finite cell line CVCL_VX92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174482 CVCL_W992 PER-607 transformed cell line human CVCL_W992 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 216 hours (PubMed=17117183) 21174483 CVCL_VX91 CpHi50 finite cell line CVCL_VX91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174484 CVCL_W991 PER-606 cancer cell line human CVCL_W991 CL:0000010 Male Doubling time: 442 hours (PubMed=17117183). 21174485 CVCL_VX90 CpHi49 finite cell line CVCL_VX90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174486 CVCL_W990 PER-604 cancer cell line human CVCL_W990 CL:0000010 Male Doubling time: 181 hours (PubMed=17117183). 21174487 CVCL_VX75 CpHi34 finite cell line CVCL_VX75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174488 CVCL_W975 PCF spontaneously immortalized cell line CVCL_W975 CL:0000010 Miscellaneous: Cell line is available for distribution but not authenticated (NRFC) Derived from sampling site: Fin. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC001 21174489 CVCL_VX74 CpHi33 finite cell line CVCL_VX74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174490 CVCL_W974 SH-IN cancer cell line human CVCL_W974 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Omics: Transcriptome analysis by microarray Female Characteristics: Intermediate type (I-type) (PubMed=15720811) 21174491 CVCL_VX73 CpHi32 finite cell line CVCL_VX73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174492 CVCL_W973 SH-FE cancer cell line human CVCL_W973 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21174493 CVCL_VX72 CpHi31 finite cell line CVCL_VX72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174494 CVCL_W972 MCF-7/6 cancer cell line human CVCL_W972 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21174495 CVCL_VX79 CpHi38 finite cell line CVCL_VX79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174496 CVCL_W979 PER-117 cancer cell line human CVCL_W979 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Doubling time: 55-65 hours (PubMed=3472019); 56 hours (PubMed=17117183) 21174497 CVCL_VX78 CpHi37 finite cell line CVCL_VX78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174498 CVCL_W978 PER-164 cancer cell line human CVCL_W978 CL:0000010 Male 21174499 CVCL_VX77 CpHi36 finite cell line CVCL_VX77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174500 CVCL_W977 PER-163 cancer cell line human CVCL_W977 CL:0000010 Male 21174501 CVCL_VX76 CpHi35 finite cell line CVCL_VX76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174502 CVCL_W976 PER-145 cancer cell line human CVCL_W976 CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: 108 hours (PubMed=17117183) 21174503 CVCL_3R30 HQ01650 transformed cell line human CVCL_3R30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174504 CVCL_4330 TR6Bc1 cancer cell line house mouse CVCL_4330 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Peripheral nervous system; trigeminal nerve Cell type=Schwann cell.; Breed/subspecies: C3H/He. 21174505 CVCL_3R23 HQ01643 transformed cell line human CVCL_3R23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174506 CVCL_4323 TGP61 cancer cell line house mouse CVCL_4323 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male Characteristics: Expresses but does not secrete somatostatin 21174507 CVCL_3R22 HQ01642 transformed cell line human CVCL_3R22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174508 CVCL_4322 TGP55 cancer cell line house mouse CVCL_4322 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Female 21174509 CVCL_3R21 HQ01641 transformed cell line human CVCL_3R21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174510 CVCL_4321 TA3/Ha cancer cell line house mouse CVCL_4321 CL:0000010 Breed/subspecies: A/HeHa. Female 21174511 CVCL_3R20 HQ01640 transformed cell line human CVCL_3R20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174512 CVCL_4320 TGP52 cancer cell line house mouse CVCL_4320 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21174513 CVCL_3R27 HQ01647 transformed cell line human CVCL_3R27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174514 CVCL_4327 TM4 spontaneously immortalized cell line house mouse CVCL_4327 CL:0000010 Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: BALB/c. Male Doubling time: 18 hours (PubMed=7046561) 21174515 CVCL_3R26 HQ01646 transformed cell line human CVCL_3R26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174516 CVCL_4326 TM3 spontaneously immortalized cell line house mouse CVCL_4326 CL:0000010 Derived from sampling site: Testis Cell type=Leydig cell.; Breed/subspecies: BALB/c. Male Doubling time: 16 hours (PubMed=7046561) 21174517 CVCL_3R25 HQ01645 transformed cell line human CVCL_3R25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174518 CVCL_4325 TK-TS 13 spontaneously immortalized cell line CVCL_4325 CL:0000010 Derived from sampling site: Kidney. Male 21174519 CVCL_3R24 HQ01644 transformed cell line human CVCL_3R24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174520 CVCL_4324 TH-1 subline B1 spontaneously immortalized cell line CVCL_4324 CL:0000010 Derived from sampling site: Heart. Discontinued: ECACC; 90102528; probable Unspecified Group: Reptilian cell line 21174521 CVCL_3R29 HQ01649 transformed cell line human CVCL_3R29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174522 CVCL_4329 TR33B cancer cell line Norway rat CVCL_4329 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: Wistar Furth. 21174523 CVCL_3R28 HQ01648 transformed cell line human CVCL_3R28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174524 CVCL_4328 TPS spontaneously immortalized cell line CVCL_4328 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21174525 CVCL_VX82 CpHi41 finite cell line CVCL_VX82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174526 CVCL_W982 PER-371 cancer cell line human CVCL_W982 CL:0000010 Omics: Transcriptome analysis by microarray. Male Doubling time: 69 hours (PubMed=17117183) 21174527 CVCL_VX81 CpHi40 finite cell line CVCL_VX81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174528 CVCL_W981 PER-278 cancer cell line human CVCL_W981 CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Doubling time: 62-68 hours (PubMed=2340491); 104 hours (PubMed=17117183) 21174529 CVCL_VX80 CpHi39 finite cell line CVCL_VX80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Male 21174530 CVCL_W980 PER-255 cancer cell line human CVCL_W980 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Doubling time: 84-95 hours (PubMed=2546623); 66 hours (PubMed=17117183) 21174531 CVCL_VX64 CpHi23 finite cell line CVCL_VX64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174532 CVCL_W964 GM17857 transformed cell line human CVCL_W964 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174533 CVCL_VX63 CpHi22 finite cell line CVCL_VX63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174534 CVCL_W963 GM17729 transformed cell line human CVCL_W963 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174535 CVCL_VX62 CpHi21 finite cell line CVCL_VX62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174536 CVCL_W962 SCRC-1 cancer cell line human CVCL_W962 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Kidney. Female Doubling time: 91.4 hours (PubMed=10688041) 21174537 CVCL_VX61 CpHi20 finite cell line CVCL_VX61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174538 CVCL_W961 SU-DHL-15 cancer cell line human CVCL_W961 CL:0000010 Female 21174539 CVCL_VX68 CpHi27 finite cell line CVCL_VX68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174540 CVCL_W968 GM17906 transformed cell line human CVCL_W968 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174541 CVCL_VX67 CpHi26 finite cell line CVCL_VX67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174542 CVCL_W967 GM17883 transformed cell line human CVCL_W967 CL:0000010 Karyotypic information: 47,XXY [49]; 46,XY [1] (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174543 CVCL_VX66 CpHi25 finite cell line CVCL_VX66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174544 CVCL_W966 GM17879 transformed cell line human CVCL_W966 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174545 CVCL_VX65 CpHi24 finite cell line CVCL_VX65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174546 CVCL_W965 GM17867 transformed cell line human CVCL_W965 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21174547 CVCL_VX69 CpHi28 finite cell line CVCL_VX69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174548 CVCL_W969 GM17908 transformed cell line human CVCL_W969 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174549 CVCL_4341 CHO-xrs-6-hamKu80 spontaneously immortalized cell line CVCL_4341 CL:0000010 Transfected with: UniProtKB; Q60449; Cricetulus griseus Xrcc5 Derived from sampling site: Ovary. Female 21174550 CVCL_3R41 HQ01664 transformed cell line human CVCL_3R41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174551 CVCL_4340 CHO-xrs-6 spontaneously immortalized cell line CVCL_4340 CL:0000010 Derived from sampling site: Ovary. Female 21174552 CVCL_3R40 HQ01663 transformed cell line human CVCL_3R40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174553 CVCL_3R34 HQ01656 transformed cell line human CVCL_3R34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174554 CVCL_4334 Vero-Hektor spontaneously immortalized cell line green monkey CVCL_4334 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to growth in the chemically defined protein- and peptide-free Hektor media from Cell Culture Technologies Group: Non-human primate cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21174555 CVCL_3R33 HQ01654 transformed cell line human CVCL_3R33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174556 CVCL_4333 V79-HG04 spontaneously immortalized cell line CVCL_4333 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21174557 CVCL_3R32 HQ01652 transformed cell line human CVCL_3R32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174558 CVCL_4332 UT-1 spontaneously immortalized cell line CVCL_4332 CL:0000010 Derived from sampling site: Ovary. Female 21174559 CVCL_3R31 HQ01651 transformed cell line human CVCL_3R31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174560 CVCL_4331 tsDC conditionally immortalized cell line house mouse CVCL_4331 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Dendritic cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21174561 CVCL_3R38 HQ01661 transformed cell line human CVCL_3R38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174562 CVCL_4338 WR19L cancer cell line house mouse CVCL_4338 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21174563 CVCL_3R37 HQ01660 transformed cell line human CVCL_3R37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174564 CVCL_4337 WES transformed cell line CVCL_4337 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Skin. Discontinued: ATCC; CRL-1609; true Group: Non-human primate cell line 21174565 CVCL_3R36 HQ01659 transformed cell line human CVCL_3R36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174566 CVCL_4336 WB2054M cancer cell line Norway rat CVCL_4336 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: Wistar Furth x Brown Norway. 21174567 CVCL_3R35 HQ01657 transformed cell line human CVCL_3R35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174568 CVCL_4335 WB2054 cancer cell line Norway rat CVCL_4335 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Breed/subspecies: Wistar Furth x Brown Norway. 21174569 CVCL_3R39 HQ01662 transformed cell line human CVCL_3R39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174570 CVCL_4339 WRC cancer cell line Norway rat CVCL_4339 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female Virology: Supports the growth of HSV, PRV and vaccinia viruses (ECACC) 21174571 CVCL_VX71 CpHi30 finite cell line CVCL_VX71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174572 CVCL_W971 MCF-7/AZ cancer cell line human CVCL_W971 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21174573 CVCL_VX70 CpHi29 finite cell line CVCL_VX70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174574 CVCL_W970 GM17931 transformed cell line human CVCL_W970 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174575 CVCL_VX53 CpHi12 finite cell line CVCL_VX53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174576 CVCL_W953 SI-PMEC spontaneously immortalized cell line pig CVCL_W953 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Landrace. Female 21174577 CVCL_VX52 CpHi11 finite cell line CVCL_VX52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174578 CVCL_W952 CTN3 cancer cell line house mouse CVCL_W952 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: Rb+/- Tg(POMC-RB)109Ayn. Male 21174579 CVCL_W951 Beta-TC-1 transformed cell line house mouse CVCL_W951 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: (C57BL/6J x DBA/2J)F2 transgenic RIPTag4. 21174580 CVCL_VX51 CpHi10 finite cell line CVCL_VX51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174581 CVCL_VX50 CpHi09 finite cell line CVCL_VX50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174582 CVCL_W950 TP31 cancer cell line human CVCL_W950 CL:0000010 Derived from sampling site: Eye; uvea. Male 21174583 CVCL_VX57 CpHi16 finite cell line CVCL_VX57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174584 CVCL_W957 EFM-63 cancer cell line human CVCL_W957 CL:0000010 Derived from metastatic site: Ovary. Female 21174585 CVCL_VX56 CpHi15 finite cell line CVCL_VX56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174586 CVCL_W956 Tu-140 cancer cell line human CVCL_W956 CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 21174587 CVCL_W955 CD cancer cell line human CVCL_W955 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DOI=10.1155/2014/286013) Population: Indian; Derived from sampling site: Oral cavity; tongue. Male Characteristics: Established from a gutka chewer Doubling time: 31 +- 1 hours (DOI=10.1155/2014/286013) 21174588 CVCL_VX55 CpHi14 finite cell line CVCL_VX55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174589 CVCL_VX54 CpHi13 finite cell line CVCL_VX54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174590 CVCL_W954 YDOV-157 cancer cell line human CVCL_W954 CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Proteome analysis by 2D-DE; Omics: Transcriptome analysis by microarray Female Doubling time: 102 hours (PubMed=18682896) 21174591 CVCL_VX59 CpHi18 finite cell line CVCL_VX59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174592 CVCL_W959 SU-DHL-12 cancer cell line human CVCL_W959 CL:0000010 Female 21174593 CVCL_VX58 CpHi17 finite cell line CVCL_VX58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174594 CVCL_W958 SU-DHL-11 cancer cell line human CVCL_W958 CL:0000010 Female 21174595 CVCL_3R01 HQ01619 transformed cell line human CVCL_3R01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174596 CVCL_4301 SJK-237-71 hybridoma house mouse CVCL_4301 CL:0000010 Discontinued: ATCC; TIB-178; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09884; Human POLA1 Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21174597 CVCL_3R00 HQ01618 transformed cell line human CVCL_3R00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174598 CVCL_4300 SJK-132-20 hybridoma house mouse CVCL_4300 CL:0000010 Discontinued: ATCC; TIB-177; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09884; Human POLA1 Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21174599 CVCL_3R05 HQ01623 transformed cell line human CVCL_3R05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174600 CVCL_4305 SSE-5 spontaneously immortalized cell line CVCL_4305 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) (CelloPub=CLPUB00703) Group: Fish cell line 21174601 CVCL_3R04 HQ01622 transformed cell line human CVCL_3R04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174602 CVCL_4304 Sp1K finite cell line CVCL_4304 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CCL-78; true; Discontinued: ATCC; CRL-6262; true; Discontinued: ECACC; 89120705; probable Male Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174603 CVCL_3R03 HQ01621 transformed cell line human CVCL_3R03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174604 CVCL_4303 SJMRF finite cell line CVCL_4303 CL:0000010 Discontinued: ATCC; CRL-6072; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21174605 CVCL_3R02 HQ01620 transformed cell line human CVCL_3R02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174606 CVCL_4302 SJK-287-38 hybridoma house mouse CVCL_4302 CL:0000010 Discontinued: ATCC; TIB-179; true. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09884; Human POLA1 Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21174607 CVCL_3R09 HQ01627 transformed cell line human CVCL_3R09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174608 CVCL_4309 Subclone 707 BUF cancer cell line house mouse CVCL_4309 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21174609 CVCL_3R08 HQ01626 transformed cell line human CVCL_3R08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174610 CVCL_4308 STE-137 spontaneously immortalized cell line CVCL_4308 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by infectious haematopoetic necrosis virus (IHNV) and infectious pancreatic necrosis virus (IPNV) (CelloPub=CLPUB00703) Doubling time: ~72 hours (ECACC=95122020) Group: Fish cell line 21174611 CVCL_3R07 HQ01625 transformed cell line human CVCL_3R07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174612 CVCL_4307 TGP54 cancer cell line house mouse CVCL_4307 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. 21174613 CVCL_3R06 HQ01624 transformed cell line human CVCL_3R06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174614 CVCL_4306 SSN-1 spontaneously immortalized cell line CVCL_4306 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Persistently infected with snakehead retrovirus (SnRV) Group: Fish cell line 21174615 CVCL_VX60 CpHi19 finite cell line CVCL_VX60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174616 CVCL_W960 SU-DHL-14 cancer cell line human CVCL_W960 CL:0000010 Female 21174617 CVCL_VX42 CpHi01 finite cell line CVCL_VX42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174618 CVCL_W942 OM-2 cancer cell line human CVCL_W942 CL:0000010 Population: Japanese. 21174619 CVCL_VX41 OCC-28 finite cell line human CVCL_VX41 CL:0000010 Male 21174620 CVCL_W941 OM-1 cancer cell line human CVCL_W941 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Unspecified (PubMed=1570156). Population: Japanese 21174621 CVCL_W940 KV6 cancer cell line human CVCL_W940 CL:0000010 21174622 CVCL_VX40 OCC-27 finite cell line human CVCL_VX40 CL:0000010 Female 21174623 CVCL_VX46 CpHi05 finite cell line CVCL_VX46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174624 CVCL_W946 INS-r3-GK27 cancer cell line Norway rat CVCL_W946 CL:0000010 Transfected with: RGD; 2670; Gck Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21174625 CVCL_VX45 CpHi04 finite cell line CVCL_VX45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174626 CVCL_W945 INS-r3 cancer cell line Norway rat CVCL_W945 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21174627 CVCL_VX44 CpHi03 finite cell line CVCL_VX44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174628 CVCL_W944 HN-11 cancer cell line human CVCL_W944 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Unspecified 21174629 CVCL_VX43 CpHi02 finite cell line CVCL_VX43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174630 CVCL_W943 HSC-5 [Human OCSCC] cancer cell line human CVCL_W943 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=1570156). Population: Japanese 21174631 CVCL_W949 Asra-EPS cancer cell line human CVCL_W949 CL:0000010 Male Doubling time: 38 hours (PubMed=23915498). 21174632 CVCL_VX49 CpHi08 finite cell line CVCL_VX49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174633 CVCL_VX48 CpHi07 finite cell line CVCL_VX48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174634 CVCL_W948 HuNET cancer cell line human CVCL_W948 CL:0000010 Male Doubling time: Several weeks (PubMed=11138979). 21174635 CVCL_W947 BTC-5 cancer cell line house mouse CVCL_W947 CL:0000010 Transformant: Polyoma small T antigen and SV40; Breed/subspecies: C57BL/6J double transgenic RIP1Tag2/Rip2pyST1. 21174636 CVCL_VX47 CpHi06 finite cell line CVCL_VX47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Markhoz. Female 21174637 CVCL_3R12 HQ01630 transformed cell line human CVCL_3R12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174638 CVCL_4312 T-3-Cl-2 cancer cell line house mouse CVCL_4312 CL:0000010 Breed/subspecies: DDD. Male 21174639 CVCL_3R11 HQ01629 transformed cell line human CVCL_3R11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174640 CVCL_4311 SV3T3B transformed cell line house mouse CVCL_4311 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. 21174641 CVCL_3R10 HQ01628 transformed cell line human CVCL_3R10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174642 CVCL_4310 Subclone 707 DAP8 cancer cell line house mouse CVCL_4310 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21174643 CVCL_3R16 HQ01636 transformed cell line human CVCL_3R16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174644 CVCL_4316 TA3/St cancer cell line house mouse CVCL_4316 CL:0000010 Breed/subspecies: A/HeHa. Female 21174645 CVCL_3R15 HQ01634 transformed cell line human CVCL_3R15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174646 CVCL_4315 TA3 cancer cell line house mouse CVCL_4315 CL:0000010 Breed/subspecies: A/HeHa. Female 21174647 CVCL_3R14 HQ01632 transformed cell line human CVCL_3R14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174648 CVCL_4314 T7 [Mouse lung] conditionally immortalized cell line house mouse CVCL_4314 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Proliferates at permissive temperature (33-35 Celsius) in the presence of IFNG, terminally differentiates at restrictive temperature (39 Celsius) in the absence of IFNG Doubling time: 48 hours (ECACC=07021402) 21174649 CVCL_3R13 HQ01631 transformed cell line human CVCL_3R13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174650 CVCL_4313 T-3-Cl-2-0.fl cancer cell line house mouse CVCL_4313 CL:0000010 Breed/subspecies: DDD. Male 21174651 CVCL_3R19 HQ01639 transformed cell line human CVCL_3R19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174652 CVCL_4319 TGP49 cancer cell line house mouse CVCL_4319 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21174653 CVCL_3R18 HQ01638 transformed cell line human CVCL_3R18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174654 CVCL_4318 TGP47 cancer cell line house mouse CVCL_4318 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.; Breed/subspecies: Tg(E1a-1-SV40E)Bri18 transgenic. Male 21174655 CVCL_3R17 HQ01637 transformed cell line human CVCL_3R17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174656 CVCL_4317 TALH SVE.1 transformed cell line CVCL_4317 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; nephron; thick ascending limb of loop of Henle. Unspecified 21174657 CVCL_EE08 ND22553 transformed cell line human CVCL_EE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174658 CVCL_EE07 ND22520 transformed cell line human CVCL_EE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174659 CVCL_EE06 ND22519 transformed cell line human CVCL_EE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174660 CVCL_EE05 ND22143 transformed cell line human CVCL_EE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174661 CVCL_EE09 ND22686 transformed cell line human CVCL_EE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174662 CVCL_EE00 ND22006 transformed cell line human CVCL_EE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174663 CVCL_EE04 ND22142 transformed cell line human CVCL_EE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174664 CVCL_EE03 ND22026 transformed cell line human CVCL_EE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174665 CVCL_EE02 ND22008 transformed cell line human CVCL_EE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174666 CVCL_EE01 ND22007 transformed cell line human CVCL_EE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174667 CVCL_3Q93 HQ01611 transformed cell line human CVCL_3Q93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174668 CVCL_4293 RN 22 cancer cell line Norway rat CVCL_4293 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Peripheral nervous system; cervical spinal nerve root Cell type=Schwann cell.; Breed/subspecies: BDIX. Doubling time: ~20 hours (PubMed=4342966) 21174669 CVCL_3Q92 HQ01610 transformed cell line human CVCL_3Q92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174670 CVCL_4292 RENTts1.1 transformed cell line Norway rat CVCL_4292 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (ECACC=92092515) 21174671 CVCL_3Q91 HQ01609 transformed cell line human CVCL_3Q91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174672 CVCL_4291 RENTts3.1 transformed cell line Norway rat CVCL_4291 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (ECACC=92092516) 21174673 CVCL_3Q90 HQ01608 transformed cell line human CVCL_3Q90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174674 CVCL_4290 RENTR03 transformed cell line Norway rat CVCL_4290 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 35 hours (ECACC=92092514) 21174675 CVCL_3Q97 HQ01615 transformed cell line human CVCL_3Q97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174676 CVCL_4297 SCL 4.1/F7 spontaneously immortalized cell line Norway rat CVCL_4297 CL:0000010 Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: Wistar. Male 21174677 CVCL_3Q96 HQ01614 transformed cell line human CVCL_3Q96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174678 CVCL_4296 SC 11 spontaneously immortalized cell line CVCL_4296 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male Group: Marsupial cell line 21174679 CVCL_3Q95 HQ01613 transformed cell line human CVCL_3Q95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174680 CVCL_4295 SAF-1 spontaneously immortalized cell line CVCL_4295 CL:0000010 Derived from sampling site: Fin Cell type=Fibroblast.. Unspecified Group: Fish cell line 21174681 CVCL_3Q94 HQ01612 transformed cell line human CVCL_3Q94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174682 CVCL_4294 RR-CHOKI spontaneously immortalized cell line CVCL_4294 CL:0000010 Derived from sampling site: Ovary. Female 21174683 CVCL_3Q89 HQ01607 transformed cell line human CVCL_3Q89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174684 CVCL_4289 RENTR01 transformed cell line Norway rat CVCL_4289 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 35 hours (ECACC=92092513) 21174685 CVCL_3Q88 HQ01606 transformed cell line human CVCL_3Q88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174686 CVCL_4288 RENT4 transformed cell line Norway rat CVCL_4288 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (ECACC=92092512) 21174687 CVCL_3Q87 HQ01605 transformed cell line human CVCL_3Q87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174688 CVCL_4287 RENE2 transformed cell line Norway rat CVCL_4287 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (ECACC=92092511) 21174689 CVCL_3Q99 HQ01617 transformed cell line human CVCL_3Q99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174690 CVCL_4299 SHK-1 spontaneously immortalized cell line CVCL_4299 CL:0000010 Derived from sampling site: Head kidney. Unspecified Virology: Susceptible to infection by infectious salmon anaemia virus (ISAV) Group: Fish cell line 21174691 CVCL_3Q98 HQ01616 transformed cell line human CVCL_3Q98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174692 CVCL_4298 SCP finite cell line CVCL_4298 CL:0000010 Derived from sampling site: Fetal brain; choroid plexus. Unspecified Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) 21174693 CVCL_3Q71 HQ01589 transformed cell line human CVCL_3Q71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174694 CVCL_4271 PDVC 57B cancer cell line house mouse CVCL_4271 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C57BL/10 LP. Unspecified 21174695 CVCL_3Q70 HQ01588 transformed cell line human CVCL_3Q70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174696 CVCL_4270 PD5 spontaneously immortalized cell line pig CVCL_4270 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Unspecified 21174697 CVCL_3Q75 HQ01593 transformed cell line human CVCL_3Q75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174698 CVCL_4275 PMK finite cell line CVCL_4275 CL:0000010 Derived from sampling site: Kidney. Discontinued: ECACC; 98020308; probable Group: Non-human primate cell line 21174699 CVCL_3Q74 HQ01592 transformed cell line human CVCL_3Q74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174700 CVCL_4274 Phi-1 cancer cell line Norway rat CVCL_4274 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21174701 CVCL_3Q73 HQ01591 transformed cell line human CVCL_3Q73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174702 CVCL_4273 PG13 transformed cell line house mouse CVCL_4273 CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol; Transfected with: UniProtKB; P21415; Gibbon ape leukemia virus (GALV) env Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10686 21174703 CVCL_3Q72 HQ01590 transformed cell line human CVCL_3Q72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174704 CVCL_4272 PG [Esox] spontaneously immortalized cell line CVCL_4272 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21174705 CVCL_3Q68 HQ01586 transformed cell line human CVCL_3Q68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174706 CVCL_4267 CHO-P22 spontaneously immortalized cell line CVCL_4267 CL:0000010 Derived from sampling site: Ovary. Female 21174707 CVCL_3Q67 HQ01585 transformed cell line human CVCL_3Q67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174708 CVCL_3Q66 HQ01584 transformed cell line human CVCL_3Q66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174709 CVCL_4266 P1.HTR.TK- cancer cell line house mouse CVCL_4266 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 21174710 CVCL_3Q65 HQ01583 transformed cell line human CVCL_3Q65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174711 CVCL_4265 P1.HTR cancer cell line house mouse CVCL_4265 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male Characteristics: Highly transfectable (ECACC) 21174712 CVCL_3Q69 HQ01587 transformed cell line human CVCL_3Q69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174713 CVCL_4269 P815-1-1 cancer cell line house mouse CVCL_4269 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 21174714 CVCL_3Q82 HQ01600 transformed cell line human CVCL_3Q82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174715 CVCL_4282 R9 transformed cell line Norway rat CVCL_4282 CL:0000010 Transformant: Rous sarcoma virus [RSV-33](NCBI-Taxonomy; 11886); Breed/subspecies: Lewis. Unspecified 21174716 CVCL_3Q81 HQ01599 transformed cell line human CVCL_3Q81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174717 CVCL_4281 R74 transformed cell line Norway rat CVCL_4281 CL:0000010 Transformant: Rous sarcoma virus [RSV-33](NCBI-Taxonomy; 11886); Breed/subspecies: Lewis. Unspecified 21174718 CVCL_3Q80 HQ01598 transformed cell line human CVCL_3Q80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174719 CVCL_4280 QT35 cancer cell line CVCL_4280 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Virology: Susceptible to infection by aquatic bird bornavirus 1 (ABBV-1) strain UoG-CG (PubMed=32005267) Group: Bird cell line 21174720 CVCL_3Q86 HQ01604 transformed cell line human CVCL_3Q86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174721 CVCL_4286 RENE1 transformed cell line Norway rat CVCL_4286 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285); Derived from sampling site: Endometrium; Breed/subspecies: Sprague Dawley. Female Doubling time: 48 hours (ECACC=92092510) 21174722 CVCL_3Q85 HQ01603 transformed cell line human CVCL_3Q85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174723 CVCL_4285 RCP transformed cell line Norway rat CVCL_4285 CL:0000010 Transformant: Ad-SV40 hybrid virus [TSOri-]; Derived from sampling site: Brain; choroid plexus; Breed/subspecies: Wistar. Unspecified 21174724 CVCL_3Q84 HQ01602 transformed cell line human CVCL_3Q84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174725 CVCL_4284 RCE transformed cell line CVCL_4284 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Eye; cornea; epithelium; Breed/subspecies: New Zealand white. Male 21174726 CVCL_3Q83 HQ01601 transformed cell line human CVCL_3Q83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174727 CVCL_4283 RC-4B/C1 cancer cell line Norway rat CVCL_4283 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: ACI x Fischer 344. Male 21174728 CVCL_3Q79 HQ01597 transformed cell line human CVCL_3Q79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174729 CVCL_4279 Psi-CRIP transformed cell line house mouse CVCL_4279 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21174730 CVCL_3Q78 HQ01596 transformed cell line human CVCL_3Q78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174731 CVCL_4278 Psi-CRE transformed cell line house mouse CVCL_4278 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Retrovirus packaging cell line 21174732 CVCL_3Q77 HQ01595 transformed cell line human CVCL_3Q77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174733 CVCL_4277 PSA1 cancer cell line house mouse CVCL_4277 CL:0000010 Breed/subspecies: 129/Sv-SlJ-CP. Male 21174734 CVCL_3Q76 HQ01594 transformed cell line human CVCL_3Q76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174735 CVCL_4276 P388 Pr8/22 cancer cell line house mouse CVCL_4276 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female Doubling time: 28.5 hours (PubMed=6627597) 21174736 CVCL_EE80 HPSI0115i-iiyk_4 induced pluripotent stem cell human CVCL_EE80 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174737 CVCL_EE84 HPSI0115i-vazt_2 induced pluripotent stem cell human CVCL_EE84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174738 CVCL_EE83 HPSI0115i-vazt_1 induced pluripotent stem cell human CVCL_EE83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174739 CVCL_EE82 HPSI0115i-qoog_6 induced pluripotent stem cell human CVCL_EE82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174740 CVCL_EE81 HPSI0115i-qoog_4 induced pluripotent stem cell human CVCL_EE81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174741 CVCL_EE77 HPSI0115i-hecn_3 induced pluripotent stem cell human CVCL_EE77 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174742 CVCL_EE76 HPSI0115i-aion_3 induced pluripotent stem cell human CVCL_EE76 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174743 CVCL_EE75 HPSI0115i-aion_2 induced pluripotent stem cell human CVCL_EE75 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174744 CVCL_EE74 HPSI0614i-fovu_2 induced pluripotent stem cell human CVCL_EE74 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21174745 CVCL_EE79 HPSI0115i-iiyk_2 induced pluripotent stem cell human CVCL_EE79 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174746 CVCL_EE78 HPSI0115i-hecn_6 induced pluripotent stem cell human CVCL_EE78 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174747 CVCL_EE91 HPSI0514i-aecv_3 induced pluripotent stem cell human CVCL_EE91 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21174748 CVCL_EE90 HPSI0514i-aecv_2 induced pluripotent stem cell human CVCL_EE90 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21174749 CVCL_EE95 HPSI0514i-letw_5 induced pluripotent stem cell human CVCL_EE95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg402Gln (c.1205G>A); ClinVar=VCV000003779; Zygosity=Homozygous (PubMed=35933957) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174750 CVCL_EE94 HPSI0514i-letw_1 induced pluripotent stem cell human CVCL_EE94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg402Gln (c.1205G>A); ClinVar=VCV000003779; Zygosity=Homozygous (from autologous cell line HPSI0514i-letw_5) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174751 CVCL_EE93 HPSI0514i-aomr_6 induced pluripotent stem cell human CVCL_EE93 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21174752 CVCL_EE92 HPSI0514i-aomr_5 induced pluripotent stem cell human CVCL_EE92 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21174753 CVCL_EE88 HPSI0414i-oikd_2 induced pluripotent stem cell human CVCL_EE88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174754 CVCL_EE87 HPSI0414i-niim_5 induced pluripotent stem cell human CVCL_EE87 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21174755 CVCL_EE86 HPSI0414i-niim_3 induced pluripotent stem cell human CVCL_EE86 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21174756 CVCL_EE85 HPSI0215i-yoch_6 induced pluripotent stem cell human CVCL_EE85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174757 CVCL_EE89 HPSI0414i-oikd_5 induced pluripotent stem cell human CVCL_EE89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174758 CVCL_EE62 HPSI0414i-oaqd_3 induced pluripotent stem cell human CVCL_EE62 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174759 CVCL_EE61 HPSI0414i-oaqd_2 induced pluripotent stem cell human CVCL_EE61 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174760 CVCL_EE60 HPSI0614i-kegd_2 induced pluripotent stem cell human CVCL_EE60 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174761 CVCL_EE55 HPSI0215i-fawm_2 induced pluripotent stem cell human CVCL_EE55 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174762 CVCL_EE54 HPSI0414i-xojn_3 induced pluripotent stem cell human CVCL_EE54 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174763 CVCL_EE53 HPSI0714i-iudw_4 induced pluripotent stem cell human CVCL_EE53 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174764 CVCL_EE52 HPSI0714i-iudw_1 induced pluripotent stem cell human CVCL_EE52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174765 CVCL_EE59 HPSI0514i-puie_5 induced pluripotent stem cell human CVCL_EE59 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174766 CVCL_EE58 HPSI0514i-puie_4 induced pluripotent stem cell human CVCL_EE58 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174767 CVCL_EE57 HPSI0314i-wigw_2 induced pluripotent stem cell human CVCL_EE57 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174768 CVCL_EE56 HPSI0215i-fawm_4 induced pluripotent stem cell human CVCL_EE56 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174769 CVCL_EE73 HPSI0613i-zisa_33 induced pluripotent stem cell human CVCL_EE73 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Cellular phenotyping; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174770 CVCL_EE72 HPSI0414i-zazi_4 induced pluripotent stem cell human CVCL_EE72 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21174771 CVCL_EE71 HPSI0414i-seru_1 induced pluripotent stem cell human CVCL_EE71 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174772 CVCL_EE70 HPSI0914i-kajh_3 induced pluripotent stem cell human CVCL_EE70 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174773 CVCL_EE66 HPSI1013i-sita_1 induced pluripotent stem cell human CVCL_EE66 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174774 CVCL_EE65 HPSI0414i-seru_7 induced pluripotent stem cell human CVCL_EE65 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174775 CVCL_EE64 HPSI1014i-qayj_4 induced pluripotent stem cell human CVCL_EE64 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174776 CVCL_EE63 HPSI1014i-qayj_3 induced pluripotent stem cell human CVCL_EE63 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174777 CVCL_EE69 HPSI0914i-kajh_2 induced pluripotent stem cell human CVCL_EE69 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174778 CVCL_EE68 HPSI1014i-quls_2 induced pluripotent stem cell human CVCL_EE68 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174779 CVCL_EE67 HPSI1014i-kefb_1 induced pluripotent stem cell human CVCL_EE67 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174780 CVCL_EE40 HPSI1213i-tolg_4 induced pluripotent stem cell human CVCL_EE40 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174781 CVCL_EE39 HPSI0614i-miaj_4 induced pluripotent stem cell human CVCL_EE39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174782 CVCL_EE38 SIGi001-A induced pluripotent stem cell human CVCL_EE38 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21174783 CVCL_EE33 UOXFi005-A induced pluripotent stem cell human CVCL_EE33 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21174784 CVCL_EE32 UOXFi003-C induced pluripotent stem cell human CVCL_EE32 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Discontinued: EBiSC; UOXFi003-C; true Male 21174785 CVCL_EE31 UOXFi003-A induced pluripotent stem cell human CVCL_EE31 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=26905200) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21174786 CVCL_EE30 UOXFi001-D induced pluripotent stem cell human CVCL_EE30 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi001-D; true Female 21174787 CVCL_EE37 RCi009-A induced pluripotent stem cell human CVCL_EE37 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Homozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Female 21174788 CVCL_EE36 RCi006-A induced pluripotent stem cell human CVCL_EE36 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Homozygous (EBiSC) Derived from sampling site: Cell type=Fibroblast. Omics: Genome sequenced Male 21174789 CVCL_EE35 UOXFi005-C induced pluripotent stem cell human CVCL_EE35 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi005-C; true Male 21174790 CVCL_EE34 UOXFi005-B induced pluripotent stem cell human CVCL_EE34 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21174791 CVCL_EE51 HPSI1014i-tixi_4 induced pluripotent stem cell human CVCL_EE51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174792 CVCL_EE50 HPSI0614i-paab_4 induced pluripotent stem cell human CVCL_EE50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174793 CVCL_EE49 HPSI0614i-paab_3 induced pluripotent stem cell human CVCL_EE49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174794 CVCL_EE44 HPSI0914i-zerv_7 induced pluripotent stem cell human CVCL_EE44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174795 CVCL_EE43 HPSI0214i-poih_4 induced pluripotent stem cell human CVCL_EE43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174796 CVCL_EE42 HPSI0214i-poih_2 induced pluripotent stem cell human CVCL_EE42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174797 CVCL_EE41 HPSI0215i-oilg_3 induced pluripotent stem cell human CVCL_EE41 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174798 CVCL_EE48 HPSI0414i-naju_1 induced pluripotent stem cell human CVCL_EE48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21174799 CVCL_EE47 HPSI0914i-laey_6 induced pluripotent stem cell human CVCL_EE47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174800 CVCL_EE46 HPSI0914i-laey_4 induced pluripotent stem cell human CVCL_EE46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174801 CVCL_EE45 HPSI0914i-zerv_8 induced pluripotent stem cell human CVCL_EE45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21174802 CVCL_EE19 ND37624 transformed cell line human CVCL_EE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174803 CVCL_EE18 ND36167 transformed cell line human CVCL_EE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174804 CVCL_EE17 ND35111 transformed cell line human CVCL_EE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174805 CVCL_EE16 ND32023 transformed cell line human CVCL_EE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174806 CVCL_EE11 ND22732 transformed cell line human CVCL_EE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174807 CVCL_EE10 ND22687 transformed cell line human CVCL_EE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174808 CVCL_EE15 ND26413 transformed cell line human CVCL_EE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174809 CVCL_EE14 ND25755 transformed cell line human CVCL_EE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174810 CVCL_EE13 ND25525 transformed cell line human CVCL_EE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174811 CVCL_EE12 ND22734 transformed cell line human CVCL_EE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174812 CVCL_EE29 UOXFi001-C induced pluripotent stem cell human CVCL_EE29 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (EBiSC) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UOXFi001-C; true Female 21174813 CVCL_EE28 UOXFi001-B induced pluripotent stem cell human CVCL_EE28 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=26905200) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21174814 CVCL_EE27 UOXFi001-A induced pluripotent stem cell human CVCL_EE27 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=26905200) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21174815 CVCL_EE22 ND39701 transformed cell line human CVCL_EE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174816 CVCL_EE21 ND39508 transformed cell line human CVCL_EE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174817 CVCL_EE20 ND39277 transformed cell line human CVCL_EE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174818 CVCL_EE26 UCLi004-B induced pluripotent stem cell human CVCL_EE26 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21174819 CVCL_EE25 Tel12 telomerase immortalized cell line human CVCL_EE25 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21174820 CVCL_EE24 ND42619 transformed cell line human CVCL_EE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174821 CVCL_EE23 ND40636 transformed cell line human CVCL_EE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174822 CVCL_VY52 EPTC2 finite cell line CVCL_VY52 CL:0000010 Derived from sampling site: Testis; epididymis; Breed/subspecies: Persian. Male 21174823 CVCL_VY51 EPTC1 finite cell line CVCL_VY51 CL:0000010 Derived from sampling site: Testis; epididymis; Breed/subspecies: Persian. Male 21174824 CVCL_VY50 KLF-06 transformed cell line human CVCL_VY50 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174825 CVCL_VY56 MoOV-03 finite cell line CVCL_VY56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21174826 CVCL_VY55 MoOV-02 finite cell line CVCL_VY55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21174827 CVCL_VY54 MoOV-01 finite cell line CVCL_VY54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21174828 CVCL_VY53 Sh01 finite cell line CVCL_VY53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21174829 CVCL_VY59 MoOV-06 finite cell line CVCL_VY59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21174830 CVCL_VY58 MoOV-05 finite cell line CVCL_VY58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21174831 CVCL_VY57 MoOV-04 finite cell line CVCL_VY57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21174832 CVCL_4400 BBM transformed cell line human CVCL_4400 CL:0000010 Transfected with: HGNC; 7553; MYC Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9482 21174833 CVCL_3S00 HQ01725 transformed cell line human CVCL_3S00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174834 CVCL_4404 AB1-2 hybridoma house mouse CVCL_4404 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21174835 CVCL_3S04 HQ01729 transformed cell line human CVCL_3S04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174836 CVCL_4403 AB1 [Mouse mesothelioma] cancer cell line house mouse CVCL_4403 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Karyotypic information: Hypo-tetraploid (PubMed=32944078); Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Omics: Array-based CGH; Omics: Deep exome analysis Female Doubling time: 30 hours (PubMed=1459729) 21174837 CVCL_3S03 HQ01728 transformed cell line human CVCL_3S03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174838 CVCL_3S02 HQ01727 transformed cell line human CVCL_3S02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174839 CVCL_4402 RERF-LC-A1 cancer cell line human CVCL_4402 HLA typing: A*24:02; B*52:01; C*12:02 (PubMed=9023415); HLA typing: A*24:02,24:02; B*35:06,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0.35%; Native American=0%; East Asian, North=91.19%; East Asian, South=6.87%; South Asian=0.45%; European, North=1.14%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Homozygous (PubMed=12794755; PubMed=15901131; DepMap) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21174840 CVCL_4401 BOSC-23 transformed cell line human CVCL_4401 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11270 21174841 CVCL_3S01 HQ01726 transformed cell line human CVCL_3S01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174842 CVCL_4408 AE17 cancer cell line house mouse CVCL_4408 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: C57BL/6J. Omics: Deep exome analysis Female 21174843 CVCL_3S08 HQ01733 transformed cell line human CVCL_3S08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174844 CVCL_4407 AC29 cancer cell line house mouse CVCL_4407 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Karyotypic information: Hyper-triploid (PubMed=32944078); Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Breed/subspecies: CBA. Omics: Array-based CGH; Omics: Deep exome analysis Discontinued: CBA; CBA-0152; true Female Doubling time: 27 hours (PubMed=1459729) Problematic cell line: Partially contaminated The stock formerly distributed by CBA under the catalog number CBA-0152 was a mixture of at least two different cell lines from different mouse strains. 21174845 CVCL_3S07 HQ01732 transformed cell line human CVCL_3S07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174846 CVCL_4406 AB22 cancer cell line house mouse CVCL_4406 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Karyotypic information: Near-tetraploid (PubMed=32944078); Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Omics: Array-based CGH; Omics: Deep exome analysis Female Doubling time: 27 hours (PubMed=1459729) 21174847 CVCL_3S06 HQ01731 transformed cell line human CVCL_3S06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174848 CVCL_4405 AB12 cancer cell line house mouse CVCL_4405 CL:0000010 Sequence variation: Gene deletion; MGI; MGI:104738; Cdkn2a; Zygosity=Homozygous (PubMed=28577549) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Omics: Deep exome analysis Female Doubling time: 24 hours (PubMed=1459729) 21174849 CVCL_3S05 HQ01730 transformed cell line human CVCL_3S05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174850 CVCL_3S09 HQ01734 transformed cell line human CVCL_3S09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174851 CVCL_4409 IIIC-BCHM undefined cell line type human CVCL_4409 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Heterozygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0160 but was never intended to be distributed 21174852 CVCL_VY41 MSD-42 transformed cell line human CVCL_VY41 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174853 CVCL_VY40 MSD-41 transformed cell line human CVCL_VY40 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174854 CVCL_VY45 KLF-01 transformed cell line human CVCL_VY45 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174855 CVCL_VY44 PeLe-03 finite cell line CVCL_VY44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21174856 CVCL_VY43 PeLe-02 finite cell line CVCL_VY43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21174857 CVCL_VY42 PeLe-01 finite cell line CVCL_VY42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21174858 CVCL_VY49 KLF-05 transformed cell line human CVCL_VY49 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174859 CVCL_VY48 KLF-04 transformed cell line human CVCL_VY48 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174860 CVCL_VY47 KLF-03 transformed cell line human CVCL_VY47 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174861 CVCL_VY46 KLF-02 transformed cell line human CVCL_VY46 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174862 CVCL_3S11 HQ01736 transformed cell line human CVCL_3S11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174863 CVCL_4411 IIICF-E6E7/C4 transformed cell line human CVCL_4411 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0049 but was never intended to be distributed 21174864 CVCL_3S10 HQ01735 transformed cell line human CVCL_3S10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174865 CVCL_4410 IIIC/H2 undefined cell line type human CVCL_4410 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Heterozygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0159 but was never intended to be distributed 21174866 CVCL_3S15 HQ01740 transformed cell line human CVCL_3S15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174867 CVCL_4415 IIICF/c spontaneously immortalized cell line human CVCL_4415 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from sampling site: Breast; stroma. Female Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0039 but was never intended to be distributed 21174868 CVCL_3S14 HQ01739 transformed cell line human CVCL_3S14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174869 CVCL_4414 IIICF/a2 spontaneously immortalized cell line human CVCL_4414 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0048 but was never intended to be distributed 21174870 CVCL_3S13 HQ01738 transformed cell line human CVCL_3S13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174871 CVCL_4413 IIICF-T/B3 transformed cell line human CVCL_4413 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0056 but was never intended to be distributed 21174872 CVCL_3S12 HQ01737 transformed cell line human CVCL_3S12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174873 CVCL_4412 IIICF-T/A6 transformed cell line human CVCL_4412 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0055 but was never intended to be distributed 21174874 CVCL_3S19 HQ01744 transformed cell line human CVCL_3S19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174875 CVCL_4419 JFCF-6/T.1D transformed cell line human CVCL_4419 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0044 but was never intended to be distributed 21174876 CVCL_3S18 HQ01743 transformed cell line human CVCL_3S18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174877 CVCL_4418 JFCF-6 finite cell line human CVCL_4418 CL:0000010 Derived from sampling site: Small intestine; jejunum. Male 21174878 CVCL_3S17 HQ01742 transformed cell line human CVCL_3S17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174879 CVCL_4417 IVG-BF/LXSN transformed cell line human CVCL_4417 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760) Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0058 but was never intended to be distributed. 21174880 CVCL_3S16 HQ01741 transformed cell line human CVCL_3S16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174881 CVCL_4416 IIICF/c/rasT21 transformed cell line human CVCL_4416 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Hemizygous; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from sampling site: Breast; stroma. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0040 but was never intended to be distributed 21174882 CVCL_VY30 MSD-31 transformed cell line human CVCL_VY30 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174883 CVCL_VY34 MSD-35 transformed cell line human CVCL_VY34 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174884 CVCL_VY33 MSD-34 transformed cell line human CVCL_VY33 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174885 CVCL_VY32 MSD-33 transformed cell line human CVCL_VY32 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174886 CVCL_VY31 MSD-32 transformed cell line human CVCL_VY31 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174887 CVCL_VY38 MSD-39 transformed cell line human CVCL_VY38 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174888 CVCL_VY37 MSD-38 transformed cell line human CVCL_VY37 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174889 CVCL_VY36 MSD-37 transformed cell line human CVCL_VY36 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174890 CVCL_VY35 MSD-36 transformed cell line human CVCL_VY35 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174891 CVCL_VY39 MSD-40 transformed cell line human CVCL_VY39 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174892 CVCL_VY23 MSD-24 transformed cell line human CVCL_VY23 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174893 CVCL_VY22 MSD-23 transformed cell line human CVCL_VY22 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174894 CVCL_VY21 MSD-22 transformed cell line human CVCL_VY21 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174895 CVCL_VY20 MSD-21 transformed cell line human CVCL_VY20 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174896 CVCL_VY27 MSD-28 transformed cell line human CVCL_VY27 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174897 CVCL_VY26 MSD-27 transformed cell line human CVCL_VY26 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174898 CVCL_VY25 MSD-26 transformed cell line human CVCL_VY25 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174899 CVCL_VY24 MSD-25 transformed cell line human CVCL_VY24 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174900 CVCL_VY29 MSD-30 transformed cell line human CVCL_VY29 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174901 CVCL_VY28 MSD-29 transformed cell line human CVCL_VY28 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174902 CVCL_VY12 MSD-13 transformed cell line human CVCL_VY12 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174903 CVCL_VY11 MSD-12 transformed cell line human CVCL_VY11 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174904 CVCL_VY10 MSD-11 transformed cell line human CVCL_VY10 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174905 CVCL_VY16 MSD-17 transformed cell line human CVCL_VY16 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174906 CVCL_VY15 MSD-16 transformed cell line human CVCL_VY15 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174907 CVCL_VY14 MSD-15 transformed cell line human CVCL_VY14 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174908 CVCL_VY13 MSD-14 transformed cell line human CVCL_VY13 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174909 CVCL_VY19 MSD-20 transformed cell line human CVCL_VY19 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174910 CVCL_VY18 MSD-19 transformed cell line human CVCL_VY18 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174911 CVCL_VY17 MSD-18 transformed cell line human CVCL_VY17 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174912 CVCL_VY01 MSD-02 transformed cell line human CVCL_VY01 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174913 CVCL_VY00 MSD-01 transformed cell line human CVCL_VY00 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174914 CVCL_VY05 MSD-06 transformed cell line human CVCL_VY05 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174915 CVCL_VY04 MSD-05 transformed cell line human CVCL_VY04 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174916 CVCL_VY03 MSD-04 transformed cell line human CVCL_VY03 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174917 CVCL_VY02 MSD-03 transformed cell line human CVCL_VY02 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174918 CVCL_VY09 MSD-10 transformed cell line human CVCL_VY09 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174919 CVCL_VY08 MSD-09 transformed cell line human CVCL_VY08 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174920 CVCL_VY07 MSD-08 transformed cell line human CVCL_VY07 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174921 CVCL_VY06 MSD-07 transformed cell line human CVCL_VY06 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174922 CVCL_4491 3E1 [Mouse hybridoma against HSV-2 p40] hybridoma house mouse CVCL_4491 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P89449; Human herpesvirus 2 (HHV-2) capsid scaffolding protein (p40). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8067 21174923 CVCL_3S91 HQ01823 transformed cell line human CVCL_3S91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174924 CVCL_4490 3C9-D11-H11 hybridoma house mouse CVCL_4490 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Porcine parvovirus. 21174925 CVCL_3S90 HQ01822 transformed cell line human CVCL_3S90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174926 CVCL_4495 6-23C6 cancer cell line Norway rat CVCL_4495 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Unspecified 21174927 CVCL_3S95 HQ01827 transformed cell line human CVCL_3S95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174928 CVCL_4494 5G3 [Mouse hybridoma against clenbuterol] hybridoma house mouse CVCL_4494 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:174690; Clenbuterol. 21174929 CVCL_3S94 HQ01826 transformed cell line human CVCL_3S94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174930 CVCL_4493 5C9 hybridoma house mouse CVCL_4493 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; K7ZJP7; Pig immunoglobulin heavy chain mu. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8371 21174931 CVCL_3S93 HQ01825 transformed cell line human CVCL_3S93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174932 CVCL_4492 4MBr-5 finite cell line CVCL_4492 CL:0000010 Derived from sampling site: Bronchus; epithelium. Female Characteristics: EGF dependent; Virology: Susceptible to infection by poliovirus type 1, type 2 and type 3 (PubMed=28046048) Senescence: Senesces at 40 PDL (PubMed=7065527) Group: Non-human primate cell line 21174933 CVCL_3S92 HQ01824 transformed cell line human CVCL_3S92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174934 CVCL_4488 34-5-8S hybridoma house mouse CVCL_4488 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse MHC class I H-2Dd. 21174935 CVCL_3S88 HQ01820 transformed cell line human CVCL_3S88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174936 CVCL_4487 34-5-3S hybridoma house mouse CVCL_4487 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse MHC class II I-Ad. 21174937 CVCL_3S87 HQ01819 transformed cell line human CVCL_3S87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174938 CVCL_4486 328/9 hybrid cell line house mouse CVCL_4486 CL:0000010 21174939 CVCL_3S86 HQ01818 transformed cell line human CVCL_3S86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174940 CVCL_4485 328/8 hybrid cell line house mouse CVCL_4485 CL:0000010 21174941 CVCL_3S85 HQ01817 transformed cell line human CVCL_3S85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174942 CVCL_4489 34-7-23S hybridoma house mouse CVCL_4489 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa (PubMed=7135466); IgM (ATCC); Monoclonal antibody target: Mouse MHC class I H-2Kd/H-2Dd. 21174943 CVCL_3S89 HQ01821 transformed cell line human CVCL_3S89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174944 CVCL_4499 ACT I hybridoma house mouse CVCL_4499 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Dictyostelium discoideum actins. 21174945 CVCL_3S99 HQ01831 transformed cell line human CVCL_3S99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174946 CVCL_4498 9BG5 hybridoma house mouse CVCL_4498 CL:0000010 Monoclonal antibody isotype: IgG2a. 21174947 CVCL_3S98 HQ01830 transformed cell line human CVCL_3S98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174948 CVCL_4497 7D4 hybridoma CVCL_4497 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. 21174949 CVCL_3S97 HQ01829 transformed cell line human CVCL_3S97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174950 CVCL_4496 7C2C5C12 hybridoma house mouse CVCL_4496 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Trichinella spiralis antigens Ts.45, Ts.49 and Ts.53. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8678 21174951 CVCL_3S96 HQ01828 transformed cell line human CVCL_3S96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174952 CVCL_4473 76-5-28 hybridoma house mouse CVCL_4473 CL:0000010 Monoclonal antibody isotype: IgM, kappa. 21174953 CVCL_3S73 HQ01804 transformed cell line human CVCL_3S73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174954 CVCL_4472 76-2-11 hybridoma house mouse CVCL_4472 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; F1SVD3; Pig CD8A. 21174955 CVCL_3S72 HQ01803 transformed cell line human CVCL_3S72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174956 CVCL_4471 74-9-3 hybridoma house mouse CVCL_4471 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; K7GMW0; Pig PTPRC/CD45. 21174957 CVCL_3S71 HQ01802 transformed cell line human CVCL_3S71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174958 CVCL_4470 74-22-15A hybridoma house mouse CVCL_4470 CL:0000010 Characteristics: Isotype switched derivative of 74-22-15; Monoclonal antibody isotype: IgG2b, kappa. 21174959 CVCL_3S70 HQ01801 transformed cell line human CVCL_3S70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174960 CVCL_4466 13C4 hybridoma house mouse CVCL_4466 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q7BQ98; Shigella dysenteriae stxB. 21174961 CVCL_3S66 HQ01795 transformed cell line human CVCL_3S66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174962 CVCL_3S65 HQ01794 transformed cell line human CVCL_3S65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174963 CVCL_3S64 HQ01793 transformed cell line human CVCL_3S64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174964 CVCL_4464 NOS4 cancer cell line human CVCL_4464 CL:0000010 Population: Japanese. Female 21174965 CVCL_3S63 HQ01792 transformed cell line human CVCL_3S63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174966 CVCL_4463 TE-13 cancer cell line human CVCL_4463 CL:0000010 Population: Japanese Discontinued: TKG; TKG 0264; probable. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00274 Problematic cell line: Contaminated TE-2, TE-3, TE-7, TE-12 and TE-13 have been shown to be identical (PubMed=17804709; PubMed=20143388). 21174967 CVCL_4469 74-22-15 hybridoma house mouse CVCL_4469 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21174968 CVCL_3S69 HQ01800 transformed cell line human CVCL_3S69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174969 CVCL_4468 74-12-4 hybridoma house mouse CVCL_4468 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q6R3N4; Pig CD4. 21174970 CVCL_3S68 HQ01799 transformed cell line human CVCL_3S68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174971 CVCL_4467 74-11-10 hybridoma house mouse CVCL_4467 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa. 21174972 CVCL_3S67 HQ01796 transformed cell line human CVCL_3S67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174973 CVCL_4480 328/10 hybrid cell line house mouse CVCL_4480 CL:0000010 21174974 CVCL_3S80 HQ01811 transformed cell line human CVCL_3S80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174975 CVCL_4484 328/7 hybrid cell line house mouse CVCL_4484 CL:0000010 21174976 CVCL_3S84 HQ01815 transformed cell line human CVCL_3S84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174977 CVCL_4483 328/14 hybrid cell line house mouse CVCL_4483 CL:0000010 21174978 CVCL_3S83 HQ01814 transformed cell line human CVCL_3S83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174979 CVCL_4482 328/12 hybrid cell line house mouse CVCL_4482 CL:0000010 21174980 CVCL_3S82 HQ01813 transformed cell line human CVCL_3S82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174981 CVCL_4481 328/11 hybrid cell line house mouse CVCL_4481 CL:0000010 21174982 CVCL_3S81 HQ01812 transformed cell line human CVCL_3S81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174983 CVCL_3S77 HQ01808 transformed cell line human CVCL_3S77 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line ND30013) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Patient indicated as not affected with HD in HQ01808, but as affected in ND30013 21174984 CVCL_4477 RK 13/1 spontaneously immortalized cell line CVCL_4477 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21174985 CVCL_4476 9-4-3 hybridoma house mouse CVCL_4476 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06828; Human parainfluenza 3 virus (strain Wash/47885/57) fusion glycoprotein (F). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8935 21174986 CVCL_3S76 HQ01807 transformed cell line human CVCL_3S76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21174987 CVCL_4475 76-7-4 hybridoma house mouse CVCL_4475 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21174988 CVCL_3S75 HQ01806 transformed cell line human CVCL_3S75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174989 CVCL_4474 76-6-7 hybridoma house mouse CVCL_4474 CL:0000010 Monoclonal antibody isotype: IgM, kappa. 21174990 CVCL_3S74 HQ01805 transformed cell line human CVCL_3S74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174991 CVCL_4479 2BD4E4 K99 hybridoma house mouse CVCL_4479 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P18103; Escherichia coli K99 fanC Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8178 21174992 CVCL_3S79 HQ01810 transformed cell line human CVCL_3S79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174993 CVCL_3S78 HQ01809 transformed cell line human CVCL_3S78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21174994 CVCL_4478 RAW 264 cancer cell line house mouse CVCL_4478 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 21174995 CVCL_VY96 MoOV-43 finite cell line CVCL_VY96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21174996 CVCL_VY95 MoOV-42 finite cell line CVCL_VY95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21174997 CVCL_VY94 MoOV-41 finite cell line CVCL_VY94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21174998 CVCL_VY93 MoOV-40 finite cell line CVCL_VY93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21174999 CVCL_VY99 MoOV-46 finite cell line CVCL_VY99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175000 CVCL_VY98 MoOV-45 finite cell line CVCL_VY98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175001 CVCL_VY97 MoOV-44 finite cell line CVCL_VY97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175002 CVCL_3S51 HQ01780 transformed cell line human CVCL_3S51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175003 CVCL_4451 MM537 cancer cell line human CVCL_4451 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21175004 CVCL_3S50 HQ01779 transformed cell line human CVCL_3S50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175005 CVCL_4450 MM473 cancer cell line human CVCL_4450 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=9354451; PubMed=17363583) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21175006 CVCL_3S44 HQ01772 transformed cell line human CVCL_3S44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175007 CVCL_4444 MCC5 cancer cell line human CVCL_4444 CL:0000010 Female Doubling time: 7 days (PubMed=8244578) Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1336 but was never distributed. 21175008 CVCL_3S43 HQ01771 transformed cell line human CVCL_3S43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175009 CVCL_4443 LIM2551 cancer cell line human CVCL_4443 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Thr578Pro (c.1732A>C); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6769; SMAD3; Simple; p.Ala202Thr (c.604G>A); ClinVar=VCV001171415; Zygosity=Unspecified (PubMed=24755471) Miscellaneous: Sex of donor from original lab book of Whitehead R.H and from patient surgeon through a personal communication of Cape-Davis A. Derived from sampling site: Colon; transverse. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053) 21175010 CVCL_3S42 HQ01770 transformed cell line human CVCL_3S42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175011 CVCL_4442 LIM2550 cancer cell line human CVCL_4442 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous (PubMed=19378335); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=19378335); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=19378335) Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053) 21175012 CVCL_3S41 HQ01769 transformed cell line human CVCL_3S41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175013 CVCL_4441 LIM2537 cancer cell line human CVCL_4441 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=19378335) Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Doubling time: 30 hours (CBA); Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053) 21175014 CVCL_3S48 HQ01777 transformed cell line human CVCL_3S48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175015 CVCL_4448 MCC19 cancer cell line human CVCL_4448 CL:0000010 Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1343 but was never distributed. 21175016 CVCL_3S47 HQ01776 transformed cell line human CVCL_3S47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175017 CVCL_4447 MCC14/1 cancer cell line human CVCL_4447 CL:0000010 Derived from metastatic site: Iliac lymph node. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1339 but is not yet ready for distribution 21175018 CVCL_3S46 HQ01774 transformed cell line human CVCL_3S46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175019 CVCL_4446 MCC12 cancer cell line human CVCL_4446 CL:0000010 Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1337 but was never distributed. 21175020 CVCL_3S45 HQ01773 transformed cell line human CVCL_3S45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175021 CVCL_4445 MCC6 cancer cell line human CVCL_4445 CL:0000010 Male Doubling time: 10.5 days (PubMed=8244578) Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1334 but was never distributed. 21175022 CVCL_3S49 HQ01778 transformed cell line human CVCL_3S49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175023 CVCL_4449 MM466 cancer cell line human CVCL_4449 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Lymph node. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175024 CVCL_VY85 MoOV-32 finite cell line CVCL_VY85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175025 CVCL_VY84 MoOV-31 finite cell line CVCL_VY84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175026 CVCL_VY83 MoOV-30 finite cell line CVCL_VY83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175027 CVCL_VY82 MoOV-29 finite cell line CVCL_VY82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175028 CVCL_VY89 MoOV-36 finite cell line CVCL_VY89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175029 CVCL_VY88 MoOV-35 finite cell line CVCL_VY88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175030 CVCL_VY87 MoOV-34 finite cell line CVCL_VY87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175031 CVCL_VY86 MoOV-33 finite cell line CVCL_VY86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175032 CVCL_3S62 HQ01791 transformed cell line human CVCL_3S62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175033 CVCL_4462 IB3-1/C38 transformed cell line human CVCL_4462 CL:0000010 Transfected with: HGNC; 1884; CFTR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad12-SV40 hybrid virus Discontinued: ATCC; CRL-2779; true; Discontinued: ATCC; JHU-54; true. Male 21175034 CVCL_3S61 HQ01790 transformed cell line human CVCL_3S61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175035 CVCL_4461 IB3-1/S9 transformed cell line human CVCL_4461 CL:0000010 Transfected with: HGNC; 1884; CFTR Transformant: Ad12-SV40 hybrid virus Omics: Metabolome analysis Discontinued: ATCC; CRL-2778; true; Discontinued: ATCC; JHU-53; true. Male Characteristics: Stably transduced to achieve low-level expression of full-length wild-type CFTR 21175036 CVCL_3S60 HQ01789 transformed cell line human CVCL_3S60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175037 CVCL_4460 UW228-1 cancer cell line human CVCL_4460 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Brain; posterior fossa. Female Doubling time: 25.2 +- 2.1 hours (PubMed=8866661) 21175038 CVCL_3S55 HQ01784 transformed cell line human CVCL_3S55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175039 CVCL_4455 TE-2 cancer cell line human CVCL_4455 CL:0000010 Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: RCB; RCB1948; true; Discontinued: TKG; TKG 0253; true. Male Doubling time: 72 hours (PubMed=520749) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00275 Problematic cell line: Contaminated TE-2, TE-3, TE-7, TE-12 and TE-13 have been shown to be identical (PubMed=17804709; PubMed=20143388). TE-2 was originally thought to originate from the primary tumor of the intrathoracic esophagus of a 57 year old Japanese male. 21175040 CVCL_3S54 HQ01783 transformed cell line human CVCL_3S54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175041 CVCL_4454 Mel-57 cancer cell line human CVCL_4454 CL:0000010 Derived from metastatic site: Skin. Female 21175042 CVCL_3S53 HQ01782 transformed cell line human CVCL_3S53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175043 CVCL_4453 MM608 cancer cell line human CVCL_4453 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=15048078) Omics: Transcriptome analysis by microarray Unspecified Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1360 but was never distributed. 21175044 CVCL_3S52 HQ01781 transformed cell line human CVCL_3S52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175045 CVCL_4452 MM595 cancer cell line human CVCL_4452 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Derived from metastatic site: Not specified. Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1358 but was never distributed 21175046 CVCL_3S59 HQ01788 transformed cell line human CVCL_3S59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175047 CVCL_4459 OSRGa cancer cell line Norway rat CVCL_4459 CL:0000010 Transformant: Cerium-144 beta radiation(NCIt; C129639); Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Male 21175048 CVCL_4458 HL-60/DNR cancer cell line human CVCL_4458 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Peripheral blood. Female 21175049 CVCL_3S58 HQ01787 transformed cell line human CVCL_3S58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175050 CVCL_3S57 HQ01786 transformed cell line human CVCL_3S57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175051 CVCL_4457 SN-56/OBR hybrid cell line house mouse CVCL_4457 CL:0000010 Transfected with: HGNC; 6554; LEPR. 21175052 CVCL_3S56 HQ01785 transformed cell line human CVCL_3S56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175053 CVCL_4456 SN56 hybrid cell line house mouse CVCL_4456 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Hybrid of septal neuronal cells from postnatal day 21 mice with the N18TG2 neuroblastoma 21175054 CVCL_VY92 MoOV-39 finite cell line CVCL_VY92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175055 CVCL_VY91 MoOV-38 finite cell line CVCL_VY91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175056 CVCL_VY90 MoOV-37 finite cell line CVCL_VY90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175057 CVCL_VY74 MoOV-21 finite cell line CVCL_VY74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175058 CVCL_VY73 MoOV-20 finite cell line CVCL_VY73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175059 CVCL_VY72 MoOV-19 finite cell line CVCL_VY72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175060 CVCL_VY71 MoOV-18 finite cell line CVCL_VY71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175061 CVCL_VY78 MoOV-25 finite cell line CVCL_VY78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175062 CVCL_VY77 MoOV-24 finite cell line CVCL_VY77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175063 CVCL_VY76 MoOV-23 finite cell line CVCL_VY76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175064 CVCL_VY75 MoOV-22 finite cell line CVCL_VY75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175065 CVCL_VY79 MoOV-26 finite cell line CVCL_VY79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175066 CVCL_3S22 HQ01747 transformed cell line human CVCL_3S22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175067 CVCL_4422 JFCF-6/T.1J/11E transformed cell line human CVCL_4422 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21175068 CVCL_3S21 HQ01746 transformed cell line human CVCL_3S21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175069 CVCL_4421 JFCF-6/T.1J/1D transformed cell line human CVCL_4421 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21175070 CVCL_3S20 HQ01745 transformed cell line human CVCL_3S20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175071 CVCL_4420 JFCF-6/T.1J/1.3C transformed cell line human CVCL_4420 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0042 but was never intended to be distributed 21175072 CVCL_3S26 HQ01751 transformed cell line human CVCL_3S26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175073 CVCL_4426 JFCF-6/T.1M transformed cell line human CVCL_4426 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0046 but was never intended to be distributed 21175074 CVCL_3S25 HQ01750 transformed cell line human CVCL_3S25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175075 CVCL_4425 JFCF-6/T.1L transformed cell line human CVCL_4425 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0045 but was never intended to be distributed 21175076 CVCL_3S24 HQ01749 transformed cell line human CVCL_3S24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175077 CVCL_4424 JFCF-6/T.1J/6B transformed cell line human CVCL_4424 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21175078 CVCL_3S23 HQ01748 transformed cell line human CVCL_3S23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175079 CVCL_4423 JFCF-6/T.1J/5H transformed cell line human CVCL_4423 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0043 but was never intended to be distributed 21175080 CVCL_3S29 HQ01754 transformed cell line human CVCL_3S29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175081 CVCL_4429 JFCF-6/T22.5M transformed cell line human CVCL_4429 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21175082 CVCL_3S28 HQ01753 transformed cell line human CVCL_3S28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175083 CVCL_4428 JFCF-6/T.1R transformed cell line human CVCL_4428 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0041 but was never intended to be distributed 21175084 CVCL_3S27 HQ01752 transformed cell line human CVCL_3S27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175085 CVCL_4427 JFCF-6/T.1Q transformed cell line human CVCL_4427 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0047 but was never intended to be distributed 21175086 CVCL_VY81 MoOV-28 finite cell line CVCL_VY81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175087 CVCL_VY80 MoOV-27 finite cell line CVCL_VY80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175088 CVCL_VY63 MoOV-10 finite cell line CVCL_VY63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175089 CVCL_VY62 MoOV-09 finite cell line CVCL_VY62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175090 CVCL_VY61 MoOV-08 finite cell line CVCL_VY61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175091 CVCL_VY60 MoOV-07 finite cell line CVCL_VY60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175092 CVCL_VY67 MoOV-14 finite cell line CVCL_VY67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175093 CVCL_VY66 MoOV-13 finite cell line CVCL_VY66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175094 CVCL_VY65 MoOV-12 finite cell line CVCL_VY65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175095 CVCL_VY64 MoOV-11 finite cell line CVCL_VY64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175096 CVCL_VY69 MoOV-16 finite cell line CVCL_VY69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175097 CVCL_VY68 MoOV-15 finite cell line CVCL_VY68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175098 CVCL_3S40 HQ01768 transformed cell line human CVCL_3S40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175099 CVCL_4440 LIM2463 cancer cell line human CVCL_4440 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from child cell line LIM2463B); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (from child cell line LIM2463B) Derived from sampling site: Rectum. Female Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0167 but was never distributed 21175100 CVCL_3S33 HQ01759 transformed cell line human CVCL_3S33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175101 CVCL_4433 LIM1839 cancer cell line human CVCL_4433 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Male Doubling time: 30 hours (PubMed=2606577). 21175102 CVCL_3S32 HQ01758 transformed cell line human CVCL_3S32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175103 CVCL_4432 PNET-2 cancer cell line human CVCL_4432 CL:0000010 Female 21175104 CVCL_3S31 HQ01757 transformed cell line human CVCL_3S31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175105 CVCL_4431 PNET cancer cell line human CVCL_4431 CL:0000010 Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1960 but was never distributed. 21175106 CVCL_3S30 HQ01755 transformed cell line human CVCL_3S30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175107 CVCL_4430 JFCF-6/T.5B transformed cell line human CVCL_4430 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum. Male 21175108 CVCL_3S37 HQ01764 transformed cell line human CVCL_3S37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175109 CVCL_4437 LIM2405 cancer cell line human CVCL_4437 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala697Val (c.2090C>T); ClinVar=VCV000216153; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val2194Phefs*5 (c.6579delA); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val290fs*8 (c.867_868insA); Zygosity=Unspecified (PubMed=24755471) Derived from sampling site: Colon. Omics: Deep proteome analysis; Omics: N-glycan profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=1427983); Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=25926053) 21175110 CVCL_3S36 HQ01763 transformed cell line human CVCL_3S36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175111 CVCL_4436 LIM2099 cancer cell line human CVCL_4436 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471) Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=1427983); Microsatellite instability: Stable (MSS) (PubMed=19378335; PubMed=25926053) 21175112 CVCL_3S35 HQ01761 transformed cell line human CVCL_3S35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175113 CVCL_4435 LIM1899 cancer cell line human CVCL_4435 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=12068308; PubMed=19378335; PubMed=24755471) Derived from sampling site: Colon. Omics: Deep proteome analysis; Omics: N-glycan profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=1427983); Microsatellite instability: Stable (MSS) (PubMed=19378335); Instable (MSI) (PubMed=25926053) 21175114 CVCL_3S34 HQ01760 transformed cell line human CVCL_3S34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175115 CVCL_4434 LIM1863 cancer cell line human CVCL_4434 HLA typing: A*03,11 (PubMed=8464898) From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Unspecified (PubMed=16418264; PubMed=19378335) Derived from sampling site: Colon. Omics: Deep proteome analysis Female Doubling time: 53 hours (PubMed=1427983); 2-3 days (CBA); Microsatellite instability: Stable (MSS) (PubMed=19378335) 21175116 CVCL_3S39 HQ01767 transformed cell line human CVCL_3S39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175117 CVCL_4439 LIM2412 cancer cell line human CVCL_4439 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714) Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Unspecified Doubling time: 30 hours (PubMed=1427983); Microsatellite instability: Instable (MSI) (PubMed=25926053) 21175118 CVCL_3S38 HQ01766 transformed cell line human CVCL_3S38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175119 CVCL_4438 LIM2408 cancer cell line human CVCL_4438 From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335) Derived from sampling site: Colon. Female Doubling time: >4 days (PubMed=1427983); Microsatellite instability: Instable (MSI) (PubMed=19378335) Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-0166 but was never distributed 21175120 CVCL_VY70 MoOV-17 finite cell line CVCL_VY70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175121 CVCL_EF18 HPSI0714i-keui_1 induced pluripotent stem cell human CVCL_EF18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175122 CVCL_EF17 HPSI0614i-zoio_2 induced pluripotent stem cell human CVCL_EF17 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175123 CVCL_EF16 HPSI0614i-zoio_1 induced pluripotent stem cell human CVCL_EF16 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175124 CVCL_EF15 HPSI0614i-voxu_2 induced pluripotent stem cell human CVCL_EF15 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175125 CVCL_EF19 HPSI0714i-keui_4 induced pluripotent stem cell human CVCL_EF19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175126 CVCL_EF10 HPSI0614i-lepk_4 induced pluripotent stem cell human CVCL_EF10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175127 CVCL_EF14 HPSI0614i-voxu_1 induced pluripotent stem cell human CVCL_EF14 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175128 CVCL_EF13 HPSI0614i-oicx_6 induced pluripotent stem cell human CVCL_EF13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175129 CVCL_EF12 HPSI0614i-oicx_2 induced pluripotent stem cell human CVCL_EF12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175130 CVCL_EF11 HPSI0614i-mesr_4 induced pluripotent stem cell human CVCL_EF11 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175131 CVCL_EF29 HPSI0715i-meue_4 induced pluripotent stem cell human CVCL_EF29 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175132 CVCL_EF28 HPSI0715i-aowh_2 induced pluripotent stem cell human CVCL_EF28 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175133 CVCL_EF27 HPSI0714i-ouzk_5 induced pluripotent stem cell human CVCL_EF27 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175134 CVCL_EF26 HPSI0714i-ouzk_4 induced pluripotent stem cell human CVCL_EF26 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175135 CVCL_EF21 HPSI0714i-kute_5 induced pluripotent stem cell human CVCL_EF21 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175136 CVCL_EF20 HPSI0714i-kute_4 induced pluripotent stem cell human CVCL_EF20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175137 CVCL_EF25 HPSI0714i-nufh_4 induced pluripotent stem cell human CVCL_EF25 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175138 CVCL_EF24 HPSI0714i-nufh_3 induced pluripotent stem cell human CVCL_EF24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175139 CVCL_EF23 HPSI0714i-mejk_1 induced pluripotent stem cell human CVCL_EF23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175140 CVCL_EF22 HPSI0714i-meet_3 induced pluripotent stem cell human CVCL_EF22 From: University of Exeter Medical School; Exeter; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175141 CVCL_EF07 HPSI0614i-laig_1 induced pluripotent stem cell human CVCL_EF07 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175142 CVCL_EF06 HPSI0614i-gawh_7 induced pluripotent stem cell human CVCL_EF06 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175143 CVCL_EF05 HPSI0614i-gawh_12 induced pluripotent stem cell human CVCL_EF05 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175144 CVCL_EF04 HPSI0614i-eisk_6 induced pluripotent stem cell human CVCL_EF04 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175145 CVCL_EF09 HPSI0614i-lepk_1 induced pluripotent stem cell human CVCL_EF09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175146 CVCL_EF08 HPSI0614i-laig_2 induced pluripotent stem cell human CVCL_EF08 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Female 21175147 CVCL_EF03 HPSI0614i-eisk_3 induced pluripotent stem cell human CVCL_EF03 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175148 CVCL_EF02 HPSI0614i-denw_6 induced pluripotent stem cell human CVCL_EF02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175149 CVCL_EF01 HPSI0514i-uenn_3 induced pluripotent stem cell human CVCL_EF01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175150 CVCL_EF00 HPSI0514i-sohd_3 induced pluripotent stem cell human CVCL_EF00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175151 CVCL_3R92 HQ01717 transformed cell line human CVCL_3R92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175152 CVCL_4392 PG-LH7 cancer cell line human CVCL_4392 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000202) It was the sole source for the STR profile of this entry. Population: Chinese; Derived from metastatic site: Pleural effusion. Male Characteristics: Low metastatic potential 21175153 CVCL_3R91 HQ01716 transformed cell line human CVCL_3R91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175154 CVCL_4391 PG-CL3 cancer cell line human CVCL_4391 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male 21175155 CVCL_3R90 HQ01715 transformed cell line human CVCL_3R90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175156 CVCL_4390 PG-BE1 cancer cell line human CVCL_4390 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male Characteristics: High metastatic potential 21175157 CVCL_3R96 HQ01721 transformed cell line human CVCL_3R96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175158 CVCL_4396 NR8383 spontaneously immortalized cell line Norway rat CVCL_4396 CL:0000010 Anecdotal: Have been flown in space on the ISS in 2014-2015 to study growth and adaptation to microgravity (PubMed=28242876) Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Sprague Dawley. Male Characteristics: Provides a homogenous source of highly responsive alveolar macrophages which can be used in vitro to study macrophage related activities (ATCC) Group: Space-flown cell line (cellonaut) 21175159 CVCL_3R95 HQ01720 transformed cell line human CVCL_3R95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175160 CVCL_4395 SVEC4-10EHR1 transformed cell line house mouse CVCL_4395 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male 21175161 CVCL_3R94 HQ01719 transformed cell line human CVCL_3R94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175162 CVCL_4394 SVEC4-10EE2 transformed cell line house mouse CVCL_4394 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male 21175163 CVCL_3R93 HQ01718 transformed cell line human CVCL_3R93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175164 CVCL_4393 SVEC4-10 transformed cell line house mouse CVCL_4393 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male 21175165 CVCL_3R89 HQ01714 transformed cell line human CVCL_3R89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175166 CVCL_4389 PG [Human lung carcinoma] cancer cell line human CVCL_4389 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male 21175167 CVCL_3R88 HQ01713 transformed cell line human CVCL_3R88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175168 CVCL_4388 hTERT-RPE1 telomerase immortalized cell line human CVCL_4388 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Eye; retina; retinal pigment epithelium. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Female 21175169 CVCL_4387 A9HT transformed cell line house mouse CVCL_4387 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21175170 CVCL_3R87 HQ01712 transformed cell line human CVCL_3R87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175171 CVCL_4386 CHO-AA8 spontaneously immortalized cell line CVCL_4386 CL:0000010 Derived from sampling site: Ovary. Female 21175172 CVCL_3R86 HQ01711 transformed cell line human CVCL_3R86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175173 CVCL_4399 BBm finite cell line CVCL_4399 CL:0000010 Derived from sampling site: Bone marrow. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175174 CVCL_3R99 HQ01724 transformed cell line human CVCL_3R99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175175 CVCL_3R98 HQ01723 transformed cell line human CVCL_3R98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175176 CVCL_4398 OP9 stromal cell line house mouse CVCL_4398 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.; Breed/subspecies: (C57BL/6 x C3H) F2-op/op. Unspecified Characteristics: Does not produce Csf1 (M-CSF) due to a mutation in the gene; Characteristics: Used as feeder cells for the differentiation of ES cells and iPS cells into hematopoietic cells 21175177 CVCL_3R97 HQ01722 transformed cell line human CVCL_3R97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175178 CVCL_4397 NRbM hybridoma house mouse CVCL_4397 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rabbit IgM. 21175179 CVCL_EF98 GM20918 transformed cell line human CVCL_EF98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21175180 CVCL_EF97 GM14084 finite cell line human CVCL_EF97 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21175181 CVCL_EF96 GM12445 finite cell line human CVCL_EF96 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (Coriell) Population: Caucasian; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21175182 CVCL_EF95 GM03878 finite cell line human CVCL_EF95 CL:0000010 Sequence variation: Mutation; HGNC; 4624; GSS; Simple; p.Arg164Gln (c.491G>A); ClinVar=VCV000008525; Zygosity=Heterozygous; Note=Affects splicing (PubMed=8896573); Sequence variation: Mutation; HGNC; 4624; GSS; Simple; p.Ala2Profs*14 (c.4delG); ClinVar=VCV000338302; Zygosity=Heterozygous (PubMed=8896573) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21175183 CVCL_EF99 GM21284 transformed cell line human CVCL_EF99 CL:0000010 Sequence variation: Mutation; HGNC; 1149; BUB1B; Simple; p.Ser738Valfs*16 (c.2208_2211dupGTTA) (2212insGTTA); ClinVar=VCV000006763; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1149; BUB1B; Simple; p.Arg814His (c.2441G>A); ClinVar=VCV000006764; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175184 CVCL_EF83 SIGi001-A-1 induced pluripotent stem cell human CVCL_EF83 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175185 CVCL_EF82 AG22621 finite cell line CVCL_EF82 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Insignis; stock IS. Female 21175186 CVCL_EF81 AG22620 finite cell line CVCL_EF81 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Insignis; stock IS. Male 21175187 CVCL_EF80 AG22619 finite cell line CVCL_EF80 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Bairdii; stock BW. Female 21175188 CVCL_EF76 AG22354 finite cell line CVCL_EF76 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Stock LL. Female 21175189 CVCL_EF75 AG22353 finite cell line CVCL_EF75 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Stock LL. Female 21175190 CVCL_EF74 AG22348 finite cell line CVCL_EF74 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Subgriseus; stock PO. Female 21175191 CVCL_EF73 AG22342 finite cell line CVCL_EF73 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Insignis; stock IS. Female 21175192 CVCL_EF79 AG22618 finite cell line CVCL_EF79 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Bairdii; stock BW. Male 21175193 CVCL_EF78 AG22615 finite cell line CVCL_EF78 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Stock LL. Male 21175194 CVCL_EF77 AG22359 finite cell line CVCL_EF77 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Bairdii; stock BW. Female 21175195 CVCL_EF90 SIGi001-A-9 induced pluripotent stem cell human CVCL_EF90 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Homozygous; Note=By method not specified (EBiSC); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175196 CVCL_EF94 GM03877 finite cell line human CVCL_EF94 CL:0000010 Sequence variation: Mutation; HGNC; 4624; GSS; Simple; p.Arg164Gln (c.491G>A); ClinVar=VCV000008525; Zygosity=Heterozygous; Note=Affects splicing (PubMed=8896573); Sequence variation: Mutation; HGNC; 4624; GSS; Simple; p.Ala2Profs*14 (c.4delG); ClinVar=VCV000338302; Zygosity=Heterozygous (PubMed=8896573) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21175197 CVCL_EF93 GM03578 transformed cell line human CVCL_EF93 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=19767587) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21175198 CVCL_EF92 GM03070 transformed cell line human CVCL_EF92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175199 CVCL_EF91 GM02522 finite cell line human CVCL_EF91 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (Coriell) Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 21175200 CVCL_EF87 SIGi001-A-6 induced pluripotent stem cell human CVCL_EF87 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175201 CVCL_EF86 SIGi001-A-5 induced pluripotent stem cell human CVCL_EF86 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Heterozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175202 CVCL_EF85 SIGi001-A-4 induced pluripotent stem cell human CVCL_EF85 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175203 CVCL_EF84 SIGi001-A-3 induced pluripotent stem cell human CVCL_EF84 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Heterozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175204 CVCL_EF89 SIGi001-A-8 induced pluripotent stem cell human CVCL_EF89 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Heterozygous; Note=By method not specified (EBiSC); Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Homozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175205 CVCL_EF88 SIGi001-A-7 induced pluripotent stem cell human CVCL_EF88 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_edited; p.Pro301Ser (c.901C>T) (P618S, c.1852C>T or P636S, c.1906C>T); ClinVar=VCV000014256; Zygosity=Heterozygous; Note=By method not specified (EBiSC) Population: Caucasian; Derived from sampling site: Cell type=Epithelial cell. Omics: Genome sequenced Female 21175206 CVCL_EF61 AG21209 finite cell line Norway rat CVCL_EF61 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175207 CVCL_EF60 AG21205 finite cell line Norway rat CVCL_EF60 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175208 CVCL_EF59 AG21201 finite cell line Norway rat CVCL_EF59 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175209 CVCL_EF54 AG17511 transformed cell line human CVCL_EF54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175210 CVCL_EF53 AG22161 finite cell line human CVCL_EF53 CL:0000010 Derived from sampling site: Toe; skin (Note=From an ulcer) Cell type=Fibroblast.. Male 21175211 CVCL_EF52 HPSI1114i-ualf_6 induced pluripotent stem cell human CVCL_EF52 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175212 CVCL_EF51 HPSI1114i-ualf_2 induced pluripotent stem cell human CVCL_EF51 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175213 CVCL_EF58 AG21197 finite cell line Norway rat CVCL_EF58 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175214 CVCL_EF57 AG21193 finite cell line Norway rat CVCL_EF57 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175215 CVCL_EF56 AG06105 finite cell line CVCL_EF56 CL:0000010 Derived from sampling site: Thoracolumbar junction; skin. Discontinued: Coriell; AG06105; probable Female Group: Non-human primate cell line 21175216 CVCL_EF55 AG12352 finite cell line pig CVCL_EF55 CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Female 21175217 CVCL_EF72 AG22341 finite cell line CVCL_EF72 From: Peromyscus Genetic Stock Center, University of South Carolina; Columbia; USA CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Insignis; stock IS. Female 21175218 CVCL_EF71 AG21280 finite cell line Norway rat CVCL_EF71 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175219 CVCL_EF70 AG21276 finite cell line Norway rat CVCL_EF70 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175220 CVCL_EF65 AG21241 finite cell line Norway rat CVCL_EF65 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175221 CVCL_EF64 AG21237 finite cell line Norway rat CVCL_EF64 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175222 CVCL_EF63 AG21233 finite cell line Norway rat CVCL_EF63 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175223 CVCL_EF62 AG21229 finite cell line Norway rat CVCL_EF62 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175224 CVCL_EF69 AG21272 finite cell line Norway rat CVCL_EF69 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175225 CVCL_EF68 AG21268 finite cell line Norway rat CVCL_EF68 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175226 CVCL_EF67 AG21264 finite cell line Norway rat CVCL_EF67 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175227 CVCL_EF66 AG21245 finite cell line Norway rat CVCL_EF66 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Male 21175228 CVCL_EF39 HPSI0914i-suop_5 induced pluripotent stem cell human CVCL_EF39 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175229 CVCL_EF38 HPSI0914i-suop_2 induced pluripotent stem cell human CVCL_EF38 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175230 CVCL_EF37 HPSI0914i-ouvb_2 induced pluripotent stem cell human CVCL_EF37 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175231 CVCL_EF32 HPSI0715i-zaie_5 induced pluripotent stem cell human CVCL_EF32 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175232 CVCL_EF31 HPSI0715i-zaie_1 induced pluripotent stem cell human CVCL_EF31 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175233 CVCL_EF30 HPSI0715i-meue_5 induced pluripotent stem cell human CVCL_EF30 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175234 CVCL_EF36 HPSI0914i-iezw_2 induced pluripotent stem cell human CVCL_EF36 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175235 CVCL_EF35 HPSI0914i-gine_2 induced pluripotent stem cell human CVCL_EF35 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175236 CVCL_EF34 HPSI0913i-rufg_4 induced pluripotent stem cell human CVCL_EF34 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175237 CVCL_EF33 HPSI0913i-rufg_3 induced pluripotent stem cell human CVCL_EF33 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175238 CVCL_EF50 HPSI1113i-wahn_2 induced pluripotent stem cell human CVCL_EF50 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175239 CVCL_EF49 HPSI1113i-wahn_1 induced pluripotent stem cell human CVCL_EF49 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175240 CVCL_EF48 HPSI1014i-vils_1 induced pluripotent stem cell human CVCL_EF48 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175241 CVCL_EF43 HPSI1014i-nosn_1 induced pluripotent stem cell human CVCL_EF43 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175242 CVCL_EF42 HPSI1013i-zagm_1 induced pluripotent stem cell human CVCL_EF42 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21175243 CVCL_EF41 HPSI0914i-tifo_2 induced pluripotent stem cell human CVCL_EF41 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male 21175244 CVCL_EF40 HPSI0914i-tifo_1 induced pluripotent stem cell human CVCL_EF40 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq; Omics: DNA methylation analysis Male 21175245 CVCL_EF47 HPSI1014i-sehl_6 induced pluripotent stem cell human CVCL_EF47 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175246 CVCL_EF46 HPSI1014i-roug_3 induced pluripotent stem cell human CVCL_EF46 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175247 CVCL_EF45 HPSI1014i-riun_1 induced pluripotent stem cell human CVCL_EF45 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175248 CVCL_EF44 HPSI1014i-nosn_6 induced pluripotent stem cell human CVCL_EF44 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175249 CVCL_VZ73 RWE02 finite cell line Norway rat CVCL_VZ73 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Wistar. Male 21175250 CVCL_VZ72 RWE01 finite cell line Norway rat CVCL_VZ72 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Wistar. Female 21175251 CVCL_VZ71 Exo-RBM-4 finite cell line Norway rat CVCL_VZ71 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Established from parent cell line using exosome free serum 21175252 CVCL_VZ70 RBM-4 finite cell line Norway rat CVCL_VZ70 CL:0000010 Derived from sampling site: Bone marrow. Male 21175253 CVCL_VZ77 XDP-1 transformed cell line human CVCL_VZ77 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175254 CVCL_VZ76 WLS-1 transformed cell line human CVCL_VZ76 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175255 CVCL_VZ75 RWT02 finite cell line Norway rat CVCL_VZ75 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: Wistar. Male 21175256 CVCL_VZ74 RWT01 finite cell line Norway rat CVCL_VZ74 CL:0000010 Derived from sampling site: Tail; skin Cell type=Fibroblast.; Breed/subspecies: Wistar. Female 21175257 CVCL_VZ79 CaBa01 finite cell line CVCL_VZ79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175258 CVCL_VZ78 CaBa002 finite cell line CVCL_VZ78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175259 CVCL_4521 FeLV-3281 cancer cell line CVCL_4521 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9116 21175260 CVCL_3T21 HQ01856 transformed cell line human CVCL_3T21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175261 CVCL_4520 EREp finite cell line CVCL_4520 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6498; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175262 CVCL_3T20 HQ01855 transformed cell line human CVCL_3T20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175263 CVCL_4525 Hermes-3 hybridoma house mouse CVCL_4525 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9480 21175264 CVCL_3T25 HQ01860 transformed cell line human CVCL_3T25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175265 CVCL_4524 H16-L10-4R5 hybridoma house mouse CVCL_4524 CL:0000010 Discontinued: Coriell; WC00007; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Influenza A virus nucleoprotein (NP) 21175266 CVCL_3T24 HQ01859 transformed cell line human CVCL_3T24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175267 CVCL_4523 GK1.5 hybridoma CVCL_4523 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P06332; Mouse Cd4. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175268 CVCL_3T23 HQ01858 transformed cell line human CVCL_3T23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175269 CVCL_4522 FRhK-4 spontaneously immortalized cell line CVCL_4522 CL:0000010 Derived from sampling site: Fetal kidney. Female Virology: Susceptible to infection by poliovirus type 1, type 2 and type 3 (PubMed=28046048) Group: Non-human primate cell line 21175270 CVCL_3T22 HQ01857 transformed cell line human CVCL_3T22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175271 CVCL_3T29 HQ01864 transformed cell line human CVCL_3T29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175272 CVCL_4529 IB-RS-2 D10 spontaneously immortalized cell line pig CVCL_4529 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-1835; true Female Virology: Infected by classical swine fever virus (CSFV) (PubMed=7989247; PubMed=34737324) These results contradict the original report that stated the cell line was not infected (PubMed=2840431). 21175273 CVCL_3T28 HQ01863 transformed cell line human CVCL_3T28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175274 CVCL_4528 IB-RS-2 spontaneously immortalized cell line pig CVCL_4528 CL:0000010 Derived from sampling site: Kidney. Discontinued: ECACC; 84100503; true; Discontinued: RCB; RCB0532; true Female 21175275 CVCL_4527 HGF24 finite cell line human CVCL_4527 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Unspecified 21175276 CVCL_3T27 HQ01862 transformed cell line human CVCL_3T27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175277 CVCL_3T26 HQ01861 transformed cell line human CVCL_3T26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175278 CVCL_VZ80 CaBa02 finite cell line CVCL_VZ80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175279 CVCL_VZ62 ATTC1 finite cell line CVCL_VZ62 CL:0000010 Derived from sampling site: Testis; tunica albuginea; Breed/subspecies: Persian. Male 21175280 CVCL_VZ61 mAGS(5) cancer cell line human CVCL_VZ61 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Established from parent cell line through a nude mice tumor 21175281 CVCL_VZ60 mAGS(4) cancer cell line human CVCL_VZ60 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Established from parent cell line through a nude mice tumor 21175282 CVCL_VZ66 OSTIM-1 transformed cell line human CVCL_VZ66 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175283 CVCL_VZ65 VTTC2 finite cell line CVCL_VZ65 CL:0000010 Derived from sampling site: Testis; tunica vaginalis; Breed/subspecies: Persian. Male 21175284 CVCL_VZ64 SMTC2 finite cell line CVCL_VZ64 CL:0000010 Derived from sampling site: Testis; Breed/subspecies: Persian. Male 21175285 CVCL_VZ63 ATTC2 finite cell line CVCL_VZ63 CL:0000010 Derived from sampling site: Testis; tunica albuginea; Breed/subspecies: Persian. Male 21175286 CVCL_VZ69 RBM-3 finite cell line Norway rat CVCL_VZ69 CL:0000010 Derived from sampling site: Bone marrow. Male 21175287 CVCL_VZ68 RBM-2 finite cell line Norway rat CVCL_VZ68 CL:0000010 Derived from sampling site: Bone marrow. Male 21175288 CVCL_VZ67 RBM-1 finite cell line Norway rat CVCL_VZ67 CL:0000010 Derived from sampling site: Bone marrow. Male 21175289 CVCL_3T32 HQ01867 transformed cell line human CVCL_3T32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175290 CVCL_4532 L2I-6 hybridoma house mouse CVCL_4532 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Chlamydia trachomatis LPS (Note=Also reacts with other Chlamydial species). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8705 21175291 CVCL_3T31 HQ01866 transformed cell line human CVCL_3T31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175292 CVCL_4531 KMP undefined cell line type house mouse CVCL_4531 CL:0000010 Derived from sampling site: Ascites Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Unspecified 21175293 CVCL_3T30 HQ01865 transformed cell line human CVCL_3T30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175294 CVCL_4530 Jurkat J6 cancer cell line human CVCL_4530 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21175295 CVCL_3T36 HQ01871 transformed cell line human CVCL_3T36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175296 CVCL_4536 L-M(TK-) spontaneously immortalized cell line house mouse CVCL_4536 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Discontinued: BCRJ; 0148; probable Male 21175297 CVCL_3T35 HQ01870 transformed cell line human CVCL_3T35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175298 CVCL_4535 L-M spontaneously immortalized cell line house mouse CVCL_4535 CL:0000010 Anecdotal: Have been flown in space on shuttle flights STS-50 (USML-1), STS-54 and STS-57 (Spacehab-1) to study TNF-mediated cytotoxicity in microgravity (PubMed=8125155) Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line; Group: Space-flown cell line (cellonaut) 21175299 CVCL_3T34 HQ01869 transformed cell line human CVCL_3T34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175300 CVCL_4534 L5.1 hybridoma house mouse CVCL_4534 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. 21175301 CVCL_3T33 HQ01868 transformed cell line human CVCL_3T33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175302 CVCL_4533 L243 hybridoma house mouse CVCL_4533 CL:0000010 Monoclonal antibody isotype: IgG2a. 21175303 CVCL_3T39 HQ01874 transformed cell line human CVCL_3T39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175304 CVCL_4539 mAb 35 hybridoma CVCL_4539 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09688; Electrophorus electricus chrna1. Group: Patented cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981); Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8857 21175305 CVCL_3T38 HQ01873 transformed cell line human CVCL_3T38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175306 CVCL_4538 M2-1C6-4R3 hybridoma house mouse CVCL_4538 CL:0000010 Discontinued: Coriell; WC00017; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus matrix protein (M) 21175307 CVCL_3T37 HQ01872 transformed cell line human CVCL_3T37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175308 CVCL_4537 M-2E6 hybridoma house mouse CVCL_4537 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human IgM. 21175309 CVCL_VZ51 VAH-01 transformed cell line human CVCL_VZ51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175310 CVCL_VZ50 ShB09 finite cell line CVCL_VZ50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175311 CVCL_VZ55 Ra01 finite cell line CVCL_VZ55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: New Zealand white. Male 21175312 CVCL_VZ54 Bo02 finite cell line CVCL_VZ54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21175313 CVCL_VZ53 Bo01 finite cell line CVCL_VZ53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21175314 CVCL_VZ52 VAH-02 transformed cell line human CVCL_VZ52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175315 CVCL_VZ59 mAGS(3) cancer cell line human CVCL_VZ59 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Established from parent cell line through a nude mice tumor 21175316 CVCL_VZ58 mAGS(2) cancer cell line human CVCL_VZ58 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Established from parent cell line through a nude mice tumor 21175317 CVCL_VZ57 mAGS(1) cancer cell line human CVCL_VZ57 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Established from parent cell line through a nude mice tumor 21175318 CVCL_VZ56 Go01 finite cell line CVCL_VZ56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21175319 CVCL_4503 B2-1 spontaneously immortalized cell line house mouse CVCL_4503 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8085 21175320 CVCL_3T03 HQ01835 transformed cell line human CVCL_3T03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175321 CVCL_4502 B-63 cancer cell line house mouse CVCL_4502 CL:0000010 Breed/subspecies: C3H. Discontinued: ATCC; CRL-6326; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175322 CVCL_3T02 HQ01834 transformed cell line human CVCL_3T02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175323 CVCL_4501 AE-2 hybridoma house mouse CVCL_4501 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. 21175324 CVCL_3T01 HQ01833 transformed cell line human CVCL_3T01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175325 CVCL_4500 AE-1 hybridoma house mouse CVCL_4500 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. 21175326 CVCL_3T00 HQ01832 transformed cell line human CVCL_3T00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175327 CVCL_4507 BBM.1 clone E9 hybridoma house mouse CVCL_4507 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21175328 CVCL_3T07 HQ01840 transformed cell line human CVCL_3T07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175329 CVCL_4506 BBM.1 hybridoma house mouse CVCL_4506 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P61769; Human B2M. 21175330 CVCL_3T06 HQ01839 transformed cell line human CVCL_3T06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175331 CVCL_3T05 HQ01838 transformed cell line human CVCL_3T05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175332 CVCL_4504 MCA B69 hybridoma house mouse CVCL_4504 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Infectious bursal disease virus (IBDV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9437 21175333 CVCL_3T04 HQ01837 transformed cell line human CVCL_3T04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175334 CVCL_4509 BS/BEK finite cell line CVCL_4509 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21175335 CVCL_3T09 HQ01842 transformed cell line human CVCL_3T09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175336 CVCL_4508 BNL SV A.8 transformed cell line house mouse CVCL_4508 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175337 CVCL_3T08 HQ01841 transformed cell line human CVCL_3T08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175338 CVCL_VZ40 ShZ08 finite cell line CVCL_VZ40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Female 21175339 CVCL_VZ44 ShB03 finite cell line CVCL_VZ44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175340 CVCL_VZ43 ShB02 finite cell line CVCL_VZ43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175341 CVCL_VZ42 ShZ10 finite cell line CVCL_VZ42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Female 21175342 CVCL_VZ41 ShZ09 finite cell line CVCL_VZ41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Female 21175343 CVCL_VZ48 ShB07 finite cell line CVCL_VZ48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175344 CVCL_VZ47 ShB06 finite cell line CVCL_VZ47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Male 21175345 CVCL_VZ46 ShB05 finite cell line CVCL_VZ46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175346 CVCL_VZ45 ShB04 finite cell line CVCL_VZ45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Female 21175347 CVCL_VZ49 ShB08 finite cell line CVCL_VZ49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Baluchi. Male 21175348 CVCL_4510 C1300 CLONE NA cancer cell line house mouse CVCL_4510 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: A/J. Male 21175349 CVCL_3T10 HQ01843 transformed cell line human CVCL_3T10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175350 CVCL_4514 CVC.4 hybridoma house mouse CVCL_4514 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04973; Bovine CLTA. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175351 CVCL_3T14 HQ01848 transformed cell line human CVCL_3T14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175352 CVCL_4513 CVC.1 hybridoma house mouse CVCL_4513 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04973; Bovine CLTA. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175353 CVCL_3T13 HQ01847 transformed cell line human CVCL_3T13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175354 CVCL_4512 Clone M-3 cancer cell line house mouse CVCL_4512 CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33596583); Breed/subspecies: DBA. Omics: Array-based CGH Discontinued: RCB; RCB2616; true; Discontinued: TKG; TKG 0554; probable Male 21175355 CVCL_3T12 HQ01845 transformed cell line human CVCL_3T12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175356 CVCL_4511 C17.2 transformed cell line house mouse CVCL_4511 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Brain; cerebellum Cell type=Neural progenitor cell.; Breed/subspecies: C57BL/6 x CD-1. Unspecified 21175357 CVCL_3T11 HQ01844 transformed cell line human CVCL_3T11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175358 CVCL_4518 ECTC spontaneously immortalized cell line green monkey CVCL_4518 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00190 Problematic cell line: Misidentified/contaminated Originally thought to be of bovine origin but found to be a monkey Vero derivative (PubMed=14505435; PubMed=20143388). 21175359 CVCL_3T18 HQ01853 transformed cell line human CVCL_3T18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175360 CVCL_4517 DB1.Tes finite cell line CVCL_4517 CL:0000010 Derived from sampling site: Testis. Discontinued: ATCC; CRL-6258; true Male Group: Cetacean cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175361 CVCL_3T17 HQ01852 transformed cell line human CVCL_3T17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175362 CVCL_4516 DB9G8 hybridoma house mouse CVCL_4516 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01317; Bovine INS (Note=Also reacts with other species including human). 21175363 CVCL_3T16 HQ01851 transformed cell line human CVCL_3T16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175364 CVCL_4515 CVC.7 hybridoma house mouse CVCL_4515 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04973; Bovine CLTA. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175365 CVCL_3T15 HQ01849 transformed cell line human CVCL_3T15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175366 CVCL_4519 EIAV 12E8.1 hybridoma house mouse CVCL_4519 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P69732; Equine infectious anemia virus (strain Wyoming) gag (AA 125-354; p26). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8917 21175367 CVCL_3T19 HQ01854 transformed cell line human CVCL_3T19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175368 CVCL_VZ33 ShZ01 finite cell line CVCL_VZ33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Male 21175369 CVCL_VZ32 ShM9 finite cell line CVCL_VZ32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175370 CVCL_VZ31 ShM8 finite cell line CVCL_VZ31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175371 CVCL_VZ30 ShM7 finite cell line CVCL_VZ30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175372 CVCL_VZ37 ShZ05 finite cell line CVCL_VZ37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Male 21175373 CVCL_NA99 BayGenomics ES cell line RRJ244 embryonic stem cell house mouse CVCL_NA99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347094; Parg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175374 CVCL_VZ36 ShZ04 finite cell line CVCL_VZ36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Male 21175375 CVCL_NA98 BayGenomics ES cell line RRJ243 embryonic stem cell house mouse CVCL_NA98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136940; Pias4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175376 CVCL_VZ35 ShZ03 finite cell line CVCL_VZ35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Male 21175377 CVCL_NA97 BayGenomics ES cell line RRJ237 embryonic stem cell house mouse CVCL_NA97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108109; Ywhag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175378 CVCL_VZ34 ShZ02 finite cell line CVCL_VZ34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Male 21175379 CVCL_NA96 BayGenomics ES cell line RRJ236 embryonic stem cell house mouse CVCL_NA96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175380 CVCL_NA95 BayGenomics ES cell line RRJ235 embryonic stem cell house mouse CVCL_NA95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338068; Pdpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175381 CVCL_NA94 BayGenomics ES cell line RRJ234 embryonic stem cell house mouse CVCL_NA94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915443; Rpl24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175382 CVCL_VZ39 ShZ07 finite cell line CVCL_VZ39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Female 21175383 CVCL_NA93 BayGenomics ES cell line RRJ233 embryonic stem cell house mouse CVCL_NA93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445110; Zdhhc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175384 CVCL_VZ38 ShZ06 finite cell line CVCL_VZ38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Zandi. Female 21175385 CVCL_NA92 BayGenomics ES cell line RRJ227 embryonic stem cell house mouse CVCL_NA92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175386 CVCL_NA91 BayGenomics ES cell line RRJ226 embryonic stem cell house mouse CVCL_NA91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175387 CVCL_NA90 BayGenomics ES cell line RRJ225 embryonic stem cell house mouse CVCL_NA90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151054; Cnnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175388 CVCL_VZ22 ShM13 finite cell line CVCL_VZ22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175389 CVCL_VZ21 ShM12 finite cell line CVCL_VZ21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175390 CVCL_VZ20 ShM11 finite cell line CVCL_VZ20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175391 CVCL_VZ26 ShM3 finite cell line CVCL_VZ26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Male 21175392 CVCL_VZ25 ShM2 finite cell line CVCL_VZ25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175393 CVCL_VZ24 ShM15 finite cell line CVCL_VZ24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175394 CVCL_VZ23 ShM14 finite cell line CVCL_VZ23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175395 CVCL_VZ29 ShM6 finite cell line CVCL_VZ29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175396 CVCL_VZ28 ShM5 finite cell line CVCL_VZ28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Male 21175397 CVCL_VZ27 ShM4 finite cell line CVCL_VZ27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175398 CVCL_VZ11 ShLb03 finite cell line CVCL_VZ11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Female 21175399 CVCL_VZ10 ShLb02 finite cell line CVCL_VZ10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Female 21175400 CVCL_NA79 BayGenomics ES cell line RRJ198 embryonic stem cell house mouse CVCL_NA79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916979; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175401 CVCL_NA78 BayGenomics ES cell line RRJ187 embryonic stem cell house mouse CVCL_NA78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99919; Vcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175402 CVCL_VZ15 ShLb07 finite cell line CVCL_VZ15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Male 21175403 CVCL_NA77 BayGenomics ES cell line RRJ186 embryonic stem cell house mouse CVCL_NA77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2674092; Zfp609 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175404 CVCL_VZ14 ShLb06 finite cell line CVCL_VZ14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Male 21175405 CVCL_NA76 BayGenomics ES cell line RRJ171 embryonic stem cell house mouse CVCL_NA76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919358; Ddhd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175406 CVCL_VZ13 ShLb05 finite cell line CVCL_VZ13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Female 21175407 CVCL_NA75 BayGenomics ES cell line RRJ168 embryonic stem cell house mouse CVCL_NA75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914323; Pi4k2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175408 CVCL_VZ12 ShLb04 finite cell line CVCL_VZ12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Male 21175409 CVCL_NA74 BayGenomics ES cell line RRJ167 embryonic stem cell house mouse CVCL_NA74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915848; Dnajc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175410 CVCL_VZ19 ShM10 finite cell line CVCL_VZ19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175411 CVCL_NA73 BayGenomics ES cell line RRJ165 embryonic stem cell house mouse CVCL_NA73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916376; Rbis Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175412 CVCL_VZ18 ShM1 finite cell line CVCL_VZ18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Mehrabani. Female 21175413 CVCL_NA72 BayGenomics ES cell line RRJ163 embryonic stem cell house mouse CVCL_NA72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175414 CVCL_VZ17 ShLb09 finite cell line CVCL_VZ17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Female 21175415 CVCL_NA71 BayGenomics ES cell line RRJ162 embryonic stem cell house mouse CVCL_NA71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175416 CVCL_VZ16 ShLb08 finite cell line CVCL_VZ16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Male 21175417 CVCL_NA70 BayGenomics ES cell line RRJ159 embryonic stem cell house mouse CVCL_NA70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913964; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175418 CVCL_VZ00 MoOV-47 finite cell line CVCL_VZ00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175419 CVCL_NA89 BayGenomics ES cell line RRJ223 embryonic stem cell house mouse CVCL_NA89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175420 CVCL_VZ04 MoOV-51 finite cell line CVCL_VZ04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175421 CVCL_NA88 BayGenomics ES cell line RRJ221 embryonic stem cell house mouse CVCL_NA88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151172; Mta3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175422 CVCL_VZ03 MoOV-50 finite cell line CVCL_VZ03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175423 CVCL_NA87 BayGenomics ES cell line RRJ220 embryonic stem cell house mouse CVCL_NA87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175424 CVCL_VZ02 MoOV-49 finite cell line CVCL_VZ02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175425 CVCL_NA86 BayGenomics ES cell line RRJ217 embryonic stem cell house mouse CVCL_NA86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917678; Polr3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175426 CVCL_VZ01 MoOV-48 finite cell line CVCL_VZ01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175427 CVCL_NA85 BayGenomics ES cell line RRJ216 embryonic stem cell house mouse CVCL_NA85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306824; Suclg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175428 CVCL_VZ08 MoOV-54 finite cell line CVCL_VZ08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175429 CVCL_NA84 BayGenomics ES cell line RRJ209 embryonic stem cell house mouse CVCL_NA84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175430 CVCL_VZ07 MoOV-53 finite cell line CVCL_VZ07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175431 CVCL_NA83 BayGenomics ES cell line RRJ208 embryonic stem cell house mouse CVCL_NA83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175432 CVCL_VZ06 MoOV-55 finite cell line CVCL_VZ06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Male 21175433 CVCL_NA82 BayGenomics ES cell line RRJ207 embryonic stem cell house mouse CVCL_NA82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353499; Baz1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175434 CVCL_VZ05 MoOV-52 finite cell line CVCL_VZ05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Moghani. Female 21175435 CVCL_NA81 BayGenomics ES cell line RRJ203 embryonic stem cell house mouse CVCL_NA81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175436 CVCL_NA80 BayGenomics ES cell line RRJ200 embryonic stem cell house mouse CVCL_NA80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145245; Srek1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175437 CVCL_VZ09 ShLb01 finite cell line CVCL_VZ09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Lori-Bakhtiari. Male 21175438 CVCL_3T90 HQ01928 transformed cell line human CVCL_3T90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175439 CVCL_4590 pgsB-618 spontaneously immortalized cell line CVCL_4590 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in beta-1,4-galactosyltransferase 7 activity 21175440 CVCL_3T94 HQ01932 transformed cell line human CVCL_3T94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175441 CVCL_4594 pgsE-606 spontaneously immortalized cell line CVCL_4594 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Partially deficient in heparin sulfate N sulfotransferase Lacks expression of NDST1. 21175442 CVCL_3T93 HQ01931 transformed cell line human CVCL_3T93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175443 CVCL_4593 pgsD-677 spontaneously immortalized cell line CVCL_4593 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Lacks both N-acetylglucosaminyltransferase and glucuronyltransferase activities that are required for synthesis of heparan sulfate 21175444 CVCL_3T92 HQ01930 transformed cell line human CVCL_3T92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175445 CVCL_4592 pgsC-605 spontaneously immortalized cell line CVCL_4592 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in sulfate transporter 21175446 CVCL_3T91 HQ01929 transformed cell line human CVCL_3T91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175447 CVCL_4591 pgsB-650 spontaneously immortalized cell line CVCL_4591 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in galactosyltransferase 1 activity 21175448 CVCL_3T87 HQ01925 transformed cell line human CVCL_3T87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175449 CVCL_4587 LA 3-5 spontaneously immortalized cell line CVCL_4587 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10101 21175450 CVCL_4586 5A-HS-MYC spontaneously immortalized cell line CVCL_4586 CL:0000010 Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9010 Caution: ATCC CRL-9010 use DUKX B1 as the name of the cell line which is a misspelling of the parent cell line from Patent=EP0232845A2 21175451 CVCL_3T86 HQ01924 transformed cell line human CVCL_3T86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175452 CVCL_4585 CHL/IU spontaneously immortalized cell line CVCL_4585 CL:0000010 Derived from sampling site: Lung. Female Characteristics: Useful for screening chemical for ability to induce chromosomal aberrations (ATCC) Doubling time: 15 hours (ATCC=CRL-1935) 21175453 CVCL_3T85 HQ01923 transformed cell line human CVCL_3T85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175454 CVCL_4584 B14FAF28-G3 transformed cell line CVCL_4584 CL:0000010 Derived from sampling site: Peritoneum Cell type=Fibroblast.. Discontinued: ECACC; 91010302; probable Female 21175455 CVCL_3T84 HQ01922 transformed cell line human CVCL_3T84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175456 CVCL_3T89 HQ01927 transformed cell line human CVCL_3T89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175457 CVCL_4589 pgsA-745 spontaneously immortalized cell line CVCL_4589 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Deficient in xylosyltransferase Does not produce glycosaminoglycans. 21175458 CVCL_3T88 HQ01926 transformed cell line human CVCL_3T88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175459 CVCL_4588 MC2/3 hybrid cell line house mouse CVCL_4588 CL:0000010 21175460 CVCL_3T98 HQ01936 transformed cell line human CVCL_3T98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175461 CVCL_4598 UV41 transformed cell line CVCL_4598 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21175462 CVCL_3T97 HQ01935 transformed cell line human CVCL_3T97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175463 CVCL_4597 UV24 transformed cell line CVCL_4597 CL:0000010 Sequence variation: Mutation; UniProtKB; A0MQ57; Ercc3; Simple; p.Ser382Pro (c.1144T>C); Zygosity=Unspecified (PubMed=16143348); Sequence variation: Mutation; UniProtKB; A0MQ57; Ercc3; Simple; p.Gln739Ter (c.2215C>T); Zygosity=Unspecified (PubMed=16143348) Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21175464 CVCL_3T96 HQ01934 transformed cell line human CVCL_3T96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175465 CVCL_4596 UV20 transformed cell line CVCL_4596 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21175466 CVCL_3T95 HQ01933 transformed cell line human CVCL_3T95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175467 CVCL_4595 UV135 transformed cell line CVCL_4595 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21175468 CVCL_3T99 HQ01937 transformed cell line human CVCL_3T99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175469 CVCL_4599 UV5 transformed cell line CVCL_4599 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Ovary. Female 21175470 CVCL_4572 COLO 60H cancer cell line human CVCL_4572 HLA typing: A*02:01 (CLS=300456) CL:0000010 Derived from sampling site: Colon; transverse. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21175471 CVCL_3T72 HQ01909 transformed cell line human CVCL_3T72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175472 CVCL_3T71 HQ01908 transformed cell line human CVCL_3T71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175473 CVCL_4571 MA-CLS-2 cancer cell line human CVCL_4571 CL:0000010 Derived from metastatic site: Pleural effusion. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175474 CVCL_3T70 HQ01907 transformed cell line human CVCL_3T70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175475 CVCL_4570 T406 [Human glioblastoma] cancer cell line human CVCL_4570 CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Male 21175476 CVCL_4565 BRL spontaneously immortalized cell line Norway rat CVCL_4565 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Buffalo. 21175477 CVCL_3T65 HQ01901 transformed cell line human CVCL_3T65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175478 CVCL_4564 A8 spontaneously immortalized cell line African clawed frog CVCL_4564 CL:0000010 Derived from sampling site: Liver. Female Group: Amphibian cell line 21175479 CVCL_3T64 HQ01900 transformed cell line human CVCL_3T64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175480 CVCL_4563 3Y1-B clone 1 spontaneously immortalized cell line Norway rat CVCL_4563 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21175481 CVCL_3T63 HQ01899 transformed cell line human CVCL_3T63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175482 CVCL_3T62 HQ01898 transformed cell line human CVCL_3T62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175483 CVCL_4562 PAb 1400 hybridoma house mouse CVCL_4562 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21175484 CVCL_3T69 HQ01906 transformed cell line human CVCL_3T69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175485 CVCL_4569 SK-N-LO cancer cell line human CVCL_4569 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=7591257) Derived from metastatic site: Bone marrow. Male Caution: It is not certain if this is a neuroblastoma cell line as indicated by CLS or an Ewing sarcoma cell line as indicated in PubMed=7591257 21175486 CVCL_4568 CCP-8 transformed cell line CVCL_4568 CL:0000010 Transformant: Coculture with X-ray irradiated hamster chondrocytes; Derived from sampling site: Bone marrow. Unspecified 21175487 CVCL_3T68 HQ01905 transformed cell line human CVCL_3T68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175488 CVCL_4567 CCP-7 transformed cell line CVCL_4567 CL:0000010 Transformant: Coculture with X-ray irradiated hamster chondrocytes; Derived from sampling site: Bone marrow. Unspecified 21175489 CVCL_3T67 HQ01904 transformed cell line human CVCL_3T67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175490 CVCL_4566 CCP-2 transformed cell line CVCL_4566 CL:0000010 Transformant: Coculture with X-ray irradiated hamster chondrocytes; Derived from sampling site: Bone marrow. Unspecified 21175491 CVCL_3T66 HQ01903 transformed cell line human CVCL_3T66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175492 CVCL_4583 B13-24 transformed cell line CVCL_4583 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with Ig heavy and light chain of humanized version of mAB produced by hybridoma 23F2g (Cellosaurus=CVCL_4W87) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11397 21175493 CVCL_3T83 HQ01921 transformed cell line human CVCL_3T83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175494 CVCL_4582 6E6 [Hamster mAB-producing] transformed cell line CVCL_4582 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Transfected with Ig heavy and light chains of humanized version of mAB produced by hybridoma 23F2g (Cellosaurus=CVCL_4W87) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11398 21175495 CVCL_3T82 HQ01920 transformed cell line human CVCL_3T82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175496 CVCL_3T81 HQ01919 transformed cell line human CVCL_3T81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175497 CVCL_4581 M3WT8 spontaneously immortalized cell line CVCL_4581 CL:0000010 Transfected with: RGD; 2343; Chrm3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21175498 CVCL_3T80 HQ01918 transformed cell line human CVCL_3T80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175499 CVCL_4580 M3WT5 spontaneously immortalized cell line CVCL_4580 CL:0000010 Transfected with: RGD; 2343; Chrm3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21175500 CVCL_4576 Anr9-1 transformed cell line Norway rat CVCL_4576 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/DuCrj. Male 21175501 CVCL_3T76 HQ01913 transformed cell line human CVCL_3T76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175502 CVCL_4575 Anr13-1 transformed cell line Norway rat CVCL_4575 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/DuCrj. Male 21175503 CVCL_3T75 HQ01912 transformed cell line human CVCL_3T75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175504 CVCL_4574 CX-2 cancer cell line human CVCL_4574 CL:0000010 Population: Caucasian; Derived from sampling site: Colon. Discontinued: CLS; 300160; true Unspecified 21175505 CVCL_3T74 HQ01911 transformed cell line human CVCL_3T74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175506 CVCL_4573 COLO 94H cancer cell line human CVCL_4573 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) 21175507 CVCL_3T73 HQ01910 transformed cell line human CVCL_3T73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175508 CVCL_3T79 HQ01917 transformed cell line human CVCL_3T79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175509 CVCL_4579 M3WT4 spontaneously immortalized cell line CVCL_4579 CL:0000010 Transfected with: RGD; 2343; Chrm3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21175510 CVCL_4578 3T3-MSV spontaneously immortalized cell line house mouse CVCL_4578 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21175511 CVCL_3T78 HQ01916 transformed cell line human CVCL_3T78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175512 CVCL_4577 HECA-452 hybridoma CVCL_4577 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:61711; Alpha-Neup5Ac-(2->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-GlcpNAc (Sialyl Lewis X). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11485 21175513 CVCL_3T77 HQ01914 transformed cell line human CVCL_3T77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175514 CVCL_VZ95 CaBa25 finite cell line CVCL_VZ95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175515 CVCL_VZ94 CaBa24 finite cell line CVCL_VZ94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175516 CVCL_VZ93 CaBa23 finite cell line CVCL_VZ93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175517 CVCL_VZ92 CaBa17 finite cell line CVCL_VZ92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175518 CVCL_VZ99 CaBa29 finite cell line CVCL_VZ99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175519 CVCL_VZ98 CaBa28 finite cell line CVCL_VZ98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175520 CVCL_VZ97 CaBa27 finite cell line CVCL_VZ97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175521 CVCL_VZ96 CaBa26 finite cell line CVCL_VZ96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175522 CVCL_3T50 HQ01886 transformed cell line human CVCL_3T50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175523 CVCL_4550 PC 61-5-3 hybridoma CVCL_4550 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01590; Mouse Il2ra/Cd25. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175524 CVCL_3T43 HQ01878 transformed cell line human CVCL_3T43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175525 CVCL_4543 MK-D6 hybridoma house mouse CVCL_4543 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21175526 CVCL_3T42 HQ01877 transformed cell line human CVCL_3T42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175527 CVCL_4542 MDCC-MSB1 cancer cell line CVCL_4542 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain bc-1)(NCBI-Taxonomy; 10387). Female Doubling time: 8-10 hours (PubMed=163334); 13.3 hours (PubMed=3273463); ~10 hours (CLS) Group: Bird cell line 21175528 CVCL_3T41 HQ01876 transformed cell line human CVCL_3T41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175529 CVCL_4541 MDBK-Bu100 spontaneously immortalized cell line CVCL_4541 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Kidney. Male 21175530 CVCL_3T40 HQ01875 transformed cell line human CVCL_3T40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175531 CVCL_4540 MARC-145 spontaneously immortalized cell line CVCL_4540 CL:0000010 Derived from sampling site: Fetal kidney. Omics: Transcriptome analysis by microarray Unspecified Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Non-human primate cell line; Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00621; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12219; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12230 Problematic cell line: Misidentified Parent cell line (MA-104) has been shown to be from African Green monkey instead of Rhesus macaque. 21175532 CVCL_3T47 HQ01883 transformed cell line human CVCL_3T47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175533 CVCL_4547 OHH1.Li finite cell line CVCL_4547 CL:0000010 Derived from sampling site: Liver. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175534 CVCL_3T46 HQ01882 transformed cell line human CVCL_3T46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175535 CVCL_4546 OHH1.K finite cell line CVCL_4546 CL:0000010 Derived from sampling site: Kidney. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175536 CVCL_3T45 HQ01881 transformed cell line human CVCL_3T45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175537 CVCL_4545 NH15-CA2 hybrid cell line CVCL_4545 CL:0000010 21175538 CVCL_3T44 HQ01880 transformed cell line human CVCL_3T44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175539 CVCL_4544 MVPK-1 spontaneously immortalized cell line pig CVCL_4544 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Virology: Susceptible to infection by foot-and-mouth disease virus Loose its susceptibility to infection at 37 Celsius (PubMed=185927). 21175540 CVCL_3T49 HQ01885 transformed cell line human CVCL_3T49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175541 CVCL_4549 P3NP/PFn hybridoma house mouse CVCL_4549 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02751; Human FN1. 21175542 CVCL_3T48 HQ01884 transformed cell line human CVCL_3T48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175543 CVCL_4548 OHH1.Lu finite cell line CVCL_4548 CL:0000010 Derived from sampling site: Lung. Discontinued: ATCC; CRL-6195; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175544 CVCL_VZ84 CaBa06 finite cell line CVCL_VZ84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175545 CVCL_VZ83 CaBa05 finite cell line CVCL_VZ83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175546 CVCL_VZ82 CaBa04 finite cell line CVCL_VZ82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175547 CVCL_VZ81 CaBa03 finite cell line CVCL_VZ81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175548 CVCL_VZ88 CaBa10 finite cell line CVCL_VZ88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175549 CVCL_VZ87 CaBa09 finite cell line CVCL_VZ87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175550 CVCL_VZ86 CaBa08 finite cell line CVCL_VZ86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175551 CVCL_VZ85 CaBa07 finite cell line CVCL_VZ85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175552 CVCL_VZ89 CaBa11 finite cell line CVCL_VZ89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21175553 CVCL_3T61 HQ01897 transformed cell line human CVCL_3T61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175554 CVCL_4561 WEHI-164R cancer cell line house mouse CVCL_4561 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. 21175555 CVCL_3T60 HQ01896 transformed cell line human CVCL_3T60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175556 CVCL_4560 JTC-35 spontaneously immortalized cell line CVCL_4560 CL:0000010 Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21175557 CVCL_3T54 HQ01890 transformed cell line human CVCL_3T54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175558 CVCL_4554 SV-T2 transformed cell line house mouse CVCL_4554 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21175559 CVCL_3T53 HQ01889 transformed cell line human CVCL_3T53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175560 CVCL_4553 RTO spontaneously immortalized cell line CVCL_4553 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21175561 CVCL_3T52 HQ01888 transformed cell line human CVCL_3T52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175562 CVCL_4552 RF/6A spontaneously immortalized cell line CVCL_4552 CL:0000010 Derived from sampling site: Fetal eye; choroid and fetal eye; retina. Omics: Transcriptome analysis by RNAseq Unspecified Group: Non-human primate cell line Problematic cell line: Probably misidentified While originally thought to be an endothelial cell line, it has been shown to lack functional and transcriptomic characteristics of such cell type (PubMed=30508043). 21175563 CVCL_3T51 HQ01887 transformed cell line human CVCL_3T51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175564 CVCL_4551 MCA R63 hybridoma house mouse CVCL_4551 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Infectious bursal disease virus (IBDV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9490 21175565 CVCL_3T58 HQ01894 transformed cell line human CVCL_3T58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175566 CVCL_4558 MCC1 [Human Merkel cell carcinoma] cancer cell line human CVCL_4558 CL:0000010 Female Characteristics: Derived from a xenograft Doubling time: 6 days (PubMed=8244578) Caution: Was briefly displayed in Cell Bank Australia under catalog number CBA-1335 but was never distributed. 21175567 CVCL_3T57 HQ01893 transformed cell line human CVCL_3T57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175568 CVCL_4557 WI-1003 finite cell line human CVCL_4557 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ATCC; CCL-154; true; Discontinued: IZSLER; BS CL 108; probable Female Senescence: Senesces at 8-10 PDL (ATCC=CCL-154) 21175569 CVCL_3T56 HQ01892 transformed cell line human CVCL_3T56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175570 CVCL_4556 WF2 spontaneously immortalized cell line CVCL_4556 CL:0000010 Unspecified Group: Fish cell line. 21175571 CVCL_3T55 HQ01891 transformed cell line human CVCL_3T55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175572 CVCL_4555 WC-1 cancer cell line CVCL_4555 CL:0000010 Unspecified Group: Fish cell line. 21175573 CVCL_3T59 HQ01895 transformed cell line human CVCL_3T59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175574 CVCL_4559 Meta 1 cancer cell line house mouse CVCL_4559 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Meta series of TS/A derived cell lines are obtained from repeated subcutaneous passage of lung metastases in BALB/c female mice 21175575 CVCL_VZ91 CaBa13 finite cell line CVCL_VZ91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175576 CVCL_VZ90 CaBa12 finite cell line CVCL_VZ90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21175577 CVCL_EG39 GM08356 transformed cell line human CVCL_EG39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175578 CVCL_EG38 GM08355 transformed cell line human CVCL_EG38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175579 CVCL_EG37 FLYA-JET cancer cell line human CVCL_EG37 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: MGI; MGI:88117; Slc7a1 Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Retrovirus packaging cell line 21175580 CVCL_EG36 YTS-Eco cancer cell line human CVCL_EG36 CL:0000010 Transfected with: MGI; MGI:88117; Slc7a1 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion Cell type=Natural killer cell.. Male 21175581 CVCL_EG31 JVE528 cancer cell line human CVCL_EG31 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=26894854); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~4 days (DSMZ=ACC-826); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175582 CVCL_EG30 JVE371 cancer cell line human CVCL_EG30 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=26894854) Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~3-5 days (DSMZ=ACC-825); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175583 CVCL_EG35 KP7038T cancer cell line human CVCL_EG35 CL:0000010 Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Instable (MSI-high) (PubMed=26894854) 21175584 CVCL_EG34 KP363T cancer cell line human CVCL_EG34 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=26894854); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: ~50 hours (DSMZ=ACC-808); Microsatellite instability: Stable (MSS) (PubMed=26894854) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175585 CVCL_EG33 KP283T cancer cell line human CVCL_EG33 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=26894854); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=26894854) Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175586 CVCL_EG32 JVE774 cancer cell line human CVCL_EG32 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln22Lys (c.64C>A); ClinVar=VCV000376325; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175587 CVCL_EG49 GM13896 transformed cell line human CVCL_EG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175588 CVCL_EG48 GM13894 transformed cell line human CVCL_EG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175589 CVCL_EG47 CS267BE finite cell line human CVCL_EG47 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21175590 CVCL_EG42 GM11538 transformed cell line human CVCL_EG42 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175591 CVCL_EG41 GM11537 finite cell line human CVCL_EG41 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM11537; probable Female 21175592 CVCL_EG40 GM11536 transformed cell line human CVCL_EG40 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175593 CVCL_EG46 CS267BE LCL transformed cell line human CVCL_EG46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175594 CVCL_EG45 GM11541 finite cell line human CVCL_EG45 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21175595 CVCL_EG44 GM11540 transformed cell line human CVCL_EG44 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175596 CVCL_EG43 GM11539 finite cell line human CVCL_EG43 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM11539; probable Male 21175597 CVCL_EG17 JVE044 cancer cell line human CVCL_EG17 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175598 CVCL_EG16 JVE015 cancer cell line human CVCL_EG16 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Unspecified (PubMed=26894854); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~3-4 days (DSMZ=ACC-786); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175599 CVCL_EG15 MBU-Ts4 transformed cell line human CVCL_EG15 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Karyotypic information: 47,XY,+20 [5]; 46,XY,-13,+20 [3]; 47,XY,-13,+20,+mar [3] (PubMed=27074337); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male Characteristics: Derived from a xenograft produced by injection of the parent cell line in nude mice Doubling time: ~80-100 hours (DSMZ=ACC-801) 21175600 CVCL_EG14 MBU-Ts1 transformed cell line human CVCL_EG14 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Karyotypic information: 47,XY,der(8)t(5;8)(q13;p21),+20 (PubMed=27074337); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Derived from a xenograft produced by injection of the parent cell line in nude mice Doubling time: ~100-140 hours (DSMZ=ACC-800) 21175601 CVCL_EG19 JVE103 cancer cell line human CVCL_EG19 CL:0000010 Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~10-14 days (DSMZ=ACC-807); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175602 CVCL_EG18 JVE059 cancer cell line human CVCL_EG18 CL:0000010 Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: ~3-4 days (DSMZ=ACC-806); Microsatellite instability: Instable (MSI-high) (PubMed=26894854) 21175603 CVCL_EG13 MBU-T transformed cell line human CVCL_EG13 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male Doubling time: ~50-60 hours (DSMZ=ACC-799) 21175604 CVCL_EG12 MBU-IM transformed cell line human CVCL_EG12 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Omics: Transcriptome analysis by microarray Male Doubling time: ~50-60 hours (DSMZ=ACC-796) 21175605 CVCL_EG11 MTD-1A cancer cell line house mouse CVCL_EG11 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: SHN. Female 21175606 CVCL_EG10 MTD-1 cancer cell line house mouse CVCL_EG10 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: SHN. Female 21175607 CVCL_EG28 JVE253 cancer cell line human CVCL_EG28 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=26894854) Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~40 hours (DSMZ=ACC-823); Microsatellite instability: Stable (MSS) (PubMed=26894854) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175608 CVCL_EG27 JVE241 cancer cell line human CVCL_EG27 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: ~8-10 days (DSMZ=ACC-822); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175609 CVCL_EG26 JVE222 cancer cell line human CVCL_EG26 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~70 hours (DSMZ=ACC-821); Microsatellite instability: Instable (MSI-high) (PubMed=26894854) 21175610 CVCL_EG25 JVE207 cancer cell line human CVCL_EG25 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=26894854); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: ~30-50 hours (DSMZ=ACC-820); Microsatellite instability: Stable (MSS) (PubMed=26894854) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175611 CVCL_EG29 JVE367 cancer cell line human CVCL_EG29 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~4-5 days (DSMZ=ACC-829); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175612 CVCL_EG20 JVE109 cancer cell line human CVCL_EG20 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~50 hours (DSMZ=ACC-809); Microsatellite instability: Instable (MSI-high) (PubMed=26894854) 21175613 CVCL_EG24 JVE192 cancer cell line human CVCL_EG24 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Doubling time: ~50 hours (DSMZ=ACC-819); Microsatellite instability: Instable (MSI-high) (PubMed=26894854) 21175614 CVCL_EG23 JVE187 cancer cell line human CVCL_EG23 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys117Asn (c.351A>C); ClinVar=VCV000375965; Zygosity=Unspecified (PubMed=26894854) Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: ~3-5 days (DSMZ=ACC-818); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175615 CVCL_EG22 JVE127 cancer cell line human CVCL_EG22 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=26894854); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26894854) Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: ~2-3 days (DSMZ=ACC-813); Microsatellite instability: Stable (MSS) (PubMed=26894854) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175616 CVCL_EG21 JVE114 cancer cell line human CVCL_EG21 CL:0000010 Derived from metastatic site: Liver. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: ~3-5 days (DSMZ=ACC-812); Microsatellite instability: Stable (MSS) (PubMed=26894854) 21175617 CVCL_EG06 OCC/PI cancer cell line human CVCL_EG06 CL:0000010 Derived from metastatic site: Ascites. Female 21175618 CVCL_EG05 Jurkat R3.25 cancer cell line human CVCL_EG05 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21175619 CVCL_EG04 GM03131 finite cell line human CVCL_EG04 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21175620 CVCL_EG03 GM23295 transformed cell line human CVCL_EG03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175621 CVCL_EG09 HUCB-NSC somatic stem cell human CVCL_EG09 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Neural stem cell.. Male 21175622 CVCL_EG08 HS181-GFP embryonic stem cell human CVCL_EG08 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female 21175623 CVCL_EG07 OCC/PII cancer cell line human CVCL_EG07 CL:0000010 Derived from metastatic site: Ascites. Female 21175624 CVCL_EG02 GM22006 transformed cell line human CVCL_EG02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175625 CVCL_EG01 GM21655 transformed cell line human CVCL_EG01 CL:0000010 Sequence variation: Mutation; HGNC; 30794; CEP57; Simple; p.Glu174Thrfs*4 (c.518_519GA[1]) (c.520_521delGA); ClinVar=VCV000030690; Zygosity=Heterozygous (PubMed=30804344); Sequence variation: Mutation; HGNC; 30794; CEP57; Simple; p.Leu309Profs*9 (c.915_925dup11) (p.His317fs); ClinVar=VCV000030691; Zygosity=Heterozygous (PubMed=30804344) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175626 CVCL_EG00 GM21654 transformed cell line human CVCL_EG00 CL:0000010 Sequence variation: Mutation; HGNC; 30794; CEP57; Simple; p.Glu174Thrfs*4 (c.518_519GA[1]) (c.520_521delGA); ClinVar=VCV000030690; Zygosity=Heterozygous (PubMed=30804344); Sequence variation: Mutation; HGNC; 30794; CEP57; Simple; p.Leu309Profs*9 (c.915_925dup11) (p.His317fs); ClinVar=VCV000030691; Zygosity=Heterozygous (PubMed=30804344) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175627 CVCL_NA59 BayGenomics ES cell line RRJ140 embryonic stem cell house mouse CVCL_NA59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88529; Cs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175628 CVCL_NA58 BayGenomics ES cell line RRJ139 embryonic stem cell house mouse CVCL_NA58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175629 CVCL_NA57 BayGenomics ES cell line RRJ138 embryonic stem cell house mouse CVCL_NA57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443882; Snx30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175630 CVCL_NA56 BayGenomics ES cell line RRJ136 embryonic stem cell house mouse CVCL_NA56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921409; Acbd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175631 CVCL_NA55 BayGenomics ES cell line RRJ135 embryonic stem cell house mouse CVCL_NA55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916400; Snx4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175632 CVCL_NA54 BayGenomics ES cell line RRJ129 embryonic stem cell house mouse CVCL_NA54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175633 CVCL_NA53 BayGenomics ES cell line RRJ128 embryonic stem cell house mouse CVCL_NA53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891691; Arpp19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175634 CVCL_NA52 BayGenomics ES cell line RRJ126 embryonic stem cell house mouse CVCL_NA52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175635 CVCL_NA51 BayGenomics ES cell line RRJ120 embryonic stem cell house mouse CVCL_NA51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175636 CVCL_NA50 BayGenomics ES cell line RRJ119 embryonic stem cell house mouse CVCL_NA50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339975; Pak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175637 CVCL_NA69 BayGenomics ES cell line RRJ158 embryonic stem cell house mouse CVCL_NA69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201691; Rnf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175638 CVCL_NA68 BayGenomics ES cell line RRJ157 embryonic stem cell house mouse CVCL_NA68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858964; Actr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175639 CVCL_NA67 BayGenomics ES cell line RRJ156 embryonic stem cell house mouse CVCL_NA67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175640 CVCL_NA66 BayGenomics ES cell line RRJ155 embryonic stem cell house mouse CVCL_NA66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175641 CVCL_NA65 BayGenomics ES cell line RRJ153 embryonic stem cell house mouse CVCL_NA65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917294; Tut1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175642 CVCL_NA64 BayGenomics ES cell line RRJ147 embryonic stem cell house mouse CVCL_NA64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138281; Lbr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175643 CVCL_NA63 BayGenomics ES cell line RRJ146 embryonic stem cell house mouse CVCL_NA63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175644 CVCL_NA62 BayGenomics ES cell line RRJ143 embryonic stem cell house mouse CVCL_NA62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175645 CVCL_NA61 BayGenomics ES cell line RRJ142 embryonic stem cell house mouse CVCL_NA61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891295; Ube3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175646 CVCL_NA60 BayGenomics ES cell line RRJ141 embryonic stem cell house mouse CVCL_NA60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2651874; Sesn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175647 CVCL_NA39 BayGenomics ES cell line RRJ097 embryonic stem cell house mouse CVCL_NA39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914743; Mettl16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175648 CVCL_NA38 BayGenomics ES cell line RRJ096 embryonic stem cell house mouse CVCL_NA38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98180; Rrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175649 CVCL_NA37 BayGenomics ES cell line RRJ094 embryonic stem cell house mouse CVCL_NA37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914988; Ppid Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175650 CVCL_NA36 BayGenomics ES cell line RRJ088 embryonic stem cell house mouse CVCL_NA36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152414; Ipo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175651 CVCL_NA35 BayGenomics ES cell line RRJ087 embryonic stem cell house mouse CVCL_NA35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175652 CVCL_NA34 BayGenomics ES cell line RRJ084 embryonic stem cell house mouse CVCL_NA34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175653 CVCL_NA33 BayGenomics ES cell line RRJ083 embryonic stem cell house mouse CVCL_NA33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146468; Urb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175654 CVCL_NA32 BayGenomics ES cell line RRJ081 embryonic stem cell house mouse CVCL_NA32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107901; Nfyc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175655 CVCL_NA31 BayGenomics ES cell line RRJ079 embryonic stem cell house mouse CVCL_NA31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175656 CVCL_NA30 BayGenomics ES cell line RRJ077 embryonic stem cell house mouse CVCL_NA30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339951; Cse1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175657 CVCL_EG97 LSJ-1 embryonic stem cell human CVCL_EG97 From: Stanford University Center for Human Embryonic Stem Cell Research and Education; Stanford; USA. CL:0000010 Female 21175658 CVCL_EG96 CSES49 embryonic stem cell human CVCL_EG96 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175659 CVCL_EG95 CSES48 embryonic stem cell human CVCL_EG95 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175660 CVCL_EG94 CSES47 embryonic stem cell human CVCL_EG94 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175661 CVCL_EG99 LSJ-3 embryonic stem cell human CVCL_EG99 From: Stanford University Center for Human Embryonic Stem Cell Research and Education; Stanford; USA. CL:0000010 Unspecified 21175662 CVCL_EG98 LSJ-2 embryonic stem cell human CVCL_EG98 From: Stanford University Center for Human Embryonic Stem Cell Research and Education; Stanford; USA. CL:0000010 Female 21175663 CVCL_NA49 BayGenomics ES cell line RRJ117 embryonic stem cell house mouse CVCL_NA49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103241; Slk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175664 CVCL_NA48 BayGenomics ES cell line RRJ115 embryonic stem cell house mouse CVCL_NA48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930751; Trpc4ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175665 CVCL_NA47 BayGenomics ES cell line RRJ114 embryonic stem cell house mouse CVCL_NA47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917672; Ints2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175666 CVCL_NA46 BayGenomics ES cell line RRJ110 embryonic stem cell house mouse CVCL_NA46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175667 CVCL_NA45 BayGenomics ES cell line RRJ107 embryonic stem cell house mouse CVCL_NA45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442117; Pogz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175668 CVCL_NA44 BayGenomics ES cell line RRJ104 embryonic stem cell house mouse CVCL_NA44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175669 CVCL_NA43 BayGenomics ES cell line RRJ103 embryonic stem cell house mouse CVCL_NA43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139354; Arfgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175670 CVCL_NA42 BayGenomics ES cell line RRJ102 embryonic stem cell house mouse CVCL_NA42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913976; Nipbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175671 CVCL_NA41 BayGenomics ES cell line RRJ099 embryonic stem cell house mouse CVCL_NA41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858910; Jmjd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175672 CVCL_NA40 BayGenomics ES cell line RRJ098 embryonic stem cell house mouse CVCL_NA40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332238; Bcl7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175673 CVCL_NA19 BayGenomics ES cell line RRJ055 embryonic stem cell house mouse CVCL_NA19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96013; Hat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175674 CVCL_NA18 BayGenomics ES cell line RRJ054 embryonic stem cell house mouse CVCL_NA18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913368; Sarnp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175675 CVCL_NA17 BayGenomics ES cell line RRJ050 embryonic stem cell house mouse CVCL_NA17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927344; Gmnn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175676 CVCL_NA16 BayGenomics ES cell line RRJ049 embryonic stem cell house mouse CVCL_NA16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175677 CVCL_EG82 CSES31 embryonic stem cell human CVCL_EG82 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175678 CVCL_NA15 BayGenomics ES cell line RRJ047 embryonic stem cell house mouse CVCL_NA15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175679 CVCL_EG81 CSES30 embryonic stem cell human CVCL_EG81 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175680 CVCL_NA14 BayGenomics ES cell line RRJ045 embryonic stem cell house mouse CVCL_NA14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175681 CVCL_EG80 CSES29 embryonic stem cell human CVCL_EG80 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175682 CVCL_NA13 BayGenomics ES cell line RRJ043 embryonic stem cell house mouse CVCL_NA13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919318; Cnot2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175683 CVCL_NA12 BayGenomics ES cell line RRJ041 embryonic stem cell house mouse CVCL_NA12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175684 CVCL_NA11 BayGenomics ES cell line RRJ040 embryonic stem cell house mouse CVCL_NA11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175685 CVCL_NA10 BayGenomics ES cell line RRJ039 embryonic stem cell house mouse CVCL_NA10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921502; Armc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175686 CVCL_EG75 CSES26 embryonic stem cell human CVCL_EG75 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Male 21175687 CVCL_EG74 GM10441 transformed cell line human CVCL_EG74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175688 CVCL_EG73 GM10440 transformed cell line human CVCL_EG73 CL:0000010 Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Pro305Thr (c.913C>A); ClinVar=VCV000029842; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175689 CVCL_EG72 GM10439 finite cell line human CVCL_EG72 CL:0000010 Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Pro305Thr (c.913C>A); ClinVar=VCV000029842; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Placenta Cell type=Fibroblast.. Female 21175690 CVCL_EG79 CSES28 embryonic stem cell human CVCL_EG79 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175691 CVCL_EG78 CSES27 embryonic stem cell human CVCL_EG78 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175692 CVCL_EG77 CSES45 embryonic stem cell human CVCL_EG77 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female 21175693 CVCL_EG76 CSES32 embryonic stem cell human CVCL_EG76 From: Cedars-Sinai Medical Center; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Female 21175694 CVCL_NA29 BayGenomics ES cell line RRJ074 embryonic stem cell house mouse CVCL_NA29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923036; Ckap5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175695 CVCL_NA28 BayGenomics ES cell line RRJ072 embryonic stem cell house mouse CVCL_NA28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107167; Tfdp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175696 CVCL_NA27 BayGenomics ES cell line RRJ068 embryonic stem cell house mouse CVCL_NA27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99638; Mark2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175697 CVCL_EG93 CSES46 embryonic stem cell human CVCL_EG93 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175698 CVCL_NA26 BayGenomics ES cell line RRJ067 embryonic stem cell house mouse CVCL_NA26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926790; Fzr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175699 CVCL_EG92 CSES44 embryonic stem cell human CVCL_EG92 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175700 CVCL_NA25 BayGenomics ES cell line RRJ066 embryonic stem cell house mouse CVCL_NA25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109530; E4f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175701 CVCL_EG91 CSES43 embryonic stem cell human CVCL_EG91 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175702 CVCL_NA24 BayGenomics ES cell line RRJ065 embryonic stem cell house mouse CVCL_NA24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261437; Atp5c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175703 CVCL_EG90 CSES42 embryonic stem cell human CVCL_EG90 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175704 CVCL_NA23 BayGenomics ES cell line RRJ064 embryonic stem cell house mouse CVCL_NA23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913393; Eef1e1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175705 CVCL_NA22 BayGenomics ES cell line RRJ063 embryonic stem cell house mouse CVCL_NA22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175706 CVCL_NA21 BayGenomics ES cell line RRJ062 embryonic stem cell house mouse CVCL_NA21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915455; Urm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175707 CVCL_NA20 BayGenomics ES cell line RRJ061 embryonic stem cell house mouse CVCL_NA20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175708 CVCL_EG86 CSES36 embryonic stem cell human CVCL_EG86 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175709 CVCL_EG85 CSES35 embryonic stem cell human CVCL_EG85 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175710 CVCL_EG84 CSES34 embryonic stem cell human CVCL_EG84 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175711 CVCL_EG83 CSES33 embryonic stem cell human CVCL_EG83 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175712 CVCL_EG89 CSES41 embryonic stem cell human CVCL_EG89 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Female 21175713 CVCL_EG88 CSES40 embryonic stem cell human CVCL_EG88 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175714 CVCL_EG87 CSES37 embryonic stem cell human CVCL_EG87 From: Cedars-Sinai Medical Center; Los Angeles; USA. CL:0000010 Male 21175715 CVCL_EG60 pREP4 cont/CHO-S #5/sf spontaneously immortalized cell line CVCL_EG60 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21175716 CVCL_EG59 LSP.M2 cancer cell line human CVCL_EG59 From: Boyd A.; Queensland Institute of Medical Research; Brisbane; Australia. CL:0000010 21175717 CVCL_EG58 FaDu/T cancer cell line human CVCL_EG58 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line) Population: Indian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Pharynx; hypopharynx. Male 21175718 CVCL_EG53 GM50332 finite cell line human CVCL_EG53 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21175719 CVCL_EG52 GM22604 transformed cell line human CVCL_EG52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175720 CVCL_EG51 CS210BE finite cell line human CVCL_EG51 CL:0000010 Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21175721 CVCL_EG50 GM14589 transformed cell line human CVCL_EG50 CL:0000010 Population: Peruvian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175722 CVCL_EG57 INS-1 832/1 cancer cell line Norway rat CVCL_EG57 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21175723 CVCL_EG56 INS-1 832/2 cancer cell line Norway rat CVCL_EG56 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male 21175724 CVCL_EG55 MCF7-TamR cancer cell line human CVCL_EG55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: Deep phosphoproteome analysis Female 21175725 CVCL_EG54 GM50333 finite cell line human CVCL_EG54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21175726 CVCL_NA09 BayGenomics ES cell line RRJ033 embryonic stem cell house mouse CVCL_NA09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175727 CVCL_NA08 BayGenomics ES cell line RRJ031 embryonic stem cell house mouse CVCL_NA08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918000; Kdsr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175728 CVCL_NA07 BayGenomics ES cell line RRJ030 embryonic stem cell house mouse CVCL_NA07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175729 CVCL_NA06 BayGenomics ES cell line RRJ029 embryonic stem cell house mouse CVCL_NA06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889023; Banp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175730 CVCL_NA05 BayGenomics ES cell line RRJ028 embryonic stem cell house mouse CVCL_NA05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930768; Arid3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175731 CVCL_EG71 GM10408 finite cell line human CVCL_EG71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21175732 CVCL_NA04 BayGenomics ES cell line RRJ027 embryonic stem cell house mouse CVCL_NA04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101771; Sntb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175733 CVCL_EG70 GM10392 finite cell line human CVCL_EG70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21175734 CVCL_NA03 BayGenomics ES cell line RRJ026 embryonic stem cell house mouse CVCL_NA03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328306; Orc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175735 CVCL_NA02 BayGenomics ES cell line RRJ025 embryonic stem cell house mouse CVCL_NA02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175736 CVCL_NA01 BayGenomics ES cell line RRJ023 embryonic stem cell house mouse CVCL_NA01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175737 CVCL_NA00 BayGenomics ES cell line RRJ021 embryonic stem cell house mouse CVCL_NA00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926143; Cnot10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175738 CVCL_EG69 HSC-4 [Macaca fascicularis] transformed cell line CVCL_EG69 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21175739 CVCL_EG64 A2780-DR cancer cell line human CVCL_EG64 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Omics: Proteome analysis Female 21175740 CVCL_EG63 VV-1H831 hybridoma house mouse CVCL_EG63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08714; Vaccinia virus HA. 21175741 CVCL_EG62 HuSI-L23-14-5 transformed cell line human CVCL_EG62 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21175742 CVCL_EG61 pREP4 cont/CHO-S #5 spontaneously immortalized cell line CVCL_EG61 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Derived from sampling site: Ovary. Female 21175743 CVCL_EG68 HSR-4 transformed cell line CVCL_EG68 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21175744 CVCL_EG67 ICH-ERMS-1 cancer cell line human CVCL_EG67 CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Glu69Lys (c.205G>A); ClinVar=VCV000224414; Zygosity=Heterozygous (PubMed=33021000); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Homozygous (PubMed=33021000) Population: Japanese; Derived from sampling site: Pelvis. Omics: SNP array analysis Female Doubling time: ~31 hours (PubMed=33021000) 21175745 CVCL_EG66 DR-EcoScreen cancer cell line house mouse CVCL_EG66 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Liver; Breed/subspecies: C57L. Biotechnology: Used in a bioassay for the determination of polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated biphenyls (DL-PCBs) in environmental and food samples Female Characteristics: Acts through the activation of a luciferase reporter gene under the control of dioxin-response elements (DREs) 21175746 CVCL_EG65 ES Tet-On/Ngn3 embryonic stem cell house mouse CVCL_EG65 CL:0000010 Transfected with: MGI; MGI:893591; Neurog3 Breed/subspecies: 129P2/OlaHsd-Hprt. Male 21175747 CVCL_3U42 HQ01982 transformed cell line human CVCL_3U42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175748 CVCL_4642 JHOC-8 cancer cell line human CVCL_4642 CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Unspecified (PubMed=25846456); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25846456) Population: Japanese; Derived from sampling site: Ovary. Female 21175749 CVCL_3U41 HQ01981 transformed cell line human CVCL_3U41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175750 CVCL_4641 JHOC-7 cancer cell line human CVCL_4641 HLA typing: B*07:02,48:01; C*07:02,08:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val540Leu (c.1618G>C) (G1606C); ClinVar=VCV000409741; Zygosity=Unspecified (PubMed=25846456); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=25846456) Population: Japanese; Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 21175751 CVCL_3U40 HQ01980 transformed cell line human CVCL_3U40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175752 CVCL_4640 JHOC-5 cancer cell line human CVCL_4640 HLA typing: A*02:01; B*35:01,46:01; C*01:02,03:03 (PubMed=25960936); HLA typing: A*02:07,02:07; B*35:01,46:01; C*01:02,03:03 (PubMed=26589293); Genome ancestry: African=0.38%; Native American=0%; East Asian, North=85.18%; East Asian, South=14.43%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 52 hours (PubMed=10695020); 30 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175753 CVCL_3U46 HQ01986 transformed cell line human CVCL_3U46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175754 CVCL_4646 JHONA cancer cell line human CVCL_4646 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female 21175755 CVCL_3U45 HQ01985 transformed cell line human CVCL_3U45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175756 CVCL_4645 JHOM-2B cancer cell line human CVCL_4645 HLA typing: A*26:01,26:01; B*35:01,35:01; C*03:03,03:03 (PubMed=26589293); Genome ancestry: African=0.86%; Native American=0.7%; East Asian, North=79.5%; East Asian, South=18.16%; South Asian=0.74%; European, North=0%; European, South=0.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg552Ter (c.1654C>T); ClinVar=VCV000126840; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175757 CVCL_3U44 HQ01984 transformed cell line human CVCL_3U44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175758 CVCL_4644 JHOM-1 cancer cell line human CVCL_4644 HLA typing: A*33:03,33:03; B*07:02,44:03; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.03%; Native American=0%; East Asian, North=82.29%; East Asian, South=16.67%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 60 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21175759 CVCL_3U43 HQ01983 transformed cell line human CVCL_3U43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175760 CVCL_4643 JHOC-9 cancer cell line human CVCL_4643 HLA typing: A*24:02,11:01; B*35:08,40:01; C*07:02,04:01; DRB1*08:01,08:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=22705003; PubMed=25846456; PubMed=28273451) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Female 21175761 CVCL_3U49 HQ01989 transformed cell line human CVCL_3U49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175762 CVCL_4649 JHOS-4 cancer cell line human CVCL_4649 HLA typing: A*24:02,33:03; B*44:03,52:01; C*12:02,14:03 (PubMed=26589293); Genome ancestry: African=0.71%; Native American=0%; East Asian, North=82.16%; East Asian, South=13.28%; South Asian=1.31%; European, North=0%; European, South=2.54% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Gly (c.440T>G); Zygosity=Homozygous (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Peritoneum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 70 hours (PubMed=25984343); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel 21175763 CVCL_3U48 HQ01988 transformed cell line human CVCL_3U48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175764 CVCL_4648 JHOS-3 cancer cell line human CVCL_4648 Genome ancestry: African=0%; Native American=0%; East Asian, North=83.55%; East Asian, South=16.2%; South Asian=0.24%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21175765 CVCL_3U47 HQ01987 transformed cell line human CVCL_3U47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175766 CVCL_4647 JHOS-2 cancer cell line human CVCL_4647 Genome ancestry: African=0%; Native American=0.18%; East Asian, North=83.51%; East Asian, South=14.94%; South Asian=0.69%; European, North=0%; European, South=0.68% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.767_782+4delTGACCTGGAGTCTTCCAGTG; Zygosity=Unspecified (Cosmic-CLP; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 61 hours (PubMed=10695020); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21175767 CVCL_3U60 HQ02000 transformed cell line human CVCL_3U60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175768 CVCL_4660 MBT-2 cancer cell line house mouse CVCL_4660 CL:0000010 Transformant: Nifurthiazole (N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide(ChEBI; CHEBI:82328); Derived from metastatic site: Urinary bladder; Breed/subspecies: C3H/He. 21175769 CVCL_3U53 HQ01993 transformed cell line human CVCL_3U53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175770 CVCL_4653 JHUCS-3 cancer cell line human CVCL_4653 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female 21175771 CVCL_3U52 HQ01992 transformed cell line human CVCL_3U52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175772 CVCL_4652 JHUCS-1 cancer cell line human CVCL_4652 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Omics: ATAC-seq Female Doubling time: 30 hours, at 25th passage (PubMed=15859159) 21175773 CVCL_3U51 HQ01991 transformed cell line human CVCL_3U51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175774 CVCL_4651 JHUAS-2-L cancer cell line human CVCL_4651 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female 21175775 CVCL_3U50 HQ01990 transformed cell line human CVCL_3U50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175776 CVCL_4650 JHUAS-1 cancer cell line human CVCL_4650 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female 21175777 CVCL_3U57 HQ01997 transformed cell line human CVCL_3U57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175778 CVCL_4657 JHUEM-3 cancer cell line human CVCL_4657 Genome ancestry: African=0.23%; Native American=0%; East Asian, North=84.53%; East Asian, South=12.99%; South Asian=0%; European, North=0%; European, South=2.25% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp33Glu (c.99T>A); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln167Ter (c.499C>T); ClinVar=VCV000528250; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21175779 CVCL_3U56 HQ01996 transformed cell line human CVCL_3U56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175780 CVCL_4656 JHUEM-2 cancer cell line human CVCL_4656 HLA typing: A*11:01,31:01; B*15:01,51:01; C*04:01,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=81.43%; East Asian, South=17.67%; South Asian=0.89%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175781 CVCL_3U55 HQ01995 transformed cell line human CVCL_3U55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175782 CVCL_4655 JHUEM-1 cancer cell line human CVCL_4655 Genome ancestry: African=0%; Native American=0%; East Asian, North=76.96%; East Asian, South=23.04%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175783 CVCL_3U54 HQ01994 transformed cell line human CVCL_3U54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175784 CVCL_4654 JHUEM-14 cancer cell line human CVCL_4654 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 21175785 CVCL_4659 HFL-AE-VI finite cell line human CVCL_4659 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 21175786 CVCL_3U59 HQ01999 transformed cell line human CVCL_3U59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175787 CVCL_3U58 HQ01998 transformed cell line human CVCL_3U58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175788 CVCL_4658 JHUEM-7 cancer cell line human CVCL_4658 HLA typing: A*24:02,31:01; B*46:01,52:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=77.1%; East Asian, South=22.67%; South Asian=0.22%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2204Ter (c.6610C>T); ClinVar=VCV000236632; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Arg1989Ter (c.5965C>T); ClinVar=VCV000225842; Zygosity=Heterozygous (DepMap) Population: Japanese; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175789 CVCL_4620 ELT6 cancer cell line Norway rat CVCL_4620 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175790 CVCL_3U20 HQ01958 transformed cell line human CVCL_3U20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175791 CVCL_3U24 HQ01962 transformed cell line human CVCL_3U24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175792 CVCL_4624 Melan-a spontaneously immortalized cell line house mouse CVCL_4624 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 22 hours (PubMed=16611417) 21175793 CVCL_4623 H4-II cancer cell line Norway rat CVCL_4623 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male Characteristics: Directly derived from the Reuber hepatoma 21175794 CVCL_3U23 HQ01961 transformed cell line human CVCL_3U23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175795 CVCL_4622 EPNT-5 cancer cell line house mouse CVCL_4622 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. 21175796 CVCL_3U22 HQ01960 transformed cell line human CVCL_3U22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175797 CVCL_4621 ELT9 cancer cell line Norway rat CVCL_4621 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175798 CVCL_3U21 HQ01959 transformed cell line human CVCL_3U21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175799 CVCL_3U28 HQ01966 transformed cell line human CVCL_3U28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175800 CVCL_4628 OE50 cancer cell line human CVCL_4628 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Discontinued: ECACC; 96061337; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00547 Problematic cell line: Contaminated Shown to be a HCT 116 derivative (PubMed=10789716). Originally thought to originate from a 71 year old female patient with an esophageal squamous cell carcinoma. 21175801 CVCL_3U27 HQ01965 transformed cell line human CVCL_3U27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175802 CVCL_4627 OE47 cancer cell line human CVCL_4627 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Discontinued: ECACC; 96061336; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00546 Problematic cell line: Contaminated Shown to be a HCT 116 derivative (PubMed=10789716). Originally thought to originate from a 76 year old male patient with an esophageal squamous cell carcinoma. 21175803 CVCL_3U26 HQ01964 transformed cell line human CVCL_3U26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175804 CVCL_4626 vEPT transformed cell line CVCL_4626 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.; Breed/subspecies: New Zealand white. Male 21175805 CVCL_3U25 HQ01963 transformed cell line human CVCL_3U25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175806 CVCL_4625 SPEV spontaneously immortalized cell line pig CVCL_4625 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21175807 CVCL_3U29 HQ01967 transformed cell line human CVCL_3U29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175808 CVCL_4629 PT-80 finite cell line CVCL_4629 CL:0000010 Derived from sampling site: Kidney. Unspecified 21175809 CVCL_4631 AVE-115 undefined cell line type Norway rat CVCL_4631 CL:0000010 Discontinued: ATCC; CRL-6507; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175810 CVCL_3U31 HQ01970 transformed cell line human CVCL_3U31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175811 CVCL_4630 35 cancer cell line Norway rat CVCL_4630 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995). Unspecified 21175812 CVCL_3U30 HQ01968 transformed cell line human CVCL_3U30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175813 CVCL_4635 HL-60-R2 cancer cell line human CVCL_4635 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27300; Vitamin D; Derived from sampling site: Peripheral blood. Female 21175814 CVCL_3U35 HQ01975 transformed cell line human CVCL_3U35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175815 CVCL_4634 DT40-ITRP1(-/-)-ITPR2(-/-)-ITPR3(-/-) cancer cell line CVCL_4634 CL:0000010 Knockout cell: Method=Targeted integration; ITPR1+ITPR2+ITPR3 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21175816 CVCL_3U34 HQ01974 transformed cell line human CVCL_3U34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175817 CVCL_4633 501-mel cancer cell line human CVCL_4633 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPB1*04:01,02:01:02; DQB1*06:03,05:01; DRB1*11:01:01,04:01:01 (PubMed=15592718); HLA typing: A*02:01,24:02; B*18:01,35:08; C*04:04,07:01 (PubMed=25960936) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Unspecified (PubMed=23851445); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=23671654) 21175818 CVCL_3U33 HQ01972 transformed cell line human CVCL_3U33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175819 CVCL_4632 888-mel cancer cell line human CVCL_4632 HLA typing: A*01,24; B*52,55; C*01:02,12:01 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15467732) Derived from metastatic site: Oral cavity; soft palate; hypodermis. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21175820 CVCL_3U32 HQ01971 transformed cell line human CVCL_3U32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175821 CVCL_3U39 HQ01979 transformed cell line human CVCL_3U39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175822 CVCL_4639 HYT-1 cancer cell line human CVCL_4639 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21175823 CVCL_4638 HFL-AE-III finite cell line human CVCL_4638 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified Senescence: Senesces at 54 PDL (PubMed=17395773) 21175824 CVCL_3U38 HQ01978 transformed cell line human CVCL_3U38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175825 CVCL_4637 HFL-AE-II finite cell line human CVCL_4637 CL:0000010 Population: Japanese; Karyotypic information: 46,XX,inv(9p+,q-) (RCB); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21175826 CVCL_3U37 HQ01977 transformed cell line human CVCL_3U37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175827 CVCL_4636 HFL-AE-I finite cell line human CVCL_4636 CL:0000010 Population: Japanese; Karyotypic information: 46,XY,17p+ or 17ph+ (RCB); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21175828 CVCL_3U36 HQ01976 transformed cell line human CVCL_3U36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175829 CVCL_3U02 HQ01940 transformed cell line human CVCL_3U02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175830 CVCL_4602 WM 1043 finite cell line house mouse CVCL_4602 CL:0000010 Discontinued: ATCC; CRL-6466; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175831 CVCL_4601 CHO-xrs-5 spontaneously immortalized cell line CVCL_4601 CL:0000010 Derived from sampling site: Ovary. Female 21175832 CVCL_3U01 HQ01939 transformed cell line human CVCL_3U01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175833 CVCL_3U00 HQ01938 transformed cell line human CVCL_3U00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175834 CVCL_4600 UVE-10 transformed cell line Norway rat CVCL_4600 CL:0000010 Transformant: Adenovirus 1(NCBI-Taxonomy; 10533) Discontinued: ATCC; CRL-6515; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21175835 CVCL_4606 F4/4.K6 factor-dependent cell line house mouse CVCL_4606 CL:0000010 Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: C57BL/10. Discontinued: DSMZ; ACC-52; true Characteristics: IL4 dependent 21175836 CVCL_3U06 HQ01944 transformed cell line human CVCL_3U06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175837 CVCL_4605 Col-7 cancer cell line house mouse CVCL_4605 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Col series of TS/A derived cell lines are obtained from repeated intravenous passage of lung colonies in BALB/c female mice 21175838 CVCL_3U05 HQ01943 transformed cell line human CVCL_3U05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175839 CVCL_4604 Col-10 cancer cell line house mouse CVCL_4604 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: The Col series of TS/A derived cell lines are obtained from repeated intravenous passage of lung colonies in BALB/c female mice 21175840 CVCL_3U04 HQ01942 transformed cell line human CVCL_3U04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175841 CVCL_4603 Cor Per finite cell line human CVCL_4603 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1145; probable; Discontinued: ATCC; CRL-1243; true Male 21175842 CVCL_3U03 HQ01941 transformed cell line human CVCL_3U03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175843 CVCL_3U09 HQ01947 transformed cell line human CVCL_3U09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175844 CVCL_4609 PAb 101 hybridoma house mouse CVCL_4609 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen (Note=Recognizes C-terminus). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175845 CVCL_3U08 HQ01946 transformed cell line human CVCL_3U08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175846 CVCL_4608 SJ-N-KP cancer cell line human CVCL_4608 CL:0000010 Derived from metastatic site: Bone marrow. Female 21175847 CVCL_3U07 HQ01945 transformed cell line human CVCL_3U07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175848 CVCL_4607 R1 [Oncorhynchus] spontaneously immortalized cell line CVCL_4607 CL:0000010 Derived from sampling site: Liver Cell type=Fibroblast.. Unspecified Doubling time: ~160 hours (DSMZ=ACC-56) Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00581 Problematic cell line: Misidentified Originally thought to be of Oncorhynchus mykiss (trout) origin but found to be from Oncorhynchus tshawytscha (DSMZ site). 21175849 CVCL_4613 BDCM cancer cell line human CVCL_4613 Genome ancestry: African=0.02%; Native American=0%; East Asian, North=0%; East Asian, South=0%; South Asian=2.51%; European, North=70.49%; European, South=26.97% (PubMed=30894373) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175850 CVCL_3U13 HQ01951 transformed cell line human CVCL_3U13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175851 CVCL_4612 B16 melanoma 4A5 cancer cell line house mouse CVCL_4612 CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33596583); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Omics: Array-based CGH Male Doubling time: 24 hours (PubMed=23890195) 21175852 CVCL_3U12 HQ01950 transformed cell line human CVCL_3U12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175853 CVCL_4611 AHL-1 spontaneously immortalized cell line CVCL_4611 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ECACC; 90120504; probable Male Senescence: Senesces at ~56 PDL (CelloPub=CLPUB00292) 21175854 CVCL_3U11 HQ01949 transformed cell line human CVCL_3U11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175855 CVCL_3U10 HQ01948 transformed cell line human CVCL_3U10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175856 CVCL_4610 PAb 108 hybridoma house mouse CVCL_4610 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175857 CVCL_4617 ELT4 cancer cell line Norway rat CVCL_4617 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175858 CVCL_3U17 HQ01955 transformed cell line human CVCL_3U17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175859 CVCL_4616 ELT3 cancer cell line Norway rat CVCL_4616 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175860 CVCL_3U16 HQ01954 transformed cell line human CVCL_3U16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175861 CVCL_4615 ELT10 cancer cell line Norway rat CVCL_4615 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175862 CVCL_3U15 HQ01953 transformed cell line human CVCL_3U15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175863 CVCL_3U14 HQ01952 transformed cell line human CVCL_3U14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175864 CVCL_4614 K-9 finite cell line Norway rat CVCL_4614 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Male 21175865 CVCL_4619 ELT5B cancer cell line Norway rat CVCL_4619 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175866 CVCL_3U19 HQ01957 transformed cell line human CVCL_3U19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175867 CVCL_4618 ELT5A cancer cell line Norway rat CVCL_4618 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21175868 CVCL_3U18 HQ01956 transformed cell line human CVCL_3U18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175869 CVCL_NB99 BayGenomics ES cell line RRJ514 embryonic stem cell house mouse CVCL_NB99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108411; Prkag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175870 CVCL_NB98 BayGenomics ES cell line RRJ510 embryonic stem cell house mouse CVCL_NB98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175871 CVCL_NB97 BayGenomics ES cell line RRJ507 embryonic stem cell house mouse CVCL_NB97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918518; Lrrfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175872 CVCL_NB96 BayGenomics ES cell line RRJ505 embryonic stem cell house mouse CVCL_NB96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105056; Cobl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175873 CVCL_NB95 BayGenomics ES cell line RRJ504 embryonic stem cell house mouse CVCL_NB95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913695; Cyc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175874 CVCL_NB94 BayGenomics ES cell line RRJ502 embryonic stem cell house mouse CVCL_NB94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175875 CVCL_NB93 BayGenomics ES cell line RRJ501 embryonic stem cell house mouse CVCL_NB93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924161; Brd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175876 CVCL_NB92 BayGenomics ES cell line RRJ500 embryonic stem cell house mouse CVCL_NB92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101924; Slc12a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175877 CVCL_NB91 BayGenomics ES cell line RRJ495 embryonic stem cell house mouse CVCL_NB91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101841; Ppm1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175878 CVCL_NB90 BayGenomics ES cell line RRJ494 embryonic stem cell house mouse CVCL_NB90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175879 CVCL_EI09 Hep-G2 SimpleCell O-GalNAc KO GalNAc-T1 cancer cell line human CVCL_EI09 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Knockout cell: Method=ZFN; HGNC; 4117; B4GALNT1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21175880 CVCL_EI04 SKBR3-AZDRa cancer cell line human CVCL_EI04 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132986; Sapitinib (AZD8931); Derived from metastatic site: Pleural effusion. Female 21175881 CVCL_EI03 BT474-LAPRb cancer cell line human CVCL_EI03 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Female 21175882 CVCL_EI02 BT474-LAPRa cancer cell line human CVCL_EI02 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Female 21175883 CVCL_EI01 ND40809 transformed cell line human CVCL_EI01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175884 CVCL_EI08 SKBR3-LAPRb cancer cell line human CVCL_EI08 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 21175885 CVCL_EI07 SKBR3-LAPRa cancer cell line human CVCL_EI07 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 21175886 CVCL_EI06 SKBR3-AZDRc cancer cell line human CVCL_EI06 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132986; Sapitinib (AZD8931); Derived from metastatic site: Pleural effusion. Female 21175887 CVCL_EI05 SKBR3-AZDRb cancer cell line human CVCL_EI05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:132986; Sapitinib (AZD8931); Derived from metastatic site: Pleural effusion. Female 21175888 CVCL_EI00 ND40608 transformed cell line human CVCL_EI00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175889 CVCL_3U93 HQ02034 transformed cell line human CVCL_3U93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175890 CVCL_4693 RLE-6TN transformed cell line Norway rat CVCL_4693 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Male Characteristics: While transformed with SV40 pRSV-T, does not express SV40 T antigen thus said to be derived from a spontaneous transformant 21175891 CVCL_3U92 HQ02033 transformed cell line human CVCL_3U92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175892 CVCL_4692 J774 cancer cell line house mouse CVCL_4692 CL:0000010 Breed/subspecies: BALB/c. Female 21175893 CVCL_4691 FL83B spontaneously immortalized cell line house mouse CVCL_4691 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: C57BL/6J. Omics: Deep phosphoproteome analysis Unspecified 21175894 CVCL_3U91 HQ02032 transformed cell line human CVCL_3U91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175895 CVCL_4690 BAEC finite cell line CVCL_4690 CL:0000010 Derived from sampling site: Aorta; endothelium. 21175896 CVCL_3U90 HQ02031 transformed cell line human CVCL_3U90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175897 CVCL_3U86 HQ02027 transformed cell line human CVCL_3U86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175898 CVCL_4686 THP-6 cancer cell line human CVCL_4686 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=10071127); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10071127); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=10071127) Population: Japanese; Derived from sampling site: Bone marrow Cell type=T-cell.. Female Doubling time: 24 hours (PubMed=2954268); Microsatellite instability: Instable (MSI) (PubMed=10739008; PubMed=11226526) 21175899 CVCL_3U85 HQ02026 transformed cell line human CVCL_3U85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175900 CVCL_4685 LSCC-HD11 transformed cell line CVCL_4685 CL:0000010 Transformant: Avian myelocytomatosis virus MC29(NCBI-Taxonomy; 11868); Derived from sampling site: Bone marrow; Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21175901 CVCL_3U84 HQ02025 transformed cell line human CVCL_3U84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175902 CVCL_4684 HUC-F finite cell line human CVCL_4684 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Senescence: Senesces at 32 PDL (PubMed=17395773) 21175903 CVCL_3U83 HQ02024 transformed cell line human CVCL_3U83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175904 CVCL_4683 HUC-Fm2 finite cell line human CVCL_4683 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Male Senescence: Senesces at 16 PDL (PubMed=17395773) 21175905 CVCL_4689 ADF cancer cell line human CVCL_4689 CL:0000010 21175906 CVCL_3U89 HQ02030 transformed cell line human CVCL_3U89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175907 CVCL_4688 184B5 transformed cell line human CVCL_4688 HLA typing: A*02:01,02:01; B*18:01,50:01; C*06:02,07:01; DQB1*06:04,06:04 (PubMed=25960936) CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 56.15 hours (GrayJW panel) Group: Patented cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: ICBP43 breast cancer cell line panel; Part of: MD Anderson Cell Lines Project; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8799 21175908 CVCL_3U88 HQ02029 transformed cell line human CVCL_3U88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175909 CVCL_3U87 HQ02028 transformed cell line human CVCL_3U87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175910 CVCL_4687 THP-8 cancer cell line human CVCL_4687 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Doubling time: 68 hours (PubMed=2954268); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21175911 CVCL_3U97 HQ02038 transformed cell line human CVCL_3U97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175912 CVCL_4697 S194/5.XXO-1 cancer cell line house mouse CVCL_4697 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21175913 CVCL_3U96 HQ02037 transformed cell line human CVCL_3U96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175914 CVCL_4696 S194/5.XXO.BU.1 cancer cell line house mouse CVCL_4696 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981); Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8837 21175915 CVCL_3U95 HQ02036 transformed cell line human CVCL_3U95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175916 CVCL_4695 Rat1-R12 spontaneously immortalized cell line Norway rat CVCL_4695 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Discontinued: ATCC; CRL-2210; true Unspecified 21175917 CVCL_3U94 HQ02035 transformed cell line human CVCL_3U94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175918 CVCL_4694 RSC96 spontaneously immortalized cell line Norway rat CVCL_4694 CL:0000010 Derived from sampling site: Peripheral nervous system; nerve Cell type=Schwann cell.. Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Unspecified 21175919 CVCL_3U99 HQ02040 transformed cell line human CVCL_3U99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175920 CVCL_4699 TC-1 [Mouse lung] transformed cell line house mouse CVCL_4699 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Discontinued: ATCC; CRL-2785; true; Discontinued: ATCC; JHU-1; true Unspecified Doubling time: 18.2 hours (PubMed=12559790); 18.5 hours (PubMed=31638243) 21175921 CVCL_3U98 HQ02039 transformed cell line human CVCL_3U98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175922 CVCL_4698 S2 hybridoma house mouse CVCL_4698 CL:0000010 Discontinued: ECACC; 99043002; probable. Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01911; Human HLA-DRB1 (Note=Recognizes allele DRB1*13) Doubling time: ~36 hours (ECACC=99043002) 21175923 CVCL_3U71 HQ02011 transformed cell line human CVCL_3U71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175924 CVCL_4671 NBT-L1 cancer cell line Norway rat CVCL_4671 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male Characteristics: Exhibits an elongated shape and moderate to high invasive activity in vitro (PubMed=9369930) Doubling time: 16.8 hours (PubMed=9369930) 21175925 CVCL_4670 CAEP [Carassius] cancer cell line CVCL_4670 CL:0000010 Unspecified Group: Fish cell line. 21175926 CVCL_3U70 HQ02010 transformed cell line human CVCL_3U70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175927 CVCL_3U64 HQ02004 transformed cell line human CVCL_3U64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175928 CVCL_4664 OGU1 cancer cell line human CVCL_4664 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Doubling time: 48 hours (PubMed=25846106) 21175929 CVCL_3U63 HQ02003 transformed cell line human CVCL_3U63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175930 CVCL_4663 NOS-10 cancer cell line human CVCL_4663 CL:0000010 Population: Japanese. Male 21175931 CVCL_3U62 HQ02002 transformed cell line human CVCL_3U62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175932 CVCL_4662 NMS-2 cancer cell line human CVCL_4662 CL:0000010 Population: Japanese; Derived from sampling site: Thigh. Male Doubling time: 50.2 hours (PubMed=9849858) 21175933 CVCL_3U61 HQ02001 transformed cell line human CVCL_3U61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175934 CVCL_4661 NMFH-1 [RCB] cancer cell line human CVCL_4661 CL:0000010 Population: Japanese; Derived from sampling site: Knee; hypodermis. Male Doubling time: 46 hours (at 50th passage), 42 hours (at 100th passage) (PubMed=16080955) Caution: There seem to be two NMFH-1 cell lines, both from myxofibrosarcomas (malignant fibrous histiocytomas) One from Niigata University (Kawashima H. et al) established from a 89 year old male patient and distributed by RCB and one from Shimada Y. established from a 43 year old male patient and distributed by JCRB. The two cell lines have very different STR profiles. 21175935 CVCL_4668 HFL-AE-VII finite cell line human CVCL_4668 CL:0000010 Population: Japanese; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21175936 CVCL_3U68 HQ02008 transformed cell line human CVCL_3U68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175937 CVCL_3U67 HQ02007 transformed cell line human CVCL_3U67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175938 CVCL_4667 StromaNKtert telomerase immortalized cell line human CVCL_4667 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Stromal cell.. Discontinued: RCB; RCB2350; probable Male 21175939 CVCL_3U66 HQ02006 transformed cell line human CVCL_3U66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175940 CVCL_4666 PCM6 cancer cell line human CVCL_4666 Genome ancestry: African=1.03%; Native American=0.38%; East Asian, North=74.85%; East Asian, South=22.81%; South Asian=0.86%; European, North=0%; European, South=0.08% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG lambda; Characteristics: IL6 dependent Doubling time: ~40-50 hours (PubMed=8112425) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21175941 CVCL_3U65 HQ02005 transformed cell line human CVCL_3U65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175942 CVCL_4665 OHTA cancer cell line house mouse CVCL_4665 CL:0000010 Breed/subspecies: ICR. 21175943 CVCL_4669 CHO-RD spontaneously immortalized cell line CVCL_4669 CL:0000010 Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21175944 CVCL_3U69 HQ02009 transformed cell line human CVCL_3U69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175945 CVCL_3U82 HQ02023 transformed cell line human CVCL_3U82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175946 CVCL_4682 HUC-F2 finite cell line human CVCL_4682 CL:0000010 Population: Japanese; Derived from sampling site: Umbilical cord Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (PubMed=17395773) 21175947 CVCL_3U81 HQ02022 transformed cell line human CVCL_3U81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175948 CVCL_4681 PC12D cancer cell line Norway rat CVCL_4681 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21175949 CVCL_3U80 HQ02021 transformed cell line human CVCL_3U80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175950 CVCL_4680 Rb-1 spontaneously immortalized cell line CVCL_4680 CL:0000010 Derived from sampling site: Aorta; smooth muscle. Female 21175951 CVCL_3U75 HQ02016 transformed cell line human CVCL_3U75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175952 CVCL_4675 NBT-T2 cancer cell line Norway rat CVCL_4675 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male Characteristics: Forms tight colonies and exhibited very low or negligible invasive activity (PubMed=9369930) Doubling time: 12.8 hours (PubMed=9369930) 21175953 CVCL_3U74 HQ02015 transformed cell line human CVCL_3U74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175954 CVCL_4674 NBT-T1 cancer cell line Norway rat CVCL_4674 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male Characteristics: Forms tight colonies and exhibited very low or negligible invasive activity (PubMed=9369930) Doubling time: 13.4 hours (PubMed=9369930) 21175955 CVCL_3U73 HQ02013 transformed cell line human CVCL_3U73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175956 CVCL_4673 NBT-L2b cancer cell line Norway rat CVCL_4673 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male Characteristics: Exhibits an elongated shape and moderate to high invasive activity in vitro (PubMed=9369930) Doubling time: 14.2 hours (PubMed=9369930) 21175957 CVCL_3U72 HQ02012 transformed cell line human CVCL_3U72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175958 CVCL_4672 NBT-L2a cancer cell line Norway rat CVCL_4672 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: Wistar. Male Characteristics: Exhibits an elongated shape and moderate to high invasive activity in vitro (PubMed=9369930) Doubling time: 15.6 hours (PubMed=9369930) 21175959 CVCL_3U79 HQ02020 transformed cell line human CVCL_3U79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175960 CVCL_4679 PST-S2 transformed cell line CVCL_4679 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male 21175961 CVCL_3U78 HQ02019 transformed cell line human CVCL_3U78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175962 CVCL_4678 PAP-HT25 spontaneously immortalized cell line CVCL_4678 CL:0000010 Karyotypic information: Polyploid; Derived from sampling site: Kidney; renal papilla. Unspecified 21175963 CVCL_4677 CNT transformed cell line CVCL_4677 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; distal tubule; Breed/subspecies: New Zealand white. Male 21175964 CVCL_3U77 HQ02018 transformed cell line human CVCL_3U77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175965 CVCL_4676 CCD-IC transformed cell line CVCL_4676 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: New Zealand white. Male 21175966 CVCL_3U76 HQ02017 transformed cell line human CVCL_3U76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175967 CVCL_EH59 ND16053 transformed cell line human CVCL_EH59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175968 CVCL_EH58 ND15918 transformed cell line human CVCL_EH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175969 CVCL_EH57 ND15872 transformed cell line human CVCL_EH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175970 CVCL_EH52 ND15729 transformed cell line human CVCL_EH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175971 CVCL_EH51 ND14562 transformed cell line human CVCL_EH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175972 CVCL_EH50 ND08720 transformed cell line human CVCL_EH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175973 CVCL_EH56 ND15855 transformed cell line human CVCL_EH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175974 CVCL_EH55 ND15842 transformed cell line human CVCL_EH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175975 CVCL_EH54 ND15818 transformed cell line human CVCL_EH54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175976 CVCL_EH53 ND15774 transformed cell line human CVCL_EH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175977 CVCL_NB08 BayGenomics ES cell line RRJ266 embryonic stem cell house mouse CVCL_NB08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175978 CVCL_NB07 BayGenomics ES cell line RRJ263 embryonic stem cell house mouse CVCL_NB07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175979 CVCL_NB06 BayGenomics ES cell line RRJ259 embryonic stem cell house mouse CVCL_NB06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429762; Rufy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175980 CVCL_NB05 BayGenomics ES cell line RRJ255 embryonic stem cell house mouse CVCL_NB05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196463; Fndc3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175981 CVCL_NB04 BayGenomics ES cell line RRJ254 embryonic stem cell house mouse CVCL_NB04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175982 CVCL_EH70 ND16497 transformed cell line human CVCL_EH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175983 CVCL_NB03 BayGenomics ES cell line RRJ253 embryonic stem cell house mouse CVCL_NB03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444486; Tarsl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175984 CVCL_NB02 BayGenomics ES cell line RRJ250 embryonic stem cell house mouse CVCL_NB02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175985 CVCL_NB01 BayGenomics ES cell line RRJ249 embryonic stem cell house mouse CVCL_NB01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925927; Rnf20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175986 CVCL_NB00 BayGenomics ES cell line RRJ248 embryonic stem cell house mouse CVCL_NB00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443008; Trappc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21175987 CVCL_EH69 ND16488 transformed cell line human CVCL_EH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175988 CVCL_EH68 ND16479 transformed cell line human CVCL_EH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175989 CVCL_EH63 ND16205 transformed cell line human CVCL_EH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175990 CVCL_EH62 ND16111 transformed cell line human CVCL_EH62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175991 CVCL_EH61 ND16110 transformed cell line human CVCL_EH61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175992 CVCL_EH60 ND16107 transformed cell line human CVCL_EH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175993 CVCL_EH67 ND16470 transformed cell line human CVCL_EH67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175994 CVCL_EH66 ND16375 transformed cell line human CVCL_EH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175995 CVCL_EH65 ND16326 transformed cell line human CVCL_EH65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175996 CVCL_EH64 ND16211 transformed cell line human CVCL_EH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175997 CVCL_EH38 ND03767 transformed cell line human CVCL_EH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21175998 CVCL_EH37 ND02817 transformed cell line human CVCL_EH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21175999 CVCL_EH36 ND02261 transformed cell line human CVCL_EH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176000 CVCL_EH35 ND01374 transformed cell line human CVCL_EH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176001 CVCL_EH39 ND03768 transformed cell line human CVCL_EH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176002 CVCL_EH30 GM25990 finite cell line human CVCL_EH30 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg402del (c.1202_1204GAA[1]) (c.1205_1207delTTC); ClinVar=VCV000126423; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg542Ter (c.1624C>T); ClinVar=VCV000126424; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176003 CVCL_EH34 ND01282 transformed cell line human CVCL_EH34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176004 CVCL_EH33 GM25598 transformed cell line human CVCL_EH33 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; c.881+5G>T (IVS5+5G>T); ClinVar=VCV000221584; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176005 CVCL_EH32 GM25597 transformed cell line human CVCL_EH32 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser116Ter (c.347C>G); ClinVar=VCV000221579; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176006 CVCL_EH31 GM25596 transformed cell line human CVCL_EH31 CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Ser116Ter (c.347C>G); ClinVar=VCV000221579; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; c.881+5G>T (IVS5+5G>T); ClinVar=VCV000221584; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176007 CVCL_EH49 ND08662 transformed cell line human CVCL_EH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176008 CVCL_EH48 ND07123 transformed cell line human CVCL_EH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176009 CVCL_EH47 ND06849 transformed cell line human CVCL_EH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176010 CVCL_EH46 ND06355 transformed cell line human CVCL_EH46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176011 CVCL_EH41 ND04236 transformed cell line human CVCL_EH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176012 CVCL_EH40 ND04090 transformed cell line human CVCL_EH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176013 CVCL_EH45 ND06343 transformed cell line human CVCL_EH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176014 CVCL_EH44 ND06059 transformed cell line human CVCL_EH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176015 CVCL_EH43 ND06058 transformed cell line human CVCL_EH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176016 CVCL_EH42 ND04300 transformed cell line human CVCL_EH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176017 CVCL_EH16 GM14025 transformed cell line human CVCL_EH16 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176018 CVCL_EH15 GM14023 transformed cell line human CVCL_EH15 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176019 CVCL_EH14 GM14018 transformed cell line human CVCL_EH14 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176020 CVCL_EH13 GM13589 transformed cell line human CVCL_EH13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176021 CVCL_EH19 GM14076 transformed cell line human CVCL_EH19 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176022 CVCL_EH18 GM14075 transformed cell line human CVCL_EH18 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176023 CVCL_EH17 GM14026 transformed cell line human CVCL_EH17 CL:0000010 Sequence variation: Mutation; HGNC; 11948; TNNT1; Simple; p.Glu180Ter (c.538G>T); ClinVar=VCV000012440; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176024 CVCL_EH12 GM13588 transformed cell line human CVCL_EH12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176025 CVCL_EH11 GM13552 transformed cell line human CVCL_EH11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176026 CVCL_EH10 GM13551 transformed cell line human CVCL_EH10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176027 CVCL_EH27 GM25421 finite cell line human CVCL_EH27 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Ser190Ter (c.569C>T); Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21176028 CVCL_EH26 GM25420 transformed cell line human CVCL_EH26 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Ser190Ter (c.569C>T); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176029 CVCL_EH25 GM25400 finite cell line human CVCL_EH25 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21176030 CVCL_EH24 GM25399 transformed cell line human CVCL_EH24 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176031 CVCL_EH29 GM25965 transformed cell line human CVCL_EH29 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Tyr315Ilefs*1 (c.941dupG); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176032 CVCL_EH28 GM25571 finite cell line human CVCL_EH28 CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg253Ter (c.757C>T); ClinVar=VCV000279774; Zygosity=Hemizygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21176033 CVCL_EH23 GM23960 transformed cell line human CVCL_EH23 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Gly210Alafs*54 (c.629delG); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176034 CVCL_EH22 GM23910 transformed cell line human CVCL_EH22 CL:0000010 Sequence variation: Mutation; HGNC; 7960; NR0B1; Simple; p.Leu295Pro (c.884T>C); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176035 CVCL_EH21 GM17932 transformed cell line human CVCL_EH21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176036 CVCL_EH20 GM15992 transformed cell line human CVCL_EH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176037 CVCL_EH05 GM09965 finite cell line human CVCL_EH05 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21176038 CVCL_EH04 GM08788 finite cell line human CVCL_EH04 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21176039 CVCL_EH03 ND19260 transformed cell line human CVCL_EH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176040 CVCL_EH02 ND04925 transformed cell line human CVCL_EH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176041 CVCL_EH09 GM12499 transformed cell line human CVCL_EH09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176042 CVCL_EH08 GM12498 transformed cell line human CVCL_EH08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176043 CVCL_EH07 GM12125 transformed cell line human CVCL_EH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176044 CVCL_EH06 GM10489 transformed cell line human CVCL_EH06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176045 CVCL_EH01 ND00147 transformed cell line human CVCL_EH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176046 CVCL_EH00 LSJ-4 embryonic stem cell human CVCL_EH00 From: Stanford University Center for Human Embryonic Stem Cell Research and Education; Stanford; USA. CL:0000010 Unspecified 21176047 CVCL_NB79 BayGenomics ES cell line RRJ465 embryonic stem cell house mouse CVCL_NB79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159614; Mia2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176048 CVCL_NB78 BayGenomics ES cell line RRJ464 embryonic stem cell house mouse CVCL_NB78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289308; Tax1bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176049 CVCL_NB77 BayGenomics ES cell line RRJ463 embryonic stem cell house mouse CVCL_NB77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384761; Rapgef6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176050 CVCL_NB76 BayGenomics ES cell line RRJ462 embryonic stem cell house mouse CVCL_NB76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917849; Itprid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176051 CVCL_NB75 BayGenomics ES cell line RRJ458 embryonic stem cell house mouse CVCL_NB75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930140; Wdr6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176052 CVCL_NB74 BayGenomics ES cell line RRJ456 embryonic stem cell house mouse CVCL_NB74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176053 CVCL_NB73 BayGenomics ES cell line RRJ453 embryonic stem cell house mouse CVCL_NB73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917581; Shprh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176054 CVCL_NB72 BayGenomics ES cell line RRJ451 embryonic stem cell house mouse CVCL_NB72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914473; Rrp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176055 CVCL_NB71 BayGenomics ES cell line RRJ450 embryonic stem cell house mouse CVCL_NB71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176056 CVCL_NB70 BayGenomics ES cell line RRJ449 embryonic stem cell house mouse CVCL_NB70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889508; Tbc1d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176057 CVCL_NB89 BayGenomics ES cell line RRJ490 embryonic stem cell house mouse CVCL_NB89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919151; Fam219a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176058 CVCL_NB88 BayGenomics ES cell line RRJ489 embryonic stem cell house mouse CVCL_NB88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347360; Cul3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176059 CVCL_NB87 BayGenomics ES cell line RRJ488 embryonic stem cell house mouse CVCL_NB87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95612; Gabpb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176060 CVCL_NB86 BayGenomics ES cell line RRJ479 embryonic stem cell house mouse CVCL_NB86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176061 CVCL_NB85 BayGenomics ES cell line RRJ478 embryonic stem cell house mouse CVCL_NB85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3050795; Mrtfb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176062 CVCL_NB84 BayGenomics ES cell line RRJ477 embryonic stem cell house mouse CVCL_NB84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176063 CVCL_NB83 BayGenomics ES cell line RRJ475 embryonic stem cell house mouse CVCL_NB83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445193; Utp6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176064 CVCL_NB82 BayGenomics ES cell line RRJ473 embryonic stem cell house mouse CVCL_NB82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913830; Esf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176065 CVCL_NB81 BayGenomics ES cell line RRJ472 embryonic stem cell house mouse CVCL_NB81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925288; Mccc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176066 CVCL_NB80 BayGenomics ES cell line RRJ470 embryonic stem cell house mouse CVCL_NB80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921494; Atg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176067 CVCL_NB59 BayGenomics ES cell line RRJ400 embryonic stem cell house mouse CVCL_NB59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108109; Ywhag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176068 CVCL_NB58 BayGenomics ES cell line RRJ398 embryonic stem cell house mouse CVCL_NB58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176069 CVCL_NB57 BayGenomics ES cell line RRJ397 embryonic stem cell house mouse CVCL_NB57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176070 CVCL_NB56 BayGenomics ES cell line RRJ396 embryonic stem cell house mouse CVCL_NB56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923539; Phf14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176071 CVCL_NB55 BayGenomics ES cell line RRJ394 embryonic stem cell house mouse CVCL_NB55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176072 CVCL_NB54 BayGenomics ES cell line RRJ393 embryonic stem cell house mouse CVCL_NB54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176073 CVCL_NB53 BayGenomics ES cell line RRJ392 embryonic stem cell house mouse CVCL_NB53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919889; Eme2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176074 CVCL_NB52 BayGenomics ES cell line RRJ388 embryonic stem cell house mouse CVCL_NB52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385619; Klhl12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176075 CVCL_NB51 BayGenomics ES cell line RRJ383 embryonic stem cell house mouse CVCL_NB51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176076 CVCL_NB50 BayGenomics ES cell line RRJ380 embryonic stem cell house mouse CVCL_NB50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141917; Prkd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176077 CVCL_NB69 BayGenomics ES cell line RRJ434 embryonic stem cell house mouse CVCL_NB69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176078 CVCL_NB68 BayGenomics ES cell line RRJ424 embryonic stem cell house mouse CVCL_NB68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176079 CVCL_NB67 BayGenomics ES cell line RRJ421 embryonic stem cell house mouse CVCL_NB67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384933; Wrap53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176080 CVCL_NB66 BayGenomics ES cell line RRJ419 embryonic stem cell house mouse CVCL_NB66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176081 CVCL_NB65 BayGenomics ES cell line RRJ417 embryonic stem cell house mouse CVCL_NB65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926227; Nup160 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176082 CVCL_NB64 BayGenomics ES cell line RRJ416 embryonic stem cell house mouse CVCL_NB64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917262; Cep85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176083 CVCL_NB63 BayGenomics ES cell line RRJ410 embryonic stem cell house mouse CVCL_NB63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931028; Recql4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176084 CVCL_NB62 BayGenomics ES cell line RRJ409 embryonic stem cell house mouse CVCL_NB62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176085 CVCL_NB61 BayGenomics ES cell line RRJ404 embryonic stem cell house mouse CVCL_NB61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349417; Zfp346 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176086 CVCL_NB60 BayGenomics ES cell line RRJ401 embryonic stem cell house mouse CVCL_NB60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344353; Katna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176087 CVCL_NB39 BayGenomics ES cell line RRJ354 embryonic stem cell house mouse CVCL_NB39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442190; Camk1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176088 CVCL_NB38 BayGenomics ES cell line RRJ352 embryonic stem cell house mouse CVCL_NB38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176089 CVCL_NB37 BayGenomics ES cell line RRJ350 embryonic stem cell house mouse CVCL_NB37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176090 CVCL_NB36 BayGenomics ES cell line RRJ340 embryonic stem cell house mouse CVCL_NB36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176091 CVCL_NB35 BayGenomics ES cell line RRJ339 embryonic stem cell house mouse CVCL_NB35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202402; Pde7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176092 CVCL_NB34 BayGenomics ES cell line RRJ336 embryonic stem cell house mouse CVCL_NB34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176093 CVCL_NB33 BayGenomics ES cell line RRJ335 embryonic stem cell house mouse CVCL_NB33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915395; Etaa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176094 CVCL_NB32 BayGenomics ES cell line RRJ332 embryonic stem cell house mouse CVCL_NB32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176095 CVCL_NB31 BayGenomics ES cell line RRJ331 embryonic stem cell house mouse CVCL_NB31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919348; Tmem68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176096 CVCL_NB30 BayGenomics ES cell line RRJ329 embryonic stem cell house mouse CVCL_NB30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99925; Mybl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176097 CVCL_EH96 ND32891 transformed cell line human CVCL_EH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176098 CVCL_EH95 ND24108 transformed cell line human CVCL_EH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176099 CVCL_EH94 ND23225 transformed cell line human CVCL_EH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176100 CVCL_EH93 ND22992 transformed cell line human CVCL_EH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176101 CVCL_EH99 ND39826 transformed cell line human CVCL_EH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176102 CVCL_EH98 ND36039 transformed cell line human CVCL_EH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176103 CVCL_EH97 ND34178 transformed cell line human CVCL_EH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176104 CVCL_NB49 BayGenomics ES cell line RRJ378 embryonic stem cell house mouse CVCL_NB49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176105 CVCL_NB48 BayGenomics ES cell line RRJ374 embryonic stem cell house mouse CVCL_NB48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927489; Pdlim5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176106 CVCL_NB47 BayGenomics ES cell line RRJ373 embryonic stem cell house mouse CVCL_NB47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176107 CVCL_NB46 BayGenomics ES cell line RRJ372 embryonic stem cell house mouse CVCL_NB46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917264; Kat14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176108 CVCL_NB45 BayGenomics ES cell line RRJ368 embryonic stem cell house mouse CVCL_NB45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921344; Tjap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176109 CVCL_NB44 BayGenomics ES cell line RRJ366 embryonic stem cell house mouse CVCL_NB44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176110 CVCL_NB43 BayGenomics ES cell line RRJ363 embryonic stem cell house mouse CVCL_NB43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146430; Cblb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176111 CVCL_NB42 BayGenomics ES cell line RRJ362 embryonic stem cell house mouse CVCL_NB42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176112 CVCL_NB41 BayGenomics ES cell line RRJ361 embryonic stem cell house mouse CVCL_NB41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351664; Ptdss2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176113 CVCL_NB40 BayGenomics ES cell line RRJ357 embryonic stem cell house mouse CVCL_NB40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384799; Enox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176114 CVCL_NB19 BayGenomics ES cell line RRJ297 embryonic stem cell house mouse CVCL_NB19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201387; Nlk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176115 CVCL_NB18 BayGenomics ES cell line RRJ295 embryonic stem cell house mouse CVCL_NB18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387217; Ift52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176116 CVCL_NB17 BayGenomics ES cell line RRJ292 embryonic stem cell house mouse CVCL_NB17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176117 CVCL_NB16 BayGenomics ES cell line RRJ291 embryonic stem cell house mouse CVCL_NB16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039616; Znrf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176118 CVCL_NB15 BayGenomics ES cell line RRJ290 embryonic stem cell house mouse CVCL_NB15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176119 CVCL_EH81 ND19510 transformed cell line human CVCL_EH81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176120 CVCL_NB14 BayGenomics ES cell line RRJ289 embryonic stem cell house mouse CVCL_NB14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176121 CVCL_EH80 ND19449 transformed cell line human CVCL_EH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176122 CVCL_NB13 BayGenomics ES cell line RRJ288 embryonic stem cell house mouse CVCL_NB13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202384; Ddb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176123 CVCL_NB12 BayGenomics ES cell line RRJ285 embryonic stem cell house mouse CVCL_NB12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333856; Klf9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176124 CVCL_NB11 BayGenomics ES cell line RRJ280 embryonic stem cell house mouse CVCL_NB11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443448; Ccdc14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176125 CVCL_NB10 BayGenomics ES cell line RRJ275 embryonic stem cell house mouse CVCL_NB10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97317; Nfyb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176126 CVCL_EH79 ND19393 transformed cell line human CVCL_EH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176127 CVCL_EH74 ND19218 transformed cell line human CVCL_EH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176128 CVCL_EH73 ND19198 transformed cell line human CVCL_EH73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176129 CVCL_EH72 ND16650 transformed cell line human CVCL_EH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176130 CVCL_EH71 ND16578 transformed cell line human CVCL_EH71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176131 CVCL_EH78 ND19388 transformed cell line human CVCL_EH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176132 CVCL_EH77 ND19354 transformed cell line human CVCL_EH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176133 CVCL_EH76 ND19347 transformed cell line human CVCL_EH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176134 CVCL_NB09 BayGenomics ES cell line RRJ270 embryonic stem cell house mouse CVCL_NB09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347352; Hunk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176135 CVCL_EH75 ND19342 transformed cell line human CVCL_EH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176136 CVCL_NB29 BayGenomics ES cell line RRJ328 embryonic stem cell house mouse CVCL_NB29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921694; Tasor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176137 CVCL_NB28 BayGenomics ES cell line RRJ324 embryonic stem cell house mouse CVCL_NB28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176138 CVCL_NB27 BayGenomics ES cell line RRJ321 embryonic stem cell house mouse CVCL_NB27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306824; Suclg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176139 CVCL_NB26 BayGenomics ES cell line RRJ318 embryonic stem cell house mouse CVCL_NB26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859150; Akap7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176140 CVCL_EH92 ND22596 transformed cell line human CVCL_EH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176141 CVCL_NB25 BayGenomics ES cell line RRJ310 embryonic stem cell house mouse CVCL_NB25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914247; Psmd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176142 CVCL_EH91 ND20919 transformed cell line human CVCL_EH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176143 CVCL_NB24 BayGenomics ES cell line RRJ309 embryonic stem cell house mouse CVCL_NB24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931027; Stx12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176144 CVCL_EH90 ND20786 transformed cell line human CVCL_EH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176145 CVCL_NB23 BayGenomics ES cell line RRJ304 embryonic stem cell house mouse CVCL_NB23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176146 CVCL_NB22 BayGenomics ES cell line RRJ302 embryonic stem cell house mouse CVCL_NB22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176147 CVCL_NB21 BayGenomics ES cell line RRJ301 embryonic stem cell house mouse CVCL_NB21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922246; Usp47 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176148 CVCL_NB20 BayGenomics ES cell line RRJ299 embryonic stem cell house mouse CVCL_NB20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176149 CVCL_EH85 ND19924 transformed cell line human CVCL_EH85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176150 CVCL_EH84 ND19913 transformed cell line human CVCL_EH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176151 CVCL_EH83 ND19850 transformed cell line human CVCL_EH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176152 CVCL_EH82 ND19767 transformed cell line human CVCL_EH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176153 CVCL_EH89 ND20237 transformed cell line human CVCL_EH89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176154 CVCL_EH88 ND20082 transformed cell line human CVCL_EH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176155 CVCL_EH87 ND20069 transformed cell line human CVCL_EH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176156 CVCL_EH86 ND19978 transformed cell line human CVCL_EH86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176157 CVCL_EA84 ND08904 transformed cell line human CVCL_EA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176158 CVCL_EA83 ND08903 transformed cell line human CVCL_EA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176159 CVCL_EA82 ND08902 transformed cell line human CVCL_EA82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176160 CVCL_EA81 ND08901 transformed cell line human CVCL_EA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176161 CVCL_EA88 ND08997 transformed cell line human CVCL_EA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176162 CVCL_EA87 ND08926 transformed cell line human CVCL_EA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176163 CVCL_EA86 ND08925 transformed cell line human CVCL_EA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176164 CVCL_MZ19 BayGenomics ES cell line RRI314 embryonic stem cell house mouse CVCL_MZ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176165 CVCL_EA85 ND08905 transformed cell line human CVCL_EA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176166 CVCL_MZ18 BayGenomics ES cell line RRI313 embryonic stem cell house mouse CVCL_MZ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176167 CVCL_MZ17 BayGenomics ES cell line RRI309 embryonic stem cell house mouse CVCL_MZ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914321; Rps6ka6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176168 CVCL_MZ16 BayGenomics ES cell line RRI307 embryonic stem cell house mouse CVCL_MZ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445089; Trappc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176169 CVCL_MZ15 BayGenomics ES cell line RRI306 embryonic stem cell house mouse CVCL_MZ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919818; Lin9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176170 CVCL_MZ14 BayGenomics ES cell line RRI305 embryonic stem cell house mouse CVCL_MZ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919891; Mob2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176171 CVCL_EA80 ND08899 transformed cell line human CVCL_EA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176172 CVCL_MZ13 BayGenomics ES cell line RRI304 embryonic stem cell house mouse CVCL_MZ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176173 CVCL_MZ12 BayGenomics ES cell line RRI298 embryonic stem cell house mouse CVCL_MZ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98834; Trp53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176174 CVCL_MZ11 BayGenomics ES cell line RRI295 embryonic stem cell house mouse CVCL_MZ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916082; Ldah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176175 CVCL_MZ10 BayGenomics ES cell line RRI293 embryonic stem cell house mouse CVCL_MZ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918590; Riok1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176176 CVCL_EA79 ND08840 transformed cell line human CVCL_EA79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176177 CVCL_EA78 ND08837 transformed cell line human CVCL_EA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176178 CVCL_EA95 ND09513 transformed cell line human CVCL_EA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176179 CVCL_EA94 ND09301 transformed cell line human CVCL_EA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176180 CVCL_EA93 ND09278 transformed cell line human CVCL_EA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176181 CVCL_EA92 ND09124 transformed cell line human CVCL_EA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176182 CVCL_EA99 ND09699 transformed cell line human CVCL_EA99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176183 CVCL_EA98 ND09657 transformed cell line human CVCL_EA98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176184 CVCL_EA97 ND09586 transformed cell line human CVCL_EA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176185 CVCL_EA96 ND09514 transformed cell line human CVCL_EA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176186 CVCL_MZ29 BayGenomics ES cell line RRI359 embryonic stem cell house mouse CVCL_MZ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344349; Rnf216 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176187 CVCL_MZ28 BayGenomics ES cell line RRI347 embryonic stem cell house mouse CVCL_MZ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98834; Trp53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176188 CVCL_MZ27 BayGenomics ES cell line RRI342 embryonic stem cell house mouse CVCL_MZ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913820; Cenpm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176189 CVCL_MZ26 BayGenomics ES cell line RRI340 embryonic stem cell house mouse CVCL_MZ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176190 CVCL_MZ25 BayGenomics ES cell line RRI332 embryonic stem cell house mouse CVCL_MZ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443370; Chtf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176191 CVCL_EA91 ND09066 transformed cell line human CVCL_EA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176192 CVCL_MZ24 BayGenomics ES cell line RRI330 embryonic stem cell house mouse CVCL_MZ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913355; Ube2d3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176193 CVCL_EA90 ND09056 transformed cell line human CVCL_EA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176194 CVCL_MZ23 BayGenomics ES cell line RRI328 embryonic stem cell house mouse CVCL_MZ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176195 CVCL_MZ22 BayGenomics ES cell line RRI325 embryonic stem cell house mouse CVCL_MZ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099436; Rad51b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176196 CVCL_MZ21 BayGenomics ES cell line RRI323 embryonic stem cell house mouse CVCL_MZ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917598; Ube2cbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176197 CVCL_MZ20 BayGenomics ES cell line RRI321 embryonic stem cell house mouse CVCL_MZ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176198 CVCL_EA89 ND09002 transformed cell line human CVCL_EA89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176199 CVCL_EA62 ND08610 transformed cell line human CVCL_EA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176200 CVCL_EA61 ND08608 transformed cell line human CVCL_EA61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176201 CVCL_EA60 ND08603 transformed cell line human CVCL_EA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176202 CVCL_EA66 ND08656 transformed cell line human CVCL_EA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176203 CVCL_EA65 ND08655 transformed cell line human CVCL_EA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176204 CVCL_EA64 ND08640 transformed cell line human CVCL_EA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176205 CVCL_EA63 ND08639 transformed cell line human CVCL_EA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176206 CVCL_EA59 ND08593 transformed cell line human CVCL_EA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176207 CVCL_EA58 ND08583 transformed cell line human CVCL_EA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176208 CVCL_EA57 ND08582 transformed cell line human CVCL_EA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176209 CVCL_EA56 ND08521 transformed cell line human CVCL_EA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176210 CVCL_EA73 ND08774 transformed cell line human CVCL_EA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176211 CVCL_EA72 ND08764 transformed cell line human CVCL_EA72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176212 CVCL_EA71 ND08763 transformed cell line human CVCL_EA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176213 CVCL_EA70 ND08737 transformed cell line human CVCL_EA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176214 CVCL_EA77 ND08805 transformed cell line human CVCL_EA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176215 CVCL_EA76 ND08804 transformed cell line human CVCL_EA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176216 CVCL_MZ09 BayGenomics ES cell line RRI288 embryonic stem cell house mouse CVCL_MZ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915149; Cmc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176217 CVCL_EA75 ND08803 transformed cell line human CVCL_EA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176218 CVCL_MZ08 BayGenomics ES cell line RRI283 embryonic stem cell house mouse CVCL_MZ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916891; Wdr20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176219 CVCL_EA74 ND08802 transformed cell line human CVCL_EA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176220 CVCL_MZ07 BayGenomics ES cell line RRI281 embryonic stem cell house mouse CVCL_MZ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925976; Scaper Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176221 CVCL_MZ06 BayGenomics ES cell line RRI275 embryonic stem cell house mouse CVCL_MZ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928469; Trip4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176222 CVCL_MZ05 BayGenomics ES cell line RRI274 embryonic stem cell house mouse CVCL_MZ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95797; Gpi1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176223 CVCL_MZ04 BayGenomics ES cell line RRI269 embryonic stem cell house mouse CVCL_MZ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176224 CVCL_MZ03 BayGenomics ES cell line RRI268 embryonic stem cell house mouse CVCL_MZ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176225 CVCL_MZ02 BayGenomics ES cell line RRI266 embryonic stem cell house mouse CVCL_MZ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95753; Glud1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176226 CVCL_MZ01 BayGenomics ES cell line RRI265 embryonic stem cell house mouse CVCL_MZ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925642; Fnbp1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176227 CVCL_MZ00 BayGenomics ES cell line RRI261 embryonic stem cell house mouse CVCL_MZ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176228 CVCL_EA69 ND08701 transformed cell line human CVCL_EA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176229 CVCL_EA68 ND08692 transformed cell line human CVCL_EA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176230 CVCL_EA67 ND08675 transformed cell line human CVCL_EA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176231 CVCL_EA40 ND08196 transformed cell line human CVCL_EA40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176232 CVCL_EA44 ND08276 transformed cell line human CVCL_EA44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176233 CVCL_EA43 ND08241 transformed cell line human CVCL_EA43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176234 CVCL_EA42 ND08208 transformed cell line human CVCL_EA42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176235 CVCL_EA41 ND08207 transformed cell line human CVCL_EA41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176236 CVCL_EA37 ND08120 transformed cell line human CVCL_EA37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176237 CVCL_EA36 ND08119 transformed cell line human CVCL_EA36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176238 CVCL_EA35 ND08117 transformed cell line human CVCL_EA35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176239 CVCL_EA34 ND08097 transformed cell line human CVCL_EA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176240 CVCL_EA39 ND08122 transformed cell line human CVCL_EA39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176241 CVCL_EA38 ND08121 transformed cell line human CVCL_EA38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176242 CVCL_EA51 ND08487 transformed cell line human CVCL_EA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176243 CVCL_EA50 ND08478 transformed cell line human CVCL_EA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176244 CVCL_EA55 ND08520 transformed cell line human CVCL_EA55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176245 CVCL_EA54 ND08491 transformed cell line human CVCL_EA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176246 CVCL_EA53 ND08490 transformed cell line human CVCL_EA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176247 CVCL_EA52 ND08488 transformed cell line human CVCL_EA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176248 CVCL_EA48 ND08403 transformed cell line human CVCL_EA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176249 CVCL_EA47 ND08380 transformed cell line human CVCL_EA47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176250 CVCL_EA46 ND08343 transformed cell line human CVCL_EA46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176251 CVCL_EA45 ND08280 transformed cell line human CVCL_EA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176252 CVCL_EA49 ND08446 transformed cell line human CVCL_EA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176253 CVCL_EA22 ND07981 transformed cell line human CVCL_EA22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176254 CVCL_EA21 ND07979 transformed cell line human CVCL_EA21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176255 CVCL_EA20 ND07964 transformed cell line human CVCL_EA20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176256 CVCL_EA15 ND07953 transformed cell line human CVCL_EA15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176257 CVCL_EA14 ND07952 transformed cell line human CVCL_EA14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176258 CVCL_EA13 ND07948 transformed cell line human CVCL_EA13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176259 CVCL_EA12 ND07947 transformed cell line human CVCL_EA12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176260 CVCL_EA19 ND07959 transformed cell line human CVCL_EA19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176261 CVCL_EA18 ND07958 transformed cell line human CVCL_EA18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176262 CVCL_EA17 ND07957 transformed cell line human CVCL_EA17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176263 CVCL_EA16 ND07954 transformed cell line human CVCL_EA16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176264 CVCL_EA33 ND08096 transformed cell line human CVCL_EA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176265 CVCL_EA32 ND08095 transformed cell line human CVCL_EA32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176266 CVCL_EA31 ND08094 transformed cell line human CVCL_EA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176267 CVCL_EA30 ND08062 transformed cell line human CVCL_EA30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176268 CVCL_EA26 ND08026 transformed cell line human CVCL_EA26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176269 CVCL_EA25 ND08024 transformed cell line human CVCL_EA25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176270 CVCL_EA24 ND07985 transformed cell line human CVCL_EA24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176271 CVCL_EA23 ND07984 transformed cell line human CVCL_EA23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176272 CVCL_EA29 ND08044 transformed cell line human CVCL_EA29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176273 CVCL_EA28 ND08035 transformed cell line human CVCL_EA28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176274 CVCL_EA27 ND08028 transformed cell line human CVCL_EA27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176275 CVCL_VT35 JHH-75 cancer cell line human CVCL_VT35 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Female 21176276 CVCL_W535 SBC-3/SN-38 cancer cell line human CVCL_W535 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from metastatic site: Bone marrow. Male 21176277 CVCL_VT34 JHH-66 cancer cell line human CVCL_VT34 CL:0000010 Derived from sampling site: Brain; right occipital lobe. Female 21176278 CVCL_W534 MTO-94 cancer cell line human CVCL_W534 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21176279 CVCL_VT33 JHH-520 cancer cell line human CVCL_VT33 CL:0000010 Derived from sampling site: Brain; right frontal lobe. Female 21176280 CVCL_W533 MLP-1 cancer cell line CVCL_W533 CL:0000010 Derived from sampling site: Ascites. Unspecified Doubling time: ~48 hours (PubMed=4280237) 21176281 CVCL_VT32 JHH-505 cancer cell line human CVCL_VT32 CL:0000010 Derived from sampling site: Brain; right parietal lobe. Male 21176282 CVCL_W532 KaMi cancer cell line human CVCL_W532 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Male Doubling time: 20.6 hours (PubMed=1279943) 21176283 CVCL_VT39 JHU-1016A cancer cell line human CVCL_VT39 CL:0000010 Derived from sampling site: Brain; right temporal lobe. Male 21176284 CVCL_W539 KO-001-25 induced pluripotent stem cell human CVCL_W539 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176285 CVCL_VT38 JHU-1014 cancer cell line human CVCL_VT38 CL:0000010 Derived from sampling site: Brain; left temporal lobe. Male 21176286 CVCL_W538 KO-001-19 induced pluripotent stem cell human CVCL_W538 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176287 CVCL_VT37 JHU-0937 cancer cell line human CVCL_VT37 CL:0000010 Derived from sampling site: Brain; left temporal lobe. Male 21176288 CVCL_W537 SA-001-3B1 induced pluripotent stem cell human CVCL_W537 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176289 CVCL_VT36 JHU-0879 cancer cell line human CVCL_VT36 CL:0000010 Derived from sampling site: Brain; left parieto-occipital lobe. Female 21176290 CVCL_W536 MCF-7/182R-6 cancer cell line human CVCL_W536 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780); Derived from metastatic site: Pleural effusion. Female Doubling time: 24 hours, in estradiol-deprived medium (PubMed=10027303) 21176291 CVCL_MZ99 BayGenomics ES cell line RRJ017 embryonic stem cell house mouse CVCL_MZ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109447; Ctcf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176292 CVCL_MZ98 BayGenomics ES cell line RRJ015 embryonic stem cell house mouse CVCL_MZ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913721; Anp32e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176293 CVCL_MZ97 BayGenomics ES cell line RRJ012 embryonic stem cell house mouse CVCL_MZ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102956; Cdk7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176294 CVCL_MZ96 BayGenomics ES cell line RRJ011 embryonic stem cell house mouse CVCL_MZ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176295 CVCL_MZ95 BayGenomics ES cell line RRJ010 embryonic stem cell house mouse CVCL_MZ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176296 CVCL_MZ94 BayGenomics ES cell line RRJ009 embryonic stem cell house mouse CVCL_MZ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176297 CVCL_MZ93 BayGenomics ES cell line RRJ005 embryonic stem cell house mouse CVCL_MZ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921269; Traf3ip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176298 CVCL_MZ92 BayGenomics ES cell line RRJ004 embryonic stem cell house mouse CVCL_MZ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176299 CVCL_MZ91 BayGenomics ES cell line RRJ003 embryonic stem cell house mouse CVCL_MZ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858943; Arl6ip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176300 CVCL_MZ90 BayGenomics ES cell line RRJ002 embryonic stem cell house mouse CVCL_MZ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176301 CVCL_W542 GM00783 finite cell line human CVCL_W542 CL:0000010 Population: African American; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21176302 CVCL_VT42 HEL23.3 induced pluripotent stem cell human CVCL_VT42 From: University of Helsinki; Helsinki; Finland. CL:0000010 21176303 CVCL_W541 GM00513 finite cell line human CVCL_W541 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (PubMed=34139597) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21176304 CVCL_VT41 NCC-MFS1-C1 cancer cell line human CVCL_VT41 CL:0000010 Population: Japanese; Derived from sampling site: Forearm; hypodermis. Omics: Deep proteome analysis Male Doubling time: 78 hours (PubMed=30737712) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21176305 CVCL_VT40 JHU-1016B cancer cell line human CVCL_VT40 CL:0000010 Derived from sampling site: Brain; right temporal lobe. Male 21176306 CVCL_W540 SA-001-1D2 induced pluripotent stem cell human CVCL_W540 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176307 CVCL_W524 HKMS cancer cell line human CVCL_W524 CL:0000010 Population: Japanese Female Doubling time: 42 hours (at 10th passage), 37 hours (at 30th passage), 38 hours (at 50th passage) (PubMed=2519215). 21176308 CVCL_VT24 Me67.5 cancer cell line human CVCL_VT24 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176309 CVCL_W523 JHP-1 cancer cell line human CVCL_W523 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 22 hours (PubMed=2979202) 21176310 CVCL_VT23 Me67.3 cancer cell line human CVCL_VT23 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176311 CVCL_W522 IT-25 cancer cell line human CVCL_W522 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male Characteristics: Established from a xenograft maintained in nude mice Doubling time: ~57.8 hours (PubMed=2979201) 21176312 CVCL_VT22 Me59/7 cancer cell line human CVCL_VT22 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176313 CVCL_W521 DAIT-6 cancer cell line human CVCL_W521 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Male Characteristics: Established from a xenograft maintained in nude mice Doubling time: ~45.0 hours (PubMed=2979201) 21176314 CVCL_VT21 Me59/4 cancer cell line human CVCL_VT21 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176315 CVCL_VT28 JHH-136 cancer cell line human CVCL_VT28 CL:0000010 Derived from sampling site: Brain; right frontal lobe. Male 21176316 CVCL_W528 W-ES cancer cell line human CVCL_W528 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=9738976); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=8221663). Population: Japanese Female Doubling time: 35 hours (PubMed=2486606) 21176317 CVCL_VT27 GAL30.19 hybrid cell line house mouse CVCL_VT27 CL:0000010 Characteristics: Fusoma, fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P00722; Escherichia coli lacZ; Monoclonal antibody target: UniProtKB; Q8IWL2; Human SFTPA. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 92042211 21176318 CVCL_W527 RMS cancer cell line human CVCL_W527 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Unspecified (PubMed=2216456) Population: Japanese Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified Doubling time: 20-24 hours (PubMed=2486618) 21176319 CVCL_W526 KUM.LK-2 cancer cell line human CVCL_W526 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Established after 2 tumor passages in nude mice; Characteristics: Produces lung metastases in nude mice 21176320 CVCL_VT26 Me67.10 cancer cell line human CVCL_VT26 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176321 CVCL_VT25 Me67.9 cancer cell line human CVCL_VT25 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176322 CVCL_VT29 JHH-211 cancer cell line human CVCL_VT29 CL:0000010 Derived from sampling site: Brain; left frontal lobe. Male 21176323 CVCL_W529 SBC-3/ETP cancer cell line human CVCL_W529 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Bone marrow. Male Doubling time: 38.0 hours (PubMed=10628341) 21176324 CVCL_3N01 HQ01316 transformed cell line human CVCL_3N01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176325 CVCL_3N00 HQ01315 transformed cell line human CVCL_3N00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176326 CVCL_VT31 JHH-245 cancer cell line human CVCL_VT31 CL:0000010 Derived from sampling site: Brain; right occipital lobe. Male 21176327 CVCL_W531 SBC-2 [Human SCLC] cancer cell line human CVCL_W531 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 33.8 hours (PubMed=8286010) Problematic cell line: Possibly misidentified/contaminated Shown to be identical to SBC-1 (JCRB web site and STR profile). 21176328 CVCL_VT30 JHH-227 cancer cell line human CVCL_VT30 CL:0000010 Derived from sampling site: Brain; right periatrial region. Male 21176329 CVCL_W530 SBC-7 [Human SCLC] cancer cell line human CVCL_W530 CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Omics: SNP array analysis Unspecified Doubling time: 39.0 hours (PubMed=8286010) 21176330 CVCL_VT13 CENSOi002-A induced pluripotent stem cell human CVCL_VT13 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln3231Ter (c.9691C>T); ClinVar=VCV000523784; Zygosity=Hemizygous (from autologous cell line CENSOi002-B) Derived from sampling site: Cell type=Fibroblast. Male 21176331 CVCL_W513 KUMA-2 cancer cell line human CVCL_W513 CL:0000010 Population: Japanese. Male 21176332 CVCL_VT12 CENSOi001-A induced pluripotent stem cell human CVCL_VT12 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (from autologous cell line CENSOi001-B) Derived from sampling site: Cell type=Fibroblast. Male 21176333 CVCL_W512 KUMA-1 cancer cell line human CVCL_W512 HLA typing: A*26:03,33:02; B*15:03,44:03:01; C*03:03,14:03 (PubMed=9178645). CL:0000010 Population: Japanese Male 21176334 CVCL_VT11 BCMi001-B induced pluripotent stem cell human CVCL_VT11 From: Baylor College of Medicine; Houston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21176335 CVCL_W511 FS-1 [Human maxillary sinus SCC] cancer cell line human CVCL_W511 HLA typing: A*02:06,24:02 (PubMed=10741724); HLA typing: A*09,28; B*48,54; C*01,04 (PubMed=7872892) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=10741724) Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male Doubling time: 72 hours, at 9th passage (PubMed=7872892) 21176336 CVCL_VT10 BCMi001-A induced pluripotent stem cell human CVCL_VT10 From: Baylor College of Medicine; Houston; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21176337 CVCL_W510 UCS-5 cancer cell line human CVCL_W510 CL:0000010 Derived from metastatic site: Lung. Female 21176338 CVCL_VT17 Me15 cancer cell line human CVCL_VT17 CL:0000010 Derived from metastatic site: Lymph node. Male 21176339 CVCL_W517 TN-3 cancer cell line human CVCL_W517 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Female 21176340 CVCL_W516 LMF5 cancer cell line human CVCL_W516 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21176341 CVCL_VT16 MST cancer cell line house mouse CVCL_VT16 CL:0000010 Doubling time: 14-17 hours (PubMed=1454815). 21176342 CVCL_W515 LMF4 cancer cell line human CVCL_W515 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21176343 CVCL_VT15 TB [Mouse] undefined cell line type house mouse CVCL_VT15 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6459; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21176344 CVCL_W514 LMF3 cancer cell line human CVCL_W514 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu120Ter (c.358G>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs (c.912_913insTAAG); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Cervical lymph node. Male 21176345 CVCL_VT14 ZJUCHi001-A induced pluripotent stem cell human CVCL_VT14 From: Children's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Arg98Cys (c.292C>T); ClinVar=VCV000014175; Zygosity=Heterozygous (PubMed=30785048) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21176346 CVCL_W519 C-HC-4 cancer cell line human CVCL_W519 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: ~20 hours (PubMed=2856442) 21176347 CVCL_VT19 Me59 cancer cell line human CVCL_VT19 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176348 CVCL_W518 C-HC-20 cancer cell line human CVCL_W518 CL:0000010 Population: Japanese. Male 21176349 CVCL_VT18 Me51 cancer cell line human CVCL_VT18 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176350 CVCL_MZ79 BayGenomics ES cell line RRI484 embryonic stem cell house mouse CVCL_MZ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176351 CVCL_MZ78 BayGenomics ES cell line RRI483 embryonic stem cell house mouse CVCL_MZ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352757; Iqgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176352 CVCL_MZ77 BayGenomics ES cell line RRI481 embryonic stem cell house mouse CVCL_MZ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176353 CVCL_MZ76 BayGenomics ES cell line RRI480 embryonic stem cell house mouse CVCL_MZ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914125; Swt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176354 CVCL_MZ75 BayGenomics ES cell line RRI473 embryonic stem cell house mouse CVCL_MZ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914125; Swt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176355 CVCL_MZ74 BayGenomics ES cell line RRI472 embryonic stem cell house mouse CVCL_MZ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176356 CVCL_MZ73 BayGenomics ES cell line RRI470 embryonic stem cell house mouse CVCL_MZ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176357 CVCL_MZ72 BayGenomics ES cell line RRI468 embryonic stem cell house mouse CVCL_MZ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917580; Bclaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176358 CVCL_MZ71 BayGenomics ES cell line RRI467 embryonic stem cell house mouse CVCL_MZ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98310; Ski Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176359 CVCL_MZ70 BayGenomics ES cell line RRI466 embryonic stem cell house mouse CVCL_MZ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176360 CVCL_W520 CH-N-1 cancer cell line human CVCL_W520 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified Characteristics: Established from a third generation xenograft produced by subcutaneous infection of tumor cells into nude mice 21176361 CVCL_VT20 Me67 cancer cell line human CVCL_VT20 CL:0000010 Derived from metastatic site: Not specified. Unspecified 21176362 CVCL_VT02 HKOA cancer cell line human CVCL_VT02 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 32 hours (PubMed=3593088) 21176363 CVCL_W502 UCCA-21 cancer cell line human CVCL_W502 CL:0000010 Population: Japanese Female Doubling time: 63.6 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319). 21176364 CVCL_VT01 HFUA cancer cell line human CVCL_VT01 CL:0000010 Population: Japanese Female Doubling time: 27 hours (PubMed=10457904). 21176365 CVCL_W501 TS-RM-1 cancer cell line human CVCL_W501 CL:0000010 Population: Japanese Female Characteristics: Established from a transplanted tumor (TS-RM-1nu) in BALB/c nu/nu mice Doubling time: 31 hours (PubMed=7669751). 21176366 CVCL_VT00 HIRS-BMS cancer cell line human CVCL_VT00 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female Doubling time: 50 hours (PubMed=3019754) 21176367 CVCL_W500 SYNb-2 cancer cell line human CVCL_W500 CL:0000010 Derived from metastatic site: Lung. Male 21176368 CVCL_VT06 HYOA cancer cell line human CVCL_VT06 CL:0000010 Population: Japanese Female Doubling time: 31 hours (PubMed=3593088). 21176369 CVCL_W506 UCCA-25 cancer cell line human CVCL_W506 CL:0000010 Population: Japanese Female Doubling time: 40.5 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319). 21176370 CVCL_VT05 HWTUA cancer cell line human CVCL_VT05 CL:0000010 Population: Japanese Female Doubling time: 29 hours (PubMed=10457904) 21176371 CVCL_W505 UCCA-24 cancer cell line human CVCL_W505 CL:0000010 Population: Japanese Female Doubling time: 37.3 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319). 21176372 CVCL_VT04 HSUA cancer cell line human CVCL_VT04 CL:0000010 Population: Japanese Female Doubling time: 35 hours (PubMed=10457904). 21176373 CVCL_W504 UCCA-23 cancer cell line human CVCL_W504 CL:0000010 Population: Japanese Female Doubling time: 44.4 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319). 21176374 CVCL_VT03 HKUA cancer cell line human CVCL_VT03 CL:0000010 Population: Japanese Female Doubling time: 32 hours (PubMed=10457904). 21176375 CVCL_W503 UCCA-22 cancer cell line human CVCL_W503 CL:0000010 Population: Japanese Female Doubling time: 43.8 hours (PubMed=15016319); Microsatellite instability: Stable (MSS) (PubMed=15016319). 21176376 CVCL_VT09 EDi023-A induced pluripotent stem cell human CVCL_VT09 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Female Part of: Lothian Birth Cohort 1936 iPSC collection 21176377 CVCL_W509 UCS-4 cancer cell line human CVCL_W509 CL:0000010 Derived from metastatic site: Lung. Male 21176378 CVCL_VT08 EDi022-A induced pluripotent stem cell human CVCL_VT08 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21176379 CVCL_W508 UCS-2 cancer cell line human CVCL_W508 CL:0000010 Male 21176380 CVCL_VT07 EDi021-A induced pluripotent stem cell human CVCL_VT07 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21176381 CVCL_W507 UCCA-3 cancer cell line human CVCL_W507 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=15016319). Population: Japanese Female Doubling time: 56.9 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319) 21176382 CVCL_MZ89 BayGenomics ES cell line RRI507 embryonic stem cell house mouse CVCL_MZ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107637; Psmb7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176383 CVCL_MZ88 BayGenomics ES cell line RRI506 embryonic stem cell house mouse CVCL_MZ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924066; Sdccag8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176384 CVCL_MZ87 BayGenomics ES cell line RRI505 embryonic stem cell house mouse CVCL_MZ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890504; Maml1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176385 CVCL_MZ86 BayGenomics ES cell line RRI504 embryonic stem cell house mouse CVCL_MZ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916884; Clybl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176386 CVCL_MZ85 BayGenomics ES cell line RRI500 embryonic stem cell house mouse CVCL_MZ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261910; Pibf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176387 CVCL_MZ84 BayGenomics ES cell line RRI499 embryonic stem cell house mouse CVCL_MZ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176388 CVCL_MZ83 BayGenomics ES cell line RRI497 embryonic stem cell house mouse CVCL_MZ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178798; Vps54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176389 CVCL_MZ82 BayGenomics ES cell line RRI494 embryonic stem cell house mouse CVCL_MZ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919070; Dync2i2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176390 CVCL_MZ81 BayGenomics ES cell line RRI492 embryonic stem cell house mouse CVCL_MZ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914125; Swt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176391 CVCL_MZ80 BayGenomics ES cell line RRI487 embryonic stem cell house mouse CVCL_MZ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107978; Klc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176392 CVCL_MZ59 BayGenomics ES cell line RRI439 embryonic stem cell house mouse CVCL_MZ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443207; Plekhm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176393 CVCL_MZ58 BayGenomics ES cell line RRI436 embryonic stem cell house mouse CVCL_MZ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277218; Rpap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176394 CVCL_MZ57 BayGenomics ES cell line RRI434 embryonic stem cell house mouse CVCL_MZ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176395 CVCL_MZ56 BayGenomics ES cell line RRI431 embryonic stem cell house mouse CVCL_MZ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181182; Nup155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176396 CVCL_MZ55 BayGenomics ES cell line RRI430 embryonic stem cell house mouse CVCL_MZ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3609241; Lonrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176397 CVCL_MZ54 BayGenomics ES cell line RRI429 embryonic stem cell house mouse CVCL_MZ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442827; Tbc1d32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176398 CVCL_MZ53 BayGenomics ES cell line RRI425 embryonic stem cell house mouse CVCL_MZ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679255; Ssh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176399 CVCL_MZ52 BayGenomics ES cell line RRI423 embryonic stem cell house mouse CVCL_MZ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107930; Pip5k1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176400 CVCL_MZ51 BayGenomics ES cell line RRI416 embryonic stem cell house mouse CVCL_MZ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176401 CVCL_MZ50 BayGenomics ES cell line RRI415 embryonic stem cell house mouse CVCL_MZ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107460; Cox6b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176402 CVCL_MZ69 BayGenomics ES cell line RRI464 embryonic stem cell house mouse CVCL_MZ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108109; Ywhag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176403 CVCL_MZ68 BayGenomics ES cell line RRI462 embryonic stem cell house mouse CVCL_MZ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919891; Mob2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176404 CVCL_MZ67 BayGenomics ES cell line RRI460 embryonic stem cell house mouse CVCL_MZ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442873; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176405 CVCL_MZ66 BayGenomics ES cell line RRI459 embryonic stem cell house mouse CVCL_MZ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146322; Deptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176406 CVCL_MZ65 BayGenomics ES cell line RRI456 embryonic stem cell house mouse CVCL_MZ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926210; Cenpk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176407 CVCL_MZ64 BayGenomics ES cell line RRI455 embryonic stem cell house mouse CVCL_MZ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442755; Glt1d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176408 CVCL_MZ63 BayGenomics ES cell line RRI454 embryonic stem cell house mouse CVCL_MZ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923539; Phf14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176409 CVCL_MZ62 BayGenomics ES cell line RRI448 embryonic stem cell house mouse CVCL_MZ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176410 CVCL_MZ61 BayGenomics ES cell line RRI443 embryonic stem cell house mouse CVCL_MZ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920538; Vps50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176411 CVCL_MZ60 BayGenomics ES cell line RRI442 embryonic stem cell house mouse CVCL_MZ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919020; Ap2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176412 CVCL_MZ39 BayGenomics ES cell line RRI388 embryonic stem cell house mouse CVCL_MZ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99211; Zfx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176413 CVCL_MZ38 BayGenomics ES cell line RRI386 embryonic stem cell house mouse CVCL_MZ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101864; Dag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176414 CVCL_MZ37 BayGenomics ES cell line RRI383 embryonic stem cell house mouse CVCL_MZ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2181182; Nup155 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176415 CVCL_MZ36 BayGenomics ES cell line RRI382 embryonic stem cell house mouse CVCL_MZ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894308; Rab21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176416 CVCL_MZ35 BayGenomics ES cell line RRI378 embryonic stem cell house mouse CVCL_MZ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353424; Timm8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176417 CVCL_MZ34 BayGenomics ES cell line RRI375 embryonic stem cell house mouse CVCL_MZ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2149961; Pawr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176418 CVCL_MZ33 BayGenomics ES cell line RRI374 embryonic stem cell house mouse CVCL_MZ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176419 CVCL_MZ32 BayGenomics ES cell line RRI372 embryonic stem cell house mouse CVCL_MZ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176420 CVCL_MZ31 BayGenomics ES cell line RRI366 embryonic stem cell house mouse CVCL_MZ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685175; Asxl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176421 CVCL_MZ30 BayGenomics ES cell line RRI363 embryonic stem cell house mouse CVCL_MZ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344351; Dlg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176422 CVCL_MZ49 BayGenomics ES cell line RRI414 embryonic stem cell house mouse CVCL_MZ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176423 CVCL_MZ48 BayGenomics ES cell line RRI409 embryonic stem cell house mouse CVCL_MZ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442836; Brip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176424 CVCL_MZ47 BayGenomics ES cell line RRI407 embryonic stem cell house mouse CVCL_MZ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138865; Dlgap4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176425 CVCL_MZ46 BayGenomics ES cell line RRI405 embryonic stem cell house mouse CVCL_MZ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338871; Btrc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176426 CVCL_MZ45 BayGenomics ES cell line RRI404 embryonic stem cell house mouse CVCL_MZ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3028576; Dhx37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176427 CVCL_MZ44 BayGenomics ES cell line RRI400 embryonic stem cell house mouse CVCL_MZ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1314653; Afdn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176428 CVCL_MZ43 BayGenomics ES cell line RRI399 embryonic stem cell house mouse CVCL_MZ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88315; Ccnd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176429 CVCL_MZ42 BayGenomics ES cell line RRI398 embryonic stem cell house mouse CVCL_MZ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176430 CVCL_MZ41 BayGenomics ES cell line RRI395 embryonic stem cell house mouse CVCL_MZ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353424; Timm8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176431 CVCL_MZ40 BayGenomics ES cell line RRI390 embryonic stem cell house mouse CVCL_MZ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176432 CVCL_VS99 HIRS-BMA cancer cell line human CVCL_VS99 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female Doubling time: 46 hours (PubMed=3019754) 21176433 CVCL_W499 SYNb-1 cancer cell line human CVCL_W499 CL:0000010 Male 21176434 CVCL_3M53 HQ01268 transformed cell line human CVCL_3M53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176435 CVCL_3M52 HQ01266 transformed cell line human CVCL_3M52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176436 CVCL_3M51 HQ01265 transformed cell line human CVCL_3M51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176437 CVCL_3M50 HQ01264 transformed cell line human CVCL_3M50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176438 CVCL_3M57 HQ01272 transformed cell line human CVCL_3M57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176439 CVCL_3M56 HQ01271 transformed cell line human CVCL_3M56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176440 CVCL_3M55 HQ01270 transformed cell line human CVCL_3M55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176441 CVCL_3M54 HQ01269 transformed cell line human CVCL_3M54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176442 CVCL_3M49 HQ01263 transformed cell line human CVCL_3M49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176443 CVCL_3M48 HQ01262 transformed cell line human CVCL_3M48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176444 CVCL_3M47 HQ01261 transformed cell line human CVCL_3M47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176445 CVCL_VS89 hTERT hESC 1441 telomerase immortalized cell line human CVCL_VS89 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176446 CVCL_W489 MFH-3 cancer cell line human CVCL_W489 CL:0000010 Derived from metastatic site: Lung. Male 21176447 CVCL_VS88 hTERT hESC 1440 telomerase immortalized cell line human CVCL_VS88 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176448 CVCL_W488 LK-52 cancer cell line human CVCL_W488 CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female Doubling time: 38 hours (PubMed=1467328) 21176449 CVCL_3M60 HQ01275 transformed cell line human CVCL_3M60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176450 CVCL_3M64 HQ01279 transformed cell line human CVCL_3M64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176451 CVCL_3M63 HQ01278 transformed cell line human CVCL_3M63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176452 CVCL_3M62 HQ01277 transformed cell line human CVCL_3M62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176453 CVCL_3M61 HQ01276 transformed cell line human CVCL_3M61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176454 CVCL_3M68 HQ01283 transformed cell line human CVCL_3M68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176455 CVCL_3M67 HQ01282 transformed cell line human CVCL_3M67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176456 CVCL_3M66 HQ01281 transformed cell line human CVCL_3M66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176457 CVCL_3M65 HQ01280 transformed cell line human CVCL_3M65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176458 CVCL_3M59 HQ01274 transformed cell line human CVCL_3M59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176459 CVCL_3M58 HQ01273 transformed cell line human CVCL_3M58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176460 CVCL_VS90 hTERT hESC 1448 telomerase immortalized cell line human CVCL_VS90 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176461 CVCL_W490 MFHm-2 cancer cell line human CVCL_W490 CL:0000010 Derived from metastatic site: Retroperitoneal space. Male 21176462 CVCL_VS94 KTaV-3 transformed cell line house mouse CVCL_VS94 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; anteroventral periventricular nucleus; Breed/subspecies: C57BL/6-Tg(Kiss1-hrGFP)KG26Cfe/J transgenic. Female Characteristics: Kisspeptin-secreting cell line 21176463 CVCL_W494 NFS-2 cancer cell line human CVCL_W494 CL:0000010 Derived from metastatic site: Retroperitoneal space. Female 21176464 CVCL_VS93 KTaR-1 transformed cell line house mouse CVCL_VS93 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; arcuate nucleus; Breed/subspecies: C57BL/6-Tg(Kiss1-hrGFP)KG26Cfe/J transgenic. Female Characteristics: Kisspeptin-secreting cell line 21176465 CVCL_W493 NB1-G cancer cell line human CVCL_W493 CL:0000010 Male Characteristics: Established from a xenograft maintained in nude rats. 21176466 CVCL_VS92 hTERT hESC 1458 telomerase immortalized cell line human CVCL_VS92 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 2.11 days (PubMed=30770928) 21176467 CVCL_W492 MT-428 cancer cell line human CVCL_W492 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 72 hours (PubMed=8025019) 21176468 CVCL_VS91 hTERT hESC 1455 telomerase immortalized cell line human CVCL_VS91 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 1.13-1.15 days (PubMed=30770928) 21176469 CVCL_W491 MRT-1 cancer cell line human CVCL_W491 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 32.5 hours, at 47th passage (PubMed=7669747) 21176470 CVCL_VS98 HTUS cancer cell line human CVCL_VS98 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female 21176471 CVCL_W498 SYN-1 cancer cell line human CVCL_W498 CL:0000010 Derived from metastatic site: Lung. Female 21176472 CVCL_VS97 HAEST cancer cell line human CVCL_VS97 CL:0000010 Population: Japanese Female Doubling time: 72 hours (PubMed=2430863). 21176473 CVCL_W497 SRM cancer cell line human CVCL_W497 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: 23 hours (PubMed=8343449) 21176474 CVCL_VS96 COG-N-452 cancer cell line human CVCL_VS96 CL:0000010 Derived from sampling site: Peripheral blood. Male 21176475 CVCL_W496 NOC-Ts cancer cell line human CVCL_W496 CL:0000010 Population: Japanese Male Doubling time: 30-32 hours (PubMed=1958631). 21176476 CVCL_VS95 HUOT cancer cell line human CVCL_VS95 CL:0000010 Population: Japanese Female Doubling time: 72-98 hours (PubMed=2411992); 80 hours (PubMed=10457904). 21176477 CVCL_W495 NOC-S cancer cell line human CVCL_W495 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 32-36 hours (PubMed=2085480) 21176478 CVCL_VS79 GM13585 transformed cell line human CVCL_VS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with hyperplastic polyps, tubular adenomas and villous adenomas; Derived from sampling site: Peripheral blood. Female 21176479 CVCL_W479 KIMI-1 cancer cell line human CVCL_W479 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Characteristics: Established from nude mice transplanted tumors Doubling time: 50 hours (PubMed=2085478) 21176480 CVCL_VS78 GM13563 transformed cell line human CVCL_VS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with hyperplastic polyps, tubular adenomas and colon cancer; Derived from sampling site: Peripheral blood. Female 21176481 CVCL_W478 KE-43C4 cancer cell line human CVCL_W478 CL:0000010 Population: Japanese Female Doubling time: 63.6 hours (PubMed=15016319); Microsatellite instability: Stable (MSS) (PubMed=15016319). 21176482 CVCL_VS77 GM13558 transformed cell line human CVCL_VS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with hyperplastic polyps, tubular adenomas and villous adenomas; Derived from sampling site: Peripheral blood. Female 21176483 CVCL_W477 KE-43 cancer cell line human CVCL_W477 CL:0000010 Population: Japanese Female Doubling time: 22.5 hours, at 105th passage (PubMed=1390419); 33.6 hours (PubMed=15016319); Microsatellite instability: Stable (MSS) (PubMed=15016319). 21176484 CVCL_3M31 HQ01245 transformed cell line human CVCL_3M31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176485 CVCL_3M30 HQ01244 transformed cell line human CVCL_3M30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176486 CVCL_3M35 HQ01249 transformed cell line human CVCL_3M35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176487 CVCL_3M34 HQ01248 transformed cell line human CVCL_3M34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176488 CVCL_3M33 HQ01247 transformed cell line human CVCL_3M33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176489 CVCL_3M32 HQ01246 transformed cell line human CVCL_3M32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176490 CVCL_3M28 HQ01242 transformed cell line human CVCL_3M28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176491 CVCL_3M27 HQ01241 transformed cell line human CVCL_3M27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176492 CVCL_3M26 HQ01240 transformed cell line human CVCL_3M26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176493 CVCL_3M25 HQ01239 transformed cell line human CVCL_3M25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176494 CVCL_3M29 HQ01243 transformed cell line human CVCL_3M29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176495 CVCL_VS83 hTERT hESC 1406 telomerase immortalized cell line human CVCL_VS83 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176496 CVCL_W483 KMU-CSN somatic stem cell human CVCL_W483 CL:0000010 Derived from sampling site: Stomach. Male 21176497 CVCL_VS82 hTERT hESC 1405 telomerase immortalized cell line human CVCL_VS82 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 1.91 days (PubMed=30770928) 21176498 CVCL_W482 KMU-CS12 somatic stem cell human CVCL_W482 CL:0000010 Derived from sampling site: Stomach. Male 21176499 CVCL_VS81 hTERT hESC 1400 telomerase immortalized cell line human CVCL_VS81 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176500 CVCL_W481 KMU100 cancer cell line human CVCL_W481 CL:0000010 Population: Japanese; Derived from sampling site: Brain; right frontal lobe. Female Doubling time: 15 hours, at 490th passage (PubMed=8025023) 21176501 CVCL_VS80 hTERT hESC 1399 telomerase immortalized cell line human CVCL_VS80 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 2.08 days (PubMed=30770928) 21176502 CVCL_W480 KIMI-2 cancer cell line human CVCL_W480 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Characteristics: Established from nude mice transplanted tumors Doubling time: 31 hours (PubMed=2085478) 21176503 CVCL_VS87 hTERT hESC 1433 telomerase immortalized cell line human CVCL_VS87 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 2.47 days (PubMed=30770928) 21176504 CVCL_W487 LK-17 cancer cell line human CVCL_W487 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 43.2 hours (PubMed=8297820) 21176505 CVCL_VS86 hTERT hESC 1429 telomerase immortalized cell line human CVCL_VS86 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Doubling time: 1.31 days (PubMed=30770928) 21176506 CVCL_W486 LEIO-2 cancer cell line human CVCL_W486 CL:0000010 Derived from metastatic site: Stomach. Male 21176507 CVCL_VS85 hTERT hESC 1418 telomerase immortalized cell line human CVCL_VS85 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176508 CVCL_W485 KT-COLO-8 cancer cell line human CVCL_W485 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 48 hours (PubMed=7873498) 21176509 CVCL_VS84 hTERT hESC 1415 telomerase immortalized cell line human CVCL_VS84 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21176510 CVCL_W484 KMU-GI2 somatic stem cell human CVCL_W484 CL:0000010 Derived from sampling site: Stomach. Male 21176511 CVCL_W469 FU-UrC-1 cancer cell line human CVCL_W469 CL:0000010 Population: Japanese; Derived from sampling site: Ureter. Female Characteristics: Established from a nude mouse xenograft Doubling time: 53 hours (PubMed=1888704) 21176512 CVCL_VS69 GTL16S5 cancer cell line human CVCL_VS69 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903); Derived from metastatic site: Liver. Female 21176513 CVCL_W468 EES-1 cancer cell line human CVCL_W468 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=9738976) Derived from metastatic site: Lung. Female Caution: Not to be confused with extraosseous Ewing sarcoma cell line EES1 (Cellosaurus=CVCL_T757) 21176514 CVCL_VS68 GTL16R3 cancer cell line human CVCL_VS68 CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903); Derived from metastatic site: Liver. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21176515 CVCL_W467 COLM-6 cancer cell line human CVCL_W467 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Female 21176516 CVCL_VS67 GTL16R1 cancer cell line human CVCL_VS67 CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903); Derived from metastatic site: Liver. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21176517 CVCL_VS66 B4.14 transformed cell line CVCL_VS66 CL:0000010 Transfected with: UniProtKB; P03347; HIV-1 isolate BH10 gag; Transfected with: UniProtKB; P03366; HIV-1 isolate BH10 pol; Transfected with: UniProtKB; P04616; HIV-1 isolate BH10 rev Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21176518 CVCL_W466 ZK-N transformed cell line human CVCL_W466 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176519 CVCL_3M42 HQ01256 transformed cell line human CVCL_3M42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176520 CVCL_3M41 HQ01255 transformed cell line human CVCL_3M41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176521 CVCL_3M40 HQ01254 transformed cell line human CVCL_3M40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176522 CVCL_3M46 HQ01260 transformed cell line human CVCL_3M46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176523 CVCL_3M45 HQ01259 transformed cell line human CVCL_3M45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176524 CVCL_3M44 HQ01258 transformed cell line human CVCL_3M44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176525 CVCL_3M43 HQ01257 transformed cell line human CVCL_3M43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176526 CVCL_3M39 HQ01253 transformed cell line human CVCL_3M39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176527 CVCL_3M38 HQ01252 transformed cell line human CVCL_3M38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176528 CVCL_3M37 HQ01251 transformed cell line human CVCL_3M37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176529 CVCL_3M36 HQ01250 transformed cell line human CVCL_3M36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176530 CVCL_VS72 ERLD/Y3 cancer cell line house mouse CVCL_VS72 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C57BL/6. 21176531 CVCL_W472 HS-MM cancer cell line human CVCL_W472 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: ~72 hours (PubMed=8492224) 21176532 CVCL_VS71 ERLD/Two cancer cell line house mouse CVCL_VS71 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C57BL/6. 21176533 CVCL_W471 H-1 [Human gingival squamous cell carcinoma] cancer cell line human CVCL_W471 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by microarray Male Doubling time: 37 hours (PubMed=8343447) 21176534 CVCL_VS70 ERLD/T cancer cell line house mouse CVCL_VS70 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C57BL/6. 21176535 CVCL_W470 GAC-1 cancer cell line human CVCL_W470 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~18.5 hours (PubMed=1467326) 21176536 CVCL_VS76 GM13543 transformed cell line human CVCL_VS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with cancer of the rectum, hyperplastic polyps and sessile villous adenomas; Derived from sampling site: Peripheral blood. Male 21176537 CVCL_W476 KE-24 cancer cell line human CVCL_W476 CL:0000010 Population: Japanese; Derived from sampling site: Colon. Male Doubling time: 32.4 hours (PubMed=15016319); Microsatellite instability: Instable (MSI-low) (PubMed=15016319) 21176538 CVCL_VS75 GM13542 transformed cell line human CVCL_VS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient affected with villus adenomas, tubular adenomas and hyperplastic polyps; Derived from sampling site: Peripheral blood. Male 21176539 CVCL_W475 KC-1 [Human colon carcinoma] cancer cell line human CVCL_W475 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Unspecified (PubMed=7873502) Population: Japanese; Derived from sampling site: Colon. Female Doubling time: 56.6 hours (PubMed=7873502) 21176540 CVCL_VS74 39/3C2.2 hybridoma house mouse CVCL_VS74 CL:0000010 Discontinued: ATCC; HB-9; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P13379; Mouse Cd5 21176541 CVCL_W474 JK-NB1 cancer cell line human CVCL_W474 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Male Doubling time: ~48 hours (PubMed=8148311) 21176542 CVCL_VS73 19/178C1 hybridoma house mouse CVCL_VS73 CL:0000010 Discontinued: ATCC; HB-8; true. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a 21176543 CVCL_W473 IN-1 cancer cell line human CVCL_W473 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Doubling time: 24-36 hours (PubMed=1964585) 21176544 CVCL_VS58 FS-3 [Human foreskin] finite cell line human CVCL_VS58 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21176545 CVCL_W458 LC114 cancer cell line human CVCL_W458 CL:0000010 Derived from sampling site: Lung. Male 21176546 CVCL_W457 HEK-293B1 transformed cell line human CVCL_W457 CL:0000010 Transfected with: HGNC; 285; ADRB1; Transfected with: UniProtKB; P42212; GFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21176547 CVCL_VS57 MET-2B cancer cell line human CVCL_VS57 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21176548 CVCL_W456 G3-3 embryonic stem cell house mouse CVCL_W456 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: 129P2/Ola. Male 21176549 CVCL_VS56 M120327_3 cancer cell line human CVCL_VS56 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap) Omics: Deep exome analysis; Omics: CNV analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21176550 CVCL_W455 KAO cancer cell line human CVCL_W455 CL:0000010 Sequence variation: Gene fusion; HGNC; 783; ATF1 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ATF1, EWS-ATF (PubMed=15150091) Anecdotal: Cell line name derived from the first name (Kaori) of the patient. Population: Japanese Female Doubling time: ~34 hours (PubMed=9247632) 21176551 CVCL_VS55 M120326_2 cancer cell line human CVCL_VS55 CL:0000010 21176552 CVCL_VS59 FSDC transformed cell line house mouse CVCL_VS59 CL:0000010 Transformant: Env(AKR)-Myc(MH2); Derived from sampling site: Skin; epidermis Cell type=Dendritic cell.; Breed/subspecies: C57BL/6 x DBA/2. Unspecified 21176553 CVCL_W459 SO-Rb70 cancer cell line human CVCL_W459 CL:0000010 Population: Chinese. 21176554 CVCL_3M13 HQ01227 transformed cell line human CVCL_3M13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176555 CVCL_3M12 HQ01226 transformed cell line human CVCL_3M12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176556 CVCL_3M11 HQ01225 transformed cell line human CVCL_3M11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176557 CVCL_3M10 HQ01224 transformed cell line human CVCL_3M10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176558 CVCL_3M06 HQ01220 transformed cell line human CVCL_3M06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176559 CVCL_3M05 HQ01219 transformed cell line human CVCL_3M05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176560 CVCL_3M04 HQ01218 transformed cell line human CVCL_3M04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176561 CVCL_3M03 HQ01217 transformed cell line human CVCL_3M03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176562 CVCL_3M09 HQ01223 transformed cell line human CVCL_3M09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176563 CVCL_3M08 HQ01222 transformed cell line human CVCL_3M08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176564 CVCL_3M07 HQ01221 transformed cell line human CVCL_3M07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176565 CVCL_VS61 AP284.B11 spontaneously immortalized cell line house mouse CVCL_VS61 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C57BL/Rij x CBA/Rij. Male 21176566 CVCL_W461 OKO160 embryonic stem cell house mouse CVCL_W461 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21176567 CVCL_VS60 AP284 spontaneously immortalized cell line house mouse CVCL_VS60 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C57BL/Rij x CBA/Rij. Male Characteristics: Able to present antigens and activate T lymphocytes 21176568 CVCL_W460 HKMFH cancer cell line human CVCL_W460 CL:0000010 Population: Japanese; Derived from sampling site: Bone; tibia. Female 21176570 CVCL_VS65 CMT3 transformed cell line CVCL_VS65 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 21176571 CVCL_W465 ZK-H cancer cell line human CVCL_W465 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21176572 CVCL_VS64 BOS4 transformed cell line CVCL_VS64 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A7D5U6M6; MT-ND6; Simple; p.Tyr50fs*25 (c.147insG) (m.13952dupC); Zygosity=Heteroplasmic (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line Problematic cell line: Misidentified Parent cell line (BS-C-1) was originally thought to be of Chlorocebus aethiops origin but originiate from Chlorocebus pygerythrus. 21176573 CVCL_W464 KG55T cancer cell line human CVCL_W464 CL:0000010 Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Virology: Contains multiple copies of integrated hepatitis B virus (HBV) genomes Doubling time: 50-60 hours, at 12th passage (PubMed=6194659) 21176574 CVCL_VS63 BMT10 transformed cell line CVCL_VS63 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A7D5U6M6; MT-ND6; Simple; p.Tyr50fs*25 (c.147insG) (m.13952dupC); Zygosity=Heteroplasmic (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line Problematic cell line: Misidentified Parent cell line (BS-C-1) was originally thought to be of Chlorocebus aethiops origin but originiate from Chlorocebus pygerythrus. 21176575 CVCL_W463 HuH-2 cancer cell line human CVCL_W463 CL:0000010 Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Virology: Contains multiple copies of integrated hepatitis B virus (HBV) genomes 21176576 CVCL_VS62 AP284.D4 spontaneously immortalized cell line house mouse CVCL_VS62 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C57BL/Rij x CBA/Rij. Male 21176577 CVCL_W462 CK spontaneously immortalized cell line CVCL_W462 CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Susceptible to infection by bovine adenovirus 3 (PubMed=4280232) Doubling time: 31.4 hours (PubMed=4280232) 21176578 CVCL_W447 MGM-1 cancer cell line human CVCL_W447 CL:0000010 Population: Japanese; Derived from sampling site: Brain; left temporal lobe. Male Doubling time: 42.9 hours, at 25th passage (PubMed=9234071) 21176579 CVCL_VS47 QIMR-MMK1 cancer cell line human CVCL_VS47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Tyr183Cys (c.548A>G); ClinVar=VCV000134517; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe56Val (c.166T>G); ClinVar=VCV000924880; Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 52.4 +- 4.5 hours (Q-cell) 21176580 CVCL_W446 HHUABM cancer cell line human CVCL_W446 CL:0000010 Population: Japanese; Derived from metastatic site: Left Bartholin gland. Female Doubling time: 70 hours (at 10th passage), 28 hours (at 40th passage) (PubMed=10834108) 21176581 CVCL_VS46 QIMR-JK2 cancer cell line human CVCL_VS46 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Leu (c.329G>T); ClinVar=VCV000406597; Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 94.2 +- 6.0 hours (Q-cell) 21176582 CVCL_W445 HAK-2 cancer cell line human CVCL_W445 HLA typing: A*02:01,11:01; B*38:01; C*12:03; DQA1*01:02; DQB1*06:04; DRB1*13:02 (PubMed=9178645) CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male Doubling time: 36.8 hours, at 47th passage (PubMed=9436038) 21176583 CVCL_VS45 QIMR-HW1 cancer cell line human CVCL_VS45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ala289Val (c.866C>T); ClinVar=VCV000376209; Zygosity=Heterozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 55.8 +- 2.7 hours (Q-cell) 21176584 CVCL_W444 IM cancer cell line human CVCL_W444 CL:0000010 Population: Japanese Female Doubling time: 28.8 hours (PubMed=9183668). 21176585 CVCL_VS44 QIMR-FPW1 cancer cell line human CVCL_VS44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 48.1 +- 4.7 hours (Q-cell) 21176586 CVCL_W449 MGM-3 cancer cell line human CVCL_W449 CL:0000010 Population: Japanese; Derived from sampling site: Brain; right frontal lobe. Female 21176587 CVCL_VS49 QIMR-PB1 cancer cell line human CVCL_VS49 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 79.4 +- 6.3 hours (Q-cell) 21176588 CVCL_W448 MGM-2 cancer cell line human CVCL_W448 CL:0000010 Population: Japanese; Derived from sampling site: Brain; left fronto-parietal lobe. Male 21176589 CVCL_VS48 QIMR-MN1 cancer cell line human CVCL_VS48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 44.9 +- 1.0 hours (Q-cell) 21176590 CVCL_3M20 HQ01234 transformed cell line human CVCL_3M20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176591 CVCL_3M24 HQ01238 transformed cell line human CVCL_3M24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176592 CVCL_3M23 HQ01237 transformed cell line human CVCL_3M23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176593 CVCL_3M22 HQ01236 transformed cell line human CVCL_3M22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176594 CVCL_3M21 HQ01235 transformed cell line human CVCL_3M21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176595 CVCL_3M17 HQ01231 transformed cell line human CVCL_3M17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176596 CVCL_3M16 HQ01230 transformed cell line human CVCL_3M16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176597 CVCL_3M15 HQ01229 transformed cell line human CVCL_3M15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176598 CVCL_3M14 HQ01228 transformed cell line human CVCL_3M14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176599 CVCL_3M19 HQ01233 transformed cell line human CVCL_3M19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176600 CVCL_3M18 HQ01232 transformed cell line human CVCL_3M18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176601 CVCL_VS50 QIMR-RKI1 cancer cell line human CVCL_VS50 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Val178Ile (c.532G>A); ClinVar=VCV000134520; Zygosity=Heterozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 72.9 +- 5.3 hours (Q-cell) 21176602 CVCL_W454 Nil-1 spontaneously immortalized cell line CVCL_W454 CL:0000010 Derived from sampling site: Whole embryo. Male 21176603 CVCL_VS54 QIMR-WK1 cancer cell line human CVCL_VS54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Tyr (c.3139C>T); ClinVar=VCV000039705; Zygosity=Heterozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 46.2 +- 1.0 hours (Q-cell) 21176604 CVCL_W453 MM214 cancer cell line human CVCL_W453 CL:0000010 Derived from metastatic site: Not specified. Female 21176605 CVCL_VS53 QIMR-SJH1 cancer cell line human CVCL_VS53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.His289Arg (c.866A>G); ClinVar=VCV000664840; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly105Cys (c.313G>T); Zygosity=Homozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 67.3 +- 4.7 hours (Q-cell) 21176606 CVCL_VS52 QIMR-SB2b cancer cell line human CVCL_VS52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ala289Val (c.866C>T); ClinVar=VCV000376209; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.His304Tyr (c.910C>T); Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 6973; MDM2; Simple; p.Trp329Cys (c.987G>T); Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Cys800Phe (c.2399G>T) (p.Cys818Phe, c.2453G>T); ClinVar=VCV000648391; Zygosity=Heterozygous (Q-cell); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Tyr1021His (c.3061T>C); ClinVar=VCV001691391; Zygosity=Heterozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 108.7 +- 6.9 hours (Q-cell) 21176607 CVCL_W452 UTO-EW1 cancer cell line human CVCL_W452 CL:0000010 Population: Japanese; Derived from sampling site: Bone; humerus. Male Doubling time: 49 hours (PubMed=9573488) 21176608 CVCL_W451 NCS-1 cancer cell line human CVCL_W451 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Characteristics: Established from a xenograft established in a nude mice 21176609 CVCL_VS51 QIMR-RN1 cancer cell line human CVCL_VS51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 37.5 +- 1.9 hours (Q-cell) 21176610 CVCL_W436 Ishikawa 3-H-7 cancer cell line human CVCL_W436 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 26.4 hours (PubMed=9183638) 21176611 CVCL_VS36 SGM5 cancer cell line human CVCL_VS36 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21418545) Derived from sampling site: Skin. Male Doubling time: 2.5 days (PubMed=21418545) 21176612 CVCL_W435 Ishikawa 3-H-4 cancer cell line human CVCL_W435 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 31.6 hours (PubMed=9183638) 21176613 CVCL_VS35 SGM4 cancer cell line human CVCL_VS35 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21418545) Derived from sampling site: Skin. Female Doubling time: 3.8 days (PubMed=21418545) 21176614 CVCL_W434 Ishikawa 3-H-3 cancer cell line human CVCL_W434 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 44.4 hours (PubMed=9183638) 21176615 CVCL_VS34 SGM3 cancer cell line human CVCL_VS34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21418545) Derived from sampling site: Skin. Unspecified Doubling time: 4.9 days (PubMed=21418545) 21176616 CVCL_W433 Ishikawa 3-D-9 cancer cell line human CVCL_W433 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 40.8 hours (PubMed=9183638) 21176617 CVCL_VS33 SGM2 cancer cell line human CVCL_VS33 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21418545) Derived from sampling site: Skin. Unspecified Doubling time: 2.8 days (PubMed=21418545) 21176618 CVCL_W439 AG02101 finite cell line human CVCL_W439 CL:0000010 Derived from sampling site: Endometrium Cell type=Fibroblast.. Female 21176619 CVCL_VS39 MHHi008-B induced pluripotent stem cell human CVCL_VS39 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21176620 CVCL_W438 371M cancer cell line human CVCL_W438 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 84 hours (at 10th passage), 37 hours (at 34th passage) (PubMed=12703547) 21176621 CVCL_VS38 MHHi008-A induced pluripotent stem cell human CVCL_VS38 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21176622 CVCL_VS37 SGM6 cancer cell line human CVCL_VS37 CL:0000010 Derived from sampling site: Skin. Unspecified Doubling time: 6.3 days (PubMed=21418545) 21176623 CVCL_W437 Watanabe cancer cell line human CVCL_W437 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 60 hours, at 10th passage (PubMed=8721091) 21176624 CVCL_MY99 BayGenomics ES cell line RRI260 embryonic stem cell house mouse CVCL_MY99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176625 CVCL_MY98 BayGenomics ES cell line RRI257 embryonic stem cell house mouse CVCL_MY98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445085; Dync2i1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176626 CVCL_MY97 BayGenomics ES cell line RRI256 embryonic stem cell house mouse CVCL_MY97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919238; Esco2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176627 CVCL_MY96 BayGenomics ES cell line RRI254 embryonic stem cell house mouse CVCL_MY96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176628 CVCL_MY95 BayGenomics ES cell line RRI253 embryonic stem cell house mouse CVCL_MY95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109301; Papola Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176629 CVCL_MY94 BayGenomics ES cell line RRI252 embryonic stem cell house mouse CVCL_MY94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176630 CVCL_MY93 BayGenomics ES cell line RRI249 embryonic stem cell house mouse CVCL_MY93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109301; Papola Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176631 CVCL_MY92 BayGenomics ES cell line RRI246 embryonic stem cell house mouse CVCL_MY92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176632 CVCL_MY91 BayGenomics ES cell line RRI243 embryonic stem cell house mouse CVCL_MY91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107929; Pip5k1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176633 CVCL_MY90 BayGenomics ES cell line RRI240 embryonic stem cell house mouse CVCL_MY90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101864; Dag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21176634 CVCL_W443 HU 214 cancer cell line human CVCL_W443 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21176635 CVCL_VS43 QIMR-BAH1 cancer cell line human CVCL_VS43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (Q-cell); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val133Ile (c.397G>A); ClinVar=VCV000971265; Zygosity=Hemizygous (Q-cell) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 79.5 +- 3.3 hours (Q-cell) 21176636 CVCL_VS42 HeLa EGFP-654 cancer cell line human CVCL_VS42 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a construct containing a mutated human beta-globin intron, IVS2-654, at nucleotide 105 of EGFP cDNA thus preventing its correct translation Treatment of the cells expressing the construct with active antisense oligonucleotide should restore proper splicing and translation of EGFP, providing a rapid and sensitive positive readout for antisense activity in the nuclei of the treated cells. 21176637 CVCL_W442 HM 162 cancer cell line human CVCL_W442 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male 21176638 CVCL_W441 EIIL cancer cell line human CVCL_W441 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female 21176639 CVCL_VS41 SKOV3-A2 cancer cell line human CVCL_VS41 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*02) Population: Caucasian; Derived from metastatic site: Ascites. Female 21176640 CVCL_W440 AG02102 finite cell line human CVCL_W440 CL:0000010 Derived from sampling site: Endometrium Cell type=Fibroblast.. Female 21176641 CVCL_VS40 MHHi008-C induced pluripotent stem cell human CVCL_VS40 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 21176642 CVCL_W425 Ishikawa 1-F-6 cancer cell line human CVCL_W425 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 37.9 hours (PubMed=9183638) 21176643 CVCL_VS25 melan-Usf1 spontaneously immortalized cell line house mouse CVCL_VS25 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:99542; Usf1 Derived from sampling site: Cell type=Melanocyte; Breed/subspecies: (129S2/SvPas x C57BL/6J)Usf1tm1Svl. 21176644 CVCL_W424 Ishikawa 1-E-8 cancer cell line human CVCL_W424 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 38.9 hours (PubMed=9183638) 21176645 CVCL_VS24 Melan-c spontaneously immortalized cell line house mouse CVCL_VS24 CL:0000010 Sequence variation: Mutation; MGI; MGI:98880; Tyr; Simple; p.Cys103Ser; Zygosity=Homozygous (inferred from genetic background of Albino mice) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: LAC-MF1. Unspecified 21176646 CVCL_W423 Ishikawa 1-D-9 cancer cell line human CVCL_W423 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 35.0 hours (PubMed=9183638) 21176647 CVCL_VS23 Melan-b spontaneously immortalized cell line house mouse CVCL_VS23 CL:0000010 Sequence variation: Mutation; MGI; MGI:98881; Tyrp1; Simple; p.Cys110Tyr; Zygosity=Homozygous (inferred from genetic background of Brown mice) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: Q. Unspecified 21176648 CVCL_VS22 DX3-LT5.1 HmR1 cancer cell line human CVCL_VS22 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from metastatic site: Hypodermis. Female 21176649 CVCL_W422 Ishikawa 1-C-10 cancer cell line human CVCL_W422 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 31.2 hours (PubMed=9183638) 21176650 CVCL_W429 Ishikawa 2-C-7 cancer cell line human CVCL_W429 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 38.4 hours (PubMed=9183638) 21176651 CVCL_VS29 Melan-b-HmR spontaneously immortalized cell line house mouse CVCL_VS29 CL:0000010 Sequence variation: Mutation; MGI; MGI:98881; Tyrp1; Simple; p.Cys110Tyr; Zygosity=Homozygous (inferred from genetic background of Brown mice); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Skin Cell type=Melanocyte.; Breed/subspecies: Q. Unspecified 21176652 CVCL_VS28 DM(act6) transformed cell line CVCL_VS28 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21176653 CVCL_W428 Ishikawa 2-C-3 cancer cell line human CVCL_W428 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 26.4 hours (PubMed=9183638) 21176654 CVCL_VS27 DM(act10) transformed cell line CVCL_VS27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21176655 CVCL_W427 Ishikawa 2-B-12 cancer cell line human CVCL_W427 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 36.5 hours (PubMed=9183638) 21176656 CVCL_VS26 4/21 transformed cell line CVCL_VS26 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female Doubling time: 20.0 +- 0.3 hours (PubMed=196977) 21176657 CVCL_W426 Ishikawa 1-H-6 cancer cell line human CVCL_W426 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 40.1 hours (PubMed=9183638) 21176658 CVCL_3M02 HQ01216 transformed cell line human CVCL_3M02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176659 CVCL_3M01 HQ01215 transformed cell line human CVCL_3M01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176660 CVCL_3M00 HQ01214 transformed cell line human CVCL_3M00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176661 CVCL_W432 Ishikawa 3-D-7 cancer cell line human CVCL_W432 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 25.2 hours (PubMed=9183638) 21176662 CVCL_VS32 SGM1 finite cell line human CVCL_VS32 CL:0000010 Derived from sampling site: Skin. Unspecified Characteristics: Long lived but not immortal Doubling time: 9.2 days (PubMed=21418545) 21176663 CVCL_W431 Ishikawa 2-F-4 cancer cell line human CVCL_W431 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 31.8 hours (PubMed=9183638) 21176664 CVCL_VS31 WM239A HmR cancer cell line human CVCL_VS31 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Lymph node. Female 21176665 CVCL_W430 Ishikawa 2-E-7 cancer cell line human CVCL_W430 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Leu570Pro (c.1709T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Pro102Ser (c.304C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9177; POLE; Simple; p.Asn751fs (c.2252delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.950_953delTACT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp49His (c.145G>C); ClinVar=VCV000135948; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 38.4 hours (PubMed=9183638) 21176666 CVCL_VS30 WM9-HmR cancer cell line human CVCL_VS30 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from metastatic site: Left axillary lymph node. Male 21176667 CVCL_EA00 ND07700 transformed cell line human CVCL_EA00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176668 CVCL_EA11 ND07900 transformed cell line human CVCL_EA11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176669 CVCL_EA10 ND07756 transformed cell line human CVCL_EA10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176670 CVCL_EA09 ND07743 transformed cell line human CVCL_EA09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176671 CVCL_EA04 ND07705 transformed cell line human CVCL_EA04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176672 CVCL_EA03 ND07703 transformed cell line human CVCL_EA03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176673 CVCL_EA02 ND07702 transformed cell line human CVCL_EA02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND07702; probable Female 21176674 CVCL_EA01 ND07701 transformed cell line human CVCL_EA01 CL:0000010 Population: Asian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176675 CVCL_EA08 ND07742 transformed cell line human CVCL_EA08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176676 CVCL_EA07 ND07741 transformed cell line human CVCL_EA07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176677 CVCL_EA06 ND07740 transformed cell line human CVCL_EA06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176678 CVCL_EA05 ND07712 transformed cell line human CVCL_EA05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176679 CVCL_3M93 HQ01308 transformed cell line human CVCL_3M93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176680 CVCL_3M92 HQ01307 transformed cell line human CVCL_3M92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176681 CVCL_3M91 HQ01306 transformed cell line human CVCL_3M91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176682 CVCL_3M90 HQ01305 transformed cell line human CVCL_3M90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176683 CVCL_3M97 HQ01312 transformed cell line human CVCL_3M97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176684 CVCL_3M96 HQ01311 transformed cell line human CVCL_3M96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176685 CVCL_3M95 HQ01310 transformed cell line human CVCL_3M95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176686 CVCL_3M94 HQ01309 transformed cell line human CVCL_3M94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176687 CVCL_3M99 HQ01314 transformed cell line human CVCL_3M99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176688 CVCL_3M98 HQ01313 transformed cell line human CVCL_3M98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176689 CVCL_3M71 HQ01286 transformed cell line human CVCL_3M71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176690 CVCL_3M70 HQ01285 transformed cell line human CVCL_3M70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176691 CVCL_3M75 HQ01290 transformed cell line human CVCL_3M75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176692 CVCL_3M74 HQ01289 transformed cell line human CVCL_3M74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176693 CVCL_3M73 HQ01288 transformed cell line human CVCL_3M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176694 CVCL_3M72 HQ01287 transformed cell line human CVCL_3M72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176695 CVCL_3M79 HQ01294 transformed cell line human CVCL_3M79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176696 CVCL_3M78 HQ01293 transformed cell line human CVCL_3M78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176697 CVCL_3M77 HQ01292 transformed cell line human CVCL_3M77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176698 CVCL_3M76 HQ01291 transformed cell line human CVCL_3M76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176699 CVCL_3M69 HQ01284 transformed cell line human CVCL_3M69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176700 CVCL_3M82 HQ01297 transformed cell line human CVCL_3M82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176701 CVCL_3M81 HQ01296 transformed cell line human CVCL_3M81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176702 CVCL_3M80 HQ01295 transformed cell line human CVCL_3M80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176703 CVCL_3M86 HQ01301 transformed cell line human CVCL_3M86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176704 CVCL_3M85 HQ01300 transformed cell line human CVCL_3M85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176705 CVCL_3M84 HQ01299 transformed cell line human CVCL_3M84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176706 CVCL_3M83 HQ01298 transformed cell line human CVCL_3M83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176707 CVCL_3M89 HQ01304 transformed cell line human CVCL_3M89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176708 CVCL_3M88 HQ01303 transformed cell line human CVCL_3M88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176709 CVCL_3M87 HQ01302 transformed cell line human CVCL_3M87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176710 CVCL_EB99 ND14146 transformed cell line human CVCL_EB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176711 CVCL_EB83 ND13675 transformed cell line human CVCL_EB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176712 CVCL_EB82 ND13653 transformed cell line human CVCL_EB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176713 CVCL_EB81 ND13618 transformed cell line human CVCL_EB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176714 CVCL_EB80 ND13497 transformed cell line human CVCL_EB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176715 CVCL_EB87 ND13852 transformed cell line human CVCL_EB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176716 CVCL_EB86 ND13850 transformed cell line human CVCL_EB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176717 CVCL_EB85 ND13797 transformed cell line human CVCL_EB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176718 CVCL_EB84 ND13766 transformed cell line human CVCL_EB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176719 CVCL_EB79 ND13495 transformed cell line human CVCL_EB79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176720 CVCL_EB78 ND13463 transformed cell line human CVCL_EB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176721 CVCL_EB77 ND13446 transformed cell line human CVCL_EB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176722 CVCL_EB94 ND13951 transformed cell line human CVCL_EB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176723 CVCL_EB93 ND13909 transformed cell line human CVCL_EB93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176724 CVCL_EB92 ND13907 transformed cell line human CVCL_EB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176725 CVCL_EB91 ND13887 transformed cell line human CVCL_EB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176726 CVCL_EB98 ND14109 transformed cell line human CVCL_EB98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176727 CVCL_EB97 ND14075 transformed cell line human CVCL_EB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176728 CVCL_EB96 ND14033 transformed cell line human CVCL_EB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176729 CVCL_EB95 ND13992 transformed cell line human CVCL_EB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176730 CVCL_EB90 ND13885 transformed cell line human CVCL_EB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176731 CVCL_EB89 ND13859 transformed cell line human CVCL_EB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176732 CVCL_EB88 ND13858 transformed cell line human CVCL_EB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176733 CVCL_EB61 ND12847 transformed cell line human CVCL_EB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176734 CVCL_EB60 ND12810 transformed cell line human CVCL_EB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176735 CVCL_EB65 ND12978 transformed cell line human CVCL_EB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176736 CVCL_EB64 ND12896 transformed cell line human CVCL_EB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176737 CVCL_EB63 ND12895 transformed cell line human CVCL_EB63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176738 CVCL_EB62 ND12852 transformed cell line human CVCL_EB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176739 CVCL_EB58 ND12784 transformed cell line human CVCL_EB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176740 CVCL_EB57 ND12718 transformed cell line human CVCL_EB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176741 CVCL_EB56 ND12715 transformed cell line human CVCL_EB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176742 CVCL_EB55 ND12698 transformed cell line human CVCL_EB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176743 CVCL_EB59 ND12800 transformed cell line human CVCL_EB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176744 CVCL_EB72 ND13388 transformed cell line human CVCL_EB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176745 CVCL_EB71 ND13356 transformed cell line human CVCL_EB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176746 CVCL_EB70 ND13209 transformed cell line human CVCL_EB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176747 CVCL_EB76 ND13430 transformed cell line human CVCL_EB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176748 CVCL_EB75 ND13402 transformed cell line human CVCL_EB75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176749 CVCL_EB74 ND13401 transformed cell line human CVCL_EB74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176750 CVCL_EB73 ND13390 transformed cell line human CVCL_EB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176751 CVCL_EB69 ND13208 transformed cell line human CVCL_EB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176752 CVCL_EB68 ND13111 transformed cell line human CVCL_EB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176753 CVCL_EB67 ND13108 transformed cell line human CVCL_EB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176754 CVCL_EB66 ND13030 transformed cell line human CVCL_EB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176755 CVCL_EB43 ND12499 transformed cell line human CVCL_EB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176756 CVCL_EB42 ND12470 transformed cell line human CVCL_EB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176757 CVCL_EB41 ND12415 transformed cell line human CVCL_EB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176758 CVCL_EB40 ND12414 transformed cell line human CVCL_EB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176759 CVCL_EB36 ND12207 transformed cell line human CVCL_EB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176760 CVCL_EB35 ND12197 transformed cell line human CVCL_EB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176761 CVCL_EB34 ND12063 transformed cell line human CVCL_EB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176762 CVCL_EB33 ND12045 transformed cell line human CVCL_EB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176763 CVCL_EB39 ND12398 transformed cell line human CVCL_EB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176764 CVCL_EB38 ND12232 transformed cell line human CVCL_EB38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176765 CVCL_EB37 ND12208 transformed cell line human CVCL_EB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176766 CVCL_EB50 ND12539 transformed cell line human CVCL_EB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176767 CVCL_EB54 ND12674 transformed cell line human CVCL_EB54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176768 CVCL_EB53 ND12624 transformed cell line human CVCL_EB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176769 CVCL_EB52 ND12605 transformed cell line human CVCL_EB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176770 CVCL_EB51 ND12590 transformed cell line human CVCL_EB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176771 CVCL_EB47 ND12527 transformed cell line human CVCL_EB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176772 CVCL_EB46 ND12510 transformed cell line human CVCL_EB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176773 CVCL_EB45 ND12502 transformed cell line human CVCL_EB45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176774 CVCL_EB44 ND12501 transformed cell line human CVCL_EB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176775 CVCL_EB49 ND12537 transformed cell line human CVCL_EB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176776 CVCL_EB48 ND12536 transformed cell line human CVCL_EB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176777 CVCL_W656 GM00615 finite cell line human CVCL_W656 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176778 CVCL_VU56 Me18105 cancer cell line human CVCL_VU56 HLA typing: A*02; B*35,41; C*w04 (PubMed=9637706) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Arg23fs*30 (c.68-2A>G) (c.68_78del11); Zygosity=Homozygous (PubMed=9637706) Derived from metastatic site: Not specified. 21176779 CVCL_W655 GM00614 finite cell line human CVCL_W655 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176780 CVCL_VU55 Me1386 cancer cell line human CVCL_VU55 HLA typing: A*01,31; B*08,51; C*w07 (PubMed=9637706) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Homozygous (PubMed=9637706) Derived from metastatic site: Not specified. 21176781 CVCL_W654 GM00298 finite cell line human CVCL_W654 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176782 CVCL_VU54 HeLa-AC free cancer cell line human CVCL_VU54 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Adapted to growth in animal component free medium (EX-CELL HeLa Serum-Free Medium) (ECACC) Group: Serum/protein free medium cell line 21176783 CVCL_W653 GM00140 finite cell line human CVCL_W653 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21176784 CVCL_VU53 GR-34-EBV transformed cell line human CVCL_VU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176785 CVCL_W659 GM01927 finite cell line human CVCL_W659 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176786 CVCL_VU59 Hybrid 15B hybrid cell line house mouse CVCL_VU59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. 21176787 CVCL_W658 GM01258 finite cell line human CVCL_W658 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176788 CVCL_VU58 SGC7901/VCR cancer cell line human CVCL_VU58 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Proteome analysis by 2D-DE/MS Female Problematic cell line: Contaminated Parent cell line (SGC-7901) has been shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 21176789 CVCL_W657 GM00690 finite cell line human CVCL_W657 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21176790 CVCL_VU57 SGC7901/ADR cancer cell line human CVCL_VU57 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (SGC-7901) has been shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from the lymph node of a 56 year old female patient with a gastric carcinoma. 21176791 CVCL_4011 PaCa-3 cancer cell line human CVCL_4011 CL:0000010 Derived from sampling site: Pancreas. Male 21176792 CVCL_4010 vT\{2\} cancer cell line house mouse CVCL_4010 CL:0000010 Transfected with: HGNC; 700; ARNT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver; Breed/subspecies: C57L. Female 21176793 CVCL_4004 OV-MZ-15 cancer cell line human CVCL_4004 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 48 hours (PubMed=7510115) 21176794 CVCL_4003 OV-MZ-10 cancer cell line human CVCL_4003 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 27 hours (PubMed=7510115) 21176795 CVCL_4002 MOPC-173 cancer cell line house mouse CVCL_4002 CL:0000010 21176796 CVCL_4001 MOPC-104E cancer cell line house mouse CVCL_4001 CL:0000010 Breed/subspecies: BALB/c. Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:52071; Dextran 21176797 CVCL_4008 TAM.T finite cell line CVCL_4008 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6001; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21176798 CVCL_4007 SGS cancer cell line Norway rat CVCL_4007 CL:0000010 Breed/subspecies: Galliera. 21176799 CVCL_4006 RT4-D6P2T cancer cell line Norway rat CVCL_4006 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Schwann cell.; Breed/subspecies: BDIX. 21176800 CVCL_4005 OV-MZ-6 cancer cell line human CVCL_4005 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938) Derived from metastatic site: Ascites. Female Doubling time: 28 hours (PubMed=1500230) 21176801 CVCL_4009 T/G HA-VSMC finite cell line human CVCL_4009 CL:0000010 Population: Caucasian; Derived from sampling site: Aorta; smooth muscle. Discontinued: ECACC; 94102702; probable Female 21176802 CVCL_W663 GM03181 finite cell line human CVCL_W663 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176803 CVCL_VU63 LEC18 spontaneously immortalized cell line CVCL_VU63 CL:0000010 Selected for resistance to: UniProtKB; P02867; Pisum sativum lectin; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21176804 CVCL_W662 GM02268 finite cell line human CVCL_W662 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21176805 CVCL_VU62 LEC14 spontaneously immortalized cell line CVCL_VU62 CL:0000010 Selected for resistance to: UniProtKB; P02867; Pisum sativum lectin; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21176806 CVCL_W661 GM01929 finite cell line human CVCL_W661 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Male 21176807 CVCL_VU61 Hybrid 27-1 hybrid cell line house mouse CVCL_VU61 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. 21176808 CVCL_W660 GM01928 finite cell line human CVCL_W660 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176809 CVCL_VU60 Hybrid 26A7 hybrid cell line house mouse CVCL_VU60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. 21176810 CVCL_W645 293T/APOBEC3G transformed cell line human CVCL_W645 CL:0000010 Transfected with: HGNC; 17357; APOBEC3G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21176811 CVCL_VU45 JRPAY transformed cell line human CVCL_VU45 HLA typing: B*39:06:02,48:01; DPB1*05:01,09:01; DRB1*04:01:01,09:01:02; DRB4*01:03 (IPD-IMGT/HLA=13545) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21176812 CVCL_W644 ADRI Cf2Th/BMVLV spontaneously immortalized cell line dog CVCL_W644 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Female Virology: In vitro infected by bovine immunodeficiency virus Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10816 21176813 CVCL_VU44 AHPEN transformed cell line human CVCL_VU44 HLA typing: A*01:11N,02:06; B*08:01,44:02; C*05,07; DQB1*02,06; DRB1*03:01:01,13:01; DRB3*01:01 (IPD-IMGT/HLA=13562) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21176814 CVCL_W643 175-62 hybridoma house mouse CVCL_W643 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06681; Human C2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1553 21176815 CVCL_VU43 Mel 99.08 cancer cell line human CVCL_VU43 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=25728708) Omics: Transcriptome analysis by RNAseq. 21176816 CVCL_VU42 Mel 90.07 cancer cell line human CVCL_VU42 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=25728708) Omics: Transcriptome analysis by RNAseq. 21176817 CVCL_W642 Psi-AM22b transformed cell line house mouse CVCL_W642 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8859 21176818 CVCL_W649 CHO ST4.2 spontaneously immortalized cell line CVCL_W649 CL:0000010 Transfected with: HGNC; 1678; CD4 Derived from sampling site: Ovary. Female 21176819 CVCL_VU49 R80-1 spontaneously immortalized cell line Norway rat CVCL_VU49 CL:0000010 Transfected with: HGNC; 12833; XRCC5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified Doubling time: 16-20 hours (PubMed=8668197) 21176820 CVCL_W648 LCC-18 cancer cell line human CVCL_W648 CL:0000010 Population: Caucasian; Derived from sampling site: Colon; transverse. Male Doubling time: ~24 hours (PubMed=1782079) 21176821 CVCL_VU48 R7080-6 spontaneously immortalized cell line Norway rat CVCL_VU48 CL:0000010 Transfected with: HGNC; 12833; XRCC5; Transfected with: HGNC; 4055; XRCC6; Transfected with: UniProtKB; P09979; Streptomyces hygroscopicus hyg; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified Doubling time: 16-20 hours (PubMed=8668197) 21176822 CVCL_W647 12D7 cancer cell line human CVCL_W647 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Clone highly expressing CD4 (HIVReagentProgram) 21176823 CVCL_VU47 R7080-20 spontaneously immortalized cell line Norway rat CVCL_VU47 CL:0000010 Transfected with: HGNC; 12833; XRCC5; Transfected with: HGNC; 4055; XRCC6; Transfected with: UniProtKB; P09979; Streptomyces hygroscopicus hyg; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified Doubling time: 16-20 hours (PubMed=8668197) 21176824 CVCL_W646 HeLa-APOBEC3G cancer cell line human CVCL_W646 CL:0000010 Transfected with: HGNC; 17357; APOBEC3G Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21176825 CVCL_VU46 R70-15 spontaneously immortalized cell line Norway rat CVCL_VU46 CL:0000010 Transfected with: HGNC; 4055; XRCC6; Transfected with: UniProtKB; P09979; Streptomyces hygroscopicus hyg Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified Doubling time: 16-20 hours (PubMed=8668197) 21176826 CVCL_4022 SK-RC-44 cancer cell line human CVCL_4022 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Male 21176827 CVCL_4021 SK-RC-39 cancer cell line human CVCL_4021 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Soft tissue. Doubling time: 42 hours (PubMed=2386958) 21176828 CVCL_4020 SK-RC-35 cancer cell line human CVCL_4020 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male Doubling time: 30 hours (PubMed=2386958) 21176829 CVCL_4015 JCA-1 cancer cell line human CVCL_4015 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00216 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=11304728; PubMed=11522622; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 67 year old male patient with prostate carcinoma. 21176830 CVCL_4014 TSU-Pr1 cancer cell line human CVCL_4014 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (PubMed=11304728; PubMed=11522622) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00280 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=11304728; PubMed=11522622; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 73 year old male patient with a prostate carcinoma. 21176831 CVCL_4013 PancTu-II cancer cell line human CVCL_4013 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959). Female 21176832 CVCL_4012 PancTu-I cancer cell line human CVCL_4012 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Ser (c.526T>A); ClinVar=VCV000376570; Zygosity=Unspecified (PubMed=8426738; PubMed=11169959; PubMed=11787853) Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Female 21176833 CVCL_4019 SK-RC-29 cancer cell line human CVCL_4019 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Ovary. Female Doubling time: 36 hours (PubMed=2386958) 21176834 CVCL_4018 SK-RC-17 cancer cell line human CVCL_4018 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, metastatic site and sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Abdominal wall. Male 21176835 CVCL_4017 SK-RC-1 cancer cell line human CVCL_4017 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and metastatic site from MSKCC antibody and bioresource core facility Derived from metastatic site: Perinodal adipose tissue. Male Doubling time: 42 hours (PubMed=2386958) 21176836 CVCL_4016 SK-RC-45 cancer cell line human CVCL_4016 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Adrenal gland. Male Doubling time: 48 hours (PubMed=2386958) 21176837 CVCL_W652 GM00047 finite cell line human CVCL_W652 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176838 CVCL_VU52 GR-34 cancer cell line human CVCL_VU52 CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser16Alafs*27 (c.45_48delTTCT); Zygosity=Hemizygous (PubMed=10395107) Derived from sampling site: Skin. Male 21176839 CVCL_VU51 BB49-EBV transformed cell line human CVCL_VU51 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21176840 CVCL_W651 GM00039 finite cell line human CVCL_W651 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21176841 CVCL_W650 HOS-CD4 cancer cell line human CVCL_W650 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1678; CD4 Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21176842 CVCL_VU50 R80-6 spontaneously immortalized cell line Norway rat CVCL_VU50 CL:0000010 Transfected with: HGNC; 12833; XRCC5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21176843 CVCL_VU34 CCC-HSM-2 finite cell line human CVCL_VU34 CL:0000010 Derived from sampling site: Fetal muscle. Male 21176844 CVCL_W634 H4 [Mouse chondrocyte] transformed cell line house mouse CVCL_W634 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Articular cartilage Cell type=Chondrocyte.; Breed/subspecies: C57BL/6. Male 21176845 CVCL_VU33 CCC-HPE-2 finite cell line human CVCL_VU33 CL:0000010 Derived from sampling site: Fetal pancreas. Male 21176846 CVCL_W633 MM-Sv/HP-2 transformed cell line house mouse CVCL_W633 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Articular cartilage Cell type=Chondrocyte.; Breed/subspecies: 129S9/SvEvH. Unspecified Characteristics: Has preserved a chondrocyte phenotype; Characteristics: Useful to help understand chondrocyte biology and provide information on the underlying mechanism of osteoarthritis 21176847 CVCL_VU32 CCC-HIE-2 finite cell line human CVCL_VU32 CL:0000010 Derived from sampling site: Fetal colon; mucosa. Male 21176848 CVCL_W632 HOBIT transformed cell line human CVCL_W632 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Female 21176849 CVCL_VU31 CCC-HEL-1 finite cell line human CVCL_VU31 CL:0000010 Derived from sampling site: Fetal liver Cell type=Epithelial cell.. Male 21176850 CVCL_W631 YROS-2 cancer cell line Norway rat CVCL_W631 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; humerus; Breed/subspecies: Wistar. Female Doubling time: 39 hours (PubMed=7479367) 21176851 CVCL_W638 GM11337 finite cell line human CVCL_W638 CL:0000010 Population: Caucasian; Karyotypic information: 47,XYY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21176852 CVCL_VU38 HCT 116-Luc2 [ATCC] cancer cell line human CVCL_VU38 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Colon. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~14 hours (ATCC=CCL-247-LUC2) 21176853 CVCL_W637 GM09326 finite cell line human CVCL_W637 CL:0000010 Population: Caucasian; English/Irish; Karyotypic information: 47,XYY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21176854 CVCL_VU37 LT73 cancer cell line human CVCL_VU37 CL:0000010 Derived from sampling site: Lung. Male 21176855 CVCL_W636 GM01250 finite cell line human CVCL_W636 CL:0000010 Population: African American; Karyotypic information: 47,XYY (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21176856 CVCL_VU36 LT259 cancer cell line human CVCL_VU36 CL:0000010 Unspecified 21176857 CVCL_W635 HES [Human contaminated endometrial epithelial] cancer cell line human CVCL_W635 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00461 Problematic cell line: Contaminated Shown to be a WISH derivative (PubMed=24520087). Originally thought to originate from an endometrium. 21176858 CVCL_VU35 LT215 cancer cell line human CVCL_VU35 CL:0000010 Unspecified 21176859 CVCL_VU39 EBSM transformed cell line human CVCL_VU39 HLA typing: DRB1*14:05:01,15:02 (IPD-IMGT/HLA=13063) CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21176860 CVCL_W639 GM18241 transformed cell line human CVCL_W639 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176861 CVCL_W641 GM02050 finite cell line human CVCL_W641 CL:0000010 Sequence variation: Mutation; HGNC; 6826; MAN2B1; Simple; p.His72Leu (c.215A>T) (H71L); ClinVar=VCV000001684; Zygosity=Homozygous (Coriell) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21176862 CVCL_VU41 Mel 02.02 cancer cell line human CVCL_VU41 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=25728708). 21176863 CVCL_W640 GM02013 finite cell line human CVCL_W640 CL:0000010 Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Tyr1079Leufs*3 (c.3231_3234dupCTAC) (3395_3398dupCTAC); ClinVar=VCV000038423; Zygosity=Heterozygous (PubMed=16465621); Sequence variation: Mutation; HGNC; 29670; GNPTAB; Simple; p.Leu1168Glnfs*5 (c.3501_3502TC[1]) (c.3503_3504delTC) (3665_3666delTC); ClinVar=VCV000002771; Zygosity=Heterozygous (PubMed=16465621) Population: Arab; Derived from sampling site: Cell type=Fibroblast. Male 21176864 CVCL_VU40 Mel 01.12 cancer cell line human CVCL_VU40 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=25728708) Omics: Transcriptome analysis by RNAseq. 21176865 CVCL_W623 GM00245 finite cell line human CVCL_W623 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21176866 CVCL_VU23 MHCC97-H CD44s shRNA cancer cell line human CVCL_VU23 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 1681; CD44; Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male 21176867 CVCL_W622 GM04375 finite cell line human CVCL_W622 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21176868 CVCL_VU22 MHCC97-H c-Met shRNA cancer cell line human CVCL_VU22 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7029; MET; Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male 21176869 CVCL_VU21 5A8 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_VU21 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5594 21176870 CVCL_W621 GM02109 finite cell line human CVCL_W621 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Arg65Ter (c.193C>T); ClinVar=VCV000558291; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.His86Tyr (c.256C>T); ClinVar=VCV000555658; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21176871 CVCL_W620 GM13195 transformed cell line human CVCL_W620 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10216 21176872 CVCL_VU20 TERT-hWA telomerase immortalized cell line human CVCL_VU20 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: White adipose tissue. Female Characteristics: Recapitulate the gene expression profile of white adipocytes Doubling time: ~1-2 days (PubMed=28957413) 21176873 CVCL_VU27 CCC-HB-2 finite cell line human CVCL_VU27 CL:0000010 Derived from sampling site: Fetal urinary bladder. Male 21176874 CVCL_W627 K37 cancer cell line house mouse CVCL_W627 CL:0000010 Breed/subspecies: BALB/c. Female 21176875 CVCL_VU26 E77.4 spontaneously immortalized cell line CVCL_VU26 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used to produce hCBE 11, a humanized antibody against human LTBR (lymphotoxin-beta receptor) Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3765 21176876 CVCL_W626 K14 cancer cell line house mouse CVCL_W626 CL:0000010 Breed/subspecies: BALB/c. Female 21176877 CVCL_VU25 E46.4 spontaneously immortalized cell line CVCL_VU25 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used to produce hCBE 11, a humanized antibody against human LTBR (lymphotoxin-beta receptor) Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3357 21176878 CVCL_W625 K12 [Mouse osteosarcoma] cancer cell line house mouse CVCL_W625 CL:0000010 Breed/subspecies: BALB/c. Omics: Transcriptome analysis by microarray Female 21176879 CVCL_W624 K7 [Mouse osteosarcoma] cancer cell line house mouse CVCL_W624 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: BALB/c. Female 21176880 CVCL_VU24 MHCC97-H Scrm shRNA cancer cell line human CVCL_VU24 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male Characteristics: Transfected with a scrambled shRNA, control cell line for MHCC97-H CD44s shRNA (Cellosaurus=CVCL_VU23) and MHCC97-H c-Met shRNA (Cellosaurus=CVCL_VU22) 21176881 CVCL_VU29 CCC-HEH-2 finite cell line human CVCL_VU29 CL:0000010 Derived from sampling site: Fetal heart. Male 21176882 CVCL_W629 Dunn osteosarcoma cancer cell line house mouse CVCL_W629 CL:0000010 Breed/subspecies: C3H/HeJ. Omics: Transcriptome analysis by microarray Female Doubling time: 14.7 hours (PubMed=9579581) 21176883 CVCL_VU28 CCC-HBE-2 finite cell line human CVCL_VU28 CL:0000010 Derived from sampling site: Fetal trachea. Male 21176884 CVCL_W628 K8 [Mouse osteosarcoma] cancer cell line house mouse CVCL_W628 CL:0000010 Breed/subspecies: BALB/c. Female 21176885 CVCL_4000 MM5MTM cancer cell line house mouse CVCL_4000 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/Crgl. Discontinued: ATCC; CRL-6379; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21176886 CVCL_VU30 CCC-HEK-1 finite cell line human CVCL_VU30 CL:0000010 Derived from sampling site: Fetal kidney. Male 21176887 CVCL_W630 YROS-1 cancer cell line Norway rat CVCL_W630 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Derived from sampling site: Bone; femur; Breed/subspecies: Wistar. Female Doubling time: 23 hours (PubMed=7479367) 21176888 CVCL_VU12 CHM13hTERT telomerase immortalized cell line human CVCL_VU12 CL:0000010 Transfected with: HGNC; 11730; TERT Anecdotal: Because of its homozygous genome it is being used to build/correct new generation of human genome assemblies. Omics: Genome sequenced Female Characteristics: Has a completely homozygous genome, thus representing a functionally haploid genome 21176889 CVCL_W612 GM13187 transformed cell line human CVCL_W612 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10208 21176890 CVCL_VU11 CHM1hTERT telomerase immortalized cell line human CVCL_VU11 CL:0000010 Transfected with: HGNC; 11730; TERT Anecdotal: Because of its homozygous genome it is being used to build/correct new generation of human genome assemblies. Omics: Genome sequenced Female Characteristics: Has a completely homozygous genome, thus representing a functionally haploid genome 21176891 CVCL_W611 GM13185 transformed cell line human CVCL_W611 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10206 21176892 CVCL_VU10 CHO-27-1 spontaneously immortalized cell line CVCL_VU10 CL:0000010 Sequence variation: Mutation; UniProtKB; A0MQ57; Ercc3; Simple; p.Lys359Glu (c.1075C>G); Zygosity=Unspecified (PubMed=16143348) Derived from sampling site: Ovary. Female 21176893 CVCL_W610 GM13184 transformed cell line human CVCL_W610 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Population: South American (Brazil, Guyana, Venezuela); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10205/10402 21176894 CVCL_W616 GM13191 transformed cell line human CVCL_W616 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10212 21176895 CVCL_VU16 WT-1 transformed cell line house mouse CVCL_VU16 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brown adipose tissue; Breed/subspecies: FVB. 21176896 CVCL_VU15 C-1300 clone C46 cancer cell line house mouse CVCL_VU15 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Non-producer of neurotransmitters clone of C-1300 21176897 CVCL_W615 GM13190 transformed cell line human CVCL_W615 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10211 21176898 CVCL_VU14 C-1300 clone S20 cancer cell line house mouse CVCL_VU14 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Cholinergic clone of C-1300 21176899 CVCL_W614 GM13189 transformed cell line human CVCL_W614 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10210 21176900 CVCL_VU13 A9.12 factor-dependent cell line house mouse CVCL_VU13 CL:0000010 Derived from sampling site: Cell type=Helper T-cell; Breed/subspecies: SJL. Characteristics: IL2 dependent 21176901 CVCL_W613 GM13188 transformed cell line human CVCL_W613 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10209 21176902 CVCL_W619 GM13194 transformed cell line human CVCL_W619 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10215 21176903 CVCL_VU19 TERT-hBA telomerase immortalized cell line human CVCL_VU19 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Brown adipose tissue. Female Characteristics: Recapitulate the gene expression profile of brown adipocytes UCP1-positive and responsive to beta-adrenergic stimulation. Doubling time: ~1-2 days (PubMed=28957413) 21176904 CVCL_VU18 BATkl2 spontaneously immortalized cell line house mouse CVCL_VU18 CL:0000010 Derived from sampling site: Brown adipose tissue Cell type=Preadipocyte.; Breed/subspecies: NMRI. Female Characteristics: FGF2 dependent 21176905 CVCL_W618 GM13193 transformed cell line human CVCL_W618 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10214 21176906 CVCL_W617 GM13192 transformed cell line human CVCL_W617 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10213 21176907 CVCL_VU17 HAECT-1 transformed cell line human CVCL_VU17 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta Cell type=Aortic endothelial cell.. Omics: Transcriptome analysis by microarray Female 21176908 CVCL_VU01 2429 SIX2:EGFP induced pluripotent stem cell human CVCL_VU01 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 SIX2 has been endogenously tagged in both alleles at the C-terminus with EGFP 21176909 CVCL_W601 L2-1Mut induced pluripotent stem cell human CVCL_W601 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176910 CVCL_VU00 2429 CITED1:mCherry induced pluripotent stem cell human CVCL_VU00 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 CITED1 has been endogenously tagged with mCherry 21176911 CVCL_W600 L2-1GC induced pluripotent stem cell human CVCL_W600 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176912 CVCL_VU05 CHO-K1 MMC-1 spontaneously immortalized cell line CVCL_VU05 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Sensitive to mitomycin C 21176913 CVCL_W605 L2-3Mut induced pluripotent stem cell human CVCL_W605 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176914 CVCL_VU04 CHO 15B spontaneously immortalized cell line CVCL_VU04 CL:0000010 Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Derived from sampling site: Ovary. Female Characteristics: Deficient in alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase activity 21176915 CVCL_W604 L2-3GC induced pluripotent stem cell human CVCL_W604 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176916 CVCL_VU03 CHO B8-300 spontaneously immortalized cell line CVCL_VU03 CL:0000010 Transfected with: HGNC; 3415; EPO Derived from sampling site: Ovary. Female 21176917 CVCL_W603 L2-2Mut induced pluripotent stem cell human CVCL_W603 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176918 CVCL_VU02 BJFF.6 induced pluripotent stem cell human CVCL_VU02 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21176919 CVCL_W602 L2-2GC induced pluripotent stem cell human CVCL_W602 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176920 CVCL_VU09 CHO-K1 MMC-5 spontaneously immortalized cell line CVCL_VU09 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Sensitive to mitomycin C 21176921 CVCL_W609 GM13183 transformed cell line human CVCL_W609 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10204 21176922 CVCL_VU08 CHO-K1 MMC-4 spontaneously immortalized cell line CVCL_VU08 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Sensitive to mitomycin C 21176923 CVCL_W608 GM13182 transformed cell line human CVCL_W608 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Venezuelan pedigree cell line collection; Registration: CEPH Families Reference Panel; 10203 21176924 CVCL_VU07 CHO-K1 MMC-3 spontaneously immortalized cell line CVCL_VU07 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Sensitive to mitomycin C 21176925 CVCL_W607 GM10867 transformed cell line human CVCL_W607 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176926 CVCL_VU06 CHO-K1 MMC-2 spontaneously immortalized cell line CVCL_VU06 CL:0000010 Sequence variation: Mutation; UniProtKB; A0MQ57; Ercc3; Simple; p.Gln739Ter (c.2215C>T); Zygosity=Unspecified (PubMed=16143348) Derived from sampling site: Ovary. Female Characteristics: Sensitive to mitomycin C 21176927 CVCL_W606 GM10866 transformed cell line human CVCL_W606 CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Simple; p.Arg468Pro (c.1403G>C); ClinVar=VCV000092615; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176928 CVCL_3N70 HQ01386 transformed cell line human CVCL_3N70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176929 CVCL_3N74 HQ01390 transformed cell line human CVCL_3N74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176930 CVCL_3N73 HQ01389 transformed cell line human CVCL_3N73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176931 CVCL_3N72 HQ01388 transformed cell line human CVCL_3N72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176932 CVCL_3N71 HQ01387 transformed cell line human CVCL_3N71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176933 CVCL_3N78 HQ01395 transformed cell line human CVCL_3N78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176934 CVCL_3N77 HQ01394 transformed cell line human CVCL_3N77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176935 CVCL_3N76 HQ01392 transformed cell line human CVCL_3N76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176936 CVCL_3N75 HQ01391 transformed cell line human CVCL_3N75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176937 CVCL_3N69 HQ01385 transformed cell line human CVCL_3N69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176938 CVCL_3N68 HQ01384 transformed cell line human CVCL_3N68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176939 CVCL_3N81 HQ01398 transformed cell line human CVCL_3N81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176940 CVCL_3N80 HQ01397 transformed cell line human CVCL_3N80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176941 CVCL_3N85 HQ01402 transformed cell line human CVCL_3N85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176942 CVCL_3N84 HQ01401 transformed cell line human CVCL_3N84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176943 CVCL_3N83 HQ01400 transformed cell line human CVCL_3N83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176944 CVCL_3N82 HQ01399 transformed cell line human CVCL_3N82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176945 CVCL_3N89 HQ01406 transformed cell line human CVCL_3N89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176946 CVCL_3N88 HQ01405 transformed cell line human CVCL_3N88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176947 CVCL_3N87 HQ01404 transformed cell line human CVCL_3N87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176948 CVCL_3N86 HQ01403 transformed cell line human CVCL_3N86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176949 CVCL_3N79 HQ01396 transformed cell line human CVCL_3N79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176950 CVCL_W599 L1-2Mut induced pluripotent stem cell human CVCL_W599 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176951 CVCL_VT99 RB44-10D5.19-21 hybridoma CVCL_VT99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05067; Human APP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5129 21176952 CVCL_W598 L1-2GC induced pluripotent stem cell human CVCL_W598 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176953 CVCL_VT98 MC3T3-E1 Subclone 8 spontaneously immortalized cell line house mouse CVCL_VT98 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Forms a well mineralized extracellular matrix (ECM) 21176954 CVCL_3N52 HQ01368 transformed cell line human CVCL_3N52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176955 CVCL_3N51 HQ01367 transformed cell line human CVCL_3N51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176956 CVCL_3N50 HQ01366 transformed cell line human CVCL_3N50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176957 CVCL_3N56 HQ01372 transformed cell line human CVCL_3N56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176958 CVCL_3N55 HQ01371 transformed cell line human CVCL_3N55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176959 CVCL_3N54 HQ01370 transformed cell line human CVCL_3N54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176960 CVCL_3N53 HQ01369 transformed cell line human CVCL_3N53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176961 CVCL_3N49 HQ01365 transformed cell line human CVCL_3N49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176962 CVCL_3N48 HQ01364 transformed cell line human CVCL_3N48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176963 CVCL_3N47 HQ01363 transformed cell line human CVCL_3N47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176964 CVCL_3N46 HQ01361 transformed cell line human CVCL_3N46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176965 CVCL_W589 HD60i.3 induced pluripotent stem cell human CVCL_W589 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176966 CVCL_VT89 ZEC-219 cancer cell line human CVCL_VT89 CL:0000010 Population: Chinese Male Doubling time: ~53 hours (Patent=CN106047816A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201688 21176967 CVCL_W588 HD33n induced pluripotent stem cell human CVCL_W588 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176968 CVCL_VT88 ZEC-166 cancer cell line human CVCL_VT88 CL:0000010 Population: Chinese Male Doubling time: ~85 hours (Patent=CN106190982A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201687 21176969 CVCL_W587 HD33i.8 induced pluripotent stem cell human CVCL_W587 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176970 CVCL_VT87 ZEC-157 cancer cell line human CVCL_VT87 CL:0000010 Population: Chinese Female Doubling time: ~22 hours (Patent=CN106047815A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201693 21176971 CVCL_3N63 HQ01379 transformed cell line human CVCL_3N63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176972 CVCL_3N62 HQ01378 transformed cell line human CVCL_3N62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176973 CVCL_3N61 HQ01377 transformed cell line human CVCL_3N61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176974 CVCL_3N60 HQ01376 transformed cell line human CVCL_3N60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176975 CVCL_3N67 HQ01383 transformed cell line human CVCL_3N67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176976 CVCL_3N66 HQ01382 transformed cell line human CVCL_3N66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176977 CVCL_3N65 HQ01381 transformed cell line human CVCL_3N65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176978 CVCL_3N64 HQ01380 transformed cell line human CVCL_3N64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176979 CVCL_3N59 HQ01375 transformed cell line human CVCL_3N59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21176980 CVCL_3N58 HQ01374 transformed cell line human CVCL_3N58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176981 CVCL_3N57 HQ01373 transformed cell line human CVCL_3N57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21176982 CVCL_W593 C4 induced pluripotent stem cell human CVCL_W593 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176983 CVCL_VT93 MC3T3-E1 Subclone 11 spontaneously immortalized cell line house mouse CVCL_VT93 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Forms a well mineralized extracellular matrix (ECM) 21176984 CVCL_W592 HDS cancer cell line human CVCL_W592 CL:0000010 Derived from sampling site: Peripheral blood. Male Doubling time: ~24 hours (PubMed=27463353) 21176985 CVCL_VT92 imGPAD transformed cell line human CVCL_VT92 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: White adipose tissue. Male Doubling time: 1.1 +- 0.05 days (PubMed=28452592) 21176986 CVCL_W591 HD60n induced pluripotent stem cell human CVCL_W591 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176987 CVCL_VT91 imAPAD transformed cell line human CVCL_VT91 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: White adipose tissue. Male Doubling time: 1.0 +- 0.03 days (PubMed=28452592) 21176988 CVCL_W590 HD60i.4 induced pluripotent stem cell human CVCL_W590 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176989 CVCL_VT90 PASH-4 finite cell line human CVCL_VT90 CL:0000010 Derived from sampling site: Adipose tissue; hypodermis Cell type=Preadipocyte.. Male Doubling time: 47-95 hours (CelloPub=CLPUB00477) 21176990 CVCL_W597 L1-1Mut induced pluripotent stem cell human CVCL_W597 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176991 CVCL_VT97 MC3T3-E1 Subclone 35 spontaneously immortalized cell line house mouse CVCL_VT97 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Does not form a mineralized extracellular matrix 21176992 CVCL_W596 L1-1GC2 induced pluripotent stem cell human CVCL_W596 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176993 CVCL_VT96 MC3T3-E1 Subclone 26 spontaneously immortalized cell line house mouse CVCL_VT96 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Forms a well mineralized extracellular matrix (ECM) 21176994 CVCL_W595 L1-1GC1 induced pluripotent stem cell human CVCL_W595 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By ZFN (PubMed=23472874) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176995 CVCL_VT95 MC3T3-E1 Subclone 20 spontaneously immortalized cell line house mouse CVCL_VT95 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Does not form a mineralized extracellular matrix 21176996 CVCL_W594 C4+G2019S induced pluripotent stem cell human CVCL_W594 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21176997 CVCL_VT94 MC3T3-E1 Subclone 17 spontaneously immortalized cell line house mouse CVCL_VT94 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Does not form a mineralized extracellular matrix 21176998 CVCL_W579 HD109i.1 induced pluripotent stem cell human CVCL_W579 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22748968) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21176999 CVCL_VT79 ZEC-014 cancer cell line human CVCL_VT79 CL:0000010 Population: Chinese Male Doubling time: ~22 hours (Patent=CN106011069A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201689 21177000 CVCL_W578 HD00n induced pluripotent stem cell human CVCL_W578 CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 21177001 CVCL_VT78 HEK-293-AChE-ST transformed cell line human CVCL_VT78 CL:0000010 Transfected with: HGNC; 1966; CHRNE; Transfected with: RGD; 3676; St6gal1 (with p.Tyr123Cys); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21177002 CVCL_VT77 HEK-293-AChE transformed cell line human CVCL_VT77 CL:0000010 Transfected with: HGNC; 1966; CHRNE; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21177003 CVCL_W577 ND36999 induced pluripotent stem cell human CVCL_W577 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND36999; true Male 21177004 CVCL_VT76 6/9CII spontaneously immortalized cell line CVCL_VT76 CL:0000010 Transfected with: MGI; MGI:95499; Fcgr2b (with Lys204_Ile330del) Derived from sampling site: Kidney. Male 21177005 CVCL_W576 GM09197 finite cell line human CVCL_W576 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=25928884) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177006 CVCL_3N30 HQ01345 transformed cell line human CVCL_3N30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177007 CVCL_3N34 HQ01349 transformed cell line human CVCL_3N34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177008 CVCL_3N33 HQ01348 transformed cell line human CVCL_3N33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177009 CVCL_3N32 HQ01347 transformed cell line human CVCL_3N32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177010 CVCL_3N31 HQ01346 transformed cell line human CVCL_3N31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177011 CVCL_3N27 HQ01342 transformed cell line human CVCL_3N27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177012 CVCL_3N26 HQ01341 transformed cell line human CVCL_3N26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177013 CVCL_3N25 HQ01340 transformed cell line human CVCL_3N25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177014 CVCL_3N24 HQ01339 transformed cell line human CVCL_3N24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177015 CVCL_3N29 HQ01344 transformed cell line human CVCL_3N29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177016 CVCL_3N28 HQ01343 transformed cell line human CVCL_3N28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177017 CVCL_W582 HD180i.7 induced pluripotent stem cell human CVCL_W582 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177018 CVCL_VT82 ZEC-061 cancer cell line human CVCL_VT82 CL:0000010 Population: Chinese Male Doubling time: ~48 hours (Patent=CN106222142A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201692 21177019 CVCL_W581 HD180i.6 induced pluripotent stem cell human CVCL_W581 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177020 CVCL_VT81 ZEC-056 cancer cell line human CVCL_VT81 CL:0000010 Population: Chinese. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201691 21177021 CVCL_W580 HD180i.5 induced pluripotent stem cell human CVCL_W580 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177022 CVCL_VT80 ZEC-043 cancer cell line human CVCL_VT80 CL:0000010 Population: Chinese. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201690 21177023 CVCL_W586 HD33i.2 induced pluripotent stem cell human CVCL_W586 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177024 CVCL_VT86 ZEC-145 cancer cell line human CVCL_VT86 CL:0000010 Population: Chinese Male Doubling time: ~26 hours (Patent=CN106011067A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201686 21177025 CVCL_W585 HD28i.2 induced pluripotent stem cell human CVCL_W585 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21177026 CVCL_VT85 ZEC-134 cancer cell line human CVCL_VT85 CL:0000010 Population: Chinese; Derived from sampling site: Pleural effusion. Male Doubling time: ~60 hours (Patent=CN105969734A) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016108 21177027 CVCL_W584 HD21i.5 induced pluripotent stem cell human CVCL_W584 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177028 CVCL_VT84 ZEC-127 cancer cell line human CVCL_VT84 CL:0000010 Population: Chinese Male Doubling time: ~60 hours (Patent=CN106190981A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201685 21177029 CVCL_W583 HD180n induced pluripotent stem cell human CVCL_W583 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177030 CVCL_VT83 ZEC-118 cancer cell line human CVCL_VT83 CL:0000010 Population: Chinese Female Doubling time: ~52 hours (Patent=CN106047814A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201694 21177031 CVCL_W568 Ctrl2-2 induced pluripotent stem cell human CVCL_W568 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177032 CVCL_VT68 IM4/V/IV-G1 spontaneously immortalized cell line CVCL_VT68 CL:0000010 Transfected with: HGNC; 924; B4GALT1; Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21177033 CVCL_W567 Ctrl1-17 induced pluripotent stem cell human CVCL_W567 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177034 CVCL_VT67 IM4/V/IV spontaneously immortalized cell line CVCL_VT67 CL:0000010 Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21177035 CVCL_W566 Ctrl1-12 induced pluripotent stem cell human CVCL_W566 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177036 CVCL_VT66 IM4/Vm spontaneously immortalized cell line CVCL_VT66 CL:0000010 Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21177037 CVCL_VT65 IM4/Vh spontaneously immortalized cell line CVCL_VT65 CL:0000010 Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female 21177038 CVCL_W565 UW83iCTR-i.8 induced pluripotent stem cell human CVCL_W565 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177039 CVCL_W569 Ctrl2-8 induced pluripotent stem cell human CVCL_W569 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177040 CVCL_VT69 IM4/V/IV-G2 spontaneously immortalized cell line CVCL_VT69 CL:0000010 Transfected with: HGNC; 924; B4GALT1; Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21177041 CVCL_3N41 HQ01356 transformed cell line human CVCL_3N41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177042 CVCL_3N40 HQ01355 transformed cell line human CVCL_3N40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177043 CVCL_3N45 HQ01360 transformed cell line human CVCL_3N45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177044 CVCL_3N44 HQ01359 transformed cell line human CVCL_3N44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177045 CVCL_3N43 HQ01358 transformed cell line human CVCL_3N43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177046 CVCL_3N42 HQ01357 transformed cell line human CVCL_3N42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177047 CVCL_3N38 HQ01353 transformed cell line human CVCL_3N38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177048 CVCL_3N37 HQ01352 transformed cell line human CVCL_3N37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177049 CVCL_3N36 HQ01351 transformed cell line human CVCL_3N36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177050 CVCL_3N35 HQ01350 transformed cell line human CVCL_3N35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177051 CVCL_3N39 HQ01354 transformed cell line human CVCL_3N39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177052 CVCL_VT71 IM4/V/IV-G4 spontaneously immortalized cell line CVCL_VT71 CL:0000010 Transfected with: HGNC; 924; B4GALT1; Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21177053 CVCL_W571 MJD1-9 induced pluripotent stem cell human CVCL_W571 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177054 CVCL_VT70 IM4/V/IV-G3 spontaneously immortalized cell line CVCL_VT70 CL:0000010 Transfected with: HGNC; 924; B4GALT1; Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21177055 CVCL_W570 MJD1-11 induced pluripotent stem cell human CVCL_W570 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177056 CVCL_VT75 17-Cl1 spontaneously immortalized cell line house mouse CVCL_VT75 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Virology: Used for cultivation of murine coronaviruses, including murine hepatitis virus (PubMed=21538303); Virology: Infection by mouse hepatitis virus (MHV) results in apoptotic cell death (PubMed=12441076) 21177057 CVCL_W575 MJD4-1 induced pluripotent stem cell human CVCL_W575 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[73]; Zygosity=Heterozygous; Note=The other allele has 20 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177058 CVCL_W574 MJD3-5 induced pluripotent stem cell human CVCL_W574 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[73]; Zygosity=Heterozygous; Note=The other allele has 27 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21177059 CVCL_VT74 Sp2/HL-BU hybridoma house mouse CVCL_VT74 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine. Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC) 21177060 CVCL_W573 MJD2-9 induced pluripotent stem cell human CVCL_W573 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 21 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177061 CVCL_VT73 Sp2/HL hybridoma house mouse CVCL_VT73 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). 21177062 CVCL_VT72 IM4/V/IV-G5 spontaneously immortalized cell line CVCL_VT72 CL:0000010 Transfected with: HGNC; 924; B4GALT1; Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 7049; MGAT5; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Ovary. Female 21177063 CVCL_W572 MJD2-2 induced pluripotent stem cell human CVCL_W572 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous; Note=The other allele has 21 repeats (PubMed=22113611) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; UKBi001-A; true; Discontinued: ECACC; 66540006; true; Discontinued: hPSCreg; UKBi001-A; true Male 21177064 CVCL_VT57 BPKU transformed cell line human CVCL_VT57 CL:0000010 Transfected with: HGNC; 2194; COL17A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a COL17A1-IgG1 Fc fusion construct Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.7801 21177065 CVCL_W557 GM02183 finite cell line human CVCL_W557 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177066 CVCL_W556 GM02182 transformed cell line human CVCL_W556 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from autologous cell line GM02183) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21177067 CVCL_VT56 PSU-AL-WS40NE spontaneously immortalized cell line CVCL_VT56 CL:0000010 Unspecified Characteristics: Can survive anoxia for close to 50 days at 30 Celsius (PubMed=30802492). Group: Fish cell line 21177068 CVCL_VT55 KS-iPSC-11 induced pluripotent stem cell human CVCL_VT55 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177069 CVCL_W555 vFOP5-22 induced pluripotent stem cell human CVCL_W555 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177070 CVCL_VT54 KS-iPSC-8 induced pluripotent stem cell human CVCL_VT54 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177071 CVCL_W554 vFOP4-3 induced pluripotent stem cell human CVCL_W554 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177072 CVCL_W559 CS29iALS-C9n1 induced pluripotent stem cell human CVCL_W559 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24154603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: ATAC-seq; Omics: Transcriptome analysis by RNAseq Male 21177073 CVCL_VT59 CTCC-1 cancer cell line human CVCL_VT59 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (CelloPub=CLPUB00475); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (CelloPub=CLPUB00475) Population: Chinese; Han; Derived from sampling site: Uterus; cervix. Female 21177074 CVCL_W558 CS28iALS-C9n1 induced pluripotent stem cell human CVCL_W558 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24154603) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177075 CVCL_VT58 GC-030-35 cancer cell line human CVCL_VT58 CL:0000010 Population: Chinese; Derived from sampling site: Stomach. Omics: Transcriptome analysis by RNAseq Male Doubling time: 29.2 hours (PubMed=30799954) 21177076 CVCL_3N12 HQ01327 transformed cell line human CVCL_3N12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177077 CVCL_3N11 HQ01326 transformed cell line human CVCL_3N11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177078 CVCL_3N10 HQ01325 transformed cell line human CVCL_3N10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177079 CVCL_3N05 HQ01320 transformed cell line human CVCL_3N05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177080 CVCL_3N04 HQ01319 transformed cell line human CVCL_3N04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177081 CVCL_3N03 HQ01318 transformed cell line human CVCL_3N03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177082 CVCL_3N02 HQ01317 transformed cell line human CVCL_3N02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177083 CVCL_3N09 HQ01324 transformed cell line human CVCL_3N09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177084 CVCL_3N08 HQ01323 transformed cell line human CVCL_3N08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177085 CVCL_3N07 HQ01322 transformed cell line human CVCL_3N07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177086 CVCL_3N06 HQ01321 transformed cell line human CVCL_3N06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177087 CVCL_VT60 BW5147.PHAR2.7 cancer cell line house mouse CVCL_VT60 CL:0000010 Selected for resistance to: UniProtKB; P05087; Phaseolus vulgaris leucoagglutinating phytohemagglutinin (PHA-L); Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Deficient in glucosidase II 21177088 CVCL_W560 CS30iALS-C9n1 induced pluripotent stem cell human CVCL_W560 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24154603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177089 CVCL_W564 GM10684 transformed cell line human CVCL_W564 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177090 CVCL_VT64 IM4/IV spontaneously immortalized cell line CVCL_VT64 CL:0000010 Transfected with: HGNC; 7047; MGAT4A; Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21177091 CVCL_VT63 IM4 spontaneously immortalized cell line CVCL_VT63 CL:0000010 Transfected with: HGNC; 5438; IFNG; Transfected with: MGI; MGI:94890; Dhfr Derived from sampling site: Ovary. Female 21177092 CVCL_W563 UW77iSMA-e.x induced pluripotent stem cell human CVCL_W563 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Eye; ocular lens Cell type=Fibroblast.. Male 21177093 CVCL_W562 GM09677 finite cell line human CVCL_W562 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Eye; ocular lens Cell type=Fibroblast.. Male 21177094 CVCL_VT62 SPC-Mb-92-C6 spontaneously immortalized cell line CVCL_VT62 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21177095 CVCL_W561 CS52iALS-C9n1 induced pluripotent stem cell human CVCL_W561 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24154603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177096 CVCL_VT61 SPC-Mb-92 spontaneously immortalized cell line CVCL_VT61 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line; Group: Recombinant protein production insect cell line 21177097 CVCL_W546 eFOP2-8 induced pluripotent stem cell human CVCL_W546 CL:0000010 Population: African American; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21177098 CVCL_VT46 HEL70.3 induced pluripotent stem cell human CVCL_VT46 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27411166) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177099 CVCL_W545 eFOP2-3 induced pluripotent stem cell human CVCL_W545 CL:0000010 Population: African American; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21177100 CVCL_VT45 HEL69.5 induced pluripotent stem cell human CVCL_VT45 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27411166) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177101 CVCL_W544 eFOP1-10 induced pluripotent stem cell human CVCL_W544 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21177102 CVCL_VT44 HEL100.2 induced pluripotent stem cell human CVCL_VT44 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27411166) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177103 CVCL_W543 eFOP1-1 induced pluripotent stem cell human CVCL_W543 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21177104 CVCL_VT43 HEL100.1 induced pluripotent stem cell human CVCL_VT43 From: University of Helsinki; Helsinki; Finland CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>200]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27411166) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177105 CVCL_VT49 REGUi001-A induced pluripotent stem cell human CVCL_VT49 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177106 CVCL_W549 vFOP1-1 induced pluripotent stem cell human CVCL_W549 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21177107 CVCL_W548 eFOP3-4 induced pluripotent stem cell human CVCL_W548 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177108 CVCL_VT48 IRR-STO-SNL2 transformed cell line house mouse CVCL_VT48 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: SIM. Discontinued: ATCC; CRL-2225.1; true Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 10000 rads 21177109 CVCL_VT47 C17 [Human nasopharyngeal carcinoma] cancer cell line human CVCL_VT47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Skin. Male Characteristics: Established from a xenograft maintained in athymic nude mice Doubling time: ~4.5 days (PubMed=29769697) 21177110 CVCL_W547 eFOP3-2 induced pluripotent stem cell human CVCL_W547 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21177111 CVCL_3N23 HQ01338 transformed cell line human CVCL_3N23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177112 CVCL_3N22 HQ01337 transformed cell line human CVCL_3N22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177113 CVCL_3N21 HQ01336 transformed cell line human CVCL_3N21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177114 CVCL_3N20 HQ01335 transformed cell line human CVCL_3N20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177115 CVCL_3N16 HQ01331 transformed cell line human CVCL_3N16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177116 CVCL_3N15 HQ01330 transformed cell line human CVCL_3N15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177117 CVCL_3N14 HQ01329 transformed cell line human CVCL_3N14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177118 CVCL_3N13 HQ01328 transformed cell line human CVCL_3N13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177119 CVCL_3N19 HQ01334 transformed cell line human CVCL_3N19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177120 CVCL_3N18 HQ01333 transformed cell line human CVCL_3N18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177121 CVCL_3N17 HQ01332 transformed cell line human CVCL_3N17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177122 CVCL_VT53 KS-iPSC-4 induced pluripotent stem cell human CVCL_VT53 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177123 CVCL_W553 vFOP4-1 induced pluripotent stem cell human CVCL_W553 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Miscellaneous: Assignment of vFOP4-1 to CiRA00041 from personal communication from CiRA Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177124 CVCL_VT52 KS-iPSC-1 induced pluripotent stem cell human CVCL_VT52 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177125 CVCL_W552 vFOP2-2 induced pluripotent stem cell human CVCL_W552 CL:0000010 Population: African American; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21177126 CVCL_VT51 N-iPSC-1 induced pluripotent stem cell human CVCL_VT51 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177127 CVCL_W551 vFOP2-1 induced pluripotent stem cell human CVCL_W551 CL:0000010 Population: African American; Derived from sampling site: Shoulder; skin Cell type=Fibroblast.. Male 21177128 CVCL_VT50 REGUi002-A induced pluripotent stem cell human CVCL_VT50 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21177129 CVCL_W550 vFOP1-4 induced pluripotent stem cell human CVCL_W550 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21177130 CVCL_EB21 ND11487 transformed cell line human CVCL_EB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177131 CVCL_EB20 ND11466 transformed cell line human CVCL_EB20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177132 CVCL_EB19 ND11351 transformed cell line human CVCL_EB19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177133 CVCL_EB14 ND11256 transformed cell line human CVCL_EB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177134 CVCL_EB13 ND11098 transformed cell line human CVCL_EB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177135 CVCL_EB12 ND10944 transformed cell line human CVCL_EB12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177136 CVCL_EB11 ND10942 transformed cell line human CVCL_EB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177137 CVCL_EB18 ND11350 transformed cell line human CVCL_EB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177138 CVCL_EB17 ND11345 transformed cell line human CVCL_EB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177139 CVCL_EB16 ND11342 transformed cell line human CVCL_EB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177140 CVCL_EB15 ND11303 transformed cell line human CVCL_EB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177141 CVCL_EB32 ND12042 transformed cell line human CVCL_EB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177142 CVCL_EB31 ND12037 transformed cell line human CVCL_EB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177143 CVCL_EB30 ND12029 transformed cell line human CVCL_EB30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177144 CVCL_EB25 ND11701 transformed cell line human CVCL_EB25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177145 CVCL_EB24 ND11699 transformed cell line human CVCL_EB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177146 CVCL_EB23 ND11653 transformed cell line human CVCL_EB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177147 CVCL_EB22 ND11644 transformed cell line human CVCL_EB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177148 CVCL_EB29 ND11991 transformed cell line human CVCL_EB29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177149 CVCL_EB28 ND11828 transformed cell line human CVCL_EB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177150 CVCL_EB27 ND11806 transformed cell line human CVCL_EB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177151 CVCL_EB26 ND11702 transformed cell line human CVCL_EB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177152 CVCL_EB10 ND10754 transformed cell line human CVCL_EB10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177153 CVCL_EB09 ND10705 transformed cell line human CVCL_EB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177154 CVCL_EB08 ND10385 transformed cell line human CVCL_EB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177155 CVCL_EB03 ND10132 transformed cell line human CVCL_EB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177156 CVCL_EB02 ND10038 transformed cell line human CVCL_EB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177157 CVCL_EB01 ND10037 transformed cell line human CVCL_EB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177158 CVCL_EB00 ND09937 transformed cell line human CVCL_EB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177159 CVCL_EB07 ND10371 transformed cell line human CVCL_EB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177160 CVCL_EB06 ND10239 transformed cell line human CVCL_EB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177161 CVCL_EB05 ND10215 transformed cell line human CVCL_EB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177162 CVCL_EB04 ND10197 transformed cell line human CVCL_EB04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177163 CVCL_3N92 HQ01409 transformed cell line human CVCL_3N92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177164 CVCL_3N91 HQ01408 transformed cell line human CVCL_3N91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177165 CVCL_3N90 HQ01407 transformed cell line human CVCL_3N90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177166 CVCL_3N96 HQ01413 transformed cell line human CVCL_3N96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177167 CVCL_3N95 HQ01412 transformed cell line human CVCL_3N95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177168 CVCL_3N94 HQ01411 transformed cell line human CVCL_3N94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177169 CVCL_3N93 HQ01410 transformed cell line human CVCL_3N93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177170 CVCL_3N99 HQ01416 transformed cell line human CVCL_3N99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177171 CVCL_3N98 HQ01415 transformed cell line human CVCL_3N98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177172 CVCL_3N97 HQ01414 transformed cell line human CVCL_3N97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177173 CVCL_EC99 ND16536 transformed cell line human CVCL_EC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177174 CVCL_EC98 ND16535 transformed cell line human CVCL_EC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177175 CVCL_EC82 ND16235 transformed cell line human CVCL_EC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177176 CVCL_EC81 ND16189 transformed cell line human CVCL_EC81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177177 CVCL_EC80 ND16186 transformed cell line human CVCL_EC80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177178 CVCL_EC86 ND16244 transformed cell line human CVCL_EC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177179 CVCL_EC85 ND16241 transformed cell line human CVCL_EC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177180 CVCL_EC84 ND16238 transformed cell line human CVCL_EC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177181 CVCL_EC83 ND16237 transformed cell line human CVCL_EC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177182 CVCL_EC79 ND16109 transformed cell line human CVCL_EC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177183 CVCL_EC78 ND16081 transformed cell line human CVCL_EC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177184 CVCL_EC77 ND16078 transformed cell line human CVCL_EC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177185 CVCL_EC76 ND16077 transformed cell line human CVCL_EC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177186 CVCL_EC93 ND16351 transformed cell line human CVCL_EC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177187 CVCL_EC92 ND16350 transformed cell line human CVCL_EC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177188 CVCL_EC91 ND16336 transformed cell line human CVCL_EC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177189 CVCL_EC90 ND16329 transformed cell line human CVCL_EC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177190 CVCL_EC97 ND16504 transformed cell line human CVCL_EC97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177191 CVCL_EC96 ND16491 transformed cell line human CVCL_EC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177192 CVCL_EC95 ND16459 transformed cell line human CVCL_EC95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177193 CVCL_EC94 ND16403 transformed cell line human CVCL_EC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177194 CVCL_EC89 ND16311 transformed cell line human CVCL_EC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177195 CVCL_EC88 ND16309 transformed cell line human CVCL_EC88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177196 CVCL_EC87 ND16245 transformed cell line human CVCL_EC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177197 CVCL_EC60 ND15849 transformed cell line human CVCL_EC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177198 CVCL_EC64 ND15887 transformed cell line human CVCL_EC64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177199 CVCL_EC63 ND15864 transformed cell line human CVCL_EC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177200 CVCL_EC62 ND15851 transformed cell line human CVCL_EC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177201 CVCL_EC61 ND15850 transformed cell line human CVCL_EC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177202 CVCL_EC57 ND15786 transformed cell line human CVCL_EC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177203 CVCL_EC56 ND15785 transformed cell line human CVCL_EC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177204 CVCL_EC55 ND15757 transformed cell line human CVCL_EC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177205 CVCL_EC54 ND15756 transformed cell line human CVCL_EC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177206 CVCL_EC59 ND15810 transformed cell line human CVCL_EC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177207 CVCL_EC58 ND15787 transformed cell line human CVCL_EC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177208 CVCL_EC71 ND15999 transformed cell line human CVCL_EC71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177209 CVCL_EC70 ND15979 transformed cell line human CVCL_EC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177210 CVCL_EC75 ND16076 transformed cell line human CVCL_EC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177211 CVCL_EC74 ND16032 transformed cell line human CVCL_EC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177212 CVCL_EC73 ND16030 transformed cell line human CVCL_EC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177213 CVCL_EC72 ND16029 transformed cell line human CVCL_EC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177214 CVCL_EC68 ND15929 transformed cell line human CVCL_EC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177215 CVCL_EC67 ND15927 transformed cell line human CVCL_EC67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177216 CVCL_EC66 ND15926 transformed cell line human CVCL_EC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177217 CVCL_EC65 ND15888 transformed cell line human CVCL_EC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177218 CVCL_EC69 ND15978 transformed cell line human CVCL_EC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177219 CVCL_VV77 NB4-A1 cancer cell line human CVCL_VV77 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=12353268); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21177220 CVCL_W777 TRL-01 cancer cell line human CVCL_W777 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: 3-4 days (PubMed=16875930) 21177221 CVCL_VV76 FUN cancer cell line human CVCL_VV76 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=18253707) Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: ~30 hours (PubMed=18253707) 21177222 CVCL_W776 OVCA633 cancer cell line human CVCL_W776 CL:0000010 Omics: Transcriptome analysis by microarray. Female 21177223 CVCL_VV75 E-PR293 transformed cell line human CVCL_VV75 CL:0000010 Transfected with: UniProtKB; P12947; HIV-1 isolate NY5 pol (PR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Can be used to screen HIV-1 protease inhibitors Produces HIV-1 PR fused to GFP in the presence of doxycycline.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21177224 CVCL_W775 Muk-BL cancer cell line human CVCL_W775 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Male 21177225 CVCL_W774 Fen Cl 3.7 cancer cell line human CVCL_W774 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified 21177226 CVCL_VV74 MUG-Mel1 clone D5 cancer cell line human CVCL_VV74 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1745Glu (c.5233A>G); Zygosity=Heterozygous (PubMed=30858407) Derived from metastatic site: Brain. Omics: SNP array analysis Male Doubling time: 75.18 +- 20.11 hours (PubMed=30858407) 21177227 CVCL_VV79 NB4-D5 cancer cell line human CVCL_VV79 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=8839862); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Bone marrow. Female 21177228 CVCL_W779 QIMR-WW1-BL cancer cell line human CVCL_W779 HLA typing: A*11,24; B*27,62 (PubMed=3037521) CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21177229 CVCL_W778 ALST cancer cell line human CVCL_W778 CL:0000010 Female 21177230 CVCL_VV78 NB4-B1 cancer cell line human CVCL_VV78 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=12353268); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21177231 CVCL_4132 BRL-1 spontaneously immortalized cell line Norway rat CVCL_4132 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Buffalo. 21177232 CVCL_3P32 HQ01449 transformed cell line human CVCL_3P32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177233 CVCL_4131 BRF41 spontaneously immortalized cell line zebrafish CVCL_4131 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21177234 CVCL_3P31 HQ01448 transformed cell line human CVCL_3P31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177235 CVCL_4130 BPAEC spontaneously immortalized cell line CVCL_4130 CL:0000010 Derived from sampling site: Lung; artery; endothelium Cell type=Endothelial cell.. Female 21177236 CVCL_3P30 HQ01447 transformed cell line human CVCL_3P30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177237 CVCL_4125 BGM spontaneously immortalized cell line CVCL_4125 CL:0000010 Derived from sampling site: Kidney. Discontinued: BCRJ; 0049; probable Male Virology: Susceptible to infection by SARS coronavirus (SARS-CoV) (PubMed=16494729); Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Group: Non-human primate cell line Caution: Assignment to Chlorocebus pygerythrus instead of Chlorocebus aethiops by PubMed=34737324 21177238 CVCL_3P25 HQ01442 transformed cell line human CVCL_3P25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177239 CVCL_4124 BFA finite cell line CVCL_4124 CL:0000010 Derived from sampling site: Fetal aorta Cell type=Endothelial cell.. Discontinued: CLS; 600124; true Unspecified 21177240 CVCL_3P24 HQ01441 transformed cell line human CVCL_3P24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177241 CVCL_4123 BF-2 spontaneously immortalized cell line CVCL_4123 CL:0000010 Derived from sampling site: Caudal trunk. Unspecified Group: Fish cell line 21177242 CVCL_3P23 HQ01440 transformed cell line human CVCL_3P23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177243 CVCL_4122 BE11-Early transformed cell line Norway rat CVCL_4122 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21177244 CVCL_3P22 HQ01439 transformed cell line human CVCL_3P22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177245 CVCL_4129 BLO-11 spontaneously immortalized cell line house mouse CVCL_4129 CL:0000010 Sequence variation: Mutation; MGI; MGI:99400; Atp7a; Simple; c.2421+3A>C (IVS11+3A>C); Zygosity=Unspecified (from inference of Blotch mice mutation) Derived from sampling site: Abdomen; skeletal muscle Cell type=Fibroblast.; Breed/subspecies: B6.Cg-Atp7aMo-blo/J. Male 21177246 CVCL_3P29 HQ01446 transformed cell line human CVCL_3P29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177247 CVCL_4128 BICR/M1Rk cancer cell line Norway rat CVCL_4128 CL:0000010 Breed/subspecies: Marshall. Female 21177248 CVCL_3P28 HQ01445 transformed cell line human CVCL_3P28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177249 CVCL_4127 BHK/AC9 spontaneously immortalized cell line CVCL_4127 CL:0000010 Derived from sampling site: Kidney. Male Characteristics: Adapted to growth in suspension 21177250 CVCL_3P27 HQ01444 transformed cell line human CVCL_3P27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177251 CVCL_4126 BHK TK- spontaneously immortalized cell line CVCL_4126 CL:0000010 Derived from sampling site: Kidney. Male 21177252 CVCL_3P26 HQ01443 transformed cell line human CVCL_3P26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177253 CVCL_VV80 NB4-MR2 cancer cell line human CVCL_VV80 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=8839862; PubMed=9192750); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Leu398Pro (c.1193T>C); Zygosity=Unspecified; Note=Equivalent to p.Leu890Pro in the PML-RARA fusion protein responsible for retinoic acid resistance (PubMed=9192750); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21177254 CVCL_W780 QIMR-WW2-BL cancer cell line human CVCL_W780 CL:0000010 Population: Papuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 21177255 CVCL_VV84 ACOSC16 cancer cell line human CVCL_VV84 CL:0000010 Population: Indian; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Oral cavity; buccal mucosa. Male Characteristics: Tumorigenic in nude mice Doubling time: 34.0 hours (PubMed=30816493) 21177256 CVCL_W784 D8-SBMC spontaneously immortalized cell line Norway rat CVCL_W784 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Sprague Dawley. 21177257 CVCL_VV83 OCUM-14 cancer cell line human CVCL_VV83 CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Ascites. Male Doubling time: 43.1 hours (PubMed=30652228) 21177258 CVCL_W783 OVCA810 cancer cell line human CVCL_W783 CL:0000010 Derived from sampling site: Ovary. Female 21177259 CVCL_VV82 NB4-R4 cancer cell line human CVCL_VV82 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=8839862; PubMed=9192750; PubMed=12353268); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Leu398Pro (c.1193T>C); Zygosity=Unspecified; Note=Equivalent to p.Leu890Pro in the PML-RARA fusion protein (PubMed=9192750); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21177260 CVCL_W782 OVCA702 cancer cell line human CVCL_W782 CL:0000010 Derived from sampling site: Ovary. Female 21177261 CVCL_VV81 NB4-MR6 cancer cell line human CVCL_VV81 CL:0000010 Sequence variation: Gene fusion; HGNC; 9113; PML + HGNC; 9864; RARA; Name(s)=PML-RARA (PubMed=9192750); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala18Asp (c.53C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Bone marrow. Female 21177262 CVCL_W781 OVCA680 cancer cell line human CVCL_W781 CL:0000010 Derived from sampling site: Ovary. Female 21177263 CVCL_VV66 GM27368 finite cell line human CVCL_VV66 CL:0000010 Sequence variation: Mutation; HGNC; 11544; TAF11; Simple; p.Ser155Phe (c.464C>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177264 CVCL_W766 NM88 cancer cell line human CVCL_W766 CL:0000010 21177265 CVCL_VV65 GM27367 finite cell line human CVCL_VV65 CL:0000010 Sequence variation: Mutation; HGNC; 11544; TAF11; Simple; p.Ser155Phe (c.464C>T); Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177266 CVCL_W765 NM47 cancer cell line human CVCL_W765 CL:0000010 21177267 CVCL_VV64 GM27337 transformed cell line human CVCL_VV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177268 CVCL_W764 NM39 cancer cell line human CVCL_W764 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23455323); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Unspecified (PubMed=23455323). 21177269 CVCL_VV63 GM27335 transformed cell line human CVCL_VV63 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Ser326Glufs*129 (c.974_975insA); Zygosity=Heterozygous (Coriell) Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177270 CVCL_W763 NM182 cancer cell line human CVCL_W763 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23455323). 21177271 CVCL_VV69 GM27371 finite cell line human CVCL_VV69 CL:0000010 Sequence variation: Mutation; HGNC; 11544; TAF11; Simple; p.Ser155Phe (c.464C>T); Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177272 CVCL_W769 SU-DHL-3 cancer cell line human CVCL_W769 CL:0000010 Population: Asian; Derived from sampling site: Peritoneal effusion. Male 21177273 CVCL_VV68 GM27370 finite cell line human CVCL_VV68 CL:0000010 Sequence variation: Mutation; HGNC; 11544; TAF11; Simple; p.Ser155Phe (c.464C>T); Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177274 CVCL_W768 PNT2-LSD transformed cell line human CVCL_W768 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 29.2 +- 1.44 hours (PubMed=21556542) 21177275 CVCL_VV67 GM27369 finite cell line human CVCL_VV67 CL:0000010 Sequence variation: Mutation; HGNC; 11544; TAF11; Simple; p.Ser155Phe (c.464C>T); Zygosity=Homozygous (Coriell) Population: Caucasian; Mennonite; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177276 CVCL_W767 PNT1B transformed cell line human CVCL_W767 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 27.88 +- 1.58 hours (PubMed=21556542) 21177277 CVCL_4143 CHH-1 spontaneously immortalized cell line CVCL_4143 CL:0000010 Derived from sampling site: Heart. Discontinued: ATCC; CRL-1680; probable Unspecified Group: Fish cell line 21177278 CVCL_3P43 HQ01460 transformed cell line human CVCL_3P43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177279 CVCL_4142 CCO spontaneously immortalized cell line CVCL_4142 CL:0000010 Discontinued: ATCC; CRL-2748; true; Discontinued: ATCC; CRL-2772; probable. Unspecified Characteristics: Grows at temperatures from 10 Celsius to 35 Celsius with the optimum at 30 Celsius (ECACC) Doubling time: 12 hours (ECACC=95060212) Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00618 Problematic cell line: Misidentified/contaminated Originally thought to originate from the ovary of a juvenile channel catfish (Ictalurus punctatus) but shown to be from brown bullhead (Ameiurus nebulosus) (PubMed=33068031). 21177280 CVCL_3P42 HQ01459 transformed cell line human CVCL_3P42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177281 CVCL_4141 CC-1 spontaneously immortalized cell line Norway rat CVCL_4141 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Wistar. Male 21177282 CVCL_3P41 HQ01458 transformed cell line human CVCL_3P41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177283 CVCL_4140 CAR spontaneously immortalized cell line CVCL_4140 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21177284 CVCL_3P40 HQ01457 transformed cell line human CVCL_3P40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177285 CVCL_3P36 HQ01453 transformed cell line human CVCL_3P36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177286 CVCL_4135 BW5147.3 cancer cell line house mouse CVCL_4135 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21177287 CVCL_3P35 HQ01452 transformed cell line human CVCL_3P35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177288 CVCL_4134 BT spontaneously immortalized cell line CVCL_4134 CL:0000010 Derived from sampling site: Nose; nasal cavity; nasal turbinate; Breed/subspecies: Holstein. Unspecified 21177289 CVCL_3P34 HQ01451 transformed cell line human CVCL_3P34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177290 CVCL_4133 BS1-B4 spontaneously immortalized cell line house mouse CVCL_4133 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21177291 CVCL_3P33 HQ01450 transformed cell line human CVCL_3P33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177292 CVCL_4139 C6-4-2 hybrid cell line Norway rat CVCL_4139 CL:0000010 Breed/subspecies: Wistar Furth. 21177293 CVCL_3P39 HQ01456 transformed cell line human CVCL_3P39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177294 CVCL_4138 C6-2-3 hybrid cell line Norway rat CVCL_4138 CL:0000010 Breed/subspecies: Wistar Furth. 21177295 CVCL_3P38 HQ01455 transformed cell line human CVCL_3P38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177296 CVCL_4137 BW5147.G.1.4.OUAR.1 cancer cell line house mouse CVCL_4137 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Doubling time: ~23 hours (lot 06212000) (JCRB) Group: Hybridoma fusion partner cell line 21177297 CVCL_3P37 HQ01454 transformed cell line human CVCL_3P37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177298 CVCL_W773 Fen cancer cell line human CVCL_W773 CL:0000010 Derived from sampling site: Urinary bladder. Unspecified 21177299 CVCL_VV73 MUG-Mel1 clone C8 cancer cell line human CVCL_VV73 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1745Glu (c.5233A>G); Zygosity=Heterozygous (PubMed=30858407) Derived from metastatic site: Brain. Omics: SNP array analysis Male Doubling time: 50.62 +- 8.63 hours (PubMed=30858407) 21177300 CVCL_W772 CAT(Wil) cancer cell line human CVCL_W772 CL:0000010 Derived from sampling site: Urinary bladder. Male 21177301 CVCL_VV72 MUG-Mel1 cancer cell line human CVCL_VV72 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1745Glu (c.5233A>G); Zygosity=Heterozygous (PubMed=30858407) Derived from metastatic site: Brain. Omics: SNP array analysis Male Doubling time: 32.16 +- 4.28 hours (PubMed=30858407) 21177302 CVCL_VV71 GM27327 induced pluripotent stem cell human CVCL_VV71 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Unspecified; Note=D4Z4 repeat contraction (to 6 repeats) (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177303 CVCL_W771 PA 16/23 finite cell line human CVCL_W771 CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Female 21177304 CVCL_VV70 GM27386 finite cell line human CVCL_VV70 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Glu139Lys (c.415G>A); ClinVar=VCV000021143; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177305 CVCL_W770 NF cancer cell line human CVCL_W770 CL:0000010 Female Doubling time: 46 hours (PubMed=2156601). 21177306 CVCL_VV55 GM27245 finite cell line human CVCL_VV55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21177307 CVCL_W755 NM008 cancer cell line human CVCL_W755 CL:0000010 21177308 CVCL_VV54 GM27244 finite cell line human CVCL_VV54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177309 CVCL_W754 WMM1215 cancer cell line human CVCL_W754 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23455323); Sequence variation: Mutation; HGNC; 8803; PDGFRA; Simple; p.Asp842Val (c.2525A>T); ClinVar=VCV000013543; Zygosity=Unspecified (PubMed=23455323). 21177310 CVCL_VV53 GM27242 transformed cell line human CVCL_VV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177311 CVCL_W753 WMM1175 cancer cell line human CVCL_W753 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15945100); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000013899; Zygosity=Unspecified (PubMed=23455323) Derived from metastatic site: Hypodermis. 21177312 CVCL_VV52 GM27240 transformed cell line human CVCL_VV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177313 CVCL_W752 QIMR-FIN cancer cell line human CVCL_W752 CL:0000010 Derived from sampling site: Peripheral blood. Female 21177314 CVCL_VV59 GM27256 transformed cell line human CVCL_VV59 CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177315 CVCL_W759 NM16 cancer cell line human CVCL_W759 CL:0000010 21177316 CVCL_VV58 GM27250 transformed cell line human CVCL_VV58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177317 CVCL_W758 NM123 cancer cell line human CVCL_W758 CL:0000010 21177318 CVCL_VV57 GM27249 transformed cell line human CVCL_VV57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177319 CVCL_W757 NM112 cancer cell line human CVCL_W757 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23455323). 21177320 CVCL_VV56 GM27251 transformed cell line human CVCL_VV56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177321 CVCL_W756 NM1007 cancer cell line human CVCL_W756 CL:0000010 21177322 CVCL_4110 AVG-16 conditionally immortalized cell line pig CVCL_4110 CL:0000010 Miscellaneous: Media supplement from personal communication of Horisberger M.A Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: Requires a media supplement called Ovagrow-S2A for continuous growth, but the company (Aivogen AG) producing this media does not exist anymore (Direct_author_submission) 21177323 CVCL_3P10 HQ01427 transformed cell line human CVCL_3P10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177324 CVCL_4103 AKR-2B spontaneously immortalized cell line house mouse CVCL_4103 CL:0000010 Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: AKR. Unspecified 21177325 CVCL_3P03 HQ01420 transformed cell line human CVCL_3P03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177326 CVCL_4102 AC2 factor-dependent cell line house mouse CVCL_4102 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Pre-B cell.. Unspecified Characteristics: IL3 dependent Doubling time: 23 hours (PubMed=6422470) 21177327 CVCL_3P02 HQ01419 transformed cell line human CVCL_3P02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177328 CVCL_4101 A6 spontaneously immortalized cell line African clawed frog CVCL_4101 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male Doubling time: ~36 hours, at 25 Celsius (PubMed=11249203) Group: Amphibian cell line 21177329 CVCL_3P01 HQ01418 transformed cell line human CVCL_3P01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177330 CVCL_4100 A2H spontaneously immortalized cell line CVCL_4100 CL:0000010 Derived from sampling site: Ovary. Female 21177331 CVCL_3P00 HQ01417 transformed cell line human CVCL_3P00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177332 CVCL_4107 ARLJ 301-3 spontaneously immortalized cell line Norway rat CVCL_4107 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/DuCrj. Male 21177333 CVCL_3P07 HQ01424 transformed cell line human CVCL_3P07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177334 CVCL_4106 ARL-6 cancer cell line Norway rat CVCL_4106 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21177335 CVCL_3P06 HQ01423 transformed cell line human CVCL_3P06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177336 CVCL_4105 Anr4 transformed cell line Norway rat CVCL_4105 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/DuCrj. Male 21177337 CVCL_3P05 HQ01422 transformed cell line human CVCL_3P05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177338 CVCL_4104 Ampli-GPE spontaneously immortalized cell line house mouse CVCL_4104 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21177339 CVCL_3P04 HQ01421 transformed cell line human CVCL_3P04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177340 CVCL_4109 AtT-20/D16v-F2 cancer cell line house mouse CVCL_4109 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 21177341 CVCL_3P09 HQ01426 transformed cell line human CVCL_3P09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177342 CVCL_4108 ASK spontaneously immortalized cell line CVCL_4108 CL:0000010 Derived from sampling site: Kidney. Omics: Transcriptome analysis by microarray Female Group: Fish cell line 21177343 CVCL_3P08 HQ01425 transformed cell line human CVCL_3P08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177344 CVCL_VV62 GM27291 induced pluripotent stem cell human CVCL_VV62 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Homozygous (PubMed=35700637) Population: Jewish; Ashkenazi; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 21177345 CVCL_W762 NM179 cancer cell line human CVCL_W762 CL:0000010 21177346 CVCL_VV61 GM27267 transformed cell line human CVCL_VV61 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Asn187Lys (c.561C>G); ClinVar=VCV000265363; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177347 CVCL_W761 NM177 cancer cell line human CVCL_W761 CL:0000010 21177348 CVCL_VV60 GM27257 transformed cell line human CVCL_VV60 CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177349 CVCL_W760 NM176 cancer cell line human CVCL_W760 CL:0000010 21177350 CVCL_VV44 AKIL-1.E8 cancer cell line house mouse CVCL_VV44 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177351 CVCL_W744 JD40 cancer cell line human CVCL_W744 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9643977). 21177352 CVCL_VV43 AKIL-1 cancer cell line house mouse CVCL_VV43 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177353 CVCL_W743 JD39 cancer cell line human CVCL_W743 CL:0000010 Derived from sampling site: Ascites. 21177354 CVCL_VV42 A9.2 factor-dependent cell line house mouse CVCL_VV42 CL:0000010 Derived from sampling site: Cell type=Helper T-cell; Breed/subspecies: SJL. Characteristics: IL2 dependent 21177355 CVCL_W742 EW36 cancer cell line human CVCL_W742 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified Virology: EBV-negative Doubling time: 24 hours (PubMed=8402660) 21177356 CVCL_W741 HH543-5 cancer cell line human CVCL_W741 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21177357 CVCL_VV41 UG26-3D4 transformed cell line house mouse CVCL_VV41 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177358 CVCL_VV48 AKIL-6 cancer cell line house mouse CVCL_VV48 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177359 CVCL_W748 JLPC119 cancer cell line human CVCL_W748 CL:0000010 Unspecified Virology: EBV-negative Doubling time: 22 hours (PubMed=8402660). 21177360 CVCL_VV47 AKIL-3.H5 cancer cell line house mouse CVCL_VV47 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177361 CVCL_W747 DS179 cancer cell line human CVCL_W747 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=8344493). 21177362 CVCL_VV46 AKIL-3 cancer cell line house mouse CVCL_VV46 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177363 CVCL_W746 DH679 cancer cell line human CVCL_W746 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 21177364 CVCL_W745 AK778 cancer cell line human CVCL_W745 CL:0000010 Population: African; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. 21177365 CVCL_VV45 AKIL-20 cancer cell line house mouse CVCL_VV45 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177366 CVCL_VV49 AKIL-6.A3 cancer cell line house mouse CVCL_VV49 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177367 CVCL_W749 QIMR-DAR transformed cell line human CVCL_W749 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177368 CVCL_4121 BE10-7 transformed cell line Norway rat CVCL_4121 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Unspecified 21177369 CVCL_3P21 HQ01438 transformed cell line human CVCL_3P21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177370 CVCL_4120 BCL1 clone CW13.20-3B3 cancer cell line house mouse CVCL_4120 CL:0000010 Breed/subspecies: BALB/c. Female 21177371 CVCL_3P20 HQ01437 transformed cell line human CVCL_3P20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177372 CVCL_4114 B82 spontaneously immortalized cell line house mouse CVCL_4114 CL:0000010 Miscellaneous: ECACC has two catalogue entries for B82 which differ in that they were deposited by different groups: B82 (ECACC 85011408) and B82 (Hamprecht) (ECACC 08062522) Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21177373 CVCL_3P14 HQ01431 transformed cell line human CVCL_3P14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177374 CVCL_4113 B65 cancer cell line Norway rat CVCL_4113 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21177375 CVCL_3P13 HQ01430 transformed cell line human CVCL_3P13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177376 CVCL_4112 B50 cancer cell line Norway rat CVCL_4112 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21177377 CVCL_3P12 HQ01429 transformed cell line human CVCL_3P12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177378 CVCL_4111 B12 cancer cell line Norway rat CVCL_4111 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21177379 CVCL_3P11 HQ01428 transformed cell line human CVCL_3P11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177380 CVCL_4118 BB [Ameiurus] spontaneously immortalized cell line CVCL_4118 CL:0000010 Derived from sampling site: Caudal trunk. Unspecified Characteristics: Grows at 4 to 34 Celsius with an optimum of between 25 and 30 Celsius (ATCC) Group: Fish cell line 21177381 CVCL_3P18 HQ01435 transformed cell line human CVCL_3P18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177382 CVCL_4117 BAOEC finite cell line CVCL_4117 CL:0000010 Derived from sampling site: Aorta; endothelium. 21177383 CVCL_3P17 HQ01434 transformed cell line human CVCL_3P17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177384 CVCL_4116 B95a transformed cell line CVCL_4116 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21177385 CVCL_3P16 HQ01433 transformed cell line human CVCL_3P16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177386 CVCL_4115 B92 cancer cell line Norway rat CVCL_4115 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Unspecified 21177387 CVCL_3P15 HQ01432 transformed cell line human CVCL_3P15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177388 CVCL_4119 BCL1 clone 5B1b cancer cell line house mouse CVCL_4119 CL:0000010 Breed/subspecies: BALB/c. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21177389 CVCL_3P19 HQ01436 transformed cell line human CVCL_3P19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177390 CVCL_VV51 GM27227 transformed cell line human CVCL_VV51 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Trp308Ter (c.924G>A); ClinVar=VCV000013871; Zygosity=Unspecified; Note=De novo mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177391 CVCL_W751 QIMR-STE transformed cell line human CVCL_W751 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177392 CVCL_VV50 AKIL-6.D12 cancer cell line house mouse CVCL_VV50 CL:0000010 Breed/subspecies: AKR. Characteristics: IL2 dependent 21177393 CVCL_W750 QIMR-GOE transformed cell line human CVCL_W750 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177394 CVCL_VV33 AM30-3F5 transformed cell line house mouse CVCL_VV33 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177395 CVCL_W733 GFP-CD16-F/F.NK-92 cancer cell line human CVCL_W733 CL:0000010 Transfected with: HGNC; 3619; FCGR3A; Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8837 21177396 CVCL_VV32 AM30-3F4 transformed cell line house mouse CVCL_VV32 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177397 CVCL_W732 RETEC transformed cell line Norway rat CVCL_W732 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Ear; Eustachian tube; Breed/subspecies: Wistar Kyoto. Male Doubling time: 36.92 hours (PubMed=12389862) 21177398 CVCL_VV31 AM20-1B4 transformed cell line house mouse CVCL_VV31 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177399 CVCL_W731 OHK [Human ovarian tumor] cancer cell line human CVCL_W731 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Unspecified (CelloPub=CLPUB00136). Population: Korean Female Doubling time: 38.4 hours (CelloPub=CLPUB00136) 21177400 CVCL_VV30 AM14-1C4 stromal cell line house mouse CVCL_VV30 CL:0000010 Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: Ly-6E.1/LacZ (BL1b) transgenic. Unspecified 21177401 CVCL_W730 OHK [Human primary effusion lymphoma] cancer cell line human CVCL_W730 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Doubling time: ~72 hours (PubMed=11841405) 21177402 CVCL_W737 TihoDProAdcarc1258 cancer cell line dog CVCL_W737 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Briard. Omics: Transcriptome analysis by RNAseq Male Doubling time: 21.6 hours (PubMed=32168360); 29.2 hours (PubMed=32368185) 21177403 CVCL_VV37 UG15-1B7 stromal cell line house mouse CVCL_VV37 CL:0000010 Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: Ly-6E.1/LacZ (BL1b) transgenic. Unspecified 21177404 CVCL_W736 GM02689 transformed cell line human CVCL_W736 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177405 CVCL_VV36 UG07-1C6 stromal cell line house mouse CVCL_VV36 CL:0000010 Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: Ly-6E.1/LacZ (BL1b) transgenic. Unspecified 21177406 CVCL_VV35 GI29-2B4 transformed cell line house mouse CVCL_VV35 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177407 CVCL_W735 GM17593 transformed cell line human CVCL_W735 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177408 CVCL_VV34 EL08-1D2 stromal cell line house mouse CVCL_VV34 CL:0000010 Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: Ly-6E.1/LacZ (BL1b) transgenic. Unspecified 21177409 CVCL_W734 GFP-CD16-V/V.NK-92 cancer cell line human CVCL_W734 CL:0000010 Transfected with: HGNC; 3619; FCGR3A (with p.Phe176Val); Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8836 21177410 CVCL_W739 EB5 [Human Burkitt lymphoma] cancer cell line human CVCL_W739 CL:0000010 Population: African; Ugandan; Derived from sampling site: Mesentery. Male Doubling time: 36 hours (PubMed=5922251) 21177411 CVCL_VV39 UG26-1B6 transformed cell line house mouse CVCL_VV39 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified 21177412 CVCL_W738 EB4 cancer cell line human CVCL_W738 CL:0000010 Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Doubling time: 24 hours (PubMed=5922251) 21177413 CVCL_VV38 UG26-1B4 transformed cell line house mouse CVCL_VV38 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177414 CVCL_W740 HH514-16 cancer cell line human CVCL_W740 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 21177415 CVCL_VV40 UG26-2D3 transformed cell line house mouse CVCL_VV40 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: (CBA/Ca x C57BL/10) beta-actin-tsA58 transgenic. Unspecified 21177416 CVCL_W722 GM00335 finite cell line human CVCL_W722 CL:0000010 Sequence variation: Mutation; HGNC; 4118; GALK1; Simple; p.Val32Met (c.94G>A); ClinVar=VCV000005628; Zygosity=Heterozygous (PubMed=7670469) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21177417 CVCL_VV22 HEK-Blue mMincle transformed cell line human CVCL_VV22 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1861232; Clec4e; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21177418 CVCL_VV21 HEK-Blue mDectin-1b transformed cell line human CVCL_VV21 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1861431; Clec7a (isoform b); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21177419 CVCL_W721 KH88 C2F8 cancer cell line human CVCL_W721 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 20-26 hours (PubMed=8289484) 21177420 CVCL_VV20 HEK-Blue hDectin-1b transformed cell line human CVCL_VV20 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 14558; CLEC7A (isoform B); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21177421 CVCL_W720 HUES 75 embryonic stem cell human CVCL_W720 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0280 21177422 CVCL_W726 GM07370 transformed cell line human CVCL_W726 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu12Profs*103 (c.34dupC) (T35insC); ClinVar=VCV000002154; Zygosity=Homozygous (from autologous cell line GM07371) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177423 CVCL_VV26 ICC1 cancer cell line human CVCL_VV26 CL:0000010 Miscellaneous: Doubling time and age/sex of donor from personal communication of El-Bardeesy N. Female Doubling time: 5 days (Direct_author_submission) 21177424 CVCL_VV25 BT169 cancer cell line human CVCL_VV25 CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 21177425 CVCL_W725 GM00228 finite cell line human CVCL_W725 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21177426 CVCL_VV24 RC-123T/E transformed cell line human CVCL_VV24 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (CelloPub=CLPUB00483); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760). Male 21177427 CVCL_W724 XP17SE finite cell line human CVCL_W724 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177428 CVCL_W723 GM00336 finite cell line human CVCL_W723 CL:0000010 Sequence variation: Mutation; HGNC; 4118; GALK1; Simple; p.Val32Met (c.94G>A); ClinVar=VCV000005628; Zygosity=Heterozygous (PubMed=7670469) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21177429 CVCL_VV23 HEK-Blue mDectin-2 transformed cell line human CVCL_VV23 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: MGI; MGI:1861231; Clec4n; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21177430 CVCL_W729 ELGH spontaneously immortalized cell line CVCL_W729 CL:0000010 Derived from sampling site: Heart. Unspecified Group: Fish cell line 21177431 CVCL_VV29 LS1034-PBL transformed cell line human CVCL_VV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177432 CVCL_W728 GM08764 transformed cell line human CVCL_W728 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177433 CVCL_VV28 ICC5 cancer cell line human CVCL_VV28 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Val (c.394_395CG>GT); Zygosity=Unspecified (PubMed=27231123; DepMap) Miscellaneous: Doubling time and age/sex of donor from personal communication of El-Bardeesy N. Male Doubling time: 5 days (Direct_author_submission) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177434 CVCL_W727 GM07371 finite cell line human CVCL_W727 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Leu12Profs*103 (c.34dupC) (T35insC); ClinVar=VCV000002154; Zygosity=Homozygous (PubMed=12851857) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21177435 CVCL_VV27 ICC2 cancer cell line human CVCL_VV27 CL:0000010 Miscellaneous: Doubling time and age/sex of donor from personal communication of El-Bardeesy N. Omics: Deep exome analysis Female Doubling time: 3 days (Direct_author_submission) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177436 CVCL_W711 ALZ.44 finite cell line human CVCL_W711 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177437 CVCL_VV11 LB265-MEL cancer cell line human CVCL_VV11 HLA typing: A*02,03; B*07,62; C*w07,w09 (PubMed=8752841) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Cervical lymph node. Female 21177438 CVCL_W710 ALZ.43 finite cell line human CVCL_W710 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177439 CVCL_VV10 LB2586-MEL cancer cell line human CVCL_VV10 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21177440 CVCL_VV15 MSR3-B37 cancer cell line human CVCL_VV15 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*37:01) Derived from metastatic site: Cutaneous. 21177441 CVCL_W715 PK15cl28/BS spontaneously immortalized cell line pig CVCL_W715 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21177442 CVCL_W714 BS/HG finite cell line human CVCL_W714 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Unspecified 21177443 CVCL_VV14 MSR3-A1 cancer cell line human CVCL_VV14 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*01:01) Derived from metastatic site: Cutaneous. 21177444 CVCL_VV13 LB583-MEL.6 cancer cell line human CVCL_VV13 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177445 CVCL_W713 VEGF-D 293 clone 11 transformed cell line human CVCL_W713 CL:0000010 Transfected with: HGNC; 3708; VEGFD; Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21177446 CVCL_VV12 LB43-MEL cancer cell line human CVCL_VV12 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177447 CVCL_W712 RK13.6 spontaneously immortalized cell line CVCL_W712 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21177448 CVCL_VV19 HEK-Blue hDectin-1a transformed cell line human CVCL_VV19 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 14558; CLEC7A (isoform A); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB and AP-1-binding sites 21177449 CVCL_W719 HUES 73 embryonic stem cell human CVCL_W719 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0283 21177450 CVCL_W718 HUES 72 embryonic stem cell human CVCL_W718 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0282 21177451 CVCL_VV18 MSR3-mel cancer cell line human CVCL_VV18 HLA typing: A*01:01,11:01; B*37:01,52:01:01:01; C*06:02,12:02 (PubMed=11668505) CL:0000010 Derived from metastatic site: Cutaneous. 21177452 CVCL_W717 HUES 71 embryonic stem cell human CVCL_W717 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified; Note=Somatic mutation acquired during proliferation (PubMed=28445466) Omics: Deep exome analysis; Omics: SNP array analysis. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0281 21177453 CVCL_VV17 MSR3-EBV transformed cell line human CVCL_VV17 HLA typing: A*01:01,11:01; B*37:01,52:01:01:01; C*06:02,12:02 (PubMed=11668505) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21177454 CVCL_W716 BME-UV1 transformed cell line CVCL_W716 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Holstein. Female Characteristics: Shows enhanced proliferation in the presence of epidermal growth factor (EGF) and insulin-like growth factor 1 (IGF1) (PubMed=8925136) Doubling time: 22.8 hours, in presence of serum and supplements (PubMed=8925136) 21177455 CVCL_VV16 MSR3-B52 cancer cell line human CVCL_VV16 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*52:01:01:01) Derived from metastatic site: Cutaneous. 21177456 CVCL_W700 ALZ.31 finite cell line human CVCL_W700 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177457 CVCL_VV00 LB11-SCLC/OC1 cancer cell line human CVCL_VV00 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177458 CVCL_W704 ALZ.35 finite cell line human CVCL_W704 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177459 CVCL_VV04 LB1751-EBV transformed cell line human CVCL_VV04 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177460 CVCL_W703 ALZ.34 finite cell line human CVCL_W703 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177461 CVCL_VV03 LB1448-MEL.2 cancer cell line human CVCL_VV03 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177462 CVCL_W702 ALZ.33 finite cell line human CVCL_W702 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177463 CVCL_VV02 LB13-SCLC/OC3 cancer cell line human CVCL_VV02 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177464 CVCL_W701 ALZ.32 finite cell line human CVCL_W701 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177465 CVCL_VV01 LB12-SCLC/OC2 cancer cell line human CVCL_VV01 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177466 CVCL_W708 ALZ.41 finite cell line human CVCL_W708 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177467 CVCL_VV08 LB2117-MEL cancer cell line human CVCL_VV08 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21177468 CVCL_W707 ALZ.40 finite cell line human CVCL_W707 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177469 CVCL_VV07 LB1828-RCC cancer cell line human CVCL_VV07 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177470 CVCL_W706 ALZ.39 finite cell line human CVCL_W706 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177471 CVCL_VV06 LB1781-MEL cancer cell line human CVCL_VV06 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21177472 CVCL_W705 ALZ.38 finite cell line human CVCL_W705 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177473 CVCL_VV05 LB1751-MEL cancer cell line human CVCL_VV05 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21177474 CVCL_W709 ALZ.42 finite cell line human CVCL_W709 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177475 CVCL_VV09 LB2259-MEL cancer cell line human CVCL_VV09 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21177476 CVCL_4091 54SCC2 hybrid cell line CVCL_4091 CL:0000010 21177477 CVCL_4090 45.6.TG1.7 cancer cell line house mouse CVCL_4090 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21177478 CVCL_4095 745C2 cancer cell line house mouse CVCL_4095 CL:0000010 Breed/subspecies: DBA/2. 21177479 CVCL_4094 707B1011C3 cancer cell line house mouse CVCL_4094 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21177480 CVCL_4093 54SCC7 hybrid cell line CVCL_4093 CL:0000010 21177481 CVCL_4092 54SCC3 hybrid cell line CVCL_4092 CL:0000010 21177482 CVCL_4099 A2 [Hamster] spontaneously immortalized cell line CVCL_4099 CL:0000010 Derived from sampling site: Ovary. Female 21177483 CVCL_4098 A15 [Rat glioma] cancer cell line Norway rat CVCL_4098 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Female 21177484 CVCL_4097 A10-85 spontaneously immortalized cell line Norway rat CVCL_4097 CL:0000010 Derived from sampling site: Thoracic aorta; smooth muscle Cell type=Myoblast.; Breed/subspecies: BDIX. Unspecified 21177485 CVCL_4096 92BR finite cell line CVCL_4096 CL:0000010 Derived from sampling site: Testis. Male 21177486 CVCL_4089 4/4 R.M.-4 spontaneously immortalized cell line Norway rat CVCL_4089 CL:0000010 Derived from sampling site: Lung; visceral pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Female 21177487 CVCL_4073 NCC-RbC-60 cancer cell line human CVCL_4073 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0501; true Male Doubling time: 47 hours (PubMed=8263010) 21177488 CVCL_4072 NCC-RbC-59 cancer cell line human CVCL_4072 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0500; true. Female 21177489 CVCL_4077 108CC5-BU hybrid cell line CVCL_4077 CL:0000010 21177490 CVCL_4076 108CC5 hybrid cell line CVCL_4076 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177491 CVCL_4075 4647 spontaneously immortalized cell line CVCL_4075 CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Susceptible to infection by poliovirus type 1, type 2 and type 3 (PubMed=28046048) Group: Non-human primate cell line; Group: Vaccine production cell line 21177492 CVCL_4074 NCC-RbC-83 cancer cell line human CVCL_4074 CL:0000010 Population: Japanese; Derived from sampling site: Eye socket. Discontinued: JCRB; NIHS0503; true Male 21177493 CVCL_4069 EoL-3 cancer cell line human CVCL_4069 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB2142; true Male 21177494 CVCL_4068 OV202 hp cancer cell line human CVCL_4068 CL:0000010 Female 21177495 CVCL_4067 OV202 cancer cell line human CVCL_4067 CL:0000010 Female 21177496 CVCL_4080 108CC5T-BU-1 hybrid cell line CVCL_4080 CL:0000010 21177497 CVCL_4084 108CC5-TG-3 hybrid cell line CVCL_4084 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177498 CVCL_4083 108CC5-TG-2 hybrid cell line CVCL_4083 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177499 CVCL_4082 108CC5-TG-1 hybrid cell line CVCL_4082 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177500 CVCL_4081 108CC5T-BU-4 hybrid cell line CVCL_4081 CL:0000010 21177501 CVCL_4088 31F4L undefined cell line type CVCL_4088 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line 21177502 CVCL_4087 26CB-1 transformed cell line CVCL_4087 CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Spleen. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Male Group: Non-human primate cell line 21177503 CVCL_4086 208F transformed cell line Norway rat CVCL_4086 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21177504 CVCL_4085 108CC5-TG-4 hybrid cell line CVCL_4085 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177505 CVCL_4079 108CC5-BU-8 hybrid cell line CVCL_4079 CL:0000010 21177506 CVCL_4078 108CC5-BU-5 hybrid cell line CVCL_4078 CL:0000010 21177507 CVCL_W699 ALZ.30 finite cell line human CVCL_W699 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177508 CVCL_VU99 KUL84-MEL cancer cell line human CVCL_VU99 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22850568). Unspecified 21177509 CVCL_W698 ALZ.29 finite cell line human CVCL_W698 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177510 CVCL_VU98 EB81-MEL.2 cancer cell line human CVCL_VU98 HLA typing: A*01:01,02:01; B*50,57; C*06 (PubMed=14999777) CL:0000010 Derived from metastatic site: Inguinal lymph node. Female 21177511 CVCL_W697 ALZ.28 finite cell line human CVCL_W697 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177512 CVCL_VU97 EB81-MEL cancer cell line human CVCL_VU97 CL:0000010 Derived from metastatic site: Inguinal lymph node. Omics: Transcriptome analysis by microarray Female 21177513 CVCL_4051 UACC-827 cancer cell line human CVCL_4051 CL:0000010 Derived from metastatic site: Breast. Female 21177514 CVCL_4050 UACC-732 cancer cell line human CVCL_4050 CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Female Part of: MD Anderson Cell Lines Project 21177515 CVCL_4055 SK-PC-3 cancer cell line human CVCL_4055 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Unspecified (PubMed=8026879) Derived from metastatic site: Omentum. Omics: Transcriptome analysis by microarray Female Doubling time: 59.5 hours (PubMed=7723277) 21177516 CVCL_4054 SK-PC-1 cancer cell line human CVCL_4054 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Leu (c.845G>T); ClinVar=VCV000182938; Zygosity=Unspecified (PubMed=11787853) Omics: Transcriptome analysis by microarray. Male Doubling time: 51.8 hours (PubMed=7723277) 21177517 CVCL_4053 UACC-930 cancer cell line human CVCL_4053 CL:0000010 Derived from metastatic site: Small intestine. Female 21177518 CVCL_4052 UACC-903 cancer cell line human CVCL_4052 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Asp (c.1799_1800delTGinsAT); ClinVar=VCV000375939; Zygosity=Unspecified (PubMed=15009714); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr76Ter (c.228T>G); ClinVar=VCV000546013; Zygosity=Unspecified (PubMed=9692547; PubMed=10766161; PubMed=15009714) Derived from metastatic site: Back. Omics: Transcriptome analysis by microarray Male 21177519 CVCL_4048 UACC-608 cancer cell line human CVCL_4048 CL:0000010 21177520 CVCL_4047 UACC-462 cancer cell line human CVCL_4047 CL:0000010 Derived from metastatic site: Peritoneum. Male 21177521 CVCL_4046 UACC-457 cancer cell line human CVCL_4046 CL:0000010 Derived from metastatic site: Abdomen. Male 21177522 CVCL_4045 UACC-456 cancer cell line human CVCL_4045 CL:0000010 21177523 CVCL_4049 UACC-647 cancer cell line human CVCL_4049 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21177524 CVCL_W689 ALZ.20 finite cell line human CVCL_W689 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177525 CVCL_VU89 HA1E transformed cell line human CVCL_VU89 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; epithelium. Omics: Deep exome analysis Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177526 CVCL_W688 ALZ.19 finite cell line human CVCL_W688 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177527 CVCL_VU88 L542 transformed cell line human CVCL_VU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177528 CVCL_W687 ALZ.18 finite cell line human CVCL_W687 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177529 CVCL_VU87 LB771-PBL transformed cell line human CVCL_VU87 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177530 CVCL_W686 ALZ.17 finite cell line human CVCL_W686 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177531 CVCL_VU86 BB30-PBL transformed cell line human CVCL_VU86 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177532 CVCL_4062 TOV-1946 cancer cell line human CVCL_4062 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=18507860; PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 1.3 +- 0.4 days (PubMed=18507860); 2.2 +- 0.26 days (PubMed=22931248) 21177533 CVCL_4061 IMIM-PC1 cancer cell line human CVCL_4061 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Unspecified (PubMed=8026879) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Male Doubling time: 50.4 hours (PubMed=7723277) 21177534 CVCL_4065 60905OM cancer cell line human CVCL_4065 CL:0000010 Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21177535 CVCL_4064 TOV-3133G cancer cell line human CVCL_4064 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Unspecified (PubMed=22931248; PubMed=28273451) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.70 +- 0.15 days (PubMed=22931248) 21177536 CVCL_4063 TOV-2223 cancer cell line human CVCL_4063 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (PubMed=18507860; PubMed=28273451) Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 2.6 +- 0.7 days (PubMed=18507860) 21177537 CVCL_4059 RGC-5 transformed cell line house mouse CVCL_4059 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Retinal cone cell.; Breed/subspecies: C57BL/6N transgenic. Male Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00472; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6600 Problematic cell line: Misidentified Originally thought to be of rat origin but found to be from mouse (PubMed=19443730; PubMed=24664692). Is probably identical to 661W (PubMed=23975727; PubMed=24021353). But the originator of the 661W cell is partially contesting this claim (PubMed=24472671). 21177538 CVCL_4058 T3M-12 cancer cell line human CVCL_4058 CL:0000010 Population: Japanese Discontinued: RCB; RCB1019; true. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00355 Problematic cell line: Partially contaminated Some stocks (such as RCB1019) were contaminated by T3M-1 (PubMed=20143388). 21177539 CVCL_4057 SW979 cancer cell line human CVCL_4057 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (PubMed=8026879); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=8026879). Male Problematic cell line: Possibly misidentified/contaminated Reported by PubMed=11787853 to contain the same HPV18 sequences as the cervix carcinoma cell line C-4-I (Cellosaurus=CVCL_2253) and to lack mutations in KRAS, TP53, CDKN2 and DPC4 often found in pancreatic adenocarcinoma. 21177540 CVCL_4056 T3M-4 cancer cell line human CVCL_4056 Genome ancestry: African=0.38%; Native American=0.38%; East Asian, North=79.41%; East Asian, South=19.66%; South Asian=0%; European, North=0%; European, South=0.16% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Heterozygous (PubMed=8426738; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=8426738; PubMed=11169959; PubMed=11787853; DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: KuDOS 95 cell line panel 21177541 CVCL_W692 ALZ.23 finite cell line human CVCL_W692 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177542 CVCL_VU92 BB90-MEL cancer cell line human CVCL_VU92 HLA typing: A*02:01,26:01; B*15:01,44:02; C*03:04,05:03 (IPD-IMGT/HLA=12039). From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Male 21177543 CVCL_W691 ALZ.22 finite cell line human CVCL_W691 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177544 CVCL_VU91 AVL3-MEL cancer cell line human CVCL_VU91 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Not specified. Unspecified 21177545 CVCL_W690 ALZ.21 finite cell line human CVCL_W690 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177546 CVCL_VU90 TV cancer cell line human CVCL_VU90 CL:0000010 Miscellaneous: Doubling time and HPV subtype from personal communication of Diaconu C. Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760) Male Doubling time: ~48 hours (Direct_author_submission) 21177547 CVCL_W696 ALZ.27 finite cell line human CVCL_W696 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177548 CVCL_VU96 EB81-EBV transformed cell line human CVCL_VU96 HLA typing: A*01:01,02:01; B*50,57; C*06 (PubMed=14999777) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177549 CVCL_W695 ALZ.26 finite cell line human CVCL_W695 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177550 CVCL_VU95 EB16-MEL cancer cell line human CVCL_VU95 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22850568). Unspecified 21177551 CVCL_W694 ALZ.25 finite cell line human CVCL_W694 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177552 CVCL_VU94 Dun cancer cell line human CVCL_VU94 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21177553 CVCL_W693 ALZ.24 finite cell line human CVCL_W693 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177554 CVCL_VU93 DDHK62-MEL cancer cell line human CVCL_VU93 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21177555 CVCL_W678 ALZ.9 finite cell line human CVCL_W678 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177556 CVCL_VU78 MED6 cancer cell line human CVCL_VU78 CL:0000010 Male 21177557 CVCL_W677 ALZ.7 finite cell line human CVCL_W677 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177558 CVCL_VU77 MED5R cancer cell line human CVCL_VU77 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Unspecified (PubMed=24887326). Male 21177559 CVCL_W676 ALZ.6 finite cell line human CVCL_W676 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177560 CVCL_VU76 MED4R cancer cell line human CVCL_VU76 CL:0000010 Female 21177561 CVCL_W675 ALZ.5 finite cell line human CVCL_W675 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177562 CVCL_VU75 MED4 cancer cell line human CVCL_VU75 CL:0000010 Female 21177563 CVCL_W679 ALZ.10 finite cell line human CVCL_W679 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177564 CVCL_VU79 MB002 cancer cell line human CVCL_VU79 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177565 CVCL_4033 N1E-115-1 cancer cell line house mouse CVCL_4033 CL:0000010 Breed/subspecies: A/J. Male Doubling time: ~100 hours (DSMZ=ACC-856); ~20 hours (ECACC=08062511) 21177566 CVCL_4032 P3X63Ag8.653 cancer cell line house mouse CVCL_4032 CL:0000010 Miscellaneous: PubMed=23430347 has a different value for STR 6-4 (17,18) than that of NIST (18,19) due to a change in the marker motif (personal communication of Almeida J.L.) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Discontinued: KCLB; 21580; probable Female Doubling time: ~30-60 hours (DSMZ=ACC-43) Group: Hybridoma fusion partner cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8008; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-251 21177567 CVCL_4031 RBA-2 spontaneously immortalized cell line Norway rat CVCL_4031 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: JAR-2. Unspecified Characteristics: Type-2 astrocyte A2B5, GFAP and glutamine synthetase positive (PubMed=10386986). 21177568 CVCL_4030 R-3327-AT-6.1 cancer cell line Norway rat CVCL_4030 CL:0000010 Breed/subspecies: Copenhagen. Male 21177569 CVCL_4026 SCC-12 cancer cell line human CVCL_4026 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (PubMed=11992403); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (PubMed=11992403). Male 21177570 CVCL_4025 SK-RC-99 cancer cell line human CVCL_4025 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21177571 CVCL_4024 SK-RC-7 cancer cell line human CVCL_4024 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21177572 CVCL_4023 SK-RC-6 cancer cell line human CVCL_4023 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male Doubling time: 60 hours (PubMed=2386958) 21177573 CVCL_4029 SCC-13 cancer cell line human CVCL_4029 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Lys (c.772G>A); ClinVar=VCV000012348; Zygosity=Unspecified (PubMed=8390283; PubMed=11992403) Derived from sampling site: Skin. Female 21177574 CVCL_4028 SCC-12F cancer cell line human CVCL_4028 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (from parent cell line). Male 21177575 CVCL_4027 SCC-12B cancer cell line human CVCL_4027 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Leu; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Gly (c.647T>G); ClinVar=VCV000376671; Zygosity=Unspecified (PubMed=8390283). Male 21177576 CVCL_W681 ALZ.12 finite cell line human CVCL_W681 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177577 CVCL_VU81 RhJT cancer cell line human CVCL_VU81 From: Houghton P.J.; King's College London; London; United Kingdom CL:0000010 Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177578 CVCL_W680 ALZ.11 finite cell line human CVCL_W680 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177579 CVCL_VU80 MB004 cancer cell line human CVCL_VU80 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified 21177580 CVCL_W685 ALZ.16 finite cell line human CVCL_W685 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177581 CVCL_VU85 Res308 cancer cell line human CVCL_VU85 From: Bobola B.; University of Washington; Seattle; USA. CL:0000010 21177582 CVCL_W684 ALZ.15 finite cell line human CVCL_W684 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177583 CVCL_VU84 Res300 cancer cell line human CVCL_VU84 From: Bobola B.; University of Washington; Seattle; USA. CL:0000010 21177584 CVCL_W683 ALZ.14 finite cell line human CVCL_W683 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177585 CVCL_VU83 Res262 cancer cell line human CVCL_VU83 From: Bobola B.; University of Washington; Seattle; USA CL:0000010 Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177586 CVCL_W682 ALZ.13 finite cell line human CVCL_W682 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177587 CVCL_VU82 LB647-PBL transformed cell line human CVCL_VU82 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177588 CVCL_W667 3T3-J2 spontaneously immortalized cell line house mouse CVCL_W667 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Doubling time: ~18 hours (Kerafast) 21177589 CVCL_VU67 CP66-EBV transformed cell line human CVCL_VU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177590 CVCL_W666 ACHN-IL2 cancer cell line human CVCL_W666 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Male 21177591 CVCL_VU66 TH-EM1 spontaneously immortalized cell line human CVCL_VU66 CL:0000010 Female Doubling time: 96 hours (PubMed=30819050). 21177592 CVCL_VU65 CHO E1a spontaneously immortalized cell line CVCL_VU65 CL:0000010 Transfected with: UniProtKB; P03255; Adenovirus 5 E1A protein Derived from sampling site: Ovary. Female 21177593 CVCL_W665 Frp/3 spontaneously immortalized cell line CVCL_W665 CL:0000010 Derived from sampling site: Fetal kidney. Female Group: Non-human primate cell line 21177594 CVCL_W664 CTSC-1 cancer cell line human CVCL_W664 CL:0000010 Population: Chinese; Derived from sampling site: Oral cavity; tongue. Doubling time: 37.52 +- 1.34 hours (at 10th passage), 30.85 +- 0.53 hours (at 30th passage) (Patent=CN103966169A) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012176 21177595 CVCL_VU64 Lec23 spontaneously immortalized cell line CVCL_VU64 CL:0000010 Sequence variation: Mutation; UniProtKB; G3I7V6; Mogs; Simple; p.Ser330Phe (c.989C>T); Zygosity=Unspecified; Note=Position based on a sequence which is probably not full length (PubMed=15383536) Selected for resistance to: UniProtKB; P02879; Ricinus communis ricin; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Ovary. Female 21177596 CVCL_W669 HKTN-2 telomerase immortalized cell line human CVCL_W669 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Keratinocyte. Unspecified 21177597 CVCL_VU69 SCCOHT-1 cancer cell line human CVCL_VU69 CL:0000010 Derived from sampling site: Ovary. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 38.1 hours (PubMed=22581215) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177598 CVCL_VU68 LB2241-EBV transformed cell line human CVCL_VU68 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177599 CVCL_W668 LNCaP clone FGC.10 cancer cell line human CVCL_W668 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10995 21177600 CVCL_4040 UACC-1598 cancer cell line human CVCL_4040 CL:0000010 Female 21177601 CVCL_4044 UACC-383 cancer cell line human CVCL_4044 CL:0000010 Derived from metastatic site: Inguinal lymph node. Male 21177602 CVCL_4043 UACC-325 cancer cell line human CVCL_4043 CL:0000010 21177603 CVCL_4042 UACC-3199 cancer cell line human CVCL_4042 CL:0000010 Derived from metastatic site: Axillary lymph node. Female 21177604 CVCL_4041 UACC-2087 cancer cell line human CVCL_4041 CL:0000010 Female 21177605 CVCL_4037 UACC-1227 cancer cell line human CVCL_4037 CL:0000010 Derived from metastatic site: Lymph node. Male 21177606 CVCL_4036 UACC-1179 cancer cell line human CVCL_4036 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21177607 CVCL_4035 UACC-1022 cancer cell line human CVCL_4035 CL:0000010 Derived from metastatic site: Chest wall. Female 21177608 CVCL_4034 FA6 cancer cell line human CVCL_4034 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=11787853); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11169959; PubMed=11787853); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser149fs (c.445del840); Zygosity=Unspecified (PubMed=11169959; PubMed=11787853) Derived from metastatic site: Supraclavicular lymph node. Female 21177609 CVCL_4039 UACC-1273EV cancer cell line human CVCL_4039 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Axillary lymph node. Male 21177610 CVCL_4038 UACC-1237 cancer cell line human CVCL_4038 CL:0000010 21177611 CVCL_VU70 HSJD-DIPG-007 cancer cell line human CVCL_VU70 CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Unspecified (PubMed=27325687); Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (PubMed=27325687; PubMed=34732238); Sequence variation: Mutation; HGNC; 9277; PPM1D; Simple; p.Pro428Glnfs*3 (c.1283delC); Zygosity=Unspecified (PubMed=32229503; PubMed=34732238) Derived from sampling site: Brainstem; pons. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177612 CVCL_W670 RC 37 undefined cell line type CVCL_W670 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Non-human primate cell line 21177613 CVCL_W674 ALZ.4 finite cell line human CVCL_W674 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177614 CVCL_VU74 MED3 cancer cell line human CVCL_VU74 CL:0000010 Female 21177615 CVCL_W673 ALZ.3 finite cell line human CVCL_W673 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177616 CVCL_VU73 MZ-1-EBV-B transformed cell line human CVCL_VU73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177617 CVCL_W672 ALZ.2 finite cell line human CVCL_W672 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177618 CVCL_VU72 MZ-7-EBV-B transformed cell line human CVCL_VU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21177619 CVCL_W671 ALZ.1 finite cell line human CVCL_W671 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21177620 CVCL_VU71 HSJD-DIPG-012 cancer cell line human CVCL_VU71 CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Lys28Met (c.83A>T) (H3.3K27M); ClinVar=VCV000376435; Zygosity=Unspecified (Patent=US20200384022; PubMed=32229503; PubMed=34732238); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=32229503; PubMed=34732238) Derived from sampling site: Brainstem; pons. Male 21177621 CVCL_EC42 ND15335 transformed cell line human CVCL_EC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177622 CVCL_EC41 ND15237 transformed cell line human CVCL_EC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177623 CVCL_EC40 ND15223 transformed cell line human CVCL_EC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177624 CVCL_EC35 ND15133 transformed cell line human CVCL_EC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177625 CVCL_EC34 ND15032 transformed cell line human CVCL_EC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177626 CVCL_EC33 ND15026 transformed cell line human CVCL_EC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177627 CVCL_EC32 ND15025 transformed cell line human CVCL_EC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177628 CVCL_EC39 ND15222 transformed cell line human CVCL_EC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177629 CVCL_EC38 ND15190 transformed cell line human CVCL_EC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177630 CVCL_EC37 ND15186 transformed cell line human CVCL_EC37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177631 CVCL_EC36 ND15185 transformed cell line human CVCL_EC36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177632 CVCL_EC53 ND15728 transformed cell line human CVCL_EC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177633 CVCL_EC52 ND15719 transformed cell line human CVCL_EC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177634 CVCL_EC51 ND15699 transformed cell line human CVCL_EC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177635 CVCL_EC50 ND15662 transformed cell line human CVCL_EC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177636 CVCL_EC46 ND15580 transformed cell line human CVCL_EC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177637 CVCL_EC45 ND15525 transformed cell line human CVCL_EC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177638 CVCL_EC44 ND15523 transformed cell line human CVCL_EC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177639 CVCL_EC43 ND15522 transformed cell line human CVCL_EC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177640 CVCL_EC49 ND15649 transformed cell line human CVCL_EC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177641 CVCL_EC48 ND15593 transformed cell line human CVCL_EC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177642 CVCL_EC47 ND15581 transformed cell line human CVCL_EC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177643 CVCL_EC20 ND14811 transformed cell line human CVCL_EC20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177644 CVCL_EC19 ND14810 transformed cell line human CVCL_EC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177645 CVCL_EC18 ND14808 transformed cell line human CVCL_EC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177646 CVCL_EC13 ND14632 transformed cell line human CVCL_EC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177647 CVCL_EC12 ND14566 transformed cell line human CVCL_EC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177648 CVCL_EC11 ND14539 transformed cell line human CVCL_EC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177649 CVCL_EC10 ND14464 transformed cell line human CVCL_EC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177650 CVCL_EC17 ND14746 transformed cell line human CVCL_EC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177651 CVCL_EC16 ND14687 transformed cell line human CVCL_EC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177652 CVCL_EC15 ND14648 transformed cell line human CVCL_EC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177653 CVCL_EC14 ND14633 transformed cell line human CVCL_EC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177654 CVCL_EC31 ND14930 transformed cell line human CVCL_EC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177655 CVCL_EC30 ND14896 transformed cell line human CVCL_EC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177656 CVCL_EC29 ND14894 transformed cell line human CVCL_EC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177657 CVCL_EC24 ND14846 transformed cell line human CVCL_EC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177658 CVCL_EC23 ND14825 transformed cell line human CVCL_EC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177659 CVCL_EC22 ND14814 transformed cell line human CVCL_EC22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177660 CVCL_EC21 ND14813 transformed cell line human CVCL_EC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177661 CVCL_EC28 ND14887 transformed cell line human CVCL_EC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177662 CVCL_EC27 ND14878 transformed cell line human CVCL_EC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177663 CVCL_EC26 ND14849 transformed cell line human CVCL_EC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177664 CVCL_EC25 ND14848 transformed cell line human CVCL_EC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177665 CVCL_EC09 ND14426 transformed cell line human CVCL_EC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177666 CVCL_EC08 ND14425 transformed cell line human CVCL_EC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177667 CVCL_EC07 ND14424 transformed cell line human CVCL_EC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177668 CVCL_EC02 ND14161 transformed cell line human CVCL_EC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177669 CVCL_EC01 ND14160 transformed cell line human CVCL_EC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177670 CVCL_EC00 ND14147 transformed cell line human CVCL_EC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177671 CVCL_EC06 ND14328 transformed cell line human CVCL_EC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177672 CVCL_EC05 ND14279 transformed cell line human CVCL_EC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177673 CVCL_EC04 ND14229 transformed cell line human CVCL_EC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177674 CVCL_EC03 ND14221 transformed cell line human CVCL_EC03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177675 CVCL_VW10 CaHo-24 finite cell line CVCL_VW10 CL:0000010 Anecdotal: From a horse named Rezvan Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177676 CVCL_W810 CS-S2 cancer cell line human CVCL_W810 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Established from the 12th passage in nude mice of the OvCa-1 xenograft 21177677 CVCL_VW14 CaHo-29 finite cell line CVCL_VW14 CL:0000010 Anecdotal: From a horse named Simin Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177678 CVCL_W814 Jurkat tet-on clone 2 cancer cell line human CVCL_W814 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21177679 CVCL_VW13 CaHo-28 finite cell line CVCL_VW13 CL:0000010 Anecdotal: From a horse named Loraz Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177680 CVCL_W813 Jurkat tet-on clone 1 cancer cell line human CVCL_W813 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 21177681 CVCL_VW12 CaHo-26 finite cell line CVCL_VW12 CL:0000010 Anecdotal: From a horse named Ghazale Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177682 CVCL_W812 MT-213-VGH cancer cell line human CVCL_W812 CL:0000010 Population: Chinese; Derived from sampling site: Uterus. Female Doubling time: 24.29 +- 1.81 hours, at 20th passage (PubMed=11575644) 21177683 CVCL_VW11 CaHo-25 finite cell line CVCL_VW11 CL:0000010 Anecdotal: From a horse named Lalin Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177684 CVCL_W811 CS-S3 cancer cell line human CVCL_W811 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Established from the 12th passage in nude mice of the OvCa-1 xenograft 21177685 CVCL_VW18 CaHo-33 finite cell line CVCL_VW18 CL:0000010 Anecdotal: From a horse named Gharan Saboor Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177686 CVCL_W818 EVLK2 transformed cell line human CVCL_W818 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Iliac vein; endothelium. Unspecified 21177687 CVCL_VW17 CaHo-32 finite cell line CVCL_VW17 CL:0000010 Anecdotal: From a horse named Hormoz Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177688 CVCL_W817 EVLK1 transformed cell line human CVCL_W817 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Iliac vein; endothelium. Unspecified 21177689 CVCL_VW16 CaHo-31 finite cell line CVCL_VW16 CL:0000010 Anecdotal: From a horse named Shervin Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177690 CVCL_W816 EVLB3 transformed cell line human CVCL_W816 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified 21177691 CVCL_VW15 CaHo-30 finite cell line CVCL_VW15 CL:0000010 Anecdotal: From a horse named Darya Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177692 CVCL_W815 REPC cancer cell line human CVCL_W815 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line) Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00487 Problematic cell line: Contaminated Shown to be a Hep 3B2.1-7 derivative. Original paper (PubMed=21406725) has been retracted.; Caution: 10.1182/blood-2014-04-571752 is a retractation of PubMed=21406725. 21177693 CVCL_VW19 CaHo-34 finite cell line CVCL_VW19 CL:0000010 Anecdotal: From a horse named Kiana Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177694 CVCL_W819 Lu-YePa cancer cell line human CVCL_W819 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 34.6 hours (PubMed=3652912) 21177695 CVCL_VW03 CaHo-17 finite cell line CVCL_VW03 CL:0000010 Anecdotal: From a horse named Amer Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177696 CVCL_W803 PC-53A cancer cell line human CVCL_W803 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Mutation; HGNC; 8619; PAX5; Simple; p.Arg38His (c.113G>A); Zygosity=Heterozygous (PubMed=34940123) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established at the final progression phase Doubling time: 70-80 hours (PubMed=2314113) 21177697 CVCL_VW02 CaHo-16 finite cell line CVCL_VW02 CL:0000010 Anecdotal: From a horse named Farhad Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177698 CVCL_W802 PC-53 cancer cell line human CVCL_W802 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 8017; NSMAF + HGNC; 29923; NUCKS1; Name(s)=NSMAF-NUCKS1; Note=NSMAF exon 1/NUCKS1 exon 2 fusion (PubMed=34940123); Sequence variation: Mutation; HGNC; 8619; PAX5; Simple; p.Arg38His (c.113G>A); Zygosity=Heterozygous (PubMed=34940123) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established at the 3rd relapse Doubling time: 70-80 hours (PubMed=2314113) 21177699 CVCL_VW01 CaHo-15 finite cell line CVCL_VW01 CL:0000010 Anecdotal: From a horse named Nima Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177700 CVCL_VW00 CaHo-14 finite cell line CVCL_VW00 CL:0000010 Anecdotal: From a horse named Vishgah Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177701 CVCL_VW07 CaHo-21 finite cell line CVCL_VW07 CL:0000010 Anecdotal: From a horse named Fariba Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177702 CVCL_W807 TSF19 finite cell line CVCL_W807 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Texel. Male Doubling time: 24.9 hours (PubMed=19448741) 21177703 CVCL_VW06 CaHo-20 finite cell line CVCL_VW06 CL:0000010 Anecdotal: From a horse named Limozin Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177704 CVCL_W806 FLC clone 745 A 19 cancer cell line house mouse CVCL_W806 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21177705 CVCL_VW05 CaHo-19 finite cell line CVCL_VW05 CL:0000010 Anecdotal: From a horse named Fozad Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177706 CVCL_W805 MEL-745A cl. DR10c3 cancer cell line house mouse CVCL_W805 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Characteristics: Resistant to the erythropoiesis-inducing effect of DMSO (PubMed=177980) 21177707 CVCL_VW04 CaHo-18 finite cell line CVCL_VW04 CL:0000010 Anecdotal: From a horse named Vakil Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177708 CVCL_W804 FLC 3Cl8 cancer cell line house mouse CVCL_W804 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21177709 CVCL_VW09 CaHo-23 finite cell line CVCL_VW09 CL:0000010 Anecdotal: From a horse named Forozan Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177710 CVCL_W809 CS-S1 cancer cell line human CVCL_W809 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Established from the 12th passage in nude mice of the OvCa-1 xenograft 21177711 CVCL_VW08 CaHo-22 finite cell line CVCL_VW08 CL:0000010 Anecdotal: From a horse named Nastaran Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177712 CVCL_W808 CS-C1 cancer cell line human CVCL_W808 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Established from the 12th passage in nude mice of the OvCa-1 xenograft 21177713 CVCL_ED99 ND21925 transformed cell line human CVCL_ED99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177714 CVCL_ED98 ND21922 transformed cell line human CVCL_ED98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177715 CVCL_ED97 ND21920 transformed cell line human CVCL_ED97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177716 CVCL_ED81 ND21023 transformed cell line human CVCL_ED81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177717 CVCL_ED80 ND20956 transformed cell line human CVCL_ED80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177718 CVCL_ED85 ND21177 transformed cell line human CVCL_ED85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177719 CVCL_ED84 ND21154 transformed cell line human CVCL_ED84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177720 CVCL_ED83 ND21113 transformed cell line human CVCL_ED83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177721 CVCL_ED82 ND21048 transformed cell line human CVCL_ED82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177722 CVCL_ED78 ND20862 transformed cell line human CVCL_ED78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177723 CVCL_ED77 ND20813 transformed cell line human CVCL_ED77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177724 CVCL_ED76 ND20812 transformed cell line human CVCL_ED76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177725 CVCL_ED75 ND20778 transformed cell line human CVCL_ED75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177726 CVCL_ED79 ND20894 transformed cell line human CVCL_ED79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177727 CVCL_ED92 ND21543 transformed cell line human CVCL_ED92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177728 CVCL_ED91 ND21457 transformed cell line human CVCL_ED91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177729 CVCL_ED90 ND21455 transformed cell line human CVCL_ED90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177730 CVCL_ED96 ND21917 transformed cell line human CVCL_ED96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177731 CVCL_ED95 ND21758 transformed cell line human CVCL_ED95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177732 CVCL_ED94 ND21629 transformed cell line human CVCL_ED94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177733 CVCL_ED93 ND21574 transformed cell line human CVCL_ED93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177734 CVCL_ED89 ND21371 transformed cell line human CVCL_ED89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177735 CVCL_ED88 ND21369 transformed cell line human CVCL_ED88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177736 CVCL_ED87 ND21288 transformed cell line human CVCL_ED87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177737 CVCL_ED86 ND21197 transformed cell line human CVCL_ED86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177738 CVCL_VW98 BoPr-9 finite cell line CVCL_VW98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177739 CVCL_W898 LUCC7 cancer cell line human CVCL_W898 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.-57A>C (c.161A>C) (A161C); ClinVar=VCV000242210; Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Kidney; renal pelvis. Unspecified 21177740 CVCL_VW97 BoPr-8 finite cell line CVCL_VW97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177741 CVCL_W897 LUCC6 cancer cell line human CVCL_W897 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Kidney; renal pelvis. Unspecified 21177742 CVCL_VW96 BoPr-7 finite cell line CVCL_VW96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177743 CVCL_W896 LUCC5 cancer cell line human CVCL_W896 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177744 CVCL_VW95 BoPr-6 finite cell line CVCL_VW95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177745 CVCL_W895 LUCC4 cancer cell line human CVCL_W895 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177746 CVCL_W899 LUCC8 cancer cell line human CVCL_W899 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177747 CVCL_VW99 SBcl3 cancer cell line human CVCL_VW99 CL:0000010 Male 21177748 CVCL_3Q53 HQ01571 transformed cell line human CVCL_3Q53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177749 CVCL_4253 N115-BU-8 cancer cell line house mouse CVCL_4253 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21177750 CVCL_3Q52 HQ01570 transformed cell line human CVCL_3Q52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177751 CVCL_4252 N115-BU-7 cancer cell line house mouse CVCL_4252 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21177752 CVCL_3Q51 HQ01569 transformed cell line human CVCL_3Q51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177753 CVCL_4251 N115-BU-2 cancer cell line house mouse CVCL_4251 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21177754 CVCL_3Q50 HQ01568 transformed cell line human CVCL_3Q50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177755 CVCL_4250 N115-BU-10 cancer cell line house mouse CVCL_4250 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21177756 CVCL_3Q46 HQ01564 transformed cell line human CVCL_3Q46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177757 CVCL_4246 mSXL 104 hybridoma house mouse CVCL_4246 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19339; Drosophila melanogaster Sxl. 21177758 CVCL_3Q45 HQ01563 transformed cell line human CVCL_3Q45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177759 CVCL_4245 MSVIF-TK+ transformed cell line house mouse CVCL_4245 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Grown in the presence of interferon 21177760 CVCL_3Q44 HQ01562 transformed cell line human CVCL_3Q44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177761 CVCL_4244 MSV.B transformed cell line house mouse CVCL_4244 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified Characteristics: Control cell line for MSVIF-TK+ 21177762 CVCL_3Q43 HQ01561 transformed cell line human CVCL_3Q43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177763 CVCL_4243 MS [Human HeLa contaminated cell line] cancer cell line human CVCL_4243 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00241 Problematic cell line: Misidentified/contaminated Originally thought to be of Chlorocebus aethiops origin but found to be a human HeLa derivative (PubMed=14505435; PubMed=20143388). 21177764 CVCL_3Q49 HQ01567 transformed cell line human CVCL_3Q49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177765 CVCL_4249 mSXL 5 hybridoma house mouse CVCL_4249 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19339; Drosophila melanogaster Sxl. 21177766 CVCL_3Q48 HQ01566 transformed cell line human CVCL_3Q48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177767 CVCL_4248 mSXL 18 hybridoma house mouse CVCL_4248 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19339; Drosophila melanogaster Sxl. 21177768 CVCL_3Q47 HQ01565 transformed cell line human CVCL_3Q47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177769 CVCL_4247 mSXL 114 hybridoma house mouse CVCL_4247 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19339; Drosophila melanogaster Sxl. 21177770 CVCL_VW87 BoPr-45 finite cell line CVCL_VW87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177771 CVCL_W887 WM1321 cancer cell line human CVCL_W887 CL:0000010 Omics: Transcriptome analysis by microarray. Unspecified Part of: Wistar Institute melanoma cell line collection 21177772 CVCL_VW86 BoPr-44 finite cell line CVCL_VW86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177773 CVCL_W886 WM1346 cancer cell line human CVCL_W886 CL:0000010 Omics: Transcriptome analysis by microarray Discontinued: Coriell; WC00121; probable. Female Part of: Wistar Institute melanoma cell line collection 21177774 CVCL_VW85 BoPr-43 finite cell line CVCL_VW85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177775 CVCL_W885 HM-2 [Hamster macrophage] cancer cell line CVCL_W885 CL:0000010 Derived from sampling site: Lymph node. Unspecified Doubling time: 90 hours (PubMed=657122) 21177776 CVCL_VW84 BoPr-42 finite cell line CVCL_VW84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177777 CVCL_W884 DB1 cancer cell line human CVCL_W884 CL:0000010 21177778 CVCL_VW89 BoPr-47 finite cell line CVCL_VW89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177779 CVCL_W889 CH34 cancer cell line human CVCL_W889 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Unspecified (PubMed=23958880) Male Caution: Cell line not maintained. 21177780 CVCL_VW88 BoPr-46 finite cell line CVCL_VW88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177781 CVCL_W888 DRHEp2 cancer cell line human CVCL_W888 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 21177782 CVCL_3Q60 HQ01578 transformed cell line human CVCL_3Q60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177783 CVCL_4260 ND8/34 hybrid cell line CVCL_4260 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Clone of ND8 which is derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21177784 CVCL_3Q64 HQ01582 transformed cell line human CVCL_3Q64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177785 CVCL_4264 OMK-637 finite cell line CVCL_4264 CL:0000010 Derived from sampling site: Kidney. Female Group: Non-human primate cell line 21177786 CVCL_3Q63 HQ01581 transformed cell line human CVCL_3Q63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177787 CVCL_4263 ND-U1 hybrid cell line CVCL_4263 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine Discontinued: ECACC; 92090916; probable. 21177788 CVCL_3Q62 HQ01580 transformed cell line human CVCL_3Q62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177789 CVCL_4262 ND-E hybrid cell line CVCL_4262 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine Discontinued: ECACC; 92090915; probable. 21177790 CVCL_3Q61 HQ01579 transformed cell line human CVCL_3Q61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177791 CVCL_4261 ND-C hybrid cell line CVCL_4261 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21177792 CVCL_3Q57 HQ01575 transformed cell line human CVCL_3Q57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177793 CVCL_4257 ND27 hybrid cell line CVCL_4257 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21177794 CVCL_3Q56 HQ01574 transformed cell line human CVCL_3Q56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177795 CVCL_4256 ND15 hybrid cell line CVCL_4256 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21177796 CVCL_3Q55 HQ01573 transformed cell line human CVCL_3Q55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177797 CVCL_4255 NCTC 2071 spontaneously immortalized cell line house mouse CVCL_4255 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Discontinued: ATCC; CCL-1.1; true; Discontinued: ATCC; CRL-6362; true Male Group: Serum/protein free medium cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21177798 CVCL_3Q54 HQ01572 transformed cell line human CVCL_3Q54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177799 CVCL_4254 N115-BU-9 cancer cell line house mouse CVCL_4254 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: A/J. Male 21177800 CVCL_3Q59 HQ01577 transformed cell line human CVCL_3Q59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177801 CVCL_4259 ND7/23 hybrid cell line CVCL_4259 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Clone of ND7 which is derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 21177802 CVCL_3Q58 HQ01576 transformed cell line human CVCL_3Q58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177803 CVCL_4258 ND3 hybrid cell line CVCL_4258 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21177804 CVCL_W890 BID007 cancer cell line human CVCL_W890 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ala763_Tyr764insPheGlnGluAla (c.2284-5_2290dup); ClinVar=VCV000045248; Zygosity=Unspecified (PubMed=24353160) Derived from metastatic site: Pleural effusion. Omics: CNV analysis Female 21177805 CVCL_VW90 BoPr-48 finite cell line CVCL_VW90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177806 CVCL_VW94 BoPr-51 finite cell line CVCL_VW94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177807 CVCL_W894 LUCC3 cancer cell line human CVCL_W894 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Glu507Gln (c.1519G>C); Zygosity=Unspecified (PubMed=24367658); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg557Pro (c.1670G>C); Zygosity=Unspecified (PubMed=24367658); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177808 CVCL_VW93 BoPr-50 finite cell line CVCL_VW93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177809 CVCL_W893 LUCC2 cancer cell line human CVCL_W893 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177810 CVCL_VW92 BoPr-5 finite cell line CVCL_VW92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177811 CVCL_W892 LUCC1 cancer cell line human CVCL_W892 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680) Derived from sampling site: Urinary bladder. Unspecified 21177812 CVCL_VW91 BoPr-49 finite cell line CVCL_VW91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177813 CVCL_W891 OANC1 cancer cell line human CVCL_W891 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (PubMed=24077944); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Homozygous (PubMed=24077944) Derived from sampling site: Esophagus. Male Doubling time: ~48 hours (PubMed=24077944) 21177814 CVCL_W876 A05 cancer cell line human CVCL_W876 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078). Unspecified 21177815 CVCL_VW76 BoPr-35 finite cell line CVCL_VW76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177816 CVCL_W875 A02-JLO cancer cell line human CVCL_W875 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21177817 CVCL_VW75 BoPr-34 finite cell line CVCL_VW75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177818 CVCL_VW74 BoPr-33 finite cell line CVCL_VW74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177819 CVCL_W874 JA cancer cell line human CVCL_W874 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis. 21177820 CVCL_VW73 BoPr-32 finite cell line CVCL_VW73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177821 CVCL_W873 MM629 cancer cell line human CVCL_W873 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078). Unspecified 21177822 CVCL_W879 A07-RM cancer cell line human CVCL_W879 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu2Lys (c.4G>A); Zygosity=Unspecified (PubMed=9354451; PubMed=17363583); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000177778; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583) Omics: CNV analysis; Omics: SNP array analysis. Unspecified 21177823 CVCL_VW79 BoPr-38 finite cell line CVCL_VW79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177824 CVCL_W878 A15 [Human melanoma] cancer cell line human CVCL_W878 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified Part of: MD Anderson Cell Lines Project 21177825 CVCL_VW78 BoPr-37 finite cell line CVCL_VW78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177826 CVCL_W877 A11 [Human melanoma] cancer cell line human CVCL_W877 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=22383533); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078) Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21177827 CVCL_VW77 BoPr-36 finite cell line CVCL_VW77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177828 CVCL_3Q31 HQ01549 transformed cell line human CVCL_3Q31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177829 CVCL_4231 KCB 89001 finite cell line CVCL_4231 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21177830 CVCL_4230 BBf finite cell line CVCL_4230 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ECACC; 93052110; probable Female 21177831 CVCL_3Q30 HQ01548 transformed cell line human CVCL_3Q30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177832 CVCL_4224 HBL-9 cancer cell line human CVCL_4224 CL:0000010 Population: Japanese. Unspecified 21177833 CVCL_3Q24 HQ01542 transformed cell line human CVCL_3Q24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177834 CVCL_4223 HBL-8 cancer cell line human CVCL_4223 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male Virology: EBV-negative Doubling time: ~58 hours (PubMed=8905871) 21177835 CVCL_3Q23 HQ01541 transformed cell line human CVCL_3Q23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177836 CVCL_4222 HBL-7 cancer cell line human CVCL_4222 CL:0000010 Population: Japanese; Derived from sampling site: Cervical lymph node. Male Virology: EBV-negative Doubling time: ~84 hours (PubMed=8905871) 21177837 CVCL_3Q22 HQ01540 transformed cell line human CVCL_3Q22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177838 CVCL_4221 HBL-6 cancer cell line human CVCL_4221 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Ascites. Male 21177839 CVCL_3Q21 HQ01539 transformed cell line human CVCL_3Q21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177840 CVCL_4228 HF1-5 hybrid cell line Norway rat CVCL_4228 CL:0000010 21177841 CVCL_3Q28 HQ01546 transformed cell line human CVCL_3Q28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177842 CVCL_4227 HF1 hybrid cell line Norway rat CVCL_4227 CL:0000010 21177843 CVCL_3Q27 HQ01545 transformed cell line human CVCL_3Q27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177844 CVCL_4226 Hepa-T1 spontaneously immortalized cell line CVCL_4226 CL:0000010 Derived from sampling site: Liver. Discontinued: ECACC; 99072813; probable; Discontinued: RCB; RCB1156; probable Unspecified Group: Fish cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00567 Problematic cell line: Misidentified Originally thought to be of tilapia origin (Oreochromis niloticus) but found to be from eel (DOI=10.1007/s12562-018-1215-4; RCB). Is probably identical to Hepa-E1. 21177845 CVCL_3Q26 HQ01544 transformed cell line human CVCL_3Q26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177846 CVCL_4225 Hepa-E1 spontaneously immortalized cell line CVCL_4225 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21177847 CVCL_3Q25 HQ01543 transformed cell line human CVCL_3Q25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177848 CVCL_3Q29 HQ01547 transformed cell line human CVCL_3Q29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177849 CVCL_4229 JH4 clone 1 spontaneously immortalized cell line CVCL_4229 CL:0000010 Derived from sampling site: Lung. Discontinued: ECACC; 93120825; probable Female Virology: Susceptible to infection and early propagation by guinea pig adenovirus (GPAdV) (PubMed=32226606) 21177850 CVCL_W883 ALL/MIK cancer cell line human CVCL_W883 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8167560; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 36-48 hours (PubMed=8167560) 21177851 CVCL_VW83 BoPr-41 finite cell line CVCL_VW83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177852 CVCL_VW82 BoPr-40 finite cell line CVCL_VW82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177853 CVCL_W882 BRG-M cancer cell line human CVCL_W882 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158His (c.473G>A); ClinVar=VCV000141963; Zygosity=Heterozygous (PubMed=9399658); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Gly (c.857_858AA>GT); Zygosity=Heterozygous (PubMed=9399658) Derived from sampling site: Peripheral blood. Female Characteristics: IgM producing subclone of BRG-P; Virology: EBV-negative 21177854 CVCL_VW81 BoPr-4 finite cell line CVCL_VW81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177855 CVCL_W881 BRG-A cancer cell line human CVCL_W881 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln354Glu (c.1060C>G); ClinVar=VCV001061283; Zygosity=Hemizygous (PubMed=9399658) Derived from sampling site: Peripheral blood. Female Characteristics: IgA1 producing subclone of BRG-P; Virology: EBV-negative 21177856 CVCL_VW80 BoPr-39 finite cell line CVCL_VW80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177857 CVCL_W880 BRG-P cancer cell line human CVCL_W880 CL:0000010 Derived from sampling site: Peripheral blood. Female Virology: EBV-negative 21177858 CVCL_VW65 BoPr-25 finite cell line CVCL_VW65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177859 CVCL_W865 TSUS-1 cancer cell line human CVCL_W865 CL:0000010 Population: Japanese; Derived from metastatic site: Pericardial effusion. Male Doubling time: 38 hours, at 40th passage (PubMed=6587762) 21177860 CVCL_VW64 BoPr-24 finite cell line CVCL_VW64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177861 CVCL_W864 PCA-23 cancer cell line human CVCL_W864 CL:0000010 Population: African; Ugandan; Derived from sampling site: Penis. Male 21177862 CVCL_VW63 BoPr-23 finite cell line CVCL_VW63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177863 CVCL_W863 MK-1 [Human gingival squamous cell carcinoma] cancer cell line human CVCL_W863 CL:0000010 Population: Japanese; Derived from sampling site: Cervical lymph node. Male Doubling time: 28 hours (PubMed=6802943) 21177864 CVCL_VW62 BoPr-22 finite cell line CVCL_VW62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177865 CVCL_W862 KS-Bu3 cancer cell line human CVCL_W862 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese Omics: Transcriptome analysis by microarray. Virology: EBV-negative 21177866 CVCL_VW69 BoPr-29 finite cell line CVCL_VW69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177867 CVCL_W869 D20 cancer cell line human CVCL_W869 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21177868 CVCL_VW68 BoPr-28 finite cell line CVCL_VW68 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177869 CVCL_W868 LP07 cancer cell line house mouse CVCL_W868 CL:0000010 Breed/subspecies: BALB/c. Female 21177870 CVCL_VW67 BoPr-27 finite cell line CVCL_VW67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177871 CVCL_W867 KU2-TP15 cancer cell line human CVCL_W867 CL:0000010 Transfected with: HGNC; 3148; TYMP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from metastatic site: Lung. Male 21177872 CVCL_VW66 BoPr-26 finite cell line CVCL_VW66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177873 CVCL_W866 PGV transformed cell line pig CVCL_W866 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female 21177874 CVCL_3Q42 HQ01560 transformed cell line human CVCL_3Q42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177875 CVCL_3Q41 HQ01559 transformed cell line human CVCL_3Q41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177876 CVCL_4241 MMT-060562 cancer cell line house mouse CVCL_4241 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6 x Af. Discontinued: ATCC; CRL-6337; true Female Characteristics: Tumorigenic in BALB/c mice (ATCC) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21177877 CVCL_3Q40 HQ01558 transformed cell line human CVCL_3Q40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177878 CVCL_4240 MEF-1 [Mouse fibroblast] transformed cell line house mouse CVCL_4240 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6 x 129. Unspecified 21177879 CVCL_3Q35 HQ01553 transformed cell line human CVCL_3Q35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177880 CVCL_4235 L-5178-Y-S cancer cell line house mouse CVCL_4235 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Discontinued: RCB; RCB2636; true; Discontinued: TKG; TKG 0576; true Female Characteristics: Compared to the parent cell line, this cell line is sensitive to X-rays 21177881 CVCL_3Q34 HQ01552 transformed cell line human CVCL_3Q34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177882 CVCL_4234 L-5178-Y-R cancer cell line house mouse CVCL_4234 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female Characteristics: Resistant to X-rays, but sensitive to ultraviolet radiation 21177883 CVCL_3Q33 HQ01551 transformed cell line human CVCL_3Q33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177884 CVCL_4233 KCB 90008 finite cell line CVCL_4233 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: ECACC; 94042031; probable Unspecified 21177885 CVCL_3Q32 HQ01550 transformed cell line human CVCL_3Q32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177886 CVCL_4232 RF-89l/t transformed cell line CVCL_4232 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21177887 CVCL_3Q39 HQ01557 transformed cell line human CVCL_3Q39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177888 CVCL_4239 LBRM-TG6 cancer cell line house mouse CVCL_4239 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Spleen Cell type=T-cell.; Breed/subspecies: B10.BR. Characteristics: Produces IL2 in response to IL1 and PHA Can be used to assay IL1 activity (ECACC). 21177889 CVCL_3Q38 HQ01556 transformed cell line human CVCL_3Q38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177890 CVCL_4238 L929S spontaneously immortalized cell line house mouse CVCL_4238 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21177891 CVCL_3Q37 HQ01555 transformed cell line human CVCL_3Q37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177892 CVCL_4237 L929/R spontaneously immortalized cell line house mouse CVCL_4237 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21177893 CVCL_3Q36 HQ01554 transformed cell line human CVCL_3Q36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177894 CVCL_4236 L8 spontaneously immortalized cell line Norway rat CVCL_4236 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-45 to study growth in microgravity (PubMed=7962182) Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Wistar. Unspecified Characteristics: Upon becoming confluent, will fuse to form cross striated multinucleated muscle fibers (ATCC) Doubling time: 19.1 +- 2.7 hours (in 10% serum), 25.1 +- 3.5 hours (in 1% serum) (PubMed=269441) Group: Space-flown cell line (cellonaut) 21177895 CVCL_VW72 BoPr-31 finite cell line CVCL_VW72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177896 CVCL_W872 D25 cancer cell line human CVCL_W872 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Unspecified 21177897 CVCL_VW71 BoPr-30 finite cell line CVCL_VW71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177898 CVCL_W871 D24 [Human melanoma] cancer cell line human CVCL_W871 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17363583); Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583; PubMed=22383533); Sequence variation: Mutation; HGNC; 7989; NRAS; None_reported; -; Zygosity=- (PubMed=15048078; PubMed=17363583; PubMed=22383533) Omics: CNV analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Unspecified 21177899 CVCL_VW70 BoPr-3 finite cell line CVCL_VW70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177900 CVCL_W870 D23 cancer cell line human CVCL_W870 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Val (c.1789C>G); ClinVar=VCV000013969; Zygosity=Unspecified (PubMed=15048078); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=22383533) Omics: Transcriptome analysis by RNAseq. Unspecified 21177901 CVCL_VW54 BoPr-15 finite cell line CVCL_VW54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177902 CVCL_W854 GCH-1m cancer cell line human CVCL_W854 CL:0000010 Population: Japanese Female Characteristics: Compared to the parent cell line, will more effectively produces pulmonary metastasis when transplanted in nude mice. 21177903 CVCL_VW53 BoPr-14 finite cell line CVCL_VW53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177904 CVCL_W853 GCH-2 cancer cell line human CVCL_W853 CL:0000010 Population: Japanese Female Doubling time: 69 hours (CelloPub=CLPUB00142). 21177905 CVCL_VW52 BoPr-13 finite cell line CVCL_VW52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177906 CVCL_W852 GCH-1 cancer cell line human CVCL_W852 CL:0000010 Population: Japanese Female Doubling time: 63 hours (CelloPub=CLPUB00142). 21177907 CVCL_VW51 BoPr-12 finite cell line CVCL_VW51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177908 CVCL_W851 ROE2 conditionally immortalized cell line Norway rat CVCL_W851 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic oral cavity; tongue Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Omics: Transcriptome analysis by microarray Unspecified 21177909 CVCL_VW58 BoPr-19 finite cell line CVCL_VW58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177910 CVCL_W858 L-1091 cancer cell line human CVCL_W858 CL:0000010 Population: Japanese. 21177911 CVCL_VW57 BoPr-18 finite cell line CVCL_VW57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177912 CVCL_W857 HCCM-5MTXr cancer cell line human CVCL_W857 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX). Female Doubling time: ~72 hours (PubMed=4039287) 21177913 CVCL_VW56 BoPr-17 finite cell line CVCL_VW56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177914 CVCL_W856 GCH-1:RII cancer cell line human CVCL_W856 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX). Female 21177915 CVCL_VW55 BoPr-16 finite cell line CVCL_VW55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177916 CVCL_W855 GCH-1:RI cancer cell line human CVCL_W855 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX). Female 21177917 CVCL_VW59 BoPr-2 finite cell line CVCL_VW59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177918 CVCL_W859 LCL-OHN transformed cell line human CVCL_W859 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21177919 CVCL_4202 FR finite cell line Norway rat CVCL_4202 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sprague Dawley. Unspecified 21177920 CVCL_3Q02 HQ01519 transformed cell line human CVCL_3Q02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177921 CVCL_4201 FM3Ats C1.T85 cancer cell line house mouse CVCL_4201 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female Characteristics: Has a thermolabile ubiquitin-like modifier-activating enzyme 1 (Uba1) (PubMed=6327059) Doubling time: 18 hours (PubMed=6153988) 21177922 CVCL_3Q01 HQ01518 transformed cell line human CVCL_3Q01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177923 CVCL_4200 FER spontaneously immortalized cell line CVCL_4200 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Produces feline endogenous retrovirus RD-114 21177924 CVCL_3Q00 HQ01517 transformed cell line human CVCL_3Q00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177925 CVCL_4206 GEM-81 cancer cell line CVCL_4206 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Wakin. Unspecified Doubling time: 31 hours (PubMed=6928999) Group: Fish cell line 21177926 CVCL_3Q06 HQ01524 transformed cell line human CVCL_3Q06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177927 CVCL_4205 GEM-218 cancer cell line CVCL_4205 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Ryukin. Unspecified Group: Fish cell line 21177928 CVCL_3Q05 HQ01522 transformed cell line human CVCL_3Q05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177929 CVCL_4204 GEM-199 cancer cell line CVCL_4204 CL:0000010 Derived from sampling site: Cell type=Erythrophore; Breed/subspecies: Wakin. Unspecified Group: Fish cell line 21177930 CVCL_3Q04 HQ01521 transformed cell line human CVCL_3Q04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177931 CVCL_4203 FT spontaneously immortalized cell line CVCL_4203 CL:0000010 Karyotypic information: Near triploid karyoty (PubMed=14169344); Derived from sampling site: Oral cavity; tongue. Female Group: Amphibian cell line 21177932 CVCL_3Q03 HQ01520 transformed cell line human CVCL_3Q03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177933 CVCL_4209 GRL101 (MIX) spontaneously immortalized cell line CVCL_4209 CL:0000010 Transfected with: UniProtKB; P46023; Lymnaea stagnalis GRL101 Derived from sampling site: Ovary. Female 21177934 CVCL_3Q09 HQ01527 transformed cell line human CVCL_3Q09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177935 CVCL_4208 GRL101 (KC7) spontaneously immortalized cell line CVCL_4208 CL:0000010 Transfected with: UniProtKB; P46023; Lymnaea stagnalis GRL101 Derived from sampling site: Ovary. Female 21177936 CVCL_3Q08 HQ01526 transformed cell line human CVCL_3Q08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177937 CVCL_4207 GL-1 [Gecko] spontaneously immortalized cell line CVCL_4207 CL:0000010 Derived from sampling site: Lung. Male Group: Reptilian cell line 21177938 CVCL_3Q07 HQ01525 transformed cell line human CVCL_3Q07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177939 CVCL_VW61 BoPr-21 finite cell line CVCL_VW61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177940 CVCL_W861 KPB-L2 cancer cell line human CVCL_W861 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Virology: EBV-negative Doubling time: 24 hours (CelloPub=CLPUB00375) 21177941 CVCL_VW60 BoPr-20 finite cell line CVCL_VW60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177942 CVCL_W860 Middle91 cancer cell line human CVCL_W860 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by microarray Female Doubling time: 27.5 hours (PubMed=8847894) Caution: Indicated as originating from a 3 year old female patient in text of PubMed=8847894 and from a 4 year old in table 1 of same paper. 21177943 CVCL_W843 AG00990 finite cell line human CVCL_W843 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Thr10Ile (c.29C>T); ClinVar=VCV000066888; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1277; probable; Discontinued: Coriell; GM00990; probable Male Senescence: Senesces at 27 PDL (PubMed=4083160) 21177944 CVCL_VW43 DoSa06 finite cell line dog CVCL_VW43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sarabi Mastiff. Female 21177945 CVCL_W842 AG00781 finite cell line human CVCL_W842 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG00781; probable 21177946 CVCL_VW42 DoSa05 finite cell line dog CVCL_VW42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sangsari. Unspecified 21177947 CVCL_W841 AG03346 transformed cell line human CVCL_W841 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177948 CVCL_VW41 DoSa04 finite cell line dog CVCL_VW41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sangsari. Unspecified 21177949 CVCL_W840 AG03345 transformed cell line human CVCL_W840 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177950 CVCL_VW40 DoSa03 finite cell line dog CVCL_VW40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sarabi Mastiff. Female 21177951 CVCL_W847 HTLA195 cancer cell line human CVCL_W847 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2253237) Derived from metastatic site: Lung. Unspecified 21177952 CVCL_VW47 Seb Nev-1 transformed cell line human CVCL_VW47 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21177953 CVCL_VW46 ADod-01 finite cell line dog CVCL_VW46 CL:0000010 Derived from sampling site: Ovary; adipose tissue; Breed/subspecies: Poodle. Female 21177954 CVCL_W846 HTLA145 cancer cell line human CVCL_W846 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=2253237) Derived from sampling site: Bone; femur. Unspecified 21177955 CVCL_VW45 CTOD1 finite cell line dog CVCL_VW45 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: Poodle. Female 21177956 CVCL_W845 EREB2-5 transformed cell line human CVCL_W845 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Doubling time: ~24-48 hours (DSMZ=ACC-914) 21177957 CVCL_VW44 DoSa07 finite cell line dog CVCL_VW44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sarabi Mastiff. Male 21177958 CVCL_W844 SVts7-1 transformed cell line human CVCL_W844 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21177959 CVCL_VW49 BoPr-10 finite cell line CVCL_VW49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177960 CVCL_W849 RCC11 cancer cell line human CVCL_W849 CL:0000010 21177961 CVCL_VW48 BoPr-1 finite cell line CVCL_VW48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Female Group: Endangered species/breed cell line 21177962 CVCL_W848 U-1761 cancer cell line human CVCL_W848 CL:0000010 Male 21177963 CVCL_4220 HBL-52 cancer cell line human CVCL_4220 CL:0000010 Population: Caucasian; Derived from sampling site: Brain; optic canal. Omics: Deep exome analysis Female 21177964 CVCL_3Q20 HQ01538 transformed cell line human CVCL_3Q20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177965 CVCL_4213 HBL-1 [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_4213 CL:0000010 Sequence variation: Mutation; HGNC; 1699; CD79B; Simple; p.Tyr196Phe (c.587A>T); Zygosity=Heterozygous (PubMed=20054396); Sequence variation: Mutation; HGNC; 7562; MYD88; Simple; p.Leu252Pro (c.755T>C) (L265P); ClinVar=VCV000037055; Zygosity=Heterozygous (PubMed=21179087) Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Doubling time: ~48 hours (PubMed=3338018) 21177966 CVCL_3Q13 HQ01531 transformed cell line human CVCL_3Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177967 CVCL_4212 H5 cancer cell line Norway rat CVCL_4212 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male Doubling time: 12 hours (ECACC=94101905) 21177968 CVCL_3Q12 HQ01530 transformed cell line human CVCL_3Q12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177969 CVCL_4211 H4S cancer cell line Norway rat CVCL_4211 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21177970 CVCL_3Q11 HQ01529 transformed cell line human CVCL_3Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177971 CVCL_4210 H2.35 transformed cell line house mouse CVCL_4210 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: BALB/c. Female Characteristics: At the permissive temperature (33 Celsius) exhibits low level of albumin transcription while at the restrictive temperature (39 Celsius) albumin mRNA increase 100-fold 21177972 CVCL_3Q10 HQ01528 transformed cell line human CVCL_3Q10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177973 CVCL_4217 HBL-3 [Human leukemia] cancer cell line human CVCL_4217 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female Doubling time: 46 hours (PubMed=2486608) 21177974 CVCL_3Q17 HQ01535 transformed cell line human CVCL_3Q17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177975 CVCL_4216 HBL-2 [Human mantle cell lymphoma] cancer cell line human CVCL_4216 HLA typing: A*31:01,24:02; B*52:01,35:01; C*04:01,12:02; DQA1*03:02,01:03; DQB1*06:01,03:03; DRB1*09:01,15:02 (PubMed=25960936) CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Cervical lymph node. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=3338018) 21177976 CVCL_3Q16 HQ01534 transformed cell line human CVCL_3Q16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177977 CVCL_4215 HBL-11 cancer cell line human CVCL_4215 CL:0000010 Population: Japanese. Unspecified 21177978 CVCL_3Q15 HQ01533 transformed cell line human CVCL_3Q15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177979 CVCL_4214 HBL-10 cancer cell line human CVCL_4214 CL:0000010 Population: Japanese. Unspecified 21177980 CVCL_3Q14 HQ01532 transformed cell line human CVCL_3Q14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177981 CVCL_4219 HBL-5 cancer cell line human CVCL_4219 CL:0000010 Sequence variation: Gene fusion; HGNC; 5817; IGKV3-20 + HGNC; 37659; RNA28S5; Name(s)=IGKV3-20-RNA28S5, IGKV3-20-RN28S1 (PubMed=24504345); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=9454894; PubMed=12967475) Population: Japanese; Karyotypic information: Near tetraploid karyotype; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Doubling time: 24 hours (PubMed=2486609); ~48 hours (PubMed=1309680) 21177982 CVCL_3Q19 HQ01537 transformed cell line human CVCL_3Q19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21177983 CVCL_4218 HBL-4 [Human Burkitt lymphoma] cancer cell line human CVCL_4218 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Male Virology: EBV-negative Doubling time: ~36 hours (PubMed=1309680) 21177984 CVCL_3Q18 HQ01536 transformed cell line human CVCL_3Q18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21177985 CVCL_VW50 BoPr-11 finite cell line CVCL_VW50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sistani cattle. Male Group: Endangered species/breed cell line 21177986 CVCL_W850 SHK [Verasper] spontaneously immortalized cell line CVCL_W850 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21177987 CVCL_VW32 CaHo-49 finite cell line CVCL_VW32 CL:0000010 Anecdotal: From a horse named Barfi Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177988 CVCL_W832 EMT-1 cancer cell line CVCL_W832 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Thoroughbred. Female Doubling time: 42 hours (DOI=10.1294/jes.11.75) 21177989 CVCL_VW31 CaHo-48 finite cell line CVCL_VW31 CL:0000010 Anecdotal: From a horse named Ozra Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177990 CVCL_W831 GSF737 finite cell line CVCL_W831 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Kiko. Unspecified 21177991 CVCL_VW30 CaHo-47 finite cell line CVCL_VW30 CL:0000010 Anecdotal: From a horse named Sanam Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177992 CVCL_W830 GSF289 finite cell line CVCL_W830 CL:0000010 Derived from sampling site: Ear; skin; Breed/subspecies: Saanen. Male Doubling time: 25 hours, at 5th passage (PubMed=21108049) 21177993 CVCL_VW36 CaHo-53 finite cell line CVCL_VW36 CL:0000010 Anecdotal: From a horse named Babak Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21177994 CVCL_W836 Yoshizaki cancer cell line human CVCL_W836 CL:0000010 Population: Japanese. Female 21177995 CVCL_VW35 CaHo-52 finite cell line CVCL_VW35 CL:0000010 Anecdotal: From a horse named Ghezel Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177996 CVCL_W835 SBL-HSC-1000 cancer cell line human CVCL_W835 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male 21177997 CVCL_VW34 CaHo-51 finite cell line CVCL_VW34 CL:0000010 Anecdotal: From a horse named Amitis Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21177998 CVCL_W834 EMT-3 cancer cell line CVCL_W834 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Thoroughbred. Female Doubling time: 32 hours (DOI=10.1294/jes.11.75) 21177999 CVCL_VW33 CaHo-50 finite cell line CVCL_VW33 CL:0000010 Anecdotal: From a horse named Shabnam Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178000 CVCL_W833 EMT-2 cancer cell line CVCL_W833 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Thoroughbred. Male Doubling time: 33 hours (DOI=10.1294/jes.11.75) 21178001 CVCL_W839 AG03344 transformed cell line human CVCL_W839 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PubMed=12714972; PubMed=12768443) Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178002 CVCL_VW39 DoSa02 finite cell line dog CVCL_VW39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sangsari. Male 21178003 CVCL_W838 AG03343 transformed cell line human CVCL_W838 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178004 CVCL_VW38 DoSa01 finite cell line dog CVCL_VW38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Sangsari. Female 21178005 CVCL_VW37 CaHo-55 finite cell line CVCL_VW37 CL:0000010 Anecdotal: From a horse named Irangol Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178006 CVCL_VW21 CaHo-36 finite cell line CVCL_VW21 CL:0000010 Anecdotal: From a horse named Gharan Ghrob Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178007 CVCL_W821 HR-8348 cancer cell line human CVCL_W821 CL:0000010 Population: Chinese; Derived from sampling site: Rectum. Male Doubling time: 36.05 hours (PubMed=3672101) 21178008 CVCL_VW20 CaHo-35 finite cell line CVCL_VW20 CL:0000010 Anecdotal: From a horse named Mehri Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178009 CVCL_W820 MCA-B1 cancer cell line dog CVCL_W820 CL:0000010 Breed/subspecies: Akita. Male Doubling time: 9 hours (PubMed=7709052); ~24 hours (DSMZ=ACC-828) 21178010 CVCL_VW25 CaHo-41 finite cell line CVCL_VW25 CL:0000010 Anecdotal: From a horse named Samaneh Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178011 CVCL_W825 DL3580 clone 1 cancer cell line dog CVCL_W825 CL:0000010 Breed/subspecies: Boston Terrier. Male Doubling time: 25.5 hours (PubMed=8320182) 21178012 CVCL_VW24 CaHo-39 finite cell line CVCL_VW24 CL:0000010 Anecdotal: From a horse named Kokab Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178013 CVCL_W824 J3T-2 cancer cell line dog CVCL_W824 CL:0000010 Unspecified 21178014 CVCL_VW23 CaHo-38 finite cell line CVCL_VW23 CL:0000010 Anecdotal: From a horse named Ghror Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178015 CVCL_W823 J3T-1 cancer cell line dog CVCL_W823 CL:0000010 Unspecified 21178016 CVCL_VW22 CaHo-37 finite cell line CVCL_VW22 CL:0000010 Anecdotal: From a horse named Nasrin Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178017 CVCL_W822 J3T cancer cell line dog CVCL_W822 CL:0000010 Unspecified 21178018 CVCL_VW29 CaHo-45 finite cell line CVCL_VW29 CL:0000010 Anecdotal: From a horse named Atiyeh Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178019 CVCL_W829 GSF2010 finite cell line CVCL_W829 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Kiko. Unspecified 21178020 CVCL_VW28 CaHo-44 finite cell line CVCL_VW28 CL:0000010 Anecdotal: From a horse named Kati Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178021 CVCL_W828 STW-1 cancer cell line human CVCL_W828 CL:0000010 Sequence variation: Gene fusion; HGNC; 1582; CCND1 + HGNC; 5477; IGH; Name(s)=IGH-CCND1 (DOI=10.6342/NTU.2004.01000); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Unspecified (DOI=10.6342/NTU.2004.01000); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu221Asp (c.663G>T); Zygosity=Unspecified (DOI=10.6342/NTU.2004.01000); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Unspecified (DOI=10.6342/NTU.2004.01000) Population: Chinese; Taiwan; Karyotypic information: Near pseudodiploid with monosomy 13 karyotype (DOI=10.6342/NTU.2004.01000); Derived from sampling site: Pleural effusion. Male Characteristics: Produces IgD lambda 21178022 CVCL_VW27 CaHo-43 finite cell line CVCL_VW27 CL:0000010 Anecdotal: From a horse named Siyah banou Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178023 CVCL_W827 DL3580 clone 3 cancer cell line dog CVCL_W827 CL:0000010 Breed/subspecies: Boston Terrier. Male Doubling time: 50.1 hours (PubMed=8320182) 21178024 CVCL_VW26 CaHo-42 finite cell line CVCL_VW26 CL:0000010 Anecdotal: From a horse named Ghotame Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178025 CVCL_W826 DL3580 clone 2 cancer cell line dog CVCL_W826 CL:0000010 Breed/subspecies: Boston Terrier. Male Doubling time: 49.0 hours (PubMed=8320182) 21178026 CVCL_4190 FC28.Lu finite cell line CVCL_4190 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6130; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178027 CVCL_3P90 HQ01507 transformed cell line human CVCL_3P90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178028 CVCL_4194 FC58.Thy finite cell line CVCL_4194 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6137; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178029 CVCL_3P94 HQ01511 transformed cell line human CVCL_3P94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178030 CVCL_4193 FC57.Thy finite cell line CVCL_4193 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6136; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178031 CVCL_3P93 HQ01510 transformed cell line human CVCL_3P93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178032 CVCL_4192 FC56.Thy finite cell line CVCL_4192 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6134; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178033 CVCL_3P92 HQ01509 transformed cell line human CVCL_3P92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178034 CVCL_4191 FC3.Tg finite cell line CVCL_4191 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Discontinued: ATCC; CRL-6570; true Female Virology: Not susceptible to infection by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Senescence: Can undergo 50 PDL Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178035 CVCL_3P91 HQ01508 transformed cell line human CVCL_3P91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178036 CVCL_4198 FEA4 + PFSC/C1 spontaneously immortalized cell line CVCL_4198 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Unspecified Virology: Infected with feline leukemia virus (FeLV) subgroup C 21178037 CVCL_3P98 HQ01515 transformed cell line human CVCL_3P98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178038 CVCL_4197 FC6.K finite cell line CVCL_4197 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6082; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178039 CVCL_3P97 HQ01514 transformed cell line human CVCL_3P97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178040 CVCL_4196 FC6.Bm finite cell line CVCL_4196 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6081; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178041 CVCL_3P96 HQ01513 transformed cell line human CVCL_3P96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178042 CVCL_4195 FC59.Thy finite cell line CVCL_4195 CL:0000010 Derived from sampling site: Fetal thymus. Discontinued: ATCC; CRL-6139; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178043 CVCL_3P95 HQ01512 transformed cell line human CVCL_3P95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178044 CVCL_4189 FC2.Lu finite cell line CVCL_4189 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6569; true Male Virology: Persistently infected by bovine viral diarrhea virus (BVDV) (PubMed=7989438) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178045 CVCL_3P89 HQ01506 transformed cell line human CVCL_3P89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178046 CVCL_4188 FC2.K finite cell line CVCL_4188 CL:0000010 Derived from sampling site: Fetal kidney. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178047 CVCL_3P88 HQ01505 transformed cell line human CVCL_3P88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178048 CVCL_4199 FEL spontaneously immortalized cell line CVCL_4199 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fauve de Bourgogne. Unspecified Virology: Susceptible to infection by rabies virus Group: Vaccine production cell line 21178049 CVCL_3P99 HQ01516 transformed cell line human CVCL_3P99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178050 CVCL_4172 EMT6/MTXR cancer cell line house mouse CVCL_4172 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Breed/subspecies: BALB/cCRGL. Female 21178051 CVCL_3P72 HQ01489 transformed cell line human CVCL_3P72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178052 CVCL_4171 EMT6/CPR cancer cell line house mouse CVCL_4171 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Breed/subspecies: BALB/cCRGL. Female 21178053 CVCL_3P71 HQ01488 transformed cell line human CVCL_3P71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178054 CVCL_4170 EB185 (JC) transformed cell line CVCL_4170 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Male Group: Non-human primate cell line 21178055 CVCL_3P70 HQ01487 transformed cell line human CVCL_3P70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178056 CVCL_4176 F4N cancer cell line house mouse CVCL_4176 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21178057 CVCL_3P76 HQ01493 transformed cell line human CVCL_3P76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178058 CVCL_4175 EMT6/VRP/R cancer cell line house mouse CVCL_4175 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9948; Verapamil (VPL); Breed/subspecies: BALB/cCRGL. Female 21178059 CVCL_3P75 HQ01492 transformed cell line human CVCL_3P75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178060 CVCL_4174 EMT6/VCR/R cancer cell line house mouse CVCL_4174 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Breed/subspecies: BALB/cCRGL. Female 21178061 CVCL_3P74 HQ01491 transformed cell line human CVCL_3P74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178062 CVCL_4173 EMT6/P cancer cell line house mouse CVCL_4173 CL:0000010 Breed/subspecies: BALB/cCRGL. Female 21178063 CVCL_3P73 HQ01490 transformed cell line human CVCL_3P73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178064 CVCL_4169 EB (JC) transformed cell line CVCL_4169 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Female Group: Non-human primate cell line 21178065 CVCL_3P69 HQ01486 transformed cell line human CVCL_3P69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178066 CVCL_4168 SSN-1 clone E-11 spontaneously immortalized cell line CVCL_4168 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Grows at 20 and 25 Celsius; Virology: Persistently infected with snakehead retrovirus (SnRV); Virology: Highly susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Also susceptible but to a less extent to infection by barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). Group: Fish cell line 21178067 CVCL_3P68 HQ01485 transformed cell line human CVCL_3P68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178068 CVCL_4167 DSL-6B/C2 cancer cell line Norway rat CVCL_4167 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.; Breed/subspecies: Lewis. Male 21178069 CVCL_3P67 HQ01484 transformed cell line human CVCL_3P67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178070 CVCL_4166 DSL-6A/C1 cancer cell line Norway rat CVCL_4166 CL:0000010 Transformant: Azaserine(ChEBI; CHEBI:74846); Derived from sampling site: Pancreas Cell type=Pancreatic acinar cell.; Breed/subspecies: Lewis. Male 21178071 CVCL_3P66 HQ01483 transformed cell line human CVCL_3P66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178072 CVCL_4183 FB3.Thy finite cell line CVCL_4183 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178073 CVCL_3P83 HQ01500 transformed cell line human CVCL_3P83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178074 CVCL_4182 FB3.Ln finite cell line CVCL_4182 CL:0000010 Derived from sampling site: Fetal lymph node. Discontinued: ATCC; CRL-6038; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178075 CVCL_3P82 HQ01499 transformed cell line human CVCL_3P82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178076 CVCL_4181 FB2.Thy finite cell line CVCL_4181 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Discontinued: ATCC; CRL-6036; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178077 CVCL_3P81 HQ01498 transformed cell line human CVCL_3P81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178078 CVCL_4180 FB2.Sp finite cell line CVCL_4180 CL:0000010 Derived from sampling site: Fetal spleen. Discontinued: ATCC; CRL-6035; true; Discontinued: ECACC; 90031908; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178079 CVCL_3P80 HQ01497 transformed cell line human CVCL_3P80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178080 CVCL_4187 FB5.Ln finite cell line CVCL_4187 CL:0000010 Derived from sampling site: Fetal lymph node. Discontinued: ATCC; CRL-6044; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178081 CVCL_3P87 HQ01504 transformed cell line human CVCL_3P87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178082 CVCL_4186 FB5.Bm finite cell line CVCL_4186 CL:0000010 Derived from sampling site: Fetal bone marrow. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178083 CVCL_3P86 HQ01503 transformed cell line human CVCL_3P86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178084 CVCL_4185 FB4.Sp/Thy finite cell line CVCL_4185 CL:0000010 Derived from sampling site: Fetal spleen and fetal thymus. Discontinued: ATCC; CRL-6042; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178085 CVCL_3P85 HQ01502 transformed cell line human CVCL_3P85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178086 CVCL_4184 FB4.Ln finite cell line CVCL_4184 CL:0000010 Derived from sampling site: Fetal lymph node. Discontinued: ATCC; CRL-6041; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178087 CVCL_3P84 HQ01501 transformed cell line human CVCL_3P84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178088 CVCL_4179 FB2.Ln finite cell line CVCL_4179 CL:0000010 Derived from sampling site: Fetal lymph node. Discontinued: ATCC; CRL-6034; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178089 CVCL_3P79 HQ01496 transformed cell line human CVCL_3P79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178090 CVCL_4178 FB2.K finite cell line CVCL_4178 CL:0000010 Derived from sampling site: Fetal kidney. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178091 CVCL_3P78 HQ01495 transformed cell line human CVCL_3P78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178092 CVCL_4177 F5-5.F1 cancer cell line house mouse CVCL_4177 CL:0000010 Breed/subspecies: DDD. Male 21178093 CVCL_3P77 HQ01494 transformed cell line human CVCL_3P77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178094 CVCL_VV99 CaHo-13 finite cell line CVCL_VV99 CL:0000010 Anecdotal: From a horse named Gharghavo Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178095 CVCL_W799 ML cancer cell line human CVCL_W799 From: Byers H.R.; Boston University Medical Center; Boston; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10766161; PubMed=15009714). 21178096 CVCL_VV98 CaHo-12 finite cell line CVCL_VV98 CL:0000010 Anecdotal: From a horse named Sabbagh Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178097 CVCL_W798 G-mel cancer cell line human CVCL_W798 Genome ancestry: African=0.75%; Native American=0.58%; East Asian, North=2.61%; East Asian, South=0.16%; South Asian=0%; European, North=66.24%; European, South=29.66% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21178098 CVCL_VV97 CaHo-11 finite cell line CVCL_VV97 CL:0000010 Anecdotal: From a horse named Atefe Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178099 CVCL_W797 J6 cancer cell line human CVCL_W797 CL:0000010 21178100 CVCL_VV96 CaHo-10 finite cell line CVCL_VV96 CL:0000010 Anecdotal: From a horse named Gharaz Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178101 CVCL_W796 K19 cancer cell line human CVCL_W796 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714). 21178102 CVCL_4150 Cri du Chat finite cell line human CVCL_4150 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ECACC; 90102533; probable Female 21178103 CVCL_3P50 HQ01467 transformed cell line human CVCL_3P50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178104 CVCL_4154 CSE-119 spontaneously immortalized cell line CVCL_4154 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Group: Fish cell line 21178105 CVCL_3P54 HQ01471 transformed cell line human CVCL_3P54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178106 CVCL_4153 CRI-G5 cancer cell line Norway rat CVCL_4153 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. 21178107 CVCL_3P53 HQ01470 transformed cell line human CVCL_3P53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178108 CVCL_4152 CRI-D2 cancer cell line Norway rat CVCL_4152 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. 21178109 CVCL_3P52 HQ01469 transformed cell line human CVCL_3P52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178110 CVCL_4151 CRI-D11 cancer cell line Norway rat CVCL_4151 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. 21178111 CVCL_3P51 HQ01468 transformed cell line human CVCL_3P51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178112 CVCL_4147 CMT93/69 cancer cell line house mouse CVCL_4147 CL:0000010 Transformant: Methylazoxymethanol acetate (MAM acetate)(ChEBI; CHEBI:82341); Derived from sampling site: Rectum; Breed/subspecies: C57BL/ICRF. Male 21178113 CVCL_3P47 HQ01464 transformed cell line human CVCL_3P47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178114 CVCL_4146 CMT64/61 cancer cell line house mouse CVCL_4146 CL:0000010 Breed/subspecies: C57BL/ICRF-a(t). Female 21178115 CVCL_3P46 HQ01463 transformed cell line human CVCL_3P46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178116 CVCL_4145 Clone 707 cancer cell line house mouse CVCL_4145 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21178117 CVCL_3P45 HQ01462 transformed cell line human CVCL_3P45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Patient indicated as not affected with HD in HQ01462, but as affected in ND30626 21178118 CVCL_4144 CLC [Cyprinus] spontaneously immortalized cell line CVCL_4144 CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-2763; true Female Group: Fish cell line 21178119 CVCL_3P44 HQ01461 transformed cell line human CVCL_3P44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178120 CVCL_4149 CRE BAG 2 transformed cell line house mouse CVCL_4149 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21178121 CVCL_3P49 HQ01466 transformed cell line human CVCL_3P49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178122 CVCL_4148 CP132 finite cell line CVCL_4148 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6304; true; Discontinued: ECACC; 91012416; probable Male Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178123 CVCL_3P48 HQ01465 transformed cell line human CVCL_3P48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178124 CVCL_VV88 CaHo-02 finite cell line CVCL_VV88 CL:0000010 Anecdotal: From a horse named Sohah Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178125 CVCL_W788 MGH-13 cancer cell line human CVCL_W788 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 55 hours (PubMed=8382008) 21178126 CVCL_VV87 CaHo-01 finite cell line CVCL_VV87 CL:0000010 Anecdotal: From a horse named Kamyar Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178127 CVCL_W787 MGH-8 cancer cell line human CVCL_W787 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=9649128) Derived from sampling site: Lung. Unspecified Doubling time: 80 hours (PubMed=8382008) 21178128 CVCL_VV86 ACOSC4 cancer cell line human CVCL_VV86 CL:0000010 Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Female Characteristics: Tumorigenic in nude mice Doubling time: 33.78 hours (PubMed=30816493) 21178129 CVCL_W786 MGH-7 cancer cell line human CVCL_W786 CL:0000010 Derived from sampling site: Lung. Female Doubling time: 120 hours (PubMed=8382008) 21178130 CVCL_VV85 ACOSC3 cancer cell line human CVCL_VV85 CL:0000010 Population: Indian; Derived from sampling site: Oral cavity; buccal mucosa. Male Characteristics: Tumorigenic in nude mice Doubling time: 45.42 hours (PubMed=30816493) 21178131 CVCL_W785 MGH-4 cancer cell line human CVCL_W785 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 125 hours (PubMed=8382008) 21178132 CVCL_VV89 CaHo-03 finite cell line CVCL_VV89 CL:0000010 Anecdotal: From a horse named Roger Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178133 CVCL_W789 MGH-14 cancer cell line human CVCL_W789 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 204 hours (PubMed=8382008) 21178134 CVCL_4161 DEOC-1 cancer cell line human CVCL_4161 HLA typing: A*24:02,26:01; B*40:02,52:01; C*03:04,12:02 (PubMed=26589293) CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Heel; skin. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 81.2 hours (at 6th passage), 100 hours (at 20th passage) (PubMed=17547717) 21178135 CVCL_3P61 HQ01478 transformed cell line human CVCL_3P61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178136 CVCL_4160 DBS-FRhL-2 finite cell line CVCL_4160 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Biotechnology: Was used from 1997 to 1999 for the production of the rhesus rotavirus vaccine-tetravalent (RRV-TV) by Wyeth Laboratories (Trade Name: RotaShield) Discontinued: ATCC; CCL-160; true; Discontinued: IZSLER; BS CL 215; probable Male Senescence: Senesces at ~74 PDL Group: Non-human primate cell line; Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-160 21178137 CVCL_3P60 HQ01477 transformed cell line human CVCL_3P60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178138 CVCL_3P65 HQ01482 transformed cell line human CVCL_3P65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178139 CVCL_4164 DoCl1 (S+L-) transformed cell line dog CVCL_4164 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21178140 CVCL_3P64 HQ01481 transformed cell line human CVCL_3P64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178141 CVCL_4163 Do-11-10 hybridoma house mouse CVCL_4163 CL:0000010 Characteristics: T-cell hybridoma originally elicited by vaccination of BALB/c mice (H-2d haplotype) with chicken ovalbumin Popular model system to study CD4+ T cell responses.. 21178142 CVCL_3P63 HQ01480 transformed cell line human CVCL_3P63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178143 CVCL_4162 DK spontaneously immortalized cell line dog CVCL_4162 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6247; true Male Doubling time: ~34 hours (PubMed=7129476) Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21178144 CVCL_3P62 HQ01479 transformed cell line human CVCL_3P62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178145 CVCL_4158 DBS-FCL-1 finite cell line CVCL_4158 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-161 21178146 CVCL_3P58 HQ01475 transformed cell line human CVCL_3P58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178147 CVCL_4157 CYNOM-K1 finite cell line CVCL_4157 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: IZSLER; BS CL 221; probable Unspecified Virology: Susceptible to infection by poliovirus type 1, type 2 and type 3 (PubMed=28046048) Group: Non-human primate cell line 21178148 CVCL_3P57 HQ01474 transformed cell line human CVCL_3P57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178149 CVCL_4156 CV-1 Clone B5 transformed cell line CVCL_4156 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Selected for sensitivity to SV40 (ECACC) Group: Non-human primate cell line 21178150 CVCL_3P56 HQ01473 transformed cell line human CVCL_3P56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178151 CVCL_4155 CTAC cancer cell line dog CVCL_4155 CL:0000010 Sequence variation: Mutation; VGNC; 40436; ERBB2; Simple; p.Val659Glu (c.1976T>A); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Thr114Met (c.341C>T); Zygosity=Homozygous (PubMed=31175136) Derived from sampling site: Thyroid gland; Breed/subspecies: Boxer. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 15 hours (PubMed=27257868) Part of: FACC canine tumor cell line panel 21178152 CVCL_3P55 HQ01472 transformed cell line human CVCL_3P55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178153 CVCL_4159 DBS-FCL-2 finite cell line CVCL_4159 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Discontinued: ATCC; CCL-162; probable Male Senescence: Senesces at ~12 PDL Group: Non-human primate cell line 21178154 CVCL_3P59 HQ01476 transformed cell line human CVCL_3P59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178155 CVCL_VV91 CaHo-05 finite cell line CVCL_VV91 CL:0000010 Anecdotal: From a horse named Aigol Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Female 21178156 CVCL_W791 MGH-26 cancer cell line human CVCL_W791 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 134 hours (PubMed=8382008) 21178157 CVCL_VV90 CaHo-04 finite cell line CVCL_VV90 CL:0000010 Anecdotal: From a horse named Logan Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178158 CVCL_W790 MGH-24 cancer cell line human CVCL_W790 CL:0000010 Derived from sampling site: Lung. Unspecified Doubling time: 53 hours (PubMed=8382008) 21178159 CVCL_VV95 CaHo-09 finite cell line CVCL_VV95 CL:0000010 Anecdotal: From a horse named Bahman Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178160 CVCL_W795 MGH-LA-1 cancer cell line human CVCL_W795 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10766161). Unspecified 21178161 CVCL_VV94 CaHo-08 finite cell line CVCL_VV94 CL:0000010 Anecdotal: From a horse named Shahryar Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178162 CVCL_W794 MGH-GO-1 cancer cell line human CVCL_W794 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=10766161). Unspecified 21178163 CVCL_VV93 CaHo-07 finite cell line CVCL_VV93 CL:0000010 Anecdotal: From a horse named Shahram Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178164 CVCL_W793 RVH-6849 cancer cell line human CVCL_W793 CL:0000010 Derived from sampling site: Lung. Male 21178165 CVCL_VV92 CaHo-06 finite cell line CVCL_VV92 CL:0000010 Anecdotal: From a horse named Jangal Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Caspian. Male 21178166 CVCL_W792 MGH-30 cancer cell line human CVCL_W792 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=9649128) Derived from sampling site: Lung. Unspecified Doubling time: 79 hours (PubMed=8382008) 21178167 CVCL_ED63 ND20515 transformed cell line human CVCL_ED63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178168 CVCL_ED62 ND20483 transformed cell line human CVCL_ED62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178169 CVCL_ED61 ND20440 transformed cell line human CVCL_ED61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178170 CVCL_ED60 ND20425 transformed cell line human CVCL_ED60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178171 CVCL_ED56 ND20397 transformed cell line human CVCL_ED56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178172 CVCL_ED55 ND20395 transformed cell line human CVCL_ED55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178173 CVCL_ED54 ND20394 transformed cell line human CVCL_ED54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178174 CVCL_ED53 ND20344 transformed cell line human CVCL_ED53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178175 CVCL_ED59 ND20417 transformed cell line human CVCL_ED59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178176 CVCL_ED58 ND20399 transformed cell line human CVCL_ED58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178177 CVCL_ED57 ND20398 transformed cell line human CVCL_ED57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178178 CVCL_ED70 ND20731 transformed cell line human CVCL_ED70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178179 CVCL_ED74 ND20770 transformed cell line human CVCL_ED74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178180 CVCL_ED73 ND20769 transformed cell line human CVCL_ED73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178181 CVCL_ED72 ND20754 transformed cell line human CVCL_ED72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178182 CVCL_ED71 ND20749 transformed cell line human CVCL_ED71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178183 CVCL_ED67 ND20628 transformed cell line human CVCL_ED67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178184 CVCL_ED66 ND20627 transformed cell line human CVCL_ED66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178185 CVCL_ED65 ND20528 transformed cell line human CVCL_ED65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178186 CVCL_ED64 ND20516 transformed cell line human CVCL_ED64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178187 CVCL_ED69 ND20683 transformed cell line human CVCL_ED69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178188 CVCL_ED68 ND20665 transformed cell line human CVCL_ED68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178189 CVCL_ED41 ND20031 transformed cell line human CVCL_ED41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178190 CVCL_ED40 ND20030 transformed cell line human CVCL_ED40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178191 CVCL_ED39 ND19987 transformed cell line human CVCL_ED39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178192 CVCL_ED34 ND19919 transformed cell line human CVCL_ED34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178193 CVCL_ED33 ND19848 transformed cell line human CVCL_ED33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178194 CVCL_ED32 ND19797 transformed cell line human CVCL_ED32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178195 CVCL_ED31 ND19794 transformed cell line human CVCL_ED31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178196 CVCL_ED38 ND19985 transformed cell line human CVCL_ED38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178197 CVCL_ED37 ND19982 transformed cell line human CVCL_ED37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178198 CVCL_ED36 ND19981 transformed cell line human CVCL_ED36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178199 CVCL_ED35 ND19922 transformed cell line human CVCL_ED35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178200 CVCL_ED52 ND20296 transformed cell line human CVCL_ED52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178201 CVCL_ED51 ND20279 transformed cell line human CVCL_ED51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178202 CVCL_ED50 ND20259 transformed cell line human CVCL_ED50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178203 CVCL_ED45 ND20146 transformed cell line human CVCL_ED45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178204 CVCL_ED44 ND20145 transformed cell line human CVCL_ED44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178205 CVCL_ED43 ND20033 transformed cell line human CVCL_ED43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178206 CVCL_ED42 ND20032 transformed cell line human CVCL_ED42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178207 CVCL_ED49 ND20245 transformed cell line human CVCL_ED49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178208 CVCL_ED48 ND20199 transformed cell line human CVCL_ED48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178209 CVCL_ED47 ND20197 transformed cell line human CVCL_ED47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178210 CVCL_ED46 ND20194 transformed cell line human CVCL_ED46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178211 CVCL_ED19 ND19409 transformed cell line human CVCL_ED19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178212 CVCL_ED18 ND19331 transformed cell line human CVCL_ED18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178213 CVCL_ED17 ND19330 transformed cell line human CVCL_ED17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178214 CVCL_ED12 ND19238 transformed cell line human CVCL_ED12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178215 CVCL_ED11 ND19237 transformed cell line human CVCL_ED11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178216 CVCL_ED10 ND19207 transformed cell line human CVCL_ED10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178217 CVCL_ED16 ND19285 transformed cell line human CVCL_ED16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178218 CVCL_ED15 ND19283 transformed cell line human CVCL_ED15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178219 CVCL_ED14 ND19251 transformed cell line human CVCL_ED14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178220 CVCL_ED13 ND19240 transformed cell line human CVCL_ED13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178221 CVCL_ED30 ND19792 transformed cell line human CVCL_ED30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178222 CVCL_ED29 ND19742 transformed cell line human CVCL_ED29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178223 CVCL_ED28 ND19740 transformed cell line human CVCL_ED28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178224 CVCL_ED23 ND19491 transformed cell line human CVCL_ED23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178225 CVCL_ED22 ND19489 transformed cell line human CVCL_ED22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178226 CVCL_ED21 ND19488 transformed cell line human CVCL_ED21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178227 CVCL_ED20 ND19424 transformed cell line human CVCL_ED20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178228 CVCL_ED27 ND19738 transformed cell line human CVCL_ED27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178229 CVCL_ED26 ND19602 transformed cell line human CVCL_ED26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178230 CVCL_ED25 ND19535 transformed cell line human CVCL_ED25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178231 CVCL_ED24 ND19531 transformed cell line human CVCL_ED24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178232 CVCL_ED09 ND19179 transformed cell line human CVCL_ED09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178233 CVCL_ED08 ND16706 transformed cell line human CVCL_ED08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178234 CVCL_ED07 ND16669 transformed cell line human CVCL_ED07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178235 CVCL_ED06 ND16667 transformed cell line human CVCL_ED06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178236 CVCL_ED01 ND16565 transformed cell line human CVCL_ED01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178237 CVCL_ED00 ND16564 transformed cell line human CVCL_ED00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178238 CVCL_ED05 ND16647 transformed cell line human CVCL_ED05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178239 CVCL_ED04 ND16636 transformed cell line human CVCL_ED04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178240 CVCL_ED03 ND16602 transformed cell line human CVCL_ED03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178241 CVCL_ED02 ND16599 transformed cell line human CVCL_ED02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178242 CVCL_EN18 UCSD075i-1-6 induced pluripotent stem cell human CVCL_EN18 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178243 CVCL_EN17 UCSD074i-1-5 induced pluripotent stem cell human CVCL_EN17 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178244 CVCL_EN16 UCSD073i-1-4 induced pluripotent stem cell human CVCL_EN16 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178245 CVCL_EN15 UCSD072i-1-3 induced pluripotent stem cell human CVCL_EN15 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178246 CVCL_EN19 UCSD076i-1-7 induced pluripotent stem cell human CVCL_EN19 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178247 CVCL_EN10 UCSD067i-19-1 induced pluripotent stem cell human CVCL_EN10 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178248 CVCL_EN14 UCSD071i-1-2 induced pluripotent stem cell human CVCL_EN14 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178249 CVCL_EN13 UCSD070i-1-1 induced pluripotent stem cell human CVCL_EN13 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178250 CVCL_EN12 UCSD069i-19-3 induced pluripotent stem cell human CVCL_EN12 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178251 CVCL_EN11 UCSD068i-19-2 induced pluripotent stem cell human CVCL_EN11 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178252 CVCL_EN29 UCSD086i-6-3 induced pluripotent stem cell human CVCL_EN29 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178253 CVCL_EN28 UCSD085i-6-2 induced pluripotent stem cell human CVCL_EN28 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178254 CVCL_EN27 UCSD084i-6-1 induced pluripotent stem cell human CVCL_EN27 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178255 CVCL_EN26 UCSD083i-40-2 induced pluripotent stem cell human CVCL_EN26 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178256 CVCL_EN21 UCSD078i-1-9 induced pluripotent stem cell human CVCL_EN21 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178257 CVCL_EN20 UCSD077i-1-8 induced pluripotent stem cell human CVCL_EN20 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178258 CVCL_EN25 UCSD082i-40-1 induced pluripotent stem cell human CVCL_EN25 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178259 CVCL_EN24 UCSD081i-1-14 induced pluripotent stem cell human CVCL_EN24 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178260 CVCL_EN23 UCSD080i-1-13 induced pluripotent stem cell human CVCL_EN23 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178261 CVCL_EN22 UCSD079i-1-12 induced pluripotent stem cell human CVCL_EN22 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African and Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178262 CVCL_EN07 UCSD064i-20-2 induced pluripotent stem cell human CVCL_EN07 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178263 CVCL_EN06 UCSD063i-20-1 induced pluripotent stem cell human CVCL_EN06 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178264 CVCL_EN05 UCSD062i-66-1 induced pluripotent stem cell human CVCL_EN05 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178265 CVCL_EN04 UCSD061i-65-1 induced pluripotent stem cell human CVCL_EN04 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178266 CVCL_EN09 UCSD066i-67-1 induced pluripotent stem cell human CVCL_EN09 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178267 CVCL_EN08 UCSD065i-20-3 induced pluripotent stem cell human CVCL_EN08 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178268 CVCL_EN03 UCSD060i-64-1 induced pluripotent stem cell human CVCL_EN03 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178269 CVCL_EN02 UCSD059i-63-1 induced pluripotent stem cell human CVCL_EN02 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178270 CVCL_EN01 UCSD058i-62-1 induced pluripotent stem cell human CVCL_EN01 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178271 CVCL_EN00 UCSD057i-61-1 induced pluripotent stem cell human CVCL_EN00 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178272 CVCL_3Z81 HQ02618 transformed cell line human CVCL_3Z81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178273 CVCL_3Z80 HQ02617 transformed cell line human CVCL_3Z80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178274 CVCL_3Z85 HQ02623 transformed cell line human CVCL_3Z85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178275 CVCL_3Z84 HQ02622 transformed cell line human CVCL_3Z84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178276 CVCL_3Z83 HQ02621 transformed cell line human CVCL_3Z83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178277 CVCL_3Z82 HQ02619 transformed cell line human CVCL_3Z82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178278 CVCL_3Z89 HQ02632 transformed cell line human CVCL_3Z89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178279 CVCL_3Z88 HQ02629 transformed cell line human CVCL_3Z88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178280 CVCL_3Z87 HQ02627 transformed cell line human CVCL_3Z87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178281 CVCL_3Z86 HQ02626 transformed cell line human CVCL_3Z86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178282 CVCL_3Z92 HQ02636 transformed cell line human CVCL_3Z92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178283 CVCL_3Z91 HQ02634 transformed cell line human CVCL_3Z91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178284 CVCL_3Z90 HQ02633 transformed cell line human CVCL_3Z90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178285 CVCL_3Z96 HQ02643 transformed cell line human CVCL_3Z96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178286 CVCL_3Z95 HQ02641 transformed cell line human CVCL_3Z95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178287 CVCL_3Z94 HQ02638 transformed cell line human CVCL_3Z94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178288 CVCL_3Z93 HQ02637 transformed cell line human CVCL_3Z93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178289 CVCL_3Z99 HQ02648 transformed cell line human CVCL_3Z99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178290 CVCL_3Z98 HQ02645 transformed cell line human CVCL_3Z98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178291 CVCL_3Z97 HQ02644 transformed cell line human CVCL_3Z97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178292 CVCL_NH35 BayGenomics ES cell line RRN257 embryonic stem cell house mouse CVCL_NH35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178293 CVCL_NH34 BayGenomics ES cell line RRN255 embryonic stem cell house mouse CVCL_NH34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178294 CVCL_NH33 BayGenomics ES cell line RRN252 embryonic stem cell house mouse CVCL_NH33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178295 CVCL_NH32 BayGenomics ES cell line RRN250 embryonic stem cell house mouse CVCL_NH32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178296 CVCL_NH31 BayGenomics ES cell line RRN247 embryonic stem cell house mouse CVCL_NH31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178297 CVCL_NH30 BayGenomics ES cell line RRN245 embryonic stem cell house mouse CVCL_NH30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914449; Pfdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178298 CVCL_EN98 UCSD155i-12-1 induced pluripotent stem cell human CVCL_EN98 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178299 CVCL_EN97 UCSD154i-90-1 induced pluripotent stem cell human CVCL_EN97 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178300 CVCL_EN96 UCSD153i-11-4 induced pluripotent stem cell human CVCL_EN96 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178301 CVCL_EN95 UCSD152i-11-3 induced pluripotent stem cell human CVCL_EN95 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178302 CVCL_EN99 UCSD156i-12-2 induced pluripotent stem cell human CVCL_EN99 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Pacific; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178303 CVCL_EN90 UCSD147i-10-2 induced pluripotent stem cell human CVCL_EN90 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178304 CVCL_NH29 BayGenomics ES cell line RRN240 embryonic stem cell house mouse CVCL_NH29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443076; Cc2d1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178305 CVCL_NH28 BayGenomics ES cell line RRN237 embryonic stem cell house mouse CVCL_NH28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444412; Phf20l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178306 CVCL_EN94 UCSD151i-11-2 induced pluripotent stem cell human CVCL_EN94 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178307 CVCL_NH27 BayGenomics ES cell line RRN227 embryonic stem cell house mouse CVCL_NH27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108420; Nfe2l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178308 CVCL_EN93 UCSD150i-11-1 induced pluripotent stem cell human CVCL_EN93 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178309 CVCL_NH26 BayGenomics ES cell line RRN226 embryonic stem cell house mouse CVCL_NH26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913398; Dnajc15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178310 CVCL_EN92 UCSD149i-10-4 induced pluripotent stem cell human CVCL_EN92 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178311 CVCL_NH25 BayGenomics ES cell line RRN225 embryonic stem cell house mouse CVCL_NH25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147194; Rbm27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178312 CVCL_EN91 UCSD148i-10-3 induced pluripotent stem cell human CVCL_EN91 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178313 CVCL_NH46 BayGenomics ES cell line RRN287 embryonic stem cell house mouse CVCL_NH46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144023; Fbxw11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178314 CVCL_NH45 BayGenomics ES cell line RRN286 embryonic stem cell house mouse CVCL_NH45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444431; Rab11fip3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178315 CVCL_NH44 BayGenomics ES cell line RRN282 embryonic stem cell house mouse CVCL_NH44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102705; Gng2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178316 CVCL_NH43 BayGenomics ES cell line RRN280 embryonic stem cell house mouse CVCL_NH43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385851; Fam193b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178317 CVCL_NH42 BayGenomics ES cell line RRN277 embryonic stem cell house mouse CVCL_NH42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920895; Ddx46 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178318 CVCL_NH41 BayGenomics ES cell line RRN270 embryonic stem cell house mouse CVCL_NH41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384589; Herc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178319 CVCL_NH40 BayGenomics ES cell line RRN269 embryonic stem cell house mouse CVCL_NH40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890651; Brwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178320 CVCL_NH39 BayGenomics ES cell line RRN268 embryonic stem cell house mouse CVCL_NH39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890651; Brwd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178321 CVCL_NH38 BayGenomics ES cell line RRN266 embryonic stem cell house mouse CVCL_NH38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915760; Ints1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178322 CVCL_NH37 BayGenomics ES cell line RRN263 embryonic stem cell house mouse CVCL_NH37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914216; Trit1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178323 CVCL_NH36 BayGenomics ES cell line RRN258 embryonic stem cell house mouse CVCL_NH36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914216; Trit1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178324 CVCL_NH13 BayGenomics ES cell line RRN197 embryonic stem cell house mouse CVCL_NH13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444222; Tmem104 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178325 CVCL_NH12 BayGenomics ES cell line RRN196 embryonic stem cell house mouse CVCL_NH12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178326 CVCL_NH11 BayGenomics ES cell line RRN187 embryonic stem cell house mouse CVCL_NH11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109656; Lasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178327 CVCL_NH10 BayGenomics ES cell line RRN186 embryonic stem cell house mouse CVCL_NH10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924337; Ankrd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178328 CVCL_EN76 UCSD133i-79-1 induced pluripotent stem cell human CVCL_EN76 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178329 CVCL_EN75 UCSD132i-78-1 induced pluripotent stem cell human CVCL_EN75 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178330 CVCL_EN74 UCSD131i-77-1 induced pluripotent stem cell human CVCL_EN74 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178331 CVCL_EN73 UCSD130i-76-1 induced pluripotent stem cell human CVCL_EN73 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178332 CVCL_EN79 UCSD136i-82-1 induced pluripotent stem cell human CVCL_EN79 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178333 CVCL_EN78 UCSD135i-81-1 induced pluripotent stem cell human CVCL_EN78 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Native American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178334 CVCL_EN77 UCSD134i-80-1 induced pluripotent stem cell human CVCL_EN77 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178335 CVCL_NH09 BayGenomics ES cell line RRN184 embryonic stem cell house mouse CVCL_NH09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104560; Nsf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178336 CVCL_NH08 BayGenomics ES cell line RRN183 embryonic stem cell house mouse CVCL_NH08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346872; Map3k1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178337 CVCL_NH07 BayGenomics ES cell line RRN181 embryonic stem cell house mouse CVCL_NH07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443419; Rps6kc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178338 CVCL_NH06 BayGenomics ES cell line RRN180 embryonic stem cell house mouse CVCL_NH06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700006; Dbnl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178339 CVCL_EN72 UCSD129i-75-1 induced pluripotent stem cell human CVCL_EN72 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Iranian; Persian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178340 CVCL_NH05 BayGenomics ES cell line RRN178 embryonic stem cell house mouse CVCL_NH05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036261; Spata5l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178341 CVCL_EN71 UCSD128i-7-5 induced pluripotent stem cell human CVCL_EN71 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178342 CVCL_NH04 BayGenomics ES cell line RRN177 embryonic stem cell house mouse CVCL_NH04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933754; Nedd4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178343 CVCL_EN70 UCSD127i-7-4 induced pluripotent stem cell human CVCL_EN70 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178344 CVCL_NH03 BayGenomics ES cell line RRN167 embryonic stem cell house mouse CVCL_NH03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444661; Susd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178345 CVCL_NH24 BayGenomics ES cell line RRN218 embryonic stem cell house mouse CVCL_NH24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178346 CVCL_NH23 BayGenomics ES cell line RRN216 embryonic stem cell house mouse CVCL_NH23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924145; Bicd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178347 CVCL_NH22 BayGenomics ES cell line RRN215 embryonic stem cell house mouse CVCL_NH22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918867; Armh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178348 CVCL_NH21 BayGenomics ES cell line RRN214 embryonic stem cell house mouse CVCL_NH21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178349 CVCL_NH20 BayGenomics ES cell line RRN212 embryonic stem cell house mouse CVCL_NH20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913495; Hspbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178350 CVCL_EN87 UCSD144i-88-1 induced pluripotent stem cell human CVCL_EN87 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178351 CVCL_EN86 UCSD143i-87-1 induced pluripotent stem cell human CVCL_EN86 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178352 CVCL_EN85 UCSD142i-86-1 induced pluripotent stem cell human CVCL_EN85 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178353 CVCL_EN84 UCSD141i-37-2 induced pluripotent stem cell human CVCL_EN84 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178354 CVCL_EN89 UCSD146i-10-1 induced pluripotent stem cell human CVCL_EN89 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178355 CVCL_EN88 UCSD145i-89-1 induced pluripotent stem cell human CVCL_EN88 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African and Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178356 CVCL_NH19 BayGenomics ES cell line RRN210 embryonic stem cell house mouse CVCL_NH19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178357 CVCL_NH18 BayGenomics ES cell line RRN207 embryonic stem cell house mouse CVCL_NH18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103007; Epb41l4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178358 CVCL_NH17 BayGenomics ES cell line RRN206 embryonic stem cell house mouse CVCL_NH17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443390; Lrch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178359 CVCL_EN83 UCSD140i-37-1 induced pluripotent stem cell human CVCL_EN83 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178360 CVCL_NH16 BayGenomics ES cell line RRN204 embryonic stem cell house mouse CVCL_NH16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097686; H3f3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178361 CVCL_EN82 UCSD139i-85-1 induced pluripotent stem cell human CVCL_EN82 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178362 CVCL_NH15 BayGenomics ES cell line RRN200 embryonic stem cell house mouse CVCL_NH15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647820; Hectd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178363 CVCL_EN81 UCSD138i-84-1 induced pluripotent stem cell human CVCL_EN81 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178364 CVCL_NH14 BayGenomics ES cell line RRN198 embryonic stem cell house mouse CVCL_NH14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924217; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178365 CVCL_EN80 UCSD137i-83-1 induced pluripotent stem cell human CVCL_EN80 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178366 CVCL_EN59 UCSD116i-71-1 induced pluripotent stem cell human CVCL_EN59 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178367 CVCL_EN54 UCSD111i-2-10 induced pluripotent stem cell human CVCL_EN54 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178368 CVCL_EN53 UCSD110i-2-9 induced pluripotent stem cell human CVCL_EN53 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178369 CVCL_EN52 UCSD109i-2-8 induced pluripotent stem cell human CVCL_EN52 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178370 CVCL_EN51 UCSD108i-2-7 induced pluripotent stem cell human CVCL_EN51 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178371 CVCL_EN58 UCSD115i-70-1 induced pluripotent stem cell human CVCL_EN58 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178372 CVCL_EN57 UCSD114i-69-1 induced pluripotent stem cell human CVCL_EN57 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178373 CVCL_EN56 UCSD113i-68-1 induced pluripotent stem cell human CVCL_EN56 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178374 CVCL_EN55 UCSD112i-2-11 induced pluripotent stem cell human CVCL_EN55 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178375 CVCL_EN50 UCSD107i-2-6 induced pluripotent stem cell human CVCL_EN50 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178376 CVCL_NH02 BayGenomics ES cell line RRN164 embryonic stem cell house mouse CVCL_NH02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104772; Cdk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178377 CVCL_NH01 BayGenomics ES cell line RRN163 embryonic stem cell house mouse CVCL_NH01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919414; Rbmx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178378 CVCL_NH00 BayGenomics ES cell line RRN159 embryonic stem cell house mouse CVCL_NH00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915080; Rer1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178379 CVCL_EN65 UCSD122i-73-1 induced pluripotent stem cell human CVCL_EN65 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178380 CVCL_EN64 UCSD121i-39-2 induced pluripotent stem cell human CVCL_EN64 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178381 CVCL_EN63 UCSD120i-39-1 induced pluripotent stem cell human CVCL_EN63 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178382 CVCL_EN62 UCSD119i-38-2 induced pluripotent stem cell human CVCL_EN62 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178383 CVCL_EN69 UCSD126i-7-3 induced pluripotent stem cell human CVCL_EN69 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178384 CVCL_EN68 UCSD125i-7-2 induced pluripotent stem cell human CVCL_EN68 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178385 CVCL_EN67 UCSD124i-7-1 induced pluripotent stem cell human CVCL_EN67 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178386 CVCL_EN66 UCSD123i-74-1 induced pluripotent stem cell human CVCL_EN66 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178387 CVCL_EN61 UCSD118i-38-1 induced pluripotent stem cell human CVCL_EN61 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178388 CVCL_EN60 UCSD117i-72-1 induced pluripotent stem cell human CVCL_EN60 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178389 CVCL_EN39 UCSD096i-34-1 induced pluripotent stem cell human CVCL_EN39 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178390 CVCL_EN38 UCSD095i-25-2 induced pluripotent stem cell human CVCL_EN38 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178391 CVCL_EN37 UCSD094i-25-1 induced pluripotent stem cell human CVCL_EN37 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Iraqi; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178392 CVCL_EN32 UCSD089i-15-1 induced pluripotent stem cell human CVCL_EN32 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178393 CVCL_EN31 UCSD088i-6-5 induced pluripotent stem cell human CVCL_EN31 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178394 CVCL_EN30 UCSD087i-6-4 induced pluripotent stem cell human CVCL_EN30 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178395 CVCL_EN36 UCSD093i-1-11 induced pluripotent stem cell human CVCL_EN36 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178396 CVCL_EN35 UCSD092i-1-10 induced pluripotent stem cell human CVCL_EN35 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178397 CVCL_EN34 UCSD091i-15-3 induced pluripotent stem cell human CVCL_EN34 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178398 CVCL_EN33 UCSD090i-15-2 induced pluripotent stem cell human CVCL_EN33 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178399 CVCL_EN49 UCSD106i-2-5 induced pluripotent stem cell human CVCL_EN49 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178400 CVCL_EN48 UCSD105i-2-4 induced pluripotent stem cell human CVCL_EN48 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178401 CVCL_EN43 UCSD100i-36-1 induced pluripotent stem cell human CVCL_EN43 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178402 CVCL_EN42 UCSD099i-35-2 induced pluripotent stem cell human CVCL_EN42 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178403 CVCL_EN41 UCSD098i-35-1 induced pluripotent stem cell human CVCL_EN41 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178404 CVCL_EN40 UCSD097i-34-2 induced pluripotent stem cell human CVCL_EN40 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian, Mexican and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178405 CVCL_EN47 UCSD104i-2-3 induced pluripotent stem cell human CVCL_EN47 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178406 CVCL_EN46 UCSD103i-2-2 induced pluripotent stem cell human CVCL_EN46 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178407 CVCL_EN45 UCSD102i-2-1 induced pluripotent stem cell human CVCL_EN45 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178408 CVCL_EN44 UCSD101i-36-2 induced pluripotent stem cell human CVCL_EN44 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178409 CVCL_NG99 BayGenomics ES cell line RRN158 embryonic stem cell house mouse CVCL_NG99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103185; Uimc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178410 CVCL_NG98 BayGenomics ES cell line RRN156 embryonic stem cell house mouse CVCL_NG98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919790; Heatr6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178411 CVCL_NG97 BayGenomics ES cell line RRN154 embryonic stem cell house mouse CVCL_NG97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153063; Parvb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178412 CVCL_NG96 BayGenomics ES cell line RRN142 embryonic stem cell house mouse CVCL_NG96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921075; Ppp1r21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178413 CVCL_NG95 BayGenomics ES cell line RRN141 embryonic stem cell house mouse CVCL_NG95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891691; Arpp19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178414 CVCL_NG94 BayGenomics ES cell line RRN136 embryonic stem cell house mouse CVCL_NG94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178415 CVCL_WA31 CaBa62 finite cell line CVCL_WA31 CL:0000010 Anecdotal: From a camel named Maryam Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178416 CVCL_NG93 BayGenomics ES cell line RRN132 embryonic stem cell house mouse CVCL_NG93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919769; Pip4p2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178417 CVCL_WA30 CaBa61 finite cell line CVCL_WA30 CL:0000010 Anecdotal: From a camel named Ghare Boghor Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178418 CVCL_NG92 BayGenomics ES cell line RRN131 embryonic stem cell house mouse CVCL_NG92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178419 CVCL_NG91 BayGenomics ES cell line RRN127 embryonic stem cell house mouse CVCL_NG91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929869; Hic2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178420 CVCL_NG90 BayGenomics ES cell line RRN126 embryonic stem cell house mouse CVCL_NG90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345964; Coro1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178421 CVCL_WA35 MSD-43 transformed cell line human CVCL_WA35 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178422 CVCL_WA34 CaBa65 finite cell line CVCL_WA34 CL:0000010 Anecdotal: From a camel named Elizabet Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178423 CVCL_WA33 CaBa64 finite cell line CVCL_WA33 CL:0000010 Anecdotal: From a camel named Maya Chai Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178424 CVCL_WA32 CaBa63 finite cell line CVCL_WA32 CL:0000010 Anecdotal: From a camel named Sari Boghor Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178425 CVCL_WA39 AZP-01 transformed cell line human CVCL_WA39 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178426 CVCL_WA38 ATX-01 transformed cell line human CVCL_WA38 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178427 CVCL_WA37 EPTH2 finite cell line human CVCL_WA37 CL:0000010 Derived from sampling site: Testis; epididymis. Male 21178428 CVCL_WA36 ACTH2 finite cell line human CVCL_WA36 CL:0000010 Derived from sampling site: Testis. Male 21178429 CVCL_WA20 CaBa51 finite cell line CVCL_WA20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178430 CVCL_WA24 CaBa55 finite cell line CVCL_WA24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178431 CVCL_WA23 CaBa54 finite cell line CVCL_WA23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178432 CVCL_WA22 CaBa53 finite cell line CVCL_WA22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178433 CVCL_WA21 CaBa52 finite cell line CVCL_WA21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178434 CVCL_WA28 CaBa59 finite cell line CVCL_WA28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178435 CVCL_WA27 CaBa58 finite cell line CVCL_WA27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178436 CVCL_WA26 CaBa57 finite cell line CVCL_WA26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178437 CVCL_WA25 CaBa56 finite cell line CVCL_WA25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178438 CVCL_WA29 CaBa60 finite cell line CVCL_WA29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178439 CVCL_NG79 BayGenomics ES cell line RRN095 embryonic stem cell house mouse CVCL_NG79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894326; Atp6v1e1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178440 CVCL_NG78 BayGenomics ES cell line RRN094 embryonic stem cell house mouse CVCL_NG78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289274; Krr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178441 CVCL_NG77 BayGenomics ES cell line RRN093 embryonic stem cell house mouse CVCL_NG77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102724; Tpp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178442 CVCL_NG76 BayGenomics ES cell line RRN092 embryonic stem cell house mouse CVCL_NG76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178443 CVCL_NG75 BayGenomics ES cell line RRN091 embryonic stem cell house mouse CVCL_NG75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158736; Senp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178444 CVCL_NG74 BayGenomics ES cell line RRN088 embryonic stem cell house mouse CVCL_NG74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152346; Taf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178445 CVCL_NG73 BayGenomics ES cell line RRN087 embryonic stem cell house mouse CVCL_NG73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914324; Mon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178446 CVCL_NG72 BayGenomics ES cell line RRN086 embryonic stem cell house mouse CVCL_NG72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888520; Brd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178447 CVCL_NG71 BayGenomics ES cell line RRN084 embryonic stem cell house mouse CVCL_NG71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3583954; Zfp961 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178448 CVCL_NG70 BayGenomics ES cell line RRN083 embryonic stem cell house mouse CVCL_NG70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915126; Coq10b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178449 CVCL_WA13 CaBa43 finite cell line CVCL_WA13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178450 CVCL_WA12 CaBa42 finite cell line CVCL_WA12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178451 CVCL_WA11 CaBa41 finite cell line CVCL_WA11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178452 CVCL_WA10 CaBa40 finite cell line CVCL_WA10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178453 CVCL_WA17 CaBa47 finite cell line CVCL_WA17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178454 CVCL_WA16 CaBa46 finite cell line CVCL_WA16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178455 CVCL_WA15 CaBa45 finite cell line CVCL_WA15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178456 CVCL_WA14 CaBa44 finite cell line CVCL_WA14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178457 CVCL_WA19 CaBa50 finite cell line CVCL_WA19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178458 CVCL_WA18 CaBa49 finite cell line CVCL_WA18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178459 CVCL_NG89 BayGenomics ES cell line RRN124 embryonic stem cell house mouse CVCL_NG89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929459; Rabgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178460 CVCL_NG88 BayGenomics ES cell line RRN121 embryonic stem cell house mouse CVCL_NG88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346875; Map3k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178461 CVCL_NG87 BayGenomics ES cell line RRN111 embryonic stem cell house mouse CVCL_NG87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891112; Gmds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178462 CVCL_NG86 BayGenomics ES cell line RRN108 embryonic stem cell house mouse CVCL_NG86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446089; Flnb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178463 CVCL_NG85 BayGenomics ES cell line RRN107 embryonic stem cell house mouse CVCL_NG85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443012; Tns3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178464 CVCL_NG84 BayGenomics ES cell line RRN101 embryonic stem cell house mouse CVCL_NG84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96623; Itpr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178465 CVCL_NG83 BayGenomics ES cell line RRN100 embryonic stem cell house mouse CVCL_NG83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352463; Nr1h2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178466 CVCL_NG82 BayGenomics ES cell line RRN099 embryonic stem cell house mouse CVCL_NG82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345186; Blmh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178467 CVCL_NG81 BayGenomics ES cell line RRN098 embryonic stem cell house mouse CVCL_NG81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178468 CVCL_NG80 BayGenomics ES cell line RRN096 embryonic stem cell house mouse CVCL_NG80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106624; Myo9b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178469 CVCL_WA02 CaBa32 finite cell line CVCL_WA02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178470 CVCL_WA01 CaBa31 finite cell line CVCL_WA01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178471 CVCL_WA00 CaBa30 finite cell line CVCL_WA00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178472 CVCL_WA06 CaBa36 finite cell line CVCL_WA06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178473 CVCL_WA05 CaBa35 finite cell line CVCL_WA05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178474 CVCL_WA04 CaBa34 finite cell line CVCL_WA04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178475 CVCL_WA03 CaBa33 finite cell line CVCL_WA03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178476 CVCL_WA09 CaBa39 finite cell line CVCL_WA09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178477 CVCL_WA08 CaBa38 finite cell line CVCL_WA08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Endangered species/breed cell line 21178478 CVCL_WA07 CaBa37 finite cell line CVCL_WA07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Endangered species/breed cell line 21178479 CVCL_NG58 BayGenomics ES cell line RRN062 embryonic stem cell house mouse CVCL_NG58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917747; Arhgap17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178480 CVCL_NG57 BayGenomics ES cell line RRN061 embryonic stem cell house mouse CVCL_NG57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344353; Katna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178481 CVCL_NG56 BayGenomics ES cell line RRN059 embryonic stem cell house mouse CVCL_NG56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338038; Aebp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178482 CVCL_NG55 BayGenomics ES cell line RRN056 embryonic stem cell house mouse CVCL_NG55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277143; Gtf2h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178483 CVCL_NG54 BayGenomics ES cell line RRN055 embryonic stem cell house mouse CVCL_NG54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924825; Kmt2e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178484 CVCL_NG53 BayGenomics ES cell line RRN053 embryonic stem cell house mouse CVCL_NG53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178485 CVCL_NG52 BayGenomics ES cell line RRN052 embryonic stem cell house mouse CVCL_NG52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888677; Gigyf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178486 CVCL_NG51 BayGenomics ES cell line RRN051 embryonic stem cell house mouse CVCL_NG51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178487 CVCL_NG50 BayGenomics ES cell line RRN049 embryonic stem cell house mouse CVCL_NG50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098658; Stag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178488 CVCL_NG49 BayGenomics ES cell line RRN046 embryonic stem cell house mouse CVCL_NG49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146836; Brpf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178489 CVCL_NG48 BayGenomics ES cell line RRN044 embryonic stem cell house mouse CVCL_NG48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178490 CVCL_NG69 BayGenomics ES cell line RRN082 embryonic stem cell house mouse CVCL_NG69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346880; Map3k11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178491 CVCL_NG68 BayGenomics ES cell line RRN081 embryonic stem cell house mouse CVCL_NG68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914389; Mis12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178492 CVCL_NG67 BayGenomics ES cell line RRN078 embryonic stem cell house mouse CVCL_NG67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178493 CVCL_NG66 BayGenomics ES cell line RRN075 embryonic stem cell house mouse CVCL_NG66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914338; Cand2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178494 CVCL_NG65 BayGenomics ES cell line RRN074 embryonic stem cell house mouse CVCL_NG65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347360; Cul3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178495 CVCL_NG64 BayGenomics ES cell line RRN072 embryonic stem cell house mouse CVCL_NG64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928469; Trip4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178496 CVCL_NG63 BayGenomics ES cell line RRN070 embryonic stem cell house mouse CVCL_NG63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109150; Mnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178497 CVCL_NG62 BayGenomics ES cell line RRN067 embryonic stem cell house mouse CVCL_NG62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178498 CVCL_NG61 BayGenomics ES cell line RRN066 embryonic stem cell house mouse CVCL_NG61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920930; Zbtb8a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178499 CVCL_NG60 BayGenomics ES cell line RRN064 embryonic stem cell house mouse CVCL_NG60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178500 CVCL_NG59 BayGenomics ES cell line RRN063 embryonic stem cell house mouse CVCL_NG59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915814; Nufip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178501 CVCL_NG36 BayGenomics ES cell line RRM390 embryonic stem cell house mouse CVCL_NG36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105089; Hsd17b4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178502 CVCL_NG35 BayGenomics ES cell line RRM388 embryonic stem cell house mouse CVCL_NG35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178503 CVCL_NG34 BayGenomics ES cell line RRM382 embryonic stem cell house mouse CVCL_NG34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919822; Spats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178504 CVCL_NG33 BayGenomics ES cell line RRM376 embryonic stem cell house mouse CVCL_NG33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178505 CVCL_NG32 BayGenomics ES cell line RRM374 embryonic stem cell house mouse CVCL_NG32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178506 CVCL_NG31 BayGenomics ES cell line RRM364 embryonic stem cell house mouse CVCL_NG31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930768; Arid3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178507 CVCL_NG30 BayGenomics ES cell line RRM285 embryonic stem cell house mouse CVCL_NG30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920136; Yju2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178508 CVCL_EM99 UCSD056i-60-1 induced pluripotent stem cell human CVCL_EM99 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178509 CVCL_EM98 UCSD055i-59-1 induced pluripotent stem cell human CVCL_EM98 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178510 CVCL_EM97 UCSD054i-58-1 induced pluripotent stem cell human CVCL_EM97 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178511 CVCL_EM96 UCSD053i-57-1 induced pluripotent stem cell human CVCL_EM96 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178512 CVCL_EM91 UCSD048i-52-1 induced pluripotent stem cell human CVCL_EM91 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178513 CVCL_EM90 UCSD047i-51-1 induced pluripotent stem cell human CVCL_EM90 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178514 CVCL_NG29 BayGenomics ES cell line RRM280 embryonic stem cell house mouse CVCL_NG29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97447; Osbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178515 CVCL_EM95 UCSD052i-56-1 induced pluripotent stem cell human CVCL_EM95 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178516 CVCL_NG28 BayGenomics ES cell line RRM279 embryonic stem cell house mouse CVCL_NG28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96009; Hadh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178517 CVCL_EM94 UCSD051i-55-1 induced pluripotent stem cell human CVCL_EM94 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178518 CVCL_NG27 BayGenomics ES cell line RRM278 embryonic stem cell house mouse CVCL_NG27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107736; Dync2h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178519 CVCL_EM93 UCSD050i-54-1 induced pluripotent stem cell human CVCL_EM93 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178520 CVCL_NG26 BayGenomics ES cell line RRM277 embryonic stem cell house mouse CVCL_NG26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446163; Fam120a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178521 CVCL_EM92 UCSD049i-53-1 induced pluripotent stem cell human CVCL_EM92 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178522 CVCL_NG47 BayGenomics ES cell line RRN038 embryonic stem cell house mouse CVCL_NG47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646907; Gm6563 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178523 CVCL_NG46 BayGenomics ES cell line RRN028 embryonic stem cell house mouse CVCL_NG46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913368; Sarnp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178524 CVCL_NG45 BayGenomics ES cell line RRN016 embryonic stem cell house mouse CVCL_NG45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646907; Gm6563 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178525 CVCL_NG44 BayGenomics ES cell line RRN005 embryonic stem cell house mouse CVCL_NG44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890695; Rab9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178526 CVCL_NG43 BayGenomics ES cell line RRM405 embryonic stem cell house mouse CVCL_NG43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913368; Sarnp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178527 CVCL_NG42 BayGenomics ES cell line RRM404 embryonic stem cell house mouse CVCL_NG42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918345; Kif24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178528 CVCL_NG41 BayGenomics ES cell line RRM402 embryonic stem cell house mouse CVCL_NG41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178529 CVCL_NG40 BayGenomics ES cell line RRM401 embryonic stem cell house mouse CVCL_NG40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444412; Phf20l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178530 CVCL_NG39 BayGenomics ES cell line RRM394 embryonic stem cell house mouse CVCL_NG39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178531 CVCL_NG38 BayGenomics ES cell line RRM393 embryonic stem cell house mouse CVCL_NG38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890619; Gan Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178532 CVCL_NG37 BayGenomics ES cell line RRM391 embryonic stem cell house mouse CVCL_NG37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277216; Gtf2h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178533 CVCL_3Z63 HQ02592 transformed cell line human CVCL_3Z63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178534 CVCL_3Z62 HQ02591 transformed cell line human CVCL_3Z62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178535 CVCL_3Z61 HQ02590 transformed cell line human CVCL_3Z61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178536 CVCL_3Z60 HQ02589 transformed cell line human CVCL_3Z60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178537 CVCL_3Z67 HQ02600 transformed cell line human CVCL_3Z67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178538 CVCL_3Z66 HQ02599 transformed cell line human CVCL_3Z66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178539 CVCL_3Z65 HQ02598 transformed cell line human CVCL_3Z65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178540 CVCL_3Z64 HQ02593 transformed cell line human CVCL_3Z64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178541 CVCL_3Z69 HQ02602 transformed cell line human CVCL_3Z69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178542 CVCL_3Z68 HQ02601 transformed cell line human CVCL_3Z68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178543 CVCL_3Z70 HQ02605 transformed cell line human CVCL_3Z70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178544 CVCL_3Z74 HQ02610 transformed cell line human CVCL_3Z74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178545 CVCL_3Z73 HQ02609 transformed cell line human CVCL_3Z73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178546 CVCL_3Z72 HQ02608 transformed cell line human CVCL_3Z72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178547 CVCL_3Z71 HQ02607 transformed cell line human CVCL_3Z71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178548 CVCL_3Z78 HQ02615 transformed cell line human CVCL_3Z78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178549 CVCL_3Z77 HQ02613 transformed cell line human CVCL_3Z77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178550 CVCL_3Z76 HQ02612 transformed cell line human CVCL_3Z76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178551 CVCL_3Z75 HQ02611 transformed cell line human CVCL_3Z75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178552 CVCL_3Z79 HQ02616 transformed cell line human CVCL_3Z79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178553 CVCL_WA93 MNR-03 transformed cell line human CVCL_WA93 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178554 CVCL_WA92 MNR-02 transformed cell line human CVCL_WA92 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178555 CVCL_WA91 MNR-01 transformed cell line human CVCL_WA91 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178556 CVCL_WA90 LAD-03 transformed cell line human CVCL_WA90 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178557 CVCL_WA97 MNR-07 transformed cell line human CVCL_WA97 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178558 CVCL_WA96 MNR-06 transformed cell line human CVCL_WA96 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178559 CVCL_WA95 MNR-05 transformed cell line human CVCL_WA95 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178560 CVCL_WA94 MNR-04 transformed cell line human CVCL_WA94 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178561 CVCL_WA99 MNR-09 transformed cell line human CVCL_WA99 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178562 CVCL_WA98 MNR-08 transformed cell line human CVCL_WA98 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178563 CVCL_3Z41 HQ02562 transformed cell line human CVCL_3Z41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178564 CVCL_3Z40 HQ02561 transformed cell line human CVCL_3Z40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178565 CVCL_3Z45 HQ02568 transformed cell line human CVCL_3Z45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178566 CVCL_3Z44 HQ02566 transformed cell line human CVCL_3Z44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178567 CVCL_3Z43 HQ02565 transformed cell line human CVCL_3Z43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178568 CVCL_3Z42 HQ02564 transformed cell line human CVCL_3Z42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178569 CVCL_3Z49 HQ02576 transformed cell line human CVCL_3Z49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178570 CVCL_3Z48 HQ02575 transformed cell line human CVCL_3Z48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178571 CVCL_3Z47 HQ02574 transformed cell line human CVCL_3Z47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178572 CVCL_3Z46 HQ02571 transformed cell line human CVCL_3Z46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178573 CVCL_WA82 HAE-03 transformed cell line human CVCL_WA82 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178574 CVCL_WA81 HAE-02 transformed cell line human CVCL_WA81 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178575 CVCL_WA80 HAE-01 transformed cell line human CVCL_WA80 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178576 CVCL_WA86 ICT-01 transformed cell line human CVCL_WA86 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178577 CVCL_WA85 HuGu finite cell line human CVCL_WA85 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Female 21178578 CVCL_WA84 Hcycu-1 transformed cell line human CVCL_WA84 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178579 CVCL_WA83 HAF-01 finite cell line human CVCL_WA83 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21178580 CVCL_WA89 LAD-02 transformed cell line human CVCL_WA89 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178581 CVCL_WA88 IDD-03 transformed cell line human CVCL_WA88 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178582 CVCL_WA87 IDD-02 transformed cell line human CVCL_WA87 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178583 CVCL_3Z52 HQ02579 transformed cell line human CVCL_3Z52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178584 CVCL_3Z51 HQ02578 transformed cell line human CVCL_3Z51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178585 CVCL_3Z50 HQ02577 transformed cell line human CVCL_3Z50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178586 CVCL_3Z56 HQ02584 transformed cell line human CVCL_3Z56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178587 CVCL_3Z55 HQ02583 transformed cell line human CVCL_3Z55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178588 CVCL_3Z54 HQ02582 transformed cell line human CVCL_3Z54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178589 CVCL_3Z53 HQ02581 transformed cell line human CVCL_3Z53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178590 CVCL_3Z59 HQ02588 transformed cell line human CVCL_3Z59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178591 CVCL_3Z58 HQ02586 transformed cell line human CVCL_3Z58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178592 CVCL_3Z57 HQ02585 transformed cell line human CVCL_3Z57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178593 CVCL_3Z29 HQ02548 transformed cell line human CVCL_3Z29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178594 CVCL_3Z28 HQ02547 transformed cell line human CVCL_3Z28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178595 CVCL_WA71 GBS-01 transformed cell line human CVCL_WA71 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178596 CVCL_WA70 DBT-04 transformed cell line human CVCL_WA70 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178597 CVCL_WA75 GBS-05 transformed cell line human CVCL_WA75 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178598 CVCL_WA74 GBS-04 transformed cell line human CVCL_WA74 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178599 CVCL_WA73 GBS-03 transformed cell line human CVCL_WA73 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178600 CVCL_WA72 GBS-02 transformed cell line human CVCL_WA72 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178601 CVCL_WA79 GGZ-01 transformed cell line human CVCL_WA79 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178602 CVCL_WA78 GBS-08 transformed cell line human CVCL_WA78 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178603 CVCL_WA77 GBS-07 transformed cell line human CVCL_WA77 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178604 CVCL_WA76 GBS-06 transformed cell line human CVCL_WA76 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178605 CVCL_3Z23 HQ02541 transformed cell line human CVCL_3Z23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178606 CVCL_3Z22 HQ02540 transformed cell line human CVCL_3Z22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178607 CVCL_3Z21 HQ02535 transformed cell line human CVCL_3Z21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178608 CVCL_3Z20 HQ02534 transformed cell line human CVCL_3Z20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178609 CVCL_3Z27 HQ02546 transformed cell line human CVCL_3Z27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178610 CVCL_3Z26 HQ02544 transformed cell line human CVCL_3Z26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178611 CVCL_3Z25 HQ02543 transformed cell line human CVCL_3Z25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178612 CVCL_3Z24 HQ02542 transformed cell line human CVCL_3Z24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178613 CVCL_3Z39 HQ02560 transformed cell line human CVCL_3Z39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178614 CVCL_WA60 CHS-03 transformed cell line human CVCL_WA60 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178615 CVCL_WA64 CMR-04 transformed cell line human CVCL_WA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178616 CVCL_WA63 CMR-03 transformed cell line human CVCL_WA63 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178617 CVCL_WA62 CMR-02 transformed cell line human CVCL_WA62 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178618 CVCL_WA61 CMR-01 transformed cell line human CVCL_WA61 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178619 CVCL_WA68 DBT-02 transformed cell line human CVCL_WA68 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178620 CVCL_WA67 DBT-01 transformed cell line human CVCL_WA67 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178621 CVCL_WA66 CMR-06 transformed cell line human CVCL_WA66 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178622 CVCL_WA65 CMR-05 transformed cell line human CVCL_WA65 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178623 CVCL_WA69 DBT-03 transformed cell line human CVCL_WA69 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178624 CVCL_3Z30 HQ02549 transformed cell line human CVCL_3Z30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178625 CVCL_3Z34 HQ02554 transformed cell line human CVCL_3Z34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178626 CVCL_3Z33 HQ02553 transformed cell line human CVCL_3Z33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178627 CVCL_3Z32 HQ02552 transformed cell line human CVCL_3Z32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178628 CVCL_3Z31 HQ02551 transformed cell line human CVCL_3Z31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178629 CVCL_3Z38 HQ02559 transformed cell line human CVCL_3Z38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178630 CVCL_3Z37 HQ02558 transformed cell line human CVCL_3Z37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178631 CVCL_3Z36 HQ02557 transformed cell line human CVCL_3Z36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178632 CVCL_3Z35 HQ02556 transformed cell line human CVCL_3Z35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178633 CVCL_3Z09 HQ02521 transformed cell line human CVCL_3Z09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178634 CVCL_3Z08 HQ02519 transformed cell line human CVCL_3Z08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178635 CVCL_3Z07 HQ02518 transformed cell line human CVCL_3Z07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178636 CVCL_3Z06 HQ02517 transformed cell line human CVCL_3Z06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178637 CVCL_WA53 CGD-12 transformed cell line human CVCL_WA53 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178638 CVCL_WA52 CGD-11 transformed cell line human CVCL_WA52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178639 CVCL_WA51 CGD-10 transformed cell line human CVCL_WA51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178640 CVCL_WA50 CGD-09 transformed cell line human CVCL_WA50 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178641 CVCL_WA57 CGD-19 transformed cell line human CVCL_WA57 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178642 CVCL_WA56 CGD-17 transformed cell line human CVCL_WA56 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178643 CVCL_WA55 CGD-14 transformed cell line human CVCL_WA55 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178644 CVCL_WA54 CGD-13 transformed cell line human CVCL_WA54 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178645 CVCL_WA59 CHS-01 transformed cell line human CVCL_WA59 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178646 CVCL_WA58 CGD-20 transformed cell line human CVCL_WA58 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178647 CVCL_3Z01 HQ02510 transformed cell line human CVCL_3Z01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178648 CVCL_3Z00 HQ02509 transformed cell line human CVCL_3Z00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178649 CVCL_3Z05 HQ02515 transformed cell line human CVCL_3Z05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178650 CVCL_3Z04 HQ02514 transformed cell line human CVCL_3Z04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178651 CVCL_3Z03 HQ02513 transformed cell line human CVCL_3Z03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178652 CVCL_3Z02 HQ02512 transformed cell line human CVCL_3Z02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178653 CVCL_3Z19 HQ02533 transformed cell line human CVCL_3Z19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178654 CVCL_3Z18 HQ02532 transformed cell line human CVCL_3Z18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178655 CVCL_3Z17 HQ02531 transformed cell line human CVCL_3Z17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178656 CVCL_WA42 CGD-01 transformed cell line human CVCL_WA42 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178657 CVCL_WA41 BLM-01 transformed cell line human CVCL_WA41 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178658 CVCL_WA40 AZP-02 transformed cell line human CVCL_WA40 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178659 CVCL_WA46 CGD-05 transformed cell line human CVCL_WA46 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178660 CVCL_WA45 CGD-04 transformed cell line human CVCL_WA45 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178661 CVCL_WA44 CGD-03 transformed cell line human CVCL_WA44 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178662 CVCL_WA43 CGD-02 transformed cell line human CVCL_WA43 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178663 CVCL_WA49 CGD-08 transformed cell line human CVCL_WA49 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178664 CVCL_WA48 CGD-07 transformed cell line human CVCL_WA48 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178665 CVCL_WA47 CGD-06 transformed cell line human CVCL_WA47 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178666 CVCL_3Z12 HQ02525 transformed cell line human CVCL_3Z12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178667 CVCL_3Z11 HQ02524 transformed cell line human CVCL_3Z11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178668 CVCL_3Z10 HQ02522 transformed cell line human CVCL_3Z10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178669 CVCL_3Z16 HQ02529 transformed cell line human CVCL_3Z16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178670 CVCL_3Z15 HQ02528 transformed cell line human CVCL_3Z15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178671 CVCL_3Z14 HQ02527 transformed cell line human CVCL_3Z14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178672 CVCL_3Z13 HQ02526 transformed cell line human CVCL_3Z13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178673 CVCL_F039 B6fc-2 embryonic stem cell house mouse CVCL_F039 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2187; true Female 21178674 CVCL_F038 B6fc-1 embryonic stem cell house mouse CVCL_F038 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2186; true Female 21178675 CVCL_F037 B6ft-2 embryonic stem cell house mouse CVCL_F037 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2185; true Female 21178676 CVCL_F036 B6ft-1 embryonic stem cell house mouse CVCL_F036 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2184; true Female 21178677 CVCL_F031 C3Hft-1 embryonic stem cell house mouse CVCL_F031 CL:0000010 Breed/subspecies: C3H/He. Discontinued: RCB; RCB2179; true Female 21178678 CVCL_F030 C3Hmt-1 embryonic stem cell house mouse CVCL_F030 CL:0000010 Breed/subspecies: C3H/He. Discontinued: RCB; RCB2178; true Male 21178679 CVCL_F035 B6mt-2 embryonic stem cell house mouse CVCL_F035 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2183; true Male 21178680 CVCL_F034 B6mt-1 embryonic stem cell house mouse CVCL_F034 CL:0000010 Breed/subspecies: C57BL/6. Discontinued: RCB; RCB2182; true Male 21178681 CVCL_F033 C3Hfc-1 embryonic stem cell house mouse CVCL_F033 CL:0000010 Breed/subspecies: C3H/He. Discontinued: RCB; RCB2181; true Female 21178682 CVCL_F032 C3Hft-2 embryonic stem cell house mouse CVCL_F032 CL:0000010 Breed/subspecies: C3H/He. Discontinued: RCB; RCB2180; true Female 21178683 CVCL_F049 BDmto-2 embryonic stem cell house mouse CVCL_F049 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2201; true Male 21178684 CVCL_F048 BDmto-1 embryonic stem cell house mouse CVCL_F048 CL:0000010 Breed/subspecies: C57BL/6 x DBA/2. Discontinued: RCB; RCB2200; true Male 21178685 CVCL_F047 ICRft-2 embryonic stem cell house mouse CVCL_F047 CL:0000010 Breed/subspecies: ICR. Discontinued: RCB; RCB2198; true Male 21178686 CVCL_F042 DBAfc-1 embryonic stem cell house mouse CVCL_F042 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB2190; true Female 21178687 CVCL_F041 DBAmt-2 embryonic stem cell house mouse CVCL_F041 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB2189; true Male 21178688 CVCL_F040 DBAmt-1 embryonic stem cell house mouse CVCL_F040 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB2188; true Male 21178689 CVCL_F046 FVB-1 embryonic stem cell house mouse CVCL_F046 CL:0000010 Breed/subspecies: FVB. Discontinued: RCB; RCB2194; true Male 21178690 CVCL_F045 129fc-2 embryonic stem cell house mouse CVCL_F045 CL:0000010 Breed/subspecies: 129/Sv. Discontinued: RCB; RCB2193; true Female 21178691 CVCL_F044 129fc-1 embryonic stem cell house mouse CVCL_F044 CL:0000010 Breed/subspecies: 129/Sv. Discontinued: RCB; RCB2192; true Female 21178692 CVCL_F043 DBAfc-2 embryonic stem cell house mouse CVCL_F043 CL:0000010 Breed/subspecies: DBA/2. Discontinued: RCB; RCB2191; true Female 21178693 CVCL_F017 GM01896 finite cell line human CVCL_F017 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21178694 CVCL_F016 GM01893 finite cell line human CVCL_F016 CL:0000010 Karyotypic information: 46,XY,del(9)(pter->q11::q21.3->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21178695 CVCL_F015 GM01892 finite cell line human CVCL_F015 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(9;18)(9qter->9p24::18q12->18qter;18pter->18q12::9p24->9pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21178696 CVCL_F014 EB-PE transformed cell line house mouse CVCL_F014 CL:0000010 Breed/subspecies: 129S/SvEv-Gpi1. Male 21178697 CVCL_F019 GM01898 finite cell line human CVCL_F019 CL:0000010 Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Gly409Arg (c.1225G>C); ClinVar=VCV000092627; Zygosity=Homozygous (PubMed=8328452); Sequence variation: Mutation; HGNC; 5391; IDUA; Simple; p.Ter654Cysext*38 (c.1962A>T); ClinVar=VCV000242721; Zygosity=Homozygous (PubMed=8328452) Population: Arab; Derived from sampling site: Cell type=Fibroblast. Male 21178698 CVCL_F018 GM01897 finite cell line human CVCL_F018 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21178699 CVCL_F013 NBFL cancer cell line human CVCL_F013 CL:0000010 21178700 CVCL_F012 Dch4F finite cell line human CVCL_F012 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2101; probable Male 21178701 CVCL_F011 Dch3 finite cell line human CVCL_F011 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2100; probable Male 21178702 CVCL_F010 Dch2 finite cell line human CVCL_F010 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2099; probable Female 21178703 CVCL_F028 GM01389 finite cell line human CVCL_F028 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Asn349del (c.1045_1047del); Zygosity=Heterozygous (PubMed=10777490; PubMed=12812979; PubMed=26184184); Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Leu350Pro (c.1049T>C); Zygosity=Heterozygous (PubMed=10777490; PubMed=12812979; PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178704 CVCL_F027 GM02795 transformed cell line human CVCL_F027 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Val44Met (c.130G>A); ClinVar=VCV000003611; Zygosity=Heterozygous (PubMed=2011574); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Met142Lys (c.425T>A); ClinVar=VCV000003609; Zygosity=Heterozygous (PubMed=2011574) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178705 CVCL_F026 GM01907 finite cell line human CVCL_F026 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Val44Met (c.130G>A); ClinVar=VCV000003611; Zygosity=Heterozygous (from autologous cell line GM02795); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Met142Lys (c.425T>A); ClinVar=VCV000003609; Zygosity=Heterozygous (from autologous cell line GM02795) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178706 CVCL_F025 GM01999 transformed cell line human CVCL_F025 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178707 CVCL_F029 XP1MI LCL transformed cell line human CVCL_F029 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Pro334His (c.1001C>A); ClinVar=VCV000000253; Zygosity=Homozygous (from autologous cell line XP1MI 2) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178708 CVCL_F020 GM01955 finite cell line human CVCL_F020 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21178709 CVCL_F024 GM01998 finite cell line human CVCL_F024 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21178710 CVCL_F023 GM01993 finite cell line human CVCL_F023 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21178711 CVCL_F022 GM01207 transformed cell line human CVCL_F022 HLA typing: A*11,28; B*15,35 (Coriell=GM01207) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21178712 CVCL_F021 GM01956 transformed cell line human CVCL_F021 CL:0000010 Sequence variation: Mutation; HGNC; 5024; HNF4A; Simple; p.Gln277Ter (c.829C>T) (Q268*); ClinVar=VCV000009210; Zygosity=Heterozygous (PubMed=8945471) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178713 CVCL_F006 PCL3091 cancer cell line human CVCL_F006 CL:0000010 Unspecified 21178714 CVCL_F005 PCL3014 cancer cell line human CVCL_F005 CL:0000010 Unspecified 21178715 CVCL_F004 PCL1771 cancer cell line human CVCL_F004 CL:0000010 Unspecified 21178716 CVCL_F003 PCL1691 cancer cell line human CVCL_F003 CL:0000010 Unspecified 21178717 CVCL_F009 Dch1 finite cell line human CVCL_F009 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2098; probable Male 21178718 CVCL_F008 BCNS1KO hTERT telomerase immortalized cell line human CVCL_F008 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB2738; probable Male 21178719 CVCL_F007 PP984 cancer cell line human CVCL_F007 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=2052620). 21178720 CVCL_F002 PCL1643 cancer cell line human CVCL_F002 CL:0000010 Unspecified 21178721 CVCL_F001 LoKe cancer cell line human CVCL_F001 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803) Omics: Array-based CGH; Omics: SNP array analysis. Male Doubling time: 4 days (PubMed=30873613) 21178722 CVCL_F000 HeRo [Human Merkel cell carcinoma] cancer cell line human CVCL_F000 CL:0000010 Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803). Female 21178723 CVCL_NI56 BayGenomics ES cell line RRO129 embryonic stem cell house mouse CVCL_NI56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929063; Copz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178724 CVCL_NI55 BayGenomics ES cell line RRO127 embryonic stem cell house mouse CVCL_NI55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385261; Cnot3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178725 CVCL_NI54 BayGenomics ES cell line RRO124 embryonic stem cell house mouse CVCL_NI54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97346; Nktr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178726 CVCL_NI53 BayGenomics ES cell line RRO123 embryonic stem cell house mouse CVCL_NI53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922855; Kdm5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178727 CVCL_NI52 BayGenomics ES cell line RRO122 embryonic stem cell house mouse CVCL_NI52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914247; Psmd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178728 CVCL_NI51 BayGenomics ES cell line RRO121 embryonic stem cell house mouse CVCL_NI51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178729 CVCL_NI50 BayGenomics ES cell line RRO120 embryonic stem cell house mouse CVCL_NI50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344380; Chd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178730 CVCL_NI49 BayGenomics ES cell line RRO115 embryonic stem cell house mouse CVCL_NI49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104912; Sf3a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178731 CVCL_NI48 BayGenomics ES cell line RRO114 embryonic stem cell house mouse CVCL_NI48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341087; Tnks Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178732 CVCL_NI47 BayGenomics ES cell line RRO113 embryonic stem cell house mouse CVCL_NI47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178733 CVCL_NI46 BayGenomics ES cell line RRO112 embryonic stem cell house mouse CVCL_NI46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178734 CVCL_NI67 BayGenomics ES cell line RRO153 embryonic stem cell house mouse CVCL_NI67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137221; Mrpl20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178735 CVCL_NI66 BayGenomics ES cell line RRO151 embryonic stem cell house mouse CVCL_NI66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178736 CVCL_NI65 BayGenomics ES cell line RRO149 embryonic stem cell house mouse CVCL_NI65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178737 CVCL_NI64 BayGenomics ES cell line RRO143 embryonic stem cell house mouse CVCL_NI64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178738 CVCL_NI63 BayGenomics ES cell line RRO142 embryonic stem cell house mouse CVCL_NI63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109360; Lmo4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178739 CVCL_NI62 BayGenomics ES cell line RRO141 embryonic stem cell house mouse CVCL_NI62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914228; Luc7l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178740 CVCL_NI61 BayGenomics ES cell line RRO140 embryonic stem cell house mouse CVCL_NI61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933124; Sh3bp5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178741 CVCL_NI60 BayGenomics ES cell line RRO138 embryonic stem cell house mouse CVCL_NI60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178742 CVCL_NI59 BayGenomics ES cell line RRO135 embryonic stem cell house mouse CVCL_NI59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919936; Usp24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178743 CVCL_NI58 BayGenomics ES cell line RRO134 embryonic stem cell house mouse CVCL_NI58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345150; Cdc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178744 CVCL_NI57 BayGenomics ES cell line RRO132 embryonic stem cell house mouse CVCL_NI57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178745 CVCL_NI34 BayGenomics ES cell line RRO088 embryonic stem cell house mouse CVCL_NI34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858234; Caprin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178746 CVCL_NI33 BayGenomics ES cell line RRO087 embryonic stem cell house mouse CVCL_NI33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098268; Kif5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178747 CVCL_NI32 BayGenomics ES cell line RRO086 embryonic stem cell house mouse CVCL_NI32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178748 CVCL_NI31 BayGenomics ES cell line RRO085 embryonic stem cell house mouse CVCL_NI31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178749 CVCL_NI30 BayGenomics ES cell line RRO079 embryonic stem cell house mouse CVCL_NI30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178750 CVCL_F097 GM19903 transformed cell line human CVCL_F097 CL:0000010 Sequence variation: Mutation; HGNC; 4162; GARS1; Simple; p.Gly294Arg (c.880G>C) (G240R); ClinVar=VCV000009204; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178751 CVCL_F096 GM19829 transformed cell line human CVCL_F096 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178752 CVCL_F095 GM19815 transformed cell line human CVCL_F095 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178753 CVCL_F094 GM03334 transformed cell line human CVCL_F094 HLA typing: A*02:02,23:DFKR; B*18:RRG,58:02; C*06:02,07:CVAG; DRB1*15:01,15:03 (IPD-IMGT/HLA=20692) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female Part of: Human variation panel 21178754 CVCL_F099 GM19974 transformed cell line human CVCL_F099 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178755 CVCL_F098 GM19926 transformed cell line human CVCL_F098 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21178756 CVCL_NI29 BayGenomics ES cell line RRO078 embryonic stem cell house mouse CVCL_NI29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178757 CVCL_NI28 BayGenomics ES cell line RRO077 embryonic stem cell house mouse CVCL_NI28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178758 CVCL_NI27 BayGenomics ES cell line RRO076 embryonic stem cell house mouse CVCL_NI27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178759 CVCL_F093 GM03325 transformed cell line human CVCL_F093 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178760 CVCL_NI26 BayGenomics ES cell line RRO073 embryonic stem cell house mouse CVCL_NI26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448506; Pi4ka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178761 CVCL_F092 GM03491 finite cell line human CVCL_F092 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178762 CVCL_NI25 BayGenomics ES cell line RRO072 embryonic stem cell house mouse CVCL_NI25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098824; Odf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178763 CVCL_F091 GM03324 transformed cell line human CVCL_F091 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178764 CVCL_NI24 BayGenomics ES cell line RRO069 embryonic stem cell house mouse CVCL_NI24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276545; Nsd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178765 CVCL_F090 GM03490 finite cell line human CVCL_F090 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178766 CVCL_NI45 BayGenomics ES cell line RRO110 embryonic stem cell house mouse CVCL_NI45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352755; Gtse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178767 CVCL_NI44 BayGenomics ES cell line RRO108 embryonic stem cell house mouse CVCL_NI44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178768 CVCL_NI43 BayGenomics ES cell line RRO107 embryonic stem cell house mouse CVCL_NI43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178769 CVCL_NI42 BayGenomics ES cell line RRO105 embryonic stem cell house mouse CVCL_NI42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178770 CVCL_NI41 BayGenomics ES cell line RRO102 embryonic stem cell house mouse CVCL_NI41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178771 CVCL_NI40 BayGenomics ES cell line RRO101 embryonic stem cell house mouse CVCL_NI40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178772 CVCL_NI39 BayGenomics ES cell line RRO097 embryonic stem cell house mouse CVCL_NI39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890081; Foxo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178773 CVCL_NI38 BayGenomics ES cell line RRO096 embryonic stem cell house mouse CVCL_NI38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178774 CVCL_NI37 BayGenomics ES cell line RRO094 embryonic stem cell house mouse CVCL_NI37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442480; Pigv Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178775 CVCL_NI36 BayGenomics ES cell line RRO091 embryonic stem cell house mouse CVCL_NI36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684864; Pfas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178776 CVCL_NI35 BayGenomics ES cell line RRO090 embryonic stem cell house mouse CVCL_NI35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385298; Zfp958 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178777 CVCL_NI12 BayGenomics ES cell line RRO033 embryonic stem cell house mouse CVCL_NI12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102806; Acvr2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178778 CVCL_NI11 BayGenomics ES cell line RRO032 embryonic stem cell house mouse CVCL_NI11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328362; Blm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178779 CVCL_NI10 BayGenomics ES cell line RRO031 embryonic stem cell house mouse CVCL_NI10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178780 CVCL_F075 GM03362 finite cell line human CVCL_F075 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21178781 CVCL_F074 GM03238 transformed cell line human CVCL_F074 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178782 CVCL_F073 GM03356 transformed cell line human CVCL_F073 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21178783 CVCL_F072 GM03237 transformed cell line human CVCL_F072 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21178784 CVCL_F079 GM02782 transformed cell line human CVCL_F079 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2251del19; Zygosity=Heterozygous (PubMed=8808599; PubMed=16166284); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5675del88; Zygosity=Heterozygous (PubMed=8808599; PubMed=16166284); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6573del81; Zygosity=Heterozygous (PubMed=8808599; PubMed=16166284) Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21178785 CVCL_F078 GM03794 transformed cell line human CVCL_F078 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Female 21178786 CVCL_F077 GM03793 finite cell line human CVCL_F077 CL:0000010 Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178787 CVCL_F076 GM01877 finite cell line human CVCL_F076 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Male 21178788 CVCL_NI09 BayGenomics ES cell line RRO030 embryonic stem cell house mouse CVCL_NI09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140950; Tent2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178789 CVCL_NI08 BayGenomics ES cell line RRO029 embryonic stem cell house mouse CVCL_NI08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097686; H3f3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178790 CVCL_NI07 BayGenomics ES cell line RRO027 embryonic stem cell house mouse CVCL_NI07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913546; Haus2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178791 CVCL_NI06 BayGenomics ES cell line RRO026 embryonic stem cell house mouse CVCL_NI06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178792 CVCL_NI05 BayGenomics ES cell line RRO024 embryonic stem cell house mouse CVCL_NI05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178793 CVCL_F071 GM02175 finite cell line human CVCL_F071 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis Male 21178794 CVCL_NI04 BayGenomics ES cell line RRO023 embryonic stem cell house mouse CVCL_NI04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341865; Mark3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178795 CVCL_F070 GM02174 transformed cell line human CVCL_F070 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21178796 CVCL_NI03 BayGenomics ES cell line RRO022 embryonic stem cell house mouse CVCL_NI03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101917; Bcap29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178797 CVCL_NI02 BayGenomics ES cell line RRO020 embryonic stem cell house mouse CVCL_NI02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913677; Cyb5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178798 CVCL_NI23 BayGenomics ES cell line RRO068 embryonic stem cell house mouse CVCL_NI23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921269; Traf3ip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178799 CVCL_NI22 BayGenomics ES cell line RRO067 embryonic stem cell house mouse CVCL_NI22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930780; Myh10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178800 CVCL_NI21 BayGenomics ES cell line RRO063 embryonic stem cell house mouse CVCL_NI21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178801 CVCL_NI20 BayGenomics ES cell line RRO059 embryonic stem cell house mouse CVCL_NI20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387188; Slc49a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178802 CVCL_F086 ATH16BE finite cell line human CVCL_F086 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys2756Ter (c.8266A>T); ClinVar=VCV000135780; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178803 CVCL_F085 ATH15BE LCL transformed cell line human CVCL_F085 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser381Argfs*27 (c.1139_1142dupACAG) (c.1141_1142ins4); ClinVar=VCV000280044; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178804 CVCL_F084 ATH15BE finite cell line human CVCL_F084 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser381Argfs*27 (c.1139_1142dupACAG) (c.1141_1142ins4); ClinVar=VCV000280044; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178805 CVCL_F083 AT4BE finite cell line human CVCL_F083 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser381Argfs*27 (c.1139_1142dupACAG) (c.1141_1142ins4); ClinVar=VCV000280044; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys2756Ter (c.8266A>T); ClinVar=VCV000135780; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178806 CVCL_F089 GM03323 transformed cell line human CVCL_F089 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21178807 CVCL_F088 GM03492 finite cell line human CVCL_F088 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178808 CVCL_F087 ATH16BE LCL transformed cell line human CVCL_F087 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys2756Ter (c.8266A>T); ClinVar=VCV000135780; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21178809 CVCL_NI19 BayGenomics ES cell line RRO057 embryonic stem cell house mouse CVCL_NI19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387188; Slc49a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178810 CVCL_NI18 BayGenomics ES cell line RRO051 embryonic stem cell house mouse CVCL_NI18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355322; Exosc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178811 CVCL_NI17 BayGenomics ES cell line RRO050 embryonic stem cell house mouse CVCL_NI17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178812 CVCL_NI16 BayGenomics ES cell line RRO049 embryonic stem cell house mouse CVCL_NI16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914247; Psmd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178813 CVCL_F082 GM02825 transformed cell line human CVCL_F082 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala329Val (c.986C>T); ClinVar=VCV000001959; Zygosity=Heterozygous (PubMed=1346349); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.219-2A>G (IVS3-2A>G); ClinVar=VCV000001969; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178814 CVCL_NI15 BayGenomics ES cell line RRO045 embryonic stem cell house mouse CVCL_NI15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443472; Atf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178815 CVCL_F081 GM02530 finite cell line human CVCL_F081 CL:0000010 Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178816 CVCL_NI14 BayGenomics ES cell line RRO044 embryonic stem cell house mouse CVCL_NI14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98535; Tcp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178817 CVCL_F080 GM02531 finite cell line human CVCL_F080 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2251del19; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5675del88; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6573del81; Zygosity=Heterozygous (Coriell) Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178818 CVCL_NI13 BayGenomics ES cell line RRO034 embryonic stem cell house mouse CVCL_NI13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920538; Vps50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178819 CVCL_F059 GM02169 finite cell line human CVCL_F059 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21178820 CVCL_F058 GM02168 transformed cell line human CVCL_F058 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21178821 CVCL_F053 GM02189 finite cell line human CVCL_F053 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178822 CVCL_F052 GM02188 transformed cell line human CVCL_F052 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178823 CVCL_F051 GM02187 finite cell line human CVCL_F051 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178824 CVCL_F050 GM02186 transformed cell line human CVCL_F050 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178825 CVCL_F057 GM02165 finite cell line human CVCL_F057 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM02164); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[56] (c.52CAG(56)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM02164) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178826 CVCL_F056 GM02164 transformed cell line human CVCL_F056 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=32656337); Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[56] (c.52CAG(56)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=32656337) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178827 CVCL_F055 GM02167 finite cell line human CVCL_F055 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178828 CVCL_F054 GM02166 transformed cell line human CVCL_F054 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178829 CVCL_NI01 BayGenomics ES cell line RRO019 embryonic stem cell house mouse CVCL_NI01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918177; Setd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178830 CVCL_NI00 BayGenomics ES cell line RRO018 embryonic stem cell house mouse CVCL_NI00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933162; Lrba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178831 CVCL_F069 GM02153 finite cell line human CVCL_F069 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21178832 CVCL_F064 GM03116 finite cell line human CVCL_F064 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal kidney Cell type=Fibroblast.. Male 21178833 CVCL_F063 GM03621 finite cell line human CVCL_F063 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[70] (c.52CAG(70)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM03620) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178834 CVCL_F062 GM03620 transformed cell line human CVCL_F062 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[70] (c.52CAG(70)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=32656337) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178835 CVCL_F061 GM02177 finite cell line human CVCL_F061 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Huntington's disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21178836 CVCL_F068 GM02152 transformed cell line human CVCL_F068 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21178837 CVCL_F067 GM02706 finite cell line human CVCL_F067 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 21178838 CVCL_F066 GM02417 transformed cell line human CVCL_F066 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178839 CVCL_F065 GM03117 finite cell line human CVCL_F065 CL:0000010 Population: Caucasian; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21178840 CVCL_F060 GM02176 transformed cell line human CVCL_F060 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Huntington's disease but at significant risk for disease; Derived from sampling site: Peripheral blood. Male 21178841 CVCL_WB52 TLS-15 transformed cell line human CVCL_WB52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178842 CVCL_WB51 TLS-14 transformed cell line human CVCL_WB51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178843 CVCL_WB50 TLS-13 transformed cell line human CVCL_WB50 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178844 CVCL_WB56 TLS-19 transformed cell line human CVCL_WB56 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178845 CVCL_WB55 TLS-18 transformed cell line human CVCL_WB55 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21178846 CVCL_WB54 TLS-17 transformed cell line human CVCL_WB54 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178847 CVCL_WB53 TLS-16 transformed cell line human CVCL_WB53 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178848 CVCL_WB59 TLS-21 transformed cell line human CVCL_WB59 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178849 CVCL_WB58 TLS-20 transformed cell line human CVCL_WB58 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178850 CVCL_WB57 TLS-2 transformed cell line human CVCL_WB57 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178851 CVCL_WB41 HTD-16 transformed cell line human CVCL_WB41 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178852 CVCL_WB40 HTD-15 transformed cell line human CVCL_WB40 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178853 CVCL_WB45 MHFB-1 finite cell line human CVCL_WB45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21178854 CVCL_WB44 LNH-1 transformed cell line human CVCL_WB44 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178855 CVCL_WB43 HTD-18 transformed cell line human CVCL_WB43 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178856 CVCL_WB42 HTD-17 transformed cell line human CVCL_WB42 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178857 CVCL_WB49 TLS-12 transformed cell line human CVCL_WB49 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178858 CVCL_WB48 TLS-11 transformed cell line human CVCL_WB48 CL:0000010 Population: Iranian; Turk; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178859 CVCL_WB47 TLS-10 transformed cell line human CVCL_WB47 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178860 CVCL_WB46 TLS-1 transformed cell line human CVCL_WB46 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178861 CVCL_NH99 BayGenomics ES cell line RRO017 embryonic stem cell house mouse CVCL_NH99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109605; Srgap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178862 CVCL_NH98 BayGenomics ES cell line RRO016 embryonic stem cell house mouse CVCL_NH98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178863 CVCL_NH97 BayGenomics ES cell line RRO015 embryonic stem cell house mouse CVCL_NH97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858313; Uba2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178864 CVCL_NH96 BayGenomics ES cell line RRO014 embryonic stem cell house mouse CVCL_NH96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915010; Slc38a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178865 CVCL_NH95 BayGenomics ES cell line RRO013 embryonic stem cell house mouse CVCL_NH95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351623; Pald1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178866 CVCL_NH94 BayGenomics ES cell line RRO011 embryonic stem cell house mouse CVCL_NH94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178867 CVCL_NH93 BayGenomics ES cell line RRO010 embryonic stem cell house mouse CVCL_NH93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178868 CVCL_WB30 HTD-04 transformed cell line human CVCL_WB30 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178869 CVCL_NH92 BayGenomics ES cell line RRO007 embryonic stem cell house mouse CVCL_NH92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135962; Gorasp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178870 CVCL_NH91 BayGenomics ES cell line RRO005 embryonic stem cell house mouse CVCL_NH91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140991; Usp30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178871 CVCL_NH90 BayGenomics ES cell line RRO003 embryonic stem cell house mouse CVCL_NH90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178872 CVCL_WB34 HTD-09 transformed cell line human CVCL_WB34 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178873 CVCL_WB33 HTD-07 transformed cell line human CVCL_WB33 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178874 CVCL_WB32 HTD-06 transformed cell line human CVCL_WB32 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178875 CVCL_WB31 HTD-05 transformed cell line human CVCL_WB31 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178876 CVCL_WB38 HTD-13 transformed cell line human CVCL_WB38 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178877 CVCL_WB37 HTD-12 transformed cell line human CVCL_WB37 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178878 CVCL_WB36 HTD-11 transformed cell line human CVCL_WB36 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178879 CVCL_WB35 HTD-10 transformed cell line human CVCL_WB35 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178880 CVCL_WB39 HTD-14 transformed cell line human CVCL_WB39 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178881 CVCL_WB23 PK4A sg-PRODH1_clone9 cancer cell line house mouse CVCL_WB23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:97770; Prodh Breed/subspecies: Pdx1-Cre;Ink4a/Arffl/fl;LSL-KrasG12D transgenic. Male 21178882 CVCL_WB22 PK4A sg-PRODH1_clone3 cancer cell line house mouse CVCL_WB22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:97770; Prodh Breed/subspecies: Pdx1-Cre;Ink4a/Arffl/fl;LSL-KrasG12D transgenic. Male 21178883 CVCL_WB21 PK4A cancer cell line house mouse CVCL_WB21 CL:0000010 Miscellaneous: Doubling time and sex of donor from personal communication of Gouirand V Breed/subspecies: Pdx1-Cre;Ink4a/Arffl/fl;LSL-KrasG12D transgenic. Male Doubling time: ~24 hours (Direct_author_submission) 21178884 CVCL_WB20 CHOpper Standard spontaneously immortalized cell line CVCL_WB20 CL:0000010 Transfected with: UniProtKB; P04753; Cricetulus griseus Dhfr Derived from sampling site: Ovary. Female Doubling time: ~22 hours (Patent=US8962312) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2910 21178885 CVCL_WB27 HIgE-02 transformed cell line human CVCL_WB27 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178886 CVCL_WB26 HIgE-01 transformed cell line human CVCL_WB26 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178887 CVCL_WB25 HFM-02 finite cell line human CVCL_WB25 CL:0000010 Female 21178888 CVCL_WB24 HFM-01 finite cell line human CVCL_WB24 CL:0000010 Female 21178889 CVCL_WB29 HTD-03 transformed cell line human CVCL_WB29 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178890 CVCL_WB28 HTD-02 transformed cell line human CVCL_WB28 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178891 CVCL_NH79 BayGenomics ES cell line RRN374 embryonic stem cell house mouse CVCL_NH79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923809; Atg2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178892 CVCL_NH78 BayGenomics ES cell line RRN369 embryonic stem cell house mouse CVCL_NH78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178893 CVCL_NH77 BayGenomics ES cell line RRN367 embryonic stem cell house mouse CVCL_NH77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353448; Eif2ak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178894 CVCL_NH76 BayGenomics ES cell line RRN366 embryonic stem cell house mouse CVCL_NH76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346881; Map3k12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178895 CVCL_NH75 BayGenomics ES cell line RRN360 embryonic stem cell house mouse CVCL_NH75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916417; Ppp1r12b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178896 CVCL_NH74 BayGenomics ES cell line RRN357 embryonic stem cell house mouse CVCL_NH74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444691; Tfcp2l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178897 CVCL_NH73 BayGenomics ES cell line RRN351 embryonic stem cell house mouse CVCL_NH73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96952; Mdm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178898 CVCL_NH72 BayGenomics ES cell line RRN350 embryonic stem cell house mouse CVCL_NH72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349400; Cops7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178899 CVCL_NH71 BayGenomics ES cell line RRN348 embryonic stem cell house mouse CVCL_NH71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178900 CVCL_NH70 BayGenomics ES cell line RRN346 embryonic stem cell house mouse CVCL_NH70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922144; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178901 CVCL_WB12 SMA-06 transformed cell line human CVCL_WB12 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178902 CVCL_WB11 SMA-05 transformed cell line human CVCL_WB11 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178903 CVCL_WB10 SMA-04 transformed cell line human CVCL_WB10 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178904 CVCL_WB16 CS2-2 spontaneously immortalized cell line CVCL_WB16 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21178905 CVCL_WB15 CS2-1 spontaneously immortalized cell line CVCL_WB15 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21178906 CVCL_WB14 ZWG2-Fib finite cell line human CVCL_WB14 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21178907 CVCL_WB13 ZWG1-Fib finite cell line human CVCL_WB13 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21178908 CVCL_WB19 CHOpper Discovery spontaneously immortalized cell line CVCL_WB19 CL:0000010 Transfected with: UniProtKB; P04753; Cricetulus griseus Dhfr Derived from sampling site: Ovary. Female Doubling time: ~17 hours (Patent=US8962312) Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2909 21178909 CVCL_WB18 WEHI-3B* cancer cell line house mouse CVCL_WB18 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male Characteristics: Adapted to growth in DMEM medium 21178910 CVCL_WB17 CS-e spontaneously immortalized cell line CVCL_WB17 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21178911 CVCL_NH69 BayGenomics ES cell line RRN343 embryonic stem cell house mouse CVCL_NH69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913755; Zmynd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178912 CVCL_NH89 BayGenomics ES cell line RRO002 embryonic stem cell house mouse CVCL_NH89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178913 CVCL_NH88 BayGenomics ES cell line RRN407 embryonic stem cell house mouse CVCL_NH88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3697726; Arhgap23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178914 CVCL_NH87 BayGenomics ES cell line RRN401 embryonic stem cell house mouse CVCL_NH87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109352; Ung Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178915 CVCL_NH86 BayGenomics ES cell line RRN400 embryonic stem cell house mouse CVCL_NH86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353510; Arhgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178916 CVCL_NH85 BayGenomics ES cell line RRN391 embryonic stem cell house mouse CVCL_NH85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106913; Abi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178917 CVCL_NH84 BayGenomics ES cell line RRN389 embryonic stem cell house mouse CVCL_NH84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924750; Ppfia1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178918 CVCL_NH83 BayGenomics ES cell line RRN388 embryonic stem cell house mouse CVCL_NH83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3708729; Rnps1-ps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178919 CVCL_NH82 BayGenomics ES cell line RRN384 embryonic stem cell house mouse CVCL_NH82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341788; Pdcd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178920 CVCL_NH81 BayGenomics ES cell line RRN378 embryonic stem cell house mouse CVCL_NH81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107726; Supt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178921 CVCL_NH80 BayGenomics ES cell line RRN376 embryonic stem cell house mouse CVCL_NH80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178922 CVCL_WB01 NiPCK-1 transformed cell line human CVCL_WB01 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178923 CVCL_WB00 MPS-1 transformed cell line human CVCL_WB00 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178924 CVCL_WB05 SCID-01 transformed cell line human CVCL_WB05 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178925 CVCL_WB04 PDA-01 transformed cell line human CVCL_WB04 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178926 CVCL_WB03 NTP-02 transformed cell line human CVCL_WB03 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178927 CVCL_WB02 NTP-01 transformed cell line human CVCL_WB02 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178928 CVCL_WB09 SMA-03 transformed cell line human CVCL_WB09 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178929 CVCL_WB08 SMA-02 transformed cell line human CVCL_WB08 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178930 CVCL_WB07 SMA-01 transformed cell line human CVCL_WB07 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178931 CVCL_WB06 SCID-03 transformed cell line human CVCL_WB06 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178932 CVCL_NH57 BayGenomics ES cell line RRN310 embryonic stem cell house mouse CVCL_NH57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178933 CVCL_NH56 BayGenomics ES cell line RRN308 embryonic stem cell house mouse CVCL_NH56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918767; Vps35l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178934 CVCL_NH55 BayGenomics ES cell line RRN307 embryonic stem cell house mouse CVCL_NH55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921701; Pgs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178935 CVCL_NH54 BayGenomics ES cell line RRN306 embryonic stem cell house mouse CVCL_NH54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178936 CVCL_NH53 BayGenomics ES cell line RRN303 embryonic stem cell house mouse CVCL_NH53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922945; Rilpl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178937 CVCL_NH52 BayGenomics ES cell line RRN298 embryonic stem cell house mouse CVCL_NH52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178938 CVCL_NH51 BayGenomics ES cell line RRN296 embryonic stem cell house mouse CVCL_NH51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924059; Bri3bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178939 CVCL_NH50 BayGenomics ES cell line RRN295 embryonic stem cell house mouse CVCL_NH50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101898; Pou2f1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178940 CVCL_NH49 BayGenomics ES cell line RRN293 embryonic stem cell house mouse CVCL_NH49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921346; Hvcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178941 CVCL_NH48 BayGenomics ES cell line RRN291 embryonic stem cell house mouse CVCL_NH48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178942 CVCL_NH47 BayGenomics ES cell line RRN290 embryonic stem cell house mouse CVCL_NH47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178943 CVCL_NH68 BayGenomics ES cell line RRN341 embryonic stem cell house mouse CVCL_NH68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144475; Usp32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178944 CVCL_NH67 BayGenomics ES cell line RRN339 embryonic stem cell house mouse CVCL_NH67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178945 CVCL_NH66 BayGenomics ES cell line RRN333 embryonic stem cell house mouse CVCL_NH66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354721; Slc25a13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178946 CVCL_NH65 BayGenomics ES cell line RRN332 embryonic stem cell house mouse CVCL_NH65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178947 CVCL_NH64 BayGenomics ES cell line RRN331 embryonic stem cell house mouse CVCL_NH64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914345; Trak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178948 CVCL_NH63 BayGenomics ES cell line RRN322 embryonic stem cell house mouse CVCL_NH63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102705; Gng2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178949 CVCL_NH62 BayGenomics ES cell line RRN319 embryonic stem cell house mouse CVCL_NH62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88039; Apc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178950 CVCL_NH61 BayGenomics ES cell line RRN317 embryonic stem cell house mouse CVCL_NH61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933532; Slc12a9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178951 CVCL_NH60 BayGenomics ES cell line RRN315 embryonic stem cell house mouse CVCL_NH60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929074; Rev1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178952 CVCL_NH59 BayGenomics ES cell line RRN312 embryonic stem cell house mouse CVCL_NH59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289326; Gpn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178953 CVCL_NH58 BayGenomics ES cell line RRN311 embryonic stem cell house mouse CVCL_NH58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107158; Sin3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21178954 CVCL_WB92 TLS-51 transformed cell line human CVCL_WB92 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178955 CVCL_WB91 TLS-50 transformed cell line human CVCL_WB91 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178956 CVCL_WB90 TLS-5 transformed cell line human CVCL_WB90 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178957 CVCL_WB96 TLS-55 transformed cell line human CVCL_WB96 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178958 CVCL_WB95 TLS-54 transformed cell line human CVCL_WB95 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178959 CVCL_WB94 TLS-53 transformed cell line human CVCL_WB94 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178960 CVCL_WB93 TLS-52 transformed cell line human CVCL_WB93 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178961 CVCL_WB99 TLS-58 transformed cell line human CVCL_WB99 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178962 CVCL_WB98 TLS-57 transformed cell line human CVCL_WB98 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178963 CVCL_WB97 TLS-56 transformed cell line human CVCL_WB97 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178964 CVCL_WB81 TLS-41 transformed cell line human CVCL_WB81 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178965 CVCL_WB80 TLS-40 transformed cell line human CVCL_WB80 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178966 CVCL_WB85 TLS-45 transformed cell line human CVCL_WB85 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178967 CVCL_WB84 TLS-44 transformed cell line human CVCL_WB84 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178968 CVCL_WB83 TLS-43 transformed cell line human CVCL_WB83 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178969 CVCL_WB82 TLS-42 transformed cell line human CVCL_WB82 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178970 CVCL_WB89 TLS-49 transformed cell line human CVCL_WB89 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178971 CVCL_WB88 TLS-48 transformed cell line human CVCL_WB88 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178972 CVCL_WB87 TLS-47 transformed cell line human CVCL_WB87 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178973 CVCL_WB86 TLS-46 transformed cell line human CVCL_WB86 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178974 CVCL_WB70 TLS-31 transformed cell line human CVCL_WB70 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178975 CVCL_WB74 TLS-35 transformed cell line human CVCL_WB74 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178976 CVCL_WB73 TLS-34 transformed cell line human CVCL_WB73 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178977 CVCL_WB72 TLS-33 transformed cell line human CVCL_WB72 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178978 CVCL_WB71 TLS-32 transformed cell line human CVCL_WB71 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178979 CVCL_WB78 TLS-39 transformed cell line human CVCL_WB78 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178980 CVCL_WB77 TLS-38 transformed cell line human CVCL_WB77 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178981 CVCL_WB76 TLS-37 transformed cell line human CVCL_WB76 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178982 CVCL_WB75 TLS-36 transformed cell line human CVCL_WB75 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178983 CVCL_WB79 TLS-4 transformed cell line human CVCL_WB79 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178984 CVCL_WB63 TLS-25 transformed cell line human CVCL_WB63 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178985 CVCL_WB62 TLS-24 transformed cell line human CVCL_WB62 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178986 CVCL_WB61 TLS-23 transformed cell line human CVCL_WB61 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178987 CVCL_WB60 TLS-22 transformed cell line human CVCL_WB60 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178988 CVCL_WB67 TLS-29 transformed cell line human CVCL_WB67 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178989 CVCL_WB66 TLS-28 transformed cell line human CVCL_WB66 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178990 CVCL_WB65 TLS-27 transformed cell line human CVCL_WB65 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178991 CVCL_WB64 TLS-26 transformed cell line human CVCL_WB64 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178992 CVCL_WB69 TLS-30 transformed cell line human CVCL_WB69 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178993 CVCL_WB68 TLS-3 transformed cell line human CVCL_WB68 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178994 CVCL_F159 GM12495 transformed cell line human CVCL_F159 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21178995 CVCL_EP59 UCSD216i-114-1 induced pluripotent stem cell human CVCL_EP59 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178996 CVCL_F158 GM12494 transformed cell line human CVCL_F158 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21178997 CVCL_EP58 UCSD215i-113-1 induced pluripotent stem cell human CVCL_EP58 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21178998 CVCL_F157 GM12583 finite cell line human CVCL_F157 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21178999 CVCL_EP57 UCSD214i-14-2 induced pluripotent stem cell human CVCL_EP57 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from dizygotic twin of UCSD213i-14-1 (Cellosaurus=CVCL_EP56); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179000 CVCL_F152 GM08668 transformed cell line human CVCL_F152 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179001 CVCL_EP52 UCSD209i-24-1 induced pluripotent stem cell human CVCL_EP52 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179002 CVCL_F151 GM10925 transformed cell line human CVCL_F151 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21179003 CVCL_EP51 UCSD208i-111-1 induced pluripotent stem cell human CVCL_EP51 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179004 CVCL_F150 GM10905 finite cell line human CVCL_F150 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (PubMed=10767341) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179005 CVCL_EP50 UCSD207i-31-2 induced pluripotent stem cell human CVCL_EP50 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD206i-31-1 (Cellosaurus=CVCL_EP49); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179006 CVCL_F156 GM11972 transformed cell line human CVCL_F156 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179007 CVCL_EP56 UCSD213i-14-1 induced pluripotent stem cell human CVCL_EP56 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from dizygotic twin of UCSD214i-14-2 (Cellosaurus=CVCL_EP57); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179008 CVCL_F155 GM11971 transformed cell line human CVCL_F155 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179009 CVCL_EP55 UCSD212i-32-2 induced pluripotent stem cell human CVCL_EP55 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from dizygotic twin of UCSD211i-32-1 (Cellosaurus=CVCL_EP54); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179010 CVCL_F154 GM08670 transformed cell line human CVCL_F154 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179011 CVCL_EP54 UCSD211i-32-1 induced pluripotent stem cell human CVCL_EP54 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from dizygotic twin of UCSD212i-32-2 (Cellosaurus=CVCL_EP55); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179012 CVCL_F153 GM08669 transformed cell line human CVCL_F153 HLA typing: A*02:01:01,31:01:02; B*39:06:02,56:01:01; C*01:02:01,07:612; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*01:01:01,03:01:01; DQB1*03:02:01,05:01:01; DRB1*01:01:01,04:01:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Lys281del (c.841_843delAAG) (2613_2615delAGA); ClinVar=VCV000039396; Zygosity=Heterozygous; Note=CYP2D6*9 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179013 CVCL_EP53 UCSD210i-112-1 induced pluripotent stem cell human CVCL_EP53 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179014 CVCL_NJ00 BayGenomics ES cell line RRO224 embryonic stem cell house mouse CVCL_NJ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196277; Tmem201 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179015 CVCL_F169 GM23225 induced pluripotent stem cell human CVCL_F169 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21179016 CVCL_EP69 mHypoA-POMC/GFP-4 transformed cell line house mouse CVCL_EP69 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6J-Tg(Pomc-EGFP)1Low/J. Male 21179017 CVCL_F168 GM23391 transformed cell line human CVCL_F168 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~170-180] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; English/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179018 CVCL_EP68 mHypoA-POMC/GFP-3 transformed cell line house mouse CVCL_EP68 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6J-Tg(Pomc-EGFP)1Low/J. Male 21179019 CVCL_F163 GM07533 transformed cell line human CVCL_F163 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179020 CVCL_EP63 UCSD220i-118-1 induced pluripotent stem cell human CVCL_EP63 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179021 CVCL_F162 GM07522 finite cell line human CVCL_F162 CL:0000010 Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Arg296Cys (c.886C>T); ClinVar=VCV000242771; Zygosity=Heterozygous; Note=CYP2D6*2 allele (from autologous cell line GM07521); Sequence variation: Mutation; HGNC; 2625; CYP2D6; Simple; p.Ser486Thr (c.1457G>C); ClinVar=VCV000242701; Zygosity=Heterozygous; Note=CYP2D6*2 allele (from autologous cell line GM07521) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21179022 CVCL_EP62 UCSD219i-117-1 induced pluripotent stem cell human CVCL_EP62 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179023 CVCL_F161 GM14447 transformed cell line human CVCL_F161 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14448 (Cellosaurus=CVCL_7553); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21179024 CVCL_EP61 UCSD218i-116-1 induced pluripotent stem cell human CVCL_EP61 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179025 CVCL_F160 GM12496 transformed cell line human CVCL_F160 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179026 CVCL_EP60 UCSD217i-115-1 induced pluripotent stem cell human CVCL_EP60 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179027 CVCL_F167 GM23392 induced pluripotent stem cell human CVCL_F167 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CNV analysis Male 21179028 CVCL_EP67 mHypoA-POMC/GFP-2 transformed cell line house mouse CVCL_EP67 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6J-Tg(Pomc-EGFP)1Low/J. Male 21179029 CVCL_F166 GM23394 induced pluripotent stem cell human CVCL_F166 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: Coriell; GM23394; probable Male 21179030 CVCL_EP66 mHypoA-POMC/GFP-1 transformed cell line house mouse CVCL_EP66 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6J-Tg(Pomc-EGFP)1Low/J. Male 21179031 CVCL_F165 GM07545 finite cell line human CVCL_F165 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21179032 CVCL_EP65 UCSD222i-120-1 induced pluripotent stem cell human CVCL_EP65 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179033 CVCL_F164 GM07555 transformed cell line human CVCL_F164 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179034 CVCL_EP64 UCSD221i-119-1 induced pluripotent stem cell human CVCL_EP64 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179035 CVCL_F138 GM06867 transformed cell line human CVCL_F138 HLA typing: A*02:01:01,02:01:01; B*15:17:01,44:02:01; C*05:01:01,07:01:02; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01; DRB3*03:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179036 CVCL_EP38 UCSD195i-29-2 induced pluripotent stem cell human CVCL_EP38 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD194i-29-1 (Cellosaurus=CVCL_EP37); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179037 CVCL_F137 GM06316 transformed cell line human CVCL_F137 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179038 CVCL_EP37 UCSD194i-29-1 induced pluripotent stem cell human CVCL_EP37 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD195i-29-2 (Cellosaurus=CVCL_EP38); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179039 CVCL_F136 GM06171 finite cell line human CVCL_F136 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21179040 CVCL_EP36 UCSD193i-106-1 induced pluripotent stem cell human CVCL_EP36 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179041 CVCL_F135 GM04502 finite cell line human CVCL_F135 CL:0000010 Donor information: Established from monozygotic twin of GM04501 (Cellosaurus=CVCL_7409); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM04502; probable Male 21179042 CVCL_EP35 UCSD192i-13-2 induced pluripotent stem cell human CVCL_EP35 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD191i-13-1 (Cellosaurus=CVCL_EP34); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179043 CVCL_F139 GM07008 transformed cell line human CVCL_F139 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134005 21179044 CVCL_EP39 UCSD196i-30-1 induced pluripotent stem cell human CVCL_EP39 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD197i-30-2 (Cellosaurus=CVCL_EP40); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179045 CVCL_F130 GM01484 transformed cell line human CVCL_F130 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; AG01484; probable Female 21179046 CVCL_EP30 UCSD187i-104-1 induced pluripotent stem cell human CVCL_EP30 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179047 CVCL_F134 GM06113 finite cell line human CVCL_F134 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179048 CVCL_EP34 UCSD191i-13-1 induced pluripotent stem cell human CVCL_EP34 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD192i-13-2 (Cellosaurus=CVCL_EP35); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179049 CVCL_F133 GM05748 transformed cell line human CVCL_F133 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179050 CVCL_EP33 UCSD190i-28-2 induced pluripotent stem cell human CVCL_EP33 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD189i-28-1 (Cellosaurus=CVCL_EP32); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179051 CVCL_F132 GM06914 transformed cell line human CVCL_F132 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Male 21179052 CVCL_EP32 UCSD189i-28-1 induced pluripotent stem cell human CVCL_EP32 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD190i-28-2 (Cellosaurus=CVCL_EP33); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179053 CVCL_F131 GM01309 finite cell line human CVCL_F131 CL:0000010 Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Male 21179054 CVCL_EP31 UCSD188i-105-1 induced pluripotent stem cell human CVCL_EP31 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179055 CVCL_F149 GM10904 transformed cell line human CVCL_F149 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179056 CVCL_EP49 UCSD206i-31-1 induced pluripotent stem cell human CVCL_EP49 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD207i-31-2 (Cellosaurus=CVCL_EP50); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179057 CVCL_F148 GM10901 finite cell line human CVCL_F148 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Heterozygous (from familial inference of GM10903 and GM10905) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179058 CVCL_EP48 UCSD205i-110-1 induced pluripotent stem cell human CVCL_EP48 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179059 CVCL_F147 GM10900 transformed cell line human CVCL_F147 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Heterozygous (from familial inference of GM10903 and GM10905) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179060 CVCL_EP47 UCSD204i-26-1 induced pluripotent stem cell human CVCL_EP47 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179061 CVCL_F146 GM10903 finite cell line human CVCL_F146 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (PubMed=10767341) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179062 CVCL_EP46 UCSD203i-109-1 induced pluripotent stem cell human CVCL_EP46 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179063 CVCL_F141 GM07040 transformed cell line human CVCL_F141 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134006 21179064 CVCL_EP41 UCSD198i-23-1 induced pluripotent stem cell human CVCL_EP41 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179065 CVCL_F140 GM07027 transformed cell line human CVCL_F140 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134008 21179066 CVCL_EP40 UCSD197i-30-2 induced pluripotent stem cell human CVCL_EP40 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD196i-30-1 (Cellosaurus=CVCL_EP39); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179067 CVCL_F145 GM07491 transformed cell line human CVCL_F145 HLA typing: A*32:01:01,33:01:01; B*14:02:01,44:02:01; C*05:01:01,08:02:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*01:01:01,01:01:02; DQB1*05:01:01,05:01:01; DRB1*01:01:01,01:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179068 CVCL_EP45 UCSD202i-108-1 induced pluripotent stem cell human CVCL_EP45 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179069 CVCL_F144 GM07078 transformed cell line human CVCL_F144 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179070 CVCL_EP44 UCSD201i-4-2 induced pluripotent stem cell human CVCL_EP44 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Donor information: Established from monozygotic twin of UCSD200i-4-1 (Cellosaurus=CVCL_EP43); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179071 CVCL_F143 GM07062 transformed cell line human CVCL_F143 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134003 21179072 CVCL_EP43 UCSD200i-4-1 induced pluripotent stem cell human CVCL_EP43 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Donor information: Established from monozygotic twin of UCSD201i-4-2 (Cellosaurus=CVCL_EP44); Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179073 CVCL_F142 GM07053 transformed cell line human CVCL_F142 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134004 21179074 CVCL_EP42 UCSD199i-107-1 induced pluripotent stem cell human CVCL_EP42 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179075 CVCL_F116 GM05090 transformed cell line human CVCL_F116 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-5del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21179076 CVCL_EP16 UCSD173i-18-1 induced pluripotent stem cell human CVCL_EP16 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179077 CVCL_F115 GM04664 finite cell line human CVCL_F115 CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference of GM04663) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179078 CVCL_EP15 UCSD172i-101-1 induced pluripotent stem cell human CVCL_EP15 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179079 CVCL_F114 GM03498 finite cell line human CVCL_F114 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Gly (c.3163T>G); Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; English and Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 87(AlFra) (BSR87); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male Caution: Coriell has p.Cys1055fs*23 (c.3159delT) (3233delT) as the second mutation for this cell line 21179080 CVCL_EP14 UCSD171i-100-1 induced pluripotent stem cell human CVCL_EP14 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179081 CVCL_F113 GM04282 transformed cell line human CVCL_F113 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line GM04281) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Venezuelan Huntington disease kindreds subcollection 21179082 CVCL_EP13 UCSD170i-22-3 induced pluripotent stem cell human CVCL_EP13 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179083 CVCL_F119 XP12BE finite cell line human CVCL_F119 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-1G>T (IVS3-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=8595429; PubMed=9671271); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell; PubMed=9671271) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1223; true Female 21179084 CVCL_EP19 UCSD176i-17-1 induced pluripotent stem cell human CVCL_EP19 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179085 CVCL_F118 XP12BESV transformed cell line human CVCL_F118 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-1G>T (IVS3-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179086 CVCL_EP18 UCSD175i-18-3 induced pluripotent stem cell human CVCL_EP18 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179087 CVCL_F117 XP12BE LCL transformed cell line human CVCL_F117 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.507-1G>T (IVS3-1G>T); Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln185His (c.555G>C); ClinVar=VCV000550646; Zygosity=Heterozygous; Note=Also produces mis-splicing (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179088 CVCL_EP17 UCSD174i-18-2 induced pluripotent stem cell human CVCL_EP17 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179089 CVCL_F112 GM04034 transformed cell line human CVCL_F112 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179090 CVCL_EP12 UCSD169i-22-2 induced pluripotent stem cell human CVCL_EP12 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179091 CVCL_F111 GM03986 transformed cell line human CVCL_F111 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179092 CVCL_EP11 UCSD168i-22-1 induced pluripotent stem cell human CVCL_EP11 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179093 CVCL_F110 GM23251 finite cell line human CVCL_F110 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Personal Genome Project (PGP) cell line collection 21179094 CVCL_EP10 UCSD167i-99-1 induced pluripotent stem cell human CVCL_EP10 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179095 CVCL_F127 GM02063 finite cell line human CVCL_F127 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00177; probable; Discontinued: Coriell; GM02063; probable Male 21179096 CVCL_EP27 UCSD184i-8-1 induced pluripotent stem cell human CVCL_EP27 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD185i-8-2 (Cellosaurus=CVCL_EP28); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179097 CVCL_F126 GM13136 transformed cell line human CVCL_F126 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179098 CVCL_EP26 UCSD183i-102-1 induced pluripotent stem cell human CVCL_EP26 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179099 CVCL_F125 GM00449 finite cell line human CVCL_F125 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21179100 CVCL_EP25 UCSD182i-3-2 induced pluripotent stem cell human CVCL_EP25 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD181i-3-1 (Cellosaurus=CVCL_EP24); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179101 CVCL_F124 GM04409 finite cell line human CVCL_F124 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21179102 CVCL_EP24 UCSD181i-3-1 induced pluripotent stem cell human CVCL_EP24 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD182i-3-2 (Cellosaurus=CVCL_EP25); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179103 CVCL_F129 GM01142 finite cell line human CVCL_F129 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Discontinued: Coriell; AG01142; probable Female 21179104 CVCL_EP29 UCSD186i-103-1 induced pluripotent stem cell human CVCL_EP29 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179105 CVCL_F128 GM03022 transformed cell line human CVCL_F128 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03022; probable Female 21179106 CVCL_EP28 UCSD185i-8-2 induced pluripotent stem cell human CVCL_EP28 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of UCSD184i-8-1 (Cellosaurus=CVCL_EP27); Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179107 CVCL_F123 FPBH cancer cell line human CVCL_F123 From: Vetterlein M.; Institute of Tumour Biology and Cancer Research, University of Vienna; Vienna; Austria CL:0000010 Derived from metastatic site: Not specified. Unspecified 21179108 CVCL_EP23 UCSD180i-27-2 induced pluripotent stem cell human CVCL_EP23 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179109 CVCL_F122 SAL2 cancer cell line human CVCL_F122 CL:0000010 Female 21179110 CVCL_EP22 UCSD179i-27-1 induced pluripotent stem cell human CVCL_EP22 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179111 CVCL_F121 Su Mor finite cell line human CVCL_F121 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1150; true Female 21179112 CVCL_EP21 UCSD178i-17-3 induced pluripotent stem cell human CVCL_EP21 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian and Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179113 CVCL_F120 Es Ke finite cell line human CVCL_F120 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1299; true; Discontinued: ATCC; CRL-1409; true Male 21179114 CVCL_EP20 UCSD177i-17-2 induced pluripotent stem cell human CVCL_EP20 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179115 CVCL_F105 GM19999 transformed cell line human CVCL_F105 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21179116 CVCL_EP05 UCSD162i-94-1 induced pluripotent stem cell human CVCL_EP05 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179117 CVCL_F104 GM19988 transformed cell line human CVCL_F104 CL:0000010 Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Ser171Phe (c.512C>T); ClinVar=VCV000004339; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3258; EIF2B2; Simple; p.Met203Trpfs*2 (c.607_612delATGGCTinsTG); ClinVar=VCV000004340; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179118 CVCL_EP04 UCSD161i-93-1 induced pluripotent stem cell human CVCL_EP04 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179119 CVCL_F103 GM19978 transformed cell line human CVCL_F103 CL:0000010 Sequence variation: Mutation; HGNC; 14234; NSD1; Simple; p.Arg2005Gln (c.6014G>A); ClinVar=VCV000159395; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179120 CVCL_EP03 UCSD160i-92-1 induced pluripotent stem cell human CVCL_EP03 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179121 CVCL_F102 GM19977 transformed cell line human CVCL_F102 CL:0000010 Sequence variation: Mutation; HGNC; 14234; NSD1; Simple; p.Lys2151Glnfs*15 (c.6450dupC) (c.6450-1insC); ClinVar=VCV000004141; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179122 CVCL_EP02 UCSD159i-91-1 induced pluripotent stem cell human CVCL_EP02 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179123 CVCL_F109 GM21877 finite cell line human CVCL_F109 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21179124 CVCL_EP09 UCSD166i-98-1 induced pluripotent stem cell human CVCL_EP09 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179125 CVCL_F108 GM03470 transformed cell line human CVCL_F108 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21179126 CVCL_EP08 UCSD165i-97-1 induced pluripotent stem cell human CVCL_EP08 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179127 CVCL_F107 GM03382 transformed cell line human CVCL_F107 HLA typing: A*30:02,74:AB; B*39:10,53:01; C*04:KBG,12:03 (IPD-IMGT/HLA=15334) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2638Ter (c.7913G>A); ClinVar=VCV000141233; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: SNP array analysis Male Part of: Human variation panel 21179128 CVCL_EP07 UCSD164i-96-1 induced pluripotent stem cell human CVCL_EP07 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179129 CVCL_F106 GM19192 transformed cell line human CVCL_F106 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21179130 CVCL_EP06 UCSD163i-95-1 induced pluripotent stem cell human CVCL_EP06 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179131 CVCL_F101 GM19976 transformed cell line human CVCL_F101 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179132 CVCL_EP01 UCSD158i-12-4 induced pluripotent stem cell human CVCL_EP01 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179133 CVCL_F100 GM19975 transformed cell line human CVCL_F100 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179134 CVCL_EP00 UCSD157i-12-3 induced pluripotent stem cell human CVCL_EP00 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21179135 CVCL_NJ77 BayGenomics ES cell line RRO514 embryonic stem cell house mouse CVCL_NJ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446235; Zfp940 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179136 CVCL_NJ76 BayGenomics ES cell line RRO513 embryonic stem cell house mouse CVCL_NJ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442456; Unk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179137 CVCL_NJ75 BayGenomics ES cell line RRO507 embryonic stem cell house mouse CVCL_NJ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179138 CVCL_NJ74 BayGenomics ES cell line RRO505 embryonic stem cell house mouse CVCL_NJ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921807; Ppp6r3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179139 CVCL_NJ73 BayGenomics ES cell line RRO504 embryonic stem cell house mouse CVCL_NJ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929699; Arl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179140 CVCL_NJ72 BayGenomics ES cell line RRO502 embryonic stem cell house mouse CVCL_NJ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179141 CVCL_NJ71 BayGenomics ES cell line RRO489 embryonic stem cell house mouse CVCL_NJ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930618; Krit1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179142 CVCL_NJ70 BayGenomics ES cell line RRO488 embryonic stem cell house mouse CVCL_NJ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923760; Trappc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179143 CVCL_WD10 DPS-6 somatic stem cell human CVCL_WD10 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21179144 CVCL_WD14 hCF finite cell line human CVCL_WD14 CL:0000010 Population: Iranian; Derived from sampling site: Eye; cornea Cell type=Fibroblast.. Male 21179145 CVCL_WD13 DPS-9 somatic stem cell human CVCL_WD13 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179146 CVCL_WD12 DPS-8 somatic stem cell human CVCL_WD12 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179147 CVCL_WD11 DPS-7 somatic stem cell human CVCL_WD11 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179148 CVCL_WD18 SXR-04 transformed cell line human CVCL_WD18 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179149 CVCL_WD17 SXR-03 transformed cell line human CVCL_WD17 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179150 CVCL_WD16 SXR-02 transformed cell line human CVCL_WD16 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179151 CVCL_WD15 SXR-01 transformed cell line human CVCL_WD15 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179152 CVCL_WD19 TSCC-1 cancer cell line human CVCL_WD19 CL:0000010 Female 21179153 CVCL_NJ69 BayGenomics ES cell line RRO482 embryonic stem cell house mouse CVCL_NJ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890695; Rab9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179154 CVCL_NJ68 BayGenomics ES cell line RRO462 embryonic stem cell house mouse CVCL_NJ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179155 CVCL_NJ67 BayGenomics ES cell line RRO456 embryonic stem cell house mouse CVCL_NJ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914446; Ube2t Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179156 CVCL_NJ88 BayGenomics ES cell line RRO550 embryonic stem cell house mouse CVCL_NJ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859150; Akap7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179157 CVCL_NJ87 BayGenomics ES cell line RRO547 embryonic stem cell house mouse CVCL_NJ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3045391; Lin52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179158 CVCL_NJ86 BayGenomics ES cell line RRO546 embryonic stem cell house mouse CVCL_NJ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919283; Tsc22d2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179159 CVCL_NJ85 BayGenomics ES cell line RRO531 embryonic stem cell house mouse CVCL_NJ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442833; Bbs9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179160 CVCL_NJ84 BayGenomics ES cell line RRO529 embryonic stem cell house mouse CVCL_NJ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179161 CVCL_NJ83 BayGenomics ES cell line RRO524 embryonic stem cell house mouse CVCL_NJ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442372; Fam168a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179162 CVCL_NJ82 BayGenomics ES cell line RRO522 embryonic stem cell house mouse CVCL_NJ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179163 CVCL_NJ81 BayGenomics ES cell line RRO520 embryonic stem cell house mouse CVCL_NJ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914643; Cxxc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179164 CVCL_NJ80 BayGenomics ES cell line RRO517 embryonic stem cell house mouse CVCL_NJ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919782; Sap130 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179165 CVCL_WD03 DPS-10 somatic stem cell human CVCL_WD03 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179166 CVCL_WD02 DPS-1 somatic stem cell human CVCL_WD02 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179167 CVCL_WD01 XP3KA(L) transformed cell line human CVCL_WD01 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179168 CVCL_WD00 AP37P(L) transformed cell line human CVCL_WD00 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys2729Asn (c.8187G>T) (8415G>T); ClinVar=VCV000038142; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser2835Ter (c.8504C>G) (8732C>A); ClinVar=VCV000267091; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179169 CVCL_WD07 DPS-2 somatic stem cell human CVCL_WD07 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179170 CVCL_WD06 DPS-13 somatic stem cell human CVCL_WD06 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21179171 CVCL_WD05 DPS-12 somatic stem cell human CVCL_WD05 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21179172 CVCL_WD04 DPS-11 somatic stem cell human CVCL_WD04 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179173 CVCL_WD09 DPS-4 somatic stem cell human CVCL_WD09 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179174 CVCL_WD08 DPS-3 somatic stem cell human CVCL_WD08 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male 21179175 CVCL_NJ79 BayGenomics ES cell line RRO516 embryonic stem cell house mouse CVCL_NJ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261827; Dnmt3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179176 CVCL_NJ78 BayGenomics ES cell line RRO515 embryonic stem cell house mouse CVCL_NJ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179177 CVCL_NJ55 BayGenomics ES cell line RRO403 embryonic stem cell house mouse CVCL_NJ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261910; Pibf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179178 CVCL_NJ54 BayGenomics ES cell line RRO390 embryonic stem cell house mouse CVCL_NJ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152345; Taf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179179 CVCL_NJ53 BayGenomics ES cell line RRO389 embryonic stem cell house mouse CVCL_NJ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139395; Golga2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179180 CVCL_NJ52 BayGenomics ES cell line RRO384 embryonic stem cell house mouse CVCL_NJ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106582; Rfx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179181 CVCL_NJ51 BayGenomics ES cell line RRO380 embryonic stem cell house mouse CVCL_NJ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384993; Paip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179182 CVCL_NJ50 BayGenomics ES cell line RRO378 embryonic stem cell house mouse CVCL_NJ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858216; Ube2k Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179183 CVCL_NJ49 BayGenomics ES cell line RRO369 embryonic stem cell house mouse CVCL_NJ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138391; Pid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179184 CVCL_NJ48 BayGenomics ES cell line RRO367 embryonic stem cell house mouse CVCL_NJ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88190; Braf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179185 CVCL_NJ47 BayGenomics ES cell line RRO360 embryonic stem cell house mouse CVCL_NJ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179186 CVCL_NJ46 BayGenomics ES cell line RRO359 embryonic stem cell house mouse CVCL_NJ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347064; Med21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179187 CVCL_NJ45 BayGenomics ES cell line RRO357 embryonic stem cell house mouse CVCL_NJ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890564; Rcan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179188 CVCL_NJ66 BayGenomics ES cell line RRO449 embryonic stem cell house mouse CVCL_NJ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347094; Parg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179189 CVCL_NJ65 BayGenomics ES cell line RRO448 embryonic stem cell house mouse CVCL_NJ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921004; Thap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179190 CVCL_NJ64 BayGenomics ES cell line RRO443 embryonic stem cell house mouse CVCL_NJ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179191 CVCL_NJ63 BayGenomics ES cell line RRO439 embryonic stem cell house mouse CVCL_NJ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922579; Atf7ip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179192 CVCL_NJ62 BayGenomics ES cell line RRO431 embryonic stem cell house mouse CVCL_NJ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98927; Vcl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179193 CVCL_NJ61 BayGenomics ES cell line RRO427 embryonic stem cell house mouse CVCL_NJ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442086; Trerf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179194 CVCL_NJ60 BayGenomics ES cell line RRO426 embryonic stem cell house mouse CVCL_NJ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179195 CVCL_NJ59 BayGenomics ES cell line RRO419 embryonic stem cell house mouse CVCL_NJ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147003; Arhgap28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179196 CVCL_NJ58 BayGenomics ES cell line RRO411 embryonic stem cell house mouse CVCL_NJ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446296; Sik3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179197 CVCL_NJ57 BayGenomics ES cell line RRO410 embryonic stem cell house mouse CVCL_NJ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442192; Eea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179198 CVCL_NJ56 BayGenomics ES cell line RRO407 embryonic stem cell house mouse CVCL_NJ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179199 CVCL_NJ33 BayGenomics ES cell line RRO327 embryonic stem cell house mouse CVCL_NJ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179200 CVCL_NJ32 BayGenomics ES cell line RRO326 embryonic stem cell house mouse CVCL_NJ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2155865; Rrm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179201 CVCL_NJ31 BayGenomics ES cell line RRO321 embryonic stem cell house mouse CVCL_NJ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917747; Arhgap17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179202 CVCL_NJ30 BayGenomics ES cell line RRO320 embryonic stem cell house mouse CVCL_NJ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3845075; Tnfsfm13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179203 CVCL_EP96 E242 transformed cell line human CVCL_EP96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179204 CVCL_F196 GM23311 finite cell line human CVCL_F196 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg683Serfs*21 (c.2045_2046AG[2]) (c.2049_2050delAG); ClinVar=VCV000038340; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg2578Ter (c.7732C>T); ClinVar=VCV000014296; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179205 CVCL_EP95 E195 transformed cell line human CVCL_EP95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179206 CVCL_F195 GM23717 induced pluripotent stem cell human CVCL_F195 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg683Serfs*21 (c.2045_2046AG[2]) (c.2049_2050delAG); ClinVar=VCV000038340; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg2578Ter (c.7732C>T); ClinVar=VCV000014296; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179207 CVCL_EP94 E335 transformed cell line human CVCL_EP94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179208 CVCL_F194 GM23413 induced pluripotent stem cell human CVCL_F194 CL:0000010 Population: African American; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21179209 CVCL_EP93 E334 transformed cell line human CVCL_EP93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179210 CVCL_F193 GM03816 finite cell line human CVCL_F193 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[330]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[380]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179211 CVCL_EP99 E254 transformed cell line human CVCL_EP99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179212 CVCL_F199 GM03654 finite cell line human CVCL_F199 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179213 CVCL_EP98 E253 transformed cell line human CVCL_EP98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179214 CVCL_F198 GM23310 finite cell line human CVCL_F198 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg2578Ter (c.7732C>T); ClinVar=VCV000014296; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179215 CVCL_EP97 E252 transformed cell line human CVCL_EP97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179216 CVCL_F197 GM23309 finite cell line human CVCL_F197 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg683Serfs*21 (c.2045_2046AG[2]) (c.2049_2050delAG); ClinVar=VCV000038340; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179217 CVCL_NJ29 BayGenomics ES cell line RRO307 embryonic stem cell house mouse CVCL_NJ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153072; Trim37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179218 CVCL_NJ28 BayGenomics ES cell line RRO305 embryonic stem cell house mouse CVCL_NJ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918073; Hmgxb4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179219 CVCL_NJ27 BayGenomics ES cell line RRO303 embryonic stem cell house mouse CVCL_NJ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183446; Agap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179220 CVCL_NJ26 BayGenomics ES cell line RRO297 embryonic stem cell house mouse CVCL_NJ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179221 CVCL_EP92 E314 transformed cell line human CVCL_EP92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179222 CVCL_F192 GM23404 induced pluripotent stem cell human CVCL_F192 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[330]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[380]; ClinVar=VCV000561195; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179223 CVCL_NJ25 BayGenomics ES cell line RRO293 embryonic stem cell house mouse CVCL_NJ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109531; Cdc37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179224 CVCL_EP91 E313 transformed cell line human CVCL_EP91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179225 CVCL_F191 GM23232 induced pluripotent stem cell human CVCL_F191 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Gly216Arg (c.646G>A); ClinVar=VCV000001968; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; c.1050_1054delGAAGA; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21179226 CVCL_NJ24 BayGenomics ES cell line RRO290 embryonic stem cell house mouse CVCL_NJ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1315200; M1ap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179227 CVCL_EP90 E303 transformed cell line human CVCL_EP90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179228 CVCL_F190 GM20390 transformed cell line human CVCL_F190 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179229 CVCL_NJ23 BayGenomics ES cell line RRO284 embryonic stem cell house mouse CVCL_NJ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918017; Prpf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179230 CVCL_NJ44 BayGenomics ES cell line RRO355 embryonic stem cell house mouse CVCL_NJ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919979; Cdc42se2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179231 CVCL_NJ43 BayGenomics ES cell line RRO353 embryonic stem cell house mouse CVCL_NJ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384933; Wrap53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179232 CVCL_NJ42 BayGenomics ES cell line RRO351 embryonic stem cell house mouse CVCL_NJ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104709; Wbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179233 CVCL_NJ41 BayGenomics ES cell line RRO347 embryonic stem cell house mouse CVCL_NJ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105982; Rfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179234 CVCL_NJ40 BayGenomics ES cell line RRO344 embryonic stem cell house mouse CVCL_NJ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922989; Mpp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179235 CVCL_NJ39 BayGenomics ES cell line RRO340 embryonic stem cell house mouse CVCL_NJ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927489; Pdlim5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179236 CVCL_NJ38 BayGenomics ES cell line RRO339 embryonic stem cell house mouse CVCL_NJ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109153; Ktn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179237 CVCL_NJ37 BayGenomics ES cell line RRO337 embryonic stem cell house mouse CVCL_NJ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179238 CVCL_NJ36 BayGenomics ES cell line RRO334 embryonic stem cell house mouse CVCL_NJ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179239 CVCL_NJ35 BayGenomics ES cell line RRO333 embryonic stem cell house mouse CVCL_NJ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676311; Crybg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179240 CVCL_NJ34 BayGenomics ES cell line RRO330 embryonic stem cell house mouse CVCL_NJ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354742; Synrg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179241 CVCL_NJ11 BayGenomics ES cell line RRO245 embryonic stem cell house mouse CVCL_NJ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179242 CVCL_NJ10 BayGenomics ES cell line RRO242 embryonic stem cell house mouse CVCL_NJ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179243 CVCL_F179 GM23280 induced pluripotent stem cell human CVCL_F179 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Coriell; GM23280; probable Female Caution: May be identical to one of the many iPSC cell lines produced from HDF1388 by the Center for iPS Cell Research and Application (CiRA) 21179244 CVCL_EP79 IC52 transformed cell line human CVCL_EP79 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys56Arg (c.167A>G); ClinVar=VCV000054324; Zygosity=Unspecified (PubMed=14647443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179245 CVCL_EP74 28SC-ES cancer cell line human CVCL_EP74 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00526 Problematic cell line: Contaminated On the basis of the STR profile the parent cell line (SC) seems to be a U-937 derivative. 21179246 CVCL_F174 GM03815 finite cell line human CVCL_F174 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (PubMed=26190808; PubMed=28284873) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21179247 CVCL_F173 GM03814 finite cell line human CVCL_F173 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (PubMed=28284873; PubMed=33197628); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (PubMed=28284873) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21179248 CVCL_EP73 HEK293-EPHB2 transformed cell line human CVCL_EP73 CL:0000010 Transfected with: HGNC; 3393; EPHB2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21179249 CVCL_F172 GM03813 finite cell line human CVCL_F172 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Problematic cell line: Misclassified Originally thought to be a SMA type 1 (SMA1) cell line but shown to be from a SMA type 2 (SMA2) (PubMed=28284873). 21179250 CVCL_EP72 HEK293-EPHB1 transformed cell line human CVCL_EP72 CL:0000010 Transfected with: HGNC; 3392; EPHB1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21179251 CVCL_EP71 CHD-1 cancer cell line human CVCL_EP71 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=22808230) Derived from sampling site: Colon. Unspecified 21179252 CVCL_F178 GM23279 induced pluripotent stem cell human CVCL_F178 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Caution: May be identical to one of the many iPSC cell lines produced from HDF1388 by the Center for iPS Cell Research and Application (CiRA) 21179253 CVCL_EP78 IC441 transformed cell line human CVCL_EP78 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Leu1404Arg (c.4211T>G); ClinVar=VCV000491071; Zygosity=Unspecified (PubMed=14647443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179254 CVCL_EP77 CHO-SNS22 spontaneously immortalized cell line CVCL_EP77 CL:0000010 Transfected with: RGD; 3629; Scn10a Derived from sampling site: Ovary. Female 21179255 CVCL_F177 GM23262 induced pluripotent stem cell human CVCL_F177 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21179256 CVCL_EP76 CCRF-CEM C7H2-2C8 cancer cell line human CVCL_EP76 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21179257 CVCL_F176 GM23230 induced pluripotent stem cell human CVCL_F176 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21179258 CVCL_NJ09 BayGenomics ES cell line RRO240 embryonic stem cell house mouse CVCL_NJ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179259 CVCL_EP75 CCRF-CEM C7H2 cancer cell line human CVCL_EP75 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21179260 CVCL_NJ08 BayGenomics ES cell line RRO237 embryonic stem cell house mouse CVCL_NJ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889576; Cntrl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179261 CVCL_NJ07 BayGenomics ES cell line RRO234 embryonic stem cell house mouse CVCL_NJ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179262 CVCL_NJ06 BayGenomics ES cell line RRO233 embryonic stem cell house mouse CVCL_NJ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923988; Paf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179263 CVCL_NJ05 BayGenomics ES cell line RRO232 embryonic stem cell house mouse CVCL_NJ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179264 CVCL_NJ04 BayGenomics ES cell line RRO231 embryonic stem cell house mouse CVCL_NJ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179265 CVCL_F170 GM23226 induced pluripotent stem cell human CVCL_F170 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21179266 CVCL_EP70 mPitA-POMC/GFP-1 transformed cell line house mouse CVCL_EP70 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pituitary gland; Breed/subspecies: C57BL/6J-Tg(Pomc-EGFP)1Low/J. Male 21179267 CVCL_NJ03 BayGenomics ES cell line RRO229 embryonic stem cell house mouse CVCL_NJ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334255; Cyth2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179268 CVCL_NJ02 BayGenomics ES cell line RRO227 embryonic stem cell house mouse CVCL_NJ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278321; Epc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179269 CVCL_NJ01 BayGenomics ES cell line RRO225 embryonic stem cell house mouse CVCL_NJ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924828; Bcl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179270 CVCL_NJ22 BayGenomics ES cell line RRO279 embryonic stem cell house mouse CVCL_NJ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919451; Otud6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179271 CVCL_NJ21 BayGenomics ES cell line RRO278 embryonic stem cell house mouse CVCL_NJ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443483; Pdzd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179272 CVCL_NJ20 BayGenomics ES cell line RRO277 embryonic stem cell house mouse CVCL_NJ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179273 CVCL_EP85 E248 transformed cell line human CVCL_EP85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179274 CVCL_F185 GM23249 finite cell line human CVCL_F185 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Personal Genome Project (PGP) cell line collection 21179275 CVCL_EP84 E247 transformed cell line human CVCL_EP84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179276 CVCL_F184 GM23340 induced pluripotent stem cell human CVCL_F184 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; GM23340; probable Male Part of: Personal Genome Project (PGP) cell line collection 21179277 CVCL_EP83 E246 transformed cell line human CVCL_EP83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179278 CVCL_F183 GM23248 finite cell line human CVCL_F183 CL:0000010 Anecdotal: Established from George Church fibroblasts Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Part of: Personal Genome Project (PGP) cell line collection 21179279 CVCL_EP82 E245 transformed cell line human CVCL_EP82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179280 CVCL_F182 GM23338 induced pluripotent stem cell human CVCL_F182 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Personal Genome Project (PGP) cell line collection 21179281 CVCL_EP89 E302 transformed cell line human CVCL_EP89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179282 CVCL_F189 GM14982 transformed cell line human CVCL_F189 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179283 CVCL_EP88 E301 transformed cell line human CVCL_EP88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179284 CVCL_F188 GM03639 cancer cell line human CVCL_F188 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2144611) Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21179285 CVCL_EP87 E250 transformed cell line human CVCL_EP87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179286 CVCL_F187 GM03638 transformed cell line human CVCL_F187 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179287 CVCL_EP86 E249 transformed cell line human CVCL_EP86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179288 CVCL_F186 GM21677 transformed cell line human CVCL_F186 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 21179289 CVCL_NJ19 BayGenomics ES cell line RRO274 embryonic stem cell house mouse CVCL_NJ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179290 CVCL_NJ18 BayGenomics ES cell line RRO272 embryonic stem cell house mouse CVCL_NJ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179291 CVCL_NJ17 BayGenomics ES cell line RRO270 embryonic stem cell house mouse CVCL_NJ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179292 CVCL_NJ16 BayGenomics ES cell line RRO268 embryonic stem cell house mouse CVCL_NJ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916106; Prrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179293 CVCL_NJ15 BayGenomics ES cell line RRO266 embryonic stem cell house mouse CVCL_NJ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179294 CVCL_F181 GM11270 finite cell line human CVCL_F181 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Heterozygous (PubMed=11738860) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179295 CVCL_EP81 IC954 transformed cell line human CVCL_EP81 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu575Lys (c.1723G>A); ClinVar=VCV000054334; Zygosity=Unspecified (PubMed=14647443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179296 CVCL_NJ14 BayGenomics ES cell line RRO261 embryonic stem cell house mouse CVCL_NJ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179297 CVCL_F180 GM23298 induced pluripotent stem cell human CVCL_F180 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM23298; probable Female 21179298 CVCL_EP80 IC692 transformed cell line human CVCL_EP80 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asp1692His (c.5074G>C); ClinVar=VCV000037633; Zygosity=Unspecified (PubMed=14647443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179299 CVCL_NJ13 BayGenomics ES cell line RRO252 embryonic stem cell house mouse CVCL_NJ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179300 CVCL_NJ12 BayGenomics ES cell line RRO248 embryonic stem cell house mouse CVCL_NJ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151839; Mreg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179301 CVCL_WC73 BRC-34 transformed cell line human CVCL_WC73 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179302 CVCL_WC72 BRC-33 transformed cell line human CVCL_WC72 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179303 CVCL_WC71 BRC-32 transformed cell line human CVCL_WC71 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179304 CVCL_WC70 BRC-31 transformed cell line human CVCL_WC70 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179305 CVCL_WC77 BRC-38 transformed cell line human CVCL_WC77 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179306 CVCL_WC76 BRC-37 transformed cell line human CVCL_WC76 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179307 CVCL_WC75 BRC-36 transformed cell line human CVCL_WC75 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179308 CVCL_WC74 BRC-35 transformed cell line human CVCL_WC74 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179309 CVCL_WC79 BRC-40 transformed cell line human CVCL_WC79 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179310 CVCL_WC78 BRC-39 transformed cell line human CVCL_WC78 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179311 CVCL_WC62 BRC-23 transformed cell line human CVCL_WC62 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179312 CVCL_WC61 BRC-22 transformed cell line human CVCL_WC61 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179313 CVCL_WC60 BRC-21 transformed cell line human CVCL_WC60 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179314 CVCL_WC66 BRC-27 transformed cell line human CVCL_WC66 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179315 CVCL_WC65 BRC-26 transformed cell line human CVCL_WC65 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179316 CVCL_WC64 BRC-25 transformed cell line human CVCL_WC64 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179317 CVCL_WC63 BRC-24 transformed cell line human CVCL_WC63 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179318 CVCL_WC69 BRC-30 transformed cell line human CVCL_WC69 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179319 CVCL_WC68 BRC-29 transformed cell line human CVCL_WC68 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179320 CVCL_WC67 BRC-28 transformed cell line human CVCL_WC67 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179321 CVCL_WC51 BRC-12 transformed cell line human CVCL_WC51 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179322 CVCL_WC50 BRC-11 transformed cell line human CVCL_WC50 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179323 CVCL_WC55 BRC-16 transformed cell line human CVCL_WC55 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179324 CVCL_WC54 BRC-15 transformed cell line human CVCL_WC54 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179325 CVCL_WC53 BRC-14 transformed cell line human CVCL_WC53 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179326 CVCL_WC52 BRC-13 transformed cell line human CVCL_WC52 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179327 CVCL_WC59 BRC-20 transformed cell line human CVCL_WC59 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179328 CVCL_WC58 BRC-19 transformed cell line human CVCL_WC58 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179329 CVCL_WC57 BRC-18 transformed cell line human CVCL_WC57 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179330 CVCL_WC56 BRC-17 transformed cell line human CVCL_WC56 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179331 CVCL_WC40 BRC-01 transformed cell line human CVCL_WC40 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179332 CVCL_WC44 BRC-05 transformed cell line human CVCL_WC44 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179333 CVCL_WC43 BRC-04 transformed cell line human CVCL_WC43 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179334 CVCL_WC42 BRC-03 transformed cell line human CVCL_WC42 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179335 CVCL_WC41 BRC-02 transformed cell line human CVCL_WC41 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179336 CVCL_WC48 BRC-09 transformed cell line human CVCL_WC48 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179337 CVCL_WC47 BRC-08 transformed cell line human CVCL_WC47 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179338 CVCL_WC46 BRC-07 transformed cell line human CVCL_WC46 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179339 CVCL_WC45 BRC-06 transformed cell line human CVCL_WC45 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179340 CVCL_WC49 BRC-10 transformed cell line human CVCL_WC49 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179341 CVCL_NI99 BayGenomics ES cell line RRO223 embryonic stem cell house mouse CVCL_NI99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179342 CVCL_NI98 BayGenomics ES cell line RRO222 embryonic stem cell house mouse CVCL_NI98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179343 CVCL_NI97 BayGenomics ES cell line RRO220 embryonic stem cell house mouse CVCL_NI97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332235; Nrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179344 CVCL_NI96 BayGenomics ES cell line RRO219 embryonic stem cell house mouse CVCL_NI96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106095; Naca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179345 CVCL_NI95 BayGenomics ES cell line RRO218 embryonic stem cell house mouse CVCL_NI95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096551; Morf4l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179346 CVCL_NI94 BayGenomics ES cell line RRO214 embryonic stem cell house mouse CVCL_NI94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179347 CVCL_NI93 BayGenomics ES cell line RRO212 embryonic stem cell house mouse CVCL_NI93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346318; Klf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179348 CVCL_NI92 BayGenomics ES cell line RRO211 embryonic stem cell house mouse CVCL_NI92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2659071; Rapgef2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179349 CVCL_NI91 BayGenomics ES cell line RRO210 embryonic stem cell house mouse CVCL_NI91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915084; Idh3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179350 CVCL_NI90 BayGenomics ES cell line RRO209 embryonic stem cell house mouse CVCL_NI90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179351 CVCL_WC33 TLS-89 transformed cell line human CVCL_WC33 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179352 CVCL_WC32 TLS-88 transformed cell line human CVCL_WC32 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179353 CVCL_WC31 TLS-87 transformed cell line human CVCL_WC31 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179354 CVCL_WC30 TLS-86 transformed cell line human CVCL_WC30 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179355 CVCL_WC37 TLS-92 transformed cell line human CVCL_WC37 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179356 CVCL_WC36 TLS-91 transformed cell line human CVCL_WC36 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179357 CVCL_WC35 TLS-90 transformed cell line human CVCL_WC35 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179358 CVCL_WC34 TLS-9 transformed cell line human CVCL_WC34 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179359 CVCL_WC39 PBD2-Fib finite cell line human CVCL_WC39 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21179360 CVCL_WC38 PBD1-Fib finite cell line human CVCL_WC38 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21179361 CVCL_WC22 TLS-79 transformed cell line human CVCL_WC22 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179362 CVCL_WC21 TLS-78 transformed cell line human CVCL_WC21 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179363 CVCL_WC20 TLS-77 transformed cell line human CVCL_WC20 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179364 CVCL_WC26 TLS-82 transformed cell line human CVCL_WC26 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179365 CVCL_WC25 TLS-81 transformed cell line human CVCL_WC25 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179366 CVCL_WC24 TLS-80 transformed cell line human CVCL_WC24 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179367 CVCL_WC23 TLS-8 transformed cell line human CVCL_WC23 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179368 CVCL_WC29 TLS-85 transformed cell line human CVCL_WC29 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179369 CVCL_WC28 TLS-84 transformed cell line human CVCL_WC28 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179370 CVCL_WC27 TLS-83 transformed cell line human CVCL_WC27 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179371 CVCL_NI78 BayGenomics ES cell line RRO174 embryonic stem cell house mouse CVCL_NI78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107795; Hnrnpc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179372 CVCL_NI77 BayGenomics ES cell line RRO173 embryonic stem cell house mouse CVCL_NI77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179373 CVCL_NI76 BayGenomics ES cell line RRO172 embryonic stem cell house mouse CVCL_NI76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179374 CVCL_NI75 BayGenomics ES cell line RRO171 embryonic stem cell house mouse CVCL_NI75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152345; Taf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179375 CVCL_NI74 BayGenomics ES cell line RRO170 embryonic stem cell house mouse CVCL_NI74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351475; Golga5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179376 CVCL_NI73 BayGenomics ES cell line RRO167 embryonic stem cell house mouse CVCL_NI73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179377 CVCL_NI72 BayGenomics ES cell line RRO163 embryonic stem cell house mouse CVCL_NI72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352493; Bag3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179378 CVCL_NI71 BayGenomics ES cell line RRO161 embryonic stem cell house mouse CVCL_NI71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88508; Crk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179379 CVCL_NI70 BayGenomics ES cell line RRO157 embryonic stem cell house mouse CVCL_NI70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913963; Actr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179380 CVCL_WC11 TLS-69 transformed cell line human CVCL_WC11 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179381 CVCL_WC10 TLS-68 transformed cell line human CVCL_WC10 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179382 CVCL_WC15 TLS-72 transformed cell line human CVCL_WC15 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179383 CVCL_WC14 TLS-71 transformed cell line human CVCL_WC14 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179384 CVCL_WC13 TLS-70 transformed cell line human CVCL_WC13 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179385 CVCL_WC12 TLS-7 transformed cell line human CVCL_WC12 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179386 CVCL_WC19 TLS-76 transformed cell line human CVCL_WC19 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179387 CVCL_WC18 TLS-75 transformed cell line human CVCL_WC18 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179388 CVCL_WC17 TLS-74 transformed cell line human CVCL_WC17 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179389 CVCL_WC16 TLS-73 transformed cell line human CVCL_WC16 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179390 CVCL_NI69 BayGenomics ES cell line RRO156 embryonic stem cell house mouse CVCL_NI69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036250; Zfp729a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179391 CVCL_NI68 BayGenomics ES cell line RRO154 embryonic stem cell house mouse CVCL_NI68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914080; Nacc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179392 CVCL_NI89 BayGenomics ES cell line RRO208 embryonic stem cell house mouse CVCL_NI89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443472; Atf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179393 CVCL_NI88 BayGenomics ES cell line RRO207 embryonic stem cell house mouse CVCL_NI88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179394 CVCL_NI87 BayGenomics ES cell line RRO203 embryonic stem cell house mouse CVCL_NI87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920977; Mcmbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179395 CVCL_NI86 BayGenomics ES cell line RRO202 embryonic stem cell house mouse CVCL_NI86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447063; Tenm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179396 CVCL_NI85 BayGenomics ES cell line RRO199 embryonic stem cell house mouse CVCL_NI85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108091; Bcar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179397 CVCL_NI84 BayGenomics ES cell line RRO184 embryonic stem cell house mouse CVCL_NI84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179398 CVCL_NI83 BayGenomics ES cell line RRO183 embryonic stem cell house mouse CVCL_NI83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385621; Nup153 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179399 CVCL_NI82 BayGenomics ES cell line RRO181 embryonic stem cell house mouse CVCL_NI82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88141; Bcr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179400 CVCL_NI81 BayGenomics ES cell line RRO179 embryonic stem cell house mouse CVCL_NI81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104811; Sub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179401 CVCL_NI80 BayGenomics ES cell line RRO177 embryonic stem cell house mouse CVCL_NI80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339939; Rpa2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179402 CVCL_WC00 TLS-59 transformed cell line human CVCL_WC00 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179403 CVCL_WC04 TLS-62 transformed cell line human CVCL_WC04 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179404 CVCL_WC03 TLS-61 transformed cell line human CVCL_WC03 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179405 CVCL_WC02 TLS-60 transformed cell line human CVCL_WC02 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179406 CVCL_WC01 TLS-6 transformed cell line human CVCL_WC01 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179407 CVCL_WC08 TLS-66 transformed cell line human CVCL_WC08 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179408 CVCL_WC07 TLS-65 transformed cell line human CVCL_WC07 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179409 CVCL_WC06 TLS-64 transformed cell line human CVCL_WC06 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179410 CVCL_WC05 TLS-63 transformed cell line human CVCL_WC05 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179411 CVCL_WC09 TLS-67 transformed cell line human CVCL_WC09 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179412 CVCL_NI79 BayGenomics ES cell line RRO175 embryonic stem cell house mouse CVCL_NI79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179413 CVCL_WC91 BRC-52 transformed cell line human CVCL_WC91 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179414 CVCL_WC90 BRC-51 transformed cell line human CVCL_WC90 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179415 CVCL_WC95 RT [Oncorhynchus] spontaneously immortalized cell line CVCL_WC95 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21179416 CVCL_WC94 BRC-55 transformed cell line human CVCL_WC94 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179417 CVCL_WC93 BRC-54 transformed cell line human CVCL_WC93 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179418 CVCL_WC92 BRC-53 transformed cell line human CVCL_WC92 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179419 CVCL_WC99 VERO/IgR spontaneously immortalized cell line green monkey CVCL_WC99 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000150) It was the sole source of information for this entry. Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21179420 CVCL_WC98 MDCK/IgR spontaneously immortalized cell line dog CVCL_WC98 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21179421 CVCL_WC97 AOXlar7y spontaneously immortalized cell line CVCL_WC97 CL:0000010 Omics: Transcriptome analysis by RNAseq. Unspecified Characteristics: Optimal growth temperature is 25 Celsius (PubMed=30862517) Doubling time: 110 hours (PubMed=30862517) Group: Fish cell line 21179422 CVCL_WC96 TMF spontaneously immortalized cell line CVCL_WC96 CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Unspecified Characteristics: Optimal growth temperature is 24 Celsius (PubMed=30888578) Group: Fish cell line 21179423 CVCL_WC80 BRC-41 transformed cell line human CVCL_WC80 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179424 CVCL_WC84 BRC-45 transformed cell line human CVCL_WC84 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179425 CVCL_WC83 BRC-44 transformed cell line human CVCL_WC83 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179426 CVCL_WC82 BRC-43 transformed cell line human CVCL_WC82 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179427 CVCL_WC81 BRC-42 transformed cell line human CVCL_WC81 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179428 CVCL_WC88 BRC-49 transformed cell line human CVCL_WC88 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179429 CVCL_WC87 BRC-48 transformed cell line human CVCL_WC87 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179430 CVCL_WC86 BRC-47 transformed cell line human CVCL_WC86 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179431 CVCL_WC85 BRC-46 transformed cell line human CVCL_WC85 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179432 CVCL_WC89 BRC-50 transformed cell line human CVCL_WC89 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a breast cancer patient who received doxorubicin and experienced cardiotoxicity; Derived from sampling site: Peripheral blood. Female 21179433 CVCL_NK10 BayGenomics ES cell line RRP025 embryonic stem cell house mouse CVCL_NK10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179434 CVCL_F279 GM18508 transformed cell line human CVCL_F279 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21179435 CVCL_EQ79 HBEC3KTRL53 telomerase immortalized cell line human CVCL_EQ79 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Female 21179436 CVCL_F278 GM18506 transformed cell line human CVCL_F278 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21179437 CVCL_EQ78 HBEC3KT53 telomerase immortalized cell line human CVCL_EQ78 CL:0000010 Knockout cell: Method=siRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Female 21179438 CVCL_F273 FGH finite cell line human CVCL_F273 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Female 21179439 CVCL_EQ73 OSA-80 cancer cell line human CVCL_EQ73 CL:0000010 21179440 CVCL_F272 ETC undefined cell line type CVCL_F272 CL:0000010 Unspecified 21179441 CVCL_EQ72 EW 7476 cancer cell line human CVCL_EQ72 CL:0000010 21179442 CVCL_F271 MBM spontaneously immortalized cell line CVCL_F271 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent (PubMed=7618261); Virology: Highly susceptible to infection by feline leukemia virus (FIV) (PubMed=7618261) Doubling time: ~48 hours (PubMed=7618261) 21179443 CVCL_EQ71 MKL-1 subclone 2 cancer cell line human CVCL_EQ71 CL:0000010 Population: Caucasian; Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Left axillary lymph node. Male 21179444 CVCL_F270 K129SV transformed cell line house mouse CVCL_F270 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: 129/Sv. 21179445 CVCL_EQ70 MKL-1 subclone 1 cancer cell line human CVCL_EQ70 CL:0000010 Population: Caucasian; Transformant: Merkel cell polyomavirus (MCPyV)(NCBI-Taxonomy; 493803); Derived from metastatic site: Left axillary lymph node. Male 21179446 CVCL_F277 C22 (Clara) conditionally immortalized cell line house mouse CVCL_F277 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Club cell.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Characteristics: Proliferates at permissive temperature (33 Celsius) in the presence of IFNG, terminally differentiates at restrictive temperature (39 Celsius) in the absence of IFNG Doubling time: 48 hours (ECACC=07021401) 21179447 CVCL_EQ77 HBEC10-KT telomerase immortalized cell line human CVCL_EQ77 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179448 CVCL_EQ76 JIH-5 cancer cell line human CVCL_EQ76 CL:0000010 Population: Chinese; Derived from sampling site: Bone marrow. Female Doubling time: 97 hours (PubMed=26293203); ~5-7 days (DSMZ=ACC-788) 21179449 CVCL_F276 R59 cancer cell line human CVCL_F276 CL:0000010 Population: Japanese; Derived from metastatic site: Eye socket. Discontinued: JCRB; KURB2344; probable Female 21179450 CVCL_NK09 BayGenomics ES cell line RRP018 embryonic stem cell house mouse CVCL_NK09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179451 CVCL_EQ75 K8 [Human melanoma] cancer cell line human CVCL_EQ75 CL:0000010 21179452 CVCL_F275 Neuro-2aTG cancer cell line house mouse CVCL_F275 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Breed/subspecies: A/J. Male 21179453 CVCL_NK08 BayGenomics ES cell line RRP015 embryonic stem cell house mouse CVCL_NK08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179454 CVCL_EQ74 IOSE-75-16SV40 transformed cell line human CVCL_EQ74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21179455 CVCL_NK07 BayGenomics ES cell line RRP013 embryonic stem cell house mouse CVCL_NK07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929492; Atl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179456 CVCL_NK06 BayGenomics ES cell line RRP011 embryonic stem cell house mouse CVCL_NK06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137355; Trim11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179457 CVCL_NK05 BayGenomics ES cell line RRP009 embryonic stem cell house mouse CVCL_NK05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108074; Sptlc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179458 CVCL_NK04 BayGenomics ES cell line RRP008 embryonic stem cell house mouse CVCL_NK04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916610; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179459 CVCL_NK03 BayGenomics ES cell line RRO626 embryonic stem cell house mouse CVCL_NK03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914053; Hmces Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179460 CVCL_NK02 BayGenomics ES cell line RRO624 embryonic stem cell house mouse CVCL_NK02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103300; Rbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179461 CVCL_NK01 BayGenomics ES cell line RRO619 embryonic stem cell house mouse CVCL_NK01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179462 CVCL_NK00 BayGenomics ES cell line RRO615 embryonic stem cell house mouse CVCL_NK00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179463 CVCL_NK21 BayGenomics ES cell line RRP065 embryonic stem cell house mouse CVCL_NK21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858961; Prc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179464 CVCL_NK20 BayGenomics ES cell line RRP062 embryonic stem cell house mouse CVCL_NK20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915671; Lmbrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179465 CVCL_F289 GM03384 transformed cell line human CVCL_F289 CL:0000010 Population: Middle Eastern; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21179466 CVCL_EQ89 HBEC26-KT telomerase immortalized cell line human CVCL_EQ89 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179467 CVCL_EQ84 HBEC15-KT telomerase immortalized cell line human CVCL_EQ84 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179468 CVCL_F284 Hs 804.Sk finite cell line human CVCL_F284 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21179469 CVCL_F283 Ad12-3Y1-Z19 transformed cell line Norway rat CVCL_F283 CL:0000010 Transformant: Adenovirus 12(NCBI-Taxonomy; 28282); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21179470 CVCL_EQ83 HBEC14-KT telomerase immortalized cell line human CVCL_EQ83 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179471 CVCL_EQ82 HBEC13-KT telomerase immortalized cell line human CVCL_EQ82 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq 21179472 CVCL_F282 Shmac 6 transformed cell line human CVCL_F282 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179473 CVCL_EQ81 HBEC12-KT telomerase immortalized cell line human CVCL_EQ81 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179474 CVCL_F281 Shmac 3 transformed cell line human CVCL_F281 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179475 CVCL_F288 AG06040 finite cell line human CVCL_F288 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Donor information: From Bloom Syndrome Registry patient 42(RaFr) (BSR42); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179476 CVCL_EQ88 HBEC24-KT telomerase immortalized cell line human CVCL_EQ88 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179477 CVCL_F287 EB [Human colon carcinoma] cancer cell line human CVCL_F287 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=24042735; PubMed=28683746); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Unspecified Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746) 21179478 CVCL_EQ87 HBEC18-KT telomerase immortalized cell line human CVCL_EQ87 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179479 CVCL_EQ86 HBEC17-KT telomerase immortalized cell line human CVCL_EQ86 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179480 CVCL_F286 HFF-1 MITC finite cell line human CVCL_F286 CL:0000010 Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: ATCC; SCRC-1041.2; true Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C 21179481 CVCL_NK19 BayGenomics ES cell line RRP061 embryonic stem cell house mouse CVCL_NK19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109349; Atf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179482 CVCL_EQ85 HBEC16-KT telomerase immortalized cell line human CVCL_EQ85 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179483 CVCL_F285 HFF-1 IRR finite cell line human CVCL_F285 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by irradiation with 6000 rads 21179484 CVCL_NK18 BayGenomics ES cell line RRP057 embryonic stem cell house mouse CVCL_NK18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354721; Slc25a13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179485 CVCL_NK17 BayGenomics ES cell line RRP045 embryonic stem cell house mouse CVCL_NK17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94909; Dmd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179486 CVCL_NK16 BayGenomics ES cell line RRP042 embryonic stem cell house mouse CVCL_NK16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179487 CVCL_NK15 BayGenomics ES cell line RRP040 embryonic stem cell house mouse CVCL_NK15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179488 CVCL_NK14 BayGenomics ES cell line RRP039 embryonic stem cell house mouse CVCL_NK14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276539; Ttc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179489 CVCL_EQ80 HBEC11-KT telomerase immortalized cell line human CVCL_EQ80 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray Female 21179490 CVCL_F280 Shmac 2 transformed cell line human CVCL_F280 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179491 CVCL_NK13 BayGenomics ES cell line RRP033 embryonic stem cell house mouse CVCL_NK13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98535; Tcp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179492 CVCL_NK12 BayGenomics ES cell line RRP030 embryonic stem cell house mouse CVCL_NK12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443207; Plekhm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179493 CVCL_NK11 BayGenomics ES cell line RRP029 embryonic stem cell house mouse CVCL_NK11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103071; Rangap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179494 CVCL_F259 AG08554 transformed cell line human CVCL_F259 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from autologous cell line AG08555) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21179495 CVCL_EQ59 IGROV-1/MX3 cancer cell line human CVCL_EQ59 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Ovary. Female 21179496 CVCL_F258 AG07647 transformed cell line human CVCL_F258 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG06844) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21179497 CVCL_F257 AG06844 finite cell line human CVCL_F257 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21179498 CVCL_EQ57 IMC-1 cancer cell line human CVCL_EQ57 CL:0000010 Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by microarray Male Characteristics: IL2 dependent Doubling time: 24-36 hours (PubMed=14687616) 21179499 CVCL_EQ56 F6C04 finite cell line human CVCL_EQ56 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Hisfs*5 (c.1157_1197del41) (p.Leu398Hisfs*5, c.1193_1233del41) (c.1156del41); ClinVar=VCV000143369; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the mutated MECP2 allele (PubMed=20569274) 21179500 CVCL_F256 GM10069 transformed cell line human CVCL_F256 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179501 CVCL_F251 14-012-8-1 transformed cell line CVCL_F251 CL:0000010 Transformant: Human herpesvirus 1 (HHV-1) [Strain 14-012](NCBI-Taxonomy; 10298); Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Cell type=Fibroblast. Unspecified 21179502 CVCL_EQ51 F2C03 finite cell line human CVCL_EQ51 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg255Ter (c.763C>T) (p.Arg267Ter, c.799C>T); ClinVar=VCV000011829; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the non-mutated MECP2 allele (PubMed=20569274) 21179503 CVCL_EQ50 FM95-14 finite cell line human CVCL_EQ50 CL:0000010 Derived from sampling site: Fetal skeletal muscle Cell type=Myoblast.. Omics: Transcriptome analysis by microarray Male 21179504 CVCL_F250 INT-MEL-16/1 cancer cell line human CVCL_F250 HLA typing: A*02; B*41,50; C*w02,06 (PubMed=9637706) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp79fs*6 (c.235_248del14); Zygosity=Homozygous (PubMed=9637706); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr86Ter (c.258C>G); Zygosity=Homozygous (PubMed=9637706). Female 21179505 CVCL_EQ55 F6C01 finite cell line human CVCL_EQ55 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Hisfs*5 (c.1157_1197del41) (p.Leu398Hisfs*5, c.1193_1233del41) (c.1156del41); ClinVar=VCV000143369; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the non-mutated MECP2 allele (PubMed=20569274) 21179506 CVCL_F255 GM10013 finite cell line human CVCL_F255 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXX (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21179507 CVCL_EQ54 F3C18 finite cell line human CVCL_EQ54 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the non-mutated MECP2 allele (PubMed=20569274) 21179508 CVCL_F254 GM07744 finite cell line human CVCL_F254 CL:0000010 Karyotypic information: 69,XXX.arr[hg19](1-22,X)x3 (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21179509 CVCL_F253 AG06266 finite cell line human CVCL_F253 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXY (Coriell); Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Male 21179510 CVCL_EQ53 F3C15 finite cell line human CVCL_EQ53 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg270Ter (c.808C>T) (p.Arg282Ter, c.844C>T); ClinVar=VCV000011815; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the mutated MECP2 allele (PubMed=20569274) 21179511 CVCL_F252 AG05025 finite cell line human CVCL_F252 CL:0000010 Population: Caucasian; Karyotypic information: 69,XXY (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Ambiguous 21179512 CVCL_EQ52 F2C14 finite cell line human CVCL_EQ52 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg255Ter (c.763C>T) (p.Arg267Ter, c.799C>T); ClinVar=VCV000011829; Zygosity=Heterozygous (PubMed=20569274) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Characteristics: This cell line only expresses the mutated MECP2 allele (PubMed=20569274) 21179513 CVCL_F269 H454 cancer cell line human CVCL_F269 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:48775; Cadmium(2+); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21179514 CVCL_EQ69 SKBR3-PR cancer cell line human CVCL_EQ69 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 9588; PTEN; Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 21179515 CVCL_F268 GM00112 finite cell line human CVCL_F268 CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Homozygous (PubMed=19815695) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21179516 CVCL_EQ68 HCC827-PR cancer cell line human CVCL_EQ68 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 9588; PTEN; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 21179517 CVCL_EQ67 A431-PR cancer cell line human CVCL_EQ67 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 9588; PTEN; Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Omics: Transcriptome analysis by microarray Female 21179518 CVCL_F267 GM02408 finite cell line human CVCL_F267 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179519 CVCL_EQ62 IGROV-1/Pt1 cancer cell line human CVCL_EQ62 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Leu (c.808T>C); ClinVar=VCV000634778; Zygosity=Heterozygous (PubMed=8564971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=8564971) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female Doubling time: 33 +- 2 hours (PubMed=9636834) 21179520 CVCL_F261 GM01972 finite cell line human CVCL_F261 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell; PubMed=12714972) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21179521 CVCL_EQ61 IGROV-1/Pt0.5 cancer cell line human CVCL_EQ61 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Leu (c.808T>C); ClinVar=VCV000634778; Zygosity=Heterozygous (PubMed=8564971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=8564971) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female Doubling time: 36 +- 2.2 hours (PubMed=9636834) 21179522 CVCL_F260 AG08555 finite cell line human CVCL_F260 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21179523 CVCL_EQ60 IGROV-1/T8 cancer cell line human CVCL_EQ60 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female 21179524 CVCL_F266 GM01606 finite cell line human CVCL_F266 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21179525 CVCL_EQ66 Hep-G2/BGAL cancer cell line human CVCL_EQ66 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 21179526 CVCL_F265 GM00488 finite cell line human CVCL_F265 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys667Tyr (c.2000G>A) (C646Y); ClinVar=VCV000003689; Zygosity=Homozygous (PubMed=29308438) Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179527 CVCL_EQ65 Hep-G2/PGC-1alpha wt cancer cell line human CVCL_EQ65 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 9237; PPARGC1A Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 21179528 CVCL_F264 GM00490 finite cell line human CVCL_F264 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Cell type=Fibroblast. Female 21179529 CVCL_EQ64 Hep-G2/PGC-1alpha L2L3 mutant cancer cell line human CVCL_EQ64 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 9237; PPARGC1A (with Leu to Ala mutations in the 2nd and 3rd LXXLL motifs) Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 21179530 CVCL_F263 GM-490 cancer cell line human CVCL_F263 CL:0000010 Derived from sampling site: Bone marrow. Male 21179531 CVCL_EQ63 Hep-G2/PGC-1alpha 2x9 mutant cancer cell line human CVCL_EQ63 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 9237; PPARGC1A (with mutations in the 2nd and 3rd LXXLL motifs region) Population: Caucasian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Male 21179532 CVCL_EQ37 iWS229T-13 induced pluripotent stem cell human CVCL_EQ37 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179533 CVCL_F237 LB70-MEL cancer cell line human CVCL_F237 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Female Characteristics: Established via a mouse xenograft. 21179534 CVCL_EQ36 iWS229-p53i-2.1 induced pluripotent stem cell human CVCL_EQ36 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179535 CVCL_F236 LB804-ALL cancer cell line human CVCL_F236 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21179536 CVCL_EQ35 iWS229 induced pluripotent stem cell human CVCL_EQ35 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179537 CVCL_F235 LB126-SCLC cancer cell line human CVCL_F235 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21179538 CVCL_EQ34 iGM440 induced pluripotent stem cell human CVCL_EQ34 CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179539 CVCL_F234 LB1017-HNSC cancer cell line human CVCL_F234 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Omics: CNV analysis. Unspecified 21179540 CVCL_EQ39 iWS300 induced pluripotent stem cell human CVCL_EQ39 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179541 CVCL_F239 LB1319-MEL cancer cell line human CVCL_F239 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Inguinal lymph node. Unspecified 21179542 CVCL_EQ38 iWS229T-21 induced pluripotent stem cell human CVCL_EQ38 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179543 CVCL_F238 LB1622-MEL cancer cell line human CVCL_F238 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Skin (Note=In-transit between skin and lymph node). Female 21179544 CVCL_EQ33 iBC induced pluripotent stem cell human CVCL_EQ33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179545 CVCL_F233 LB929-MEL cancer cell line human CVCL_F233 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Hypodermis. Male 21179546 CVCL_EQ32 iAN3 induced pluripotent stem cell human CVCL_EQ32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179547 CVCL_F232 LB188-SAR cancer cell line human CVCL_F232 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21179548 CVCL_EQ31 iAN2 induced pluripotent stem cell human CVCL_EQ31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179549 CVCL_F231 TG2 transformed cell line CVCL_F231 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Kidney. Male 21179550 CVCL_EQ30 iAN1 induced pluripotent stem cell human CVCL_EQ30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179551 CVCL_F248 2211 cancer cell line Norway rat CVCL_F248 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102). 21179552 CVCL_EQ48 8807 finite cell line human CVCL_EQ48 CL:0000010 Sequence variation: Mutation; HGNC; 7708; NDUFS2; Simple; p.Asp446Asn (c.1336G>A); Zygosity=Homozygous (PubMed=22033105) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21179553 CVCL_EQ47 8328 finite cell line human CVCL_EQ47 CL:0000010 Sequence variation: Mutation; HGNC; 7707; NDUFS1; Simple; p.Glu211del (c.631_633delGAA) (211delE); Zygosity=Heterozygous (PubMed=20382551; PubMed=22033105); Sequence variation: Mutation; HGNC; 7707; NDUFS1; Simple; p.Val228Ala (c.683T>C); ClinVar=VCV000429933; Zygosity=Heterozygous (PubMed=20382551; PubMed=22033105) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179554 CVCL_F247 TM 903 hybridoma house mouse CVCL_F247 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21179555 CVCL_EQ46 7898 finite cell line human CVCL_EQ46 CL:0000010 Sequence variation: Mutation; HGNC; 7711; NDUFS4; Simple; p.Arg106Ter (c.316C>T); ClinVar=VCV000006889; Zygosity=Homozygous (PubMed=22033105) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179556 CVCL_F246 TM 902 hybridoma house mouse CVCL_F246 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21179557 CVCL_EQ45 6613 finite cell line human CVCL_EQ45 CL:0000010 Sequence variation: Mutation; HGNC; 7715; NDUFS8; Simple; p.Arg94Cys; Zygosity=Homozygous (PubMed=22033105) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179558 CVCL_F245 TEK finite cell line CVCL_F245 CL:0000010 Derived from sampling site: Fetal thymus. Unspecified 21179559 CVCL_EQ49 HT-29R cancer cell line human CVCL_EQ49 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:132984; RO4927350 Female 21179560 CVCL_F249 INT-MEL-58 cancer cell line human CVCL_F249 CL:0000010 Derived from metastatic site: Lymph node. Male 21179561 CVCL_EQ40 iWS780-1.9 induced pluripotent stem cell human CVCL_EQ40 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=24749076) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179562 CVCL_F240 LB39-MEL cancer cell line human CVCL_F240 HLA typing: A*02,24; B*07,51; C*w01,w07 (PubMed=12747757) From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Hypodermis. Female Characteristics: Established via a mouse xenograft 21179563 CVCL_EQ44 5175 finite cell line human CVCL_EQ44 CL:0000010 Sequence variation: Mutation; HGNC; 7714; NDUFS7; Simple; p.Val122Met (c.364G>A); ClinVar=VCV000007681; Zygosity=Homozygous (PubMed=22033105) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179564 CVCL_F244 T-1387 cancer cell line human CVCL_F244 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21179565 CVCL_EQ43 iWS797T induced pluripotent stem cell human CVCL_EQ43 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179566 CVCL_F243 KD2SV transformed cell line house mouse CVCL_F243 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/10 x DBA/2. 21179567 CVCL_EQ42 iWS797 induced pluripotent stem cell human CVCL_EQ42 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179568 CVCL_F242 JM1 cancer cell line Norway rat CVCL_F242 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Breed/subspecies: Fischer 344. Male 21179569 CVCL_EQ41 iWS780-2.10 induced pluripotent stem cell human CVCL_EQ41 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Arg369Ter (c.1105C>T) (c.1336C>T); ClinVar=VCV000005449; Zygosity=Homozygous (PubMed=24749076) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21179570 CVCL_F241 LB4-MEL cancer cell line human CVCL_F241 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium. CL:0000010 Unspecified 21179571 CVCL_EQ15 E330 transformed cell line human CVCL_EQ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179572 CVCL_F215 GM09818 transformed cell line human CVCL_F215 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179573 CVCL_EQ14 E329 transformed cell line human CVCL_EQ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179574 CVCL_F214 GM09740 transformed cell line human CVCL_F214 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21179575 CVCL_EQ13 E326 transformed cell line human CVCL_EQ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179576 CVCL_F213 GM09550 transformed cell line human CVCL_F213 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179577 CVCL_EQ12 E325 transformed cell line human CVCL_EQ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179578 CVCL_F212 GM09549 transformed cell line human CVCL_F212 HLA typing: A*03:01:01,03:02:01; B*15:01:01,35:03:01; C*03:03:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,04:01:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRB1*11:01:01,11:01:01; DRB3*02:02:01;02:02:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179579 CVCL_EQ19 Calu3-GemR cancer cell line human CVCL_EQ19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male 21179580 CVCL_F219 GM14502 transformed cell line human CVCL_F219 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14501 (Cellosaurus=CVCL_7571); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21179581 CVCL_EQ18 E333 transformed cell line human CVCL_EQ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179582 CVCL_F218 GM14455 transformed cell line human CVCL_F218 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM14454 (Cellosaurus=CVCL_7556); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21179583 CVCL_EQ17 E332 transformed cell line human CVCL_EQ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179584 CVCL_F217 GM09868 transformed cell line human CVCL_F217 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21179585 CVCL_EQ16 E331 transformed cell line human CVCL_EQ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179586 CVCL_F216 GM09987 transformed cell line human CVCL_F216 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21179587 CVCL_EQ11 E322 transformed cell line human CVCL_EQ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179588 CVCL_F211 GM09548 transformed cell line human CVCL_F211 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179589 CVCL_EQ10 E321 transformed cell line human CVCL_EQ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179590 CVCL_F210 GM09547 transformed cell line human CVCL_F210 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21179591 CVCL_F226 180BRneo transformed cell line human CVCL_F226 CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg278His (c.833G>A); ClinVar=VCV000007675; Zygosity=Unspecified (PubMed=10395545); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21179592 CVCL_EQ26 HPET-11 telomerase immortalized cell line human CVCL_EQ26 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21179593 CVCL_EQ25 HPET-5 telomerase immortalized cell line human CVCL_EQ25 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21179594 CVCL_F224 XPH27TA finite cell line human CVCL_F224 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Heterozygous (PubMed=11121128) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179595 CVCL_EQ24 HPET-1 telomerase immortalized cell line human CVCL_EQ24 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179596 CVCL_F223 XPH26TA finite cell line human CVCL_F223 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Heterozygous (PubMed=11121128) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179597 CVCL_EQ23 HT29-R cancer cell line human CVCL_EQ23 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female 21179598 CVCL_F229 AG06849 transformed cell line human CVCL_F229 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Heterozygous (from autologous cell line AG06848) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21179599 CVCL_EQ29 MCF7/XBP1 cancer cell line human CVCL_EQ29 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12801; XBP1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 21179600 CVCL_F228 GM15805 transformed cell line human CVCL_F228 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM15805; probable Female 21179601 CVCL_EQ28 MCF7/c cancer cell line human CVCL_EQ28 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female 21179602 CVCL_F227 GM15806 transformed cell line human CVCL_F227 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM15806; probable Male 21179603 CVCL_EQ27 HPET-13 telomerase immortalized cell line human CVCL_EQ27 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: HGNC; 11730; TERT Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male 21179604 CVCL_EQ22 GES-1 transformed cell line human CVCL_EQ22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal stomach; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Unspecified 21179605 CVCL_F222 XP25TA finite cell line human CVCL_F222 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr189Serfs*10 (c.564_565AT[1]) (del AT 669-670); ClinVar=VCV000000258; Zygosity=Homozygous (PubMed=11121128) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179606 CVCL_EQ21 DY36T2 cancer cell line human CVCL_EQ21 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1657Ser (c.4970A>G); ClinVar=VCV000409419; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met52Ile (c.156G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys567Arg (c.1700A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Brain. Omics: Transcriptome analysis by RNAseq Female 21179607 CVCL_F221 GM03724 finite cell line human CVCL_F221 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21179608 CVCL_EQ20 2LMP cancer cell line human CVCL_EQ20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Group: Triple negative breast cancer (TNBC) cell line 21179609 CVCL_F220 GM14505 transformed cell line human CVCL_F220 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21179610 CVCL_NK98 BayGenomics ES cell line RRQ051 embryonic stem cell house mouse CVCL_NK98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138261; Smap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179611 CVCL_NK97 BayGenomics ES cell line RRQ046 embryonic stem cell house mouse CVCL_NK97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443658; Prr14l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179612 CVCL_NK96 BayGenomics ES cell line RRQ041 embryonic stem cell house mouse CVCL_NK96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109257; Smn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179613 CVCL_NK95 BayGenomics ES cell line RRQ034 embryonic stem cell house mouse CVCL_NK95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443658; Prr14l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179614 CVCL_NK94 BayGenomics ES cell line RRQ033 embryonic stem cell house mouse CVCL_NK94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921020; Wdr70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179615 CVCL_NK93 BayGenomics ES cell line RRQ032 embryonic stem cell house mouse CVCL_NK93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893577; Stx4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179616 CVCL_NK92 BayGenomics ES cell line RRQ031 embryonic stem cell house mouse CVCL_NK92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179617 CVCL_NK91 BayGenomics ES cell line RRQ030 embryonic stem cell house mouse CVCL_NK91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108086; Hdac1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179618 CVCL_NK90 BayGenomics ES cell line RRQ028 embryonic stem cell house mouse CVCL_NK90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353636; Abt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179619 CVCL_WE31 KD-215 transformed cell line human CVCL_WE31 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179620 CVCL_WE30 KD-184 transformed cell line human CVCL_WE30 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179621 CVCL_WE35 KD-301 transformed cell line human CVCL_WE35 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179622 CVCL_WE34 KD-299 transformed cell line human CVCL_WE34 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179623 CVCL_WE33 KD-285 transformed cell line human CVCL_WE33 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179624 CVCL_WE32 KD-223 transformed cell line human CVCL_WE32 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179625 CVCL_WE39 KD-334 transformed cell line human CVCL_WE39 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179626 CVCL_WE38 KD-332 transformed cell line human CVCL_WE38 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179627 CVCL_WE37 KD-322 transformed cell line human CVCL_WE37 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179628 CVCL_WE36 KD-305 transformed cell line human CVCL_WE36 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179629 CVCL_NK89 BayGenomics ES cell line RRQ026 embryonic stem cell house mouse CVCL_NK89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179630 CVCL_NK88 BayGenomics ES cell line RRQ024 embryonic stem cell house mouse CVCL_NK88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179631 CVCL_WE20 GL-176 transformed cell line human CVCL_WE20 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179632 CVCL_WE24 GL-31 transformed cell line human CVCL_WE24 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179633 CVCL_WE23 GL-29 transformed cell line human CVCL_WE23 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179634 CVCL_WE22 GL-24 transformed cell line human CVCL_WE22 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179635 CVCL_WE21 GL-194 transformed cell line human CVCL_WE21 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179636 CVCL_WE28 KD-164 transformed cell line human CVCL_WE28 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179637 CVCL_WE27 GL-338 transformed cell line human CVCL_WE27 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179638 CVCL_WE26 GL-324 transformed cell line human CVCL_WE26 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179639 CVCL_WE25 GL-310 transformed cell line human CVCL_WE25 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179640 CVCL_WE29 KD-168 transformed cell line human CVCL_WE29 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179641 CVCL_NK99 BayGenomics ES cell line RRQ052 embryonic stem cell house mouse CVCL_NK99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915984; Ppp4r3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179642 CVCL_NK76 BayGenomics ES cell line RRQ001 embryonic stem cell house mouse CVCL_NK76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926143; Cnot10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179643 CVCL_NK75 BayGenomics ES cell line RRP266 embryonic stem cell house mouse CVCL_NK75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917164; Ints4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179644 CVCL_NK74 BayGenomics ES cell line RRP258 embryonic stem cell house mouse CVCL_NK74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298375; Cabin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179645 CVCL_NK73 BayGenomics ES cell line RRP257 embryonic stem cell house mouse CVCL_NK73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107714; Dnah8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179646 CVCL_NK72 BayGenomics ES cell line RRP251 embryonic stem cell house mouse CVCL_NK72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443895; Fry Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179647 CVCL_NK71 BayGenomics ES cell line RRP230 embryonic stem cell house mouse CVCL_NK71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923264; Zc3h18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179648 CVCL_NK70 BayGenomics ES cell line RRP227 embryonic stem cell house mouse CVCL_NK70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101760; Bicd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179649 CVCL_WE13 FS-42 transformed cell line human CVCL_WE13 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179650 CVCL_WE12 FS-4 [Human EBV-transformed] transformed cell line human CVCL_WE12 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179651 CVCL_WE11 FS-344 transformed cell line human CVCL_WE11 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179652 CVCL_WE10 FS-341 transformed cell line human CVCL_WE10 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179653 CVCL_WE17 GHY-268 transformed cell line human CVCL_WE17 CL:0000010 Population: Iranian; Ghashghayi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179654 CVCL_WE16 GHY-238 transformed cell line human CVCL_WE16 CL:0000010 Population: Iranian; Ghashghayi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179655 CVCL_WE15 FS-9 transformed cell line human CVCL_WE15 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179656 CVCL_WE14 FS-8 transformed cell line human CVCL_WE14 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179657 CVCL_WE19 GL-175 transformed cell line human CVCL_WE19 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179658 CVCL_WE18 GHY-369 transformed cell line human CVCL_WE18 CL:0000010 Population: Iranian; Ghashghayi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179659 CVCL_NK69 BayGenomics ES cell line RRP223 embryonic stem cell house mouse CVCL_NK69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289230; Pxk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179660 CVCL_NK68 BayGenomics ES cell line RRP219 embryonic stem cell house mouse CVCL_NK68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343161; Snf8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179661 CVCL_NK67 BayGenomics ES cell line RRP217 embryonic stem cell house mouse CVCL_NK67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918110; Septin10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179662 CVCL_NK66 BayGenomics ES cell line RRP214 embryonic stem cell house mouse CVCL_NK66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919570; Kifbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179663 CVCL_NK87 BayGenomics ES cell line RRQ022 embryonic stem cell house mouse CVCL_NK87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179664 CVCL_NK86 BayGenomics ES cell line RRQ021 embryonic stem cell house mouse CVCL_NK86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921570; Wdr33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179665 CVCL_NK85 BayGenomics ES cell line RRQ018 embryonic stem cell house mouse CVCL_NK85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916139; Ubac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179666 CVCL_NK84 BayGenomics ES cell line RRQ016 embryonic stem cell house mouse CVCL_NK84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197010; Sumo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179667 CVCL_NK83 BayGenomics ES cell line RRQ015 embryonic stem cell house mouse CVCL_NK83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107914; Tia1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179668 CVCL_NK82 BayGenomics ES cell line RRQ014 embryonic stem cell house mouse CVCL_NK82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890077; Foxo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179669 CVCL_NK81 BayGenomics ES cell line RRQ012 embryonic stem cell house mouse CVCL_NK81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179670 CVCL_NK80 BayGenomics ES cell line RRQ011 embryonic stem cell house mouse CVCL_NK80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179671 CVCL_WE02 FS-325 transformed cell line human CVCL_WE02 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179672 CVCL_WE01 FS-321 transformed cell line human CVCL_WE01 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179673 CVCL_WE00 FS-318 transformed cell line human CVCL_WE00 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179674 CVCL_WE06 FS-336 transformed cell line human CVCL_WE06 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179675 CVCL_WE05 FS-329 [1st copy] transformed cell line human CVCL_WE05 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: There are two cell lines named FS-329 at IBRC 21179676 CVCL_WE04 FS-329 [2nd copy] transformed cell line human CVCL_WE04 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: There are two cell lines named FS-329 at IBRC 21179677 CVCL_WE03 FS-328 transformed cell line human CVCL_WE03 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179678 CVCL_WE09 FS-340 transformed cell line human CVCL_WE09 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179679 CVCL_WE08 FS-339 transformed cell line human CVCL_WE08 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179680 CVCL_WE07 FS-337 transformed cell line human CVCL_WE07 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179681 CVCL_NK79 BayGenomics ES cell line RRQ010 embryonic stem cell house mouse CVCL_NK79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179682 CVCL_NK78 BayGenomics ES cell line RRQ007 embryonic stem cell house mouse CVCL_NK78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928268; Ireb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179683 CVCL_NK77 BayGenomics ES cell line RRQ004 embryonic stem cell house mouse CVCL_NK77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146156; Espl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179684 CVCL_NK54 BayGenomics ES cell line RRP186 embryonic stem cell house mouse CVCL_NK54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346331; Def8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179685 CVCL_NK53 BayGenomics ES cell line RRP185 embryonic stem cell house mouse CVCL_NK53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97312; Nfkb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179686 CVCL_NK52 BayGenomics ES cell line RRP184 embryonic stem cell house mouse CVCL_NK52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179687 CVCL_NK51 BayGenomics ES cell line RRP183 embryonic stem cell house mouse CVCL_NK51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921831; Sbf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179688 CVCL_NK50 BayGenomics ES cell line RRP169 embryonic stem cell house mouse CVCL_NK50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924001; Chd9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179689 CVCL_NK49 BayGenomics ES cell line RRP160 embryonic stem cell house mouse CVCL_NK49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179690 CVCL_NK48 BayGenomics ES cell line RRP157 embryonic stem cell house mouse CVCL_NK48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919579; Pcf11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179691 CVCL_NK47 BayGenomics ES cell line RRP155 embryonic stem cell house mouse CVCL_NK47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157980; Vac14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179692 CVCL_NK46 BayGenomics ES cell line RRP144 embryonic stem cell house mouse CVCL_NK46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913758; Lamtor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179693 CVCL_NK45 BayGenomics ES cell line RRP143 embryonic stem cell house mouse CVCL_NK45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179694 CVCL_NK44 BayGenomics ES cell line RRP140 embryonic stem cell house mouse CVCL_NK44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179695 CVCL_NK65 BayGenomics ES cell line RRP213 embryonic stem cell house mouse CVCL_NK65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151152; Baz2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179696 CVCL_NK64 BayGenomics ES cell line RRP212 embryonic stem cell house mouse CVCL_NK64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341865; Mark3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179697 CVCL_NK63 BayGenomics ES cell line RRP208 embryonic stem cell house mouse CVCL_NK63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196463; Fndc3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179698 CVCL_NK62 BayGenomics ES cell line RRP206 embryonic stem cell house mouse CVCL_NK62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179699 CVCL_NK61 BayGenomics ES cell line RRP202 embryonic stem cell house mouse CVCL_NK61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277113; Pacs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179700 CVCL_NK60 BayGenomics ES cell line RRP201 embryonic stem cell house mouse CVCL_NK60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277162; Cdk6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179701 CVCL_NK59 BayGenomics ES cell line RRP200 embryonic stem cell house mouse CVCL_NK59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384579; Msantd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179702 CVCL_NK58 BayGenomics ES cell line RRP198 embryonic stem cell house mouse CVCL_NK58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277186; Atg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179703 CVCL_NK57 BayGenomics ES cell line RRP197 embryonic stem cell house mouse CVCL_NK57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3603158; Tmem120b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179704 CVCL_NK56 BayGenomics ES cell line RRP196 embryonic stem cell house mouse CVCL_NK56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448530; Vps13d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179705 CVCL_NK55 BayGenomics ES cell line RRP195 embryonic stem cell house mouse CVCL_NK55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339956; Cdyl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179706 CVCL_NK32 BayGenomics ES cell line RRP100 embryonic stem cell house mouse CVCL_NK32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919257; Fndc3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179707 CVCL_NK31 BayGenomics ES cell line RRP098 embryonic stem cell house mouse CVCL_NK31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926395; Wtap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179708 CVCL_NK30 BayGenomics ES cell line RRP097 embryonic stem cell house mouse CVCL_NK30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108415; Pafah1b2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179709 CVCL_F295 GM06418 finite cell line human CVCL_F295 CL:0000010 Population: Iranian; Persian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179710 CVCL_EQ95 HBEC33-KT telomerase immortalized cell line human CVCL_EQ95 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179711 CVCL_F294 GM06417 transformed cell line human CVCL_F294 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21179712 CVCL_EQ94 HBEC32-KT telomerase immortalized cell line human CVCL_EQ94 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179713 CVCL_F293 GM05392 transformed cell line human CVCL_F293 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21179714 CVCL_EQ93 HBEC31-KT telomerase immortalized cell line human CVCL_EQ93 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179715 CVCL_F292 GM05161 transformed cell line human CVCL_F292 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21179716 CVCL_EQ92 HBEC29-KT telomerase immortalized cell line human CVCL_EQ92 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179717 CVCL_F299 GM06895 transformed cell line human CVCL_F299 HLA typing: A*02:01:01,26:01:01; B*40:01:02,40:02:01; C*02:02:02,03:04:01; DPA1*01:03:01,02:06; DPB1*02:01:02,05:01:01; DQA1*01:02:01,01:03:01; DQB1*06:03:01,06:04:01; DRB1*13:01:01,13:02:01; DRB3*02:02:01,03:01:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[23]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=25776194) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179718 CVCL_EQ99 HBEC38-KT telomerase immortalized cell line human CVCL_EQ99 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179719 CVCL_F298 GM06859 transformed cell line human CVCL_F298 HLA typing: A*02:01:01,26:01:01; B*07:02:01,51:01:01; C*07:02:01,15:02:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01G,04:01:01G; DQA1*03:01:01,05:05:01; DQB1*03:01:01,03:02:01; DRB1*04:04:01,11:01:01; DRB3*02:02:01; DRB4*01:03:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21179720 CVCL_EQ98 HBEC37-KT telomerase immortalized cell line human CVCL_EQ98 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179721 CVCL_F297 GM06855 finite cell line human CVCL_F297 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179722 CVCL_EQ97 HBEC36-KT telomerase immortalized cell line human CVCL_EQ97 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179723 CVCL_EQ96 HBEC35-KT telomerase immortalized cell line human CVCL_EQ96 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179724 CVCL_NK29 BayGenomics ES cell line RRP094 embryonic stem cell house mouse CVCL_NK29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700014; Sorbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179725 CVCL_NK28 BayGenomics ES cell line RRP092 embryonic stem cell house mouse CVCL_NK28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924823; Vps33a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179726 CVCL_NK27 BayGenomics ES cell line RRP083 embryonic stem cell house mouse CVCL_NK27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098641; Wasf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179727 CVCL_NK26 BayGenomics ES cell line RRP079 embryonic stem cell house mouse CVCL_NK26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179728 CVCL_NK25 BayGenomics ES cell line RRP078 embryonic stem cell house mouse CVCL_NK25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179729 CVCL_F291 GM05160 finite cell line human CVCL_F291 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179730 CVCL_EQ91 HBEC28-KT telomerase immortalized cell line human CVCL_EQ91 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179731 CVCL_NK24 BayGenomics ES cell line RRP073 embryonic stem cell house mouse CVCL_NK24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891112; Gmds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179732 CVCL_F290 GM03580 transformed cell line human CVCL_F290 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Heterozygous; Note=MZ allele (Coriell) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21179733 CVCL_EQ90 HBEC27-KT telomerase immortalized cell line human CVCL_EQ90 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21179734 CVCL_NK23 BayGenomics ES cell line RRP068 embryonic stem cell house mouse CVCL_NK23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448514; R3hdm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179735 CVCL_NK22 BayGenomics ES cell line RRP067 embryonic stem cell house mouse CVCL_NK22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104736; Evi5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179736 CVCL_NK43 BayGenomics ES cell line RRP138 embryonic stem cell house mouse CVCL_NK43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102718; Vav2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179737 CVCL_NK42 BayGenomics ES cell line RRP132 embryonic stem cell house mouse CVCL_NK42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352483; Mga Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179738 CVCL_NK41 BayGenomics ES cell line RRP124 embryonic stem cell house mouse CVCL_NK41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179739 CVCL_NK40 BayGenomics ES cell line RRP123 embryonic stem cell house mouse CVCL_NK40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179740 CVCL_NK39 BayGenomics ES cell line RRP121 embryonic stem cell house mouse CVCL_NK39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915546; Smu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179741 CVCL_NK38 BayGenomics ES cell line RRP119 embryonic stem cell house mouse CVCL_NK38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914416; Arl8b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179742 CVCL_NK37 BayGenomics ES cell line RRP117 embryonic stem cell house mouse CVCL_NK37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179743 CVCL_NK36 BayGenomics ES cell line RRP115 embryonic stem cell house mouse CVCL_NK36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98488; Slc6a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179744 CVCL_NK35 BayGenomics ES cell line RRP113 embryonic stem cell house mouse CVCL_NK35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915982; Carmil1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179745 CVCL_NK34 BayGenomics ES cell line RRP109 embryonic stem cell house mouse CVCL_NK34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178445; Ppan Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179746 CVCL_NK33 BayGenomics ES cell line RRP106 embryonic stem cell house mouse CVCL_NK33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104880; Psmb6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179747 CVCL_WD90 FS-236 transformed cell line human CVCL_WD90 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179748 CVCL_WD94 FS-300 transformed cell line human CVCL_WD94 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179749 CVCL_WD93 FS-3 [Human EBV-transformed] transformed cell line human CVCL_WD93 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179750 CVCL_WD92 FS-295 transformed cell line human CVCL_WD92 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179751 CVCL_WD91 FS-290 transformed cell line human CVCL_WD91 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179752 CVCL_WD98 FS-312 transformed cell line human CVCL_WD98 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179753 CVCL_WD97 FS-311 transformed cell line human CVCL_WD97 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179754 CVCL_WD96 FS-308 transformed cell line human CVCL_WD96 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179755 CVCL_WD95 FS-302 transformed cell line human CVCL_WD95 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179756 CVCL_WD99 FS-315 transformed cell line human CVCL_WD99 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179757 CVCL_WD83 FS-210 transformed cell line human CVCL_WD83 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179758 CVCL_WD82 FS-21 transformed cell line human CVCL_WD82 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179759 CVCL_WD81 FS-209 transformed cell line human CVCL_WD81 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179760 CVCL_WD80 FS-207 transformed cell line human CVCL_WD80 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179761 CVCL_WD87 FS-220 transformed cell line human CVCL_WD87 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179762 CVCL_WD86 FS-22 transformed cell line human CVCL_WD86 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179763 CVCL_WD85 FS-219 transformed cell line human CVCL_WD85 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179764 CVCL_WD84 FS-212 transformed cell line human CVCL_WD84 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179765 CVCL_WD89 FS-226 transformed cell line human CVCL_WD89 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179766 CVCL_WD88 FS-222 transformed cell line human CVCL_WD88 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179767 CVCL_WD72 FS-196 transformed cell line human CVCL_WD72 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179768 CVCL_WD71 FS-195 transformed cell line human CVCL_WD71 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179769 CVCL_WD70 FS-190 transformed cell line human CVCL_WD70 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179770 CVCL_WD76 FS-203 transformed cell line human CVCL_WD76 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179771 CVCL_WD75 FS-200 transformed cell line human CVCL_WD75 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179772 CVCL_WD74 FS-2 transformed cell line human CVCL_WD74 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179773 CVCL_WD73 FS-199 transformed cell line human CVCL_WD73 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179774 CVCL_WD79 FS-206 transformed cell line human CVCL_WD79 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179775 CVCL_WD78 FS-205 transformed cell line human CVCL_WD78 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179776 CVCL_WD77 FS-204 transformed cell line human CVCL_WD77 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179777 CVCL_WD61 FS-167 transformed cell line human CVCL_WD61 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179778 CVCL_WD60 FS-163 transformed cell line human CVCL_WD60 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179779 CVCL_WD65 FS-179 transformed cell line human CVCL_WD65 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179780 CVCL_WD64 FS-174 transformed cell line human CVCL_WD64 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179781 CVCL_WD63 FS-171 transformed cell line human CVCL_WD63 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179782 CVCL_WD62 FS-169 transformed cell line human CVCL_WD62 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179783 CVCL_WD69 FS-189 transformed cell line human CVCL_WD69 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179784 CVCL_WD68 FS-187 transformed cell line human CVCL_WD68 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179785 CVCL_WD67 FS-186 transformed cell line human CVCL_WD67 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179786 CVCL_WD66 FS-185 transformed cell line human CVCL_WD66 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179787 CVCL_WD50 AB-278 transformed cell line human CVCL_WD50 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179788 CVCL_WD54 AB-284 transformed cell line human CVCL_WD54 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179789 CVCL_WD53 AB-282 transformed cell line human CVCL_WD53 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179790 CVCL_WD52 AB-280 transformed cell line human CVCL_WD52 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179791 CVCL_WD51 AB-279 transformed cell line human CVCL_WD51 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179792 CVCL_WD58 FS-15 transformed cell line human CVCL_WD58 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179793 CVCL_WD57 FS-14 transformed cell line human CVCL_WD57 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179794 CVCL_WD56 FS-13 transformed cell line human CVCL_WD56 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179795 CVCL_WD55 FS-1 [Human EBV-transformed] transformed cell line human CVCL_WD55 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179796 CVCL_WD59 FS-162 transformed cell line human CVCL_WD59 CL:0000010 Population: Iranian; Persian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179797 CVCL_WD43 AB-265 transformed cell line human CVCL_WD43 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179798 CVCL_WD42 AB-264 transformed cell line human CVCL_WD42 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179799 CVCL_WD41 AB-263 transformed cell line human CVCL_WD41 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179800 CVCL_WD40 AB-262 transformed cell line human CVCL_WD40 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179801 CVCL_WD47 AB-270 transformed cell line human CVCL_WD47 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179802 CVCL_WD46 AB-269 transformed cell line human CVCL_WD46 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179803 CVCL_WD45 AB-267 transformed cell line human CVCL_WD45 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179804 CVCL_WD44 AB-266 transformed cell line human CVCL_WD44 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179805 CVCL_WD49 AB-276 transformed cell line human CVCL_WD49 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179806 CVCL_WD48 AB-271 transformed cell line human CVCL_WD48 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179807 CVCL_NJ99 BayGenomics ES cell line RRO614 embryonic stem cell house mouse CVCL_NJ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2667185; Myo18a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179808 CVCL_NJ98 BayGenomics ES cell line RRO611 embryonic stem cell house mouse CVCL_NJ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179809 CVCL_NJ97 BayGenomics ES cell line RRO610 embryonic stem cell house mouse CVCL_NJ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179810 CVCL_NJ96 BayGenomics ES cell line RRO608 embryonic stem cell house mouse CVCL_NJ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443308; Mcph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179811 CVCL_NJ95 BayGenomics ES cell line RRO600 embryonic stem cell house mouse CVCL_NJ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179812 CVCL_NJ94 BayGenomics ES cell line RRO595 embryonic stem cell house mouse CVCL_NJ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917285; Rab28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179813 CVCL_NJ93 BayGenomics ES cell line RRO592 embryonic stem cell house mouse CVCL_NJ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179814 CVCL_NJ92 BayGenomics ES cell line RRO574 embryonic stem cell house mouse CVCL_NJ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179815 CVCL_NJ91 BayGenomics ES cell line RRO564 embryonic stem cell house mouse CVCL_NJ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180098; Csad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179816 CVCL_NJ90 BayGenomics ES cell line RRO553 embryonic stem cell house mouse CVCL_NJ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914864; Atp6v1h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179817 CVCL_WD32 AB-247 transformed cell line human CVCL_WD32 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179818 CVCL_WD31 AB-245 transformed cell line human CVCL_WD31 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179819 CVCL_WD30 AB-244 transformed cell line human CVCL_WD30 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179820 CVCL_WD36 AB-255 transformed cell line human CVCL_WD36 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179821 CVCL_WD35 AB-251 transformed cell line human CVCL_WD35 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179822 CVCL_WD34 AB-250 transformed cell line human CVCL_WD34 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179823 CVCL_WD33 AB-248 transformed cell line human CVCL_WD33 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179824 CVCL_WD39 AB-261 transformed cell line human CVCL_WD39 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179825 CVCL_WD38 AB-260 transformed cell line human CVCL_WD38 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179826 CVCL_WD37 AB-257 transformed cell line human CVCL_WD37 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179827 CVCL_NJ89 BayGenomics ES cell line RRO551 embryonic stem cell house mouse CVCL_NJ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921690; Cmip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21179828 CVCL_WD21 AB-231 transformed cell line human CVCL_WD21 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179829 CVCL_WD20 AB-170 transformed cell line human CVCL_WD20 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179830 CVCL_WD25 AB-235 transformed cell line human CVCL_WD25 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179831 CVCL_WD24 AB-234 transformed cell line human CVCL_WD24 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179832 CVCL_WD23 AB-233 transformed cell line human CVCL_WD23 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179833 CVCL_WD22 AB-232 transformed cell line human CVCL_WD22 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179834 CVCL_WD29 AB-243 transformed cell line human CVCL_WD29 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179835 CVCL_WD28 AB-241 transformed cell line human CVCL_WD28 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179836 CVCL_WD27 AB-239 transformed cell line human CVCL_WD27 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179837 CVCL_WD26 AB-237 transformed cell line human CVCL_WD26 CL:0000010 Population: Iranian; Arab; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179838 CVCL_EQ09 E320 transformed cell line human CVCL_EQ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179839 CVCL_F209 GM09546 finite cell line human CVCL_F209 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (Coriell) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179840 CVCL_EQ04 E306 transformed cell line human CVCL_EQ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179841 CVCL_F204 ND27760 finite cell line human CVCL_F204 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: Coriell; ND27760; true Female 21179842 CVCL_EQ03 E305 transformed cell line human CVCL_EQ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179843 CVCL_F203 ND00139 transformed cell line human CVCL_F203 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179844 CVCL_EQ02 E270 transformed cell line human CVCL_EQ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179845 CVCL_F202 ND34391 induced pluripotent stem cell human CVCL_F202 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34391; true Female 21179846 CVCL_EQ01 E265 transformed cell line human CVCL_EQ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179847 CVCL_F201 GM03700 finite cell line human CVCL_F201 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179848 CVCL_EQ08 E319 transformed cell line human CVCL_EQ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179849 CVCL_F208 GM08436 transformed cell line human CVCL_F208 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp1548Thrfs*14 (c.4638_4641GATA[1]) (c.4642_4645delGATA); ClinVar=VCV000232070; Zygosity=Heterozygous (PubMed=8808599); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179850 CVCL_EQ07 E311 transformed cell line human CVCL_EQ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179851 CVCL_F207 GM08389 finite cell line human CVCL_F207 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21179852 CVCL_EQ06 E308 transformed cell line human CVCL_EQ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179853 CVCL_F206 GM17940 finite cell line human CVCL_F206 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 3 repeats) (Coriell) Derived from sampling site: Skeletal muscle Cell type=Myoblast.. Discontinued: Coriell; GM17940; probable Male 21179854 CVCL_EQ05 E307 transformed cell line human CVCL_EQ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179855 CVCL_F205 GM17939 transformed cell line human CVCL_F205 CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Heterozygous; Note=D4Z4 repeat contraction (to 3 repeats) (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179856 CVCL_EQ00 E264 transformed cell line human CVCL_EQ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179857 CVCL_F200 GM03704 hybridoma CVCL_F200 CL:0000010 Monoclonal antibody isotype: IgM. 21179858 CVCL_3V70 HQ02117 transformed cell line human CVCL_3V70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179859 CVCL_4770 J774.1 cancer cell line house mouse CVCL_4770 CL:0000010 Breed/subspecies: BALB/c. Female 21179860 CVCL_3V63 HQ02110 transformed cell line human CVCL_3V63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179861 CVCL_4762 BRF-55T transformed cell line human CVCL_4762 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179862 CVCL_3V62 HQ02109 transformed cell line human CVCL_3V62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179863 CVCL_4761 BRF-41T transformed cell line human CVCL_4761 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179864 CVCL_3V61 HQ02108 transformed cell line human CVCL_3V61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179865 CVCL_4760 BPH-1-CAFTD-08 transformed cell line human CVCL_4760 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179866 CVCL_3V60 HQ02107 transformed cell line human CVCL_3V60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179867 CVCL_3V67 HQ02114 transformed cell line human CVCL_3V67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179868 CVCL_4767 RC-58T/hTERT telomerase immortalized cell line human CVCL_4767 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21179869 CVCL_3V66 HQ02113 transformed cell line human CVCL_3V66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179870 CVCL_4766 S006AA finite cell line human CVCL_4766 CL:0000010 Derived from sampling site: Prostate. Male Problematic cell line: Possibly misidentified Was reported to originate from the same patient as E006AA (Cellosaurus=CVCL_4834) which has been shown to be a 786-O derivative (Cellosaurus=CVCL_1051). But as this cell line is non-tumorigenic it could well originate from the prostate carcinoma patient. 21179871 CVCL_3V65 HQ02112 transformed cell line human CVCL_3V65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179872 CVCL_4765 Ten12 cancer cell line human CVCL_4765 CL:0000010 Male 21179873 CVCL_3V64 HQ02111 transformed cell line human CVCL_3V64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179874 CVCL_4764 SO-MI cancer cell line human CVCL_4764 CL:0000010 Population: Japanese; Derived from sampling site: Prostate. Male Doubling time: 52-72 hours (PubMed=12772193) 21179875 CVCL_4769 CABA I cancer cell line human CVCL_4769 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: ~18 hours (PubMed=9220498) Problematic cell line: Authors of PubMed=26934856 have only been able to detect 3 out of 16 STR loci Either there was a problem with the STR detection or this cell line is contaminated by non-human DNA (CelloPub=CLPUB00451). 21179876 CVCL_3V69 HQ02116 transformed cell line human CVCL_3V69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179877 CVCL_4768 CA-7T2 transformed cell line human CVCL_4768 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21179878 CVCL_3V68 HQ02115 transformed cell line human CVCL_3V68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179879 CVCL_3V81 HQ02129 transformed cell line human CVCL_3V81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179880 CVCL_4781 ND-1 cancer cell line human CVCL_4781 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (PubMed=11304728); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (PubMed=11304728) Population: Caucasian; Derived from metastatic site: Brain. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00244 Problematic cell line: Contaminated Shown to be a DU145 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a patient of unknown age with a primary prostate adenocarcinoma. 21179881 CVCL_3V80 HQ02128 transformed cell line human CVCL_3V80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179882 CVCL_3V74 HQ02122 transformed cell line human CVCL_3V74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179883 CVCL_4774 MX-1 cancer cell line human CVCL_4774 HLA typing: A*11:01,74:01; B*15:03,35:01; C*02:02,04:01; DQB1*03:09,05:01; DRB1*01:03,11:08 (PubMed=25960936); HLA typing: A*11:01,74:01; B*15:03,35:01; C*02:02,04:01; DRB1*01:03,01:03 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52Valfs*3 (c.154_158delCAATG); Zygosity=Unspecified (PubMed=29045385) Population: Caucasian; Derived from sampling site: Breast. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a tumor xenograft established in atyhmic mice Doubling time: 30-35 hours (CLS); 113.83 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21179884 CVCL_3V73 HQ02121 transformed cell line human CVCL_3V73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179885 CVCL_4773 U-343MGa cancer cell line human CVCL_4773 Genome ancestry: African=1.11%; Native American=0%; East Asian, North=4.21%; East Asian, South=0%; South Asian=0%; European, North=72.65%; European, South=22.03% (PubMed=30894373) CL:0000010 Derived from sampling site: Brain; temporal lobe. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21179886 CVCL_3V72 HQ02120 transformed cell line human CVCL_3V72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179887 CVCL_4772 MEB-4 cancer cell line house mouse CVCL_4772 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21179888 CVCL_3V71 HQ02118 transformed cell line human CVCL_3V71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179889 CVCL_4771 KP-N-NS cancer cell line human CVCL_4771 CL:0000010 Population: Japanese; Derived from metastatic site: Brain. Female Characteristics: Neuroblastic type (N-type) (PubMed=8297818) 21179890 CVCL_3V78 HQ02126 transformed cell line human CVCL_3V78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179891 CVCL_4778 PPC-1 cancer cell line human CVCL_4778 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728) Population: Caucasian; Derived from metastatic site: Bone. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: ATCC; HTB-190; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00153 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from a 67 year old male patient with prostate carcinoma. 21179892 CVCL_3V77 HQ02125 transformed cell line human CVCL_3V77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179893 CVCL_4777 NCU-F1 finite cell line human CVCL_4777 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179894 CVCL_4776 HeLa-80 cancer cell line human CVCL_4776 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21179895 CVCL_3V76 HQ02124 transformed cell line human CVCL_3V76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179896 CVCL_4775 Faza 967 cancer cell line Norway rat CVCL_4775 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21179897 CVCL_3V75 HQ02123 transformed cell line human CVCL_3V75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179898 CVCL_3V79 HQ02127 transformed cell line human CVCL_3V79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179899 CVCL_4779 Y-ML-1B cancer cell line human CVCL_4779 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Unspecified (PubMed=12377411) Population: Japanese; Derived from sampling site: Lung. Male Characteristics: Expresses high levels of CSF2, CSF3, IL6 and IL8 (PubMed=12377411) Doubling time: 19 hours (PubMed=12377411) 21179900 CVCL_4741 CWR21 cancer cell line human CVCL_4741 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from sampling site: Prostate. Male 21179901 CVCL_3V41 HQ02088 transformed cell line human CVCL_3V41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179902 CVCL_4740 CWR31 cancer cell line human CVCL_4740 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from sampling site: Prostate. Male 21179903 CVCL_3V40 HQ02087 transformed cell line human CVCL_3V40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179904 CVCL_3V45 HQ02092 transformed cell line human CVCL_3V45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179905 CVCL_4745 LAPC-4*2 cancer cell line human CVCL_4745 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Lymph node. Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21179906 CVCL_3V44 HQ02091 transformed cell line human CVCL_3V44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179907 CVCL_4744 LAPC-4 cancer cell line human CVCL_4744 HLA typing: A*01:01,02:01; B*14:06,46:01; C*05:01,05:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=11304728; PubMed=14518029) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Lymph node. Omics: Array-based CGH; Omics: Deep quantitative phosphoproteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-13009; true Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104; PubMed=21750403) Doubling time: ~72 hours; 60.87 hours (GrayJW panel) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1441 21179908 CVCL_3V43 HQ02090 transformed cell line human CVCL_3V43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179909 CVCL_4743 LAPC-3 cancer cell line human CVCL_4743 CL:0000010 Derived from sampling site: Prostate. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1440 21179910 CVCL_4742 DuK50 finite cell line human CVCL_4742 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21179911 CVCL_3V42 HQ02089 transformed cell line human CVCL_3V42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179912 CVCL_3V49 HQ02096 transformed cell line human CVCL_3V49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179913 CVCL_4749 N15C6 transformed cell line human CVCL_4749 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Array-based CGH; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21179914 CVCL_3V48 HQ02095 transformed cell line human CVCL_3V48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179915 CVCL_4748 MDA-PCa-2b cancer cell line human CVCL_4748 Genome ancestry: African=90.02%; Native American=0%; East Asian, North=2.64%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=7.34% (PubMed=30894373) CL:0000010 Population: African American; Derived from metastatic site: Bone. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42-53 hours (in BRFF-HPC1 + 20% FBS), 61-73 hours (in F12K(+) + 20% FBS) (PubMed=9815652); 89.15 hours (GrayJW panel); Microsatellite instability: Instable (MSI) (PubMed=23671654; PubMed=31068700;) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21179916 CVCL_3V47 HQ02094 transformed cell line human CVCL_3V47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179917 CVCL_4747 MDA-PCa-2a cancer cell line human CVCL_4747 CL:0000010 Population: African American; Derived from metastatic site: Bone. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2421; true Male Doubling time: 82 hours (in BRFF-HPC1 + 20% FBS), 87-93 hours (in F12K(+) + 20% FBS) (PubMed=9815652) 21179918 CVCL_3V46 HQ02093 transformed cell line human CVCL_3V46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179919 CVCL_4746 LAPC-9 cancer cell line human CVCL_4746 CL:0000010 Derived from metastatic site: Bone; femur. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1442 21179920 CVCL_4752 BPH-1 TETD-B transformed cell line human CVCL_4752 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179921 CVCL_3V52 HQ02099 transformed cell line human CVCL_3V52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179922 CVCL_4751 BPH-1 TETD-A transformed cell line human CVCL_4751 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179923 CVCL_3V51 HQ02098 transformed cell line human CVCL_3V51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179924 CVCL_3V50 HQ02097 transformed cell line human CVCL_3V50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179925 CVCL_4750 LuCaP 49 cancer cell line human CVCL_4750 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21179926 CVCL_4756 BPH-1-CAFTD-04 transformed cell line human CVCL_4756 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179927 CVCL_3V56 HQ02103 transformed cell line human CVCL_3V56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179928 CVCL_4755 BPH-1-CAFTD-03 transformed cell line human CVCL_4755 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179929 CVCL_3V55 HQ02102 transformed cell line human CVCL_3V55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179930 CVCL_4754 BPH-1-CAFTD-02 transformed cell line human CVCL_4754 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179931 CVCL_3V54 HQ02101 transformed cell line human CVCL_3V54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179932 CVCL_4753 BPH-1-CAFTD-01 transformed cell line human CVCL_4753 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179933 CVCL_3V53 HQ02100 transformed cell line human CVCL_3V53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179934 CVCL_4759 BPH-1-CAFTD-07 transformed cell line human CVCL_4759 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179935 CVCL_3V59 HQ02106 transformed cell line human CVCL_3V59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179936 CVCL_4758 BPH-1-CAFTD-06 transformed cell line human CVCL_4758 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179937 CVCL_3V58 HQ02105 transformed cell line human CVCL_3V58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179938 CVCL_4757 BPH-1-CAFTD-05 transformed cell line human CVCL_4757 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate. Male 21179939 CVCL_3V57 HQ02104 transformed cell line human CVCL_3V57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179940 CVCL_3V23 HQ02065 transformed cell line human CVCL_3V23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179941 CVCL_4723 N18 hybrid cell line CVCL_4723 CL:0000010 21179942 CVCL_4722 Faof1C2 cancer cell line Norway rat CVCL_4722 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21179943 CVCL_3V22 HQ02064 transformed cell line human CVCL_3V22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179944 CVCL_4721 C3H/MCA clone 16 transformed cell line house mouse CVCL_4721 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21179945 CVCL_3V21 HQ02063 transformed cell line human CVCL_3V21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179946 CVCL_4720 C3H/MCA clone 15 transformed cell line house mouse CVCL_4720 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21179947 CVCL_3V20 HQ02062 transformed cell line human CVCL_3V20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179948 CVCL_3V27 HQ02071 transformed cell line human CVCL_3V27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179949 CVCL_4727 NCU-F2 finite cell line human CVCL_4727 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179950 CVCL_3V26 HQ02070 transformed cell line human CVCL_3V26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179951 CVCL_4726 NCU-F10 finite cell line human CVCL_4726 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179952 CVCL_3V25 HQ02069 transformed cell line human CVCL_3V25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179953 CVCL_4724 C-1300 clone N18 cancer cell line house mouse CVCL_4724 CL:0000010 Breed/subspecies: A/J. Omics: Transcriptome analysis by microarray Male 21179954 CVCL_3V24 HQ02066 transformed cell line human CVCL_3V24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179955 CVCL_3V29 HQ02074 transformed cell line human CVCL_3V29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179956 CVCL_4729 NCU-F4 finite cell line human CVCL_4729 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179957 CVCL_3V28 HQ02072 transformed cell line human CVCL_3V28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179958 CVCL_4728 NCU-F3 finite cell line human CVCL_4728 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179959 CVCL_3V30 HQ02075 transformed cell line human CVCL_3V30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179960 CVCL_4730 NCU-F6 finite cell line human CVCL_4730 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21179961 CVCL_4734 ALVA-41 cancer cell line human CVCL_4734 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: 22-24 hours (PubMed=7533340); 20 hours (PubMed=8561862) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00174 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from the bone metastasis in a patient with well differentiated, stage B2, adenocarcinoma of the prostate. 21179962 CVCL_3V34 HQ02079 transformed cell line human CVCL_3V34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179963 CVCL_4733 A-875 cancer cell line human CVCL_4733 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 21179964 CVCL_3V33 HQ02078 transformed cell line human CVCL_3V33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179965 CVCL_3V32 HQ02077 transformed cell line human CVCL_3V32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179966 CVCL_4732 NCU-F8 finite cell line human CVCL_4732 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21179967 CVCL_3V31 HQ02076 transformed cell line human CVCL_3V31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179968 CVCL_4731 NCU-F7 finite cell line human CVCL_4731 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21179969 CVCL_4738 DuPro-1 cancer cell line human CVCL_4738 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=8510267) Population: Caucasian; Derived from metastatic site: Bone. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00189 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=14518029; PubMed=20143388). 21179970 CVCL_3V38 HQ02085 transformed cell line human CVCL_3V38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179971 CVCL_4737 ALVA-31 cancer cell line human CVCL_4737 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: ~26 hours (PubMed=7681207); 23 hours (PubMed=8561862) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00173 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=11304728; PubMed=20143388; CelloPub=CLPUB00698). Originally thought to originate from the tumor mass removed during a radical prostatectomy in a patient with well differentiated, stage B2, adenocarcinoma of the prostate. 21179972 CVCL_3V37 HQ02084 transformed cell line human CVCL_3V37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179973 CVCL_4736 ALVA-55 cancer cell line human CVCL_4736 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: 22 hours (PubMed=8561862) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00175 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=14518029; PubMed=20143388). Originally thought to originate from the lymph node metastasis in a patient with well differentiated, stage B2, adenocarcinoma of the prostate. 21179974 CVCL_3V36 HQ02083 transformed cell line human CVCL_3V36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179975 CVCL_4735 ALVA-101 cancer cell line human CVCL_4735 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: 24 hours (PubMed=8561862) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00176 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=14518029; PubMed=20143388). 21179976 CVCL_3V35 HQ02082 transformed cell line human CVCL_3V35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179977 CVCL_4739 CWR91 cancer cell line human CVCL_4739 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from sampling site: Prostate. Male 21179978 CVCL_3V39 HQ02086 transformed cell line human CVCL_3V39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179979 CVCL_4701 CHO-LY-B spontaneously immortalized cell line CVCL_4701 CL:0000010 Derived from sampling site: Ovary. Female 21179980 CVCL_3V01 HQ02042 transformed cell line human CVCL_3V01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179981 CVCL_4700 CHO-6 spontaneously immortalized cell line CVCL_4700 CL:0000010 Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ovary. Female Characteristics: Resistant to infection by Chlamydia pneumoniae, Chlamydia psittaci and Chlamydia trachomatis; Characteristics: Has a defect in the processing of the signal sequence of P4HB/PDIA1 which lead to impaired chlamydial attachment and infectivity 21179982 CVCL_3V00 HQ02041 transformed cell line human CVCL_3V00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179983 CVCL_4705 DC3F/ADX spontaneously immortalized cell line CVCL_4705 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21179984 CVCL_3V05 HQ02046 transformed cell line human CVCL_3V05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179985 CVCL_4704 DC3F spontaneously immortalized cell line CVCL_4704 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21179986 CVCL_3V04 HQ02045 transformed cell line human CVCL_3V04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179987 CVCL_4703 CHO-CHRB30 spontaneously immortalized cell line CVCL_4703 CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female 21179988 CVCL_3V03 HQ02044 transformed cell line human CVCL_3V03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179989 CVCL_4702 CHOP transformed cell line CVCL_4702 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Ovary. Female Characteristics: Supports the extrachromosomal replication of eukaryotic expression vector carrying a polyoma origin of replication 21179990 CVCL_3V02 HQ02043 transformed cell line human CVCL_3V02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179991 CVCL_3V09 HQ02050 transformed cell line human CVCL_3V09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179992 CVCL_4709 V79MZh11B1 spontaneously immortalized cell line CVCL_4709 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2591; CYP11B1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21179993 CVCL_3V08 HQ02049 transformed cell line human CVCL_3V08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179994 CVCL_4708 SK32 spontaneously immortalized cell line CVCL_4708 CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Female 21179995 CVCL_3V07 HQ02048 transformed cell line human CVCL_3V07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21179996 CVCL_4707 IIC9 spontaneously immortalized cell line CVCL_4707 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21179997 CVCL_4706 Hpr-4 spontaneously immortalized cell line CVCL_4706 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21179998 CVCL_3V06 HQ02047 transformed cell line human CVCL_3V06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21179999 CVCL_3V12 HQ02053 transformed cell line human CVCL_3V12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180000 CVCL_4712 KU-1 cancer cell line human CVCL_4712 CL:0000010 Population: Japanese. 21180001 CVCL_4711 BLSC-KU-1 cancer cell line CVCL_4711 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese black. Female Virology: Contains a single copy of a defective provirus with with approximately 1.7 kbp deleted from the C-terminal of the pol gene to most of the env-gp51 gene The provirus is integrated in a an intron of the RPTOR gene (PubMed=35632737). 21180002 CVCL_3V11 HQ02052 transformed cell line human CVCL_3V11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180003 CVCL_3V10 HQ02051 transformed cell line human CVCL_3V10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180004 CVCL_4710 V79MZh11B2 spontaneously immortalized cell line CVCL_4710 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2592; CYP11B2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21180005 CVCL_3V16 HQ02057 transformed cell line human CVCL_3V16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180006 CVCL_4716 NOR-P1 cancer cell line human CVCL_4716 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Discontinued: RCB; RCB2139; true Male Doubling time: 16 hours (PubMed=10822130) 21180007 CVCL_3V15 HQ02056 transformed cell line human CVCL_3V15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180008 CVCL_4715 M10 [Human melanoma] cancer cell line human CVCL_4715 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12269. 21180009 CVCL_3V14 HQ02055 transformed cell line human CVCL_3V14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180010 CVCL_4714 KU-7 cancer cell line human CVCL_4714 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Part of: BLA-40 bladder carcinoma cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00480 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=23500642). Was thought to originate from an urinary bladder papillary carcinoma. 21180011 CVCL_4713 BLSC-KU-17 cancer cell line CVCL_4713 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Japanese Shorthorn. Female Virology: Contains a single copy of a complete provirus The provirus is integrated in the intergenic region between the RTN4IPI and ATG5 genes (PubMed=35632737). 21180012 CVCL_3V13 HQ02054 transformed cell line human CVCL_3V13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180013 CVCL_3V19 HQ02061 transformed cell line human CVCL_3V19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180014 CVCL_4719 S-2 cancer cell line human CVCL_4719 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male 21180015 CVCL_3V18 HQ02059 transformed cell line human CVCL_3V18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180016 CVCL_4718 PK-8 cancer cell line human CVCL_4718 HLA typing: A*24:02,31:01; B*27:04,35:01; C*04:01,12:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Hemizygous (PubMed=11115575); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln167Ter (c.499C>T); ClinVar=VCV000528250; Zygosity=Unspecified (PubMed=11115575) Population: Japanese; Derived from metastatic site: Liver. Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Discontinued: RCB; RCB2096; true Unspecified Characteristics: Established from a xenograft Doubling time: 56 hours (PubMed=3547771) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21180017 CVCL_3V17 HQ02058 transformed cell line human CVCL_3V17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180018 CVCL_4717 PK-1 cancer cell line human CVCL_4717 Genome ancestry: African=0.26%; Native American=0%; East Asian, North=88.21%; East Asian, South=8.65%; South Asian=0.93%; European, North=0.7%; European, South=1.25% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11115575; PubMed=22490663; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (PubMed=11115575; PubMed=22490663; DepMap) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=3547771; PubMed=6205469); 24.1 hours (PubMed=8872523) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21180019 CVCL_EJ19 LD660 cancer cell line human CVCL_EJ19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9850064). Unspecified 21180020 CVCL_EJ14 LD600 cancer cell line human CVCL_EJ14 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Gln (c.239G>A) (p.Pro94Pro, c.282G>A); ClinVar=VCV000376385; Zygosity=Unspecified (PubMed=9850064). Unspecified 21180021 CVCL_EJ13 LD583 cancer cell line human CVCL_EJ13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064) Derived from metastatic site: Lymph node. Unspecified 21180022 CVCL_EJ12 LD137 cancer cell line human CVCL_EJ12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=9850064). 21180023 CVCL_EJ11 HCC827 ER5 cancer cell line human CVCL_EJ11 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Female 21180024 CVCL_EJ18 LD630 cancer cell line human CVCL_EJ18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Unspecified (PubMed=9850064). Unspecified 21180025 CVCL_EJ17 LD627 cancer cell line human CVCL_EJ17 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Unspecified (PubMed=9850064). Unspecified 21180026 CVCL_EJ16 LD611 cancer cell line human CVCL_EJ16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064) Derived from metastatic site: Lymph node. Unspecified 21180027 CVCL_EJ15 LD605 cancer cell line human CVCL_EJ15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064). Unspecified 21180028 CVCL_EJ10 HCC827 ER4 cancer cell line human CVCL_EJ10 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Female 21180029 CVCL_EJ25 TTN-45 cancer cell line human CVCL_EJ25 CL:0000010 21180030 CVCL_EJ24 RTK(J)-4N cancer cell line human CVCL_EJ24 CL:0000010 Population: Japanese. 21180031 CVCL_EJ23 NDCS-1 cancer cell line human CVCL_EJ23 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 5383; IDH2; None_reported; -; Zygosity=- (PubMed=22057234); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.724T>A); ClinVar=VCV000376579; Zygosity=Unspecified (PubMed=17653762) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 30 hours (PubMed=17653762) 21180032 CVCL_EJ22 LD71 cancer cell line human CVCL_EJ22 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9850064). Unspecified 21180033 CVCL_EJ29 GM01562 transformed cell line human CVCL_EJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180034 CVCL_EJ28 GM01461 transformed cell line human CVCL_EJ28 HLA typing: A*02,03; B*w22,w40 (Coriell=GM01461) CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr67Ile (c.200C>T); ClinVar=VCV000002939; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180035 CVCL_EJ27 GM01456 transformed cell line human CVCL_EJ27 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr67Ile (c.200C>T); ClinVar=VCV000002939; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180036 CVCL_EJ26 YAMRT cancer cell line human CVCL_EJ26 CL:0000010 21180037 CVCL_EJ21 LD700 cancer cell line human CVCL_EJ21 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Unspecified (PubMed=9850064). Unspecified 21180038 CVCL_EJ20 LD692 cancer cell line human CVCL_EJ20 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=9850064) Derived from metastatic site: Lymph node. Unspecified 21180039 CVCL_EJ09 HCC827 ER3 cancer cell line human CVCL_EJ09 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 21180040 CVCL_EJ08 HCC827 ER2 cancer cell line human CVCL_EJ08 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 21180041 CVCL_EJ03 HN-6n1 cancer cell line human CVCL_EJ03 CL:0000010 Derived from metastatic site: Submandibular lymph node. Male Doubling time: 30 hours (PubMed=7284233) 21180042 CVCL_EJ02 UKEAC-99 cancer cell line human CVCL_EJ02 CL:0000010 Miscellaneous: Cell line has been discarded (PubMed=26951071) Derived from sampling site: Pancreas; ampulla of Vater. Male Doubling time: 27 hours (PubMed=12680226) 21180043 CVCL_EJ01 POE cancer cell line human CVCL_EJ01 From: Delattre O.; Institut Curie; Paris; France CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=11423975); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (PubMed=25223734). Unspecified 21180044 CVCL_EJ00 OLGS1 cancer cell line human CVCL_EJ00 CL:0000010 Female 21180045 CVCL_EJ07 HCC827 ER1 cancer cell line human CVCL_EJ07 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Lung. Omics: Transcriptome analysis by microarray Female 21180046 CVCL_EJ06 794CSF cancer cell line human CVCL_EJ06 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22082607) Derived from metastatic site: Cerebrospinal fluid. Male 21180047 CVCL_EJ05 YT-1 cancer cell line human CVCL_EJ05 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion Cell type=Natural killer cell.. Male 21180048 CVCL_EJ04 HN-16 cancer cell line human CVCL_EJ04 CL:0000010 Derived from sampling site: Pharynx; hypopharynx. 21180049 CVCL_3V92 HQ02140 transformed cell line human CVCL_3V92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180050 CVCL_4792 LNCaP-Rf cancer cell line human CVCL_4792 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Doubling time: 34.14 hours (GrayJW panel) 21180051 CVCL_3V91 HQ02139 transformed cell line human CVCL_3V91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180052 CVCL_4791 LNCaP-AI cancer cell line human CVCL_4791 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by microarray Male 21180053 CVCL_3V90 HQ02138 transformed cell line human CVCL_3V90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180054 CVCL_4790 SF [Human fibroblast] finite cell line human CVCL_4790 CL:0000010 Miscellaneous: Cell line no longer available; was distributed by Viromed Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21180055 CVCL_3V85 HQ02133 transformed cell line human CVCL_3V85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180056 CVCL_4785 LNCaP C4-2B2 cancer cell line human CVCL_4785 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21180057 CVCL_3V84 HQ02132 transformed cell line human CVCL_3V84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180058 CVCL_4784 LNCaP C4-2B cancer cell line human CVCL_4784 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Bone metastatic Doubling time: 24-36 hours (ATCC=CRL-3315) 21180059 CVCL_3V83 HQ02131 transformed cell line human CVCL_3V83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180060 CVCL_4783 LNCaP C4 cancer cell line human CVCL_4783 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Derived from a tumor that developed in castrated nude mice injected with LNCaP cells Doubling time: 26.30 hours (GrayJW panel) 21180061 CVCL_3V82 HQ02130 transformed cell line human CVCL_3V82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180062 CVCL_4782 LNCaP C4-2 cancer cell line human CVCL_4782 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=26499105); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Exhibits androgen-independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice Doubling time: 28.96 hours (GrayJW panel) 21180063 CVCL_3V89 HQ02137 transformed cell line human CVCL_3V89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180064 CVCL_3V88 HQ02136 transformed cell line human CVCL_3V88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180065 CVCL_4788 LNCaP C4-2B5 cancer cell line human CVCL_4788 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21180066 CVCL_3V87 HQ02135 transformed cell line human CVCL_3V87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180067 CVCL_4787 LNCaP C4-2B4 cancer cell line human CVCL_4787 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21180068 CVCL_3V86 HQ02134 transformed cell line human CVCL_3V86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180069 CVCL_4786 LNCaP C4-2B3 cancer cell line human CVCL_4786 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male 21180070 CVCL_3V96 HQ02144 transformed cell line human CVCL_3V96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180071 CVCL_4796 Z-33 cancer cell line human CVCL_4796 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=8751477; PubMed=10071072) Population: Caucasian; Derived from sampling site: Bone marrow. Female Doubling time: 24-30 hours (PubMed=8751477) 21180072 CVCL_3V95 HQ02143 transformed cell line human CVCL_3V95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180073 CVCL_4795 PU-34 transformed cell line CVCL_4795 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Unspecified Group: Non-human primate cell line 21180074 CVCL_4794 CTPE transformed cell line human CVCL_4794 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Cadmium(2+)(ChEBI; CHEBI:48775); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180075 CVCL_3V94 HQ02142 transformed cell line human CVCL_3V94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180076 CVCL_3V93 HQ02141 transformed cell line human CVCL_3V93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180077 CVCL_4793 LNCaP-abl cancer cell line human CVCL_4793 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established after 10 months of propagation of LNCaP in steroid-depleted medium 21180078 CVCL_3V99 HQ02147 transformed cell line human CVCL_3V99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180079 CVCL_4799 XG-3 cancer cell line human CVCL_4799 HLA typing: A*02,32; B*35,44; C*04,05 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21180080 CVCL_3V98 HQ02146 transformed cell line human CVCL_3V98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180081 CVCL_4798 XG-2 cancer cell line human CVCL_4798 HLA typing: A*01,29; B*08,44; C*07,16:01 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=1373872; PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: IL6 dependent; Characteristics: Produces IgG lambda 21180082 CVCL_3V97 HQ02145 transformed cell line human CVCL_3V97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180083 CVCL_4797 XG-1 cancer cell line human CVCL_4797 HLA typing: A*02:01,29; B*40,44; C*02:02,16:01 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000040469; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asn (c.376T>A); ClinVar=VCV000428871; Zygosity=Unspecified (PubMed=1373872; PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: IL6 dependent; Characteristics: Produces IgA kappa 21180084 CVCL_NC18 BayGenomics ES cell line RRJ565 embryonic stem cell house mouse CVCL_NC18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109127; Tsc22d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180085 CVCL_NC17 BayGenomics ES cell line RRJ560 embryonic stem cell house mouse CVCL_NC17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180086 CVCL_NC16 BayGenomics ES cell line RRJ558 embryonic stem cell house mouse CVCL_NC16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700014; Sorbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180087 CVCL_NC15 BayGenomics ES cell line RRJ557 embryonic stem cell house mouse CVCL_NC15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180088 CVCL_NC14 BayGenomics ES cell line RRJ555 embryonic stem cell house mouse CVCL_NC14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180089 CVCL_EI80 M229 R13 cancer cell line human CVCL_EI80 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180090 CVCL_NC13 BayGenomics ES cell line RRJ552 embryonic stem cell house mouse CVCL_NC13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914672; Dhdds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180091 CVCL_NC12 BayGenomics ES cell line RRJ551 embryonic stem cell house mouse CVCL_NC12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146236; Slc45a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180092 CVCL_NC11 BayGenomics ES cell line RRJ548 embryonic stem cell house mouse CVCL_NC11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99948; Zfhx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180093 CVCL_NC10 BayGenomics ES cell line RRJ545 embryonic stem cell house mouse CVCL_NC10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915401; Wls Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180094 CVCL_EI79 M229 R12 cancer cell line human CVCL_EI79 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180095 CVCL_EI78 M229 R11 cancer cell line human CVCL_EI78 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180096 CVCL_EI73 HDC-8NMIIK1 cancer cell line human CVCL_EI73 CL:0000010 Male Characteristics: Derived from parent cell line after passage in nude mice. 21180097 CVCL_EI72 HCLv-07 cancer cell line human CVCL_EI72 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180098 CVCL_EI71 EW-23 cancer cell line human CVCL_EI71 From: Delattre O.; Institut Curie; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg807fs; Zygosity=Unspecified (PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=25223734). Unspecified 21180099 CVCL_EI70 DCR9 cancer cell line human CVCL_EI70 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ser492Arg (c.1476C>A); ClinVar=VCV000376341; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22270724) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Ascites. Female 21180100 CVCL_EI77 M229 R10 cancer cell line human CVCL_EI77 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180101 CVCL_EI76 M229 R1 cancer cell line human CVCL_EI76 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180102 CVCL_NC09 BayGenomics ES cell line RRJ543 embryonic stem cell house mouse CVCL_NC09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180103 CVCL_EI75 K8 [Human thyroid carcinoma] cancer cell line human CVCL_EI75 CL:0000010 Derived from sampling site: Thyroid gland. 21180104 CVCL_NC08 BayGenomics ES cell line RRJ538 embryonic stem cell house mouse CVCL_NC08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180105 CVCL_EI74 HDC-9NMI cancer cell line human CVCL_EI74 CL:0000010 Derived from sampling site: Colon. Male Characteristics: Derived from parent cell line after passage in nude mice 21180106 CVCL_NC29 BayGenomics ES cell line RRJ593 embryonic stem cell house mouse CVCL_NC29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202302; Pms1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180107 CVCL_NC28 BayGenomics ES cell line RRJ592 embryonic stem cell house mouse CVCL_NC28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917822; Ipo5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180108 CVCL_NC27 BayGenomics ES cell line RRJ588 embryonic stem cell house mouse CVCL_NC27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180109 CVCL_NC26 BayGenomics ES cell line RRJ583 embryonic stem cell house mouse CVCL_NC26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924363; Klhl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180110 CVCL_NC25 BayGenomics ES cell line RRJ579 embryonic stem cell house mouse CVCL_NC25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98728; Tgfbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180111 CVCL_EI91 M238 R1 cancer cell line human CVCL_EI91 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180112 CVCL_NC24 BayGenomics ES cell line RRJ578 embryonic stem cell house mouse CVCL_NC24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925503; Map4k5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180113 CVCL_EI90 M229 R9 cancer cell line human CVCL_EI90 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=22194965). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180114 CVCL_NC23 BayGenomics ES cell line RRJ574 embryonic stem cell house mouse CVCL_NC23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917056; Slc39a11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180115 CVCL_NC22 BayGenomics ES cell line RRJ572 embryonic stem cell house mouse CVCL_NC22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180116 CVCL_NC21 BayGenomics ES cell line RRJ571 embryonic stem cell house mouse CVCL_NC21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180117 CVCL_NC20 BayGenomics ES cell line RRJ569 embryonic stem cell house mouse CVCL_NC20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180118 CVCL_EI89 M229 R8 cancer cell line human CVCL_EI89 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180119 CVCL_EI84 M229 R3 cancer cell line human CVCL_EI84 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180120 CVCL_EI83 M229 R2 cancer cell line human CVCL_EI83 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180121 CVCL_EI82 M229 R15 cancer cell line human CVCL_EI82 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180122 CVCL_EI81 M229 R14 cancer cell line human CVCL_EI81 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180123 CVCL_EI88 M229 R7 cancer cell line human CVCL_EI88 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180124 CVCL_EI87 M229 R6 cancer cell line human CVCL_EI87 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180125 CVCL_EI86 M229 R5 cancer cell line human CVCL_EI86 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180126 CVCL_NC19 BayGenomics ES cell line RRJ566 embryonic stem cell house mouse CVCL_NC19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443895; Fry Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180127 CVCL_EI85 M229 R4 cancer cell line human CVCL_EI85 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180128 CVCL_EI59 C084 cancer cell line human CVCL_EI59 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180129 CVCL_EI58 C083 cancer cell line human CVCL_EI58 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. 21180130 CVCL_EI57 C081 cancer cell line human CVCL_EI57 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180131 CVCL_EI56 C078 cancer cell line human CVCL_EI56 CL:0000010 Sequence variation: Mutation; HGNC; 1076; BMPR1A; Simple; p.Tyr245Ser (c.734A>C); Zygosity=Heterozygous (PubMed=22250051); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22250051; PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180132 CVCL_EI51 C062 cancer cell line human CVCL_EI51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22250051; PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180133 CVCL_EI50 C060 cancer cell line human CVCL_EI50 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180134 CVCL_EI55 C077 cancer cell line human CVCL_EI55 CL:0000010 Sequence variation: Mutation; HGNC; 3432; ERBB4; Simple; p.Glu452Lys (c.1354G>A); ClinVar=VCV000091898; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180135 CVCL_EI54 C071 cancer cell line human CVCL_EI54 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180136 CVCL_EI53 C067 cancer cell line human CVCL_EI53 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180137 CVCL_EI52 C065 cancer cell line human CVCL_EI52 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180138 CVCL_NC07 BayGenomics ES cell line RRJ533 embryonic stem cell house mouse CVCL_NC07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180139 CVCL_NC06 BayGenomics ES cell line RRJ530 embryonic stem cell house mouse CVCL_NC06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2652875; Wnk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180140 CVCL_NC05 BayGenomics ES cell line RRJ527 embryonic stem cell house mouse CVCL_NC05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890470; Pcbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180141 CVCL_NC04 BayGenomics ES cell line RRJ526 embryonic stem cell house mouse CVCL_NC04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180142 CVCL_NC03 BayGenomics ES cell line RRJ523 embryonic stem cell house mouse CVCL_NC03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180143 CVCL_NC02 BayGenomics ES cell line RRJ520 embryonic stem cell house mouse CVCL_NC02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442401; Ppp1r9a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180144 CVCL_NC01 BayGenomics ES cell line RRJ519 embryonic stem cell house mouse CVCL_NC01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96958; Golga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180145 CVCL_NC00 BayGenomics ES cell line RRJ516 embryonic stem cell house mouse CVCL_NC00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442842; Mtmr9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180146 CVCL_EI69 DCR7 cancer cell line human CVCL_EI69 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ser492Arg (c.1476C>A); ClinVar=VCV000376341; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22270724) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Ascites. Female 21180147 CVCL_EI68 DCR10 cancer cell line human CVCL_EI68 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ser492Arg (c.1476C>A); ClinVar=VCV000376341; Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=22270724) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Ascites. Female 21180148 CVCL_EI67 C106 [Human melanoma] cancer cell line human CVCL_EI67 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180149 CVCL_EI62 C091 cancer cell line human CVCL_EI62 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Characteristics: Early passage culture 21180150 CVCL_EI61 C089 cancer cell line human CVCL_EI61 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533; PubMed=23890154); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Early passage culture 21180151 CVCL_EI60 C086 cancer cell line human CVCL_EI60 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Early passage culture 21180152 CVCL_EI66 C100 cancer cell line human CVCL_EI66 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>A); ClinVar=VCV000177775; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg88Gln (c.263G>A); ClinVar=VCV000376049; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Characteristics: Early passage culture 21180153 CVCL_EI65 C097 cancer cell line human CVCL_EI65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Characteristics: Early passage culture 21180154 CVCL_EI64 C096 cancer cell line human CVCL_EI64 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Characteristics: Early passage culture 21180155 CVCL_EI63 C092 cancer cell line human CVCL_EI63 CL:0000010 Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21180156 CVCL_EI37 C021 cancer cell line human CVCL_EI37 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180157 CVCL_EI36 C017 cancer cell line human CVCL_EI36 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 9612; PTK2B; Simple; p.Gly414Val (c.1241G>T); Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180158 CVCL_EI35 C013 cancer cell line human CVCL_EI35 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180159 CVCL_EI34 C011 cancer cell line human CVCL_EI34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180160 CVCL_EI39 C025 cancer cell line human CVCL_EI39 CL:0000010 Sequence variation: Mutation; HGNC; 18592; NEK10; Simple; p.Glu379Lys (c.1135G>A); Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180161 CVCL_EI38 C022 cancer cell line human CVCL_EI38 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180162 CVCL_EI33 C008 cancer cell line human CVCL_EI33 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Leu349Phe (c.1045C>T); Zygosity=Unspecified (PubMed=23890154) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female 21180163 CVCL_EI32 C004 cancer cell line human CVCL_EI32 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis Female Characteristics: Early passage culture 21180164 CVCL_EI31 C002 cancer cell line human CVCL_EI31 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Homozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180165 CVCL_EI30 AVO cancer cell line human CVCL_EI30 CL:0000010 Female 21180166 CVCL_EI48 C057 cancer cell line human CVCL_EI48 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24Cys (c.70C>T); ClinVar=VCV000016928; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180167 CVCL_EI47 C054 cancer cell line human CVCL_EI47 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180168 CVCL_EI46 C052 cancer cell line human CVCL_EI46 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180169 CVCL_EI45 C044 cancer cell line human CVCL_EI45 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180170 CVCL_EI49 C058 cancer cell line human CVCL_EI49 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Heterozygous (PubMed=22383533; PubMed=23890154) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Early passage culture 21180171 CVCL_EI40 C027 cancer cell line human CVCL_EI40 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Unspecified Characteristics: Early passage culture 21180172 CVCL_EI44 C042 cancer cell line human CVCL_EI44 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22250051; PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180173 CVCL_EI43 C038 cancer cell line human CVCL_EI43 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180174 CVCL_EI42 C037 cancer cell line human CVCL_EI42 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; None_reported; -; Zygosity=- (PubMed=22383533) Derived from metastatic site: Not specified. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Early passage culture 21180175 CVCL_EI41 C028 cancer cell line human CVCL_EI41 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=22250051; PubMed=22383533) Derived from metastatic site: Not specified. Omics: SNP array analysis Unspecified Characteristics: Early passage culture 21180176 CVCL_EI15 YUCYLO cancer cell line human CVCL_EI15 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Female Part of: Yale University (YU) melanoma cell collection 21180177 CVCL_EI14 YUCHIME cancer cell line human CVCL_EI14 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys1714Asn; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21180178 CVCL_EI13 YUAME cancer cell line human CVCL_EI13 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180179 CVCL_EI12 SHEP-TR-miR-17-92 cancer cell line human CVCL_EI12 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Population: Caucasian; Derived from metastatic site: Bone marrow. Female Characteristics: Transfected with a Tet-on system to induce the oncogenic miR-17-92 cluster with the addition of tetracycline to the culture medium 21180180 CVCL_EI19 YULOCUS cancer cell line human CVCL_EI19 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ile (c.34_35GG>AT) (c.34_35delinsAT); Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln2239Ter (c.6715C>T); ClinVar=VCV000428972; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21180181 CVCL_EI18 YUZAZ cancer cell line human CVCL_EI18 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180182 CVCL_EI17 YUGATOR cancer cell line human CVCL_EI17 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180183 CVCL_EI16 YUSIPU cancer cell line human CVCL_EI16 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180184 CVCL_EI11 Hep-G2 SimpleCell O-GalNAc KI GalNAc-T3 cancer cell line human CVCL_EI11 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 24137; B4GALNT3 Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21180185 CVCL_EI10 Hep-G2 SimpleCell O-GalNAc KO GalNAc-T2 cancer cell line human CVCL_EI10 CL:0000010 Knockout cell: Method=ZFN; HGNC; 24338; C1GALT1C1; Knockout cell: Method=ZFN; HGNC; 24136; B4GALNT2; Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Cell engineered to produce only truncated GalNAc or NeuAc-alpha-2-6-GalNAc O-glycans 21180186 CVCL_EI26 ER-Cal-27 cancer cell line human CVCL_EI26 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by microarray Male 21180187 CVCL_EI25 Hep 40 cancer cell line human CVCL_EI25 CL:0000010 Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male 21180188 CVCL_EI24 YUZEST cancer cell line human CVCL_EI24 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180189 CVCL_EI23 YUPOM cancer cell line human CVCL_EI23 CL:0000010 Omics: Deep exome analysis. Male Part of: Yale University (YU) melanoma cell collection 21180190 CVCL_EI29 ER-SQ20B cancer cell line human CVCL_EI29 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Larynx. Omics: Transcriptome analysis by microarray Male 21180191 CVCL_EI28 ER-SCC-25 cancer cell line human CVCL_EI28 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Lysfs*6 (c.626_627delGA); ClinVar=VCV000372539; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Oral cavity; tongue. Omics: Transcriptome analysis by microarray Male 21180192 CVCL_EI27 ER-Fadu cancer cell line human CVCL_EI27 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line) Population: Indian; Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Pharynx; hypopharynx. Omics: Transcriptome analysis by microarray Male 21180193 CVCL_EI22 YUPAC7 cancer cell line human CVCL_EI22 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Female Part of: Yale University (YU) melanoma cell collection 21180194 CVCL_EI21 YUNACK cancer cell line human CVCL_EI21 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590) Omics: Deep exome analysis. Female Part of: Yale University (YU) melanoma cell collection 21180195 CVCL_EI20 YUMOBER cancer cell line human CVCL_EI20 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Not specified. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21180196 CVCL_NC99 BayGenomics ES cell line RRK089 embryonic stem cell house mouse CVCL_NC99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180197 CVCL_NC98 BayGenomics ES cell line RRK086 embryonic stem cell house mouse CVCL_NC98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180198 CVCL_NC97 BayGenomics ES cell line RRK085 embryonic stem cell house mouse CVCL_NC97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927170; Spata5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180199 CVCL_NC96 BayGenomics ES cell line RRK082 embryonic stem cell house mouse CVCL_NC96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180200 CVCL_NC95 BayGenomics ES cell line RRK081 embryonic stem cell house mouse CVCL_NC95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914152; Mtap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180201 CVCL_NC94 BayGenomics ES cell line RRK080 embryonic stem cell house mouse CVCL_NC94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920454; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180202 CVCL_NC93 BayGenomics ES cell line RRK077 embryonic stem cell house mouse CVCL_NC93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180203 CVCL_NC92 BayGenomics ES cell line RRK076 embryonic stem cell house mouse CVCL_NC92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180204 CVCL_NC91 BayGenomics ES cell line RRK075 embryonic stem cell house mouse CVCL_NC91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196256; Kdm1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180205 CVCL_NC90 BayGenomics ES cell line RRK073 embryonic stem cell house mouse CVCL_NC90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180206 CVCL_NC79 BayGenomics ES cell line RRK057 embryonic stem cell house mouse CVCL_NC79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180207 CVCL_NC78 BayGenomics ES cell line RRK056 embryonic stem cell house mouse CVCL_NC78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919240; Ddx54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180208 CVCL_NC77 BayGenomics ES cell line RRK052 embryonic stem cell house mouse CVCL_NC77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180209 CVCL_NC76 BayGenomics ES cell line RRK051 embryonic stem cell house mouse CVCL_NC76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915087; Tiprl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180210 CVCL_NC75 BayGenomics ES cell line RRK050 embryonic stem cell house mouse CVCL_NC75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180211 CVCL_NC74 BayGenomics ES cell line RRK043 embryonic stem cell house mouse CVCL_NC74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180212 CVCL_NC73 BayGenomics ES cell line RRK038 embryonic stem cell house mouse CVCL_NC73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913489; Rsrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180213 CVCL_NC72 BayGenomics ES cell line RRK033 embryonic stem cell house mouse CVCL_NC72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107184; Cct7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180214 CVCL_NC71 BayGenomics ES cell line RRK032 embryonic stem cell house mouse CVCL_NC71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103251; Acly Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180215 CVCL_NC70 BayGenomics ES cell line RRK030 embryonic stem cell house mouse CVCL_NC70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344694; Chic1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180216 CVCL_NC89 BayGenomics ES cell line RRK072 embryonic stem cell house mouse CVCL_NC89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180217 CVCL_NC88 BayGenomics ES cell line RRK071 embryonic stem cell house mouse CVCL_NC88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180218 CVCL_NC87 BayGenomics ES cell line RRK069 embryonic stem cell house mouse CVCL_NC87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106314; Tars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180219 CVCL_NC86 BayGenomics ES cell line RRK067 embryonic stem cell house mouse CVCL_NC86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180220 CVCL_NC85 BayGenomics ES cell line RRK065 embryonic stem cell house mouse CVCL_NC85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921968; Snx16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180221 CVCL_NC84 BayGenomics ES cell line RRK064 embryonic stem cell house mouse CVCL_NC84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180222 CVCL_NC83 BayGenomics ES cell line RRK062 embryonic stem cell house mouse CVCL_NC83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684063; Asxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180223 CVCL_NC82 BayGenomics ES cell line RRK060 embryonic stem cell house mouse CVCL_NC82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926135; Coro7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180224 CVCL_NC81 BayGenomics ES cell line RRK059 embryonic stem cell house mouse CVCL_NC81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351337; Ddx24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180225 CVCL_NC80 BayGenomics ES cell line RRK058 embryonic stem cell house mouse CVCL_NC80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180226 CVCL_NC59 BayGenomics ES cell line RRK004 embryonic stem cell house mouse CVCL_NC59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95412; Ercc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180227 CVCL_NC58 BayGenomics ES cell line RRK003 embryonic stem cell house mouse CVCL_NC58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96163; Hmox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180228 CVCL_NC57 BayGenomics ES cell line RRK001 embryonic stem cell house mouse CVCL_NC57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913721; Anp32e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180229 CVCL_NC56 BayGenomics ES cell line RRJ692 embryonic stem cell house mouse CVCL_NC56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442833; Bbs9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180230 CVCL_NC55 BayGenomics ES cell line RRJ689 embryonic stem cell house mouse CVCL_NC55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107629; Luzp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180231 CVCL_NC54 BayGenomics ES cell line RRJ687 embryonic stem cell house mouse CVCL_NC54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923164; Exoc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180232 CVCL_NC53 BayGenomics ES cell line RRJ686 embryonic stem cell house mouse CVCL_NC53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102465; Tex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180233 CVCL_NC52 BayGenomics ES cell line RRJ682 embryonic stem cell house mouse CVCL_NC52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96628; Jak1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180234 CVCL_NC51 BayGenomics ES cell line RRJ681 embryonic stem cell house mouse CVCL_NC51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919862; Hpf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180235 CVCL_NC50 BayGenomics ES cell line RRJ678 embryonic stem cell house mouse CVCL_NC50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914705; Klhl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180236 CVCL_NC69 BayGenomics ES cell line RRK028 embryonic stem cell house mouse CVCL_NC69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590554; BC055324 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180237 CVCL_NC68 BayGenomics ES cell line RRK025 embryonic stem cell house mouse CVCL_NC68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106184; Npm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180238 CVCL_NC67 BayGenomics ES cell line RRK023 embryonic stem cell house mouse CVCL_NC67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180239 CVCL_NC66 BayGenomics ES cell line RRK020 embryonic stem cell house mouse CVCL_NC66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180240 CVCL_NC65 BayGenomics ES cell line RRK019 embryonic stem cell house mouse CVCL_NC65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98447; Surf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180241 CVCL_NC64 BayGenomics ES cell line RRK010 embryonic stem cell house mouse CVCL_NC64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3645495; Alkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180242 CVCL_NC63 BayGenomics ES cell line RRK009 embryonic stem cell house mouse CVCL_NC63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109353; Ufd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180243 CVCL_NC62 BayGenomics ES cell line RRK007 embryonic stem cell house mouse CVCL_NC62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180244 CVCL_NC61 BayGenomics ES cell line RRK006 embryonic stem cell house mouse CVCL_NC61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146388; Ubxn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180245 CVCL_NC60 BayGenomics ES cell line RRK005 embryonic stem cell house mouse CVCL_NC60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97447; Osbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180246 CVCL_NC39 BayGenomics ES cell line RRJ628 embryonic stem cell house mouse CVCL_NC39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2654703; Otud7b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180247 CVCL_NC38 BayGenomics ES cell line RRJ627 embryonic stem cell house mouse CVCL_NC38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180248 CVCL_NC37 BayGenomics ES cell line RRJ622 embryonic stem cell house mouse CVCL_NC37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103008; Epb41l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180249 CVCL_NC36 BayGenomics ES cell line RRJ620 embryonic stem cell house mouse CVCL_NC36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917394; Lrch3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180250 CVCL_NC35 BayGenomics ES cell line RRJ608 embryonic stem cell house mouse CVCL_NC35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98386; Sptan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180251 CVCL_NC34 BayGenomics ES cell line RRJ605 embryonic stem cell house mouse CVCL_NC34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102657; Cdc34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180252 CVCL_NC33 BayGenomics ES cell line RRJ603 embryonic stem cell house mouse CVCL_NC33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859649; Ctnnal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180253 CVCL_NC32 BayGenomics ES cell line RRJ602 embryonic stem cell house mouse CVCL_NC32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913881; Mfsd14b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180254 CVCL_NC31 BayGenomics ES cell line RRJ599 embryonic stem cell house mouse CVCL_NC31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927234; Suclg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180255 CVCL_NC30 BayGenomics ES cell line RRJ595 embryonic stem cell house mouse CVCL_NC30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913755; Zmynd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180256 CVCL_EI95 MGH056-1 cancer cell line human CVCL_EI95 CL:0000010 Derived from metastatic site: Liver. 21180257 CVCL_EI94 MDA-AMP7 cancer cell line human CVCL_EI94 CL:0000010 Derived from metastatic site: Peritoneum. Omics: Deep proteome analysis Male Doubling time: ~30 hours (PubMed=1582987) 21180258 CVCL_EI93 M249 R4 cancer cell line human CVCL_EI93 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=22194965; PubMed=25645078); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=25645078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=21107323; PubMed=22194965; PubMed=25645078). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180259 CVCL_EI92 M238 R2 cancer cell line human CVCL_EI92 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21180260 CVCL_EI99 OCCC33 cancer cell line human CVCL_EI99 CL:0000010 Female 21180261 CVCL_EI98 MUTJ cancer cell line human CVCL_EI98 From: Arizona Cancer Center; Tucson; USA CL:0000010 Omics: Protein expression by reverse-phase protein arrays. Part of: MD Anderson Cell Lines Project 21180262 CVCL_EI97 MM.1-144 cancer cell line human CVCL_EI97 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=11157491); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Peripheral blood. Female Characteristics: Produces IgA lambda 21180263 CVCL_EI96 MIC cancer cell line human CVCL_EI96 From: Delattre O.; Institut Curie; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg216Ter (c.646C>T); Zygosity=Unspecified (PubMed=25223734); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Unspecified (PubMed=25223734). 21180264 CVCL_NC49 BayGenomics ES cell line RRJ672 embryonic stem cell house mouse CVCL_NC49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442697; Zfp473 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180265 CVCL_NC48 BayGenomics ES cell line RRJ666 embryonic stem cell house mouse CVCL_NC48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88354; Cdh1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180266 CVCL_NC47 BayGenomics ES cell line RRJ662 embryonic stem cell house mouse CVCL_NC47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919213; Cdca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180267 CVCL_NC46 BayGenomics ES cell line RRJ658 embryonic stem cell house mouse CVCL_NC46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923760; Trappc9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180268 CVCL_NC45 BayGenomics ES cell line RRJ655 embryonic stem cell house mouse CVCL_NC45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180269 CVCL_NC44 BayGenomics ES cell line RRJ653 embryonic stem cell house mouse CVCL_NC44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920428; Wasl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180270 CVCL_NC43 BayGenomics ES cell line RRJ650 embryonic stem cell house mouse CVCL_NC43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334462; Copa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180271 CVCL_NC42 BayGenomics ES cell line RRJ641 embryonic stem cell house mouse CVCL_NC42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88175; Manba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180272 CVCL_NC41 BayGenomics ES cell line RRJ635 embryonic stem cell house mouse CVCL_NC41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934950; Csnk1a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180273 CVCL_NC40 BayGenomics ES cell line RRJ632 embryonic stem cell house mouse CVCL_NC40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109367; Impdh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180274 CVCL_3W91 HQ02246 transformed cell line human CVCL_3W91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180275 CVCL_4891 pRNS-1-1/ras transformed cell line human CVCL_4891 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180276 CVCL_3W90 HQ02245 transformed cell line human CVCL_3W90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180277 CVCL_4890 pRNS-1-1 transformed cell line human CVCL_4890 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180278 CVCL_3W84 HQ02238 transformed cell line human CVCL_3W84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180279 CVCL_4884 PC-374 cancer cell line human CVCL_4884 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Skin. Male 21180280 CVCL_3W83 HQ02237 transformed cell line human CVCL_3W83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180281 CVCL_4883 PC-346C cancer cell line human CVCL_4883 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=14518029) Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Established from the PC-346 xenograft (CelloPub=CLPUB00699); Characteristics: Optimal proliferation of the cell line requires androgens and is inhibited by the antiandrogen hydroxyflutamide Doubling time: 4-5 days (CelloPub=CLPUB00699) 21180282 CVCL_3W82 HQ02236 transformed cell line human CVCL_3W82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180283 CVCL_4882 PC-346 cancer cell line human CVCL_4882 CL:0000010 Miscellaneous: This is not a cell line but a xenograft, it is the parent tumor for many cell lines Derived from sampling site: Prostate. Male 21180284 CVCL_3W81 HQ02235 transformed cell line human CVCL_3W81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180285 CVCL_4881 PC-339 cancer cell line human CVCL_4881 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21180286 CVCL_3W88 HQ02243 transformed cell line human CVCL_3W88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180287 CVCL_4888 PC-93 cancer cell line human CVCL_4888 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 20 hours (PubMed=6602397) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00256 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=14518029; PubMed=20143388). Originally thought to originate from a moderately differentiated primary adenocarcinoma of the prostate. 21180288 CVCL_3W87 HQ02241 transformed cell line human CVCL_3W87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180289 CVCL_4887 PC-82 cancer cell line human CVCL_4887 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Population: Caucasian; Derived from sampling site: Prostate. Male 21180290 CVCL_3W86 HQ02240 transformed cell line human CVCL_3W86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180291 CVCL_4886 PC-3N cancer cell line human CVCL_4886 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21180292 CVCL_3W85 HQ02239 transformed cell line human CVCL_3W85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180293 CVCL_4885 PC3-MM2 cancer cell line human CVCL_4885 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (PubMed=11304728) Population: Caucasian; Derived from metastatic site: Bone. Male 21180294 CVCL_3W89 HQ02244 transformed cell line human CVCL_3W89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180295 CVCL_4889 PNT2-C2 transformed cell line human CVCL_4889 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180296 CVCL_3W95 HQ02251 transformed cell line human CVCL_3W95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180297 CVCL_4895 R198 [Human bladder carcinoma] cancer cell line human CVCL_4895 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Male 21180298 CVCL_3W94 HQ02250 transformed cell line human CVCL_3W94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180299 CVCL_4894 PSK-1 cancer cell line human CVCL_4894 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly279Glu (c.836G>A); ClinVar=VCV000419454; Zygosity=Unspecified (PubMed=14518029) Population: Japanese; Derived from sampling site: Prostate. Male Doubling time: ~34 hours (at 15th passage), ~28 hours (at 35th passage) (PubMed=10679758) 21180300 CVCL_3W93 HQ02249 transformed cell line human CVCL_3W93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180301 CVCL_4893 PS-1 [Rat prostate] spontaneously immortalized cell line Norway rat CVCL_4893 CL:0000010 Derived from sampling site: Prostate; smooth muscle; Breed/subspecies: Sprague Dawley. Male 21180302 CVCL_3W92 HQ02247 transformed cell line human CVCL_3W92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180303 CVCL_4892 PS-1 [Human urinary bladder carcinoma] cancer cell line human CVCL_4892 CL:0000010 Derived from sampling site: Urinary bladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Part of: BLA-40 bladder carcinoma cell line panel; Part of: UBC-40 urothelial bladder cancer cell line index 21180304 CVCL_3W99 HQ02256 transformed cell line human CVCL_3W99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180305 CVCL_4899 SCID 5045-4 transformed cell line human CVCL_4899 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRNS-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180306 CVCL_3W98 HQ02255 transformed cell line human CVCL_3W98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180307 CVCL_4898 Sawano cancer cell line human CVCL_4898 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 43.2 hours, at 10th passage (PubMed=8555123) Caution: Erroneously indicated as originating from a 67 year old patient in RCB=RCB1152 21180308 CVCL_3W97 HQ02254 transformed cell line human CVCL_3W97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180309 CVCL_4897 PK-59 cancer cell line human CVCL_4897 HLA typing: A*31:01,33:03; B*35:01,58:01; C*03:02,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.12%; East Asian, North=83.8%; East Asian, South=14.64%; South Asian=0%; European, North=0%; European, South=1.44% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=11115575; PubMed=22490663; DepMap) Population: Japanese; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 52 hours (PubMed=7622937) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI RAS program mutant KRAS cell line panel 21180310 CVCL_3W96 HQ02252 transformed cell line human CVCL_3W96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180311 CVCL_4896 RBE cancer cell line human CVCL_4896 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Ser (c.394C>A); ClinVar=VCV000375893; Zygosity=Unspecified (PubMed=27231123; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap) Population: Japanese; Derived from sampling site: Liver. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 45 hours (PubMed=9358283) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel 21180312 CVCL_4862 A2780/R cancer cell line human CVCL_4862 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:48120; Anthracycline; Derived from sampling site: Ovary. Female 21180313 CVCL_3W62 HQ02212 transformed cell line human CVCL_3W62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180314 CVCL_3W61 HQ02211 transformed cell line human CVCL_3W61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180315 CVCL_4861 P69SV40T-M15 transformed cell line human CVCL_4861 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Metastatic to the lungs and/or diaphragm Obtained by subcutaneous injection of parental cell line into male athymic nude miceObtained by subcutaneous injection of parental cell line into male athymic nude mice (PubMed=9496902). 21180316 CVCL_3W60 HQ02210 transformed cell line human CVCL_3W60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180317 CVCL_4860 P69SV40T-M12 transformed cell line human CVCL_4860 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Metastatic to the lungs and/or diaphragm Obtained by subcutaneous injection of parental cell line into male athymic nude miceObtained by subcutaneous injection of parental cell line into male athymic nude mice (PubMed=9496902). 21180318 CVCL_3W66 HQ02217 transformed cell line human CVCL_3W66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180319 CVCL_4866 P69SV40T-M2205 transformed cell line human CVCL_4866 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180320 CVCL_3W65 HQ02216 transformed cell line human CVCL_3W65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180321 CVCL_4865 P69SV40T-M2182 transformed cell line human CVCL_4865 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic Obtained by subcutaneous injection of parental cell line into male athymic nude mice (PubMed=8077059). 21180322 CVCL_3W64 HQ02215 transformed cell line human CVCL_3W64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180323 CVCL_4864 P69SV40T-M1929 transformed cell line human CVCL_4864 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Characteristics: Tumorigenic Obtained by subcutaneous injection of parental cell line into male athymic nude mice (PubMed=8077059). 21180324 CVCL_4863 A2780/S cancer cell line human CVCL_4863 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Ovary. Female 21180325 CVCL_3W63 HQ02214 transformed cell line human CVCL_3W63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180326 CVCL_3W69 HQ02222 transformed cell line human CVCL_3W69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180327 CVCL_4869 NRP-152 transformed cell line Norway rat CVCL_4869 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Transformant: Testosterone propionate(ChEBI; CHEBI:9466); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Lobund-Wistar (L-W). Male Characteristics: Non-tumorigenic (PubMed=8012960) 21180328 CVCL_3W68 HQ02220 transformed cell line human CVCL_3W68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180329 CVCL_4868 MPC-3-10 cancer cell line human CVCL_4868 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21180330 CVCL_3W67 HQ02218 transformed cell line human CVCL_3W67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180331 CVCL_4867 MDA-PCa-2b-hr cancer cell line human CVCL_4867 CL:0000010 Population: African American; Derived from metastatic site: Bone. Male 21180332 CVCL_3W80 HQ02234 transformed cell line human CVCL_3W80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180333 CVCL_4880 PC-329 cancer cell line human CVCL_4880 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21180334 CVCL_3W73 HQ02226 transformed cell line human CVCL_3W73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180335 CVCL_4873 OLHE-131 cancer cell line CVCL_4873 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: HO4C. Unspecified Doubling time: 67 hours (CelloPub=CLPUB00092) Group: Fish cell line 21180336 CVCL_3W72 HQ02225 transformed cell line human CVCL_3W72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180337 CVCL_4872 OIH-1 cancer cell line human CVCL_4872 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=9631582); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21180338 CVCL_3W71 HQ02224 transformed cell line human CVCL_3W71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180339 CVCL_4871 NRS-1 cancer cell line human CVCL_4871 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=7599791) Population: Japanese; Derived from metastatic site: Left calf muscle. Female Doubling time: 68 hours (at 15th passage), 64 hours (at 25th passage) (PubMed=7599791) 21180340 CVCL_3W70 HQ02223 transformed cell line human CVCL_3W70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180341 CVCL_4870 NRP-154 transformed cell line Norway rat CVCL_4870 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Transformant: Testosterone propionate(ChEBI; CHEBI:9466); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.; Breed/subspecies: Lobund-Wistar (L-W). Male Characteristics: Tumorigenic (PubMed=8012960) 21180342 CVCL_3W77 HQ02231 transformed cell line human CVCL_3W77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180343 CVCL_4877 PC-3-1A cancer cell line human CVCL_4877 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 21180344 CVCL_3W76 HQ02229 transformed cell line human CVCL_3W76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180345 CVCL_4876 PC-295 cancer cell line human CVCL_4876 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Lymph node. Male 21180346 CVCL_3W75 HQ02228 transformed cell line human CVCL_3W75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180347 CVCL_4875 P69SV40T transformed cell line human CVCL_4875 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180348 CVCL_3W74 HQ02227 transformed cell line human CVCL_3W74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180349 CVCL_4874 P153SV40T transformed cell line human CVCL_4874 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180350 CVCL_3W79 HQ02233 transformed cell line human CVCL_3W79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180351 CVCL_4879 PC-324 cancer cell line human CVCL_4879 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21180352 CVCL_3W78 HQ02232 transformed cell line human CVCL_3W78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180353 CVCL_4878 PC-310 cancer cell line human CVCL_4878 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21180354 CVCL_4840 HOCE cancer cell line human CVCL_4840 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female 21180355 CVCL_3W40 HQ02188 transformed cell line human CVCL_3W40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180356 CVCL_4844 HPV-18-C1 transformed cell line human CVCL_4844 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180357 CVCL_3W44 HQ02192 transformed cell line human CVCL_3W44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180358 CVCL_4843 HPV-18-A2 transformed cell line human CVCL_4843 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180359 CVCL_3W43 HQ02191 transformed cell line human CVCL_3W43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180360 CVCL_4842 HOMM cancer cell line human CVCL_4842 CL:0000010 Population: Japanese; Derived from sampling site: Uterus; cervix. Female Doubling time: 48 hours (at 5th passage), 37 hours (at 15th passage) (PubMed=9777403) 21180361 CVCL_3W42 HQ02190 transformed cell line human CVCL_3W42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180362 CVCL_4841 HOEF finite cell line human CVCL_4841 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female 21180363 CVCL_3W41 HQ02189 transformed cell line human CVCL_3W41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180364 CVCL_3W48 HQ02196 transformed cell line human CVCL_3W48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180365 CVCL_4848 KUSA-A1 somatic stem cell house mouse CVCL_4848 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Discontinued: JCRB; NIHS0427; true Female 21180366 CVCL_3W47 HQ02195 transformed cell line human CVCL_3W47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180367 CVCL_4847 HuG1-PI cancer cell line human CVCL_4847 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male 21180368 CVCL_3W46 HQ02194 transformed cell line human CVCL_3W46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180369 CVCL_4846 HuG1-N cancer cell line human CVCL_4846 Genome ancestry: African=1.71%; Native American=0.2%; East Asian, North=75.56%; East Asian, South=21.1%; South Asian=0%; European, North=0%; European, South=1.43% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Pro (c.578A>C); ClinVar=VCV000376612; Zygosity=Unspecified (PubMed=15901131) Population: Japanese; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 33 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: TCGA-110-CL cell line panel 21180370 CVCL_3W45 HQ02193 transformed cell line human CVCL_3W45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180371 CVCL_4845 HuG-1 cancer cell line human CVCL_4845 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~38 hours (PubMed=2334935) 21180372 CVCL_3W49 HQ02198 transformed cell line human CVCL_3W49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180373 CVCL_4849 LMSU cancer cell line human CVCL_4849 HLA typing: A*02:06,24:02; B*13:01,52:01; C*03:04,12:02; DQA1*03:02,05:02; DQB1*02:02,03:04; DRB1*12:01,15:01 (PubMed=26589293); Genome ancestry: African=0.29%; Native American=0.32%; East Asian, North=85.74%; East Asian, South=12.36%; South Asian=0.58%; European, North=0%; European, South=0.71% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21180374 CVCL_3W51 HQ02200 transformed cell line human CVCL_3W51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180375 CVCL_4851 LuCaP 23.12 cancer cell line human CVCL_4851 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Liver. Male 21180376 CVCL_3W50 HQ02199 transformed cell line human CVCL_3W50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180377 CVCL_4850 LuCaP 23.1 cancer cell line human CVCL_4850 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Lymph node. Male 21180378 CVCL_3W55 HQ02204 transformed cell line human CVCL_3W55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180379 CVCL_4855 LuCaP 41 cancer cell line human CVCL_4855 CL:0000010 Male 21180380 CVCL_3W54 HQ02203 transformed cell line human CVCL_3W54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180381 CVCL_4854 LuCaP 35V cancer cell line human CVCL_4854 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Lymph node. Male 21180382 CVCL_3W53 HQ02202 transformed cell line human CVCL_3W53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180383 CVCL_4853 LuCaP 35 cancer cell line human CVCL_4853 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Lymph node. Male 21180384 CVCL_3W52 HQ02201 transformed cell line human CVCL_3W52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180385 CVCL_4852 LuCaP 23.8 cancer cell line human CVCL_4852 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Lymph node. Male 21180386 CVCL_3W59 HQ02209 transformed cell line human CVCL_3W59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180387 CVCL_4859 LYM-1 cancer cell line Norway rat CVCL_4859 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from metastatic site: Lymph node; Breed/subspecies: JAR-2. Female Doubling time: 19 hours (CelloPub=CLPUB00074) 21180388 CVCL_3W58 HQ02208 transformed cell line human CVCL_3W58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180389 CVCL_4858 LuCap 73 cancer cell line human CVCL_4858 CL:0000010 Male 21180390 CVCL_3W57 HQ02206 transformed cell line human CVCL_3W57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180391 CVCL_4857 LuCaP 58 cancer cell line human CVCL_4857 CL:0000010 Male 21180392 CVCL_3W56 HQ02205 transformed cell line human CVCL_3W56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180393 CVCL_4856 RCR-1 spontaneously immortalized cell line Norway rat CVCL_4856 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: JAR-2. Discontinued: JCRB; NIHS0229; true Unspecified 21180394 CVCL_4822 1542-CPTX-2 transformed cell line human CVCL_4822 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180395 CVCL_3W22 HQ02170 transformed cell line human CVCL_3W22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180396 CVCL_4821 1542-CPTX-1 transformed cell line human CVCL_4821 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male 21180397 CVCL_3W21 HQ02169 transformed cell line human CVCL_3W21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180398 CVCL_4820 1535-seminal vesicle transformed cell line human CVCL_4820 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Seminal vesicle. Male 21180399 CVCL_3W20 HQ02168 transformed cell line human CVCL_3W20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180400 CVCL_4826 CKS cancer cell line human CVCL_4826 CL:0000010 Female Doubling time: 32-36 hours (PubMed=6268719). 21180401 CVCL_3W26 HQ02174 transformed cell line human CVCL_3W26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180402 CVCL_4825 1542-seminal vesicle transformed cell line human CVCL_4825 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Seminal vesicle. Male 21180403 CVCL_3W25 HQ02173 transformed cell line human CVCL_3W25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180404 CVCL_4824 1542-normal transformed cell line human CVCL_4824 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180405 CVCL_3W24 HQ02172 transformed cell line human CVCL_3W24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180406 CVCL_4823 1542-CPTX-3 transformed cell line human CVCL_4823 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180407 CVCL_3W23 HQ02171 transformed cell line human CVCL_3W23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180408 CVCL_4829 ACH-3P hybrid cell line human CVCL_4829 CL:0000010 Karyotypic information: Near tetraploid karyotype (PubMed=33096371). Characteristics: Fusion of the AC1-1 choriocarcinoma cell line with primary first trimester trophoblasts (week 12 of gestation) (PubMed=18093301) 21180409 CVCL_3W29 HQ02177 transformed cell line human CVCL_3W29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180410 CVCL_4828 DU9479 cancer cell line human CVCL_4828 CL:0000010 Derived from metastatic site: Iliac crest. Male 21180411 CVCL_3W28 HQ02176 transformed cell line human CVCL_3W28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180412 CVCL_4827 267B1 transformed cell line human CVCL_4827 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180413 CVCL_3W27 HQ02175 transformed cell line human CVCL_3W27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180414 CVCL_4833 CWR-R1 cancer cell line human CVCL_4833 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (PubMed=11306464); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=14518029); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (PubMed=14518029) Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Co-culture of polygonal closely aggregated epithelial cells surrounded by bipolar stromal fibroblasts Doubling time: 33.57 hours (GrayJW panel) 21180415 CVCL_3W33 HQ02181 transformed cell line human CVCL_3W33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180416 CVCL_4832 BM18 cancer cell line human CVCL_4832 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from metastatic site: Bone. Male 21180417 CVCL_3W32 HQ02180 transformed cell line human CVCL_3W32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180418 CVCL_3W31 HQ02179 transformed cell line human CVCL_3W31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180419 CVCL_4831 Tu-113 cancer cell line human CVCL_4831 CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 21180420 CVCL_4830 ARCaP cancer cell line human CVCL_4830 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=14518029) Derived from metastatic site: Ascites. Male 21180421 CVCL_3W30 HQ02178 transformed cell line human CVCL_3W30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180422 CVCL_4837 FU-RPNT-1 cancer cell line human CVCL_4837 CL:0000010 Population: Japanese Male Doubling time: 45 hours (PubMed=9559290). 21180423 CVCL_3W37 HQ02185 transformed cell line human CVCL_3W37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180424 CVCL_4836 ECPC-4 transformed cell line house mouse CVCL_4836 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus; Breed/subspecies: C57BL/6 IgH-T-Ag transgenic. Omics: Proteome analysis by 2D-DE/MS Unspecified 21180425 CVCL_3W36 HQ02184 transformed cell line human CVCL_3W36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180426 CVCL_4835 ECPC-3 transformed cell line house mouse CVCL_4835 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus; Breed/subspecies: C57BL/6 IgH-T-Ag transgenic. Unspecified 21180427 CVCL_3W35 HQ02183 transformed cell line human CVCL_3W35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180428 CVCL_4834 E006AA cancer cell line human CVCL_4834 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Discontinued: Millipore; SCC102; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00585 Problematic cell line: Contaminated Shown to be a 786-O derivative (PubMed=31416301). Originally thought to originate from a 50 year old patient with prostate carcinoma. 21180429 CVCL_3W34 HQ02182 transformed cell line human CVCL_3W34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180430 CVCL_4839 HH870 cancer cell line human CVCL_4839 CL:0000010 Population: Caucasian; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Prostate. Male Doubling time: ~36 hours (PubMed=15468172); 29.33 hours (GrayJW panel) 21180431 CVCL_3W39 HQ02187 transformed cell line human CVCL_3W39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180432 CVCL_4838 FU-RPNT-2 cancer cell line human CVCL_4838 CL:0000010 Population: Japanese Discontinued: RCB; RCB1496; true. Male Doubling time: 72 hours (PubMed=9559290) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00352 Problematic cell line: Contaminated Shown to be a FU-RPNT-1 derivative (PubMed=20143388). 21180433 CVCL_3W38 HQ02186 transformed cell line human CVCL_3W38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180434 CVCL_EK35 PENN035i-746-3 induced pluripotent stem cell human CVCL_EK35 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180435 CVCL_EK34 PENN034i-322-1 induced pluripotent stem cell human CVCL_EK34 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180436 CVCL_EK33 PENN033i-182-2 induced pluripotent stem cell human CVCL_EK33 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180437 CVCL_EK32 PENN032i-15-5 induced pluripotent stem cell human CVCL_EK32 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180438 CVCL_EK39 PENN039i-63-1 induced pluripotent stem cell human CVCL_EK39 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180439 CVCL_EK38 PENN038i-366-6 induced pluripotent stem cell human CVCL_EK38 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180440 CVCL_EK37 PENN037i-90-3 induced pluripotent stem cell human CVCL_EK37 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180441 CVCL_EK36 PENN036i-286-3 induced pluripotent stem cell human CVCL_EK36 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180442 CVCL_EK31 PENN031i-56-1 induced pluripotent stem cell human CVCL_EK31 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180443 CVCL_EK30 PENN030i-384-4 induced pluripotent stem cell human CVCL_EK30 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180444 CVCL_EK46 PENN046i-271-1 induced pluripotent stem cell human CVCL_EK46 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180445 CVCL_EK45 PENN045i-25-12 induced pluripotent stem cell human CVCL_EK45 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180446 CVCL_EK44 PENN044i-51-1 induced pluripotent stem cell human CVCL_EK44 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180447 CVCL_EK43 PENN043i-633-3 induced pluripotent stem cell human CVCL_EK43 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180448 CVCL_EK49 PENN049i-334-8 induced pluripotent stem cell human CVCL_EK49 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180449 CVCL_EK48 PENN048i-41-6 induced pluripotent stem cell human CVCL_EK48 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180450 CVCL_EK47 PENN047i-254-60 induced pluripotent stem cell human CVCL_EK47 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180451 CVCL_EK42 PENN042i-258-12 induced pluripotent stem cell human CVCL_EK42 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180452 CVCL_EK41 PENN041i-177-46 induced pluripotent stem cell human CVCL_EK41 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180453 CVCL_EK40 PENN040i-134-2 induced pluripotent stem cell human CVCL_EK40 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180454 CVCL_EK19 PENN019i-136-2 induced pluripotent stem cell human CVCL_EK19 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180455 CVCL_EK18 PENN018i-487-4 induced pluripotent stem cell human CVCL_EK18 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180456 CVCL_EK13 PENN013i-72-1 induced pluripotent stem cell human CVCL_EK13 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180457 CVCL_EK12 PENN012i-93-2 induced pluripotent stem cell human CVCL_EK12 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180458 CVCL_EK11 PENN011i-719-2 induced pluripotent stem cell human CVCL_EK11 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180459 CVCL_EK10 PENN010i-486-2 induced pluripotent stem cell human CVCL_EK10 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180460 CVCL_EK17 PENN017i-638-2 induced pluripotent stem cell human CVCL_EK17 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180461 CVCL_EK16 PENN016i-821-1 induced pluripotent stem cell human CVCL_EK16 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180462 CVCL_EK15 PENN015i-668-5 induced pluripotent stem cell human CVCL_EK15 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180463 CVCL_EK14 PENN014i-37-3 induced pluripotent stem cell human CVCL_EK14 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180464 CVCL_EK29 PENN029i-752-3 induced pluripotent stem cell human CVCL_EK29 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180465 CVCL_EK24 PENN024i-370-3 induced pluripotent stem cell human CVCL_EK24 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180466 CVCL_EK23 PENN023i-82-1 induced pluripotent stem cell human CVCL_EK23 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180467 CVCL_EK22 PENN022i-89-1 induced pluripotent stem cell human CVCL_EK22 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180468 CVCL_EK21 PENN021i-749-4 induced pluripotent stem cell human CVCL_EK21 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180469 CVCL_EK28 PENN028i-637-2 induced pluripotent stem cell human CVCL_EK28 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180470 CVCL_EK27 PENN027i-40-2 induced pluripotent stem cell human CVCL_EK27 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180471 CVCL_EK26 PENN026i-124-1 induced pluripotent stem cell human CVCL_EK26 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180472 CVCL_EK25 PENN025i-71-58 induced pluripotent stem cell human CVCL_EK25 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180473 CVCL_EK20 PENN020i-588-6 induced pluripotent stem cell human CVCL_EK20 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180474 CVCL_EK09 PENN009i-57-52 induced pluripotent stem cell human CVCL_EK09 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180475 CVCL_EK08 PENN008i-77-5 induced pluripotent stem cell human CVCL_EK08 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180476 CVCL_EK07 PENN007i-765-3 induced pluripotent stem cell human CVCL_EK07 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180477 CVCL_EK02 PENN002i-442-1 induced pluripotent stem cell human CVCL_EK02 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180478 CVCL_EK01 PENN001i-87-2 induced pluripotent stem cell human CVCL_EK01 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180479 CVCL_EK00 UCSD240i-APP2-2 induced pluripotent stem cell human CVCL_EK00 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd240i-app2-2; true Female 21180480 CVCL_EK06 PENN006i-149-1 induced pluripotent stem cell human CVCL_EK06 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180481 CVCL_EK05 PENN005i-35-3 induced pluripotent stem cell human CVCL_EK05 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180482 CVCL_EK04 PENN004i-277-1 induced pluripotent stem cell human CVCL_EK04 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180483 CVCL_EK03 PENN003i-661-4 induced pluripotent stem cell human CVCL_EK03 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180484 CVCL_ND39 BayGenomics ES cell line RRK170 embryonic stem cell house mouse CVCL_ND39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444496; Prr11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180485 CVCL_ND38 BayGenomics ES cell line RRK169 embryonic stem cell house mouse CVCL_ND38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147194; Rbm27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180486 CVCL_ND37 BayGenomics ES cell line RRK168 embryonic stem cell house mouse CVCL_ND37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180487 CVCL_ND36 BayGenomics ES cell line RRK166 embryonic stem cell house mouse CVCL_ND36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180488 CVCL_ND35 BayGenomics ES cell line RRK165 embryonic stem cell house mouse CVCL_ND35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913758; Lamtor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180489 CVCL_ND34 BayGenomics ES cell line RRK164 embryonic stem cell house mouse CVCL_ND34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919369; Tpx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180490 CVCL_ND33 BayGenomics ES cell line RRK162 embryonic stem cell house mouse CVCL_ND33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443665; Numa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180491 CVCL_ND32 BayGenomics ES cell line RRK160 embryonic stem cell house mouse CVCL_ND32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180492 CVCL_ND31 BayGenomics ES cell line RRK159 embryonic stem cell house mouse CVCL_ND31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913560; Dpy30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180493 CVCL_ND30 BayGenomics ES cell line RRK156 embryonic stem cell house mouse CVCL_ND30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926227; Nup160 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180494 CVCL_EJ99 UCSD239i-APP2-1 induced pluripotent stem cell human CVCL_EJ99 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180495 CVCL_EJ94 UCSD234i-SAD2-3 induced pluripotent stem cell human CVCL_EJ94 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180496 CVCL_EJ93 UCSD232i-SAD2-1 induced pluripotent stem cell human CVCL_EJ93 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd232i-sad2-1; true Male 21180497 CVCL_EJ92 UCSD231i-SAD1-3 induced pluripotent stem cell human CVCL_EJ92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180498 CVCL_EJ91 UCSD230i-SAD1-2 induced pluripotent stem cell human CVCL_EJ91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd230i-sad1-2; true Female 21180499 CVCL_EJ98 UCSD238i-APP1-3 induced pluripotent stem cell human CVCL_EJ98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180500 CVCL_EJ97 UCSD237i-APP1-2 induced pluripotent stem cell human CVCL_EJ97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd237i-app1-2; true Male 21180501 CVCL_EJ96 UCSD236i-APP1-1 induced pluripotent stem cell human CVCL_EJ96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180502 CVCL_ND29 BayGenomics ES cell line RRK154 embryonic stem cell house mouse CVCL_ND29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444248; Gcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180503 CVCL_EJ95 UCSD235i-SAD2-4 induced pluripotent stem cell human CVCL_EJ95 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd235i-sad2-4; true Male 21180504 CVCL_ND49 BayGenomics ES cell line RRK189 embryonic stem cell house mouse CVCL_ND49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98507; Tcf7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180505 CVCL_ND48 BayGenomics ES cell line RRK187 embryonic stem cell house mouse CVCL_ND48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99700; Cenpc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180506 CVCL_ND47 BayGenomics ES cell line RRK186 embryonic stem cell house mouse CVCL_ND47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922066; Tpr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180507 CVCL_ND46 BayGenomics ES cell line RRK184 embryonic stem cell house mouse CVCL_ND46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180508 CVCL_ND45 BayGenomics ES cell line RRK181 embryonic stem cell house mouse CVCL_ND45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180509 CVCL_ND44 BayGenomics ES cell line RRK179 embryonic stem cell house mouse CVCL_ND44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180510 CVCL_ND43 BayGenomics ES cell line RRK178 embryonic stem cell house mouse CVCL_ND43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446163; Fam120a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180511 CVCL_ND42 BayGenomics ES cell line RRK177 embryonic stem cell house mouse CVCL_ND42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933204; Rbm5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180512 CVCL_ND41 BayGenomics ES cell line RRK176 embryonic stem cell house mouse CVCL_ND41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917458; Med23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180513 CVCL_ND40 BayGenomics ES cell line RRK171 embryonic stem cell house mouse CVCL_ND40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916482; Qrich1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180514 CVCL_ND17 BayGenomics ES cell line RRK125 embryonic stem cell house mouse CVCL_ND17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277218; Rpap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180515 CVCL_ND16 BayGenomics ES cell line RRK122 embryonic stem cell house mouse CVCL_ND16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917113; Ttc39b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180516 CVCL_ND15 BayGenomics ES cell line RRK121 embryonic stem cell house mouse CVCL_ND15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926143; Cnot10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180517 CVCL_ND14 BayGenomics ES cell line RRK119 embryonic stem cell house mouse CVCL_ND14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928484; Nudt3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180518 CVCL_ND13 BayGenomics ES cell line RRK118 embryonic stem cell house mouse CVCL_ND13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932395; Rrbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180519 CVCL_ND12 BayGenomics ES cell line RRK117 embryonic stem cell house mouse CVCL_ND12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934029; Usp8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180520 CVCL_ND11 BayGenomics ES cell line RRK116 embryonic stem cell house mouse CVCL_ND11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180521 CVCL_ND10 BayGenomics ES cell line RRK115 embryonic stem cell house mouse CVCL_ND10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98884; U2af1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180522 CVCL_EJ79 WC009i-FX08-01 induced pluripotent stem cell human CVCL_EJ79 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>435]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=24654675) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180523 CVCL_EJ78 WC007i-FX13-2 induced pluripotent stem cell human CVCL_EJ78 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>435]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=24654675) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180524 CVCL_EJ77 WC006i-FX11-9U induced pluripotent stem cell human CVCL_EJ77 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[114]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=24654675) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180525 CVCL_EJ72 WIC04i-127-33 induced pluripotent stem cell human CVCL_EJ72 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Hemizygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180526 CVCL_EJ71 PH-2 [Monkey] spontaneously immortalized cell line green monkey CVCL_EJ71 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2165 21180527 CVCL_EJ70 Vero M spontaneously immortalized cell line green monkey CVCL_EJ70 From: Middle America Research Unit (MARU); Corozal; Panama CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21180528 CVCL_EJ76 WC005i-FX11-7 induced pluripotent stem cell human CVCL_EJ76 CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[>435]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=24654675) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180529 CVCL_ND09 BayGenomics ES cell line RRK114 embryonic stem cell house mouse CVCL_ND09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928898; Usp14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180530 CVCL_EJ75 WIC07i-07982-4 induced pluripotent stem cell human CVCL_EJ75 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180531 CVCL_ND08 BayGenomics ES cell line RRK111 embryonic stem cell house mouse CVCL_ND08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152453; Gsk3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180532 CVCL_EJ74 WIC06i-07982-2 induced pluripotent stem cell human CVCL_EJ74 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Austrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 21180533 CVCL_ND07 BayGenomics ES cell line RRK106 embryonic stem cell house mouse CVCL_ND07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916380; Vps13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180534 CVCL_EJ73 WIC05i-127-325 induced pluripotent stem cell human CVCL_EJ73 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Hemizygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180535 CVCL_ND28 BayGenomics ES cell line RRK152 embryonic stem cell house mouse CVCL_ND28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180536 CVCL_ND27 BayGenomics ES cell line RRK149 embryonic stem cell house mouse CVCL_ND27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180537 CVCL_ND26 BayGenomics ES cell line RRK143 embryonic stem cell house mouse CVCL_ND26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915943; Hnrnpul2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180538 CVCL_ND25 BayGenomics ES cell line RRK142 embryonic stem cell house mouse CVCL_ND25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106067; Smc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180539 CVCL_ND24 BayGenomics ES cell line RRK141 embryonic stem cell house mouse CVCL_ND24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919834; Cul4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180540 CVCL_EJ90 UCSD229i-SAD1-1 induced pluripotent stem cell human CVCL_EJ90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21180541 CVCL_ND23 BayGenomics ES cell line RRK138 embryonic stem cell house mouse CVCL_ND23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180542 CVCL_ND22 BayGenomics ES cell line RRK137 embryonic stem cell house mouse CVCL_ND22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915525; Rpa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180543 CVCL_ND21 BayGenomics ES cell line RRK135 embryonic stem cell house mouse CVCL_ND21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97286; Ncl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180544 CVCL_ND20 BayGenomics ES cell line RRK133 embryonic stem cell house mouse CVCL_ND20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180545 CVCL_EJ89 UCSD228i-NDC2-3 induced pluripotent stem cell human CVCL_EJ89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180546 CVCL_EJ88 UCSD227i-NDC2-2 induced pluripotent stem cell human CVCL_EJ88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd227i-ndc2-2; true Male 21180547 CVCL_EJ83 WISCi005-B induced pluripotent stem cell human CVCL_EJ83 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21180548 CVCL_EJ82 WISCi005-C induced pluripotent stem cell human CVCL_EJ82 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Karyotypic information: Lost the third copy of chromosome 21; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21180549 CVCL_EJ81 WISCi005-A induced pluripotent stem cell human CVCL_EJ81 From: University of Wisconsin; Madison; USA CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21180550 CVCL_EJ80 WISCi006-A induced pluripotent stem cell human CVCL_EJ80 From: University of Wisconsin; Madison; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180551 CVCL_EJ87 UCSD226i-NDC2-1 induced pluripotent stem cell human CVCL_EJ87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: WiCell; ucsd226i-ndc2-1; true Male 21180552 CVCL_EJ86 UCSD225i-NDC1-3 induced pluripotent stem cell human CVCL_EJ86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180553 CVCL_ND19 BayGenomics ES cell line RRK129 embryonic stem cell house mouse CVCL_ND19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920136; Yju2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180554 CVCL_EJ85 UCSD224i-NDC1-2 induced pluripotent stem cell human CVCL_EJ85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180555 CVCL_ND18 BayGenomics ES cell line RRK128 embryonic stem cell house mouse CVCL_ND18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913489; Rsrc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180556 CVCL_EJ84 UCSD223i-NDC1-1 induced pluripotent stem cell human CVCL_EJ84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21180557 CVCL_EJ58 GM08834 transformed cell line human CVCL_EJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180558 CVCL_EJ57 GM08698 transformed cell line human CVCL_EJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180559 CVCL_EJ56 GM08697 transformed cell line human CVCL_EJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180560 CVCL_EJ55 GM08372 transformed cell line human CVCL_EJ55 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180561 CVCL_EJ59 GM10014 finite cell line human CVCL_EJ59 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM10014; probable Female 21180562 CVCL_EJ50 GM07423 transformed cell line human CVCL_EJ50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180563 CVCL_EJ54 GM08247 finite cell line human CVCL_EJ54 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180564 CVCL_EJ53 GM07551 finite cell line human CVCL_EJ53 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180565 CVCL_EJ52 GM07550 transformed cell line human CVCL_EJ52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180566 CVCL_EJ51 GM07424 finite cell line human CVCL_EJ51 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180567 CVCL_ND06 BayGenomics ES cell line RRK105 embryonic stem cell house mouse CVCL_ND06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923483; Dnttip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180568 CVCL_ND05 BayGenomics ES cell line RRK104 embryonic stem cell house mouse CVCL_ND05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180569 CVCL_ND04 BayGenomics ES cell line RRK101 embryonic stem cell house mouse CVCL_ND04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180570 CVCL_ND03 BayGenomics ES cell line RRK097 embryonic stem cell house mouse CVCL_ND03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683537; Tapt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180571 CVCL_ND02 BayGenomics ES cell line RRK095 embryonic stem cell house mouse CVCL_ND02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888993; Api5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180572 CVCL_ND01 BayGenomics ES cell line RRK094 embryonic stem cell house mouse CVCL_ND01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445089; Trappc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180573 CVCL_ND00 BayGenomics ES cell line RRK090 embryonic stem cell house mouse CVCL_ND00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442620; Nup133 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180574 CVCL_EJ69 RMS-E3 cancer cell line human CVCL_EJ69 CL:0000010 21180575 CVCL_EJ68 RMS-E2 cancer cell line human CVCL_EJ68 CL:0000010 21180576 CVCL_EJ67 RMS-A1 cancer cell line human CVCL_EJ67 CL:0000010 21180577 CVCL_EJ66 GM20399 transformed cell line human CVCL_EJ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180578 CVCL_EJ61 GM10078 transformed cell line human CVCL_EJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180579 CVCL_EJ60 GM10016 finite cell line human CVCL_EJ60 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180580 CVCL_EJ65 GM14733 transformed cell line human CVCL_EJ65 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; CH-5 30kb del (CH-5 type CYP21A1P/CYP21A2 chimer); Zygosity=Heterozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180581 CVCL_EJ64 GM14732 transformed cell line human CVCL_EJ64 CL:0000010 Sequence variation: Mutation; HGNC; 2600; CYP21A2; Unexplicit; Ex1-8del; Zygosity=Heterozygous (PubMed=27896104) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180582 CVCL_EJ63 GM14556 transformed cell line human CVCL_EJ63 CL:0000010 Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Tyr312Ter (c.936T>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180583 CVCL_EJ62 GM10079 transformed cell line human CVCL_EJ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180584 CVCL_EJ36 GM04234 finite cell line human CVCL_EJ36 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Arg71Cys (c.211C>T) (R54C, 378T); ClinVar=VCV000013663; Zygosity=Heterozygous (PubMed=1409720) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180585 CVCL_EJ35 GM03328 finite cell line human CVCL_EJ35 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180586 CVCL_EJ34 GM03327 finite cell line human CVCL_EJ34 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180587 CVCL_EJ33 GM03192 finite cell line human CVCL_EJ33 CL:0000010 Population: Caucasian; Irish/Scottish; Derived from sampling site: Cell type=Fibroblast. Female 21180588 CVCL_EJ39 GM20937 transformed cell line human CVCL_EJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180589 CVCL_EJ38 GM20400 transformed cell line human CVCL_EJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180590 CVCL_EJ37 GM04236 finite cell line human CVCL_EJ37 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Asp294Ala (c.881A>C) (D277A, 1057C); ClinVar=VCV000013664; Zygosity=Heterozygous (PubMed=1409720) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180591 CVCL_EJ32 GM03191 finite cell line human CVCL_EJ32 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180592 CVCL_EJ31 GM02815 finite cell line human CVCL_EJ31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180593 CVCL_EJ30 GM01868 transformed cell line human CVCL_EJ30 CL:0000010 Sequence variation: Mutation; HGNC; 2501; CTH; Simple; p.Thr355Ilefs (c.1220delC); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180594 CVCL_EJ47 GM07317 finite cell line human CVCL_EJ47 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180595 CVCL_EJ46 GM07316 transformed cell line human CVCL_EJ46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180596 CVCL_EJ45 GM07269 finite cell line human CVCL_EJ45 CL:0000010 Population: Jewish; Derived from sampling site: Cell type=Fibroblast. Female 21180597 CVCL_EJ44 GM07268 transformed cell line human CVCL_EJ44 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180598 CVCL_EJ49 GM07336 finite cell line human CVCL_EJ49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21180599 CVCL_EJ48 GM07335 transformed cell line human CVCL_EJ48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180600 CVCL_EJ43 GM07244 finite cell line human CVCL_EJ43 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180601 CVCL_EJ42 GM07243 transformed cell line human CVCL_EJ42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180602 CVCL_EJ41 GM07223 finite cell line human CVCL_EJ41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21180603 CVCL_EJ40 GM07222 transformed cell line human CVCL_EJ40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180604 CVCL_4809 1510-CPTX transformed cell line human CVCL_4809 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180605 CVCL_3W09 HQ02157 transformed cell line human CVCL_3W09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180606 CVCL_3W00 HQ02148 transformed cell line human CVCL_3W00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180607 CVCL_4800 XG-4 cancer cell line human CVCL_4800 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (PubMed=1373872; PubMed=21173094) Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG kappa 21180608 CVCL_3W04 HQ02152 transformed cell line human CVCL_3W04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180609 CVCL_4804 PNT1 transformed cell line human CVCL_4804 CL:0000010 Transformant: Simian virus 40 (SV40) [pMK16](NCBI-Taxonomy; 1891767); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 40 hours (PubMed=1714974) 21180610 CVCL_3W03 HQ02151 transformed cell line human CVCL_3W03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180611 CVCL_4803 Saka transformed cell line human CVCL_4803 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Unspecified 21180612 CVCL_3W02 HQ02150 transformed cell line human CVCL_3W02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180613 CVCL_4802 UTMC-2 cancer cell line human CVCL_4802 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq Female Characteristics: IL6 dependent; Characteristics: Produces IgA kappa Doubling time: 48 hours (PubMed=7528862) 21180614 CVCL_3W01 HQ02149 transformed cell line human CVCL_3W01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180615 CVCL_4801 XG-5 cancer cell line human CVCL_4801 HLA typing: A*02:01; B*44,49; C*05:01,07 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=1373872; PubMed=21173094) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21180616 CVCL_4808 129 Nu 5010-5 Tu transformed cell line human CVCL_4808 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180617 CVCL_3W08 HQ02156 transformed cell line human CVCL_3W08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180618 CVCL_4807 129 Nu 5002-1 Tu transformed cell line human CVCL_4807 CL:0000010 Population: Caucasian; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 21180619 CVCL_3W07 HQ02155 transformed cell line human CVCL_3W07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180620 CVCL_4806 1013L cancer cell line human CVCL_4806 CL:0000010 Karyotypic information: Hypertriploid (CelloPub=CLPUB00698); Derived from sampling site: Prostate. Male 21180621 CVCL_3W06 HQ02154 transformed cell line human CVCL_3W06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180622 CVCL_3W05 HQ02153 transformed cell line human CVCL_3W05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180623 CVCL_4805 TALL-103/2 cancer cell line human CVCL_4805 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: IL2 dependent 21180624 CVCL_4811 1512-normal transformed cell line human CVCL_4811 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180625 CVCL_3W11 HQ02159 transformed cell line human CVCL_3W11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180626 CVCL_4810 1512-CPTX transformed cell line human CVCL_4810 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180627 CVCL_3W10 HQ02158 transformed cell line human CVCL_3W10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180628 CVCL_4815 1532-CPTX-2 transformed cell line human CVCL_4815 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180629 CVCL_3W15 HQ02163 transformed cell line human CVCL_3W15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180630 CVCL_4814 1532-CPTX-1 transformed cell line human CVCL_4814 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male 21180631 CVCL_3W14 HQ02162 transformed cell line human CVCL_3W14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180632 CVCL_4813 1519-normal transformed cell line human CVCL_4813 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180633 CVCL_3W13 HQ02161 transformed cell line human CVCL_3W13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180634 CVCL_4812 1519-CPTX transformed cell line human CVCL_4812 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180635 CVCL_3W12 HQ02160 transformed cell line human CVCL_3W12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180636 CVCL_4819 1535-normal prostate transformed cell line human CVCL_4819 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180637 CVCL_3W19 HQ02167 transformed cell line human CVCL_3W19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180638 CVCL_4818 1535-CPTX-2 transformed cell line human CVCL_4818 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180639 CVCL_3W18 HQ02166 transformed cell line human CVCL_3W18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180640 CVCL_4817 1535-CPTX-1 transformed cell line human CVCL_4817 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180641 CVCL_3W17 HQ02165 transformed cell line human CVCL_3W17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180642 CVCL_4816 1532-normal transformed cell line human CVCL_4816 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate. Male 21180643 CVCL_3W16 HQ02164 transformed cell line human CVCL_3W16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180644 CVCL_ND99 BayGenomics ES cell line RRK280 embryonic stem cell house mouse CVCL_ND99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442563; Naa25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180645 CVCL_ND98 BayGenomics ES cell line RRK279 embryonic stem cell house mouse CVCL_ND98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915452; Ndufa5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180646 CVCL_ND97 BayGenomics ES cell line RRK278 embryonic stem cell house mouse CVCL_ND97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915082; Brix1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180647 CVCL_ND96 BayGenomics ES cell line RRK275 embryonic stem cell house mouse CVCL_ND96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351500; Nup62 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180648 CVCL_ND95 BayGenomics ES cell line RRK271 embryonic stem cell house mouse CVCL_ND95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109531; Cdc37 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180649 CVCL_ND94 BayGenomics ES cell line RRK261 embryonic stem cell house mouse CVCL_ND94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890467; Vps35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180650 CVCL_ND93 BayGenomics ES cell line RRK260 embryonic stem cell house mouse CVCL_ND93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180651 CVCL_ND92 BayGenomics ES cell line RRK256 embryonic stem cell house mouse CVCL_ND92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142786; Tango6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180652 CVCL_ND91 BayGenomics ES cell line RRK255 embryonic stem cell house mouse CVCL_ND91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924203; Emsy Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180653 CVCL_ND90 BayGenomics ES cell line RRK254 embryonic stem cell house mouse CVCL_ND90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180654 CVCL_ND79 BayGenomics ES cell line RRK234 embryonic stem cell house mouse CVCL_ND79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933973; Rbfox2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180655 CVCL_ND78 BayGenomics ES cell line RRK233 embryonic stem cell house mouse CVCL_ND78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106314; Tars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180656 CVCL_ND77 BayGenomics ES cell line RRK232 embryonic stem cell house mouse CVCL_ND77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917477; Zfp619 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180657 CVCL_ND76 BayGenomics ES cell line RRK231 embryonic stem cell house mouse CVCL_ND76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180658 CVCL_ND75 BayGenomics ES cell line RRK230 embryonic stem cell house mouse CVCL_ND75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180659 CVCL_ND74 BayGenomics ES cell line RRK227 embryonic stem cell house mouse CVCL_ND74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346877; Map3k7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180660 CVCL_ND73 BayGenomics ES cell line RRK224 embryonic stem cell house mouse CVCL_ND73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180661 CVCL_ND72 BayGenomics ES cell line RRK223 embryonic stem cell house mouse CVCL_ND72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097668; Upp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180662 CVCL_ND71 BayGenomics ES cell line RRK222 embryonic stem cell house mouse CVCL_ND71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87881; Acp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180663 CVCL_ND70 BayGenomics ES cell line RRK221 embryonic stem cell house mouse CVCL_ND70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180664 CVCL_ND89 BayGenomics ES cell line RRK251 embryonic stem cell house mouse CVCL_ND89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153272; Trrap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180665 CVCL_ND88 BayGenomics ES cell line RRK250 embryonic stem cell house mouse CVCL_ND88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180666 CVCL_ND87 BayGenomics ES cell line RRK249 embryonic stem cell house mouse CVCL_ND87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104558; Rps6ka1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180667 CVCL_ND86 BayGenomics ES cell line RRK247 embryonic stem cell house mouse CVCL_ND86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922670; Secisbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180668 CVCL_ND85 BayGenomics ES cell line RRK246 embryonic stem cell house mouse CVCL_ND85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925953; Zfp972 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180669 CVCL_ND84 BayGenomics ES cell line RRK245 embryonic stem cell house mouse CVCL_ND84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099786; Dhx15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180670 CVCL_ND83 BayGenomics ES cell line RRK243 embryonic stem cell house mouse CVCL_ND83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98180; Rrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180671 CVCL_ND82 BayGenomics ES cell line RRK241 embryonic stem cell house mouse CVCL_ND82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3046173; Nup85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180672 CVCL_ND81 BayGenomics ES cell line RRK239 embryonic stem cell house mouse CVCL_ND81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684789; Lrsam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180673 CVCL_ND80 BayGenomics ES cell line RRK236 embryonic stem cell house mouse CVCL_ND80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104560; Nsf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180674 CVCL_ND59 BayGenomics ES cell line RRK201 embryonic stem cell house mouse CVCL_ND59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99511; Ptpn11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180675 CVCL_ND58 BayGenomics ES cell line RRK199 embryonic stem cell house mouse CVCL_ND58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915082; Brix1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180676 CVCL_ND57 BayGenomics ES cell line RRK198 embryonic stem cell house mouse CVCL_ND57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88529; Cs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180677 CVCL_ND56 BayGenomics ES cell line RRK197 embryonic stem cell house mouse CVCL_ND56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894681; Usp9x Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180678 CVCL_ND55 BayGenomics ES cell line RRK196 embryonic stem cell house mouse CVCL_ND55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201607; Blzf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180679 CVCL_ND54 BayGenomics ES cell line RRK195 embryonic stem cell house mouse CVCL_ND54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98372; Sp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180680 CVCL_ND53 BayGenomics ES cell line RRK194 embryonic stem cell house mouse CVCL_ND53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039623; Thada Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180681 CVCL_ND52 BayGenomics ES cell line RRK193 embryonic stem cell house mouse CVCL_ND52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913348; Chchd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180682 CVCL_ND51 BayGenomics ES cell line RRK191 embryonic stem cell house mouse CVCL_ND51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87911; Acvr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180683 CVCL_ND50 BayGenomics ES cell line RRK190 embryonic stem cell house mouse CVCL_ND50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140796; Slc15a4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180684 CVCL_ND69 BayGenomics ES cell line RRK220 embryonic stem cell house mouse CVCL_ND69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922832; Relch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180685 CVCL_ND68 BayGenomics ES cell line RRK218 embryonic stem cell house mouse CVCL_ND68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921078; Dcaf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180686 CVCL_ND67 BayGenomics ES cell line RRK213 embryonic stem cell house mouse CVCL_ND67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337100; Wdr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180687 CVCL_ND66 BayGenomics ES cell line RRK212 embryonic stem cell house mouse CVCL_ND66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100818; Crcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180688 CVCL_ND65 BayGenomics ES cell line RRK210 embryonic stem cell house mouse CVCL_ND65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890430; Paxip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180689 CVCL_ND64 BayGenomics ES cell line RRK208 embryonic stem cell house mouse CVCL_ND64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180690 CVCL_ND63 BayGenomics ES cell line RRK206 embryonic stem cell house mouse CVCL_ND63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180691 CVCL_ND62 BayGenomics ES cell line RRK204 embryonic stem cell house mouse CVCL_ND62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180692 CVCL_ND61 BayGenomics ES cell line RRK203 embryonic stem cell house mouse CVCL_ND61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99638; Mark2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180693 CVCL_ND60 BayGenomics ES cell line RRK202 embryonic stem cell house mouse CVCL_ND60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098230; Cenpe Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180694 CVCL_3X90 HQ02370 transformed cell line human CVCL_3X90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180695 CVCL_4990 U-CH1-N cancer cell line human CVCL_4990 CL:0000010 Derived from sampling site: Bone; sacrum. Male Doubling time: ~3 days (PubMed=21914223) 21180696 CVCL_3X83 HQ02360 transformed cell line human CVCL_3X83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180697 CVCL_4983 MC1A-C1 cancer cell line house mouse CVCL_4983 CL:0000010 Breed/subspecies: C57BL/10. Male 21180698 CVCL_3X82 HQ02359 transformed cell line human CVCL_3X82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180699 CVCL_4982 MC-TGS17-51 cancer cell line house mouse CVCL_4982 CL:0000010 Breed/subspecies: C57BL/10. Male 21180700 CVCL_3X81 HQ02358 transformed cell line human CVCL_3X81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180701 CVCL_4981 TM-7 cancer cell line house mouse CVCL_4981 CL:0000010 Breed/subspecies: C57BL/10. Discontinued: ATCC; CRL-2798; true Male 21180702 CVCL_3X80 HQ02357 transformed cell line human CVCL_3X80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180703 CVCL_4980 TM-34 cancer cell line house mouse CVCL_4980 CL:0000010 Breed/subspecies: C57BL/10. Discontinued: ATCC; CRL-2801; true Male 21180704 CVCL_3X87 HQ02364 transformed cell line human CVCL_3X87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180705 CVCL_4987 ME 1 [Mouse hybridoma] hybridoma house mouse CVCL_4987 CL:0000010 Monoclonal antibody isotype: IgG1. 21180706 CVCL_3X86 HQ02363 transformed cell line human CVCL_3X86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180707 CVCL_4986 ME [Mouse] undefined cell line type house mouse CVCL_4986 CL:0000010 Discontinued: ATCC; CRL-6371; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180708 CVCL_3X85 HQ02362 transformed cell line human CVCL_3X85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180709 CVCL_4985 MC57G cancer cell line house mouse CVCL_4985 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: C57BL/6J. 21180710 CVCL_3X84 HQ02361 transformed cell line human CVCL_3X84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180711 CVCL_4984 Walker-256-TC cancer cell line Norway rat CVCL_4984 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21180712 CVCL_3X89 HQ02369 transformed cell line human CVCL_3X89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180713 CVCL_4989 U-CH2 cancer cell line human CVCL_4989 HLA typing: A*11:01; B*07; C*07:02; DQA1*02:01; DQB1*03; DRB4*01:03N (Chordoma_Foundation); Genome ancestry: African=0%; Native American=0.92%; East Asian, North=0%; East Asian, South=0.34%; South Asian=1.36%; European, North=67.93%; European, South=29.44% (PubMed=30894373). CL:0000010 Population: Caucasian Omics: CNV analysis; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 4 days (PubMed=26183925); ~5-7 days (DSMZ=ACC-749); 3 days (Chordoma_Foundation); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21180714 CVCL_3X88 HQ02368 transformed cell line human CVCL_3X88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180715 CVCL_4988 U-CH1 cancer cell line human CVCL_4988 HLA typing: A*2 (Chordoma_Foundation) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=28515451) Derived from sampling site: Bone; sacrum. Omics: CNV analysis; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~1 week, but can be significantly longer after recovery from liquid nitrogen freezing (DSMZ=ACC-748); 2 days (PubMed=26183925); 9 days (Chordoma_Foundation) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: ENCODE project common cell types; tier 3 21180716 CVCL_3X94 HQ02374 transformed cell line human CVCL_3X94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180717 CVCL_4994 PXN/94 cancer cell line human CVCL_4994 CL:0000010 Female Characteristics: Established from a xenograft established in female nude mice (PubMed=2653399) Doubling time: 23 hours (PubMed=2653399). 21180718 CVCL_4993 41M cancer cell line human CVCL_4993 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Discontinued: ECACC; 93061002; probable Female Doubling time: 27 hours (PubMed=2653399) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00110 Problematic cell line: Contaminated Shown to be a OAW28 derivative (PubMed=20143388). 21180719 CVCL_3X93 HQ02373 transformed cell line human CVCL_3X93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180720 CVCL_4992 CH1 [Human ovarian carcinoma] cancer cell line human CVCL_4992 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro316Pro (c.948C>T); ClinVar=VCV000750727; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: 17 hours (PubMed=2653399) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00459 Problematic cell line: Contaminated Shown to be a PA-1 derivative (PubMed=22710073). 21180721 CVCL_3X92 HQ02372 transformed cell line human CVCL_3X92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180722 CVCL_3X91 HQ02371 transformed cell line human CVCL_3X91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180723 CVCL_4991 UCH1 cancer cell line human CVCL_4991 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 60 hours (PubMed=17454636) 21180724 CVCL_4998 GLC-4/CDDP cancer cell line human CVCL_4998 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Omics: Array-based CGH Male 21180725 CVCL_3X98 HQ02380 transformed cell line human CVCL_3X98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180726 CVCL_4997 GLC-4/ADR cancer cell line human CVCL_4997 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Male Doubling time: 26 hours (PubMed=3028613) 21180727 CVCL_3X97 HQ02378 transformed cell line human CVCL_3X97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180728 CVCL_3X96 HQ02376 transformed cell line human CVCL_3X96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180729 CVCL_4996 MS751 cancer cell line human CVCL_4996 HLA typing: A*02:01,24:02; B*35:03,40:01; C*03:04,12:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.44%; East Asian, North=0%; East Asian, South=0.42%; South Asian=0.41%; European, North=67.07%; European, South=31.66% (PubMed=30894373) CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Transformant: Human papillomavirus type 45 (HPV45)(NCBI-Taxonomy; 10593); Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: Contains a partial HPV45 genome Doubling time: 2.4 days (PubMed=29156801); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21180730 CVCL_3X95 HQ02375 transformed cell line human CVCL_3X95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180731 CVCL_4995 HX/62 cancer cell line human CVCL_4995 CL:0000010 Population: Caucasian Female Characteristics: Established from a xenograft established in female nude mice (PubMed=2653399) Doubling time: 32 hours (PubMed=2653399). 21180732 CVCL_4999 GLC-4/MIT60x cancer cell line human CVCL_4999 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Male Doubling time: 16.9 hours (PubMed=8980384) 21180733 CVCL_3X99 HQ02381 transformed cell line human CVCL_3X99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180734 CVCL_4961 FC83.Sp cancer cell line CVCL_4961 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6110; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180735 CVCL_3X61 HQ02333 transformed cell line human CVCL_3X61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180736 CVCL_4960 FC83.Res cancer cell line CVCL_4960 CL:0000010 Derived from sampling site: Bone marrow, spleen and thymus. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180737 CVCL_3X60 HQ02332 transformed cell line human CVCL_3X60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180738 CVCL_3X65 HQ02338 transformed cell line human CVCL_3X65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180739 CVCL_4965 KOPT-K1 cancer cell line human CVCL_4965 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (PubMed=15472075); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (PubMed=15472075). Population: Japanese Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21180740 CVCL_4964 FC95.Thy finite cell line CVCL_4964 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6114; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180741 CVCL_3X64 HQ02337 transformed cell line human CVCL_3X64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180742 CVCL_4963 FC94.T cancer cell line CVCL_4963 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-6113; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180743 CVCL_3X63 HQ02336 transformed cell line human CVCL_3X63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180744 CVCL_4962 FC87.Sk finite cell line CVCL_4962 CL:0000010 Karyotypic information: 38,XX; 38,XY (ATCC); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6150; true Ambiguous Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180745 CVCL_3X62 HQ02335 transformed cell line human CVCL_3X62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180746 CVCL_4969 DC3F/S16 spontaneously immortalized cell line CVCL_4969 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21180747 CVCL_3X69 HQ02342 transformed cell line human CVCL_3X69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180748 CVCL_4968 DC3F/9-OH-E spontaneously immortalized cell line CVCL_4968 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88297; 9-hydroxyellipticine (9-OH-E); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21180749 CVCL_3X68 HQ02341 transformed cell line human CVCL_3X68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180750 CVCL_4967 HL-60/Vinc cancer cell line human CVCL_4967 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Peripheral blood. Female 21180751 CVCL_3X67 HQ02340 transformed cell line human CVCL_3X67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180752 CVCL_4966 CUTLL1 cancer cell line human CVCL_4966 CL:0000010 Sequence variation: Gene fusion; HGNC; 7881; NOTCH1 + HGNC; 12155; TRB; Name(s)=TRB-NOTCH1, TCRB-NOTCH1 (PubMed=16688224); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=16688224) Derived from sampling site: Pleural effusion Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 21180753 CVCL_3X66 HQ02339 transformed cell line human CVCL_3X66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180754 CVCL_3X72 HQ02347 transformed cell line human CVCL_3X72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180755 CVCL_4972 MHCC97-H cancer cell line human CVCL_4972 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Deep phosphoproteome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Characteristics: High metastatic potential Doubling time: 28.79 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 21180756 CVCL_3X71 HQ02346 transformed cell line human CVCL_3X71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180757 CVCL_4971 MHCC97 cancer cell line human CVCL_4971 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Transcriptome analysis by microarray. Male Doubling time: ~31 hours (PubMed=10555751) 21180758 CVCL_4970 HaCa-4 cancer cell line house mouse CVCL_4970 CL:0000010 Transformant: Harvey murine sarcoma virus (Ha-MSV)(NCBI-Taxonomy; 11807). 21180759 CVCL_3X70 HQ02343 transformed cell line human CVCL_3X70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180760 CVCL_4976 GIST-T1 cancer cell line human CVCL_4976 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=12004007; PubMed=16077968) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep tyrosine phosphoproteome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 48 hours (PubMed=12004007) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21180761 CVCL_3X76 HQ02352 transformed cell line human CVCL_3X76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180762 CVCL_3X75 HQ02351 transformed cell line human CVCL_3X75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180763 CVCL_4975 SKO-007 clone J3 cancer cell line human CVCL_4975 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgE lambda Group: Hybridoma fusion partner cell line 21180764 CVCL_3X74 HQ02350 transformed cell line human CVCL_3X74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180765 CVCL_4974 SKO-007 cancer cell line human CVCL_4974 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Gly141Asp (c.422G>A); ClinVar=VCV001491786; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys550Leufs*3 (c.1648_1649insT); Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Male Characteristics: Produces IgE lambda Group: Hybridoma fusion partner cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8033 21180766 CVCL_3X73 HQ02349 transformed cell line human CVCL_3X73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180767 CVCL_4973 MHCC97-L cancer cell line human CVCL_4973 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Characteristics: Low metastatic potential 21180768 CVCL_3X79 HQ02356 transformed cell line human CVCL_3X79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180769 CVCL_4979 TM-28 cancer cell line house mouse CVCL_4979 CL:0000010 Breed/subspecies: C57BL/10. Discontinued: ATCC; CRL-2803; true Male 21180770 CVCL_3X78 HQ02355 transformed cell line human CVCL_3X78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180771 CVCL_4978 MT-6 cancer cell line house mouse CVCL_4978 CL:0000010 Breed/subspecies: C57BL/10. Discontinued: ATCC; CRL-2805; true Male 21180772 CVCL_4977 +/+ Li finite cell line house mouse CVCL_4977 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6467; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180773 CVCL_3X77 HQ02353 transformed cell line human CVCL_3X77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180774 CVCL_4943 FC119 finite cell line CVCL_4943 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6125; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180775 CVCL_3X43 HQ02312 transformed cell line human CVCL_3X43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180776 CVCL_4942 FC118 finite cell line CVCL_4942 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6124; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180777 CVCL_3X42 HQ02311 transformed cell line human CVCL_3X42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180778 CVCL_4941 FC115.K finite cell line CVCL_4941 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Discontinued: ATCC; CRL-6122; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180779 CVCL_3X41 HQ02308 transformed cell line human CVCL_3X41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180780 CVCL_4940 FC114E.Tr finite cell line CVCL_4940 CL:0000010 Derived from sampling site: Fetal trachea Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180781 CVCL_3X40 HQ02307 transformed cell line human CVCL_3X40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180782 CVCL_4947 FC60(A).We finite cell line CVCL_4947 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6140; true; Discontinued: ATCC; CRL-6571; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180783 CVCL_3X47 HQ02317 transformed cell line human CVCL_3X47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180784 CVCL_4946 FC5.K finite cell line CVCL_4946 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6078; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180785 CVCL_3X46 HQ02316 transformed cell line human CVCL_3X46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180786 CVCL_4945 FC47 finite cell line CVCL_4945 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180787 CVCL_3X45 HQ02315 transformed cell line human CVCL_3X45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180788 CVCL_4944 FC16.Sp cancer cell line CVCL_4944 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6174; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180789 CVCL_3X44 HQ02313 transformed cell line human CVCL_3X44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180790 CVCL_3X49 HQ02319 transformed cell line human CVCL_3X49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180791 CVCL_4948 FC60(B).We finite cell line CVCL_4948 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6098; true; Discontinued: ATCC; CRL-6141; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180792 CVCL_3X48 HQ02318 transformed cell line human CVCL_3X48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180793 CVCL_3X50 HQ02321 transformed cell line human CVCL_3X50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180794 CVCL_4954 FC71A.We finite cell line CVCL_4954 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6145; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180795 CVCL_3X54 HQ02326 transformed cell line human CVCL_3X54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180796 CVCL_4953 FC70.We finite cell line CVCL_4953 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6102; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180797 CVCL_3X53 HQ02325 transformed cell line human CVCL_3X53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180798 CVCL_4952 FC63.Res finite cell line CVCL_4952 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6143; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180799 CVCL_3X52 HQ02324 transformed cell line human CVCL_3X52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180800 CVCL_4951 FC61 finite cell line CVCL_4951 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6099; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180801 CVCL_3X51 HQ02322 transformed cell line human CVCL_3X51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180802 CVCL_4958 FC81.T cancer cell line CVCL_4958 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-6108; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180803 CVCL_3X58 HQ02330 transformed cell line human CVCL_3X58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180804 CVCL_4957 FC81.Sp finite cell line CVCL_4957 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6107; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180805 CVCL_3X57 HQ02329 transformed cell line human CVCL_3X57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180806 CVCL_4956 FC79.We finite cell line CVCL_4956 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6106; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180807 CVCL_3X56 HQ02328 transformed cell line human CVCL_3X56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21180808 CVCL_4955 FC77.T cancer cell line CVCL_4955 CL:0000010 Derived from sampling site: Hypodermis Cell type=Fibroblast.. Discontinued: ATCC; CRL-6105; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180809 CVCL_3X55 HQ02327 transformed cell line human CVCL_3X55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180810 CVCL_4959 FC81.Thy finite cell line CVCL_4959 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6109; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21180811 CVCL_3X59 HQ02331 transformed cell line human CVCL_3X59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21180812 CVCL_EL56 PENN156i-M8-2 induced pluripotent stem cell human CVCL_EL56 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180813 CVCL_EL55 PENN155i-M3-21 induced pluripotent stem cell human CVCL_EL55 CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Lys531Asn; Zygosity=Heterozygous (PubMed=25904599) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180814 CVCL_EL54 PENN154i-M18-2 induced pluripotent stem cell human CVCL_EL54 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180815 CVCL_EL53 PENN153i-M4-10 induced pluripotent stem cell human CVCL_EL53 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180816 CVCL_EL59 PENN159i-M14-4 induced pluripotent stem cell human CVCL_EL59 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 1664; SCARB1; Simple; p.Pro376Leu (c.1127C>T); ClinVar=VCV000253091; Zygosity=Homozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180817 CVCL_EL58 PENN158i-M12-4 induced pluripotent stem cell human CVCL_EL58 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180818 CVCL_EL57 PENN157i-M2-6 induced pluripotent stem cell human CVCL_EL57 CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Lys531Asn; Zygosity=Heterozygous (PubMed=25904599); Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Ser2046Arg; Zygosity=Heterozygous (PubMed=25904599) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180819 CVCL_EL52 PENN152i-M18-1 induced pluripotent stem cell human CVCL_EL52 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180820 CVCL_EL51 PENN151i-M1-5 induced pluripotent stem cell human CVCL_EL51 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180821 CVCL_EL50 PENN150i-M7-9 induced pluripotent stem cell human CVCL_EL50 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 7467; MTTP; Simple; p.Arg46Gly (c.136C>G); ClinVar=VCV000347020; Zygosity=Homozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180822 CVCL_NF04 BayGenomics ES cell line RRM019 embryonic stem cell house mouse CVCL_NF04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915848; Dnajc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180823 CVCL_NF03 BayGenomics ES cell line RRM017 embryonic stem cell house mouse CVCL_NF03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914127; Crnkl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180824 CVCL_NF02 BayGenomics ES cell line RRM015 embryonic stem cell house mouse CVCL_NF02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924894; Steep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180825 CVCL_NF01 BayGenomics ES cell line RRM014 embryonic stem cell house mouse CVCL_NF01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88547; Csnk2a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180826 CVCL_NF00 BayGenomics ES cell line RRM013 embryonic stem cell house mouse CVCL_NF00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447768; Fam193a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180827 CVCL_EL67 PENN167i-M5-3 induced pluripotent stem cell human CVCL_EL67 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex3-6del; Zygosity=Homozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180828 CVCL_EL66 PENN166i-M15-4 induced pluripotent stem cell human CVCL_EL66 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180829 CVCL_EL65 PENN165i-M2-21 induced pluripotent stem cell human CVCL_EL65 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Lys531Asn; Zygosity=Heterozygous (PubMed=25904599); Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Ser2046Arg; Zygosity=Heterozygous (PubMed=25904599) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180830 CVCL_EL64 PENN164i-M11-1 induced pluripotent stem cell human CVCL_EL64 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180831 CVCL_EL69 PENN169i-M17-3 induced pluripotent stem cell human CVCL_EL69 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Arg1270Ter (c.3808C>T); dbSNP=rs575627531; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 29; ABCA1; Unexplicit; IVS32-25G>C; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180832 CVCL_EL68 PENN168i-M16-1 induced pluripotent stem cell human CVCL_EL68 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Leu605Glufs*38; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex4-6del; Zygosity=Heterozygous (WiCell) Population: Latino and Native American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180833 CVCL_EL63 PENN163i-M4-4 induced pluripotent stem cell human CVCL_EL63 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180834 CVCL_EL62 PENN162i-M14-11 induced pluripotent stem cell human CVCL_EL62 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 1664; SCARB1; Simple; p.Pro376Leu (c.1127C>T); ClinVar=VCV000253091; Zygosity=Homozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180835 CVCL_EL61 PENN161i-M10-5 induced pluripotent stem cell human CVCL_EL61 CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Glu1005Ter (c.3013G>T); Zygosity=Homozygous (PubMed=25904599) Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180836 CVCL_EL60 PENN160i-M6-6 induced pluripotent stem cell human CVCL_EL60 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180837 CVCL_EL39 PENN139i-M5-4 induced pluripotent stem cell human CVCL_EL39 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex3-6del; Zygosity=Homozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180838 CVCL_EL34 PENN134i-61-26 induced pluripotent stem cell human CVCL_EL34 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180839 CVCL_EL33 PENN133i-252-23 induced pluripotent stem cell human CVCL_EL33 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180840 CVCL_EL32 PENN132i-131-5 induced pluripotent stem cell human CVCL_EL32 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180841 CVCL_EL31 PENN131i-86-3 induced pluripotent stem cell human CVCL_EL31 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180842 CVCL_EL38 PENN138i-24-4 induced pluripotent stem cell human CVCL_EL38 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180843 CVCL_EL37 PENN137i-18-11 induced pluripotent stem cell human CVCL_EL37 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180844 CVCL_EL36 PENN136i-262-1 induced pluripotent stem cell human CVCL_EL36 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180845 CVCL_EL35 PENN135i-30-8 induced pluripotent stem cell human CVCL_EL35 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180846 CVCL_EL30 PENN130i-78-3 induced pluripotent stem cell human CVCL_EL30 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180847 CVCL_EL45 PENN145i-M16-2 induced pluripotent stem cell human CVCL_EL45 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Leu605Glufs*38; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 6547; LDLR; Unexplicit; Ex4-6del; Zygosity=Heterozygous (WiCell) Population: Latino and Native American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180848 CVCL_EL44 PENN144i-M7-16 induced pluripotent stem cell human CVCL_EL44 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 7467; MTTP; Simple; p.Arg46Gly (c.136C>G); ClinVar=VCV000347020; Zygosity=Homozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180849 CVCL_EL43 PENN143i-M10-11 induced pluripotent stem cell human CVCL_EL43 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Glu1005Ter (c.3013G>T); Zygosity=Homozygous (PubMed=25904599) Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180850 CVCL_EL42 PENN142i-M3-19 induced pluripotent stem cell human CVCL_EL42 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Lys531Asn; Zygosity=Heterozygous (PubMed=25904599) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180851 CVCL_EL49 PENN149i-M1-6 induced pluripotent stem cell human CVCL_EL49 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180852 CVCL_EL48 PENN148i-M8-3 induced pluripotent stem cell human CVCL_EL48 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180853 CVCL_EL47 PENN147i-M9-7 induced pluripotent stem cell human CVCL_EL47 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Trp483Ter (c.1448G>A); ClinVar=VCV000226356; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly549Asp (c.1646G>A); ClinVar=VCV000003698; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180854 CVCL_EL46 PENN146i-M11-5 induced pluripotent stem cell human CVCL_EL46 CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180855 CVCL_EL41 PENN141i-M6-2 induced pluripotent stem cell human CVCL_EL41 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180856 CVCL_EL40 PENN140i-M12-7 induced pluripotent stem cell human CVCL_EL40 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180857 CVCL_EL19 PENN119i-197-25 induced pluripotent stem cell human CVCL_EL19 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180858 CVCL_EL18 PENN118i-113-2 induced pluripotent stem cell human CVCL_EL18 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180859 CVCL_EL17 PENN117i-88-32 induced pluripotent stem cell human CVCL_EL17 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180860 CVCL_EL12 PENN112i-304-6 induced pluripotent stem cell human CVCL_EL12 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180861 CVCL_EL11 PENN111i-222-5 induced pluripotent stem cell human CVCL_EL11 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180862 CVCL_EL10 PENN110i-389-6 induced pluripotent stem cell human CVCL_EL10 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180863 CVCL_EL16 PENN116i-125-16 induced pluripotent stem cell human CVCL_EL16 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180864 CVCL_EL15 PENN115i-316-1 induced pluripotent stem cell human CVCL_EL15 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180865 CVCL_EL14 PENN114i-127-2 induced pluripotent stem cell human CVCL_EL14 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180866 CVCL_EL13 PENN113i-126-66 induced pluripotent stem cell human CVCL_EL13 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180867 CVCL_EL29 PENN129i-20-14 induced pluripotent stem cell human CVCL_EL29 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180868 CVCL_EL28 PENN128i-8-4 induced pluripotent stem cell human CVCL_EL28 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180869 CVCL_EL23 PENN123i-SV20 induced pluripotent stem cell human CVCL_EL23 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180870 CVCL_EL22 PENN122i-627-5 induced pluripotent stem cell human CVCL_EL22 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180871 CVCL_EL21 PENN121i-69-1 induced pluripotent stem cell human CVCL_EL21 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180872 CVCL_EL20 PENN120i-444-1 induced pluripotent stem cell human CVCL_EL20 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180873 CVCL_EL27 PENN127i-415-1 induced pluripotent stem cell human CVCL_EL27 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180874 CVCL_EL26 PENN126i-120-1 induced pluripotent stem cell human CVCL_EL26 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180875 CVCL_EL25 PENN125i-233-4 induced pluripotent stem cell human CVCL_EL25 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180876 CVCL_EL24 PENN124i-28-3 induced pluripotent stem cell human CVCL_EL24 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180877 CVCL_EL09 PENN109i-802-2 induced pluripotent stem cell human CVCL_EL09 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180878 CVCL_EL08 PENN108i-781-3 induced pluripotent stem cell human CVCL_EL08 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180879 CVCL_EL07 PENN107i-145-1 induced pluripotent stem cell human CVCL_EL07 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180880 CVCL_EL06 PENN106i-75-39 induced pluripotent stem cell human CVCL_EL06 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180881 CVCL_EL01 PENN101i-263-39 induced pluripotent stem cell human CVCL_EL01 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180882 CVCL_EL00 PENN100i-623-3 induced pluripotent stem cell human CVCL_EL00 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180883 CVCL_EL05 PENN105i-342-5 induced pluripotent stem cell human CVCL_EL05 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180884 CVCL_EL04 PENN104i-321-6 induced pluripotent stem cell human CVCL_EL04 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180885 CVCL_EL03 PENN103i-330-4 induced pluripotent stem cell human CVCL_EL03 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180886 CVCL_EL02 PENN102i-96-1 induced pluripotent stem cell human CVCL_EL02 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180887 CVCL_NE59 BayGenomics ES cell line RRK456 embryonic stem cell house mouse CVCL_NE59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097668; Upp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180888 CVCL_NE58 BayGenomics ES cell line RRK454 embryonic stem cell house mouse CVCL_NE58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182303; Ddx50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180889 CVCL_NE57 BayGenomics ES cell line RRK453 embryonic stem cell house mouse CVCL_NE57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180890 CVCL_NE56 BayGenomics ES cell line RRK452 embryonic stem cell house mouse CVCL_NE56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180891 CVCL_NE55 BayGenomics ES cell line RRK451 embryonic stem cell house mouse CVCL_NE55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3041177; Taok3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180892 CVCL_NE54 BayGenomics ES cell line RRK447 embryonic stem cell house mouse CVCL_NE54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180893 CVCL_NE53 BayGenomics ES cell line RRK446 embryonic stem cell house mouse CVCL_NE53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100818; Crcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180894 CVCL_NE52 BayGenomics ES cell line RRK433 embryonic stem cell house mouse CVCL_NE52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915549; Vps53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180895 CVCL_NE51 BayGenomics ES cell line RRK432 embryonic stem cell house mouse CVCL_NE51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180896 CVCL_NE50 BayGenomics ES cell line RRK431 embryonic stem cell house mouse CVCL_NE50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099436; Rad51b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180897 CVCL_NE69 BayGenomics ES cell line RRK477 embryonic stem cell house mouse CVCL_NE69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143977; Mbtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180898 CVCL_NE68 BayGenomics ES cell line RRK474 embryonic stem cell house mouse CVCL_NE68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444023; Tdrd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180899 CVCL_NE67 BayGenomics ES cell line RRK473 embryonic stem cell house mouse CVCL_NE67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194492; Hdgfl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180900 CVCL_NE66 BayGenomics ES cell line RRK469 embryonic stem cell house mouse CVCL_NE66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039623; Thada Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180901 CVCL_NE65 BayGenomics ES cell line RRK468 embryonic stem cell house mouse CVCL_NE65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180902 CVCL_NE64 BayGenomics ES cell line RRK467 embryonic stem cell house mouse CVCL_NE64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104653; Atp2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180903 CVCL_NE63 BayGenomics ES cell line RRK464 embryonic stem cell house mouse CVCL_NE63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180904 CVCL_NE62 BayGenomics ES cell line RRK461 embryonic stem cell house mouse CVCL_NE62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684789; Lrsam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180905 CVCL_NE61 BayGenomics ES cell line RRK459 embryonic stem cell house mouse CVCL_NE61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180906 CVCL_NE60 BayGenomics ES cell line RRK457 embryonic stem cell house mouse CVCL_NE60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919240; Ddx54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180907 CVCL_NE38 BayGenomics ES cell line RRK375 embryonic stem cell house mouse CVCL_NE38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95401; Epb41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180908 CVCL_NE37 BayGenomics ES cell line RRK374 embryonic stem cell house mouse CVCL_NE37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180909 CVCL_NE36 BayGenomics ES cell line RRK373 embryonic stem cell house mouse CVCL_NE36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916375; Cnot8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180910 CVCL_NE35 BayGenomics ES cell line RRK372 embryonic stem cell house mouse CVCL_NE35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889276; Dgke Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180911 CVCL_NE34 BayGenomics ES cell line RRK371 embryonic stem cell house mouse CVCL_NE34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919057; Tars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180912 CVCL_NE33 BayGenomics ES cell line RRK370 embryonic stem cell house mouse CVCL_NE33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934229; Setdb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180913 CVCL_NE32 BayGenomics ES cell line RRK369 embryonic stem cell house mouse CVCL_NE32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927470; Spag5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180914 CVCL_NE31 BayGenomics ES cell line RRK368 embryonic stem cell house mouse CVCL_NE31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146974; Safb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180915 CVCL_NE30 BayGenomics ES cell line RRK366 embryonic stem cell house mouse CVCL_NE30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105050; Mtf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180916 CVCL_EK99 PENN099i-218-1 induced pluripotent stem cell human CVCL_EK99 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180917 CVCL_EK98 PENN098i-50-18 induced pluripotent stem cell human CVCL_EK98 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180918 CVCL_EK93 PENN093i-16-7 induced pluripotent stem cell human CVCL_EK93 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180919 CVCL_EK92 PENN092i-560-3 induced pluripotent stem cell human CVCL_EK92 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180920 CVCL_EK91 PENN091i-588-2 induced pluripotent stem cell human CVCL_EK91 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180921 CVCL_EK90 PENN090i-111-4 induced pluripotent stem cell human CVCL_EK90 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180922 CVCL_EK97 PENN097i-17-1 induced pluripotent stem cell human CVCL_EK97 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180923 CVCL_EK96 PENN096i-44-4 induced pluripotent stem cell human CVCL_EK96 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180924 CVCL_NE29 BayGenomics ES cell line RRK365 embryonic stem cell house mouse CVCL_NE29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95412; Ercc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180925 CVCL_EK95 PENN095i-123-7 induced pluripotent stem cell human CVCL_EK95 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180926 CVCL_NE28 BayGenomics ES cell line RRK364 embryonic stem cell house mouse CVCL_NE28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97286; Ncl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180927 CVCL_EK94 PENN094i-161-1 induced pluripotent stem cell human CVCL_EK94 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180928 CVCL_NE49 BayGenomics ES cell line RRK430 embryonic stem cell house mouse CVCL_NE49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180929 CVCL_NE48 BayGenomics ES cell line RRK421 embryonic stem cell house mouse CVCL_NE48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100819; Aff1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180930 CVCL_NE47 BayGenomics ES cell line RRK420 embryonic stem cell house mouse CVCL_NE47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105128; Rad23b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180931 CVCL_NE46 BayGenomics ES cell line RRK418 embryonic stem cell house mouse CVCL_NE46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347075; Nbea Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180932 CVCL_NE45 BayGenomics ES cell line RRK410 embryonic stem cell house mouse CVCL_NE45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443665; Numa1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180933 CVCL_NE44 BayGenomics ES cell line RRK408 embryonic stem cell house mouse CVCL_NE44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278322; Epc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180934 CVCL_NE43 BayGenomics ES cell line RRK405 embryonic stem cell house mouse CVCL_NE43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913721; Anp32e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180935 CVCL_NE42 BayGenomics ES cell line RRK388 embryonic stem cell house mouse CVCL_NE42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106624; Myo9b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180936 CVCL_NE41 BayGenomics ES cell line RRK387 embryonic stem cell house mouse CVCL_NE41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336201; Sumo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180937 CVCL_NE40 BayGenomics ES cell line RRK385 embryonic stem cell house mouse CVCL_NE40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99511; Ptpn11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180938 CVCL_NE39 BayGenomics ES cell line RRK377 embryonic stem cell house mouse CVCL_NE39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180939 CVCL_NE16 BayGenomics ES cell line RRK340 embryonic stem cell house mouse CVCL_NE16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446526; Cpt1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180940 CVCL_NE15 BayGenomics ES cell line RRK338 embryonic stem cell house mouse CVCL_NE15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180941 CVCL_NE14 BayGenomics ES cell line RRK335 embryonic stem cell house mouse CVCL_NE14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447762; Yeats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180942 CVCL_NE13 BayGenomics ES cell line RRK327 embryonic stem cell house mouse CVCL_NE13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920136; Yju2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180943 CVCL_NE12 BayGenomics ES cell line RRK322 embryonic stem cell house mouse CVCL_NE12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098824; Odf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180944 CVCL_NE11 BayGenomics ES cell line RRK315 embryonic stem cell house mouse CVCL_NE11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934835; Ube2n Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180945 CVCL_NE10 BayGenomics ES cell line RRK309 embryonic stem cell house mouse CVCL_NE10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180946 CVCL_EK79 PENN079i-33-1 induced pluripotent stem cell human CVCL_EK79 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180947 CVCL_EK78 PENN078i-SV10 induced pluripotent stem cell human CVCL_EK78 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180948 CVCL_EK77 PENN077i-521-1 induced pluripotent stem cell human CVCL_EK77 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180949 CVCL_EK76 PENN076i-361-2 induced pluripotent stem cell human CVCL_EK76 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180950 CVCL_EK71 PENN071i-216-13 induced pluripotent stem cell human CVCL_EK71 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180951 CVCL_EK70 PENN070i-408-1 induced pluripotent stem cell human CVCL_EK70 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180952 CVCL_NE09 BayGenomics ES cell line RRK304 embryonic stem cell house mouse CVCL_NE09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929651; Supt20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180953 CVCL_EK75 PENN075i-309-1 induced pluripotent stem cell human CVCL_EK75 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180954 CVCL_NE08 BayGenomics ES cell line RRK302 embryonic stem cell house mouse CVCL_NE08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384917; Cep290 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180955 CVCL_EK74 PENN074i-415-3 induced pluripotent stem cell human CVCL_EK74 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180956 CVCL_NE07 BayGenomics ES cell line RRK301 embryonic stem cell house mouse CVCL_NE07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180957 CVCL_EK73 PENN073i-133-8 induced pluripotent stem cell human CVCL_EK73 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180958 CVCL_NE06 BayGenomics ES cell line RRK299 embryonic stem cell house mouse CVCL_NE06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180959 CVCL_EK72 PENN072i-187-3 induced pluripotent stem cell human CVCL_EK72 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180960 CVCL_NE27 BayGenomics ES cell line RRK360 embryonic stem cell house mouse CVCL_NE27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447794; Sfmbt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180961 CVCL_NE26 BayGenomics ES cell line RRK359 embryonic stem cell house mouse CVCL_NE26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180962 CVCL_NE25 BayGenomics ES cell line RRK357 embryonic stem cell house mouse CVCL_NE25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442697; Zfp473 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180963 CVCL_NE24 BayGenomics ES cell line RRK355 embryonic stem cell house mouse CVCL_NE24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180964 CVCL_NE23 BayGenomics ES cell line RRK354 embryonic stem cell house mouse CVCL_NE23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180965 CVCL_NE22 BayGenomics ES cell line RRK351 embryonic stem cell house mouse CVCL_NE22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913974; Tab3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180966 CVCL_NE21 BayGenomics ES cell line RRK350 embryonic stem cell house mouse CVCL_NE21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180967 CVCL_NE20 BayGenomics ES cell line RRK349 embryonic stem cell house mouse CVCL_NE20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180968 CVCL_EK89 PENN089i-758-4 induced pluripotent stem cell human CVCL_EK89 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180969 CVCL_EK88 PENN088i-854-7 induced pluripotent stem cell human CVCL_EK88 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180970 CVCL_EK87 PENN087i-38-1 induced pluripotent stem cell human CVCL_EK87 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180971 CVCL_EK82 PENN082i-562-6 induced pluripotent stem cell human CVCL_EK82 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180972 CVCL_EK81 PENN081i-352-4 induced pluripotent stem cell human CVCL_EK81 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180973 CVCL_EK80 PENN080i-603-1 induced pluripotent stem cell human CVCL_EK80 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180974 CVCL_EK86 PENN086i-278-1 induced pluripotent stem cell human CVCL_EK86 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180975 CVCL_NE19 BayGenomics ES cell line RRK346 embryonic stem cell house mouse CVCL_NE19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923396; Stx16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180976 CVCL_EK85 PENN085i-76-5 induced pluripotent stem cell human CVCL_EK85 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180977 CVCL_NE18 BayGenomics ES cell line RRK345 embryonic stem cell house mouse CVCL_NE18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918521; Gca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180978 CVCL_EK84 PENN084i-555-2 induced pluripotent stem cell human CVCL_EK84 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180979 CVCL_NE17 BayGenomics ES cell line RRK343 embryonic stem cell house mouse CVCL_NE17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923483; Dnttip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180980 CVCL_EK83 PENN083i-679-4 induced pluripotent stem cell human CVCL_EK83 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180981 CVCL_EK57 PENN057i-427-3 induced pluripotent stem cell human CVCL_EK57 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180982 CVCL_EK56 PENN056i-1-1 induced pluripotent stem cell human CVCL_EK56 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180983 CVCL_EK55 PENN055i-106-2 induced pluripotent stem cell human CVCL_EK55 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180984 CVCL_EK54 PENN054i-225-33 induced pluripotent stem cell human CVCL_EK54 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180985 CVCL_EK59 PENN059i-555-1 induced pluripotent stem cell human CVCL_EK59 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180986 CVCL_EK58 PENN058i-285-3 induced pluripotent stem cell human CVCL_EK58 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180987 CVCL_EK53 PENN053i-292-3 induced pluripotent stem cell human CVCL_EK53 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180988 CVCL_EK52 PENN052i-444-2 induced pluripotent stem cell human CVCL_EK52 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180989 CVCL_EK51 PENN051i-108-1 induced pluripotent stem cell human CVCL_EK51 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180990 CVCL_EK50 PENN050i-245-10 induced pluripotent stem cell human CVCL_EK50 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180991 CVCL_NE05 BayGenomics ES cell line RRK293 embryonic stem cell house mouse CVCL_NE05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917820; Tent4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180992 CVCL_NE04 BayGenomics ES cell line RRK292 embryonic stem cell house mouse CVCL_NE04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921807; Ppp6r3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180993 CVCL_NE03 BayGenomics ES cell line RRK291 embryonic stem cell house mouse CVCL_NE03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3780550; Mthfsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180994 CVCL_NE02 BayGenomics ES cell line RRK290 embryonic stem cell house mouse CVCL_NE02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919784; Rcc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180995 CVCL_NE01 BayGenomics ES cell line RRK287 embryonic stem cell house mouse CVCL_NE01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158736; Senp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180996 CVCL_NE00 BayGenomics ES cell line RRK281 embryonic stem cell house mouse CVCL_NE00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100510; Bub1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21180997 CVCL_EK68 PENN068i-697-3 induced pluripotent stem cell human CVCL_EK68 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180998 CVCL_EK67 PENN067i-312-1 induced pluripotent stem cell human CVCL_EK67 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21180999 CVCL_EK66 PENN066i-427-6 induced pluripotent stem cell human CVCL_EK66 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181000 CVCL_EK65 PENN065i-553-2 induced pluripotent stem cell human CVCL_EK65 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181001 CVCL_EK69 PENN069i-60-1 induced pluripotent stem cell human CVCL_EK69 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181002 CVCL_EK60 PENN060i-23-1 induced pluripotent stem cell human CVCL_EK60 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181003 CVCL_EK64 PENN064i-22-2 induced pluripotent stem cell human CVCL_EK64 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181004 CVCL_EK63 PENN063i-114-1 induced pluripotent stem cell human CVCL_EK63 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181005 CVCL_EK62 PENN062i-278-2 induced pluripotent stem cell human CVCL_EK62 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181006 CVCL_EK61 PENN061i-821-2 induced pluripotent stem cell human CVCL_EK61 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181007 CVCL_3X21 HQ02283 transformed cell line human CVCL_3X21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181008 CVCL_4921 SPEV-13-D5-TK- spontaneously immortalized cell line pig CVCL_4921 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male 21181009 CVCL_3X20 HQ02282 transformed cell line human CVCL_3X20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181010 CVCL_4920 S-PS spontaneously immortalized cell line pig CVCL_4920 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21181011 CVCL_3X25 HQ02288 transformed cell line human CVCL_3X25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181012 CVCL_4925 PC12K cancer cell line Norway rat CVCL_4925 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21181013 CVCL_3X24 HQ02286 transformed cell line human CVCL_3X24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181014 CVCL_4924 LNCaP-CL1-GFP cancer cell line human CVCL_4924 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Has highly locally invasive and metastatic properties. 21181015 CVCL_3X23 HQ02285 transformed cell line human CVCL_3X23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181016 CVCL_4923 TALL-103 cancer cell line human CVCL_4923 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: IL3 dependent 21181017 CVCL_3X22 HQ02284 transformed cell line human CVCL_3X22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181018 CVCL_4922 TALL-101 cancer cell line human CVCL_4922 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Characteristics: CSF2 dependent Caution: Indicated as originating from a 3 year old boy in PubMed=1706955 and from a 9 year old boy in PubMed=3496132 21181019 CVCL_4929 FC101 finite cell line CVCL_4929 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6118; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181020 CVCL_3X29 HQ02293 transformed cell line human CVCL_3X29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181021 CVCL_4928 FC100.T cancer cell line CVCL_4928 CL:0000010 Discontinued: ATCC; CRL-6115; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181022 CVCL_3X28 HQ02291 transformed cell line human CVCL_3X28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181023 CVCL_4927 FC100.Sp finite cell line CVCL_4927 CL:0000010 Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6116; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181024 CVCL_3X27 HQ02290 transformed cell line human CVCL_3X27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181025 CVCL_4926 FC100.Ln finite cell line CVCL_4926 CL:0000010 Derived from sampling site: Cervical lymph node. Discontinued: ATCC; CRL-6117; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181026 CVCL_3X26 HQ02289 transformed cell line human CVCL_3X26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181027 CVCL_4932 FC106.We finite cell line CVCL_4932 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6154; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181028 CVCL_3X32 HQ02297 transformed cell line human CVCL_3X32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181029 CVCL_4931 FC104.We finite cell line CVCL_4931 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6152; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181030 CVCL_3X31 HQ02296 transformed cell line human CVCL_3X31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181031 CVCL_4930 FC102 finite cell line CVCL_4930 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6119; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181032 CVCL_3X30 HQ02295 transformed cell line human CVCL_3X30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181033 CVCL_4936 FC11.BM cancer cell line CVCL_4936 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6088; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181034 CVCL_3X36 HQ02303 transformed cell line human CVCL_3X36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181035 CVCL_4935 FC109.We finite cell line CVCL_4935 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6157; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181036 CVCL_3X35 HQ02300 transformed cell line human CVCL_3X35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181037 CVCL_4934 FC108.We finite cell line CVCL_4934 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6156; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181038 CVCL_3X34 HQ02299 transformed cell line human CVCL_3X34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181039 CVCL_4933 FC107.We finite cell line CVCL_4933 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6155; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181040 CVCL_3X33 HQ02298 transformed cell line human CVCL_3X33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181041 CVCL_4939 FC113 finite cell line CVCL_4939 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6121; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181042 CVCL_3X39 HQ02306 transformed cell line human CVCL_3X39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181043 CVCL_4938 FC112 finite cell line CVCL_4938 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6120; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181044 CVCL_3X38 HQ02305 transformed cell line human CVCL_3X38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181045 CVCL_4937 FC110.We finite cell line CVCL_4937 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6158; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21181046 CVCL_3X37 HQ02304 transformed cell line human CVCL_3X37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181047 CVCL_3X09 HQ02268 transformed cell line human CVCL_3X09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181048 CVCL_4909 Tu-132 cancer cell line human CVCL_4909 CL:0000010 Derived from sampling site: Brain. Characteristics: Primary glioma cell culture 21181049 CVCL_4908 FRIWT-8 cancer cell line Norway rat CVCL_4908 CL:0000010 Transfected with: MGI; MGI:104878; Prkar1a; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21181050 CVCL_3X08 HQ02267 transformed cell line human CVCL_3X08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181051 CVCL_3X03 HQ02260 transformed cell line human CVCL_3X03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181052 CVCL_4903 SUSM-1 transformed cell line human CVCL_4903 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Heterozygous (PubMed=8790940) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male Characteristics: Cell line positive for alternative lengthening of telomeres (ALT+) (CelloPub=CLPUB00712; PubMed=19935656) 21181053 CVCL_3X02 HQ02259 transformed cell line human CVCL_3X02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181054 CVCL_4902 SSP-25 cancer cell line human CVCL_4902 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: 64 hours (PubMed=9358283) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: JFCR45 cancer cell line panel Problematic cell line: Contaminated Shown to be a ETK-1 derivative (RCB). Originally thought to originate from a 64 year old female patient with an intrahepatic cholangiocarcinoma. 21181055 CVCL_3X01 HQ02258 transformed cell line human CVCL_3X01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181056 CVCL_4901 SR DU-145 cancer cell line human CVCL_4901 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45906; Suramin; Derived from metastatic site: Brain. Male 21181057 CVCL_3X00 HQ02257 transformed cell line human CVCL_3X00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181058 CVCL_4900 Sq-1 cancer cell line human CVCL_4900 HLA typing: A*11:01,24:02; B*15:01,52:01; C*04:01,12:02 (PubMed=9023415); Genome ancestry: African=0.4%; Native American=0%; East Asian, North=81.37%; East Asian, South=17.66%; South Asian=0.56%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous; Note=In 10% of cells (PubMed=16105816); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+2T>C (IVS4+2T>C); ClinVar=VCV000439316; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=20557307; DepMap) Population: Japanese Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21181059 CVCL_3X07 HQ02265 transformed cell line human CVCL_3X07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181060 CVCL_4907 WISH-PC2 cancer cell line human CVCL_4907 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Population: Caucasian; Derived from sampling site: Prostate. Male 21181061 CVCL_3X06 HQ02264 transformed cell line human CVCL_3X06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181062 CVCL_4906 UM-SCP-1 cancer cell line human CVCL_4906 CL:0000010 Population: Caucasian; Derived from sampling site: Prostate. Male Doubling time: ~36 hours (PubMed=6378378) 21181063 CVCL_3X05 HQ02263 transformed cell line human CVCL_3X05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181064 CVCL_4905 UCRU-Pr-2 cancer cell line human CVCL_4905 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Derived from sampling site: Prostate. Male 21181065 CVCL_3X04 HQ02262 transformed cell line human CVCL_3X04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181066 CVCL_4904 UCRU-BL-28 cancer cell line human CVCL_4904 CL:0000010 Male 21181067 CVCL_3X19 HQ02281 transformed cell line human CVCL_3X19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181068 CVCL_4919 PSP [Pig] undefined cell line type pig CVCL_4919 CL:0000010 Derived from sampling site: Kidney. Unspecified 21181069 CVCL_3X10 HQ02271 transformed cell line human CVCL_3X10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181070 CVCL_4910 Tu 138 cancer cell line human CVCL_4910 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00428. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). Originally thought to originate from a gingivo-labial moderately differentiated squamous carcinoma. 21181071 CVCL_3X14 HQ02276 transformed cell line human CVCL_3X14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181072 CVCL_4914 Tu 182 cancer cell line human CVCL_4914 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00432. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21181073 CVCL_3X13 HQ02274 transformed cell line human CVCL_3X13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181074 CVCL_4913 Tu 177 cancer cell line human CVCL_4913 CL:0000010 21181075 CVCL_3X12 HQ02273 transformed cell line human CVCL_3X12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181076 CVCL_4912 Tu 167 cancer cell line human CVCL_4912 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00431 Problematic cell line: Contaminated Shown to be a UM-SCC-1 derivative (PubMed=21868764). 21181077 CVCL_3X11 HQ02272 transformed cell line human CVCL_3X11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181078 CVCL_4911 Tu 159 cancer cell line human CVCL_4911 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00430. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21181079 CVCL_3X18 HQ02280 transformed cell line human CVCL_3X18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181080 CVCL_4918 KTP undefined cell line type pig CVCL_4918 CL:0000010 Derived from sampling site: Testis. Male 21181081 CVCL_3X17 HQ02279 transformed cell line human CVCL_3X17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181082 CVCL_4917 KShS undefined cell line type pig CVCL_4917 CL:0000010 Derived from sampling site: Thyroid gland. 21181083 CVCL_3X16 HQ02278 transformed cell line human CVCL_3X16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181084 CVCL_4916 Tu 686 cancer cell line human CVCL_4916 CL:0000010 21181085 CVCL_3X15 HQ02277 transformed cell line human CVCL_3X15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181086 CVCL_4915 Tu 212 cancer cell line human CVCL_4915 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00433. Problematic cell line: Contaminated T404, T406, Tu 138, Tu 158LN, Tu 159, Tu 182, Tu 212 and Tu 212LN have been shown to be identical (PubMed=21868764). 21181087 CVCL_NE99 BayGenomics ES cell line RRM011 embryonic stem cell house mouse CVCL_NE99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349767; Polk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181088 CVCL_NE98 BayGenomics ES cell line RRM010 embryonic stem cell house mouse CVCL_NE98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181089 CVCL_NE97 BayGenomics ES cell line RRM007 embryonic stem cell house mouse CVCL_NE97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889585; Sall1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181090 CVCL_NE96 BayGenomics ES cell line RRM006 embryonic stem cell house mouse CVCL_NE96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918893; Zgrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181091 CVCL_NE95 BayGenomics ES cell line RRM005 embryonic stem cell house mouse CVCL_NE95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918893; Zgrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181092 CVCL_NE94 BayGenomics ES cell line RRM004 embryonic stem cell house mouse CVCL_NE94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102706; Fdft1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181093 CVCL_NE93 BayGenomics ES cell line RRM003 embryonic stem cell house mouse CVCL_NE93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181094 CVCL_NE92 BayGenomics ES cell line RRM002 embryonic stem cell house mouse CVCL_NE92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917447; Srp68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181095 CVCL_NE91 BayGenomics ES cell line RRL021 embryonic stem cell house mouse CVCL_NE91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443878; Slc4a7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181096 CVCL_NE90 BayGenomics ES cell line RRL016 embryonic stem cell house mouse CVCL_NE90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99523; Prdx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181097 CVCL_NE79 BayGenomics ES cell line RRK505 embryonic stem cell house mouse CVCL_NE79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443926; Dmxl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181098 CVCL_NE78 BayGenomics ES cell line RRK501 embryonic stem cell house mouse CVCL_NE78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448530; Vps13d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181099 CVCL_NE77 BayGenomics ES cell line RRK500 embryonic stem cell house mouse CVCL_NE77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2153887; Eri3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181100 CVCL_NE76 BayGenomics ES cell line RRK495 embryonic stem cell house mouse CVCL_NE76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922945; Rilpl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181101 CVCL_NE75 BayGenomics ES cell line RRK494 embryonic stem cell house mouse CVCL_NE75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101835; Traf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181102 CVCL_NE74 BayGenomics ES cell line RRK490 embryonic stem cell house mouse CVCL_NE74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181103 CVCL_NE73 BayGenomics ES cell line RRK485 embryonic stem cell house mouse CVCL_NE73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106351; Fam104a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181104 CVCL_NE72 BayGenomics ES cell line RRK484 embryonic stem cell house mouse CVCL_NE72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917118; Ppie Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181105 CVCL_NE71 BayGenomics ES cell line RRK483 embryonic stem cell house mouse CVCL_NE71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181106 CVCL_NE70 BayGenomics ES cell line RRK479 embryonic stem cell house mouse CVCL_NE70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928098; Tspan3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181107 CVCL_NE89 BayGenomics ES cell line RRL013 embryonic stem cell house mouse CVCL_NE89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145977; Dip2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181108 CVCL_NE88 BayGenomics ES cell line RRL009 embryonic stem cell house mouse CVCL_NE88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181109 CVCL_NE87 BayGenomics ES cell line RRL006 embryonic stem cell house mouse CVCL_NE87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201685; Ctbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181110 CVCL_NE86 BayGenomics ES cell line RRL004 embryonic stem cell house mouse CVCL_NE86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106330; Larp4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181111 CVCL_NE85 BayGenomics ES cell line RRL002 embryonic stem cell house mouse CVCL_NE85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181112 CVCL_NE84 BayGenomics ES cell line RRL001 embryonic stem cell house mouse CVCL_NE84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036234; Hdac4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181113 CVCL_NE83 BayGenomics ES cell line RRK517 embryonic stem cell house mouse CVCL_NE83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443713; Ythdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181114 CVCL_NE82 BayGenomics ES cell line RRK515 embryonic stem cell house mouse CVCL_NE82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107185; Cct5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181115 CVCL_NE81 BayGenomics ES cell line RRK513 embryonic stem cell house mouse CVCL_NE81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384876; Cdc73 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181116 CVCL_NE80 BayGenomics ES cell line RRK507 embryonic stem cell house mouse CVCL_NE80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194492; Hdgfl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181117 CVCL_EM08 STAN037i-118-1 induced pluripotent stem cell human CVCL_EM08 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181118 CVCL_EM07 STAN036i-49-2 induced pluripotent stem cell human CVCL_EM07 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181119 CVCL_EM06 STAN035i-49-1 induced pluripotent stem cell human CVCL_EM06 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181120 CVCL_EM05 STAN034i-48-2 induced pluripotent stem cell human CVCL_EM05 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181121 CVCL_EM09 STAN038i-118-2 induced pluripotent stem cell human CVCL_EM09 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181122 CVCL_EM00 STAN028i-42-1 induced pluripotent stem cell human CVCL_EM00 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181123 CVCL_EM04 STAN032i-48-1 induced pluripotent stem cell human CVCL_EM04 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181124 CVCL_EM03 STAN031i-46-2 induced pluripotent stem cell human CVCL_EM03 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Arg491Trp (c.1471C>T); ClinVar=VCV000008802; Zygosity=Heterozygous (WiCell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181125 CVCL_EM02 STAN030i-46-1 induced pluripotent stem cell human CVCL_EM02 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Arg491Trp (c.1471C>T); ClinVar=VCV000008802; Zygosity=Heterozygous (WiCell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181126 CVCL_EM01 STAN029i-42-2 induced pluripotent stem cell human CVCL_EM01 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181127 CVCL_3Y82 HQ02489 transformed cell line human CVCL_3Y82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181128 CVCL_3Y81 HQ02488 transformed cell line human CVCL_3Y81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181129 CVCL_3Y80 HQ02487 transformed cell line human CVCL_3Y80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181130 CVCL_3Y86 HQ02493 transformed cell line human CVCL_3Y86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181131 CVCL_3Y85 HQ02492 transformed cell line human CVCL_3Y85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181132 CVCL_3Y84 HQ02491 transformed cell line human CVCL_3Y84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181133 CVCL_3Y83 HQ02490 transformed cell line human CVCL_3Y83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181134 CVCL_3Y89 HQ02496 transformed cell line human CVCL_3Y89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181135 CVCL_3Y88 HQ02495 transformed cell line human CVCL_3Y88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181136 CVCL_3Y87 HQ02494 transformed cell line human CVCL_3Y87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181137 CVCL_3Y93 HQ02501 transformed cell line human CVCL_3Y93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181138 CVCL_3Y92 HQ02500 transformed cell line human CVCL_3Y92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181139 CVCL_3Y91 HQ02498 transformed cell line human CVCL_3Y91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181140 CVCL_3Y90 HQ02497 transformed cell line human CVCL_3Y90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181141 CVCL_3Y97 HQ02506 transformed cell line human CVCL_3Y97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181142 CVCL_3Y96 HQ02504 transformed cell line human CVCL_3Y96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181143 CVCL_3Y95 HQ02503 transformed cell line human CVCL_3Y95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181144 CVCL_3Y94 HQ02502 transformed cell line human CVCL_3Y94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181145 CVCL_3Y99 HQ02508 transformed cell line human CVCL_3Y99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181146 CVCL_3Y98 HQ02507 transformed cell line human CVCL_3Y98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181147 CVCL_3Y60 HQ02459 transformed cell line human CVCL_3Y60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181148 CVCL_3Y64 HQ02464 transformed cell line human CVCL_3Y64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181149 CVCL_3Y63 HQ02463 transformed cell line human CVCL_3Y63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181150 CVCL_3Y62 HQ02462 transformed cell line human CVCL_3Y62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181151 CVCL_3Y61 HQ02460 transformed cell line human CVCL_3Y61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181152 CVCL_3Y68 HQ02468 transformed cell line human CVCL_3Y68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181153 CVCL_3Y67 HQ02467 transformed cell line human CVCL_3Y67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181154 CVCL_3Y66 HQ02466 transformed cell line human CVCL_3Y66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181155 CVCL_3Y65 HQ02465 transformed cell line human CVCL_3Y65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181156 CVCL_3Y69 HQ02469 transformed cell line human CVCL_3Y69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181157 CVCL_3Y71 HQ02471 transformed cell line human CVCL_3Y71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181158 CVCL_3Y70 HQ02470 transformed cell line human CVCL_3Y70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181159 CVCL_3Y75 HQ02478 transformed cell line human CVCL_3Y75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181160 CVCL_3Y74 HQ02477 transformed cell line human CVCL_3Y74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181161 CVCL_3Y73 HQ02473 transformed cell line human CVCL_3Y73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181162 CVCL_3Y72 HQ02472 transformed cell line human CVCL_3Y72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181163 CVCL_3Y79 HQ02486 transformed cell line human CVCL_3Y79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181164 CVCL_3Y78 HQ02483 transformed cell line human CVCL_3Y78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181165 CVCL_3Y77 HQ02482 transformed cell line human CVCL_3Y77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181166 CVCL_3Y76 HQ02479 transformed cell line human CVCL_3Y76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181167 CVCL_NG14 BayGenomics ES cell line RRM235 embryonic stem cell house mouse CVCL_NG14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181168 CVCL_NG13 BayGenomics ES cell line RRM229 embryonic stem cell house mouse CVCL_NG13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181169 CVCL_NG12 BayGenomics ES cell line RRM225 embryonic stem cell house mouse CVCL_NG12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181170 CVCL_NG11 BayGenomics ES cell line RRM224 embryonic stem cell house mouse CVCL_NG11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386741; Slc30a6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181171 CVCL_NG10 BayGenomics ES cell line RRM222 embryonic stem cell house mouse CVCL_NG10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921331; Cep350 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181172 CVCL_EM77 UCSD034i-4-3 induced pluripotent stem cell human CVCL_EM77 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181173 CVCL_EM76 UCSD033i-41-2 induced pluripotent stem cell human CVCL_EM76 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181174 CVCL_EM75 UCSD032i-41-1 induced pluripotent stem cell human CVCL_EM75 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181175 CVCL_EM74 UCSD031i-45-1 induced pluripotent stem cell human CVCL_EM74 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181176 CVCL_EM79 UCSD036i-4-5 induced pluripotent stem cell human CVCL_EM79 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181177 CVCL_EM78 UCSD035i-4-4 induced pluripotent stem cell human CVCL_EM78 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181178 CVCL_NG09 BayGenomics ES cell line RRM221 embryonic stem cell house mouse CVCL_NG09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143132; Plekho2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181179 CVCL_NG08 BayGenomics ES cell line RRM217 embryonic stem cell house mouse CVCL_NG08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385139; Rabgap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181180 CVCL_NG07 BayGenomics ES cell line RRM213 embryonic stem cell house mouse CVCL_NG07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270863; Prep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181181 CVCL_EM73 UCSD030i-23-2 induced pluripotent stem cell human CVCL_EM73 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181182 CVCL_NG06 BayGenomics ES cell line RRM212 embryonic stem cell house mouse CVCL_NG06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925860; Uvrag Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181183 CVCL_EM72 UCSD029i-9-4 induced pluripotent stem cell human CVCL_EM72 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181184 CVCL_NG05 BayGenomics ES cell line RRM210 embryonic stem cell house mouse CVCL_NG05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321392; Pex7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181185 CVCL_EM71 UCSD028i-9-3 induced pluripotent stem cell human CVCL_EM71 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181186 CVCL_NG04 BayGenomics ES cell line RRM206 embryonic stem cell house mouse CVCL_NG04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181187 CVCL_EM70 UCSD027i-9-2 induced pluripotent stem cell human CVCL_EM70 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181188 CVCL_NG25 BayGenomics ES cell line RRM275 embryonic stem cell house mouse CVCL_NG25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337080; Ncor2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181189 CVCL_NG24 BayGenomics ES cell line RRM270 embryonic stem cell house mouse CVCL_NG24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181190 CVCL_NG23 BayGenomics ES cell line RRM269 embryonic stem cell house mouse CVCL_NG23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95301; Eif3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181191 CVCL_NG22 BayGenomics ES cell line RRM268 embryonic stem cell house mouse CVCL_NG22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919448; Mtrex Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181192 CVCL_NG21 BayGenomics ES cell line RRM266 embryonic stem cell house mouse CVCL_NG21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916225; Med27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181193 CVCL_NG20 BayGenomics ES cell line RRM261 embryonic stem cell house mouse CVCL_NG20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914259; Ttc23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181194 CVCL_EM88 UCSD045i-49-1 induced pluripotent stem cell human CVCL_EM88 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181195 CVCL_EM87 UCSD044i-48-1 induced pluripotent stem cell human CVCL_EM87 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181196 CVCL_EM86 UCSD043i-47-1 induced pluripotent stem cell human CVCL_EM86 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181197 CVCL_EM85 UCSD042i-46-1 induced pluripotent stem cell human CVCL_EM85 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181198 CVCL_EM89 UCSD046i-50-1 induced pluripotent stem cell human CVCL_EM89 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181199 CVCL_EM80 UCSD037i-26-2 induced pluripotent stem cell human CVCL_EM80 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181200 CVCL_NG19 BayGenomics ES cell line RRM254 embryonic stem cell house mouse CVCL_NG19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446526; Cpt1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181201 CVCL_NG18 BayGenomics ES cell line RRM248 embryonic stem cell house mouse CVCL_NG18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337008; Ankfy1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181202 CVCL_EM84 UCSD041i-33-2 induced pluripotent stem cell human CVCL_EM84 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181203 CVCL_NG17 BayGenomics ES cell line RRM247 embryonic stem cell house mouse CVCL_NG17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181204 CVCL_EM83 UCSD040i-33-1 induced pluripotent stem cell human CVCL_EM83 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181205 CVCL_NG16 BayGenomics ES cell line RRM243 embryonic stem cell house mouse CVCL_NG16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181206 CVCL_EM82 UCSD039i-14-3 induced pluripotent stem cell human CVCL_EM82 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181207 CVCL_NG15 BayGenomics ES cell line RRM241 embryonic stem cell house mouse CVCL_NG15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181208 CVCL_EM81 UCSD038i-24-2 induced pluripotent stem cell human CVCL_EM81 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181209 CVCL_EM55 UCSD012i-5-5 induced pluripotent stem cell human CVCL_EM55 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181210 CVCL_EM54 UCSD011i-5-4 induced pluripotent stem cell human CVCL_EM54 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181211 CVCL_EM53 UCSD010i-5-3 induced pluripotent stem cell human CVCL_EM53 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181212 CVCL_EM52 UCSD009i-5-2 induced pluripotent stem cell human CVCL_EM52 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181213 CVCL_EM59 UCSD016i-3-4 induced pluripotent stem cell human CVCL_EM59 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181214 CVCL_EM58 UCSD015i-3-3 induced pluripotent stem cell human CVCL_EM58 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian, Japanese and Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181215 CVCL_EM57 UCSD014i-21-3 induced pluripotent stem cell human CVCL_EM57 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181216 CVCL_EM56 UCSD013i-16-3 induced pluripotent stem cell human CVCL_EM56 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181217 CVCL_EM51 UCSD008i-44-1 induced pluripotent stem cell human CVCL_EM51 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181218 CVCL_EM50 UCSD007i-21-2 induced pluripotent stem cell human CVCL_EM50 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181219 CVCL_NG03 BayGenomics ES cell line RRM204 embryonic stem cell house mouse CVCL_NG03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922946; Prpf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181220 CVCL_NG02 BayGenomics ES cell line RRM203 embryonic stem cell house mouse CVCL_NG02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859661; Atp11c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181221 CVCL_NG01 BayGenomics ES cell line RRM202 embryonic stem cell house mouse CVCL_NG01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145310; Rnf44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181222 CVCL_NG00 BayGenomics ES cell line RRM201 embryonic stem cell house mouse CVCL_NG00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352754; Clic4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181223 CVCL_EM66 UCSD023i-8-4 induced pluripotent stem cell human CVCL_EM66 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181224 CVCL_EM65 UCSD022i-8-3 induced pluripotent stem cell human CVCL_EM65 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181225 CVCL_EM64 UCSD021i-3-9 induced pluripotent stem cell human CVCL_EM64 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181226 CVCL_EM63 UCSD020i-3-8 induced pluripotent stem cell human CVCL_EM63 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181227 CVCL_EM69 UCSD026i-9-1 induced pluripotent stem cell human CVCL_EM69 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181228 CVCL_EM68 UCSD025i-13-4 induced pluripotent stem cell human CVCL_EM68 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181229 CVCL_EM67 UCSD024i-13-3 induced pluripotent stem cell human CVCL_EM67 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181230 CVCL_EM62 UCSD019i-3-7 induced pluripotent stem cell human CVCL_EM62 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181231 CVCL_EM61 UCSD018i-3-6 induced pluripotent stem cell human CVCL_EM61 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181232 CVCL_EM60 UCSD017i-3-5 induced pluripotent stem cell human CVCL_EM60 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181233 CVCL_EM39 STAN070i-169-2 induced pluripotent stem cell human CVCL_EM39 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181234 CVCL_EM38 STAN069i-169-1 induced pluripotent stem cell human CVCL_EM38 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181235 CVCL_EM33 STAN064i-166-2 induced pluripotent stem cell human CVCL_EM33 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181236 CVCL_EM32 STAN063i-166-1 induced pluripotent stem cell human CVCL_EM32 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181237 CVCL_EM31 STAN062i-164-2 induced pluripotent stem cell human CVCL_EM31 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181238 CVCL_EM30 STAN061i-164-1 induced pluripotent stem cell human CVCL_EM30 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181239 CVCL_EM37 STAN068i-168-2 induced pluripotent stem cell human CVCL_EM37 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181240 CVCL_EM36 STAN067i-168-1 induced pluripotent stem cell human CVCL_EM36 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181241 CVCL_EM35 STAN066i-167-2 induced pluripotent stem cell human CVCL_EM35 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181242 CVCL_EM34 STAN065i-167-1 induced pluripotent stem cell human CVCL_EM34 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181243 CVCL_EM49 UCSD006i-21-1 induced pluripotent stem cell human CVCL_EM49 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181244 CVCL_EM44 UCSD001i-5-1 induced pluripotent stem cell human CVCL_EM44 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181245 CVCL_EM43 STAN074i-180-2 induced pluripotent stem cell human CVCL_EM43 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181246 CVCL_EM42 STAN073i-180-1 induced pluripotent stem cell human CVCL_EM42 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181247 CVCL_EM41 STAN072i-179-2 induced pluripotent stem cell human CVCL_EM41 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181248 CVCL_EM48 UCSD005i-43-1 induced pluripotent stem cell human CVCL_EM48 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181249 CVCL_EM47 UCSD004i-42-1 induced pluripotent stem cell human CVCL_EM47 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181250 CVCL_EM46 UCSD003i-16-2 induced pluripotent stem cell human CVCL_EM46 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181251 CVCL_EM45 UCSD002i-16-1 induced pluripotent stem cell human CVCL_EM45 From: Frazer K.A.; University of California, San Diego; San Diego; USA CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: iPSC Collection for Omic Research (iPSCORE); Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181252 CVCL_EM40 STAN071i-179-1 induced pluripotent stem cell human CVCL_EM40 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181253 CVCL_EM19 STAN048i-126-2 induced pluripotent stem cell human CVCL_EM19 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181254 CVCL_EM18 STAN047i-126-1 induced pluripotent stem cell human CVCL_EM18 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181255 CVCL_EM17 STAN046i-125-2 induced pluripotent stem cell human CVCL_EM17 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181256 CVCL_EM16 STAN045i-125-1 induced pluripotent stem cell human CVCL_EM16 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181257 CVCL_EM11 STAN040i-119-2 induced pluripotent stem cell human CVCL_EM11 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181258 CVCL_EM10 STAN039i-119-1 induced pluripotent stem cell human CVCL_EM10 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181259 CVCL_EM15 STAN044i-124-2 induced pluripotent stem cell human CVCL_EM15 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181260 CVCL_EM14 STAN043i-124-1 induced pluripotent stem cell human CVCL_EM14 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181261 CVCL_EM13 STAN042i-122-2 induced pluripotent stem cell human CVCL_EM13 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181262 CVCL_EM12 STAN041i-122-1 induced pluripotent stem cell human CVCL_EM12 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181263 CVCL_EM29 STAN060i-163-2 induced pluripotent stem cell human CVCL_EM29 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181264 CVCL_EM28 STAN059i-163-1 induced pluripotent stem cell human CVCL_EM28 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181265 CVCL_EM27 STAN058i-162-2 induced pluripotent stem cell human CVCL_EM27 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181266 CVCL_EM22 STAN053i-149-1 induced pluripotent stem cell human CVCL_EM22 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181267 CVCL_EM21 STAN052i-146-2 induced pluripotent stem cell human CVCL_EM21 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181268 CVCL_EM20 STAN051i-146-1 induced pluripotent stem cell human CVCL_EM20 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181269 CVCL_EM26 STAN057i-162-1 induced pluripotent stem cell human CVCL_EM26 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181270 CVCL_EM25 STAN056i-160-2 induced pluripotent stem cell human CVCL_EM25 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181271 CVCL_EM24 STAN055i-160-1 induced pluripotent stem cell human CVCL_EM24 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181272 CVCL_EM23 STAN054i-149-2 induced pluripotent stem cell human CVCL_EM23 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181273 CVCL_NF79 BayGenomics ES cell line RRM145 embryonic stem cell house mouse CVCL_NF79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183752; Tubgcp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181274 CVCL_NF78 BayGenomics ES cell line RRM143 embryonic stem cell house mouse CVCL_NF78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181275 CVCL_NF77 BayGenomics ES cell line RRM142 embryonic stem cell house mouse CVCL_NF77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181276 CVCL_NF76 BayGenomics ES cell line RRM139 embryonic stem cell house mouse CVCL_NF76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101760; Bicd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181277 CVCL_NF75 BayGenomics ES cell line RRM136 embryonic stem cell house mouse CVCL_NF75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922928; Ippk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181278 CVCL_NF74 BayGenomics ES cell line RRM135 embryonic stem cell house mouse CVCL_NF74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181279 CVCL_NF73 BayGenomics ES cell line RRM134 embryonic stem cell house mouse CVCL_NF73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181280 CVCL_NF72 BayGenomics ES cell line RRM133 embryonic stem cell house mouse CVCL_NF72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87948; Adss Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181281 CVCL_NF71 BayGenomics ES cell line RRM132 embryonic stem cell house mouse CVCL_NF71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144305; Nsrp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181282 CVCL_NF70 BayGenomics ES cell line RRM130 embryonic stem cell house mouse CVCL_NF70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913378; Mrps36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181283 CVCL_NF89 BayGenomics ES cell line RRM164 embryonic stem cell house mouse CVCL_NF89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334458; Pex19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181284 CVCL_NF88 BayGenomics ES cell line RRM162 embryonic stem cell house mouse CVCL_NF88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103038; Stat3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181285 CVCL_NF87 BayGenomics ES cell line RRM159 embryonic stem cell house mouse CVCL_NF87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95768; Gna13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181286 CVCL_NF86 BayGenomics ES cell line RRM158 embryonic stem cell house mouse CVCL_NF86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447762; Yeats2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181287 CVCL_NF85 BayGenomics ES cell line RRM155 embryonic stem cell house mouse CVCL_NF85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917004; Fbxo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181288 CVCL_NF84 BayGenomics ES cell line RRM154 embryonic stem cell house mouse CVCL_NF84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444668; Fnip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181289 CVCL_NF83 BayGenomics ES cell line RRM153 embryonic stem cell house mouse CVCL_NF83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923935; Eif4g3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181290 CVCL_NF82 BayGenomics ES cell line RRM151 embryonic stem cell house mouse CVCL_NF82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181291 CVCL_NF81 BayGenomics ES cell line RRM150 embryonic stem cell house mouse CVCL_NF81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139746; Ankrd13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181292 CVCL_NF80 BayGenomics ES cell line RRM146 embryonic stem cell house mouse CVCL_NF80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925152; Prune1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181293 CVCL_NF59 BayGenomics ES cell line RRM105 embryonic stem cell house mouse CVCL_NF59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926129; Arid1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181294 CVCL_NF58 BayGenomics ES cell line RRM104 embryonic stem cell house mouse CVCL_NF58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916469; Ddah1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181295 CVCL_NF57 BayGenomics ES cell line RRM103 embryonic stem cell house mouse CVCL_NF57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106478; Eif3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181296 CVCL_NF56 BayGenomics ES cell line RRM102 embryonic stem cell house mouse CVCL_NF56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921092; Neurl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181297 CVCL_NF55 BayGenomics ES cell line RRM097 embryonic stem cell house mouse CVCL_NF55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181298 CVCL_NF54 BayGenomics ES cell line RRM096 embryonic stem cell house mouse CVCL_NF54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140945; Pds5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181299 CVCL_NF53 BayGenomics ES cell line RRM093 embryonic stem cell house mouse CVCL_NF53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445052; Tbck Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181300 CVCL_NF52 BayGenomics ES cell line RRM089 embryonic stem cell house mouse CVCL_NF52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181301 CVCL_NF51 BayGenomics ES cell line RRM088 embryonic stem cell house mouse CVCL_NF51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3782817; Gm4635 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181302 CVCL_NF50 BayGenomics ES cell line RRM087 embryonic stem cell house mouse CVCL_NF50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181303 CVCL_NF49 BayGenomics ES cell line RRM086 embryonic stem cell house mouse CVCL_NF49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914497; Mtarc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181304 CVCL_NF69 BayGenomics ES cell line RRM126 embryonic stem cell house mouse CVCL_NF69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918984; Pan2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181305 CVCL_NF68 BayGenomics ES cell line RRM124 embryonic stem cell house mouse CVCL_NF68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1270849; Rps6kb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181306 CVCL_NF67 BayGenomics ES cell line RRM121 embryonic stem cell house mouse CVCL_NF67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95804; Gsr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181307 CVCL_NF66 BayGenomics ES cell line RRM120 embryonic stem cell house mouse CVCL_NF66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181308 CVCL_NF65 BayGenomics ES cell line RRM119 embryonic stem cell house mouse CVCL_NF65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442115; Wdr59 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181309 CVCL_NF64 BayGenomics ES cell line RRM118 embryonic stem cell house mouse CVCL_NF64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181310 CVCL_NF63 BayGenomics ES cell line RRM117 embryonic stem cell house mouse CVCL_NF63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919831; Edrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181311 CVCL_NF62 BayGenomics ES cell line RRM110 embryonic stem cell house mouse CVCL_NF62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891112; Gmds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181312 CVCL_NF61 BayGenomics ES cell line RRM107 embryonic stem cell house mouse CVCL_NF61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135604; Gmeb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181313 CVCL_NF60 BayGenomics ES cell line RRM106 embryonic stem cell house mouse CVCL_NF60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181314 CVCL_NF37 BayGenomics ES cell line RRM066 embryonic stem cell house mouse CVCL_NF37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137221; Mrpl20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181315 CVCL_NF36 BayGenomics ES cell line RRM065 embryonic stem cell house mouse CVCL_NF36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181316 CVCL_NF35 BayGenomics ES cell line RRM064 embryonic stem cell house mouse CVCL_NF35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919270; Zfp654 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181317 CVCL_NF34 BayGenomics ES cell line RRM063 embryonic stem cell house mouse CVCL_NF34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97295; Casp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181318 CVCL_NF33 BayGenomics ES cell line RRM062 embryonic stem cell house mouse CVCL_NF33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443008; Trappc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181319 CVCL_NF32 BayGenomics ES cell line RRM061 embryonic stem cell house mouse CVCL_NF32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103063; Stat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181320 CVCL_NF31 BayGenomics ES cell line RRM060 embryonic stem cell house mouse CVCL_NF31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343460; Gnpat Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181321 CVCL_NF30 BayGenomics ES cell line RRM058 embryonic stem cell house mouse CVCL_NF30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925976; Scaper Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181322 CVCL_EL99 STAN027i-30-2 induced pluripotent stem cell human CVCL_EL99 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181323 CVCL_EL98 STAN026i-30-1 induced pluripotent stem cell human CVCL_EL98 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181324 CVCL_EL97 STAN025i-29-2 induced pluripotent stem cell human CVCL_EL97 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181325 CVCL_EL92 STAN020i-177-2 induced pluripotent stem cell human CVCL_EL92 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181326 CVCL_EL91 STAN019i-177-1 induced pluripotent stem cell human CVCL_EL91 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181327 CVCL_EL90 STAN018i-171-2 induced pluripotent stem cell human CVCL_EL90 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181328 CVCL_EL96 STAN024i-29-1 induced pluripotent stem cell human CVCL_EL96 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181329 CVCL_NF29 BayGenomics ES cell line RRM057 embryonic stem cell house mouse CVCL_NF29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181330 CVCL_EL95 STAN023i-41-1 induced pluripotent stem cell human CVCL_EL95 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181331 CVCL_NF28 BayGenomics ES cell line RRM055 embryonic stem cell house mouse CVCL_NF28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923484; Magi3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181332 CVCL_EL94 STAN022i-170-2 induced pluripotent stem cell human CVCL_EL94 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181333 CVCL_NF27 BayGenomics ES cell line RRM051 embryonic stem cell house mouse CVCL_NF27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444490; Syt14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181334 CVCL_EL93 STAN021i-170-1 induced pluripotent stem cell human CVCL_EL93 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181335 CVCL_NF48 BayGenomics ES cell line RRM084 embryonic stem cell house mouse CVCL_NF48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590554; BC055324 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181336 CVCL_NF47 BayGenomics ES cell line RRM083 embryonic stem cell house mouse CVCL_NF47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353654; Vps26a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181337 CVCL_NF46 BayGenomics ES cell line RRM082 embryonic stem cell house mouse CVCL_NF46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914632; Brd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181338 CVCL_NF45 BayGenomics ES cell line RRM081 embryonic stem cell house mouse CVCL_NF45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141070; Ccz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181339 CVCL_NF44 BayGenomics ES cell line RRM078 embryonic stem cell house mouse CVCL_NF44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890081; Foxo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181340 CVCL_NF43 BayGenomics ES cell line RRM077 embryonic stem cell house mouse CVCL_NF43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915848; Dnajc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181341 CVCL_NF42 BayGenomics ES cell line RRM076 embryonic stem cell house mouse CVCL_NF42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181342 CVCL_NF41 BayGenomics ES cell line RRM074 embryonic stem cell house mouse CVCL_NF41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920907; Fbrsl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181343 CVCL_NF40 BayGenomics ES cell line RRM071 embryonic stem cell house mouse CVCL_NF40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933946; Ptov1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181344 CVCL_NF39 BayGenomics ES cell line RRM068 embryonic stem cell house mouse CVCL_NF39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444323; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181345 CVCL_NF38 BayGenomics ES cell line RRM067 embryonic stem cell house mouse CVCL_NF38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97547; Pfkl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181346 CVCL_NF15 BayGenomics ES cell line RRM035 embryonic stem cell house mouse CVCL_NF15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913776; Tceanc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181347 CVCL_NF14 BayGenomics ES cell line RRM033 embryonic stem cell house mouse CVCL_NF14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181348 CVCL_NF13 BayGenomics ES cell line RRM032 embryonic stem cell house mouse CVCL_NF13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347064; Med21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181349 CVCL_NF12 BayGenomics ES cell line RRM030 embryonic stem cell house mouse CVCL_NF12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97355; Nme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181350 CVCL_NF11 BayGenomics ES cell line RRM029 embryonic stem cell house mouse CVCL_NF11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97355; Nme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181351 CVCL_NF10 BayGenomics ES cell line RRM028 embryonic stem cell house mouse CVCL_NF10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97355; Nme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181352 CVCL_EL78 STAN006i-148-1 induced pluripotent stem cell human CVCL_EL78 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181353 CVCL_EL77 STAN005i-147-2 induced pluripotent stem cell human CVCL_EL77 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181354 CVCL_EL76 STAN004i-147-1 induced pluripotent stem cell human CVCL_EL76 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181355 CVCL_EL75 STAN003i-161-2 induced pluripotent stem cell human CVCL_EL75 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181356 CVCL_EL79 STAN007i-148-2 induced pluripotent stem cell human CVCL_EL79 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181357 CVCL_EL70 PENN170i-M17-4 induced pluripotent stem cell human CVCL_EL70 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 29; ABCA1; Simple; p.Arg1270Ter (c.3808C>T); dbSNP=rs575627531; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 29; ABCA1; Unexplicit; IVS32-25G>C; Zygosity=Heterozygous (WiCell) Population: Asian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181358 CVCL_NF09 BayGenomics ES cell line RRM027 embryonic stem cell house mouse CVCL_NF09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914004; Foxp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181359 CVCL_NF08 BayGenomics ES cell line RRM026 embryonic stem cell house mouse CVCL_NF08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181360 CVCL_EL74 STAN002i-161-1 induced pluripotent stem cell human CVCL_EL74 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181361 CVCL_NF07 BayGenomics ES cell line RRM025 embryonic stem cell house mouse CVCL_NF07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181362 CVCL_EL73 STAN001i-047-1 induced pluripotent stem cell human CVCL_EL73 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181363 CVCL_NF06 BayGenomics ES cell line RRM023 embryonic stem cell house mouse CVCL_NF06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919094; Nupl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181364 CVCL_EL72 PENN172i-M15-10 induced pluripotent stem cell human CVCL_EL72 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181365 CVCL_NF05 BayGenomics ES cell line RRM021 embryonic stem cell house mouse CVCL_NF05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913776; Tceanc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181366 CVCL_EL71 PENN171i-M9-9 induced pluripotent stem cell human CVCL_EL71 From: Rader D.J.; University of Pennsylvania; Philadelphia; USA CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Trp483Ter (c.1448G>A); ClinVar=VCV000226356; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly549Asp (c.1646G>A); ClinVar=VCV000003698; Zygosity=Heterozygous (WiCell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181367 CVCL_NF26 BayGenomics ES cell line RRM050 embryonic stem cell house mouse CVCL_NF26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179717; Glcci1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181368 CVCL_NF25 BayGenomics ES cell line RRM049 embryonic stem cell house mouse CVCL_NF25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98285; Srsf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181369 CVCL_NF24 BayGenomics ES cell line RRM048 embryonic stem cell house mouse CVCL_NF24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918917; Tmem248 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181370 CVCL_NF23 BayGenomics ES cell line RRM047 embryonic stem cell house mouse CVCL_NF23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346832; Esrrb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181371 CVCL_NF22 BayGenomics ES cell line RRM046 embryonic stem cell house mouse CVCL_NF22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922088; Naa15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181372 CVCL_NF21 BayGenomics ES cell line RRM044 embryonic stem cell house mouse CVCL_NF21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289172; Scyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181373 CVCL_NF20 BayGenomics ES cell line RRM042 embryonic stem cell house mouse CVCL_NF20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918518; Lrrfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181374 CVCL_EL89 STAN017i-171-1 induced pluripotent stem cell human CVCL_EL89 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181375 CVCL_EL88 STAN016i-178-2 induced pluripotent stem cell human CVCL_EL88 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181376 CVCL_EL87 STAN015i-178-1 induced pluripotent stem cell human CVCL_EL87 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181377 CVCL_EL86 STAN014i-121-2 induced pluripotent stem cell human CVCL_EL86 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181378 CVCL_EL81 STAN009i-165-2 induced pluripotent stem cell human CVCL_EL81 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181379 CVCL_EL80 STAN008i-165-1 induced pluripotent stem cell human CVCL_EL80 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181380 CVCL_NF19 BayGenomics ES cell line RRM041 embryonic stem cell house mouse CVCL_NF19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3651986; Zfp985 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181381 CVCL_EL85 STAN013i-121-1 induced pluripotent stem cell human CVCL_EL85 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181382 CVCL_NF18 BayGenomics ES cell line RRM040 embryonic stem cell house mouse CVCL_NF18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916340; Ascc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181383 CVCL_EL84 STAN012i-123-2 induced pluripotent stem cell human CVCL_EL84 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181384 CVCL_NF17 BayGenomics ES cell line RRM039 embryonic stem cell house mouse CVCL_NF17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683592; Dhps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181385 CVCL_EL83 STAN011i-123-1 induced pluripotent stem cell human CVCL_EL83 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181386 CVCL_NF16 BayGenomics ES cell line RRM036 embryonic stem cell house mouse CVCL_NF16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181387 CVCL_EL82 STAN010i-041-2 induced pluripotent stem cell human CVCL_EL82 From: Rabinovitch M.; Stanford University; Stanford; USA CL:0000010 Population: Caucasian and Latino; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 21181388 CVCL_3Y42 HQ02437 transformed cell line human CVCL_3Y42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181389 CVCL_3Y41 HQ02436 transformed cell line human CVCL_3Y41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181390 CVCL_3Y40 HQ02435 transformed cell line human CVCL_3Y40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181391 CVCL_3Y46 HQ02443 transformed cell line human CVCL_3Y46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181392 CVCL_3Y45 HQ02441 transformed cell line human CVCL_3Y45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181393 CVCL_3Y44 HQ02439 transformed cell line human CVCL_3Y44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181394 CVCL_3Y43 HQ02438 transformed cell line human CVCL_3Y43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181395 CVCL_3Y49 HQ02446 transformed cell line human CVCL_3Y49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181396 CVCL_3Y48 HQ02445 transformed cell line human CVCL_3Y48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181397 CVCL_3Y47 HQ02444 transformed cell line human CVCL_3Y47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181398 CVCL_3Y53 HQ02451 transformed cell line human CVCL_3Y53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181399 CVCL_3Y52 HQ02450 transformed cell line human CVCL_3Y52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181400 CVCL_3Y51 HQ02449 transformed cell line human CVCL_3Y51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181401 CVCL_3Y50 HQ02447 transformed cell line human CVCL_3Y50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181402 CVCL_3Y57 HQ02456 transformed cell line human CVCL_3Y57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181403 CVCL_3Y56 HQ02455 transformed cell line human CVCL_3Y56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181404 CVCL_3Y55 HQ02454 transformed cell line human CVCL_3Y55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181405 CVCL_3Y54 HQ02452 transformed cell line human CVCL_3Y54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181406 CVCL_3Y59 HQ02458 transformed cell line human CVCL_3Y59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181407 CVCL_3Y58 HQ02457 transformed cell line human CVCL_3Y58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181408 CVCL_3Y29 HQ02418 transformed cell line human CVCL_3Y29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181409 CVCL_3Y20 HQ02406 transformed cell line human CVCL_3Y20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181410 CVCL_3Y24 HQ02412 transformed cell line human CVCL_3Y24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181411 CVCL_3Y23 HQ02411 transformed cell line human CVCL_3Y23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181412 CVCL_3Y22 HQ02410 transformed cell line human CVCL_3Y22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181413 CVCL_3Y21 HQ02408 transformed cell line human CVCL_3Y21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181414 CVCL_3Y28 HQ02417 transformed cell line human CVCL_3Y28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181415 CVCL_3Y27 HQ02416 transformed cell line human CVCL_3Y27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181416 CVCL_3Y26 HQ02415 transformed cell line human CVCL_3Y26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181417 CVCL_3Y25 HQ02413 transformed cell line human CVCL_3Y25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181418 CVCL_3Y31 HQ02421 transformed cell line human CVCL_3Y31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181419 CVCL_3Y30 HQ02419 transformed cell line human CVCL_3Y30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181420 CVCL_3Y35 HQ02427 transformed cell line human CVCL_3Y35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181421 CVCL_3Y34 HQ02424 transformed cell line human CVCL_3Y34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181422 CVCL_3Y33 HQ02423 transformed cell line human CVCL_3Y33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181423 CVCL_3Y32 HQ02422 transformed cell line human CVCL_3Y32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181424 CVCL_3Y39 HQ02433 transformed cell line human CVCL_3Y39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181425 CVCL_3Y38 HQ02432 transformed cell line human CVCL_3Y38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181426 CVCL_3Y37 HQ02431 transformed cell line human CVCL_3Y37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181427 CVCL_3Y36 HQ02428 transformed cell line human CVCL_3Y36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181428 CVCL_3Y09 HQ02393 transformed cell line human CVCL_3Y09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181429 CVCL_3Y08 HQ02392 transformed cell line human CVCL_3Y08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181430 CVCL_3Y07 HQ02391 transformed cell line human CVCL_3Y07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181431 CVCL_3Y02 HQ02384 transformed cell line human CVCL_3Y02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181432 CVCL_3Y01 HQ02383 transformed cell line human CVCL_3Y01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181433 CVCL_3Y00 HQ02382 transformed cell line human CVCL_3Y00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181434 CVCL_3Y06 HQ02390 transformed cell line human CVCL_3Y06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181435 CVCL_3Y05 HQ02389 transformed cell line human CVCL_3Y05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181436 CVCL_3Y04 HQ02386 transformed cell line human CVCL_3Y04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181437 CVCL_3Y03 HQ02385 transformed cell line human CVCL_3Y03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181438 CVCL_3Y19 HQ02405 transformed cell line human CVCL_3Y19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181439 CVCL_3Y18 HQ02404 transformed cell line human CVCL_3Y18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181440 CVCL_3Y13 HQ02397 transformed cell line human CVCL_3Y13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181441 CVCL_3Y12 HQ02396 transformed cell line human CVCL_3Y12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181442 CVCL_3Y11 HQ02395 transformed cell line human CVCL_3Y11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181443 CVCL_3Y10 HQ02394 transformed cell line human CVCL_3Y10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181444 CVCL_3Y17 HQ02403 transformed cell line human CVCL_3Y17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181445 CVCL_3Y16 HQ02401 transformed cell line human CVCL_3Y16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181446 CVCL_3Y15 HQ02399 transformed cell line human CVCL_3Y15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181447 CVCL_3Y14 HQ02398 transformed cell line human CVCL_3Y14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181448 CVCL_NF99 BayGenomics ES cell line RRM195 embryonic stem cell house mouse CVCL_NF99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181449 CVCL_NF98 BayGenomics ES cell line RRM192 embryonic stem cell house mouse CVCL_NF98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444298; G2e3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181450 CVCL_NF97 BayGenomics ES cell line RRM187 embryonic stem cell house mouse CVCL_NF97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181451 CVCL_NF96 BayGenomics ES cell line RRM182 embryonic stem cell house mouse CVCL_NF96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181452 CVCL_NF95 BayGenomics ES cell line RRM176 embryonic stem cell house mouse CVCL_NF95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347043; Orc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181453 CVCL_NF94 BayGenomics ES cell line RRM174 embryonic stem cell house mouse CVCL_NF94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181454 CVCL_NF93 BayGenomics ES cell line RRM169 embryonic stem cell house mouse CVCL_NF93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890752; Zfp81 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181455 CVCL_NF92 BayGenomics ES cell line RRM168 embryonic stem cell house mouse CVCL_NF92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181456 CVCL_NF91 BayGenomics ES cell line RRM167 embryonic stem cell house mouse CVCL_NF91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916996; Znhit6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181457 CVCL_NF90 BayGenomics ES cell line RRM165 embryonic stem cell house mouse CVCL_NF90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354704; Fbxl17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181458 CVCL_4D00 HQ03096 transformed cell line human CVCL_4D00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181459 CVCL_4D04 MCF-7/CG-5 cancer cell line human CVCL_4D04 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Estrogen supersensitive (PubMed=6575841) Doubling time: 13 hours (PubMed=8712686) 21181460 CVCL_4D03 MCF-7/CG-4 cancer cell line human CVCL_4D03 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Estrogen supersensitive (PubMed=6575841) 21181461 CVCL_4D02 HQ03103 transformed cell line human CVCL_4D02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181462 CVCL_4D01 HQ03097 transformed cell line human CVCL_4D01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181463 CVCL_4D08 VMM609 cancer cell line human CVCL_4D08 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21181464 CVCL_4D07 VMM425 cancer cell line human CVCL_4D07 CL:0000010 Derived from metastatic site: Pelvic soft tissue. Male 21181465 CVCL_4D06 Cx30.2 finite cell line house mouse CVCL_4D06 CL:0000010 Breed/subspecies: 129S1/SvImJ. Male 21181466 CVCL_4D05 MCF-7/CG-5/Dx cancer cell line human CVCL_4D05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Doubling time: 47 hours (PubMed=8712686) 21181467 CVCL_4D09 VMM917 cancer cell line human CVCL_4D09 CL:0000010 Derived from metastatic site: Right posterior thigh adjacent to buttocks; hypodermis. Male 21181468 CVCL_WJ52 HPSI0616i-fayz_2 induced pluripotent stem cell human CVCL_WJ52 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181469 CVCL_WJ51 HPSI0816i-uosa_6 induced pluripotent stem cell human CVCL_WJ51 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181470 CVCL_WJ50 HMGUi001-A-1 induced pluripotent stem cell human CVCL_WJ50 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a T2A-H2B-Cherry construct was inserted in one allele of INS exon 3 (PubMed=32361463) 21181471 CVCL_WJ56 HPSI1116i-geve_3 induced pluripotent stem cell human CVCL_WJ56 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181472 CVCL_WJ55 HPSI0616i-vaqr_4 induced pluripotent stem cell human CVCL_WJ55 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181473 CVCL_WJ54 HPSI0516i-suyj_2 induced pluripotent stem cell human CVCL_WJ54 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181474 CVCL_WJ53 HPSI0516i-suyj_1 induced pluripotent stem cell human CVCL_WJ53 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181475 CVCL_WJ59 HPSI0516i-vebd_4 induced pluripotent stem cell human CVCL_WJ59 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181476 CVCL_WJ58 HPSI0516i-vebd_2 induced pluripotent stem cell human CVCL_WJ58 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181477 CVCL_WJ57 HPSI1116i-geve_4 induced pluripotent stem cell human CVCL_WJ57 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181478 CVCL_4D11 MP38 cancer cell line human CVCL_4D11 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; c.68-9_72del; Zygosity=Unspecified (PubMed=24994677); Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=24994677) Derived from sampling site: Eye; uvea. Omics: SNP array analysis Male Doubling time: 80 hours (PubMed=24994677) 21181479 CVCL_4D10 HBEC-5i transformed cell line human CVCL_4D10 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Brain microvascular endothelial cell.. Male 21181480 CVCL_4D15 MM28 cancer cell line human CVCL_4D15 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Tyr627Ter (c.1881C>A); Zygosity=Unspecified (PubMed=24994677); Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677) Derived from metastatic site: Liver. Omics: SNP array analysis Male Doubling time: 109 hours (PubMed=24994677) 21181481 CVCL_4D14 MP65 cancer cell line human CVCL_4D14 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Leu573Trpfs*3 (c.1717delC); ClinVar=VCV000221278; Zygosity=Unspecified (PubMed=24994677); Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677) Derived from sampling site: Eye; uvea. Omics: SNP array analysis Female Doubling time: 120 hours (PubMed=24994677) 21181482 CVCL_4D13 MP46 cancer cell line human CVCL_4D13 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000375955; Zygosity=Unspecified (PubMed=24994677) Derived from sampling site: Eye; uvea. Omics: SNP array analysis Male Characteristics: Established from a patient-derived xenograft Doubling time: 110 hours (PubMed=24994677) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21181483 CVCL_4D12 MP41 cancer cell line human CVCL_4D12 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677) Derived from sampling site: Eye; uvea. Omics: SNP array analysis Female Characteristics: Established from a patient-derived xenograft Doubling time: 41 hours (PubMed=24994677) 21181484 CVCL_4D19 GM00862 finite cell line human CVCL_4D19 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Male 21181485 CVCL_4D18 GM00613 finite cell line human CVCL_4D18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21181486 CVCL_4D17 MM66 cancer cell line human CVCL_4D17 CL:0000010 Sequence variation: Mutation; HGNC; 4379; GNA11; Simple; p.Gln209Leu (c.626A>T); ClinVar=VCV000376002; Zygosity=Unspecified (PubMed=24994677) Derived from metastatic site: Liver. Omics: SNP array analysis Unspecified Doubling time: 80 hours (PubMed=24994677) 21181487 CVCL_4D16 MM33 cancer cell line human CVCL_4D16 CL:0000010 Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Unspecified (PubMed=24994677) Derived from metastatic site: Skin. Omics: SNP array analysis Unspecified Doubling time: 91 hours (PubMed=24994677) 21181488 CVCL_WJ41 WAe009-A-19 embryonic stem cell human CVCL_WJ41 From: VIB - KU Leuven Center for Brain and Disease Research; Leuven; Belgium CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9. Female Characteristics: Using homologous recombination a doxycycline inducible dCAS9 along with GFP and rtTA driven by CAGS promoter was introduced in the AAVS1 safe harbor locus 21181489 CVCL_WJ40 PSMi001-A induced pluripotent stem cell human CVCL_WJ40 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ala341Val (c.1022C>T) (p.Ala214Val, c.641C>T); ClinVar=VCV000003121; Zygosity=Heterozygous (PubMed=31398660) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181490 CVCL_WJ45 LEIi005-B induced pluripotent stem cell human CVCL_WJ45 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 10263; RP1; Simple; p.Glu700Ter (c.2098G>T); Zygosity=Heterozygous (PubMed=31059986) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21181491 CVCL_WJ44 LEIi010-B induced pluripotent stem cell human CVCL_WJ44 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr318Cysfs*17 (c.949C>A); Zygosity=Heterozygous (PubMed=30904819); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys419Phe (c.1256G>T); ClinVar=VCV000002359; Zygosity=Heterozygous (PubMed=30904819) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21181492 CVCL_WJ43 LEIi010-A induced pluripotent stem cell human CVCL_WJ43 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr318Cysfs*17 (c.949C>A); Zygosity=Heterozygous (PubMed=30904819); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys419Phe (c.1256G>T); ClinVar=VCV000002359; Zygosity=Heterozygous (PubMed=30904819) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21181493 CVCL_WJ42 WAe009-A-20 embryonic stem cell human CVCL_WJ42 From: VIB - KU Leuven Center for Brain and Disease Research; Leuven; Belgium CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9. Female Characteristics: Using homologous recombination a doxycycline inducible dCAS9 fused with VP64-P16-RTA along with GFP and rtTA driven by CAGS promoter was introduced in the AAVS1 safe harbor locus 21181494 CVCL_WJ49 HMGUi001-A induced pluripotent stem cell human CVCL_WJ49 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21181495 CVCL_WJ48 HHUUKDi005-A induced pluripotent stem cell human CVCL_WJ48 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous; Note=Allele UGT1A1*2 (PubMed=33485181) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The parent fibroblast seem to contain both male and female cells but the iPSC cells seem to be derived from the male cells (PubMed=33485181) 21181496 CVCL_WJ47 CBTCi004-A induced pluripotent stem cell human CVCL_WJ47 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Female 21181497 CVCL_WJ46 CBTCi003-A induced pluripotent stem cell human CVCL_WJ46 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Male 21181498 CVCL_NP93 BayGenomics ES cell line RRR759 embryonic stem cell house mouse CVCL_NP93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181499 CVCL_NP92 BayGenomics ES cell line RRR757 embryonic stem cell house mouse CVCL_NP92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3800296; Gm9631 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181500 CVCL_NP91 BayGenomics ES cell line RRR754 embryonic stem cell house mouse CVCL_NP91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384756; Phf21a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181501 CVCL_NP90 BayGenomics ES cell line RRR748 embryonic stem cell house mouse CVCL_NP90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919790; Heatr6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181502 CVCL_WJ30 CDS11 cancer cell line human CVCL_WJ30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=30987403); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Leu (c.395G>T); ClinVar=VCV000375889; Zygosity=Heterozygous (PubMed=30987403); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=30987403). Male 21181503 CVCL_WJ34 CynESC-3X embryonic stem cell CVCL_WJ34 CL:0000010 Female Group: Non-human primate cell line. 21181504 CVCL_WJ33 PSMi005-A induced pluripotent stem cell human CVCL_WJ33 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg190Trp (c.568C>T) (p.Arg63Trp, c.187C>T); ClinVar=VCV000053070; Zygosity=Heterozygous (PubMed=31009818) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181505 CVCL_WJ32 T-CDS17 cancer cell line human CVCL_WJ32 CL:0000010 Sequence variation: Mutation; HGNC; 5383; IDH2; Simple; p.Arg172Gly (c.514A>G); ClinVar=VCV000376439; Zygosity=Heterozygous (PubMed=30987403); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.645T>G); ClinVar=VCV000376661; Zygosity=Homozygous (PubMed=30987403) Omics: Deep exome analysis. Male Characteristics: Established from a xenograft obtained by subcutaneous inoculation of parent cell line in immunodeficient mice 21181506 CVCL_WJ31 CDS17 cancer cell line human CVCL_WJ31 CL:0000010 Sequence variation: Mutation; HGNC; 5383; IDH2; Simple; p.Arg172Gly (c.514A>G); ClinVar=VCV000376439; Zygosity=Heterozygous (PubMed=30987403); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.645T>G); ClinVar=VCV000376661; Zygosity=Homozygous (PubMed=30987403) Omics: Deep exome analysis. Male 21181507 CVCL_WJ38 PSMi008-A induced pluripotent stem cell human CVCL_WJ38 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 16859; NOS1AP; Simple; g.chr1:162065484T>C (g.694T>C); dbSNP=rs16847548; Zygosity=Heterozygous (PubMed=31398660) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181508 CVCL_NP89 BayGenomics ES cell line RRR746 embryonic stem cell house mouse CVCL_NP89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891963; Ywhaq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181509 CVCL_WJ37 PSMi006-A induced pluripotent stem cell human CVCL_WJ37 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly179Ser (c.535G>A); ClinVar=VCV000053063; Zygosity=Homozygous (PubMed=31785541) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181510 CVCL_NP88 BayGenomics ES cell line RRR743 embryonic stem cell house mouse CVCL_NP88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107901; Nfyc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181511 CVCL_WJ36 PSMi004-A induced pluripotent stem cell human CVCL_WJ36 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg594Gln (c.1781G>A); ClinVar=VCV000053018; Zygosity=Heterozygous (PubMed=30974404) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181512 CVCL_NP87 BayGenomics ES cell line RRR740 embryonic stem cell house mouse CVCL_NP87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890773; Actn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181513 CVCL_WJ35 CynESC-OTZ4 embryonic stem cell CVCL_WJ35 CL:0000010 Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using CRISPR/Cas9 the stop codon of POU5F1 was replaced with a P2A-tdTomato-IRES-ZeocinR construct Group: Non-human primate cell line 21181514 CVCL_NP86 BayGenomics ES cell line RRR738 embryonic stem cell house mouse CVCL_NP86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261890; Fbxo28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181515 CVCL_NP85 BayGenomics ES cell line RRR731 embryonic stem cell house mouse CVCL_NP85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181516 CVCL_NP84 BayGenomics ES cell line RRR730 embryonic stem cell house mouse CVCL_NP84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928738; Slc25a20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181517 CVCL_NP83 BayGenomics ES cell line RRR727 embryonic stem cell house mouse CVCL_NP83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181518 CVCL_WJ39 PSMi009-A induced pluripotent stem cell human CVCL_WJ39 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy. CL:0000010 21181519 CVCL_WJ23 F56 [Misidentified human neoplasm] undefined cell line type house mouse CVCL_WJ23 CL:0000010 Unspecified Problematic cell line: Misidentified/contaminated Originally thought to be of human origin but found to be from mouse (PubMed=28851942). Originally thought to originate from an adenocarcinoma.. 21181520 CVCL_WJ22 MSFIB finite cell line human CVCL_WJ22 CL:0000010 Anecdotal: Established from Michael Snyder, a Stanford geneticist that pioneer the concept of integrative personal omics profile (iPOP) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181521 CVCL_WJ21 C1 100 08 0013 finite cell line human CVCL_WJ21 CL:0000010 Male Characteristics: Olfactory neurosphere derived cell line. 21181522 CVCL_WJ20 C1 100 08 0003 finite cell line human CVCL_WJ20 CL:0000010 Female Characteristics: Olfactory neurosphere derived cell line. 21181523 CVCL_WJ27 NRCs spontaneously immortalized cell line Norway rat CVCL_WJ27 CL:0000010 Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: Fischer 344. Male Doubling time: ~16 hours (PubMed=8569194) 21181524 CVCL_WJ26 PCK-CCL spontaneously immortalized cell line Norway rat CVCL_WJ26 CL:0000010 Sequence variation: Mutation; RGD; 1308476; Pkhd1; Unexplicit; IVS35-2A>T; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16783394) Derived from sampling site: Liver Cell type=Cholangiocyte.; Breed/subspecies: PCK/CrljCrl-Pkhd1pck/Crl. Unspecified Characteristics: Animal model of autosomal recessive polycystic kidney disease (PubMed=16783394) Doubling time: 28.8 hours (PubMed=16783394) 21181525 CVCL_NP99 BayGenomics ES cell line RRR772 embryonic stem cell house mouse CVCL_NP99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276116; Ep300 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181526 CVCL_WJ25 L8824 spontaneously immortalized cell line CVCL_WJ25 CL:0000010 Derived from sampling site: Liver. Unspecified Group: Fish cell line 21181527 CVCL_NP98 BayGenomics ES cell line RRR771 embryonic stem cell house mouse CVCL_NP98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919213; Cdca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181528 CVCL_WJ24 HIC cancer cell line human CVCL_WJ24 CL:0000010 21181529 CVCL_NP97 BayGenomics ES cell line RRR770 embryonic stem cell house mouse CVCL_NP97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355322; Exosc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181530 CVCL_NP96 BayGenomics ES cell line RRR767 embryonic stem cell house mouse CVCL_NP96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196439; Cbx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181531 CVCL_NP95 BayGenomics ES cell line RRR765 embryonic stem cell house mouse CVCL_NP95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137022; Tm2d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181532 CVCL_WJ29 CDS06 cancer cell line human CVCL_WJ29 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; None_reported; -; Zygosity=- (PubMed=30987403); Sequence variation: Mutation; HGNC; 5383; IDH2; None_reported; -; Zygosity=- (PubMed=30987403); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=30987403). Female 21181533 CVCL_NP94 BayGenomics ES cell line RRR761 embryonic stem cell house mouse CVCL_NP94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181534 CVCL_WJ28 BV2-mCherry transformed cell line house mouse CVCL_WJ28 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Female 21181535 CVCL_NP71 BayGenomics ES cell line RRR709 embryonic stem cell house mouse CVCL_NP71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181536 CVCL_NP70 BayGenomics ES cell line RRR706 embryonic stem cell house mouse CVCL_NP70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96247; Hsp90ab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181537 CVCL_WJ12 ZE cancer cell line human CVCL_WJ12 CL:0000010 Derived from metastatic site: Bone marrow. Female 21181538 CVCL_WJ11 KM22 cancer cell line human CVCL_WJ11 CL:0000010 Derived from metastatic site: Bone marrow. Female 21181539 CVCL_WJ10 1590 cancer cell line human CVCL_WJ10 CL:0000010 Derived from metastatic site: Bone marrow. Female 21181540 CVCL_NP69 BayGenomics ES cell line RRR705 embryonic stem cell house mouse CVCL_NP69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914265; Ccdc91 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181541 CVCL_NP68 BayGenomics ES cell line RRR703 embryonic stem cell house mouse CVCL_NP68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181542 CVCL_WJ16 SVP spontaneously immortalized cell line green monkey CVCL_WJ16 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21181543 CVCL_NP67 BayGenomics ES cell line RRR700 embryonic stem cell house mouse CVCL_NP67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140230; Camta1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181544 CVCL_WJ15 CSL 503 finite cell line CVCL_WJ15 CL:0000010 Derived from sampling site: Fetal lung. Unspecified Virology: Susceptible to infection by ovine adebonviruses Senescence: Senesces at 50-70 PDL (PubMed=2549933) 21181545 CVCL_NP66 BayGenomics ES cell line RRR698 embryonic stem cell house mouse CVCL_NP66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915545; Aar2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181546 CVCL_WJ14 HVO-156 finite cell line CVCL_WJ14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by ovine adebonviruses Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2440 21181547 CVCL_NP65 BayGenomics ES cell line RRR696 embryonic stem cell house mouse CVCL_NP65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3800296; Gm9631 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181548 CVCL_WJ13 HCCLM3-GFP-LC3 cancer cell line human CVCL_WJ13 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 23177; KEAP1; Simple; p.Pro445Glnfs*13 (c.1334delC); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6838; MAP1LC3A; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2010102 21181549 CVCL_NP64 BayGenomics ES cell line RRR695 embryonic stem cell house mouse CVCL_NP64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88279; Cbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181550 CVCL_NP63 BayGenomics ES cell line RRR694 embryonic stem cell house mouse CVCL_NP63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3800296; Gm9631 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181551 CVCL_WJ19 C1 100 08 0002 finite cell line human CVCL_WJ19 CL:0000010 Male Characteristics: Olfactory neurosphere derived cell line. 21181552 CVCL_NP62 BayGenomics ES cell line RRR693 embryonic stem cell house mouse CVCL_NP62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918890; Zfp949 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181553 CVCL_WJ18 MSiPS induced pluripotent stem cell human CVCL_WJ18 CL:0000010 Anecdotal: Established from Michael Snyder, a Stanford geneticist that pioneer the concept of integrative personal omics profile (iPOP) Derived from sampling site: Peripheral blood. Male 21181554 CVCL_NP61 BayGenomics ES cell line RRR690 embryonic stem cell house mouse CVCL_NP61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933204; Rbm5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181555 CVCL_WJ17 MSLCL transformed cell line human CVCL_WJ17 CL:0000010 Anecdotal: Established from Michael Snyder, a Stanford geneticist that pioneer the concept of integrative personal omics profile (iPOP) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181556 CVCL_NP82 BayGenomics ES cell line RRR726 embryonic stem cell house mouse CVCL_NP82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913284; Psmd14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181557 CVCL_NP81 BayGenomics ES cell line RRR723 embryonic stem cell house mouse CVCL_NP81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448530; Vps13d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181558 CVCL_NP80 BayGenomics ES cell line RRR722 embryonic stem cell house mouse CVCL_NP80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181559 CVCL_WJ01 RLD-10 transformed cell line Norway rat CVCL_WJ01 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21181560 CVCL_WJ00 RLD-9 transformed cell line Norway rat CVCL_WJ00 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21181561 CVCL_NP79 BayGenomics ES cell line RRR721 embryonic stem cell house mouse CVCL_NP79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338001; Gdap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181562 CVCL_WJ05 hEM15A transformed cell line human CVCL_WJ05 CL:0000010 Karyotypic information: Normal diploid karyotype (CelloPub=CLPUB00490); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Doubling time: ~24 hours (CelloPub=CLPUB00490) 21181563 CVCL_NP78 BayGenomics ES cell line RRR720 embryonic stem cell house mouse CVCL_NP78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97851; Slc20a2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181564 CVCL_WJ04 RLD-13 transformed cell line Norway rat CVCL_WJ04 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21181565 CVCL_NP77 BayGenomics ES cell line RRR719 embryonic stem cell house mouse CVCL_NP77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104874; Akt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181566 CVCL_WJ03 RLD-12 transformed cell line Norway rat CVCL_WJ03 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21181567 CVCL_NP76 BayGenomics ES cell line RRR718 embryonic stem cell house mouse CVCL_NP76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196439; Cbx7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181568 CVCL_WJ02 RLD-11 transformed cell line Norway rat CVCL_WJ02 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21181569 CVCL_NP75 BayGenomics ES cell line RRR716 embryonic stem cell house mouse CVCL_NP75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181570 CVCL_WJ09 Huh-7/F24 cancer cell line human CVCL_WJ09 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male Group: Patented cell line 21181571 CVCL_NP74 BayGenomics ES cell line RRR714 embryonic stem cell house mouse CVCL_NP74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859353; Mkrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181572 CVCL_WJ08 EAC-E2G8 cancer cell line house mouse CVCL_WJ08 CL:0000010 Derived from sampling site: Ascites. Female 21181573 CVCL_NP73 BayGenomics ES cell line RRR713 embryonic stem cell house mouse CVCL_NP73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181574 CVCL_WJ07 MA782/5s-8101 cancer cell line house mouse CVCL_WJ07 CL:0000010 Female 21181575 CVCL_NP72 BayGenomics ES cell line RRR712 embryonic stem cell house mouse CVCL_NP72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3608327; Marchf11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181576 CVCL_WJ06 hEM5B2 transformed cell line human CVCL_WJ06 CL:0000010 Karyotypic information: Hypertetraploid karyotype Contains between 78 and 123 chromosomes. Has chromosome breakage, deletion and translocation in ~84% of the cells (CelloPub=CLPUB00490).; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Doubling time: ~64.8 hours (CelloPub=CLPUB00490) 21181577 CVCL_NP49 BayGenomics ES cell line RRR664 embryonic stem cell house mouse CVCL_NP49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181578 CVCL_NP48 BayGenomics ES cell line RRR660 embryonic stem cell house mouse CVCL_NP48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917875; Med26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181579 CVCL_NP47 BayGenomics ES cell line RRR657 embryonic stem cell house mouse CVCL_NP47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343463; Bub3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181580 CVCL_NP46 BayGenomics ES cell line RRR653 embryonic stem cell house mouse CVCL_NP46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917458; Med23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181581 CVCL_NP45 BayGenomics ES cell line RRR652 embryonic stem cell house mouse CVCL_NP45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338864; Stau1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181582 CVCL_NP44 BayGenomics ES cell line RRR650 embryonic stem cell house mouse CVCL_NP44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351657; Abcf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181583 CVCL_NP43 BayGenomics ES cell line RRR648 embryonic stem cell house mouse CVCL_NP43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442317; Mier3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181584 CVCL_NP42 BayGenomics ES cell line RRR647 embryonic stem cell house mouse CVCL_NP42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914538; Srek1ip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181585 CVCL_NP41 BayGenomics ES cell line RRR644 embryonic stem cell house mouse CVCL_NP41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289318; Ccdc43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181586 CVCL_NP40 BayGenomics ES cell line RRR639 embryonic stem cell house mouse CVCL_NP40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891832; Patz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181587 CVCL_NP60 BayGenomics ES cell line RRR689 embryonic stem cell house mouse CVCL_NP60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1345643; Sufu Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181588 CVCL_NP59 BayGenomics ES cell line RRR688 embryonic stem cell house mouse CVCL_NP59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926048; Eml4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181589 CVCL_NP58 BayGenomics ES cell line RRR680 embryonic stem cell house mouse CVCL_NP58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443882; Snx30 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181590 CVCL_NP57 BayGenomics ES cell line RRR677 embryonic stem cell house mouse CVCL_NP57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96247; Hsp90ab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181591 CVCL_NP56 BayGenomics ES cell line RRR676 embryonic stem cell house mouse CVCL_NP56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388633; Cltc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181592 CVCL_NP55 BayGenomics ES cell line RRR675 embryonic stem cell house mouse CVCL_NP55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890520; Vps4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181593 CVCL_NP54 BayGenomics ES cell line RRR674 embryonic stem cell house mouse CVCL_NP54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343188; Ube2g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181594 CVCL_NP53 BayGenomics ES cell line RRR673 embryonic stem cell house mouse CVCL_NP53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181595 CVCL_NP52 BayGenomics ES cell line RRR671 embryonic stem cell house mouse CVCL_NP52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107901; Nfyc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181596 CVCL_NP51 BayGenomics ES cell line RRR669 embryonic stem cell house mouse CVCL_NP51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139369; Rtel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181597 CVCL_NP50 BayGenomics ES cell line RRR667 embryonic stem cell house mouse CVCL_NP50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182472; Tpcn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181598 CVCL_4D88 GM06109 finite cell line human CVCL_4D88 CL:0000010 Karyotypic information: 46,XX,inv(10)(pter->p11.2::q21->p11.2::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181599 CVCL_4D87 GM05754 finite cell line human CVCL_4D87 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(6) [29]; 45,XY,-6 [21] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181600 CVCL_4D86 GM05563 finite cell line human CVCL_4D86 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(13) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181601 CVCL_4D85 GM05297 finite cell line human CVCL_4D85 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,ins(11;10)(11pter->11p13::10q21->10q24::11p13->11qter;10pter->10q21::10q24->10qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181602 CVCL_4D89 GM06199 finite cell line human CVCL_4D89 CL:0000010 Population: African American; Karyotypic information: 46,XY,r(21)(p13->q22) (Coriell); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21181603 CVCL_4D80 GM01118 finite cell line human CVCL_4D80 CL:0000010 Population: Mexican; Karyotypic information: 46,XX,r(18) [39]; 45,XX,-18 [11] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181604 CVCL_4D84 GM04347 transformed cell line human CVCL_4D84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181605 CVCL_4D83 GM03233 finite cell line human CVCL_4D83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181606 CVCL_4D82 GM03003 finite cell line human CVCL_4D82 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(14) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181607 CVCL_4D81 GM01222 finite cell line human CVCL_4D81 CL:0000010 Population: African American; Karyotypic information: 46,XX,ins(5;6)(5pter->5q33::6q15->6q25::5q33->5qter;6pter->6q15::6q25->6qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181608 CVCL_4D99 GM09706 transformed cell line human CVCL_4D99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21181609 CVCL_4D98 GM09687 transformed cell line human CVCL_4D98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21181610 CVCL_4D97 GM09654 transformed cell line human CVCL_4D97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181611 CVCL_4D96 GM09643 finite cell line human CVCL_4D96 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21181612 CVCL_4D91 GM06626 transformed cell line human CVCL_4D91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181613 CVCL_4D90 GM06420 finite cell line human CVCL_4D90 CL:0000010 Population: African American; Karyotypic information: 46,XY,r(22) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181614 CVCL_4D95 GM09229 finite cell line human CVCL_4D95 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(12)(p13.3;q24.33) [18]; 46,XY,inv(12)(p11.2;q24.33) [13]; 45,X [9]; 45,XY,-12 [2]; 46,XY [8] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181615 CVCL_4D94 GM09025 transformed cell line human CVCL_4D94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21181616 CVCL_4D93 GM08205 transformed cell line human CVCL_4D93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181617 CVCL_4D92 GM07364 finite cell line human CVCL_4D92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21181618 CVCL_4D66 GM17951 transformed cell line human CVCL_4D66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181619 CVCL_4D65 GM17949 transformed cell line human CVCL_4D65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181620 CVCL_4D64 GM17948 transformed cell line human CVCL_4D64 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181621 CVCL_4D63 GM17947 transformed cell line human CVCL_4D63 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181622 CVCL_4D69 GM17954 finite cell line human CVCL_4D69 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181623 CVCL_4D68 GM17953 finite cell line human CVCL_4D68 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181624 CVCL_4D67 GM17952 transformed cell line human CVCL_4D67 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181625 CVCL_4D62 GM17945 transformed cell line human CVCL_4D62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181626 CVCL_4D61 GM17944 transformed cell line human CVCL_4D61 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181627 CVCL_4D60 GM17605 transformed cell line human CVCL_4D60 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181628 CVCL_4D77 GM00413 finite cell line human CVCL_4D77 CL:0000010 Karyotypic information: 46,XY,inv(4)(pter->p14::q2?->p14::q2?->qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181629 CVCL_4D76 GM00285 finite cell line human CVCL_4D76 CL:0000010 Population: African American; Karyotypic information: 46,XY,r(13) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181630 CVCL_4D75 GM00109 finite cell line human CVCL_4D75 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,r(6) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181631 CVCL_4D74 GM17960 finite cell line human CVCL_4D74 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181632 CVCL_4D79 GM00861 finite cell line human CVCL_4D79 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,ins(5;1)(5pter->5q15::1q25->1q32::5q15->5qter;1pter->1q25::1q32->1qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21181633 CVCL_4D78 GM00414 finite cell line human CVCL_4D78 CL:0000010 Karyotypic information: 46,XX,inv(4)(pter->p14::q2?->p14::q2?->qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21181634 CVCL_4D73 GM17959 finite cell line human CVCL_4D73 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM17959; probable Female 21181635 CVCL_4D72 GM17957 finite cell line human CVCL_4D72 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM17957; probable Male 21181636 CVCL_4D71 GM17956 finite cell line human CVCL_4D71 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181637 CVCL_4D70 GM17955 finite cell line human CVCL_4D70 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM17955; probable Male 21181638 CVCL_4D44 GM17576 finite cell line human CVCL_4D44 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21181639 CVCL_4D43 GM17504 transformed cell line human CVCL_4D43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181640 CVCL_4D42 GM17503 finite cell line human CVCL_4D42 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181641 CVCL_4D41 GM17502 transformed cell line human CVCL_4D41 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181642 CVCL_4D48 GM17590 finite cell line human CVCL_4D48 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181643 CVCL_4D47 GM17579 transformed cell line human CVCL_4D47 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181644 CVCL_4D46 GM17578 finite cell line human CVCL_4D46 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181645 CVCL_4D45 GM17577 transformed cell line human CVCL_4D45 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181646 CVCL_4D49 GM17591 transformed cell line human CVCL_4D49 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181647 CVCL_WJ92 PBG.PK-21 spontaneously immortalized cell line pig CVCL_WJ92 From: ProBioGen AG; Berlin; Germany CL:0000010 Derived from sampling site: Kidney. Virology: Free from porcine circovirus type 1 (PCV1) infection Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21181648 CVCL_WJ91 HPSI1114i-yair_2 induced pluripotent stem cell human CVCL_WJ91 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181649 CVCL_WJ90 HPSI1014i-xejd_1 induced pluripotent stem cell human CVCL_WJ90 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181650 CVCL_WJ96 HPSI0816i-keit_1 induced pluripotent stem cell human CVCL_WJ96 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181651 CVCL_WJ95 HPSI0314i-uict_3 induced pluripotent stem cell human CVCL_WJ95 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181652 CVCL_WJ94 HPSI0314i-uict_1 induced pluripotent stem cell human CVCL_WJ94 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181653 CVCL_WJ93 CHO-S FUT8-/- spontaneously immortalized cell line CVCL_WJ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3HCE4; Fut8 Derived from sampling site: Ovary. Female Characteristics: Useful for the production of fucose-negative antibodies 21181654 CVCL_WJ99 HPSI0816i-youd_8 induced pluripotent stem cell human CVCL_WJ99 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181655 CVCL_WJ98 HPSI0816i-youd_6 induced pluripotent stem cell human CVCL_WJ98 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181656 CVCL_WJ97 HPSI0816i-keit_2 induced pluripotent stem cell human CVCL_WJ97 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181657 CVCL_4D40 GM17501 finite cell line human CVCL_4D40 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181658 CVCL_4D55 GM17599 transformed cell line human CVCL_4D55 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181659 CVCL_4D54 GM17598 finite cell line human CVCL_4D54 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181660 CVCL_4D53 GM17597 transformed cell line human CVCL_4D53 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181661 CVCL_4D52 GM17596 finite cell line human CVCL_4D52 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181662 CVCL_4D59 GM17604 finite cell line human CVCL_4D59 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181663 CVCL_4D58 GM17603 transformed cell line human CVCL_4D58 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181664 CVCL_4D57 GM17602 finite cell line human CVCL_4D57 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181665 CVCL_4D56 GM17600 finite cell line human CVCL_4D56 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181666 CVCL_WJ81 HPSI0514i-yafr_3 induced pluripotent stem cell human CVCL_WJ81 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21181667 CVCL_WJ80 HPSI0816i-daah_6 induced pluripotent stem cell human CVCL_WJ80 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181668 CVCL_WJ85 HPSI0115i-rakz_6 induced pluripotent stem cell human CVCL_WJ85 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181669 CVCL_WJ84 HPSI0115i-pitg_2 induced pluripotent stem cell human CVCL_WJ84 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181670 CVCL_WJ83 HPSI0115i-payf_2 induced pluripotent stem cell human CVCL_WJ83 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181671 CVCL_WJ82 HPSI0115i-bimq_5 induced pluripotent stem cell human CVCL_WJ82 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: Genome sequenced; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21181672 CVCL_WJ89 HPSI0514i-xufp_2 induced pluripotent stem cell human CVCL_WJ89 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21181673 CVCL_WJ88 HPSI0215i-romx_2 induced pluripotent stem cell human CVCL_WJ88 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21181674 CVCL_WJ87 HPSI0115i-rehy_3 induced pluripotent stem cell human CVCL_WJ87 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181675 CVCL_WJ86 HPSI0115i-rehy_2 induced pluripotent stem cell human CVCL_WJ86 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21181676 CVCL_4D51 GM17595 transformed cell line human CVCL_4D51 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181677 CVCL_4D50 GM17594 finite cell line human CVCL_4D50 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181678 CVCL_4D22 GM16853 transformed cell line human CVCL_4D22 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181679 CVCL_4D21 GM12366 finite cell line human CVCL_4D21 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21181680 CVCL_4D20 GM03180 finite cell line human CVCL_4D20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21181681 CVCL_4D26 GM16923 finite cell line human CVCL_4D26 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181682 CVCL_4D25 GM16879 finite cell line human CVCL_4D25 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181683 CVCL_4D24 GM16878 transformed cell line human CVCL_4D24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181684 CVCL_4D23 GM16854 finite cell line human CVCL_4D23 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21181685 CVCL_4D29 GM16963 transformed cell line human CVCL_4D29 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181686 CVCL_4D28 GM16925 finite cell line human CVCL_4D28 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181687 CVCL_4D27 GM16924 transformed cell line human CVCL_4D27 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181688 CVCL_WJ70 HPSI1116i-peru_4 induced pluripotent stem cell human CVCL_WJ70 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Greek; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181689 CVCL_WJ74 HPSI0816i-oexh_2 induced pluripotent stem cell human CVCL_WJ74 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181690 CVCL_WJ73 HPSI0816i-keha_5 induced pluripotent stem cell human CVCL_WJ73 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181691 CVCL_WJ72 HPSI0816i-keha_2 induced pluripotent stem cell human CVCL_WJ72 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181692 CVCL_WJ71 HPSI1116i-uabf_6 induced pluripotent stem cell human CVCL_WJ71 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181693 CVCL_WJ78 HPSI0816i-uixy_2 induced pluripotent stem cell human CVCL_WJ78 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181694 CVCL_WJ77 HPSI0816i-uixy_1 induced pluripotent stem cell human CVCL_WJ77 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181695 CVCL_WJ76 HPSI0916i-zaue_2 induced pluripotent stem cell human CVCL_WJ76 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21181696 CVCL_WJ75 HPSI0816i-oexh_5 induced pluripotent stem cell human CVCL_WJ75 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181697 CVCL_WJ79 HPSI0816i-daah_1 induced pluripotent stem cell human CVCL_WJ79 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181698 CVCL_4D33 GM16967 transformed cell line human CVCL_4D33 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181699 CVCL_4D32 GM16966 finite cell line human CVCL_4D32 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181700 CVCL_4D31 GM16965 transformed cell line human CVCL_4D31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181701 CVCL_4D30 GM16964 finite cell line human CVCL_4D30 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181702 CVCL_4D37 GM17412 finite cell line human CVCL_4D37 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181703 CVCL_4D36 GM17411 transformed cell line human CVCL_4D36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181704 CVCL_4D35 GM16972 finite cell line human CVCL_4D35 CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly700Cys (c.2098G>T) (G610C); ClinVar=VCV000641929; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181705 CVCL_4D34 GM16968 finite cell line human CVCL_4D34 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181706 CVCL_4D39 GM17416 finite cell line human CVCL_4D39 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21181707 CVCL_4D38 GM17415 transformed cell line human CVCL_4D38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181708 CVCL_WJ63 HPSI0516i-raet_6 induced pluripotent stem cell human CVCL_WJ63 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181709 CVCL_WJ62 HPSI0516i-raet_4 induced pluripotent stem cell human CVCL_WJ62 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181710 CVCL_WJ61 HPSI0316i-beqm_9 induced pluripotent stem cell human CVCL_WJ61 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181711 CVCL_WJ60 HPSI0316i-beqm_12 induced pluripotent stem cell human CVCL_WJ60 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21181712 CVCL_WJ67 HPSI1116i-yiek_2 induced pluripotent stem cell human CVCL_WJ67 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Romani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181713 CVCL_WJ66 HPSI0816i-kije_4 induced pluripotent stem cell human CVCL_WJ66 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181714 CVCL_WJ65 HPSI0816i-kije_1 induced pluripotent stem cell human CVCL_WJ65 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181715 CVCL_WJ64 HPSI1116i-zalc_1 induced pluripotent stem cell human CVCL_WJ64 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181716 CVCL_WJ69 HPSI1116i-sozw_2 induced pluripotent stem cell human CVCL_WJ69 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181717 CVCL_WJ68 HPSI1116i-yiek_6 induced pluripotent stem cell human CVCL_WJ68 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Romani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181718 CVCL_F718 ML108 transformed cell line human CVCL_F718 HLA typing: A*02:01,26:08; B*15:18,44:02; C*05:01,07:04 (IPD-IMGT/HLA=11083) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181719 CVCL_EV18 ND09768 transformed cell line human CVCL_EV18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181720 CVCL_F717 DMBA-8 clone 4 cancer cell line Norway rat CVCL_F717 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Fischer 344. Female 21181721 CVCL_EV17 ND09739 transformed cell line human CVCL_EV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181722 CVCL_F716 DMBA-8 cancer cell line Norway rat CVCL_F716 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: Fischer 344. Female 21181723 CVCL_EV16 ND09737 transformed cell line human CVCL_EV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181724 CVCL_EV15 ND09730 transformed cell line human CVCL_EV15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181725 CVCL_F715 TRLEC-03 transformed cell line Norway rat CVCL_F715 From: Tsurufuji S.; Institute of Cytosignal Research; Tokyo; Japan CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; endothelium Cell type=Lung endothelial cell.. 21181726 CVCL_F719 ML108U transformed cell line human CVCL_F719 HLA typing: A*02:01,26:08; B*15:18,44:02; C*05:01 (IPD-IMGT/HLA=11084) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181727 CVCL_EV19 ND09773 transformed cell line human CVCL_EV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181728 CVCL_F710 C11.2 transformed cell line CVCL_F710 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain. Unspecified Doubling time: ~24 hours (PubMed=17049468) 21181729 CVCL_EV10 ND09687 transformed cell line human CVCL_EV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181730 CVCL_F714 A6-2F3 spontaneously immortalized cell line African clawed frog CVCL_F714 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male Group: Amphibian cell line 21181731 CVCL_EV14 ND09729 transformed cell line human CVCL_EV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181732 CVCL_F713 DCH036 transformed cell line human CVCL_F713 HLA typing: A*11,24:07; B*15:32 (IPD-IMGT/HLA=10478) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181733 CVCL_EV13 ND09717 transformed cell line human CVCL_EV13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181734 CVCL_EV12 ND09716 transformed cell line human CVCL_EV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181735 CVCL_F712 TY08 conditionally immortalized cell line human CVCL_F712 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; microvascular endothelium. Unspecified Characteristics: Exhibits a robust proliferation at the permissive temperature of 33 Celsius Cell growth is arrested at 37 Celsius (PubMed=20458752).; Characteristics: These cells do not grow beyond the 16th to 18th passages, even under the permissive temperature (DOI=10.1111/cen3.12001) Doubling time: ~3 days (PubMed=20458752) 21181736 CVCL_F711 C9 transformed cell line CVCL_F711 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain. Unspecified Doubling time: ~24 hours (PubMed=17049468) 21181737 CVCL_EV11 ND09691 transformed cell line human CVCL_EV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181738 CVCL_F729 LIE transformed cell line human CVCL_F729 HLA typing: A*02,11; B*27:06,51; C*03:04,14; DPB1*13:01,28:01 (IPD-IMGT/HLA=10987) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181739 CVCL_EV29 ND09861 transformed cell line human CVCL_EV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181740 CVCL_EV28 ND09857 transformed cell line human CVCL_EV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181741 CVCL_F728 T560.2.G4 cancer cell line house mouse CVCL_F728 CL:0000010 Breed/subspecies: B10 x B10.H-2aH-4b. 21181742 CVCL_EV27 ND09830 transformed cell line human CVCL_EV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181743 CVCL_F727 T560.2.F7 cancer cell line house mouse CVCL_F727 CL:0000010 Breed/subspecies: B10 x B10.H-2aH-4b. 21181744 CVCL_EV26 ND09806 transformed cell line human CVCL_EV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181745 CVCL_F726 T560.2 cancer cell line house mouse CVCL_F726 CL:0000010 Breed/subspecies: B10 x B10.H-2aH-4b. 21181746 CVCL_F721 LB96-SAR transformed cell line human CVCL_F721 HLA typing: B*35:01,38:01:01; C*04:01 (IPD-IMGT/HLA=10968) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181747 CVCL_EV21 ND09778 transformed cell line human CVCL_EV21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181748 CVCL_EV20 ND09777 transformed cell line human CVCL_EV20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181749 CVCL_F720 TC106 transformed cell line human CVCL_F720 HLA typing: A*24:02,32:01; B*44:03,51:01; C*14:02:01,16:01:01; DRB1*07,15 (IPD-IMGT/HLA=11433) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181750 CVCL_EV25 ND09791 transformed cell line human CVCL_EV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181751 CVCL_F725 T560.1 cancer cell line house mouse CVCL_F725 CL:0000010 Breed/subspecies: B10 x B10.H-2aH-4b. 21181752 CVCL_EV24 ND09789 transformed cell line human CVCL_EV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181753 CVCL_F724 T560 cancer cell line house mouse CVCL_F724 CL:0000010 Breed/subspecies: B10 x B10.H-2aH-4b. 21181754 CVCL_EV23 ND09784 transformed cell line human CVCL_EV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181755 CVCL_F723 SLUGEO transformed cell line human CVCL_F723 HLA typing: A*02:13,11:01; B*35,44:02; C*04,05:01; DPB1*02:01:02,11:01:01 (IPD-IMGT/HLA=11392) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181756 CVCL_F722 LEE743 transformed cell line human CVCL_F722 HLA typing: B*15:11:01 (IPD-IMGT/HLA=10980) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21181757 CVCL_EV22 ND09779 transformed cell line human CVCL_EV22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181758 CVCL_F707 Gsn-1 transformed cell line CVCL_F707 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; cerebral cortex. Unspecified Group: Reptilian cell line 21181759 CVCL_EV07 ND09671 transformed cell line human CVCL_EV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181760 CVCL_EV06 ND09660 transformed cell line human CVCL_EV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181761 CVCL_F706 tsAM5NE conditionally immortalized cell line house mouse CVCL_F706 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; medulla Cell type=Chromaffin cell.; Breed/subspecies: C57BL/6J SV40-tsA58 transgenic. Unspecified 21181762 CVCL_F705 EnCL-1 transformed cell line CVCL_F705 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; corpus luteum Cell type=Endothelial cell.. Female 21181763 CVCL_EV05 ND09659 transformed cell line human CVCL_EV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181764 CVCL_F704 G-1410 transformed cell line pig CVCL_F704 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Female 21181765 CVCL_EV04 ND09650 transformed cell line human CVCL_EV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181766 CVCL_F709 FBBC-1 transformed cell line CVCL_F709 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain. Unspecified Doubling time: ~24 hours (PubMed=19032985) 21181767 CVCL_EV09 ND09676 transformed cell line human CVCL_EV09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181768 CVCL_F708 Gsn-3 transformed cell line CVCL_F708 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; cerebral cortex. Unspecified Group: Reptilian cell line 21181769 CVCL_EV08 ND09672 transformed cell line human CVCL_EV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181770 CVCL_EV03 ND09649 transformed cell line human CVCL_EV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181771 CVCL_F703 T-YFP-SF1 transformed cell line CVCL_F703 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Breed/subspecies: Asiaeorientalis. Male Doubling time: 27.27 hours (in 15% FBS), 29.4 hours (in 10% FBS) (PubMed=21959845) Group: Endangered species/breed cell line; Group: Cetacean cell line 21181772 CVCL_EV02 ND09616 transformed cell line human CVCL_EV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181773 CVCL_F702 YFP-SF1 finite cell line CVCL_F702 CL:0000010 Breed/subspecies: Asiaeorientalis. Male Doubling time: 31.45 hours (at 7th passage), 50.24 hours (at 20th passage) (PubMed=21959845) Group: Endangered species/breed cell line; Group: Cetacean cell line 21181774 CVCL_F701 cdLEC transformed cell line dog CVCL_F701 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.; Breed/subspecies: Wire Fox Terrier. Male 21181775 CVCL_EV01 ND09613 transformed cell line human CVCL_EV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181776 CVCL_F700 FH-BNB conditionally immortalized cell line human CVCL_F700 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Peripheral nervous system; sciatic nerve Cell type=Microvascular endothelial cell.. Female Characteristics: At the non-permissive temperature (37 Celsius) the cells stop growing and die after 7 days 21181777 CVCL_EV00 ND09612 transformed cell line human CVCL_EV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181778 CVCL_4C89 HQ03077 transformed cell line human CVCL_4C89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181779 CVCL_4C88 HQ03076 transformed cell line human CVCL_4C88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181780 CVCL_4C87 HQ03075 transformed cell line human CVCL_4C87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181781 CVCL_4C86 HQ03074 transformed cell line human CVCL_4C86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181782 CVCL_4C81 HQ03069 transformed cell line human CVCL_4C81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181783 CVCL_4C80 HQ03067 transformed cell line human CVCL_4C80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181784 CVCL_4C85 HQ03073 transformed cell line human CVCL_4C85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181785 CVCL_4C84 HQ03072 transformed cell line human CVCL_4C84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181786 CVCL_4C83 HQ03071 transformed cell line human CVCL_4C83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181787 CVCL_4C82 HQ03070 transformed cell line human CVCL_4C82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181788 CVCL_4C99 HQ03093 transformed cell line human CVCL_4C99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181789 CVCL_4C98 HQ03092 transformed cell line human CVCL_4C98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181790 CVCL_4C97 HQ03090 transformed cell line human CVCL_4C97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181791 CVCL_4C92 HQ03082 transformed cell line human CVCL_4C92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181792 CVCL_4C91 HQ03080 transformed cell line human CVCL_4C91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181793 CVCL_4C90 HQ03078 transformed cell line human CVCL_4C90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181794 CVCL_4C96 HQ03088 transformed cell line human CVCL_4C96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181795 CVCL_4C95 HQ03086 transformed cell line human CVCL_4C95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181796 CVCL_4C94 HQ03085 transformed cell line human CVCL_4C94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181797 CVCL_4C93 HQ03084 transformed cell line human CVCL_4C93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181798 CVCL_EV98 ND10469 transformed cell line human CVCL_EV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181799 CVCL_F798 TSHR-T3-365 hybridoma house mouse CVCL_F798 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16473; Human TSHR. 21181800 CVCL_EV97 ND10468 transformed cell line human CVCL_EV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181801 CVCL_F797 TSHR-R5T-44 hybridoma house mouse CVCL_F797 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16473; Human TSHR. 21181802 CVCL_EV96 ND10463 transformed cell line human CVCL_EV96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181803 CVCL_F796 TSHR-R5T-34 hybridoma house mouse CVCL_F796 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16473; Human TSHR. 21181804 CVCL_EV95 ND10462 transformed cell line human CVCL_EV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181805 CVCL_F795 TS2/9.1.4.3 hybridoma house mouse CVCL_F795 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19256; Human CD58. 21181806 CVCL_EV99 ND10470 transformed cell line human CVCL_EV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181807 CVCL_F799 TSHR-T5-51 hybridoma house mouse CVCL_F799 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16473; Human TSHR. 21181808 CVCL_EV90 ND10420 transformed cell line human CVCL_EV90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181809 CVCL_F790 TS1/22.1.1.13 hybridoma house mouse CVCL_F790 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20701; Human ITGAL/CD11a. 21181810 CVCL_NP29 BayGenomics ES cell line RRR615 embryonic stem cell house mouse CVCL_NP29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99211; Zfx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181811 CVCL_NP28 BayGenomics ES cell line RRR611 embryonic stem cell house mouse CVCL_NP28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444218; Ahdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181812 CVCL_EV94 ND10447 transformed cell line human CVCL_EV94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181813 CVCL_F794 TS2/7.1.1 hybridoma house mouse CVCL_F794 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P56199; Human ITGA1/CD49a. 21181814 CVCL_NP27 BayGenomics ES cell line RRR610 embryonic stem cell house mouse CVCL_NP27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107901; Nfyc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181815 CVCL_EV93 ND10446 transformed cell line human CVCL_EV93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181816 CVCL_F793 TS2/4.1.1 hybridoma house mouse CVCL_F793 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20701; Human ITGAL/CD11a. 21181817 CVCL_NP26 BayGenomics ES cell line RRR609 embryonic stem cell house mouse CVCL_NP26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181818 CVCL_EV92 ND10444 transformed cell line human CVCL_EV92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181819 CVCL_F792 TS2/18.1.1 hybridoma house mouse CVCL_F792 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06729; Human CD2. 21181820 CVCL_NP25 BayGenomics ES cell line RRR608 embryonic stem cell house mouse CVCL_NP25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446977; Kif18a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181821 CVCL_EV91 ND10427 transformed cell line human CVCL_EV91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181822 CVCL_F791 TS2/16.2.1 hybridoma house mouse CVCL_F791 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. 21181823 CVCL_NP24 BayGenomics ES cell line RRR607 embryonic stem cell house mouse CVCL_NP24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181824 CVCL_NP23 BayGenomics ES cell line RRR606 embryonic stem cell house mouse CVCL_NP23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147987; Pcyt1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181825 CVCL_NP22 BayGenomics ES cell line RRR602 embryonic stem cell house mouse CVCL_NP22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3525201; Mdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181826 CVCL_NP21 BayGenomics ES cell line RRR601 embryonic stem cell house mouse CVCL_NP21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3590652; Txlng Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181827 CVCL_NP20 BayGenomics ES cell line RRR600 embryonic stem cell house mouse CVCL_NP20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384756; Phf21a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181828 CVCL_NP39 BayGenomics ES cell line RRR636 embryonic stem cell house mouse CVCL_NP39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334417; Grpel1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181829 CVCL_NP38 BayGenomics ES cell line RRR634 embryonic stem cell house mouse CVCL_NP38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102467; Ptpn14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181830 CVCL_NP37 BayGenomics ES cell line RRR633 embryonic stem cell house mouse CVCL_NP37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855693; Nap1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181831 CVCL_NP36 BayGenomics ES cell line RRR632 embryonic stem cell house mouse CVCL_NP36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96412; Ide Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181832 CVCL_NP35 BayGenomics ES cell line RRR629 embryonic stem cell house mouse CVCL_NP35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918685; Arhgap21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181833 CVCL_NP34 BayGenomics ES cell line RRR627 embryonic stem cell house mouse CVCL_NP34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104810; Plaa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181834 CVCL_NP33 BayGenomics ES cell line RRR624 embryonic stem cell house mouse CVCL_NP33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201691; Rnf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181835 CVCL_NP32 BayGenomics ES cell line RRR622 embryonic stem cell house mouse CVCL_NP32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181836 CVCL_NP31 BayGenomics ES cell line RRR620 embryonic stem cell house mouse CVCL_NP31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442988; Arfgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181837 CVCL_NP30 BayGenomics ES cell line RRR617 embryonic stem cell house mouse CVCL_NP30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3800296; Gm9631 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181838 CVCL_EV76 ND10298 transformed cell line human CVCL_EV76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181839 CVCL_F776 TA99 hybridoma house mouse CVCL_F776 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P17643; Human TYRP1 (Note=Also reacts with mouse). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8704; Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 413 21181840 CVCL_EV75 ND10297 transformed cell line human CVCL_EV75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181841 CVCL_F775 T84.66A3.1A.1F2 hybridoma house mouse CVCL_F775 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM1/CD66e. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8747 21181842 CVCL_EV74 ND10277 transformed cell line human CVCL_EV74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181843 CVCL_F774 T529-15D3-2E5-4G12-1 hybridoma house mouse CVCL_F774 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10501 21181844 CVCL_EV73 ND10276 transformed cell line human CVCL_EV73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181845 CVCL_F773 T529-15D3-18-1A3-1B7 hybridoma house mouse CVCL_F773 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10500 21181846 CVCL_EV79 ND10341 transformed cell line human CVCL_EV79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181847 CVCL_F779 TD.1 hybridoma house mouse CVCL_F779 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P49951; Bovine CLTC (Note=Also reacts with human). 21181848 CVCL_EV78 ND10334 transformed cell line human CVCL_EV78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181849 CVCL_F778 TB 28-2 hybridoma house mouse CVCL_F778 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Ig kappa light chains. 21181850 CVCL_EV77 ND10332 transformed cell line human CVCL_EV77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181851 CVCL_F777 TA-1 [Mouse hybridoma against human ERBB2] hybridoma house mouse CVCL_F777 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10206 21181852 CVCL_NP09 BayGenomics ES cell line RRR569 embryonic stem cell house mouse CVCL_NP09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181853 CVCL_NP08 BayGenomics ES cell line RRR568 embryonic stem cell house mouse CVCL_NP08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106264; Trim36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181854 CVCL_NP07 BayGenomics ES cell line RRR565 embryonic stem cell house mouse CVCL_NP07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341872; Tjp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181855 CVCL_F772 443-15D3-2F12 hybridoma house mouse CVCL_F772 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08183; Human ABCB1/CD243. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11342; Registration: Chiron Master Culture Collection; CMCC 10748 (CMCC #10748) 21181856 CVCL_NP06 BayGenomics ES cell line RRR564 embryonic stem cell house mouse CVCL_NP06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888677; Gigyf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181857 CVCL_EV72 ND10275 transformed cell line human CVCL_EV72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181858 CVCL_NP05 BayGenomics ES cell line RRR563 embryonic stem cell house mouse CVCL_NP05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349394; Map4k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181859 CVCL_EV71 ND10274 transformed cell line human CVCL_EV71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181860 CVCL_F771 T4 Clone 5 (10-0101, 0062-83) hybridoma house mouse CVCL_F771 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:18332; L-thyroxine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8500 21181861 CVCL_NP04 BayGenomics ES cell line RRR557 embryonic stem cell house mouse CVCL_NP04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3646776; Gm4779 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181862 CVCL_EV70 ND10273 transformed cell line human CVCL_EV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181863 CVCL_F770 T3-3A1 hybridoma house mouse CVCL_F770 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09564; Human CD7. 21181864 CVCL_NP03 BayGenomics ES cell line RRR552 embryonic stem cell house mouse CVCL_NP03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181865 CVCL_NP02 BayGenomics ES cell line RRR550 embryonic stem cell house mouse CVCL_NP02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2183436; Nrbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181866 CVCL_NP01 BayGenomics ES cell line RRR548 embryonic stem cell house mouse CVCL_NP01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181867 CVCL_NP00 BayGenomics ES cell line RRR547 embryonic stem cell house mouse CVCL_NP00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181868 CVCL_EV87 ND10408 transformed cell line human CVCL_EV87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181869 CVCL_F787 TM1 hybridoma house mouse CVCL_F787 CL:0000010 Monoclonal antibody isotype: IgM. 21181870 CVCL_EV86 ND10399 transformed cell line human CVCL_EV86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181871 CVCL_F786 TE8 hybridoma house mouse CVCL_F786 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human Hassall's corpuscles. 21181872 CVCL_EV85 ND10393 transformed cell line human CVCL_EV85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181873 CVCL_F785 TE7 hybridoma house mouse CVCL_F785 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human thymic stroma antigen. 21181874 CVCL_EV84 ND10380 transformed cell line human CVCL_EV84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181875 CVCL_F784 TE4 [Mouse hybridoma against human thymic antigen] hybridoma house mouse CVCL_F784 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human thymic endocrine epithelium antigen. 21181876 CVCL_EV89 ND10417 transformed cell line human CVCL_EV89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181877 CVCL_F789 TS1/18.1.2.11 hybridoma house mouse CVCL_F789 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 21181878 CVCL_EV88 ND10409 transformed cell line human CVCL_EV88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181879 CVCL_F788 TS 106 hybridoma house mouse CVCL_F788 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04818; Human TYMS. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12497 21181880 CVCL_NP19 BayGenomics ES cell line RRR599 embryonic stem cell house mouse CVCL_NP19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181881 CVCL_NP18 BayGenomics ES cell line RRR598 embryonic stem cell house mouse CVCL_NP18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922855; Kdm5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181882 CVCL_NP17 BayGenomics ES cell line RRR593 embryonic stem cell house mouse CVCL_NP17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914295; Riok2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181883 CVCL_EV83 ND10378 transformed cell line human CVCL_EV83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181884 CVCL_F783 TE3 [Mouse hybridoma against human thymic antigen] hybridoma house mouse CVCL_F783 CL:0000010 Monoclonal antibody isotype: IgG2; Monoclonal antibody target: Human thymic cortical epithelium antigen. 21181885 CVCL_NP16 BayGenomics ES cell line RRR592 embryonic stem cell house mouse CVCL_NP16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442988; Arfgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181886 CVCL_EV82 ND10365 transformed cell line human CVCL_EV82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181887 CVCL_F782 TE19 hybridoma house mouse CVCL_F782 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human Hassall's corpuscles. 21181888 CVCL_NP15 BayGenomics ES cell line RRR590 embryonic stem cell house mouse CVCL_NP15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446126; Phf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181889 CVCL_EV81 ND10349 transformed cell line human CVCL_EV81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181890 CVCL_F781 TE16 hybridoma house mouse CVCL_F781 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human Hassall's corpuscles. 21181891 CVCL_NP14 BayGenomics ES cell line RRR587 embryonic stem cell house mouse CVCL_NP14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888526; Xpo4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181892 CVCL_EV80 ND10345 transformed cell line human CVCL_EV80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181893 CVCL_F780 TE15 hybridoma house mouse CVCL_F780 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human Hassall's corpuscles. 21181894 CVCL_NP13 BayGenomics ES cell line RRR577 embryonic stem cell house mouse CVCL_NP13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181895 CVCL_NP12 BayGenomics ES cell line RRR576 embryonic stem cell house mouse CVCL_NP12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181896 CVCL_NP11 BayGenomics ES cell line RRR573 embryonic stem cell house mouse CVCL_NP11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105307; Ptpn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181897 CVCL_NP10 BayGenomics ES cell line RRR570 embryonic stem cell house mouse CVCL_NP10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21181898 CVCL_F759 HAA58OD-8C conditionally immortalized cell line human CVCL_F759 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Amnion Cell type=Epithelial.. Unspecified Characteristics: At the permissive temperature (33 Celsius) the cells exhibits a transformed phenotype with low levels of expression of PSG1, CGA and CGB At the non-permissive temperature (39.5 Celsius) exhibits a differentiated phenotype with increased expression of PSG1, CGA and CGB. 21181899 CVCL_EV59 ND10227 transformed cell line human CVCL_EV59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181900 CVCL_EV54 ND10099 transformed cell line human CVCL_EV54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181901 CVCL_F754 NP39E6/E7 transformed cell line human CVCL_F754 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Pharynx; nasopharynx. Unspecified 21181902 CVCL_EV53 ND10057 transformed cell line human CVCL_EV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181903 CVCL_F753 Z310 transformed cell line Norway rat CVCL_F753 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. Unspecified 21181904 CVCL_F752 HYKO6 transformed cell line house mouse CVCL_F752 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1340806; Parp1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart Cell type=Cardiac endothelial cell.. Unspecified 21181905 CVCL_EV52 ND10040 transformed cell line human CVCL_EV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181906 CVCL_F751 ES-8047 2-1 cancer cell line house mouse CVCL_F751 CL:0000010 Breed/subspecies: C3H/He. Male 21181907 CVCL_EV51 ND10021 transformed cell line human CVCL_EV51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181908 CVCL_F758 56/10 A1 transformed cell line human CVCL_F758 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerular visceral epithelium. Unspecified Doubling time: 30 hours (PubMed=1662315) 21181909 CVCL_EV58 ND10189 transformed cell line human CVCL_EV58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181910 CVCL_F757 HOB-02-C1 conditionally immortalized cell line human CVCL_F757 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone Cell type=Osteoblast.. Male Characteristics: Proliferates at the permissive temperature (34 Celsius) Stop dividing at the restrictive temperature (40 Celsius). Doubling time: ~2 days (PubMed=8725178) 21181911 CVCL_EV57 ND10138 transformed cell line human CVCL_EV57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181912 CVCL_EV56 ND10119 transformed cell line human CVCL_EV56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181913 CVCL_F756 SLET-1 transformed cell line CVCL_F756 CL:0000010 Transformant: Simian virus 40 (SV40) [776](NCBI-Taxonomy; 1891767); Derived from sampling site: Mesenteric lymphatic vessel Cell type=Endothelial cell.. Unspecified 21181914 CVCL_EV55 ND10107 transformed cell line human CVCL_EV55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181915 CVCL_F755 NP69SV40T transformed cell line human CVCL_F755 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pharynx; nasopharynx. Discontinued: ABM; T0634; probable Male Doubling time: 31-34 hours (ABM) 21181916 CVCL_F750 ES-8040 20-2 cancer cell line house mouse CVCL_F750 CL:0000010 Breed/subspecies: C3H/He. Male 21181917 CVCL_EV50 ND10020 transformed cell line human CVCL_EV50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181918 CVCL_EV65 ND10259 transformed cell line human CVCL_EV65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181919 CVCL_F765 SM27-1045 hybridoma house mouse CVCL_F765 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human stem and progenitor cells marker EM10. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11917 21181920 CVCL_EV64 ND10249 transformed cell line human CVCL_EV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181921 CVCL_F764 SH-34 hybridoma house mouse CVCL_F764 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:27938; Asialo-GM1 ganglioside. 21181922 CVCL_F763 Ch-8-OA transformed cell line human CVCL_F763 CL:0000010 Population: Japanese; Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Femoral head; cartilage. Unspecified 21181923 CVCL_EV63 ND10240 transformed cell line human CVCL_EV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181924 CVCL_F762 J3K spontaneously immortalized cell line CVCL_F762 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 17 hours (PubMed=12513117) Group: Non-human primate cell line 21181925 CVCL_EV62 ND10233 transformed cell line human CVCL_EV62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181926 CVCL_EV69 ND10272 transformed cell line human CVCL_EV69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181927 CVCL_F769 T11D7e2 hybridoma house mouse CVCL_F769 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90 (allotype 1.1). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21181928 CVCL_EV68 ND10268 transformed cell line human CVCL_EV68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181929 CVCL_F768 SV63 hybridoma house mouse CVCL_F768 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human choriocarcinoma tumor cell 68 kDa glycoprotein antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8766 21181930 CVCL_EV67 ND10266 transformed cell line human CVCL_EV67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181931 CVCL_F767 S-S.3 hybridoma house mouse CVCL_F767 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21181932 CVCL_EV66 ND10265 transformed cell line human CVCL_EV66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181933 CVCL_F766 S-S.1 hybridoma house mouse CVCL_F766 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21181934 CVCL_EV61 ND10232 transformed cell line human CVCL_EV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181935 CVCL_F761 RTC4 transformed cell line Norway rat CVCL_F761 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T155c](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon; Breed/subspecies: Sprague Dawley. Unspecified 21181936 CVCL_EV60 ND10231 transformed cell line human CVCL_EV60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181937 CVCL_F760 RTC3 transformed cell line Norway rat CVCL_F760 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T155c](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon; Breed/subspecies: Sprague Dawley. Unspecified 21181938 CVCL_F739 L-M(TK-)1D transformed cell line house mouse CVCL_F739 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21181939 CVCL_EV39 ND09950 transformed cell line human CVCL_EV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181940 CVCL_EV38 ND09944 transformed cell line human CVCL_EV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181941 CVCL_F738 SGS/3A cancer cell line Norway rat CVCL_F738 CL:0000010 Breed/subspecies: Galliera. 21181942 CVCL_F737 L142 transformed cell line pig CVCL_F737 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21181943 CVCL_EV37 ND09939 transformed cell line human CVCL_EV37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181944 CVCL_F732 B6.1.1 embryonic stem cell house mouse CVCL_F732 CL:0000010 Breed/subspecies: C57BL/6. Unspecified 21181945 CVCL_EV32 ND09880 transformed cell line human CVCL_EV32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181946 CVCL_EV31 ND09879 transformed cell line human CVCL_EV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181947 CVCL_F731 SCIT-C8 transformed cell line Norway rat CVCL_F731 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Wistar. Male 21181948 CVCL_F730 FCCM-9 cancer cell line human CVCL_F730 CL:0000010 Unspecified Doubling time: 26.7 +- 2.6 hours (PubMed=8095141). 21181949 CVCL_EV30 ND09877 transformed cell line human CVCL_EV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181950 CVCL_EV36 ND09891 transformed cell line human CVCL_EV36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181951 CVCL_F736 TS/A cancer cell line house mouse CVCL_F736 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg270His (c.809G>A); Zygosity=Unspecified (PubMed=11263530) Karyotypic information: Triploid karyotype (PubMed=15004469); Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cAnNCrlBR. Female Characteristics: Metastatic When injected subcutaneously into syngeneic BALB/c mice, give rise to local tumors rapidly disseminating to the lungs. 21181952 CVCL_EV35 ND09888 transformed cell line human CVCL_EV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181953 CVCL_F735 P815-X2 cancer cell line house mouse CVCL_F735 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Male 21181954 CVCL_F734 FNB6 hTERT telomerase immortalized cell line human CVCL_F734 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Discontinued: Ximbio; 151634; probable Unspecified 21181955 CVCL_EV34 ND09887 transformed cell line human CVCL_EV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181956 CVCL_EV33 ND09883 transformed cell line human CVCL_EV33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181957 CVCL_F749 B1 [Pig] transformed cell line pig CVCL_F749 CL:0000010 Transformant: Porcine endogenous retrovirus Tsukuba-1(NCBI-Taxonomy; 71581); Derived from sampling site: Peripheral blood Cell type=B-cell.; Breed/subspecies: Miniature boar (d/d haplotype). Male 21181958 CVCL_EV49 ND10015 transformed cell line human CVCL_EV49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181959 CVCL_EV48 ND10012 transformed cell line human CVCL_EV48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181960 CVCL_F748 Shimozuma-1 cancer cell line pig CVCL_F748 CL:0000010 Virology: Infected by porcine retrovirus Tsukuba-1. 21181961 CVCL_EV43 ND09963 transformed cell line human CVCL_EV43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181962 CVCL_F743 Py 1-18 MuLV transformed cell line house mouse CVCL_F743 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV). 21181963 CVCL_F742 LEK finite cell line CVCL_F742 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21181964 CVCL_EV42 ND09962 transformed cell line human CVCL_EV42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181965 CVCL_F741 EPI cancer cell line Norway rat CVCL_F741 CL:0000010 Breed/subspecies: Fischer 344. Female 21181966 CVCL_EV41 ND09961 transformed cell line human CVCL_EV41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181967 CVCL_EV40 ND09957 transformed cell line human CVCL_EV40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21181968 CVCL_F740 TR-Ag-9-HPRT- undefined cell line type CVCL_F740 CL:0000010 Derived from sampling site: Fetal trachea. Unspecified 21181969 CVCL_F747 BWTG3 cancer cell line house mouse CVCL_F747 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Liver; Breed/subspecies: C57L/J. Characteristics: Established from a transplantable mouse hepatoma BW7756 21181970 CVCL_EV47 ND10009 transformed cell line human CVCL_EV47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181971 CVCL_F746 CO-MZ-6 cancer cell line human CVCL_F746 CL:0000010 Derived from metastatic site: Ovary. Female Doubling time: 11 hours (PubMed=7510115) 21181972 CVCL_EV46 ND09989 transformed cell line human CVCL_EV46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181973 CVCL_F745 CO-MZ-5 cancer cell line human CVCL_F745 CL:0000010 Derived from metastatic site: Ovary. Female Doubling time: 17 days (PubMed=7510115) 21181974 CVCL_EV45 ND09985 transformed cell line human CVCL_EV45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181975 CVCL_EV44 ND09965 transformed cell line human CVCL_EV44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181976 CVCL_F744 STF1-169 transformed cell line human CVCL_F744 CL:0000010 Sequence variation: Mutation; HGNC; 44; TAP2; Simple; p.Arg273Ter (c.817C>T) (R253*); ClinVar=VCV000013727; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Moroccan; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21181977 CVCL_4E21 GM50170 transformed cell line human CVCL_4E21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181978 CVCL_4E20 GM50146 transformed cell line human CVCL_4E20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181979 CVCL_4E25 GM01912 finite cell line human CVCL_4E25 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21181980 CVCL_4E24 GM00844 finite cell line human CVCL_4E24 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21181981 CVCL_4E23 GM00843 finite cell line human CVCL_4E23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21181982 CVCL_4E22 GM50189 transformed cell line human CVCL_4E22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181983 CVCL_4E29 ICRmt-1 embryonic stem cell house mouse CVCL_4E29 CL:0000010 Discontinued: RCB; RCB2196; true. Unspecified Caution: Not from strain ICR as originally assigned (DOI=10.4051/ibc.2010.2.4.0014) 21181984 CVCL_4E28 FVB-2 embryonic stem cell house mouse CVCL_4E28 CL:0000010 Discontinued: RCB; RCB2195; true. Unspecified Caution: Not from strain FVB as originally assigned (DOI=10.4051/ibc.2010.2.4.0014) 21181985 CVCL_4E27 GM00782 finite cell line human CVCL_4E27 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21181986 CVCL_4E26 GM01913 transformed cell line human CVCL_4E26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21181987 CVCL_WK73 MCF-7 R27 cancer cell line human CVCL_WK73 HLA typing: A*02:01; B*44:02; C*05:01 (PubMed=9023415) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21181988 CVCL_WK72 45 M spontaneously immortalized cell line CVCL_WK72 CL:0000010 Unspecified Group: Insect cell line. 21181989 CVCL_WK71 E-Aldox-n1 spontaneously immortalized cell line fruit fly CVCL_WK71 CL:0000010 Unspecified Group: Insect cell line. 21181990 CVCL_WK70 IBT-EP 1 spontaneously immortalized cell line CVCL_WK70 CL:0000010 Unspecified Group: Insect cell line. 21181991 CVCL_WK77 KE-6 cancer cell line human CVCL_WK77 CL:0000010 Population: Japanese. Unspecified 21181992 CVCL_WK76 KE-5 cancer cell line human CVCL_WK76 CL:0000010 Population: Japanese. Unspecified 21181993 CVCL_WK75 KE-10 cancer cell line human CVCL_WK75 CL:0000010 Population: Japanese. 21181994 CVCL_WK74 YT803 cancer cell line human CVCL_WK74 HLA typing: A*31:01,33:02; B*44:03:01,51:01; C*14:02,14:03 (PubMed=9023415). From: Nomoto K.; Kyushu University; Fukuoka; Japan CL:0000010 Population: Japanese Unspecified 21181995 CVCL_WK79 KE-8 cancer cell line human CVCL_WK79 CL:0000010 Population: Japanese. Unspecified 21181996 CVCL_WK78 KE-7 cancer cell line human CVCL_WK78 CL:0000010 Population: Japanese. Unspecified 21181997 CVCL_4E32 BALB/3T3-APR-MUC1 cl.16 undefined cell line type house mouse CVCL_4E32 CL:0000010 Transfected with: HGNC; 7508; MUC1 Discontinued: RCB; RCB2632; true; Discontinued: TKG; TKG 0566; true. Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (DOI=10.4051/ibc.2010.2.4.0014). It is therefore not a BALB/3T3 derivative. 21181998 CVCL_4E31 UV male 1d cancer cell line house mouse CVCL_4E31 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6 x BALB/c. Male 21181999 CVCL_4E30 UV female 1A cancer cell line house mouse CVCL_4E30 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6 x BALB/c. Female 21182000 CVCL_4E36 UV.B6-5.1 transformed cell line house mouse CVCL_4E36 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. 21182001 CVCL_4E35 UV.B6-4.1 transformed cell line house mouse CVCL_4E35 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. 21182002 CVCL_4E34 UV.B6-2.1A transformed cell line house mouse CVCL_4E34 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. 21182003 CVCL_4E33 UV.B6-1.1 transformed cell line house mouse CVCL_4E33 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. 21182004 CVCL_4E39 UV.BAL-13.1 transformed cell line house mouse CVCL_4E39 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182005 CVCL_4E38 UV.BAL-12.1 transformed cell line house mouse CVCL_4E38 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182006 CVCL_4E37 UV.BAL-1.1 transformed cell line house mouse CVCL_4E37 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182007 CVCL_WK62 RCFBF finite cell line CVCL_WK62 CL:0000010 Derived from sampling site: Eye; cornea. 21182008 CVCL_WK61 RCBBF finite cell line CVCL_WK61 CL:0000010 Derived from sampling site: Eye; cornea Cell type=Fibroblast.. 21182009 CVCL_WK60 ME [Human hepatocellular carcinoma] cancer cell line human CVCL_WK60 HLA typing: A*24:02,26:03; B*54,62; C*01,03 (PubMed=9178645). CL:0000010 Population: Japanese 21182010 CVCL_WK66 KUR-62 cancer cell line human CVCL_WK66 CL:0000010 Population: Japanese. Unspecified 21182011 CVCL_WK65 KUR-21 cancer cell line human CVCL_WK65 HLA typing: A*02:01 (PubMed=7671230) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21182012 CVCL_WK64 KUR-20 cancer cell line human CVCL_WK64 HLA typing: A*02:01,02:11 (PubMed=7671230); HLA typing: A*02:01,02:10 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21182013 CVCL_WK63 KUR-11 cancer cell line human CVCL_WK63 HLA typing: A*24:02,33:03 (PubMed=7671230); HLA typing: A*24:02,33:02 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21182014 CVCL_WK69 BTYH-3 finite cell line CVCL_WK69 CL:0000010 Group: Endangered species/breed cell line; Group: Non-human primate cell line. 21182015 CVCL_WK68 BTYH-2 finite cell line CVCL_WK68 CL:0000010 Group: Endangered species/breed cell line; Group: Non-human primate cell line. 21182016 CVCL_WK67 BTYH-1 finite cell line CVCL_WK67 CL:0000010 Group: Endangered species/breed cell line; Group: Non-human primate cell line. 21182017 CVCL_4E03 GM10457 transformed cell line human CVCL_4E03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182018 CVCL_4E02 GM10284 transformed cell line human CVCL_4E02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182019 CVCL_4E01 GM10173 transformed cell line human CVCL_4E01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182020 CVCL_4E00 GM09867 transformed cell line human CVCL_4E00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM09867; probable Female 21182021 CVCL_4E07 GM11510 transformed cell line human CVCL_4E07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182022 CVCL_4E06 GM11338 finite cell line human CVCL_4E06 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX dic,r(21) [36]; 45,XX,-21 [10]; 46,XX,r(21) [4] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21182023 CVCL_4E05 GM10934 finite cell line human CVCL_4E05 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Omics: CNV analysis Female 21182024 CVCL_4E04 GM10763 transformed cell line human CVCL_4E04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182025 CVCL_4E09 GM11675 transformed cell line human CVCL_4E09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182026 CVCL_4E08 GM11511 transformed cell line human CVCL_4E08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182027 CVCL_WK51 SES-Bm-e 21-12 spontaneously immortalized cell line CVCL_WK51 CL:0000010 Breed/subspecies: e21. Unspecified Doubling time: 2-3 days (PubMed=3467322) Group: Insect cell line 21182028 CVCL_WK50 iLite VEGF Assay Ready Cells transformed cell line human CVCL_WK50 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Genetically engineered and optimized to respond to VEGF with specific, proportional expression of firefly luciferase (Svar Life Science) 21182029 CVCL_WK55 YMMK-1 cancer cell line human CVCL_WK55 CL:0000010 Population: Japanese. Female 21182030 CVCL_WK54 YPK-4 cancer cell line human CVCL_WK54 HLA typing: A*10,26; B*40; C*03 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21182031 CVCL_WK53 YPK-3 cancer cell line human CVCL_WK53 HLA typing: A*01,02; B*13,48; C*03,08 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21182032 CVCL_WK52 YPK-2 cancer cell line human CVCL_WK52 HLA typing: A*02,24; B*03,39; C*12 (PubMed=18575732). CL:0000010 Population: Japanese Unspecified 21182033 CVCL_WK59 SSTW-9 cancer cell line human CVCL_WK59 HLA typing: A*24:02,26:01; B*15:01,46:01; C*01:02,03:03 (PubMed=9023415). CL:0000010 Population: Japanese 21182034 CVCL_WK58 RMA-S-A*2402 cancer cell line house mouse CVCL_WK58 CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*24:02); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938); Breed/subspecies: C57BL/6. 21182035 CVCL_WK57 MAMIYA-HLAG cancer cell line human CVCL_WK57 CL:0000010 Transfected with: HGNC; 4964; HLA-G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Population: Japanese 21182036 CVCL_WK56 MAMIYA cancer cell line human CVCL_WK56 CL:0000010 Population: Japanese. 21182037 CVCL_4E10 GM14157 finite cell line human CVCL_4E10 CL:0000010 Population: Hispanic; Karyotypic information: 47,XX,+r(16).ish r(16)(D16Z1+) [27]; 48,XX,+r(1).ish r(1)(D1Z5+),+r(16).ish r(16)(D16Z1+) [15]; 47,XX,+r(1).ish r(1)(D1Z5+) [2]; 46,XX [6] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21182038 CVCL_4E14 GM15006 transformed cell line human CVCL_4E14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21182039 CVCL_4E13 GM14396 transformed cell line human CVCL_4E13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182040 CVCL_4E12 GM14266 transformed cell line human CVCL_4E12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21182041 CVCL_4E11 GM14217 transformed cell line human CVCL_4E11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182042 CVCL_4E18 GM21075 transformed cell line human CVCL_4E18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182043 CVCL_4E17 GM21074 transformed cell line human CVCL_4E17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21182044 CVCL_4E16 GM20567 transformed cell line human CVCL_4E16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182045 CVCL_4E15 GM17437 transformed cell line human CVCL_4E15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182046 CVCL_4E19 GM21077 transformed cell line human CVCL_4E19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21182047 CVCL_WK40 RU-ASE-IV spontaneously immortalized cell line CVCL_WK40 CL:0000010 Unspecified Group: Insect cell line. 21182048 CVCL_WK44 CWR22Rv1-AR-EK cancer cell line human CVCL_WK44 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Has lost the ability to express full-length AR (FL-AR), but retains that of expressing alternatively spliced forms of the AR termed AR variants (AR-Vs); Characteristics: Using CRISPR/Cas9 a stop codon was introduced downstream of the DNA-binding domain in exon 5 of the AR gene 21182049 CVCL_WK43 iDP6 transformed cell line house mouse CVCL_WK43 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Hair follicle Cell type=Hair follicle dermal papilla cell.; Breed/subspecies: C57BL/6. Unspecified 21182050 CVCL_WK42 SES-Bm-e 21 spontaneously immortalized cell line CVCL_WK42 CL:0000010 Breed/subspecies: e21. Unspecified Doubling time: 2-3 days (CelloPub=CLPUB00498) Group: Insect cell line 21182051 CVCL_WK41 SES-Bm-1 30 spontaneously immortalized cell line CVCL_WK41 CL:0000010 Breed/subspecies: 1 30(pM, Ze, L, q). Unspecified Doubling time: 3-4 days (CelloPub=CLPUB00498) Group: Insect cell line 21182052 CVCL_WK48 Do-11-10 mutant 51 hybridoma house mouse CVCL_WK48 CL:0000010 Characteristics: T-cell hybridoma that has defects in the TCR-mediated apoptotic pathway (reduced death in response to dexamethasone). 21182053 CVCL_WK47 AC5 hybridoma human CVCL_WK47 CL:0000010 Characteristics: T-cell hybridoma Produces MIF.; Monoclonal antibody target: UniProtKB; P00630; Apis mellifera phospholipase A2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10473 21182054 CVCL_WK46 Peng-EBV transformed cell line human CVCL_WK46 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: lncRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21182055 CVCL_WK45 IMEDEAi006-A induced pluripotent stem cell human CVCL_WK45 From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu280Ala (c.839A>C); ClinVar=VCV000018131; Zygosity=Heterozygous (PubMed=31026686) Derived from sampling site: Oral cavity; oral mucosa Cell type=Fibroblast.. Female 21182056 CVCL_WK49 iLite IL-2 Assay Ready Cells cancer cell line CVCL_WK49 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P27652; Renilla-type luciferase Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Characteristics: Genetically engineered and optimized to be responsive to IL2, resulting in a proportional expression of firefly luciferase Normalization of cell counts and serum matrix effects are obtained by a second reporter gene, a Renilla-type luciferase reporter gene construct, under control of a constitutive promoter (Svar Life Science). Group: Bird cell line 21182057 CVCL_NQ92 BayGenomics ES cell line RRS142 embryonic stem cell house mouse CVCL_NQ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2655711; Rbm28 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182058 CVCL_NQ91 BayGenomics ES cell line RRS141 embryonic stem cell house mouse CVCL_NQ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098265; Kif13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182059 CVCL_NQ90 BayGenomics ES cell line RRS136 embryonic stem cell house mouse CVCL_NQ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182060 CVCL_WK33 DFK1 transformed cell line Norway rat CVCL_WK33 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182061 CVCL_WK32 FKAd6 transformed cell line Norway rat CVCL_WK32 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182062 CVCL_WK31 FKAd5 transformed cell line Norway rat CVCL_WK31 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182063 CVCL_WK30 FKAd3 transformed cell line Norway rat CVCL_WK30 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182064 CVCL_NQ89 BayGenomics ES cell line RRS131 embryonic stem cell house mouse CVCL_NQ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182065 CVCL_WK37 CmOv-1 spontaneously immortalized cell line CVCL_WK37 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: ~30 hours (PubMed=5458787) Group: Insect cell line 21182066 CVCL_NQ88 BayGenomics ES cell line RRS126 embryonic stem cell house mouse CVCL_NQ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916188; Aspscr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182067 CVCL_WK36 IBT-EP 2 spontaneously immortalized cell line CVCL_WK36 CL:0000010 Unspecified Group: Insect cell line. 21182068 CVCL_NQ87 BayGenomics ES cell line RRS123 embryonic stem cell house mouse CVCL_NQ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444631; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182069 CVCL_WK35 IPRI-CF-124-2 spontaneously immortalized cell line CVCL_WK35 CL:0000010 Unspecified Group: Insect cell line. 21182070 CVCL_NQ86 BayGenomics ES cell line RRS116 embryonic stem cell house mouse CVCL_NQ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182071 CVCL_WK34 FKAugDNA3 transformed cell line Norway rat CVCL_WK34 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182072 CVCL_NQ85 BayGenomics ES cell line RRS115 embryonic stem cell house mouse CVCL_NQ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444661; Susd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182073 CVCL_NQ84 BayGenomics ES cell line RRS112 embryonic stem cell house mouse CVCL_NQ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916241; Ssu72 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182074 CVCL_NQ83 BayGenomics ES cell line RRS111 embryonic stem cell house mouse CVCL_NQ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353654; Vps26a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182075 CVCL_WK39 CEC CC 228 spontaneously immortalized cell line CVCL_WK39 CL:0000010 Breed/subspecies: J.R.C Ispra.. Unspecified Virology: Infected by Drosophila X virus (DXV) (DOI=10.1016/S0769-2617(81)80057-3) Group: Insect cell line 21182076 CVCL_NQ82 BayGenomics ES cell line RRS110 embryonic stem cell house mouse CVCL_NQ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685541; Wdtc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182077 CVCL_WK38 IPLB-TpE1 spontaneously immortalized cell line CVCL_WK38 CL:0000010 Unspecified Doubling time: 72 hours, at 40th passage (DOI=10.1007/BF02623443). Group: Insect cell line 21182078 CVCL_WK22 CSSi008-A induced pluripotent stem cell human CVCL_WK22 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3033; ATN1; Repeat_expansion; CAG[65] (g.17267CAG[(54-68)]); ClinVar=VCV000590267; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[13] (PubMed=31493762) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182079 CVCL_WK21 CSSi007-A induced pluripotent stem cell human CVCL_WK21 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 21575; AHI1; Simple; p.Arg723Gln (c.2168G>A); ClinVar=VCV000002015; Zygosity=Homozygous (PubMed=31202121) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21182080 CVCL_WK20 HPSI0616i-rurd_3 induced pluripotent stem cell human CVCL_WK20 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182081 CVCL_WK26 HPSI1116i-uacs_3 induced pluripotent stem cell human CVCL_WK26 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; French; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182082 CVCL_NQ99 BayGenomics ES cell line RRS162 embryonic stem cell house mouse CVCL_NQ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916851; Dab2ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182083 CVCL_WK25 KURNDi007-A induced pluripotent stem cell human CVCL_WK25 From: Department of Biotechnology, College of Life Sciences and Biotechnology, Korea University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; c.1240_1253delGGCTACACAGCCCGinsCCGTCC; Zygosity=Hemizygous (PubMed=30921588) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182084 CVCL_NQ98 BayGenomics ES cell line RRS152 embryonic stem cell house mouse CVCL_NQ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108025; Prkar2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182085 CVCL_WK24 HPSI0714i-tosj_4 induced pluripotent stem cell human CVCL_WK24 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182086 CVCL_NQ97 BayGenomics ES cell line RRS151 embryonic stem cell house mouse CVCL_NQ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106583; Rfx2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182087 CVCL_WK23 HPSI0714i-tosj_3 induced pluripotent stem cell human CVCL_WK23 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182088 CVCL_NQ96 BayGenomics ES cell line RRS150 embryonic stem cell house mouse CVCL_NQ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928948; Scamp5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182089 CVCL_NQ95 BayGenomics ES cell line RRS147 embryonic stem cell house mouse CVCL_NQ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860086; Crlf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182090 CVCL_WK29 FKAd1 transformed cell line Norway rat CVCL_WK29 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Unspecified 21182091 CVCL_NQ94 BayGenomics ES cell line RRS144 embryonic stem cell house mouse CVCL_NQ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444451; Rnf214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182092 CVCL_WK28 MCF-7/S7 cancer cell line human CVCL_WK28 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Group: Serum/protein free medium cell line 21182093 CVCL_NQ93 BayGenomics ES cell line RRS143 embryonic stem cell house mouse CVCL_NQ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921620; Rptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182094 CVCL_WK27 IISHDOi005-A induced pluripotent stem cell house mouse CVCL_WK27 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: C57BL/6J. Female 21182095 CVCL_NQ70 BayGenomics ES cell line RRS092 embryonic stem cell house mouse CVCL_NQ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182096 CVCL_WK09 HPSI0115i-quze_4 induced pluripotent stem cell human CVCL_WK09 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182097 CVCL_WK11 HPSI0115i-vehl_2 induced pluripotent stem cell human CVCL_WK11 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182098 CVCL_WK10 HPSI0115i-timk_2 induced pluripotent stem cell human CVCL_WK10 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182099 CVCL_NQ69 BayGenomics ES cell line RRS090 embryonic stem cell house mouse CVCL_NQ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349394; Map4k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182100 CVCL_NQ68 BayGenomics ES cell line RRS087 embryonic stem cell house mouse CVCL_NQ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449121; Nme7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182101 CVCL_NQ67 BayGenomics ES cell line RRS083 embryonic stem cell house mouse CVCL_NQ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95305; Eif4e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182102 CVCL_WK15 HPSI0115i-zagk_3 induced pluripotent stem cell human CVCL_WK15 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male 21182103 CVCL_NQ66 BayGenomics ES cell line RRS081 embryonic stem cell house mouse CVCL_NQ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182104 CVCL_WK14 HPSI0115i-yaqw_3 induced pluripotent stem cell human CVCL_WK14 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182105 CVCL_NQ65 BayGenomics ES cell line RRS080 embryonic stem cell house mouse CVCL_NQ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182106 CVCL_WK13 HPSI0115i-yaqw_1 induced pluripotent stem cell human CVCL_WK13 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182107 CVCL_NQ64 BayGenomics ES cell line RRS078 embryonic stem cell house mouse CVCL_NQ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182108 CVCL_WK12 HPSI0115i-vehl_3 induced pluripotent stem cell human CVCL_WK12 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182109 CVCL_NQ63 BayGenomics ES cell line RRS077 embryonic stem cell house mouse CVCL_NQ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444188; Dgkh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182110 CVCL_WK19 HPSI1014i-xejd_2 induced pluripotent stem cell human CVCL_WK19 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182111 CVCL_NQ62 BayGenomics ES cell line RRS075 embryonic stem cell house mouse CVCL_NQ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203524; Smarcc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182112 CVCL_WK18 HPSI0814i-uepz_4 induced pluripotent stem cell human CVCL_WK18 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182113 CVCL_NQ61 BayGenomics ES cell line RRS073 embryonic stem cell house mouse CVCL_NQ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182114 CVCL_WK17 HPSI0814i-uepz_3 induced pluripotent stem cell human CVCL_WK17 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182115 CVCL_NQ60 BayGenomics ES cell line RRS072 embryonic stem cell house mouse CVCL_NQ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916188; Aspscr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182116 CVCL_WK16 HPSI0115i-zagk_4 induced pluripotent stem cell human CVCL_WK16 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male 21182117 CVCL_NQ81 BayGenomics ES cell line RRS108 embryonic stem cell house mouse CVCL_NQ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915437; Fam135a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182118 CVCL_NQ80 BayGenomics ES cell line RRS107 embryonic stem cell house mouse CVCL_NQ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182119 CVCL_WK00 HPSI0115i-qecv_1 induced pluripotent stem cell human CVCL_WK00 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182120 CVCL_NQ79 BayGenomics ES cell line RRS105 embryonic stem cell house mouse CVCL_NQ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182121 CVCL_NQ78 BayGenomics ES cell line RRS103 embryonic stem cell house mouse CVCL_NQ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182122 CVCL_WK04 HPSI0416i-iazw_4 induced pluripotent stem cell human CVCL_WK04 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182123 CVCL_NQ77 BayGenomics ES cell line RRS102 embryonic stem cell house mouse CVCL_NQ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108405; Apbb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182124 CVCL_WK03 HPSI0115i-womt_1 induced pluripotent stem cell human CVCL_WK03 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 21182125 CVCL_NQ76 BayGenomics ES cell line RRS101 embryonic stem cell house mouse CVCL_NQ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915403; Gtf2e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182126 CVCL_WK02 HPSI0115i-quze_6 induced pluripotent stem cell human CVCL_WK02 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182127 CVCL_NQ75 BayGenomics ES cell line RRS100 embryonic stem cell house mouse CVCL_NQ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349717; Ncor1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182128 CVCL_WK01 HPSI0115i-qecv_2 induced pluripotent stem cell human CVCL_WK01 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21182129 CVCL_NQ74 BayGenomics ES cell line RRS099 embryonic stem cell house mouse CVCL_NQ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096875; Wdfy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182130 CVCL_WK08 HPSI0115i-boqx_1 induced pluripotent stem cell human CVCL_WK08 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female 21182131 CVCL_NQ73 BayGenomics ES cell line RRS098 embryonic stem cell house mouse CVCL_NQ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891963; Ywhaq Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182132 CVCL_WK07 HPSI0114i-wegi_3 induced pluripotent stem cell human CVCL_WK07 From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21182133 CVCL_NQ72 BayGenomics ES cell line RRS094 embryonic stem cell house mouse CVCL_NQ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98931; Ezr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182134 CVCL_WK06 HPSI0616i-aauq_2 induced pluripotent stem cell human CVCL_WK06 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182135 CVCL_NQ71 BayGenomics ES cell line RRS093 embryonic stem cell house mouse CVCL_NQ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926966; Eif3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182136 CVCL_WK05 HPSI0616i-aauq_1 induced pluripotent stem cell human CVCL_WK05 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182137 CVCL_4E87 ND00027 transformed cell line human CVCL_4E87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182138 CVCL_4E86 ND00026 transformed cell line human CVCL_4E86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182139 CVCL_4E85 ND00023 transformed cell line human CVCL_4E85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182140 CVCL_4E84 ND00021 transformed cell line human CVCL_4E84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182141 CVCL_4E89 ND00030 transformed cell line human CVCL_4E89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182142 CVCL_4E88 ND00029 transformed cell line human CVCL_4E88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182143 CVCL_4E83 ND00020 transformed cell line human CVCL_4E83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182144 CVCL_4E82 ND00019 transformed cell line human CVCL_4E82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182145 CVCL_4E81 ND00018 transformed cell line human CVCL_4E81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182146 CVCL_4E80 ND00017 transformed cell line human CVCL_4E80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182147 CVCL_4E98 GM11206 transformed cell line human CVCL_4E98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182148 CVCL_4E97 ND00039 transformed cell line human CVCL_4E97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182149 CVCL_4E96 ND00038 transformed cell line human CVCL_4E96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182150 CVCL_4E95 ND00037 transformed cell line human CVCL_4E95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182151 CVCL_4E99 GM11207 transformed cell line human CVCL_4E99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182152 CVCL_4E90 ND00031 transformed cell line human CVCL_4E90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182153 CVCL_4E94 ND00036 transformed cell line human CVCL_4E94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182154 CVCL_4E93 ND00035 transformed cell line human CVCL_4E93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182155 CVCL_4E92 ND00034 transformed cell line human CVCL_4E92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182156 CVCL_4E91 ND00033 transformed cell line human CVCL_4E91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182157 CVCL_4E65 DT40-RAD18(-/-)-XPA(-/-) cancer cell line CVCL_4E65 CL:0000010 Knockout cell: Method=Targeted integration; RAD18+XPA Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182158 CVCL_4E64 DT40-PIK3CA(-/-) cancer cell line CVCL_4E64 CL:0000010 Knockout cell: Method=Targeted integration; PIK3CA Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182159 CVCL_4E63 7T1 spontaneously immortalized cell line house mouse CVCL_4E63 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified 21182160 CVCL_4E62 DT40-BLNK(-/-)-GRB2(-/-) cancer cell line CVCL_4E62 CL:0000010 Knockout cell: Method=Targeted integration; BLNK+GRB2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182161 CVCL_4E69 ND00002 transformed cell line human CVCL_4E69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182162 CVCL_4E68 DT40-GRB2(-/-)-GRAP(-/-) cancer cell line CVCL_4E68 CL:0000010 Knockout cell: Method=Targeted integration; GRAP+GRB2 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182163 CVCL_4E67 DT40-RAD18(-/-)-POLK(-/-) cancer cell line CVCL_4E67 CL:0000010 Knockout cell: Method=Targeted integration; POLK+RAD18 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182164 CVCL_4E66 DT40-POLK(-/-)-XPA(-/-) cancer cell line CVCL_4E66 CL:0000010 Knockout cell: Method=Targeted integration; POLK+XPA Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21182165 CVCL_4E61 UV.CC3-11.1 transformed cell line house mouse CVCL_4E61 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c x C3H. 21182166 CVCL_4E60 UV.CB6-6.1B cancer cell line house mouse CVCL_4E60 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21182167 CVCL_4E76 ND00012 transformed cell line human CVCL_4E76 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182168 CVCL_4E75 ND00010 transformed cell line human CVCL_4E75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182169 CVCL_4E74 ND00008 transformed cell line human CVCL_4E74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182170 CVCL_4E73 ND00007 transformed cell line human CVCL_4E73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182171 CVCL_4E79 ND00015 transformed cell line human CVCL_4E79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182172 CVCL_4E78 ND00014 transformed cell line human CVCL_4E78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182173 CVCL_4E77 ND00013 transformed cell line human CVCL_4E77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182174 CVCL_4E72 ND00006 transformed cell line human CVCL_4E72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182175 CVCL_4E71 ND00004 transformed cell line human CVCL_4E71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182176 CVCL_4E70 ND00003 transformed cell line human CVCL_4E70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182177 CVCL_4E43 UV.BAL-17.1 transformed cell line house mouse CVCL_4E43 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182178 CVCL_4E42 UV.BAL-16.1 transformed cell line house mouse CVCL_4E42 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182179 CVCL_4E41 UV.BAL-15.1 transformed cell line house mouse CVCL_4E41 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182180 CVCL_4E40 UV.BAL-14.2 transformed cell line house mouse CVCL_4E40 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182181 CVCL_4E47 UV.BAL-20.1 transformed cell line house mouse CVCL_4E47 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182182 CVCL_4E46 UV.BAL-2.1D transformed cell line house mouse CVCL_4E46 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182183 CVCL_4E45 UV.BAL-19.1A transformed cell line house mouse CVCL_4E45 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182184 CVCL_4E44 UV.BAL-18.1 transformed cell line house mouse CVCL_4E44 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182185 CVCL_4E49 UV.BAL-23.1 transformed cell line house mouse CVCL_4E49 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182186 CVCL_4E48 UV.BAL-21.1 transformed cell line house mouse CVCL_4E48 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182187 CVCL_WK91 BT-J finite cell line CVCL_WK91 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182188 CVCL_WK90 BT-I finite cell line CVCL_WK90 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182189 CVCL_WK95 GG-CL PRL-R(L) conditionally immortalized cell line Norway rat CVCL_WK95 CL:0000010 Transfected with: RGD; 3407; Prlr (isoform Long); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; corpus luteum Cell type=Luteal cell.; Breed/subspecies: Sprague Dawley. Female 21182190 CVCL_WK94 GG-CL conditionally immortalized cell line Norway rat CVCL_WK94 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; corpus luteum Cell type=Luteal cell.; Breed/subspecies: Sprague Dawley. Female Characteristics: Responds to stimulation by PRL, estradiol and cAMP, making the cells a useful model for studies involving gene expression and regulation of luteal cells (ABM); Characteristics: At the permissive temperature (33 Celsius) these cells are small and compact and divide At the non-permissive temperature (40 Celsius) the cells assume a monolayer appearance and become differentiated (PubMed=9528980). 21182191 CVCL_WK93 BT-L finite cell line CVCL_WK93 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182192 CVCL_WK92 BT-K finite cell line CVCL_WK92 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182193 CVCL_WK99 RBM1-IT4 cancer cell line human CVCL_WK99 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asp179Thrfs*21 (c.535delG); Zygosity=Hemizygous (PubMed=17332933) Derived from metastatic site: Bone; left humerus. Male Characteristics: Established from a xenograft obtained by intratibial injection of the parent cell line in nude mice 21182194 CVCL_WK98 tsCLC-D conditionally immortalized cell line CVCL_WK98 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; corpus luteum Cell type=Luteal cell.; Breed/subspecies: Taiwan native. Female Characteristics: At the permissive temperature (34 Celsius) these cells are spindle-shaped and grow rapidly At the non-permissive temperature (40 Celsius) the cells exhibits a round shape and ceases to proliferate. 21182195 CVCL_WK97 HTS-1 finite cell line CVCL_WK97 CL:0000010 Derived from sampling site: Trophoblast; Breed/subspecies: Shiba. Female 21182196 CVCL_WK96 hTERT-CLCs telomerase immortalized cell line CVCL_WK96 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary; corpus luteum Cell type=Luteal cell.; Breed/subspecies: Saanen. Female Doubling time: 23.5 hours (PubMed=22578611) 21182197 CVCL_4E54 UV.BAL-8.1 transformed cell line house mouse CVCL_4E54 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182198 CVCL_4E53 UV.BAL-7.1 transformed cell line house mouse CVCL_4E53 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182199 CVCL_4E52 UV.BAL-6.1E transformed cell line house mouse CVCL_4E52 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182200 CVCL_4E51 UV.BAL-5.4G transformed cell line house mouse CVCL_4E51 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182201 CVCL_4E58 UV.CB6-2.1F cancer cell line house mouse CVCL_4E58 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21182202 CVCL_4E57 UV.C3H-8.2 transformed cell line house mouse CVCL_4E57 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C3H/HeN. 21182203 CVCL_4E56 UV.C3H-3.3 transformed cell line house mouse CVCL_4E56 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C3H/HeN. 21182204 CVCL_4E55 UV.C3B6-1.1 transformed cell line house mouse CVCL_4E55 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x C3H/HeN. 21182205 CVCL_4E59 UV.CB6-5.2B cancer cell line house mouse CVCL_4E59 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x BALB/c. 21182206 CVCL_WK80 HOS-B55 cancer cell line human CVCL_WK80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4932; HLA-B (allele B*55:02) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21182207 CVCL_WK84 BT-C finite cell line CVCL_WK84 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182208 CVCL_WK83 BT-B [Bovine trophoblast] finite cell line CVCL_WK83 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182209 CVCL_WK82 BT-A finite cell line CVCL_WK82 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182210 CVCL_WK81 BT-1 finite cell line CVCL_WK81 CL:0000010 Derived from sampling site: Trophoblast. Omics: Transcriptome analysis by microarray Unspecified Doubling time: ~2.72 days (in fibroblast-conditioned medium), ~2.97 days (in 10% FBS) (PubMed=11504534) 21182211 CVCL_WK88 BT-G finite cell line CVCL_WK88 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182212 CVCL_WK87 BT-F finite cell line CVCL_WK87 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182213 CVCL_WK86 BT-E finite cell line CVCL_WK86 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182214 CVCL_WK85 BT-D finite cell line CVCL_WK85 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182215 CVCL_WK89 BT-H finite cell line CVCL_WK89 CL:0000010 Derived from sampling site: Trophoblast. Unspecified 21182216 CVCL_4E50 UV.BAL-3.3 transformed cell line house mouse CVCL_4E50 CL:0000010 Transformant: Ultraviolet radiation(NCIt; C17231); Derived from sampling site: Skin; Breed/subspecies: BALB/c. 21182217 CVCL_EW39 ND10745 transformed cell line human CVCL_EW39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182218 CVCL_F839 SSH23 transformed cell line human CVCL_F839 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21182219 CVCL_EW38 ND10743 transformed cell line human CVCL_EW38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182220 CVCL_F838 SAJ119 transformed cell line human CVCL_F838 HLA typing: DPB1*47:01 (IPD-IMGT/HLA=11359) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182221 CVCL_EW37 ND10736 transformed cell line human CVCL_EW37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182222 CVCL_F837 SAJ022 transformed cell line human CVCL_F837 HLA typing: A*26:05,33; DPB1*05:01,09:01; DQA1*01:02,01:03; DQB1*06:01,06:04; DRB1*13:02,15:02; DRB3*03:01 (IPD-IMGT/HLA=11358) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182223 CVCL_EW36 ND10728 transformed cell line human CVCL_EW36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182224 CVCL_F836 SAJ008 transformed cell line human CVCL_F836 HLA typing: DPB1*47:01; DQA1*01:02,06:01; DQB1*03:01,06:02; DRB1*08:03:02,15:01 (IPD-IMGT/HLA=11357) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182225 CVCL_EW31 ND10683 transformed cell line human CVCL_EW31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182226 CVCL_F831 SC3VA4 transformed cell line house mouse CVCL_F831 CL:0000010 Sequence variation: Mutation; MGI; MGI:104779; Prkdc; Simple; p.Tyr4046Ter (c.12138T>A) (Prkdc(scid)); Zygosity=Homozygous (inferred from genetic background of Scid mice) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: C.B.-17-scid (CB17/Icr-Prkdcscid/IcrIcoCrl). Unspecified 21182227 CVCL_F830 MOLT-4V cancer cell line human CVCL_F830 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21182228 CVCL_EW30 ND10679 transformed cell line human CVCL_EW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182229 CVCL_EW35 ND10727 transformed cell line human CVCL_EW35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182230 CVCL_F835 RTS11 spontaneously immortalized cell line CVCL_F835 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.. Unspecified Group: Fish cell line 21182231 CVCL_EW34 ND10722 transformed cell line human CVCL_EW34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182232 CVCL_F834 SL12.4 cancer cell line house mouse CVCL_F834 CL:0000010 Breed/subspecies: AKR. 21182233 CVCL_EW33 ND10699 transformed cell line human CVCL_EW33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182234 CVCL_F833 SL12.1 cancer cell line house mouse CVCL_F833 CL:0000010 Breed/subspecies: AKR. 21182235 CVCL_EW32 ND10694 transformed cell line human CVCL_EW32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182236 CVCL_F832 SL12 cancer cell line house mouse CVCL_F832 CL:0000010 Breed/subspecies: AKR. 21182237 CVCL_EW49 ND10827 transformed cell line human CVCL_EW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182238 CVCL_F849 VMR-0 cancer cell line house mouse CVCL_F849 CL:0000010 Female 21182239 CVCL_EW48 ND10817 transformed cell line human CVCL_EW48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182240 CVCL_F848 WOL-1 stromal cell line house mouse CVCL_F848 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL7 dependent 21182241 CVCL_EW47 ND10815 transformed cell line human CVCL_EW47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182242 CVCL_F847 SPOC1 spontaneously immortalized cell line Norway rat CVCL_F847 CL:0000010 Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/NCR. Unspecified Doubling time: ~24 hours (PubMed=7535063) 21182243 CVCL_F842 Gin-1 finite cell line human CVCL_F842 CL:0000010 Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Discontinued: ATCC; CRL-1292; true Male 21182244 CVCL_EW42 ND10766 transformed cell line human CVCL_EW42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182245 CVCL_EW41 ND10765 transformed cell line human CVCL_EW41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182246 CVCL_F841 U-1242MG cancer cell line human CVCL_F841 CL:0000010 Miscellaneous: Sex of donor from personal communication of Westermark B. Female 21182247 CVCL_EW40 ND10750 transformed cell line human CVCL_EW40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182248 CVCL_F840 TpM(803) transformed cell line CVCL_F840 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: Infected by Theileria parva isolate Muguga 21182249 CVCL_EW46 ND10811 transformed cell line human CVCL_EW46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182250 CVCL_F846 ROHA-9 transformed cell line human CVCL_F846 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Secretes IL1 21182251 CVCL_F845 MH [Human ovarian carcinoma] cancer cell line human CVCL_F845 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: ~6.3 days (PubMed=8217948); 36 hours (PubMed=8375936) 21182252 CVCL_EW45 ND10777 transformed cell line human CVCL_EW45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182253 CVCL_F844 KK cancer cell line human CVCL_F844 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female Doubling time: ~4 days, at 70th passage (PubMed=8148309); 31 hours (PubMed=8375936) Part of: MD Anderson Cell Lines Project 21182254 CVCL_EW44 ND10775 transformed cell line human CVCL_EW44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182255 CVCL_F843 KF-1 cancer cell line human CVCL_F843 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 16 hours (PubMed=6541042); 18 hours (PubMed=8375936) 21182256 CVCL_EW43 ND10769 transformed cell line human CVCL_EW43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182257 CVCL_EW17 ND10594 transformed cell line human CVCL_EW17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182258 CVCL_F817 XMMME-001 hybridoma house mouse CVCL_F817 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was conjugated to a ricin chain A to produce XomaZyme-Mel (XMMME-001-RTA) which was evaluated in several clinical trials for metastatic melanoma patients (DOI=10.3390/antib1010039) Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma tumor specific HMW antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8759 21182259 CVCL_EW16 ND10593 transformed cell line human CVCL_EW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182260 CVCL_F816 XMMEN-OE5 hybridoma house mouse CVCL_F816 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9081 21182261 CVCL_EW15 ND10592 transformed cell line human CVCL_EW15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182262 CVCL_F815 XMMCO-791 hybridoma house mouse CVCL_F815 CL:0000010 Biotechnology: Was used to produce monoclonal antibody MoAb 791T which when conjugated to ricin chain A produces XomaZyme-791 (79IT/36-RTA) XomaZyme-791 was evaluated in two phase 1 clinical trials to treat patients with metastatic colorectal carcinoma (DOI=10.3390/antib1010039). Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Human colorectal tumour-associated antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9173 21182263 CVCL_EW14 ND10587 transformed cell line human CVCL_EW14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182264 CVCL_F814 X22 hybridoma house mouse CVCL_F814 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q00610; Human CLTC (Note=Also reacts with other species). 21182265 CVCL_EW19 ND10601 transformed cell line human CVCL_EW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182266 CVCL_F819 XVI E6E6G10 hybridoma house mouse CVCL_F819 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A3RGC1; Pig VDR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9496 21182267 CVCL_EW18 ND10596 transformed cell line human CVCL_EW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182268 CVCL_F818 XMMME-002 hybridoma house mouse CVCL_F818 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human melanoma tumor specific HMW antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8760 21182269 CVCL_EW13 ND10583 transformed cell line human CVCL_EW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182270 CVCL_F813 WU E-4 hybridoma house mouse CVCL_F813 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02649; Human APOE. 21182271 CVCL_EW12 ND10581 transformed cell line human CVCL_EW12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182272 CVCL_F812 WU E-14 hybridoma house mouse CVCL_F812 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02649; Human APOE. 21182273 CVCL_EW11 ND10580 transformed cell line human CVCL_EW11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182274 CVCL_F811 WI-MN-1 hybridoma house mouse CVCL_F811 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human melanoma cell surface antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8672 21182275 CVCL_EW10 ND10577 transformed cell line human CVCL_EW10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182276 CVCL_F810 WAPS 12.2 hybridoma house mouse CVCL_F810 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P. 21182277 CVCL_F828 K1735 cancer cell line house mouse CVCL_F828 CL:0000010 Breed/subspecies: C3H/HeN. 21182278 CVCL_EW28 ND10656 transformed cell line human CVCL_EW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182279 CVCL_F827 MOLT-4 clone 8 cancer cell line human CVCL_F827 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21182280 CVCL_EW27 ND10655 transformed cell line human CVCL_EW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182281 CVCL_F826 HMy2.DRN transformed cell line human CVCL_F826 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182282 CVCL_EW26 ND10653 transformed cell line human CVCL_EW26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182283 CVCL_F825 HMy2.A3m transformed cell line human CVCL_F825 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182284 CVCL_EW25 ND10636 transformed cell line human CVCL_EW25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182285 CVCL_F829 K1735-C23 cancer cell line house mouse CVCL_F829 CL:0000010 Breed/subspecies: C3H/HeN. 21182286 CVCL_EW29 ND10668 transformed cell line human CVCL_EW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182287 CVCL_EW20 ND10602 transformed cell line human CVCL_EW20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182288 CVCL_F820 WP [Human B-cell IHW] transformed cell line human CVCL_F820 HLA typing: A*02:30,03:01; B*35:01,38:01; C*04:01,12:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=11819) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182289 CVCL_F824 AR-5 transformed cell line Norway rat CVCL_F824 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic amygdala; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: ~2 days (PubMed=9886832) 21182290 CVCL_EW24 ND10635 transformed cell line human CVCL_EW24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182291 CVCL_F823 ANDP transformed cell line human CVCL_F823 HLA typing: A*24:02,32:01; B*08:01,18:01; C*07:01,12:05; DPB1*01:01,04:01; DQB1*02:01,03:01; DRB1*03:01,11:01; DRB3*01:01,02:01 (IPD-IMGT/HLA=10250) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182292 CVCL_EW23 ND10611 transformed cell line human CVCL_EW23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182293 CVCL_EW22 ND10604 transformed cell line human CVCL_EW22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182294 CVCL_F822 SV-3Y1-C66 transformed cell line Norway rat CVCL_F822 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21182295 CVCL_EW21 ND10603 transformed cell line human CVCL_EW21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182296 CVCL_F821 WWAI transformed cell line human CVCL_F821 HLA typing: A*34:02:01:01 (IPD-IMGT/HLA=11577) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21182297 CVCL_EW06 ND10530 transformed cell line human CVCL_EW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182298 CVCL_F806 VD-10 hybridoma house mouse CVCL_F806 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Electrophorus electricus saxitoxin-binding component of electroplex. 21182299 CVCL_EW05 ND10529 transformed cell line human CVCL_EW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182300 CVCL_F805 USASK/DSIL-LHRH-A1 hybridoma house mouse CVCL_F805 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01148; Human GNRH1 (Gonadoliberin-1). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9094 21182301 CVCL_EW04 ND10513 transformed cell line human CVCL_EW04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182302 CVCL_F804 UCD/PR 10.11 hybridoma house mouse CVCL_F804 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05783; Human KRT18; Monoclonal antibody target: UniProtKB; P05787; Human KRT8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8694 21182303 CVCL_EW03 ND10497 transformed cell line human CVCL_EW03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182304 CVCL_F803 UCD/AB 6.11 hybridoma house mouse CVCL_F803 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05783; Human KRT18. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8458 21182305 CVCL_EW09 ND10546 transformed cell line human CVCL_EW09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182306 CVCL_F809 W4F.5B hybridoma house mouse CVCL_F809 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9282 21182307 CVCL_EW08 ND10542 transformed cell line human CVCL_EW08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182308 CVCL_F808 VM-2 hybridoma house mouse CVCL_F808 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8530 21182309 CVCL_EW07 ND10541 transformed cell line human CVCL_EW07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182310 CVCL_F807 VIII-6G10 hybridoma house mouse CVCL_F807 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P19320; Human VCAM1/CD106. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10519 21182311 CVCL_EW02 ND10496 transformed cell line human CVCL_EW02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182312 CVCL_F802 UCD/AB 6.01 hybridoma house mouse CVCL_F802 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05787; Human KRT8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8693 21182313 CVCL_EW01 ND10487 transformed cell line human CVCL_EW01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182314 CVCL_F801 UC7 hybridoma house mouse CVCL_F801 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9753 21182315 CVCL_EW00 ND10475 transformed cell line human CVCL_EW00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182316 CVCL_F800 TSHR-T5U-317 hybridoma house mouse CVCL_F800 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16473; Human TSHR. 21182317 CVCL_NQ49 BayGenomics ES cell line RRS048 embryonic stem cell house mouse CVCL_NQ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891829; Rbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182318 CVCL_NQ48 BayGenomics ES cell line RRS046 embryonic stem cell house mouse CVCL_NQ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920018; Topbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182319 CVCL_NQ47 BayGenomics ES cell line RRS042 embryonic stem cell house mouse CVCL_NQ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100818; Crcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182320 CVCL_NQ46 BayGenomics ES cell line RRS041 embryonic stem cell house mouse CVCL_NQ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3583954; Zfp961 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182321 CVCL_NQ45 BayGenomics ES cell line RRS040 embryonic stem cell house mouse CVCL_NQ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196908; Tcea3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182322 CVCL_NQ44 BayGenomics ES cell line RRS037 embryonic stem cell house mouse CVCL_NQ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182323 CVCL_NQ43 BayGenomics ES cell line RRS035 embryonic stem cell house mouse CVCL_NQ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104557; Rps6ka3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182324 CVCL_NQ42 BayGenomics ES cell line RRS034 embryonic stem cell house mouse CVCL_NQ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925237; Ascc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182325 CVCL_NQ41 BayGenomics ES cell line RRS032 embryonic stem cell house mouse CVCL_NQ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891829; Rbx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182326 CVCL_NQ40 BayGenomics ES cell line RRS031 embryonic stem cell house mouse CVCL_NQ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443114; Larp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182327 CVCL_NQ59 BayGenomics ES cell line RRS070 embryonic stem cell house mouse CVCL_NQ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920909; Pdxdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182328 CVCL_NQ58 BayGenomics ES cell line RRS064 embryonic stem cell house mouse CVCL_NQ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182329 CVCL_NQ57 BayGenomics ES cell line RRS062 embryonic stem cell house mouse CVCL_NQ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444343; Nbeal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182330 CVCL_NQ56 BayGenomics ES cell line RRS061 embryonic stem cell house mouse CVCL_NQ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:92356; Csde1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182331 CVCL_NQ55 BayGenomics ES cell line RRS058 embryonic stem cell house mouse CVCL_NQ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182332 CVCL_NQ54 BayGenomics ES cell line RRS057 embryonic stem cell house mouse CVCL_NQ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914321; Rps6ka6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182333 CVCL_NQ53 BayGenomics ES cell line RRS056 embryonic stem cell house mouse CVCL_NQ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182334 CVCL_NQ52 BayGenomics ES cell line RRS055 embryonic stem cell house mouse CVCL_NQ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914265; Ccdc91 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182335 CVCL_NQ51 BayGenomics ES cell line RRS054 embryonic stem cell house mouse CVCL_NQ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182336 CVCL_NQ50 BayGenomics ES cell line RRS052 embryonic stem cell house mouse CVCL_NQ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158813; Sumo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182337 CVCL_F897 DM646 cancer cell line human CVCL_F897 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182338 CVCL_EW97 ND11264 transformed cell line human CVCL_EW97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182339 CVCL_F896 DM636 cancer cell line human CVCL_F896 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182340 CVCL_EW96 ND11263 transformed cell line human CVCL_EW96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182341 CVCL_F895 DM608 cancer cell line human CVCL_F895 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182342 CVCL_EW95 ND11196 transformed cell line human CVCL_EW95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182343 CVCL_EW94 ND11191 transformed cell line human CVCL_EW94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182344 CVCL_F899 DM711 cancer cell line human CVCL_F899 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182345 CVCL_EW99 ND11298 transformed cell line human CVCL_EW99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182346 CVCL_F898 DM7 cancer cell line human CVCL_F898 HLA typing: A*09,29; B*15,38; C*03 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182347 CVCL_EW98 ND11289 transformed cell line human CVCL_EW98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182348 CVCL_NQ29 BayGenomics ES cell line RRS014 embryonic stem cell house mouse CVCL_NQ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109547; Dnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182349 CVCL_NQ28 BayGenomics ES cell line RRS012 embryonic stem cell house mouse CVCL_NQ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1332236; Cds2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182350 CVCL_NQ27 BayGenomics ES cell line RRS011 embryonic stem cell house mouse CVCL_NQ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919752; Cwf19l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182351 CVCL_F893 DM598 cancer cell line human CVCL_F893 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182352 CVCL_EW93 ND11151 transformed cell line human CVCL_EW93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182353 CVCL_NQ26 BayGenomics ES cell line RRS010 embryonic stem cell house mouse CVCL_NQ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97838; Eprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182354 CVCL_F892 DM578 cancer cell line human CVCL_F892 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182355 CVCL_EW92 ND11144 transformed cell line human CVCL_EW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182356 CVCL_NQ25 BayGenomics ES cell line RRS009 embryonic stem cell house mouse CVCL_NQ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182357 CVCL_F891 DM515 cancer cell line human CVCL_F891 From: Duke University Medical Center; Durham; USA. CL:0000010 21182358 CVCL_EW91 ND11107 transformed cell line human CVCL_EW91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182359 CVCL_NQ24 BayGenomics ES cell line RRS008 embryonic stem cell house mouse CVCL_NQ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182360 CVCL_F890 DM451 cancer cell line human CVCL_F890 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182361 CVCL_EW90 ND11105 transformed cell line human CVCL_EW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182362 CVCL_NQ23 BayGenomics ES cell line RRS005 embryonic stem cell house mouse CVCL_NQ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145425; Depdc1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182363 CVCL_NQ22 BayGenomics ES cell line RRS003 embryonic stem cell house mouse CVCL_NQ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182364 CVCL_NQ21 BayGenomics ES cell line RRS001 embryonic stem cell house mouse CVCL_NQ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684817; Snhg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182365 CVCL_NQ20 BayGenomics ES cell line RRR817 embryonic stem cell house mouse CVCL_NQ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917758; Bbx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182366 CVCL_NQ39 BayGenomics ES cell line RRS027 embryonic stem cell house mouse CVCL_NQ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182367 CVCL_NQ38 BayGenomics ES cell line RRS026 embryonic stem cell house mouse CVCL_NQ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915467; Prrc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182368 CVCL_NQ37 BayGenomics ES cell line RRS025 embryonic stem cell house mouse CVCL_NQ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203484; Zfp638 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182369 CVCL_NQ36 BayGenomics ES cell line RRS024 embryonic stem cell house mouse CVCL_NQ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915546; Smu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182370 CVCL_NQ35 BayGenomics ES cell line RRS022 embryonic stem cell house mouse CVCL_NQ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919244; Cnn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182371 CVCL_NQ34 BayGenomics ES cell line RRS021 embryonic stem cell house mouse CVCL_NQ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921020; Wdr70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182372 CVCL_NQ33 BayGenomics ES cell line RRS020 embryonic stem cell house mouse CVCL_NQ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351465; G3bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182373 CVCL_NQ32 BayGenomics ES cell line RRS019 embryonic stem cell house mouse CVCL_NQ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932339; Sf3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182374 CVCL_NQ31 BayGenomics ES cell line RRS018 embryonic stem cell house mouse CVCL_NQ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347048; Clcn7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182375 CVCL_NQ30 BayGenomics ES cell line RRS015 embryonic stem cell house mouse CVCL_NQ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182376 CVCL_F875 DM179 cancer cell line human CVCL_F875 HLA typing: A*02; B*07 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182377 CVCL_EW75 ND10910 transformed cell line human CVCL_EW75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182378 CVCL_F874 DM175 cancer cell line human CVCL_F874 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182379 CVCL_EW74 ND10909 transformed cell line human CVCL_EW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182380 CVCL_F873 DM169 cancer cell line human CVCL_F873 HLA typing: A*01,02; B*08,40 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182381 CVCL_EW73 ND10906 transformed cell line human CVCL_EW73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182382 CVCL_F872 DM166 cancer cell line human CVCL_F872 HLA typing: A*02; B*05,40 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182383 CVCL_EW72 ND10897 transformed cell line human CVCL_EW72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182384 CVCL_F879 DM336 cancer cell line human CVCL_F879 From: Duke University Medical Center; Durham; USA. CL:0000010 21182385 CVCL_EW79 ND10954 transformed cell line human CVCL_EW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182386 CVCL_F878 DM268 cancer cell line human CVCL_F878 From: Duke University Medical Center; Durham; USA. CL:0000010 21182387 CVCL_EW78 ND10952 transformed cell line human CVCL_EW78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182388 CVCL_F877 DM208 cancer cell line human CVCL_F877 From: Duke University Medical Center; Durham; USA. CL:0000010 21182389 CVCL_EW77 ND10951 transformed cell line human CVCL_EW77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182390 CVCL_F876 DM196 cancer cell line human CVCL_F876 From: Duke University Medical Center; Durham; USA. CL:0000010 21182391 CVCL_EW76 ND10933 transformed cell line human CVCL_EW76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182392 CVCL_NQ09 BayGenomics ES cell line RRR799 embryonic stem cell house mouse CVCL_NQ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182393 CVCL_NQ08 BayGenomics ES cell line RRR794 embryonic stem cell house mouse CVCL_NQ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179723; Casc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182394 CVCL_NQ07 BayGenomics ES cell line RRR793 embryonic stem cell house mouse CVCL_NQ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106621; Myo1e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182395 CVCL_NQ06 BayGenomics ES cell line RRR792 embryonic stem cell house mouse CVCL_NQ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914280; Fancl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182396 CVCL_NQ05 BayGenomics ES cell line RRR789 embryonic stem cell house mouse CVCL_NQ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103241; Slk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182397 CVCL_F871 DM161 cancer cell line human CVCL_F871 HLA typing: A*02,11; B*07,49; C*01 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182398 CVCL_EW71 ND10896 transformed cell line human CVCL_EW71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182399 CVCL_NQ04 BayGenomics ES cell line RRR786 embryonic stem cell house mouse CVCL_NQ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918708; Bcor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182400 CVCL_F870 DM154 cancer cell line human CVCL_F870 HLA typing: A*11,29; B*05,12 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182401 CVCL_EW70 ND10885 transformed cell line human CVCL_EW70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182402 CVCL_NQ03 BayGenomics ES cell line RRR785 embryonic stem cell house mouse CVCL_NQ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916858; Sec24d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182403 CVCL_NQ02 BayGenomics ES cell line RRR778 embryonic stem cell house mouse CVCL_NQ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104673; Ptpn12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182404 CVCL_NQ01 BayGenomics ES cell line RRR776 embryonic stem cell house mouse CVCL_NQ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182405 CVCL_NQ00 BayGenomics ES cell line RRR774 embryonic stem cell house mouse CVCL_NQ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337062; Ap3s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182406 CVCL_F886 DM424 cancer cell line human CVCL_F886 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182407 CVCL_EW86 ND11052 transformed cell line human CVCL_EW86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182408 CVCL_F885 DM422 cancer cell line human CVCL_F885 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182409 CVCL_EW85 ND10981 transformed cell line human CVCL_EW85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182410 CVCL_F884 DM414 cancer cell line human CVCL_F884 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182411 CVCL_EW84 ND10978 transformed cell line human CVCL_EW84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182412 CVCL_F883 DM391 cancer cell line human CVCL_F883 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182413 CVCL_EW83 ND10977 transformed cell line human CVCL_EW83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182414 CVCL_F889 DM443 cancer cell line human CVCL_F889 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182415 CVCL_EW89 ND11067 transformed cell line human CVCL_EW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182416 CVCL_F888 DM440 cancer cell line human CVCL_F888 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182417 CVCL_EW88 ND11061 transformed cell line human CVCL_EW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182418 CVCL_F887 DM425 cancer cell line human CVCL_F887 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182419 CVCL_EW87 ND11058 transformed cell line human CVCL_EW87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182420 CVCL_NQ19 BayGenomics ES cell line RRR816 embryonic stem cell house mouse CVCL_NQ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891700; Ncstn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182421 CVCL_NQ18 BayGenomics ES cell line RRR815 embryonic stem cell house mouse CVCL_NQ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:892995; Dnajc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182422 CVCL_NQ17 BayGenomics ES cell line RRR812 embryonic stem cell house mouse CVCL_NQ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920274; Emc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182423 CVCL_NQ16 BayGenomics ES cell line RRR811 embryonic stem cell house mouse CVCL_NQ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354698; Fbxw4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182424 CVCL_F882 DM377 cancer cell line human CVCL_F882 From: Duke University Medical Center; Durham; USA. CL:0000010 21182425 CVCL_EW82 ND10960 transformed cell line human CVCL_EW82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182426 CVCL_NQ15 BayGenomics ES cell line RRR810 embryonic stem cell house mouse CVCL_NQ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182427 CVCL_F881 DM368 cancer cell line human CVCL_F881 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182428 CVCL_EW81 ND10957 transformed cell line human CVCL_EW81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182429 CVCL_NQ14 BayGenomics ES cell line RRR809 embryonic stem cell house mouse CVCL_NQ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447834; Fam13b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182430 CVCL_F880 DM366 cancer cell line human CVCL_F880 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182431 CVCL_EW80 ND10955 transformed cell line human CVCL_EW80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182432 CVCL_NQ13 BayGenomics ES cell line RRR807 embryonic stem cell house mouse CVCL_NQ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182433 CVCL_NQ12 BayGenomics ES cell line RRR805 embryonic stem cell house mouse CVCL_NQ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182434 CVCL_NQ11 BayGenomics ES cell line RRR804 embryonic stem cell house mouse CVCL_NQ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104872; Ppp1cc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182435 CVCL_NQ10 BayGenomics ES cell line RRR800 embryonic stem cell house mouse CVCL_NQ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88039; Apc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182436 CVCL_EW59 ND10862 transformed cell line human CVCL_EW59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182437 CVCL_F859 RNK-4 cancer cell line Norway rat CVCL_F859 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182438 CVCL_EW58 ND10861 transformed cell line human CVCL_EW58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182439 CVCL_F858 RNK-6 cancer cell line Norway rat CVCL_F858 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182440 CVCL_EW53 ND10843 transformed cell line human CVCL_EW53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182441 CVCL_F853 RNK-8 cancer cell line Norway rat CVCL_F853 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182442 CVCL_EW52 ND10838 transformed cell line human CVCL_EW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182443 CVCL_F852 RNK-11 cancer cell line Norway rat CVCL_F852 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182444 CVCL_EW51 ND10837 transformed cell line human CVCL_EW51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182445 CVCL_F851 VMR-100-Ov cancer cell line house mouse CVCL_F851 CL:0000010 Female 21182446 CVCL_EW50 ND10834 transformed cell line human CVCL_EW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182447 CVCL_F850 VMR-100-Liv cancer cell line house mouse CVCL_F850 CL:0000010 Female 21182448 CVCL_EW57 ND10860 transformed cell line human CVCL_EW57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182449 CVCL_F857 RNK-10 cancer cell line Norway rat CVCL_F857 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182450 CVCL_EW56 ND10858 transformed cell line human CVCL_EW56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182451 CVCL_F856 RNK-1 cancer cell line Norway rat CVCL_F856 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182452 CVCL_EW55 ND10857 transformed cell line human CVCL_EW55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182453 CVCL_F855 RNK-7 cancer cell line Norway rat CVCL_F855 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182454 CVCL_EW54 ND10852 transformed cell line human CVCL_EW54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182455 CVCL_F854 RNK-0 cancer cell line Norway rat CVCL_F854 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182456 CVCL_F869 DM150 cancer cell line human CVCL_F869 From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182457 CVCL_EW69 ND10882 transformed cell line human CVCL_EW69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182458 CVCL_EW64 ND10872 transformed cell line human CVCL_EW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182459 CVCL_F864 OS1 [Human osteosarcoma] cancer cell line human CVCL_F864 CL:0000010 Population: Chinese; Singaporian; Derived from sampling site: Bone; right femur. Female 21182460 CVCL_EW63 ND10871 transformed cell line human CVCL_EW63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182461 CVCL_F863 VMM12-EBV transformed cell line human CVCL_F863 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21182462 CVCL_EW62 ND10869 transformed cell line human CVCL_EW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182463 CVCL_F862 VMM18-EBV transformed cell line human CVCL_F862 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182464 CVCL_EW61 ND10868 transformed cell line human CVCL_EW61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182465 CVCL_F861 RNK-9 cancer cell line Norway rat CVCL_F861 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182466 CVCL_F868 DM128 cancer cell line human CVCL_F868 HLA typing: A*28,29; B*14,35; C*04 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182467 CVCL_EW68 ND10880 transformed cell line human CVCL_EW68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182468 CVCL_F867 DM105 cancer cell line human CVCL_F867 HLA typing: A*01,10; B*18,53; C*01,02 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182469 CVCL_EW67 ND10879 transformed cell line human CVCL_EW67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182470 CVCL_EW66 ND10876 transformed cell line human CVCL_EW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182471 CVCL_F866 OS3 [Human osteosarcoma] cancer cell line human CVCL_F866 CL:0000010 Population: Chinese; Indonesia; Derived from sampling site: Bone. Female 21182472 CVCL_EW65 ND10875 transformed cell line human CVCL_EW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182473 CVCL_F865 OS2 [Human osteosarcoma] cancer cell line human CVCL_F865 CL:0000010 Population: Chinese; Indonesia; Derived from sampling site: Bone. Female 21182474 CVCL_EW60 ND10864 transformed cell line human CVCL_EW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182475 CVCL_F860 RNK-5 cancer cell line Norway rat CVCL_F860 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: Fischer 344. Male 21182476 CVCL_4F42 GM16548 finite cell line human CVCL_4F42 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gln244Ter (c.730C>T) (p.Gln256Ter, c.766C>T); ClinVar=VCV000095200; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182477 CVCL_4F41 GM16547 transformed cell line human CVCL_4F41 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gln244Ter (c.730C>T) (p.Gln256Ter, c.766C>T); ClinVar=VCV000095200; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182478 CVCL_4F40 GM16546 transformed cell line human CVCL_4F40 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182479 CVCL_4F46 GM17567 finite cell line human CVCL_4F46 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ter487Trp (c.1461A>G) (p.Ter499Trp, c.1497A>G); ClinVar=VCV000143490; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182480 CVCL_4F45 GM17540 transformed cell line human CVCL_4F45 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ser134Cys (c.401C>G) (p.Ser146Cys, c.437C>G); ClinVar=VCV000143562; Zygosity=Heterozygous (PubMed=24508304) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182481 CVCL_4F44 GM17539 transformed cell line human CVCL_4F44 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ser134Cys (c.401C>G) (p.Ser146Cys, c.437C>G); ClinVar=VCV000143562; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182482 CVCL_4F43 GM17538 transformed cell line human CVCL_4F43 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Ser134Cys (c.401C>G) (p.Ser146Cys, c.437C>G); ClinVar=VCV000143562; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182483 CVCL_4F49 GM21426 transformed cell line human CVCL_4F49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182484 CVCL_4F48 GM17880 finite cell line human CVCL_4F48 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Thr158Met (c.473C>T) (p.Thr170Met, c.509C>T); ClinVar=VCV000011811; Zygosity=Heterozygous (Coriell) Derived from sampling site: Oral cavity; tonsil Cell type=Fibroblast.. Female Senescence: Senesces at 56 PDL (Coriell=GM17880) 21182485 CVCL_4F47 GM17583 transformed cell line human CVCL_4F47 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu100Val (c.298C>G) (p.Leu112Val, c.334C>G); ClinVar=VCV000011835; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182486 CVCL_WL90 HPB-MB 18E spontaneously immortalized cell line CVCL_WL90 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182487 CVCL_WL94 HPB-MB 19S spontaneously immortalized cell line CVCL_WL94 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182488 CVCL_WL93 HPB-MB 19E spontaneously immortalized cell line CVCL_WL93 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182489 CVCL_WL92 HPB-MB 18S spontaneously immortalized cell line CVCL_WL92 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182490 CVCL_WL91 HPB-MB 18M spontaneously immortalized cell line CVCL_WL91 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182491 CVCL_WL98 HPB-SL 25S spontaneously immortalized cell line CVCL_WL98 CL:0000010 Unspecified Group: Insect cell line. 21182492 CVCL_WL97 HPB-SL 24S spontaneously immortalized cell line CVCL_WL97 CL:0000010 Unspecified Group: Insect cell line. 21182493 CVCL_WL96 HPB-SL 24E spontaneously immortalized cell line CVCL_WL96 CL:0000010 Unspecified Group: Insect cell line. 21182494 CVCL_WL95 HPB-SL spontaneously immortalized cell line CVCL_WL95 CL:0000010 Unspecified Group: Insect cell line. 21182495 CVCL_WL99 SV-HGEC-1 transformed cell line human CVCL_WL99 CL:0000010 Miscellaneous: The paper indicates that 3 SV-HGEC cell lines have been established but do not name them We have therefore arbitrarly named them SV-HGEC-1 to -3. Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Endothelial cell.. Unspecified 21182496 CVCL_4F53 GM06125 finite cell line human CVCL_4F53 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182497 CVCL_4F52 GM06094 finite cell line human CVCL_4F52 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182498 CVCL_4F51 GM05872 finite cell line human CVCL_4F51 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182499 CVCL_4F50 GM04488 finite cell line human CVCL_4F50 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182500 CVCL_4F57 GM07844 finite cell line human CVCL_4F57 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21182501 CVCL_4F56 GM07842 finite cell line human CVCL_4F56 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182502 CVCL_4F55 GM07523 transformed cell line human CVCL_4F55 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182503 CVCL_4F54 GM06256 finite cell line human CVCL_4F54 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(9)(pter->p11::q21->p11::q21->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21182504 CVCL_4F59 GM08684 finite cell line human CVCL_4F59 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Cys116Tyr (c.347G>A); ClinVar=VCV000226068; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182505 CVCL_4F58 GM08040 finite cell line human CVCL_4F58 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182506 CVCL_WL83 IZD-Ld-1307 spontaneously immortalized cell line CVCL_WL83 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21182507 CVCL_WL82 IZD-Cp 4/13 hybrid cell line CVCL_WL82 CL:0000010 Group: Insect cell line. 21182508 CVCL_WL81 IZD-Cp-2507 spontaneously immortalized cell line CVCL_WL81 CL:0000010 Unspecified Group: Insect cell line. 21182509 CVCL_WL80 IZD-Cp-2202 spontaneously immortalized cell line CVCL_WL80 CL:0000010 Unspecified Group: Insect cell line. 21182510 CVCL_WL87 UCB-Od-1 C-21 spontaneously immortalized cell line CVCL_WL87 CL:0000010 Unspecified Group: Insect cell line. 21182511 CVCL_WL86 UCB-Od-1 spontaneously immortalized cell line CVCL_WL86 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description. Unspecified Doubling time: ~46 hours (at 12th passage), 22 hours (at 95th passage) (PubMed=27445) Group: Insect cell line 21182512 CVCL_WL85 HPB-MB spontaneously immortalized cell line CVCL_WL85 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182513 CVCL_WL84 IZD-Ld-1407 spontaneously immortalized cell line CVCL_WL84 CL:0000010 Derived from sampling site: Testis. Male Group: Insect cell line 21182514 CVCL_WL89 HPB-MB 17S spontaneously immortalized cell line CVCL_WL89 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21182515 CVCL_WL88 UCB-Od-1 C-23 spontaneously immortalized cell line CVCL_WL88 CL:0000010 Unspecified Group: Insect cell line. 21182516 CVCL_4F20 GM11302 transformed cell line human CVCL_4F20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182517 CVCL_4F24 GM11306 transformed cell line human CVCL_4F24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182518 CVCL_4F23 GM11305 transformed cell line human CVCL_4F23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182519 CVCL_4F22 GM11304 transformed cell line human CVCL_4F22 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg294Ter (c.880C>T) (p.Arg306Ter, c.916C>T); ClinVar=VCV000011819; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182520 CVCL_4F21 GM11303 transformed cell line human CVCL_4F21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11303; probable Male 21182521 CVCL_4F28 GM11311 transformed cell line human CVCL_4F28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182522 CVCL_4F27 GM11310 transformed cell line human CVCL_4F27 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg168Ter (c.502C>T) (p.Arg180Ter, c.538C>T); ClinVar=VCV000011828; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182523 CVCL_4F26 GM11308 transformed cell line human CVCL_4F26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11308; probable Female 21182524 CVCL_4F25 GM11307 transformed cell line human CVCL_4F25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11307; probable Male 21182525 CVCL_4F29 GM11312 transformed cell line human CVCL_4F29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182526 CVCL_WL72 MDCK.Xeno spontaneously immortalized cell line dog CVCL_WL72 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Adapted to growth in supsension in Xeno-S001S medium Doubling time: <20 hours (PubMed=31047676) Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21182527 CVCL_WL71 MDCK.SUS2 spontaneously immortalized cell line dog CVCL_WL71 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Adapted to growth in suspension in SMIF8 medium Doubling time: 24 hours (in wave bioreactor), 37 hours (in stirred-tank reactor) (PubMed=20638458) Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21182528 CVCL_WL70 MDCK.SUS1 spontaneously immortalized cell line dog CVCL_WL70 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Adapted to growth in suspension in SMIF8 medium Doubling time: ~50 hours (PubMed=20638458) Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21182529 CVCL_WL76 ssf-MDCK spontaneously immortalized cell line dog CVCL_WL76 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Adapted to growth in suspension in MDCK-SFM medium Group: Serum/protein free medium cell line 21182530 CVCL_WL75 16G9 hybridoma house mouse CVCL_WL75 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P02253; Bovine HIST1H1C (Note=Also reacts with human histone H1). 21182531 CVCL_WL74 MDCK-SFS spontaneously immortalized cell line dog CVCL_WL74 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Adapted to growth in suspension in SFM4BHK21 medium; Virology: Potentially useful for large scale influenza virus production Group: Serum/protein free medium cell line 21182532 CVCL_WL73 HPR116 cancer cell line human CVCL_WL73 CL:0000010 Derived from sampling site: Liver. Female Characteristics: HepaRG cells cryopreserved after differentiation 21182533 CVCL_WL79 IZD-Cp-1508 spontaneously immortalized cell line CVCL_WL79 CL:0000010 Unspecified Group: Insect cell line. 21182534 CVCL_WL78 IZD-Cp-0508 spontaneously immortalized cell line CVCL_WL78 CL:0000010 Unspecified Group: Insect cell line. 21182535 CVCL_WL77 PTM spontaneously immortalized cell line CVCL_WL77 CL:0000010 Unspecified Doubling time: ~25 hours (CelloPub=CLPUB00496). Group: Insect cell line 21182536 CVCL_4F31 GM11314 transformed cell line human CVCL_4F31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182537 CVCL_4F30 GM11313 transformed cell line human CVCL_4F30 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182538 CVCL_4F35 GM16368 transformed cell line human CVCL_4F35 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Thr158Met (c.473C>T) (p.Thr170Met, c.509C>T); ClinVar=VCV000011811; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182539 CVCL_4F34 GM16271 transformed cell line human CVCL_4F34 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Thr158Met (c.473C>T) (p.Thr170Met, c.509C>T); ClinVar=VCV000011811; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182540 CVCL_4F33 GM16270 transformed cell line human CVCL_4F33 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg255Ter (c.763C>T) (p.Arg267Ter, c.799C>T); ClinVar=VCV000011829; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182541 CVCL_4F32 GM11315 transformed cell line human CVCL_4F32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182542 CVCL_4F39 GM16497 transformed cell line human CVCL_4F39 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg255Ter (c.763C>T) (p.Arg267Ter, c.799C>T); ClinVar=VCV000011829; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182543 CVCL_4F38 GM16480 transformed cell line human CVCL_4F38 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182544 CVCL_4F37 GM16405 transformed cell line human CVCL_4F37 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly161Val (c.482G>T) (p.Gly173Val, c.518G>T); ClinVar=VCV000143598; Zygosity=Unspecified (Coriell) Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182545 CVCL_4F36 GM16382 transformed cell line human CVCL_4F36 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Pro387Leufs*9 (c.1160_1185del) (c.1160del26); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182546 CVCL_WL61 HPS-11 cancer cell line human CVCL_WL61 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182547 CVCL_WL60 HPS-10 finite cell line human CVCL_WL60 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182548 CVCL_WL65 HPS-15 finite cell line human CVCL_WL65 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182549 CVCL_WL64 HPS-14 finite cell line human CVCL_WL64 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182550 CVCL_WL63 HPS-13 finite cell line human CVCL_WL63 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182551 CVCL_WL62 HPS-12 finite cell line human CVCL_WL62 CL:0000010 Derived from sampling site: Prostate; stroma Cell type=Prostate stromal cell.. Male 21182552 CVCL_WL69 GR [Mouse mammary tumor] cancer cell line house mouse CVCL_WL69 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757). Female Characteristics: Secretes MMTV 21182553 CVCL_WL68 HTC-M1 cancer cell line Norway rat CVCL_WL68 CL:0000010 Derived from metastatic site: Ascites; Breed/subspecies: Buffalo. Male Virology: Infected by MMTV from GR cell line 21182554 CVCL_WL67 HXEX-ALL1 cancer cell line human CVCL_WL67 CL:0000010 Population: Chinese; Derived from sampling site: Bone marrow. Omics: Genome sequenced Male Doubling time: 26-32 hours (PubMed=31168295) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017232 21182555 CVCL_WL66 HPE-15 cancer cell line human CVCL_WL66 CL:0000010 Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: ~31 hours (PubMed=31020641) 21182556 CVCL_4F02 GM11210 transformed cell line human CVCL_4F02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182557 CVCL_4F01 GM11209 transformed cell line human CVCL_4F01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182558 CVCL_4F00 GM11208 transformed cell line human CVCL_4F00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182559 CVCL_4F06 GM13310 transformed cell line human CVCL_4F06 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182560 CVCL_4F05 GM13309 transformed cell line human CVCL_4F05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182561 CVCL_4F04 GM11212 transformed cell line human CVCL_4F04 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182562 CVCL_4F03 GM11211 transformed cell line human CVCL_4F03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182563 CVCL_4F09 GM13313 transformed cell line human CVCL_4F09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182564 CVCL_4F08 GM13312 transformed cell line human CVCL_4F08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182565 CVCL_4F07 GM13311 transformed cell line human CVCL_4F07 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182566 CVCL_WL50 PANC-1-Cas9-556 cancer cell line human CVCL_WL50 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182567 CVCL_WL54 Teth-CRFK spontaneously immortalized cell line CVCL_WL54 CL:0000010 Transfected with: HGNC; 1119; BST2 Derived from sampling site: Kidney. Female Characteristics: Has a reduced risk of RD-114 contamination by suppressing the release of infectious RD-114 from cells by the antiviral action of BST2/tetherin; Virology: Persistently infected by feline endogenous virus RD-114 Group: Vaccine production cell line 21182568 CVCL_WL53 PANC-1-Cas9-559 cancer cell line human CVCL_WL53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182569 CVCL_WL52 PANC-1-Cas9-558 cancer cell line human CVCL_WL52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182570 CVCL_WL51 PANC-1-Cas9-557 cancer cell line human CVCL_WL51 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182571 CVCL_WL58 GNM cancer cell line human CVCL_WL58 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=26116706). Originally thought to originate from a patient with a gingival carcinoma neck metastasis. 21182572 CVCL_WL57 WCF spontaneously immortalized cell line CVCL_WL57 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3142C0001000000106) It was the sole source of information for this entry. Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 21182573 CVCL_WL56 UM finite cell line human CVCL_WL56 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000209) It was the sole source of information for this entry. Derived from sampling site: Eye; uvea Cell type=Melanocyte.. Male 21182574 CVCL_WL55 VK219 spontaneously immortalized cell line green monkey CVCL_WL55 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; epithelium. Female Characteristics: rKSHV.219 includes a RFP-GFP-Puro construct that contains RFP under the control of the lytic PAN RNA promoter, GFP under the control of human EF-1 alpha promoter and PuroR expressed by the RSV promoter; Virology: Infected with a recombinant human herpesvirus 8 (HHV-8/KSHV) rKSHV.219 Group: Non-human primate cell line 21182575 CVCL_WL59 MDCK-6A8 spontaneously immortalized cell line dog CVCL_WL59 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017154 21182576 CVCL_4F13 GM11271 finite cell line human CVCL_4F13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182577 CVCL_4F12 GM11269 finite cell line human CVCL_4F12 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182578 CVCL_4F11 GM13315 transformed cell line human CVCL_4F11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182579 CVCL_4F10 GM13314 transformed cell line human CVCL_4F10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182580 CVCL_4F17 GM11299 transformed cell line human CVCL_4F17 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg106Trp (c.316C>T) (p.Arg118Trp, c.352C>T); ClinVar=VCV000011814; Zygosity=Heterozygous (PubMed=24508304) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21182581 CVCL_4F16 GM11298 transformed cell line human CVCL_4F16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182582 CVCL_4F15 GM11273 finite cell line human CVCL_4F15 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg106Trp (c.316C>T) (p.Arg118Trp, c.352C>T); ClinVar=VCV000011814; Zygosity=Unspecified (PubMed=11738860; PubMed=12418965) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182583 CVCL_4F14 GM11272 finite cell line human CVCL_4F14 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Argfs*8 (c.1157_1188del32) (p.Leu398Argfs*8, c.1193_1224del32) (1155del32); ClinVar=VCV000143366; Zygosity=Unspecified (PubMed=12418965) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21182584 CVCL_4F19 GM11301 transformed cell line human CVCL_4F19 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Val247Terfs (c.739delG) (p.Met246_Val247insTer) (p.Met258_Val259insTer, c.775delG); ClinVar=VCV000143674; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182585 CVCL_4F18 GM11300 transformed cell line human CVCL_4F18 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg106Trp (c.316C>T) (p.Arg118Trp, c.352C>T); ClinVar=VCV000011814; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182586 CVCL_WL43 hCK spontaneously immortalized cell line dog CVCL_WL43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 46850; ST3GAL1; Knockout cell: Method=CRISPR/Cas9; VGNC; 46851; ST3GAL2; Knockout cell: Method=CRISPR/Cas9; VGNC; -; ST3GAL3; Knockout cell: Method=CRISPR/Cas9; VGNC; 46852; ST3GAL4; Knockout cell: Method=CRISPR/Cas9; VGNC; 46853; ST3GAL5; Knockout cell: Method=CRISPR/Cas9; VGNC; 46854; ST3GAL6; Knockout cell: Method=CRISPR/Cas9; UniProtKB; F1Q495; ST3GAL2L; Transfected with: HGNC; 10860; ST6GAL1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Expresses large amounts of alpha-2,6-sialoglycans and small amounts of alpha-2,3-sialoglycans; Virology: Will be useful for influenza virus research, particularly studies involving human A/H3N2 influenza viruses and possibly for vaccine production Group: Vaccine production cell line 21182587 CVCL_WL42 UMK-1 [Human gastric carcinoma] cancer cell line human CVCL_WL42 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 28 hours (CelloPub=CLPUB00504) 21182588 CVCL_WL41 UMK-2 cancer cell line human CVCL_WL41 CL:0000010 Population: Japanese. 21182589 CVCL_WL40 UMK-1 [Human bladder carcinoma] cancer cell line human CVCL_WL40 CL:0000010 Population: Japanese; Derived from sampling site: Urinary bladder. Male Doubling time: 48 hours (PubMed=7610502) 21182590 CVCL_WL47 537-EBV transformed cell line human CVCL_WL47 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182591 CVCL_WL46 HITS glioma cancer cell line Norway rat CVCL_WL46 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: Wistar. Unspecified 21182592 CVCL_WL45 MM-Sv/HP transformed cell line house mouse CVCL_WL45 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad5-SV40 hybrid virus; Derived from sampling site: Articular cartilage Cell type=Chondrocyte.; Breed/subspecies: 129S9/SvEvH. Unspecified 21182593 CVCL_WL44 GM07166VA7 transformed cell line human CVCL_WL44 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Could be identical to GM15989 (Cellosaurus=CVCL_F626) 21182594 CVCL_WL49 PANC-1-Cas9-555 cancer cell line human CVCL_WL49 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182595 CVCL_WL48 PANC-1-Cas9-554 cancer cell line human CVCL_WL48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21182596 CVCL_NR91 BayGenomics ES cell line RRS439 embryonic stem cell house mouse CVCL_NR91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109153; Ktn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182597 CVCL_NR90 BayGenomics ES cell line RRS435 embryonic stem cell house mouse CVCL_NR90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444554; Mapkap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182598 CVCL_WL32 KIZ-8401 transformed cell line CVCL_WL32 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21182599 CVCL_WL31 KIZ-7901 finite cell line CVCL_WL31 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21182600 CVCL_WL30 KCB 96008 finite cell line CVCL_WL30 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21182601 CVCL_NR89 BayGenomics ES cell line RRS434 embryonic stem cell house mouse CVCL_NR89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338071; Ikbkb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182602 CVCL_NR88 BayGenomics ES cell line RRS432 embryonic stem cell house mouse CVCL_NR88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108202; Pcbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182603 CVCL_WL36 RCM-2 cancer cell line human CVCL_WL36 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Unspecified 21182604 CVCL_NR87 BayGenomics ES cell line RRS431 embryonic stem cell house mouse CVCL_NR87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442794; Dennd1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182605 CVCL_WL35 extEqFL transformed cell line CVCL_WL35 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Doubling time, sex of donor and breed of donor from personal communication of Thorsteinsdottir L Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal liver; Breed/subspecies: Icelandic. Female Virology: Susceptible to infection by equine herpesvirus type 2 (EHV-2) and equine herpesvirus type 5 (EHV-5) Senescence: Has an extended life span, but it is not sure if it is immortal; Doubling time: ~24 hours (Direct_author_submission) 21182606 CVCL_NR86 BayGenomics ES cell line RRS430 embryonic stem cell house mouse CVCL_NR86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142810; Ppip5k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182607 CVCL_WL34 extEqFK transformed cell line CVCL_WL34 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Doubling time, sex of donor and breed of donor from personal communication of Thorsteinsdottir L Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fetal kidney; Breed/subspecies: Icelandic. Female Virology: Susceptible to infection by equine herpesvirus type 2 (EHV-2) and equine herpesvirus type 5 (EHV-5) Can produce a high titer of EHV-5. Senescence: Has an extended life span, but it is not sure if it is immortal; Doubling time: ~24 hours (Direct_author_submission) 21182608 CVCL_NR85 BayGenomics ES cell line RRS427 embryonic stem cell house mouse CVCL_NR85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182609 CVCL_WL33 TSR6 transformed cell line CVCL_WL33 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Age/sex of donor and doubling time from personal communication of Gu T.-L Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Doubling time: ~20 hours (Direct_author_submission) 21182610 CVCL_NR84 BayGenomics ES cell line RRS424 embryonic stem cell house mouse CVCL_NR84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136980; Kdm5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182611 CVCL_NR83 BayGenomics ES cell line RRS419 embryonic stem cell house mouse CVCL_NR83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679787; Nploc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182612 CVCL_WL39 HSG-S6 cancer cell line human CVCL_WL39 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 30.5 hours (DOI=10.2330/joralbiosci1965.34.164) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (HSG) has been shown to be a HeLa derivative. 21182613 CVCL_NR82 BayGenomics ES cell line RRS415 embryonic stem cell house mouse CVCL_NR82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182614 CVCL_WL38 HSG-S8 cancer cell line human CVCL_WL38 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 49.3 hours (DOI=10.2330/joralbiosci1965.34.164); 53.6 hours, in medium SFM101 (PubMed=8439320) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (HSG) has been shown to be a HeLa derivative. 21182615 CVCL_NR81 BayGenomics ES cell line RRS410 embryonic stem cell house mouse CVCL_NR81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923304; Prrc2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182616 CVCL_WL37 RCM-3 cancer cell line human CVCL_WL37 CL:0000010 Population: Japanese; Derived from sampling site: Rectum. Unspecified 21182617 CVCL_WL19 G-OF3iPS25 induced pluripotent stem cell human CVCL_WL19 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Asp461fs (c.1383delC); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182618 CVCL_WL21 G-OF4iPS12 induced pluripotent stem cell human CVCL_WL21 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Leu506Arg (c.1517T>G); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182619 CVCL_WL20 G-OF3iPS26 induced pluripotent stem cell human CVCL_WL20 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Asp461fs (c.1383delC); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182620 CVCL_NR99 BayGenomics ES cell line RRS469 embryonic stem cell house mouse CVCL_NR99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2679787; Nploc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182621 CVCL_WL25 G-OF4iPS18 induced pluripotent stem cell human CVCL_WL25 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182622 CVCL_NR98 BayGenomics ES cell line RRS466 embryonic stem cell house mouse CVCL_NR98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201408; Srpk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182623 CVCL_WL24 G-OF2iPS10 induced pluripotent stem cell human CVCL_WL24 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182624 CVCL_NR97 BayGenomics ES cell line RRS464 embryonic stem cell house mouse CVCL_NR97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106639; Mthfr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182625 CVCL_WL23 G-OF2iPS3 induced pluripotent stem cell human CVCL_WL23 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182626 CVCL_NR96 BayGenomics ES cell line RRS455 embryonic stem cell house mouse CVCL_NR96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182627 CVCL_WL22 G-OF4iPS23 induced pluripotent stem cell human CVCL_WL22 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Leu506Arg (c.1517T>G); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182628 CVCL_NR95 BayGenomics ES cell line RRS453 embryonic stem cell house mouse CVCL_NR95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182629 CVCL_WL29 Hepama-18 hybridoma house mouse CVCL_WL29 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human hepatocellular carcinoma cell lines. Group: Patented cell line 21182630 CVCL_NR94 BayGenomics ES cell line RRS446 embryonic stem cell house mouse CVCL_NR94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926159; Mdn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182631 CVCL_WL28 G-OF4iPS15 induced pluripotent stem cell human CVCL_WL28 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182632 CVCL_NR93 BayGenomics ES cell line RRS445 embryonic stem cell house mouse CVCL_NR93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109473; Usp34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182633 CVCL_WL27 G-OF4iPS8 induced pluripotent stem cell human CVCL_WL27 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182634 CVCL_NR92 BayGenomics ES cell line RRS440 embryonic stem cell house mouse CVCL_NR92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99948; Zfhx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182635 CVCL_WL26 G-OF4iPS3 induced pluripotent stem cell human CVCL_WL26 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182636 CVCL_EY04 ND13769 transformed cell line human CVCL_EY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182637 CVCL_EY03 ND13710 transformed cell line human CVCL_EY03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182638 CVCL_EY02 ND13709 transformed cell line human CVCL_EY02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182639 CVCL_EY01 ND13701 transformed cell line human CVCL_EY01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182640 CVCL_EY08 ND13813 transformed cell line human CVCL_EY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182641 CVCL_EY07 ND13810 transformed cell line human CVCL_EY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182642 CVCL_EY06 ND13807 transformed cell line human CVCL_EY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182643 CVCL_EY05 ND13800 transformed cell line human CVCL_EY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182644 CVCL_EY00 ND13672 transformed cell line human CVCL_EY00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182645 CVCL_4F86 GM01304 finite cell line human CVCL_4F86 CL:0000010 Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21182646 CVCL_4F85 GM23919 transformed cell line human CVCL_4F85 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182647 CVCL_4F84 GM23496 finite cell line human CVCL_4F84 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182648 CVCL_4F83 GM23495 transformed cell line human CVCL_4F83 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182649 CVCL_4F89 GM01307 finite cell line human CVCL_4F89 CL:0000010 Population: Caucasian; Derived from sampling site: Fallopian tube Cell type=Fibroblast.. Female 21182650 CVCL_4F88 GM01306 finite cell line human CVCL_4F88 CL:0000010 Population: Caucasian; Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21182651 CVCL_4F87 GM01305 finite cell line human CVCL_4F87 CL:0000010 Derived from sampling site: Uterus Cell type=Fibroblast.. Female 21182652 CVCL_4F82 GM21192 transformed cell line human CVCL_4F82 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182653 CVCL_4F81 GM17475 finite cell line human CVCL_4F81 CL:0000010 Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; p.Asn122Asp (c.364A>G); ClinVar=VCV000376917; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182654 CVCL_4F80 GM17473 finite cell line human CVCL_4F80 CL:0000010 Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Gly209Ser (c.625G>A) (G185S); ClinVar=VCV000003831; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182655 CVCL_4F97 GM05890 transformed cell line human CVCL_4F97 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182656 CVCL_4F96 GM05889 finite cell line human CVCL_4F96 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182657 CVCL_4F95 GM05888 transformed cell line human CVCL_4F95 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182658 CVCL_4F94 GM07924 finite cell line human CVCL_4F94 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21182659 CVCL_4F99 GM05892 transformed cell line human CVCL_4F99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182660 CVCL_4F98 GM05891 finite cell line human CVCL_4F98 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182661 CVCL_4F93 GM07800 transformed cell line human CVCL_4F93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182662 CVCL_4F92 GM08154 finite cell line human CVCL_4F92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182663 CVCL_4F91 GM05156 transformed cell line human CVCL_4F91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182664 CVCL_4F90 GM05966 transformed cell line human CVCL_4F90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21182665 CVCL_4F64 GM11408 finite cell line human CVCL_4F64 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21182666 CVCL_4F63 GM11320 transformed cell line human CVCL_4F63 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Ala56Pro (c.166G>C); Zygosity=Heterozygous (from familial inference of GM11319) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182667 CVCL_4F62 GM11319 transformed cell line human CVCL_4F62 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Ala56Pro (c.166G>C); Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182668 CVCL_4F61 GM09093 finite cell line human CVCL_4F61 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182669 CVCL_4F68 GM13269 finite cell line human CVCL_4F68 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182670 CVCL_4F67 GM13267 finite cell line human CVCL_4F67 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182671 CVCL_4F66 GM13266 finite cell line human CVCL_4F66 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182672 CVCL_4F65 GM11657 transformed cell line human CVCL_4F65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182673 CVCL_4F69 GM13272 finite cell line human CVCL_4F69 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182674 CVCL_4F60 GM08768 finite cell line human CVCL_4F60 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182675 CVCL_4F75 GM16866 finite cell line human CVCL_4F75 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21182676 CVCL_4F74 GM16514 finite cell line human CVCL_4F74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182677 CVCL_4F73 GM16513 finite cell line human CVCL_4F73 CL:0000010 Sequence variation: Mutation; HGNC; 8850; PEX1; Simple; p.Ile700Tyrfs*42 (c.2097dupT); ClinVar=VCV000007519; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182678 CVCL_4F72 GM16495 transformed cell line human CVCL_4F72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182679 CVCL_4F79 GM17472 finite cell line human CVCL_4F79 CL:0000010 Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Arg171Trp (c.511C>T) (R147W); ClinVar=VCV000003830; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Gly209Ser (c.625G>A) (G185S); ClinVar=VCV000003831; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182680 CVCL_4F78 GM17471 finite cell line human CVCL_4F78 CL:0000010 Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Arg171Trp (c.511C>T) (R147W); ClinVar=VCV000003830; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182681 CVCL_4F77 GM17470 finite cell line human CVCL_4F77 CL:0000010 Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Arg107Cys (c.319C>T); ClinVar=VCV000003826; Zygosity=Homozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21182682 CVCL_4F76 GM17398 finite cell line human CVCL_4F76 CL:0000010 Sequence variation: Mutation; HGNC; 22965; PEX26; Simple; p.Thr77fs*139 (c.230+1G>T) (IVS2+1G>T); Zygosity=Homozygous (PubMed=16257970) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21182683 CVCL_4F71 GM13275 finite cell line human CVCL_4F71 CL:0000010 Sequence variation: Mutation; HGNC; 89; ACADM; Simple; p.Lys329Glu (c.985A>G); ClinVar=VCV000003586; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21182684 CVCL_4F70 GM13273 finite cell line human CVCL_4F70 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21182685 CVCL_F959 K-231 cancer cell line Norway rat CVCL_F959 CL:0000010 Breed/subspecies: ACI/N. Female 21182686 CVCL_EX59 ND12482 transformed cell line human CVCL_EX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182687 CVCL_F958 EI cancer cell line human CVCL_F958 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 50.5 hours (PubMed=7669752) Part of: MD Anderson Cell Lines Project 21182688 CVCL_EX58 ND12431 transformed cell line human CVCL_EX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182689 CVCL_F957 225-G11 transformed cell line human CVCL_F957 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21182690 CVCL_EX57 ND12418 transformed cell line human CVCL_EX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182691 CVCL_F952 BP-8 cancer cell line house mouse CVCL_F952 CL:0000010 Breed/subspecies: C3H/HeN. Male 21182692 CVCL_EX52 ND12311 transformed cell line human CVCL_EX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182693 CVCL_F951 5L cancer cell line Norway rat CVCL_F951 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Omics: Proteome analysis Male 21182694 CVCL_EX51 ND12259 transformed cell line human CVCL_EX51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182695 CVCL_F950 1616-MUC1 transformed cell line human CVCL_F950 CL:0000010 Transfected with: HGNC; 7508; MUC1 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB1877; true Male 21182696 CVCL_EX50 ND12230 transformed cell line human CVCL_EX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182697 CVCL_EX56 ND12379 transformed cell line human CVCL_EX56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182698 CVCL_F956 TLR4 conditionally immortalized cell line house mouse CVCL_F956 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21182699 CVCL_EX55 ND12335 transformed cell line human CVCL_EX55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182700 CVCL_F955 TLR1 conditionally immortalized cell line house mouse CVCL_F955 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21182701 CVCL_EX54 ND12330 transformed cell line human CVCL_EX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182702 CVCL_F954 SN36 cancer cell line house mouse CVCL_F954 CL:0000010 21182703 CVCL_EX53 ND12328 transformed cell line human CVCL_EX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182704 CVCL_F953 SC-6-JCK cancer cell line human CVCL_F953 CL:0000010 Miscellaneous: This is not a cell line but a xenograft Population: Japanese; Derived from metastatic site: Lymph node. Discontinued: RCB; RCB2130; true Male 21182705 CVCL_F969 AH60C-TC cancer cell line Norway rat CVCL_F969 CL:0000010 Breed/subspecies: Donryu. Male 21182706 CVCL_EX69 ND12723 transformed cell line human CVCL_EX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182707 CVCL_F968 AH44-TC cancer cell line Norway rat CVCL_F968 CL:0000010 Breed/subspecies: Wistar. Male 21182708 CVCL_EX68 ND12710 transformed cell line human CVCL_EX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182709 CVCL_F963 AH13-TC cancer cell line Norway rat CVCL_F963 CL:0000010 Derived from metastatic site: Ascites. 21182710 CVCL_EX63 ND12534 transformed cell line human CVCL_EX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182711 CVCL_F962 A4 [Mouse] transformed cell line house mouse CVCL_F962 CL:0000010 Transfected with: HGNC; 3430; ERBB2 (with p.Val659Glu) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21182712 CVCL_EX62 ND12529 transformed cell line human CVCL_EX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182713 CVCL_EX61 ND12497 transformed cell line human CVCL_EX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182714 CVCL_F961 TBR10-1 conditionally immortalized cell line house mouse CVCL_F961 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21182715 CVCL_EX60 ND12486 transformed cell line human CVCL_EX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182716 CVCL_F960 SMAP1dm cancer cell line house mouse CVCL_F960 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:2138261; Smap1 Breed/subspecies: C57BL/6. Female 21182717 CVCL_F967 AH34-TC cancer cell line Norway rat CVCL_F967 CL:0000010 Breed/subspecies: Wistar. Male 21182718 CVCL_EX67 ND12708 transformed cell line human CVCL_EX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182719 CVCL_F966 6C3HED-OG cancer cell line house mouse CVCL_F966 CL:0000010 Breed/subspecies: C3H/He. 21182720 CVCL_EX66 ND12678 transformed cell line human CVCL_EX66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182721 CVCL_F965 AH13/NMO-R-TC cancer cell line Norway rat CVCL_F965 CL:0000010 Selected for resistance to: ChEBI; CHEBI:82354; Nitrogen mustard N-oxide; Derived from metastatic site: Ascites. 21182722 CVCL_EX65 ND12623 transformed cell line human CVCL_EX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182723 CVCL_F964 AH13/6MP-R-TC cancer cell line Norway rat CVCL_F964 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Derived from metastatic site: Ascites. 21182724 CVCL_EX64 ND12595 transformed cell line human CVCL_EX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182725 CVCL_F938 GM-95 cancer cell line house mouse CVCL_F938 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21182726 CVCL_EX38 ND11902 transformed cell line human CVCL_EX38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182727 CVCL_F937 B16VDXR cancer cell line house mouse CVCL_F937 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: 25 +- 1.75 hours (PubMed=3730255) 21182728 CVCL_EX37 ND11891 transformed cell line human CVCL_EX37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182729 CVCL_F936 B16 cancer cell line house mouse CVCL_F936 CL:0000010 Miscellaneous: This line seems to be the B78 line described in PubMed=4981070 which itself seems to be derived from the HFH-18 line that itself originate from a B16 melanoma Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: ~28 hours (lot 07242000), 20-21 hours (lot 06122003), ~1 day (lot 10062005), ~20 hours (lot 03232009), ~27 hours (lot 03312017), ~33 hours (lot 01122021) (JCRB) 21182730 CVCL_EX36 ND11888 transformed cell line human CVCL_EX36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182731 CVCL_F935 LY-80-TC cancer cell line Norway rat CVCL_F935 CL:0000010 Derived from metastatic site: Ascites. 21182732 CVCL_EX35 ND11865 transformed cell line human CVCL_EX35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182733 CVCL_F939 GM-20 cancer cell line house mouse CVCL_F939 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21182734 CVCL_EX39 ND11925 transformed cell line human CVCL_EX39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182735 CVCL_F930 LY-336-TC cancer cell line Norway rat CVCL_F930 CL:0000010 Derived from metastatic site: Ascites. 21182736 CVCL_EX30 ND11716 transformed cell line human CVCL_EX30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182737 CVCL_F934 LY-7-TC cancer cell line Norway rat CVCL_F934 CL:0000010 Derived from metastatic site: Ascites. 21182738 CVCL_EX34 ND11825 transformed cell line human CVCL_EX34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182739 CVCL_F933 LY-54-TC cancer cell line Norway rat CVCL_F933 CL:0000010 Derived from metastatic site: Ascites. 21182740 CVCL_EX33 ND11819 transformed cell line human CVCL_EX33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182741 CVCL_F932 LY-52-TC cancer cell line Norway rat CVCL_F932 CL:0000010 Derived from metastatic site: Ascites. 21182742 CVCL_EX32 ND11811 transformed cell line human CVCL_EX32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182743 CVCL_F931 LY-5-TC cancer cell line Norway rat CVCL_F931 CL:0000010 Derived from metastatic site: Ascites. 21182744 CVCL_EX31 ND11751 transformed cell line human CVCL_EX31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182745 CVCL_F949 1616-EB transformed cell line human CVCL_F949 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB1931; true Male 21182746 CVCL_EX49 ND12177 transformed cell line human CVCL_EX49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182747 CVCL_F948 KPK13 cancer cell line human CVCL_F948 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 51 hours (PubMed=7176042) 21182748 CVCL_EX48 ND12170 transformed cell line human CVCL_EX48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182749 CVCL_F947 KPK1 cancer cell line human CVCL_F947 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 29 hours (PubMed=7176042) 21182750 CVCL_EX47 ND12146 transformed cell line human CVCL_EX47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182751 CVCL_F946 FAL3 transformed cell line human CVCL_F946 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB2284; true Male 21182752 CVCL_EX46 ND12127 transformed cell line human CVCL_EX46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182753 CVCL_F941 GM-89 cancer cell line house mouse CVCL_F941 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21182754 CVCL_EX41 ND12026 transformed cell line human CVCL_EX41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182755 CVCL_F940 GM-70 cancer cell line house mouse CVCL_F940 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21182756 CVCL_EX40 ND11927 transformed cell line human CVCL_EX40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182757 CVCL_F945 IT832 cancer cell line human CVCL_F945 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB2289; true Male 21182758 CVCL_EX45 ND12123 transformed cell line human CVCL_EX45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182759 CVCL_F944 JLS-V9 BudR spontaneously immortalized cell line house mouse CVCL_F944 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Bone marrow; Breed/subspecies: BALB/c. Discontinued: RCB; RCB2644; true Unspecified 21182760 CVCL_EX44 ND12108 transformed cell line human CVCL_EX44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182761 CVCL_F943 EL4-TK cancer cell line house mouse CVCL_F943 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified 21182762 CVCL_EX43 ND12056 transformed cell line human CVCL_EX43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182763 CVCL_F942 B16-F10-Nex2 cancer cell line house mouse CVCL_F942 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Melanotic Shows low immunogenicity and moderate virulence. Forms subcutaneous tumours which are lethal, but do not metastasize to the lung unless injected intravenously (PubMed=15457088). 21182764 CVCL_EX42 ND12055 transformed cell line human CVCL_EX42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182765 CVCL_EX16 ND11540 transformed cell line human CVCL_EX16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182766 CVCL_F916 YN-1-0-A cancer cell line human CVCL_F916 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21182767 CVCL_F915 ILT-Yan transformed cell line human CVCL_F915 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182768 CVCL_EX15 ND11538 transformed cell line human CVCL_EX15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182769 CVCL_F914 ILT-Ter transformed cell line human CVCL_F914 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182770 CVCL_EX14 ND11534 transformed cell line human CVCL_EX14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182771 CVCL_F913 ILT-Su transformed cell line human CVCL_F913 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182772 CVCL_EX13 ND11531 transformed cell line human CVCL_EX13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182773 CVCL_F919 DBLA-10-TC cancer cell line Norway rat CVCL_F919 CL:0000010 Breed/subspecies: Donryu. Female 21182774 CVCL_EX19 ND11575 transformed cell line human CVCL_EX19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182775 CVCL_F918 DBLA-1 cancer cell line Norway rat CVCL_F918 CL:0000010 Breed/subspecies: Donryu. Female 21182776 CVCL_EX18 ND11552 transformed cell line human CVCL_EX18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182777 CVCL_F917 AMC-60-TC cancer cell line Norway rat CVCL_F917 CL:0000010 Breed/subspecies: ACI/N. Male 21182778 CVCL_EX17 ND11549 transformed cell line human CVCL_EX17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182779 CVCL_F912 ILT-Om transformed cell line human CVCL_F912 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182780 CVCL_EX12 ND11519 transformed cell line human CVCL_EX12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182781 CVCL_F911 ILT-My transformed cell line human CVCL_F911 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182782 CVCL_EX11 ND11518 transformed cell line human CVCL_EX11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182783 CVCL_F910 ILT-Mor transformed cell line human CVCL_F910 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182784 CVCL_EX10 ND11515 transformed cell line human CVCL_EX10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182785 CVCL_EX27 ND11689 transformed cell line human CVCL_EX27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182786 CVCL_F927 TR-CSFB5 conditionally immortalized cell line Norway rat CVCL_F927 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21182787 CVCL_EX26 ND11640 transformed cell line human CVCL_EX26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182788 CVCL_F926 TR-CSFB4 conditionally immortalized cell line Norway rat CVCL_F926 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21182789 CVCL_EX25 ND11639 transformed cell line human CVCL_EX25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182790 CVCL_F925 TR-CSFB3 conditionally immortalized cell line Norway rat CVCL_F925 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-6508 21182791 CVCL_EX24 ND11622 transformed cell line human CVCL_EX24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182792 CVCL_F924 TR-CSFB2 conditionally immortalized cell line Norway rat CVCL_F924 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21182793 CVCL_F929 L1210 TGR3 cancer cell line house mouse CVCL_F929 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21182794 CVCL_EX29 ND11713 transformed cell line human CVCL_EX29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182795 CVCL_F928 IHGGK cancer cell line human CVCL_F928 CL:0000010 Population: Japanese Discontinued: RCB; RCB2091; true. 21182796 CVCL_EX28 ND11695 transformed cell line human CVCL_EX28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182797 CVCL_EX23 ND11613 transformed cell line human CVCL_EX23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182798 CVCL_F923 TR-CSFB1 conditionally immortalized cell line Norway rat CVCL_F923 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; choroid plexus Cell type=Epithelial cell.; Breed/subspecies: Wistar SV40-tsA58 transgenic. Male 21182799 CVCL_F922 CPC-2 cancer cell line human CVCL_F922 CL:0000010 Population: Japanese; Derived from sampling site: Brain; choroid plexus. Male 21182800 CVCL_EX22 ND11609 transformed cell line human CVCL_EX22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182801 CVCL_F921 DBLA-9-TC cancer cell line Norway rat CVCL_F921 CL:0000010 Breed/subspecies: Donryu. Female 21182802 CVCL_EX21 ND11604 transformed cell line human CVCL_EX21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182803 CVCL_F920 DBLA-6-TC cancer cell line Norway rat CVCL_F920 CL:0000010 Breed/subspecies: Donryu. Female 21182804 CVCL_EX20 ND11603 transformed cell line human CVCL_EX20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182805 CVCL_F905 DM868 cancer cell line human CVCL_F905 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. 21182806 CVCL_EX05 ND11416 transformed cell line human CVCL_EX05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182807 CVCL_F904 DM833 cancer cell line human CVCL_F904 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182808 CVCL_EX04 ND11415 transformed cell line human CVCL_EX04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182809 CVCL_F903 DM792 cancer cell line human CVCL_F903 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182810 CVCL_EX03 ND11409 transformed cell line human CVCL_EX03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182811 CVCL_F902 DM751 cancer cell line human CVCL_F902 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182812 CVCL_EX02 ND11383 transformed cell line human CVCL_EX02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182813 CVCL_F909 ILT-As transformed cell line human CVCL_F909 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21182814 CVCL_EX09 ND11509 transformed cell line human CVCL_EX09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182815 CVCL_EX08 ND11502 transformed cell line human CVCL_EX08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182816 CVCL_F908 XPPL17 transformed cell line human CVCL_F908 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182817 CVCL_EX07 ND11500 transformed cell line human CVCL_EX07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182818 CVCL_F907 XPML17 transformed cell line human CVCL_F907 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182819 CVCL_F906 DM92 cancer cell line human CVCL_F906 HLA typing: A*01,03; B*15; C*03 (PubMed=2404572) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 21182820 CVCL_EX06 ND11442 transformed cell line human CVCL_EX06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182821 CVCL_F901 DM738 cancer cell line human CVCL_F901 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182822 CVCL_EX01 ND11373 transformed cell line human CVCL_EX01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182823 CVCL_F900 DM733 cancer cell line human CVCL_F900 From: Duke University Medical Center; Durham; USA CL:0000010 Omics: Transcriptome analysis by microarray. Microsatellite instability: Stable (MSS) (PubMed=19147755) 21182824 CVCL_EX00 ND11322 transformed cell line human CVCL_EX00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182825 CVCL_WL09 OC-3 cancer cell line human CVCL_WL09 CL:0000010 Derived from metastatic site: Lymph node. Male 21182826 CVCL_WL08 OC-2 cancer cell line human CVCL_WL08 CL:0000010 Derived from metastatic site: Lymph node. Female 21182827 CVCL_WL10 388F1 hybridoma house mouse CVCL_WL10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14174; Human MIF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10472 21182828 CVCL_NR69 BayGenomics ES cell line RRS364 embryonic stem cell house mouse CVCL_NR69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99146; Ybx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182829 CVCL_NR68 BayGenomics ES cell line RRS360 embryonic stem cell house mouse CVCL_NR68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182830 CVCL_NR67 BayGenomics ES cell line RRS358 embryonic stem cell house mouse CVCL_NR67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182831 CVCL_NR66 BayGenomics ES cell line RRS349 embryonic stem cell house mouse CVCL_NR66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144013; Xpo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182832 CVCL_WL14 HuO9-L6 cancer cell line human CVCL_WL14 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Female Characteristics: Low metastatic phenotype Doubling time: 48.6 hours (PubMed=14669798) 21182833 CVCL_NR65 BayGenomics ES cell line RRS345 embryonic stem cell house mouse CVCL_NR65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917829; Zc3h11a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182834 CVCL_WL13 HuO9-L13 cancer cell line human CVCL_WL13 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Female Characteristics: Low metastatic phenotype Doubling time: 48.6 hours (PubMed=14669798) 21182835 CVCL_NR64 BayGenomics ES cell line RRS344 embryonic stem cell house mouse CVCL_NR64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182836 CVCL_WL12 HuO9-L12 cancer cell line human CVCL_WL12 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Female Characteristics: Low metastatic phenotype Doubling time: 44.9 hours (PubMed=14669798) 21182837 CVCL_NR63 BayGenomics ES cell line RRS343 embryonic stem cell house mouse CVCL_NR63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102465; Tex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182838 CVCL_WL11 HuO9-H3 cancer cell line human CVCL_WL11 CL:0000010 Population: Japanese; Derived from sampling site: Bone; right distal femur. Omics: Transcriptome analysis by microarray Female Characteristics: Highly metastatic Doubling time: 49.3 hours (PubMed=14669798) 21182839 CVCL_NR62 BayGenomics ES cell line RRS341 embryonic stem cell house mouse CVCL_NR62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330294; Hnrnpab Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182840 CVCL_WL18 G-OF2iPS8 induced pluripotent stem cell human CVCL_WL18 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182841 CVCL_NR61 BayGenomics ES cell line RRS339 embryonic stem cell house mouse CVCL_NR61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136459; Cdc42bpb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182842 CVCL_WL17 G-OF2iPS5 induced pluripotent stem cell human CVCL_WL17 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; c.652G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182843 CVCL_NR60 BayGenomics ES cell line RRS338 embryonic stem cell house mouse CVCL_NR60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182844 CVCL_WL16 G-OF1iPS6 induced pluripotent stem cell human CVCL_WL16 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Leu447fs (c.1341_1344delACTC); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182845 CVCL_WL15 G-OF1iPS1 induced pluripotent stem cell human CVCL_WL15 CL:0000010 Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Leu447fs (c.1341_1344delACTC); Zygosity=Heterozygous (PubMed=28915250) Derived from sampling site: Oral cavity; oral mucosa. Male 21182846 CVCL_NR80 BayGenomics ES cell line RRS409 embryonic stem cell house mouse CVCL_NR80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137355; Trim11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182847 CVCL_NR79 BayGenomics ES cell line RRS408 embryonic stem cell house mouse CVCL_NR79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203517; Birc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182848 CVCL_NR78 BayGenomics ES cell line RRS405 embryonic stem cell house mouse CVCL_NR78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182849 CVCL_NR77 BayGenomics ES cell line RRS400 embryonic stem cell house mouse CVCL_NR77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922928; Ippk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182850 CVCL_WL03 RBM2 cancer cell line human CVCL_WL03 CL:0000010 Derived from metastatic site: Bone marrow; rib. Unspecified 21182851 CVCL_NR76 BayGenomics ES cell line RRS388 embryonic stem cell house mouse CVCL_NR76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182852 CVCL_WL02 RBM1 [Human esophagogastric carcinoma] cancer cell line human CVCL_WL02 CL:0000010 Derived from metastatic site: Bone marrow. Unspecified 21182853 CVCL_NR75 BayGenomics ES cell line RRS382 embryonic stem cell house mouse CVCL_NR75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182854 CVCL_WL01 MG63.3 cancer cell line human CVCL_WL01 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone; left femur. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Has a high metastatic potential 21182855 CVCL_NR74 BayGenomics ES cell line RRS381 embryonic stem cell house mouse CVCL_NR74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97316; Nfya Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182856 CVCL_WL00 KD iPS induced pluripotent stem cell human CVCL_WL00 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; lip Cell type=Fibroblast.. Female 21182857 CVCL_NR73 BayGenomics ES cell line RRS380 embryonic stem cell house mouse CVCL_NR73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914006; Cfap97 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182858 CVCL_WL07 OC-1 cancer cell line human CVCL_WL07 CL:0000010 Derived from metastatic site: Ascites. Male 21182859 CVCL_NR72 BayGenomics ES cell line RRS377 embryonic stem cell house mouse CVCL_NR72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144157; Usp22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182860 CVCL_WL06 RBM5 cancer cell line human CVCL_WL06 CL:0000010 Derived from metastatic site: Bone marrow; rib. Unspecified 21182861 CVCL_NR71 BayGenomics ES cell line RRS369 embryonic stem cell house mouse CVCL_NR71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341828; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182862 CVCL_WL05 RBM4 cancer cell line human CVCL_WL05 CL:0000010 Derived from metastatic site: Bone marrow; rib. Unspecified 21182863 CVCL_NR70 BayGenomics ES cell line RRS365 embryonic stem cell house mouse CVCL_NR70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929510; Zfand6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182864 CVCL_WL04 RBM3 cancer cell line human CVCL_WL04 CL:0000010 Derived from metastatic site: Bone marrow; rib. Unspecified 21182865 CVCL_NR49 BayGenomics ES cell line RRS318 embryonic stem cell house mouse CVCL_NR49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347044; Orc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182866 CVCL_NR48 BayGenomics ES cell line RRS317 embryonic stem cell house mouse CVCL_NR48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3649821; Gm14411 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182867 CVCL_NR47 BayGenomics ES cell line RRS314 embryonic stem cell house mouse CVCL_NR47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196224; Cdk8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182868 CVCL_NR46 BayGenomics ES cell line RRS313 embryonic stem cell house mouse CVCL_NR46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681271; Pigl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182869 CVCL_NR45 BayGenomics ES cell line RRS310 embryonic stem cell house mouse CVCL_NR45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182870 CVCL_NR44 BayGenomics ES cell line RRS307 embryonic stem cell house mouse CVCL_NR44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914451; Glod4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182871 CVCL_NR43 BayGenomics ES cell line RRS305 embryonic stem cell house mouse CVCL_NR43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182872 CVCL_NR42 BayGenomics ES cell line RRS300 embryonic stem cell house mouse CVCL_NR42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893579; Khdrbs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182873 CVCL_NR41 BayGenomics ES cell line RRS297 embryonic stem cell house mouse CVCL_NR41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109377; Ell Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182874 CVCL_NR40 BayGenomics ES cell line RRS294 embryonic stem cell house mouse CVCL_NR40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343489; Mpdz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182875 CVCL_NR59 BayGenomics ES cell line RRS337 embryonic stem cell house mouse CVCL_NR59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107943; Cct6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182876 CVCL_NR58 BayGenomics ES cell line RRS334 embryonic stem cell house mouse CVCL_NR58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309481; Trip12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182877 CVCL_NR57 BayGenomics ES cell line RRS331 embryonic stem cell house mouse CVCL_NR57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182878 CVCL_NR56 BayGenomics ES cell line RRS330 embryonic stem cell house mouse CVCL_NR56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925836; Srbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182879 CVCL_NR55 BayGenomics ES cell line RRS329 embryonic stem cell house mouse CVCL_NR55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859026; Cnot4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182880 CVCL_NR54 BayGenomics ES cell line RRS326 embryonic stem cell house mouse CVCL_NR54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923827; Faf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182881 CVCL_NR53 BayGenomics ES cell line RRS325 embryonic stem cell house mouse CVCL_NR53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182882 CVCL_NR52 BayGenomics ES cell line RRS323 embryonic stem cell house mouse CVCL_NR52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098280; Crebbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182883 CVCL_NR51 BayGenomics ES cell line RRS322 embryonic stem cell house mouse CVCL_NR51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914831; Tbc1d23 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182884 CVCL_NR50 BayGenomics ES cell line RRS321 embryonic stem cell house mouse CVCL_NR50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104627; Dst Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182885 CVCL_F996 AH414-TC cancer cell line Norway rat CVCL_F996 CL:0000010 Breed/subspecies: ACI/N. Male 21182886 CVCL_EX96 ND13590 transformed cell line human CVCL_EX96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182887 CVCL_F995 AH143A-TC cancer cell line Norway rat CVCL_F995 CL:0000010 Derived from metastatic site: Ascites. Male 21182888 CVCL_EX95 ND13545 transformed cell line human CVCL_EX95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182889 CVCL_F994 AH602-TC cancer cell line Norway rat CVCL_F994 CL:0000010 Derived from metastatic site: Ascites. 21182890 CVCL_EX94 ND13541 transformed cell line human CVCL_EX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182891 CVCL_EX93 ND13540 transformed cell line human CVCL_EX93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182892 CVCL_F999 MZ93 cancer cell line human CVCL_F999 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=11792418) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21182893 CVCL_EX99 ND13644 transformed cell line human CVCL_EX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182894 CVCL_F998 AH61B-TC cancer cell line Norway rat CVCL_F998 CL:0000010 Breed/subspecies: Donryu. Male 21182895 CVCL_EX98 ND13643 transformed cell line human CVCL_EX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182896 CVCL_F997 AH63F-TC cancer cell line Norway rat CVCL_F997 CL:0000010 21182897 CVCL_EX97 ND13607 transformed cell line human CVCL_EX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182898 CVCL_NR29 BayGenomics ES cell line RRS265 embryonic stem cell house mouse CVCL_NR29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344373; Ubl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182899 CVCL_NR28 BayGenomics ES cell line RRS264 embryonic stem cell house mouse CVCL_NR28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443584; L3mbtl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182900 CVCL_NR27 BayGenomics ES cell line RRS262 embryonic stem cell house mouse CVCL_NR27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647820; Hectd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182901 CVCL_F992 AH3683-TC cancer cell line Norway rat CVCL_F992 CL:0000010 Breed/subspecies: ACI/N. Female 21182902 CVCL_NR26 BayGenomics ES cell line RRS260 embryonic stem cell house mouse CVCL_NR26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916225; Med27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182903 CVCL_EX92 ND13527 transformed cell line human CVCL_EX92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182904 CVCL_F991 AH3924A-TC cancer cell line Norway rat CVCL_F991 CL:0000010 Breed/subspecies: ACI/N. Female 21182905 CVCL_NR25 BayGenomics ES cell line RRS255 embryonic stem cell house mouse CVCL_NR25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921729; Snx11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182906 CVCL_EX91 ND13516 transformed cell line human CVCL_EX91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182907 CVCL_F990 AH7974F-TC cancer cell line Norway rat CVCL_F990 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21182908 CVCL_NR24 BayGenomics ES cell line RRS254 embryonic stem cell house mouse CVCL_NR24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88190; Braf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182909 CVCL_EX90 ND13436 transformed cell line human CVCL_EX90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182910 CVCL_NR23 BayGenomics ES cell line RRS253 embryonic stem cell house mouse CVCL_NR23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138391; Pid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182911 CVCL_NR22 BayGenomics ES cell line RRS252 embryonic stem cell house mouse CVCL_NR22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88353; Cdk11b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182912 CVCL_NR21 BayGenomics ES cell line RRS250 embryonic stem cell house mouse CVCL_NR21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182913 CVCL_NR20 BayGenomics ES cell line RRS246 embryonic stem cell house mouse CVCL_NR20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104976; Ddx6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182914 CVCL_NR39 BayGenomics ES cell line RRS287 embryonic stem cell house mouse CVCL_NR39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098236; Cast Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182915 CVCL_NR38 BayGenomics ES cell line RRS284 embryonic stem cell house mouse CVCL_NR38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99695; Cttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182916 CVCL_NR37 BayGenomics ES cell line RRS282 embryonic stem cell house mouse CVCL_NR37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179327; Mvd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182917 CVCL_NR36 BayGenomics ES cell line RRS277 embryonic stem cell house mouse CVCL_NR36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928899; Tacc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182918 CVCL_NR35 BayGenomics ES cell line RRS276 embryonic stem cell house mouse CVCL_NR35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182919 CVCL_NR34 BayGenomics ES cell line RRS275 embryonic stem cell house mouse CVCL_NR34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888526; Xpo4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182920 CVCL_NR33 BayGenomics ES cell line RRS274 embryonic stem cell house mouse CVCL_NR33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918419; Nbas Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182921 CVCL_NR32 BayGenomics ES cell line RRS272 embryonic stem cell house mouse CVCL_NR32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100863; Kpna3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182922 CVCL_NR31 BayGenomics ES cell line RRS271 embryonic stem cell house mouse CVCL_NR31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97591; Pkm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182923 CVCL_NR30 BayGenomics ES cell line RRS266 embryonic stem cell house mouse CVCL_NR30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104976; Ddx6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182924 CVCL_F979 AH108A-TC cancer cell line Norway rat CVCL_F979 CL:0000010 Breed/subspecies: Donryu. Male 21182925 CVCL_EX79 ND13185 transformed cell line human CVCL_EX79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182926 CVCL_F974 CHO/OAR6-6 spontaneously immortalized cell line CVCL_F974 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44658; Okadaic acid; Derived from sampling site: Ovary. Female 21182927 CVCL_EX74 ND12982 transformed cell line human CVCL_EX74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182928 CVCL_F973 CHO/OAR2-3 spontaneously immortalized cell line CVCL_F973 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44658; Okadaic acid; Derived from sampling site: Ovary. Female 21182929 CVCL_EX73 ND12953 transformed cell line human CVCL_EX73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182930 CVCL_EX72 ND12820 transformed cell line human CVCL_EX72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182931 CVCL_F972 S2-VP10 cancer cell line human CVCL_F972 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male 21182932 CVCL_EX71 ND12809 transformed cell line human CVCL_EX71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182933 CVCL_F971 S2-CP8 cancer cell line human CVCL_F971 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Male 21182934 CVCL_F978 AH107B-TC cancer cell line Norway rat CVCL_F978 CL:0000010 Breed/subspecies: Donryu. Male 21182935 CVCL_EX78 ND13060 transformed cell line human CVCL_EX78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182936 CVCL_F977 AH100B-TC cancer cell line Norway rat CVCL_F977 CL:0000010 Breed/subspecies: Donryu. Male 21182937 CVCL_EX77 ND13045 transformed cell line human CVCL_EX77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182938 CVCL_EX76 ND13042 transformed cell line human CVCL_EX76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182939 CVCL_F976 NK7801 cancer cell line Norway rat CVCL_F976 CL:0000010 Transformant: N-nitrosodimethylamine (NDMA(ChEBI; CHEBI:35807); Derived from sampling site: Kidney; Breed/subspecies: BDIX. Unspecified 21182940 CVCL_NR09 BayGenomics ES cell line RRS222 embryonic stem cell house mouse CVCL_NR09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2175912; Arid5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182941 CVCL_F975 FM3A/R cancer cell line house mouse CVCL_F975 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: C3H/He. Female 21182942 CVCL_EX75 ND12983 transformed cell line human CVCL_EX75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182943 CVCL_NR08 BayGenomics ES cell line RRS216 embryonic stem cell house mouse CVCL_NR08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861100; Ubr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182944 CVCL_NR07 BayGenomics ES cell line RRS215 embryonic stem cell house mouse CVCL_NR07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346023; Tlk2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182945 CVCL_NR06 BayGenomics ES cell line RRS213 embryonic stem cell house mouse CVCL_NR06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2155936; Pask Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182946 CVCL_NR05 BayGenomics ES cell line RRS190 embryonic stem cell house mouse CVCL_NR05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923992; Snx27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182947 CVCL_F970 AH62-TC cancer cell line Norway rat CVCL_F970 CL:0000010 Male 21182948 CVCL_NR04 BayGenomics ES cell line RRS186 embryonic stem cell house mouse CVCL_NR04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1337062; Ap3s1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182949 CVCL_EX70 ND12771 transformed cell line human CVCL_EX70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182950 CVCL_NR03 BayGenomics ES cell line RRS172 embryonic stem cell house mouse CVCL_NR03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3644026; Fam169b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182951 CVCL_NR02 BayGenomics ES cell line RRS169 embryonic stem cell house mouse CVCL_NR02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328787; Smad5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182952 CVCL_NR01 BayGenomics ES cell line RRS166 embryonic stem cell house mouse CVCL_NR01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178217; Akap9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182953 CVCL_NR00 BayGenomics ES cell line RRS163 embryonic stem cell house mouse CVCL_NR00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443298; Tet2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182954 CVCL_F985 AH131B-TC cancer cell line Norway rat CVCL_F985 CL:0000010 Breed/subspecies: Donryu. Male 21182955 CVCL_EX85 ND13310 transformed cell line human CVCL_EX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182956 CVCL_F984 AH131A-TC cancer cell line Norway rat CVCL_F984 CL:0000010 Breed/subspecies: Donryu. Male 21182957 CVCL_EX84 ND13307 transformed cell line human CVCL_EX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182958 CVCL_F983 AH150A-TC cancer cell line Norway rat CVCL_F983 CL:0000010 Derived from metastatic site: Ascites. Male 21182959 CVCL_EX83 ND13306 transformed cell line human CVCL_EX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182960 CVCL_F982 AH130FG-TC cancer cell line Norway rat CVCL_F982 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21182961 CVCL_EX82 ND13305 transformed cell line human CVCL_EX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182962 CVCL_F989 AH7974-TC cancer cell line Norway rat CVCL_F989 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21182963 CVCL_EX89 ND13435 transformed cell line human CVCL_EX89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182964 CVCL_F988 AS-D-653-TC cancer cell line Norway rat CVCL_F988 CL:0000010 Breed/subspecies: Donryu. 21182965 CVCL_EX88 ND13336 transformed cell line human CVCL_EX88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182966 CVCL_F987 AH130FN II-TC cancer cell line Norway rat CVCL_F987 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21182967 CVCL_EX87 ND13333 transformed cell line human CVCL_EX87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182968 CVCL_F986 AH136B-TC cancer cell line Norway rat CVCL_F986 CL:0000010 Derived from metastatic site: Ascites. Male 21182969 CVCL_EX86 ND13313 transformed cell line human CVCL_EX86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182970 CVCL_NR19 BayGenomics ES cell line RRS244 embryonic stem cell house mouse CVCL_NR19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351825; Cstf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182971 CVCL_NR18 BayGenomics ES cell line RRS239 embryonic stem cell house mouse CVCL_NR18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182972 CVCL_NR17 BayGenomics ES cell line RRS238 embryonic stem cell house mouse CVCL_NR17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098672; Szrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182973 CVCL_NR16 BayGenomics ES cell line RRS235 embryonic stem cell house mouse CVCL_NR16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182974 CVCL_F981 AH109A-TC cancer cell line Norway rat CVCL_F981 CL:0000010 Breed/subspecies: Donryu. Male 21182975 CVCL_NR15 BayGenomics ES cell line RRS231 embryonic stem cell house mouse CVCL_NR15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342291; Rlim Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182976 CVCL_EX81 ND13259 transformed cell line human CVCL_EX81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21182977 CVCL_F980 AH108AF-TC cancer cell line Norway rat CVCL_F980 CL:0000010 Breed/subspecies: Donryu. Male 21182978 CVCL_NR14 BayGenomics ES cell line RRS228 embryonic stem cell house mouse CVCL_NR14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1101358; Npepps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182979 CVCL_EX80 ND13211 transformed cell line human CVCL_EX80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21182980 CVCL_NR13 BayGenomics ES cell line RRS227 embryonic stem cell house mouse CVCL_NR13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922552; Asxl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182981 CVCL_NR12 BayGenomics ES cell line RRS226 embryonic stem cell house mouse CVCL_NR12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924555; Wdr82 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182982 CVCL_NR11 BayGenomics ES cell line RRS225 embryonic stem cell house mouse CVCL_NR11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342005; Mthfd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182983 CVCL_NR10 BayGenomics ES cell line RRS223 embryonic stem cell house mouse CVCL_NR10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21182984 CVCL_4G63 GM05983 transformed cell line human CVCL_4G63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182985 CVCL_4G62 GM05981 transformed cell line human CVCL_4G62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182986 CVCL_4G61 GM05980 finite cell line human CVCL_4G61 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182987 CVCL_4G60 GM05979 transformed cell line human CVCL_4G60 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182988 CVCL_4G67 GM05987 transformed cell line human CVCL_4G67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182989 CVCL_4G66 GM05986 finite cell line human CVCL_4G66 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182990 CVCL_4G65 GM05985 transformed cell line human CVCL_4G65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182991 CVCL_4G64 GM05984 finite cell line human CVCL_4G64 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182992 CVCL_4G69 GM05989 transformed cell line human CVCL_4G69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182993 CVCL_4G68 GM05988 finite cell line human CVCL_4G68 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182994 CVCL_4G74 GM05994 finite cell line human CVCL_4G74 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182995 CVCL_4G73 GM05993 transformed cell line human CVCL_4G73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21182996 CVCL_4G72 GM05992 finite cell line human CVCL_4G72 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182997 CVCL_4G71 GM05991 transformed cell line human CVCL_4G71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182998 CVCL_4G78 GM05999 transformed cell line human CVCL_4G78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21182999 CVCL_4G77 GM05997 transformed cell line human CVCL_4G77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183000 CVCL_4G76 GM05996 finite cell line human CVCL_4G76 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183001 CVCL_4G75 GM05995 transformed cell line human CVCL_4G75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183002 CVCL_4G79 GM06000 finite cell line human CVCL_4G79 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183003 CVCL_4G70 GM05990 finite cell line human CVCL_4G70 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183004 CVCL_4G41 GM05940 finite cell line human CVCL_4G41 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183005 CVCL_4G40 GM05939 transformed cell line human CVCL_4G40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183006 CVCL_4G45 GM05960 finite cell line human CVCL_4G45 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183007 CVCL_4G44 GM05947 transformed cell line human CVCL_4G44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183008 CVCL_4G43 GM05943 transformed cell line human CVCL_4G43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183009 CVCL_4G42 GM05941 transformed cell line human CVCL_4G42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183010 CVCL_4G49 GM05968 finite cell line human CVCL_4G49 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183011 CVCL_4G48 GM05963 transformed cell line human CVCL_4G48 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183012 CVCL_4G47 GM05962 finite cell line human CVCL_4G47 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183013 CVCL_4G46 GM05961 transformed cell line human CVCL_4G46 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183014 CVCL_WM93 IL-A28 hybridoma house mouse CVCL_WM93 CL:0000010 Monoclonal antibody isotype: IgM. 21183015 CVCL_WM92 IL-A27 hybridoma house mouse CVCL_WM92 CL:0000010 Monoclonal antibody isotype: IgG1. 21183016 CVCL_WM91 IL-A26 hybridoma house mouse CVCL_WM91 CL:0000010 Monoclonal antibody isotype: IgM. 21183017 CVCL_WM90 B413 hybridoma house mouse CVCL_WM90 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3835 21183018 CVCL_WM97 MLB13MYC clone 17 transformed cell line house mouse CVCL_WM97 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Limb bud; Breed/subspecies: C57BL/6J. Unspecified 21183019 CVCL_WM96 MLB13MYC clone 14 transformed cell line house mouse CVCL_WM96 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Limb bud; Breed/subspecies: C57BL/6J. Unspecified 21183020 CVCL_WM95 SMS-KCN-A cancer cell line human CVCL_WM95 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (from parent cell line) Omics: Deep tyrosine phosphoproteome analysis. Male Characteristics: Adherent phenotype Selected by culturing parent cells on collagen coated plates and removing floating cell spheres. 21183021 CVCL_WM94 IL-A17 hybridoma house mouse CVCL_WM94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine CD8. 21183022 CVCL_WM99 MCF10A1 spontaneously immortalized cell line human CVCL_WM99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast; epithelium. Omics: Deep proteome analysis Female 21183023 CVCL_WM98 MCF10AT1k.cl2 transformed cell line human CVCL_WM98 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: Deep proteome analysis Female 21183024 CVCL_4G52 GM05971 transformed cell line human CVCL_4G52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183025 CVCL_4G51 GM05970 finite cell line human CVCL_4G51 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183026 CVCL_4G50 GM05969 transformed cell line human CVCL_4G50 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183027 CVCL_4G56 GM05975 transformed cell line human CVCL_4G56 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183028 CVCL_4G55 GM05974 finite cell line human CVCL_4G55 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183029 CVCL_4G54 GM05973 transformed cell line human CVCL_4G54 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183030 CVCL_4G53 GM05972 finite cell line human CVCL_4G53 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183031 CVCL_4G59 GM05978 finite cell line human CVCL_4G59 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183032 CVCL_4G58 GM05977 transformed cell line human CVCL_4G58 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183033 CVCL_4G57 GM05976 finite cell line human CVCL_4G57 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183034 CVCL_WM82 XCL-1 induced pluripotent stem cell human CVCL_WM82 From: XCell Science, Inc.; Novato; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21183035 CVCL_WM81 HTC75 T4 cancer cell line human CVCL_WM81 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11729; TERF2 (with p.Met1_Ala44del and p.Lys501_Asn542 and a N-terminal FLAG tag = TRF2deltaBdeltaM); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21183036 CVCL_WM80 HTC75 T19 cancer cell line human CVCL_WM80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11729; TERF2 (with p.Met1_Ala44del and p.Lys501_Asn542 and a N-terminal FLAG tag = TRF2deltaBdeltaM); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21183037 CVCL_WM86 B207 hybridoma house mouse CVCL_WM86 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Also reacts with LHB). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1626 21183038 CVCL_WM85 B152 hybridoma house mouse CVCL_WM85 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P0DN86; Human CGB (Note=Binds to the O-glycan on Ser-132). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12467 21183039 CVCL_WM84 XCL-6 induced pluripotent stem cell human CVCL_WM84 From: XCell Science, Inc.; Novato; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21183040 CVCL_WM83 XCL-5 induced pluripotent stem cell human CVCL_WM83 From: XCell Science, Inc.; Novato; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21183041 CVCL_WM89 B409 hybridoma house mouse CVCL_WM89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3834 21183042 CVCL_WM88 B408 hybridoma house mouse CVCL_WM88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3833 21183043 CVCL_WM87 B406 hybridoma house mouse CVCL_WM87 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01215; Human CGA; Monoclonal antibody target: UniProtKB; P01229; Human LHB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3832 21183044 CVCL_4G23 GM05919 finite cell line human CVCL_4G23 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183045 CVCL_4G22 GM05918 transformed cell line human CVCL_4G22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183046 CVCL_4G21 GM05916 transformed cell line human CVCL_4G21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183047 CVCL_4G20 GM05915 finite cell line human CVCL_4G20 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183048 CVCL_4G27 GM05926 finite cell line human CVCL_4G27 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183049 CVCL_4G26 GM05923 transformed cell line human CVCL_4G26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183050 CVCL_4G25 GM05922 transformed cell line human CVCL_4G25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183051 CVCL_4G24 GM05921 transformed cell line human CVCL_4G24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183052 CVCL_4G29 GM05928 finite cell line human CVCL_4G29 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183053 CVCL_4G28 GM05927 transformed cell line human CVCL_4G28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183054 CVCL_WM71 RCK105 hybridoma house mouse CVCL_WM71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08729; Human KRT7 (Note=Also reacts with mouse, rat, dog, pig, etc.). 21183055 CVCL_WM70 NCI-H82-A cancer cell line human CVCL_WM70 CL:0000010 Sequence variation: Gene fusion; HGNC; 7577; MYH7 + HGNC; 9709; PVT1; Name(s)=PVT1-MYH7 (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>T); ClinVar=VCV000237948; Zygosity=Unspecified; Note=Impairs TP53 splicing dramatically (from parent cell line) Derived from metastatic site: Pleural effusion. Male Characteristics: Established from parent cell line by selection of the adherent cells 21183056 CVCL_WM75 IGR-CaP1-R-caba cancer cell line human CVCL_WM75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Derived from sampling site: Prostate. Male 21183057 CVCL_WM74 EPLC-65M2 cancer cell line human CVCL_WM74 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (EPLC-65H) has been shown to be a HeLa derivative. 21183058 CVCL_WM73 RV202 hybridoma house mouse CVCL_WM73 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P48616; Bovine VIM (Note=Also reacts with human, mouse, rat, etc.). 21183059 CVCL_WM72 RCK106 hybridoma house mouse CVCL_WM72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05783; Human KRT18. 21183060 CVCL_WM79 HTC75 cancer cell line human CVCL_WM79 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 21183061 CVCL_WM78 B16-MO4 cancer cell line house mouse CVCL_WM78 CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (Millipore) 21183062 CVCL_WM77 B16-MO5 cancer cell line house mouse CVCL_WM77 CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21183063 CVCL_WM76 PC3-R-caba cancer cell line human CVCL_WM76 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Derived from metastatic site: Bone. Male 21183064 CVCL_4G30 GM05929 transformed cell line human CVCL_4G30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183065 CVCL_4G34 GM05933 transformed cell line human CVCL_4G34 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183066 CVCL_4G33 GM05932 finite cell line human CVCL_4G33 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183067 CVCL_4G32 GM05931 transformed cell line human CVCL_4G32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183068 CVCL_4G31 GM05930 finite cell line human CVCL_4G31 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183069 CVCL_4G38 GM05937 transformed cell line human CVCL_4G38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183070 CVCL_4G37 GM05936 finite cell line human CVCL_4G37 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183071 CVCL_4G36 GM05935 transformed cell line human CVCL_4G36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183072 CVCL_4G35 GM05934 finite cell line human CVCL_4G35 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183073 CVCL_4G39 GM05938 finite cell line human CVCL_4G39 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183074 CVCL_WM60 GLC-A1 cancer cell line human CVCL_WM60 CL:0000010 21183075 CVCL_WM64 NL-SCLC3 cancer cell line human CVCL_WM64 CL:0000010 Derived from metastatic site: Pleural effusion. 21183076 CVCL_WM63 NL-SCLC2 cancer cell line human CVCL_WM63 CL:0000010 Derived from metastatic site: Pleural effusion. 21183077 CVCL_WM62 GLC-A3 cancer cell line human CVCL_WM62 CL:0000010 21183078 CVCL_WM61 GLC-A2 cancer cell line human CVCL_WM61 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=104087879). 21183079 CVCL_WM68 RNL-3 hybridoma house mouse CVCL_WM68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16799; Human RTN1. 21183080 CVCL_WM67 RNL-2 hybridoma house mouse CVCL_WM67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16799; Human RTN1. 21183081 CVCL_WM66 RNL-1 hybridoma house mouse CVCL_WM66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13591; Human NCAM1/CD56. 21183082 CVCL_WM65 NL-AC1 cancer cell line human CVCL_WM65 CL:0000010 Derived from metastatic site: Pericardial effusion. 21183083 CVCL_WM69 NCI-H524-A cancer cell line human CVCL_WM69 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr155Asn (c.464C>A); ClinVar=VCV000406564; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male Characteristics: Established from parent cell line by selection of the adherent cells 21183084 CVCL_4G01 GM05894 transformed cell line human CVCL_4G01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183085 CVCL_4G00 GM05893 finite cell line human CVCL_4G00 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183086 CVCL_4G05 GM05898 transformed cell line human CVCL_4G05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183087 CVCL_4G04 GM05897 finite cell line human CVCL_4G04 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183088 CVCL_4G03 GM05896 transformed cell line human CVCL_4G03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183089 CVCL_4G02 GM05895 finite cell line human CVCL_4G02 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183090 CVCL_4G09 GM05902 finite cell line human CVCL_4G09 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183091 CVCL_4G08 GM05901 transformed cell line human CVCL_4G08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183092 CVCL_4G07 GM05900 transformed cell line human CVCL_4G07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183093 CVCL_4G06 GM05899 finite cell line human CVCL_4G06 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183094 CVCL_WM53 26414M cancer cell line human CVCL_WM53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Female 21183095 CVCL_WM52 3962M cancer cell line human CVCL_WM52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137) Derived from metastatic site: Cutaneous. Female 21183096 CVCL_WM51 3988M cancer cell line human CVCL_WM51 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Female 21183097 CVCL_WM50 20706M cancer cell line human CVCL_WM50 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Female 21183098 CVCL_WM57 16396M cancer cell line human CVCL_WM57 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Colon. Male 21183099 CVCL_WM56 6854M cancer cell line human CVCL_WM56 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183100 CVCL_WM55 21545M cancer cell line human CVCL_WM55 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183101 CVCL_WM54 21768M cancer cell line human CVCL_WM54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183102 CVCL_WM59 GLC-5 cancer cell line human CVCL_WM59 CL:0000010 21183103 CVCL_WM58 1568M cancer cell line human CVCL_WM58 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lung. Male 21183104 CVCL_4G12 GM05905 transformed cell line human CVCL_4G12 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183105 CVCL_4G11 GM05904 finite cell line human CVCL_4G11 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183106 CVCL_4G10 GM05903 transformed cell line human CVCL_4G10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183107 CVCL_4G16 GM05909 transformed cell line human CVCL_4G16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183108 CVCL_4G15 GM05908 finite cell line human CVCL_4G15 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183109 CVCL_4G14 GM05907 transformed cell line human CVCL_4G14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183110 CVCL_4G13 GM05906 finite cell line human CVCL_4G13 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183111 CVCL_4G19 GM05914 transformed cell line human CVCL_4G19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183112 CVCL_4G18 GM05911 transformed cell line human CVCL_4G18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183113 CVCL_4G17 GM05910 transformed cell line human CVCL_4G17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183114 CVCL_WM42 14362M cancer cell line human CVCL_WM42 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Lys (c.772G>A); ClinVar=VCV000012348; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183115 CVCL_WM41 4473M cancer cell line human CVCL_WM41 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183116 CVCL_WM40 879M cancer cell line human CVCL_WM40 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183117 CVCL_WM46 20842M2 cancer cell line human CVCL_WM46 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly187Ser (c.559G>A); ClinVar=VCV000840399; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183118 CVCL_WM45 33365M cancer cell line human CVCL_WM45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183119 CVCL_WM44 26396M cancer cell line human CVCL_WM44 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-2A>G (IVS2-2A>G); ClinVar=VCV000487034; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183120 CVCL_WM43 30966M cancer cell line human CVCL_WM43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys105Valfs*8 (c.313delT); ClinVar=VCV000940879; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183121 CVCL_WM49 26258M cancer cell line human CVCL_WM49 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183122 CVCL_WM48 10249M cancer cell line human CVCL_WM48 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Male 21183123 CVCL_WM47 18588M cancer cell line human CVCL_WM47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Cutaneous. Female 21183124 CVCL_EZ14 ND35976 finite cell line human CVCL_EZ14 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35976; true Male 21183125 CVCL_EZ13 ND35843 finite cell line human CVCL_EZ13 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35843; true Male 21183126 CVCL_EZ12 ND35425 finite cell line human CVCL_EZ12 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35425; true Female 21183127 CVCL_EZ11 ND35322 finite cell line human CVCL_EZ11 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35322; true Male 21183128 CVCL_EZ18 ND37180 finite cell line human CVCL_EZ18 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37180; true; Discontinued: NHCDR; ND37180; true Male 21183129 CVCL_EZ17 ND37132 finite cell line human CVCL_EZ17 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37132; true Male 21183130 CVCL_EZ16 ND36320 finite cell line human CVCL_EZ16 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND36320; true Female 21183131 CVCL_EZ15 ND36091 finite cell line human CVCL_EZ15 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND36091; true; Discontinued: NHCDR; ND36091; true Female 21183132 CVCL_EZ10 ND35320 finite cell line human CVCL_EZ10 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35320; true Male 21183133 CVCL_EZ09 ND35302 finite cell line human CVCL_EZ09 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35302; true Male 21183134 CVCL_EZ08 ND35044 finite cell line human CVCL_EZ08 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35044; true; Discontinued: NHCDR; ND35044; true Male 21183135 CVCL_EZ25 ND38136 finite cell line human CVCL_EZ25 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38136; true Female 21183136 CVCL_EZ24 ND38020 finite cell line human CVCL_EZ24 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38020; true Male 21183137 CVCL_EZ23 ND37757 finite cell line human CVCL_EZ23 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37757; true Male 21183138 CVCL_EZ22 ND37732 finite cell line human CVCL_EZ22 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3 40bp del; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37732; true Female 21183139 CVCL_EZ29 ND38791 finite cell line human CVCL_EZ29 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38791; true Female 21183140 CVCL_EZ28 ND38530 finite cell line human CVCL_EZ28 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38530; true Male 21183141 CVCL_EZ27 ND38528 finite cell line human CVCL_EZ27 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38528; true Female 21183142 CVCL_EZ26 ND38262 finite cell line human CVCL_EZ26 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38262; true Male 21183143 CVCL_EZ21 ND37731 finite cell line human CVCL_EZ21 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3 40bp del; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37731; true Female 21183144 CVCL_EZ20 ND37609 finite cell line human CVCL_EZ20 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37609; true Male 21183145 CVCL_EZ19 ND37517 finite cell line human CVCL_EZ19 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND37517; true Female 21183146 CVCL_EZ03 ND34732 finite cell line human CVCL_EZ03 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Ile (c.438G>A); ClinVar=VCV000018137; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34732; true Female 21183147 CVCL_EZ02 ND34730 finite cell line human CVCL_EZ02 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Glu184Asp (c.552A>C); ClinVar=VCV000098049; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34730; true Male 21183148 CVCL_EZ01 ND34267 finite cell line human CVCL_EZ01 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34267; true Male 21183149 CVCL_EZ00 ND34265 finite cell line human CVCL_EZ00 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34265; true Male 21183150 CVCL_EZ07 ND34982 finite cell line human CVCL_EZ07 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34982; true Female 21183151 CVCL_EZ06 ND34980 finite cell line human CVCL_EZ06 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NHCDR); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34980; true Male 21183152 CVCL_EZ05 ND34854 finite cell line human CVCL_EZ05 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34854; true Female 21183153 CVCL_EZ04 ND34769 finite cell line human CVCL_EZ04 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34769; true Female 21183154 CVCL_4G85 GM06006 finite cell line human CVCL_4G85 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183155 CVCL_4G84 GM06005 transformed cell line human CVCL_4G84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183156 CVCL_4G83 GM06004 finite cell line human CVCL_4G83 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183157 CVCL_4G82 GM06003 transformed cell line human CVCL_4G82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183158 CVCL_4G89 GM06014 finite cell line human CVCL_4G89 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183159 CVCL_4G88 GM06013 transformed cell line human CVCL_4G88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183160 CVCL_4G87 GM06012 finite cell line human CVCL_4G87 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183161 CVCL_4G86 GM06011 transformed cell line human CVCL_4G86 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183162 CVCL_4G81 GM06002 finite cell line human CVCL_4G81 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183163 CVCL_4G80 GM06001 transformed cell line human CVCL_4G80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183164 CVCL_4G96 GM06023 transformed cell line human CVCL_4G96 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183165 CVCL_4G95 GM06022 transformed cell line human CVCL_4G95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183166 CVCL_4G94 GM06021 transformed cell line human CVCL_4G94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183167 CVCL_4G93 GM06018 finite cell line human CVCL_4G93 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183168 CVCL_4G99 GM06026 finite cell line human CVCL_4G99 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183169 CVCL_4G98 GM06025 transformed cell line human CVCL_4G98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183170 CVCL_4G97 GM06024 finite cell line human CVCL_4G97 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183171 CVCL_4G92 GM06017 transformed cell line human CVCL_4G92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21183172 CVCL_4G91 GM06016 finite cell line human CVCL_4G91 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183173 CVCL_4G90 GM06015 transformed cell line human CVCL_4G90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21183174 CVCL_EY79 ND32603 finite cell line human CVCL_EY79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32603; true Female 21183175 CVCL_EY78 ND32462 finite cell line human CVCL_EY78 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32462; true Male 21183176 CVCL_EY73 ND31551 finite cell line human CVCL_EY73 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31551; true Male 21183177 CVCL_EY72 ND31508 finite cell line human CVCL_EY72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31508; true Male 21183178 CVCL_EY71 ND31038 finite cell line human CVCL_EY71 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(44)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31038; true Female 21183179 CVCL_EY70 ND31037 finite cell line human CVCL_EY70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31037; true Male 21183180 CVCL_EY77 ND32157 finite cell line human CVCL_EY77 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32157; true Female 21183181 CVCL_EY76 ND31846 finite cell line human CVCL_EY76 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31846; true Female 21183182 CVCL_NS09 BayGenomics ES cell line RRS502 embryonic stem cell house mouse CVCL_NS09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676921; Focad Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183183 CVCL_EY75 ND31845 finite cell line human CVCL_EY75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31845; true Female 21183184 CVCL_NS08 BayGenomics ES cell line RRS501 embryonic stem cell house mouse CVCL_NS08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183185 CVCL_EY74 ND31717 finite cell line human CVCL_EY74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31717; true Female 21183186 CVCL_NS07 BayGenomics ES cell line RRS498 embryonic stem cell house mouse CVCL_NS07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919241; Ercc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183187 CVCL_NS06 BayGenomics ES cell line RRS496 embryonic stem cell house mouse CVCL_NS06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183188 CVCL_NS05 BayGenomics ES cell line RRS491 embryonic stem cell house mouse CVCL_NS05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933162; Lrba Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183189 CVCL_NS04 BayGenomics ES cell line RRS482 embryonic stem cell house mouse CVCL_NS04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277218; Rpap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183190 CVCL_NS03 BayGenomics ES cell line RRS478 embryonic stem cell house mouse CVCL_NS03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932610; Noc3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183191 CVCL_NS02 BayGenomics ES cell line RRS475 embryonic stem cell house mouse CVCL_NS02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157166; Rp9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183192 CVCL_NS01 BayGenomics ES cell line RRS474 embryonic stem cell house mouse CVCL_NS01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915301; Nutf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183193 CVCL_NS00 BayGenomics ES cell line RRS472 embryonic stem cell house mouse CVCL_NS00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916891; Wdr20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183194 CVCL_EY89 ND32975 finite cell line human CVCL_EY89 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32975; true Female 21183195 CVCL_EY84 ND32955 finite cell line human CVCL_EY84 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32955; true Male 21183196 CVCL_EY83 ND32954 finite cell line human CVCL_EY83 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32954; true Male 21183197 CVCL_EY82 ND32947 finite cell line human CVCL_EY82 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly298Ser (c.892G>A); ClinVar=VCV000005232; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32947; true Male 21183198 CVCL_EY81 ND32946 finite cell line human CVCL_EY81 CL:0000010 Sequence variation: Mutation; HGNC; 2711; DCTN1; Simple; p.Thr72Pro (c.214A>C); ClinVar=VCV000021392; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32946; true Female 21183199 CVCL_EY88 ND32974 finite cell line human CVCL_EY88 CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Arg747Trp (c.2239C>T); ClinVar=VCV000006204; Zygosity=Homozygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32974; true Male 21183200 CVCL_EY87 ND32973 finite cell line human CVCL_EY87 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32973; true Male 21183201 CVCL_EY86 ND32969 finite cell line human CVCL_EY86 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile114Thr (c.341T>C) (I113T); ClinVar=VCV000197145; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32969; true Male 21183202 CVCL_NS19 BayGenomics ES cell line RRS532 embryonic stem cell house mouse CVCL_NS19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918767; Vps35l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183203 CVCL_EY85 ND32956 finite cell line human CVCL_EY85 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Polish; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32956; true Male 21183204 CVCL_NS18 BayGenomics ES cell line RRS530 embryonic stem cell house mouse CVCL_NS18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933196; Rad54l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183205 CVCL_NS17 BayGenomics ES cell line RRS529 embryonic stem cell house mouse CVCL_NS17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183206 CVCL_NS16 BayGenomics ES cell line RRS528 embryonic stem cell house mouse CVCL_NS16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98354; Sos1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183207 CVCL_NS15 BayGenomics ES cell line RRS519 embryonic stem cell house mouse CVCL_NS15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919241; Ercc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183208 CVCL_NS14 BayGenomics ES cell line RRS515 embryonic stem cell house mouse CVCL_NS14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894676; Mast2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183209 CVCL_EY80 ND32697 finite cell line human CVCL_EY80 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32697; true Male 21183210 CVCL_NS13 BayGenomics ES cell line RRS514 embryonic stem cell house mouse CVCL_NS13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183211 CVCL_NS12 BayGenomics ES cell line RRS512 embryonic stem cell house mouse CVCL_NS12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860486; Tdp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183212 CVCL_NS11 BayGenomics ES cell line RRS510 embryonic stem cell house mouse CVCL_NS11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442362; Zfp653 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183213 CVCL_NS10 BayGenomics ES cell line RRS508 embryonic stem cell house mouse CVCL_NS10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145645; Exoc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183214 CVCL_EY59 ND30015 finite cell line human CVCL_EY59 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30015; true Female 21183215 CVCL_EY58 ND29971 finite cell line human CVCL_EY58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29971; true Female 21183216 CVCL_EY57 ND29970 finite cell line human CVCL_EY57 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29970; true Male 21183217 CVCL_EY56 ND29969 finite cell line human CVCL_EY56 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29969; true Female 21183218 CVCL_EY51 ND29523 finite cell line human CVCL_EY51 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu39Val (c.115C>G) (L38V); ClinVar=VCV000014753; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29523; true Male 21183219 CVCL_EY50 ND29494 finite cell line human CVCL_EY50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29494; true Male 21183220 CVCL_EY55 ND29968 finite cell line human CVCL_EY55 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Gln34Arg (c.101A>G); ClinVar=VCV000468584; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29968; true Male 21183221 CVCL_EY54 ND29801 finite cell line human CVCL_EY54 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29801; true Female 21183222 CVCL_EY53 ND29689 finite cell line human CVCL_EY53 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29689; true Male 21183223 CVCL_EY52 ND29541 finite cell line human CVCL_EY52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29541; true Male 21183224 CVCL_EY69 ND30967 finite cell line human CVCL_EY69 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30967; true Male 21183225 CVCL_EY68 ND30422 finite cell line human CVCL_EY68 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30422; true Male 21183226 CVCL_EY67 ND30364 finite cell line human CVCL_EY67 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30364; true; Discontinued: NHCDR; ND30364; true Female 21183227 CVCL_EY62 ND30116 finite cell line human CVCL_EY62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30116; true Female 21183228 CVCL_EY61 ND30047 finite cell line human CVCL_EY61 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30047; true Female 21183229 CVCL_EY60 ND30016 finite cell line human CVCL_EY60 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Donor information: At sampling donor was not affected with Huntington's disease but at risk for disease (HTT has CAG repeat length greater than or equal to 36); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30016; true Female 21183230 CVCL_EY66 ND30260 finite cell line human CVCL_EY66 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30260; true Female 21183231 CVCL_EY65 ND30259 finite cell line human CVCL_EY65 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[38] (c.52CAG(38)) (c.52CAG[(36_39)]); ClinVar=VCV000031916; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30259; true Female 21183232 CVCL_EY64 ND30244 finite cell line human CVCL_EY64 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30244; true Male 21183233 CVCL_EY63 ND30159 finite cell line human CVCL_EY63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30159; true Female 21183234 CVCL_EY37 ND32945 finite cell line human CVCL_EY37 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32945; probable Male 21183235 CVCL_EY36 ND30327 finite cell line human CVCL_EY36 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Gly (c.1561C>G); ClinVar=VCV000016222; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30327; probable 21183236 CVCL_EY35 ND29423 finite cell line human CVCL_EY35 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29423; probable Male 21183237 CVCL_EY34 ND29194 finite cell line human CVCL_EY34 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29194; probable Female 21183238 CVCL_EY39 ND32951 finite cell line human CVCL_EY39 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32951; probable Female 21183239 CVCL_EY38 ND32949 finite cell line human CVCL_EY38 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32949; probable Male 21183240 CVCL_EY33 ND33995 finite cell line human CVCL_EY33 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33995; probable Male 21183241 CVCL_EY32 ND31960 finite cell line human CVCL_EY32 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND31960; probable Female 21183242 CVCL_EY31 ND29688 finite cell line human CVCL_EY31 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu101Gly (c.302A>G) (E100G); ClinVar=VCV000014761; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29688; probable Male 21183243 CVCL_EY30 ND42493 finite cell line human CVCL_EY30 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000016009; Zygosity=Unspecified (NHCDR) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21183244 CVCL_EY48 ND29179 finite cell line human CVCL_EY48 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29179; true Male 21183245 CVCL_EY47 ND29178 finite cell line human CVCL_EY47 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29178; true Male 21183246 CVCL_EY46 ND35200 finite cell line human CVCL_EY46 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35200; probable Female 21183247 CVCL_EY45 ND34810 finite cell line human CVCL_EY45 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34810; probable Male 21183248 CVCL_EY49 ND29370 finite cell line human CVCL_EY49 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29370; true Male 21183249 CVCL_EY40 ND32953 finite cell line human CVCL_EY40 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ala9Asp (c.26C>A); ClinVar=VCV000016013; Zygosity=Unspecified (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32953; probable Female 21183250 CVCL_EY44 ND34770 finite cell line human CVCL_EY44 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34770; probable Male 21183251 CVCL_EY43 ND34733 finite cell line human CVCL_EY43 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Pro264Leu (c.791C>T); ClinVar=VCV000098080; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34733; probable Male 21183252 CVCL_EY42 ND34198 finite cell line human CVCL_EY42 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34198; probable Male 21183253 CVCL_EY41 ND32970 finite cell line human CVCL_EY41 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635; PubMed=27191603) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32970; probable 21183254 CVCL_EY15 ND14071 transformed cell line human CVCL_EY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183255 CVCL_EY14 ND14032 transformed cell line human CVCL_EY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183256 CVCL_EY13 ND14003 transformed cell line human CVCL_EY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183257 CVCL_EY12 ND13891 transformed cell line human CVCL_EY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183258 CVCL_EY19 ND14519 transformed cell line human CVCL_EY19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183259 CVCL_EY18 ND14384 transformed cell line human CVCL_EY18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183260 CVCL_EY17 ND14309 transformed cell line human CVCL_EY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183261 CVCL_EY16 ND14128 transformed cell line human CVCL_EY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183262 CVCL_EY11 ND13844 transformed cell line human CVCL_EY11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183263 CVCL_EY10 ND13842 transformed cell line human CVCL_EY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183264 CVCL_EY09 ND13836 transformed cell line human CVCL_EY09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183265 CVCL_EY26 ND29415 finite cell line human CVCL_EY26 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29415; true Male Caution: SOD1 mutation wrongly indicated as L144P in PubMed=22952635 21183266 CVCL_EY25 CLB-Hu-TT-1 transformed cell line human CVCL_EY25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04958; Clostridium tetani tetanus toxin (tetX) 21183267 CVCL_EY24 CLB-Hut cancer cell line human CVCL_EY24 CL:0000010 Miscellaneous: Sex of donor and metastatic site from personal communication of Combaret V Derived from metastatic site: Bone marrow. Male 21183268 CVCL_EY23 ND12254 transformed cell line human CVCL_EY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183269 CVCL_EY29 ND40068 finite cell line human CVCL_EY29 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (NHCDR) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40068; true Female 21183270 CVCL_EY28 ND32944 finite cell line human CVCL_EY28 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32944; true Male 21183271 CVCL_EY27 ND32943 finite cell line human CVCL_EY27 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32943; true Female 21183272 CVCL_EY22 ND15210 transformed cell line human CVCL_EY22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183273 CVCL_EY21 ND15116 transformed cell line human CVCL_EY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183274 CVCL_EY20 ND15009 transformed cell line human CVCL_EY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183275 CVCL_NS90 BayGenomics ES cell line RRS734 embryonic stem cell house mouse CVCL_NS90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183276 CVCL_WM29 15392M cancer cell line human CVCL_WM29 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183277 CVCL_WM31 14464M cancer cell line human CVCL_WM31 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183278 CVCL_WM30 18656M cancer cell line human CVCL_WM30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183279 CVCL_NS89 BayGenomics ES cell line RRS733 embryonic stem cell house mouse CVCL_NS89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183280 CVCL_NS88 BayGenomics ES cell line RRS732 embryonic stem cell house mouse CVCL_NS88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919241; Ercc8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183281 CVCL_WM35 8959M cancer cell line human CVCL_WM35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183282 CVCL_NS87 BayGenomics ES cell line RRS730 embryonic stem cell house mouse CVCL_NS87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183283 CVCL_WM34 4686M cancer cell line human CVCL_WM34 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Arg (c.65A>G); Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro38Ser (c.112C>T); ClinVar=VCV000127688; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380_381CC>TT); Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183284 CVCL_NS86 BayGenomics ES cell line RRS729 embryonic stem cell house mouse CVCL_NS86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346873; Map3k2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183285 CVCL_WM33 4023M cancer cell line human CVCL_WM33 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183286 CVCL_NS85 BayGenomics ES cell line RRS728 embryonic stem cell house mouse CVCL_NS85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183287 CVCL_WM32 2934M cancer cell line human CVCL_WM32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183288 CVCL_NS84 BayGenomics ES cell line RRS726 embryonic stem cell house mouse CVCL_NS84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929063; Copz1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183289 CVCL_WM39 18732M cancer cell line human CVCL_WM39 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183290 CVCL_NS83 BayGenomics ES cell line RRS723 embryonic stem cell house mouse CVCL_NS83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919979; Cdc42se2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183291 CVCL_WM38 2211M cancer cell line human CVCL_WM38 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro246Ser (c.737C>T); Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380_381CC>TT); Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183292 CVCL_NS82 BayGenomics ES cell line RRS720 embryonic stem cell house mouse CVCL_NS82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88451; Col18a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183293 CVCL_WM37 17697M cancer cell line human CVCL_WM37 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183294 CVCL_NS81 BayGenomics ES cell line RRS716 embryonic stem cell house mouse CVCL_NS81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919488; Tbc1d5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183295 CVCL_WM36 13923M cancer cell line human CVCL_WM36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183296 CVCL_NS80 BayGenomics ES cell line RRS711 embryonic stem cell house mouse CVCL_NS80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923257; Zmym2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183297 CVCL_WM19 20842P cancer cell line human CVCL_WM19 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly187Ser (c.559G>A); ClinVar=VCV000840399; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Leg; skin. Male 21183298 CVCL_WM18 1007P cancer cell line human CVCL_WM18 CL:0000010 Derived from sampling site: Leg; skin. Male 21183299 CVCL_WM20 5810P cancer cell line human CVCL_WM20 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Leg; skin. Female 21183300 CVCL_NS99 BayGenomics ES cell line RRS759 embryonic stem cell house mouse CVCL_NS99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321393; Timeless Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183301 CVCL_WM24 9923P cancer cell line human CVCL_WM24 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000177778; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Foot; skin. Female 21183302 CVCL_NS98 BayGenomics ES cell line RRS754 embryonic stem cell house mouse CVCL_NS98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683538; Lyrm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183303 CVCL_WM23 4405P cancer cell line human CVCL_WM23 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Head; skin. Female 21183304 CVCL_NS97 BayGenomics ES cell line RRS748 embryonic stem cell house mouse CVCL_NS97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109331; Nxn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183305 CVCL_WM22 10538P cancer cell line human CVCL_WM22 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Leg; skin. Female 21183306 CVCL_NS96 BayGenomics ES cell line RRS746 embryonic stem cell house mouse CVCL_NS96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97806; Ptpn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183307 CVCL_WM21 1402P cancer cell line human CVCL_WM21 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236His (c.706T>C); ClinVar=VCV000216469; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Trunk; skin. Male 21183308 CVCL_NS95 BayGenomics ES cell line RRS740 embryonic stem cell house mouse CVCL_NS95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107585; Srebf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183309 CVCL_WM28 9460M cancer cell line human CVCL_WM28 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183310 CVCL_NS94 BayGenomics ES cell line RRS739 embryonic stem cell house mouse CVCL_NS94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442912; Zcchc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183311 CVCL_WM27 9923M cancer cell line human CVCL_WM27 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000177778; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Female 21183312 CVCL_NS93 BayGenomics ES cell line RRS737 embryonic stem cell house mouse CVCL_NS93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442782; Baz2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183313 CVCL_WM26 20842M1 cancer cell line human CVCL_WM26 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Leu597Ser (c.1789_1790delCTinsTC); ClinVar=VCV000375942; Zygosity=Unspecified (PubMed=15195137) Derived from metastatic site: Lymph node. Male 21183314 CVCL_NS92 BayGenomics ES cell line RRS736 embryonic stem cell house mouse CVCL_NS92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917347; Sash1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183315 CVCL_WM25 1402R cancer cell line human CVCL_WM25 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15195137); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr236His (c.706T>C); ClinVar=VCV000216469; Zygosity=Unspecified (PubMed=15195137) Derived from sampling site: Trunk; skin. Male 21183316 CVCL_NS91 BayGenomics ES cell line RRS735 embryonic stem cell house mouse CVCL_NS91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183317 CVCL_WM09 0.57 spontaneously immortalized cell line fruit fly CVCL_WM09 CL:0000010 Male Group: Insect cell line. 21183318 CVCL_WM08 GENYOi004-A induced pluripotent stem cell human CVCL_WM08 HLA typing: A*03,24; B*35,55; DQA1*01,01; DQB1*05:03,05:03; DRB1*14:01,14:01 (PubMed=31035039) From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Sequence variation: Mutation; HGNC; 15766; ADNP; Simple; p.Tyr719Ter (c.2157C>G); ClinVar=VCV000139635; Zygosity=Heterozygous (PubMed=31035039) Population: Caucasian; Spanish; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21183319 CVCL_WM07 WAe009-A-40 embryonic stem cell human CVCL_WM07 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 1537; CBFA2T3 (CBFA2T3-GLIS2 fusion); Transfected with: HGNC; 29450; GLIS2 (CBFA2T3-GLIS2 fusion). Female 21183320 CVCL_NS69 BayGenomics ES cell line RRS685 embryonic stem cell house mouse CVCL_NS69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913667; Mat2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183321 CVCL_NS68 BayGenomics ES cell line RRS683 embryonic stem cell house mouse CVCL_NS68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88568; Cux1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183322 CVCL_NS67 BayGenomics ES cell line RRS678 embryonic stem cell house mouse CVCL_NS67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141625; Nup205 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183323 CVCL_NS66 BayGenomics ES cell line RRS676 embryonic stem cell house mouse CVCL_NS66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194912; Rbbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183324 CVCL_NS65 BayGenomics ES cell line RRS675 embryonic stem cell house mouse CVCL_NS65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106341; Atp5o Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183325 CVCL_WM13 GM27446 induced pluripotent stem cell human CVCL_WM13 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ala199Cysfs*13 (c.594dupT); ClinVar=VCV000000080; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000000078; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21183326 CVCL_NS64 BayGenomics ES cell line RRS674 embryonic stem cell house mouse CVCL_NS64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913415; Bccip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183327 CVCL_WM12 WR73-Gm-1 spontaneously immortalized cell line CVCL_WM12 CL:0000010 Unspecified Group: Insect cell line. 21183328 CVCL_WM11 3XIII spontaneously immortalized cell line fruit fly CVCL_WM11 CL:0000010 Male Group: Insect cell line. 21183329 CVCL_NS63 BayGenomics ES cell line RRS672 embryonic stem cell house mouse CVCL_NS63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183330 CVCL_WM10 1.59 spontaneously immortalized cell line fruit fly CVCL_WM10 CL:0000010 Male Group: Insect cell line. 21183331 CVCL_NS62 BayGenomics ES cell line RRS666 embryonic stem cell house mouse CVCL_NS62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924140; Memo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183332 CVCL_NS61 BayGenomics ES cell line RRS647 embryonic stem cell house mouse CVCL_NS61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916139; Ubac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183333 CVCL_WM17 WTC-mEGFP-Safe harbor locus (AAVS1)-cl28 induced pluripotent stem cell human CVCL_WM17 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 mEGFP under the control of a CAG promoter was inserted into one allele of the AAVS1 safe harbor locus Part of: Allen Cell Collection 21183334 CVCL_NS60 BayGenomics ES cell line RRS645 embryonic stem cell house mouse CVCL_NS60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914496; Resf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183335 CVCL_WM16 WTC dual tagged FBL-mEGFP/NPM1-mTagRFPT-cl18 induced pluripotent stem cell human CVCL_WM16 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 FBL has been endogenously tagged in one allele at the C-terminus with mEGFP and NPM1 has been endogenously tagged in one allele at the C-terminus with mTagRFP-T Part of: Allen Cell Collection 21183336 CVCL_WM15 WTC-mEGFP-SOX2-cl26 induced pluripotent stem cell human CVCL_WM15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 SOX2 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21183337 CVCL_WM14 WTC-mEGFP-ACTN2-cl85 induced pluripotent stem cell human CVCL_WM14 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 ACTN2 has been endogenously tagged in one allele at the C-terminus with mEGFP Part of: Allen Cell Collection 21183338 CVCL_NS79 BayGenomics ES cell line RRS708 embryonic stem cell house mouse CVCL_NS79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918025; Zmynd8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183339 CVCL_NS78 BayGenomics ES cell line RRS703 embryonic stem cell house mouse CVCL_NS78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921487; Tubgcp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183340 CVCL_NS77 BayGenomics ES cell line RRS702 embryonic stem cell house mouse CVCL_NS77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107637; Psmb7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183341 CVCL_NS76 BayGenomics ES cell line RRS701 embryonic stem cell house mouse CVCL_NS76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384939; Fam222b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183342 CVCL_WM02 HPB-SL 26M spontaneously immortalized cell line CVCL_WM02 CL:0000010 Unspecified Group: Insect cell line. 21183343 CVCL_NS75 BayGenomics ES cell line RRS699 embryonic stem cell house mouse CVCL_NS75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183344 CVCL_WM01 SV-HGEC-3 transformed cell line human CVCL_WM01 CL:0000010 Miscellaneous: The paper indicates that 3 SV-HGEC cell lines have been established but do not name them We have therefore arbitrarly named them SV-HGEC-1 to -3. Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Endothelial cell.. Unspecified 21183345 CVCL_NS74 BayGenomics ES cell line RRS697 embryonic stem cell house mouse CVCL_NS74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919020; Ap2b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183346 CVCL_WM00 SV-HGEC-2 transformed cell line human CVCL_WM00 CL:0000010 Miscellaneous: The paper indicates that 3 SV-HGEC cell lines have been established but do not name them We have therefore arbitrarly named them SV-HGEC-1 to -3. Transformant: Simian virus 40 (SV40) [777](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Endothelial cell.. Unspecified 21183347 CVCL_NS73 BayGenomics ES cell line RRS693 embryonic stem cell house mouse CVCL_NS73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106008; Anxa5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183348 CVCL_NS72 BayGenomics ES cell line RRS689 embryonic stem cell house mouse CVCL_NS72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103198; Cdc25a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183349 CVCL_WM06 CIAUi003-A induced pluripotent stem cell human CVCL_WM06 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1513; CASQ2; Simple; p.Lys180Arg (c.539A>G); ClinVar=VCV000265850; Zygosity=Heterozygous (PubMed=31039485) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21183350 CVCL_NS71 BayGenomics ES cell line RRS688 embryonic stem cell house mouse CVCL_NS71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924968; Slf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183351 CVCL_WM05 UT-EC-2C cancer cell line human CVCL_WM05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from metastatic site: Intra-abdominal. Female 21183352 CVCL_NS70 BayGenomics ES cell line RRS687 embryonic stem cell house mouse CVCL_NS70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891703; Gpa33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183353 CVCL_WM04 cp-73 spontaneously immortalized cell line CVCL_WM04 CL:0000010 Unspecified Group: Insect cell line. 21183354 CVCL_WM03 Aa4 spontaneously immortalized cell line CVCL_WM03 CL:0000010 Unspecified Group: Insect cell line. 21183355 CVCL_NS49 BayGenomics ES cell line RRS624 embryonic stem cell house mouse CVCL_NS49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927222; Diaph3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183356 CVCL_NS48 BayGenomics ES cell line RRS623 embryonic stem cell house mouse CVCL_NS48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442092; Wnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183357 CVCL_NS47 BayGenomics ES cell line RRS618 embryonic stem cell house mouse CVCL_NS47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860197; Wdr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183358 CVCL_NS46 BayGenomics ES cell line RRS614 embryonic stem cell house mouse CVCL_NS46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183359 CVCL_NS45 BayGenomics ES cell line RRS613 embryonic stem cell house mouse CVCL_NS45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2676556; Akap13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183360 CVCL_NS44 BayGenomics ES cell line RRS612 embryonic stem cell house mouse CVCL_NS44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443517; Hnrnpul1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183361 CVCL_NS43 BayGenomics ES cell line RRS610 embryonic stem cell house mouse CVCL_NS43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104583; Eps15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183362 CVCL_NS42 BayGenomics ES cell line RRS609 embryonic stem cell house mouse CVCL_NS42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183363 CVCL_NS41 BayGenomics ES cell line RRS606 embryonic stem cell house mouse CVCL_NS41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351651; Yme1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183364 CVCL_NS40 BayGenomics ES cell line RRS596 embryonic stem cell house mouse CVCL_NS40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183365 CVCL_NS59 BayGenomics ES cell line RRS642 embryonic stem cell house mouse CVCL_NS59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916356; Stoml1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183366 CVCL_NS58 BayGenomics ES cell line RRS639 embryonic stem cell house mouse CVCL_NS58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916139; Ubac2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183367 CVCL_NS57 BayGenomics ES cell line RRS638 embryonic stem cell house mouse CVCL_NS57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384818; Mtss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183368 CVCL_NS56 BayGenomics ES cell line RRS637 embryonic stem cell house mouse CVCL_NS56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914496; Resf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183369 CVCL_NS55 BayGenomics ES cell line RRS634 embryonic stem cell house mouse CVCL_NS55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916356; Stoml1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183370 CVCL_NS54 BayGenomics ES cell line RRS631 embryonic stem cell house mouse CVCL_NS54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:891964; Xrn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183371 CVCL_NS53 BayGenomics ES cell line RRS630 embryonic stem cell house mouse CVCL_NS53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140983; Fam185a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183372 CVCL_NS52 BayGenomics ES cell line RRS629 embryonic stem cell house mouse CVCL_NS52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99400; Atp7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183373 CVCL_NS51 BayGenomics ES cell line RRS626 embryonic stem cell house mouse CVCL_NS51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101838; Tbp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183374 CVCL_NS50 BayGenomics ES cell line RRS625 embryonic stem cell house mouse CVCL_NS50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888594; Icmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183375 CVCL_EY95 ND33947 finite cell line human CVCL_EY95 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[40] (c.52CAG(40)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33947; true Female 21183376 CVCL_EY94 ND33879 finite cell line human CVCL_EY94 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33879; true Female 21183377 CVCL_EY93 ND33847 finite cell line human CVCL_EY93 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33847; true Female 21183378 CVCL_EY92 ND33424 finite cell line human CVCL_EY92 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33424; true Male 21183379 CVCL_EY99 ND34263 finite cell line human CVCL_EY99 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Homozygous (PubMed=22952635; PubMed=30497978) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34263; true Male 21183380 CVCL_EY98 ND34235 finite cell line human CVCL_EY98 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34235; true Male 21183381 CVCL_EY97 ND34106 finite cell line human CVCL_EY97 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34106; true Male 21183382 CVCL_EY96 ND33965 finite cell line human CVCL_EY96 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33965; true Male 21183383 CVCL_NS29 BayGenomics ES cell line RRS556 embryonic stem cell house mouse CVCL_NS29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921807; Ppp6r3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183384 CVCL_NS28 BayGenomics ES cell line RRS555 embryonic stem cell house mouse CVCL_NS28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105307; Ptpn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183385 CVCL_NS27 BayGenomics ES cell line RRS553 embryonic stem cell house mouse CVCL_NS27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107793; Crmp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183386 CVCL_NS26 BayGenomics ES cell line RRS552 embryonic stem cell house mouse CVCL_NS26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890564; Rcan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183387 CVCL_NS25 BayGenomics ES cell line RRS549 embryonic stem cell house mouse CVCL_NS25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919725; Ssbp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183388 CVCL_EY91 ND33391 finite cell line human CVCL_EY91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33391; true Female 21183389 CVCL_NS24 BayGenomics ES cell line RRS547 embryonic stem cell house mouse CVCL_NS24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923164; Exoc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183390 CVCL_EY90 ND32976 finite cell line human CVCL_EY90 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Arg1441Gly (c.4321C>G); ClinVar=VCV000001936; Zygosity=Unspecified (PubMed=22952635) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32976; true Female 21183391 CVCL_NS23 BayGenomics ES cell line RRS545 embryonic stem cell house mouse CVCL_NS23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923792; Hibch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183392 CVCL_NS22 BayGenomics ES cell line RRS543 embryonic stem cell house mouse CVCL_NS22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98386; Sptan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183393 CVCL_NS21 BayGenomics ES cell line RRS535 embryonic stem cell house mouse CVCL_NS21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443036; Dnajc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183394 CVCL_NS20 BayGenomics ES cell line RRS534 embryonic stem cell house mouse CVCL_NS20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444022; Mapk1ip1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183395 CVCL_NS39 BayGenomics ES cell line RRS590 embryonic stem cell house mouse CVCL_NS39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924165; Mnd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183396 CVCL_NS38 BayGenomics ES cell line RRS582 embryonic stem cell house mouse CVCL_NS38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925939; Naa35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183397 CVCL_NS37 BayGenomics ES cell line RRS577 embryonic stem cell house mouse CVCL_NS37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109153; Ktn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183398 CVCL_NS36 BayGenomics ES cell line RRS576 embryonic stem cell house mouse CVCL_NS36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384756; Phf21a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183399 CVCL_NS35 BayGenomics ES cell line RRS575 embryonic stem cell house mouse CVCL_NS35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915095; Rnf115 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183400 CVCL_NS34 BayGenomics ES cell line RRS571 embryonic stem cell house mouse CVCL_NS34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183401 CVCL_NS33 BayGenomics ES cell line RRS565 embryonic stem cell house mouse CVCL_NS33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923661; Ift43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183402 CVCL_NS32 BayGenomics ES cell line RRS564 embryonic stem cell house mouse CVCL_NS32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913976; Nipbl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183403 CVCL_NS31 BayGenomics ES cell line RRS561 embryonic stem cell house mouse CVCL_NS31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2149543; Ubap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183404 CVCL_NS30 BayGenomics ES cell line RRS558 embryonic stem cell house mouse CVCL_NS30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107476; Stim1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183405 CVCL_NL31 BayGenomics ES cell line RRQ171 embryonic stem cell house mouse CVCL_NL31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98386; Sptan1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183406 CVCL_NL30 BayGenomics ES cell line RRQ167 embryonic stem cell house mouse CVCL_NL30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87930; Adk Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183407 CVCL_F399 COLO201 transformed cell line human CVCL_F399 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183408 CVCL_ER99 ND01843 transformed cell line human CVCL_ER99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183409 CVCL_F394 COLO165 transformed cell line human CVCL_F394 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183410 CVCL_ER94 ND01696 transformed cell line human CVCL_ER94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183411 CVCL_F393 COLO164 transformed cell line human CVCL_F393 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183412 CVCL_ER93 ND01669 transformed cell line human CVCL_ER93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183413 CVCL_F392 COLO158 transformed cell line human CVCL_F392 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183414 CVCL_ER92 ND01667 transformed cell line human CVCL_ER92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183415 CVCL_F391 COLO157 transformed cell line human CVCL_F391 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183416 CVCL_ER91 ND01663 transformed cell line human CVCL_ER91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183417 CVCL_F398 COLO200 transformed cell line human CVCL_F398 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183418 CVCL_ER98 ND01789 transformed cell line human CVCL_ER98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183419 CVCL_F397 COLO198 transformed cell line human CVCL_F397 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183420 CVCL_ER97 ND01782 transformed cell line human CVCL_ER97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183421 CVCL_F396 COLO167 transformed cell line human CVCL_F396 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183422 CVCL_ER96 ND01760 transformed cell line human CVCL_ER96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183423 CVCL_NL29 BayGenomics ES cell line RRQ165 embryonic stem cell house mouse CVCL_NL29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105069; Rab4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183424 CVCL_F395 COLO166 transformed cell line human CVCL_F395 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183425 CVCL_ER95 ND01698 transformed cell line human CVCL_ER95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183426 CVCL_NL28 BayGenomics ES cell line RRQ163 embryonic stem cell house mouse CVCL_NL28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183427 CVCL_NL27 BayGenomics ES cell line RRQ162 embryonic stem cell house mouse CVCL_NL27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935145; Mllt6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183428 CVCL_NL26 BayGenomics ES cell line RRQ161 embryonic stem cell house mouse CVCL_NL26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683538; Lyrm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183429 CVCL_NL25 BayGenomics ES cell line RRQ150 embryonic stem cell house mouse CVCL_NL25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183430 CVCL_NL24 BayGenomics ES cell line RRQ149 embryonic stem cell house mouse CVCL_NL24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913867; Ntmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183431 CVCL_F390 COLO142 transformed cell line human CVCL_F390 CL:0000010 Population: Colombian; native South American and Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183432 CVCL_ER90 ND01658 transformed cell line human CVCL_ER90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183433 CVCL_NL23 BayGenomics ES cell line RRQ148 embryonic stem cell house mouse CVCL_NL23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923580; Sephs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183434 CVCL_NL22 BayGenomics ES cell line RRQ144 embryonic stem cell house mouse CVCL_NL22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098684; Eif2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183435 CVCL_NL21 BayGenomics ES cell line RRQ142 embryonic stem cell house mouse CVCL_NL21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183436 CVCL_NL42 BayGenomics ES cell line RRR014 embryonic stem cell house mouse CVCL_NL42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103199; Mcm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183437 CVCL_NL41 BayGenomics ES cell line RRR012 embryonic stem cell house mouse CVCL_NL41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105307; Ptpn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183438 CVCL_NL40 BayGenomics ES cell line RRR011 embryonic stem cell house mouse CVCL_NL40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096376; Exoc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183439 CVCL_NL39 BayGenomics ES cell line RRR010 embryonic stem cell house mouse CVCL_NL39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929705; Xpo7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183440 CVCL_NL38 BayGenomics ES cell line RRR008 embryonic stem cell house mouse CVCL_NL38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183441 CVCL_NL37 BayGenomics ES cell line RRR007 embryonic stem cell house mouse CVCL_NL37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194910; Rbbp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183442 CVCL_NL36 BayGenomics ES cell line RRR006 embryonic stem cell house mouse CVCL_NL36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183443 CVCL_NL35 BayGenomics ES cell line RRR005 embryonic stem cell house mouse CVCL_NL35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920442; Xpot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183444 CVCL_NL34 BayGenomics ES cell line RRR004 embryonic stem cell house mouse CVCL_NL34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183445 CVCL_NL33 BayGenomics ES cell line RRR003 embryonic stem cell house mouse CVCL_NL33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137706; Actn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183446 CVCL_NL32 BayGenomics ES cell line RRR002 embryonic stem cell house mouse CVCL_NL32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101845; Mcm3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183447 CVCL_F379 CHP04 transformed cell line human CVCL_F379 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183448 CVCL_ER79 ND00131 transformed cell line human CVCL_ER79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183449 CVCL_F378 CHP02 transformed cell line human CVCL_F378 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183450 CVCL_ER78 ND00092 transformed cell line human CVCL_ER78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183451 CVCL_F377 CHP01 transformed cell line human CVCL_F377 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183452 CVCL_ER77 ND00090 transformed cell line human CVCL_ER77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183453 CVCL_F372 CHI89 transformed cell line human CVCL_F372 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183454 CVCL_ER72 ND00077 transformed cell line human CVCL_ER72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183455 CVCL_F371 CHI88 transformed cell line human CVCL_F371 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183456 CVCL_ER71 ND00074 transformed cell line human CVCL_ER71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183457 CVCL_F370 CHI85 transformed cell line human CVCL_F370 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183458 CVCL_ER70 ND00056 transformed cell line human CVCL_ER70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183459 CVCL_F376 CHI99 transformed cell line human CVCL_F376 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183460 CVCL_ER76 ND00089 transformed cell line human CVCL_ER76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183461 CVCL_NL09 BayGenomics ES cell line RRQ108 embryonic stem cell house mouse CVCL_NL09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923858; Hectd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183462 CVCL_F375 CHI94 transformed cell line human CVCL_F375 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183463 CVCL_ER75 ND00086 transformed cell line human CVCL_ER75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183464 CVCL_NL08 BayGenomics ES cell line RRQ101 embryonic stem cell house mouse CVCL_NL08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919267; Cyb5r1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183465 CVCL_F374 CHI91 transformed cell line human CVCL_F374 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183466 CVCL_ER74 ND00085 transformed cell line human CVCL_ER74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183467 CVCL_NL07 BayGenomics ES cell line RRQ090 embryonic stem cell house mouse CVCL_NL07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328366; Smarcb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183468 CVCL_F373 CHI90 transformed cell line human CVCL_F373 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183469 CVCL_ER73 ND00078 transformed cell line human CVCL_ER73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183470 CVCL_NL06 BayGenomics ES cell line RRQ088 embryonic stem cell house mouse CVCL_NL06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096584; Psmd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183471 CVCL_NL05 BayGenomics ES cell line RRQ069 embryonic stem cell house mouse CVCL_NL05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109337; Brca2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183472 CVCL_NL04 BayGenomics ES cell line RRQ067 embryonic stem cell house mouse CVCL_NL04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924834; Spidr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183473 CVCL_NL03 BayGenomics ES cell line RRQ062 embryonic stem cell house mouse CVCL_NL03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917135; Aunip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183474 CVCL_NL02 BayGenomics ES cell line RRQ061 embryonic stem cell house mouse CVCL_NL02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683537; Tapt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183475 CVCL_NL01 BayGenomics ES cell line RRQ060 embryonic stem cell house mouse CVCL_NL01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183476 CVCL_NL00 BayGenomics ES cell line RRQ059 embryonic stem cell house mouse CVCL_NL00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914210; Mindy3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183477 CVCL_NL20 BayGenomics ES cell line RRQ141 embryonic stem cell house mouse CVCL_NL20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183478 CVCL_F389 COLO134 transformed cell line human CVCL_F389 CL:0000010 Population: Colombian; native South American and Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183479 CVCL_ER89 ND01605 transformed cell line human CVCL_ER89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183480 CVCL_F388 COLO133 transformed cell line human CVCL_F388 CL:0000010 Population: Colombian; native South American and Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183481 CVCL_ER88 ND01604 transformed cell line human CVCL_ER88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183482 CVCL_F383 CHP09 transformed cell line human CVCL_F383 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183483 CVCL_ER83 ND01057 transformed cell line human CVCL_ER83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183484 CVCL_F382 CHP08 transformed cell line human CVCL_F382 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183485 CVCL_ER82 ND01024 transformed cell line human CVCL_ER82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183486 CVCL_F381 CHP07 transformed cell line human CVCL_F381 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183487 CVCL_ER81 ND00484 transformed cell line human CVCL_ER81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183488 CVCL_F380 CHP06 transformed cell line human CVCL_F380 CL:0000010 Population: Bolivian; native South American; Chipayan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183489 CVCL_ER80 ND00414 transformed cell line human CVCL_ER80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183490 CVCL_F387 COLO131 transformed cell line human CVCL_F387 CL:0000010 Population: Colombian; native South American and Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183491 CVCL_ER87 ND01559 transformed cell line human CVCL_ER87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183492 CVCL_F386 COLO129 transformed cell line human CVCL_F386 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183493 CVCL_ER86 ND01399 transformed cell line human CVCL_ER86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183494 CVCL_NL19 BayGenomics ES cell line RRQ139 embryonic stem cell house mouse CVCL_NL19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355333; Nckap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183495 CVCL_F385 COLO119 transformed cell line human CVCL_F385 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183496 CVCL_ER85 ND01372 transformed cell line human CVCL_ER85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183497 CVCL_NL18 BayGenomics ES cell line RRQ138 embryonic stem cell house mouse CVCL_NL18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355333; Nckap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183498 CVCL_F384 COLO383 transformed cell line human CVCL_F384 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183499 CVCL_ER84 ND01336 transformed cell line human CVCL_ER84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183500 CVCL_NL17 BayGenomics ES cell line RRQ134 embryonic stem cell house mouse CVCL_NL17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145043; Cep170b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183501 CVCL_NL16 BayGenomics ES cell line RRQ133 embryonic stem cell house mouse CVCL_NL16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1343188; Ube2g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183502 CVCL_NL15 BayGenomics ES cell line RRQ119 embryonic stem cell house mouse CVCL_NL15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183503 CVCL_NL14 BayGenomics ES cell line RRQ117 embryonic stem cell house mouse CVCL_NL14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183504 CVCL_NL13 BayGenomics ES cell line RRQ115 embryonic stem cell house mouse CVCL_NL13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183505 CVCL_NL12 BayGenomics ES cell line RRQ114 embryonic stem cell house mouse CVCL_NL12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183506 CVCL_NL11 BayGenomics ES cell line RRQ113 embryonic stem cell house mouse CVCL_NL11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913125; Pias1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183507 CVCL_NL10 BayGenomics ES cell line RRQ110 embryonic stem cell house mouse CVCL_NL10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2687282; Cep104 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183508 CVCL_F358 CHI214 transformed cell line human CVCL_F358 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Part of: Sonoda-Tajima cell collection 21183509 CVCL_ER58 CW40247 induced pluripotent stem cell human CVCL_ER58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40247; true Female 21183510 CVCL_F357 CHI212 transformed cell line human CVCL_F357 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Sonoda-Tajima cell collection 21183511 CVCL_ER57 CW40213 induced pluripotent stem cell human CVCL_ER57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40213; true Female 21183512 CVCL_F356 CHI147 transformed cell line human CVCL_F356 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183513 CVCL_ER56 CW40212 induced pluripotent stem cell human CVCL_ER56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40212; true Male 21183514 CVCL_F355 CHI146 transformed cell line human CVCL_F355 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183515 CVCL_ER55 CW40193 induced pluripotent stem cell human CVCL_ER55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40193; true Female 21183516 CVCL_F359 CHI215 transformed cell line human CVCL_F359 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Sonoda-Tajima cell collection 21183517 CVCL_ER59 CW50072 induced pluripotent stem cell human CVCL_ER59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50072; true Male 21183518 CVCL_F350 CHI08 transformed cell line human CVCL_F350 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183519 CVCL_ER50 CW30431 induced pluripotent stem cell human CVCL_ER50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30431; true Male 21183520 CVCL_F354 CHI144 transformed cell line human CVCL_F354 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183521 CVCL_ER54 CW40044 induced pluripotent stem cell human CVCL_ER54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40044; true. Male 21183522 CVCL_F353 CHI142 transformed cell line human CVCL_F353 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183523 CVCL_ER53 CW30462 induced pluripotent stem cell human CVCL_ER53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30462; true Male 21183524 CVCL_F352 CHI139 transformed cell line human CVCL_F352 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183525 CVCL_ER52 CW30434 induced pluripotent stem cell human CVCL_ER52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30434; true Male 21183526 CVCL_F351 CHI101 transformed cell line human CVCL_F351 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183527 CVCL_ER51 CW30432 induced pluripotent stem cell human CVCL_ER51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30432; true Female 21183528 CVCL_F369 CHI84 transformed cell line human CVCL_F369 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183529 CVCL_ER69 ND00053 transformed cell line human CVCL_ER69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183530 CVCL_F368 CHI76 transformed cell line human CVCL_F368 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183531 CVCL_ER68 ND00052 transformed cell line human CVCL_ER68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183532 CVCL_F367 CHI60 transformed cell line human CVCL_F367 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183533 CVCL_ER67 ND00051 transformed cell line human CVCL_ER67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21183534 CVCL_F366 CHI3 transformed cell line human CVCL_F366 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Sonoda-Tajima cell collection 21183535 CVCL_ER66 ND00044 transformed cell line human CVCL_ER66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183536 CVCL_F361 CHI220 transformed cell line human CVCL_F361 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Sonoda-Tajima cell collection 21183537 CVCL_ER61 CW50136 induced pluripotent stem cell human CVCL_ER61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50136; true Male 21183538 CVCL_F360 CHI217 transformed cell line human CVCL_F360 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: Sonoda-Tajima cell collection 21183539 CVCL_ER60 CW50076 induced pluripotent stem cell human CVCL_ER60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50076; true Female 21183540 CVCL_F365 CHI244 transformed cell line human CVCL_F365 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183541 CVCL_ER65 ND06792 transformed cell line human CVCL_ER65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183542 CVCL_F364 CHI236 transformed cell line human CVCL_F364 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183543 CVCL_ER64 ND06803 transformed cell line human CVCL_ER64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183544 CVCL_F363 CHI233 transformed cell line human CVCL_F363 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183545 CVCL_ER63 ND06648 transformed cell line human CVCL_ER63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183546 CVCL_F362 CHI232 transformed cell line human CVCL_F362 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183547 CVCL_ER62 CW50137 induced pluripotent stem cell human CVCL_ER62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50137; true Female 21183548 CVCL_F336 2C088 transformed cell line human CVCL_F336 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183549 CVCL_ER36 CW30068 induced pluripotent stem cell human CVCL_ER36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30068; true Female 21183550 CVCL_F335 2C087 transformed cell line human CVCL_F335 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183551 CVCL_ER35 CW30054 induced pluripotent stem cell human CVCL_ER35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30054; true Female 21183552 CVCL_F334 2C076 transformed cell line human CVCL_F334 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183553 CVCL_ER34 CW30032 induced pluripotent stem cell human CVCL_ER34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30032; true. Female 21183554 CVCL_F333 2C067 transformed cell line human CVCL_F333 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183555 CVCL_ER33 CW10206 induced pluripotent stem cell human CVCL_ER33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10206; true Male 21183556 CVCL_F339 2C092 transformed cell line human CVCL_F339 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183557 CVCL_ER39 CW30244 induced pluripotent stem cell human CVCL_ER39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30244; true Female 21183558 CVCL_F338 2C090 transformed cell line human CVCL_F338 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183559 CVCL_ER38 CW30226 induced pluripotent stem cell human CVCL_ER38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30226; true Male 21183560 CVCL_F337 2C089 transformed cell line human CVCL_F337 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183561 CVCL_ER37 CW30157 induced pluripotent stem cell human CVCL_ER37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30157; true Male 21183562 CVCL_F332 2C012 transformed cell line human CVCL_F332 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183563 CVCL_ER32 CW10178 induced pluripotent stem cell human CVCL_ER32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10178; true Male 21183564 CVCL_ER31 CW10165 induced pluripotent stem cell human CVCL_ER31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10165; true Female 21183565 CVCL_F331 MEMOR 06 cancer cell line human CVCL_F331 CL:0000010 Derived from metastatic site: Hypodermis. Male 21183566 CVCL_ER30 CW10158 induced pluripotent stem cell human CVCL_ER30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10158; true Female 21183567 CVCL_F330 MeMo 05 cancer cell line human CVCL_F330 CL:0000010 Derived from metastatic site: Lymph node. Male 21183568 CVCL_F347 CHI037 transformed cell line human CVCL_F347 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183569 CVCL_ER47 CW30359 induced pluripotent stem cell human CVCL_ER47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30359; true Male 21183570 CVCL_F346 2C123 transformed cell line human CVCL_F346 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183571 CVCL_ER46 CW30358 induced pluripotent stem cell human CVCL_ER46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30358; true Female 21183572 CVCL_F345 2C122 transformed cell line human CVCL_F345 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183573 CVCL_ER45 CW30354 induced pluripotent stem cell human CVCL_ER45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30354; true Male 21183574 CVCL_F344 2C118 transformed cell line human CVCL_F344 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183575 CVCL_ER44 CW30345 induced pluripotent stem cell human CVCL_ER44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30345; true Male 21183576 CVCL_F349 CHI059 transformed cell line human CVCL_F349 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183577 CVCL_ER49 CW30427 induced pluripotent stem cell human CVCL_ER49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30427; true Female 21183578 CVCL_F348 CHI05 transformed cell line human CVCL_F348 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183579 CVCL_ER48 CW30406 induced pluripotent stem cell human CVCL_ER48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30406; true Male 21183580 CVCL_F343 2C116 transformed cell line human CVCL_F343 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183581 CVCL_ER43 CW30344 induced pluripotent stem cell human CVCL_ER43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30344; true Male 21183582 CVCL_F342 2C114 transformed cell line human CVCL_F342 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183583 CVCL_ER42 CW30342 induced pluripotent stem cell human CVCL_ER42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30342; true Male 21183584 CVCL_F341 2C101 transformed cell line human CVCL_F341 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183585 CVCL_ER41 CW30339 induced pluripotent stem cell human CVCL_ER41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30339; true Female 21183586 CVCL_F340 2C100 transformed cell line human CVCL_F340 CL:0000010 Population: Colombian; native South American and Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183587 CVCL_ER40 CW30333 induced pluripotent stem cell human CVCL_ER40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30333; true Male 21183588 CVCL_WF52 TK-294 transformed cell line human CVCL_WF52 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183589 CVCL_WF51 TK-293 transformed cell line human CVCL_WF51 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183590 CVCL_WF50 TK-292 transformed cell line human CVCL_WF50 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183591 CVCL_WF56 TK-307 transformed cell line human CVCL_WF56 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183592 CVCL_WF55 TK-304 transformed cell line human CVCL_WF55 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183593 CVCL_WF54 TK-303 transformed cell line human CVCL_WF54 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183594 CVCL_WF53 TK-296 transformed cell line human CVCL_WF53 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183595 CVCL_WF59 TK-314 transformed cell line human CVCL_WF59 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183596 CVCL_WF58 TK-313 transformed cell line human CVCL_WF58 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183597 CVCL_WF57 TK-309 transformed cell line human CVCL_WF57 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183598 CVCL_WF41 TK-20 transformed cell line human CVCL_WF41 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183599 CVCL_WF40 TK-198 transformed cell line human CVCL_WF40 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183600 CVCL_WF45 TK-221 transformed cell line human CVCL_WF45 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183601 CVCL_WF44 TK-217 transformed cell line human CVCL_WF44 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183602 CVCL_WF43 TK-213 transformed cell line human CVCL_WF43 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183603 CVCL_WF42 TK-211 transformed cell line human CVCL_WF42 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183604 CVCL_WF49 TK-291 transformed cell line human CVCL_WF49 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183605 CVCL_WF48 TK-28 transformed cell line human CVCL_WF48 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183606 CVCL_WF47 TK-256 transformed cell line human CVCL_WF47 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183607 CVCL_WF46 TK-23 transformed cell line human CVCL_WF46 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183608 CVCL_NL97 BayGenomics ES cell line RRR109 embryonic stem cell house mouse CVCL_NL97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194910; Rbbp7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183609 CVCL_NL96 BayGenomics ES cell line RRR108 embryonic stem cell house mouse CVCL_NL96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183610 CVCL_NL95 BayGenomics ES cell line RRR107 embryonic stem cell house mouse CVCL_NL95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924001; Chd9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183611 CVCL_NL94 BayGenomics ES cell line RRR106 embryonic stem cell house mouse CVCL_NL94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183612 CVCL_NL93 BayGenomics ES cell line RRR105 embryonic stem cell house mouse CVCL_NL93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346858; Mapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183613 CVCL_NL92 BayGenomics ES cell line RRR103 embryonic stem cell house mouse CVCL_NL92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99470; Dnajc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183614 CVCL_NL91 BayGenomics ES cell line RRR102 embryonic stem cell house mouse CVCL_NL91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107891; Nop2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183615 CVCL_NL90 BayGenomics ES cell line RRR100 embryonic stem cell house mouse CVCL_NL90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338037; Rbm6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183616 CVCL_WF30 TK-165 transformed cell line human CVCL_WF30 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183617 CVCL_WF34 TK-181 transformed cell line human CVCL_WF34 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183618 CVCL_WF33 TK-180 transformed cell line human CVCL_WF33 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183619 CVCL_WF32 TK-177 transformed cell line human CVCL_WF32 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183620 CVCL_WF31 TK-173 transformed cell line human CVCL_WF31 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183621 CVCL_WF38 TK-193 transformed cell line human CVCL_WF38 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183622 CVCL_WF37 TK-191 transformed cell line human CVCL_WF37 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183623 CVCL_WF36 TK-183 transformed cell line human CVCL_WF36 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183624 CVCL_WF35 TK-182 transformed cell line human CVCL_WF35 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183625 CVCL_WF39 TK-197 transformed cell line human CVCL_WF39 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183626 CVCL_NL89 BayGenomics ES cell line RRR099 embryonic stem cell house mouse CVCL_NL89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276124; Ep400 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183627 CVCL_NL88 BayGenomics ES cell line RRR098 embryonic stem cell house mouse CVCL_NL88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138968; Clp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183628 CVCL_NL87 BayGenomics ES cell line RRR091 embryonic stem cell house mouse CVCL_NL87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934950; Csnk1a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183629 CVCL_WF23 TK-151 transformed cell line human CVCL_WF23 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183630 CVCL_WF22 TK-150 transformed cell line human CVCL_WF22 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183631 CVCL_WF21 TK-148 transformed cell line human CVCL_WF21 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183632 CVCL_WF20 TK-146 transformed cell line human CVCL_WF20 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183633 CVCL_WF27 TK-156 transformed cell line human CVCL_WF27 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183634 CVCL_WF26 TK-155 transformed cell line human CVCL_WF26 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183635 CVCL_WF25 TK-153 transformed cell line human CVCL_WF25 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183636 CVCL_WF24 TK-152 transformed cell line human CVCL_WF24 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183637 CVCL_WF29 TK-160 transformed cell line human CVCL_WF29 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183638 CVCL_WF28 TK-159 transformed cell line human CVCL_WF28 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183639 CVCL_NL99 BayGenomics ES cell line RRR114 embryonic stem cell house mouse CVCL_NL99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96623; Itpr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183640 CVCL_NL98 BayGenomics ES cell line RRR112 embryonic stem cell house mouse CVCL_NL98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152895; Helb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183641 CVCL_NL75 BayGenomics ES cell line RRR067 embryonic stem cell house mouse CVCL_NL75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920174; Anln Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183642 CVCL_NL74 BayGenomics ES cell line RRR066 embryonic stem cell house mouse CVCL_NL74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933184; Nop58 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183643 CVCL_NL73 BayGenomics ES cell line RRR065 embryonic stem cell house mouse CVCL_NL73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183644 CVCL_NL72 BayGenomics ES cell line RRR064 embryonic stem cell house mouse CVCL_NL72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920524; Gpbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183645 CVCL_NL71 BayGenomics ES cell line RRR062 embryonic stem cell house mouse CVCL_NL71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933169; Sacm1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183646 CVCL_NL70 BayGenomics ES cell line RRR061 embryonic stem cell house mouse CVCL_NL70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183647 CVCL_WF12 MZ-396 transformed cell line human CVCL_WF12 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183648 CVCL_WF11 MZ-395 transformed cell line human CVCL_WF11 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183649 CVCL_WF10 MZ-393 transformed cell line human CVCL_WF10 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183650 CVCL_WF16 TK-140 transformed cell line human CVCL_WF16 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183651 CVCL_WF15 MZ-45 transformed cell line human CVCL_WF15 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183652 CVCL_WF14 MZ-398 transformed cell line human CVCL_WF14 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183653 CVCL_WF13 MZ-397 transformed cell line human CVCL_WF13 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183654 CVCL_WF19 TK-145 transformed cell line human CVCL_WF19 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183655 CVCL_WF18 TK-144 transformed cell line human CVCL_WF18 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21183656 CVCL_NL69 BayGenomics ES cell line RRR059 embryonic stem cell house mouse CVCL_NL69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921783; Gzf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183657 CVCL_WF17 TK-142 transformed cell line human CVCL_WF17 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183658 CVCL_NL68 BayGenomics ES cell line RRR057 embryonic stem cell house mouse CVCL_NL68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444782; Fkbp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183659 CVCL_NL67 BayGenomics ES cell line RRR056 embryonic stem cell house mouse CVCL_NL67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3525201; Mdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183660 CVCL_NL66 BayGenomics ES cell line RRR055 embryonic stem cell house mouse CVCL_NL66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147987; Pcyt1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183661 CVCL_NL65 BayGenomics ES cell line RRR054 embryonic stem cell house mouse CVCL_NL65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330299; Dyrk1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183662 CVCL_NL86 BayGenomics ES cell line RRR090 embryonic stem cell house mouse CVCL_NL86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443114; Larp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183663 CVCL_NL85 BayGenomics ES cell line RRR087 embryonic stem cell house mouse CVCL_NL85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108559; Macf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183664 CVCL_NL84 BayGenomics ES cell line RRR084 embryonic stem cell house mouse CVCL_NL84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929865; Nampt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183665 CVCL_NL83 BayGenomics ES cell line RRR082 embryonic stem cell house mouse CVCL_NL83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918771; Pds5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183666 CVCL_NL82 BayGenomics ES cell line RRR079 embryonic stem cell house mouse CVCL_NL82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108177; Dhx9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183667 CVCL_NL81 BayGenomics ES cell line RRR078 embryonic stem cell house mouse CVCL_NL81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183668 CVCL_NL80 BayGenomics ES cell line RRR075 embryonic stem cell house mouse CVCL_NL80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183669 CVCL_WF01 MZ-380 transformed cell line human CVCL_WF01 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183670 CVCL_WF00 MZ-377 transformed cell line human CVCL_WF00 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183671 CVCL_WF05 MZ-385 transformed cell line human CVCL_WF05 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183672 CVCL_WF04 MZ-384 transformed cell line human CVCL_WF04 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183673 CVCL_WF03 MZ-383 transformed cell line human CVCL_WF03 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183674 CVCL_WF02 MZ-381 transformed cell line human CVCL_WF02 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183675 CVCL_WF09 MZ-392 transformed cell line human CVCL_WF09 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183676 CVCL_WF08 MZ-388 transformed cell line human CVCL_WF08 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183677 CVCL_WF07 MZ-387 transformed cell line human CVCL_WF07 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183678 CVCL_WF06 MZ-386 transformed cell line human CVCL_WF06 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183679 CVCL_NL79 BayGenomics ES cell line RRR071 embryonic stem cell house mouse CVCL_NL79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197527; Top3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183680 CVCL_NL78 BayGenomics ES cell line RRR070 embryonic stem cell house mouse CVCL_NL78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103010; Epb41l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183681 CVCL_NL77 BayGenomics ES cell line RRR069 embryonic stem cell house mouse CVCL_NL77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385621; Nup153 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183682 CVCL_NL76 BayGenomics ES cell line RRR068 embryonic stem cell house mouse CVCL_NL76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183683 CVCL_NL53 BayGenomics ES cell line RRR031 embryonic stem cell house mouse CVCL_NL53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446630; Ago1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183684 CVCL_NL52 BayGenomics ES cell line RRR030 embryonic stem cell house mouse CVCL_NL52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107862; Nop16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183685 CVCL_NL51 BayGenomics ES cell line RRR024 embryonic stem cell house mouse CVCL_NL51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918850; Ythdf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183686 CVCL_NL50 BayGenomics ES cell line RRR023 embryonic stem cell house mouse CVCL_NL50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138261; Smap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183687 CVCL_NL49 BayGenomics ES cell line RRR022 embryonic stem cell house mouse CVCL_NL49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183688 CVCL_NL48 BayGenomics ES cell line RRR021 embryonic stem cell house mouse CVCL_NL48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385902; Picalm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183689 CVCL_NL47 BayGenomics ES cell line RRR020 embryonic stem cell house mouse CVCL_NL47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183690 CVCL_NL46 BayGenomics ES cell line RRR019 embryonic stem cell house mouse CVCL_NL46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894681; Usp9x Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183691 CVCL_NL45 BayGenomics ES cell line RRR018 embryonic stem cell house mouse CVCL_NL45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917579; Gon4l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183692 CVCL_NL44 BayGenomics ES cell line RRR017 embryonic stem cell house mouse CVCL_NL44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183693 CVCL_NL43 BayGenomics ES cell line RRR016 embryonic stem cell house mouse CVCL_NL43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194492; Hdgfl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183694 CVCL_NL64 BayGenomics ES cell line RRR053 embryonic stem cell house mouse CVCL_NL64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341857; Mad1l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183695 CVCL_NL63 BayGenomics ES cell line RRR052 embryonic stem cell house mouse CVCL_NL63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929092; Rbm14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183696 CVCL_NL62 BayGenomics ES cell line RRR051 embryonic stem cell house mouse CVCL_NL62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384876; Cdc73 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183697 CVCL_NL61 BayGenomics ES cell line RRR049 embryonic stem cell house mouse CVCL_NL61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914750; Ccar1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183698 CVCL_NL60 BayGenomics ES cell line RRR048 embryonic stem cell house mouse CVCL_NL60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183699 CVCL_NL59 BayGenomics ES cell line RRR047 embryonic stem cell house mouse CVCL_NL59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135610; Dync1li1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183700 CVCL_NL58 BayGenomics ES cell line RRR045 embryonic stem cell house mouse CVCL_NL58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1278328; Dnpep Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183701 CVCL_NL57 BayGenomics ES cell line RRR044 embryonic stem cell house mouse CVCL_NL57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183702 CVCL_NL56 BayGenomics ES cell line RRR043 embryonic stem cell house mouse CVCL_NL56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183703 CVCL_NL55 BayGenomics ES cell line RRR040 embryonic stem cell house mouse CVCL_NL55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328322; Rex2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183704 CVCL_NL54 BayGenomics ES cell line RRR032 embryonic stem cell house mouse CVCL_NL54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143886; Dot1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183705 CVCL_WE93 LR-370 transformed cell line human CVCL_WE93 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183706 CVCL_WE92 LR-367 transformed cell line human CVCL_WE92 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183707 CVCL_WE91 LR-366 transformed cell line human CVCL_WE91 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183708 CVCL_WE90 LR-326 transformed cell line human CVCL_WE90 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183709 CVCL_WE97 MZ-208 transformed cell line human CVCL_WE97 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183710 CVCL_WE96 MZ-201 transformed cell line human CVCL_WE96 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183711 CVCL_WE95 MZ-188 transformed cell line human CVCL_WE95 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183712 CVCL_WE94 MZ-172 transformed cell line human CVCL_WE94 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183713 CVCL_WE99 MZ-375 transformed cell line human CVCL_WE99 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183714 CVCL_WE98 MZ-218 transformed cell line human CVCL_WE98 CL:0000010 Population: Iranian; Mazanderanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183715 CVCL_WE82 LR-272 transformed cell line human CVCL_WE82 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183716 CVCL_WE81 LR-259 transformed cell line human CVCL_WE81 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183717 CVCL_WE80 LR-258 transformed cell line human CVCL_WE80 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183718 CVCL_WE86 LR-277 transformed cell line human CVCL_WE86 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183719 CVCL_WE85 LR-275 transformed cell line human CVCL_WE85 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183720 CVCL_WE84 LR-274 transformed cell line human CVCL_WE84 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183721 CVCL_WE83 LR-273 transformed cell line human CVCL_WE83 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183722 CVCL_WE89 LR-323 transformed cell line human CVCL_WE89 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183723 CVCL_WE88 LR-320 transformed cell line human CVCL_WE88 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183724 CVCL_WE87 LR-283 transformed cell line human CVCL_WE87 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183725 CVCL_WE71 LR-228 transformed cell line human CVCL_WE71 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183726 CVCL_WE70 LR-227 transformed cell line human CVCL_WE70 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183727 CVCL_WE75 LR-246 transformed cell line human CVCL_WE75 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183728 CVCL_WE74 LR-240 transformed cell line human CVCL_WE74 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183729 CVCL_WE73 LR-230 transformed cell line human CVCL_WE73 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183730 CVCL_WE72 LR-229 transformed cell line human CVCL_WE72 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183731 CVCL_WE79 LR-254 transformed cell line human CVCL_WE79 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183732 CVCL_WE78 LR-253 transformed cell line human CVCL_WE78 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183733 CVCL_WE77 LR-252 transformed cell line human CVCL_WE77 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183734 CVCL_WE76 LR-249 transformed cell line human CVCL_WE76 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183735 CVCL_WE60 KD-391 transformed cell line human CVCL_WE60 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183736 CVCL_WE64 LR-161 transformed cell line human CVCL_WE64 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183737 CVCL_WE63 LK-306 transformed cell line human CVCL_WE63 CL:0000010 Population: Iranian; Laks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183738 CVCL_WE62 KD-399 transformed cell line human CVCL_WE62 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183739 CVCL_WE61 KD-394 transformed cell line human CVCL_WE61 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183740 CVCL_WE68 LR-214 transformed cell line human CVCL_WE68 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183741 CVCL_WE67 LR-202 transformed cell line human CVCL_WE67 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183742 CVCL_WE66 LR-178 transformed cell line human CVCL_WE66 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183743 CVCL_WE65 LR-166 transformed cell line human CVCL_WE65 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183744 CVCL_WE69 LR-216 transformed cell line human CVCL_WE69 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183745 CVCL_WE53 KD-373 transformed cell line human CVCL_WE53 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183746 CVCL_WE52 KD-365 transformed cell line human CVCL_WE52 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183747 CVCL_WE51 KD-364 transformed cell line human CVCL_WE51 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183748 CVCL_WE50 KD-363 transformed cell line human CVCL_WE50 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183749 CVCL_WE57 KD-379 transformed cell line human CVCL_WE57 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183750 CVCL_WE56 KD-378 transformed cell line human CVCL_WE56 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183751 CVCL_WE55 KD-376 transformed cell line human CVCL_WE55 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183752 CVCL_WE54 KD-374 transformed cell line human CVCL_WE54 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183753 CVCL_WE59 KD-389 transformed cell line human CVCL_WE59 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183754 CVCL_WE58 KD-382 transformed cell line human CVCL_WE58 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183755 CVCL_WE42 KD-353 transformed cell line human CVCL_WE42 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183756 CVCL_WE41 KD-351 transformed cell line human CVCL_WE41 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183757 CVCL_WE40 KD-347 transformed cell line human CVCL_WE40 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183758 CVCL_WE46 KD-358 transformed cell line human CVCL_WE46 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183759 CVCL_WE45 KD-357 transformed cell line human CVCL_WE45 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183760 CVCL_WE44 KD-355 transformed cell line human CVCL_WE44 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183761 CVCL_WE43 KD-354 transformed cell line human CVCL_WE43 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183762 CVCL_WE49 KD-361 transformed cell line human CVCL_WE49 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183763 CVCL_WE48 KD-360 transformed cell line human CVCL_WE48 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183764 CVCL_WE47 KD-359 transformed cell line human CVCL_WE47 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183765 CVCL_F319 GM13768 transformed cell line human CVCL_F319 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21183766 CVCL_ER19 MKL-1-FB finite cell line human CVCL_ER19 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21183767 CVCL_F314 GM07514 transformed cell line human CVCL_F314 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183768 CVCL_ER14 HSAEC37-KT telomerase immortalized cell line human CVCL_ER14 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183769 CVCL_F313 GM07513 transformed cell line human CVCL_F313 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21183770 CVCL_ER13 HSAEC36-KT telomerase immortalized cell line human CVCL_ER13 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183771 CVCL_F312 GM07512 transformed cell line human CVCL_F312 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183772 CVCL_ER12 HSAEC35-KT telomerase immortalized cell line human CVCL_ER12 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183773 CVCL_F311 GM07511 transformed cell line human CVCL_F311 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183774 CVCL_ER11 HSAEC31-KT telomerase immortalized cell line human CVCL_ER11 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183775 CVCL_F318 GM13070 transformed cell line human CVCL_F318 HLA typing: A*03:01:01,30:02:01; B*07:02:01,57:01:01; C*06:02:01,07:02:01; DPA1*01:03:01,02:01:01; DPB1*02:01:02,13:01:01G; DQA1*01:03:01,02:01:01; DQB1*03:03:02,05:03:01; DRB1*07:01:01,13:01:01; DRB3*02:02:01; DRB4*01:03:01:02N (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21183776 CVCL_ER18 IMR-32_pCMV-SQSTM1 cancer cell line human CVCL_ER18 CL:0000010 Transfected with: HGNC; 11280; SQSTM1 Population: Caucasian; Derived from metastatic site: Abdomen. Omics: Transcriptome analysis by microarray Male 21183777 CVCL_F317 GM08036 transformed cell line human CVCL_F317 HLA typing: A*01:01:01,11:01:01; B*08:01:01,18:01:01; C*07:01:01,07:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01G,04:02:01G; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,11:04:01; DRB3*01:01:02,02:02:01 (PubMed=29959025) CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21183778 CVCL_ER17 IMR-32_pCMV-DPP3 cancer cell line human CVCL_ER17 CL:0000010 Transfected with: HGNC; 3008; DPP3 Population: Caucasian; Derived from metastatic site: Abdomen. Omics: Transcriptome analysis by microarray Male 21183779 CVCL_F316 GM07973 transformed cell line human CVCL_F316 HLA typing: A*01:01:01,02:01:01; B*08:01:01,39:01:01; C*07:01:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*04:01:01,05:01:01; DQB1*02:01:01,04:02:01; DRB1*03:01:01,08:01:01; DRB3*01:01:02 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21183780 CVCL_ER16 HSAEC49-KT telomerase immortalized cell line human CVCL_ER16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183781 CVCL_F315 GM07515 transformed cell line human CVCL_F315 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183782 CVCL_ER15 HSAEC45-KT telomerase immortalized cell line human CVCL_ER15 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183783 CVCL_F310 GM07509 transformed cell line human CVCL_F310 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183784 CVCL_ER10 HSAEC30-KT telomerase immortalized cell line human CVCL_ER10 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183785 CVCL_ER25 CIN-612 3E transformed cell line human CVCL_ER25 CL:0000010 Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585). Female Virology: Contains about 50 HPV31b episomes per cell 21183786 CVCL_F325 GM14699 transformed cell line human CVCL_F325 HLA typing: A*03:CVAB,74:AB; B*35:BEZX,42:02; C*07:CVAG,17:MN; DRB1*08:04,08:06 (IPD-IMGT/HLA=15818); HLA typing: A*03:01:01,74:01:01; B*35:01:01,42:02:01; C*07:18,17:01:01; DPA1*02:01:01,03:NEW-1; DPB1*131:01,584:01; DQA1*01:02:01,05:05:01; DQB1*03:01:04,06:02:01; DRB1*08:04:01,08:06 (PubMed=29959025) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21183787 CVCL_ER24 CIN-612 transformed cell line human CVCL_ER24 CL:0000010 Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585). Female Virology: Contains about 50 HPV31b episomes per cell 21183788 CVCL_F324 GM14697 transformed cell line human CVCL_F324 HLA typing: A*02:DFKP,23:DFKR; B*49:01,58:VE; C*03:02,07:CVAG; DRB1*07:01,09:01 (IPD-IMGT/HLA=20206) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21183789 CVCL_F323 GM14696 transformed cell line human CVCL_F323 HLA typing: A*68:02,74:AB; B*15:BKNX,52:01; C*02:10,16:01; DRB1*03:01,07:01 (IPD-IMGT/HLA=20695) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Female Part of: Human variation panel 21183790 CVCL_ER23 RECA cancer cell line human CVCL_ER23 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Virology: Contains a copy of the HPV16 genome 21183791 CVCL_ER22 AWCA cancer cell line human CVCL_ER22 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761). Female Virology: Contains 2 copies of the HPV18 genome 21183792 CVCL_F322 GM14492 transformed cell line human CVCL_F322 HLA typing: A*24:02:01,29:02:01; B*40:01:02,44:03:01; C*03:04:01,16:01:01; DPA1*01:03:01,01:03:01; DPB1*04:01:01,06:01:01; DQA1*01:02:01,02:01:01; DQB1*02:02:01,06:04:01; DRB1*07:01:01,13:02:01; DRB3*03:01:01; DRB4*01:01:01 (PubMed=29959025) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: Human variation panel 21183793 CVCL_ER29 Kera5 spontaneously immortalized cell line CVCL_ER29 CL:0000010 Transformant: Y-27632(ChEBI; CHEBI:75393); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Unspecified 21183794 CVCL_F329 MEGR 07 cancer cell line human CVCL_F329 CL:0000010 Population: Caucasian; Derived from metastatic site: Cutaneous. Male 21183795 CVCL_ER28 CIN-680 transformed cell line human CVCL_ER28 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Female Virology: Contains integrated HPV16 genome(s) 21183796 CVCL_F328 IST-MELA 16 cancer cell line human CVCL_F328 CL:0000010 Derived from metastatic site: Hypodermis. Male 21183797 CVCL_ER27 CIN-612 9E transformed cell line human CVCL_ER27 CL:0000010 Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585) Omics: Transcriptome analysis by microarray. Female Virology: Contains about 50 HPV31b episomes per cell 21183798 CVCL_F327 CM-S transformed cell line human CVCL_F327 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 21183799 CVCL_ER26 CIN-612 6E transformed cell line human CVCL_ER26 CL:0000010 Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585). Female Virology: Contains 2 to 5 copies of integrated HPV31b genomes 21183800 CVCL_F326 XP14BE LCL transformed cell line human CVCL_F326 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS6-13_-21del9; Zygosity=Homozygous (from autologous cell line XP14BE) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183801 CVCL_F321 GM14490 transformed cell line human CVCL_F321 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21183802 CVCL_ER21 HPCT-2E9 hybrid cell line Norway rat CVCL_ER21 CL:0000010 21183803 CVCL_F320 GM14441 transformed cell line human CVCL_F320 HLA typing: A*30:AUX,34:02; B*42:02,58:02; C*06:02,17:MN; DRB1*08:04,11:02 (IPD-IMGT/HLA=20684) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from dizygotic twin of GM14442 (Cellosaurus=CVCL_9Y34); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21183804 CVCL_ER20 HPCT-1F9 hybrid cell line Norway rat CVCL_ER20 CL:0000010 21183805 CVCL_F309 GM07500 transformed cell line human CVCL_F309 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183806 CVCL_ER09 HSAEC24-KT telomerase immortalized cell line human CVCL_ER09 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183807 CVCL_F308 GM07499 transformed cell line human CVCL_F308 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183808 CVCL_ER08 HSAEC22-KT telomerase immortalized cell line human CVCL_ER08 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183809 CVCL_F303 GM07400 transformed cell line human CVCL_F303 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183810 CVCL_ER03 HSAEC13-KT telomerase immortalized cell line human CVCL_ER03 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183811 CVCL_F302 GM07399 transformed cell line human CVCL_F302 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183812 CVCL_ER02 HBEC7-KT telomerase immortalized cell line human CVCL_ER02 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray Female 21183813 CVCL_F301 GM07094 transformed cell line human CVCL_F301 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21183814 CVCL_ER01 HBEC6-KT telomerase immortalized cell line human CVCL_ER01 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21183815 CVCL_F300 GM06965 finite cell line human CVCL_F300 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21183816 CVCL_ER00 HBEC39-KT telomerase immortalized cell line human CVCL_ER00 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21183817 CVCL_F307 GM07428 transformed cell line human CVCL_F307 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+6T>C (IVS1,T>C,+6) (IVS I-6 T>C); ClinVar=VCV000015450; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-106C>G (IVS2,C>G,+745); ClinVar=VCV000015457; Zygosity=Heterozygous (Coriell) Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Human variation panel 21183818 CVCL_ER07 HSAEC2-KT telomerase immortalized cell line human CVCL_ER07 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183819 CVCL_F306 GM07422 transformed cell line human CVCL_F306 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183820 CVCL_ER06 HSAEC19-KT telomerase immortalized cell line human CVCL_ER06 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183821 CVCL_F305 GM07402 transformed cell line human CVCL_F305 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: DNA methylation analysis Male Part of: Human variation panel 21183822 CVCL_ER05 HSAEC18-KT telomerase immortalized cell line human CVCL_ER05 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183823 CVCL_F304 GM07401 transformed cell line human CVCL_F304 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21183824 CVCL_ER04 HSAEC15-KT telomerase immortalized cell line human CVCL_ER04 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray 21183825 CVCL_NM52 BayGenomics ES cell line RRR213 embryonic stem cell house mouse CVCL_NM52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183826 CVCL_NM51 BayGenomics ES cell line RRR211 embryonic stem cell house mouse CVCL_NM51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921361; Rbm19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183827 CVCL_NM50 BayGenomics ES cell line RRR210 embryonic stem cell house mouse CVCL_NM50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136980; Kdm5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183828 CVCL_NM49 BayGenomics ES cell line RRR209 embryonic stem cell house mouse CVCL_NM49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183829 CVCL_NM48 BayGenomics ES cell line RRR207 embryonic stem cell house mouse CVCL_NM48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138741; Hnrnpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183830 CVCL_NM47 BayGenomics ES cell line RRR205 embryonic stem cell house mouse CVCL_NM47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104517; Xrcc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183831 CVCL_NM46 BayGenomics ES cell line RRR203 embryonic stem cell house mouse CVCL_NM46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914595; Herc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183832 CVCL_NM45 BayGenomics ES cell line RRR199 embryonic stem cell house mouse CVCL_NM45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107690; Zfp462 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183833 CVCL_NM44 BayGenomics ES cell line RRR198 embryonic stem cell house mouse CVCL_NM44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923012; Aftph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183834 CVCL_NM43 BayGenomics ES cell line RRR196 embryonic stem cell house mouse CVCL_NM43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926227; Nup160 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183835 CVCL_NM42 BayGenomics ES cell line RRR195 embryonic stem cell house mouse CVCL_NM42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179326; Oxr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183836 CVCL_NM63 BayGenomics ES cell line RRR236 embryonic stem cell house mouse CVCL_NM63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442401; Ppp1r9a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183837 CVCL_NM62 BayGenomics ES cell line RRR235 embryonic stem cell house mouse CVCL_NM62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306796; Apaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183838 CVCL_NM61 BayGenomics ES cell line RRR234 embryonic stem cell house mouse CVCL_NM61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88274; Ctnna1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183839 CVCL_NM60 BayGenomics ES cell line RRR232 embryonic stem cell house mouse CVCL_NM60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913937; Tbc1d15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183840 CVCL_NM59 BayGenomics ES cell line RRR229 embryonic stem cell house mouse CVCL_NM59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183841 CVCL_NM58 BayGenomics ES cell line RRR225 embryonic stem cell house mouse CVCL_NM58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443726; Zswim4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183842 CVCL_NM57 BayGenomics ES cell line RRR221 embryonic stem cell house mouse CVCL_NM57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919784; Rcc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183843 CVCL_NM56 BayGenomics ES cell line RRR219 embryonic stem cell house mouse CVCL_NM56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442401; Ppp1r9a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183844 CVCL_NM55 BayGenomics ES cell line RRR217 embryonic stem cell house mouse CVCL_NM55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036250; Zfp729a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183845 CVCL_NM54 BayGenomics ES cell line RRR215 embryonic stem cell house mouse CVCL_NM54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442192; Eea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183846 CVCL_NM53 BayGenomics ES cell line RRR214 embryonic stem cell house mouse CVCL_NM53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1097682; Rps5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183847 CVCL_NM30 BayGenomics ES cell line RRR177 embryonic stem cell house mouse CVCL_NM30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1316717; Ifrd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183848 CVCL_F499 K-1.fl cancer cell line house mouse CVCL_F499 CL:0000010 Breed/subspecies: DDD. Male 21183849 CVCL_ES99 ND05868 transformed cell line human CVCL_ES99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183850 CVCL_F498 Cle-H3 spontaneously immortalized cell line house mouse CVCL_F498 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21183851 CVCL_ES98 ND05809 transformed cell line human CVCL_ES98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183852 CVCL_F493 XP25RO finite cell line human CVCL_F493 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Homozygous (Coriell; PubMed=1372102; PubMed=9671271) Population: Palestinian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1261; true Male 21183853 CVCL_ES93 ND05773 transformed cell line human CVCL_ES93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183854 CVCL_F492 XP4SL finite cell line human CVCL_F492 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (from familial inference of XP8BE and XP9BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21183855 CVCL_ES92 ND05771 transformed cell line human CVCL_ES92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183856 CVCL_F491 XP2BE finite cell line human CVCL_F491 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (from familial inference of XP8BE and XP9BE) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1166; probable Male Senescence: Senesces at 22 PDL (PubMed=6492896) 21183857 CVCL_ES91 ND05770 transformed cell line human CVCL_ES91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183858 CVCL_F490 XP9BE LCL transformed cell line human CVCL_F490 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (from autologous cell line XP9BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183859 CVCL_ES90 ND05769 transformed cell line human CVCL_ES90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183860 CVCL_F497 XP3RO LCL transformed cell line human CVCL_F497 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000008788; Zygosity=Homozygous (from autologous cell line XP3RO) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183861 CVCL_ES97 ND05808 transformed cell line human CVCL_ES97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183862 CVCL_F496 XP2RO finite cell line human CVCL_F496 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000008788; Zygosity=Homozygous (PubMed=8798680; PubMed=10777490) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1259; true; Discontinued: Coriell; GM00708; true; Discontinued: Coriell; GM01762; probable Female 21183863 CVCL_ES96 ND05807 transformed cell line human CVCL_ES96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183864 CVCL_NM29 BayGenomics ES cell line RRR173 embryonic stem cell house mouse CVCL_NM29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88141; Bcr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183865 CVCL_F495 XP3BE LCL transformed cell line human CVCL_F495 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.621_622ins83 (XPCins83); ClinVar=VCV000000254; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183866 CVCL_ES95 ND05805 transformed cell line human CVCL_ES95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183867 CVCL_NM28 BayGenomics ES cell line RRR171 embryonic stem cell house mouse CVCL_NM28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147538; Btaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183868 CVCL_F494 XP3BE finite cell line human CVCL_F494 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.621_622ins83 (XPCins83); ClinVar=VCV000000254; Zygosity=Unspecified (PubMed=26184184) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1189; true Male 21183869 CVCL_ES94 ND05802 transformed cell line human CVCL_ES94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183870 CVCL_NM27 BayGenomics ES cell line RRR170 embryonic stem cell house mouse CVCL_NM27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147538; Btaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183871 CVCL_NM26 BayGenomics ES cell line RRR168 embryonic stem cell house mouse CVCL_NM26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913546; Haus2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183872 CVCL_NM25 BayGenomics ES cell line RRR163 embryonic stem cell house mouse CVCL_NM25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96247; Hsp90ab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183873 CVCL_NM24 BayGenomics ES cell line RRR162 embryonic stem cell house mouse CVCL_NM24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921355; Gga2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183874 CVCL_NM23 BayGenomics ES cell line RRR160 embryonic stem cell house mouse CVCL_NM23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107428; Cfap20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183875 CVCL_NM22 BayGenomics ES cell line RRR159 embryonic stem cell house mouse CVCL_NM22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923809; Atg2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183876 CVCL_NM21 BayGenomics ES cell line RRR158 embryonic stem cell house mouse CVCL_NM21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924968; Slf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183877 CVCL_NM20 BayGenomics ES cell line RRR157 embryonic stem cell house mouse CVCL_NM20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924968; Slf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183878 CVCL_NM41 BayGenomics ES cell line RRR194 embryonic stem cell house mouse CVCL_NM41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:94912; Dnmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183879 CVCL_NM40 BayGenomics ES cell line RRR189 embryonic stem cell house mouse CVCL_NM40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99445; Mtpn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183880 CVCL_NM39 BayGenomics ES cell line RRR188 embryonic stem cell house mouse CVCL_NM39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384849; Tnpo2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183881 CVCL_NM38 BayGenomics ES cell line RRR187 embryonic stem cell house mouse CVCL_NM38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183882 CVCL_NM37 BayGenomics ES cell line RRR185 embryonic stem cell house mouse CVCL_NM37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183883 CVCL_NM36 BayGenomics ES cell line RRR183 embryonic stem cell house mouse CVCL_NM36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261845; Esyt2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183884 CVCL_NM35 BayGenomics ES cell line RRR182 embryonic stem cell house mouse CVCL_NM35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99173; Zfp26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183885 CVCL_NM34 BayGenomics ES cell line RRR181 embryonic stem cell house mouse CVCL_NM34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916249; Anapc10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183886 CVCL_NM33 BayGenomics ES cell line RRR180 embryonic stem cell house mouse CVCL_NM33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146156; Espl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183887 CVCL_NM32 BayGenomics ES cell line RRR179 embryonic stem cell house mouse CVCL_NM32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098693; Tet1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183888 CVCL_NM31 BayGenomics ES cell line RRR178 embryonic stem cell house mouse CVCL_NM31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261847; Vrk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183889 CVCL_ES79 ND05618 transformed cell line human CVCL_ES79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183890 CVCL_F479 YAN3286 transformed cell line human CVCL_F479 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183891 CVCL_ES78 ND05617 transformed cell line human CVCL_ES78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183892 CVCL_F478 YAN3285 transformed cell line human CVCL_F478 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183893 CVCL_ES77 ND05616 transformed cell line human CVCL_ES77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183894 CVCL_F477 YAN3280 transformed cell line human CVCL_F477 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183895 CVCL_ES76 ND05521 transformed cell line human CVCL_ES76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183896 CVCL_F476 YAN3275 transformed cell line human CVCL_F476 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Part of: Sonoda-Tajima cell collection 21183897 CVCL_ES71 ND05295 transformed cell line human CVCL_ES71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183898 CVCL_F471 YAN3268 transformed cell line human CVCL_F471 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Part of: Sonoda-Tajima cell collection 21183899 CVCL_ES70 ND05292 transformed cell line human CVCL_ES70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183900 CVCL_F470 YAN3265 transformed cell line human CVCL_F470 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183901 CVCL_NM09 BayGenomics ES cell line RRR125 embryonic stem cell house mouse CVCL_NM09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917497; Psmd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183902 CVCL_ES75 ND05501 transformed cell line human CVCL_ES75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183903 CVCL_F475 YAN3274 transformed cell line human CVCL_F475 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183904 CVCL_NM08 BayGenomics ES cell line RRR124 embryonic stem cell house mouse CVCL_NM08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98788; Top1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183905 CVCL_ES74 ND05414 transformed cell line human CVCL_ES74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183906 CVCL_F474 YAN3273 transformed cell line human CVCL_F474 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183907 CVCL_NM07 BayGenomics ES cell line RRR122 embryonic stem cell house mouse CVCL_NM07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919016; Raver1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183908 CVCL_ES73 ND05405 transformed cell line human CVCL_ES73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183909 CVCL_F473 YAN3270 transformed cell line human CVCL_F473 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183910 CVCL_NM06 BayGenomics ES cell line RRR121 embryonic stem cell house mouse CVCL_NM06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183911 CVCL_ES72 ND05338 transformed cell line human CVCL_ES72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183912 CVCL_F472 YAN3269 transformed cell line human CVCL_F472 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183913 CVCL_NM05 BayGenomics ES cell line RRR120 embryonic stem cell house mouse CVCL_NM05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183914 CVCL_NM04 BayGenomics ES cell line RRR119 embryonic stem cell house mouse CVCL_NM04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183915 CVCL_NM03 BayGenomics ES cell line RRR118 embryonic stem cell house mouse CVCL_NM03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446242; Atxn2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183916 CVCL_NM02 BayGenomics ES cell line RRR117 embryonic stem cell house mouse CVCL_NM02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183917 CVCL_NM01 BayGenomics ES cell line RRR116 embryonic stem cell house mouse CVCL_NM01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388481; Ppp2r5d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183918 CVCL_NM00 BayGenomics ES cell line RRR115 embryonic stem cell house mouse CVCL_NM00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328363; Ccnt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183919 CVCL_F489 XP9BE finite cell line human CVCL_F489 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (from familial inference of XP8BE) Population: Caucasian; Donor information: Established from monozygotic twin of XP8BE (Cellosaurus=CVCL_F487); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1161; true Male 21183920 CVCL_ES89 ND05767 transformed cell line human CVCL_ES89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183921 CVCL_F488 XP8BE LCL transformed cell line human CVCL_F488 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (PubMed=18809580) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183922 CVCL_ES88 ND05765 transformed cell line human CVCL_ES88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183923 CVCL_F487 XP8BE finite cell line human CVCL_F487 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val696_Val697insVal (c.2092_2093insGTG); Zygosity=Homozygous (from autologous cell line XP8BE LCL) Population: Caucasian; Donor information: Established from monozygotic twin of XP9BE (Cellosaurus=CVCL_F489); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1158; probable Male Senescence: Senesces at 24 PDL (PubMed=6492896) 21183924 CVCL_ES87 ND05764 transformed cell line human CVCL_ES87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183925 CVCL_ES82 ND05679 transformed cell line human CVCL_ES82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183926 CVCL_ES81 ND05672 transformed cell line human CVCL_ES81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183927 CVCL_F481 ZSM transformed cell line human CVCL_F481 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183928 CVCL_ES80 ND05653 transformed cell line human CVCL_ES80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183929 CVCL_F480 YAN3301 transformed cell line human CVCL_F480 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183930 CVCL_F486 AG04450 finite cell line human CVCL_F486 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by RNAseq Male Part of: ENCODE project common cell types; tier 3 21183931 CVCL_ES86 ND05685 transformed cell line human CVCL_ES86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183932 CVCL_F485 AG04449 finite cell line human CVCL_F485 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Omics: CTCF ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: DNA methylation analysis Male Senescence: Senesces at 31 PDL (PubMed=9724752) Part of: ENCODE project common cell types; tier 3 21183933 CVCL_NM19 BayGenomics ES cell line RRR155 embryonic stem cell house mouse CVCL_NM19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915821; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183934 CVCL_ES85 ND05684 transformed cell line human CVCL_ES85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183935 CVCL_NM18 BayGenomics ES cell line RRR154 embryonic stem cell house mouse CVCL_NM18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915821; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183936 CVCL_F484 GM02796 transformed cell line human CVCL_F484 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Ser135Leu (c.404C>T); ClinVar=VCV000003618; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Phe171Ser (c.512T>C); ClinVar=VCV000003616; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183937 CVCL_ES84 ND05682 transformed cell line human CVCL_ES84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183938 CVCL_NM17 BayGenomics ES cell line RRR153 embryonic stem cell house mouse CVCL_NM17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96623; Itpr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183939 CVCL_F483 GM01908 finite cell line human CVCL_F483 CL:0000010 Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Ser135Leu (c.404C>T); ClinVar=VCV000003618; Zygosity=Heterozygous (from autologous cell line GM02796); Sequence variation: Mutation; HGNC; 4135; GALT; Simple; p.Phe171Ser (c.512T>C); ClinVar=VCV000003616; Zygosity=Heterozygous (from autologous cell line GM02796) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21183940 CVCL_ES83 ND05681 transformed cell line human CVCL_ES83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183941 CVCL_NM16 BayGenomics ES cell line RRR148 embryonic stem cell house mouse CVCL_NM16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919228; Ppp2r2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183942 CVCL_NM15 BayGenomics ES cell line RRR146 embryonic stem cell house mouse CVCL_NM15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202301; Itch Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183943 CVCL_NM14 BayGenomics ES cell line RRR143 embryonic stem cell house mouse CVCL_NM14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1339973; Ilf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183944 CVCL_NM13 BayGenomics ES cell line RRR141 embryonic stem cell house mouse CVCL_NM13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105982; Rfx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183945 CVCL_NM12 BayGenomics ES cell line RRR139 embryonic stem cell house mouse CVCL_NM12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443386; Dnajc11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183946 CVCL_NM11 BayGenomics ES cell line RRR136 embryonic stem cell house mouse CVCL_NM11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444748; Chd7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183947 CVCL_NM10 BayGenomics ES cell line RRR133 embryonic stem cell house mouse CVCL_NM10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87978; Ak2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21183948 CVCL_ES57 ND05028 transformed cell line human CVCL_ES57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183949 CVCL_F457 YAN3161 transformed cell line human CVCL_F457 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183950 CVCL_ES56 ND05008 transformed cell line human CVCL_ES56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183951 CVCL_F456 YAN3154 transformed cell line human CVCL_F456 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183952 CVCL_ES55 ND04792 transformed cell line human CVCL_ES55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183953 CVCL_F455 YAN3152 transformed cell line human CVCL_F455 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183954 CVCL_ES54 ND04673 transformed cell line human CVCL_ES54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183955 CVCL_F454 YAN3150 transformed cell line human CVCL_F454 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Part of: Sonoda-Tajima cell collection 21183956 CVCL_ES59 ND05166 transformed cell line human CVCL_ES59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183957 CVCL_F459 YAN3206 transformed cell line human CVCL_F459 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183958 CVCL_ES58 ND05066 transformed cell line human CVCL_ES58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183959 CVCL_F458 YAN3191 transformed cell line human CVCL_F458 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male Part of: Sonoda-Tajima cell collection 21183960 CVCL_ES53 ND04596 transformed cell line human CVCL_ES53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183961 CVCL_F453 YAN3143 transformed cell line human CVCL_F453 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female Part of: Sonoda-Tajima cell collection 21183962 CVCL_ES52 ND04583 transformed cell line human CVCL_ES52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183963 CVCL_F452 YAN3142 transformed cell line human CVCL_F452 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183964 CVCL_ES51 ND04542 transformed cell line human CVCL_ES51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183965 CVCL_F451 YAN3141 transformed cell line human CVCL_F451 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183966 CVCL_ES50 ND04382 transformed cell line human CVCL_ES50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183967 CVCL_F450 YAN3140 transformed cell line human CVCL_F450 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183968 CVCL_ES68 ND05280 transformed cell line human CVCL_ES68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183969 CVCL_F468 YAN3261 transformed cell line human CVCL_F468 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183970 CVCL_ES67 ND05279 transformed cell line human CVCL_ES67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183971 CVCL_F467 YAN3260 transformed cell line human CVCL_F467 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183972 CVCL_ES66 ND05253 transformed cell line human CVCL_ES66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183973 CVCL_F466 YAN3259 transformed cell line human CVCL_F466 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183974 CVCL_ES65 ND05232 transformed cell line human CVCL_ES65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183975 CVCL_F465 YAN3255 transformed cell line human CVCL_F465 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183976 CVCL_ES69 ND05281 transformed cell line human CVCL_ES69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183977 CVCL_F469 YAN3264 transformed cell line human CVCL_F469 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183978 CVCL_ES60 ND05168 transformed cell line human CVCL_ES60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183979 CVCL_F460 YAN3241 transformed cell line human CVCL_F460 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183980 CVCL_ES64 ND05212 transformed cell line human CVCL_ES64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183981 CVCL_F464 YAN3252 transformed cell line human CVCL_F464 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183982 CVCL_ES63 ND05208 transformed cell line human CVCL_ES63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183983 CVCL_F463 YAN3245 transformed cell line human CVCL_F463 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183984 CVCL_ES62 ND05207 transformed cell line human CVCL_ES62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183985 CVCL_F462 YAN3244 transformed cell line human CVCL_F462 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21183986 CVCL_ES61 ND05169 transformed cell line human CVCL_ES61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183987 CVCL_F461 YAN3242 transformed cell line human CVCL_F461 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21183988 CVCL_4A25 HQ02684 transformed cell line human CVCL_4A25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183989 CVCL_4A24 HQ02683 transformed cell line human CVCL_4A24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183990 CVCL_4A23 HQ02681 transformed cell line human CVCL_4A23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183991 CVCL_4A22 HQ02680 transformed cell line human CVCL_4A22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21183992 CVCL_4A29 HQ02690 transformed cell line human CVCL_4A29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183993 CVCL_4A28 HQ02687 transformed cell line human CVCL_4A28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183994 CVCL_4A27 HQ02686 transformed cell line human CVCL_4A27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183995 CVCL_4A26 HQ02685 transformed cell line human CVCL_4A26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21183996 CVCL_WG73 L3-1-54 hybridoma house mouse CVCL_WG73 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P40225; Human THPO. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C95002; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4955 21183997 CVCL_WG72 SW1573/3R80 cancer cell line human CVCL_WG72 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21183998 CVCL_WG71 SW1573/2R160 cancer cell line human CVCL_WG71 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female Doubling time: 30 hours (PubMed=9256160) 21183999 CVCL_WG70 SW1573/2R120 cancer cell line human CVCL_WG70 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female Doubling time: 42 hours (PubMed=9256160) 21184000 CVCL_WG77 SW1573/2R250 cancer cell line human CVCL_WG77 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184001 CVCL_WG76 SW1573/2R80 cancer cell line human CVCL_WG76 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184002 CVCL_WG75 SW1573/2R50 cancer cell line human CVCL_WG75 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184003 CVCL_WG74 L4-1-31 hybridoma house mouse CVCL_WG74 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P40225; Human THPO. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C95003; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4956 21184004 CVCL_WG79 H542C cancer cell line human CVCL_WG79 CL:0000010 21184005 CVCL_WG78 H534C cancer cell line human CVCL_WG78 CL:0000010 21184006 CVCL_4A21 HQ02679 transformed cell line human CVCL_4A21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184007 CVCL_4A20 HQ02678 transformed cell line human CVCL_4A20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184008 CVCL_4A36 HQ02697 transformed cell line human CVCL_4A36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184009 CVCL_4A35 HQ02696 transformed cell line human CVCL_4A35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184010 CVCL_4A34 HQ02695 transformed cell line human CVCL_4A34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184011 CVCL_4A33 HQ02694 transformed cell line human CVCL_4A33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184012 CVCL_4A39 HQ02701 transformed cell line human CVCL_4A39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184013 CVCL_4A38 HQ02699 transformed cell line human CVCL_4A38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184014 CVCL_4A37 HQ02698 transformed cell line human CVCL_4A37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184015 CVCL_WG62 hAMSC-02 somatic stem cell human CVCL_WG62 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Mesenchymal stem cell.. Male 21184016 CVCL_WG61 hAMSC-01 somatic stem cell human CVCL_WG61 CL:0000010 Derived from sampling site: Amniotic fluid Cell type=Mesenchymal stem cell.. Female 21184017 CVCL_WG60 P-MSC-01 somatic stem cell human CVCL_WG60 CL:0000010 Derived from sampling site: Placenta Cell type=Mesenchymal stem cell.. Female 21184018 CVCL_WG66 CGMHi001-A induced pluripotent stem cell human CVCL_WG66 From: Chang Gung Memorial Hospital, Lin-Kou Medical Centre, Chang Gung University; Tao-Yuan; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; c.919-2A>G (IVS7AS,A-G,-2); ClinVar=VCV000004840; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=31415960) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 21184019 CVCL_WG65 DHMCi005-A induced pluripotent stem cell human CVCL_WG65 From: Dietmar Hopp Metabolic Center, Center for Child and Adolescent Medicine Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 14372; SCYL1; Simple; p.Gln628Ter (c.1882C>T); ClinVar=VCV000446290; Zygosity=Homozygous (PubMed=30959346) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21184020 CVCL_WG64 UOXFi003-B induced pluripotent stem cell human CVCL_WG64 From: University of Oxford; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21184021 CVCL_WG63 ZJUCHi002-A induced pluripotent stem cell human CVCL_WG63 From: Children's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Pro251Leu (c.752C>T); ClinVar=VCV000637945; Zygosity=Heterozygous (PubMed=30807887) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21184022 CVCL_WG69 SW1573/1R10000 cancer cell line human CVCL_WG69 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184023 CVCL_WG68 SW1573/1R500 cancer cell line human CVCL_WG68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184024 CVCL_WG67 SW1573/1R50 cancer cell line human CVCL_WG67 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Glu (c.331A>G); ClinVar=VCV000376482; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; c.362+1G>C; ClinVar=VCV000582116; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21184025 CVCL_4A32 HQ02693 transformed cell line human CVCL_4A32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184026 CVCL_4A31 HQ02692 transformed cell line human CVCL_4A31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184027 CVCL_4A30 HQ02691 transformed cell line human CVCL_4A30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184028 CVCL_4A03 HQ02652 transformed cell line human CVCL_4A03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184029 CVCL_4A02 HQ02651 transformed cell line human CVCL_4A02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184030 CVCL_4A01 HQ02650 transformed cell line human CVCL_4A01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184031 CVCL_4A00 HQ02649 transformed cell line human CVCL_4A00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184032 CVCL_4A07 HQ02657 transformed cell line human CVCL_4A07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184033 CVCL_4A06 HQ02655 transformed cell line human CVCL_4A06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184034 CVCL_4A05 HQ02654 transformed cell line human CVCL_4A05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184035 CVCL_4A04 HQ02653 transformed cell line human CVCL_4A04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184036 CVCL_4A09 HQ02662 transformed cell line human CVCL_4A09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184037 CVCL_4A08 HQ02659 transformed cell line human CVCL_4A08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184038 CVCL_WG51 32D-Flt3-WT factor-dependent cell line house mouse CVCL_WG51 CL:0000010 Transfected with: HGNC; 3765; FLT3 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Omics: Deep quantitative phosphoproteome analysis Male 21184039 CVCL_WG50 32D-Flt3-ITD factor-dependent cell line house mouse CVCL_WG50 CL:0000010 Transfected with: HGNC; 3765; FLT3 (with ITD) Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Omics: Deep quantitative phosphoproteome analysis Male 21184040 CVCL_WG55 AD-MSC-01 somatic stem cell human CVCL_WG55 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21184041 CVCL_WG54 Z-6 cancer cell line human CVCL_WG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow Cell type=T-cell.. Male Doubling time: 24 hours (PubMed=8382256) 21184042 CVCL_WG53 Z-55 cancer cell line human CVCL_WG53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: 12 hours (PubMed=8382256) 21184043 CVCL_WG52 Z-43 cancer cell line human CVCL_WG52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female Doubling time: 16 hours (PubMed=8382256) 21184044 CVCL_WG59 CH-MSC-02 somatic stem cell human CVCL_WG59 CL:0000010 Derived from sampling site: Placenta; chorion Cell type=Mesenchymal cell.. Female 21184045 CVCL_WG58 CH-MSC-01 somatic stem cell human CVCL_WG58 CL:0000010 Derived from sampling site: Placenta; chorion Cell type=Mesenchymal cell.. Female 21184046 CVCL_WG57 AD-MSC-03 somatic stem cell human CVCL_WG57 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21184047 CVCL_WG56 AD-MSC-02 somatic stem cell human CVCL_WG56 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21184048 CVCL_4A14 HQ02672 transformed cell line human CVCL_4A14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184049 CVCL_4A13 HQ02670 transformed cell line human CVCL_4A13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184050 CVCL_4A12 HQ02668 transformed cell line human CVCL_4A12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184051 CVCL_4A11 HQ02667 transformed cell line human CVCL_4A11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184052 CVCL_4A18 HQ02676 transformed cell line human CVCL_4A18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184053 CVCL_4A17 HQ02675 transformed cell line human CVCL_4A17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184054 CVCL_4A16 HQ02674 transformed cell line human CVCL_4A16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184055 CVCL_4A15 HQ02673 transformed cell line human CVCL_4A15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184056 CVCL_4A19 HQ02677 transformed cell line human CVCL_4A19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184057 CVCL_WG40 BHZ-05 transformed cell line human CVCL_WG40 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184058 CVCL_WG44 Hu02-KP finite cell line human CVCL_WG44 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21184059 CVCL_WG43 Hu02 finite cell line human CVCL_WG43 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21184060 CVCL_WG42 BHZ-07 transformed cell line human CVCL_WG42 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184061 CVCL_WG41 BHZ-06 transformed cell line human CVCL_WG41 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184062 CVCL_WG48 HEBHMUi001-A induced pluripotent stem cell human CVCL_WG48 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184063 CVCL_WG47 PSMi007-A induced pluripotent stem cell human CVCL_WG47 From: Institution Fondazione IRCCS Policlinico San Matteo; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ala341Val (c.1022C>T) (p.Ala214Val, c.641C>T); ClinVar=VCV000003121; Zygosity=Heterozygous (PubMed=30878014); Sequence variation: Mutation; HGNC; 16859; NOS1AP; Simple; g.chr1:162060117A>T; dbSNP=rs4657139; Zygosity=Homozygous (PubMed=30878014); Sequence variation: Mutation; HGNC; 16859; NOS1AP; Simple; g.chr1:162065484T>C (g.694T>C); dbSNP=rs16847548; Zygosity=Homozygous (PubMed=30878014) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184064 CVCL_WG46 Hu02-OhT/KP telomerase immortalized cell line human CVCL_WG46 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21184065 CVCL_WG45 Hu02-OhT telomerase immortalized cell line human CVCL_WG45 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21184066 CVCL_WG49 CMUi001-A induced pluripotent stem cell human CVCL_WG49 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Glu2130Lys (c.6388G>A); ClinVar=VCV000200191; Zygosity=Heterozygous (PubMed=30870686) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21184067 CVCL_4A10 HQ02663 transformed cell line human CVCL_4A10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184068 CVCL_NM96 BayGenomics ES cell line RRR316 embryonic stem cell house mouse CVCL_NM96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444233; Ythdf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184069 CVCL_NM95 BayGenomics ES cell line RRR315 embryonic stem cell house mouse CVCL_NM95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184070 CVCL_NM94 BayGenomics ES cell line RRR311 embryonic stem cell house mouse CVCL_NM94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919936; Usp24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184071 CVCL_NM93 BayGenomics ES cell line RRR310 embryonic stem cell house mouse CVCL_NM93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184072 CVCL_NM92 BayGenomics ES cell line RRR308 embryonic stem cell house mouse CVCL_NM92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104662; Pml Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184073 CVCL_NM91 BayGenomics ES cell line RRR307 embryonic stem cell house mouse CVCL_NM91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443699; Fubp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184074 CVCL_NM90 BayGenomics ES cell line RRR301 embryonic stem cell house mouse CVCL_NM90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184075 CVCL_WG33 OCC-41 finite cell line human CVCL_WG33 CL:0000010 Male 21184076 CVCL_WG32 OCC-40 finite cell line human CVCL_WG32 CL:0000010 Male 21184077 CVCL_WG31 OCC-39 finite cell line human CVCL_WG31 CL:0000010 Female 21184078 CVCL_WG30 OCC-38 finite cell line human CVCL_WG30 CL:0000010 Female 21184079 CVCL_WG37 BHZ-02 transformed cell line human CVCL_WG37 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184080 CVCL_WG36 BHZ-01 transformed cell line human CVCL_WG36 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184081 CVCL_WG35 End M somatic stem cell human CVCL_WG35 CL:0000010 Population: Iranian; Persian. Female 21184082 CVCL_WG34 NID-2 transformed cell line human CVCL_WG34 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184083 CVCL_WG39 BHZ-04 transformed cell line human CVCL_WG39 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184084 CVCL_WG38 BHZ-03 transformed cell line human CVCL_WG38 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184085 CVCL_NM89 BayGenomics ES cell line RRR300 embryonic stem cell house mouse CVCL_NM89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107231; Dlg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184086 CVCL_NM88 BayGenomics ES cell line RRR298 embryonic stem cell house mouse CVCL_NM88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349394; Map4k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184087 CVCL_NM87 BayGenomics ES cell line RRR296 embryonic stem cell house mouse CVCL_NM87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920992; Lima1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184088 CVCL_NM86 BayGenomics ES cell line RRR294 embryonic stem cell house mouse CVCL_NM86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184089 CVCL_WG22 Hu-04 finite cell line human CVCL_WG22 CL:0000010 Population: Iranian; Derived from sampling site: Muscle. Female 21184090 CVCL_WG21 OCC-24 finite cell line human CVCL_WG21 CL:0000010 Male 21184091 CVCL_WG20 OCC-23 finite cell line human CVCL_WG20 CL:0000010 Female 21184092 CVCL_WG26 NID-1 transformed cell line human CVCL_WG26 CL:0000010 Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184093 CVCL_WG25 OCC-33 finite cell line human CVCL_WG25 CL:0000010 Female 21184094 CVCL_WG24 OCC-30 finite cell line human CVCL_WG24 CL:0000010 Female 21184095 CVCL_WG23 OCC-29 finite cell line human CVCL_WG23 CL:0000010 Male 21184096 CVCL_WG29 OCC-37 finite cell line human CVCL_WG29 CL:0000010 Female 21184097 CVCL_WG28 OCC-36 finite cell line human CVCL_WG28 CL:0000010 Female 21184098 CVCL_WG27 OCC-35 finite cell line human CVCL_WG27 CL:0000010 Female 21184099 CVCL_NM99 BayGenomics ES cell line RRR320 embryonic stem cell house mouse CVCL_NM99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914324; Mon2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184100 CVCL_NM98 BayGenomics ES cell line RRR319 embryonic stem cell house mouse CVCL_NM98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098658; Stag1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184101 CVCL_NM97 BayGenomics ES cell line RRR317 embryonic stem cell house mouse CVCL_NM97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184102 CVCL_NM74 BayGenomics ES cell line RRR266 embryonic stem cell house mouse CVCL_NM74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860078; Txnl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184103 CVCL_NM73 BayGenomics ES cell line RRR265 embryonic stem cell house mouse CVCL_NM73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351331; Chaf1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184104 CVCL_NM72 BayGenomics ES cell line RRR258 embryonic stem cell house mouse CVCL_NM72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446180; Anks1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184105 CVCL_NM71 BayGenomics ES cell line RRR257 embryonic stem cell house mouse CVCL_NM71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2159614; Mia2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184106 CVCL_NM70 BayGenomics ES cell line RRR256 embryonic stem cell house mouse CVCL_NM70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184107 CVCL_WG11 OCC-09 finite cell line human CVCL_WG11 CL:0000010 Female 21184108 CVCL_WG10 OCC-08 finite cell line human CVCL_WG10 CL:0000010 Female 21184109 CVCL_WG15 OCC-13 finite cell line human CVCL_WG15 CL:0000010 Male 21184110 CVCL_WG14 OCC-12 finite cell line human CVCL_WG14 CL:0000010 Female 21184111 CVCL_WG13 OCC-11 finite cell line human CVCL_WG13 CL:0000010 Male 21184112 CVCL_WG12 OCC-10 finite cell line human CVCL_WG12 CL:0000010 Female 21184113 CVCL_WG19 OCC-20 finite cell line human CVCL_WG19 CL:0000010 Female 21184114 CVCL_WG18 OCC-18 finite cell line human CVCL_WG18 CL:0000010 Male 21184115 CVCL_NM69 BayGenomics ES cell line RRR249 embryonic stem cell house mouse CVCL_NM69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922855; Kdm5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184116 CVCL_WG17 OCC-17 finite cell line human CVCL_WG17 CL:0000010 Male 21184117 CVCL_NM68 BayGenomics ES cell line RRR248 embryonic stem cell house mouse CVCL_NM68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913874; Spcs2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184118 CVCL_WG16 OCC-14 finite cell line human CVCL_WG16 CL:0000010 Female 21184119 CVCL_NM67 BayGenomics ES cell line RRR244 embryonic stem cell house mouse CVCL_NM67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913895; Pspc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184120 CVCL_NM66 BayGenomics ES cell line RRR242 embryonic stem cell house mouse CVCL_NM66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344349; Rnf216 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184121 CVCL_NM65 BayGenomics ES cell line RRR241 embryonic stem cell house mouse CVCL_NM65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443623; Raver2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184122 CVCL_NM64 BayGenomics ES cell line RRR237 embryonic stem cell house mouse CVCL_NM64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106624; Myo9b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184123 CVCL_NM85 BayGenomics ES cell line RRR291 embryonic stem cell house mouse CVCL_NM85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184124 CVCL_NM84 BayGenomics ES cell line RRR290 embryonic stem cell house mouse CVCL_NM84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184125 CVCL_NM83 BayGenomics ES cell line RRR284 embryonic stem cell house mouse CVCL_NM83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855695; Clasrp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184126 CVCL_NM82 BayGenomics ES cell line RRR282 embryonic stem cell house mouse CVCL_NM82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098268; Kif5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184127 CVCL_NM81 BayGenomics ES cell line RRR279 embryonic stem cell house mouse CVCL_NM81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913747; Cmss1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184128 CVCL_NM80 BayGenomics ES cell line RRR278 embryonic stem cell house mouse CVCL_NM80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890773; Actn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184129 CVCL_WG00 ZL-71 transformed cell line human CVCL_WG00 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184130 CVCL_WG04 ZL-77 transformed cell line human CVCL_WG04 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184131 CVCL_WG03 ZL-76 transformed cell line human CVCL_WG03 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184132 CVCL_WG02 ZL-74 transformed cell line human CVCL_WG02 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184133 CVCL_WG01 ZL-73 transformed cell line human CVCL_WG01 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184134 CVCL_WG08 OCC-04 finite cell line human CVCL_WG08 CL:0000010 Female 21184135 CVCL_WG07 OCC-03 finite cell line human CVCL_WG07 CL:0000010 Male 21184136 CVCL_WG06 OCC-02 finite cell line human CVCL_WG06 CL:0000010 Male 21184137 CVCL_NM79 BayGenomics ES cell line RRR277 embryonic stem cell house mouse CVCL_NM79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445126; Tut4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184138 CVCL_WG05 ZL-78 transformed cell line human CVCL_WG05 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184139 CVCL_NM78 BayGenomics ES cell line RRR276 embryonic stem cell house mouse CVCL_NM78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890081; Foxo3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184140 CVCL_NM77 BayGenomics ES cell line RRR275 embryonic stem cell house mouse CVCL_NM77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101785; Mybl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184141 CVCL_NM76 BayGenomics ES cell line RRR272 embryonic stem cell house mouse CVCL_NM76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384583; Zfp280d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184142 CVCL_NM75 BayGenomics ES cell line RRR267 embryonic stem cell house mouse CVCL_NM75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352755; Gtse1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184143 CVCL_WG09 OCC-07 finite cell line human CVCL_WG09 CL:0000010 Male 21184144 CVCL_WF92 TN-287 transformed cell line human CVCL_WF92 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184145 CVCL_WF91 TN-286 transformed cell line human CVCL_WF91 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184146 CVCL_WF90 TK-93 transformed cell line human CVCL_WF90 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184147 CVCL_WF96 TN-346 transformed cell line human CVCL_WF96 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184148 CVCL_WF95 TN-345 transformed cell line human CVCL_WF95 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184149 CVCL_WF94 TN-289 transformed cell line human CVCL_WF94 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184150 CVCL_WF93 TN-288 transformed cell line human CVCL_WF93 CL:0000010 Population: Iranian; Turkamans; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184151 CVCL_WF99 ZL-70 transformed cell line human CVCL_WF99 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184152 CVCL_WF98 ZL-117 transformed cell line human CVCL_WF98 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184153 CVCL_WF97 ZL-114 transformed cell line human CVCL_WF97 CL:0000010 Population: Iranian; Zabolis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184154 CVCL_WF81 TK-56 transformed cell line human CVCL_WF81 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184155 CVCL_WF80 TK-54 transformed cell line human CVCL_WF80 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184156 CVCL_WF85 TK-86 transformed cell line human CVCL_WF85 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184157 CVCL_WF84 TK-84 transformed cell line human CVCL_WF84 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184158 CVCL_WF83 TK-7 transformed cell line human CVCL_WF83 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184159 CVCL_WF82 TK-6 [Human EBV-transformed] transformed cell line human CVCL_WF82 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184160 CVCL_WF89 TK-92 transformed cell line human CVCL_WF89 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184161 CVCL_WF88 TK-90 transformed cell line human CVCL_WF88 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184162 CVCL_WF87 TK-89 transformed cell line human CVCL_WF87 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184163 CVCL_WF86 TK-88 transformed cell line human CVCL_WF86 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184164 CVCL_WF70 TK-36 transformed cell line human CVCL_WF70 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184165 CVCL_WF74 TK-48 transformed cell line human CVCL_WF74 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184166 CVCL_WF73 TK-47 transformed cell line human CVCL_WF73 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184167 CVCL_WF72 TK-46 transformed cell line human CVCL_WF72 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184168 CVCL_WF71 TK-44 transformed cell line human CVCL_WF71 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184169 CVCL_WF78 TK-52 transformed cell line human CVCL_WF78 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184170 CVCL_WF77 TK-51 transformed cell line human CVCL_WF77 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184171 CVCL_WF76 TK-50 transformed cell line human CVCL_WF76 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184172 CVCL_WF75 TK-5 transformed cell line human CVCL_WF75 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184173 CVCL_WF79 TK-53 transformed cell line human CVCL_WF79 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184174 CVCL_WF63 TK-32 transformed cell line human CVCL_WF63 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184175 CVCL_WF62 TK-319 transformed cell line human CVCL_WF62 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184176 CVCL_WF61 TK-317 transformed cell line human CVCL_WF61 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184177 CVCL_WF60 TK-316 transformed cell line human CVCL_WF60 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184178 CVCL_WF67 TK-335 transformed cell line human CVCL_WF67 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184179 CVCL_WF66 TK-333 transformed cell line human CVCL_WF66 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184180 CVCL_WF65 TK-330 transformed cell line human CVCL_WF65 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184181 CVCL_WF64 TK-327 transformed cell line human CVCL_WF64 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184182 CVCL_WF69 TK-343 transformed cell line human CVCL_WF69 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184183 CVCL_WF68 TK-342 transformed cell line human CVCL_WF68 CL:0000010 Population: Iranian; Azerbaijanis; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184184 CVCL_ES35 ND04233 transformed cell line human CVCL_ES35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184185 CVCL_F435 WY075 transformed cell line human CVCL_F435 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184186 CVCL_ES34 ND04203 transformed cell line human CVCL_ES34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184187 CVCL_F434 WY074 transformed cell line human CVCL_F434 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184188 CVCL_ES33 ND04190 transformed cell line human CVCL_ES33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184189 CVCL_F433 WY073 transformed cell line human CVCL_F433 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184190 CVCL_ES32 ND04188 transformed cell line human CVCL_ES32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184191 CVCL_F432 WY072 transformed cell line human CVCL_F432 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184192 CVCL_ES39 ND04279 transformed cell line human CVCL_ES39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184193 CVCL_F439 WY080 transformed cell line human CVCL_F439 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184194 CVCL_ES38 ND04239 transformed cell line human CVCL_ES38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184195 CVCL_F438 WY078 transformed cell line human CVCL_F438 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184196 CVCL_ES37 ND04238 transformed cell line human CVCL_ES37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184197 CVCL_F437 WY077 transformed cell line human CVCL_F437 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184198 CVCL_ES36 ND04237 transformed cell line human CVCL_ES36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184199 CVCL_F436 WY076 transformed cell line human CVCL_F436 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184200 CVCL_ES31 ND04114 transformed cell line human CVCL_ES31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184201 CVCL_F431 WY071 transformed cell line human CVCL_F431 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184202 CVCL_ES30 ND04108 transformed cell line human CVCL_ES30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184203 CVCL_F430 WY065 transformed cell line human CVCL_F430 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184204 CVCL_ES46 ND04339 transformed cell line human CVCL_ES46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184205 CVCL_F446 YAN3102 transformed cell line human CVCL_F446 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184206 CVCL_ES45 ND04338 transformed cell line human CVCL_ES45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184207 CVCL_F445 YAM-P transformed cell line human CVCL_F445 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184208 CVCL_ES44 ND04336 transformed cell line human CVCL_ES44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184209 CVCL_F444 WY102 transformed cell line human CVCL_F444 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male Part of: Sonoda-Tajima cell collection 21184210 CVCL_ES43 ND04314 transformed cell line human CVCL_ES43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184211 CVCL_F443 WY092 transformed cell line human CVCL_F443 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184212 CVCL_ES49 ND04376 transformed cell line human CVCL_ES49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184213 CVCL_F449 YAN3136 transformed cell line human CVCL_F449 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184214 CVCL_ES48 ND04356 transformed cell line human CVCL_ES48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184215 CVCL_F448 YAN3119 transformed cell line human CVCL_F448 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184216 CVCL_ES47 ND04355 transformed cell line human CVCL_ES47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184217 CVCL_F447 YAN3103 transformed cell line human CVCL_F447 CL:0000010 Population: Venezuelan; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184218 CVCL_ES42 ND04310 transformed cell line human CVCL_ES42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184219 CVCL_F442 WY091 transformed cell line human CVCL_F442 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184220 CVCL_ES41 ND04284 transformed cell line human CVCL_ES41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184221 CVCL_F441 WY086 transformed cell line human CVCL_F441 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184222 CVCL_ES40 ND04280 transformed cell line human CVCL_ES40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184223 CVCL_F440 WY083 transformed cell line human CVCL_F440 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184224 CVCL_ES19 ND03632 transformed cell line human CVCL_ES19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184225 CVCL_F419 WY048 transformed cell line human CVCL_F419 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184226 CVCL_ES18 ND03609 transformed cell line human CVCL_ES18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184227 CVCL_F418 WY047 transformed cell line human CVCL_F418 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184228 CVCL_ES13 ND02961 transformed cell line human CVCL_ES13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184229 CVCL_F413 WY038 transformed cell line human CVCL_F413 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184230 CVCL_ES12 ND02820 transformed cell line human CVCL_ES12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184231 CVCL_F412 WY037 transformed cell line human CVCL_F412 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184232 CVCL_ES11 ND02810 transformed cell line human CVCL_ES11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184233 CVCL_F411 WY036 transformed cell line human CVCL_F411 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184234 CVCL_ES10 ND02715 transformed cell line human CVCL_ES10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184235 CVCL_F410 WY035 transformed cell line human CVCL_F410 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184236 CVCL_ES17 ND03363 transformed cell line human CVCL_ES17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184237 CVCL_F417 WY046 transformed cell line human CVCL_F417 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male Part of: Sonoda-Tajima cell collection 21184238 CVCL_ES16 ND03128 transformed cell line human CVCL_ES16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184239 CVCL_F416 WY043 transformed cell line human CVCL_F416 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184240 CVCL_ES15 ND03126 transformed cell line human CVCL_ES15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184241 CVCL_F415 WY040 transformed cell line human CVCL_F415 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184242 CVCL_ES14 ND03107 transformed cell line human CVCL_ES14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184243 CVCL_F414 WY039 transformed cell line human CVCL_F414 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184244 CVCL_ES29 ND04071 transformed cell line human CVCL_ES29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184245 CVCL_F429 WY064 transformed cell line human CVCL_F429 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184246 CVCL_ES24 ND03927 transformed cell line human CVCL_ES24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184247 CVCL_F424 WY054 transformed cell line human CVCL_F424 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184248 CVCL_ES23 ND03867 transformed cell line human CVCL_ES23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184249 CVCL_F423 WY053 transformed cell line human CVCL_F423 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184250 CVCL_ES22 ND03659 transformed cell line human CVCL_ES22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184251 CVCL_F422 WY051 transformed cell line human CVCL_F422 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184252 CVCL_ES21 ND03654 transformed cell line human CVCL_ES21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184253 CVCL_F421 WY050 transformed cell line human CVCL_F421 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184254 CVCL_ES28 ND04068 transformed cell line human CVCL_ES28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184255 CVCL_F428 WY059 transformed cell line human CVCL_F428 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184256 CVCL_ES27 ND04014 transformed cell line human CVCL_ES27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184257 CVCL_F427 WY058 transformed cell line human CVCL_F427 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184258 CVCL_ES26 ND03969 transformed cell line human CVCL_ES26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184259 CVCL_F426 WY057 transformed cell line human CVCL_F426 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184260 CVCL_ES25 ND03937 transformed cell line human CVCL_ES25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184261 CVCL_F425 WY055 transformed cell line human CVCL_F425 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184262 CVCL_ES20 ND03635 transformed cell line human CVCL_ES20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184263 CVCL_F420 WY049 transformed cell line human CVCL_F420 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184264 CVCL_ES09 ND02596 transformed cell line human CVCL_ES09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184265 CVCL_F409 WY034 transformed cell line human CVCL_F409 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184266 CVCL_ES08 ND02551 transformed cell line human CVCL_ES08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184267 CVCL_F408 WY020 transformed cell line human CVCL_F408 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184268 CVCL_ES07 ND02534 transformed cell line human CVCL_ES07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184269 CVCL_F407 WY005 transformed cell line human CVCL_F407 CL:0000010 Population: Colombian; native South American; Wayuu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184270 CVCL_F402 COLO205 transformed cell line human CVCL_F402 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184271 CVCL_ES02 ND02206 transformed cell line human CVCL_ES02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184272 CVCL_F401 COLO204 transformed cell line human CVCL_F401 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184273 CVCL_ES01 ND02200 transformed cell line human CVCL_ES01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184274 CVCL_F400 COLO202 transformed cell line human CVCL_F400 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184275 CVCL_ES00 ND02155 transformed cell line human CVCL_ES00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184276 CVCL_ES06 ND02528 transformed cell line human CVCL_ES06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184277 CVCL_F406 SIB186 transformed cell line human CVCL_F406 CL:0000010 Population: Colombian; native South American; Sibundoy; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184278 CVCL_ES05 ND02432 transformed cell line human CVCL_ES05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184279 CVCL_F405 RHO transformed cell line human CVCL_F405 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Sonoda-Tajima cell collection 21184280 CVCL_ES04 ND02299 transformed cell line human CVCL_ES04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184281 CVCL_F404 RAM transformed cell line human CVCL_F404 CL:0000010 Population: Chilean; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184282 CVCL_F403 COLO209 transformed cell line human CVCL_F403 CL:0000010 Population: Colombian; native South American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Sonoda-Tajima cell collection 21184283 CVCL_ES03 ND02208 transformed cell line human CVCL_ES03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184284 CVCL_NN73 BayGenomics ES cell line RRR483 embryonic stem cell house mouse CVCL_NN73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914128; Riok3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184285 CVCL_NN72 BayGenomics ES cell line RRR480 embryonic stem cell house mouse CVCL_NN72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96247; Hsp90ab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184286 CVCL_NN71 BayGenomics ES cell line RRR479 embryonic stem cell house mouse CVCL_NN71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444266; Ube2o Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184287 CVCL_NN70 BayGenomics ES cell line RRR478 embryonic stem cell house mouse CVCL_NN70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2178217; Akap9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184288 CVCL_WH10 SK-N-ER cancer cell line human CVCL_WH10 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Characteristics: Intermediate type (I-type) (PubMed=15720811). 21184289 CVCL_WH14 FB-LCH01 cancer cell line dog CVCL_WH14 CL:0000010 Breed/subspecies: French Bulldog. Female Doubling time: ~35.4 hours (PubMed=30884050) 21184290 CVCL_WH13 SK-N-LP cancer cell line human CVCL_WH13 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Omics: Transcriptome analysis by microarray. Characteristics: Intermediate type (I-type) (PubMed=15720811) 21184291 CVCL_WH12 SK-N-JD cancer cell line human CVCL_WH12 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Characteristics: Intermediate type (I-type) (PubMed=15720811). 21184292 CVCL_WH11 SK-N-HM cancer cell line human CVCL_WH11 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Omics: Transcriptome analysis by microarray. Characteristics: Intermediate type (I-type) (PubMed=15720811) 21184293 CVCL_WH18 CMM11 cancer cell line dog CVCL_WH18 CL:0000010 21184294 CVCL_NN69 BayGenomics ES cell line RRR477 embryonic stem cell house mouse CVCL_NN69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927138; Net1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184295 CVCL_WH17 CMM10 cancer cell line dog CVCL_WH17 CL:0000010 21184296 CVCL_WH16 13020 cancer cell line dog CVCL_WH16 CL:0000010 Unspecified 21184297 CVCL_NN68 BayGenomics ES cell line RRR476 embryonic stem cell house mouse CVCL_NN68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101919; Ap1g1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184298 CVCL_WH15 13008 cancer cell line dog CVCL_WH15 CL:0000010 Unspecified 21184299 CVCL_NN67 BayGenomics ES cell line RRR475 embryonic stem cell house mouse CVCL_NN67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923520; Cyrib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184300 CVCL_NN66 BayGenomics ES cell line RRR472 embryonic stem cell house mouse CVCL_NN66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184301 CVCL_NN65 BayGenomics ES cell line RRR468 embryonic stem cell house mouse CVCL_NN65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276535; Ncoa3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184302 CVCL_NN64 BayGenomics ES cell line RRR467 embryonic stem cell house mouse CVCL_NN64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353606; Siva1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184303 CVCL_NN63 BayGenomics ES cell line RRR464 embryonic stem cell house mouse CVCL_NN63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196453; Klhl7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184304 CVCL_WH19 CMM12 cancer cell line dog CVCL_WH19 CL:0000010 21184305 CVCL_NN84 BayGenomics ES cell line RRR507 embryonic stem cell house mouse CVCL_NN84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184306 CVCL_NN83 BayGenomics ES cell line RRR504 embryonic stem cell house mouse CVCL_NN83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429765; Dock1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184307 CVCL_NN82 BayGenomics ES cell line RRR503 embryonic stem cell house mouse CVCL_NN82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444401; Snrnp200 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184308 CVCL_NN81 BayGenomics ES cell line RRR502 embryonic stem cell house mouse CVCL_NN81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889508; Tbc1d1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184309 CVCL_NN80 BayGenomics ES cell line RRR499 embryonic stem cell house mouse CVCL_NN80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858965; Atf7ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184310 CVCL_WH03 AKG HR cancer cell line human CVCL_WH03 CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Leu1061Pro (c.3182T>C); ClinVar=VCV000134079; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1170Ala (c.3508C>G); ClinVar=VCV000134082; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (from parent cell line) Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from metastatic site: Pleural effusion. Male Doubling time: 33 hours (PubMed=26919099) 21184311 CVCL_WH02 AKG cancer cell line human CVCL_WH02 CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Leu1061Pro (c.3182T>C); ClinVar=VCV000134079; Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1170Ala (c.3508C>G); ClinVar=VCV000134082; Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=10841287) Derived from metastatic site: Pleural effusion. Male Doubling time: ~36 hours (PubMed=9723033); 42 hours (PubMed=26919099) 21184312 CVCL_WH01 NCI-N87 HR cancer cell line human CVCL_WH01 CL:0000010 Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from metastatic site: Liver. Male Characteristics: Parent cell line established from a nude mouse xenograft Doubling time: 26 hours (PubMed=26919099) 21184313 CVCL_WH00 L-OL hybrid cell line CVCL_WH00 CL:0000010 21184314 CVCL_WH07 SCLC-R1 cancer cell line human CVCL_WH07 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Male Doubling time: ~62 hours (PubMed=9713281) 21184315 CVCL_WH06 KKP HR cancer cell line human CVCL_WH06 CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ser903Arg (c.2709T>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1170Ala (c.3508C>G); ClinVar=VCV000134082; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line) Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin); Derived from sampling site: Ascites. Male Doubling time: 27 hours (PubMed=26919099) 21184316 CVCL_NN79 BayGenomics ES cell line RRR497 embryonic stem cell house mouse CVCL_NN79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196368; Carhsp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184317 CVCL_WH05 KKP cancer cell line human CVCL_WH05 CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ser903Arg (c.2709T>G); Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1170Ala (c.3508C>G); ClinVar=VCV000134082; Zygosity=Unspecified (PubMed=26919099); Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (PubMed=26919099) Derived from sampling site: Ascites. Male Doubling time: 48 hours (PubMed=9689929); 30 hours (PubMed=26919099) 21184318 CVCL_NN78 BayGenomics ES cell line RRR495 embryonic stem cell house mouse CVCL_NN78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184319 CVCL_WH04 GK2 cancer cell line human CVCL_WH04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=10841287) Derived from sampling site: Ascites. Male Doubling time: ~48 hours (PubMed=9723033) 21184320 CVCL_NN77 BayGenomics ES cell line RRR494 embryonic stem cell house mouse CVCL_NN77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103147; Dync1h1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184321 CVCL_NN76 BayGenomics ES cell line RRR490 embryonic stem cell house mouse CVCL_NN76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919670; Rbm33 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184322 CVCL_NN75 BayGenomics ES cell line RRR487 embryonic stem cell house mouse CVCL_NN75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444490; Syt14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184323 CVCL_WH09 RAL cancer cell line human CVCL_WH09 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=9809028); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Cys (c.730G>T); ClinVar=VCV000376599; Zygosity=Unspecified (PubMed=9809028; PubMed=10841287) Derived from metastatic site: Pleural effusion. Female Doubling time: ~65 hours (PubMed=9809028) 21184324 CVCL_NN74 BayGenomics ES cell line RRR484 embryonic stem cell house mouse CVCL_NN74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102467; Ptpn14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184325 CVCL_WH08 CAEP [Human lung carcinoma] cancer cell line human CVCL_WH08 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg209Ter (c.625A>T); Zygosity=Unspecified (PubMed=10841287) Derived from metastatic site: Skin. Male Doubling time: ~50 hours (PubMed=9809028) 21184326 CVCL_NN51 BayGenomics ES cell line RRR441 embryonic stem cell house mouse CVCL_NN51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860512; Prpf40a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184327 CVCL_NN50 BayGenomics ES cell line RRR440 embryonic stem cell house mouse CVCL_NN50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098258; Kif15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184328 CVCL_NN49 BayGenomics ES cell line RRR437 embryonic stem cell house mouse CVCL_NN49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914803; Gstcd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184329 CVCL_NN48 BayGenomics ES cell line RRR435 embryonic stem cell house mouse CVCL_NN48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96525; Rbpj-ps3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184330 CVCL_NN47 BayGenomics ES cell line RRR432 embryonic stem cell house mouse CVCL_NN47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184331 CVCL_NN46 BayGenomics ES cell line RRR430 embryonic stem cell house mouse CVCL_NN46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346875; Map3k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184332 CVCL_NN45 BayGenomics ES cell line RRR429 embryonic stem cell house mouse CVCL_NN45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914751; Ccdc50 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184333 CVCL_NN44 BayGenomics ES cell line RRR426 embryonic stem cell house mouse CVCL_NN44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184334 CVCL_NN43 BayGenomics ES cell line RRR425 embryonic stem cell house mouse CVCL_NN43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1355274; Uchl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184335 CVCL_NN42 BayGenomics ES cell line RRR424 embryonic stem cell house mouse CVCL_NN42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107760; Chka Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184336 CVCL_NN41 BayGenomics ES cell line RRR423 embryonic stem cell house mouse CVCL_NN41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922896; Rai14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184337 CVCL_NN62 BayGenomics ES cell line RRR463 embryonic stem cell house mouse CVCL_NN62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184338 CVCL_NN61 BayGenomics ES cell line RRR458 embryonic stem cell house mouse CVCL_NN61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3652219; Zfp345 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184339 CVCL_NN60 BayGenomics ES cell line RRR455 embryonic stem cell house mouse CVCL_NN60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918518; Lrrfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184340 CVCL_NN59 BayGenomics ES cell line RRR454 embryonic stem cell house mouse CVCL_NN59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336167; Prkab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184341 CVCL_NN58 BayGenomics ES cell line RRR453 embryonic stem cell house mouse CVCL_NN58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351331; Chaf1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184342 CVCL_NN57 BayGenomics ES cell line RRR452 embryonic stem cell house mouse CVCL_NN57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919806; Zfp566 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184343 CVCL_NN56 BayGenomics ES cell line RRR450 embryonic stem cell house mouse CVCL_NN56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915208; U2surp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184344 CVCL_NN55 BayGenomics ES cell line RRR449 embryonic stem cell house mouse CVCL_NN55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860236; Rabep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184345 CVCL_NN54 BayGenomics ES cell line RRR447 embryonic stem cell house mouse CVCL_NN54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918023; Cwf19l2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184346 CVCL_NN53 BayGenomics ES cell line RRR446 embryonic stem cell house mouse CVCL_NN53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109520; Pafah1b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184347 CVCL_NN52 BayGenomics ES cell line RRR445 embryonic stem cell house mouse CVCL_NN52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1930134; Ern1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184348 CVCL_F599 XP6BE finite cell line human CVCL_F599 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly36_Arg61del; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1157; probable Female 21184349 CVCL_ET99 ND07723 transformed cell line human CVCL_ET99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184350 CVCL_ET98 ND07698 transformed cell line human CVCL_ET98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184351 CVCL_F598 XP2YO finite cell line human CVCL_F598 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Thr567Ala (c.1699A>G) (T556A); Zygosity=Heterozygous (PubMed=9580660); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Val657Glufs*28 (c.1971delT); Zygosity=Heterozygous (PubMed=9580660) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184352 CVCL_ET97 ND07696 transformed cell line human CVCL_ET97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184353 CVCL_F597 OE-E6/E7 transformed cell line human CVCL_F597 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Fallopian tube; ampulla Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female 21184354 CVCL_F592 GM01984 transformed cell line human CVCL_F592 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Ile220Serfs*9 (c.659_663delTCTCA) (803_807delATCTC) (p.Leu219fs); Zygosity=Hemizygous (from familial inference of GM01981 and GM01982) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184355 CVCL_ET92 ND07553 transformed cell line human CVCL_ET92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184356 CVCL_F591 GM01983 finite cell line human CVCL_F591 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Ile220Serfs*9 (c.659_663delTCTCA) (803_807delATCTC) (p.Leu219fs); Zygosity=Hemizygous (from familial inference of GM01981 and GM01982) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184357 CVCL_ET91 ND07552 transformed cell line human CVCL_ET91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184358 CVCL_F590 GM01982 transformed cell line human CVCL_F590 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Ile220Serfs*9 (c.659_663delTCTCA) (803_807delATCTC) (p.Leu219fs); Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184359 CVCL_ET90 ND07551 transformed cell line human CVCL_ET90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184360 CVCL_F596 mpkCCDc14 transformed cell line house mouse CVCL_F596 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct; Breed/subspecies: SV-PK/Tag transgenic. Unspecified 21184361 CVCL_ET96 ND07655 transformed cell line human CVCL_ET96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184362 CVCL_NN29 BayGenomics ES cell line RRR386 embryonic stem cell house mouse CVCL_NN29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1096327; Axin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184363 CVCL_ET95 ND07617 transformed cell line human CVCL_ET95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184364 CVCL_F595 RB22 transformed cell line human CVCL_F595 HLA typing: A*01:01,02:01; B*35:04:01,82:01; C*03:02,04:01; DPB1*01:01:01,04:02; DQA1*03:03,05:03; DQB1*03:01,03:02; DRB1*04:05,14:02; DRB3*01:01; DRB4*01:03 (IPD-IMGT/HLA=11298) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184365 CVCL_NN28 BayGenomics ES cell line RRR383 embryonic stem cell house mouse CVCL_NN28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914832; Slc25a26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184366 CVCL_F594 GM06935 transformed cell line human CVCL_F594 CL:0000010 Population: Arab; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184367 CVCL_ET94 ND07615 transformed cell line human CVCL_ET94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184368 CVCL_NN27 BayGenomics ES cell line RRR380 embryonic stem cell house mouse CVCL_NN27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104987; Mxd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184369 CVCL_F593 GM02053 finite cell line human CVCL_F593 CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184370 CVCL_ET93 ND07554 transformed cell line human CVCL_ET93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184371 CVCL_NN26 BayGenomics ES cell line RRR379 embryonic stem cell house mouse CVCL_NN26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333766; Epn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184372 CVCL_NN25 BayGenomics ES cell line RRR376 embryonic stem cell house mouse CVCL_NN25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098240; Kif16b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184373 CVCL_NN24 BayGenomics ES cell line RRR372 embryonic stem cell house mouse CVCL_NN24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352499; Ndrg3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184374 CVCL_NN23 BayGenomics ES cell line RRR366 embryonic stem cell house mouse CVCL_NN23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137738; Prcc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184375 CVCL_NN22 BayGenomics ES cell line RRR365 embryonic stem cell house mouse CVCL_NN22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928898; Usp14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184376 CVCL_NN21 BayGenomics ES cell line RRR362 embryonic stem cell house mouse CVCL_NN21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95453; Smarcad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184377 CVCL_NN20 BayGenomics ES cell line RRR358 embryonic stem cell house mouse CVCL_NN20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97621; Plk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184378 CVCL_NN40 BayGenomics ES cell line RRR414 embryonic stem cell house mouse CVCL_NN40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105085; Rbl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184379 CVCL_NN39 BayGenomics ES cell line RRR406 embryonic stem cell house mouse CVCL_NN39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919840; Ppme1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184380 CVCL_NN38 BayGenomics ES cell line RRR405 embryonic stem cell house mouse CVCL_NN38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184381 CVCL_NN37 BayGenomics ES cell line RRR404 embryonic stem cell house mouse CVCL_NN37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927224; Yeats4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184382 CVCL_NN36 BayGenomics ES cell line RRR402 embryonic stem cell house mouse CVCL_NN36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444236; Ubn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184383 CVCL_NN35 BayGenomics ES cell line RRR400 embryonic stem cell house mouse CVCL_NN35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333879; Ap3b1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184384 CVCL_NN34 BayGenomics ES cell line RRR399 embryonic stem cell house mouse CVCL_NN34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922004; Dhcr24 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184385 CVCL_NN33 BayGenomics ES cell line RRR398 embryonic stem cell house mouse CVCL_NN33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1861437; Gsk3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184386 CVCL_NN32 BayGenomics ES cell line RRR396 embryonic stem cell house mouse CVCL_NN32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184387 CVCL_NN31 BayGenomics ES cell line RRR395 embryonic stem cell house mouse CVCL_NN31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388656; Zfp334 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184388 CVCL_NN30 BayGenomics ES cell line RRR392 embryonic stem cell house mouse CVCL_NN30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444961; Dennd2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184389 CVCL_ET78 ND07511 transformed cell line human CVCL_ET78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184390 CVCL_F578 NIE transformed cell line human CVCL_F578 HLA typing: A*01:01; B*07:02,15:01; C*03:03,07:02; DPB1*01:01,04:01; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:01,04:32; DRB3*01:01; DRB4*01:03 (IPD-IMGT/HLA=11141) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184391 CVCL_ET77 ND07428 transformed cell line human CVCL_ET77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184392 CVCL_F577 NIC transformed cell line human CVCL_F577 HLA typing: A*24:02; B*38:01,57:01; C*07:01,12:03; DPB1*02:01,14:01; DQA1*01:03,03:01; DQB1*06:03,03:02; DRB1*04:15,13:01; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=11140) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184393 CVCL_ET76 ND07427 transformed cell line human CVCL_ET76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184394 CVCL_F576 NDS-NH transformed cell line human CVCL_F576 HLA typing: A*24:17,33:03; B*07:02,15:02; C*07:02,08:01; DPB1*04:01,13:01; DQA1*02:01,06:01; DQB1*03:01,03:03; DRB1*07:01,12:02; DRB3*03:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=11134) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184395 CVCL_ET75 ND07424 transformed cell line human CVCL_ET75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184396 CVCL_F575 NDS-MA transformed cell line human CVCL_F575 HLA typing: A*03:01,31:03; B*07:02,27:03; C*02:02,07:02; DQB1*02,04; DRB1*03:01,08; DRB3*02:02 (IPD-IMGT/HLA=11133) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184397 CVCL_ET79 ND07512 transformed cell line human CVCL_ET79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184398 CVCL_F579 POS [Human B-cell] transformed cell line human CVCL_F579 HLA typing: DPB1*02:01,03:01; DQB1*05:01,05:03; DRB1*01:01,14:01; DRB3*02:03 (IPD-IMGT/HLA=11273) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184399 CVCL_ET70 ND07186 transformed cell line human CVCL_ET70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184400 CVCL_F570 NDS-AN transformed cell line human CVCL_F570 HLA typing: A*02:32N,03:01; B*51:01; C*14; DRB1*08,13:01; DRB3*01:01 (IPD-IMGT/HLA=11787) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184401 CVCL_NN09 BayGenomics ES cell line RRR339 embryonic stem cell house mouse CVCL_NN09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101816; Msh2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184402 CVCL_NN08 BayGenomics ES cell line RRR338 embryonic stem cell house mouse CVCL_NN08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96677; Kit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184403 CVCL_ET74 ND07423 transformed cell line human CVCL_ET74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184404 CVCL_F574 NDS-JD transformed cell line human CVCL_F574 HLA typing: A*24:33,68:01:02; B*07:02:01,51:06; C*07:02,12:04:02; DPB1*04:02,26:01; DQA1*01:03; DQB1*06:01; DRB1*15:02; DRB5*01:02 (IPD-IMGT/HLA=11132) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184405 CVCL_NN07 BayGenomics ES cell line RRR335 embryonic stem cell house mouse CVCL_NN07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182799; Kat7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184406 CVCL_ET73 ND07334 transformed cell line human CVCL_ET73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184407 CVCL_F573 NDS-IH transformed cell line human CVCL_F573 HLA typing: A*02:01,30:01; B*39:24,51:01:01; C*07:AG,16:02; DPB1*04:01,17:01; DQB1*02:02,03:02; DRB1*04:03,04:05; DRB4*01 (IPD-IMGT/HLA=12173) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184408 CVCL_NN06 BayGenomics ES cell line RRR332 embryonic stem cell house mouse CVCL_NN06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445126; Tut4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184409 CVCL_ET72 ND07300 transformed cell line human CVCL_ET72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184410 CVCL_F572 NDS-HM transformed cell line human CVCL_F572 HLA typing: A*68:01:01,68:01:02; B*35:03,44:02; C*04:01:01,07:04:02; DQB1*04:02,05:01; DRB1*01:01,08:01/08:05/08:05/08:07/08:08/08:11/08:16 (IPD-IMGT/HLA=12739) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184411 CVCL_NN05 BayGenomics ES cell line RRR331 embryonic stem cell house mouse CVCL_NN05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915347; Dynll2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184412 CVCL_ET71 ND07270 transformed cell line human CVCL_ET71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184413 CVCL_F571 NDS-DG transformed cell line human CVCL_F571 HLA typing: A*02:01; B*18:01,51:08; C*07:01,16:02; DQB1*03:AD,03:02; DRB1*04,11; DRB3*02:BC; DRB4*01:03:01:02N (IPD-IMGT/HLA=11131) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184414 CVCL_NN04 BayGenomics ES cell line RRR330 embryonic stem cell house mouse CVCL_NN04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919444; Fbxl20 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184415 CVCL_NN03 BayGenomics ES cell line RRR328 embryonic stem cell house mouse CVCL_NN03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442310; Ubxn2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184416 CVCL_NN02 BayGenomics ES cell line RRR327 embryonic stem cell house mouse CVCL_NN02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913557; Isoc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184417 CVCL_NN01 BayGenomics ES cell line RRR323 embryonic stem cell house mouse CVCL_NN01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921268; Als2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184418 CVCL_NN00 BayGenomics ES cell line RRR322 embryonic stem cell house mouse CVCL_NN00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926163; Ltn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184419 CVCL_F589 GM01981 finite cell line human CVCL_F589 CL:0000010 Sequence variation: Mutation; HGNC; 869; ATP7A; Simple; p.Ile220Serfs*9 (c.659_663delTCTCA) (803_807delATCTC) (p.Leu219fs); Zygosity=Hemizygous (PubMed=7977350) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21184420 CVCL_ET89 ND07550 transformed cell line human CVCL_ET89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184421 CVCL_F588 CHAUT-C cancer cell line CVCL_F588 CL:0000010 Derived from sampling site: Uterus. Female 21184422 CVCL_ET88 ND07549 transformed cell line human CVCL_ET88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184423 CVCL_ET87 ND07548 transformed cell line human CVCL_ET87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184424 CVCL_F587 UBM13129406 transformed cell line human CVCL_F587 HLA typing: A*11:01,24:02; B*50:02,55:01; C*03:03,06:02; DQA1*01,03; DQB1*04:02,05:03; DRB1*04:06,14:01; DRB3*02; DRB4*01 (IPD-IMGT/HLA=11510) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184425 CVCL_ET86 ND07545 transformed cell line human CVCL_ET86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184426 CVCL_F586 UBM12218693 transformed cell line human CVCL_F586 HLA typing: A*03,26; B*27,57; DPB1*04:01:01,04:01:01; DQA1*01:02,02:01; DQB1*03:03:02,06:02:01; DRB1*07:01:01,15:07:01; DRB4*01:03:01:02N; DRB5*01:01:01 (IPD-IMGT/HLA=11509) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184427 CVCL_ET81 ND07536 transformed cell line human CVCL_ET81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184428 CVCL_F581 RC654 transformed cell line human CVCL_F581 HLA typing: A*02:01; B*08:01,78:02:01; C*05:01,07:01 (IPD-IMGT/HLA=11304) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184429 CVCL_ET80 ND07535 transformed cell line human CVCL_ET80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184430 CVCL_F580 R.B transformed cell line human CVCL_F580 HLA typing: DPB1*04:01,04:02; DQA1*03:01,04:01; DQB1*03:02,04:02; DRB1*04:01,13:17; DRB3*02:02; DRB4*01:03 (IPD-IMGT/HLA=11283) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184431 CVCL_NN19 BayGenomics ES cell line RRR356 embryonic stem cell house mouse CVCL_NN19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105056; Cobl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184432 CVCL_ET85 ND07543 transformed cell line human CVCL_ET85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184433 CVCL_F585 TW transformed cell line human CVCL_F585 HLA typing: A*02:01,25:02; B*08:01,44:02; C*05:01,07:01; DQA1*03,05; DQB1*02:01,03:01; DRB1*03:01,04:01; DRB3*01:01; DRB4*01:AC (IPD-IMGT/HLA=11856) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184434 CVCL_NN18 BayGenomics ES cell line RRR354 embryonic stem cell house mouse CVCL_NN18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137738; Prcc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184435 CVCL_ET84 ND07542 transformed cell line human CVCL_ET84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184436 CVCL_F584 TGI transformed cell line human CVCL_F584 HLA typing: A*02:01,03:01; B*44:02,57:01; C*05:01,06:02; DPB1*04:01; DQA1*01:03,02:01; DQB1*06:03,03:03; DRB1*14:21,07:01; DRB3*01:01; DRB4*01:03:01:02N (IPD-IMGT/HLA=11452) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184437 CVCL_NN17 BayGenomics ES cell line RRR353 embryonic stem cell house mouse CVCL_NN17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184438 CVCL_ET83 ND07541 transformed cell line human CVCL_ET83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184439 CVCL_F583 SS713 transformed cell line human CVCL_F583 HLA typing: A*24:02,25:01; B*15:14,18:01; C*03:03,12:03 (IPD-IMGT/HLA=11400) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184440 CVCL_NN16 BayGenomics ES cell line RRR351 embryonic stem cell house mouse CVCL_NN16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98180; Rrm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184441 CVCL_ET82 ND07537 transformed cell line human CVCL_ET82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184442 CVCL_F582 SIA transformed cell line human CVCL_F582 HLA typing: A*01:01,02:01; B*08:01,53:06; C*02:02,07:01 (IPD-IMGT/HLA=12184) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184443 CVCL_NN15 BayGenomics ES cell line RRR350 embryonic stem cell house mouse CVCL_NN15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184444 CVCL_NN14 BayGenomics ES cell line RRR349 embryonic stem cell house mouse CVCL_NN14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916976; Smyd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184445 CVCL_NN13 BayGenomics ES cell line RRR347 embryonic stem cell house mouse CVCL_NN13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926007; Rictor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184446 CVCL_NN12 BayGenomics ES cell line RRR345 embryonic stem cell house mouse CVCL_NN12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96103; Hk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184447 CVCL_NN11 BayGenomics ES cell line RRR343 embryonic stem cell house mouse CVCL_NN11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107547; Zfp101 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184448 CVCL_NN10 BayGenomics ES cell line RRR341 embryonic stem cell house mouse CVCL_NN10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184449 CVCL_4B46 HQ02861 transformed cell line human CVCL_4B46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184450 CVCL_4B45 HQ02860 transformed cell line human CVCL_4B45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184451 CVCL_4B44 HQ02859 transformed cell line human CVCL_4B44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184452 CVCL_4B43 HQ02858 transformed cell line human CVCL_4B43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184453 CVCL_4B49 HQ02865 transformed cell line human CVCL_4B49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184454 CVCL_4B48 HQ02864 transformed cell line human CVCL_4B48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184455 CVCL_4B47 HQ02862 transformed cell line human CVCL_4B47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184456 CVCL_WH90 RL34-EC transformed cell line Norway rat CVCL_WH90 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184457 CVCL_WH94 Ban cancer cell line human CVCL_WH94 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (HEp-2) has been shown to be a HeLa derivative. 21184458 CVCL_WH93 RL34-HT transformed cell line Norway rat CVCL_WH93 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184459 CVCL_WH92 RL34-NQ transformed cell line Norway rat CVCL_WH92 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184460 CVCL_WH91 RL34-HII transformed cell line Norway rat CVCL_WH91 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184461 CVCL_WH98 MK 2 cancer cell line human CVCL_WH98 From: Inoue J.; Department of Surgery, Tokyo Medical College; Tokyo; Japan CL:0000010 Population: Japanese. 21184462 CVCL_WH97 HeLa MR cancer cell line human CVCL_WH97 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21184463 CVCL_WH96 HeLa 292 cancer cell line human CVCL_WH96 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21184464 CVCL_WH95 HeLa P110 cancer cell line human CVCL_WH95 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21184465 CVCL_WH99 K-MK-2 cancer cell line human CVCL_WH99 CL:0000010 Population: Japanese. 21184466 CVCL_4B42 HQ02857 transformed cell line human CVCL_4B42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184467 CVCL_4B41 HQ02856 transformed cell line human CVCL_4B41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184468 CVCL_4B40 HQ02855 transformed cell line human CVCL_4B40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184469 CVCL_4B57 HQ02879 transformed cell line human CVCL_4B57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184470 CVCL_4B56 HQ02878 transformed cell line human CVCL_4B56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184471 CVCL_4B55 HQ02877 transformed cell line human CVCL_4B55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184472 CVCL_4B54 HQ02876 transformed cell line human CVCL_4B54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184473 CVCL_4B59 HQ02881 transformed cell line human CVCL_4B59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184474 CVCL_4B58 HQ02880 transformed cell line human CVCL_4B58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184475 CVCL_WH83 OUMS-24F/p53 transformed cell line human CVCL_WH83 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His) Population: Japanese; Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Cell type=Fibroblast. Female 21184476 CVCL_WH82 OUMS-24F/RAS transformed cell line human CVCL_WH82 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Population: Japanese; Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Cell type=Fibroblast. Female 21184477 CVCL_WH81 KMST-6/p53 transformed cell line human CVCL_WH81 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Pro (c.536A>C); ClinVar=VCV000376611; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His) Population: Japanese; Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Female 21184478 CVCL_WH80 OV-MZ-13 cancer cell line human CVCL_WH80 CL:0000010 Female 21184479 CVCL_WH87 RL-36 spontaneously immortalized cell line Norway rat CVCL_WH87 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Unspecified 21184480 CVCL_WH86 RL-33 [Rat] spontaneously immortalized cell line Norway rat CVCL_WH86 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Unspecified 21184481 CVCL_WH85 RL-1 spontaneously immortalized cell line Norway rat CVCL_WH85 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Unspecified 21184482 CVCL_WH84 SUSM-1/RAS transformed cell line human CVCL_WH84 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Asn (c.535C>A); ClinVar=VCV000376609; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gln61Leu) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Fetal liver Cell type=Fibroblast.. Male 21184483 CVCL_WH89 RL34-ESA transformed cell line Norway rat CVCL_WH89 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184484 CVCL_WH88 RL34-BP transformed cell line Norway rat CVCL_WH88 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (from parent cell line) Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Liver; Breed/subspecies: Wistar. Male 21184485 CVCL_4B53 HQ02874 transformed cell line human CVCL_4B53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184486 CVCL_4B52 HQ02873 transformed cell line human CVCL_4B52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184487 CVCL_4B51 HQ02872 transformed cell line human CVCL_4B51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184488 CVCL_4B50 HQ02869 transformed cell line human CVCL_4B50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184489 CVCL_4B24 HQ02832 transformed cell line human CVCL_4B24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184490 CVCL_4B23 HQ02831 transformed cell line human CVCL_4B23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184491 CVCL_4B22 HQ02829 transformed cell line human CVCL_4B22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184492 CVCL_4B21 HQ02828 transformed cell line human CVCL_4B21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184493 CVCL_4B28 HQ02838 transformed cell line human CVCL_4B28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184494 CVCL_4B27 HQ02835 transformed cell line human CVCL_4B27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184495 CVCL_4B26 HQ02834 transformed cell line human CVCL_4B26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184496 CVCL_4B25 HQ02833 transformed cell line human CVCL_4B25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184497 CVCL_4B29 HQ02839 transformed cell line human CVCL_4B29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184498 CVCL_WH72 L.P3 Co-3 spontaneously immortalized cell line house mouse CVCL_WH72 CL:0000010 Selected for resistance to: NCIt; C129640; Cobalt-60 gamma radiation; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21184499 CVCL_WH71 HuL-1-317 cancer cell line human CVCL_WH71 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: ~72 hours (PubMed=2836073) Group: Serum/protein free medium cell line Problematic cell line: Contaminated Grand-parent cell line (HuL-1) has been shown to be a HeLa derivative. 21184500 CVCL_WH70 HuL-1.P3 cancer cell line human CVCL_WH70 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (HuL-1) has been shown to be a HeLa derivative. 21184501 CVCL_WH76 HuK-1.P3 undefined cell line type human CVCL_WH76 CL:0000010 Derived from sampling site: Kidney. Male Group: Serum/protein free medium cell line 21184502 CVCL_WH75 HuK-1 undefined cell line type human CVCL_WH75 CL:0000010 Derived from sampling site: Kidney. Male 21184503 CVCL_WH74 RSP-2.P3 spontaneously immortalized cell line Norway rat CVCL_WH74 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: JAR-1. Female Group: Serum/protein free medium cell line 21184504 CVCL_WH73 RSP-2 spontaneously immortalized cell line Norway rat CVCL_WH73 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: JAR-1. Female 21184505 CVCL_WH79 L.P3.31 spontaneously immortalized cell line house mouse CVCL_WH79 CL:0000010 Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: Proliferates at 31 Celsius Group: Serum/protein free medium cell line 21184506 CVCL_WH78 COLO 229 cancer cell line human CVCL_WH78 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Male 21184507 CVCL_WH77 JTC-4D finite cell line Norway rat CVCL_WH77 CL:0000010 Derived from sampling site: Heart; Breed/subspecies: Wistar. Unspecified Characteristics: Passaged with EDTA 21184508 CVCL_4B20 HQ02827 transformed cell line human CVCL_4B20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184509 CVCL_4B35 HQ02849 transformed cell line human CVCL_4B35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184510 CVCL_4B34 HQ02848 transformed cell line human CVCL_4B34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184511 CVCL_4B33 HQ02847 transformed cell line human CVCL_4B33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184512 CVCL_4B32 HQ02846 transformed cell line human CVCL_4B32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184513 CVCL_4B39 HQ02853 transformed cell line human CVCL_4B39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184514 CVCL_4B38 HQ02852 transformed cell line human CVCL_4B38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184515 CVCL_4B37 HQ02851 transformed cell line human CVCL_4B37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184516 CVCL_4B36 HQ02850 transformed cell line human CVCL_4B36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184517 CVCL_WH61 GRINCH cancer cell line Norway rat CVCL_WH61 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Phe64Leu, p.Ser65Thr, p.Gln80Arg, p.Phe99Ser, p.Asn105Thr, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val and p.Ala206Val = SuperfolderGFP) Derived from sampling site: Pancreas; islets of Langerhans; Breed/subspecies: NEDH. Male Characteristics: Transfected with the hPro-CpepSfGFP construct containing human insulin with a C-peptide modified with a C-terminal superfolderGFP insert 21184518 CVCL_WH60 SCC131/R cancer cell line human CVCL_WH60 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Oral cavity; floor of mouth. Male 21184519 CVCL_WH65 JTC-23 spontaneously immortalized cell line Norway rat CVCL_WH65 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified 21184520 CVCL_WH64 JTC-22 spontaneously immortalized cell line Norway rat CVCL_WH64 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified 21184521 CVCL_WH63 JTC-21 spontaneously immortalized cell line Norway rat CVCL_WH63 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified 21184522 CVCL_WH62 CB-JMN cancer cell line human CVCL_WH62 From: Reynolds C.P.; Children's Hospital of Los Angeles; Los Angeles; USA CL:0000010 Omics: Transcriptome analysis by microarray. Characteristics: Intermediate type (I-type) (PubMed=15720811) 21184523 CVCL_WH69 JTC-20 spontaneously immortalized cell line Norway rat CVCL_WH69 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.. 21184524 CVCL_WH68 LRWZ cancer cell line human CVCL_WH68 CL:0000010 Derived from metastatic site: Ascites. Male Doubling time: 42 hours (PubMed=12699884) 21184525 CVCL_WH67 JTC-25 spontaneously immortalized cell line Norway rat CVCL_WH67 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. 21184526 CVCL_WH66 JTC-24 spontaneously immortalized cell line Norway rat CVCL_WH66 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Unspecified 21184527 CVCL_4B31 HQ02844 transformed cell line human CVCL_4B31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184528 CVCL_4B30 HQ02840 transformed cell line human CVCL_4B30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184529 CVCL_4B02 HQ02794 transformed cell line human CVCL_4B02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184530 CVCL_4B01 HQ02793 transformed cell line human CVCL_4B01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184531 CVCL_4B00 HQ02792 transformed cell line human CVCL_4B00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184532 CVCL_4B06 HQ02808 transformed cell line human CVCL_4B06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184533 CVCL_4B05 HQ02807 transformed cell line human CVCL_4B05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184534 CVCL_4B04 HQ02800 transformed cell line human CVCL_4B04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184535 CVCL_4B03 HQ02798 transformed cell line human CVCL_4B03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184536 CVCL_4B09 HQ02813 transformed cell line human CVCL_4B09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184537 CVCL_4B08 HQ02812 transformed cell line human CVCL_4B08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184538 CVCL_4B07 HQ02811 transformed cell line human CVCL_4B07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184539 CVCL_WH50 CSCC-R1 cancer cell line dog CVCL_WH50 CL:0000010 Derived from sampling site: Oral cavity. 21184540 CVCL_WH54 POCO cancer cell line dog CVCL_WH54 CL:0000010 Derived from sampling site: Oral cavity; tonsil. 21184541 CVCL_WH53 KUCKY cancer cell line dog CVCL_WH53 CL:0000010 Derived from sampling site: Snout. 21184542 CVCL_WH52 HAPPY cancer cell line dog CVCL_WH52 CL:0000010 Derived from sampling site: Oral cavity. 21184543 CVCL_WH51 CTCJ cancer cell line dog CVCL_WH51 CL:0000010 21184544 CVCL_WH58 WH12/6 cancer cell line CVCL_WH58 From: Bannasch P.; Deutsches Krebsforschungszentrum; Heidelberg; Germany CL:0000010 Transformant: Woodchuck hepatitis virus(NCBI-Taxonomy; 35269); Derived from sampling site: Liver. 21184545 CVCL_WH57 KP1#3 transformed cell line human CVCL_WH57 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21184546 CVCL_WH56 SYRUP cancer cell line dog CVCL_WH56 CL:0000010 Derived from sampling site: Oral cavity. 21184547 CVCL_WH55 SQ4 cancer cell line dog CVCL_WH55 CL:0000010 21184548 CVCL_WH59 SCC084/R cancer cell line human CVCL_WH59 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220fs*27 (c.655delC) (p.P219Lfs); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Oral cavity; retromolar trigone. Male 21184549 CVCL_4B13 HQ02820 transformed cell line human CVCL_4B13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184550 CVCL_4B12 HQ02817 transformed cell line human CVCL_4B12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184551 CVCL_4B11 HQ02816 transformed cell line human CVCL_4B11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184552 CVCL_4B10 HQ02814 transformed cell line human CVCL_4B10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184553 CVCL_4B17 HQ02824 transformed cell line human CVCL_4B17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184554 CVCL_4B16 HQ02823 transformed cell line human CVCL_4B16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184555 CVCL_4B15 HQ02822 transformed cell line human CVCL_4B15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184556 CVCL_4B14 HQ02821 transformed cell line human CVCL_4B14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184557 CVCL_4B19 HQ02826 transformed cell line human CVCL_4B19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184558 CVCL_4B18 HQ02825 transformed cell line human CVCL_4B18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184559 CVCL_WH43 VI-MC cancer cell line dog CVCL_WH43 CL:0000010 Derived from sampling site: Viscera Cell type=Mast cell.; Breed/subspecies: Maltese. Male Doubling time: 27.5 +- 2.3 hours (PubMed=11490155) 21184560 CVCL_WH42 CM-MC cancer cell line dog CVCL_WH42 CL:0000010 Derived from sampling site: Skin Cell type=Mast cell.; Breed/subspecies: Shiba. Female Doubling time: 52.2 +- 6.8 hours (PubMed=11490155) 21184561 CVCL_WH41 OMS cancer cell line dog CVCL_WH41 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468). 21184562 CVCL_WH40 OMK cancer cell line dog CVCL_WH40 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468). 21184563 CVCL_WH47 Pv11-Luc spontaneously immortalized cell line CVCL_WH47 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Unspecified Characteristics: Dessication tolerant Cells can be preserved in the dry state for 372 days and retain their proliferation potential. Group: Insect cell line 21184564 CVCL_WH46 Pv11-KH spontaneously immortalized cell line CVCL_WH46 CL:0000010 Transfected with: UniProtKB; Q6YGZ0; Aequorea coerulescens GFP (AcGFP1). Unspecified Characteristics: Dessication tolerant Cells can be preserved in the dry state for over 6 months and retain their proliferation potential. Group: Insect cell line 21184565 CVCL_WH45 NIAS-Pv-210 spontaneously immortalized cell line CVCL_WH45 CL:0000010 Unspecified Group: Insect cell line. 21184566 CVCL_WH44 NIAS-Pv-11 spontaneously immortalized cell line CVCL_WH44 CL:0000010 Unspecified Characteristics: Dessication tolerant Cells can be preserved in the dry state for 251 days and retain their proliferation potential (PubMed=27207249).. Group: Insect cell line 21184567 CVCL_WH49 ChMC cancer cell line dog CVCL_WH49 CL:0000010 Derived from sampling site: Oral cavity. 21184568 CVCL_WH48 PEK finite cell line CVCL_WH48 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21184569 CVCL_NN95 BayGenomics ES cell line RRR534 embryonic stem cell house mouse CVCL_NN95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1934031; Pi4k2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184570 CVCL_NN94 BayGenomics ES cell line RRR532 embryonic stem cell house mouse CVCL_NN94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289265; Tbc1d22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184571 CVCL_NN93 BayGenomics ES cell line RRR529 embryonic stem cell house mouse CVCL_NN93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921705; Nsun6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184572 CVCL_NN92 BayGenomics ES cell line RRR527 embryonic stem cell house mouse CVCL_NN92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443713; Ythdc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184573 CVCL_NN91 BayGenomics ES cell line RRR524 embryonic stem cell house mouse CVCL_NN91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2675306; Zfp930 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184574 CVCL_NN90 BayGenomics ES cell line RRR523 embryonic stem cell house mouse CVCL_NN90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184575 CVCL_WH32 M25 cancer cell line dog CVCL_WH32 CL:0000010 Miscellaneous: Breed and age of donor from personal communication of Cordeiro Y.G Breed/subspecies: Rough Collie. Omics: Transcriptome analysis by RNAseq Female Doubling time: 42.8 hours (PubMed=28834169) 21184576 CVCL_WH31 MonoTCC cancer cell line dog CVCL_WH31 CL:0000010 21184577 CVCL_WH30 MegTCC cancer cell line dog CVCL_WH30 CL:0000010 21184578 CVCL_WH36 EMC-1 cancer cell line dog CVCL_WH36 CL:0000010 Derived from sampling site: Mammary gland. Female 21184579 CVCL_WH35 RION cancer cell line dog CVCL_WH35 CL:0000010 Derived from sampling site: Bone. 21184580 CVCL_WH34 RIAM cancer cell line dog CVCL_WH34 CL:0000010 Derived from sampling site: Bone. 21184581 CVCL_WH33 M5 cancer cell line dog CVCL_WH33 CL:0000010 Miscellaneous: Breed and age of donor from personal communication of Cordeiro Y.G Breed/subspecies: Mixed breed. Omics: Transcriptome analysis by RNAseq Female Doubling time: 26 hours (PubMed=28834169) 21184582 CVCL_WH39 OMJ cancer cell line dog CVCL_WH39 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468). 21184583 CVCL_WH38 NML cancer cell line dog CVCL_WH38 CL:0000010 Sequence variation: Mutation; VGNC; 38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468) Derived from sampling site: Nail bed. 21184584 CVCL_NN89 BayGenomics ES cell line RRR520 embryonic stem cell house mouse CVCL_NN89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184585 CVCL_WH37 NIP cancer cell line dog CVCL_WH37 CL:0000010 21184586 CVCL_NN88 BayGenomics ES cell line RRR515 embryonic stem cell house mouse CVCL_NN88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158502; Usp48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184587 CVCL_NN87 BayGenomics ES cell line RRR512 embryonic stem cell house mouse CVCL_NN87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184588 CVCL_NN86 BayGenomics ES cell line RRR511 embryonic stem cell house mouse CVCL_NN86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184589 CVCL_NN85 BayGenomics ES cell line RRR509 embryonic stem cell house mouse CVCL_NN85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924567; Miga1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184590 CVCL_WH21 CMM8 cancer cell line dog CVCL_WH21 CL:0000010 21184591 CVCL_WH20 CMM7 cancer cell line dog CVCL_WH20 CL:0000010 21184592 CVCL_WH25 Peace cancer cell line dog CVCL_WH25 CL:0000010 21184593 CVCL_WH24 Love cancer cell line dog CVCL_WH24 CL:0000010 21184594 CVCL_WH23 Gen cancer cell line dog CVCL_WH23 CL:0000010 21184595 CVCL_WH22 CMM9 cancer cell line dog CVCL_WH22 CL:0000010 21184596 CVCL_WH29 MCTCC cancer cell line dog CVCL_WH29 CL:0000010 21184597 CVCL_WH28 LCTCC cancer cell line dog CVCL_WH28 CL:0000010 21184598 CVCL_WH27 TCCUB cancer cell line dog CVCL_WH27 CL:0000010 21184599 CVCL_WH26 Sora cancer cell line dog CVCL_WH26 CL:0000010 21184600 CVCL_NN99 BayGenomics ES cell line RRR545 embryonic stem cell house mouse CVCL_NN99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184601 CVCL_NN98 BayGenomics ES cell line RRR544 embryonic stem cell house mouse CVCL_NN98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184602 CVCL_NN97 BayGenomics ES cell line RRR541 embryonic stem cell house mouse CVCL_NN97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1306824; Suclg2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184603 CVCL_NN96 BayGenomics ES cell line RRR540 embryonic stem cell house mouse CVCL_NN96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681836; Polr3a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21184604 CVCL_4A89 HQ02773 transformed cell line human CVCL_4A89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184605 CVCL_4A88 HQ02772 transformed cell line human CVCL_4A88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184606 CVCL_4A83 HQ02765 transformed cell line human CVCL_4A83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184607 CVCL_4A82 HQ02764 transformed cell line human CVCL_4A82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184608 CVCL_4A81 HQ02760 transformed cell line human CVCL_4A81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184609 CVCL_4A80 HQ02759 transformed cell line human CVCL_4A80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184610 CVCL_4A87 HQ02770 transformed cell line human CVCL_4A87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184611 CVCL_4A86 HQ02769 transformed cell line human CVCL_4A86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184612 CVCL_4A85 HQ02767 transformed cell line human CVCL_4A85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184613 CVCL_4A84 HQ02766 transformed cell line human CVCL_4A84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184614 CVCL_4A99 HQ02791 transformed cell line human CVCL_4A99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184615 CVCL_4A90 HQ02774 transformed cell line human CVCL_4A90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184616 CVCL_4A94 HQ02779 transformed cell line human CVCL_4A94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184617 CVCL_4A93 HQ02778 transformed cell line human CVCL_4A93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184618 CVCL_4A92 HQ02777 transformed cell line human CVCL_4A92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184619 CVCL_4A91 HQ02776 transformed cell line human CVCL_4A91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184620 CVCL_4A98 HQ02788 transformed cell line human CVCL_4A98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184621 CVCL_4A97 HQ02785 transformed cell line human CVCL_4A97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184622 CVCL_4A96 HQ02784 transformed cell line human CVCL_4A96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184623 CVCL_4A95 HQ02781 transformed cell line human CVCL_4A95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184624 CVCL_4A69 HQ02744 transformed cell line human CVCL_4A69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184625 CVCL_4A68 HQ02743 transformed cell line human CVCL_4A68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184626 CVCL_4A67 HQ02742 transformed cell line human CVCL_4A67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184627 CVCL_4A66 HQ02741 transformed cell line human CVCL_4A66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184628 CVCL_4A61 HQ02733 transformed cell line human CVCL_4A61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184629 CVCL_4A60 HQ02732 transformed cell line human CVCL_4A60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184630 CVCL_4A65 HQ02739 transformed cell line human CVCL_4A65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184631 CVCL_4A64 HQ02737 transformed cell line human CVCL_4A64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184632 CVCL_4A63 HQ02736 transformed cell line human CVCL_4A63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184633 CVCL_4A62 HQ02735 transformed cell line human CVCL_4A62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184634 CVCL_4A79 HQ02758 transformed cell line human CVCL_4A79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184635 CVCL_4A78 HQ02757 transformed cell line human CVCL_4A78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184636 CVCL_4A77 HQ02756 transformed cell line human CVCL_4A77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184637 CVCL_4A72 HQ02750 transformed cell line human CVCL_4A72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184638 CVCL_4A71 HQ02746 transformed cell line human CVCL_4A71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184639 CVCL_4A70 HQ02745 transformed cell line human CVCL_4A70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184640 CVCL_4A76 HQ02754 transformed cell line human CVCL_4A76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184641 CVCL_4A75 HQ02753 transformed cell line human CVCL_4A75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184642 CVCL_4A74 HQ02752 transformed cell line human CVCL_4A74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184643 CVCL_4A73 HQ02751 transformed cell line human CVCL_4A73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184644 CVCL_4A47 HQ02715 transformed cell line human CVCL_4A47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184645 CVCL_4A46 HQ02714 transformed cell line human CVCL_4A46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184646 CVCL_4A45 HQ02713 transformed cell line human CVCL_4A45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184647 CVCL_4A44 HQ02711 transformed cell line human CVCL_4A44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184648 CVCL_4A49 HQ02717 transformed cell line human CVCL_4A49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184649 CVCL_4A48 HQ02716 transformed cell line human CVCL_4A48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184650 CVCL_WG91 ICI 104A cancer cell line human CVCL_WG91 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21184651 CVCL_WG90 ICI 101 cancer cell line human CVCL_WG90 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: ~85 hours (PubMed=5252515) 21184652 CVCL_WG95 Line 12 spontaneously immortalized cell line house mouse CVCL_WG95 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C57BL/6. Female Doubling time: 24-36 hours (PubMed=6451031) 21184653 CVCL_WG94 ICI 202 cancer cell line human CVCL_WG94 CL:0000010 Derived from sampling site: Peripheral blood. Male 21184654 CVCL_WG93 ICI 104C cancer cell line human CVCL_WG93 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21184655 CVCL_WG92 ICI 104B cancer cell line human CVCL_WG92 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21184656 CVCL_WG99 ICI 107 cancer cell line human CVCL_WG99 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. 21184657 CVCL_WG98 ICI 106 cancer cell line human CVCL_WG98 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21184658 CVCL_WG97 11-YX-1 cancer cell line human CVCL_WG97 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6563; LGALS3 Population: Caucasian; Derived from sampling site: Breast. Female Group: Triple negative breast cancer (TNBC) cell line 21184659 CVCL_WG96 682B cancer cell line human CVCL_WG96 CL:0000010 Derived from sampling site: Urinary bladder. Male 21184660 CVCL_4A43 HQ02710 transformed cell line human CVCL_4A43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184661 CVCL_4A42 HQ02709 transformed cell line human CVCL_4A42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184662 CVCL_4A41 HQ02708 transformed cell line human CVCL_4A41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184663 CVCL_4A40 HQ02705 transformed cell line human CVCL_4A40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184664 CVCL_4A58 HQ02730 transformed cell line human CVCL_4A58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184665 CVCL_4A57 HQ02729 transformed cell line human CVCL_4A57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184666 CVCL_4A56 HQ02728 transformed cell line human CVCL_4A56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184667 CVCL_4A55 HQ02726 transformed cell line human CVCL_4A55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184668 CVCL_4A59 HQ02731 transformed cell line human CVCL_4A59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184669 CVCL_WG80 H566C cancer cell line human CVCL_WG80 CL:0000010 21184670 CVCL_WG84 P5424 cancer cell line house mouse CVCL_WG84 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97848; Rag1; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me2 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: Pol2 ChIP-seq epigenome analysis. 21184671 CVCL_WG83 P4980 cancer cell line house mouse CVCL_WG83 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97849; Rag2; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53. 21184672 CVCL_WG82 HD10.6 transformed cell line human CVCL_WG82 CL:0000010 Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Triezenberg S.J Transformant: v-Myc; tetracycline-regulated; Derived from sampling site: Dorsal root ganglion Cell type=Neuron.. Male Characteristics: Immortalized dorsal root ganglion (DRG) cell line that in the presence of doxycycline can differentiate into sensory neurons with nociceptive features (PubMed=10377351); Virology: Susceptible to infection by herpes simplex virus 1 (HHV-1) A quiescent state resembling latency can be established in the HSV-1 infection in the presence of acyclovir (PubMed=28404842). Doubling time: 1.2 days (PubMed=10377351) 21184673 CVCL_WG81 HCC20 cancer cell line human CVCL_WG81 CL:0000010 21184674 CVCL_WG88 HEK293-Nrf2 clone 2-FVII transformed cell line human CVCL_WG88 CL:0000010 Transfected with: HGNC; 3544; F7; Transfected with: HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21184675 CVCL_WG87 HEK293-Nrf2 clone 2 transformed cell line human CVCL_WG87 CL:0000010 Transfected with: HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21184676 CVCL_WG86 HEK293-Nrf2 clone 1 transformed cell line human CVCL_WG86 CL:0000010 Transfected with: HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21184677 CVCL_WG85 Mel-67 cancer cell line human CVCL_WG85 CL:0000010 Derived from metastatic site: Not specified. 21184678 CVCL_WG89 IPC-48 cancer cell line human CVCL_WG89 CL:0000010 21184679 CVCL_4A50 HQ02718 transformed cell line human CVCL_4A50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184680 CVCL_4A54 HQ02725 transformed cell line human CVCL_4A54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184681 CVCL_4A53 HQ02721 transformed cell line human CVCL_4A53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184682 CVCL_4A52 HQ02720 transformed cell line human CVCL_4A52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184683 CVCL_4A51 HQ02719 transformed cell line human CVCL_4A51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184684 CVCL_F556 GU2092 transformed cell line human CVCL_F556 HLA typing: B*15:10,49:01 (IPD-IMGT/HLA=10691) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184685 CVCL_ET56 ND06787 transformed cell line human CVCL_ET56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184686 CVCL_F555 GU2040 transformed cell line human CVCL_F555 HLA typing: A*74:01:01:01 (IPD-IMGT/HLA=10690) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184687 CVCL_ET55 ND06762 transformed cell line human CVCL_ET55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184688 CVCL_F554 GU2037 transformed cell line human CVCL_F554 HLA typing: A*74:01; B*15:10,50:01 (IPD-IMGT/HLA=10689) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184689 CVCL_ET54 ND06758 transformed cell line human CVCL_ET54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184690 CVCL_F553 GR1202 transformed cell line human CVCL_F553 HLA typing: A*24:02,26:01; B*15:80,51:01; C*07:04,14:BE; DQB1*04:02; DRB1*08:01:01 (IPD-IMGT/HLA=13137) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184691 CVCL_ET53 ND06756 transformed cell line human CVCL_ET53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184692 CVCL_F559 GU5175 transformed cell line human CVCL_F559 HLA typing: A*23:01,66:01; B*15:10,41:02; C*16:01,17 (IPD-IMGT/HLA=10695) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184693 CVCL_ET59 ND06859 transformed cell line human CVCL_ET59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184694 CVCL_F558 GU2760 transformed cell line human CVCL_F558 HLA typing: B*15:18,37:01:01 (IPD-IMGT/HLA=10693) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184695 CVCL_ET58 ND06855 transformed cell line human CVCL_ET58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184696 CVCL_F557 GU2739 transformed cell line human CVCL_F557 HLA typing: B*15:18,35:01:01 (IPD-IMGT/HLA=10692) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184697 CVCL_ET57 ND06828 transformed cell line human CVCL_ET57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184698 CVCL_F552 GE47192 transformed cell line human CVCL_F552 HLA typing: A*02,31; B*18,51; DPB1*04:01:01,04:01:01; DQA1*01:02:02,03:03; DQB1*03:01:01,05:02:01; DRB1*04:31,16:02:01; DRB4*01:03:01:01; DRB5*02:02 (IPD-IMGT/HLA=10607) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184699 CVCL_ET52 ND06680 transformed cell line human CVCL_ET52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184700 CVCL_ET51 ND06597 transformed cell line human CVCL_ET51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184701 CVCL_F550 CR-30609 transformed cell line human CVCL_F550 HLA typing: A*68:01,68:02; B*51:01,58:02; C*06:02,16:01; DPA1*02:01,02:02; DPB1*01:01,11:01/74:01; DQA1*01,03; DQB1*02:02,05:01; DRB1*11:01,13:02; DRB3*02,03 (IPD-IMGT/HLA=11823) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184702 CVCL_ET50 ND06450 transformed cell line human CVCL_ET50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184703 CVCL_F567 MOV002AN transformed cell line human CVCL_F567 HLA typing: A*02:01,02:291; B*35:03:01,44:12; C*04:01,05:01:01; DPB1*02:FZGN,04:EHKN; DQA1*01:MV,05:EF; DQB1*03:01,05:01; DRB1*01:GNCX,12EJVY; DRB3*02:02 (IPD-IMGT/HLA=11809) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184704 CVCL_ET67 ND07112 transformed cell line human CVCL_ET67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184705 CVCL_F566 ML1805 transformed cell line human CVCL_F566 HLA typing: A*24:02,68:02; B*15:10,44:15; C*03:04:02,04:07; DPB1*01:01,04:01; DQA1*01:02,05:01; DQB1*06:02,02:01; DRB1*15:03,03:01; DRB3*02:02; DRB5*01:01 (IPD-IMGT/HLA=11814) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184706 CVCL_ET66 ND07105 transformed cell line human CVCL_ET66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184707 CVCL_F565 MA-31750 transformed cell line human CVCL_F565 HLA typing: A*01:03,02:01; B*39:10; C*12:03:01; DPB1*02:01,11:01; DQA1*02:01,05:05; DQB1*02:02,03:01; DRB1*07:01,08:04; DRB4*01:03 (IPD-IMGT/HLA=11939) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184708 CVCL_ET65 ND07048 transformed cell line human CVCL_ET65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184709 CVCL_F564 K.I. transformed cell line human CVCL_F564 HLA typing: A*24:02; B*15:26N; C*04:01 (IPD-IMGT/HLA=10886) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184710 CVCL_ET64 ND07031 transformed cell line human CVCL_ET64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184711 CVCL_ET69 ND07142 transformed cell line human CVCL_ET69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184712 CVCL_F569 NDS-758 transformed cell line human CVCL_F569 HLA typing: A*02:01,29:02; B*44:03,15:57; C*04:01,16:01; DQB1*02,05; DRB1*01:01,07:01; DRB4*01 (IPD-IMGT/HLA=12014) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184713 CVCL_F568 BD [Human B-cell IHW] transformed cell line human CVCL_F568 HLA typing: DPB1*02:01,06:01; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:01,04:04; DRB3*01:01:03; DRB4*01:03 (IPD-IMGT/HLA=10301) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184714 CVCL_ET68 ND07113 transformed cell line human CVCL_ET68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184715 CVCL_ET63 ND07015 transformed cell line human CVCL_ET63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184716 CVCL_F562 JAC transformed cell line human CVCL_F562 HLA typing: A*01:01,29:02; B*08:01,35:27; C*04:01,07:01; DQA1*03,05; DQB1*02:01,03:02; DRB1*03:01,04:04; DRB3*01:01; DRB4*01:AC (IPD-IMGT/HLA=10818) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184717 CVCL_ET62 ND06971 transformed cell line human CVCL_ET62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184718 CVCL_F561 IP transformed cell line human CVCL_F561 HLA typing: A*02:01:01,03:01:01; B*14:02,44:14; C*05:01,08:02; DPA1*01:CG,02:01; DPB1*04:AGGH,14:01; DQA1*01,03; DQB1*03:JV,06:09; DRB1*04:01,13:CZJ; DRB3*03:01; DRB4*01:NY (IPD-IMGT/HLA=11850) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184719 CVCL_ET61 ND06878 transformed cell line human CVCL_ET61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184720 CVCL_ET60 ND06868 transformed cell line human CVCL_ET60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184721 CVCL_ET39 ND06362 transformed cell line human CVCL_ET39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184722 CVCL_F534 AP106 transformed cell line human CVCL_F534 HLA typing: DQB1*05:03:02 (IPD-IMGT/HLA=10252) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184723 CVCL_ET34 ND06349 transformed cell line human CVCL_ET34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184724 CVCL_F533 ANO transformed cell line human CVCL_F533 HLA typing: A*01:01,02:17; B*08:09,18:01; C*07:01; DQB1*05:03:01,06:03; DRB1*13:AB,14:AH; DRB3*02 (IPD-IMGT/HLA=12178) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184725 CVCL_ET33 ND06348 transformed cell line human CVCL_ET33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184726 CVCL_ET32 ND06347 transformed cell line human CVCL_ET32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184727 CVCL_F532 TC-268 cancer cell line human CVCL_F532 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=8577710) Derived from metastatic site: Paraspinal mass. Female 21184728 CVCL_ET31 ND06346 transformed cell line human CVCL_ET31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184729 CVCL_F531 TC-106 cancer cell line human CVCL_F531 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=25010205); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (PubMed=25010205) Derived from metastatic site: Scalp. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21184730 CVCL_F538 AP630 transformed cell line human CVCL_F538 HLA typing: A*03:01:01:01,66:01; B*07:02,81:01; C*15:05,18:01; DPB1*01:01,18:01; DQA1*01,04:01; DQB1*05:01,04:02; DRB1*03:02,12:01; DRB3*01:01,02:02 (IPD-IMGT/HLA=10256) CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184731 CVCL_ET38 ND06358 transformed cell line human CVCL_ET38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184732 CVCL_F537 AP115 transformed cell line human CVCL_F537 HLA typing: DQB1*05:03:02 (IPD-IMGT/HLA=10255) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184733 CVCL_ET37 ND06356 transformed cell line human CVCL_ET37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184734 CVCL_F536 AP110 transformed cell line human CVCL_F536 HLA typing: DQB1*05:03:02 (IPD-IMGT/HLA=10254) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184735 CVCL_ET36 ND06351 transformed cell line human CVCL_ET36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184736 CVCL_F535 AP109 transformed cell line human CVCL_F535 HLA typing: DQB1*05:03:02 (IPD-IMGT/HLA=10253) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184737 CVCL_ET35 ND06350 transformed cell line human CVCL_ET35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184738 CVCL_ET30 ND06329 transformed cell line human CVCL_ET30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184739 CVCL_F530 RPMI-4265 cancer cell line human CVCL_F530 CL:0000010 Male 21184740 CVCL_ET45 ND06382 transformed cell line human CVCL_ET45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184741 CVCL_ET44 ND06381 transformed cell line human CVCL_ET44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184742 CVCL_F544 TK765 transformed cell line human CVCL_F544 HLA typing: A*25:01,68:01; B*55:01,15:23; C*03:03,07:12; DPB1*04:01,03:01; DQA1*03:01,03:03; DQB1*03:01,03:02; DRB1*04:01,04:08; DRB4*01:03 (IPD-IMGT/HLA=11480) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184743 CVCL_ET43 ND06380 transformed cell line human CVCL_ET43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184744 CVCL_F543 XX406 transformed cell line human CVCL_F543 HLA typing: A*11:01,24:02; B*48:01,27:06; C*01:02,08:01; DPB1*01:01,05:01; DQA1*01:02,05; DQB1*05:02,03:01; DRB1*15:02,13:13; DRB5*01:01 (IPD-IMGT/HLA=11581) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184745 CVCL_F542 KRC-033 transformed cell line human CVCL_F542 HLA typing: A*02:12,31:01:02; B*35:05,39:03; C*04:01:01:01,07:02 (IPD-IMGT/HLA=10932) CL:0000010 Population: Native South American; Kaingang; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184746 CVCL_ET42 ND06378 transformed cell line human CVCL_ET42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184747 CVCL_F549 DM [Human B-cell IHW] transformed cell line human CVCL_F549 HLA typing: A*01:01:01,02:01:01; B*08:01,44:08; C*05:01,07:01; DQA1*03,05; DQB1*02:01,03; DRB1*03,04:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=11815) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184748 CVCL_ET49 ND06434 transformed cell line human CVCL_ET49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184749 CVCL_F548 ARA transformed cell line human CVCL_F548 HLA typing: A*11:01,24:02; B*07:02,40:06; C*07:02,12:02; DPB1*02:01,14:01; DQA1*01:03,02:01; DQB1*06:03,02:02; DRB1*13:10,07:01; DRB3*01:01; DRB4*01:01 (IPD-IMGT/HLA=10260) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184750 CVCL_ET48 ND06432 transformed cell line human CVCL_ET48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184751 CVCL_F547 AMI005AN transformed cell line human CVCL_F547 HLA typing: A*02:01,23:01; B*44:09,44:13; C*04:01,05:01 (IPD-IMGT/HLA=11803) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184752 CVCL_ET47 ND06395 transformed cell line human CVCL_ET47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184753 CVCL_F546 AA859 transformed cell line human CVCL_F546 HLA typing: A*32:01,68:03:01; B*07:02,39:05; C*07:02 (IPD-IMGT/HLA=10216) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184754 CVCL_ET46 ND06393 transformed cell line human CVCL_ET46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184755 CVCL_F541 FH33 transformed cell line human CVCL_F541 HLA typing: A*02:01,03:01; B*44:23N,07:02; C*05,07; DQB1*02,03:01; DRB1*03:01,01:03; DRB3*02 (IPD-IMGT/HLA=12668); HLA typing: A*03:01:01:01,02:01:01:01; B*07:02:01,44:23N; C*07:02:01:03,05:01:01:02; DPA1*01:03:01:02,01:03:01:04; DPB1*04:01:01:01; DQA1*05:05:01,05:01:01:03; DQB1*02:01:01,03:01:01:03; DRB1*03:01:01,01:03; DRB3*02:02:01:01 (PubMed=30844424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21184756 CVCL_ET41 ND06377 transformed cell line human CVCL_ET41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184757 CVCL_F540 ARAC25 transformed cell line human CVCL_F540 HLA typing: DRB1*08:11,10:01 (IPD-IMGT/HLA=10262) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184758 CVCL_ET40 ND06374 transformed cell line human CVCL_ET40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184759 CVCL_ET19 ND06233 transformed cell line human CVCL_ET19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184760 CVCL_F519 XR-V12B spontaneously immortalized cell line CVCL_F519 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21184761 CVCL_ET18 ND06232 transformed cell line human CVCL_ET18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184762 CVCL_F518 XR-V11B spontaneously immortalized cell line CVCL_F518 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21184763 CVCL_ET17 ND06229 transformed cell line human CVCL_ET17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21184764 CVCL_F517 XR-V10B spontaneously immortalized cell line CVCL_F517 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21184765 CVCL_F512 XP2OS LCL transformed cell line human CVCL_F512 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel 21184766 CVCL_ET12 ND06022 transformed cell line human CVCL_ET12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184767 CVCL_ET11 ND06021 transformed cell line human CVCL_ET11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184768 CVCL_F510 XP2OS finite cell line human CVCL_F510 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM04419; probable; Discontinued: JCRB; KURB1007; probable Female 21184769 CVCL_ET10 ND06010 transformed cell line human CVCL_ET10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184770 CVCL_F516 Maja transformed cell line human CVCL_F516 HLA typing: A*02; B*35; C*04 (Coriell=GM03099) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184771 CVCL_ET16 ND06228 transformed cell line human CVCL_ET16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184772 CVCL_ET15 ND06143 transformed cell line human CVCL_ET15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184773 CVCL_ET14 ND06080 transformed cell line human CVCL_ET14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184774 CVCL_F514 XP24KO finite cell line human CVCL_F514 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Homozygous (PubMed=22466610) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Discontinued: JCRB; KURB1081; probable Female 21184775 CVCL_ET13 ND06026 transformed cell line human CVCL_ET13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184776 CVCL_F513 XP70TO finite cell line human CVCL_F513 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Homozygous (PubMed=22466610) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1082; probable; Discontinued: JCRB; KURB1083; probable Female 21184777 CVCL_ET29 ND06294 transformed cell line human CVCL_ET29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184778 CVCL_F529 SC-115 cancer cell line house mouse CVCL_F529 CL:0000010 Female 21184779 CVCL_ET28 ND06261 transformed cell line human CVCL_ET28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184780 CVCL_F528 WEHI-105.7 cancer cell line house mouse CVCL_F528 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: NZB. Doubling time: ~18 hours (PubMed=4630643) 21184781 CVCL_ET23 ND06244 transformed cell line human CVCL_ET23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184782 CVCL_F523 WT87 transformed cell line human CVCL_F523 HLA typing: A*02; B*w16 (Coriell=GM08601) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184783 CVCL_ET22 ND06242 transformed cell line human CVCL_ET22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184784 CVCL_F522 WT17 transformed cell line human CVCL_F522 HLA typing: A*03; B*35; C*w04 (Coriell=GM08599) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184785 CVCL_ET21 ND06235 transformed cell line human CVCL_ET21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184786 CVCL_F521 XR-V16B spontaneously immortalized cell line CVCL_F521 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21184787 CVCL_ET20 ND06234 transformed cell line human CVCL_ET20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184788 CVCL_F520 XR-V13B spontaneously immortalized cell line CVCL_F520 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21184789 CVCL_ET27 ND06260 transformed cell line human CVCL_ET27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184790 CVCL_F527 WEHI-7TG cancer cell line house mouse CVCL_F527 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 21184791 CVCL_ET26 ND06259 transformed cell line human CVCL_ET26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184792 CVCL_F526 WEHI-7 cancer cell line house mouse CVCL_F526 CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 21184793 CVCL_F525 IBW4 transformed cell line human CVCL_F525 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21184794 CVCL_ET25 ND06258 transformed cell line human CVCL_ET25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184795 CVCL_ET24 ND06256 transformed cell line human CVCL_ET24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184796 CVCL_F524 WT20 transformed cell line human CVCL_F524 HLA typing: A*w30; B*18; C*w05 (Coriell=GM08067) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21184797 CVCL_F509 GM15876 transformed cell line human CVCL_F509 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: HGNC; 12814; XPA Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transfection of wildtype XPA corrects the c.390-1G>C mutation of this gene in the cell line 21184798 CVCL_ET09 ND06008 transformed cell line human CVCL_ET09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184799 CVCL_F508 GM15877 transformed cell line human CVCL_F508 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly36_Arg61del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3434; ERCC2 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transfection of wildtype ERCC2 corrects the defects of this gene in the cell line 21184800 CVCL_ET08 ND05997 transformed cell line human CVCL_ET08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184801 CVCL_F507 XP6CA finite cell line human CVCL_F507 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21184802 CVCL_ET07 ND05995 transformed cell line human CVCL_ET07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184803 CVCL_F506 XP1PO finite cell line human CVCL_F506 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21184804 CVCL_ET06 ND05981 transformed cell line human CVCL_ET06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184805 CVCL_F501 IN24 cancer cell line CVCL_F501 CL:0000010 Female Group: Bird cell line. 21184806 CVCL_ET01 ND05897 transformed cell line human CVCL_ET01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184807 CVCL_ET00 ND05869 transformed cell line human CVCL_ET00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184808 CVCL_F500 TSFAT-3.fl cancer cell line house mouse CVCL_F500 CL:0000010 Breed/subspecies: DDD. Male 21184809 CVCL_F505 XP6BE(SV) transformed cell line human CVCL_F505 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly36_Arg61del; Zygosity=Heterozygous (PubMed=7585650; Coriell); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=7585650; Coriell) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184810 CVCL_ET05 ND05977 transformed cell line human CVCL_ET05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184811 CVCL_ET04 ND05951 transformed cell line human CVCL_ET04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184812 CVCL_F504 OLD1612 cancer cell line human CVCL_F504 CL:0000010 Omics: Exosome proteome analysis; Omics: Secretome proteome analysis; Omics: SNP array analysis. Male 21184813 CVCL_ET03 ND05900 transformed cell line human CVCL_ET03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184814 CVCL_F503 OHR cancer cell line human CVCL_F503 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281His (c.841G>C); ClinVar=VCV000376588; Zygosity=Unspecified (PubMed=8721685) Population: Japanese; Derived from metastatic site: Ascites. Male 21184815 CVCL_ET02 ND05899 transformed cell line human CVCL_ET02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184816 CVCL_F502 OS 99-1 cancer cell line human CVCL_F502 CL:0000010 Population: African American; Derived from sampling site: Bone; distal femur. Female Doubling time: ~16 hours (PubMed=18247100) 21184817 CVCL_WI31 RLC-17 spontaneously immortalized cell line Norway rat CVCL_WI31 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184818 CVCL_WI30 243L1 cancer cell line CVCL_WI30 CL:0000010 Group: Bird cell line. 21184819 CVCL_WI35 RLC-22 spontaneously immortalized cell line Norway rat CVCL_WI35 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184820 CVCL_WI34 RLC-21 spontaneously immortalized cell line Norway rat CVCL_WI34 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: JAR-1. Unspecified 21184821 CVCL_WI33 RLC-20 spontaneously immortalized cell line Norway rat CVCL_WI33 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184822 CVCL_WI32 RLC-19 spontaneously immortalized cell line Norway rat CVCL_WI32 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184823 CVCL_WI39 Culb-TC cancer cell line Norway rat CVCL_WI39 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Liver; Breed/subspecies: JAR-1. Female 21184824 CVCL_WI38 RLC-3 spontaneously immortalized cell line Norway rat CVCL_WI38 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184825 CVCL_WI37 RLC-24 spontaneously immortalized cell line Norway rat CVCL_WI37 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184826 CVCL_WI36 RLC-23 spontaneously immortalized cell line Norway rat CVCL_WI36 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-2. Female 21184827 CVCL_WI20 MOLM/AZA-1 cancer cell line human CVCL_WI20 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Peripheral blood. Male Doubling time: 17 hours (PubMed=28052028) 21184828 CVCL_WI24 MIA PaCa-2 GR300 cancer cell line human CVCL_WI24 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 21184829 CVCL_WI23 MIA PaCa-2 GR2000 cancer cell line human CVCL_WI23 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 21184830 CVCL_WI22 bTAN20 hybridoma CVCL_WI22 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P46531; Human NOTCH1 (Note=Also reacts with dog and mouse). 21184831 CVCL_WI21 MOLM/DEC-5 cancer cell line human CVCL_WI21 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Unexplicit; Internal tandem duplication (FLT3-ITD); ClinVar=VCV000016270; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:50131; 5-aza-2'-deoxycytidine (Decitabine); Derived from sampling site: Peripheral blood. Male Doubling time: 17 hours (PubMed=28052028) 21184832 CVCL_WI28 LSCC-BK25 cancer cell line CVCL_WI28 CL:0000010 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Breed/subspecies: White Leghorn line BK. Group: Bird cell line 21184833 CVCL_WI27 HL60/AR cancer cell line human CVCL_WI27 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Peripheral blood. Female Caution: Not to be confused with HL-60/AR (Cellosaurus=CVCL_WR44) which is an anthracycline resistant subline of HL-60 21184834 CVCL_WI26 THP-1/AR cancer cell line human CVCL_WI26 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Peripheral blood. Male 21184835 CVCL_WI25 MIA PaCa-2 GR800 cancer cell line human CVCL_WI25 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 21184836 CVCL_WI29 CT-3 [Mouse hybridoma against chicken CD3] hybridoma house mouse CVCL_WI29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Chicken CD3 complex. 21184837 CVCL_WI13 HEK293-hNOTCH1 transformed cell line human CVCL_WI13 CL:0000010 Transfected with: HGNC; 7881; NOTCH1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21184838 CVCL_WI11 N2a-R33 cancer cell line house mouse CVCL_WI11 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Not susceptible to infection by prion (PrPsc) 21184839 CVCL_WI10 N2a-PK1 cancer cell line house mouse CVCL_WI10 CL:0000010 Breed/subspecies: A/J. Biotechnology: Used in the scrapie cell (SC) assay This susceptible cell line is exposed to mouse prion-containing samples for 3 days, grown to confluence and split 1:10 three times. The proportion of PrPSc-containing cells is determined with automated counting equipment. Male Characteristics: Highly susceptible to infection by prion (PrPsc) 21184840 CVCL_WI17 JMAR C42 cancer cell line human CVCL_WI17 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Characteristics: Anoikis-resistant (PubMed=16978912) Problematic cell line: Contaminated Grand-parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative. 21184841 CVCL_WI16 JMAR C39 cancer cell line human CVCL_WI16 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Characteristics: Anoikis-resistant (PubMed=16978912) Problematic cell line: Contaminated Grand-parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative. 21184842 CVCL_WI15 C651.6DbHN hybridoma Norway rat CVCL_WI15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q04721; Human NOTCH2 (Note=Also reacts with dog and mouse). 21184843 CVCL_WI14 HEK293-hNOTCH2 transformed cell line human CVCL_WI14 CL:0000010 Transfected with: HGNC; 7882; NOTCH2 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21184844 CVCL_WI19 K562/DAC cancer cell line human CVCL_WI19 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50131; 5-aza-2'-deoxycytidine (Decitabine); Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 21184845 CVCL_WI18 Tu 167 c2 cancer cell line human CVCL_WI18 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Male Problematic cell line: Contaminated Parent cell line (Tu 167) has been shown to be a UM-SCC-1 derivative. 21184846 CVCL_WI02 NUT cancer cell line human CVCL_WI02 CL:0000010 Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Lymph node. Male 21184847 CVCL_WI01 KO-RCC-1 cancer cell line human CVCL_WI01 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: ~38 hours (PubMed=3747314) 21184848 CVCL_WI00 NRC-12 cancer cell line human CVCL_WI00 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 48 hours (PubMed=745323) 21184849 CVCL_WI06 S-72-3 hybridoma house mouse CVCL_WI06 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Hepatitis B virus E-antigen (HBeAg). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200517 21184850 CVCL_WI05 Yak-2 finite cell line CVCL_WI05 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 21184851 CVCL_WI04 SSH-S1 finite cell line CVCL_WI04 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male 21184852 CVCL_WI03 KMM-M1 finite cell line house mouse CVCL_WI03 CL:0000010 Derived from sampling site: Small intestine; smooth muscle Cell type=Fibroblast.; Breed/subspecies: Kunming. Male 21184853 CVCL_WI09 N2a-PD88 cancer cell line house mouse CVCL_WI09 CL:0000010 Breed/subspecies: A/J. Biotechnology: Used in the scrapie cell (SC) assay This susceptible cell line is exposed to mouse prion-containing samples for 3 days, grown to confluence and split 1:10 three times. The proportion of PrPSc-containing cells is determined with automated counting equipment. Male Characteristics: Highly susceptible to infection by prion (PrPsc) 21184854 CVCL_WI08 N2a/Gary cancer cell line house mouse CVCL_WI08 CL:0000010 Breed/subspecies: A/J. Biotechnology: Used in the scrapie cell (SC) assay This susceptible cell line is exposed to mouse prion-containing samples for 3 days, grown to confluence and split 1:10 three times. The proportion of PrPSc-containing cells is determined with automated counting equipment. Male Characteristics: Highly susceptible to infection by prion (PrPsc) Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 02031337 21184855 CVCL_WI07 SCGN-F9 hybridoma house mouse CVCL_WI07 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O76038; Human SCGN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200729 21184856 CVCL_F699 MOCP-5 transformed cell line house mouse CVCL_F699 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Osteoclast.. Unspecified Doubling time: ~2 days (on tissue culture dish), ~20 hours (when co-cultured with MS12) (PubMed=9661075) 21184857 CVCL_EU99 ND09608 transformed cell line human CVCL_EU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184858 CVCL_F698 ALBA transformed cell line human CVCL_F698 HLA typing: A*01,32; B*44:19N,82:02; C*04,05 (IPD-IMGT/HLA=12067) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21184859 CVCL_EU98 ND09602 transformed cell line human CVCL_EU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184860 CVCL_F697 AG01523 finite cell line human CVCL_F697 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21184861 CVCL_EU97 ND09598 transformed cell line human CVCL_EU97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184862 CVCL_F696 AG01518 finite cell line human CVCL_F696 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21184863 CVCL_EU96 ND09594 transformed cell line human CVCL_EU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184864 CVCL_EU91 ND09561 transformed cell line human CVCL_EU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184865 CVCL_F691 SUP-T12 cancer cell line human CVCL_F691 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21184866 CVCL_F690 K-T1 cancer cell line human CVCL_F690 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male Doubling time: 68 hours (PubMed=3004618); 36 hours (PubMed=2786436) 21184867 CVCL_EU90 ND09557 transformed cell line human CVCL_EU90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184868 CVCL_EU95 ND09589 transformed cell line human CVCL_EU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184869 CVCL_F695 SUP-T4 cancer cell line human CVCL_F695 CL:0000010 Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Doubling time: 33 hours (PubMed=3004618) 21184870 CVCL_EU94 ND09579 transformed cell line human CVCL_EU94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184871 CVCL_F694 SUP-T3 cancer cell line human CVCL_F694 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 61 hours (PubMed=3004618) 21184872 CVCL_EU93 ND09577 transformed cell line human CVCL_EU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184873 CVCL_F693 SUP-T2 cancer cell line human CVCL_F693 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Female Doubling time: 130 hours (PubMed=3004618) 21184874 CVCL_EU92 ND09563 transformed cell line human CVCL_EU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184875 CVCL_F692 SUP-T14 cancer cell line human CVCL_F692 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21184876 CVCL_4C67 HQ03053 transformed cell line human CVCL_4C67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184877 CVCL_4C66 HQ03052 transformed cell line human CVCL_4C66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184878 CVCL_4C65 HQ03050 transformed cell line human CVCL_4C65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184879 CVCL_4C64 HQ03048 transformed cell line human CVCL_4C64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184880 CVCL_4C69 HQ03056 transformed cell line human CVCL_4C69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184881 CVCL_4C68 HQ03054 transformed cell line human CVCL_4C68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184882 CVCL_4C63 HQ03047 transformed cell line human CVCL_4C63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184883 CVCL_4C62 HQ03046 transformed cell line human CVCL_4C62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184884 CVCL_4C61 HQ03045 transformed cell line human CVCL_4C61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184885 CVCL_4C60 HQ03043 transformed cell line human CVCL_4C60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184886 CVCL_4C78 HQ03065 transformed cell line human CVCL_4C78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184887 CVCL_4C77 HQ03064 transformed cell line human CVCL_4C77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184888 CVCL_4C76 HQ03063 transformed cell line human CVCL_4C76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184889 CVCL_4C75 HQ03062 transformed cell line human CVCL_4C75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184890 CVCL_4C79 HQ03066 transformed cell line human CVCL_4C79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184891 CVCL_4C70 HQ03057 transformed cell line human CVCL_4C70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184892 CVCL_4C74 HQ03061 transformed cell line human CVCL_4C74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184893 CVCL_4C73 HQ03060 transformed cell line human CVCL_4C73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184894 CVCL_4C72 HQ03059 transformed cell line human CVCL_4C72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184895 CVCL_4C71 HQ03058 transformed cell line human CVCL_4C71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184896 CVCL_4C45 HQ03015 transformed cell line human CVCL_4C45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184897 CVCL_4C44 HQ03014 transformed cell line human CVCL_4C44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184898 CVCL_4C43 HQ03010 transformed cell line human CVCL_4C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184899 CVCL_4C42 HQ03009 transformed cell line human CVCL_4C42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184900 CVCL_4C49 HQ03025 transformed cell line human CVCL_4C49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184901 CVCL_4C48 HQ03021 transformed cell line human CVCL_4C48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184902 CVCL_4C47 HQ03020 transformed cell line human CVCL_4C47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184903 CVCL_4C46 HQ03016 transformed cell line human CVCL_4C46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184905 CVCL_WI92 1D3 [Mouse hybridoma against human neutrophils] hybridoma house mouse CVCL_WI92 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human neutrophils. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9445 21184906 CVCL_WI91 MELN cancer cell line human CVCL_WI91 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Biotechnology: Used in a bioluminescent bioassay to quantitatively measure estrogenic compounds Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the beta-globin promoter 21184907 CVCL_WI90 HGELN cancer cell line human CVCL_WI90 CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used in a bioluminescent bioassay to quantitatively measure estrogenic compounds Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the beta-globin promoter; Characteristics: Transfected with the DNA-binding domain (DBD) of GAL4 fused to the ligand-binding domain (LBD) of ESR1 (GAL4-ER) 21184908 CVCL_WI97 MFC-B5-GFP cancer cell line house mouse CVCL_WI97 CL:0000010 Transfected with: UniProtKB; P21115; Vaccinia virus protein B5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Stomach; forestomach. 21184909 CVCL_WI96 TaH46 transformed cell line CVCL_WI96 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: In vitro infected by Theileria annulata isolate Hissar 21184910 CVCL_WI95 TaA46 transformed cell line CVCL_WI95 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: Infected by Theileria annulata isolate Ankara 21184911 CVCL_WI94 GATA-1- ES cell clone 74 embryonic stem cell house mouse CVCL_WI94 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:95661; Gata1 Breed/subspecies: 129S/SvEv-Gpi1. Male 21184912 CVCL_WI99 RLD-8 transformed cell line Norway rat CVCL_WI99 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184913 CVCL_WI98 RLD-7 transformed cell line Norway rat CVCL_WI98 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184914 CVCL_4C41 HQ03008 transformed cell line human CVCL_4C41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184915 CVCL_4C40 HQ03007 transformed cell line human CVCL_4C40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184916 CVCL_4C56 HQ03036 transformed cell line human CVCL_4C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184917 CVCL_4C55 HQ03035 transformed cell line human CVCL_4C55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184918 CVCL_4C54 HQ03034 transformed cell line human CVCL_4C54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184919 CVCL_4C53 HQ03033 transformed cell line human CVCL_4C53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184920 CVCL_4C59 HQ03040 transformed cell line human CVCL_4C59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184921 CVCL_4C58 HQ03038 transformed cell line human CVCL_4C58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184922 CVCL_4C57 HQ03037 transformed cell line human CVCL_4C57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184923 CVCL_WI82 RLD-2 transformed cell line Norway rat CVCL_WI82 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184924 CVCL_WI81 RLD-1 [Rat] transformed cell line Norway rat CVCL_WI81 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184925 CVCL_WI80 RLD-0 transformed cell line Norway rat CVCL_WI80 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184926 CVCL_WI86 RLD-6 transformed cell line Norway rat CVCL_WI86 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184927 CVCL_WI85 RLD-5 transformed cell line Norway rat CVCL_WI85 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184928 CVCL_WI84 RLD-4 transformed cell line Norway rat CVCL_WI84 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184929 CVCL_WI83 RLD-3 transformed cell line Norway rat CVCL_WI83 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184930 CVCL_WI89 HELN(beta) cancer cell line human CVCL_WI89 CL:0000010 Transfected with: HGNC; 3468; ESR2; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used in a bioluminescent bioassay to quantitatively measure estrogenic compounds Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the beta-globin promoter 21184931 CVCL_WI88 HELN(alpha) cancer cell line human CVCL_WI88 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Biotechnology: Used in a bioluminescent bioassay to quantitatively measure estrogenic compounds Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the beta-globin promoter 21184932 CVCL_WI87 HELN cancer cell line human CVCL_WI87 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the beta-globin promoter 21184933 CVCL_4C52 HQ03032 transformed cell line human CVCL_4C52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184934 CVCL_4C51 HQ03031 transformed cell line human CVCL_4C51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184935 CVCL_4C50 HQ03027 transformed cell line human CVCL_4C50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184936 CVCL_4C23 HQ02976 transformed cell line human CVCL_4C23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184937 CVCL_4C22 HQ02975 transformed cell line human CVCL_4C22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184938 CVCL_4C21 HQ02973 transformed cell line human CVCL_4C21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184939 CVCL_4C20 HQ02968 transformed cell line human CVCL_4C20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184940 CVCL_4C27 HQ02980 transformed cell line human CVCL_4C27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184941 CVCL_4C26 HQ02979 transformed cell line human CVCL_4C26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184942 CVCL_4C25 HQ02978 transformed cell line human CVCL_4C25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184943 CVCL_4C24 HQ02977 transformed cell line human CVCL_4C24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184944 CVCL_4C29 HQ02986 transformed cell line human CVCL_4C29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184945 CVCL_4C28 HQ02981 transformed cell line human CVCL_4C28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184946 CVCL_WI71 IR-M1 induced pluripotent stem cell human CVCL_WI71 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Arg924Ter (c.2770C>T) (R897*); ClinVar=VCV000014686; Zygosity=Heterozygous (PubMed=25059784) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184947 CVCL_WI70 EHBC-512 cancer cell line human CVCL_WI70 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Doubling time: 48 hours (DOI=10.3724/SP.J.1008.2009.01115) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200911 21184948 CVCL_WI75 NU cancer cell line human CVCL_WI75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Glu (c.672G>A); ClinVar=VCV000080709; Zygosity=Unspecified; Note=Splice site mutation (PubMed=1570156). Population: Japanese 21184949 CVCL_WI74 IR-M4 induced pluripotent stem cell human CVCL_WI74 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Glu151Ter (c.451G>T) (E124X); Zygosity=Homozygous (PubMed=26831110) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184950 CVCL_WI73 IR-M3 induced pluripotent stem cell human CVCL_WI73 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Leu260Pro (c.779T>C) (L233P); ClinVar=VCV000014689; Zygosity=Homozygous (PubMed=25059784) Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21184951 CVCL_WI72 IR-M2 induced pluripotent stem cell human CVCL_WI72 CL:0000010 Sequence variation: Mutation; HGNC; 6091; INSR; Simple; p.Ala2Gly (c.5C>G); ClinVar=VCV000193063; Zygosity=Homozygous (PubMed=25059784) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21184952 CVCL_WI79 JTC-15 AC-5 cancer cell line Norway rat CVCL_WI79 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21184953 CVCL_WI78 JTC-15 AC-4 cancer cell line Norway rat CVCL_WI78 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21184954 CVCL_WI77 JTC-2 Co-2 cancer cell line Norway rat CVCL_WI77 CL:0000010 Selected for resistance to: NCIt; C129640; Cobalt-60 gamma radiation; Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21184955 CVCL_WI76 RLC-10(2) finite cell line Norway rat CVCL_WI76 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR-1. Female 21184956 CVCL_4C34 HQ02999 transformed cell line human CVCL_4C34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184957 CVCL_4C33 HQ02998 transformed cell line human CVCL_4C33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184958 CVCL_4C32 HQ02997 transformed cell line human CVCL_4C32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184959 CVCL_4C31 HQ02996 transformed cell line human CVCL_4C31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184960 CVCL_4C38 HQ03005 transformed cell line human CVCL_4C38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184961 CVCL_4C37 HQ03004 transformed cell line human CVCL_4C37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184962 CVCL_4C36 HQ03002 transformed cell line human CVCL_4C36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184963 CVCL_4C35 HQ03001 transformed cell line human CVCL_4C35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184964 CVCL_4C39 HQ03006 transformed cell line human CVCL_4C39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184965 CVCL_WI60 SOJ-4 cancer cell line human CVCL_WI60 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 70-90 hours (PubMed=2083222) 21184966 CVCL_WI64 RLC-4 spontaneously immortalized cell line Norway rat CVCL_WI64 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184967 CVCL_WI63 RLC-2 spontaneously immortalized cell line Norway rat CVCL_WI63 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184968 CVCL_WI62 RLC-1 spontaneously immortalized cell line Norway rat CVCL_WI62 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184969 CVCL_WI61 CAP-T transformed cell line human CVCL_WI61 CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX; Transfected with: UniProtKB; P03070; SV40 large T antigen Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Characteristics: Used for stable production of recombinant proteins 21184973 CVCL_WI65 RLC-5 spontaneously immortalized cell line Norway rat CVCL_WI65 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 21184975 CVCL_4C30 HQ02988 transformed cell line human CVCL_4C30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184976 CVCL_4C01 HQ02942 transformed cell line human CVCL_4C01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184977 CVCL_4C00 HQ02940 transformed cell line human CVCL_4C00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184978 CVCL_4C05 HQ02949 transformed cell line human CVCL_4C05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184979 CVCL_4C04 HQ02948 transformed cell line human CVCL_4C04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184980 CVCL_4C03 HQ02947 transformed cell line human CVCL_4C03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184981 CVCL_4C02 HQ02944 transformed cell line human CVCL_4C02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184982 CVCL_4C09 HQ02955 transformed cell line human CVCL_4C09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184983 CVCL_4C08 HQ02954 transformed cell line human CVCL_4C08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184984 CVCL_4C07 HQ02952 transformed cell line human CVCL_4C07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184985 CVCL_4C06 HQ02950 transformed cell line human CVCL_4C06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184986 CVCL_WI53 B6.1.SF.1 VV6 factor-dependent cell line house mouse CVCL_WI53 CL:0000010 Selected for resistance to: UniProtKB; P56625; Vicia villosa lectin B4; Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6. Female Characteristics: Deficient in UDP-GalNAc:beta-galactose beta 1,4-N-acetylgalactosaminyltransferase (PubMed=6436236); Characteristics: IL2 dependent 21184987 CVCL_WI52 B6.1.SF.1 factor-dependent cell line house mouse CVCL_WI52 CL:0000010 Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6. Female Characteristics: IL2 dependent 21184988 CVCL_WI51 B6.1.2.TG5 factor-dependent cell line house mouse CVCL_WI51 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6. Female Characteristics: IL2 dependent 21184989 CVCL_WI50 B6.1.2 factor-dependent cell line house mouse CVCL_WI50 CL:0000010 Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6. Female Characteristics: IL2 dependent 21184990 CVCL_WI57 OP6 conditionally immortalized cell line house mouse CVCL_WI57 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Olfactory placode; Breed/subspecies: C3H. Unspecified Characteristics: At the permissive temperature of 33 Celsius express a transcriptional profile representing intermediate-late developmental stages in the olfactory receptor neuron (ORN) lineage At the non-permissive temperature of 39 Celsius can be induced by all-trans retinoic acid to differentiate into a population of mature bipolar olfactory receptor neuron-like cells. Doubling time: 99 hours (PubMed=12093156) Caution: PubMed=10630978 incorrectly describes this cell line as originating from a mouse neuroblastoma 21184991 CVCL_WI56 C58(NT)D cancer cell line Norway rat CVCL_WI56 CL:0000010 Breed/subspecies: Wistar Furth. 21184992 CVCL_WI55 SAM-19 hybrid cell line CVCL_WI55 CL:0000010 21184993 CVCL_WI54 PC60.21.14.4 hybrid cell line CVCL_WI54 CL:0000010 Doubling time: 18 hours (PubMed=8344349). 21184994 CVCL_WI59 SOJ-3 cancer cell line human CVCL_WI59 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 50-70 hours (PubMed=2083222) 21184995 CVCL_WI58 OP27 conditionally immortalized cell line house mouse CVCL_WI58 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Olfactory placode; Breed/subspecies: C3H. Unspecified Characteristics: At the permissive temperature (33 Celsius) expresses a transcriptional profile representing intermediate-late developmental stages in the olfactory receptor neuron (ORN) lineage At the non-permissive temperature (39 Celsius) can be induced by all-trans retinoic acid to differentiate into a population of mature bipolar olfactory receptor neuron-like cells. Doubling time: 52 hours (PubMed=12093156) Caution: PubMed=10630978 incorrectly describes this cell line as originating from a mouse neuroblastoma 21184996 CVCL_4C12 HQ02959 transformed cell line human CVCL_4C12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21184997 CVCL_4C11 HQ02958 transformed cell line human CVCL_4C11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184998 CVCL_4C10 HQ02956 transformed cell line human CVCL_4C10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21184999 CVCL_4C16 HQ02963 transformed cell line human CVCL_4C16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185000 CVCL_4C15 HQ02962 transformed cell line human CVCL_4C15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185001 CVCL_4C14 HQ02961 transformed cell line human CVCL_4C14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185002 CVCL_4C13 HQ02960 transformed cell line human CVCL_4C13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185003 CVCL_4C19 HQ02967 transformed cell line human CVCL_4C19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185004 CVCL_4C18 HQ02966 transformed cell line human CVCL_4C18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185005 CVCL_4C17 HQ02965 transformed cell line human CVCL_4C17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185006 CVCL_WI42 L.P3 Q-3 transformed cell line house mouse CVCL_WI42 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21185007 CVCL_WI41 L.P3 Q-2 transformed cell line house mouse CVCL_WI41 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21185008 CVCL_WI40 L.P3 Co-2 spontaneously immortalized cell line house mouse CVCL_WI40 CL:0000010 Selected for resistance to: NCIt; C129640; Cobalt-60 gamma radiation; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Group: Serum/protein free medium cell line 21185009 CVCL_WI46 hiPS-201B7-Rm induced pluripotent stem cell human CVCL_WI46 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple_edited; p.Glu181Lys (c.541G>A); ClinVar=VCV000196282; Zygosity=Heterozygous; Note=By helper-dependent adenoviral vector (PubMed=24935155) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185010 CVCL_WI45 hiPS-RP#5Rw induced pluripotent stem cell human CVCL_WI45 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple_corrected; p.Glu181Lys (c.541G>A); ClinVar=VCV000196282; Zygosity=Heterozygous; Note=By helper-dependent adenoviral vector (PubMed=24935155) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185011 CVCL_WI44 hiPS-RP#5 induced pluripotent stem cell human CVCL_WI44 CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Glu181Lys (c.541G>A); ClinVar=VCV000196282; Zygosity=Heterozygous (PubMed=24935155) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185012 CVCL_WI43 anti-beta8-crystallin hybridoma house mouse CVCL_WI43 CL:0000010 Monoclonal antibody isotype: IgG. 21185013 CVCL_WI49 B6.1 factor-dependent cell line house mouse CVCL_WI49 CL:0000010 Derived from sampling site: Spleen Cell type=Cytotoxic T-cell.; Breed/subspecies: C57BL/6. Female Characteristics: IL2 dependent 21185014 CVCL_WI48 GP2-293 transformed cell line human CVCL_WI48 CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21185015 CVCL_WI47 AmphoPack-293 transformed cell line human CVCL_WI47 CL:0000010 Transfected with: UniProtKB; A7UJ19; Murine leukemia virus isolate 4070A gag-pol; Transfected with: UniProtKB; Q89683; Murine leukemia virus isolate 4070A env; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21185016 CVCL_F608 GM05267 transformed cell line house mouse CVCL_F608 CL:0000010 Karyotypic information: 84% of cells lack a Y chromosome (Coriell); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: Tfm. Male 21185017 CVCL_EU08 ND08005 transformed cell line human CVCL_EU08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185018 CVCL_EU07 ND08002 transformed cell line human CVCL_EU07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185019 CVCL_F606 GM03560 finite cell line human CVCL_F606 CL:0000010 Sequence variation: Mutation; HGNC; 318; AGA; Simple; c.940+1G>T (IVS8DS,G-T,+1) (c.807_940del134); ClinVar=VCV000000227; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=1722323) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21185020 CVCL_EU06 ND07980 transformed cell line human CVCL_EU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185021 CVCL_F605 GM03030 finite cell line human CVCL_F605 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21185022 CVCL_EU05 ND07951 transformed cell line human CVCL_EU05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185023 CVCL_F609 GM06804 transformed cell line human CVCL_F609 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex2-3dup; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185024 CVCL_EU09 ND08020 transformed cell line human CVCL_EU09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185025 CVCL_F600 GM00089 finite cell line human CVCL_F600 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;19)(q22;q13.3) (PubMed=10377420); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185026 CVCL_EU00 ND07728 transformed cell line human CVCL_EU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185027 CVCL_F604 GM02894 transformed cell line human CVCL_F604 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Homozygous (PubMed=9792862) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21185028 CVCL_EU04 ND07950 transformed cell line human CVCL_EU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185029 CVCL_F603 GM02756 transformed cell line human CVCL_F603 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg211His (c.632G>A); ClinVar=VCV000001957; Zygosity=Heterozygous (PubMed=1346349); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Ala329Val (c.986C>T); ClinVar=VCV000001959; Zygosity=Heterozygous (PubMed=1346349) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185030 CVCL_EU03 ND07949 transformed cell line human CVCL_EU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185031 CVCL_F602 GM01662 finite cell line human CVCL_F602 CL:0000010 Sequence variation: Mutation; HGNC; 5157; HPRT1; Unexplicit; Ex2-3dup; Zygosity=Hemizygous (PubMed=3296189) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21185032 CVCL_EU02 ND07899 transformed cell line human CVCL_EU02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185033 CVCL_F601 GM04912 finite cell line human CVCL_F601 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp481Glyfs*39 (c.1441delT); ClinVar=VCV000972761; Zygosity=Heterozygous (PubMed=10189220); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp746Ter (c.2237G>A); ClinVar=VCV000280063; Zygosity=Heterozygous (PubMed=10189220) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185034 CVCL_EU01 ND07730 transformed cell line human CVCL_EU01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185035 CVCL_4B89 HQ02927 transformed cell line human CVCL_4B89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185036 CVCL_4B88 HQ02926 transformed cell line human CVCL_4B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185037 CVCL_4B87 HQ02925 transformed cell line human CVCL_4B87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185038 CVCL_4B82 HQ02919 transformed cell line human CVCL_4B82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185039 CVCL_4B81 HQ02918 transformed cell line human CVCL_4B81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185040 CVCL_4B80 HQ02913 transformed cell line human CVCL_4B80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185041 CVCL_4B86 HQ02924 transformed cell line human CVCL_4B86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185042 CVCL_4B85 HQ02923 transformed cell line human CVCL_4B85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185043 CVCL_4B84 HQ02922 transformed cell line human CVCL_4B84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185044 CVCL_4B83 HQ02921 transformed cell line human CVCL_4B83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185045 CVCL_4B99 HQ02939 transformed cell line human CVCL_4B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185046 CVCL_4B98 HQ02938 transformed cell line human CVCL_4B98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185047 CVCL_4B93 HQ02933 transformed cell line human CVCL_4B93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185048 CVCL_4B92 HQ02930 transformed cell line human CVCL_4B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185049 CVCL_4B91 HQ02929 transformed cell line human CVCL_4B91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185050 CVCL_4B90 HQ02928 transformed cell line human CVCL_4B90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185051 CVCL_4B97 HQ02937 transformed cell line human CVCL_4B97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185052 CVCL_4B96 HQ02936 transformed cell line human CVCL_4B96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185053 CVCL_4B95 HQ02935 transformed cell line human CVCL_4B95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185054 CVCL_4B94 HQ02934 transformed cell line human CVCL_4B94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185055 CVCL_4B68 HQ02891 transformed cell line human CVCL_4B68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185056 CVCL_4B67 HQ02890 transformed cell line human CVCL_4B67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185057 CVCL_4B66 HQ02889 transformed cell line human CVCL_4B66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185058 CVCL_4B65 HQ02888 transformed cell line human CVCL_4B65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185059 CVCL_4B69 HQ02892 transformed cell line human CVCL_4B69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185060 CVCL_4B60 HQ02882 transformed cell line human CVCL_4B60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185061 CVCL_4B64 HQ02886 transformed cell line human CVCL_4B64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185062 CVCL_4B63 HQ02885 transformed cell line human CVCL_4B63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185063 CVCL_4B62 HQ02884 transformed cell line human CVCL_4B62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185064 CVCL_4B61 HQ02883 transformed cell line human CVCL_4B61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185065 CVCL_4B79 HQ02912 transformed cell line human CVCL_4B79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185066 CVCL_4B78 HQ02910 transformed cell line human CVCL_4B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185067 CVCL_4B77 HQ02908 transformed cell line human CVCL_4B77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185068 CVCL_4B76 HQ02907 transformed cell line human CVCL_4B76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185069 CVCL_4B71 HQ02898 transformed cell line human CVCL_4B71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185070 CVCL_4B70 HQ02897 transformed cell line human CVCL_4B70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185071 CVCL_4B75 HQ02904 transformed cell line human CVCL_4B75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185072 CVCL_4B74 HQ02903 transformed cell line human CVCL_4B74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185073 CVCL_4B73 HQ02900 transformed cell line human CVCL_4B73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185074 CVCL_4B72 HQ02899 transformed cell line human CVCL_4B72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185075 CVCL_F677 NCR-EW1 cancer cell line human CVCL_F677 CL:0000010 Population: Japanese; Derived from sampling site: Neck. Male Doubling time: 48 hours (PubMed=1764362) 21185076 CVCL_EU77 ND09422 transformed cell line human CVCL_EU77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185077 CVCL_F676 N1043 cancer cell line human CVCL_F676 CL:0000010 21185078 CVCL_EU76 ND09409 transformed cell line human CVCL_EU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185079 CVCL_F675 N1016 cancer cell line human CVCL_F675 CL:0000010 Derived from metastatic site: Bone marrow. Female 21185080 CVCL_EU75 ND09408 transformed cell line human CVCL_EU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185081 CVCL_F674 N1008 cancer cell line human CVCL_F674 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21185082 CVCL_EU74 ND09397 transformed cell line human CVCL_EU74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185083 CVCL_F679 NCR-EW3 cancer cell line human CVCL_F679 CL:0000010 Sequence variation: Gene fusion; HGNC; 3493; ETV4 + HGNC; 3508; EWSR1; Name(s)=EWSR1-ETV4, EWSR1-E1AF (PubMed=9858836; PubMed=9738976) Population: Japanese; Derived from sampling site: Chest wall. Male Doubling time: 55.4 hours (PubMed=1764362) 21185084 CVCL_EU79 ND09425 transformed cell line human CVCL_EU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185085 CVCL_F678 NCR-EW2 cancer cell line human CVCL_F678 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=9738976) Population: Japanese; Derived from sampling site: Pelvis. Male Doubling time: 34.3 hours (PubMed=1764362) 21185086 CVCL_EU78 ND09423 transformed cell line human CVCL_EU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185087 CVCL_F673 N1002 cancer cell line human CVCL_F673 CL:0000010 Derived from metastatic site: Bone marrow. Male 21185088 CVCL_EU73 ND09374 transformed cell line human CVCL_EU73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185089 CVCL_F672 N1001 cancer cell line human CVCL_F672 CL:0000010 Derived from metastatic site: Bone marrow. Female 21185090 CVCL_EU72 ND09351 transformed cell line human CVCL_EU72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185091 CVCL_F671 N1000 cancer cell line human CVCL_F671 CL:0000010 Male 21185092 CVCL_EU71 ND09330 transformed cell line human CVCL_EU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185093 CVCL_F670 GM06275 transformed cell line human CVCL_F670 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185094 CVCL_EU70 ND09324 transformed cell line human CVCL_EU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185095 CVCL_EU88 ND09545 transformed cell line human CVCL_EU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185096 CVCL_F688 SUP-T9 cancer cell line human CVCL_F688 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Female 21185097 CVCL_EU87 ND09522 transformed cell line human CVCL_EU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185098 CVCL_F687 SUP-T6 cancer cell line human CVCL_F687 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21185099 CVCL_EU86 ND09499 transformed cell line human CVCL_EU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185100 CVCL_F686 SUP-T5 cancer cell line human CVCL_F686 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=2786436) Derived from sampling site: Bone marrow. Male 21185101 CVCL_EU85 ND09497 transformed cell line human CVCL_EU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185102 CVCL_F685 SUP-T8 cancer cell line human CVCL_F685 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Female 21185103 CVCL_EU89 ND09556 transformed cell line human CVCL_EU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185104 CVCL_F689 SUP-T10 cancer cell line human CVCL_F689 CL:0000010 Derived from sampling site: Bone marrow Cell type=T-cell.. Male 21185105 CVCL_F680 NCR-EW4 cancer cell line human CVCL_F680 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 40 hours (PubMed=1764362) 21185106 CVCL_EU80 ND09433 transformed cell line human CVCL_EU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185107 CVCL_F684 K1735-M2 cancer cell line house mouse CVCL_F684 CL:0000010 Breed/subspecies: C3H/HeN. 21185108 CVCL_EU84 ND09488 transformed cell line human CVCL_EU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185109 CVCL_EU83 ND09467 transformed cell line human CVCL_EU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185110 CVCL_F683 UMR-201 finite cell line Norway rat CVCL_F683 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.. Unspecified Doubling time: ~24 hours (PubMed=3213604) 21185111 CVCL_F682 A2243 cancer cell line human CVCL_F682 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA. CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (PubMed=7539744). 21185112 CVCL_EU82 ND09465 transformed cell line human CVCL_EU82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185113 CVCL_EU81 ND09457 transformed cell line human CVCL_EU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185114 CVCL_F681 RAW-D cancer cell line house mouse CVCL_F681 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Differentiates into osteoclast-like multinucleated cells at a very high rate even at low concentrations of RANKL (PubMed=14709158) 21185115 CVCL_F655 GM06061 transformed cell line human CVCL_F655 CL:0000010 Population: Caucasian; Karyotypic information: 49,XXXXX.arr(X)x4 (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21185116 CVCL_EU55 ND08985 transformed cell line human CVCL_EU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185117 CVCL_F654 CC-ML3 cancer cell line human CVCL_F654 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male 21185118 CVCL_EU54 ND08981 transformed cell line human CVCL_EU54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185119 CVCL_EU53 ND08978 transformed cell line human CVCL_EU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185120 CVCL_F653 SW608 cancer cell line human CVCL_F653 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00091 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 55 year old female patient with a fibrillary astrocytoma. 21185121 CVCL_EU52 ND08977 transformed cell line human CVCL_EU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185122 CVCL_F652 SW733 cancer cell line human CVCL_F652 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00093 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 69 year old female patient with a urinary bladder transitional cell carcinoma. 21185123 CVCL_EU59 ND09026 transformed cell line human CVCL_EU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185124 CVCL_F659 PC-12 Adh cancer cell line Norway rat CVCL_F659 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male Characteristics: Adherent subline of PC12 Doubling time: 48 hours (ATCC=CRL-1721.1) 21185125 CVCL_F658 MVL transformed cell line human CVCL_F658 HLA typing: B*27:05:02; C*02:02:01; DQB1*05:01:01 (IPD-IMGT/HLA=11116) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21185126 CVCL_EU58 ND09015 transformed cell line human CVCL_EU58 CL:0000010 Population: Caucasian; English; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185127 CVCL_F657 GM01416 transformed cell line human CVCL_F657 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21185128 CVCL_EU57 ND08999 transformed cell line human CVCL_EU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185129 CVCL_F656 GM01415 finite cell line human CVCL_F656 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185130 CVCL_EU56 ND08998 transformed cell line human CVCL_EU56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185131 CVCL_EU51 ND08958 transformed cell line human CVCL_EU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185132 CVCL_F651 SW732 cancer cell line human CVCL_F651 HLA typing: A*02,09; B*07,w22; C*w03,w06 (PubMed=77569) From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00093 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 67 year old female patient with a cervical squamous cell carcinoma metastasized to the lung. 21185133 CVCL_EU50 ND08956 transformed cell line human CVCL_EU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185134 CVCL_F650 SW613 cancer cell line human CVCL_F650 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Discontinued: ATCC; CRL-2146; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00092 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 86 year old female patient with a breast adenocarcinoma. 21185135 CVCL_F666 EJ-30tgr cancer cell line human CVCL_F666 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Characteristics: Spontaneous HPRT- mutant of EJ30 Problematic cell line: Contaminated Grand-parent cell line (Ej138) has been shown to be a T24 derivative. 21185136 CVCL_EU66 ND09230 transformed cell line human CVCL_EU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185137 CVCL_F665 1682A cancer cell line Norway rat CVCL_F665 CL:0000010 Transformant: DL-ethionine(ChEBI; CHEBI:68664); Derived from sampling site: Kidney; Breed/subspecies: ACI. Male 21185138 CVCL_EU65 ND09226 transformed cell line human CVCL_EU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185139 CVCL_F664 Flow13000 finite cell line human CVCL_F664 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00303 Problematic cell line: Contaminated Shown to be a MRC-5 derivative (PubMed=20143388). 21185140 CVCL_EU64 ND09152 transformed cell line human CVCL_EU64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185141 CVCL_F663 Flow11000 finite cell line human CVCL_F663 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal intestine Cell type=Fibroblast.. Unspecified Senescence: Senesces at ~50 PDL (DOI=10.1007/978-94-009-8715-9_45) 21185142 CVCL_EU63 ND09151 transformed cell line human CVCL_EU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185143 CVCL_F669 GM06229 transformed cell line human CVCL_F669 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185144 CVCL_EU69 ND09289 transformed cell line human CVCL_EU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185145 CVCL_F668 GM07489 cancer cell line human CVCL_F668 CL:0000010 Omics: CNV analysis. Female 21185146 CVCL_EU68 ND09287 transformed cell line human CVCL_EU68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185147 CVCL_F667 GM05373 cancer cell line house mouse CVCL_F667 CL:0000010 Breed/subspecies: A.SW. Discontinued: Coriell; GM05373; probable Male 21185148 CVCL_EU67 ND09233 transformed cell line human CVCL_EU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185149 CVCL_F662 Flow6000 finite cell line human CVCL_F662 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00305 Problematic cell line: Contaminated Shown to be a Flow1000 derivative. 21185150 CVCL_EU62 ND09150 transformed cell line human CVCL_EU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185151 CVCL_F661 Flow2002 finite cell line human CVCL_F661 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 21185152 CVCL_EU61 ND09135 transformed cell line human CVCL_EU61 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185153 CVCL_F660 KS Y-1 cancer cell line human CVCL_F660 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Derived from sampling site: Urinary bladder. Female Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00408; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11448 Problematic cell line: Contaminated Shown to be a T24 derivative (PubMed=22987579). Was thought to originate from the pleural effusion of a male AIDS patient with Kaposi sarcoma. 21185154 CVCL_EU60 ND09113 transformed cell line human CVCL_EU60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185155 CVCL_F639 A2780/C30 cancer cell line human CVCL_F639 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21185156 CVCL_EU39 ND08538 transformed cell line human CVCL_EU39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185157 CVCL_F638 A2780/C200 cancer cell line human CVCL_F638 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21185158 CVCL_EU38 ND08492 transformed cell line human CVCL_EU38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185159 CVCL_F633 CS3BE LCL transformed cell line human CVCL_F633 HLA typing: A*09,11; B*07,w15 (Coriell=GM01857) CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (from autologous cell line CS3B2); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Ala160Val (c.479C>T); ClinVar=VCV000001717; Zygosity=Heterozygous (from autologous cell line CS3BE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185160 CVCL_EU33 ND08393 transformed cell line human CVCL_EU33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185161 CVCL_F632 CS3BE finite cell line human CVCL_F632 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (PubMed=15744458); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Ala160Val (c.479C>T); ClinVar=VCV000001717; Zygosity=Heterozygous (PubMed=15744458) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185162 CVCL_EU32 ND08392 transformed cell line human CVCL_EU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185163 CVCL_F631 CS3BE-S3-G1 transformed cell line human CVCL_F631 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Ala160Val (c.479C>T); ClinVar=VCV000001717; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185164 CVCL_EU31 ND08391 transformed cell line human CVCL_EU31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185165 CVCL_F630 XP14BRneo17 finite cell line human CVCL_F630 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg718Ter (c.2152C>T); ClinVar=VCV000551486; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Pakistani; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185166 CVCL_EU30 ND08368 transformed cell line human CVCL_EU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185167 CVCL_F637 GM20005 transformed cell line human CVCL_F637 CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp481Glyfs*39 (c.1441delT); ClinVar=VCV000972761; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Trp746Ter (c.2237G>A); ClinVar=VCV000280063; Zygosity=Heterozygous (Coriell) Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM20005; probable Male 21185168 CVCL_EU37 ND08489 transformed cell line human CVCL_EU37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185169 CVCL_F636 AT22IJE-T pEBS7-YZ5 transformed cell line human CVCL_F636 CL:0000010 Transfected with: HGNC; 795; ATM Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185170 CVCL_EU36 ND08467 transformed cell line human CVCL_EU36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185171 CVCL_F635 AT22IJE-T pEBS7 transformed cell line human CVCL_F635 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu762Valfs (c.2282_2283CT[1]) (c.2284_2285delCT); ClinVar=VCV000141325; Zygosity=Unspecified (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185172 CVCL_EU35 ND08447 transformed cell line human CVCL_EU35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185173 CVCL_F634 GM16635 transformed cell line human CVCL_F634 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV7](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185174 CVCL_EU34 ND08394 transformed cell line human CVCL_EU34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185175 CVCL_EU49 ND08955 transformed cell line human CVCL_EU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185176 CVCL_F649 SW598 cancer cell line human CVCL_F649 From: Scott and White Clinic; Temple; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Discontinued: ATCC; CRL-2176; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00090 Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 63 year old female patient with a meningioma. 21185177 CVCL_F644 ITC-1 cancer cell line CVCL_F644 CL:0000010 Transformant: BK polyomavirus (BKPyV)(NCBI-Taxonomy; 1891762); Derived from sampling site: Pancreas; islets of Langerhans. Characteristics: Produces glucagon (PubMed=1311428) 21185178 CVCL_EU44 ND08724 transformed cell line human CVCL_EU44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185179 CVCL_F643 GMK-5 cancer cell line human CVCL_F643 CL:0000010 Population: Japanese Omics: Transcriptome analysis by microarray. Male Part of: JFCR45 cancer cell line panel 21185180 CVCL_EU43 ND08721 transformed cell line human CVCL_EU43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185181 CVCL_F642 IST-1 [Human contaminated placenta] cancer cell line human CVCL_F642 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: ATCC; CRL-2734; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00402 Problematic cell line: Contaminated Shown to be a SK-OV-3 derivative. Originally thought to originate from an HPV16 immortalized first trimester placenta. 21185182 CVCL_EU42 ND08674 transformed cell line human CVCL_EU42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185183 CVCL_F641 COLO 587 cancer cell line human CVCL_F641 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Discontinued: ATCC; CRL-2000; true Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00396 Problematic cell line: Contaminated Shown to be a COLO 320DM derivative. Originally thought to originate from the ascites of a 56 year old female patient with a mesothelioma. 21185184 CVCL_EU41 ND08543 transformed cell line human CVCL_EU41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185185 CVCL_F648 Hs 622.T cancer cell line human CVCL_F648 CL:0000010 Derived from sampling site: Pituitary gland. Discontinued: ATCC; CRL-7386; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185186 CVCL_EU48 ND08927 transformed cell line human CVCL_EU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185187 CVCL_F647 Hs 579.T cancer cell line human CVCL_F647 CL:0000010 Derived from sampling site: Breast. Discontinued: ATCC; CRL-7348; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185188 CVCL_EU47 ND08900 transformed cell line human CVCL_EU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185189 CVCL_F646 Hs 677.St undefined cell line type house mouse CVCL_F646 CL:0000010 Discontinued: ATCC; CRL-7407; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00401 Problematic cell line: Misidentified Originally thought to be of human origin but found to be from mouse. 21185190 CVCL_EU46 ND08851 transformed cell line human CVCL_EU46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185191 CVCL_F645 ISt-1 cancer cell line human CVCL_F645 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Male Characteristics: Produces high level of AFP Doubling time: 31 hours (PubMed=1716623) Group: Serum/protein free medium cell line; Part of: JFCR45 cancer cell line panel 21185192 CVCL_EU45 ND08767 transformed cell line human CVCL_EU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185193 CVCL_F640 HISM finite cell line human CVCL_F640 CL:0000010 Derived from sampling site: Small intestine; jejunum; smooth muscle Cell type=Fibroblast.. Discontinued: ATCC; CRL-1692; true Female Senescence: Senesces at ~25 PDL (ATCC=CRL-1692) Has been discontinued from ATCC because the cells senesced. 21185194 CVCL_EU40 ND08539 transformed cell line human CVCL_EU40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185195 CVCL_F619 XPCS2LV finite cell line human CVCL_F619 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Arg263Ter (c.787C>T) (984C>T); ClinVar=VCV000016570; Zygosity=Heterozygous (PubMed=9096355); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ser659Valfs*1 (c.1975delA) (2172delA); ClinVar=VCV001696064; Zygosity=Heterozygous (PubMed=9096355) Population: Caucasian; Flemish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185196 CVCL_EU19 ND08079 transformed cell line human CVCL_EU19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185197 CVCL_F618 GM11201 transformed cell line human CVCL_F618 CL:0000010 Population: Native South American; Quechuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21185198 CVCL_EU18 ND08061 transformed cell line human CVCL_EU18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185199 CVCL_F617 GM11197 transformed cell line human CVCL_F617 CL:0000010 Population: Native South American; Quechuan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Human variation panel; Part of: Yale-Stanford Collection from NIGMS Human Genetic Cell Repository 21185200 CVCL_EU17 ND08060 transformed cell line human CVCL_EU17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185201 CVCL_F616 GM10876 transformed cell line human CVCL_F616 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21185202 CVCL_EU16 ND08059 transformed cell line human CVCL_EU16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185203 CVCL_F611 TAT2SF transformed cell line human CVCL_F611 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1774Lysfs*17 (c.5320_5326del) (c.5320del7); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp2769Ter (c.8307G>A); ClinVar=VCV000189104; Zygosity=Heterozygous (Coriell) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185204 CVCL_EU11 ND08027 transformed cell line human CVCL_EU11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185205 CVCL_F610 GM07213 finite cell line human CVCL_F610 CL:0000010 Population: African American; Karyotypic information: 46,X,i(X)(q28) (PubMed=10377420); Derived from sampling site: Ovary Cell type=Fibroblast.. Omics: CNV analysis Female 21185206 CVCL_EU10 ND08025 transformed cell line human CVCL_EU10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185207 CVCL_F615 GM10618 transformed cell line human CVCL_F615 CL:0000010 Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185208 CVCL_EU15 ND08058 transformed cell line human CVCL_EU15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185209 CVCL_F614 GM10603 transformed cell line human CVCL_F614 CL:0000010 Population: Caucasian; Transformant: Ad5-SV40 hybrid virus [1613]; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185210 CVCL_EU14 ND08056 transformed cell line human CVCL_EU14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185211 CVCL_F613 GM10354 transformed cell line human CVCL_F613 CL:0000010 Sequence variation: Mutation; HGNC; 12597; USH1C; Simple; p.Val72Glufs*65 (c.216G>A) (p.Val72Val); ClinVar=VCV000005143; Zygosity=Homozygous; Note=New splice site creation (PubMed=15578223) Population: Caucasian; Acadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185212 CVCL_EU13 ND08030 transformed cell line human CVCL_EU13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185213 CVCL_F612 GM09852 transformed cell line human CVCL_F612 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Sardinian; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185214 CVCL_EU12 ND08029 transformed cell line human CVCL_EU12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185215 CVCL_F629 XP14BR.2 finite cell line human CVCL_F629 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg718Ter (c.2152C>T); ClinVar=VCV000551486; Zygosity=Unspecified (PubMed=10766188) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185216 CVCL_EU29 ND08350 transformed cell line human CVCL_EU29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185217 CVCL_EU28 ND08319 transformed cell line human CVCL_EU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185218 CVCL_F628 XP4PA-SE2 transformed cell line human CVCL_F628 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12816; XPC; Transfected with: UniProtKB; P03211; EBV EBNA1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Male 21185219 CVCL_EU27 ND08318 transformed cell line human CVCL_EU27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185220 CVCL_F627 XP4PA-SE1 transformed cell line human CVCL_F627 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12816; XPC; Transfected with: UniProtKB; P03211; EBV EBNA1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Male 21185221 CVCL_F622 XPCS1LV SV40 transformed cell line human CVCL_F622 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ser659Valfs*1 (c.1975delA) (2172delA); ClinVar=VCV001696064; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Flemish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185222 CVCL_EU22 ND08230 transformed cell line human CVCL_EU22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185223 CVCL_F621 XPCS2LV SV40 transformed cell line human CVCL_F621 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Arg263Ter (c.787C>T) (984C>T); ClinVar=VCV000016570; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ser659Valfs*1 (c.1975delA) (2172delA); ClinVar=VCV001696064; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Flemish; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185224 CVCL_EU21 ND08188 transformed cell line human CVCL_EU21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185225 CVCL_F620 XPCS1LV finite cell line human CVCL_F620 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ser659Valfs*1 (c.1975delA) (2172delA); ClinVar=VCV001696064; Zygosity=Homozygous (PubMed=9096355) Population: Caucasian; Flemish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185226 CVCL_EU20 ND08083 transformed cell line human CVCL_EU20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185227 CVCL_F626 GM15989 transformed cell line human CVCL_F626 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Could be identical to GM07166VA7 (Cellosaurus=CVCL_WL44) 21185228 CVCL_EU26 ND08287 transformed cell line human CVCL_EU26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185229 CVCL_EU25 ND08286 transformed cell line human CVCL_EU25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185230 CVCL_F625 XP4PA-SV-EB transformed cell line human CVCL_F625 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Male 21185231 CVCL_F624 GM15859 transformed cell line human CVCL_F624 CL:0000010 Population: African American; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21185232 CVCL_EU24 ND08277 transformed cell line human CVCL_EU24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185233 CVCL_F623 GM15696 transformed cell line human CVCL_F623 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (Coriell) Population: Caucasian; Transformant: Ad5-SV40 hybrid virus [1613]; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185234 CVCL_EU23 ND08240 transformed cell line human CVCL_EU23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185235 CVCL_NY49 BayGenomics ES cell line RRY490 embryonic stem cell house mouse CVCL_NY49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445107; Tmem245 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185236 CVCL_NY48 BayGenomics ES cell line RRY476 embryonic stem cell house mouse CVCL_NY48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441856; Sf3b2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185237 CVCL_NY47 BayGenomics ES cell line RRY470 embryonic stem cell house mouse CVCL_NY47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100863; Kpna3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185238 CVCL_NY46 BayGenomics ES cell line RRY465 embryonic stem cell house mouse CVCL_NY46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923661; Ift43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185239 CVCL_NY45 BayGenomics ES cell line RRY463 embryonic stem cell house mouse CVCL_NY45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1336172; Tbl1x Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185240 CVCL_NY44 BayGenomics ES cell line RRY459 embryonic stem cell house mouse CVCL_NY44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347488; Foxk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185241 CVCL_NY43 BayGenomics ES cell line RRY454 embryonic stem cell house mouse CVCL_NY43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185242 CVCL_NY42 BayGenomics ES cell line RRY446 embryonic stem cell house mouse CVCL_NY42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99960; Ewsr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185243 CVCL_NY41 BayGenomics ES cell line RRY441 embryonic stem cell house mouse CVCL_NY41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100863; Kpna3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185244 CVCL_NY40 BayGenomics ES cell line RRY429 embryonic stem cell house mouse CVCL_NY40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185245 CVCL_NY59 BayGenomics ES cell line RRZ003 embryonic stem cell house mouse CVCL_NY59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349427; Exo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185246 CVCL_NY58 BayGenomics ES cell line RRY604 embryonic stem cell house mouse CVCL_NY58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185247 CVCL_NY57 BayGenomics ES cell line RRY587 embryonic stem cell house mouse CVCL_NY57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919293; Sulf2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185248 CVCL_NY56 BayGenomics ES cell line RRY581 embryonic stem cell house mouse CVCL_NY56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185249 CVCL_NY55 BayGenomics ES cell line RRY566 embryonic stem cell house mouse CVCL_NY55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443065; Agps Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185250 CVCL_NY54 BayGenomics ES cell line RRY563 embryonic stem cell house mouse CVCL_NY54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136459; Cdc42bpb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185251 CVCL_NY53 BayGenomics ES cell line RRY540 embryonic stem cell house mouse CVCL_NY53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349475; Ppp2r5c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185252 CVCL_NY52 BayGenomics ES cell line RRY535 embryonic stem cell house mouse CVCL_NY52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441730; Tbl1xr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185253 CVCL_NY51 BayGenomics ES cell line RRY496 embryonic stem cell house mouse CVCL_NY51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185254 CVCL_NY50 BayGenomics ES cell line RRY492 embryonic stem cell house mouse CVCL_NY50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917866; Sugp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185255 CVCL_NY29 BayGenomics ES cell line RRY310 embryonic stem cell house mouse CVCL_NY29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443034; Mtmr12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185256 CVCL_NY28 BayGenomics ES cell line RRY282 embryonic stem cell house mouse CVCL_NY28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185257 CVCL_NY27 BayGenomics ES cell line RRY279 embryonic stem cell house mouse CVCL_NY27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442860; Eda2r Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185258 CVCL_NY26 BayGenomics ES cell line RRY275 embryonic stem cell house mouse CVCL_NY26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913748; Dda1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185259 CVCL_NY25 BayGenomics ES cell line RRY272 embryonic stem cell house mouse CVCL_NY25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138327; Phlpp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185260 CVCL_NY24 BayGenomics ES cell line RRY265 embryonic stem cell house mouse CVCL_NY24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927616; Trps1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185261 CVCL_NY23 BayGenomics ES cell line RRY264 embryonic stem cell house mouse CVCL_NY23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914638; Rab5if Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185262 CVCL_NY22 BayGenomics ES cell line RRY262 embryonic stem cell house mouse CVCL_NY22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923864; Immt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185263 CVCL_NY21 BayGenomics ES cell line RRY261 embryonic stem cell house mouse CVCL_NY21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185264 CVCL_NY20 BayGenomics ES cell line RRY257 embryonic stem cell house mouse CVCL_NY20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354949; Dlc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185265 CVCL_NY39 BayGenomics ES cell line RRY422 embryonic stem cell house mouse CVCL_NY39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95886; H13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185266 CVCL_NY38 BayGenomics ES cell line RRY420 embryonic stem cell house mouse CVCL_NY38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95886; H13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185267 CVCL_NY37 BayGenomics ES cell line RRY414 embryonic stem cell house mouse CVCL_NY37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353561; Vapa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185268 CVCL_NY36 BayGenomics ES cell line RRY379 embryonic stem cell house mouse CVCL_NY36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444268; Fam169a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185269 CVCL_NY35 BayGenomics ES cell line RRY376 embryonic stem cell house mouse CVCL_NY35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3046173; Nup85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185270 CVCL_NY34 BayGenomics ES cell line RRY372 embryonic stem cell house mouse CVCL_NY34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3647820; Hectd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185271 CVCL_NY33 BayGenomics ES cell line RRY361 embryonic stem cell house mouse CVCL_NY33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107532; Kpnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185272 CVCL_NY32 BayGenomics ES cell line RRY357 embryonic stem cell house mouse CVCL_NY32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2180003; Xpnpep1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185273 CVCL_NY31 BayGenomics ES cell line RRY352 embryonic stem cell house mouse CVCL_NY31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136459; Cdc42bpb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185274 CVCL_NY30 BayGenomics ES cell line RRY338 embryonic stem cell house mouse CVCL_NY30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277958; Pcm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185275 CVCL_NY09 BayGenomics ES cell line RRY175 embryonic stem cell house mouse CVCL_NY09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104652; Capzb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185276 CVCL_NY08 BayGenomics ES cell line RRY158 embryonic stem cell house mouse CVCL_NY08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185277 CVCL_NY07 BayGenomics ES cell line RRY156 embryonic stem cell house mouse CVCL_NY07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm2393 (MGI:3780561) which is no longer considered a gene by MGI 21185278 CVCL_NY06 BayGenomics ES cell line RRY145 embryonic stem cell house mouse CVCL_NY06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103248; Phc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185279 CVCL_NY05 BayGenomics ES cell line RRY138 embryonic stem cell house mouse CVCL_NY05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2177178; Dicer1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185280 CVCL_NY04 BayGenomics ES cell line RRY135 embryonic stem cell house mouse CVCL_NY04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104537; Brca1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185281 CVCL_NY03 BayGenomics ES cell line RRY132 embryonic stem cell house mouse CVCL_NY03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448567; Chd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185282 CVCL_NY02 BayGenomics ES cell line RRY128 embryonic stem cell house mouse CVCL_NY02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185283 CVCL_NY01 BayGenomics ES cell line RRY122 embryonic stem cell house mouse CVCL_NY01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914917; Alkbh8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185284 CVCL_NY00 BayGenomics ES cell line RRY115 embryonic stem cell house mouse CVCL_NY00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859730; Sh3glb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185285 CVCL_NY19 BayGenomics ES cell line RRY252 embryonic stem cell house mouse CVCL_NY19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923012; Aftph Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185286 CVCL_NY18 BayGenomics ES cell line RRY250 embryonic stem cell house mouse CVCL_NY18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918625; Foxn3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185287 CVCL_NY17 BayGenomics ES cell line RRY240 embryonic stem cell house mouse CVCL_NY17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670178; Med13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185288 CVCL_NY16 BayGenomics ES cell line RRY226 embryonic stem cell house mouse CVCL_NY16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185289 CVCL_NY15 BayGenomics ES cell line RRY210 embryonic stem cell house mouse CVCL_NY15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185290 CVCL_NY14 BayGenomics ES cell line RRY209 embryonic stem cell house mouse CVCL_NY14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141161; Tyw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185291 CVCL_NY13 BayGenomics ES cell line RRY208 embryonic stem cell house mouse CVCL_NY13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95281; Ect2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185292 CVCL_NY12 BayGenomics ES cell line RRY185 embryonic stem cell house mouse CVCL_NY12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354755; Fbxo15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185293 CVCL_NY11 BayGenomics ES cell line RRY179 embryonic stem cell house mouse CVCL_NY11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925836; Srbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185294 CVCL_NY10 BayGenomics ES cell line RRY178 embryonic stem cell house mouse CVCL_NY10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103202; Adsl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185295 CVCL_WR49 19f induced pluripotent stem cell human CVCL_WR49 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24704492) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Female 21185296 CVCL_X349 GM02566 transformed cell line human CVCL_X349 CL:0000010 Population: Native Central American; Pima; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185297 CVCL_X348 GM02565 finite cell line human CVCL_X348 CL:0000010 Population: Native Central American; Pima; Derived from sampling site: Cell type=Fibroblast. Male 21185298 CVCL_WR48 M337V iPSC clone 2 induced pluripotent stem cell human CVCL_WR48 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Met337Val (c.1009A>G); ClinVar=VCV000005228; Zygosity=Heterozygous (PubMed=22451909) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185299 CVCL_X347 GM12015 transformed cell line human CVCL_X347 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185300 CVCL_WR47 M337V iPSC clone 1 induced pluripotent stem cell human CVCL_WR47 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Met337Val (c.1009A>G); ClinVar=VCV000005228; Zygosity=Heterozygous (PubMed=22451909) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185301 CVCL_WR46 ESIBIe003-A-5 embryonic stem cell human CVCL_WR46 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany. CL:0000010 Female 21185302 CVCL_X346 GM12014 finite cell line human CVCL_X346 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185303 CVCL_4L00 AG08553 finite cell line human CVCL_4L00 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185304 CVCL_4L04 AG08559 finite cell line human CVCL_4L04 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185305 CVCL_4L03 AG08558 transformed cell line human CVCL_4L03 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185306 CVCL_4L02 AG08557 finite cell line human CVCL_4L02 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185307 CVCL_4L01 AG08556 transformed cell line human CVCL_4L01 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185308 CVCL_X352 UWKOS3 cancer cell line dog CVCL_X352 CL:0000010 Derived from sampling site: Bone; proximal tibia; Breed/subspecies: Mastiff. Male 21185309 CVCL_WR52 VR-ALL cancer cell line human CVCL_WR52 CL:0000010 Sequence variation: Mutation; HGNC; 3386; EPHA2; Simple; p.Arg876His (c.2627G>A); ClinVar=VCV000259391; Zygosity=Heterozygous (Direct_author_submission); Sequence variation: Mutation; HGNC; 6188; JAG1; Simple; p.Pro871Arg (c.2612C>G); ClinVar=VCV000042475; Zygosity=Unspecified (PubMed=29719609); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Lys1821Asn; Zygosity=Heterozygous (Direct_author_submission); Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Val1952Met (c.5854G>A); ClinVar=VCV000256146; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: STR profile and sequence variation from personal communication of Kamga P.T Derived from sampling site: Bone marrow. Omics: Deep exome analysis Male Doubling time: ~56 hours (PubMed=29719609) 21185310 CVCL_WR51 T3-PA transformed cell line house mouse CVCL_WR51 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Obtained by intravenous injection of parent cell line (T2-A) in the tail vein of nude NIH Swiss mice and selection of cells from a lung metastasis 21185311 CVCL_X351 UWKOS2 cancer cell line dog CVCL_X351 CL:0000010 Derived from sampling site: Bone; proximal humerus; Breed/subspecies: Irish Terrier. Male 21185312 CVCL_WR50 RB8B induced pluripotent stem cell human CVCL_WR50 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=24704492) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Male 21185313 CVCL_X350 UWKOS1 cancer cell line dog CVCL_X350 CL:0000010 Derived from sampling site: Bone; proximal humerus; Breed/subspecies: Rottweiler. Female 21185314 CVCL_X356 BW1 cancer cell line house mouse CVCL_X356 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L/J. Characteristics: Established from a transplantable mouse hepatoma BW7756 21185315 CVCL_WR56 NAN-8 cancer cell line human CVCL_WR56 HLA typing: A*11:01,34:01; B*40:01,55:02; C*01:02,03:04 (Direct_author_submission) CL:0000010 Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Characteristics: Produces IgA; Characteristics: IL6 dependent 21185316 CVCL_WR55 NAN-11 cancer cell line human CVCL_WR55 HLA typing: A*01,11; B*13,27; C*02,06 (Direct_author_submission) CL:0000010 Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Characteristics: IL6 dependent 21185317 CVCL_X355 UWKOS8 cancer cell line dog CVCL_X355 CL:0000010 Derived from sampling site: Bone; distal radius; Breed/subspecies: Border Collie. Male 21185318 CVCL_WR54 NAN-10 cancer cell line human CVCL_WR54 HLA typing: A*01,02; B*08,15; C*03,07 (Direct_author_submission) CL:0000010 Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Characteristics: IL6 dependent 21185319 CVCL_X354 UWKOS7 cancer cell line dog CVCL_X354 CL:0000010 Derived from sampling site: Bone; distal radius; Breed/subspecies: German Shepherd. Female 21185320 CVCL_WR53 OSE-MG63 cancer cell line human CVCL_WR53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Bone; left femur. Male Characteristics: Transfected with a construct containing 6 tandem repeats of the osteoblastic specific element 2 (OSE2) and a minimal mOG2 promoter upstream of eGFP 21185321 CVCL_X353 UWKOS6 cancer cell line dog CVCL_X353 CL:0000010 Derived from sampling site: Bone; distal radius; Breed/subspecies: Labrador Retriever. Male 21185322 CVCL_WR38 CBMC iPSC #1 induced pluripotent stem cell human CVCL_WR38 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21185323 CVCL_X338 NT-1 [Human leukemia] cancer cell line human CVCL_X338 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Unspecified (PubMed=25012564) Population: Chinese; Derived from sampling site: Bone marrow. Female Doubling time: ~72 hours (PubMed=25012564) Caution: According to PubMed=25012564 the TP53 mutation is p.Pro215Arg; which does not correspond to the DNA sequence shown in figure 3 21185324 CVCL_WR37 SCZ#4-9 iPSC induced pluripotent stem cell human CVCL_WR37 From: CIBIO, University of Trento; Trento; Italy CL:0000010 Derived from sampling site: Peripheral blood. Male 21185325 CVCL_X337 SKMES-1-Taxotere cancer cell line human CVCL_X337 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Pleural effusion. Omics: Proteome analysis Male 21185326 CVCL_WR36 SCZ#3-4 iPSC induced pluripotent stem cell human CVCL_WR36 From: CIBIO, University of Trento; Trento; Italy CL:0000010 Derived from sampling site: Peripheral blood. Male 21185327 CVCL_X336 SKMES-1-Taxol cancer cell line human CVCL_X336 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu298Ter (c.892G>T); ClinVar=VCV000093323; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Omics: Proteome analysis Male 21185328 CVCL_WR35 CMC-hiPSC-013 induced pluripotent stem cell human CVCL_WR35 HLA typing: A*33:03; B*58:01; C*03:02; DPA1*01:03; DPB1*02:01,04:02; DQA1*01:01,01:02; DQB1*06:09; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 21185329 CVCL_X335 KB-CV60 cancer cell line human CVCL_X335 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21185330 CVCL_WR39 CBMC iPSC #2 induced pluripotent stem cell human CVCL_WR39 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21185331 CVCL_X339 OK [Sheep] finite cell line CVCL_X339 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6551; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185332 CVCL_4L11 AG08566 transformed cell line human CVCL_4L11 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185333 CVCL_4L10 AG08565 finite cell line human CVCL_4L10 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185334 CVCL_4L15 AG08597 finite cell line human CVCL_4L15 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21185335 CVCL_4L14 AG08596 transformed cell line human CVCL_4L14 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from autologous cell line AG08597) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185336 CVCL_4L13 AG08578 finite cell line human CVCL_4L13 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185337 CVCL_4L12 AG08567 finite cell line human CVCL_4L12 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185338 CVCL_4L08 AG08563 finite cell line human CVCL_4L08 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185339 CVCL_4L07 AG08562 transformed cell line human CVCL_4L07 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from autologous cell line AG08563) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185340 CVCL_4L06 AG08561 finite cell line human CVCL_4L06 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21185341 CVCL_4L05 AG08560 transformed cell line human CVCL_4L05 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185342 CVCL_4L09 AG08564 transformed cell line human CVCL_4L09 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185343 CVCL_X341 BM111 finite cell line CVCL_X341 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6029; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185344 CVCL_WR41 PBMC iPSC #1 induced pluripotent stem cell human CVCL_WR41 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Peripheral blood. Male 21185345 CVCL_X340 BM102 finite cell line CVCL_X340 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6028; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185346 CVCL_WR40 CBMC iPSC #3 induced pluripotent stem cell human CVCL_WR40 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21185347 CVCL_X345 #822 hybridoma house mouse CVCL_X345 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cronartium ribicola antigens. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12030 21185348 CVCL_WR45 INSRMi001-A induced pluripotent stem cell human CVCL_WR45 From: INSERM; Paris; France. CL:0000010 21185349 CVCL_X344 BM64 finite cell line CVCL_X344 CL:0000010 Derived from sampling site: Mammary gland. Female 21185350 CVCL_WR44 HL-60/AR cancer cell line human CVCL_WR44 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Anecdotal: Have been flown in space on shuttle flight STS-67 to study the effect of microgravity on multidrug resistance (PubMed=9434637) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:48120; Anthracycline; Derived from sampling site: Peripheral blood. Female Group: Space-flown cell line (cellonaut) Caution: Not to be confused with HL60/AR (Cellosaurus=CVCL_WI27) which is an 5-azacytidine resistant subline of HL-60 21185351 CVCL_X343 BM55 finite cell line CVCL_X343 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6027; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185352 CVCL_WR43 PBMC iPSC #3 induced pluripotent stem cell human CVCL_WR43 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Peripheral blood. Male 21185353 CVCL_X342 BM123 finite cell line CVCL_X342 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6030; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21185354 CVCL_WR42 PBMC iPSC #2 induced pluripotent stem cell human CVCL_WR42 From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Peripheral blood. Male 21185355 CVCL_WR27 CMC-hiPSC-005 induced pluripotent stem cell human CVCL_WR27 HLA typing: A*33:03; B*58:01; C*03:02; DPA1*01:03; DPB1*02:01,05:01; DQA1*02:01,01:02; DQB1*06:09; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female 21185356 CVCL_X327 GM05832 finite cell line human CVCL_X327 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185357 CVCL_WR26 CMC-hiPSC-004 induced pluripotent stem cell human CVCL_WR26 HLA typing: A*33:03; B*44:03; C*07:06; DPA1*02:02; DPB1*02:01,13:01; DQA1*02:01; DQB1*02:02; DRB1*07:01 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 21185358 CVCL_X326 GM05750 transformed cell line human CVCL_X326 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21185359 CVCL_WR25 CMC-hiPSC-002 induced pluripotent stem cell human CVCL_WR25 HLA typing: A*33:03; B*44:03; C*07:06; DPA1*02:01; DPB1*13:01; DQA1*02:01; DQB1*02:02; DRB1*07:01 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 21185360 CVCL_X325 GM05655 finite cell line human CVCL_X325 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(21)(21qter->21p11.2::6q22.2->6qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21185361 CVCL_WR24 CMC-hiPSC-001 induced pluripotent stem cell human CVCL_WR24 HLA typing: A*33:03; B*44:03; C*14:03; DPA1*01:03; DPB1*02:01,04:01; DQA1*01:01,01:02; DQB1*06:04; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Female 21185362 CVCL_X324 GM05401 finite cell line human CVCL_X324 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185363 CVCL_WR29 CMC-hiPSC-007 induced pluripotent stem cell human CVCL_WR29 HLA typing: A*02:01; B*48:01; C*14:54; DPA1*01:03; DPB1*02:01; DQA1*01:01,01:02; DQB1*05:02,05:03; DRB1*14:54 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Female 21185364 CVCL_X329 GM06033 finite cell line human CVCL_X329 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM06033; probable Female 21185365 CVCL_WR28 CMC-hiPSC-006 induced pluripotent stem cell human CVCL_WR28 HLA typing: A*33:03; B*44:03; C*07:06; DPA1*01:03; DPB1*04:01,13:01; DQA1*01:01,01:02; DQB1*02:02; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 21185366 CVCL_X328 GM05875 finite cell line human CVCL_X328 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185367 CVCL_NX89 BayGenomics ES cell line RRY030 embryonic stem cell house mouse CVCL_NX89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185368 CVCL_NX88 BayGenomics ES cell line RRY017 embryonic stem cell house mouse CVCL_NX88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926079; Tsc22d4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185369 CVCL_NX87 BayGenomics ES cell line RRY010 embryonic stem cell house mouse CVCL_NX87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109547; Dnm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185370 CVCL_NX86 BayGenomics ES cell line RRY002 embryonic stem cell house mouse CVCL_NX86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914037; Gskip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185371 CVCL_NX85 BayGenomics ES cell line RRX375 embryonic stem cell house mouse CVCL_NX85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385071; Etf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185372 CVCL_NX84 BayGenomics ES cell line RRX366 embryonic stem cell house mouse CVCL_NX84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933277; Gtf2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185373 CVCL_NX83 BayGenomics ES cell line RRX365 embryonic stem cell house mouse CVCL_NX83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185374 CVCL_NX82 BayGenomics ES cell line RRX358 embryonic stem cell house mouse CVCL_NX82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914320; Lsm14a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185375 CVCL_WR30 CMC-hiPSC-008 induced pluripotent stem cell human CVCL_WR30 HLA typing: A*33:03; B*44:03; C*14:03; DPA1*01:03; DPB1*04:01,13:01; DQA1*01:01,01:02; DQB1*06:04; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 21185376 CVCL_X330 GM06038 finite cell line human CVCL_X330 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185377 CVCL_NX81 BayGenomics ES cell line RRX352 embryonic stem cell house mouse CVCL_NX81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95304; Eif4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185378 CVCL_NX80 BayGenomics ES cell line RRX350 embryonic stem cell house mouse CVCL_NX80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102706; Fdft1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185379 CVCL_WR34 CMC-hiPSC-012 induced pluripotent stem cell human CVCL_WR34 HLA typing: A*33:03; B*58:01; C*03:02; DPA1*01:03; DPB1*05:01; DQA1*03:01; DQB1*06:09; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Female 21185380 CVCL_X334 GM03901 finite cell line human CVCL_X334 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg216Ter (c.646C>T); ClinVar=VCV000127312; Zygosity=Unspecified (Coriell) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185381 CVCL_WR33 CMC-hiPSC-011 induced pluripotent stem cell human CVCL_WR33 HLA typing: A*11:01; B*15:01; C*04:01; DPA1*01:03,02:01; DPB1*02:01; DQA1*01:01,01:02; DQB1*03:02; DRB1*04:06 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21185382 CVCL_X333 EPG85-257P cancer cell line human CVCL_X333 CL:0000010 Omics: Transcriptome analysis by microarray. 21185383 CVCL_WR32 CMC-hiPSC-010 induced pluripotent stem cell human CVCL_WR32 HLA typing: A*02:01; B*51:01; C*14:02; DPA1*02:02; DPB1*03:01,04:02; DQA1*01:01,01:02; DQB1*03:02; DRB1*04:03 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Male 21185384 CVCL_X332 GM06222 finite cell line human CVCL_X332 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185385 CVCL_WR31 CMC-hiPSC-009 induced pluripotent stem cell human CVCL_WR31 HLA typing: A*24:02; B*07:02; C*07:02; DPA1*01:03; DPB1*04:02; DQA1*03:01; DQB1*05:01; DRB1*01:01 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21185386 CVCL_X331 GM06136 transformed cell line human CVCL_X331 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21185387 CVCL_X316 GM05047 transformed cell line human CVCL_X316 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21185388 CVCL_WR16 KSCBi005-A-6 induced pluripotent stem cell human CVCL_WR16 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11849; TLR3 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Male 21185389 CVCL_X315 GM05009 finite cell line human CVCL_X315 CL:0000010 Population: Caucasian; Karyotypic information: 49,XXXXX [31]; 48,XXXX [15]; 48,XXXX,t(1;18)(1qter->1p36::18q21->18qter;18pter->18q21::1p36->1pter) [2]; 49,XXXXX,t(1;18)(1qter->1p36::18q21->18qter;18pter->18q21::1p36->1pter) [2] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185390 CVCL_WR15 KSCBi005-A-5 induced pluripotent stem cell human CVCL_WR15 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15632; TLR8 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Male 21185391 CVCL_X314 GM04993 finite cell line human CVCL_X314 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185392 CVCL_WR14 KSCBi005-A-4 induced pluripotent stem cell human CVCL_WR14 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15631; TLR7 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Male 21185393 CVCL_X313 GM04940 finite cell line human CVCL_X313 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(1)(pter->q25::q32->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185394 CVCL_WR13 KSCBi005-A-3 induced pluripotent stem cell human CVCL_WR13 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Omics: SNP array analysis Male Characteristics: Using CRISPR/Cas9 PDX1 has been endogenously tagged at the C-terminus with EGFP (PubMed=31683099) 21185395 CVCL_X319 GM05302 finite cell line human CVCL_X319 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(1)(pter->q41::q43->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185396 CVCL_WR19 KSCBi007-A induced pluripotent stem cell human CVCL_WR19 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21185397 CVCL_X318 GM05296 finite cell line human CVCL_X318 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,der(11)(11pter->11p13::10q21->10q24::11p13->11qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185398 CVCL_WR18 KSCBi006-A induced pluripotent stem cell human CVCL_WR18 HLA typing: A*24:02,24:02; B*15:01,54:01; DRB1*04:03,15:01 (PubMed=31715426) From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Gly1055Alafs*53 (c.3162delT); ClinVar=VCV000285398; Zygosity=Unspecified (PubMed=31715426) Population: Asian; Derived from sampling site: Peripheral blood. Male 21185399 CVCL_X317 GM05133 finite cell line human CVCL_X317 CL:0000010 Population: African American; Karyotypic information: 46,XY,der(14)(14qter->14p11.2::20p11.1->20pter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21185400 CVCL_WR17 KSCBi005-A-7 induced pluripotent stem cell human CVCL_WR17 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11848; TLR2 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Male 21185401 CVCL_NX99 BayGenomics ES cell line RRY107 embryonic stem cell house mouse CVCL_NX99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915723; Mob1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185402 CVCL_NX98 BayGenomics ES cell line RRY104 embryonic stem cell house mouse CVCL_NX98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916378; Zfp507 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185403 CVCL_NX97 BayGenomics ES cell line RRY092 embryonic stem cell house mouse CVCL_NX97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384560; Aars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185404 CVCL_NX96 BayGenomics ES cell line RRY091 embryonic stem cell house mouse CVCL_NX96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445019; Pik3c3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185405 CVCL_NX95 BayGenomics ES cell line RRY071 embryonic stem cell house mouse CVCL_NX95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107716; Myo10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185406 CVCL_NX94 BayGenomics ES cell line RRY069 embryonic stem cell house mouse CVCL_NX94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919891; Mob2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185407 CVCL_NX93 BayGenomics ES cell line RRY066 embryonic stem cell house mouse CVCL_NX93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145645; Exoc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185408 CVCL_NX92 BayGenomics ES cell line RRY061 embryonic stem cell house mouse CVCL_NX92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100846; Med1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185409 CVCL_NX91 BayGenomics ES cell line RRY059 embryonic stem cell house mouse CVCL_NX91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185410 CVCL_NX90 BayGenomics ES cell line RRY050 embryonic stem cell house mouse CVCL_NX90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929282; Ptges3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185411 CVCL_X323 GM05396 finite cell line human CVCL_X323 CL:0000010 Population: Caucasian; Karyotypic information: 45,X,dic(X;22)(p11;p12) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21185412 CVCL_WR23 KSCBi011-A induced pluripotent stem cell human CVCL_WR23 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 17877; NMNAT1; Simple; p.Arg237Cys (c.709C>T); ClinVar=VCV000845745; Zygosity=Homozygous (PubMed=32036247) Population: Korean; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21185413 CVCL_X322 GM05347 finite cell line human CVCL_X322 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185414 CVCL_WR22 KSCBi010-A induced pluripotent stem cell human CVCL_WR22 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 18340; WDR19; Simple; p.Arg1178Glu (c.3533G>A); Zygosity=Homozygous (PubMed=31734643) Population: Korean; Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 21185415 CVCL_X321 GM05336 finite cell line human CVCL_X321 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(4)(4qter->4p15::3p21.3->3pter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21185416 CVCL_WR21 KSCBi009-A induced pluripotent stem cell human CVCL_WR21 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 21185417 CVCL_X320 GM05319 finite cell line human CVCL_X320 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185418 CVCL_WR20 KSCBi008-A induced pluripotent stem cell human CVCL_WR20 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea. CL:0000010 21185419 CVCL_X305 GM04371 finite cell line human CVCL_X305 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185420 CVCL_WR05 INSRMi005-A induced pluripotent stem cell human CVCL_WR05 From: INSERM; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21185421 CVCL_X304 GM04370 finite cell line human CVCL_X304 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+der(22)(22pter->22q11::11q23->11qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185422 CVCL_WR04 INSRMi004-A induced pluripotent stem cell human CVCL_WR04 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg865Ter (c.2593C>T); ClinVar=VCV000189844; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21185423 CVCL_X303 GM04127 finite cell line human CVCL_X303 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21185424 CVCL_WR03 INSRMi003-A induced pluripotent stem cell human CVCL_WR03 From: INSERM; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21185425 CVCL_X302 GM04111 finite cell line human CVCL_X302 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,t(4;5)(4pter->4q31.1::5p15->5pter;5qter->5p15::4q31.1->4qter),del(21)(qter->p11) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185426 CVCL_WR02 INMi004-A induced pluripotent stem cell human CVCL_WR02 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 2383; CRX; Simple; p.Pro232Argfs*139 (c.695delC); ClinVar=VCV000191298; Zygosity=Heterozygous (PubMed=31247521) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185427 CVCL_X309 GM04610 finite cell line human CVCL_X309 CL:0000010 Karyotypic information: 47,XX,+8 [75]; 46,XX,+8,dic(14;21)(14qter->14p13::21p13->21qter) [25] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21185428 CVCL_WR09 KARO1 embryonic stem cell human CVCL_WR09 From: Karolinska Institutet; Stockholm; Sweden CL:0000010 Omics: Genome sequenced. Female Group: Clinical grade hESC cell line 21185429 CVCL_X308 GM04514 finite cell line human CVCL_X308 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185430 CVCL_WR08 IPTi001-A induced pluripotent stem cell human CVCL_WR08 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21185431 CVCL_X307 GM04435 finite cell line human CVCL_X307 CL:0000010 Derived from sampling site: Amnion. Omics: CNV analysis Ambiguous 21185432 CVCL_WR07 INSRMi007-A induced pluripotent stem cell human CVCL_WR07 From: INSERM; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21185433 CVCL_X306 GM04430 finite cell line human CVCL_X306 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185434 CVCL_WR06 INSRMi006-A induced pluripotent stem cell human CVCL_WR06 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 18423; DEPDC5; Simple; p.Glu1385Ter (c.4151_4152insC); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21185435 CVCL_NX69 BayGenomics ES cell line RRX150 embryonic stem cell house mouse CVCL_NX69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685992; Bclaf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185436 CVCL_NX68 BayGenomics ES cell line RRX144 embryonic stem cell house mouse CVCL_NX68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95792; Got2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185437 CVCL_NX67 BayGenomics ES cell line RRX137 embryonic stem cell house mouse CVCL_NX67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859661; Atp11c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185438 CVCL_NX66 BayGenomics ES cell line RRX136 embryonic stem cell house mouse CVCL_NX66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185439 CVCL_NX65 BayGenomics ES cell line RRX130 embryonic stem cell house mouse CVCL_NX65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313302; Cenpf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185440 CVCL_NX64 BayGenomics ES cell line RRX127 embryonic stem cell house mouse CVCL_NX64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1313291; Vezf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185441 CVCL_NX63 BayGenomics ES cell line RRX125 embryonic stem cell house mouse CVCL_NX63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185442 CVCL_NX62 BayGenomics ES cell line RRX123 embryonic stem cell house mouse CVCL_NX62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277223; Atxn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185443 CVCL_NX61 BayGenomics ES cell line RRX115 embryonic stem cell house mouse CVCL_NX61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442184; Flcn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185444 CVCL_NX60 BayGenomics ES cell line RRX108 embryonic stem cell house mouse CVCL_NX60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137512; Arid4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185445 CVCL_X312 GM04926 finite cell line human CVCL_X312 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185446 CVCL_WR12 KSCBi005-A-2 induced pluripotent stem cell human CVCL_WR12 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Male Characteristics: Using CRISPR/Cas9 SOX1 has been endogenously tagged at the C-terminus with EGFP 21185447 CVCL_X311 GM04627 finite cell line human CVCL_X311 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21185448 CVCL_WR11 KSCBi005-A-1 induced pluripotent stem cell human CVCL_WR11 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Omics: SNP array analysis Male Characteristics: Using CRISPR/Cas9 NES has been endogenously tagged at the C-terminus with EGFP (PubMed=31499408) 21185449 CVCL_WR10 CMC-hiPSC-003 induced pluripotent stem cell human CVCL_WR10 HLA typing: A*33:03; B*44:03; C*14:03; DPA1*01:03; DPB1*02:02,04:01; DQA1*01:01,01:02; DQB1*06:04; DRB1*13:02 (PubMed=28941241) From: Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow Cell type=Hematopoietic cell.. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male 21185450 CVCL_X310 GM04626 finite cell line human CVCL_X310 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Omics: CNV analysis; Omics: SNP array analysis Female 21185451 CVCL_NX79 BayGenomics ES cell line RRX349 embryonic stem cell house mouse CVCL_NX79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1352501; Bcar3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185452 CVCL_NX78 BayGenomics ES cell line RRX347 embryonic stem cell house mouse CVCL_NX78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916338; Snapc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185453 CVCL_NX77 BayGenomics ES cell line RRX343 embryonic stem cell house mouse CVCL_NX77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:700009; Sh3gl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185454 CVCL_NX76 BayGenomics ES cell line RRX337 embryonic stem cell house mouse CVCL_NX76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924367; Zfp934 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185455 CVCL_NX75 BayGenomics ES cell line RRX325 embryonic stem cell house mouse CVCL_NX75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2136825; N4bp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185456 CVCL_NX74 BayGenomics ES cell line RRX310 embryonic stem cell house mouse CVCL_NX74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926967; Hsd17b12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185457 CVCL_NX73 BayGenomics ES cell line RRX302 embryonic stem cell house mouse CVCL_NX73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1203484; Zfp638 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185458 CVCL_NX72 BayGenomics ES cell line RRX193 embryonic stem cell house mouse CVCL_NX72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185459 CVCL_NX71 BayGenomics ES cell line RRX169 embryonic stem cell house mouse CVCL_NX71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99887; Pitpna Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185460 CVCL_NX70 BayGenomics ES cell line RRX154 embryonic stem cell house mouse CVCL_NX70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922312; Sf3a3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185461 CVCL_X301 GM03935 finite cell line human CVCL_X301 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X)(q26) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21185462 CVCL_WR01 INMi003-A induced pluripotent stem cell human CVCL_WR01 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 2383; CRX; Simple; p.Arg41Trp (c.121C>T); ClinVar=VCV000007418; Zygosity=Heterozygous (PubMed=31203166) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185463 CVCL_X300 GM03810 finite cell line human CVCL_X300 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185464 CVCL_WR00 IGIBi001-A induced pluripotent stem cell human CVCL_WR00 From: Institute of Genomics and Integrative Biology (CSIR-IGIB); New Delhi; India CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=31255831) Population: Indian; Derived from sampling site: Peripheral blood. Male 21185465 CVCL_NX49 BayGenomics ES cell line RRU666 embryonic stem cell house mouse CVCL_NX49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351656; Abcf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185466 CVCL_NX48 BayGenomics ES cell line RRU665 embryonic stem cell house mouse CVCL_NX48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2141505; Parp11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185467 CVCL_NX47 BayGenomics ES cell line RRU661 embryonic stem cell house mouse CVCL_NX47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353606; Siva1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185468 CVCL_NX46 BayGenomics ES cell line RRU653 embryonic stem cell house mouse CVCL_NX46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109352; Ung Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185469 CVCL_NX45 BayGenomics ES cell line RRU652 embryonic stem cell house mouse CVCL_NX45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385325; Pnpla7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185470 CVCL_NX44 BayGenomics ES cell line RRU647 embryonic stem cell house mouse CVCL_NX44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929215; Vps41 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185471 CVCL_NX43 BayGenomics ES cell line RRU646 embryonic stem cell house mouse CVCL_NX43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444304; Vps13a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185472 CVCL_NX42 BayGenomics ES cell line RRU643 embryonic stem cell house mouse CVCL_NX42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915229; Atad1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185473 CVCL_NX41 BayGenomics ES cell line RRU637 embryonic stem cell house mouse CVCL_NX41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918079; Ccdc93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185474 CVCL_NX40 BayGenomics ES cell line RRU634 embryonic stem cell house mouse CVCL_NX40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185475 CVCL_NX59 BayGenomics ES cell line RRX085 embryonic stem cell house mouse CVCL_NX59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104899; Mob4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185476 CVCL_NX58 BayGenomics ES cell line RRX082 embryonic stem cell house mouse CVCL_NX58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103257; Inpp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185477 CVCL_NX57 BayGenomics ES cell line RRX078 embryonic stem cell house mouse CVCL_NX57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915205; Sugt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185478 CVCL_NX56 BayGenomics ES cell line RRX057 embryonic stem cell house mouse CVCL_NX56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95773; Gnai3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185479 CVCL_NX55 BayGenomics ES cell line RRX055 embryonic stem cell house mouse CVCL_NX55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109336; Etv6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185480 CVCL_NX54 BayGenomics ES cell line RRX045 embryonic stem cell house mouse CVCL_NX54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444918; Fbxo46 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185481 CVCL_NX53 BayGenomics ES cell line RRX032 embryonic stem cell house mouse CVCL_NX53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916241; Ssu72 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185482 CVCL_NX52 BayGenomics ES cell line RRX012 embryonic stem cell house mouse CVCL_NX52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185483 CVCL_NX51 BayGenomics ES cell line RRU671 embryonic stem cell house mouse CVCL_NX51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2681271; Pigl Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185484 CVCL_NX50 BayGenomics ES cell line RRU668 embryonic stem cell house mouse CVCL_NX50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185485 CVCL_4L80 AG09187 transformed cell line human CVCL_4L80 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185486 CVCL_4L84 AG09275 transformed cell line human CVCL_4L84 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185487 CVCL_4L83 AG09260 finite cell line human CVCL_4L83 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21185488 CVCL_4L82 AG09259 transformed cell line human CVCL_4L82 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185489 CVCL_4L81 AG09188 transformed cell line human CVCL_4L81 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185490 CVCL_4L88 AG09492 transformed cell line human CVCL_4L88 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185491 CVCL_4L87 AG09397 transformed cell line human CVCL_4L87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185492 CVCL_4L86 AG09396 transformed cell line human CVCL_4L86 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185493 CVCL_4L85 AG09315 transformed cell line human CVCL_4L85 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185494 CVCL_4L89 AG09493 transformed cell line human CVCL_4L89 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185495 CVCL_4L91 AG09525 transformed cell line human CVCL_4L91 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185496 CVCL_4L90 AG09524 transformed cell line human CVCL_4L90 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185497 CVCL_4L95 AG09530 transformed cell line human CVCL_4L95 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185498 CVCL_4L94 AG09529 transformed cell line human CVCL_4L94 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185499 CVCL_4L93 AG09527 transformed cell line human CVCL_4L93 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185500 CVCL_4L92 AG09526 transformed cell line human CVCL_4L92 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185501 CVCL_4L99 AG09798 transformed cell line human CVCL_4L99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185502 CVCL_4L98 AG09715 transformed cell line human CVCL_4L98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185503 CVCL_4L97 AG09714 transformed cell line human CVCL_4L97 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185504 CVCL_4L96 AG09710 transformed cell line human CVCL_4L96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185505 CVCL_4L62 AG09169 finite cell line human CVCL_4L62 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185506 CVCL_4L61 AG09167 finite cell line human CVCL_4L61 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21185507 CVCL_4L60 AG09166 transformed cell line human CVCL_4L60 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185508 CVCL_4L66 AG09173 finite cell line human CVCL_4L66 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185509 CVCL_4L65 AG09172 transformed cell line human CVCL_4L65 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185510 CVCL_4L64 AG09171 finite cell line human CVCL_4L64 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21185511 CVCL_4L63 AG09170 transformed cell line human CVCL_4L63 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185512 CVCL_4L69 AG09176 transformed cell line human CVCL_4L69 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185513 CVCL_4L68 AG09175 finite cell line human CVCL_4L68 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185514 CVCL_4L67 AG09174 transformed cell line human CVCL_4L67 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185515 CVCL_4L73 AG09180 transformed cell line human CVCL_4L73 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185516 CVCL_4L72 AG09179 finite cell line human CVCL_4L72 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG09179; probable Male Part of: German Alzheimer disease kindred subcollection 21185517 CVCL_4L71 AG09178 transformed cell line human CVCL_4L71 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185518 CVCL_4L70 AG09177 finite cell line human CVCL_4L70 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21185519 CVCL_4L77 AG09184 transformed cell line human CVCL_4L77 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185520 CVCL_4L76 AG09183 transformed cell line human CVCL_4L76 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21185521 CVCL_4L75 AG09182 transformed cell line human CVCL_4L75 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185522 CVCL_4L74 AG09181 finite cell line human CVCL_4L74 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21185523 CVCL_4L79 AG09186 transformed cell line human CVCL_4L79 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185524 CVCL_4L78 AG09185 transformed cell line human CVCL_4L78 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185525 CVCL_4L40 AG09021 finite cell line human CVCL_4L40 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185526 CVCL_4L44 AG09098 finite cell line human CVCL_4L44 CL:0000010 Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185527 CVCL_4L43 AG09097 transformed cell line human CVCL_4L43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185528 CVCL_4L42 AG09096 finite cell line human CVCL_4L42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG09096; probable Female 21185529 CVCL_4L41 AG09095 transformed cell line human CVCL_4L41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185530 CVCL_4L48 AG09106 transformed cell line human CVCL_4L48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185531 CVCL_4L47 AG09105 transformed cell line human CVCL_4L47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185532 CVCL_4L46 AG09104 transformed cell line human CVCL_4L46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185533 CVCL_4L45 AG09103 transformed cell line human CVCL_4L45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185534 CVCL_4L39 AG09019 finite cell line human CVCL_4L39 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185535 CVCL_4L38 AG08918 transformed cell line human CVCL_4L38 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185536 CVCL_X392 COLO 353 cancer cell line human CVCL_X392 CL:0000010 Unspecified 21185537 CVCL_WR92 LaNCE hiPSC-42 induced pluripotent stem cell human CVCL_WR92 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185538 CVCL_X391 COLO 527 cancer cell line human CVCL_X391 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E Derived from metastatic site: Bone. Male Caution: From a melanoma according to PubMed=6277475 and from a lung carcinoma according to archive documents of Moore G.E 21185539 CVCL_WR91 LaNCE hiPSC-41 induced pluripotent stem cell human CVCL_WR91 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185540 CVCL_X390 COLO 525 cancer cell line human CVCL_X390 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E Derived from metastatic site: Bone. Male Caution: From a melanoma according to PubMed=6277475 and from a lung carcinoma according to archive documents of Moore G.E 21185541 CVCL_WR90 LaNCE hiPSC-40 induced pluripotent stem cell human CVCL_WR90 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185542 CVCL_X396 COLO 511 cancer cell line human CVCL_X396 CL:0000010 Derived from metastatic site: Brain. Male 21185543 CVCL_WR96 LaNCE hiPSC-46 induced pluripotent stem cell human CVCL_WR96 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185544 CVCL_X395 COLO 509 cancer cell line human CVCL_X395 CL:0000010 Derived from metastatic site: Brain. Male 21185545 CVCL_WR95 LaNCE hiPSC-45 induced pluripotent stem cell human CVCL_WR95 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185546 CVCL_X394 COLO 338 cancer cell line human CVCL_X394 CL:0000010 Derived from metastatic site: Brain. Male 21185547 CVCL_WR94 LaNCE hiPSC-44 induced pluripotent stem cell human CVCL_WR94 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185548 CVCL_X393 COLO 534 cancer cell line human CVCL_X393 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E. Male 21185549 CVCL_WR93 LaNCE hiPSC-43 induced pluripotent stem cell human CVCL_WR93 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185550 CVCL_X399 COLO 463 cancer cell line human CVCL_X399 CL:0000010 Unspecified 21185551 CVCL_WR99 LaNCE hiPSC-50 induced pluripotent stem cell human CVCL_WR99 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185552 CVCL_X398 COLO 397 cancer cell line human CVCL_X398 CL:0000010 Unspecified 21185553 CVCL_WR98 LaNCE hiPSC-49 induced pluripotent stem cell human CVCL_WR98 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185554 CVCL_X397 COLO 293 cancer cell line human CVCL_X397 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E Derived from sampling site: Kidney. Male 21185555 CVCL_WR97 LaNCE hiPSC-47 induced pluripotent stem cell human CVCL_WR97 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185556 CVCL_X379 COLO 53 cancer cell line human CVCL_X379 CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Derived from metastatic site: Not specified. Female 21185557 CVCL_WR79 LaNCE hiPSC-26 induced pluripotent stem cell human CVCL_WR79 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185558 CVCL_4L51 AG09109 transformed cell line human CVCL_4L51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185559 CVCL_4L50 AG09108 transformed cell line human CVCL_4L50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185560 CVCL_4L55 AG09122 transformed cell line human CVCL_4L55 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male 21185561 CVCL_4L54 AG09121 transformed cell line human CVCL_4L54 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male 21185562 CVCL_4L53 AG09120 transformed cell line human CVCL_4L53 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female 21185563 CVCL_4L52 AG09119 transformed cell line human CVCL_4L52 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185564 CVCL_4L59 AG09126 transformed cell line human CVCL_4L59 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185565 CVCL_4L58 AG09125 transformed cell line human CVCL_4L58 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male 21185566 CVCL_4L57 AG09124 transformed cell line human CVCL_4L57 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185567 CVCL_4L56 AG09123 transformed cell line human CVCL_4L56 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female 21185568 CVCL_4L49 AG09107 transformed cell line human CVCL_4L49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185569 CVCL_X381 COLO 103 cancer cell line human CVCL_X381 CL:0000010 Derived from metastatic site: Not specified. Male 21185570 CVCL_WR81 LaNCE hiPSC-28 induced pluripotent stem cell human CVCL_WR81 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185571 CVCL_X380 COLO 55 cancer cell line human CVCL_X380 CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Derived from metastatic site: Not specified. Female 21185572 CVCL_WR80 LaNCE hiPSC-27 induced pluripotent stem cell human CVCL_WR80 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185573 CVCL_X385 COLO 349 cancer cell line human CVCL_X385 CL:0000010 Miscellaneous: Sex of donor from archive documents of Moore G.E. Male 21185574 CVCL_WR85 LaNCE hiPSC-32 induced pluripotent stem cell human CVCL_WR85 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185575 CVCL_X384 COLO 381 cancer cell line human CVCL_X384 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E. Male 21185576 CVCL_WR84 LaNCE hiPSC-31 induced pluripotent stem cell human CVCL_WR84 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185577 CVCL_X383 COLO 324 cancer cell line human CVCL_X383 CL:0000010 Unspecified 21185578 CVCL_WR83 LaNCE hiPSC-30 induced pluripotent stem cell human CVCL_WR83 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185579 CVCL_X382 COLO 297F cancer cell line human CVCL_X382 CL:0000010 Unspecified 21185580 CVCL_WR82 LaNCE hiPSC-29 induced pluripotent stem cell human CVCL_WR82 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185581 CVCL_X389 COLO 368 cancer cell line human CVCL_X389 CL:0000010 Miscellaneous: Sex of donor from archive documents of Moore G.E Derived from metastatic site: Bone. Male 21185582 CVCL_WR89 LaNCE hiPSC-39 induced pluripotent stem cell human CVCL_WR89 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185583 CVCL_X388 COLO 298 cancer cell line human CVCL_X388 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E. Female 21185584 CVCL_WR88 LaNCE hiPSC-38 induced pluripotent stem cell human CVCL_WR88 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185585 CVCL_X387 COLO 417 cancer cell line human CVCL_X387 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E. Male 21185586 CVCL_WR87 LaNCE hiPSC-34 induced pluripotent stem cell human CVCL_WR87 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185587 CVCL_X386 COLO 415 cancer cell line human CVCL_X386 CL:0000010 Miscellaneous: Age/sex of donor from archive documents of Moore G.E. Female 21185588 CVCL_WR86 LaNCE hiPSC-33 induced pluripotent stem cell human CVCL_WR86 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185589 CVCL_WR69 LaNCE hiPSC-12 induced pluripotent stem cell human CVCL_WR69 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185590 CVCL_X369 UM112-1 PGD embryonic stem cell human CVCL_X369 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM112-2 PGD (Cellosaurus=CVCL_Z077). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0285 21185591 CVCL_WR68 LaNCE hiPSC-09 induced pluripotent stem cell human CVCL_WR68 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185592 CVCL_X368 UM114-10 embryonic stem cell human CVCL_X368 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0290. 21185593 CVCL_4L22 AG08657 transformed cell line human CVCL_4L22 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185594 CVCL_4L21 AG08656 transformed cell line human CVCL_4L21 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185595 CVCL_4L20 AG08655 transformed cell line human CVCL_4L20 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185596 CVCL_4L26 AG08836 transformed cell line human CVCL_4L26 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185597 CVCL_4L25 AG08744 transformed cell line human CVCL_4L25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185598 CVCL_4L24 AG08659 transformed cell line human CVCL_4L24 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185599 CVCL_4L23 AG08658 transformed cell line human CVCL_4L23 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185600 CVCL_4L19 AG08654 transformed cell line human CVCL_4L19 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185601 CVCL_4L18 AG08653 transformed cell line human CVCL_4L18 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185602 CVCL_4L17 AG08620 finite cell line human CVCL_4L17 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185603 CVCL_4L16 AG08619 transformed cell line human CVCL_4L16 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185604 CVCL_X370 IMA 2.1 transformed cell line house mouse CVCL_X370 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Sex of donor and STR profile from personal communication of Gemma R.-T Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: BALB/c. Male 21185605 CVCL_WR70 LaNCE hiPSC-15 induced pluripotent stem cell human CVCL_WR70 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185606 CVCL_WR74 LaNCE hiPSC-20 induced pluripotent stem cell human CVCL_WR74 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185607 CVCL_X374 MMH-D3 spontaneously immortalized cell line house mouse CVCL_X374 CL:0000010 Transfected with: HGNC; 7029; MET (with p.Met1_Leu955del = cyto-Met) Derived from sampling site: Liver Cell type=Hepatocyte.. Unspecified 21185608 CVCL_X373 IAC transformed cell line Norway rat CVCL_X373 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: Sprague Dawley. 21185609 CVCL_WR73 LaNCE hiPSC-18 induced pluripotent stem cell human CVCL_WR73 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185610 CVCL_WR72 LaNCE hiPSC-17 induced pluripotent stem cell human CVCL_WR72 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185611 CVCL_X372 STA spontaneously immortalized cell line CVCL_X372 CL:0000010 Derived from sampling site: Carotid artery. Unspecified Virology: Susceptible to infection by soft-shelled turtle iridovirus (STIV) Group: Reptilian cell line 21185612 CVCL_X371 A735 transformed cell line human CVCL_X371 CL:0000010 Transformant: Simian virus 40 (SV40) [p375.6](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 21185613 CVCL_WR71 LaNCE hiPSC-16 induced pluripotent stem cell human CVCL_WR71 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185614 CVCL_X378 COLO 52 cancer cell line human CVCL_X378 CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Derived from metastatic site: Not specified. Female 21185615 CVCL_WR78 LaNCE hiPSC-24 induced pluripotent stem cell human CVCL_WR78 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185616 CVCL_X377 COLO 93 cancer cell line human CVCL_X377 CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Derived from metastatic site: Not specified. Female 21185617 CVCL_WR77 LaNCE hiPSC-23 induced pluripotent stem cell human CVCL_WR77 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185618 CVCL_WR76 LaNCE hiPSC-22 induced pluripotent stem cell human CVCL_WR76 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185619 CVCL_X376 RPMI-8372 cancer cell line human CVCL_X376 CL:0000010 Derived from metastatic site: Lymph node. Male 21185620 CVCL_WR75 LaNCE hiPSC-21 induced pluripotent stem cell human CVCL_WR75 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185621 CVCL_X375 RPMI-8362 cancer cell line human CVCL_X375 CL:0000010 Derived from metastatic site: Lymph node. Male 21185622 CVCL_X359 H5D.61 cancer cell line Norway rat CVCL_X359 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver. 21185623 CVCL_WR59 LUMCi007-A induced pluripotent stem cell human CVCL_WR59 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=31326748) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185624 CVCL_X358 H4AzC2 cancer cell line Norway rat CVCL_X358 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21185625 CVCL_WR58 NAN-7 cancer cell line human CVCL_WR58 HLA typing: A*03; B*07; C*07 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Characteristics: IL6 dependent 21185626 CVCL_X357 BW2 cancer cell line house mouse CVCL_X357 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: C57L/J. Characteristics: Established from a transplantable mouse hepatoma BW7756 21185627 CVCL_WR57 NAN-9 cancer cell line human CVCL_WR57 HLA typing: A*01:01,24:02; B*08:01,15:24; C*03:03,07:01 (Direct_author_submission) CL:0000010 Miscellaneous: Age at sampling and HLA typing from personal communication of Pellat-Deceunynck C Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Characteristics: Produces IgA; Characteristics: IL6 dependent 21185628 CVCL_4L33 AG08846 transformed cell line human CVCL_4L33 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185629 CVCL_4L32 AG08845 transformed cell line human CVCL_4L32 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185630 CVCL_4L31 AG08844 transformed cell line human CVCL_4L31 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185631 CVCL_4L30 AG08843 transformed cell line human CVCL_4L30 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185632 CVCL_4L37 AG08900 transformed cell line human CVCL_4L37 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185633 CVCL_4L36 AG08899 transformed cell line human CVCL_4L36 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185634 CVCL_4L35 AG08897 transformed cell line human CVCL_4L35 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185635 CVCL_4L34 AG08847 transformed cell line human CVCL_4L34 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185636 CVCL_4L29 AG08842 transformed cell line human CVCL_4L29 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185637 CVCL_4L28 AG08839 transformed cell line human CVCL_4L28 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185638 CVCL_4L27 AG08838 transformed cell line human CVCL_4L27 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185639 CVCL_WR63 LUMCi008-C induced pluripotent stem cell human CVCL_WR63 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=31326748) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185640 CVCL_X363 UM78-2 embryonic stem cell human CVCL_X363 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0288 21185641 CVCL_WR62 LUMCi008-B induced pluripotent stem cell human CVCL_WR62 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=31326748) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185642 CVCL_X362 UM76-1 PGS embryonic stem cell human CVCL_X362 From: University of Michigan; Ann Arbor; USA CL:0000010 Karyotypic information: 45,XX,der(13;14)(q10;q10) (NIHhESC); Donor information: Embryo is sibling to that giving rise to UM76-2 (Cellosaurus=CVCL_5H68). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0289 21185643 CVCL_X361 FHK-78 undefined cell line type CVCL_X361 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21185644 CVCL_WR61 LUMCi008-A induced pluripotent stem cell human CVCL_WR61 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=31326748) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185645 CVCL_X360 H5D.7 cancer cell line Norway rat CVCL_X360 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver. 21185646 CVCL_WR60 LUMCi007-B induced pluripotent stem cell human CVCL_WR60 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=31326748) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185647 CVCL_WR67 LaNCE hiPSC-08 induced pluripotent stem cell human CVCL_WR67 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21185648 CVCL_X367 UM121-7 embryonic stem cell human CVCL_X367 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0291 21185649 CVCL_WR66 LaNCE hiPSC-07 induced pluripotent stem cell human CVCL_WR66 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Female 21185650 CVCL_X366 UM139-2 PGD embryonic stem cell human CVCL_X366 From: University of Michigan; Ann Arbor; USA CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0292 21185651 CVCL_WR65 LUMCi010-A induced pluripotent stem cell human CVCL_WR65 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 171; ACVR1; Simple; p.Arg206His (c.617G>A); ClinVar=VCV000018309; Zygosity=Heterozygous (PubMed=31733439) Population: Caucasian; Derived from sampling site: Tooth; periodontal ligament. Female 21185652 CVCL_X365 UM134-1 PGD embryonic stem cell human CVCL_X365 From: University of Michigan; Ann Arbor; USA CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[70]; Zygosity=Heterozygous; Note=The other allele has 13 repeats (PubMed=31374463; PubMed=35952620). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0286 21185653 CVCL_WR64 LUMCi009-A induced pluripotent stem cell human CVCL_WR64 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Tooth; periodontal ligament. Female 21185654 CVCL_X364 UM90-12 PGS embryonic stem cell human CVCL_X364 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM90-14 PGD (Cellosaurus=CVCL_Z075). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0287 21185655 CVCL_FA52 ND10079 transformed cell line human CVCL_FA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185656 CVCL_FA51 ND09860 transformed cell line human CVCL_FA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185657 CVCL_FA50 ND09820 transformed cell line human CVCL_FA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185658 CVCL_FA56 ND10228 transformed cell line human CVCL_FA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185659 CVCL_FA55 ND10158 transformed cell line human CVCL_FA55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185660 CVCL_FA54 ND10100 transformed cell line human CVCL_FA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185661 CVCL_FA53 ND10093 transformed cell line human CVCL_FA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185662 CVCL_FA49 ND09552 transformed cell line human CVCL_FA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185663 CVCL_FA48 ND13004 transformed cell line human CVCL_FA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185664 CVCL_FA47 ND12803 transformed cell line human CVCL_FA47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185665 CVCL_FA46 ND12806 transformed cell line human CVCL_FA46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185666 CVCL_FA63 ND10493 transformed cell line human CVCL_FA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185667 CVCL_FA62 ND10490 transformed cell line human CVCL_FA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185668 CVCL_FA61 ND10489 transformed cell line human CVCL_FA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185669 CVCL_FA60 ND10488 transformed cell line human CVCL_FA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185670 CVCL_FA67 ND10642 transformed cell line human CVCL_FA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185671 CVCL_FA66 ND10553 transformed cell line human CVCL_FA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185672 CVCL_FA65 ND10551 transformed cell line human CVCL_FA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185673 CVCL_FA64 ND10494 transformed cell line human CVCL_FA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185674 CVCL_FA59 ND10484 transformed cell line human CVCL_FA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185675 CVCL_FA58 ND10482 transformed cell line human CVCL_FA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185676 CVCL_FA57 ND10449 transformed cell line human CVCL_FA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185677 CVCL_FA30 COS-1/B2T.cl.17 transformed cell line CVCL_FA30 CL:0000010 Transfected with: HGNC; 17755; TNFRSF13C (region 1-78); Transfected with: HGNC; 11916; TNFRSF1A (region 204-443) Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Characteristics: Transfected with a TNFRSF13C-TNFRSF1A (BAFFR-TNFR1) hybrid receptor containing the extracellular BAFF-binding portion of the TNFRSF13C and the intracellular signaling portion of TNFRSF1A Group: Non-human primate cell line 21185678 CVCL_FA34 GM06921 transformed cell line human CVCL_FA34 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185679 CVCL_FA33 GM06830 transformed cell line human CVCL_FA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185680 CVCL_FA32 GM02814 finite cell line human CVCL_FA32 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185681 CVCL_FA31 ND00716 transformed cell line human CVCL_FA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185682 CVCL_FA27 FOS_1140 cancer cell line CVCL_FA27 CL:0000010 Derived from sampling site: Bone; tibia; Breed/subspecies: Domestic shorthair. Male 21185683 CVCL_FA26 FOS_1077 cancer cell line CVCL_FA26 CL:0000010 Derived from sampling site: Bone; rib; Breed/subspecies: Domestic shorthair. Female 21185684 CVCL_FA25 COS_1033 cancer cell line dog CVCL_FA25 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: Boxer. Female 21185685 CVCL_FA24 COS_1220 cancer cell line dog CVCL_FA24 CL:0000010 Derived from sampling site: Bone; radius; Breed/subspecies: Boxer. Female 21185686 CVCL_FA29 HaCaT HSP70B'-GFP reporter spontaneously immortalized cell line human CVCL_FA29 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Stably expresses GFP under the control of the stress-inducible HSPA6 (HSP70B') promoter; Characteristics: Used as a sensor cell line to quantify skin response upon exposure to chemical substances that are known to cause irritation or allergies through the generation of reactive oxygen species 21185687 CVCL_FA28 WG-59 transformed cell line human CVCL_FA28 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; tunica media Cell type=Vascular associated smooth muscle cell.. Male 21185688 CVCL_FA41 GM14554 transformed cell line human CVCL_FA41 CL:0000010 Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Asn792Ser (c.2375A>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185689 CVCL_FA40 GM14553 finite cell line human CVCL_FA40 CL:0000010 Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Tyr312Ter (c.936T>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3356; ENPP1; Simple; p.Asn792Ser (c.2375A>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185690 CVCL_FA45 ND12805 transformed cell line human CVCL_FA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185691 CVCL_FA44 GM16534 transformed cell line human CVCL_FA44 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala76Cysfs*64 (c.225_243del19) (p.Arg90Valfs*76, c.268_286del19) (p16-Leiden); ClinVar=VCV000182411; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185692 CVCL_FA43 GM16533 transformed cell line human CVCL_FA43 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala76Cysfs*64 (c.225_243del19) (p.Arg90Valfs*76, c.268_286del19) (p16-Leiden); ClinVar=VCV000182411; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185693 CVCL_FA42 GM16532 transformed cell line human CVCL_FA42 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ile49Thr (c.146T>C); ClinVar=VCV000127523; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185694 CVCL_FA38 GM10407 finite cell line human CVCL_FA38 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Male 21185695 CVCL_FA37 GM10274 finite cell line human CVCL_FA37 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185696 CVCL_FA36 GM10273 transformed cell line human CVCL_FA36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185697 CVCL_FA35 GM10272 transformed cell line human CVCL_FA35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185698 CVCL_FA39 GM10634 finite cell line human CVCL_FA39 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185699 CVCL_FA12 DLC 01 cancer cell line dog CVCL_FA12 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Mixed breed. Male Virology: Infected by a retrovirus called DLCV-1 Doubling time: 24 hours (PubMed=10450758) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2200 21185700 CVCL_FA11 CLB70 cancer cell line dog CVCL_FA11 CL:0000010 Derived from sampling site: Submandibular lymph node; Breed/subspecies: Shih Tzu. Female Doubling time: ~28 hours (PubMed=27506920) 21185701 CVCL_FA10 OS 179 cancer cell line human CVCL_FA10 CL:0000010 21185702 CVCL_FA05 TALS9-12.3 induced pluripotent stem cell human CVCL_FA05 From: Target ALS Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185703 CVCL_FA04 TALS9-11.2 induced pluripotent stem cell human CVCL_FA04 From: Target ALS Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease (mutation in C9orf72); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185704 CVCL_FA03 TALSTDP-47.10 induced pluripotent stem cell human CVCL_FA03 From: Target ALS Foundation; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185705 CVCL_FA02 TALSSPO21.21 induced pluripotent stem cell human CVCL_FA02 From: Target ALS Foundation; New York; USA CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185706 CVCL_FA09 COL [Human neuroblastoma] cancer cell line human CVCL_FA09 CL:0000010 Problematic cell line: Misclassified Originally thought to originate from an osteosarcoma and is now identified as a neuroblastoma cell line (PubMed=22415601; PubMed=24046071).. 21185707 CVCL_FA08 HNE-3 cancer cell line human CVCL_FA08 CL:0000010 Population: Chinese Virology: EBV-negative. 21185708 CVCL_FA07 HNE-2 cancer cell line human CVCL_FA07 CL:0000010 Omics: Transcriptome analysis by RNAseq. Problematic cell line: Possibly contaminated The STR profile is very similar to that of the HeLa cell line and almost identical to that of HNE-1 (Cellosaurus=CVCL_0308). 21185709 CVCL_FA06 TALSSOD1A4V-39.7 induced pluripotent stem cell human CVCL_FA06 From: Target ALS Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185710 CVCL_FA23 COS_1189 cancer cell line dog CVCL_FA23 CL:0000010 Derived from sampling site: Bone; humerus; Breed/subspecies: Mixed breed. Male 21185711 CVCL_FA22 COS_1186w cancer cell line dog CVCL_FA22 CL:0000010 Derived from sampling site: Bone; scapula; Breed/subspecies: Dachshund. Male 21185712 CVCL_FA21 COS_1186h cancer cell line dog CVCL_FA21 CL:0000010 Derived from sampling site: Bone; scapula; Breed/subspecies: Dachshund. Male 21185713 CVCL_FA20 CHKS-4 cancer cell line dog CVCL_FA20 CL:0000010 Breed/subspecies: Pomeranian. Male Doubling time: 35 hours (PubMed=16678911) 21185714 CVCL_FA16 Yamada undefined cell line type house mouse CVCL_FA16 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00445. Problematic cell line: Misidentified Originally thought to be an osteosarcoma cell line of dog origin but found to be from mouse (PubMed=21908323). 21185715 CVCL_FA15 Hepa-RP3 cancer cell line human CVCL_FA15 CL:0000010 Derived from sampling site: Liver. Female 21185716 CVCL_FA14 Hepa-SC cancer cell line human CVCL_FA14 CL:0000010 Derived from sampling site: Liver. Female Characteristics: Has stem-like cell properties Can be differentiated/reprogrammed using mechanical stress and in the presence of at least one differentiation factor. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4980 21185717 CVCL_FA13 DLC 02 cancer cell line dog CVCL_FA13 CL:0000010 Derived from sampling site: Peripheral blood; Breed/subspecies: Siberian Husky. Female 21185718 CVCL_FA19 CHKS-3 cancer cell line dog CVCL_FA19 CL:0000010 Breed/subspecies: Pomeranian. Male Doubling time: 36 hours (PubMed=16678911) 21185719 CVCL_FA18 CHKS-2 cancer cell line dog CVCL_FA18 CL:0000010 Breed/subspecies: Pomeranian. Male Doubling time: 45 hours (PubMed=16678911) 21185720 CVCL_FA17 CHKS-1 cancer cell line dog CVCL_FA17 CL:0000010 Breed/subspecies: Pomeranian. Male Doubling time: 21 hours (PubMed=16678911) 21185721 CVCL_FA01 TALSSPO16.2 induced pluripotent stem cell human CVCL_FA01 From: Target ALS Foundation; New York; USA CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185722 CVCL_FA00 TALSCTRL15.12 induced pluripotent stem cell human CVCL_FA00 From: Target ALS Foundation; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185723 CVCL_WT03 NUIGi010-B induced pluripotent stem cell human CVCL_WT03 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185724 CVCL_X503 U-2946 cancer cell line human CVCL_X503 HLA typing: A*01:01:01,02:01:01; B*35:01:01,52:01:01; C*04:01:01,12:02:02; DPA1*01:03:01,01:03:01; DPB1*04:02:01,02:01:02; DQA1*01:03:01,01:01:01; DQB1*05:01:01,06:01:01; DRA*01:01:01,01:02:02; DRB1*01:01:01,15:02:01 (DSMZCellDive=ACC-795) CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=31160637) Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=27907212); ~20-30 hours (DSMZ=ACC-795) Part of: LL-100 blood cancer cell line panel 21185725 CVCL_WT02 NUIGi010-A induced pluripotent stem cell human CVCL_WT02 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185726 CVCL_X502 OV25R cancer cell line human CVCL_X502 CL:0000010 Derived from metastatic site: Ascites. Female 21185727 CVCL_X501 BT142 mut/- cancer cell line human CVCL_X501 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Homozygous (PubMed=22166263) Population: Caucasian; Derived from sampling site: Brain; left frontal lobe. Male Group: Cancer stem cell line 21185728 CVCL_WT01 NUIGi009-C induced pluripotent stem cell human CVCL_WT01 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185729 CVCL_X500 ATCC-HYS0103 induced pluripotent stem cell human CVCL_X500 CL:0000010 Population: Hispanic; Derived from sampling site: Liver Cell type=Fibroblast.. Male 21185730 CVCL_WT00 NUIGi009-B induced pluripotent stem cell human CVCL_WT00 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185731 CVCL_WT07 NUIGi011-C induced pluripotent stem cell human CVCL_WT07 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185733 CVCL_X506 NCC021 cancer cell line human CVCL_X506 Genome ancestry: African=0.31%; Native American=0.02%; East Asian, North=27.12%; East Asian, South=71.39%; South Asian=1.05%; European, North=0%; European, South=0.12% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21185734 CVCL_WT06 NUIGi011-B induced pluripotent stem cell human CVCL_WT06 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185735 CVCL_X505 NCC010 cancer cell line human CVCL_X505 Genome ancestry: African=0%; Native American=0%; East Asian, North=22.3%; East Asian, South=77.7%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21185736 CVCL_WT05 NUIGi011-A induced pluripotent stem cell human CVCL_WT05 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21185737 CVCL_WT04 NUIGi010-C induced pluripotent stem cell human CVCL_WT04 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185738 CVCL_X504 U-2904 cancer cell line human CVCL_X504 CL:0000010 Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, centroblastic-type Derived from sampling site: Pleural effusion. Omics: Deep exome analysis Male Doubling time: 24 hours (PubMed=7591289); ~25-35 hours (DSMZ=ACC-768) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21185739 CVCL_X509 MEC-HH finite cell line CVCL_X509 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Chinese Holstein. Female 21185740 CVCL_WT09 OSRi005-A induced pluripotent stem cell human CVCL_WT09 From: Ospedale San Raffaele; Milan; Italy. CL:0000010 Male 21185741 CVCL_WT08 NUIGi022-A induced pluripotent stem cell human CVCL_WT08 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21185742 CVCL_X508 STS-0421 cancer cell line human CVCL_X508 Genome ancestry: African=0.99%; Native American=0.12%; East Asian, North=0.8%; East Asian, South=0%; South Asian=1.87%; European, North=67.02%; European, South=29.19% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21185743 CVCL_NZ69 BayGenomics ES cell line RRZ683 embryonic stem cell house mouse CVCL_NZ69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858230; Sart3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185744 CVCL_NZ68 BayGenomics ES cell line RRZ679 embryonic stem cell house mouse CVCL_NZ68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3645888; Gm6712 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185745 CVCL_NZ67 BayGenomics ES cell line RRZ678 embryonic stem cell house mouse CVCL_NZ67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185746 CVCL_NZ66 BayGenomics ES cell line RRZ673 embryonic stem cell house mouse CVCL_NZ66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918084; Spag9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185747 CVCL_NZ65 BayGenomics ES cell line RRZ672 embryonic stem cell house mouse CVCL_NZ65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95640; Gapdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185748 CVCL_NZ64 BayGenomics ES cell line RRZ670 embryonic stem cell house mouse CVCL_NZ64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196624; Tcea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185749 CVCL_NZ63 BayGenomics ES cell line RRZ668 embryonic stem cell house mouse CVCL_NZ63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138605; Rabif Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185750 CVCL_NZ62 BayGenomics ES cell line RRZ663 embryonic stem cell house mouse CVCL_NZ62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344415; Dmtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185751 CVCL_NZ61 BayGenomics ES cell line RRZ657 embryonic stem cell house mouse CVCL_NZ61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916214; Ctc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185752 CVCL_NZ60 BayGenomics ES cell line RRZ655 embryonic stem cell house mouse CVCL_NZ60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914454; Eif2s2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185753 CVCL_X510 MEC-LL finite cell line CVCL_X510 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Chinese Holstein. Female 21185754 CVCL_WT10 OSRi006-A induced pluripotent stem cell human CVCL_WT10 From: Ospedale San Raffaele; Milan; Italy. CL:0000010 21185755 CVCL_NZ79 BayGenomics ES cell line RST008 embryonic stem cell house mouse CVCL_NZ79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2157953; Rbm39 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185756 CVCL_NZ78 BayGenomics ES cell line RST007 embryonic stem cell house mouse CVCL_NZ78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185757 CVCL_NZ77 BayGenomics ES cell line RST005 embryonic stem cell house mouse CVCL_NZ77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185758 CVCL_NZ76 BayGenomics ES cell line RRZ714 embryonic stem cell house mouse CVCL_NZ76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915446; Hsbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185759 CVCL_NZ75 BayGenomics ES cell line RRZ713 embryonic stem cell house mouse CVCL_NZ75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185760 CVCL_NZ74 BayGenomics ES cell line RRZ712 embryonic stem cell house mouse CVCL_NZ74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918073; Hmgxb4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185761 CVCL_NZ73 BayGenomics ES cell line RRZ702 embryonic stem cell house mouse CVCL_NZ73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102657; Cdc34 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185762 CVCL_NZ72 BayGenomics ES cell line RRZ700 embryonic stem cell house mouse CVCL_NZ72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926609; Trp53inp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185763 CVCL_NZ71 BayGenomics ES cell line RRZ699 embryonic stem cell house mouse CVCL_NZ71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915035; Zmym4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185764 CVCL_NZ70 BayGenomics ES cell line RRZ698 embryonic stem cell house mouse CVCL_NZ70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670969; Nrde2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185765 CVCL_NZ49 BayGenomics ES cell line RRZ587 embryonic stem cell house mouse CVCL_NZ49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109339; Eya3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185766 CVCL_NZ48 BayGenomics ES cell line RRZ586 embryonic stem cell house mouse CVCL_NZ48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185767 CVCL_NZ47 BayGenomics ES cell line RRZ579 embryonic stem cell house mouse CVCL_NZ47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1328362; Blm Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185768 CVCL_NZ46 BayGenomics ES cell line RRZ573 embryonic stem cell house mouse CVCL_NZ46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334460; Bop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185769 CVCL_NZ45 BayGenomics ES cell line RRZ563 embryonic stem cell house mouse CVCL_NZ45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926231; Tdh Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185770 CVCL_NZ44 BayGenomics ES cell line RRZ557 embryonic stem cell house mouse CVCL_NZ44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1194492; Hdgfl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185771 CVCL_NZ43 BayGenomics ES cell line RRZ528 embryonic stem cell house mouse CVCL_NZ43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107889; Exosc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185772 CVCL_NZ42 BayGenomics ES cell line RRZ512 embryonic stem cell house mouse CVCL_NZ42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2143977; Mbtd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185773 CVCL_NZ41 BayGenomics ES cell line RRZ510 embryonic stem cell house mouse CVCL_NZ41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444401; Snrnp200 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185774 CVCL_NZ40 BayGenomics ES cell line RRZ508 embryonic stem cell house mouse CVCL_NZ40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3042273; Nsfl1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185775 CVCL_NZ59 BayGenomics ES cell line RRZ644 embryonic stem cell house mouse CVCL_NZ59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2135608; Pard3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185776 CVCL_NZ58 BayGenomics ES cell line RRZ642 embryonic stem cell house mouse CVCL_NZ58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442402; Cnot1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185777 CVCL_NZ57 BayGenomics ES cell line RRZ638 embryonic stem cell house mouse CVCL_NZ57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146322; Deptor Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185778 CVCL_NZ56 BayGenomics ES cell line RRZ634 embryonic stem cell house mouse CVCL_NZ56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929261; Mtch1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185779 CVCL_NZ55 BayGenomics ES cell line RRZ625 embryonic stem cell house mouse CVCL_NZ55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105066; Rab10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185780 CVCL_NZ54 BayGenomics ES cell line RRZ624 embryonic stem cell house mouse CVCL_NZ54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185781 CVCL_NZ53 BayGenomics ES cell line RRZ604 embryonic stem cell house mouse CVCL_NZ53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185782 CVCL_NZ52 BayGenomics ES cell line RRZ597 embryonic stem cell house mouse CVCL_NZ52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915467; Prrc2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185783 CVCL_NZ51 BayGenomics ES cell line RRZ596 embryonic stem cell house mouse CVCL_NZ51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338938; Bmpr1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185784 CVCL_NZ50 BayGenomics ES cell line RRZ588 embryonic stem cell house mouse CVCL_NZ50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918843; Llgl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185785 CVCL_FA96 ND11761 transformed cell line human CVCL_FA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185786 CVCL_FA95 ND11753 transformed cell line human CVCL_FA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185787 CVCL_FA94 ND11717 transformed cell line human CVCL_FA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185788 CVCL_FA93 ND11692 transformed cell line human CVCL_FA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185789 CVCL_FA99 ND11872 transformed cell line human CVCL_FA99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185790 CVCL_FA98 ND11870 transformed cell line human CVCL_FA98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185791 CVCL_FA97 ND11855 transformed cell line human CVCL_FA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185792 CVCL_NZ29 BayGenomics ES cell line RRZ363 embryonic stem cell house mouse CVCL_NZ29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104860; Fxr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185793 CVCL_NZ28 BayGenomics ES cell line RRZ340 embryonic stem cell house mouse CVCL_NZ28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144423; Arhgap44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185794 CVCL_NZ27 BayGenomics ES cell line RRZ326 embryonic stem cell house mouse CVCL_NZ27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185795 CVCL_NZ26 BayGenomics ES cell line RRZ316 embryonic stem cell house mouse CVCL_NZ26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1197514; Pole2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185796 CVCL_FA92 ND11684 transformed cell line human CVCL_FA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185797 CVCL_NZ25 BayGenomics ES cell line RRZ315 embryonic stem cell house mouse CVCL_NZ25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917600; Basp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185798 CVCL_FA91 ND11632 transformed cell line human CVCL_FA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185799 CVCL_NZ24 BayGenomics ES cell line RRZ307 embryonic stem cell house mouse CVCL_NZ24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346858; Mapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185800 CVCL_FA90 ND11579 transformed cell line human CVCL_FA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185801 CVCL_NZ23 BayGenomics ES cell line RRZ301 embryonic stem cell house mouse CVCL_NZ23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185802 CVCL_NZ22 BayGenomics ES cell line RRZ298 embryonic stem cell house mouse CVCL_NZ22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97542; Pepd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185803 CVCL_NZ21 BayGenomics ES cell line RRZ296 embryonic stem cell house mouse CVCL_NZ21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144726; Tmem11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185804 CVCL_NZ20 BayGenomics ES cell line RRZ288 embryonic stem cell house mouse CVCL_NZ20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106908; Srpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185805 CVCL_NZ39 BayGenomics ES cell line RRZ506 embryonic stem cell house mouse CVCL_NZ39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1859920; Ebag9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185806 CVCL_NZ38 BayGenomics ES cell line RRZ501 embryonic stem cell house mouse CVCL_NZ38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105072; Rab22a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185807 CVCL_NZ37 BayGenomics ES cell line RRZ491 embryonic stem cell house mouse CVCL_NZ37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107934; Mdm4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185808 CVCL_NZ36 BayGenomics ES cell line RRZ462 embryonic stem cell house mouse CVCL_NZ36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924933; Ehmt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185809 CVCL_NZ35 BayGenomics ES cell line RRZ449 embryonic stem cell house mouse CVCL_NZ35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109242; Spin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185810 CVCL_NZ34 BayGenomics ES cell line RRZ438 embryonic stem cell house mouse CVCL_NZ34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185811 CVCL_NZ33 BayGenomics ES cell line RRZ433 embryonic stem cell house mouse CVCL_NZ33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923802; Plekha5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185812 CVCL_NZ32 BayGenomics ES cell line RRZ425 embryonic stem cell house mouse CVCL_NZ32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185813 CVCL_NZ31 BayGenomics ES cell line RRZ410 embryonic stem cell house mouse CVCL_NZ31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3588234; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185814 CVCL_NZ30 BayGenomics ES cell line RRZ384 embryonic stem cell house mouse CVCL_NZ30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145895; Slc38a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185815 CVCL_FA74 ND10842 transformed cell line human CVCL_FA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185816 CVCL_FA73 ND10806 transformed cell line human CVCL_FA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185817 CVCL_FA72 ND10733 transformed cell line human CVCL_FA72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185818 CVCL_FA71 ND10731 transformed cell line human CVCL_FA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185819 CVCL_FA78 ND11007 transformed cell line human CVCL_FA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185820 CVCL_FA77 ND11006 transformed cell line human CVCL_FA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185821 CVCL_FA76 ND10936 transformed cell line human CVCL_FA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185822 CVCL_NZ09 BayGenomics ES cell line RRZ243 embryonic stem cell house mouse CVCL_NZ09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429770; Nle1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185823 CVCL_FA75 ND10934 transformed cell line human CVCL_FA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185824 CVCL_NZ08 BayGenomics ES cell line RRZ235 embryonic stem cell house mouse CVCL_NZ08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918052; Pwwp2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185825 CVCL_NZ07 BayGenomics ES cell line RRZ234 embryonic stem cell house mouse CVCL_NZ07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917275; Acot7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185826 CVCL_NZ06 BayGenomics ES cell line RRZ233 embryonic stem cell house mouse CVCL_NZ06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914247; Psmd12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185827 CVCL_NZ05 BayGenomics ES cell line RRZ232 embryonic stem cell house mouse CVCL_NZ05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1095411; Nup214 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185828 CVCL_NZ04 BayGenomics ES cell line RRZ229 embryonic stem cell house mouse CVCL_NZ04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146974; Safb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185829 CVCL_FA70 ND10648 transformed cell line human CVCL_FA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185830 CVCL_NZ03 BayGenomics ES cell line RRZ227 embryonic stem cell house mouse CVCL_NZ03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103071; Rangap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185831 CVCL_NZ02 BayGenomics ES cell line RRZ226 embryonic stem cell house mouse CVCL_NZ02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921584; Ranbp10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185832 CVCL_NZ01 BayGenomics ES cell line RRZ224 embryonic stem cell house mouse CVCL_NZ01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923206; Srrm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185833 CVCL_NZ00 BayGenomics ES cell line RRZ211 embryonic stem cell house mouse CVCL_NZ00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88192; Smarca4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185834 CVCL_FA69 ND10647 transformed cell line human CVCL_FA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185835 CVCL_FA68 ND10644 transformed cell line human CVCL_FA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185836 CVCL_FA85 ND11485 transformed cell line human CVCL_FA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185837 CVCL_FA84 ND11446 transformed cell line human CVCL_FA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185838 CVCL_FA83 ND11423 transformed cell line human CVCL_FA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185839 CVCL_FA82 ND11422 transformed cell line human CVCL_FA82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185840 CVCL_FA89 ND11574 transformed cell line human CVCL_FA89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185841 CVCL_FA88 ND11557 transformed cell line human CVCL_FA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185842 CVCL_FA87 ND11516 transformed cell line human CVCL_FA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185843 CVCL_FA86 ND11495 transformed cell line human CVCL_FA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185844 CVCL_NZ19 BayGenomics ES cell line RRZ287 embryonic stem cell house mouse CVCL_NZ19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137379; Med15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185845 CVCL_NZ18 BayGenomics ES cell line RRZ280 embryonic stem cell house mouse CVCL_NZ18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137379; Med15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185846 CVCL_NZ17 BayGenomics ES cell line RRZ274 embryonic stem cell house mouse CVCL_NZ17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347094; Parg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185847 CVCL_NZ16 BayGenomics ES cell line RRZ268 embryonic stem cell house mouse CVCL_NZ16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917623; Gpatch2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185848 CVCL_NZ15 BayGenomics ES cell line RRZ266 embryonic stem cell house mouse CVCL_NZ15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103239; Tfap4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185849 CVCL_FA81 ND11260 transformed cell line human CVCL_FA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185850 CVCL_NZ14 BayGenomics ES cell line RRZ260 embryonic stem cell house mouse CVCL_NZ14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3026886; Cdin1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185851 CVCL_FA80 ND11091 transformed cell line human CVCL_FA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185852 CVCL_NZ13 BayGenomics ES cell line RRZ254 embryonic stem cell house mouse CVCL_NZ13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858730; Vamp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185853 CVCL_NZ12 BayGenomics ES cell line RRZ253 embryonic stem cell house mouse CVCL_NZ12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185854 CVCL_NZ11 BayGenomics ES cell line RRZ249 embryonic stem cell house mouse CVCL_NZ11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927479; Sap30bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185855 CVCL_NZ10 BayGenomics ES cell line RRZ246 embryonic stem cell house mouse CVCL_NZ10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914440; Eif4e2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185856 CVCL_FA79 ND11090 transformed cell line human CVCL_FA79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185857 CVCL_X469 GM08296 transformed cell line human CVCL_X469 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Pro824Alafs*59 (c.2468dupT); ClinVar=VCV000050183; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185858 CVCL_WS69 ITOC-04 cancer cell line human CVCL_WS69 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.74+38C>G (IVS2+38C>G); ClinVar=VCV000137691; Zygosity=Unspecified (PubMed=31164688); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.96+41_97-54delCTCCAGGTCCCCAGCC (c.96+41_96+56del16) (IVS3+36_52del16); ClinVar=VCV000440349; Zygosity=Unspecified (PubMed=31164688); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=31164688) Population: Indian Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 47.75 hours (PubMed=31164688) 21185859 CVCL_X468 GM11030 transformed cell line human CVCL_X468 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185860 CVCL_WS68 ITOC-03 cancer cell line human CVCL_WS68 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.74+38C>G (IVS2+38C>G); ClinVar=VCV000137691; Zygosity=Unspecified (PubMed=31164688) Population: Indian Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 67.82 hours (PubMed=31164688) 21185861 CVCL_X467 GM07517 transformed cell line human CVCL_X467 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185862 CVCL_WS67 ITOC-02 cancer cell line human CVCL_WS67 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=31164688) Population: Indian Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 51.15 hours (PubMed=31164688) 21185863 CVCL_4M21 AG10299 transformed cell line human CVCL_4M21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185864 CVCL_4M20 AG10293 transformed cell line human CVCL_4M20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185865 CVCL_4M25 AG10599 transformed cell line human CVCL_4M25 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185866 CVCL_4M24 AG10598 transformed cell line human CVCL_4M24 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185867 CVCL_4M23 AG10312 transformed cell line human CVCL_4M23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185868 CVCL_4M22 AG10307 transformed cell line human CVCL_4M22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185869 CVCL_4M18 AG10278 transformed cell line human CVCL_4M18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185870 CVCL_4M17 AG10265 transformed cell line human CVCL_4M17 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21185871 CVCL_4M16 AG10039 transformed cell line human CVCL_4M16 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185872 CVCL_4M15 AG10037 transformed cell line human CVCL_4M15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185873 CVCL_4M19 AG10279 transformed cell line human CVCL_4M19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185874 CVCL_X473 GM09563 transformed cell line human CVCL_X473 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185875 CVCL_WS73 NHAHTDD transformed cell line human CVCL_WS73 CL:0000010 Derived from sampling site: Central nervous system Cell type=Epithelial cell.. Omics: Deep exome analysis Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: No information is available about this cell line except that it is an immortalized epithelial central nervous system cell line 21185876 CVCL_WS72 A431PF cancer cell line human CVCL_WS72 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Skin; epidermis. Female Group: Serum/protein free medium cell line 21185877 CVCL_X472 GM09566 transformed cell line human CVCL_X472 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185878 CVCL_WS71 Calu-1 W5S2 cancer cell line human CVCL_WS71 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Derived from metastatic site: Pleural effusion. Male 21185879 CVCL_X471 GM08300 transformed cell line human CVCL_X471 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Pro824Alafs*59 (c.2468dupT); ClinVar=VCV000050183; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185880 CVCL_X470 GM08299 transformed cell line human CVCL_X470 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Pro824Alafs*59 (c.2468dupT); ClinVar=VCV000050183; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185881 CVCL_WS70 NCI-H2004RT cancer cell line human CVCL_WS70 CL:0000010 Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21185882 CVCL_X477 RC-165N/hTERT telomerase immortalized cell line human CVCL_X477 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 35 hours (PubMed=16413016) 21185883 CVCL_WS77 RW-972 cancer cell line human CVCL_WS77 CL:0000010 Derived from sampling site: Breast; stroma. Female Doubling time: ~24 hours (PubMed=2846143) 21185884 CVCL_X476 957E/hTERT telomerase immortalized cell line human CVCL_X476 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 32 hours (PubMed=16413016) 21185885 CVCL_WS76 Ca2-83 cancer cell line human CVCL_WS76 CL:0000010 Derived from sampling site: Breast. Female 21185886 CVCL_WS75 18B8 hybridoma house mouse CVCL_WS75 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:78438; Alpha-N-acetylneuraminosyl-(2->8)-alpha-N-acetylneuraminosyl-(2->8)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1')-N-acylsphingosine(3-) (Ganglioside GT3). 21185887 CVCL_X475 RC-58T/hTERT/SA#4 telomerase immortalized cell line human CVCL_X475 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 30 hours (PubMed=16413016) 21185888 CVCL_X474 GM09816 finite cell line human CVCL_X474 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185889 CVCL_WS74 SW1231 cancer cell line human CVCL_WS74 CL:0000010 21185890 CVCL_X459 GM06864 transformed cell line human CVCL_X459 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185891 CVCL_WS59 HEK TE transformed cell line human CVCL_WS59 CL:0000010 Derived from sampling site: Kidney. Omics: Deep exome analysis Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: No information is available about this cell line except that it is an immortalized kidney cell line 21185892 CVCL_X458 GM06912 transformed cell line human CVCL_X458 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185893 CVCL_WS58 ME-1f2 cancer cell line human CVCL_WS58 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (PubMed=14736823); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21185894 CVCL_WS57 CHO-pEDdc-hPRL spontaneously immortalized cell line CVCL_WS57 CL:0000010 Transfected with: HGNC; 9445; PRL; Transfected with: MGI; MGI:94890; Dhfr Derived from sampling site: Ovary. Female Characteristics: The sequence of PRL was inserted in the pEDdc construct 21185895 CVCL_X457 GM06863 transformed cell line human CVCL_X457 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185896 CVCL_WS56 CHO-p658-hPRL spontaneously immortalized cell line CVCL_WS56 CL:0000010 Transfected with: HGNC; 9445; PRL; Transfected with: MGI; MGI:94890; Dhfr; Transfected with: UniProtKB; P69714; Hepatitis B virus genotype A2 subtype adw protein X Derived from sampling site: Ovary. Female Characteristics: The sequence of PRL was inserted in the p658 (p7047 derivative) construct 21185897 CVCL_X456 GM06144 finite cell line human CVCL_X456 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ala199Cysfs*13 (c.594dupT); ClinVar=VCV000000080; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000000078; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185898 CVCL_4M32 AG10758 transformed cell line human CVCL_4M32 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185899 CVCL_4M31 AG10757 transformed cell line human CVCL_4M31 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185900 CVCL_4M30 AG10727 transformed cell line human CVCL_4M30 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185901 CVCL_4M36 AG10762 transformed cell line human CVCL_4M36 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Female 21185902 CVCL_4M35 AG10761 transformed cell line human CVCL_4M35 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185903 CVCL_4M34 AG10760 transformed cell line human CVCL_4M34 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185904 CVCL_4M33 AG10759 transformed cell line human CVCL_4M33 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185905 CVCL_4M29 AG10645 transformed cell line human CVCL_4M29 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185906 CVCL_4M28 AG10644 transformed cell line human CVCL_4M28 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185907 CVCL_4M27 AG10643 transformed cell line human CVCL_4M27 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185908 CVCL_4M26 AG10600 transformed cell line human CVCL_4M26 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185909 CVCL_X462 GM07415 transformed cell line human CVCL_X462 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185910 CVCL_WS62 Kinsey cancer cell line dog CVCL_WS62 CL:0000010 Breed/subspecies: Australian Shepherd. Omics: Deep exome analysis Male 21185911 CVCL_WS61 Angus cancer cell line dog CVCL_WS61 CL:0000010 Sequence variation: Mutation; VGNC; 42508; KRAS; Simple; p.Gly12Asp (c.35G>A); Zygosity=Heterozygous (PubMed=31175136) Breed/subspecies: Scottish Terrier. Omics: Deep exome analysis Male 21185912 CVCL_X461 GM07414 transformed cell line human CVCL_X461 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185913 CVCL_X460 GM07103 transformed cell line human CVCL_X460 CL:0000010 Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Arg76Trp (c.226C>T); ClinVar=VCV000001962; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 186; ADA; Simple; p.Leu107Pro (c.320T>C); ClinVar=VCV000001965; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185914 CVCL_WS60 SALE transformed cell line human CVCL_WS60 CL:0000010 Derived from sampling site: Lung. Omics: Deep exome analysis Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: No information is available about this cell line except that it is a immortalized lung cell line 21185915 CVCL_X466 GM07469 transformed cell line human CVCL_X466 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Arg553Ter (c.1657C>T); ClinVar=VCV000007122; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185916 CVCL_WS66 ITOC-01 cancer cell line human CVCL_WS66 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln1214Ter (c.3640C>T); Zygosity=Unspecified (PubMed=31164688); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=31164688); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126His (c.376T>C); Zygosity=Unspecified (PubMed=31164688); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=31164688) Population: Indian Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 47.31 hours (PubMed=31164688) 21185917 CVCL_X465 GM07459 transformed cell line human CVCL_X465 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185918 CVCL_WS65 Tyler2 cancer cell line dog CVCL_WS65 CL:0000010 Sequence variation: Mutation; VGNC; 38093; ARID1A; Simple; p.Ala901fs (c.2700_2701insA); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 38297; ATRX; Simple; p.Cys1810Ter (c.5430T>A); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 38514; BRAF; Simple; p.Val588Glu (c.1763T>A); Zygosity=Heterozygous (PubMed=31175136) Derived from sampling site: Urinary bladder; Breed/subspecies: Beagle. Omics: Deep exome analysis Male 21185919 CVCL_X464 GM07758 transformed cell line human CVCL_X464 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.2988+1G>A (3120+1G>A); ClinVar=VCV000007224; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185920 CVCL_WS64 Tyler1 cancer cell line dog CVCL_WS64 CL:0000010 Sequence variation: Mutation; VGNC; 38093; ARID1A; Simple; p.Ala901fs (c.2700_2701insA); Zygosity=Heterozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 38297; ATRX; Simple; p.Cys1810Ter (c.5430T>A); Zygosity=Homozygous (PubMed=31175136); Sequence variation: Mutation; VGNC; 38514; BRAF; Simple; p.Val588Glu (c.1763T>A); Zygosity=Heterozygous (PubMed=31175136) Derived from sampling site: Urinary bladder; Breed/subspecies: Beagle. Omics: Deep exome analysis Male 21185921 CVCL_WS63 Cindy cancer cell line dog CVCL_WS63 CL:0000010 Miscellaneous: Breed, age of donor and equivalence of Cyndy with HSA-1 from personal communication of MacNeill A.L Breed/subspecies: Labrador Retriever. Omics: Deep exome analysis Female 21185922 CVCL_X463 GM07440 transformed cell line human CVCL_X463 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.489+1G>T (621+1G>T); ClinVar=VCV000038799; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; c.2988+1G>A (3120+1G>A); ClinVar=VCV000007224; Zygosity=Heterozygous; Note=Splice donor mutation (from familial inference) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185923 CVCL_X448 GM02057 finite cell line human CVCL_X448 CL:0000010 Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000809707; Zygosity=Heterozygous (PubMed=1904874); Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Cys163Ser (c.488G>C); ClinVar=VCV000000219; Zygosity=Homozygous (PubMed=1904874) Population: Caucasian; Finnish; Derived from sampling site: Cell type=Fibroblast. Female 21185924 CVCL_WS48 SpESF cancer cell line house mouse CVCL_WS48 CL:0000010 Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine Female Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct Group: Hybridoma fusion partner cell line; Group: Patented cell line; Group: Serum/protein free medium cell line 21185925 CVCL_X447 GM02056 finite cell line human CVCL_X447 CL:0000010 Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000809707; Zygosity=Heterozygous (PubMed=1904874); Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Cys163Ser (c.488G>C); ClinVar=VCV000000219; Zygosity=Heterozygous (PubMed=1904874) Population: Caucasian; Finnish; Derived from sampling site: Cell type=Fibroblast. Male 21185926 CVCL_WS47 SpEEE cancer cell line house mouse CVCL_WS47 CL:0000010 Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine Female Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct Group: Hybridoma fusion partner cell line; Group: Patented cell line 21185927 CVCL_X446 GM00568 finite cell line human CVCL_X446 CL:0000010 Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Arg161Gln (c.482G>A); ClinVar=VCV000809707; Zygosity=Heterozygous (PubMed=1904874); Sequence variation: Mutation; HGNC; 318; AGA; Simple; p.Cys163Ser (c.488G>C); ClinVar=VCV000000219; Zygosity=Heterozygous (PubMed=1904874) Population: Caucasian; Finnish; Derived from sampling site: Cell type=Fibroblast. Female 21185928 CVCL_WS46 MN7 transformed cell line house mouse CVCL_WS46 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Anecdotal: Have been flown in space on Cosmos-2229 (Bion-10) to study growth microgravity (CelloPub=CLPUB00511; PubMed=9813886) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow; stroma; Breed/subspecies: BALB/c. Omics: Secretome proteome analysis by 2D-DE Unspecified Characteristics: Osteogenic stromal cell line Can mineralize in vitro when cultured on a collagen type I matrix. Group: Space-flown cell line (cellonaut) 21185929 CVCL_WS45 A61140087P hybridoma house mouse CVCL_WS45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with bovine). Doubling time: 36.9 +- 3.2 hours (in FBS-containing medium), 30.9 +- 6.0 hours (in serum/protein free medium) (PubMed=17123500) 21185930 CVCL_X445 GM06123 finite cell line human CVCL_X445 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Ala199Cysfs*13 (c.594dupT); ClinVar=VCV000000080; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21185931 CVCL_X449 GM10417 transformed cell line human CVCL_X449 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185932 CVCL_WS49 SpESFX cancer cell line house mouse CVCL_WS49 CL:0000010 Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine Female Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct Group: Hybridoma fusion partner cell line; Group: Patented cell line; Group: Serum/protein free medium cell line 21185933 CVCL_4M03 AG09904 transformed cell line human CVCL_4M03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185934 CVCL_4M02 AG09903 transformed cell line human CVCL_4M02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185935 CVCL_4M01 AG09896 transformed cell line human CVCL_4M01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185936 CVCL_4M00 AG09831 transformed cell line human CVCL_4M00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185937 CVCL_X451 GM13201 finite cell line human CVCL_X451 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185938 CVCL_WS51 SpESFX-2 cancer cell line house mouse CVCL_WS51 CL:0000010 Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine Female Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct Group: Hybridoma fusion partner cell line; Group: Patented cell line; Group: Serum/protein free medium cell line 21185939 CVCL_X450 GM10418 transformed cell line human CVCL_X450 CL:0000010 Population: Caucasian; Finnish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185940 CVCL_WS50 SpESFX-10 cancer cell line house mouse CVCL_WS50 CL:0000010 Transfected with: HGNC; 990; BCL2 (with p.Thr69Glu, p.Ser70Glu and p.Ser87Glu = BCL2-EEE); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR). Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine Female Characteristics: Transfected with a hBCL2-EEE-pZeoSV2+ construct Group: Hybridoma fusion partner cell line; Group: Patented cell line; Group: Serum/protein free medium cell line 21185941 CVCL_X455 GM04211 transformed cell line human CVCL_X455 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185942 CVCL_WS55 sfBT transformed cell line CVCL_WS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Characteristics: Grows in serum-free RPMI-1640 medium supplemented with transferrin and selenium Doubling time: 2.8 days (PubMed=2841494) Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21185943 CVCL_X454 GM04210 finite cell line human CVCL_X454 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185944 CVCL_WS54 sfBIT transformed cell line CVCL_WS54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Characteristics: Grows in serum-free RPMI-1640 medium supplemented with insulin, transferrin and selenium Doubling time: 2.5 days (PubMed=2841494) Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21185945 CVCL_X453 GM03723 transformed cell line human CVCL_X453 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185946 CVCL_WS53 sfRamos cancer cell line human CVCL_WS53 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Group: Serum/protein free medium cell line 21185947 CVCL_X452 GM03722 finite cell line human CVCL_X452 CL:0000010 Population: African American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21185948 CVCL_WS52 R1-Oct4-EGFP embryonic stem cell house mouse CVCL_WS52 CL:0000010 Transfected with: MGI; MGI:101893; Pou5f1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: 129X1/SvJ x 129S1/Sv-Oca2+Tyr+KitlSl-J. Male Characteristics: Transfected with a construct containing Pou5f1/Oct4-eGFP and Pgk-neo-pA 21185949 CVCL_WS37 BRF-69T transformed cell line human CVCL_WS37 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from metastatic site: Lymph node. Female 21185950 CVCL_X437 GM20568 transformed cell line human CVCL_X437 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21185951 CVCL_X436 GM16549 finite cell line human CVCL_X436 CL:0000010 Derived from sampling site: Placenta Cell type=Fibroblast.. Male 21185952 CVCL_WS36 SGT11 1T3.1D9 transformed cell line human CVCL_WS36 CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Characteristics: Can be used for adenoviral vector production under serum-free conditions Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3134 21185953 CVCL_X435 GM03291 finite cell line human CVCL_X435 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21185954 CVCL_WS35 SGT11 1T3.1G3 transformed cell line human CVCL_WS35 CL:0000010 Transfected with: UniProtKB; P03281; Adenovirus 5 pIX Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Amniotic fluid Cell type=Amniocyte.. Female Characteristics: Can be used for adenoviral vector production under serum-free conditions Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3135 21185955 CVCL_WS34 GhrasT-NIH/Swiss transformed cell line house mouse CVCL_WS34 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21185956 CVCL_X434 GM03289 finite cell line human CVCL_X434 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185957 CVCL_WS39 BRF-71T2 transformed cell line human CVCL_WS39 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from metastatic site: Lymph node. Female 21185958 CVCL_X439 GM03360 finite cell line human CVCL_X439 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185959 CVCL_WS38 BRF-71T1 transformed cell line human CVCL_WS38 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from metastatic site: Lymph node. Female 21185960 CVCL_X438 GM03361 finite cell line human CVCL_X438 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03361; probable Male 21185961 CVCL_4M10 AG09997 transformed cell line human CVCL_4M10 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21185962 CVCL_4M14 AG10010 transformed cell line human CVCL_4M14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185963 CVCL_4M13 AG10009 transformed cell line human CVCL_4M13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185964 CVCL_4M12 AG10008 transformed cell line human CVCL_4M12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185965 CVCL_4M11 AG10007 transformed cell line human CVCL_4M11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185966 CVCL_4M07 AG09953 transformed cell line human CVCL_4M07 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185967 CVCL_4M06 AG09952 transformed cell line human CVCL_4M06 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185968 CVCL_4M05 AG09951 transformed cell line human CVCL_4M05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Male 21185969 CVCL_4M04 AG09945 transformed cell line human CVCL_4M04 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21185970 CVCL_4M09 AG09983 transformed cell line human CVCL_4M09 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185971 CVCL_4M08 AG09955 transformed cell line human CVCL_4M08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21185972 CVCL_WS40 BRF-97T transformed cell line human CVCL_WS40 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast. Female 21185973 CVCL_X440 GM03236 transformed cell line human CVCL_X440 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185974 CVCL_WS44 A61130087P hybridoma house mouse CVCL_WS44 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01308; Human INS. Doubling time: 28.4 +- 1.8 hours (in FBS-containing medium), 26.0 +- 3.9 hours (in serum/protein free medium) (PubMed=17123500) 21185975 CVCL_X444 GM06124 finite cell line human CVCL_X444 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21185976 CVCL_X443 GM06122 finite cell line human CVCL_X443 CL:0000010 Sequence variation: Mutation; HGNC; 6617; LIPA; Simple; p.Gly266Ter (c.796G>T); ClinVar=VCV000000078; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21185977 CVCL_WS43 Hybridoma 84 hybridoma house mouse CVCL_WS43 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; O00592; Human PODXL. 21185978 CVCL_X442 GM03358 finite cell line human CVCL_X442 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21185979 CVCL_WS42 TCC-NECT-2 cancer cell line human CVCL_WS42 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=30559933); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783-1G>A; ClinVar=VCV000458565; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=30559933) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: ~31.4 hours (PubMed=30559933) 21185980 CVCL_X441 GM03235 transformed cell line human CVCL_X441 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21185981 CVCL_WS41 OVCA12 cancer cell line human CVCL_WS41 CL:0000010 Female 21185982 CVCL_X426 MZ2905RC cancer cell line human CVCL_X426 CL:0000010 Derived from sampling site: Kidney. Unspecified 21185983 CVCL_WS26 W9.5 embryonic stem cell house mouse CVCL_WS26 CL:0000010 Breed/subspecies: 129/Sv.C3-+c+p. Unspecified 21185984 CVCL_X425 MZ2902RC cancer cell line human CVCL_X425 CL:0000010 Derived from sampling site: Kidney. Unspecified 21185985 CVCL_WS25 UCD-Mel-N-PEDF cancer cell line human CVCL_WS25 CL:0000010 Transfected with: HGNC; 8824; SERPINF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Stably transfected with a pLZR-PEDF-IRES-EGFP construct 21185986 CVCL_X424 MZ2885RC cancer cell line human CVCL_X424 CL:0000010 Derived from sampling site: Kidney. Unspecified 21185987 CVCL_WS24 UCD-Mel-N-GFP cancer cell line human CVCL_WS24 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Characteristics: Stably transfected with a pLZR-IRES-EGFP construct 21185988 CVCL_X423 MZ2877RC cancer cell line human CVCL_X423 CL:0000010 Derived from sampling site: Kidney. Unspecified 21185989 CVCL_WS23 UCD-Mel-N(Ski+/Fhl2+) cancer cell line human CVCL_WS23 CL:0000010 Transfected with: HGNC; 3703; FHL2; Transfected with: HGNC; 10896; SKI; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph). 21185990 CVCL_X429 GM03035 finite cell line human CVCL_X429 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21185991 CVCL_WS29 LN-2669GS cancer cell line human CVCL_WS29 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323Valfs*19; Zygosity=Homozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=22570425) Miscellaneous: STR profile from personal communication of Gusyatiner O. Omics: Array-based CGH; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Glioma-derived sphere line Tumorigenic in nude mice. 21185992 CVCL_X428 GM03034 finite cell line human CVCL_X428 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Male 21185993 CVCL_WS28 LN-2540GS cancer cell line human CVCL_WS28 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.253+5G>A; ClinVar=VCV000427618; Zygosity=Heterozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 9588; PTEN; Unexplicit; Ex1-9del; Zygosity=Heterozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (PubMed=22570425) Omics: Array-based CGH; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray. Male Characteristics: Glioma-derived sphere line Tumorigenic in nude mice. 21185994 CVCL_WS27 LN-2207GS cancer cell line human CVCL_WS27 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=22570425) Miscellaneous: STR profile from personal communication of Gusyatiner O. Omics: Array-based CGH; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Characteristics: Glioma-derived sphere line Non-tumorigenic in nude mice. 21185995 CVCL_X427 OH-2 [Human lung carcinoma] cancer cell line human CVCL_X427 CL:0000010 21185996 CVCL_NY89 BayGenomics ES cell line RRZ148 embryonic stem cell house mouse CVCL_NY89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384879; Prmt7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185997 CVCL_NY88 BayGenomics ES cell line RRZ141 embryonic stem cell house mouse CVCL_NY88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185998 CVCL_NY87 BayGenomics ES cell line RRZ138 embryonic stem cell house mouse CVCL_NY87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21185999 CVCL_NY86 BayGenomics ES cell line RRZ134 embryonic stem cell house mouse CVCL_NY86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103067; Atrx Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186000 CVCL_NY85 BayGenomics ES cell line RRZ132 embryonic stem cell house mouse CVCL_NY85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039623; Thada Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186001 CVCL_NY84 BayGenomics ES cell line RRZ124 embryonic stem cell house mouse CVCL_NY84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109369; Hp1bp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186002 CVCL_NY83 BayGenomics ES cell line RRZ121 embryonic stem cell house mouse CVCL_NY83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098231; Kif11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186003 CVCL_NY82 BayGenomics ES cell line RRZ115 embryonic stem cell house mouse CVCL_NY82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104813; Jarid2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186004 CVCL_NY81 BayGenomics ES cell line RRZ105 embryonic stem cell house mouse CVCL_NY81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2147538; Btaf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186005 CVCL_NY80 BayGenomics ES cell line RRZ104 embryonic stem cell house mouse CVCL_NY80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917606; St13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186006 CVCL_X433 GM03278 finite cell line human CVCL_X433 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186007 CVCL_WS33 LN-229_indWIF1 cancer cell line human CVCL_WS33 CL:0000010 Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 18081; WIF1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; Q9U6Y8; RFP Derived from sampling site: Brain; right frontal parieto-occipital cortex. Female Characteristics: Dox-induced expression (using rtTA) of WIF1 and dsRED 21186008 CVCL_X432 GM03277 finite cell line human CVCL_X432 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186009 CVCL_WS32 LN-2669GS_WIF1 cancer cell line human CVCL_WS32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp323Valfs*19; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line); Transfected with: HGNC; 18081; WIF1. Male Characteristics: Glioma-derived sphere line Tumorigenic in nude mice (from parent cell line). 21186010 CVCL_X431 GM03276 finite cell line human CVCL_X431 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21186011 CVCL_WS31 LN-2826GS cancer cell line human CVCL_WS31 CL:0000010 Miscellaneous: Cell line has been lost (from personal communication of Gusyatiner O.). Male Characteristics: Glioma-derived sphere line 21186012 CVCL_X430 GM03273 finite cell line human CVCL_X430 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21186013 CVCL_WS30 LN-2683GS cancer cell line human CVCL_WS30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 9588; PTEN; Unexplicit; Ex1-9del; Zygosity=Heterozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Lys (c.670G>A); ClinVar=VCV000480767; Zygosity=Heterozygous (PubMed=22570425); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250Leu (c.749C>T); ClinVar=VCV000420136; Zygosity=Heterozygous (PubMed=22570425) Omics: DNA methylation analysis; Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male Characteristics: Glioma-derived sphere line Tumorigenic in nude mice. 21186014 CVCL_WS15 DogMTC cancer cell line dog CVCL_WS15 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned one temporarily pending the authors responding to our emails Derived from sampling site: Thyroid gland; Breed/subspecies: Cocker Spaniel. Female Doubling time: 33.3 hours (PubMed=31144267) 21186015 CVCL_X415 MZ1774RC cancer cell line human CVCL_X415 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186016 CVCL_WS14 H1 iCas9 embryonic stem cell human CVCL_WS14 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile from personal communication of Huangfu D. Male Characteristics: Cell line with robust Dox-inducible expression of Cas9 Can be used for rapid and highly efficient generation of biallelic knockout hPSCs for loss-of-function studies. Using TALEN two constructs SA-2A-Hygro-Cas9-TRE and SA-2A-Neo-M2rtTA were introduced in the AAVS1 locus, one in each allele. 21186017 CVCL_X414 N1050 cancer cell line human CVCL_X414 CL:0000010 21186018 CVCL_X413 N1046 cancer cell line human CVCL_X413 CL:0000010 21186019 CVCL_WS13 PANC-1RG7 cancer cell line human CVCL_WS13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male Doubling time: 33.83 +- 2.15 hours (PubMed=25394408) 21186020 CVCL_X412 N1024 cancer cell line human CVCL_X412 CL:0000010 Male 21186021 CVCL_WS12 SW1990/GZ cancer cell line human CVCL_WS12 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 21186022 CVCL_WS19 C8161-GFP cancer cell line human CVCL_WS19 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Abdominal wall. Female 21186023 CVCL_X419 MZ2733RC cancer cell line human CVCL_X419 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Male 21186024 CVCL_WS18 HEK293 SCN1A/SCN1B/SCN2B transformed cell line human CVCL_WS18 CL:0000010 Transfected with: HGNC; 10585; SCN1A; Transfected with: HGNC; 10586; SCN1B; Transfected with: HGNC; 10589; SCN2B Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Co-transfected the constructs pT-SCN1A:3X-FLAG and pT-SCN1B:cMyc-IRES-SCN2B:HA 21186025 CVCL_X418 MZ1851LN cancer cell line human CVCL_X418 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21186026 CVCL_WS17 HK42/1 transformed cell line human CVCL_WS17 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified 21186027 CVCL_X417 MZ1846RC cancer cell line human CVCL_X417 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Unspecified 21186028 CVCL_X416 MZ1795RC cancer cell line human CVCL_X416 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186029 CVCL_WS16 OLENDO transformed cell line CVCL_WS16 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; corpus luteum Cell type=Endothelial cell.. Female 21186030 CVCL_NY99 BayGenomics ES cell line RRZ200 embryonic stem cell house mouse CVCL_NY99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915283; Cox19 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186031 CVCL_NY98 BayGenomics ES cell line RRZ199 embryonic stem cell house mouse CVCL_NY98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186032 CVCL_NY97 BayGenomics ES cell line RRZ194 embryonic stem cell house mouse CVCL_NY97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914632; Brd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186033 CVCL_NY96 BayGenomics ES cell line RRZ184 embryonic stem cell house mouse CVCL_NY96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445094; Plekha7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186034 CVCL_NY95 BayGenomics ES cell line RRZ178 embryonic stem cell house mouse CVCL_NY95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186035 CVCL_NY94 BayGenomics ES cell line RRZ163 embryonic stem cell house mouse CVCL_NY94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924992; Fbxo42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186036 CVCL_NY93 BayGenomics ES cell line RRZ161 embryonic stem cell house mouse CVCL_NY93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88393; Chd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186037 CVCL_NY92 BayGenomics ES cell line RRZ155 embryonic stem cell house mouse CVCL_NY92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103040; Rsu1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186038 CVCL_NY91 BayGenomics ES cell line RRZ154 embryonic stem cell house mouse CVCL_NY91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351655; Shroom3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186039 CVCL_NY90 BayGenomics ES cell line RRZ150 embryonic stem cell house mouse CVCL_NY90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915020; Caap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186040 CVCL_X422 MZ2862RC cancer cell line human CVCL_X422 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186041 CVCL_WS22 UCD-Mel-N(Ski+) cancer cell line human CVCL_WS22 CL:0000010 Transfected with: HGNC; 10896; SKI; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). 21186042 CVCL_X421 MZ2861RC cancer cell line human CVCL_X421 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186043 CVCL_WS21 UCD-Mel-N cancer cell line human CVCL_WS21 CL:0000010 21186044 CVCL_WS20 C8161-PEDF cancer cell line human CVCL_WS20 CL:0000010 Transfected with: HGNC; 8824; SERPINF1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Abdominal wall. Female 21186045 CVCL_X420 MZ2858RC cancer cell line human CVCL_X420 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186046 CVCL_X404 COLO 346 cancer cell line human CVCL_X404 CL:0000010 Population: Hispanic; Derived from metastatic site: Liver. Female Doubling time: 36 hours (PubMed=7262900) 21186047 CVCL_WS04 LAnCE hiPSC-66 induced pluripotent stem cell human CVCL_WS04 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186048 CVCL_WS03 LAnCE hiPSC-65 induced pluripotent stem cell human CVCL_WS03 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186049 CVCL_X403 RPMI-7451 cancer cell line human CVCL_X403 CL:0000010 Male 21186050 CVCL_X402 COLO 508 cancer cell line human CVCL_X402 CL:0000010 Derived from metastatic site: Brain. Male 21186051 CVCL_WS02 LAnCE hiPSC-64 induced pluripotent stem cell human CVCL_WS02 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186052 CVCL_X401 COLO 510 cancer cell line human CVCL_X401 CL:0000010 Derived from metastatic site: Brain. Male 21186053 CVCL_WS01 LAnCE hiPSC-63 induced pluripotent stem cell human CVCL_WS01 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186054 CVCL_WS08 HVRDi015-A induced pluripotent stem cell human CVCL_WS08 From: Harvard University; Boston; USA. CL:0000010 Male 21186055 CVCL_X408 MZ1979RC cancer cell line human CVCL_X408 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186056 CVCL_WS07 LAnCE hiPSC-70 induced pluripotent stem cell human CVCL_WS07 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186057 CVCL_X407 MZ1940RC cancer cell line human CVCL_X407 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Unspecified 21186058 CVCL_WS06 LAnCE hiPSC-69 induced pluripotent stem cell human CVCL_WS06 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186059 CVCL_X406 MZ1879RC cancer cell line human CVCL_X406 CL:0000010 Derived from sampling site: Kidney. Omics: Proteome analysis by 2D-DE/MS Unspecified 21186060 CVCL_WS05 LAnCE hiPSC-68 induced pluripotent stem cell human CVCL_WS05 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil. CL:0000010 21186061 CVCL_X405 V-C8 transformed cell line CVCL_X405 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21186062 CVCL_WS09 HVRDi016-A induced pluripotent stem cell human CVCL_WS09 From: Harvard University; Boston; USA. CL:0000010 Female 21186063 CVCL_X409 MZ1790RC cancer cell line human CVCL_X409 CL:0000010 Derived from sampling site: Kidney. Unspecified 21186064 CVCL_NY69 BayGenomics ES cell line RRZ039 embryonic stem cell house mouse CVCL_NY69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98341; Snrnp70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186065 CVCL_NY68 BayGenomics ES cell line RRZ035 embryonic stem cell house mouse CVCL_NY68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450151; Cog3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186066 CVCL_NY67 BayGenomics ES cell line RRZ028 embryonic stem cell house mouse CVCL_NY67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342292; Hspa4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186067 CVCL_NY66 BayGenomics ES cell line RRZ027 embryonic stem cell house mouse CVCL_NY66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344406; Ptpn21 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186068 CVCL_NY65 BayGenomics ES cell line RRZ026 embryonic stem cell house mouse CVCL_NY65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186069 CVCL_NY64 BayGenomics ES cell line RRZ021 embryonic stem cell house mouse CVCL_NY64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3694697; Mfap1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186070 CVCL_NY63 BayGenomics ES cell line RRZ018 embryonic stem cell house mouse CVCL_NY63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923257; Zmym2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186071 CVCL_NY62 BayGenomics ES cell line RRZ012 embryonic stem cell house mouse CVCL_NY62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107412; Ube2e3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186072 CVCL_NY61 BayGenomics ES cell line RRZ011 embryonic stem cell house mouse CVCL_NY61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101785; Mybl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186073 CVCL_NY60 BayGenomics ES cell line RRZ009 embryonic stem cell house mouse CVCL_NY60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442355; Kdm4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186074 CVCL_WS11 FRIMOi005-A induced pluripotent stem cell human CVCL_WS11 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10012; RHO; Simple; p.Pro215Leu (c.644C>T); ClinVar=VCV000870955; Zygosity=Heterozygous (PubMed=31146251) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21186075 CVCL_X411 N1007 cancer cell line human CVCL_X411 CL:0000010 Derived from metastatic site: Bone marrow. Male 21186076 CVCL_WS10 HVRDi017-A induced pluripotent stem cell human CVCL_WS10 From: Harvard University; Boston; USA. CL:0000010 Male 21186077 CVCL_X410 N1003 cancer cell line human CVCL_X410 CL:0000010 Derived from metastatic site: Bone marrow. Male 21186078 CVCL_NY79 BayGenomics ES cell line RRZ103 embryonic stem cell house mouse CVCL_NY79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151152; Baz2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186079 CVCL_NY78 BayGenomics ES cell line RRZ100 embryonic stem cell house mouse CVCL_NY78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186080 CVCL_NY77 BayGenomics ES cell line RRZ092 embryonic stem cell house mouse CVCL_NY77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442653; Rbm48 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186081 CVCL_NY76 BayGenomics ES cell line RRZ090 embryonic stem cell house mouse CVCL_NY76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384863; Tbl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186082 CVCL_NY75 BayGenomics ES cell line RRZ080 embryonic stem cell house mouse CVCL_NY75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925705; Helz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186083 CVCL_NY74 BayGenomics ES cell line RRZ074 embryonic stem cell house mouse CVCL_NY74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915783; Mphosph6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186084 CVCL_NY73 BayGenomics ES cell line RRZ071 embryonic stem cell house mouse CVCL_NY73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107717; Myh9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186085 CVCL_NY72 BayGenomics ES cell line RRZ062 embryonic stem cell house mouse CVCL_NY72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346858; Mapk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186086 CVCL_NY71 BayGenomics ES cell line RRZ054 embryonic stem cell house mouse CVCL_NY71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338889; Uhrf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186087 CVCL_NY70 BayGenomics ES cell line RRZ048 embryonic stem cell house mouse CVCL_NY70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919792; Pgam5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186088 CVCL_X400 COLO 526 cancer cell line human CVCL_X400 CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Derived from metastatic site: Bone. Female 21186089 CVCL_WS00 LaNCE hiPSC-51 induced pluripotent stem cell human CVCL_WS00 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21186090 CVCL_4M83 AG13346 transformed cell line human CVCL_4M83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186091 CVCL_4M82 AG13283 transformed cell line human CVCL_4M82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186092 CVCL_4M81 AG12991 transformed cell line human CVCL_4M81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186093 CVCL_4M80 AG12990 transformed cell line human CVCL_4M80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186094 CVCL_4M87 AG14253 transformed cell line human CVCL_4M87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186095 CVCL_4M86 AG14244 finite cell line human CVCL_4M86 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186096 CVCL_4M85 AG14176 transformed cell line human CVCL_4M85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186097 CVCL_4M84 AG14149 finite cell line human CVCL_4M84 CL:0000010 Population: Caucasian; Derived from sampling site: Scalp; skin Cell type=Fibroblast.. Unspecified 21186098 CVCL_4M89 AG14435 transformed cell line human CVCL_4M89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186099 CVCL_4M88 AG14254 transformed cell line human CVCL_4M88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186100 CVCL_4M90 AG14497 transformed cell line human CVCL_4M90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186101 CVCL_4M94 KM12-LX cancer cell line human CVCL_4M94 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Unspecified 21186102 CVCL_4M93 KM12-HX cancer cell line human CVCL_4M93 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Unspecified 21186103 CVCL_4M92 AG14539 transformed cell line human CVCL_4M92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186104 CVCL_4M91 AG14531 transformed cell line human CVCL_4M91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186105 CVCL_4M98 SHEE61 transformed cell line human CVCL_4M98 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186106 CVCL_4M97 SHEE31 transformed cell line human CVCL_4M97 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186107 CVCL_4M96 SHEE10 transformed cell line human CVCL_4M96 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186108 CVCL_4M95 BAR-T telomerase immortalized cell line human CVCL_4M95 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Esophagus; epithelium (Note=From a Barrett esophagus) Cell type=Epithelial cell.. Male 21186109 CVCL_4M99 SHEE61A transformed cell line human CVCL_4M99 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186110 CVCL_4M61 AG11070 transformed cell line human CVCL_4M61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186111 CVCL_4M60 AG11015 transformed cell line human CVCL_4M60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186112 CVCL_4M65 AG11367 transformed cell line human CVCL_4M65 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186113 CVCL_4M64 AG11366 transformed cell line human CVCL_4M64 CL:0000010 Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186114 CVCL_4M63 AG11089 transformed cell line human CVCL_4M63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186115 CVCL_4M62 AG11088 transformed cell line human CVCL_4M62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186116 CVCL_4M69 AG11415 finite cell line human CVCL_4M69 CL:0000010 Population: Caucasian; French Canadian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21186117 CVCL_4M68 AG11414 finite cell line human CVCL_4M68 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186118 CVCL_4M67 AG11369 finite cell line human CVCL_4M67 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186119 CVCL_4M66 AG11368 finite cell line human CVCL_4M66 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186120 CVCL_4M59 AG11009 transformed cell line human CVCL_4M59 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (from autologous cell line AG14244) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186121 CVCL_4M72 AG11755 transformed cell line human CVCL_4M72 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186122 CVCL_4M71 AG11514 transformed cell line human CVCL_4M71 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21186123 CVCL_4M70 AG11455 transformed cell line human CVCL_4M70 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21186124 CVCL_4M76 AG12729 transformed cell line human CVCL_4M76 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186125 CVCL_4M75 AG11758 transformed cell line human CVCL_4M75 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186126 CVCL_4M74 AG11757 transformed cell line human CVCL_4M74 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186127 CVCL_4M73 AG11756 transformed cell line human CVCL_4M73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186128 CVCL_4M79 AG12982 transformed cell line human CVCL_4M79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186129 CVCL_4M78 AG12981 transformed cell line human CVCL_4M78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186130 CVCL_4M77 AG12731 transformed cell line human CVCL_4M77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186131 CVCL_X489 HBEC1-KT telomerase immortalized cell line human CVCL_X489 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. 21186132 CVCL_WS89 NUIGi005-C induced pluripotent stem cell human CVCL_WS89 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186133 CVCL_4M43 AG10824 transformed cell line human CVCL_4M43 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186134 CVCL_4M42 AG10823 transformed cell line human CVCL_4M42 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21186135 CVCL_4M41 AG10822 transformed cell line human CVCL_4M41 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21186136 CVCL_4M40 AG10821 transformed cell line human CVCL_4M40 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21186137 CVCL_4M47 AG10950 transformed cell line human CVCL_4M47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186138 CVCL_4M46 AG10891 transformed cell line human CVCL_4M46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186139 CVCL_4M45 AG10877 transformed cell line human CVCL_4M45 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21186140 CVCL_4M44 AG10825 transformed cell line human CVCL_4M44 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21186141 CVCL_4M39 AG10820 transformed cell line human CVCL_4M39 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186142 CVCL_4M38 AG10819 transformed cell line human CVCL_4M38 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21186143 CVCL_4M37 AG10788 finite cell line human CVCL_4M37 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female 21186144 CVCL_X491 HBEC3-KT telomerase immortalized cell line human CVCL_X491 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36-48 hours (Evercyte) 21186145 CVCL_WS91 NUIGi006-B induced pluripotent stem cell human CVCL_WS91 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186146 CVCL_X490 HBEC2-KT telomerase immortalized cell line human CVCL_X490 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21186147 CVCL_WS90 NUIGi006-A induced pluripotent stem cell human CVCL_WS90 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186148 CVCL_X495 A375-MA2 cancer cell line human CVCL_X495 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Metastatic Derived by intravenous injection of parental cells into nude mice and harvesting of the mung metastases. 21186149 CVCL_WS95 NUIGi008-A induced pluripotent stem cell human CVCL_WS95 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186150 CVCL_X494 A375-MA1 cancer cell line human CVCL_X494 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Metastatic Derived by intravenous injection of parental cells into nude mice and harvesting of the mung metastases. 21186151 CVCL_WS94 NUIGi007-B induced pluripotent stem cell human CVCL_WS94 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186152 CVCL_X493 HBEC5-KT telomerase immortalized cell line human CVCL_X493 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: Transcriptome analysis by microarray 21186153 CVCL_WS93 NUIGi007-A induced pluripotent stem cell human CVCL_WS93 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186154 CVCL_X492 HBEC4-KT telomerase immortalized cell line human CVCL_X492 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Bronchus; epithelium. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21186155 CVCL_WS92 NUIGi006-C induced pluripotent stem cell human CVCL_WS92 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186156 CVCL_X499 ATCC-DYS0100 induced pluripotent stem cell human CVCL_X499 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186157 CVCL_WS99 NUIGi009-A induced pluripotent stem cell human CVCL_WS99 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186158 CVCL_X498 ATCC-CYS0105 induced pluripotent stem cell human CVCL_X498 CL:0000010 Derived from sampling site: Heart Cell type=Fibroblast.. Male 21186159 CVCL_WS98 RS773 transformed cell line human CVCL_WS98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Male Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be a B-lymphoblastoid cell line (PubMed=29533902). 21186160 CVCL_X497 ATCC-BXS0114 induced pluripotent stem cell human CVCL_X497 CL:0000010 Population: African American; Derived from sampling site: Bone marrow. Female 21186161 CVCL_WS97 NUIGi008-C induced pluripotent stem cell human CVCL_WS97 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186162 CVCL_X496 ATCC-BYS0110 induced pluripotent stem cell human CVCL_X496 CL:0000010 Population: African American; Derived from sampling site: Bone marrow. Male 21186163 CVCL_WS96 NUIGi008-B induced pluripotent stem cell human CVCL_WS96 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Arg401Profs*62 (c.1201dupC) (p.Arg274Profs, c.820dupC); ClinVar=VCV000052972; Zygosity=Heterozygous (PubMed=31765965) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186164 CVCL_X479 RC-92a/hTERT telomerase immortalized cell line human CVCL_X479 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 29 hours (PubMed=16413016) 21186165 CVCL_WS79 UACC-2436 cancer cell line human CVCL_WS79 CL:0000010 Derived from metastatic site: Pubis. Female 21186166 CVCL_X478 RC-170N/hTERT telomerase immortalized cell line human CVCL_X478 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 34 hours (PubMed=16413016) 21186167 CVCL_WS78 UACC-2116 cancer cell line human CVCL_WS78 CL:0000010 Female Characteristics: Established from a xenograft. 21186168 CVCL_4M50 AG10955 transformed cell line human CVCL_4M50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186169 CVCL_4M54 AG10986 transformed cell line human CVCL_4M54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186170 CVCL_4M53 AG10984 transformed cell line human CVCL_4M53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186171 CVCL_4M52 AG10957 transformed cell line human CVCL_4M52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186172 CVCL_4M51 AG10956 transformed cell line human CVCL_4M51 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186173 CVCL_4M58 AG11008 transformed cell line human CVCL_4M58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186174 CVCL_4M57 AG11001 transformed cell line human CVCL_4M57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186175 CVCL_4M56 AG11000 transformed cell line human CVCL_4M56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186176 CVCL_4M55 AG10987 transformed cell line human CVCL_4M55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186177 CVCL_4M49 AG10953 transformed cell line human CVCL_4M49 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21186178 CVCL_4M48 AG10952 transformed cell line human CVCL_4M48 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186179 CVCL_X480 E006AA-hT cancer cell line human CVCL_X480 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Kidney. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00586 Problematic cell line: Contaminated Parent cell line (E006AA) has been shown to be a 786-O derivative. 21186180 CVCL_WS80 UACC-245 cancer cell line human CVCL_WS80 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21186181 CVCL_X484 CHSA0108 cancer cell line human CVCL_X484 Genome ancestry: African=2.14%; Native American=0.79%; East Asian, North=1.29%; East Asian, South=0%; South Asian=0%; European, North=63.46%; European, South=32.32% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186182 CVCL_WS84 MW [Human chondrosarcoma] cancer cell line human CVCL_WS84 CL:0000010 Unspecified 21186183 CVCL_X483 CHSA0011 cancer cell line human CVCL_X483 Genome ancestry: African=1.37%; Native American=0.01%; East Asian, North=3.14%; East Asian, South=0%; South Asian=0%; European, North=66.06%; European, South=29.42% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186184 CVCL_WS83 MW [Human breast carcinoma] cancer cell line human CVCL_WS83 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Ter (c.702C>A); Zygosity=Unspecified (from child cell line MW1C 6.3) Derived from metastatic site: Pleural effusion. Female Doubling time: 31 hours (PubMed=3971380) 21186185 CVCL_X482 273T cancer cell line human CVCL_X482 From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Tyr727Cys (c.2180A>G); dbSNP=rs138240620; Zygosity=Unspecified (PubMed=15735034) Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Omics: SNP array analysis Female 21186186 CVCL_WS82 EP [Human breast carcinoma] cancer cell line human CVCL_WS82 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 27 hours (PubMed=3971380) 21186187 CVCL_X481 201T cancer cell line human CVCL_X481 Genome ancestry: African=88.81%; Native American=0%; East Asian, North=2.58%; East Asian, South=0%; South Asian=0%; European, North=3.06%; European, South=5.55% (PubMed=30894373) From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Ala (c.721T>G); ClinVar=VCV000376665; Zygosity=Homozygous (Cosmic-CLP; DepMap) Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-low) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186188 CVCL_WS81 UACC-265 cancer cell line human CVCL_WS81 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21186189 CVCL_X488 HSAEC1-KT telomerase immortalized cell line human CVCL_X488 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4 Derived from sampling site: Lung Cell type=Airway epithelium basal cell.. Omics: Transcriptome analysis by microarray Male 21186190 CVCL_WS88 NUIGi005-B induced pluripotent stem cell human CVCL_WS88 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186191 CVCL_X487 EMC-BAC-2 cancer cell line human CVCL_X487 Genome ancestry: African=0.13%; Native American=0%; East Asian, North=1.05%; East Asian, South=0%; South Asian=0%; European, North=72.26%; European, South=26.55% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186192 CVCL_WS87 NUIGi005-A induced pluripotent stem cell human CVCL_WS87 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Ser566Tyr (c.1697C>A) (p.Ser439Tyr, c.1316C>A); ClinVar=VCV000053005; Zygosity=Heterozygous (PubMed=31415974) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186193 CVCL_X486 EMC-BAC-1 cancer cell line human CVCL_X486 Genome ancestry: African=74.47%; Native American=0%; East Asian, North=2.69%; East Asian, South=12.82%; South Asian=0%; European, North=3.5%; European, South=6.52% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Glu165Ter (c.493G>T) (c.637C>T); Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Homozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186194 CVCL_WS86 NUIGi002-A induced pluripotent stem cell human CVCL_WS86 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 21186195 CVCL_X485 CHSA8926 cancer cell line human CVCL_X485 Genome ancestry: African=0%; Native American=0.93%; East Asian, North=0%; East Asian, South=0.11%; South Asian=4.08%; European, North=68.86%; European, South=26.02% (PubMed=30894373). CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21186196 CVCL_WS85 HVRDi014-A induced pluripotent stem cell human CVCL_WS85 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly298Ser (c.892G>A); ClinVar=VCV000005232; Zygosity=Heterozygous (PubMed=24507191) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186197 CVCL_FB73 ND00188 transformed cell line human CVCL_FB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186198 CVCL_FB72 ND00184 transformed cell line human CVCL_FB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186199 CVCL_FB71 ND00181 transformed cell line human CVCL_FB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186200 CVCL_FB70 ND07704 transformed cell line human CVCL_FB70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186201 CVCL_FB77 ND12535 transformed cell line human CVCL_FB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186202 CVCL_FB76 ND12018 transformed cell line human CVCL_FB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186203 CVCL_FB75 ND11488 transformed cell line human CVCL_FB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186204 CVCL_FB74 ND11106 transformed cell line human CVCL_FB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186205 CVCL_FB69 ND00174 transformed cell line human CVCL_FB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186206 CVCL_FB68 ND00172 transformed cell line human CVCL_FB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186207 CVCL_FB67 ND07616 transformed cell line human CVCL_FB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186208 CVCL_FB84 ND13389 transformed cell line human CVCL_FB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186209 CVCL_FB83 ND13110 transformed cell line human CVCL_FB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186210 CVCL_FB82 ND12980 transformed cell line human CVCL_FB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186211 CVCL_FB81 ND12848 transformed cell line human CVCL_FB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186212 CVCL_FB88 ND13599 transformed cell line human CVCL_FB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186213 CVCL_FB87 ND13518 transformed cell line human CVCL_FB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186214 CVCL_FB86 ND13465 transformed cell line human CVCL_FB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186215 CVCL_FB85 ND13431 transformed cell line human CVCL_FB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186216 CVCL_FB80 ND12717 transformed cell line human CVCL_FB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186217 CVCL_FB79 ND12716 transformed cell line human CVCL_FB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186218 CVCL_FB78 ND12538 transformed cell line human CVCL_FB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186219 CVCL_FB51 ND00166 transformed cell line human CVCL_FB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186220 CVCL_FB50 ND00157 transformed cell line human CVCL_FB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186221 CVCL_FB55 ND06922 transformed cell line human CVCL_FB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186222 CVCL_FB54 ND06920 transformed cell line human CVCL_FB54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186223 CVCL_FB53 ND06871 transformed cell line human CVCL_FB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186224 CVCL_FB52 ND06759 transformed cell line human CVCL_FB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186225 CVCL_FB48 ND04535 transformed cell line human CVCL_FB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186226 CVCL_FB47 ND02249 transformed cell line human CVCL_FB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186227 CVCL_FB46 ND02160 transformed cell line human CVCL_FB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186228 CVCL_FB45 ND01581 transformed cell line human CVCL_FB45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186229 CVCL_FB49 ND04868 transformed cell line human CVCL_FB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186230 CVCL_FB62 ND07187 transformed cell line human CVCL_FB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186231 CVCL_FB61 ND07185 transformed cell line human CVCL_FB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186232 CVCL_FB60 ND07137 transformed cell line human CVCL_FB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186233 CVCL_FB66 ND07583 transformed cell line human CVCL_FB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186234 CVCL_FB65 ND00169 transformed cell line human CVCL_FB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186235 CVCL_FB64 ND07298 transformed cell line human CVCL_FB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186236 CVCL_FB63 ND07221 transformed cell line human CVCL_FB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186237 CVCL_FB59 ND07045 transformed cell line human CVCL_FB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186238 CVCL_FB58 ND07017 transformed cell line human CVCL_FB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186239 CVCL_FB57 ND07013 transformed cell line human CVCL_FB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186240 CVCL_FB56 ND06923 transformed cell line human CVCL_FB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186241 CVCL_FB33 ND14733 transformed cell line human CVCL_FB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186242 CVCL_FB32 ND14178 transformed cell line human CVCL_FB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186243 CVCL_FB31 ND14176 transformed cell line human CVCL_FB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186244 CVCL_FB30 ND14056 transformed cell line human CVCL_FB30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186245 CVCL_FB26 ND13749 transformed cell line human CVCL_FB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186246 CVCL_FB25 ND13481 transformed cell line human CVCL_FB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186247 CVCL_FB24 ND13341 transformed cell line human CVCL_FB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186248 CVCL_FB23 ND13338 transformed cell line human CVCL_FB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186249 CVCL_FB29 ND13962 transformed cell line human CVCL_FB29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186250 CVCL_FB28 ND13868 transformed cell line human CVCL_FB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186251 CVCL_FB27 ND13823 transformed cell line human CVCL_FB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186252 CVCL_FB40 ND00254 transformed cell line human CVCL_FB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186253 CVCL_FB44 ND00156 transformed cell line human CVCL_FB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186254 CVCL_FB43 ND00367 transformed cell line human CVCL_FB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186255 CVCL_FB42 ND00330 transformed cell line human CVCL_FB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186256 CVCL_FB41 ND00297 transformed cell line human CVCL_FB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186257 CVCL_FB37 ND14537 transformed cell line human CVCL_FB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186258 CVCL_FB36 ND04067 transformed cell line human CVCL_FB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186259 CVCL_FB35 ND04066 transformed cell line human CVCL_FB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186260 CVCL_FB34 ND14965 transformed cell line human CVCL_FB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186261 CVCL_FB39 ND00215 transformed cell line human CVCL_FB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186262 CVCL_FB38 ND00214 transformed cell line human CVCL_FB38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186263 CVCL_FB11 ND12360 transformed cell line human CVCL_FB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186264 CVCL_FB10 ND12354 transformed cell line human CVCL_FB10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186265 CVCL_FB09 ND12353 transformed cell line human CVCL_FB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186266 CVCL_FB04 ND12198 transformed cell line human CVCL_FB04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186267 CVCL_FB03 ND12169 transformed cell line human CVCL_FB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186268 CVCL_FB02 ND12154 transformed cell line human CVCL_FB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186269 CVCL_FB01 ND12083 transformed cell line human CVCL_FB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186270 CVCL_FB08 ND12322 transformed cell line human CVCL_FB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186271 CVCL_FB07 ND12312 transformed cell line human CVCL_FB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186272 CVCL_FB06 ND12293 transformed cell line human CVCL_FB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186273 CVCL_FB05 ND12263 transformed cell line human CVCL_FB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186274 CVCL_FB22 ND13196 transformed cell line human CVCL_FB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186275 CVCL_FB21 ND13005 transformed cell line human CVCL_FB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186276 CVCL_FB20 ND12865 transformed cell line human CVCL_FB20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186277 CVCL_FB15 ND12584 transformed cell line human CVCL_FB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186278 CVCL_FB14 ND12485 transformed cell line human CVCL_FB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186279 CVCL_FB13 ND12478 transformed cell line human CVCL_FB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186280 CVCL_FB12 ND12451 transformed cell line human CVCL_FB12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186281 CVCL_FB19 ND12706 transformed cell line human CVCL_FB19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186282 CVCL_FB18 ND12665 transformed cell line human CVCL_FB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186283 CVCL_FB17 ND12640 transformed cell line human CVCL_FB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186284 CVCL_FB16 ND12631 transformed cell line human CVCL_FB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186285 CVCL_X624 CEM.NKR-CCR5-Luc cancer cell line human CVCL_X624 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Resistant to NK cell-mediated cell lysis (from parent cell line); Characteristics: The luciferase reporter gene is under the transcriptional control of the HIV-2 LTR 21186286 CVCL_WU24 IRFMNi003-A induced pluripotent stem cell human CVCL_WU24 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21186287 CVCL_X623 CEM.NKR-CCR5 cancer cell line human CVCL_X623 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Resistant to NK cell-mediated cell lysis (from parent cell line) 21186288 CVCL_WU23 MUSIi009-A induced pluripotent stem cell human CVCL_WU23 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186289 CVCL_X622 CEM.NKR cancer cell line human CVCL_X622 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Resistant to NK cell-mediated cell lysis 21186290 CVCL_WU22 MUSIi010-A induced pluripotent stem cell human CVCL_WU22 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Occipital scalp Cell type=Fibroblast.. Male 21186291 CVCL_X621 H9/HTLV-IIICC cancer cell line human CVCL_X621 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: In vitro infected by HIV-1 21186292 CVCL_WU21 HMUi001-A induced pluripotent stem cell human CVCL_WU21 From: Eye Hospital, Harbin Medical University; Harbin; China CL:0000010 Population: Chinese; Derived from sampling site: Eye; cornea Cell type=Fibroblast.. Male 21186293 CVCL_WU28 ICGi009-B induced pluripotent stem cell human CVCL_WU28 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2176; CNTN6; Unexplicit; Microdeletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=31678775) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186294 CVCL_X628 U87.CD4.CCR2 cancer cell line human CVCL_X628 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1603; CCR2 (isoform B); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186295 CVCL_WU27 TCIERi001-A induced pluripotent stem cell human CVCL_WU27 From: Institute of Eye Research, Hualien Tzu Chi Hospital; Hualien; Taiwan CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 21186296 CVCL_X627 U87.CD4.CCR1 cancer cell line human CVCL_X627 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186298 CVCL_X626 U87.CD4 cancer cell line human CVCL_X626 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186299 CVCL_WU25 RCi007-B induced pluripotent stem cell human CVCL_WU25 From: Censo Biotechnologies, Ltd (Roslin Cells, Ltd); Roslin; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 30299; LRIF1; Simple; p.Arg346Ter (c.1036C>T); Zygosity=Heterozygous (from autologous cell lines RCi007-A and RCi007-C) Derived from sampling site: Cell type=Fibroblast. Discontinued: EBiSC; RCi007-B; true Female 21186300 CVCL_X625 WE17/10 factor-dependent cell line human CVCL_X625 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent Doubling time: 24 hours (CelloPub=CLPUB00150) 21186301 CVCL_WU29 ICGi013-A induced pluripotent stem cell human CVCL_WU29 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2176; CNTN6; Unexplicit; Microdeletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=31678775) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186302 CVCL_X629 U87.CD4.CCR3 cancer cell line human CVCL_X629 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186303 CVCL_WU31 NUIGi012-A induced pluripotent stem cell human CVCL_WU31 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Ala614Val (c.1841C>T); ClinVar=VCV000029777; Zygosity=Heterozygous (PubMed=34628246) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186304 CVCL_X631 U87.CD4.CCR5.CXCR4 cancer cell line human CVCL_X631 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186305 CVCL_WU30 ICGi013-B induced pluripotent stem cell human CVCL_WU30 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2176; CNTN6; Unexplicit; Microdeletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=31678775) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186306 CVCL_X630 U87.CD4.CCR5 cancer cell line human CVCL_X630 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186307 CVCL_X613 3201/EECC cancer cell line CVCL_X613 CL:0000010 Virology: Infected with feline leukemia virus (FeLV) isolate EECC Doubling time: 15-20 hours (HIVReagentProgram). 21186308 CVCL_WU13 HPB-MLp-2 cancer cell line human CVCL_WU13 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21186309 CVCL_X612 3201 cancer cell line CVCL_X612 CL:0000010 21186310 CVCL_WU12 AG27427 induced pluripotent stem cell human CVCL_WU12 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu578Val (c.1733A>T); ClinVar=VCV000066863; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21186311 CVCL_X611 HUT 78/SIV-BK28 cancer cell line human CVCL_X611 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with simian immunodeficiency virus isolate BK28 (HIVReagentProgram) Doubling time: 3 days (HIVReagentProgram) 21186312 CVCL_WU11 MW3 hybridoma house mouse CVCL_WU11 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Gln region). 21186313 CVCL_X610 H9/SIVmac186 cancer cell line human CVCL_X610 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with simian immunodeficiency virus isolate SIVmac316 (HIVReagentProgram) 21186314 CVCL_WU10 MW8 hybridoma house mouse CVCL_WU10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P42858; Human HTT. 21186315 CVCL_WU17 CSUASOi002-A induced pluripotent stem cell human CVCL_WU17 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 6938; CHST6; Simple; p.Leu21delinsArgfs (c.62_63delTinsGA); Zygosity=Heterozygous (PubMed=31669782); Sequence variation: Mutation; HGNC; 6938; CHST6; Simple; p.Gln298Ter (c.892C>T); ClinVar=VCV000320606; Zygosity=Heterozygous (PubMed=31669782) Population: Chinese; Derived from sampling site: Urine. Female 21186316 CVCL_X617 HUT 78/HIV-1SF2 cancer cell line human CVCL_X617 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186317 CVCL_WU16 CSUASOi001-A induced pluripotent stem cell human CVCL_WU16 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 10457; RS1; Simple; p.Arg102Trp (c.304C>T); ClinVar=VCV000009887; Zygosity=Hemizygous (PubMed=31141763) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21186318 CVCL_X616 HUT 78/SIV-BK44 cancer cell line human CVCL_X616 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with simian immunodeficiency virus isolate BK44 (HIVReagentProgram) Doubling time: 3 days (HIVReagentProgram) 21186319 CVCL_WU15 4063-21-1 hybridoma house mouse CVCL_WU15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:15930; Atrazine. 21186320 CVCL_X615 CEMx174/HIV-2ST hybrid cell line human CVCL_X615 CL:0000010 Virology: Infected with HIV-2 isolate ST (HIVReagentProgram) Doubling time: ~18 hours (HIVReagentProgram). 21186321 CVCL_WU14 2G3-6E3-2E2 hybridoma house mouse CVCL_WU14 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 21186322 CVCL_X614 3201/61E cancer cell line CVCL_X614 CL:0000010 Virology: Infected with feline leukemia virus (FeLV) isolate 61E Doubling time: 15-20 hours (HIVReagentProgram). 21186323 CVCL_X619 H9/HTLV-IIIRF cancer cell line human CVCL_X619 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21186324 CVCL_WU19 TRNDi009-B induced pluripotent stem cell human CVCL_WU19 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186325 CVCL_X618 RL-5 transformed cell line CVCL_X618 CL:0000010 Transformant: Ateline herpesvirus 3 (Herpesvirus ateles)(NCBI-Taxonomy; 85618); Derived from sampling site: Lymph node Cell type=T-cell.; Breed/subspecies: B/J. Unspecified Doubling time: 14 hours (HIVReagentProgram) 21186326 CVCL_WU18 TRNDi009-A induced pluripotent stem cell human CVCL_WU18 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186327 CVCL_X620 H9/HTLV-IIIMN cancer cell line human CVCL_X620 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186328 CVCL_WU20 TRNDi009-C induced pluripotent stem cell human CVCL_WU20 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 11120; SMPD1; Simple; p.Leu304Pro (c.911T>C) (L302P); ClinVar=VCV000002989; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186329 CVCL_X602 B16-Blue ISG cancer cell line house mouse CVCL_X602 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter enhanced by a multimeric ISRE 21186330 CVCL_WU02 NYSCFi001-D induced pluripotent stem cell human CVCL_WU02 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21186331 CVCL_WU01 NYSCFi001-C induced pluripotent stem cell human CVCL_WU01 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21186332 CVCL_X601 THP1-Null cancer cell line human CVCL_X601 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21186333 CVCL_WU00 NYSCFi001-B induced pluripotent stem cell human CVCL_WU00 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21186334 CVCL_X600 THP1-defNLRP3 cancer cell line human CVCL_X600 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 16400; NLRP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21186335 CVCL_X606 C3H/TLR4mut MEF transformed cell line house mouse CVCL_X606 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/HeJ. Discontinued: InVivoGen; Catalog number mef-c3h4m Unspecified 21186336 CVCL_WU06 MW4 hybridoma house mouse CVCL_WU06 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Gln region). 21186337 CVCL_X605 B16-Blue IFN-alpha/beta cancer cell line house mouse CVCL_X605 CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:107655; Ifngr1; Knockout cell: Method=Not specified; MGI; MGI:107654; Ifngr2; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-alpha/beta-inducible ISG54 promoter enhanced by a multimeric ISRE 21186338 CVCL_WU05 MW1 [Mouse hybridoma against human HTT] hybridoma house mouse CVCL_WU05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Gln region). 21186339 CVCL_X604 B16-Blue IFN-gamma cancer cell line house mouse CVCL_X604 CL:0000010 Knockout cell: Method=Not specified; MGI; MGI:107658; Ifnar1; Knockout cell: Method=Not specified; MGI; MGI:1098243; Ifnar2; Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 11362; STAT1; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter fused to 4 IFNG-activated sites (GAS) 21186340 CVCL_WU04 NYSCFi002-B induced pluripotent stem cell human CVCL_WU04 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21186341 CVCL_X603 B16-Blue ISG-KO-STING cancer cell line house mouse CVCL_X603 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1919762; Sting1; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter enhanced by a multimeric ISRE 21186342 CVCL_WU03 NYSCFi002-A induced pluripotent stem cell human CVCL_WU03 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Female 21186343 CVCL_X609 HUT 78/SIVmac251 cancer cell line human CVCL_X609 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with simian immunodeficiency virus isolate SIVmac251 (HIVReagentProgram) 21186344 CVCL_WU09 MW7 hybridoma house mouse CVCL_WU09 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Pro region). 21186345 CVCL_WU08 MW6 hybridoma house mouse CVCL_WU08 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Gln region). 21186346 CVCL_X608 U937/HIV-2MS cancer cell line human CVCL_X608 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male Virology: Infected with HIV-2 isolate MS (HIVReagentProgram) 21186347 CVCL_X607 C3H/WT MEF transformed cell line house mouse CVCL_X607 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H/HeN. Discontinued: InVivoGen; Catalog number mef-c3hwt Unspecified 21186348 CVCL_WU07 MW5 hybridoma house mouse CVCL_WU07 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P42858; Human HTT (Note=Recognizes poly-Gln region). 21186349 CVCL_FB95 ND14501 transformed cell line human CVCL_FB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186350 CVCL_FB94 ND14378 transformed cell line human CVCL_FB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186351 CVCL_FB93 ND14376 transformed cell line human CVCL_FB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186352 CVCL_FB92 ND13996 transformed cell line human CVCL_FB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186353 CVCL_FB99 ND14897 transformed cell line human CVCL_FB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186354 CVCL_FB98 ND14807 transformed cell line human CVCL_FB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186355 CVCL_FB97 ND14689 transformed cell line human CVCL_FB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186356 CVCL_FB96 ND14688 transformed cell line human CVCL_FB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186357 CVCL_FB91 ND13995 transformed cell line human CVCL_FB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186358 CVCL_FB90 ND13994 transformed cell line human CVCL_FB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186359 CVCL_FB89 ND13886 transformed cell line human CVCL_FB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186360 CVCL_WT89 AG27297 finite cell line CVCL_WT89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21186361 CVCL_X589 THP1-Blue ISG-KD-STING cancer cell line human CVCL_X589 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 27962; STING1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Discontinued: InVivoGen; Catalog number thp-kdstg Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter enhanced by a multimeric ISRE 21186362 CVCL_WT88 AG27253 finite cell line CVCL_WT88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21186363 CVCL_X588 THP1-Blue ISG cancer cell line human CVCL_X588 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter enhanced by a multimeric ISRE 21186364 CVCL_4N42 GM03218 finite cell line human CVCL_4N42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21186365 CVCL_4N41 GM03208 finite cell line human CVCL_4N41 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21186366 CVCL_4N40 GM03164 transformed cell line human CVCL_4N40 HLA typing: A*02,24; B*27; C*02 (Coriell=GM03164) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186367 CVCL_4N46 GM06224 transformed cell line human CVCL_4N46 CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186368 CVCL_4N45 GM04863 finite cell line human CVCL_4N45 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Arg247Trp (c.739C>T); ClinVar=VCV000003922; Zygosity=Heterozygous (PubMed=19815695); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (PubMed=19815695) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21186369 CVCL_4N44 GM04391 transformed cell line human CVCL_4N44 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Asn215Ser (c.644A>G); ClinVar=VCV000010730; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186370 CVCL_4N43 GM04368 transformed cell line human CVCL_4N43 CL:0000010 Sequence variation: Mutation; HGNC; 7459; MT-ND4; Simple; p.Arg340His (m.11778G>A); ClinVar=VCV000009708; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186371 CVCL_4N39 GM03065 finite cell line human CVCL_4N39 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly219del (c.651TGG[1]) (c.654_656delTGG) (G197del, c.652delGGT); ClinVar=VCV000226329; Zygosity=Heterozygous (By familial inference of GM03040) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186372 CVCL_4N38 GM03064 finite cell line human CVCL_4N38 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly219del (c.651TGG[1]) (c.654_656delTGG) (G197del, c.652delGGT); ClinVar=VCV000226329; Zygosity=Heterozygous (By familial inference of GM03040) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186373 CVCL_4N37 GM03052 finite cell line human CVCL_4N37 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21186374 CVCL_4N36 GM03051 finite cell line human CVCL_4N36 CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=3375249) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 21186375 CVCL_WT90 AG27298 finite cell line CVCL_WT90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 21186376 CVCL_X590 THP1-Lucia NF-kappaB cancer cell line human CVCL_X590 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: The Lucia luciferase reporter gene is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 c-Rel binding sites 21186377 CVCL_X594 RAW-Blue cancer cell line house mouse CVCL_X594 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter 21186378 CVCL_WT94 UCLAi001-C induced pluripotent stem cell human CVCL_WT94 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi004-A (Cellosaurus=CVCL_A5HJ), UCLAi004-B (Cellosaurus=CVCL_A5HK) and UCLAi004-C (Cellosaurus=CVCL_A5HL); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186379 CVCL_X593 Jurkat-Dual cancer cell line human CVCL_X593 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). The Lucia luciferase reporter gene is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 c-Rel binding sites. 21186380 CVCL_WT93 UCLAi001-B induced pluripotent stem cell human CVCL_WT93 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi004-A (Cellosaurus=CVCL_A5HJ), UCLAi004-B (Cellosaurus=CVCL_A5HK) and UCLAi004-C (Cellosaurus=CVCL_A5HL); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186381 CVCL_X592 Ramos-Blue KD-Myd cancer cell line human CVCL_X592 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7562; MYD88; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Ascites. Male Characteristics: MyD88-deficient This cell line does not respond or respond weakly to the activation of receptors which signaling is dependent on MyD88, such as TLR7 and TLR9. However, they are still responsive to TLR3 which is MyD88-independent (InVivoGen).; Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter; Virology: EBV-negative 21186382 CVCL_WT92 UCLAi001-A induced pluripotent stem cell human CVCL_WT92 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Donor information: Established from monozygotic twin of UCLAi004-A (Cellosaurus=CVCL_A5HJ), UCLAi004-B (Cellosaurus=CVCL_A5HK) and UCLAi004-C (Cellosaurus=CVCL_A5HL); Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186383 CVCL_X591 Ramos-Blue cancer cell line human CVCL_X591 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Ascites. Male Characteristics: Can be used to study the NF-kappaB and AP-1 signaling pathways in B-lymphocytes and in particular the TLR3, TLR7, TLR9 and NOD1 signaling pathways (InVivoGen); Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter; Virology: EBV-negative 21186384 CVCL_WT91 UCLAi089-A induced pluripotent stem cell CVCL_WT91 From: University of California, Los Angeles; Los Angeles; USA CL:0000010 Derived from sampling site: Trunk; skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21186385 CVCL_X598 THP1-defASC cancer cell line human CVCL_X598 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 16608; PYCARD; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21186386 CVCL_WT98 UOWi009-A induced pluripotent stem cell human CVCL_WT98 From: University of Wollongong; Wollongong; Australia. CL:0000010 21186387 CVCL_X597 RAW-Lucia ISG-KO-STING cancer cell line house mouse CVCL_X597 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1919762; Sting1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21186388 CVCL_WT97 XDCMHi001-A induced pluripotent stem cell human CVCL_WT97 From: Xiaoshan District Chinese Medicine Hospital; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Tyr570Cys (c.1709A>G); Zygosity=Heterozygous (PubMed=32388440) Derived from sampling site: Urine. Male 21186389 CVCL_X596 RAW-Lucia ISG cancer cell line house mouse CVCL_X596 CL:0000010 Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21186390 CVCL_WT96 UCLi012-A induced pluripotent stem cell human CVCL_WT96 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg3381Ter (c.10141C>T); ClinVar=VCV000011273; Zygosity=Hemizygous (PubMed=32087527) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186391 CVCL_X595 RAW-Blue ISG cancer cell line house mouse CVCL_X595 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Discontinued: InVivoGen; Catalog number raw-isg Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an ISG54 promoter enhanced by a multimeric ISRE 21186392 CVCL_WT95 UCLi011-A induced pluripotent stem cell human CVCL_WT95 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Trp3284Ter (c.9851G>A); ClinVar=VCV001322632; Zygosity=Hemizygous (PubMed=32087527) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186393 CVCL_X579 ClearCa-28 cancer cell line human CVCL_X579 CL:0000010 Unspecified 21186394 CVCL_WT79 UUIGPi002-A induced pluripotent stem cell human CVCL_WT79 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Leu (c.194C>T); ClinVar=VCV000182975; Zygosity=Heterozygous (PubMed=31176917) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186395 CVCL_X578 ClearCa-9 cancer cell line human CVCL_X578 CL:0000010 Female Doubling time: 64 hours (PubMed=9146668). 21186396 CVCL_WT78 UUIGPi001-A induced pluripotent stem cell human CVCL_WT78 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser65Trp (c.194C>G); ClinVar=VCV000043597; Zygosity=Heterozygous (PubMed=31176917) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186397 CVCL_X577 ClearCa-8 cancer cell line human CVCL_X577 CL:0000010 Male Doubling time: 112 hours (PubMed=9146668). 21186398 CVCL_WT77 UNIBSi005-C induced pluripotent stem cell human CVCL_WT77 From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21186399 CVCL_4N53 AG07562 transformed cell line human CVCL_4N53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186400 CVCL_4N52 AG07561 finite cell line human CVCL_4N52 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186401 CVCL_4N51 AG07560 transformed cell line human CVCL_4N51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186402 CVCL_4N50 AG07559 finite cell line human CVCL_4N50 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186403 CVCL_4N57 AG07566 transformed cell line human CVCL_4N57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186404 CVCL_4N56 AG07565 finite cell line human CVCL_4N56 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186405 CVCL_4N55 AG07564 transformed cell line human CVCL_4N55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186406 CVCL_4N54 AG07563 finite cell line human CVCL_4N54 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186407 CVCL_4N49 AG07558 transformed cell line human CVCL_4N49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186408 CVCL_4N48 AG07091 transformed cell line human CVCL_4N48 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg471Cys (c.1411C>T) (c.1623C>T); ClinVar=VCV000014503; Zygosity=Heterozygous (PubMed=12768443); Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Cys (c.1579C>T) (c.1791C>T); ClinVar=VCV000014487; Zygosity=Heterozygous (PubMed=12768443) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186409 CVCL_4N47 GM06225 finite cell line human CVCL_4N47 CL:0000010 Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186410 CVCL_X583 THP1-Xblue-CD14 cancer cell line human CVCL_X583 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter 21186411 CVCL_WT83 UUIGPi006-A induced pluripotent stem cell human CVCL_WT83 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Pro1837fs (c.5502_5509dupGCTTGAAC); Zygosity=Heterozygous (PubMed=31400703) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186412 CVCL_X582 THP1-Xblue cancer cell line human CVCL_X582 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter 21186413 CVCL_WT82 UUIGPi005-A induced pluripotent stem cell human CVCL_WT82 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 14881; ZEB2; Simple; p.Arg343Ter (c.1027C>T); ClinVar=VCV000189281; Zygosity=Heterozygous (PubMed=31376723) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21186414 CVCL_X581 ClearCa-29 cancer cell line human CVCL_X581 CL:0000010 Unspecified 21186415 CVCL_WT81 UUIGPi004-A induced pluripotent stem cell human CVCL_WT81 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 14881; ZEB2; Simple; p.Arg343Ter (c.1027C>T); ClinVar=VCV000189281; Zygosity=Heterozygous (PubMed=31376723) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186416 CVCL_X580 ClearCa-39 cancer cell line human CVCL_X580 CL:0000010 Unspecified 21186417 CVCL_WT80 UUIGPi003-A induced pluripotent stem cell human CVCL_WT80 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Phe76del (c.227_229delTCT); Zygosity=Heterozygous (PubMed=31176917) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186418 CVCL_WT87 AG27252 finite cell line CVCL_WT87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 21186419 CVCL_X587 THP1-Lucia ISG cancer cell line human CVCL_X587 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21186420 CVCL_WT86 AG27415 induced pluripotent stem cell human CVCL_WT86 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21186421 CVCL_X586 THP1-XBlue-defMyD cancer cell line human CVCL_X586 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter 21186422 CVCL_X585 THP1-Blue NF-kappaB cancer cell line human CVCL_X585 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 copies of the NF-kappaB consensus TRE and 3 copies of the c-Rel binding site 21186423 CVCL_WT85 UUIGPi008-A induced pluripotent stem cell human CVCL_WT85 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Thr217Arg (c.651C>G); Zygosity=Heterozygous (PubMed=31400703) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186424 CVCL_X584 THP1-Xblue-MD2-CD14 cancer cell line human CVCL_X584 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 17156; LY96 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of a NF-KappaB/AP-1 promoter 21186425 CVCL_WT84 UUIGPi007-A induced pluripotent stem cell human CVCL_WT84 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Ala989Phe (c.2965G>C); Zygosity=Heterozygous (PubMed=31400703) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186426 CVCL_X569 ClearCa-31 cancer cell line human CVCL_X569 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Phe76Tyr (c.227T>A); ClinVar=VCV000625224; Zygosity=Unspecified (PubMed=10925357); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Cys77Ser (c.229T>A); Zygosity=Unspecified (PubMed=10925357). Unspecified 21186427 CVCL_WT69 HPE-MLp-K cancer cell line human CVCL_WT69 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21186428 CVCL_X568 ClearCa-3 cancer cell line human CVCL_X568 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265). Female Doubling time: 31 hours (PubMed=9146668) 21186429 CVCL_WT68 HCF-MLp-N cancer cell line human CVCL_WT68 CL:0000010 Population: Japanese; Derived from sampling site: Cerebrospinal fluid. 21186430 CVCL_X567 ClearCa-27 cancer cell line human CVCL_X567 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val130Asp (c.389T>A); Zygosity=Unspecified (PubMed=10925357). Male 21186431 CVCL_WT67 HBM-Noda cancer cell line human CVCL_WT67 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG lambda; Virology: Contains an EBV genome 21186432 CVCL_X566 ClearCa-26 cancer cell line human CVCL_X566 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asn78Ile (c.233A>T); ClinVar=VCV000223169; Zygosity=Unspecified (PubMed=10925357). Female 21186433 CVCL_WT66 HPE-Ret-3 cancer cell line human CVCL_WT66 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from 'reticulum cell sarcoma'; Derived from sampling site: Pleural effusion. Male 21186434 CVCL_4N20 GM01931 finite cell line human CVCL_4N20 CL:0000010 Population: Caucasian; Swiss; Derived from sampling site: Cell type=Fibroblast. Male 21186435 CVCL_4N24 GM02307 transformed cell line human CVCL_4N24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186436 CVCL_4N23 GM02306 finite cell line human CVCL_4N23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21186437 CVCL_4N22 GM02256 transformed cell line human CVCL_4N22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186438 CVCL_4N21 GM02255 finite cell line human CVCL_4N21 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21186439 CVCL_4N17 GM01506 finite cell line human CVCL_4N17 CL:0000010 Karyotypic information: 46,XY,rec(3)(qter->p25::q21->qter) [46]; 46,XY,rec(3)(qter->p25::q21->qter),+8 [4] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21186440 CVCL_4N16 GM01460 transformed cell line human CVCL_4N16 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys667Tyr (c.2000G>A) (C646Y); ClinVar=VCV000003689; Zygosity=Heterozygous (Coriell) Population: Caucasian; French Canadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186441 CVCL_4N15 GM01459 transformed cell line human CVCL_4N15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186442 CVCL_4N14 GM01458 transformed cell line human CVCL_4N14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186443 CVCL_4N19 GM01915 finite cell line human CVCL_4N19 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys197Phe (c.590G>T) (C176F); ClinVar=VCV000251309; Zygosity=Heterozygous (PubMed=29308438); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Asp304Asn (c.910G>A) (D283N); ClinVar=VCV000003692; Zygosity=Heterozygous (PubMed=29308438) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21186444 CVCL_4N18 GM01567 transformed cell line human CVCL_4N18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186445 CVCL_X572 ClearCa-36 cancer cell line human CVCL_X572 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asn78Thr (c.233A>C); ClinVar=VCV000223168; Zygosity=Unspecified (PubMed=10925357). Unspecified 21186446 CVCL_WT72 OmGFP66 transformed cell line house mouse CVCL_WT72 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Gly, p.Ser72Ala, Lys79Arg, Thr203Tyr and His231Leu = Topaz); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteocyte.; Breed/subspecies: C57BL/6-Tg(Dmp1-Topaz)1Ikal/J. Unspecified Characteristics: Model for osteocyte differentiation Forms mineralized structures that closely mimick in vivo bone, with a highly organized bone-like appearance and clearly defined lacunae.; Characteristics: Expresses GFP Topaz under the control of the Dmp1 promoter 21186447 CVCL_X571 ClearCa-35 cancer cell line human CVCL_X571 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Ser68Ter (c.203_204CG>AA); Zygosity=Unspecified (PubMed=10925357). Unspecified 21186448 CVCL_WT71 OmGFP10 transformed cell line house mouse CVCL_WT71 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Gly, p.Ser72Ala, Lys79Arg, Thr203Tyr and His231Leu = Topaz); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteocyte.; Breed/subspecies: C57BL/6-Tg(Dmp1-Topaz)1Ikal/J. Unspecified Characteristics: Expresses GFP Topaz under the control of the Dmp1 promoter 21186449 CVCL_X570 ClearCa-32 cancer cell line human CVCL_X570 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Arg108Alafs*51 (c.322delC); Zygosity=Unspecified (PubMed=10925357). Unspecified 21186450 CVCL_WT70 HPE-MLp-M cancer cell line human CVCL_WT70 CL:0000010 Population: Japanese. Unspecified 21186451 CVCL_X576 ClearCa-7 cancer cell line human CVCL_X576 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265). Male Doubling time: 60 hours (PubMed=9146668) 21186452 CVCL_WT76 UNIBSi005-B induced pluripotent stem cell human CVCL_WT76 From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21186453 CVCL_X575 ClearCa-6 cancer cell line human CVCL_X575 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg290His (c.869G>A); ClinVar=VCV000127825; Zygosity=Unspecified (PubMed=11139287; PubMed=15863265); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu178Glnfs (c.532_533insC); Zygosity=Unspecified (PubMed=10925357). Male Doubling time: 45 hours (PubMed=9146668) 21186454 CVCL_WT75 UNIBSi005-A induced pluripotent stem cell human CVCL_WT75 From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21186455 CVCL_X574 ClearCa-5 cancer cell line human CVCL_X574 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.952_966del15; Zygosity=Unspecified (PubMed=15863265). Female Doubling time: 32 hours (PubMed=9146668) 21186456 CVCL_WT74 ZZUi015-A induced pluripotent stem cell human CVCL_WT74 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[>50] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Homozygous (PubMed=34915310) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186457 CVCL_X573 ClearCa-4 cancer cell line human CVCL_X573 CL:0000010 Female Doubling time: 33 hours (PubMed=9146668). 21186458 CVCL_WT73 ZZUNEUi001-A induced pluripotent stem cell human CVCL_WT73 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 21186459 CVCL_X558 ClearCa-19 cancer cell line human CVCL_X558 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265). Male 21186460 CVCL_WT58 HPL-MmC cancer cell line human CVCL_WT58 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21186461 CVCL_X557 ClearCa-18 cancer cell line human CVCL_X557 CL:0000010 Male 21186462 CVCL_WT57 HPE-GAC-T cancer cell line human CVCL_WT57 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21186463 CVCL_X556 ClearCa-17 cancer cell line human CVCL_X556 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Leu (c.638G>T); ClinVar=VCV000376650; Zygosity=Unspecified (PubMed=11139287). Male 21186464 CVCL_WT56 HLN-GAC-5 cancer cell line human CVCL_WT56 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. 21186465 CVCL_X555 ClearCa-16 cancer cell line human CVCL_X555 CL:0000010 Female 21186466 CVCL_WT55 HPE-GAC-4 cancer cell line human CVCL_WT55 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21186467 CVCL_X559 ClearCa-2 cancer cell line human CVCL_X559 CL:0000010 Male Doubling time: 37 hours (PubMed=9146668). 21186468 CVCL_WT59 MA IV cancer cell line human CVCL_WT59 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male Doubling time: 33.6 hours (PubMed=2997265) 21186469 CVCL_4N31 GM02770 finite cell line human CVCL_4N31 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21186470 CVCL_4N30 GM02768 finite cell line human CVCL_4N30 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186471 CVCL_4N35 GM03040 finite cell line human CVCL_4N35 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly219del (c.651TGG[1]) (c.654_656delTGG) (G197del, c.652delGGT); ClinVar=VCV000226329; Zygosity=Homozygous (PubMed=29308438) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186472 CVCL_4N34 GM02774 finite cell line human CVCL_4N34 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186473 CVCL_4N33 GM02772 finite cell line human CVCL_4N33 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Heterozygous (from familial inference of GM02769) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186474 CVCL_4N32 GM02771 finite cell line human CVCL_4N32 CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000167140; Zygosity=Heterozygous (PubMed=29982630) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186475 CVCL_4N28 GM02694 finite cell line human CVCL_4N28 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln215Ter (c.643C>T); ClinVar=VCV000000814; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186476 CVCL_4N27 GM02633 transformed cell line human CVCL_4N27 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln215Ter (c.643C>T); ClinVar=VCV000000814; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186477 CVCL_4N26 GM02551 finite cell line human CVCL_4N26 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Female 21186478 CVCL_4N25 GM02373 transformed cell line human CVCL_4N25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186479 CVCL_4N29 GM02739 finite cell line human CVCL_4N29 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21186480 CVCL_X561 ClearCa-21 cancer cell line human CVCL_X561 CL:0000010 Male 21186481 CVCL_WT61 HNGA cancer cell line human CVCL_WT61 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 35 hours (CelloPub=CLPUB00513) 21186482 CVCL_X560 ClearCa-20 cancer cell line human CVCL_X560 CL:0000010 Male 21186483 CVCL_WT60 MKO cancer cell line human CVCL_WT60 CL:0000010 Population: Japanese; Derived from sampling site: Stomach. 21186484 CVCL_X565 ClearCa-25 cancer cell line human CVCL_X565 CL:0000010 Male 21186485 CVCL_WT65 HLN-Ret-2 cancer cell line human CVCL_WT65 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from 'reticulum cell sarcoma'; Derived from sampling site: Lymph node. Male 21186486 CVCL_X564 ClearCa-24 cancer cell line human CVCL_X564 CL:0000010 Male 21186487 CVCL_WT64 HLN-Ret-1 cancer cell line human CVCL_WT64 CL:0000010 Population: Japanese; Donor information: Established from a patient suffering from 'reticulum cell sarcoma'; Derived from sampling site: Lymph node. Male 21186488 CVCL_X563 ClearCa-23 cancer cell line human CVCL_X563 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Pro172Leufs*30 (c.514delC); Zygosity=Unspecified (PubMed=10925357). Male 21186489 CVCL_WT63 HPL-Hod-2 cancer cell line human CVCL_WT63 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21186490 CVCL_X562 ClearCa-22 cancer cell line human CVCL_X562 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Tyr98Ter (c.294C>G); ClinVar=VCV000625235; Zygosity=Unspecified (PubMed=10925357). Male 21186491 CVCL_WT62 HPL-Hod-1 cancer cell line human CVCL_WT62 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Male 21186492 CVCL_X547 Chromphi-4 cancer cell line human CVCL_X547 CL:0000010 Male Doubling time: 51 hours (PubMed=8932342) 21186493 CVCL_WT47 HPL-Ad-K cancer cell line human CVCL_WT47 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21186494 CVCL_WT46 5F11 hybridoma house mouse CVCL_WT46 CL:0000010 Miscellaneous: As the immunized splenic B-cells are from HuMAb mice the produced mAB is of human origin. Biotechnology: The monoclonal antibody produced by this hybridoma was developed by Medarex into a therapeutic mAB known as Iratumumab (MDX-060) to be used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30 21186495 CVCL_X546 Chromphi-3 cancer cell line human CVCL_X546 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11139287) Male Doubling time: 40 hours (PubMed=8932342) 21186496 CVCL_WT45 22 hybridoma house mouse CVCL_WT45 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P12314; Human FCGR1A/CD64. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12147 21186497 CVCL_X545 Chromphi-2 cancer cell line human CVCL_X545 CL:0000010 Male Doubling time: 40 hours (PubMed=8932342) 21186498 CVCL_X544 Chromphi-1 cancer cell line human CVCL_X544 CL:0000010 Male Doubling time: 24 hours (PubMed=8932342) 21186499 CVCL_WT44 Ki-7 hybridoma house mouse CVCL_WT44 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186500 CVCL_X549 ClearCa-10 cancer cell line human CVCL_X549 CL:0000010 Female Doubling time: 51 hours (PubMed=9146668). 21186501 CVCL_WT49 HPL-GCC-2 cancer cell line human CVCL_WT49 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21186502 CVCL_X548 ClearCa-1 cancer cell line human CVCL_X548 CL:0000010 Male Doubling time: 34 hours (PubMed=9146668). 21186503 CVCL_WT48 HPL-GCC-1 cancer cell line human CVCL_WT48 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21186504 CVCL_4N02 EC8501 cancer cell line human CVCL_4N02 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Male 21186505 CVCL_4N01 SHEE100 transformed cell line human CVCL_4N01 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186506 CVCL_4N00 SHEE85 transformed cell line human CVCL_4N00 CL:0000010 Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761); Derived from sampling site: Fetal esophagus. 21186507 CVCL_X550 ClearCa-11 cancer cell line human CVCL_X550 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265). Female Doubling time: 27 hours (PubMed=9146668) 21186508 CVCL_WT50 HLT-Oat-1 cancer cell line human CVCL_WT50 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21186509 CVCL_X554 ClearCa-15 cancer cell line human CVCL_X554 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11139287; PubMed=15863265). Male 21186510 CVCL_WT54 HPE-GAC-3 cancer cell line human CVCL_WT54 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21186511 CVCL_X553 ClearCa-14 cancer cell line human CVCL_X553 CL:0000010 Male 21186512 CVCL_WT53 HPE-GAC-2 cancer cell line human CVCL_WT53 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Unspecified 21186513 CVCL_X552 ClearCa-13 cancer cell line human CVCL_X552 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Cys77Ter (c.231C>A); Zygosity=Unspecified (PubMed=10925357). Female Doubling time: 42 hours (PubMed=9146668) 21186514 CVCL_WT52 HPL-Oat-3 cancer cell line human CVCL_WT52 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified 21186515 CVCL_X551 ClearCa-12 cancer cell line human CVCL_X551 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15863265). Male Doubling time: 104 hours (PubMed=9146668) 21186516 CVCL_WT51 HLT-Oat-2 cancer cell line human CVCL_WT51 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21186517 CVCL_X536 Chrompho-A cancer cell line human CVCL_X536 CL:0000010 Female Doubling time: 51 hours (PubMed=7717462). 21186518 CVCL_WT36 Ki-Mcm6 hybridoma house mouse CVCL_WT36 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q14566; Human MCM6. 21186519 CVCL_WT35 B411-4 transformed cell line human CVCL_WT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186520 CVCL_X535 RCC98 cancer cell line human CVCL_X535 HLA typing: A*02,24; B*35,46; C*w01,w09(3) (PubMed=18704411) CL:0000010 Population: Chinese; Derived from sampling site: Kidney. Unspecified 21186521 CVCL_X534 RCC52 cancer cell line human CVCL_X534 HLA typing: A*02,11; B*46,60(40); C*w01,w07 (PubMed=18704411) CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ala6Profs*1 (c.16delG); Zygosity=Heterozygous (PubMed=18704411); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous; Note=Total loss of HLA class 1 expression (PubMed=18704411) Population: Chinese; Derived from sampling site: Kidney. Male Doubling time: 23.4 hours (PubMed=24222125) 21186522 CVCL_WT34 TASH transformed cell line human CVCL_WT34 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21186523 CVCL_WT33 1E8 [Mouse hybridoma against human DSCs] hybridoma house mouse CVCL_WT33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human dendritically shapped cells. 21186524 CVCL_X533 HH332 cancer cell line human CVCL_X533 HLA typing: A*24,24; B*51,58; C*07,14 (PubMed=18704411) CL:0000010 Derived from sampling site: Kidney. Unspecified 21186525 CVCL_WT39 Ki-2 hybridoma house mouse CVCL_WT39 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186526 CVCL_X539 VH-Renal cancer cell line human CVCL_X539 CL:0000010 21186527 CVCL_WT38 Ki-S5 hybridoma house mouse CVCL_WT38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46013; Human MKI67. 21186528 CVCL_X538 SGE-RC cancer cell line human CVCL_X538 CL:0000010 21186529 CVCL_X537 Chrompho-B cancer cell line human CVCL_X537 CL:0000010 Female Doubling time: 43 hours (PubMed=7717462). 21186530 CVCL_WT37 Ki-S3 hybridoma house mouse CVCL_WT37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P46013; Human MKI67. 21186531 CVCL_4N13 GM01448 transformed cell line human CVCL_4N13 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Gly219del (c.651TGG[1]) (c.654_656delTGG) (G197del, c.652delGGT); ClinVar=VCV000226329; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186532 CVCL_4N12 GM01386 finite cell line human CVCL_4N12 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186533 CVCL_4N11 GM01385 finite cell line human CVCL_4N11 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186534 CVCL_4N10 GM01377 finite cell line human CVCL_4N10 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186535 CVCL_4N06 GM00701 finite cell line human CVCL_4N06 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys681Ter (c.2043C>A) (C660X); ClinVar=VCV000003699; Zygosity=Homozygous (PubMed=29308438) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186536 CVCL_4N05 GM00700 finite cell line human CVCL_4N05 CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Cys681Ter (c.2043C>A) (C660X); ClinVar=VCV000003699; Zygosity=Heterozygous (By familial inference of GM00701) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186537 CVCL_4N04 GM00486 finite cell line human CVCL_4N04 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186538 CVCL_4N03 GM00480 finite cell line human CVCL_4N03 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21186539 CVCL_4N09 GM01355 finite cell line human CVCL_4N09 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21186540 CVCL_4N08 GM01354 finite cell line human CVCL_4N08 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186541 CVCL_4N07 GM01353 finite cell line human CVCL_4N07 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21186542 CVCL_WT43 Ki-6 hybridoma house mouse CVCL_WT43 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186543 CVCL_WT42 Ki-5 hybridoma house mouse CVCL_WT42 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186544 CVCL_X542 NSK-RC cancer cell line human CVCL_X542 CL:0000010 21186545 CVCL_WT41 Ki-4 hybridoma house mouse CVCL_WT41 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186546 CVCL_X541 KWA-RC cancer cell line human CVCL_X541 CL:0000010 21186547 CVCL_WT40 Ki-3 hybridoma house mouse CVCL_WT40 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P28908; Human TNFRSF8/CD30. 21186548 CVCL_X540 MTS-RC cancer cell line human CVCL_X540 CL:0000010 Unspecified 21186549 CVCL_WT25 Ki-M1 hybridoma house mouse CVCL_WT25 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human interdigitating reticulum cells. 21186550 CVCL_X525 OX-129 hybridoma CVCL_X525 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q61003; Mouse Cd6. 21186551 CVCL_WT24 Ki-M4 hybridoma house mouse CVCL_WT24 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: Human follicular dendritic cells. 21186552 CVCL_X524 OX-119 hybridoma house mouse CVCL_X524 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P1W8; Human SIRPG. 21186553 CVCL_X523 OX-118 hybridoma house mouse CVCL_X523 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P1W8; Human SIRPG. 21186554 CVCL_WT23 RN transformed cell line human CVCL_WT23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Male Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line but is probably a B-lymphoblastoid cell line (PubMed=29533902). 21186555 CVCL_WT22 Ad-220/SV40 transformed cell line human CVCL_WT22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland. Unspecified 21186556 CVCL_X522 OX-117 hybridoma house mouse CVCL_X522 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P1W8; Human SIRPG. 21186557 CVCL_WT29 Ki-M7 hybridoma house mouse CVCL_WT29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P34810; Human CD68. 21186558 CVCL_X529 SiHa-NTRpuro cancer cell line human CVCL_X529 CL:0000010 Transfected with: UniProtKB; P38489; Escherichia coli nitroreductase nfnB; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line) 21186559 CVCL_WT28 Ki-M8 hybridoma house mouse CVCL_WT28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86VB7; Human CD163. 21186560 CVCL_X528 T79-A3 spontaneously immortalized cell line CVCL_X528 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P38489; Escherichia coli nitroreductase nfnB Derived from sampling site: Lung Cell type=Fibroblast.. Male 21186561 CVCL_WT27 Ki-M3 hybridoma house mouse CVCL_WT27 CL:0000010 Monoclonal antibody isotype: IgM. 21186562 CVCL_X527 T78-1 spontaneously immortalized cell line CVCL_X527 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P38489; Escherichia coli nitroreductase nfnB Derived from sampling site: Lung Cell type=Fibroblast.. Male 21186563 CVCL_WT26 Ki-M2 hybridoma house mouse CVCL_WT26 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human Kupffer cells and splenic macrophages. 21186564 CVCL_X526 OX-131 hybridoma Norway rat CVCL_X526 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9ES57; Mouse Cd200r1. 21186565 CVCL_NZ89 BayGenomics ES cell line RST053 embryonic stem cell house mouse CVCL_NZ89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105382; Lama5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186566 CVCL_NZ88 BayGenomics ES cell line RST050 embryonic stem cell house mouse CVCL_NZ88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186567 CVCL_NZ87 BayGenomics ES cell line RST035 embryonic stem cell house mouse CVCL_NZ87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108076; Frrs1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186568 CVCL_NZ86 BayGenomics ES cell line RST027 embryonic stem cell house mouse CVCL_NZ86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186569 CVCL_NZ85 BayGenomics ES cell line RST022 embryonic stem cell house mouse CVCL_NZ85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97527; Pdgfa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186570 CVCL_NZ84 BayGenomics ES cell line RST020 embryonic stem cell house mouse CVCL_NZ84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186571 CVCL_NZ83 BayGenomics ES cell line RST019 embryonic stem cell house mouse CVCL_NZ83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99914; Lamc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186572 CVCL_NZ82 BayGenomics ES cell line RST018 embryonic stem cell house mouse CVCL_NZ82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186573 CVCL_NZ81 BayGenomics ES cell line RST011 embryonic stem cell house mouse CVCL_NZ81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109168; Fat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186574 CVCL_NZ80 BayGenomics ES cell line RST009 embryonic stem cell house mouse CVCL_NZ80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95278; Epha2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186575 CVCL_X532 HH244 cancer cell line human CVCL_X532 HLA typing: A*01,24; B*08,35; C*04,07 (PubMed=18704411) CL:0000010 Derived from sampling site: Kidney. Unspecified 21186576 CVCL_WT32 Ki-M9 hybridoma house mouse CVCL_WT32 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human 70 kDa protein on sinus-lining dendritic cells. 21186577 CVCL_X531 HH050 cancer cell line human CVCL_X531 HLA typing: A*02,03; B*62,35; C*03,04 (PubMed=18704411) CL:0000010 Derived from sampling site: Kidney. Unspecified 21186578 CVCL_WT31 Ki-M6 hybridoma house mouse CVCL_WT31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P34810; Human CD68. 21186579 CVCL_X530 ATL-5T cancer cell line human CVCL_X530 CL:0000010 Population: Japanese; Derived from sampling site: Pericardial effusion. Male Doubling time: 58 hours (PubMed=2890613) 21186580 CVCL_WT30 PG-M1 hybridoma house mouse CVCL_WT30 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P34810; Human CD68. 21186581 CVCL_X514 OX-83 hybridoma house mouse CVCL_X514 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Rat bone marrow cells. 21186582 CVCL_WT14 UAMi004-A induced pluripotent stem cell human CVCL_WT14 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Homozygous (PubMed=31132581) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21186583 CVCL_X513 OX-82 hybridoma house mouse CVCL_X513 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat bone marrow cells. 21186584 CVCL_WT13 SHEHDNi001-A induced pluripotent stem cell human CVCL_WT13 From: Department of Neurology, Shanghai East Hospital; Shanghai; China CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186585 CVCL_WT12 OSRi008-A induced pluripotent stem cell human CVCL_WT12 From: Ospedale San Raffaele; Milan; Italy. CL:0000010 21186586 CVCL_X512 OX-48 hybridoma house mouse CVCL_X512 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O35531; Rat Cd86. 21186587 CVCL_X511 CP5 finite cell line CVCL_X511 CL:0000010 Derived from sampling site: Articular cartilage Cell type=Fibroblast.; Breed/subspecies: Holstein Friesian. Characteristics: Able to re-differentiate into articular chondrocytes after extensive population doublings (>30 PDL) (ECACC=08052101) 21186588 CVCL_WT11 OSRi007-A induced pluripotent stem cell human CVCL_WT11 From: Ospedale San Raffaele; Milan; Italy. CL:0000010 21186589 CVCL_WT18 NTS-3 cancer cell line human CVCL_WT18 HLA typing: A*01,02; B*08,15; C*07 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C. Omics: Transcriptome analysis by microarray Female 21186590 CVCL_X518 OX-108 hybridoma house mouse CVCL_X518 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q8TD46; Human CD200R1. 21186591 CVCL_WT17 NTS-2 cancer cell line human CVCL_WT17 HLA typing: A*23,25; B*18,49; C*07,12 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C. Omics: Transcriptome analysis by microarray Female 21186592 CVCL_X517 OX-106 hybridoma house mouse CVCL_X517 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Rat neutrophils. 21186593 CVCL_WT16 NTS-1 cancer cell line human CVCL_WT16 HLA typing: A*02,29; B*08,51; C*02,07 (Direct_author_submission) CL:0000010 Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C. Female 21186594 CVCL_X516 OX-97 hybridoma CVCL_X516 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21186595 CVCL_X515 OX-96 hybridoma CVCL_X515 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. 21186596 CVCL_WT15 UAMi005-A induced pluripotent stem cell human CVCL_WT15 From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4313; GLDC; Simple; p.Pro581Arg (c.1742C>G); ClinVar=VCV000216936; Zygosity=Heterozygous (PubMed=31349202); Sequence variation: Mutation; HGNC; 4313; GLDC; Simple; p.Arg790Trp (c.2368C>T); ClinVar=VCV000056075; Zygosity=Heterozygous (PubMed=31349202) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21186597 CVCL_X519 OX-110 hybridoma Norway rat CVCL_X519 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q9ES57; Mouse Cd200r1. 21186598 CVCL_NZ99 BayGenomics ES cell line RST083 embryonic stem cell house mouse CVCL_NZ99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277969; Zfp143 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186599 CVCL_NZ98 BayGenomics ES cell line RST082 embryonic stem cell house mouse CVCL_NZ98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923206; Srrm2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186600 CVCL_NZ97 BayGenomics ES cell line RST076 embryonic stem cell house mouse CVCL_NZ97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97750; Ppib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186601 CVCL_NZ96 BayGenomics ES cell line RST072 embryonic stem cell house mouse CVCL_NZ96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1329016; Sel1l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186602 CVCL_NZ95 BayGenomics ES cell line RST069 embryonic stem cell house mouse CVCL_NZ95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104669; Man2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186603 CVCL_NZ94 BayGenomics ES cell line RST067 embryonic stem cell house mouse CVCL_NZ94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924059; Bri3bp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186604 CVCL_NZ93 BayGenomics ES cell line RST066 embryonic stem cell house mouse CVCL_NZ93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913522; Cox16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186605 CVCL_NZ92 BayGenomics ES cell line RST063 embryonic stem cell house mouse CVCL_NZ92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104967; Glg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186606 CVCL_NZ91 BayGenomics ES cell line RST061 embryonic stem cell house mouse CVCL_NZ91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96765; Ldlr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186607 CVCL_NZ90 BayGenomics ES cell line RST059 embryonic stem cell house mouse CVCL_NZ90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97750; Ppib Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21186608 CVCL_WT21 EuHe cancer cell line human CVCL_WT21 CL:0000010 Derived from sampling site: Lymph node. Female Doubling time: 16 hours (CelloPub=CLPUB00512) 21186609 CVCL_X521 OX-116 hybridoma house mouse CVCL_X521 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9P1W8; Human SIRPG. 21186610 CVCL_X520 OX-115 hybridoma Norway rat CVCL_X520 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P18572; Mouse Bsg/Cd147. 21186611 CVCL_FB00 ND12073 transformed cell line human CVCL_FB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186612 CVCL_4N82 AG07597 finite cell line human CVCL_4N82 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186613 CVCL_4N81 AG07596 transformed cell line human CVCL_4N81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186614 CVCL_4N80 AG07594 transformed cell line human CVCL_4N80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186615 CVCL_4N86 AG07601 finite cell line human CVCL_4N86 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186616 CVCL_4N85 AG07600 transformed cell line human CVCL_4N85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186617 CVCL_4N84 AG07599 finite cell line human CVCL_4N84 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186618 CVCL_4N83 AG07598 transformed cell line human CVCL_4N83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186619 CVCL_4N89 AG07604 transformed cell line human CVCL_4N89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186620 CVCL_4N88 AG07603 finite cell line human CVCL_4N88 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 24-32 PDL (PubMed=9724752) Part of: Canadian Alzheimer disease kindred subcollection 21186621 CVCL_4N87 AG07602 transformed cell line human CVCL_4N87 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186622 CVCL_4N93 AG07610 transformed cell line human CVCL_4N93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186623 CVCL_4N92 AG07609 finite cell line human CVCL_4N92 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186624 CVCL_4N91 AG07608 transformed cell line human CVCL_4N91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186625 CVCL_4N90 AG07607 finite cell line human CVCL_4N90 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186626 CVCL_4N97 AG07616 transformed cell line human CVCL_4N97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186627 CVCL_4N96 AG07615 finite cell line human CVCL_4N96 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186628 CVCL_4N95 AG07614 transformed cell line human CVCL_4N95 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186629 CVCL_4N94 AG07613 finite cell line human CVCL_4N94 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Karyotypic information: 46,XY,inv(Y)(pter->p11.2::q12->p11.2::q12->qter) (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Canadian Alzheimer disease kindred subcollection 21186630 CVCL_4N99 AG07618 transformed cell line human CVCL_4N99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186631 CVCL_4N98 AG07617 finite cell line human CVCL_4N98 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186632 CVCL_4N60 AG07569 finite cell line human CVCL_4N60 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186633 CVCL_4N64 AG07573 finite cell line human CVCL_4N64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186634 CVCL_4N63 AG07572 transformed cell line human CVCL_4N63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186635 CVCL_4N62 AG07571 finite cell line human CVCL_4N62 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186636 CVCL_4N61 AG07570 transformed cell line human CVCL_4N61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186637 CVCL_4N68 AG07578 transformed cell line human CVCL_4N68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186638 CVCL_4N67 AG07576 transformed cell line human CVCL_4N67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186639 CVCL_4N66 AG07575 finite cell line human CVCL_4N66 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186640 CVCL_4N65 AG07574 transformed cell line human CVCL_4N65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186641 CVCL_4N59 AG07568 transformed cell line human CVCL_4N59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186642 CVCL_4N58 AG07567 finite cell line human CVCL_4N58 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186643 CVCL_WT99 NYSCFi001-A induced pluripotent stem cell human CVCL_WT99 From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21186644 CVCL_X599 THP1-Dual cancer cell line human CVCL_X599 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 21186645 CVCL_4N71 AG07581 finite cell line human CVCL_4N71 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186646 CVCL_4N70 AG07580 transformed cell line human CVCL_4N70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186647 CVCL_4N75 AG07588 transformed cell line human CVCL_4N75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186648 CVCL_4N74 AG07584 transformed cell line human CVCL_4N74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186649 CVCL_4N73 AG07583 finite cell line human CVCL_4N73 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186650 CVCL_4N72 AG07582 transformed cell line human CVCL_4N72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186651 CVCL_4N79 AG07593 finite cell line human CVCL_4N79 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Canadian Alzheimer disease kindred subcollection 21186652 CVCL_4N78 AG07592 transformed cell line human CVCL_4N78 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186653 CVCL_4N77 AG07590 transformed cell line human CVCL_4N77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186654 CVCL_4N76 AG07589 finite cell line human CVCL_4N76 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186655 CVCL_4N69 AG07579 finite cell line human CVCL_4N69 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21186656 CVCL_FC94 ND11293 transformed cell line human CVCL_FC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186657 CVCL_FC93 ND11291 transformed cell line human CVCL_FC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186658 CVCL_FC92 ND11266 transformed cell line human CVCL_FC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186659 CVCL_FC91 ND11249 transformed cell line human CVCL_FC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186660 CVCL_FC98 ND11372 transformed cell line human CVCL_FC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186661 CVCL_FC97 ND11355 transformed cell line human CVCL_FC97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186662 CVCL_FC96 ND11326 transformed cell line human CVCL_FC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186663 CVCL_FC95 ND11317 transformed cell line human CVCL_FC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186664 CVCL_FC90 ND11236 transformed cell line human CVCL_FC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186665 CVCL_FC89 ND11234 transformed cell line human CVCL_FC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186666 CVCL_FC88 ND11197 transformed cell line human CVCL_FC88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186667 CVCL_FC99 ND11379 transformed cell line human CVCL_FC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186668 CVCL_FC72 ND10785 transformed cell line human CVCL_FC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186669 CVCL_FC71 ND10737 transformed cell line human CVCL_FC71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186670 CVCL_FC70 ND10725 transformed cell line human CVCL_FC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186671 CVCL_FC76 ND11042 transformed cell line human CVCL_FC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186672 CVCL_FC75 ND10975 transformed cell line human CVCL_FC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186673 CVCL_FC74 ND10958 transformed cell line human CVCL_FC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186674 CVCL_FC73 ND10816 transformed cell line human CVCL_FC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186675 CVCL_FC69 ND10665 transformed cell line human CVCL_FC69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186676 CVCL_FC68 ND10613 transformed cell line human CVCL_FC68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186677 CVCL_FC67 ND10582 transformed cell line human CVCL_FC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186678 CVCL_FC66 ND10498 transformed cell line human CVCL_FC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186679 CVCL_FC83 ND11113 transformed cell line human CVCL_FC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186680 CVCL_FC82 ND11089 transformed cell line human CVCL_FC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186681 CVCL_FC81 ND11064 transformed cell line human CVCL_FC81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186682 CVCL_FC80 ND11062 transformed cell line human CVCL_FC80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186683 CVCL_FC87 ND11176 transformed cell line human CVCL_FC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186684 CVCL_FC86 ND11171 transformed cell line human CVCL_FC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186685 CVCL_FC85 ND11167 transformed cell line human CVCL_FC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186686 CVCL_FC84 ND11159 transformed cell line human CVCL_FC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186687 CVCL_FC79 ND11060 transformed cell line human CVCL_FC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186688 CVCL_FC78 ND11045 transformed cell line human CVCL_FC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186689 CVCL_FC77 ND11044 transformed cell line human CVCL_FC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186690 CVCL_FC50 ND09114 transformed cell line human CVCL_FC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186691 CVCL_FC54 ND09692 transformed cell line human CVCL_FC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186692 CVCL_FC53 ND09681 transformed cell line human CVCL_FC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186693 CVCL_FC52 ND09463 transformed cell line human CVCL_FC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186694 CVCL_FC51 ND09434 transformed cell line human CVCL_FC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186695 CVCL_FC47 ND08352 transformed cell line human CVCL_FC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186696 CVCL_FC46 ND08186 transformed cell line human CVCL_FC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186697 CVCL_FC45 ND08128 transformed cell line human CVCL_FC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186698 CVCL_FC44 ND07982 transformed cell line human CVCL_FC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186699 CVCL_FC49 ND08588 transformed cell line human CVCL_FC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186700 CVCL_FC48 ND08532 transformed cell line human CVCL_FC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186701 CVCL_FC61 ND10242 transformed cell line human CVCL_FC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186702 CVCL_FC60 ND10241 transformed cell line human CVCL_FC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186703 CVCL_FC65 ND10479 transformed cell line human CVCL_FC65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186704 CVCL_FC64 ND10362 transformed cell line human CVCL_FC64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186705 CVCL_FC63 ND10269 transformed cell line human CVCL_FC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186706 CVCL_FC62 ND10243 transformed cell line human CVCL_FC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186707 CVCL_FC58 ND10127 transformed cell line human CVCL_FC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186708 CVCL_FC57 ND10126 transformed cell line human CVCL_FC57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186709 CVCL_FC56 ND09875 transformed cell line human CVCL_FC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186710 CVCL_FC55 ND09827 transformed cell line human CVCL_FC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186711 CVCL_FC59 ND10159 transformed cell line human CVCL_FC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186712 CVCL_FC32 ND06077 transformed cell line human CVCL_FC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186713 CVCL_FC31 ND04739 transformed cell line human CVCL_FC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186714 CVCL_FC30 ND04519 transformed cell line human CVCL_FC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186715 CVCL_FC25 ND03351 transformed cell line human CVCL_FC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186716 CVCL_FC24 ND03203 transformed cell line human CVCL_FC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186717 CVCL_FC23 ND03134 transformed cell line human CVCL_FC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186718 CVCL_FC22 ND03118 transformed cell line human CVCL_FC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186719 CVCL_FC29 ND04107 transformed cell line human CVCL_FC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186720 CVCL_FC28 ND03952 transformed cell line human CVCL_FC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186721 CVCL_FC27 ND03680 transformed cell line human CVCL_FC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186722 CVCL_FC26 ND03472 transformed cell line human CVCL_FC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186723 CVCL_FC43 ND07828 transformed cell line human CVCL_FC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186724 CVCL_FC42 ND07457 transformed cell line human CVCL_FC42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186725 CVCL_FC41 ND07183 transformed cell line human CVCL_FC41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186726 CVCL_FC40 ND06842 transformed cell line human CVCL_FC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186727 CVCL_FC36 ND06436 transformed cell line human CVCL_FC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186728 CVCL_FC35 ND06379 transformed cell line human CVCL_FC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186729 CVCL_FC34 ND06376 transformed cell line human CVCL_FC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186730 CVCL_FC33 ND06081 transformed cell line human CVCL_FC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186731 CVCL_FC39 ND06789 transformed cell line human CVCL_FC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186732 CVCL_FC38 ND06786 transformed cell line human CVCL_FC38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186733 CVCL_FC37 ND06475 transformed cell line human CVCL_FC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21186734 CVCL_X745 OPL-3 cancer cell line human CVCL_X745 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 72 hours (PubMed=14556658); Microsatellite instability: Instable (MSI) (PubMed=14556658) 21186735 CVCL_WV45 SJG-30 cancer cell line human CVCL_WV45 CL:0000010 Male 21186736 CVCL_WV44 ARR cancer cell line human CVCL_WV44 CL:0000010 21186737 CVCL_X744 OPL-2 cancer cell line human CVCL_X744 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 24 hours (PubMed=8690530) 21186738 CVCL_X743 OPL-1 cancer cell line human CVCL_X743 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Doubling time: 48 hours (PubMed=8690530) 21186739 CVCL_WV43 RPMI-8432 transformed cell line human CVCL_WV43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21186740 CVCL_X742 7.16.4 hybridoma house mouse CVCL_X742 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10493 21186741 CVCL_WV42 LB5871-LYMP cancer cell line human CVCL_WV42 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=30277098); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=30277098); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro2139fs (c.6415_6424delCCCCCCTTCA); Zygosity=Heterozygous (PubMed=30277098); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Tyr1467Asp (c.4399T>G); Zygosity=Heterozygous (PubMed=30277098); Sequence variation: Mutation; HGNC; 11912; TNFRSF14; Simple; p.Trp7Ter (c.20G>A); Zygosity=Heterozygous (PubMed=30277098); Sequence variation: Mutation; HGNC; 11912; TNFRSF14; Simple; p.Ala194fs (c.578dup); Zygosity=Heterozygous (PubMed=30277098); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Arg (c.526T>C); ClinVar=VCV000376573; Zygosity=Hemizygous (PubMed=30277098) Derived from sampling site: Cervical lymph node. Female Doubling time: 62 hours (PubMed=30277098); ~70 hours (DSMZ=ACC-869) 21186742 CVCL_X749 Pal-1 cancer cell line human CVCL_X749 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pleural effusion. Male Doubling time: 48 hours (PubMed=12028021) 21186743 CVCL_WV49 SJG-36 cancer cell line human CVCL_WV49 CL:0000010 Male 21186744 CVCL_X748 OPL-7 cancer cell line human CVCL_X748 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Doubling time: 108 hours (PubMed=14556658); Microsatellite instability: Stable (MSS) (PubMed=14556658) 21186745 CVCL_WV48 SJG-35 cancer cell line human CVCL_WV48 CL:0000010 Male 21186746 CVCL_X747 OPL-5 cancer cell line human CVCL_X747 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Doubling time: 48 hours (PubMed=14556658); Microsatellite instability: Stable (MSS) (PubMed=14556658) 21186747 CVCL_WV47 SJG-34 cancer cell line human CVCL_WV47 CL:0000010 Female 21186748 CVCL_X746 OPL-4 cancer cell line human CVCL_X746 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Doubling time: 168 hours (PubMed=14556658); Microsatellite instability: Stable (MSS) (PubMed=14556658) 21186749 CVCL_WV46 SJG-29 cancer cell line human CVCL_WV46 CL:0000010 Male 21186750 CVCL_4P00 AG07619 finite cell line human CVCL_4P00 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186751 CVCL_5100 SNU-840 cancer cell line human CVCL_5100 HLA typing: A*03:01,31:01; B*15:07,44:02; C*03:03,05:01 (PubMed=26589293); Genome ancestry: African=3.49%; Native American=0%; East Asian, North=68.16%; East Asian, South=24.79%; South Asian=0%; European, North=0%; European, South=3.57% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (DepMap) Population: Korean Omics: Deep exome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 40 hours (PubMed=9299249); 36 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186752 CVCL_X752 AG06278 finite cell line human CVCL_X752 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21186753 CVCL_WV52 SJG-40 cancer cell line human CVCL_WV52 CL:0000010 Male 21186754 CVCL_X751 HLN-STL-C cancer cell line human CVCL_X751 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Unspecified 21186755 CVCL_WV51 SJG-39 cancer cell line human CVCL_WV51 CL:0000010 Male 21186756 CVCL_WV50 SJG-38 cancer cell line human CVCL_WV50 CL:0000010 Female 21186757 CVCL_X750 ZMAC-1 factor-dependent cell line pig CVCL_X750 CL:0000010 Derived from sampling site: Fetal lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace x Yorkshire x Duroc. Unspecified Characteristics: CSF1 dependent; Virology: Susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) (PubMed=22648044) Doubling time: ~72 hours (Patent=US9169465) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8764 21186758 CVCL_WV34 SJG-20 cancer cell line human CVCL_WV34 CL:0000010 Male 21186759 CVCL_X734 STiPS A4 induced pluripotent stem cell human CVCL_X734 From: Harvard University; Boston; USA. CL:0000010 Female 21186760 CVCL_WV33 SJG-19 cancer cell line human CVCL_WV33 CL:0000010 Male 21186761 CVCL_X733 STiPS A3 induced pluripotent stem cell human CVCL_X733 From: Harvard University; Boston; USA. CL:0000010 Female 21186762 CVCL_X732 BJ epi iPS-C induced pluripotent stem cell human CVCL_X732 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186763 CVCL_WV32 SJG-16 cancer cell line human CVCL_WV32 CL:0000010 Male 21186764 CVCL_X731 ery ED4 SiPSA induced pluripotent stem cell human CVCL_X731 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Cell type=Erythroblast. Female 21186765 CVCL_WV31 SJG-14 cancer cell line human CVCL_WV31 CL:0000010 Female 21186766 CVCL_X738 BJ RiPS-D induced pluripotent stem cell human CVCL_X738 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186767 CVCL_WV38 SJG-24 cancer cell line human CVCL_WV38 CL:0000010 Female 21186768 CVCL_X737 BJ RiPS-A induced pluripotent stem cell human CVCL_X737 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186769 CVCL_WV37 SJG-23 cancer cell line human CVCL_WV37 CL:0000010 Female 21186770 CVCL_WV36 SJG-22 cancer cell line human CVCL_WV36 CL:0000010 Male 21186771 CVCL_X736 STiPS A6 induced pluripotent stem cell human CVCL_X736 From: Harvard University; Boston; USA. CL:0000010 Female 21186772 CVCL_WV35 SJG-21 cancer cell line human CVCL_WV35 CL:0000010 Male 21186773 CVCL_X735 STiPS A5 induced pluripotent stem cell human CVCL_X735 From: Harvard University; Boston; USA. CL:0000010 Female 21186774 CVCL_X739 BJ RiPS-E induced pluripotent stem cell human CVCL_X739 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186775 CVCL_WV39 SJG-25 cancer cell line human CVCL_WV39 CL:0000010 Male 21186776 CVCL_4P11 AG07632 transformed cell line human CVCL_4P11 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186777 CVCL_5111 SNU-C4 cancer cell line human CVCL_5111 HLA typing: A*02:01,24:02; B*35:12,48:01; C*03:04,08:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.62%; East Asian, North=57.31%; East Asian, South=42.07%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (PubMed=10674020); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu288fs*3 (c.863delA); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=10674020); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (DepMap) Population: Korean Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a nude mouse xenograft Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186778 CVCL_4P10 AG07631 finite cell line human CVCL_4P10 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186779 CVCL_5110 SNU-99 transformed cell line human CVCL_5110 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a rectal carcinoma; Derived from sampling site: Rectum. Male Part of: Seoul National University (SNU) cell line collection 21186780 CVCL_4P04 AG07623 finite cell line human CVCL_4P04 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186781 CVCL_5104 SNU-889 transformed cell line human CVCL_5104 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a rectal carcinoma; Derived from sampling site: Rectum. Male Part of: Seoul National University (SNU) cell line collection 21186782 CVCL_4P03 AG07622 transformed cell line human CVCL_4P03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186783 CVCL_5103 SNU-886 cancer cell line human CVCL_5103 HLA typing: A*24:02,33:03; B*13:02,44:03; C*06:02,07:01 (PubMed=26589293); Genome ancestry: African=1.56%; Native American=0.92%; East Asian, North=64.25%; East Asian, South=33.26%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220fs*27 (c.655delC) (p.P219Lfs); Zygosity=Homozygous (PubMed=8824565; DepMap) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 29 hours (PubMed=11819450); 25.19 hours (PubMed=31378681) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21186784 CVCL_4P02 AG07621 finite cell line human CVCL_4P02 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186785 CVCL_5102 SNU-878 cancer cell line human CVCL_5102 HLA typing: A*33:03,33:03; B*58:01,58:01; C*03:02,03:02 (PubMed=26589293); Genome ancestry: African=5.81%; Native American=0%; East Asian, North=66.98%; East Asian, South=21.49%; South Asian=0%; European, North=0%; European, South=5.72% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Asn (c.752T>A); ClinVar=VCV000528254; Zygosity=Homozygous (PubMed=8824565; PubMed=31378681; DepMap); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1514Ter (c.4541C>G); ClinVar=VCV000620335; Zygosity=Homozygous (PubMed=31378681; DepMap) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 25 hours (PubMed=11819450); 40.35 hours (PubMed=31378681) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21186786 CVCL_4P01 AG07620 transformed cell line human CVCL_4P01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186787 CVCL_5101 SNU-869 cancer cell line human CVCL_5101 HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03 (PubMed=26589293); Genome ancestry: African=15.94%; Native American=0%; East Asian, North=64.53%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=19.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp48Gly (c.143A>G); Zygosity=Unspecified (PubMed=12107841) Population: Korean; Derived from sampling site: Pancreas; ampulla of Vater. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 48 hours (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21186788 CVCL_4P08 AG07629 finite cell line human CVCL_4P08 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21186789 CVCL_5108 SNU-963 cancer cell line human CVCL_5108 CL:0000010 Population: Korean Male Doubling time: 149 hours (PubMed=21290211). Part of: Seoul National University (SNU) cell line collection 21186790 CVCL_4P07 AG07628 transformed cell line human CVCL_4P07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21186791 CVCL_5107 SNU-902 cancer cell line human CVCL_5107 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV16 genome Doubling time: 52 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21186792 CVCL_4P06 AG07627 finite cell line human CVCL_4P06 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07627; probable Female Part of: Canadian Alzheimer disease kindred subcollection 21186793 CVCL_5106 SNU-9 transformed cell line human CVCL_5106 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Pleural effusion. Male Part of: Seoul National University (SNU) cell line collection 21186794 CVCL_4P05 AG07624 transformed cell line human CVCL_4P05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186795 CVCL_5105 SNU-899 cancer cell line human CVCL_5105 HLA typing: A*02:06,02:06; B*15:01,15:01; C*04:01,04:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.85%; East Asian, North=62.64%; East Asian, South=35.88%; South Asian=0%; European, North=0%; European, South=0.63% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Heterozygous (DepMap) Population: Korean; Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=10369293) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186796 CVCL_4P09 AG07630 transformed cell line human CVCL_4P09 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21186797 CVCL_5109 SNU-977 cancer cell line human CVCL_5109 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1355fs*20 (c.4063_4064insT); Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=20176655) Population: Korean; Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Female Doubling time: 63 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21186798 CVCL_X741 BJ SiPS-D induced pluripotent stem cell human CVCL_X741 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186799 CVCL_WV41 LB5848-LYMP cancer cell line human CVCL_WV41 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=30277098); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=30277098); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Hemizygous (PubMed=30277098) Derived from sampling site: Parotid lymph node. Male Doubling time: 54 hours (PubMed=30277098); ~50-70 hours (DSMZ=ACC-870) 21186800 CVCL_X740 BJ SiPS-C induced pluripotent stem cell human CVCL_X740 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21186801 CVCL_WV40 DH-My6 cancer cell line human CVCL_WV40 CL:0000010 Sequence variation: Gene fusion; HGNC; 1001; BCL6 + HGNC; 5477; IGH; Name(s)=IGH-BCL6 (PubMed=30323893); Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=30323893) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 20 hours (PubMed=30323893) 21186802 CVCL_WV23 HPSI1014i-suok_4 induced pluripotent stem cell human CVCL_WV23 From: University College London; London; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21186803 CVCL_X723 rdES2-1 embryonic stem cell CVCL_X723 CL:0000010 Breed/subspecies: Dutch Belted. Unspecified 21186804 CVCL_X722 rES9-7 embryonic stem cell CVCL_X722 CL:0000010 Breed/subspecies: Japanese white. Unspecified 21186805 CVCL_WV22 SupT1/Blam cancer cell line human CVCL_WV22 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pleural effusion Cell type=T-cell.. Male 21186806 CVCL_X721 rES9-6 embryonic stem cell CVCL_X721 CL:0000010 Breed/subspecies: Japanese white. Unspecified 21186807 CVCL_WV21 SJG-42 cancer cell line human CVCL_WV21 CL:0000010 Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186808 CVCL_X720 rES9-2 embryonic stem cell CVCL_X720 CL:0000010 Breed/subspecies: Japanese white. Unspecified 21186809 CVCL_WV20 SJG-41 cancer cell line human CVCL_WV20 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg1279His (c.3836G>A); ClinVar=VCV000134930; Zygosity=Heterozygous (CelloPub=CLPUB00517; PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr73fs (c.218_219insT); Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186810 CVCL_X727 E14-nlsrtTA-7 embryonic stem cell house mouse CVCL_X727 CL:0000010 Breed/subspecies: 129P2/Ola. Male 21186811 CVCL_WV27 SJG-5 cancer cell line human CVCL_WV27 CL:0000010 Female 21186812 CVCL_X726 RB9d induced pluripotent stem cell human CVCL_X726 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (PubMed=24704492) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Female 21186813 CVCL_WV26 SJG-2 cancer cell line human CVCL_WV26 CL:0000010 Male 21186814 CVCL_X725 39b induced pluripotent stem cell human CVCL_X725 From: Harvard University; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (PubMed=24704492) Derived from sampling site: Forearm; skin; dermis Cell type=Fibroblast.. Female 21186815 CVCL_WV25 SJG-1 cancer cell line human CVCL_WV25 CL:0000010 Male 21186816 CVCL_X724 HUES 3 Hb9::GFP embryonic stem cell human CVCL_X724 From: Harvard University; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP. Male 21186817 CVCL_WV24 SJG-15 cancer cell line human CVCL_WV24 CL:0000010 Female 21186818 CVCL_WV29 SJG-9 cancer cell line human CVCL_WV29 CL:0000010 Male 21186819 CVCL_X729 STiPS O-XX2 induced pluripotent stem cell human CVCL_X729 From: Harvard University; Boston; USA. CL:0000010 Female 21186820 CVCL_WV28 SJG-7 cancer cell line human CVCL_WV28 CL:0000010 Male 21186821 CVCL_X728 STiPS O-XX1 induced pluripotent stem cell human CVCL_X728 From: Harvard University; Boston; USA. CL:0000010 Female 21186822 CVCL_X730 ery ED3 SiPSA induced pluripotent stem cell human CVCL_X730 From: Harvard University; Boston; USA CL:0000010 Derived from sampling site: Cell type=Erythroblast. Female 21186823 CVCL_WV30 SJG-12 cancer cell line human CVCL_WV30 CL:0000010 Female 21186824 CVCL_X712 El Man finite cell line human CVCL_X712 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1101; true Male 21186825 CVCL_WV12 SJG-18 cancer cell line human CVCL_WV12 CL:0000010 Sequence variation: Mutation; HGNC; 1509; CASP8; Simple; p.Lys148Thr (c.443A>C) (p.Lys207Thr, c.620A>C); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; c.9854-1G>C; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu257Gln (c.770T>A); ClinVar=VCV000012372; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Ter (c.772G>T); ClinVar=VCV000486557; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186826 CVCL_X711 GMM-1 cancer cell line CVCL_X711 CL:0000010 Derived from sampling site: Cell type=Erythrophore. Unspecified Group: Fish cell line 21186827 CVCL_WV11 SJG-17 cancer cell line human CVCL_WV11 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Thr968Met (c.2903C>T); ClinVar=VCV001494610; Zygosity=Heterozygous (CelloPub=CLPUB00517; PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258fs (c.773_774insG); Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186828 CVCL_X710 RJH4 finite cell line human CVCL_X710 From: Trimmer R.; National Cancer Institute; Bethesda; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186829 CVCL_WV10 SJG-13 cancer cell line human CVCL_WV10 CL:0000010 Sequence variation: Mutation; HGNC; 1509; CASP8; Simple; p.Ser115Ter (c.698C>A) (p.Ser174Ter, c.521C>A); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012602; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Asp (c.658T>G); ClinVar=VCV000376689; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259His (c.775G>C); ClinVar=VCV001349622; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186830 CVCL_WV16 SJG-31 cancer cell line human CVCL_WV16 CL:0000010 Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186831 CVCL_X716 Ter Loy finite cell line human CVCL_X716 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1147; probable 21186832 CVCL_X715 Le San finite cell line human CVCL_X715 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1229; true Female 21186833 CVCL_WV15 SJG-28 cancer cell line human CVCL_WV15 CL:0000010 Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186834 CVCL_X714 Le Mor finite cell line human CVCL_X714 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1224; probable Female 21186835 CVCL_WV14 SJG-27 cancer cell line human CVCL_WV14 CL:0000010 Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186836 CVCL_X713 Ro Bel finite cell line human CVCL_X713 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1187; probable Male 21186837 CVCL_WV13 SJG-26 cancer cell line human CVCL_WV13 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186838 CVCL_X719 rES9-1 embryonic stem cell CVCL_X719 CL:0000010 Breed/subspecies: Japanese white. Unspecified 21186839 CVCL_WV19 SJG-37 cancer cell line human CVCL_WV19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186840 CVCL_X718 rES8-2 embryonic stem cell CVCL_X718 CL:0000010 Breed/subspecies: Japanese white. Unspecified 21186841 CVCL_WV18 SJG-33 cancer cell line human CVCL_WV18 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Trp110Ter (c.330G>A) (p.Gly125Arg, c.373G>A); ClinVar=VCV000376303; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Val (c.736A>G); ClinVar=VCV000100815; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu258Gly (c.773A>G); ClinVar=VCV000406590; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186842 CVCL_X717 GM03559 transformed cell line human CVCL_X717 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21186843 CVCL_WV17 SJG-32 cancer cell line human CVCL_WV17 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Gly2470fs (c.7408_7409delCC); Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186844 CVCL_X701 HLM30 cancer cell line human CVCL_X701 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Transfected with a HIV proviral DNA (pHXB2gpt) that contains a tat-defective mutant pMtat34 which has a Tat p.Cys30Gly (c.88T>G) mutation 21186845 CVCL_WV01 NT-27a cancer cell line Norway rat CVCL_WV01 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male Doubling time: ~24-30 hours (DSMZ=ACC-857) 21186846 CVCL_X700 HLM107 cancer cell line human CVCL_X700 CL:0000010 Transfected with: HGNC; 1678; CD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Transfected with a HIV proviral DNA (pHXB2gpt) that contains a rev-defective mutant pMrev- which has a Rev p.Gly6Ter (c.16G>T) mutation 21186847 CVCL_WV00 NT-27 cancer cell line Norway rat CVCL_WV00 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 21186848 CVCL_X705 AT3BE finite cell line human CVCL_X705 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1347; probable 21186849 CVCL_WV05 HPSI0913i-ffdl_2 induced pluripotent stem cell human CVCL_WV05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21186850 CVCL_WV04 COH [Human colon adenocarcinoma] cancer cell line human CVCL_WV04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser227Phe (c.680C>T); Zygosity=Unspecified (PubMed=15144569) Population: Chinese; Derived from metastatic site: Liver. 21186851 CVCL_X704 JA2/R7Hyg cancer cell line human CVCL_X704 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*02) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186852 CVCL_X703 Jurkat-A2 cancer cell line human CVCL_X703 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*02) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186853 CVCL_WV03 US8-93A cancer cell line human CVCL_WV03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Heterozygous (PubMed=21528241). Male 21186854 CVCL_WV02 LMS6-93 cancer cell line human CVCL_WV02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214fs (c.642_643insG); Zygosity=Heterozygous (PubMed=9664117). Male Doubling time: 20.3 +- 5.1 hours (PubMed=9664117) 21186855 CVCL_X702 U87-CD4 clone 2 cancer cell line human CVCL_X702 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21186856 CVCL_X709 Pal Man finite cell line human CVCL_X709 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1116; probable Male 21186857 CVCL_WV09 SJG-8 cancer cell line human CVCL_WV09 CL:0000010 Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Thr677fs (c.2029_2036delACACCAGT); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Asp154His (c.460G>C); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp53Ter (c.159G>A); ClinVar=VCV000420659; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186858 CVCL_X708 Pat Bru finite cell line human CVCL_X708 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1121; probable Male 21186859 CVCL_WV08 SJG-6 cancer cell line human CVCL_WV08 CL:0000010 Sequence variation: Mutation; HGNC; 1509; CASP8; Simple; p.His278Tyr (c.832C>T); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Glu833Ter (c.2497G>T); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Ser3065Ter (c.9194C>G); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Gln3524Ter (c.10570C>T); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys312Ter (c.936C>A); Zygosity=Heterozygous (CelloPub=CLPUB00517; PubMed=27693639); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Trp1843Ter (c.5529G>A); Zygosity=Heterozygous (CelloPub=CLPUB00517; PubMed=27693639); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln171Ter (c.511C>T); ClinVar=VCV000189411; Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu201Gln (c.601G>C); Zygosity=Unspecified (PubMed=27693639); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly209Glu (c.626G>A); Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186860 CVCL_X707 AT1BE finite cell line human CVCL_X707 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1312; probable 21186861 CVCL_WV07 SJG-4 cancer cell line human CVCL_WV07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Unspecified (PubMed=27693639) Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Female 21186862 CVCL_X706 Rid Mor finite cell line human CVCL_X706 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1220; probable Male 21186863 CVCL_WV06 SJG-3 cancer cell line human CVCL_WV06 CL:0000010 Miscellaneous: STR profile from personal communication of Broad S. Omics: Deep exome analysis Male 21186864 CVCL_5063 SNU-46 cancer cell line human CVCL_5063 Genome ancestry: African=1.74%; Native American=0%; East Asian, North=68.94%; East Asian, South=24.69%; South Asian=0%; European, North=0%; European, South=4.64% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114His (c.341C>A) (p.Ala128Ala, c.384C>A); ClinVar=VCV000376383; Zygosity=Homozygous (PubMed=10369293; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Homozygous (PubMed=10369293; DepMap) Population: Korean; Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=10369293) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186865 CVCL_5062 SNU-447 transformed cell line human CVCL_5062 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Peripheral blood. Male Part of: Seoul National University (SNU) cell line collection 21186866 CVCL_5061 SNU-445 transformed cell line human CVCL_5061 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Peripheral blood. Female Part of: Seoul National University (SNU) cell line collection 21186867 CVCL_5060 SNU-444 cancer cell line human CVCL_5060 CL:0000010 Population: Korean; Derived from sampling site: Brain. Male Doubling time: 48 hours (PubMed=11776963) Part of: Seoul National University (SNU) cell line collection 21186868 CVCL_5067 SNU-482 cancer cell line human CVCL_5067 CL:0000010 Population: Korean; Derived from sampling site: Kidney. Male Doubling time: 60 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Seoul National University (SNU) cell line collection 21186869 CVCL_5066 SNU-479 cancer cell line human CVCL_5066 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile162Phe (c.484A>T); ClinVar=VCV000948225; Zygosity=Unspecified (PubMed=20176655) Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Male Doubling time: 44 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21186870 CVCL_5065 SNU-478 cancer cell line human CVCL_5065 HLA typing: A*11:01,33:03; B*52:01,58:01; C*03:02,12:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.85%; East Asian, North=60.73%; East Asian, South=37.41%; South Asian=0%; European, North=0%; European, South=1.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266fs*4 (c.797_801delGACGG); Zygosity=Homozygous (PubMed=12107841; DepMap) Population: Korean; Derived from sampling site: Pancreas; ampulla of Vater. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 52 hours (PubMed=12107841); Microsatellite instability: Stable (MSS) (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21186871 CVCL_5064 SNU-466 cancer cell line human CVCL_5064 HLA typing: A*02:01,11:01; B*39:01,40:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=0.92%; Native American=0%; East Asian, North=61.85%; East Asian, South=36.86%; South Asian=0%; European, North=0%; European, South=0.36% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg159Ser (c.477G>T); ClinVar=VCV000375959; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 54 hours (PubMed=11776963) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186872 CVCL_5059 SNU-410 cancer cell line human CVCL_5059 HLA typing: A*02:01,33:03; B*07:02,59:01; C*01:02,07:02 (PubMed=26589293); Genome ancestry: African=0.52%; Native American=0%; East Asian, North=66.58%; East Asian, South=32.02%; South Asian=0%; European, North=0%; European, South=0.89% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Homozygous (DepMap) Population: Korean; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=12037578) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection Caution: KRAS mutation indicated incorrectly as being p.Gly12Val in PubMed=12037578 21186873 CVCL_5058 SNU-407 cancer cell line human CVCL_5058 Genome ancestry: African=1.29%; Native American=0.4%; East Asian, North=66.65%; East Asian, South=29.61%; South Asian=0%; European, North=0%; European, South=2.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 886; ATRX; Simple; p.Lys1169del (c.3505_3507delAAG); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 2768; DEK; Simple; p.Leu98fs*1 (c.291delT); Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 3512; EXT1; Simple; p.Ser478Profs*10 (c.1431delC); ClinVar=VCV000947295; Zygosity=Heterozygous (Cosmic-CLP); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=10362137; Cosmic-CLP); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Heterozygous (Cosmic-CLP) Population: Korean; Derived from metastatic site: Buttock. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 42 hours (PubMed=10362137); Microsatellite instability: Instable (MSI-high) (PubMed=10674020; PubMed=25926053; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: NCI RAS program mutant KRAS cell line panel; Part of: Seoul National University (SNU) cell line collection 21186874 CVCL_5057 SNU-374 transformed cell line human CVCL_5057 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a stomach cancer; Derived from sampling site: Stomach. Female Part of: Seoul National University (SNU) cell line collection 21186875 CVCL_WU99 CL-52a transformed cell line Norway rat CVCL_WU99 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 21186876 CVCL_X699 HLM1 cancer cell line human CVCL_X699 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Transfected with a HIV proviral DNA (pHXB2gpt) that contains a tat-defective mutant pMtat1 which has a Tat p.Met1Ter (c.1_3ATG>TGA) mutation 21186877 CVCL_X698 CEM A2.01 cancer cell line human CVCL_X698 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Virology: Not susceptible to infection by HIV-1 (HIVReagentProgram) 21186878 CVCL_WU98 CL-50 cancer cell line Norway rat CVCL_WU98 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 21186879 CVCL_5070 SNU-494 cancer cell line human CVCL_5070 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=12037578); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Tyr (c.713G>A); ClinVar=VCV000182935; Zygosity=Unspecified (PubMed=12037578) Population: Korean; Derived from sampling site: Pancreas. Male Doubling time: 120 hours (PubMed=12037578) Part of: Seoul National University (SNU) cell line collection 21186880 CVCL_5074 SNU-538 transformed cell line human CVCL_5074 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a stomach cancer; Derived from sampling site: Stomach. Male Part of: Seoul National University (SNU) cell line collection 21186881 CVCL_5073 SNU-523 cancer cell line human CVCL_5073 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Discontinued: KCLB; 00523; probable Female Virology: Contains an episomal HPV16 genome Doubling time: 72 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21186882 CVCL_5072 SNU-520 cancer cell line human CVCL_5072 HLA typing: A*24:02,30:01; B*50,53; C*05:01,06:02; DQB1*06:13,06:13 (PubMed=25960936); HLA typing: A*24:02,30:01; B*07:17,35:01; C*05:01,06:02; DQB1*06:11,06:11; DRB1*11:01,13:01 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=57.76%; East Asian, South=42.23%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9033653) Population: Korean; Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186883 CVCL_5071 SNU-503 cancer cell line human CVCL_5071 HLA typing: A*33:03,33:03; B*51:01,51:01; C*14:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=62.02%; East Asian, South=37.59%; South Asian=0%; European, North=0%; European, South=0.39% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=10362137; DepMap) Population: Korean; Derived from metastatic site: Abdominal wall. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 64 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186884 CVCL_5078 SNU-61 cancer cell line human CVCL_5078 Genome ancestry: African=1.54%; Native American=0.17%; East Asian, North=63.73%; East Asian, South=33.22%; South Asian=0%; European, North=0%; European, South=1.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=10362137; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=10362137; Cosmic-CLP; DepMap) Population: Korean; Derived from metastatic site: Liver. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 39 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21186885 CVCL_5077 SNU-585 cancer cell line human CVCL_5077 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gln50Arg (c.149A>G); ClinVar=VCV000232304; Zygosity=Unspecified (PubMed=10369293); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp153Tyr (c.457G>T); ClinVar=VCV000216035; Zygosity=Unspecified (PubMed=10369293); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Unspecified (PubMed=10369293) Population: Korean; Derived from sampling site: Larynx. Discontinued: KCLB; 00585; probable Male Doubling time: 54 hours (PubMed=10369293) Part of: Seoul National University (SNU) cell line collection 21186886 CVCL_5076 SNU-563 cancer cell line human CVCL_5076 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Gly (c.844C>G); ClinVar=VCV000140821; Zygosity=Unspecified (PubMed=9299249) Population: Korean; Derived from sampling site: Ovary. Discontinued: KCLB; 00563; probable Female Doubling time: 67 hours (PubMed=9299249) Part of: Seoul National University (SNU) cell line collection 21186887 CVCL_5075 SNU-539 cancer cell line human CVCL_5075 CL:0000010 Population: Korean; Derived from sampling site: Endometrium. Female Doubling time: 46 hours (PubMed=9299262) Part of: Seoul National University (SNU) cell line collection 21186888 CVCL_5069 SNU-489 cancer cell line human CVCL_5069 HLA typing: A*11:01,33:03; B*40:06,44:03; C*07:06,08:01 (PubMed=26589293); Genome ancestry: African=0.11%; Native American=0.3%; East Asian, North=61.65%; East Asian, South=37.93%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.994-1G>C; ClinVar=VCV000232659; Zygosity=Homozygous; Note=Splice acceptor mutation (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=11776963) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21186889 CVCL_5068 SNU-487 cancer cell line human CVCL_5068 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV18 genome Doubling time: 52 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21186890 CVCL_X689 Ra-IIA transformed cell line CVCL_X689 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood. Male 21186891 CVCL_WU89 SupT1-R5 cancer cell line human CVCL_WU89 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 21186892 CVCL_X688 HLfB cancer cell line human CVCL_X688 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21186893 CVCL_WU88 SupT1.CCR5 cancer cell line human CVCL_WU88 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 21186894 CVCL_X687 BF24 cancer cell line human CVCL_X687 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62577; Escherichia coli cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Contains stably integrated, silent copies of the HIV-1 LTR promoter linked to the CAT gene (PubMed=2789383); Virology: Sensitive indicator cell line for HIV-1 Tat When infected by HIV-1, BF24 produces high levels of chloramphenicol acetyl transferase (CAT) (HIVReagentProgram). 21186895 CVCL_WU87 YAHKMUi001-A induced pluripotent stem cell human CVCL_WU87 From: Yan'an Affiliated Hospital of Kunming Medical University; Kunming; China CL:0000010 Sequence variation: Mutation; HGNC; 11592; TBX1; Simple; p.Gly310Ser (c.928G>A); ClinVar=VCV000007564; Zygosity=Heterozygous (PubMed=31869684) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21186896 CVCL_5041 SNU-254 cancer cell line human CVCL_5041 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu1488Tyrfs*19 (c.4463delT); ClinVar=VCV000428136; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu286Lys (c.856G>A); ClinVar=VCV000183752; Zygosity=Unspecified (PubMed=20176655) Population: Korean; Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Female Doubling time: 50 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21186897 CVCL_5040 SNU-251 cancer cell line human CVCL_5040 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Trp1815Ter (c.5445G>A); ClinVar=VCV000055581; Zygosity=Homozygous or hemizygous (PubMed=9299249); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ala723Asp (c.2168C>A); Zygosity=Heterozygous (PubMed=9299249) Population: Korean; Derived from metastatic site: Ascites. Female Doubling time: 46 hours (PubMed=9299249) Part of: Seoul National University (SNU) cell line collection 21186898 CVCL_5045 SNU-285 transformed cell line human CVCL_5045 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Peripheral blood. Female Part of: Seoul National University (SNU) cell line collection 21186899 CVCL_5044 SNU-283 cancer cell line human CVCL_5044 Genome ancestry: African=1.3%; Native American=0.52%; East Asian, North=60.74%; East Asian, South=36.27%; South Asian=0%; European, North=0%; European, South=1.16% (PubMed=30894373) CL:0000010 Population: Korean; Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 42 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21186900 CVCL_5043 SNU-267 cancer cell line human CVCL_5043 CL:0000010 Population: Korean; Derived from sampling site: Kidney. Male Doubling time: 24 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Seoul National University (SNU) cell line collection 21186901 CVCL_5042 SNU-265 transformed cell line human CVCL_5042 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Peripheral blood. Male Part of: Seoul National University (SNU) cell line collection 21186902 CVCL_5038 SNU-245 cancer cell line human CVCL_5038 HLA typing: A*02:01,33:03; B*35:01,44:03; C*03:03,14:03 (PubMed=26589293); Genome ancestry: African=0.84%; Native American=0.55%; East Asian, North=65.45%; East Asian, South=33.11%; South Asian=0%; European, North=0%; European, South=0.05% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Bile duct. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 54 hours (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21186903 CVCL_5037 SNU-2315 cancer cell line human CVCL_5037 CL:0000010 Population: Korean; Derived from metastatic site: Lymph node. Male Doubling time: 141 hours (PubMed=21290211) Part of: Seoul National University (SNU) cell line collection 21186904 CVCL_5036 SNU-2292 cancer cell line human CVCL_5036 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Female Doubling time: 72 hours (PubMed=21290211) Part of: Seoul National University (SNU) cell line collection 21186905 CVCL_5035 SNU-228 cancer cell line human CVCL_5035 CL:0000010 Population: Korean; Derived from sampling site: Kidney. Male Doubling time: 24 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Seoul National University (SNU) cell line collection 21186906 CVCL_5039 SNU-247 transformed cell line human CVCL_5039 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a ureter cancer; Derived from sampling site: Ureter. Male Part of: Seoul National University (SNU) cell line collection 21186907 CVCL_X693 CRFK/FIV-AZR-1 spontaneously immortalized cell line CVCL_X693 CL:0000010 Selected for resistance to: ChEBI; CHEBI:10110; Zidovudine (3'-azido-3'-deoxythymidine); Derived from sampling site: Kidney. Female Doubling time: 16-24 hours (HIVReagentProgram) 21186908 CVCL_WU93 US8-93 cancer cell line human CVCL_WU93 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Heterozygous (PubMed=21528241). Male Doubling time: 21 +- 3.8 hours (PubMed=21528241) 21186909 CVCL_X692 Jurkat-tat cancer cell line human CVCL_X692 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 25 hours (HIVReagentProgram) Group: Patented cell line 21186910 CVCL_WU92 MOLT-4.CCR5 cancer cell line human CVCL_WU92 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186911 CVCL_X691 Ham-IIA transformed cell line CVCL_X691 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Spleen. Male 21186912 CVCL_WU91 SCS214 cancer cell line human CVCL_WU91 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11336; SSX2; Name(s)=SS18-SSX2 (DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Tyr (c.94G>T); ClinVar=VCV000017581; Zygosity=Heterozygous (DepMap) Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21186913 CVCL_WU90 CEMss/CCR5 cancer cell line human CVCL_WU90 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21186914 CVCL_X690 Si-IIA transformed cell line CVCL_X690 CL:0000010 Transformant: Cynomolgus Epstein-Barr Virus Si-IIA(NCBI-Taxonomy; 114769); Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 21186915 CVCL_X697 CEM-TART cancer cell line human CVCL_X697 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Doubling time: ~48 hours (HIVReagentProgram) 21186916 CVCL_WU97 CL-49 cancer cell line Norway rat CVCL_WU97 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 21186917 CVCL_X696 CHO-SIVmac239 gp130 Clone 3 spontaneously immortalized cell line CVCL_X696 CL:0000010 Derived from sampling site: Ovary. Female 21186918 CVCL_WU96 US8-93C cancer cell line human CVCL_WU96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Heterozygous (PubMed=21528241). Male 21186919 CVCL_X695 CHO-SIVsmH4 gp130 Clone AD5 spontaneously immortalized cell line CVCL_X695 CL:0000010 Derived from sampling site: Ovary. Female 21186920 CVCL_WU95 US8-93B cancer cell line human CVCL_WU95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Ter (c.272G>A); ClinVar=VCV000233650; Zygosity=Heterozygous (PubMed=21528241). Male 21186921 CVCL_X694 1G5 [Human Jurkat derivative] cancer cell line human CVCL_X694 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186922 CVCL_WU94 SupT1/CCR5/Blam cancer cell line human CVCL_WU94 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Pleural effusion Cell type=T-cell.. Male 21186923 CVCL_X679 Een217 finite cell line human CVCL_X679 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21186924 CVCL_WU79 NTUH-iPSC-001-05-FFXF induced pluripotent stem cell human CVCL_WU79 From: National Taiwan University; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21186925 CVCL_X678 KT56 hybridoma house mouse CVCL_X678 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21186926 CVCL_WU78 NTUH-iPSC-012-04 induced pluripotent stem cell human CVCL_WU78 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 21186927 CVCL_WU77 HT [Human HeLa contaminated cell line] cancer cell line human CVCL_WU77 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: BCRC; 60527; true Female Problematic cell line: Contaminated Shown to be a HeLa derivative (BCRC). Originally thought to originate from the placenta a 29 year old female donor. 21186928 CVCL_X677 KT54 hybridoma house mouse CVCL_X677 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and centrosome. 21186929 CVCL_X676 KT38 hybridoma house mouse CVCL_X676 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and pharynx. 21186930 CVCL_WU76 TLouaR cancer cell line human CVCL_WU76 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: BCRC; 60529; true Female Problematic cell line: Contaminated Shown to be a HeLa derivative (BCRC). Originally thought to originate from the TL cell line (Cellosaurus=CVCL_WU75) which was supposed to originate from the placenta of a 29 year old woman but is a SiHa contaminated cell line. 21186931 CVCL_5052 SNU-328 cancer cell line human CVCL_5052 CL:0000010 Population: Korean; Derived from sampling site: Kidney. Male Doubling time: 120 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Seoul National University (SNU) cell line collection 21186932 CVCL_5051 SNU-324 cancer cell line human CVCL_5051 HLA typing: A*24:02,26:02; B*40:06,40:06; C*03:03,03:03 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=60.53%; East Asian, South=39.47%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (DepMap) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 52 hours (PubMed=12037578); Microsatellite instability: Instable (MSI) (PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186933 CVCL_5050 SNU-321 transformed cell line human CVCL_5050 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a lymphoma; Derived from sampling site: Bone marrow. Male Part of: Seoul National University (SNU) cell line collection 21186934 CVCL_5056 SNU-373 cancer cell line human CVCL_5056 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Homozygous (PubMed=17134824) Population: Korean; Derived from sampling site: Thyroid gland. Male Doubling time: 41 hours (PubMed=17134824) Part of: Seoul National University (SNU) cell line collection 21186935 CVCL_5055 SNU-371 cancer cell line human CVCL_5055 CL:0000010 Population: Korean Male Doubling time: 98 hours (PubMed=21290211). Part of: Seoul National University (SNU) cell line collection 21186936 CVCL_5054 SNU-349 cancer cell line human CVCL_5054 HLA typing: A*02:01,24:02; B*39:01,51:01; C*14:02,14:02 (PubMed=26589293); Genome ancestry: African=0.29%; Native American=0.68%; East Asian, North=61.84%; East Asian, South=37.03%; South Asian=0%; European, North=0.16%; European, South=0% (PubMed=30894373) CL:0000010 Population: Korean; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 120 hours (PubMed=10619961); Microsatellite instability: Instable (MSI) (PubMed=10619961; PubMed=31068700) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186937 CVCL_5053 SNU-333 cancer cell line human CVCL_5053 CL:0000010 Population: Korean; Derived from sampling site: Kidney. Male Doubling time: 76 hours (PubMed=10619961); Microsatellite instability: Stable (MSS) (PubMed=10619961) Part of: Seoul National University (SNU) cell line collection 21186938 CVCL_5049 SNU-315 transformed cell line human CVCL_5049 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a esophageal cancer; Derived from sampling site: Esophagus. Male Part of: Seoul National University (SNU) cell line collection 21186939 CVCL_5048 SNU-308 cancer cell line human CVCL_5048 HLA typing: A*24:02,33:03; B*48:01,58:01; C*03:02,08:03 (PubMed=26589293); Genome ancestry: African=0.26%; Native American=0%; East Asian, North=62.71%; East Asian, South=35.2%; South Asian=0%; European, North=0%; European, South=1.83% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val217Gly (c.650T>G); Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Gallbladder. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 48 hours (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186940 CVCL_5047 SNU-299 transformed cell line human CVCL_5047 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Bone marrow. Female Part of: Seoul National University (SNU) cell line collection 21186941 CVCL_5046 SNU-291 transformed cell line human CVCL_5046 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a leukemia; Derived from sampling site: Peripheral blood. Male Part of: Seoul National University (SNU) cell line collection 21186942 CVCL_WU82 BIHi004-C induced pluripotent stem cell human CVCL_WU82 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186943 CVCL_X682 HUT 78/HIV-2D194 cancer cell line human CVCL_X682 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with HIV-2 isolate D194 (HIVReagentProgram) 21186944 CVCL_WU81 BIHi004-B induced pluripotent stem cell human CVCL_WU81 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21186945 CVCL_X681 H9/HIV-2MVP-15132 cancer cell line human CVCL_X681 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186946 CVCL_X680 H9/HIV-2MVP-11971 cancer cell line human CVCL_X680 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21186947 CVCL_WU80 NTU-1-FFXF embryonic stem cell human CVCL_WU80 From: National Taiwan University; Taipei; Taiwan. CL:0000010 Female 21186948 CVCL_WU86 GSPHi001-A induced pluripotent stem cell human CVCL_WU86 From: Gansu Provincial Hospital; Lanzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21186949 CVCL_X686 HLCD4-CAT cancer cell line human CVCL_X686 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat; Transfected with: HGNC; 1678; CD4 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21186950 CVCL_WU85 BIHi027-A induced pluripotent stem cell human CVCL_WU85 From: Berlin Institute of Health; Berlin; Germany. CL:0000010 21186951 CVCL_X685 HL2/3 cancer cell line human CVCL_X685 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Contains stably integrated copies of HIV-1 clone HXB2/3gpt 21186952 CVCL_WU84 BIHi026-A induced pluripotent stem cell human CVCL_WU84 From: Berlin Institute of Health; Berlin; Germany. CL:0000010 21186953 CVCL_X684 SC-1/MuLV LP-BM5 spontaneously immortalized cell line house mouse CVCL_X684 CL:0000010 Unspecified Virology: Infected with LP-BM5 retrovirus. 21186954 CVCL_WU83 BIHi014-A induced pluripotent stem cell human CVCL_WU83 From: Berlin Institute of Health; Berlin; Germany. CL:0000010 21186955 CVCL_X683 HUT 78/HIV-2D205 cancer cell line human CVCL_X683 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: Infected with HIV-2 isolate D205 (HIVReagentProgram) 21186956 CVCL_WU68 04T036 cancer cell line human CVCL_WU68 CL:0000010 Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male 21186957 CVCL_X668 KT28 hybridoma house mouse CVCL_X668 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on unidentified structure. 21186958 CVCL_WU67 95T1000 cancer cell line human CVCL_WU67 CL:0000010 Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Genome sequenced; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21186959 CVCL_X667 KT27 hybridoma house mouse CVCL_X667 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on dorsal hypodermis. 21186960 CVCL_X666 KT26 hybridoma house mouse CVCL_X666 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on centrosome. 21186961 CVCL_WU66 OS252 cancer cell line human CVCL_WU66 CL:0000010 Derived from sampling site: Bone. Omics: Deep exome analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21186962 CVCL_X665 KT23 hybridoma house mouse CVCL_X665 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on nuclear membrane. 21186963 CVCL_WU65 MUSIi011-B induced pluripotent stem cell human CVCL_WU65 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21186964 CVCL_X669 KT29 hybridoma house mouse CVCL_X669 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on eggshell. 21186965 CVCL_WU69 UACC62R cancer cell line human CVCL_WU69 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Omics: Transcriptome analysis by RNAseq. Unspecified 21186966 CVCL_5023 SNU-1330 cancer cell line human CVCL_5023 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Male Doubling time: 39 hours (PubMed=21290211) Part of: Seoul National University (SNU) cell line collection 21186967 CVCL_5022 SNU-1327 cancer cell line human CVCL_5022 CL:0000010 Population: Korean; Derived from metastatic site: Pleural effusion. Male Doubling time: 42 hours (PubMed=21290211) Part of: Seoul National University (SNU) cell line collection 21186968 CVCL_5021 SNU-1299 cancer cell line human CVCL_5021 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV16 genome Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21186969 CVCL_5016 SNU-1197 cancer cell line human CVCL_5016 HLA typing: A*24:02,24:02; B*48:01,55:02; C*03:03,08:01; DQA1*04:01,04:01; DQB1*03:01,03:01; DRB1*03:38,12:01 (PubMed=26589293); Genome ancestry: African=1.84%; Native American=0.35%; East Asian, North=62.22%; East Asian, South=34.04%; South Asian=0%; European, North=0%; European, South=1.55% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg232Ter (c.694C>T); ClinVar=VCV000042248; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Homozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (PubMed=10362137; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=10362137; DepMap) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 60 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186970 CVCL_5015 SNU-1196 cancer cell line human CVCL_5015 HLA typing: A*24:02,24:02; B*54:01,54:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0.3%; Native American=0%; East Asian, North=61.64%; East Asian, South=37.54%; South Asian=0%; European, North=0%; European, South=0.51% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=12107841; DepMap) Population: Korean; Derived from sampling site: Common hepatic duct. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 48 hours (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186971 CVCL_5014 SNU-119 cancer cell line human CVCL_5014 HLA typing: A*31:01,31:01; B*35:01,51:01; C*14:02,14:02 (PubMed=26589293); Genome ancestry: African=2.1%; Native American=0%; East Asian, North=63.25%; East Asian, South=31.5%; South Asian=0%; European, North=0%; European, South=3.15% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151Ala (c.451C>G); ClinVar=VCV000376641; Zygosity=Homozygous (PubMed=9299249; DepMap) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 53 hours (PubMed=9299249) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21186972 CVCL_5013 SNU-1181 cancer cell line human CVCL_5013 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys1370Ter (c.4108A>T); Zygosity=Homozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=20176655) Population: Korean; Derived from metastatic site: Liver. Omics: Transcriptome analysis by microarray Male Doubling time: 52 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21186973 CVCL_5019 SNU-1245 cancer cell line human CVCL_5019 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Contains an episomal HPV18 genome Doubling time: 54 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21186974 CVCL_5018 SNU-1235 cancer cell line human CVCL_5018 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (PubMed=20176655) Population: Korean; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Doubling time: 45 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21186975 CVCL_5017 SNU-1214 cancer cell line human CVCL_5017 HLA typing: A*11:01,11:01; B*13:01,13:01; C*07:02,07:02 (PubMed=26589293); Genome ancestry: African=1.38%; Native American=0%; East Asian, North=61.21%; East Asian, South=37.41%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (PubMed=10369293; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Pro (c.475G>C); ClinVar=VCV000182929; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 96 hours (PubMed=10369293) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21186976 CVCL_X671 KT31 hybridoma house mouse CVCL_X671 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on sensory cilia and excretory pore. 21186977 CVCL_WU71 NIHTVBi002-A induced pluripotent stem cell human CVCL_WU71 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1606; CCR5; Simple; p.Ser185Ilefs (c.554_585del32) (CCR5del32); ClinVar=VCV000008184; Zygosity=Homozygous (PubMed=31234109) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186978 CVCL_X670 KT30 hybridoma house mouse CVCL_X670 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on eggshell. 21186979 CVCL_WU70 NIHTVBi001-A induced pluripotent stem cell human CVCL_WU70 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1606; CCR5; Simple; p.Ser185Ilefs (c.554_585del32) (CCR5del32); ClinVar=VCV000008184; Zygosity=Homozygous (PubMed=31234109) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21186980 CVCL_X675 KT37 hybridoma house mouse CVCL_X675 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21186981 CVCL_WU75 TL [Human SiHa contaminated cell line] cancer cell line human CVCL_WU75 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Discontinued: BCRC; 60528; true Female Doubling time: ~34 hours (PubMed=3581066) Problematic cell line: Contaminated Shown to be a Siha derivative (BCRC). Originally thought to originate from the placenta of a 29 year old woman donor. 21186982 CVCL_WU74 CG1001 finite cell line human CVCL_WU74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: BCRC; 60403; true Female Problematic cell line: Misidentified/contaminated Shown to be 100% identical to CG1000 (BCRC). 21186983 CVCL_X674 KT36 hybridoma house mouse CVCL_X674 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21186984 CVCL_WU73 HL-CZ cancer cell line human CVCL_WU73 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: BCRC; 60043; true Female Doubling time: 22-26 hours (CelloPub=CLPUB00515) Problematic cell line: Contaminated Shown to be a K-562 derivative (BCRC). Originally thought to originate from a 50 year old male patient with a acute T-cell leukemia. 21186985 CVCL_X673 KT35 hybridoma house mouse CVCL_X673 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and centrosome. 21186986 CVCL_X672 KT32 hybridoma house mouse CVCL_X672 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and pharynx. 21186987 CVCL_WU72 NIHTVBi003-A induced pluripotent stem cell human CVCL_WU72 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1606; CCR5; Simple; p.Ser185Ilefs (c.554_585del32) (CCR5del32); ClinVar=VCV000008184; Zygosity=Homozygous (PubMed=31234109) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21186988 CVCL_X657 KT14 [Mouse hybridoma] hybridoma house mouse CVCL_X657 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx basement membrane. 21186989 CVCL_WU57 TISSUi002-A induced pluripotent stem cell human CVCL_WU57 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21186990 CVCL_X656 KT13 hybridoma house mouse CVCL_X656 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on hypodermis/seam cells. 21186991 CVCL_WU56 TISSUi001-A induced pluripotent stem cell human CVCL_WU56 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21186992 CVCL_WU55 CDIi006-A induced pluripotent stem cell human CVCL_WU55 From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 Male 21186993 CVCL_X655 KT12 [Mouse hybridoma] hybridoma house mouse CVCL_X655 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on body muscle. 21186994 CVCL_X654 KT11 [Mouse hybridoma] hybridoma house mouse CVCL_X654 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on body muscle. 21186995 CVCL_WU54 MCRIi001-A-2 induced pluripotent stem cell human CVCL_WU54 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 SOX9 has been endogenously tagged at the C-terminus with TdTomato 21186996 CVCL_X659 KT17 [Mouse hybridoma] hybridoma house mouse CVCL_X659 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21186997 CVCL_WU59 TISSUi004-A induced pluripotent stem cell human CVCL_WU59 From: TissUse GmbH; Berlin; Germany. CL:0000010 21186998 CVCL_X658 KT16 hybridoma house mouse CVCL_X658 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21186999 CVCL_WU58 TISSUi003-A induced pluripotent stem cell human CVCL_WU58 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21187000 CVCL_5030 SNU-1746 cancer cell line human CVCL_5030 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr562fs*19 (c.1682_1683insA); Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1429Ter (c.4285C>T); ClinVar=VCV000376063; Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Glu523Lys (c.1567G>A); Zygosity=Homozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Doubling time: 42 hours (PubMed=20176655); Microsatellite instability: Instable (MSI-high) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187001 CVCL_5034 SNU-213 cancer cell line human CVCL_5034 HLA typing: A*02:01,33:03; B*44:02,51:01; C*07:01,15:02 (PubMed=26589293); Genome ancestry: African=1.77%; Native American=0%; East Asian, North=68.61%; East Asian, South=29.21%; South Asian=0%; European, North=0%; European, South=0.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=12037578; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=12037578); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Ile (c.644G>T); ClinVar=VCV000376660; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Pancreas. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=12037578) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187002 CVCL_5033 SNU-201 cancer cell line human CVCL_5033 HLA typing: A*24:02,33:03; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=2.24%; Native American=2.29%; East Asian, North=64.8%; East Asian, South=30.66%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Asn (c.841G>A); ClinVar=VCV000376586; Zygosity=Heterozygous (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 61 hours (PubMed=11776963); 58 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21187003 CVCL_5032 SNU-20 transformed cell line human CVCL_5032 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a stomach cancer; Derived from sampling site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21187004 CVCL_5031 SNU-175 cancer cell line human CVCL_5031 Genome ancestry: African=0.24%; Native American=0.33%; East Asian, North=60.01%; East Asian, South=39.42%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg232Ter (c.694C>T); ClinVar=VCV000042248; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly1499Ter (c.4495G>T); ClinVar=VCV000217983; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (PubMed=10362137; Cosmic-CLP; DepMap) Population: Korean; Derived from metastatic site: Peritoneum. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 33 hours (PubMed=10362137); Microsatellite instability: Instable (MSI-high) (PubMed=10674020; PubMed=25926053; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21187005 CVCL_5027 SNU-1544 cancer cell line human CVCL_5027 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ser2Leu (c.5C>T); ClinVar=VCV000182533; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Doubling time: 42 hours (PubMed=20176655); Microsatellite instability: Instable (MSI-high) (PubMed=20176655; PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187006 CVCL_5026 SNU-1460 cancer cell line human CVCL_5026 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from sampling site: Colon; sigmoid. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 67 hours (PubMed=20176655); 48 hours (PubMed=31228769); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187007 CVCL_5025 SNU-1411 cancer cell line human CVCL_5025 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser94Ter (c.281C>A); Zygosity=Homozygous (PubMed=20176655) Population: Korean; Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Male Doubling time: 38 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187008 CVCL_5024 SNU-1406 cancer cell line human CVCL_5024 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Female Doubling time: 25 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187009 CVCL_5029 SNU-17 cancer cell line human CVCL_5029 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV16 genome Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187010 CVCL_5028 SNU-1684 cancer cell line human CVCL_5028 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg554Ter (c.1660C>T); ClinVar=VCV000000807; Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1557fs*1 (c.4669_4670delAT); Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from sampling site: Colon; ascending. Omics: Transcriptome analysis by microarray Male Doubling time: 53 hours (PubMed=20176655); Microsatellite instability: Instable (MSI-high) (PubMed=20176655; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187011 CVCL_X660 KT18 hybridoma house mouse CVCL_X660 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21187012 CVCL_WU60 TISSUi005-A induced pluripotent stem cell human CVCL_WU60 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Donor information: Established from a patient suffering from leukemia; Derived from sampling site: Peripheral blood. Male 21187013 CVCL_X664 KT22 hybridoma house mouse CVCL_X664 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21187014 CVCL_WU64 MUSIi011-A induced pluripotent stem cell human CVCL_WU64 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 21187015 CVCL_X663 KT21 hybridoma house mouse CVCL_X663 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on intestine. 21187016 CVCL_WU63 NUIGi003-A induced pluripotent stem cell human CVCL_WU63 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Val822Met (c.2464G>A); ClinVar=VCV000014424; Zygosity=Heterozygous (PubMed=33002718) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187017 CVCL_X662 KT20 hybridoma house mouse CVCL_X662 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21187018 CVCL_WU62 TISSUi007-A induced pluripotent stem cell human CVCL_WU62 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187019 CVCL_X661 KT19 hybridoma house mouse CVCL_X661 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on pharynx. 21187020 CVCL_WU61 TISSUi006-A induced pluripotent stem cell human CVCL_WU61 From: TissUse GmbH; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187021 CVCL_X646 KT03 hybridoma house mouse CVCL_X646 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and body wall muscle. 21187022 CVCL_WU46 NUIGi020-B induced pluripotent stem cell human CVCL_WU46 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187023 CVCL_X645 KT02 hybridoma house mouse CVCL_X645 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187024 CVCL_WU45 NUIGi020-A induced pluripotent stem cell human CVCL_WU45 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187025 CVCL_X644 KT01 hybridoma house mouse CVCL_X644 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187026 CVCL_WU44 NUIGi019-A induced pluripotent stem cell human CVCL_WU44 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187027 CVCL_X643 GM03127 finite cell line human CVCL_X643 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21187028 CVCL_WU43 NUIGi018-C induced pluripotent stem cell human CVCL_WU43 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21187029 CVCL_X649 KT06 hybridoma house mouse CVCL_X649 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule and adult muscle. 21187030 CVCL_WU49 NUIGi023-A induced pluripotent stem cell human CVCL_WU49 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187031 CVCL_X648 KT05 hybridoma house mouse CVCL_X648 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187032 CVCL_WU48 NUIGi021-A induced pluripotent stem cell human CVCL_WU48 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187033 CVCL_X647 KT04 hybridoma house mouse CVCL_X647 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187034 CVCL_WU47 NUIGi020-C induced pluripotent stem cell human CVCL_WU47 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187035 CVCL_5001 SNU-1005 cancer cell line human CVCL_5001 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV16 genome Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187036 CVCL_5000 SNU-1000 cancer cell line human CVCL_5000 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Has both integrated and episomal forms of HPV16 Doubling time: 96 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187037 CVCL_X653 KT10 hybridoma house mouse CVCL_X653 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on body muscle. 21187038 CVCL_WU53 STBCi295-B induced pluripotent stem cell human CVCL_WU53 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21187039 CVCL_X652 KT09 hybridoma house mouse CVCL_X652 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on body muscle. 21187040 CVCL_WU52 STBCi041-C induced pluripotent stem cell human CVCL_WU52 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21187041 CVCL_X651 KT08 hybridoma house mouse CVCL_X651 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187042 CVCL_WU51 STBCi320-A induced pluripotent stem cell human CVCL_WU51 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21187043 CVCL_X650 KT07 hybridoma house mouse CVCL_X650 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Caenorhabditis elegans antigen on P granule. 21187044 CVCL_WU50 NUIGi004-A induced pluripotent stem cell human CVCL_WU50 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Val822Met (c.2464G>A); ClinVar=VCV000014424; Zygosity=Heterozygous (PubMed=34628246) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187045 CVCL_X635 CEM-CL10 cancer cell line human CVCL_X635 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Doubling time: 18-24 hours (HIVReagentProgram) 21187046 CVCL_WU35 NUIGi015-B induced pluripotent stem cell human CVCL_WU35 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val411Met (c.1231G>A); ClinVar=VCV000067651; Zygosity=Unspecified (hPSCreg) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187047 CVCL_X634 HeLa CD4-Clone 6C cancer cell line human CVCL_X634 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21187048 CVCL_WU34 NUIGi015-A induced pluripotent stem cell human CVCL_WU34 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val411Met (c.1231G>A); ClinVar=VCV000067651; Zygosity=Unspecified (hPSCreg) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187049 CVCL_WU33 NUIGi014-A induced pluripotent stem cell human CVCL_WU33 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187050 CVCL_X633 Sup-T1-CCR5 cancer cell line human CVCL_X633 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Miscellaneous: STR profile from personal communication of Fernandez M Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Caution: There seem to be at least 6 different cell lines derived from Sup-T1 by transfection of human CCR5: Sup-T1-CCR5 (Cellosaurus=CVCL_X633), SupT1.CCR5 (Cellosaurus=CVCL_WU88), SupT1-R5 (Cellosaurus=CVCL_WU89), Sup-T1 CCR5+ H6 (Cellosaurus=CVCL_A9NU), Sup-T1 CCR5+ L23 (Cellosaurus=CVCL_A9NV) and Sup-T1 CCR5+ M10 (Cellosaurus=CVCL_A9NW) 21187051 CVCL_WU32 NUIGi013-A induced pluripotent stem cell human CVCL_WU32 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187052 CVCL_X632 U87.CD4.CXCR4 cancer cell line human CVCL_X632 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 1678; CD4; Transfected with: HGNC; 2561; CXCR4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Problematic cell line: Misidentified Grand-parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21187053 CVCL_X639 DT40-RAD51D(-/-) cancer cell line CVCL_X639 CL:0000010 Knockout cell: Method=Targeted integration; RAD51D Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21187054 CVCL_WU39 NUIGi016-C induced pluripotent stem cell human CVCL_WU39 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187055 CVCL_X638 DT40-RAD51C(-/-) cancer cell line CVCL_X638 CL:0000010 Knockout cell: Method=Targeted integration; RAD51C Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21187056 CVCL_WU38 NUIGi016-B induced pluripotent stem cell human CVCL_WU38 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187057 CVCL_X637 DT40-RAD51B(-/-) cancer cell line CVCL_X637 CL:0000010 Knockout cell: Method=Targeted integration; RAD51B Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21187058 CVCL_WU37 NUIGi016-A induced pluripotent stem cell human CVCL_WU37 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187059 CVCL_X636 LSCEF61 finite cell line CVCL_X636 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Langshan. Male Doubling time: 49.5 hours (PubMed=20447061) Group: Bird cell line 21187060 CVCL_WU36 NUIGi015-C induced pluripotent stem cell human CVCL_WU36 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Val411Met (c.1231G>A); ClinVar=VCV000067651; Zygosity=Unspecified (hPSCreg) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187061 CVCL_5012 SNU-1160 cancer cell line human CVCL_5012 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV18 genome Doubling time: 54 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187062 CVCL_5011 SNU-1118 cancer cell line human CVCL_5011 CL:0000010 Population: Korean; Derived from sampling site: Brain. Male Doubling time: 78 hours (PubMed=11776963) Part of: Seoul National University (SNU) cell line collection 21187063 CVCL_5010 SNU-1105 cancer cell line human CVCL_5010 HLA typing: A*11:01,24:02; B*35:01,51:01; C*08:01,14:02 (PubMed=26589293); Genome ancestry: African=0.33%; Native American=1.43%; East Asian, North=63.75%; East Asian, South=34.48%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Gly (c.472C>G); ClinVar=VCV000856171; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 84 hours (PubMed=11776963); 73 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187064 CVCL_5005 SNU-1066 cancer cell line human CVCL_5005 HLA typing: A*02:06,24:02; B*15:01,27:05; C*01:02,04:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp92fs*54 (c.274delG); Zygosity=Homozygous (PubMed=10369293; DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.514_559del46; Zygosity=Homozygous (PubMed=10369293; DepMap) Population: Korean; Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 48 hours (PubMed=10369293) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187065 CVCL_5004 SNU-1047 cancer cell line human CVCL_5004 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Thr (c.761T>C); Zygosity=Unspecified (PubMed=10362137) Population: Korean; Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=10362137); Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187066 CVCL_5003 SNU-1040 cancer cell line human CVCL_5003 HLA typing: A*24:02,24:02; B*38:02,51:01; C*07:02,14:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.04%; East Asian, North=58.5%; East Asian, South=40.46%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10362137) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 63 hours (PubMed=10362137); Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053; PubMed=31068700); Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21187067 CVCL_5002 SNU-1033 cancer cell line human CVCL_5002 HLA typing: A*24:02,24:02; B*40:01,51:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=18.67%; Native American=0%; East Asian, North=56.8%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=24.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=10362137; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leu (c.569C>T); ClinVar=VCV000418517; Zygosity=Homozygous (PubMed=10362137; DepMap) Population: Korean; Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 42 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187068 CVCL_5009 SNU-1103 transformed cell line human CVCL_5009 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a rectal carcinoma; Derived from sampling site: Rectum. Male Part of: Seoul National University (SNU) cell line collection 21187069 CVCL_5008 SNU-1079 cancer cell line human CVCL_5008 HLA typing: A*31:01,33:03; B*44:03,48:01; C*03:03,14:03 (PubMed=26589293); Genome ancestry: African=0.24%; Native American=0%; East Asian, North=64.18%; East Asian, South=34.91%; South Asian=0%; European, North=0%; European, South=0.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (PubMed=27231123; DepMap) Population: Korean; Derived from sampling site: Liver; intrahepatic bile duct. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 72 hours (PubMed=12107841) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21187070 CVCL_5007 SNU-1077 cancer cell line human CVCL_5007 HLA typing: A*02:06,24:02; B*40:06,67:01; C*07:02,08:01 (PubMed=26589293); Genome ancestry: African=0.64%; Native American=0%; East Asian, North=64.52%; East Asian, South=33.3%; South Asian=0%; European, North=0%; European, South=1.53% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Ser (c.584T>G); ClinVar=VCV000376619; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Endometrium. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 43 hours (PubMed=9299262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187071 CVCL_5006 SNU-1076 cancer cell line human CVCL_5006 HLA typing: A*01:01,02:01; B*13:01,13:01; C*03:04,06:02 (PubMed=26589293); Genome ancestry: African=2.88%; Native American=0%; East Asian, North=66.81%; East Asian, South=28.32%; South Asian=0%; European, North=0%; European, South=1.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Pro114His (c.341C>A) (p.Ala128Ala, c.384C>A); ClinVar=VCV000376383; Zygosity=Unspecified (PubMed=10369293); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (DepMap) Population: Korean; Derived from sampling site: Larynx. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=10369293) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187072 CVCL_WU42 NUIGi018-B induced pluripotent stem cell human CVCL_WU42 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21187073 CVCL_X642 SAOS-alpha2beta1 cancer cell line human CVCL_X642 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6137; ITGA2 Population: Caucasian; Derived from sampling site: Bone. Female 21187074 CVCL_WU41 NUIGi018-A induced pluripotent stem cell human CVCL_WU41 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21187075 CVCL_X641 PC-J cancer cell line human CVCL_X641 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Androgen-independent clone of PC-3 21187076 CVCL_X640 DT40-RAD52(-/-) cancer cell line CVCL_X640 CL:0000010 Knockout cell: Method=Targeted integration; RAD52 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21187077 CVCL_WU40 NUIGi017-A induced pluripotent stem cell human CVCL_WU40 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21187078 CVCL_FC10 ND02067 transformed cell line human CVCL_FC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187079 CVCL_FC09 ND02065 transformed cell line human CVCL_FC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187080 CVCL_FC08 ND01668 transformed cell line human CVCL_FC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187081 CVCL_FC03 ND00142 transformed cell line human CVCL_FC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187082 CVCL_FC02 ND19180 transformed cell line human CVCL_FC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187083 CVCL_FC01 ND16058 transformed cell line human CVCL_FC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187084 CVCL_FC00 ND14898 transformed cell line human CVCL_FC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187085 CVCL_FC07 ND01505 transformed cell line human CVCL_FC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187086 CVCL_FC06 ND01184 transformed cell line human CVCL_FC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187087 CVCL_FC05 ND00660 transformed cell line human CVCL_FC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187088 CVCL_FC04 ND00452 transformed cell line human CVCL_FC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187089 CVCL_FC21 ND02662 transformed cell line human CVCL_FC21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187090 CVCL_FC20 ND02658 transformed cell line human CVCL_FC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187091 CVCL_FC19 ND02580 transformed cell line human CVCL_FC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187092 CVCL_FC14 ND02143 transformed cell line human CVCL_FC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187093 CVCL_FC13 ND02141 transformed cell line human CVCL_FC13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187094 CVCL_FC12 ND02114 transformed cell line human CVCL_FC12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187095 CVCL_FC11 ND02074 transformed cell line human CVCL_FC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187096 CVCL_FC18 ND02560 transformed cell line human CVCL_FC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187097 CVCL_FC17 ND02550 transformed cell line human CVCL_FC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187098 CVCL_FC16 ND02400 transformed cell line human CVCL_FC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187099 CVCL_FC15 ND02399 transformed cell line human CVCL_FC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187100 CVCL_5081 SNU-668 cancer cell line human CVCL_5081 HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03 (PubMed=25960936); HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03; DQA1*05:02,05:02; DQB1*06:01,06:01 (PubMed=26589293); Genome ancestry: African=1.18%; Native American=0%; East Asian, North=71.14%; East Asian, South=25.86%; South Asian=0%; European, North=0%; European, South=1.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (PubMed=9033653; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (PubMed=9033653; DepMap) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187101 CVCL_5080 SNU-626 cancer cell line human CVCL_5080 HLA typing: A*24:02,29:01; B*07:06,15:01; C*01:02,15:05 (PubMed=26589293); Genome ancestry: African=0.03%; Native American=0%; East Asian, North=63.88%; East Asian, South=35.09%; South Asian=0.99%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Arg (c.385G>A); ClinVar=VCV000189484; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys238Ser (c.713G>C); ClinVar=VCV000376575; Zygosity=Heterozygous (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 92 hours (PubMed=11776963) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21187102 CVCL_5085 SNU-703 cancer cell line human CVCL_5085 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains an integrated HPV16 genome Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187103 CVCL_5084 SNU-70 cancer cell line human CVCL_5084 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1294Ter (c.3880C>T); ClinVar=VCV000469942; Zygosity=Unspecified (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282fs (c.845delG); Zygosity=Homozygous (PubMed=20176655) Population: Korean; Derived from sampling site: Rectum. Omics: Transcriptome analysis by microarray Male Doubling time: 118 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655) Part of: Seoul National University (SNU) cell line collection 21187104 CVCL_5083 SNU-685 cancer cell line human CVCL_5083 HLA typing: A*02:01,33:03; B*44:02,54:01; C*14:03,14:03; DQA1*04:01,04:01; DQB1*03:23,03:23; DRB1*04:03,13:01 (PubMed=26589293); Genome ancestry: African=1.15%; Native American=0.59%; East Asian, North=63.21%; East Asian, South=35.03%; South Asian=0%; European, North=0%; European, South=0.02% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>T (IVS8+1G>T); ClinVar=VCV000495326; Zygosity=Homozygous; Note=Splice donor mutation (DepMap) Population: Korean; Derived from sampling site: Endometrium. Omics: ATAC-seq; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 20 hours (PubMed=9299262) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187105 CVCL_5082 SNU-682 cancer cell line human CVCL_5082 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 33 (HPV33)(NCBI-Taxonomy; 10586); Derived from sampling site: Uterus; cervix. Female Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187106 CVCL_5089 SNU-761 cancer cell line human CVCL_5089 HLA typing: A*11:01,11:01; B*13:01,13:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.61%; Native American=0%; East Asian, North=59.84%; East Asian, South=38.16%; South Asian=0%; European, North=0%; European, South=1.38% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser313Glyfs*13 (c.937_968delAGCTCCTCTCCCCAGCCAAAGAAGAAACCACT); Zygosity=Unspecified (PubMed=8824565; PubMed=31378681) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=11819450); 24.32 hours (PubMed=31378681) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21187107 CVCL_5088 SNU-739 cancer cell line human CVCL_5088 CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Gln149Serfs*83 (c.444dupT); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.645T>G); ClinVar=VCV000376661; Zygosity=Unspecified (PubMed=8824565; PubMed=31378681) Population: Korean; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407) Omics: Deep exome analysis; Omics: Genome sequenced; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 20 hours (PubMed=11819450); 24.99 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE); Part of: Seoul National University (SNU) cell line collection 21187108 CVCL_5087 SNU-738 cancer cell line human CVCL_5087 HLA typing: A*02:06,24:02; B*35:01,52:01; C*03:03,12:02 (PubMed=26589293); Genome ancestry: African=1.32%; Native American=0%; East Asian, North=64.14%; East Asian, South=32.96%; South Asian=0%; European, North=0%; European, South=1.57% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln192Ter (c.574C>T); ClinVar=VCV000406579; Zygosity=Homozygous (DepMap) Population: Korean; Derived from sampling site: Brain. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 56 hours (PubMed=11776963) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187109 CVCL_5086 SNU-719 cancer cell line human CVCL_5086 HLA typing: A*24:02,24:02; B*07:02,52:01; C*07:02,12:02; DQB1*05:01,05:01; DRB1*01:01,15:02 (PubMed=25960936); HLA typing: A*24:02,24:02; B*07:02,52:01; C*07:02,12:02; DQA1*05:02,05:02; DQB1*05:01,05:01; DRB1*01:01,15:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=1.31%; East Asian, North=60.01%; East Asian, South=38.67%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Val (c.101G>T); ClinVar=VCV000017582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro104Arg (c.311C>G); ClinVar=VCV001480334; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9033653) Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Stomach. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Virology: Contains a complete EBV genome (strain SNU-719) which has been sequenced (PubMed=26889033) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187110 CVCL_5079 SNU-620 cancer cell line human CVCL_5079 HLA typing: A*33:03,33:03; B*44:07,58:01; C*03:02,07:01; DQB1*06:05,06:05; DRB1*13:02,14:05 (PubMed=25960936); HLA typing: A*33:03,33:03; B*44:03,58:01; C*03:02,07:01 (PubMed=26589293); Genome ancestry: African=0.37%; Native American=1.1%; East Asian, North=58.94%; East Asian, South=38.87%; South Asian=0%; European, North=0.05%; European, South=0.67% (PubMed=30894373) CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=9033653) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection; Part of: TCGA-110-CL cell line panel 21187111 CVCL_5092 SNU-778 cancer cell line human CVCL_5092 CL:0000010 Population: Korean; Transformant: Human papillomavirus type 31 (HPV31)(NCBI-Taxonomy; 10585); Derived from sampling site: Uterus; cervix. Female Doubling time: 48 hours (PubMed=9219839) Part of: Seoul National University (SNU) cell line collection 21187112 CVCL_5091 SNU-769B cancer cell line human CVCL_5091 CL:0000010 Population: Korean; Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Doubling time: 42 hours (PubMed=10362137); Microsatellite instability: Instable (MSI) (PubMed=10674020; PubMed=25926053) Part of: Seoul National University (SNU) cell line collection 21187113 CVCL_5090 SNU-769A cancer cell line human CVCL_5090 CL:0000010 Population: Korean; Derived from metastatic site: Lymph node. Male Doubling time: 45 hours (PubMed=10362137); Microsatellite instability: Instable (MSI) (PubMed=10674020) Part of: Seoul National University (SNU) cell line collection 21187114 CVCL_5096 SNU-8 cancer cell line human CVCL_5096 HLA typing: A*02:06,24:02; B*39:01,40:02; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0.06%; Native American=0.79%; East Asian, North=58.48%; East Asian, South=40.21%; South Asian=0%; European, North=0.01%; European, South=0.45% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro142fs (c.425_426delCT); Zygosity=Homozygous (DepMap) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 44 hours (PubMed=9299249) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Seoul National University (SNU) cell line collection 21187115 CVCL_5095 SNU-796 cancer cell line human CVCL_5095 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg554Ter (c.1660C>T); ClinVar=VCV000000807; Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1364fs*11 (c.4090_4091insA); Zygosity=Heterozygous (PubMed=20176655); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=20176655) Population: Korean; Derived from sampling site: Rectum. Female Doubling time: 121 hours (PubMed=20176655); Microsatellite instability: Stable (MSS) (PubMed=20176655) Part of: Seoul National University (SNU) cell line collection 21187116 CVCL_5094 SNU-791 cancer cell line human CVCL_5094 CL:0000010 Population: Korean; Derived from sampling site: Brain. Male Doubling time: 60 hours (PubMed=11776963) Part of: Seoul National University (SNU) cell line collection 21187117 CVCL_5093 SNU-790 cancer cell line human CVCL_5093 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17134824) Population: Korean; Derived from sampling site: Thyroid gland. Male Doubling time: 33 hours (PubMed=17134824) Part of: Seoul National University (SNU) cell line collection 21187118 CVCL_5099 SNU-817 transformed cell line human CVCL_5099 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from a stomach cancer; Derived from sampling site: Ascites. Male Part of: Seoul National University (SNU) cell line collection 21187119 CVCL_5098 SNU-81 cancer cell line human CVCL_5098 Genome ancestry: African=0%; Native American=1.37%; East Asian, North=56.62%; East Asian, South=42%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1392Ter (c.4175C>A); ClinVar=VCV000188240; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2204Ter (c.6610C>T); ClinVar=VCV000236632; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg479Gln (c.1436G>A); ClinVar=VCV000376419; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Gln (c.389G>A); ClinVar=VCV000007829; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu299Ter (c.895G>T); ClinVar=VCV000428263; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11602; TBX3; Simple; p.Glu111Ter (c.331G>T); Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11602; TBX3; Simple; c.942-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Thr (c.395A>C); ClinVar=VCV000376627; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 30 hours (PubMed=10362137); Microsatellite instability: Stable (MSS) (PubMed=10674020; PubMed=25926053; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21187120 CVCL_5097 SNU-80 cancer cell line human CVCL_5097 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Arg (c.1405G>C); ClinVar=VCV000013970; Zygosity=Unspecified (PubMed=17134824); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (PubMed=17134824) Population: Korean; Derived from sampling site: Thyroid gland. Female Doubling time: 37 hours (PubMed=17134824) Part of: Seoul National University (SNU) cell line collection 21187121 CVCL_4H84 GM08915 transformed cell line human CVCL_4H84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187122 CVCL_4H83 GM08914 transformed cell line human CVCL_4H83 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187123 CVCL_4H82 GM08912 transformed cell line human CVCL_4H82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187124 CVCL_4H81 GM08911 transformed cell line human CVCL_4H81 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187125 CVCL_4H88 GM09044 transformed cell line human CVCL_4H88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187126 CVCL_4H87 GM09043 transformed cell line human CVCL_4H87 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187127 CVCL_4H86 GM09042 transformed cell line human CVCL_4H86 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187128 CVCL_4H85 GM09041 transformed cell line human CVCL_4H85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187129 CVCL_4H89 GM09045 transformed cell line human CVCL_4H89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187130 CVCL_4H80 GM08880 transformed cell line human CVCL_4H80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187131 CVCL_4H95 GM09213 transformed cell line human CVCL_4H95 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187132 CVCL_4H94 GM09212 transformed cell line human CVCL_4H94 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187133 CVCL_4H93 GM09211 transformed cell line human CVCL_4H93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187134 CVCL_4H92 GM09193 transformed cell line human CVCL_4H92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187135 CVCL_4H99 GM09730 transformed cell line human CVCL_4H99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187136 CVCL_4H98 GM09729 transformed cell line human CVCL_4H98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187137 CVCL_4H97 GM09215 transformed cell line human CVCL_4H97 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187138 CVCL_4H96 GM09214 transformed cell line human CVCL_4H96 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187139 CVCL_4H91 GM09138 transformed cell line human CVCL_4H91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187140 CVCL_4H90 GM09046 transformed cell line human CVCL_4H90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187141 CVCL_4H62 GM08850 transformed cell line human CVCL_4H62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187142 CVCL_4H61 GM08849 transformed cell line human CVCL_4H61 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187143 CVCL_4H60 GM08826 transformed cell line human CVCL_4H60 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187144 CVCL_4H66 GM08861 transformed cell line human CVCL_4H66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187145 CVCL_4H65 GM08860 transformed cell line human CVCL_4H65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187146 CVCL_4H64 GM08853 transformed cell line human CVCL_4H64 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187147 CVCL_4H63 GM08852 transformed cell line human CVCL_4H63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187148 CVCL_4H69 GM08864 transformed cell line human CVCL_4H69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187149 CVCL_4H68 GM08863 transformed cell line human CVCL_4H68 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187150 CVCL_4H67 GM08862 transformed cell line human CVCL_4H67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187151 CVCL_4H73 GM08870 transformed cell line human CVCL_4H73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187152 CVCL_4H72 GM08868 transformed cell line human CVCL_4H72 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187153 CVCL_4H71 GM08867 transformed cell line human CVCL_4H71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187154 CVCL_4H70 GM08865 transformed cell line human CVCL_4H70 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187155 CVCL_4H77 GM08876 transformed cell line human CVCL_4H77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187156 CVCL_4H76 GM08875 transformed cell line human CVCL_4H76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187157 CVCL_4H75 GM08872 transformed cell line human CVCL_4H75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187158 CVCL_4H74 GM08871 transformed cell line human CVCL_4H74 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187159 CVCL_4H79 GM08879 transformed cell line human CVCL_4H79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187160 CVCL_4H78 GM08877 transformed cell line human CVCL_4H78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187161 CVCL_4H40 GM07848 transformed cell line human CVCL_4H40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187162 CVCL_4H44 GM07876 transformed cell line human CVCL_4H44 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187163 CVCL_4H43 GM07875 transformed cell line human CVCL_4H43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187164 CVCL_4H42 GM07874 transformed cell line human CVCL_4H42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187165 CVCL_4H41 GM07849 transformed cell line human CVCL_4H41 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187166 CVCL_4H48 GM07948 transformed cell line human CVCL_4H48 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187167 CVCL_4H47 GM07944 transformed cell line human CVCL_4H47 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187168 CVCL_4H46 GM07943 transformed cell line human CVCL_4H46 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187169 CVCL_4H45 GM07942 transformed cell line human CVCL_4H45 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187170 CVCL_4H49 GM07949 transformed cell line human CVCL_4H49 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187171 CVCL_WN92 OSRi004-A induced pluripotent stem cell human CVCL_WN92 From: Ospedale San Raffaele; Milan; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187172 CVCL_WN91 OSRi001-A induced pluripotent stem cell human CVCL_WN91 From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Ala495Val (c.1484C>T); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Arm; skeletal muscle Cell type=Fibroblast.. Male 21187173 CVCL_WN90 INSRMi002-A induced pluripotent stem cell human CVCL_WN90 From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 18423; DEPDC5; Simple; p.Glu1420Argfs*153 (c.4260delG); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187174 CVCL_WN96 Jurkat E6.1 NF-kappaB::eGFP cancer cell line human CVCL_WN96 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The eGFP reporter gene is under control of a NF-kappaB promoter element 21187175 CVCL_WN95 NK101 cancer cell line human CVCL_WN95 CL:0000010 Miscellaneous: STR profile from personal communication of Kim S.W. Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by RNAseq Male Characteristics: Possesses fundamental characteristics of natural killer NK (cells) Potential to simultaneously act as a cytokine producer and a cytotoxic effector. Doubling time: 21.9 +- 2.4 hours (PubMed=31126350) 21187176 CVCL_WN94 ehiPSC-derived pNSCs finite cell line human CVCL_WN94 CL:0000010 Miscellaneous: Cell line information from personal communication of Do T.J Derived from sampling site: Cell type=Neural stem cell. Male 21187177 CVCL_WN93 BHK-21-Bi spontaneously immortalized cell line CVCL_WN93 CL:0000010 Sequence variation: Mutation; UniProtKB; A0A3Q0D700; Ttn; Unexplicit; Partial deletion; Zygosity=Unspecified (PubMed=9180260; PubMed=10725223) Derived from sampling site: Kidney. Male 21187178 CVCL_WN99 EBV-RS transformed cell line human CVCL_WN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21187179 CVCL_WN98 HIAE-35 finite cell line human CVCL_WN98 CL:0000010 Derived from sampling site: Iliac artery; endothelium. Male Part of: Wistar Institute Special Collection vascular cell lines 21187180 CVCL_WN97 JE6-1REP-iNKT cancer cell line human CVCL_WN97 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12027; TRA (iNKT-TCR V-alpha24); Transfected with: HGNC; 12155; TRB (iNKT-TCR V-beta11); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Fluorescence-based iNKT-TCR reporter system, applicable for screening potential new lipid antigens that infuence iNKT cell activation; Characteristics: The eGFP reporter gene is under control of a NF-kappaB promoter element 21187181 CVCL_4H51 GM08810 transformed cell line human CVCL_4H51 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187182 CVCL_4H50 GM08809 transformed cell line human CVCL_4H50 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187183 CVCL_4H55 GM08821 transformed cell line human CVCL_4H55 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187184 CVCL_4H54 GM08814 transformed cell line human CVCL_4H54 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187185 CVCL_4H53 GM08813 transformed cell line human CVCL_4H53 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187186 CVCL_4H52 GM08811 transformed cell line human CVCL_4H52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187187 CVCL_4H59 GM08825 transformed cell line human CVCL_4H59 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187188 CVCL_4H58 GM08824 transformed cell line human CVCL_4H58 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187189 CVCL_4H57 GM08823 transformed cell line human CVCL_4H57 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187190 CVCL_4H56 GM08822 transformed cell line human CVCL_4H56 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187191 CVCL_WN81 SP212Corr induced pluripotent stem cell human CVCL_WN81 CL:0000010 Sequence variation: Mutation; HGNC; 10801; SFTPB; Simple_corrected; p.Pro121Glufs*95 (c.361delCinsGAA) (121ins2); ClinVar=VCV000013201; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=28965766) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187192 CVCL_WN80 SP212 induced pluripotent stem cell human CVCL_WN80 CL:0000010 Sequence variation: Mutation; HGNC; 10801; SFTPB; Simple; p.Pro121Glufs*95 (c.361delCinsGAA) (121ins2); ClinVar=VCV000013201; Zygosity=Homozygous (PubMed=28965766) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21187193 CVCL_WN85 CF iPSC clone 17 induced pluripotent stem cell human CVCL_WN85 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (PubMed=25772471); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=25772471) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187194 CVCL_WN84 HEK-ptdTomato-N1 8 transformed cell line human CVCL_WN84 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expression of the tdTomato gene is under control of the CMV promoter 21187195 CVCL_WN83 C17 NKX2-1-GFP SFTPC-tdTomato induced pluripotent stem cell human CVCL_WN83 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Ile507del (c.1516_1518ATC[1]) (c.1519_1521delATC); ClinVar=VCV000007106; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using TALEN a eGFP-pA-loxP-PGK-Puro-pA-loxP was inserted at the NKX2-1 translational start site and a tdTomato-pA-loxP-PGK-Puro-pA-loxP was inserted at the SFTPC translational start site 21187196 CVCL_WN82 BU3 NKX2-1-GFP SFTPC-tdTomato induced pluripotent stem cell human CVCL_WN82 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using CRISPR/Cas9 a 2A-eGFP-pA was inserted after the NKX2-1 coding sequence and using TALENs a tdTomato-pA-loxP-PGK-Puro-pA-loxP was inserted at the SFTPC translational start site 21187197 CVCL_WN89 ehiPSC induced pluripotent stem cell human CVCL_WN89 CL:0000010 Miscellaneous: Cell line information from personal communication of Do T.J. Male 21187198 CVCL_WN88 HOB-01-C1 conditionally immortalized cell line human CVCL_WN88 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; femoral neck Cell type=Osteocyte.. Female Characteristics: Proliferates at the permissive temperature (34 Celsius) Stop dividing at the restrictive temperature (39-40 Celsius). Doubling time: 4-6 days (PubMed=8895322) 21187199 CVCL_WN87 OCT-2 transformed cell line house mouse CVCL_WN87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 rat Bgla promoter T-Ag transgenic. Unspecified 21187200 CVCL_WN86 OCT-1 transformed cell line house mouse CVCL_WN86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 rat Bgla promoter T-Ag transgenic. Unspecified Doubling time: 27.3 hours (CelloPub=CLPUB00625) 21187201 CVCL_4H22 GM07790 transformed cell line human CVCL_4H22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187202 CVCL_4H21 GM07789 transformed cell line human CVCL_4H21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187203 CVCL_4H20 GM07788 transformed cell line human CVCL_4H20 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187204 CVCL_4H26 GM07797 transformed cell line human CVCL_4H26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187205 CVCL_4H25 GM07796 transformed cell line human CVCL_4H25 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187206 CVCL_4H24 GM07795 transformed cell line human CVCL_4H24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187207 CVCL_4H23 GM07794 transformed cell line human CVCL_4H23 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187208 CVCL_4H29 GM07812 transformed cell line human CVCL_4H29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187209 CVCL_4H28 GM07811 transformed cell line human CVCL_4H28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187210 CVCL_4H27 GM07798 transformed cell line human CVCL_4H27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187211 CVCL_WN70 B11d-ii-FAF 28 clone 431 spontaneously immortalized cell line CVCL_WN70 CL:0000010 Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female 21187212 CVCL_WN74 Mono-1 transformed cell line human CVCL_WN74 CL:0000010 Derived from sampling site: Peripheral blood. Male 21187213 CVCL_WN73 K-23-M transformed cell line human CVCL_WN73 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187214 CVCL_WN72 CaVe K-10V cancer cell line human CVCL_WN72 CL:0000010 Anecdotal: Have been flown in space on Zond-5 to study growth in microgravity (PubMed=11942358) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Space-flown cell line (cellonaut) Problematic cell line: Contaminated Parent cell line (CaVe) has been shown to be a HeLa derivative. 21187215 CVCL_WN71 HeLa-EM2-11ht cancer cell line human CVCL_WN71 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Stably expresses an improved version of the reverse tetracycline controlled transactivator (rtTA2S-M2) under the control of the human EF-1 alpha promoter Also express an hygromycin B phosphotransferase-thymidine kinase (HygTk) fusion gene as a positive/negative selection marker. 21187216 CVCL_WN78 hTERT-BTY telomerase immortalized cell line CVCL_WN78 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: HGNC; 11730; TERT Derived from sampling site: Thyroid gland; Breed/subspecies: Holstein. Omics: Transcriptome analysis by RNAseq Male Virology: Susceptible to infection by foot-and-mouth disease virus 21187217 CVCL_WN77 HT-29KM cancer cell line human CVCL_WN77 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Established from parent cell line by passages in BALB/c nude mice 21187218 CVCL_WN76 NHF-23 finite cell line human CVCL_WN76 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-65 (Spacelab IML-2) to study DNA repair in microgravity (PubMed=9052686) Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Space-flown cell line (cellonaut) 21187219 CVCL_WN75 Mono-1-207 transformed cell line human CVCL_WN75 CL:0000010 Derived from sampling site: Peripheral blood. Male 21187220 CVCL_WN79 RUES2 SFTPC-tdTomato embryonic stem cell human CVCL_WN79 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using TALEN a tdTomato-pA-loxP-PGK-Puro-pA-loxP was inserted at the SFTPC translational start site 21187221 CVCL_4H33 GM07816 transformed cell line human CVCL_4H33 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187222 CVCL_4H32 GM07815 transformed cell line human CVCL_4H32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187223 CVCL_4H31 GM07814 transformed cell line human CVCL_4H31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187224 CVCL_4H30 GM07813 transformed cell line human CVCL_4H30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187225 CVCL_4H37 GM07845 transformed cell line human CVCL_4H37 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187226 CVCL_4H36 GM07840 transformed cell line human CVCL_4H36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187227 CVCL_4H35 GM07837 transformed cell line human CVCL_4H35 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187228 CVCL_4H34 GM07835 transformed cell line human CVCL_4H34 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187229 CVCL_4H39 GM07847 transformed cell line human CVCL_4H39 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187230 CVCL_4H38 GM07846 transformed cell line human CVCL_4H38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187231 CVCL_WN63 MCRIi014-A induced pluripotent stem cell human CVCL_WN63 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21187232 CVCL_WN62 MCRIi013-A induced pluripotent stem cell human CVCL_WN62 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187233 CVCL_WN61 MCRIi012-A induced pluripotent stem cell human CVCL_WN61 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187234 CVCL_WN60 MCRIi011-A induced pluripotent stem cell human CVCL_WN60 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187235 CVCL_WN67 MOSJ-Dkk1 cancer cell line house mouse CVCL_WN67 CL:0000010 Transfected with: HGNC; 2891; DKK1 Breed/subspecies: C57BL/6J. Female 21187236 CVCL_WN66 MCRIi017-A induced pluripotent stem cell human CVCL_WN66 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21187237 CVCL_WN65 MCRIi016-A induced pluripotent stem cell human CVCL_WN65 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187238 CVCL_WN64 MCRIi015-A induced pluripotent stem cell human CVCL_WN64 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187239 CVCL_WN69 B11d-ii-FAF 28 clone 237 spontaneously immortalized cell line CVCL_WN69 CL:0000010 Anecdotal: Have been flown in space on Cosmos-782 to study growth in microgravity (PubMed=563224) Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female Group: Space-flown cell line (cellonaut) 21187240 CVCL_WN68 EMS-3 cancer cell line house mouse CVCL_WN68 CL:0000010 Anecdotal: Have been flown in space on the ISS in 2011 to study growth in microgravity. Transformant: Rauscher murine leukemia virus (R-MuLV)(NCBI-Taxonomy; 11938) Group: Space-flown cell line (cellonaut) 21187241 CVCL_EZ99 TALSCTRL11.5 induced pluripotent stem cell human CVCL_EZ99 From: Target ALS Foundation; New York; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187242 CVCL_EZ94 ND50017 induced pluripotent stem cell human CVCL_EZ94 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000016009; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187243 CVCL_EZ93 ND50016 induced pluripotent stem cell human CVCL_EZ93 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000016009; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187244 CVCL_EZ92 ND50015 induced pluripotent stem cell human CVCL_EZ92 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000016009; Zygosity=Unspecified (from parent cell line) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187245 CVCL_EZ91 ND50014 induced pluripotent stem cell human CVCL_EZ91 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: NHCDR; ND50014; true Female 21187246 CVCL_EZ98 TALS9-8.6 induced pluripotent stem cell human CVCL_EZ98 From: Target ALS Foundation; New York; USA CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187247 CVCL_EZ97 TALS9-8.1 induced pluripotent stem cell human CVCL_EZ97 From: Target ALS Foundation; New York; USA CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187248 CVCL_EZ96 TALS9-9.5 induced pluripotent stem cell human CVCL_EZ96 From: Target ALS Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187249 CVCL_NT29 BayGenomics ES cell line RRS882 embryonic stem cell house mouse CVCL_NT29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891112; Gmds Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187250 CVCL_EZ95 TALS9-9.3 induced pluripotent stem cell human CVCL_EZ95 From: Target ALS Foundation; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187251 CVCL_NT28 BayGenomics ES cell line RRS879 embryonic stem cell house mouse CVCL_NT28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927225; Tbc1d8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187252 CVCL_NT27 BayGenomics ES cell line RRS876 embryonic stem cell house mouse CVCL_NT27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342335; Asap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187253 CVCL_NT26 BayGenomics ES cell line RRS874 embryonic stem cell house mouse CVCL_NT26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99147; Yes1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187254 CVCL_NT25 BayGenomics ES cell line RRS873 embryonic stem cell house mouse CVCL_NT25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342335; Asap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187255 CVCL_NT24 BayGenomics ES cell line RRS870 embryonic stem cell house mouse CVCL_NT24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97824; Pvt1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187256 CVCL_EZ90 ND50013 induced pluripotent stem cell human CVCL_EZ90 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187257 CVCL_NT23 BayGenomics ES cell line RRS868 embryonic stem cell house mouse CVCL_NT23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97891; Rfc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187258 CVCL_NT22 BayGenomics ES cell line RRS864 embryonic stem cell house mouse CVCL_NT22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917870; Ube2v2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187259 CVCL_NT21 BayGenomics ES cell line RRS858 embryonic stem cell house mouse CVCL_NT21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921717; Pus10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187260 CVCL_NT20 BayGenomics ES cell line RRS851 embryonic stem cell house mouse CVCL_NT20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924256; Ddrgk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187261 CVCL_NT39 BayGenomics ES cell line RRT020 embryonic stem cell house mouse CVCL_NT39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2685973; Trim71 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187262 CVCL_NT38 BayGenomics ES cell line RRT014 embryonic stem cell house mouse CVCL_NT38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108515; Cbx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187263 CVCL_NT37 BayGenomics ES cell line RRT011 embryonic stem cell house mouse CVCL_NT37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187264 CVCL_NT36 BayGenomics ES cell line RRT010 embryonic stem cell house mouse CVCL_NT36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187265 CVCL_NT35 BayGenomics ES cell line RRT009 embryonic stem cell house mouse CVCL_NT35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142808; Cog4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187266 CVCL_NT34 BayGenomics ES cell line RRT008 embryonic stem cell house mouse CVCL_NT34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187267 CVCL_NT33 BayGenomics ES cell line RRT003 embryonic stem cell house mouse CVCL_NT33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919451; Otud6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187268 CVCL_NT32 BayGenomics ES cell line RRT002 embryonic stem cell house mouse CVCL_NT32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917262; Cep85 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187269 CVCL_NT31 BayGenomics ES cell line RRT001 embryonic stem cell house mouse CVCL_NT31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1298379; Matr3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187270 CVCL_NT30 BayGenomics ES cell line RRS890 embryonic stem cell house mouse CVCL_NT30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915549; Vps53 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187271 CVCL_EZ79 ND42496 finite cell line human CVCL_EZ79 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187272 CVCL_EZ78 ND42494 finite cell line human CVCL_EZ78 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187273 CVCL_EZ77 ND42492 finite cell line human CVCL_EZ77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187274 CVCL_EZ72 ND41125 finite cell line human CVCL_EZ72 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187275 CVCL_EZ71 ND41016 finite cell line human CVCL_EZ71 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187276 CVCL_EZ70 ND41015 finite cell line human CVCL_EZ70 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187277 CVCL_EZ76 ND42491 finite cell line human CVCL_EZ76 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187278 CVCL_NT09 BayGenomics ES cell line RRS800 embryonic stem cell house mouse CVCL_NT09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099818; Pkd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187279 CVCL_EZ75 ND42490 finite cell line human CVCL_EZ75 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187280 CVCL_NT08 BayGenomics ES cell line RRS794 embryonic stem cell house mouse CVCL_NT08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929618; Stard3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187281 CVCL_EZ74 ND42487 finite cell line human CVCL_EZ74 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187282 CVCL_NT07 BayGenomics ES cell line RRS789 embryonic stem cell house mouse CVCL_NT07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929459; Rabgef1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187283 CVCL_EZ73 ND42485 finite cell line human CVCL_EZ73 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Pro301Leu (c.902C>T) (P618L, c.1853C>T or P636L, c.1907C>T); ClinVar=VCV000014245; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187284 CVCL_NT06 BayGenomics ES cell line RRS786 embryonic stem cell house mouse CVCL_NT06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915408; Tecr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187285 CVCL_NT05 BayGenomics ES cell line RRS785 embryonic stem cell house mouse CVCL_NT05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915408; Tecr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187286 CVCL_NT04 BayGenomics ES cell line RRS780 embryonic stem cell house mouse CVCL_NT04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917447; Srp68 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187287 CVCL_NT03 BayGenomics ES cell line RRS774 embryonic stem cell house mouse CVCL_NT03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107862; Nop16 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187288 CVCL_NT02 BayGenomics ES cell line RRS767 embryonic stem cell house mouse CVCL_NT02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913353; Naxd Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187289 CVCL_NT01 BayGenomics ES cell line RRS763 embryonic stem cell house mouse CVCL_NT01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2653690; Agap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187290 CVCL_NT00 BayGenomics ES cell line RRS761 embryonic stem cell house mouse CVCL_NT00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914705; Klhl13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187291 CVCL_EZ89 ND50012 induced pluripotent stem cell human CVCL_EZ89 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187292 CVCL_EZ88 ND43209 induced pluripotent stem cell human CVCL_EZ88 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND43209; true; Discontinued: NHCDR; ND43209; true Male 21187293 CVCL_EZ83 ND42504 finite cell line human CVCL_EZ83 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187294 CVCL_EZ82 ND42503 finite cell line human CVCL_EZ82 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187295 CVCL_EZ81 ND42498 finite cell line human CVCL_EZ81 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187296 CVCL_EZ80 ND42497 finite cell line human CVCL_EZ80 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187297 CVCL_EZ87 ND42767 induced pluripotent stem cell human CVCL_EZ87 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42767; true; Discontinued: NHCDR; ND42767; true Male 21187298 CVCL_EZ86 ND42717 finite cell line human CVCL_EZ86 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187299 CVCL_NT19 BayGenomics ES cell line RRS841 embryonic stem cell house mouse CVCL_NT19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Caution: Was said to be a knockout for Gm3813 (MGI:3781985) which is no longer considered a gene by MGI 21187300 CVCL_EZ85 ND42716 finite cell line human CVCL_EZ85 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187301 CVCL_NT18 BayGenomics ES cell line RRS837 embryonic stem cell house mouse CVCL_NT18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107629; Luzp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187302 CVCL_EZ84 ND42506 finite cell line human CVCL_EZ84 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187303 CVCL_NT17 BayGenomics ES cell line RRS826 embryonic stem cell house mouse CVCL_NT17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915147; Rnmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187304 CVCL_NT16 BayGenomics ES cell line RRS824 embryonic stem cell house mouse CVCL_NT16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933163; Trim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187305 CVCL_NT15 BayGenomics ES cell line RRS823 embryonic stem cell house mouse CVCL_NT15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3036282; Zfp532 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187306 CVCL_NT14 BayGenomics ES cell line RRS822 embryonic stem cell house mouse CVCL_NT14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2677480; Thoc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187307 CVCL_NT13 BayGenomics ES cell line RRS819 embryonic stem cell house mouse CVCL_NT13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920243; Appl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187308 CVCL_NT12 BayGenomics ES cell line RRS815 embryonic stem cell house mouse CVCL_NT12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187309 CVCL_NT11 BayGenomics ES cell line RRS812 embryonic stem cell house mouse CVCL_NT11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187310 CVCL_NT10 BayGenomics ES cell line RRS805 embryonic stem cell house mouse CVCL_NT10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353655; Usp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187311 CVCL_EZ58 ND40082 finite cell line human CVCL_EZ58 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ala9Asp (c.26C>A); ClinVar=VCV000016013; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40082; true; Discontinued: NHCDR; ND40082; true Female 21187312 CVCL_EZ57 ND40081 finite cell line human CVCL_EZ57 CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Arg1345Ter (c.4033C>T) (p.Arg1346Ter, c.4036C>T) (R1346*); ClinVar=VCV000585570; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40081; true Female 21187313 CVCL_EZ56 ND40080 finite cell line human CVCL_EZ56 CL:0000010 Sequence variation: Mutation; HGNC; 2711; DCTN1; Simple; p.Gly71Arg (c.211G>A); ClinVar=VCV000008406; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40080; true Female 21187314 CVCL_EZ55 ND40079 finite cell line human CVCL_EZ55 CL:0000010 Sequence variation: Mutation; HGNC; 2711; DCTN1; Simple; p.Gly71Arg (c.211G>A); ClinVar=VCV000008406; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40079; true Female 21187315 CVCL_EZ59 ND40260 finite cell line human CVCL_EZ59 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40260; true Male 21187316 CVCL_EZ50 ND40074 finite cell line human CVCL_EZ50 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40074; true Male 21187317 CVCL_EZ54 ND40078 finite cell line human CVCL_EZ54 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Gln (c.824G>A); ClinVar=VCV000931482; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg275Trp (c.823C>T); ClinVar=VCV000007050; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Swedish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40078; true Female 21187318 CVCL_EZ53 ND40077 finite cell line human CVCL_EZ53 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Gly (c.1561C>G); ClinVar=VCV000016222; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40077; true Female 21187319 CVCL_EZ52 ND40076 finite cell line human CVCL_EZ52 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40076; true Female 21187320 CVCL_EZ51 ND40075 finite cell line human CVCL_EZ51 CL:0000010 Sequence variation: Mutation; HGNC; 20856; THAP1; Simple; p.Ile149Thr (c.446T>C); Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40075; true Male 21187321 CVCL_EZ69 ND41014 finite cell line human CVCL_EZ69 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Homozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187322 CVCL_EZ68 ND41010 finite cell line human CVCL_EZ68 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Arg246Ter (c.736C>T); ClinVar=VCV000002407; Zygosity=Homozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex4-6del; Zygosity=Heterozygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41010; true Male 21187323 CVCL_EZ67 ND41007 finite cell line human CVCL_EZ67 CL:0000010 Sequence variation: Mutation; HGNC; 16812; COQ8A; Simple; p.Ser616Leufs*114 (c.1844dupG) (p.Gly615fs) (c.1844_1845insG); ClinVar=VCV000214046; Zygosity=Unspecified (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187324 CVCL_EZ66 ND41006 finite cell line human CVCL_EZ66 CL:0000010 Sequence variation: Mutation; HGNC; 12666; VCP; Simple; p.Arg191Gln (c.572G>A); ClinVar=VCV000008473; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187325 CVCL_EZ61 ND40536 finite cell line human CVCL_EZ61 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[66] (c.52CAG(66)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187326 CVCL_EZ60 ND40534 finite cell line human CVCL_EZ60 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[46] (c.52CAG(46)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187327 CVCL_EZ65 ND41004 finite cell line human CVCL_EZ65 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp110Tyr (c.328G>T) (D109Y); ClinVar=VCV000899185; Zygosity=Unspecified (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187328 CVCL_EZ64 ND41003 finite cell line human CVCL_EZ64 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41003; true Female 21187329 CVCL_EZ63 ND41001 finite cell line human CVCL_EZ63 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; c.338+1delG (p.Leu113_Ile114insThr) (int4del); ClinVar=VCV000098013; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187330 CVCL_EZ62 ND40992 finite cell line human CVCL_EZ62 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187331 CVCL_EZ36 ND39528 finite cell line human CVCL_EZ36 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39528; true Female 21187332 CVCL_EZ35 ND39510 finite cell line human CVCL_EZ35 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39510; true Male 21187333 CVCL_EZ34 ND39450 finite cell line human CVCL_EZ34 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39450; true Female 21187334 CVCL_EZ33 ND39183 finite cell line human CVCL_EZ33 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39183; true Male 21187335 CVCL_EZ39 ND39957 finite cell line human CVCL_EZ39 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39957; true Female 21187336 CVCL_EZ38 ND39955 finite cell line human CVCL_EZ38 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39955; true Male 21187337 CVCL_EZ37 ND39538 finite cell line human CVCL_EZ37 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39538; true Female 21187338 CVCL_EZ32 ND39022 finite cell line human CVCL_EZ32 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39022; true Female 21187339 CVCL_EZ31 ND39021 finite cell line human CVCL_EZ31 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ile113Thr (c.338T>C) (I112T); ClinVar=VCV000014762; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39021; true Female 21187340 CVCL_EZ30 ND38865 finite cell line human CVCL_EZ30 CL:0000010 Population: Pacific; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38865; true Male 21187341 CVCL_EZ47 ND40070 finite cell line human CVCL_EZ47 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40070; true Female 21187342 CVCL_EZ46 ND40069 finite cell line human CVCL_EZ46 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40069; true; Discontinued: NHCDR; ND40069; true Female 21187343 CVCL_EZ45 ND40067 finite cell line human CVCL_EZ45 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; c.203_204delAG; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex4-7del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40067; true Female 21187344 CVCL_EZ44 ND40066 finite cell line human CVCL_EZ44 CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Ile368Asn (c.1103T>A); dbSNP=rs774647122; Zygosity=Homozygous (NHCDR) Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40066; true Male 21187345 CVCL_EZ49 ND40072 finite cell line human CVCL_EZ49 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40072; true Female 21187346 CVCL_EZ48 ND40071 finite cell line human CVCL_EZ48 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40071; true Male 21187347 CVCL_EZ43 ND40065 finite cell line human CVCL_EZ43 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40065; true Female 21187348 CVCL_EZ42 ND40064 finite cell line human CVCL_EZ42 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[366]; ClinVar=VCV000561195; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1066]; ClinVar=VCV000561195; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40064; true Male 21187349 CVCL_EZ41 ND40061 finite cell line human CVCL_EZ41 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[71]; Zygosity=Heterozygous; Note=The other allele has 23 repeats (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40061; true Male 21187350 CVCL_EZ40 ND39999 finite cell line human CVCL_EZ40 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39999; true Male 21187351 CVCL_4H00 GM06027 transformed cell line human CVCL_4H00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187352 CVCL_4H04 GM06031 transformed cell line human CVCL_4H04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187353 CVCL_4H03 GM06030 finite cell line human CVCL_4H03 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187354 CVCL_4H02 GM06029 transformed cell line human CVCL_4H02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187355 CVCL_4H01 GM06028 finite cell line human CVCL_4H01 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187356 CVCL_4H08 GM07749 finite cell line human CVCL_4H08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187357 CVCL_4H07 GM07748 transformed cell line human CVCL_4H07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187358 CVCL_4H06 GM06039 transformed cell line human CVCL_4H06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187359 CVCL_4H05 GM06032 transformed cell line human CVCL_4H05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187360 CVCL_WN52 AM2 [Mouse hybridoma] hybridoma house mouse CVCL_WN52 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-61A (Spacelab D-1) to study antibody production in microgravity (PubMed=3762712). Group: Space-flown cell line (cellonaut) 21187361 CVCL_WN51 TSCER2 transformed cell line human CVCL_WN51 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=14673874); Sequence variation: Mutation; HGNC; 11830; TK1; Unexplicit; G>A at bp 23 of exon 5; Zygosity=Heterozygous (PubMed=14673874) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 21187362 CVCL_WN50 TSCE5 transformed cell line human CVCL_WN50 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (from parent cell line) Anecdotal: Have been flown in space on the ISS in 2008-2009 to study the biological effects of space radiations, microgravity and the space environment on the expression of TP53-regulated genes (PubMed=20673130; PubMed=21161544) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Male Group: Space-flown cell line (cellonaut) 21187363 CVCL_WN56 ESi066-A induced pluripotent stem cell human CVCL_WN56 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 21699; CERKL; Simple; p.Arg283Ter (c.847C>T) (p.Arg257Ter, c.769C>T); ClinVar=VCV000002364; Zygosity=Homozygous (PubMed=31082679) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187364 CVCL_WN55 UJSi001-A induced pluripotent stem cell human CVCL_WN55 From: Jiangsu University; Jiangsu; China CL:0000010 Population: Chinese; Derived from sampling site: Peripheral blood. Female 21187365 CVCL_WN54 FAF-28 spontaneously immortalized cell line CVCL_WN54 CL:0000010 Derived from sampling site: Peritoneum Cell type=Fibroblast.. Female 21187366 CVCL_WN53 B6MP102 factor-dependent cell line house mouse CVCL_WN53 CL:0000010 Anecdotal: Have been flown in space on shuttle flights STS-37, STS-43 and STS-50 to study cytokine secretion in microgravity (PubMed=1640164) Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6. Characteristics: CSF1 dependent Group: Space-flown cell line (cellonaut) 21187367 CVCL_WN59 MCRIi018-B induced pluripotent stem cell human CVCL_WN59 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple_corrected; p.Trp1312Cys (c.3936G>T); ClinVar=VCV000017335; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31082677) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21187368 CVCL_WN58 MCRIi018-A induced pluripotent stem cell human CVCL_WN58 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Trp1312Cys (c.3936G>T); ClinVar=VCV000017335; Zygosity=Heterozygous (PubMed=31082677) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21187369 CVCL_WN57 ESi067-A induced pluripotent stem cell human CVCL_WN57 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187370 CVCL_WN39 BP(p)Tu transformed cell line Norway rat CVCL_WN39 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Simple; p.Lys130Arg (c.389A>G); Zygosity=Homozygous (PubMed=8302588) Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Fetal lung; Breed/subspecies: WAG. Unspecified 21187371 CVCL_4H11 GM07776 transformed cell line human CVCL_4H11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187372 CVCL_4H10 GM07775 transformed cell line human CVCL_4H10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187373 CVCL_4H15 GM07783 transformed cell line human CVCL_4H15 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187374 CVCL_4H14 GM07779 transformed cell line human CVCL_4H14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187375 CVCL_4H13 GM07778 transformed cell line human CVCL_4H13 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187376 CVCL_4H12 GM07777 transformed cell line human CVCL_4H12 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187377 CVCL_4H19 GM07787 transformed cell line human CVCL_4H19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187378 CVCL_4H18 GM07786 transformed cell line human CVCL_4H18 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187379 CVCL_4H17 GM07785 transformed cell line human CVCL_4H17 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187380 CVCL_4H16 GM07784 transformed cell line human CVCL_4H16 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187381 CVCL_4H09 GM07774 transformed cell line human CVCL_4H09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187382 CVCL_WN41 UM-E7 hybridoma house mouse CVCL_WN41 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human cell surface antigen on many cell types. 21187383 CVCL_WN40 HL-7702BaPT cancer cell line human CVCL_WN40 CL:0000010 Population: African American; Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014243 Problematic cell line: Contaminated Parent cell line (L-02) has been shown to be a HeLa derivative. 21187384 CVCL_WN45 UM-LAd-1 cancer cell line human CVCL_WN45 CL:0000010 Unspecified 21187385 CVCL_WN44 UM-PAd-1 cancer cell line human CVCL_WN44 CL:0000010 Unspecified 21187386 CVCL_WN43 UM-G10 hybridoma house mouse CVCL_WN43 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:42088; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-beta-D-GlcpNAc (Human blood group H type 2 trisaccharide). 21187387 CVCL_WN42 UM-A9 hybridoma house mouse CVCL_WN42 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16144; Human ITGB4/CD104. 21187388 CVCL_WN49 L8SF spontaneously immortalized cell line Norway rat CVCL_WN49 CL:0000010 Anecdotal: Have arisen from the parent cell line during the space shuttle flight STS-45 Derived from sampling site: Skeletal muscle Cell type=Myoblast.; Breed/subspecies: Wistar. Unspecified Characteristics: Has lost the capacity to fuse and differentiate into myotubes Group: Space-flown cell line (cellonaut) 21187389 CVCL_WN48 7E3-N hybridoma house mouse CVCL_WN48 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-42 (Spacelab IML-1) to study growth in microgravity (PubMed=8118409). Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; Q53QV2; Human LBP Group: Space-flown cell line (cellonaut) 21187390 CVCL_WN47 FLC-707-02 cancer cell line house mouse CVCL_WN47 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-42 (Spacelab IML-1) to study growth in microgravity (PubMed=8118409) Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Characteristics: Optimized hemoglobin biosynthesis Group: Space-flown cell line (cellonaut) 21187391 CVCL_WN46 RTiv3 transformed cell line Norway rat CVCL_WN46 CL:0000010 Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Sprague Dawley. 21187392 CVCL_WN29 UMRCC10 cancer cell line human CVCL_WN29 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Male 21187393 CVCL_WN28 UMRCC9 cancer cell line human CVCL_WN28 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Female 21187394 CVCL_WN30 Ewing1 cancer cell line human CVCL_WN30 CL:0000010 Population: Malaysian. Male 21187395 CVCL_NT89 BayGenomics ES cell line RRT139 embryonic stem cell house mouse CVCL_NT89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106209; Hells Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187396 CVCL_NT88 BayGenomics ES cell line RRT136 embryonic stem cell house mouse CVCL_NT88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922152; Ccdc171 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187397 CVCL_NT87 BayGenomics ES cell line RRT134 embryonic stem cell house mouse CVCL_NT87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928760; Ruvbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187398 CVCL_NT86 BayGenomics ES cell line RRT133 embryonic stem cell house mouse CVCL_NT86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444957; Taf6l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187399 CVCL_WN34 hTERT-POMEC telomerase immortalized cell line pig CVCL_WN34 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Oral cavity; oral mucosa Cell type=Epithelial cell.. Male Virology: Susceptible to infection by porcine circovirus type 2 (PCV2) 21187400 CVCL_NT85 BayGenomics ES cell line RRT132 embryonic stem cell house mouse CVCL_NT85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109564; Kif5a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187401 CVCL_WN33 EOE-3M transformed cell line house mouse CVCL_WN33 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Tooth; enamel organ; dental epithelium. Unspecified Characteristics: Useful for studies regarding enamel bioengineering; Characteristics: Expresses enamel matrix markers and produces a mineralized extracellular matrix Doubling time: 53.24 +- 9.50 hours (PubMed=31074144) 21187402 CVCL_NT84 BayGenomics ES cell line RRT131 embryonic stem cell house mouse CVCL_NT84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201610; Tex9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187403 CVCL_WN32 EOE-2M transformed cell line house mouse CVCL_WN32 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Tooth; enamel organ; dental epithelium. Unspecified Characteristics: Useful for studies regarding enamel bioengineering; Characteristics: Expresses enamel matrix markers and produces a mineralized extracellular matrix Doubling time: 92.78 +- 11.35 hours (PubMed=31074144) 21187404 CVCL_NT83 BayGenomics ES cell line RRT128 embryonic stem cell house mouse CVCL_NT83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914974; Pop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187405 CVCL_WN31 HEK293T G6PD p.Gly131Val transformed cell line human CVCL_WN31 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple_edited; p.Gly131Val (c.392G>T); ClinVar=VCV000010404; Zygosity=Unspecified; Note=By CRISPR/Cas9 (PubMed=31068316); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21187406 CVCL_NT82 BayGenomics ES cell line RRT125 embryonic stem cell house mouse CVCL_NT82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97852; Rap1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187407 CVCL_WN38 BP transformed cell line Norway rat CVCL_WN38 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Fetal lung; Breed/subspecies: WAG. Unspecified 21187408 CVCL_NT81 BayGenomics ES cell line RRT124 embryonic stem cell house mouse CVCL_NT81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97297; Nedd4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187409 CVCL_WN37 PuD2 cancer cell line Norway rat CVCL_WN37 CL:0000010 Transformant: Plutonium-239 alpha particle radiation(NCIt; C160658); Derived from sampling site: Lung; Breed/subspecies: Wistar. Unspecified 21187410 CVCL_WN36 38290-TTT cancer cell line house mouse CVCL_WN36 CL:0000010 Breed/subspecies: BALB/cAnN. 21187411 CVCL_NT80 BayGenomics ES cell line RRT120 embryonic stem cell house mouse CVCL_NT80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388097; Taf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187412 CVCL_WN35 SGHPL-4sG1 transformed cell line human CVCL_WN35 CL:0000010 Transfected with: HGNC; 4964; HLA-G (soluble isoform); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Placenta. Male 21187413 CVCL_WN19 SV40-T2 transformed cell line Norway rat CVCL_WN19 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: 22 hours (PubMed=1716583) 21187414 CVCL_WN18 ZZUi014-A induced pluripotent stem cell human CVCL_WN18 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[64]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=31639609) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187415 CVCL_WN17 HELPi001-A induced pluripotent stem cell human CVCL_WN17 From: Help Stem Cell Innovations Co., Ltd; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 3604; FBN2; Simple; p.Ile243Thr (c.728T>C); ClinVar=VCV000137358; Zygosity=Heterozygous (PubMed=31426022) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21187416 CVCL_NT99 BayGenomics ES cell line RRT158 embryonic stem cell house mouse CVCL_NT99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917338; Meaf6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187417 CVCL_NT98 BayGenomics ES cell line RRT156 embryonic stem cell house mouse CVCL_NT98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187418 CVCL_NT97 BayGenomics ES cell line RRT154 embryonic stem cell house mouse CVCL_NT97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1321159; Ppp2ca Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187419 CVCL_WN23 UMRCC4 cancer cell line human CVCL_WN23 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Female 21187420 CVCL_NT96 BayGenomics ES cell line RRT153 embryonic stem cell house mouse CVCL_NT96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:894687; Xrn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187421 CVCL_WN22 UMRCC3 cancer cell line human CVCL_WN22 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Female 21187422 CVCL_NT95 BayGenomics ES cell line RRT152 embryonic stem cell house mouse CVCL_NT95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140050; Ints3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187423 CVCL_WN21 UMRCC2 cancer cell line human CVCL_WN21 CL:0000010 Miscellaneous: Doubling time from personal communication of Yap N.Y Population: Malaysian; Derived from sampling site: Kidney. Male Doubling time: 2-3 days (Direct_author_submission) 21187424 CVCL_NT94 BayGenomics ES cell line RRT151 embryonic stem cell house mouse CVCL_NT94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444896; Enox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187425 CVCL_WN20 UMRCC1 cancer cell line human CVCL_WN20 CL:0000010 Miscellaneous: Doubling time from personal communication of Yap N.Y Population: Malaysian; Derived from sampling site: Kidney. Female Doubling time: 6-7 days (Direct_author_submission) 21187426 CVCL_NT93 BayGenomics ES cell line RRT149 embryonic stem cell house mouse CVCL_NT93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913696; Exosc7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187427 CVCL_WN27 UMRCC8 cancer cell line human CVCL_WN27 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Male 21187428 CVCL_NT92 BayGenomics ES cell line RRT146 embryonic stem cell house mouse CVCL_NT92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922570; Etnk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187429 CVCL_WN26 UMRCC7 cancer cell line human CVCL_WN26 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Male 21187430 CVCL_NT91 BayGenomics ES cell line RRT143 embryonic stem cell house mouse CVCL_NT91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919955; Zcchc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187431 CVCL_WN25 UMRCC6 cancer cell line human CVCL_WN25 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Male 21187432 CVCL_NT90 BayGenomics ES cell line RRT142 embryonic stem cell house mouse CVCL_NT90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919955; Zcchc17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187433 CVCL_WN24 UMRCC5 cancer cell line human CVCL_WN24 CL:0000010 Population: Malaysian; Derived from sampling site: Kidney. Male 21187434 CVCL_WN09 UFRJi006-A induced pluripotent stem cell human CVCL_WN09 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21187435 CVCL_WN08 UFRJi005-A induced pluripotent stem cell human CVCL_WN08 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[36] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous (PubMed=31077962); Sequence variation: Mutation; HGNC; 12649; VAPB; Simple; p.Pro56Ser (c.166C>T); ClinVar=VCV000004806; Zygosity=Heterozygous (PubMed=31077962) Derived from sampling site: Peripheral blood. Male 21187436 CVCL_WN07 INSTEMe001-A embryonic stem cell human CVCL_WN07 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India. CL:0000010 Female 21187437 CVCL_WN06 MCRIi001-A-1 induced pluripotent stem cell human CVCL_WN06 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2197; COL1A1; Simple; p.Val1324Cysfs (c.3969dupT) (c.3969_3970insT); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31075690) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21187438 CVCL_NT69 BayGenomics ES cell line RRT092 embryonic stem cell house mouse CVCL_NT69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187439 CVCL_NT68 BayGenomics ES cell line RRT086 embryonic stem cell house mouse CVCL_NT68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101876; Tead1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187440 CVCL_NT67 BayGenomics ES cell line RRT083 embryonic stem cell house mouse CVCL_NT67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201409; Pknox1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187441 CVCL_NT66 BayGenomics ES cell line RRT068 embryonic stem cell house mouse CVCL_NT66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916990; Dph5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187442 CVCL_NT65 BayGenomics ES cell line RRT067 embryonic stem cell house mouse CVCL_NT65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187443 CVCL_NT64 BayGenomics ES cell line RRT066 embryonic stem cell house mouse CVCL_NT64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917819; Wdr36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187444 CVCL_WN12 UFRJi009-A induced pluripotent stem cell human CVCL_WN12 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21187445 CVCL_NT63 BayGenomics ES cell line RRT065 embryonic stem cell house mouse CVCL_NT63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917819; Wdr36 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187446 CVCL_WN11 UFRJi008-A induced pluripotent stem cell human CVCL_WN11 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Derived from sampling site: Peripheral blood. Male 21187447 CVCL_NT62 BayGenomics ES cell line RRT064 embryonic stem cell house mouse CVCL_NT62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187448 CVCL_WN10 UFRJi007-A induced pluripotent stem cell human CVCL_WN10 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; c.521_523+3delGAGGTG; ClinVar=VCV000540281; Zygosity=Unspecified (PubMed=31301488); Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Phe21Cys (c.62T>G) (F20C); ClinVar=VCV001459352; Zygosity=Unspecified (PubMed=31301488) Derived from sampling site: Peripheral blood. Male 21187449 CVCL_NT61 BayGenomics ES cell line RRT063 embryonic stem cell house mouse CVCL_NT61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196624; Tcea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187450 CVCL_NT60 BayGenomics ES cell line RRT061 embryonic stem cell house mouse CVCL_NT60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187451 CVCL_WN16 HREC24T telomerase immortalized cell line human CVCL_WN16 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Characteristics: CD133-/CD24+ subpopulation of parent cell line that is not capable of tubulogenic, adipogenic and osteogenic differentiation Doubling time: 108.3 hours (PubMed=31078587) 21187452 CVCL_WN15 HRTPT telomerase immortalized cell line human CVCL_WN15 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Male Characteristics: CD133+/CD24+ subpopulation of parent cell line that shows tubulogenic, adipogenic and osteogenic differentiation Doubling time: 79.2 hours (PubMed=31078587) 21187453 CVCL_WN14 HIHDNEi003-A induced pluripotent stem cell human CVCL_WN14 From: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Thr374Ala (c.1120A>G); ClinVar=VCV000559647; Zygosity=Heterozygous (PubMed=31465893) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21187454 CVCL_WN13 HIHDNEi002-A induced pluripotent stem cell human CVCL_WN13 From: Department of Neurology and Epileptology, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Arg297Gln (c.890G>A); ClinVar=VCV000190328; Zygosity=Heterozygous (PubMed=31075689) Population: Caucasian; German; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21187455 CVCL_NT79 BayGenomics ES cell line RRT117 embryonic stem cell house mouse CVCL_NT79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187456 CVCL_NT78 BayGenomics ES cell line RRT116 embryonic stem cell house mouse CVCL_NT78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922250; Stk38l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187457 CVCL_NT77 BayGenomics ES cell line RRT115 embryonic stem cell house mouse CVCL_NT77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446632; Ago2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187458 CVCL_NT76 BayGenomics ES cell line RRT114 embryonic stem cell house mouse CVCL_NT76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2388481; Ppp2r5d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187459 CVCL_WN01 4F10F4 hybridoma house mouse CVCL_WN01 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13891; Budgerigar fledgling disease virus VP1. 21187460 CVCL_NT75 BayGenomics ES cell line RRT113 embryonic stem cell house mouse CVCL_NT75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289172; Scyl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187461 CVCL_WN00 3G10G5 hybridoma house mouse CVCL_WN00 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-77 to study antibody production in microgravity (PubMed=9024803). Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13891; Budgerigar fledgling disease virus VP1 Group: Space-flown cell line (cellonaut) 21187462 CVCL_NT74 BayGenomics ES cell line RRT110 embryonic stem cell house mouse CVCL_NT74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915261; Snrpg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187463 CVCL_NT73 BayGenomics ES cell line RRT105 embryonic stem cell house mouse CVCL_NT73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918965; Dhx35 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187464 CVCL_NT72 BayGenomics ES cell line RRT104 embryonic stem cell house mouse CVCL_NT72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925123; Zbtb44 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187465 CVCL_NT71 BayGenomics ES cell line RRT103 embryonic stem cell house mouse CVCL_NT71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932101; Ankrd17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187466 CVCL_WN05 CBTCi008-A induced pluripotent stem cell human CVCL_WN05 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 10588; SCN2A; Simple; p.Arg856Ter (c.2566C>T); ClinVar=VCV000436662; Zygosity=Heterozygous (PubMed=31272037) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female Caution: Incorrectly called CBTCi007-A in PubMed=31272037 21187467 CVCL_NT70 BayGenomics ES cell line RRT102 embryonic stem cell house mouse CVCL_NT70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187468 CVCL_WN04 HLM34 cancer cell line human CVCL_WN04 CL:0000010 Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: Transfected with a HIV proviral DNA (pHXB2gpt) that contains a tat-defective mutant pMtat34 which has a Tat p.Cys34Gly (c.100T>G) mutation 21187469 CVCL_WN03 JC-1 hybridoma human CVCL_WN03 CL:0000010 Anecdotal: Have been flown in space on shuttle flight STS-47 (Spacelab-J) to study antibody production in microgravity (PubMed=12101352). Monoclonal antibody isotype: IgM; Monoclonal antibody target: Sheep red blood cells (SRBC) Group: Space-flown cell line (cellonaut) 21187470 CVCL_WN02 6D9F4 hybridoma house mouse CVCL_WN02 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13891; Budgerigar fledgling disease virus VP1. 21187471 CVCL_NT49 BayGenomics ES cell line RRT047 embryonic stem cell house mouse CVCL_NT49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916487; Gtpbp4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187472 CVCL_NT48 BayGenomics ES cell line RRT043 embryonic stem cell house mouse CVCL_NT48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187473 CVCL_NT47 BayGenomics ES cell line RRT040 embryonic stem cell house mouse CVCL_NT47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919904; Ccdc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187474 CVCL_NT46 BayGenomics ES cell line RRT039 embryonic stem cell house mouse CVCL_NT46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919055; Nup93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187475 CVCL_NT45 BayGenomics ES cell line RRT035 embryonic stem cell house mouse CVCL_NT45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918995; Cul2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187476 CVCL_NT44 BayGenomics ES cell line RRT034 embryonic stem cell house mouse CVCL_NT44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145374; Dhx29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187477 CVCL_NT43 BayGenomics ES cell line RRT033 embryonic stem cell house mouse CVCL_NT43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109419; Faf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187478 CVCL_NT42 BayGenomics ES cell line RRT032 embryonic stem cell house mouse CVCL_NT42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187479 CVCL_NT41 BayGenomics ES cell line RRT022 embryonic stem cell house mouse CVCL_NT41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187480 CVCL_NT40 BayGenomics ES cell line RRT021 embryonic stem cell house mouse CVCL_NT40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187481 CVCL_NT59 BayGenomics ES cell line RRT060 embryonic stem cell house mouse CVCL_NT59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384568; Kank2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187482 CVCL_NT58 BayGenomics ES cell line RRT059 embryonic stem cell house mouse CVCL_NT58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916327; Psmd11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187483 CVCL_NT57 BayGenomics ES cell line RRT058 embryonic stem cell house mouse CVCL_NT57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921494; Atg7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187484 CVCL_NT56 BayGenomics ES cell line RRT057 embryonic stem cell house mouse CVCL_NT56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923041; Fbxw8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187485 CVCL_NT55 BayGenomics ES cell line RRT055 embryonic stem cell house mouse CVCL_NT55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914167; Chordc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187486 CVCL_NT54 BayGenomics ES cell line RRT054 embryonic stem cell house mouse CVCL_NT54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187487 CVCL_NT53 BayGenomics ES cell line RRT053 embryonic stem cell house mouse CVCL_NT53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187488 CVCL_NT52 BayGenomics ES cell line RRT051 embryonic stem cell house mouse CVCL_NT52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96960; Rab8a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187489 CVCL_NT51 BayGenomics ES cell line RRT049 embryonic stem cell house mouse CVCL_NT51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914824; Alg13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187490 CVCL_NT50 BayGenomics ES cell line RRT048 embryonic stem cell house mouse CVCL_NT50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923784; Osbpl9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187491 CVCL_4I83 GM12793 transformed cell line human CVCL_4I83 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187492 CVCL_4I82 GM12792 transformed cell line human CVCL_4I82 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187493 CVCL_4I81 GM12791 transformed cell line human CVCL_4I81 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187494 CVCL_4I80 GM12790 transformed cell line human CVCL_4I80 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187495 CVCL_4I87 GM13525 transformed cell line human CVCL_4I87 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187496 CVCL_4I86 GM13524 transformed cell line human CVCL_4I86 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187497 CVCL_4I85 GM13523 transformed cell line human CVCL_4I85 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187498 CVCL_4I84 GM13316 transformed cell line human CVCL_4I84 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187499 CVCL_4I89 GM13794 transformed cell line human CVCL_4I89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187500 CVCL_4I88 GM13526 transformed cell line human CVCL_4I88 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187501 CVCL_4I94 GM13799 transformed cell line human CVCL_4I94 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187502 CVCL_4I93 GM13798 transformed cell line human CVCL_4I93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187503 CVCL_4I92 GM13797 transformed cell line human CVCL_4I92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187504 CVCL_4I91 GM13796 transformed cell line human CVCL_4I91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187505 CVCL_4I98 GM08851 transformed cell line human CVCL_4I98 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187506 CVCL_4I97 GM08812 transformed cell line human CVCL_4I97 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187507 CVCL_4I96 GM13890 transformed cell line human CVCL_4I96 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187508 CVCL_4I95 GM13800 transformed cell line human CVCL_4I95 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187509 CVCL_4I99 GM08869 transformed cell line human CVCL_4I99 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187510 CVCL_4I90 GM13795 transformed cell line human CVCL_4I90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187511 CVCL_4I61 GM11129 transformed cell line human CVCL_4I61 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187512 CVCL_4I60 GM11128 transformed cell line human CVCL_4I60 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187513 CVCL_4I65 GM11194 transformed cell line human CVCL_4I65 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187514 CVCL_4I64 GM11193 transformed cell line human CVCL_4I64 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187515 CVCL_4I63 GM11192 transformed cell line human CVCL_4I63 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187516 CVCL_4I62 GM11190 transformed cell line human CVCL_4I62 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187517 CVCL_4I69 GM11205 transformed cell line human CVCL_4I69 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187518 CVCL_4I68 GM11204 transformed cell line human CVCL_4I68 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187519 CVCL_4I67 GM11203 transformed cell line human CVCL_4I67 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187520 CVCL_4I66 GM11202 transformed cell line human CVCL_4I66 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187521 CVCL_4I72 GM11492 transformed cell line human CVCL_4I72 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187522 CVCL_4I71 GM11491 transformed cell line human CVCL_4I71 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187523 CVCL_4I70 GM11475 transformed cell line human CVCL_4I70 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187524 CVCL_4I76 GM12781 transformed cell line human CVCL_4I76 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187525 CVCL_4I75 GM12780 transformed cell line human CVCL_4I75 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187526 CVCL_4I74 GM11502 transformed cell line human CVCL_4I74 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187527 CVCL_4I73 GM11501 transformed cell line human CVCL_4I73 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187528 CVCL_4I79 GM12784 transformed cell line human CVCL_4I79 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187529 CVCL_4I78 GM12783 transformed cell line human CVCL_4I78 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187530 CVCL_4I77 GM12782 transformed cell line human CVCL_4I77 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187531 CVCL_4I43 GM11057 transformed cell line human CVCL_4I43 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187532 CVCL_4I42 GM11056 transformed cell line human CVCL_4I42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187533 CVCL_4I41 GM11055 transformed cell line human CVCL_4I41 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187534 CVCL_4I40 GM11054 transformed cell line human CVCL_4I40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187535 CVCL_4I47 GM11061 transformed cell line human CVCL_4I47 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187536 CVCL_4I46 GM11060 transformed cell line human CVCL_4I46 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187537 CVCL_4I45 GM11059 transformed cell line human CVCL_4I45 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187538 CVCL_4I44 GM11058 transformed cell line human CVCL_4I44 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187539 CVCL_4I49 GM11063 transformed cell line human CVCL_4I49 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187540 CVCL_4I48 GM11062 transformed cell line human CVCL_4I48 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187541 CVCL_X091 GM02346 finite cell line human CVCL_X091 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,t(4;16)(4pter->4q35::16q22.1->16qter;16pter->16q22.1::4q35->4qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187542 CVCL_X090 GM02337 finite cell line human CVCL_X090 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(5)(qter->p14) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187543 CVCL_X095 GM02800 finite cell line human CVCL_X095 CL:0000010 Population: African American; Karyotypic information: 46,XX,del(5)(qter->p14) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187544 CVCL_X094 GM02730 finite cell line human CVCL_X094 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(Y)(pter->q11) [77]; 45,X [33] (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21187545 CVCL_X093 GM02668 finite cell line human CVCL_X093 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(Y)(pter->q11.2) [77]; 45,X [33] (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21187546 CVCL_X092 GM02356 finite cell line human CVCL_X092 CL:0000010 Karyotypic information: 46,XY,del(9)(9qter->9p22) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187547 CVCL_X099 GM02980 finite cell line human CVCL_X099 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(18)(pter>q21) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187548 CVCL_X098 GM02957 finite cell line human CVCL_X098 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(6)(pter->p23::q21->p23::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187549 CVCL_X097 GM02946 finite cell line human CVCL_X097 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,rec(1)dup(q)ins(1)(pter->p22::q32->q31::p22->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187550 CVCL_X096 GM02906 finite cell line human CVCL_X096 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187551 CVCL_4I50 GM11064 transformed cell line human CVCL_4I50 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187552 CVCL_4I54 GM11120 transformed cell line human CVCL_4I54 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187553 CVCL_4I53 GM11119 transformed cell line human CVCL_4I53 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187554 CVCL_4I52 GM11116 transformed cell line human CVCL_4I52 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187555 CVCL_4I51 GM11065 transformed cell line human CVCL_4I51 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187556 CVCL_4I58 GM11126 transformed cell line human CVCL_4I58 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187557 CVCL_4I57 GM11124 transformed cell line human CVCL_4I57 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187558 CVCL_4I56 GM11122 transformed cell line human CVCL_4I56 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187559 CVCL_4I55 GM11121 transformed cell line human CVCL_4I55 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187560 CVCL_4I59 GM11127 transformed cell line human CVCL_4I59 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187561 CVCL_X080 GM01359 finite cell line human CVCL_X080 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+18.arr(18)x3 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187562 CVCL_X084 GM01941 finite cell line human CVCL_X084 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Female 21187563 CVCL_X083 GM01727 finite cell line human CVCL_X083 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(18)(qter>p11) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187564 CVCL_X082 GM01667 finite cell line human CVCL_X082 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(9)(qter>p22) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187565 CVCL_X081 GM01549 finite cell line human CVCL_X081 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187566 CVCL_X088 GM02137 finite cell line human CVCL_X088 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,inv(5)(pter->p13::q13->p13::q13>qter)mat,+mar (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187567 CVCL_X087 GM02054 transformed cell line human CVCL_X087 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187568 CVCL_X086 GM02008 finite cell line human CVCL_X086 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187569 CVCL_X085 GM02003 finite cell line human CVCL_X085 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187570 CVCL_X089 GM02335 finite cell line human CVCL_X089 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187571 CVCL_NU49 BayGenomics ES cell line RRT317 embryonic stem cell house mouse CVCL_NU49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915265; Trap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187572 CVCL_NU48 BayGenomics ES cell line RRT307 embryonic stem cell house mouse CVCL_NU48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929865; Nampt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187573 CVCL_NU47 BayGenomics ES cell line RRT305 embryonic stem cell house mouse CVCL_NU47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858746; Kat6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187574 CVCL_NU46 BayGenomics ES cell line RRT300 embryonic stem cell house mouse CVCL_NU46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344363; Arih1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187575 CVCL_NU45 BayGenomics ES cell line RRT293 embryonic stem cell house mouse CVCL_NU45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187576 CVCL_NU44 BayGenomics ES cell line RRT290 embryonic stem cell house mouse CVCL_NU44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923802; Plekha5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187577 CVCL_NU43 BayGenomics ES cell line RRT289 embryonic stem cell house mouse CVCL_NU43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442117; Pogz Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187578 CVCL_NU42 BayGenomics ES cell line RRT286 embryonic stem cell house mouse CVCL_NU42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448514; R3hdm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187579 CVCL_NU41 BayGenomics ES cell line RRT285 embryonic stem cell house mouse CVCL_NU41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913917; Hspbap1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187580 CVCL_NU40 BayGenomics ES cell line RRT284 embryonic stem cell house mouse CVCL_NU40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449311; Gemin5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187581 CVCL_NU59 BayGenomics ES cell line RRT345 embryonic stem cell house mouse CVCL_NU59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915192; Atp5g2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187582 CVCL_NU58 BayGenomics ES cell line RRT343 embryonic stem cell house mouse CVCL_NU58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107777; Atp5j Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187583 CVCL_NU57 BayGenomics ES cell line RRT342 embryonic stem cell house mouse CVCL_NU57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3039590; Tmtc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187584 CVCL_NU56 BayGenomics ES cell line RRT341 embryonic stem cell house mouse CVCL_NU56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139309; Garnl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187585 CVCL_NU55 BayGenomics ES cell line RRT336 embryonic stem cell house mouse CVCL_NU55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347093; Fto Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187586 CVCL_NU54 BayGenomics ES cell line RRT330 embryonic stem cell house mouse CVCL_NU54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2151839; Mreg Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187587 CVCL_NU53 BayGenomics ES cell line RRT326 embryonic stem cell house mouse CVCL_NU53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187588 CVCL_NU52 BayGenomics ES cell line RRT325 embryonic stem cell house mouse CVCL_NU52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684060; Akap11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187589 CVCL_NU51 BayGenomics ES cell line RRT324 embryonic stem cell house mouse CVCL_NU51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442308; Arl15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187590 CVCL_NU50 BayGenomics ES cell line RRT320 embryonic stem cell house mouse CVCL_NU50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889002; Wdr4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187591 CVCL_NU29 BayGenomics ES cell line RRT251 embryonic stem cell house mouse CVCL_NU29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921765; Cdkal1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187592 CVCL_NU28 BayGenomics ES cell line RRT240 embryonic stem cell house mouse CVCL_NU28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146350; Scaf4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187593 CVCL_NU27 BayGenomics ES cell line RRT236 embryonic stem cell house mouse CVCL_NU27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202876; Tcf7l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187594 CVCL_NU26 BayGenomics ES cell line RRT235 embryonic stem cell house mouse CVCL_NU26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:87929; Adh5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187595 CVCL_NU25 BayGenomics ES cell line RRT234 embryonic stem cell house mouse CVCL_NU25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99495; Brd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187596 CVCL_NU24 BayGenomics ES cell line RRT230 embryonic stem cell house mouse CVCL_NU24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916976; Smyd3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187597 CVCL_NU23 BayGenomics ES cell line RRT229 embryonic stem cell house mouse CVCL_NU23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351605; Rpl3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187598 CVCL_NU22 BayGenomics ES cell line RRT226 embryonic stem cell house mouse CVCL_NU22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916858; Sec24d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187599 CVCL_NU21 BayGenomics ES cell line RRT224 embryonic stem cell house mouse CVCL_NU21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924386; Cep78 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187600 CVCL_NU20 BayGenomics ES cell line RRT223 embryonic stem cell house mouse CVCL_NU20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187601 CVCL_NU39 BayGenomics ES cell line RRT283 embryonic stem cell house mouse CVCL_NU39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102726; Dck Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187602 CVCL_NU38 BayGenomics ES cell line RRT280 embryonic stem cell house mouse CVCL_NU38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889276; Dgke Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187603 CVCL_NU37 BayGenomics ES cell line RRT274 embryonic stem cell house mouse CVCL_NU37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914491; Smc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187604 CVCL_NU36 BayGenomics ES cell line RRT272 embryonic stem cell house mouse CVCL_NU36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1202400; Supt5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187605 CVCL_NU35 BayGenomics ES cell line RRT271 embryonic stem cell house mouse CVCL_NU35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387357; Wac Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187606 CVCL_NU34 BayGenomics ES cell line RRT264 embryonic stem cell house mouse CVCL_NU34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924550; Raph1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187607 CVCL_NU33 BayGenomics ES cell line RRT262 embryonic stem cell house mouse CVCL_NU33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914724; Snap29 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187608 CVCL_NU32 BayGenomics ES cell line RRT259 embryonic stem cell house mouse CVCL_NU32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95454; Etl4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187609 CVCL_NU31 BayGenomics ES cell line RRT256 embryonic stem cell house mouse CVCL_NU31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924841; Ddx10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187610 CVCL_NU30 BayGenomics ES cell line RRT253 embryonic stem cell house mouse CVCL_NU30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351486; Trappc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187611 CVCL_NU09 BayGenomics ES cell line RRT177 embryonic stem cell house mouse CVCL_NU09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187612 CVCL_NU08 BayGenomics ES cell line RRT176 embryonic stem cell house mouse CVCL_NU08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2139360; Sall4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187613 CVCL_NU07 BayGenomics ES cell line RRT173 embryonic stem cell house mouse CVCL_NU07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108498; Nbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187614 CVCL_NU06 BayGenomics ES cell line RRT172 embryonic stem cell house mouse CVCL_NU06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138080; Utp25 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187615 CVCL_NU05 BayGenomics ES cell line RRT170 embryonic stem cell house mouse CVCL_NU05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107183; Cct8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187616 CVCL_NU04 BayGenomics ES cell line RRT168 embryonic stem cell house mouse CVCL_NU04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449121; Nme7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187617 CVCL_NU03 BayGenomics ES cell line RRT167 embryonic stem cell house mouse CVCL_NU03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921020; Wdr70 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187618 CVCL_NU02 BayGenomics ES cell line RRT164 embryonic stem cell house mouse CVCL_NU02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97805; Ptpn1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187619 CVCL_NU01 BayGenomics ES cell line RRT161 embryonic stem cell house mouse CVCL_NU01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2444207; Vps13c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187620 CVCL_NU00 BayGenomics ES cell line RRT159 embryonic stem cell house mouse CVCL_NU00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921450; Khdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187621 CVCL_NU19 BayGenomics ES cell line RRT219 embryonic stem cell house mouse CVCL_NU19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179432; Mycbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187622 CVCL_NU18 BayGenomics ES cell line RRT216 embryonic stem cell house mouse CVCL_NU18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349635; Sec23a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187623 CVCL_NU17 BayGenomics ES cell line RRT212 embryonic stem cell house mouse CVCL_NU17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2663721; Zc3h3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187624 CVCL_NU16 BayGenomics ES cell line RRT211 embryonic stem cell house mouse CVCL_NU16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670178; Med13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187625 CVCL_NU15 BayGenomics ES cell line RRT204 embryonic stem cell house mouse CVCL_NU15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103257; Inpp5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187626 CVCL_NU14 BayGenomics ES cell line RRT203 embryonic stem cell house mouse CVCL_NU14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920442; Xpot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187627 CVCL_NU13 BayGenomics ES cell line RRT195 embryonic stem cell house mouse CVCL_NU13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109656; Lasp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187628 CVCL_NU12 BayGenomics ES cell line RRT189 embryonic stem cell house mouse CVCL_NU12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914130; Rsrc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187629 CVCL_NU11 BayGenomics ES cell line RRT183 embryonic stem cell house mouse CVCL_NU11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2683486; Rere Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187630 CVCL_NU10 BayGenomics ES cell line RRT180 embryonic stem cell house mouse CVCL_NU10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921537; Kcmf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187631 CVCL_4I21 GM10509 transformed cell line human CVCL_4I21 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187632 CVCL_4I20 GM10460 transformed cell line human CVCL_4I20 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187633 CVCL_4I25 GM10514 transformed cell line human CVCL_4I25 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187634 CVCL_4I24 GM10513 transformed cell line human CVCL_4I24 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187635 CVCL_4I23 GM10512 transformed cell line human CVCL_4I23 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187636 CVCL_4I22 GM10510 transformed cell line human CVCL_4I22 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187637 CVCL_4I29 GM10703 transformed cell line human CVCL_4I29 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187638 CVCL_4I28 GM10701 transformed cell line human CVCL_4I28 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187639 CVCL_4I27 GM10700 transformed cell line human CVCL_4I27 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187640 CVCL_4I26 GM10699 transformed cell line human CVCL_4I26 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187641 CVCL_4I19 GM10459 transformed cell line human CVCL_4I19 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187642 CVCL_X073 GM00447 finite cell line human CVCL_X073 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p11::q13->p11::q13->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187643 CVCL_X072 GM00445 finite cell line human CVCL_X072 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p11::q13->p11::q13->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187644 CVCL_X071 GM00437 finite cell line human CVCL_X071 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(13)(qter->q21::p1->q21) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187645 CVCL_X070 mGC8 cancer cell line house mouse CVCL_X070 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm transgenic. Female 21187646 CVCL_X077 GM00803 finite cell line human CVCL_X077 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187647 CVCL_X076 GM00735 finite cell line human CVCL_X076 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X)(p11) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187648 CVCL_X075 GM00526 finite cell line human CVCL_X075 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187649 CVCL_X074 GM00448 finite cell line human CVCL_X074 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(10)(pter->p11::q21->p11::q21->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187650 CVCL_X079 GM01059 finite cell line human CVCL_X079 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187651 CVCL_X078 GM00945 finite cell line human CVCL_X078 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187652 CVCL_4I32 GM10706 transformed cell line human CVCL_4I32 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187653 CVCL_4I31 GM10705 transformed cell line human CVCL_4I31 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187654 CVCL_4I30 GM10704 transformed cell line human CVCL_4I30 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187655 CVCL_4I36 GM11049 transformed cell line human CVCL_4I36 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187656 CVCL_4I35 GM11048 transformed cell line human CVCL_4I35 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187657 CVCL_4I34 GM11047 transformed cell line human CVCL_4I34 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187658 CVCL_4I33 GM10708 transformed cell line human CVCL_4I33 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187659 CVCL_4I39 GM11053 transformed cell line human CVCL_4I39 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187660 CVCL_4I38 GM11051 transformed cell line human CVCL_4I38 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187661 CVCL_4I37 GM11050 transformed cell line human CVCL_4I37 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187662 CVCL_X062 GM00605 transformed cell line human CVCL_X062 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM00605; probable Female 21187663 CVCL_X061 GM03128 transformed cell line human CVCL_X061 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187664 CVCL_X060 GM00956 finite cell line human CVCL_X060 CL:0000010 Derived from sampling site: Amniotic fluid. Discontinued: Coriell; GM00956; probable Female 21187665 CVCL_X066 mGC2CEA cancer cell line house mouse CVCL_X066 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm x C57BL/6-Tg(CEACAM5)2682Wzm transgenic. Male 21187666 CVCL_X065 mGC11CEA cancer cell line house mouse CVCL_X065 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm x C57BL/6-Tg(CEACAM5)2682Wzm transgenic. Female 21187667 CVCL_X064 424GC cancer cell line house mouse CVCL_X064 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm transgenic. Male 21187668 CVCL_X063 PC-EN cancer cell line human CVCL_X063 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107). Population: Chinese Male Characteristics: Established from a xenograft established in a nude mice 21187669 CVCL_X069 mGC5 cancer cell line house mouse CVCL_X069 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm transgenic. Male 21187670 CVCL_X068 mGC4CEA cancer cell line house mouse CVCL_X068 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm x C57BL/6-Tg(CEACAM5)2682Wzm transgenic. Male 21187671 CVCL_X067 mGC3 cancer cell line house mouse CVCL_X067 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Stomach; Breed/subspecies: C57BL/6-Tg(CEACAM5-Tag)L5496Wzm transgenic. Female 21187672 CVCL_4I03 GM09743 transformed cell line human CVCL_4I03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187673 CVCL_4I02 GM09742 transformed cell line human CVCL_4I02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187674 CVCL_4I01 GM09733 transformed cell line human CVCL_4I01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187675 CVCL_4I00 GM09731 transformed cell line human CVCL_4I00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187676 CVCL_4I07 GM09747 transformed cell line human CVCL_4I07 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187677 CVCL_4I06 GM09746 transformed cell line human CVCL_4I06 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187678 CVCL_4I05 GM09745 transformed cell line human CVCL_4I05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187679 CVCL_4I04 GM09744 transformed cell line human CVCL_4I04 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187680 CVCL_X051 GM00450 finite cell line human CVCL_X051 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p13::q13->p13::q13->qter) (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187681 CVCL_X050 GM03900 finite cell line human CVCL_X050 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg216Ter (c.646C>T); ClinVar=VCV000127312; Zygosity=Unspecified (Coriell) Population: African American; Derived from sampling site: Abdomen Cell type=Fibroblast.. Female 21187682 CVCL_X055 GM03121 finite cell line human CVCL_X055 CL:0000010 Derived from sampling site: Gonad Cell type=Fibroblast.. Discontinued: Coriell; GM03121; probable Female 21187683 CVCL_X054 GM03120 finite cell line human CVCL_X054 CL:0000010 Karyotypic information: 45,X,-Y,inv(9)(p11;q13) [13]; 46,XY,inv(9)(p11;q13) [7] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187684 CVCL_X053 GM00452 finite cell line human CVCL_X053 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(10)(pter->p11::q21->p11::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187685 CVCL_X052 GM00451 finite cell line human CVCL_X052 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,inv(9)(pter->p13::q13->p13::q13->qter) (Coriell); Derived from sampling site: Testis Cell type=Fibroblast.. Male 21187686 CVCL_X059 GM02470 finite cell line human CVCL_X059 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02470; probable Female 21187687 CVCL_X058 GM03828 finite cell line human CVCL_X058 CL:0000010 Population: African American; Karyotypic information: 46,X,del(X)(pter->q21) (Coriell); Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21187688 CVCL_X057 GM03827 finite cell line human CVCL_X057 CL:0000010 Population: African American; Karyotypic information: 46,X,del(X)(pter->q21) (Coriell); Derived from sampling site: Ovary Cell type=Fibroblast.. Female 21187689 CVCL_X056 GM03122 finite cell line human CVCL_X056 CL:0000010 Derived from sampling site: Gonad Cell type=Fibroblast.. Discontinued: Coriell; GM03122; probable Female 21187690 CVCL_X039 MS-TY finite cell line CVCL_X039 CL:0000010 Derived from sampling site: Thyroid gland. Female Group: Endangered species/breed cell line 21187691 CVCL_X038 MS-SP finite cell line CVCL_X038 CL:0000010 Derived from sampling site: Spleen. Female Group: Endangered species/breed cell line 21187692 CVCL_4I10 GM10333 transformed cell line human CVCL_4I10 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187693 CVCL_4I14 GM10340 transformed cell line human CVCL_4I14 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187694 CVCL_4I13 GM10336 transformed cell line human CVCL_4I13 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187695 CVCL_4I12 GM10335 transformed cell line human CVCL_4I12 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187696 CVCL_4I11 GM10334 transformed cell line human CVCL_4I11 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187697 CVCL_4I18 GM10344 transformed cell line human CVCL_4I18 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21187698 CVCL_4I17 GM10343 transformed cell line human CVCL_4I17 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187699 CVCL_4I16 GM10342 transformed cell line human CVCL_4I16 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187700 CVCL_4I15 GM10341 transformed cell line human CVCL_4I15 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187701 CVCL_4I09 GM10332 transformed cell line human CVCL_4I09 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187702 CVCL_4I08 GM09748 transformed cell line human CVCL_4I08 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21187703 CVCL_X040 MS-UB finite cell line CVCL_X040 CL:0000010 Derived from sampling site: Urinary bladder. Female Group: Endangered species/breed cell line 21187704 CVCL_X044 CAL-43 cancer cell line human CVCL_X044 CL:0000010 Female 21187705 CVCL_X043 CAL-32 cancer cell line human CVCL_X043 CL:0000010 Unspecified Doubling time: 124 hours (PubMed=2145926). 21187706 CVCL_X042 CAL-26 cancer cell line human CVCL_X042 CL:0000010 Unspecified 21187707 CVCL_X041 AP-18 spontaneously immortalized cell line house mouse CVCL_X041 CL:0000010 Derived from sampling site: Adipose tissue; hypodermis Cell type=Preadipocyte.; Breed/subspecies: C3H/HeNCrlBR. Female Doubling time: 50-60 hours (PubMed=16210832) 21187708 CVCL_X048 GM07151 finite cell line human CVCL_X048 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;17)(p11.2;p11.2).arr(1-22,X)x2 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187709 CVCL_X047 GM03197 transformed cell line human CVCL_X047 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(5)(pter->p13::q13->p13::q13->qter),t(17;22)(17qter->17p13::22q11->22qter;22pter->22q11::17p13->17pter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187710 CVCL_X046 Gratch cancer cell line human CVCL_X046 From: Wang N.; University of Rochester; New York; USA. CL:0000010 Female 21187711 CVCL_X045 FCCM-2 cancer cell line human CVCL_X045 CL:0000010 Unspecified 21187712 CVCL_X029 H69/Txl cancer cell line human CVCL_X029 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Male 21187713 CVCL_X028 RPET conditionally immortalized cell line house mouse CVCL_X028 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina; retinal pigment epithelium; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21187714 CVCL_X027 YCC-17 cancer cell line human CVCL_X027 From: Yonsei Cancer Center; Seoul; South Korea CL:0000010 Population: Korean Omics: Transcriptome analysis by microarray. Male 21187715 CVCL_NU89 BayGenomics ES cell line RRT481 embryonic stem cell house mouse CVCL_NU89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917057; Trim32 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187716 CVCL_NU88 BayGenomics ES cell line RRT480 embryonic stem cell house mouse CVCL_NU88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921571; Tipin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187717 CVCL_NU87 BayGenomics ES cell line RRT475 embryonic stem cell house mouse CVCL_NU87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101857; Usp15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187718 CVCL_NU86 BayGenomics ES cell line RRT473 embryonic stem cell house mouse CVCL_NU86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107158; Sin3b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187719 CVCL_NU85 BayGenomics ES cell line RRT464 embryonic stem cell house mouse CVCL_NU85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2670178; Med13l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187720 CVCL_X033 MS-KD finite cell line CVCL_X033 CL:0000010 Derived from sampling site: Kidney. Female Virology: Highly susceptible to infection by herpes simplex virus 1 (HHV-1), vaccinia virus and vesicular stomatitis virus (VSV) (PubMed=14960030) Group: Endangered species/breed cell line 21187721 CVCL_NU84 BayGenomics ES cell line RRT449 embryonic stem cell house mouse CVCL_NU84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919742; Smg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187722 CVCL_X032 MS-HT finite cell line CVCL_X032 CL:0000010 Derived from sampling site: Heart. Female Virology: Highly susceptible to infection by herpes simplex virus 1 (HHV-1), reovirus type 3, vaccinia virus and vesicular stomatitis virus (VSV) (PubMed=14960030) Group: Endangered species/breed cell line 21187723 CVCL_NU83 BayGenomics ES cell line RRT447 embryonic stem cell house mouse CVCL_NU83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144727; Ddx1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187724 CVCL_X031 MS-EY finite cell line CVCL_X031 CL:0000010 Derived from sampling site: Eye socket. Female Group: Endangered species/breed cell line 21187725 CVCL_NU82 BayGenomics ES cell line RRT432 embryonic stem cell house mouse CVCL_NU82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1289252; Ppp2r2d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187726 CVCL_X030 MS-BR finite cell line CVCL_X030 CL:0000010 Derived from sampling site: Brain. Female Group: Endangered species/breed cell line 21187727 CVCL_NU81 BayGenomics ES cell line RRT430 embryonic stem cell house mouse CVCL_NU81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1354737; Kdm2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187728 CVCL_X037 MS-SN finite cell line CVCL_X037 CL:0000010 Derived from sampling site: Snout. Female Virology: Highly susceptible to infection by herpes simplex virus 1 (HHV-1), reovirus type 3, vaccinia virus and vesicular stomatitis virus (VSV) (PubMed=14960030) Group: Endangered species/breed cell line 21187729 CVCL_NU80 BayGenomics ES cell line RRT428 embryonic stem cell house mouse CVCL_NU80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443627; Plekhm3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187730 CVCL_X036 MS-SK finite cell line CVCL_X036 CL:0000010 Derived from sampling site: Skin. Female Group: Endangered species/breed cell line 21187731 CVCL_X035 MS-LV finite cell line CVCL_X035 CL:0000010 Derived from sampling site: Liver. Female Group: Endangered species/breed cell line 21187732 CVCL_X034 MS-LG finite cell line CVCL_X034 CL:0000010 Derived from sampling site: Lung. Female Group: Endangered species/breed cell line 21187733 CVCL_X019 GLM-1 cancer cell line human CVCL_X019 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Characteristics: Established from a transplantable tumor established in nude mice 21187734 CVCL_X018 SMC-L001 cancer cell line human CVCL_X018 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=24569940); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=24569940) Population: Korean; Derived from sampling site: Lung. Male Doubling time: 70 hours (PubMed=24569940) 21187735 CVCL_X017 CPA-Yang2 cancer cell line human CVCL_X017 CL:0000010 Population: Chinese. Female 21187736 CVCL_X016 CPA-Yang1-BR cancer cell line human CVCL_X016 CL:0000010 Population: Chinese; Derived from metastatic site: Pericardial effusion. Male Characteristics: Brain metastatic phenotype Obtained after passage of the parent cell line in the brain of nude mice. 21187737 CVCL_NU99 BayGenomics ES cell line RRT493 embryonic stem cell house mouse CVCL_NU99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187738 CVCL_NU98 BayGenomics ES cell line RRT492 embryonic stem cell house mouse CVCL_NU98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913892; Ctnnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187739 CVCL_NU97 BayGenomics ES cell line RRT491 embryonic stem cell house mouse CVCL_NU97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913892; Ctnnbl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187740 CVCL_NU96 BayGenomics ES cell line RRT490 embryonic stem cell house mouse CVCL_NU96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919765; Wdr43 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187741 CVCL_X022 MDCK-MRP2 spontaneously immortalized cell line dog CVCL_X022 CL:0000010 Transfected with: HGNC; 53; ABCC2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Caution: There is another MDCK-II cell line with transfected human ABCC2: MDCK2-ABCC2 (Cellosaurus=CVCL_A2JY) 21187742 CVCL_NU95 BayGenomics ES cell line RRT488 embryonic stem cell house mouse CVCL_NU95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187743 CVCL_X021 GLM-3 cancer cell line human CVCL_X021 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male 21187744 CVCL_NU94 BayGenomics ES cell line RRT487 embryonic stem cell house mouse CVCL_NU94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187745 CVCL_X020 GLM-2 cancer cell line human CVCL_X020 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male 21187746 CVCL_NU93 BayGenomics ES cell line RRT486 embryonic stem cell house mouse CVCL_NU93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891037; Mtrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187747 CVCL_NU92 BayGenomics ES cell line RRT485 embryonic stem cell house mouse CVCL_NU92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1891037; Mtrr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187748 CVCL_X026 SCLC-16HV cancer cell line human CVCL_X026 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Male Problematic cell line: Contaminated Parent cell line (SCLC-16HC) has been shown to be a SCLC-21H (or SCLC-22H) derivative. 21187749 CVCL_NU91 BayGenomics ES cell line RRT484 embryonic stem cell house mouse CVCL_NU91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446630; Ago1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187750 CVCL_X025 SCLC-16HC cancer cell line human CVCL_X025 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00158 Problematic cell line: Contaminated Shown to be a SCLC-21H (or SCLC-22H) derivative (PubMed=10508494; PubMed=20143388). 21187751 CVCL_NU90 BayGenomics ES cell line RRT483 embryonic stem cell house mouse CVCL_NU90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446630; Ago1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187752 CVCL_X024 SCLC-86M2 cancer cell line human CVCL_X024 CL:0000010 Derived from metastatic site: Pleural effusion. Female Characteristics: Established from a second passage xenograft maintained in nude mice Doubling time: 70 hours (PubMed=2438285) 21187753 CVCL_X023 SCLC-203H cancer cell line human CVCL_X023 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: >200 hours (PubMed=2438285; PubMed=3029138) 21187754 CVCL_X008 SK-OV-4 cancer cell line human CVCL_X008 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Uterus; cervix. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00469 Problematic cell line: Contaminated Shown to be a C-33 A derivative (PubMed=22710073). 21187755 CVCL_X007 hTERT-EEC-B37 cancer cell line human CVCL_X007 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00462 Problematic cell line: Contaminated Shown to be a MCF-7 derivative (PubMed=22710073). 21187756 CVCL_X006 UT-EC-3 cancer cell line human CVCL_X006 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 28 hours (PubMed=8123477) 21187757 CVCL_X005 UT-EC-2B cancer cell line human CVCL_X005 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from metastatic site: Supraclavicular lymph node. Female Doubling time: 30 hours, at 14th passage (PubMed=7821848) 21187758 CVCL_X009 HEY C2 cancer cell line human CVCL_X009 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Caucasian Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray. Female Part of: MD Anderson Cell Lines Project 21187759 CVCL_NU69 BayGenomics ES cell line RRT374 embryonic stem cell house mouse CVCL_NU69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2684957; Rexo4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187760 CVCL_NU68 BayGenomics ES cell line RRT373 embryonic stem cell house mouse CVCL_NU68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187761 CVCL_NU67 BayGenomics ES cell line RRT363 embryonic stem cell house mouse CVCL_NU67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1277178; Fam91a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187762 CVCL_NU66 BayGenomics ES cell line RRT360 embryonic stem cell house mouse CVCL_NU66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2450915; Sec23ip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187763 CVCL_NU65 BayGenomics ES cell line RRT358 embryonic stem cell house mouse CVCL_NU65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107943; Cct6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187764 CVCL_NU64 BayGenomics ES cell line RRT353 embryonic stem cell house mouse CVCL_NU64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448419; H4c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187765 CVCL_NU63 BayGenomics ES cell line RRT351 embryonic stem cell house mouse CVCL_NU63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923864; Immt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187766 CVCL_X011 NOSE-07 cancer cell line human CVCL_X011 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Ovary. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00465 Problematic cell line: Contaminated Shown to be a DOV13 derivative (PubMed=22710073). 21187767 CVCL_NU62 BayGenomics ES cell line RRT350 embryonic stem cell house mouse CVCL_NU62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349457; Serinc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187768 CVCL_X010 NOSE-06 cancer cell line human CVCL_X010 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ser (c.840A>T); ClinVar=VCV000988616; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Ovary. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00464 Problematic cell line: Contaminated Shown to be a DOV13 derivative (PubMed=22710073). 21187769 CVCL_NU61 BayGenomics ES cell line RRT349 embryonic stem cell house mouse CVCL_NU61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448419; H4c1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187770 CVCL_NU60 BayGenomics ES cell line RRT348 embryonic stem cell house mouse CVCL_NU60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187771 CVCL_X015 CPA-Yang1 cancer cell line human CVCL_X015 CL:0000010 Population: Chinese; Derived from metastatic site: Pericardial effusion. Male 21187772 CVCL_X014 NM11 cancer cell line house mouse CVCL_X014 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21187773 CVCL_X013 LuM1 cancer cell line house mouse CVCL_X013 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: BALB/c. Female 21187774 CVCL_X012 CH1-cisR cancer cell line human CVCL_X012 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00559 Problematic cell line: Contaminated Parent cell line (CH1) has been shown to be a PA-1 derivative. 21187775 CVCL_NU79 BayGenomics ES cell line RRT416 embryonic stem cell house mouse CVCL_NU79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187776 CVCL_NU78 BayGenomics ES cell line RRT415 embryonic stem cell house mouse CVCL_NU78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107184; Cct7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187777 CVCL_NU77 BayGenomics ES cell line RRT400 embryonic stem cell house mouse CVCL_NU77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95781; Gnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187778 CVCL_NU76 BayGenomics ES cell line RRT399 embryonic stem cell house mouse CVCL_NU76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187779 CVCL_NU75 BayGenomics ES cell line RRT398 embryonic stem cell house mouse CVCL_NU75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441683; Tlk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187780 CVCL_NU74 BayGenomics ES cell line RRT397 embryonic stem cell house mouse CVCL_NU74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140998; Ube3c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187781 CVCL_X000 U-937-AG cancer cell line human CVCL_X000 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21187782 CVCL_NU73 BayGenomics ES cell line RRT396 embryonic stem cell house mouse CVCL_NU73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924053; Zfp998 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187783 CVCL_NU72 BayGenomics ES cell line RRT394 embryonic stem cell house mouse CVCL_NU72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349452; Polr3e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187784 CVCL_NU71 BayGenomics ES cell line RRT390 embryonic stem cell house mouse CVCL_NU71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914596; Daam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187785 CVCL_NU70 BayGenomics ES cell line RRT382 embryonic stem cell house mouse CVCL_NU70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140945; Pds5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187786 CVCL_X004 UT-EC-2A cancer cell line human CVCL_X004 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 40 hours, at 17th passage (PubMed=7821848) 21187787 CVCL_X003 UT-EC-1 cancer cell line human CVCL_X003 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 72 hours (PubMed=1541432) 21187788 CVCL_X002 UM-EC-3 cancer cell line human CVCL_X002 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 45 hours (PubMed=1541432) 21187789 CVCL_X001 UM-EC-2 cancer cell line human CVCL_X001 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 36 hours (PubMed=1541432) 21187790 CVCL_4J82 AG07865 finite cell line human CVCL_4J82 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21187791 CVCL_4J81 AG07864 transformed cell line human CVCL_4J81 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187792 CVCL_4J80 C-430 cancer cell line human CVCL_4J80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; humerus. Discontinued: ATCC; CRL-2084; true Male Problematic cell line: Probably contaminated The STR profile is identical to that of the RD-ES cell line. Originally thought to originate from a giant cell tumor excised in 1986 from tumor tissue of a 42 year old female patient. 21187793 CVCL_4J86 AG07869 finite cell line human CVCL_4J86 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21187794 CVCL_4J85 AG07868 transformed cell line human CVCL_4J85 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21187795 CVCL_4J84 AG07867 finite cell line human CVCL_4J84 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21187796 CVCL_4J83 AG07866 transformed cell line human CVCL_4J83 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21187797 CVCL_4J89 AG07872 finite cell line human CVCL_4J89 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21187798 CVCL_4J88 AG07871 finite cell line human CVCL_4J88 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21187799 CVCL_4J87 AG07870 transformed cell line human CVCL_4J87 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187800 CVCL_4J93 AG07880 transformed cell line human CVCL_4J93 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21187801 CVCL_4J92 AG07879 transformed cell line human CVCL_4J92 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female 21187802 CVCL_4J91 AG07878 transformed cell line human CVCL_4J91 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187803 CVCL_4J90 AG07877 transformed cell line human CVCL_4J90 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from autologous cell line AG07872) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187804 CVCL_4J97 AG07884 transformed cell line human CVCL_4J97 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female 21187805 CVCL_4J96 AG07883 finite cell line human CVCL_4J96 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21187806 CVCL_4J95 AG07882 transformed cell line human CVCL_4J95 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21187807 CVCL_4J94 AG07881 finite cell line human CVCL_4J94 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21187808 CVCL_4J99 AG07886 transformed cell line human CVCL_4J99 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21187809 CVCL_4J98 AG07885 finite cell line human CVCL_4J98 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21187810 CVCL_4J60 GM21698 transformed cell line human CVCL_4J60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21187811 CVCL_4J64 Ge Mar finite cell line human CVCL_4J64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1103; probable 21187812 CVCL_4J63 Al Pos finite cell line human CVCL_4J63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1120; probable Unspecified 21187813 CVCL_4J62 Sa Nar finite cell line human CVCL_4J62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1105; probable 21187814 CVCL_4J61 GM21699 transformed cell line human CVCL_4J61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21187815 CVCL_4J68 YS08 hybridoma house mouse CVCL_4J68 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human mesenchymal stem cells membrane protein antigen. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00123 21187816 CVCL_4J67 hntES embryonic stem cell human CVCL_4J67 CL:0000010 Female Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00092. Problematic cell line: As this cell line is reported in a patent originating from authors who have retracted their papers based on the same type of techniques, this cell line origin is doubtful 21187817 CVCL_4J66 3M transformed cell line CVCL_4J66 CL:0000010 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-10481 21187818 CVCL_4J65 CG-1 cancer cell line human CVCL_4J65 CL:0000010 Population: Japanese; Derived from sampling site: Bone; fibula. Female 21187819 CVCL_4J69 YS14 hybridoma house mouse CVCL_4J69 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human mesenchymal stem cells membrane protein antigen. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00124 21187820 CVCL_4J71 HOE6V cancer cell line human CVCL_4J71 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 (variant form) Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00218 21187821 CVCL_4J70 YS18 hybridoma house mouse CVCL_4J70 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human mesenchymal stem cells membrane protein antigen. Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00125 21187822 CVCL_4J75 SKG-I/TS cancer cell line human CVCL_4J75 CL:0000010 Transfected with: HGNC; 12441; TYMS Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21187823 CVCL_4J74 KML1-7 cancer cell line house mouse CVCL_4J74 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: MRL/lpr. Female Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 86091801 21187824 CVCL_4J73 KML1 cancer cell line house mouse CVCL_4J73 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: MRL/lpr. Female Doubling time: 24 hours (PubMed=3091508) 21187825 CVCL_4J72 KS-1 [Human primary effusion lymphoma] cancer cell line human CVCL_4J72 CL:0000010 Transformant: Human herpesvirus 8 (HHV-8/KSHV)(NCBI-Taxonomy; 37296); Derived from sampling site: Pleural effusion. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12247 21187826 CVCL_4J79 C-378 cancer cell line human CVCL_4J79 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; humerus. Discontinued: ATCC; CRL-2083; true Male Problematic cell line: Probably contaminated The STR profile is identical to that of the RD-ES cell line. Originally thought to originate from a giant cell tumor excised in 1986 from tumor tissue of a 33 year old female patient. 21187827 CVCL_4J78 PNG-1 transformed cell line human CVCL_4J78 CL:0000010 Anecdotal: The patent concerning this cell line caused a highly-mediatic controversy The cell line is derived from a member of the Hagahai people from New Guinea and it was deemed outrageous that a patent be deposited on biological material originating from an indigenous population without an explicit consent. Population: Papuan; Hagahai; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Virology: HTLV-1 isolate PNG producing cell line Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10528 21187828 CVCL_4J77 SKG-II/TS cancer cell line human CVCL_4J77 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 12441; TYMS Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21187829 CVCL_4J76 SKG-II/LUC cancer cell line human CVCL_4J76 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Ser87Ter (c.260C>A); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21187830 CVCL_NW09 BayGenomics ES cell line RRU286 embryonic stem cell house mouse CVCL_NW09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100818; Crcp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187831 CVCL_NW08 BayGenomics ES cell line RRU282 embryonic stem cell house mouse CVCL_NW08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2152345; Taf4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187832 CVCL_NW07 BayGenomics ES cell line RRU278 embryonic stem cell house mouse CVCL_NW07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2146901; Trip10 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187833 CVCL_NW06 BayGenomics ES cell line RRU249 embryonic stem cell house mouse CVCL_NW06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:105313; Cit Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187834 CVCL_NW05 BayGenomics ES cell line RRU248 embryonic stem cell house mouse CVCL_NW05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931749; Pum1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187835 CVCL_NW04 BayGenomics ES cell line RRU243 embryonic stem cell house mouse CVCL_NW04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106014; Nudc Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187836 CVCL_NW03 BayGenomics ES cell line RRU242 embryonic stem cell house mouse CVCL_NW03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2429950; Xpo6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187837 CVCL_NW02 BayGenomics ES cell line RRU229 embryonic stem cell house mouse CVCL_NW02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099804; Hip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187838 CVCL_NW01 BayGenomics ES cell line RRU225 embryonic stem cell house mouse CVCL_NW01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2448514; R3hdm1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187839 CVCL_NW00 BayGenomics ES cell line RRU216 embryonic stem cell house mouse CVCL_NW00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1858500; Diaph2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187840 CVCL_NW19 BayGenomics ES cell line RRU338 embryonic stem cell house mouse CVCL_NW19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917349; Smc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187841 CVCL_NW18 BayGenomics ES cell line RRU333 embryonic stem cell house mouse CVCL_NW18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915217; Pold3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187842 CVCL_NW17 BayGenomics ES cell line RRU332 embryonic stem cell house mouse CVCL_NW17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923747; Ppp1r11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187843 CVCL_NW16 BayGenomics ES cell line RRU327 embryonic stem cell house mouse CVCL_NW16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145130; Cog5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187844 CVCL_NW15 BayGenomics ES cell line RRU317 embryonic stem cell house mouse CVCL_NW15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100537; Mid1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187845 CVCL_NW14 BayGenomics ES cell line RRU314 embryonic stem cell house mouse CVCL_NW14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918614; Jmjd1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187846 CVCL_NW13 BayGenomics ES cell line RRU308 embryonic stem cell house mouse CVCL_NW13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187847 CVCL_NW12 BayGenomics ES cell line RRU302 embryonic stem cell house mouse CVCL_NW12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1342294; Uri1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187848 CVCL_NW11 BayGenomics ES cell line RRU300 embryonic stem cell house mouse CVCL_NW11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889023; Banp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187849 CVCL_NW10 BayGenomics ES cell line RRU298 embryonic stem cell house mouse CVCL_NW10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99400; Atp7a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187850 CVCL_X107 GM03595 finite cell line human CVCL_X107 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,del(Y)(pter->q11) [42]; 45,X [8] (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21187851 CVCL_WP07 GM27106 transformed cell line human CVCL_WP07 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000004491; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187852 CVCL_X106 GM03371 finite cell line human CVCL_X106 CL:0000010 Population: African American; Karyotypic information: 47,XX,inv(9)(pter->p11::q13->p11::q13->qter)pat,+der(22)(22pter->22q11::11q23->11qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187853 CVCL_WP06 GM27105 transformed cell line human CVCL_WP06 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000004491; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187854 CVCL_X105 GM03367 finite cell line human CVCL_X105 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21187855 CVCL_WP05 GM27104 transformed cell line human CVCL_WP05 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000004491; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Gly315Ser (c.943G>A); ClinVar=VCV000004496; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187856 CVCL_X104 GM03240 finite cell line human CVCL_X104 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21187857 CVCL_WP04 GM27300 finite cell line human CVCL_WP04 CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Ser269Asn (c.806G>A); ClinVar=VCV000373714; Zygosity=Heterozygous (from autologous cell line GM27325); Sequence variation: Mutation; HGNC; 3791; FOLR1; Simple; c.493+2T>C (IVS4+2T>C); ClinVar=VCV000095750; Zygosity=Heterozygous (from autologous cell line GM27325); Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly224Ser (c.670G>A); ClinVar=VCV000167092; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Pro8Thr (c.22C>A); ClinVar=VCV000205598; Zygosity=Heterozygous (from autologous cell line GM27325) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187858 CVCL_X109 GM03666 finite cell line human CVCL_X109 CL:0000010 Karyotypic information: 47,XY,+idic(15)(pter->q11::q11->pter) [31]; 47,XY,+idic(15)(pter->q11::q11->pter),inv(7)(pter->p22::q32->p22::q32->qter) [19] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187859 CVCL_WP09 GM27115 transformed cell line human CVCL_WP09 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Met1fs (c.-11_c.81del92); ClinVar=VCV000373075; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Gly315Ser (c.943G>A); ClinVar=VCV000004496; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187860 CVCL_X108 GM03624 finite cell line human CVCL_X108 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187861 CVCL_WP08 GM27108 transformed cell line human CVCL_WP08 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; p.Gly290Trp (c.868G>T); ClinVar=VCV000476441; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187862 CVCL_NV69 BayGenomics ES cell line RRU050 embryonic stem cell house mouse CVCL_NV69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1309480; Rtf1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187863 CVCL_NV68 BayGenomics ES cell line RRU049 embryonic stem cell house mouse CVCL_NV68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187864 CVCL_NV67 BayGenomics ES cell line RRU047 embryonic stem cell house mouse CVCL_NV67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925836; Srbd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187865 CVCL_NV66 BayGenomics ES cell line RRU042 embryonic stem cell house mouse CVCL_NV66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920336; Rps6ka5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187866 CVCL_NV65 BayGenomics ES cell line RRU036 embryonic stem cell house mouse CVCL_NV65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95768; Gna13 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187867 CVCL_NV64 BayGenomics ES cell line RRU035 embryonic stem cell house mouse CVCL_NV64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2154405; Map4k3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187868 CVCL_NV63 BayGenomics ES cell line RRU031 embryonic stem cell house mouse CVCL_NV63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384875; Cdk5rap2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187869 CVCL_NV62 BayGenomics ES cell line RRU030 embryonic stem cell house mouse CVCL_NV62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1889276; Dgke Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187870 CVCL_X110 GM03733 finite cell line human CVCL_X110 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(7)(pter->q34) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21187871 CVCL_WP10 GM27122 transformed cell line human CVCL_WP10 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Asn238Lysfs*63 (c.713dupA) (c.713_714insA); ClinVar=VCV000004494; Zygosity=Homozygous (Coriell) Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187872 CVCL_NV61 BayGenomics ES cell line RRU029 embryonic stem cell house mouse CVCL_NV61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109606; Fnbp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187873 CVCL_NV60 BayGenomics ES cell line RRU027 embryonic stem cell house mouse CVCL_NV60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341822; Eif4h Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187874 CVCL_WP14 CENSOi012-B induced pluripotent stem cell human CVCL_WP14 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21187875 CVCL_X114 GM03912 finite cell line human CVCL_X114 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187876 CVCL_WP13 CENSOi012-A induced pluripotent stem cell human CVCL_WP13 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21187877 CVCL_X113 GM03887 transformed cell line human CVCL_X113 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21187878 CVCL_X112 GM03883 finite cell line human CVCL_X112 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,inv(5)(q15;q33)pat.arr(1-22,X)x2 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187879 CVCL_WP12 GM27127 transformed cell line human CVCL_WP12 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Arg268Cys (c.802C>T); ClinVar=VCV000657794; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Arg469Gln (c.1406G>A); ClinVar=VCV000461629; Zygosity=Heterozygous (Coriell) Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187880 CVCL_X111 GM03767 finite cell line human CVCL_X111 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(18)(qter->p11) (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187881 CVCL_WP11 GM27126 transformed cell line human CVCL_WP11 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg249Trp (c.745C>T); ClinVar=VCV000014524; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187882 CVCL_NV79 BayGenomics ES cell line RRU083 embryonic stem cell house mouse CVCL_NV79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1347053; Git2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187883 CVCL_NV78 BayGenomics ES cell line RRU077 embryonic stem cell house mouse CVCL_NV78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926884; Huwe1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187884 CVCL_NV77 BayGenomics ES cell line RRU070 embryonic stem cell house mouse CVCL_NV77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921456; Sipa1l3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187885 CVCL_NV76 BayGenomics ES cell line RRU069 embryonic stem cell house mouse CVCL_NV76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913808; Lars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187886 CVCL_NV75 BayGenomics ES cell line RRU067 embryonic stem cell house mouse CVCL_NV75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2140050; Ints3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187887 CVCL_NV74 BayGenomics ES cell line RRU061 embryonic stem cell house mouse CVCL_NV74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443816; Snx8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187888 CVCL_NV73 BayGenomics ES cell line RRU060 embryonic stem cell house mouse CVCL_NV73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914132; Bzw1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187889 CVCL_NV72 BayGenomics ES cell line RRU055 embryonic stem cell house mouse CVCL_NV72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447768; Fam193a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187890 CVCL_NV71 BayGenomics ES cell line RRU053 embryonic stem cell house mouse CVCL_NV71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187891 CVCL_NV70 BayGenomics ES cell line RRU051 embryonic stem cell house mouse CVCL_NV70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2158736; Senp3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187892 CVCL_X103 GM03134 finite cell line human CVCL_X103 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187893 CVCL_WP03 GM27437 induced pluripotent stem cell human CVCL_WP03 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Argfs*8 (c.1157_1188del32) (p.Leu398Argfs*8, c.1193_1224del32) (1155del32); ClinVar=VCV000143366; Zygosity=Unspecified (Coriell) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21187894 CVCL_X102 GM03126 finite cell line human CVCL_X102 CL:0000010 Population: African American; Karyotypic information: 46,XX,der(1)(pter->p13.1::q21.1->p13.1::q21.1->q42.3) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21187895 CVCL_WP02 TH-69 hybridoma house mouse CVCL_WP02 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09564; Human CD7. 21187896 CVCL_X101 GM03047 finite cell line human CVCL_X101 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21187897 CVCL_WP01 TH-111 hybridoma house mouse CVCL_WP01 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40200; Human CD96. 21187898 CVCL_X100 GM03013 finite cell line human CVCL_X100 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21187899 CVCL_WP00 TC-12 hybridoma house mouse CVCL_WP00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen on T-cell leukemia cells. 21187900 CVCL_NV49 BayGenomics ES cell line RRU006 embryonic stem cell house mouse CVCL_NV49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1346074; Fxr2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187901 CVCL_NV48 BayGenomics ES cell line RRU005 embryonic stem cell house mouse CVCL_NV48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99660; Pola1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187902 CVCL_NV47 BayGenomics ES cell line RRU004 embryonic stem cell house mouse CVCL_NV47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915867; Mtcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187903 CVCL_NV46 BayGenomics ES cell line RRU003 embryonic stem cell house mouse CVCL_NV46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2387217; Ift52 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187904 CVCL_NV45 BayGenomics ES cell line RRT702 embryonic stem cell house mouse CVCL_NV45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137670; Ybx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187905 CVCL_NV44 BayGenomics ES cell line RRT701 embryonic stem cell house mouse CVCL_NV44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445054; Senp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187906 CVCL_NV43 BayGenomics ES cell line RRT699 embryonic stem cell house mouse CVCL_NV43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931035; Nelfb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187907 CVCL_NV42 BayGenomics ES cell line RRT691 embryonic stem cell house mouse CVCL_NV42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100518; Smad7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187908 CVCL_NV41 BayGenomics ES cell line RRT686 embryonic stem cell house mouse CVCL_NV41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341865; Mark3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187909 CVCL_NV40 BayGenomics ES cell line RRT682 embryonic stem cell house mouse CVCL_NV40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201610; Tex9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187910 CVCL_NV59 BayGenomics ES cell line RRU022 embryonic stem cell house mouse CVCL_NV59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919240; Ddx54 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187911 CVCL_NV58 BayGenomics ES cell line RRU019 embryonic stem cell house mouse CVCL_NV58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929266; Snd1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187912 CVCL_NV57 BayGenomics ES cell line RRU017 embryonic stem cell house mouse CVCL_NV57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187913 CVCL_NV56 BayGenomics ES cell line RRU015 embryonic stem cell house mouse CVCL_NV56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1935147; Arid1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187914 CVCL_NV55 BayGenomics ES cell line RRU014 embryonic stem cell house mouse CVCL_NV55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187915 CVCL_NV54 BayGenomics ES cell line RRU013 embryonic stem cell house mouse CVCL_NV54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913754; Prrc2c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187916 CVCL_NV53 BayGenomics ES cell line RRU011 embryonic stem cell house mouse CVCL_NV53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929955; Akr1a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187917 CVCL_NV52 BayGenomics ES cell line RRU009 embryonic stem cell house mouse CVCL_NV52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922462; Rnf121 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187918 CVCL_NV51 BayGenomics ES cell line RRU008 embryonic stem cell house mouse CVCL_NV51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443730; Tnrc6b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187919 CVCL_NV50 BayGenomics ES cell line RRU007 embryonic stem cell house mouse CVCL_NV50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349394; Map4k4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187920 CVCL_NV29 BayGenomics ES cell line RRT591 embryonic stem cell house mouse CVCL_NV29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921571; Tipin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187921 CVCL_NV28 BayGenomics ES cell line RRT590 embryonic stem cell house mouse CVCL_NV28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97815; Ptprs Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187922 CVCL_NV27 BayGenomics ES cell line RRT586 embryonic stem cell house mouse CVCL_NV27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:103234; Herc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187923 CVCL_NV26 BayGenomics ES cell line RRT583 embryonic stem cell house mouse CVCL_NV26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95753; Glud1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187924 CVCL_NV25 BayGenomics ES cell line RRT582 embryonic stem cell house mouse CVCL_NV25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1330276; Cops2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187925 CVCL_NV24 BayGenomics ES cell line RRT580 embryonic stem cell house mouse CVCL_NV24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923264; Zc3h18 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187926 CVCL_NV23 BayGenomics ES cell line RRT555 embryonic stem cell house mouse CVCL_NV23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3028642; Iqgap3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187927 CVCL_NV22 BayGenomics ES cell line RRT552 embryonic stem cell house mouse CVCL_NV22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919055; Nup93 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187928 CVCL_NV21 BayGenomics ES cell line RRT550 embryonic stem cell house mouse CVCL_NV21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914167; Chordc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187929 CVCL_NV20 BayGenomics ES cell line RRT549 embryonic stem cell house mouse CVCL_NV20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196624; Tcea1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187930 CVCL_NV39 BayGenomics ES cell line RRT670 embryonic stem cell house mouse CVCL_NV39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137670; Ybx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187931 CVCL_NV38 BayGenomics ES cell line RRT669 embryonic stem cell house mouse CVCL_NV38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915208; U2surp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187932 CVCL_NV37 BayGenomics ES cell line RRT661 embryonic stem cell house mouse CVCL_NV37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916477; Selenot Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187933 CVCL_NV36 BayGenomics ES cell line RRT660 embryonic stem cell house mouse CVCL_NV36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2445052; Tbck Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187934 CVCL_NV35 BayGenomics ES cell line RRT650 embryonic stem cell house mouse CVCL_NV35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137670; Ybx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187935 CVCL_NV34 BayGenomics ES cell line RRT627 embryonic stem cell house mouse CVCL_NV34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88311; Ccnb2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187936 CVCL_NV33 BayGenomics ES cell line RRT618 embryonic stem cell house mouse CVCL_NV33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109233; Kif22 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187937 CVCL_NV32 BayGenomics ES cell line RRT616 embryonic stem cell house mouse CVCL_NV32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918659; Fmnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187938 CVCL_NV31 BayGenomics ES cell line RRT603 embryonic stem cell house mouse CVCL_NV31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351477; Cars Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187939 CVCL_NV30 BayGenomics ES cell line RRT592 embryonic stem cell house mouse CVCL_NV30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921571; Tipin Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187940 CVCL_NV09 BayGenomics ES cell line RRT507 embryonic stem cell house mouse CVCL_NV09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098268; Kif5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187941 CVCL_NV08 BayGenomics ES cell line RRT506 embryonic stem cell house mouse CVCL_NV08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098268; Kif5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187942 CVCL_NV07 BayGenomics ES cell line RRT503 embryonic stem cell house mouse CVCL_NV07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187943 CVCL_NV06 BayGenomics ES cell line RRT502 embryonic stem cell house mouse CVCL_NV06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929004; Stk4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187944 CVCL_NV05 BayGenomics ES cell line RRT500 embryonic stem cell house mouse CVCL_NV05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106918; Hif1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187945 CVCL_NV04 BayGenomics ES cell line RRT499 embryonic stem cell house mouse CVCL_NV04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97537; Pecam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187946 CVCL_NV03 BayGenomics ES cell line RRT498 embryonic stem cell house mouse CVCL_NV03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97537; Pecam1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187947 CVCL_NV02 BayGenomics ES cell line RRT496 embryonic stem cell house mouse CVCL_NV02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99257; Eif3e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187948 CVCL_NV01 BayGenomics ES cell line RRT495 embryonic stem cell house mouse CVCL_NV01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99257; Eif3e Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187949 CVCL_NV00 BayGenomics ES cell line RRT494 embryonic stem cell house mouse CVCL_NV00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1261425; Drosha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187950 CVCL_NV19 BayGenomics ES cell line RRT536 embryonic stem cell house mouse CVCL_NV19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99430; Hira Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187951 CVCL_NV18 BayGenomics ES cell line RRT533 embryonic stem cell house mouse CVCL_NV18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1925835; Jade1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187952 CVCL_NV17 BayGenomics ES cell line RRT532 embryonic stem cell house mouse CVCL_NV17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919904; Ccdc12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187953 CVCL_NV16 BayGenomics ES cell line RRT524 embryonic stem cell house mouse CVCL_NV16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187954 CVCL_NV15 BayGenomics ES cell line RRT517 embryonic stem cell house mouse CVCL_NV15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2449121; Nme7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187955 CVCL_NV14 BayGenomics ES cell line RRT513 embryonic stem cell house mouse CVCL_NV14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187956 CVCL_NV13 BayGenomics ES cell line RRT511 embryonic stem cell house mouse CVCL_NV13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2137670; Ybx3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187957 CVCL_NV12 BayGenomics ES cell line RRT510 embryonic stem cell house mouse CVCL_NV12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187958 CVCL_NV11 BayGenomics ES cell line RRT509 embryonic stem cell house mouse CVCL_NV11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187959 CVCL_NV10 BayGenomics ES cell line RRT508 embryonic stem cell house mouse CVCL_NV10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98241; Stmn2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21187960 CVCL_4J42 GM01887 finite cell line human CVCL_4J42 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187961 CVCL_4J41 GM01886 finite cell line human CVCL_4J41 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187962 CVCL_4J40 GM01871 finite cell line human CVCL_4J40 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21187963 CVCL_4J46 GM02133 transformed cell line human CVCL_4J46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187964 CVCL_4J45 GM02124 transformed cell line human CVCL_4J45 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Val93Phe (c.277G>T); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187965 CVCL_4J44 GM02026 finite cell line human CVCL_4J44 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21187966 CVCL_4J43 GM01888 finite cell line human CVCL_4J43 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187967 CVCL_4J49 GM02230 transformed cell line human CVCL_4J49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187968 CVCL_4J48 GM02229 transformed cell line human CVCL_4J48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187969 CVCL_4J47 GM02213 transformed cell line human CVCL_4J47 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg167Trp (c.499C>T); ClinVar=VCV000001456; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187970 CVCL_WP90 FDEENTi002-A induced pluripotent stem cell human CVCL_WP90 From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Asn296Lys (c.888C>A); ClinVar=VCV000546666; Zygosity=Heterozygous (PubMed=31146250) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21187971 CVCL_X190 L9981-BoM cancer cell line human CVCL_X190 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Chinese 21187972 CVCL_WP94 ICGi017-A induced pluripotent stem cell human CVCL_WP94 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187973 CVCL_X194 Maben cancer cell line human CVCL_X194 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21187974 CVCL_WP93 CABi003-A induced pluripotent stem cell human CVCL_WP93 From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Tyr402His (c.1204T>C); ClinVar=VCV000294490; Zygosity=Heterozygous (PubMed=31176916) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187975 CVCL_X193 L9981-LuM cancer cell line human CVCL_X193 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Chinese 21187976 CVCL_WP92 HUBi001-A-2 induced pluripotent stem cell human CVCL_WP92 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; HUBi001-A-2; true Male 21187977 CVCL_X192 L9981-LnM cancer cell line human CVCL_X192 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Chinese 21187978 CVCL_WP91 HUBi001-A-1 induced pluripotent stem cell human CVCL_WP91 From: The Hubrecht Institute; Utrecht; Netherlands CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; HUBi001-A-1; true Male 21187979 CVCL_X191 L9981-BrM cancer cell line human CVCL_X191 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Chinese 21187980 CVCL_WP98 ICGi009-A induced pluripotent stem cell human CVCL_WP98 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 2176; CNTN6; Unexplicit; Microdeletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=31678775) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21187981 CVCL_X198 MGM-S cancer cell line CVCL_X198 CL:0000010 Male 21187982 CVCL_WP97 ICCSICi009-A induced pluripotent stem cell human CVCL_WP97 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187983 CVCL_X197 MGM-A cancer cell line CVCL_X197 CL:0000010 Derived from metastatic site: Ascites. Male Doubling time: 32 hours, at 38th passage (PubMed=8513002) 21187984 CVCL_WP96 ICCSICi010-A induced pluripotent stem cell human CVCL_WP96 From: Instituto Cajal; Madrid; Spain CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187985 CVCL_X196 QTTK- cancer cell line CVCL_X196 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342). Unspecified Group: Bird cell line 21187986 CVCL_X195 FBM-17 spontaneously immortalized cell line CVCL_X195 CL:0000010 Derived from sampling site: Fetal thymus Cell type=Thymic macrophage.. Unspecified Doubling time: 48 hours (PubMed=8593321) 21187987 CVCL_WP95 ICCSICi005-A induced pluripotent stem cell human CVCL_WP95 From: Instituto Cajal; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31539859) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21187988 CVCL_X199 WB311 transformed cell line Norway rat CVCL_X199 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344. Omics: Transcriptome analysis by microarray Male 21187989 CVCL_4J53 GM03171 finite cell line human CVCL_4J53 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Male 21187990 CVCL_4J52 GM03165 finite cell line human CVCL_4J52 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Male 21187991 CVCL_4J51 GM02336 finite cell line human CVCL_4J51 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21187992 CVCL_4J50 GM02334 finite cell line human CVCL_4J50 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21187993 CVCL_4J57 GM07077 finite cell line human CVCL_4J57 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg116Trp (c.346C>T); ClinVar=VCV000001445; Zygosity=Heterozygous (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21187994 CVCL_4J56 GM03175 finite cell line human CVCL_4J56 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Male 21187995 CVCL_4J55 GM03174 finite cell line human CVCL_4J55 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Unspecified (Coriell) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Female 21187996 CVCL_4J54 GM03173 finite cell line human CVCL_4J54 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (Coriell) Population: Caucasian; Greek; Derived from sampling site: Cell type=Fibroblast. Male 21187997 CVCL_4J59 GM14890 transformed cell line human CVCL_4J59 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser106Cys (c.317C>G); ClinVar=VCV000242797; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Arg182Trp (c.544C>T); ClinVar=VCV000242750; Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Arg198Cys (c.592C>T); ClinVar=VCV000010391; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21187998 CVCL_4J58 GM09239 transformed cell line human CVCL_4J58 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; c.33+1G>A (IVS1+1G>A); ClinVar=VCV000001441; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21187999 CVCL_X183 EPP85-181RNOV cancer cell line human CVCL_X183 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone. 21188000 CVCL_WP83 FAMRCi004-B induced pluripotent stem cell human CVCL_WP83 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.His1684Arg (c.5051A>G); ClinVar=VCV000431487; Zygosity=Heterozygous (PubMed=32062131) Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21188001 CVCL_X182 EPP85-181RDB cancer cell line human CVCL_X182 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin). 21188002 CVCL_WP82 FAMRCi004-A induced pluripotent stem cell human CVCL_WP82 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.His1684Arg (c.5051A>G); ClinVar=VCV000431487; Zygosity=Heterozygous (PubMed=32062131) Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 21188003 CVCL_X181 EPP85-181P cancer cell line human CVCL_X181 CL:0000010 21188004 CVCL_WP81 ESi074-A induced pluripotent stem cell human CVCL_WP81 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Donor information: Established from a patient showing cardiotoxicity to anthracyclines; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21188005 CVCL_X180 EPG85-257RNOV-TR cancer cell line human CVCL_X180 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone. 21188006 CVCL_WP80 ESi071-A induced pluripotent stem cell human CVCL_WP80 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21188007 CVCL_WP87 FAMRCi006-B induced pluripotent stem cell human CVCL_WP87 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Pro (c.1580G>C); ClinVar=VCV000014481; Zygosity=Heterozygous (PubMed=32059175) Derived from sampling site: Peripheral blood. Female 21188008 CVCL_X187 NL9980 cancer cell line human CVCL_X187 CL:0000010 Population: Chinese. 21188009 CVCL_WP86 FAMRCi006-A induced pluripotent stem cell human CVCL_WP86 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg527Pro (c.1580G>C); ClinVar=VCV000014481; Zygosity=Heterozygous (PubMed=32059175) Derived from sampling site: Peripheral blood. Female 21188010 CVCL_X186 WCQH-9801 cancer cell line human CVCL_X186 CL:0000010 Population: Chinese. 21188011 CVCL_WP85 FAMRCi005-B induced pluripotent stem cell human CVCL_WP85 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Asp357Val (c.1070A>T); ClinVar=VCV000428603; Zygosity=Heterozygous (PubMed=32062135) Derived from sampling site: Peripheral blood. Female 21188012 CVCL_X185 OAT-1975 cancer cell line human CVCL_X185 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Male Doubling time: 24 hours (PubMed=195719) 21188013 CVCL_X184 CCF-K104 spontaneously immortalized cell line CVCL_X184 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Optimal growth at 25 to 30 Celsius Group: Fish cell line 21188014 CVCL_WP84 FAMRCi005-A induced pluripotent stem cell human CVCL_WP84 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Asp357Val (c.1070A>T); ClinVar=VCV000428603; Zygosity=Heterozygous (PubMed=32062135) Derived from sampling site: Peripheral blood. Female 21188015 CVCL_WP89 FAMRCi007-B induced pluripotent stem cell human CVCL_WP89 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg249Gln (c.746G>A); ClinVar=VCV000066931; Zygosity=Heterozygous (PubMed=32659731) Derived from sampling site: Peripheral blood. Male 21188016 CVCL_X189 L9981-Luc cancer cell line human CVCL_X189 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Population: Chinese 21188017 CVCL_WP88 FAMRCi007-A induced pluripotent stem cell human CVCL_WP88 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg249Gln (c.746G>A); ClinVar=VCV000066931; Zygosity=Heterozygous (PubMed=32659731) Derived from sampling site: Peripheral blood. Male 21188018 CVCL_X188 L9981 cancer cell line human CVCL_X188 CL:0000010 Population: Chinese Characteristics: Has a high tumorigenic potential and lung metastatic ability in nude mice (PubMed=21310132). 21188019 CVCL_4J20 GM01150 finite cell line human CVCL_4J20 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188020 CVCL_4J24 GM01154 finite cell line human CVCL_4J24 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188021 CVCL_4J23 GM01153 finite cell line human CVCL_4J23 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188022 CVCL_4J22 GM01152 finite cell line human CVCL_4J22 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (Coriell) Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Male 21188023 CVCL_4J21 GM01151 finite cell line human CVCL_4J21 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (Coriell) Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Male 21188024 CVCL_4J28 GM01179 finite cell line human CVCL_4J28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188025 CVCL_4J27 GM01165 finite cell line human CVCL_4J27 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188026 CVCL_4J26 GM01163 finite cell line human CVCL_4J26 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188027 CVCL_4J25 GM01157 finite cell line human CVCL_4J25 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Female 21188028 CVCL_4J19 GM01041 finite cell line human CVCL_4J19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188029 CVCL_4J18 GM00977 finite cell line human CVCL_4J18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188030 CVCL_WP72 cc-006cpm8 cancer cell line human CVCL_WP72 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=31115570) Population: Chinese; Derived from metastatic site: Liver. Omics: Deep exome analysis Female Doubling time: 27 hours (PubMed=31115570) 21188031 CVCL_X172 JNU-hES-02 embryonic stem cell human CVCL_X172 From: Jeju National University Stem Cell Research Center; Jeju; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010050. 21188032 CVCL_WP71 CENSOi062-A induced pluripotent stem cell human CVCL_WP71 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188033 CVCL_X171 JNU-hES-01 embryonic stem cell human CVCL_X171 From: Jeju National University Stem Cell Research Center; Jeju; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12010049. 21188034 CVCL_WP70 CENSOi061-A induced pluripotent stem cell human CVCL_WP70 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188035 CVCL_X170 CHA-hES4-RFP embryonic stem cell human CVCL_X170 From: CHA University; Seongnam; South Korea CL:0000010 Transfected with: UniProtKB; Q9U6Y8; RFP. Male 21188036 CVCL_WP76 EDi014-C induced pluripotent stem cell human CVCL_WP76 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: EBiSC; EDi014-C; true Male 21188037 CVCL_X176 EPG85-257RNOV cancer cell line human CVCL_X176 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone Omics: Transcriptome analysis by microarray. 21188038 CVCL_WP75 CIMHi005-A induced pluripotent stem cell human CVCL_WP75 From: Central Institute of Mental Health; Mannheim; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1033; BDNF; Simple; p.Val66Met (c.196G>A); ClinVar=VCV000017697; Zygosity=Homozygous (PubMed=36473250) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21188039 CVCL_X175 EPG85-257RDB cancer cell line human CVCL_X175 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin) Omics: Transcriptome analysis by microarray. 21188040 CVCL_WP74 CIMHi004-A induced pluripotent stem cell human CVCL_WP74 From: Central Institute of Mental Health; Mannheim; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1033; BDNF; Simple; p.Val66Met (c.196G>A); ClinVar=VCV000017697; Zygosity=Heterozygous (PubMed=36473250) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21188041 CVCL_X174 ELM-D cancer cell line house mouse CVCL_X174 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C3H/HeNSlc. Female 21188042 CVCL_WP73 CGMHi002-A induced pluripotent stem cell human CVCL_WP73 From: Chang Gung Memorial Hospital, Lin-Kou Medical Centre, Chang Gung University; Tao-Yuan; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Asp331Tyr (c.991G>T); ClinVar=VCV000030371; Zygosity=Heterozygous (PubMed=31493761); Sequence variation: Mutation; HGNC; 9039; PLA2G6; Simple; p.Met358Ilefs*7 (c.1077G>A) (p.Ser359Ser); ClinVar=VCV000279875; Zygosity=Heterozygous; Note=Cryptic splice site mutation (PubMed=31493761) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 21188043 CVCL_X173 HC-2 cancer cell line human CVCL_X173 CL:0000010 Female 21188044 CVCL_X179 EPG85-257RDB-TR cancer cell line human CVCL_X179 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin). 21188045 CVCL_WP79 ESi070-A induced pluripotent stem cell human CVCL_WP79 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21188046 CVCL_X178 EPG85-257P-TR cancer cell line human CVCL_X178 CL:0000010 21188047 CVCL_WP78 ESi069-A induced pluripotent stem cell human CVCL_WP78 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21188048 CVCL_X177 EPG85-257DAU cancer cell line human CVCL_X177 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin). 21188049 CVCL_WP77 ESi068-A induced pluripotent stem cell human CVCL_WP77 From: Centro de Medecina Regenerativa de Barcelona (CMRB); Barcelona; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21188050 CVCL_WP59 CENSOi050-A induced pluripotent stem cell human CVCL_WP59 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188051 CVCL_X159 SCCNC5 cancer cell line human CVCL_X159 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Lys (c.511G>A); ClinVar=VCV000141566; Zygosity=Unspecified (PubMed=24816148) Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Male 21188052 CVCL_4J31 GM01193 finite cell line human CVCL_4J31 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Homozygous (PubMed=7803800) Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Female 21188053 CVCL_4J30 GM01192 finite cell line human CVCL_4J30 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Heterozygous (Coriell) Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Female 21188054 CVCL_4J35 GM01624 finite cell line human CVCL_4J35 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Thr35Met (c.104C>T); ClinVar=VCV000449465; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188055 CVCL_4J34 GM01623 finite cell line human CVCL_4J34 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Thr35Met (c.104C>T); ClinVar=VCV000449465; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188056 CVCL_4J33 GM01622 finite cell line human CVCL_4J33 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Thr35Met (c.104C>T); ClinVar=VCV000449465; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188057 CVCL_4J32 GM01621 finite cell line human CVCL_4J32 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Thr35Met (c.104C>T); ClinVar=VCV000449465; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188058 CVCL_4J39 GM01870 finite cell line human CVCL_4J39 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188059 CVCL_4J38 GM01869 finite cell line human CVCL_4J38 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188060 CVCL_4J37 GM01647 finite cell line human CVCL_4J37 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; c.578T>A; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; c.582_586delGCGCA; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188061 CVCL_4J36 GM01625 finite cell line human CVCL_4J36 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Thr35Met (c.104C>T); ClinVar=VCV000449465; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188062 CVCL_4J29 GM01188 finite cell line human CVCL_4J29 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Asp282His (c.844G>C); ClinVar=VCV000010372; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Sardinian; Karyotypic information: 46,XY,inv(9) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188063 CVCL_WP61 CENSOi052-A induced pluripotent stem cell human CVCL_WP61 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188064 CVCL_X161 SCCNC7 cancer cell line human CVCL_X161 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=24816148) Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Male 21188065 CVCL_WP60 CENSOi051-A induced pluripotent stem cell human CVCL_WP60 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188066 CVCL_X160 SCCNC6 cancer cell line human CVCL_X160 CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Male Doubling time: ~34 hours (PubMed=24816148) 21188067 CVCL_WP65 CENSOi056-A induced pluripotent stem cell human CVCL_WP65 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188068 CVCL_X165 HxMm cancer cell line human CVCL_X165 CL:0000010 21188069 CVCL_WP64 CENSOi055-A induced pluripotent stem cell human CVCL_WP64 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188070 CVCL_X164 HxLL cancer cell line human CVCL_X164 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=12068308). Unspecified 21188071 CVCL_WP63 CENSOi054-A induced pluripotent stem cell human CVCL_WP63 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188072 CVCL_X163 HxLe cancer cell line human CVCL_X163 CL:0000010 Unspecified 21188073 CVCL_WP62 CENSOi053-A induced pluripotent stem cell human CVCL_WP62 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188074 CVCL_X162 SCCMM cancer cell line human CVCL_X162 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 21188075 CVCL_WP69 CENSOi060-A induced pluripotent stem cell human CVCL_WP69 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188076 CVCL_X169 CHA-hES4-eGFP embryonic stem cell human CVCL_X169 From: CHA University; Seongnam; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21188077 CVCL_WP68 CENSOi059-A induced pluripotent stem cell human CVCL_WP68 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188078 CVCL_X168 CHA-hES3-RFP embryonic stem cell human CVCL_X168 From: CHA University; Seongnam; South Korea CL:0000010 Transfected with: UniProtKB; Q9U6Y8; RFP. Male 21188079 CVCL_WP67 CENSOi058-A induced pluripotent stem cell human CVCL_WP67 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188080 CVCL_X167 CHA-hES3-eGFP embryonic stem cell human CVCL_X167 From: CHA University; Seongnam; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male 21188081 CVCL_WP66 CENSOi057-A induced pluripotent stem cell human CVCL_WP66 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188082 CVCL_X166 SS78 cancer cell line human CVCL_X166 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly144Aspfs*15 (c.431delG); ClinVar=VCV000223209; Zygosity=Unspecified (PubMed=7915601) Population: Caucasian; Derived from sampling site: Kidney. Male Doubling time: 1.5 days, at 29th passage (PubMed=7319533) 21188083 CVCL_WP49 CENSOi042-A induced pluripotent stem cell human CVCL_WP49 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188084 CVCL_X149 HLE/2E1 cancer cell line human CVCL_X149 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Ala (c.731G>C); ClinVar=VCV000458560; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2631; CYP2E1 Population: Japanese; Derived from sampling site: Liver Cell type=Epithelial cell.. Male 21188085 CVCL_WP48 CENSOi041-B induced pluripotent stem cell human CVCL_WP48 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188086 CVCL_X148 OM449 cancer cell line human CVCL_X148 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Female Characteristics: Highly pigmented 21188087 CVCL_4J02 GM10707 transformed cell line human CVCL_4J02 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Old Order Amish Major Affective Disorder cell line collection 21188088 CVCL_4J01 GM10511 transformed cell line human CVCL_4J01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188089 CVCL_4J00 GM08913 transformed cell line human CVCL_4J00 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188090 CVCL_4J06 GM07836 transformed cell line human CVCL_4J06 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188091 CVCL_4J05 GM11500 transformed cell line human CVCL_4J05 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188092 CVCL_4J04 GM11191 transformed cell line human CVCL_4J04 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188093 CVCL_4J03 GM11117 transformed cell line human CVCL_4J03 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Old Order Amish Major Affective Disorder cell line collection 21188094 CVCL_X150 BT4A cancer cell line Norway rat CVCL_X150 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. 21188095 CVCL_WP50 CENSOi043-A induced pluripotent stem cell human CVCL_WP50 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188096 CVCL_WP54 CENSOi047-A induced pluripotent stem cell human CVCL_WP54 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188097 CVCL_X154 KKM-C cancer cell line human CVCL_X154 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 21188098 CVCL_WP53 CENSOi046-A induced pluripotent stem cell human CVCL_WP53 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188099 CVCL_X153 KKM-B cancer cell line human CVCL_X153 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 21188100 CVCL_WP52 CENSOi045-A induced pluripotent stem cell human CVCL_WP52 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188101 CVCL_X152 KKM-A cancer cell line human CVCL_X152 CL:0000010 Population: Japanese; Derived from sampling site: Nose; nasal cavity; maxillary sinus. Male 21188102 CVCL_WP51 CENSOi044-A induced pluripotent stem cell human CVCL_WP51 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188103 CVCL_X151 JFEN cancer cell line human CVCL_X151 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1 (PubMed=8577710) Derived from metastatic site: Chest wall. Male 21188104 CVCL_WP58 CENSOi049-B induced pluripotent stem cell human CVCL_WP58 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188105 CVCL_X158 SCCNC4 cancer cell line human CVCL_X158 CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Female 21188106 CVCL_WP57 CENSOi049-A induced pluripotent stem cell human CVCL_WP57 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188107 CVCL_X157 SCCNC2 cancer cell line human CVCL_X157 CL:0000010 Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Male 21188108 CVCL_WP56 CENSOi048-A induced pluripotent stem cell human CVCL_WP56 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188109 CVCL_X156 SCCNC1 cancer cell line human CVCL_X156 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=24816148) Derived from sampling site: Nose; nasal cavity; maxillary sinus. Omics: Array-based CGH Male 21188110 CVCL_WP55 CENSOi047-B induced pluripotent stem cell human CVCL_WP55 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188111 CVCL_X155 KKM-D cancer cell line human CVCL_X155 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male 21188112 CVCL_WP39 CENSOi034-A induced pluripotent stem cell human CVCL_WP39 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188113 CVCL_X139 GM03225 finite cell line human CVCL_X139 CL:0000010 Population: Caribbean; Trinidadian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21188114 CVCL_WP38 CENSOi033-A induced pluripotent stem cell human CVCL_WP38 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188115 CVCL_X138 GM05066 transformed cell line human CVCL_X138 CL:0000010 Population: Caribbean; Trinidadian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188116 CVCL_WP37 CENSOi032-A induced pluripotent stem cell human CVCL_WP37 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188117 CVCL_X137 GM02820 transformed cell line human CVCL_X137 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21188118 CVCL_4J13 GM00931 finite cell line human CVCL_4J13 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg26Cys (c.76C>T); ClinVar=VCV000645443; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21188119 CVCL_4J12 GM00738 finite cell line human CVCL_4J12 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188120 CVCL_4J11 GM00412 finite cell line human CVCL_4J11 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188121 CVCL_4J10 GM00325 finite cell line human CVCL_4J10 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Male 21188122 CVCL_4J17 GM00961 finite cell line human CVCL_4J17 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188123 CVCL_4J16 GM00941 finite cell line human CVCL_4J16 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 21188124 CVCL_4J15 GM00933 finite cell line human CVCL_4J15 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg26Cys (c.76C>T); ClinVar=VCV000645443; Zygosity=Heterozygous (from familial inference of GM00931) Population: Caucasian; Donor information: At sampling donor was not affected with acute intermittent porphyria but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Has decreased HMBS activity 21188125 CVCL_4J14 GM00932 finite cell line human CVCL_4J14 CL:0000010 Sequence variation: Mutation; HGNC; 4982; HMBS; Simple; p.Arg26Cys (c.76C>T); ClinVar=VCV000645443; Zygosity=Heterozygous (from familial inference of GM00931) Population: Caucasian; Donor information: At sampling donor was not affected with acute intermittent porphyria but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Has decreased HMBS activity 21188126 CVCL_4J09 GM00324 finite cell line human CVCL_4J09 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Ser188Phe (c.653C>T); ClinVar=VCV000100057; Zygosity=Hemizygous (PubMed=7803800) Population: Caucasian; Sardinian; Karyotypic information: 47,XY,t(X;7)(q24;q32) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Male 21188127 CVCL_4J08 GM00120 finite cell line human CVCL_4J08 CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Asn126Asp (c.376A>G) (p.Asn156Asp, c.466A>G); ClinVar=VCV000100055; Zygosity=Heterozygous (PubMed=7803800) Population: African; Kenyan; Derived from sampling site: Cell type=Fibroblast. Female 21188128 CVCL_4J07 GM08272 finite cell line human CVCL_4J07 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188129 CVCL_WP43 CENSOi037-A induced pluripotent stem cell human CVCL_WP43 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188130 CVCL_X143 NCL-2 spontaneously immortalized cell line house mouse CVCL_X143 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: NC/Kuj. Male 21188131 CVCL_WP42 CENSOi036-A induced pluripotent stem cell human CVCL_WP42 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188132 CVCL_X142 CR4 [Human colon carcinoma] cancer cell line human CVCL_X142 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (Millipore) Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Liver. Omics: Transcriptome analysis by RNAseq Male 21188133 CVCL_WP41 CENSOi035-B induced pluripotent stem cell human CVCL_WP41 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188134 CVCL_X141 GM07312 transformed cell line human CVCL_X141 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21188135 CVCL_WP40 CENSOi035-A induced pluripotent stem cell human CVCL_WP40 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188136 CVCL_X140 GM05877 finite cell line human CVCL_X140 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188137 CVCL_WP47 CENSOi041-A induced pluripotent stem cell human CVCL_WP47 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188138 CVCL_X147 OM443 cancer cell line human CVCL_X147 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Male 21188139 CVCL_WP46 CENSOi040-A induced pluripotent stem cell human CVCL_WP46 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188140 CVCL_X146 OM439 cancer cell line human CVCL_X146 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Female 21188141 CVCL_WP45 CENSOi039-A induced pluripotent stem cell human CVCL_WP45 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188142 CVCL_X145 OM421 cancer cell line human CVCL_X145 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Female 21188143 CVCL_WP44 CENSOi038-A induced pluripotent stem cell human CVCL_WP44 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188144 CVCL_X144 HL165 cancer cell line human CVCL_X144 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; uvea. Male 21188145 CVCL_WP29 CENSOi027-C induced pluripotent stem cell human CVCL_WP29 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188146 CVCL_X129 PC-7 [Human pancreatic carcinoma] cancer cell line human CVCL_X129 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107). Population: Chinese 21188147 CVCL_WP28 CENSOi027-B induced pluripotent stem cell human CVCL_WP28 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188148 CVCL_X128 PC-4 cancer cell line human CVCL_X128 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107). Population: Chinese 21188149 CVCL_WP27 CENSOi027-A induced pluripotent stem cell human CVCL_WP27 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188150 CVCL_X127 GM03989 finite cell line human CVCL_X127 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~2000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188151 CVCL_WP26 CENSOi026-C induced pluripotent stem cell human CVCL_WP26 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188152 CVCL_X126 GM03991 finite cell line human CVCL_X126 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[50-80] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188153 CVCL_NV89 BayGenomics ES cell line RRU155 embryonic stem cell house mouse CVCL_NV89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104631; Utrn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188154 CVCL_NV88 BayGenomics ES cell line RRU154 embryonic stem cell house mouse CVCL_NV88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188155 CVCL_NV87 BayGenomics ES cell line RRU153 embryonic stem cell house mouse CVCL_NV87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108360; Enah Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188156 CVCL_NV86 BayGenomics ES cell line RRU152 embryonic stem cell house mouse CVCL_NV86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97517; Cdk17 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188157 CVCL_NV85 BayGenomics ES cell line RRU128 embryonic stem cell house mouse CVCL_NV85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384159; Gga3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188158 CVCL_NV84 BayGenomics ES cell line RRU122 embryonic stem cell house mouse CVCL_NV84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1100495; Atp5pb Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188159 CVCL_WP32 CENSOi029-A induced pluripotent stem cell human CVCL_WP32 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188160 CVCL_X132 GM00681 finite cell line human CVCL_X132 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: Coriell; GM00681; probable Male 21188161 CVCL_NV83 BayGenomics ES cell line RRU103 embryonic stem cell house mouse CVCL_NV83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913906; Eef1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188162 CVCL_WP31 CENSOi028-A induced pluripotent stem cell human CVCL_WP31 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188163 CVCL_X131 GM00419 finite cell line human CVCL_X131 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM00419; probable Female 21188164 CVCL_NV82 BayGenomics ES cell line RRU099 embryonic stem cell house mouse CVCL_NV82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1340806; Parp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188165 CVCL_WP30 CENSOi027-D induced pluripotent stem cell human CVCL_WP30 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188166 CVCL_X130 PC-3 [Human pancreatic carcinoma] cancer cell line human CVCL_X130 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=14640107). Population: Chinese 21188167 CVCL_NV81 BayGenomics ES cell line RRU085 embryonic stem cell house mouse CVCL_NV81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:96610; Itgb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188168 CVCL_NV80 BayGenomics ES cell line RRU084 embryonic stem cell house mouse CVCL_NV80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924113; Dcun1d5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188169 CVCL_WP36 CENSOi031-A induced pluripotent stem cell human CVCL_WP36 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188170 CVCL_X136 GM02819 finite cell line human CVCL_X136 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188171 CVCL_WP35 CENSOi030-A induced pluripotent stem cell human CVCL_WP35 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188172 CVCL_X135 GM05011 transformed cell line human CVCL_X135 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21188173 CVCL_WP34 CENSOi029-C induced pluripotent stem cell human CVCL_WP34 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188174 CVCL_X134 GM05010 finite cell line human CVCL_X134 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;8;2)(Xpter->Xq21.2::2q14.2->2qter;8qter->8p11.1::Xq21.2->Xqter;2pter->2q14.2::8p11.1->8pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188175 CVCL_WP33 CENSOi029-B induced pluripotent stem cell human CVCL_WP33 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188176 CVCL_X133 GM00682 finite cell line human CVCL_X133 CL:0000010 Karyotypic information: 46,XX [32]; 47,XX,+15 [18] (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21188177 CVCL_WP18 CENSOi020-A induced pluripotent stem cell human CVCL_WP18 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188178 CVCL_X118 GM04045 finite cell line human CVCL_X118 CL:0000010 Population: Caucasian; Greek; Karyotypic information: 46,XY,t(2;4)(2pter->2q14::4q31.3->4qter;4pter->4q31.1::2q14->2qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188179 CVCL_WP17 CENSOi019-A induced pluripotent stem cell human CVCL_WP17 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21188180 CVCL_X117 GM03999 finite cell line human CVCL_X117 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188181 CVCL_WP16 CENSOi018-A induced pluripotent stem cell human CVCL_WP16 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188182 CVCL_X116 GM03923 finite cell line human CVCL_X116 CL:0000010 Population: Caucasian; English; Karyotypic information: 46,X,del(X)(q13;q22) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188183 CVCL_WP15 CENSOi012-C induced pluripotent stem cell human CVCL_WP15 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 Female 21188184 CVCL_X115 GM03918 finite cell line human CVCL_X115 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188185 CVCL_WP19 CENSOi021-A induced pluripotent stem cell human CVCL_WP19 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188186 CVCL_X119 GM04513 finite cell line human CVCL_X119 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+del(2)(qter->p23) [38]; 47,XX,+2 [12] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188187 CVCL_NV99 BayGenomics ES cell line RRU215 embryonic stem cell house mouse CVCL_NV99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920037; Ndc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188188 CVCL_NV98 BayGenomics ES cell line RRU210 embryonic stem cell house mouse CVCL_NV98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1855699; Vti1a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188189 CVCL_NV97 BayGenomics ES cell line RRU209 embryonic stem cell house mouse CVCL_NV97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916188; Aspscr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188190 CVCL_NV96 BayGenomics ES cell line RRU200 embryonic stem cell house mouse CVCL_NV96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3652185; Gm14322 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188191 CVCL_NV95 BayGenomics ES cell line RRU178 embryonic stem cell house mouse CVCL_NV95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101769; Mcl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188192 CVCL_WP21 CENSOi023-A induced pluripotent stem cell human CVCL_WP21 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188193 CVCL_X121 GM05299 finite cell line human CVCL_X121 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188194 CVCL_NV94 BayGenomics ES cell line RRU170 embryonic stem cell house mouse CVCL_NV94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914195; Sdha Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188195 CVCL_WP20 CENSOi022-A induced pluripotent stem cell human CVCL_WP20 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188196 CVCL_X120 GM04536 finite cell line human CVCL_X120 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21188197 CVCL_NV93 BayGenomics ES cell line RRU167 embryonic stem cell house mouse CVCL_NV93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104861; Bcat1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188198 CVCL_NV92 BayGenomics ES cell line RRU165 embryonic stem cell house mouse CVCL_NV92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351315; Eloa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188199 CVCL_NV91 BayGenomics ES cell line RRU161 embryonic stem cell house mouse CVCL_NV91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142347; Zfp568 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188200 CVCL_WP25 CENSOi026-B induced pluripotent stem cell human CVCL_WP25 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188201 CVCL_X125 GM03990 transformed cell line human CVCL_X125 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[50-80] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188202 CVCL_NV90 BayGenomics ES cell line RRU156 embryonic stem cell house mouse CVCL_NV90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2386251; Eif3l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188203 CVCL_WP24 CENSOi026-A induced pluripotent stem cell human CVCL_WP24 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188204 CVCL_X124 GM03756 transformed cell line human CVCL_X124 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188205 CVCL_WP23 CENSOi025-A induced pluripotent stem cell human CVCL_WP23 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188206 CVCL_X123 GM03755 finite cell line human CVCL_X123 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03755; probable Male 21188207 CVCL_WP22 CENSOi024-A induced pluripotent stem cell human CVCL_WP22 From: Censo Biotechnologies, Ltd; Roslin; United Kingdom. CL:0000010 21188208 CVCL_X122 GM03697 transformed cell line human CVCL_X122 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~500] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21188209 CVCL_4K81 AG08532 transformed cell line human CVCL_4K81 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188210 CVCL_4K80 AG08531 finite cell line human CVCL_4K80 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188211 CVCL_4K85 AG08536 transformed cell line human CVCL_4K85 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188212 CVCL_4K84 AG08535 finite cell line human CVCL_4K84 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188213 CVCL_4K83 AG08534 transformed cell line human CVCL_4K83 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188214 CVCL_4K82 AG08533 finite cell line human CVCL_4K82 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188215 CVCL_4K89 AG08542 transformed cell line human CVCL_4K89 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188216 CVCL_4K88 AG08541 finite cell line human CVCL_4K88 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from familial inference) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188217 CVCL_4K87 AG08539 finite cell line human CVCL_4K87 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188218 CVCL_4K86 AG08537 finite cell line human CVCL_4K86 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188219 CVCL_4K92 AG08545 finite cell line human CVCL_4K92 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: German Alzheimer disease kindred subcollection 21188220 CVCL_4K91 AG08544 transformed cell line human CVCL_4K91 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188221 CVCL_4K90 AG08543 finite cell line human CVCL_4K90 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188222 CVCL_4K96 AG08549 finite cell line human CVCL_4K96 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188223 CVCL_4K95 AG08548 transformed cell line human CVCL_4K95 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188224 CVCL_4K94 AG08547 finite cell line human CVCL_4K94 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188225 CVCL_4K93 AG08546 transformed cell line human CVCL_4K93 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188226 CVCL_4K99 AG08552 transformed cell line human CVCL_4K99 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188227 CVCL_4K98 AG08551 finite cell line human CVCL_4K98 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188228 CVCL_4K97 AG08550 transformed cell line human CVCL_4K97 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188229 CVCL_NX29 BayGenomics ES cell line RRU613 embryonic stem cell house mouse CVCL_NX29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916411; Manbal Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188230 CVCL_NX28 BayGenomics ES cell line RRU609 embryonic stem cell house mouse CVCL_NX28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919016; Raver1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188231 CVCL_NX27 BayGenomics ES cell line RRU608 embryonic stem cell house mouse CVCL_NX27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919016; Raver1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188232 CVCL_NX26 BayGenomics ES cell line RRU602 embryonic stem cell house mouse CVCL_NX26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353427; Eif2ak4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188233 CVCL_NX25 BayGenomics ES cell line RRU598 embryonic stem cell house mouse CVCL_NX25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384569; Klhdc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188234 CVCL_NX24 BayGenomics ES cell line RRU593 embryonic stem cell house mouse CVCL_NX24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919782; Sap130 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188235 CVCL_NX23 BayGenomics ES cell line RRU591 embryonic stem cell house mouse CVCL_NX23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1931237; Wwox Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188236 CVCL_NX22 BayGenomics ES cell line RRU590 embryonic stem cell house mouse CVCL_NX22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916977; Usp46 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188237 CVCL_NX21 BayGenomics ES cell line RRU584 embryonic stem cell house mouse CVCL_NX21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860489; Ptbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188238 CVCL_NX20 BayGenomics ES cell line RRU580 embryonic stem cell house mouse CVCL_NX20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2385237; Aimp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188239 CVCL_NX39 BayGenomics ES cell line RRU630 embryonic stem cell house mouse CVCL_NX39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145425; Depdc1b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188240 CVCL_NX38 BayGenomics ES cell line RRU629 embryonic stem cell house mouse CVCL_NX38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1341200; Pwp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188241 CVCL_NX37 BayGenomics ES cell line RRU628 embryonic stem cell house mouse CVCL_NX37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1919045; Pitpnc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188242 CVCL_NX36 BayGenomics ES cell line RRU624 embryonic stem cell house mouse CVCL_NX36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99187; Zfp42 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188243 CVCL_NX35 BayGenomics ES cell line RRU623 embryonic stem cell house mouse CVCL_NX35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913833; Exosc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188244 CVCL_NX34 BayGenomics ES cell line RRU622 embryonic stem cell house mouse CVCL_NX34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2182543; Grhl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188245 CVCL_NX33 BayGenomics ES cell line RRU621 embryonic stem cell house mouse CVCL_NX33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914172; Rras2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188246 CVCL_NX32 BayGenomics ES cell line RRU620 embryonic stem cell house mouse CVCL_NX32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2144117; Smg6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188247 CVCL_NX31 BayGenomics ES cell line RRU618 embryonic stem cell house mouse CVCL_NX31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188248 CVCL_NX30 BayGenomics ES cell line RRU615 embryonic stem cell house mouse CVCL_NX30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923159; Vmp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188249 CVCL_NX09 BayGenomics ES cell line RRU538 embryonic stem cell house mouse CVCL_NX09 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1860197; Wdr7 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188250 CVCL_NX08 BayGenomics ES cell line RRU537 embryonic stem cell house mouse CVCL_NX08 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924705; Rlf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188251 CVCL_NX07 BayGenomics ES cell line RRU533 embryonic stem cell house mouse CVCL_NX07 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915317; Mrnip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188252 CVCL_NX06 BayGenomics ES cell line RRU532 embryonic stem cell house mouse CVCL_NX06 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923876; Msi2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188253 CVCL_NX05 BayGenomics ES cell line RRU530 embryonic stem cell house mouse CVCL_NX05 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932576; Akap12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188254 CVCL_NX04 BayGenomics ES cell line RRU529 embryonic stem cell house mouse CVCL_NX04 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104517; Xrcc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188255 CVCL_NX03 BayGenomics ES cell line RRU528 embryonic stem cell house mouse CVCL_NX03 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:88543; Csnk2a1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188256 CVCL_NX02 BayGenomics ES cell line RRU521 embryonic stem cell house mouse CVCL_NX02 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:106624; Myo9b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188257 CVCL_NX01 BayGenomics ES cell line RRU520 embryonic stem cell house mouse CVCL_NX01 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443111; Abcc4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188258 CVCL_NX00 BayGenomics ES cell line RRU519 embryonic stem cell house mouse CVCL_NX00 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933134; Tusc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188259 CVCL_NX19 BayGenomics ES cell line RRU573 embryonic stem cell house mouse CVCL_NX19 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:101934; Tfdp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188260 CVCL_NX18 BayGenomics ES cell line RRU568 embryonic stem cell house mouse CVCL_NX18 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921633; Ubap2l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188261 CVCL_NX17 BayGenomics ES cell line RRU566 embryonic stem cell house mouse CVCL_NX17 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918952; Cdc5l Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188262 CVCL_NX16 BayGenomics ES cell line RRU563 embryonic stem cell house mouse CVCL_NX16 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95286; Eed Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188263 CVCL_NX15 BayGenomics ES cell line RRU558 embryonic stem cell house mouse CVCL_NX15 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1098597; Ift81 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188264 CVCL_NX14 BayGenomics ES cell line RRU548 embryonic stem cell house mouse CVCL_NX14 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927086; Ube4b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188265 CVCL_NX13 BayGenomics ES cell line RRU546 embryonic stem cell house mouse CVCL_NX13 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95781; Gnb1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188266 CVCL_NX12 BayGenomics ES cell line RRU544 embryonic stem cell house mouse CVCL_NX12 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2682937; Zfp341 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188267 CVCL_NX11 BayGenomics ES cell line RRU543 embryonic stem cell house mouse CVCL_NX11 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:109519; Msh3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188268 CVCL_NX10 BayGenomics ES cell line RRU542 embryonic stem cell house mouse CVCL_NX10 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443805; Bnc2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188269 CVCL_X228 GM00314 finite cell line human CVCL_X228 CL:0000010 Population: Caucasian; Karyotypic information: 45,X/46,X,i(X)(p22) (30%/70%) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21188270 CVCL_X227 GM00230 finite cell line human CVCL_X227 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21188271 CVCL_X226 GM00143 finite cell line human CVCL_X226 CL:0000010 Population: African American; Karyotypic information: 47,XX,+18 (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21188272 CVCL_X225 GM00137 finite cell line human CVCL_X225 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188273 CVCL_X229 GM00339 finite cell line human CVCL_X229 CL:0000010 Population: Caucasian; Karyotypic information: 45,X/46,X,i(X)(p11) (60%/40%) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21188274 CVCL_NW89 BayGenomics ES cell line RRU488 embryonic stem cell house mouse CVCL_NW89 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:107236; Lsg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188275 CVCL_NW88 BayGenomics ES cell line RRU487 embryonic stem cell house mouse CVCL_NW88 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1276108; Birc6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188276 CVCL_NW87 BayGenomics ES cell line RRU486 embryonic stem cell house mouse CVCL_NW87 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1338068; Pdpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188277 CVCL_NW86 BayGenomics ES cell line RRU483 embryonic stem cell house mouse CVCL_NW86 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442377; Ipo11 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188278 CVCL_NW85 BayGenomics ES cell line RRU481 embryonic stem cell house mouse CVCL_NW85 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1888594; Icmt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188279 CVCL_NW84 BayGenomics ES cell line RRU479 embryonic stem cell house mouse CVCL_NW84 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914155; Plin3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188280 CVCL_NW83 BayGenomics ES cell line RRU475 embryonic stem cell house mouse CVCL_NW83 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442782; Baz2b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188281 CVCL_X231 GM00496 finite cell line human CVCL_X231 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21188282 CVCL_NW82 BayGenomics ES cell line RRU473 embryonic stem cell house mouse CVCL_NW82 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913586; Cenpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188283 CVCL_X230 GM00366 finite cell line human CVCL_X230 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,rec(3)(qter->p25::q21->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188284 CVCL_NW81 BayGenomics ES cell line RRU471 embryonic stem cell house mouse CVCL_NW81 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923969; Kansl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188285 CVCL_NW80 BayGenomics ES cell line RRU470 embryonic stem cell house mouse CVCL_NW80 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179288; Rttn Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188286 CVCL_X235 GM00692 finite cell line human CVCL_X235 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188287 CVCL_X234 GM00563 finite cell line human CVCL_X234 CL:0000010 Population: African American; Karyotypic information: 45,X0 (Coriell); Derived from sampling site: Gonad Cell type=Fibroblast.. Female 21188288 CVCL_X233 GM00562 finite cell line human CVCL_X233 CL:0000010 Population: African American; Karyotypic information: 45,X0 [46]; 46,XX [4] (Coriell); Derived from sampling site: Gonad Cell type=Fibroblast.. Female 21188289 CVCL_X232 GM00503 finite cell line human CVCL_X232 CL:0000010 Karyotypic information: 47,XY,+13 [8]; 46,XY,arr(1-22)x2,(X,Y)x1 [11] (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by single cell RNAseq Male 21188290 CVCL_X217 VJ-300 cancer cell line human CVCL_X217 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (KB) has been shown to be a HeLa derivative. 21188291 CVCL_X216 HC-7-5/VCR cancer cell line human CVCL_X216 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Female 21188292 CVCL_X215 HC-7-5 cancer cell line human CVCL_X215 CL:0000010 Female 21188293 CVCL_X214 HC-9 cancer cell line human CVCL_X214 CL:0000010 Female 21188295 CVCL_X218 CMT-1 [Poodle] cancer cell line dog CVCL_X218 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female Doubling time: ~30 hours (PubMed=3462415) 21188296 CVCL_NW99 BayGenomics ES cell line RRU515 embryonic stem cell house mouse CVCL_NW99 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:95742; Glo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188297 CVCL_NW98 BayGenomics ES cell line RRU514 embryonic stem cell house mouse CVCL_NW98 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916401; Lzic Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188298 CVCL_NW97 BayGenomics ES cell line RRU513 embryonic stem cell house mouse CVCL_NW97 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924054; Kdm4c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188299 CVCL_NW96 BayGenomics ES cell line RRU509 embryonic stem cell house mouse CVCL_NW96 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:893577; Stx4a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188300 CVCL_NW95 BayGenomics ES cell line RRU506 embryonic stem cell house mouse CVCL_NW95 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914410; Eef1g Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188301 CVCL_NW94 BayGenomics ES cell line RRU502 embryonic stem cell house mouse CVCL_NW94 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2145597; Mbnl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188302 CVCL_X220 CMT-5 cancer cell line dog CVCL_X220 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Doubling time: ~30 hours (PubMed=3462415) 21188303 CVCL_NW93 BayGenomics ES cell line RRU497 embryonic stem cell house mouse CVCL_NW93 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1932404; Phip Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188304 CVCL_NW92 BayGenomics ES cell line RRU496 embryonic stem cell house mouse CVCL_NW92 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1340806; Parp1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188305 CVCL_NW91 BayGenomics ES cell line RRU493 embryonic stem cell house mouse CVCL_NW91 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918639; Chd6 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188306 CVCL_NW90 BayGenomics ES cell line RRU489 embryonic stem cell house mouse CVCL_NW90 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2138605; Rabif Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188307 CVCL_X224 GM00088 finite cell line human CVCL_X224 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X)(p11.21) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188308 CVCL_X222 GM00017 finite cell line human CVCL_X222 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188309 CVCL_X221 CMT-6 cancer cell line dog CVCL_X221 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Poodle. Female Doubling time: ~24 hours (PubMed=3462415) 21188310 CVCL_X206 L-428 KS cancer cell line human CVCL_X206 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly112_Val122del11 (c.334_366del33); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Adapted to growth in calf serum (PubMed=2690233; PubMed=6303739) 21188311 CVCL_X205 NP460hTert telomerase immortalized cell line human CVCL_X205 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Chinese; Derived from sampling site: Pharynx; nasopharynx; epithelium. Male 21188312 CVCL_X204 NPC-KT hybrid cell line human CVCL_X204 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by RNAseq. Characteristics: Hybrid of an EBV-positive NPC cells from 74 year old Japanese female with Ad-AH cells Doubling time: 24 hours (PubMed=6088881) 21188313 CVCL_X203 D98/HR-1 hybrid cell line human CVCL_X203 CL:0000010 21188314 CVCL_X209 BT-410 cancer cell line human CVCL_X209 CL:0000010 Female 21188315 CVCL_X208 SK-OV-1 cancer cell line human CVCL_X208 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Pleural effusion. Female 21188316 CVCL_X207 L-428 KSA cancer cell line human CVCL_X207 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly112_Val122del11 (c.334_366del33); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Characteristics: Adapted to growth in calf serum and adherent (PubMed=2690233; PubMed=6303739) 21188317 CVCL_NW69 BayGenomics ES cell line RRU450 embryonic stem cell house mouse CVCL_NW69 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1920145; Setd5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188318 CVCL_NW68 BayGenomics ES cell line RRU448 embryonic stem cell house mouse CVCL_NW68 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344352; Dido1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188319 CVCL_NW67 BayGenomics ES cell line RRU446 embryonic stem cell house mouse CVCL_NW67 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918850; Ythdf3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188320 CVCL_NW66 BayGenomics ES cell line RRU445 embryonic stem cell house mouse CVCL_NW66 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1353557; Schip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188321 CVCL_NW65 BayGenomics ES cell line RRU442 embryonic stem cell house mouse CVCL_NW65 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102695; Ptprf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188322 CVCL_NW64 BayGenomics ES cell line RRU439 embryonic stem cell house mouse CVCL_NW64 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:99173; Zfp26 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188323 CVCL_NW63 BayGenomics ES cell line RRU438 embryonic stem cell house mouse CVCL_NW63 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917799; Tln2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188324 CVCL_NW62 BayGenomics ES cell line RRU424 embryonic stem cell house mouse CVCL_NW62 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927224; Yeats4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188325 CVCL_NW61 BayGenomics ES cell line RRU423 embryonic stem cell house mouse CVCL_NW61 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926421; Tcerg1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188326 CVCL_NW60 BayGenomics ES cell line RRU422 embryonic stem cell house mouse CVCL_NW60 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1921446; Ttc27 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188327 CVCL_X213 HC-7 cancer cell line human CVCL_X213 CL:0000010 Female 21188328 CVCL_X212 HC-4 cancer cell line human CVCL_X212 CL:0000010 Female 21188329 CVCL_X211 HC-3 cancer cell line human CVCL_X211 CL:0000010 Female 21188330 CVCL_X210 SA4 [Human glioblastoma] cancer cell line human CVCL_X210 CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Doubling time: 1 day (PubMed=899730) 21188331 CVCL_NW79 BayGenomics ES cell line RRU469 embryonic stem cell house mouse CVCL_NW79 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917856; Zfp398 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188332 CVCL_NW78 BayGenomics ES cell line RRU468 embryonic stem cell house mouse CVCL_NW78 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2142973; Lars2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188333 CVCL_NW77 BayGenomics ES cell line RRU466 embryonic stem cell house mouse CVCL_NW77 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446159; Itpk1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188334 CVCL_NW76 BayGenomics ES cell line RRU465 embryonic stem cell house mouse CVCL_NW76 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:3650650; Zfp534 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188335 CVCL_NW75 BayGenomics ES cell line RRU462 embryonic stem cell house mouse CVCL_NW75 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1344349; Rnf216 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188336 CVCL_NW74 BayGenomics ES cell line RRU459 embryonic stem cell house mouse CVCL_NW74 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442220; Zfp182 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188337 CVCL_NW73 BayGenomics ES cell line RRU458 embryonic stem cell house mouse CVCL_NW73 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1933972; Tra2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188338 CVCL_NW72 BayGenomics ES cell line RRU456 embryonic stem cell house mouse CVCL_NW72 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2652875; Wnk3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188339 CVCL_NW71 BayGenomics ES cell line RRU453 embryonic stem cell house mouse CVCL_NW71 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1928469; Trip4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188340 CVCL_NW70 BayGenomics ES cell line RRU451 embryonic stem cell house mouse CVCL_NW70 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98790; Top2a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188341 CVCL_X202 A2L/AH hybrid cell line human CVCL_X202 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Doubling time: 30 hours (PubMed=6088881) 21188342 CVCL_X201 A2L transformed cell line human CVCL_X201 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Unspecified Doubling time: 26 hours, at 65th passage (PubMed=6088881) 21188343 CVCL_X200 Ad-AH transformed cell line human CVCL_X200 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Pharynx; nasopharynx Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Male Virology: EBV-negative Doubling time: 26 hours, at 59th passage (PubMed=6088881) 21188344 CVCL_NW49 BayGenomics ES cell line RRU402 embryonic stem cell house mouse CVCL_NW49 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:98728; Tgfbr1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188345 CVCL_NW48 BayGenomics ES cell line RRU401 embryonic stem cell house mouse CVCL_NW48 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188346 CVCL_NW47 BayGenomics ES cell line RRU399 embryonic stem cell house mouse CVCL_NW47 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1927868; Pex14 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188347 CVCL_NW46 BayGenomics ES cell line RRU397 embryonic stem cell house mouse CVCL_NW46 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915511; Cep57l1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188348 CVCL_NW45 BayGenomics ES cell line RRU396 embryonic stem cell house mouse CVCL_NW45 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1890773; Actn4 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188349 CVCL_NW44 BayGenomics ES cell line RRU395 embryonic stem cell house mouse CVCL_NW44 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2441849; Lpp Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188350 CVCL_NW43 BayGenomics ES cell line RRU393 embryonic stem cell house mouse CVCL_NW43 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915408; Tecr Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188351 CVCL_NW42 BayGenomics ES cell line RRU391 embryonic stem cell house mouse CVCL_NW42 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1196405; Ctdspl2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188352 CVCL_NW41 BayGenomics ES cell line RRU390 embryonic stem cell house mouse CVCL_NW41 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1099804; Hip1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188353 CVCL_NW40 BayGenomics ES cell line RRU389 embryonic stem cell house mouse CVCL_NW40 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1916610; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188354 CVCL_NW59 BayGenomics ES cell line RRU421 embryonic stem cell house mouse CVCL_NW59 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1914393; Ikzf5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188355 CVCL_NW58 BayGenomics ES cell line RRU419 embryonic stem cell house mouse CVCL_NW58 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2442415; Kat6a Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188356 CVCL_NW57 BayGenomics ES cell line RRU416 embryonic stem cell house mouse CVCL_NW57 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923728; Haus8 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188357 CVCL_NW56 BayGenomics ES cell line RRU415 embryonic stem cell house mouse CVCL_NW56 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1349427; Exo1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188358 CVCL_NW55 BayGenomics ES cell line RRU414 embryonic stem cell house mouse CVCL_NW55 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2443205; Rbm15 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188359 CVCL_NW54 BayGenomics ES cell line RRU412 embryonic stem cell house mouse CVCL_NW54 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1929722; Anapc5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188360 CVCL_NW53 BayGenomics ES cell line RRU410 embryonic stem cell house mouse CVCL_NW53 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1926395; Wtap Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188361 CVCL_NW52 BayGenomics ES cell line RRU408 embryonic stem cell house mouse CVCL_NW52 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1913557; Isoc1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188362 CVCL_NW51 BayGenomics ES cell line RRU407 embryonic stem cell house mouse CVCL_NW51 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1333796; Klf12 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188363 CVCL_NW50 BayGenomics ES cell line RRU403 embryonic stem cell house mouse CVCL_NW50 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1351315; Eloa Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188364 CVCL_NW29 BayGenomics ES cell line RRU364 embryonic stem cell house mouse CVCL_NW29 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:104636; Tle1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188365 CVCL_NW28 BayGenomics ES cell line RRU362 embryonic stem cell house mouse CVCL_NW28 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334446; Rbpms Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188366 CVCL_NW27 BayGenomics ES cell line RRU358 embryonic stem cell house mouse CVCL_NW27 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108088; Gab1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188367 CVCL_NW26 BayGenomics ES cell line RRU357 embryonic stem cell house mouse CVCL_NW26 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384811; Kbtbd2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188368 CVCL_NW25 BayGenomics ES cell line RRU356 embryonic stem cell house mouse CVCL_NW25 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:97758; Prim2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188369 CVCL_NW24 BayGenomics ES cell line RRU354 embryonic stem cell house mouse CVCL_NW24 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918398; Mier1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188370 CVCL_NW23 BayGenomics ES cell line RRU351 embryonic stem cell house mouse CVCL_NW23 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2447364; Smg5 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188371 CVCL_NW22 BayGenomics ES cell line RRU347 embryonic stem cell house mouse CVCL_NW22 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1915295; Rtraf Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188372 CVCL_NW21 BayGenomics ES cell line RRU345 embryonic stem cell house mouse CVCL_NW21 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2179723; Casc3 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188373 CVCL_NW20 BayGenomics ES cell line RRU340 embryonic stem cell house mouse CVCL_NW20 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1201686; Ctbp2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188374 CVCL_NW39 BayGenomics ES cell line RRU388 embryonic stem cell house mouse CVCL_NW39 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:102722; Pcnt Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188375 CVCL_NW38 BayGenomics ES cell line RRU387 embryonic stem cell house mouse CVCL_NW38 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1334460; Bop1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188376 CVCL_NW37 BayGenomics ES cell line RRU386 embryonic stem cell house mouse CVCL_NW37 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1924001; Chd9 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188377 CVCL_NW36 BayGenomics ES cell line RRU380 embryonic stem cell house mouse CVCL_NW36 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2384298; Sbno1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188378 CVCL_NW35 BayGenomics ES cell line RRU379 embryonic stem cell house mouse CVCL_NW35 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1917029; Pphln1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188379 CVCL_NW34 BayGenomics ES cell line RRU377 embryonic stem cell house mouse CVCL_NW34 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1918518; Lrrfip2 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188380 CVCL_NW33 BayGenomics ES cell line RRU372 embryonic stem cell house mouse CVCL_NW33 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:2446526; Cpt1c Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188381 CVCL_NW32 BayGenomics ES cell line RRU369 embryonic stem cell house mouse CVCL_NW32 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:108403; Polr1d Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188382 CVCL_NW31 BayGenomics ES cell line RRU368 embryonic stem cell house mouse CVCL_NW31 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1923714; Knl1 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188383 CVCL_NW30 BayGenomics ES cell line RRU366 embryonic stem cell house mouse CVCL_NW30 CL:0000010 Knockout cell: Method=Gene trap; MGI; MGI:1922855; Kdm5b Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male 21188384 CVCL_4K63 AG08512 transformed cell line human CVCL_4K63 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188385 CVCL_4K62 AG08511 finite cell line human CVCL_4K62 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188386 CVCL_4K61 AG08509 finite cell line human CVCL_4K61 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188387 CVCL_4K60 AG08507 finite cell line human CVCL_4K60 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188388 CVCL_4K67 AG08516 transformed cell line human CVCL_4K67 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188389 CVCL_4K66 AG08515 finite cell line human CVCL_4K66 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188390 CVCL_4K65 AG08514 transformed cell line human CVCL_4K65 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188391 CVCL_4K64 AG08513 finite cell line human CVCL_4K64 CL:0000010 Population: Caucasian; German; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188392 CVCL_4K69 AG08518 transformed cell line human CVCL_4K69 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188393 CVCL_4K68 AG08517 finite cell line human CVCL_4K68 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188394 CVCL_4K70 AG08520 transformed cell line human CVCL_4K70 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188395 CVCL_4K74 AG08525 finite cell line human CVCL_4K74 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188396 CVCL_4K73 AG08524 transformed cell line human CVCL_4K73 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188397 CVCL_4K72 AG08523 finite cell line human CVCL_4K72 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188398 CVCL_4K71 AG08522 transformed cell line human CVCL_4K71 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from autologous cell line AG08523) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188399 CVCL_4K78 AG08529 finite cell line human CVCL_4K78 CL:0000010 Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: German Alzheimer disease kindred subcollection 21188400 CVCL_4K77 AG08528 transformed cell line human CVCL_4K77 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188401 CVCL_4K76 AG08527 finite cell line human CVCL_4K76 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: German Alzheimer disease kindred subcollection 21188402 CVCL_4K75 AG08526 transformed cell line human CVCL_4K75 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Leu286Val (c.856C>G); ClinVar=VCV000018126; Zygosity=Unspecified (from autologous cell line AG08527) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188403 CVCL_4K79 AG08530 transformed cell line human CVCL_4K79 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: German Alzheimer disease kindred subcollection 21188404 CVCL_4K41 AG08259 finite cell line human CVCL_4K41 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21188405 CVCL_4K40 AG08258 transformed cell line human CVCL_4K40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188406 CVCL_4K45 AG08266 transformed cell line human CVCL_4K45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188407 CVCL_4K44 AG08265 finite cell line human CVCL_4K44 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188408 CVCL_4K43 AG08264 transformed cell line human CVCL_4K43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188409 CVCL_4K42 AG08260 finite cell line human CVCL_4K42 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188410 CVCL_4K49 AG08374 transformed cell line human CVCL_4K49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21188411 CVCL_4K48 AG08311 transformed cell line human CVCL_4K48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188412 CVCL_4K47 AG08269 finite cell line human CVCL_4K47 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188413 CVCL_4K46 AG08268 transformed cell line human CVCL_4K46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188414 CVCL_4K39 AG08257 transformed cell line human CVCL_4K39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188415 CVCL_X293 GM03576 finite cell line human CVCL_X293 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM03576; probable Male 21188416 CVCL_X292 GM03563 finite cell line human CVCL_X292 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188417 CVCL_X291 GM03543 transformed cell line human CVCL_X291 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188418 CVCL_X290 GM03538 finite cell line human CVCL_X290 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+18 (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188419 CVCL_X297 GM03648 finite cell line human CVCL_X297 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188420 CVCL_X296 GM03647 finite cell line human CVCL_X296 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,der(6)(6qter->6p25::1q32->1qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188421 CVCL_X295 GM03623 finite cell line human CVCL_X295 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188422 CVCL_X294 GM03577 finite cell line human CVCL_X294 CL:0000010 Population: Caucasian; Karyotypic information: 45,XY,der(3)(3pter->3q29::22q11->22qter),-22 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188423 CVCL_X299 GM03769 finite cell line human CVCL_X299 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21188424 CVCL_X298 GM03689 finite cell line human CVCL_X298 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21188425 CVCL_4K52 AG08378 transformed cell line human CVCL_4K52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188426 CVCL_4K51 AG08376 transformed cell line human CVCL_4K51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188427 CVCL_4K50 AG08375 finite cell line human CVCL_4K50 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188428 CVCL_4K56 AG08440 transformed cell line human CVCL_4K56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Male 21188429 CVCL_4K55 AG08381 finite cell line human CVCL_4K55 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188430 CVCL_4K54 AG08380 transformed cell line human CVCL_4K54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188431 CVCL_4K53 AG08379 finite cell line human CVCL_4K53 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188432 CVCL_4K59 AG08506 transformed cell line human CVCL_4K59 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: German Alzheimer disease kindred subcollection 21188433 CVCL_4K58 AG08446 finite cell line human CVCL_4K58 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (PubMed=10408806; PubMed=24416243) Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188434 CVCL_4K57 AG08445 transformed cell line human CVCL_4K57 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from autologous cell line AG08446) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188435 CVCL_X282 GM03255 finite cell line human CVCL_X282 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21188436 CVCL_X281 GM03241 finite cell line human CVCL_X281 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188437 CVCL_X280 GM03184 finite cell line human CVCL_X280 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188438 CVCL_X286 GM03435 finite cell line human CVCL_X286 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Male 21188439 CVCL_X285 GM03369 finite cell line human CVCL_X285 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188440 CVCL_X284 GM03330 finite cell line human CVCL_X284 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21188441 CVCL_X283 GM03268 finite cell line human CVCL_X283 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21188442 CVCL_X289 GM03518 finite cell line human CVCL_X289 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188443 CVCL_X288 GM03493 finite cell line human CVCL_X288 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188444 CVCL_X287 GM03462 finite cell line human CVCL_X287 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188445 CVCL_X269 GM02596 finite cell line human CVCL_X269 CL:0000010 Population: African American; Karyotypic information: 47,XX,+8 [29]; 46,XX [21]; mosaic (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by single cell RNAseq Female 21188446 CVCL_4K23 AG08124 transformed cell line human CVCL_4K23 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188447 CVCL_4K22 AG08112 finite cell line human CVCL_4K22 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188448 CVCL_4K21 AG08111 transformed cell line human CVCL_4K21 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21188449 CVCL_4K20 AG08110 finite cell line human CVCL_4K20 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (PubMed=10408806) Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188450 CVCL_4K27 AG08136 transformed cell line human CVCL_4K27 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188451 CVCL_4K26 AG08127 finite cell line human CVCL_4K26 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188452 CVCL_4K25 AG08126 transformed cell line human CVCL_4K25 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21188453 CVCL_4K24 AG08125 finite cell line human CVCL_4K24 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) 21188454 CVCL_4K19 AG08109 transformed cell line human CVCL_4K19 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from autologous cell line AG08110) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188455 CVCL_4K18 AG08064 finite cell line human CVCL_4K18 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from familial inference) Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188456 CVCL_4K17 AG08063 transformed cell line human CVCL_4K17 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Met146Leu (c.436A>C); ClinVar=VCV000018123; Zygosity=Unspecified (from familial inference) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188457 CVCL_X271 GM02732 finite cell line human CVCL_X271 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02732; probable Male 21188458 CVCL_X270 GM02729 finite cell line human CVCL_X270 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+der(15)(15pter->15q13::15p11->15pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188459 CVCL_X275 GM02948 finite cell line human CVCL_X275 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM02948; probable Male 21188460 CVCL_X274 GM02944 finite cell line human CVCL_X274 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188461 CVCL_X273 GM02836 finite cell line human CVCL_X273 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21188462 CVCL_X272 GM02813 finite cell line human CVCL_X272 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,+13,der(13;15)(13qter->q10::q10->15qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188463 CVCL_X279 GM03089 finite cell line human CVCL_X279 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188464 CVCL_X278 GM03085 finite cell line human CVCL_X278 CL:0000010 Population: Caucasian; French Canadian; Karyotypic information: 46,XY,rec(3)(qter->p25::q21->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188465 CVCL_X277 GM03084 finite cell line human CVCL_X277 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM03084; probable Male 21188466 CVCL_X276 GM03039 finite cell line human CVCL_X276 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,rec(3)(qter->p25::q21->qter)pat (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188467 CVCL_X259 GM02030 finite cell line human CVCL_X259 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188468 CVCL_X258 GM01849 finite cell line human CVCL_X258 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188469 CVCL_4K30 AG08139 finite cell line human CVCL_4K30 CL:0000010 Population: Caucasian; Italian; Karyotypic information: 46,XY,t(1;5)(1qter->1p13::5p13->5pter::5qter->5p13::1p13->1pter) [2]; 46,XY [48] (Coriell); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) 21188470 CVCL_4K34 AG08143 transformed cell line human CVCL_4K34 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188471 CVCL_4K33 AG08142 transformed cell line human CVCL_4K33 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188472 CVCL_4K32 AG08141 finite cell line human CVCL_4K32 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188473 CVCL_4K31 AG08140 transformed cell line human CVCL_4K31 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188474 CVCL_4K38 AG08245 finite cell line human CVCL_4K38 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21188475 CVCL_4K37 AG08244 transformed cell line human CVCL_4K37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188476 CVCL_4K36 AG08243 finite cell line human CVCL_4K36 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188477 CVCL_4K35 AG08242 transformed cell line human CVCL_4K35 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188478 CVCL_4K29 AG08138 transformed cell line human CVCL_4K29 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188479 CVCL_4K28 AG08137 finite cell line human CVCL_4K28 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188480 CVCL_X260 GM02103 finite cell line human CVCL_X260 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;Y)(q11;q11) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21188481 CVCL_X264 GM02469 finite cell line human CVCL_X264 CL:0000010 Karyotypic information: 46,X,der(X)(Xpter->Xq22::Yq11->Yqter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188482 CVCL_X263 GM02329 finite cell line human CVCL_X263 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+9 [5]; 46,XX [45] (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188483 CVCL_X262 GM02325 finite cell line human CVCL_X262 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+der(22)(22pter->22q11.21::16p13.11->16pter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188484 CVCL_X261 GM02324 transformed cell line human CVCL_X261 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,9qh+,t(16;22)(16qter->16p13.11::22q11.21->22qter;22pter->22q11.21::16p13.11->16pter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188485 CVCL_X268 GM02595 finite cell line human CVCL_X268 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X)(q10) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21188486 CVCL_X267 GM02524 finite cell line human CVCL_X267 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+21 [41]; 46,XY,dic(21;21)(pter->q21::p12->qter) [9] (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188487 CVCL_X266 GM02521 finite cell line human CVCL_X266 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM02521; probable Male 21188488 CVCL_X265 GM02488 finite cell line human CVCL_X265 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21188489 CVCL_X249 GM01524 finite cell line human CVCL_X249 CL:0000010 Population: African American; Karyotypic information: 46,XY,der(5)(5pter->5q33::6q15->6q25::5q33->5qter)mat (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188490 CVCL_X248 GM01441 finite cell line human CVCL_X248 CL:0000010 Population: Caucasian; Derived from sampling site: Testis Cell type=Fibroblast.. Male 21188491 CVCL_X247 GM01429 finite cell line human CVCL_X247 CL:0000010 Population: African American; Karyotypic information: 46,X,t(X;9)(q13;q34) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21188492 CVCL_4K01 AG07888 transformed cell line human CVCL_4K01 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male 21188493 CVCL_4K00 AG07887 finite cell line human CVCL_4K00 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188494 CVCL_4K05 AG07927 transformed cell line human CVCL_4K05 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21188495 CVCL_4K04 AG07926 finite cell line human CVCL_4K04 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188496 CVCL_4K03 AG07925 transformed cell line human CVCL_4K03 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188497 CVCL_4K02 AG07889 finite cell line human CVCL_4K02 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188498 CVCL_X253 GM01723 finite cell line human CVCL_X253 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21188499 CVCL_X252 GM01709 finite cell line human CVCL_X252 CL:0000010 Population: Caucasian; Derived from sampling site: Gonad Cell type=Fibroblast.. Omics: CNV analysis Ambiguous 21188500 CVCL_X251 GM01564 finite cell line human CVCL_X251 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188501 CVCL_X250 GM01535 finite cell line human CVCL_X250 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188502 CVCL_X257 GM01848 finite cell line human CVCL_X257 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188503 CVCL_X256 GM01750 finite cell line human CVCL_X256 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188504 CVCL_X255 GM01734 finite cell line human CVCL_X255 CL:0000010 Karyotypic information: 46,XY,+der(9)(9pter->9q12::15q11->15qter)mat,-15 (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21188505 CVCL_X254 GM01724 finite cell line human CVCL_X254 CL:0000010 Population: Caucasian; Derived from sampling site: Uterus. Discontinued: Coriell; GM01724; probable Female 21188506 CVCL_X239 GM00980 finite cell line human CVCL_X239 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188507 CVCL_X238 GM00860 finite cell line human CVCL_X238 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM00860; probable Female 21188508 CVCL_X237 GM00857 finite cell line human CVCL_X237 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21188509 CVCL_X236 GM00734 finite cell line human CVCL_X236 CL:0000010 Karyotypic information: 47,XX,+18 (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21188510 CVCL_4K12 AG07935 transformed cell line human CVCL_4K12 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188511 CVCL_4K11 AG07934 finite cell line human CVCL_4K11 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21188512 CVCL_4K10 AG07933 transformed cell line human CVCL_4K10 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male 21188513 CVCL_4K16 AG08027 transformed cell line human CVCL_4K16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188514 CVCL_4K15 AG08026 finite cell line human CVCL_4K15 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG08026; probable Male 21188515 CVCL_4K14 AG08025 transformed cell line human CVCL_4K14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Male 21188516 CVCL_4K13 AG07936 finite cell line human CVCL_4K13 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188517 CVCL_4K09 AG07931 transformed cell line human CVCL_4K09 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but at risk for disease; Derived from sampling site: Peripheral blood. Female 21188518 CVCL_4K08 AG07930 finite cell line human CVCL_4K08 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188519 CVCL_4K07 AG07929 transformed cell line human CVCL_4K07 CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female 21188520 CVCL_4K06 AG07928 finite cell line human CVCL_4K06 CL:0000010 Population: Caucasian; Italian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21188521 CVCL_X242 GM01183 finite cell line human CVCL_X242 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188522 CVCL_X241 GM01176 finite cell line human CVCL_X241 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21188523 CVCL_X240 GM00983 finite cell line human CVCL_X240 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21188524 CVCL_X246 GM01414 finite cell line human CVCL_X246 CL:0000010 Population: African American; Karyotypic information: 46,X,der(9)t(X;9)(q34;q12) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21188525 CVCL_X245 GM01399 finite cell line human CVCL_X245 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188526 CVCL_X244 GM01221 finite cell line human CVCL_X244 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21188527 CVCL_X243 GM01201 transformed cell line human CVCL_X243 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21188528 CVCL_4U10 Sf900+ spontaneously immortalized cell line CVCL_4U10 CL:0000010 Derived from sampling site: Ovary. Biotechnology: Used for the production of the porcine circovirus type 2 (PCV2) vaccine CircoFLEX Used to produce the PCV2 ORF2 capsid protein (PubMed=29133148). Female Group: Insect cell line; Group: Patented cell line; Group: Recombinant protein production insect cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12579 21188529 CVCL_5610 XTC-2 spontaneously immortalized cell line African clawed frog CVCL_5610 CL:0000010 Karyotypic information: Diploid karyotype (PubMed=4708349); Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Not susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=33389257) Doubling time: ~24 hours (DOI=10.17037/PUBS.04656048) Group: Amphibian cell line Caution: According to RCB RCB0771 XTC-YF and XTC-2 are identical 21188530 CVCL_4U14 DWFb1-rho0 transformed cell line human CVCL_4U14 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin. Omics: Transcriptome analysis by microarray Characteristics: Cell line devoid of mitochondrial DNA (rho0) Doubling time: 23.09 hours (PubMed=15913645) 21188531 CVCL_5614 ZR-75-B cancer cell line human CVCL_5614 HLA typing: B*35:01,35:01; C*04:01,04:01; DQB1*05:01,05:01 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 30.5 hours (PubMed=8562478; PubMed=9815641); 44.80 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21188532 CVCL_4U13 SV-BR-1-GM cancer cell line human CVCL_4U13 CL:0000010 Transfected with: HGNC; 2434; CSF2 Derived from metastatic site: Chest wall. Female Characteristics: ER/PR-negative and ERBB2-positive Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7813 21188533 CVCL_5613 ZR-75-9a1 cancer cell line human CVCL_5613 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Ascites. Female 21188534 CVCL_4U12 SV-BR-1 cancer cell line human CVCL_4U12 CL:0000010 Derived from metastatic site: Chest wall. Female Characteristics: ER/PR-negative and ERBB2-positive Doubling time: 48 hours (Patent=US7674456) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-7812 21188535 CVCL_5612 ZR-75-27 cancer cell line human CVCL_5612 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 144 hours, at 14th passage (PubMed=688225) 21188536 CVCL_4U11 3T3-M2 spontaneously immortalized cell line house mouse CVCL_4U11 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male Caution: Could be identical to 3T3-C2 (Cellosaurus=CVCL_0121) 21188537 CVCL_5611 XTY cancer cell line African clawed frog CVCL_5611 CL:0000010 Derived from sampling site: Back; hypodermis. Female Doubling time: 75.5 hours (PubMed=1737584) Group: Amphibian cell line 21188538 CVCL_4U18 AC16 [Human hybrid cardiomyocyte] hybrid cell line human CVCL_4U18 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; ventricle Cell type=Cardiomyocyte.. Characteristics: Hybrid of adult ventricular cardiomiocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645); Characteristics: Can differentiate when cultured in mitogen-free medium The cells may be used to study developmental regulation of cardiomyocytes (Millipore). Doubling time: 24.49 hours (PubMed=15913645) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1500 21188539 CVCL_4U17 AC12 hybrid cell line human CVCL_4U17 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; ventricle Cell type=Cardiomyocyte.. Characteristics: Hybrid of adult ventricular cardiomiocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645) 21188540 CVCL_5617 DU528 cancer cell line human CVCL_5617 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2144611) Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Doubling time: 48-72 hours (PubMed=4056659); 40 hours (PubMed=17117183) 21188541 CVCL_4U16 AC10 hybrid cell line human CVCL_4U16 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; ventricle Cell type=Cardiomyocyte.. Characteristics: Hybrid of adult ventricular cardiomiocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1501 21188542 CVCL_5616 KYM-1D4 cancer cell line human CVCL_5616 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Neck. Male Problematic cell line: Possibly misclassified It is not certain that the parent cell line originate from a alveolar rhabdomyosarcoma (ARMS). It lacks the PAXA3-FOXO1 gene fusion characteristics of ARMS. Many papers classify it as an embryonal rhabdomyosarcoma (ERMS) and we accordingly describe it as such. 21188543 CVCL_4U15 AC1 [Human hybrid cardiomyocyte] hybrid cell line human CVCL_4U15 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Heart; ventricle Cell type=Cardiomyocyte.. Characteristics: Hybrid of adult ventricular cardiomiocytes with a SV40 transformed, uridine auxotroph human fibroblast cell line devoid of mitochondrial DNA (PubMed=15913645) 21188544 CVCL_5615 Flow1000 finite cell line human CVCL_5615 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Unspecified 21188545 CVCL_5619 MEL-CLS-1 cancer cell line human CVCL_5619 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from metastatic site: Iliac lymph node. Female Characteristics: Established from a xenograft (CLS) Doubling time: 38 hours, at 49th passage (PubMed=994214) 21188546 CVCL_4U19 RL14 hybrid cell line human CVCL_4U19 CL:0000010 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-1499. 21188547 CVCL_4U21 BHK-MS-HA16 spontaneously immortalized cell line CVCL_4U21 CL:0000010 Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-12461 21188548 CVCL_5621 INER-37 cancer cell line human CVCL_5621 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: SNP array analysis Unspecified Doubling time: 30 hours (PubMed=16271071); 79 hours (PubMed=26221079) 21188549 CVCL_4U20 BHK-M spontaneously immortalized cell line CVCL_4U20 CL:0000010 Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4506 21188550 CVCL_5620 HM3KO cancer cell line human CVCL_5620 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21188551 CVCL_5625 MNT-3 cancer cell line human CVCL_5625 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21188552 CVCL_4U25 SQ-Mitox-BCRP cancer cell line human CVCL_4U25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male 21188553 CVCL_4U24 44-3 cancer cell line Norway rat CVCL_4U24 CL:0000010 Derived from sampling site: Thyroid gland Cell type=Parafollicular cell.; Breed/subspecies: WAG/Rij. Unspecified 21188554 CVCL_5624 MNT-1 cancer cell line human CVCL_5624 CL:0000010 Derived from metastatic site: Lymph node. Unspecified Characteristics: Highly pigmented; Virology: Susceptible to infection by human metapneumovirus (MNPV) (PubMed=28940687) 21188555 CVCL_4U23 CA5171 cancer cell line human CVCL_4U23 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=25394645); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Tyr27Cys (c.80A>G); ClinVar=VCV000404160; Zygosity=Unspecified (PubMed=25394645); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Unspecified (PubMed=25394645) Omics: SNP array analysis. Female Doubling time: ~24 hours (PubMed=25394645) 21188556 CVCL_5623 INER-51/VP-1 cancer cell line human CVCL_5623 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pleural effusion. 21188557 CVCL_4U22 HEK-SC-293T transformed cell line human CVCL_4U22 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-12593 21188558 CVCL_5622 INER-51/PSC-1 cancer cell line human CVCL_5622 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. 21188559 CVCL_5629 FLS4.1 stromal cell line house mouse CVCL_5629 CL:0000010 Derived from sampling site: Embryonic liver; stroma; Breed/subspecies: BALB/c. Unspecified 21188560 CVCL_4U29 MZ-GC-2 cancer cell line human CVCL_4U29 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 45 hours (PubMed=7599790) 21188561 CVCL_4U28 MZ-GC-1 cancer cell line human CVCL_4U28 CL:0000010 Derived from metastatic site: Liver. Male Doubling time: 7 days (PubMed=7599790) 21188562 CVCL_5628 NB-1691 cancer cell line human CVCL_5628 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058) Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Unspecified 21188563 CVCL_5627 NB-1643 cancer cell line human CVCL_5627 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359; PubMed=28350380; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9802058) Omics: ATAC-seq; Omics: Deep exome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 43 hours (PubMed=20922763) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel 21188564 CVCL_4U27 NT2-D3 cancer cell line human CVCL_4U27 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male 21188565 CVCL_5626 MRN-1 cancer cell line human CVCL_5626 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21188566 CVCL_4U26 SQ-Mitox-MDR cancer cell line human CVCL_4U26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male 21188567 CVCL_4U03 SK-MEL-129 cancer cell line human CVCL_4U03 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188568 CVCL_5603 TOM-2 cancer cell line human CVCL_5603 CL:0000010 Population: Japanese; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from metastatic site: Lymph node. Female Doubling time: 83 hours (PubMed=9590502) 21188569 CVCL_4U02 SK-MEL-125 cancer cell line human CVCL_4U02 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188570 CVCL_5602 TN-2 cancer cell line human CVCL_5602 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male Doubling time: 48 hours (PubMed=2486612) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21188571 CVCL_4U01 SK-MEL-123 cancer cell line human CVCL_4U01 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188572 CVCL_5601 TLR3 conditionally immortalized cell line house mouse CVCL_5601 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21188573 CVCL_4U00 SK-MEL-122 cancer cell line human CVCL_4U00 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188574 CVCL_5600 TLR2 conditionally immortalized cell line house mouse CVCL_5600 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21188575 CVCL_4U07 SK-MEL-139 cancer cell line human CVCL_4U07 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188576 CVCL_5607 WSU-AML cancer cell line human CVCL_5607 CL:0000010 Sequence variation: Gene fusion; HGNC; 1537; CBFA2T3 + HGNC; 29450; GLIS2; Name(s)=CBFA2T3-GLIS2, ETO2-GLIS2 (PubMed=28109323) Derived from sampling site: Peripheral blood. 21188577 CVCL_4U06 SK-MEL-104 cancer cell line human CVCL_4U06 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188578 CVCL_5606 WR216 transformed cell line human CVCL_5606 CL:0000010 Sequence variation: Mutation; HGNC; 626; APRT; Simple; p.Lys88Profs*23 (c.258_261dupCCGA); ClinVar=VCV000018299; Zygosity=Homozygous; Note=APRT*Q0 allele (RCB) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21188579 CVCL_4U05 SK-MEL-102 cancer cell line human CVCL_4U05 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188580 CVCL_5605 WI-38 Tr spontaneously immortalized cell line human CVCL_5605 CL:0000010 Population: Caucasian; Swedish; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21188581 CVCL_4U04 SK-MEL-132 cancer cell line human CVCL_4U04 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188582 CVCL_5604 WBE spontaneously immortalized cell line CVCL_5604 CL:0000010 Unspecified Group: Fish cell line. 21188583 CVCL_4U09 SK-MEL-177 cancer cell line human CVCL_4U09 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188584 CVCL_5609 WSU-WM cancer cell line human CVCL_5609 CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: ~16 hours (PubMed=8499639) Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11586 21188585 CVCL_4U08 SK-MEL-162 cancer cell line human CVCL_4U08 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21188586 CVCL_5608 WSU-Pre-B-ALL cancer cell line human CVCL_5608 CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: BioIVT/Asterand Bioscience; Catalog number WSU-Pre-B-ALL Female 21188587 CVCL_5698 BALM-21 cancer cell line human CVCL_5698 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 23 hours (PubMed=12703546) 21188588 CVCL_4U98 HMF3C conditionally immortalized cell line human CVCL_4U98 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 21188589 CVCL_5697 BALM-20 cancer cell line human CVCL_5697 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 36 hours (PubMed=12703546) 21188590 CVCL_4U97 HMF3B conditionally immortalized cell line human CVCL_4U97 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 21188591 CVCL_5696 BALM-2 cancer cell line human CVCL_5696 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male 21188592 CVCL_4U96 HMF3A conditionally immortalized cell line human CVCL_4U96 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21188593 CVCL_5695 BALM-19 cancer cell line human CVCL_5695 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 36 hours (PubMed=12703546) 21188594 CVCL_4U95 HBMEC/cibeta conditionally immortalized cell line human CVCL_4U95 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; endothelium Cell type=Brain microvascular endothelial cell.. Omics: Deep quantitative membrane proteome analysis Unspecified 21188595 CVCL_5699 BALM-22 cancer cell line human CVCL_5699 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 80 hours (PubMed=12703546) 21188596 CVCL_4U99 HMF3D conditionally immortalized cell line human CVCL_4U99 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 21188597 CVCL_5683 AH130FN-TC cancer cell line Norway rat CVCL_5683 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21188598 CVCL_4U83 Lipo624 finite cell line human CVCL_4U83 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188599 CVCL_5682 HCT-8/S11 cancer cell line human CVCL_5682 CL:0000010 Male 21188600 CVCL_4U82 Lipo601 finite cell line human CVCL_4U82 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188601 CVCL_5681 EL4.IL-2 cancer cell line house mouse CVCL_5681 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Characteristics: Produces IL2 in response to phorbol-12-myristate-13-acetate (PMA) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21188602 CVCL_4U81 Lipo585 finite cell line human CVCL_4U81 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188603 CVCL_5680 EL4.BU.1.OUAr.1.1 cancer cell line house mouse CVCL_5680 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21188604 CVCL_4U80 Lipo573 cancer cell line human CVCL_4U80 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188605 CVCL_4U76 Lipo314 finite cell line human CVCL_4U76 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188606 CVCL_5676 NALM-37 cancer cell line human CVCL_5676 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Female 21188607 CVCL_4U75 Lipo276 finite cell line human CVCL_4U75 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188608 CVCL_5675 NALM-36KL cancer cell line human CVCL_5675 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Characteristics: Expresses both kappa and lambda light chains 21188609 CVCL_4U74 Lipo256 cancer cell line human CVCL_4U74 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188610 CVCL_5674 NALM-36 cancer cell line human CVCL_5674 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: 48 hours (PubMed=11734297) 21188611 CVCL_4U73 Lipo246 cancer cell line human CVCL_4U73 CL:0000010 Derived from sampling site: Retroperitoneal space. Male Doubling time: ~1.7 days (PubMed=26373732) 21188612 CVCL_5673 NALM-35 cancer cell line human CVCL_5673 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female Doubling time: ~48 hours (PubMed=12889857) 21188613 CVCL_5679 HCT-8/E11 cancer cell line human CVCL_5679 CL:0000010 Male 21188614 CVCL_4U79 Lipo514 finite cell line human CVCL_4U79 CL:0000010 Derived from sampling site: Abdomen. Male 21188615 CVCL_4U78 Lipo502 finite cell line human CVCL_4U78 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188616 CVCL_5678 ZEM-2 spontaneously immortalized cell line zebrafish CVCL_5678 CL:0000010 Unspecified Group: Fish cell line. 21188617 CVCL_4U77 Lipo355 finite cell line human CVCL_4U77 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188618 CVCL_5677 NALM-7 cancer cell line human CVCL_5677 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21188619 CVCL_5690 BALM-12 cancer cell line human CVCL_5690 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188620 CVCL_4U90 USP-13-Med cancer cell line human CVCL_4U90 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=26358937) Omics: CNV analysis; Omics: Transcriptome analysis by microarray. Male Doubling time: 24.5 hours (PubMed=26358937) 21188621 CVCL_5694 BALM-18 cancer cell line human CVCL_5694 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Virology: EBV-negative Doubling time: 36 hours (PubMed=10374849) 21188622 CVCL_4U94 PLS-1 cancer cell line human CVCL_4U94 CL:0000010 Male Doubling time: ~1.6 days (PubMed=26373732). 21188623 CVCL_5693 BALM-16 cancer cell line human CVCL_5693 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Virology: EBV-negative Doubling time: 32 hours (PubMed=9447837) 21188624 CVCL_4U93 ZQNK-29 cancer cell line human CVCL_4U93 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 35.6 hours (PubMed=26299072) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201278 21188625 CVCL_4U92 AMJ13 cancer cell line human CVCL_4U92 CL:0000010 Population: Iraqi; Derived from sampling site: Breast. Female Doubling time: 22 hours (PubMed=26300657) 21188626 CVCL_5692 BALM-14 cancer cell line human CVCL_5692 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male 21188627 CVCL_5691 BALM-13 cancer cell line human CVCL_5691 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow Cell type=B-cell.. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21188628 CVCL_4U91 FUHEN transformed cell line CVCL_4U91 CL:0000010 Transformant: X-Ray(NCIt; C17262). Unspecified Group: Amphibian cell line 21188629 CVCL_5687 BALM-1 cancer cell line human CVCL_5687 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21188630 CVCL_4U87 Lipo815 cancer cell line human CVCL_4U87 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188631 CVCL_5686 ASB-XIV cancer cell line house mouse CVCL_5686 CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Unspecified Doubling time: ~70 hours (CLS=400120) 21188632 CVCL_4U86 Lipo723 finite cell line human CVCL_4U86 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188633 CVCL_5685 ASB-XIII cancer cell line house mouse CVCL_5685 CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Lung; Breed/subspecies: BALB/c. Unspecified 21188634 CVCL_4U85 Lipo675 finite cell line human CVCL_4U85 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188635 CVCL_4U84 Lipo651 finite cell line human CVCL_4U84 CL:0000010 Derived from sampling site: Abdomen. Male 21188636 CVCL_5689 BALM-11 cancer cell line human CVCL_5689 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188637 CVCL_4U89 Lipo956 finite cell line human CVCL_4U89 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188638 CVCL_5688 BALM-10 cancer cell line human CVCL_5688 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188639 CVCL_4U88 Lipo863 cancer cell line human CVCL_4U88 CL:0000010 Derived from sampling site: Retroperitoneal space. Male 21188640 CVCL_4U61 AH1091B-TC cancer cell line Norway rat CVCL_4U61 CL:0000010 Derived from metastatic site: Ascites. 21188641 CVCL_5661 NALM-18 cancer cell line human CVCL_5661 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21188642 CVCL_5660 NALM-12 cancer cell line human CVCL_5660 HLA typing: A*01,02; B*15 (PubMed=2939141) CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21188643 CVCL_4U60 YS-TM-R-TC cancer cell line Norway rat CVCL_4U60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:34638; Chromomycin A3; Derived from metastatic site: Ascites. 21188644 CVCL_5654 TBM-54 spontaneously immortalized cell line CVCL_5654 CL:0000010 Derived from sampling site: Urinary bladder Cell type=Epithelial cell.. Unspecified Group: Amphibian cell line 21188645 CVCL_4U54 Yoshida sarcoma cancer cell line Norway rat CVCL_4U54 CL:0000010 Miscellaneous: This is not a cell line but a xenograft, it is the parent tumor for many cell lines Derived from metastatic site: Ascites. 21188646 CVCL_5653 3LL cancer cell line house mouse CVCL_5653 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Doubling time: ~2 days (lot 07112016), ~33 hours (lot 08232018) (JCRB) Caution: Could be identical to LL/2 (LLC1) (Cellosaurus=CVCL_4358) 21188647 CVCL_4U53 AH130/5A cancer cell line Norway rat CVCL_4U53 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21188648 CVCL_4U52 HROG63 cancer cell line human CVCL_4U52 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left temporal lobe. Male 21188649 CVCL_5652 SK-MEL-93 DX-2 cancer cell line human CVCL_5652 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Hypodermis. Female 21188650 CVCL_4U51 HROG59 cancer cell line human CVCL_4U51 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; right temporal lobe. Male 21188651 CVCL_5651 SK-MEL-93 DX-1 cancer cell line human CVCL_5651 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Left thigh; hypodermis. Female 21188652 CVCL_5658 C6/lacZ7 cancer cell line Norway rat CVCL_5658 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male 21188653 CVCL_4U58 YS-G-TC cancer cell line Norway rat CVCL_4U58 CL:0000010 Selected for resistance to: ChEBI; CHEBI:82354; Nitrogen mustard N-oxide; Derived from metastatic site: Ascites. 21188654 CVCL_5657 C6/lacZ cancer cell line Norway rat CVCL_5657 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male 21188655 CVCL_4U57 YS-EX-R-TC cancer cell line Norway rat CVCL_4U57 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Derived from metastatic site: Ascites. 21188656 CVCL_5656 9L/lacZ cancer cell line Norway rat CVCL_5656 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21188657 CVCL_4U56 YS-DM-R-TC cancer cell line Norway rat CVCL_4U56 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from metastatic site: Ascites. 21188658 CVCL_5655 XLK-WG finite cell line African clawed frog CVCL_5655 CL:0000010 Derived from sampling site: Kidney. Female Group: Amphibian cell line 21188659 CVCL_4U55 YS-6MP-R-TC cancer cell line Norway rat CVCL_4U55 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Derived from metastatic site: Ascites. 21188660 CVCL_5659 G355-5 finite cell line CVCL_5659 CL:0000010 Derived from sampling site: Fetal brain Cell type=Astrocyte.. Unspecified 21188661 CVCL_4U59 YS-MC-R-TC cancer cell line Norway rat CVCL_4U59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; Derived from metastatic site: Ascites. 21188662 CVCL_4U72 Lipo224 cancer cell line human CVCL_4U72 CL:0000010 Derived from sampling site: Pelvis. Female 21188663 CVCL_5672 NALM-34 cancer cell line human CVCL_5672 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 72 hours (PubMed=10609789) 21188664 CVCL_4U71 Lipo203 cancer cell line human CVCL_4U71 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188665 CVCL_5671 NALM-33 cancer cell line human CVCL_5671 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 72 hours (PubMed=10609789); ~48 hours (DSMZ=ACC-782) 21188666 CVCL_4U70 Lipo191 finite cell line human CVCL_4U70 CL:0000010 Derived from sampling site: Retroperitoneal space. Female 21188667 CVCL_5670 NALM-32 cancer cell line human CVCL_5670 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10363160) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21188668 CVCL_4U65 BTV10XSp2/0-Ag-14-10A1.34 hybridoma house mouse CVCL_4U65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P69361; Bluetongue virus 10 VP7 (Note=Also reacts with most other BPV serotypes). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8219 21188669 CVCL_5665 NALM-27 cancer cell line human CVCL_5665 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9710720; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 4-5 days (PubMed=9710720) 21188670 CVCL_5664 NALM-25 cancer cell line human CVCL_5664 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=1667895; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21188671 CVCL_4U64 OTT6050(B) cancer cell line house mouse CVCL_4U64 CL:0000010 Breed/subspecies: 129/Sv. Male 21188672 CVCL_5663 NALM-23 cancer cell line human CVCL_5663 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Male 21188673 CVCL_4U63 OTT6050(A) cancer cell line house mouse CVCL_4U63 CL:0000010 Breed/subspecies: 129/Sv. Male 21188674 CVCL_5662 NALM-22 cancer cell line human CVCL_5662 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072) Population: Japanese; Derived from sampling site: Bone marrow. Male 21188675 CVCL_4U62 YS-5Fu-R-TC cancer cell line Norway rat CVCL_4U62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Ascites. 21188676 CVCL_4U69 HASTR/ci35 conditionally immortalized cell line human CVCL_4U69 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.. Unspecified 21188677 CVCL_5669 NALM-31 cancer cell line human CVCL_5669 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10363160) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21188678 CVCL_4U68 Lipo-DUE1 cancer cell line human CVCL_4U68 CL:0000010 Derived from metastatic site: Ascites. Omics: Array-based CGH Female Doubling time: ~2.8 days (PubMed=26373732) 21188679 CVCL_5668 NALM-30 cancer cell line human CVCL_5668 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=34940123); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10363160) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male 21188680 CVCL_4U67 HuWa2 finite cell line CVCL_4U67 CL:0000010 Miscellaneous: Doubling time from personal communication of Burkard M Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Developed to test the toxicity of persistent organic pollutants (POPs) on marine mammals Doubling time: ~42 hours (Direct_author_submission) Group: Endangered species/breed cell line; Group: Cetacean cell line 21188681 CVCL_5667 NALM-29 cancer cell line human CVCL_5667 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 46 hours (PubMed=10456671) 21188682 CVCL_4U66 HuWa1 finite cell line CVCL_4U66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Developed to test the toxicity of persistent organic pollutants (POPs) on marine mammals Doubling time: ~41 hours (PubMed=26363275) Group: Endangered species/breed cell line; Group: Cetacean cell line 21188683 CVCL_5666 NALM-28 cancer cell line human CVCL_5666 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=9710720; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21188684 CVCL_4U32 C11STH spontaneously immortalized cell line human CVCL_4U32 CL:0000010 Karyotypic information: Trisomy of 8 and 11 (PubMed=7526034); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Male Doubling time: ~48 hours (PubMed=7526034) 21188685 CVCL_5632 T80-6 spontaneously immortalized cell line CVCL_5632 CL:0000010 Derived from sampling site: Lung. Male 21188686 CVCL_4U31 DLKP-Mitox cancer cell line human CVCL_4U31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Lymph node. Omics: Proteome analysis by 2D-DE/MS Male 21188687 CVCL_5631 T80-4 spontaneously immortalized cell line CVCL_5631 CL:0000010 Derived from sampling site: Lung. Male 21188688 CVCL_5630 MMSr-1 spontaneously immortalized cell line CVCL_5630 CL:0000010 Derived from sampling site: Lung. Male 21188689 CVCL_4U30 MZ-PC-3 cancer cell line human CVCL_4U30 From: Knuth A.; Johannes Gutenberg Universitat; Mainz; Germany. CL:0000010 Unspecified 21188690 CVCL_4U36 CFSC-5H spontaneously immortalized cell line Norway rat CVCL_4U36 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21188691 CVCL_5636 TaD-1-3 cancer cell line Norway rat CVCL_5636 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21188692 CVCL_4U35 CFSC-3H spontaneously immortalized cell line Norway rat CVCL_4U35 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21188693 CVCL_5635 TaD-1 cancer cell line Norway rat CVCL_5635 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21188694 CVCL_4U34 CFSC-2G spontaneously immortalized cell line Norway rat CVCL_4U34 CL:0000010 Karyotypic information: Hyperdiploid karyotype (PubMed=36139474); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Omics: Transcriptome analysis by RNAseq Male 21188695 CVCL_5634 Don D-6 spontaneously immortalized cell line CVCL_5634 CL:0000010 Derived from sampling site: Lung. Male 21188696 CVCL_4U33 NT2-B9 cancer cell line human CVCL_4U33 CL:0000010 Population: Caucasian; Derived from metastatic site: Lung. Male 21188697 CVCL_5633 T80-7 spontaneously immortalized cell line CVCL_5633 CL:0000010 Derived from sampling site: Lung. Male 21188698 CVCL_4U39 HROG04 cancer cell line human CVCL_4U39 HLA typing: A*01,02 (Direct_author_submission); HLA typing: A*01:01:01,05:35; B*08:01,03:01:01; C*07:01:01,15:02:01; DPB1*01:01:01,04:01:01; DQA1*05:01:01,05:05:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,11:01:01 (CLS=300932) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Trp274Leu (c.821G>T); ClinVar=VCV000427600; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Brain; right frontal lobe. Female 21188699 CVCL_5639 TuD-1-3 spontaneously immortalized cell line Norway rat CVCL_5639 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21188700 CVCL_4U38 HROG02 cancer cell line human CVCL_4U38 HLA typing: A*01:01,02:01; B*08:01,13:02; C*06:02,07:01; DPA1*01:03; DPB1*04:01; DQA1*02:01,05:01; DQB1*02:01,02:02; DRB1*03:01,07:01; DRB3*01:01; DRB4*01:03 (PubMed=33592498) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=23951083) Population: Caucasian; Derived from sampling site: Brain; right parieto-occipital lobe. Omics: Deep exome analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Male Doubling time: 36-54 hours (CLS) 21188701 CVCL_5638 TuD-1 spontaneously immortalized cell line Norway rat CVCL_5638 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21188702 CVCL_4U37 CFSC-8B spontaneously immortalized cell line Norway rat CVCL_4U37 CL:0000010 Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: Wistar. Male 21188703 CVCL_5637 TaD-1-8 cancer cell line Norway rat CVCL_5637 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM x Buffalo/Mna. Male 21188704 CVCL_4U50 HROG38 cancer cell line human CVCL_4U50 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ile224Met (c.672A>G); ClinVar=VCV000189505; Zygosity=Unspecified (CLS); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg234Trp (c.700C>T); ClinVar=VCV000184844; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Brain; right parieto-occipital lobe. Female Doubling time: 63 hours (CLS) 21188705 CVCL_5650 SK-MEL-93 DX-3 cancer cell line human CVCL_5650 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Hypodermis. Omics: Proteome analysis by 2D-DE Female 21188706 CVCL_4U43 HROG10 cancer cell line human CVCL_4U43 HLA typing: A*02:01:01,23:01:01; B*15:01:01,20:03:01; C*01:02:01,04:01:01; DPB1*02:01,04:01; DQA1*02:01:01,03:02:01; DQB1*02:02:01,03:03:02; DRB1*07:01:01,09:01:02 (CLS=300935) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; right temporal lobe. Male 21188707 CVCL_5643 TXM-1 cancer cell line human CVCL_5643 From: University of Texas M.D Anderson Cancer Center; Houston; USA. CL:0000010 Derived from metastatic site: Lymph node. Discontinued: KCLB; 80028; probable Unspecified 21188708 CVCL_4U42 HROG07 cancer cell line human CVCL_4U42 HLA typing: A*02:01:01,02:01:01; B*15:01:01,03:05:02; C*03:03:01,07:04:01; DPB1*04:01:01G,05:01:01G; DQA1*01:03:01,04:01:01; DQB1*04:02:01,06:01:01; DRB1*08:01:01,15:02:01 (CLS=300934) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; right temporo-parietal lobe. Male 21188709 CVCL_5642 ULF-23HU spontaneously immortalized cell line CVCL_5642 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21188710 CVCL_4U41 HROG06 cancer cell line human CVCL_4U41 HLA typing: A*01:01:01,03:01:01; B*08:01:01,11:01:01; C*04:01:01,07:01:01; DPB1*03:01,04:02; DQA1*01:01:01,01:02:01; DQB1*05:01:01,06:04:01; DRB1*01:01:01,13:02:01 (CLS=300933) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=23951083); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=23951083) Population: Caucasian; Derived from sampling site: Brain; left frontal lobe. Male Doubling time: 57-59 hours (CLS) 21188711 CVCL_5641 ULF-23 spontaneously immortalized cell line CVCL_5641 CL:0000010 Derived from sampling site: Fin. Unspecified Doubling time: 72 hours (CelloPub=CLPUB00124) Group: Fish cell line 21188712 CVCL_4U40 HROG05 cancer cell line human CVCL_4U40 HLA typing: A*02 (Direct_author_submission) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=23951083) Population: Caucasian; Derived from sampling site: Brain; left temporal lobe. Female Doubling time: 44-48 hours (CLS) 21188713 CVCL_5640 TuD-1-5 spontaneously immortalized cell line Norway rat CVCL_5640 CL:0000010 Derived from sampling site: Thymus Cell type=Thymic epithelial cell.; Breed/subspecies: ACI/NM. Male 21188714 CVCL_4U47 HROG33 cancer cell line human CVCL_4U47 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left temporo-occipital lobe. Female 21188715 CVCL_5647 TXM-34 cancer cell line human CVCL_5647 From: University of Texas M.D Anderson Cancer Center; Houston; USA. CL:0000010 Derived from metastatic site: Brain. Unspecified 21188716 CVCL_4U46 HROG24 cancer cell line human CVCL_4U46 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left occipital lobe. Female Doubling time: 70 hours (CLS) 21188717 CVCL_5646 TXM-18 cancer cell line human CVCL_5646 From: University of Texas M.D Anderson Cancer Center; Houston; USA. CL:0000010 Derived from metastatic site: Brain. Unspecified 21188718 CVCL_4U45 HROG17 cancer cell line human CVCL_4U45 HLA typing: A*11:01,66:01; B*14:02,40:02; C*01:02,08:02; DPA1*01:03,02:01; DPB1*04:01,11:01; DQA1*01:01,05:05; DQB1*03:01,05:01; DRB1*01:02,12:01; DRB3*02:02 (PubMed=33592498) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Brain; left parieto-occipital lobe. Omics: Deep exome analysis; Omics: HLA class I peptidome analysis by proteomics; Omics: HLA class II peptidome analysis by proteomics Male Doubling time: 32-42 hours (CLS) 21188719 CVCL_5645 TXM-13 cancer cell line human CVCL_5645 From: University of Texas M.D Anderson Cancer Center; Houston; USA. CL:0000010 Derived from metastatic site: Brain. Unspecified Characteristics: Pigmented 21188720 CVCL_5644 DM-4 cancer cell line human CVCL_5644 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21188721 CVCL_4U44 HROG13 cancer cell line human CVCL_4U44 HLA typing: A*02:01:01; B*15:01:01,20:02:01; C*03:03:01,05:01:01; DPB1*01:01,19:01; DQA1*01:03:01,03:03:01; DQB1*03:01:01,06:03:01; DRB1*04:01:01,13:01:01 (CLS=300936) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left temporal lobe. Female 21188722 CVCL_5649 A375-SM cancer cell line human CVCL_5649 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Highly metastatic Established from a tumor obtained in nude mice injected with the parent cell line. 21188723 CVCL_4U49 HROG36 cancer cell line human CVCL_4U49 HLA typing: A*02:01:01,01:01:01; B*40:01:02,55:01:01; C*03:03:01,03:04:01; DPB1*04:01:01G,06:01:01G; DQA1*01:04:01,03:01:01; DQB1*03:02:01,05:03:01; DRB1*04:04:01,14:54:01 (CLS=300939) From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; right parietal lobe. Female Doubling time: 35-40 hours (CLS) 21188724 CVCL_4U48 HROG33 T0 M1 cancer cell line human CVCL_4U48 From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Brain; left temporo-occipital lobe. Female 21188725 CVCL_5648 TXM-40 cancer cell line human CVCL_5648 From: University of Texas M.D Anderson Cancer Center; Houston; USA. CL:0000010 Derived from metastatic site: Brain. Unspecified 21188726 CVCL_FH28 ND02280 transformed cell line human CVCL_FH28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188727 CVCL_FH27 ND02180 transformed cell line human CVCL_FH27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188728 CVCL_FH26 ND02163 transformed cell line human CVCL_FH26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188729 CVCL_FH25 ND02110 transformed cell line human CVCL_FH25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188730 CVCL_FH29 ND02281 transformed cell line human CVCL_FH29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188731 CVCL_FH20 ND02009 transformed cell line human CVCL_FH20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188732 CVCL_FH24 ND02082 transformed cell line human CVCL_FH24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188733 CVCL_FH23 ND02037 transformed cell line human CVCL_FH23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188734 CVCL_FH22 ND02034 transformed cell line human CVCL_FH22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188735 CVCL_FH21 ND02010 transformed cell line human CVCL_FH21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188736 CVCL_FH39 ND02418 transformed cell line human CVCL_FH39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188737 CVCL_FH38 ND02416 transformed cell line human CVCL_FH38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188738 CVCL_FH37 ND02415 transformed cell line human CVCL_FH37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188739 CVCL_FH36 ND02396 transformed cell line human CVCL_FH36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188740 CVCL_FH31 ND02289 transformed cell line human CVCL_FH31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188741 CVCL_FH30 ND02288 transformed cell line human CVCL_FH30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188742 CVCL_FH35 ND02383 transformed cell line human CVCL_FH35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188743 CVCL_FH34 ND02382 transformed cell line human CVCL_FH34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188744 CVCL_FH33 ND02292 transformed cell line human CVCL_FH33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188745 CVCL_FH32 ND02290 transformed cell line human CVCL_FH32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188746 CVCL_FH06 ND01647 transformed cell line human CVCL_FH06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188747 CVCL_FH05 ND01599 transformed cell line human CVCL_FH05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188748 CVCL_FH04 ND01441 transformed cell line human CVCL_FH04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188749 CVCL_FH03 ND01440 transformed cell line human CVCL_FH03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188750 CVCL_FH09 ND01853 transformed cell line human CVCL_FH09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188751 CVCL_FH08 ND01841 transformed cell line human CVCL_FH08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188752 CVCL_FH07 ND01811 transformed cell line human CVCL_FH07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188753 CVCL_FH02 ND01438 transformed cell line human CVCL_FH02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188754 CVCL_FH01 ND01367 transformed cell line human CVCL_FH01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188755 CVCL_FH00 ND01361 transformed cell line human CVCL_FH00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188756 CVCL_FH17 ND02003 transformed cell line human CVCL_FH17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188757 CVCL_FH16 ND01974 transformed cell line human CVCL_FH16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188758 CVCL_FH15 ND01924 transformed cell line human CVCL_FH15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188759 CVCL_FH14 ND01868 transformed cell line human CVCL_FH14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188760 CVCL_FH19 ND02006 transformed cell line human CVCL_FH19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188761 CVCL_FH18 ND02004 transformed cell line human CVCL_FH18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188762 CVCL_FH13 ND01867 transformed cell line human CVCL_FH13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188763 CVCL_FH12 ND01866 transformed cell line human CVCL_FH12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188764 CVCL_FH11 ND01865 transformed cell line human CVCL_FH11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188765 CVCL_FH10 ND01857 transformed cell line human CVCL_FH10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188766 CVCL_4T99 A2780-DX6 cancer cell line human CVCL_4T99 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21188767 CVCL_5599 TKKK cancer cell line human CVCL_5599 CL:0000010 Population: Japanese. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21188768 CVCL_4T98 A2780-DX5 cancer cell line human CVCL_4T98 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21188769 CVCL_5598 TKD2 conditionally immortalized cell line house mouse CVCL_5598 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; renal tubule Cell type=Endothelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Doubling time: ~33 hours (lot 04152002), ~32 hours (lot 02252021) (JCRB) 21188770 CVCL_4T97 A2780-DX4 cancer cell line human CVCL_4T97 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21188771 CVCL_5597 TKC2 conditionally immortalized cell line house mouse CVCL_5597 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; renal tubule Cell type=Epithelial cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Doubling time: ~27 hours (lot 04192002) (JCRB) 21188772 CVCL_4T96 A2780-DX2 cancer cell line human CVCL_4T96 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21188773 CVCL_5596 T-23 clone 8 finite cell line CVCL_5596 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188774 CVCL_FH93 ND03460 transformed cell line human CVCL_FH93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188775 CVCL_FH92 ND03459 transformed cell line human CVCL_FH92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188776 CVCL_FH91 ND03441 transformed cell line human CVCL_FH91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188777 CVCL_FH90 ND03383 transformed cell line human CVCL_FH90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188778 CVCL_FH86 ND03364 transformed cell line human CVCL_FH86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188779 CVCL_FH85 ND03303 transformed cell line human CVCL_FH85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188780 CVCL_FH84 ND03295 transformed cell line human CVCL_FH84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188781 CVCL_FH83 ND03294 transformed cell line human CVCL_FH83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188782 CVCL_FH89 ND03380 transformed cell line human CVCL_FH89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188783 CVCL_FH88 ND03424 transformed cell line human CVCL_FH88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188784 CVCL_FH87 ND03423 transformed cell line human CVCL_FH87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188785 CVCL_FH97 ND03528 transformed cell line human CVCL_FH97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188786 CVCL_FH96 ND03485 transformed cell line human CVCL_FH96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188787 CVCL_FH95 ND03481 transformed cell line human CVCL_FH95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188788 CVCL_FH94 ND03480 transformed cell line human CVCL_FH94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188789 CVCL_FH99 ND03551 transformed cell line human CVCL_FH99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188790 CVCL_FH98 ND03530 transformed cell line human CVCL_FH98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188791 CVCL_FH71 ND03075 transformed cell line human CVCL_FH71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188792 CVCL_FH70 ND03074 transformed cell line human CVCL_FH70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188793 CVCL_FH69 ND03043 transformed cell line human CVCL_FH69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188794 CVCL_FH64 ND02980 transformed cell line human CVCL_FH64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188795 CVCL_FH63 ND02967 transformed cell line human CVCL_FH63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188796 CVCL_FH62 ND02965 transformed cell line human CVCL_FH62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188797 CVCL_FH61 ND02920 transformed cell line human CVCL_FH61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188798 CVCL_FH68 ND02999 transformed cell line human CVCL_FH68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188799 CVCL_FH67 ND02998 transformed cell line human CVCL_FH67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188800 CVCL_FH66 ND02996 transformed cell line human CVCL_FH66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188801 CVCL_FH65 ND02995 transformed cell line human CVCL_FH65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188802 CVCL_FH82 ND03285 transformed cell line human CVCL_FH82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188803 CVCL_FH81 ND03276 transformed cell line human CVCL_FH81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188804 CVCL_FH80 ND03273 transformed cell line human CVCL_FH80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188805 CVCL_FH75 ND03147 transformed cell line human CVCL_FH75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188806 CVCL_FH74 ND03145 transformed cell line human CVCL_FH74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188807 CVCL_FH73 ND03144 transformed cell line human CVCL_FH73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188808 CVCL_FH72 ND03076 transformed cell line human CVCL_FH72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188809 CVCL_FH79 ND03244 transformed cell line human CVCL_FH79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188810 CVCL_FH78 ND03241 transformed cell line human CVCL_FH78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188811 CVCL_FH77 ND03212 transformed cell line human CVCL_FH77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188812 CVCL_FH76 ND03151 transformed cell line human CVCL_FH76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188813 CVCL_FH49 ND02605 transformed cell line human CVCL_FH49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188814 CVCL_FH48 ND02581 transformed cell line human CVCL_FH48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188815 CVCL_FH47 ND02570 transformed cell line human CVCL_FH47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188816 CVCL_FH42 ND02491 transformed cell line human CVCL_FH42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188817 CVCL_FH41 ND02486 transformed cell line human CVCL_FH41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188818 CVCL_FH40 ND02442 transformed cell line human CVCL_FH40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188819 CVCL_FH46 ND02558 transformed cell line human CVCL_FH46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188820 CVCL_FH45 ND02537 transformed cell line human CVCL_FH45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188821 CVCL_FH44 ND02524 transformed cell line human CVCL_FH44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188822 CVCL_FH43 ND02522 transformed cell line human CVCL_FH43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188823 CVCL_FH60 ND02919 transformed cell line human CVCL_FH60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188824 CVCL_FH59 ND02867 transformed cell line human CVCL_FH59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188825 CVCL_FH58 ND02839 transformed cell line human CVCL_FH58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188826 CVCL_FH53 ND02719 transformed cell line human CVCL_FH53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188827 CVCL_FH52 ND02687 transformed cell line human CVCL_FH52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188828 CVCL_FH51 ND02657 transformed cell line human CVCL_FH51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188829 CVCL_FH50 ND02618 transformed cell line human CVCL_FH50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188830 CVCL_FH57 ND02835 transformed cell line human CVCL_FH57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188831 CVCL_FH56 ND02795 transformed cell line human CVCL_FH56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21188832 CVCL_FH55 ND02768 transformed cell line human CVCL_FH55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188833 CVCL_FH54 ND02742 transformed cell line human CVCL_FH54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21188834 CVCL_4V31 CHO 15DACT spontaneously immortalized cell line CVCL_4V31 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Ovary. Female 21188835 CVCL_5731 COMMA-D spontaneously immortalized cell line house mouse CVCL_5731 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Omics: Transcriptome analysis by single cell RNAseq Female Characteristics: Can functionally differentiate to preneoplastic and neoplastic phenotypes (PubMed=36630696) 21188836 CVCL_4V30 CHO 100DACT spontaneously immortalized cell line CVCL_4V30 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Ovary. Female 21188837 CVCL_5730 CLS-CD3575 cancer cell line house mouse CVCL_5730 CL:0000010 Derived from sampling site: Kidney. Unspecified 21188838 CVCL_4V35 C6/ACNU cancer cell line Norway rat CVCL_4V35 CL:0000010 Selected for resistance to: ChEBI; CHEBI:75270; Nimustine (ACNU); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male 21188839 CVCL_5735 D-54MG cancer cell line human CVCL_5735 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9090379); Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1539; CBFB; Name(s)=ABL1-CBFB (from parent cell line) Miscellaneous: STR profile from personal communication of Bigner D.D Population: Caucasian; Derived from sampling site: Brain. Male Doubling time: 40.0 +- 3.6 hours (in serum-supplemented media), 46.0 +- 0.7 hours (in serum-free media) (PubMed=3178168) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00505 Problematic cell line: Contaminated Shown to be a A-172 derivative (ICLAC, from personal communication of Bigner D.D.). Originally thought to originate from a 39 year old female patient with a glioblastoma. 21188840 CVCL_4V34 9L/ACNU cancer cell line Norway rat CVCL_4V34 CL:0000010 Selected for resistance to: ChEBI; CHEBI:75270; Nimustine (ACNU); Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Fischer 344. Male 21188841 CVCL_5734 D-37MG cancer cell line human CVCL_5734 CL:0000010 Female 21188842 CVCL_5733 COMMA-D beta-geo spontaneously immortalized cell line house mouse CVCL_5733 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female Caution: Could be identical to COMMA-D beta (Cellosaurus=CVCL_5732) 21188843 CVCL_4V33 DM(adb-0.8) transformed cell line CVCL_4V33 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21188844 CVCL_5732 COMMA-D beta spontaneously immortalized cell line house mouse CVCL_5732 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female Caution: Could be identical to COMMA-D beta-geo (Cellosaurus=CVCL_5733) 21188845 CVCL_4V32 DM(act12) transformed cell line CVCL_4V32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21188846 CVCL_5739 EGG cancer cell line house mouse CVCL_5739 CL:0000010 Breed/subspecies: DBA. Unspecified 21188847 CVCL_4V39 V79-hCYP1A2 spontaneously immortalized cell line CVCL_4V39 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188848 CVCL_5738 ECF-R finite cell line CVCL_5738 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: CLS; 601469; true Unspecified Senescence: Senesces at 50-60 PDL (CLS=601469) Group: Bird cell line 21188849 CVCL_4V38 V79NH spontaneously immortalized cell line CVCL_4V38 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188850 CVCL_5737 E11 conditionally immortalized cell line house mouse CVCL_5737 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21188851 CVCL_4V37 V79-hCYP1A1 spontaneously immortalized cell line CVCL_4V37 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188852 CVCL_5736 D-65MG cancer cell line human CVCL_5736 CL:0000010 Female 21188853 CVCL_4V36 V79MZ spontaneously immortalized cell line CVCL_4V36 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188854 CVCL_5742 EKL undefined cell line type CVCL_5742 CL:0000010 Derived from sampling site: Skin. Unspecified 21188855 CVCL_4V42 MCF-7/TPT300 cancer cell line human CVCL_4V42 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from metastatic site: Pleural effusion. Female 21188856 CVCL_4V41 A431/TPT cancer cell line human CVCL_4V41 CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from sampling site: Skin; epidermis. Female 21188857 CVCL_5741 EJ-6-2-Bam-6a transformed cell line house mouse CVCL_5741 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with Bam H1 digested DNA from bladder carcinoma cell line Ej138 (Cellosaurus=CVCL_2443) 21188858 CVCL_5740 Endor-CLS finite cell line CVCL_5740 CL:0000010 Derived from sampling site: Vein; endothelium. Discontinued: CLS; 600173; true Unspecified 21188859 CVCL_4V40 V79NHh1A2 spontaneously immortalized cell line CVCL_4V40 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2596; CYP1A2 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21188860 CVCL_5746 ES-C57BL/6 embryonic stem cell house mouse CVCL_5746 CL:0000010 Breed/subspecies: C57BL/6. Male 21188861 CVCL_4V46 KCL22/SR cancer cell line human CVCL_4V46 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Leufs*5 (c.3261dupC) (3261_3262insC); ClinVar=VCV000089364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro301Glnfs*44 (c.902delC); ClinVar=VCV000233908; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21188862 CVCL_4V45 A2780/TPT cancer cell line human CVCL_4V45 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from sampling site: Ovary. Female 21188863 CVCL_5745 EOC 20 factor-dependent cell line house mouse CVCL_5745 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21188864 CVCL_5744 EOC 2 factor-dependent cell line house mouse CVCL_5744 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21188865 CVCL_4V44 MCF-7/5-23 cancer cell line human CVCL_4V44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21188866 CVCL_5743 EOC 13.31 factor-dependent cell line house mouse CVCL_5743 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21188867 CVCL_4V43 MCF-7/RTx6 cancer cell line human CVCL_4V43 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21188868 CVCL_4V49 DLDSNR6 cancer cell line human CVCL_4V49 CL:0000010 Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin). Male 21188869 CVCL_5749 FAMPAC cancer cell line human CVCL_5749 HLA typing: A*03:01:01; B*27:05:01; C*15:02:01; DPB1*03.01:01; DQA1*05:05:01; DQB1*03:01:01; DRB1*12:01:01 (CLS=300309) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (CLS); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=15112280) Population: Caucasian; Derived from sampling site: Pancreas. Female Doubling time: 24-48 hours (PubMed=15112280) 21188870 CVCL_5748 Ex-3LL cancer cell line house mouse CVCL_5748 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. 21188871 CVCL_4V48 IGROV(T100r) cancer cell line human CVCL_4V48 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63632; Topotecan; Derived from sampling site: Ovary. Female 21188872 CVCL_5747 ES-D3 GL embryonic stem cell house mouse CVCL_5747 CL:0000010 Breed/subspecies: 129S2/SvPas. Discontinued: ATCC; SCRC-1003; true Male 21188873 CVCL_4V47 K562/G01 cancer cell line human CVCL_4V47 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21188874 CVCL_5713 BT5C cancer cell line Norway rat CVCL_5713 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. Doubling time: 22.7 +- 1.2 hours (in serum-supplemented media), 23.3 +- 1.9 hours (in serum-free media) (PubMed=3178168) 21188875 CVCL_4V13 NCI-H2228-Luc cancer cell line human CVCL_4V13 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (from parent cell line); Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 9655; PTPN3; Name(s)=ALK-PTPN3 (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0726; true. Female 21188876 CVCL_5712 BT4C cancer cell line Norway rat CVCL_5712 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Breed/subspecies: BDIX. 21188877 CVCL_4V12 CEM/VLB500 cancer cell line human CVCL_4V12 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Caution: Seems to be interchangeably called VLB500 or VBL500 21188878 CVCL_5711 BJAB cancer cell line human CVCL_5711 HLA typing: A*01:01,02:01; B*13:02,35:01; C*04:01,06:02 (PubMed=26589293); HLA typing: A*01:02:83,02:01:01; B*13:02:01,35:01:01; C*04:01:01,06:02:01; DPB1*04:02:01G; DQA1*01:02:01,05:05:01; DQB1*03:01,06:04:01; DRB1*12:01:01,13:02:01 (CLS=302006); HLA typing: A*02:01:01,02:01:01; B*13:02:01,35:01:01; C*04:01:01,06:02:01; DPA1*01:03:01,01:03:01; DPB1*105:01,105:01; DQB1*03:01:01,06:09:01; DRA*01:01:01,01:02:02; DRB1*12:01:01,13:02:01 (DSMZCellDive=ACC-757) CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 7132; KMT2A; Name(s)=KMT2A-CLTC (PubMed=31160637); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (PubMed=1915267; PubMed=8344493) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Groin. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Virology: EBV-negative Even so that the original tumor tissue was infected with the B95-8 strain of EBV. Doubling time: ~22 hours (PubMed=179629); ~40-60 hours (DSMZ=ACC-757); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) Part of: LL-100 blood cancer cell line panel 21188879 CVCL_4V11 CEM/VLB55-8 cancer cell line human CVCL_4V11 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188880 CVCL_5710 BALM-9N cancer cell line human CVCL_5710 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188881 CVCL_4V10 CEM/VLB10-2 cancer cell line human CVCL_4V10 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188882 CVCL_4V17 CCRF/CEM/ara-C/3A cancer cell line human CVCL_4V17 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188883 CVCL_5717 CDNR1 spontaneously immortalized cell line house mouse CVCL_5717 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21188884 CVCL_5716 CarC cancer cell line house mouse CVCL_5716 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin. 21188885 CVCL_4V16 U87-MG/Pt cancer cell line human CVCL_4V16 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21188886 CVCL_5715 CarB cancer cell line house mouse CVCL_5715 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin. 21188887 CVCL_4V15 P388/PtR4 cancer cell line house mouse CVCL_4V15 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21188888 CVCL_5714 CaD2 cancer cell line house mouse CVCL_5714 CL:0000010 Breed/subspecies: C3H. Female 21188889 CVCL_4V14 L1210/PtR4 cancer cell line house mouse CVCL_4V14 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21188890 CVCL_5719 CDNR4 spontaneously immortalized cell line house mouse CVCL_5719 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21188891 CVCL_4V19 HL-60/ara-C [Japan 2011] cancer cell line human CVCL_4V19 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Female 21188892 CVCL_4V18 CCRF/CEM/ara-C/7A cancer cell line human CVCL_4V18 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188893 CVCL_5718 CDNR2 spontaneously immortalized cell line house mouse CVCL_5718 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21188894 CVCL_5720 CERV-186 cancer cell line human CVCL_5720 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains around 26 copies of the HPV16 genome; some complete and others truncated 21188895 CVCL_4V20 K562/ara-C cancer cell line human CVCL_4V20 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Pleural effusion. Female 21188896 CVCL_5724 CH-235MG cancer cell line human CVCL_5724 CL:0000010 Female 21188897 CVCL_4V24 JL/AMSA cancer cell line human CVCL_4V24 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21188898 CVCL_5723 CH-157MN cancer cell line human CVCL_5723 Genome ancestry: African=0.5%; Native American=0%; East Asian, North=2.54%; East Asian, South=0%; South Asian=0.15%; European, North=57.82%; European, South=38.99% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28552950) Omics: Deep exome analysis; Omics: shRNA library screening Female Doubling time: 22 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: Indicated as originating from a 41 year old female patient in PubMed=7714613, from a 59 year old in PubMed=10083766 and from a 55 year old in PubMed=18261772. 21188899 CVCL_4V23 U937/ara-C cancer cell line human CVCL_4V23 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Pleural effusion. Male 21188900 CVCL_5722 CERV-215 cancer cell line human CVCL_5722 HLA typing: A*02:01,03:01; B*11:08,40:01:00; C*03:04,04:01 (CLS=300292) CL:0000010 Transformant: Human papillomavirus type 45 (HPV45)(NCBI-Taxonomy; 10593); Derived from sampling site: Uterus; cervix. Female Virology: Contains a HPV45 genome 21188901 CVCL_4V22 THP-1/ara-C cancer cell line human CVCL_4V22 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood. Male 21188902 CVCL_4V21 CEM/ara-C cancer cell line human CVCL_4V21 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188903 CVCL_5721 CERV-196 cancer cell line human CVCL_5721 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains 4 to 6 copies of the HPV16 genome 21188904 CVCL_5728 CLS-54 cancer cell line human CVCL_5728 CL:0000010 Population: Caucasian; Derived from sampling site: Lung. Male 21188905 CVCL_4V28 HCT 116R11 cancer cell line human CVCL_4V28 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; Derived from sampling site: Colon. Male 21188906 CVCL_5727 CLS-145 cancer cell line human CVCL_5727 CL:0000010 Population: Caucasian; Derived from sampling site: Stomach. Omics: Transcriptome analysis by microarray Female Doubling time: 36 hours (CLS) 21188907 CVCL_4V27 HT-29R13 cancer cell line human CVCL_4V27 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC Female 21188908 CVCL_4V26 293-CD40L-sCD40L transformed cell line human CVCL_4V26 CL:0000010 Transfected with: HGNC; 11935; CD40LG Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21188909 CVCL_5726 CLS-138 cancer cell line house mouse CVCL_5726 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Breed/subspecies: NMRI. Female 21188910 CVCL_4V25 293-CD40L transformed cell line human CVCL_4V25 CL:0000010 Transfected with: HGNC; 11935; CD40LG Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21188911 CVCL_5725 CLS-103 cancer cell line house mouse CVCL_5725 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Stomach; epithelium; Breed/subspecies: NMRI. Unspecified 21188912 CVCL_5729 CLS-ACI-1 cancer cell line Norway rat CVCL_5729 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: ACI. Female 21188913 CVCL_4V29 HCT 116R26 cancer cell line human CVCL_4V29 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; Derived from sampling site: Colon. Male 21188914 CVCL_5702 BALM-26 cancer cell line human CVCL_5702 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 35 hours (PubMed=12703546) 21188915 CVCL_4V02 SCC-1-Cet-R cancer cell line human CVCL_4V02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Oral cavity; floor of mouth. Male 21188916 CVCL_5701 BALM-25 cancer cell line human CVCL_5701 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Virology: EBV-negative Doubling time: 30 hours (PubMed=15160921) 21188917 CVCL_4V01 H1650-ER1 cancer cell line human CVCL_4V01 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from metastatic site: Pleural effusion. Male 21188918 CVCL_5700 BALM-23 cancer cell line human CVCL_5700 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: 25 hours (PubMed=12703546) 21188919 CVCL_4V00 HMF3Dwt conditionally immortalized cell line human CVCL_4V00 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 21188920 CVCL_4V06 A549(VM)28 cancer cell line human CVCL_4V06 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from sampling site: Lung. Male 21188921 CVCL_5706 BALM-8 cancer cell line human CVCL_5706 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male 21188922 CVCL_5705 BALM-7 cancer cell line human CVCL_5705 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male 21188923 CVCL_4V05 HCT-116/VM34 cancer cell line human CVCL_4V05 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from sampling site: Colon. Male 21188924 CVCL_5704 BALM-6 cancer cell line human CVCL_5704 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow Cell type=B-cell.. Male Doubling time: ~60 hours (PubMed=1390421) 21188925 CVCL_4V04 SCC-1-Gef-R cancer cell line human CVCL_4V04 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Selected for resistance to: ChEBI; CHEBI:49668; Gefitinib (ZD1839; Derived from sampling site: Oral cavity; floor of mouth. Male 21188926 CVCL_5703 BALM-27 cancer cell line human CVCL_5703 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Virology: EBV-negative Doubling time: 32 hours (PubMed=12389627) 21188927 CVCL_4V03 SCC-1-Erl-R cancer cell line human CVCL_4V03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (from parent cell line) Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib; Derived from sampling site: Oral cavity; floor of mouth. Male 21188928 CVCL_5709 BALM-9KL cancer cell line human CVCL_5709 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188929 CVCL_4V09 CEM/VLB55 cancer cell line human CVCL_4V09 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188930 CVCL_5708 BALM-9K cancer cell line human CVCL_5708 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Female 21188931 CVCL_4V08 CEM-VLB cancer cell line human CVCL_4V08 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21188932 CVCL_4V07 A549(VP)28 cancer cell line human CVCL_4V07 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Lung. Male 21188933 CVCL_5707 BALM-9 cancer cell line human CVCL_5707 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Array-based CGH Female Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21188934 CVCL_5797 MCa3D transformed cell line house mouse CVCL_5797 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Female 21188935 CVCL_4V97 MCF-7-TaxR cancer cell line human CVCL_4V97 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female 21188936 CVCL_5796 MaMi cancer cell line human CVCL_5796 CL:0000010 Population: Japanese; Derived from sampling site: Endometrium. Female Doubling time: 30.2 +- 1.1 hours (PubMed=9740146) 21188937 CVCL_4V96 MCF-7-EpiR cancer cell line human CVCL_4V96 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:47898; 4'-epidoxorubicin (Epirubicin); Derived from metastatic site: Pleural effusion. Female 21188938 CVCL_4V95 HEK293SF-3F6 transformed cell line human CVCL_4V95 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Biotechnology: Used for the production of the CanSino Biologics Ebola virus vaccine (Trade name: Ad5-EBOV); Biotechnology: Used for the production of the CanSino Biologics SARS-CoV-2 (COVID-19) vaccine (Trade name: Convidecia; also known as Ad5-nCOV) (DrugBank=DB15655) Female Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12585 21188939 CVCL_5795 MA-Balb cancer cell line house mouse CVCL_5795 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21188940 CVCL_4V94 HEK293SF transformed cell line human CVCL_4V94 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21188941 CVCL_5794 M2-10B4 spontaneously immortalized cell line house mouse CVCL_5794 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6J x C3H/HeJ. 21188942 CVCL_4V99 HEK293SF-PacLV transformed cell line human CVCL_4V99 CL:0000010 Transfected with: UniProtKB; O33453; Pseudomonas putida cymR Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line; Group: Serum/protein free medium cell line 21188943 CVCL_5799 MH-3924A cancer cell line Norway rat CVCL_5799 CL:0000010 Breed/subspecies: ACI. Unspecified Doubling time: ~25-35 hours (CLS) 21188944 CVCL_4V98 J82-NVB cancer cell line human CVCL_4V98 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser770Pro (c.2308T>C); ClinVar=VCV000140988; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro124Leu (c.371C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn212fs*1 (c.635_1212del578); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.2107-2A>G; ClinVar=VCV000013077; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu271Lys (c.811G>A); ClinVar=VCV000406566; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys320Asn (c.960G>C); Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine Male 21188945 CVCL_5798 Meth A Sarcoma cancer cell line house mouse CVCL_5798 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female Doubling time: ~28-30 hours (CLS) 21188946 CVCL_5782 Kera-308 cancer cell line house mouse CVCL_5782 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified 21188947 CVCL_4V82 SOSP-9607/F4 cancer cell line human CVCL_4V82 CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male Doubling time: 31 +- 3 hours (PubMed=20016965) 21188948 CVCL_5781 KCSV transformed cell line house mouse CVCL_5781 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6. 21188949 CVCL_4V81 SOSP-9607/CDDP cancer cell line human CVCL_4V81 CL:0000010 Population: Chinese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Bone. Male Doubling time: 45.11 +- 2.37 hours (PubMed=25017716) 21188950 CVCL_5780 JR8 cancer cell line human CVCL_5780 CL:0000010 Derived from metastatic site: Lymph node. Female 21188951 CVCL_4V80 SOSP-9607 cancer cell line human CVCL_4V80 CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male Doubling time: 29.79 +- 0.57 hours (PubMed=25017716) 21188952 CVCL_5775 Hep-CLS-1W cancer cell line house mouse CVCL_5775 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female Doubling time: ~12 hours (CLS) 21188953 CVCL_4V75 LoVo/L-OHP cancer cell line human CVCL_4V75 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Left supraclavicular lymph node. Male 21188954 CVCL_5774 Hep-CLS-1H cancer cell line house mouse CVCL_5774 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female 21188955 CVCL_4V74 HT29/L-OHP cancer cell line human CVCL_4V74 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Female 21188956 CVCL_4V73 HCT 116-OX cancer cell line human CVCL_4V73 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from sampling site: Colon. Male 21188957 CVCL_5773 Hep-74.3A cancer cell line house mouse CVCL_5773 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female 21188958 CVCL_5772 Hep-70.4 cancer cell line house mouse CVCL_5772 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Ala135Pro (c.403G>C); Zygosity=Heterozygous (PubMed=1382443); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Cys138Trp (c.414C>G); Zygosity=Heterozygous (PubMed=1382443) Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female 21188959 CVCL_4V72 OPM-2/BTZ cancer cell line human CVCL_4V72 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Female Characteristics: Produces Ig lambda 21188960 CVCL_5779 IOMM-Lee cancer cell line human CVCL_5779 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28552950) Population: Chinese; Derived from sampling site: Brain. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: shRNA library screening Male Doubling time: ~62 hours (PubMed=2234331); 18 hours (PubMed=25984343); 22 hours (ATCC=CRL-3370) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21188961 CVCL_4V79 TYPK-2 cancer cell line human CVCL_4V79 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Unspecified (PubMed=26124327) Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 40.4 hours (PubMed=26124327) 21188962 CVCL_4V78 TYPK-1 cancer cell line human CVCL_4V78 CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 22.1 hours (PubMed=26124327) 21188963 CVCL_5777 Hep-CLS-E1 cancer cell line house mouse CVCL_5777 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female 21188964 CVCL_4V77 SW620/L-OHP cancer cell line human CVCL_4V77 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Lymph node. Male 21188965 CVCL_5776 Hep-CLS-C9 cancer cell line house mouse CVCL_5776 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C3H/He. Female 21188966 CVCL_4V76 SW620-OX cancer cell line human CVCL_4V76 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; Derived from metastatic site: Lymph node. Male 21188967 CVCL_4V93 HEK293T/17 SF transformed cell line human CVCL_4V93 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Serum/protein free medium cell line 21188968 CVCL_5793 M-MSV-BALB/3T3 transformed cell line house mouse CVCL_5793 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: BALB/c. Unspecified 21188969 CVCL_4V92 COLO206F-AR cancer cell line human CVCL_4V92 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from metastatic site: Ascites. Male 21188970 CVCL_5792 LX-2 transformed cell line human CVCL_5792 CL:0000010 Anecdotal: Cell line name is derived from the name of the first author of the original paper Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Omics: Extracellular matrix proteome analysis; Omics: Deep quantitative proteome analysis Male Characteristics: Able to grow under reduced serum conditions (1% FBS) (PubMed=15591520) Doubling time: ~3-4 days (PubMed=15591520); 53.3 +- 2.3 hours (PubMed=21930125) 21188971 CVCL_4V91 COLO201-AR cancer cell line human CVCL_4V91 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90227; Selumetinib (AZD6244); Derived from metastatic site: Ascites. Male 21188972 CVCL_5791 LX-1 [Human lung carcinoma] cancer cell line human CVCL_5791 CL:0000010 Discontinued: CLS; 300268; true. Male 21188973 CVCL_5790 LX-1 [Human HSC] transformed cell line human CVCL_5790 CL:0000010 Anecdotal: Cell line name is derived from the name of the first author of the original paper Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.. Male Doubling time: 24 hours (PubMed=15591520) 21188974 CVCL_4V90 RPMI-8226/MR4 cancer cell line human CVCL_4V90 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgG lambda (from parent cell line) 21188975 CVCL_5786 KF1SV transformed cell line house mouse CVCL_5786 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: C57BL/6 x BALB/c. 21188976 CVCL_4V86 N14A transformed cell line human CVCL_4V86 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female Doubling time: ~48 hours (PubMed=25929336) 21188977 CVCL_4V85 K562/AS2 cancer cell line human CVCL_4V85 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Pleural effusion. Female 21188978 CVCL_5785 KERA-SP1 cancer cell line house mouse CVCL_5785 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: SENCAR. Discontinued: CLS; 400430; true Female 21188979 CVCL_4V84 K562/AS-3 cancer cell line human CVCL_4V84 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:30621; Diarsenic trioxide (ATO; Derived from sampling site: Pleural effusion. Female 21188980 CVCL_5784 KERA-LC14 spontaneously immortalized cell line house mouse CVCL_5784 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified 21188981 CVCL_5783 KERA-BP4 cancer cell line house mouse CVCL_5783 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: BALB/c. Unspecified 21188982 CVCL_4V83 SOSP-9607/F5M2 cancer cell line human CVCL_4V83 CL:0000010 Population: Chinese; Derived from sampling site: Bone. Male Doubling time: 20 +- 2 hours (PubMed=20016965) 21188983 CVCL_5789 LS-CLS cancer cell line CVCL_5789 CL:0000010 Unspecified 21188984 CVCL_4V89 SKOV-3TR cancer cell line human CVCL_4V89 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21188985 CVCL_4V88 MOLP-2/R cancer cell line human CVCL_4V88 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala159Val (c.476C>T); ClinVar=VCV000458545; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgD lambda 21188986 CVCL_5787 L-5222 cancer cell line Norway rat CVCL_5787 CL:0000010 Breed/subspecies: BDIX. Discontinued: CLS; 500259; true 21188987 CVCL_4V87 N15A transformed cell line human CVCL_4V87 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Male Doubling time: ~48 hours (PubMed=25929336) 21188988 CVCL_5760 H-MESO-1A cancer cell line human CVCL_5760 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Glu685Val (c.2054A>T); Zygosity=Heterozygous (PubMed=21642991) Omics: SNP array analysis Male 21188989 CVCL_4V60 K562-IMA[r] cancer cell line human CVCL_4V60 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21188990 CVCL_5753 FRTL spontaneously immortalized cell line Norway rat CVCL_5753 CL:0000010 Derived from sampling site: Thyroid gland; Breed/subspecies: Fischer. Discontinued: ATCC; CRL-1468; true Unspecified Doubling time: 5-7 days (PubMed=1726925) 21188991 CVCL_4V53 MCF-7/4-HC cancer cell line human CVCL_4V53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:196991; 4-hydroperoxycyclophosphamide; Derived from metastatic site: Pleural effusion. Female 21188992 CVCL_5752 FOM 78 finite cell line human CVCL_5752 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Omics: Proteome analysis by 2D-DE/MS Male 21188993 CVCL_4V52 SK-BR-3-LR cancer cell line human CVCL_4V52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 21188994 CVCL_5751 FOM 71 finite cell line human CVCL_5751 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 21188995 CVCL_4V51 K562/NIL-50 cancer cell line human CVCL_4V51 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Derived from sampling site: Pleural effusion. Female 21188996 CVCL_5750 FAMPAC-A cancer cell line human CVCL_5750 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (CLS); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Pancreas. Female Doubling time: ~32 hours (CLS) 21188997 CVCL_4V50 LoVo/irinotecan cancer cell line human CVCL_4V50 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Left supraclavicular lymph node. Omics: Proteome analysis by 2D-DE/MS Male 21188998 CVCL_5757 GC7 spontaneously immortalized cell line CVCL_5757 CL:0000010 Derived from sampling site: Kidney. Group: Non-human primate cell line 21188999 CVCL_4V57 NALM6/Clo cancer cell line human CVCL_4V57 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:681569; Clofarabine (CAFdA); Derived from sampling site: Peripheral blood. Male 21189000 CVCL_5756 FS-C57BL cancer cell line house mouse CVCL_5756 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Female 21189001 CVCL_4V56 HL/CAFdA80 cancer cell line human CVCL_4V56 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:681569; Clofarabine (CAFdA); Derived from sampling site: Peripheral blood. Female 21189002 CVCL_5755 FS-C3H cancer cell line house mouse CVCL_5755 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C3H. 21189003 CVCL_4V55 HL/CAFdA20 cancer cell line human CVCL_4V55 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:681569; Clofarabine (CAFdA); Derived from sampling site: Peripheral blood. Female 21189004 CVCL_5754 FS-Balb cancer cell line house mouse CVCL_5754 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: BALB/c. 21189005 CVCL_4V54 K562-BMS-R cancer cell line human CVCL_4V54 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825); Derived from sampling site: Pleural effusion. Female 21189006 CVCL_5759 H-MESO-1 cancer cell line human CVCL_5759 CL:0000010 Omics: SNP array analysis Male Caution: Indicated as originating from a 35 year old male patient in PubMed=3555770 and from a 42 year old male patient in PubMed=3496960. 21189007 CVCL_4V59 K562-DAS[r] cancer cell line human CVCL_4V59 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825); Derived from sampling site: Pleural effusion. Female 21189008 CVCL_5758 GC-BJAB cancer cell line human CVCL_5758 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Groin. Female Virology: EBV-negative cell line infected with EBV strain B95-8 (PubMed=170210) 21189009 CVCL_4V58 SKW3/Clo cancer cell line human CVCL_4V58 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln2459Ter (c.7375C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg571Gln (c.1712G>A); ClinVar=VCV000819886; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Gly310Glu (c.929G>A); ClinVar=VCV000237678; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line). Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:681569; Clofarabine (CAFdA) Male Problematic cell line: Contaminated Parent cell line (SKW-3) has been shown to be a KE-37 derivative. 21189010 CVCL_5771 Hep-66.3A cancer cell line house mouse CVCL_5771 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x C3H. Female 21189011 CVCL_4V71 KMS-11/BTZ cancer cell line human CVCL_4V71 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5739; IGKV1-37; Name(s)=IGKV1-37-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5816; IGKV3-15; Name(s)=IGKV3-15-IGKJ5 (from parent cell line); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Tyr373Cys (c.1118A>G); ClinVar=VCV000016342; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*3; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa 21189012 CVCL_5770 Hep-64.1 cancer cell line house mouse CVCL_5770 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6 x C3H. Female 21189013 CVCL_4V70 SK24 spontaneously immortalized cell line CVCL_4V70 CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Ovary. Female 21189014 CVCL_4V64 K562-PON[r] cancer cell line human CVCL_4V64 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:78543; Ponatinib (AP24534; Derived from sampling site: Pleural effusion. Female 21189015 CVCL_5764 MOLP-3 cancer cell line human CVCL_5764 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Produces IgD lambda Doubling time: ~96 hours (PubMed=8148313) 21189016 CVCL_5763 HCTK-1 cancer cell line human CVCL_5763 CL:0000010 Derived from sampling site: Oral cavity; tongue. Male 21189017 CVCL_4V63 K562-NIL[r] cancer cell line human CVCL_4V63 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:52172; Nilotinib (AMN107; Derived from sampling site: Pleural effusion. Female 21189018 CVCL_5762 HCFMK-1 cancer cell line human CVCL_5762 CL:0000010 Derived from sampling site: Oral cavity; floor of mouth. Female 21189019 CVCL_4V62 K562-IMA[r]+PON[r] cancer cell line human CVCL_4V62 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Selected for resistance to: ChEBI; CHEBI:78543; Ponatinib (AP24534; Derived from sampling site: Pleural effusion. Female 21189020 CVCL_5761 HB-CLS-3 cancer cell line Norway rat CVCL_5761 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: ACI. Male 21189021 CVCL_4V61 K562-IMA[r]+DAS[r] cancer cell line human CVCL_4V61 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49375; Dasatinib (BMS-354825); Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21189022 CVCL_5768 Hep-56.1C cancer cell line house mouse CVCL_5768 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6J. Female 21189023 CVCL_4V68 SKBR3-LAP[r] cancer cell line human CVCL_4V68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 21189024 CVCL_5767 Hep-56.1B cancer cell line house mouse CVCL_5767 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Arg277Thr (c.830G>C); Zygosity=Heterozygous (PubMed=1382443) Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6J. Female 21189025 CVCL_4V67 MDA231-DOX[r] cancer cell line human CVCL_4V67 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21189026 CVCL_5766 Hep-55.1C cancer cell line house mouse CVCL_5766 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6J. Female 21189027 CVCL_4V66 MCF7-AFA[r] cancer cell line human CVCL_4V66 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:61390; Afatinib (BIBW-2992); Derived from metastatic site: Pleural effusion. Female 21189028 CVCL_4V65 BT474-5FU[r] cancer cell line human CVCL_4V65 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Breast. Female 21189029 CVCL_5765 Hep-53.4 cancer cell line house mouse CVCL_5765 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6J. Female 21189030 CVCL_4V69 BFTC-905-DOXO-II cancer cell line human CVCL_4V69 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Chinese; Taiwan; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Urinary bladder. Female 21189031 CVCL_5769 Hep-56.1D cancer cell line house mouse CVCL_5769 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Cys132Trp (c.396C>G); Zygosity=Heterozygous (PubMed=1382443) Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: C57BL/6J. Female Doubling time: ~25-30 hours (CLS) 21189032 CVCL_FI49 ND04408 transformed cell line human CVCL_FI49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189033 CVCL_FI48 ND04388 transformed cell line human CVCL_FI48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189034 CVCL_FI47 ND04353 transformed cell line human CVCL_FI47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189035 CVCL_FI46 ND04290 transformed cell line human CVCL_FI46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189036 CVCL_FI41 ND04285 transformed cell line human CVCL_FI41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189037 CVCL_FI40 ND04283 transformed cell line human CVCL_FI40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189038 CVCL_FI45 ND04289 transformed cell line human CVCL_FI45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189039 CVCL_FI44 ND04288 transformed cell line human CVCL_FI44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189040 CVCL_FI43 ND04287 transformed cell line human CVCL_FI43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189041 CVCL_FI42 ND04286 transformed cell line human CVCL_FI42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189042 CVCL_FI59 ND04615 transformed cell line human CVCL_FI59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189043 CVCL_FI58 ND04614 transformed cell line human CVCL_FI58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189044 CVCL_FI57 ND04613 transformed cell line human CVCL_FI57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189045 CVCL_FI52 ND04520 transformed cell line human CVCL_FI52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189046 CVCL_FI51 ND04505 transformed cell line human CVCL_FI51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189047 CVCL_FI50 ND04496 transformed cell line human CVCL_FI50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189048 CVCL_FI56 ND04538 transformed cell line human CVCL_FI56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189049 CVCL_FI55 ND04530 transformed cell line human CVCL_FI55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189050 CVCL_FI54 ND04524 transformed cell line human CVCL_FI54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189051 CVCL_FI53 ND04523 transformed cell line human CVCL_FI53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189052 CVCL_FI27 ND04194 transformed cell line human CVCL_FI27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189053 CVCL_FI26 ND04193 transformed cell line human CVCL_FI26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189054 CVCL_FI25 ND04192 transformed cell line human CVCL_FI25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189055 CVCL_FI24 ND04191 transformed cell line human CVCL_FI24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189056 CVCL_FI29 ND04196 transformed cell line human CVCL_FI29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189057 CVCL_FI28 ND04195 transformed cell line human CVCL_FI28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189058 CVCL_FI23 ND04183 transformed cell line human CVCL_FI23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189059 CVCL_FI22 ND04153 transformed cell line human CVCL_FI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189060 CVCL_FI21 ND04123 transformed cell line human CVCL_FI21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189061 CVCL_FI20 ND04119 transformed cell line human CVCL_FI20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189062 CVCL_FI38 ND04278 transformed cell line human CVCL_FI38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189063 CVCL_FI37 ND04260 transformed cell line human CVCL_FI37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189064 CVCL_FI36 ND04244 transformed cell line human CVCL_FI36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189065 CVCL_FI35 ND04243 transformed cell line human CVCL_FI35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189066 CVCL_FI39 ND04282 transformed cell line human CVCL_FI39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189067 CVCL_FI30 ND04197 transformed cell line human CVCL_FI30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189068 CVCL_FI34 ND04242 transformed cell line human CVCL_FI34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189069 CVCL_FI33 ND04241 transformed cell line human CVCL_FI33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189070 CVCL_FI32 ND04226 transformed cell line human CVCL_FI32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189071 CVCL_FI31 ND04224 transformed cell line human CVCL_FI31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189072 CVCL_FI05 ND03702 transformed cell line human CVCL_FI05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189073 CVCL_FI04 ND03597 transformed cell line human CVCL_FI04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189074 CVCL_FI03 ND03598 transformed cell line human CVCL_FI03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189075 CVCL_FI02 ND03595 transformed cell line human CVCL_FI02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189076 CVCL_FI09 ND03837 transformed cell line human CVCL_FI09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189077 CVCL_FI08 ND03825 transformed cell line human CVCL_FI08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189078 CVCL_FI07 ND03786 transformed cell line human CVCL_FI07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189079 CVCL_FI06 ND03771 transformed cell line human CVCL_FI06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189080 CVCL_FI01 ND03578 transformed cell line human CVCL_FI01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189081 CVCL_FI00 ND03552 transformed cell line human CVCL_FI00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189082 CVCL_FI16 ND04082 transformed cell line human CVCL_FI16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189083 CVCL_FI15 ND04081 transformed cell line human CVCL_FI15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189084 CVCL_FI14 ND04080 transformed cell line human CVCL_FI14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189085 CVCL_FI13 ND04079 transformed cell line human CVCL_FI13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189086 CVCL_FI19 ND04102 transformed cell line human CVCL_FI19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189087 CVCL_FI18 ND04084 transformed cell line human CVCL_FI18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189088 CVCL_FI17 ND04083 transformed cell line human CVCL_FI17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189089 CVCL_FI12 ND04078 transformed cell line human CVCL_FI12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189090 CVCL_FI11 ND04077 transformed cell line human CVCL_FI11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189091 CVCL_FI10 ND04021 transformed cell line human CVCL_FI10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189092 CVCL_FI92 ND05219 transformed cell line human CVCL_FI92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189093 CVCL_FI91 ND05194 transformed cell line human CVCL_FI91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189094 CVCL_FI90 ND05139 transformed cell line human CVCL_FI90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189095 CVCL_FI85 ND05073 transformed cell line human CVCL_FI85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189096 CVCL_FI84 ND05049 transformed cell line human CVCL_FI84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189097 CVCL_FI83 ND05039 transformed cell line human CVCL_FI83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189098 CVCL_FI82 ND05023 transformed cell line human CVCL_FI82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189099 CVCL_FI89 ND05138 transformed cell line human CVCL_FI89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189100 CVCL_FI88 ND05135 transformed cell line human CVCL_FI88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189101 CVCL_FI87 ND05120 transformed cell line human CVCL_FI87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189102 CVCL_FI86 ND05099 transformed cell line human CVCL_FI86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189103 CVCL_FI96 ND05284 transformed cell line human CVCL_FI96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189104 CVCL_FI95 ND05260 transformed cell line human CVCL_FI95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189105 CVCL_FI94 ND05236 transformed cell line human CVCL_FI94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189106 CVCL_FI93 ND05234 transformed cell line human CVCL_FI93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189107 CVCL_FI99 ND05320 transformed cell line human CVCL_FI99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189108 CVCL_FI98 ND05286 transformed cell line human CVCL_FI98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189109 CVCL_FI97 ND05285 transformed cell line human CVCL_FI97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189110 CVCL_FI70 ND04797 transformed cell line human CVCL_FI70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189111 CVCL_FI69 ND04787 transformed cell line human CVCL_FI69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189112 CVCL_FI68 ND04786 transformed cell line human CVCL_FI68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189113 CVCL_FI63 ND04692 transformed cell line human CVCL_FI63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189114 CVCL_FI62 ND04671 transformed cell line human CVCL_FI62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189115 CVCL_FI61 ND04658 transformed cell line human CVCL_FI61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189116 CVCL_FI60 ND04633 transformed cell line human CVCL_FI60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189117 CVCL_FI67 ND04777 transformed cell line human CVCL_FI67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189118 CVCL_FI66 ND04774 transformed cell line human CVCL_FI66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189119 CVCL_FI65 ND04750 transformed cell line human CVCL_FI65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189120 CVCL_FI64 ND04708 transformed cell line human CVCL_FI64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189121 CVCL_FI81 ND05020 transformed cell line human CVCL_FI81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189122 CVCL_FI80 ND05014 transformed cell line human CVCL_FI80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189123 CVCL_FI79 ND04996 transformed cell line human CVCL_FI79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189124 CVCL_FI74 ND04920 transformed cell line human CVCL_FI74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189125 CVCL_FI73 ND04918 transformed cell line human CVCL_FI73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189126 CVCL_FI72 ND04876 transformed cell line human CVCL_FI72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189127 CVCL_FI71 ND04850 transformed cell line human CVCL_FI71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189128 CVCL_FI78 ND04993 transformed cell line human CVCL_FI78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189129 CVCL_FI77 ND04969 transformed cell line human CVCL_FI77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189130 CVCL_FI76 ND04955 transformed cell line human CVCL_FI76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189131 CVCL_FI75 ND03425 transformed cell line human CVCL_FI75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189132 CVCL_4W52 HUEhT-2 telomerase immortalized cell line human CVCL_4W52 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Umbilical vein. Female 21189133 CVCL_5852 PA-CLS-52 cancer cell line human CVCL_5852 CL:0000010 Derived from sampling site: Pancreas Cell type=Epithelial cell.. Discontinued: CLS; 300386; true Female Doubling time: ~45 hours (CLS) 21189134 CVCL_4W51 HUEhT-1 telomerase immortalized cell line human CVCL_4W51 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Umbilical vein. Female 21189135 CVCL_5851 OS1-CLS cancer cell line Norway rat CVCL_5851 CL:0000010 Derived from sampling site: Bone; Breed/subspecies: Sprague Dawley. Unspecified 21189136 CVCL_4W50 hTf9-11E hybridoma house mouse CVCL_4W50 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21189137 CVCL_5850 OLN-93 spontaneously immortalized cell line Norway rat CVCL_5850 CL:0000010 Derived from sampling site: Brain Cell type=Oligodendrocyte.; Breed/subspecies: Wistar. Unspecified Doubling time: 16-18 hours (PubMed=8843033) 21189138 CVCL_4W56 IKK-i-DEF finite cell line house mouse CVCL_4W56 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1929612; Ikbke Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21189139 CVCL_5856 PCC4 AG Cap cancer cell line house mouse CVCL_5856 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Breed/subspecies: 129/Sv. Male 21189140 CVCL_4W55 HuSI-L23-9-10 transformed cell line human CVCL_4W55 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21189141 CVCL_5855 PCC4 AG cancer cell line house mouse CVCL_5855 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: 129/Sv. Male 21189142 CVCL_4W54 HuSI-L23 transformed cell line human CVCL_4W54 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21189143 CVCL_5854 PCC4 cancer cell line house mouse CVCL_5854 CL:0000010 Breed/subspecies: 129/Sv. Discontinued: JCRB; JCRB0205; true Male 21189144 CVCL_4W53 Huh7S1 cancer cell line human CVCL_4W53 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 21189145 CVCL_5853 PAC2 spontaneously immortalized cell line zebrafish CVCL_5853 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21189146 CVCL_4W59 KCMC-1379 finite cell line human CVCL_4W59 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189147 CVCL_5859 PECA cancer cell line house mouse CVCL_5859 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: NMRI. Characteristics: Forms primary metastatic lesions in the lung (CLS) 21189148 CVCL_4W58 JMU-RTK-2 cancer cell line human CVCL_4W58 CL:0000010 Population: Japanese; Derived from metastatic site: Cerebrospinal fluid. Omics: Deep exome analysis Female Doubling time: ~18 hours (PubMed=19383826); ~36 hours (lot 11242017) (JCRB) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21189149 CVCL_5858 PDV transformed cell line house mouse CVCL_5858 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C57BL/10 LP. Unspecified 21189150 CVCL_4W57 JMU-RTK-1 cancer cell line human CVCL_4W57 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: ~9 hours (PubMed=19383826) 21189151 CVCL_5857 PCC4-azal cancer cell line house mouse CVCL_5857 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: 129/Sv. Male 21189152 CVCL_5870 KTCTL-13 cancer cell line human CVCL_5870 Genome ancestry: African=0.27%; Native American=0.52%; East Asian, North=1.51%; East Asian, South=0%; South Asian=1.01%; European, North=76.23%; European, South=20.46% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Asp143Glufs*16 (c.429del); Zygosity=Unspecified (PubMed=7915601) Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189153 CVCL_4W70 Onda 9R-B12 cancer cell line human CVCL_4W70 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ile101del (c.301_303delATC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Brain. Male 21189154 CVCL_4W63 KYAE-2 cancer cell line human CVCL_4W63 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Female 21189155 CVCL_5863 PHL spontaneously immortalized cell line CVCL_5863 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Group: Fish cell line 21189156 CVCL_4W62 KMRM-S2 cancer cell line human CVCL_4W62 CL:0000010 Population: Japanese; Karyotypic information: Hypertriploid karyotype Has lost chromosome Y (PubMed=23379954).; Derived from metastatic site: Head; skin. Male Doubling time: 51 hours (PubMed=23379954) 21189157 CVCL_5862 PH5 transformed cell line pig CVCL_5862 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; vitreous body Cell type=Hyalocyte.. Unspecified Doubling time: 56.9 +- 22.6 hours (PubMed=17707370) 21189158 CVCL_4W61 KCMC-1694 finite cell line human CVCL_4W61 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ile500Thr (c.1499T>C); ClinVar=VCV000030149; Zygosity=Unspecified (JCRB) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189159 CVCL_5861 PECA-4451 cancer cell line human CVCL_5861 CL:0000010 21189160 CVCL_4W60 KCMC-1528 transformed cell line human CVCL_4W60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189161 CVCL_5860 PECA-4197 cancer cell line human CVCL_5860 CL:0000010 21189162 CVCL_4W67 Onda 7 cancer cell line human CVCL_4W67 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asp252Gly (c.755A>G); ClinVar=VCV000007849; Zygosity=Unspecified (PubMed=10551321) Population: Japanese; Derived from sampling site: Brain; right temporal lobe. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189163 CVCL_5867 RC-124 finite cell line human CVCL_5867 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney Cell type=Epithelial cell.. Discontinued: CLS; 300251; true Male 21189164 CVCL_4W66 NP-8 cancer cell line human CVCL_4W66 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Unspecified (PubMed=8878451) Population: Japanese; Derived from sampling site: Brain; left temporal lobe. Omics: Deep exome analysis Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189165 CVCL_5866 Raszip 6 transformed cell line house mouse CVCL_5866 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21189166 CVCL_4W65 L5178Y TK+/- (clone 3.7.2C) (IVGT) cancer cell line house mouse CVCL_4W65 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female Part of: In Vitro Genetic Toxicity (IVGT) cell line panel 21189167 CVCL_5865 PMJ2-R transformed cell line house mouse CVCL_5865 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Peritoneal effusion Cell type=Peritoneal macrophage.; Breed/subspecies: C57BL/6J. Female 21189168 CVCL_4W64 L12.28-1/1 transformed cell line human CVCL_4W64 CL:0000010 Transformant: Unknown; Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21189169 CVCL_5864 PMJ2-PC transformed cell line house mouse CVCL_5864 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Peritoneal effusion Cell type=Peritoneal macrophage.; Breed/subspecies: C57BL/6J. Female 21189170 CVCL_5869 KTCTL-135 cancer cell line human CVCL_5869 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Discontinued: CLS; 300239; true Male 21189171 CVCL_4W69 Onda 9R cancer cell line human CVCL_4W69 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Ile101del (c.301_303delATC); Zygosity=Unspecified (from autologous cell line Onda 9) Population: Japanese; Derived from sampling site: Brain. Male 21189172 CVCL_5868 KTCTL-21 cancer cell line human CVCL_5868 Genome ancestry: African=0%; Native American=0.07%; East Asian, North=0.03%; East Asian, South=0%; South Asian=1.41%; European, North=62.87%; European, South=35.62% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Discontinued: CLS; 300247; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21189173 CVCL_4W68 Onda 8 cancer cell line human CVCL_4W68 CL:0000010 Population: Japanese; Derived from sampling site: Brain; parietal lobe. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189174 CVCL_4W30 EM-E6E7TERT-2 transformed cell line human CVCL_4W30 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium; glandular epithelium. Female 21189175 CVCL_5830 MM5.1 [Mouse] cancer cell line house mouse CVCL_5830 CL:0000010 Breed/subspecies: C3H. Discontinued: ATCC; CRL-6380; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189176 CVCL_4W34 EPC-1 transformed cell line human CVCL_4W34 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium. Female 21189177 CVCL_5834 MM52.T cancer cell line house mouse CVCL_5834 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6429; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189178 CVCL_4W33 EMC214 transformed cell line human CVCL_4W33 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium. Female 21189179 CVCL_5833 MM52.Sp finite cell line house mouse CVCL_5833 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6428; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189180 CVCL_4W32 EMC100 transformed cell line human CVCL_4W32 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium. Female 21189181 CVCL_5832 MM51.Sp finite cell line house mouse CVCL_5832 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6427; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189182 CVCL_4W31 EM-E6E7TERT-3 transformed cell line human CVCL_4W31 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium; glandular epithelium. Female 21189183 CVCL_5831 MM5/C1 cancer cell line house mouse CVCL_5831 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/Crgl. Discontinued: ATCC; CRL-6444; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189184 CVCL_4W38 HAdpc-26-E6-Bmi-1-TERT transformed cell line human CVCL_4W38 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6 Transformant: Human papillomavirus type 16 (HPV16) [E6](NCBI-Taxonomy; 333760); Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21189185 CVCL_5838 MM55.K finite cell line house mouse CVCL_5838 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: AKR. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189186 CVCL_4W37 HAdpc-25-Bmi-1-TERT telomerase immortalized cell line human CVCL_4W37 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: HGNC; 11730; TERT Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21189187 CVCL_5837 MM54.Sp/Thy finite cell line house mouse CVCL_5837 CL:0000010 Derived from sampling site: Spleen and thymus; Breed/subspecies: CBA/T6. Discontinued: ATCC; CRL-6434; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189188 CVCL_4W36 H-1A(H123) finite cell line house mouse CVCL_4W36 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C57BL/6. 21189189 CVCL_5836 MM54.K finite cell line house mouse CVCL_5836 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: CBA/T6. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189190 CVCL_4W35 FRTK-1 cancer cell line human CVCL_4W35 CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Glu300Ter (c.898G>T); Zygosity=Unspecified (PubMed=16820901) Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: ~24 hours (PubMed=16820901) 21189191 CVCL_5835 MM53.Sp finite cell line house mouse CVCL_5835 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6430; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189192 CVCL_4W39 HAdpc-28-E6E7-TERT transformed cell line human CVCL_4W39 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21189193 CVCL_5839 MM55.Sp/Thy finite cell line house mouse CVCL_5839 CL:0000010 Derived from sampling site: Spleen and thymus; Breed/subspecies: AKR. Discontinued: ATCC; CRL-6437; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189194 CVCL_4W41 HeLa PurRII7 cancer cell line human CVCL_4W41 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:17939; Puromycin; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21189195 CVCL_5841 MM7-11.Sp cancer cell line house mouse CVCL_5841 CL:0000010 Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Derived from sampling site: Spleen. Discontinued: ATCC; CRL-6381; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189196 CVCL_4W40 HAdpc-29-E7-TERT transformed cell line human CVCL_4W40 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female 21189197 CVCL_5840 Mm5MT cancer cell line house mouse CVCL_5840 CL:0000010 Transformant: Mouse mammary tumor virus (MMTV)(NCBI-Taxonomy; 11757); Derived from sampling site: Mammary gland; Breed/subspecies: C3H/Crgl. Discontinued: ATCC; CRL-6590; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189198 CVCL_4W45 hTf18-10C/sf hybridoma house mouse CVCL_4W45 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. Group: Serum/protein free medium cell line 21189199 CVCL_5845 NIH 3T3-ras transformed cell line house mouse CVCL_5845 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21189200 CVCL_4W44 HepG2S3 cancer cell line human CVCL_4W44 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 21189201 CVCL_5844 MT1.K finite cell line CVCL_5844 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6309; true Unspecified Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189202 CVCL_4W43 HepG2S2 cancer cell line human CVCL_4W43 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 21189203 CVCL_5843 MSC-P5 cancer cell line house mouse CVCL_5843 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C3H. 21189204 CVCL_4W42 HepG2S1 cancer cell line human CVCL_4W42 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Derived from sampling site: Liver. Male 21189205 CVCL_5842 MOLP-5 cancer cell line human CVCL_5842 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Produces Ig kappa Doubling time: ~48 hours (PubMed=10848782) 21189206 CVCL_4W49 hTf30-8H/sf hybridoma house mouse CVCL_4W49 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. Group: Serum/protein free medium cell line 21189207 CVCL_5849 OKM-2T cancer cell line human CVCL_5849 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 21189208 CVCL_4W48 hTf30-8H hybridoma house mouse CVCL_4W48 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21189209 CVCL_5848 OCD cancer cell line house mouse CVCL_5848 CL:0000010 Derived from sampling site: Bone; Breed/subspecies: NMRI. Unspecified 21189210 CVCL_4W47 hTf26-9B hybridoma house mouse CVCL_4W47 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21189211 CVCL_5847 O-342 cancer cell line Norway rat CVCL_5847 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: BDIX. Female Doubling time: ~24 hours (PubMed=1744159) 21189212 CVCL_4W46 hTf2-9F hybridoma house mouse CVCL_4W46 From: Mebiopharm Co., Ltd; Tokyo; Japan CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02787; Human TF. 21189213 CVCL_5846 NOG8 spontaneously immortalized cell line house mouse CVCL_5846 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female 21189214 CVCL_4W12 B13 factor-dependent cell line house mouse CVCL_4W12 CL:0000010 Derived from sampling site: Cell type=Pre-B cell. Characteristics: IL5 dependent 21189215 CVCL_5812 MM29.We finite cell line house mouse CVCL_5812 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6403; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189216 CVCL_4W11 MK2-23 hybridoma house mouse CVCL_4W11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody 763.74. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10288 21189217 CVCL_5811 MM27.We finite cell line house mouse CVCL_5811 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6402; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189218 CVCL_4W10 GM16028 transformed cell line human CVCL_4W10 CL:0000010 Sequence variation: Mutation; HGNC; 3535; F2; Simple; c.*97G>A (20210G>A); ClinVar=VCV000013310; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Heterozygous; Note=Factor V Leiden (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Ser65Cys (c.193A>T); ClinVar=VCV000000011; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189219 CVCL_5810 MM23.We finite cell line house mouse CVCL_5810 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6401; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189220 CVCL_4W16 KYSE-2880 cancer cell line human CVCL_4W16 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21189221 CVCL_5816 MM36.We finite cell line house mouse CVCL_5816 CL:0000010 Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6413; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: Indicated to be from an embryo but sister cell lines are from an adult mouse 21189222 CVCL_4W15 KYSE-2710 cancer cell line human CVCL_4W15 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21189223 CVCL_5815 MM36T(C) cancer cell line house mouse CVCL_5815 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6411; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189224 CVCL_4W14 KYSE-2300 cancer cell line human CVCL_4W14 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21189225 CVCL_5814 MM34.We finite cell line house mouse CVCL_5814 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6408; true Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189226 CVCL_4W13 DT40-RAD54L(-/-)-XRCC6(-/-) cancer cell line CVCL_4W13 CL:0000010 Knockout cell: Method=Targeted integration; RAD54L, XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21189227 CVCL_5813 MM31.We finite cell line house mouse CVCL_5813 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6405; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189228 CVCL_4W19 GM00947 finite cell line human CVCL_4W19 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21189229 CVCL_5819 MM4.We finite cell line house mouse CVCL_5819 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6377; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189230 CVCL_5818 MM3MG finite cell line house mouse CVCL_5818 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6376; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189231 CVCL_4W18 NMFH-2 cancer cell line human CVCL_4W18 CL:0000010 Population: Japanese; Derived from sampling site: Arm; hypodermis. Male 21189232 CVCL_4W17 KYSE-3940 cancer cell line human CVCL_4W17 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male 21189233 CVCL_5817 MM37T cancer cell line house mouse CVCL_5817 CL:0000010 Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6414; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189234 CVCL_4W23 GM17478 finite cell line human CVCL_4W23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189235 CVCL_5823 MM45T.Bl cancer cell line house mouse CVCL_5823 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6420; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189236 CVCL_4W22 GM13347 transformed cell line human CVCL_4W22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189237 CVCL_5822 MM44.Sp finite cell line house mouse CVCL_5822 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Namru. Discontinued: ATCC; CRL-6419; true Mixed Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189238 CVCL_4W21 GM13164 transformed cell line human CVCL_4W21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21189239 CVCL_5821 MM43T cancer cell line house mouse CVCL_5821 CL:0000010 Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6418; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189240 CVCL_4W20 GM07490 finite cell line human CVCL_4W20 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21189241 CVCL_5820 MM41.We finite cell line house mouse CVCL_5820 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6416; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189242 CVCL_4W27 ACI-RCC cancer cell line Norway rat CVCL_4W27 CL:0000010 Transformant: Iron(III) nitrilotriacetate(ChEBI; CHEBI:132238); Derived from sampling site: Kidney; Breed/subspecies: ACI. Male 21189243 CVCL_5827 MM47T cancer cell line house mouse CVCL_5827 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6424; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189244 CVCL_4W26 293 TRE/FLAG-POLK transformed cell line human CVCL_4W26 CL:0000010 Transfected with: HGNC; 9183; POLK Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: JCRB; JCRB1532; probable Female Characteristics: Expresses POLK induced by doxycyclin 21189245 CVCL_5826 MM46T cancer cell line house mouse CVCL_5826 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6423; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189246 CVCL_4W25 293 TRE/Cont transformed cell line human CVCL_4W25 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Control cell line for 293 TRE/FLAG-POLK (Cellosaurus=CVCL_4W26) 21189247 CVCL_5825 MM45T.Sp cancer cell line house mouse CVCL_5825 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6422; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189248 CVCL_4W24 GM20841 transformed cell line human CVCL_4W24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189249 CVCL_5824 MM45T.Li cancer cell line house mouse CVCL_5824 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6421; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189250 CVCL_4W29 EM-E6E7TERT-1 transformed cell line human CVCL_4W29 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium; glandular epithelium. Female 21189251 CVCL_5829 MM49T cancer cell line house mouse CVCL_5829 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6426; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189252 CVCL_4W28 CLM-7 spontaneously immortalized cell line CVCL_4W28 CL:0000010 Derived from sampling site: Bone marrow. Male 21189253 CVCL_5828 MM48T cancer cell line house mouse CVCL_5828 CL:0000010 Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6425; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189254 CVCL_4W01 BHP2-7 Pazopanib selected cancer cell line human CVCL_4W01 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:71219; Pazopanib (Votrient); Derived from sampling site: Thyroid gland. Female Problematic cell line: Contaminated Parent cell line (BHP 2-7) has been shown to be a TPC-1 derivative. 21189255 CVCL_5801 MM.1 cancer cell line human CVCL_5801 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from child cell line MM1.S); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Val536_Asn545delValPheValAlaGlnThrValLeuGluAsninsAsp (c.1604-1630delTCTTTGTGGCCCAAACTGTTCTAGAAA); Zygosity=Homozygous (from child cell line MM1.S) Population: African American; Derived from sampling site: Peripheral blood. Omics: Protein expression by reverse-phase protein arrays Female Characteristics: Produces IgA lambda Doubling time: 72 hours (PubMed=12691914) Part of: MD Anderson Cell Lines Project 21189256 CVCL_4W00 B-thy-ts.1 conditionally immortalized cell line human CVCL_4W00 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Thyroid gland Cell type=Follicular cell.. Unspecified Doubling time: ~2 days, in 10% FCS (PubMed=1374682) 21189257 CVCL_5800 MH-TC-5123 cancer cell line Norway rat CVCL_5800 CL:0000010 Derived from metastatic site: Liver; Breed/subspecies: Buffalo. Unspecified 21189258 CVCL_5805 MM15.Sp/Thy finite cell line house mouse CVCL_5805 CL:0000010 Derived from sampling site: Spleen and thymus; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6388; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189259 CVCL_4W05 P388/VFL-10 cancer cell line house mouse CVCL_4W05 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90241; Vinflunine (VFL; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21189260 CVCL_5804 MM14.Ov finite cell line house mouse CVCL_5804 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: HRS/J. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189261 CVCL_4W04 P388/NVB-2.5 cancer cell line house mouse CVCL_4W04 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21189262 CVCL_5803 MM14.OT cancer cell line house mouse CVCL_5803 CL:0000010 Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6384; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189263 CVCL_4W03 P388/NVB-0.63 cancer cell line house mouse CVCL_4W03 CL:0000010 Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21189264 CVCL_4W02 HTori-3 transformed cell line human CVCL_4W02 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Thyroid gland Cell type=Follicular cell.. Female 21189265 CVCL_5802 MM14.Lu finite cell line house mouse CVCL_5802 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: HRS/J. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189266 CVCL_4W09 DM(ch-2/1) transformed cell line CVCL_4W09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Selected for resistance to: ChEBI; CHEBI:50667; Mercaptopurine (6-MP); Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Female 21189267 CVCL_5809 MM22.We finite cell line house mouse CVCL_5809 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6400; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189268 CVCL_4W08 AtT-20/D16v cancer cell line house mouse CVCL_4W08 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 21189269 CVCL_5808 MM19.Lu finite cell line house mouse CVCL_5808 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: NIH Swiss. Discontinued: ATCC; CRL-6396; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189270 CVCL_4W07 HEK-293.2sus transformed cell line human CVCL_4W07 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Adapted to growth in suspension Doubling time: ~34 hours (ATCC=CRL-1573.3) 21189271 CVCL_5807 MM16.Ov finite cell line house mouse CVCL_5807 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6390; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189272 CVCL_5806 MM15.OT cancer cell line house mouse CVCL_5806 CL:0000010 Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6438; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189273 CVCL_4W06 P388/VFL-2.5 cancer cell line house mouse CVCL_4W06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90241; Vinflunine (VFL; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21189274 CVCL_FK09 ND07925 transformed cell line human CVCL_FK09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189275 CVCL_FK08 ND07918 transformed cell line human CVCL_FK08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189276 CVCL_FK03 ND07599 transformed cell line human CVCL_FK03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189277 CVCL_FK02 ND07579 transformed cell line human CVCL_FK02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189278 CVCL_FK01 ND07578 transformed cell line human CVCL_FK01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189279 CVCL_FK00 ND07577 transformed cell line human CVCL_FK00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189280 CVCL_FK07 ND07901 transformed cell line human CVCL_FK07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189281 CVCL_FK06 ND07710 transformed cell line human CVCL_FK06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189282 CVCL_FK05 ND07674 transformed cell line human CVCL_FK05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189283 CVCL_FK04 ND07604 transformed cell line human CVCL_FK04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189284 CVCL_FK19 ND08021 transformed cell line human CVCL_FK19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189285 CVCL_FK14 ND07987 transformed cell line human CVCL_FK14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189286 CVCL_FK13 ND07986 transformed cell line human CVCL_FK13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189287 CVCL_FK12 ND07968 transformed cell line human CVCL_FK12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189288 CVCL_FK11 ND07929 transformed cell line human CVCL_FK11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189289 CVCL_FK18 ND08018 transformed cell line human CVCL_FK18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189290 CVCL_FK17 ND08009 transformed cell line human CVCL_FK17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189291 CVCL_FK16 ND08004 transformed cell line human CVCL_FK16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189292 CVCL_FK15 ND07996 transformed cell line human CVCL_FK15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189293 CVCL_FK10 ND07927 transformed cell line human CVCL_FK10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189294 CVCL_4W96 NCI-H1975-Luc cancer cell line human CVCL_4W96 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0724; true. Female 21189295 CVCL_5896 SJL/JB finite cell line house mouse CVCL_5896 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: SJL/J. Discontinued: ATCC; CRL-6452; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189296 CVCL_4W95 NCI-H1650-Luc cancer cell line human CVCL_4W95 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>G (IVS6-2A>G); ClinVar=VCV000458555; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS0723; true Male 21189297 CVCL_5895 SJD.1 spontaneously immortalized cell line zebrafish CVCL_5895 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: SJD. Unspecified Group: Fish cell line 21189298 CVCL_4W94 HCC827-Luc cancer cell line human CVCL_4W94 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Discontinued: JCRB; NIHS0709; true Female 21189299 CVCL_5894 SF4433 finite cell line human CVCL_5894 CL:0000010 Derived from sampling site: Brain; meninges. Unspecified Senescence: Has a finite life span like most meningioma-derived cell lines 21189300 CVCL_4W93 HCC1954-Luc cancer cell line human CVCL_4W93 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: East Indian; Derived from sampling site: Breast. Discontinued: JCRB; NIHS0708; true Female 21189301 CVCL_5893 SF4068 finite cell line human CVCL_5893 CL:0000010 Derived from sampling site: Brain; meninges. Unspecified Senescence: Has a finite life span like most meningioma-derived cell lines 21189302 CVCL_4W99 B16-F0-Luc cancer cell line house mouse CVCL_4W99 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS0698; true Male 21189303 CVCL_5899 SMRC-3 cancer cell line human CVCL_5899 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: ~2 days (PubMed=11737483) 21189304 CVCL_4W98 KP-2/CMV-Luc cancer cell line human CVCL_4W98 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp415Glufs*20 (c.1245_1248delCAGA); ClinVar=VCV000142253; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Pancreas. Discontinued: JCRB; NIHS0715; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21189305 CVCL_5898 SMRC-1 cancer cell line human CVCL_5898 CL:0000010 Population: Japanese; Karyotypic information: The number of chromosomes varies from 92 to 100 and the modal number is 95 (PubMed=11737483); Derived from sampling site: Kidney. Male Doubling time: ~6 days (PubMed=11737483) 21189306 CVCL_4W97 NCI-H23-Luc cancer cell line human CVCL_4W97 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1919Pro (c.5756A>C); ClinVar=VCV000580726; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Trp332Ter (c.996G>A); ClinVar=VCV000376339; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>C); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Derived from sampling site: Lung. Discontinued: JCRB; NIHS0727; true Male 21189307 CVCL_5897 SJL/JC finite cell line house mouse CVCL_5897 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: SJL/J. Discontinued: ATCC; CRL-6453; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189308 CVCL_5881 RCC-KL cancer cell line human CVCL_5881 HLA typing: A*02:01:01,08:01:01; B*35:01:01,49:01:01; C*04:01:01,07:01:01; DPB1*02:01,19:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:04:01; DRB1*13:02:01,14:01:01 (CLS=300281) CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189309 CVCL_4W81 TYGBK-8 cancer cell line human CVCL_4W81 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (JCRB). Population: Japanese Female 21189310 CVCL_5880 KTCTL-195 cancer cell line human CVCL_5880 Genome ancestry: African=0%; Native American=1.71%; East Asian, North=0%; East Asian, South=0%; South Asian=1.93%; European, North=62.95%; European, South=33.4% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189311 CVCL_4W80 TYBDC-1 cancer cell line human CVCL_4W80 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Female Doubling time: 1.6-2.4 days (lot 12152016) (JCRB) 21189312 CVCL_5874 RCC-GH cancer cell line human CVCL_5874 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male 21189313 CVCL_4W74 RTK [Human kidney tumor] cancer cell line human CVCL_4W74 CL:0000010 Derived from sampling site: Kidney. Male Doubling time: ~4 days (PubMed=1706306) 21189314 CVCL_5873 KTCTL-26A cancer cell line human CVCL_5873 Genome ancestry: African=0%; Native American=0.87%; East Asian, North=1.55%; East Asian, South=0%; South Asian=1.66%; European, North=66.58%; European, South=29.34% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Phe148Leufs*11 (c.444delT); ClinVar=VCV000223212; Zygosity=Unspecified (PubMed=7915601) Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI-low) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21189315 CVCL_4W73 POLK KO homo MSH- cancer cell line human CVCL_4W73 CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21189316 CVCL_5872 KTCTL-26 cancer cell line human CVCL_5872 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189317 CVCL_4W72 POLK KO hetero MSH- cancer cell line human CVCL_4W72 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21189318 CVCL_5871 KTCTL-2 cancer cell line human CVCL_5871 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; c.341-2A>T; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=7915601) Discontinued: CLS; 300246; true. Female Problematic cell line: Contaminated KTCTL-2 and KTCTL-30 have been shown to be identical (CLS; on the basis of STR profile). 21189319 CVCL_4W71 POLK F171A MSH- cancer cell line human CVCL_4W71 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 9183; POLK; Knockout cell: Method=Homologous recombination (1 of 2 alleles); HGNC; 11830; TK1; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9183; POLK; Simple_edited; p.Phe171Ala; Zygosity=Unspecified; Note=By homologous recombination (PubMed=24461735); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21189320 CVCL_5878 KTCTL-30 cancer cell line human CVCL_5878 CL:0000010 Discontinued: CLS; 300250; true. Female Problematic cell line: Contaminated KTCTL-2 and KTCTL-30 have been shown to be identical (CLS; on the basis of STR profile). 21189321 CVCL_4W78 TBK1-DEF finite cell line house mouse CVCL_4W78 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1929658; Tbk1 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6. Unspecified 21189322 CVCL_5877 KTCTL-48 cancer cell line human CVCL_5877 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189323 CVCL_4W77 SWT-2 cancer cell line human CVCL_4W77 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 18.7 +- 1.9 hours (PubMed=8760591) 21189324 CVCL_5876 RCC-GW cancer cell line human CVCL_5876 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney Cell type=Epithelial cell.. Discontinued: CLS; 300256; true Male 21189325 CVCL_4W76 SWT-1 cancer cell line human CVCL_4W76 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 16.4 +- 2.2 hours (PubMed=8760591) 21189326 CVCL_5875 KTCTL-185 cancer cell line human CVCL_5875 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189327 CVCL_4W75 SR-CDF1 DBT transformed cell line house mouse CVCL_4W75 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: BALB/c x DBA/2. Female Virology: Used for propagation and assay of mouse hepatitis virus (MHV) (PubMed=209230; PubMed=21538303) 21189328 CVCL_5879 KTCTL-140 cancer cell line human CVCL_5879 Genome ancestry: African=0%; Native American=0.77%; East Asian, North=2.03%; East Asian, South=0%; South Asian=1.72%; European, North=62.07%; European, South=33.41% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.His115Tyr (c.343C>T); dbSNP=rs5030811; Zygosity=Unspecified (PubMed=7915601) Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189329 CVCL_4W79 TMNK-1 transformed cell line human CVCL_4W79 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Sinusoidal endothelial cell.. Female Characteristics: Because it has been transduced by two constructs containing LoxP sites, transfection with the Cre recombinase eliminates both the SV40 T gene and TERT thus reverting the cells to a non-immortal phenotype; Characteristics: Transduced with two retroviral vectors: 1) SSR#197 (MoMLV/LTR-LoxP-hTERT-IRES-EGFP-LoxP-MoMLV/LTR) expressing hTERT and eGFP flanked by two loxP sites and 2) SSR#69 (MoMLV/LTR-LoxP-HygroR-HSV/TK-IRES-SV40T-LoxP-NeoR-MoMLV/LTR) expressing HygroR, HSV-1 TK and SV40 T-antigen flanked by two loxP sites Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8017 21189330 CVCL_4W92 HCC1937/CMV-Luc cancer cell line human CVCL_4W92 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Thr738_Arg775del38 (c.2212_2325del114); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Breast. Discontinued: JCRB; NIHS0707; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter Group: Triple negative breast cancer (TNBC) cell line 21189331 CVCL_5892 SF3061 finite cell line human CVCL_5892 CL:0000010 Derived from sampling site: Brain; meninges. Omics: Array-based CGH Unspecified Senescence: Has a finite life span like most meningioma-derived cell lines 21189332 CVCL_4W91 HARA-B4 cancer cell line human CVCL_4W91 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val143Ala (c.428T>C); ClinVar=VCV000804214; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Pleural effusion. Male Characteristics: Produces high level of parathyroid hormone-related peptide (PTHrP) 21189333 CVCL_5891 SAT [Mouse mammary carcinoma] cancer cell line house mouse CVCL_5891 CL:0000010 Breed/subspecies: NMRI. Female 21189334 CVCL_4W90 PJS1JTO(SVT) transformed cell line human CVCL_4W90 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189335 CVCL_5890 SAS-1 cancer cell line human CVCL_5890 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: CSF2 and IL3 dependent Doubling time: 72 hours (PubMed=9220659) 21189336 CVCL_5885 KTCTL-129 cancer cell line human CVCL_5885 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21189337 CVCL_4W85 UCB408E7TERT-34 transformed cell line human CVCL_4W85 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Male 21189338 CVCL_5884 KTCTL-1M cancer cell line human CVCL_5884 Genome ancestry: African=0%; Native American=0%; East Asian, North=0%; East Asian, South=0.82%; South Asian=1.22%; European, North=63.61%; European, South=34.35% (PubMed=30894373) CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189339 CVCL_4W84 TYUC-1 cancer cell line human CVCL_4W84 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Omics: Deep exome analysis Female Doubling time: ~30 hours (DOI=10.1158/1538-7445.AM2015-5126) 21189340 CVCL_5883 KTCTL-120 cancer cell line human CVCL_5883 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Female 21189341 CVCL_4W83 TYLMS-1 cancer cell line human CVCL_4W83 CL:0000010 Population: Japanese; Derived from sampling site: Retroperitoneal space. Female Doubling time: 38.8 hours (JCRB) 21189342 CVCL_5882 KTCTL-53 cancer cell line human CVCL_5882 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val84Profs*73 (c.250_256del); Zygosity=Unspecified (PubMed=7915601) Population: Caucasian; Derived from sampling site: Kidney. Male 21189343 CVCL_4W82 TYHPC-1 cancer cell line human CVCL_4W82 CL:0000010 Population: Japanese; Derived from metastatic site: Liver. Male Doubling time: 38.8 hours (JCRB) 21189344 CVCL_4W89 GBM2603 cancer cell line human CVCL_4W89 CL:0000010 Population: Chinese Omics: Array-based CGH. 21189345 CVCL_5889 RTE2 finite cell line Norway rat CVCL_5889 CL:0000010 Derived from sampling site: Oral cavity; tongue; epithelium; Breed/subspecies: Sprague Dawley. Unspecified 21189346 CVCL_4W88 FM116 cancer cell line human CVCL_4W88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012) Omics: Array-based CGH. Unspecified 21189347 CVCL_5888 KTCTL-87 cancer cell line human CVCL_5888 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189348 CVCL_4W87 23F2G hybridoma house mouse CVCL_4W87 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11081 21189349 CVCL_5887 RCC-PR cancer cell line human CVCL_5887 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Female 21189350 CVCL_5886 KTCTL-54 cancer cell line human CVCL_5886 CL:0000010 Population: Caucasian; Derived from sampling site: Kidney. Male 21189351 CVCL_4W86 WRLS1 cancer cell line human CVCL_4W86 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:50924; Sorafenib (Nexavar); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (WRL-68) has been shown to be a HeLa derivative. 21189352 CVCL_FJ69 ND06809 transformed cell line human CVCL_FJ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189353 CVCL_FJ68 ND06807 transformed cell line human CVCL_FJ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189354 CVCL_FJ67 ND06755 transformed cell line human CVCL_FJ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189355 CVCL_FJ62 ND06691 transformed cell line human CVCL_FJ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189356 CVCL_FJ61 ND06665 transformed cell line human CVCL_FJ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189357 CVCL_FJ60 ND06663 transformed cell line human CVCL_FJ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189358 CVCL_FJ66 ND06754 transformed cell line human CVCL_FJ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189359 CVCL_FJ65 ND06753 transformed cell line human CVCL_FJ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189360 CVCL_FJ64 ND06709 transformed cell line human CVCL_FJ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189361 CVCL_FJ63 ND06707 transformed cell line human CVCL_FJ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189362 CVCL_FJ80 ND07059 transformed cell line human CVCL_FJ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189363 CVCL_FJ79 ND07043 transformed cell line human CVCL_FJ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189364 CVCL_FJ78 ND07041 transformed cell line human CVCL_FJ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189365 CVCL_FJ73 ND06912 transformed cell line human CVCL_FJ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189366 CVCL_FJ72 ND06840 transformed cell line human CVCL_FJ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189367 CVCL_FJ71 ND06825 transformed cell line human CVCL_FJ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189368 CVCL_FJ70 ND06824 transformed cell line human CVCL_FJ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189369 CVCL_FJ77 ND07038 transformed cell line human CVCL_FJ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189370 CVCL_FJ76 ND06972 transformed cell line human CVCL_FJ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189371 CVCL_FJ75 ND06950 transformed cell line human CVCL_FJ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189372 CVCL_FJ74 ND06917 transformed cell line human CVCL_FJ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189373 CVCL_FJ48 ND06429 transformed cell line human CVCL_FJ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189374 CVCL_FJ47 ND06303 transformed cell line human CVCL_FJ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189375 CVCL_FJ46 ND06269 transformed cell line human CVCL_FJ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189376 CVCL_FJ45 ND06211 transformed cell line human CVCL_FJ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189377 CVCL_FJ49 ND06430 transformed cell line human CVCL_FJ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189378 CVCL_FJ40 ND06049 transformed cell line human CVCL_FJ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189379 CVCL_FJ44 ND06167 transformed cell line human CVCL_FJ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189380 CVCL_FJ43 ND06087 transformed cell line human CVCL_FJ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189381 CVCL_FJ42 ND06054 transformed cell line human CVCL_FJ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189382 CVCL_FJ41 ND06052 transformed cell line human CVCL_FJ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189383 CVCL_FJ59 ND06633 transformed cell line human CVCL_FJ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189384 CVCL_FJ58 ND06631 transformed cell line human CVCL_FJ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189385 CVCL_FJ57 ND06629 transformed cell line human CVCL_FJ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189386 CVCL_FJ56 ND06600 transformed cell line human CVCL_FJ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189387 CVCL_FJ51 ND06498 transformed cell line human CVCL_FJ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189388 CVCL_FJ50 ND06486 transformed cell line human CVCL_FJ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189389 CVCL_FJ55 ND06598 transformed cell line human CVCL_FJ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189390 CVCL_FJ54 ND06556 transformed cell line human CVCL_FJ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189391 CVCL_FJ53 ND06552 transformed cell line human CVCL_FJ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189392 CVCL_FJ52 ND06530 transformed cell line human CVCL_FJ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189393 CVCL_FJ26 ND05844 transformed cell line human CVCL_FJ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189394 CVCL_FJ25 ND05819 transformed cell line human CVCL_FJ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189395 CVCL_FJ24 ND05794 transformed cell line human CVCL_FJ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189396 CVCL_FJ23 ND05759 transformed cell line human CVCL_FJ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189397 CVCL_FJ29 ND05943 transformed cell line human CVCL_FJ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189398 CVCL_FJ28 ND05942 transformed cell line human CVCL_FJ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189399 CVCL_FJ27 ND05925 transformed cell line human CVCL_FJ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189400 CVCL_FJ22 ND05736 transformed cell line human CVCL_FJ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189401 CVCL_FJ21 ND05719 transformed cell line human CVCL_FJ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189402 CVCL_FJ20 ND05718 transformed cell line human CVCL_FJ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189403 CVCL_FJ37 ND06003 transformed cell line human CVCL_FJ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189404 CVCL_FJ36 ND06002 transformed cell line human CVCL_FJ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189405 CVCL_FJ35 ND05970 transformed cell line human CVCL_FJ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189406 CVCL_FJ34 ND05967 transformed cell line human CVCL_FJ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189407 CVCL_FJ39 ND06047 transformed cell line human CVCL_FJ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189408 CVCL_FJ38 ND06033 transformed cell line human CVCL_FJ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189409 CVCL_FJ33 ND05947 transformed cell line human CVCL_FJ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189410 CVCL_FJ32 ND05946 transformed cell line human CVCL_FJ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189411 CVCL_FJ31 ND05945 transformed cell line human CVCL_FJ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189412 CVCL_FJ30 ND05944 transformed cell line human CVCL_FJ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189413 CVCL_FJ09 ND05508 transformed cell line human CVCL_FJ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189414 CVCL_FJ04 ND05406 transformed cell line human CVCL_FJ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189415 CVCL_FJ03 ND05400 transformed cell line human CVCL_FJ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189416 CVCL_FJ02 ND05339 transformed cell line human CVCL_FJ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189417 CVCL_FJ01 ND05330 transformed cell line human CVCL_FJ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189418 CVCL_FJ08 ND05480 transformed cell line human CVCL_FJ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189419 CVCL_FJ07 ND05463 transformed cell line human CVCL_FJ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189420 CVCL_FJ06 ND05434 transformed cell line human CVCL_FJ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189421 CVCL_FJ05 ND05418 transformed cell line human CVCL_FJ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189422 CVCL_FJ00 ND05321 transformed cell line human CVCL_FJ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189423 CVCL_FJ15 ND05613 transformed cell line human CVCL_FJ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189424 CVCL_FJ14 ND05597 transformed cell line human CVCL_FJ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189425 CVCL_FJ13 ND05596 transformed cell line human CVCL_FJ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189426 CVCL_FJ12 ND05595 transformed cell line human CVCL_FJ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189427 CVCL_FJ19 ND05678 transformed cell line human CVCL_FJ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189428 CVCL_FJ18 ND05671 transformed cell line human CVCL_FJ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189429 CVCL_FJ17 ND05670 transformed cell line human CVCL_FJ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189430 CVCL_FJ16 ND05669 transformed cell line human CVCL_FJ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189431 CVCL_FJ11 ND05594 transformed cell line human CVCL_FJ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189432 CVCL_FJ10 ND05586 transformed cell line human CVCL_FJ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189433 CVCL_FJ91 ND07260 transformed cell line human CVCL_FJ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189434 CVCL_FJ90 ND07258 transformed cell line human CVCL_FJ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189435 CVCL_FJ89 ND07252 transformed cell line human CVCL_FJ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189436 CVCL_FJ84 ND07102 transformed cell line human CVCL_FJ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189437 CVCL_FJ83 ND07101 transformed cell line human CVCL_FJ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189438 CVCL_FJ82 ND07082 transformed cell line human CVCL_FJ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189439 CVCL_FJ81 ND07064 transformed cell line human CVCL_FJ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189440 CVCL_FJ88 ND07250 transformed cell line human CVCL_FJ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189441 CVCL_FJ87 ND07247 transformed cell line human CVCL_FJ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189442 CVCL_FJ86 ND07212 transformed cell line human CVCL_FJ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189443 CVCL_FJ85 ND07153 transformed cell line human CVCL_FJ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189444 CVCL_FJ95 ND07329 transformed cell line human CVCL_FJ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189445 CVCL_FJ94 ND07328 transformed cell line human CVCL_FJ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189446 CVCL_FJ93 ND07272 transformed cell line human CVCL_FJ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189447 CVCL_FJ92 ND07261 transformed cell line human CVCL_FJ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189448 CVCL_FJ99 ND07576 transformed cell line human CVCL_FJ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189449 CVCL_FJ98 ND07477 transformed cell line human CVCL_FJ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189450 CVCL_FJ97 ND07466 transformed cell line human CVCL_FJ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189451 CVCL_FJ96 ND07448 transformed cell line human CVCL_FJ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189452 CVCL_5980 AC-6.21 stromal cell line house mouse CVCL_5980 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BALB/c. Unspecified 21189453 CVCL_5973 UM-SCV-1B cancer cell line human CVCL_5973 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=7503188; PubMed=9887230) Derived from metastatic site: Pleural effusion. Female Doubling time: 34 hours (PubMed=15047230) 21189454 CVCL_5972 UM-EC-1 cancer cell line human CVCL_5972 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9887230) Derived from sampling site: Endometrium. Female Doubling time: 24 hours (PubMed=1541432) 21189455 CVCL_5971 CLS-354 cancer cell line human CVCL_5971 CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; mouth. Male 21189456 CVCL_5977 UM-SCV-7 cancer cell line human CVCL_5977 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=7503188; PubMed=9887230); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Serfs*95 (c.747delG); Zygosity=Unspecified (PubMed=7503188; PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 37 hours (PubMed=15047230) 21189457 CVCL_5976 UM-SCV-4 cancer cell line human CVCL_5976 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro151His (c.452C>A); ClinVar=VCV000376639; Zygosity=Unspecified (PubMed=7503188; PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 56 hours (PubMed=15047230); 54.7 +- 5.27 hours (PubMed=31654625) 21189458 CVCL_5975 UM-SCV-3 cancer cell line human CVCL_5975 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=7503188; PubMed=9887230); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser314Ser (c.942C>T); dbSNP=rs765930028; Zygosity=Unspecified (PubMed=7503188; PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 76 hours (PubMed=15047230) 21189459 CVCL_5974 UM-SCV-2 cancer cell line human CVCL_5974 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Unspecified (PubMed=7503188; PubMed=9887230) Derived from sampling site: Vulva. Female Doubling time: 58 hours (PubMed=15047230) 21189460 CVCL_5979 2MAC spontaneously immortalized cell line human CVCL_5979 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Macrophage.. Unspecified 21189461 CVCL_5978 HS1-CLS cancer cell line human CVCL_5978 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 21189462 CVCL_5991 JHU-022 cancer cell line human CVCL_5991 Genome ancestry: African=0.81%; Native American=0.12%; East Asian, North=1.81%; East Asian, South=0%; South Asian=0%; European, North=63.12%; European, South=34.14% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2722; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189463 CVCL_5990 JHU-020 cancer cell line human CVCL_5990 CL:0000010 21189464 CVCL_5984 J2E-NR transformed cell line house mouse CVCL_5984 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Embryonic liver Cell type=Erythroblast.; Breed/subspecies: CBA. Unspecified Characteristics: Compared to the parent cell line, does not respond to EPO 21189465 CVCL_5983 EJ-28 cancer cell line human CVCL_5983 CL:0000010 Discontinued: CLS; 300172; true. Female 21189466 CVCL_5982 CLS-439 cancer cell line human CVCL_5982 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21189467 CVCL_5981 B6SUtA factor-dependent cell line house mouse CVCL_5981 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: B6.S. Characteristics: IL3 dependent 21189468 CVCL_5988 JHU-013 cancer cell line human CVCL_5988 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line) Population: Indian; Derived from sampling site: Pharynx; hypopharynx. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00404 Problematic cell line: Contaminated Shown to be a FaDu derivative (PubMed=21868764). 21189469 CVCL_5987 JHU-012 cancer cell line human CVCL_5987 CL:0000010 Discontinued: ATCC; CRL-2720; true. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00403 Problematic cell line: Contaminated Shown to be a JHU-022 derivative (PubMed=21868764). Originally thought to originate from the lymph node of a metastatic floor of mouth carcinoma in a 62 year old female patient. 21189470 CVCL_5986 JHU-011 cancer cell line human CVCL_5986 Genome ancestry: African=2.03%; Native American=0%; East Asian, North=2.06%; East Asian, South=0%; South Asian=0.29%; European, North=66.03%; European, South=29.59% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2719; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189471 CVCL_5985 JHU-06 cancer cell line human CVCL_5985 CL:0000010 Discontinued: ATCC; CRL-2718; true. Male 21189472 CVCL_5989 JHU-019 cancer cell line human CVCL_5989 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Discontinued: ATCC; CRL-2721; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00405 Problematic cell line: Contaminated Shown to be a PC-3 derivative (PubMed=21868764). Originally thought to originate from a 58 year old female patient with oropharyngeal squamous cell carcinoma. 21189473 CVCL_5951 MMAc cancer cell line human CVCL_5951 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from child cell line MMAc-SF). Population: Japanese Female 21189474 CVCL_5950 K-562R cancer cell line human CVCL_5950 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Pleural effusion. Female 21189475 CVCL_5955 TUHR25TKB cancer cell line human CVCL_5955 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female 21189476 CVCL_5954 TUHR16TKB cancer cell line human CVCL_5954 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Unspecified 21189477 CVCL_5953 TUHR14TKB cancer cell line human CVCL_5953 HLA typing: A*24:02,24:02; B*39:01,40:02; C*03:04,03:04; DRB1*08:02,08:02 (PubMed=26589293); Genome ancestry: African=0.62%; Native American=0.46%; East Asian, North=87.1%; East Asian, South=7.82%; South Asian=0%; European, North=0%; European, South=4% (PubMed=30894373). CL:0000010 Population: Japanese Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189478 CVCL_5952 TUHR10TKB cancer cell line human CVCL_5952 HLA typing: A*24:02 (PubMed=9914789); HLA typing: A*02:01,24:02; B*40:01,40:01; C*03:04,03:04 (PubMed=26589293); Genome ancestry: African=0%; Native American=0%; East Asian, North=79.7%; East Asian, South=19.89%; South Asian=0.4%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189479 CVCL_5959 AMC-HN-1 cancer cell line human CVCL_5959 CL:0000010 Population: Korean; Derived from sampling site: Oral cavity; tongue. Male 21189480 CVCL_5958 CHAUT-G cancer cell line CVCL_5958 CL:0000010 Derived from sampling site: Uterus. Female 21189481 CVCL_5957 TUHR4TKB cancer cell line human CVCL_5957 HLA typing: A*02:06,02:06; B*15:18,15:18; C*07:04,07:04; DQA1*03:02,03:02; DQB1*03:02,03:02; DRB1*08:02,08:02 (PubMed=26589293); Genome ancestry: African=3.62%; Native American=0%; East Asian, North=85.09%; East Asian, South=5.8%; South Asian=0%; European, North=0%; European, South=5.48% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189482 CVCL_5956 TUHR3TKB cancer cell line human CVCL_5956 HLA typing: A*02,24:02 (PubMed=9914789) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21189483 CVCL_5962 AMC-HN-4 cancer cell line human CVCL_5962 CL:0000010 Population: Korean; Derived from sampling site: Oral cavity; tongue. Female 21189484 CVCL_5961 AMC-HN-3 cancer cell line human CVCL_5961 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Heterozygous (PubMed=24336076) Population: Korean; Derived from sampling site: Larynx. Male 21189485 CVCL_5960 AMC-HN-2 cancer cell line human CVCL_5960 CL:0000010 Population: Korean; Derived from sampling site: Pharynx; hypopharynx. Male 21189486 CVCL_5966 AMC-HN-8 cancer cell line human CVCL_5966 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly293del (c.877_879delGGG); Zygosity=Unspecified (PubMed=24336076) Population: Korean; Derived from metastatic site: Lymph node. Male 21189487 CVCL_5965 AMC-HN-7 cancer cell line human CVCL_5965 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Gly (c.470T>G); ClinVar=VCV000915695; Zygosity=Heterozygous (PubMed=24336076) Population: Korean; Derived from sampling site: Larynx. Male 21189488 CVCL_5964 AMC-HN-6 cancer cell line human CVCL_5964 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=24336076) Population: Korean; Derived from sampling site: Oral cavity; floor of mouth. Male 21189489 CVCL_5963 AMC-HN-5 cancer cell line human CVCL_5963 CL:0000010 Population: Korean; Derived from sampling site: Nose; nasal cavity. Male 21189490 CVCL_5969 C-643 cancer cell line human CVCL_5969 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe341Leu (c.1023T>G); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (PubMed=14522906; PubMed=30737244); Sequence variation: Mutation; HGNC; 28873; VTCN1; Simple; p.Tyr215Ter (c.645C>G); Zygosity=Unspecified (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 23 hours (PubMed=31368081) 21189491 CVCL_5968 A64-CLS cancer cell line human CVCL_5968 CL:0000010 Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland. Male 21189492 CVCL_5967 AMC-HN-9 cancer cell line human CVCL_5967 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=24336076) Population: Korean; Derived from metastatic site: Lymph node. Female 21189493 CVCL_5933 C6PV finite cell line human CVCL_5933 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189494 CVCL_5932 C5PV finite cell line human CVCL_5932 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189495 CVCL_5931 C4PV finite cell line human CVCL_5931 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189496 CVCL_5930 C3PV finite cell line human CVCL_5930 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189497 CVCL_5937 CN96 finite cell line human CVCL_5937 From: Galliera Genetic Bank, E.O Ospedali Galliera; Genova; Italy. CL:0000010 Population: Caucasian. 21189498 CVCL_5936 C9PV finite cell line human CVCL_5936 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189499 CVCL_5935 C8PV finite cell line human CVCL_5935 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189500 CVCL_5934 C7PV finite cell line human CVCL_5934 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189501 CVCL_5939 TM-791 cancer cell line human CVCL_5939 CL:0000010 Discontinued: CLS; 300358; true. Female 21189502 CVCL_5940 HT29-18 cancer cell line human CVCL_5940 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21189503 CVCL_5944 RenCa-IL2 cancer cell line house mouse CVCL_5944 CL:0000010 Transfected with: MGI; MGI:96548; Il2 Breed/subspecies: BALB/c. Male 21189504 CVCL_5943 SVI conditionally immortalized cell line house mouse CVCL_5943 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney Cell type=Podocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21189505 CVCL_5942 HT29-18-N2 cancer cell line human CVCL_5942 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Characteristics: Mucus-secreting clone of parent cell line When grown in the absence of glucose they form homogeneous epithelial monolayers of columnar cells with typical goblet cell morphology (PubMed=3360261). 21189506 CVCL_5941 HT29-18-C1 cancer cell line human CVCL_5941 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21189507 CVCL_5948 11-9-1-4 cancer cell line human CVCL_5948 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val275fs*1 (c.821delG) (p.W274fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.265_607del343; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>C); ClinVar=VCV000406598; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6563; LGALS3 Population: Caucasian; Derived from sampling site: Breast. Female Group: Triple negative breast cancer (TNBC) cell line 21189508 CVCL_5947 HCT-8/S10 cancer cell line human CVCL_5947 CL:0000010 Male 21189509 CVCL_5946 KM12-L4 cancer cell line human CVCL_5946 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line) Omics: Transcriptome analysis by microarray. Unspecified Microsatellite instability: Instable (MSI) (PubMed=25926053) 21189510 CVCL_5945 HCT-8/R1 cancer cell line human CVCL_5945 CL:0000010 Male 21189511 CVCL_5949 HT29-OxR cancer cell line human CVCL_5949 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Female 21189512 CVCL_5911 PCC4-F cancer cell line house mouse CVCL_5911 CL:0000010 Breed/subspecies: 129/Sv. Male 21189513 CVCL_5910 Flow5000 finite cell line human CVCL_5910 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal muscle and skin Cell type=Fibroblast.. Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00304 Problematic cell line: Contaminated Shown to be a Flow1000 derivative. 21189514 CVCL_5914 AMJ2-C8 transformed cell line house mouse CVCL_5914 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21189515 CVCL_5913 AMJ2-C11 transformed cell line house mouse CVCL_5913 CL:0000010 Transformant: Recombinant retrovirus J2; Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: C57BL/6J. Female 21189516 CVCL_5912 PCC4-AzaR cancer cell line house mouse CVCL_5912 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: 129/Sv. Male 21189517 CVCL_5917 Rh5 cancer cell line human CVCL_5917 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086) Omics: Transcriptome analysis by microarray. Unspecified 21189518 CVCL_5916 Rh4 cancer cell line human CVCL_5916 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086; PubMed=23578105; PubMed=25806826) Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189519 CVCL_5922 SCMC-N3 cancer cell line human CVCL_5922 CL:0000010 Population: Japanese Discontinued: JCRB; NIHS0040; true. Male 21189520 CVCL_5921 SCMC-N2 cancer cell line human CVCL_5921 CL:0000010 Population: Japanese Omics: SNP array analysis Discontinued: JCRB; NIHS0039; true. Male 21189521 CVCL_5920 KM12-OxR cancer cell line human CVCL_5920 CL:0000010 Sequence variation: Gene fusion; HGNC; 8031; NTRK1 + HGNC; 12012; TPM3; Name(s)=TPM3-NTRK1 (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn1819fs*7 (c.5454_5455insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129Ter (c.385G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val73Trpfs*50 (c.216delC) (p.P72fs); ClinVar=VCV000428897; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Arg (c.536A>G); ClinVar=VCV000376606; Zygosity=Heterozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin Unspecified 21189522 CVCL_5926 B/CMBA.Ov finite cell line house mouse CVCL_5926 CL:0000010 Derived from sampling site: Ovary; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6331; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189523 CVCL_5925 B/C3T3.We spontaneously immortalized cell line house mouse CVCL_5925 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: BALB/c. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189524 CVCL_5924 SCMC-N5 cancer cell line human CVCL_5924 CL:0000010 Population: Japanese Omics: SNP array analysis Discontinued: JCRB; NIHS0042; true. Female 21189525 CVCL_5923 SCMC-N4 cancer cell line human CVCL_5923 CL:0000010 Population: Japanese Omics: SNP array analysis Discontinued: JCRB; NIHS0041; true. Male 21189526 CVCL_5929 C2PV finite cell line human CVCL_5929 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189527 CVCL_5928 C1PV finite cell line human CVCL_5928 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189528 CVCL_5927 B/CWE finite cell line house mouse CVCL_5927 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: BALB/c. Discontinued: ATCC; CRL-6334; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21189529 CVCL_FL29 ND09708 transformed cell line human CVCL_FL29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189530 CVCL_FL24 ND09617 transformed cell line human CVCL_FL24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189531 CVCL_FL23 ND09590 transformed cell line human CVCL_FL23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189532 CVCL_FL22 ND09583 transformed cell line human CVCL_FL22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189533 CVCL_FL21 ND09543 transformed cell line human CVCL_FL21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189534 CVCL_FL28 ND09707 transformed cell line human CVCL_FL28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189535 CVCL_FL27 ND09661 transformed cell line human CVCL_FL27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189536 CVCL_FL26 ND09619 transformed cell line human CVCL_FL26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189537 CVCL_FL25 ND09618 transformed cell line human CVCL_FL25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189538 CVCL_FL20 ND09520 transformed cell line human CVCL_FL20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189539 CVCL_FL35 ND09822 transformed cell line human CVCL_FL35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189540 CVCL_FL34 ND09747 transformed cell line human CVCL_FL34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189541 CVCL_FL33 ND09741 transformed cell line human CVCL_FL33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189542 CVCL_FL32 ND09738 transformed cell line human CVCL_FL32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189543 CVCL_FL39 ND09872 transformed cell line human CVCL_FL39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189544 CVCL_FL38 ND09871 transformed cell line human CVCL_FL38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189545 CVCL_FL37 ND09870 transformed cell line human CVCL_FL37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189546 CVCL_FL36 ND09855 transformed cell line human CVCL_FL36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189547 CVCL_FL31 ND09720 transformed cell line human CVCL_FL31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189548 CVCL_FL30 ND09709 transformed cell line human CVCL_FL30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189549 CVCL_FL09 ND09322 transformed cell line human CVCL_FL09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189550 CVCL_FL08 ND09306 transformed cell line human CVCL_FL08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189551 CVCL_FL07 ND09282 transformed cell line human CVCL_FL07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189552 CVCL_FL02 ND09243 transformed cell line human CVCL_FL02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189553 CVCL_FL01 ND09220 transformed cell line human CVCL_FL01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189554 CVCL_FL00 ND09218 transformed cell line human CVCL_FL00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189555 CVCL_FL06 ND09277 transformed cell line human CVCL_FL06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189556 CVCL_FL05 ND09276 transformed cell line human CVCL_FL05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189557 CVCL_FL04 ND09275 transformed cell line human CVCL_FL04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189558 CVCL_FL03 ND09259 transformed cell line human CVCL_FL03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189559 CVCL_FL19 ND09509 transformed cell line human CVCL_FL19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189560 CVCL_FL18 ND09501 transformed cell line human CVCL_FL18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189561 CVCL_FL13 ND09385 transformed cell line human CVCL_FL13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189562 CVCL_FL12 ND09332 transformed cell line human CVCL_FL12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189563 CVCL_FL11 ND09328 transformed cell line human CVCL_FL11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189564 CVCL_FL10 ND09326 transformed cell line human CVCL_FL10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189565 CVCL_FL17 ND09484 transformed cell line human CVCL_FL17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189566 CVCL_FL16 ND09480 transformed cell line human CVCL_FL16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189567 CVCL_FL15 ND09475 transformed cell line human CVCL_FL15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189568 CVCL_FL14 ND09444 transformed cell line human CVCL_FL14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189569 CVCL_5995 LCL41 transformed cell line human CVCL_5995 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Expresses only IgM, with principally kappa light chain on the membrane and cytoplasmic IgM kappa (PubMed=1326002) 21189570 CVCL_5994 KB-ChR-8-5 cancer cell line human CVCL_5994 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Grand-parent cell line (KB) has been shown to be a HeLa derivative. 21189571 CVCL_5993 JHU-029 cancer cell line human CVCL_5993 Genome ancestry: African=92.58%; Native American=0%; East Asian, North=2.96%; East Asian, South=0%; South Asian=0%; European, North=0%; European, South=4.45% (PubMed=30894373) CL:0000010 Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2723; true. Male Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: MD Anderson Cell Lines Project 21189572 CVCL_5992 JHU-028 cancer cell line human CVCL_5992 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (DepMap) Population: Caucasian; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00406 Problematic cell line: Contaminated Shown to be a A-549 derivative (PubMed=21868764). Originally thought to originate from a base of tongue squamous cell carcinoma. 21189573 CVCL_5999 ME15.C2 transformed cell line house mouse CVCL_5999 CL:0000010 Transformant: Myc; Derived from sampling site: Embryonic liver Cell type=Erythroid lineage cell.; Breed/subspecies: CBA. Unspecified 21189574 CVCL_5998 MDA231-LM2-4175 cancer cell line human CVCL_5998 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Proteome analysis by 2D-DE Female Characteristics: Established from MDA231-TGL cell line after 3 passage in nude mice Group: Triple negative breast cancer (TNBC) cell line 21189575 CVCL_5997 KB-ChR-8-5-11 cancer cell line human CVCL_5997 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Resistant to paclitaxel and many other chemotherapy agents as it overexpresses the P-glycoprotein (ABCB1) Problematic cell line: Contaminated Ancestral cell line (KB) has been shown to be a HeLa derivative. 21189576 CVCL_5996 LCL48 transformed cell line human CVCL_5996 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Characteristics: Expresses membrane IgM lambda and IgD and synthesizes IgM lambda (PubMed=1326002) 21189577 CVCL_FK90 ND09058 transformed cell line human CVCL_FK90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189578 CVCL_FK89 ND09057 transformed cell line human CVCL_FK89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189579 CVCL_FK88 ND09045 transformed cell line human CVCL_FK88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189580 CVCL_FK83 ND09027 transformed cell line human CVCL_FK83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189581 CVCL_FK82 ND09025 transformed cell line human CVCL_FK82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189582 CVCL_FK81 ND09000 transformed cell line human CVCL_FK81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189583 CVCL_FK80 ND08960 transformed cell line human CVCL_FK80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189584 CVCL_FK87 ND09044 transformed cell line human CVCL_FK87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189585 CVCL_FK86 ND09030 transformed cell line human CVCL_FK86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189586 CVCL_FK85 ND09029 transformed cell line human CVCL_FK85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189587 CVCL_FK84 ND09028 transformed cell line human CVCL_FK84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189588 CVCL_FK99 ND09217 transformed cell line human CVCL_FK99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189589 CVCL_FK94 ND09099 transformed cell line human CVCL_FK94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189590 CVCL_FK93 ND09083 transformed cell line human CVCL_FK93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189591 CVCL_FK92 ND09072 transformed cell line human CVCL_FK92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189592 CVCL_FK91 ND09071 transformed cell line human CVCL_FK91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189593 CVCL_FK98 ND09154 transformed cell line human CVCL_FK98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189594 CVCL_FK97 ND09153 transformed cell line human CVCL_FK97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189595 CVCL_FK96 ND09128 transformed cell line human CVCL_FK96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189596 CVCL_FK95 ND09127 transformed cell line human CVCL_FK95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189597 CVCL_FK69 ND08856 transformed cell line human CVCL_FK69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189598 CVCL_FK68 ND08855 transformed cell line human CVCL_FK68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189599 CVCL_FK67 ND08854 transformed cell line human CVCL_FK67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189600 CVCL_FK66 ND08853 transformed cell line human CVCL_FK66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189601 CVCL_FK61 ND08801 transformed cell line human CVCL_FK61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189602 CVCL_FK60 ND08800 transformed cell line human CVCL_FK60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189603 CVCL_FK65 ND08847 transformed cell line human CVCL_FK65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189604 CVCL_FK64 ND08836 transformed cell line human CVCL_FK64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189605 CVCL_FK63 ND08812 transformed cell line human CVCL_FK63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189606 CVCL_FK62 ND08811 transformed cell line human CVCL_FK62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189607 CVCL_FK79 ND08959 transformed cell line human CVCL_FK79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189608 CVCL_FK78 ND08939 transformed cell line human CVCL_FK78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189609 CVCL_FK77 ND08938 transformed cell line human CVCL_FK77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189610 CVCL_FK72 ND08871 transformed cell line human CVCL_FK72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189611 CVCL_FK71 ND08870 transformed cell line human CVCL_FK71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189612 CVCL_FK70 ND08857 transformed cell line human CVCL_FK70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189613 CVCL_FK76 ND08936 transformed cell line human CVCL_FK76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189614 CVCL_FK75 ND08935 transformed cell line human CVCL_FK75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189615 CVCL_FK74 ND08897 transformed cell line human CVCL_FK74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189616 CVCL_FK73 ND08877 transformed cell line human CVCL_FK73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189617 CVCL_FK47 ND08678 transformed cell line human CVCL_FK47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189618 CVCL_FK46 ND08677 transformed cell line human CVCL_FK46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189619 CVCL_FK45 ND08672 transformed cell line human CVCL_FK45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189620 CVCL_FK44 ND08669 transformed cell line human CVCL_FK44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189621 CVCL_FK49 ND08704 transformed cell line human CVCL_FK49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189622 CVCL_FK48 ND08703 transformed cell line human CVCL_FK48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189623 CVCL_FK43 ND08641 transformed cell line human CVCL_FK43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189624 CVCL_FK42 ND08632 transformed cell line human CVCL_FK42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189625 CVCL_FK41 ND08613 transformed cell line human CVCL_FK41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189626 CVCL_FK40 ND08580 transformed cell line human CVCL_FK40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189627 CVCL_FK58 ND08788 transformed cell line human CVCL_FK58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189628 CVCL_FK57 ND08771 transformed cell line human CVCL_FK57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189629 CVCL_FK56 ND08768 transformed cell line human CVCL_FK56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189630 CVCL_FK55 ND08766 transformed cell line human CVCL_FK55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189631 CVCL_FK59 ND08798 transformed cell line human CVCL_FK59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189632 CVCL_FK50 ND08708 transformed cell line human CVCL_FK50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189633 CVCL_FK54 ND08750 transformed cell line human CVCL_FK54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189634 CVCL_FK53 ND08734 transformed cell line human CVCL_FK53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189635 CVCL_FK52 ND08725 transformed cell line human CVCL_FK52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189636 CVCL_FK51 ND08710 transformed cell line human CVCL_FK51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189637 CVCL_FK25 ND08273 transformed cell line human CVCL_FK25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189638 CVCL_FK24 ND08217 transformed cell line human CVCL_FK24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189639 CVCL_FK23 ND08216 transformed cell line human CVCL_FK23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189640 CVCL_FK22 ND08129 transformed cell line human CVCL_FK22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189641 CVCL_FK29 ND08369 transformed cell line human CVCL_FK29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189642 CVCL_FK28 ND08335 transformed cell line human CVCL_FK28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189643 CVCL_FK27 ND08324 transformed cell line human CVCL_FK27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189644 CVCL_FK26 ND08321 transformed cell line human CVCL_FK26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189645 CVCL_FK21 ND08109 transformed cell line human CVCL_FK21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189646 CVCL_FK20 ND08067 transformed cell line human CVCL_FK20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189647 CVCL_FK36 ND08503 transformed cell line human CVCL_FK36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189648 CVCL_FK35 ND08474 transformed cell line human CVCL_FK35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189649 CVCL_FK34 ND08473 transformed cell line human CVCL_FK34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189650 CVCL_FK33 ND08389 transformed cell line human CVCL_FK33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189651 CVCL_FK39 ND08534 transformed cell line human CVCL_FK39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189652 CVCL_FK38 ND08509 transformed cell line human CVCL_FK38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189653 CVCL_FK37 ND08505 transformed cell line human CVCL_FK37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189654 CVCL_FK32 ND08386 transformed cell line human CVCL_FK32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189655 CVCL_FK31 ND08377 transformed cell line human CVCL_FK31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189656 CVCL_FK30 ND08370 transformed cell line human CVCL_FK30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189657 CVCL_5909 Flow4000 finite cell line human CVCL_5909 From: Flow Laboratories (which ceased operation); Rockville; USA CL:0000010 Derived from sampling site: Fetal kidney Cell type=Fibroblast.. Unspecified 21189658 CVCL_5900 TIMI.4G.1.3 cancer cell line house mouse CVCL_5900 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Radiation murine leukemia virus(NCBI-Taxonomy; 11787); Breed/subspecies: C57BL/6. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21189659 CVCL_5904 WT-CLS1 cancer cell line human CVCL_5904 CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Gln318Ter (c.952C>T); Zygosity=Hemizygous (DOI=10.1002/cnr2.1110) Population: Turkish Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Problematic cell line: Misclassified Originally thought to be a Wilms tumor cell line but is a kidney rhabdoid tumor cell line (DOI=10.1002/cnr2.1110). 21189660 CVCL_5903 U-105MG cancer cell line human CVCL_5903 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21189661 CVCL_5902 TRI-C3H cancer cell line house mouse CVCL_5902 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C3H. Female 21189662 CVCL_5901 LXF 297 cancer cell line human CVCL_5901 CL:0000010 21189663 CVCL_5908 ZL55 cancer cell line human CVCL_5908 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Omics: Cell surface proteome. Male Doubling time: 38 hours (PubMed=1373705) 21189664 CVCL_5907 ZL5 cancer cell line human CVCL_5907 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Derived from sampling site: Pleural effusion. Male Doubling time: 31 hours (PubMed=1373705) 21189665 CVCL_5906 ZL34 cancer cell line human CVCL_5906 From: University Hospital of Zurich; Zurich; Switzerland CL:0000010 Male Doubling time: 29 hours (PubMed=1373705); 24 hours (PubMed=23840376). 21189666 CVCL_5905 ZKS stromal cell line zebrafish CVCL_5905 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: AB. Unspecified Group: Fish cell line 21189667 CVCL_FD93 ND14085 transformed cell line human CVCL_FD93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189668 CVCL_FD92 ND14062 transformed cell line human CVCL_FD92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189669 CVCL_FD91 ND14028 transformed cell line human CVCL_FD91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189670 CVCL_FD90 ND14023 transformed cell line human CVCL_FD90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189671 CVCL_FD97 ND14242 transformed cell line human CVCL_FD97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189672 CVCL_FD96 ND14124 transformed cell line human CVCL_FD96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189673 CVCL_FD95 ND14119 transformed cell line human CVCL_FD95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189674 CVCL_FD94 ND14099 transformed cell line human CVCL_FD94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189675 CVCL_FD89 ND14021 transformed cell line human CVCL_FD89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189676 CVCL_FD88 ND14004 transformed cell line human CVCL_FD88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189677 CVCL_FD87 ND14002 transformed cell line human CVCL_FD87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189678 CVCL_FD99 ND14251 transformed cell line human CVCL_FD99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189679 CVCL_FD98 ND14248 transformed cell line human CVCL_FD98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189680 CVCL_FD71 ND13616 transformed cell line human CVCL_FD71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189681 CVCL_FD70 ND13596 transformed cell line human CVCL_FD70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189682 CVCL_FD75 ND13804 transformed cell line human CVCL_FD75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189683 CVCL_FD74 ND13759 transformed cell line human CVCL_FD74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189684 CVCL_FD73 ND13758 transformed cell line human CVCL_FD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189685 CVCL_FD72 ND13727 transformed cell line human CVCL_FD72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189686 CVCL_FD68 ND13586 transformed cell line human CVCL_FD68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189687 CVCL_FD67 ND13581 transformed cell line human CVCL_FD67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189688 CVCL_FD66 ND13580 transformed cell line human CVCL_FD66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189689 CVCL_FD65 ND13571 transformed cell line human CVCL_FD65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189690 CVCL_FD69 ND13588 transformed cell line human CVCL_FD69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189691 CVCL_FD82 ND13934 transformed cell line human CVCL_FD82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189692 CVCL_FD81 ND13926 transformed cell line human CVCL_FD81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189693 CVCL_FD80 ND13912 transformed cell line human CVCL_FD80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189694 CVCL_FD86 ND13985 transformed cell line human CVCL_FD86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189695 CVCL_FD85 ND13971 transformed cell line human CVCL_FD85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189696 CVCL_FD84 ND13967 transformed cell line human CVCL_FD84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189697 CVCL_FD83 ND13943 transformed cell line human CVCL_FD83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189698 CVCL_FD79 ND13830 transformed cell line human CVCL_FD79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189699 CVCL_FD78 ND13817 transformed cell line human CVCL_FD78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189700 CVCL_FD77 ND13816 transformed cell line human CVCL_FD77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189701 CVCL_FD76 ND13811 transformed cell line human CVCL_FD76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189702 CVCL_FD53 ND13072 transformed cell line human CVCL_FD53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189703 CVCL_FD52 ND13068 transformed cell line human CVCL_FD52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189704 CVCL_FD51 ND13046 transformed cell line human CVCL_FD51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189705 CVCL_FD50 ND13007 transformed cell line human CVCL_FD50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189706 CVCL_FD46 ND12769 transformed cell line human CVCL_FD46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189707 CVCL_FD45 ND12751 transformed cell line human CVCL_FD45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189708 CVCL_FD44 ND12740 transformed cell line human CVCL_FD44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189709 CVCL_FD43 ND12622 transformed cell line human CVCL_FD43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189710 CVCL_FD49 ND12946 transformed cell line human CVCL_FD49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189711 CVCL_FD48 ND12912 transformed cell line human CVCL_FD48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189712 CVCL_FD47 ND12777 transformed cell line human CVCL_FD47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189713 CVCL_FD60 ND13332 transformed cell line human CVCL_FD60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189714 CVCL_FD64 ND13570 transformed cell line human CVCL_FD64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189715 CVCL_FD63 ND13515 transformed cell line human CVCL_FD63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189716 CVCL_FD62 ND13415 transformed cell line human CVCL_FD62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189717 CVCL_FD61 ND13379 transformed cell line human CVCL_FD61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189718 CVCL_FD57 ND13304 transformed cell line human CVCL_FD57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189719 CVCL_FD56 ND13290 transformed cell line human CVCL_FD56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189720 CVCL_FD55 ND13285 transformed cell line human CVCL_FD55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189721 CVCL_FD54 ND13080 transformed cell line human CVCL_FD54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189722 CVCL_FD59 ND13329 transformed cell line human CVCL_FD59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189723 CVCL_FD58 ND13322 transformed cell line human CVCL_FD58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189724 CVCL_X866 AG05121 finite cell line human CVCL_X866 CL:0000010 Derived from sampling site: Amniotic fluid. Female 21189725 CVCL_WW66 BT 428 cancer cell line human CVCL_WW66 CL:0000010 Characteristics: Low-passage-number culture. 21189726 CVCL_X865 AG05120 finite cell line human CVCL_X865 CL:0000010 Derived from sampling site: Umbilical cord. Female 21189727 CVCL_WW65 BT 422 cancer cell line human CVCL_WW65 CL:0000010 Characteristics: Low-passage-number culture. 21189728 CVCL_X864 6C12 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X864 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5597 21189729 CVCL_WW64 BT 416 cancer cell line human CVCL_WW64 CL:0000010 Characteristics: Low-passage-number culture. 21189730 CVCL_X863 6B3 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X863 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5262 21189731 CVCL_WW63 BT 359 cancer cell line human CVCL_WW63 CL:0000010 Characteristics: Low-passage-number culture. 21189732 CVCL_X869 AG07409 finite cell line human CVCL_X869 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21189733 CVCL_WW69 BT 482 cancer cell line human CVCL_WW69 CL:0000010 Characteristics: Low-passage-number culture. 21189734 CVCL_X868 AG07096 finite cell line human CVCL_X868 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21189735 CVCL_WW68 BT 444 cancer cell line human CVCL_WW68 CL:0000010 Characteristics: Low-passage-number culture. 21189736 CVCL_X867 AG06872 finite cell line human CVCL_X867 CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 21189737 CVCL_WW67 BT 440 cancer cell line human CVCL_WW67 CL:0000010 Characteristics: Low-passage-number culture. 21189738 CVCL_4Q21 AG20843 transformed cell line human CVCL_4Q21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189739 CVCL_5221 MEB5 transformed cell line house mouse CVCL_5221 CL:0000010 Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E7](NCBI-Taxonomy; 333760); Derived from sampling site: Embryonic brain; forebrain; Breed/subspecies: C3H/He. Characteristics: EGF dependent When deprived of EGF, about 50% of the cells die due to apoptosis within 24h. The remaining cells differentiated into neurons, astrncytes, or oligndendrocytes within 2 weeks. 21189740 CVCL_4Q20 AG20840 transformed cell line human CVCL_4Q20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189741 CVCL_5220 LAD 1 factor-dependent cell line human CVCL_5220 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.. Male Characteristics: KITLG dependent Doubling time: ~28 days (DOI=10.1016/j.jaci.2018.12.550) 21189742 CVCL_4Q14 AG20698 transformed cell line human CVCL_4Q14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189743 CVCL_4Q13 AG20629 transformed cell line human CVCL_4Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189744 CVCL_5213 KU-19-20 cancer cell line human CVCL_5213 CL:0000010 Population: Japanese; Derived from metastatic site: Hypodermis. Male Doubling time: 58.7 hours, at 50th passage (PubMed=10994781) 21189745 CVCL_4Q12 AG20605 transformed cell line human CVCL_4Q12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189746 CVCL_5212 KU-20-01 cancer cell line human CVCL_5212 CL:0000010 Population: Japanese. 21189747 CVCL_4Q11 AG20584 transformed cell line human CVCL_4Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189748 CVCL_5211 NFS-22 cancer cell line house mouse CVCL_5211 CL:0000010 21189749 CVCL_4Q18 AG20749 transformed cell line human CVCL_4Q18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189750 CVCL_5218 SK-BR-7 cancer cell line human CVCL_5218 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=19593635) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189751 CVCL_4Q17 AG20728 transformed cell line human CVCL_4Q17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189752 CVCL_5217 SK-BR-5 cancer cell line human CVCL_5217 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.532-1G>C; ClinVar=VCV000406644; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=19593635); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Asp (c.482C>A); ClinVar=VCV000422295; Zygosity=Unspecified (PubMed=16541312) Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189753 CVCL_4Q16 AG20727 transformed cell line human CVCL_4Q16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189754 CVCL_5216 PMC42-LA cancer cell line human CVCL_5216 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21189755 CVCL_4Q15 AG20699 transformed cell line human CVCL_4Q15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189756 CVCL_5215 PMC42 cancer cell line human CVCL_5215 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis Female Doubling time: 2.3 days (PubMed=6572752) Part of: GrayJW breast cancer cell line panel 21189757 CVCL_4Q19 AG20789 transformed cell line human CVCL_4Q19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189758 CVCL_5219 NW-16 spontaneously immortalized cell line Norway rat CVCL_5219 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21189759 CVCL_X873 AG10098 transformed cell line human CVCL_X873 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189760 CVCL_WW73 BT 240 cancer cell line human CVCL_WW73 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser227Tyr (c.680C>A); Zygosity=Unspecified (PubMed=27723727). Characteristics: Low-passage-number culture 21189761 CVCL_X872 AG08942 finite cell line human CVCL_X872 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189762 CVCL_WW72 BT 504 cancer cell line human CVCL_WW72 CL:0000010 Characteristics: Low-passage-number culture. 21189763 CVCL_X871 AG08941 finite cell line human CVCL_X871 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21189764 CVCL_WW71 BT 498 cancer cell line human CVCL_WW71 CL:0000010 Characteristics: Low-passage-number culture. 21189765 CVCL_X870 AG07438 finite cell line human CVCL_X870 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21189766 CVCL_WW70 BT 484 cancer cell line human CVCL_WW70 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Cys136Tyr (c.407G>A); ClinVar=VCV000189406; Zygosity=Unspecified (PubMed=27723727). Characteristics: Low-passage-number culture 21189767 CVCL_X855 3F5 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X855 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5259 21189768 CVCL_WW55 BT 248 cancer cell line human CVCL_WW55 CL:0000010 Characteristics: Low-passage-number culture. 21189769 CVCL_X854 3F4 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X854 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5590 21189770 CVCL_WW54 BT 239 cancer cell line human CVCL_WW54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727). Characteristics: Low-passage-number culture 21189771 CVCL_X853 2A5 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X853 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5589 21189772 CVCL_WW53 BT 232 cancer cell line human CVCL_WW53 CL:0000010 Characteristics: Low-passage-number culture. 21189773 CVCL_X852 Bartlett 96 transformed cell line human CVCL_X852 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21189774 CVCL_WW52 BT 231 cancer cell line human CVCL_WW52 CL:0000010 Characteristics: Low-passage-number culture. 21189775 CVCL_X859 4F10 [Mouse USA hybridoma against human GRN] hybridoma house mouse CVCL_X859 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8763 21189776 CVCL_WW59 BT 328 cancer cell line human CVCL_WW59 CL:0000010 Characteristics: Low-passage-number culture. 21189777 CVCL_X858 4D1 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X858 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5593 21189778 CVCL_WW58 BT 320 cancer cell line human CVCL_WW58 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=27723727); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly132Ala (c.395G>C); Zygosity=Unspecified (PubMed=27723727). Characteristics: Low-passage-number culture 21189779 CVCL_X857 3G2 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X857 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5592 21189780 CVCL_WW57 BT 286 cancer cell line human CVCL_WW57 CL:0000010 Characteristics: Low-passage-number culture. 21189781 CVCL_X856 3F8 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X856 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5591 21189782 CVCL_WW56 BT 271 cancer cell line human CVCL_WW56 CL:0000010 Characteristics: Low-passage-number culture. 21189783 CVCL_4Q32 AG22107 finite cell line human CVCL_4Q32 CL:0000010 Population: African American; Donor information: Donor has history of diabetes mellitus; chronic renal failure; neurogenic bladder; fourniers gangrene and multiple ulcers; Derived from sampling site: Ischium; skin (Note=From a right ischial pressure wound); Cell type=Fibroblast. Male 21189784 CVCL_5232 NFS-58 cancer cell line house mouse CVCL_5232 CL:0000010 Breed/subspecies: NFS x DBA/2. 21189785 CVCL_4Q31 AG22105 finite cell line human CVCL_4Q31 CL:0000010 Derived from sampling site: Foot; skin Cell type=Fibroblast.. Female 21189786 CVCL_5231 NFS-124 cancer cell line house mouse CVCL_5231 CL:0000010 Transformant: Cas-Br-E murine leukemia virus(NCBI-Taxonomy; 11792); Breed/subspecies: NFS. 21189787 CVCL_4Q30 AG22097 finite cell line human CVCL_4Q30 CL:0000010 Population: African American; Donor information: Donor was bedbound with bilateral ischial ulcers and multiple sclerosis; Derived from sampling site: Ischium; skin (Note=From a right ischial pressure ulcer); Cell type=Fibroblast. Male 21189788 CVCL_5230 NFS-107 cancer cell line house mouse CVCL_5230 CL:0000010 Transformant: Cas-Br-E murine leukemia virus(NCBI-Taxonomy; 11792); Breed/subspecies: NFS. 21189789 CVCL_4Q25 AG20940 transformed cell line human CVCL_4Q25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189790 CVCL_5225 OCI-AML-1a cancer cell line human CVCL_5225 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: CSF3 dependent 21189791 CVCL_4Q24 AG20939 transformed cell line human CVCL_4Q24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189792 CVCL_5224 OCI-AML-4 cancer cell line human CVCL_5224 CL:0000010 Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Female Doubling time: ~24-30 hours (DSMZ=ACC-729) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189793 CVCL_4Q23 AG20934 transformed cell line human CVCL_4Q23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189794 CVCL_5223 KUSA-O somatic stem cell house mouse CVCL_5223 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21189795 CVCL_4Q22 AG20931 transformed cell line human CVCL_4Q22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189796 CVCL_5222 KUSA-H1 somatic stem cell house mouse CVCL_5222 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21189797 CVCL_4Q29 AG21222 transformed cell line human CVCL_4Q29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189798 CVCL_5229 ST-1 [Human liver] spontaneously immortalized cell line human CVCL_5229 CL:0000010 Derived from sampling site: Fetal liver; stroma Cell type=Fibroblast.. Unspecified Doubling time: 30 hours (PubMed=3514636) 21189799 CVCL_4Q28 AG21151 transformed cell line human CVCL_4Q28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189800 CVCL_5228 OCI-AML-1 cancer cell line human CVCL_5228 CL:0000010 Derived from sampling site: Peripheral blood. Female Characteristics: CSF2 dependent Doubling time: ~3-4 days (DSMZ=ACC-726) 21189801 CVCL_4Q27 AG20963 transformed cell line human CVCL_4Q27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189802 CVCL_5227 OCI-AML-6.2 cancer cell line human CVCL_5227 CL:0000010 Derived from sampling site: Peripheral blood. Female 21189803 CVCL_4Q26 AG20962 transformed cell line human CVCL_4Q26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189804 CVCL_5226 OCI-AML-6 cancer cell line human CVCL_5226 CL:0000010 Derived from sampling site: Peripheral blood. Female Doubling time: ~3-5 days (DSMZ=ACC-730) 21189805 CVCL_X862 6B2 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X862 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5261 21189806 CVCL_WW62 BT 340 cancer cell line human CVCL_WW62 CL:0000010 Characteristics: Low-passage-number culture. 21189807 CVCL_X861 5G6 hybridoma house mouse CVCL_X861 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5595 21189808 CVCL_WW61 BT 333 cancer cell line human CVCL_WW61 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=27723727); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Met (c.517G>A); ClinVar=VCV000233951; Zygosity=Unspecified (PubMed=27723727). Characteristics: Low-passage-number culture 21189809 CVCL_X860 5B4 [Mouse hybridoma against human GRN] hybridoma house mouse CVCL_X860 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P28799; Human GRN. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5260 21189810 CVCL_WW60 BT 330 cancer cell line human CVCL_WW60 CL:0000010 Characteristics: Low-passage-number culture. 21189811 CVCL_X844 AG08162 finite cell line human CVCL_X844 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189812 CVCL_WW44 BT 181 cancer cell line human CVCL_WW44 CL:0000010 Characteristics: Low-passage-number culture. 21189813 CVCL_X843 AG08161 transformed cell line human CVCL_X843 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189814 CVCL_WW43 BT 179 cancer cell line human CVCL_WW43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Thr (c.764T>C); ClinVar=VCV000376623; Zygosity=Unspecified (PubMed=27723727). Characteristics: Low-passage-number culture 21189815 CVCL_X842 AG07376 finite cell line human CVCL_X842 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189816 CVCL_WW42 BT 168 cancer cell line human CVCL_WW42 CL:0000010 Characteristics: Low-passage-number culture. 21189817 CVCL_X841 AG07375 finite cell line human CVCL_X841 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189818 CVCL_WW41 BT 164 cancer cell line human CVCL_WW41 CL:0000010 Characteristics: Low-passage-number culture. 21189819 CVCL_X848 AG08166 finite cell line human CVCL_X848 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189820 CVCL_WW48 BT 189 cancer cell line human CVCL_WW48 CL:0000010 Characteristics: Low-passage-number culture. 21189821 CVCL_X847 AG08165 transformed cell line human CVCL_X847 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189822 CVCL_WW47 BT 188 cancer cell line human CVCL_WW47 CL:0000010 Characteristics: Low-passage-number culture. 21189823 CVCL_X846 AG08164 finite cell line human CVCL_X846 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189824 CVCL_WW46 BT 187 cancer cell line human CVCL_WW46 CL:0000010 Characteristics: Low-passage-number culture. 21189825 CVCL_X845 AG08163 transformed cell line human CVCL_X845 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189826 CVCL_WW45 BT 182 cancer cell line human CVCL_WW45 CL:0000010 Characteristics: Low-passage-number culture. 21189827 CVCL_X849 AG08167 transformed cell line human CVCL_X849 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189828 CVCL_WW49 BT 216 cancer cell line human CVCL_WW49 CL:0000010 Characteristics: Low-passage-number culture. 21189829 CVCL_X851 AG05749 transformed cell line human CVCL_X851 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189830 CVCL_WW51 BT 228 cancer cell line human CVCL_WW51 CL:0000010 Characteristics: Low-passage-number culture. 21189831 CVCL_X850 AG08168 finite cell line human CVCL_X850 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189832 CVCL_WW50 BT 224 cancer cell line human CVCL_WW50 CL:0000010 Characteristics: Low-passage-number culture. 21189833 CVCL_X833 AG09844 finite cell line human CVCL_X833 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [45]; 47,XY,+8 [5] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21189834 CVCL_WW33 SV40-iISEMF transformed cell line CVCL_WW33 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; ileum Cell type=Myofibroblast.; Breed/subspecies: Holstein. Male Characteristics: Useful as a model to study ISEMF's origin, physiology and functions 21189835 CVCL_X832 AG05192 finite cell line human CVCL_X832 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 54 PDL (PubMed=7307581) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21189836 CVCL_WW32 tsA Cl2A transformed cell line Norway rat CVCL_WW32 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Wistar. Unspecified 21189837 CVCL_X831 XPH294BE LCL transformed cell line human CVCL_X831 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189838 CVCL_WW31 RC.SVtsA58 conditionally immortalized cell line CVCL_WW31 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule; Breed/subspecies: New Zealand white. Male Characteristics: Exhibits rapid cell growth at the permissive temperature (33 Celsius) Growth is totally inhibited within 48 hours when cells are shifted to the restrictive temperature (39.5 Celsius). 21189839 CVCL_X830 XPH294BE finite cell line human CVCL_X830 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Native North American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21189840 CVCL_WW30 RC.SV2 transformed cell line CVCL_WW30 CL:0000010 Transformant: Simian virus 40 (SV40) [Strain LP](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule; Breed/subspecies: New Zealand white. Male Doubling time: 30 hours (PubMed=2550481) 21189841 CVCL_X837 AG12800 finite cell line human CVCL_X837 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21189842 CVCL_WW37 BT 112 cancer cell line human CVCL_WW37 CL:0000010 Characteristics: Low-passage-number culture. 21189843 CVCL_X836 AG12799 finite cell line human CVCL_X836 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21189844 CVCL_WW36 IMSUTi001-C induced pluripotent stem cell human CVCL_WW36 From: Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Simple; p.Arg551His (c.1652G>A); ClinVar=VCV000566474; Zygosity=Heterozygous (PubMed=31255830) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21189845 CVCL_X835 AG05229 finite cell line human CVCL_X835 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21189846 CVCL_WW35 IMSUTi001-B induced pluripotent stem cell human CVCL_WW35 From: Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Simple; p.Arg551His (c.1652G>A); ClinVar=VCV000566474; Zygosity=Heterozygous (PubMed=31255830) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21189847 CVCL_X834 AG12587 finite cell line human CVCL_X834 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Senescence: Senesces at 22 PDL (Coriell=AG12587) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21189848 CVCL_WW34 IMSUTi001-A induced pluripotent stem cell human CVCL_WW34 From: Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Simple; p.Arg551His (c.1652G>A); ClinVar=VCV000566474; Zygosity=Heterozygous (PubMed=31255830) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21189849 CVCL_X839 AG06263 finite cell line human CVCL_X839 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21189850 CVCL_WW39 BT 139 cancer cell line human CVCL_WW39 CL:0000010 Characteristics: Low-passage-number culture. 21189851 CVCL_X838 AG06262 finite cell line human CVCL_X838 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189852 CVCL_WW38 BT 131 cancer cell line human CVCL_WW38 CL:0000010 Characteristics: Low-passage-number culture. 21189853 CVCL_4Q10 AG20583 transformed cell line human CVCL_4Q10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189854 CVCL_5210 OPM-1 cancer cell line human CVCL_5210 Genome ancestry: African=0.52%; Native American=0%; East Asian, North=74.49%; East Asian, South=22.3%; South Asian=0%; European, North=0%; European, South=2.68% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T); ClinVar=VCV000376307; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Lys650Glu (c.1948A>G); ClinVar=VCV000016331; Zygosity=Heterozygous (PubMed=11157491; DepMap); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Leu87Arg (c.260T>G); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces Ig lambda Doubling time: 36-42 hours (PubMed=3926660) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189855 CVCL_4Q03 AG20473 transformed cell line human CVCL_4Q03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189856 CVCL_5203 UT-7/GM cancer cell line human CVCL_5203 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783_919del137; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male 21189857 CVCL_4Q02 AG20465 transformed cell line human CVCL_4Q02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189858 CVCL_5202 UT-7/Epo cancer cell line human CVCL_5202 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: EPO dependent 21189859 CVCL_4Q01 AG20464 transformed cell line human CVCL_4Q01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189860 CVCL_5201 PCI-72 cancer cell line human CVCL_5201 CL:0000010 Derived from sampling site: Pancreas. Female 21189861 CVCL_4Q00 AG20420 transformed cell line human CVCL_4Q00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189862 CVCL_5200 PCI-68 cancer cell line human CVCL_5200 CL:0000010 Derived from sampling site: Pancreas. Male 21189863 CVCL_4Q07 AG20500 transformed cell line human CVCL_4Q07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189864 CVCL_5207 HESS-5 stromal cell line house mouse CVCL_5207 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/HeN-Crj. 21189865 CVCL_4Q06 AG20499 transformed cell line human CVCL_4Q06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189866 CVCL_5206 ATH8 transformed cell line human CVCL_5206 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 21189867 CVCL_4Q05 AG20497 transformed cell line human CVCL_4Q05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189868 CVCL_5205 BALM-5 cancer cell line human CVCL_5205 CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Doubling time: 36-48 hours (PubMed=160894) 21189869 CVCL_4Q04 AG20487 transformed cell line human CVCL_4Q04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Male 21189870 CVCL_5204 UT-7/TPO cancer cell line human CVCL_5204 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.783_919del137; Zygosity=Unspecified (from parent cell line) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: TPO dependent 21189871 CVCL_4Q09 AG20579 transformed cell line human CVCL_4Q09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189872 CVCL_5209 INA-6 cancer cell line human CVCL_5209 Genome ancestry: African=0.46%; Native American=0.15%; East Asian, North=2.2%; East Asian, South=0%; South Asian=0%; European, North=63.38%; European, South=33.82% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Met (c.395A>T); ClinVar=VCV000376629; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Heterozygous (DepMap) Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Produces Ig kappa; Characteristics: IL6 dependent Doubling time: ~30-50 hours (DSMZ=ACC-862) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189873 CVCL_4Q08 AG20578 transformed cell line human CVCL_4Q08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189874 CVCL_5208 HESS-M28 stromal cell line house mouse CVCL_5208 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C3H/HeN. 21189875 CVCL_X840 AG07374 finite cell line human CVCL_X840 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189876 CVCL_WW40 BT 147 cancer cell line human CVCL_WW40 CL:0000010 Characteristics: Low-passage-number culture. 21189877 CVCL_X822 AG18377 transformed cell line human CVCL_X822 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189878 CVCL_WW22 PA-JEB transformed cell line human CVCL_WW22 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Unspecified Doubling time: ~36 hours (PubMed=9660880) 21189879 CVCL_X821 AG18376 transformed cell line human CVCL_X821 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; g.2626G>A; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189880 CVCL_WW21 OST-1-PF cancer cell line human CVCL_WW21 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Serum/protein free medium cell line Problematic cell line: Contaminated Parent cell line (OST) has been shown to be a HeLa derivative. 21189881 CVCL_X820 AG18375 finite cell line human CVCL_X820 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; g.2626G>A; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Cys525Alafs*33 (c.1573delT) (g.2886delT); ClinVar=VCV000006066; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by microarray Male 21189882 CVCL_WW20 OST-II cancer cell line human CVCL_WW20 CL:0000010 Population: Japanese. Female 21189883 CVCL_X826 AG18469 transformed cell line human CVCL_X826 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189884 CVCL_WW26 HCD transformed cell line human CVCL_WW26 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVHB1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortical collecting duct. Unspecified 21189885 CVCL_X825 AG18466 finite cell line human CVCL_X825 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Gln810Ter (c.2428C>T) (g.4503C>T); Zygosity=Heterozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Female 21189886 CVCL_WW25 RC.SV3 transformed cell line CVCL_WW25 CL:0000010 Transformant: Simian virus 40 (SV40) [Strain LP](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule; Breed/subspecies: New Zealand white. Male Doubling time: 26 hours (PubMed=2550481) 21189887 CVCL_X824 AG18465 transformed cell line human CVCL_X824 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Gln810Ter (c.2428C>T) (g.4503C>T); Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189888 CVCL_WW24 PA-JEB/beta4-EGFP transformed cell line human CVCL_WW24 CL:0000010 Transfected with: HGNC; 6158; ITGB4; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Unspecified 21189889 CVCL_X823 AG18459 finite cell line human CVCL_X823 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; g.2626G>A; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21189890 CVCL_WW23 PA-JEB/beta4 transformed cell line human CVCL_WW23 CL:0000010 Transfected with: HGNC; 6158; ITGB4 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760). Unspecified 21189891 CVCL_X829 XP23BE LCL transformed cell line human CVCL_X829 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Native North American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189892 CVCL_WW29 RC.SV1 transformed cell line CVCL_WW29 CL:0000010 Transformant: Simian virus 40 (SV40) [Strain LP](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule; Breed/subspecies: New Zealand white. Male Doubling time: 20 hours (PubMed=2550481) 21189893 CVCL_X828 XP23BE finite cell line human CVCL_X828 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=16081512) Population: Native North American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21189894 CVCL_WW28 HGVEC.SV1A4 transformed cell line human CVCL_WW28 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVHB1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerular visceral epithelium Cell type=Glomerular epithelial cell.. Unspecified Doubling time: ~36 hours (PubMed=1354670) 21189895 CVCL_X827 AG18471 transformed cell line human CVCL_X827 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189896 CVCL_WW27 HGVEC.SV1 transformed cell line human CVCL_WW27 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVHB1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerular visceral epithelium Cell type=Glomerular epithelial cell.. Unspecified 21189897 CVCL_X811 AG03587 finite cell line human CVCL_X811 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189898 CVCL_WW11 HAD-C 105 embryonic stem cell human CVCL_WW11 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Unspecified Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0413. 21189899 CVCL_X810 AG02506 finite cell line human CVCL_X810 CL:0000010 Sequence variation: Mutation; HGNC; 7523; TRIM37; Simple; c.493-2A>G (p.Arg166Cysfs*10, r.493_497delGAAAG); Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189900 CVCL_WW10 HAD-C 104 embryonic stem cell human CVCL_WW10 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Unspecified Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0412. 21189901 CVCL_X815 AG17524 finite cell line human CVCL_X815 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; g.2626G>A; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.His831Argfs*52 (c.2492_2493delAT) (2-BP DEL,NT2492); ClinVar=VCV000006064; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189902 CVCL_WW15 NCC-375 cancer cell line human CVCL_WW15 CL:0000010 Sequence variation: Gene fusion; HGNC; 24943; FAM174A + HGNC; 29435; WWC1; Name(s)=FAM174A-WWC1; Note=In frame (PubMed=31228769) Population: Korean Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 35 hours (PubMed=31228769) 21189903 CVCL_X814 AG05140 transformed cell line human CVCL_X814 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189904 CVCL_WW14 CTVT cell line cancer cell line dog CVCL_WW14 CL:0000010 Derived from sampling site: Vulva. Female 21189905 CVCL_X813 AG05139 finite cell line human CVCL_X813 CL:0000010 Population: Caucasian; Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Male 21189906 CVCL_WW13 UM181-1 PDG embryonic stem cell human CVCL_WW13 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0408. 21189907 CVCL_X812 AG05013 finite cell line human CVCL_X812 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.2059-1G>T (IVS12AS,G-T,-1); ClinVar=VCV000006065; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.His831Argfs*52 (c.2492_2493delAT) (2-BP DEL,NT2492); ClinVar=VCV000006064; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21189908 CVCL_WW12 HAD-C 107 embryonic stem cell human CVCL_WW12 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Unspecified Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0414. 21189909 CVCL_X819 AG18374 transformed cell line human CVCL_X819 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; g.2626G>A; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Cys525Alafs*33 (c.1573delT) (g.2886delT); ClinVar=VCV000006066; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189910 CVCL_WW19 AT41RM transformed cell line human CVCL_WW19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu2904Gly (c.8711A>G); ClinVar=VCV000186276; Zygosity=Homozygous (PubMed=8845835; PubMed=9244351) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21189911 CVCL_X818 AG18373 finite cell line human CVCL_X818 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.1483+25del11 (g.2746del11); Zygosity=Heterozygous (Coriell) Population: Mexican; Derived from sampling site: Cell type=Fibroblast. Female 21189912 CVCL_WW18 AT24RM transformed cell line human CVCL_WW18 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Cys252Terfs (c.756_757delTG); Zygosity=Homozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21189913 CVCL_X817 AG18372 transformed cell line human CVCL_X817 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.1483+25del11 (g.2746del11); Zygosity=Heterozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189914 CVCL_WW17 SNU-2446 cancer cell line human CVCL_WW17 CL:0000010 Population: Korean; Derived from sampling site: Colon; descending. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Female Doubling time: 82 hours (PubMed=31228769) Part of: Seoul National University (SNU) cell line collection 21189915 CVCL_X816 AG18371 finite cell line human CVCL_X816 CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.1483+25del11 (g.2746del11); Zygosity=Homozygous (Coriell) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21189916 CVCL_WW16 SNU-1826 cancer cell line human CVCL_WW16 CL:0000010 Population: Korean; Derived from sampling site: Cecum. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: 45 hours (PubMed=31228769) Part of: Seoul National University (SNU) cell line collection 21189917 CVCL_X800 AG16782 transformed cell line human CVCL_X800 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189918 CVCL_WW00 NVS3 hybridoma house mouse CVCL_WW00 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P08677; Plasmodium vivax (strain Belem) circumsporozoite protein (CS) (Note=Also reacts with other strains). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10615 21189919 CVCL_X804 AG20440 transformed cell line human CVCL_X804 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189920 CVCL_WW04 UM205-1 embryonic stem cell human CVCL_WW04 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0404. 21189921 CVCL_X803 AG20439 finite cell line human CVCL_X803 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG20439; probable Male 21189922 CVCL_WW03 UM204-1 PGD embryonic stem cell human CVCL_WW03 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM204-4 PGD (Cellosaurus=CVCL_C3F2) and UM204-7 PGD (Cellosaurus=CVCL_C3F3). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0401 21189923 CVCL_X802 AG16504 transformed cell line human CVCL_X802 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189924 CVCL_WW02 PLA-801E cancer cell line human CVCL_WW02 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male 21189925 CVCL_X801 AG13074 finite cell line human CVCL_X801 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [30%]; 47,XX,+18 [70%]; mosaic (Coriell); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by single cell RNAseq Female 21189926 CVCL_WW01 PLA-801A cancer cell line human CVCL_WW01 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Male 21189927 CVCL_X808 AG02122 finite cell line human CVCL_X808 CL:0000010 Sequence variation: Mutation; HGNC; 7523; TRIM37; Simple; c.493-2A>G (p.Arg166Cysfs*10, r.493_497delGAAAG); Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189928 CVCL_WW08 UM4-13 embryonic stem cell human CVCL_WW08 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM4-6 (Cellosaurus=CVCL_B840), UM4-9 (Cellosaurus=CVCL_5H77), UM4-11 (Cellosaurus=CVCL_5H75) and UM4-12 (Cellosaurus=CVCL_5H76). Unspecified 21189929 CVCL_X807 AG20445 finite cell line human CVCL_X807 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189930 CVCL_WW07 UM4-10 embryonic stem cell human CVCL_WW07 From: University of Michigan; Ann Arbor; USA. CL:0000010 Unspecified 21189931 CVCL_X806 AG20442 finite cell line human CVCL_X806 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21189932 CVCL_WW06 UM178-1 embryonic stem cell human CVCL_WW06 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0403. 21189933 CVCL_X805 AG20441 transformed cell line human CVCL_X805 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189934 CVCL_WW05 UM207-3 PGD embryonic stem cell human CVCL_WW05 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM207-4 PGD (Cellosaurus=CVCL_XD47). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0402 21189935 CVCL_X809 AG02505 finite cell line human CVCL_X809 CL:0000010 Sequence variation: Mutation; HGNC; 7523; TRIM37; Simple; c.493-2A>G (p.Arg166Cysfs*10, r.493_497delGAAAG); Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21189936 CVCL_WW09 HAD-C 103 embryonic stem cell human CVCL_WW09 From: Hadassah Hebrew University Medical Center; Jerusalem; Israel CL:0000010 Unspecified Group: Clinical grade hESC cell line; Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0411. 21189937 CVCL_4P80 AG08709 finite cell line human CVCL_4P80 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189938 CVCL_5180 Y-MESO-21 cancer cell line human CVCL_5180 CL:0000010 Sequence variation: Gene deletion; HGNC; 6515; LATS2; Zygosity=Homozygous (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189939 CVCL_4P84 AG08713 transformed cell line human CVCL_4P84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189940 CVCL_5184 Y-MESO-27 cancer cell line human CVCL_5184 CL:0000010 Sequence variation: Gene deletion; HGNC; 6515; LATS2; Zygosity=Homozygous (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189941 CVCL_4P83 AG08712 finite cell line human CVCL_4P83 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189942 CVCL_5183 Y-MESO-26B cancer cell line human CVCL_5183 CL:0000010 Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=21245096); Sequence variation: Mutation; HGNC; 6515; LATS2; Simple; p.Tyr649Ter (c.1947G>C); Zygosity=Unspecified (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189943 CVCL_4P82 AG08711 finite cell line human CVCL_4P82 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189944 CVCL_5182 Y-MESO-25 cancer cell line human CVCL_5182 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Unexplicit; Ex13-17del; Zygosity=Homozygous (PubMed=26011428); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; c.532_571del40; Zygosity=Unspecified (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189945 CVCL_4P81 AG08710 transformed cell line human CVCL_4P81 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189946 CVCL_5181 Y-MESO-22 cancer cell line human CVCL_5181 CL:0000010 Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189947 CVCL_4P88 AG09235 transformed cell line human CVCL_4P88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189948 CVCL_5188 Y-MESO-8A cancer cell line human CVCL_5188 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH Male 21189949 CVCL_4P87 AG09035 finite cell line human CVCL_4P87 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189950 CVCL_5187 Y-MESO-30 cancer cell line human CVCL_5187 CL:0000010 Sequence variation: Mutation; HGNC; 6515; LATS2; Simple; c.2652_2665+111del125; Zygosity=Unspecified (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189951 CVCL_4P86 AG09034 transformed cell line human CVCL_4P86 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189952 CVCL_5186 Y-MESO-29 cancer cell line human CVCL_5186 CL:0000010 Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189953 CVCL_4P85 AG08746 transformed cell line human CVCL_4P85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189954 CVCL_5185 Y-MESO-28 cancer cell line human CVCL_5185 CL:0000010 Sequence variation: Gene deletion; HGNC; 17795; SAV1; Zygosity=Homozygous (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189955 CVCL_4P79 AG08708 transformed cell line human CVCL_4P79 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189956 CVCL_5179 Y-MESO-14 cancer cell line human CVCL_5179 CL:0000010 Sequence variation: Gene deletion; HGNC; 6515; LATS2; Zygosity=Homozygous (PubMed=21245096); Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Lys116Glyfs*5 (c.349_359del11); Zygosity=Unspecified (PubMed=26011428); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000457921; Zygosity=Unspecified (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189957 CVCL_4P78 AG08707 finite cell line human CVCL_4P78 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189958 CVCL_5178 Y-MESO-12 cancer cell line human CVCL_5178 CL:0000010 Sequence variation: Gene deletion; HGNC; 7773; NF2; Zygosity=Homozygous (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Female 21189959 CVCL_4P91 AG09905 transformed cell line human CVCL_4P91 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189960 CVCL_5191 PCI-35 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_5191 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11115575) Derived from sampling site: Pancreas. Male Doubling time: 33.6 hours (PubMed=7804431) 21189961 CVCL_4P90 AG09750 transformed cell line human CVCL_4P90 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189962 CVCL_5190 Y-MESO-9 cancer cell line human CVCL_5190 CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Phe678Leufs*37 (c.2035_2036del2); Zygosity=Unspecified (PubMed=26011428); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Tyr177fs (c.527_528delTG); Zygosity=Unspecified (PubMed=21245096) Population: Japanese Omics: Array-based CGH; Omics: Transcriptome analysis by microarray. Male 21189963 CVCL_4P95 AG17512 transformed cell line human CVCL_4P95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189964 CVCL_5195 PCI-24 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_5195 CL:0000010 Derived from sampling site: Pancreas. Male Doubling time: 39.2 hours (PubMed=7804431) 21189965 CVCL_4P94 AG13518 transformed cell line human CVCL_4P94 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189966 CVCL_5194 PCI-19 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_5194 CL:0000010 Derived from sampling site: Pancreas. Male Doubling time: 38.4 hours (PubMed=7804431) 21189967 CVCL_4P93 AG09949 transformed cell line human CVCL_4P93 CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189968 CVCL_5193 PCI-10 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_5193 CL:0000010 Derived from sampling site: Pancreas. Doubling time: 34.0 hours (PubMed=7804431) 21189969 CVCL_4P92 AG09906 transformed cell line human CVCL_4P92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189970 CVCL_5192 YST-1 cancer cell line human CVCL_5192 CL:0000010 Population: Japanese; Derived from sampling site: Arm; hypodermis Cell type=Schwann cell.. Female Doubling time: ~40 hours (PubMed=1980563) 21189971 CVCL_4P99 AG20405 transformed cell line human CVCL_4P99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Umbilical cord blood. Female 21189972 CVCL_5199 PCI-66 cancer cell line human CVCL_5199 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Hemizygous (PubMed=11115575) Derived from sampling site: Pancreas. Female 21189973 CVCL_4P98 AG17574 transformed cell line human CVCL_4P98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189974 CVCL_5198 PCI-64 cancer cell line human CVCL_5198 CL:0000010 Derived from sampling site: Pancreas. Male 21189975 CVCL_4P97 AG17529 transformed cell line human CVCL_4P97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189976 CVCL_5197 PCI-6 cancer cell line human CVCL_5197 CL:0000010 Derived from sampling site: Pancreas. Male 21189977 CVCL_4P96 AG17514 transformed cell line human CVCL_4P96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21189978 CVCL_5196 PCI-55 cancer cell line human CVCL_5196 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=11115575); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Unspecified (PubMed=11115575) Derived from sampling site: Pancreas. Male 21189979 CVCL_4P89 AG09369 transformed cell line human CVCL_4P89 CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21189980 CVCL_5189 Y-MESO-8D cancer cell line human CVCL_5189 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21189981 CVCL_4P62 AG08179 finite cell line human CVCL_4P62 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189982 CVCL_5162 RHEK-1/200R transformed cell line human CVCL_5162 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21189983 CVCL_4P61 AG08178 transformed cell line human CVCL_4P61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189984 CVCL_5161 RHEK-1 transformed cell line human CVCL_5161 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21189985 CVCL_4P60 AG08176 finite cell line human CVCL_4P60 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189986 CVCL_5160 NCI-H3122 cancer cell line human CVCL_5160 Genome ancestry: African=0%; Native American=0%; East Asian, North=1.36%; East Asian, South=0%; South Asian=1.48%; European, North=65.9%; European, South=31.26% (PubMed=30894373). CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010; DepMap) Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 48.5 hours (PubMed=29681454); Microsatellite instability: Stable (MSS) (Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21189987 CVCL_4P66 AG08183 finite cell line human CVCL_4P66 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189988 CVCL_5166 ROVA cancer cell line human CVCL_5166 CL:0000010 Population: Mexican; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21189989 CVCL_4P65 AG08182 transformed cell line human CVCL_4P65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21189990 CVCL_5165 RHEK-1/800R transformed cell line human CVCL_5165 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21189991 CVCL_4P64 AG08181 finite cell line human CVCL_4P64 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189992 CVCL_5164 RHEK-1/600R transformed cell line human CVCL_5164 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21189993 CVCL_4P63 AG08180 transformed cell line human CVCL_4P63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21189994 CVCL_5163 RHEK-1/400R transformed cell line human CVCL_5163 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21189995 CVCL_4P59 AG08175 finite cell line human CVCL_4P59 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21189996 CVCL_5159 NCI-H2887 cancer cell line human CVCL_5159 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 43.1 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21189997 CVCL_4P58 AG08174 finite cell line human CVCL_4P58 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21189998 CVCL_5158 NCI-H2882 cancer cell line human CVCL_5158 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq. Female Doubling time: 34.8 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21189999 CVCL_4P57 AG08173 transformed cell line human CVCL_4P57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190000 CVCL_5157 NCI-H2077 cancer cell line human CVCL_5157 CL:0000010 Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-5919; true. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190001 CVCL_4P56 AG08172 finite cell line human CVCL_4P56 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Canadian Alzheimer disease kindred subcollection 21190002 CVCL_5156 MRMT-1 cancer cell line Norway rat CVCL_5156 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Sprague Dawley. Female 21190003 CVCL_X799 AG16778 transformed cell line human CVCL_X799 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190004 CVCL_WV99 NCI-H1975/OSIR cancer cell line human CVCL_WV99 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:90943; Osimertinib (AZD9291) Female 21190005 CVCL_X798 AG16704 transformed cell line human CVCL_X798 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190006 CVCL_WV98 BON1 RR2 cancer cell line human CVCL_WV98 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001); Derived from metastatic site: Lymph node. Male 21190007 CVCL_X797 AG16714 transformed cell line human CVCL_X797 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190008 CVCL_WV97 BON1 RR1 cancer cell line human CVCL_WV97 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001); Derived from metastatic site: Lymph node. Male 21190009 CVCL_4P73 AG08702 transformed cell line human CVCL_4P73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190010 CVCL_5173 SJES-7 cancer cell line human CVCL_5173 CL:0000010 21190011 CVCL_4P72 AG08701 finite cell line human CVCL_4P72 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190012 CVCL_5172 SJES-6 cancer cell line human CVCL_5172 CL:0000010 21190013 CVCL_4P71 AG08700 transformed cell line human CVCL_4P71 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190014 CVCL_5171 SJES-5 cancer cell line human CVCL_5171 CL:0000010 21190015 CVCL_4P70 AG08253 finite cell line human CVCL_4P70 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190016 CVCL_5170 SJES-3 cancer cell line human CVCL_5170 CL:0000010 21190017 CVCL_4P77 AG08706 transformed cell line human CVCL_4P77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190018 CVCL_5177 VIPA cancer cell line human CVCL_5177 CL:0000010 Population: Mexican; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21190019 CVCL_4P76 AG08705 finite cell line human CVCL_4P76 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190020 CVCL_5176 VACO 411 cancer cell line human CVCL_5176 CL:0000010 Omics: Transcriptome analysis by microarray. Female Microsatellite instability: Stable (MSS) (PubMed=25926053) 21190021 CVCL_4P75 AG08704 transformed cell line human CVCL_4P75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190022 CVCL_5175 VACO 235 cancer cell line human CVCL_5175 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=2253215). Female 21190023 CVCL_4P74 AG08703 finite cell line human CVCL_4P74 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190024 CVCL_5174 SJES-8 cancer cell line human CVCL_5174 CL:0000010 21190025 CVCL_4P69 AG08252 transformed cell line human CVCL_4P69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190026 CVCL_5169 SJES-2 cancer cell line human CVCL_5169 CL:0000010 21190027 CVCL_4P68 AG08185 finite cell line human CVCL_4P68 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190028 CVCL_5168 SJES-1 cancer cell line human CVCL_5168 CL:0000010 21190029 CVCL_4P67 AG08184 transformed cell line human CVCL_4P67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190030 CVCL_5167 SH-10-TC cancer cell line human CVCL_5167 Genome ancestry: African=0%; Native American=0%; East Asian, North=64.56%; East Asian, South=34.04%; South Asian=0%; European, North=0%; European, South=1.4% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (DepMap) Population: Japanese Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190031 CVCL_X789 AG05024 finite cell line human CVCL_X789 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 21190032 CVCL_WV89 FPMI-CF-30 spontaneously immortalized cell line CVCL_WV89 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190033 CVCL_X788 AG04823 finite cell line human CVCL_X788 CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 21190034 CVCL_WV88 FPMI-CF-27 spontaneously immortalized cell line CVCL_WV88 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190035 CVCL_X787 AG04646 finite cell line human CVCL_X787 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190036 CVCL_WV87 FPMI-CF-22 spontaneously immortalized cell line CVCL_WV87 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190037 CVCL_X786 AG04645 finite cell line human CVCL_X786 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190038 CVCL_WV86 FPMI-CF-300 spontaneously immortalized cell line CVCL_WV86 CL:0000010 Female Group: Insect cell line. 21190039 CVCL_4P40 AG07672 transformed cell line human CVCL_4P40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190040 CVCL_5140 INBL cancer cell line human CVCL_5140 CL:0000010 Population: Mexican; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21190041 CVCL_4P44 AG07759 transformed cell line human CVCL_4P44 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190042 CVCL_5144 K562/MTX-2 cancer cell line human CVCL_5144 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Pleural effusion. Female 21190043 CVCL_4P43 AG07757 finite cell line human CVCL_4P43 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190044 CVCL_5143 K029 cancer cell line human CVCL_5143 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23418523). Population: Caucasian 21190045 CVCL_4P42 AG07756 transformed cell line human CVCL_4P42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190046 CVCL_5142 K008 cancer cell line human CVCL_5142 CL:0000010 21190047 CVCL_4P41 AG07673 transformed cell line human CVCL_4P41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190048 CVCL_5141 K-251 cancer cell line Norway rat CVCL_5141 CL:0000010 Breed/subspecies: ACI/N. Female 21190049 CVCL_4P37 AG07669 finite cell line human CVCL_4P37 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190050 CVCL_5137 HCC95 cancer cell line human CVCL_5137 HLA typing: A*11:01,29:02; B*13:02,18:01; C*16:01,16:01 (PubMed=26589293); Genome ancestry: African=0.18%; Native American=0.36%; East Asian, North=1.64%; East Asian, South=0%; South Asian=2.05%; European, North=62.63%; European, South=33.13% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg335Valfs*10 (c.1002delG) (p.Gly334fs); Zygosity=Homozygous (PubMed=20557307; DepMap) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40.6 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project; Part of: TCGA-110-CL cell line panel Caution: Indicated as originating from a 65 year old male patient in PubMed=10353731 and from a 70 year old in PubMed=9559342 21190051 CVCL_4P36 AG07668 transformed cell line human CVCL_4P36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190052 CVCL_5136 HCC515 cancer cell line human CVCL_5136 HLA typing: A*11:01,11:01; B*51:01,51:01; C*15:02,15:02; DRB1*15:01,15:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84His (c.250G>C); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (PubMed=20557307; DepMap) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 39.3 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190053 CVCL_4P35 AG07667 finite cell line human CVCL_4P35 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Doubling time: Slow growth (Coriell) Part of: Canadian Alzheimer disease kindred subcollection 21190054 CVCL_5135 HCC461 cancer cell line human CVCL_5135 HLA typing: A*03:01,03:01; B*07:02,40:01; C*03:04,07:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=10353731; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser149Profs*21 (c.445delT); ClinVar=VCV000419519; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Gln (c.800G>A); ClinVar=VCV000127823; Zygosity=Heterozygous (DepMap) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190055 CVCL_4P34 AG07666 transformed cell line human CVCL_4P34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190056 CVCL_5134 HCC364 cancer cell line human CVCL_5134 HLA typing: A*24:02,24:02; B*35:02,35:02; C*04:01,04:01; DQA1*05:01,05:01; DQB1*03:01,03:01; DRB1*03:17,11:04 (PubMed=26589293); Genome ancestry: African=2.01%; Native American=0.31%; East Asian, North=6.71%; East Asian, South=0%; South Asian=5.19%; European, North=21.75%; European, South=64.04% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Lys (c.538G>A); ClinVar=VCV000245711; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: shRNA library screening; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 24 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190057 CVCL_4P39 AG07671 finite cell line human CVCL_4P39 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (PubMed=24416243) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190058 CVCL_5139 PCI-43 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_5139 CL:0000010 Derived from sampling site: Pancreas. Female Doubling time: 52.8 hours (PubMed=7804431) 21190059 CVCL_4P38 AG07670 transformed cell line human CVCL_4P38 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from autologous cell line AG07671) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190060 CVCL_5138 HCE-7 cancer cell line human CVCL_5138 CL:0000010 Derived from sampling site: Esophagus. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Established from a tumor transplanted in nude mice Doubling time: 53 hours (PubMed=2415247) 21190061 CVCL_X792 AG04526 finite cell line human CVCL_X792 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21190062 CVCL_WV92 FPMI-CF-40 spontaneously immortalized cell line CVCL_WV92 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190063 CVCL_X791 AG04525 finite cell line human CVCL_X791 CL:0000010 Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male Senescence: Senesces at 27-36 PDL (PubMed=9724752) 21190064 CVCL_WV91 FPMI-CF-34 spontaneously immortalized cell line CVCL_WV91 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190065 CVCL_X790 AG04475 finite cell line human CVCL_X790 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~4000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21190066 CVCL_WV90 FPMI-CF-33 spontaneously immortalized cell line CVCL_WV90 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190067 CVCL_X796 AG16711 transformed cell line human CVCL_X796 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190068 CVCL_WV96 CGMCC-14696 hybridoma house mouse CVCL_WV96 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:3732; Clarithromycin. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.14696 21190069 CVCL_WV95 786-OR cancer cell line human CVCL_WV95 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001); Derived from sampling site: Kidney. Male 21190070 CVCL_X795 AG16710 transformed cell line human CVCL_X795 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190071 CVCL_X794 AG09802 transformed cell line human CVCL_X794 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190072 CVCL_WV94 IPRI-CF-16T spontaneously immortalized cell line CVCL_WV94 CL:0000010 Unspecified Characteristics: Has increased attachment adherence compared to the parent cell line. Group: Insect cell line 21190073 CVCL_X793 AG06922 finite cell line human CVCL_X793 CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Male 21190074 CVCL_WV93 FPMI-CF-41 spontaneously immortalized cell line CVCL_WV93 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 21190075 CVCL_X778 AG14460 transformed cell line human CVCL_X778 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190076 CVCL_WV78 HT patient 1 line 2 induced pluripotent stem cell human CVCL_WV78 CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Val166Gly (c.497T>G) (553T>G); ClinVar=VCV000558415; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00286, the patient description and its mutation description are identical (up tp the point of using the same obsolete cDNA position information) 21190077 CVCL_X777 AG14249 transformed cell line human CVCL_X777 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190078 CVCL_WV77 HT patient 1 line 1 induced pluripotent stem cell human CVCL_WV77 CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Val166Gly (c.497T>G) (553T>G); ClinVar=VCV000558415; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00286, the patient description and its mutation description are identical (up tp the point of using the same obsolete cDNA position information) 21190079 CVCL_X776 AG14177 transformed cell line human CVCL_X776 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190080 CVCL_WV76 GSD1a patient 1 line 3 induced pluripotent stem cell human CVCL_WV76 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gly222Arg (c.666G>C) (G743C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00574, the patient description is identical 21190081 CVCL_X775 AG14263 finite cell line human CVCL_X775 CL:0000010 Population: Caucasian; Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 21190082 CVCL_WV75 GSD1a patient 1 line 2 induced pluripotent stem cell human CVCL_WV75 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gly222Arg (c.666G>C) (G743C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00574, the patient description is identical 21190083 CVCL_X779 AG14461 transformed cell line human CVCL_X779 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190084 CVCL_WV79 HT patient 1 line 3 induced pluripotent stem cell human CVCL_WV79 CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Val166Gly (c.497T>G) (553T>G); ClinVar=VCV000558415; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00286, the patient description and its mutation description are identical (up tp the point of using the same obsolete cDNA position information) 21190085 CVCL_4P51 AG07771 transformed cell line human CVCL_4P51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190086 CVCL_5151 KUM5 somatic stem cell house mouse CVCL_5151 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190087 CVCL_4P50 AG07769 transformed cell line human CVCL_4P50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190088 CVCL_5150 KUM4 somatic stem cell house mouse CVCL_5150 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190089 CVCL_4P55 AG08171 transformed cell line human CVCL_4P55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190090 CVCL_4P54 AG08129 finite cell line human CVCL_4P54 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190091 CVCL_5154 KUM9 somatic stem cell house mouse CVCL_5154 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190092 CVCL_4P53 AG08128 transformed cell line human CVCL_4P53 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190093 CVCL_5153 KUM7 somatic stem cell house mouse CVCL_5153 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190094 CVCL_4P52 AG07989 transformed cell line human CVCL_4P52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190095 CVCL_5152 KUM6 somatic stem cell house mouse CVCL_5152 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190096 CVCL_4P48 AG07765 transformed cell line human CVCL_4P48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190097 CVCL_5148 KUM10 somatic stem cell house mouse CVCL_5148 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Discontinued: JCRB; NIHS0493; true Female 21190098 CVCL_4P47 AG07763 transformed cell line human CVCL_4P47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190099 CVCL_5147 KP-PN-TTBm2 cancer cell line human CVCL_5147 CL:0000010 21190100 CVCL_4P46 AG07762 finite cell line human CVCL_4P46 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190101 CVCL_5146 KLM-1 cancer cell line human CVCL_5146 HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02 (PubMed=26589293); Genome ancestry: African=0.52%; Native American=0%; East Asian, North=88.41%; East Asian, South=10.63%; South Asian=0.44%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Omics: Metabolome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Characteristics: Established after 2 rounds of injection of cell suspensions of subcutaneous tumors arising from PK-1 in BALB/c nude mice Doubling time: 44.1 hours (PubMed=8872523) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190102 CVCL_4P45 AG07761 transformed cell line human CVCL_4P45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 25% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190103 CVCL_5145 K562/Vin cancer cell line human CVCL_5145 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Pleural effusion. Female Doubling time: 24.1 +- 1.8 hours (PubMed=6580255) 21190104 CVCL_4P49 AG07766 finite cell line human CVCL_4P49 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190105 CVCL_5149 KUM3 somatic stem cell house mouse CVCL_5149 CL:0000010 Derived from sampling site: Bone marrow Cell type=Osteoblast.; Breed/subspecies: C3H/He. Female 21190106 CVCL_X781 XP1SA [Santiago] finite cell line human CVCL_X781 CL:0000010 Population: Chilean; Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Female 21190107 CVCL_WV81 L1-C5 induced pluripotent stem cell human CVCL_WV81 From: Peking University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.605-2A>G; ClinVar=VCV001342708; Zygosity=Heterozygous; Note=Splice acceptor mutation (from autologous cell line L1-C4); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly272Asp (c.815G>A) (p.Gly145Asp, c.434G>A); ClinVar=VCV000053109; Zygosity=Heterozygous (from autologous cell line L1-C4) Population: Chinese; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21190108 CVCL_X780 AG02871 finite cell line human CVCL_X780 CL:0000010 Population: Chilean; Derived from sampling site: Sacrum; skin Cell type=Fibroblast.. Female 21190109 CVCL_WV80 L1-C4 induced pluripotent stem cell human CVCL_WV80 From: Peking University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; c.605-2A>G; ClinVar=VCV001342708; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31226583); Sequence variation: Mutation; HGNC; 6294; KCNQ1; Simple; p.Gly272Asp (c.815G>A) (p.Gly145Asp, c.434G>A); ClinVar=VCV000053109; Zygosity=Heterozygous (PubMed=31226583) Population: Chinese; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21190110 CVCL_X785 AG03738 transformed cell line human CVCL_X785 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190111 CVCL_WV85 FPMI-CF-205 spontaneously immortalized cell line CVCL_WV85 CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 21190112 CVCL_X784 XP14CA finite cell line human CVCL_X784 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 22 PDL (PubMed=6492896) 21190113 CVCL_WV84 FPMI-CF-204 spontaneously immortalized cell line CVCL_WV84 CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 21190114 CVCL_X783 XP12CA finite cell line human CVCL_X783 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 22 PDL (PubMed=6492896) 21190115 CVCL_WV83 FPMI-CF-200 spontaneously immortalized cell line CVCL_WV83 CL:0000010 Derived from sampling site: Midgut. Unspecified Group: Insect cell line 21190116 CVCL_X782 XP11CA finite cell line human CVCL_X782 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21190117 CVCL_WV82 HCT-116/SN-38 cancer cell line human CVCL_WV82 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male Doubling time: 29 hours (PubMed=23546019) 21190118 CVCL_WV67 A1ATD patient 2 line 2 induced pluripotent stem cell human CVCL_WV67 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190119 CVCL_X767 AG03141 finite cell line human CVCL_X767 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln748Ter (c.2242C>T) (2476C>T); ClinVar=VCV000835212; Zygosity=Homozygous (Coriell) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female 21190120 CVCL_WV66 A1ATD patient 2 line 1 induced pluripotent stem cell human CVCL_WV66 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190121 CVCL_X766 AG03059 finite cell line human CVCL_X766 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190122 CVCL_WV65 A1ATD patient 1 line 3 induced pluripotent stem cell human CVCL_WV65 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190123 CVCL_X765 AG03058 finite cell line human CVCL_X765 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190124 CVCL_WV64 A1ATD patient 1 line 2 induced pluripotent stem cell human CVCL_WV64 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190125 CVCL_X764 AG03057 finite cell line human CVCL_X764 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190126 CVCL_WV69 A1ATD patient 3 line 1 induced pluripotent stem cell human CVCL_WV69 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190127 CVCL_X769 AG12797 finite cell line human CVCL_X769 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Male 21190128 CVCL_WV68 A1ATD patient 2 line 3 induced pluripotent stem cell human CVCL_WV68 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190129 CVCL_X768 AG05233 finite cell line human CVCL_X768 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21190130 CVCL_4P22 AG07652 transformed cell line human CVCL_4P22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190131 CVCL_5122 ES-1-OT cancer cell line human CVCL_5122 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr284Glnfs*61 (c.849delC) (p.Arg283fs); Zygosity=Unspecified (PubMed=8221663) Population: Japanese; Derived from metastatic site: Bone marrow. Male 21190132 CVCL_4P21 AG07644 transformed cell line human CVCL_4P21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190133 CVCL_5121 CaLo cancer cell line human CVCL_5121 CL:0000010 Population: Mexican; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21190134 CVCL_4P20 AG07642 transformed cell line human CVCL_4P20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190135 CVCL_5120 BT-325 cancer cell line human CVCL_5120 CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Doubling time: ~36.5 hours (CelloPub=CLPUB00249) 21190136 CVCL_5115 A-THP-1 cancer cell line human CVCL_5115 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Enriched with adherent cells Maintains an activated state without exogenous stimulation (PubMed=10223614). 21190137 CVCL_4P15 AG07637 finite cell line human CVCL_4P15 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190138 CVCL_5114 ACC-MESO-4 cancer cell line human CVCL_5114 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Tyr724Ter (c.2172delC); Zygosity=Unspecified (PubMed=26011428); Sequence variation: Mutation; HGNC; 20796; RASSF6; Simple; p.Arg155fs (c.464_465insA); Zygosity=Unspecified (PubMed=25902174) Population: Japanese Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Male 21190139 CVCL_4P14 AG07636 transformed cell line human CVCL_4P14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190140 CVCL_5113 ACC-MESO-1 cancer cell line human CVCL_5113 HLA typing: A*31:01,31:01; B*15:01,46:01; C*15:02,15:02 (PubMed=26589293); Genome ancestry: African=1.98%; Native American=0.64%; East Asian, North=84.83%; East Asian, South=11.7%; South Asian=0%; European, North=0%; European, South=0.85% (PubMed=30894373). CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=16630136); Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Gln389Ter (c.1165C>T); Zygosity=Homozygous (PubMed=16630136; DepMap) Population: Japanese Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190141 CVCL_4P13 AG07635 finite cell line human CVCL_4P13 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190142 CVCL_4P12 AG07634 transformed cell line human CVCL_4P12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190143 CVCL_5112 SNU-C5 cancer cell line human CVCL_5112 HLA typing: A*02:07,24:22; B*15:05,46:01; C*01:02,01:02 (PubMed=26589293); Genome ancestry: African=0%; Native American=0.84%; East Asian, North=58.4%; East Asian, South=40.75%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218Leu (c.652G>T); Zygosity=Heterozygous (PubMed=8556707; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=8556707; Cosmic-CLP; DepMap) Population: Korean; Derived from sampling site: Cecum. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a nude mouse xenograft Microsatellite instability: Instable (MSI-high) (PubMed=25926053; PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Seoul National University (SNU) cell line collection 21190144 CVCL_4P19 AG07641 finite cell line human CVCL_4P19 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190145 CVCL_5119 BL407 cancer cell line CVCL_5119 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood; Breed/subspecies: Holstein Friesian. Female 21190146 CVCL_4P18 AG07640 transformed cell line human CVCL_4P18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190147 CVCL_5118 BL3M7 cancer cell line CVCL_5118 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood; Breed/subspecies: Japanese black. Female 21190148 CVCL_4P17 AG07639 finite cell line human CVCL_4P17 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190149 CVCL_5117 BL312 cancer cell line CVCL_5117 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood; Breed/subspecies: Holstein Friesian. Female 21190150 CVCL_4P16 AG07638 transformed cell line human CVCL_4P16 CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from familial inference) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190151 CVCL_5116 BL2M3 cancer cell line CVCL_5116 CL:0000010 Transformant: Bovine leukemia virus (BLV)(NCBI-Taxonomy; 11901); Derived from sampling site: Peripheral blood; Breed/subspecies: Japanese black. Discontinued: RCB; RCB0422; true Female 21190152 CVCL_X770 AG12798 finite cell line human CVCL_X770 CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21190153 CVCL_WV70 CN patient 1 line 1 induced pluripotent stem cell human CVCL_WV70 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous (PubMed=20739751) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM09551, the patient description and its mutation description are identical 21190154 CVCL_X774 AG14262 finite cell line human CVCL_X774 CL:0000010 Population: Caucasian; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 21190155 CVCL_WV74 GSD1a patient 1 line 1 induced pluripotent stem cell human CVCL_WV74 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gly222Arg (c.666G>C) (G743C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Gln347Ter (c.1039C>T) (C1118T); ClinVar=VCV000012000; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM00574, the patient description is identical 21190156 CVCL_X773 AG04407 finite cell line human CVCL_X773 CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female Doubling time: Slow growth (Coriell) 21190157 CVCL_WV73 FH patient 1 line 1 induced pluripotent stem cell human CVCL_WV73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21190158 CVCL_X772 AG04405 finite cell line human CVCL_X772 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21190159 CVCL_WV72 CN patient 1 line 3 induced pluripotent stem cell human CVCL_WV72 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous (PubMed=20739751) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM09551, the patient description and its mutation description are identical 21190160 CVCL_X771 AG02496 finite cell line human CVCL_X771 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190161 CVCL_WV71 CN patient 1 line 2 induced pluripotent stem cell human CVCL_WV71 CL:0000010 Sequence variation: Mutation; HGNC; 12530; UGT1A1; Simple; p.Tyr293Metfs*69 (c.877_890delTACATTAATGCTTCinsA) (p.Tyr292Metfs, c.874_887delTACATTAATGCTTCinsA) (879 del 13); ClinVar=VCV000012266; Zygosity=Homozygous (PubMed=20739751) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: While PubMed=20739751 does not specifically indicates that this cell line is derived from Coriell GM09551, the patient description and its mutation description are identical 21190162 CVCL_X756 AG14271 finite cell line human CVCL_X756 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX [90%]; 46,XX,t(5;12)(q34;q21) [10%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 56 PDL (Coriell=AG14271) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190163 CVCL_WV56 U-937 RERC cancer cell line human CVCL_WV56 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Asp533Asn (c.1597G>A); Zygosity=Unspecified (PubMed=9371509); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90225; Rubitecan (Orathecin; Derived from sampling site: Pleural effusion. Male Doubling time: ~22 hours (PubMed=9371509) 21190164 CVCL_X755 AG12493 finite cell line human CVCL_X755 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female Senescence: Senesces at 26 PDL (Coriell=AG12493) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190165 CVCL_WV55 U-937/CR cancer cell line human CVCL_WV55 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Phe361Ser (c.1082T>C); Zygosity=Unspecified (PubMed=8300570); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90225; Rubitecan (Orathecin; Derived from sampling site: Pleural effusion. Male 21190166 CVCL_X754 AG07308 finite cell line human CVCL_X754 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190167 CVCL_WV54 SJG-44 cancer cell line human CVCL_WV54 CL:0000010 Male 21190168 CVCL_X753 AG07307 finite cell line human CVCL_X753 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190169 CVCL_WV53 SJG-43 cancer cell line human CVCL_WV53 CL:0000010 Female 21190170 CVCL_WV59 MMRU/CR1 cancer cell line human CVCL_WV59 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Cervical lymph node. Omics: Array-based CGH Male 21190171 CVCL_X758 AG08817 finite cell line human CVCL_X758 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Senescence: Senesces at 26-31 PDL (PubMed=9724752); 39 PDL (Coriell=AG08817) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190172 CVCL_WV58 SF295/hCPT50 cancer cell line human CVCL_WV58 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:144047; Homocamptothecin; Derived from sampling site: Brain; left temporal lobe. Female Doubling time: 69 hours (PubMed=17984197) 21190173 CVCL_X757 AG09561 finite cell line human CVCL_X757 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Senescence: Senesces at 39 PDL (Coriell=AG09561) Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 21190174 CVCL_WV57 SF295/BN50 cancer cell line human CVCL_WV57 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg233Ter (c.697C>T); ClinVar=VCV000007813; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:144046; Diflomotecan (BN80915); Derived from sampling site: Brain; left temporal lobe. Female Doubling time: 99 hours (PubMed=17984197) 21190175 CVCL_4P33 AG07665 finite cell line human CVCL_4P33 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Doubling time: Slow growth (Coriell) Part of: Canadian Alzheimer disease kindred subcollection 21190176 CVCL_5133 HCC2450 cancer cell line human CVCL_5133 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Thr (c.746G>C); ClinVar=VCV000376015; Zygosity=Homozygous (PubMed=10353731; DepMap) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190177 CVCL_4P32 AG07664 transformed cell line human CVCL_4P32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Canadian Alzheimer disease kindred subcollection 21190178 CVCL_5132 HCC2429 cancer cell line human CVCL_5132 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Gln (c.800G>A); ClinVar=VCV000127823; Zygosity=Homozygous (DepMap) Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190179 CVCL_4P31 AG07663 finite cell line human CVCL_4P31 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190180 CVCL_5131 HCC2279 cancer cell line human CVCL_5131 HLA typing: A*11:01,11:01; B*40:01,40:01; C*03:04,03:04; DQA1*01:02,01:02; DQB1*06:01,03:02; DRB1*08:03,08:03 (PubMed=26589293); Genome ancestry: African=4.25%; Native American=0%; East Asian, North=46.33%; East Asian, South=40.38%; South Asian=0%; European, North=0%; European, South=9.04% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Unspecified (PubMed=10353731) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Discontinued: ATCC; CRL-2870; true Female Doubling time: 49.3 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190181 CVCL_4P30 AG07662 transformed cell line human CVCL_4P30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190182 CVCL_5130 HCC193 cancer cell line human CVCL_5130 HLA typing: A*01:01,24:02; B*08:01,40:01; C*03:04,07:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=20557307) Miscellaneous: Direct author submission of STR profile from Girard L and Gazdar A.F. Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 45.5 hours (PubMed=29681454) Part of: MD Anderson Cell Lines Project 21190183 CVCL_4P26 AG07656 transformed cell line human CVCL_4P26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190184 CVCL_5126 HCC1171 cancer cell line human CVCL_5126 HLA typing: A*02:01,03:01; B*40:01,40:01; C*02:02,03:04 (PubMed=26589293); Genome ancestry: African=1.8%; Native American=0%; East Asian, North=0.4%; East Asian, South=0%; South Asian=0%; European, North=65.59%; European, South=32.21% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=10353731; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn247Ile (c.740A>T); ClinVar=VCV000184882; Zygosity=Homozygous (PubMed=10353731; DepMap) Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 47.5 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190185 CVCL_4P25 AG07655 finite cell line human CVCL_4P25 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190186 CVCL_5125 Fu5-5 cancer cell line Norway rat CVCL_5125 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21190187 CVCL_4P24 AG07654 transformed cell line human CVCL_4P24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190188 CVCL_5124 FTO-2B cancer cell line Norway rat CVCL_5124 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21190189 CVCL_4P23 AG07653 finite cell line human CVCL_4P23 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Canadian Alzheimer disease kindred subcollection 21190190 CVCL_5123 FT-2 cancer cell line Norway rat CVCL_5123 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Liver; Breed/subspecies: AxC. Male 21190191 CVCL_4P29 AG07661 finite cell line human CVCL_4P29 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190192 CVCL_5129 HCC1833 cancer cell line human CVCL_5129 HLA typing: A*24:02,24:02; B*35:03,35:03; C*12:03,12:03; DQA1*01:02,03:02; DQB1*03:02,05:03; DRB1*04:01,11:01 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr284_Glu286del (c.850_858delACAGAGGAA); Zygosity=Unspecified (PubMed=10353731) Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Deep quantitative proteome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 46.8 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190193 CVCL_4P28 AG07660 transformed cell line human CVCL_4P28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Canadian Alzheimer disease kindred subcollection 21190194 CVCL_5128 HCC1359 cancer cell line human CVCL_5128 HLA typing: A*30:01,66:01; B*35:01,58:02; C*06:02,16:01 (PubMed=26589293); Genome ancestry: African=86.21%; Native American=0%; East Asian, North=3%; East Asian, South=0%; South Asian=0%; European, North=1.07%; European, South=9.72% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Phe (c.388C>T); ClinVar=VCV000216466; Zygosity=Unspecified (PubMed=10353731) Population: African American; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 62.8 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190195 CVCL_4P27 AG07657 finite cell line human CVCL_4P27 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female Part of: Canadian Alzheimer disease kindred subcollection 21190196 CVCL_5127 HCC1195 cancer cell line human CVCL_5127 HLA typing: A*30:01,33:03; B*42:02,58:02; C*06:02,17:01 (PubMed=26589293); Genome ancestry: African=70.13%; Native American=0%; East Asian, North=4.8%; East Asian, South=0%; South Asian=0%; European, North=6.41%; European, South=18.66% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262_Asn263delinsProAsp (c.784_789del6insCCTGAT); Zygosity=Heterozygous (PubMed=10353731; DepMap) Population: African American; Derived from sampling site: Lung. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Doubling time: 70.4 hours (PubMed=29681454) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: MD Anderson Cell Lines Project 21190197 CVCL_WV63 A1ATD patient 1 line 1 induced pluripotent stem cell human CVCL_WV63 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=20739751) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21190200 CVCL_WV62 G2C51A2 hybridoma house mouse CVCL_WV62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04558; Porcine reproductive and respiratory syndrome virus (strain Lelystad) nucleoprotein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200851 21190201 CVCL_WV61 HT-29/SN-38 cancer cell line human CVCL_WV61 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin) Female Doubling time: 30 hours (PubMed=23546019) 21190202 CVCL_X760 AG01439 finite cell line human CVCL_X760 CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21190203 CVCL_WV60 MMRU/CR2 cancer cell line human CVCL_WV60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11; Derived from metastatic site: Cervical lymph node. Omics: Array-based CGH Male 21190204 CVCL_FD31 ND12221 transformed cell line human CVCL_FD31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190205 CVCL_FD30 ND12220 transformed cell line human CVCL_FD30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190206 CVCL_FD29 ND12219 transformed cell line human CVCL_FD29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190207 CVCL_FD24 ND12092 transformed cell line human CVCL_FD24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190208 CVCL_FD23 ND12082 transformed cell line human CVCL_FD23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190209 CVCL_FD22 ND12014 transformed cell line human CVCL_FD22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190210 CVCL_FD21 ND11977 transformed cell line human CVCL_FD21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190211 CVCL_FD28 ND12212 transformed cell line human CVCL_FD28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190212 CVCL_FD27 ND12191 transformed cell line human CVCL_FD27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190213 CVCL_FD26 ND12110 transformed cell line human CVCL_FD26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190214 CVCL_FD25 ND12106 transformed cell line human CVCL_FD25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190215 CVCL_FD42 ND12575 transformed cell line human CVCL_FD42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190216 CVCL_FD41 ND12573 transformed cell line human CVCL_FD41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190217 CVCL_FD40 ND12453 transformed cell line human CVCL_FD40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190218 CVCL_FD35 ND12326 transformed cell line human CVCL_FD35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190219 CVCL_FD34 ND12308 transformed cell line human CVCL_FD34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190220 CVCL_FD33 ND12291 transformed cell line human CVCL_FD33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190221 CVCL_FD32 ND12279 transformed cell line human CVCL_FD32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190222 CVCL_FD39 ND12394 transformed cell line human CVCL_FD39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190223 CVCL_FD38 ND12373 transformed cell line human CVCL_FD38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190224 CVCL_FD37 ND12367 transformed cell line human CVCL_FD37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190225 CVCL_FD36 ND12366 transformed cell line human CVCL_FD36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190226 CVCL_FD09 ND11712 transformed cell line human CVCL_FD09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190227 CVCL_FD08 ND11678 transformed cell line human CVCL_FD08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190228 CVCL_FD07 ND11657 transformed cell line human CVCL_FD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190229 CVCL_FD02 ND11463 transformed cell line human CVCL_FD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190230 CVCL_FD01 ND11427 transformed cell line human CVCL_FD01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190231 CVCL_FD00 ND11417 transformed cell line human CVCL_FD00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190232 CVCL_FD06 ND11560 transformed cell line human CVCL_FD06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190233 CVCL_FD05 ND11503 transformed cell line human CVCL_FD05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190234 CVCL_FD04 ND11483 transformed cell line human CVCL_FD04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190235 CVCL_FD03 ND11482 transformed cell line human CVCL_FD03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190236 CVCL_FD20 ND11940 transformed cell line human CVCL_FD20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190237 CVCL_FD19 ND11921 transformed cell line human CVCL_FD19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190238 CVCL_FD18 ND11885 transformed cell line human CVCL_FD18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190239 CVCL_FD13 ND11772 transformed cell line human CVCL_FD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190240 CVCL_FD12 ND11766 transformed cell line human CVCL_FD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190241 CVCL_FD11 ND11734 transformed cell line human CVCL_FD11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190242 CVCL_FD10 ND11732 transformed cell line human CVCL_FD10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190243 CVCL_FD17 ND11822 transformed cell line human CVCL_FD17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190244 CVCL_FD16 ND11815 transformed cell line human CVCL_FD16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190245 CVCL_FD15 ND11810 transformed cell line human CVCL_FD15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190246 CVCL_FD14 ND11789 transformed cell line human CVCL_FD14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190247 CVCL_WX03 ERC-31(A) cancer cell line Norway rat CVCL_WX03 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190248 CVCL_X903 Ku-Ep cancer cell line human CVCL_X903 CL:0000010 Population: Japanese. Male 21190249 CVCL_WX02 ERC-27 cancer cell line Norway rat CVCL_WX02 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190250 CVCL_X902 HOKN9 cancer cell line human CVCL_X902 HLA typing: A*04,24(9); B*35,46; C*01,03 (PubMed=18704411) CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male 21190251 CVCL_WX01 ERC-24 cancer cell line Norway rat CVCL_WX01 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Male 21190252 CVCL_X901 HsBt cancer cell line human CVCL_X901 CL:0000010 Population: Japanese. Male 21190253 CVCL_WX00 ERC-23 cancer cell line Norway rat CVCL_WX00 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190254 CVCL_X900 RSC261 cancer cell line human CVCL_X900 CL:0000010 Population: Japanese. Unspecified 21190255 CVCL_WX07 Lk9dL cancer cell line Norway rat CVCL_WX07 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (from autologous cell line Lk9dR) Breed/subspecies: Eker x Long-Evans. 21190256 CVCL_X907 TK-6 [Human leukemia] cancer cell line human CVCL_X907 HLA typing: A*02:06:01,33:03:01; B*40:02:01,44:03:01; C*03:04:01;14:03 (DSMZCellDive=ACC-723) CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=10071072; PubMed=31160637); Sequence variation: Gene fusion; HGNC; 28904; AIF1L + HGNC; 6871; MAPK1; Name(s)=MAPK1-AIF1L (PubMed=31160637); Sequence variation: Mutation; HGNC; 7545; MYB; Unexplicit; Rearranged and truncated; Zygosity=Unspecified (PubMed=9737692) Population: Japanese; Derived from sampling site: Pleural effusion. Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~60-72 hours (DSMZ=ACC-723) Part of: LL-100 blood cancer cell line panel 21190257 CVCL_WX06 ERC-39 cancer cell line Norway rat CVCL_WX06 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190258 CVCL_X906 HH4 transformed cell line human CVCL_X906 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Characteristics: Compared to the parent cell line, does not require a feeder layer in order to form colonies in soft agarose 21190259 CVCL_X905 C6-3 cancer cell line human CVCL_X905 CL:0000010 Population: Japanese. Unspecified 21190260 CVCL_WX05 ERC-37 cancer cell line Norway rat CVCL_WX05 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21190261 CVCL_WX04 ERC-33(A) cancer cell line Norway rat CVCL_WX04 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190262 CVCL_X904 KC12 cancer cell line human CVCL_X904 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: ~24 hours (PubMed=8105119) 21190263 CVCL_X909 KK-5 cancer cell line human CVCL_X909 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21190264 CVCL_WX09 S-Lk9d-SLM cancer cell line Norway rat CVCL_WX09 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (from parent cell line) Breed/subspecies: Eker x Long-Evans. Characteristics: Metastatic 21190265 CVCL_X908 KK-1 [Human leukemia] cancer cell line human CVCL_X908 CL:0000010 Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Ser345Phe (c.1034C>T); Zygosity=Heterozygous (CelloPub=CLPUB00592); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val31Ile (c.91G>A); ClinVar=VCV000127827; Zygosity=Unspecified (PubMed=19220422; PubMed=19710698); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Arg (c.455C>G); ClinVar=VCV000824998; Zygosity=Unspecified (PubMed=19220422; PubMed=19710698) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21190266 CVCL_WX08 Lk9dR cancer cell line Norway rat CVCL_WX08 CL:0000010 Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (PubMed=7704028) Breed/subspecies: Eker x Long-Evans. 21190267 CVCL_FE92 ND02185 transformed cell line human CVCL_FE92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190268 CVCL_FE91 ND02135 transformed cell line human CVCL_FE91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190269 CVCL_FE90 ND02063 transformed cell line human CVCL_FE90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190270 CVCL_FE96 ND02225 transformed cell line human CVCL_FE96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190271 CVCL_FE95 ND02224 transformed cell line human CVCL_FE95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190272 CVCL_FE94 ND02187 transformed cell line human CVCL_FE94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190273 CVCL_FE93 ND02186 transformed cell line human CVCL_FE93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190274 CVCL_FE89 ND23206 transformed cell line human CVCL_FE89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190275 CVCL_FE88 ND23205 transformed cell line human CVCL_FE88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190276 CVCL_FE87 ND23204 transformed cell line human CVCL_FE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190277 CVCL_FE86 ND21619 transformed cell line human CVCL_FE86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190278 CVCL_FE99 ND03648 transformed cell line human CVCL_FE99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190279 CVCL_FE98 ND02899 transformed cell line human CVCL_FE98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190280 CVCL_FE97 ND02371 transformed cell line human CVCL_FE97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190281 CVCL_FE70 ND20119 transformed cell line human CVCL_FE70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190282 CVCL_FE74 ND20434 transformed cell line human CVCL_FE74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190283 CVCL_FE73 ND20431 transformed cell line human CVCL_FE73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190284 CVCL_FE72 ND20423 transformed cell line human CVCL_FE72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190285 CVCL_FE71 ND20419 transformed cell line human CVCL_FE71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190286 CVCL_FE67 ND19263 transformed cell line human CVCL_FE67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190287 CVCL_FE66 ND19256 transformed cell line human CVCL_FE66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190288 CVCL_FE65 ND16597 transformed cell line human CVCL_FE65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190289 CVCL_FE64 ND16556 transformed cell line human CVCL_FE64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190290 CVCL_FE69 ND19909 transformed cell line human CVCL_FE69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190291 CVCL_FE68 ND19908 transformed cell line human CVCL_FE68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190292 CVCL_FE81 ND20818 transformed cell line human CVCL_FE81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190293 CVCL_FE80 ND20751 transformed cell line human CVCL_FE80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190294 CVCL_FE85 ND21370 transformed cell line human CVCL_FE85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190295 CVCL_FE84 ND21239 transformed cell line human CVCL_FE84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190296 CVCL_FE83 ND21111 transformed cell line human CVCL_FE83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190297 CVCL_FE82 ND20905 transformed cell line human CVCL_FE82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190298 CVCL_FE78 ND20531 transformed cell line human CVCL_FE78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190299 CVCL_FE77 ND20527 transformed cell line human CVCL_FE77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190300 CVCL_FE76 ND20474 transformed cell line human CVCL_FE76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190301 CVCL_FE75 ND20473 transformed cell line human CVCL_FE75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190302 CVCL_FE79 ND20697 transformed cell line human CVCL_FE79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190303 CVCL_WX87 HG1624 transformed cell line human CVCL_WX87 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Ser (c.3164G>C); ClinVar=VCV000042078; Zygosity=Homozygous (PubMed=7585968; PubMed=17407155) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 113(DaDem) (BSR113); Derived from sampling site: Peripheral blood. Male 21190304 CVCL_X987 OV-MZ-36 cancer cell line human CVCL_X987 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938). Female 21190305 CVCL_X986 GL261-luc2 cancer cell line house mouse CVCL_X986 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Brain; Breed/subspecies: C57BL/6. Discontinued: PerkinElmer; 134246; true 21190306 CVCL_WX86 HG1584 transformed cell line human CVCL_WX86 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ile770fs (c.2308-953_2555+4719del6126) (Ex11-12fdel); Zygosity=Homozygous (PubMed=17407155) Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 92(VaBia) (BSR92); Derived from sampling site: Peripheral blood. Female 21190307 CVCL_X985 AB.11 cancer cell line Norway rat CVCL_X985 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21190308 CVCL_WX85 HG1321 transformed cell line human CVCL_WX85 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln700Ter (c.2098C>T); ClinVar=VCV000042067; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 59(FrFi) (BSR59); Derived from sampling site: Peripheral blood. Male 21190309 CVCL_X984 A208-7 cancer cell line Norway rat CVCL_X984 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21190310 CVCL_WX84 KS86 transformed cell line human CVCL_WX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190311 CVCL_WX89 HG1742 transformed cell line human CVCL_WX89 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155) Population: Jewish; Ashkenazi/Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 107(MyAsa) (BSR107); Derived from sampling site: Peripheral blood. Female 21190312 CVCL_X989 rHypoE-1 transformed cell line Norway rat CVCL_X989 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190313 CVCL_WX88 HG1647 finite cell line human CVCL_WX88 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155) Donor information: From Bloom Syndrome Registry patient 32(MiKo) (BSR32); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190314 CVCL_X988 OV-MZ-6#8 cancer cell line human CVCL_X988 CL:0000010 Derived from metastatic site: Ascites. Female 21190315 CVCL_4R42 CW30120 induced pluripotent stem cell human CVCL_4R42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30120; true Male 21190316 CVCL_5342 MyLa 2059 cancer cell line human CVCL_5342 CL:0000010 Derived from sampling site: Skin Cell type=T-cell.. Unspecified 21190317 CVCL_4R41 CW30118 induced pluripotent stem cell human CVCL_4R41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30118; true; Discontinued: FCDI; CW30118; probable. Male 21190318 CVCL_5341 MyLa 2039 cancer cell line human CVCL_5341 CL:0000010 Derived from sampling site: Skin Cell type=T-cell.. Unspecified 21190319 CVCL_4R40 CW30117 induced pluripotent stem cell human CVCL_4R40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30117; true; Discontinued: FCDI; CW30117; probable. Male 21190320 CVCL_5340 MyLa 1929 cancer cell line human CVCL_5340 CL:0000010 Derived from sampling site: Skin Cell type=T-cell.. Unspecified 21190321 CVCL_4R35 CW30105 induced pluripotent stem cell human CVCL_4R35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30105; true Female 21190322 CVCL_5335 Morris 5123D-TC cancer cell line Norway rat CVCL_5335 CL:0000010 Breed/subspecies: Buffalo. Female 21190323 CVCL_4R34 CW30103 induced pluripotent stem cell human CVCL_4R34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30103; true Male 21190324 CVCL_5334 MGC-803 cancer cell line human CVCL_5334 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000227, 3131C0001000700084) They were one of the sources for the STR profile of this entry. Omics: Secretome proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by microarray Male Doubling time: 22.5 hours (PubMed=29683800) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00588 Problematic cell line: Possibly contaminated May be a derivative of HeLa and another cell of unknown origin. The STR profile is highly similar to that of HeLa yet shows some specific differences that suggest a possible hybrid cell line. 21190325 CVCL_4R33 CW30102 induced pluripotent stem cell human CVCL_4R33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30102; true Male 21190326 CVCL_5333 MFB-F11 spontaneously immortalized cell line house mouse CVCL_5333 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98725; Tgfb1; Transfected with: HGNC; 439; ALPP Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Can detect and quantify TGF-beta in biological samples without prior enrichment of TGF-betas, and can detect biologically activated TGF-beta in a cell co-culture system (PubMed=16549026); Characteristics: Transfected with a synthetic promoter element containing twelve CAGA boxes fused to a SEAP reporter gene 21190327 CVCL_4R32 CW30101 induced pluripotent stem cell human CVCL_4R32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30101; true Male 21190328 CVCL_5332 MCL-5 transformed cell line human CVCL_5332 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 2610; CYP2A6; Transfected with: HGNC; 2631; CYP2E1; Transfected with: HGNC; 2637; CYP3A4; Transfected with: HGNC; 3401; EPHX1; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10575 21190329 CVCL_4R39 CW30113 induced pluripotent stem cell human CVCL_4R39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30113; true Male 21190330 CVCL_5339 MV-3D9 spontaneously immortalized cell line CVCL_5339 CL:0000010 Derived from sampling site: Fetal lung Cell type=Epithelial cell.. Mixed Characteristics: TGFB dependent 21190331 CVCL_4R38 CW30112 induced pluripotent stem cell human CVCL_4R38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30112; true Female 21190332 CVCL_5338 MT-9 cancer cell line Norway rat CVCL_5338 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21190333 CVCL_4R37 CW30111 induced pluripotent stem cell human CVCL_4R37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30111; true Male 21190334 CVCL_5337 MT-8 cancer cell line Norway rat CVCL_5337 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21190335 CVCL_4R36 CW30108 induced pluripotent stem cell human CVCL_4R36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30108; true Male 21190336 CVCL_5336 MSK-C5.8G cancer cell line Norway rat CVCL_5336 CL:0000010 Transformant: Phosphorus-32 beta radiation(NCIt; C176700); Breed/subspecies: Fischer 344. Female 21190337 CVCL_WX90 HG1751 transformed cell line human CVCL_WX90 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; c.98+1G>T; ClinVar=VCV000370200; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155) Population: Jewish; Ashkenazi/Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 126(BrNa) (BSR126); Derived from sampling site: Peripheral blood. Male 21190338 CVCL_X990 rHypoE-12 transformed cell line Norway rat CVCL_X990 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190339 CVCL_WX94 HG1926 transformed cell line human CVCL_WX94 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Homozygous (PubMed=7585968; PubMed=17407155) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 97(AsOk) (BSR97); Derived from sampling site: Peripheral blood. Female 21190340 CVCL_X994 rHypoE-26 transformed cell line Norway rat CVCL_X994 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190341 CVCL_WX93 HG1785 transformed cell line human CVCL_WX93 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 100(YuMat) (BSR100); Derived from sampling site: Peripheral blood. Female 21190342 CVCL_X993 rHypoE-2 transformed cell line Norway rat CVCL_X993 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190343 CVCL_WX92 HG1783 finite cell line human CVCL_WX92 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (PubMed=17407155) Donor information: From Bloom Syndrome Registry patient 129(MaWat) (BSR129); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190344 CVCL_X992 rHypoE-17 transformed cell line Norway rat CVCL_X992 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190345 CVCL_WX91 HG1782 finite cell line human CVCL_WX91 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Homozygous (PubMed=17407155) Donor information: From Bloom Syndrome Registry patient 110(MaKur) (BSR110); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190346 CVCL_X991 rHypoE-14 transformed cell line Norway rat CVCL_X991 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21190347 CVCL_X976 CHO-mL1 spontaneously immortalized cell line CVCL_X976 CL:0000010 Transfected with: MGI; MGI:96721; L1cam Derived from sampling site: Ovary. Female 21190348 CVCL_WX76 HG1805 transformed cell line human CVCL_WX76 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (PubMed=17407155) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 86(NoKi) (BSR86); Derived from sampling site: Peripheral blood. Female 21190349 CVCL_X975 CHO-hL1 spontaneously immortalized cell line CVCL_X975 CL:0000010 Transfected with: HGNC; 6470; L1CAM Derived from sampling site: Ovary. Female 21190350 CVCL_WX75 HG2166 transformed cell line human CVCL_WX75 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe1087Leufs*11 (c.3261delT); Zygosity=Heterozygous (PubMed=17407155) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 26(SaTi) (BSR26); Derived from sampling site: Peripheral blood. Female 21190351 CVCL_WX74 HG2727 transformed cell line human CVCL_WX74 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (from autologous cell line HG2703) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 171 (BSR171) (Nr2(CrSPe)); Derived from sampling site: Peripheral blood. 21190352 CVCL_X974 OV-MZ-7a cancer cell line human CVCL_X974 CL:0000010 Female 21190353 CVCL_WX73 HG1947 transformed cell line human CVCL_WX73 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 53(StAs) (BSR53); Derived from sampling site: Peripheral blood. Female 21190354 CVCL_X973 OV-MZ-33 cancer cell line human CVCL_X973 CL:0000010 Female 21190355 CVCL_WX79 HG1547 transformed cell line human CVCL_WX79 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 11(IaTh) (BSR11); Derived from sampling site: Peripheral blood. Male 21190356 CVCL_X979 NCI-H3166 cancer cell line human CVCL_X979 CL:0000010 Unspecified 21190357 CVCL_WX78 HG1544 transformed cell line human CVCL_WX78 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 11(IaTh) (BSR11); Derived from sampling site: Peripheral blood. Male 21190358 CVCL_X978 NCI-H3211 cancer cell line human CVCL_X978 CL:0000010 Unspecified 21190359 CVCL_WX77 HG1542 transformed cell line human CVCL_WX77 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 11(IaTh) (BSR11); Derived from sampling site: Peripheral blood. Male 21190360 CVCL_X977 NCI-H2562 cancer cell line human CVCL_X977 CL:0000010 21190361 CVCL_4R53 CW30133 induced pluripotent stem cell human CVCL_4R53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30133; true Female 21190362 CVCL_5353 RLN-J-5-2 spontaneously immortalized cell line Norway rat CVCL_5353 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male 21190363 CVCL_4R52 CW30132 induced pluripotent stem cell human CVCL_4R52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30132; true Female 21190364 CVCL_5352 RLN-B2 spontaneously immortalized cell line Norway rat CVCL_5352 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Male Doubling time: ~38 hours (lot 09132010) (JCRB) 21190365 CVCL_4R51 CW30130 induced pluripotent stem cell human CVCL_4R51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30130; true Female 21190366 CVCL_5351 RLN-8 spontaneously immortalized cell line Norway rat CVCL_5351 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21190367 CVCL_4R50 CW30129 induced pluripotent stem cell human CVCL_4R50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30129; true; Discontinued: FCDI; CW30129; probable. Female 21190368 CVCL_5350 RLN-10 spontaneously immortalized cell line Norway rat CVCL_5350 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 21190369 CVCL_4R46 CW30125 induced pluripotent stem cell human CVCL_4R46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30125; true Male 21190370 CVCL_5346 PB-3c factor-dependent cell line house mouse CVCL_5346 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: DBA/2. Female Characteristics: IL3 dependent 21190371 CVCL_4R45 CW30123 induced pluripotent stem cell human CVCL_4R45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30123; true; Discontinued: FCDI; CW30123; probable. Female 21190372 CVCL_5345 OTT1 factor-dependent cell line house mouse CVCL_5345 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6. Female Characteristics: CFS2, IL3 or IL5 dependent 21190373 CVCL_4R44 CW30122 induced pluripotent stem cell human CVCL_4R44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30122; true Male 21190374 CVCL_5344 NIM-1 cancer cell line human CVCL_5344 CL:0000010 Population: Japanese; Derived from metastatic site: Bone; sacrum. Female Characteristics: Established from a xenograft established in a nude mice 21190375 CVCL_4R43 CW30121 induced pluripotent stem cell human CVCL_4R43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30121; true Male 21190376 CVCL_5343 N521J cancer cell line human CVCL_5343 CL:0000010 Characteristics: Produces significant quantity of IL6 (PubMed=1693429). 21190377 CVCL_4R49 CW30128 induced pluripotent stem cell human CVCL_4R49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30128; true Male 21190378 CVCL_5349 RCN-9 cancer cell line Norway rat CVCL_5349 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Derived from sampling site: Colon; Breed/subspecies: Fischer 344. Discontinued: JCRB; FDSC0024; true Male 21190379 CVCL_4R48 CW30127 induced pluripotent stem cell human CVCL_4R48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30127; true; Discontinued: FCDI; CW30127; probable. Male 21190380 CVCL_5348 PK-2 transformed cell line human CVCL_5348 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. 21190381 CVCL_4R47 CW30126 induced pluripotent stem cell human CVCL_4R47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30126; true Female 21190382 CVCL_5347 PIL-6 cancer cell line house mouse CVCL_5347 CL:0000010 Breed/subspecies: BALB/c. 21190383 CVCL_X983 A208-4 cancer cell line Norway rat CVCL_X983 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21190384 CVCL_WX83 HG1052 transformed cell line human CVCL_WX83 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Unexplicit; Ex22-22Fdel; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 50(JeBl) (BSR50); Derived from sampling site: Peripheral blood. Female 21190385 CVCL_WX82 HG1514 transformed cell line human CVCL_WX82 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=7585968; PubMed=17407155) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 15(MaRo) (BSR15); Derived from sampling site: Peripheral blood. Male 21190386 CVCL_X982 PL14 [Human pancreatic adenocarcinoma] cancer cell line human CVCL_X982 CL:0000010 21190387 CVCL_X981 AGPN cancer cell line human CVCL_X981 CL:0000010 Omics: Deep exome analysis. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190388 CVCL_WX81 HG1435 finite cell line human CVCL_WX81 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gly891Glu (c.2672G>A); ClinVar=VCV000524780; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 54(AlTu) (BSR54); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190389 CVCL_WX80 HG1374 finite cell line human CVCL_WX80 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Homozygous (PubMed=17407155) Donor information: From Bloom Syndrome Registry patient 128(YaWa) (BSR128); Derived from sampling site: Skin Cell type=Fibroblast.. 21190390 CVCL_X980 NCI-H3282 cancer cell line human CVCL_X980 CL:0000010 21190391 CVCL_WX65 EBV-BS4-1 transformed cell line human CVCL_WX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Caution: Could be identical to BS-SHI-4 (Cellosaurus=CVCL_6G17) 21190392 CVCL_X965 OV-MZ-12 cancer cell line human CVCL_X965 CL:0000010 Female 21190393 CVCL_WX64 EBV-BS3-1 transformed cell line human CVCL_WX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190394 CVCL_X964 OV-MZ-9 cancer cell line human CVCL_X964 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21190395 CVCL_WX63 EBV-BS2-2 transformed cell line human CVCL_WX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190396 CVCL_X963 OV-UL-2 cancer cell line human CVCL_X963 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Cys (c.614A>G); ClinVar=VCV000376681; Zygosity=Unspecified (PubMed=15153938). Female 21190397 CVCL_WX62 EBV-BS2-1 transformed cell line human CVCL_WX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190398 CVCL_X962 OV-MZ-1a cancer cell line human CVCL_X962 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Serfs*52 (c.582delT) (Leu194fs); Zygosity=Unspecified (PubMed=15153938) Derived from metastatic site: Ascites. Female 21190399 CVCL_WX69 AT1BR finite cell line human CVCL_WX69 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190400 CVCL_X969 OV-MZ-26 cancer cell line human CVCL_X969 CL:0000010 Female 21190401 CVCL_WX68 BST-SY2 transformed cell line human CVCL_WX68 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908). Male 21190402 CVCL_X968 OV-MZ-21 cancer cell line human CVCL_X968 CL:0000010 Female 21190403 CVCL_WX67 BST-SY1 transformed cell line human CVCL_WX67 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908). Male 21190404 CVCL_X967 OV-MZ-20 cancer cell line human CVCL_X967 CL:0000010 Female 21190405 CVCL_WX66 EBV-BS5-1 transformed cell line human CVCL_WX66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190406 CVCL_X966 OV-MZ-14 cancer cell line human CVCL_X966 CL:0000010 Female 21190407 CVCL_4R20 CW30078 induced pluripotent stem cell human CVCL_4R20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30078; true Male 21190408 CVCL_5320 LB9.Bm cancer cell line CVCL_5320 CL:0000010 Derived from metastatic site: Lymph node; Breed/subspecies: Holstein. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190409 CVCL_4R13 CW30069 induced pluripotent stem cell human CVCL_4R13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30069; true Male 21190410 CVCL_5313 LB10.K finite cell line CVCL_5313 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Holstein. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190411 CVCL_4R12 CW30067 induced pluripotent stem cell human CVCL_4R12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30067; true Female 21190412 CVCL_5312 LB10.Bm cancer cell line CVCL_5312 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6060; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190413 CVCL_4R11 CW30066 induced pluripotent stem cell human CVCL_4R11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30066; true. Male 21190414 CVCL_5311 KPMM2 cancer cell line human CVCL_5311 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Characteristics: Produces IgG lambda; Characteristics: IL6 dependent Doubling time: ~48 hours (with IL6), ~72 hours (without IL6) (PubMed=7723407) 21190415 CVCL_4R10 CW30065 induced pluripotent stem cell human CVCL_4R10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30065; true Male 21190416 CVCL_5310 KPL-4 cancer cell line human CVCL_5310 HLA typing: A*26:02,26:02; B*15:01,15:01; C*03:03,03:03; DQB1*03:02,03:02; DRB1*11:83,11:83 (PubMed=25960936); HLA typing: A*24:17,26:09; B*15:01,15:01; C*03:03,03:03 (PubMed=26589293) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: ER-negative, PR-negative and ERBB2-positive Doubling time: ~30 hours (PubMed=10070858); Microsatellite instability: Stable (MSS) (PubMed=23671654) Part of: JFCR45 cancer cell line panel 21190417 CVCL_4R17 CW30074 induced pluripotent stem cell human CVCL_4R17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30074; true Male 21190418 CVCL_5317 LB11.Ln finite cell line CVCL_5317 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Hereford. Discontinued: ATCC; CRL-6066; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190419 CVCL_4R16 CW30073 induced pluripotent stem cell human CVCL_4R16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30073; true Male 21190420 CVCL_5316 LB10.Thy cancer cell line CVCL_5316 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6064; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190421 CVCL_4R15 CW30071 induced pluripotent stem cell human CVCL_4R15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30071; true Male 21190422 CVCL_5315 LB10.Sp cancer cell line CVCL_5315 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6063; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190423 CVCL_4R14 CW30070 induced pluripotent stem cell human CVCL_4R14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30070; true Female 21190424 CVCL_5314 LB10.Ln finite cell line CVCL_5314 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6062; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190425 CVCL_4R19 CW30076 induced pluripotent stem cell human CVCL_4R19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30076; true Male 21190426 CVCL_5319 LB11.Thy cancer cell line CVCL_5319 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Hereford. Discontinued: ATCC; CRL-6068; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190427 CVCL_4R18 CW30075 induced pluripotent stem cell human CVCL_4R18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30075; true Male 21190428 CVCL_5318 LB11.Sp cancer cell line CVCL_5318 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Hereford. Discontinued: ATCC; CRL-6067; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190429 CVCL_WX72 HG2654 transformed cell line human CVCL_WX72 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=7585968) Population: Jewish; Ashkenazi/Sephardic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 107(MyAsa) (BSR107); Derived from sampling site: Peripheral blood. Female 21190430 CVCL_X972 OV-MZ-31 cancer cell line human CVCL_X972 CL:0000010 Female 21190431 CVCL_WX71 AT5BR finite cell line human CVCL_WX71 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5763-1050A>G (5762ins137); ClinVar=VCV000003021; Zygosity=Unspecified (PubMed=12082606) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190432 CVCL_X971 OV-MZ-30 cancer cell line human CVCL_X971 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21190433 CVCL_WX70 AT3BR finite cell line human CVCL_WX70 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190434 CVCL_X970 OV-MZ-27 cancer cell line human CVCL_X970 CL:0000010 Female 21190435 CVCL_WX54 HG2162 transformed cell line human CVCL_WX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21190436 CVCL_X954 OV-MZ-5 cancer cell line human CVCL_X954 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938) Derived from metastatic site: Ascites. Female Doubling time: 40 hours (PubMed=1500230) 21190437 CVCL_WX53 HG1943 transformed cell line human CVCL_WX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21190438 CVCL_X953 OV-MZ-4 cancer cell line human CVCL_X953 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 26 hours (PubMed=1500230) 21190439 CVCL_WX52 HG2703 transformed cell line human CVCL_WX52 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=10521302; PubMed=17407155) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 171 (BSR171) (Nr2(CrSPe)); Derived from sampling site: Peripheral blood. 21190440 CVCL_X952 OV-MZ-3 cancer cell line human CVCL_X952 CL:0000010 Female Doubling time: 52 hours (PubMed=1500230). 21190441 CVCL_WX51 ATH96TO finite cell line human CVCL_WX51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190442 CVCL_X951 OV-MZ-2 cancer cell line human CVCL_X951 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 24 hours (PubMed=1500230) 21190443 CVCL_WX58 EBV-NL1-1 transformed cell line human CVCL_WX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190444 CVCL_X958 OV-MZ-8 cancer cell line human CVCL_X958 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273del; Zygosity=Unspecified (PubMed=15153938); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala276Gly (c.827C>G); ClinVar=VCV000185319; Zygosity=Unspecified (PubMed=15153938). Female 21190445 CVCL_WX57 HG149 finite cell line human CVCL_WX57 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln700Ter (c.2098C>T); ClinVar=VCV000042067; Zygosity=Homozygous (PubMed=17407155) Donor information: From Bloom Syndrome Registry patient 5(JaOa) (BSR5); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190446 CVCL_X957 OV-MZ-35 cancer cell line human CVCL_X957 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser127Phe (c.380C>T); ClinVar=VCV000182928; Zygosity=Unspecified (PubMed=15153938). Female 21190447 CVCL_WX56 BS2KAF finite cell line human CVCL_WX56 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190448 CVCL_X956 OV-MZ-32 cancer cell line human CVCL_X956 CL:0000010 Female 21190449 CVCL_WX55 HG1626 transformed cell line human CVCL_WX55 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (PubMed=7585968; PubMed=17407155) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 93(YoYa) (BSR93); Derived from sampling site: Peripheral blood. Male 21190450 CVCL_X955 OV-MZ-2a cancer cell line human CVCL_X955 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=15153938) Derived from metastatic site: Ascites. Female 21190451 CVCL_WX59 EBV-NL2-1 transformed cell line human CVCL_WX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190452 CVCL_X959 OV-MZ-16 cancer cell line human CVCL_X959 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938). Female 21190453 CVCL_4R31 CW30099 induced pluripotent stem cell human CVCL_4R31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30099; true Male 21190454 CVCL_5331 MC4000 cancer cell line human CVCL_5331 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00143 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21190455 CVCL_4R30 CW30098 induced pluripotent stem cell human CVCL_4R30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30098; true Female 21190456 CVCL_5330 MBC(5) undefined cell line type CVCL_5330 CL:0000010 Discontinued: ATCC; CRL-6069; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190457 CVCL_4R24 CW30085 induced pluripotent stem cell human CVCL_4R24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30085; true Male 21190458 CVCL_5324 LB9.Sp/Thy/Bm cancer cell line CVCL_5324 CL:0000010 Derived from sampling site: Bone marrow, spleen and thymus; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6052; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190459 CVCL_4R23 CW30083 induced pluripotent stem cell human CVCL_4R23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30083; true Male 21190460 CVCL_5323 LB9.Sp cancer cell line CVCL_5323 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6058; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190461 CVCL_4R22 CW30082 induced pluripotent stem cell human CVCL_4R22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30082; true Male 21190462 CVCL_5322 LB9.Ln finite cell line CVCL_5322 CL:0000010 Derived from sampling site: Lymph node; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6057; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190463 CVCL_4R21 CW30079 induced pluripotent stem cell human CVCL_4R21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30079; true Male 21190464 CVCL_5321 LB9.D finite cell line CVCL_5321 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: Holstein. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190465 CVCL_4R28 CW30096 induced pluripotent stem cell human CVCL_4R28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30096; true Male 21190466 CVCL_5328 MaTu cancer cell line human CVCL_5328 CL:0000010 Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.4790del138 (Ex20-21del); Zygosity=Heterozygous (PubMed=10700188); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; c.5061+2T>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10700188) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Microsatellite instability: Stable (MSS) (PubMed=15677628) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00142 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=10508494; PubMed=20143388). Originally thought to originate from a breast carcinoma. 21190467 CVCL_4R27 CW30093 induced pluripotent stem cell human CVCL_4R27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30093; true Male 21190468 CVCL_5327 LY-6-TC cancer cell line Norway rat CVCL_5327 CL:0000010 Derived from metastatic site: Ascites. 21190469 CVCL_4R26 CW30089 induced pluripotent stem cell human CVCL_4R26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30089; true Female 21190470 CVCL_5326 LBLN finite cell line CVCL_5326 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6046; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190471 CVCL_4R25 CW30086 induced pluripotent stem cell human CVCL_4R25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30086; true Male 21190472 CVCL_5325 LB9.Thy finite cell line CVCL_5325 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Holstein. Discontinued: ATCC; CRL-6059; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190473 CVCL_4R29 CW30097 induced pluripotent stem cell human CVCL_4R29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30097; true Male 21190474 CVCL_5329 MaTu/Ham cancer cell line human CVCL_5329 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Problematic cell line: Contaminated Parent cell line (Matu) has been shown to be a HeLa derivative. 21190475 CVCL_WX61 EBV-BS1-2 transformed cell line human CVCL_WX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190476 CVCL_X961 OV-MZ-38 cancer cell line human CVCL_X961 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15153938). Female 21190477 CVCL_WX60 EBV-BS1-1 transformed cell line human CVCL_WX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190478 CVCL_X960 OV-MZ-37 cancer cell line human CVCL_X960 CL:0000010 Female 21190479 CVCL_WX43 BCNS1BI finite cell line human CVCL_WX43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190480 CVCL_X943 Huh-5-2 cancer cell line human CVCL_X943 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male 21190481 CVCL_WX42 AT1BI finite cell line human CVCL_WX42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190482 CVCL_X942 HKUS cancer cell line human CVCL_X942 CL:0000010 Population: Japanese Female Doubling time: 24 hours, at 200th passage (PubMed=2838556). 21190483 CVCL_WX41 2BI finite cell line human CVCL_WX41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190484 CVCL_X941 HIOAnu2 cancer cell line human CVCL_X941 CL:0000010 Population: Japanese; Derived from metastatic site: Left supraclavicular lymph node. Female 21190485 CVCL_WX40 AT6BI finite cell line human CVCL_WX40 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2427_Arg2428del (c.7278_7283delCCTTAG); ClinVar=VCV000003020; Zygosity=Heterozygous (PubMed=7792600) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190486 CVCL_X940 W3UF cancer cell line human CVCL_X940 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 22-24 hours (PubMed=10457904) 21190487 CVCL_X947 HWUS-1 cancer cell line human CVCL_X947 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 46 hours (at 10th passage), 34 hours (at 30th passage), 31 hours (at 50th passage) (PubMed=7194144) 21190488 CVCL_WX47 XP102LO finite cell line human CVCL_WX47 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=7585650); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=7585650); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=7585650) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190489 CVCL_X946 HWUA-2 cancer cell line human CVCL_X946 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 40 hours (at 10th passage), 32 hours (at 30th passage), 31 hours (at 50th passage) (PubMed=7194144) 21190490 CVCL_WX46 XP4BR finite cell line human CVCL_WX46 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Ser225Glnfs*45 (c.671insT); Zygosity=Homozygous (PubMed=10766188) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190491 CVCL_WX45 BCNS3BI finite cell line human CVCL_WX45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190492 CVCL_X945 HWUA-1 cancer cell line human CVCL_X945 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 41 hours (at 10th passage), 33 hours (at 30th passage), 31 hours (at 50th passage) (PubMed=7194144) 21190493 CVCL_WX44 BCNS2BI finite cell line human CVCL_WX44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Indicated as originating from a female in PubMed=1196376 and from a male in PubMed=7471106 21190494 CVCL_X944 NCH465 cancer cell line human CVCL_X944 CL:0000010 Derived from sampling site: Brain. Group: Cancer stem cell line 21190495 CVCL_WX49 AT97TO finite cell line human CVCL_WX49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190496 CVCL_X949 HWUS-1a cancer cell line human CVCL_X949 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 30 hours (at 5th passage), 26 hours (at 30th passage), 24 hours (at 50th passage) (PubMed=7194144) 21190497 CVCL_WX48 AT95TO finite cell line human CVCL_WX48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190498 CVCL_X948 HWUS-2 cancer cell line human CVCL_X948 CL:0000010 Population: Japanese; Derived from sampling site: Uterus. Female Doubling time: 38 hours (at 10th passage), 31 hours (at 30th passage), 29 hours (at 50th passage) (PubMed=7194144) 21190499 CVCL_WX50 ATH7BI finite cell line human CVCL_WX50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190500 CVCL_X950 OV-MZ-1 cancer cell line human CVCL_X950 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 38 hours (PubMed=1500230) 21190501 CVCL_X932 Esther cancer cell line human CVCL_X932 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Female 21190502 CVCL_WX32 GM-Y2M factor-dependent cell line house mouse CVCL_WX32 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r (with p.Tyr753Met); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190503 CVCL_X931 AL1 cancer cell line human CVCL_X931 CL:0000010 Male Virology: EBV-negative. 21190504 CVCL_WX31 GM-Y1M factor-dependent cell line house mouse CVCL_WX31 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r (with p.Tyr728Met); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190505 CVCL_X930 CML-C-1 cancer cell line human CVCL_X930 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7540608; PubMed=10071072) Population: Japanese; Derived from sampling site: Peripheral blood. Female Characteristics: Dependent on mouse bone marrow stromal cells for growth 21190506 CVCL_WX30 GM-S3F factor-dependent cell line house mouse CVCL_WX30 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r; Transfected with: MGI; MGI:103038; Stat3 (with p.Tyr705Phe = STAT3F); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190507 CVCL_WX36 180BRhTERT telomerase immortalized cell line human CVCL_WX36 CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg278His (c.833G>A); ClinVar=VCV000007675; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21190508 CVCL_X936 KF28Tx cancer cell line human CVCL_X936 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from sampling site: Ovary. Female 21190509 CVCL_WX35 Fq/11 spontaneously immortalized cell line house mouse CVCL_WX35 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95766; Gna11; Knockout cell: Method=KO mouse; MGI; MGI:95776; Gnaq Unspecified Caution: We are not certain that Fq/11 and EF88 are the same cell line. 21190510 CVCL_X935 HUOA cancer cell line human CVCL_X935 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 78 hours (at 40th passage), 77 hours (at 100th passage) (PubMed=3598277); 80 hours (PubMed=3593088) 21190511 CVCL_WX34 GM-Y4M factor-dependent cell line house mouse CVCL_WX34 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r (with p.Tyr788Met); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190512 CVCL_X934 SL1 cancer cell line human CVCL_X934 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; mandible. Male 21190513 CVCL_WX33 GM-Y3M factor-dependent cell line house mouse CVCL_WX33 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r (with p.Tyr768Met); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190514 CVCL_X933 HIG cancer cell line human CVCL_X933 CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow. Male 21190515 CVCL_WX39 F07/402-iPSC induced pluripotent stem cell human CVCL_WX39 CL:0000010 Sequence variation: Mutation; HGNC; 25737; NHEJ1; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV001323363; Zygosity=Homozygous (PubMed=23818183) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190516 CVCL_X939 HTBOA cancer cell line human CVCL_X939 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: 26 hours (PubMed=3259199); 28 hours (PubMed=3593088) 21190517 CVCL_WX38 F07/402 finite cell line human CVCL_WX38 CL:0000010 Sequence variation: Mutation; HGNC; 25737; NHEJ1; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV001323363; Zygosity=Homozygous (PubMed=19056826; PubMed=23818183) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190518 CVCL_X938 HMKOA cancer cell line human CVCL_X938 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female 21190519 CVCL_WX37 48BRhTERT telomerase immortalized cell line human CVCL_WX37 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190520 CVCL_X937 HIOAnu cancer cell line human CVCL_X937 CL:0000010 Population: Japanese; Derived from metastatic site: Left supraclavicular lymph node. Female Characteristics: Established from a xenograft produced in a BALB-c/nu nude mouse Doubling time: 34 hours (CelloPub=CLPUB00153) 21190521 CVCL_4R02 CW30052 induced pluripotent stem cell human CVCL_4R02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30052; true Male 21190522 CVCL_5302 KMY-1 cancer cell line Norway rat CVCL_5302 CL:0000010 Breed/subspecies: Fischer 344. Female 21190523 CVCL_4R01 CW30051 induced pluripotent stem cell human CVCL_4R01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30051; true Male 21190524 CVCL_5301 KMT-2 cancer cell line human CVCL_5301 CL:0000010 Sequence variation: Gene fusion; HGNC; 3688; FGFR1 + HGNC; 23098; FGFR1OP2; Name(s)=FGFR1OP2-FGFR1 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.672+1G>A; ClinVar=VCV000216078; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Caucasian; Derived from sampling site: Bone marrow. Discontinued: RCB; RCB0712; true Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00229 Problematic cell line: Contaminated Shown to be a KG-1 derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from umbilical cord blood cells. 21190525 CVCL_4R00 CW30046 induced pluripotent stem cell human CVCL_4R00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30046; true Female 21190526 CVCL_5300 KD83 cancer cell line house mouse CVCL_5300 CL:0000010 Breed/subspecies: BALB/c. 21190527 CVCL_4R06 CW30061 induced pluripotent stem cell human CVCL_4R06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30061; true Male 21190528 CVCL_5306 KOC-5C cancer cell line human CVCL_5306 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 97.9 hours (CelloPub=CLPUB00067) 21190529 CVCL_4R05 CW30060 induced pluripotent stem cell human CVCL_4R05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30060; true Female 21190530 CVCL_5305 KMY-J cancer cell line Norway rat CVCL_5305 CL:0000010 Breed/subspecies: Fischer 344. Female 21190531 CVCL_4R04 CW30059 induced pluripotent stem cell human CVCL_4R04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30059; true Female 21190532 CVCL_5304 KMY-3 cancer cell line Norway rat CVCL_5304 CL:0000010 Breed/subspecies: Fischer 344. Female 21190533 CVCL_4R03 CW30058 induced pluripotent stem cell human CVCL_4R03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30058; true Male 21190534 CVCL_5303 KMY-2 cancer cell line Norway rat CVCL_5303 CL:0000010 Breed/subspecies: Fischer 344. Female 21190535 CVCL_4R09 CW30064 induced pluripotent stem cell human CVCL_4R09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30064; true Female 21190536 CVCL_5309 KPB-M8 cancer cell line human CVCL_5309 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=3461189) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 18 hours (PubMed=3461189) 21190537 CVCL_4R08 CW30063 induced pluripotent stem cell human CVCL_4R08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30063; true Female 21190538 CVCL_5308 KPB-M15 cancer cell line human CVCL_5308 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 24 hours (PubMed=3461189) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00230 Problematic cell line: Contaminated Shown to be a KYO-1 derivative (PubMed=12592342; PubMed=20143388). Originally thought to originate from the peripheral blood of a 39 year old male patient with chronic myelogenous leukemia, BCR-ABL1 positive. 21190539 CVCL_4R07 CW30062 induced pluripotent stem cell human CVCL_4R07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Pacific; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30062; true Male 21190540 CVCL_5307 KOC-7C cancer cell line human CVCL_5307 HLA typing: A*02:01,31:01; B*51,52 (PubMed=9023415) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis; Omics: Deep quantitative phosphoproteome analysis; Omics: Genome sequenced; Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 45.9 hours (CelloPub=CLPUB00067) Part of: MD Anderson Cell Lines Project 21190541 CVCL_WX21 BC-DS cancer cell line human CVCL_WX21 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 43.8 +- 3.3 hours (PubMed=26782109) Problematic cell line: Contaminated Parent cell line (BCaP-37) has been shown to be a HeLa derivative. 21190542 CVCL_X921 RfM26-1 transformed cell line CVCL_X921 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent Group: Non-human primate cell line 21190543 CVCL_WX20 GH4T2 cancer cell line Norway rat CVCL_WX20 CL:0000010 Derived from sampling site: Pituitary gland; Breed/subspecies: Wistar Furth. Female Characteristics: Produced from a tumor produced by the passage of the parent cell line through female Wistar Furth rats (PubMed=1620544) 21190544 CVCL_X920 PtM3 transformed cell line CVCL_X920 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 21190545 CVCL_WX25 L-G factor-dependent cell line house mouse CVCL_WX25 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: Can differentiate into neutrophils in the presence of CSF3; Characteristics: IL3 or CSF3 dependent 21190546 CVCL_X925 Matsu transformed cell line CVCL_X925 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Doubling time: ~20 hours (PubMed=7535998) Group: Non-human primate cell line 21190547 CVCL_X924 BM5 transformed cell line CVCL_X924 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21190548 CVCL_WX24 ST2-S10 stromal cell line house mouse CVCL_WX24 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BC8. Unspecified 21190549 CVCL_X923 FM34 transformed cell line CVCL_X923 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent Group: Non-human primate cell line 21190550 CVCL_WX23 MHHi006-A-2 induced pluripotent stem cell human CVCL_WX23 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Umbilical cord blood. Male Characteristics: Using TALEN a P2A-eGFP-T2A-PGK-hph construct was integrated in front of the stop codon of NXK2-1 21190551 CVCL_WX22 BC-TS cancer cell line human CVCL_WX22 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:480999; Vinorelbine (Navelbine; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Doubling time: 35.0 +- 3.9 hours (PubMed=26782109) Problematic cell line: Contaminated Parent cell line (BCaP-37) has been shown to be a HeLa derivative. 21190552 CVCL_X922 RfM26-2 transformed cell line CVCL_X922 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent Group: Non-human primate cell line 21190553 CVCL_WX29 GM-S3D factor-dependent cell line house mouse CVCL_WX29 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r; Transfected with: MGI; MGI:103038; Stat3 (with p.Glu434Ala and p.Glu435Ala = STAT3D); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent (from parent cell line) 21190554 CVCL_X929 Margret cancer cell line human CVCL_X929 CL:0000010 Population: African; Kenyan Female Virology: EBV-negative. 21190555 CVCL_WX28 GM-I62M factor-dependent cell line house mouse CVCL_WX28 CL:0000010 Transfected with: MGI; MGI:1339755; Csf3r; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent 21190556 CVCL_X928 Kia transformed cell line CVCL_X928 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Doubling time: ~20 hours (PubMed=7535998) Group: Non-human primate cell line 21190557 CVCL_WX27 LGM-1 factor-dependent cell line house mouse CVCL_WX27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 or CSF2 dependent 21190558 CVCL_X927 VG transformed cell line CVCL_X927 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Doubling time: ~30 hours (PubMed=7535998) Group: Non-human primate cell line 21190559 CVCL_WX26 L-GM factor-dependent cell line house mouse CVCL_WX26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: Can differentiate into macrophages and granulocytes in the presence of CSF2; Characteristics: IL3 or CSF2 dependent 21190560 CVCL_X926 G12.1 transformed cell line human CVCL_X926 CL:0000010 Population: Native Central American; Ngabe from Panama; Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 21190561 CVCL_WX10 BHK 21 C.13/T.6/Ascites transformed cell line CVCL_WX10 CL:0000010 Transformant: Murine polyomavirus (MPyV)(NCBI-Taxonomy; 1891730); Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-10.1 21190562 CVCL_X910 NCH421k cancer cell line human CVCL_X910 CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Male Group: Cancer stem cell line 21190563 CVCL_WX14 AHT-54 hybridoma house mouse CVCL_WX14 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 86041801 21190564 CVCL_X914 NCH644 cancer cell line human CVCL_X914 CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Female 21190565 CVCL_WX13 AHT-107 hybridoma house mouse CVCL_WX13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01589; Human IL2RA/CD25. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 86041802 21190566 CVCL_X913 NCH612 cancer cell line human CVCL_X913 CL:0000010 Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132His (c.395G>A); ClinVar=VCV000156444; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Brain. Male Group: Cancer stem cell line 21190567 CVCL_WX12 DK (SK&F) spontaneously immortalized cell line dog CVCL_WX12 CL:0000010 Derived from sampling site: Kidney. Female Virology: Supports growth of canine distemper virus, infectious canine hepatic virus, canine herpes virus and rabies virus Doubling time: 13 hours (PubMed=4301040) Group: Patented cell line 21190568 CVCL_X912 NCH441 cancer cell line human CVCL_X912 CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 21190569 CVCL_X911 NCH440 cancer cell line human CVCL_X911 CL:0000010 Derived from sampling site: Brain. Female Group: Cancer stem cell line 21190570 CVCL_WX11 S4374-M32 undefined cell line type human CVCL_WX11 CL:0000010 Derived from sampling site: Fetal pituitary gland. Unspecified Characteristics: Produces gonadotropin 21190571 CVCL_X918 ChM114-2 transformed cell line CVCL_X918 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21190572 CVCL_WX18 LA-27.1 hybridoma house mouse CVCL_WX18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; A0A0H3BZK9; Borrelia burgdorferi strain ZS7 outer surface protein B (ospB). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 90050407 21190573 CVCL_X917 ChM114-1 transformed cell line CVCL_X917 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21190574 CVCL_WX17 LA-25.1 hybridoma house mouse CVCL_WX17 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; A0A0H3BZK9; Borrelia burgdorferi strain ZS7 outer surface protein B (ospB). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 90050405 21190575 CVCL_X916 JM86 transformed cell line CVCL_X916 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Group: Non-human primate cell line 21190576 CVCL_WX16 LA-26.1 hybridoma house mouse CVCL_WX16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B7IZU3; Borrelia burgdorferi (strain ZS7) outer surface protein A (ospA). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 90050406 21190577 CVCL_WX15 LA-2 hybridoma house mouse CVCL_WX15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; B7IZU3; Borrelia burgdorferi (strain ZS7) outer surface protein A (ospA). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 89091302 21190578 CVCL_X915 NCH690 cancer cell line human CVCL_X915 CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Female 21190579 CVCL_X919 GM0650 transformed cell line green monkey CVCL_X919 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Unspecified Group: Non-human primate cell line 21190580 CVCL_WX19 HHL-17 transformed cell line human CVCL_WX19 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Liver Cell type=Hepatocyte.. Male Caution: Not directly described in PubMed=15780065 21190581 CVCL_4Q99 CW30044 induced pluripotent stem cell human CVCL_4Q99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30044; true Male 21190582 CVCL_5299 JTC-11 cancer cell line house mouse CVCL_5299 CL:0000010 Derived from sampling site: Ascites. Female 21190583 CVCL_4Q83 CW20046 induced pluripotent stem cell human CVCL_4Q83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20046; true Female 21190584 CVCL_5283 EKS3 cancer cell line human CVCL_5283 CL:0000010 Characteristics: Produces significant quantity of IL6 (PubMed=1693429). 21190585 CVCL_4Q82 CW20042 induced pluripotent stem cell human CVCL_4Q82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of CW20002 (Cellosaurus=CVCL_4Q71); Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20042; true Female 21190586 CVCL_5282 EB [Human skin fibroblast] finite cell line human CVCL_5282 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190587 CVCL_4Q81 CW20035 induced pluripotent stem cell human CVCL_4Q81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20035; true Male 21190588 CVCL_5281 Ea3.17 factor-dependent cell line house mouse CVCL_5281 CL:0000010 Derived from sampling site: Spleen Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Unspecified Characteristics: IL3 dependent Doubling time: 15-17 hours (PubMed=6201749) 21190589 CVCL_4Q80 CW20034 induced pluripotent stem cell human CVCL_4Q80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20034; true Female 21190590 CVCL_5280 DW34 stromal cell line house mouse CVCL_5280 CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: BC8. Unspecified 21190591 CVCL_4Q87 CW20070 induced pluripotent stem cell human CVCL_4Q87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20070; true Male 21190592 CVCL_5287 HAS303 transformed cell line human CVCL_5287 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Endothelial cell.. Unspecified 21190593 CVCL_4Q86 CW20051 induced pluripotent stem cell human CVCL_4Q86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20051; true Female 21190594 CVCL_5286 HAS301 transformed cell line human CVCL_5286 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Fibroblast.. Unspecified 21190595 CVCL_4Q85 CW20050 induced pluripotent stem cell human CVCL_4Q85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20050; true Female 21190596 CVCL_5285 GFPu-1 transformed cell line human CVCL_5285 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Reporter cell line to study protein aggregation and the function of the ubiquitin-proteasome system (UPS); Characteristics: Expresses GFP tagged at the C-terminus with the degradation signal CL1 (ACKNWFSSLSHFVIHL) 21190597 CVCL_4Q84 CW20047 induced pluripotent stem cell human CVCL_4Q84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20047; true Male 21190598 CVCL_5284 FDC-P2 factor-dependent cell line house mouse CVCL_5284 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. Characteristics: IL3 dependent 21190599 CVCL_4Q79 CW20032 induced pluripotent stem cell human CVCL_4Q79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20032; true Female 21190600 CVCL_5279 DS-1 [Mouse hybridoma against dog SFTPA1] hybridoma house mouse CVCL_5279 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P06908; Dog SFTPA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8906 21190601 CVCL_4Q78 CW20031 induced pluripotent stem cell human CVCL_4Q78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20031; true Female 21190602 CVCL_5278 DS-1 [Human] cancer cell line human CVCL_5278 CL:0000010 Derived from sampling site: Pleural effusion. Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11102 21190603 CVCL_4Q77 CW20027 induced pluripotent stem cell human CVCL_4Q77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20027; true Female 21190604 CVCL_5277 MEF (DR4) finite cell line house mouse CVCL_5277 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: DR4. Mixed Characteristics: Expresses transgenes that make this cell line resistant to four different drugs: geneticin (G418), puromycin, hygromycin and 6-tioguanine 21190605 CVCL_4Q90 CW30003 induced pluripotent stem cell human CVCL_4Q90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30003; true. Female 21190606 CVCL_5290 HKB-1 cancer cell line human CVCL_5290 CL:0000010 Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00209. Problematic cell line: Misclassified Originally though to be a Hodgkin lymphoma cell line, but its real origin is not clear (PubMed=12592342; PubMed=20143388; PubMed=29533902). 21190607 CVCL_4Q94 CW30014 induced pluripotent stem cell human CVCL_4Q94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30014; true. Female 21190608 CVCL_5294 HYMEQ-5 stromal cell line house mouse CVCL_5294 CL:0000010 Breed/subspecies: C57BL/6J. Unspecified Doubling time: ~3 days (PubMed=12662435) 21190609 CVCL_4Q93 CW30011 induced pluripotent stem cell human CVCL_4Q93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American Discontinued: Coriell; CW30011; true. Female 21190610 CVCL_5293 HYMEQ-1 stromal cell line house mouse CVCL_5293 CL:0000010 Breed/subspecies: C57BL/6J. Unspecified Doubling time: ~3 days (PubMed=12662435) 21190611 CVCL_4Q92 CW30010 induced pluripotent stem cell human CVCL_4Q92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30010; true. Female 21190612 CVCL_5292 HuGC-OOHIRA cancer cell line human CVCL_5292 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Doubling time: 25-30 hours (PubMed=7541602) 21190613 CVCL_4Q91 CW30009 induced pluripotent stem cell human CVCL_4Q91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW30009; true. Male 21190614 CVCL_5291 HS-P cancer cell line Norway rat CVCL_5291 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21190615 CVCL_4Q98 CW30029 induced pluripotent stem cell human CVCL_4Q98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30029; true. Male 21190616 CVCL_5298 JR-2(82) transformed cell line human CVCL_5298 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Characteristics: Partially IL4 dependent Only dies in the absence of IL4 if seeded at 1 X 1000 cells per well or less. 21190617 CVCL_4Q97 CW30028 induced pluripotent stem cell human CVCL_4Q97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30028; true. Male 21190618 CVCL_5297 J-87 factor-dependent cell line house mouse CVCL_5297 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: DBA/2J. Female Characteristics: IL3 or IL5 dependent; Characteristics: Requires feeder cells Maintenance of J-87 depends on the presence of cell line ST2 (Cellosaurus=CVCL_2205). 21190619 CVCL_4Q96 CW30018 induced pluripotent stem cell human CVCL_4Q96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW30018; true. Female 21190620 CVCL_5296 IAR 20 finite cell line Norway rat CVCL_5296 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: BDVI. Unspecified 21190621 CVCL_4Q95 CW30016 induced pluripotent stem cell human CVCL_4Q95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American Discontinued: Coriell; CW30016; true. Female 21190622 CVCL_5295 HYMEQ-8 stromal cell line house mouse CVCL_5295 CL:0000010 Breed/subspecies: C57BL/6J. Unspecified Doubling time: ~3 days (PubMed=12662435) 21190623 CVCL_4Q89 CW30002 induced pluripotent stem cell human CVCL_4Q89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW30002; true. Male 21190624 CVCL_5289 HCD-57 cancer cell line house mouse CVCL_5289 CL:0000010 Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: NIH Swiss. Characteristics: EPO dependent 21190625 CVCL_4Q88 CW30001 induced pluripotent stem cell human CVCL_4Q88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW30001; true. Female 21190626 CVCL_5288 HAS304 transformed cell line human CVCL_5288 CL:0000010 Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Bone marrow; stroma Cell type=Macrophage.. Unspecified 21190627 CVCL_5261 CF35.Mg cancer cell line dog CVCL_5261 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6229; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190628 CVCL_4Q61 CW10044 induced pluripotent stem cell human CVCL_4Q61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10044; true Male 21190629 CVCL_5260 CF34.Mg cancer cell line dog CVCL_5260 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6228; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190630 CVCL_4Q60 CW10041 induced pluripotent stem cell human CVCL_4Q60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10041; true Male 21190631 CVCL_5265 CF43.Mg finite cell line dog CVCL_5265 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6234; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190632 CVCL_4Q65 CW10050 induced pluripotent stem cell human CVCL_4Q65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10050; true Male 21190633 CVCL_5264 CF41.Mg cancer cell line dog CVCL_5264 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190634 CVCL_4Q64 CW10049 induced pluripotent stem cell human CVCL_4Q64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10049; true. Male 21190635 CVCL_5263 CF38.Mg finite cell line dog CVCL_5263 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190636 CVCL_4Q63 CW10046 induced pluripotent stem cell human CVCL_4Q63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10046; true; Discontinued: FCDI; CW10046; probable. Male 21190637 CVCL_5262 CF37.Mg finite cell line dog CVCL_5262 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190638 CVCL_4Q62 CW10045 induced pluripotent stem cell human CVCL_4Q62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Mongolian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10045; true Female 21190639 CVCL_5258 CF30.Mg finite cell line dog CVCL_5258 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6225; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190640 CVCL_4Q58 CW10038 induced pluripotent stem cell human CVCL_4Q58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10038; true Female 21190641 CVCL_5257 CF3.Th finite cell line dog CVCL_5257 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Mixed breed. Discontinued: ATCC; CRL-6575; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190642 CVCL_4Q57 CW10037 induced pluripotent stem cell human CVCL_4Q57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10037; true. Male 21190643 CVCL_5256 CF28 finite cell line dog CVCL_5256 CL:0000010 Discontinued: ATCC; CRL-6223; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190644 CVCL_4Q56 CW10036 induced pluripotent stem cell human CVCL_4Q56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American and Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10036; true Male 21190645 CVCL_5255 CF24.T cancer cell line dog CVCL_5255 CL:0000010 Discontinued: ATCC; CRL-6221; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190646 CVCL_4Q55 CW10035 induced pluripotent stem cell human CVCL_4Q55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10035; true Male 21190647 CVCL_5259 CF33.MT cancer cell line dog CVCL_5259 CL:0000010 Derived from sampling site: Mammary gland. Discontinued: ATCC; CRL-6227; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190648 CVCL_4Q59 CW10039 induced pluripotent stem cell human CVCL_4Q59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10039; true Male 21190649 CVCL_WW99 ERC-21 cancer cell line Norway rat CVCL_WW99 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Male 21190650 CVCL_X899 RTC274 cancer cell line human CVCL_X899 CL:0000010 Population: Japanese; Derived from sampling site: Kidney; renal pelvis. Unspecified 21190651 CVCL_WW98 ERC-19 cancer cell line Norway rat CVCL_WW98 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Male 21190652 CVCL_X898 RCC266 cancer cell line human CVCL_X898 CL:0000010 Population: Japanese. Unspecified 21190653 CVCL_WW97 ERC-18M cancer cell line Norway rat CVCL_WW97 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female Characteristics: Established from a tumor in SCID mice implanted with the parent cell line in the testis 21190654 CVCL_X897 RCC826 cancer cell line human CVCL_X897 CL:0000010 Population: Japanese. Male 21190655 CVCL_WW96 ERC-18 cancer cell line Norway rat CVCL_WW96 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Female 21190656 CVCL_X896 RCC270 cancer cell line human CVCL_X896 CL:0000010 Population: Japanese. Female 21190657 CVCL_5272 CF4-C4 hybridoma house mouse CVCL_5272 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). 21190658 CVCL_4Q72 CW20006 induced pluripotent stem cell human CVCL_4Q72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Indian Discontinued: Coriell; CW20006; true. Male 21190659 CVCL_5271 CF49.Mg finite cell line dog CVCL_5271 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6241; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190660 CVCL_4Q71 CW20002 induced pluripotent stem cell human CVCL_4Q71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of CW20042 (Cellosaurus=CVCL_4Q82); Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20002; true Female 21190661 CVCL_5270 CF48.Mg finite cell line dog CVCL_5270 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6240; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190662 CVCL_4Q70 CW10077 induced pluripotent stem cell human CVCL_4Q70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10077; true Female 21190663 CVCL_5276 CNS-1 cancer cell line Norway rat CVCL_5276 CL:0000010 Breed/subspecies: Lewis. Male 21190664 CVCL_4Q76 CW20025 induced pluripotent stem cell human CVCL_4Q76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20025; true Female 21190665 CVCL_5275 Ch2.D finite cell line CVCL_5275 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6270; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190666 CVCL_4Q75 CW20023 induced pluripotent stem cell human CVCL_4Q75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW20023; true Male 21190667 CVCL_5274 CF8.Thy finite cell line dog CVCL_5274 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: Boxer. Discontinued: ATCC; CRL-6211; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190668 CVCL_4Q74 CW20013 induced pluripotent stem cell human CVCL_4Q74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW20013; true; Discontinued: FCDI; CW20013; probable. Male 21190669 CVCL_5273 CF52.Tr finite cell line dog CVCL_5273 CL:0000010 Derived from sampling site: Trachea. Discontinued: ATCC; CRL-6244; probable Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190670 CVCL_4Q73 CW20008 induced pluripotent stem cell human CVCL_4Q73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW20008; true. Male 21190671 CVCL_5269 CF47.Mg finite cell line dog CVCL_5269 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6239; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190672 CVCL_4Q69 CW10076 induced pluripotent stem cell human CVCL_4Q69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Burmese; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10076; true Female 21190673 CVCL_5268 CF46.Tr finite cell line dog CVCL_5268 CL:0000010 Derived from sampling site: Fetal trachea. Discontinued: ATCC; CRL-6238; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190674 CVCL_4Q68 CW10067 induced pluripotent stem cell human CVCL_4Q68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10067; true Male 21190675 CVCL_5267 CF45B.Mg cancer cell line dog CVCL_5267 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6237; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190676 CVCL_4Q67 CW10060 induced pluripotent stem cell human CVCL_4Q67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10060; true Male 21190677 CVCL_5266 CF44.Mg finite cell line dog CVCL_5266 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6235; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190678 CVCL_4Q66 CW10054 induced pluripotent stem cell human CVCL_4Q66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW10054; true Female 21190679 CVCL_X888 AG17485 transformed cell line human CVCL_X888 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190680 CVCL_WW88 LNCaP-19 cancer cell line human CVCL_WW88 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 46 hours (PubMed=15389782); 50.00 hours (GrayJW panel) 21190681 CVCL_X887 AG17484 transformed cell line human CVCL_X887 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190682 CVCL_WW87 Meth A ML-02 cancer cell line house mouse CVCL_WW87 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female 21190683 CVCL_X886 AG16945 transformed cell line human CVCL_X886 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190684 CVCL_WW86 Meth A ML-01 cancer cell line house mouse CVCL_WW86 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female 21190685 CVCL_X885 AG16944 transformed cell line human CVCL_X885 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190686 CVCL_WW85 Meth A MH-03 cancer cell line house mouse CVCL_WW85 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female 21190687 CVCL_X889 AG17487 transformed cell line human CVCL_X889 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190688 CVCL_WW89 WAe009-A-16 embryonic stem cell human CVCL_WW89 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1. Female 21190689 CVCL_5243 ARLJ 301-3TR1 transformed cell line Norway rat CVCL_5243 CL:0000010 Derived from sampling site: Liver Cell type=Epithelial cell.; Breed/subspecies: Fischer 344/DuCrj. Male 21190690 CVCL_4Q43 CW10012 induced pluripotent stem cell human CVCL_4Q43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10012; true. Female 21190691 CVCL_4Q42 CW10011 induced pluripotent stem cell human CVCL_4Q42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino Discontinued: Coriell; CW10011; true. Female 21190692 CVCL_5242 ES-OMC-MN cancer cell line human CVCL_5242 CL:0000010 Population: Japanese Female Doubling time: 68.5 hours, at 90th passage (PubMed=9143739). 21190693 CVCL_5241 AH272-TC cancer cell line Norway rat CVCL_5241 CL:0000010 Breed/subspecies: Donryu. Male 21190694 CVCL_4Q41 CW10010 induced pluripotent stem cell human CVCL_4Q41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Native North American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10010; true Male 21190695 CVCL_5240 AGM-S3 stromal cell line house mouse CVCL_5240 CL:0000010 Breed/subspecies: C3H/HeN. Unspecified 21190696 CVCL_4Q40 CW10009 induced pluripotent stem cell human CVCL_4Q40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10009; true. Female 21190697 CVCL_4Q36 GM24383 transformed cell line human CVCL_4Q36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190698 CVCL_5236 Lovo-273X17 cancer cell line human CVCL_5236 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His) Derived from metastatic site: Left supraclavicular lymph node. Male 21190699 CVCL_4Q35 AG22160 finite cell line human CVCL_4Q35 CL:0000010 Derived from sampling site: Toe; skin Cell type=Fibroblast.. Male 21190700 CVCL_5235 Lovo-175X2 cancer cell line human CVCL_5235 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg175His) Derived from metastatic site: Left supraclavicular lymph node. Male 21190701 CVCL_4Q34 AG22140 finite cell line human CVCL_4Q34 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21190702 CVCL_5234 NFS-78 cancer cell line house mouse CVCL_5234 CL:0000010 Transformant: Cas-Br-E murine leukemia virus(NCBI-Taxonomy; 11792); Breed/subspecies: NFS. 21190703 CVCL_4Q33 AG22139 finite cell line human CVCL_4Q33 CL:0000010 Population: Caucasian; Derived from sampling site: Buttock; skin (Note=From an ulcer) Cell type=Fibroblast.. Male 21190704 CVCL_5233 NFS-61 cancer cell line house mouse CVCL_5233 CL:0000010 Transformant: Cas-Br-E murine leukemia virus(NCBI-Taxonomy; 11792); Derived from sampling site: Peripheral blood; Breed/subspecies: NFS. 21190705 CVCL_5239 1205Lu cancer cell line human CVCL_5239 HLA typing: A*01:01,29:01; B*35:01,57:01; C*06:02,04:01:01; DPB1*04:01,04:01; DQB1*03:01:01,03:01:01; DRB1*11:03:01,11:03:01 (PubMed=15592718) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=16827748; PubMed=18632627; Wistar); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Unspecified (Wistar) Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2812; true; Discontinued: Coriell; WC00058; probable; Discontinued: Rockland; 51603; true. Male Characteristics: Established from serial passaging of the parent cell line through immune deficient mice and harvesting lung metastasis Part of: Wistar Institute melanoma cell line collection; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00483 Problematic cell line: Partially contaminated The stock formerly distributed by Coriell (WC00058) contains a significant amount of mouse DNA (DOI=10.4172/1948-5956.1000196). This is not the case of the original Wistar stock which was distributed by Rockland (DOI=10.4172/1948-5956.1000401).; Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: Amelogenin 21190706 CVCL_4Q39 CW10007 induced pluripotent stem cell human CVCL_4Q39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10007; true. Female 21190707 CVCL_4Q38 CW10003 induced pluripotent stem cell human CVCL_4Q38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10003; true Male 21190708 CVCL_5238 LoVo-li cancer cell line human CVCL_5238 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Left supraclavicular lymph node. Male 21190709 CVCL_4Q37 CW10001 induced pluripotent stem cell human CVCL_4Q37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW10001; true. Female 21190710 CVCL_5237 LoVo-92 cancer cell line human CVCL_5237 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Left supraclavicular lymph node. Male 21190711 CVCL_X891 RCC23 cancer cell line human CVCL_X891 CL:0000010 Population: Japanese. Female 21190712 CVCL_WW91 teno-iPSC2 induced pluripotent stem cell CVCL_WW91 CL:0000010 Derived from sampling site: Tendon. Unspecified 21190713 CVCL_X890 RCC19 cancer cell line human CVCL_X890 CL:0000010 Population: Japanese. Male 21190714 CVCL_WW90 teno-iPSC1 induced pluripotent stem cell CVCL_WW90 CL:0000010 Derived from sampling site: Tendon. Unspecified 21190715 CVCL_WW95 ERC-17 cancer cell line Norway rat CVCL_WW95 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (inferred from genetic background of other Eker-derived cell lines); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Male 21190716 CVCL_X895 RCC217 cancer cell line human CVCL_X895 CL:0000010 Population: Japanese. Male 21190717 CVCL_WW94 ERC-15 cancer cell line Norway rat CVCL_WW94 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Male 21190718 CVCL_X894 RCC213 cancer cell line human CVCL_X894 CL:0000010 Population: Japanese. Male 21190719 CVCL_WW93 ERC-13 cancer cell line Norway rat CVCL_WW93 CL:0000010 Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Gly13Val (c.38_39GC>TT); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Val14Ile (c.40G>A); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3205; Nras; Simple; p.Ala18Val (c.53C>T); Zygosity=Unspecified (PubMed=1910479); Sequence variation: Mutation; RGD; 3908; Tsc2; Simple; p.Val1272fs; Zygosity=Heterozygous; Note=Insertion of a 5 kb retrotransposon (inferred from genetic background of other Eker-derived cell lines) Breed/subspecies: Eker x Long-Evans. Unspecified 21190720 CVCL_X893 RCC149 cancer cell line human CVCL_X893 CL:0000010 Population: Japanese. Female 21190721 CVCL_X892 RCC31 cancer cell line human CVCL_X892 CL:0000010 Population: Japanese. Male 21190722 CVCL_WW92 teno-iPSC3 induced pluripotent stem cell CVCL_WW92 CL:0000010 Derived from sampling site: Tendon. Unspecified 21190723 CVCL_X877 AG11552 finite cell line human CVCL_X877 CL:0000010 Derived from sampling site: Amniotic fluid. Male 21190724 CVCL_WW77 HMC-2-1 cancer cell line human CVCL_WW77 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 22 hours (DOI=10.15114/tr.22.27) 21190725 CVCL_X876 AG10317 transformed cell line human CVCL_X876 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190726 CVCL_WW76 B85 transformed cell line human CVCL_WW76 HLA typing: A*01,02; B*15 (PubMed=2939141) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190727 CVCL_X875 AG10316 transformed cell line human CVCL_X875 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190728 CVCL_WW75 HL-60-Y3 cancer cell line human CVCL_WW75 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Doubling time: 48 hours (PubMed=8343448) Group: Serum/protein free medium cell line 21190729 CVCL_X874 AG10106 transformed cell line human CVCL_X874 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190730 CVCL_WW74 WEHI-3B-Y1 cancer cell line house mouse CVCL_WW74 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male Doubling time: 24 hours (PubMed=8343448) Group: Serum/protein free medium cell line 21190731 CVCL_WW79 7IJY1 transformed cell line Norway rat CVCL_WW79 CL:0000010 Transformant: Adenovirus 7(NCBI-Taxonomy; 10519); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21190732 CVCL_X879 AG13453 transformed cell line human CVCL_X879 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190733 CVCL_X878 AG13429 transformed cell line human CVCL_X878 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190734 CVCL_WW78 TcOSC-20 finite cell line human CVCL_WW78 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21190735 CVCL_5250 C84 cancer cell line human CVCL_5250 HLA typing: A*02,03 (PubMed=8464898) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg283Ter (c.847C>T); ClinVar=VCV000184999; Zygosity=Unspecified (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg640Trp (c.1918C>T); ClinVar=VCV000428132; Zygosity=Unspecified (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp54Asn (c.160G>A); ClinVar=VCV001479725; Zygosity=Heterozygous (PubMed=8197130; DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=16418264; PubMed=24755471; DepMap) Derived from sampling site: Cecum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190736 CVCL_4Q50 CW10024 induced pluripotent stem cell human CVCL_4Q50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Southeast Asian; Filipino Discontinued: Coriell; CW10024; true. Female 21190737 CVCL_5254 CF21.T cancer cell line dog CVCL_5254 CL:0000010 Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982). 21190738 CVCL_4Q54 CW10031 induced pluripotent stem cell human CVCL_4Q54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10031; true; Discontinued: FCDI; CW10031; probable. Female 21190739 CVCL_5253 CF17.T cancer cell line dog CVCL_5253 CL:0000010 Derived from sampling site: Connective tissue. Discontinued: ATCC; CRL-6219; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190740 CVCL_4Q53 CW10030 induced pluripotent stem cell human CVCL_4Q53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian and Native North American Discontinued: Coriell; CW10030; true. Male 21190741 CVCL_5252 CF11.T cancer cell line dog CVCL_5252 CL:0000010 Discontinued: ATCC; CRL-6217; probable. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190742 CVCL_4Q52 CW10028 induced pluripotent stem cell human CVCL_4Q52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10028; true; Discontinued: FCDI; CW10028; probable. Male 21190743 CVCL_5251 CF-1 MEF finite cell line house mouse CVCL_5251 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: CF-1. Mixed 21190744 CVCL_4Q51 CW10026 induced pluripotent stem cell human CVCL_4Q51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10026; true Female 21190745 CVCL_5247 C70 cancer cell line human CVCL_5247 HLA typing: A*28,30 (PubMed=8464898) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1309Ter (c.3925G>T); ClinVar=VCV000824390; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+2T>G (IVS8+2T>G); ClinVar=VCV000428877; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=16418264) Derived from sampling site: Colon; sigmoid. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053) 21190746 CVCL_4Q47 CW10020 induced pluripotent stem cell human CVCL_4Q47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW10020; true. Male 21190747 CVCL_5246 C32 [Human colon adenocarcinoma] cancer cell line human CVCL_5246 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asp777Leufs*2 (c.2329_2332delGACA); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Ser42Ile (c.125G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=16418264) Derived from sampling site: Colon. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21190748 CVCL_4Q46 CW10019 induced pluripotent stem cell human CVCL_4Q46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10019; true; Discontinued: FCDI; CW10019; probable. Female 21190749 CVCL_5245 C10 cancer cell line human CVCL_5245 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Colon; descending. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: N-glycan profiling; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Instable (MSI) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190750 CVCL_4Q45 CW10018 induced pluripotent stem cell human CVCL_4Q45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10018; true Female 21190751 CVCL_5244 BThy finite cell line CVCL_5244 CL:0000010 Derived from sampling site: Spleen and thymus. Discontinued: ATCC; CRL-6020; probable Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190752 CVCL_4Q44 CW10014 induced pluripotent stem cell human CVCL_4Q44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10014; true Male 21190753 CVCL_5249 C80 cancer cell line human CVCL_5249 HLA typing: A*03 (PubMed=8464898) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu629Ter (c.1886T>G); ClinVar=VCV000429049; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Val (c.437C>T); ClinVar=VCV000375962; Zygosity=Unspecified (PubMed=20570890; DepMap); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52Ter (c.154C>T); ClinVar=VCV001455400; Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Rectum. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190754 CVCL_4Q49 CW10023 induced pluripotent stem cell human CVCL_4Q49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW10023; true Male 21190755 CVCL_5248 C75 cancer cell line human CVCL_5248 HLA typing: A*01,11 (PubMed=8464898) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=16418264; DepMap) Derived from sampling site: Colon; sigmoid. Omics: Deep exome analysis; Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Microsatellite instability: Stable (MSS) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21190756 CVCL_4Q48 CW10022 induced pluripotent stem cell human CVCL_4Q48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW10022; true. Female 21190757 CVCL_WW80 7WY1 transformed cell line Norway rat CVCL_WW80 CL:0000010 Transformant: Adenovirus 7(NCBI-Taxonomy; 10519); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Female 21190758 CVCL_X880 AG13455 transformed cell line human CVCL_X880 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190759 CVCL_X884 AG16516 transformed cell line human CVCL_X884 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190760 CVCL_WW84 Meth A MH-02 cancer cell line house mouse CVCL_WW84 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female 21190761 CVCL_X883 AG16360 transformed cell line human CVCL_X883 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190762 CVCL_WW83 Meth A MH-01 cancer cell line house mouse CVCL_WW83 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: BALB/c. Female 21190763 CVCL_WW82 4F9 [Mouse hybridoma against human PTPRC] hybridoma house mouse CVCL_WW82 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21190764 CVCL_X882 AG13902 finite cell line human CVCL_X882 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21190765 CVCL_WW81 7IJY1-1 transformed cell line Norway rat CVCL_WW81 CL:0000010 Transformant: Adenovirus 7(NCBI-Taxonomy; 10519); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Fischer 344. Female 21190766 CVCL_X881 AG13901 finite cell line human CVCL_X881 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190767 CVCL_FE52 ND15403 transformed cell line human CVCL_FE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190768 CVCL_FE51 ND15373 transformed cell line human CVCL_FE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190769 CVCL_FE50 ND15348 transformed cell line human CVCL_FE50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190770 CVCL_FE45 ND15249 transformed cell line human CVCL_FE45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190771 CVCL_FE44 ND15241 transformed cell line human CVCL_FE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190772 CVCL_FE43 ND15232 transformed cell line human CVCL_FE43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190773 CVCL_FE42 ND15173 transformed cell line human CVCL_FE42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190774 CVCL_FE49 ND15343 transformed cell line human CVCL_FE49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190775 CVCL_FE48 ND15294 transformed cell line human CVCL_FE48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190776 CVCL_FE47 ND15272 transformed cell line human CVCL_FE47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190777 CVCL_FE46 ND15271 transformed cell line human CVCL_FE46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190778 CVCL_FE63 ND16437 transformed cell line human CVCL_FE63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190779 CVCL_FE62 ND16275 transformed cell line human CVCL_FE62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190780 CVCL_FE61 ND16217 transformed cell line human CVCL_FE61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190781 CVCL_FE60 ND16188 transformed cell line human CVCL_FE60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190782 CVCL_FE56 ND15566 transformed cell line human CVCL_FE56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190783 CVCL_FE55 ND15494 transformed cell line human CVCL_FE55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190784 CVCL_FE54 ND15487 transformed cell line human CVCL_FE54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190785 CVCL_FE53 ND15411 transformed cell line human CVCL_FE53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190786 CVCL_FE59 ND15903 transformed cell line human CVCL_FE59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190787 CVCL_FE58 ND15897 transformed cell line human CVCL_FE58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190788 CVCL_FE57 ND15836 transformed cell line human CVCL_FE57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190789 CVCL_FE30 ND14915 transformed cell line human CVCL_FE30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190790 CVCL_FE29 ND14904 transformed cell line human CVCL_FE29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190791 CVCL_FE28 ND14845 transformed cell line human CVCL_FE28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190792 CVCL_FE23 ND14669 transformed cell line human CVCL_FE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190793 CVCL_FE22 ND14668 transformed cell line human CVCL_FE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190794 CVCL_FE21 ND14645 transformed cell line human CVCL_FE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190795 CVCL_FE20 ND14642 transformed cell line human CVCL_FE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190796 CVCL_FE27 ND14836 transformed cell line human CVCL_FE27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190797 CVCL_FE26 ND14792 transformed cell line human CVCL_FE26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190798 CVCL_FE25 ND14750 transformed cell line human CVCL_FE25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190799 CVCL_FE24 ND14749 transformed cell line human CVCL_FE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190800 CVCL_FE41 ND15137 transformed cell line human CVCL_FE41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190801 CVCL_FE40 ND15074 transformed cell line human CVCL_FE40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190802 CVCL_FE39 ND15057 transformed cell line human CVCL_FE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190803 CVCL_FE34 ND14957 transformed cell line human CVCL_FE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190804 CVCL_FE33 ND14956 transformed cell line human CVCL_FE33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190805 CVCL_FE32 ND14949 transformed cell line human CVCL_FE32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190806 CVCL_FE31 ND14929 transformed cell line human CVCL_FE31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190807 CVCL_FE38 ND15019 transformed cell line human CVCL_FE38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190808 CVCL_FE37 ND15018 transformed cell line human CVCL_FE37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190809 CVCL_FE36 ND14961 transformed cell line human CVCL_FE36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190810 CVCL_FE35 ND14960 transformed cell line human CVCL_FE35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190811 CVCL_FE09 ND14438 transformed cell line human CVCL_FE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190812 CVCL_FE08 ND14385 transformed cell line human CVCL_FE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190813 CVCL_FE07 ND14304 transformed cell line human CVCL_FE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190814 CVCL_FE06 ND14303 transformed cell line human CVCL_FE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190815 CVCL_FE01 ND14264 transformed cell line human CVCL_FE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190816 CVCL_FE00 ND14254 transformed cell line human CVCL_FE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190817 CVCL_FE05 ND14296 transformed cell line human CVCL_FE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190818 CVCL_FE04 ND14280 transformed cell line human CVCL_FE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190819 CVCL_FE03 ND14278 transformed cell line human CVCL_FE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190820 CVCL_FE02 ND14265 transformed cell line human CVCL_FE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190821 CVCL_FE19 ND14639 transformed cell line human CVCL_FE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190822 CVCL_FE18 ND14568 transformed cell line human CVCL_FE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190823 CVCL_FE17 ND14557 transformed cell line human CVCL_FE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190824 CVCL_FE12 ND14491 transformed cell line human CVCL_FE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190825 CVCL_FE11 ND14477 transformed cell line human CVCL_FE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190826 CVCL_FE10 ND14475 transformed cell line human CVCL_FE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190827 CVCL_FE16 ND14527 transformed cell line human CVCL_FE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190828 CVCL_FE15 ND14525 transformed cell line human CVCL_FE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190829 CVCL_FE14 ND14523 transformed cell line human CVCL_FE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190830 CVCL_FE13 ND14499 transformed cell line human CVCL_FE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190831 CVCL_WY20 HG2620 finite cell line human CVCL_WY20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21190832 CVCL_WY24 KS82 transformed cell line human CVCL_WY24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190833 CVCL_WY23 KS72 transformed cell line human CVCL_WY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190834 CVCL_WY22 BS-SY2 transformed cell line human CVCL_WY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190835 CVCL_WY21 BS-SY1 transformed cell line human CVCL_WY21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190836 CVCL_WY28 87RD102 finite cell line human CVCL_WY28 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (PubMed=10987302) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190837 CVCL_WY27 851129W finite cell line human CVCL_WY27 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (PubMed=10987302) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190838 CVCL_WY26 CZD82CH finite cell line human CVCL_WY26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21190839 CVCL_WY25 AT2BR finite cell line human CVCL_WY25 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2547_Ser2549del (c.7638_7646delTAGAATTTC) (7636del9); ClinVar=VCV000003019; Zygosity=Homozygous (PubMed=7792600) Population: Caucasian; Irish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190840 CVCL_WY29 DB333 finite cell line human CVCL_WY29 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Unspecified 21190841 CVCL_WY13 HG2829 transformed cell line human CVCL_WY13 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Arg364Ter (c.1090A>T); ClinVar=VCV000632671; Zygosity=Homozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Trp567Ter (c.1701G>A); ClinVar=VCV000819865; Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 98(RoMo) (BSR98); Derived from sampling site: Peripheral blood. Male 21190842 CVCL_WY12 HG2820 transformed cell line human CVCL_WY12 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 142(MaMatu) (BSR142); Derived from sampling site: Peripheral blood. 21190843 CVCL_WY11 HG2726 finite cell line human CVCL_WY11 CL:0000010 Population: Lebanese; Donor information: From Bloom Syndrome Registry patient 70(DY) (BSR70); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190844 CVCL_WY10 HG2721 transformed cell line human CVCL_WY10 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Arg899Ter (c.2695C>T); ClinVar=VCV000127491; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 177 (BSR177); Derived from sampling site: Peripheral blood. 21190845 CVCL_WY17 HG2917 transformed cell line human CVCL_WY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 175 (BSR175); Derived from sampling site: Peripheral blood. 21190846 CVCL_WY16 HG2915 transformed cell line human CVCL_WY16 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1066Tyr (c.3197G>A); Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 197 (BSR197); Derived from sampling site: Peripheral blood. 21190847 CVCL_WY15 HG2912 transformed cell line human CVCL_WY15 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Leu751Lysfs*25 (c.2250_2251insAAAT); ClinVar=VCV000188790; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe1087Leufs*11 (c.3261delT); Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 193 (BSR193); Derived from sampling site: Peripheral blood. 21190848 CVCL_WY14 HG2830 transformed cell line human CVCL_WY14 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln700Ter (c.2098C>T); ClinVar=VCV000042067; Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 51(KeMc) (BSR51); Derived from sampling site: Peripheral blood. Male 21190849 CVCL_WY19 HG2619 finite cell line human CVCL_WY19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21190850 CVCL_WY18 HG2940 finite cell line human CVCL_WY18 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe194Leufs (c.582delT); Zygosity=Homozygous (PubMed=17407155) Population: Ecuadorian and El Salvadoran; Donor information: From Bloom Syndrome Registry patient 232 (BSR232); Derived from sampling site: Skin Cell type=Fibroblast.. 21190851 CVCL_WY02 HG2169 transformed cell line human CVCL_WY02 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys901Tyr (c.2702G>A); dbSNP=rs758311406; Zygosity=Homozygous (PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 40(DoRoe) (BSR40); Derived from sampling site: Peripheral blood. Female 21190852 CVCL_WY01 HG2122 transformed cell line human CVCL_WY01 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 61(DoHop) (BSR61); Derived from sampling site: Peripheral blood. Male 21190853 CVCL_WY00 HG2118 transformed cell line human CVCL_WY00 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Thr830Asnfs*5 (c.2488dupA); ClinVar=VCV000042178; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Lys1227Asnfs*52 (c.3681delA); Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 65(AnPa) (BSR65); Derived from sampling site: Peripheral blood. Male 21190854 CVCL_WY06 HG2252 finite cell line human CVCL_WY06 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser104Ter (c.311C>A); ClinVar=VCV001683330; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Ser (c.3164G>C); ClinVar=VCV000042078; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Italian; Donor information: From Bloom Syndrome Registry patient 80(ErPal) (BSR80); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190855 CVCL_WY05 HG2231 transformed cell line human CVCL_WY05 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln672Arg (c.2015A>G) (2089A>G); ClinVar=VCV000188963; Zygosity=Heterozygous (PubMed=7585968; PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Cys1055Arg (c.3163T>C); ClinVar=VCV000549904; Zygosity=Heterozygous (PubMed=7585968; PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 139(ViKre) (BSR139); Derived from sampling site: Peripheral blood. 21190856 CVCL_WY04 HG2225 transformed cell line human CVCL_WY04 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe1087Leufs*11 (c.3261delT); Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 22(ElHa) (BSR22); Derived from sampling site: Peripheral blood. Male 21190857 CVCL_WY03 HG2193 transformed cell line human CVCL_WY03 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Phe1087Leufs*11 (c.3261delT); Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 170 (BSR170); Derived from sampling site: Peripheral blood. 21190858 CVCL_WY09 HG2709 transformed cell line human CVCL_WY09 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 54(AlTu) (BSR54); Derived from sampling site: Peripheral blood. Male 21190859 CVCL_WY08 HG2510 transformed cell line human CVCL_WY08 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Lys272Ter (c.814A>T) (888A>T); Zygosity=Heterozygous (PubMed=7585968; PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ala363fs (c.1220+3A>G); ClinVar=VCV000949363; Zygosity=Heterozygous (PubMed=7585968; PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 112(NaSch) (BSR112); Derived from sampling site: Peripheral blood. Male 21190860 CVCL_WY07 HG2508 finite cell line human CVCL_WY07 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln645Ter (c.1933C>T); ClinVar=VCV000454091; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Gln909Ter (c.2725C>T); ClinVar=VCV001454098; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 105(ShWo) (BSR105); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190861 CVCL_FF91 ND23105 transformed cell line human CVCL_FF91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190862 CVCL_FF90 ND23104 transformed cell line human CVCL_FF90 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190863 CVCL_FF95 ND23118 transformed cell line human CVCL_FF95 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190864 CVCL_FF94 ND23114 transformed cell line human CVCL_FF94 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190865 CVCL_FF93 ND23110 transformed cell line human CVCL_FF93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190866 CVCL_FF92 ND23106 transformed cell line human CVCL_FF92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190867 CVCL_FF88 ND23069 transformed cell line human CVCL_FF88 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190868 CVCL_FF87 ND23025 transformed cell line human CVCL_FF87 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190869 CVCL_FF86 ND23024 transformed cell line human CVCL_FF86 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190870 CVCL_FF85 ND23023 transformed cell line human CVCL_FF85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190871 CVCL_FF89 ND23076 transformed cell line human CVCL_FF89 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190872 CVCL_FF99 ND23129 transformed cell line human CVCL_FF99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190873 CVCL_FF98 ND23125 transformed cell line human CVCL_FF98 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190874 CVCL_FF97 ND23123 transformed cell line human CVCL_FF97 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21190875 CVCL_FF96 ND23122 transformed cell line human CVCL_FF96 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21190876 CVCL_4S63 CW70012 induced pluripotent stem cell human CVCL_4S63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70012; true. Male 21190877 CVCL_5463 SK-LC-14 cancer cell line human CVCL_5463 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190878 CVCL_4S62 CW70008 induced pluripotent stem cell human CVCL_4S62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70008; true. Female 21190879 CVCL_5462 SK-LC-13 cancer cell line human CVCL_5462 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190880 CVCL_4S61 CW70007 induced pluripotent stem cell human CVCL_4S61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70007; true. Female 21190881 CVCL_5461 SK-LC-12 cancer cell line human CVCL_5461 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190882 CVCL_4S60 CW70006 induced pluripotent stem cell human CVCL_4S60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70006; true. Male 21190883 CVCL_5460 SK-LC-11 cancer cell line human CVCL_5460 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190884 CVCL_4S56 CW70001 induced pluripotent stem cell human CVCL_4S56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70001; true. Male 21190885 CVCL_5456 HOC-8 cancer cell line human CVCL_5456 CL:0000010 Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 72.06 hours (GrayJW panel) Part of: MD Anderson Cell Lines Project 21190886 CVCL_4S55 CW60224 induced pluripotent stem cell human CVCL_4S55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60224; true Male 21190887 CVCL_5455 HOC-7 cancer cell line human CVCL_5455 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=25230021); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Phe (c.824G>T); ClinVar=VCV000376582; Zygosity=Unspecified (PubMed=25230021) Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray Female Doubling time: 16.4 hours (PubMed=4016745); 26.68 hours (GrayJW panel) Part of: MD Anderson Cell Lines Project; Part of: OCCP ovarian cancer cell line panel 21190888 CVCL_4S54 CW60115 induced pluripotent stem cell human CVCL_4S54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60115; true Male 21190889 CVCL_5454 HOC-1 cancer cell line human CVCL_5454 CL:0000010 Derived from metastatic site: Ascites. Omics: Protein expression by reverse-phase protein arrays Female Doubling time: 36 hours (PubMed=4016745); 24.87 hours (GrayJW panel) Part of: MD Anderson Cell Lines Project 21190890 CVCL_5453 COLO 330 cancer cell line human CVCL_5453 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21190891 CVCL_4S53 CW60109 induced pluripotent stem cell human CVCL_4S53 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW60109; true Male 21190892 CVCL_4S59 CW70005 induced pluripotent stem cell human CVCL_4S59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70005; true. Male 21190893 CVCL_5459 SK-LC-10 cancer cell line human CVCL_5459 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190894 CVCL_4S58 CW70004 induced pluripotent stem cell human CVCL_4S58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70004; true. Male 21190895 CVCL_5458 SK-LC-1 cancer cell line human CVCL_5458 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, age/sex of donor and ethnicity from MSKCC antibody and bioresource core facility. Population: Caucasian Female 21190896 CVCL_4S57 CW70002 induced pluripotent stem cell human CVCL_4S57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70002; true. Female 21190897 CVCL_5457 HTOA cancer cell line human CVCL_5457 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Discontinued: RCB; RCB0692; probable Female Doubling time: 74.5 hours (at 5th passage), 68.2 hours (at 25th passage), 72 hours (at 50th passage) (PubMed=2435620); 70 hours (PubMed=3593088) 21190898 CVCL_WY97 EB0405 cancer cell line human CVCL_WY97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Cell line name, age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190899 CVCL_WY96 17268 cancer cell line human CVCL_WY96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190900 CVCL_WY95 17201 cancer cell line human CVCL_WY95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190901 CVCL_WY94 17066 cancer cell line human CVCL_WY94 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage) Female 21190902 CVCL_WY99 16471 cancer cell line human CVCL_WY99 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Trp2626Cys (c.7878G>C); ClinVar=VCV000038125; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr253Pro (c.757A>C); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190903 CVCL_WY98 8684 cancer cell line human CVCL_WY98 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp184Glufs*24 (c.552_553del2); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190904 CVCL_4S70 CW70034 induced pluripotent stem cell human CVCL_4S70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70034; true Male 21190905 CVCL_5470 SK-LC-21 cancer cell line human CVCL_5470 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190906 CVCL_4S74 CW70038 induced pluripotent stem cell human CVCL_4S74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70038; true Female 21190907 CVCL_5474 SK-LC-6 cancer cell line human CVCL_5474 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Unspecified (PubMed=12794755). Female 21190908 CVCL_4S73 CW70037 induced pluripotent stem cell human CVCL_4S73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70037; true Male 21190909 CVCL_5473 SK-LC-5 cancer cell line human CVCL_5473 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190910 CVCL_4S72 CW70036 induced pluripotent stem cell human CVCL_4S72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70036; true Female 21190911 CVCL_5472 SK-LC-4 cancer cell line human CVCL_5472 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190912 CVCL_4S71 CW70035 induced pluripotent stem cell human CVCL_4S71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70035; true Female 21190913 CVCL_5471 SK-LC-3 cancer cell line human CVCL_5471 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190914 CVCL_4S67 CW70017 induced pluripotent stem cell human CVCL_4S67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70017; true. Male 21190915 CVCL_5467 SK-LC-19 cancer cell line human CVCL_5467 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190916 CVCL_4S66 CW70015 induced pluripotent stem cell human CVCL_4S66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70015; true. Male 21190917 CVCL_5466 SK-LC-17 cancer cell line human CVCL_5466 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21190918 CVCL_4S65 CW70014 induced pluripotent stem cell human CVCL_4S65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70014; true. Male 21190919 CVCL_5465 SK-LC-16 cancer cell line human CVCL_5465 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190920 CVCL_4S64 CW70013 induced pluripotent stem cell human CVCL_4S64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW70013; true. Male 21190921 CVCL_5464 SK-LC-15 cancer cell line human CVCL_5464 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190922 CVCL_4S69 CW70019 induced pluripotent stem cell human CVCL_4S69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70019; true. Female 21190923 CVCL_5469 SK-LC-20 cancer cell line human CVCL_5469 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21190924 CVCL_4S68 CW70018 induced pluripotent stem cell human CVCL_4S68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW70018; true. Male 21190925 CVCL_5468 SK-LC-2 cancer cell line human CVCL_5468 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro85fs (c.253delC); Zygosity=Unspecified (PubMed=12794755) Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21190926 CVCL_WY86 ATHM4BI finite cell line human CVCL_WY86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190927 CVCL_WY85 54BR finite cell line human CVCL_WY85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 45.9 hours (PubMed=6459055) 21190928 CVCL_WY84 CL89-17872 cancer cell line human CVCL_WY84 CL:0000010 Sequence variation: Gene fusion; HGNC; 9343; PRCC + HGNC; 11752; TFE3; Name(s)=PRCC-TFE3 (PubMed=8986805). Male 21190929 CVCL_WY83 CL89-12117 cancer cell line human CVCL_WY83 CL:0000010 Sequence variation: Gene fusion; HGNC; 9343; PRCC + HGNC; 11752; TFE3; Name(s)=PRCC-TFE3 (PubMed=8986805). Male 21190930 CVCL_WY89 MPEK-BL6 spontaneously immortalized cell line house mouse CVCL_WY89 CL:0000010 Miscellaneous: Doubling time and culture characteristics from personal communication of Girling P (CELLnTEC). Donor information: Culture was isolated from the skin of several neonatal mice combined; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 24-30 hours (Direct_author_submission) 21190931 CVCL_WY88 XPHM4LO finite cell line human CVCL_WY88 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.468_469delAA; Zygosity=Heterozygous (from familial inference of XP4LO) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21190932 CVCL_WY87 XPHF4LO finite cell line human CVCL_WY87 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.468_469delAA; Zygosity=Heterozygous (from familial inference of XP4LO) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21190933 CVCL_4S41 CW50001 induced pluripotent stem cell human CVCL_4S41 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW50001; true; Discontinued: FCDI; CW50001; probable. Male 21190934 CVCL_5441 MC3T3-G2/PA6 stromal cell line house mouse CVCL_5441 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Preadipocyte.; Breed/subspecies: C57BL/6. Unspecified 21190935 CVCL_4S40 CW40149 induced pluripotent stem cell human CVCL_4S40 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40149; true Female 21190936 CVCL_5440 MC3T3-E1 Subclone 4 spontaneously immortalized cell line house mouse CVCL_5440 CL:0000010 Miscellaneous: STR profile from personal communication of Almeida J.L.; PubMed=23430347 has a different value for STR 6-4 (17) than that submitted (18) due to a change in the marker motif Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Exhibits high levels of osteoblast differentiation after growth in ascorbic acid and 3 to 4 mM inorganic phosphate Forms a well mineralized extracellular matrix (ECM) after 10 days (ATCC). Doubling time: 51.6 hours (CelloPub=CLPUB00625); ~38 hours (ATCC=CRL-2593) 21190937 CVCL_4S34 CW40135 induced pluripotent stem cell human CVCL_4S34 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40135; true Male 21190938 CVCL_5434 MU14.K undefined cell line type CVCL_5434 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6485; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21190939 CVCL_4S33 CW40132 induced pluripotent stem cell human CVCL_4S33 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40132; true Male 21190940 CVCL_5433 LyD9 factor-dependent cell line house mouse CVCL_5433 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent 21190941 CVCL_5432 AP-16 spontaneously immortalized cell line house mouse CVCL_5432 CL:0000010 Derived from sampling site: Brain Cell type=Immature astrocyte.; Breed/subspecies: C3H/He. Unspecified Doubling time: ~23 hours (PubMed=8391585); ~1.1 days (lot 03282005) (JCRB) 21190942 CVCL_4S32 CW40131 induced pluripotent stem cell human CVCL_4S32 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40131; true Male 21190943 CVCL_5431 AFT024 transformed cell line house mouse CVCL_5431 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic liver; stroma; Breed/subspecies: C57BL/6J. Unspecified 21190944 CVCL_4S31 CW40129 induced pluripotent stem cell human CVCL_4S31 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40129; true Male 21190945 CVCL_4S38 CW40142 induced pluripotent stem cell human CVCL_4S38 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40142; true Male 21190946 CVCL_5438 MC3T3-E1 Subclone 24 spontaneously immortalized cell line house mouse CVCL_5438 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Exhibits poor osteoblast differentiation after growth in ascorbic acid Does not form a mineralized extracellular matrix (ATCC). Doubling time: 90.5 hours (CelloPub=CLPUB00625) 21190947 CVCL_4S37 CW40139 induced pluripotent stem cell human CVCL_4S37 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40139; true Male 21190948 CVCL_5437 MC3T3-E1 Subclone 14 spontaneously immortalized cell line house mouse CVCL_5437 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Exhibits high levels of osteoblast differentiation after growth in ascorbic acid and 3 to 4 mM inorganic phosphate Forms a well mineralized extracellular matrix (ECM) after 10 days (ATCC). 21190949 CVCL_4S36 CW40137 induced pluripotent stem cell human CVCL_4S36 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40137; true Female 21190950 CVCL_5436 YS-PPB spontaneously immortalized cell line house mouse CVCL_5436 CL:0000010 Derived from sampling site: Yolk sac; Breed/subspecies: BALB/c. Unspecified 21190951 CVCL_4S35 CW40136 induced pluripotent stem cell human CVCL_4S35 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40136; true Male 21190952 CVCL_5435 THS119 conditionally immortalized cell line house mouse CVCL_5435 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Characteristics: Requires feeder cells Maintenance of THS119 depends on the presence of cell line TBR59 (Cellosaurus=CVCL_5372). 21190953 CVCL_4S39 CW40147 induced pluripotent stem cell human CVCL_4S39 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40147; true Female 21190954 CVCL_5439 MC3T3-E1 Subclone 30 spontaneously immortalized cell line house mouse CVCL_5439 CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoblast.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Exhibits poor osteoblast differentiation after growth in ascorbic acid Does not form a mineralized extracellular matrix (ATCC). 21190955 CVCL_WY93 16106 cancer cell line human CVCL_WY93 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190956 CVCL_WY92 15876 cancer cell line human CVCL_WY92 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Aspfs*9 (c.409_416del7); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190957 CVCL_WY91 8540 cancer cell line human CVCL_WY91 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190958 CVCL_WY90 13781 cancer cell line human CVCL_WY90 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr2515Ile (c.7544C>T); ClinVar=VCV000038102; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Met (c.814G>A); ClinVar=VCV000185814; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21190959 CVCL_WY75 RF [Sebastes] spontaneously immortalized cell line CVCL_WY75 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190960 CVCL_WY74 ITOF spontaneously immortalized cell line CVCL_WY74 CL:0000010 Unspecified Group: Endangered species/breed cell line; Group: Fish cell line. 21190961 CVCL_WY73 FRF spontaneously immortalized cell line CVCL_WY73 CL:0000010 Unspecified Group: Fish cell line. 21190962 CVCL_WY72 SBK [Pagrus] spontaneously immortalized cell line CVCL_WY72 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21190963 CVCL_WY79 CF [Cyprinus] spontaneously immortalized cell line CVCL_WY79 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190964 CVCL_WY78 GON spontaneously immortalized cell line CVCL_WY78 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21190965 CVCL_WY77 LF spontaneously immortalized cell line CVCL_WY77 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190966 CVCL_WY76 SK [Channa] spontaneously immortalized cell line CVCL_WY76 CL:0000010 Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21190967 CVCL_5452 COLO 319 cancer cell line human CVCL_5452 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21190968 CVCL_4S52 CW60039 induced pluripotent stem cell human CVCL_4S52 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of CW60040 (Cellosaurus=CVCL_DL20) Discontinued: Coriell; CW60039; true; Discontinued: FCDI; CW60039; probable. Male 21190969 CVCL_5451 COLO 316 cancer cell line human CVCL_5451 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21190970 CVCL_4S51 CW60026 induced pluripotent stem cell human CVCL_4S51 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW60026; true. Female 21190971 CVCL_5450 COLO 110 cancer cell line human CVCL_5450 CL:0000010 Population: Caucasian; Derived from metastatic site: Fallopian tube. Female 21190972 CVCL_4S50 CW60021 induced pluripotent stem cell human CVCL_4S50 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Israeli; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; CW60021; true Male 21190973 CVCL_4S45 CW50005 induced pluripotent stem cell human CVCL_4S45 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW50005; true; Discontinued: FCDI; CW50005; probable. Male 21190974 CVCL_5445 Kit225/K6 cancer cell line human CVCL_5445 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0002000000021) It was the sole source for the STR profile of this entry. Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 21190975 CVCL_4S44 CW50004 induced pluripotent stem cell human CVCL_4S44 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50004; true Male 21190976 CVCL_5444 PT-18 factor-dependent cell line house mouse CVCL_5444 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C3H.SW. Characteristics: IL3 and CSF2 dependent 21190977 CVCL_4S43 CW50003 induced pluripotent stem cell human CVCL_4S43 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50003; true Male 21190978 CVCL_5443 Kit225 cancer cell line human CVCL_5443 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male Characteristics: IL2 dependent 21190979 CVCL_4S42 CW50002 induced pluripotent stem cell human CVCL_4S42 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50002; true Male 21190980 CVCL_5442 OH-2 [Human plasma cell myeloma] cancer cell line human CVCL_5442 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces IgG kappa; Characteristics: IL6 dependent 21190981 CVCL_5449 253D cancer cell line human CVCL_5449 CL:0000010 Derived from metastatic site: Ascites. Discontinued: ECACC; 93090807; probable Female Doubling time: ~80 hours, at 18th passage (PubMed=8795574) 21190982 CVCL_4S49 CW50013 induced pluripotent stem cell human CVCL_4S49 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50013; true Male 21190983 CVCL_5448 200D cancer cell line human CVCL_5448 CL:0000010 Discontinued: ECACC; 93092101; probable. Female Doubling time: ~52 hours, at 7th passage (PubMed=8795574) 21190984 CVCL_4S48 CW50008 induced pluripotent stem cell human CVCL_4S48 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50008; true Female 21190985 CVCL_5447 180D cancer cell line human CVCL_5447 CL:0000010 Derived from metastatic site: Ascites. Discontinued: ECACC; 93090809; probable Female Doubling time: ~74 hours, at 17th passage (PubMed=8795574) 21190986 CVCL_4S47 CW50007 induced pluripotent stem cell human CVCL_4S47 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW50007; true; Discontinued: FCDI; CW50007; probable. Female 21190987 CVCL_5446 138D cancer cell line human CVCL_5446 CL:0000010 Derived from metastatic site: Ascites. Discontinued: ECACC; 93090808; probable Female Doubling time: ~60 hours, at 7th passage (PubMed=8795574) 21190988 CVCL_4S46 CW50006 induced pluripotent stem cell human CVCL_4S46 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW50006; true Male 21190989 CVCL_WY82 JU-PI cancer cell line human CVCL_WY82 CL:0000010 Karyotypic information: Has lost chromosome Y; Derived from metastatic site: Groin. Male Doubling time: 1.1 days (PubMed=29788803) 21190990 CVCL_WY81 HNROA cancer cell line human CVCL_WY81 CL:0000010 Population: Japanese Female Doubling time: 83 hours (CelloPub=CLPUB00525). 21190991 CVCL_WY80 CPEK spontaneously immortalized cell line dog CVCL_WY80 CL:0000010 Miscellaneous: Sex of donor from personal communication of Girling P (CELLnTEC). Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: Beagle. Omics: Transcriptome analysis by microarray Male Characteristics: Useful for investigating the immunopathogenesis of inflammatory skin diseases Doubling time: 14.8 +- 1.50 hours (PubMed=18772565) 21190992 CVCL_WY64 67j25A spontaneously immortalized cell line fruit fly CVCL_WY64 CL:0000010 Breed/subspecies: Oregon R-C. Female Group: Insect cell line 21190993 CVCL_WY63 8FR23 spontaneously immortalized cell line Norway rat CVCL_WY63 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Wistar. Unspecified 21190994 CVCL_WY62 18FR22 spontaneously immortalized cell line Norway rat CVCL_WY62 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: Wistar. Unspecified 21190995 CVCL_WY61 T51 spontaneously immortalized cell line Norway rat CVCL_WY61 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Unspecified 21190996 CVCL_WY68 SBF spontaneously immortalized cell line CVCL_WY68 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190997 CVCL_WY67 WF-2 spontaneously immortalized cell line CVCL_WY67 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190998 CVCL_WY66 AF-29 spontaneously immortalized cell line CVCL_WY66 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21190999 CVCL_WY65 MSE spontaneously immortalized cell line CVCL_WY65 CL:0000010 Unspecified Group: Fish cell line. 21191000 CVCL_WY69 SCF spontaneously immortalized cell line CVCL_WY69 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21191001 CVCL_4S12 CW40086 induced pluripotent stem cell human CVCL_4S12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40086; true Male 21191002 CVCL_5412 VACO 9M cancer cell line human CVCL_5412 CL:0000010 Derived from metastatic site: Liver. Male Doubling time: 80 hours (PubMed=6498841) 21191003 CVCL_4S11 CW40085 induced pluripotent stem cell human CVCL_4S11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40085; true Male 21191004 CVCL_5411 VACO 8 cancer cell line human CVCL_5411 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leu (c.569C>T); ClinVar=VCV000418517; Zygosity=Hemizygous (PubMed=9715273) Derived from sampling site: Cecum. Male Doubling time: 46 hours (PubMed=6498841) 21191005 CVCL_4S10 CW40084 induced pluripotent stem cell human CVCL_4S10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40084; true Female 21191006 CVCL_5410 VACO 6 cancer cell line human CVCL_5410 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=9715273) Derived from sampling site: Cecum. Omics: Transcriptome analysis by microarray Male Doubling time: 26 hours (PubMed=6498841); Microsatellite instability: Instable (MSI) (PubMed=25926053) 21191007 CVCL_4S16 CW40106 induced pluripotent stem cell human CVCL_4S16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40106; true Male 21191008 CVCL_5416 Y16 factor-dependent cell line house mouse CVCL_5416 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: BALB/c. Characteristics: IL5 dependent 21191009 CVCL_4S15 CW40105 induced pluripotent stem cell human CVCL_4S15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40105; true Male 21191010 CVCL_5415 WR19M.1 cancer cell line house mouse CVCL_5415 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: BALB/c. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21191011 CVCL_4S14 CW40102 induced pluripotent stem cell human CVCL_4S14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40102; true; Discontinued: FCDI; CW40102; probable. Male 21191012 CVCL_4S13 CW40091 induced pluripotent stem cell human CVCL_4S13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40091; true. Male 21191013 CVCL_5413 VACO 9P cancer cell line human CVCL_5413 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Homozygous (PubMed=9000147; PubMed=24042735; PubMed=28683746) Miscellaneous: STR profile mentioned but not shown in PubMed=24042735; obtained by personal communication of Lind G.E Derived from sampling site: Rectum. Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 110 hours (PubMed=6498841); Microsatellite instability: Stable (MSS) (PubMed=9000147; PubMed=24042735; PubMed=28683746) 21191014 CVCL_4S19 CW40113 induced pluripotent stem cell human CVCL_4S19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40113; true Female 21191015 CVCL_5419 DA-3 [Mouse lymphoma] cancer cell line house mouse CVCL_5419 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: DBA/2. Characteristics: IL3 dependent Caution: Not from strain BALB/c as originally published but from strain DBA/2 (DOI=10.4051/ibc.2010.2.4.0014) 21191016 CVCL_4S18 CW40112 induced pluripotent stem cell human CVCL_4S18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40112; true Female 21191017 CVCL_5418 ZZ-R 127 spontaneously immortalized cell line CVCL_5418 CL:0000010 Derived from sampling site: Fetal oral cavity; tongue. Unspecified Virology: Susceptible to infection by foot-and-mouth disease virus 21191018 CVCL_4S17 CW40111 induced pluripotent stem cell human CVCL_4S17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40111; true Male 21191019 CVCL_5417 ZEN hybridoma house mouse CVCL_5417 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: ChEBI; CHEBI:10106; Zearalenone. 21191020 CVCL_WY71 SET spontaneously immortalized cell line CVCL_WY71 CL:0000010 Unspecified Group: Fish cell line. 21191021 CVCL_WY70 HIME spontaneously immortalized cell line CVCL_WY70 CL:0000010 Unspecified Group: Fish cell line. 21191022 CVCL_WY53 RB174 finite cell line human CVCL_WY53 CL:0000010 21191023 CVCL_WY52 SW13/cl.2 vim- cancer cell line human CVCL_WY52 CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Gln164Ter (c.490C>T); ClinVar=VCV001436624; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Does not express vimentin 21191024 CVCL_WY51 SW13/cl.1 vim+ cancer cell line human CVCL_WY51 CL:0000010 Sequence variation: Mutation; HGNC; 11100; SMARCA4; Simple; p.Gln164Ter (c.490C>T); ClinVar=VCV001436624; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Tyr (c.577C>T); ClinVar=VCV000230256; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Adrenal gland. Female Characteristics: Expresses vimentin 21191025 CVCL_WY50 SKF6 cancer cell line human CVCL_WY50 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Leu682_Ala1210del; HERRet fusion); Transfected with: HGNC; 9967; RET (with p.Met1_Lys662del; HERRet fusion) Population: Caucasian; Derived from metastatic site: Supra-orbital region. Female Problematic cell line: Misclassified Parent cell line (SK-N-MC) was originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor. 21191026 CVCL_WY57 RB191 finite cell line human CVCL_WY57 CL:0000010 21191027 CVCL_WY56 RB178 finite cell line human CVCL_WY56 CL:0000010 21191028 CVCL_WY55 RB177 finite cell line human CVCL_WY55 CL:0000010 21191029 CVCL_WY54 RB176 finite cell line human CVCL_WY54 CL:0000010 Omics: SNP array analysis. 21191030 CVCL_WY59 T51B spontaneously immortalized cell line Norway rat CVCL_WY59 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Unspecified 21191031 CVCL_WY58 RALA255-10G transformed cell line Norway rat CVCL_WY58 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA255](NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Fischer 344. Male Characteristics: Grows faster and achieves higher cell densities at the permissive temperature (33 Celsius) than at the non-permissive temperature (40 Celsius) 21191032 CVCL_4S30 CW40128 induced pluripotent stem cell human CVCL_4S30 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40128; true Male 21191033 CVCL_5430 MPRO clone 2.1 spontaneously immortalized cell line house mouse CVCL_5430 CL:0000010 Transfected with: HGNC; 9864; RARA (RARalpha403; truncated version AA 1-403) Breed/subspecies: C57BL/6 x DBA/2. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11422 21191034 CVCL_4S23 CW40118 induced pluripotent stem cell human CVCL_4S23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40118; true Male 21191035 CVCL_5423 SUM159PT cancer cell line human CVCL_5423 HLA typing: A*02:01,24:02; B*15:01,51:01; C*03:03,15:02 (PubMed=25960936); HLA typing: A*02:01,24:02; B*15:01,51:01; C*03:03,15:02 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Heterozygous (PubMed=19593635; PubMed=28889351); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157_Arg158insLeu (c.472_473ins3); Zygosity=Unspecified (PubMed=16541312; PubMed=28889351) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 21.73 hours (GrayJW panel); Microsatellite instability: Stable (MSS) (PubMed=15677628) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21191036 CVCL_4S22 CW40116 induced pluripotent stem cell human CVCL_4S22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40116; true Male 21191037 CVCL_5422 PCI-79 cancer cell line human CVCL_5422 CL:0000010 Derived from sampling site: Pancreas. Male 21191038 CVCL_4S21 CW40115 induced pluripotent stem cell human CVCL_4S21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40115; true Male 21191039 CVCL_5421 IMR-6 cancer cell line human CVCL_5421 From: Kennett R.; Department of Genetics, University of Pennsylvania; Philadelphia; USA. CL:0000010 21191040 CVCL_4S20 CW40114 induced pluripotent stem cell human CVCL_4S20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40114; true Female 21191041 CVCL_5420 IMR-91 finite cell line human CVCL_5420 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21191042 CVCL_5427 BALM-4 cancer cell line human CVCL_5427 HLA typing: A*02; B*13,44 (PubMed=2939141) CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Doubling time: 60-72 hours (PubMed=160894) 21191043 CVCL_4S27 CW40123 induced pluripotent stem cell human CVCL_4S27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40123; true Male 21191044 CVCL_5426 BALM-3 cancer cell line human CVCL_5426 CL:0000010 Population: Caucasian; Derived from sampling site: Pleural effusion. Female Doubling time: 60-72 hours (PubMed=160894); Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21191045 CVCL_4S26 CW40121 induced pluripotent stem cell human CVCL_4S26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40121; true Male 21191046 CVCL_5425 ANBL-6 cancer cell line human CVCL_5425 HLA typing: A*01,03; B*51,52; C*12:02,12:03 (Direct_author_submission) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Ter (c.991C>T); ClinVar=VCV000922893; Zygosity=Unspecified (PubMed=21173094); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Tyr425Thrfs*36 (c.1272delC); Zygosity=Homozygous (PubMed=17692805) Miscellaneous: HLA typing from personal communication of Pellat-Deceunynck C Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Produces Ig lambda; Characteristics: IL6 dependent 21191047 CVCL_4S25 CW40120 induced pluripotent stem cell human CVCL_4S25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40120; true Male 21191048 CVCL_5424 CH1 [Mouse lymphoma] cancer cell line house mouse CVCL_5424 CL:0000010 Breed/subspecies: B10.H-2aH-4bp/Wts. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21191049 CVCL_4S24 CW40119 induced pluripotent stem cell human CVCL_4S24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40119; true Male 21191050 CVCL_4S29 CW40126 induced pluripotent stem cell human CVCL_4S29 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40126; true Male 21191051 CVCL_5429 MPC-11/OUAr cancer cell line house mouse CVCL_5429 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Breed/subspecies: BALB/c. Female Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21191052 CVCL_4S28 CW40124 induced pluripotent stem cell human CVCL_4S28 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40124; true Male 21191053 CVCL_5428 MC/9.IL4 factor-dependent cell line house mouse CVCL_5428 CL:0000010 Derived from sampling site: Liver Cell type=Mast cell.; Breed/subspecies: C57BL/6 x A/J. Unspecified Characteristics: IL4 dependent 21191054 CVCL_WY60 T51B-Ni spontaneously immortalized cell line Norway rat CVCL_WY60 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Unspecified 21191055 CVCL_WY42 CV-1 clone 3.9.2 finite cell line CVCL_WY42 CL:0000010 Transfected with: RGD; 2147; Ar; Transfected with: UniProtKB; P62577; Escherichia coli cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male Characteristics: Transfected with the pMMTV-CAT plasmid Group: Non-human primate cell line 21191056 CVCL_WY41 MP48 transformed cell line Norway rat CVCL_WY41 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Ad2-Ad5 hybrid E1A; Derived from sampling site: Lung; alveolus Cell type=Type 2 pneumocyte.; Breed/subspecies: Sprague Dawley. Male Doubling time: 22-24 hours (PubMed=8886757) 21191057 CVCL_WY40 YY-8103 cancer cell line human CVCL_WY40 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Virology: Susceptible to infection by herpes simplex virus and measles virus (CelloPub=CLPUB00523) 21191058 CVCL_WY46 2048-EBV transformed cell line human CVCL_WY46 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21191059 CVCL_WY45 1363-EBV transformed cell line human CVCL_WY45 From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21191060 CVCL_WY44 LMCAT spontaneously immortalized cell line house mouse CVCL_WY44 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: Transfected with the pMMTV-CAT plasmid 21191061 CVCL_WY43 1471.1 [Mouse mammary gland cancer] cancer cell line house mouse CVCL_WY43 CL:0000010 Transfected with: UniProtKB; P62577; Escherichia coli cat Derived from sampling site: Mammary gland; Breed/subspecies: RIII. Female Characteristics: Transfected with the pMMTV-CAT plasmid 21191062 CVCL_WY49 SKF5 cancer cell line human CVCL_WY49 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.170_572del; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Leu682_Ala1210del; HERRet fusion); Transfected with: HGNC; 9967; RET (with p.Met1_Lys662del; HERRet fusion). Population: Caucasian; Derived from metastatic site: Supra-orbital region. Female Problematic cell line: Misclassified Parent cell line (SK-N-MC) was originally thought to be a neuroblastoma cell line but shown to be from an Askin tumor. 21191063 CVCL_WY48 MDCK-17 spontaneously immortalized cell line dog CVCL_WY48 CL:0000010 Transfected with: HGNC; 6530; LCT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21191064 CVCL_WY47 2048-mel cancer cell line human CVCL_WY47 CL:0000010 Unspecified 21191065 CVCL_WY31 CJ179 finite cell line human CVCL_WY31 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21191066 CVCL_WY30 347BR finite cell line human CVCL_WY30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21191067 CVCL_WY35 F96/224 finite cell line human CVCL_WY35 CL:0000010 Sequence variation: Mutation; HGNC; 17642; DCLRE1C; Simple; p.Leu70del (c.201_203GTT[2]) (c.207_209delGTT); dbSNP=rs753202682; Zygosity=Heterozygous (PubMed=16540517); Sequence variation: Mutation; HGNC; 17642; DCLRE1C; Simple; p.Gly126Asp (c.377G>A); Zygosity=Heterozygous (PubMed=16540517) Derived from sampling site: Cell type=Fibroblast. Male 21191068 CVCL_WY34 F02/385 finite cell line human CVCL_WY34 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21191069 CVCL_WY33 F01/240 finite cell line human CVCL_WY33 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21191070 CVCL_WY32 CJ179-hTERT telomerase immortalized cell line human CVCL_WY32 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Unspecified 21191071 CVCL_WY39 TR30-9 finite cell line human CVCL_WY39 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ala35fs (c.104_116del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9181; POLH Population: Lebanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Wild type transfected POLH can be expressed upon addition of tetracycline 21191072 CVCL_WY38 SNU-16alpha5 cancer cell line human CVCL_WY38 CL:0000010 Sequence variation: Gene fusion; HGNC; 1681; CD44 + HGNC; 10940; SLC1A2; Name(s)=CD44-SLC1A2 (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4065_4066insTTGA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Phe (c.614A>T); ClinVar=VCV000376682; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6141; ITGA5 Population: Korean; Derived from metastatic site: Ascites. Female 21191073 CVCL_WY37 SNU-16Ad cancer cell line human CVCL_WY37 CL:0000010 Sequence variation: Gene fusion; HGNC; 1681; CD44 + HGNC; 10940; SLC1A2; Name(s)=CD44-SLC1A2 (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1358fs*2 (c.4065_4066insTTGA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr205Phe (c.614A>T); ClinVar=VCV000376682; Zygosity=Homozygous (from parent cell line) Population: Korean; Derived from metastatic site: Ascites. Female 21191074 CVCL_WY36 AG06692 finite cell line human CVCL_WY36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG06692; probable 21191075 CVCL_4S01 CW40029 induced pluripotent stem cell human CVCL_4S01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40029; true. Male 21191076 CVCL_5401 VACO 429 cancer cell line human CVCL_5401 CL:0000010 Sequence variation: Mutation; HGNC; 1148; BUB1; Simple; p.Ser492Tyr (c.1542C>A); ClinVar=VCV000007083; Zygosity=Unspecified (PubMed=15162061); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (PubMed=16418264). Male 21191077 CVCL_4S00 CW40028 induced pluripotent stem cell human CVCL_4S00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40028; true. Female 21191078 CVCL_5400 VACO 400 cancer cell line human CVCL_5400 CL:0000010 Sequence variation: Mutation; HGNC; 1148; BUB1; Simple; IVS4+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=15162061); Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Thr45Thr (c.135G>A); ClinVar=VCV000186358; Zygosity=Heterozygous (PubMed=18167186); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys52Thr (c.155A>C); Zygosity=Heterozygous (PubMed=9927040); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Tyr470Asp (c.1408T>G); ClinVar=VCV000217016; Zygosity=Heterozygous (PubMed=9927040); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.74+2T>C; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=16418264) Derived from metastatic site: Liver. Male Microsatellite instability: Stable (MSS) (PubMed=9927040) 21191079 CVCL_4S05 CW40036 induced pluripotent stem cell human CVCL_4S05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40036; true. Male 21191080 CVCL_5405 VACO 4A cancer cell line human CVCL_5405 HLA typing: A*01,03 (PubMed=8464898) CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1355fs*18 (c.4062_4066delTTCTT); Zygosity=Unspecified (from autologous cell line VACO 4S); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (from autologous cell line VACO 4S); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Trp524Cys (c.1572G>T); Zygosity=Unspecified (from autologous cell line VACO 4S); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239fs*1 (c.715_717AAC>T); Zygosity=Unspecified (PubMed=16418264) Derived from sampling site: Rectum. Omics: Deep proteome analysis; Omics: Transcriptome analysis by microarray Male Doubling time: 30 hours (PubMed=6498841) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21191081 CVCL_4S04 CW40035 induced pluripotent stem cell human CVCL_4S04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40035; true. Male 21191082 CVCL_5404 VACO 456 cancer cell line human CVCL_5404 CL:0000010 Female Microsatellite instability: Stable (MSS) (PubMed=27004849). 21191083 CVCL_4S03 CW40032 induced pluripotent stem cell human CVCL_4S03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40032; true Male 21191084 CVCL_5403 VACO 441 cancer cell line human CVCL_5403 CL:0000010 Female Microsatellite instability: Stable (MSS) (PubMed=27004849). 21191085 CVCL_4S02 CW40031 induced pluripotent stem cell human CVCL_4S02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40031; true. Male 21191086 CVCL_5402 VACO 432 cancer cell line human CVCL_5402 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=25926053) Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Microsatellite instability: Instable (MSI) (PubMed=25926053) 21191087 CVCL_4S09 CW40068 induced pluripotent stem cell human CVCL_4S09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40068; true Male 21191088 CVCL_5409 VACO 5A cancer cell line human CVCL_5409 CL:0000010 Derived from sampling site: Cecum. Female Doubling time: 42 hours (PubMed=6498841) 21191089 CVCL_4S08 CW40067 induced pluripotent stem cell human CVCL_4S08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40067; true Female 21191090 CVCL_5408 VACO 576 cancer cell line human CVCL_5408 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=9715273) Derived from metastatic site: Liver. Female 21191091 CVCL_4S07 CW40051 induced pluripotent stem cell human CVCL_4S07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40051; true Male 21191092 CVCL_5407 VACO 5 cancer cell line human CVCL_5407 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=20570890; PubMed=25926053); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=20570890; PubMed=25926053); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (PubMed=12615714); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=9715273; PubMed=16418264) Derived from sampling site: Cecum. Omics: Transcriptome analysis by microarray Female Doubling time: 29 hours (PubMed=6498841); Microsatellite instability: Instable (MSI) (PubMed=25926053) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21191093 CVCL_4S06 CW40049 induced pluripotent stem cell human CVCL_4S06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW40049; true Female 21191094 CVCL_5406 VACO 4S cancer cell line human CVCL_5406 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1355fs*18 (c.4062_4066delTTCTT); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Trp524Cys (c.1572G>T); Zygosity=Unspecified (PubMed=24755471); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn239fs*1 (c.715_717AAC>T); Zygosity=Unspecified (PubMed=24755471) Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 30 hours (PubMed=6498841) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21191095 CVCL_4R99 CW40027 induced pluripotent stem cell human CVCL_4R99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40027; true. Male 21191096 CVCL_5399 VACO 330 cancer cell line human CVCL_5399 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=2253215). Male 21191097 CVCL_4R98 CW40026 induced pluripotent stem cell human CVCL_4R98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40026; true. Male 21191098 CVCL_5398 VACO 310 cancer cell line human CVCL_5398 CL:0000010 Male 21191099 CVCL_4R82 CW30237 induced pluripotent stem cell human CVCL_4R82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30237; true Male 21191100 CVCL_5382 UG3 cancer cell line human CVCL_5382 CL:0000010 Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (PubMed=14671638) Population: Japanese; Derived from sampling site: Peripheral blood. Female Characteristics: IL3 dependent Doubling time: 60-70 hours (PubMed=9616150) 21191101 CVCL_4R81 CW30236 induced pluripotent stem cell human CVCL_4R81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30236; true Male 21191102 CVCL_5381 UCI 107 cancer cell line human CVCL_5381 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 24-36 hours (PubMed=7672698); Microsatellite instability: Instable (MSI) (PubMed=15677628) 21191103 CVCL_4R80 CW30198 induced pluripotent stem cell human CVCL_4R80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30198; true Male 21191104 CVCL_5380 UCI 101 cancer cell line human CVCL_5380 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: 24 hours (PubMed=8428692); Microsatellite instability: Instable (MSI) (PubMed=15677628) 21191105 CVCL_4R86 CW40002 induced pluripotent stem cell human CVCL_4R86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40002; true. Male 21191106 CVCL_5386 UTP-L20 cancer cell line human CVCL_5386 CL:0000010 Population: Japanese. 21191107 CVCL_4R85 CW30251 induced pluripotent stem cell human CVCL_4R85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30251; true Male 21191108 CVCL_5385 UTP-L10 cancer cell line human CVCL_5385 CL:0000010 Population: Japanese. Unspecified 21191109 CVCL_5384 1G8 [Ictalurus] spontaneously immortalized cell line CVCL_5384 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Group: Fish cell line 21191110 CVCL_4R84 CW30249 induced pluripotent stem cell human CVCL_4R84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30249; true Male 21191111 CVCL_4R83 CW30246 induced pluripotent stem cell human CVCL_4R83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30246; true Male 21191112 CVCL_5383 UTP-2 cancer cell line human CVCL_5383 CL:0000010 Population: Japanese. 21191113 CVCL_4R79 CW30197 induced pluripotent stem cell human CVCL_4R79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30197; true Male 21191114 CVCL_5379 TSGH-9201 cancer cell line human CVCL_5379 CL:0000010 Derived from metastatic site: Ascites. Male Doubling time: 33-38 hours (PubMed=7823569) 21191115 CVCL_4R78 CW30196 induced pluripotent stem cell human CVCL_4R78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30196; true Female 21191116 CVCL_5378 TMD7 cancer cell line human CVCL_5378 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21191117 CVCL_4R77 CW30192 induced pluripotent stem cell human CVCL_4R77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30192; true Male 21191118 CVCL_5377 TMD2 cancer cell line human CVCL_5377 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: IL3 dependent 21191119 CVCL_4R76 CW30189 induced pluripotent stem cell human CVCL_4R76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30189; true Male 21191120 CVCL_5376 TIGMEC-3 transformed cell line CVCL_5376 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.; Breed/subspecies: Saanen. Female 21191121 CVCL_4R93 CW40014 induced pluripotent stem cell human CVCL_4R93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40014; true. Male 21191122 CVCL_5393 VACO 10MS cancer cell line human CVCL_5393 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=16418264) Derived from metastatic site: Omentum. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 36 hours (PubMed=6498841) Part of: AstraZeneca Colorectal cell line (AZCL) panel 21191123 CVCL_4R92 CW40013 induced pluripotent stem cell human CVCL_4R92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40013; true. Male 21191124 CVCL_5392 VACO 1 cancer cell line human CVCL_5392 CL:0000010 Derived from metastatic site: Liver. Female Doubling time: 65 hours (PubMed=6498841) 21191125 CVCL_4R91 CW40009 induced pluripotent stem cell human CVCL_4R91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40009; true. Female 21191126 CVCL_5391 UTP-M2 cancer cell line human CVCL_5391 CL:0000010 Population: Japanese. 21191127 CVCL_4R90 CW40008 induced pluripotent stem cell human CVCL_4R90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40008; true. Male 21191128 CVCL_5390 UTP-M1 cancer cell line human CVCL_5390 CL:0000010 Population: Japanese. 21191129 CVCL_4R97 CW40025 induced pluripotent stem cell human CVCL_4R97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40025; true. Female 21191130 CVCL_5397 VACO 3 cancer cell line human CVCL_5397 CL:0000010 Male Doubling time: 39 hours (PubMed=6498841). 21191131 CVCL_4R96 CW40023 induced pluripotent stem cell human CVCL_4R96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian Discontinued: Coriell; CW40023; true. Male 21191132 CVCL_5396 VACO 241 cancer cell line human CVCL_5396 CL:0000010 Male 21191133 CVCL_4R95 CW40022 induced pluripotent stem cell human CVCL_4R95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40022; true. Male 21191134 CVCL_5395 VACO 206 cancer cell line human CVCL_5395 CL:0000010 Female 21191135 CVCL_4R94 CW40015 induced pluripotent stem cell human CVCL_4R94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40015; true. Male 21191136 CVCL_5394 VACO 10P cancer cell line human CVCL_5394 CL:0000010 Derived from sampling site: Cecum. Female Doubling time: 45 hours (PubMed=6498841) 21191137 CVCL_4R89 CW40007 induced pluripotent stem cell human CVCL_4R89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW40007; true; Discontinued: FCDI; CW40007; probable. Male 21191138 CVCL_5389 UTP-L51 cancer cell line human CVCL_5389 CL:0000010 Population: Japanese. Unspecified 21191139 CVCL_4R88 CW40006 induced pluripotent stem cell human CVCL_4R88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40006; true. Male 21191140 CVCL_5388 UTP-L5 cancer cell line human CVCL_5388 CL:0000010 Population: Japanese Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21191141 CVCL_4R87 CW40004 induced pluripotent stem cell human CVCL_4R87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian Discontinued: Coriell; CW40004; true. Male 21191142 CVCL_5387 UTP-L3 cancer cell line human CVCL_5387 CL:0000010 Population: Japanese. Unspecified 21191143 CVCL_4R60 CW30141 induced pluripotent stem cell human CVCL_4R60 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30141; true Female 21191144 CVCL_5360 RMT-1 E4 cancer cell line Norway rat CVCL_5360 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female Doubling time: 14 hours (PubMed=2411993) 21191145 CVCL_4R64 CW30150 induced pluripotent stem cell human CVCL_4R64 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30150; true; Discontinued: FCDI; CW30150; probable. Male 21191146 CVCL_5364 Sez627 cancer cell line human CVCL_5364 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 21191147 CVCL_4R63 CW30147 induced pluripotent stem cell human CVCL_4R63 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30147; true; Discontinued: FCDI; CW30147; probable. Male 21191148 CVCL_5363 Se-Ax cancer cell line human CVCL_5363 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent Doubling time: ~3 days (PubMed=3498444) 21191149 CVCL_4R62 CW30144 induced pluripotent stem cell human CVCL_4R62 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30144; true; Discontinued: FCDI; CW30144; probable. Male 21191150 CVCL_5362 SCCKN cancer cell line human CVCL_5362 CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: 24.4 hours (PubMed=1373668) 21191151 CVCL_4R61 CW30142 induced pluripotent stem cell human CVCL_4R61 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30142; true Female 21191152 CVCL_5361 RMT-1 M2 cancer cell line Norway rat CVCL_5361 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female Doubling time: 24.4 hours (PubMed=2411993) 21191153 CVCL_4R57 CW30138 induced pluripotent stem cell human CVCL_4R57 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30138; true Male 21191154 CVCL_5357 RMC-2 cancer cell line Norway rat CVCL_5357 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191155 CVCL_4R56 CW30137 induced pluripotent stem cell human CVCL_4R56 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30137; true Female 21191156 CVCL_5356 RMC-17 cancer cell line Norway rat CVCL_5356 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191157 CVCL_4R55 CW30136 induced pluripotent stem cell human CVCL_4R55 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30136; true; Discontinued: FCDI; CW30136; probable. Male 21191158 CVCL_5355 RMC-11 cancer cell line Norway rat CVCL_5355 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191159 CVCL_4R54 CW30134 induced pluripotent stem cell human CVCL_4R54 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30134; true; Discontinued: FCDI; CW30134; probable. Male 21191160 CVCL_5354 RMC-1 cancer cell line Norway rat CVCL_5354 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191161 CVCL_4R59 CW30140 induced pluripotent stem cell human CVCL_4R59 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30140; true Female 21191162 CVCL_5359 RMC-6 cancer cell line Norway rat CVCL_5359 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191163 CVCL_4R58 CW30139 induced pluripotent stem cell human CVCL_4R58 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30139; true Female 21191164 CVCL_5358 RMC-3 cancer cell line Norway rat CVCL_5358 CL:0000010 Transfected with: HGNC; 5173; HRAS Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Jcl:SD-Tg(HRAS)128Ncc/Jcl (Hras128/Jcl) transgenic. Female 21191165 CVCL_WX98 HG1987 transformed cell line human CVCL_WX98 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Arg899Ter (c.2695C>T); ClinVar=VCV000127491; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asp1010Metfs*24 (c.3028delG); ClinVar=VCV000189048; Zygosity=Heterozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 30(MaKa) (BSR30); Derived from sampling site: Peripheral blood. Male 21191166 CVCL_X998 rHypoE-32 transformed cell line Norway rat CVCL_X998 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21191167 CVCL_WX97 HG1974 transformed cell line human CVCL_WX97 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Tyr736Leufs*5 (c.2207_2212delATCTGAinsTAGATTC) (2281del6ins7) (BLMAsh); ClinVar=VCV000005454; Zygosity=Homozygous (PubMed=17407155) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 121(NiRos) (BSR121); Derived from sampling site: Peripheral blood. Male 21191168 CVCL_X997 rHypoE-5 transformed cell line Norway rat CVCL_X997 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21191169 CVCL_WX96 HG1972 transformed cell line human CVCL_WX96 CL:0000010 Population: Jewish; Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 140(DrKas) (BSR140); Derived from sampling site: Peripheral blood. 21191170 CVCL_X996 rHypoE-4 transformed cell line Norway rat CVCL_X996 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21191171 CVCL_WX95 HG1929 finite cell line human CVCL_WX95 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Lys657Glufs*5 (c.1968dupG); ClinVar=VCV000495425; Zygosity=Homozygous (PubMed=17407155) Population: Caucasian; Donor information: From Bloom Syndrome Registry patient 17(ChSm) (BSR17); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191172 CVCL_X995 rHypoE-3 transformed cell line Norway rat CVCL_X995 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21191173 CVCL_WX99 HG2045 transformed cell line human CVCL_WX99 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ile770fs (c.2308-117_2555+7420del7811) (Ex11-12fdel); Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Arg899Ter (c.2695C>T); ClinVar=VCV000127491; Zygosity=Heterozygous (PubMed=17407155) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 111(JaKir) (BSR111); Derived from sampling site: Peripheral blood. Male 21191174 CVCL_X999 rHypoE-10 transformed cell line Norway rat CVCL_X999 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hypothalamus; Breed/subspecies: Sprague Dawley. Unspecified 21191175 CVCL_4R71 CW30184 induced pluripotent stem cell human CVCL_4R71 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30184; true Male 21191176 CVCL_5371 TBR31-1 conditionally immortalized cell line house mouse CVCL_5371 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21191177 CVCL_4R70 CW30177 induced pluripotent stem cell human CVCL_4R70 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30177; true Female 21191178 CVCL_5370 TAD-2 transformed cell line human CVCL_5370 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal thyroid gland. Omics: Mitochondrial genome sequenced Discontinued: ATCC; CRL-2855; true Female 21191179 CVCL_4R75 CW30188 induced pluripotent stem cell human CVCL_4R75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30188; true Female 21191180 CVCL_5375 TIGMEC-2 transformed cell line CVCL_5375 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.; Breed/subspecies: Saanen. Female 21191181 CVCL_4R74 CW30187 induced pluripotent stem cell human CVCL_4R74 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30187; true; Discontinued: FCDI; CW30187; probable. Female 21191182 CVCL_5374 TIGMEC-1 transformed cell line CVCL_5374 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.; Breed/subspecies: Saanen. Female 21191183 CVCL_4R73 CW30186 induced pluripotent stem cell human CVCL_4R73 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW30186; true; Discontinued: FCDI; CW30186; probable. Male 21191184 CVCL_5373 TCL-1 transformed cell line human CVCL_5373 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [ZipSV40-6](NCBI-Taxonomy; 1891767); Derived from sampling site: Trophoblast. Unspecified 21191185 CVCL_4R72 CW30185 induced pluripotent stem cell human CVCL_4R72 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30185; true Female 21191186 CVCL_5372 TBR59 conditionally immortalized cell line house mouse CVCL_5372 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 21191187 CVCL_4R68 CW30165 induced pluripotent stem cell human CVCL_4R68 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30165; true Female 21191188 CVCL_5368 SV40 MES 13 transformed cell line house mouse CVCL_5368 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Mesangial cell.; Breed/subspecies: C57BL/6J x SJL/J transgenic. Omics: Transcriptome analysis by microarray; Omics: SNP array analysis Unspecified Doubling time: 26 hours (ATCC=CRL-1927) 21191189 CVCL_4R67 CW30155 induced pluripotent stem cell human CVCL_4R67 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30155; true Female 21191190 CVCL_5367 SS-A3-1 cancer cell line Norway rat CVCL_5367 CL:0000010 Breed/subspecies: Fischer 344/DuCrj. Male 21191191 CVCL_4R66 CW30154 induced pluripotent stem cell human CVCL_4R66 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30154; true Female 21191192 CVCL_5366 SPY3-2 stromal cell line house mouse CVCL_5366 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C3H/He. Unspecified 21191193 CVCL_4R65 CW30152 induced pluripotent stem cell human CVCL_4R65 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30152; true Male 21191194 CVCL_5365 SLC cancer cell line Norway rat CVCL_5365 CL:0000010 Breed/subspecies: Donryu. Male 21191195 CVCL_4R69 CW30169 induced pluripotent stem cell human CVCL_4R69 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW30169; true Male 21191196 CVCL_5369 T-88 factor-dependent cell line house mouse CVCL_5369 CL:0000010 Derived from sampling site: Bone marrow Cell type=Pre-B cell.; Breed/subspecies: C3H/He. Female Characteristics: IL3 or IL5 dependent Caution: Not from strain DBA/2J as originally published but from strain C3H/He (DOI=10.4051/ibc.2010.2.4.0014) 21191197 CVCL_FF73 ND22954 transformed cell line human CVCL_FF73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191198 CVCL_FF72 ND22942 transformed cell line human CVCL_FF72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191199 CVCL_FF71 ND22927 transformed cell line human CVCL_FF71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191200 CVCL_FF70 ND22926 transformed cell line human CVCL_FF70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191201 CVCL_FF66 ND22868 transformed cell line human CVCL_FF66 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191202 CVCL_FF65 ND22856 transformed cell line human CVCL_FF65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191203 CVCL_FF64 ND22798 transformed cell line human CVCL_FF64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191204 CVCL_FF63 ND22797 transformed cell line human CVCL_FF63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191205 CVCL_FF69 ND22914 transformed cell line human CVCL_FF69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191206 CVCL_FF68 ND22892 transformed cell line human CVCL_FF68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191207 CVCL_FF67 ND22879 transformed cell line human CVCL_FF67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191208 CVCL_FF80 ND23014 transformed cell line human CVCL_FF80 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191209 CVCL_FF84 ND23022 transformed cell line human CVCL_FF84 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191210 CVCL_FF83 ND23020 transformed cell line human CVCL_FF83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191211 CVCL_FF82 ND23019 transformed cell line human CVCL_FF82 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191212 CVCL_FF81 ND23017 transformed cell line human CVCL_FF81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND23017; probable Male 21191213 CVCL_FF77 ND23011 transformed cell line human CVCL_FF77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191214 CVCL_FF76 ND23009 transformed cell line human CVCL_FF76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191215 CVCL_FF75 ND23002 transformed cell line human CVCL_FF75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191216 CVCL_FF74 ND22998 transformed cell line human CVCL_FF74 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191217 CVCL_FF79 ND23013 transformed cell line human CVCL_FF79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191218 CVCL_FF78 ND23012 transformed cell line human CVCL_FF78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191219 CVCL_FF51 ND16512 transformed cell line human CVCL_FF51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191220 CVCL_FF50 ND16028 transformed cell line human CVCL_FF50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191221 CVCL_FF49 ND15917 transformed cell line human CVCL_FF49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191222 CVCL_FF44 ND15520 transformed cell line human CVCL_FF44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191223 CVCL_FF43 ND15510 transformed cell line human CVCL_FF43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191224 CVCL_FF42 ND15406 transformed cell line human CVCL_FF42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191225 CVCL_FF41 ND15381 transformed cell line human CVCL_FF41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191226 CVCL_FF48 ND15809 transformed cell line human CVCL_FF48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191227 CVCL_FF47 ND15577 transformed cell line human CVCL_FF47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191228 CVCL_FF46 ND15570 transformed cell line human CVCL_FF46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191229 CVCL_FF45 ND15550 transformed cell line human CVCL_FF45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191230 CVCL_FF62 ND22793 transformed cell line human CVCL_FF62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191231 CVCL_FF61 ND22790 transformed cell line human CVCL_FF61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191232 CVCL_FF60 ND22789 transformed cell line human CVCL_FF60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191233 CVCL_FF55 ND20080 transformed cell line human CVCL_FF55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191234 CVCL_FF54 ND20043 transformed cell line human CVCL_FF54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191235 CVCL_FF53 ND19731 transformed cell line human CVCL_FF53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191236 CVCL_FF52 ND16555 transformed cell line human CVCL_FF52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191237 CVCL_FF59 ND22787 transformed cell line human CVCL_FF59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191238 CVCL_FF58 ND22786 transformed cell line human CVCL_FF58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191239 CVCL_FF57 ND22785 transformed cell line human CVCL_FF57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191240 CVCL_FF56 ND20288 transformed cell line human CVCL_FF56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191241 CVCL_FF29 ND13471 transformed cell line human CVCL_FF29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191242 CVCL_FF28 ND12503 transformed cell line human CVCL_FF28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191243 CVCL_FF27 ND12275 transformed cell line human CVCL_FF27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191244 CVCL_FF22 ND10669 transformed cell line human CVCL_FF22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191245 CVCL_FF21 ND09998 transformed cell line human CVCL_FF21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191246 CVCL_FF20 ND09966 transformed cell line human CVCL_FF20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191247 CVCL_FF26 ND12179 transformed cell line human CVCL_FF26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191248 CVCL_FF25 ND12144 transformed cell line human CVCL_FF25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191249 CVCL_FF24 ND12142 transformed cell line human CVCL_FF24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191250 CVCL_FF23 ND11910 transformed cell line human CVCL_FF23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191251 CVCL_FF40 ND15371 transformed cell line human CVCL_FF40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191252 CVCL_FF39 ND15369 transformed cell line human CVCL_FF39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191253 CVCL_FF38 ND15334 transformed cell line human CVCL_FF38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191254 CVCL_FF33 ND14754 transformed cell line human CVCL_FF33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191255 CVCL_FF32 ND14228 transformed cell line human CVCL_FF32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191256 CVCL_FF31 ND13779 transformed cell line human CVCL_FF31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191257 CVCL_FF30 ND13577 transformed cell line human CVCL_FF30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191258 CVCL_FF37 ND15296 transformed cell line human CVCL_FF37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191259 CVCL_FF36 ND15287 transformed cell line human CVCL_FF36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191260 CVCL_FF35 ND00546 transformed cell line human CVCL_FF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191261 CVCL_FF34 ND15028 transformed cell line human CVCL_FF34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191262 CVCL_FF08 ND04591 transformed cell line human CVCL_FF08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191263 CVCL_FF07 ND04527 transformed cell line human CVCL_FF07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191264 CVCL_FF06 ND04429 transformed cell line human CVCL_FF06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191265 CVCL_FF05 ND04098 transformed cell line human CVCL_FF05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191266 CVCL_FF09 ND04666 transformed cell line human CVCL_FF09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191267 CVCL_FF00 ND03651 transformed cell line human CVCL_FF00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191268 CVCL_FF04 ND04097 transformed cell line human CVCL_FF04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191269 CVCL_FF03 ND04086 transformed cell line human CVCL_FF03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191270 CVCL_FF02 ND04029 transformed cell line human CVCL_FF02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191271 CVCL_FF01 ND03691 transformed cell line human CVCL_FF01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191272 CVCL_FF19 ND09920 transformed cell line human CVCL_FF19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191273 CVCL_FF18 ND09731 transformed cell line human CVCL_FF18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191274 CVCL_FF17 ND08045 transformed cell line human CVCL_FF17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191275 CVCL_FF16 ND05619 transformed cell line human CVCL_FF16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191276 CVCL_FF11 ND04874 transformed cell line human CVCL_FF11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191277 CVCL_FF10 ND04684 transformed cell line human CVCL_FF10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191278 CVCL_FF15 ND05229 transformed cell line human CVCL_FF15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191279 CVCL_FF14 ND05228 transformed cell line human CVCL_FF14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191280 CVCL_FF13 ND05057 transformed cell line human CVCL_FF13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191281 CVCL_FF12 ND04928 transformed cell line human CVCL_FF12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191282 CVCL_WZ41 LA20207 hybridoma house mouse CVCL_WZ41 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human lung adenocarcinoma tumor antigen of 50-80 kDa Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10224 21191283 CVCL_WZ40 6B3 [Mouse hybridoma against human LGALS3BP] hybridoma house mouse CVCL_WZ40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08380; Human LGALS3BP. 21191284 CVCL_WZ45 KJON cancer cell line human CVCL_WZ45 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (PubMed=27311012); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Ter (c.702C>A); Zygosity=Hemizygous (PubMed=27311012) Derived from sampling site: Peripheral blood. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female Doubling time: ~72 hours (PubMed=27311012) 21191285 CVCL_WZ44 IH-1 cancer cell line human CVCL_WZ44 CL:0000010 Derived from sampling site: Pleural effusion. Characteristics: IL6 dependent 21191286 CVCL_WZ43 A23-16 hybridoma house mouse CVCL_WZ43 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human sulfated glycoprotein preferentially expressed by small cell lung cancer cells. 21191287 CVCL_WZ42 HLC-2 cancer cell line human CVCL_WZ42 CL:0000010 Population: Japanese. Male 21191288 CVCL_WZ49 BEAS-2B/CYP2A6 transformed cell line human CVCL_WZ49 CL:0000010 Transfected with: HGNC; 2610; CYP2A6; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male 21191289 CVCL_WZ48 BEAS-2B/CYP2A13 transformed cell line human CVCL_WZ48 CL:0000010 Transfected with: HGNC; 2608; CYP2A13; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2010127 21191290 CVCL_WZ47 VOLIN cancer cell line human CVCL_WZ47 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Val (c.388C>G); ClinVar=VCV000458543; Zygosity=Homozygous (PubMed=27311012) Derived from sampling site: Bone marrow. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Characteristics: Produces IgG lambda Doubling time: ~5 days (PubMed=27311012) 21191291 CVCL_WZ46 URVIN cancer cell line human CVCL_WZ46 CL:0000010 21191292 CVCL_WZ30 SMS-KCN11s cancer cell line human CVCL_WZ30 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (from parent cell line). Male Characteristics: Substrate-adherent type (S-type) (PubMed=2019470) 21191293 CVCL_WZ34 TCPH-MM05 cancer cell line human CVCL_WZ34 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Omics: Genome sequenced. Male 21191294 CVCL_WZ33 TCPH-MM02 cancer cell line human CVCL_WZ33 CL:0000010 Derived from sampling site: Pleural effusion. Omics: Genome sequenced Male 21191295 CVCL_WZ32 TCPH-MM01 cancer cell line human CVCL_WZ32 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Omics: Genome sequenced. Male 21191296 CVCL_WZ31 SMS-KCN5n cancer cell line human CVCL_WZ31 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (from parent cell line). Male Characteristics: Neuroblastic type (N-type) (PubMed=2019470) 21191297 CVCL_WZ38 TCPH-MM10 cancer cell line human CVCL_WZ38 CL:0000010 Omics: Genome sequenced. Male 21191298 CVCL_WZ37 TCPH-MM01-pleural cancer cell line human CVCL_WZ37 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Derived from sampling site: Pleural effusion. Omics: Genome sequenced Male 21191299 CVCL_WZ36 TCPH-MM08 cancer cell line human CVCL_WZ36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Omics: Genome sequenced. Male 21191300 CVCL_WZ35 TCPH-MM07 cancer cell line human CVCL_WZ35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31038674) Derived from sampling site: Pleural effusion. Omics: Genome sequenced Male 21191301 CVCL_WZ39 5G3 [Mouse hybridoma against human L1CAM] hybridoma house mouse CVCL_WZ39 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P32004; Human L1CAM/CD171. 21191302 CVCL_4T00 CW70082 induced pluripotent stem cell human CVCL_4T00 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70082; true; Discontinued: FCDI; CW70082; probable. Female 21191303 CVCL_5500 EGV-4T transformed cell line Norway rat CVCL_5500 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Trachea; Breed/subspecies: Fischer 344. Male Doubling time: ~37 hours (lot 03222005) (JCRB) 21191304 CVCL_4T04 CW70091 induced pluripotent stem cell human CVCL_4T04 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70091; true Male 21191305 CVCL_5504 FLS5 stromal cell line house mouse CVCL_5504 CL:0000010 Derived from sampling site: Embryonic liver; stroma; Breed/subspecies: C57BL/6J. Unspecified 21191306 CVCL_4T03 CW70089 induced pluripotent stem cell human CVCL_4T03 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70089; true Female 21191307 CVCL_5503 FLS3 stromal cell line house mouse CVCL_5503 CL:0000010 Derived from sampling site: Embryonic liver; stroma; Breed/subspecies: C57BL/6J. Unspecified 21191308 CVCL_4T02 CW70088 induced pluripotent stem cell human CVCL_4T02 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70088; true Female 21191309 CVCL_5502 FLS11 stromal cell line house mouse CVCL_5502 CL:0000010 Derived from sampling site: Embryonic liver; stroma; Breed/subspecies: C57BL/6J. Unspecified 21191310 CVCL_4T01 CW70087 induced pluripotent stem cell human CVCL_4T01 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70087; true Female 21191311 CVCL_5501 FRSK transformed cell line Norway rat CVCL_5501 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: Sprague Dawley. Unspecified 21191312 CVCL_4T08 CW70096 induced pluripotent stem cell human CVCL_4T08 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70096; true Female 21191313 CVCL_5508 GAKS spontaneously immortalized cell line CVCL_5508 CL:0000010 Derived from sampling site: Scale. Discontinued: RCB; RCB0082; probable; Discontinued: RCB; RCB1452; probable Unspecified Group: Fish cell line 21191314 CVCL_4T07 CW70095 induced pluripotent stem cell human CVCL_4T07 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70095; true; Discontinued: FCDI; CW70095; probable. Male 21191315 CVCL_5507 G3S1 cancer cell line human CVCL_5507 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Female 21191316 CVCL_4T06 CW70094 induced pluripotent stem cell human CVCL_4T06 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70094; true Male 21191317 CVCL_5506 G1B spontaneously immortalized cell line CVCL_5506 CL:0000010 Derived from sampling site: Gill. Unspecified Virology: Susceptible to infection by channel catfish virus (CelloPub=CLPUB00706; DOI=10.1139/f81-125) Group: Fish cell line 21191318 CVCL_4T05 CW70093 induced pluripotent stem cell human CVCL_4T05 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70093; true Male 21191319 CVCL_5505 G14D spontaneously immortalized cell line CVCL_5505 CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Group: Fish cell line 21191320 CVCL_4T09 CW70116 induced pluripotent stem cell human CVCL_4T09 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70116; true Female 21191321 CVCL_5509 GRSL cancer cell line house mouse CVCL_5509 CL:0000010 Breed/subspecies: GRS/A. 21191322 CVCL_WZ23 WAe009-A-23 embryonic stem cell human CVCL_WZ23 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Using CRISPR/Cas9 a T2A-mCherry-P2A-PGK-NeoR-P2A construct was integrated in front of the stop codon of PITX3 21191323 CVCL_WZ22 HF-1 [Paralichthys] spontaneously immortalized cell line CVCL_WZ22 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21191324 CVCL_WZ21 HEK293 ABCA4-WT transformed cell line human CVCL_WZ21 CL:0000010 Transfected with: HGNC; 34; ABCA4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21191325 CVCL_WZ20 HEK293 ABCA4-R1129C transformed cell line human CVCL_WZ20 CL:0000010 Transfected with: HGNC; 34; ABCA4 (with p.Arg1129Cys); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21191326 CVCL_WZ27 VCaP-SL cancer cell line human CVCL_WZ27 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone; vertebra. Omics: Transcriptome analysis by microarray Male Characteristics: Reprogrammed to, maintained and propagated as cancer stem-like cells (CSCs) by growth in androgen-free neural/neural crest (N/NC) stem medium; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21191327 CVCL_WZ26 LAPC4-SL cancer cell line human CVCL_WZ26 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Reprogrammed to, maintained and propagated as cancer stem-like cells (CSCs) by growth in androgen-free neural/neural crest (N/NC) stem medium; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 21191328 CVCL_WZ25 LNCaP-SL cancer cell line human CVCL_WZ25 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Reprogrammed to, maintained and propagated as cancer stem-like cells (CSCs) by growth in androgen-free neural/neural crest (N/NC) stem medium 21191329 CVCL_WZ24 GENYOi005-A induced pluripotent stem cell human CVCL_WZ24 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Sequence variation: Mutation; HGNC; 10471; RUNX1; Simple; p.Thr196Ala (c.586A>G); ClinVar=VCV000988811; Zygosity=Heterozygous (PubMed=31698193) Population: Caucasian; Spanish; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21191330 CVCL_WZ29 XACHi001-A induced pluripotent stem cell human CVCL_WZ29 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Ala1855Asp (c.5564C>A); Zygosity=Heterozygous (PubMed=31382203); Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Gln1362His (c.4086G>T); Zygosity=Heterozygous (PubMed=31382203) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21191331 CVCL_WZ28 22Rv1-SL cancer cell line human CVCL_WZ28 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Prostate. Omics: Transcriptome analysis by microarray Male Characteristics: Reprogrammed to, maintained and propagated as cancer stem-like cells (CSCs) by growth in androgen-free neural/neural crest (N/NC) stem medium 21191332 CVCL_WZ12 8732 cancer cell line human CVCL_WZ12 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr253del (c.757_759delACC); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191333 CVCL_WZ11 8724 cancer cell line human CVCL_WZ11 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Thr3013Ile (c.9038C>T); ClinVar=VCV000038205; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191334 CVCL_WZ10 8716 cancer cell line human CVCL_WZ10 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191335 CVCL_WZ16 18605 cancer cell line human CVCL_WZ16 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu188Trpfs*3 (c.560_672del); Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191336 CVCL_WZ15 18507 cancer cell line human CVCL_WZ15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser185Metfs*68 (c.535_551dup17); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191337 CVCL_WZ14 18483 cancer cell line human CVCL_WZ14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191338 CVCL_WZ13 17978 cancer cell line human CVCL_WZ13 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191339 CVCL_WZ19 HEK293 ABCA4-R1108C transformed cell line human CVCL_WZ19 CL:0000010 Transfected with: HGNC; 34; ABCA4 (with p.Arg1108Cys); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21191340 CVCL_WZ18 CF8Flp transformed cell line human CVCL_WZ18 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Unspecified Characteristics: Contains a single recombination Flp-in target site for the stable integration and expression of a single cDNA, mini-gene, or complete gene; Characteristics: Transfected with the pFRT/lacZeo plasmid A single Flp recombination target (FRT) was integrated into chromosome 8. 21191341 CVCL_WZ17 HL-60 DeltaF508-CF cancer cell line human CVCL_WZ17 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_edited; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=30670178); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21191342 CVCL_WZ01 17249 cancer cell line human CVCL_WZ01 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Phe (c.583A>T); ClinVar=VCV000376617; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191343 CVCL_WZ00 17142 cancer cell line human CVCL_WZ00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Phe (c.583A>T); ClinVar=VCV000376617; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Pleural effusion. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191344 CVCL_WZ05 8714 cancer cell line human CVCL_WZ05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191345 CVCL_WZ04 8713 cancer cell line human CVCL_WZ04 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Gln1138Leu (c.3413A>T); ClinVar=VCV000051458; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191346 CVCL_WZ03 17399 cancer cell line human CVCL_WZ03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glufs*18 (c.834_853del20); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191347 CVCL_WZ02 17330 cancer cell line human CVCL_WZ02 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly226Serfs*21 (c.673-1_698del27ins48); Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling and TP53 mutation cDNA coordinates from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191348 CVCL_WZ09 8715 cancer cell line human CVCL_WZ09 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from sampling site: Ovary. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191349 CVCL_WZ08 17480 cancer cell line human CVCL_WZ08 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys3326Ter (c.9976A>T) (10204A>T); ClinVar=VCV000038266; Zygosity=Unspecified (PubMed=31150822); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191350 CVCL_WZ07 EK_R1 cancer cell line human CVCL_WZ07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Pleural effusion. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191351 CVCL_WZ06 17457 cancer cell line human CVCL_WZ06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Tyr (c.824G>A); ClinVar=VCV000215997; Zygosity=Unspecified (PubMed=31150822) Miscellaneous: Age at sampling from personal communication of Cacsire Castillo-Tong D Derived from metastatic site: Ascites. Omics: Genome sequenced (low read coverage); Omics: Transcriptome analysis by RNAseq Female 21191352 CVCL_4T80 HMC-1 5C6 cancer cell line human CVCL_4T80 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560Gly (c.1679T>G); ClinVar=VCV000375916; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Peripheral blood Cell type=Mast cell.. Male 21191353 CVCL_5580 RFGd3WE finite cell line CVCL_5580 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6183; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191354 CVCL_4T84 HET1AR transformed cell line human CVCL_4T84 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:3098; Bile acids; Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Esophagus Cell type=Epithelial cell.. Male Doubling time: 27.6 +- 4.6 hours (PubMed=21127259) 21191355 CVCL_5584 RSMG-1 spontaneously immortalized cell line Norway rat CVCL_5584 CL:0000010 Derived from sampling site: Salivary gland; submandibular gland; epithelium; Breed/subspecies: Wistar. Female Doubling time: ~35 hours (PubMed=10476908) 21191356 CVCL_4T83 HET-2A transformed cell line human CVCL_4T83 CL:0000010 Karyotypic information: Hypotriploid karyotype (PubMed=1703038); Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767). Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10210 Problematic cell line: Probably contaminated Shown not to be originating from the normal human esophageal cell HE-451 as previously thought and to be of a female origin (PubMed=1703038). 21191357 CVCL_5583 RL-34 spontaneously immortalized cell line Norway rat CVCL_5583 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Unexplicit; TC->GA in 3'splicing signal of intron 4; Zygosity=Unspecified (DOI=10.11418/jtca1981.15.2_141) Derived from sampling site: Liver; Breed/subspecies: Wistar. Male Doubling time: ~1 day (lot 03022017) (JCRB) 21191358 CVCL_4T82 EMT-6-1.1(2) cancer cell line house mouse CVCL_4T82 CL:0000010 Transfected with: UniProtKB; P27967; Barley nitrate reductase Breed/subspecies: BALB/cCRGL. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12185 21191359 CVCL_5582 RFGd5WE finite cell line CVCL_5582 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6185; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191360 CVCL_4T81 EMT-6-1.1(1) cancer cell line house mouse CVCL_4T81 CL:0000010 Transfected with: UniProtKB; P27967; Barley nitrate reductase Breed/subspecies: BALB/cCRGL. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12184 21191361 CVCL_5581 RFGd4WE finite cell line CVCL_5581 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6184; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191362 CVCL_4T77 8H7 [Human hybridoma against P.aeruginosa LPS] transformed cell line human CVCL_4T77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9258 21191363 CVCL_5577 RFGd11WE finite cell line CVCL_5577 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6191; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191364 CVCL_4T76 6D6 transformed cell line human CVCL_4T76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 2 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9171 21191365 CVCL_5576 RFGd10WE finite cell line CVCL_5576 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6190; probable Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191366 CVCL_4T75 1C1 [Human LCL] transformed cell line human CVCL_4T75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotypes 3 and 7 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8941 21191367 CVCL_5575 RCN-H-4 cancer cell line Norway rat CVCL_5575 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Derived from sampling site: Colon; Breed/subspecies: Fischer 344. Male 21191368 CVCL_4T74 GM24415 transformed cell line human CVCL_4T74 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; p.Gly311Asp (c.932G>A); ClinVar=VCV000289651; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191369 CVCL_5574 PC-12TG cancer cell line Norway rat CVCL_5574 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Male 21191370 CVCL_4T79 HCN-1 finite cell line human CVCL_4T79 CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.. Female Doubling time: ~72 hours (PubMed=7700510) 21191371 CVCL_5579 RFGd2WE finite cell line CVCL_5579 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6182; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191372 CVCL_4T78 H69PR cancer cell line human CVCL_4T78 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly106_Arg108del (c.317_325delGGCAACCGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu748Ter (c.2242G>T); ClinVar=VCV000013078; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11350 21191373 CVCL_5578 RFGd12WE finite cell line CVCL_5578 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: ATCC; CRL-6192; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191374 CVCL_4T91 iPS-DF6-9-12T induced pluripotent stem cell human CVCL_4T91 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21191375 CVCL_5591 SUM185PE cancer cell line human CVCL_5591 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln144Ter (c.430C>T); ClinVar=VCV000634688; Zygosity=Unspecified (PubMed=16541312) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 92.43 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel 21191376 CVCL_4T90 iPS-DF6-9 induced pluripotent stem cell human CVCL_4T90 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: H3K4me3 ChIP-seq epigenome analysis Male 21191377 CVCL_4T95 A2780-DX1 cancer cell line human CVCL_4T95 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Ovary. Female 21191378 CVCL_5595 T-23 finite cell line CVCL_5595 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male Doubling time: 18-19 hours (PubMed=3331674) 21191379 CVCL_4T94 MES-SA/DxP5002 cancer cell line human CVCL_4T94 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Uterus. Female 21191380 CVCL_5594 SUM229PE cancer cell line human CVCL_5594 HLA typing: A*02:01,11:01; B*40:02,44:02; C*02:02,03:04; DQB1*05:01,05:01; DRB1*01:01,15:01 (PubMed=25960936); HLA typing: A*68:01,68:01; B*53:02,78:01; C*06:02,16:01 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (PubMed=19593635; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=16541312; DepMap) Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Glycoproteome analysis by proteomics; Omics: miRNA expression profiling; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 42.27 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00548 Problematic cell line: Partially misidentified For a period of time Asterand (now BioIVT) mistakenly distributed SUM149PT (Cellosaurus=CVCL_3422) under the designation of SUM229PE. This leads to the publication of a STR profile (PubMed=25877200) which was almost identical to that of SUM149PT. 21191381 CVCL_4T93 MES-SA/Dx1 cancer cell line human CVCL_4T93 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly1610Trpfs*38 (c.4826dupC) (p.S1609fs) (c.4825_4826insC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Thr1690Asnfs*8 (c.5068dupA) (c.5067_5068insA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His272Thrfs*4 (c.813delT) (p.Phe271fs) (c.811delT); ClinVar=VCV000428208; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Uterus. Female 21191382 CVCL_5593 SUM225CWN cancer cell line human CVCL_5593 HLA typing: A*01:01,02:01; B*08:01,39:01; C*07:01,12:03; DQB1*05:01,05:01; DRB1*16:05,16:05 (PubMed=25960936) CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu265Pro (c.794T>C); ClinVar=VCV000245777; Zygosity=Unspecified (PubMed=16541312) Derived from metastatic site: Chest wall. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Doubling time: 73.20 hours (GrayJW panel) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: MD Anderson Cell Lines Project 21191383 CVCL_4T92 iPS-DF19-9 induced pluripotent stem cell human CVCL_4T92 From: University of Wisconsin; Madison; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21191384 CVCL_5592 SUM206CWN finite cell line human CVCL_5592 CL:0000010 Miscellaneous: Cell line not distributed (from personal communication of Ethier S.) Derived from metastatic site: Chest wall. Omics: Array-based CGH Female Senescence: Has a finite life span Senesces at about 20 PDL (from personal communication of Ethier S.). 21191385 CVCL_4T88 Patas-BARF1 transformed cell line CVCL_4T88 CL:0000010 Transfected with: UniProtKB; P03228; Epstein-Barr virus (strain B95-8) BARF1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Epstein-Barr virus (EBV) [BARF1](NCBI-Taxonomy; 10376); Derived from sampling site: Kidney Cell type=Epithelial cell.. Unspecified Group: Non-human primate cell line 21191386 CVCL_5588 Sm-MT cancer cell line CVCL_5588 CL:0000010 Derived from sampling site: Mammary gland. Female 21191387 CVCL_4T87 K562/DNR cancer cell line human CVCL_4T87 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Pleural effusion. Female 21191388 CVCL_5587 SL-29 finite cell line CVCL_5587 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: White Leghorn SPAFAS. Discontinued: BCRJ; 0367; probable Unspecified Senescence: Can undergo 35 PDL (ATCC=CRL-1590) Group: Bird cell line 21191389 CVCL_4T86 Ker-CT-Ras telomerase immortalized cell line human CVCL_4T86 CL:0000010 Transfected with: HGNC; 5173; HRAS; Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88357; Cdk4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 21191390 CVCL_5586 SEP2 finite cell line CVCL_5586 CL:0000010 Derived from sampling site: Whole embryo. Discontinued: RCB; RCB0269; probable Unspecified 21191391 CVCL_5585 S68 cancer cell line human CVCL_5585 From: Catros V.; Cell Biology Department, CHU Rennes; Rennes; France. CL:0000010 Female 21191392 CVCL_4T85 SV-HFO transformed cell line human CVCL_4T85 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal bone Cell type=Osteoblast.. Female 21191393 CVCL_5589 SUM1315MO2 cancer cell line human CVCL_5589 HLA typing: A*31:01,32:01; B*39:01,40:01; C*03:04,12:03; DQA1*01:02,05:02; DQB1*03:02,06:04; DRB1*15:01,04 (PubMed=25960936); HLA typing: A*31:01,32:01; B*39:01,40:01; C*03:04,12:03 (PubMed=26589293) CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=19593635); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Hemizygous (PubMed=16397213; PubMed=19593635; PubMed=22032724); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (PubMed=16541312) Derived from metastatic site: Skin. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: DNA methylation analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from tumor tissue after two passages in nude mice; Characteristics: EGF dependent Doubling time: 94.59 hours (GrayJW panel) Group: Triple negative breast cancer (TNBC) cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: GrayJW breast cancer cell line panel; Part of: KuDOS 95 cell line panel 21191394 CVCL_4T89 U-715-M cancer cell line human CVCL_4T89 CL:0000010 Derived from sampling site: Lymph node. Female Doubling time: 125-130 hours (PubMed=4136723) 21191395 CVCL_4T62 GM24236 transformed cell line human CVCL_4T62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191396 CVCL_5562 MSS57 stromal cell line house mouse CVCL_5562 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Unspecified 21191397 CVCL_4T61 GM24232 transformed cell line human CVCL_4T61 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; c.856-3C>G (IVS6-3C>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Lys796Ter (c.2386A>T); Zygosity=Heterozygous (Coriell) Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191398 CVCL_5561 MSS31 stromal cell line house mouse CVCL_5561 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Unspecified 21191399 CVCL_4T60 GM24231 transformed cell line human CVCL_4T60 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; c.1770+1delG; ClinVar=VCV000289581; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Arg784His (c.2351G>A); ClinVar=VCV000093938; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191400 CVCL_5560 MSS16 stromal cell line house mouse CVCL_5560 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Unspecified 21191401 CVCL_4T55 GM24220 transformed cell line human CVCL_4T55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191402 CVCL_5555 MCF-10AT transformed cell line human CVCL_5555 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: CNV analysis; Omics: Glycoproteome analysis by proteomics Female 21191403 CVCL_4T54 GM23892 finite cell line human CVCL_4T54 CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Male 21191404 CVCL_5554 MCF-10A-neoT transformed cell line human CVCL_5554 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Female 21191405 CVCL_4T53 GM23782 transformed cell line human CVCL_4T53 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Gly319_Lys333del (c.955-2A>G); ClinVar=VCV000520800; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; British/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191406 CVCL_5553 MCF-10-2F spontaneously immortalized cell line human CVCL_5553 CL:0000010 Derived from sampling site: Breast; epithelium. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10780 21191407 CVCL_4T52 GM23778 finite cell line human CVCL_4T52 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; c.1053+1G>T (IVS11+1G>T); Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM23778; probable Male 21191408 CVCL_5552 MCF10DCIS.com transformed cell line human CVCL_5552 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=23401782); Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Breast; epithelium. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Female Characteristics: Derived from a xenograft originating from MCF-10AT cells that were injected into severe combined immune-deficient mice Doubling time: 20.5 hours (PubMed=34238275) 21191409 CVCL_4T59 GM24224 finite cell line human CVCL_4T59 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Arg784His (c.2351G>A); ClinVar=VCV000093938; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; c.1770+1delG; ClinVar=VCV000289581; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM24224; probable Male 21191410 CVCL_5559 MS-653-G cancer cell line Norway rat CVCL_5559 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Donryu. Characteristics: Less tumorigenic than parent cell line 21191411 CVCL_4T58 GM24223 finite cell line human CVCL_4T58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191412 CVCL_5558 MS-653-A cancer cell line Norway rat CVCL_5558 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Donryu. Characteristics: Highly tumorigenic 21191413 CVCL_4T57 GM24222 transformed cell line human CVCL_4T57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191414 CVCL_5557 Mm1 cancer cell line house mouse CVCL_5557 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: SL. 21191415 CVCL_4T56 GM24221 transformed cell line human CVCL_4T56 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; p.Gly293Arg (c.877G>A); ClinVar=VCV000093895; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191416 CVCL_5556 MG5 spontaneously immortalized cell line house mouse CVCL_5556 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Brain Cell type=Microglial cell.. Unspecified Doubling time: ~3 days (lots 12222008 and 02122009), ~82 hours (lot 02232011), 20-84 hours (lot 07172017) (JCRB) 21191417 CVCL_WZ96 4E1 hybridoma house mouse CVCL_WZ96 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191418 CVCL_WZ95 4D3 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ95 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191419 CVCL_WZ94 4D2 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ94 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191420 CVCL_WZ93 3H8H6B1D1 hybridoma house mouse CVCL_WZ93 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191421 CVCL_WZ99 B4B5C5 hybridoma house mouse CVCL_WZ99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O14602; Human EIF1AY. 21191422 CVCL_WZ98 4G11 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191423 CVCL_WZ97 4G10 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ97 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191424 CVCL_4T73 GM24405 finite cell line human CVCL_4T73 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.957+1G>A; ClinVar=VCV000290695; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191425 CVCL_5573 PC12.P3 cancer cell line Norway rat CVCL_5573 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: NEDH. Discontinued: JCRB; NIHS0197; true; Discontinued: JCRB; NIHS0373; true Male Group: Serum/protein free medium cell line 21191426 CVCL_4T72 GM24391 transformed cell line human CVCL_4T72 CL:0000010 Sequence variation: Mutation; HGNC; 2213; COL6A3; Simple; p.Gln1682Serfs*12 (c.5044delC); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2213; COL6A3; Simple; p.Gly2356Ter (c.7066G>T); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191427 CVCL_5572 OTT6050 cancer cell line house mouse CVCL_5572 CL:0000010 Breed/subspecies: 129/Sv. Male 21191428 CVCL_4T71 GM24384 finite cell line human CVCL_4T71 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; p.Gly284Arg (c.850G>A); ClinVar=VCV000017180; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.1182+3G>A; ClinVar=VCV000162526; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.1814-6C>G; ClinVar=VCV000093830; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191429 CVCL_5571 OPCT-3 transformed cell line human CVCL_5571 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 1.9 +- 0.3 days (CelloPub=CLPUB00396) 21191430 CVCL_4T70 GM24259 finite cell line human CVCL_4T70 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.1002+1G>A; ClinVar=VCV000287971; Zygosity=Unspecified; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191431 CVCL_5570 OPCT-2 transformed cell line human CVCL_5570 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 1.8 +- 0.2 days (CelloPub=CLPUB00396) 21191432 CVCL_4T66 GM24240 transformed cell line human CVCL_4T66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191433 CVCL_5566 OPCN-1 transformed cell line human CVCL_5566 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 2.7 +- 0.5 days (CelloPub=CLPUB00396) 21191434 CVCL_4T65 GM24239 transformed cell line human CVCL_4T65 CL:0000010 Sequence variation: Mutation; HGNC; 2213; COL6A3; Simple; c.6310-2A>G; ClinVar=VCV000571080; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191435 CVCL_5565 NRG somatic stem cell house mouse CVCL_5565 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C3H/He. Female 21191436 CVCL_4T64 GM24238 transformed cell line human CVCL_4T64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191437 CVCL_5564 MSS72 stromal cell line house mouse CVCL_5564 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Unspecified 21191438 CVCL_4T63 GM24237 transformed cell line human CVCL_4T63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191439 CVCL_5563 MSS62 stromal cell line house mouse CVCL_5563 CL:0000010 Derived from sampling site: Spleen Cell type=Stromal cell.; Breed/subspecies: C57BL/6J. Unspecified 21191440 CVCL_4T69 GM24252 transformed cell line human CVCL_4T69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191441 CVCL_5569 OPCT-1 transformed cell line human CVCL_5569 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.1 +- 0.02 days (CelloPub=CLPUB00396) 21191442 CVCL_4T68 GM24251 transformed cell line human CVCL_4T68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191443 CVCL_5568 OPCN-3 transformed cell line human CVCL_5568 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Discontinued: BioIVT/Asterand Bioscience; Catalog number OPCN-3 Male Doubling time: 2.5 +- 0.5 days (CelloPub=CLPUB00396) 21191444 CVCL_4T67 GM24250 transformed cell line human CVCL_4T67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191445 CVCL_5567 OPCN-2 transformed cell line human CVCL_5567 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male Doubling time: 2.9 +- 0.5 days (CelloPub=CLPUB00396) 21191446 CVCL_WZ85 2E8E9E10F2 hybridoma house mouse CVCL_WZ85 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191447 CVCL_WZ84 2C8G10D6F9 hybridoma house mouse CVCL_WZ84 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191448 CVCL_WZ83 2B2F1E6G3 hybridoma house mouse CVCL_WZ83 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191449 CVCL_WZ82 2A3 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ82 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191450 CVCL_WZ89 3B10 hybridoma house mouse CVCL_WZ89 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191451 CVCL_WZ88 2H7 hybridoma house mouse CVCL_WZ88 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191452 CVCL_WZ87 2G9B9H6A2 hybridoma house mouse CVCL_WZ87 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191453 CVCL_WZ86 2F1 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ86 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191454 CVCL_5540 IOSE-364 transformed cell line human CVCL_5540 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21191455 CVCL_4T40 XP165MA finite cell line human CVCL_4T40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21191456 CVCL_4T33 ID00036 transformed cell line human CVCL_4T33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21191457 CVCL_5533 IOSE-144 transformed cell line human CVCL_5533 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 28 hours (PubMed=10329039) 21191458 CVCL_4T32 ID00018 transformed cell line human CVCL_4T32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21191459 CVCL_5532 IOSE-10 transformed cell line human CVCL_5532 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191460 CVCL_4T31 GM20722 transformed cell line human CVCL_4T31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191461 CVCL_5531 INER-51 cancer cell line human CVCL_5531 CL:0000010 Derived from metastatic site: Pleural effusion. Doubling time: 51 hours (PubMed=26221079) 21191462 CVCL_4T30 GM07280 finite cell line human CVCL_4T30 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21191463 CVCL_5530 I51T transformed cell line house mouse CVCL_5530 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88151; Glb1; Transfected with: HGNC; 4298; GLB1 (with p.Ile51Thr); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x CBA. Problematic cell line: Contaminated/misidentified Not from strain C57BL/6 as originally assigned but from a C57BL/6 x CBA cross (PubMed=27844419). 21191464 CVCL_4T37 ID00058 transformed cell line human CVCL_4T37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21191465 CVCL_5537 IOSE-29EC/T4 transformed cell line human CVCL_5537 CL:0000010 Transfected with: MGI; MGI:88354; Cdh1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191466 CVCL_4T36 ID00057 transformed cell line human CVCL_4T36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: US Immunodeficiency Network (USIDNET) cell repository 21191467 CVCL_5536 IOSE-29EC transformed cell line human CVCL_5536 CL:0000010 Transfected with: MGI; MGI:88354; Cdh1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female 21191468 CVCL_4T35 ID00038 transformed cell line human CVCL_4T35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21191469 CVCL_5535 IOSE-29 transformed cell line human CVCL_5535 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Female Doubling time: 33.7 hours (PubMed=10329039) 21191470 CVCL_4T34 ID00037 transformed cell line human CVCL_4T34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: US Immunodeficiency Network (USIDNET) cell repository 21191471 CVCL_5534 IOSE-144RZ transformed cell line human CVCL_5534 CL:0000010 Transfected with: HGNC; 13009; ZNF217; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Characteristics: Transfected with HA-tagged ZNF217 21191472 CVCL_4T39 48BR finite cell line human CVCL_4T39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Doubling time: 45.5 hours (PubMed=6459055) 21191473 CVCL_5539 IOSE-2Ap2 transformed cell line human CVCL_5539 From: Katabuchi H.; Kumamoto University School of Medicine; Kumamoto; Japan CL:0000010 Transformant: Unknown; Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191474 CVCL_4T38 47BR finite cell line human CVCL_4T38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191475 CVCL_5538 IOSE-29EC/T5 transformed cell line human CVCL_5538 CL:0000010 Transfected with: MGI; MGI:88354; Cdh1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191476 CVCL_WZ92 3H11G12C8D6 hybridoma house mouse CVCL_WZ92 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191477 CVCL_WZ91 3E11F1D8F9 hybridoma house mouse CVCL_WZ91 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191478 CVCL_WZ90 3D2 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ90 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191479 CVCL_WZ74 1C9H6F2C1 hybridoma house mouse CVCL_WZ74 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191480 CVCL_WZ73 H2H5 hybridoma house mouse CVCL_WZ73 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16793; Mercury(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200948 21191481 CVCL_WZ72 H1H8 hybridoma house mouse CVCL_WZ72 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:16793; Mercury(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200949 21191482 CVCL_WZ71 MRK-nu-2 cancer cell line human CVCL_WZ71 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Characteristics: Established from the ascitic cells from BALB/c nu/nu mice injected intraperitoneal with the parent tumoral cells 21191483 CVCL_WZ78 1H6 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ78 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191484 CVCL_WZ77 1F8G5D6D2 hybridoma house mouse CVCL_WZ77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191485 CVCL_WZ76 1F3 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ76 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191486 CVCL_WZ75 1D5H12F1A7 hybridoma house mouse CVCL_WZ75 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191487 CVCL_WZ79 1H7G10D10F7 hybridoma house mouse CVCL_WZ79 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191488 CVCL_4T51 GM23735 transformed cell line human CVCL_4T51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191489 CVCL_5551 M.P3 transformed cell line Norway rat CVCL_5551 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Discontinued: JCRB; NIHS0228.1; true; Discontinued: JCRB; NIHS0356; true Unspecified Group: Serum/protein free medium cell line 21191490 CVCL_4T50 GM23728 transformed cell line human CVCL_4T50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191491 CVCL_5550 M [Rat] transformed cell line Norway rat CVCL_5550 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Discontinued: JCRB; NIHS0228; true Unspecified 21191492 CVCL_4T44 GM23306 transformed cell line human CVCL_4T44 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191493 CVCL_5544 IOSE-592F transformed cell line human CVCL_5544 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Val1234fs (c.3695_3699GTAAA[1]) (3819del5) (3819_3823delGTAAA); ClinVar=VCV000037542; Zygosity=Unspecified (PubMed=22685544) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191494 CVCL_4T43 GM23305 transformed cell line human CVCL_4T43 CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191495 CVCL_5543 IOSE-4p2 transformed cell line human CVCL_5543 From: Katabuchi H.; Kumamoto University School of Medicine; Kumamoto; Japan CL:0000010 Transformant: Unknown; Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191496 CVCL_5542 IOSE-398 transformed cell line human CVCL_5542 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 21191497 CVCL_4T42 XP40GO finite cell line human CVCL_4T42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21191498 CVCL_5541 IOSE-397 transformed cell line human CVCL_5541 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Transcriptome analysis by microarray Female 21191499 CVCL_4T41 XP72MA finite cell line human CVCL_4T41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21191500 CVCL_4T48 GM23666 transformed cell line human CVCL_4T48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191501 CVCL_5548 IOSE-80RZ transformed cell line human CVCL_5548 CL:0000010 Transfected with: HGNC; 13009; ZNF217 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191502 CVCL_4T47 GM23330 finite cell line human CVCL_4T47 CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.1823-8G>A; ClinVar=VCV000093837; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191503 CVCL_5547 IOSE-80PC transformed cell line human CVCL_5547 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191504 CVCL_4T46 GM23308 finite cell line human CVCL_4T46 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; c.856-3C>G (IVS6-3C>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Lys796Ter (c.2386A>T); Zygosity=Heterozygous (Coriell) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191505 CVCL_5546 IOSE-80 transformed cell line human CVCL_5546 From: Canadian Ovarian Tissue Bank, University of British Columbia; Vancouver; Canada CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female Doubling time: 26.2 hours (PubMed=10329039) 21191506 CVCL_4T45 GM23307 finite cell line human CVCL_4T45 CL:0000010 Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191507 CVCL_5545 IOSE-7 transformed cell line human CVCL_5545 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 21191508 CVCL_4T49 GM23681 transformed cell line human CVCL_4T49 CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Gly301Ser (c.901G>A); ClinVar=VCV000283758; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Pro518Ser (c.1552C>T); ClinVar=VCV000093911; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191509 CVCL_5549 KT-5 cancer cell line house mouse CVCL_5549 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: C3H/He. Doubling time: 17 hours (CelloPub=CLPUB00482); ~7 days (lot 03242005) (JCRB) 21191510 CVCL_WZ81 2A1H1D1D4 hybridoma house mouse CVCL_WZ81 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191511 CVCL_WZ80 1H8 [Mouse hybridoma against human unknown protein] hybridoma house mouse CVCL_WZ80 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Unknown human protein. 21191512 CVCL_WZ63 8H3 [Mouse hybridoma against hepatitis E virus] hybridoma house mouse CVCL_WZ63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 capsid protein (ORF2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200117 21191513 CVCL_WZ62 8C11 hybridoma house mouse CVCL_WZ62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 capsid protein (ORF2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200116 21191514 CVCL_WZ61 SSC-S2 finite cell line pig CVCL_WZ61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Wuzhishan miniature pig. Male Group: Endangered species/breed cell line 21191515 CVCL_WZ60 Caki-1-Cas9-593 cancer cell line human CVCL_WZ60 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Leu98Pro (c.293T>C); ClinVar=VCV001502192; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Skin. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21191516 CVCL_WZ67 23M-D9 hybridoma house mouse CVCL_WZ67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01160; Human NPPA. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 85031402 21191517 CVCL_WZ66 11A-A11 hybridoma house mouse CVCL_WZ66 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01161; Rat Nppa. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 85031401 21191518 CVCL_WZ65 16D17 hybridoma house mouse CVCL_WZ65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 capsid protein (ORF2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200115 21191519 CVCL_WZ64 13D8 hybridoma house mouse CVCL_WZ64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 capsid protein (ORF2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200114 21191520 CVCL_WZ69 UTP-L2 cancer cell line human CVCL_WZ69 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=7647001; PubMed=8139288). Population: Japanese Unspecified Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526) 21191521 CVCL_WZ68 2D8F9H12 hybridoma house mouse CVCL_WZ68 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02462; Human COL4A1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201057 21191522 CVCL_4T11 CW70122 induced pluripotent stem cell human CVCL_4T11 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70122; true Female 21191523 CVCL_5511 H-111-TC cancer cell line human CVCL_5511 CL:0000010 Derived from sampling site: Stomach. Characteristics: Established from a nude mouse xenograft 21191524 CVCL_4T10 CW70117 induced pluripotent stem cell human CVCL_4T10 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70117; true Female 21191525 CVCL_5510 GP8 [Mouse] transformed cell line house mouse CVCL_5510 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88151; Glb1; Transfected with: HGNC; 4298; GLB1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; Breed/subspecies: C57BL/6 x CBA. Problematic cell line: Contaminated/misidentified Not from strain C57BL/6 as originally assigned but from a C57BL/6 x CBA cross (PubMed=27844419). 21191526 CVCL_4T15 CW70128 induced pluripotent stem cell human CVCL_4T15 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70128; true Male 21191527 CVCL_5515 WSU-HN4 cancer cell line human CVCL_5515 CL:0000010 Female 21191528 CVCL_4T14 CW70127 induced pluripotent stem cell human CVCL_4T14 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70127; true Male 21191529 CVCL_5514 HFSKF-AE-VII finite cell line human CVCL_5514 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191530 CVCL_4T13 CW70125 induced pluripotent stem cell human CVCL_4T13 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70125; true Male 21191531 CVCL_5513 HFSKF-AE-V finite cell line human CVCL_5513 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 30 PDL (PubMed=17395773) 21191532 CVCL_4T12 CW70123 induced pluripotent stem cell human CVCL_4T12 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70123; true Female 21191533 CVCL_5512 HFLI-AE-VII finite cell line human CVCL_5512 CL:0000010 Population: Japanese; Derived from sampling site: Fetal liver Cell type=Fibroblast.. Female 21191534 CVCL_4T19 CW70135 induced pluripotent stem cell human CVCL_4T19 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70135; true Male 21191535 CVCL_5519 WSU-HN13 cancer cell line human CVCL_5519 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (PubMed=25275298) Omics: Deep exome analysis. Female Part of: OPC-22 oral and pharyngeal cancer cell line panel 21191536 CVCL_4T18 CW70134 induced pluripotent stem cell human CVCL_4T18 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70134; true Male 21191537 CVCL_5518 WSU-HN12 cancer cell line human CVCL_5518 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis Female Part of: OPC-22 oral and pharyngeal cancer cell line panel 21191538 CVCL_4T17 CW70130 induced pluripotent stem cell human CVCL_4T17 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70130; true Female 21191539 CVCL_5517 WSU-HN8 cancer cell line human CVCL_5517 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=25275298) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: OPC-22 oral and pharyngeal cancer cell line panel 21191540 CVCL_4T16 CW70129 induced pluripotent stem cell human CVCL_4T16 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70129; true Male 21191541 CVCL_5516 WSU-HN6 cancer cell line human CVCL_5516 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Leu (c.536A>T); ClinVar=VCV000376608; Zygosity=Unspecified (PubMed=9049184; PubMed=25275298) Omics: Deep exome analysis. Male Part of: OPC-22 oral and pharyngeal cancer cell line panel 21191542 CVCL_WZ70 ITO-I cancer cell line human CVCL_WZ70 CL:0000010 Population: Japanese. Male 21191543 CVCL_WZ52 14C1 transformed cell line human CVCL_WZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P72151; Pseudomonas aeruginosa B-type flagellin (fliC) Group: Patented cell line 21191544 CVCL_WZ51 HKC transformed cell line human CVCL_WZ51 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Kidney. Male Problematic cell line: Contaminated Shown to be a HK-2 derivative (CCRID). Originally thought to be a renal tubular epithelial cell line. 21191545 CVCL_WZ50 BEAS-2B/CYP1A2 transformed cell line human CVCL_WZ50 CL:0000010 Transfected with: HGNC; 2596; CYP1A2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Bronchus; epithelium. Male 21191546 CVCL_WZ56 HEK-2 finite cell line human CVCL_WZ56 CL:0000010 Derived from sampling site: Fetal kidney Cell type=Epithelial cell.. Female 21191547 CVCL_WZ55 IRFMNi003-A-2 induced pluripotent stem cell human CVCL_WZ55 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Simple_edited; p.Gln85Leufs*119 (c.254_279delAGGCGTGGAGCCGCGATAACCCCGGC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31830647); Sequence variation: Mutation; HGNC; 9009; PKD2; Simple_edited; p.Gly93Alafs*24 (c.276delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31830647) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21191548 CVCL_WZ54 IRFMNi003-A-1 induced pluripotent stem cell human CVCL_WZ54 From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Simple_edited; p.Arg89Profs*25 (c.266_275delGCGATAACCC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31830647); Sequence variation: Mutation; HGNC; 9009; PKD2; Simple_edited; p.Gly93Alafs*24 (c.276delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31830647) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21191549 CVCL_WZ53 HYL transformed cell line human CVCL_WZ53 CL:0000010 Population: Chinese/Asian ethnic group; Yi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191550 CVCL_WZ59 L45 [Mouse hybridoma against human CD166] hybridoma house mouse CVCL_WZ59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q13740; Human CD166. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9804 21191551 CVCL_WZ58 HEL-2 finite cell line human CVCL_WZ58 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21191552 CVCL_WZ57 HEL-1 finite cell line human CVCL_WZ57 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21191553 CVCL_4T22 CW70141 induced pluripotent stem cell human CVCL_4T22 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70141; true Female 21191554 CVCL_5522 WSU-HN22 cancer cell line human CVCL_5522 CL:0000010 Male 21191555 CVCL_4T21 CW70137 induced pluripotent stem cell human CVCL_4T21 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70137; true Female 21191556 CVCL_5521 WSU-HN19 cancer cell line human CVCL_5521 CL:0000010 Derived from metastatic site: Lymph node. Unspecified 21191557 CVCL_4T20 CW70136 induced pluripotent stem cell human CVCL_4T20 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70136; true; Discontinued: FCDI; CW70136; probable. Female 21191558 CVCL_5520 WSU-HN17 cancer cell line human CVCL_5520 CL:0000010 Unspecified 21191559 CVCL_4T26 CW70181 induced pluripotent stem cell human CVCL_4T26 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70181; true Male 21191560 CVCL_5526 WSU-HN31 cancer cell line human CVCL_5526 CL:0000010 Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq Male Part of: MD Anderson Cell Lines Project 21191561 CVCL_4T25 CW70178 induced pluripotent stem cell human CVCL_4T25 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70178; true; Discontinued: FCDI; CW70178; probable. Male 21191562 CVCL_5525 WSU-HN30 cancer cell line human CVCL_5525 CL:0000010 Omics: Deep exome analysis; Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Male Part of: MD Anderson Cell Lines Project; Part of: OPC-22 oral and pharyngeal cancer cell line panel 21191563 CVCL_4T24 CW70167 induced pluripotent stem cell human CVCL_4T24 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70167; true Female 21191564 CVCL_5524 WSU-HN27 cancer cell line human CVCL_5524 CL:0000010 Derived from metastatic site: Larynx. Unspecified 21191565 CVCL_4T23 CW70142 induced pluripotent stem cell human CVCL_4T23 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70142; true Female 21191566 CVCL_5523 WSU-HN26 cancer cell line human CVCL_5523 CL:0000010 Unspecified 21191567 CVCL_4T29 GM02295 finite cell line human CVCL_4T29 CL:0000010 Sequence variation: Mutation; HGNC; 7160; MMP14; Simple; p.Thr17Arg (c.50C>G) (n.284C>G); ClinVar=VCV000065463; Zygosity=Homozygous (PubMed=22922033) Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Female 21191568 CVCL_5529 HLC-1 cancer cell line human CVCL_5529 Genome ancestry: African=4.37%; Native American=0%; East Asian, North=90.08%; East Asian, South=3.53%; South Asian=0%; European, North=0%; European, South=2.02% (PubMed=30894373) CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Unspecified Doubling time: ~33 hours, at 29th passage (PubMed=140093) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) Caution: Indicated by Riken to originate from Okabe T but with no reference provided. Therefore it is not certain that HLC-1 from Riken and HLC-1 originating from Akagi T. and Kimoto T. (PubMed=140093) are identical. 21191569 CVCL_5528 DU #2 cancer cell line human CVCL_5528 CL:0000010 Derived from metastatic site: Inguinal lymph node. Male Doubling time: 44 hours, at 61th passage (PubMed=994214) 21191570 CVCL_4T28 GM00911 finite cell line human CVCL_4T28 CL:0000010 Sequence variation: Mutation; HGNC; 6903; MAT1A; Simple; p.Leu305Pro (c.914T>C); ClinVar=VCV000001205; Zygosity=Heterozygous (PubMed=7560086); Sequence variation: Mutation; HGNC; 6903; MAT1A; Simple; p.Ile322Met (c.966T>G); ClinVar=VCV000001202; Zygosity=Heterozygous (PubMed=7560086) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21191571 CVCL_4T27 CW70230 induced pluripotent stem cell human CVCL_4T27 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70230; true Male 21191572 CVCL_5527 HS-22 somatic stem cell house mouse CVCL_5527 CL:0000010 Breed/subspecies: C3H/He. Discontinued: JCRB; JCRB1215; probable 21191573 CVCL_FG07 ND23538 transformed cell line human CVCL_FG07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191574 CVCL_FG06 ND23537 transformed cell line human CVCL_FG06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191575 CVCL_FG05 ND23536 transformed cell line human CVCL_FG05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191576 CVCL_FG04 ND23535 transformed cell line human CVCL_FG04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191577 CVCL_FG09 ND23540 transformed cell line human CVCL_FG09 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191578 CVCL_FG08 ND23539 transformed cell line human CVCL_FG08 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191579 CVCL_FG03 ND23534 transformed cell line human CVCL_FG03 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191580 CVCL_FG02 ND23514 transformed cell line human CVCL_FG02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191581 CVCL_FG01 ND23419 transformed cell line human CVCL_FG01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191582 CVCL_FG00 ND23248 transformed cell line human CVCL_FG00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191583 CVCL_FG18 ND24017 transformed cell line human CVCL_FG18 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191584 CVCL_FG17 ND24015 transformed cell line human CVCL_FG17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191585 CVCL_FG16 ND24012 transformed cell line human CVCL_FG16 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191586 CVCL_FG15 ND24010 transformed cell line human CVCL_FG15 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191587 CVCL_FG19 ND24018 transformed cell line human CVCL_FG19 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191588 CVCL_FG10 ND23756 transformed cell line human CVCL_FG10 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191589 CVCL_FG14 ND23890 transformed cell line human CVCL_FG14 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191590 CVCL_FG13 ND23889 transformed cell line human CVCL_FG13 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191591 CVCL_FG12 ND23848 transformed cell line human CVCL_FG12 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191592 CVCL_FG11 ND23786 transformed cell line human CVCL_FG11 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191593 CVCL_4S99 CW70081 induced pluripotent stem cell human CVCL_4S99 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70081; true Female 21191594 CVCL_5499 EM-G3 cancer cell line human CVCL_5499 CL:0000010 Population: Caucasian; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female Doubling time: ~34 hours (PubMed=17063277) 21191595 CVCL_5498 ConA-C1-VICK transformed cell line CVCL_5498 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Derived from sampling site: Spleen Cell type=T-cell.. Female Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12135 21191596 CVCL_4S98 CW70080 induced pluripotent stem cell human CVCL_4S98 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70080; true; Discontinued: FCDI; CW70080; probable. Male 21191597 CVCL_5497 ConA-B1-VICK transformed cell line CVCL_5497 CL:0000010 Transformant: Avian reticuloendotheliosis virus (REV) [Strain T](NCBI-Taxonomy; 11636); Derived from sampling site: Spleen Cell type=T-cell.. Female Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12357 21191598 CVCL_4S97 CW70079 induced pluripotent stem cell human CVCL_4S97 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70079; true Male 21191599 CVCL_4S81 CW70048 induced pluripotent stem cell human CVCL_4S81 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70048; true Female 21191600 CVCL_5481 Mm2T.P3 spontaneously immortalized cell line CVCL_5481 CL:0000010 Derived from sampling site: Thymus. Discontinued: JCRB; NIHS0358; true Male Group: Serum/protein free medium cell line 21191601 CVCL_4S80 CW70045 induced pluripotent stem cell human CVCL_4S80 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70045; true Female 21191602 CVCL_5480 LC-1/sq-SF cancer cell line human CVCL_5480 Genome ancestry: African=1.68%; Native American=0%; East Asian, North=96.94%; East Asian, South=1.38%; South Asian=0%; European, North=0%; European, South=0% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Arg1475Ter (c.4423C>T); Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (DepMap) Population: Japanese; Derived from sampling site: Lung. Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male Group: Serum/protein free medium cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21191603 CVCL_4S85 CW70052 induced pluripotent stem cell human CVCL_4S85 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70052; true Female 21191604 CVCL_5485 HSC-F transformed cell line CVCL_5485 CL:0000010 Transformant: Saimiriine herpesvirus 2 (Herpesvirus saimiri)(NCBI-Taxonomy; 10381); Derived from sampling site: Fetal spleen Cell type=T-cell.. Unspecified Group: Non-human primate cell line 21191605 CVCL_4S84 CW70051 induced pluripotent stem cell human CVCL_4S84 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70051; true; Discontinued: FCDI; CW70051; probable. Female 21191606 CVCL_5484 JTC-12.P3(F) spontaneously immortalized cell line CVCL_5484 CL:0000010 Derived from sampling site: Kidney. Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21191607 CVCL_4S83 CW70050 induced pluripotent stem cell human CVCL_4S83 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70050; true Female 21191608 CVCL_5483 JTC-12.P3 spontaneously immortalized cell line CVCL_5483 CL:0000010 Derived from sampling site: Kidney. Discontinued: JCRB; NIHS0354; true Female Group: Non-human primate cell line; Group: Serum/protein free medium cell line 21191609 CVCL_4S82 CW70049 induced pluripotent stem cell human CVCL_4S82 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70049; true Female 21191610 CVCL_5482 Mm2T12.P3 spontaneously immortalized cell line CVCL_5482 CL:0000010 Derived from sampling site: Thymus. Discontinued: JCRB; NIHS0369; true Male Group: Serum/protein free medium cell line 21191611 CVCL_4S78 CW70043 induced pluripotent stem cell human CVCL_4S78 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70043; true Female 21191612 CVCL_5478 DO-s cancer cell line human CVCL_5478 CL:0000010 Derived from metastatic site: Ascites. Female Doubling time: ~47 hours (PubMed=2548714) 21191613 CVCL_4S77 CW70042 induced pluripotent stem cell human CVCL_4S77 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70042; true Male 21191614 CVCL_5477 SK-LC-9 cancer cell line human CVCL_5477 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21191615 CVCL_4S76 CW70040 induced pluripotent stem cell human CVCL_4S76 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70040; true Male 21191616 CVCL_5476 SK-LC-8 cancer cell line human CVCL_5476 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21191617 CVCL_4S75 CW70039 induced pluripotent stem cell human CVCL_4S75 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70039; true Female 21191618 CVCL_5475 SK-LC-7 cancer cell line human CVCL_5475 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21191619 CVCL_4S79 CW70044 induced pluripotent stem cell human CVCL_4S79 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Latino or Hispanic; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70044; true Female 21191620 CVCL_5479 Gd1T undefined cell line type CVCL_5479 CL:0000010 Discontinued: ATCC; CRL-6180; true. Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21191621 CVCL_5492 BEL-7402 cancer cell line human CVCL_5492 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3131C0001000700010, 3142C0001000000035) They were the sole source for the STR profile of this entry. Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep quantitative proteome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 20 hours (PubMed=6154311); 31.2 +- 1.1 hours (PubMed=23167424) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00549 Problematic cell line: Contaminated Shown to be a HeLa derivative (PubMed=28807831). Originally thought to originate from a 53 year old male patient with a hepatocellular carcinoma. 21191622 CVCL_4S92 CW70071 induced pluripotent stem cell human CVCL_4S92 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70071; true Male 21191623 CVCL_5491 ACL-15 cancer cell line Norway rat CVCL_5491 CL:0000010 Transformant: 1,2-dimethylhydrazine (DMH)(ChEBI; CHEBI:73755); Derived from sampling site: Colon; Breed/subspecies: Fischer 344. Male Doubling time: 24 hours (CelloPub=CLPUB00016) 21191624 CVCL_4S91 CW70067 induced pluripotent stem cell human CVCL_4S91 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70067; true; Discontinued: FCDI; CW70067; probable. Female 21191625 CVCL_5490 5RP7 transformed cell line Norway rat CVCL_5490 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Fibroblast. Unspecified 21191626 CVCL_4S90 CW70063 induced pluripotent stem cell human CVCL_4S90 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70063; true Male 21191627 CVCL_5496 BrCa-MZ-02 cancer cell line human CVCL_5496 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 40 hours (PubMed=9663605) 21191628 CVCL_4S96 CW70078 induced pluripotent stem cell human CVCL_4S96 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70078; true. Male 21191629 CVCL_5495 BrCa-MZ-01 cancer cell line human CVCL_5495 CL:0000010 Female Doubling time: 36 hours (PubMed=9663605). 21191630 CVCL_4S95 CW70077 induced pluripotent stem cell human CVCL_4S95 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70077; true Female 21191631 CVCL_5494 Bhas42 transformed cell line house mouse CVCL_5494 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Ha-Ras; Breed/subspecies: Swiss albino. Biotechnology: Part of the 'Bhas 42 cell transformation assay' which is a sensitive short-term system for predicting chemical carcinogenicity (PubMed=21801851) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00530 Problematic cell line: Misidentified/contaminated Not from strain BALB/c as originally assigned but from a NIH Swiss strain derivative (PubMed=27844419). 21191632 CVCL_4S94 CW70075 induced pluripotent stem cell human CVCL_4S94 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70075; true Male 21191633 CVCL_5493 BEL-7402/5-FU cancer cell line human CVCL_5493 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Omics: Deep quantitative proteome analysis Female Doubling time: 42.3 +- 3.3 hours (PubMed=23167424) Problematic cell line: Contaminated Parent cell line (BEL-7402) has been shown to be a HeLa derivative. 21191634 CVCL_4S93 CW70073 induced pluripotent stem cell human CVCL_4S93 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70073; true Male 21191635 CVCL_5489 42TA spontaneously immortalized cell line CVCL_5489 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Omics: Transcriptome analysis by microarray Unspecified Group: Fish cell line 21191636 CVCL_4S89 CW70061 induced pluripotent stem cell human CVCL_4S89 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70061; true Male 21191637 CVCL_5488 3B11 spontaneously immortalized cell line CVCL_5488 CL:0000010 Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Group: Fish cell line 21191638 CVCL_4S88 CW70056 induced pluripotent stem cell human CVCL_4S88 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Discontinued: Coriell; CW70056; true Male 21191639 CVCL_5487 3B-11 transformed cell line house mouse CVCL_5487 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from metastatic site: Axillary lymph node Cell type=Epithelial cell.; Breed/subspecies: C3H/HeJ. Male Characteristics: Derived from a SVEC4-10EHR1 induced ascite tumor (PubMed=8496612) 21191640 CVCL_4S87 CW70055 induced pluripotent stem cell human CVCL_4S87 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70055; true; Discontinued: FCDI; CW70055; probable. Female 21191641 CVCL_5486 28S.3 spontaneously immortalized cell line CVCL_5486 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Group: Fish cell line Caution: It is not clear if 28S.1 and 28S.3 are distinct entities: PubMed=9809582 refers to this cell line as 28S.1 while ATCC refers to it as 28S.3 21191642 CVCL_4S86 CW70054 induced pluripotent stem cell human CVCL_4S86 From: California Institute for Regenerative Medicine (CIRM); San Francisco; USA CL:0000010 Discontinued: Coriell; CW70054; true; Discontinued: FCDI; CW70054; probable. Male 21191643 CVCL_FG90 ND01080 transformed cell line human CVCL_FG90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191644 CVCL_FG94 ND01199 transformed cell line human CVCL_FG94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191645 CVCL_FG93 ND01118 transformed cell line human CVCL_FG93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191646 CVCL_FG92 ND01117 transformed cell line human CVCL_FG92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191647 CVCL_FG91 ND01114 transformed cell line human CVCL_FG91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191648 CVCL_FG87 ND01036 transformed cell line human CVCL_FG87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191649 CVCL_FG86 ND00976 transformed cell line human CVCL_FG86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191650 CVCL_FG85 ND00975 transformed cell line human CVCL_FG85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191651 CVCL_FG84 ND00928 transformed cell line human CVCL_FG84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191652 CVCL_FG89 ND01056 transformed cell line human CVCL_FG89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191653 CVCL_FG88 ND01054 transformed cell line human CVCL_FG88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191654 CVCL_FG98 ND01290 transformed cell line human CVCL_FG98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191655 CVCL_FG97 ND01286 transformed cell line human CVCL_FG97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191656 CVCL_FG96 ND01284 transformed cell line human CVCL_FG96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191657 CVCL_FG95 ND01250 transformed cell line human CVCL_FG95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191658 CVCL_FG99 ND01324 transformed cell line human CVCL_FG99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191659 CVCL_FG72 ND27790 transformed cell line human CVCL_FG72 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191660 CVCL_FG71 ND27522 transformed cell line human CVCL_FG71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191661 CVCL_FG70 ND26941 transformed cell line human CVCL_FG70 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191662 CVCL_FG65 ND26433 transformed cell line human CVCL_FG65 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191663 CVCL_FG64 ND26262 transformed cell line human CVCL_FG64 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191664 CVCL_FG63 ND26261 transformed cell line human CVCL_FG63 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191665 CVCL_FG62 ND26221 transformed cell line human CVCL_FG62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191666 CVCL_FG69 ND26894 transformed cell line human CVCL_FG69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191667 CVCL_FG68 ND26531 transformed cell line human CVCL_FG68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191668 CVCL_FG67 ND26513 transformed cell line human CVCL_FG67 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191669 CVCL_FG66 ND26512 transformed cell line human CVCL_FG66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND26512; probable Male 21191670 CVCL_FG83 ND00921 transformed cell line human CVCL_FG83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191671 CVCL_FG82 ND00888 transformed cell line human CVCL_FG82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191672 CVCL_FG81 ND00826 transformed cell line human CVCL_FG81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191673 CVCL_FG80 ND00612 transformed cell line human CVCL_FG80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191674 CVCL_FG76 GM13750 transformed cell line human CVCL_FG76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191675 CVCL_FG75 GM13694 transformed cell line human CVCL_FG75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191676 CVCL_FG74 L1M1 cancer cell line human CVCL_FG74 CL:0000010 Derived from metastatic site: Left inguinal lymph node. Female 21191677 CVCL_FG73 G1M2 cancer cell line human CVCL_FG73 CL:0000010 Derived from metastatic site: Left groin; hypodermis. Female 21191678 CVCL_FG79 ND00399 transformed cell line human CVCL_FG79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191679 CVCL_FG78 ND00380 transformed cell line human CVCL_FG78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191680 CVCL_FG77 ND21741 transformed cell line human CVCL_FG77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191681 CVCL_FG50 ND25318 transformed cell line human CVCL_FG50 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191682 CVCL_FG49 ND25311 transformed cell line human CVCL_FG49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191683 CVCL_FG48 ND25228 transformed cell line human CVCL_FG48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191684 CVCL_FG43 ND24985 transformed cell line human CVCL_FG43 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191685 CVCL_FG42 ND24826 transformed cell line human CVCL_FG42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191686 CVCL_FG41 ND24670 transformed cell line human CVCL_FG41 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191687 CVCL_FG40 ND24631 transformed cell line human CVCL_FG40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191688 CVCL_FG47 ND25223 transformed cell line human CVCL_FG47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191689 CVCL_FG46 ND25222 transformed cell line human CVCL_FG46 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191690 CVCL_FG45 ND25221 transformed cell line human CVCL_FG45 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191691 CVCL_FG44 ND25220 transformed cell line human CVCL_FG44 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191692 CVCL_FG61 ND26190 transformed cell line human CVCL_FG61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191693 CVCL_FG60 ND26189 transformed cell line human CVCL_FG60 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191694 CVCL_FG59 ND26186 transformed cell line human CVCL_FG59 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191695 CVCL_FG54 ND26043 transformed cell line human CVCL_FG54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND26043; probable Male 21191696 CVCL_FG53 ND25632 transformed cell line human CVCL_FG53 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191697 CVCL_FG52 ND25433 transformed cell line human CVCL_FG52 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191698 CVCL_FG51 ND25400 transformed cell line human CVCL_FG51 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191699 CVCL_FG58 ND26184 transformed cell line human CVCL_FG58 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191700 CVCL_FG57 ND26130 transformed cell line human CVCL_FG57 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191701 CVCL_FG56 ND26129 transformed cell line human CVCL_FG56 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191702 CVCL_FG55 ND26128 transformed cell line human CVCL_FG55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191703 CVCL_FG29 ND24112 transformed cell line human CVCL_FG29 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191704 CVCL_FG28 ND24111 transformed cell line human CVCL_FG28 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191705 CVCL_FG27 ND24062 transformed cell line human CVCL_FG27 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191706 CVCL_FG26 ND24031 transformed cell line human CVCL_FG26 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191707 CVCL_FG21 ND24020 transformed cell line human CVCL_FG21 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191708 CVCL_FG20 ND24019 transformed cell line human CVCL_FG20 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191709 CVCL_FG25 ND24030 transformed cell line human CVCL_FG25 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191710 CVCL_FG24 ND24029 transformed cell line human CVCL_FG24 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191711 CVCL_FG23 ND24024 transformed cell line human CVCL_FG23 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191712 CVCL_FG22 ND24023 transformed cell line human CVCL_FG22 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191713 CVCL_FG39 ND24630 transformed cell line human CVCL_FG39 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191714 CVCL_FG38 ND24311 transformed cell line human CVCL_FG38 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191715 CVCL_FG37 ND24151 transformed cell line human CVCL_FG37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191716 CVCL_FG32 ND24135 transformed cell line human CVCL_FG32 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191717 CVCL_FG31 ND24118 transformed cell line human CVCL_FG31 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191718 CVCL_FG30 ND24113 transformed cell line human CVCL_FG30 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191719 CVCL_FG36 ND24149 transformed cell line human CVCL_FG36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191720 CVCL_FG35 ND24146 transformed cell line human CVCL_FG35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191721 CVCL_FG34 ND24138 transformed cell line human CVCL_FG34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191722 CVCL_FG33 ND24136 transformed cell line human CVCL_FG33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191723 CVCL_FQ49 ND30915 transformed cell line human CVCL_FQ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191724 CVCL_G249 PI-11 hybridoma house mouse CVCL_G249 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P20810; Human CAST. 21191725 CVCL_FQ48 ND30908 transformed cell line human CVCL_FQ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191726 CVCL_G248 PDL-1 hybridoma house mouse CVCL_G248 CL:0000010 Monoclonal antibody isotype: IgM. 21191727 CVCL_FQ47 ND30880 transformed cell line human CVCL_FQ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191728 CVCL_G247 PCA 33.28 hybridoma house mouse CVCL_G247 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Human colorectal carcinoma-associated antigen (CCAA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12315; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-5413 21191729 CVCL_FQ46 ND30857 transformed cell line human CVCL_FQ46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191730 CVCL_G246 PCA 31.1 hybridoma house mouse CVCL_G246 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human colorectal carcinoma-associated antigen (CCAA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12314; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2497 21191731 CVCL_FQ41 ND30795 transformed cell line human CVCL_FQ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191732 CVCL_G241 P3D hybridoma house mouse CVCL_G241 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q66T51; Brugia malayi beta-tubulin (Note=Also reacts with other nematods). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11129 21191733 CVCL_FQ40 ND30756 transformed cell line human CVCL_FQ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191734 CVCL_G240 P25.48 hybridoma house mouse CVCL_G240 CL:0000010 Monoclonal antibody isotype: IgG3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9119 21191735 CVCL_FQ45 ND30836 transformed cell line human CVCL_FQ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191736 CVCL_G245 PA2.1 hybridoma house mouse CVCL_G245 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04439; Human HLA-A (Note=Recognizes allele A*69). 21191737 CVCL_FQ44 ND30835 transformed cell line human CVCL_FQ44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191738 CVCL_G244 PA2.6 hybridoma house mouse CVCL_G244 CL:0000010 Monoclonal antibody isotype: IgG1. 21191739 CVCL_FQ43 ND30798 transformed cell line human CVCL_FQ43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191740 CVCL_G243 P-9 hybridoma house mouse CVCL_G243 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07384; Human CAPN1. 21191741 CVCL_FQ42 ND30796 transformed cell line human CVCL_FQ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191742 CVCL_G242 P-6 hybridoma house mouse CVCL_G242 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P07384; Human CAPN1. 21191743 CVCL_G259 KMY0902 transformed cell line human CVCL_G259 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191744 CVCL_FQ59 ND31136 transformed cell line human CVCL_FQ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191745 CVCL_G258 KMY0901 transformed cell line human CVCL_G258 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21191746 CVCL_FQ58 ND31134 transformed cell line human CVCL_FQ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191747 CVCL_FQ57 ND31124 transformed cell line human CVCL_FQ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191748 CVCL_G257 PC-3M-1E8 cancer cell line human CVCL_G257 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: High metastatic potential 21191749 CVCL_FQ52 ND30966 transformed cell line human CVCL_FQ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191750 CVCL_G252 PS 41 hybridoma house mouse CVCL_G252 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01186; Rat Avp. 21191751 CVCL_FQ51 ND30965 transformed cell line human CVCL_FQ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191752 CVCL_G251 PS 38 hybridoma house mouse CVCL_G251 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01179; Rat Oxt. 21191753 CVCL_FQ50 ND30929 transformed cell line human CVCL_FQ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191754 CVCL_G250 PI 153/3 hybridoma house mouse CVCL_G250 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human glycoprotein expressed on neuroectoderm derived tumors (neuroblastoma, retinoblastoma and glioblastoma). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21191755 CVCL_FQ56 ND31120 transformed cell line human CVCL_FQ56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191756 CVCL_G256 PC-3M-2B4 cancer cell line human CVCL_G256 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Low metastatic potential 21191757 CVCL_FQ55 ND31115 transformed cell line human CVCL_FQ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191758 CVCL_G255 PS 67 hybridoma house mouse CVCL_G255 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P01179; Rat Oxt. 21191759 CVCL_FQ54 ND30971 transformed cell line human CVCL_FQ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191760 CVCL_G254 PS 60 hybridoma house mouse CVCL_G254 CL:0000010 Monoclonal antibody isotype: IgG3, kappa (PubMed=3880813); IgG2b (ATCC); Monoclonal antibody target: UniProtKB; P01179; Rat Oxt. 21191761 CVCL_FQ53 ND30970 transformed cell line human CVCL_FQ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191762 CVCL_G253 PS 45 hybridoma house mouse CVCL_G253 CL:0000010 Monoclonal antibody isotype: IgG3, kappa (PubMed=3880813); IgG2b (ATCC); Monoclonal antibody target: UniProtKB; P01186; Rat Avp. 21191763 CVCL_G227 K66 hybridoma house mouse CVCL_G227 CL:0000010 Monoclonal antibody isotype: IgG2a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8767 21191764 CVCL_FQ27 ND30574 transformed cell line human CVCL_FQ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191765 CVCL_G226 K117 [Mouse hybridoma against human THY1] hybridoma house mouse CVCL_G226 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04216; Human THY1/CD90. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8553 21191766 CVCL_FQ26 ND30573 transformed cell line human CVCL_FQ26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191767 CVCL_G225 K 114 hybridoma house mouse CVCL_G225 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human melanoma cell surface antigen M-16. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8444 21191768 CVCL_FQ25 ND30563 transformed cell line human CVCL_FQ25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191769 CVCL_G224 IVD12 hybridoma house mouse CVCL_G224 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21191770 CVCL_FQ24 ND30562 transformed cell line human CVCL_FQ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191771 CVCL_G229 KC-4M1 hybridoma house mouse CVCL_G229 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8710 21191772 CVCL_FQ29 ND30610 transformed cell line human CVCL_FQ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191773 CVCL_G228 KC-4G3 hybridoma house mouse CVCL_G228 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8709 21191774 CVCL_FQ28 ND30595 transformed cell line human CVCL_FQ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191775 CVCL_G223 IVA12 hybridoma house mouse CVCL_G223 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21191776 CVCL_FQ23 ND30561 transformed cell line human CVCL_FQ23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191777 CVCL_G222 12.1 [Mouse hybridoma against human CD6] hybridoma house mouse CVCL_G222 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30203; Human CD6. 21191778 CVCL_FQ22 ND30556 transformed cell line human CVCL_FQ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191779 CVCL_G221 116-13.1 hybridoma house mouse CVCL_G221 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 21191780 CVCL_FQ21 ND30554 transformed cell line human CVCL_FQ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191781 CVCL_G220 116 hybridoma house mouse CVCL_G220 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9367 21191782 CVCL_FQ20 ND30552 transformed cell line human CVCL_FQ20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191783 CVCL_FQ38 ND30731 transformed cell line human CVCL_FQ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191784 CVCL_G238 OM 3-1.1 hybridoma house mouse CVCL_G238 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02771; Human AFP. 21191785 CVCL_FQ37 ND30710 transformed cell line human CVCL_FQ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191786 CVCL_G237 OD-3 hybridoma house mouse CVCL_G237 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Doubling time: 14 hours (ATCC=HB-10204) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10204 21191787 CVCL_G236 MBL-Sm-4B1 hybridoma house mouse CVCL_G236 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06198; Schistosoma mansoni paramyosin. 21191788 CVCL_FQ36 ND30709 transformed cell line human CVCL_FQ36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191789 CVCL_G235 MBL-Sm-1A6 hybridoma house mouse CVCL_G235 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06198; Schistosoma mansoni paramyosin. 21191790 CVCL_FQ35 ND30703 transformed cell line human CVCL_FQ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191791 CVCL_FQ39 ND30753 transformed cell line human CVCL_FQ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191792 CVCL_G239 P-1 hybridoma house mouse CVCL_G239 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P13135; Bovine CPNS1 (Note=Also reacts with dog and human). 21191793 CVCL_G230 KL295 hybridoma house mouse CVCL_G230 CL:0000010 Monoclonal antibody isotype: IgG1. 21191794 CVCL_FQ30 ND30616 transformed cell line human CVCL_FQ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191795 CVCL_G234 MB40.5 hybridoma house mouse CVCL_G234 CL:0000010 Monoclonal antibody isotype: IgG1. 21191796 CVCL_FQ34 ND30681 transformed cell line human CVCL_FQ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191797 CVCL_G233 MB40.3 hybridoma house mouse CVCL_G233 CL:0000010 Monoclonal antibody isotype: IgG1. 21191798 CVCL_FQ33 ND30679 transformed cell line human CVCL_FQ33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191799 CVCL_G232 MB40.2 hybridoma house mouse CVCL_G232 CL:0000010 Monoclonal antibody isotype: IgG1. 21191800 CVCL_FQ32 ND30642 transformed cell line human CVCL_FQ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191801 CVCL_G231 KL304 hybridoma house mouse CVCL_G231 CL:0000010 Monoclonal antibody isotype: IgG2b. 21191802 CVCL_FQ31 ND30632 transformed cell line human CVCL_FQ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191803 CVCL_G205 LHR-1055 hybridoma house mouse CVCL_G205 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22888; Human LHCGR. 21191804 CVCL_FQ05 ND30378 transformed cell line human CVCL_FQ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191805 CVCL_FQ04 ND30377 transformed cell line human CVCL_FQ04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191806 CVCL_G204 QPN1 22F5 hybridoma house mouse CVCL_G204 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9509 21191807 CVCL_FQ03 ND30373 transformed cell line human CVCL_FQ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191808 CVCL_G203 QPN1 12C9 hybridoma house mouse CVCL_G203 CL:0000010 Characteristics: Produces a catalytic monoclonal antibody; Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9500 21191809 CVCL_FQ02 ND30372 transformed cell line human CVCL_FQ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191810 CVCL_G202 QCRL-3 hybridoma house mouse CVCL_G202 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P33527; Human ABCC1/MRP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11766 21191811 CVCL_G209 IBEP-1 cancer cell line human CVCL_G209 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: miRNA expression profiling; Omics: Transcriptome analysis by microarray Female Doubling time: 68 hours (PubMed=9610725) 21191812 CVCL_FQ09 ND30431 transformed cell line human CVCL_FQ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191813 CVCL_G208 LK-4 hybridoma house mouse CVCL_G208 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 21191814 CVCL_FQ08 ND30430 transformed cell line human CVCL_FQ08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191815 CVCL_G207 LHR-74 hybridoma house mouse CVCL_G207 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22888; Human LHCGR. 21191816 CVCL_FQ07 ND30400 transformed cell line human CVCL_FQ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191817 CVCL_G206 LHR-29 hybridoma house mouse CVCL_G206 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22888; Human LHCGR. 21191818 CVCL_FQ06 ND30384 transformed cell line human CVCL_FQ06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191819 CVCL_FQ01 ND30330 transformed cell line human CVCL_FQ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191820 CVCL_G201 QCRL-1 hybridoma house mouse CVCL_G201 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33527; Human ABCC1/MRP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11765 21191821 CVCL_G200 8D12 hybridoma house mouse CVCL_G200 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22032; Cavia porcellus MBP1. 21191822 CVCL_FQ00 ND30314 transformed cell line human CVCL_FQ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191823 CVCL_FQ16 ND30494 transformed cell line human CVCL_FQ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191824 CVCL_G216 ND8 hybrid cell line CVCL_G216 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. Characteristics: Derived from the fusion of primary neonatal rat dorsal root ganglion neurons with mouse neuroblastoma cell line N18TG2 (PubMed=1979443) 21191825 CVCL_G215 M18/2.a.8 hybridoma CVCL_G215 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11835; Mouse Itgb2/Cd18. 21191826 CVCL_FQ15 ND30482 transformed cell line human CVCL_FQ15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191827 CVCL_G214 CFT1 transformed cell line human CVCL_G214 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=15463957) Transformant: Human papillomavirus type 18 (HPV18) [E6/E7](NCBI-Taxonomy; 333761). Male Group: Patented cell line 21191828 CVCL_FQ14 ND30480 transformed cell line human CVCL_FQ14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191829 CVCL_FQ13 ND30479 transformed cell line human CVCL_FQ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191830 CVCL_G213 SHT290 telomerase immortalized cell line human CVCL_G213 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female 21191831 CVCL_G219 11-4.1 hybridoma house mouse CVCL_G219 CL:0000010 Monoclonal antibody isotype: IgG2a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21191832 CVCL_FQ19 ND30527 transformed cell line human CVCL_FQ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191833 CVCL_G218 1116NS-19-9 hybridoma house mouse CVCL_G218 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8059 21191834 CVCL_FQ18 ND30523 transformed cell line human CVCL_FQ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191835 CVCL_G217 (BF1) 8A3.31 hybridoma house mouse CVCL_G217 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05067; Human APP (Note=Binds to APP42). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9283 21191836 CVCL_FQ17 ND30514 transformed cell line human CVCL_FQ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191837 CVCL_G212 HUNC-S cancer cell line Norway rat CVCL_G212 CL:0000010 Breed/subspecies: Copenhagen. Male 21191838 CVCL_FQ12 ND30474 transformed cell line human CVCL_FQ12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191839 CVCL_G211 HUNC-E cancer cell line Norway rat CVCL_G211 CL:0000010 Breed/subspecies: Copenhagen. Male 21191840 CVCL_FQ11 ND30441 transformed cell line human CVCL_FQ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191841 CVCL_G210 IBEP-3 cancer cell line human CVCL_G210 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Doubling time: 39 hours (PubMed=9610725) 21191842 CVCL_FQ10 ND30439 transformed cell line human CVCL_FQ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191843 CVCL_XE03 ZJU-0430 cancer cell line human CVCL_XE03 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Male Doubling time: 19.81 hours (PubMed=31367188) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017174 Problematic cell line: Possibly contaminated STR profile is 100% identical to that of GBC-SD (Cellosaurus=CVCL_6903). 21191844 CVCL_XE02 CCB-J spontaneously immortalized cell line CVCL_XE02 CL:0000010 Derived from sampling site: Brain; Breed/subspecies: Jian. Unspecified Virology: Susceptible to infection by koi herpesvirus (KHV) (PubMed=33409805) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201933 21191845 CVCL_XE01 BP1-7 hybridoma house mouse CVCL_XE01 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; A6NLP5; Human TTC36. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018205 21191846 CVCL_XE00 BOS-1 finite cell line CVCL_XE00 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Genome sequenced Female 21191847 CVCL_XE07 AP3M finite cell line human CVCL_XE07 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191848 CVCL_XE06 FA18JTO(SVT)-1 transformed cell line human CVCL_XE06 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1811delT; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191849 CVCL_XE05 ZJU-1125 cancer cell line human CVCL_XE05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Ser (c.403T>A); ClinVar=VCV000376562; Zygosity=Unspecified (PubMed=31359275). Population: Chinese Female Doubling time: 44.73 hours (PubMed=31359275) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017176 21191850 CVCL_XE04 ZJU-0826 cancer cell line human CVCL_XE04 CL:0000010 Population: Chinese Female Doubling time: 63.84 hours (PubMed=31359275). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017175 Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21191851 CVCL_XE09 XP1MG finite cell line human CVCL_XE09 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191852 CVCL_XE08 AP3P finite cell line human CVCL_XE08 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191853 CVCL_G285 AH99-TC cancer cell line Norway rat CVCL_G285 CL:0000010 Female 21191854 CVCL_FQ85 ND31652 transformed cell line human CVCL_FQ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191855 CVCL_G284 AH70B-TC cancer cell line Norway rat CVCL_G284 CL:0000010 Breed/subspecies: Donryu. Male 21191856 CVCL_FQ84 ND31635 transformed cell line human CVCL_FQ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191857 CVCL_FQ83 ND31633 transformed cell line human CVCL_FQ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191858 CVCL_G283 NHSF46 finite cell line human CVCL_G283 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 37 PDL (PubMed=4083160); 45 PDL (RCB=RCB0162) 21191859 CVCL_G282 KMYM transformed cell line human CVCL_G282 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191860 CVCL_FQ82 ND31607 transformed cell line human CVCL_FQ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191861 CVCL_G289 HH-16 transformed cell line human CVCL_G289 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191862 CVCL_FQ89 ND31700 transformed cell line human CVCL_FQ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191863 CVCL_G288 HH-01 transformed cell line human CVCL_G288 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191864 CVCL_FQ88 ND31696 transformed cell line human CVCL_FQ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191865 CVCL_G287 Ac2F(ST) spontaneously immortalized cell line Norway rat CVCL_G287 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21191866 CVCL_FQ87 ND31694 transformed cell line human CVCL_FQ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191867 CVCL_G286 Ac2F(DT) transformed cell line Norway rat CVCL_G286 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 21191868 CVCL_FQ86 ND31656 transformed cell line human CVCL_FQ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191869 CVCL_G281 KMYF transformed cell line human CVCL_G281 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191870 CVCL_FQ81 ND31602 transformed cell line human CVCL_FQ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191871 CVCL_G280 KMYB transformed cell line human CVCL_G280 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191872 CVCL_FQ80 ND31600 transformed cell line human CVCL_FQ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191873 CVCL_FQ96 ND31898 transformed cell line human CVCL_FQ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191874 CVCL_G296 RatB1a spontaneously immortalized cell line Norway rat CVCL_G296 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Fischer 344. Unspecified 21191875 CVCL_G295 C57MG-A5 spontaneously immortalized cell line house mouse CVCL_G295 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Female Characteristics: Clone of C57BL/6 which is more reliable for Wnt assays than the parent cell line (Cornell TTO) 21191876 CVCL_FQ95 ND31878 transformed cell line human CVCL_FQ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191877 CVCL_G294 A121(P) cancer cell line human CVCL_G294 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 22 hours (PubMed=2910777) 21191878 CVCL_FQ94 ND31855 transformed cell line human CVCL_FQ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191879 CVCL_FQ93 ND31853 transformed cell line human CVCL_FQ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191880 CVCL_G293 SV/HF-5/39 transformed cell line human CVCL_G293 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal bone marrow. Female 21191881 CVCL_FQ99 ND31963 transformed cell line human CVCL_FQ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191882 CVCL_G299 SC-M1 cancer cell line human CVCL_G299 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Stomach. Omics: Deep quantitative proteome analysis Male Doubling time: 17 hours (PubMed=8083436) 21191883 CVCL_G298 M93-047 cancer cell line human CVCL_G298 CL:0000010 Derived from metastatic site: Axillary lymph node. Female 21191884 CVCL_FQ98 ND31961 transformed cell line human CVCL_FQ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191885 CVCL_FQ97 ND31899 transformed cell line human CVCL_FQ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191886 CVCL_G297 UACC-1273 cancer cell line human CVCL_G297 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21191888 CVCL_FQ92 ND31821 transformed cell line human CVCL_FQ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191889 CVCL_G291 Mar Bel finite cell line human CVCL_G291 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1186; true Female 21191890 CVCL_FQ91 ND31770 transformed cell line human CVCL_FQ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191891 CVCL_G290 HH-29 transformed cell line human CVCL_G290 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191892 CVCL_FQ90 ND31702 transformed cell line human CVCL_FQ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191893 CVCL_G269 KMY0919 transformed cell line human CVCL_G269 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191894 CVCL_FQ69 ND31305 transformed cell line human CVCL_FQ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191895 CVCL_G268 KMY0911 transformed cell line human CVCL_G268 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191896 CVCL_FQ68 ND31300 transformed cell line human CVCL_FQ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191897 CVCL_G263 KMY0906 transformed cell line human CVCL_G263 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191898 CVCL_FQ63 ND31228 transformed cell line human CVCL_FQ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191899 CVCL_G262 KMY0905 transformed cell line human CVCL_G262 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191900 CVCL_FQ62 ND31222 transformed cell line human CVCL_FQ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191901 CVCL_G261 KMY0904 transformed cell line human CVCL_G261 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191902 CVCL_FQ61 ND31190 transformed cell line human CVCL_FQ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191903 CVCL_G260 KMY0903 transformed cell line human CVCL_G260 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191904 CVCL_FQ60 ND31179 transformed cell line human CVCL_FQ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191905 CVCL_G267 KMY0910 transformed cell line human CVCL_G267 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191906 CVCL_FQ67 ND31269 transformed cell line human CVCL_FQ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191907 CVCL_G266 KMY0909 transformed cell line human CVCL_G266 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191908 CVCL_FQ66 ND31267 transformed cell line human CVCL_FQ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191909 CVCL_G265 KMY0908 transformed cell line human CVCL_G265 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191910 CVCL_FQ65 ND31244 transformed cell line human CVCL_FQ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191911 CVCL_G264 KMY0907 transformed cell line human CVCL_G264 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191912 CVCL_FQ64 ND31243 transformed cell line human CVCL_FQ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191913 CVCL_G279 KMY1036 transformed cell line human CVCL_G279 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191914 CVCL_FQ79 ND31574 transformed cell line human CVCL_FQ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191915 CVCL_G274 KMY0927 transformed cell line human CVCL_G274 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191916 CVCL_FQ74 ND31501 transformed cell line human CVCL_FQ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191917 CVCL_G273 KMY0926 transformed cell line human CVCL_G273 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191918 CVCL_FQ73 ND31498 transformed cell line human CVCL_FQ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191919 CVCL_G272 KMY0923 transformed cell line human CVCL_G272 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191920 CVCL_FQ72 ND31467 transformed cell line human CVCL_FQ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191921 CVCL_G271 KMY0922 transformed cell line human CVCL_G271 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191922 CVCL_FQ71 ND31364 transformed cell line human CVCL_FQ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191923 CVCL_G278 KMY1022 transformed cell line human CVCL_G278 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191924 CVCL_FQ78 ND31552 transformed cell line human CVCL_FQ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191925 CVCL_G277 KMY1008 transformed cell line human CVCL_G277 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191926 CVCL_FQ77 ND31533 transformed cell line human CVCL_FQ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191927 CVCL_G276 KMY1002 transformed cell line human CVCL_G276 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191928 CVCL_FQ76 ND31531 transformed cell line human CVCL_FQ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191929 CVCL_G275 KMY0928 transformed cell line human CVCL_G275 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191930 CVCL_FQ75 ND31530 transformed cell line human CVCL_FQ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191931 CVCL_G270 KMY0920 transformed cell line human CVCL_G270 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21191932 CVCL_FQ70 ND31308 transformed cell line human CVCL_FQ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191933 CVCL_XD62 HOS-Luc2-tdT cancer cell line human CVCL_XD62 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21191934 CVCL_XD61 HepG2-Luc2-tdT cancer cell line human CVCL_XD61 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Liver. Male 21191935 CVCL_XD60 HD6 hybridoma house mouse CVCL_XD60 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q66479; Human enterovirus 71 genome polyprotein. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.2937 21191936 CVCL_XD66 BV2-tDT transformed cell line house mouse CVCL_XD66 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Female 21191937 CVCL_XD65 HGC27-mCherry-2 cancer cell line human CVCL_XD65 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly2316fs*9 (c.6947delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21191938 CVCL_XD64 HOS-tdT cancer cell line human CVCL_XD64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21191939 CVCL_XD63 HOS-mCherry cancer cell line human CVCL_XD63 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Bone; right femur. Female 21191940 CVCL_XD69 MCF7-Cas9-543 cancer cell line human CVCL_XD69 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21191941 CVCL_XD68 MCF7-Cas9-542 cancer cell line human CVCL_XD68 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21191942 CVCL_XD67 BV2-EGFP transformed cell line house mouse CVCL_XD67 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000628) It was the sole source of information for this entry. Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Female 21191943 CVCL_XD51 IBMS-iPSC-044-05 induced pluripotent stem cell human CVCL_XD51 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21191944 CVCL_XD50 EV7_VP1_20K2_IgG hybridoma house mouse CVCL_XD50 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q66479; Human enterovirus 71 genome polyprotein (AA 568-862; protein VP1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016133 21191945 CVCL_XD55 NTUH-iPSC-013-01 induced pluripotent stem cell human CVCL_XD55 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21191946 CVCL_XD54 IBMS-iPSC-047-03 induced pluripotent stem cell human CVCL_XD54 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 6239; KCND3; Simple; p.Phe227del (c.677_679TCT[1]) (c.679_681delTTC); ClinVar=VCV000066061; Zygosity=Unspecified (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Female 21191947 CVCL_XD53 IBMS-iPSC-046-06 induced pluripotent stem cell human CVCL_XD53 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 6239; KCND3; Simple; p.Phe227del (c.677_679TCT[1]) (c.679_681delTTC); ClinVar=VCV000066061; Zygosity=Unspecified (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Female 21191948 CVCL_XD52 IBMS-iPSC-045-02 induced pluripotent stem cell human CVCL_XD52 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Arg2639Gln (c.7916G>A); ClinVar=VCV000163287; Zygosity=Unspecified (BCRC) Population: Asian; Derived from sampling site: Peripheral blood. Male 21191949 CVCL_XD59 A9 [Mouse hybridoma against Ev71] hybridoma house mouse CVCL_XD59 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q66479; Human enterovirus 71 genome polyprotein. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.5330 21191950 CVCL_XD58 TVGH-iPSC-026-11 induced pluripotent stem cell human CVCL_XD58 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21191951 CVCL_XD57 TVGH-iPSC-025-06 induced pluripotent stem cell human CVCL_XD57 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21191952 CVCL_XD56 NTUH-iPSC-014-01 induced pluripotent stem cell human CVCL_XD56 From: National Taiwan University Hospital; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 21191953 CVCL_XD40 AP18P finite cell line human CVCL_XD40 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21191954 CVCL_XD44 AP39P(L) transformed cell line human CVCL_XD44 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (from autologous cell line AP39P); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Ala278Pro (c.832G>C); ClinVar=VCV000995827; Zygosity=Heterozygous (from autologous cell line AP39P); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (from autologous cell line AP39P) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191955 CVCL_XD43 AP39P(SVT) transformed cell line human CVCL_XD43 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Ala278Pro (c.832G>C); ClinVar=VCV000995827; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191956 CVCL_XD42 AP39P finite cell line human CVCL_XD42 CL:0000010 Sequence variation: Mutation; HGNC; 253; ADH5; Simple; c.564+1G>A (p.Leu188Profs*4); ClinVar=VCV000995826; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33355142); Sequence variation: Mutation; HGNC; 253; ADH5; Simple; p.Ala278Pro (c.832G>C); ClinVar=VCV000995827; Zygosity=Heterozygous (PubMed=33355142); Sequence variation: Mutation; HGNC; 404; ALDH2; Simple; p.Glu504Lys (c.1510G>A) (p.Glu487Lys); ClinVar=VCV000018390; Zygosity=Heterozygous; Note=Allele ALDH2*2 (PubMed=33355142) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191957 CVCL_XD41 AP18S finite cell line human CVCL_XD41 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191958 CVCL_XD48 UM127-1 embryonic stem cell human CVCL_XD48 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0410. 21191959 CVCL_XD47 UM207-4 PGD embryonic stem cell human CVCL_XD47 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM207-1 PGD (Cellosaurus=CVCL_WW05). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-19-0409 21191960 CVCL_XD46 AP39F(SVT) transformed cell line human CVCL_XD46 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191961 CVCL_XD45 AP39F finite cell line human CVCL_XD45 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191962 CVCL_XD49 EV7_VP1_11G12_IgA hybridoma house mouse CVCL_XD49 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: UniProtKB; Q66479; Human enterovirus 71 genome polyprotein (AA 568-862; protein VP1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016132 21191963 CVCL_XD33 AP25F finite cell line human CVCL_XD33 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191964 CVCL_XD32 AP25B(SVT) transformed cell line human CVCL_XD32 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191965 CVCL_XD31 AP25B finite cell line human CVCL_XD31 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191966 CVCL_XD30 AP37M(L) transformed cell line human CVCL_XD30 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191967 CVCL_XD37 AP25P(SVT) transformed cell line human CVCL_XD37 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191968 CVCL_XD36 AP25M(SVT) transformed cell line human CVCL_XD36 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191969 CVCL_XD35 AP25M finite cell line human CVCL_XD35 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191970 CVCL_XD34 AP25F(SVT) transformed cell line human CVCL_XD34 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191971 CVCL_XD39 AP18M finite cell line human CVCL_XD39 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21191972 CVCL_XD38 AP18F finite cell line human CVCL_XD38 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191973 CVCL_XD22 KMP5-Luc#9 cancer cell line human CVCL_XD22 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from metastatic site: Liver. Discontinued: JCRB; NIHS1214; true Male 21191974 CVCL_XD21 OCUG-1-Luc#5 cancer cell line human CVCL_XD21 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Trp (c.799C>T); ClinVar=VCV000141764; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from metastatic site: Peritoneal effusion. Discontinued: JCRB; NIHS1213; true Male 21191975 CVCL_XD20 KKK-D138 cancer cell line human CVCL_XD20 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Female Characteristics: Established from a second generation xenograft established in BALB/c Rag-2-/-/Jak3-/- mice 21191976 CVCL_XD26 MK-4 finite cell line human CVCL_XD26 CL:0000010 Discontinued: JCRB; KURB2768; probable. Male 21191977 CVCL_XD25 RD-Luc cancer cell line human CVCL_XD25 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pelvis; muscle. Discontinued: JCRB; NIHS1212; true Female 21191978 CVCL_XD24 KMP8-Luc#8 cancer cell line human CVCL_XD24 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Liver. Discontinued: JCRB; JCRB1799; probable; Discontinued: JCRB; NIHS1215; true Unspecified 21191979 CVCL_XD23 JMMT-1-Luc#10 cancer cell line house mouse CVCL_XD23 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; JCRB1793; probable; Discontinued: JCRB; NIHS1216; true. Female 21191980 CVCL_XD29 AP37S(L) transformed cell line human CVCL_XD29 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21191981 CVCL_XD28 FA18JTO(SVT)-2 transformed cell line human CVCL_XD28 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1811delT; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; KURB1388; probable Male 21191982 CVCL_XD27 AP37F finite cell line human CVCL_XD27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21191983 CVCL_XD11 DT8082 cancer cell line house mouse CVCL_XD11 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: LSL-KrasG12D:LSL-Trp53R270H:Pdx1-Cre (KPC). 21191984 CVCL_XD10 1-H4 hybridoma house mouse CVCL_XD10 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. 21191985 CVCL_XD15 WISe001-A embryonic stem cell human CVCL_XD15 From: Weizmann Institute of Science; Rehovot; Israel CL:0000010 Population: Jewish Omics: Transcriptome analysis by RNAseq. Male 21191986 CVCL_XD14 IDVi005-A induced pluripotent stem cell human CVCL_XD14 From: Institut de la Vision; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Eye; retina Cell type=Muller glia.. Omics: SNP array analysis Female 21191987 CVCL_XD13 K8675 cancer cell line house mouse CVCL_XD13 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: LSL-KrasG12D:LSL-Trp53R270H:Pdx1-Cre (KPC). 21191988 CVCL_XD12 K8484 cancer cell line house mouse CVCL_XD12 CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: LSL-KrasG12D:LSL-Trp53R270H:Pdx1-Cre (KPC). 21191989 CVCL_XD19 KKK-D131 cancer cell line human CVCL_XD19 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Male Characteristics: Established from a first generation xenograft established in BALB/c Rag-2-/-/Jak3-/- mice 21191990 CVCL_XD18 KKK-D068 cancer cell line human CVCL_XD18 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Male Characteristics: Established from a first generation xenograft established in BALB/c Rag-2-/-/Jak3-/- mice 21191991 CVCL_XD17 KKK-D049 cancer cell line human CVCL_XD17 CL:0000010 Population: Southeast Asian; Thai; Derived from sampling site: Bile duct. Male Characteristics: Established from a third generation xenograft established in BALB/c Rag-2-/-/Jak3-/- mice 21191992 CVCL_XD16 WISe001-A-1 embryonic stem cell human CVCL_XD16 From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Population: Jewish. Male 21191993 CVCL_XD00 HCT116-Cas9-568 cancer cell line human CVCL_XD00 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21191994 CVCL_XD04 NCI-H1975-Cas9-596 cancer cell line human CVCL_XD04 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21191995 CVCL_XD03 NCI-H1975-Cas9-595 cancer cell line human CVCL_XD03 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21191996 CVCL_XD02 NCI-H1975-Cas9-594 cancer cell line human CVCL_XD02 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr790Met (c.2369C>T); ClinVar=VCV000016613; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly118Asp (c.353G>A); ClinVar=VCV000156446; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21191997 CVCL_XD01 HCT116-Cas9-TSC22KO-569 cancer cell line human CVCL_XD01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16826; TSC22D1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 21191998 CVCL_XD08 COLO 320DM-RFP cancer cell line human CVCL_XD08 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 21191999 CVCL_XD07 COLO 320DM-EGFP cancer cell line human CVCL_XD07 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser811Ter (c.2432C>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Colon; sigmoid. Female 21192000 CVCL_XD06 CHO-HRH1 spontaneously immortalized cell line CVCL_XD06 CL:0000010 Transfected with: HGNC; 5182; HRH1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016176 21192001 CVCL_XD05 CHO-5-HT1B spontaneously immortalized cell line CVCL_XD05 CL:0000010 Transfected with: HGNC; 5287; HTR1B; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016175 21192002 CVCL_XD09 3-H11 hybridoma house mouse CVCL_XD09 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. 21192003 CVCL_XD91 SK-HEP-1-Cas9-733 cancer cell line human CVCL_XD91 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Puro construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192004 CVCL_XD90 SK-HEP-1-Cas9-732 cancer cell line human CVCL_XD90 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Puro construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192005 CVCL_XD95 THP-1/IL21 cancer cell line human CVCL_XD95 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6005; IL21 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21192006 CVCL_XD94 THP-1/IL15 cancer cell line human CVCL_XD94 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5977; IL15 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000462) It was the sole source of information for this entry. Population: Japanese; Derived from sampling site: Peripheral blood. Male 21192007 CVCL_XD93 SK-HEP-1-Cas9-735 cancer cell line human CVCL_XD93 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Puro construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192008 CVCL_XD92 SK-HEP-1-Cas9-734 cancer cell line human CVCL_XD92 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Puro construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192009 CVCL_XD99 161CT7112 hybridoma house mouse CVCL_XD99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75832; Human PSMD10. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201154 21192010 CVCL_XD98 160CT8531 hybridoma house mouse CVCL_XD98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O75832; Human PSMD10. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201153 21192011 CVCL_XD97 FDEENTi003-A induced pluripotent stem cell human CVCL_XD97 From: Eye & ENT Hospital, Shanghai Medical School, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21192012 CVCL_XD96 CCMB-Me-14-CM1 embryonic stem cell house mouse CVCL_XD96 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Using CRISPR/Cas9 a T2A-mCherry construct was integrated in front of the stop codon of Cdx2 21192013 CVCL_XD80 LaNCE hiPSC-35 induced pluripotent stem cell human CVCL_XD80 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=31401455); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31401455) Derived from sampling site: Peripheral blood. Male 21192014 CVCL_XD84 SK-HEP-1-Cas9-726 cancer cell line human CVCL_XD84 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Neo construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192015 CVCL_XD83 ARD cancer cell line human CVCL_XD83 From: Epstein J.; Myeloma and Transplantation Research Center, Arkansas Cancer Research Center; Little Rock; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=29045832); Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ4 (CelloPub=CLPUB00604); Sequence variation: Gene fusion; HGNC; 5723; IGKJ5 + HGNC; 5732; IGKV1-16; Name(s)=IGKV1-16-IGKJ5 (CelloPub=CLPUB00604) Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Female 21192016 CVCL_XD82 LaNCE hiPSC-37 induced pluripotent stem cell human CVCL_XD82 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Glu365Lys (c.1093G>A) (E326K); ClinVar=VCV000199044; Zygosity=Heterozygous (PubMed=31401455); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31401455) Derived from sampling site: Peripheral blood. Male 21192017 CVCL_XD81 LaNCE hiPSC-36 induced pluripotent stem cell human CVCL_XD81 From: National Laboratory of Embryonic Stem Cell (LaNCE), University of Sao Paulo; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31401455) Derived from sampling site: Peripheral blood. Male 21192018 CVCL_XD88 SK-HEP-1-Cas9-730 cancer cell line human CVCL_XD88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Neo construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192019 CVCL_XD87 SK-HEP-1-Cas9-729 cancer cell line human CVCL_XD87 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Neo construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192020 CVCL_XD86 SK-HEP-1-Cas9-728 cancer cell line human CVCL_XD86 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Neo construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192021 CVCL_XD85 SK-HEP-1-Cas9-727 cancer cell line human CVCL_XD85 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Neo construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192022 CVCL_XD89 SK-HEP-1-Cas9-731 cancer cell line human CVCL_XD89 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Characteristics: Transfected with a Cas9-Flag-Puro construct Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21192023 CVCL_XD73 PC-3-Cas9-577 cancer cell line human CVCL_XD73 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192024 CVCL_XD72 PC-3-Cas9-576 cancer cell line human CVCL_XD72 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192025 CVCL_XD71 Vero E6-S spontaneously immortalized cell line green monkey CVCL_XD71 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to suspension growth Group: Non-human primate cell line; Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017101 21192026 CVCL_XD70 MCF7-Cas9-544 cancer cell line human CVCL_XD70 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Cas9-Flag-Puro construct 21192027 CVCL_XD77 WAe001-A-26 embryonic stem cell human CVCL_XD77 From: Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple_edited; p.Thr160_Lys233del; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=31450191). Male 21192028 CVCL_XD76 WAe001-A-25 embryonic stem cell human CVCL_XD76 From: Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple_edited; p.Pro230fs; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=31450191). Male 21192029 CVCL_XD75 PC-3-Cas9-579 cancer cell line human CVCL_XD75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192030 CVCL_XD74 PC-3-Cas9-578 cancer cell line human CVCL_XD74 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192031 CVCL_XD79 WAe001-A-28 embryonic stem cell human CVCL_XD79 From: Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple_edited; p.Gln110fs; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=31450191). Male 21192032 CVCL_XD78 WAe001-A-27 embryonic stem cell human CVCL_XD78 From: Translational Laboratory in Genetic Medicine, Agency for Science, Technology and Research; Singapore; Singapore CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple_edited; p.Pro230fs; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=31450191). Male 21192033 CVCL_G369 AH21-TC cancer cell line Norway rat CVCL_G369 CL:0000010 Female 21192034 CVCL_FR69 ND33202 transformed cell line human CVCL_FR69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192035 CVCL_G368 AH13/MMC-R-TC cancer cell line Norway rat CVCL_G368 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; Derived from metastatic site: Ascites. 21192036 CVCL_FR68 ND33197 transformed cell line human CVCL_FR68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192037 CVCL_G367 D8G hybridoma CVCL_G367 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P01027; Mouse C3. 21192038 CVCL_FR67 ND33177 transformed cell line human CVCL_FR67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192039 CVCL_G362 COCA finite cell line house mouse CVCL_G362 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.; Breed/subspecies: C57BL/6 x DBA/2. Female 21192040 CVCL_FR62 ND33126 transformed cell line human CVCL_FR62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192041 CVCL_G361 AB1 HA cancer cell line house mouse CVCL_G361 CL:0000010 Transfected with: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: BALB/c. Female 21192042 CVCL_FR61 ND33125 transformed cell line human CVCL_FR61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192043 CVCL_G360 AH66F-TC cancer cell line Norway rat CVCL_G360 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from metastatic site: Ascites. 21192044 CVCL_FR60 ND33117 transformed cell line human CVCL_FR60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192045 CVCL_FR66 ND33175 transformed cell line human CVCL_FR66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192046 CVCL_G366 SKR1 cancer cell line human CVCL_G366 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Female Doubling time: 28 hours, at 50th passage (PubMed=9183637) Caution: The age/sex of donor of this cell line and that of NKK1 (Cellosaurus=CVCL_G365), both described in PubMed=9183637 are inverted in the abstract of that paper We believe that the information in the material and methods section is the correct one as it is corroborated by the karyotype information in the same paper. 21192047 CVCL_FR65 ND33174 transformed cell line human CVCL_FR65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192048 CVCL_G365 NKK1 cancer cell line human CVCL_G365 CL:0000010 Population: Japanese; Derived from sampling site: Kidney. Male Doubling time: 45 hours, at 20th passage (PubMed=9183637) Caution: The age/sex of donor of this cell line and that of SKR1 (Cellosaurus=CVCL_G366), both described in PubMed=9183637 are inverted in the abstract of that paper We believe that the information in the material and methods section is the correct one as it is corroborated by the karyotype information in the same paper. 21192049 CVCL_G364 KH88 cancer cell line human CVCL_G364 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from child cell lines KH88 B4D6 and KH88 C2F8) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21192050 CVCL_FR64 ND33171 transformed cell line human CVCL_FR64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192051 CVCL_G363 LA-795 cancer cell line house mouse CVCL_G363 CL:0000010 Breed/subspecies: T739. Male 21192052 CVCL_FR63 ND33150 transformed cell line human CVCL_FR63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192053 CVCL_FR79 ND33323 transformed cell line human CVCL_FR79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192054 CVCL_FR78 ND33322 transformed cell line human CVCL_FR78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192055 CVCL_FR73 ND33262 transformed cell line human CVCL_FR73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192056 CVCL_G373 RADA-1-TC cancer cell line house mouse CVCL_G373 CL:0000010 Female 21192057 CVCL_FR72 ND33259 transformed cell line human CVCL_FR72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192058 CVCL_G372 NS-8 cancer cell line human CVCL_G372 CL:0000010 Discontinued: RCB; RCB2089; true. Unspecified 21192059 CVCL_G371 KM105 hybridoma house mouse CVCL_G371 CL:0000010 Monoclonal antibody isotype: IgG2a. 21192060 CVCL_FR71 ND33225 transformed cell line human CVCL_FR71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192061 CVCL_FR70 ND33203 transformed cell line human CVCL_FR70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192062 CVCL_G370 QT-1-TC cancer cell line Norway rat CVCL_G370 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: Donryu. Female 21192063 CVCL_FR77 ND33296 transformed cell line human CVCL_FR77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192064 CVCL_FR76 ND33283 transformed cell line human CVCL_FR76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192065 CVCL_FR75 ND33266 transformed cell line human CVCL_FR75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192066 CVCL_FR74 ND33264 transformed cell line human CVCL_FR74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192067 CVCL_G348 KH-R finite cell line CVCL_G348 CL:0000010 Derived from sampling site: Fetal heart. 21192068 CVCL_FR48 ND32767 transformed cell line human CVCL_FR48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192069 CVCL_G347 CHSE/F spontaneously immortalized cell line CVCL_G347 CL:0000010 Unspecified Group: Fish cell line Problematic cell line: Misidentified Originally thought to be of Oncorhynchus tschawytscha origin and to be CHSE-214 but found to be from Lepomis macrochirus.. 21192070 CVCL_FR47 ND32766 transformed cell line human CVCL_FR47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192071 CVCL_FR46 ND32763 transformed cell line human CVCL_FR46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192072 CVCL_G346 NS0-Turbodoma cancer cell line house mouse CVCL_G346 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21192073 CVCL_FR45 ND32760 transformed cell line human CVCL_FR45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192074 CVCL_G345 NS0-SFM cancer cell line house mouse CVCL_G345 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21192075 CVCL_G349 CARM-L1 TG3 cancer cell line Norway rat CVCL_G349 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. Female Doubling time: 34.1 +- 2.0 hours (at 8th passage), 40.8 +- 2.6 hours (at 21th passage) (PubMed=2981541) 21192076 CVCL_FR49 ND32802 transformed cell line human CVCL_FR49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192077 CVCL_G340 N-S.7 hybridoma house mouse CVCL_G340 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21192078 CVCL_FR40 ND32722 transformed cell line human CVCL_FR40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192079 CVCL_G344 1107F-HA hybridoma house mouse CVCL_G344 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mycoplasma bovis (BCG). 21192080 CVCL_FR44 ND32757 transformed cell line human CVCL_FR44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192081 CVCL_FR43 ND32754 transformed cell line human CVCL_FR43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192082 CVCL_G343 RP-3 hybridoma house mouse CVCL_G343 CL:0000010 Discontinued: JCRB; NIHS0254; true. Monoclonal antibody isotype: IgM 21192083 CVCL_FR42 ND32753 transformed cell line human CVCL_FR42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192084 CVCL_G342 RP-1 hybridoma house mouse CVCL_G342 CL:0000010 Discontinued: JCRB; NIHS0253; true. Monoclonal antibody isotype: IgG1 21192085 CVCL_G341 N-S.8.1 hybridoma house mouse CVCL_G341 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Sheep red blood cells (SRBC). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21192086 CVCL_FR41 ND32723 transformed cell line human CVCL_FR41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192087 CVCL_FR59 ND33035 transformed cell line human CVCL_FR59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192088 CVCL_G359 YS-TC cancer cell line Norway rat CVCL_G359 CL:0000010 Derived from metastatic site: Ascites. 21192089 CVCL_G358 LIM2358 cancer cell line human CVCL_G358 CL:0000010 Derived from sampling site: Colon. Unspecified Doubling time: >4 days (PubMed=1427983) 21192090 CVCL_FR58 ND33031 transformed cell line human CVCL_FR58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192091 CVCL_G357 m17.ASC somatic stem cell house mouse CVCL_G357 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female Doubling time: 32 hours (PubMed=23777308) Group: Patented cell line; Registration: International Depositary Authority, Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC), Italy; PD 10001 21192092 CVCL_FR57 ND33030 transformed cell line human CVCL_FR57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192093 CVCL_G356 HT-29-MTX-E12 cancer cell line human CVCL_G356 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female 21192094 CVCL_FR56 ND33012 transformed cell line human CVCL_FR56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192095 CVCL_G351 Me11-TG6 cancer cell line Norway rat CVCL_G351 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. 21192096 CVCL_FR51 ND32823 transformed cell line human CVCL_FR51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192097 CVCL_G350 CARM-L12 TG3 cancer cell line Norway rat CVCL_G350 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. Female Doubling time: 43.2 +- 1.4 hours (at 8th passage), 40.8 +- 4.0 hours (at 20th passage) (PubMed=2981541) 21192098 CVCL_FR50 ND32805 transformed cell line human CVCL_FR50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192099 CVCL_G355 CARM-L11 TG3 cancer cell line Norway rat CVCL_G355 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. Female Doubling time: 47.4 +- 7.6 hours (at 9th passage), 41.5 +- 3.3 hours (at 21th passage) (PubMed=2981541) 21192100 CVCL_FR55 ND32979 transformed cell line human CVCL_FR55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192101 CVCL_G354 Me9-TG3 cancer cell line Norway rat CVCL_G354 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. Female Doubling time: 42.1 +- 1.4 hours (at 3th passage), 40.0 +- 2.7 hours (at 8th passage) (PubMed=2981541) 21192102 CVCL_FR54 ND32880 transformed cell line human CVCL_FR54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192103 CVCL_G353 Me19-TG2 cancer cell line Norway rat CVCL_G353 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. 21192104 CVCL_FR53 ND32848 transformed cell line human CVCL_FR53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192105 CVCL_G352 Me17-TG6 cancer cell line Norway rat CVCL_G352 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Lung; Breed/subspecies: PVG/c. 21192106 CVCL_FR52 ND32847 transformed cell line human CVCL_FR52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192107 CVCL_FR26 ND32645 transformed cell line human CVCL_FR26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192108 CVCL_G326 YUHEF cancer cell line human CVCL_G326 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Gln853Ter (c.2557C>T); ClinVar=VCV001318665; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Lys2552Thrfs*2; Zygosity=Unspecified (PubMed=26214590) Anecdotal: Established from the lung metastatic melanoma cells of Robert V Heffernan (the 'HEF' in the cell name) who wrote about his successful fight against cancer in an autobiographical book (CelloPub=CLPUB00386). Population: Caucasian; Derived from metastatic site: Lung. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21192109 CVCL_FR25 ND32644 transformed cell line human CVCL_FR25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192110 CVCL_G325 YUFULO cancer cell line human CVCL_G325 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=20149136). Male Part of: Yale University (YU) melanoma cell collection 21192111 CVCL_FR24 ND32582 transformed cell line human CVCL_FR24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192112 CVCL_G324 YUFIC cancer cell line human CVCL_G324 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21192113 CVCL_FR23 ND32560 transformed cell line human CVCL_FR23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192114 CVCL_G323 YUDOSO cancer cell line human CVCL_G323 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26214590); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Male Part of: Yale University (YU) melanoma cell collection 21192115 CVCL_FR29 ND32650 transformed cell line human CVCL_FR29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192116 CVCL_G329 YUKOLI cancer cell line human CVCL_G329 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21192117 CVCL_FR28 ND32648 transformed cell line human CVCL_FR28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192118 CVCL_G328 YUKIM cancer cell line human CVCL_G328 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=26214590) Derived from metastatic site: Lymph node. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Yale University (YU) melanoma cell collection 21192119 CVCL_FR27 ND32646 transformed cell line human CVCL_FR27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192120 CVCL_G327 YUHUY cancer cell line human CVCL_G327 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Part of: Yale University (YU) melanoma cell collection 21192121 CVCL_FR22 ND32557 transformed cell line human CVCL_FR22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192122 CVCL_G322 YUDEDE cancer cell line human CVCL_G322 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Pretibial; soft tissue. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21192123 CVCL_FR21 ND32556 transformed cell line human CVCL_FR21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192124 CVCL_G321 WW165 cancer cell line human CVCL_G321 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray. Female 21192125 CVCL_FR20 ND32550 transformed cell line human CVCL_FR20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192126 CVCL_G320 PNP-Mel cancer cell line human CVCL_G320 From: Guadagni F.; Regina Elena Institute for Cancer Research; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Trp (c.301G>T) (p.Arg115Leu, c.344G>T); ClinVar=VCV000009412; Zygosity=Unspecified (PubMed=19799798; PubMed=29492214) Derived from sampling site: Skin. Unspecified 21192127 CVCL_G337 MYB 2-32 hybridoma house mouse CVCL_G337 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01104; Avian myeloblastosis virus v-Myb (Note=Also reacts with chicken MYB). 21192128 CVCL_FR37 ND32703 transformed cell line human CVCL_FR37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192129 CVCL_G336 MK-S4 hybridoma house mouse CVCL_G336 CL:0000010 Monoclonal antibody isotype: IgG2b. 21192130 CVCL_FR36 ND32702 transformed cell line human CVCL_FR36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192131 CVCL_G335 25-9-17S II hybridoma house mouse CVCL_G335 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192132 CVCL_FR35 ND32681 transformed cell line human CVCL_FR35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192133 CVCL_FR34 ND32676 transformed cell line human CVCL_FR34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192134 CVCL_G339 N-S.4.1 hybridoma house mouse CVCL_G339 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Sheep red blood cells (SRBC). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21192135 CVCL_FR39 ND32721 transformed cell line human CVCL_FR39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192136 CVCL_G338 N-S.2.1 hybridoma house mouse CVCL_G338 CL:0000010 Monoclonal antibody isotype: IgM, lambda. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21192137 CVCL_FR38 ND32706 transformed cell line human CVCL_FR38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192138 CVCL_FR33 ND32671 transformed cell line human CVCL_FR33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192139 CVCL_G333 YUVON3 cancer cell line human CVCL_G333 CL:0000010 Male Part of: Yale University (YU) melanoma cell collection. 21192140 CVCL_FR32 ND32670 transformed cell line human CVCL_FR32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192141 CVCL_G332 YUSIV cancer cell line human CVCL_G332 CL:0000010 Derived from metastatic site: Chest. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Part of: Yale University (YU) melanoma cell collection 21192142 CVCL_FR31 ND32652 transformed cell line human CVCL_FR31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192143 CVCL_G331 YUMUT cancer cell line human CVCL_G331 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Derived from metastatic site: Wrist; soft tissue. Omics: Deep exome analysis Male Part of: Yale University (YU) melanoma cell collection 21192144 CVCL_FR30 ND32651 transformed cell line human CVCL_FR30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192145 CVCL_G330 YULOVY cancer cell line human CVCL_G330 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (PubMed=20149136; PubMed=26214590) Omics: Deep exome analysis. Female Part of: Yale University (YU) melanoma cell collection 21192146 CVCL_FR09 ND32244 transformed cell line human CVCL_FR09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192147 CVCL_G309 SCCT3 cancer cell line human CVCL_G309 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Unspecified (PubMed=21602893). Male 21192148 CVCL_FR04 ND32122 transformed cell line human CVCL_FR04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192149 CVCL_G304 SCCRDEB3 cancer cell line human CVCL_G304 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Arg525Ter (c.1573C>T); ClinVar=VCV000279785; Zygosity=Heterozygous (PubMed=21602893); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Arg578Ter (c.1732C>T); ClinVar=VCV000372330; Zygosity=Heterozygous (PubMed=21602893); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Lys176Arg (c.527A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg353Cys (c.1057C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767). Female 21192150 CVCL_FR03 ND32121 transformed cell line human CVCL_FR03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192151 CVCL_G303 SCCRDEB2 cancer cell line human CVCL_G303 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Glu143Gly (c.428A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Thr1090Ser (c.3269C>G); ClinVar=VCV000544171; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val173Leu (c.517G>T); ClinVar=VCV000376668; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767). Male 21192152 CVCL_FR02 ND32066 transformed cell line human CVCL_FR02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192153 CVCL_G302 SCCIC8 cancer cell line human CVCL_G302 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gln1687Ter (c.5059C>T); Zygosity=Unspecified (PubMed=22006338; PubMed=24662767) Derived from metastatic site: Buttock; skin. Female 21192154 CVCL_FR01 ND32002 transformed cell line human CVCL_FR01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192155 CVCL_G301 SCCIC12 cancer cell line human CVCL_G301 CL:0000010 Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Gly49Glu (c.146G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Pro (c.800G>C); ClinVar=VCV000428867; Zygosity=Unspecified (PubMed=24662767) Derived from metastatic site: Left calf; skin. Female 21192156 CVCL_FR08 ND32224 transformed cell line human CVCL_FR08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192157 CVCL_G308 SCCT2 cancer cell line human CVCL_G308 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asn71Ile (c.212A>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys409Phe (c.1226G>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Glu415Asp (c.1245G>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp469Gly (c.1406A>G); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; c.1108+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys433Tyr (c.1298G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Gly1751Asp (c.5252G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Arg2131Lys (c.6392G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Pro2343Ser (c.7027C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.375+1G>T; ClinVar=VCV000635393; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=21602893; PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767) Derived from sampling site: Hand; skin. Male 21192158 CVCL_FR07 ND32165 transformed cell line human CVCL_FR07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192159 CVCL_G307 SCCT1 cancer cell line human CVCL_G307 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; c.1555+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly95Glu (c.284G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly115Ser (c.343G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Tyr577Ter (c.1731C>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly578Arg (c.1732G>C); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly578Ser (c.1732G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys861Tyr (c.2582G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Asp1515Glu (c.4545C>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Ser (c.701A>C); ClinVar=VCV000376690; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767). Male 21192160 CVCL_FR06 ND32132 transformed cell line human CVCL_FR06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192161 CVCL_G306 SCCRDEB5 cancer cell line human CVCL_G306 CL:0000010 Female 21192162 CVCL_FR05 ND32131 transformed cell line human CVCL_FR05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192163 CVCL_G305 SCCRDEB4 cancer cell line human CVCL_G305 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly2749fs (c.8244insC); Zygosity=Homozygous (PubMed=21602893); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asp1517Asn (c.4549G>A); ClinVar=VCV000523598; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1797Pro (c.5390T>C); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Arg113Ter (c.337C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136Ter (c.406C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Unspecified (PubMed=21602893). Female 21192164 CVCL_FR00 ND31964 transformed cell line human CVCL_FR00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192165 CVCL_G300 SCCIC1 cancer cell line human CVCL_G300 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>A; ClinVar=VCV000635365; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=24662767); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp154Asn (c.460G>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys456Ser (c.1366T>A); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Cys456Phe (c.1367G>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Asn1809His; Zygosity=Unspecified (PubMed=22006338); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Pro1913Leu (c.5738C>T); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=21602893; PubMed=24662767) Derived from sampling site: Right temple; skin. Male 21192166 CVCL_G315 ME-F2/ADM100 cancer cell line human CVCL_G315 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male 21192167 CVCL_FR15 ND32497 transformed cell line human CVCL_FR15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192168 CVCL_G314 ME-F3 cancer cell line human CVCL_G314 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 9-12 days (PubMed=8018932) 21192169 CVCL_FR14 ND32466 transformed cell line human CVCL_FR14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192170 CVCL_G313 ME-F2 cancer cell line human CVCL_G313 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Deep quantitative phosphoproteome analysis Male Doubling time: 2-3 days (PubMed=8018932) 21192171 CVCL_FR13 ND32454 transformed cell line human CVCL_FR13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192172 CVCL_G312 ME-F1 cancer cell line human CVCL_G312 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male Doubling time: 5-7 days (PubMed=8018932) 21192173 CVCL_FR12 ND32411 transformed cell line human CVCL_FR12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192174 CVCL_FR19 ND32547 transformed cell line human CVCL_FR19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192175 CVCL_G319 SCMC-L4 cancer cell line human CVCL_G319 CL:0000010 Population: Japanese. Male 21192176 CVCL_FR18 ND32524 transformed cell line human CVCL_FR18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192177 CVCL_G318 SCMC-L3 cancer cell line human CVCL_G318 CL:0000010 Population: Japanese. Male 21192178 CVCL_FR17 ND32523 transformed cell line human CVCL_FR17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192179 CVCL_G316 ME-F2/ADM200 cancer cell line human CVCL_G316 CL:0000010 Sequence variation: Gene fusion; HGNC; 1539; CBFB + HGNC; 7569; MYH11; Name(s)=CBFB-MYH11 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Male 21192180 CVCL_FR16 ND32511 transformed cell line human CVCL_FR16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192181 CVCL_G311 Meg-J cancer cell line human CVCL_G311 CL:0000010 Population: Japanese Unspecified Microsatellite instability: Stable (MSS) (PubMed=10739008; PubMed=11226526). 21192182 CVCL_FR11 ND32382 transformed cell line human CVCL_FR11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192183 CVCL_FR10 ND32340 transformed cell line human CVCL_FR10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192184 CVCL_G310 SCCT8 cancer cell line human CVCL_G310 CL:0000010 Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys616Phe (c.1847G>T); ClinVar=VCV000498790; Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Cys616Ser (c.1847G>C); Zygosity=Unspecified (PubMed=24662767); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp91Gly (c.271T>G); Zygosity=Unspecified (PubMed=21602893) Derived from sampling site: Ear; skin. Male 21192185 CVCL_XF20 AT31RM transformed cell line human CVCL_XF20 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Homozygous (PubMed=9497252) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192186 CVCL_XF24 AT42RM transformed cell line human CVCL_XF24 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Heterozygous (PubMed=9497252; PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp1858Ter (c.5574G>A); ClinVar=VCV001380184; Zygosity=Heterozygous (PubMed=9497252; PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192187 CVCL_XF23 AT43RM transformed cell line human CVCL_XF23 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Homozygous (PubMed=8845835; PubMed=10864201; PubMed=12105990) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192188 CVCL_XF22 AT35RM transformed cell line human CVCL_XF22 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Heterozygous (PubMed=9497252; PubMed=10864201; PubMed=12105990); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp1858Ter (c.5574G>A); ClinVar=VCV001380184; Zygosity=Heterozygous (PubMed=9497252; PubMed=10864201; PubMed=12105990) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192189 CVCL_XF21 AT32RM transformed cell line human CVCL_XF21 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1267_Val1268insTer (c.3802delG) (p.Val1268Terfs); ClinVar=VCV000127374; Zygosity=Homozygous (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192190 CVCL_XF28 AT54RM transformed cell line human CVCL_XF28 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2598Ter (c.7792C>T); ClinVar=VCV000265383; Zygosity=Heterozygous (PubMed=10864201; PubMed=12105990); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2762Alafs*6 (c.8283_8284delTC); Zygosity=Heterozygous (PubMed=10864201; PubMed=12105990) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192191 CVCL_XF27 AT53RM transformed cell line human CVCL_XF27 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ala1812_Phe1813delinsVal (c.5435_5437del3); Zygosity=Heterozygous (PubMed=9497252); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6573-9G>A (IVS47-9G>A); ClinVar=VCV000642095; Zygosity=Heterozygous; Note=Activates a cryptic splice site (PubMed=9497252) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192192 CVCL_XF26 AT52RM transformed cell line human CVCL_XF26 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2443Ter (c.7327C>T); ClinVar=VCV000003036; Zygosity=Heterozygous (PubMed=10864201; PubMed=12105990); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8365delA; Zygosity=Heterozygous (PubMed=10864201; PubMed=12105990) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192193 CVCL_XF25 AT44RM transformed cell line human CVCL_XF25 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.1607+1G>T (IVS12+1G>T); ClinVar=VCV000220555; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192194 CVCL_XF29 AT57RM transformed cell line human CVCL_XF29 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser151Terfs (c.450_453delTTCT); Zygosity=Heterozygous (PubMed=8845835; PubMed=10864201; PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Heterozygous (PubMed=8845835; PubMed=10864201; PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192195 CVCL_XF13 Reg4-G7 hybridoma house mouse CVCL_XF13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9BYZ8; Human REG4 Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200728 21192196 CVCL_XF12 Met-1 hybridoma house mouse CVCL_XF12 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:6809; Methamphetamine. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200914 21192197 CVCL_XF11 DF-1\\J spontaneously immortalized cell line CVCL_XF11 CL:0000010 Transfected with: UniProtKB; Q9YJY0; Avian leukosis virus subgroup J isolate ADOL-Hc-1 envelope protein (Env); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Not susceptible to infection by avian leukosis virus subgroup J Group: Bird cell line 21192198 CVCL_XF10 DF-1/K spontaneously immortalized cell line CVCL_XF10 CL:0000010 Transfected with: UniProtKB; A0A0H4LXT3; Avian leukosis virus subgroup K isolate GDFX0601 envelope protein (Env); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Not susceptible to infection by avian leukosis virus subgroup K Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201610 21192199 CVCL_XF17 AT21RM transformed cell line human CVCL_XF17 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Unexplicit; IVS18+1delG (p.Lys793_Leu822del30, c.2377_2466del90); Zygosity=Homozygous (PubMed=8845835; PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192200 CVCL_XF16 AT15RM transformed cell line human CVCL_XF16 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu43Leu (c.129T>C); Zygosity=Heterozygous (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192201 CVCL_XF15 THC10A hybridoma house mouse CVCL_XF15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:66964; Delta(9)-tetrahydrocannabinol (THC). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200915 21192202 CVCL_XF14 ST03 hybridoma house mouse CVCL_XF14 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:18227; Sterigmatocystin (ST). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013187 21192203 CVCL_XF19 AT28RM transformed cell line human CVCL_XF19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2598Ter (c.7792C>T); ClinVar=VCV000265383; Zygosity=Heterozygous (PubMed=10864201); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2762Alafs*6 (c.8283_8284delTC); Zygosity=Heterozygous (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192204 CVCL_XF18 AT27RM transformed cell line human CVCL_XF18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192205 CVCL_XF02 14E4 hybridoma house mouse CVCL_XF02 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01151; Human CD83. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014188 21192206 CVCL_XF01 11A7 hybridoma house mouse CVCL_XF01 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01151; Human CD83. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014187 21192207 CVCL_XF00 SG5B7 hybridoma house mouse CVCL_XF00 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human antigen on esophageal carcinoma cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200311 21192208 CVCL_XF06 BCSP31-1F1 hybridoma house mouse CVCL_XF06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A3T2; Brucella melitensis biotype 1 31 kDa immunogenic protein (bcsP31). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200806 21192209 CVCL_XF05 BCSP31-1E5 hybridoma house mouse CVCL_XF05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0A3T2; Brucella melitensis biotype 1 31 kDa immunogenic protein (bcsP31). 21192210 CVCL_XF04 1H10 hybridoma house mouse CVCL_XF04 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q01151; Human CD83. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014186 21192211 CVCL_XF03 18A4 hybridoma house mouse CVCL_XF03 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O95994; Human AGR2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200902 21192212 CVCL_XF09 DF-1/B spontaneously immortalized cell line CVCL_XF09 CL:0000010 Transfected with: Avian leukosis virus subgroup B isolate CD08 envelope protein (Env); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Not susceptible to infection by avian leukosis virus subgroup B Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201609 21192213 CVCL_XF08 DF-1/A spontaneously immortalized cell line CVCL_XF08 CL:0000010 Transfected with: UniProtKB; P03397; Avian leukosis virus subgroup A isolate Schmidt-Ruppin A envelope protein (Env); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Not susceptible to infection by avian leukosis virus subgroup A Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014180 21192214 CVCL_XF07 CHO-S/K70E10-1D6 spontaneously immortalized cell line CVCL_XF07 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Expresses the anti-AGR2 humanized monoclonal antibody K70E10-1D6 Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014189 21192215 CVCL_FR89 ND33518 transformed cell line human CVCL_FR89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192216 CVCL_FR84 ND33456 transformed cell line human CVCL_FR84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192217 CVCL_FR83 ND03045 transformed cell line human CVCL_FR83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192218 CVCL_FR82 ND03044 transformed cell line human CVCL_FR82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192219 CVCL_FR81 ND33408 transformed cell line human CVCL_FR81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192220 CVCL_FR88 ND33516 transformed cell line human CVCL_FR88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192221 CVCL_FR87 ND33515 transformed cell line human CVCL_FR87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192222 CVCL_FR86 ND33498 transformed cell line human CVCL_FR86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192223 CVCL_G385 GM07007 transformed cell line human CVCL_G385 HLA typing: A*02:01,31:01; B*18:01,40:01; C*03:04:01:01,07:01; DPA1*01:03,01:03; DPB1*03:01,06:01; DQA1*01:01,03:01; DQB1*03:02,05:03; DRB1*14:01,04:04; DRB3*02,30:01; DRB4*01 (IPD-IMGT/HLA=25813) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM07007; probable Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133112 21192224 CVCL_FR85 ND33465 transformed cell line human CVCL_FR85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192225 CVCL_FR80 ND33352 transformed cell line human CVCL_FR80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192226 CVCL_FR95 ND33620 transformed cell line human CVCL_FR95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192227 CVCL_FR94 ND33613 transformed cell line human CVCL_FR94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192228 CVCL_G393 CEPH-1332-NA00000 transformed cell line human CVCL_G393 HLA typing: A*03:01,03:01; B*27:05,35:01; C*02:02:02,04:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,03:01; DQB1*03:02:01,05:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25821) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21192229 CVCL_FR93 ND33581 transformed cell line human CVCL_FR93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192230 CVCL_FR92 ND33563 transformed cell line human CVCL_FR92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192231 CVCL_FR99 ND33744 transformed cell line human CVCL_FR99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192232 CVCL_FR98 ND33706 transformed cell line human CVCL_FR98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192233 CVCL_FR97 ND33660 transformed cell line human CVCL_FR97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192234 CVCL_FR96 ND33651 transformed cell line human CVCL_FR96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192235 CVCL_FR91 ND33520 transformed cell line human CVCL_FR91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192236 CVCL_FR90 ND33519 transformed cell line human CVCL_FR90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192237 CVCL_XE83 PK15-IL-2 spontaneously immortalized cell line pig CVCL_XE83 CL:0000010 Transfected with: VGNC; 98935; Pig IL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Porcine circovirus type 2 (PCV2) proliferation is significantly enhanced compared to the parent cell line Group: Patented cell line 21192238 CVCL_XE82 7C72F7 hybridoma house mouse CVCL_XE82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q52UN8; Cyprinid herpesvirus 3 major capsid protein (ORF92). 21192239 CVCL_XE81 1B71B4 hybridoma house mouse CVCL_XE81 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q52UN8; Cyprinid herpesvirus 3 major capsid protein (ORF92). Group: Patented cell line 21192240 CVCL_XE80 Li-7-Cas9-760 cancer cell line human CVCL_XE80 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21192241 CVCL_XE87 STL-C2 cancer cell line human CVCL_XE87 CL:0000010 Population: Chinese. 21192242 CVCL_XE86 STL-C1 cancer cell line human CVCL_XE86 CL:0000010 Population: Chinese; Derived from sampling site: Liver. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201630 21192243 CVCL_XE85 Huh-7/M8 cancer cell line human CVCL_XE85 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Highly metastatic Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014247 21192244 CVCL_XE84 MKN45-Cas9-526 cancer cell line human CVCL_XE84 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from metastatic site: Liver. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192245 CVCL_XE89 CTNI-C4 hybridoma house mouse CVCL_XE89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19429; Human TNNI3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013185 21192246 CVCL_XE88 TP-D5 hybridoma house mouse CVCL_XE88 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08515; Schistosoma japonicum glutathione S-transferase class-mu 26 kDa isozyme. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013184 21192247 CVCL_XE72 Li-7-Cas9-752 cancer cell line human CVCL_XE72 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192248 CVCL_XE71 Li-7-Cas9-751 cancer cell line human CVCL_XE71 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192249 CVCL_XE70 Li-7-Luc2-tdT cancer cell line human CVCL_XE70 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Japanese; Derived from sampling site: Liver. Male 21192250 CVCL_XE76 Li-7-Cas9-756 cancer cell line human CVCL_XE76 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192251 CVCL_XE75 Li-7-Cas9-755 cancer cell line human CVCL_XE75 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192252 CVCL_XE74 Li-7-Cas9-754 cancer cell line human CVCL_XE74 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192253 CVCL_XE73 Li-7-Cas9-753 cancer cell line human CVCL_XE73 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192254 CVCL_XE79 Li-7-Cas9-759 cancer cell line human CVCL_XE79 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21192255 CVCL_XE78 Li-7-Cas9-758 cancer cell line human CVCL_XE78 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21192256 CVCL_XE77 Li-7-Cas9-757 cancer cell line human CVCL_XE77 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21192257 CVCL_XE61 CJF cancer cell line human CVCL_XE61 CL:0000010 Population: Chinese; Derived from metastatic site: Liver. Unspecified Doubling time: 48 hours (Patent=CN101993854B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200956 21192258 CVCL_XE60 MDA-MB-231sci cancer cell line human CVCL_XE60 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Highly metastatic Group: Patented cell line; Group: Triple negative breast cancer (TNBC) cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200955 21192259 CVCL_XE65 H9C2(2-1)-mCherry spontaneously immortalized cell line Norway rat CVCL_XE65 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Embryonic heart; cardiac muscle; Breed/subspecies: BDIX. Unspecified 21192260 CVCL_XE64 H9C2(2-1)-Luc2-tdT spontaneously immortalized cell line Norway rat CVCL_XE64 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Embryonic heart; cardiac muscle; Breed/subspecies: BDIX. Unspecified 21192261 CVCL_XE63 HCT116-EGFP cancer cell line human CVCL_XE63 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000661) It was the sole source of information for this entry. Derived from sampling site: Colon. Male 21192262 CVCL_XE62 NCI-H1299-Luc2-tdT-2 cancer cell line human CVCL_XE62 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male 21192263 CVCL_XE69 A549-Luc2-tdT-2 cancer cell line human CVCL_XE69 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Lung. Male 21192264 CVCL_XE68 A549-Cas9-538 cancer cell line human CVCL_XE68 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192265 CVCL_XE67 A549-5Fu cancer cell line human CVCL_XE67 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Lung. Male 21192266 CVCL_XE66 H9C2(2-1)-tdT spontaneously immortalized cell line Norway rat CVCL_XE66 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Embryonic heart; cardiac muscle; Breed/subspecies: BDIX. Unspecified 21192267 CVCL_XE50 K562-Wnt5a cancer cell line human CVCL_XE50 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 12784; WNT5A Population: Caucasian; Derived from sampling site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200958 21192268 CVCL_XE54 Hep3b-Cas9-744 cancer cell line human CVCL_XE54 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192269 CVCL_XE53 Hep3b-Cas9-743 cancer cell line human CVCL_XE53 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192270 CVCL_XE52 Hep3b-Cas9-742 cancer cell line human CVCL_XE52 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192271 CVCL_XE51 Hep3b-Cas9-741 cancer cell line human CVCL_XE51 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192272 CVCL_XE58 hT279 hybridoma house mouse CVCL_XE58 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q96KW9; Human SPACA7. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200953 21192273 CVCL_XE57 hTSC29 hybridoma house mouse CVCL_XE57 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q5T0L3; Human SPATA46. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200952 21192274 CVCL_XE56 CSQT-1 cancer cell line human CVCL_XE56 CL:0000010 Population: Chinese; Derived from metastatic site: Portal vein. Male Doubling time: 48.2 hours (Patent=CN101597591B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200814 21192275 CVCL_XE55 Hep3b-Cas9-745 cancer cell line human CVCL_XE55 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Arg146Ter (c.436C>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser576Ter (c.1727C>G); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Karyotypic information: Has lost chromosome Y; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21192276 CVCL_XE59 A375sci cancer cell line human CVCL_XE59 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Highly metastatic Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200954 21192277 CVCL_XE43 HeLa-Cas9-531 cancer cell line human CVCL_XE43 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192278 CVCL_XE42 HeLa-Cas9-530 cancer cell line human CVCL_XE42 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192279 CVCL_XE41 HeLa-Cas9-529 cancer cell line human CVCL_XE41 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192280 CVCL_XE40 HeLa-Cas9-528 cancer cell line human CVCL_XE40 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192281 CVCL_XE47 HeLa-Cas9-535 cancer cell line human CVCL_XE47 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192282 CVCL_XE46 HeLa-Cas9-534 cancer cell line human CVCL_XE46 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192283 CVCL_XE45 HeLa-Cas9-533 cancer cell line human CVCL_XE45 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192284 CVCL_XE44 HeLa-Cas9-532 cancer cell line human CVCL_XE44 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192285 CVCL_XE49 HeLa-Cas9-537 cancer cell line human CVCL_XE49 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192286 CVCL_XE48 HeLa-Cas9-536 cancer cell line human CVCL_XE48 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192287 CVCL_XE32 Ax7 hybridoma house mouse CVCL_XE32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10850 21192288 CVCL_XE31 Ax51 hybridoma house mouse CVCL_XE31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10851 21192289 CVCL_XE30 Ax292 hybridoma house mouse CVCL_XE30 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10859 21192290 CVCL_XE36 GCCF-2 spontaneously immortalized cell line CVCL_XE36 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Virology: Susceptible to infection by grass carp reovirus (GCRV) (CelloPub=CLPUB00675) Doubling time: 21-33 hours (CelloPub=CLPUB00675) Group: Fish cell line 21192291 CVCL_XE35 OLM spontaneously immortalized cell line CVCL_XE35 CL:0000010 Derived from sampling site: Muscle. Unspecified Doubling time: 34.60 +- 2.87 hours (DOI=10.7541/2019.040) Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201812 21192292 CVCL_XE34 LYCB spontaneously immortalized cell line CVCL_XE34 CL:0000010 Miscellaneous: As no cell line name was provided in the patent, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Brain. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013156 21192293 CVCL_XE33 Ax96 hybridoma house mouse CVCL_XE33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10852 21192294 CVCL_XE39 HeLa-Cas9-527 cancer cell line human CVCL_XE39 CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21192295 CVCL_XE38 HL-60/RS cancer cell line human CVCL_XE38 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201430 21192297 CVCL_XE21 10F10 hybridoma house mouse CVCL_XE21 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; CHEBI:37659; Oleanolic acid. 21192298 CVCL_XE20 TMDNG2 hybridoma house mouse CVCL_XE20 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human nephropathy-related immunoglobulin-like protein (NRIg). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10491 21192299 CVCL_XE25 Ax225 hybridoma house mouse CVCL_XE25 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10855 21192300 CVCL_XE24 Ax223 hybridoma house mouse CVCL_XE24 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10853 21192301 CVCL_XE23 7A6 hybridoma house mouse CVCL_XE23 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:37659; Oleanolic acid. 21192302 CVCL_XE22 6C2 hybridoma house mouse CVCL_XE22 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:37659; Oleanolic acid. 21192303 CVCL_XE29 Ax285 hybridoma house mouse CVCL_XE29 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10858 21192304 CVCL_XE28 Ax284 hybridoma house mouse CVCL_XE28 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10857 21192305 CVCL_XE27 Ax258 hybridoma house mouse CVCL_XE27 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10856 21192306 CVCL_XE26 Ax232 hybridoma house mouse CVCL_XE26 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P30530; Human AXL. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10854 21192307 CVCL_XE10 292.118.6.4 hybridoma house mouse CVCL_XE10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6830 21192308 CVCL_XE14 292.84.1.6 hybridoma house mouse CVCL_XE14 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6871 21192309 CVCL_XE13 292.72.3.1 hybridoma house mouse CVCL_XE13 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6816 21192310 CVCL_XE12 292.63.5.3 hybridoma house mouse CVCL_XE12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6829 21192311 CVCL_XE11 292.12.3.1 hybridoma house mouse CVCL_XE11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6815 21192312 CVCL_XE18 294.35.2.6.3 hybridoma house mouse CVCL_XE18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6872 21192313 CVCL_XE17 294.163.2.1 hybridoma house mouse CVCL_XE17 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6831 21192314 CVCL_XE16 294.154.5.6 hybridoma house mouse CVCL_XE16 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6875 21192315 CVCL_XE15 294.144.3.5 hybridoma house mouse CVCL_XE15 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q6EBC2; Human IL31. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-6873 21192316 CVCL_XE19 TMDNM3 hybridoma house mouse CVCL_XE19 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human nephropathy-related immunoglobulin-like protein (NRIg). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10490 21192317 CVCL_XE90 S-10-4 hybridoma house mouse CVCL_XE90 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200933 21192318 CVCL_XE94 TSCC1 cancer cell line human CVCL_XE94 CL:0000010 Group: Patented cell line. 21192319 CVCL_XE93 S-77-1 hybridoma house mouse CVCL_XE93 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200935 21192320 CVCL_XE92 S-294-4 hybridoma house mouse CVCL_XE92 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200931 21192321 CVCL_XE91 S-113-6 hybridoma house mouse CVCL_XE91 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200932 21192322 CVCL_XE98 SG5B11 hybridoma house mouse CVCL_XE98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human antigen on esophageal carcinoma cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200309 21192323 CVCL_XE97 SG5B8 hybridoma house mouse CVCL_XE97 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human antigen on esophageal carcinoma cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200308 21192324 CVCL_XE96 AV2G1 hybridoma house mouse CVCL_XE96 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6Q788; Human APOA5. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200805 21192325 CVCL_XE95 AV1F1 hybridoma house mouse CVCL_XE95 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6Q788; Human APOA5. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200804 21192326 CVCL_XE99 SGD5 hybridoma house mouse CVCL_XE99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human antigen on esophageal carcinoma cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200310 21192327 CVCL_FS89 ND35454 transformed cell line human CVCL_FS89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192328 CVCL_FS88 ND35453 transformed cell line human CVCL_FS88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192329 CVCL_FS83 ND35377 transformed cell line human CVCL_FS83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192330 CVCL_FS82 ND35376 transformed cell line human CVCL_FS82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192331 CVCL_FS81 ND35324 transformed cell line human CVCL_FS81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192332 CVCL_FS80 ND35278 transformed cell line human CVCL_FS80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192333 CVCL_FS87 ND35451 transformed cell line human CVCL_FS87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192334 CVCL_FS86 ND35427 transformed cell line human CVCL_FS86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192335 CVCL_FS85 ND35413 transformed cell line human CVCL_FS85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192336 CVCL_FS84 ND35409 transformed cell line human CVCL_FS84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192337 CVCL_FS99 ND35702 transformed cell line human CVCL_FS99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192338 CVCL_FS94 ND35574 transformed cell line human CVCL_FS94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192339 CVCL_FS93 ND35564 transformed cell line human CVCL_FS93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192340 CVCL_FS92 ND35503 transformed cell line human CVCL_FS92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192341 CVCL_FS91 ND35499 transformed cell line human CVCL_FS91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192342 CVCL_FS98 ND35639 transformed cell line human CVCL_FS98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192343 CVCL_FS97 ND35636 transformed cell line human CVCL_FS97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192344 CVCL_FS96 ND35618 transformed cell line human CVCL_FS96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192345 CVCL_FS95 ND35575 transformed cell line human CVCL_FS95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192346 CVCL_FS90 ND35498 transformed cell line human CVCL_FS90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192347 CVCL_FS69 ND34994 transformed cell line human CVCL_FS69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192348 CVCL_FS68 ND34991 transformed cell line human CVCL_FS68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192349 CVCL_FS67 ND34983 transformed cell line human CVCL_FS67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192350 CVCL_FS66 ND34968 transformed cell line human CVCL_FS66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192351 CVCL_FS61 ND34948 transformed cell line human CVCL_FS61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192352 CVCL_FS60 ND34930 transformed cell line human CVCL_FS60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192353 CVCL_FS65 ND34952 transformed cell line human CVCL_FS65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192354 CVCL_FS64 ND34951 transformed cell line human CVCL_FS64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192355 CVCL_FS63 ND34950 transformed cell line human CVCL_FS63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192356 CVCL_FS62 ND34949 transformed cell line human CVCL_FS62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192357 CVCL_FS79 ND35259 transformed cell line human CVCL_FS79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192358 CVCL_FS78 ND35227 transformed cell line human CVCL_FS78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192359 CVCL_FS77 ND35226 transformed cell line human CVCL_FS77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192360 CVCL_FS72 ND35056 transformed cell line human CVCL_FS72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192361 CVCL_FS71 ND35055 transformed cell line human CVCL_FS71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192362 CVCL_G470 GM11874 transformed cell line human CVCL_G470 HLA typing: A*03:01,68:01:02; B*07:02,44:04; C*07:02,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:01,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=25898) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM11874; probable Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134707 21192363 CVCL_FS70 ND34995 transformed cell line human CVCL_FS70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192364 CVCL_FS76 ND35151 transformed cell line human CVCL_FS76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192365 CVCL_FS75 ND35150 transformed cell line human CVCL_FS75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192366 CVCL_FS74 ND35081 transformed cell line human CVCL_FS74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192367 CVCL_FS73 ND35068 transformed cell line human CVCL_FS73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192368 CVCL_FS47 ND34545 transformed cell line human CVCL_FS47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192369 CVCL_FS46 ND34530 transformed cell line human CVCL_FS46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192370 CVCL_FS45 ND34529 transformed cell line human CVCL_FS45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192371 CVCL_FS44 ND34463 transformed cell line human CVCL_FS44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192372 CVCL_FS49 ND34611 transformed cell line human CVCL_FS49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192373 CVCL_FS48 ND34548 transformed cell line human CVCL_FS48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192374 CVCL_FS43 ND34462 transformed cell line human CVCL_FS43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192375 CVCL_FS42 ND34430 transformed cell line human CVCL_FS42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192376 CVCL_FS41 ND34406 transformed cell line human CVCL_FS41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192377 CVCL_FS40 ND34405 transformed cell line human CVCL_FS40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192378 CVCL_FS58 ND34817 transformed cell line human CVCL_FS58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192379 CVCL_FS57 ND34816 transformed cell line human CVCL_FS57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192380 CVCL_FS56 ND34815 transformed cell line human CVCL_FS56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192381 CVCL_FS55 ND34750 transformed cell line human CVCL_FS55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192382 CVCL_FS59 ND34885 transformed cell line human CVCL_FS59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192383 CVCL_FS50 ND34616 transformed cell line human CVCL_FS50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192384 CVCL_FS54 ND34709 transformed cell line human CVCL_FS54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192385 CVCL_FS53 ND34639 transformed cell line human CVCL_FS53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192386 CVCL_FS52 ND34618 transformed cell line human CVCL_FS52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192387 CVCL_FS51 ND34617 transformed cell line human CVCL_FS51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192388 CVCL_FS25 ND34126 transformed cell line human CVCL_FS25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192389 CVCL_FS24 ND34116 transformed cell line human CVCL_FS24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192390 CVCL_FS23 ND34110 transformed cell line human CVCL_FS23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192391 CVCL_FS22 ND34097 transformed cell line human CVCL_FS22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192392 CVCL_FS29 ND34187 transformed cell line human CVCL_FS29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192393 CVCL_FS28 ND34170 transformed cell line human CVCL_FS28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192394 CVCL_FS27 ND34169 transformed cell line human CVCL_FS27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192395 CVCL_FS26 ND34128 transformed cell line human CVCL_FS26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192396 CVCL_FS21 ND34095 transformed cell line human CVCL_FS21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192397 CVCL_FS20 ND34078 transformed cell line human CVCL_FS20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192398 CVCL_G436 CEPH-1344-NA00000 transformed cell line human CVCL_G436 HLA typing: A*03:01; B*51:01; C*01:02; DPA1*01:03; DPB1*03:01:01; DQA1*01:01; DQB1*05:01:01; DRB1*01:01; DRB4*01 (IPD-IMGT/HLA=25864) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21192399 CVCL_FS36 ND34338 transformed cell line human CVCL_FS36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192400 CVCL_FS35 ND34321 transformed cell line human CVCL_FS35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192401 CVCL_FS34 ND34304 transformed cell line human CVCL_FS34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192402 CVCL_FS33 ND34274 transformed cell line human CVCL_FS33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192403 CVCL_FS39 ND34404 transformed cell line human CVCL_FS39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192404 CVCL_FS38 ND34401 transformed cell line human CVCL_FS38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192405 CVCL_FS37 ND34400 transformed cell line human CVCL_FS37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192406 CVCL_FS32 ND34242 transformed cell line human CVCL_FS32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192407 CVCL_FS31 ND34239 transformed cell line human CVCL_FS31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192408 CVCL_FS30 ND34200 transformed cell line human CVCL_FS30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192409 CVCL_XG41 TRMP PDGFRB-p.Phe771 spontaneously immortalized cell line dog CVCL_XG41 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr771Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192410 CVCL_XG40 TRMP PDGFRB-p.Phe763 spontaneously immortalized cell line dog CVCL_XG40 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr763Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192411 CVCL_XG45 TRMP PDGFRB-p.Phe966 spontaneously immortalized cell line dog CVCL_XG45 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr966Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192412 CVCL_XG44 TRMP PDGFRB-p.Phe857 spontaneously immortalized cell line dog CVCL_XG44 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr857Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192413 CVCL_XG43 TRMP PDGFRB-p.Phe778 spontaneously immortalized cell line dog CVCL_XG43 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr778Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192414 CVCL_XG42 TRMP PDGFRB-p.Phe775 spontaneously immortalized cell line dog CVCL_XG42 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr775Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192415 CVCL_XG49 DRA12 transformed cell line human CVCL_XG49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192416 CVCL_XG48 DAA-3 transformed cell line human CVCL_XG48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192417 CVCL_XG47 TRMP PDGFRB-WT spontaneously immortalized cell line dog CVCL_XG47 CL:0000010 Transfected with: HGNC; 8804; PDGFRB Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192418 CVCL_XG46 TRMP PDGFRB-p.Phe970 spontaneously immortalized cell line dog CVCL_XG46 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr970Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192419 CVCL_5A04 WLC-3 transformed cell line CVCL_5A04 CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver Cell type=Hepatocyte.. Male Doubling time: ~38 hours (PubMed=2888713) 21192420 CVCL_5A03 PLC/AN/2 cancer cell line human CVCL_5A03 CL:0000010 Derived from sampling site: Liver. Male Doubling time: 20 hours (in 2% and 10% FCS), 26 hours (in serum and hormone free medium) (PubMed=1694812) 21192421 CVCL_5A02 Mz-Hep-1 cancer cell line human CVCL_5A02 CL:0000010 Derived from sampling site: Liver. Female Doubling time: 60 hours (PubMed=2415435) 21192422 CVCL_5A01 HH29 spontaneously immortalized cell line human CVCL_5A01 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Female 21192423 CVCL_5A08 GK129/1 embryonic stem cell house mouse CVCL_5A08 CL:0000010 Breed/subspecies: 129P2/OlaHsd. Male 21192424 CVCL_5A07 GK129 embryonic stem cell house mouse CVCL_5A07 CL:0000010 Breed/subspecies: 129P2/OlaHsd. Male 21192425 CVCL_5A06 Trex1-/- MEF spontaneously immortalized cell line house mouse CVCL_5A06 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1328317; Trex1 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129P2/OlaHsd. Unspecified 21192426 CVCL_5A05 KY-Rb cancer cell line human CVCL_5A05 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000375871; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Brain; meninges. Male 21192427 CVCL_5A09 MCF-7/AnaR-1 cancer cell line human CVCL_5A09 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole; Derived from metastatic site: Pleural effusion. Female 21192428 CVCL_XG30 TRMP PDGFRB-p.Arg634 spontaneously immortalized cell line dog CVCL_XG30 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Lys634Arg) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192429 CVCL_XG34 TRMP PDGFRB-p.Phe1021 spontaneously immortalized cell line dog CVCL_XG34 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr1021Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192430 CVCL_XG33 TRMP PDGFRB-p.Phe1009-p.Phe1021 spontaneously immortalized cell line dog CVCL_XG33 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr1009Phe and p.Tyr1021Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192431 CVCL_XG32 TRMP PDGFRB-p.Phe1009 spontaneously immortalized cell line dog CVCL_XG32 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr1009Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192432 CVCL_XG31 TRMP PDGFRB-p.Gly751 spontaneously immortalized cell line dog CVCL_XG31 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr751Gly) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192433 CVCL_XG38 TRMP PDGFRB-p.Phe740-p.Phe751-p.Phe771 spontaneously immortalized cell line dog CVCL_XG38 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr740Phe, p.Tyr751Phe and p.Tyr771Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192434 CVCL_XG37 TRMP PDGFRB-p.Phe740-p.Phe751 spontaneously immortalized cell line dog CVCL_XG37 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr740Phe and p.Tyr751Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192435 CVCL_XG36 TRMP PDGFRB-p.Phe740 spontaneously immortalized cell line dog CVCL_XG36 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr740Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192436 CVCL_XG35 TRMP PDGFRB-p.Phe716 spontaneously immortalized cell line dog CVCL_XG35 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr716Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192437 CVCL_XG39 TRMP PDGFRB-p.Phe751 spontaneously immortalized cell line dog CVCL_XG39 CL:0000010 Transfected with: HGNC; 8804; PDGFRB (with p.Tyr751Phe) Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female 21192438 CVCL_5A00 HH25 spontaneously immortalized cell line human CVCL_5A00 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Female 21192439 CVCL_XG23 MSU-1.1-v-Ki-ras 1 transformed cell line human CVCL_XG23 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Tumorigenic 21192440 CVCL_XG22 MSU-1.1-S62 transformed cell line human CVCL_XG22 CL:0000010 Transfected with: HGNC; 11270; SPRY2 (V5-tagged); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21192441 CVCL_XG21 MSU-1.1-S41 transformed cell line human CVCL_XG21 CL:0000010 Transfected with: HGNC; 11270; SPRY2 (V5-tagged); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21192442 CVCL_XG20 MSU-1.1-N-ras 3 transformed cell line human CVCL_XG20 CL:0000010 Transfected with: HGNC; 7989; NRAS; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Tumorigenic 21192443 CVCL_XG27 PH2MT transformed cell line human CVCL_XG27 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Derived from a tumor formed in athymic mice by injection of the parent cell line 21192444 CVCL_XG26 MSU-1.1-T24 3 transformed cell line human CVCL_XG26 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21192445 CVCL_XG25 MSU-1.1-T24 2 transformed cell line human CVCL_XG25 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21192446 CVCL_XG24 MSU-1.1-v-Ki-ras 2 transformed cell line human CVCL_XG24 CL:0000010 Transfected with: UniProtKB; P01117; Kirsten murine sarcoma virus Ki-Ras; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Tumorigenic 21192447 CVCL_XG29 AT22IJE-T pEBS7-YZ3 transformed cell line human CVCL_XG29 CL:0000010 Transfected with: HGNC; 795; ATM Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192448 CVCL_XG28 PH3MT transformed cell line human CVCL_XG28 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Growth factor-independent, form large-sized colonies in agarose and form fibrosarcomas in athymic mice at the site of injection with a very short latency; Characteristics: Derived from a tumor formed in athymic mice by injection of the parent cell line 21192449 CVCL_XG12 TTD1VI-LAS-KMT11 transformed cell line human CVCL_XG12 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Expression of the SV40 large T antigen is under the control of the metal ion-inducible mouse metallothionein-1 promoter (PubMed=7563073) 21192450 CVCL_XG11 AzcHAT-1X400C spontaneously immortalized cell line dog CVCL_XG11 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192451 CVCL_XG10 AzcHAT-1X100C spontaneously immortalized cell line dog CVCL_XG10 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192452 CVCL_XG16 PC-p53(143Ala) Cl4 spontaneously immortalized cell line Norway rat CVCL_XG16 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thyroid gland. Unspecified 21192453 CVCL_XG15 PC-p53(143Ala) Cl1 spontaneously immortalized cell line Norway rat CVCL_XG15 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thyroid gland. Unspecified 21192454 CVCL_XG14 TTD2VILasCl1 transformed cell line human CVCL_XG14 CL:0000010 Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192455 CVCL_XG13 TTD1VI-LAS-KMT11-D10 transformed cell line human CVCL_XG13 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3434; ERCC2; Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Transfection of wildtype ERCC2 corrects the defects in the parent cell line; Characteristics: Expression of the SV40 large T antigen is under the control of the metal ion-inducible mouse metallothionein-1 promoter (PubMed=7563073) 21192456 CVCL_XG19 MSU-1.1-N-ras 2 transformed cell line human CVCL_XG19 CL:0000010 Transfected with: HGNC; 7989; NRAS; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: v-Myc; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Tumorigenic 21192457 CVCL_XG18 LG1 finite cell line human CVCL_XG18 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21192458 CVCL_XG17 PC-p53(143Ala) Cl5 spontaneously immortalized cell line Norway rat CVCL_XG17 CL:0000010 Transfected with: HGNC; 11998; TP53 (with p.Val143Ala); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thyroid gland. Unspecified 21192459 CVCL_XG01 TTD2VILas transformed cell line human CVCL_XG01 CL:0000010 Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192460 CVCL_XG00 TTD2VI finite cell line human CVCL_XG00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192461 CVCL_XG05 4TG-11 spontaneously immortalized cell line dog CVCL_XG05 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192462 CVCL_XG04 TRMP spontaneously immortalized cell line dog CVCL_XG04 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Does not express PDGFRs (PubMed=2550144) Doubling time: 24 hours (PubMed=7669722) 21192463 CVCL_XG03 XPCS2VILas transformed cell line human CVCL_XG03 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly602Asp (c.1805G>A); Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21192464 CVCL_XG02 XPCS2VI finite cell line human CVCL_XG02 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly602Asp (c.1805G>A); Zygosity=Heterozygous (from autologous cell lines XP-CS2 and XP-CS2 LCL) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21192465 CVCL_XG09 AzcHAT-15X spontaneously immortalized cell line dog CVCL_XG09 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192466 CVCL_XG08 AzcHAT-8X spontaneously immortalized cell line dog CVCL_XG08 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192467 CVCL_XG07 AzcHAT-4X spontaneously immortalized cell line dog CVCL_XG07 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192468 CVCL_XG06 AzcHAT-1X spontaneously immortalized cell line dog CVCL_XG06 CL:0000010 Selected for resistance to: ChEBI; CHEBI:2038; 5-azacytidine (5-azaC); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Kidney; Breed/subspecies: Beagle. Female Characteristics: Deficient in HPRT 21192469 CVCL_XF93 HiB5.pNS-6 conditionally immortalized cell line Norway rat CVCL_XF93 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Expresses eGFP under the control of the CMV promoter 21192470 CVCL_XF92 HiB5.LV-BA8 conditionally immortalized cell line Norway rat CVCL_XF92 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Expresses eGFP under the control of the CMV promoter 21192471 CVCL_XF91 HiB5 conditionally immortalized cell line Norway rat CVCL_XF91 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Proliferates at the permissive temperature (33 Celsius) Differentiates at the restrictive temperature (37 Celsius). 21192472 CVCL_XF90 RN33B.LV-AA2 conditionally immortalized cell line Norway rat CVCL_XF90 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; medullary raphe nucleus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Expresses eGFP under the control of the CMV promoter 21192473 CVCL_XF97 NBS-ILB1 transformed cell line human CVCL_XF97 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (PubMed=10377945) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767). Unspecified 21192474 CVCL_XF96 MFT-6 transformed cell line house mouse CVCL_XF96 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Control cell line for MFT-16 which is KO for vimentin (Vim) 21192475 CVCL_XF95 MFT-16 transformed cell line house mouse CVCL_XF95 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98932; Vim Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: 129S2/SvPas Vimtm1Cba. Unspecified 21192476 CVCL_XF94 HiB5.pUbi-11 conditionally immortalized cell line Norway rat CVCL_XF94 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; hippocampus; Breed/subspecies: Sprague Dawley. Unspecified Characteristics: Expresses eGFP under the control of the ubiquitin (UbC) promoter 21192477 CVCL_XF99 TTD1VILas transformed cell line human CVCL_XF99 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21192478 CVCL_XF98 TTD1VI finite cell line human CVCL_XF98 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=8571952) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21192479 CVCL_XF82 UTA21.15 cancer cell line human CVCL_XF82 CL:0000010 Transfected with: HGNC; 1784; CDKN1A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Expresses very little CDKN1A when cultured in the presence of tetracycline, whereas CDKN1A expression is dramatically induced upon removal of tetracycline from the culture medium; Characteristics: Transfected with an expression plasmid containing CKN1A (p21waf1) under control of a minimal CMV promoter fused to tetracycline operator sequences 21192480 CVCL_XF81 UISO-MEL-4 cancer cell line human CVCL_XF81 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Male 21192481 CVCL_XF80 UISO-MEL-1 cancer cell line human CVCL_XF80 CL:0000010 Population: Caucasian; Derived from metastatic site: Submandibular lymph node. Male 21192482 CVCL_XF86 VL3-3L2 cancer cell line house mouse CVCL_XF86 CL:0000010 Transformant: Radiation murine leukemia virus(NCBI-Taxonomy; 11787); Breed/subspecies: C57BL/6Ka. 21192483 CVCL_XF85 BL/VL3 cancer cell line house mouse CVCL_XF85 CL:0000010 Transformant: Radiation murine leukemia virus(NCBI-Taxonomy; 11787); Breed/subspecies: C57BL/6Ka. 21192484 CVCL_XF84 BL/RL12-NP cancer cell line house mouse CVCL_XF84 CL:0000010 Transformant: X-Ray(NCIt; C17262); Breed/subspecies: C57BL/6Ka. Doubling time: 16 hours (PubMed=6290043) 21192485 CVCL_XF83 UTA21.9 cancer cell line human CVCL_XF83 CL:0000010 Transfected with: HGNC; 1784; CDKN1A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Expresses very little CDKN1A when cultured in the presence of tetracycline, whereas CDKN1A expression is dramatically induced upon removal of tetracycline from the culture medium; Characteristics: Transfected with an expression plasmid containing CKN1A (p21waf1) under control of a minimal CMV promoter fused to tetracycline operator sequences 21192486 CVCL_XF89 2DNA1D7 conditionally immortalized cell line Norway rat CVCL_XF89 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; glomerulus Cell type=Podocyte.. Characteristics: Proliferates at the permissive temperature (33 Celsius) Differentiates at the restrictive temperature (37 Celsius). 21192487 CVCL_XF88 Bewo31 cancer cell line human CVCL_XF88 CL:0000010 Transfected with: HGNC; 4197; GCM1 Derived from metastatic site: Fetal brain. Male Characteristics: Stably expresses HA-tagged GCM1 under the control of the CMV promoter 21192488 CVCL_XF87 VL3-3M2 cancer cell line house mouse CVCL_XF87 CL:0000010 Transformant: Radiation murine leukemia virus(NCBI-Taxonomy; 11787); Breed/subspecies: C57BL/6Ka. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K9me2 ChIP-seq epigenome analysis 21192489 CVCL_XF71 S2R+-spin-GFP-2 spontaneously immortalized cell line fruit fly CVCL_XF71 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the spin locus (FBgn0086676) Group: Insect cell line 21192490 CVCL_XF70 S2R+-Sec23-GFP-6 spontaneously immortalized cell line fruit fly CVCL_XF70 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Sec23 locus (FBgn0262125) Group: Insect cell line 21192491 CVCL_XF75 S2R+-Tom20-GFP-2 spontaneously immortalized cell line fruit fly CVCL_XF75 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Tom20 locus (FBgn0036928) Group: Insect cell line 21192492 CVCL_XF74 S2R+-Tnks-KO-3H spontaneously immortalized cell line fruit fly CVCL_XF74 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0027508; Tnks; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: Using CRISPR/Cas Tnks alleles were replaced with an insertion cassette carrying the puromycin resistance gene Group: Insect cell line 21192493 CVCL_XF73 S2R+-Tnks-KO-12A spontaneously immortalized cell line fruit fly CVCL_XF73 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0027508; Tnks; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: Using CRISPR/Cas Tnks alleles were replaced with an insertion cassette carrying the puromycin resistance gene Group: Insect cell line 21192494 CVCL_XF72 S2R+-Tnks-KO-10B spontaneously immortalized cell line fruit fly CVCL_XF72 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0027508; Tnks; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: Using CRISPR/Cas Tnks alleles were replaced with an insertion cassette carrying the puromycin resistance gene Group: Insect cell line 21192495 CVCL_XF79 UTA6 cancer cell line human CVCL_XF79 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female 21192496 CVCL_XF78 STA5 cancer cell line human CVCL_XF78 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone. Female 21192497 CVCL_XF77 S-195-5 hybridoma house mouse CVCL_XF77 CL:0000010 Monoclonal antibody isotype: IgG, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200934 21192498 CVCL_XF76 143B rho-0#25 cancer cell line human CVCL_XF76 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Characteristics: Cell line devoid of mitochondrial DNA (rho0) Produced by transient transfection with plasmid pMA4008 encoding HSV-1 UL12.5M185 protein, which damages mtDNA by an unknown mechanism. 21192499 CVCL_XF60 NR6WT spontaneously immortalized cell line house mouse CVCL_XF60 CL:0000010 Transfected with: HGNC; 3236; EGFR; Transfected with: UniProtKB; P03211; EBV EBNA1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: Swiss albino. Male 21192500 CVCL_XF64 S2R+-Fib-GFP-12 spontaneously immortalized cell line fruit fly CVCL_XF64 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Fib locus (FBgn0003062) Group: Insect cell line 21192501 CVCL_XF63 S2R+-Fib-GFP-11 spontaneously immortalized cell line fruit fly CVCL_XF63 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Fib locus (FBgn0003062) Group: Insect cell line 21192502 CVCL_XF62 S2R+-Cnx99a-GFP-4 spontaneously immortalized cell line fruit fly CVCL_XF62 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Cnx99a locus (FBgn0015622) Group: Insect cell line 21192503 CVCL_XF61 S2R+-arl8-GFP-4 spontaneously immortalized cell line fruit fly CVCL_XF61 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Arl8 locus (FBgn0037551) Group: Insect cell line 21192504 CVCL_XF68 S2R+-Golgin245-GFP-1 spontaneously immortalized cell line fruit fly CVCL_XF68 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Golgin245 locus (FBgn0034854) Group: Insect cell line 21192505 CVCL_XF67 S2R+-Gmap-GFP-7 spontaneously immortalized cell line fruit fly CVCL_XF67 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Gmap locus (FBgn0027287) Group: Insect cell line 21192506 CVCL_XF66 S2R+-Gmap-GFP-4 spontaneously immortalized cell line fruit fly CVCL_XF66 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Gmap locus (FBgn0027287) Group: Insect cell line 21192507 CVCL_XF65 S2R+-gig-KO spontaneously immortalized cell line fruit fly CVCL_XF65 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0005198; gig Breed/subspecies: Oregon-R. Male Group: Insect cell line 21192508 CVCL_XF69 S2R+-Lam-GFP-7 spontaneously immortalized cell line fruit fly CVCL_XF69 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of eGFP into the Lam locus (FBgn0002525) Group: Insect cell line 21192509 CVCL_XF53 btl>Ras attP-L7 spontaneously immortalized cell line fruit fly CVCL_XF53 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Characteristics: btl-Gal4 driving UAS-RasV12 and UAS-p35 (baculovirus anti-apoptotic factor p35) with an attP flanked cassette for RMCE Group: Insect cell line 21192510 CVCL_XF52 24B>Ras attP-L5 spontaneously immortalized cell line fruit fly CVCL_XF52 CL:0000010 Derived from sampling site: Embryonic muscle. Unspecified Characteristics: how(24B)-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE Group: Insect cell line 21192511 CVCL_XF51 24B>Ras attP GFP-L1 spontaneously immortalized cell line fruit fly CVCL_XF51 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic muscle. Unspecified Characteristics: how(24B)-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE and co-expression of GFP Group: Insect cell line 21192512 CVCL_XF57 repo>Ras bratdsRNA-L6 spontaneously immortalized cell line fruit fly CVCL_XF57 CL:0000010 Unspecified Characteristics: repo-Gal4 driving UAS-RasV12 and UAS-bratdsRNA (P\{y[+t7.7] v[+t1.8]=TRiP.HMS01121\}attP2). Group: Insect cell line 21192513 CVCL_XF56 OK6>Ras attP-L3 spontaneously immortalized cell line fruit fly CVCL_XF56 CL:0000010 Unspecified Characteristics: OK6-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE. Group: Insect cell line 21192514 CVCL_XF55 OK6>Ras attP-L2 spontaneously immortalized cell line fruit fly CVCL_XF55 CL:0000010 Unspecified Characteristics: OK6-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE. Group: Insect cell line 21192515 CVCL_XF54 btl>Ras attP-L8 spontaneously immortalized cell line fruit fly CVCL_XF54 CL:0000010 Derived from sampling site: Cell type=Epithelial cell. Unspecified Characteristics: btl-Gal4 driving UAS-RasV12 and UAS-p35 (baculovirus anti-apoptotic factor p35) with an attP flanked cassette for RMCE Group: Insect cell line 21192516 CVCL_XF59 S2-GFP-RFP-Atg8a spontaneously immortalized cell line fruit fly CVCL_XF59 CL:0000010 Transfected with: FlyBase_Gene; FBgn0052672; Atg8a; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Breed/subspecies: Oregon-R. Male Group: Insect cell line 21192517 CVCL_XF58 delta l(3)mbt-OSC spontaneously immortalized cell line fruit fly CVCL_XF58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0002441; l(3)mbt Derived from sampling site: Ovary. Female Group: Insect cell line 21192518 CVCL_XF42 JCaM1/Lck+ cancer cell line human CVCL_XF42 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6524; LCK (with p.Arg154Lys); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Parent cell line is deficient for LCK activity due to a deletion of exon 7 but this cell line has a restored wildtype LCK activity 21192519 CVCL_XF41 JCaM1/TAg cancer cell line human CVCL_XF41 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P03070; SV40 large T antigen Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Deficient for LCK activity due to a deletion of exon 7 21192520 CVCL_XF40 UISO-H-MEL-2-IL-2 cancer cell line human CVCL_XF40 CL:0000010 Transfected with: HGNC; 6001; IL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21192521 CVCL_XF45 JSL4 cancer cell line human CVCL_XF45 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expresses relatively high levels of the larger PTPRC/CD45 isoforms relative to isoform CD45R0 (PubMed=10594010) 21192522 CVCL_XF44 JSL1 cancer cell line human CVCL_XF44 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expresses relatively high levels of the larger PTPRC/CD45 isoforms relative to isoform CD45R0 (PubMed=10594010) 21192523 CVCL_XF43 JCaM1/LckR154K cancer cell line human CVCL_XF43 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6524; LCK (with p.Arg154Lys); Transfected with: UniProtKB; P03070; SV40 large T antigen; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Parent cell line is deficient for LCK activity due to a deletion of exon 7 This cell line with a transfected LCK with the p.Arg154Lys substitution within the SH2 domain does not have a restored signaling activity (PubMed=8626636). 21192524 CVCL_XF31 AT65RM transformed cell line human CVCL_XF31 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6573-9G>A (IVS47-9G>A); ClinVar=VCV000642095; Zygosity=Heterozygous; Note=Activates a cryptic splice site (PubMed=10864201); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Met2938Ilefs (c.8814_8824delGAGAAACTCTC) (8814del11); Zygosity=Heterozygous (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192525 CVCL_XF30 AT58RM transformed cell line human CVCL_XF30 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys750Lys (c.2250G>A); ClinVar=VCV000003044; Zygosity=Heterozygous; Note=Causes skipping of exon 14 (p.Ile709_Lys750del, c.2125_2250del) (PubMed=10864201; PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Asp2708Asn (c.8122G>A); ClinVar=VCV000142791; Zygosity=Heterozygous (PubMed=10864201; PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192526 CVCL_XF35 JGFP1 cancer cell line human CVCL_XF35 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expression of the eGFP reporter gene is under the control of four tandem copies of the NF-kappaB response element 21192528 CVCL_XF33 AT74RM transformed cell line human CVCL_XF33 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.3993ins29; Zygosity=Homozygous (PubMed=10864201) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192529 CVCL_XF32 AT68RM transformed cell line human CVCL_XF32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21192530 CVCL_XF39 UISO-MEL-2 cancer cell line human CVCL_XF39 CL:0000010 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21192531 CVCL_XF38 UISO-GCT-1 cancer cell line human CVCL_XF38 CL:0000010 Derived from sampling site: Bone; proximal tibia. Male Doubling time: 76.8 hours, at 5th passage (PubMed=8095436) 21192532 CVCL_XF37 GCTB28 cancer cell line human CVCL_XF37 CL:0000010 Population: Chinese; Derived from sampling site: Bone; spine. Male Doubling time: 44 hours (PubMed=26801673) 21192533 CVCL_XF36 JPM50.6 cancer cell line human CVCL_XF36 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: CARMA1-deficient mutant; Characteristics: The eGFP reporter gene is under the control of four tandem copies of the NF-kappaB response element 21192534 CVCL_FS09 ND33856 transformed cell line human CVCL_FS09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192535 CVCL_FS08 ND33854 transformed cell line human CVCL_FS08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192536 CVCL_FS03 ND33794 transformed cell line human CVCL_FS03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192537 CVCL_FS02 ND33793 transformed cell line human CVCL_FS02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192538 CVCL_FS01 ND33791 transformed cell line human CVCL_FS01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192539 CVCL_FS00 ND33789 transformed cell line human CVCL_FS00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192540 CVCL_FS07 ND33835 transformed cell line human CVCL_FS07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192541 CVCL_FS06 ND33834 transformed cell line human CVCL_FS06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192542 CVCL_FS05 ND33807 transformed cell line human CVCL_FS05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192543 CVCL_FS04 ND33795 transformed cell line human CVCL_FS04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192544 CVCL_FS19 ND34077 transformed cell line human CVCL_FS19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192545 CVCL_FS14 ND33950 transformed cell line human CVCL_FS14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192546 CVCL_FS13 ND33948 transformed cell line human CVCL_FS13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192547 CVCL_FS12 ND33884 transformed cell line human CVCL_FS12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192548 CVCL_FS11 ND33861 transformed cell line human CVCL_FS11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192549 CVCL_FS18 ND34059 transformed cell line human CVCL_FS18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192550 CVCL_FS17 ND34058 transformed cell line human CVCL_FS17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192551 CVCL_FS16 ND34056 transformed cell line human CVCL_FS16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192552 CVCL_FS15 ND33951 transformed cell line human CVCL_FS15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192553 CVCL_FS10 ND33860 transformed cell line human CVCL_FS10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192554 CVCL_G589 28-13-3S hybridoma house mouse CVCL_G589 CL:0000010 Monoclonal antibody isotype: IgM. 21192555 CVCL_FT89 ND37377 transformed cell line human CVCL_FT89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192556 CVCL_G588 28-11-5S hybridoma house mouse CVCL_G588 CL:0000010 Discontinued: IZSLER; BS Hy 60; probable. Monoclonal antibody isotype: IgM 21192557 CVCL_FT88 ND37357 transformed cell line human CVCL_FT88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192558 CVCL_G587 26-8-16S hybridoma house mouse CVCL_G587 CL:0000010 Monoclonal antibody isotype: IgM. 21192559 CVCL_FT87 ND37356 transformed cell line human CVCL_FT87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192560 CVCL_G582 23A-5-21S hybridoma house mouse CVCL_G582 CL:0000010 Monoclonal antibody isotype: IgM. 21192561 CVCL_FT82 ND37183 transformed cell line human CVCL_FT82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192562 CVCL_G581 232 hybridoma house mouse CVCL_G581 CL:0000010 Monoclonal antibody isotype: IgG2b (Patent=US5175255); IgG2a (ATCC); Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9372 21192563 CVCL_FT81 ND37178 transformed cell line human CVCL_FT81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192564 CVCL_G580 219 hybridoma house mouse CVCL_G580 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P01127; Human PDGFB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9371 21192565 CVCL_FT80 ND37176 transformed cell line human CVCL_FT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192566 CVCL_G586 26-7-11S hybridoma house mouse CVCL_G586 CL:0000010 Monoclonal antibody isotype: IgM, kappa. 21192567 CVCL_FT86 ND37346 transformed cell line human CVCL_FT86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192568 CVCL_G585 25-9-3S hybridoma house mouse CVCL_G585 CL:0000010 Monoclonal antibody isotype: IgM. 21192569 CVCL_FT85 ND37321 transformed cell line human CVCL_FT85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192570 CVCL_G584 25-5-16S hybridoma house mouse CVCL_G584 CL:0000010 Monoclonal antibody isotype: IgM. 21192571 CVCL_FT84 ND37306 transformed cell line human CVCL_FT84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192572 CVCL_G583 24IA2E2E10D5 hybridoma house mouse CVCL_G583 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P10262; Feline leukemia virus gag (AA 198-445; p27/p30). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8049 21192573 CVCL_FT83 ND37199 transformed cell line human CVCL_FT83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192574 CVCL_G599 34-4-20S hybridoma house mouse CVCL_G599 CL:0000010 Discontinued: IZSLER; BS Hy 61; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse MHC class I H-2Dd 21192575 CVCL_FT99 ND38558 transformed cell line human CVCL_FT99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192576 CVCL_G598 34-2-12S hybridoma house mouse CVCL_G598 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse MHC class I H-2Dd. 21192577 CVCL_FT98 ND38534 transformed cell line human CVCL_FT98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192578 CVCL_G593 2D7F10 hybridoma house mouse CVCL_G593 CL:0000010 Monoclonal antibody isotype: IgA; Monoclonal antibody target: Leptospira interrogans serovar Kennewicki. 21192579 CVCL_FT93 ND37601 transformed cell line human CVCL_FT93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192580 CVCL_G592 28-8-6S hybridoma house mouse CVCL_G592 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192581 CVCL_FT92 ND37503 transformed cell line human CVCL_FT92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192582 CVCL_G591 28-16-8S hybridoma house mouse CVCL_G591 CL:0000010 Monoclonal antibody isotype: IgM. 21192583 CVCL_FT91 ND37428 transformed cell line human CVCL_FT91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192584 CVCL_G590 28-14-8S hybridoma house mouse CVCL_G590 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192585 CVCL_FT90 ND37378 transformed cell line human CVCL_FT90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192586 CVCL_G597 34-1-2S hybridoma house mouse CVCL_G597 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Mouse MHC class I H-2Kd/H-2Dd. 21192587 CVCL_FT97 ND38409 transformed cell line human CVCL_FT97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192588 CVCL_G596 31-3-4S hybridoma house mouse CVCL_G596 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse MHC class I H-2Kd. 21192589 CVCL_FT96 ND38258 transformed cell line human CVCL_FT96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192590 CVCL_G595 30-5-7S hybridoma house mouse CVCL_G595 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192591 CVCL_FT95 ND38209 transformed cell line human CVCL_FT95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192592 CVCL_G594 2G8.D6 hybridoma house mouse CVCL_G594 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:74956; O(4)-phosphotyrosine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8190 21192593 CVCL_FT94 ND37766 transformed cell line human CVCL_FT94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192594 CVCL_G568 141PF11 hybridoma house mouse CVCL_G568 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Ig kappa light chains. 21192595 CVCL_FT68 ND36967 transformed cell line human CVCL_FT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192596 CVCL_G567 1410 KG7 hybridoma house mouse CVCL_G567 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human IgG heavy chain. 21192597 CVCL_FT67 ND36966 transformed cell line human CVCL_FT67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192598 CVCL_G566 12A5B7 hybridoma house mouse CVCL_G566 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02745; Human C1QA; Monoclonal antibody target: UniProtKB; P02746; Human C1QB; Monoclonal antibody target: UniProtKB; P02747; Human C1QC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8328 21192599 CVCL_FT66 ND36965 transformed cell line human CVCL_FT66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192600 CVCL_G565 12-2-2S (clone 5F11) hybridoma house mouse CVCL_G565 CL:0000010 Monoclonal antibody isotype: IgM. 21192601 CVCL_FT65 ND36943 transformed cell line human CVCL_FT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192602 CVCL_G569 14-4-4S hybridoma house mouse CVCL_G569 CL:0000010 Discontinued: IZSLER; BS Hy 59; probable. Monoclonal antibody isotype: IgG2a, kappa 21192603 CVCL_FT69 ND36976 transformed cell line human CVCL_FT69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192604 CVCL_G560 9-2-4 hybridoma house mouse CVCL_G560 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody TC31. 21192605 CVCL_FT60 ND36883 transformed cell line human CVCL_FT60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192606 CVCL_G564 10F7MN hybridoma house mouse CVCL_G564 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (Note=Recognizes both M and N blood group antigens). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8162 21192607 CVCL_FT64 ND36942 transformed cell line human CVCL_FT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192608 CVCL_G563 10D2F6 hybridoma house mouse CVCL_G563 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen expressed on antigen stimulated T cells and some T cell derived cell lines. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11103 21192609 CVCL_FT63 ND36940 transformed cell line human CVCL_FT63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192610 CVCL_FT62 ND36939 transformed cell line human CVCL_FT62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192611 CVCL_G562 TC31 hybridoma house mouse CVCL_G562 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta). 21192612 CVCL_FT61 ND36921 transformed cell line human CVCL_FT61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192613 CVCL_G561 TC1 [Mouse hybridoma against P.aeruginosa eta] hybridoma house mouse CVCL_G561 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P11439; Pseudomonas aeruginosa exotoxin A (eta). 21192614 CVCL_G579 20-8-4S hybridoma house mouse CVCL_G579 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192615 CVCL_FT79 ND37151 transformed cell line human CVCL_FT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192616 CVCL_G578 20-10-5S hybridoma house mouse CVCL_G578 CL:0000010 Monoclonal antibody isotype: IgM. 21192617 CVCL_FT78 ND37149 transformed cell line human CVCL_FT78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192618 CVCL_G577 1H3 hybridoma house mouse CVCL_G577 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14151; Human SELL/CD62L. 21192619 CVCL_FT77 ND37147 transformed cell line human CVCL_FT77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192620 CVCL_G576 1B2A3 hybridoma house mouse CVCL_G576 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17452; Pasteurella multocida toxA. 21192621 CVCL_FT76 ND37136 transformed cell line human CVCL_FT76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192622 CVCL_G571 16-3-22S hybridoma house mouse CVCL_G571 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192623 CVCL_FT71 ND37002 transformed cell line human CVCL_FT71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192624 CVCL_G570 15-3-1S hybridoma house mouse CVCL_G570 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192625 CVCL_FT70 ND36980 transformed cell line human CVCL_FT70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192626 CVCL_G575 1939-8G2 hybridoma house mouse CVCL_G575 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Treponema pallidum (strain Nichols). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8134 21192627 CVCL_FT75 ND37114 transformed cell line human CVCL_FT75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192628 CVCL_G574 1939-3G5 hybridoma house mouse CVCL_G574 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Treponema pallidum (strain Nichols). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8133 21192629 CVCL_FT74 ND37083 transformed cell line human CVCL_FT74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192630 CVCL_G573 171-4 hybridoma house mouse CVCL_G573 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192631 CVCL_FT73 ND37066 transformed cell line human CVCL_FT73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192632 CVCL_G572 17-3-3S hybridoma house mouse CVCL_G572 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21192633 CVCL_FT72 ND37057 transformed cell line human CVCL_FT72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192634 CVCL_FT46 ND36610 transformed cell line human CVCL_FT46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192635 CVCL_G545 GM12242 transformed cell line human CVCL_G545 HLA typing: A*02:05,23:01; B*41:01,49:01; C*07:01,17:01; DPA1*01:03,02:01:01; DPB1*02:01:02,13:01; DQA1*01:02,02:01; DQB1*02:01,06:09; DRB1*07:01,13:02 (IPD-IMGT/HLA=25968) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141605 21192636 CVCL_FT45 ND36580 transformed cell line human CVCL_FT45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192637 CVCL_FT44 ND36578 transformed cell line human CVCL_FT44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192638 CVCL_FT43 ND36561 transformed cell line human CVCL_FT43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192639 CVCL_FT49 ND36712 transformed cell line human CVCL_FT49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192640 CVCL_FT48 ND36646 transformed cell line human CVCL_FT48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192641 CVCL_FT47 ND36629 transformed cell line human CVCL_FT47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192642 CVCL_FT42 ND36530 transformed cell line human CVCL_FT42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192643 CVCL_FT41 ND36496 transformed cell line human CVCL_FT41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192644 CVCL_FT40 ND36495 transformed cell line human CVCL_FT40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192645 CVCL_FT57 ND36861 transformed cell line human CVCL_FT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192646 CVCL_FT56 ND36860 transformed cell line human CVCL_FT56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192647 CVCL_FT55 ND36839 transformed cell line human CVCL_FT55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192648 CVCL_FT54 ND36836 transformed cell line human CVCL_FT54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192649 CVCL_G559 DS1 [Mouse hybridoma] hybridoma house mouse CVCL_G559 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21192650 CVCL_FT59 ND36867 transformed cell line human CVCL_FT59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192651 CVCL_G558 FH73 transformed cell line human CVCL_G558 HLA typing: A*02,29; B*45:01; C*06:09,14; DQB1*02,06; DRB1*15:03,09:01 (IPD-IMGT/HLA=13328) CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: 13th International Histocompatibility Workshop (13IHW) cell line panel 21192652 CVCL_FT58 ND36865 transformed cell line human CVCL_FT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192653 CVCL_FT53 ND36817 transformed cell line human CVCL_FT53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192654 CVCL_FT52 ND36798 transformed cell line human CVCL_FT52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192655 CVCL_FT51 ND36775 transformed cell line human CVCL_FT51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192656 CVCL_FT50 ND36735 transformed cell line human CVCL_FT50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192657 CVCL_5B14 GM06980 transformed cell line human CVCL_5B14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329106 21192658 CVCL_5B13 GM14715 transformed cell line human CVCL_5B13 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192659 CVCL_5B12 GM14712 transformed cell line human CVCL_5B12 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192660 CVCL_5B11 GM14703 transformed cell line human CVCL_5B11 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192661 CVCL_5B18 GM06987 transformed cell line human CVCL_5B18 HLA typing: A*01:01:01,03:01; B*07:02,58:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*04:01,05:01; DQB1*03:01,04:02; DRB1*08:01,13:03 (IPD-IMGT/HLA=25845) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133302 21192662 CVCL_5B17 GM06983 transformed cell line human CVCL_5B17 HLA typing: A*02:01,31:01; B*13:02,07:02:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*02:01,03:01; DQB1*02:01,03:02; DRB1*04:04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25809) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133109 21192663 CVCL_5B16 GM06982 transformed cell line human CVCL_5B16 HLA typing: A*01:01:01,24:02; B*39:06:01,58:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*04:01,05:01; DQB1*03:01,04:02; DRB1*08:01,13:03; DRB3*02,03:01 (IPD-IMGT/HLA=25848) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133305 21192664 CVCL_5B15 GM06981 transformed cell line human CVCL_5B15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329105 21192665 CVCL_5B19 GM06988 transformed cell line human CVCL_5B19 HLA typing: A*02:01,02:01; B*13:02,51:01; C*15:03,06:02; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:03,02:01; DQB1*02:01,06:03; DRB1*13:01,07:01; DRB3*10:01; DRB4*01 (IPD-IMGT/HLA=25805) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133108 21192666 CVCL_XH62 Clone 12.6 hybridoma house mouse CVCL_XH62 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2390 21192667 CVCL_XH61 7.2 hybridoma house mouse CVCL_XH61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00481; Human BTN3A1/CD277. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4402 21192668 CVCL_XH60 20.1 [Mouse hybridoma against human BTN3A1] hybridoma house mouse CVCL_XH60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O00481; Human BTN3A1/CD277. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4401 21192669 CVCL_XH66 Clone 50.30 hybridoma house mouse CVCL_XH66 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2394 21192670 CVCL_XH65 Clone 30 hybridoma house mouse CVCL_XH65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2393 21192671 CVCL_XH64 Clone 29.8 hybridoma house mouse CVCL_XH64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2392 21192672 CVCL_XH63 Clone 28 hybridoma house mouse CVCL_XH63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2391 21192673 CVCL_XH69 8A4 hybridoma house mouse CVCL_XH69 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q1W367; Chikungunya virus (strain 06-049) spike glycoprotein E2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3823 21192674 CVCL_XH68 3E4 [Mouse hybridoma against Chikungunya virus E2] hybridoma house mouse CVCL_XH68 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q1W367; Chikungunya virus (strain 06-049) spike glycoprotein E2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3824 21192675 CVCL_XH67 3C3 [Mouse hybridoma against Chikungunya virus E2] hybridoma house mouse CVCL_XH67 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q1W367; Chikungunya virus (strain 06-049) spike glycoprotein E2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3822 21192676 CVCL_5B10 GM14702 transformed cell line human CVCL_5B10 CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Heterozygous; Note=Z allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192677 CVCL_5B25 GM07002 transformed cell line human CVCL_5B25 HLA typing: A*03:01:01:01,24:02; B*35:01,51:01; C*04:01,07:04; DPA1*01:03,01:03; DPB1*02:02,16:01; DQA1*01:01,01:02; DQB1*05:02,05:03; DRB1*14:01,16:01; DRB3*02,03:01; DRB4*01:02; DRB5*02:01 (IPD-IMGT/HLA=25838) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Doubling time: Slow growth (Coriell) Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133312 21192678 CVCL_5B24 GM07001 transformed cell line human CVCL_5B24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329208 21192679 CVCL_5B23 GM06999 transformed cell line human CVCL_5B23 HLA typing: A*24:02,31:01; B*40:01,07:02:01; C*03:04:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,06:01; DQA1*03:01,03:01; DQB1*03:02,03:02; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25806) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133107 21192680 CVCL_5B22 GM06998 transformed cell line human CVCL_5B22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329206 21192681 CVCL_5B29 GM07006 transformed cell line human CVCL_5B29 HLA typing: A*02:01,03:01; B*07:02:01,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25849) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134108 21192682 CVCL_5B28 GM07005 transformed cell line human CVCL_5B28 HLA typing: A*24:02,31:01; B*40:01,07:02:01; C*03:04:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,06:01; DQA1*03:01,03:01; DQB1*03:02,03:02; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25807) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133106 21192683 CVCL_5B27 GM07004 transformed cell line human CVCL_5B27 HLA typing: A*01:01:01,03:01:01:01; B*35:01,58:01; C*04:01,07:01; DPA1*01:03,01:03; DPB1*04:01:01,16:01; DQA1*01:01,05:01; DQB1*03:01,05:03; DRB1*13:03,14:01; DRB3*01 (IPD-IMGT/HLA=25844) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133303 21192684 CVCL_5B26 GM07003 transformed cell line human CVCL_5B26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329203 21192685 CVCL_XH51 1B6A11F2 hybridoma house mouse CVCL_XH51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4372 21192686 CVCL_XH50 1B4A11D11 hybridoma house mouse CVCL_XH50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4371 21192687 CVCL_XH55 1E9A4A4 hybridoma house mouse CVCL_XH55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4376 21192688 CVCL_XH54 2B11E6G4 hybridoma house mouse CVCL_XH54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4375 21192689 CVCL_XH53 2B4C8C8 hybridoma house mouse CVCL_XH53 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4374 21192690 CVCL_XH52 1B11E4B11 hybridoma house mouse CVCL_XH52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01350; Human GAST. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4373 21192691 CVCL_XH59 103.2 hybridoma house mouse CVCL_XH59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; O00481; Human BTN3A1/CD277. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4403 21192692 CVCL_XH58 BY40 hybridoma house mouse CVCL_XH58 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P49961; Human ENTPD1/CD39. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3889 21192693 CVCL_XH57 BA54g hybridoma house mouse CVCL_XH57 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P49961; Human ENTPD1/CD39. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4171 21192694 CVCL_XH56 16D3-C1 hybridoma house mouse CVCL_XH56 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P21860; Human ERBB3. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4486 21192695 CVCL_5B21 GM06996 transformed cell line human CVCL_5B21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329405 21192696 CVCL_5B20 GM06992 transformed cell line human CVCL_5B20 HLA typing: A*02:01,31:01; B*40:01,51:01; C*15:03,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,06:01; DQA1*01:03,03:01; DQB1*03:02,06:03; DRB1*13:01,04:04; DRB3*10:01; DRB4*01 (IPD-IMGT/HLA=25810) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133111 21192697 CVCL_XH40 LCM07 spontaneously immortalized cell line CVCL_XH40 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21192698 CVCL_XH44 GrE spontaneously immortalized cell line CVCL_XH44 CL:0000010 Unspecified Virology: Susceptible to infection by grass carp reovirus (GCRV) genotypes 1 and 2. Group: Fish cell line 21192699 CVCL_XH43 DM-77 spontaneously immortalized cell line CVCL_XH43 CL:0000010 Unspecified Doubling time: 2.8 +- 0.3 days (DOI=10.1134/S102279541908012X). Group: Tick cell line 21192700 CVCL_XH42 Bff-K4DT telomerase immortalized cell line CVCL_XH42 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Group: Bat cell line; Group: Endangered species/breed cell line 21192701 CVCL_XH41 LCM10 spontaneously immortalized cell line CVCL_XH41 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21192702 CVCL_XH48 LICR-LON-M8 hybridoma house mouse CVCL_XH48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. 21192703 CVCL_XH47 LICR-LON-M24 hybridoma house mouse CVCL_XH47 CL:0000010 Monoclonal antibody isotype: IgM. 21192704 CVCL_XH46 LICR-LON-M18 hybridoma house mouse CVCL_XH46 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Oligosaccharide with a Gal-beta-1,4-GlcNAc-beta1,6 sequence. 21192705 CVCL_XH45 LICR-LON-Fib-75 hybridoma house mouse CVCL_XH45 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human 19 kDa cell surface glycoprotein. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-211 21192706 CVCL_XH49 XMMBR-B55 hybridoma house mouse CVCL_XH49 CL:0000010 Monoclonal antibody isotype: IgM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9485 21192707 CVCL_5B03 GM14652 transformed cell line human CVCL_5B03 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192708 CVCL_5B02 GM14651 transformed cell line human CVCL_5B02 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192709 CVCL_5B01 GM14650 transformed cell line human CVCL_5B01 CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Heterozygous; Note=Factor V Leiden (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192710 CVCL_5B00 GM14640 transformed cell line human CVCL_5B00 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192711 CVCL_5B07 GM14688 transformed cell line human CVCL_5B07 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192712 CVCL_5B06 GM14686 transformed cell line human CVCL_5B06 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192713 CVCL_5B05 GM14685 transformed cell line human CVCL_5B05 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192714 CVCL_5B04 GM14657 transformed cell line human CVCL_5B04 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192715 CVCL_5B09 GM14691 transformed cell line human CVCL_5B09 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.His63Asp (c.187C>G); ClinVar=VCV000000010; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192716 CVCL_5B08 GM14689 transformed cell line human CVCL_5B08 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192717 CVCL_XH33 HDN-1-R finite cell line dog CVCL_XH33 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified 21192718 CVCL_XH32 KD-1-R finite cell line CVCL_XH32 CL:0000010 Derived from sampling site: Fetal small intestine. Male 21192719 CVCL_XH31 KLU-1-R finite cell line CVCL_XH31 CL:0000010 Derived from sampling site: Fetal lung. Male 21192720 CVCL_XH30 KTR-1-R finite cell line CVCL_XH30 CL:0000010 Derived from sampling site: Trachea. 21192721 CVCL_XH37 PKSU spontaneously immortalized cell line pig CVCL_XH37 CL:0000010 Derived from sampling site: Kidney. 21192722 CVCL_XH36 RLK-1-R finite cell line CVCL_XH36 CL:0000010 Derived from sampling site: Lymph node. Female 21192723 CVCL_XH35 RN-1-R finite cell line CVCL_XH35 CL:0000010 Derived from sampling site: Kidney. Female 21192724 CVCL_XH34 KM-1-R finite cell line CVCL_XH34 CL:0000010 Derived from sampling site: Fetal spleen. Male 21192725 CVCL_XH39 NE-R finite cell line CVCL_XH39 CL:0000010 Unspecified 21192726 CVCL_XH38 SWH-R finite cell line CVCL_XH38 CL:0000010 Derived from sampling site: Embryonic heart. Unspecified Group: Bird cell line 21192727 CVCL_XH22 GF-R finite cell line CVCL_XH22 CL:0000010 Unspecified Senescence: Senesces at 30-35 PDL (CCLV=CCLV-RIE 0045). Group: Bird cell line 21192728 CVCL_XH21 KHO-R finite cell line CVCL_XH21 CL:0000010 Derived from sampling site: Fetal testis. Male Senescence: Senesces at 100 PDL (CCLV=CCLV-RIE 0041) 21192729 CVCL_XH20 SFN-R finite cell line CVCL_XH20 CL:0000010 Derived from sampling site: Kidney. Male Senescence: Senesces at 40 PDL (CCLV=CCLV-RIE 0039) 21192730 CVCL_XH26 ETH-2-R finite cell line CVCL_XH26 CL:0000010 Derived from sampling site: Fetal thymus. Unspecified 21192731 CVCL_XH25 ETH-1-R finite cell line CVCL_XH25 CL:0000010 Derived from sampling site: Fetal thymus. Unspecified 21192732 CVCL_XH24 ETH-R finite cell line CVCL_XH24 CL:0000010 Derived from sampling site: Fetal thymus. Unspecified 21192733 CVCL_XH23 AHOL1 cancer cell line human CVCL_XH23 CL:0000010 Derived from sampling site: Brain. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male 21192734 CVCL_XH29 RM-R finite cell line CVCL_XH29 CL:0000010 Derived from sampling site: Spleen. Female 21192735 CVCL_XH28 RLK-R finite cell line CVCL_XH28 CL:0000010 Derived from sampling site: Lymph node. Female 21192736 CVCL_XH11 KM-R finite cell line CVCL_XH11 CL:0000010 Derived from sampling site: Fetal spleen. Unspecified 21192737 CVCL_XH10 KLE-R finite cell line CVCL_XH10 CL:0000010 Derived from sampling site: Fetal liver. Unspecified 21192738 CVCL_XH15 KAL-R spontaneously immortalized cell line CVCL_XH15 CL:0000010 Derived from sampling site: Fetal lung. Unspecified 21192739 CVCL_XH14 KAH-R finite cell line CVCL_XH14 CL:0000010 Derived from sampling site: Fetal heart. Unspecified 21192740 CVCL_XH13 PFM-R finite cell line CVCL_XH13 CL:0000010 Derived from sampling site: Fetal spleen. Unspecified 21192741 CVCL_XH12 HDN-R finite cell line dog CVCL_XH12 CL:0000010 Derived from sampling site: Kidney. 21192742 CVCL_XH19 KTN-R finite cell line CVCL_XH19 CL:0000010 Derived from sampling site: Kidney. Female 21192743 CVCL_XH18 GN-R finite cell line CVCL_XH18 CL:0000010 Derived from sampling site: Fetal kidney. Unspecified Group: Bird cell line 21192744 CVCL_XH17 HDH-R finite cell line dog CVCL_XH17 CL:0000010 Derived from sampling site: Heart. Unspecified 21192745 CVCL_XH16 HDL-R finite cell line dog CVCL_XH16 CL:0000010 Derived from sampling site: Lung. 21192746 CVCL_XH00 ARA-M5 hybridoma house mouse CVCL_XH00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200414 21192747 CVCL_XH04 PAL-M2 hybridoma house mouse CVCL_XH04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human melanoma cells. 21192748 CVCL_XH03 PAL-M1 hybridoma house mouse CVCL_XH03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. 21192749 CVCL_XH02 OIF-KG4 hybridoma house mouse CVCL_XH02 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P20774; Human OGN/OIF. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200409 21192750 CVCL_XH01 ARA-M7 hybridoma house mouse CVCL_XH01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200415 21192751 CVCL_XH08 MPC2013 cancer cell line house mouse CVCL_XH08 CL:0000010 Breed/subspecies: NOD. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201601 21192752 CVCL_XH07 4C2 hybridoma house mouse CVCL_XH07 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Duck IgG. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201608 21192753 CVCL_XH06 8B5D4 hybridoma house mouse CVCL_XH06 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; R4J9I3; Bluetongue virus 8 outer capsid protein VP2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201769 21192754 CVCL_XH05 8B3G11 hybridoma house mouse CVCL_XH05 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; R4J9I3; Bluetongue virus 8 outer capsid protein VP2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201770 21192755 CVCL_XH09 RN-R finite cell line CVCL_XH09 CL:0000010 Derived from sampling site: Kidney. 21192756 CVCL_5A79 GM13706 transformed cell line human CVCL_5A79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM13706; probable Female 21192757 CVCL_5A78 GM14093 transformed cell line human CVCL_5A78 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu402Serfs*8 (c.1204delG); ClinVar=VCV000054162; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192758 CVCL_5A73 GM13711 transformed cell line human CVCL_5A73 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ser1040Asn (c.3119G>A); ClinVar=VCV000017670; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192759 CVCL_5A72 GM13710 transformed cell line human CVCL_5A72 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Arg1443Gly (c.4327C>G); ClinVar=VCV000017676; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192760 CVCL_5A71 GM13707 transformed cell line human CVCL_5A71 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Leu392Glnfs (c.1175_1214del40); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192761 CVCL_5A70 REM 367 cancer cell line dog CVCL_5A70 CL:0000010 Female 21192762 CVCL_5A77 GM14092 transformed cell line human CVCL_5A77 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Val1713Ala (c.5138T>C); ClinVar=VCV000055412; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192763 CVCL_5A76 GM14091 transformed cell line human CVCL_5A76 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192764 CVCL_5A75 GM13714 transformed cell line human CVCL_5A75 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asn1774Glnfs*56 (c.5319dupC); ClinVar=VCV000055523; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192765 CVCL_5A74 GM13713 transformed cell line human CVCL_5A74 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Glu1250Ter (c.3748G>T); ClinVar=VCV000017672; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192766 CVCL_5A89 BR1H945.2 hybridoma house mouse CVCL_5A89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4303 21192767 CVCL_5A80 GM14634 transformed cell line human CVCL_5A80 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Asn1355Lysfs*10 (c.4065_4068delTCAA) (4184del4); ClinVar=VCV000017674; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192768 CVCL_5A84 GM14684 transformed cell line human CVCL_5A84 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Ser267Lysfs*19 (c.798_799delTT) (916delTT); ClinVar=VCV000037698; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192769 CVCL_5A83 GM14638 transformed cell line human CVCL_5A83 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.213-11T>G (332-11T>G); ClinVar=VCV000037449; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192770 CVCL_5A82 GM14637 transformed cell line human CVCL_5A82 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Arg1443Ter (c.4327C>T); ClinVar=VCV000017675; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192771 CVCL_5A81 GM14636 transformed cell line human CVCL_5A81 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Tyr1853Terfs (c.5558dupA) (p.Tyr1853Ter) (5677insA); ClinVar=VCV000055628; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192772 CVCL_5A88 BR1H826.5 hybridoma house mouse CVCL_5A88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4302 21192773 CVCL_5A87 BR1H788.6 hybridoma house mouse CVCL_5A87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4301 21192774 CVCL_5A86 GM17509 transformed cell line human CVCL_5A86 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.81-2delA (IVS2-2delA); ClinVar=VCV000055717; Zygosity=Unspecified; Note=Splice acceptor mutation (Coriell); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gly890Arg (c.2668G>A); ClinVar=VCV000054634; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val2739Ile (c.8215G>A); ClinVar=VCV000052529; Zygosity=Unspecified (Coriell) Population: Southeast Asian; Filipino; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192775 CVCL_5A85 GM16105 transformed cell line human CVCL_5A85 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; c.547+2T>A (IVS8+2T>A); ClinVar=VCV000037674; Zygosity=Unspecified; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192776 CVCL_5A59 RJK0 spontaneously immortalized cell line CVCL_5A59 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192777 CVCL_5A58 V79/E36 spontaneously immortalized cell line CVCL_5A58 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192778 CVCL_5A57 ULK1+ULK2 DKO MEF (SV40) transformed cell line house mouse CVCL_5A57 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1270126; Ulk1; Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1352758; Ulk2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21192779 CVCL_5A56 ULK1+ULK2 DKO MEF (SIM) spontaneously immortalized cell line house mouse CVCL_5A56 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1270126; Ulk1; Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1352758; Ulk2 Derived from sampling site: Cell type=Fibroblast. Unspecified 21192780 CVCL_5A51 ULK1/2 WT MEF (SV40) transformed cell line house mouse CVCL_5A51 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21192781 CVCL_5A50 ULK1/2 WT MEF (SIM) spontaneously immortalized cell line house mouse CVCL_5A50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified 21192782 CVCL_5A55 ULK2 KO MEF (SV40) transformed cell line house mouse CVCL_5A55 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1352758; Ulk2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21192783 CVCL_5A54 ULK2 KO MEF (SIM) spontaneously immortalized cell line house mouse CVCL_5A54 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1352758; Ulk2 Derived from sampling site: Cell type=Fibroblast. Unspecified 21192784 CVCL_5A53 ULK1 KO MEF (SV40) transformed cell line house mouse CVCL_5A53 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1270126; Ulk1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified 21192785 CVCL_5A52 ULK1 KO MEF (SIM) spontaneously immortalized cell line house mouse CVCL_5A52 CL:0000010 Knockout cell: Method=Gene-targeted KO mouse; MGI; MGI:1270126; Ulk1 Derived from sampling site: Cell type=Fibroblast. Unspecified 21192786 CVCL_5A69 REM 111 cancer cell line dog CVCL_5A69 CL:0000010 Derived from metastatic site: Pleural effusion. Female 21192787 CVCL_5A68 RJK526 spontaneously immortalized cell line CVCL_5A68 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192788 CVCL_5A67 V79-ETO3 transformed cell line CVCL_5A67 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192789 CVCL_XG92 9A10C3 hybridoma house mouse CVCL_XG92 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95407; Human TNFRSF6B. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200113 21192790 CVCL_XG91 3H5 [Mouse hybridoma against human TNFRSF6B] hybridoma house mouse CVCL_XG91 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95407; Human TNFRSF6B. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200112 21192791 CVCL_XG90 HT-1080 JH-1/FIX cancer cell line human CVCL_XG90 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3551; F9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200005 21192792 CVCL_XG96 3A4 hybridoma house mouse CVCL_XG96 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16035; Human TIMP2. 21192793 CVCL_XG95 2C3 [Mouse hybridoma against human MMP9] hybridoma house mouse CVCL_XG95 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P14780; Human MMP9. 21192794 CVCL_XG94 2A5 [Mouse hybridoma against human TIMP1] hybridoma house mouse CVCL_XG94 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01033; Human TIMP1. 21192795 CVCL_XG93 1B4 [Mouse hybridoma against human MMP3] hybridoma house mouse CVCL_XG93 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08254; Human MMP3. 21192796 CVCL_XG99 ARA-M1 hybridoma house mouse CVCL_XG99 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P22303; Human ACHE. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200413 21192797 CVCL_XG98 4D3 [Mouse hybridoma against human MMP2] hybridoma house mouse CVCL_XG98 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08253; Human MMP2. 21192798 CVCL_XG97 3B6 [Mouse hybridoma against human MMP1] hybridoma house mouse CVCL_XG97 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03956; Human MMP1. 21192799 CVCL_5A62 PUC4-2 spontaneously immortalized cell line CVCL_5A62 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:35668; 6-azauridine (6AUR); Selected for resistance to: ChEBI; CHEBI:90284; Pyrazofurin (PF); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192800 CVCL_5A61 V79 A3 spontaneously immortalized cell line CVCL_5A61 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192801 CVCL_5A60 V79-hCYP2E1-hSULT1A1 spontaneously immortalized cell line CVCL_5A60 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: HGNC; 11453; SULT1A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192802 CVCL_5A66 V79-ETO2 transformed cell line CVCL_5A66 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192803 CVCL_5A65 V79-ETO1 transformed cell line CVCL_5A65 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192804 CVCL_5A64 Azr7 spontaneously immortalized cell line CVCL_5A64 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:6198; (S)-azetidine-2-carboxylic acid (AZCA); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192805 CVCL_5A63 Azr3 spontaneously immortalized cell line CVCL_5A63 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:6198; (S)-azetidine-2-carboxylic acid (AZCA); Derived from sampling site: Lung Cell type=Fibroblast.. Male 21192806 CVCL_5A37 CHO-CUR2 spontaneously immortalized cell line CVCL_5A37 CL:0000010 Selected for resistance to: ChEBI; CHEBI:29036; Copper(2+); Derived from sampling site: Ovary. Female 21192807 CVCL_5A36 hsAQC2 spontaneously immortalized cell line CVCL_5A36 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Lacks both copies of the Dhfr gene Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3356 21192808 CVCL_5A35 haAQC2 spontaneously immortalized cell line CVCL_5A35 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Lacks both copies of the Dhfr gene Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3274 21192809 CVCL_5A34 hAQC2 spontaneously immortalized cell line CVCL_5A34 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Cobalt-60 gamma radiation(NCIt; C129640); Derived from sampling site: Ovary. Female Characteristics: Lacks both copies of the Dhfr gene Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3275 21192810 CVCL_5A39 CHO-xrs-4 spontaneously immortalized cell line CVCL_5A39 CL:0000010 Derived from sampling site: Ovary. Female 21192811 CVCL_5A38 CHO-xrs-1 spontaneously immortalized cell line CVCL_5A38 CL:0000010 Derived from sampling site: Ovary. Female 21192812 CVCL_XG81 45C6A hybridoma house mouse CVCL_XG81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11320 21192813 CVCL_XG80 45A5G hybridoma house mouse CVCL_XG80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11318 21192814 CVCL_XG85 C57iPS-C5 induced pluripotent stem cell house mouse CVCL_XG85 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Derived from sampling site: Brain; meninges; Breed/subspecies: C57BL/6J. Unspecified 21192815 CVCL_XG84 GIBH001 finite cell line house mouse CVCL_XG84 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Derived from sampling site: Brain; meninges; Breed/subspecies: C57BL/6J. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200838 21192816 CVCL_XG83 GCTB28-luc cancer cell line human CVCL_XG83 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Chinese; Derived from sampling site: Bone; spine. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018178 21192817 CVCL_XG82 64G11F hybridoma house mouse CVCL_XG82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11527 21192818 CVCL_XG89 V1C12A1 hybridoma house mouse CVCL_XG89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04558; Porcine reproductive and respiratory syndrome virus (strain Lelystad) nucleoprotein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200850 21192819 CVCL_XG88 2F2F7 hybridoma house mouse CVCL_XG88 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95925; Human EPPIN. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200849 21192820 CVCL_XG87 C57iPS-C12 induced pluripotent stem cell house mouse CVCL_XG87 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Derived from sampling site: Brain; meninges; Breed/subspecies: C57BL/6J. Unspecified 21192821 CVCL_XG86 C57iPS-C6 induced pluripotent stem cell house mouse CVCL_XG86 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Derived from sampling site: Brain; meninges; Breed/subspecies: C57BL/6J. Unspecified 21192822 CVCL_5A33 mAQC2 hybridoma house mouse CVCL_5A33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P56199; Human ITGA1/CD49a. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3273 21192823 CVCL_5A32 FL653 cancer cell line house mouse CVCL_5A32 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 21192824 CVCL_5A31 F435 spontaneously immortalized cell line CVCL_5A31 CL:0000010 Transfected with: HGNC; 3546; F8 (construct called N8 with 20-769 and 1657-2351) Derived from sampling site: Ovary. Omics: Genome sequenced Female 21192825 CVCL_5A30 CHO-AUXB3 spontaneously immortalized cell line CVCL_5A30 CL:0000010 Derived from sampling site: Ovary. Female 21192826 CVCL_5A48 CHO 51D1 spontaneously immortalized cell line CVCL_5A48 CL:0000010 Knockout cell: Method=Homologous recombination; Rad51d Derived from sampling site: Ovary. Female 21192827 CVCL_5A47 CHO-43-3B spontaneously immortalized cell line CVCL_5A47 CL:0000010 Derived from sampling site: Ovary. Female 21192828 CVCL_5A46 CLM-7/AD XV spontaneously immortalized cell line CVCL_5A46 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Bone marrow. Male 21192829 CVCL_5A45 DC3F/VCRm spontaneously immortalized cell line CVCL_5A45 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21192830 CVCL_5A49 CHO 51D1.3 spontaneously immortalized cell line CVCL_5A49 CL:0000010 Knockout cell: Method=Homologous recombination; Rad51d; Transfected with: UniProtKB; G3GTU6; Cricetulus griseus Rad51d Derived from sampling site: Ovary. Female 21192831 CVCL_XG70 GP8/3.9 transformed cell line Norway rat CVCL_XG70 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Cerebral cortex endothelial cell.; Breed/subspecies: Lewis. Female 21192832 CVCL_XG74 CCH-OS-G cancer cell line human CVCL_XG74 CL:0000010 Derived from metastatic site: Lung. 21192833 CVCL_XG73 CCH-OS-C cancer cell line human CVCL_XG73 CL:0000010 Derived from sampling site: Bone. 21192834 CVCL_XG72 CCH-OS-O cancer cell line human CVCL_XG72 CL:0000010 Derived from sampling site: Bone. 21192835 CVCL_XG71 CCH-OS-K cancer cell line human CVCL_XG71 CL:0000010 Derived from metastatic site: Pleural effusion. 21192836 CVCL_XG78 30S2F hybridoma house mouse CVCL_XG78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11319 21192837 CVCL_XG77 CCH-OS-T cancer cell line human CVCL_XG77 CL:0000010 Derived from metastatic site: Pleural effusion. 21192838 CVCL_XG76 CCH-OS-R cancer cell line human CVCL_XG76 CL:0000010 Derived from metastatic site: Lung. 21192839 CVCL_XG75 CCH-OS-M cancer cell line human CVCL_XG75 CL:0000010 Derived from metastatic site: Pleural effusion. 21192840 CVCL_XG79 30T11G hybridoma house mouse CVCL_XG79 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11324 21192841 CVCL_5A40 CHO-xrs-7 spontaneously immortalized cell line CVCL_5A40 CL:0000010 Derived from sampling site: Ovary. Female 21192842 CVCL_5A44 DC3F/VCRd5L spontaneously immortalized cell line CVCL_5A44 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21192843 CVCL_5A43 DC3F/DMXX spontaneously immortalized cell line CVCL_5A43 CL:0000010 Selected for resistance to: ChEBI; CHEBI:41977; Daunorubicin (Daunomycin); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21192844 CVCL_5A42 DC3F/ADXC spontaneously immortalized cell line CVCL_5A42 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27666; Actinomycin D (ActD); Derived from sampling site: Lung Cell type=Fibroblast.. Female 21192845 CVCL_5A41 CHO-xrs-6C spontaneously immortalized cell line CVCL_5A41 CL:0000010 Derived from sampling site: Ovary. Female 21192846 CVCL_5A15 MCF-7/ExeR-3 cancer cell line human CVCL_5A15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4953; Exemestane; Derived from metastatic site: Pleural effusion. Female 21192847 CVCL_5A14 MCF-7/ExeR-2 cancer cell line human CVCL_5A14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4953; Exemestane; Derived from metastatic site: Pleural effusion. Female 21192848 CVCL_5A13 MCF-7/ExeR-1 cancer cell line human CVCL_5A13 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4953; Exemestane; Derived from metastatic site: Pleural effusion. Female 21192849 CVCL_5A12 MCF-7/AnaR-4 cancer cell line human CVCL_5A12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole; Derived from metastatic site: Pleural effusion. Female 21192850 CVCL_5A19 MCF-7/LetR-3 cancer cell line human CVCL_5A19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:6413; Letrozole; Derived from metastatic site: Pleural effusion. Female 21192851 CVCL_5A18 MCF-7/LetR-2 cancer cell line human CVCL_5A18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:6413; Letrozole; Derived from metastatic site: Pleural effusion. Female 21192852 CVCL_5A17 MCF-7/LetR-1 cancer cell line human CVCL_5A17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:6413; Letrozole; Derived from metastatic site: Pleural effusion. Female 21192853 CVCL_5A16 MCF-7/ExeR-4 cancer cell line human CVCL_5A16 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4953; Exemestane; Derived from metastatic site: Pleural effusion. Female 21192854 CVCL_XG63 58As1 cancer cell line human CVCL_XG63 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Characteristics: Highly metastatic Strong capability of inducing the formation of ascites.; Characteristics: Parent cell line was injected subcutaneously into BALB/c nude mice Cells from metastatic ascitic tumor cells were harvested and re-injected into mice. This process was carried out 12 times. 21192855 CVCL_XG62 44As3 cancer cell line human CVCL_XG62 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Characteristics: Highly metastatic Strong capability of inducing the formation of ascites.; Characteristics: Parent cell line was injected subcutaneously into BALB/c nude mice Cells from metastatic ascitic tumor cells were harvested and re-injected into mice. This process was carried out 12 times. 21192856 CVCL_XG61 BW125.1C cancer cell line house mouse CVCL_XG61 CL:0000010 Transfected with: MGI; MGI:99919; Vcp (with a C-terminal human MYC epitope); Transfected with: HGNC; 1674; CD3E (with p.Met1_Ser152del; IL2RA-CD3E chimeric receptor); Transfected with: HGNC; 6008; IL2RA (with p.Thr260_Ile272del; IL2RA-CD3E chimeric receptor); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Thymus; Breed/subspecies: AKR/J. 21192857 CVCL_XG60 AK7B4 hybridoma house mouse CVCL_XG60 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN (Note=Also reacts with mouse). 21192858 CVCL_XG67 CCH-OS-D cancer cell line human CVCL_XG67 CL:0000010 Derived from sampling site: Bone. 21192859 CVCL_XG66 30Q4H hybridoma house mouse CVCL_XG66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11317 21192860 CVCL_XG65 30Q8A hybridoma house mouse CVCL_XG65 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11316 21192861 CVCL_XG64 58As9 cancer cell line human CVCL_XG64 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Male Characteristics: Highly metastatic Strong capability of inducing the formation of ascites.; Characteristics: Parent cell line was injected subcutaneously into BALB/c nude mice Cells from metastatic ascitic tumor cells were harvested and re-injected into mice. This process was carried out 12 times. 21192862 CVCL_XG69 4T1/GFP/FlucII cancer cell line house mouse CVCL_XG69 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase Miscellaneous: Cell line information from personal communication of Lorger M Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female 21192863 CVCL_XG68 K7M3 cancer cell line house mouse CVCL_XG68 CL:0000010 Derived from metastatic site: Lung; Breed/subspecies: BALB/c. Female Characteristics: Established by intravenous injection of parent cell line into mice and then harvesting the lung metastases 21192864 CVCL_5A11 MCF-7/AnaR-3 cancer cell line human CVCL_5A11 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole; Derived from metastatic site: Pleural effusion. Female 21192865 CVCL_5A10 MCF-7/AnaR-2 cancer cell line human CVCL_5A10 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:2704; Anastrozole; Derived from metastatic site: Pleural effusion. Female 21192866 CVCL_5A26 CHO-S/C0101 spontaneously immortalized cell line CVCL_5A26 CL:0000010 Derived from sampling site: Ovary. Omics: Genome sequenced Female 21192867 CVCL_5A25 CHO-AR7 spontaneously immortalized cell line CVCL_5A25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:16335; Adenosine; Derived from sampling site: Ovary. Female 21192868 CVCL_5A24 CHO-AR1 spontaneously immortalized cell line CVCL_5A24 CL:0000010 Selected for resistance to: ChEBI; CHEBI:16335; Adenosine; Derived from sampling site: Ovary. Female 21192869 CVCL_5A23 CHO-UKB25 spontaneously immortalized cell line CVCL_5A23 CL:0000010 Derived from sampling site: Ovary. Female 21192870 CVCL_5A29 5B-HS-MYC spontaneously immortalized cell line CVCL_5A29 CL:0000010 Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Ovary. Female 21192871 CVCL_5A28 4-HS-MYC spontaneously immortalized cell line CVCL_5A28 CL:0000010 Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Ovary. Female 21192872 CVCL_5A27 6A-HS-MYC spontaneously immortalized cell line CVCL_5A27 CL:0000010 Transfected with: MGI; MGI:97250; Myc Derived from sampling site: Ovary. Female 21192873 CVCL_XG52 DP5-2 transformed cell line Norway rat CVCL_XG52 CL:0000010 Transformant: Adenovirus 5 [E1A](NCBI-Taxonomy; 28285); Breed/subspecies: Lister Hooded. 21192874 CVCL_XG51 HDNS13 transformed cell line human CVCL_XG51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Unspecified 21192875 CVCL_XG50 HDE-14 transformed cell line human CVCL_XG50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Unspecified 21192876 CVCL_XG56 AK1H3 hybridoma house mouse CVCL_XG56 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. 21192877 CVCL_XG55 AK1G4 hybridoma house mouse CVCL_XG55 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN. 21192878 CVCL_XG54 AK10F6 hybridoma house mouse CVCL_XG54 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN (Note=Also reacts with mouse). 21192879 CVCL_XG53 275-3-2 transformed cell line house mouse CVCL_XG53 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras) Transformant: v-Ha-Ras; Breed/subspecies: (129 x C57BL/6) F2. Unspecified 21192880 CVCL_XG59 AK3D9 hybridoma house mouse CVCL_XG59 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN (Note=Also reacts with mouse). 21192881 CVCL_XG58 AK2C5 hybridoma house mouse CVCL_XG58 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN (Note=Also reacts with mouse). 21192882 CVCL_XG57 AK2A1 hybridoma house mouse CVCL_XG57 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P10451; Human SPP1/OPN (Note=Also reacts with mouse). 21192883 CVCL_5A22 HEK293/GFP-DFCP1 transformed cell line human CVCL_5A22 CL:0000010 Transfected with: HGNC; 13180; ZFYVE1; Transfected with: UniProtKB; P42212; GFP Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21192884 CVCL_5A21 HEK293A/GFP-WIPI2 transformed cell line human CVCL_5A21 CL:0000010 Transfected with: HGNC; 32225; WIPI2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21192885 CVCL_5A20 MCF-7/LetR-4 cancer cell line human CVCL_5A20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:6413; Letrozole; Derived from metastatic site: Pleural effusion. Female 21192886 CVCL_FT29 ND36206 transformed cell line human CVCL_FT29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192887 CVCL_FT24 ND36133 transformed cell line human CVCL_FT24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192888 CVCL_FT23 ND36107 transformed cell line human CVCL_FT23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192889 CVCL_FT22 ND36106 transformed cell line human CVCL_FT22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192890 CVCL_FT21 ND36094 transformed cell line human CVCL_FT21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192891 CVCL_FT28 ND36161 transformed cell line human CVCL_FT28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192892 CVCL_FT27 ND36160 transformed cell line human CVCL_FT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192893 CVCL_FT26 ND36159 transformed cell line human CVCL_FT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192894 CVCL_FT25 ND36158 transformed cell line human CVCL_FT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192895 CVCL_FT20 ND36093 transformed cell line human CVCL_FT20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192896 CVCL_FT35 ND36375 transformed cell line human CVCL_FT35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192897 CVCL_FT34 ND36326 transformed cell line human CVCL_FT34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192898 CVCL_FT33 ND36281 transformed cell line human CVCL_FT33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192899 CVCL_FT32 ND36223 transformed cell line human CVCL_FT32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192900 CVCL_FT39 ND36440 transformed cell line human CVCL_FT39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192901 CVCL_FT38 ND36439 transformed cell line human CVCL_FT38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192902 CVCL_FT37 ND36396 transformed cell line human CVCL_FT37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192903 CVCL_FT36 ND36394 transformed cell line human CVCL_FT36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192904 CVCL_FT31 ND36211 transformed cell line human CVCL_FT31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192905 CVCL_FT30 ND36210 transformed cell line human CVCL_FT30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192906 CVCL_FT09 ND35868 transformed cell line human CVCL_FT09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192907 CVCL_FT08 ND35866 transformed cell line human CVCL_FT08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192908 CVCL_FT07 ND35865 transformed cell line human CVCL_FT07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192909 CVCL_FT02 ND35743 transformed cell line human CVCL_FT02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192910 CVCL_FT01 ND35739 transformed cell line human CVCL_FT01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192911 CVCL_FT00 ND35703 transformed cell line human CVCL_FT00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192912 CVCL_FT06 ND35845 transformed cell line human CVCL_FT06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192913 CVCL_FT05 ND35820 transformed cell line human CVCL_FT05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192914 CVCL_FT04 ND35815 transformed cell line human CVCL_FT04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192915 CVCL_FT03 ND35787 transformed cell line human CVCL_FT03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192916 CVCL_FT19 ND36066 transformed cell line human CVCL_FT19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192917 CVCL_FT18 ND36055 transformed cell line human CVCL_FT18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192918 CVCL_FT13 ND35929 transformed cell line human CVCL_FT13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192919 CVCL_FT12 ND35910 transformed cell line human CVCL_FT12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192920 CVCL_FT11 ND35907 transformed cell line human CVCL_FT11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192921 CVCL_FT10 ND35888 transformed cell line human CVCL_FT10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192922 CVCL_FT17 ND36041 transformed cell line human CVCL_FT17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192923 CVCL_FT16 ND36022 transformed cell line human CVCL_FT16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192924 CVCL_FT15 ND36015 transformed cell line human CVCL_FT15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192925 CVCL_FT14 ND35951 transformed cell line human CVCL_FT14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192926 CVCL_5A91 BR1N411.4 hybridoma house mouse CVCL_5A91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4305 21192927 CVCL_5A90 BR1N129.5 hybridoma house mouse CVCL_5A90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4304 21192928 CVCL_5A95 BR1S425.1 hybridoma house mouse CVCL_5A95 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4309 21192929 CVCL_5A94 BR1S384.5 hybridoma house mouse CVCL_5A94 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4308 21192930 CVCL_5A93 BR1S218.1 hybridoma house mouse CVCL_5A93 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4307 21192931 CVCL_5A92 BR1S060.2 hybridoma house mouse CVCL_5A92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P38398; Human BRCA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-4306 21192932 CVCL_5A99 GM14631 transformed cell line human CVCL_5A99 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21192933 CVCL_5A98 GM14628 transformed cell line human CVCL_5A98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192934 CVCL_5A97 GM14621 transformed cell line human CVCL_5A97 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192935 CVCL_5A96 GM14620 transformed cell line human CVCL_5A96 CL:0000010 Sequence variation: Mutation; HGNC; 4886; HFE; Simple; p.Cys282Tyr (c.845G>A); ClinVar=VCV000000009; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21192936 CVCL_4Y94 3548P transformed cell line human CVCL_4Y94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192937 CVCL_4Y93 3543P transformed cell line human CVCL_4Y93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192938 CVCL_4Y92 3535P transformed cell line human CVCL_4Y92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192939 CVCL_4Y91 3530P transformed cell line human CVCL_4Y91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192940 CVCL_4Y98 3585P transformed cell line human CVCL_4Y98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192941 CVCL_4Y97 3573P transformed cell line human CVCL_4Y97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192942 CVCL_4Y96 3570P transformed cell line human CVCL_4Y96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from head and neck squamous cell carcinoma; Derived from sampling site: Peripheral blood. Unspecified 21192943 CVCL_4Y95 3566P transformed cell line human CVCL_4Y95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192944 CVCL_4Y99 3590P transformed cell line human CVCL_4Y99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from head and neck squamous cell carcinoma; Derived from sampling site: Peripheral blood. Unspecified 21192945 CVCL_4Y72 MOLT-4/ADR cancer cell line human CVCL_4Y72 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21192946 CVCL_4Y71 PG19T3:MTXR10-4M cancer cell line house mouse CVCL_4Y71 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: C57BL/6J. Female 21192947 CVCL_4Y70 P388/BR/D cancer cell line house mouse CVCL_4Y70 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88353; Bryostatin-1; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21192948 CVCL_4Y76 SEWA/TC13 cancer cell line house mouse CVCL_4Y76 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21192949 CVCL_4Y75 SEWA/Rec4 cancer cell line house mouse CVCL_4Y75 CL:0000010 Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21192950 CVCL_4Y74 Mayes finite cell line human CVCL_4Y74 CL:0000010 Miscellaneous: Cell line has been lost. Male 21192951 CVCL_4Y73 NG2-2.16 cancer cell line house mouse CVCL_4Y73 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Selected for resistance to: UniProtKB; P02866; Canavalia ensiformis concanavalin-A; Breed/subspecies: 129/Sv-SlJ-CP. Male 21192952 CVCL_4Y79 HB4C5 hybridoma human CVCL_4Y79 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human histone H2B. 21192953 CVCL_4Y78 HF10F7 hybridoma human CVCL_4Y78 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human lung cancer cell lines. 21192954 CVCL_4Y77 SEWA/TC13MTXr10 cancer cell line house mouse CVCL_4Y77 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Transformant: Murine polyomavirus (MPyV) [Isolate 1956-11C](NCBI-Taxonomy; 1891730); Breed/subspecies: A.SW. Male 21192955 CVCL_4Y90 3529P transformed cell line human CVCL_4Y90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192956 CVCL_4Y83 3445P transformed cell line human CVCL_4Y83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192957 CVCL_4Y82 3402P transformed cell line human CVCL_4Y82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192958 CVCL_4Y81 3200P transformed cell line human CVCL_4Y81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192959 CVCL_4Y80 HB4G7 hybridoma human CVCL_4Y80 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human lung cancer cell lines. 21192960 CVCL_4Y87 3513P transformed cell line human CVCL_4Y87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192961 CVCL_4Y86 3512P transformed cell line human CVCL_4Y86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192962 CVCL_4Y85 3498P transformed cell line human CVCL_4Y85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from head and neck squamous cell carcinoma; Derived from sampling site: Peripheral blood. Male 21192963 CVCL_4Y84 3446P transformed cell line human CVCL_4Y84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192964 CVCL_4Y89 3528P transformed cell line human CVCL_4Y89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192965 CVCL_4Y88 3519P transformed cell line human CVCL_4Y88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21192966 CVCL_4Y50 NovrA2 spontaneously immortalized cell line CVCL_4Y50 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28368; Novobiocin; Derived from sampling site: Kidney. Male 21192967 CVCL_4Y54 MCF-7-2a cancer cell line human CVCL_4Y54 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (Cellosaurus=CVCL_4Y53), L-mimosine-resistant MCF-7/2a (Cellosaurus=CVCL_0412) and EREwtcluc transfected MCF-7-2a (Cellosaurus=CVCL_4Y54) 21192968 CVCL_4Y53 MCF-7:2A cancer cell line human CVCL_4Y53 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Caution: There is confusion in the literature between estrogen-independent MCF-7:2A (Cellosaurus=CVCL_4Y53), L-mimosine-resistant MCF-7/2a (Cellosaurus=CVCL_0412) and EREwtcluc transfected MCF-7-2a (Cellosaurus=CVCL_4Y54) 21192969 CVCL_4Y52 WEHI-3B/CTRES cancer cell line house mouse CVCL_4Y52 CL:0000010 Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 21192970 CVCL_4Y51 NovrA41 spontaneously immortalized cell line CVCL_4Y51 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28368; Novobiocin; Derived from sampling site: Kidney. Male 21192971 CVCL_4Y58 P388/CPA cancer cell line house mouse CVCL_4Y58 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21192972 CVCL_4Y57 L1210/CPA cancer cell line house mouse CVCL_4Y57 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4027; Cyclophosphamide (CP; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21192973 CVCL_4Y56 MVLN cancer cell line human CVCL_4Y56 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Biotechnology: Used in a bioluminescent bioassay to quantitatively measure estrogenic compounds Female Characteristics: The luciferase reporter gene is under the control of an estrogen-responsive element from the Xenopus vitellogenin A2 gene Doubling time: 0.8 +- 0.1 day (PubMed=7954415) 21192974 CVCL_4Y55 CHOC 400 spontaneously immortalized cell line CVCL_4Y55 CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Ovary. Female 21192975 CVCL_4Y59 Hec50Co cancer cell line human CVCL_4Y59 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Female 21192976 CVCL_4Y61 IGROV-1/APL cancer cell line human CVCL_4Y61 CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90205; Plitidepsin (Dehydrodidemnin B; Derived from sampling site: Ovary. Female 21192977 CVCL_4Y60 Namalwa KJM-1 cancer cell line human CVCL_4Y60 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: Contains 2 integrated copies of EBV genome on chromosome 1 Group: Serum/protein free medium cell line 21192978 CVCL_4Y65 MCF-7 clone 33 cancer cell line human CVCL_4Y65 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21192979 CVCL_4Y64 MCF-7/TMX2-11 cancer cell line human CVCL_4Y64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: DNA methylation analysis Female 21192980 CVCL_4Y63 MCF-7/TMX2 cancer cell line human CVCL_4Y63 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Female 21192981 CVCL_4Y62 L1210/TZR cancer cell line house mouse CVCL_4Y62 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90239; Tiazofurine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female Doubling time: ~13 hours (PubMed=9328141) 21192982 CVCL_4Y69 P388/BR/C cancer cell line house mouse CVCL_4Y69 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88353; Bryostatin-1; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21192983 CVCL_4Y68 P388/BR/B cancer cell line house mouse CVCL_4Y68 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88353; Bryostatin-1; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21192984 CVCL_4Y67 P388/BR/A cancer cell line house mouse CVCL_4Y67 CL:0000010 Selected for resistance to: ChEBI; CHEBI:88353; Bryostatin-1; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Female 21192985 CVCL_4Y66 CA-CD437R cancer cell line human CVCL_4Y66 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136Ter (c.406C>T); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:88334; AHPN (6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalenecarboxylic acid; Derived from sampling site: Ovary. Female 21192986 CVCL_4Y32 XP39OS(SVT) transformed cell line human CVCL_4Y32 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192987 CVCL_4Y31 XP35OS(SVT) transformed cell line human CVCL_4Y31 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21192988 CVCL_4Y30 XPET6/1 transformed cell line human CVCL_4Y30 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 21192989 CVCL_4Y36 DU-145 R cancer cell line human CVCL_4Y36 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Brain. Male 21192990 CVCL_4Y35 22Rv1 R cancer cell line human CVCL_4Y35 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from sampling site: Prostate. Male 21192991 CVCL_4Y34 Subclone 707 DAP9 cancer cell line house mouse CVCL_4Y34 CL:0000010 Selected for resistance to: ChEBI; CHEBI:38001; 2,6-diaminopurine (2,6-DAP); Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21192992 CVCL_4Y33 MED17.11 conditionally immortalized cell line house mouse CVCL_4Y33 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic dorsal root ganglion Cell type=Neuron.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified 21192993 CVCL_4Y39 MDA-MB-231 50PACR cancer cell line human CVCL_4Y39 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21192994 CVCL_4Y38 MDA-MB-231 25PACR cancer cell line human CVCL_4Y38 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21192995 CVCL_4Y37 NCI-H3122-CHR-A1 cancer cell line human CVCL_4Y37 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (from parent cell line). Selected for resistance to: ChEBI; CHEBI:62268; Alectinib (CH5424802 Male 21192996 CVCL_4Y43 ZR75-1 50DOCR cancer cell line human CVCL_4Y43 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Ascites. Female 21192997 CVCL_4Y42 ZR75-1 25DOCR cancer cell line human CVCL_4Y42 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Ascites. Female 21192998 CVCL_4Y41 PC-3 D8 cancer cell line human CVCL_4Y41 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone. Male 21192999 CVCL_4Y40 PC-3 D12 cancer cell line human CVCL_4Y40 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone. Male 21193000 CVCL_4Y47 MCF/MX cancer cell line human CVCL_4Y47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:50729; Mitoxantrone; Derived from metastatic site: Pleural effusion. Female 21193001 CVCL_4Y46 MCF-7/AdrVp cancer cell line human CVCL_4Y46 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Selected for resistance to: ChEBI; CHEBI:9948; Verapamil (VPL); Derived from metastatic site: Pleural effusion. Female 21193002 CVCL_4Y45 ZR75-1 50PACR cancer cell line human CVCL_4Y45 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21193003 CVCL_4Y44 ZR75-1 25PACR cancer cell line human CVCL_4Y44 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female 21193004 CVCL_4Y49 COV353 cancer cell line human CVCL_4Y49 CL:0000010 Derived from metastatic site: Urinary bladder; bladder dome. Female 21193005 CVCL_4Y48 S1A cancer cell line house mouse CVCL_4Y48 CL:0000010 Breed/subspecies: BALB/c. 21193006 CVCL_FM45 ND22484 transformed cell line human CVCL_FM45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193007 CVCL_FM44 ND22176 transformed cell line human CVCL_FM44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193008 CVCL_FM43 ND22070 transformed cell line human CVCL_FM43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193009 CVCL_FM42 ND21986 transformed cell line human CVCL_FM42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193010 CVCL_FM49 ND22674 transformed cell line human CVCL_FM49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193011 CVCL_FM48 ND22672 transformed cell line human CVCL_FM48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193012 CVCL_FM47 ND22488 transformed cell line human CVCL_FM47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193013 CVCL_FM46 ND22487 transformed cell line human CVCL_FM46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193014 CVCL_FM41 ND21938 transformed cell line human CVCL_FM41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193015 CVCL_FM40 ND21937 transformed cell line human CVCL_FM40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193016 CVCL_FM56 ND22819 transformed cell line human CVCL_FM56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193017 CVCL_FM55 ND22801 transformed cell line human CVCL_FM55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193018 CVCL_FM54 ND22800 transformed cell line human CVCL_FM54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193019 CVCL_FM53 ND22750 transformed cell line human CVCL_FM53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193020 CVCL_FM59 ND22993 transformed cell line human CVCL_FM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193021 CVCL_FM58 ND22963 transformed cell line human CVCL_FM58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193022 CVCL_FM57 ND22835 transformed cell line human CVCL_FM57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193023 CVCL_FM52 ND22681 transformed cell line human CVCL_FM52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193024 CVCL_FM51 ND22680 transformed cell line human CVCL_FM51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193025 CVCL_FM50 ND22677 transformed cell line human CVCL_FM50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193026 CVCL_FM29 ND21586 transformed cell line human CVCL_FM29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193027 CVCL_FM28 ND21585 transformed cell line human CVCL_FM28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193028 CVCL_FM23 ND21475 transformed cell line human CVCL_FM23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193029 CVCL_FM22 ND21462 transformed cell line human CVCL_FM22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193030 CVCL_FM21 ND21454 transformed cell line human CVCL_FM21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193031 CVCL_FM20 ND21451 transformed cell line human CVCL_FM20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193032 CVCL_FM27 ND21584 transformed cell line human CVCL_FM27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193033 CVCL_FM26 ND21562 transformed cell line human CVCL_FM26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193034 CVCL_FM25 ND21548 transformed cell line human CVCL_FM25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193035 CVCL_FM24 ND21533 transformed cell line human CVCL_FM24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193036 CVCL_FM39 ND21873 transformed cell line human CVCL_FM39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193037 CVCL_FM34 ND21689 transformed cell line human CVCL_FM34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193038 CVCL_FM33 ND21676 transformed cell line human CVCL_FM33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193039 CVCL_FM32 ND21631 transformed cell line human CVCL_FM32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193040 CVCL_FM31 ND21601 transformed cell line human CVCL_FM31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193041 CVCL_FM38 ND21751 transformed cell line human CVCL_FM38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193042 CVCL_FM37 ND21739 transformed cell line human CVCL_FM37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193043 CVCL_FM36 ND21704 transformed cell line human CVCL_FM36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193044 CVCL_FM35 ND21693 transformed cell line human CVCL_FM35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193045 CVCL_FM30 ND21587 transformed cell line human CVCL_FM30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193046 CVCL_FM09 ND21202 transformed cell line human CVCL_FM09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193047 CVCL_FM08 ND21171 transformed cell line human CVCL_FM08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193048 CVCL_FM07 ND21148 transformed cell line human CVCL_FM07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193049 CVCL_FM06 ND21147 transformed cell line human CVCL_FM06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193050 CVCL_FM01 ND21069 transformed cell line human CVCL_FM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193051 CVCL_FM00 ND21063 transformed cell line human CVCL_FM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193052 CVCL_FM05 ND21146 transformed cell line human CVCL_FM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193053 CVCL_FM04 ND21121 transformed cell line human CVCL_FM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193054 CVCL_FM03 ND21120 transformed cell line human CVCL_FM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193055 CVCL_FM02 ND21102 transformed cell line human CVCL_FM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193056 CVCL_FM19 ND21450 transformed cell line human CVCL_FM19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193057 CVCL_FM18 ND21356 transformed cell line human CVCL_FM18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193058 CVCL_FM17 ND21353 transformed cell line human CVCL_FM17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193059 CVCL_FM12 ND21280 transformed cell line human CVCL_FM12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193060 CVCL_FM11 ND21269 transformed cell line human CVCL_FM11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193061 CVCL_FM10 ND21258 transformed cell line human CVCL_FM10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193062 CVCL_FM16 ND21345 transformed cell line human CVCL_FM16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193063 CVCL_FM15 ND21328 transformed cell line human CVCL_FM15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193064 CVCL_FM14 ND21298 transformed cell line human CVCL_FM14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193065 CVCL_FM13 ND21286 transformed cell line human CVCL_FM13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193066 CVCL_FL89 ND21010 transformed cell line human CVCL_FL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193067 CVCL_FL88 ND20794 transformed cell line human CVCL_FL88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193068 CVCL_FL87 ND20779 transformed cell line human CVCL_FL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193069 CVCL_FL82 ND19972 transformed cell line human CVCL_FL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193070 CVCL_FL81 ND19946 transformed cell line human CVCL_FL81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193071 CVCL_FL80 ND19303 transformed cell line human CVCL_FL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193072 CVCL_FL86 ND20740 transformed cell line human CVCL_FL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193073 CVCL_FL85 ND20689 transformed cell line human CVCL_FL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193074 CVCL_FL84 ND20688 transformed cell line human CVCL_FL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193075 CVCL_FL83 ND20578 transformed cell line human CVCL_FL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193076 CVCL_FL99 ND21059 transformed cell line human CVCL_FL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193077 CVCL_FL98 ND21045 transformed cell line human CVCL_FL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193078 CVCL_FL93 ND21017 transformed cell line human CVCL_FL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193079 CVCL_FL92 ND21016 transformed cell line human CVCL_FL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193080 CVCL_FL91 ND21015 transformed cell line human CVCL_FL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193081 CVCL_FL90 ND21013 transformed cell line human CVCL_FL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193082 CVCL_FL97 ND21039 transformed cell line human CVCL_FL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193083 CVCL_FL96 ND21026 transformed cell line human CVCL_FL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193084 CVCL_FL95 ND21024 transformed cell line human CVCL_FL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193085 CVCL_FL94 ND21020 transformed cell line human CVCL_FL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193086 CVCL_FL68 ND14009 transformed cell line human CVCL_FL68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193087 CVCL_FL67 ND13746 transformed cell line human CVCL_FL67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193088 CVCL_FL66 ND13621 transformed cell line human CVCL_FL66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193089 CVCL_FL65 ND13279 transformed cell line human CVCL_FL65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193090 CVCL_FL69 ND14016 transformed cell line human CVCL_FL69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193091 CVCL_FL60 ND11278 transformed cell line human CVCL_FL60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193092 CVCL_FL64 ND12948 transformed cell line human CVCL_FL64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193093 CVCL_FL63 ND12728 transformed cell line human CVCL_FL63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193094 CVCL_FL62 ND12506 transformed cell line human CVCL_FL62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193095 CVCL_FL61 ND12445 transformed cell line human CVCL_FL61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193096 CVCL_FL79 ND16332 transformed cell line human CVCL_FL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193097 CVCL_FL78 ND16293 transformed cell line human CVCL_FL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193098 CVCL_FL77 ND16087 transformed cell line human CVCL_FL77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193099 CVCL_FL76 ND15769 transformed cell line human CVCL_FL76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193100 CVCL_FL71 ND14722 transformed cell line human CVCL_FL71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193101 CVCL_FL70 ND14373 transformed cell line human CVCL_FL70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193102 CVCL_FL75 ND15638 transformed cell line human CVCL_FL75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193103 CVCL_FL74 ND15163 transformed cell line human CVCL_FL74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193104 CVCL_FL73 ND15043 transformed cell line human CVCL_FL73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193105 CVCL_FL72 ND14936 transformed cell line human CVCL_FL72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193106 CVCL_FL46 ND10137 transformed cell line human CVCL_FL46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193107 CVCL_FL45 ND10129 transformed cell line human CVCL_FL45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193108 CVCL_FL44 ND10031 transformed cell line human CVCL_FL44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193109 CVCL_FL43 ND10029 transformed cell line human CVCL_FL43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193110 CVCL_FL49 ND10219 transformed cell line human CVCL_FL49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193111 CVCL_FL48 ND10199 transformed cell line human CVCL_FL48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193112 CVCL_FL47 ND10160 transformed cell line human CVCL_FL47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193113 CVCL_FL42 ND10010 transformed cell line human CVCL_FL42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193114 CVCL_FL41 ND09906 transformed cell line human CVCL_FL41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193115 CVCL_FL40 ND09905 transformed cell line human CVCL_FL40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193116 CVCL_FL57 ND10992 transformed cell line human CVCL_FL57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193117 CVCL_FL56 ND10918 transformed cell line human CVCL_FL56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193118 CVCL_FL55 ND10632 transformed cell line human CVCL_FL55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193119 CVCL_FL54 ND10573 transformed cell line human CVCL_FL54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193120 CVCL_FL59 ND11123 transformed cell line human CVCL_FL59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193121 CVCL_FL58 ND11021 transformed cell line human CVCL_FL58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193122 CVCL_FL53 ND10548 transformed cell line human CVCL_FL53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193123 CVCL_FL52 ND10402 transformed cell line human CVCL_FL52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193124 CVCL_FL51 ND10375 transformed cell line human CVCL_FL51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193125 CVCL_FL50 ND10323 transformed cell line human CVCL_FL50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193126 CVCL_4Y19 SK-OV-3/CMV-Luc cancer cell line human CVCL_4Y19 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0736; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21193127 CVCL_4Y10 MDA-MB-435-Luc#1 cancer cell line human CVCL_4Y10 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Right buttock; hypodermis. Discontinued: JCRB; NIHS0719; true Male Problematic cell line: Contaminated Parent cell line (MDA-MB-435) has been shown to be a M14 derivative. 21193128 CVCL_4Y14 HLC-1-Luc cancer cell line human CVCL_4Y14 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS0711; true Unspecified 21193129 CVCL_4Y13 SW480/CMV-Luc cancer cell line human CVCL_4Y13 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Colon. Discontinued: JCRB; NIHS0738; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193130 CVCL_4Y12 G-361/CMV-Luc cancer cell line human CVCL_4Y12 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.242_243CC>TT (-138/-139CC>TT); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0705; true. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193131 CVCL_4Y11 SK-BR-3-Luc cancer cell line human CVCL_4Y11 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: JCRB; NIHS0735; true Female 21193132 CVCL_4Y18 OVCAR-3/CMV-Luc cancer cell line human CVCL_4Y18 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0732; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21193133 CVCL_4Y17 RERF-LC-KJ/CMV-Luc cancer cell line human CVCL_4Y17 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu224Valfs (c.670_671insTGTCT); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese Discontinued: JCRB; NIHS0733; true. Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193134 CVCL_4Y16 NCI-H650-Luc cancer cell line human CVCL_4Y16 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser871Ter (c.2612C>A); ClinVar=VCV000051315; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Pro41Glnfs*6 (c.121delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Glu306Ter (c.916G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys164Asn (c.492G>T); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0729; true. Male 21193135 CVCL_4Y15 NCI-H2009-Luc cancer cell line human CVCL_4Y15 CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Val (c.1A>G); ClinVar=VCV000376369; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Gln28Ter (c.82C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0725; true Female 21193136 CVCL_4Y21 KP-1NL-Luc#2 cancer cell line human CVCL_4Y21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Pancreas. Discontinued: JCRB; NIHS0714; true Male Problematic cell line: Contaminated Grand-parent cell line (KP-1N) has been shown to be a PANC-1 derivative. 21193137 CVCL_4Y20 SK-OV-3-Luc cancer cell line human CVCL_4Y20 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS0737; true Female 21193138 CVCL_4Y25 M3 cancer cell line house mouse CVCL_4Y25 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female Doubling time: 19.2 hours (PubMed=8691844) 21193139 CVCL_4Y24 RSV-M cancer cell line house mouse CVCL_4Y24 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: C3H/He. Unspecified 21193140 CVCL_4Y23 F6B3 cancer cell line house mouse CVCL_4Y23 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Brain; Breed/subspecies: C3H/St. Unspecified 21193141 CVCL_4Y22 KP-3L-Luc#5 cancer cell line human CVCL_4Y22 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Glu538Ter (c.1612G>T); ClinVar=VCV000581974; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Liver. Discontinued: JCRB; NIHS0716; true Male 21193142 CVCL_4Y29 XP95TO finite cell line human CVCL_4Y29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 21193143 CVCL_4Y28 AT4BI(SV) transformed cell line human CVCL_4Y28 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193144 CVCL_4Y26 GM1629(SV) transformed cell line human CVCL_4Y26 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg670Trp (c.2008C>T) (C2087T); ClinVar=VCV000190158; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Tyr1179Leufs*22 (c.3536delA) (3615delA); ClinVar=VCV000190167; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21193145 CVCL_4Y09 MDA-MB-361-Luc#1 cancer cell line human CVCL_4Y09 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1657Ser (c.4970A>G); ClinVar=VCV000409419; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Met52Ile (c.156G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys567Arg (c.1700A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu56Ter (c.166G>T); ClinVar=VCV001329425; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Brain. Discontinued: JCRB; NIHS0718; true Female 21193146 CVCL_4Y08 BT-474/CMV-Luc cancer cell line human CVCL_4Y08 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Breast. Discontinued: JCRB; NIHS0701; true Female Characteristics: Expression of luciferase is under the control of the CMV promoter 21193147 CVCL_4Y03 LoVo-Luc#2 cancer cell line human CVCL_4Y03 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Left supraclavicular lymph node. Discontinued: JCRB; NIHS0717; true Male 21193148 CVCL_4Y02 HCT 15-Luc#1 cancer cell line human CVCL_4Y02 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; c.68-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr30Ter (c.90C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg145Trp (c.433C>T); ClinVar=VCV000005592; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>C; ClinVar=VCV000635383; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS0710; true. Male 21193149 CVCL_4Y01 NIH3T3/ATCC/CMV-Luc spontaneously immortalized cell line house mouse CVCL_4Y01 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Discontinued: JCRB; NIHS0730; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193150 CVCL_4Y00 B16-F10-Luc 1-#3 cancer cell line house mouse CVCL_4Y00 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Discontinued: JCRB; NIHS0699; true Male 21193151 CVCL_4Y07 NUGC-3-Luc cancer cell line human CVCL_4Y07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Brachialis muscle. Discontinued: JCRB; NIHS0731; true Male 21193152 CVCL_4Y06 MKN74/CMV-Luc cancer cell line human CVCL_4Y06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Leu (c.751A>C); ClinVar=VCV000182937; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Liver. Discontinued: JCRB; NIHS0722; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193153 CVCL_4Y05 MKN7/CMV-Luc cancer cell line human CVCL_4Y05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Lymph node. Discontinued: JCRB; NIHS0721; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193154 CVCL_4Y04 IM95/CMV-Luc cancer cell line human CVCL_4Y04 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from sampling site: Stomach. Discontinued: JCRB; NIHS0712; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 21193155 CVCL_4Z93 GM03010 transformed cell line human CVCL_4Z93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193156 CVCL_4Z92 GM02832 finite cell line human CVCL_4Z92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193157 CVCL_4Z91 GM02831 finite cell line human CVCL_4Z91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21193158 CVCL_4Z90 GM02830 finite cell line human CVCL_4Z90 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21193159 CVCL_4Z97 HH01 spontaneously immortalized cell line human CVCL_4Z97 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Female 21193160 CVCL_4Z96 WH44KA cancer cell line CVCL_4Z96 CL:0000010 Transformant: Woodchuck hepatitis virus(NCBI-Taxonomy; 35269); Derived from sampling site: Liver. Unspecified Doubling time: ~36 hours (PubMed=2453497) 21193161 CVCL_4Z95 WH257GE10 cancer cell line CVCL_4Z95 CL:0000010 Transformant: Woodchuck hepatitis virus(NCBI-Taxonomy; 35269). Unspecified Characteristics: Derived from a serially transplanted tumor maintained in nude mice Doubling time: ~40 hours, at 110th passage (PubMed=3905560) 21193162 CVCL_4Z94 T3-HEP-W1 cancer cell line CVCL_4Z94 CL:0000010 Transformant: Woodchuck hepatitis virus(NCBI-Taxonomy; 35269); Derived from sampling site: Liver. Male Doubling time: 24 hours, at 20th passage (PubMed=3338696) 21193163 CVCL_4Z99 HH09 spontaneously immortalized cell line human CVCL_4Z99 CL:0000010 Donor information: Established from the normal liver from a patient suffering from hepatoblastoma; Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21193164 CVCL_4Z98 HH02 spontaneously immortalized cell line human CVCL_4Z98 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Male 21193165 CVCL_4Z71 GM13287 finite cell line human CVCL_4Z71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193166 CVCL_4Z70 GM13286 transformed cell line human CVCL_4Z70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193167 CVCL_4Z75 GM15751 finite cell line human CVCL_4Z75 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193168 CVCL_4Z74 GM14579 transformed cell line human CVCL_4Z74 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Met1Thr (c.2T>C); Zygosity=Heterozygous (from familial inference of TTD13PV) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193169 CVCL_4Z73 TTD14PV LCL transformed cell line human CVCL_4Z73 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Met1Thr (c.2T>C); Zygosity=Homozygous (from autologous cell line TTD14PV) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193170 CVCL_4Z72 TTD13PV LCL transformed cell line human CVCL_4Z72 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Met1Thr (c.2T>C); Zygosity=Homozygous (from autologous cell line TTD13PV) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193171 CVCL_4Z79 TTD14PV finite cell line human CVCL_4Z79 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Met1Thr (c.2T>C); Zygosity=Homozygous (PubMed=15220921; PubMed=18470933) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193172 CVCL_4Z78 TTD2GL finite cell line human CVCL_4Z78 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Heterozygous (PubMed=7920640); Sequence variation: Mutation; HGNC; 3434; ERCC2; Unexplicit; IVS15+2dupT; Zygosity=Heterozygous (PubMed=7920640) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193173 CVCL_4Z77 TTD1BEL finite cell line human CVCL_4Z77 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=7920640; PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=7920640; PubMed=8571952) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193174 CVCL_4Z76 TTD2BR finite cell line human CVCL_4Z76 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Val488_Met493del (c.1462_1479del18) (1540-1557del); Zygosity=Heterozygous (PubMed=7920640); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Glu731Argfs*14 (c.2190delG) (730fs); Zygosity=Heterozygous (PubMed=7920640) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193175 CVCL_4Z82 GM03031 finite cell line human CVCL_4Z82 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193176 CVCL_4Z81 GM16391 finite cell line human CVCL_4Z81 CL:0000010 Population: Caucasian; Welsh; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193177 CVCL_4Z80 TTD13PV finite cell line human CVCL_4Z80 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Met1Thr (c.2T>C); Zygosity=Homozygous (PubMed=15220921; PubMed=18470933) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193178 CVCL_4Z86 GM12059 finite cell line human CVCL_4Z86 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM12059; probable Male 21193179 CVCL_4Z85 GM03283 finite cell line human CVCL_4Z85 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193180 CVCL_4Z84 GM03281 finite cell line human CVCL_4Z84 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193181 CVCL_4Z83 GM03033 finite cell line human CVCL_4Z83 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Cell type=Fibroblast. Female 21193182 CVCL_4Z89 GM00540 finite cell line human CVCL_4Z89 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193183 CVCL_4Z88 GM00533 finite cell line human CVCL_4Z88 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193184 CVCL_4Z87 GM00525 finite cell line human CVCL_4Z87 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193185 CVCL_4Z53 SB-CEV-1/P cancer cell line CVCL_4Z53 CL:0000010 Derived from sampling site: Embryonic visceral connective tissue; Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10497 21193186 CVCL_4Z52 ZFTMA cancer cell line CVCL_4Z52 CL:0000010 Karyotypic information: Tetraploid karyotype (PubMed=21359817) Omics: Transcriptome analysis by RNAseq. Female Doubling time: 9.68 hours, at 300 days of culture (PubMed=21359817) Group: Bird cell line 21193187 CVCL_4Z51 G266 cancer cell line CVCL_4Z51 CL:0000010 Karyotypic information: Diploid karyotype (PubMed=21359817); Derived from sampling site: Skin. Omics: Transcriptome analysis by RNAseq Male Doubling time: 8.92 hours, at 186 days of culture (PubMed=21359817) Group: Bird cell line 21193188 CVCL_4Z50 RN5 cancer cell line house mouse CVCL_4Z50 CL:0000010 Breed/subspecies: C57BL/6J Nf2+/-. 21193189 CVCL_4Z57 EB14 embryonic stem cell CVCL_4Z57 From: Valneva SE; Saint-Herblain; France CL:0000010 Breed/subspecies: S86N. Unspecified Group: Bird cell line; Group: Patented cell line 21193190 CVCL_4Z56 SB-CEV-1/G7 cancer cell line CVCL_4Z56 CL:0000010 Derived from sampling site: Embryonic visceral connective tissue; Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10496 21193191 CVCL_4Z55 SB-CEV-1/F7 cancer cell line CVCL_4Z55 CL:0000010 Derived from sampling site: Embryonic visceral connective tissue; Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10495 21193192 CVCL_4Z54 SB-CEV-1/A2 cancer cell line CVCL_4Z54 CL:0000010 Derived from sampling site: Embryonic visceral connective tissue; Breed/subspecies: White Leghorn SPAFAS. Group: Bird cell line 21193193 CVCL_4Z59 SVK14 transformed cell line human CVCL_4Z59 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 21193194 CVCL_4Z58 EB45 embryonic stem cell CVCL_4Z58 From: Valneva SE; Saint-Herblain; France CL:0000010 Breed/subspecies: S86N. Unspecified Group: Bird cell line 21193195 CVCL_XA90 FT2-14 hybridoma house mouse CVCL_XA90 CL:0000010 Discontinued: JCRB; IFO50180; probable. Characteristics: This is a tetradoma, a fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P02675; Human FGB; Monoclonal antibody target: UniProtKB; P00750; Human PLAT Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2158 21193196 CVCL_XA94 UP3-175 hybridoma house mouse CVCL_XA94 CL:0000010 Discontinued: JCRB; IFO50224; probable. Characteristics: This is a tetradoma, a fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P00749; Human PLAU; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2845 21193197 CVCL_XA93 2T60 hybridoma house mouse CVCL_XA93 CL:0000010 Discontinued: JCRB; IFO50211; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2623 21193198 CVCL_XA92 FU2-16 hybridoma house mouse CVCL_XA92 CL:0000010 Discontinued: JCRB; IFO50207; probable. Characteristics: This is a tetradoma, a fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P02675; Human FGB; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2547 21193199 CVCL_XA91 FU1-74 hybridoma house mouse CVCL_XA91 CL:0000010 Discontinued: JCRB; IFO50185; probable. Characteristics: This is a tetradoma, a fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P02675; Human FGB; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2334 21193200 CVCL_XA98 AtT-20-FlpIn cancer cell line house mouse CVCL_XA98 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. Characteristics: Transfected with the pFRT/lacZeo2 plasmid 21193201 CVCL_XA97 8C10 hybridoma house mouse CVCL_XA97 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5T2D2; Human TREML2. 21193202 CVCL_XA96 10F5 hybridoma house mouse CVCL_XA96 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5T2D2; Human TREML2. 21193203 CVCL_XA95 UP4-33 hybridoma house mouse CVCL_XA95 CL:0000010 Discontinued: JCRB; IFO50251; probable. Characteristics: This is a tetradoma, a fusion of two hybridomas; Monoclonal antibody target: UniProtKB; P00749; Human PLAU; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-3018 21193204 CVCL_XA99 AtT-20-CB1 cancer cell line house mouse CVCL_XA99 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. Characteristics: Transfected with the pFRT/lacZeo2 plasmid 21193205 CVCL_4Z60 HaCaT/SM spontaneously immortalized cell line human CVCL_4Z60 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:25434; Bis(2-chloroethyl) sulfide (Sulfur mustard; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 21193206 CVCL_4Z64 MDA-MB-231/PacR cancer cell line human CVCL_4Z64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21193207 CVCL_4Z63 P815 MB cancer cell line house mouse CVCL_4Z63 CL:0000010 Sequence variation: Mutation; MGI; MGI:96677; Kit; Simple; p.Asp818Tyr (c.2452G>T) (D814Y); Zygosity=Unspecified (from parent cell line) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: DBA/2. Discontinued: ATCC; CRL-6448; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193208 CVCL_4Z62 UKE-1/TGR cancer cell line human CVCL_4Z62 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:90304; TG101209 (N-(tert-butyl)-3-((5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide); Derived from sampling site: Peripheral blood. Female 21193209 CVCL_4Z61 HEL/TGR cancer cell line human CVCL_4Z61 CL:0000010 Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:90304; TG101209 (N-(tert-butyl)-3-((5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide); Donor information: Originally the patient was suffering from Hodgkin lymphoma; Derived from sampling site: Peripheral blood. Male 21193210 CVCL_4Z68 J5 [Human hepatocellular carcinoma] cancer cell line human CVCL_4Z68 CL:0000010 Population: Chinese. Unspecified 21193211 CVCL_4Z67 TB [Human] cancer cell line human CVCL_4Z67 CL:0000010 Derived from sampling site: Cerebrospinal fluid. Unspecified Doubling time: 18 +- 2 hours (PubMed=10320710) 21193212 CVCL_4Z66 DT40-MRE11(-/-)-XRCC6(-/-) cancer cell line CVCL_4Z66 CL:0000010 Knockout cell: Method=Targeted integration; MRE11+XRCC6 Transformant: Avian leukosis virus (ALV)(NCBI-Taxonomy; 11864); Derived from sampling site: Cell type=B-cell; Breed/subspecies: Hy-Line SC. Female Group: Bird cell line 21193213 CVCL_4Z65 MDA-MB-231DR cancer cell line human CVCL_4Z65 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Group: Triple negative breast cancer (TNBC) cell line 21193214 CVCL_4Z69 J7 cancer cell line human CVCL_4Z69 CL:0000010 Population: Chinese. Male 21193215 CVCL_FN66 ND27348 transformed cell line human CVCL_FN66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193216 CVCL_FN65 ND27253 transformed cell line human CVCL_FN65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193217 CVCL_FN64 ND27124 transformed cell line human CVCL_FN64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193218 CVCL_FN63 ND27110 transformed cell line human CVCL_FN63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193219 CVCL_FN69 ND27474 transformed cell line human CVCL_FN69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193220 CVCL_FN68 ND27408 transformed cell line human CVCL_FN68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193221 CVCL_FN67 ND27371 transformed cell line human CVCL_FN67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193222 CVCL_FN62 ND27062 transformed cell line human CVCL_FN62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193223 CVCL_FN61 ND26974 transformed cell line human CVCL_FN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193224 CVCL_FN60 ND26558 transformed cell line human CVCL_FN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193225 CVCL_FN77 ND27947 transformed cell line human CVCL_FN77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193226 CVCL_FN76 ND27935 transformed cell line human CVCL_FN76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193227 CVCL_FN75 ND27880 transformed cell line human CVCL_FN75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193228 CVCL_FN74 ND27841 transformed cell line human CVCL_FN74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193229 CVCL_FN79 ND27949 transformed cell line human CVCL_FN79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193230 CVCL_FN78 ND27948 transformed cell line human CVCL_FN78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193231 CVCL_FN73 ND27755 transformed cell line human CVCL_FN73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193232 CVCL_FN72 ND27734 transformed cell line human CVCL_FN72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193233 CVCL_FN71 ND27733 transformed cell line human CVCL_FN71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193234 CVCL_FN70 ND27654 transformed cell line human CVCL_FN70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193235 CVCL_FN49 ND25904 transformed cell line human CVCL_FN49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193236 CVCL_FN44 ND25739 transformed cell line human CVCL_FN44 CL:0000010 Population: Bolivian and Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193237 CVCL_FN43 ND25686 transformed cell line human CVCL_FN43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193238 CVCL_FN42 ND25683 transformed cell line human CVCL_FN42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193239 CVCL_FN41 ND25682 transformed cell line human CVCL_FN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193240 CVCL_FN48 ND25874 transformed cell line human CVCL_FN48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193241 CVCL_FN47 ND25839 transformed cell line human CVCL_FN47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193242 CVCL_FN46 ND25819 transformed cell line human CVCL_FN46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193243 CVCL_FN45 ND25818 transformed cell line human CVCL_FN45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193244 CVCL_FN40 ND25582 transformed cell line human CVCL_FN40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193245 CVCL_FN55 ND26164 transformed cell line human CVCL_FN55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193246 CVCL_FN54 ND26163 transformed cell line human CVCL_FN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193247 CVCL_FN53 ND26123 transformed cell line human CVCL_FN53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193248 CVCL_FN52 ND26122 transformed cell line human CVCL_FN52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193249 CVCL_FN59 ND26557 transformed cell line human CVCL_FN59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193250 CVCL_FN58 ND26524 transformed cell line human CVCL_FN58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193251 CVCL_FN57 ND26252 transformed cell line human CVCL_FN57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193252 CVCL_FN56 ND26250 transformed cell line human CVCL_FN56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193253 CVCL_FN51 ND26121 transformed cell line human CVCL_FN51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193254 CVCL_FN50 ND26087 transformed cell line human CVCL_FN50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193255 CVCL_FN29 ND25261 transformed cell line human CVCL_FN29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193256 CVCL_FN28 ND25260 transformed cell line human CVCL_FN28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193257 CVCL_FN27 ND25250 transformed cell line human CVCL_FN27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193258 CVCL_FN22 ND25071 transformed cell line human CVCL_FN22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193259 CVCL_FN21 ND25070 transformed cell line human CVCL_FN21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193260 CVCL_FN20 ND25026 transformed cell line human CVCL_FN20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193261 CVCL_FN26 ND25207 transformed cell line human CVCL_FN26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193262 CVCL_FN25 ND25206 transformed cell line human CVCL_FN25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193263 CVCL_FN24 ND25193 transformed cell line human CVCL_FN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193264 CVCL_FN23 ND25181 transformed cell line human CVCL_FN23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193265 CVCL_FN39 ND25545 transformed cell line human CVCL_FN39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193266 CVCL_FN38 ND25544 transformed cell line human CVCL_FN38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193267 CVCL_FN33 ND25412 transformed cell line human CVCL_FN33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193268 CVCL_FN32 ND25386 transformed cell line human CVCL_FN32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193269 CVCL_FN31 ND25301 transformed cell line human CVCL_FN31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193270 CVCL_FN30 ND25300 transformed cell line human CVCL_FN30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193271 CVCL_FN37 ND25540 transformed cell line human CVCL_FN37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193272 CVCL_FN36 ND25486 transformed cell line human CVCL_FN36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193273 CVCL_FN35 ND25485 transformed cell line human CVCL_FN35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193274 CVCL_FN34 ND25465 transformed cell line human CVCL_FN34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193275 CVCL_FN08 ND24782 transformed cell line human CVCL_FN08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193276 CVCL_FN07 ND24710 transformed cell line human CVCL_FN07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193277 CVCL_FN06 ND24687 transformed cell line human CVCL_FN06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193278 CVCL_FN05 ND24657 transformed cell line human CVCL_FN05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193279 CVCL_FN09 ND24785 transformed cell line human CVCL_FN09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193280 CVCL_FN00 ND24612 transformed cell line human CVCL_FN00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193281 CVCL_FN04 ND24647 transformed cell line human CVCL_FN04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193282 CVCL_FN03 ND24646 transformed cell line human CVCL_FN03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193283 CVCL_FN02 ND24643 transformed cell line human CVCL_FN02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193284 CVCL_FN01 ND24613 transformed cell line human CVCL_FN01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193285 CVCL_FN19 ND25008 transformed cell line human CVCL_FN19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193286 CVCL_FN18 ND24996 transformed cell line human CVCL_FN18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193287 CVCL_FN17 ND24980 transformed cell line human CVCL_FN17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193288 CVCL_FN16 ND24979 transformed cell line human CVCL_FN16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193289 CVCL_FN11 ND24839 transformed cell line human CVCL_FN11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193290 CVCL_FN10 ND24838 transformed cell line human CVCL_FN10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193291 CVCL_FN15 ND24948 transformed cell line human CVCL_FN15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193292 CVCL_FN14 ND24933 transformed cell line human CVCL_FN14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193293 CVCL_FN13 ND24922 transformed cell line human CVCL_FN13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193294 CVCL_FN12 ND24891 transformed cell line human CVCL_FN12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193295 CVCL_XA03 3B6 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA03 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9399 21193296 CVCL_XA02 2F11 hybridoma house mouse CVCL_XA02 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9373 21193297 CVCL_XA01 2D9 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9396 21193298 CVCL_XA00 1C1 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9398 21193299 CVCL_XA07 5A5 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8528 21193300 CVCL_XA06 4F8 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA06 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9397 21193301 CVCL_XA05 3H11 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA05 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9374 21193302 CVCL_XA04 3D4 [Mouse hybridoma against influenza A virus NA] hybridoma house mouse CVCL_XA04 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 neuraminidase (NA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9395 21193303 CVCL_XA09 6C6 [Mouse hybridoma against influenza A virus NA] hybridoma house mouse CVCL_XA09 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 neuraminidase (NA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8526 21193304 CVCL_XA08 5C5 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XA08 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8529 21193305 CVCL_FM89 ND24343 transformed cell line human CVCL_FM89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193306 CVCL_FM88 ND24291 transformed cell line human CVCL_FM88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193307 CVCL_FM87 ND24290 transformed cell line human CVCL_FM87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193308 CVCL_FM86 ND24218 transformed cell line human CVCL_FM86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193309 CVCL_FM81 ND24105 transformed cell line human CVCL_FM81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193310 CVCL_FM80 ND24104 transformed cell line human CVCL_FM80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193311 CVCL_FM85 ND24217 transformed cell line human CVCL_FM85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193312 CVCL_FM84 ND24191 transformed cell line human CVCL_FM84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193313 CVCL_FM83 ND24188 transformed cell line human CVCL_FM83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193314 CVCL_FM82 ND24174 transformed cell line human CVCL_FM82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193315 CVCL_FM99 ND24589 transformed cell line human CVCL_FM99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193316 CVCL_FM98 ND24550 transformed cell line human CVCL_FM98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193317 CVCL_FM97 ND24549 transformed cell line human CVCL_FM97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193318 CVCL_FM92 ND24389 transformed cell line human CVCL_FM92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193319 CVCL_FM91 ND24360 transformed cell line human CVCL_FM91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193320 CVCL_FM90 ND24346 transformed cell line human CVCL_FM90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193321 CVCL_FM96 ND24539 transformed cell line human CVCL_FM96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193322 CVCL_FM95 ND24514 transformed cell line human CVCL_FM95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193323 CVCL_FM94 ND24453 transformed cell line human CVCL_FM94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193324 CVCL_FM93 ND24444 transformed cell line human CVCL_FM93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193325 CVCL_FM67 ND23578 transformed cell line human CVCL_FM67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193326 CVCL_FM66 ND23531 transformed cell line human CVCL_FM66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193327 CVCL_FM65 ND23488 transformed cell line human CVCL_FM65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193328 CVCL_FM64 ND23465 transformed cell line human CVCL_FM64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193329 CVCL_FM69 ND23637 transformed cell line human CVCL_FM69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193330 CVCL_FM68 ND23579 transformed cell line human CVCL_FM68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193331 CVCL_FM63 ND23245 transformed cell line human CVCL_FM63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193332 CVCL_FM62 ND23244 transformed cell line human CVCL_FM62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193333 CVCL_FM61 ND23231 transformed cell line human CVCL_FM61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193334 CVCL_FM60 ND23230 transformed cell line human CVCL_FM60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193335 CVCL_FM78 ND24065 transformed cell line human CVCL_FM78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193336 CVCL_FM77 ND24005 transformed cell line human CVCL_FM77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193337 CVCL_FM76 ND23989 transformed cell line human CVCL_FM76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193338 CVCL_FM75 ND23852 transformed cell line human CVCL_FM75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193339 CVCL_FM79 ND24096 transformed cell line human CVCL_FM79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193340 CVCL_FM70 ND23719 transformed cell line human CVCL_FM70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193341 CVCL_FM74 ND23828 transformed cell line human CVCL_FM74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193342 CVCL_FM73 ND23824 transformed cell line human CVCL_FM73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193343 CVCL_FM72 ND23813 transformed cell line human CVCL_FM72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193344 CVCL_FM71 ND23743 transformed cell line human CVCL_FM71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193345 CVCL_XA83 TPA1-70 hybridoma house mouse CVCL_XA83 CL:0000010 Discontinued: JCRB; IFO50179; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2086 21193346 CVCL_XA82 TPA1-41 hybridoma house mouse CVCL_XA82 CL:0000010 Discontinued: JCRB; IFO50178; probable. Monoclonal antibody isotype: IgG2b, kappa Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2085 21193347 CVCL_XA81 TPA1-39 hybridoma house mouse CVCL_XA81 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT. 21193348 CVCL_XA80 TPA1-148 hybridoma house mouse CVCL_XA80 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT. 21193349 CVCL_XA87 UK1-3 hybridoma house mouse CVCL_XA87 CL:0000010 Discontinued: JCRB; IFO50176; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2083 21193350 CVCL_XA86 TPA2-6 hybridoma house mouse CVCL_XA86 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT. 21193351 CVCL_XA85 TPA2-14 hybridoma house mouse CVCL_XA85 CL:0000010 Discontinued: JCRB; IFO50194; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2519 21193352 CVCL_XA84 TPA2-135 hybridoma house mouse CVCL_XA84 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00750; Human PLAT. 21193353 CVCL_XA89 UK1-87 hybridoma house mouse CVCL_XA89 CL:0000010 Discontinued: JCRB; IFO50177; probable. Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2084 21193354 CVCL_XA88 UK1-6 hybridoma house mouse CVCL_XA88 CL:0000010 Discontinued: JCRB; IFO50208; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2548 21193355 CVCL_4Z31 TC-205 cancer cell line human CVCL_4Z31 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 18562; FEV; Name(s)=EWSR1-FEV, EWS-FEV; Note=EWSR1 exon 7 fused to FEV exon 3 (DOI=10.5282/edoc.27750) Omics: Deep exome analysis. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21193356 CVCL_4Z30 TC-138 cancer cell line human CVCL_4Z30 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 4 fusion (Ex10/Ex5) (PubMed=25010205) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21193357 CVCL_4Z35 TC-248 cancer cell line human CVCL_4Z35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Unspecified (PubMed=25010205) Omics: Protein expression by reverse-phase protein arrays; Omics: Transcriptome analysis by RNAseq. Part of: MD Anderson Cell Lines Project 21193358 CVCL_4Z34 TC-244 cancer cell line human CVCL_4Z34 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=25010205); Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 1 fusion (Ex7/Ex6) (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Male 21193359 CVCL_4Z33 TC-240 cancer cell line human CVCL_4Z33 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 3 fusion (Ex10/Ex6) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Arg216Ter (c.646C>T); Zygosity=Unspecified (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Male 21193360 CVCL_4Z32 TC-215 cancer cell line human CVCL_4Z32 CL:0000010 Sequence variation: Gene fusion; HGNC; 3508; EWSR1 + HGNC; 3749; FLI1; Name(s)=EWSR1-FLI1, EWS-FLI1; Note=Type 2 fusion (Ex7/Ex5) (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Male 21193361 CVCL_4Z39 LA-9 spontaneously immortalized cell line house mouse CVCL_4Z39 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21193362 CVCL_4Z38 2B4 [Mouse T-cell hybridoma] hybridoma house mouse CVCL_4Z38 CL:0000010 Characteristics: T-cell hybridoma. 21193363 CVCL_4Z37 TC-4C cancer cell line human CVCL_4Z37 CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 3508; EWSR1; Name(s)=EWSR1-ERG, EWS-ERG (PubMed=25010205); Sequence variation: Mutation; HGNC; 11355; STAG2; Unexplicit; Ex5-12del; Zygosity=Hemizygous (PubMed=25010205); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Arg (c.581T>G); ClinVar=VCV000376633; Zygosity=Unspecified (PubMed=25010205) Omics: Transcriptome analysis by RNAseq. Male 21193364 CVCL_4Z36 TC-249 cancer cell line human CVCL_4Z36 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male 21193365 CVCL_XA72 ML-DmD12 spontaneously immortalized cell line fruit fly CVCL_XA72 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21193366 CVCL_XA71 Bayer/BCIRL-SfTS2-0714-TR spontaneously immortalized cell line CVCL_XA71 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 47.6 hours, at 48th passage (PubMed=31410641) Group: Insect cell line 21193367 CVCL_XA70 Bayer/BCIRL-SfTS-0624-TR spontaneously immortalized cell line CVCL_XA70 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 91.3 hours, at 32th passage (PubMed=31410641) Group: Insect cell line 21193368 CVCL_XA76 N-176-15 hybridoma house mouse CVCL_XA76 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200507 21193369 CVCL_XA75 ML-DmD19 spontaneously immortalized cell line fruit fly CVCL_XA75 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21193370 CVCL_XA74 ML-DmD18 spontaneously immortalized cell line fruit fly CVCL_XA74 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21193371 CVCL_XA73 ML-DmD13 spontaneously immortalized cell line fruit fly CVCL_XA73 CL:0000010 Derived from sampling site: Imaginal disc. Unspecified Group: Insect cell line 21193372 CVCL_XA79 FIB2-11 hybridoma house mouse CVCL_XA79 CL:0000010 Discontinued: JCRB; IFO50175; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02675; Human FGB Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2082 21193373 CVCL_XA78 FIB1-11 hybridoma house mouse CVCL_XA78 CL:0000010 Discontinued: JCRB; IFO50174; probable. Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02675; Human FGB Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-2081 21193374 CVCL_XA77 S-9-11 hybridoma house mouse CVCL_XA77 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200515 21193375 CVCL_4Z42 TK [Human cholangiocarcinoma] cancer cell line human CVCL_4Z42 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 29 hours, at 13th passage (PubMed=10718366) 21193376 CVCL_4Z41 MT-CHC01 cancer cell line human CVCL_4Z41 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=26486326) Population: Caucasian; Italian; Derived from sampling site: Liver. Omics: Transcriptome analysis by microarray Female Characteristics: Established from a mouse xenograft (PubMed=26486326) Doubling time: ~40 hours (PubMed=26486326); 25.3 hours (PubMed=30979003) 21193377 CVCL_4Z40 AM-1 transformed cell line human CVCL_4Z40 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Bone; jaw; mandible Cell type=Ameloblast.. Female 21193378 CVCL_4Z46 iMESO-NF6 transformed cell line house mouse CVCL_4Z46 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:97307; Nf2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193379 CVCL_4Z45 iMESO-NF5 transformed cell line house mouse CVCL_4Z45 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:97307; Nf2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193380 CVCL_4Z44 iMESO-NF3 transformed cell line house mouse CVCL_4Z44 CL:0000010 Knockout cell: Method=KO mouse (1 of 2 alleles); MGI; MGI:97307; Nf2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193381 CVCL_4Z43 C/wStr spontaneously immortalized cell line CVCL_4Z43 CL:0000010 Unspecified Characteristics: In vitro infected by the intracellular symbiont Wolbachia pipientis strain wStr. Group: Insect cell line 21193382 CVCL_4Z49 iMESO-WT3 transformed cell line house mouse CVCL_4Z49 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193383 CVCL_4Z48 iMESO-WT2 transformed cell line house mouse CVCL_4Z48 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193384 CVCL_4Z47 iMESO-WT1 transformed cell line house mouse CVCL_4Z47 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneal cavity Cell type=Mesothelial cell.; Breed/subspecies: C57BL/6J. Unspecified 21193385 CVCL_4Z19 ARL-14 finite cell line Norway rat CVCL_4Z19 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21193386 CVCL_4Z18 UKF-Rhb-1rVCR10 cancer cell line human CVCL_4Z18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys291Ter (c.871A>T); Zygosity=Unspecified (PubMed=19147553) Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Part of: Resistant Cancer Cell Line (RCCL) collection 21193387 CVCL_XA61 Bayer/BCIRL-SfNS2-0714-C44-TR spontaneously immortalized cell line CVCL_XA61 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193388 CVCL_XA60 Bayer/BCIRL-SfNS2-0714-C43-TR spontaneously immortalized cell line CVCL_XA60 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193389 CVCL_XA65 Bayer/BCIRL-SfNS2-0827-TR spontaneously immortalized cell line CVCL_XA65 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 100.9 hours, at 65th passage (PubMed=31410641) Group: Insect cell line 21193390 CVCL_XA64 Bayer/BCIRL-SfNS2-0813-TR spontaneously immortalized cell line CVCL_XA64 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 46.4 hours, at 58th passage (PubMed=31410641) Group: Insect cell line 21193391 CVCL_XA63 BAYER/BCIRL-SfNS1-0813-TR spontaneously immortalized cell line CVCL_XA63 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 34.1 hours, at 41th passage (PubMed=31410641) Group: Insect cell line 21193392 CVCL_XA62 Bayer/BCIRL-SfNS-0806-TR spontaneously immortalized cell line CVCL_XA62 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 67.0 hours, at 41th passage (PubMed=31410641) Group: Insect cell line 21193393 CVCL_XA69 Bayer/BCIRL-SfTS-0403-CLG spontaneously immortalized cell line CVCL_XA69 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 119.3 hours, at 63th passage (PubMed=31410641) Group: Insect cell line 21193394 CVCL_XA68 Bayer/BCIRL-SfTS-0331-CLG spontaneously immortalized cell line CVCL_XA68 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 75.6 hours, at 59th passage (PubMed=31410641) Group: Insect cell line 21193395 CVCL_XA67 Bayer/BCIRL-SfNS4-0827-TR spontaneously immortalized cell line CVCL_XA67 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 127.8 hours, at 47th passage (PubMed=31410641) Group: Insect cell line 21193396 CVCL_XA66 Bayer/BCIRL-SfNS3-0827-TR spontaneously immortalized cell line CVCL_XA66 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 141.1 hours, at 58th passage (PubMed=31410641) Group: Insect cell line 21193397 CVCL_4Z13 HeLa.EpoA9 cancer cell line human CVCL_4Z13 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31549; Epothilone A (EpoA); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21193398 CVCL_4Z12 M1RW5 cancer cell line human CVCL_4Z12 CL:0000010 Derived from metastatic site: Lymph node. Male 21193399 CVCL_4Z11 M1RW cancer cell line human CVCL_4Z11 CL:0000010 Derived from metastatic site: Hypodermis. Male Doubling time: 24 hours (PubMed=6770995); 23.6 hours (PubMed=6773878) 21193400 CVCL_4Z10 C8442 cancer cell line human CVCL_4Z10 CL:0000010 21193401 CVCL_4Z17 UKF-Rhb-1 cancer cell line human CVCL_4Z17 CL:0000010 Derived from metastatic site: Bone marrow. 21193402 CVCL_4Z16 UOKCR cancer cell line human CVCL_4Z16 CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu153Pro (c.458T>C); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Kidney. Male 21193403 CVCL_4Z15 A549.EpoB40 cancer cell line human CVCL_4Z15 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31550; Epothilone B (EpoB); Derived from sampling site: Lung. Male 21193404 CVCL_4Z14 HeLa.EpoB1.8 cancer cell line human CVCL_4Z14 CL:0000010 Population: African American; Selected for resistance to: ChEBI; CHEBI:31550; Epothilone B (EpoB); Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 21193405 CVCL_4Z29 SK-MEL-235 cancer cell line human CVCL_4Z29 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21193406 CVCL_XA50 Bayer/BCIRL-SfNS-0624-C13-TR spontaneously immortalized cell line CVCL_XA50 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193407 CVCL_XA54 Bayer/BCIRL-SfNS1-0714-C37-TR spontaneously immortalized cell line CVCL_XA54 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193408 CVCL_XA53 Bayer/BCIRL-SfNS1-0714-C36-TR spontaneously immortalized cell line CVCL_XA53 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193409 CVCL_XA52 Bayer/BCIRL-SfNS1-0714-TR spontaneously immortalized cell line CVCL_XA52 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 56.4 hours, at 42th passage (PubMed=31410641) Group: Insect cell line 21193410 CVCL_XA51 Bayer/BCIRL-SfNS-0624-C15-TR spontaneously immortalized cell line CVCL_XA51 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193411 CVCL_XA58 Bayer/BCIRL-SfNS2-0714-C12-TR spontaneously immortalized cell line CVCL_XA58 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193412 CVCL_XA57 Bayer/BCIRL-SfNS2-0714-TR spontaneously immortalized cell line CVCL_XA57 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 37.3 hours, at 57th passage (PubMed=31410641) Group: Insect cell line 21193413 CVCL_XA56 Bayer/BCIRL-SfNS1-0714-C47-TR spontaneously immortalized cell line CVCL_XA56 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193414 CVCL_XA55 Bayer/BCIRL-SfNS1-0714-C46-TR spontaneously immortalized cell line CVCL_XA55 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193415 CVCL_XA59 Bayer/BCIRL-SfNS2-0714-C31-TR spontaneously immortalized cell line CVCL_XA59 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193416 CVCL_4Z20 ARL-18 finite cell line Norway rat CVCL_4Z20 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21193417 CVCL_4Z24 OV90C-D cancer cell line human CVCL_4Z24 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193418 CVCL_4Z23 OV90C-A cancer cell line human CVCL_4Z23 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193419 CVCL_4Z22 HT-29-D9 cancer cell line human CVCL_4Z22 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female 21193420 CVCL_4Z21 ARL-19 finite cell line Norway rat CVCL_4Z21 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male 21193421 CVCL_4Z28 OV90P-7 cancer cell line human CVCL_4Z28 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193422 CVCL_4Z27 OV90P-3 cancer cell line human CVCL_4Z27 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193423 CVCL_4Z26 OV90D-7 cancer cell line human CVCL_4Z26 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193424 CVCL_4Z25 OV90D-6 cancer cell line human CVCL_4Z25 CL:0000010 Sequence variation: Gene fusion; HGNC; 1790; CDKN2D + HGNC; 20482; WDFY2; Name(s)=CDKN2D-WDFY2 (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg445Ter (c.1333C>T); ClinVar=VCV000024850; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Arg (c.643A>C); ClinVar=VCV000428895; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21193425 CVCL_XA43 Bayer/BCIRL-SfNS-0624-TR spontaneously immortalized cell line CVCL_XA43 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Doubling time: 37.3 hours, at 11th passage (PubMed=31410641) Group: Insect cell line 21193426 CVCL_XA42 Bayer/BCIRL-SfAO2-0813-TR spontaneously immortalized cell line CVCL_XA42 CL:0000010 Derived from sampling site: Aorta. Unspecified Doubling time: 138.5 hours, at 26th passage (PubMed=31410641) Group: Insect cell line 21193427 CVCL_XA41 Bayer/BCIRL-SfAO-0806-TR spontaneously immortalized cell line CVCL_XA41 CL:0000010 Derived from sampling site: Aorta. Unspecified Doubling time: 66.8 hours, at 49th passage (PubMed=31410641) Group: Insect cell line 21193428 CVCL_XA40 Bayer/BCIRL-SfAO2-0714-TR spontaneously immortalized cell line CVCL_XA40 CL:0000010 Derived from sampling site: Aorta. Unspecified Doubling time: 34.4 hours, at 38th passage (PubMed=31410641) Group: Insect cell line 21193429 CVCL_XA47 Bayer/BCIRL-SfNS-0624-C6-TR spontaneously immortalized cell line CVCL_XA47 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193430 CVCL_XA46 Bayer/BCIRL-SfNS-0624-C5-TR spontaneously immortalized cell line CVCL_XA46 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193431 CVCL_XA45 Bayer/BCIRL-SfNS-0624-C3-TR spontaneously immortalized cell line CVCL_XA45 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193432 CVCL_XA44 Bayer/BCIRL-SfNS-0624-C2-TR spontaneously immortalized cell line CVCL_XA44 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193433 CVCL_XA49 Bayer/BCIRL-SfNS-0624-C11-TR spontaneously immortalized cell line CVCL_XA49 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193434 CVCL_XA48 Bayer/BCIRL-SfNS-0624-C8-TR spontaneously immortalized cell line CVCL_XA48 CL:0000010 Derived from sampling site: Ventral nerve cord and brain. Unspecified Group: Insect cell line 21193435 CVCL_4Z09 C832C cancer cell line human CVCL_4Z09 CL:0000010 21193436 CVCL_4Z08 C827A cancer cell line human CVCL_4Z08 CL:0000010 21193437 CVCL_4Z07 C822 cancer cell line human CVCL_4Z07 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21193438 CVCL_XA32 GL37 spontaneously immortalized cell line CVCL_XA32 CL:0000010 Group: Non-human primate cell line. 21193439 CVCL_XA31 GIK spontaneously immortalized cell line CVCL_XA31 CL:0000010 Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3142C0001000000101, 3142C0001000000105) They were the sole source of information for this entry. Derived from sampling site: Kidney. Unspecified Group: Fish cell line 21193440 CVCL_XA30 UKF-NB-1 cancer cell line human CVCL_XA30 CL:0000010 21193441 CVCL_XA36 SAC-IIC3 cancer cell line house mouse CVCL_XA36 CL:0000010 Derived from sampling site: Ascites. 21193442 CVCL_XA35 SRS-82 cancer cell line house mouse CVCL_XA35 CL:0000010 Derived from sampling site: Ascites. 21193443 CVCL_XA34 MKM150-2 hybridoma house mouse CVCL_XA34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q16881; Human TXNRD1. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-5086 21193444 CVCL_XA33 GZHMD1F10 hybridoma house mouse CVCL_XA33 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:28306; Semicarbazide. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200640 21193445 CVCL_XA39 SAC-IID9 cancer cell line house mouse CVCL_XA39 CL:0000010 Derived from sampling site: Ascites. 21193446 CVCL_XA38 DUL LCL transformed cell line human CVCL_XA38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 48-60 hours (PubMed=2156585) 21193447 CVCL_XA37 SAC-IIB2 cancer cell line house mouse CVCL_XA37 CL:0000010 Derived from sampling site: Ascites. 21193448 CVCL_4Z02 C8054 cancer cell line human CVCL_4Z02 CL:0000010 Derived from metastatic site: Axillary lymph node. Male 21193449 CVCL_4Z01 PC-8 cancer cell line human CVCL_4Z01 From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 21193450 CVCL_4Z00 3640P transformed cell line human CVCL_4Z00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from a patient suffering from head and neck squamous cell carcinoma; Derived from sampling site: Peripheral blood. Female 21193451 CVCL_4Z06 C8157 cancer cell line human CVCL_4Z06 CL:0000010 Derived from metastatic site: Supraclavicular lymph node. Male 21193452 CVCL_4Z05 C8146C cancer cell line human CVCL_4Z05 CL:0000010 Derived from metastatic site: Hypodermis. Female 21193453 CVCL_4Z04 C8146A cancer cell line human CVCL_4Z04 CL:0000010 Derived from metastatic site: Hypodermis. Female 21193454 CVCL_4Z03 C8130 cancer cell line human CVCL_4Z03 CL:0000010 Derived from metastatic site: Lymph node. Female 21193455 CVCL_XA21 H2030-TGL cancer cell line human CVCL_XA21 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Caution: In PubMed=19576624 and the associated GEO data sets H2030-TGL is termed H2030 Parental 21193456 CVCL_XA20 PC9-LeptoM cancer cell line human CVCL_XA20 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Male Characteristics: Brain leptomeningeal space metastatic derivative of parental cell line Established after 3 passages in nude mice from intracisternal injection, followed by one passage from intracardiac injection and obtained from mice bearing leptomeningeal metastases.; Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Part of: Brain metastasis cell lines panel 21193457 CVCL_XA25 GeneBLAzer Gqi5-NFAT-bla FreeStyle 293F transformed cell line human CVCL_XA25 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193458 CVCL_XA24 CellSensor NFAT-bla Freestyle 293F transformed cell line human CVCL_XA24 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193459 CVCL_XA23 HCC1954-LeptoM cancer cell line human CVCL_XA23 CL:0000010 Sequence variation: Gene fusion; HGNC; 2092; CLTC + HGNC; 29559; VMP1; Name(s)=CLTC-VMP1 (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163Cys (c.488A>G); ClinVar=VCV000127814; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: East Indian; Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Characteristics: Brain leptomeningeal space metastatic derivative of parental cell line Established after 3 passages in nude mice from intracisternal injection, followed by one passage from intracardiac injection and obtained from mice bearing leptomeningeal metastases.; Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) and with PuroR/pac Part of: Brain metastasis cell lines panel 21193460 CVCL_XA22 H2030-BrM3 cancer cell line human CVCL_XA22 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly262Val (c.785G>T); ClinVar=VCV000428889; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) 21193461 CVCL_XA29 GeneBLAzer EDG7-NFAT-bla HEK 293T transformed cell line human CVCL_XA29 CL:0000010 Transfected with: HGNC; 14298; LPAR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193462 CVCL_XA28 GeneBLAzer H1-NFAT-bla HEK 293T transformed cell line human CVCL_XA28 CL:0000010 Transfected with: HGNC; 5182; HRH1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193463 CVCL_XA27 GeneBLAzer T-REx-G2A-NFAT-bla FreeStyle 293F transformed cell line human CVCL_XA27 CL:0000010 Transfected with: HGNC; 17482; GPR132; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193464 CVCL_XA26 GeneBLAzer OPRL1-Gqi5-NFAT-bla FreeStyle 293F transformed cell line human CVCL_XA26 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: HGNC; 8155; OPRL1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 21193465 CVCL_XA10 8H12 hybridoma house mouse CVCL_XA10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 neuraminidase (NA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9394 21193466 CVCL_XA14 CO2 [Human iPSC] induced pluripotent stem cell human CVCL_XA14 From: Heinrich-Heine-Universitat Dusseldorf; Dusseldorf; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21193467 CVCL_XA13 chHES-472 embryonic stem cell human CVCL_XA13 From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[~74]; Zygosity=Heterozygous (PubMed=27934588). Male 21193468 CVCL_XA12 OC1C3 hybridoma house mouse CVCL_XA12 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3131C0001000600039) It was the sole source of information for this entry.. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human antigen on ovarian epithelial carcinoma cells 21193469 CVCL_XA11 9C1 hybridoma house mouse CVCL_XA11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Influenza A virus H5N1 hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9372 21193470 CVCL_XA18 PC9-TGL cancer cell line human CVCL_XA18 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Caution: In PubMed=19576624, PubMed=28283064 and the associated GEO data sets H2030-TGL is termed PC9 Parental 21193471 CVCL_XA17 MEL-1 INSGFP/w NEUROD1(-/-) embryonic stem cell human CVCL_XA17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7762; NEUROD1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Cell line information from personal communication of Romer A. Male Characteristics: Using homologous recombination an EGFP reporter gene was introduced in the INS locus 21193472 CVCL_XA16 MEL-1 INSGFP/w embryonic stem cell human CVCL_XA16 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Male Characteristics: Using homologous recombination an EGFP reporter gene was introduced in the INS locus (PubMed=22120512) 21193473 CVCL_XA15 HES-3 INSGFP/w embryonic stem cell human CVCL_XA15 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Using homologous recombination an EGFP reporter gene was introduced in one allele of the INS locus (PubMed=22120512) 21193474 CVCL_XA19 PC9-BrM3 cancer cell line human CVCL_XA19 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Japanese; Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Brain metastatic derivative of parental cell line Established after 3 passages in nude mice from intracardial injection. Obtained from mice bearing brain tumors.; Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Part of: Brain metastasis cell lines panel 21193475 CVCL_G007 PBL-Om transformed cell line human CVCL_G007 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Male 21193476 CVCL_G006 SV-HUC-2 transformed cell line human CVCL_G006 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ureter Cell type=Epithelial cell.. Unspecified 21193477 CVCL_G005 TT1 [Human lung] transformed cell line human CVCL_G005 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Type 1 pneumocyte.. 21193478 CVCL_G004 HepT3 cancer cell line human CVCL_G004 CL:0000010 Derived from sampling site: Liver. Female 21193479 CVCL_G009 TCL-Haz transformed cell line human CVCL_G009 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193480 CVCL_G008 TCL-As transformed cell line human CVCL_G008 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193481 CVCL_G003 HepT1 cancer cell line human CVCL_G003 CL:0000010 Derived from sampling site: Liver. Female Doubling time: 1-2 days (PubMed=8606490) 21193482 CVCL_G002 HCC60 cancer cell line human CVCL_G002 HLA typing: A*80:01,80:01; B*50:01,50:01; C*06:02,06:02; DQB1*06:13,06:13; DRB1*13:01,03:17 (PubMed=26589293) CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1919Pro (c.5756A>C); ClinVar=VCV000580726; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Trp332Ter (c.996G>A); ClinVar=VCV000376339; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>C); Zygosity=Homozygous (from parent cell line) Population: African American; Derived from sampling site: Lung. Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00533 Problematic cell line: Contaminated Shown to be a NCI-H23 derivative (PubMed=25877200). Originally thought to originate from a 26 year old female patient with an ovarian cystadenocarcinoma. 21193483 CVCL_G001 TT1 [Human ovarian carcinoma] cancer cell line human CVCL_G001 CL:0000010 Female 21193484 CVCL_G000 TH-1 cancer cell line human CVCL_G000 CL:0000010 Population: Japanese; Derived from sampling site: Liver. Male 21193485 CVCL_G018 Hs 597.Sk finite cell line human CVCL_G018 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7356; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193486 CVCL_G017 Hs 597.T cancer cell line human CVCL_G017 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7357; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193487 CVCL_G016 10E5 hybridoma house mouse CVCL_G016 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8513 21193488 CVCL_G015 TL-Mat transformed cell line human CVCL_G015 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908) Discontinued: RCB; RCB1969; true. Male 21193489 CVCL_G019 Hs 600.Sk finite cell line human CVCL_G019 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7359; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193490 CVCL_G010 TCL-Kan transformed cell line human CVCL_G010 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: RCB; RCB2085; true Female 21193491 CVCL_G014 TL-Hir transformed cell line human CVCL_G014 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood. Discontinued: RCB; RCB1987; true; Discontinued: TKG; TKG 0176; probable Unspecified 21193492 CVCL_G013 TL-Su transformed cell line human CVCL_G013 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: RCB; RCB1986; true Male Characteristics: IL2 independent 21193493 CVCL_G012 TCL-Ter transformed cell line human CVCL_G012 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193494 CVCL_G011 TCL-Mor transformed cell line human CVCL_G011 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193495 CVCL_G087 CAL-7 cancer cell line human CVCL_G087 CL:0000010 Female Doubling time: 160 hours (PubMed=2145926). 21193496 CVCL_G086 CAL-4 cancer cell line human CVCL_G086 CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 130 hours (PubMed=2145926) 21193497 CVCL_G085 CAL-1 [Human melanoma] cancer cell line human CVCL_G085 CL:0000010 Derived from metastatic site: Bone marrow. Female Doubling time: 60 hours (PubMed=2145926) 21193498 CVCL_G084 CAL-18B cancer cell line human CVCL_G084 CL:0000010 Derived from sampling site: Breast. Female Doubling time: 26 hours (PubMed=2982486) 21193499 CVCL_G089 1B8-F11 hybridoma house mouse CVCL_G089 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0CK30; Bovine herpesvirus 1.1 gD. 21193500 CVCL_G088 17D hybridoma house mouse CVCL_G088 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05542; Sheep CD4. 21193501 CVCL_G083 CAL-18A cancer cell line human CVCL_G083 CL:0000010 Derived from sampling site: Breast. Female Doubling time: 15 hours (PubMed=2982486) 21193502 CVCL_G082 CAL-44 cancer cell line human CVCL_G082 CL:0000010 Female 21193503 CVCL_G081 CAL-185 cancer cell line human CVCL_G081 CL:0000010 Derived from sampling site: Urinary bladder. Male Doubling time: 72 hours, at 26th passage (PubMed=11720483) 21193504 CVCL_G080 5T33MMvt cancer cell line house mouse CVCL_G080 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: C57BL/KaLwRij. Characteristics: Produces IgG2b kappa 21193505 CVCL_G098 CC13 hybridoma house mouse CVCL_G098 CL:0000010 Monoclonal antibody isotype: IgG3. 21193506 CVCL_G097 B72.3 hybridoma house mouse CVCL_G097 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8108 21193507 CVCL_G096 B3/25 hybridoma house mouse CVCL_G096 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8034 21193508 CVCL_G095 86D hybridoma house mouse CVCL_G095 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Sheep T-cell receptor gamma/delta. 21193509 CVCL_G099 CC14 hybridoma house mouse CVCL_G099 CL:0000010 Monoclonal antibody isotype: IgG1. 21193510 CVCL_G090 2D4 [Mouse hybridoma against ganglioside GM2] hybridoma house mouse CVCL_G090 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:27731; Asialo-GM2 ganglioside. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193511 CVCL_G094 6D8MB4 hybridoma house mouse CVCL_G094 CL:0000010 Monoclonal antibody isotype: IgG2b. 21193512 CVCL_G093 T3-5E9 hybridoma house mouse CVCL_G093 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. 21193513 CVCL_G092 4F2C13 hybridoma house mouse CVCL_G092 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21193514 CVCL_G091 2H6-C2 hybridoma house mouse CVCL_G091 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P0CK30; Bovine herpesvirus 1.1 gD. 21193515 CVCL_G065 EUFA353 transformed cell line human CVCL_G065 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg52Ter (c.154C>T); ClinVar=VCV000371668; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193516 CVCL_G064 EUFA349 transformed cell line human CVCL_G064 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193517 CVCL_G063 EUFA316 transformed cell line human CVCL_G063 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193518 CVCL_G062 EUFA268 transformed cell line human CVCL_G062 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Gln772Ter (c.2314C>T); ClinVar=VCV000656626; Zygosity=Homozygous (PubMed=10468606) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193519 CVCL_G069 EUFA426 transformed cell line human CVCL_G069 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Val135Cysfs*46 (c.401dupC) (c.401insC); ClinVar=VCV000558097; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193520 CVCL_G068 EUFA423L transformed cell line human CVCL_G068 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asp2489Terfs (c.7464_7465insTA) (7691insAT); Zygosity=Heterozygous (PubMed=12065746); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr3225Ilefs*30 (c.9672dupA) (9900insA); ClinVar=VCV000126217; Zygosity=Heterozygous (PubMed=12065746) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193521 CVCL_G067 EUFA410 transformed cell line human CVCL_G067 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193522 CVCL_G066 EUFA409 transformed cell line human CVCL_G066 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193523 CVCL_G061 EUFA275 transformed cell line human CVCL_G061 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Glu1254Ter (c.3760G>T); ClinVar=VCV000974261; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193524 CVCL_G060 EUFA202 transformed cell line human CVCL_G060 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193525 CVCL_G076 PCC4-Azal-ECA2 cancer cell line house mouse CVCL_G076 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: 129/Sv. Male 21193526 CVCL_G075 EUFA704 transformed cell line human CVCL_G075 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193527 CVCL_G074 EUFA689 transformed cell line human CVCL_G074 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Phe1263del (c.3788_3790delTCT); ClinVar=VCV000041003; Zygosity=Homozygous (PubMed=10468606; PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193528 CVCL_G073 EUFA622 transformed cell line human CVCL_G073 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193529 CVCL_G079 S2.2 hybridoma pig CVCL_G079 CL:0000010 Monoclonal antibody isotype: IgA. 21193530 CVCL_G078 S2.1 hybridoma pig CVCL_G078 CL:0000010 Monoclonal antibody isotype: IgA. 21193531 CVCL_G077 HT-29-M6 cancer cell line human CVCL_G077 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female 21193532 CVCL_G072 EUFA598 transformed cell line human CVCL_G072 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4267_4404del138 (Ex42del); Zygosity=Homozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193533 CVCL_G071 EUFA528 transformed cell line human CVCL_G071 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Phe1263del (c.3788_3790delTCT); ClinVar=VCV000041003; Zygosity=Heterozygous (PubMed=10094191); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.4267_4404del138 (Ex42del); Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193534 CVCL_G070 EUFA444 transformed cell line human CVCL_G070 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.827_1225del399 (Ex10-13del); Zygosity=Heterozygous (PubMed=10094191); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Val372Alafs*42 (c.1111_1114TTGG[1]) (c.1115_1118delTTGG); ClinVar=VCV000003440; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193535 CVCL_G049 HSC 93 transformed cell line human CVCL_G049 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193536 CVCL_G048 HSC 92 transformed cell line human CVCL_G048 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193537 CVCL_G042 GM16633 transformed cell line human CVCL_G042 CL:0000010 Sequence variation: Mutation; HGNC; 3585; FANCD2; Simple; p.Ser126Gly (c.376A>G); ClinVar=VCV000012039; Zygosity=Heterozygous; Note=Also causes abnormal splicing (Coriell); Sequence variation: Mutation; HGNC; 3585; FANCD2; Simple; p.Arg1236His (c.3707G>A); ClinVar=VCV000012038; Zygosity=Heterozygous (Coriell); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193538 CVCL_G041 GM16756 transformed cell line human CVCL_G041 CL:0000010 Sequence variation: Mutation; HGNC; 3585; FANCD2; Simple; p.Ser126Gly (c.376A>G); ClinVar=VCV000012039; Zygosity=Heterozygous; Note=Also causes abnormal splicing (Coriell); Sequence variation: Mutation; HGNC; 3585; FANCD2; Simple; p.Arg1236His (c.3707G>A); ClinVar=VCV000012038; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193539 CVCL_G040 EUFA121 transformed cell line human CVCL_G040 CL:0000010 Sequence variation: Mutation; HGNC; 3587; FANCF; Simple; p.Gln6Ter (c.16C>T); ClinVar=VCV000006342; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3587; FANCF; Simple; p.Gly120Profs*17 (c.351_397del) (349_395del); ClinVar=VCV000006341; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193540 CVCL_G046 HSC 62 transformed cell line human CVCL_G046 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; c.8488-1G>A (IVS19-1G>A); ClinVar=VCV000038164; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=12065746) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193541 CVCL_G045 HSC 536 transformed cell line human CVCL_G045 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Leu554Pro (c.1661T>C); ClinVar=VCV000012043; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193542 CVCL_G044 HSC 231 transformed cell line human CVCL_G044 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193543 CVCL_G059 EUFA166 transformed cell line human CVCL_G059 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Asp23Ilefs*23 (c.67delG) (322delG); ClinVar=VCV000012049; Zygosity=Homozygous (PubMed=10468606) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193544 CVCL_G054 EUFA123 transformed cell line human CVCL_G054 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.597-2A>G (IVS6-2A>G); ClinVar=VCV000974288; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193545 CVCL_G053 EUFA056 transformed cell line human CVCL_G053 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193546 CVCL_G052 EUFA006 transformed cell line human CVCL_G052 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; c.1360_1826del467 (Ex15-20del); Zygosity=Heterozygous (PubMed=10094191); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Phe1263del (c.3788_3790delTCT); ClinVar=VCV000041003; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193547 CVCL_G051 EUFA001 transformed cell line human CVCL_G051 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193548 CVCL_G058 EUFA158 transformed cell line human CVCL_G058 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193549 CVCL_G057 EUFA143 transformed cell line human CVCL_G057 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Glu105Ter (c.313G>T); ClinVar=VCV000006712; Zygosity=Homozygous Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193550 CVCL_G056 EUFA134 transformed cell line human CVCL_G056 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Asp598Asn (c.1792G>A); ClinVar=VCV000974125; Zygosity=Heterozygous (PubMed=10094191) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21193551 CVCL_G055 EUFA130 transformed cell line human CVCL_G055 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193552 CVCL_G050 HSC 99 transformed cell line human CVCL_G050 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193553 CVCL_G029 2013 transformed cell line human CVCL_G029 HLA typing: DQA1*01:02,01:04:01; DQB1*06:05:01; DRB1*13:02; DRB3*03:01 (IPD-IMGT/HLA=10096) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193554 CVCL_G028 DCH027 transformed cell line human CVCL_G028 CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193555 CVCL_G027 DCH013 transformed cell line human CVCL_G027 HLA typing: B*39:01,57:01 (IPD-IMGT/HLA=12419) CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193556 CVCL_G026 Hs 804.T cancer cell line human CVCL_G026 CL:0000010 Discontinued: ATCC; CRL-7889; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193557 CVCL_G021 Hs 496.T cancer cell line human CVCL_G021 CL:0000010 Discontinued: ATCC; CRL-7303; true. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193558 CVCL_G020 Hs 496.Sk finite cell line human CVCL_G020 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7302; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193559 CVCL_G025 Hs 836.T cancer cell line human CVCL_G025 CL:0000010 Discontinued: ATCC; CRL-7571; true. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193560 CVCL_G024 Hs 735.Sk finite cell line human CVCL_G024 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7865; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) Caution: Established from same individual as Hs 735.T (Cellosaurus=CVCL_0877) which is said to originate from a 16 year old female 21193561 CVCL_G023 Hs 939.Sk finite cell line human CVCL_G023 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7689; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193562 CVCL_G022 Hs 748.Sk finite cell line human CVCL_G022 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-7485; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21193563 CVCL_G039 GM04510 transformed cell line human CVCL_G039 CL:0000010 Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; c.456+4A>T (IVS4+4A>T); ClinVar=VCV000012045; Zygosity=Homozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193564 CVCL_G038 KUT-3 cancer cell line human CVCL_G038 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193565 CVCL_G037 KUT-2 cancer cell line human CVCL_G037 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193566 CVCL_G032 HGOM transformed cell line human CVCL_G032 HLA typing: B*39:05; DPB1*04:02 (IPD-IMGT/HLA=10731) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193567 CVCL_G031 GSW002 transformed cell line human CVCL_G031 HLA typing: B*18:03; DRB1*03,11 (IPD-IMGT/HLA=10688) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193568 CVCL_G030 GSW001 transformed cell line human CVCL_G030 HLA typing: B*18:05; DRB1*13,16 (IPD-IMGT/HLA=10687) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193569 CVCL_G036 KUT-1 cancer cell line human CVCL_G036 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21193570 CVCL_G035 MAME transformed cell line human CVCL_G035 HLA typing: B*57:03:01,82:01 (IPD-IMGT/HLA=11048) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21193571 CVCL_G034 HSV48 transformed cell line human CVCL_G034 HLA typing: A*01,68; B*15:24,35; C*03,04 (IPD-IMGT/HLA=13095) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21193572 CVCL_G033 HSV33 transformed cell line human CVCL_G033 HLA typing: A*02,24; B*44:05,49; C*02,07; DRB1*01,16; DRB5*02 (IPD-IMGT/HLA=12983) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: International Histocompatibility Workshop cell lines 21193573 CVCL_XB20 ZUF10 hybridoma house mouse CVCL_XB20 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human mesenchymal stem cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200513 21193574 CVCL_XB24 NCI-H1299-mCherry cancer cell line human CVCL_XB24 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from metastatic site: Lymph node. Male 21193575 CVCL_XB23 DV2-M6 hybridoma house mouse CVCL_XB23 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P29990; Dengue virus type 2 non-structural protein 1 (NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200736 21193576 CVCL_XB22 DV2-M14 hybridoma house mouse CVCL_XB22 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P29990; Dengue virus type 2 non-structural protein 1 (NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200737 21193577 CVCL_XB21 D12E9F11 hybridoma house mouse CVCL_XB21 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03141; Hepatitis B virus HBsAg. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200505 21193578 CVCL_XB28 HGC27-EGFP cancer cell line human CVCL_XB28 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly2316fs*9 (c.6947delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000648) It was the sole source of information for this entry. Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21193579 CVCL_XB27 A549-tdT cancer cell line human CVCL_XB27 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Lung. Male 21193580 CVCL_XB26 NCI-H1299-tdT cancer cell line human CVCL_XB26 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male 21193581 CVCL_XB25 NCI-H1299-EGFP cancer cell line human CVCL_XB25 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000644) It was the sole source of information for this entry. Population: Caucasian; Derived from metastatic site: Lymph node. Male 21193582 CVCL_XB29 HGC27-tdT cancer cell line human CVCL_XB29 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly2316fs*9 (c.6947delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro153Alafs*28 (c.455dupC) (c.455_456insC) (p.P152fs) (c.459_460insC); ClinVar=VCV000182958; Zygosity=Heterozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 21193583 CVCL_XB13 CBF245 hybridoma house mouse CVCL_XB13 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P28845; Human HSD11B1. 21193584 CVCL_XB12 HES [Human embryonic skin fibroblast] finite cell line human CVCL_XB12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193585 CVCL_XB11 BrE3 hybridoma house mouse CVCL_XB11 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10028 21193586 CVCL_XB10 BrE2 hybridoma house mouse CVCL_XB10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9795 21193587 CVCL_XB17 ZUB4 hybridoma house mouse CVCL_XB17 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human mesenchymal stem cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200511 21193588 CVCL_XB16 ZUB1 hybridoma house mouse CVCL_XB16 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human mesenchymal stem cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200510 21193589 CVCL_XB15 3-H5 hybridoma house mouse CVCL_XB15 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012140 21193590 CVCL_XB14 1-F10 hybridoma house mouse CVCL_XB14 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2012139 21193591 CVCL_XB19 ZUE12 hybridoma house mouse CVCL_XB19 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human mesenchymal stem cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200514 21193592 CVCL_XB18 ZUC3 hybridoma house mouse CVCL_XB18 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human mesenchymal stem cells. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200512 21193593 CVCL_XB02 4T1-Par3 cancer cell line house mouse CVCL_XB02 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Omics: Transcriptome analysis by microarray Female Characteristics: Brain parenchymal space metastatic derivative of parental cell line Established after 3 passages in BALC/cAn mice from internal carotid artery injection. Part of: Brain metastasis cell lines panel 21193594 CVCL_XB01 4T1-Dura3 cancer cell line house mouse CVCL_XB01 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Omics: Transcriptome analysis by microarray Female Characteristics: Brain leptomeningeal space metastatic derivative of parental cell line Established after 3 passages in BALC/cAn mice from internal carotid artery injection. Part of: Brain metastasis cell lines panel 21193595 CVCL_XB00 MDA231-LeptoM cancer cell line human CVCL_XB00 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9QNF7; Human herpesvirus 1 TK Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Brain leptomeningeal space metastatic derivative of parental cell line Established after 3 passages in nude mice from intracisternal injection, followed by one passage from intracardiac injection and obtained from mice bearing leptomeningeal metastases.; Characteristics: Transfected with HSV1-TK/GFP/Fluc (TGL) Group: Triple negative breast cancer (TNBC) cell line; Part of: Brain metastasis cell lines panel 21193596 CVCL_XB06 P-14C6 hybridoma house mouse CVCL_XB06 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q83138; Peste-des-petits-ruminants virus (PPRV) isolate Nigeria 75/1 nucleocapsid protein (N). 21193597 CVCL_XB05 P-13A9 hybridoma house mouse CVCL_XB05 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q83138; Peste-des-petits-ruminants virus (PPRV) isolate Nigeria 75/1 nucleocapsid protein (N). 21193598 CVCL_XB04 P-11A6 hybridoma house mouse CVCL_XB04 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q83138; Peste-des-petits-ruminants virus (PPRV) isolate Nigeria 75/1 nucleocapsid protein (N). 21193599 CVCL_XB03 MF4C4 hybridoma house mouse CVCL_XB03 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200111 21193600 CVCL_XB09 BrE1 hybridoma house mouse CVCL_XB09 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9738 21193601 CVCL_XB08 P-9H10 hybridoma house mouse CVCL_XB08 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q83138; Peste-des-petits-ruminants virus (PPRV) isolate Nigeria 75/1 nucleocapsid protein (N). 21193602 CVCL_XB07 P-3H12 hybridoma house mouse CVCL_XB07 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q83138; Peste-des-petits-ruminants virus (PPRV) isolate Nigeria 75/1 nucleocapsid protein (N). Group: Patented cell line; Registration: International Depositary Authority, Korean Cell Line Research Foundation; KCLRF-BP-00104 21193603 CVCL_FN88 ND28404 transformed cell line human CVCL_FN88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193604 CVCL_FN87 ND28295 transformed cell line human CVCL_FN87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193605 CVCL_FN86 ND28294 transformed cell line human CVCL_FN86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193606 CVCL_FN85 ND28255 transformed cell line human CVCL_FN85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193607 CVCL_FN89 ND28405 transformed cell line human CVCL_FN89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193608 CVCL_FN80 ND27970 transformed cell line human CVCL_FN80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193609 CVCL_FN84 ND28114 transformed cell line human CVCL_FN84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193610 CVCL_FN83 ND28079 transformed cell line human CVCL_FN83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193611 CVCL_FN82 ND28052 transformed cell line human CVCL_FN82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193612 CVCL_FN81 ND28051 transformed cell line human CVCL_FN81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193613 CVCL_FN99 ND28682 transformed cell line human CVCL_FN99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193614 CVCL_FN98 ND28661 transformed cell line human CVCL_FN98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193615 CVCL_FN97 ND28659 transformed cell line human CVCL_FN97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193616 CVCL_FN96 ND28645 transformed cell line human CVCL_FN96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193617 CVCL_FN91 ND28472 transformed cell line human CVCL_FN91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193618 CVCL_FN90 ND28426 transformed cell line human CVCL_FN90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193619 CVCL_FN95 ND28634 transformed cell line human CVCL_FN95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193620 CVCL_FN94 ND28570 transformed cell line human CVCL_FN94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193621 CVCL_FN93 ND28560 transformed cell line human CVCL_FN93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193622 CVCL_FN92 ND28478 transformed cell line human CVCL_FN92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193623 CVCL_XB93 DG-K1 finite cell line CVCL_XB93 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Male 21193624 CVCL_XB92 WSSV-K2 hybridoma house mouse CVCL_XB92 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: White spot syndrome virus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014161 21193625 CVCL_XB91 WSSV-K1 hybridoma house mouse CVCL_XB91 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: White spot syndrome virus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014160 21193626 CVCL_XB90 0225-02Sp cancer cell line human CVCL_XB90 CL:0000010 Population: Chinese; Derived from sampling site: Lung. Male Doubling time: 40.32 hours (Patent=CN102433305B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201028 21193627 CVCL_XB97 B16-F10-tdT cancer cell line house mouse CVCL_XB97 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21193628 CVCL_XB96 B16-F10-EGFP cancer cell line house mouse CVCL_XB96 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000625) It was the sole source of information for this entry. Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21193629 CVCL_XB95 B16-F10-mCherry cancer cell line house mouse CVCL_XB95 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21193630 CVCL_XB94 DG-S1 finite cell line CVCL_XB94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193631 CVCL_XB99 20A11 hybridoma house mouse CVCL_XB99 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200638 21193632 CVCL_XB98 13D4 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XB98 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200721 21193633 CVCL_XB82 SK-OV-3-Cas9-560 cancer cell line human CVCL_XB82 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193634 CVCL_XB81 SKOV3/VP16 cancer cell line human CVCL_XB81 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Ascites. Female Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200905 21193635 CVCL_XB80 SiHa/VP16 cancer cell line human CVCL_XB80 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Uterus; cervix. Female Virology: Contains a complete HPV16 genome with a disruption of the E2 region and a small deletion (from parent cell line) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200904 21193636 CVCL_XB86 SK-OV-3-Cas9-564 cancer cell line human CVCL_XB86 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193637 CVCL_XB85 SK-OV-3-Cas9-563 cancer cell line human CVCL_XB85 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193638 CVCL_XB84 SK-OV-3-Cas9-562 cancer cell line human CVCL_XB84 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193639 CVCL_XB83 SK-OV-3-Cas9-561 cancer cell line human CVCL_XB83 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193640 CVCL_XB89 CTSC-3 cancer cell line human CVCL_XB89 CL:0000010 Population: Chinese; Derived from sampling site: Oral cavity; tongue. Group: Patented cell line 21193641 CVCL_XB88 CTSC-2 cancer cell line human CVCL_XB88 CL:0000010 Population: Chinese; Derived from sampling site: Oral cavity; tongue. Doubling time: 31.48 +- 0.79 hours (at 10th passage), 32.72 +- 0.81 hours (at 30th passage) (Patent=CN102911916A) Group: Patented cell line 21193642 CVCL_XB87 ZLSC-423 cancer cell line human CVCL_XB87 CL:0000010 Group: Patented cell line. 21193643 CVCL_XB71 BDRXN hybridoma house mouse CVCL_XB71 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:9328; Sulfadiazine. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200522 21193644 CVCL_XB70 BDRPDP hybridoma house mouse CVCL_XB70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q5S1V8; Influenza A virus isolate A/chicken/China/HSS2004(H9N2) nucleoprotein (NP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200501 21193645 CVCL_XB75 RP12-2 hybridoma house mouse CVCL_XB75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26441; Human CNTF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10532 21193646 CVCL_XB74 RP3-17 hybridoma house mouse CVCL_XB74 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P26441; Human CNTF. 21193647 CVCL_XB73 RP3-12 hybridoma house mouse CVCL_XB73 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P26441; Human CNTF. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10531 21193648 CVCL_XB72 BDRXN-2 hybridoma house mouse CVCL_XB72 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:35358; Sulfonamide. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200629 21193649 CVCL_XB79 3F16A4 hybridoma house mouse CVCL_XB79 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; Q9Q0U6; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200738 21193650 CVCL_XB78 MabHS1 hybridoma house mouse CVCL_XB78 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:61040; Phosphorylcholine chloride. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200304 21193651 CVCL_XB77 KMM-L1 finite cell line house mouse CVCL_XB77 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Kunming. Unspecified 21193652 CVCL_XB76 RP12-9 hybridoma house mouse CVCL_XB76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P26441; Human CNTF. 21193653 CVCL_XB60 RM1 [Rat muscle] finite cell line Norway rat CVCL_XB60 CL:0000010 Derived from sampling site: Muscle Cell type=Fibroblast.. Unspecified 21193654 CVCL_XB64 BADCPPF1-151K hybridoma house mouse CVCL_XB64 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8961 21193655 CVCL_XB63 GH-S1 finite cell line CVCL_XB63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193656 CVCL_XB62 FCA-S1 finite cell line CVCL_XB62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193657 CVCL_XB61 FCA-L1 finite cell line CVCL_XB61 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21193658 CVCL_XB68 BADCPPF1-63D hybridoma house mouse CVCL_XB68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8958 21193659 CVCL_XB67 BADCPPF1-4C hybridoma house mouse CVCL_XB67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8962 21193660 CVCL_XB66 BADCPPF1-35B hybridoma house mouse CVCL_XB66 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8960 21193661 CVCL_XB65 BADCPPF1-28A hybridoma house mouse CVCL_XB65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8957 21193662 CVCL_XB69 BADCPPF1-75A hybridoma house mouse CVCL_XB69 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09919; Human CSF3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8959 21193663 CVCL_XB53 PsL-EGFmAb-2 hybridoma human CVCL_XB53 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200634 21193664 CVCL_XB52 PsL-EGFmAb-CSRJZT-1 hybridoma house mouse CVCL_XB52 CL:0000010 Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: UniProtKB; P16109; Human SELP/CD62P. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200312 21193665 CVCL_XB51 RL1 finite cell line Norway rat CVCL_XB51 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Unspecified 21193666 CVCL_XB50 FCA-L2 finite cell line CVCL_XB50 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21193667 CVCL_XB57 WNSs 239F1A8 hybridoma house mouse CVCL_XB57 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P89253; Watermelon silver mottle virus (WSMoV) nonstructural protein NSs. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200718 21193668 CVCL_XB56 WSSV-3B7 hybridoma house mouse CVCL_XB56 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: White spot syndrome virus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201398 21193669 CVCL_XB55 HepG2-RHBV cancer cell line human CVCL_XB55 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Liver. Male Virology: Transfected with a wild-type hepatitis B virus (HBV) genome Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200635 21193670 CVCL_XB54 HFF finite cell line human CVCL_XB54 CL:0000010 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000036) It was the sole source of information for this entry. Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21193671 CVCL_XB59 WTR-L1 finite cell line Norway rat CVCL_XB59 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21193672 CVCL_XB58 WM-L2 finite cell line house mouse CVCL_XB58 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Male 21193673 CVCL_XB42 PLC/PRF/5-Cas9-715 cancer cell line human CVCL_XB42 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193674 CVCL_XB41 PLC/PRF/5-Cas9-714 cancer cell line human CVCL_XB41 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193675 CVCL_XB40 PLC/PRF/5-Cas9-713 cancer cell line human CVCL_XB40 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193676 CVCL_XB46 S-29-3 hybridoma house mouse CVCL_XB46 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Hepatitis B virus E-antigen (HBeAg). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200516 21193677 CVCL_XB45 ZMB5 hybridoma house mouse CVCL_XB45 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96S97; Human MYADM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200617 21193678 CVCL_XB44 ZMA6 hybridoma house mouse CVCL_XB44 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96S97; Human MYADM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200616 21193679 CVCL_XB43 ZMA1 hybridoma house mouse CVCL_XB43 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q96S97; Human MYADM. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200615 21193680 CVCL_XB49 GBJd spontaneously immortalized cell line CVCL_XB49 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line Caution: We are not certain of the species due to contradictory information in CCRID and KCB 21193681 CVCL_XB48 FC33 transformed cell line human CVCL_XB48 CL:0000010 Transfected with: HGNC; 933; BACE1 Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000137) It was the sole source of information for this entry. Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21193682 CVCL_XB47 TsCD146 hybridoma CVCL_XB47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P43121; Human MCAM/CD146. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-5246 21193683 CVCL_XB31 A549-EGFP cancer cell line human CVCL_XB31 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: Formerly the CCRID database had an entry describing this cell line (3111C0001CCC000631) It was the sole source of information for this entry. Population: Caucasian; Derived from sampling site: Lung. Male 21193684 CVCL_XB30 A549-mCherry cancer cell line human CVCL_XB30 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Lung. Male 21193685 CVCL_XB35 PLC/PRF/5-Cas9-708 cancer cell line human CVCL_XB35 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193686 CVCL_XB34 PLC/PRF/5-Cas9-707 cancer cell line human CVCL_XB34 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193687 CVCL_XB33 PLC/PRF/5-Cas9-706 cancer cell line human CVCL_XB33 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193688 CVCL_XB32 PLC/PRF/5-Cas9-705 cancer cell line human CVCL_XB32 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193689 CVCL_XB39 PLC/PRF/5-Cas9-712 cancer cell line human CVCL_XB39 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193690 CVCL_XB38 PLC/PRF/5-Cas9-711 cancer cell line human CVCL_XB38 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193691 CVCL_XB37 PLC/PRF/5-Cas9-710 cancer cell line human CVCL_XB37 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193692 CVCL_XB36 PLC/PRF/5-Cas9-709 cancer cell line human CVCL_XB36 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg112Gly (c.334C>G) (p.Pro126Arg, c.377C>G); ClinVar=VCV000233484; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Asn1651Ser (c.4952A>G); ClinVar=VCV000049335; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African; Shangaan; Karyotypic information: Has lost chromosome Y (from parent cell line); Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male Characteristics: Transfected with a Cas9-Flag-Neo construct 21193693 CVCL_G128 IL-A29 hybridoma house mouse CVCL_G128 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30205; Bovine WC1. 21193694 CVCL_FP28 ND29051 transformed cell line human CVCL_FP28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193695 CVCL_G127 IL-A11 hybridoma house mouse CVCL_G127 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; I0J0K0; Bovine CD4. 21193696 CVCL_FP27 ND29050 transformed cell line human CVCL_FP27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193697 CVCL_G126 IgG-B16 hybridoma house mouse CVCL_G126 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mesocricetus auratus OSBP (Note=Currently not in UniProtKB). 21193698 CVCL_FP26 ND29047 transformed cell line human CVCL_FP26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193699 CVCL_G125 IFGCP-F1BA10 hybridoma house mouse CVCL_G125 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8291 21193700 CVCL_FP25 ND29034 transformed cell line human CVCL_FP25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193701 CVCL_G129 IL-A30 hybridoma house mouse CVCL_G129 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine IgM (monomorphic determinant). 21193702 CVCL_FP29 ND29055 transformed cell line human CVCL_FP29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193703 CVCL_G120 FW11-24-17-36 hybridoma house mouse CVCL_G120 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21193704 CVCL_FP20 ND29001 transformed cell line human CVCL_FP20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193705 CVCL_G124 GAD-1 hybridoma house mouse CVCL_G124 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00368; Chicken GLUD1 (Note=Also reacts with other species). 21193706 CVCL_FP24 ND29010 transformed cell line human CVCL_FP24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193707 CVCL_G123 FW4-101-1-1 hybridoma house mouse CVCL_G123 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; B0FYY4; Sheep ITGB1/CD29. 21193708 CVCL_FP23 ND29009 transformed cell line human CVCL_FP23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193709 CVCL_G122 FW3-218-1 hybridoma house mouse CVCL_G122 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; W5Q5Y1; Sheep ITGA4/CD49d. 21193710 CVCL_FP22 ND29006 transformed cell line human CVCL_FP22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193711 CVCL_G121 FW11-9-2 hybridoma house mouse CVCL_G121 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21193712 CVCL_FP21 ND29002 transformed cell line human CVCL_FP21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193713 CVCL_G139 HuT-13 cancer cell line human CVCL_G139 CL:0000010 Female Problematic cell line: Contaminated Shown to be a Hs 633.T derivative (PubMed=2902939). Originally thought to originate from the chemical transformation of KD (Cellosaurus=CVCL_2970) fibroblast cells.. 21193714 CVCL_FP39 ND29267 transformed cell line human CVCL_FP39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193715 CVCL_G138 HuT-12 cancer cell line human CVCL_G138 CL:0000010 Female Problematic cell line: Contaminated Shown to be a Hs 633.T derivative (PubMed=2902939). Originally thought to originate from the chemical transformation of KD (Cellosaurus=CVCL_2970) fibroblast cells.. 21193716 CVCL_FP38 ND29257 transformed cell line human CVCL_FP38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193717 CVCL_G137 HuT-11 cancer cell line human CVCL_G137 CL:0000010 Female Problematic cell line: Contaminated Shown to be a Hs 633.T derivative (PubMed=2902939).. 21193718 CVCL_FP37 ND29199 transformed cell line human CVCL_FP37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193719 CVCL_G136 HuT11 cancer cell line human CVCL_G136 CL:0000010 Derived from sampling site: Lymph node. Female Doubling time: 12.3 +- 0.6 hours (PubMed=209894) 21193720 CVCL_FP36 ND29125 transformed cell line human CVCL_FP36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193721 CVCL_G131 IL-A51 hybridoma house mouse CVCL_G131 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine CD8. 21193722 CVCL_FP31 ND29058 transformed cell line human CVCL_FP31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193723 CVCL_G130 IL-A42 hybridoma house mouse CVCL_G130 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q148M9; Bovine CD2. 21193724 CVCL_FP30 ND29057 transformed cell line human CVCL_FP30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193725 CVCL_FP35 ND29115 transformed cell line human CVCL_FP35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193726 CVCL_G135 W6/32HL hybridoma house mouse CVCL_G135 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193727 CVCL_FP34 ND29069 transformed cell line human CVCL_FP34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193728 CVCL_G134 W6/32HK hybridoma house mouse CVCL_G134 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193729 CVCL_G133 DREG56 hybridoma house mouse CVCL_G133 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14151; Human SELL/CD62L. 21193730 CVCL_FP33 ND29068 transformed cell line human CVCL_FP33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193731 CVCL_FP32 ND29065 transformed cell line human CVCL_FP32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193732 CVCL_G132 OKM1 hybridoma house mouse CVCL_G132 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P11215; Human ITGAM/CD11b. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8026 21193733 CVCL_G106 CC37 hybridoma house mouse CVCL_G106 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; C9EGT0; Bovine CR2/CD21 (BoWC3). 21193734 CVCL_FP06 ND28749 transformed cell line human CVCL_FP06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193735 CVCL_G105 CC30 hybridoma house mouse CVCL_G105 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; I0J0K0; Bovine CD4. 21193736 CVCL_FP05 ND28747 transformed cell line human CVCL_FP05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193737 CVCL_G104 CC29 hybridoma house mouse CVCL_G104 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19238; Bovine CD5. 21193738 CVCL_FP04 ND28731 transformed cell line human CVCL_FP04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193739 CVCL_G103 CC21 [Mouse hybridoma against bovine CR2] hybridoma house mouse CVCL_G103 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; C9EGT0; Bovine CR2/CD21 (BoWC3). 21193740 CVCL_FP03 ND28707 transformed cell line human CVCL_FP03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193741 CVCL_G109 CC42 hybridoma house mouse CVCL_G109 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q148M9; Bovine CD2. 21193742 CVCL_FP09 ND28840 transformed cell line human CVCL_FP09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193743 CVCL_G108 CC39 hybridoma house mouse CVCL_G108 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P30205; Bovine WC1. 21193744 CVCL_FP08 ND28810 transformed cell line human CVCL_FP08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193745 CVCL_G107 CC38 hybridoma house mouse CVCL_G107 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; F1MU15; Bovine CD6. 21193746 CVCL_FP07 ND28752 transformed cell line human CVCL_FP07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193747 CVCL_G102 CC20 [Mouse hybridoma] hybridoma house mouse CVCL_G102 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193748 CVCL_FP02 ND28699 transformed cell line human CVCL_FP02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193749 CVCL_G101 CC17 hybridoma house mouse CVCL_G101 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19238; Bovine CD5. 21193750 CVCL_FP01 ND28697 transformed cell line human CVCL_FP01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193751 CVCL_G100 CC15 hybridoma house mouse CVCL_G100 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P30205; Bovine WC1. 21193752 CVCL_FP00 ND28696 transformed cell line human CVCL_FP00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193753 CVCL_G117 DREG200 hybridoma house mouse CVCL_G117 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P14151; Human SELL/CD62L. 21193754 CVCL_FP17 ND28946 transformed cell line human CVCL_FP17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193755 CVCL_G116 CC8 hybridoma house mouse CVCL_G116 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; I0J0K0; Bovine CD4. 21193756 CVCL_FP16 ND28940 transformed cell line human CVCL_FP16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193757 CVCL_G115 CC63 hybridoma house mouse CVCL_G115 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193758 CVCL_FP15 ND28926 transformed cell line human CVCL_FP15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193759 CVCL_G114 CC58 hybridoma house mouse CVCL_G114 CL:0000010 Monoclonal antibody isotype: IgG1. 21193760 CVCL_FP14 ND28921 transformed cell line human CVCL_FP14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193761 CVCL_G119 FW11-10-3 hybridoma house mouse CVCL_G119 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 21193762 CVCL_FP19 ND28982 transformed cell line human CVCL_FP19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193763 CVCL_G118 Du1-29 hybridoma house mouse CVCL_G118 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5PMK6; Sheep SELL/CD62L (Note=Also reacts with bovine). 21193764 CVCL_FP18 ND28968 transformed cell line human CVCL_FP18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193765 CVCL_G113 CC57 hybridoma house mouse CVCL_G113 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine WC4 antigen (BoWC4). 21193766 CVCL_FP13 ND28902 transformed cell line human CVCL_FP13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193767 CVCL_G112 CC56 hybridoma house mouse CVCL_G112 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193768 CVCL_FP12 ND28899 transformed cell line human CVCL_FP12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193769 CVCL_G111 CC55 hybridoma house mouse CVCL_G111 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Bovine WC4 antigen (BoWC4). 21193770 CVCL_FP11 ND28872 transformed cell line human CVCL_FP11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193771 CVCL_G110 CC51 hybridoma house mouse CVCL_G110 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; C9EGT0; Bovine CR2/CD21 (BoWC3). 21193772 CVCL_FP10 ND28841 transformed cell line human CVCL_FP10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193773 CVCL_FP86 ND30160 transformed cell line human CVCL_FP86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193774 CVCL_G186 W3/15 hybridoma house mouse CVCL_G186 CL:0000010 Monoclonal antibody isotype: IgG1. 21193775 CVCL_FP85 ND30125 transformed cell line human CVCL_FP85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193776 CVCL_G185 W3/13 hybridoma house mouse CVCL_G185 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13838; Rat Spn. 21193777 CVCL_FP84 ND30109 transformed cell line human CVCL_FP84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193778 CVCL_G184 YBM 6.1.10 hybridoma Norway rat CVCL_G184 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05555; Mouse Itgam/Cd11b. 21193779 CVCL_FP83 ND30102 transformed cell line human CVCL_FP83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193780 CVCL_G183 YBM 5.10.4 hybridoma Norway rat CVCL_G183 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P24807; Mouse Cd24. 21193781 CVCL_G189 11-5.2.1.9 hybridoma house mouse CVCL_G189 CL:0000010 Monoclonal antibody isotype: IgG2b. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193782 CVCL_FP89 ND30221 transformed cell line human CVCL_FP89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193783 CVCL_FP88 ND30201 transformed cell line human CVCL_FP88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193784 CVCL_G188 P-tyr-1 hybridoma house mouse CVCL_G188 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:74956; O(4)-phosphotyrosine. 21193785 CVCL_FP87 ND30172 transformed cell line human CVCL_FP87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193786 CVCL_G187 W3/25 hybridoma house mouse CVCL_G187 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05540; Rat Cd4. 21193787 CVCL_FP82 ND30099 transformed cell line human CVCL_FP82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193788 CVCL_G182 YBM 29.2.1 hybridoma Norway rat CVCL_G182 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P01831; Mouse Thy1/Cd90. 21193789 CVCL_FP81 ND30092 transformed cell line human CVCL_FP81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193790 CVCL_G181 YBM 15.1.6 hybridoma Norway rat CVCL_G181 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P05555; Mouse Itgam/Cd11b. 21193791 CVCL_FP80 ND30086 transformed cell line human CVCL_FP80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193792 CVCL_G180 VPM 8 hybridoma house mouse CVCL_G180 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Sheep Ig light chains. 21193793 CVCL_G197 JO1-1 hybridoma house mouse CVCL_G197 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00734; Human F2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8638 21193794 CVCL_FP97 ND30294 transformed cell line human CVCL_FP97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193795 CVCL_G196 JAA-F11 hybridoma house mouse CVCL_G196 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:546807; Beta-D-Galp-(1->3)-D-GalpNAc (T-antigen). 21193796 CVCL_FP96 ND30282 transformed cell line human CVCL_FP96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193797 CVCL_G195 J5-2 hybridoma house mouse CVCL_G195 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Escherichia coli J5 endotoxin core. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8298 21193798 CVCL_FP95 ND30280 transformed cell line human CVCL_FP95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193799 CVCL_G194 J5-1 hybridoma house mouse CVCL_G194 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Escherichia coli J5 endotoxin core. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8297 21193800 CVCL_FP94 ND30279 transformed cell line human CVCL_FP94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193801 CVCL_G199 NA1/34.HLK hybridoma house mouse CVCL_G199 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06126; Human CD1A. 21193802 CVCL_FP99 ND30313 transformed cell line human CVCL_FP99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193803 CVCL_G198 J5 [Mouse hybridoma] hybridoma house mouse CVCL_G198 CL:0000010 Monoclonal antibody isotype: IgG2b. 21193804 CVCL_FP98 ND30299 transformed cell line human CVCL_FP98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193805 CVCL_G193 BC9-E5 hybridoma house mouse CVCL_G193 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:61793; Alpha-Neu5Ac-(2->3)-beta-D-Gal-(1->3)-[alpha-L-Fuc-(1->4)]-D-GlcNAc (Sialyl Lewis A). 21193806 CVCL_FP93 ND30272 transformed cell line human CVCL_FP93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193807 CVCL_G192 BC9 hybridoma house mouse CVCL_G192 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q06599; Bovine TNF. 21193808 CVCL_FP92 ND30253 transformed cell line human CVCL_FP92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193809 CVCL_G191 455 hybridoma house mouse CVCL_G191 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8507 21193810 CVCL_FP91 ND30251 transformed cell line human CVCL_FP91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193811 CVCL_G190 36F-18C hybridoma house mouse CVCL_G190 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; W5QG93; Sheep CD2. 21193812 CVCL_FP90 ND30239 transformed cell line human CVCL_FP90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193813 CVCL_FP69 ND29838 transformed cell line human CVCL_FP69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193814 CVCL_G169 VPM 40 hybridoma house mouse CVCL_G169 CL:0000010 Monoclonal antibody isotype: IgG1. 21193815 CVCL_FP64 ND29727 transformed cell line human CVCL_FP64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193816 CVCL_G164 VPM 18 hybridoma house mouse CVCL_G164 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5Q2E5; Sheep PTPRC/CD45 (Note=Also reacts with bovine). 21193817 CVCL_G163 BMAC-3 hybridoma house mouse CVCL_G163 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21193818 CVCL_FP63 ND29711 transformed cell line human CVCL_FP63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193819 CVCL_G162 BMAC-1 hybridoma house mouse CVCL_G162 CL:0000010 Discontinued: ECACC; 89062103; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45 21193820 CVCL_FP62 ND29646 transformed cell line human CVCL_FP62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193821 CVCL_FP61 ND29645 transformed cell line human CVCL_FP61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193822 CVCL_G161 RmcB hybridoma house mouse CVCL_G161 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P78310; Human CXADR/CAR. 21193823 CVCL_FP68 ND29825 transformed cell line human CVCL_FP68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193824 CVCL_G168 VPM 38 hybridoma house mouse CVCL_G168 CL:0000010 Monoclonal antibody isotype: IgG1. 21193825 CVCL_FP67 ND29810 transformed cell line human CVCL_FP67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193826 CVCL_G167 VPM 37 hybridoma house mouse CVCL_G167 CL:0000010 Monoclonal antibody isotype: IgG1. 21193827 CVCL_FP66 ND29785 transformed cell line human CVCL_FP66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193828 CVCL_G166 VPM 36 hybridoma house mouse CVCL_G166 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. 21193829 CVCL_FP65 ND29761 transformed cell line human CVCL_FP65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193830 CVCL_G165 VPM 19 hybridoma house mouse CVCL_G165 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Sheep MHC class I heavy chain. 21193831 CVCL_FP60 ND29599 transformed cell line human CVCL_FP60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193832 CVCL_G160 RLTM02 hybridoma house mouse CVCL_G160 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15309; Human ACPP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8523 21193833 CVCL_FP75 ND29900 transformed cell line human CVCL_FP75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193834 CVCL_G175 VPM 47 hybridoma house mouse CVCL_G175 CL:0000010 Monoclonal antibody isotype: IgG1. 21193835 CVCL_FP74 ND29897 transformed cell line human CVCL_FP74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193836 CVCL_G174 VPM 46 hybridoma house mouse CVCL_G174 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193837 CVCL_FP73 ND29885 transformed cell line human CVCL_FP73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193838 CVCL_G173 VPM 45 hybridoma house mouse CVCL_G173 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193839 CVCL_FP72 ND29877 transformed cell line human CVCL_FP72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193840 CVCL_G172 VPM 44 hybridoma house mouse CVCL_G172 CL:0000010 Monoclonal antibody isotype: IgG1. 21193841 CVCL_FP79 ND30075 transformed cell line human CVCL_FP79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193842 CVCL_G179 VPM 6 hybridoma house mouse CVCL_G179 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Sheep IgG heavy chain. 21193843 CVCL_FP78 ND30071 transformed cell line human CVCL_FP78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193844 CVCL_G178 VPM 54 hybridoma house mouse CVCL_G178 CL:0000010 Monoclonal antibody isotype: IgG1. 21193845 CVCL_FP77 ND30005 transformed cell line human CVCL_FP77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193846 CVCL_G177 VPM 5 hybridoma house mouse CVCL_G177 CL:0000010 Monoclonal antibody isotype: IgM. 21193847 CVCL_FP76 ND29975 transformed cell line human CVCL_FP76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193848 CVCL_G176 VPM 48 hybridoma house mouse CVCL_G176 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Sheep MHC class II alpha chain. 21193849 CVCL_FP71 ND29868 transformed cell line human CVCL_FP71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193850 CVCL_G171 VPM 43 hybridoma house mouse CVCL_G171 CL:0000010 Monoclonal antibody isotype: IgG1. 21193851 CVCL_FP70 ND29844 transformed cell line human CVCL_FP70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193852 CVCL_G170 VPM 41 hybridoma house mouse CVCL_G170 CL:0000010 Monoclonal antibody isotype: IgG1. 21193853 CVCL_FP49 ND29429 transformed cell line human CVCL_FP49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193854 CVCL_G149 RAN-2 hybridoma house mouse CVCL_G149 CL:0000010 Monoclonal antibody isotype: IgG2a. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193855 CVCL_FP48 ND29418 transformed cell line human CVCL_FP48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193856 CVCL_G148 R6.5.D6.E9.B2 hybridoma house mouse CVCL_G148 CL:0000010 Biotechnology: Was used to produce the monoclonal antibody enlimomab (BIRR-1) which is used in clinical trials in refractory rheumatoid arthritis and to reduce the incidence of acute rejection after kidney and liver allograft transplantations Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P05362; Human ICAM1/CD54. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9580 21193857 CVCL_FP47 ND29414 transformed cell line human CVCL_FP47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193858 CVCL_G147 SF1-1.1.10 hybridoma house mouse CVCL_G147 CL:0000010 Monoclonal antibody isotype: IgG2a. 21193859 CVCL_FP42 ND29305 transformed cell line human CVCL_FP42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193860 CVCL_G142 S3D3 hybridoma house mouse CVCL_G142 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8331 21193861 CVCL_FP41 ND29304 transformed cell line human CVCL_FP41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193862 CVCL_G141 S1E4 hybridoma house mouse CVCL_G141 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Eimeria tenella sporozoite antigen. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8332 21193863 CVCL_G140 HuT-14 cancer cell line human CVCL_G140 CL:0000010 Female Problematic cell line: Contaminated Shown to be a Hs 633.T derivative (PubMed=2902939). Originally thought to originate from the chemical transformation of KD (Cellosaurus=CVCL_2970) fibroblast cells.. 21193864 CVCL_FP40 ND29292 transformed cell line human CVCL_FP40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193865 CVCL_FP46 ND29383 transformed cell line human CVCL_FP46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193866 CVCL_G146 SE-1.3 hybridoma house mouse CVCL_G146 CL:0000010 Monoclonal antibody isotype: IgE; Monoclonal antibody target: ChEBI; CHEBI:64449; Phenylarsonate. 21193867 CVCL_FP45 ND29378 transformed cell line human CVCL_FP45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193868 CVCL_G145 SA22 hybridoma house mouse CVCL_G145 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09428; Bovine IL1B (Note=Also reacts with human). 21193869 CVCL_FP44 ND29377 transformed cell line human CVCL_FP44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193870 CVCL_G144 S9.6 hybridoma house mouse CVCL_G144 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma is used for an antibody-based microarray assay for small RNA detection Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: DNA:RNA hybrids. Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8730 21193871 CVCL_FP43 ND29319 transformed cell line human CVCL_FP43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193872 CVCL_G143 S5 [Mouse hybridoma against human astrocytoma 120 kd protein] hybridoma house mouse CVCL_G143 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human astrocytoma 120 kd protein. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9255 21193873 CVCL_FP59 ND29598 transformed cell line human CVCL_FP59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193874 CVCL_G159 RLTM01 hybridoma house mouse CVCL_G159 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15309; Human ACPP. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8526 21193875 CVCL_FP58 ND29588 transformed cell line human CVCL_FP58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193876 CVCL_G158 RLSD09 hybridoma house mouse CVCL_G158 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8525 21193877 CVCL_FP53 ND29479 transformed cell line human CVCL_FP53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193878 CVCL_G153 RG7/11.1 hybridoma house mouse CVCL_G153 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Rat IgG2b (Fc). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193879 CVCL_FP52 ND29432 transformed cell line human CVCL_FP52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193880 CVCL_G152 RG7/1.30 hybridoma house mouse CVCL_G152 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Rat IgG2a (Fc). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193881 CVCL_FP51 ND29431 transformed cell line human CVCL_FP51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193882 CVCL_G151 RG11/39.4 hybridoma house mouse CVCL_G151 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Rat IgG1 (Fc). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193883 CVCL_FP50 ND29430 transformed cell line human CVCL_FP50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193884 CVCL_G150 RDP 45/20 hybridoma house mouse CVCL_G150 CL:0000010 Monoclonal antibody isotype: IgM. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193885 CVCL_FP57 ND29582 transformed cell line human CVCL_FP57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193886 CVCL_G157 RLSD06 hybridoma house mouse CVCL_G157 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P07288; Human KLK3/PSA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8527 21193887 CVCL_FP56 ND29549 transformed cell line human CVCL_FP56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193888 CVCL_G156 RG9/6.13 HLK hybridoma house mouse CVCL_G156 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Rat IgG2a (Fab'). Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193889 CVCL_FP55 ND29530 transformed cell line human CVCL_FP55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193890 CVCL_G155 RG7/9.1 HLK hybridoma house mouse CVCL_G155 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: Rat Ig kappa light chains. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193891 CVCL_FP54 ND29516 transformed cell line human CVCL_FP54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193892 CVCL_G154 RG7/7.6 HL hybridoma house mouse CVCL_G154 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rat Ig kappa light chains. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21193893 CVCL_XC41 IBCHi002-A induced pluripotent stem cell human CVCL_XC41 From: Institute of Bioorganic Chemistry Polish Academy of Sciences; Poznan; Poland CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[71]; Zygosity=Heterozygous; Note=The other allele has 23 repeats (PubMed=32361312) Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Male 21193894 CVCL_XC40 IBCHi001-A induced pluripotent stem cell human CVCL_XC40 From: Institute of Bioorganic Chemistry Polish Academy of Sciences; Poznan; Poland CL:0000010 Sequence variation: Mutation; HGNC; 3033; ATN1; Repeat_expansion; CAG[68] (g.17267CAG[(54-68)]); ClinVar=VCV000590267; Zygosity=Heterozygous; Note=The non-expanded allele has CAG[16] (PubMed=31374462) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21193895 CVCL_XC45 GM27458 transformed cell line human CVCL_XC45 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ser181Cysfs*5 (c.542_543delCT); Zygosity=Heterozygous (Coriell) Population: Caucasian and Native North American; Alaskan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193896 CVCL_XC44 GM27408 finite cell line human CVCL_XC44 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ser181Cysfs*5 (c.542_543delCT); Zygosity=Heterozygous (Coriell) Population: Caucasian and Native North American; Alaskan; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21193897 CVCL_XC43 WAe001-A-32 embryonic stem cell human CVCL_XC43 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1. Male 21193898 CVCL_XC42 WAe001-A-31 embryonic stem cell human CVCL_XC42 From: Universitat Duisburg-Essen; Duisburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1. Male 21193899 CVCL_XC49 GM27353 finite cell line human CVCL_XC49 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Arg497Ter (c.1489C>T); ClinVar=VCV000210050; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193900 CVCL_XC48 GM27412 transformed cell line human CVCL_XC48 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Arg497Ter (c.1489C>T); ClinVar=VCV000210050; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193901 CVCL_XC47 GM27409 finite cell line human CVCL_XC47 CL:0000010 Population: Native North American; Alaskan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193902 CVCL_XC46 GM27407 finite cell line human CVCL_XC46 CL:0000010 Population: Caucasian; Derived from sampling site: Hip; skin Cell type=Fibroblast.. Male 21193903 CVCL_XC30 PE 9 hybridoma house mouse CVCL_XC30 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04179; Human SOD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1607 21193904 CVCL_XC34 HCY-23 spontaneously immortalized cell line human CVCL_XC34 CL:0000010 Derived from sampling site: Tooth; cementum Cell type=Cementocyte.. Characteristics: Produces mineral-like nodules in vitro under differentiation conditions 21193905 CVCL_XC33 WAZ-2T +SA cancer cell line house mouse CVCL_XC33 CL:0000010 Breed/subspecies: BALB/c. Female 21193906 CVCL_XC32 WAZ-2T -SA cancer cell line house mouse CVCL_XC32 CL:0000010 Breed/subspecies: BALB/c. Female 21193907 CVCL_XC31 PG 11 hybridoma house mouse CVCL_XC31 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04179; Human SOD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1608 21193908 CVCL_XC38 SDQLCHi002-A induced pluripotent stem cell human CVCL_XC38 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 21193909 CVCL_XC37 SDQLCHi001-A induced pluripotent stem cell human CVCL_XC37 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 21193910 CVCL_XC36 HMGUi002-A induced pluripotent stem cell human CVCL_XC36 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21193911 CVCL_XC35 IDG-CM6 conditionally immortalized cell line house mouse CVCL_XC35 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Gly, p.Ser72Ala, Lys79Arg, Thr203Tyr and His231Leu = Topaz) Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Tooth root Cell type=Cementocyte.; Breed/subspecies: C57BL/6-Tg(Dmp1-Topaz)1Ikal/J x (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Female Characteristics: Expresses GFP Topaz under the control of the Dmp1 promoter 21193912 CVCL_XC39 SDQLCHi003-A induced pluripotent stem cell human CVCL_XC39 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2962; DYNC2H1; Simple; p.Trp314Arg (c.940T>C); Zygosity=Heterozygous (PubMed=31415973); Sequence variation: Mutation; HGNC; 2962; DYNC2H1; Simple; p.Pro3388Leu (c.10163C>T) (p.Pro3381Leu, c.10142C>T); ClinVar=VCV000439631; Zygosity=Heterozygous (PubMed=31415973) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21193913 CVCL_XC23 LCDV-E1 hybridoma house mouse CVCL_XC23 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Lymphocystis disease virus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200419 21193914 CVCL_XC22 MAPR-S2 hybridoma house mouse CVCL_XC22 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06401; Human PGR. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96006 21193915 CVCL_XC21 MAER-S1 hybridoma house mouse CVCL_XC21 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03372; Human ESR1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C96005 21193916 CVCL_XC20 D6D hybridoma house mouse CVCL_XC20 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201052 21193917 CVCL_XC27 HEV-NICPBP07 hybridoma house mouse CVCL_XC27 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 (isolate Human/China/HeBei/1987) secreted protein ORF2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200520 21193918 CVCL_XC26 HEV-NICPBP04 hybridoma house mouse CVCL_XC26 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 (isolate Human/China/HeBei/1987) secreted protein ORF2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200519 21193919 CVCL_XC25 LCDV-V hybridoma house mouse CVCL_XC25 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P22176; Lymphocystis disease virus 1 capsid protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200619 21193920 CVCL_XC24 LCDV-E2 hybridoma house mouse CVCL_XC24 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Lymphocystis disease virus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200420 21193921 CVCL_XC29 NI 8 hybridoma house mouse CVCL_XC29 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P04179; Human SOD2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-1606 21193922 CVCL_XC28 HEV-NICPBP58 hybridoma house mouse CVCL_XC28 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q81871; Hepatitis E virus genotype 1 (isolate Human/China/HeBei/1987) secreted protein ORF2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200521 21193923 CVCL_XC12 7E11A1 hybridoma house mouse CVCL_XC12 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Aspergillus fumigatus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200730 21193924 CVCL_XC11 ZJU-1127 cancer cell line human CVCL_XC11 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asn (c.376T>A); ClinVar=VCV000428871; Zygosity=Unspecified (PubMed=30140169). Population: Chinese Female Doubling time: 18.8 hours (Patent=CN108034636B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017172 21193925 CVCL_XC10 ZJU-0725 cancer cell line human CVCL_XC10 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asn (c.376T>A); ClinVar=VCV000428871; Zygosity=Unspecified (PubMed=30140169) Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 57.5 hours (Patent=CN108034636B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017171 21193926 CVCL_XC16 10G2 hybridoma house mouse CVCL_XC16 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). 21193927 CVCL_XC15 2F1.E10 hybridoma house mouse CVCL_XC15 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:141524; Ochratoxin B (OTB). 21193928 CVCL_XC14 C7G25 hybridoma house mouse CVCL_XC14 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). 21193929 CVCL_XC13 9D47A1 hybridoma house mouse CVCL_XC13 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Aspergillus fumigatus. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200731 21193930 CVCL_XC19 F-3-3 hybridoma house mouse CVCL_XC19 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.14303 21193931 CVCL_XC18 1H2 hybridoma house mouse CVCL_XC18 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201329 21193932 CVCL_XC17 9C9H9 hybridoma house mouse CVCL_XC17 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:7719; Ochratoxin A (OTA). Group: Patented cell line 21193933 CVCL_XC01 8G9 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XC01 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200639 21193934 CVCL_XC00 3C8 [Mouse hybridoma against influenza A virus HA] hybridoma house mouse CVCL_XC00 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q6DQ18; Influenza A virus isolate A/Chicken/Hong Kong/YU22/2002(H5N1) hemagglutinin (HA) (Note=Also reacts with other H5 isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200605 21193935 CVCL_XC05 RF-851 finite cell line CVCL_XC05 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Female 21193936 CVCL_XC04 LDG-3 finite cell line CVCL_XC04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: Jianzhou big-eared. Male 21193937 CVCL_XC03 LDG-1 finite cell line CVCL_XC03 CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Jianzhou big-eared. Male 21193938 CVCL_XC02 SSC-S1 finite cell line pig CVCL_XC02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21193939 CVCL_XC09 ZJU-0327 cancer cell line human CVCL_XC09 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Asn (c.376T>A); ClinVar=VCV000428871; Zygosity=Unspecified (PubMed=30140169) Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 18.7 hours (Patent=CN108034636B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2017173 21193940 CVCL_XC08 SZCIQASFV2 hybridoma house mouse CVCL_XC08 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q65194; African swine fever virus envelope protein p54 (Note=Also reacts with many isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014213 21193941 CVCL_XC07 SZCIQASFV1 hybridoma house mouse CVCL_XC07 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q65194; African swine fever virus envelope protein p54 (Note=Also reacts with many isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014212 21193942 CVCL_XC06 TS-EL-1 finite cell line CVCL_XC06 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21193943 CVCL_XC92 HEC-1-B-Cas9-588 cancer cell line human CVCL_XC92 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193944 CVCL_XC91 HEC-1-B-Cas9-587 cancer cell line human CVCL_XC91 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193945 CVCL_XC90 HEC-1-B-Cas9-586 cancer cell line human CVCL_XC90 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193946 CVCL_XC96 HEC-1-B-Cas9-592 cancer cell line human CVCL_XC96 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Puro construct 21193947 CVCL_XC95 HEC-1-B-Cas9-591 cancer cell line human CVCL_XC95 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Puro construct 21193948 CVCL_XC94 HEC-1-B-Cas9-590 cancer cell line human CVCL_XC94 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Puro construct 21193949 CVCL_XC93 HEC-1-B-Cas9-589 cancer cell line human CVCL_XC93 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193950 CVCL_XC99 HCT116-Cas9-567 cancer cell line human CVCL_XC99 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193951 CVCL_XC98 HCT116-Cas9-566 cancer cell line human CVCL_XC98 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193952 CVCL_XC97 HCT116-Cas9-565 cancer cell line human CVCL_XC97 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Characteristics: Transfected with a Cas9-Flag-Puro construct 21193953 CVCL_XC81 HAb18Gedomab2 hybridoma house mouse CVCL_XC81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200636 21193954 CVCL_XC80 HAb18Gedomab1 hybridoma house mouse CVCL_XC80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200408 21193955 CVCL_XC85 HEC-1-B-Cas9-581 cancer cell line human CVCL_XC85 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193956 CVCL_XC84 HEC-1-B-Cas9-580 cancer cell line human CVCL_XC84 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193957 CVCL_XC83 3B3 [Mouse hybridoma against human BSG] hybridoma house mouse CVCL_XC83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 21193958 CVCL_XC82 1B3 [Mouse hybridoma against human BSG] hybridoma house mouse CVCL_XC82 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35613; Human BSG/CD147. 21193959 CVCL_XC89 HEC-1-B-Cas9-585 cancer cell line human CVCL_XC89 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193960 CVCL_XC88 HEC-1-B-Cas9-584 cancer cell line human CVCL_XC88 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193961 CVCL_XC87 HEC-1-B-Cas9-583 cancer cell line human CVCL_XC87 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193962 CVCL_XC86 HEC-1-B-Cas9-582 cancer cell line human CVCL_XC86 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; c.4001+1G>T; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 9122; PMS2; Simple; p.Arg802Ter (c.2404C>T); ClinVar=VCV000009237; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Endometrium. Female Characteristics: Transfected with a Cas9-Flag-Neo construct 21193963 CVCL_XC70 1R10F11.34.16 hybridoma house mouse CVCL_XC70 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P13725; Human OSM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10397 21193964 CVCL_XC74 A27.15 hybridoma house mouse CVCL_XC74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10395 21193965 CVCL_XC73 42/6 hybridoma house mouse CVCL_XC73 CL:0000010 Monoclonal antibody isotype: IgA, kappa; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8094 21193966 CVCL_XC72 12R13D7.2 hybridoma house mouse CVCL_XC72 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13725; Human OSM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10396 21193967 CVCL_XC71 11R2F8.9 hybridoma house mouse CVCL_XC71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13725; Human OSM. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10398 21193968 CVCL_XC78 6C9A hybridoma house mouse CVCL_XC78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21583; Human KITLG. 21193969 CVCL_XC77 4G12-13 hybridoma house mouse CVCL_XC77 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21583; Human KITLG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10561 21193970 CVCL_XC76 E2.3 hybridoma house mouse CVCL_XC76 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10746 21193971 CVCL_XC75 D65.30 hybridoma house mouse CVCL_XC75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02786; Human TFRC/CD71. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10394 21193972 CVCL_XC79 8H7A hybridoma house mouse CVCL_XC79 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21583; Human KITLG. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10560 21193973 CVCL_XC63 G17-2 hybridoma house mouse CVCL_XC63 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. 21193974 CVCL_XC62 G10-1 hybridoma house mouse CVCL_XC62 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human CD8. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10268 21193975 CVCL_XC61 BFR87-70 hybridoma house mouse CVCL_XC61 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01227; Sheep FSHB. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 89010301 21193976 CVCL_XC60 BFR87-124 hybridoma house mouse CVCL_XC60 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P01227; Sheep FSHB. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 89010302 21193977 CVCL_XC67 KC-57 hybridoma house mouse CVCL_XC67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03347; HIV-1 isolate BH10 gag (Note=Also reacts with other isolates). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9585 21193978 CVCL_XC66 KC-48 hybridoma house mouse CVCL_XC66 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human neutrophils and eosinophils. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9584 21193979 CVCL_XC65 G19-4 hybridoma house mouse CVCL_XC65 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human CD3. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9536 21193980 CVCL_XC64 G19-2 hybridoma house mouse CVCL_XC64 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01730; Human CD4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10324 21193981 CVCL_XC69 C-69 hybridoma house mouse CVCL_XC69 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P38646; Human HSPA9. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21876 21193982 CVCL_XC68 C-26 hybridoma house mouse CVCL_XC68 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P38646; Human HSPA9. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-21875 21193983 CVCL_XC52 GM27270 induced pluripotent stem cell human CVCL_XC52 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg174Ter (c.520C>T); ClinVar=VCV000235853; Zygosity=Heterozygous (Coriell) Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 21193984 CVCL_XC51 GM27336 transformed cell line human CVCL_XC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21193985 CVCL_XC50 GM27381 induced pluripotent stem cell human CVCL_XC50 CL:0000010 Sequence variation: Mutation; HGNC; 1397; CACNA1S; Simple; p.Thr1354Ser (c.4060A>T); ClinVar=VCV000161208; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gln208Ter (c.622C>T); ClinVar=VCV000221578; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Gly310Gly (c.930C>T); ClinVar=VCV000221583; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193986 CVCL_XC56 FDCHi001-A induced pluripotent stem cell human CVCL_XC56 From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 21193987 CVCL_XC55 AG27009 transformed cell line human CVCL_XC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21193988 CVCL_XC54 GM27145 finite cell line human CVCL_XC54 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000974929; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21193989 CVCL_XC53 GM27144 transformed cell line human CVCL_XC53 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000974929; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21193990 CVCL_XC59 BHK-21 CIAPIN1+ spontaneously immortalized cell line CVCL_XC59 CL:0000010 Transfected with: HGNC; 28050; CIAPIN1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014149 21193991 CVCL_XC58 REGUi003-A induced pluripotent stem cell human CVCL_XC58 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Tyr1263Ter (c.3789C>G); Zygosity=Homozygous (PubMed=31404747) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21193992 CVCL_XC57 FDCHi002-A induced pluripotent stem cell human CVCL_XC57 From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Milk Cell type=Lactiferous duct luminal epithelial cell.. Female 21193993 CVCL_5G31 HTM-2 finite cell line human CVCL_5G31 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Male 21193994 CVCL_5G30 Porco Rosso-622-14 iPSC induced pluripotent stem cell pig CVCL_5G30 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: [(Landrace x Large White) x Duroc] humanized Kusabira-Orange transgenic. 21193995 CVCL_5G35 BTM-28T spontaneously immortalized cell line CVCL_5G35 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 21193996 CVCL_5G34 NTM-5 transformed cell line human CVCL_5G34 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; trabecular meshwork. Male 21193997 CVCL_5G33 GTM-3 transformed cell line human CVCL_5G33 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; trabecular meshwork. Omics: Proteome analysis by 2D-DE/MS Male 21193998 CVCL_5G32 HTM-4 finite cell line human CVCL_5G32 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Male 21193999 CVCL_5G39 AICHI-4 transformed cell line human CVCL_5G39 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Lymph node. Male Doubling time: ~24 hours (PubMed=5728341) Problematic cell line: Misclassified Originally thought to be a Hodgkin lymphoma cell line, but seems to be a B-lymphoblastoid cell line (PubMed=29533902). 21194000 CVCL_5G38 AHAP spontaneously immortalized cell line CVCL_5G38 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Pancreas; adipose tissue. Unspecified Doubling time: ~2 weeks (DOI=10.3354/ab00317) Group: Fish cell line 21194001 CVCL_5G37 Evsa-E cancer cell line human CVCL_5G37 CL:0000010 Population: Caucasian; Derived from metastatic site: Ascites. Female 21194002 CVCL_5G36 TM-1 [Human trabecular meshwork] transformed cell line human CVCL_5G36 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; trabecular meshwork. Unspecified 21194003 CVCL_XM83 HAP1 CLN5 (-) cancer cell line human CVCL_XM83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2076; CLN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194004 CVCL_XM82 HAP1 CLCN5 (-) cancer cell line human CVCL_XM82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2023; CLCN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194005 CVCL_XM81 HAP1 CHST10 (-) 2 cancer cell line human CVCL_XM81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19650; CHST10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194006 CVCL_XM80 HAP1 CHMP7 (-) 2 cancer cell line human CVCL_XM80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28439; CHMP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194007 CVCL_XM87 HAP1 CLPX (-) cancer cell line human CVCL_XM87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2088; CLPX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC10845; probable Male Group: Haploid karyotype cell line 21194008 CVCL_XM86 HAP1 CLPTM1 (-) 2 cancer cell line human CVCL_XM86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2087; CLPTM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194009 CVCL_XM85 HAP1 CLPP (-) cancer cell line human CVCL_XM85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2084; CLPP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194010 CVCL_XM84 HAP1 CLN8 (-) cancer cell line human CVCL_XM84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2079; CLN8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194011 CVCL_XM89 HAP1 CMTM6 (-) cancer cell line human CVCL_XM89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19177; CMTM6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194012 CVCL_XM88 HAP1 CLU (-) 2 cancer cell line human CVCL_XM88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2095; CLU; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194013 CVCL_5G42 HC11-BC44 spontaneously immortalized cell line house mouse CVCL_5G42 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21194014 CVCL_5G41 HC11-BC20 spontaneously immortalized cell line house mouse CVCL_5G41 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21194015 CVCL_5G40 ICR B20 spontaneously immortalized cell line CVCL_5G40 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Benzo(b)(1,5)naphthyridine,7-chloro-10-(3-(N-(2-chloroethyl)-N-ethyl)aminopropylamino)-2-methoxy-,dihydrochloride (ICR 340)(ChEBI; CHEBI:189531). Unspecified Group: Amphibian cell line; Group: Haploid karyotype cell line 21194016 CVCL_5G46 CAL-1 [Human plasmacytoid dendritic] cancer cell line human CVCL_5G46 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Plasmacytoid dendritic cell.. Male Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM P-20595 21194017 CVCL_5G45 GEN3 cancer cell line human CVCL_5G45 CL:0000010 Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3110. 21194018 CVCL_5G44 GEN2.2 cancer cell line human CVCL_5G44 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Plasmacytoid dendritic cell.. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2938 21194019 CVCL_5G43 BTM-1 cancer cell line human CVCL_5G43 CL:0000010 Derived from sampling site: Breast. Female 21194020 CVCL_5G49 ROSA KIT WT factor-dependent cell line human CVCL_5G49 CL:0000010 Male Characteristics: KITLG dependent. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4551 21194021 CVCL_5G48 LUVA spontaneously immortalized cell line human CVCL_5G48 CL:0000010 Donor information: Established from a donor with aspirin-exacerbated respiratory disease; Derived from sampling site: Peripheral blood Cell type=Mast cell.. Unspecified Doubling time: 54.0 +- 0.5 hours (in the absence of SCF), 43.3 +- 2.9 hours (in the presence of SCF) (PubMed=21281958) 21194022 CVCL_5G47 PMDC05 cancer cell line human CVCL_5G47 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Plasmacytoid dendritic cell.. Male Doubling time: ~60 hours (PubMed=19443030) 21194023 CVCL_XM72 HAP1 CECR5 (-) 4 cancer cell line human CVCL_XM72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194024 CVCL_XM71 HAP1 CECR5 (-) 3 cancer cell line human CVCL_XM71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194025 CVCL_XM70 HAP1 CECR5 (-) 2 cancer cell line human CVCL_XM70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194026 CVCL_XM76 HAP1 CHMP1A (-) 2 cancer cell line human CVCL_XM76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194027 CVCL_XM75 HAP1 CFLAR (-) 2 cancer cell line human CVCL_XM75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1876; CFLAR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194028 CVCL_XM74 HAP1 CERS2 (-) cancer cell line human CVCL_XM74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14076; CERS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC29956; probable Male Group: Haploid karyotype cell line 21194029 CVCL_XM73 HAP1 CECR5 (-) 5 cancer cell line human CVCL_XM73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1843; HDHD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194030 CVCL_XM79 HAP1 CHMP1B (-) cancer cell line human CVCL_XM79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24287; CHMP1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194031 CVCL_XM78 HAP1 CHMP1A (-) 4 cancer cell line human CVCL_XM78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194032 CVCL_XM77 HAP1 CHMP1A (-) 3 cancer cell line human CVCL_XM77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8740; CHMP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194033 CVCL_5G13 SVG-A transformed cell line human CVCL_5G13 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Omics: Transcriptome analysis by microarray Male Characteristics: Used to study trinucleotide repeat (TNR) expansion as these cells support expansiosns in culture Caution: In contrast to SVG p12 (Cellosaurus=CVCL_3797), this cell line is not contaminated with BK polyomavirus (PubMed=24760884) 21194034 CVCL_5G12 RAD5.2 conditionally immortalized cell line Norway rat CVCL_5G12 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic adrenal gland; medulla Cell type=Chromaffin cell.; Breed/subspecies: Sprague Dawley. Unspecified 21194035 CVCL_5G11 BADA.20 conditionally immortalized cell line CVCL_5G11 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; medulla Cell type=Chromaffin cell.. Unspecified 21194036 CVCL_5G10 HTG-2 embryonic stem cell house mouse CVCL_5G10 CL:0000010 Female Group: Haploid karyotype cell line. 21194037 CVCL_5G17 Y1-Cyc-103 cancer cell line house mouse CVCL_5G17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194038 CVCL_5G16 Y1-Cyc-102 cancer cell line house mouse CVCL_5G16 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194039 CVCL_5G15 Y1-Cyc-101 cancer cell line house mouse CVCL_5G15 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194040 CVCL_5G14 SVG transformed cell line human CVCL_5G14 CL:0000010 Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male 21194041 CVCL_5G19 Y1-Forsk-10r-6 cancer cell line house mouse CVCL_5G19 CL:0000010 Selected for resistance to: ChEBI; CHEBI:42471; Forskolin; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194042 CVCL_5G18 Y1-Forsk-10r-1 cancer cell line house mouse CVCL_5G18 CL:0000010 Selected for resistance to: ChEBI; CHEBI:42471; Forskolin; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194043 CVCL_XM61 HAP1 CD74 (-) cancer cell line human CVCL_XM61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1697; CD74; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194044 CVCL_XM60 HAP1 CD47 (-) 2 cancer cell line human CVCL_XM60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1682; CD47; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194045 CVCL_XM65 HAP1 CDC42BPA (-) 1 cancer cell line human CVCL_XM65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1737; CDC42BPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194046 CVCL_XM64 HAP1 CDC25A (-) 2 cancer cell line human CVCL_XM64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1725; CDC25A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194047 CVCL_XM63 HAP1 CDAN1 (-) cancer cell line human CVCL_XM63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1713; CDAN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194048 CVCL_XM62 HAP1 CD9 (-) 2 cancer cell line human CVCL_XM62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1709; CD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194049 CVCL_XM69 HAP1 CDKN1C (-) 2 cancer cell line human CVCL_XM69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1786; CDKN1C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194050 CVCL_XM68 HAP1 CDH6 (-) cancer cell line human CVCL_XM68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1765; CDH6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194051 CVCL_XM67 HAP1 CDH2 (-) 2 cancer cell line human CVCL_XM67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1759; CDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194052 CVCL_XM66 HAP1 CDC42BPA (-) 2 cancer cell line human CVCL_XM66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1737; CDC42BPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194053 CVCL_5G20 Y1-Forsk-10r-9 cancer cell line house mouse CVCL_5G20 CL:0000010 Selected for resistance to: ChEBI; CHEBI:42471; Forskolin; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194054 CVCL_5G24 Y1-8BrcAMPr-1 cancer cell line house mouse CVCL_5G24 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194055 CVCL_5G23 Y1-Kin-8 cancer cell line house mouse CVCL_5G23 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194056 CVCL_5G22 Y1-Kin-7 cancer cell line house mouse CVCL_5G22 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194057 CVCL_5G21 Y1-Kin-2 cancer cell line house mouse CVCL_5G21 CL:0000010 Selected for resistance to: ChEBI; CHEBI:64211; 8-bromo-3',5'-cyclic AMP (8-bromoadenosine 3',5'-cyclic monophosphate; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194058 CVCL_5G28 Porco Rosso-4 iPSC induced pluripotent stem cell pig CVCL_5G28 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: [(Landrace x Large White) x Duroc] humanized Kusabira-Orange transgenic. Female 21194059 CVCL_5G27 Porco Clawn iPSC induced pluripotent stem cell pig CVCL_5G27 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: Clawn miniature. Unspecified 21194060 CVCL_5G26 Y1-HGPRT- cancer cell line house mouse CVCL_5G26 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194061 CVCL_5G25 OS3-HGPRT- cancer cell line house mouse CVCL_5G25 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21194062 CVCL_5G29 Porco Rosso-6 iPSC induced pluripotent stem cell pig CVCL_5G29 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: [(Landrace x Large White) x Duroc] humanized Kusabira-Orange transgenic. Female 21194063 CVCL_XM50 HAP1 CCDC51 (-) 5 cancer cell line human CVCL_XM50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25714; CCDC51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194064 CVCL_XM54 HAP1 CCNE1 (-) 2 cancer cell line human CVCL_XM54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1589; CCNE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194065 CVCL_XM53 HAP1 CCNB1IP1 (-) 2 cancer cell line human CVCL_XM53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19437; CCNB1IP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194066 CVCL_XM52 HAP1 CCL2 (-) 2 cancer cell line human CVCL_XM52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10618; CCL2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194067 CVCL_XM51 HAP1 CCDC92 (-) 1 cancer cell line human CVCL_XM51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29563; CCDC92; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194068 CVCL_XM58 HAP1 CD36 (-) 2 cancer cell line human CVCL_XM58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1663; CD36; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194069 CVCL_XM57 HAP1 CD274 (-) 2 cancer cell line human CVCL_XM57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17635; CD274; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194070 CVCL_XM56 HAP1 CCSER1 (-) 2 cancer cell line human CVCL_XM56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29349; CCSER1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194071 CVCL_XM55 HAP1 CCNG2 (-) 2 cancer cell line human CVCL_XM55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1593; CCNG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194072 CVCL_XM59 HAP1 CD44 (-) 2 cancer cell line human CVCL_XM59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1681; CD44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194073 CVCL_XM43 HAP1 CALB1 (-) 2 cancer cell line human CVCL_XM43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1434; CALB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194074 CVCL_XM42 HAP1 CAD (-) cancer cell line human CVCL_XM42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1424; CAD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194075 CVCL_XM41 HAP1 CABIN1 (-) 3 cancer cell line human CVCL_XM41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24187; CABIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194076 CVCL_XM40 HAP1 CABIN1 (-) 2 cancer cell line human CVCL_XM40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24187; CABIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194077 CVCL_P499 GM19093 transformed cell line human CVCL_P499 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194078 CVCL_XM47 HAP1 CCDC51 (-) 2 cancer cell line human CVCL_XM47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25714; CCDC51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194079 CVCL_P498 GM19092 transformed cell line human CVCL_P498 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194080 CVCL_XM46 HAP1 CCDC109B (-) cancer cell line human CVCL_XM46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26076; MCUB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194081 CVCL_P497 GM18934 transformed cell line human CVCL_P497 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194082 CVCL_XM45 HAP1 CBL (-) 2 cancer cell line human CVCL_XM45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1541; CBL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194083 CVCL_P496 GM18933 transformed cell line human CVCL_P496 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194084 CVCL_XM44 HAP1 CAPN2 (-) cancer cell line human CVCL_XM44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1479; CAPN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194085 CVCL_P495 GM18924 transformed cell line human CVCL_P495 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194086 CVCL_P494 GM18923 transformed cell line human CVCL_P494 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194087 CVCL_P493 GM18917 transformed cell line human CVCL_P493 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194088 CVCL_XM49 HAP1 CCDC51 (-) 4 cancer cell line human CVCL_XM49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25714; CCDC51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194089 CVCL_P492 GM18916 transformed cell line human CVCL_P492 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194090 CVCL_XM48 HAP1 CCDC51 (-) 3 cancer cell line human CVCL_XM48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25714; CCDC51; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194091 CVCL_5G02 AHGFP-2 embryonic stem cell house mouse CVCL_5G02 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194092 CVCL_5G01 AH129-NC1 embryonic stem cell house mouse CVCL_5G01 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194093 CVCL_5G00 AH129-N1 embryonic stem cell house mouse CVCL_5G00 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194094 CVCL_5G06 H129-2 embryonic stem cell house mouse CVCL_5G06 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194095 CVCL_5G05 H129-1 embryonic stem cell house mouse CVCL_5G05 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194096 CVCL_5G04 AHGFP-6 embryonic stem cell house mouse CVCL_5G04 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194097 CVCL_5G03 AHGFP-4 embryonic stem cell house mouse CVCL_5G03 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21194098 CVCL_5G09 HTG-1 embryonic stem cell house mouse CVCL_5G09 CL:0000010 Female Group: Haploid karyotype cell line. 21194099 CVCL_5G08 HAP-2 embryonic stem cell house mouse CVCL_5G08 CL:0000010 Breed/subspecies: C57BL/6 x CBA. Female Group: Haploid karyotype cell line; Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3220 21194100 CVCL_5G07 HAP-1 embryonic stem cell house mouse CVCL_5G07 CL:0000010 Breed/subspecies: C57BL/6 x CBA. Female Group: Haploid karyotype cell line 21194101 CVCL_XM32 HAP1 C2orf69 (-) 4 cancer cell line human CVCL_XM32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26799; C2orf69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194102 CVCL_XM31 HAP1 C2orf69 (-) 3 cancer cell line human CVCL_XM31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26799; C2orf69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194103 CVCL_XM30 HAP1 C2orf69 (-) 2 cancer cell line human CVCL_XM30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26799; C2orf69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194104 CVCL_XM36 HAP1 C3orf33 (-) 3 cancer cell line human CVCL_XM36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26434; C3orf33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194105 CVCL_XM35 HAP1 C3orf33 (-) 2 cancer cell line human CVCL_XM35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26434; C3orf33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194106 CVCL_XM34 HAP1 C3 (-) cancer cell line human CVCL_XM34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1318; C3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194107 CVCL_XM33 HAP1 C2orf69 (-) 5 cancer cell line human CVCL_XM33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26799; C2orf69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194108 CVCL_XM39 HAP1 C7orf55 (-) 1 cancer cell line human CVCL_XM39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26946; FMC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194109 CVCL_XM38 HAP1 C6orf106 (-) cancer cell line human CVCL_XM38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21215; ILRUN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194110 CVCL_XM37 HAP1 C3orf33 (-) 4 cancer cell line human CVCL_XM37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26434; C3orf33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194111 CVCL_P480 GM18871 transformed cell line human CVCL_P480 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194112 CVCL_XM19 HAP1 C14orf159 (-) 4 cancer cell line human CVCL_XM19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20498; DGLUCY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194113 CVCL_XM21 HAP1 C15orf40 (-) 3 cancer cell line human CVCL_XM21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28443; C15orf40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194114 CVCL_XM20 HAP1 C15orf40 (-) 2 cancer cell line human CVCL_XM20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28443; C15orf40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194115 CVCL_P479 GM18870 transformed cell line human CVCL_P479 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194116 CVCL_P478 GM18868 transformed cell line human CVCL_P478 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194117 CVCL_P477 GM18867 transformed cell line human CVCL_P477 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194118 CVCL_XM25 HAP1 C15orf61 (-) 5 cancer cell line human CVCL_XM25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34453; C15orf61; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194119 CVCL_P476 GM18862 transformed cell line human CVCL_P476 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194120 CVCL_XM24 HAP1 C15orf61 (-) 4 cancer cell line human CVCL_XM24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34453; C15orf61; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194121 CVCL_P475 GM18861 transformed cell line human CVCL_P475 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194122 CVCL_XM23 HAP1 C15orf61 (-) 3 cancer cell line human CVCL_XM23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34453; C15orf61; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194123 CVCL_P474 GM18859 transformed cell line human CVCL_P474 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194124 CVCL_XM22 HAP1 C15orf61 (-) 2 cancer cell line human CVCL_XM22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 34453; C15orf61; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194125 CVCL_P473 GM18858 transformed cell line human CVCL_P473 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194126 CVCL_XM29 HAP1 C20orf24 (-) 2 cancer cell line human CVCL_XM29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15870; RAB5IF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194127 CVCL_P472 GM18856 transformed cell line human CVCL_P472 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194128 CVCL_XM28 HAP1 C1orf112 (-) 4 cancer cell line human CVCL_XM28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25565; C1orf112; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194129 CVCL_P471 GM18855 transformed cell line human CVCL_P471 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194130 CVCL_XM27 HAP1 C1orf112 (-) 3 cancer cell line human CVCL_XM27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25565; C1orf112; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194131 CVCL_P470 GM18853 transformed cell line human CVCL_P470 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194132 CVCL_XM26 HAP1 C17orf80 (-) 1 cancer cell line human CVCL_XM26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29601; C17orf80; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194133 CVCL_P491 GM18915 transformed cell line human CVCL_P491 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194134 CVCL_P490 GM18913 transformed cell line human CVCL_P490 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194135 CVCL_XM09 HAP1 BRD1 (-) 3 cancer cell line human CVCL_XM09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194136 CVCL_XM08 HAP1 BRD1 (-) 2 cancer cell line human CVCL_XM08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194137 CVCL_XM10 HAP1 BRD1 (-) 4 cancer cell line human CVCL_XM10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194138 CVCL_P489 GM18912 transformed cell line human CVCL_P489 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194139 CVCL_P488 GM18910 transformed cell line human CVCL_P488 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194140 CVCL_XM14 HAP1 BTG1 (-) cancer cell line human CVCL_XM14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1130; BTG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194141 CVCL_P487 GM18909 transformed cell line human CVCL_P487 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194142 CVCL_XM13 HAP1 BTD (-) 2 cancer cell line human CVCL_XM13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1122; BTD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194143 CVCL_P486 GM18908 transformed cell line human CVCL_P486 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194144 CVCL_XM12 HAP1 BRIP1 (-) 2 cancer cell line human CVCL_XM12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20473; BRIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194145 CVCL_P485 GM18907 transformed cell line human CVCL_P485 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194146 CVCL_XM11 HAP1 BRD1 (-) 5 cancer cell line human CVCL_XM11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194147 CVCL_P484 GM18881 transformed cell line human CVCL_P484 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194148 CVCL_XM18 HAP1 C14orf159 (-) 3 cancer cell line human CVCL_XM18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20498; DGLUCY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194149 CVCL_P483 GM18877 transformed cell line human CVCL_P483 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194150 CVCL_XM17 HAP1 C14orf159 (-) 2 cancer cell line human CVCL_XM17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20498; DGLUCY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194151 CVCL_P482 GM18874 transformed cell line human CVCL_P482 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194152 CVCL_XM16 HAP1 C12orf10 (-) 2 cancer cell line human CVCL_XM16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17590; MYG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194153 CVCL_P481 GM18873 transformed cell line human CVCL_P481 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194154 CVCL_XM15 HAP1 C10orf2 (-) cancer cell line human CVCL_XM15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1160; TWNK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194155 CVCL_5G97 C0043 transformed cell line human CVCL_5G97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194156 CVCL_5G96 C0001 transformed cell line human CVCL_5G96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194157 CVCL_5G95 RBM129 transformed cell line Norway rat CVCL_5G95 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Microglial cell.. Unspecified Characteristics: Proliferated actively at 37 Celsius The dividing rate is significantly decreased at 40.5 Celsius (PubMed=1331896). Doubling time: ~16 hours (PubMed=1331896) 21194158 CVCL_5G94 HMO6 transformed cell line human CVCL_5G94 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P01110; Avian myelocytomatosis virus MC29 v-Myc Transformant: v-Myc; Derived from sampling site: Brain Cell type=Microglial cell.. Male Doubling time: 34.5 hours (PubMed=11741401) Group: Patented cell line 21194159 CVCL_5G99 SG0002 transformed cell line human CVCL_5G99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194160 CVCL_5G98 C0163 transformed cell line human CVCL_5G98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194161 CVCL_5G93 N13 transformed cell line house mouse CVCL_5G93 CL:0000010 Transformant: Recombinant retrovirus 3RV/VN-11; Derived from sampling site: Embryonic brain Cell type=Microglial cell.; Breed/subspecies: CD-1. Unspecified 21194162 CVCL_5G92 RSS18 cancer cell line Norway rat CVCL_5G92 CL:0000010 Breed/subspecies: Fischer 344. Female 21194163 CVCL_5G91 TYS cancer cell line human CVCL_5G91 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281His (c.841G>C); ClinVar=VCV000376588; Zygosity=Unspecified (PubMed=17390010). Population: Japanese Female Doubling time: 44.4 hours (PubMed=2429552) 21194164 CVCL_5G90 UM-Ly(ebv)-17 transformed cell line human CVCL_5G90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194165 CVCL_5G75 TC 379 cancer cell line human CVCL_5G75 CL:0000010 Male 21194166 CVCL_5G74 TC 396 cancer cell line human CVCL_5G74 CL:0000010 Female 21194167 CVCL_5G73 TC 691 cancer cell line human CVCL_5G73 CL:0000010 Unspecified 21194168 CVCL_5G72 TC620.6A2 cancer cell line human CVCL_5G72 CL:0000010 Male 21194169 CVCL_5G79 CHP-404 cancer cell line human CVCL_5G79 CL:0000010 Unspecified 21194170 CVCL_5G78 CHP-382/JK cancer cell line human CVCL_5G78 CL:0000010 Derived from sampling site: Abdomen. Male 21194171 CVCL_5G77 CHP-382 cancer cell line human CVCL_5G77 CL:0000010 Derived from sampling site: Abdomen. Male 21194172 CVCL_5G76 TC 491 cancer cell line human CVCL_5G76 CL:0000010 Miscellaneous: Cell line has been lost (PubMed=5578746) Derived from metastatic site: Brain; cerebellum. Unspecified 21194173 CVCL_5G71 U-706S cancer cell line human CVCL_5G71 CL:0000010 Derived from sampling site: Brain. Female Characteristics: Grows in suspension (PubMed=7319677) 21194174 CVCL_5G70 U-706MG cancer cell line human CVCL_5G70 CL:0000010 Derived from sampling site: Brain. Female 21194175 CVCL_5G86 YN-4 spontaneously immortalized cell line house mouse CVCL_5G86 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.. Female 21194176 CVCL_5G85 MOMA-2 [Mouse mammary gland] spontaneously immortalized cell line house mouse CVCL_5G85 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21194177 CVCL_5G84 MOMA-1 [Mouse mammary gland] spontaneously immortalized cell line house mouse CVCL_5G84 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: BALB/c. Female 21194178 CVCL_5G83 COMMA-T spontaneously immortalized cell line house mouse CVCL_5G83 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21194179 CVCL_5G89 Sarc9371 cancer cell line human CVCL_5G89 Genome ancestry: African=0.55%; Native American=0%; East Asian, North=3.77%; East Asian, South=0%; South Asian=23.42%; European, North=14.57%; European, South=57.68% (PubMed=30894373). CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu130Phe (c.388C>T); ClinVar=VCV000216466; Zygosity=Heterozygous (Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe134Leu (c.400T>C); ClinVar=VCV000080710; Zygosity=Heterozygous (Cosmic-CLP; DepMap) Omics: Deep exome analysis Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project 21194180 CVCL_5G88 WAZ-2T cancer cell line house mouse CVCL_5G88 CL:0000010 Breed/subspecies: BALB/c. Female 21194181 CVCL_5G87 MOD cancer cell line house mouse CVCL_5G87 CL:0000010 Female 21194182 CVCL_5G82 COMMA-F spontaneously immortalized cell line house mouse CVCL_5G82 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: BALB/c. Female 21194183 CVCL_5G81 NUB-20 cancer cell line human CVCL_5G81 CL:0000010 Male Doubling time: 24 hours (PubMed=2158399). 21194184 CVCL_5G80 SK-N-LE cancer cell line human CVCL_5G80 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21194185 CVCL_5G53 LC5-HIV cancer cell line human CVCL_5G53 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Virology: HIV-1 producing cell line Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00516; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-843 Problematic cell line: Contaminated Grand-parent cell line (L-132) has been shown to be a HeLa derivative. 21194186 CVCL_5G52 LC5 cancer cell line human CVCL_5G52 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00515; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-842 Problematic cell line: Contaminated Parent cell line (L-132) has been shown to be a HeLa derivative. 21194187 CVCL_5G51 ROSA KIT Delta 417-419 insY transformed cell line human CVCL_5G51 CL:0000010 Transfected with: HGNC; 6342; KIT (with del 417-419 insY). Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4553 21194188 CVCL_5G50 ROSA KIT D816V transformed cell line human CVCL_5G50 CL:0000010 Transfected with: HGNC; 6342; KIT (with p.Asp816Val). Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4552 21194189 CVCL_5G57 D-259MG cancer cell line human CVCL_5G57 CL:0000010 Derived from sampling site: Brain. Male Doubling time: 46.30 hours (PubMed=2881426) 21194190 CVCL_5G56 U-251MG sp cancer cell line human CVCL_5G56 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male Characteristics: Spindle cell variant obtained by differential trypsinization of parent cell line 21194191 CVCL_5G55 U-1231MG cancer cell line human CVCL_5G55 CL:0000010 Male 21194192 CVCL_5G54 U-1240MG cancer cell line human CVCL_5G54 CL:0000010 Male 21194193 CVCL_5G59 ONS-21-C2 cancer cell line human CVCL_5G59 CL:0000010 Population: Japanese; Derived from sampling site: Brain. Male 21194194 CVCL_5G58 ONS-21 cancer cell line human CVCL_5G58 CL:0000010 Population: Japanese; Derived from sampling site: Brain. Male 21194195 CVCL_5G64 IPSB-18 cancer cell line human CVCL_5G64 CL:0000010 Male 21194196 CVCL_5G63 U-251MG AgCl1 cancer cell line human CVCL_5G63 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu242Valfs*15 (c.723_724dupTG); ClinVar=VCV000536553; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Brain; parietal lobe. Male 21194197 CVCL_5G62 D-18MG cancer cell line human CVCL_5G62 CL:0000010 Female 21194198 CVCL_5G61 U-1796MG cancer cell line human CVCL_5G61 CL:0000010 Miscellaneous: Sex of donor from personal communication of Westermark B. Female 21194199 CVCL_5G68 IPPS-11 cancer cell line human CVCL_5G68 CL:0000010 21194200 CVCL_5G67 IPNN-8 cancer cell line human CVCL_5G67 CL:0000010 Derived from sampling site: Brain; fourth ventricle. Male Doubling time: 24 hours (PubMed=9428346) 21194201 CVCL_5G66 IPRM-5 cancer cell line human CVCL_5G66 CL:0000010 Derived from sampling site: Brain; frontal lobe. Female 21194202 CVCL_5G65 IPNT-H cancer cell line human CVCL_5G65 CL:0000010 Derived from sampling site: Brain; hypothalamus. Male Doubling time: 27 hours (PubMed=9428346) 21194203 CVCL_5G69 IPTR-6 cancer cell line human CVCL_5G69 CL:0000010 21194204 CVCL_XM90 HAP1 CNP (-) 2 cancer cell line human CVCL_XM90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2158; CNP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194205 CVCL_XM94 HAP1 COX6A1 (-) cancer cell line human CVCL_XM94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2277; COX6A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194206 CVCL_XM93 HAP1 COL4A3BP (-) 2 cancer cell line human CVCL_XM93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2205; CERT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194207 CVCL_XM92 HAP1 COL1A1 (-) 2 cancer cell line human CVCL_XM92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2197; COL1A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194208 CVCL_XM91 HAP1 CNTNAP1 (-) 2 cancer cell line human CVCL_XM91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8011; CNTNAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194209 CVCL_XM98 HAP1 CSF1 (-) 4 cancer cell line human CVCL_XM98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194210 CVCL_XM97 HAP1 CSF1 (-) 3 cancer cell line human CVCL_XM97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194211 CVCL_XM96 HAP1 CSF1 (-) 2 cancer cell line human CVCL_XM96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2432; CSF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194212 CVCL_XM95 HAP1 CREBBP (-) 2 cancer cell line human CVCL_XM95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2348; CREBBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194213 CVCL_XM99 HAP1 CTH (-) 2 cancer cell line human CVCL_XM99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2501; CTH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194214 CVCL_5G60 U-372MG cancer cell line human CVCL_5G60 CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 21194215 CVCL_FY49 ND07473 transformed cell line human CVCL_FY49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194216 CVCL_FY48 ND07472 transformed cell line human CVCL_FY48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194217 CVCL_FY47 ND07415 transformed cell line human CVCL_FY47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194218 CVCL_FY46 ND07316 transformed cell line human CVCL_FY46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194219 CVCL_FY41 ND07152 transformed cell line human CVCL_FY41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194220 CVCL_FY40 ND07027 transformed cell line human CVCL_FY40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194221 CVCL_FY45 ND07283 transformed cell line human CVCL_FY45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194222 CVCL_FY44 ND07282 transformed cell line human CVCL_FY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194223 CVCL_FY43 ND07246 transformed cell line human CVCL_FY43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194224 CVCL_FY42 ND07165 transformed cell line human CVCL_FY42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194225 CVCL_FY59 ND07719 transformed cell line human CVCL_FY59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194226 CVCL_FY58 ND07707 transformed cell line human CVCL_FY58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194227 CVCL_FY57 ND07668 transformed cell line human CVCL_FY57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194228 CVCL_FY52 ND07521 transformed cell line human CVCL_FY52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194229 CVCL_FY51 ND07506 transformed cell line human CVCL_FY51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194230 CVCL_FY50 ND07504 transformed cell line human CVCL_FY50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194231 CVCL_FY56 ND07646 transformed cell line human CVCL_FY56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194232 CVCL_FY55 ND07638 transformed cell line human CVCL_FY55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194233 CVCL_FY54 ND07630 transformed cell line human CVCL_FY54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194234 CVCL_FY53 ND07595 transformed cell line human CVCL_FY53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194235 CVCL_FY27 ND06621 transformed cell line human CVCL_FY27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194236 CVCL_FY26 ND06577 transformed cell line human CVCL_FY26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194237 CVCL_FY25 ND06575 transformed cell line human CVCL_FY25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194238 CVCL_FY24 ND06524 transformed cell line human CVCL_FY24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194239 CVCL_FY29 ND06627 transformed cell line human CVCL_FY29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194240 CVCL_FY28 ND06623 transformed cell line human CVCL_FY28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194241 CVCL_FY23 ND06505 transformed cell line human CVCL_FY23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194242 CVCL_FY22 ND06458 transformed cell line human CVCL_FY22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194243 CVCL_FY21 ND06407 transformed cell line human CVCL_FY21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194244 CVCL_FY20 ND06405 transformed cell line human CVCL_FY20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194245 CVCL_FY38 ND06951 transformed cell line human CVCL_FY38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194246 CVCL_FY37 ND06949 transformed cell line human CVCL_FY37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194247 CVCL_FY36 ND06948 transformed cell line human CVCL_FY36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194248 CVCL_FY35 ND06906 transformed cell line human CVCL_FY35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194249 CVCL_FY39 ND06985 transformed cell line human CVCL_FY39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194250 CVCL_FY30 ND06628 transformed cell line human CVCL_FY30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194251 CVCL_FY34 ND06829 transformed cell line human CVCL_FY34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194252 CVCL_FY33 ND06819 transformed cell line human CVCL_FY33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194253 CVCL_FY32 ND06682 transformed cell line human CVCL_FY32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194254 CVCL_FY31 ND06657 transformed cell line human CVCL_FY31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194255 CVCL_FY05 ND05919 transformed cell line human CVCL_FY05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194256 CVCL_FY04 ND05918 transformed cell line human CVCL_FY04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194257 CVCL_FY03 ND05916 transformed cell line human CVCL_FY03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194258 CVCL_FY02 ND05902 transformed cell line human CVCL_FY02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194259 CVCL_FY09 ND05940 transformed cell line human CVCL_FY09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194260 CVCL_FY08 ND05939 transformed cell line human CVCL_FY08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194261 CVCL_FY07 ND05938 transformed cell line human CVCL_FY07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194262 CVCL_FY06 ND05935 transformed cell line human CVCL_FY06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194263 CVCL_FY01 ND05887 transformed cell line human CVCL_FY01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194264 CVCL_FY00 ND05886 transformed cell line human CVCL_FY00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194265 CVCL_FY16 ND06159 transformed cell line human CVCL_FY16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194266 CVCL_FY15 ND06107 transformed cell line human CVCL_FY15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194267 CVCL_FY14 ND06060 transformed cell line human CVCL_FY14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194268 CVCL_FY13 ND06044 transformed cell line human CVCL_FY13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194269 CVCL_FY19 ND06241 transformed cell line human CVCL_FY19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194270 CVCL_FY18 ND06163 transformed cell line human CVCL_FY18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194271 CVCL_FY17 ND06161 transformed cell line human CVCL_FY17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194272 CVCL_FY12 ND06006 transformed cell line human CVCL_FY12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194273 CVCL_FY11 ND05986 transformed cell line human CVCL_FY11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194274 CVCL_FY10 ND05985 transformed cell line human CVCL_FY10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194275 CVCL_P459 GM18502 transformed cell line human CVCL_P459 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194276 CVCL_P458 GM18501 transformed cell line human CVCL_P458 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194277 CVCL_P457 GM18499 transformed cell line human CVCL_P457 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194278 CVCL_P456 GM18498 transformed cell line human CVCL_P456 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194279 CVCL_P455 GM18489 transformed cell line human CVCL_P455 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194280 CVCL_XM03 HAP1 BMP4 (-) 2 cancer cell line human CVCL_XM03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1071; BMP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194281 CVCL_P454 GM18488 transformed cell line human CVCL_P454 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194282 CVCL_XM02 HAP1 BCL7A (-) 3 cancer cell line human CVCL_XM02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1004; BCL7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194283 CVCL_P453 GM18487 transformed cell line human CVCL_P453 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194284 CVCL_XM01 HAP1 BCL7A (-) 2 cancer cell line human CVCL_XM01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1004; BCL7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194285 CVCL_P452 GM18486 transformed cell line human CVCL_P452 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194286 CVCL_XM00 HAP1 BCL6 (-) 2 cancer cell line human CVCL_XM00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1001; BCL6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194287 CVCL_P451 GM19795 transformed cell line human CVCL_P451 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194288 CVCL_XM07 HAP1 BPGM (-) 2 cancer cell line human CVCL_XM07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1093; BPGM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194289 CVCL_P450 GM19794 transformed cell line human CVCL_P450 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194290 CVCL_XM06 HAP1 BOLA3 (-) cancer cell line human CVCL_XM06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24415; BOLA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194291 CVCL_XM05 HAP1 BNIP3 (-) 2 cancer cell line human CVCL_XM05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1084; BNIP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194292 CVCL_XM04 HAP1 BMP7 (-) 2 cancer cell line human CVCL_XM04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1074; BMP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194293 CVCL_P469 GM18852 transformed cell line human CVCL_P469 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194294 CVCL_P468 GM18523 transformed cell line human CVCL_P468 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194295 CVCL_P467 GM18522 transformed cell line human CVCL_P467 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194296 CVCL_P466 GM18520 transformed cell line human CVCL_P466 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194297 CVCL_P465 GM18519 transformed cell line human CVCL_P465 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194298 CVCL_P464 GM18517 transformed cell line human CVCL_P464 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194299 CVCL_P463 GM18516 transformed cell line human CVCL_P463 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194300 CVCL_P462 GM18511 transformed cell line human CVCL_P462 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194301 CVCL_P461 GM18510 transformed cell line human CVCL_P461 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194302 CVCL_P460 GM18504 transformed cell line human CVCL_P460 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194303 CVCL_P439 GM19776 transformed cell line human CVCL_P439 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194304 CVCL_P438 GM19774 transformed cell line human CVCL_P438 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194305 CVCL_P437 GM19773 transformed cell line human CVCL_P437 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194306 CVCL_P436 GM19771 transformed cell line human CVCL_P436 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194307 CVCL_P435 GM19770 transformed cell line human CVCL_P435 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194308 CVCL_P434 GM19764 transformed cell line human CVCL_P434 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194309 CVCL_P433 GM19762 transformed cell line human CVCL_P433 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194310 CVCL_P432 GM19761 transformed cell line human CVCL_P432 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194311 CVCL_P431 GM19759 transformed cell line human CVCL_P431 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194312 CVCL_P430 GM19758 transformed cell line human CVCL_P430 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194313 CVCL_P449 GM19792 transformed cell line human CVCL_P449 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194314 CVCL_P448 GM19789 transformed cell line human CVCL_P448 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194315 CVCL_P447 GM19788 transformed cell line human CVCL_P447 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194316 CVCL_P446 GM19786 transformed cell line human CVCL_P446 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194317 CVCL_P445 GM19785 transformed cell line human CVCL_P445 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194318 CVCL_P444 GM19783 transformed cell line human CVCL_P444 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194319 CVCL_P443 GM19782 transformed cell line human CVCL_P443 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194320 CVCL_P442 GM19780 transformed cell line human CVCL_P442 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194321 CVCL_P441 GM19779 transformed cell line human CVCL_P441 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194322 CVCL_P440 GM19777 transformed cell line human CVCL_P440 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194323 CVCL_FY85 ND08717 transformed cell line human CVCL_FY85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194324 CVCL_FY84 ND08676 transformed cell line human CVCL_FY84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194325 CVCL_FY83 ND08666 transformed cell line human CVCL_FY83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194326 CVCL_FY82 ND08628 transformed cell line human CVCL_FY82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194327 CVCL_FY89 ND08794 transformed cell line human CVCL_FY89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194328 CVCL_FY88 ND08753 transformed cell line human CVCL_FY88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194329 CVCL_FY87 ND08752 transformed cell line human CVCL_FY87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194330 CVCL_FY86 ND08751 transformed cell line human CVCL_FY86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194331 CVCL_P419 GM19738 transformed cell line human CVCL_P419 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194332 CVCL_P418 GM19737 transformed cell line human CVCL_P418 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194333 CVCL_P417 GM19735 transformed cell line human CVCL_P417 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194334 CVCL_P416 GM19734 transformed cell line human CVCL_P416 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194335 CVCL_P415 GM19732 transformed cell line human CVCL_P415 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194336 CVCL_FY81 ND08508 transformed cell line human CVCL_FY81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194337 CVCL_P414 GM19731 transformed cell line human CVCL_P414 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194338 CVCL_FY80 ND08476 transformed cell line human CVCL_FY80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194339 CVCL_P413 GM19729 transformed cell line human CVCL_P413 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194340 CVCL_P412 GM19728 transformed cell line human CVCL_P412 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194341 CVCL_P411 GM19726 transformed cell line human CVCL_P411 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194342 CVCL_P410 GM19725 transformed cell line human CVCL_P410 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194343 CVCL_FY96 ND09017 transformed cell line human CVCL_FY96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194344 CVCL_FY95 ND08968 transformed cell line human CVCL_FY95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194345 CVCL_FY94 ND08918 transformed cell line human CVCL_FY94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194346 CVCL_FY93 ND08895 transformed cell line human CVCL_FY93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194347 CVCL_FY99 ND09069 transformed cell line human CVCL_FY99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194348 CVCL_FY98 ND09050 transformed cell line human CVCL_FY98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194349 CVCL_FY97 ND09049 transformed cell line human CVCL_FY97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194350 CVCL_P429 GM19756 transformed cell line human CVCL_P429 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194351 CVCL_P428 GM19755 transformed cell line human CVCL_P428 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194352 CVCL_P427 GM19753 transformed cell line human CVCL_P427 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194353 CVCL_P426 GM19752 transformed cell line human CVCL_P426 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194354 CVCL_FY92 ND08891 transformed cell line human CVCL_FY92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194355 CVCL_P425 GM19750 transformed cell line human CVCL_P425 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194356 CVCL_FY91 ND08835 transformed cell line human CVCL_FY91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194357 CVCL_P424 GM19749 transformed cell line human CVCL_P424 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194358 CVCL_FY90 ND08828 transformed cell line human CVCL_FY90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194359 CVCL_P423 GM19747 transformed cell line human CVCL_P423 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194360 CVCL_P422 GM19746 transformed cell line human CVCL_P422 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194361 CVCL_P421 GM19741 transformed cell line human CVCL_P421 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194362 CVCL_P420 GM19740 transformed cell line human CVCL_P420 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194363 CVCL_FY69 ND08108 transformed cell line human CVCL_FY69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194364 CVCL_FY68 ND08080 transformed cell line human CVCL_FY68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194365 CVCL_FY63 ND07896 transformed cell line human CVCL_FY63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194366 CVCL_FY62 ND07832 transformed cell line human CVCL_FY62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194367 CVCL_FY61 ND07831 transformed cell line human CVCL_FY61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194368 CVCL_FY60 ND07826 transformed cell line human CVCL_FY60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194369 CVCL_FY67 ND08055 transformed cell line human CVCL_FY67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194370 CVCL_FY66 ND07970 transformed cell line human CVCL_FY66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194371 CVCL_FY65 ND07934 transformed cell line human CVCL_FY65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194372 CVCL_FY64 ND07933 transformed cell line human CVCL_FY64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194373 CVCL_FY79 ND08445 transformed cell line human CVCL_FY79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194374 CVCL_FY74 ND08313 transformed cell line human CVCL_FY74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194375 CVCL_FY73 ND08258 transformed cell line human CVCL_FY73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194376 CVCL_FY72 ND08257 transformed cell line human CVCL_FY72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194377 CVCL_FY71 ND08228 transformed cell line human CVCL_FY71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194378 CVCL_FY78 ND08400 transformed cell line human CVCL_FY78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194379 CVCL_FY77 ND08399 transformed cell line human CVCL_FY77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194380 CVCL_FY76 ND08320 transformed cell line human CVCL_FY76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194381 CVCL_P409 GM19723 transformed cell line human CVCL_P409 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194382 CVCL_FY75 ND08316 transformed cell line human CVCL_FY75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194383 CVCL_P408 GM19722 transformed cell line human CVCL_P408 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194384 CVCL_P407 GM19720 transformed cell line human CVCL_P407 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194385 CVCL_P406 GM19719 transformed cell line human CVCL_P406 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194386 CVCL_P405 GM19717 transformed cell line human CVCL_P405 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194387 CVCL_P404 GM19716 transformed cell line human CVCL_P404 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194388 CVCL_FY70 ND08143 transformed cell line human CVCL_FY70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194389 CVCL_P403 GM19685 transformed cell line human CVCL_P403 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194390 CVCL_P402 GM19684 transformed cell line human CVCL_P402 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194391 CVCL_P401 GM19682 transformed cell line human CVCL_P401 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194392 CVCL_P400 GM19681 transformed cell line human CVCL_P400 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194393 CVCL_5H52 SG0101 transformed cell line human CVCL_5H52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194394 CVCL_5H51 SG0100 transformed cell line human CVCL_5H51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194395 CVCL_5H50 SG0099 transformed cell line human CVCL_5H50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194396 CVCL_5H56 SG0107 transformed cell line human CVCL_5H56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194397 CVCL_5H55 SG0105 transformed cell line human CVCL_5H55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194398 CVCL_5H54 SG0104 transformed cell line human CVCL_5H54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194399 CVCL_5H53 SG0102 transformed cell line human CVCL_5H53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194400 CVCL_5H59 SG0112 transformed cell line human CVCL_5H59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194401 CVCL_5H58 SG0111 transformed cell line human CVCL_5H58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194402 CVCL_5H57 SG0109 transformed cell line human CVCL_5H57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194403 CVCL_5H63 SG0118 transformed cell line human CVCL_5H63 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194404 CVCL_5H62 SG0117 transformed cell line human CVCL_5H62 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194405 CVCL_5H61 SG0115 transformed cell line human CVCL_5H61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194406 CVCL_5H60 SG0114 transformed cell line human CVCL_5H60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194407 CVCL_5H67 TC 314 cancer cell line human CVCL_5H67 CL:0000010 Unspecified 21194408 CVCL_5H66 SG0125 transformed cell line human CVCL_5H66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194409 CVCL_5H65 SG0121 transformed cell line human CVCL_5H65 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194410 CVCL_5H64 SG0120 transformed cell line human CVCL_5H64 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194411 CVCL_5H69 UM89-2 embryonic stem cell human CVCL_5H69 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM89-1 PGD (Cellosaurus=CVCL_N809), UM89-3 PGD (Cellosaurus=CVCL_5H70), UM89-4 PGD (Cellosaurus=CVCL_5H71) and UM89-5 PGD (Cellosaurus=CVCL_HF79). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0362 21194412 CVCL_5H68 UM76-2 embryonic stem cell human CVCL_5H68 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM76-1 PGD (Cellosaurus=CVCL_X362). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0361 21194413 CVCL_XN93 HAP1 FRYL (-) 3 cancer cell line human CVCL_XN93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29127; FRYL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194414 CVCL_XN92 HAP1 FRYL (-) 2 cancer cell line human CVCL_XN92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29127; FRYL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194415 CVCL_XN91 HAP1 FOXO1 (-) 3 cancer cell line human CVCL_XN91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194416 CVCL_XN90 HAP1 FOXO1 (-) 2 cancer cell line human CVCL_XN90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194417 CVCL_XN97 HAP1 FUNDC2 (-) 4 cancer cell line human CVCL_XN97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24925; FUNDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194418 CVCL_XN96 HAP1 FUNDC2 (-) 3 cancer cell line human CVCL_XN96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24925; FUNDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194419 CVCL_XN95 HAP1 FUNDC2 (-) 2 cancer cell line human CVCL_XN95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24925; FUNDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194420 CVCL_XN94 HAP1 FTSJ1 (-) 2 cancer cell line human CVCL_XN94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13254; FTSJ1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194421 CVCL_XN99 HAP1 FXR1 (-) 2 cancer cell line human CVCL_XN99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4023; FXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194422 CVCL_XN98 HAP1 FUNDC2 (-) 5 cancer cell line human CVCL_XN98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24925; FUNDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194423 CVCL_5H30 SG0067 transformed cell line human CVCL_5H30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194424 CVCL_5H34 SG0072 transformed cell line human CVCL_5H34 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194425 CVCL_5H33 SG0071 transformed cell line human CVCL_5H33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194426 CVCL_5H32 SG0070 transformed cell line human CVCL_5H32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194427 CVCL_5H31 SG0069 transformed cell line human CVCL_5H31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194428 CVCL_5H38 SG0078 transformed cell line human CVCL_5H38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194429 CVCL_5H37 SG0077 transformed cell line human CVCL_5H37 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194430 CVCL_5H36 SG0074 transformed cell line human CVCL_5H36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194431 CVCL_5H35 SG0073 transformed cell line human CVCL_5H35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194432 CVCL_5H39 SG0080 transformed cell line human CVCL_5H39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194433 CVCL_XN82 HAP1 FMR1 (-) 2 cancer cell line human CVCL_XN82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194434 CVCL_XN81 HAP1 FLOT1 (-) 2 cancer cell line human CVCL_XN81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3757; FLOT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194435 CVCL_XN80 HAP1 FLNA (-) 2 cancer cell line human CVCL_XN80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3754; FLNA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194436 CVCL_XN86 HAP1 FNIP1 (-) cancer cell line human CVCL_XN86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29418; FNIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194437 CVCL_XN85 HAP1 FNDC5 (-) 2 cancer cell line human CVCL_XN85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20240; FNDC5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194438 CVCL_XN84 HAP1 FMR1 (-) 4 cancer cell line human CVCL_XN84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194439 CVCL_XN83 HAP1 FMR1 (-) 3 cancer cell line human CVCL_XN83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3775; FMR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194440 CVCL_XN89 HAP1 FOXA1 (-) 2 cancer cell line human CVCL_XN89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5021; FOXA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194441 CVCL_XN88 HAP1 FOLR1 (-) 2 cancer cell line human CVCL_XN88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3791; FOLR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194442 CVCL_XN87 HAP1 FNIP2 (-) cancer cell line human CVCL_XN87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29280; FNIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194443 CVCL_5H41 SG0082 transformed cell line human CVCL_5H41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194444 CVCL_5H40 SG0081 transformed cell line human CVCL_5H40 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194445 CVCL_5H45 SG0089 transformed cell line human CVCL_5H45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194446 CVCL_5H44 SG0088 transformed cell line human CVCL_5H44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194447 CVCL_5H43 SG0086 transformed cell line human CVCL_5H43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194448 CVCL_5H42 SG0084 transformed cell line human CVCL_5H42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194449 CVCL_5H49 SG0097 transformed cell line human CVCL_5H49 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194450 CVCL_5H48 SG0095 transformed cell line human CVCL_5H48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194451 CVCL_5H47 SG0094 transformed cell line human CVCL_5H47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194452 CVCL_5H46 SG0090 transformed cell line human CVCL_5H46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194453 CVCL_XN71 HAP1 FBXO18 (-) 2 cancer cell line human CVCL_XN71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13620; FBH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194454 CVCL_XN70 HAP1 FAT1 (-) 2 cancer cell line human CVCL_XN70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3595; FAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194455 CVCL_XN75 HAP1 FGFR1 (-) 4 cancer cell line human CVCL_XN75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3688; FGFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194456 CVCL_XN74 HAP1 FGFR1 (-) 3 cancer cell line human CVCL_XN74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3688; FGFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194457 CVCL_XN73 HAP1 FBXW11 (-) 2 cancer cell line human CVCL_XN73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13607; FBXW11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194458 CVCL_XN72 HAP1 FBXO18 (-) 3 cancer cell line human CVCL_XN72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13620; FBH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194459 CVCL_XN79 HAP1 FKBP5 (-) 2 cancer cell line human CVCL_XN79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3721; FKBP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194460 CVCL_XN78 HAP1 FKBP1A (-) 3 cancer cell line human CVCL_XN78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3711; FKBP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194461 CVCL_XN77 HAP1 FKBP1A (-) 2 cancer cell line human CVCL_XN77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3711; FKBP1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194462 CVCL_XN76 HAP1 FGGY (-) 2 cancer cell line human CVCL_XN76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25610; FGGY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194463 CVCL_5H12 SG0034 transformed cell line human CVCL_5H12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194464 CVCL_5H11 SG0030 transformed cell line human CVCL_5H11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194465 CVCL_5H10 SG0026 transformed cell line human CVCL_5H10 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194466 CVCL_5H16 SG0041 transformed cell line human CVCL_5H16 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194467 CVCL_5H15 SG0040 transformed cell line human CVCL_5H15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194468 CVCL_5H14 SG0038 transformed cell line human CVCL_5H14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194469 CVCL_5H13 SG0035 transformed cell line human CVCL_5H13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194470 CVCL_5H19 SG0052 transformed cell line human CVCL_5H19 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194471 CVCL_5H18 SG0046 transformed cell line human CVCL_5H18 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194472 CVCL_5H17 SG0042 transformed cell line human CVCL_5H17 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194473 CVCL_XN60 HAP1 EZR (-) 2 cancer cell line human CVCL_XN60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12691; EZR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194474 CVCL_XN64 HAP1 FAM134B (-) 2 cancer cell line human CVCL_XN64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25964; RETREG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194475 CVCL_XN63 HAP1 FAM122A (-) 2 cancer cell line human CVCL_XN63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23490; PABIR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194476 CVCL_XN62 HAP1 F2RL1 (-) 2 cancer cell line human CVCL_XN62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3538; F2RL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194477 CVCL_XN61 HAP1 F11R (-) 2 cancer cell line human CVCL_XN61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14685; F11R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194478 CVCL_XN68 HAP1 FASTKD2 (-) 1 cancer cell line human CVCL_XN68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29160; FASTKD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194479 CVCL_XN67 HAP1 FAM20B (-) cancer cell line human CVCL_XN67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23017; FAM20B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194480 CVCL_XN66 HAP1 FAM168A (-) cancer cell line human CVCL_XN66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28999; FAM168A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194481 CVCL_XN65 HAP1 FAM136A (-) 2 cancer cell line human CVCL_XN65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25911; FAM136A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194482 CVCL_XN69 HAP1 FASTKD3 (-) 2 cancer cell line human CVCL_XN69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28758; FASTKD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194483 CVCL_5H23 SG0058 transformed cell line human CVCL_5H23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194484 CVCL_5H22 SG0057 transformed cell line human CVCL_5H22 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194485 CVCL_5H21 SG0055 transformed cell line human CVCL_5H21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194486 CVCL_5H20 SG0054 transformed cell line human CVCL_5H20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194487 CVCL_5H27 SG0063 transformed cell line human CVCL_5H27 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194488 CVCL_5H26 SG0062 transformed cell line human CVCL_5H26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194489 CVCL_5H25 SG0060 transformed cell line human CVCL_5H25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194490 CVCL_5H24 SG0059 transformed cell line human CVCL_5H24 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194491 CVCL_5H29 SG0066 transformed cell line human CVCL_5H29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194492 CVCL_5H28 SG0064 transformed cell line human CVCL_5H28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194493 CVCL_XN53 HAP1 ESR1 (-) 1 cancer cell line human CVCL_XN53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3467; ESR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194494 CVCL_XN52 HAP1 ERN1 (-) 2 cancer cell line human CVCL_XN52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3449; ERN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC000742c018; probable Male Group: Haploid karyotype cell line 21194495 CVCL_XN51 HAP1 ERCC6L2 (-) 2 cancer cell line human CVCL_XN51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26922; ERCC6L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194496 CVCL_XN50 HAP1 ERAP1 (-) cancer cell line human CVCL_XN50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18173; ERAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194497 CVCL_XN57 HAP1 EXO1 (-) 2 cancer cell line human CVCL_XN57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3511; EXO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194498 CVCL_XN56 HAP1 ETHE1 (-) cancer cell line human CVCL_XN56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23287; ETHE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194499 CVCL_XN55 HAP1 ESRRA (-) 2 cancer cell line human CVCL_XN55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3471; ESRRA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194500 CVCL_XN54 HAP1 ESR2 (-) cancer cell line human CVCL_XN54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3468; ESR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194501 CVCL_XN59 HAP1 EXOG (-) cancer cell line human CVCL_XN59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3347; EXOG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194502 CVCL_XN58 HAP1 EXO5 (-) 2 cancer cell line human CVCL_XN58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26115; EXO5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194503 CVCL_XN42 HAP1 ELOVL1 (-) 4 cancer cell line human CVCL_XN42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14418; ELOVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194504 CVCL_XN41 HAP1 ELOVL1 (-) 3 cancer cell line human CVCL_XN41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14418; ELOVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194505 CVCL_XN40 HAP1 ELOVL1 (-) 2 cancer cell line human CVCL_XN40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14418; ELOVL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194506 CVCL_P599 GM20542 transformed cell line human CVCL_P599 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194507 CVCL_P598 GM20541 transformed cell line human CVCL_P598 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194508 CVCL_XN46 HAP1 ENTPD1 (-) 2 cancer cell line human CVCL_XN46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3363; ENTPD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194509 CVCL_P597 GM20540 transformed cell line human CVCL_P597 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194510 CVCL_XN45 HAP1 EMD (-) 4 cancer cell line human CVCL_XN45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3331; EMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194511 CVCL_P596 GM20539 transformed cell line human CVCL_P596 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194512 CVCL_XN44 HAP1 EMD (-) 3 cancer cell line human CVCL_XN44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3331; EMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194513 CVCL_P595 GM20538 transformed cell line human CVCL_P595 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194514 CVCL_XN43 HAP1 EMD (-) 2 cancer cell line human CVCL_XN43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3331; EMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194515 CVCL_P594 GM20537 transformed cell line human CVCL_P594 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194516 CVCL_P593 GM20536 transformed cell line human CVCL_P593 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194517 CVCL_XN49 HAP1 EPSTI1 (-) cancer cell line human CVCL_XN49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16465; EPSTI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194518 CVCL_P592 GM20535 transformed cell line human CVCL_P592 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194519 CVCL_XN48 HAP1 EPS15 (-) 2 cancer cell line human CVCL_XN48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3419; EPS15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194520 CVCL_P591 GM20534 transformed cell line human CVCL_P591 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194521 CVCL_XN47 HAP1 EP400 (-) cancer cell line human CVCL_XN47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11958; EP400; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194522 CVCL_XN29 HAP1 DHX40 (-) cancer cell line human CVCL_XN29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18018; DHX40; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194523 CVCL_5H01 SG0004 transformed cell line human CVCL_5H01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194524 CVCL_5H00 SG0003 transformed cell line human CVCL_5H00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194525 CVCL_5H05 SG0015 transformed cell line human CVCL_5H05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194526 CVCL_5H04 SG0010 transformed cell line human CVCL_5H04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194527 CVCL_5H03 SG0008 transformed cell line human CVCL_5H03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194528 CVCL_5H02 SG0005 transformed cell line human CVCL_5H02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194529 CVCL_5H09 SG0024 transformed cell line human CVCL_5H09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194530 CVCL_5H08 SG0022 transformed cell line human CVCL_5H08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194531 CVCL_5H07 SG0020 transformed cell line human CVCL_5H07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194532 CVCL_5H06 SG0018 transformed cell line human CVCL_5H06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: ECACC randomly selected UK Caucasian blood donors cell line selection 21194533 CVCL_XN31 HAP1 DSG2 (-) 2 cancer cell line human CVCL_XN31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3049; DSG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194534 CVCL_XN30 HAP1 DLAT (-) 2 cancer cell line human CVCL_XN30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2896; DLAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194535 CVCL_XN35 HAP1 ECHS1 (-) 1 cancer cell line human CVCL_XN35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3151; ECHS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194536 CVCL_XN34 HAP1 ECH1 (-) 3 cancer cell line human CVCL_XN34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3149; ECH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194537 CVCL_XN33 HAP1 ECH1 (-) 2 cancer cell line human CVCL_XN33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3149; ECH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194538 CVCL_XN32 HAP1 E2F8 (-) 2 cancer cell line human CVCL_XN32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24727; E2F8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194539 CVCL_XN39 HAP1 ELK1 (-) 2 cancer cell line human CVCL_XN39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3321; ELK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194540 CVCL_XN38 HAP1 EGR1 (-) cancer cell line human CVCL_XN38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3238; EGR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194541 CVCL_XN37 HAP1 EGLN2 (-) cancer cell line human CVCL_XN37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14660; EGLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194542 CVCL_XN36 HAP1 ECI2 (-) 2 cancer cell line human CVCL_XN36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14601; ECI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194543 CVCL_5H96 GL22 cancer cell line human CVCL_5H96 CL:0000010 Male 21194544 CVCL_5H95 GL15 cancer cell line human CVCL_5H95 CL:0000010 Male 21194545 CVCL_5H94 MOCH-1 transformed cell line house mouse CVCL_5H94 CL:0000010 Transfected with: RGD; 2561; Erbb2 Transformant: Activated Erbb2/neu; Breed/subspecies: (C57BL/6 x DBA/2) F2 transgenic. Doubling time: ~2 days (PubMed=1377283) 21194546 CVCL_5H93 ROC-1 hybrid cell line Norway rat CVCL_5H93 CL:0000010 21194547 CVCL_5H99 LMS04 cancer cell line human CVCL_5H99 CL:0000010 Female 21194548 CVCL_5H98 LMS03 cancer cell line human CVCL_5H98 CL:0000010 21194549 CVCL_5H97 J82-EBV transformed cell line human CVCL_5H97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: SNP array analysis Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21194550 CVCL_5H92 tsU19-5 conditionally immortalized cell line Norway rat CVCL_5H92 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [U19tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Optic nerve Cell type=Oligodendrocyte precursor cell.; Breed/subspecies: Sprague Dawley. Unspecified Doubling time: 24-36 hours (PubMed=1628212) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9729 21194551 CVCL_5H91 CO-13-7 hybrid cell line Norway rat CVCL_5H91 CL:0000010 21194552 CVCL_5H90 C6TK- cancer cell line Norway rat CVCL_5H90 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male 21194553 CVCL_5H74 UM126-2 embryonic stem cell human CVCL_5H74 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0356. 21194554 CVCL_5H73 UM14-3 embryonic stem cell human CVCL_5H73 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0355. 21194555 CVCL_5H72 UM141-6 PGD embryonic stem cell human CVCL_5H72 From: University of Michigan; Ann Arbor; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0360. 21194556 CVCL_5H71 UM89-4 PGD embryonic stem cell human CVCL_5H71 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM89-1 PGD (Cellosaurus=CVCL_N809), UM89-2 PGD (Cellosaurus=CVCL_5H69), UM89-3 PGD (Cellosaurus=CVCL_5H70) and UM89-5 PGD (Cellosaurus=CVCL_HF79). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0359 21194557 CVCL_5H78 UM59-4 PGD embryonic stem cell human CVCL_5H78 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM59-2 PGD (Cellosaurus=CVCL_N808). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0357 21194558 CVCL_5H77 UM4-9 embryonic stem cell human CVCL_5H77 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM4-6 (Cellosaurus=CVCL_B840), UM4-11 (Cellosaurus=CVCL_5H75), UM4-12 (Cellosaurus=CVCL_5H76) and UM4-13 (Cellosaurus=CVCL_WW08). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0352 21194559 CVCL_5H76 UM4-12 embryonic stem cell human CVCL_5H76 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM4-6 (Cellosaurus=CVCL_B840), UM4-9 (Cellosaurus=CVCL_5H77), UM4-11 (Cellosaurus=CVCL_5H75) and UM4-13 (Cellosaurus=CVCL_WW08). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0354 21194560 CVCL_5H75 UM4-11 embryonic stem cell human CVCL_5H75 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM4-6 (Cellosaurus=CVCL_B840), UM4-9 (Cellosaurus=CVCL_5H77), UM4-12 (Cellosaurus=CVCL_5H76) and UM4-13 (Cellosaurus=CVCL_WW08). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0353 21194561 CVCL_5H79 CCRF-CEM/HU-R cancer cell line human CVCL_5H79 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194562 CVCL_5H70 UM89-3 PGD embryonic stem cell human CVCL_5H70 From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to those giving rise to UM89-1 PGD (Cellosaurus=CVCL_N809), UM89-2 PGD (Cellosaurus=CVCL_5H69), UM89-4 PGD (Cellosaurus=CVCL_5H71) and UM89-5 PGD (Cellosaurus=CVCL_HF79). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-16-0358 21194563 CVCL_5H85 CCRF-CEM/MTX5000-PGA cancer cell line human CVCL_5H85 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194564 CVCL_5H84 CCRF-CEM/MTX1500-LV cancer cell line human CVCL_5H84 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194565 CVCL_5H83 CCRF-CEM/MTX140-LV cancer cell line human CVCL_5H83 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194566 CVCL_5H82 CCRF-CEM/MTX R3 cancer cell line human CVCL_5H82 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194567 CVCL_5H89 LSC-AXC-C/3 cancer cell line Norway rat CVCL_5H89 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: AXC. Male 21194568 CVCL_5H88 LSC-AXC-T/5 cancer cell line Norway rat CVCL_5H88 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: AXC. Male 21194569 CVCL_5H87 SK-5 finite cell line human CVCL_5H87 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 21194570 CVCL_5H86 CCRF-CEM/MTX60-PGA cancer cell line human CVCL_5H86 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194571 CVCL_5H81 CCRF-CEM/MTX R2 cancer cell line human CVCL_5H81 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194572 CVCL_5H80 CCRF-CEM/MTX R1 cancer cell line human CVCL_5H80 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21194573 CVCL_FZ69 ND15770 transformed cell line human CVCL_FZ69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194574 CVCL_FZ68 ND15722 transformed cell line human CVCL_FZ68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194575 CVCL_FZ67 ND15721 transformed cell line human CVCL_FZ67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194576 CVCL_FZ62 ND14830 transformed cell line human CVCL_FZ62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194577 CVCL_FZ61 ND14805 transformed cell line human CVCL_FZ61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194578 CVCL_FZ60 ND14788 transformed cell line human CVCL_FZ60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194579 CVCL_FZ66 ND15596 transformed cell line human CVCL_FZ66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194580 CVCL_FZ65 ND15246 transformed cell line human CVCL_FZ65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194581 CVCL_FZ64 ND15164 transformed cell line human CVCL_FZ64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194582 CVCL_FZ63 ND15085 transformed cell line human CVCL_FZ63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194583 CVCL_FZ79 ND22290 transformed cell line human CVCL_FZ79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194584 CVCL_FZ78 ND22288 transformed cell line human CVCL_FZ78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194585 CVCL_FZ73 ND19188 transformed cell line human CVCL_FZ73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194586 CVCL_FZ72 ND16710 transformed cell line human CVCL_FZ72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194587 CVCL_FZ71 ND16268 transformed cell line human CVCL_FZ71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194588 CVCL_FZ70 ND16097 transformed cell line human CVCL_FZ70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194589 CVCL_FZ77 ND22287 transformed cell line human CVCL_FZ77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194590 CVCL_FZ76 ND22281 transformed cell line human CVCL_FZ76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194591 CVCL_P509 GM19114 transformed cell line human CVCL_P509 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194592 CVCL_FZ75 ND22276 transformed cell line human CVCL_FZ75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194593 CVCL_P508 GM19113 transformed cell line human CVCL_P508 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194594 CVCL_FZ74 ND22263 transformed cell line human CVCL_FZ74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194595 CVCL_P507 GM19108 transformed cell line human CVCL_P507 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194596 CVCL_P506 GM19107 transformed cell line human CVCL_P506 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194597 CVCL_P505 GM19105 transformed cell line human CVCL_P505 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194598 CVCL_P504 GM19102 transformed cell line human CVCL_P504 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194599 CVCL_P503 GM19101 transformed cell line human CVCL_P503 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: DNA methylation analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194600 CVCL_P502 GM19098 transformed cell line human CVCL_P502 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194601 CVCL_P501 GM19096 transformed cell line human CVCL_P501 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194602 CVCL_P500 GM19095 transformed cell line human CVCL_P500 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194603 CVCL_FZ48 ND12153 transformed cell line human CVCL_FZ48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194604 CVCL_FZ47 ND11961 transformed cell line human CVCL_FZ47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194605 CVCL_FZ46 ND11832 transformed cell line human CVCL_FZ46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194606 CVCL_FZ45 ND11569 transformed cell line human CVCL_FZ45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194607 CVCL_FZ49 ND12466 transformed cell line human CVCL_FZ49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194608 CVCL_FZ40 ND10998 transformed cell line human CVCL_FZ40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194609 CVCL_FZ44 ND11478 transformed cell line human CVCL_FZ44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194610 CVCL_FZ43 ND11476 transformed cell line human CVCL_FZ43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194611 CVCL_FZ42 ND11100 transformed cell line human CVCL_FZ42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194612 CVCL_FZ41 ND11001 transformed cell line human CVCL_FZ41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194613 CVCL_FZ59 ND13878 transformed cell line human CVCL_FZ59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194614 CVCL_FZ58 ND13658 transformed cell line human CVCL_FZ58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194615 CVCL_FZ57 ND13407 transformed cell line human CVCL_FZ57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194616 CVCL_FZ56 ND13270 transformed cell line human CVCL_FZ56 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194617 CVCL_FZ51 ND12688 transformed cell line human CVCL_FZ51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194618 CVCL_FZ50 ND12582 transformed cell line human CVCL_FZ50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194619 CVCL_FZ55 ND13269 transformed cell line human CVCL_FZ55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194620 CVCL_FZ54 ND13205 transformed cell line human CVCL_FZ54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194621 CVCL_FZ53 ND12762 transformed cell line human CVCL_FZ53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194622 CVCL_FZ52 ND12690 transformed cell line human CVCL_FZ52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194623 CVCL_FZ26 ND10065 transformed cell line human CVCL_FZ26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194624 CVCL_FZ25 ND10064 transformed cell line human CVCL_FZ25 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194625 CVCL_FZ24 ND10034 transformed cell line human CVCL_FZ24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194626 CVCL_FZ23 ND09753 transformed cell line human CVCL_FZ23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194627 CVCL_FZ29 ND10193 transformed cell line human CVCL_FZ29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194628 CVCL_FZ28 ND10170 transformed cell line human CVCL_FZ28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194629 CVCL_FZ27 ND10115 transformed cell line human CVCL_FZ27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194630 CVCL_FZ22 ND09752 transformed cell line human CVCL_FZ22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194631 CVCL_FZ21 ND09751 transformed cell line human CVCL_FZ21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194632 CVCL_FZ20 ND09750 transformed cell line human CVCL_FZ20 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194633 CVCL_FZ37 ND10640 transformed cell line human CVCL_FZ37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194634 CVCL_FZ36 ND10639 transformed cell line human CVCL_FZ36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194635 CVCL_FZ35 ND10638 transformed cell line human CVCL_FZ35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194636 CVCL_FZ34 ND10522 transformed cell line human CVCL_FZ34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194637 CVCL_FZ39 ND10716 transformed cell line human CVCL_FZ39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194638 CVCL_FZ38 ND10673 transformed cell line human CVCL_FZ38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194639 CVCL_FZ33 ND10459 transformed cell line human CVCL_FZ33 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194640 CVCL_FZ32 ND10320 transformed cell line human CVCL_FZ32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194641 CVCL_FZ31 ND10319 transformed cell line human CVCL_FZ31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194642 CVCL_FZ30 ND10200 transformed cell line human CVCL_FZ30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194643 CVCL_FZ04 ND09164 transformed cell line human CVCL_FZ04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194644 CVCL_FZ03 ND09133 transformed cell line human CVCL_FZ03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194645 CVCL_FZ02 ND09129 transformed cell line human CVCL_FZ02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194646 CVCL_FZ01 ND09109 transformed cell line human CVCL_FZ01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194647 CVCL_FZ08 ND09257 transformed cell line human CVCL_FZ08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194648 CVCL_FZ07 ND09248 transformed cell line human CVCL_FZ07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194649 CVCL_FZ06 ND09167 transformed cell line human CVCL_FZ06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194650 CVCL_FZ05 ND09166 transformed cell line human CVCL_FZ05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194651 CVCL_FZ00 ND09082 transformed cell line human CVCL_FZ00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194652 CVCL_FZ15 ND09483 transformed cell line human CVCL_FZ15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194653 CVCL_FZ14 ND09431 transformed cell line human CVCL_FZ14 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194654 CVCL_FZ13 ND09387 transformed cell line human CVCL_FZ13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194655 CVCL_FZ12 ND09312 transformed cell line human CVCL_FZ12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194656 CVCL_FZ19 ND09748 transformed cell line human CVCL_FZ19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194657 CVCL_FZ18 ND09665 transformed cell line human CVCL_FZ18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194658 CVCL_FZ17 ND09593 transformed cell line human CVCL_FZ17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194659 CVCL_FZ16 ND09505 transformed cell line human CVCL_FZ16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194660 CVCL_FZ11 ND09311 transformed cell line human CVCL_FZ11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194661 CVCL_FZ10 ND09303 transformed cell line human CVCL_FZ10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194662 CVCL_FZ09 ND09261 transformed cell line human CVCL_FZ09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194663 CVCL_XN19 HAP1 DDX1 (-) 2 cancer cell line human CVCL_XN19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2734; DDX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194664 CVCL_XN18 HAP1 DDHD2 (-) cancer cell line human CVCL_XN18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29106; DDHD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194665 CVCL_XN20 HAP1 DDX17 (-) cancer cell line human CVCL_XN20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2740; DDX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194666 CVCL_P579 GM20521 transformed cell line human CVCL_P579 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194667 CVCL_P578 GM20520 transformed cell line human CVCL_P578 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194668 CVCL_P577 GM20519 transformed cell line human CVCL_P577 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194669 CVCL_P576 GM20518 transformed cell line human CVCL_P576 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194670 CVCL_XN24 HAP1 DHODH (-) cancer cell line human CVCL_XN24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2867; DHODH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194671 CVCL_P575 GM20517 transformed cell line human CVCL_P575 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194672 CVCL_XN23 HAP1 DHCR7 (-) 2 cancer cell line human CVCL_XN23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2860; DHCR7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194673 CVCL_P574 GM20516 transformed cell line human CVCL_P574 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194674 CVCL_XN22 HAP1 DGUOK (-) 1 cancer cell line human CVCL_XN22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2858; DGUOK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194675 CVCL_P573 GM20515 transformed cell line human CVCL_P573 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194676 CVCL_XN21 HAP1 DDX5 (-) 2 cancer cell line human CVCL_XN21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2746; DDX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194677 CVCL_P572 GM20514 transformed cell line human CVCL_P572 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194678 CVCL_XN28 HAP1 DHTKD1 (-) 1 cancer cell line human CVCL_XN28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23537; DHTKD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194679 CVCL_P571 GM20513 transformed cell line human CVCL_P571 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194680 CVCL_XN27 HAP1 DHRS1 (-) 4 cancer cell line human CVCL_XN27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16445; DHRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194681 CVCL_P570 GM20512 transformed cell line human CVCL_P570 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194682 CVCL_XN26 HAP1 DHRS1 (-) 3 cancer cell line human CVCL_XN26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16445; DHRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194683 CVCL_XN25 HAP1 DHRS1 (-) 2 cancer cell line human CVCL_XN25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16445; DHRS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194684 CVCL_P590 GM20533 transformed cell line human CVCL_P590 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194685 CVCL_XN09 HAP1 DALRD3 (-) cancer cell line human CVCL_XN09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25536; DALRD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194686 CVCL_XN08 HAP1 CYR61 (-) 3 cancer cell line human CVCL_XN08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2654; CCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194687 CVCL_XN07 HAP1 CYR61 (-) 2 cancer cell line human CVCL_XN07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2654; CCN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194688 CVCL_P589 GM20532 transformed cell line human CVCL_P589 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194689 CVCL_P588 GM20531 transformed cell line human CVCL_P588 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194690 CVCL_P587 GM20530 transformed cell line human CVCL_P587 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194691 CVCL_XN13 HAP1 DCAKD (-) 4 cancer cell line human CVCL_XN13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26238; DCAKD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194692 CVCL_P586 GM20529 transformed cell line human CVCL_P586 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194693 CVCL_XN12 HAP1 DCAKD (-) 3 cancer cell line human CVCL_XN12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26238; DCAKD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194694 CVCL_P585 GM20528 transformed cell line human CVCL_P585 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194695 CVCL_XN11 HAP1 DCAKD (-) 2 cancer cell line human CVCL_XN11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26238; DCAKD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194696 CVCL_P584 GM20527 transformed cell line human CVCL_P584 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194697 CVCL_XN10 HAP1 DBN1 (-) 2 cancer cell line human CVCL_XN10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2695; DBN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194698 CVCL_P583 GM20526 transformed cell line human CVCL_P583 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194699 CVCL_XN17 HAP1 DCTD (-) cancer cell line human CVCL_XN17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2710; DCTD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194700 CVCL_P582 GM20525 transformed cell line human CVCL_P582 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194701 CVCL_XN16 HAP1 DCLK2 (-) cancer cell line human CVCL_XN16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19002; DCLK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194702 CVCL_P581 GM20524 transformed cell line human CVCL_P581 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194703 CVCL_XN15 HAP1 DCK (-) 2 cancer cell line human CVCL_XN15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2704; DCK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194704 CVCL_P580 GM20522 transformed cell line human CVCL_P580 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194705 CVCL_XN14 HAP1 DCAKD (-) 5 cancer cell line human CVCL_XN14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26238; DCAKD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194706 CVCL_P559 GM19256 transformed cell line human CVCL_P559 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194707 CVCL_P558 GM19248 transformed cell line human CVCL_P558 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194708 CVCL_P557 GM19247 transformed cell line human CVCL_P557 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194709 CVCL_P556 GM19236 transformed cell line human CVCL_P556 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194710 CVCL_P555 GM19235 transformed cell line human CVCL_P555 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Quadruplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Homozygous (PubMed=33197628) Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194711 CVCL_P554 GM19225 transformed cell line human CVCL_P554 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194712 CVCL_XN02 HAP1 CTSB (-) 2 cancer cell line human CVCL_XN02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194713 CVCL_P553 GM19223 transformed cell line human CVCL_P553 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194714 CVCL_XN01 HAP1 CTNS (-) 2 cancer cell line human CVCL_XN01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2518; CTNS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194715 CVCL_P552 GM19222 transformed cell line human CVCL_P552 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194716 CVCL_XN00 HAP1 CTNNA1 (-) 2 cancer cell line human CVCL_XN00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2509; CTNNA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194717 CVCL_P551 GM19214 transformed cell line human CVCL_P551 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194718 CVCL_P550 GM19213 transformed cell line human CVCL_P550 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194719 CVCL_XN06 HAP1 CYP19A1 (-) cancer cell line human CVCL_XN06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2594; CYP19A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194720 CVCL_XN05 HAP1 CYC1 (-) cancer cell line human CVCL_XN05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2579; CYC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194721 CVCL_XN04 HAP1 CXADR (-) 2 cancer cell line human CVCL_XN04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2559; CXADR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194722 CVCL_XN03 HAP1 CTSB (-) 3 cancer cell line human CVCL_XN03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21194723 CVCL_P569 GM20510 transformed cell line human CVCL_P569 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194724 CVCL_P568 GM20509 transformed cell line human CVCL_P568 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194725 CVCL_P567 GM20508 transformed cell line human CVCL_P567 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194726 CVCL_P566 GM20507 transformed cell line human CVCL_P566 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194727 CVCL_P565 GM20506 transformed cell line human CVCL_P565 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194728 CVCL_P564 GM20505 transformed cell line human CVCL_P564 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194729 CVCL_P563 GM20504 transformed cell line human CVCL_P563 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194730 CVCL_P562 GM20503 transformed cell line human CVCL_P562 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194731 CVCL_P561 GM20502 transformed cell line human CVCL_P561 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194732 CVCL_P560 GM19257 transformed cell line human CVCL_P560 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194733 CVCL_P539 GM19189 transformed cell line human CVCL_P539 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194734 CVCL_P538 GM19185 transformed cell line human CVCL_P538 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194735 CVCL_P537 GM19184 transformed cell line human CVCL_P537 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194736 CVCL_P536 GM19175 transformed cell line human CVCL_P536 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194737 CVCL_P535 GM19172 transformed cell line human CVCL_P535 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194738 CVCL_P534 GM19171 transformed cell line human CVCL_P534 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194739 CVCL_P533 GM19160 transformed cell line human CVCL_P533 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194740 CVCL_P532 GM19159 transformed cell line human CVCL_P532 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194741 CVCL_P531 GM19153 transformed cell line human CVCL_P531 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194742 CVCL_P530 GM19152 transformed cell line human CVCL_P530 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194743 CVCL_P549 GM19210 transformed cell line human CVCL_P549 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194744 CVCL_P548 GM19209 transformed cell line human CVCL_P548 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194745 CVCL_P547 GM19207 transformed cell line human CVCL_P547 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194746 CVCL_P546 GM19206 transformed cell line human CVCL_P546 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194747 CVCL_P545 GM19204 transformed cell line human CVCL_P545 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194748 CVCL_P544 GM19201 transformed cell line human CVCL_P544 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194749 CVCL_P543 GM19200 transformed cell line human CVCL_P543 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194750 CVCL_P542 GM19198 transformed cell line human CVCL_P542 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194751 CVCL_P541 GM19197 transformed cell line human CVCL_P541 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194752 CVCL_P540 GM19190 transformed cell line human CVCL_P540 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194753 CVCL_FZ89 ND22399 transformed cell line human CVCL_FZ89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194754 CVCL_FZ84 ND22366 transformed cell line human CVCL_FZ84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194755 CVCL_FZ83 ND22362 transformed cell line human CVCL_FZ83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194756 CVCL_FZ82 ND22322 transformed cell line human CVCL_FZ82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194757 CVCL_FZ81 ND22308 transformed cell line human CVCL_FZ81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194758 CVCL_FZ88 ND22396 transformed cell line human CVCL_FZ88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21194759 CVCL_FZ87 ND22390 transformed cell line human CVCL_FZ87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194760 CVCL_FZ86 ND22378 transformed cell line human CVCL_FZ86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194761 CVCL_P519 GM19131 transformed cell line human CVCL_P519 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194762 CVCL_FZ85 ND22371 transformed cell line human CVCL_FZ85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194763 CVCL_P518 GM19130 transformed cell line human CVCL_P518 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194764 CVCL_P517 GM19129 transformed cell line human CVCL_P517 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194765 CVCL_P516 GM19127 transformed cell line human CVCL_P516 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194766 CVCL_P515 GM19122 transformed cell line human CVCL_P515 CL:0000010 Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Homozygous (PubMed=33197628) Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194767 CVCL_P514 GM19121 transformed cell line human CVCL_P514 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194768 CVCL_FZ80 ND22307 transformed cell line human CVCL_FZ80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194769 CVCL_P513 GM19119 transformed cell line human CVCL_P513 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194770 CVCL_P512 GM19118 transformed cell line human CVCL_P512 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194771 CVCL_P511 GM19117 transformed cell line human CVCL_P511 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194772 CVCL_P510 GM19116 transformed cell line human CVCL_P510 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194773 CVCL_FZ95 ND27464 transformed cell line human CVCL_FZ95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194774 CVCL_FZ94 ND22462 transformed cell line human CVCL_FZ94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194775 CVCL_FZ93 ND22460 transformed cell line human CVCL_FZ93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194776 CVCL_FZ92 ND22420 transformed cell line human CVCL_FZ92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194777 CVCL_FZ99 ND29830 transformed cell line human CVCL_FZ99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194778 CVCL_FZ98 ND29089 transformed cell line human CVCL_FZ98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194779 CVCL_FZ97 ND28987 transformed cell line human CVCL_FZ97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194780 CVCL_FZ96 ND27897 transformed cell line human CVCL_FZ96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194781 CVCL_P529 GM19150 transformed cell line human CVCL_P529 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194782 CVCL_P528 GM19149 transformed cell line human CVCL_P528 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194783 CVCL_P527 GM19147 transformed cell line human CVCL_P527 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194784 CVCL_P526 GM19146 transformed cell line human CVCL_P526 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194785 CVCL_P525 GM19144 transformed cell line human CVCL_P525 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194786 CVCL_FZ91 ND22418 transformed cell line human CVCL_FZ91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194787 CVCL_P524 GM19143 transformed cell line human CVCL_P524 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194788 CVCL_FZ90 ND22404 transformed cell line human CVCL_FZ90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21194789 CVCL_P523 GM19141 transformed cell line human CVCL_P523 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194790 CVCL_P522 GM19140 transformed cell line human CVCL_P522 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194791 CVCL_P521 GM19138 transformed cell line human CVCL_P521 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194792 CVCL_P520 GM19137 transformed cell line human CVCL_P520 CL:0000010 Population: African; Yoruba in Ibadan, Nigeria (YRI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194793 CVCL_5I73 A549-Dual cancer cell line human CVCL_5I73 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 21194794 CVCL_5I72 RAW-Lucia ISG-KO-TREX1 cancer cell line house mouse CVCL_5I72 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1328317; Trex1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194795 CVCL_5I71 RAW-Lucia ISG-KO-TBK1 cancer cell line house mouse CVCL_5I71 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1929658; Tbk1; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194796 CVCL_5I70 RAW-Lucia ISG-KO-RIG-I cancer cell line house mouse CVCL_5I70 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2442858; Ddx58; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194797 CVCL_5I77 THP1-NLRC4 cancer cell line human CVCL_5I77 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 16412; NLRC4; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male 21194798 CVCL_5I76 THP1-defCASP1 cancer cell line human CVCL_5I76 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 1499; CASP1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21194799 CVCL_5I75 J774-Dual cancer cell line house mouse CVCL_5I75 CL:0000010 Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Breed/subspecies: BALB/c. Female Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 c-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 21194800 CVCL_5I74 HCT116-Dual cancer cell line human CVCL_5I74 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Colon. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 21194801 CVCL_5I79 ValiScreen human KCNA3 spontaneously immortalized cell line CVCL_5I79 CL:0000010 Transfected with: HGNC; 6221; KCNA3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 21194802 CVCL_5I78 HEK-Blue KD-TLR5 transformed cell line human CVCL_5I78 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11851; TLR5; Transfected with: HGNC; 439; ALPP; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: SEAP (secreted ALPP) reporter cell line, in this cell line SEAP is under the control of the ISG54 promoter 21194803 CVCL_5I84 4T1-Red-FLuc cancer cell line house mouse CVCL_5I84 CL:0000010 Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Doubling time: 14 hours (PerkinElmer) 21194804 CVCL_5I83 1321N1 AequoScreen cancer cell line human CVCL_5I83 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P07164; Aequorin Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21194805 CVCL_5I82 1321N1 (+Galpha16) AequoScreen cancer cell line human CVCL_5I82 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P07164; Aequorin Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 21194806 CVCL_5I81 ValiScreen human TRPC6 transformed cell line human CVCL_5I81 CL:0000010 Transfected with: HGNC; 12338; TRPC6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194807 CVCL_5I88 BxPC3-Red-FLuc cancer cell line human CVCL_5I88 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pancreas. Female Doubling time: 36 hours (PerkinElmer) 21194808 CVCL_5I87 B16-F10-Red-FLuc cancer cell line house mouse CVCL_5I87 CL:0000010 Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Doubling time: 15 hours (PerkinElmer) 21194809 CVCL_5I86 A549-Red-FLuc cancer cell line human CVCL_5I86 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Lung. Male Doubling time: 22 hours (PerkinElmer) 21194810 CVCL_5I85 4T1-Red-FLuc-GFP cancer cell line house mouse CVCL_5I85 CL:0000010 Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Doubling time: 14 hours (PerkinElmer) 21194811 CVCL_5I89 CHO-K1 (+Galpha16) AequoScreen spontaneously immortalized cell line CVCL_5I89 CL:0000010 Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21194812 CVCL_5I80 ValiScreen human TRPC3 transformed cell line human CVCL_5I80 CL:0000010 Transfected with: HGNC; 12335; TRPC3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194813 CVCL_5I51 PWS-iPSC-2-B induced pluripotent stem cell human CVCL_5I51 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21194814 CVCL_5I50 PWS-iPSC-2-A induced pluripotent stem cell human CVCL_5I50 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21194815 CVCL_5I55 RST2 cancer cell line human CVCL_5I55 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male Characteristics: Resistant to the various effects of interferon-alpha; Characteristics: Expresses a STAT2 mRNA with an alternative splice site between exon 19 and 20 that causes STAT2 translation termination at the beginning of the SH2 domain 21194816 CVCL_5I54 SH-SY5Y-HFE H63D cancer cell line human CVCL_5I54 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4886; HFE (with p.His63Asp) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21194817 CVCL_5I53 SH-SY5Y-HFE C282Y cancer cell line human CVCL_5I53 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4886; HFE (with p.Cys282Tyr) Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21194818 CVCL_5I52 SH-SY5Y-HFE cancer cell line human CVCL_5I52 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4886; HFE Population: Caucasian; Derived from metastatic site: Bone marrow. Female 21194819 CVCL_5I59 CET.IPS.FFHFF-500 induced pluripotent stem cell human CVCL_5I59 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Discontinued: CLS; 300611; true Male 21194820 CVCL_5I58 CET.IPS.FFAD-500 induced pluripotent stem cell human CVCL_5I58 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Discontinued: CLS; 300612; true 21194821 CVCL_5I57 CET.IPS ALZ-500 induced pluripotent stem cell human CVCL_5I57 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21194822 CVCL_5I56 mHypoA-SCN transformed cell line house mouse CVCL_5I56 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: C57BL/6. Female 21194823 CVCL_5I62 CET.IPS MULT-500 induced pluripotent stem cell human CVCL_5I62 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA. CL:0000010 Unspecified 21194824 CVCL_5I61 CET.IPS HFF-500 induced pluripotent stem cell human CVCL_5I61 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21194825 CVCL_5I60 CET.IPS.FFMP-500 induced pluripotent stem cell human CVCL_5I60 From: Cellular Engineering Technologies (CET), Inc.; Coralville; USA CL:0000010 Derived from sampling site: Umbilical cord blood. 21194826 CVCL_5I66 Dgcr8 knockout ES embryonic stem cell house mouse CVCL_5I66 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2151114; Dgcr8 Breed/subspecies: C57BL/6 x 129S4/SvJae. Male 21194827 CVCL_5I65 MCF-7/VP cancer cell line human CVCL_5I65 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pleural effusion. Female Doubling time: 47 hours (PubMed=8562478) 21194828 CVCL_5I64 MCF-7-FLV1000 cancer cell line human CVCL_5I64 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:47344; Alvocidib (Flavopiridol; Derived from metastatic site: Pleural effusion. Female 21194829 CVCL_5I63 K177 transformed cell line human CVCL_5I63 CL:0000010 Transfected with: HGNC; 1958; CHRNA4; Transfected with: HGNC; 1962; CHRNB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194830 CVCL_5I69 RAW-Lucia ISG-KO-IRF3 cancer cell line house mouse CVCL_5I69 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1859179; Irf3; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194831 CVCL_5I68 RAW-Lucia ISG-KO-IFI16 cancer cell line house mouse CVCL_5I68 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:96429; Ifi204; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194832 CVCL_5I67 RAW-Lucia ISG-KO-cGAS cancer cell line house mouse CVCL_5I67 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:2442261; Cgas; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE) 21194833 CVCL_Y091 GM03322 finite cell line human CVCL_Y091 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;11)(q22;q13) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21194834 CVCL_Y090 FL-74 cancer cell line CVCL_Y090 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). Virology: Infected with feline leukemia virus (FeLV) Doubling time: ~36 hours (PubMed=5818677) 21194835 CVCL_Y096 CC-M1 cancer cell line human CVCL_Y096 CL:0000010 Population: Chinese; Derived from sampling site: Colon; ascending. Male Doubling time: 16-20 hours (BCRC) 21194836 CVCL_Y095 HURP-196 hybridoma CVCL_Y095 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15398; Human DLGAP5. 21194837 CVCL_Y094 HURP-159 hybridoma CVCL_Y094 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q15398; Human DLGAP5. 21194838 CVCL_Y093 H184B5F5/M10 transformed cell line human CVCL_Y093 CL:0000010 Transformant: Benzo[a]pyrene(ChEBI; CHEBI:29865); Derived from sampling site: Breast; epithelium. Female 21194839 CVCL_Y099 CC-M3 cancer cell line human CVCL_Y099 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Colon. Discontinued: BCRC; 60450; true Male Doubling time: 16.6 hours (at 25th passage), 16.1 hours (at 50th passage) (PubMed=1696674) Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (BCRC). Originally thought to originate from a 80 year old female patient with a transverse colorectal carcinoma. 21194840 CVCL_Y098 CC-M2MN cancer cell line human CVCL_Y098 CL:0000010 Population: Chinese Male Characteristics: Established by subcutaneous injection of the tumor cells into nude mice Doubling time: 64.5 hours (at 25th passage), 57.4 hours (at 50th passage) (PubMed=1696674) Caution: Supposed to be established from the same patient as CC-M2 which was shown to be a SW480/SW620 derivative. 21194841 CVCL_Y097 CC-M2 cancer cell line human CVCL_Y097 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser227Phe (c.680C>T); Zygosity=Unspecified (PubMed=15144569) Population: Caucasian; Derived from sampling site: Colon. Discontinued: BCRC; 60449; true Male Doubling time: 20.0 hours (at 25th passage), 18.5 hours (at 50th passage) (PubMed=1696674) Problematic cell line: Contaminated Shown to be a SW480 (or SW620) derivative (BCRC). Originally thought to originate from a 58 year old male patient with a sigmoid colorectal carcinoma. 21194842 CVCL_5I33 COSB cancer cell line dog CVCL_5I33 CL:0000010 Sequence variation: Mutation; VGNC; 84862; EP300; Simple; p.Asn1570fs (c.4704dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; VGNC; 44555; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Ala150fs (c.447delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; VGNC; 47719; TP53; Simple; p.Leu184Phe (c.550C>T); Zygosity=Heterozygous (from parent cell line) Breed/subspecies: German Shepherd. Male 21194843 CVCL_5I32 C3H/10T1/2-mRuby clone 2 spontaneously immortalized cell line house mouse CVCL_5I32 CL:0000010 Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the bright RFP mRuby2) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21194844 CVCL_5I31 SIM-A9 spontaneously immortalized cell line house mouse CVCL_5I31 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 2-3 days (Kerafast) 21194845 CVCL_5I30 RB143 cancer cell line human CVCL_5I30 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex3-17del; Zygosity=Unspecified (PubMed=20371623). Unspecified 21194846 CVCL_5I37 MC-38-CEA-2 cancer cell line house mouse CVCL_5I37 CL:0000010 Transfected with: HGNC; 1817; CEACAM5 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 21194847 CVCL_5I36 MC-38-CEA-1 cancer cell line house mouse CVCL_5I36 CL:0000010 Transfected with: HGNC; 1817; CEACAM5 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 21194848 CVCL_5I35 R28 transformed cell line Norway rat CVCL_5I35 CL:0000010 Transformant: Psi2 defective retrovirus adenovirus E1A; Derived from sampling site: Eye; retina; neuroretina; Breed/subspecies: Sprague Dawley. Omics: Transcriptome analysis by microarray Female Doubling time: 24 hours (Kerafast) 21194849 CVCL_5I34 E1A-NR.3 transformed cell line Norway rat CVCL_5I34 CL:0000010 Transformant: Psi2 defective retrovirus adenovirus E1A; Derived from sampling site: Eye; retina; neuroretina; Breed/subspecies: Sprague Dawley. Female Doubling time: ~24 hours (Kerafast) 21194850 CVCL_5I39 EL-4-B5 cancer cell line house mouse CVCL_5I39 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Characteristics: Can be used as a feeder layer to generate B cell cultures yielding human monoclonal antibodies (Kerafast) 21194851 CVCL_5I38 MC-38-MUC-1 cancer cell line house mouse CVCL_5I38 CL:0000010 Transfected with: HGNC; 7508; MUC1 Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female 21194852 CVCL_Y081 HxURC cancer cell line human CVCL_Y081 CL:0000010 Unspecified 21194853 CVCL_Y080 HxMu cancer cell line human CVCL_Y080 CL:0000010 Female 21194854 CVCL_Y085 AGS/EPI cancer cell line human CVCL_Y085 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:47898; 4'-epidoxorubicin (Epirubicin); Derived from sampling site: Stomach. Female 21194855 CVCL_Y084 LMBG spontaneously immortalized cell line CVCL_Y084 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21194856 CVCL_Y083 SSP-9 spontaneously immortalized cell line CVCL_Y083 CL:0000010 Derived from sampling site: Head kidney. Unspecified Group: Fish cell line 21194857 CVCL_Y082 HxWe cancer cell line human CVCL_Y082 CL:0000010 Male 21194858 CVCL_Y089 MDCK-E [Taiwan] spontaneously immortalized cell line dog CVCL_Y089 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 21194859 CVCL_Y088 ALTS1C1 transformed cell line house mouse CVCL_Y088 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J. Male 21194860 CVCL_Y087 ALT transformed cell line house mouse CVCL_Y087 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Astrocyte.; Breed/subspecies: C57BL/6J. Male 21194861 CVCL_Y086 ETCC016 cancer cell line human CVCL_Y086 CL:0000010 Population: Chinese; Singaporian; Derived from metastatic site: Pleural effusion. Male Characteristics: Has 4 copies of EGFR Doubling time: 24 hours (PubMed=25126481); ~50 hours (DSMZ=ACC-798) 21194862 CVCL_5I40 JHE cancer cell line dog CVCL_5I40 CL:0000010 Derived from sampling site: Heart; Breed/subspecies: Golden Retriever. Male Doubling time: ~72 hours (Kerafast) 21194863 CVCL_5I44 NaV 1.3 KIR 2.1 transformed cell line human CVCL_5I44 CL:0000010 Transfected with: RGD; 3635; Scn3a; Transfected with: MGI; MGI:104744; Kcnj2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Generate spontaneous electrical action potentials (PubMed=24391999) 21194864 CVCL_5I43 HEK293-Nav 1.3 transformed cell line human CVCL_5I43 CL:0000010 Transfected with: RGD; 3635; Scn3a; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194865 CVCL_5I42 JLU cancer cell line dog CVCL_5I42 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male 21194866 CVCL_5I41 JLI cancer cell line dog CVCL_5I41 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Male 21194867 CVCL_5I48 PWS-iPSC-1-A induced pluripotent stem cell human CVCL_5I48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21194868 CVCL_5I47 WG1534 finite cell line human CVCL_5I47 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Female 21194869 CVCL_5I46 WG1631 finite cell line human CVCL_5I46 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. Male 21194870 CVCL_5I45 NIH 2/4 spontaneously immortalized cell line house mouse CVCL_5I45 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21194871 CVCL_5I49 PWS-iPSC-1-B induced pluripotent stem cell human CVCL_5I49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21194872 CVCL_Y070 Hx90 cancer cell line human CVCL_Y070 CL:0000010 Unspecified 21194873 CVCL_Y074 HxAC4 cancer cell line human CVCL_Y074 CL:0000010 Unspecified 21194874 CVCL_Y073 Hx96 cancer cell line human CVCL_Y073 CL:0000010 Unspecified 21194875 CVCL_Y072 Hx94 cancer cell line human CVCL_Y072 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Unspecified (PubMed=12068308). Unspecified 21194876 CVCL_Y071 Hx93 cancer cell line human CVCL_Y071 CL:0000010 Unspecified 21194877 CVCL_Y078 HxHC1 cancer cell line human CVCL_Y078 CL:0000010 Unspecified 21194878 CVCL_Y077 HxGo cancer cell line human CVCL_Y077 CL:0000010 Unspecified 21194879 CVCL_Y076 HxGC3 cancer cell line human CVCL_Y076 CL:0000010 Miscellaneous: This is not a cell line but a xenograft. Male 21194880 CVCL_Y075 HxEC4 cancer cell line human CVCL_Y075 CL:0000010 Unspecified 21194881 CVCL_Y079 HxLo cancer cell line human CVCL_Y079 CL:0000010 Female 21194882 CVCL_5I11 Kc167-PP-50Ab spontaneously immortalized cell line fruit fly CVCL_5I11 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194883 CVCL_5I10 Kc167-PP-50Aa spontaneously immortalized cell line fruit fly CVCL_5I10 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194884 CVCL_5I15 Kc167-PP-93E spontaneously immortalized cell line fruit fly CVCL_5I15 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194885 CVCL_5I14 Kc167-PP-89B spontaneously immortalized cell line fruit fly CVCL_5I14 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194886 CVCL_5I13 Kc167-PP-61C spontaneously immortalized cell line fruit fly CVCL_5I13 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194887 CVCL_5I12 Kc167-PP-52E spontaneously immortalized cell line fruit fly CVCL_5I12 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194888 CVCL_5I19 Sg4-PP-3A spontaneously immortalized cell line fruit fly CVCL_5I19 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194889 CVCL_5I18 Sg4-PP-27F spontaneously immortalized cell line fruit fly CVCL_5I18 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194890 CVCL_5I17 Kc167-PP-99A spontaneously immortalized cell line fruit fly CVCL_5I17 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194891 CVCL_5I16 Kc167-PP-93E-Mt-mCherry spontaneously immortalized cell line fruit fly CVCL_5I16 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Group: Insect cell line 21194892 CVCL_5I09 Kc167-PP-21D spontaneously immortalized cell line fruit fly CVCL_5I09 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Group: Insect cell line 21194893 CVCL_Y063 Hx72 cancer cell line human CVCL_Y063 CL:0000010 Unspecified 21194894 CVCL_Y062 Hx71 cancer cell line human CVCL_Y062 CL:0000010 Unspecified 21194895 CVCL_Y061 Hx60 cancer cell line human CVCL_Y061 CL:0000010 Female 21194896 CVCL_Y060 Hx55 cancer cell line human CVCL_Y060 CL:0000010 Unspecified 21194897 CVCL_Y067 Hx83 cancer cell line human CVCL_Y067 CL:0000010 Unspecified 21194898 CVCL_Y066 Hx81 cancer cell line human CVCL_Y066 CL:0000010 Unspecified 21194899 CVCL_Y065 Hx78 cancer cell line human CVCL_Y065 CL:0000010 Unspecified 21194900 CVCL_Y064 Hx74 cancer cell line human CVCL_Y064 CL:0000010 Unspecified 21194901 CVCL_Y069 Hx88 cancer cell line human CVCL_Y069 CL:0000010 Unspecified 21194902 CVCL_Y068 Hx87 cancer cell line human CVCL_Y068 CL:0000010 Unspecified 21194903 CVCL_5I22 Sg4-PP-70F spontaneously immortalized cell line fruit fly CVCL_5I22 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194904 CVCL_5I21 Sg4-PP-57B spontaneously immortalized cell line fruit fly CVCL_5I21 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194905 CVCL_5I20 Sg4-PP-49B spontaneously immortalized cell line fruit fly CVCL_5I20 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194906 CVCL_5I26 Ras[V12]-H1 spontaneously immortalized cell line fruit fly CVCL_5I26 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP. Unspecified Doubling time: 41 hours (DGRC) Group: Insect cell line 21194907 CVCL_5I25 Ras-attP-L2 spontaneously immortalized cell line fruit fly CVCL_5I25 CL:0000010 Unspecified Doubling time: 76 hours (DGRC). Group: Insect cell line 21194908 CVCL_5I24 Ras-attP-L1 spontaneously immortalized cell line fruit fly CVCL_5I24 CL:0000010 Unspecified Doubling time: 75 hours (DGRC). Group: Insect cell line 21194909 CVCL_5I23 Sg4-PP-84E spontaneously immortalized cell line fruit fly CVCL_5I23 CL:0000010 Transfected with: UniProtKB; P42212; GFP Breed/subspecies: Oregon-R. Male Group: Insect cell line 21194910 CVCL_5I29 Emma-spleen cancer cell line dog CVCL_5I29 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by microarray Female Doubling time: ~3 days (Kerafast) 21194911 CVCL_5I28 ALKO spontaneously immortalized cell line house mouse CVCL_5I28 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:1341870; Stk11 Derived from sampling site: Brain Cell type=Astrocyte.. Doubling time: 18-24 hours (Kerafast) 21194912 CVCL_5I27 Ras[V12]-H4 spontaneously immortalized cell line fruit fly CVCL_5I27 CL:0000010 Transfected with: FlyBase_Gene; FBgn0003205; Ras85D (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP. Unspecified Doubling time: ~39 hours (DGRC) Group: Insect cell line 21194913 CVCL_Y052 Hx138A cancer cell line human CVCL_Y052 CL:0000010 Unspecified 21194914 CVCL_Y051 Hx132 cancer cell line human CVCL_Y051 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=12068308). Female 21194915 CVCL_Y050 Hx129 cancer cell line human CVCL_Y050 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=12068308). Unspecified 21194916 CVCL_Y056 Hx169 cancer cell line human CVCL_Y056 CL:0000010 Unspecified 21194917 CVCL_Y055 Hx163 cancer cell line human CVCL_Y055 CL:0000010 Unspecified 21194918 CVCL_Y054 Hx159 cancer cell line human CVCL_Y054 CL:0000010 Female 21194919 CVCL_Y053 Hx147 cancer cell line human CVCL_Y053 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Unspecified (PubMed=12068308) Omics: Transcriptome analysis by microarray. Unspecified 21194920 CVCL_Y059 Hx53 cancer cell line human CVCL_Y059 CL:0000010 Male 21194921 CVCL_Y058 Hx39 cancer cell line human CVCL_Y058 CL:0000010 Male 21194922 CVCL_Y057 Hx29 cancer cell line human CVCL_Y057 CL:0000010 Unspecified 21194923 CVCL_5I95 HepG2-luc2 cancer cell line human CVCL_5I95 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Liver. Discontinued: PerkinElmer; 134280; true Male 21194924 CVCL_5I94 HCT 116-Red-FLuc cancer cell line human CVCL_5I94 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Colon. Male Doubling time: 16 hours (PerkinElmer) 21194925 CVCL_5I93 GL261-Red-FLuc cancer cell line house mouse CVCL_5I93 CL:0000010 Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Brain; Breed/subspecies: C57BL/6. Doubling time: 26 hours (PerkinElmer) 21194926 CVCL_5I92 Colo205-Red-FLuc cancer cell line human CVCL_5I92 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Ascites. Male Doubling time: 28 hours (PerkinElmer) 21194927 CVCL_5I99 HT1080-Red-FLuc cancer cell line human CVCL_5I99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male Doubling time: 22 hours (PerkinElmer) 21194928 CVCL_5I98 HepG2-Red-FLuc cancer cell line human CVCL_5I98 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Liver. Male Doubling time: 30 hours (PerkinElmer) 21194929 CVCL_5I97 HEK293 AequoScreen transformed cell line human CVCL_5I97 CL:0000010 Transfected with: UniProtKB; P07164; Aequorin; Transfected with: HGNC; 4383; GNA15 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194930 CVCL_5I96 HEK293 (+Galpha16) AequoScreen transformed cell line human CVCL_5I96 CL:0000010 Transfected with: UniProtKB; P07164; Aequorin Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21194931 CVCL_5I91 CHO-K1 AequoScreen spontaneously immortalized cell line CVCL_5I91 CL:0000010 Transfected with: UniProtKB; P07164; Aequorin Derived from sampling site: Ovary. Female 21194932 CVCL_5I90 CHO-K1 (+Gqi5) AequoScreen spontaneously immortalized cell line CVCL_5I90 CL:0000010 Transfected with: UniProtKB; P07164; Aequorin; Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1) Derived from sampling site: Ovary. Female 21194933 CVCL_P619 GM20762 transformed cell line human CVCL_P619 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194934 CVCL_P618 GM20761 transformed cell line human CVCL_P618 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194935 CVCL_P617 GM20760 transformed cell line human CVCL_P617 CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Heterozygous (PubMed=33197628) Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194936 CVCL_P616 GM20759 transformed cell line human CVCL_P616 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194937 CVCL_P615 GM20758 transformed cell line human CVCL_P615 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194938 CVCL_P614 GM20757 transformed cell line human CVCL_P614 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194939 CVCL_P613 GM20756 transformed cell line human CVCL_P613 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194940 CVCL_P612 GM20755 transformed cell line human CVCL_P612 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194941 CVCL_P611 GM20754 transformed cell line human CVCL_P611 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194942 CVCL_P610 GM20753 transformed cell line human CVCL_P610 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194943 CVCL_P629 GM20772 transformed cell line human CVCL_P629 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194944 CVCL_P628 GM20771 transformed cell line human CVCL_P628 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194945 CVCL_P627 GM20770 transformed cell line human CVCL_P627 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194946 CVCL_P626 GM20769 transformed cell line human CVCL_P626 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194947 CVCL_P625 GM20768 transformed cell line human CVCL_P625 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194948 CVCL_P624 GM20767 transformed cell line human CVCL_P624 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194949 CVCL_P623 GM20766 transformed cell line human CVCL_P623 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194950 CVCL_P622 GM20765 transformed cell line human CVCL_P622 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194951 CVCL_P621 GM20764 transformed cell line human CVCL_P621 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194952 CVCL_P620 GM20763 transformed cell line human CVCL_P620 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194953 CVCL_P609 GM20752 transformed cell line human CVCL_P609 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194954 CVCL_P608 GM20589 transformed cell line human CVCL_P608 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194955 CVCL_P607 GM20588 transformed cell line human CVCL_P607 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194956 CVCL_P606 GM20587 transformed cell line human CVCL_P606 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194957 CVCL_P605 GM20586 transformed cell line human CVCL_P605 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194958 CVCL_P604 GM20585 transformed cell line human CVCL_P604 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194959 CVCL_P603 GM20582 transformed cell line human CVCL_P603 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194960 CVCL_P602 GM20581 transformed cell line human CVCL_P602 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194961 CVCL_P601 GM20544 transformed cell line human CVCL_P601 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194962 CVCL_P600 GM20543 transformed cell line human CVCL_P600 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194963 CVCL_Y039 D13 cancer cell line human CVCL_Y039 CL:0000010 Unspecified 21194964 CVCL_Y041 Hx109 cancer cell line human CVCL_Y041 CL:0000010 Female 21194965 CVCL_Y040 Hx104 cancer cell line human CVCL_Y040 CL:0000010 Female 21194966 CVCL_P699 HG00119 transformed cell line human CVCL_P699 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194967 CVCL_P698 HG00118 transformed cell line human CVCL_P698 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194968 CVCL_P697 HG00117 transformed cell line human CVCL_P697 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194969 CVCL_Y045 Hx117 cancer cell line human CVCL_Y045 CL:0000010 Unspecified 21194970 CVCL_P696 HG00116 transformed cell line human CVCL_P696 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194971 CVCL_Y044 Hx113 cancer cell line human CVCL_Y044 CL:0000010 Female 21194972 CVCL_P695 HG00115 transformed cell line human CVCL_P695 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194973 CVCL_Y043 Hx110b cancer cell line human CVCL_Y043 CL:0000010 Female 21194974 CVCL_P694 HG00114 transformed cell line human CVCL_P694 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194975 CVCL_Y042 Hx110a cancer cell line human CVCL_Y042 CL:0000010 Female 21194976 CVCL_P693 HG00113 transformed cell line human CVCL_P693 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194977 CVCL_Y049 Hx128 cancer cell line human CVCL_Y049 CL:0000010 Male 21194978 CVCL_P692 HG00112 transformed cell line human CVCL_P692 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194979 CVCL_Y048 Hx126 cancer cell line human CVCL_Y048 CL:0000010 Unspecified 21194980 CVCL_P691 HG00111 transformed cell line human CVCL_P691 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194981 CVCL_Y047 Hx124 cancer cell line human CVCL_Y047 CL:0000010 Unspecified 21194982 CVCL_P690 HG00110 transformed cell line human CVCL_P690 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21194983 CVCL_Y046 Hx122 cancer cell line human CVCL_Y046 CL:0000010 Female 21194984 CVCL_Y029 HKT-8 cancer cell line human CVCL_Y029 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 40.0 hours (PubMed=2224863) 21194985 CVCL_Y028 HKT-7 cancer cell line human CVCL_Y028 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 95.3 hours (PubMed=2224863) 21194986 CVCL_5I00 LMS05 cancer cell line human CVCL_5I00 CL:0000010 21194987 CVCL_5I04 Kc167-Mt-mCherry-c1 spontaneously immortalized cell line fruit fly CVCL_5I04 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Group: Insect cell line 21194988 CVCL_5I03 Kc167-IPPI-66D-Mt-mCherry spontaneously immortalized cell line fruit fly CVCL_5I03 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Characteristics: Has Mt-mCherry targeted to phiC31 docking site Group: Insect cell line 21194989 CVCL_5I02 Kc167-IPPI-66D spontaneously immortalized cell line fruit fly CVCL_5I02 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Characteristics: Has a nuclear eGFP targeted to phiC31 docking site Doubling time: ~1 day (DGRC) Group: Insect cell line 21194990 CVCL_5I01 MA214L transformed cell line human CVCL_5I01 CL:0000010 Population: Caucasian; Karyotypic information: t(5;6)(q21;q21) (ECACC); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: ECACC chromosomal abnormality collection 21194991 CVCL_5I08 Kc167-PP-21B spontaneously immortalized cell line fruit fly CVCL_5I08 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194992 CVCL_5I07 Kc167-PP-16F spontaneously immortalized cell line fruit fly CVCL_5I07 CL:0000010 Transfected with: UniProtKB; P42212; GFP. Female Doubling time: ~1 day (DGRC) Group: Insect cell line 21194993 CVCL_5I06 Kc167-Mt-mCherry-c3 spontaneously immortalized cell line fruit fly CVCL_5I06 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Group: Insect cell line 21194994 CVCL_5I05 Kc167-Mt-mCherry-c2 spontaneously immortalized cell line fruit fly CVCL_5I05 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Female Group: Insect cell line 21194995 CVCL_Y030 HUT15 cancer cell line human CVCL_Y030 CL:0000010 Population: Japanese. Unspecified 21194996 CVCL_Y034 DLD-2 cancer cell line human CVCL_Y034 CL:0000010 Unspecified Doubling time: ~50 hours (PubMed=7139607); 48 hours (PubMed=7247963). 21194997 CVCL_Y033 OV(hyg)CAR3 cancer cell line human CVCL_Y033 CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:16976; Hygromycin B; Derived from metastatic site: Ascites. Female 21194998 CVCL_Y032 PEO1-CDDP cancer cell line human CVCL_Y032 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Tyr1655Ter (c.4965C>G) (5193C>G); ClinVar=VCV000037936; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly244Asp (c.731G>A); ClinVar=VCV000372785; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Female 21194999 CVCL_Y031 HUT29 cancer cell line human CVCL_Y031 CL:0000010 Population: Japanese. Unspecified 21195000 CVCL_Y038 A2095 cancer cell line human CVCL_Y038 CL:0000010 Unspecified 21195001 CVCL_Y037 41M47 cancer cell line human CVCL_Y037 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (41M) has been shown to be a OAW28 derivative. 21195002 CVCL_Y036 Hx62-26 cancer cell line human CVCL_Y036 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Glu (c.1391G>A); ClinVar=VCV000013964; Zygosity=Unspecified (PubMed=12068308); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=12068308). Population: Caucasian Female 21195003 CVCL_Y035 Raji 6-TGR cancer cell line human CVCL_Y035 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21195004 CVCL_Y019 HAP1 cancer cell line human CVCL_Y019 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Karyotypic information: Has lost the second copy of chromosome 8 of parent cell line KBM-7 Retains a second copy of a fragment of chromosome 15 fused to chromosome 19.; Derived from sampling site: Bone marrow. Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Group: Haploid karyotype cell line; Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21195005 CVCL_Y018 HA59T/VGH cancer cell line human CVCL_Y018 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Male 21195006 CVCL_Y017 TW5 embryonic stem cell human CVCL_Y017 From: Industrial Technology Research Institute (ITRI) and Lee Women's Hospital; Hsinchu City; Taiwan. CL:0000010 Male 21195007 CVCL_P679 HG00099 transformed cell line human CVCL_P679 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195008 CVCL_P678 HG00098 transformed cell line human CVCL_P678 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195009 CVCL_P677 HG00097 transformed cell line human CVCL_P677 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195010 CVCL_P676 HG00096 transformed cell line human CVCL_P676 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195011 CVCL_Y023 ABC-1#IL-6 cancer cell line human CVCL_Y023 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Leu858Arg (c.2573T>G); ClinVar=VCV000016609; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ser (c.832C>T); ClinVar=VCV000376642; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 6018; IL6 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21195012 CVCL_P675 MBA C57.Li finite cell line house mouse CVCL_P675 CL:0000010 Derived from sampling site: Embryonic liver. Discontinued: ATCC; CRL-6369; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21195013 CVCL_P674 GM20832 transformed cell line human CVCL_P674 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195014 CVCL_Y022 HX3 embryonic stem cell CVCL_Y022 CL:0000010 Female Group: Fish cell line; Group: Haploid karyotype cell line. 21195015 CVCL_P673 GM20831 transformed cell line human CVCL_P673 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195016 CVCL_Y021 HX2 embryonic stem cell CVCL_Y021 CL:0000010 Female Group: Fish cell line; Group: Haploid karyotype cell line. 21195017 CVCL_P672 GM20828 transformed cell line human CVCL_P672 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195018 CVCL_Y020 HX1 embryonic stem cell CVCL_Y020 CL:0000010 Female Group: Fish cell line; Group: Haploid karyotype cell line. 21195019 CVCL_P671 GM20827 transformed cell line human CVCL_P671 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195020 CVCL_Y027 HKT-6 cancer cell line human CVCL_Y027 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 79.5 hours (PubMed=2224863) 21195021 CVCL_P670 GM20826 transformed cell line human CVCL_P670 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195022 CVCL_Y026 HKT-5 cancer cell line human CVCL_Y026 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 86.7 hours (PubMed=2224863) 21195023 CVCL_Y025 HKT-3 cancer cell line human CVCL_Y025 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 63.7 hours (PubMed=2224863) 21195024 CVCL_Y024 HKT-2 cancer cell line human CVCL_Y024 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified Doubling time: 43.6 hours (PubMed=2224863) 21195025 CVCL_Y009 CE48T/VGH cancer cell line human CVCL_Y009 CL:0000010 Population: Chinese; Taiwan Discontinued: BCRC; 60165; true. Male Doubling time: ~55 hours (PubMed=6583441) 21195026 CVCL_Y008 CE146T/VGH cancer cell line human CVCL_Y008 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Male 21195027 CVCL_Y007 T3M-15 cancer cell line human CVCL_Y007 CL:0000010 Population: Japanese. Male 21195028 CVCL_Y006 TC-78 cancer cell line human CVCL_Y006 CL:0000010 Derived from sampling site: Thyroid gland. 21195029 CVCL_P689 HG00109 transformed cell line human CVCL_P689 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195030 CVCL_P688 HG00108 transformed cell line human CVCL_P688 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195031 CVCL_P687 HG00107 transformed cell line human CVCL_P687 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195032 CVCL_Y012 CHOS-XE spontaneously immortalized cell line CVCL_Y012 CL:0000010 Transfected with: HGNC; 12801; XBP1; Transfected with: HGNC; 13280; ERO1A Derived from sampling site: Ovary. Female 21195033 CVCL_P686 HG00106 transformed cell line human CVCL_P686 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195034 CVCL_Y011 CE81T/VGH cancer cell line human CVCL_Y011 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male Doubling time: ~72 hours (PubMed=6583441) 21195035 CVCL_P685 HG00105 transformed cell line human CVCL_P685 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195036 CVCL_Y010 CE69T/VGH cancer cell line human CVCL_Y010 CL:0000010 Population: Chinese; Taiwan Female Doubling time: ~48 hours (PubMed=6583441). 21195037 CVCL_P684 HG00104 transformed cell line human CVCL_P684 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195038 CVCL_P683 HG00103 transformed cell line human CVCL_P683 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195039 CVCL_P682 HG00102 transformed cell line human CVCL_P682 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195040 CVCL_Y016 TW4 embryonic stem cell human CVCL_Y016 From: Industrial Technology Research Institute (ITRI) and Lee Women's Hospital; Hsinchu City; Taiwan. CL:0000010 Female 21195041 CVCL_P681 HG00101 transformed cell line human CVCL_P681 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195042 CVCL_Y015 TW3 embryonic stem cell human CVCL_Y015 From: Industrial Technology Research Institute (ITRI) and Lee Women's Hospital; Hsinchu City; Taiwan. CL:0000010 Female 21195043 CVCL_P680 HG00100 transformed cell line human CVCL_P680 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195044 CVCL_Y014 TW2 embryonic stem cell human CVCL_Y014 From: Industrial Technology Research Institute (ITRI) and Lee Women's Hospital; Hsinchu City; Taiwan. CL:0000010 Female 21195045 CVCL_Y013 TW1 embryonic stem cell human CVCL_Y013 From: Industrial Technology Research Institute (ITRI) and Lee Women's Hospital; Hsinchu City; Taiwan. CL:0000010 Female 21195046 CVCL_P659 GM20812 transformed cell line human CVCL_P659 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195047 CVCL_P658 GM20811 transformed cell line human CVCL_P658 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195048 CVCL_P657 GM20810 transformed cell line human CVCL_P657 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195049 CVCL_P656 GM20809 transformed cell line human CVCL_P656 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195050 CVCL_P655 GM20808 transformed cell line human CVCL_P655 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195051 CVCL_P654 GM20807 transformed cell line human CVCL_P654 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195052 CVCL_Y001 1A2 [Rat glioma] cancer cell line Norway rat CVCL_Y001 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Discontinued: ECACC; 93040129; probable Female 21195053 CVCL_P653 GM20806 transformed cell line human CVCL_P653 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195054 CVCL_P652 GM20805 transformed cell line human CVCL_P652 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195055 CVCL_Y000 mHypoA-NPY/GFP transformed cell line house mouse CVCL_Y000 CL:0000010 Transfected with: UniProtKB; Q963I9; Renilla GFP; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus; Breed/subspecies: B6.FVB-Tg(Npy-hrGFP)1Lowl/J. 21195056 CVCL_P651 GM20804 transformed cell line human CVCL_P651 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195057 CVCL_P650 GM20803 transformed cell line human CVCL_P650 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195058 CVCL_Y005 HT [Human ovarian serous cystadenocarcinoma] cancer cell line human CVCL_Y005 CL:0000010 Population: Japanese. Female 21195059 CVCL_Y004 Panc 12.01 cancer cell line human CVCL_Y004 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=9612602). Unspecified 21195060 CVCL_Y003 GL261 cancer cell line house mouse CVCL_Y003 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Brain; Breed/subspecies: C57BL/6. Omics: Cell surface proteome; Omics: Deep exome analysis; Omics: HLA class I peptidome analysis by proteomics Doubling time: ~100-120 hours (DSMZ=ACC-802) 21195061 CVCL_Y002 A15A10 cancer cell line Norway rat CVCL_Y002 CL:0000010 Transformant: N-ethyl-N-nitrosourea (ENU)(ChEBI; CHEBI:23995); Derived from sampling site: Brain; Breed/subspecies: BDIX. Female 21195062 CVCL_P669 GM20822 transformed cell line human CVCL_P669 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195063 CVCL_P668 GM20821 transformed cell line human CVCL_P668 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195064 CVCL_P667 GM20820 transformed cell line human CVCL_P667 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195065 CVCL_P666 GM20819 transformed cell line human CVCL_P666 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195066 CVCL_P665 GM20818 transformed cell line human CVCL_P665 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195067 CVCL_P664 GM20817 transformed cell line human CVCL_P664 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195068 CVCL_P663 GM20816 transformed cell line human CVCL_P663 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195069 CVCL_P662 GM20815 transformed cell line human CVCL_P662 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195070 CVCL_P661 GM20814 transformed cell line human CVCL_P661 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195071 CVCL_P660 GM20813 transformed cell line human CVCL_P660 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195072 CVCL_P639 GM20790 transformed cell line human CVCL_P639 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195073 CVCL_P638 GM20787 transformed cell line human CVCL_P638 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195074 CVCL_P637 GM20786 transformed cell line human CVCL_P637 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195075 CVCL_P636 GM20785 transformed cell line human CVCL_P636 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195076 CVCL_P635 GM20783 transformed cell line human CVCL_P635 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195077 CVCL_P634 GM20780 transformed cell line human CVCL_P634 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195078 CVCL_P633 GM20778 transformed cell line human CVCL_P633 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195079 CVCL_P632 GM20775 transformed cell line human CVCL_P632 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Triplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Heterozygous (PubMed=33197628) Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195080 CVCL_P631 GM20774 transformed cell line human CVCL_P631 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195081 CVCL_P630 GM20773 transformed cell line human CVCL_P630 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195082 CVCL_P649 GM20802 transformed cell line human CVCL_P649 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195083 CVCL_P648 GM20801 transformed cell line human CVCL_P648 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195084 CVCL_P647 GM20800 transformed cell line human CVCL_P647 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195085 CVCL_P646 GM20799 transformed cell line human CVCL_P646 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195086 CVCL_P645 GM20798 transformed cell line human CVCL_P645 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195087 CVCL_P644 GM20797 transformed cell line human CVCL_P644 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195088 CVCL_P643 GM20796 transformed cell line human CVCL_P643 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195089 CVCL_P642 GM20795 transformed cell line human CVCL_P642 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195090 CVCL_P641 GM20792 transformed cell line human CVCL_P641 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195091 CVCL_P640 GM20791 transformed cell line human CVCL_P640 CL:0000010 Population: Caucasian; Toscani in Italia (TSI); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195092 CVCL_5J94 H37-82 hybridoma house mouse CVCL_5J94 CL:0000010 Discontinued: Coriell; WC00033; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195093 CVCL_5J93 H37-80 hybridoma house mouse CVCL_5J93 CL:0000010 Discontinued: Coriell; WC00032; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195094 CVCL_5J92 H37-66 hybridoma house mouse CVCL_5J92 CL:0000010 Discontinued: Coriell; WC00026; probable. Monoclonal antibody isotype: IgA 21195095 CVCL_5J91 H37-65 hybridoma house mouse CVCL_5J91 CL:0000010 Discontinued: Coriell; WC00025; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195096 CVCL_5J98 H35-C2 hybridoma house mouse CVCL_5J98 CL:0000010 Discontinued: Coriell; WC00037; probable. Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195097 CVCL_5J97 H9-D3 hybridoma house mouse CVCL_5J97 CL:0000010 Discontinued: Coriell; WC00039; probable. Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195098 CVCL_5J96 H9-A15 hybridoma house mouse CVCL_5J96 CL:0000010 Discontinued: Coriell; WC00040; probable. Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195099 CVCL_5J95 H37-88 hybridoma house mouse CVCL_5J95 CL:0000010 Discontinued: Coriell; WC00023; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195100 CVCL_5J99 H33-48 hybridoma house mouse CVCL_5J99 CL:0000010 Discontinued: Coriell; WC00036; probable. Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195101 CVCL_5J90 H37-63 hybridoma house mouse CVCL_5J90 CL:0000010 Discontinued: Coriell; WC00027; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195102 CVCL_5J72 GM12531 transformed cell line human CVCL_5J72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195103 CVCL_5J71 GM12530 transformed cell line human CVCL_5J71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195104 CVCL_5J70 GM12529 transformed cell line human CVCL_5J70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195105 CVCL_5J76 GM12536 transformed cell line human CVCL_5J76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195106 CVCL_5J75 GM12534 transformed cell line human CVCL_5J75 CL:0000010 Sequence variation: Mutation; HGNC; 560; AP1S2; Simple; c.426+1G>T (p.Val97_Glu142del); ClinVar=VCV000140457; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=23756445) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195107 CVCL_5J74 GM12533 transformed cell line human CVCL_5J74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195108 CVCL_5J73 GM12532 transformed cell line human CVCL_5J73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195109 CVCL_5J79 GM12539 transformed cell line human CVCL_5J79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195110 CVCL_5J78 GM12538 transformed cell line human CVCL_5J78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195111 CVCL_5J77 GM12537 transformed cell line human CVCL_5J77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195112 CVCL_5J83 H14-A11 hybridoma house mouse CVCL_5J83 CL:0000010 Discontinued: Coriell; WC00013; probable. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P03449; Influenza A virus isolate A/Memphis/1/1971 hemagglutinin (HA) 21195113 CVCL_5J82 GM12543 transformed cell line human CVCL_5J82 CL:0000010 Sequence variation: Mutation; HGNC; 560; AP1S2; Simple; c.426+1G>T (p.Val97_Glu142del); ClinVar=VCV000140457; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=23756445) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195114 CVCL_5J81 GM12542 transformed cell line human CVCL_5J81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195115 CVCL_5J80 GM12541 transformed cell line human CVCL_5J80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195116 CVCL_5J87 H36-2 hybridoma house mouse CVCL_5J87 CL:0000010 Discontinued: Coriell; WC00030; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195117 CVCL_5J86 H14-B18 hybridoma house mouse CVCL_5J86 CL:0000010 Discontinued: Coriell; WC00042; probable. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P03449; Influenza A virus isolate A/Memphis/1/1971 hemagglutinin (HA) 21195118 CVCL_5J85 H14-A21 hybridoma house mouse CVCL_5J85 CL:0000010 Discontinued: Coriell; WC00010; probable. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P03449; Influenza A virus isolate A/Memphis/1/1971 hemagglutinin (HA) 21195119 CVCL_5J84 H14-A20 hybridoma house mouse CVCL_5J84 CL:0000010 Discontinued: Coriell; WC00024; probable. Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P03449; Influenza A virus isolate A/Memphis/1/1971 hemagglutinin (HA) 21195120 CVCL_5J89 H37-59 hybridoma house mouse CVCL_5J89 CL:0000010 Discontinued: Coriell; WC00021; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195121 CVCL_5J88 H37-22 hybridoma house mouse CVCL_5J88 CL:0000010 Discontinued: Coriell; WC00035; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21195122 CVCL_5J50 Walvax-2 finite cell line human CVCL_5J50 CL:0000010 Anecdotal: Is causing an outrage in some pro-lifer circles because it is a cell line originating from an aborted (for medical reasons) 3-month old female fetus Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female Senescence: Maintains excellent capabilities for growth and proliferation until PDL 50 (maximum PDL is 58); Doubling time: 39-41 hours (at 28th passage), 40-42 hours (at 38th passage), 57-62 hours (at 48th passage) (PubMed=25803132) Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201055 21195123 CVCL_5J54 THP1-Dual KO-MyD cancer cell line human CVCL_5J54 CL:0000010 Knockout cell: Method=Not specified; HGNC; 7562; MYD88; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 439; ALPP; Transfected with: Lucia luciferase, a synthetic gene designed on natural secreted luciferase genes from marine copepods; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses two reporter genes: SEAP (secreted ALPP) and the Lucia luciferase In this cell line SEAP is under the control of an IFN-beta minimal promoter fused to 5 NF-kappaB binding sites and 3 C-Rel binding sites. The Lucia luciferase reporter gene is under the control of an ISG54 minimal promoter in conjunction with 5 IFN-stimulated response elements (ISRE). 21195124 CVCL_5J53 CHME-5 transformed cell line human CVCL_5J53 CL:0000010 Miscellaneous: The cell line name was not assigned in the original paper (PubMed=7478261) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Microglial cell.. Unspecified Virology: Supports the replication of M-tropic HIV-1 strain YU-2 (PubMed=17157319) 21195125 CVCL_5J52 TH7 transformed cell line human CVCL_5J52 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Unspecified Characteristics: Reversible immortalized The transfected hTERT and SV40 Tag genes are flanked by loxP sites. Transient Cre expression in this cell line leads to deletion of the two genes thus leading to a decrease in the rate of cell proliferation and ultimately to cell senescence. Doubling time: 40-48 hours (PubMed=15208689) Group: Patented cell line 21195126 CVCL_5J51 TH1 transformed cell line human CVCL_5J51 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Unspecified Characteristics: Reversible immortalized The transfected hTERT and SV40 Tag genes are flanked by loxP sites. Transient Cre expression in this cell line leads to deletion of the two genes thus leading to a decrease in the rate of cell proliferation and ultimately to cell senescence. Doubling time: 40-48 hours (PubMed=15208689) Group: Patented cell line 21195127 CVCL_5J58 GM12132 transformed cell line human CVCL_5J58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195128 CVCL_5J57 GM12018 transformed cell line human CVCL_5J57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195129 CVCL_5J56 GM12017 transformed cell line human CVCL_5J56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195130 CVCL_5J55 GM12016 transformed cell line human CVCL_5J55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195131 CVCL_5J59 GM12133 transformed cell line human CVCL_5J59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195132 CVCL_5J61 GM12228 transformed cell line human CVCL_5J61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195133 CVCL_5J60 GM12227 transformed cell line human CVCL_5J60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195134 CVCL_5J65 GM12524 transformed cell line human CVCL_5J65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195135 CVCL_5J64 GM12523 transformed cell line human CVCL_5J64 CL:0000010 Sequence variation: Mutation; HGNC; 560; AP1S2; Simple; c.426+1G>T (p.Val97_Glu142del); ClinVar=VCV000140457; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=23756445) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195136 CVCL_5J63 GM12522 transformed cell line human CVCL_5J63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195137 CVCL_5J62 GM12521 transformed cell line human CVCL_5J62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195138 CVCL_5J69 GM12528 transformed cell line human CVCL_5J69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195139 CVCL_5J68 GM12527 transformed cell line human CVCL_5J68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195140 CVCL_5J67 GM12526 transformed cell line human CVCL_5J67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195141 CVCL_5J66 GM12525 transformed cell line human CVCL_5J66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195142 CVCL_Y191 CE81T2-1 cancer cell line human CVCL_Y191 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195143 CVCL_XP91 HAP1 KAT6B (-) 3 cancer cell line human CVCL_XP91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17582; KAT6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195144 CVCL_Y190 CE81T1-4 cancer cell line human CVCL_Y190 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195145 CVCL_XP90 HAP1 KAT6B (-) 2 cancer cell line human CVCL_XP90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17582; KAT6B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195146 CVCL_XP95 HAP1 KDELR1 (-) 2 cancer cell line human CVCL_XP95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6304; KDELR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195147 CVCL_Y195 SK-MG-21 cancer cell line human CVCL_Y195 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Ile (c.765C>T); ClinVar=VCV001532094; Zygosity=Unspecified (PubMed=8934553). 21195148 CVCL_XP94 HAP1 KCNC3 (-) cancer cell line human CVCL_XP94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6235; KCNC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195149 CVCL_Y194 POVD cancer cell line human CVCL_Y194 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu171Ter (c.511G>T); ClinVar=VCV000634771; Zygosity=Unspecified (PubMed=9274917). 21195150 CVCL_XP93 HAP1 KAT7 (-) 4 cancer cell line human CVCL_XP93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195151 CVCL_Y193 HEVE-II cancer cell line human CVCL_Y193 CL:0000010 Derived from metastatic site: Lymph node. Female 21195152 CVCL_Y192 CE81T2-4 cancer cell line human CVCL_Y192 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195153 CVCL_XP92 HAP1 KAT7 (-) 3 cancer cell line human CVCL_XP92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195154 CVCL_XP99 HAP1 KIAA0100 (-) 4 cancer cell line human CVCL_XP99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28960; BLTP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195155 CVCL_XP98 HAP1 KIAA0100 (-) 3 cancer cell line human CVCL_XP98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28960; BLTP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195156 CVCL_Y198 K562/AC cancer cell line human CVCL_Y198 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Derived from sampling site: Pleural effusion. Female 21195157 CVCL_XP97 HAP1 KIAA0100 (-) 2 cancer cell line human CVCL_XP97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28960; BLTP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195158 CVCL_Y197 L804L cancer cell line human CVCL_Y197 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Unspecified 21195159 CVCL_XP96 HAP1 KDELR2 (-) cancer cell line human CVCL_XP96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6305; KDELR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195160 CVCL_Y196 SK-MG-8 cancer cell line human CVCL_Y196 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile255Met (c.765C>G); Zygosity=Unspecified (PubMed=8934553). 21195161 CVCL_5J32 eHAP A11 cancer cell line human CVCL_5J32 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Omics: Genome sequenced Male Group: Haploid karyotype cell line 21195162 CVCL_5J31 ExpiCHO-S spontaneously immortalized cell line CVCL_5J31 CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Has been selected for high protein expression Group: Serum/protein free medium cell line 21195163 CVCL_5J30 LNCaP-luc-M6 cancer cell line human CVCL_5J30 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Discontinued: PerkinElmer; 119271; true Male 21195164 CVCL_5J36 MCF-7/Luc cancer cell line human CVCL_5J36 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21195165 CVCL_5J35 MCF-7-luc-F5 cancer cell line human CVCL_5J35 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 119262; true Female 21195166 CVCL_5J34 HT-29-luc-D6 cancer cell line human CVCL_5J34 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: PerkinElmer; 119264; true. Female 21195167 CVCL_5J33 eHAP E9 cancer cell line human CVCL_5J33 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Omics: Genome sequenced Male Group: Haploid karyotype cell line 21195168 CVCL_5J39 B16-F10-luc-G5 cancer cell line house mouse CVCL_5J39 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Discontinued: PerkinElmer; 119269; true Male 21195169 CVCL_5J38 SKOV3-luc-D3 cancer cell line human CVCL_5J38 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Ascites. Discontinued: PerkinElmer; 119276; true Female 21195170 CVCL_5J37 MCF-7/GFP cancer cell line human CVCL_5J37 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21195171 CVCL_Y180 A2780/cDDP cancer cell line human CVCL_Y180 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary. Female 21195172 CVCL_XP80 HAP1 IMMP2L (-) 2 cancer cell line human CVCL_XP80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14598; IMMP2L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195173 CVCL_Y184 CE81T1 cancer cell line human CVCL_Y184 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195174 CVCL_XP84 HAP1 IRAK2 (-) 2 cancer cell line human CVCL_XP84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6113; IRAK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195175 CVCL_XP83 HAP1 IQGAP2 (-) 2 cancer cell line human CVCL_XP83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6111; IQGAP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195176 CVCL_Y183 T24/DDP7 cancer cell line human CVCL_Y183 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21195177 CVCL_XP82 HAP1 INPP5A (-) 3 cancer cell line human CVCL_XP82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6076; INPP5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195178 CVCL_Y182 T24/DDP5 cancer cell line human CVCL_Y182 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21195179 CVCL_XP81 HAP1 INPP5A (-) 2 cancer cell line human CVCL_XP81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6076; INPP5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195180 CVCL_Y181 T24/DDP10 cancer cell line human CVCL_Y181 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 21195181 CVCL_Y188 CE81T1-2 cancer cell line human CVCL_Y188 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195182 CVCL_XP88 HAP1 JAG1 (-) 2 cancer cell line human CVCL_XP88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195183 CVCL_Y187 CE81T1-1 cancer cell line human CVCL_Y187 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195184 CVCL_XP87 HAP1 ISOC2 (-) 2 cancer cell line human CVCL_XP87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26278; ISOC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195185 CVCL_Y186 CE81T1-0 cancer cell line human CVCL_Y186 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195186 CVCL_XP86 HAP1 ISL1 (-) 2 cancer cell line human CVCL_XP86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6132; ISL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195187 CVCL_Y185 CE81T2 cancer cell line human CVCL_Y185 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195188 CVCL_XP85 HAP1 IRF2BPL (-) 2 cancer cell line human CVCL_XP85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14282; IRF2BPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195189 CVCL_Y189 CE81T1-3 cancer cell line human CVCL_Y189 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Esophagus. Male 21195190 CVCL_XP89 HAP1 KAT6A (-) 2 cancer cell line human CVCL_XP89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13013; KAT6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195191 CVCL_5J43 hVEGF-luc/PC3M cancer cell line human CVCL_5J43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; 119273; true Male 21195192 CVCL_5J42 LoVo-6-luc-1 cancer cell line human CVCL_5J42 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1114Ter (c.3340C>T); ClinVar=VCV000236589; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met1431fs*42 (c.4289delC) (p.T1430fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2816Gln (c.8447G>A); ClinVar=VCV000419681; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu15Phefs*41 (c.43_44delCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Ala292Val (c.875C>T); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Derived from metastatic site: Left supraclavicular lymph node. Discontinued: PerkinElmer; 119265; true Male 21195193 CVCL_5J41 HeLa-luc cancer cell line human CVCL_5J41 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: PerkinElmer; 119272; true Female Caution: Probably not identical with HeLa-Luc (upper case luc) (Cellosaurus=CVCL_YA88) from the from NCI Developmental Therapeutics Program (DTP) 21195194 CVCL_5J40 LL/2-luc-M38 cancer cell line house mouse CVCL_5J40 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Discontinued: PerkinElmer; 119267; true 21195195 CVCL_5J47 O-342/DDP cancer cell line Norway rat CVCL_5J47 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Ovary; Breed/subspecies: BDIX. Female Doubling time: ~24 hours (PubMed=1744159) 21195196 CVCL_5J46 4T1-luc2-tdTomato cancer cell line house mouse CVCL_5J46 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: PerkinElmer; 125669; true Female 21195197 CVCL_5J45 4T1-tdTomato cancer cell line house mouse CVCL_5J45 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: PerkinElmer; 125668; true Female 21195198 CVCL_5J44 p53-RE-luc/A549 cancer cell line human CVCL_5J44 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Discontinued: PerkinElmer; 119274; true Male 21195199 CVCL_5J49 PP1084 cancer cell line human CVCL_5J49 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=8344493). 21195200 CVCL_5J48 MFC cancer cell line house mouse CVCL_5J48 CL:0000010 Derived from sampling site: Stomach; forestomach. Doubling time: 24.7 hours (PubMed=3678016) 21195201 CVCL_XP73 HAP1 IFI6 (-) cancer cell line human CVCL_XP73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4054; IFI6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195202 CVCL_Y173 U937/clone49 cancer cell line human CVCL_Y173 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Male 21195203 CVCL_XP72 HAP1 IFI44L (-) cancer cell line human CVCL_XP72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17817; IFI44L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195204 CVCL_Y172 U937/clone41 cancer cell line human CVCL_Y172 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Male 21195205 CVCL_XP71 HAP1 IFI44 (-) cancer cell line human CVCL_XP71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16938; IFI44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195206 CVCL_Y171 U937/clone36 cancer cell line human CVCL_Y171 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Male 21195207 CVCL_XP70 HAP1 ID1 (-) 3 cancer cell line human CVCL_XP70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5360; ID1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195208 CVCL_Y170 U937/clone21 cancer cell line human CVCL_Y170 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Male 21195209 CVCL_XP77 HAP1 IL17RA (-) 2 cancer cell line human CVCL_XP77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5985; IL17RA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195210 CVCL_Y177 HT-29/cDDP cancer cell line human CVCL_Y177 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Female 21195211 CVCL_XP76 HAP1 IGF2R (-) 2 cancer cell line human CVCL_XP76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5467; IGF2R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195212 CVCL_Y176 St-4/cDDP cancer cell line human CVCL_Y176 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). 21195213 CVCL_XP75 HAP1 IGF2BP3 (-) 4 cancer cell line human CVCL_XP75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195214 CVCL_Y175 U937/UK711 cancer cell line human CVCL_Y175 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 12796; WT1; Simple; p.Arg301Ter (c.901C>T) (p.Arg352Ter, c.1054C>T) (p.Arg374Ter, c.1120C>T); ClinVar=VCV000449416; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Male 21195215 CVCL_XP74 HAP1 IGF2BP3 (-) 3 cancer cell line human CVCL_XP74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28868; IGF2BP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195216 CVCL_Y174 U937/UK110 cancer cell line human CVCL_Y174 CL:0000010 Sequence variation: Gene fusion; HGNC; 16063; MLLT10 + HGNC; 15514; PICALM; Name(s)=PICALM-MLLT10, CALM-AF10 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly129fs*51 (c.387_388insCGCC); Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Gly60Arg (c.178G>C); ClinVar=VCV000372590; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.559+1G>A (p.Val173Trpfs*59); ClinVar=VCV000428908; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Male 21195217 CVCL_XP79 HAP1 IL4R (-) 2 cancer cell line human CVCL_XP79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6015; IL4R; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195218 CVCL_Y179 HT-29/ETP cancer cell line human CVCL_Y179 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16) Female 21195219 CVCL_XP78 HAP1 IL32 (-) cancer cell line human CVCL_XP78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16830; IL32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195220 CVCL_Y178 HT-29/ADM cancer cell line human CVCL_Y178 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female 21195221 CVCL_P739 HG00173 transformed cell line human CVCL_P739 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195222 CVCL_P738 HG00171 transformed cell line human CVCL_P738 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195223 CVCL_P737 HG00160 transformed cell line human CVCL_P737 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195224 CVCL_P736 HG00159 transformed cell line human CVCL_P736 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195225 CVCL_P735 HG00158 transformed cell line human CVCL_P735 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195226 CVCL_P734 HG00157 transformed cell line human CVCL_P734 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195227 CVCL_P733 HG00156 transformed cell line human CVCL_P733 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195228 CVCL_P732 HG00155 transformed cell line human CVCL_P732 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195229 CVCL_P731 HG00154 transformed cell line human CVCL_P731 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195230 CVCL_P730 HG00152 transformed cell line human CVCL_P730 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195231 CVCL_P749 HG00185 transformed cell line human CVCL_P749 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195232 CVCL_P748 HG00183 transformed cell line human CVCL_P748 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195233 CVCL_P747 HG00182 transformed cell line human CVCL_P747 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195234 CVCL_P746 HG00181 transformed cell line human CVCL_P746 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195235 CVCL_P745 HG00180 transformed cell line human CVCL_P745 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195236 CVCL_P744 HG00179 transformed cell line human CVCL_P744 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195237 CVCL_P743 HG00178 transformed cell line human CVCL_P743 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195238 CVCL_P742 HG00177 transformed cell line human CVCL_P742 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195239 CVCL_P741 HG00176 transformed cell line human CVCL_P741 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195240 CVCL_P740 HG00174 transformed cell line human CVCL_P740 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195241 CVCL_P719 HG00139 transformed cell line human CVCL_P719 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195242 CVCL_P718 HG00138 transformed cell line human CVCL_P718 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195243 CVCL_P717 HG00137 transformed cell line human CVCL_P717 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195244 CVCL_P716 HG00136 transformed cell line human CVCL_P716 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195245 CVCL_P715 HG00135 transformed cell line human CVCL_P715 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195246 CVCL_P714 HG00134 transformed cell line human CVCL_P714 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195247 CVCL_P713 HG00133 transformed cell line human CVCL_P713 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195248 CVCL_P712 HG00132 transformed cell line human CVCL_P712 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195249 CVCL_P711 HG00131 transformed cell line human CVCL_P711 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195250 CVCL_P710 HG00130 transformed cell line human CVCL_P710 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195251 CVCL_P729 HG00151 transformed cell line human CVCL_P729 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195252 CVCL_P728 HG00150 transformed cell line human CVCL_P728 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195253 CVCL_P727 HG00149 transformed cell line human CVCL_P727 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195254 CVCL_P726 HG00148 transformed cell line human CVCL_P726 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195255 CVCL_P725 HG00146 transformed cell line human CVCL_P725 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195256 CVCL_P724 HG00145 transformed cell line human CVCL_P724 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195257 CVCL_P723 HG00143 transformed cell line human CVCL_P723 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195258 CVCL_P722 HG00142 transformed cell line human CVCL_P722 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195259 CVCL_P721 HG00141 transformed cell line human CVCL_P721 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195260 CVCL_P720 HG00140 transformed cell line human CVCL_P720 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195261 CVCL_P709 HG00129 transformed cell line human CVCL_P709 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195262 CVCL_P708 HG00128 transformed cell line human CVCL_P708 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195263 CVCL_P707 HG00127 transformed cell line human CVCL_P707 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195264 CVCL_P706 HG00126 transformed cell line human CVCL_P706 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195265 CVCL_P705 HG00125 transformed cell line human CVCL_P705 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195266 CVCL_P704 HG00124 transformed cell line human CVCL_P704 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195267 CVCL_P703 HG00123 transformed cell line human CVCL_P703 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195268 CVCL_P702 HG00122 transformed cell line human CVCL_P702 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195269 CVCL_P701 HG00121 transformed cell line human CVCL_P701 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195270 CVCL_P700 HG00120 transformed cell line human CVCL_P700 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195271 CVCL_5J10 PC-3M-Red-FLuc cancer cell line human CVCL_5J10 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; BW124089; probable Male Doubling time: 20 hours (PerkinElmer) 21195272 CVCL_5J14 BxPc-3-luc2 cancer cell line human CVCL_5J14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Pancreas. Discontinued: PerkinElmer; 125058; true Female 21195273 CVCL_5J13 A549-luc-C8 cancer cell line human CVCL_5J13 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Discontinued: PerkinElmer; 119266; true Male 21195274 CVCL_5J12 U87 MG-Red-FLuc cancer cell line human CVCL_5J12 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Doubling time: 34 hours (PerkinElmer) Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21195275 CVCL_5J11 SKOV3-Red-FLuc cancer cell line human CVCL_5J11 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Ascites. Female Doubling time: 35 hours (PerkinElmer) 21195276 CVCL_5J18 Colo205-luc2 cancer cell line human CVCL_5J18 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asn287Ser (c.860A>G); ClinVar=VCV000133954; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr103fs*37 (c.308_321delTGTGTAACAGTTCC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from metastatic site: Ascites. Discontinued: PerkinElmer; 124317; true Male 21195277 CVCL_5J17 B16-F10-luc2 [Caliper] cancer cell line house mouse CVCL_5J17 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Discontinued: PerkinElmer; 124734; true Male 21195278 CVCL_5J16 MOLT-4-luc2 cancer cell line human CVCL_5J16 CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Discontinued: PerkinElmer; 125057; true Male 21195279 CVCL_5J15 U-87 MG-luc2 cancer cell line human CVCL_5J15 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Phe1247Ilefs*18 (c.3739_3742delTTTG) (3737_3740delTGTT); ClinVar=VCV000420078; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.209+1G>T; ClinVar=VCV000229705; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Discontinued: PerkinElmer; 124577; true. Male Problematic cell line: Misidentified Parent cell line (U-87MG ATCC) is not the original glioblastoma cell line established in 1968 at the University of Uppsala. 21195280 CVCL_5J09 PC-3-Red-FLuc-GFP cancer cell line human CVCL_5J09 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: 24 hours (PerkinElmer) 21195281 CVCL_5J08 PC-3-Red-FLuc cancer cell line human CVCL_5J08 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Bone. Male Doubling time: 24 hours (PerkinElmer) 21195282 CVCL_XP62 HAP1 HSD17B12 (-) cancer cell line human CVCL_XP62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18646; HSD17B12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195283 CVCL_Y162 LC20 cancer cell line human CVCL_Y162 CL:0000010 Unspecified 21195284 CVCL_XP61 HAP1 HPS1 (-) 3 cancer cell line human CVCL_XP61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5163; HPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195285 CVCL_Y161 LC18 cancer cell line human CVCL_Y161 CL:0000010 Unspecified 21195286 CVCL_XP60 HAP1 HPS1 (-) 2 cancer cell line human CVCL_XP60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5163; HPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195287 CVCL_Y160 LC17 cancer cell line human CVCL_Y160 CL:0000010 Unspecified 21195288 CVCL_XP66 HAP1 ICAM5 (-) 2 cancer cell line human CVCL_XP66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5348; ICAM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195289 CVCL_Y166 LC26 cancer cell line human CVCL_Y166 CL:0000010 Unspecified 21195290 CVCL_XP65 HAP1 ICAM1 (-) 2 cancer cell line human CVCL_XP65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5344; ICAM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195291 CVCL_Y165 LC25 cancer cell line human CVCL_Y165 CL:0000010 Unspecified 21195292 CVCL_XP64 HAP1 HTRA2 (-) cancer cell line human CVCL_XP64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14348; HTRA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195293 CVCL_Y164 LC23 cancer cell line human CVCL_Y164 CL:0000010 Unspecified 21195294 CVCL_XP63 HAP1 HSP90AA1 (-) 2 cancer cell line human CVCL_XP63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5253; HSP90AA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195295 CVCL_Y163 LC21 cancer cell line human CVCL_Y163 CL:0000010 Unspecified 21195296 CVCL_XP69 HAP1 ID1 (-) 2 cancer cell line human CVCL_XP69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5360; ID1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195297 CVCL_Y169 K562/etop80 cancer cell line human CVCL_Y169 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Female 21195298 CVCL_XP68 HAP1 ICAM5 (-) 4 cancer cell line human CVCL_XP68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5348; ICAM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195299 CVCL_Y168 K562/etop20 cancer cell line human CVCL_Y168 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Pleural effusion. Female 21195300 CVCL_XP67 HAP1 ICAM5 (-) 3 cancer cell line human CVCL_XP67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5348; ICAM5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195301 CVCL_Y167 LC27 cancer cell line human CVCL_Y167 CL:0000010 Unspecified 21195302 CVCL_XP49 HAP1 HDHD3 (-) 5 cancer cell line human CVCL_XP49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28171; HDHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195303 CVCL_Y149 LC03 cancer cell line human CVCL_Y149 CL:0000010 Unspecified 21195304 CVCL_5J21 K562-luc2 cancer cell line human CVCL_5J21 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Pleural effusion. Discontinued: PerkinElmer; 124735; true Female 21195305 CVCL_5J20 HT29-luc2 cancer cell line human CVCL_5J20 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Discontinued: PerkinElmer; 124353; true. Female 21195306 CVCL_5J25 PC-3M-luc2 cancer cell line human CVCL_5J25 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; 128444; true Male 21195307 CVCL_5J24 LNCaP-luc2 cancer cell line human CVCL_5J24 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Discontinued: PerkinElmer; 125055; true Male 21195308 CVCL_5J23 NCI-H460-luc2 cancer cell line human CVCL_5J23 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 124316; true Male 21195309 CVCL_5J22 EL4-luc2 [Caliper] cancer cell line house mouse CVCL_5J22 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Discontinued: PerkinElmer; 124088; true Unspecified 21195310 CVCL_5J29 PC-3-luc2-GFP cancer cell line human CVCL_5J29 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; 133416; true Male 21195311 CVCL_5J28 4T1-luc2-GFP cancer cell line house mouse CVCL_5J28 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Discontinued: PerkinElmer; 129090; true Female 21195312 CVCL_5J27 ACHN-luc2 cancer cell line human CVCL_5J27 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; 125056; true Male 21195313 CVCL_5J26 PC-3-luc2 cancer cell line human CVCL_5J26 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Bone. Discontinued: PerkinElmer; 124089; true Male 21195314 CVCL_5J19 HCT 116-luc2 [Caliper] cancer cell line human CVCL_5J19 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Colon. Discontinued: PerkinElmer; 124318; true Male 21195315 CVCL_XP51 HAP1 HERC1 (-) cancer cell line human CVCL_XP51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4867; HERC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC8925; probable Male Group: Haploid karyotype cell line 21195316 CVCL_Y151 LC05 cancer cell line human CVCL_Y151 CL:0000010 Unspecified 21195317 CVCL_XP50 HAP1 HECTD1 (-) 1 cancer cell line human CVCL_XP50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20157; HECTD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195318 CVCL_Y150 LC04 cancer cell line human CVCL_Y150 CL:0000010 Unspecified 21195319 CVCL_XP55 HAP1 HIP1 (-) 2 cancer cell line human CVCL_XP55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4913; HIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195320 CVCL_Y155 LC09 cancer cell line human CVCL_Y155 CL:0000010 Unspecified 21195321 CVCL_XP54 HAP1 HIF1AN (-) 1 cancer cell line human CVCL_XP54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17113; HIF1AN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195322 CVCL_Y154 LC08 cancer cell line human CVCL_Y154 CL:0000010 Unspecified 21195323 CVCL_XP53 HAP1 HIAT1 (-) 2 cancer cell line human CVCL_XP53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23363; MFSD14A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195324 CVCL_Y153 LC07 cancer cell line human CVCL_Y153 CL:0000010 Unspecified 21195325 CVCL_XP52 HAP1 HERPUD2 (-) 2 cancer cell line human CVCL_XP52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21915; HERPUD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195326 CVCL_Y152 LC06 cancer cell line human CVCL_Y152 CL:0000010 Unspecified 21195327 CVCL_XP59 HAP1 HMOX2 (-) 2 cancer cell line human CVCL_XP59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5014; HMOX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195328 CVCL_Y159 LC16 cancer cell line human CVCL_Y159 CL:0000010 Unspecified 21195329 CVCL_XP58 HAP1 HMOX1 (-) 2 cancer cell line human CVCL_XP58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5013; HMOX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195330 CVCL_Y158 LC15 cancer cell line human CVCL_Y158 CL:0000010 Unspecified 21195331 CVCL_XP57 HAP1 HLA-G (-) 2 cancer cell line human CVCL_XP57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4964; HLA-G; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195332 CVCL_Y157 LC11 cancer cell line human CVCL_Y157 CL:0000010 Unspecified 21195333 CVCL_XP56 HAP1 HLA-E (-) cancer cell line human CVCL_XP56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4962; HLA-E; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195334 CVCL_Y156 LC10 cancer cell line human CVCL_Y156 CL:0000010 Unspecified 21195335 CVCL_XP39 HAP1 GRINA (-) 4 cancer cell line human CVCL_XP39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4589; GRINA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195336 CVCL_Y139 MP-N-MS cancer cell line human CVCL_Y139 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. Female 21195337 CVCL_XP38 HAP1 GRINA (-) 3 cancer cell line human CVCL_XP38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4589; GRINA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195338 CVCL_Y138 KP-N-YuNo cancer cell line human CVCL_Y138 CL:0000010 Population: Japanese; Derived from sampling site: Retroperitoneal space. 21195339 CVCL_XP40 HAP1 GSDMD (-) 1 cancer cell line human CVCL_XP40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25697; GSDMD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195340 CVCL_Y140 MP-N-TS cancer cell line human CVCL_Y140 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male 21195341 CVCL_P799 HG00278 transformed cell line human CVCL_P799 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195342 CVCL_P798 HG00277 transformed cell line human CVCL_P798 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195343 CVCL_P797 HG00276 transformed cell line human CVCL_P797 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195344 CVCL_XP44 HAP1 GTF2I (-) 2 cancer cell line human CVCL_XP44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4659; GTF2I; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195345 CVCL_Y144 Hep-KANO clone 2 cancer cell line human CVCL_Y144 CL:0000010 Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Doubling time: 36 hours (PubMed=7829395) 21195346 CVCL_P796 HG00275 transformed cell line human CVCL_P796 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195347 CVCL_XP43 HAP1 GSTM2 (-) 2 cancer cell line human CVCL_XP43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4634; GSTM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195348 CVCL_Y143 Hep-KANO clone 1 cancer cell line human CVCL_Y143 CL:0000010 Population: Japanese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407). Male Doubling time: 45 hours (PubMed=7829395) 21195349 CVCL_P795 HG00274 transformed cell line human CVCL_P795 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195350 CVCL_XP42 HAP1 GSN (-) 2 cancer cell line human CVCL_XP42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4620; GSN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195351 CVCL_P794 HG00273 transformed cell line human CVCL_P794 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195352 CVCL_Y142 KP-4-4 cancer cell line human CVCL_Y142 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Male 21195353 CVCL_XP41 HAP1 GSKIP (-) cancer cell line human CVCL_XP41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20343; GSKIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195354 CVCL_P793 HG00272 transformed cell line human CVCL_P793 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195355 CVCL_Y141 SJ-N-CG cancer cell line human CVCL_Y141 CL:0000010 Female 21195356 CVCL_XP48 HAP1 HDHD3 (-) 4 cancer cell line human CVCL_XP48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28171; HDHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195357 CVCL_P792 HG00271 transformed cell line human CVCL_P792 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195358 CVCL_Y148 LC02-No.2 cancer cell line human CVCL_Y148 CL:0000010 Unspecified 21195359 CVCL_XP47 HAP1 HDHD3 (-) 3 cancer cell line human CVCL_XP47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28171; HDHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195360 CVCL_P791 HG00270 transformed cell line human CVCL_P791 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195361 CVCL_Y147 LC02 cancer cell line human CVCL_Y147 CL:0000010 Unspecified 21195362 CVCL_XP46 HAP1 HDHD3 (-) 2 cancer cell line human CVCL_XP46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28171; HDHD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195363 CVCL_P790 HG00269 transformed cell line human CVCL_P790 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195364 CVCL_Y146 LC01 cancer cell line human CVCL_Y146 CL:0000010 Unspecified 21195365 CVCL_XP45 HAP1 H2AFY (-) 2 cancer cell line human CVCL_XP45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4740; MACROH2A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195366 CVCL_Y145 Hep-Tabata cancer cell line human CVCL_Y145 CL:0000010 Population: Japanese; Derived from sampling site: Liver. 21195367 CVCL_XP29 HAP1 GORAB (-) 2 cancer cell line human CVCL_XP29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25676; GORAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195368 CVCL_Y129 HUT70 cancer cell line human CVCL_Y129 CL:0000010 Population: Japanese. Unspecified 21195369 CVCL_XP28 HAP1 GOLM1 (-) cancer cell line human CVCL_XP28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15451; GOLM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195370 CVCL_Y128 Tes Man finite cell line human CVCL_Y128 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1154; true Female 21195371 CVCL_XP27 HAP1 GOLGB1 (-) 2 cancer cell line human CVCL_XP27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4429; GOLGB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195372 CVCL_Y127 Ro Das finite cell line human CVCL_Y127 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1114; probable Female 21195373 CVCL_5J03 LNCaP-Red-FLuc cancer cell line human CVCL_5J03 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Doubling time: 60 hours (PerkinElmer) 21195374 CVCL_5J02 LL/2-Red-FLuc cancer cell line house mouse CVCL_5J02 CL:0000010 Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Doubling time: 24 hours (PerkinElmer) 21195375 CVCL_5J01 K562-Red-FLuc cancer cell line human CVCL_5J01 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Pleural effusion. Female Doubling time: 15 hours (PerkinElmer) 21195376 CVCL_5J00 HT-29-Red-FLuc cancer cell line human CVCL_5J00 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Doubling time: 24 hours (PerkinElmer) 21195377 CVCL_5J07 NCI-H460-Red-Fluc cancer cell line human CVCL_5J07 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from metastatic site: Pleural effusion. Male Doubling time: 16 hours (PerkinElmer) 21195378 CVCL_5J06 MDA-MB-231-Red-FLuc-GFP cancer cell line human CVCL_5J06 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; BW128442; probable Female Doubling time: 24 hours (PerkinElmer) Group: Triple negative breast cancer (TNBC) cell line 21195379 CVCL_5J05 MDA-MB-231-Red-FLuc cancer cell line human CVCL_5J05 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Discontinued: PerkinElmer; BW124319; probable Female Doubling time: 24 hours (PerkinElmer) Group: Triple negative breast cancer (TNBC) cell line 21195380 CVCL_5J04 MCF-7-Red-Fluc cancer cell line human CVCL_5J04 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; Q1AG35; Italian firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Doubling time: 40 hours (PerkinElmer) 21195381 CVCL_XP33 HAP1 GPR137C (-) 3 cancer cell line human CVCL_XP33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25445; GPR137C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195382 CVCL_Y133 KP-N-YS2s cancer cell line human CVCL_Y133 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Bone marrow. Male 21195383 CVCL_XP32 HAP1 GPD2 (-) cancer cell line human CVCL_XP32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4456; GPD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195384 CVCL_Y132 KP-N-YS1n cancer cell line human CVCL_Y132 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Bone marrow. Male 21195385 CVCL_XP31 HAP1 GOT2 (-) cancer cell line human CVCL_XP31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4433; GOT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195386 CVCL_XP30 HAP1 GORAB (-) 3 cancer cell line human CVCL_XP30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25676; GORAB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195387 CVCL_XP37 HAP1 GRINA (-) 2 cancer cell line human CVCL_XP37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4589; GRINA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195388 CVCL_Y137 KP-N-TK cancer cell line human CVCL_Y137 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male 21195389 CVCL_XP36 HAP1 GRHL1 (-) cancer cell line human CVCL_XP36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17923; GRHL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195390 CVCL_Y136 KP-N-SK cancer cell line human CVCL_Y136 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. 21195391 CVCL_XP35 HAP1 GPX4 (-) 2 cancer cell line human CVCL_XP35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4556; GPX4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195392 CVCL_Y135 KP-N-NY cancer cell line human CVCL_Y135 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. 21195393 CVCL_XP34 HAP1 GPR78 (-) cancer cell line human CVCL_XP34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4528; GPR78; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195394 CVCL_Y134 KP-N-HN cancer cell line human CVCL_Y134 CL:0000010 Population: Japanese; Derived from metastatic site: Bone marrow. 21195395 CVCL_Y119 CCD-57Sk finite cell line human CVCL_Y119 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1517; true Female 21195396 CVCL_XP19 HAP1 GLUD1 (-) 2 cancer cell line human CVCL_XP19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4335; GLUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195397 CVCL_Y118 CCD-21Sk finite cell line human CVCL_Y118 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1467; true Female 21195398 CVCL_XP18 HAP1 GLRX5 (-) cancer cell line human CVCL_XP18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20134; GLRX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195399 CVCL_Y117 CCD-187Sk finite cell line human CVCL_Y117 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1564; true Female 21195400 CVCL_XP17 HAP1 GLOD4 (-) 3 cancer cell line human CVCL_XP17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14111; GLOD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195401 CVCL_Y116 CCD-118Sk finite cell line human CVCL_Y116 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1537; true Male 21195402 CVCL_XP16 HAP1 GLOD4 (-) 2 cancer cell line human CVCL_XP16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14111; GLOD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195403 CVCL_P779 HG00258 transformed cell line human CVCL_P779 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195404 CVCL_P778 HG00257 transformed cell line human CVCL_P778 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195405 CVCL_P777 HG00256 transformed cell line human CVCL_P777 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195406 CVCL_P776 HG00255 transformed cell line human CVCL_P776 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195407 CVCL_P775 HG00254 transformed cell line human CVCL_P775 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195408 CVCL_XP22 HAP1 GLUD1 (-) 5 cancer cell line human CVCL_XP22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4335; GLUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195409 CVCL_P774 HG00253 transformed cell line human CVCL_P774 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195410 CVCL_Y122 TS-ED finite cell line human CVCL_Y122 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1406; true Female 21195411 CVCL_Y121 CCD-82Sk finite cell line human CVCL_Y121 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1527; true Female 21195412 CVCL_XP21 HAP1 GLUD1 (-) 4 cancer cell line human CVCL_XP21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4335; GLUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195413 CVCL_P773 HG00252 transformed cell line human CVCL_P773 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195414 CVCL_Y120 CCD-76Sk finite cell line human CVCL_Y120 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1521; true Male 21195415 CVCL_XP20 HAP1 GLUD1 (-) 3 cancer cell line human CVCL_XP20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4335; GLUD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195416 CVCL_P772 HG00251 transformed cell line human CVCL_P772 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195417 CVCL_P771 HG00250 transformed cell line human CVCL_P771 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195418 CVCL_XP26 HAP1 GOLGA2 (-) 2 cancer cell line human CVCL_XP26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4425; GOLGA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195419 CVCL_P770 HG00249 transformed cell line human CVCL_P770 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195420 CVCL_Y126 MF finite cell line human CVCL_Y126 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1375; true Female 21195421 CVCL_XP25 HAP1 GNPDA2 (-) cancer cell line human CVCL_XP25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21526; GNPDA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195422 CVCL_Y125 Kin Sun finite cell line human CVCL_Y125 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1241; true Male 21195423 CVCL_XP24 HAP1 GNG5 (-) 2 cancer cell line human CVCL_XP24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4408; GNG5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195424 CVCL_Y124 Jay Ver finite cell line human CVCL_Y124 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1127; true Male 21195425 CVCL_Y123 Flo Tel finite cell line human CVCL_Y123 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1128; true Female 21195426 CVCL_XP23 HAP1 GLUL (-) 2 cancer cell line human CVCL_XP23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4341; GLUL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195427 CVCL_Y108 5E9 TLK-2 hybridoma CVCL_Y108 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q86UE8; Human TLK2. 21195428 CVCL_XP08 HAP1 GBE1 (-) 2 cancer cell line human CVCL_XP08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4180; GBE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195429 CVCL_XP07 HAP1 GATA3 (-) 2 cancer cell line human CVCL_XP07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4172; GATA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195430 CVCL_Y107 VGH-EPY cancer cell line human CVCL_Y107 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Brain; ventricle. Female 21195431 CVCL_XP06 HAP1 GATA2 (-) 4 cancer cell line human CVCL_XP06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195432 CVCL_Y106 VGH-MED cancer cell line human CVCL_Y106 CL:0000010 Discontinued: BCRC; 60375; probable. Male 21195433 CVCL_Y105 BXD-1425EPN cancer cell line human CVCL_Y105 CL:0000010 Male Characteristics: Established from a second generation patient-derived xenograft established in the brain of RAG2/SCID mice. 21195434 CVCL_XP05 HAP1 GATA2 (-) 3 cancer cell line human CVCL_XP05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195435 CVCL_Y109 GM04994 finite cell line human CVCL_Y109 CL:0000010 Sequence variation: Mutation; HGNC; 57; ABCC6; Simple; p.Arg1141Ter (c.3421C>T); ClinVar=VCV000006559; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 57; ABCC6; Simple; p.Arg1164Ter (c.3490C>T); ClinVar=VCV000006572; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21195436 CVCL_XP09 HAP1 GID4 (-) 2 cancer cell line human CVCL_XP09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28453; GID4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195437 CVCL_P789 HG00268 transformed cell line human CVCL_P789 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195438 CVCL_P788 HG00267 transformed cell line human CVCL_P788 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195439 CVCL_P787 HG00266 transformed cell line human CVCL_P787 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195440 CVCL_P786 HG00265 transformed cell line human CVCL_P786 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195441 CVCL_XP11 HAP1 GID4 (-) 4 cancer cell line human CVCL_XP11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28453; GID4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195442 CVCL_P785 HG00264 transformed cell line human CVCL_P785 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195443 CVCL_Y111 HS-57 cancer cell line human CVCL_Y111 CL:0000010 Derived from metastatic site: Lung. Unspecified 21195444 CVCL_XP10 HAP1 GID4 (-) 3 cancer cell line human CVCL_XP10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28453; GID4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195445 CVCL_P784 HG00263 transformed cell line human CVCL_P784 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195446 CVCL_Y110 HS-24 cancer cell line human CVCL_Y110 CL:0000010 Male 21195447 CVCL_P783 HG00262 transformed cell line human CVCL_P783 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195448 CVCL_P782 HG00261 transformed cell line human CVCL_P782 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195449 CVCL_Y115 Ar Lip finite cell line human CVCL_Y115 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1233; true Male 21195450 CVCL_XP15 HAP1 GLO1 (-) 2 cancer cell line human CVCL_XP15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4323; GLO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195451 CVCL_P781 HG00260 transformed cell line human CVCL_P781 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195452 CVCL_XP14 HAP1 GLB1 (-) 1 cancer cell line human CVCL_XP14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4298; GLB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195453 CVCL_P780 HG00259 transformed cell line human CVCL_P780 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195454 CVCL_Y114 KM transformed cell line human CVCL_Y114 CL:0000010 Anecdotal: Cell line name corresponds to the first letters of the names of the first and last authors. Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Female Doubling time: 16 hours (PubMed=11676982) 21195455 CVCL_XP13 HAP1 GLA (-) 2 cancer cell line human CVCL_XP13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195456 CVCL_Y113 SKT-1B cancer cell line human CVCL_Y113 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21195457 CVCL_XP12 HAP1 GIT1 (-) 2 cancer cell line human CVCL_XP12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4272; GIT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195458 CVCL_Y112 SKT-1A cancer cell line human CVCL_Y112 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21195459 CVCL_P759 HG00236 transformed cell line human CVCL_P759 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195460 CVCL_P758 HG00235 transformed cell line human CVCL_P758 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195461 CVCL_P757 HG00234 transformed cell line human CVCL_P757 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195462 CVCL_P756 HG00233 transformed cell line human CVCL_P756 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195463 CVCL_P755 HG00232 transformed cell line human CVCL_P755 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195464 CVCL_P754 HG00231 transformed cell line human CVCL_P754 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195465 CVCL_P753 HG00190 transformed cell line human CVCL_P753 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195466 CVCL_Y100 CC-M4 cancer cell line human CVCL_Y100 CL:0000010 Population: Chinese Male Doubling time: 17.2 hours (at 25th passage), 16.8 hours (at 50th passage) (PubMed=1696674). 21195467 CVCL_XP00 HAP1 FXR1 (-) 3 cancer cell line human CVCL_XP00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4023; FXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195468 CVCL_P752 HG00188 transformed cell line human CVCL_P752 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195469 CVCL_P751 HG00187 transformed cell line human CVCL_P751 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195470 CVCL_P750 HG00186 transformed cell line human CVCL_P750 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195471 CVCL_XP04 HAP1 GATA2 (-) 2 cancer cell line human CVCL_XP04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4171; GATA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195472 CVCL_Y104 NU 2-26 cancer cell line human CVCL_Y104 CL:0000010 Population: Japanese; Derived from metastatic site: Brain; cerebellum. Male Doubling time: 24 hours (PubMed=6305379) 21195473 CVCL_Y103 CHO-betaGal-SF spontaneously immortalized cell line CVCL_Y103 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Ovary. Female Group: Serum/protein free medium cell line 21195474 CVCL_XP03 HAP1 GAD1 (-) 2 cancer cell line human CVCL_XP03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4092; GAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195475 CVCL_Y102 CHO-betaGal spontaneously immortalized cell line CVCL_Y102 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Derived from sampling site: Ovary. Discontinued: BCRC; 60377; probable Female 21195476 CVCL_XP02 HAP1 GAB1 (-) 2 cancer cell line human CVCL_XP02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4066; GAB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195477 CVCL_Y101 293/LacZ transformed cell line human CVCL_Y101 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21195478 CVCL_XP01 HAP1 FXR1 (-) 4 cancer cell line human CVCL_XP01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4023; FXR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21195479 CVCL_P769 HG00247 transformed cell line human CVCL_P769 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195480 CVCL_P768 HG00246 transformed cell line human CVCL_P768 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195481 CVCL_P767 HG00245 transformed cell line human CVCL_P767 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195482 CVCL_P766 HG00244 transformed cell line human CVCL_P766 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195483 CVCL_P765 HG00243 transformed cell line human CVCL_P765 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195484 CVCL_P764 HG00242 transformed cell line human CVCL_P764 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195485 CVCL_P763 HG00240 transformed cell line human CVCL_P763 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195486 CVCL_P762 HG00239 transformed cell line human CVCL_P762 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195487 CVCL_P761 HG00238 transformed cell line human CVCL_P761 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195488 CVCL_P760 HG00237 transformed cell line human CVCL_P760 CL:0000010 Population: Caucasian; British from England and Scotland (GBR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K27ac ChIP-seq epigenome analysis; Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195489 CVCL_P062 GM18978 transformed cell line human CVCL_P062 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195490 CVCL_P061 GM18977 transformed cell line human CVCL_P061 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195491 CVCL_P060 GM18976 transformed cell line human CVCL_P060 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195492 CVCL_XI03 7B11 [Mouse hybridoma against human AFP] hybridoma house mouse CVCL_XI03 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02771; Human AFP. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.5194 21195493 CVCL_XI02 3D5 [Mouse hybridoma against human AFP] hybridoma house mouse CVCL_XI02 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02771; Human AFP. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.5193 21195494 CVCL_XI01 7-142 hybridoma house mouse CVCL_XI01 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11716 21195495 CVCL_XI00 6-4-11 hybridoma house mouse CVCL_XI00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11715 21195496 CVCL_P059 GM18975 transformed cell line human CVCL_P059 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195497 CVCL_XI07 MEP01 hybridoma house mouse CVCL_XI07 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. 21195498 CVCL_XI06 A549-ESM cancer cell line human CVCL_XI06 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3466; ESM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1972 21195499 CVCL_P058 GM18974 transformed cell line human CVCL_P058 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195500 CVCL_XI05 293-ESM transformed cell line human CVCL_XI05 CL:0000010 Transfected with: HGNC; 3466; ESM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1971 21195501 CVCL_P057 GM18973 transformed cell line human CVCL_P057 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195502 CVCL_XI04 CHO-K1-ESM spontaneously immortalized cell line CVCL_XI04 CL:0000010 Transfected with: HGNC; 3466; ESM1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1970 21195503 CVCL_P056 GM18972 transformed cell line human CVCL_P056 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195504 CVCL_P055 GM18971 transformed cell line human CVCL_P055 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195505 CVCL_P054 GM18970 transformed cell line human CVCL_P054 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195506 CVCL_P053 GM18969 transformed cell line human CVCL_P053 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195507 CVCL_XI09 MEP06 hybridoma house mouse CVCL_XI09 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. 21195508 CVCL_P052 GM18968 transformed cell line human CVCL_P052 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195509 CVCL_XI08 MEP04 hybridoma house mouse CVCL_XI08 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. 21195510 CVCL_P073 GM18989 transformed cell line human CVCL_P073 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195511 CVCL_P072 GM18988 transformed cell line human CVCL_P072 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195512 CVCL_P071 GM18987 transformed cell line human CVCL_P071 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195513 CVCL_P070 GM18986 transformed cell line human CVCL_P070 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195514 CVCL_P069 GM18985 transformed cell line human CVCL_P069 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195515 CVCL_P068 GM18984 transformed cell line human CVCL_P068 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195516 CVCL_P067 GM18983 transformed cell line human CVCL_P067 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195517 CVCL_P066 GM18982 transformed cell line human CVCL_P066 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195518 CVCL_P065 GM18981 transformed cell line human CVCL_P065 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195519 CVCL_P064 GM18980 transformed cell line human CVCL_P064 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195520 CVCL_P063 GM18979 transformed cell line human CVCL_P063 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195521 CVCL_P040 GM18955 transformed cell line human CVCL_P040 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195522 CVCL_P039 GM18954 transformed cell line human CVCL_P039 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195523 CVCL_P038 GM18953 transformed cell line human CVCL_P038 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195524 CVCL_P037 GM18952 transformed cell line human CVCL_P037 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195525 CVCL_P036 GM18527 transformed cell line human CVCL_P036 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195526 CVCL_P035 GM18950 transformed cell line human CVCL_P035 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195527 CVCL_P034 GM18949 transformed cell line human CVCL_P034 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195528 CVCL_P033 GM18948 transformed cell line human CVCL_P033 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195529 CVCL_P032 GM18947 transformed cell line human CVCL_P032 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195530 CVCL_P031 GM18946 transformed cell line human CVCL_P031 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195531 CVCL_P030 GM18945 transformed cell line human CVCL_P030 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195532 CVCL_P051 GM18967 transformed cell line human CVCL_P051 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195533 CVCL_P050 GM18966 transformed cell line human CVCL_P050 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195534 CVCL_P049 GM18965 transformed cell line human CVCL_P049 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195535 CVCL_P048 GM18964 transformed cell line human CVCL_P048 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195536 CVCL_P047 GM18963 transformed cell line human CVCL_P047 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195537 CVCL_P046 GM18962 transformed cell line human CVCL_P046 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195538 CVCL_P045 GM18961 transformed cell line human CVCL_P045 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195539 CVCL_P044 GM18960 transformed cell line human CVCL_P044 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195540 CVCL_P043 GM18959 transformed cell line human CVCL_P043 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195541 CVCL_P042 GM18957 transformed cell line human CVCL_P042 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195542 CVCL_P041 GM18956 transformed cell line human CVCL_P041 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195543 CVCL_G689 anti-SR hybridoma house mouse CVCL_G689 CL:0000010 Monoclonal antibody isotype: IgG1. 21195544 CVCL_FU89 ND30247 transformed cell line human CVCL_FU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195545 CVCL_G688 FB2 hybridoma house mouse CVCL_G688 CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: ChEBI; CHEBI:74956; O(4)-phosphotyrosine. 21195546 CVCL_FU88 ND30246 transformed cell line human CVCL_FU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195547 CVCL_FU87 ND30200 transformed cell line human CVCL_FU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195548 CVCL_G687 P3 8D2 hybridoma house mouse CVCL_G687 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9169 21195549 CVCL_FU86 ND30166 transformed cell line human CVCL_FU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195550 CVCL_G686 OX-32 hybridoma house mouse CVCL_G686 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21195551 CVCL_FU81 ND29567 transformed cell line human CVCL_FU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195552 CVCL_G681 OX-19 hybridoma house mouse CVCL_G681 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P51882; Rat Cd5. 21195553 CVCL_FU80 ND29564 transformed cell line human CVCL_FU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195554 CVCL_G680 OX-18 hybridoma house mouse CVCL_G680 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat MHC class II RT1-A. 21195555 CVCL_P019 GM21137 transformed cell line human CVCL_P019 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195556 CVCL_FU85 ND29937 transformed cell line human CVCL_FU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195557 CVCL_G685 OX-22 hybridoma house mouse CVCL_G685 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21195558 CVCL_P018 GM21135 transformed cell line human CVCL_P018 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195559 CVCL_FU84 ND29797 transformed cell line human CVCL_FU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195560 CVCL_G684 OX-21 hybridoma house mouse CVCL_G684 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05156; Human CFI. 21195561 CVCL_P017 GM21133 transformed cell line human CVCL_P017 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195562 CVCL_FU83 ND29796 transformed cell line human CVCL_FU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195563 CVCL_G683 OX-20 hybridoma Norway rat CVCL_G683 CL:0000010 Discontinued: ECACC; 88070801; probable. Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Mouse Ig kappa light chains 21195564 CVCL_P016 GM21130 transformed cell line human CVCL_P016 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195565 CVCL_FU82 ND29572 transformed cell line human CVCL_FU82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195566 CVCL_G682 OX-2 hybridoma house mouse CVCL_G682 CL:0000010 Monoclonal antibody isotype: IgG1. 21195567 CVCL_P015 GM21129 transformed cell line human CVCL_P015 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195568 CVCL_P014 GM21128 transformed cell line human CVCL_P014 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195569 CVCL_P013 GM21127 transformed cell line human CVCL_P013 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195570 CVCL_P012 GM21126 transformed cell line human CVCL_P012 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195571 CVCL_P011 GM21125 transformed cell line human CVCL_P011 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195572 CVCL_P010 GM21124 transformed cell line human CVCL_P010 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195573 CVCL_G699 KYSE-360 cancer cell line human CVCL_G699 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 61.6 hours (PubMed=1728357) 21195574 CVCL_FU99 ND31789 transformed cell line human CVCL_FU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195575 CVCL_G698 KYSE-200 cancer cell line human CVCL_G698 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (PubMed=8575860) Population: Japanese; Derived from sampling site: Esophagus. Discontinued: JCRB; JCRB1085; probable; Discontinued: JCRB; NIHS0364; true Male Doubling time: 23.5 hours (PubMed=1728357) 21195576 CVCL_FU98 ND31740 transformed cell line human CVCL_FU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195577 CVCL_FU97 ND31660 transformed cell line human CVCL_FU97 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195578 CVCL_G697 Sp2/0-Ag14-Turbodoma cancer cell line house mouse CVCL_G697 CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line; Group: Serum/protein free medium cell line 21195579 CVCL_G692 DII 33.1 hybridoma house mouse CVCL_G692 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06213; Human INSR/CD220. 21195580 CVCL_FU92 ND30687 transformed cell line human CVCL_FU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195581 CVCL_G691 BUC cancer cell line human CVCL_G691 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 21195582 CVCL_FU91 ND30411 transformed cell line human CVCL_FU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195583 CVCL_G690 anti-SRp20 hybridoma house mouse CVCL_G690 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P84103; Human SRSF3. 21195584 CVCL_FU90 ND30387 transformed cell line human CVCL_FU90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195585 CVCL_G696 7E12H12 hybridoma house mouse CVCL_G696 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human colonic epithelial protein (CEP) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9397 21195586 CVCL_FU96 ND31514 transformed cell line human CVCL_FU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195587 CVCL_G695 BA-G5 hybridoma house mouse CVCL_G695 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; F1N2G0; Bovine MYH6 (Note=Also recognizes other mammalian species). 21195588 CVCL_P029 GM18944 transformed cell line human CVCL_P029 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195589 CVCL_FU95 ND30925 transformed cell line human CVCL_FU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195590 CVCL_G694 50-6 hybridoma house mouse CVCL_G694 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P48509; Human CD151. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-227 21195591 CVCL_P028 GM18943 transformed cell line human CVCL_P028 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195592 CVCL_FU94 ND30700 transformed cell line human CVCL_FU94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195593 CVCL_G693 41-2 hybridoma house mouse CVCL_G693 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q9H5V8; Human CDCDP1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-226 21195594 CVCL_P027 GM18942 transformed cell line human CVCL_P027 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195595 CVCL_FU93 ND30692 transformed cell line human CVCL_FU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195596 CVCL_P026 GM18941 transformed cell line human CVCL_P026 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195597 CVCL_P025 GM18940 transformed cell line human CVCL_P025 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195598 CVCL_P024 GM18939 transformed cell line human CVCL_P024 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195599 CVCL_P023 GM21144 transformed cell line human CVCL_P023 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195600 CVCL_P022 GM21143 transformed cell line human CVCL_P022 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195601 CVCL_P021 GM21142 transformed cell line human CVCL_P021 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195602 CVCL_P020 GM21141 transformed cell line human CVCL_P020 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195603 CVCL_G667 LB3.1 hybridoma house mouse CVCL_G667 CL:0000010 Monoclonal antibody isotype: IgG2a. 21195604 CVCL_FU67 ND27547 transformed cell line human CVCL_FU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195605 CVCL_G666 IgG-1B7 hybridoma house mouse CVCL_G666 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q04631; Rat Fnta. 21195606 CVCL_FU66 ND27404 transformed cell line human CVCL_FU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195607 CVCL_G665 IgG-7D4 hybridoma house mouse CVCL_G665 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q60429; Cricetulus griseus Srebf2. 21195608 CVCL_FU65 ND27378 transformed cell line human CVCL_FU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195609 CVCL_G664 IgG-6A6 hybridoma house mouse CVCL_G664 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P98166; Rat Vldlr (Note=Also reacts with other species). 21195610 CVCL_FU64 ND27174 transformed cell line human CVCL_FU64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195611 CVCL_G669 MLH1 hybridoma house mouse CVCL_G669 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plants light-harvesting complex II (LHC-II). 21195612 CVCL_FU69 ND28088 transformed cell line human CVCL_FU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195613 CVCL_G668 MAb104 hybridoma house mouse CVCL_G668 CL:0000010 Monoclonal antibody isotype: IgM. 21195614 CVCL_FU68 ND28086 transformed cell line human CVCL_FU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195615 CVCL_G663 IgG-5D7 hybridoma house mouse CVCL_G663 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G1T4Z1; Rabbit LRP1. 21195616 CVCL_FU63 ND26355 transformed cell line human CVCL_FU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195617 CVCL_G662 IgG-4A4 hybridoma house mouse CVCL_G662 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01130; Human LDLR. 21195618 CVCL_FU62 ND26031 transformed cell line human CVCL_FU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195619 CVCL_G661 IgG-3B2 hybridoma house mouse CVCL_G661 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9VW37; Drosophila melanogaster SREBP. 21195620 CVCL_FU61 ND26028 transformed cell line human CVCL_FU61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195621 CVCL_G660 IgG-2F1 hybridoma house mouse CVCL_G660 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24386; Human CHM. 21195622 CVCL_FU60 ND25948 transformed cell line human CVCL_FU60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195623 CVCL_FU78 ND28925 transformed cell line human CVCL_FU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195624 CVCL_G678 OX-12 hybridoma house mouse CVCL_G678 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Rat Ig kappa light chains. 21195625 CVCL_FU77 ND28745 transformed cell line human CVCL_FU77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195626 CVCL_G677 OX-1 hybridoma house mouse CVCL_G677 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04157; Rat Ptprc/Cd45. 21195627 CVCL_FU76 ND28737 transformed cell line human CVCL_FU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195628 CVCL_G676 NN-5 [Mouse hybridoma against human GYPA] hybridoma house mouse CVCL_G676 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8476 21195629 CVCL_FU75 ND28600 transformed cell line human CVCL_FU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195630 CVCL_G675 NN-4 hybridoma house mouse CVCL_G675 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8473 21195631 CVCL_FU79 ND29481 transformed cell line human CVCL_FU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195632 CVCL_G679 OX-14 hybridoma house mouse CVCL_G679 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Rat IgG2b. 21195633 CVCL_G670 MLH2 hybridoma house mouse CVCL_G670 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Plants light-harvesting complex II (LHC-II). 21195634 CVCL_FU70 ND28244 transformed cell line human CVCL_FU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195635 CVCL_P009 GM21123 transformed cell line human CVCL_P009 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195636 CVCL_P008 GM21122 transformed cell line human CVCL_P008 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195637 CVCL_FU74 ND28597 transformed cell line human CVCL_FU74 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195638 CVCL_G674 NN-3 hybridoma house mouse CVCL_G674 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8474 21195639 CVCL_P007 GM21121 transformed cell line human CVCL_P007 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195640 CVCL_G673 MYC CT 9-B7.3 hybridoma house mouse CVCL_G673 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21195641 CVCL_FU73 ND28584 transformed cell line human CVCL_FU73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195642 CVCL_P006 GM21120 transformed cell line human CVCL_P006 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195643 CVCL_G672 MYC CT 14-G4.3 hybridoma house mouse CVCL_G672 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21195644 CVCL_FU72 ND28543 transformed cell line human CVCL_FU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195645 CVCL_P005 GM21119 transformed cell line human CVCL_P005 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195646 CVCL_G671 MYC 1-9E10.2 hybridoma house mouse CVCL_G671 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01106; Human MYC. 21195647 CVCL_FU71 ND28267 transformed cell line human CVCL_FU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195648 CVCL_P004 GM21118 transformed cell line human CVCL_P004 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195649 CVCL_P003 GM21117 transformed cell line human CVCL_P003 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195650 CVCL_P002 GM21116 transformed cell line human CVCL_P002 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195651 CVCL_P001 GM21115 transformed cell line human CVCL_P001 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195652 CVCL_P000 GM21114 transformed cell line human CVCL_P000 CL:0000010 Population: Indian; Gujarati in Houston, Texas, USA (GIH); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195653 CVCL_5C35 GM11921 transformed cell line human CVCL_5C35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142315 21195654 CVCL_5C34 GM11916 transformed cell line human CVCL_5C34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142310 21195655 CVCL_5C33 GM11915 transformed cell line human CVCL_5C33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142309 21195656 CVCL_5C32 GM11914 transformed cell line human CVCL_5C32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142308 21195657 CVCL_5C39 GM11925 transformed cell line human CVCL_5C39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142406 21195658 CVCL_5C38 GM11924 transformed cell line human CVCL_5C38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142405 21195659 CVCL_5C37 GM11923 transformed cell line human CVCL_5C37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142404 21195660 CVCL_5C36 GM11922 transformed cell line human CVCL_5C36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142403 21195661 CVCL_XI83 CDMLe012-A-1 embryonic stem cell human CVCL_XI83 From: Cancer Disease Modeling Laboratory, University of Texas Health Center at Houston; Houston; USA CL:0000010 Karyotypic information: 45,X0 Spontaneously lost an X-chromosome during cell culture.. Female 21195662 CVCL_XI82 SORMi002-A induced pluripotent stem cell human CVCL_XI82 From: School of Regenerative Medicine, Manipal University; Bengaluru; India CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21195663 CVCL_XI81 CCMi003-A induced pluripotent stem cell human CVCL_XI81 From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex51-53del; Zygosity=Hemizygous (PubMed=31465894) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21195664 CVCL_XI80 MHHi002-A-2 induced pluripotent stem cell human CVCL_XI80 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous; Note=By TALEN (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male Characteristics: Using TALEN a NeoR-T2A-dTomato(nuc) construct was integrated in frame in front of the start codon of one of the two alleles of CFTR (PubMed=31080112) 21195665 CVCL_XI87 TRNDi010-B induced pluripotent stem cell human CVCL_XI87 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21195666 CVCL_XI86 TRNDi010-A induced pluripotent stem cell human CVCL_XI86 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21195667 CVCL_XI85 NCCSi006-A induced pluripotent stem cell human CVCL_XI85 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21195668 CVCL_XI84 NCCSi005-A induced pluripotent stem cell human CVCL_XI84 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Female 21195669 CVCL_XI89 MDCUi001-A induced pluripotent stem cell human CVCL_XI89 From: Center of Excellence for Medical Genomics, Chulalongkorn University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 15455; MBTPS2; Simple; p.Asn459Ser (c.1376A>G); ClinVar=VCV000558767; Zygosity=Hemizygous (PubMed=31326747) Population: Southeast Asian; Thai; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21195670 CVCL_XI88 TRNDi010-C induced pluripotent stem cell human CVCL_XI88 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 17646; NGLY1; Simple; p.Arg401Ter (c.1201A>T); ClinVar=VCV000050962; Zygosity=Homozygous (PubMed=31326749) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21195671 CVCL_5C31 GM11913 transformed cell line human CVCL_5C31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142307 21195672 CVCL_5C30 GM11912 transformed cell line human CVCL_5C30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142306 21195673 CVCL_5C46 GM11984 transformed cell line human CVCL_5C46 HLA typing: A*01:01,29:02; B*44:03,57:01; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,01:03; DQB1*05:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25922) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136205 21195674 CVCL_5C45 GM11983 transformed cell line human CVCL_5C45 HLA typing: A*01:01,29:02; B*07:02,44:03; C*07:02,16:01; DPA1*01:03,01:03; DPB1*02:01:02,15:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25924) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136204 21195675 CVCL_5C44 GM11982 transformed cell line human CVCL_5C44 HLA typing: A*01:01,29:02; B*44:03,57:01; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,01:03; DQB1*05:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25926) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136203 21195676 CVCL_5C43 GM11929 transformed cell line human CVCL_5C43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142410 21195677 CVCL_5C49 GM11987 transformed cell line human CVCL_5C49 HLA typing: A*01:01,02:01; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*04:02,04:02; DQA1*01:01,01:03; DQB1*05:01:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25923) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136208 21195678 CVCL_5C48 GM11986 transformed cell line human CVCL_5C48 HLA typing: A*01:01,29:02; B*07:02,44:03; C*07:02,16:01; DPA1*01:03,01:03; DPB1*02:01:02,15:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25920) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136207 21195679 CVCL_5C47 GM11985 transformed cell line human CVCL_5C47 HLA typing: A*01:01,02:01; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*04:02,04:02; DQA1*01:01,01:03; DQB1*05:01:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25935) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136206 21195680 CVCL_XI72 CSSi010-A induced pluripotent stem cell human CVCL_XI72 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4401; GNB5; Simple_edited; c.204_208delCATGG; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31479876) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195681 CVCL_XI71 CSSi009-A induced pluripotent stem cell human CVCL_XI71 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 4401; GNB5; Simple; p.Glu88Argfs*8 (c.262delG) (p.Glu46Argfs*8, c.136delG); ClinVar=VCV001210290; Zygosity=Homozygous (PubMed=31479876) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21195682 CVCL_XI70 ZJB-ATC1 cancer cell line human CVCL_XI70 CL:0000010 Population: Chinese; Derived from sampling site: Thyroid gland. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201753 21195683 CVCL_XI76 IMSUTi002-A induced pluripotent stem cell human CVCL_XI76 From: Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 21195684 CVCL_XI75 SDQLCHi008-A induced pluripotent stem cell human CVCL_XI75 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 14262; AUTS2; Unexplicit; Ex1del; Zygosity=Heterozygous; Note=De novo mutation (PubMed=31505389) Population: Chinese; Han; Derived from sampling site: Urine. Male 21195685 CVCL_XI74 SDQLCHi004-A induced pluripotent stem cell human CVCL_XI74 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 12011; TPM2; Simple; p.Arg133Trp (c.397C>T); ClinVar=VCV000012463; Zygosity=Heterozygous (PubMed=31526942) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21195686 CVCL_XI73 IISHDOi006-A induced pluripotent stem cell human CVCL_XI73 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 118; ACO2; Simple; p.Glu667Lys (c.1999G>A); ClinVar=VCV001444087; Zygosity=Heterozygous (PubMed=31509793) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21195687 CVCL_XI79 MHHi002-A-3 induced pluripotent stem cell human CVCL_XI79 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (from parent cell line); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood Cell type=Endothelial colony forming cell.. Male Characteristics: Using TALEN a NeoR-T2A-dTomato(nuc) construct was integrated in frame in front of the start codon of one of the two alleles of CFTR (PubMed=31080112) 21195688 CVCL_XI78 MHHi006-A-1 induced pluripotent stem cell human CVCL_XI78 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Umbilical cord blood. Male Characteristics: Using TALEN a ZeoR-T2A-dTomato(nuc) construct was integrated in frame in front of the start codon of one of the two alleles of CFTR (PubMed=31473565) 21195689 CVCL_XI77 IMSUTi002-A-1 induced pluripotent stem cell human CVCL_XI77 From: Institute of Medical Science, University of Tokyo; Tokyo; Japan CL:0000010 Transfected with: HGNC; 3495; ETV6 (ETV6-RUNX1 fusion); Transfected with: HGNC; 10471; RUNX1 (ETV6-RUNX1 fusion); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Transfected with a Tet-on system so as to induce the expression of a mCherry and the ETV6-RUNX fusion protein with the addition of doxycycline to the culture medium 21195690 CVCL_5C42 GM11928 transformed cell line human CVCL_5C42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142409 21195691 CVCL_5C41 GM11927 transformed cell line human CVCL_5C41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142408 21195692 CVCL_5C40 GM11926 transformed cell line human CVCL_5C40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142407 21195693 CVCL_5C13 GM11872 transformed cell line human CVCL_5C13 HLA typing: A*03:01,68:01:02; B*07:02,44:04; C*07:02,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:01,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=25900) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134705 21195694 CVCL_5C12 GM11871 transformed cell line human CVCL_5C12 HLA typing: A*03:01,25:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,02:01:02; DPB1*01:01:01,04:02; DQA1*01:02,05:01; DQB1*02:01,06:02; DRB1*03:01,15:01; DRB3*01 (IPD-IMGT/HLA=25899) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134704 21195695 CVCL_5C11 GM11870 transformed cell line human CVCL_5C11 HLA typing: A*01:01,68:01:02; B*15:01,44:04; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:02; DRB1*04:01,11:01; DRB3*02; DRB4*01 (IPD-IMGT/HLA=25894) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134703 21195696 CVCL_5C10 GM11842 transformed cell line human CVCL_5C10 HLA typing: A*02:01,02:01; B*15:01,44:02:01:01; C*03:04:01,05:01; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:01,03:03; DRB1*04:01,07:01 (IPD-IMGT/HLA=25909) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134906 21195697 CVCL_5C17 GM11877 transformed cell line human CVCL_5C17 HLA typing: A*03:01,68:01:02; B*07:02,44:04; C*07:02,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:01,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=25904) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134710 21195698 CVCL_5C16 GM11876 transformed cell line human CVCL_5C16 HLA typing: A*03:01,68:01:02; B*07:02,44:04; C*07:02,16:01; DPA1*01:03,01:03; DPB1*04:01,04:02; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*11:01,15:01; DRB3*02; DRB5*01 (IPD-IMGT/HLA=25905) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134709 21195699 CVCL_5C15 GM11875 transformed cell line human CVCL_5C15 HLA typing: A*03:01,25:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,02:01:02; DPB1*01:01:01,04:02; DQA1*01:02,05:01; DQB1*02:01,06:02; DRB1*03:01,15:01; DRB3*01; DRB5*01 (IPD-IMGT/HLA=25902) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134708 21195700 CVCL_5C14 GM11873 transformed cell line human CVCL_5C14 HLA typing: A*01:01,68:01:02; B*15:01,44:04; C*06:02:01:01,16:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:02; DRB1*04:01,11:01; DRB3*02; DRB4*01 (IPD-IMGT/HLA=25903) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134706 21195701 CVCL_5C19 GM11879 transformed cell line human CVCL_5C19 HLA typing: A*01:01,68:01:02; B*44:04,08:01; C*16:01,07:01; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,11:01; DRB3*01,02 (IPD-IMGT/HLA=25896) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134712 21195702 CVCL_5C18 GM11878 transformed cell line human CVCL_5C18 HLA typing: A*01:01,25:01; B*08:01,15:01; C*06:02:01:01,07:01; DPA1*01:03,02:01:02; DPB1*01:01:01,04:02; DQA1*03:01,05:01; DQB1*02:01,03:02; DRB1*03:01,04:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25897) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134711 21195703 CVCL_XI61 COMM-1 cancer cell line human CVCL_XI61 CL:0000010 Population: Chinese Doubling time: 104.43 hours (Patent=CN105462928B). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201586 21195704 CVCL_XI60 1-5-2 hybridoma house mouse CVCL_XI60 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201588 21195705 CVCL_XI65 ZJB-ENC1 cancer cell line human CVCL_XI65 CL:0000010 Population: Chinese; Derived from sampling site: Endometrium. Omics: Deep exome analysis Female Doubling time: ~43 hours (PubMed=31772679) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016118 21195706 CVCL_XI64 ACSuR cancer cell line human CVCL_XI64 CL:0000010 Sequence variation: Mutation; HGNC; 7773; NF2; Simple; p.Arg57Ter (c.169C>T); ClinVar=VCV000003285; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:38940; Sunitinib; Derived from metastatic site: Pleural effusion. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014238 21195707 CVCL_XI63 7SuR cancer cell line human CVCL_XI63 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln149Ter (c.445C>T); ClinVar=VCV000404164; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Ala (c.832C>G); ClinVar=VCV000376645; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Gly104Alafs*55 (c.311delG); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:38940; Sunitinib; Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014217 21195708 CVCL_XI62 CSRCC01 cancer cell line human CVCL_XI62 CL:0000010 Population: Chinese Female Doubling time: ~48 hours (Patent=CN107058227B). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201722 21195709 CVCL_XI69 HepG2-CYP2B6-hCAR cancer cell line human CVCL_XI69 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2615; CYP2B6; Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 21195710 CVCL_XI68 ST-2014S spontaneously immortalized cell line pig CVCL_XI68 CL:0000010 Derived from sampling site: Fetal testis. Male Characteristics: Adapted to growth in suspension Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201567 21195711 CVCL_XI67 2D1C11 hybridoma house mouse CVCL_XI67 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q96EV8; Human DTNBP1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201564 21195712 CVCL_XI66 1E8H3 hybridoma house mouse CVCL_XI66 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q96EV8; Human DTNBP1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201565 21195713 CVCL_5C24 GM11887 transformed cell line human CVCL_5C24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137706 21195714 CVCL_5C23 GM11886 transformed cell line human CVCL_5C23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137705 21195715 CVCL_5C22 GM11885 transformed cell line human CVCL_5C22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137704 21195716 CVCL_5C21 GM11884 transformed cell line human CVCL_5C21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137703 21195717 CVCL_5C28 GM11910 transformed cell line human CVCL_5C28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142304 21195718 CVCL_5C27 GM11909 transformed cell line human CVCL_5C27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142303 21195719 CVCL_5C26 GM11895 transformed cell line human CVCL_5C26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137714 21195720 CVCL_5C25 GM11889 transformed cell line human CVCL_5C25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137708 21195721 CVCL_5C29 GM11911 transformed cell line human CVCL_5C29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142305 21195722 CVCL_XI50 HepG2-CAR cancer cell line human CVCL_XI50 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Liver. Male 21195723 CVCL_XI54 iSCA2 E209-9 induced pluripotent stem cell human CVCL_XI54 CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=30718627) Derived from sampling site: Peripheral blood. Female 21195724 CVCL_XI53 iSCA2 E209-6 induced pluripotent stem cell human CVCL_XI53 CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[44] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=30718627) Derived from sampling site: Peripheral blood. Female 21195725 CVCL_XI52 iSCA2-28 induced pluripotent stem cell human CVCL_XI52 CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[35] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21195726 CVCL_XI51 iSCA2-17 induced pluripotent stem cell human CVCL_XI51 CL:0000010 Sequence variation: Mutation; HGNC; 10555; ATXN2; Repeat_expansion; p.Gln166[35] (p.Gln166(>=33)); ClinVar=VCV000065668; Zygosity=Heterozygous; Note=The other allele has 22 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21195727 CVCL_XI58 iSCA3 E149-12 induced pluripotent stem cell human CVCL_XI58 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[73]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195728 CVCL_XI57 iSCA3 E149-10 induced pluripotent stem cell human CVCL_XI57 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[73]; Zygosity=Heterozygous; Note=The other allele has 14 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195729 CVCL_XI56 iSCA3-36 induced pluripotent stem cell human CVCL_XI56 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[70]; Zygosity=Heterozygous; Note=The other allele has 37 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195730 CVCL_XI55 iSCA3-1 induced pluripotent stem cell human CVCL_XI55 CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[70]; Zygosity=Heterozygous; Note=The other allele has 37 repeats (PubMed=30718627) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195731 CVCL_XI59 1-19-1 hybridoma house mouse CVCL_XI59 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human tumor-associated glycoprotein 72 (TAG-72) (CA72-4). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201589 21195732 CVCL_5C20 GM11880 transformed cell line human CVCL_5C20 HLA typing: A*02:01,25:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,02:01:02; DPB1*01:01:01,02:01; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:01,13:01; DRB3*01,01 (IPD-IMGT/HLA=25895) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134713 21195733 CVCL_XI43 GPTEC-T transformed cell line CVCL_XI43 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pRSVneoT](NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Hartley. Male Virology: Susceptible to infection and early propagation by guinea pig adenovirus (GPAdV) (PubMed=32226606) 21195734 CVCL_XI42 CSUXHi001-A induced pluripotent stem cell human CVCL_XI42 From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[74]; Zygosity=Heterozygous (PubMed=31491691) Population: Chinese; Han; Donor information: At sampling donor was not affected with Machado-Joseph disease but at significant risk for disease; Derived from sampling site: Urine. Female 21195735 CVCL_XI41 LEIi011-C induced pluripotent stem cell human CVCL_XI41 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Gly57Glufs*12 (c.170delG); Zygosity=Heterozygous (PubMed=31494449); Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Asn236Thrfs*11 (c.707delA); Zygosity=Heterozygous (PubMed=31494449) Population: Chinese; Singaporian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195736 CVCL_XI40 LEIi011-B induced pluripotent stem cell human CVCL_XI40 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Gly57Glufs*12 (c.170delG); Zygosity=Heterozygous (PubMed=31494449); Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Asn236Thrfs*11 (c.707delA); Zygosity=Heterozygous (PubMed=31494449) Population: Chinese; Singaporian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195737 CVCL_XI47 THP-1 TLR9 mCherry cancer cell line human CVCL_XI47 CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Transfected with a Tet-on system so as to induce the expression of a TLR9-mCherry fusion protein with the addition of doxycycline to the culture medium 21195738 CVCL_XI46 CAL-1 TLR9 mCherry cancer cell line human CVCL_XI46 CL:0000010 Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=Plasmacytoid dendritic cell.. Male Characteristics: Transfected with a Tet-on system so as to induce the expression of a TLR9-mCherry fusion protein with the addition of doxycycline to the culture medium 21195739 CVCL_XI45 Tera-2_CDDP cancer cell line human CVCL_XI45 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lung. Male 21195740 CVCL_XI44 NCCIT_CDDP cancer cell line human CVCL_XI44 CL:0000010 Sequence variation: Mutation; HGNC; 6844; MAP2K4; Simple; p.Lys309Asn (c.927G>C); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Pro (c.518G>C); ClinVar=VCV000185195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Cysfs*73 (c.814delG); Zygosity=Homozygous (from parent cell line). Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP) Male 21195741 CVCL_XI49 HepaRG-CAR cancer cell line human CVCL_XI49 CL:0000010 Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Liver. Female Characteristics: Compared to the parent cell line, has improved liver functionality Drug metabolism is highly improved. Culturing can be performed in serum-free conditions both in the presence or absence of DMSO. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3291 21195742 CVCL_XI48 SDQLCHi005-A induced pluripotent stem cell human CVCL_XI48 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Val (c.2447A>T); ClinVar=VCV000013852; Zygosity=Heterozygous (PubMed=31522012) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21195743 CVCL_P099 GM19058 transformed cell line human CVCL_P099 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195744 CVCL_P098 GM19057 transformed cell line human CVCL_P098 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195745 CVCL_P097 GM19056 transformed cell line human CVCL_P097 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195746 CVCL_P096 GM19055 transformed cell line human CVCL_P096 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195747 CVCL_5C02 GM11828 transformed cell line human CVCL_5C02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135009 21195748 CVCL_5C01 GM11827 transformed cell line human CVCL_5C01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135008 21195749 CVCL_5C00 GM11826 transformed cell line human CVCL_5C00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135007 21195750 CVCL_5C06 GM11836 transformed cell line human CVCL_5C06 HLA typing: A*01:01,02:01; B*27:03,57:01; C*02:02:02,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25912) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134908 21195751 CVCL_5C05 GM11835 transformed cell line human CVCL_5C05 HLA typing: A*01:01,02:01; B*44:02:01:01,57:01; C*05:01,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:01,03:03; DRB1*04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25910) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134907 21195752 CVCL_5C04 GM11834 transformed cell line human CVCL_5C04 HLA typing: A*01:01,02:01; B*27:03,57:01; C*02:02:02,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25917) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134905 21195753 CVCL_5C03 GM11833 transformed cell line human CVCL_5C03 HLA typing: A*02:01,02:01; B*15:01,44:02:01:01; C*03:04:01,05:01; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*03:01,03:01; DQB1*03:01,03:01; DRB1*04:01,04:01 (IPD-IMGT/HLA=25908) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134903 21195754 CVCL_5C09 GM11841 transformed cell line human CVCL_5C09 HLA typing: A*02:01,02:01; B*15:01,44:02:01:01; C*03:04:01,05:01; DPA1*01:03,01:03; DPB1*04:01,04:01; DQA1*03:01,03:01; DQB1*03:01,03:01; DRB1*04:01,04:01 (IPD-IMGT/HLA=25919) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134904 21195755 CVCL_5C08 GM11838 transformed cell line human CVCL_5C08 HLA typing: A*01:01,02:01; B*27:03,57:01; C*02:02:02,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25918) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134910 21195756 CVCL_5C07 GM11837 transformed cell line human CVCL_5C07 HLA typing: A*01:01,02:01; B*27:03,57:01; C*02:02:02,06:02; DPA1*01:03,01:03; DPB1*04:01,20:01; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04,07:01 (IPD-IMGT/HLA=25911) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134909 21195757 CVCL_XI32 RHD5 hybridoma house mouse CVCL_XI32 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00451; Human F8. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 6165CB 21195758 CVCL_XI31 KRIX-1 hybridoma house mouse CVCL_XI31 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00451; Human F8. Group: Patented cell line; Registration: International Depositary Authority, Belgian Coordinated Collections of Micro-organisms (BCCM); LMBP 5089CB 21195759 CVCL_XI30 1F42E31FG7 hybridoma human CVCL_XI30 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: ChEBI; CHEBI:144806; N-glycolylneuraminyllactosylceramide (GM3(NeuGc); HD3 ganglioside). 21195760 CVCL_XI36 hpSC-Hhom-2 induced pluripotent stem cell human CVCL_XI36 HLA typing: A*68; B*18; DRB1*13 (PubMed=18092905) CL:0000010 Donor information: Embryo is sibling to that giving rise to hpSC-Hhom-3 (Cellosaurus=CVCL_XI37). Female Characteristics: Established from parthenogenetically activated oocytes 21195761 CVCL_XI35 hpSC-Hhom-1 induced pluripotent stem cell human CVCL_XI35 HLA typing: A*25; B*18; DRB1*15 (PubMed=18092905). CL:0000010 Female Characteristics: Established from parthenogenetically activated oocytes 21195762 CVCL_XI34 Cyno-1 induced pluripotent stem cell CVCL_XI34 CL:0000010 Female Characteristics: Established from parthenogenetically activated oocytes. Group: Non-human primate cell line 21195763 CVCL_XI33 18B6 [Mouse hybridoma against mAB RHD5] hybridoma house mouse CVCL_XI33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody RHD5. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3559 21195764 CVCL_XI39 LEIi011-A induced pluripotent stem cell human CVCL_XI39 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Gly57Glufs*12 (c.170delG); Zygosity=Heterozygous (PubMed=31494449); Sequence variation: Mutation; HGNC; 18243; RCBTB1; Simple; p.Asn236Thrfs*11 (c.707delA); Zygosity=Heterozygous (PubMed=31494449) Population: Chinese; Singaporian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21195765 CVCL_XI38 hpSC-Hhom-4 induced pluripotent stem cell human CVCL_XI38 HLA typing: A*01; B*08; DRB1*03 (PubMed=18092905). CL:0000010 Female Characteristics: Established from parthenogenetically activated oocytes 21195766 CVCL_XI37 hpSC-Hhom-3 induced pluripotent stem cell human CVCL_XI37 HLA typing: A*02; B*13; DRB1*07 (PubMed=18092905) CL:0000010 Donor information: Embryo is sibling to that giving rise to hpSC-Hhom-2 (Cellosaurus=CVCL_XI36). Female Characteristics: Established from parthenogenetically activated oocytes 21195767 CVCL_P084 GM19001 transformed cell line human CVCL_P084 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195768 CVCL_P083 GM19000 transformed cell line human CVCL_P083 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195769 CVCL_P082 GM18999 transformed cell line human CVCL_P082 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Virology: Contains a chromosomally integrated human herpesvirus 6A (CI-HHV-6A) Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195770 CVCL_P081 GM18998 transformed cell line human CVCL_P081 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195771 CVCL_P080 GM18997 transformed cell line human CVCL_P080 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195772 CVCL_XI21 PM-1 [Human/mouse hybridoma] hybridoma CVCL_XI21 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2599 21195773 CVCL_XI20 LM-1 [Human/mouse hybridoma against human NONO] hybridoma CVCL_XI20 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; Q15233; Human NONO. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2623 21195774 CVCL_XI25 NORM-2 hybridoma CVCL_XI25 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2626 21195775 CVCL_XI24 NORM-1 hybridoma CVCL_XI24 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2624 21195776 CVCL_XI23 SAM-6 hybridoma CVCL_XI23 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P11021; Human HSPA5/GRP78 (isoform SAM-6). Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2903 21195777 CVCL_XI22 PM-2 hybridoma CVCL_XI22 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2600 21195778 CVCL_XI29 14F7 hybridoma house mouse CVCL_XI29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:144806; N-glycolylneuraminyllactosylceramide (GM3(NeuGc); HD3 ganglioside). 21195779 CVCL_XI28 MIL-38 IF5 hybridoma house mouse CVCL_XI28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35052; Human GPC1. Group: Patented cell line; Registration: International Depositary Authority, Cell Bank Australia; CBA20140026 21195780 CVCL_XI27 BARB4 hybridoma CVCL_XI27 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; Q92804; Human TAF15. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2876 21195781 CVCL_P079 GM18995 transformed cell line human CVCL_P079 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195782 CVCL_XI26 BARB3 hybridoma CVCL_XI26 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2859 21195783 CVCL_P078 GM18994 transformed cell line human CVCL_P078 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195784 CVCL_P077 GM18993 transformed cell line human CVCL_P077 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195785 CVCL_P076 GM18992 transformed cell line human CVCL_P076 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195786 CVCL_P075 GM18991 transformed cell line human CVCL_P075 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195787 CVCL_P074 GM18990 transformed cell line human CVCL_P074 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195788 CVCL_P095 GM19054 transformed cell line human CVCL_P095 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195789 CVCL_P094 GM19012 transformed cell line human CVCL_P094 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195790 CVCL_P093 GM19011 transformed cell line human CVCL_P093 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195791 CVCL_P092 GM19010 transformed cell line human CVCL_P092 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195792 CVCL_P091 GM19009 transformed cell line human CVCL_P091 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195793 CVCL_P090 GM19007 transformed cell line human CVCL_P090 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195794 CVCL_XI10 MEP08 hybridoma house mouse CVCL_XI10 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1941 21195795 CVCL_XI14 MEP21 hybridoma house mouse CVCL_XI14 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1944 21195796 CVCL_XI13 MEP19 hybridoma house mouse CVCL_XI13 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1943 21195797 CVCL_XI12 MEP14 hybridoma house mouse CVCL_XI12 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-1942 21195798 CVCL_XI11 MEP13 hybridoma house mouse CVCL_XI11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NQ30; Human ESM1. 21195799 CVCL_XI18 CM-1 [Human/mouse hybridoma] hybridoma CVCL_XI18 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2584 21195800 CVCL_XI17 PAM-1 hybridoma CVCL_XI17 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; Q92896; Human GLG1/CFR1. 21195801 CVCL_XI16 6/22-10-30-13 hybridoma house mouse CVCL_XI16 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody SC-1. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2625 21195802 CVCL_P089 GM19006 transformed cell line human CVCL_P089 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195803 CVCL_XI15 SC-1 [Human/mouse hybridoma against human CD55] hybridoma CVCL_XI15 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P08174; Human CD55. 21195804 CVCL_P088 GM19005 transformed cell line human CVCL_P088 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195805 CVCL_P087 GM19004 transformed cell line human CVCL_P087 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195806 CVCL_P086 GM19003 transformed cell line human CVCL_P086 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195807 CVCL_XI19 CM-2 [Human/mouse hybridoma] hybridoma CVCL_XI19 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human cancer cells. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-2598 21195808 CVCL_P085 GM19002 transformed cell line human CVCL_P085 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21195809 CVCL_5B99 GM11825 transformed cell line human CVCL_5B99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135006 21195810 CVCL_5B90 GM10849 transformed cell line human CVCL_5B90 HLA typing: A*03:01,03:01; B*27:05,35:01; C*02:02:02,04:01; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25831) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133202 21195811 CVCL_5B94 GM11819 transformed cell line human CVCL_5B94 HLA typing: A*24:02,31:01; B*40:01,07:02:01; C*03:04:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,06:01; DQA1*03:01,03:01; DQB1*03:02,03:02; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25803) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133117 21195812 CVCL_5B93 GM11818 transformed cell line human CVCL_5B93 HLA typing: A*02:01,24:02; B*13:02,07:02:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*02:01,03:01; DQB1*02:01,03:02; DRB1*04:04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25802) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133116 21195813 CVCL_5B92 GM10862 transformed cell line human CVCL_5B92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137501 21195814 CVCL_5B91 GM10858 transformed cell line human CVCL_5B91 HLA typing: A*25:01,68:01:02; B*08:01,44:04; C*07:01,16:01; DPA1*01:03,02:01:02; DPB1*01:01:01,04:01:01; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,11:01; DRB3*01,02 (IPD-IMGT/HLA=25901) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134701 21195815 CVCL_5B98 GM11824 transformed cell line human CVCL_5B98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135005 21195816 CVCL_5B97 GM11822 transformed cell line human CVCL_5B97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135003 21195817 CVCL_5B96 GM11821 transformed cell line human CVCL_5B96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134013 21195818 CVCL_5B95 GM11820 transformed cell line human CVCL_5B95 HLA typing: A*03:01,03:01:01:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:01,16:01; DQA1*01:01,04:01; DQB1*04:02,05:03; DRB1*08:01,14:01; DRB3*02:02,03:01 (IPD-IMGT/HLA=25835) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133315 21195819 CVCL_5B79 GM07436 transformed cell line human CVCL_5B79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329204 21195820 CVCL_5B78 GM07434 transformed cell line human CVCL_5B78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329402 21195821 CVCL_5B77 GM07433 transformed cell line human CVCL_5B77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329108 21195822 CVCL_5B72 GM07354 transformed cell line human CVCL_5B72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134507 21195823 CVCL_5B71 GM07353 transformed cell line human CVCL_5B71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134506 21195824 CVCL_5B70 GM07352 transformed cell line human CVCL_5B70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134505 21195825 CVCL_5B76 GM07432 transformed cell line human CVCL_5B76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329309 21195826 CVCL_5B75 GM07431 transformed cell line human CVCL_5B75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329209 21195827 CVCL_5B74 GM07356 transformed cell line human CVCL_5B74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134509 21195828 CVCL_5B73 GM07355 transformed cell line human CVCL_5B73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134508 21195829 CVCL_5B89 GM10848 transformed cell line human CVCL_5B89 HLA typing: A*03:01,03:01; B*35:01,56:01; C*01:02,04:01; DPA1*01:03,02:01:01; DPB1*04:01:01,11:01:01; DQA1*04:01,04:01; DQB1*04:02,04:02; DRB1*08:01,08:01 (IPD-IMGT/HLA=25829) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133201 21195830 CVCL_5B88 GM10844 transformed cell line human CVCL_5B88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142402 21195831 CVCL_5B83 GM07694 transformed cell line human CVCL_5B83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329205 21195832 CVCL_5B82 GM07679 transformed cell line human CVCL_5B82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133310 21195833 CVCL_5B81 GM07678 transformed cell line human CVCL_5B81 HLA typing: A*01:01:01,24:02; B*39:06:01,58:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*04:01,05:01; DQB1*03:01,04:02; DRB1*08:01,13:03; DRB3*01:01 (IPD-IMGT/HLA=25841) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133308 21195834 CVCL_5B80 GM07437 transformed cell line human CVCL_5B80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329306 21195835 CVCL_5B87 GM10841 transformed cell line human CVCL_5B87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142101 21195836 CVCL_5B86 GM10834 transformed cell line human CVCL_5B86 HLA typing: A*02:01,02:05; B*15:01,49:01; C*03:03,07:01; DPA1*01:03,02:01:01; DPB1*04:01:01,13:01; DQA1*01:02,03:01; DQB1*03:02:01,06:09; DRB1*04:01,13:02; DRB3*01; DRB4*01 (IPD-IMGT/HLA=13832) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141602 21195837 CVCL_5B85 GM10833 transformed cell line human CVCL_5B85 HLA typing: A*02:01,02:01; B*44:02,44:02; C*05:01,07:04; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*03:01,05:01; DQB1*03:01:01,03:01:01; DRB1*04:01,11:01; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25960) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141302 21195838 CVCL_5B84 GM10832 transformed cell line human CVCL_5B84 HLA typing: A*01:01,68:01:02; B*08:01,13:02; C*03:03,07:01; DPA1*01:03,02:01:01; DPB1*04:01:01,14:01; DQA1*01:02,02:01; DQB1*02:01,06:02; DRB1*07:01,15:01; DRB4*01 (IPD-IMGT/HLA=25955) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141301 21195839 CVCL_5B58 GM07047 transformed cell line human CVCL_5B58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329107 21195840 CVCL_5B57 GM07046 transformed cell line human CVCL_5B57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329301 21195841 CVCL_5B56 GM07044 transformed cell line human CVCL_5B56 HLA typing: A*02:01,03:01; B*07:02:01,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01; DRB4*01 (IPD-IMGT/HLA=25850) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134104 21195842 CVCL_5B55 GM07043 transformed cell line human CVCL_5B55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329408 21195843 CVCL_5B59 GM07049 transformed cell line human CVCL_5B59 HLA typing: A*02:01,24:02; B*15:01,39:06:01; C*03:03,07:02; DPA1*01:03,01:03; DPB1*03:01,03:01:01; DQA1*04:01,05:01; DQB1*03:01,04:02; DRB1*08:01,11:03; DRB3*02,03:01 (IPD-IMGT/HLA=25847) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133311 21195844 CVCL_5B50 GM07036 transformed cell line human CVCL_5B50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329104 21195845 CVCL_5B54 GM07042 transformed cell line human CVCL_5B54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329201 21195846 CVCL_5B53 GM07041 transformed cell line human CVCL_5B53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132803 21195847 CVCL_5B52 GM07039 transformed cell line human CVCL_5B52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329304 21195848 CVCL_5B51 GM07038 transformed cell line human CVCL_5B51 HLA typing: A*03:01:01:01,24:02; B*35:01,39:06:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*03:01:01,16:01; DQA1*01:01,04:01; DQB1*04:02,05:03; DRB1*08:01,14:01 (IPD-IMGT/HLA=25846) CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133301 21195849 CVCL_5B69 GM07351 transformed cell line human CVCL_5B69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134504 21195850 CVCL_5B68 GM07350 transformed cell line human CVCL_5B68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134503 21195851 CVCL_5B67 GM07061 transformed cell line human CVCL_5B67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329308 21195852 CVCL_5B66 GM07060 transformed cell line human CVCL_5B66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329307 21195853 CVCL_XH91 CJ.F4 hybridoma house mouse CVCL_XH91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. 21195854 CVCL_XH90 CP.B8 hybridoma house mouse CVCL_XH90 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12107 21195855 CVCL_XH95 PL08 spontaneously immortalized cell line house mouse CVCL_XH95 CL:0000010 Derived from sampling site: Embryonic liver; Breed/subspecies: C57BL/6. Unspecified Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201297 21195856 CVCL_XH94 CMEC-4 transformed cell line CVCL_XH94 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Chinese Holstein. Female Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.8707 21195857 CVCL_XH93 RDDF-1 spontaneously immortalized cell line CVCL_XH93 CL:0000010 Derived from sampling site: Dorsal fin. Unspecified Group: Fish cell line 21195858 CVCL_XH92 CQ.C11 hybridoma house mouse CVCL_XH92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12105 21195859 CVCL_XH99 AS 3 hybridoma house mouse CVCL_XH99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03300; Poliovirus type 1 (strain Mahoney) capsid protein VP1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-209 21195860 CVCL_XH98 AS 2 hybridoma house mouse CVCL_XH98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03300; Poliovirus type 1 (strain Mahoney) capsid protein VP1. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-208 21195861 CVCL_XH97 LGMN-2 hybridoma house mouse CVCL_XH97 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q99538; Human LGMN. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.12995 21195862 CVCL_XH96 LGMN-1 hybridoma house mouse CVCL_XH96 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99538; Human LGMN. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.12994 21195863 CVCL_5B61 GM07052 transformed cell line human CVCL_5B61 HLA typing: A*01:01:01,24:02; B*39:06:01,58:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*04:01,05:01; DQB1*03:01,04:02; DRB1*08:01,13:03; DRB3*01,01 (IPD-IMGT/HLA=25840) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133304 21195864 CVCL_5B60 GM07050 transformed cell line human CVCL_5B60 HLA typing: A*01:01,24:02; B*57:01,07:02:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*03:01,04:02; DQA1*02:01,03:01; DQB1*03:02,03:03; DRB1*04:04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25815) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133115 21195865 CVCL_5B65 GM07059 transformed cell line human CVCL_5B65 HLA typing: A*24:02,31:01; B*40:01,07:02:01; C*03:04:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,06:01; DQA1*03:01,03:01; DQB1*03:02,03:02; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25808) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133105 21195866 CVCL_5B64 GM07058 transformed cell line human CVCL_5B64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329109 21195867 CVCL_5B63 GM07057 transformed cell line human CVCL_5B63 HLA typing: A*02:01,31:01; B*13:02,40:01; C*03:04:01:01,06:02:01:01; DPA1*01:03,01:03; DPB1*04:01:01,06:01; DQA1*02:01,03:01; DQB1*02:01,03:02; DRB1*04:04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25811) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133101 21195868 CVCL_5B62 GM07054 transformed cell line human CVCL_5B62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329404 21195869 CVCL_5B36 GM07016 transformed cell line human CVCL_5B36 HLA typing: A*02:01,03:01; B*18:01,51:01; C*15:03,07:01; DPA1*01:03,02:01:01; DPB1*02:01:02,14:01; DQA1*01:02,01:03; DQB1*06:03,06:04; DRB1*13:01,13:02; DRB3*10:01 (IPD-IMGT/HLA=25816) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133114 21195870 CVCL_5B35 GM07015 transformed cell line human CVCL_5B35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329406 21195871 CVCL_5B34 GM07013 transformed cell line human CVCL_5B34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329401 21195872 CVCL_5B33 GM07012 transformed cell line human CVCL_5B33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134105 21195873 CVCL_5B39 GM07020 transformed cell line human CVCL_5B39 HLA typing: A*02:01,03:01; B*07:02,07:02:01; C*07:02,07:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01; DQA1*01:02,01:02; DQB1*06:02,06:02; DRB1*15:01,15:01; DRB5*01,01 (IPD-IMGT/HLA=25853) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134110 21195874 CVCL_5B38 GM07018 transformed cell line human CVCL_5B38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329103 21195875 CVCL_5B37 GM07017 transformed cell line human CVCL_5B37 HLA typing: A*01:01:01,02:01; B*07:02,58:01; C*07:01,07:02; DPA1*01:03,02:02:02; DPB1*04:01:01,05:01; DQA1*01:02,05:01; DQB1*03:01,06:02; DRB1*13:03,15:01; DRB3*01:01; DRB5*01:01 (IPD-IMGT/HLA=25837) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133313 21195876 CVCL_XH80 BS107 hybridoma house mouse CVCL_XH80 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-647 21195877 CVCL_XH84 AE.C9 hybridoma house mouse CVCL_XH84 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12106 21195878 CVCL_XH83 BS111 hybridoma house mouse CVCL_XH83 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobactera (Note=Reacts with many species). 21195879 CVCL_XH82 BS110 hybridoma house mouse CVCL_XH82 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobactera (Note=Reacts with many species). 21195880 CVCL_XH81 BS108 hybridoma house mouse CVCL_XH81 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis. 21195881 CVCL_XH88 AK.F12 hybridoma house mouse CVCL_XH88 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. 21195882 CVCL_XH87 AH.H8 hybridoma house mouse CVCL_XH87 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. 21195883 CVCL_XH86 AF.F4 hybridoma house mouse CVCL_XH86 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12104 21195884 CVCL_XH85 AE.F8 hybridoma house mouse CVCL_XH85 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. 21195885 CVCL_XH89 BI.B12 hybridoma house mouse CVCL_XH89 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P31785; Human IL2RG/CD132. 21195886 CVCL_5B32 GM07011 transformed cell line human CVCL_5B32 HLA typing: A*03:01,03:01:01:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:01,16:01; DQA1*01:01,04:01; DQB1*04:02,05:03; DRB1*08:01,14:01; DRB3*02,03:01 (IPD-IMGT/HLA=25839) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133306 21195887 CVCL_5B31 GM07010 transformed cell line human CVCL_5B31 HLA typing: A*02:01,03:01; B*07:02:01,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:03; DPB1*04:01,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01; DRB4*01 (IPD-IMGT/HLA=25852) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134109 21195888 CVCL_5B30 GM07009 transformed cell line human CVCL_5B30 HLA typing: A*01:01:01,03:01:01:01; B*35:01,58:01; C*04:01,07:01; DPA1*01:03,01:03; DPB1*04:01:01,16:01; DQA1*01:01,05:01; DQB1*03:01,05:03; DRB1*13:03,14:01; DRB3*02,03:01 (IPD-IMGT/HLA=25842) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133307 21195889 CVCL_5B47 GM07032 transformed cell line human CVCL_5B47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329207 21195890 CVCL_5B46 GM07030 transformed cell line human CVCL_5B46 HLA typing: A*02:01,24:02; B*13:02,07:02:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*02:01,03:01; DQB1*02:01,03:02; DRB1*04:04:01,07:01; DRB4*01 (IPD-IMGT/HLA=25814) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133110 21195891 CVCL_5B45 GM07028 transformed cell line human CVCL_5B45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329303 21195892 CVCL_5B44 GM07026 transformed cell line human CVCL_5B44 HLA typing: A*03:01,03:01:01:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:01,16:01; DQA1*01:01,04:01; DQB1*04:02,05:03; DRB1*08:01,14:01; DRB3*02,03:01 (IPD-IMGT/HLA=25843) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133309 21195893 CVCL_5B49 GM07035 transformed cell line human CVCL_5B49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329403 21195894 CVCL_5B48 GM07033 transformed cell line human CVCL_5B48 HLA typing: A*02:01,31:01; B*40:01,51:01; C*15:03,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,06:01; DQA1*01:03,03:01; DQB1*03:02,06:03; DRB1*13:01,04:04; DRB3*01; DRB4*01 (IPD-IMGT/HLA=25818) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133104 21195895 CVCL_XH73 A2058-RFP/H2B-GFP cancer cell line human CVCL_XH73 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4761; H2BC11 (with p.Gly26Asp and p.Ile119Val and fused in frame with eGFP); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: The H2B-eGFP fusion construct is under the control of the pPGK promoter and localizes to the nucleus 21195896 CVCL_XH72 7N4-1 hybridoma house mouse CVCL_XH72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01563; Human IFNA2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-277 21195897 CVCL_XH71 7N2-4 hybridoma house mouse CVCL_XH71 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01563; Human IFNA2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-278 21195898 CVCL_XH70 6N5-2-1 hybridoma house mouse CVCL_XH70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01563; Human IFNA2. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-279 21195899 CVCL_XH77 BS101 hybridoma house mouse CVCL_XH77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis. 21195900 CVCL_XH76 BS100 hybridoma house mouse CVCL_XH76 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-644 21195901 CVCL_XH75 LICR-LON-Fib-86 hybridoma house mouse CVCL_XH75 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Human breast cells. 21195902 CVCL_XH74 A2058-RFP/H2B-GFP BrM cancer cell line human CVCL_XH74 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4761; H2BC11 (with p.Gly26Asp and p.Ile119Val and fused in frame with eGFP); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from metastatic site: Lymph node. Male Characteristics: Brain parenchymal space metastatic derivative of parental cell line Established after 3 passages in NMRI-nu/nu mice 4 weeks after intra-cardiac injection.; Characteristics: The H2B-eGFP fusion construct is under the control of the pPGK promoter and localizes to the nucleus Part of: Brain metastasis cell lines panel 21195903 CVCL_XH79 BS104 hybridoma house mouse CVCL_XH79 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis 71 kDa antigen. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-646 21195904 CVCL_XH78 BS102 hybridoma house mouse CVCL_XH78 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Mycobacterium tuberculosis. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-645 21195905 CVCL_5B43 GM07025 transformed cell line human CVCL_5B43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329305 21195906 CVCL_5B42 GM07024 transformed cell line human CVCL_5B42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329407 21195907 CVCL_5B41 GM07023 transformed cell line human CVCL_5B41 HLA typing: A*24:02,31:01; B*40:01,07:02:01; C*03:04:01:01,07:02; DPA1*01:03,01:03; DPB1*04:02,06:01; DQA1*03:01,03:01; DQB1*03:02,03:02; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25817) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133103 21195908 CVCL_5B40 GM07021 transformed cell line human CVCL_5B40 HLA typing: A*02:01,02:01; B*07:02,44:02:01:01; C*05:01,07:02; DPA1*01:03,01:04; DPB1*04:01:01,15:01; DQA1*03:01,03:01; DQB1*03:01:01,03:02:01; DRB1*04:01,04:04; DRB4*01 (IPD-IMGT/HLA=25855) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134107 21195909 CVCL_G645 CG7C7 hybridoma house mouse CVCL_G645 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with other species). 21195910 CVCL_FU45 ND23252 transformed cell line human CVCL_FU45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195911 CVCL_G644 CE9H9 hybridoma house mouse CVCL_G644 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with other species). 21195912 CVCL_FU44 ND23132 transformed cell line human CVCL_FU44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195913 CVCL_G643 CC9C10 hybridoma house mouse CVCL_G643 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01317; Bovine INS (Note=Also reacts with other species including human). 21195914 CVCL_FU43 ND22967 transformed cell line human CVCL_FU43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195915 CVCL_G642 BTV10XSp2/0-Ag-14-10D4.90 hybridoma house mouse CVCL_G642 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Bluetongue virus. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8377 21195916 CVCL_FU42 ND22063 transformed cell line human CVCL_FU42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195917 CVCL_G649 F1A3-23 hybridoma house mouse CVCL_G649 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09603; Human CSF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8207 21195918 CVCL_FU49 ND23778 transformed cell line human CVCL_FU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195919 CVCL_G648 F18 AF1 hybridoma house mouse CVCL_G648 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09603; Human CSF1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8208 21195920 CVCL_FU48 ND23626 transformed cell line human CVCL_FU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195921 CVCL_G647 Cy34.1.2 hybridoma house mouse CVCL_G647 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P35329; Mouse Cd22. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21195922 CVCL_FU47 ND23624 transformed cell line human CVCL_FU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195923 CVCL_G646 CON.1 hybridoma house mouse CVCL_G646 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04973; Bovine CLTA (Note=Also reacts with human); Monoclonal antibody target: UniProtKB; P04975; Bovine CLTB (Note=Also reacts with human). 21195924 CVCL_FU46 ND23439 transformed cell line human CVCL_FU46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195925 CVCL_G641 BP107.2.2 hybridoma house mouse CVCL_G641 CL:0000010 Monoclonal antibody isotype: IgG3. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21195926 CVCL_FU41 ND21942 transformed cell line human CVCL_FU41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195927 CVCL_G640 BE3F9 hybridoma house mouse CVCL_G640 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P01317; Bovine INS (Note=Also reacts with other species including human). 21195928 CVCL_FU40 ND21798 transformed cell line human CVCL_FU40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195929 CVCL_G656 IgG-1B3 hybridoma house mouse CVCL_G656 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; G1T4Z1; Rabbit LRP1. 21195930 CVCL_FU56 ND24791 transformed cell line human CVCL_FU56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195931 CVCL_G655 IgG-11H9 hybridoma house mouse CVCL_G655 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16258; Rabbit OSBP. 21195932 CVCL_FU55 ND24788 transformed cell line human CVCL_FU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195933 CVCL_G654 I1-Hybridoma hybridoma house mouse CVCL_G654 CL:0000010 Monoclonal antibody isotype: IgG1. 21195934 CVCL_FU54 ND24581 transformed cell line human CVCL_FU54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195935 CVCL_G653 HS-21 (subclone 1H3) hybridoma house mouse CVCL_G653 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human sperm acrosomal vesicle. 21195936 CVCL_FU53 ND24498 transformed cell line human CVCL_FU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195937 CVCL_G659 IgG-2A4 hybridoma house mouse CVCL_G659 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P36956; Human SREBF1. 21195938 CVCL_FU59 ND25720 transformed cell line human CVCL_FU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195939 CVCL_G658 IgG-1D2 hybridoma house mouse CVCL_G658 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q12772; Human SREBF2. 21195940 CVCL_FU58 ND25283 transformed cell line human CVCL_FU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195941 CVCL_G657 IgG-1C6 hybridoma house mouse CVCL_G657 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q12772; Human SREBF2. 21195942 CVCL_FU57 ND24792 transformed cell line human CVCL_FU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195943 CVCL_G652 GAP A3 hybridoma house mouse CVCL_G652 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa. 21195944 CVCL_FU52 ND24433 transformed cell line human CVCL_FU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195945 CVCL_G651 GAP 8.3 hybridoma house mouse CVCL_G651 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P08575; Human PTPRC/CD45. 21195946 CVCL_FU51 ND24199 transformed cell line human CVCL_FU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195947 CVCL_G650 F21-1D3G7C8 hybridoma house mouse CVCL_G650 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Agrobacterium tumefaciens biovar 3 strain CG-49. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9463 21195948 CVCL_FU50 ND23780 transformed cell line human CVCL_FU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195949 CVCL_G629 A3.6B10 hybridoma house mouse CVCL_G629 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12318 21195950 CVCL_FU29 ND21131 transformed cell line human CVCL_FU29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195951 CVCL_G628 A3.4H2 hybridoma house mouse CVCL_G628 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16410; Human CTLA4/CD152. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12319 21195952 CVCL_FU28 ND21035 transformed cell line human CVCL_FU28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195953 CVCL_G623 73/1 hybridoma house mouse CVCL_G623 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03441; Influenza A virus isolate A/Bangkok/1/1979 hemagglutinin (HA). 21195954 CVCL_FU23 ND20045 transformed cell line human CVCL_FU23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195955 CVCL_G622 7-34-1 hybridoma house mouse CVCL_G622 CL:0000010 Monoclonal antibody isotype: IgG2a. 21195956 CVCL_FU22 ND40877 transformed cell line human CVCL_FU22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195957 CVCL_G621 6A7M hybridoma house mouse CVCL_G621 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8159 21195958 CVCL_FU21 ND40874 transformed cell line human CVCL_FU21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195959 CVCL_G620 63D3 hybridoma house mouse CVCL_G620 CL:0000010 Monoclonal antibody isotype: IgG1. 21195960 CVCL_FU20 ND40653 transformed cell line human CVCL_FU20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195961 CVCL_G627 91MS441 hybridoma house mouse CVCL_G627 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Anti-idiotypic against monoclonal antibody GLXA-Ab1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11301 21195962 CVCL_FU27 ND20963 transformed cell line human CVCL_FU27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195963 CVCL_G626 8A2N hybridoma house mouse CVCL_G626 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Leu20 and p.Glu24) (Note=Recognizes N blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8161 21195964 CVCL_FU26 ND20827 transformed cell line human CVCL_FU26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195965 CVCL_G625 89MS30 hybridoma house mouse CVCL_G625 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Chlamydia trachomatis exoglycolipid antigen (GLXA). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11300 21195966 CVCL_FU25 ND20576 transformed cell line human CVCL_FU25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195967 CVCL_G624 7F2-6D4-8E7 hybridoma house mouse CVCL_G624 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human astrovirus 2 (Note=Also reacts with other serotypes). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11945 21195968 CVCL_FU24 ND20499 transformed cell line human CVCL_FU24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195969 CVCL_G639 B8-24-3 hybridoma house mouse CVCL_G639 CL:0000010 Monoclonal antibody isotype: IgG1, kappa. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21195970 CVCL_FU39 ND21797 transformed cell line human CVCL_FU39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195971 CVCL_G634 AP.6 hybridoma house mouse CVCL_G634 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95782; Human AP2A1 (Note=Also reacts with many other mammalian species). 21195972 CVCL_FU34 ND21780 transformed cell line human CVCL_FU34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195973 CVCL_G633 AE9D6 hybridoma house mouse CVCL_G633 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P01308; Human INS (Note=Also reacts with other species). 21195974 CVCL_FU33 ND21488 transformed cell line human CVCL_FU33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195975 CVCL_G632 AC133.1 hybridoma house mouse CVCL_G632 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; O43490; Human PROM1/CD133. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-12346 21195976 CVCL_FU32 ND21330 transformed cell line human CVCL_FU32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195977 CVCL_G631 A717 hybridoma house mouse CVCL_G631 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02768; Human ALB (Note=Glycated). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9596 21195978 CVCL_FU31 ND21313 transformed cell line human CVCL_FU31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195979 CVCL_G638 B3D hybridoma house mouse CVCL_G638 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q48245; Helicobacter pylori vacA. 21195980 CVCL_FU38 ND21792 transformed cell line human CVCL_FU38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195981 CVCL_G637 MCA B29 hybridoma house mouse CVCL_G637 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Infectious bursal disease virus (IBDV). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9746 21195982 CVCL_FU37 ND21789 transformed cell line human CVCL_FU37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195983 CVCL_G636 B1B6 hybridoma house mouse CVCL_G636 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21195984 CVCL_FU36 ND21787 transformed cell line human CVCL_FU36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195985 CVCL_G635 B1B3 hybridoma house mouse CVCL_G635 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 21195986 CVCL_FU35 ND21783 transformed cell line human CVCL_FU35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195987 CVCL_G630 A5.4 hybridoma house mouse CVCL_G630 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. 21195988 CVCL_FU30 ND21309 transformed cell line human CVCL_FU30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195989 CVCL_G609 46-5 hybridoma house mouse CVCL_G609 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120. 21195990 CVCL_FU09 ND39472 transformed cell line human CVCL_FU09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195991 CVCL_G608 46-4 hybridoma house mouse CVCL_G608 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120. 21195992 CVCL_FU08 ND39132 transformed cell line human CVCL_FU08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195993 CVCL_G607 46/4 hybridoma house mouse CVCL_G607 CL:0000010 Monoclonal antibody isotype: IgG1. 21195994 CVCL_FU07 ND39131 transformed cell line human CVCL_FU07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195995 CVCL_G606 46-2 hybridoma house mouse CVCL_G606 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120. 21195996 CVCL_FU06 ND38965 transformed cell line human CVCL_FU06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21195997 CVCL_G601 3C11 hybridoma house mouse CVCL_G601 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8511 21195998 CVCL_FU01 ND38630 transformed cell line human CVCL_FU01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21195999 CVCL_G600 34-4-21S hybridoma house mouse CVCL_G600 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse MHC class I H-2Dd. 21196000 CVCL_FU00 ND38582 transformed cell line human CVCL_FU00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196001 CVCL_G605 454C11 hybridoma house mouse CVCL_G605 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8484; Registration: International Depositary Authority, In Vitro International Inc., USA; IVI-10085 21196002 CVCL_FU05 ND38947 transformed cell line human CVCL_FU05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196003 CVCL_G604 3G9F3 hybridoma house mouse CVCL_G604 CL:0000010 Monoclonal antibody isotype: IgG2b. 21196004 CVCL_FU04 ND38912 transformed cell line human CVCL_FU04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196005 CVCL_G603 3G3 [Mouse hybridoma against cell wall peptidoglycans] hybridoma house mouse CVCL_G603 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8516 21196006 CVCL_FU03 ND38836 transformed cell line human CVCL_FU03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196007 CVCL_G602 3F6 [Mouse hybridoma against cell wall peptidoglycans] hybridoma house mouse CVCL_G602 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Cell wall peptidoglycans from a variety of Gram- and Gram+ bacteria. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8512 21196008 CVCL_FU02 ND38771 transformed cell line human CVCL_FU02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196009 CVCL_G619 5H8 hybridoma house mouse CVCL_G619 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q62009; Mouse Postn. 21196010 CVCL_FU19 ND40629 transformed cell line human CVCL_FU19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196011 CVCL_G618 5G5 hybridoma house mouse CVCL_G618 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q48245; Helicobacter pylori vacA. 21196012 CVCL_FU18 ND40459 transformed cell line human CVCL_FU18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196013 CVCL_G617 5E4 hybridoma house mouse CVCL_G617 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q48245; Helicobacter pylori vacA. 21196014 CVCL_FU17 ND40026 transformed cell line human CVCL_FU17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196015 CVCL_G612 520C9 hybridoma house mouse CVCL_G612 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8696 21196016 CVCL_FU12 ND39708 transformed cell line human CVCL_FU12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196017 CVCL_G611 4E8C12 hybridoma house mouse CVCL_G611 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Escherichia coli (O157:H7 strain 932). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10452 21196018 CVCL_FU11 ND39518 transformed cell line human CVCL_FU11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196019 CVCL_G610 4A4B11 hybridoma house mouse CVCL_G610 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P02745; Human C1QA; Monoclonal antibody target: UniProtKB; P02746; Human C1QB; Monoclonal antibody target: UniProtKB; P02747; Human C1QC. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8327 21196020 CVCL_FU10 ND39515 transformed cell line human CVCL_FU10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196021 CVCL_G616 55-83 hybridoma house mouse CVCL_G616 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: HIV-1 gp120. 21196022 CVCL_FU16 ND40021 transformed cell line human CVCL_FU16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196023 CVCL_G615 55-6 hybridoma house mouse CVCL_G615 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: HIV-1 gp120. 21196024 CVCL_FU15 ND39985 transformed cell line human CVCL_FU15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196025 CVCL_G614 55-36 hybridoma house mouse CVCL_G614 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120. 21196026 CVCL_FU14 ND39793 transformed cell line human CVCL_FU14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196027 CVCL_G613 55-2 hybridoma house mouse CVCL_G613 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 gp120. 21196028 CVCL_FU13 ND39757 transformed cell line human CVCL_FU13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196029 CVCL_P183 GM18569 transformed cell line human CVCL_P183 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196030 CVCL_P182 GM18567 transformed cell line human CVCL_P182 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196031 CVCL_P181 GM18566 transformed cell line human CVCL_P181 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196032 CVCL_P180 GM18565 transformed cell line human CVCL_P180 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196033 CVCL_XJ20 BCHNEUi006-A induced pluripotent stem cell human CVCL_XJ20 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Leu443Pro (c.1328T>C); ClinVar=VCV000389026; Zygosity=Heterozygous (PubMed=31525725) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196034 CVCL_XJ24 DANi004-A induced pluripotent stem cell human CVCL_XJ24 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys253Tyr (c.758G>A); ClinVar=VCV000645725; Zygosity=Homozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196035 CVCL_XJ23 DANi002-C induced pluripotent stem cell human CVCL_XJ23 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196036 CVCL_XJ22 DANi002-B induced pluripotent stem cell human CVCL_XJ22 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi002-C) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196037 CVCL_XJ21 DANi002-A induced pluripotent stem cell human CVCL_XJ21 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (from autologous cell line DANi002-C) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196038 CVCL_XJ28 DANi011-A induced pluripotent stem cell human CVCL_XJ28 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=32305865) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196039 CVCL_XJ27 DANi010-A induced pluripotent stem cell human CVCL_XJ27 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Male 21196040 CVCL_P179 GM18564 transformed cell line human CVCL_P179 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196041 CVCL_XJ26 DANi007-A induced pluripotent stem cell human CVCL_XJ26 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Gln456Ter (c.1366C>T); ClinVar=VCV000002415; Zygosity=Homozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196042 CVCL_P178 GM18563 transformed cell line human CVCL_P178 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196043 CVCL_XJ25 DANi005-A induced pluripotent stem cell human CVCL_XJ25 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=31786474); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196044 CVCL_P177 GM18562 transformed cell line human CVCL_P177 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196045 CVCL_P176 GM18561 transformed cell line human CVCL_P176 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196046 CVCL_P175 GM18560 transformed cell line human CVCL_P175 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196047 CVCL_P174 GM18559 transformed cell line human CVCL_P174 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196048 CVCL_XJ29 DANi009-A induced pluripotent stem cell human CVCL_XJ29 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (from autologous cell line DANi009-C) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196049 CVCL_P173 GM18558 transformed cell line human CVCL_P173 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196050 CVCL_P194 GM18591 transformed cell line human CVCL_P194 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196051 CVCL_P193 GM18582 transformed cell line human CVCL_P193 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196052 CVCL_P192 GM18580 transformed cell line human CVCL_P192 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196053 CVCL_P191 GM18579 transformed cell line human CVCL_P191 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196054 CVCL_P190 GM18577 transformed cell line human CVCL_P190 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196055 CVCL_XJ13 NUIGi036-A induced pluripotent stem cell human CVCL_XJ13 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196056 CVCL_XJ12 NUIGi035-A induced pluripotent stem cell human CVCL_XJ12 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196057 CVCL_XJ11 NUIGi034-A induced pluripotent stem cell human CVCL_XJ11 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196058 CVCL_XJ10 NUIGi033-A induced pluripotent stem cell human CVCL_XJ10 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196059 CVCL_XJ17 BCHNEUi003-A induced pluripotent stem cell human CVCL_XJ17 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; c.114-2A>C; ClinVar=VCV000252667; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31525725); Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Asn178Glufs*20 (c.530_531insA); ClinVar=VCV000252668; Zygosity=Heterozygous (PubMed=31525725) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196060 CVCL_XJ16 BCHNEUi002-A induced pluripotent stem cell human CVCL_XJ16 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Thr387Argfs*30 (c.1160_1161delCA); ClinVar=VCV000156414; Zygosity=Heterozygous (PubMed=31525725) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196061 CVCL_XJ15 BCHNEUi001-A induced pluripotent stem cell human CVCL_XJ15 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Thr387Argfs*30 (c.1160_1161delCA); ClinVar=VCV000156414; Zygosity=Heterozygous (PubMed=31525725); Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Arg449Ter (c.1345A>T); ClinVar=VCV000521444; Zygosity=Heterozygous (PubMed=31525725) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196062 CVCL_P189 GM18576 transformed cell line human CVCL_P189 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196063 CVCL_P188 GM18574 transformed cell line human CVCL_P188 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196064 CVCL_XJ14 NUIGi037-A induced pluripotent stem cell human CVCL_XJ14 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196065 CVCL_P187 GM18573 transformed cell line human CVCL_P187 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196066 CVCL_P186 GM18572 transformed cell line human CVCL_P186 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196067 CVCL_XJ19 BCHNEUi005-A induced pluripotent stem cell human CVCL_XJ19 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Arg406Ter (c.1216C>T); ClinVar=VCV000422147; Zygosity=Heterozygous (PubMed=31525725); Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; p.Leu443Pro (c.1328T>C); ClinVar=VCV000389026; Zygosity=Heterozygous (PubMed=31525725) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196068 CVCL_P185 GM18571 transformed cell line human CVCL_P185 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196069 CVCL_XJ18 BCHNEUi004-A induced pluripotent stem cell human CVCL_XJ18 From: Department of Neurology, Children's Hospital Boston; Boston; USA CL:0000010 Sequence variation: Mutation; HGNC; 572; AP4B1; Simple; c.114-2A>C; ClinVar=VCV000252667; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31525725) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21196070 CVCL_P184 GM18570 transformed cell line human CVCL_P184 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196071 CVCL_P161 GM18543 transformed cell line human CVCL_P161 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196072 CVCL_P160 GM18542 transformed cell line human CVCL_P160 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196073 CVCL_XJ02 NUIGi044-A induced pluripotent stem cell human CVCL_XJ02 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196074 CVCL_XJ01 NUIGi043-C induced pluripotent stem cell human CVCL_XJ01 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196075 CVCL_XJ00 NUIGi043-B induced pluripotent stem cell human CVCL_XJ00 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196076 CVCL_P159 GM18541 transformed cell line human CVCL_P159 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196077 CVCL_P158 GM18540 transformed cell line human CVCL_P158 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female 21196078 CVCL_XJ06 NUIGi039-A induced pluripotent stem cell human CVCL_XJ06 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex6-15del; Zygosity=Heterozygous; Note=De novo mutation (PubMed=31893021; PubMed=33631419) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196079 CVCL_P157 GM18539 transformed cell line human CVCL_P157 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196080 CVCL_XJ05 NUIGi045-A induced pluripotent stem cell human CVCL_XJ05 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31893021) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196081 CVCL_P156 GM18538 transformed cell line human CVCL_P156 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196082 CVCL_XJ04 NUIGi044-C induced pluripotent stem cell human CVCL_XJ04 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196083 CVCL_P155 GM18537 transformed cell line human CVCL_P155 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196084 CVCL_XJ03 NUIGi044-B induced pluripotent stem cell human CVCL_XJ03 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196085 CVCL_P154 GM18536 transformed cell line human CVCL_P154 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196086 CVCL_P153 GM18535 transformed cell line human CVCL_P153 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196087 CVCL_XJ09 NUIGi032-A induced pluripotent stem cell human CVCL_XJ09 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21196088 CVCL_P152 GM18534 transformed cell line human CVCL_P152 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196089 CVCL_XJ08 NUIGi031-A induced pluripotent stem cell human CVCL_XJ08 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21196090 CVCL_P151 GM18533 transformed cell line human CVCL_P151 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196091 CVCL_XJ07 NUIGi039-B induced pluripotent stem cell human CVCL_XJ07 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex6-15del; Zygosity=Heterozygous; Note=De novo mutation (PubMed=33631419) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196092 CVCL_P172 GM18557 transformed cell line human CVCL_P172 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196093 CVCL_P171 GM18555 transformed cell line human CVCL_P171 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196094 CVCL_P170 GM18553 transformed cell line human CVCL_P170 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196095 CVCL_P169 GM18552 transformed cell line human CVCL_P169 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196096 CVCL_P168 GM18550 transformed cell line human CVCL_P168 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196097 CVCL_P167 GM18549 transformed cell line human CVCL_P167 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196098 CVCL_P166 GM18548 transformed cell line human CVCL_P166 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196099 CVCL_P165 GM18547 transformed cell line human CVCL_P165 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196100 CVCL_P164 GM18546 transformed cell line human CVCL_P164 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196101 CVCL_P163 GM18545 transformed cell line human CVCL_P163 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196102 CVCL_P162 GM18544 transformed cell line human CVCL_P162 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196103 CVCL_P139 GM19564 transformed cell line human CVCL_P139 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196104 CVCL_P138 GM19563 transformed cell line human CVCL_P138 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196105 CVCL_P137 GM19562 transformed cell line human CVCL_P137 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196106 CVCL_P136 GM19559 transformed cell line human CVCL_P136 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196107 CVCL_P135 GM19558 transformed cell line human CVCL_P135 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196108 CVCL_P134 GM19557 transformed cell line human CVCL_P134 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196109 CVCL_P133 GM19556 transformed cell line human CVCL_P133 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196110 CVCL_P132 GM19550 transformed cell line human CVCL_P132 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196111 CVCL_P131 GM19548 transformed cell line human CVCL_P131 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196112 CVCL_P130 GM19546 transformed cell line human CVCL_P130 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196113 CVCL_P150 GM18532 transformed cell line human CVCL_P150 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196114 CVCL_P149 GM18531 transformed cell line human CVCL_P149 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196115 CVCL_P148 GM18530 transformed cell line human CVCL_P148 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196116 CVCL_P147 GM18529 transformed cell line human CVCL_P147 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female 21196117 CVCL_P146 GM18528 transformed cell line human CVCL_P146 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196118 CVCL_P145 GM18525 transformed cell line human CVCL_P145 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196119 CVCL_P144 GM18524 transformed cell line human CVCL_P144 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Male 21196120 CVCL_P143 GM19573 transformed cell line human CVCL_P143 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female 21196121 CVCL_P142 GM19570 transformed cell line human CVCL_P142 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196122 CVCL_P141 GM19569 transformed cell line human CVCL_P141 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196123 CVCL_P140 GM19566 transformed cell line human CVCL_P140 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196124 CVCL_G788 BY00786 transformed cell line human CVCL_G788 HLA typing: A*24:EPWM,68:DGJC; B*39:09,51:EKNW; C*07:EYCV,15:AJUE; DRB1*14:02,14:109 (IPD-IMGT/HLA=23043) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196125 CVCL_FV88 GM13199 finite cell line human CVCL_FV88 CL:0000010 Population: Caucasian; Amish; Derived from sampling site: Cell type=Fibroblast. Male 21196126 CVCL_G787 BY00782 transformed cell line human CVCL_G787 HLA typing: A*03:EKFM; B*44:03,57:BZCF; C*04:EKHJ,07:EKHM; DRB1*08:04:06,15:03 (IPD-IMGT/HLA=23045) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196127 CVCL_FV87 GM10388 finite cell line human CVCL_FV87 CL:0000010 Population: Pakistani; Derived from sampling site: Cell type=Fibroblast. Female 21196128 CVCL_G786 BY00779 transformed cell line human CVCL_G786 HLA typing: A*02:EAGM,03:EKPR; B*07:EKFP,35:EKFW; C*04:EJUE,07:EPWA; DRB1*13:11,11:102 (IPD-IMGT/HLA=23046) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196129 CVCL_FV86 GM10367 finite cell line human CVCL_FV86 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196130 CVCL_G785 BY00773 transformed cell line human CVCL_G785 HLA typing: A*11:FDNV,32:ENRH; B*14:BPYK,38:BPSA; DRB1*15:01,07:20 (IPD-IMGT/HLA=23018) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196131 CVCL_FV85 GM10366 finite cell line human CVCL_FV85 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196132 CVCL_G789 BY00829 transformed cell line human CVCL_G789 HLA typing: A*23:31,68:01; B*44:DNBV,58:BG; DRB1*12:DUKV,13:31 (IPD-IMGT/HLA=24698) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196133 CVCL_FV89 GM13301 transformed cell line human CVCL_FV89 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196134 CVCL_G780 BY00766 transformed cell line human CVCL_G780 HLA typing: A*30:EKJJ,68:EKJK; B*13:UUB,15:EATR; C*03:ECYV,06:EMRN; DRB1*08:01,07:21 (IPD-IMGT/HLA=23024) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196135 CVCL_FV80 GM10306 finite cell line human CVCL_FV80 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196136 CVCL_P119 GM19082 transformed cell line human CVCL_P119 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196137 CVCL_G784 BY00772 transformed cell line human CVCL_G784 HLA typing: A*01:EJTF,02:EJTK; B*08:EANG,40:EABM; C*03:EBCY,07:EJWS; DRB1*13:02,03:60 (IPD-IMGT/HLA=23039) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196138 CVCL_FV84 GM10365 transformed cell line human CVCL_FV84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196139 CVCL_P118 GM19081 transformed cell line human CVCL_P118 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196140 CVCL_G783 BY00771 transformed cell line human CVCL_G783 HLA typing: A*11:ERNP,24:ERNW; B*15:CRSD,35:EVNK; DRB1*12:02:01,16:18 (IPD-IMGT/HLA=23020) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196141 CVCL_FV83 GM10364 finite cell line human CVCL_FV83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196142 CVCL_P117 GM19080 transformed cell line human CVCL_P117 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196143 CVCL_G782 BY00770 transformed cell line human CVCL_G782 HLA typing: A*24:EPMK,24:EPMK; B*15:21,40:EGCH; C*04:EKVK,04:03; DRB1*09:01:02,04:95 (IPD-IMGT/HLA=23021) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196144 CVCL_FV82 GM10363 transformed cell line human CVCL_FV82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196145 CVCL_P116 GM19079 transformed cell line human CVCL_P116 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196146 CVCL_G781 BY00769 transformed cell line human CVCL_G781 HLA typing: A*31:ERPK,68:ERYU; B*35:BHH,40:CMFM; DRB1*04:05:01,08:42 (IPD-IMGT/HLA=23022) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196147 CVCL_FV81 GM10319 finite cell line human CVCL_FV81 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196148 CVCL_P115 GM19078 transformed cell line human CVCL_P115 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196149 CVCL_P114 GM19077 transformed cell line human CVCL_P114 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196150 CVCL_P113 GM19076 transformed cell line human CVCL_P113 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196151 CVCL_P112 GM19075 transformed cell line human CVCL_P112 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196152 CVCL_P111 GM19074 transformed cell line human CVCL_P111 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196153 CVCL_P110 GM19072 transformed cell line human CVCL_P110 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196154 CVCL_G799 BY00158 transformed cell line human CVCL_G799 HLA typing: A*01:01:01:01,02:114; B*27:EKN,38:01; DRB1*03:01:01,11:03 (IPD-IMGT/HLA=14840) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196155 CVCL_FV99 GM13956 transformed cell line human CVCL_FV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196156 CVCL_G798 BY00157 transformed cell line human CVCL_G798 HLA typing: A*02:05,01:23; B*44:AXGG,58:01; DRB1*13:02,15:03 (IPD-IMGT/HLA=14832) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196157 CVCL_FV98 GM13955 transformed cell line human CVCL_FV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196158 CVCL_G797 BY00156 transformed cell line human CVCL_G797 HLA typing: A*03:01:01:01,24:72; B*07:ASKU,58:01; DRB1*15:AK,16:01 (IPD-IMGT/HLA=14839) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196159 CVCL_FV97 GM13934 transformed cell line human CVCL_FV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196160 CVCL_G796 BY00154 transformed cell line human CVCL_G796 HLA typing: A*01:24,24:02:01:01; B*51:BVND,57:AC; DRB1*01:01,04:11 (IPD-IMGT/HLA=14837) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196161 CVCL_FV96 GM13933 transformed cell line human CVCL_FV96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196162 CVCL_G791 BY00832 transformed cell line human CVCL_G791 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196163 CVCL_FV91 GM13568 transformed cell line human CVCL_FV91 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196164 CVCL_G790 BY00831 transformed cell line human CVCL_G790 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196165 CVCL_FV90 GM13550 transformed cell line human CVCL_FV90 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196166 CVCL_G795 BY00153 transformed cell line human CVCL_G795 HLA typing: A*68:02:01:01,03:29; B*15:BYXW,35:BZBW; DRB1*03:BYBY,11:BBJ (IPD-IMGT/HLA=14836) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196167 CVCL_FV95 GM13730 transformed cell line human CVCL_FV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196168 CVCL_P129 GM19545 transformed cell line human CVCL_P129 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196169 CVCL_G794 BY00152 transformed cell line human CVCL_G794 HLA typing: A*33:03:01,23:15; B*37:01,07:NTH; DRB1*15:03,13:02 (IPD-IMGT/HLA=14834) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196170 CVCL_FV94 GM13695 transformed cell line human CVCL_FV94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196171 CVCL_P128 GM19091 transformed cell line human CVCL_P128 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196172 CVCL_G793 BY00151 transformed cell line human CVCL_G793 HLA typing: A*02:CAKM,01:23; B*27:EKN,35:BEZX; DRB1*04:04,12:CVT (IPD-IMGT/HLA=14833) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196173 CVCL_FV93 GM13571 transformed cell line human CVCL_FV93 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196174 CVCL_P127 GM19090 transformed cell line human CVCL_P127 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196175 CVCL_G792 BY00877 transformed cell line human CVCL_G792 HLA typing: A*01:FTZP,11:FEXH; B*35:08:01,41:14; DRB1*11:04,07:01 (IPD-IMGT/HLA=25477) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196176 CVCL_FV92 GM13570 transformed cell line human CVCL_FV92 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196177 CVCL_P126 GM19089 transformed cell line human CVCL_P126 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196178 CVCL_P125 GM19088 transformed cell line human CVCL_P125 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196179 CVCL_P124 GM19087 transformed cell line human CVCL_P124 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196180 CVCL_P123 GM19086 transformed cell line human CVCL_P123 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196181 CVCL_P122 GM19085 transformed cell line human CVCL_P122 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196182 CVCL_P121 GM19084 transformed cell line human CVCL_P121 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196183 CVCL_P120 GM19083 transformed cell line human CVCL_P120 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196184 CVCL_5D56 GM12332 transformed cell line human CVCL_5D56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132809 21196185 CVCL_5D55 GM12331 transformed cell line human CVCL_5D55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132806 21196186 CVCL_5D54 GM12330 transformed cell line human CVCL_5D54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132805 21196187 CVCL_5D53 GM12328 transformed cell line human CVCL_5D53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141803 21196188 CVCL_5D59 GM12337 transformed cell line human CVCL_5D59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133004 21196189 CVCL_5D58 GM12334 transformed cell line human CVCL_5D58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132811 21196190 CVCL_5D57 GM12333 transformed cell line human CVCL_5D57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132810 21196191 CVCL_5D52 GM12285 transformed cell line human CVCL_5D52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142112 21196192 CVCL_5D51 GM12284 transformed cell line human CVCL_5D51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142111 21196193 CVCL_5D50 GM12281 transformed cell line human CVCL_5D50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142108 21196194 CVCL_5D67 GM12378 transformed cell line human CVCL_5D67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135305 21196195 CVCL_5D66 GM12377 transformed cell line human CVCL_5D66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135304 21196196 CVCL_5D65 GM12351 transformed cell line human CVCL_5D65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1328114 21196197 CVCL_5D64 GM12349 transformed cell line human CVCL_5D64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1328110 21196198 CVCL_5D69 GM12380 transformed cell line human CVCL_5D69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135307 21196199 CVCL_5D68 GM12379 transformed cell line human CVCL_5D68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135306 21196200 CVCL_XJ93 LCL-21353.1B2 cancer cell line pig CVCL_XJ93 CL:0000010 Transformant: Porcine lymphotropic herpesvirus 3(NCBI-Taxonomy; 199308); Derived from sampling site: Peripheral blood; Breed/subspecies: Miniature boar (d/d haplotype). Female 21196201 CVCL_XJ92 SU-211-10 hybridoma house mouse CVCL_XJ92 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:30958; Sudan I (CI Solvent Yellow 14). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200813 21196202 CVCL_XJ91 PKD3.54 induced pluripotent stem cell human CVCL_XJ91 From: Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT); Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9020; PKLR; Simple; c.1269+1G>C (IVS9+1G>C); Zygosity=Homozygous; Note=Splice donor mutation (PubMed=26549847) Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196203 CVCL_XJ90 PKD2.78 induced pluripotent stem cell human CVCL_XJ90 From: Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT); Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9020; PKLR; Simple; p.Ser120Phe (c.359C>T); Zygosity=Heterozygous (PubMed=26549847); Sequence variation: Mutation; HGNC; 9020; PKLR; Simple; p.Asp390Asn (c.1168G>A); ClinVar=VCV001469002; Zygosity=Heterozygous (PubMed=26549847) Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196204 CVCL_XJ97 M370 cancer cell line human CVCL_XJ97 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=24735930) Derived from metastatic site: Heart. Unspecified 21196205 CVCL_XJ96 MC38-OVA cancer cell line house mouse CVCL_XJ96 CL:0000010 Transfected with: UniProtKB; P01012; Chicken ovalbumin (SERPINB14); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Colon; Breed/subspecies: C57BL/6. Female Characteristics: Transfected with a OVA-IRES-EGFP construct 21196206 CVCL_XJ95 LCL-21353.2F8-23482 cancer cell line pig CVCL_XJ95 CL:0000010 Transformant: Porcine lymphotropic herpesvirus 3(NCBI-Taxonomy; 199308); Derived from sampling site: Peripheral blood; Breed/subspecies: Miniature boar (d/d haplotype). Female Characteristics: Established after passage of parent cell line into a immunosuppressed MHC-matching pig 21196207 CVCL_XJ94 LCL-21353.2F8 cancer cell line pig CVCL_XJ94 CL:0000010 Transformant: Porcine lymphotropic herpesvirus 3(NCBI-Taxonomy; 199308); Derived from sampling site: Peripheral blood; Breed/subspecies: Miniature boar (d/d haplotype). Female 21196208 CVCL_XJ99 M395 cancer cell line human CVCL_XJ99 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=22194965; PubMed=29229836) Derived from metastatic site: Adrenal gland. Omics: Transcriptome analysis by RNAseq Unspecified 21196209 CVCL_XJ98 M381 cancer cell line human CVCL_XJ98 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29229836) Omics: Transcriptome analysis by RNAseq. Unspecified 21196210 CVCL_5D63 GM12346 transformed cell line human CVCL_5D63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1328105 21196211 CVCL_5D62 GM12345 transformed cell line human CVCL_5D62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1328103 21196212 CVCL_5D61 GM12339 transformed cell line human CVCL_5D61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133006 21196213 CVCL_5D60 GM12338 transformed cell line human CVCL_5D60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133005 21196214 CVCL_5D34 GM12251 transformed cell line human CVCL_5D34 HLA typing: A*01:01,02:01; B*08:01,15:01; C*03:03,07:01; DPA1*01:03,01:03; DPB1*04:01:01; DQA1*02:01,03:01; DQB1*03:02:01,03:03; DRB1*04:01,07:01 (IPD-IMGT/HLA=25975) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141614 21196215 CVCL_5D33 GM12250 transformed cell line human CVCL_5D33 HLA typing: A*02:05,25:01; B*44:02,49:01; C*05:01,07:01; DPA1*01:03,02:01:01; DPB1*04:01,13:01; DQA1*01:02,05:01; DQB1*03:01,06:09; DRB1*11:01,13:02 (IPD-IMGT/HLA=25974) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141613 21196216 CVCL_5D32 GM12247 transformed cell line human CVCL_5D32 HLA typing: A*02:01,23:01; B*41:01,49:01; C*07:01,17:01; DPA1*01:03,02:01:01; DPB1*02:01:02,13:01; DQA1*01:02,02:01; DQB1*02:01,06:09; DRB1*07:01,13:02 (IPD-IMGT/HLA=25973) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141610 21196217 CVCL_5D31 GM12246 transformed cell line human CVCL_5D31 HLA typing: A*02:01,02:01; B*15:01,40:01; C*03:03,03:04:01; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:02,03:01; DQB1*03:02:01,06:04; DRB1*04:01,13:02 (IPD-IMGT/HLA=25969) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141609 21196218 CVCL_5D38 GM12265 transformed cell line human CVCL_5D38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141804 21196219 CVCL_5D37 GM12263 transformed cell line human CVCL_5D37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137508 21196220 CVCL_5D36 GM12253 transformed cell line human CVCL_5D36 HLA typing: A*02:01,02:05; B*40:01,49:01; C*03:04:01,07:01; DPA1*01:03,02:01:01; DPB1*03:01:01,13:01; DQA1*01:02,01:02; DQB1*06:04,06:09; DRB1*13:02,13:02 (IPD-IMGT/HLA=25977) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141616 21196221 CVCL_5D35 GM12252 transformed cell line human CVCL_5D35 HLA typing: A*02:05,23:01; B*41:01,49:01; C*07:01,17:01; DPA1*01:03,02:01:01; DPB1*02:01:02,13:01; DQA1*01:02,02:01; DQB1*02:01,06:09; DRB1*07:01,13:02 (IPD-IMGT/HLA=25976) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141615 21196222 CVCL_5D39 GM12266 transformed cell line human CVCL_5D39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141805 21196223 CVCL_XJ82 LUMCi011-A induced pluripotent stem cell human CVCL_XJ82 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196224 CVCL_XJ81 GIBHi001-A induced pluripotent stem cell human CVCL_XJ81 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3614; FCGR1BP; Simple; p.Arg139Ter (c.415C>T); Zygosity=Heterozygous (PubMed=31520889) Derived from sampling site: Urine. Male 21196225 CVCL_XJ80 FRIMOi007-A induced pluripotent stem cell human CVCL_XJ80 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8787; PDE6C; Simple; p.Arg557Gln (c.1670G>A); Zygosity=Homozygous (PubMed=31520890) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196226 CVCL_XJ86 CUBi002-A induced pluripotent stem cell human CVCL_XJ86 From: Charite, Universitatsmedizin Berlin; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1348; SAMD9; Simple; p.Ile983Ser (c.2948T>G); Zygosity=Heterozygous (from autologous cell line CUBi002-B) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196227 CVCL_XJ85 LUMCi012-B induced pluripotent stem cell human CVCL_XJ85 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Mosaic; Note=D4Z4 repeat contraction (to 2 repeats) (PubMed=31518905) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: While the patient is suffering from facioscapulohumeral muscular dystrophy 1 he is mosaic for the D4Z4 repeat contraction The fibroblast from which this iPSC was derived bears the contraction. 21196228 CVCL_XJ84 LUMCi012-A induced pluripotent stem cell human CVCL_XJ84 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: While the patient is suffering from facioscapulohumeral muscular dystrophy 1 he is mosaic for the D4Z4 repeat contraction The fibroblast from which this iPSC was derived was normal. 21196229 CVCL_XJ83 LUMCi011-B induced pluripotent stem cell human CVCL_XJ83 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Gene deletion; HGNC; 50800; DUX4; Zygosity=Mosaic; Note=D4Z4 repeat contraction (to 3 repeats) (PubMed=31518905) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: While the patient is suffering from facioscapulohumeral muscular dystrophy 1 he is mosaic for the D4Z4 repeat contraction The fibroblast from which this iPSC was derived bears the contraction. 21196230 CVCL_XJ89 PB2.33 induced pluripotent stem cell human CVCL_XJ89 From: Centro de Investigaciones Energeticas, Medioambientales y Tecnologicas (CIEMAT); Madrid; Spain CL:0000010 Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196231 CVCL_XJ88 FRIMOi006-A induced pluripotent stem cell human CVCL_XJ88 From: Fundacio de Recerca de l'Institut de Microcirurgia Ocular; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 12703; BEST1; Simple; p.Pro77Ser (c.229C>T); Zygosity=Heterozygous (PubMed=31518904) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196232 CVCL_XJ87 RBi001-B induced pluripotent stem cell human CVCL_XJ87 From: R Biomedical, Ltd; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196233 CVCL_5D30 GM12245 transformed cell line human CVCL_5D30 HLA typing: A*02:01,02:01; B*15:01,40:01; C*03:03,03:04:01; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:02,03:01; DQB1*03:02:01,06:04; DRB1*04:01,13:02 (IPD-IMGT/HLA=25971) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141608 21196234 CVCL_5D45 GM12276 transformed cell line human CVCL_5D45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142103 21196235 CVCL_5D44 GM12271 transformed cell line human CVCL_5D44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141810 21196236 CVCL_5D43 GM12270 transformed cell line human CVCL_5D43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141809 21196237 CVCL_5D42 GM12269 transformed cell line human CVCL_5D42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM12269; probable Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141808 21196238 CVCL_5D49 GM12280 transformed cell line human CVCL_5D49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142107 21196239 CVCL_5D48 GM12279 transformed cell line human CVCL_5D48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142106 21196240 CVCL_5D47 GM12278 transformed cell line human CVCL_5D47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142105 21196241 CVCL_5D46 GM12277 transformed cell line human CVCL_5D46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142104 21196242 CVCL_XJ71 S-200-23 hybridoma house mouse CVCL_XJ71 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Q0U8; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) nucleoprotein (NP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200812 21196243 CVCL_XJ70 S-171-9 hybridoma house mouse CVCL_XJ70 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Q0U8; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) nucleoprotein (NP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200811 21196244 CVCL_XJ75 MGLU-2-R spontaneously immortalized cell line CVCL_XJ75 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: Eastern lineage. Female Virology: Susceptible to infection by cowpox virus, murine gammaherpesvirus 68 (MHV-68), Rift Valley fever virus (RVFV), Schmallenberg virus (SBV), Sindbis virus and vaccinia virus 21196245 CVCL_XJ74 FMG-R spontaneously immortalized cell line CVCL_XJ74 CL:0000010 Donor information: Established from the brains of six newborn common voles minced together; Derived from sampling site: Brain. Mixed Virology: Susceptible to infection by cowpox virus, murine gammaherpesvirus 68 (MHV-68), Rift Valley fever virus (RVFV) and vaccinia virus 21196246 CVCL_XJ73 S-98-10 hybridoma house mouse CVCL_XJ73 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9Q0U6; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200807 21196247 CVCL_XJ72 S-290-3 hybridoma house mouse CVCL_XJ72 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9Q0U8; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) nucleoprotein (NP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200810 21196248 CVCL_XJ79 SDQLCHi007-A induced pluripotent stem cell human CVCL_XJ79 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (PubMed=31812072) Derived from sampling site: Peripheral blood. Male 21196249 CVCL_XJ78 SDQLCHi006-A induced pluripotent stem cell human CVCL_XJ78 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 987; BCKDHB; Simple; p.Arg168Cys (c.502C>T); ClinVar=VCV000096586; Zygosity=Heterozygous (PubMed=31610500); Sequence variation: Mutation; HGNC; 987; BCKDHB; Simple; p.Thr322Ile (c.965C>T); Zygosity=Heterozygous (PubMed=31610500) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21196250 CVCL_XJ77 hESC-PRLY telomerase immortalized cell line human CVCL_XJ77 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female Characteristics: Allows a quantifiable visual readout of the decidualization response; Characteristics: YFP expression is under the control of a prolactin promoter (pPRL) 21196251 CVCL_XJ76 MGN-2-R spontaneously immortalized cell line CVCL_XJ76 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Carpathian lineage. Male Virology: Susceptible to infection by Puumala orthohantavirus (PUUV) 21196252 CVCL_5D41 GM12268 transformed cell line human CVCL_5D41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141807 21196253 CVCL_5D40 GM12267 transformed cell line human CVCL_5D40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 141806 21196254 CVCL_5D12 GM12149 transformed cell line human CVCL_5D12 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,12:01 (IPD-IMGT/HLA=25946) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140805 21196255 CVCL_5D11 GM12148 transformed cell line human CVCL_5D11 HLA typing: A*01:01,02:01; B*07:02,51:01; C*07:02,15:02; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:01; DRB1*04:07,12:01 (IPD-IMGT/HLA=25940) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140804 21196256 CVCL_5D10 GM12147 transformed cell line human CVCL_5D10 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,12:01 (IPD-IMGT/HLA=25937) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140803 21196257 CVCL_5D16 GM12153 transformed cell line human CVCL_5D16 HLA typing: A*01:01,01:01; B*08:01,51:01; C*07:01,15:02; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*03:01,05:01; DQB1*02:01,03:01; DRB1*03:01,04:07 (IPD-IMGT/HLA=25938) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140809 21196258 CVCL_5D15 GM12152 transformed cell line human CVCL_5D15 HLA typing: A*01:01,02:01; B*07:02,51:01; C*07:02,15:02; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:01; DRB1*04:07,12:01 (IPD-IMGT/HLA=25939) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140808 21196259 CVCL_5D14 GM12151 transformed cell line human CVCL_5D14 HLA typing: A*01:01,01:01; B*08:01,08:01; C*07:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*05:01,05:01; DQB1*02:01,02:01; DRB1*03:01,03:01 (IPD-IMGT/HLA=13836) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140807 21196260 CVCL_5D13 GM12150 transformed cell line human CVCL_5D13 HLA typing: A*01:01,02:01; B*07:02,51:01; C*07:02,15:02; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*03:01,05:01; DQB1*03:01,03:01; DRB1*04:07,12:01 (IPD-IMGT/HLA=25945) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140806 21196261 CVCL_5D19 GM12230 transformed cell line human CVCL_5D19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137504 21196262 CVCL_5D18 GM12229 transformed cell line human CVCL_5D18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137503 21196263 CVCL_5D17 GM12157 transformed cell line human CVCL_5D17 HLA typing: A*01:01,02:01; B*07:02,08:01; C*07:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*05:01,05:01; DQB1*02:01,03:01; DRB1*03:01,12:01 (IPD-IMGT/HLA=25947) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 140814 21196264 CVCL_XJ60 5F8 [Mouse hybridoma against S.typhimurium spiC] hybridoma house mouse CVCL_XJ60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0CZ04; Salmonella typhimurium spiC. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201563 21196265 CVCL_XJ64 PT1-1 spontaneously immortalized cell line CVCL_XJ64 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Transfected with a vector carrying cDNA of the heavy and light chain of a murine IgG2a antibody 21196266 CVCL_XJ63 SHOV4 cancer cell line human CVCL_XJ63 CL:0000010 Population: Chinese; Han; Derived from sampling site: Ovary. Female Doubling time: ~48 hours (Patent=CN109486767B) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018195 21196267 CVCL_XJ62 MON/4C9 hybridoma house mouse CVCL_XJ62 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:27617; Monensin A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018117 21196268 CVCL_XJ61 2H8 [Mouse hybridoma against monensin A] hybridoma house mouse CVCL_XJ61 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:27617; Monensin A. 21196269 CVCL_XJ68 S-145-9 hybridoma house mouse CVCL_XJ68 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9Q0U6; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200808 21196270 CVCL_XJ67 PT1-55 spontaneously immortalized cell line CVCL_XJ67 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Transfected with a vector carrying cDNA of the heavy and light chain of a murine IgG2a antibody 21196271 CVCL_XJ66 PT1-30 spontaneously immortalized cell line CVCL_XJ66 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Transfected with a vector carrying cDNA of the heavy and light chain of a murine IgG2a antibody 21196272 CVCL_XJ65 PT1-7 spontaneously immortalized cell line CVCL_XJ65 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Ovary. Female Characteristics: Transfected with a vector carrying cDNA of the heavy and light chain of a murine IgG2a antibody 21196273 CVCL_XJ69 S-157-6 hybridoma house mouse CVCL_XJ69 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9Q0U6; Influenza A virus isolate A/Goose/Guangdong/1/1996(H5N1) hemagglutinin (HA). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200809 21196274 CVCL_5D23 GM12235 transformed cell line human CVCL_5D23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137513 21196275 CVCL_5D22 GM12233 transformed cell line human CVCL_5D22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137507 21196276 CVCL_5D21 GM12232 transformed cell line human CVCL_5D21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137506 21196277 CVCL_5D20 GM12231 transformed cell line human CVCL_5D20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 137505 21196278 CVCL_5D27 GM12241 transformed cell line human CVCL_5D27 HLA typing: A*02:01,23:01; B*15:01,41:01; C*03:03,17:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*02:01,03:01; DQB1*02:01,03:02:01; DRB1*04:01,07:01 (IPD-IMGT/HLA=13833) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141604 21196279 CVCL_5D26 GM12240 transformed cell line human CVCL_5D26 HLA typing: A*02:01,02:05; B*40:01,49:01; C*03:04:01,07:01; DPA1*01:03,02:01:01; DPB1*03:01:01,13:01; DQA1*01:02,01:02; DQB1*06:04:01,06:09; DRB1*13:02,13:02 (IPD-IMGT/HLA=13841) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141603 21196280 CVCL_5D25 GM12238 transformed cell line human CVCL_5D25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133408 21196281 CVCL_5D24 GM12237 transformed cell line human CVCL_5D24 HLA typing: A*03:01,03:01; B*27:05,35:01; C*02:02:02,04:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*03:01,04:01; DQB1*03:02:01,04:02; DRB1*04:04,08:01; DRB4*01 (IPD-IMGT/HLA=25828) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133210 21196282 CVCL_5D29 GM12244 transformed cell line human CVCL_5D29 HLA typing: A*02:01,23:01; B*15:01,41:01; C*03:03,17:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*02:01,03:01; DQB1*02:01,03:02:01; DRB1*04:01,07:01 (IPD-IMGT/HLA=25970); HLA typing: A*02:01:01,23:01:01; B*15:01:01,41:01:01; C*03:03:01,17:01:01; DPA1*01:03:01,01:03:01; DPB1*02:01:02,04:01:01; DQA1*02:01:01,03:01:01; DQB1*02:02:01,03:02:01; DRB1*04:01:01,07:01:01; DRB4*01:03:01,01:03:01 (PubMed=29959025) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: Genetic Testing Reference Material (GeT-RM) samples; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141607 21196283 CVCL_5D28 GM12243 transformed cell line human CVCL_5D28 HLA typing: A*02:01,02:01; B*15:01,40:01; C*03:03,03:04:01; DPA1*01:03,01:03; DPB1*03:01:01,04:01:01; DQA1*01:02,03:01; DQB1*03:02:01,06:04; DRB1*04:01,13:02 (IPD-IMGT/HLA=25972) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141606 21196284 CVCL_XJ53 11F4 hybridoma house mouse CVCL_XJ53 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q5ZPR3; Human CD276. 21196285 CVCL_XJ52 10H4 hybridoma house mouse CVCL_XJ52 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Canine parvovirus isolate AV298 (Note=Also reacts with other isolates). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201579 21196286 CVCL_XJ51 10B11 hybridoma house mouse CVCL_XJ51 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Canine parvovirus isolate AV298. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201578 21196287 CVCL_XJ50 FFA-C hybridoma house mouse CVCL_XJ50 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:87185; Florfenicol. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201575 21196288 CVCL_XJ57 3B8 [Mouse hybridoma against M.tuberculosis Ag85A] hybridoma house mouse CVCL_XJ57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WQP3; Mycobacterium tuberculosis diacylglycerol acyltransferase/mycolyltransferase Ag85A (fbpA). 21196289 CVCL_XJ56 2F2 [Mouse hybridoma against M.tuberculosis Ag85A] hybridoma house mouse CVCL_XJ56 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WQP3; Mycobacterium tuberculosis diacylglycerol acyltransferase/mycolyltransferase Ag85A (fbpA) (Note=Also reacts with Ag85B/fbpB). 21196290 CVCL_XJ55 2E6 [Mouse hybridoma against M.tuberculosis Ag85A] hybridoma house mouse CVCL_XJ55 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WQP3; Mycobacterium tuberculosis diacylglycerol acyltransferase/mycolyltransferase Ag85A (fbpA) (Note=Also reacts with Ag85C/fbpC). 21196291 CVCL_XJ54 1C6 [Mouse hybridoma against M.tuberculosis Ag85A] hybridoma house mouse CVCL_XJ54 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WQP3; Mycobacterium tuberculosis diacylglycerol acyltransferase/mycolyltransferase Ag85A (fbpA). 21196292 CVCL_XJ59 2F2 [Mouse hybridoma against mercury] hybridoma house mouse CVCL_XJ59 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:16793; Mercury(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201512 21196293 CVCL_XJ58 3D9 [Mouse hybridoma against M.tuberculosis Ag85A] hybridoma house mouse CVCL_XJ58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WQP3; Mycobacterium tuberculosis diacylglycerol acyltransferase/mycolyltransferase Ag85A (fbpA) (Note=Also reacts with Ag85B/fbpB and Ag85C/fbpC). 21196294 CVCL_XJ42 IDVi003-C induced pluripotent stem cell human CVCL_XJ42 From: Institut de la Vision; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 6174; ITM2B; Simple; p.Glu261Ala (c.782A>C); ClinVar=VCV000157606; Zygosity=Heterozygous (PubMed=31731182) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196295 CVCL_XJ41 IDVi003-B induced pluripotent stem cell human CVCL_XJ41 From: Institut de la Vision; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 6174; ITM2B; Simple; p.Glu261Ala (c.782A>C); ClinVar=VCV000157606; Zygosity=Heterozygous (PubMed=31731182) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196296 CVCL_XJ40 IDVi003-A induced pluripotent stem cell human CVCL_XJ40 From: Institut de la Vision; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 6174; ITM2B; Simple; p.Glu261Ala (c.782A>C); ClinVar=VCV000157606; Zygosity=Heterozygous (PubMed=31731182) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196297 CVCL_XJ46 NUIGi026-B induced pluripotent stem cell human CVCL_XJ46 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196298 CVCL_XJ45 MHHi006-A-3 induced pluripotent stem cell human CVCL_XJ45 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Umbilical cord blood. Male Characteristics: Using TALEN a ZeoR-T2A-dTomato(nuc) construct was integrated in one of the alleles of CFTR which has a 4 bp deletion in its Kozak sequence (PubMed=31080112) 21196299 CVCL_XJ44 IDVi004-B induced pluripotent stem cell human CVCL_XJ44 From: Institut de la Vision; Paris; France CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196300 CVCL_XJ43 IDVi004-A induced pluripotent stem cell human CVCL_XJ43 From: Institut de la Vision; Paris; France CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196301 CVCL_XJ49 CDH5-2C11 hybridoma house mouse CVCL_XJ49 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P33151; Human CDH5/CD144. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201581 21196302 CVCL_XJ48 AND-1 NEO embryonic stem cell human CVCL_XJ48 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Characteristics: Transfected with a pRRL-EF1a-PGK-Neo construct Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21196303 CVCL_P199 GM18596 transformed cell line human CVCL_P199 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196304 CVCL_XJ47 NUIGi030-A induced pluripotent stem cell human CVCL_XJ47 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 21196305 CVCL_P198 GM18595 transformed cell line human CVCL_P198 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196306 CVCL_P197 GM18594 transformed cell line human CVCL_P197 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Transcriptome analysis by microarray Female 21196307 CVCL_P196 GM18593 transformed cell line human CVCL_P196 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196308 CVCL_P195 GM18592 transformed cell line human CVCL_P195 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196309 CVCL_5D01 GM12114 transformed cell line human CVCL_5D01 HLA typing: A*01:01,02:01; B*13:02,44:02; C*05:01,07:01; DPA1*01:03,02:01:01; DPB1*02:01:02,14:01; DQA1*02:01,03:01; DQB1*02:01,03:01:01; DRB1*04:01,07:01 (IPD-IMGT/HLA=25959) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141316 21196310 CVCL_5D00 GM12113 transformed cell line human CVCL_5D00 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25958) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141315 21196311 CVCL_5D05 GM12138 transformed cell line human CVCL_5D05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133403 21196312 CVCL_5D04 GM12117 transformed cell line human CVCL_5D04 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01; DQA1*03:01,05:01; DQB1*02:01,03:01:01; DRB1*03:01,04:01 (IPD-IMGT/HLA=25948) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141319 21196313 CVCL_5D03 GM12116 transformed cell line human CVCL_5D03 HLA typing: A*11:01,68:01:02; B*07:02,13:02; C*03:03,07:02; DPA1*01:03,02:01:01; DPB1*04:01,14:01; DQA1*01:02,02:01; DQB1*02:01,06:02; DRB1*07:01,15:01 (IPD-IMGT/HLA=25964) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141318 21196314 CVCL_5D02 GM12115 transformed cell line human CVCL_5D02 HLA typing: A*02:01,68:01:02; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25961) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141317 21196315 CVCL_5D09 GM12143 transformed cell line human CVCL_5D09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133409 21196316 CVCL_5D08 GM12142 transformed cell line human CVCL_5D08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133407 21196317 CVCL_5D07 GM12141 transformed cell line human CVCL_5D07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133406 21196318 CVCL_5D06 GM12139 transformed cell line human CVCL_5D06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133404 21196319 CVCL_XJ31 DANi009-C induced pluripotent stem cell human CVCL_XJ31 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (PubMed=31786474) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196320 CVCL_XJ30 DANi009-B induced pluripotent stem cell human CVCL_XJ30 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (from autologous cell line DANi009-C) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196321 CVCL_XJ35 DANi003-D induced pluripotent stem cell human CVCL_XJ35 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196322 CVCL_XJ34 DANi003-C induced pluripotent stem cell human CVCL_XJ34 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196323 CVCL_XJ33 DANi003-B induced pluripotent stem cell human CVCL_XJ33 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196324 CVCL_XJ32 DANi003-A induced pluripotent stem cell human CVCL_XJ32 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196325 CVCL_XJ39 DANi003-H induced pluripotent stem cell human CVCL_XJ39 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (PubMed=31786474) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196326 CVCL_XJ38 DANi003-G induced pluripotent stem cell human CVCL_XJ38 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196327 CVCL_XJ37 DANi003-F induced pluripotent stem cell human CVCL_XJ37 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196328 CVCL_XJ36 DANi003-E induced pluripotent stem cell human CVCL_XJ36 From: Danish Research Institute of Translational Neuroscience, Aarhus University; Aarhus; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from autologous cell line DANi003-H) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196329 CVCL_5C99 GM12112 transformed cell line human CVCL_5C99 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,07:04; DPA1*01:03,02:01:01; DPB1*04:01:01,14:01; DQA1*02:01,05:01; DQB1*02:01,03:01:01; DRB1*07:01,11:01 (IPD-IMGT/HLA=25957) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141314 21196330 CVCL_5C98 GM12111 transformed cell line human CVCL_5C98 HLA typing: A*01:01,02:01; B*08:01,44:02; C*07:01,07:04; DPA1*01:03,01:03; DPB1*04:01:01,04:01:01; DQA1*01:02,05:01; DQB1*03:01:01,06:02; DRB1*11:01,15:01 (IPD-IMGT/HLA=25951) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141313 21196331 CVCL_5C93 GM12106 transformed cell line human CVCL_5C93 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,07:04; DPA1*01:03,02:01:01; DPB1*04:01:01,14:01; DQA1*02:01,05:01; DQB1*02:01,03:01:01; DRB1*07:01,11:01 (IPD-IMGT/HLA=25962) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141308 21196332 CVCL_5C92 GM12105 transformed cell line human CVCL_5C92 HLA typing: A*01:01,02:01; B*08:01,44:02; C*07:01,07:04; DPA1*01:03,01:03; DPB1*04:01:01,04:01:01; DQA1*01:02,05:01; DQB1*03:01:01,06:02; DRB1*11:01,15:01 (IPD-IMGT/HLA=25966) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141307 21196333 CVCL_5C91 GM12104 transformed cell line human CVCL_5C91 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25963) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141306 21196334 CVCL_5C90 GM12103 transformed cell line human CVCL_5C90 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,05:01; DPA1*01:03,02:01:01; DPB1*02:01:02,14:01; DQA1*02:01,03:01; DQB1*02:01,03:01:01; DRB1*04:01,07:01 (IPD-IMGT/HLA=25953) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141305 21196335 CVCL_5C97 GM12110 transformed cell line human CVCL_5C97 HLA typing: A*01:01,02:01; B*08:01,44:02; C*07:01,07:04; DPA1*01:03,01:03; DPB1*04:01:01,04:01:01; DQA1*01:02,05:01; DQB1*03:01:01,06:02; DRB1*11:01,15:01 (IPD-IMGT/HLA=25950) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141312 21196336 CVCL_5C96 GM12109 transformed cell line human CVCL_5C96 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25949) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141311 21196337 CVCL_5C95 GM12108 transformed cell line human CVCL_5C95 HLA typing: A*01:01,02:01; B*08:01,44:02; C*05:01,07:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:02,03:01; DQB1*03:01:01,06:02; DRB1*04:01,15:01 (IPD-IMGT/HLA=25952) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141310 21196338 CVCL_5C94 GM12107 transformed cell line human CVCL_5C94 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,07:04; DPA1*01:03,02:01:01; DPB1*04:01:01,14:01; DQA1*02:01,05:01; DQB1*02:01,03:01:01; DRB1*07:01,11:01 (IPD-IMGT/HLA=25965) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141309 21196339 CVCL_5C79 GM12089 transformed cell line human CVCL_5C79 HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25822) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133203 21196340 CVCL_5C78 GM12055 transformed cell line human CVCL_5C78 HLA typing: A*01:01,02:01; B*08:01,40:01; C*03:04:01,07:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*02:01,03:01; DQB1*03:02:01,03:03:02; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25874) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134411 21196341 CVCL_5C77 GM12054 transformed cell line human CVCL_5C77 HLA typing: A*03:01,24:02; B*40:01,51:01; C*01:02,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25873) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134410 21196342 CVCL_5C76 GM12053 transformed cell line human CVCL_5C76 HLA typing: A*03:01,24:02; B*40:01,51:01; C*01:02,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25870) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134409 21196343 CVCL_5C71 GM12048 transformed cell line human CVCL_5C71 HLA typing: A*01:01,03:01; B*08:01,51:01; C*01:02,07:01; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*01:01,02:01; DQB1*03:03:02,05:01:01; DRB1*01:01,07:01; DRB4*01 (IPD-IMGT/HLA=25876) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134404 21196344 CVCL_5C70 GM12047 transformed cell line human CVCL_5C70 HLA typing: A*03:01,24:02; B*40:01,51:01; C*01:02,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25867) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134403 21196345 CVCL_5C75 GM12052 transformed cell line human CVCL_5C75 HLA typing: A*01:01,03:01; B*08:01,51:01; C*01:02,07:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25871) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134408 21196346 CVCL_5C74 GM12051 transformed cell line human CVCL_5C74 HLA typing: A*02:01,24:02; B*40:01,40:01; C*03:04:01,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*03:01,03:01; DQB1*03:02:01,03:02:01; DRB1*04:04,04:04; DRB4*01 (IPD-IMGT/HLA=25869) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134407 21196347 CVCL_5C73 GM12050 transformed cell line human CVCL_5C73 HLA typing: A*01:01,02:01; B*08:01,40:01; C*03:04:01,07:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*02:01,03:01; DQB1*03:02:01,03:03:02; DRB1*04:04,07:01; DRB4*01 (IPD-IMGT/HLA=25868) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134406 21196348 CVCL_5C72 GM12049 transformed cell line human CVCL_5C72 HLA typing: A*03:01,24:02; B*40:01,51:01; C*01:02,03:04:01; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04; DRB4*01 (IPD-IMGT/HLA=25866) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134405 21196349 CVCL_5C89 GM12102 transformed cell line human CVCL_5C89 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,05:01; DPA1*01:03,02:01:01; DPB1*02:01:02,14:01; DQA1*02:01,03:01; DQB1*02:01,03:01:01; DRB1*04:01,07:01 (IPD-IMGT/HLA=25954) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141304 21196350 CVCL_5C88 GM12101 transformed cell line human CVCL_5C88 HLA typing: A*02:01,68:01:02; B*13:02,44:02; C*03:03,07:04; DPA1*01:03,02:01:01; DPB1*04:01:01,14:01; DQA1*02:01,05:01; DQB1*02:01,03:01:01; DRB1*07:01,11:01 (IPD-IMGT/HLA=25956) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 141303 21196351 CVCL_5C87 GM12100 transformed cell line human CVCL_5C87 HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25820) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133217 21196352 CVCL_5C82 GM12092 transformed cell line human CVCL_5C82 HLA typing: A*03:01,03:01; B*27:05,56:01; C*01:02,02:02:02; DPA1*01:03,02:01:01; DPB1*02:01:02,11:01:01; DQA1*03:01,04:01; DQB1*03:02:01,04:02; DRB1*04:04,08:01; DRB4*01 (IPD-IMGT/HLA=25826) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133207 21196353 CVCL_5C81 GM12091 transformed cell line human CVCL_5C81 HLA typing: A*03:01,03:01; B*35:01,56:01; C*01:02,04:01; DPA1*01:03,02:01:01; DPB1*04:02,11:01:01; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25830) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133206 21196354 CVCL_5C80 GM12090 transformed cell line human CVCL_5C80 HLA typing: A*03:01,03:01; B*35:01,56:01; C*01:02,04:01; DPA1*01:03,02:01:01; DPB1*04:02,11:01:01; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25819) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133204 21196355 CVCL_5C86 GM12099 transformed cell line human CVCL_5C86 HLA typing: A*03:01,30:01; B*35:01,07:02; C*04:01,07:02; DPA1*01:03,01:03; DPB1*03:01,04:02; DQA1*01:01,01:02; DQB1*05:01:01,06:02; DRB1*01:01,15:01; DRB5*01:01 (IPD-IMGT/HLA=25827) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133216 21196356 CVCL_5C85 GM12095 transformed cell line human CVCL_5C85 HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25824) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133212 21196357 CVCL_5C84 GM12094 transformed cell line human CVCL_5C84 HLA typing: A*03:01,03:01; B*35:01,56:01; C*01:02,04:01; DPA1*01:03,02:01:01; DPB1*04:02,11:01:01; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25823) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133211 21196358 CVCL_5C83 GM12093 transformed cell line human CVCL_5C83 HLA typing: A*03:01,03:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25825) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133208 21196359 CVCL_5C57 GM11999 transformed cell line human CVCL_5C57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142005 21196360 CVCL_5C56 GM11998 transformed cell line human CVCL_5C56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142004 21196361 CVCL_5C55 GM11997 transformed cell line human CVCL_5C55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142003 21196362 CVCL_5C54 GM11996 transformed cell line human CVCL_5C54 HLA typing: A*01:01,29:02; B*44:03,57:01; C*06:02,06:02; DPA1*01:03,01:03; DPB1*02:01:02,04:02; DQA1*01:01,01:03; DQB1*05:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25936) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136217 21196363 CVCL_5C59 GM12001 transformed cell line human CVCL_5C59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142007 21196364 CVCL_5C58 GM12000 transformed cell line human CVCL_5C58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142006 21196365 CVCL_5C53 GM11991 transformed cell line human CVCL_5C53 HLA typing: A*01:01,02:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:02,15:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25929) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136212 21196366 CVCL_5C52 GM11990 transformed cell line human CVCL_5C52 HLA typing: A*01:01,02:01; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*04:02,04:02; DQA1*01:01,01:03; DQB1*05:01:01,06:03; DRB1*01:01,13:01 (IPD-IMGT/HLA=25928) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136211 21196367 CVCL_5C51 GM11989 transformed cell line human CVCL_5C51 HLA typing: A*01:01,02:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:02,15:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25927) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136210 21196368 CVCL_5C50 GM11988 transformed cell line human CVCL_5C50 HLA typing: A*01:01,02:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*04:02,15:01; DQA1*01:01,03:01; DQB1*03:02:01,05:01:01; DRB1*01:01,04:04 (IPD-IMGT/HLA=25925) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 136209 21196369 CVCL_5C68 GM12041 transformed cell line human CVCL_5C68 HLA typing: A*01:01,02:01; B*07:02,57:01; C*06:02:01:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,03:01:01; DQA1*01:03,05:01; DQB1*02:01,06:03; DRB1*03:01,13:01; DRB3*01,01 (IPD-IMGT/HLA=25881) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134609 21196370 CVCL_5C67 GM12040 transformed cell line human CVCL_5C67 HLA typing: A*02:06,11:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,01:01; DQB1*05:01,05:03:01; DRB1*01:01,14:01; DRB3*02 (IPD-IMGT/HLA=25885) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134608 21196371 CVCL_5C66 GM12039 transformed cell line human CVCL_5C66 HLA typing: A*02:06,11:01; B*35:01,35:01; C*04:01,04:01; DPA1*01:03,01:03; DPB1*04:01:01,04:02; DQA1*01:01,01:01; DQB1*05:01,05:03:01; DRB1*01:01,14:01; DRB3*02 (IPD-IMGT/HLA=25877) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134607 21196372 CVCL_5C65 GM12038 transformed cell line human CVCL_5C65 HLA typing: A*02:01,11:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:01,01:03; DQB1*05:03:01,06:03; DRB1*13:01,14:01; DRB3*01,02 (IPD-IMGT/HLA=25880) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134606 21196373 CVCL_5C69 GM12042 transformed cell line human CVCL_5C69 HLA typing: A*01:01,02:06; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*01:01,05:01; DQB1*02:01,05:01; DRB1*01:01,03:01; DRB3*01 (IPD-IMGT/HLA=25882) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134610 21196374 CVCL_XI90 MDCUi001-B induced pluripotent stem cell human CVCL_XI90 From: Center of Excellence for Medical Genomics, Chulalongkorn University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 15455; MBTPS2; Simple; p.Asn459Ser (c.1376A>G); ClinVar=VCV000558767; Zygosity=Hemizygous (PubMed=31326747) Population: Southeast Asian; Thai; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196375 CVCL_XI94 NUIGi024-A induced pluripotent stem cell human CVCL_XI94 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196376 CVCL_XI93 NUIGi026-A induced pluripotent stem cell human CVCL_XI93 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196377 CVCL_XI92 NUIGi023-B induced pluripotent stem cell human CVCL_XI92 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196378 CVCL_XI91 ICGi014-A induced pluripotent stem cell human CVCL_XI91 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Homozygous (PubMed=31830646) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21196379 CVCL_XI98 NUIGi022-B induced pluripotent stem cell human CVCL_XI98 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196380 CVCL_XI97 NUIGi025-B induced pluripotent stem cell human CVCL_XI97 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196381 CVCL_XI96 NUIGi025-A induced pluripotent stem cell human CVCL_XI96 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=31759289) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196382 CVCL_XI95 NUIGi024-B induced pluripotent stem cell human CVCL_XI95 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21196383 CVCL_XI99 NUIGi043-A induced pluripotent stem cell human CVCL_XI99 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21196384 CVCL_5C60 GM12002 transformed cell line human CVCL_5C60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142008 21196385 CVCL_5C64 GM12037 transformed cell line human CVCL_5C64 HLA typing: A*02:01,11:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:01,01:03; DQB1*05:03:01,06:03; DRB1*13:01,14:01; DRB3*01,02 (IPD-IMGT/HLA=25890) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134605 21196386 CVCL_5C63 GM12036 transformed cell line human CVCL_5C63 HLA typing: A*01:01,02:06; B*35:01,57:01; C*04:01,06:02; DPA1*01:03,01:03; DPB1*03:01:01,04:02; DQA1*01:01,05:01; DQB1*02:01,05:01; DRB1*01:01,03:01; DRB3*01 (IPD-IMGT/HLA=25878) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134604 21196387 CVCL_5C62 GM12035 transformed cell line human CVCL_5C62 HLA typing: A*02:01,11:01; B*07:02,35:01; C*04:01,07:02; DPA1*01:03,01:03; DPB1*02:01:02,04:01:01; DQA1*01:01,01:03; DQB1*05:03:01,06:03; DRB1*13:01,14:01; DRB3*02 (IPD-IMGT/HLA=25883) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 134603 21196388 CVCL_5C61 GM12007 transformed cell line human CVCL_5C61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142013 21196389 CVCL_G766 BY00733 transformed cell line human CVCL_G766 HLA typing: A*24:EPMK; B*40:157,07:EH; C*07:EYCV,15:AJUE; DRB1*14:04,15:02 (IPD-IMGT/HLA=22284) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196390 CVCL_FV66 GM09992 finite cell line human CVCL_FV66 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196391 CVCL_G765 BY00732 transformed cell line human CVCL_G765 HLA typing: A*02:EKXW,02:EBGK; B*07:EKXK,44:43:02; C*07:EJZY,07:EKAA; DRB1*07:01,13:01 (IPD-IMGT/HLA=22285) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196392 CVCL_FV65 GM09991 finite cell line human CVCL_FV65 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196393 CVCL_G764 BY00731 transformed cell line human CVCL_G764 HLA typing: A*02:EAGM,11:DHVB; B*27:EKN,35:148; DRB1*01:01,01:03 (IPD-IMGT/HLA=22260) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196394 CVCL_FV64 GM09990 finite cell line human CVCL_FV64 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196395 CVCL_G763 BY00730 transformed cell line human CVCL_G763 HLA typing: A*01:EJTF,02:EJTK; B*08:66,15:DFRA; C*03:EMHG,07:EMHF; DRB1*03:01,04:01 (IPD-IMGT/HLA=22286) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196396 CVCL_FV63 GM09989 finite cell line human CVCL_FV63 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196397 CVCL_G769 BY00736 transformed cell line human CVCL_G769 HLA typing: A*02:EK,03:EKGN; B*27:02,41:16; C*02:EKDE,07:EKHN; DRB1*13:05,16:01 (IPD-IMGT/HLA=22270) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196398 CVCL_FV69 GM10161 finite cell line human CVCL_FV69 CL:0000010 Population: Caucasian; French/Scottish; Derived from sampling site: Cell type=Fibroblast. Male 21196399 CVCL_G768 BY00735 transformed cell line human CVCL_G768 HLA typing: A*02:AF,02:GNF; B*51:CVAE,49:01:01; C*07:AG,15:02; DRB1*04:05,11:01 (IPD-IMGT/HLA=22271) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196400 CVCL_FV68 GM10159 transformed cell line human CVCL_FV68 CL:0000010 Population: Caucasian; German/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196401 CVCL_G767 BY00734 transformed cell line human CVCL_G767 HLA typing: A*02:CVYA,32:EKCH; B*44:114,51:ENFB; C*15:CUYF,16:EKPE; DRB1*07:FX,12:DUKV (IPD-IMGT/HLA=22283) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196402 CVCL_FV67 GM10158 finite cell line human CVCL_FV67 CL:0000010 Population: Caucasian; German/Irish; Derived from sampling site: Cell type=Fibroblast. Male 21196403 CVCL_G762 12/49 hybridoma house mouse CVCL_G762 CL:0000010 Monoclonal antibody isotype: IgM, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9071 21196404 CVCL_FV62 GM09979 finite cell line human CVCL_FV62 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21196405 CVCL_G761 BY00729 transformed cell line human CVCL_G761 HLA typing: A*01:EJTF,02:EJTK; B*49:01:01,53:24; C*04:EKHJ,07:EKHM; DRB1*04:05,11:01 (IPD-IMGT/HLA=22287) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196406 CVCL_FV61 GM09884 transformed cell line human CVCL_FV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196407 CVCL_G760 BY00726 transformed cell line human CVCL_G760 HLA typing: A*02:EGBK,02:ECWK; B*15:CCWG,15:25; C*07:FEU,08:42; DRB1*12:02,12:UF (IPD-IMGT/HLA=22289) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196408 CVCL_FV60 GM09870 transformed cell line human CVCL_FV60 CL:0000010 Population: Ecuadorian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196409 CVCL_G777 BY00759 transformed cell line human CVCL_G777 HLA typing: A*29:CNFU,68:ARGF; B*07:EH,51:DNXY; C*15:02:01,15:36; DRB1*08:02,10:AC (IPD-IMGT/HLA=23031) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196410 CVCL_FV77 GM10294 transformed cell line human CVCL_FV77 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196411 CVCL_G776 BY00752 transformed cell line human CVCL_G776 HLA typing: A*02:06,2402; B*35:17,39:06; C*03:04,07:02; DRB1*16:02:01,14:108 (IPD-IMGT/HLA=23040) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196412 CVCL_FV76 GM10280 finite cell line human CVCL_FV76 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21196413 CVCL_G775 BY00751 transformed cell line human CVCL_G775 HLA typing: A*11:EJRU,24:EPWF; B*52:DZXA,54:EPUA; C*01:CYS,12:44; DRB1*04:05,15:02 (IPD-IMGT/HLA=22645) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196414 CVCL_FV75 GM10269 finite cell line human CVCL_FV75 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21196415 CVCL_G774 BY00750 transformed cell line human CVCL_G774 HLA typing: A*03:EKYG,26:DYRT; B*35:156,08:XKT; DRB1*13:02,13:04 (IPD-IMGT/HLA=22646) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196416 CVCL_FV74 GM10268 transformed cell line human CVCL_FV74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196417 CVCL_G779 BY00765 transformed cell line human CVCL_G779 HLA typing: A*24ENPX; B*07:EJRA,39:06; C*07:EMBK,07:EKXY; DRB1*14:106,15:01 (IPD-IMGT/HLA=23025) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196418 CVCL_FV79 GM10301 finite cell line human CVCL_FV79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196419 CVCL_G778 BY00763 transformed cell line human CVCL_G778 HLA typing: A*11:ANRC,24:CNFM; B*27:AETG,52:01; DRB1*12:DUKV,14:107 (IPD-IMGT/HLA=23027) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196420 CVCL_FV78 GM10295 finite cell line human CVCL_FV78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21196421 CVCL_P109 GM19070 transformed cell line human CVCL_P109 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196422 CVCL_P108 GM19068 transformed cell line human CVCL_P108 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196423 CVCL_G773 BY00749 transformed cell line human CVCL_G773 HLA typing: A*02:EJZF,03:EJZG; B*18:54,51:CVAE; C*01:EBNM,07:EJNH; DRB1*01:01,15:01 (IPD-IMGT/HLA=22647) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196424 CVCL_FV73 GM10257 finite cell line human CVCL_FV73 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196425 CVCL_P107 GM19067 transformed cell line human CVCL_P107 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196426 CVCL_G772 BY00739 transformed cell line human CVCL_G772 HLA typing: A*24:CNFR,68:PNP; B*14:02:01,35:149; C*04:ZFD,08:BE; DRB1*01:DGMG,04:DSJ (IPD-IMGT/HLA=22264) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196427 CVCL_FV72 GM10256 transformed cell line human CVCL_FV72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196428 CVCL_P106 GM19066 transformed cell line human CVCL_P106 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196429 CVCL_G771 BY00738 transformed cell line human CVCL_G771 HLA typing: A*03:EKFM,03:EKFM; B*35:150,07:FAPG; C*04:EJUE,07:EPWA; DRB1*07:FX,11:01 (IPD-IMGT/HLA=22266) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196430 CVCL_FV71 GM10245 finite cell line human CVCL_FV71 CL:0000010 Population: Caucasian; Italian; Derived from sampling site: Cell type=Fibroblast. Female 21196431 CVCL_P105 GM19065 transformed cell line human CVCL_P105 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196432 CVCL_G770 BY00737 transformed cell line human CVCL_G770 HLA typing: A*01:EKMV,24:EPMF; B*40:06,40:110; C*07:EPDC,12:CGCW; DRB1*07:FX,15;01 (IPD-IMGT/HLA=22267) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196433 CVCL_FV70 GM10233 transformed cell line human CVCL_FV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196434 CVCL_P104 GM19064 transformed cell line human CVCL_P104 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196435 CVCL_P103 GM19063 transformed cell line human CVCL_P103 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196436 CVCL_P102 GM19062 transformed cell line human CVCL_P102 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196437 CVCL_P101 GM19060 transformed cell line human CVCL_P101 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196438 CVCL_P100 GM19059 transformed cell line human CVCL_P100 CL:0000010 Population: Japanese in Tokyo (JPT); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196439 CVCL_G749 BY00713 transformed cell line human CVCL_G749 HLA typing: A*03:88,01:FJUK; B*07:EJZK,08:EAAY; C*07:EJZY,07:EKAA; DRB1*04:DZTN,13:CVMG (IPD-IMGT/HLA=21799) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196440 CVCL_FV49 GM09615 finite cell line human CVCL_FV49 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21196441 CVCL_G744 BY00706 transformed cell line human CVCL_G744 HLA typing: A*01:FJUK,23:01:04; B*53:JV,57:EJRM; C*04:EJUD,06:EJUH; DRB1*03:DFXV,07:EJVX (IPD-IMGT/HLA=21808) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196442 CVCL_FV44 GM08935 finite cell line human CVCL_FV44 CL:0000010 Sequence variation: Mutation; HGNC; 21576; NHLRC1; Simple; p.Pro129His (c.386C>A); ClinVar=VCV000206187; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196443 CVCL_G743 BY00705 transformed cell line human CVCL_G743 HLA typing: A*01:EJUP; B*08:DZZC,08:EABG; C*07:151,07:CVAG; DRB1*03:01,08:04 (IPD-IMGT/HLA=21809) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196444 CVCL_FV43 GM02857 finite cell line human CVCL_FV43 CL:0000010 Population: Puerto Rican; Derived from sampling site: Cell type=Fibroblast. Male 21196445 CVCL_G742 BY00704 transformed cell line human CVCL_G742 HLA typing: A*29:DEJK,31:EPMN; B*27:ADDM,44:DKBZ; C*02:ATZ,16:27; DRB1*04:01,11:01 (IPD-IMGT/HLA=21810) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196446 CVCL_FV42 GM13578 transformed cell line human CVCL_FV42 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196447 CVCL_G741 BY00702 transformed cell line human CVCL_G741 HLA typing: A*74:AB,23:31; B*35:EAZA,44:CUBJ; C*04:EKDN; DRB1*03:02,13:01 (IPD-IMGT/HLA=21812) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196448 CVCL_FV41 GM13574 transformed cell line human CVCL_FV41 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196449 CVCL_G748 BY00712 transformed cell line human CVCL_G748 HLA typing: A*03:ECAM,30:44; B*15:10,44:EAPH; C*03:EAJZ,05:EKRG; DRB1*04:01,13:02 (IPD-IMGT/HLA=21803) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196450 CVCL_FV48 GM09614 transformed cell line human CVCL_FV48 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196451 CVCL_G747 BY00711 transformed cell line human CVCL_G747 HLA typing: A*68:02,03:89; B*08:DYSE,18:EKCS; DRB1*08:04,13:04 (IPD-IMGT/HLA=21804) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196452 CVCL_FV47 GM09591 transformed cell line human CVCL_FV47 CL:0000010 Population: Belizean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196453 CVCL_G746 BY00709 transformed cell line human CVCL_G746 HLA typing: A*02:ANJ,02:267; B*39:09,46:DNXM; DRB1*04:05,14:BCAD (IPD-IMGT/HLA=21806) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196454 CVCL_FV46 GM09590 finite cell line human CVCL_FV46 CL:0000010 Population: Belizean; Derived from sampling site: Cell type=Fibroblast. Female 21196455 CVCL_G745 BY00708 transformed cell line human CVCL_G745 HLA typing: A*31:02,31:40; B*35:11,40:EGNX; DRB1*04:07,15:01 (IPD-IMGT/HLA=21807) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196456 CVCL_FV45 GM08936 finite cell line human CVCL_FV45 CL:0000010 Sequence variation: Mutation; HGNC; 21576; NHLRC1; Simple; p.Pro129His (c.386C>A); ClinVar=VCV000206187; Zygosity=Homozygous (Coriell) Derived from sampling site: Cell type=Fibroblast. Male 21196457 CVCL_G740 BY00701 transformed cell line human CVCL_G740 HLA typing: A*01:FJUK,02:271; B*08:DZFC,50:01; DRB1*03:01,07:FX (IPD-IMGT/HLA=21813) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196458 CVCL_FV40 GM13569 transformed cell line human CVCL_FV40 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196459 CVCL_G755 BY00720 transformed cell line human CVCL_G755 HLA typing: A*03:AUW,24:ERZA; B*35:CGAH,40:148; C*04:EJUB,15:DCJC; DRB1*07:FX,15:02 (IPD-IMGT/HLA=21787) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196460 CVCL_FV55 GM09734 transformed cell line human CVCL_FV55 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196461 CVCL_G754 BY00718 transformed cell line human CVCL_G754 HLA typing: A*01:DHUY,68:01; B*53:01:01,41:14; DRB1*07:01,13:02 (IPD-IMGT/HLA=21789) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196462 CVCL_FV54 GM09726 transformed cell line human CVCL_FV54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196463 CVCL_G753 12/44 hybridoma house mouse CVCL_G753 CL:0000010 Monoclonal antibody isotype: IgM, kappa. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9070 21196464 CVCL_FV53 GM09680 transformed cell line human CVCL_FV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196465 CVCL_G752 BY00716 transformed cell line human CVCL_G752 HLA typing: A*02:AKEF,32:EKAP; B*08:CTZR,44:EPAF; C*05:AC,07:150Q; DRB1*03:01,15:01 (IPD-IMGT/HLA=21796) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196466 CVCL_FV52 GM09673 finite cell line human CVCL_FV52 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21196467 CVCL_G759 BY00725 transformed cell line human CVCL_G759 HLA typing: A*03:EKGJ,32:EKGV; B*14:02:01,41:15; C*08:DPG,17:RV; DRB1*01:02,13:03 (IPD-IMGT/HLA=21782) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196468 CVCL_FV59 GM09865 finite cell line human CVCL_FV59 CL:0000010 Population: Ecuadorian; Derived from sampling site: Cell type=Fibroblast. Male 21196469 CVCL_G758 BY00723 transformed cell line human CVCL_G758 HLA typing: A*02:EJUS,24:EPMH; B*44:111,51:CVAE; C*04:ENPE,14:EKVH; DRB1*04:02,13:01 (IPD-IMGT/HLA=21784) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196470 CVCL_FV58 GM09739 finite cell line human CVCL_FV58 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21196471 CVCL_G757 BY00722 transformed cell line human CVCL_G757 HLA typing: A*24:EPMP,33:EKYT; B*35:03:06,13:02; C*06:EJZW,12:AUGY; DRB1*07:FX,14:BCAD (IPD-IMGT/HLA=21785) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196472 CVCL_FV57 GM09738 transformed cell line human CVCL_FV57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196473 CVCL_G756 BY00721 transformed cell line human CVCL_G756 HLA typing: A*11:EJUY,68:CVZG; B*44:ENWF,51:101; C*05:EKRG,15;DCJC; DRB1*04:09,14:02 (IPD-IMGT/HLA=21786) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196474 CVCL_FV56 GM09735 finite cell line human CVCL_FV56 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Male 21196475 CVCL_G751 BY00715 transformed cell line human CVCL_G751 HLA typing: A*03:ECAM,11:70; B*35:EKCX,55:EKCY; C*01:EARV,04:EJZV; DRB1*09:EU,14:DGWD (IPD-IMGT/HLA=21797) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196476 CVCL_FV51 GM09648 finite cell line human CVCL_FV51 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Female 21196477 CVCL_G750 BY00714 transformed cell line human CVCL_G750 HLA typing: A*03:ECAM,01:01:20; B*08:EANF,35:CWPY; C*07:EMBN,12:AUCW; DRB1*04:ZX,15:01 (IPD-IMGT/HLA=21798) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196478 CVCL_FV50 GM09647 transformed cell line human CVCL_FV50 CL:0000010 Population: Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196479 CVCL_G729 BY00682 transformed cell line human CVCL_G729 HLA typing: A*24:CWFP,02:263; B*18:RRG,51:01; C*12:03,15:02; DRB1*11:03,07:01 (IPD-IMGT/HLA=21536) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196480 CVCL_FV29 ND35217 transformed cell line human CVCL_FV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196481 CVCL_G728 BY00625 transformed cell line human CVCL_G728 HLA typing: A*01:WUS,33:DWH; B*08:CEMC,51:DFXA; C*02:02,07:140; DRB1*03:XEV,13:ASGS (IPD-IMGT/HLA=21152) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196482 CVCL_FV28 ND35026 transformed cell line human CVCL_FV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196483 CVCL_G727 BY00624 transformed cell line human CVCL_G727 HLA typing: A*01:TUS,01:WCS; B*08:DGXF,08:DRFR; C*07:CVAG,07:140; DRB1*01:EW,03:XBD (IPD-IMGT/HLA=21153) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196484 CVCL_FV27 ND34449 transformed cell line human CVCL_FV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196485 CVCL_G722 BY00601 transformed cell line human CVCL_G722 HLA typing: A*02:DUEK,03:DUDJ; B*08:XKT,07:114; DRB1*01:01,03:01 (IPD-IMGT/HLA=21160) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196486 CVCL_FV22 ND33594 transformed cell line human CVCL_FV22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196487 CVCL_G721 BY00599 transformed cell line human CVCL_G721 HLA typing: A*02:ANJ,11:DHVB; B*46:DNXM,40:134; DRB1*09:AB (IPD-IMGT/HLA=21159) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196488 CVCL_FV21 ND33592 transformed cell line human CVCL_FV21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196489 CVCL_G720 BY00597 transformed cell line human CVCL_G720 HLA typing: A*01:WUS,23:ANXH; B*08:XKT,44:108N; C*04:TSR,07:ANHC; DRB1*03:VHY,07:APA (IPD-IMGT/HLA=21158) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196490 CVCL_FV20 ND33286 transformed cell line human CVCL_FV20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196491 CVCL_G726 BY00619 transformed cell line human CVCL_G726 HLA typing: A*02:BANP,23:ANJU; B*08:DGUB,14:BPYK; C*08:02,07:141; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=21154) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196492 CVCL_FV26 ND34158 transformed cell line human CVCL_FV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196493 CVCL_G725 BY00612 transformed cell line human CVCL_G725 HLA typing: A*02:DUEK,03:DUDJ; B*44:ENWF,41:136; DRB1*01:02,11:01 (IPD-IMGT/HLA=21163) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196494 CVCL_FV25 ND33801 transformed cell line human CVCL_FV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196495 CVCL_G724 BY00606 transformed cell line human CVCL_G724 HLA typing: A*03:ANGK,31:KP; B*40:135,07:CZZS; DRB1*04:AFRF,15:JH (IPD-IMGT/HLA=21162) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196496 CVCL_FV24 ND33798 transformed cell line human CVCL_FV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196497 CVCL_G723 BY00602 transformed cell line human CVCL_G723 HLA typing: A*01:YAG,02:ANGR; B*13:02,07:115; C*06AJB,07:BJ; DRB1*04:APPB,11:ARAP (IPD-IMGT/HLA=21161) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196498 CVCL_FV23 ND33778 transformed cell line human CVCL_FV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196499 CVCL_G739 BY00699 transformed cell line human CVCL_G739 HLA typing: A*01:FJUK,68:03:03; B*52:EWD,78:01; C*12:CWNM,16:DBJV; DRB1*13:02,15:02 (IPD-IMGT/HLA=21815) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196500 CVCL_FV39 ND40346 transformed cell line human CVCL_FV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196501 CVCL_G738 BY00698 transformed cell line human CVCL_G738 HLA typing: A*29:02:01,23:30; B*13:CYFZ,50:02; DRB1*07:01 (IPD-IMGT/HLA=21816) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196502 CVCL_FV38 ND39997 transformed cell line human CVCL_FV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196503 CVCL_G733 BY00686 transformed cell line human CVCL_G733 HLA typing: A*02:EJUS,24:EPMH; B*39:EVKD,52:FJH; C*07:02,12:44; DRB1*08:03,15:02 (IPD-IMGT/HLA=21531) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196504 CVCL_FV33 ND38724 transformed cell line human CVCL_FV33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196505 CVCL_G732 BY00685 transformed cell line human CVCL_G732 HLA typing: A*02:EKGH,68:EKGW; B*48:CKTN; C*08:01:01,08:35; DRB1*08:02,09:01 (IPD-IMGT/HLA=21532) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196506 CVCL_FV32 ND36301 transformed cell line human CVCL_FV32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196507 CVCL_G731 BY00684 transformed cell line human CVCL_G731 HLA typing: A*02:ANDA,26:PEU; B*40:DBET,56:BD; C*03:94,07:02; DRB1*12:BJ,14:04 (IPD-IMGT/HLA=21533) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196508 CVCL_FV31 ND36265 transformed cell line human CVCL_FV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196509 CVCL_G730 BY00683 transformed cell line human CVCL_G730 HLA typing: A*01:EMRP,03:AUW; B*37:JTB,44:EBEA; C*05:AC,06:44; DRB1*11:04,13:01 (IPD-IMGT/HLA=21534) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196510 CVCL_FV30 ND36080 transformed cell line human CVCL_FV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196511 CVCL_G737 BY00697 transformed cell line human CVCL_G737 HLA typing: A*02:EKAE,29:DFUS; B*07:EH,44:AXJM; C*16:02:01,15:36; DRB1*04:02,10:01 (IPD-IMGT/HLA=21817) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196512 CVCL_FV37 ND39326 transformed cell line human CVCL_FV37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196513 CVCL_G736 BY00695 transformed cell line human CVCL_G736 HLA typing: A*33:EPZE,74;CWPF; B*37:EJPY,50;01; C*15:05:01,06:47; DRB1*11:02,15:03 (IPD-IMGT/HLA=21819) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196514 CVCL_FV36 ND39276 transformed cell line human CVCL_FV36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196515 CVCL_G735 BY00690 transformed cell line human CVCL_G735 HLA typing: A*01:66,02:DFKP; B*35:EAZA,44:EAPK; C*04:EJUE,07:EMCY; DRB1*11:04,15:01 (IPD-IMGT/HLA=21535) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196516 CVCL_FV35 ND39064 transformed cell line human CVCL_FV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196517 CVCL_G734 BY00688 transformed cell line human CVCL_G734 HLA typing: A*30:BSXK,68:54; B*15:BJXJ,18:DNWR; DRB1*01:02,14:01 (IPD-IMGT/HLA=21529) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196518 CVCL_FV34 ND38960 transformed cell line human CVCL_FV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196519 CVCL_FV08 ND32487 transformed cell line human CVCL_FV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196520 CVCL_G708 TRM-6 transformed cell line human CVCL_G708 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal pancreas. Unspecified 21196521 CVCL_FV07 ND32486 transformed cell line human CVCL_FV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196522 CVCL_G707 Vester cancer cell line human CVCL_G707 CL:0000010 Miscellaneous: Only mentioned as a mesothelioma cell line in PubMed=16177958. Unspecified 21196523 CVCL_G706 Nb2-SP cancer cell line Norway rat CVCL_G706 CL:0000010 Breed/subspecies: Nb. Male 21196524 CVCL_FV06 ND32483 transformed cell line human CVCL_FV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196525 CVCL_G705 Nb2 cancer cell line Norway rat CVCL_G705 CL:0000010 Breed/subspecies: Nb. Male 21196526 CVCL_FV05 ND32400 transformed cell line human CVCL_FV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196527 CVCL_FV09 ND32574 transformed cell line human CVCL_FV09 CL:0000010 Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196528 CVCL_G709 TRM-1 transformed cell line human CVCL_G709 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal pancreas. Unspecified 21196529 CVCL_G700 C3-44 transformed cell line human CVCL_G700 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Virology: Persistently infected with HTLV-2 isolate Mo (PubMed=6095307) 21196530 CVCL_FV00 ND32012 transformed cell line human CVCL_FV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196531 CVCL_FV04 ND32281 transformed cell line human CVCL_FV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196532 CVCL_G704 PER.C6 transformed cell line human CVCL_G704 From: Johnson & Johnson Janssen (originally Crucell); Beerse; Belgium CL:0000010 Transformant: Adenovirus 5 [E1A/E1B](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina Cell type=Retinoblast.. Biotechnology: Used for the production of follitropin delta (Trade name: Rekovelle) Unspecified Group: Patented cell line; Group: Vaccine production cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 96022940 21196533 CVCL_G703 EB66 embryonic stem cell CVCL_G703 From: Valneva SE; Saint-Herblain; France CL:0000010 Breed/subspecies: GL30. Male Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Group: Vaccine production cell line 21196534 CVCL_FV03 ND32137 transformed cell line human CVCL_FV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196535 CVCL_G702 AFRC MAC 252 hybridoma Norway rat CVCL_G702 CL:0000010 Discontinued: ECACC; 92012453; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:2365; (+)-abscisic acid 21196536 CVCL_FV02 ND32136 transformed cell line human CVCL_FV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196537 CVCL_G701 AFRC MAC 60 hybridoma Norway rat CVCL_G701 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:2365; (+)-abscisic acid. 21196538 CVCL_FV01 ND32123 transformed cell line human CVCL_FV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196539 CVCL_G719 BY00591 transformed cell line human CVCL_G719 HLA typing: A*03:ANPZ,11:ANRC; B*35:08:01,35:115; C*04:ANJM,04:TSR; DRB1*07:APA,13:02 (IPD-IMGT/HLA=21157) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196540 CVCL_FV19 ND33229 transformed cell line human CVCL_FV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196541 CVCL_G718 BY00587 transformed cell line human CVCL_G718 HLA typing: A*01:YAG,32:GC; B*51:01:02,35:117; DRB1*04:07,15:AAXP (IPD-IMGT/HLA=21156) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196542 CVCL_FV18 ND33228 transformed cell line human CVCL_FV18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196543 CVCL_G717 BY00582 transformed cell line human CVCL_G717 HLA typing: A*11:BDFZ,31:01:08; B*46:JV,55:02; DRB1*04:05,09:01 (IPD-IMGT/HLA=21155) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196544 CVCL_FV17 ND33227 transformed cell line human CVCL_FV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196545 CVCL_G716 BY00535 transformed cell line human CVCL_G716 HLA typing: A*24:AZUR,26:PEU; B*07:CZZS,35:136; DRB1*04:NJV,11:APWP (IPD-IMGT/HLA=20734) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196546 CVCL_FV16 ND33145 transformed cell line human CVCL_FV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196547 CVCL_G711 BY00476 transformed cell line human CVCL_G711 HLA typing: A*24,36; B*35:135,53:01:01; DRB1*04:YK,11:MFF; DRB3*02:BMP (IPD-IMGT/HLA=20724) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196548 CVCL_FV11 ND32773 transformed cell line human CVCL_FV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196549 CVCL_G710 CMD004AN transformed cell line human CVCL_G710 HLA typing: A*29:03 (IPD-IMGT/HLA=10424) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: International Histocompatibility Workshop cell lines 21196550 CVCL_FV10 ND32772 transformed cell line human CVCL_FV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196551 CVCL_G715 BY00517 transformed cell line human CVCL_G715 HLA typing: A*11:BDFZ,24:131; B*35:05,40:XCG; DRB1*11:APWP,15:AAXP (IPD-IMGT/HLA=20729) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196552 CVCL_FV15 ND33021 transformed cell line human CVCL_FV15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196553 CVCL_G714 BY00487 transformed cell line human CVCL_G714 HLA typing: A*02:BYWG,23:BZAP; B*35:113,44:03; DRB1*01:02,08:02 (IPD-IMGT/HLA=20727) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196554 CVCL_FV14 ND32892 transformed cell line human CVCL_FV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196555 CVCL_G713 BY00485 transformed cell line human CVCL_G713 HLA typing: A*26:UUA,68:AVDJ; B*40:130,52:AH; DRB1*07:APA,15:AAXP (IPD-IMGT/HLA=20726) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196556 CVCL_FV13 ND32787 transformed cell line human CVCL_FV13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196557 CVCL_G712 BY00484 transformed cell line human CVCL_G712 HLA typing: A*01:TUS,68:AEBF; B*52:01:01,40:110; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=20725) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196558 CVCL_FV12 ND32786 transformed cell line human CVCL_FV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196559 CVCL_XK41 N3G6C7 hybridoma house mouse CVCL_XK41 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:100246; Norfloxacin (NOR) (Note=Also reacts with ciprofloxacin, enrofloxacin and ofloxacin). 21196560 CVCL_XK40 N2H3A8 hybridoma house mouse CVCL_XK40 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:100246; Norfloxacin (NOR) (Note=Also reacts with ciprofloxacin, enrofloxacin and ofloxacin). 21196561 CVCL_XK45 F5-1 transformed cell line CVCL_XK45 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Unspecified 21196562 CVCL_XK44 O3D4G9 hybridoma house mouse CVCL_XK44 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:7731; Ofloxacin (OFL). 21196563 CVCL_XK43 O2A6B5 hybridoma house mouse CVCL_XK43 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:7731; Ofloxacin (OFL). 21196564 CVCL_XK42 N4D5G3 hybridoma house mouse CVCL_XK42 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:100246; Norfloxacin (NOR) (Note=Also reacts with ciprofloxacin, enrofloxacin and ofloxacin). 21196565 CVCL_XK49 PAb 405 hybridoma house mouse CVCL_XK49 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen (Note=Recognizes C-terminus). 21196566 CVCL_XK48 PAb 404 hybridoma house mouse CVCL_XK48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196567 CVCL_P299 GM19327 transformed cell line human CVCL_P299 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196568 CVCL_XK47 PAb 402 hybridoma house mouse CVCL_XK47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196569 CVCL_XK46 F2 transformed cell line CVCL_XK46 CL:0000010 Selected for resistance to: ChEBI; CHEBI:4883; Ethidium bromide; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Urinary bladder; urothelium Cell type=Urothelial cell.. Unspecified 21196570 CVCL_P298 GM19324 transformed cell line human CVCL_P298 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196571 CVCL_P297 GM19323 transformed cell line human CVCL_P297 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196572 CVCL_P296 GM19321 transformed cell line human CVCL_P296 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196573 CVCL_P295 GM19319 transformed cell line human CVCL_P295 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196574 CVCL_P294 GM19318 transformed cell line human CVCL_P294 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196575 CVCL_5E00 GM12459 transformed cell line human CVCL_5E00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135606 21196576 CVCL_5E04 GM12463 transformed cell line human CVCL_5E04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135610 21196577 CVCL_5E03 GM12462 transformed cell line human CVCL_5E03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135609 21196578 CVCL_5E02 GM12461 transformed cell line human CVCL_5E02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135608 21196579 CVCL_5E01 GM12460 transformed cell line human CVCL_5E01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135607 21196580 CVCL_5E08 GM12467 transformed cell line human CVCL_5E08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135615 21196581 CVCL_5E07 GM12466 transformed cell line human CVCL_5E07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135614 21196582 CVCL_5E06 GM12465 transformed cell line human CVCL_5E06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135613 21196583 CVCL_5E05 GM12464 transformed cell line human CVCL_5E05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135611 21196584 CVCL_5E09 GM12470 transformed cell line human CVCL_5E09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135701 21196585 CVCL_XK30 FQ-Ba2 hybridoma house mouse CVCL_XK30 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:48775; Cadmium(2+) (Note=When chelated). 21196586 CVCL_XK34 CL1-R2 hybridoma house mouse CVCL_XK34 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; O95971; Human CD160. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-3204 21196587 CVCL_XK33 3E12/B6 hybridoma house mouse CVCL_XK33 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:34632; Chlorpyrifos-methyl. 21196588 CVCL_XK32 FQ-2G3 hybridoma house mouse CVCL_XK32 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:34632; Chlorpyrifos-methyl. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014106 21196589 CVCL_XK31 FQ-E7 hybridoma house mouse CVCL_XK31 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:39169; (Z)-imidacloprid. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014107 21196590 CVCL_XK38 E2F4C5 hybridoma house mouse CVCL_XK38 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:35720; Enrofloxacin (ENR) (Note=Also reacts with ciprofloxacin). 21196591 CVCL_XK37 C4A9H1 hybridoma house mouse CVCL_XK37 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:100241; Ciprofloxacin (CIP) (Note=Also reacts with enrofloxacin, norfloxacin and ofloxacin). 21196592 CVCL_XK36 C1G6B8 hybridoma house mouse CVCL_XK36 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:100241; Ciprofloxacin (CIP) (Note=Also reacts with enrofloxacin, norfloxacin and ofloxacin). 21196593 CVCL_XK35 JY-I hybridoma house mouse CVCL_XK35 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:100241; Ciprofloxacin (CIP). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200947 21196594 CVCL_XK39 E5B7E8 hybridoma house mouse CVCL_XK39 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:35720; Enrofloxacin (ENR). 21196595 CVCL_P282 GM19046 transformed cell line human CVCL_P282 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196596 CVCL_P281 GM19045 transformed cell line human CVCL_P281 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196597 CVCL_P280 GM19044 transformed cell line human CVCL_P280 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196598 CVCL_XK23 672-3 hybridoma house mouse CVCL_XK23 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:27732; Caffeine. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9544 21196599 CVCL_XK22 672-2 hybridoma house mouse CVCL_XK22 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:27732; Caffeine. 21196600 CVCL_XK21 672-1 hybridoma house mouse CVCL_XK21 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:27732; Caffeine. 21196601 CVCL_XK20 5G7 [Mouse hybridoma against P.olivaceus IgD] hybridoma house mouse CVCL_XK20 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Paralichthys olivaceus IgD heavy chain. 21196602 CVCL_XK27 FQ-Aa4 hybridoma house mouse CVCL_XK27 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:48775; Cadmium(2+) (Note=When chelated). 21196603 CVCL_P279 GM19043 transformed cell line human CVCL_P279 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196604 CVCL_XK26 FQ-6E hybridoma house mouse CVCL_XK26 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:38704; Isocarbophos; Monoclonal antibody target: ChEBI; CHEBI:6009; Isofenphos. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2013105 21196605 CVCL_P278 GM19041 transformed cell line human CVCL_P278 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196606 CVCL_XK25 FQ-4F12 hybridoma house mouse CVCL_XK25 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:16793; Mercury(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014131 21196607 CVCL_P277 GM19039 transformed cell line human CVCL_P277 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196608 CVCL_XK24 672-4 hybridoma house mouse CVCL_XK24 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:27732; Caffeine. 21196609 CVCL_P276 GM19038 transformed cell line human CVCL_P276 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196610 CVCL_P275 GM19037 transformed cell line human CVCL_P275 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196611 CVCL_P274 GM19036 transformed cell line human CVCL_P274 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196612 CVCL_XK29 FQ-Ac4 hybridoma house mouse CVCL_XK29 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:48775; Cadmium(2+) (Note=When chelated). 21196613 CVCL_P273 GM19035 transformed cell line human CVCL_P273 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196614 CVCL_XK28 FQ-Aa6 hybridoma house mouse CVCL_XK28 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:48775; Cadmium(2+) (Note=When chelated). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201458 21196615 CVCL_P272 GM19031 transformed cell line human CVCL_P272 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196616 CVCL_P293 GM19317 transformed cell line human CVCL_P293 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196617 CVCL_P292 GM19316 transformed cell line human CVCL_P292 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196618 CVCL_P291 GM19315 transformed cell line human CVCL_P291 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196619 CVCL_P290 GM19314 transformed cell line human CVCL_P290 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196620 CVCL_XK12 M380 cancer cell line human CVCL_XK12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965) Derived from metastatic site: Hypodermis. Unspecified 21196621 CVCL_XK11 M376 cancer cell line human CVCL_XK11 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Heterozygous (PubMed=22194965); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=22194965; PubMed=27533468) Derived from metastatic site: Lymph node. Unspecified 21196622 CVCL_XK10 M424 cancer cell line human CVCL_XK10 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=24735930). Unspecified 21196623 CVCL_XK16 HaCaT A-5 spontaneously immortalized cell line human CVCL_XK16 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Non-tumorigenic 21196624 CVCL_P289 GM19313 transformed cell line human CVCL_P289 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196625 CVCL_XK15 HaCaT RT3 spontaneously immortalized cell line human CVCL_XK15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Metastatic 21196626 CVCL_P288 GM19312 transformed cell line human CVCL_P288 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196627 CVCL_XK14 M409-AR cancer cell line human CVCL_XK14 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21196628 CVCL_P287 GM19311 transformed cell line human CVCL_P287 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196629 CVCL_XK13 M397-AR cancer cell line human CVCL_XK13 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf Unspecified 21196630 CVCL_P286 GM19310 transformed cell line human CVCL_P286 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196631 CVCL_XK19 1D12-B5 hybridoma house mouse CVCL_XK19 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: 3-[4-(O,O-dimethylphosphorothioyloxy)phenyl]-1-propionic acid. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200906 21196632 CVCL_P285 GM19309 transformed cell line human CVCL_P285 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196633 CVCL_P284 GM19308 transformed cell line human CVCL_P284 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196634 CVCL_XK18 HaCaT40degree spontaneously immortalized cell line human CVCL_XK18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 5173; HRAS Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Adapted to grow at 40 Celsius 21196635 CVCL_P283 GM19307 transformed cell line human CVCL_P283 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196636 CVCL_XK17 RPMI-8226-R cancer cell line human CVCL_XK17 CL:0000010 Sequence variation: Gene fusion; HGNC; 5722; IGKJ4 + HGNC; 5783; IGKV2-28; Name(s)=IGKV2-28-IGKJ4 (from parent cell line); Sequence variation: Gene fusion; HGNC; 5865; IGLJ3 + HGNC; 5888; IGLV2-14; Name(s)=IGLV2-14-IGLJ3 (from parent cell line); Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Thr751Ile (c.2252C>T); ClinVar=VCV000177773; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12033; TRAF3; Simple; p.Lys191Leufs*60; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:52717; Bortezomib (Velcade); Derived from sampling site: Peripheral blood. Omics: Deep quantitative proteome analysis Male Characteristics: Produces IgG lambda (from parent cell line) 21196637 CVCL_P260 GM18798 transformed cell line human CVCL_P260 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196638 CVCL_XK01 M399 cancer cell line human CVCL_XK01 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Unspecified 21196639 CVCL_XK00 M397 cancer cell line human CVCL_XK00 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930) Omics: Deep proteome analysis; Omics: Metabolome analysis; Omics: Transcriptome analysis by RNAseq. Unspecified 21196640 CVCL_P259 GM18794 transformed cell line human CVCL_P259 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196641 CVCL_P258 GM18790 transformed cell line human CVCL_P258 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196642 CVCL_P257 GM18785 transformed cell line human CVCL_P257 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196643 CVCL_XK05 M410 cancer cell line human CVCL_XK05 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Unspecified 21196644 CVCL_P256 GM18771 transformed cell line human CVCL_P256 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196645 CVCL_XK04 M409 [Human melanoma] cancer cell line human CVCL_XK04 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930) Omics: Transcriptome analysis by RNAseq. Unspecified 21196646 CVCL_P255 GM18769 transformed cell line human CVCL_P255 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196647 CVCL_XK03 M406 cancer cell line human CVCL_XK03 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Unspecified 21196648 CVCL_P254 GM18757 transformed cell line human CVCL_P254 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196649 CVCL_XK02 M403 cancer cell line human CVCL_XK02 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=29229836). Unspecified 21196650 CVCL_P253 GM18749 transformed cell line human CVCL_P253 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196651 CVCL_XK09 M414 cancer cell line human CVCL_XK09 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=24735930). Unspecified 21196652 CVCL_P252 GM18748 transformed cell line human CVCL_P252 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196653 CVCL_XK08 M407 cancer cell line human CVCL_XK08 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Unspecified 21196654 CVCL_P251 GM18747 transformed cell line human CVCL_P251 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196655 CVCL_XK07 M390 cancer cell line human CVCL_XK07 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24735930). Unspecified 21196656 CVCL_P250 GM18745 transformed cell line human CVCL_P250 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196657 CVCL_XK06 M411 cancer cell line human CVCL_XK06 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=24735930). Unspecified 21196658 CVCL_P271 GM19030 transformed cell line human CVCL_P271 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196659 CVCL_P270 GM19028 transformed cell line human CVCL_P270 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196660 CVCL_P269 GM19027 transformed cell line human CVCL_P269 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196661 CVCL_P268 GM19026 transformed cell line human CVCL_P268 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196662 CVCL_P267 GM19025 transformed cell line human CVCL_P267 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196663 CVCL_P266 GM19024 transformed cell line human CVCL_P266 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196664 CVCL_P265 GM19023 transformed cell line human CVCL_P265 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196665 CVCL_P264 GM19022 transformed cell line human CVCL_P264 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196666 CVCL_P263 GM19020 transformed cell line human CVCL_P263 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196667 CVCL_P262 GM19019 transformed cell line human CVCL_P262 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196668 CVCL_P261 GM19017 transformed cell line human CVCL_P261 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196669 CVCL_P239 GM18641 transformed cell line human CVCL_P239 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196670 CVCL_P238 GM18640 transformed cell line human CVCL_P238 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196671 CVCL_P237 GM18639 transformed cell line human CVCL_P237 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196672 CVCL_P236 GM18638 transformed cell line human CVCL_P236 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196673 CVCL_P235 GM18637 transformed cell line human CVCL_P235 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196674 CVCL_P234 GM18636 transformed cell line human CVCL_P234 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196675 CVCL_P233 GM18635 transformed cell line human CVCL_P233 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196676 CVCL_P232 GM18634 transformed cell line human CVCL_P232 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196677 CVCL_P231 GM18633 transformed cell line human CVCL_P231 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196678 CVCL_P230 GM18632 transformed cell line human CVCL_P230 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196679 CVCL_P249 GM18742 transformed cell line human CVCL_P249 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196680 CVCL_P248 GM18741 transformed cell line human CVCL_P248 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196681 CVCL_P247 GM18740 transformed cell line human CVCL_P247 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196682 CVCL_P246 GM18739 transformed cell line human CVCL_P246 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196683 CVCL_P245 GM18649 transformed cell line human CVCL_P245 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196684 CVCL_P244 GM18648 transformed cell line human CVCL_P244 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196685 CVCL_P243 GM18647 transformed cell line human CVCL_P243 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196686 CVCL_P242 GM18645 transformed cell line human CVCL_P242 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196687 CVCL_P241 GM18643 transformed cell line human CVCL_P241 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196688 CVCL_P240 GM18642 transformed cell line human CVCL_P240 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196689 CVCL_5E77 GM12839 transformed cell line human CVCL_5E77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145809 21196690 CVCL_5E76 GM12838 transformed cell line human CVCL_5E76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145808 21196691 CVCL_5E75 GM12837 transformed cell line human CVCL_5E75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145807 21196692 CVCL_5E74 GM12836 transformed cell line human CVCL_5E74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145806 21196693 CVCL_5E79 GM12841 transformed cell line human CVCL_5E79 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Ile359Leu (c.1075A>C); ClinVar=VCV000008408; Zygosity=Heterozygous; Note=CYP2C9*3 allele (from autologous cell line GM12875) Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145811/145912 21196694 CVCL_5E78 GM12840 transformed cell line human CVCL_5E78 CL:0000010 Sequence variation: Mutation; HGNC; 2621; CYP2C19; Simple; p.Pro227Pro (c.681G>A); ClinVar=VCV000016897; Zygosity=Unspecified; Note=Cryptic splice acceptor activation CYP2C19*2 allele (from autologous cell line GM12874). Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145810/145911 21196695 CVCL_5E73 GM12835 transformed cell line human CVCL_5E73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145805 21196696 CVCL_5E72 GM12834 transformed cell line human CVCL_5E72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145804 21196697 CVCL_5E71 GM12833 transformed cell line human CVCL_5E71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145803 21196698 CVCL_5E70 GM12831 transformed cell line human CVCL_5E70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145801 21196699 CVCL_5E88 GM12857 transformed cell line human CVCL_5E88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140006 21196700 CVCL_5E87 GM12856 transformed cell line human CVCL_5E87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140005 21196701 CVCL_5E86 GM12855 transformed cell line human CVCL_5E86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140004 21196702 CVCL_5E85 GM12854 transformed cell line human CVCL_5E85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140003 21196703 CVCL_5E89 GM12858 transformed cell line human CVCL_5E89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140007 21196704 CVCL_5E80 GM12844 transformed cell line human CVCL_5E80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145814 21196705 CVCL_5E84 GM12853 transformed cell line human CVCL_5E84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140002 21196706 CVCL_5E83 GM12852 transformed cell line human CVCL_5E83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140001 21196707 CVCL_5E82 GM12848 transformed cell line human CVCL_5E82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145109 21196708 CVCL_5E81 GM12847 transformed cell line human CVCL_5E81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144409 21196709 CVCL_5E55 GM12771 transformed cell line human CVCL_5E55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145106 21196710 CVCL_5E54 GM12770 transformed cell line human CVCL_5E54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145105 21196711 CVCL_5E53 GM12769 transformed cell line human CVCL_5E53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145104 21196712 CVCL_5E52 GM12768 transformed cell line human CVCL_5E52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145103 21196713 CVCL_5E59 GM12810 transformed cell line human CVCL_5E59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145410 21196714 CVCL_5E58 GM12774 transformed cell line human CVCL_5E58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145110 21196715 CVCL_5E57 GM12773 transformed cell line human CVCL_5E57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145108 21196716 CVCL_5E56 GM12772 transformed cell line human CVCL_5E56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145107 21196717 CVCL_5E51 GM12765 transformed cell line human CVCL_5E51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144714 21196718 CVCL_5E50 GM12764 transformed cell line human CVCL_5E50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144713 21196719 CVCL_5E66 GM12823 transformed cell line human CVCL_5E66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145607 21196720 CVCL_5E65 GM12822 transformed cell line human CVCL_5E65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145606 21196721 CVCL_5E64 GM12821 transformed cell line human CVCL_5E64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145605 21196722 CVCL_5E63 GM12820 transformed cell line human CVCL_5E63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145604 21196723 CVCL_5E69 GM12826 transformed cell line human CVCL_5E69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145610 21196724 CVCL_5E68 GM12825 transformed cell line human CVCL_5E68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145609 21196725 CVCL_5E67 GM12824 transformed cell line human CVCL_5E67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145608 21196726 CVCL_XK92 HAP1 ABCD1 (-) 3 cancer cell line human CVCL_XK92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 61; ABCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196727 CVCL_XK91 HAP1 ABCD1 (-) 2 cancer cell line human CVCL_XK91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 61; ABCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196728 CVCL_XK90 HAP1 ABCC4 (-) 3 cancer cell line human CVCL_XK90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 55; ABCC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196729 CVCL_XK96 HAP1 ACAD10 (-) 2 cancer cell line human CVCL_XK96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21597; ACAD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196730 CVCL_XK95 HAP1 ABCB8 (-) cancer cell line human CVCL_XK95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 49; ABCB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196731 CVCL_XK94 HAP1 ABCD3 (-) 2 cancer cell line human CVCL_XK94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 67; ABCD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196732 CVCL_XK93 HAP1 ABCD1 (-) 4 cancer cell line human CVCL_XK93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 61; ABCD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196733 CVCL_XK99 HAP1 ACSL4 (-) 1 cancer cell line human CVCL_XK99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3571; ACSL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196734 CVCL_XK98 HAP1 ACSL3 (-) cancer cell line human CVCL_XK98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3570; ACSL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196735 CVCL_XK97 HAP1 ACLY (-) 2 cancer cell line human CVCL_XK97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 115; ACLY; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196736 CVCL_5E62 GM12819 transformed cell line human CVCL_5E62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145603 21196737 CVCL_5E61 GM12816 transformed cell line human CVCL_5E61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145416 21196738 CVCL_5E60 GM12811 transformed cell line human CVCL_5E60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 145411 21196739 CVCL_5E33 GM12713 transformed cell line human CVCL_5E33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135807 21196740 CVCL_5E32 GM12712 transformed cell line human CVCL_5E32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135806 21196741 CVCL_5E31 GM12711 transformed cell line human CVCL_5E31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135805 21196742 CVCL_5E30 GM12710 transformed cell line human CVCL_5E30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135804 21196743 CVCL_5E37 GM12741 transformed cell line human CVCL_5E37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144403 21196744 CVCL_5E36 GM12719 transformed cell line human CVCL_5E36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135815 21196745 CVCL_5E35 GM12715 transformed cell line human CVCL_5E35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135809 21196746 CVCL_5E34 GM12714 transformed cell line human CVCL_5E34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135808 21196747 CVCL_5E39 GM12743 transformed cell line human CVCL_5E39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144405 21196748 CVCL_5E38 GM12742 transformed cell line human CVCL_5E38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144404 21196749 CVCL_XK81 B16.1#1C5 hybridoma house mouse CVCL_XK81 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196750 CVCL_XK80 B16.1#1C1 hybridoma house mouse CVCL_XK80 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196751 CVCL_XK85 B16.1#2C4 hybridoma house mouse CVCL_XK85 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196752 CVCL_XK84 B16.1#2A5 hybridoma house mouse CVCL_XK84 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196753 CVCL_XK83 B16.1#2A3 hybridoma house mouse CVCL_XK83 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196754 CVCL_XK82 B16.1#2A2 hybridoma house mouse CVCL_XK82 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196755 CVCL_XK89 HAP1 ABCC4 (-) 2 cancer cell line human CVCL_XK89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 55; ABCC4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196756 CVCL_XK88 HAP1 ABCA3 (-) 2 cancer cell line human CVCL_XK88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33; ABCA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21196757 CVCL_XK87 B16.1#2D5 hybridoma house mouse CVCL_XK87 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196758 CVCL_XK86 B16.1#2D2 hybridoma house mouse CVCL_XK86 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196759 CVCL_5E44 GM12754 transformed cell line human CVCL_5E44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144703 21196760 CVCL_5E43 GM12747 transformed cell line human CVCL_5E43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144410 21196761 CVCL_5E42 GM12746 transformed cell line human CVCL_5E42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144408 21196762 CVCL_5E41 GM12745 transformed cell line human CVCL_5E41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144407 21196763 CVCL_5E48 GM12758 transformed cell line human CVCL_5E48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144707 21196764 CVCL_5E47 GM12757 transformed cell line human CVCL_5E47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144706 21196765 CVCL_5E46 GM12756 transformed cell line human CVCL_5E46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144705 21196766 CVCL_5E45 GM12755 transformed cell line human CVCL_5E45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144704 21196767 CVCL_5E49 GM12759 transformed cell line human CVCL_5E49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144708 21196768 CVCL_XK70 PAb 439 hybridoma house mouse CVCL_XK70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196769 CVCL_XK74 PAb 443 hybridoma house mouse CVCL_XK74 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196770 CVCL_XK73 PAb 442 hybridoma house mouse CVCL_XK73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196771 CVCL_XK72 PAb 441 hybridoma house mouse CVCL_XK72 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196772 CVCL_XK71 PAb 440 hybridoma house mouse CVCL_XK71 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196773 CVCL_XK78 B16.1#1B2 hybridoma house mouse CVCL_XK78 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196774 CVCL_XK77 A25.1#1B3 hybridoma house mouse CVCL_XK77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196775 CVCL_XK76 A17.2#1 hybridoma house mouse CVCL_XK76 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196776 CVCL_XK75 PAb 444 hybridoma house mouse CVCL_XK75 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196777 CVCL_XK79 B16.1#1B6 hybridoma house mouse CVCL_XK79 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196778 CVCL_5E40 GM12744 transformed cell line human CVCL_5E40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 144406 21196779 CVCL_5E11 GM12472 transformed cell line human CVCL_5E11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135703 21196780 CVCL_5E10 GM12471 transformed cell line human CVCL_5E10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135702 21196781 CVCL_5E15 GM12476 transformed cell line human CVCL_5E15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135707 21196782 CVCL_5E14 GM12475 transformed cell line human CVCL_5E14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135706 21196783 CVCL_5E13 GM12474 transformed cell line human CVCL_5E13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135705 21196784 CVCL_5E12 GM12473 transformed cell line human CVCL_5E12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135704 21196785 CVCL_5E19 GM12480 transformed cell line human CVCL_5E19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135712 21196786 CVCL_5E18 GM12479 transformed cell line human CVCL_5E18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135711 21196787 CVCL_5E17 GM12478 transformed cell line human CVCL_5E17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135709 21196788 CVCL_5E16 GM12477 transformed cell line human CVCL_5E16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135708 21196789 CVCL_XK63 PAb 431 hybridoma house mouse CVCL_XK63 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196790 CVCL_XK62 PAb 430 hybridoma house mouse CVCL_XK62 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196791 CVCL_XK61 PAb 427 hybridoma house mouse CVCL_XK61 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196792 CVCL_XK60 PAb 423 hybridoma house mouse CVCL_XK60 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196793 CVCL_XK67 PAb 436 hybridoma house mouse CVCL_XK67 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196794 CVCL_XK66 PAb 435 hybridoma house mouse CVCL_XK66 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196795 CVCL_XK65 PAb 433 hybridoma house mouse CVCL_XK65 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196796 CVCL_XK64 PAb 432 hybridoma house mouse CVCL_XK64 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196797 CVCL_XK69 PAb 438 hybridoma house mouse CVCL_XK69 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196798 CVCL_XK68 PAb 437 hybridoma house mouse CVCL_XK68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196799 CVCL_5E22 GM12483 transformed cell line human CVCL_5E22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135717 21196800 CVCL_5E21 GM12482 transformed cell line human CVCL_5E21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135716 21196801 CVCL_5E20 GM12481 transformed cell line human CVCL_5E20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135715 21196802 CVCL_5E26 GM12488 transformed cell line human CVCL_5E26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135303 21196803 CVCL_5E25 GM12487 transformed cell line human CVCL_5E25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135518 21196804 CVCL_5E24 GM12486 transformed cell line human CVCL_5E24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135505 21196805 CVCL_5E23 GM12484 transformed cell line human CVCL_5E23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135718 21196806 CVCL_5E29 GM12709 transformed cell line human CVCL_5E29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135803 21196807 CVCL_5E28 GM12491 transformed cell line human CVCL_5E28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 133003 21196808 CVCL_5E27 GM12490 transformed cell line human CVCL_5E27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132808 21196809 CVCL_XK52 PAb 409 hybridoma house mouse CVCL_XK52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196810 CVCL_XK51 PAb 407 hybridoma house mouse CVCL_XK51 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196811 CVCL_XK50 PAb 406 hybridoma house mouse CVCL_XK50 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196812 CVCL_XK56 PAb 416 hybridoma house mouse CVCL_XK56 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196813 CVCL_XK55 PAb 414 hybridoma house mouse CVCL_XK55 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196814 CVCL_XK54 PAb 413 hybridoma house mouse CVCL_XK54 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196815 CVCL_XK53 PAb 410 hybridoma house mouse CVCL_XK53 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196816 CVCL_XK59 PAb 421 hybridoma house mouse CVCL_XK59 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196817 CVCL_XK58 PAb 420 hybridoma house mouse CVCL_XK58 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196818 CVCL_XK57 PAb 418 hybridoma house mouse CVCL_XK57 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03070; SV40 large T antigen. 21196819 CVCL_G807 BY00166 transformed cell line human CVCL_G807 HLA typing: A*02:06,26:35; B*15:25,51:WBA; DRB1*09:01,15:02 (IPD-IMGT/HLA=14896) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196820 CVCL_FW07 GM15998 transformed cell line human CVCL_FW07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196821 CVCL_G806 BY00165 transformed cell line human CVCL_G806 HLA typing: A*34:02,68:39; B*15:BHJ,35:BZDD; DRB1*03:AC,03:BE (IPD-IMGT/HLA=14897) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196822 CVCL_FW06 GM15996 transformed cell line human CVCL_FW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196823 CVCL_G805 BY00164 transformed cell line human CVCL_G805 HLA typing: A*24:02/24:02L/24:03/24:09N/24:11N/24:33/24:40N/24:50,02:06:04; B*35:BEZX,48:AF; DRB1*15:01 (IPD-IMGT/HLA=14866) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196824 CVCL_FW05 GM15904 transformed cell line human CVCL_FW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196825 CVCL_G804 BY00163 transformed cell line human CVCL_G804 HLA typing: A*33:03:01,33:11; B*53:01,58:01; C*03:XV,04:BEYC; DRB1*03:02:01,08:04 (IPD-IMGT/HLA=14865) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196826 CVCL_FW04 GM15903 transformed cell line human CVCL_FW04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196827 CVCL_G809 BY00169 transformed cell line human CVCL_G809 HLA typing: A*68:01:01,02:120; B*07:ASKU,27:PEN; DRB1*01:ASDH,04:AGCB (IPD-IMGT/HLA=14893) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196828 CVCL_FW09 GM18310 transformed cell line human CVCL_FW09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196829 CVCL_G808 BY00168 transformed cell line human CVCL_G808 HLA typing: A*02:04,02:35:03; B*51:WBA,51:WBA; DRB1*03:01,04:11 (IPD-IMGT/HLA=14894) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196830 CVCL_FW08 GM15999 transformed cell line human CVCL_FW08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196831 CVCL_G803 BY00162 transformed cell line human CVCL_G803 HLA typing: A*01:26,01:BMFN; B*14:02:01,35:02:01; DRB1*01:02:01,13:02:01 (IPD-IMGT/HLA=14867) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196832 CVCL_FW03 GM15900 transformed cell line human CVCL_FW03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196833 CVCL_G802 BY00161 transformed cell line human CVCL_G802 HLA typing: A*68:01:02,31:16; B*35:03,52:AH; DRB1*03:BYBY,11:BBJ (IPD-IMGT/HLA=14842) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196834 CVCL_FW02 GM15893 transformed cell line human CVCL_FW02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196835 CVCL_G801 BY00160 transformed cell line human CVCL_G801 HLA typing: A*29:02:01,02:115; B*35:WAZ,58:01; DRB1*08:04,15:03 (IPD-IMGT/HLA=14843) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196836 CVCL_FW01 GM14001 transformed cell line human CVCL_FW01 CL:0000010 Population: Caucasian; Amish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196837 CVCL_G800 BY00159 transformed cell line human CVCL_G800 HLA typing: A*01:25,02:HHJS; B*27:EKN,57:01:01; DRB1*01:01:01,07:01:01 (IPD-IMGT/HLA=14841) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196838 CVCL_FW00 ND00938 transformed cell line human CVCL_FW00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196839 CVCL_G818 BY00182 transformed cell line human CVCL_G818 HLA typing: A*02:CAKM,30:22; B*18,44; DRB1*07:MT,03:JZW (IPD-IMGT/HLA=15020) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196840 CVCL_FW18 ND00873 transformed cell line human CVCL_FW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196841 CVCL_G817 BY00180 transformed cell line human CVCL_G817 HLA typing: A*02:CAKM,33:12; B*44,58:01; DRB1*07:01,13:02 (IPD-IMGT/HLA=14995) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196842 CVCL_FW17 ND00862 transformed cell line human CVCL_FW17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196843 CVCL_G816 BY00178 transformed cell line human CVCL_G816 HLA typing: A*02:CAKM,02:122; B*15:10,45:AC; DRB1*01:02,01:02 (IPD-IMGT/HLA=14990) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196844 CVCL_FW16 ND00851 transformed cell line human CVCL_FW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196845 CVCL_G815 BY00177 transformed cell line human CVCL_G815 HLA typing: A*24:77,24:02:01:01; B*07:AECG,35:SUW; DRB1*14:04,15:GEP (IPD-IMGT/HLA=14993) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196846 CVCL_FW15 ND00776 transformed cell line human CVCL_FW15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196847 CVCL_G819 BY00183 transformed cell line human CVCL_G819 HLA typing: A*32:01,02:122; B*15:BHK,18; DRB1*01:02,03:AEK (IPD-IMGT/HLA=15021) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196848 CVCL_FW19 ND00899 transformed cell line human CVCL_FW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196849 CVCL_G810 BY00170 transformed cell line human CVCL_G810 HLA typing: A*02:CAKM,02:119; B*15:BYYC,44:SDC; DRB1*04:BWFJ,04:BWFK (IPD-IMGT/HLA=14892) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196850 CVCL_FW10 ND00605 transformed cell line human CVCL_FW10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196851 CVCL_G814 BY00176 transformed cell line human CVCL_G814 HLA typing: A*02:123,23:01; B*44:03,51:WBA; DRB1*13:02,07:01 (IPD-IMGT/HLA=14992) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196852 CVCL_FW14 ND00775 transformed cell line human CVCL_FW14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196853 CVCL_G813 BY00174 transformed cell line human CVCL_G813 HLA typing: A*02:CAKM,02:136; B*35:05,40:02; DRB1*14:02,09:01 (IPD-IMGT/HLA=15290) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196854 CVCL_FW13 ND00773 transformed cell line human CVCL_FW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196855 CVCL_G812 BY00172 transformed cell line human CVCL_G812 HLA typing: A*74:AB,31:18; B*15:BKNX,48:AF; DRB1*13:ATNW,14:SM (IPD-IMGT/HLA=14890) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196856 CVCL_FW12 ND00653 transformed cell line human CVCL_FW12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196857 CVCL_G811 BY00171 transformed cell line human CVCL_G811 HLA typing: A*24:CEKU,02:118; B*15:APJS,40:XPM (IPD-IMGT/HLA=14891) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196858 CVCL_FW11 ND00610 transformed cell line human CVCL_FW11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196859 CVCL_5D99 GM12458 transformed cell line human CVCL_5D99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135605 21196860 CVCL_5D98 GM12457 transformed cell line human CVCL_5D98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135604 21196861 CVCL_5D97 GM12456 transformed cell line human CVCL_5D97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135602 21196862 CVCL_5D92 GM12409 transformed cell line human CVCL_5D92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135511 21196863 CVCL_5D91 GM12408 transformed cell line human CVCL_5D91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM12408; probable Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135510 21196864 CVCL_5D90 GM12407 transformed cell line human CVCL_5D90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135509 21196865 CVCL_5D96 GM12455 transformed cell line human CVCL_5D96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135601 21196866 CVCL_5D95 GM12415 transformed cell line human CVCL_5D95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135517 21196867 CVCL_5D94 GM12411 transformed cell line human CVCL_5D94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135513 21196868 CVCL_5D93 GM12410 transformed cell line human CVCL_5D93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135512 21196869 CVCL_5D78 GM12392 transformed cell line human CVCL_5D78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135408 21196870 CVCL_5D77 GM12391 transformed cell line human CVCL_5D77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135407 21196871 CVCL_5D76 GM12390 transformed cell line human CVCL_5D76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135406 21196872 CVCL_5D75 GM12389 transformed cell line human CVCL_5D75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135405 21196873 CVCL_5D79 GM12393 transformed cell line human CVCL_5D79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135409 21196874 CVCL_5D70 GM12381 transformed cell line human CVCL_5D70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135308 21196875 CVCL_5D74 GM12388 transformed cell line human CVCL_5D74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135404 21196876 CVCL_5D73 GM12387 transformed cell line human CVCL_5D73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135403 21196877 CVCL_5D72 GM12385 transformed cell line human CVCL_5D72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135401 21196878 CVCL_5D71 GM12382 transformed cell line human CVCL_5D71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135309 21196879 CVCL_5D89 GM12406 transformed cell line human CVCL_5D89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135508 21196880 CVCL_5D88 GM12405 transformed cell line human CVCL_5D88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135507 21196881 CVCL_5D87 GM12404 transformed cell line human CVCL_5D87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135506 21196882 CVCL_5D86 GM12403 transformed cell line human CVCL_5D86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135504 21196883 CVCL_5D81 GM12395 transformed cell line human CVCL_5D81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135411 21196884 CVCL_5D80 GM12394 transformed cell line human CVCL_5D80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135410 21196885 CVCL_5D85 GM12401 transformed cell line human CVCL_5D85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135502 21196886 CVCL_5D84 GM12398 transformed cell line human CVCL_5D84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135414 21196887 CVCL_5D83 GM12397 transformed cell line human CVCL_5D83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135413 21196888 CVCL_5D82 GM12396 transformed cell line human CVCL_5D82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135412 21196889 CVCL_G887 BY00285 transformed cell line human CVCL_G887 HLA typing: A*02:GNF,02:GNF; B*15:143,15:27:01; DRB1*14:12,15:01 (IPD-IMGT/HLA=15476) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196890 CVCL_FW87 ND03417 transformed cell line human CVCL_FW87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196891 CVCL_G886 BY00284 transformed cell line human CVCL_G886 HLA typing: A*01:TUS,24:AZUP; B*56:22,40:06; DRB1*04:APPB,11:APWP (IPD-IMGT/HLA=15475) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196892 CVCL_FW86 ND03413 transformed cell line human CVCL_FW86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196893 CVCL_G885 BY00283 transformed cell line human CVCL_G885 HLA typing: A*23:ANSM; B*53:01:01,08:36; DRB1*08:04,11:APWP (IPD-IMGT/HLA=15474) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196894 CVCL_FW85 ND03412 transformed cell line human CVCL_FW85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196895 CVCL_G884 BY00282 transformed cell line human CVCL_G884 HLA typing: A*01:YAG,03:ANPZ; B*07:64,07:CZZS; DRB1*01:EW,15:GEP (IPD-IMGT/HLA=15473) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196896 CVCL_FW84 ND03400 transformed cell line human CVCL_FW84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196897 CVCL_G889 BY00287 transformed cell line human CVCL_G889 HLA typing: A*02,11; B*51:55,15:01:01:01; DRB1*04:01,15:01 (IPD-IMGT/HLA=15495) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196898 CVCL_FW89 ND03461 transformed cell line human CVCL_FW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196899 CVCL_G888 BY00286 transformed cell line human CVCL_G888 HLA typing: A*02:ANDC,11:XSH; B*14:08,15:01:01:01/15:01:06/15:01:07/15:102/15:104; DRB1*01:EW,07:APA (IPD-IMGT/HLA=15496) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196900 CVCL_FW88 ND03458 transformed cell line human CVCL_FW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196901 CVCL_P219 GM18621 transformed cell line human CVCL_P219 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196902 CVCL_P218 GM18620 transformed cell line human CVCL_P218 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196903 CVCL_G883 BY00281 transformed cell line human CVCL_G883 HLA typing: A*02:BEJX; B*44:03:01/44:03:03,18:29; DRB1*07:APA,11:ARAP (IPD-IMGT/HLA=15472) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196904 CVCL_P217 GM18619 transformed cell line human CVCL_P217 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196905 CVCL_FW83 ND03373 transformed cell line human CVCL_FW83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196906 CVCL_G882 BY00280 transformed cell line human CVCL_G882 HLA typing: A*02:BYVR,24:BYVG; B*35:68:02,35:12; DRB1*16:02,09:01 (IPD-IMGT/HLA=15471) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196907 CVCL_P216 GM18618 transformed cell line human CVCL_P216 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196908 CVCL_FW82 ND03327 transformed cell line human CVCL_FW82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196909 CVCL_G881 BY00279 transformed cell line human CVCL_G881 HLA typing: A*01:CRY,30:01; B*81:04N,35:BEZX; DRB1*11:01,13:02 (IPD-IMGT/HLA=15469) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196910 CVCL_P215 GM18617 transformed cell line human CVCL_P215 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196911 CVCL_FW81 ND03324 transformed cell line human CVCL_FW81 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196912 CVCL_G880 BY00278 transformed cell line human CVCL_G880 HLA typing: A*02:SWY,03:BBSA; B*07:22:02,35:BEZX; DRB1*01:01,07:01 (IPD-IMGT/HLA=15468) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196913 CVCL_P214 GM18616 transformed cell line human CVCL_P214 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196914 CVCL_FW80 ND03311 transformed cell line human CVCL_FW80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196915 CVCL_P213 GM18615 transformed cell line human CVCL_P213 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196916 CVCL_P212 GM18614 transformed cell line human CVCL_P212 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196917 CVCL_P211 GM18613 transformed cell line human CVCL_P211 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196918 CVCL_P210 GM18612 transformed cell line human CVCL_P210 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196919 CVCL_G898 BY00299 transformed cell line human CVCL_G898 HLA typing: A*24:GMP; B*39:19:02,15:15; DRB1*14:02,08:02 (IPD-IMGT/HLA=15485) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196920 CVCL_FW98 ND03668 transformed cell line human CVCL_FW98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196921 CVCL_G897 BY00298 transformed cell line human CVCL_G897 HLA typing: A*24:AZWC,68:AEAN; B*27:41,07:CZZS; DRB1*11:APWP,15:VYF (IPD-IMGT/HLA=15486) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196922 CVCL_FW97 ND03645 transformed cell line human CVCL_FW97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196923 CVCL_G896 BY00297 transformed cell line human CVCL_G896 HLA typing: A*31:TE; B*51:53,27:05:02; DRB1*01:EW,08:02 (IPD-IMGT/HLA=15487) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196924 CVCL_FW96 ND03639 transformed cell line human CVCL_FW96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196925 CVCL_G895 BY00296 transformed cell line human CVCL_G895 HLA typing: A*02:BEJX; B*35:68:02,44:WRJ; DRB1*09:01,13:APWN (IPD-IMGT/HLA=15563) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196926 CVCL_FW95 ND03614 transformed cell line human CVCL_FW95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196927 CVCL_G899 BY00300 transformed cell line human CVCL_G899 HLA typing: A*02:BPNJ,02:ZJW; B*53:16,50:01; DRB1*07:SAF (IPD-IMGT/HLA=15484) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196928 CVCL_FW99 ND03669 transformed cell line human CVCL_FW99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196929 CVCL_G890 BY00288 transformed cell line human CVCL_G890 HLA typing: A*02:ANDC,11:XSH; B*15:145,08:XKT; DRB1*15:DWK,15:VYF (IPD-IMGT/HLA=15494) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196930 CVCL_FW90 ND03514 transformed cell line human CVCL_FW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196931 CVCL_P229 GM18631 transformed cell line human CVCL_P229 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196932 CVCL_G894 BY00295 transformed cell line human CVCL_G894 HLA typing: A*02:GNF; B*35:68:02,13:02:01; C*04:ARHA,06:BG; DQB1*02:MN,03:CA; DRB1*07:01,09:01 (IPD-IMGT/HLA=15470) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196933 CVCL_P228 GM18630 transformed cell line human CVCL_P228 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196934 CVCL_FW94 ND03612 transformed cell line human CVCL_FW94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196935 CVCL_G893 BY00292 transformed cell line human CVCL_G893 HLA typing: A*02:GNF,11:01; B*27:42,55:02:01; DRB1*15:01,08:03 (IPD-IMGT/HLA=15490) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196936 CVCL_P227 GM18629 transformed cell line human CVCL_P227 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196937 CVCL_FW93 ND03584 transformed cell line human CVCL_FW93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196938 CVCL_G892 BY00291 transformed cell line human CVCL_G892 HLA typing: A*02,24; B*51:54,14:02:01; DRB1*07:01,10:01 (IPD-IMGT/HLA=15491) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196939 CVCL_P226 GM18628 transformed cell line human CVCL_P226 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196940 CVCL_FW92 ND03547 transformed cell line human CVCL_FW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196941 CVCL_G891 BY00290 transformed cell line human CVCL_G891 HLA typing: A*02:ANDC,11:XSH; B*51:55,44:WRJ; DRB1*04:AFNC,15:GUX (IPD-IMGT/HLA=15564) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196942 CVCL_P225 GM18627 transformed cell line human CVCL_P225 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196943 CVCL_FW91 ND03538 transformed cell line human CVCL_FW91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196944 CVCL_P224 GM18626 transformed cell line human CVCL_P224 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196945 CVCL_P223 GM18625 transformed cell line human CVCL_P223 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196946 CVCL_P222 GM18624 transformed cell line human CVCL_P222 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196947 CVCL_P221 GM18623 transformed cell line human CVCL_P221 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196948 CVCL_P220 GM18622 transformed cell line human CVCL_P220 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196949 CVCL_G865 BY00245 transformed cell line human CVCL_G865 HLA typing: A*11:BMTS,24:BZBD; B*15:17,51:WBA; DRB1*04:69,13:02:01 (IPD-IMGT/HLA=15199) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196950 CVCL_FW65 ND02866 transformed cell line human CVCL_FW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196951 CVCL_G864 BY00244 transformed cell line human CVCL_G864 HLA typing: A*30:GSH,68:AJCN; B*15:17,18:AERZ; DRB1*11:65:01,15 (IPD-IMGT/HLA=15282) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196952 CVCL_FW64 ND02730 transformed cell line human CVCL_FW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196953 CVCL_G863 BY00243 transformed cell line human CVCL_G863 HLA typing: A*30,36; B*18,42:01; DRB1*11:65:01,03:02 (IPD-IMGT/HLA=15281) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196954 CVCL_FW63 ND02701 transformed cell line human CVCL_FW63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196955 CVCL_G862 BY00242 transformed cell line human CVCL_G862 HLA typing: A*30:GSH,68:AEAV; B*40:XCG,50:01; DRB1*04:68,07:01 (IPD-IMGT/HLA=15370) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196956 CVCL_FW62 ND02604 transformed cell line human CVCL_FW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196957 CVCL_G869 BY00250 transformed cell line human CVCL_G869 HLA typing: A*03:BUVE,11:BDFZ; B*35:BEZX,49:01; DRB1*04:71,01:01:01 (IPD-IMGT/HLA=15204) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196958 CVCL_FW69 ND03015 transformed cell line human CVCL_FW69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196959 CVCL_G868 BY00249 transformed cell line human CVCL_G868 HLA typing: A*02:16,02:AZGG; B*40:06,44:03; DRB1*11:66,07:01 (IPD-IMGT/HLA=15369) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196960 CVCL_FW68 ND02994 transformed cell line human CVCL_FW68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196961 CVCL_G867 BY00248 transformed cell line human CVCL_G867 HLA typing: A*02:BRHJ; B*15:BYYS,44:APGK; DRB1*04:70,01:01:01 (IPD-IMGT/HLA=15203) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196962 CVCL_FW67 ND02987 transformed cell line human CVCL_FW67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196963 CVCL_G866 BY00246 transformed cell line human CVCL_G866 HLA typing: A*02:AZGG,24:10; B*18:02,40:06; DRB1*11:66,12:02:01 (IPD-IMGT/HLA=15200) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196964 CVCL_FW66 ND02976 transformed cell line human CVCL_FW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196965 CVCL_G861 BY00241 transformed cell line human CVCL_G861 HLA typing: A*01:WUS,30:GSH; B*50:01,51:AFKG; DRB1*04:68,11:01 (IPD-IMGT/HLA=15198) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196966 CVCL_FW61 ND02603 transformed cell line human CVCL_FW61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196967 CVCL_G860 BY00240 transformed cell line human CVCL_G860 HLA typing: A*11; B*15:02,40:YFU; DRB1*08:34,15:01 (IPD-IMGT/HLA=15175) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196968 CVCL_FW60 ND02599 transformed cell line human CVCL_FW60 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196969 CVCL_G876 BY00271 transformed cell line human CVCL_G876 HLA typing: A*03:XKS,23:RRF; B*44:03:01,40:87; DRB1*13:01,07:01 (IPD-IMGT/HLA=15460) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196970 CVCL_FW76 ND03283 transformed cell line human CVCL_FW76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196971 CVCL_G875 BY00263 transformed cell line human CVCL_G875 HLA typing: A*02:ANFV,33:DWH; B*51:CMCY,35:84; DRB1*03:WZD,11:APNV (IPD-IMGT/HLA=15267) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196972 CVCL_FW75 ND03266 transformed cell line human CVCL_FW75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196973 CVCL_G874 BY00260 transformed cell line human CVCL_G874 HLA typing: A*02:EXE,33:DWH; B*51:CMCY,58:16; DRB1*03:YMP,04:GEX (IPD-IMGT/HLA=15265) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196974 CVCL_FW74 ND03211 transformed cell line human CVCL_FW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196975 CVCL_G873 BY00256 transformed cell line human CVCL_G873 HLA typing: A*68:FKZ; B*40:ANHP,44:BHHP; DRB1*15:01:01,15:27 (IPD-IMGT/HLA=15244) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196976 CVCL_FW73 ND03210 transformed cell line human CVCL_FW73 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196977 CVCL_G879 BY00274 transformed cell line human CVCL_G879 HLA typing: A*03:02,24:ANRD; B*15:17:01:01,44:60; DRB1*04:BDJV,07:APA (IPD-IMGT/HLA=15463) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196978 CVCL_FW79 ND03310 transformed cell line human CVCL_FW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196979 CVCL_G878 BY00273 transformed cell line human CVCL_G878 HLA typing: A*03:ANGK,29:ANJP; B*55:01:01/55:01:03,45:08; DRB1*07:APA,08:FX (IPD-IMGT/HLA=15462) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196980 CVCL_FW78 ND03307 transformed cell line human CVCL_FW78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21196981 CVCL_G877 BY00272 transformed cell line human CVCL_G877 HLA typing: A*02:ANDC,11:XSH; B*46:01:01,56:23; DRB1*09:01,12:02 (IPD-IMGT/HLA=15461) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196982 CVCL_FW77 ND03292 transformed cell line human CVCL_FW77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196983 CVCL_P209 GM18611 transformed cell line human CVCL_P209 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196984 CVCL_P208 GM18610 transformed cell line human CVCL_P208 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196985 CVCL_P207 GM18609 transformed cell line human CVCL_P207 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196986 CVCL_G872 BY00254 transformed cell line human CVCL_G872 HLA typing: A*02; B*18,44; DRB1*03:37,08:01 (IPD-IMGT/HLA=15285) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196987 CVCL_P206 GM18608 transformed cell line human CVCL_P206 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Deep proteome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196988 CVCL_FW72 ND03209 transformed cell line human CVCL_FW72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196989 CVCL_G871 BY00253 transformed cell line human CVCL_G871 HLA typing: A*02,24; B*08,49:01; DRB1*03:39,01:01 (IPD-IMGT/HLA=15206) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196990 CVCL_P205 GM18606 transformed cell line human CVCL_P205 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196991 CVCL_FW71 ND03158 transformed cell line human CVCL_FW71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196992 CVCL_G870 BY00251 transformed cell line human CVCL_G870 HLA typing: A*11:01,24:GMP; B*55:02,58:01; DRB1*04:05:05,03:01:01 (IPD-IMGT/HLA=15284) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21196993 CVCL_P204 GM18605 transformed cell line human CVCL_P204 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196994 CVCL_FW70 ND03051 transformed cell line human CVCL_FW70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21196995 CVCL_P203 GM18603 transformed cell line human CVCL_P203 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196996 CVCL_P202 GM18602 transformed cell line human CVCL_P202 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196997 CVCL_P201 GM18599 transformed cell line human CVCL_P201 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196998 CVCL_P200 GM18597 transformed cell line human CVCL_P200 CL:0000010 Population: Chinese; Han in Beijing (CHB); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21196999 CVCL_G849 BY00226 transformed cell line human CVCL_G849 HLA typing: A*02,24; B*35; DRB1*16:12,14:06 (IPD-IMGT/HLA=15140) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197000 CVCL_FW49 ND02165 transformed cell line human CVCL_FW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197001 CVCL_G848 BY00225 transformed cell line human CVCL_G848 HLA typing: A*02:ANDA,26:PEU; B*07:ASKP,39:AFBG; DRB1*15:25,09:01 (IPD-IMGT/HLA=15153) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197002 CVCL_FW48 ND02131 transformed cell line human CVCL_FW48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197003 CVCL_G843 BY00218 transformed cell line human CVCL_G843 HLA typing: A*02; B*07,51; DRB1*15:24,07:APA (IPD-IMGT/HLA=15127) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197004 CVCL_FW43 ND01973 transformed cell line human CVCL_FW43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197005 CVCL_G842 BY00216 transformed cell line human CVCL_G842 HLA typing: A*03:BKS,11:YPP; B*40:YPJ,52:AE; DRB1*14:73,15:02 (IPD-IMGT/HLA=15142) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197006 CVCL_FW42 ND01972 transformed cell line human CVCL_FW42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197007 CVCL_G841 BY00215 transformed cell line human CVCL_G841 HLA typing: A*02:XAP,02:ZKP; B*15:07,51:AFKG; DRB1*14:44:02,08:02 (IPD-IMGT/HLA=15130) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197008 CVCL_FW41 ND01971 transformed cell line human CVCL_FW41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197009 CVCL_G840 BY00214 transformed cell line human CVCL_G840 HLA typing: A*01:WUS,29:ANJP; B*35:23,44:AXGG; DRB1*01:17,04:07 (IPD-IMGT/HLA=15131) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197010 CVCL_FW40 ND01970 transformed cell line human CVCL_FW40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197011 CVCL_G847 BY00224 transformed cell line human CVCL_G847 HLA typing: A*03:ANDB; B*07:BMAB,35:BMAC; DRB1*15:24,01:01 (IPD-IMGT/HLA=15128) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197012 CVCL_FW47 ND02087 transformed cell line human CVCL_FW47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197013 CVCL_G846 BY00222 transformed cell line human CVCL_G846 HLA typing: A*29:WWP,30:GSH; B*44:ABXK,57:CG; DRB1*07:APA,15:23 (IPD-IMGT/HLA=15124) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197014 CVCL_FW46 ND02086 transformed cell line human CVCL_FW46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197015 CVCL_G845 BY00221 transformed cell line human CVCL_G845 HLA typing: A*02,11; B*44,58; DRB1*13:80,04:BK (IPD-IMGT/HLA=15125) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197016 CVCL_FW45 ND02069 transformed cell line human CVCL_FW45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197017 CVCL_G844 BY00219 transformed cell line human CVCL_G844 HLA typing: A*24,80:01; B*35:43,39:SPC; DRB1*16:12,04:07 (IPD-IMGT/HLA=15141) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197018 CVCL_FW44 ND02055 transformed cell line human CVCL_FW44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197019 CVCL_G859 BY00238 transformed cell line human CVCL_G859 HLA typing: A*01:YAG,03:ANPZ; B*07:AWBG,08:AMXJ; DRB1*04:01:03,03:XBD (IPD-IMGT/HLA=15178) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197020 CVCL_FW59 ND02498 transformed cell line human CVCL_FW59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197021 CVCL_G854 BY00233 transformed cell line human CVCL_G854 HLA typing: A*31:TE,74:ZVV; B*55:ANXC,57:03; DRB1*15:23,01:01 (IPD-IMGT/HLA=15123) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197022 CVCL_FW54 ND02438 transformed cell line human CVCL_FW54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197023 CVCL_G853 BY00232 transformed cell line human CVCL_G853 HLA typing: A*02,11; B*18,44; DRB1*03:37,01:03 (IPD-IMGT/HLA=15161) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197024 CVCL_FW53 ND02411 transformed cell line human CVCL_FW53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197025 CVCL_G852 BY00230 transformed cell line human CVCL_G852 HLA typing: A*02:02,68:PNP; B*15:10,45:AC; DRB1*13:81,03:01 (IPD-IMGT/HLA=15159) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197026 CVCL_FW52 ND02283 transformed cell line human CVCL_FW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197027 CVCL_G851 BY00229 transformed cell line human CVCL_G851 HLA typing: A*02:06,11:01; B*38:02,40:02; DRB1*15:26,04:03:01 (IPD-IMGT/HLA=15158) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197028 CVCL_FW51 ND02274 transformed cell line human CVCL_FW51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197029 CVCL_G858 BY00237 transformed cell line human CVCL_G858 HLA typing: A*30,68; B*42:01,58:02; DRB1*03:38,12:AG (IPD-IMGT/HLA=15182) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197030 CVCL_FW58 ND02497 transformed cell line human CVCL_FW58 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197031 CVCL_G857 BY00236 transformed cell line human CVCL_G857 HLA typing: A*11,24; B*15:02,27; DRB1*04:05:05,12:02 (IPD-IMGT/HLA=15183) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197032 CVCL_FW57 ND02460 transformed cell line human CVCL_FW57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197033 CVCL_G856 BY00235 transformed cell line human CVCL_G856 HLA typing: A*30:ZUA,31:KP; B*18:AETB,58:02; DRB1*11:65:01,12:CVT (IPD-IMGT/HLA=15184) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197034 CVCL_FW56 ND02459 transformed cell line human CVCL_FW56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197035 CVCL_G855 BY00234 transformed cell line human CVCL_G855 HLA typing: A*30:GSH,33:DWH; B*18:ADUA,53:AB; DRB1*11:65:01,01:RY (IPD-IMGT/HLA=15283) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197036 CVCL_FW55 ND02449 transformed cell line human CVCL_FW55 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197037 CVCL_G850 BY00228 transformed cell line human CVCL_G850 HLA typing: A*11:HGV,33:DWH; B*15:02,18:ADSC; DRB1*10:02,12:02 (IPD-IMGT/HLA=15155) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197038 CVCL_FW50 ND02168 transformed cell line human CVCL_FW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197039 CVCL_G829 BY00200 transformed cell line human CVCL_G829 HLA typing: A*02:CAKM,01:30; B*38:01,51:WBA; DRB1*15:AD,16:AE (IPD-IMGT/HLA=15119) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197040 CVCL_FW29 ND01357 transformed cell line human CVCL_FW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197041 CVCL_G828 BY00199 transformed cell line human CVCL_G828 HLA typing: A*03:CTSA,02:128; B*07:02:01,27:EKN; C*02:02:02,07:02; DRB1*07:01:01,12:02:01 (IPD-IMGT/HLA=15105) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197042 CVCL_FW28 ND01264 transformed cell line human CVCL_FW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197043 CVCL_G827 BY00197 transformed cell line human CVCL_G827 HLA typing: A*11:CRGR,24:82; B*07:EH,40:06; DRB1*15:02,15:ANVF (IPD-IMGT/HLA=15122) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197044 CVCL_FW27 ND01256 transformed cell line human CVCL_FW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197045 CVCL_G826 BY00196 transformed cell line human CVCL_G826 HLA typing: A*03:32,24:CNSY; B*15:AKNE,55:ANXC; DRB1*13:ARCR,15:VYF (IPD-IMGT/HLA=15106) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197046 CVCL_FW26 ND01201 transformed cell line human CVCL_FW26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197047 CVCL_G821 BY00186 transformed cell line human CVCL_G821 HLA typing: A*68:01:01,01:25; B*15:GYF,58:02; DRB1*01:02,16:02 (IPD-IMGT/HLA=15024) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197048 CVCL_FW21 ND00999 transformed cell line human CVCL_FW21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197049 CVCL_G820 BY00185 transformed cell line human CVCL_G820 HLA typing: A*24:ATEA,33:13; B*35:03,44; DRB1*07:01,08:CST (IPD-IMGT/HLA=15023) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197050 CVCL_FW20 ND00970 transformed cell line human CVCL_FW20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197051 CVCL_G825 BY00193 transformed cell line human CVCL_G825 HLA typing: A*68:01:02,02:06:05; B*39:09,40:TTM; DRB1*04:07,16:02 (IPD-IMGT/HLA=15114) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197052 CVCL_FW25 ND01191 transformed cell line human CVCL_FW25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197053 CVCL_G824 BY00190 transformed cell line human CVCL_G824 HLA typing: A*32:01:03,32:01:01/32:01:02; B*40:06,51:07; DRB1*10:01,15:AK (IPD-IMGT/HLA=15144) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197054 CVCL_FW24 ND01124 transformed cell line human CVCL_FW24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197055 CVCL_G823 BY00189 transformed cell line human CVCL_G823 HLA typing: A*02:CAKM,24:81; B*15:GYF,51:WBA; DRB1*03:01,04:04 (IPD-IMGT/HLA=15120) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197056 CVCL_FW23 ND01035 transformed cell line human CVCL_FW23 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197057 CVCL_G822 BY00188 transformed cell line human CVCL_G822 HLA typing: A*30:02:01,68:40; B*15:10,57:03:01; C*03:02,18:AB; DRB1*07:01:01,11:02 (IPD-IMGT/HLA=15026) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197058 CVCL_FW22 ND01003 transformed cell line human CVCL_FW22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197059 CVCL_G839 BY00212 transformed cell line human CVCL_G839 HLA typing: A*11:HGV,34:BD; B*35:02,35:BJYD; DRB1*01:18,11:04 (IPD-IMGT/HLA=15133) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197060 CVCL_FW39 ND01914 transformed cell line human CVCL_FW39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197061 CVCL_G838 BY00211 transformed cell line human CVCL_G838 HLA typing: A*29,31; B*39,44; DRB1*14:72,04:01 (IPD-IMGT/HLA=15143) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197062 CVCL_FW38 ND01890 transformed cell line human CVCL_FW38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197063 CVCL_G837 BY00210 transformed cell line human CVCL_G837 HLA typing: A*01:YAG,02:11; B*51:AFJR,57:GW; DRB1*14:69,07:01 (IPD-IMGT/HLA=15134) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197064 CVCL_FW37 ND01819 transformed cell line human CVCL_FW37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197065 CVCL_G832 BY00204 transformed cell line human CVCL_G832 HLA typing: A*03:CGAG,29:17; B*07:EH,27:02; DRB1*11:01,04:04 (IPD-IMGT/HLA=15109) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197066 CVCL_FW32 ND01463 transformed cell line human CVCL_FW32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197067 CVCL_G831 BY00202 transformed cell line human CVCL_G831 HLA typing: A*01:15N,68:01:02; B*08:AKNJ,44:BNGF; DRB1*03:WHX,11:ARAP (IPD-IMGT/HLA=15111) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197068 CVCL_FW31 ND01411 transformed cell line human CVCL_FW31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197069 CVCL_G830 BY00201 transformed cell line human CVCL_G830 HLA typing: A*02:CAKM,01:29; B*08,40; DRB1*03:01,14:04 (IPD-IMGT/HLA=15118) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197070 CVCL_FW30 ND01365 transformed cell line human CVCL_FW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197071 CVCL_G836 BY00209 transformed cell line human CVCL_G836 HLA typing: A*02:GNF,26:02; B*15:11,40:02; DRB1*01:19,09:01:02 (IPD-IMGT/HLA=15135) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197072 CVCL_FW36 ND01816 transformed cell line human CVCL_FW36 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197073 CVCL_G835 BY00208 transformed cell line human CVCL_G835 HLA typing: A*02:TDF,31:AB; B*15:11,48:01; DRB1*01:19,04:07:01 (IPD-IMGT/HLA=15136) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197074 CVCL_FW35 ND01744 transformed cell line human CVCL_FW35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197075 CVCL_G834 BY00207 transformed cell line human CVCL_G834 HLA typing: A*02,23; B*07,49:01; DRB1*14:70,15:01 (IPD-IMGT/HLA=15138) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197076 CVCL_FW34 ND01652 transformed cell line human CVCL_FW34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197077 CVCL_G833 BY00206 transformed cell line human CVCL_G833 HLA typing: A*24,33; B*35,44; DRB1*14:71,07:01 (IPD-IMGT/HLA=15139) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197078 CVCL_FW33 ND01616 transformed cell line human CVCL_FW33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197079 CVCL_5F10 GM12901 transformed cell line human CVCL_5F10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147705 21197080 CVCL_5F14 GM12905 transformed cell line human CVCL_5F14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147709 21197081 CVCL_5F13 GM12904 transformed cell line human CVCL_5F13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147708 21197082 CVCL_5F12 GM12903 transformed cell line human CVCL_5F12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147707 21197083 CVCL_5F11 GM12902 transformed cell line human CVCL_5F11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147706 21197084 CVCL_5F18 GM12909 transformed cell line human CVCL_5F18 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142012/147713 21197085 CVCL_5F17 GM12908 transformed cell line human CVCL_5F17 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142011/147712 21197086 CVCL_5F16 GM12907 transformed cell line human CVCL_5F16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147711 21197087 CVCL_5F15 GM12906 transformed cell line human CVCL_5F15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147710 21197088 CVCL_5F19 GM12910 transformed cell line human CVCL_5F19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147714 21197089 CVCL_XL62 HAP1 ASPM (-) 3 cancer cell line human CVCL_XL62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19048; ASPM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC003472c010; probable Male Group: Haploid karyotype cell line 21197090 CVCL_XL61 HAP1 ASPM (-) 2 cancer cell line human CVCL_XL61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19048; ASPM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC003472c008; probable Male Group: Haploid karyotype cell line 21197091 CVCL_XL60 HAP1 ASMTL (-) 2 cancer cell line human CVCL_XL60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 751; ASMTL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197092 CVCL_XL66 HAP1 ATF3 (-) 3 cancer cell line human CVCL_XL66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197093 CVCL_XL65 HAP1 ATF3 (-) 2 cancer cell line human CVCL_XL65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197094 CVCL_XL64 HAP1 ATE1 (-) 1 cancer cell line human CVCL_XL64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 782; ATE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197095 CVCL_XL63 HAP1 ASS1 (-) 2 cancer cell line human CVCL_XL63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 758; ASS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197096 CVCL_XL69 HAP1 ATP11C (-) 2 cancer cell line human CVCL_XL69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13554; ATP11C; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197097 CVCL_XL68 HAP1 ATF5 (-) 3 cancer cell line human CVCL_XL68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197098 CVCL_XL67 HAP1 ATF3 (-) 4 cancer cell line human CVCL_XL67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 785; ATF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197099 CVCL_5F21 GM12912 transformed cell line human CVCL_5F21 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158202 21197100 CVCL_5F20 GM12911 transformed cell line human CVCL_5F20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158201 21197101 CVCL_5F25 GM12916 transformed cell line human CVCL_5F25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158206 21197102 CVCL_5F24 GM12915 transformed cell line human CVCL_5F24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158205 21197103 CVCL_5F23 GM12914 transformed cell line human CVCL_5F23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158204 21197104 CVCL_5F22 GM12913 transformed cell line human CVCL_5F22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158203 21197105 CVCL_5F29 GM12920 transformed cell line human CVCL_5F29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158210 21197106 CVCL_5F28 GM12919 transformed cell line human CVCL_5F28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158209 21197107 CVCL_5F27 GM12918 transformed cell line human CVCL_5F27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158208 21197108 CVCL_5F26 GM12917 transformed cell line human CVCL_5F26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158207 21197109 CVCL_XL51 HAP1 ARMCX2 (-) cancer cell line human CVCL_XL51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16869; ARMCX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197110 CVCL_XL50 HAP1 ARIH1 (-) 2 cancer cell line human CVCL_XL50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 689; ARIH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Discontinued: Horizon_Discovery; HZGHC003064c005; probable Male Group: Haploid karyotype cell line 21197111 CVCL_XL55 HAP1 ARRDC1 (-) 1 cancer cell line human CVCL_XL55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28633; ARRDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197112 CVCL_XL54 HAP1 ARRB1 (-) 2 cancer cell line human CVCL_XL54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 711; ARRB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197113 CVCL_XL53 HAP1 ARNTL (-) 2 cancer cell line human CVCL_XL53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 701; BMAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197114 CVCL_XL52 HAP1 ARNT (-) cancer cell line human CVCL_XL52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 700; ARNT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197115 CVCL_XL59 HAP1 ASF1B (-) cancer cell line human CVCL_XL59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20996; ASF1B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197116 CVCL_XL58 HAP1 ASF1A (-) cancer cell line human CVCL_XL58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20995; ASF1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197117 CVCL_XL57 HAP1 ASCC1 (-) 2 cancer cell line human CVCL_XL57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24268; ASCC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197118 CVCL_XL56 HAP1 ARSB (-) cancer cell line human CVCL_XL56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 714; ARSB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197119 CVCL_XL40 HAP1 APP (-) 2 cancer cell line human CVCL_XL40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 620; APP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197120 CVCL_XL44 HAP1 ARFGAP3 (-) cancer cell line human CVCL_XL44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 661; ARFGAP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197121 CVCL_XL43 HAP1 ARFGAP2 (-) cancer cell line human CVCL_XL43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13504; ARFGAP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197122 CVCL_XL42 HAP1 AQP3 (-) 2 cancer cell line human CVCL_XL42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 636; AQP3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197123 CVCL_XL41 HAP1 APPL1 (-) cancer cell line human CVCL_XL41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24035; APPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197124 CVCL_XL48 HAP1 ARHGEF39 (-) 2 cancer cell line human CVCL_XL48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25909; ARHGEF39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197125 CVCL_P399 GM19679 transformed cell line human CVCL_P399 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197126 CVCL_XL47 HAP1 ARHGEF39 (-) 1 cancer cell line human CVCL_XL47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25909; ARHGEF39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197127 CVCL_P398 GM19678 transformed cell line human CVCL_P398 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197128 CVCL_XL46 HAP1 ARHGAP32 (-) 4 cancer cell line human CVCL_XL46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17399; ARHGAP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197129 CVCL_P397 GM19676 transformed cell line human CVCL_P397 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197130 CVCL_XL45 HAP1 ARHGAP32 (-) 3 cancer cell line human CVCL_XL45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17399; ARHGAP32; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197131 CVCL_P396 GM19675 transformed cell line human CVCL_P396 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197132 CVCL_P395 GM19672 transformed cell line human CVCL_P395 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197133 CVCL_P394 GM19670 transformed cell line human CVCL_P394 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197134 CVCL_P393 GM19669 transformed cell line human CVCL_P393 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197135 CVCL_XL49 HAP1 ARHGEF39 (-) 3 cancer cell line human CVCL_XL49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25909; ARHGEF39; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197136 CVCL_5F03 GM12887 transformed cell line human CVCL_5F03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146311 21197137 CVCL_5F02 GM12886 transformed cell line human CVCL_5F02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146310 21197138 CVCL_5F01 GM12885 transformed cell line human CVCL_5F01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146309 21197139 CVCL_5F00 GM12884 transformed cell line human CVCL_5F00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146308 21197140 CVCL_5F07 GM12898 transformed cell line human CVCL_5F07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147702 21197141 CVCL_5F06 GM12897 transformed cell line human CVCL_5F06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147701 21197142 CVCL_5F05 GM12893 transformed cell line human CVCL_5F05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146317 21197143 CVCL_5F04 GM12888 transformed cell line human CVCL_5F04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146312 21197144 CVCL_5F09 GM12900 transformed cell line human CVCL_5F09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147704 21197145 CVCL_5F08 GM12899 transformed cell line human CVCL_5F08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 147703 21197146 CVCL_XL33 HAP1 ANGPTL4 (-) 2 cancer cell line human CVCL_XL33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16039; ANGPTL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197147 CVCL_XL32 HAP1 ANAPC16 (-) cancer cell line human CVCL_XL32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26976; ANAPC16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197148 CVCL_XL31 HAP1 ALOX5 (-) 1 cancer cell line human CVCL_XL31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 435; ALOX5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197149 CVCL_XL30 HAP1 ALKBH8 (-) cancer cell line human CVCL_XL30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25189; ALKBH8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197150 CVCL_XL37 HAP1 ANXA5 (-) 2 cancer cell line human CVCL_XL37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 543; ANXA5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197151 CVCL_XL36 HAP1 ANO10 (-) 2 cancer cell line human CVCL_XL36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25519; ANO10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197152 CVCL_XL35 HAP1 ANKHD1 (-) 2 cancer cell line human CVCL_XL35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24714; ANKHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197153 CVCL_XL34 HAP1 ANKHD1 (-) 1 cancer cell line human CVCL_XL34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24714; ANKHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197154 CVCL_XL39 HAP1 APOE (-) 2 cancer cell line human CVCL_XL39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 613; APOE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197155 CVCL_XL38 HAP1 APEX1 (-) 2 cancer cell line human CVCL_XL38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 587; APEX1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197156 CVCL_P381 GM19648 transformed cell line human CVCL_P381 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197157 CVCL_P380 GM19475 transformed cell line human CVCL_P380 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197158 CVCL_XL22 HAP1 AKT1S1 (-) 4 cancer cell line human CVCL_XL22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28426; AKT1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197159 CVCL_XL21 HAP1 AKT1S1 (-) 3 cancer cell line human CVCL_XL21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28426; AKT1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197160 CVCL_XL20 HAP1 AKT1S1 (-) 2 cancer cell line human CVCL_XL20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28426; AKT1S1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197161 CVCL_P379 GM19474 transformed cell line human CVCL_P379 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197162 CVCL_P378 GM19473 transformed cell line human CVCL_P378 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197163 CVCL_XL26 HAP1 ALDH9A1 (-) 2 cancer cell line human CVCL_XL26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 412; ALDH9A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197164 CVCL_P377 GM19472 transformed cell line human CVCL_P377 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197165 CVCL_XL25 HAP1 ALDH3A2 (-) 2 cancer cell line human CVCL_XL25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 403; ALDH3A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197166 CVCL_P376 GM19471 transformed cell line human CVCL_P376 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197167 CVCL_XL24 HAP1 ALDH18A1 (-) cancer cell line human CVCL_XL24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9722; ALDH18A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197168 CVCL_P375 GM19470 transformed cell line human CVCL_P375 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197169 CVCL_XL23 HAP1 ALCAM (-) 2 cancer cell line human CVCL_XL23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 400; ALCAM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197170 CVCL_P374 GM19469 transformed cell line human CVCL_P374 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197171 CVCL_P373 GM19468 transformed cell line human CVCL_P373 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197172 CVCL_XL29 HAP1 ALKBH6 (-) cancer cell line human CVCL_XL29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28243; ALKBH6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197173 CVCL_P372 GM19467 transformed cell line human CVCL_P372 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197174 CVCL_XL28 HAP1 ALKBH3 (-) 2 cancer cell line human CVCL_XL28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30141; ALKBH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197175 CVCL_P371 GM19466 transformed cell line human CVCL_P371 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197176 CVCL_XL27 HAP1 ALKBH1 (-) 2 cancer cell line human CVCL_XL27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17911; ALKBH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197177 CVCL_P392 GM19664 transformed cell line human CVCL_P392 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197178 CVCL_P391 GM19663 transformed cell line human CVCL_P391 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197179 CVCL_P390 GM19661 transformed cell line human CVCL_P390 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197180 CVCL_XL09 HAP1 ADIPOR1 (-) 2 cancer cell line human CVCL_XL09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24040; ADIPOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197181 CVCL_XL11 HAP1 ADIPOR1 (-) 4 cancer cell line human CVCL_XL11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24040; ADIPOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197182 CVCL_XL10 HAP1 ADIPOR1 (-) 3 cancer cell line human CVCL_XL10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24040; ADIPOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197183 CVCL_P389 GM19660 transformed cell line human CVCL_P389 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197184 CVCL_XL15 HAP1 AJUBA (-) cancer cell line human CVCL_XL15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20250; AJUBA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197185 CVCL_P388 GM19658 transformed cell line human CVCL_P388 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197186 CVCL_XL14 HAP1 AHSA1 (-) cancer cell line human CVCL_XL14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1189; AHSA1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197187 CVCL_P387 GM19657 transformed cell line human CVCL_P387 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197188 CVCL_XL13 HAP1 AGER (-) 2 cancer cell line human CVCL_XL13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 320; AGER; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197189 CVCL_P386 GM19655 transformed cell line human CVCL_P386 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197190 CVCL_XL12 HAP1 ADIPOR2 (-) 2 cancer cell line human CVCL_XL12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24041; ADIPOR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197191 CVCL_P385 GM19654 transformed cell line human CVCL_P385 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197192 CVCL_XL19 HAP1 AKR1B1 (-) 4 cancer cell line human CVCL_XL19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197193 CVCL_P384 GM19652 transformed cell line human CVCL_P384 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197194 CVCL_XL18 HAP1 AKR1B1 (-) 3 cancer cell line human CVCL_XL18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197195 CVCL_P383 GM19651 transformed cell line human CVCL_P383 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197196 CVCL_XL17 HAP1 AKR1B1 (-) 2 cancer cell line human CVCL_XL17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 381; AKR1B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197197 CVCL_P382 GM19649 transformed cell line human CVCL_P382 CL:0000010 Population: Mexican ancestry in Los Angeles, USA (MXL); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197198 CVCL_XL16 HAP1 AKAP8 (-) cancer cell line human CVCL_XL16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 378; AKAP8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197199 CVCL_XL00 HAP1 ACSS2 (-) 2 cancer cell line human CVCL_XL00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15814; ACSS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197200 CVCL_P359 GM19448 transformed cell line human CVCL_P359 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197201 CVCL_P358 GM19446 transformed cell line human CVCL_P358 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197202 CVCL_P357 GM19445 transformed cell line human CVCL_P357 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197203 CVCL_P356 GM19444 transformed cell line human CVCL_P356 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197204 CVCL_XL04 HAP1 ADCY3 (-) 2 cancer cell line human CVCL_XL04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 234; ADCY3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197205 CVCL_P355 GM19443 transformed cell line human CVCL_P355 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197206 CVCL_P354 GM19441 transformed cell line human CVCL_P354 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197207 CVCL_XL02 HAP1 ACTN4 (-) 2 cancer cell line human CVCL_XL02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 166; ACTN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197208 CVCL_P353 GM19440 transformed cell line human CVCL_P353 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197209 CVCL_XL01 HAP1 ACTN1 (-) 2 cancer cell line human CVCL_XL01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 163; ACTN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197210 CVCL_P352 GM19439 transformed cell line human CVCL_P352 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197211 CVCL_XL08 HAP1 ADH5 (-) cancer cell line human CVCL_XL08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 253; ADH5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197212 CVCL_P351 GM19438 transformed cell line human CVCL_P351 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197213 CVCL_XL07 HAP1 ADCY9 (-) 2 cancer cell line human CVCL_XL07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 240; ADCY9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197214 CVCL_P350 GM19437 transformed cell line human CVCL_P350 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197215 CVCL_XL06 HAP1 ADCY7 (-) 2 cancer cell line human CVCL_XL06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 238; ADCY7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197216 CVCL_XL05 HAP1 ADCY6 (-) 2 cancer cell line human CVCL_XL05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 237; ADCY6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197217 CVCL_P370 GM19463 transformed cell line human CVCL_P370 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197218 CVCL_P369 GM19462 transformed cell line human CVCL_P369 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197219 CVCL_P368 GM19461 transformed cell line human CVCL_P368 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197220 CVCL_P367 GM19457 transformed cell line human CVCL_P367 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197221 CVCL_P366 GM19456 transformed cell line human CVCL_P366 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Doubling time: Slow growth (Coriell) Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197222 CVCL_P365 GM19455 transformed cell line human CVCL_P365 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197223 CVCL_P364 GM19454 transformed cell line human CVCL_P364 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197224 CVCL_P363 GM19453 transformed cell line human CVCL_P363 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197225 CVCL_P362 GM19452 transformed cell line human CVCL_P362 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197226 CVCL_P361 GM19451 transformed cell line human CVCL_P361 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197227 CVCL_P360 GM19449 transformed cell line human CVCL_P360 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197228 CVCL_5F98 AH129-4 embryonic stem cell house mouse CVCL_5F98 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21197229 CVCL_5F97 MPH2 embryonic stem cell CVCL_5F97 CL:0000010 Female Group: Non-human primate cell line; Group: Haploid karyotype cell line. 21197230 CVCL_5F96 MPH1 embryonic stem cell CVCL_5F96 CL:0000010 Female Group: Non-human primate cell line; Group: Haploid karyotype cell line. 21197231 CVCL_5F95 RAH-9 embryonic stem cell Norway rat CVCL_5F95 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197232 CVCL_5F99 AH129-5 embryonic stem cell house mouse CVCL_5F99 CL:0000010 Breed/subspecies: 129/Sv. Female Group: Haploid karyotype cell line 21197233 CVCL_5F90 RAH-3 embryonic stem cell Norway rat CVCL_5F90 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197234 CVCL_5F94 RAH-8 embryonic stem cell Norway rat CVCL_5F94 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197235 CVCL_5F93 RAH-7 embryonic stem cell Norway rat CVCL_5F93 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197236 CVCL_5F92 RAH-6 embryonic stem cell Norway rat CVCL_5F92 CL:0000010 Breed/subspecies: Dark Agouti. Omics: Transcriptome analysis by microarray Female Group: Haploid karyotype cell line 21197237 CVCL_5F91 RAH-4 embryonic stem cell Norway rat CVCL_5F91 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197238 CVCL_5F76 AcA201 conditionally immortalized cell line house mouse CVCL_5F76 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Doubling time: 24-30 hours, at 33 Celsius (PubMed=11784300) 21197239 CVCL_5F75 AcA101 conditionally immortalized cell line house mouse CVCL_5F75 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Doubling time: 24-30 hours, at 33 Celsius (PubMed=11784300) 21197240 CVCL_5F74 Y6 cancer cell line house mouse CVCL_5F74 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male Doubling time: 76.8 hours (PubMed=4311571) 21197241 CVCL_5F73 OS3 [Mouse adrenocortical tumor] cancer cell line house mouse CVCL_5F73 CL:0000010 Derived from sampling site: Adrenal gland; Breed/subspecies: LAF1. Male 21197242 CVCL_5F79 SD-Tg.EC1 embryonic stem cell Norway rat CVCL_5F79 CL:0000010 Breed/subspecies: Sprague Dawley. Male 21197243 CVCL_5F78 SVG-TH transformed cell line human CVCL_5F78 CL:0000010 Transfected with: HGNC; 11782; TH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain Cell type=Astrocyte.. Male 21197244 CVCL_5F77 AcE60 conditionally immortalized cell line house mouse CVCL_5F77 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Adrenal gland; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified Doubling time: 24-30 hours, at 33 Celsius (PubMed=11784300) 21197245 CVCL_5F71 293GP/LZRNL transformed cell line human CVCL_5F71 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21197246 CVCL_5F70 293GP/bsr transformed cell line human CVCL_5F70 CL:0000010 Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P03355; Moloney murine leukemia virus (MoMLV) gag-pol Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Retrovirus packaging cell line 21197247 CVCL_5F87 DA5-3 embryonic stem cell Norway rat CVCL_5F87 CL:0000010 Breed/subspecies: Dark Agouti. Omics: Transcriptome analysis by microarray Female 21197248 CVCL_5F86 DA1-1 embryonic stem cell Norway rat CVCL_5F86 CL:0000010 Breed/subspecies: Dark Agouti. Unspecified 21197249 CVCL_5F85 F344-Tg.EC4011 embryonic stem cell Norway rat CVCL_5F85 CL:0000010 Breed/subspecies: Fischer 344. Male 21197250 CVCL_5F84 SD-Tg.EC12 embryonic stem cell Norway rat CVCL_5F84 CL:0000010 Breed/subspecies: Sprague Dawley. Female 21197251 CVCL_5F89 RAH-2 embryonic stem cell Norway rat CVCL_5F89 CL:0000010 Breed/subspecies: Dark Agouti. Omics: Transcriptome analysis by microarray Female Group: Haploid karyotype cell line 21197252 CVCL_5F88 RAH-1 embryonic stem cell Norway rat CVCL_5F88 CL:0000010 Breed/subspecies: Dark Agouti. Female Group: Haploid karyotype cell line 21197253 CVCL_5F83 SD-Tg.EC11 embryonic stem cell Norway rat CVCL_5F83 CL:0000010 Breed/subspecies: Sprague Dawley. Female 21197254 CVCL_5F82 SD-Tg.EC8 embryonic stem cell Norway rat CVCL_5F82 CL:0000010 Breed/subspecies: Sprague Dawley. Male 21197255 CVCL_5F81 SD-Tg.EC7 embryonic stem cell Norway rat CVCL_5F81 CL:0000010 Breed/subspecies: Sprague Dawley. Female 21197256 CVCL_5F80 SD-Tg.EC2 embryonic stem cell Norway rat CVCL_5F80 CL:0000010 Breed/subspecies: Sprague Dawley. Female 21197257 CVCL_5F54 GM13049 transformed cell line human CVCL_5F54 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329110/1329210/1329310/1329411 21197258 CVCL_5F53 GM13048 transformed cell line human CVCL_5F53 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329110/1329210/1329310/1329411 21197259 CVCL_5F52 GM13047 transformed cell line human CVCL_5F52 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329110/1329210/1329310/1329411 21197260 CVCL_5F51 GM13046 transformed cell line human CVCL_5F51 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329213/1329410 21197261 CVCL_5F58 GM13053 transformed cell line human CVCL_5F58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329302 21197262 CVCL_5F57 GM13052 transformed cell line human CVCL_5F57 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329111/1329211/1329311/1329412 21197263 CVCL_5F56 GM13051 transformed cell line human CVCL_5F56 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329111/1329211/1329311/1329412 21197264 CVCL_5F55 GM13050 transformed cell line human CVCL_5F55 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329111/1329211/1329311/1329412 21197265 CVCL_5F59 GM13054 transformed cell line human CVCL_5F59 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132804/1328102 21197266 CVCL_5F50 GM13045 transformed cell line human CVCL_5F50 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 1329212/1329409 21197267 CVCL_5F65 GM13355 transformed cell line human CVCL_5F65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135603 21197268 CVCL_5F64 GM13133 transformed cell line human CVCL_5F64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135612 21197269 CVCL_5F63 GM13132 transformed cell line human CVCL_5F63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135713 21197270 CVCL_5F62 GM13131 transformed cell line human CVCL_5F62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 135710 21197271 CVCL_5F69 HetA spontaneously immortalized cell line zebrafish CVCL_5F69 CL:0000010 Unspecified Group: Fish cell line. 21197272 CVCL_5F68 hTERT-RPE1 mRuby-APC15 telomerase immortalized cell line human CVCL_5F68 CL:0000010 Transfected with: HGNC; 24531; ANAPC15; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q8ISF8; Entacmaea quadricolor eqFP611 (modified to produce the bright RFP mRuby2) Derived from sampling site: Eye; retina; retinal pigment epithelium. Female Characteristics: Tetracycline-inducible expression of APC15-IRES2-mRuby 21197273 CVCL_5F67 HEK293A/GFP-WIPI1 transformed cell line human CVCL_5F67 CL:0000010 Transfected with: HGNC; 25471; WIPI1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21197274 CVCL_5F66 A375P-beta6/puro cancer cell line human CVCL_5F66 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6161; ITGB6; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin. Female 21197275 CVCL_XL91 HAP1 B4GALT5 (-) cancer cell line human CVCL_XL91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 928; B4GALT5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197276 CVCL_XL90 HAP1 B4GALNT2 (-) 3 cancer cell line human CVCL_XL90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24136; B4GALNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197277 CVCL_XL95 HAP1 BAG3 (-) 2 cancer cell line human CVCL_XL95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 939; BAG3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197278 CVCL_XL94 HAP1 BAD (-) 2 cancer cell line human CVCL_XL94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 936; BAD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197279 CVCL_XL93 HAP1 BACH1 (-) 2 cancer cell line human CVCL_XL93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 935; BACH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197280 CVCL_XL92 HAP1 BACE1 (-) 2 cancer cell line human CVCL_XL92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 933; BACE1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197281 CVCL_XL99 HAP1 BCKDHA (-) 1 cancer cell line human CVCL_XL99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 986; BCKDHA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197282 CVCL_XL98 HAP1 BCDIN3D (-) cancer cell line human CVCL_XL98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27050; BCDIN3D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197283 CVCL_XL97 HAP1 BCAT2 (-) cancer cell line human CVCL_XL97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 977; BCAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197284 CVCL_XL96 HAP1 BAK1 (-) 2 cancer cell line human CVCL_XL96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197285 CVCL_5F61 GM13130 transformed cell line human CVCL_5F61 HLA typing: A*03:01,03:01; B*35:01,56:01; C*01:02,04:01; DPA1*01:03,02:01:01; DPB1*04:02,11:01:01; DQA1*01:01,04:01; DQB1*04:02,05:01:01; DRB1*01:01,08:01 (IPD-IMGT/HLA=25834) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Histocompatibility Workshop cell lines; Registration: CEPH Families Reference Panel; 133205 21197286 CVCL_5F60 GM13060 transformed cell line human CVCL_5F60 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 134415/137509 21197287 CVCL_5F32 GM12923 transformed cell line human CVCL_5F32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158213 21197288 CVCL_5F31 GM12922 transformed cell line human CVCL_5F31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158212 21197289 CVCL_5F30 GM12921 transformed cell line human CVCL_5F30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158211 21197290 CVCL_5F36 GM12971 transformed cell line human CVCL_5F36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142704 21197291 CVCL_5F35 GM12969 transformed cell line human CVCL_5F35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142702 21197292 CVCL_5F34 GM12968 transformed cell line human CVCL_5F34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142701 21197293 CVCL_5F33 GM12924 transformed cell line human CVCL_5F33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 158214 21197294 CVCL_5F39 GM12974 transformed cell line human CVCL_5F39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142707 21197295 CVCL_5F38 GM12973 transformed cell line human CVCL_5F38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM12973; probable Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142706 21197296 CVCL_5F37 GM12972 transformed cell line human CVCL_5F37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142705 21197297 CVCL_XL80 HAP1 ATP9B (-) 3 cancer cell line human CVCL_XL80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13541; ATP9B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197298 CVCL_XL84 HAP1 AXIN2 (-) 2 cancer cell line human CVCL_XL84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 904; AXIN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197299 CVCL_XL83 HAP1 AUNIP (-) cancer cell line human CVCL_XL83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28363; AUNIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197300 CVCL_XL82 HAP1 ATRX (-) 3 cancer cell line human CVCL_XL82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197301 CVCL_XL81 HAP1 ATRX (-) 2 cancer cell line human CVCL_XL81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 886; ATRX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197302 CVCL_XL88 HAP1 B4GALNT1 (-) cancer cell line human CVCL_XL88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4117; B4GALNT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197303 CVCL_XL87 HAP1 B3GNT4 (-) 2 cancer cell line human CVCL_XL87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15683; B3GNT4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197304 CVCL_XL86 HAP1 B2M (-) 2 cancer cell line human CVCL_XL86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 914; B2M; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197305 CVCL_XL85 HAP1 AXIN2 (-) 3 cancer cell line human CVCL_XL85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 904; AXIN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197306 CVCL_XL89 HAP1 B4GALNT2 (-) 2 cancer cell line human CVCL_XL89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24136; B4GALNT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197307 CVCL_5F43 GM12978 transformed cell line human CVCL_5F43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142711 21197308 CVCL_5F42 GM12977 transformed cell line human CVCL_5F42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142710 21197309 CVCL_5F41 GM12976 transformed cell line human CVCL_5F41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142709 21197310 CVCL_5F40 GM12975 transformed cell line human CVCL_5F40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142708 21197311 CVCL_5F47 GM13042 transformed cell line human CVCL_5F47 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132801/1328108/1329312 21197312 CVCL_5F46 GM13041 transformed cell line human CVCL_5F46 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132801/1328108/1329312 21197313 CVCL_5F45 GM12980 transformed cell line human CVCL_5F45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142713 21197314 CVCL_5F44 GM12979 transformed cell line human CVCL_5F44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 142712 21197315 CVCL_5F49 GM13044 transformed cell line human CVCL_5F49 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132802/1328109/1329313 21197316 CVCL_5F48 GM13043 transformed cell line human CVCL_5F48 CL:0000010 Population: Caucasian; Utah residents with ancestry from Northern and Western Europe; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 132802/1328109/1329313 21197317 CVCL_XL73 HAP1 ATP5I (-) 4 cancer cell line human CVCL_XL73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 846; ATP5ME; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197318 CVCL_XL72 HAP1 ATP1A3 (-) 4 cancer cell line human CVCL_XL72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 801; ATP1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197319 CVCL_XL71 HAP1 ATP1A3 (-) 3 cancer cell line human CVCL_XL71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 801; ATP1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197320 CVCL_XL70 HAP1 ATP1A3 (-) 2 cancer cell line human CVCL_XL70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 801; ATP1A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197321 CVCL_XL77 HAP1 ATP7B (-) cancer cell line human CVCL_XL77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 870; ATP7B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197322 CVCL_XL76 HAP1 ATP5L (-) 3 cancer cell line human CVCL_XL76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14247; ATP5MG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197323 CVCL_XL75 HAP1 ATP5L (-) 2 cancer cell line human CVCL_XL75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14247; ATP5MG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197324 CVCL_XL74 HAP1 ATP5L (-) 1 cancer cell line human CVCL_XL74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14247; ATP5MG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197325 CVCL_XL79 HAP1 ATP9B (-) 2 cancer cell line human CVCL_XL79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13541; ATP9B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197326 CVCL_XL78 HAP1 ATP9A (-) 2 cancer cell line human CVCL_XL78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13540; ATP9A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197327 CVCL_G928 BY00661 transformed cell line human CVCL_G928 HLA typing: A*03:ECAM,68:CAKR; B*40:06,51:CVAE; C*15:BJ; DRB1*04:05:10,04:07:01 (IPD-IMGT/HLA=20663) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197328 CVCL_FX28 ND04268 transformed cell line human CVCL_FX28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197329 CVCL_G927 BY00660 transformed cell line human CVCL_G927 HLA typing: A*03:ECAM,68:CAKR; B*13:02,15:18; C*07:04:04,06:02; DRB1*07:01,08:03:02 (IPD-IMGT/HLA=21464) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197330 CVCL_FX27 ND04227 transformed cell line human CVCL_FX27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197331 CVCL_G926 BY00659 transformed cell line human CVCL_G926 HLA typing: A*24:CWFP,68:CAKR; B*51:CVAE,52:AH; C*12:02:05,16:02; DRB1*01:01:01,04:03:01 (IPD-IMGT/HLA=20665) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197332 CVCL_FX26 ND04217 transformed cell line human CVCL_FX26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197333 CVCL_G925 BY00657 transformed cell line human CVCL_G925 HLA typing: A*24:02:35,31:DUKU; B*07:CVAG,52:AH; C*07:WCP,12:02; DRB1*13:01:01,04:03:01 (IPD-IMGT/HLA=21465) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197334 CVCL_FX25 ND04216 transformed cell line human CVCL_FX25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197335 CVCL_G929 BY00668 transformed cell line human CVCL_G929 HLA typing: A*02:03,24:DZRG; B*18:01:01,18:50; C*07:EMCY,12:DPG; DRB1*09:MV,15:DFZE (IPD-IMGT/HLA=21215) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197336 CVCL_FX29 ND04269 transformed cell line human CVCL_FX29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197337 CVCL_G920 BY00358 transformed cell line human CVCL_G920 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197338 CVCL_FX20 ND04121 transformed cell line human CVCL_FX20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197339 CVCL_G924 BY00656 transformed cell line human CVCL_G924 HLA typing: A*03:76,24:07; B*07:EH,08:XKT; C*07:WCP,15:05; DRB1*03:01:01,15:01:01 (IPD-IMGT/HLA=20667) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197340 CVCL_FX24 ND04182 transformed cell line human CVCL_FX24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197341 CVCL_G923 BY00654 transformed cell line human CVCL_G923 HLA typing: A*24:140,31:DUKU; B*15:25,51:CVAE; C*07:26,14:02:01; DRB1*10:01:01,15:02:01 (IPD-IMGT/HLA=21188) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197342 CVCL_FX23 ND04140 transformed cell line human CVCL_FX23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197343 CVCL_G922 BY00653 transformed cell line human CVCL_G922 HLA typing: A*01:CNJK,26:01:14; B*40:AZAY,52:AH; C*03:04,12:02; DRB1*14:07:01,14:04 (IPD-IMGT/HLA=21463) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197344 CVCL_FX22 ND04135 transformed cell line human CVCL_FX22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197345 CVCL_G921 BY00448 transformed cell line human CVCL_G921 HLA typing: A*24:CWFP,31:DUKU; B*15:DKGD,35:102; C*01:02,01:02+; DRB1*16:02:01,04:07:01 (IPD-IMGT/HLA=20707) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197346 CVCL_FX21 ND04122 transformed cell line human CVCL_FX21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197347 CVCL_G939 BY00327 transformed cell line human CVCL_G939 HLA typing: A*02:ANDC,11:XSH; B*15:AKZB,56:MS; DRB1*11:69,04:01:01 (IPD-IMGT/HLA=15642) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197348 CVCL_FX39 ND04540 transformed cell line human CVCL_FX39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197349 CVCL_G938 BY00326 transformed cell line human CVCL_G938 HLA typing: A*01:CNJK,33:19; B*35:BJGU,57:AG; DRB1*01:EW,07:APA (IPD-IMGT/HLA=15641) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197350 CVCL_FX38 ND04511 transformed cell line human CVCL_FX38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197351 CVCL_G937 BY00325 transformed cell line human CVCL_G937 HLA typing: A*03:CVAB,11:34; B*07:ARKU,40:JMM; DRB1*01:EW,13:APWN (IPD-IMGT/HLA=15640) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197352 CVCL_FX37 ND04494 transformed cell line human CVCL_FX37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197353 CVCL_G936 BY00324 transformed cell line human CVCL_G936 HLA typing: A*01:CRY,02:GNF; B*18:RRG,44:63; DRB1*03:CVT,14:JGS (IPD-IMGT/HLA=15604) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197354 CVCL_FX36 ND04439 transformed cell line human CVCL_FX36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197355 CVCL_G931 BY00674 transformed cell line human CVCL_G931 HLA typing: A*68:50,02:DFKP; B*15:17,73:01; DRB1*04:05,13:02 (IPD-IMGT/HLA=21213) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197356 CVCL_FX31 ND04386 transformed cell line human CVCL_FX31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197357 CVCL_G930 BY00669 transformed cell line human CVCL_G930 HLA typing: A*02:CNDW,02:BDDA; B*15:DAFZ,35:DHXM; C*03:86,04:FEAS; DRB1*09:01,11:01 (IPD-IMGT/HLA=21208) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197358 CVCL_FX30 ND04332 transformed cell line human CVCL_FX30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197359 CVCL_G935 BY00323 transformed cell line human CVCL_G935 HLA typing: A*24:TYW,32:AC; B*44:62,40:AZAY; DRB1*11:01,04:01 (IPD-IMGT/HLA=15603) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197360 CVCL_FX35 ND04438 transformed cell line human CVCL_FX35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197361 CVCL_G934 BY00322 transformed cell line human CVCL_G934 HLA typing: A*02:VE,33:DWH; B*44:03:02,44:64; DRB1*07:SAF (IPD-IMGT/HLA=15605) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197362 CVCL_FX34 ND04432 transformed cell line human CVCL_FX34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197363 CVCL_G933 BY00741 transformed cell line human CVCL_G933 HLA typing: A*24:APEC,24:CNFP; B*40:JMM,54:AB; DRB1*15:01:01:01/02,14:100 (IPD-IMGT/HLA=22261) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197364 CVCL_FX33 ND04405 transformed cell line human CVCL_FX33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197365 CVCL_G932 BY00676 transformed cell line human CVCL_G932 HLA typing: A*02:CMXA,24:CPDZ; B*15:20,18:50; DRB1*03:ATHX,04:11 (IPD-IMGT/HLA=21377) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197366 CVCL_FX32 ND04387 transformed cell line human CVCL_FX32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197367 CVCL_G906 BY00312 transformed cell line human CVCL_G906 HLA typing: A*02:AZGG,11:BDFZ; B*44:03:02,52:13; DRB1*04:03 (IPD-IMGT/HLA=15543) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197368 CVCL_FX06 ND03747 transformed cell line human CVCL_FX06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197369 CVCL_G905 BY00310 transformed cell line human CVCL_G905 HLA typing: A*24:APTB,33:03:01; B*40:06:01,58:18; DRB1*03:UKV,13:UKW (IPD-IMGT/HLA=15542) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197370 CVCL_FX05 ND03721 transformed cell line human CVCL_FX05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197371 CVCL_G904 BY00309 transformed cell line human CVCL_G904 HLA typing: A*24:BZAZ,26:BYVK; B*08:01:01/08:19N,13:22; DRB1*13:01,15:01 (IPD-IMGT/HLA=15541) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197372 CVCL_FX04 ND03720 transformed cell line human CVCL_FX04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197373 CVCL_G903 BY00306 transformed cell line human CVCL_G903 HLA typing: A*02:06:01,68:FKZ; B*15:15,39:01:05; DRB1*08:02,14:06 (IPD-IMGT/HLA=15537) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197374 CVCL_FX03 ND03699 transformed cell line human CVCL_FX03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197375 CVCL_G909 BY00315 transformed cell line human CVCL_G909 HLA typing: A*02:BRHJ,30:02; B*07:CZZS,57:17; DRB1*15:03,13:02 (IPD-IMGT/HLA=15547) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197376 CVCL_FX09 ND03763 transformed cell line human CVCL_FX09 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197377 CVCL_G908 BY00314 transformed cell line human CVCL_G908 HLA typing: A*01:CRY,02:BRHJ; B*08:01:01/08:19N,15:147; DRB1*03:01,04:01 (IPD-IMGT/HLA=15546) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197378 CVCL_FX08 ND03749 transformed cell line human CVCL_FX08 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197379 CVCL_G907 BY00313 transformed cell line human CVCL_G907 HLA typing: A*03:BZAE,24:BZBB; B*44:03:01/44:03:03,14:09; C*04:WGY,08:BE; DRB1*15:03,12:CVT (IPD-IMGT/HLA=15545) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197380 CVCL_FX07 ND03748 transformed cell line human CVCL_FX07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197381 CVCL_G902 BY00305 transformed cell line human CVCL_G902 HLA typing: A*01:YAG,02:ANGR; B*57:01:01,51:56; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=15536) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197382 CVCL_FX02 ND03675 transformed cell line human CVCL_FX02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197383 CVCL_G901 BY00304 transformed cell line human CVCL_G901 HLA typing: A*31:01,68:01; B*58:02,40:90; DRB1*04:04,12:AG (IPD-IMGT/HLA=15535) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197384 CVCL_FX01 ND03671 transformed cell line human CVCL_FX01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197385 CVCL_G900 BY00303 transformed cell line human CVCL_G900 HLA typing: A*29:APBA,33:FDX; B*44:03:01/44:03:03,58:17N; DRB1*07:APA,13:02 (IPD-IMGT/HLA=15506) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197386 CVCL_FX00 ND03670 transformed cell line human CVCL_FX00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197387 CVCL_G917 BY00355 transformed cell line human CVCL_G917 HLA typing: A*11:01,30:26; B*07:EH,35:BJGT; DRB1*04:07,14:KNC (IPD-IMGT/HLA=15859) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197388 CVCL_FX17 ND04035 transformed cell line human CVCL_FX17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197389 CVCL_G916 BY00344 transformed cell line human CVCL_G916 HLA typing: A*02:122,23:DFKR; B*15:10,44:ANHY; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=15776) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197390 CVCL_FX16 ND03965 transformed cell line human CVCL_FX16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197391 CVCL_G915 BY00341 transformed cell line human CVCL_G915 HLA typing: A*01:TUS,11:ZPF; B*51:55,08:01:01; DRB1*03:WHX,15:VYF (IPD-IMGT/HLA=15689) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197392 CVCL_FX15 ND03948 transformed cell line human CVCL_FX15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197393 CVCL_G914 BY00330 transformed cell line human CVCL_G914 HLA typing: A*24,31; B*39:06,48; DRB1*04:04,14:72 (IPD-IMGT/HLA=15645) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197394 CVCL_FX14 ND03940 transformed cell line human CVCL_FX14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197395 CVCL_G919 BY00357 transformed cell line human CVCL_G919 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197396 CVCL_FX19 ND04120 transformed cell line human CVCL_FX19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197397 CVCL_G918 BY00356 transformed cell line human CVCL_G918 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197398 CVCL_FX18 ND04099 transformed cell line human CVCL_FX18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197399 CVCL_G913 BY00319 transformed cell line human CVCL_G913 HLA typing: A*02:BYWE,11:BZAM; B*44:03:02,35:91; DRB1*13:01,13:02 (IPD-IMGT/HLA=15551) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197400 CVCL_FX13 ND03916 transformed cell line human CVCL_FX13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197401 CVCL_G912 BY00318 transformed cell line human CVCL_G912 HLA typing: A*11:BMTS,24:BZBD; B*44:03:02,27:43; DRB1*07:01,09:01 (IPD-IMGT/HLA=15550) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197402 CVCL_FX12 ND03823 transformed cell line human CVCL_FX12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197403 CVCL_G911 BY00317 transformed cell line human CVCL_G911 HLA typing: A*11:BDFZ,32:01; B*14:01,55:31; C*03:BPSK,08:02; DRB1*01:01,07:01 (IPD-IMGT/HLA=15549) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197404 CVCL_FX11 ND03818 transformed cell line human CVCL_FX11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197405 CVCL_G910 BY00316 transformed cell line human CVCL_G910 HLA typing: A*02:ANFV,31:AF; B*40:AVGG,35:90; DRB1*04:07,07:APA (IPD-IMGT/HLA=15548) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197406 CVCL_FX10 ND03812 transformed cell line human CVCL_FX10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197407 CVCL_5E99 GM12883 transformed cell line human CVCL_5E99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146307 21197408 CVCL_5E98 GM12882 transformed cell line human CVCL_5E98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146306 21197409 CVCL_5E97 GM12881 transformed cell line human CVCL_5E97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146305 21197410 CVCL_5E96 GM12880 transformed cell line human CVCL_5E96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146304 21197411 CVCL_5E91 GM12860 transformed cell line human CVCL_5E91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140009 21197412 CVCL_5E90 GM12859 transformed cell line human CVCL_5E90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140008 21197413 CVCL_5E95 GM12879 transformed cell line human CVCL_5E95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced; Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Part of: International Genome Sample Resource (1000 genomes project) cell lines; Registration: CEPH Families Reference Panel; 146303 21197414 CVCL_5E94 GM12863 transformed cell line human CVCL_5E94 CL:0000010 Sequence variation: Mutation; HGNC; 2623; CYP2C9; Simple; p.Arg144Cys (c.430C>T) (416C>T); ClinVar=VCV000008409; Zygosity=Heterozygous; Note=CYP2C9*2 allele (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Discontinued: Coriell; GM12863; probable Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140012 21197415 CVCL_5E93 GM12862 transformed cell line human CVCL_5E93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140011 21197416 CVCL_5E92 GM12861 transformed cell line human CVCL_5E92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female Part of: CEPH/Utah pedigree cell line collection; Registration: CEPH Families Reference Panel; 140010 21197417 CVCL_P339 GM19402 transformed cell line human CVCL_P339 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197418 CVCL_P338 GM19401 transformed cell line human CVCL_P338 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197419 CVCL_P337 GM19399 transformed cell line human CVCL_P337 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197420 CVCL_P336 GM19398 transformed cell line human CVCL_P336 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197421 CVCL_P335 GM19397 transformed cell line human CVCL_P335 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197422 CVCL_P334 GM19396 transformed cell line human CVCL_P334 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197423 CVCL_P333 GM19395 transformed cell line human CVCL_P333 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197424 CVCL_P332 GM19394 transformed cell line human CVCL_P332 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197425 CVCL_P331 GM19393 transformed cell line human CVCL_P331 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197426 CVCL_P330 GM19392 transformed cell line human CVCL_P330 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197427 CVCL_P349 GM19436 transformed cell line human CVCL_P349 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197428 CVCL_P348 GM19435 transformed cell line human CVCL_P348 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197429 CVCL_P347 GM19434 transformed cell line human CVCL_P347 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197430 CVCL_P346 GM19432 transformed cell line human CVCL_P346 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197431 CVCL_P345 GM19431 transformed cell line human CVCL_P345 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197432 CVCL_P344 GM19430 transformed cell line human CVCL_P344 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197433 CVCL_P343 GM19429 transformed cell line human CVCL_P343 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Quadruplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Heterozygous (PubMed=33197628) Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197434 CVCL_P342 GM19428 transformed cell line human CVCL_P342 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197435 CVCL_P341 GM19404 transformed cell line human CVCL_P341 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197436 CVCL_P340 GM19403 transformed cell line human CVCL_P340 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197437 CVCL_G986 BY00402 transformed cell line human CVCL_G986 HLA typing: A*02:BYVR,24:BYVG; B*51:65,44:03; DRB1*15:01,11:01 (IPD-IMGT/HLA=15992) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197438 CVCL_FX86 ND05637 transformed cell line human CVCL_FX86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197439 CVCL_G985 BY00401 transformed cell line human CVCL_G985 HLA typing: A*11:BMTS,24:BZBD; B*27:46,39:06:02; C*02:02:02,07:02; DRB1*16:01,08:01 (IPD-IMGT/HLA=15991) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197440 CVCL_FX85 ND05635 transformed cell line human CVCL_FX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197441 CVCL_G984 BY00400 transformed cell line human CVCL_G984 HLA typing: A*02:BYVR,24:BYVG; B*15:155,35:BEZX; DRB1*08:02,09:01 (IPD-IMGT/HLA=15990) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197442 CVCL_FX84 ND05627 transformed cell line human CVCL_FX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197443 CVCL_G983 BY00399 transformed cell line human CVCL_G983 HLA typing: A*02:BRHJ,68:01; B*07:72,44:WRJ; DRB1*12:CVT,15:01:01 (IPD-IMGT/HLA=16008) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197444 CVCL_FX83 ND05610 transformed cell line human CVCL_FX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197445 CVCL_G989 BY00417 transformed cell line human CVCL_G989 HLA typing: A*11,33; B*39:47,15:DFRA; DRB1*08:BMT,15:DKN; DRB5*01:BRG (IPD-IMGT/HLA=16007) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197446 CVCL_FX89 ND05752 transformed cell line human CVCL_FX89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197447 CVCL_G988 BY00416 transformed cell line human CVCL_G988 HLA typing: A*02:ANFV,33:DWH; B*42:01,15:156; DRB1*03:02,07:APA (IPD-IMGT/HLA=16006) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197448 CVCL_FX88 ND05748 transformed cell line human CVCL_FX88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197449 CVCL_G987 BY00414 transformed cell line human CVCL_G987 HLA typing: A*24; B*44:62,07:CZZS; DRB1*15:DEW,11:DJZ; DRB3*02:BMP; DRB5*01:BMK (IPD-IMGT/HLA=16004) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197450 CVCL_FX87 ND05638 transformed cell line human CVCL_FX87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197451 CVCL_P319 GM19377 transformed cell line human CVCL_P319 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197452 CVCL_P318 GM19376 transformed cell line human CVCL_P318 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197453 CVCL_P317 GM19375 transformed cell line human CVCL_P317 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197454 CVCL_G982 BY00398 transformed cell line human CVCL_G982 HLA typing: A*11:BMTS,24:BZBD; B*15:154,35:DNXN; DRB1*13:01,08:01 (IPD-IMGT/HLA=15989) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197455 CVCL_P316 GM19374 transformed cell line human CVCL_P316 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197456 CVCL_FX82 ND05600 transformed cell line human CVCL_FX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197457 CVCL_G981 BY00397 transformed cell line human CVCL_G981 HLA typing: A*02,24; B*46:13:02,35:DNXN; DRB1*04:EUK,08:KAV (IPD-IMGT/HLA=15988) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197458 CVCL_P315 GM19373 transformed cell line human CVCL_P315 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197459 CVCL_FX81 ND05555 transformed cell line human CVCL_FX81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197460 CVCL_G980 BY00396 transformed cell line human CVCL_G980 HLA typing: A*32:AE,33:FDX; B*18:33,14:01; DRB1*07:APA,11:ARAP (IPD-IMGT/HLA=15987) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197461 CVCL_P314 GM19372 transformed cell line human CVCL_P314 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197462 CVCL_FX80 ND05514 transformed cell line human CVCL_FX80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197463 CVCL_P313 GM19371 transformed cell line human CVCL_P313 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197464 CVCL_P312 GM19360 transformed cell line human CVCL_P312 CL:0000010 Sequence variation: Gene amplification; HGNC; 11117; SMN1; Quadruplication; Zygosity=Unspecified (PubMed=33197628); Sequence variation: Gene deletion; HGNC; 11118; SMN2; Zygosity=Homozygous (PubMed=33197628) Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197465 CVCL_P311 GM19359 transformed cell line human CVCL_P311 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197466 CVCL_P310 GM19355 transformed cell line human CVCL_P310 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197467 CVCL_G997 BY00430 transformed cell line human CVCL_G997 HLA typing: A*01; B*08:40,39:06:02; DRB1*03:JZS,08:KAV; DRB3*01:GM (IPD-IMGT/HLA=16060) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197468 CVCL_FX97 ND05859 transformed cell line human CVCL_FX97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197469 CVCL_G996 BY00426 transformed cell line human CVCL_G996 HLA typing: A*03:BZAE,24:BZBB; B*07:CDMS,15:CDKN; DRB1*01:21,09:01:02 (IPD-IMGT/HLA=16042) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197470 CVCL_FX96 ND05837 transformed cell line human CVCL_FX96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197471 CVCL_G995 BY00425 transformed cell line human CVCL_G995 HLA typing: A*33,36; B*53; DRB1*11:72,03:02:01 (IPD-IMGT/HLA=16041) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197472 CVCL_FX95 ND05831 transformed cell line human CVCL_FX95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197473 CVCL_G994 BY00423 transformed cell line human CVCL_G994 HLA typing: A*23:ANXH,36:01; B*07:BMAB,35:BMAC; DRB1*03:41,09:01:02 (IPD-IMGT/HLA=16040) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197474 CVCL_FX94 ND05828 transformed cell line human CVCL_FX94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197475 CVCL_G999 BY00432 transformed cell line human CVCL_G999 HLA typing: A*01:TUS,11:ANXJ; B*15:157,27:EKN; DRB1*13:ARCM,04:AFMZ (IPD-IMGT/HLA=16058) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197476 CVCL_FX99 ND05864 transformed cell line human CVCL_FX99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197477 CVCL_G998 BY00431 transformed cell line human CVCL_G998 HLA typing: A*30,03; B*35:02:01,39:48; DRB1*07:MT,13:KAF; DRB3*02:KBM (IPD-IMGT/HLA=16059) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197478 CVCL_FX98 ND05863 transformed cell line human CVCL_FX98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197479 CVCL_P329 GM19391 transformed cell line human CVCL_P329 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197480 CVCL_P328 GM19390 transformed cell line human CVCL_P328 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197481 CVCL_G993 BY00422 transformed cell line human CVCL_G993 HLA typing: A*01,68; B*08,14; DRB1*03:01,13:88; DRB3*01:GM (IPD-IMGT/HLA=16039) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197482 CVCL_P327 GM19385 transformed cell line human CVCL_P327 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197483 CVCL_FX93 ND05816 transformed cell line human CVCL_FX93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197484 CVCL_G992 BY00420 transformed cell line human CVCL_G992 HLA typing: A*01:TUS,11:ANXJ; B*44:67,08:XKT; C*05,07; DRB1*03:WHX,15:VYF (IPD-IMGT/HLA=16013) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197485 CVCL_P326 GM19384 transformed cell line human CVCL_P326 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197486 CVCL_FX92 ND05799 transformed cell line human CVCL_FX92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197487 CVCL_G991 BY00419 transformed cell line human CVCL_G991 HLA typing: A*01,68; B*35:95,40:AZAY; DRB1*11:04,14:BME; DRB3*02:KBP (IPD-IMGT/HLA=16014) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197488 CVCL_P325 GM19383 transformed cell line human CVCL_P325 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197489 CVCL_FX91 ND05792 transformed cell line human CVCL_FX91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197490 CVCL_G990 BY00418 transformed cell line human CVCL_G990 HLA typing: A*34,24; B*40:95,15:35; DRB1*08:BMT,15:DKN; DRB5*01:BRG (IPD-IMGT/HLA=16015) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197491 CVCL_P324 GM19382 transformed cell line human CVCL_P324 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197492 CVCL_FX90 ND05760 transformed cell line human CVCL_FX90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197493 CVCL_P323 GM19381 transformed cell line human CVCL_P323 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197494 CVCL_P322 GM19380 transformed cell line human CVCL_P322 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197495 CVCL_P321 GM19379 transformed cell line human CVCL_P321 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197496 CVCL_P320 GM19378 transformed cell line human CVCL_P320 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197497 CVCL_G969 BY00378 transformed cell line human CVCL_G969 HLA typing: A*74:AB,30:28; B*50:01,58:02; DRB1*11:ASZR,14:PRK (IPD-IMGT/HLA=15929) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197498 CVCL_FX69 ND05188 transformed cell line human CVCL_FX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197499 CVCL_G964 BY00372 transformed cell line human CVCL_G964 HLA typing: A*31:24,24:CWFP; B*15:KSB,54; C*01:02,15:02; DRB1*04:05,09:01 (IPD-IMGT/HLA=15935) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197500 CVCL_FX64 ND05086 transformed cell line human CVCL_FX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197501 CVCL_G963 BY00371 transformed cell line human CVCL_G963 HLA typing: A*02:DFKP,32:18; B*35:BEZX,40:AZAY; DRB1*13:KNK,14:BZFM (IPD-IMGT/HLA=15937) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197502 CVCL_FX63 ND05007 transformed cell line human CVCL_FX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197503 CVCL_G962 BY00370 transformed cell line human CVCL_G962 HLA typing: A*32:18,24:CWFP; B*08:XKT,27:02; DRB1*03:01,07:01 (IPD-IMGT/HLA=15936) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197504 CVCL_FX62 ND05004 transformed cell line human CVCL_FX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197505 CVCL_G961 BY00368 transformed cell line human CVCL_G961 HLA typing: A*33:BEKE,68:45; B*15:18,52:01; DRB1*15:JST,13:BMD; DRB3*01:MS; DRB5*01:BMK (IPD-IMGT/HLA=15921) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197506 CVCL_FX61 ND04968 transformed cell line human CVCL_FX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197507 CVCL_G968 BY00377 transformed cell line human CVCL_G968 HLA typing: A*11:BDFZ,25:08; B*18:ADSC,35:HNH; DRB1*08:ASET,15:FJH (IPD-IMGT/HLA=15930) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197508 CVCL_FX68 ND05173 transformed cell line human CVCL_FX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197509 CVCL_G967 BY00375 transformed cell line human CVCL_G967 HLA typing: A*01:CNJK,02:153; B*44:ANHY,51:AFJR; DRB1*07:NZC,11:APKF (IPD-IMGT/HLA=15932) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197510 CVCL_FX67 ND05172 transformed cell line human CVCL_FX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197511 CVCL_G966 BY00374 transformed cell line human CVCL_G966 HLA typing: A*03:46,02:DFKP; B*07:EH,58:VE; DRB1*07:01,13:02 (IPD-IMGT/HLA=15933) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197512 CVCL_FX66 ND05116 transformed cell line human CVCL_FX66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197513 CVCL_G965 BY00373 transformed cell line human CVCL_G965 HLA typing: A*01:CNJK,24:97; B*40:DG,52; DRB1*04:YK,04:DJX (IPD-IMGT/HLA=15934) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197514 CVCL_FX65 ND05087 transformed cell line human CVCL_FX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197515 CVCL_G960 BY00367 transformed cell line human CVCL_G960 HLA typing: A*68:CAKR,29:19; B*40:CBSU,44:APAP; DRB1*04:AFRF,15:FJH (IPD-IMGT/HLA=15920) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197516 CVCL_FX60 ND04965 transformed cell line human CVCL_FX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197517 CVCL_G975 BY00390 transformed cell line human CVCL_G975 HLA typing: A*02:06:05,68:46; B*40:ZBH,48:01; DRB1*04:AGCB,14:AMGJ (IPD-IMGT/HLA=15949) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197518 CVCL_FX75 ND05342 transformed cell line human CVCL_FX75 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197519 CVCL_G974 BY00389 transformed cell line human CVCL_G974 HLA typing: A*02:86,02:155; B*39:BMFM,44:03; DRB1*11:02,08:11 (IPD-IMGT/HLA=15948) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197520 CVCL_FX74 ND05277 transformed cell line human CVCL_FX74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197521 CVCL_G973 BY00388 transformed cell line human CVCL_G973 HLA typing: A*68:CAKR,02:154; B*27:PEN,50:01; DRB1*01:EW,07:APA (IPD-IMGT/HLA=15947) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197522 CVCL_FX73 ND05266 transformed cell line human CVCL_FX73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197523 CVCL_G972 BY00387 transformed cell line human CVCL_G972 HLA typing: A*30:02:01,03; B*15:BKVK,51:WBA; DRB1*08:01,11:01 (IPD-IMGT/HLA=15946) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197524 CVCL_FX72 ND05198 transformed cell line human CVCL_FX72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197525 CVCL_G979 BY00395 transformed cell line human CVCL_G979 HLA typing: A*02:BZNT,24:BZKA; B*35:DNXN,07:71; DRB1*08:APPA,15:AK (IPD-IMGT/HLA=15986) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197526 CVCL_FX79 ND05510 transformed cell line human CVCL_FX79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197527 CVCL_G978 BY00394 transformed cell line human CVCL_G978 HLA typing: A*02:BYWF,68:XV; B*53:18,15:10; DRB1*01:02,13:03 (IPD-IMGT/HLA=15984) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197528 CVCL_FX78 ND05456 transformed cell line human CVCL_FX78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197529 CVCL_G977 BY00393 transformed cell line human CVCL_G977 HLA typing: A*23:ANJU,30:01; B*51:64,15:BKNX; DRB1*03:WHX,15:03 (IPD-IMGT/HLA=15983) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197530 CVCL_FX77 ND05402 transformed cell line human CVCL_FX77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197531 CVCL_G976 BY00391 transformed cell line human CVCL_G976 HLA typing: A*26:GAX,02:156; B*38:AF,56:01; DRB1*01:EW,13:APWN (IPD-IMGT/HLA=15951) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197532 CVCL_FX76 ND05357 transformed cell line human CVCL_FX76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197533 CVCL_P309 GM19352 transformed cell line human CVCL_P309 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197534 CVCL_P308 GM19351 transformed cell line human CVCL_P308 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197535 CVCL_P307 GM19350 transformed cell line human CVCL_P307 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197536 CVCL_P306 GM19347 transformed cell line human CVCL_P306 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197537 CVCL_G971 BY00386 transformed cell line human CVCL_G971 HLA typing: A*01:CNJK,01:33; B*51:BVND,57:AC; DRB1*03:UGN,13:FSN (IPD-IMGT/HLA=15945) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197538 CVCL_P305 GM19346 transformed cell line human CVCL_P305 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197539 CVCL_FX71 ND05197 transformed cell line human CVCL_FX71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197540 CVCL_G970 BY00385 transformed cell line human CVCL_G970 HLA typing: A*24:CWFP,11; B*35:HNH,40:06; DRB1*07:APA,13:APWN (IPD-IMGT/HLA=15944) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197541 CVCL_P304 GM19338 transformed cell line human CVCL_P304 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197542 CVCL_FX70 ND05196 transformed cell line human CVCL_FX70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197543 CVCL_P303 GM19334 transformed cell line human CVCL_P303 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197544 CVCL_P302 GM19332 transformed cell line human CVCL_P302 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197545 CVCL_P301 GM19331 transformed cell line human CVCL_P301 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197546 CVCL_P300 GM19328 transformed cell line human CVCL_P300 CL:0000010 Population: African; Luhya in Webuye, Kenya (LWK); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21197547 CVCL_G949 BY00347 transformed cell line human CVCL_G949 HLA typing: A*02:BDCH,24:AZRT; B*39:AFCS,40:ABUC; DRB1*16:02:01,14:83 (IPD-IMGT/HLA=15774) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197548 CVCL_FX49 ND04747 transformed cell line human CVCL_FX49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197549 CVCL_G948 BY00345 transformed cell line human CVCL_G948 HLA typing: A*02:BEJX; B*15:DKGD,18:31; DRB1*15:AK,16:01 (IPD-IMGT/HLA=15777) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197550 CVCL_FX48 ND04746 transformed cell line human CVCL_FX48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197551 CVCL_G947 BY00340 transformed cell line human CVCL_G947 HLA typing: A*02:AJPE,34:BD; B*27:PEN,81:AB; DRB1*04:04,13:85 (IPD-IMGT/HLA=15690) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197552 CVCL_FX47 ND04709 transformed cell line human CVCL_FX47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197553 CVCL_G942 BY00332 transformed cell line human CVCL_G942 HLA typing: A*02:DRPX,02:148; B*40:AZAY,52:AH; DRB1*01:01,14:BCAD (IPD-IMGT/HLA=15679) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197554 CVCL_FX42 ND04617 transformed cell line human CVCL_FX42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197555 CVCL_G941 BY00331 transformed cell line human CVCL_G941 HLA typing: A*30:01:01,24:90N; B*15:03,55:01; DRB1*13:02,04:05 (IPD-IMGT/HLA=15646) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197556 CVCL_FX41 ND04588 transformed cell line human CVCL_FX41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197557 CVCL_G940 BY00328 transformed cell line human CVCL_G940 HLA typing: A*24:APFZ,26:CYK; B*13:01,51:02; DRB1*03:01:01,15:31 (IPD-IMGT/HLA=15643) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197558 CVCL_FX40 ND04570 transformed cell line human CVCL_FX40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197559 CVCL_G946 BY00339 transformed cell line human CVCL_G946 HLA typing: A*30:01,32:AE; B*13:AFB,40:PJA; DRB1*07:01:01,13:86 (IPD-IMGT/HLA=15691) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197560 CVCL_FX46 ND04690 transformed cell line human CVCL_FX46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197561 CVCL_G945 BY00338 transformed cell line human CVCL_G945 HLA typing: A*02:ANGN,03:ANGP; B*35:AWZB,44:AGWY; DRB1*11:01:01,13:84 (IPD-IMGT/HLA=15678) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197562 CVCL_FX45 ND04665 transformed cell line human CVCL_FX45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197563 CVCL_G944 BY00337 transformed cell line human CVCL_G944 HLA typing: A*24:AZSP,33:DWH; B*18:ADSC,41:02; DRB1*13:03:01,13:11:02 (IPD-IMGT/HLA=15677) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197564 CVCL_FX44 ND04661 transformed cell line human CVCL_FX44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197565 CVCL_G943 BY00334 transformed cell line human CVCL_G943 HLA typing: A*02,24; B*35,52; DRB1*14:81,01:03; DRB3*01:MS (IPD-IMGT/HLA=15674) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197566 CVCL_FX43 ND04647 transformed cell line human CVCL_FX43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197567 CVCL_G959 BY00364 transformed cell line human CVCL_G959 HLA typing: A*68:CAKR,24:95; B*07:BVED,39:EM; C*07:02; DRB1*08:02:01,15:01:01 (IPD-IMGT/HLA=15879) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197568 CVCL_FX59 ND04954 transformed cell line human CVCL_FX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197569 CVCL_G958 BY00363 transformed cell line human CVCL_G958 HLA typing: A*02:DFKP,24:95; B*38:01,39:BMFM; DRB1*11:01,11:04 (IPD-IMGT/HLA=15939) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197570 CVCL_FX58 ND04953 transformed cell line human CVCL_FX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197571 CVCL_G953 BY00354 transformed cell line human CVCL_G953 HLA typing: A*03:CTSA,33:21; B*52:01,58:01; DRB1*13:05,13:BMD (IPD-IMGT/HLA=15842) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197572 CVCL_FX53 ND04835 transformed cell line human CVCL_FX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197573 CVCL_G952 BY00352 transformed cell line human CVCL_G952 HLA typing: A*74:01,74:13; B*49,07; DRB1*15:03,07:MT (IPD-IMGT/HLA=15843) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197574 CVCL_FX52 ND04796 transformed cell line human CVCL_FX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197575 CVCL_G951 BY00350 transformed cell line human CVCL_G951 HLA typing: A*26:GAX,24:94; B*35,56; DRB1*04:BK,04:YK (IPD-IMGT/HLA=15836) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197576 CVCL_FX51 ND04795 transformed cell line human CVCL_FX51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197577 CVCL_G950 BY00348 transformed cell line human CVCL_G950 HLA typing: A*23:01,02:152; B*15:03,39; DRB1*01:MV,07:MT (IPD-IMGT/HLA=15837) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197578 CVCL_FX50 ND04757 transformed cell line human CVCL_FX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197579 CVCL_G957 BY00362 transformed cell line human CVCL_G957 HLA typing: A*02:01:22,24:CWFP; B*15:BKVK,15; DRB1*04:01,13:01 (IPD-IMGT/HLA=15878) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197580 CVCL_FX57 ND04940 transformed cell line human CVCL_FX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197581 CVCL_G956 BY00361 transformed cell line human CVCL_G956 HLA typing: A*23:01,68:44; B*42:01:01,53:01:01; C*04:FEAS,17:MN; DRB1*11:US,13:AEK (IPD-IMGT/HLA=15877) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197582 CVCL_FX56 ND04914 transformed cell line human CVCL_FX56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197583 CVCL_G955 BY00359 transformed cell line human CVCL_G955 HLA typing: A*11:39,26:GA; B*27,51; DRB1*15:STF; DRB5*01:BMK,01:KBJ (IPD-IMGT/HLA=15876) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21197584 CVCL_FX55 ND04913 transformed cell line human CVCL_FX55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197585 CVCL_FX54 ND04896 transformed cell line human CVCL_FX54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197586 CVCL_G954 TAC-2 spontaneously immortalized cell line house mouse CVCL_G954 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Namru. Female 21197587 CVCL_GC62 ND09323 transformed cell line human CVCL_GC62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197588 CVCL_GC61 ND09305 transformed cell line human CVCL_GC61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197589 CVCL_GC60 ND09221 transformed cell line human CVCL_GC60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197590 CVCL_GC66 ND09349 transformed cell line human CVCL_GC66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197591 CVCL_GC65 ND09347 transformed cell line human CVCL_GC65 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197592 CVCL_GC64 ND09331 transformed cell line human CVCL_GC64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197593 CVCL_GC63 ND09325 transformed cell line human CVCL_GC63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197594 CVCL_GC59 ND09219 transformed cell line human CVCL_GC59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197595 CVCL_GC58 ND09211 transformed cell line human CVCL_GC58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197596 CVCL_GC57 ND09194 transformed cell line human CVCL_GC57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197597 CVCL_GC56 ND09182 transformed cell line human CVCL_GC56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197598 CVCL_GC73 ND09402 transformed cell line human CVCL_GC73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197599 CVCL_GC72 ND09401 transformed cell line human CVCL_GC72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197600 CVCL_GC71 ND09400 transformed cell line human CVCL_GC71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197601 CVCL_GC70 ND09399 transformed cell line human CVCL_GC70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197602 CVCL_GC77 ND09458 transformed cell line human CVCL_GC77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197603 CVCL_GC76 ND09456 transformed cell line human CVCL_GC76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197604 CVCL_GC75 ND09424 transformed cell line human CVCL_GC75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197605 CVCL_GC74 ND09419 transformed cell line human CVCL_GC74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197606 CVCL_GC69 ND09376 transformed cell line human CVCL_GC69 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197607 CVCL_GC68 ND09363 transformed cell line human CVCL_GC68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197608 CVCL_GC67 ND09353 transformed cell line human CVCL_GC67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197609 CVCL_GC40 ND08533 transformed cell line human CVCL_GC40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197610 CVCL_GC44 ND08573 transformed cell line human CVCL_GC44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197611 CVCL_GC43 ND08572 transformed cell line human CVCL_GC43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197612 CVCL_GC42 ND08560 transformed cell line human CVCL_GC42 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197613 CVCL_GC41 ND08556 transformed cell line human CVCL_GC41 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197614 CVCL_GC37 ND08390 transformed cell line human CVCL_GC37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197615 CVCL_GC36 ND08351 transformed cell line human CVCL_GC36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197616 CVCL_GC35 ND08278 transformed cell line human CVCL_GC35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197617 CVCL_GC34 ND08253 transformed cell line human CVCL_GC34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197618 CVCL_GC39 ND08502 transformed cell line human CVCL_GC39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197619 CVCL_GC38 ND08468 transformed cell line human CVCL_GC38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197620 CVCL_GC51 ND08971 transformed cell line human CVCL_GC51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197621 CVCL_GC50 ND08966 transformed cell line human CVCL_GC50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197622 CVCL_GC55 ND08898 transformed cell line human CVCL_GC55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197623 CVCL_GC54 ND08995 transformed cell line human CVCL_GC54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197624 CVCL_GC53 ND08986 transformed cell line human CVCL_GC53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197625 CVCL_GC52 ND08984 transformed cell line human CVCL_GC52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197626 CVCL_GC48 ND08964 transformed cell line human CVCL_GC48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197627 CVCL_GC47 ND08934 transformed cell line human CVCL_GC47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197628 CVCL_GC46 ND08673 transformed cell line human CVCL_GC46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197629 CVCL_GC45 ND08589 transformed cell line human CVCL_GC45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197630 CVCL_GC49 ND08965 transformed cell line human CVCL_GC49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197631 CVCL_GC22 ND07540 transformed cell line human CVCL_GC22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197632 CVCL_GC21 ND07302 transformed cell line human CVCL_GC21 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197633 CVCL_GC20 ND07114 transformed cell line human CVCL_GC20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197634 CVCL_GC15 ND06668 transformed cell line human CVCL_GC15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197635 CVCL_GC14 ND06501 transformed cell line human CVCL_GC14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197636 CVCL_GC13 ND06433 transformed cell line human CVCL_GC13 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197637 CVCL_GC12 ND06431 transformed cell line human CVCL_GC12 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197638 CVCL_GC19 ND07107 transformed cell line human CVCL_GC19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197639 CVCL_GC18 ND07103 transformed cell line human CVCL_GC18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197640 CVCL_GC17 ND06942 transformed cell line human CVCL_GC17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197641 CVCL_GC16 ND06881 transformed cell line human CVCL_GC16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197642 CVCL_GC33 ND08244 transformed cell line human CVCL_GC33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197643 CVCL_GC32 ND08239 transformed cell line human CVCL_GC32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197644 CVCL_GC31 ND08152 transformed cell line human CVCL_GC31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197645 CVCL_GC30 ND08077 transformed cell line human CVCL_GC30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197646 CVCL_GC26 ND07935 transformed cell line human CVCL_GC26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197647 CVCL_GC25 ND07734 transformed cell line human CVCL_GC25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197648 CVCL_GC24 ND07601 transformed cell line human CVCL_GC24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197649 CVCL_GC23 ND07547 transformed cell line human CVCL_GC23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197650 CVCL_GC29 ND07956 transformed cell line human CVCL_GC29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197651 CVCL_GC28 ND07955 transformed cell line human CVCL_GC28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197652 CVCL_GC27 ND07944 transformed cell line human CVCL_GC27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197653 CVCL_GC00 ND05278 transformed cell line human CVCL_GC00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197654 CVCL_GC11 ND06302 transformed cell line human CVCL_GC11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197655 CVCL_GC10 ND06247 transformed cell line human CVCL_GC10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197656 CVCL_GC09 ND06166 transformed cell line human CVCL_GC09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197657 CVCL_GC04 ND05601 transformed cell line human CVCL_GC04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197658 CVCL_GC03 ND05573 transformed cell line human CVCL_GC03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197659 CVCL_GC02 ND05439 transformed cell line human CVCL_GC02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197660 CVCL_GC01 ND05438 transformed cell line human CVCL_GC01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197661 CVCL_GC08 ND06141 transformed cell line human CVCL_GC08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197662 CVCL_GC07 ND06140 transformed cell line human CVCL_GC07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197663 CVCL_GC06 ND05873 transformed cell line human CVCL_GC06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197664 CVCL_GC05 ND05706 transformed cell line human CVCL_GC05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197665 CVCL_Y713 GM23419 transformed cell line human CVCL_Y713 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Thr178Met (c.533C>T); ClinVar=VCV000097237; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197666 CVCL_XV13 HAP1 WIPI2 (-) 2 cancer cell line human CVCL_XV13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 32225; WIPI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197667 CVCL_Y712 GM23416 transformed cell line human CVCL_Y712 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Asp196Val (c.587A>T); ClinVar=VCV000097259; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was asymptomatic for ornithine carbamoyltransferase deficiency; Derived from sampling site: Peripheral blood. Female 21197668 CVCL_XV12 HAP1 WHSC1 (-) 3 cancer cell line human CVCL_XV12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197669 CVCL_Y711 GM23410 transformed cell line human CVCL_Y711 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg23Ter (c.67C>T); ClinVar=VCV000097292; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197670 CVCL_XV11 SDQLCHi012-A induced pluripotent stem cell human CVCL_XV11 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 5964; IL10RA; Simple; c.188+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=31648101); Sequence variation: Mutation; HGNC; 5964; IL10RA; Simple; p.Arg101Trp (c.301C>T); ClinVar=VCV000039432; Zygosity=Heterozygous (PubMed=31648101) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21197671 CVCL_Y710 GM23390 transformed cell line human CVCL_Y710 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197672 CVCL_XV10 HAP1 WHSC1 (-) 2 cancer cell line human CVCL_XV10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12766; NSD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197673 CVCL_Y717 GM23431 transformed cell line human CVCL_Y717 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Unexplicit; IVS6+1delG; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197674 CVCL_XV17 HAP1 XYLT2 (-) cancer cell line human CVCL_XV17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15517; XYLT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197675 CVCL_Y716 GM23429 transformed cell line human CVCL_Y716 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000097371; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was asymptomatic for ornithine carbamoyltransferase deficiency; Derived from sampling site: Peripheral blood. Female 21197676 CVCL_XV16 HAP1 XKR8 (-) 2 cancer cell line human CVCL_XV16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25508; XKR8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197677 CVCL_Y715 GM23427 transformed cell line human CVCL_Y715 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Unexplicit; Ex5del; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was asymptomatic for ornithine carbamoyltransferase deficiency; Derived from sampling site: Peripheral blood. Female 21197678 CVCL_XV15 HAP1 WWTR1 (-) 2 cancer cell line human CVCL_XV15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24042; WWTR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197679 CVCL_Y714 GM23423 transformed cell line human CVCL_Y714 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197680 CVCL_XV14 HAP1 WWOX (-) 2 cancer cell line human CVCL_XV14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12799; WWOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197681 CVCL_Y719 GM23441 transformed cell line human CVCL_Y719 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Met213Thr (c.638T>C); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197682 CVCL_XV19 HAP1 YTHDF1 (-) 1 cancer cell line human CVCL_XV19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197683 CVCL_Y718 GM23439 transformed cell line human CVCL_Y718 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Gln279Ter (c.835C>T); ClinVar=VCV000097341; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was asymptomatic for ornithine carbamoyltransferase deficiency; Derived from sampling site: Peripheral blood. Female 21197684 CVCL_XV18 HAP1 YTHDC2 (-) cancer cell line human CVCL_XV18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24721; YTHDC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197685 CVCL_Y720 GM23455 transformed cell line human CVCL_Y720 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Pro347Ser (c.1039C>T); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197686 CVCL_XV20 HAP1 YTHDF2 (-) 2 cancer cell line human CVCL_XV20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31675; YTHDF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197687 CVCL_XV02 HAP1 VPS13A (-) 2 cancer cell line human CVCL_XV02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1908; VPS13A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197688 CVCL_Y702 iPM9 induced pluripotent stem cell human CVCL_Y702 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21197689 CVCL_XV01 HAP1 VIMP (-) cancer cell line human CVCL_XV01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30396; SELENOS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197690 CVCL_Y701 iPM2 induced pluripotent stem cell human CVCL_Y701 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21197691 CVCL_XV00 HAP1 VHL (-) cancer cell line human CVCL_XV00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12687; VHL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197692 CVCL_Y700 iPM1 induced pluripotent stem cell human CVCL_Y700 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21197693 CVCL_Y706 GM12604 finite cell line human CVCL_Y706 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Asp175Val (c.524A>T); ClinVar=VCV000097233; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Liver Cell type=Fibroblast.. Female 21197694 CVCL_XV06 HAP1 WDR6 (-) 2 cancer cell line human CVCL_XV06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12758; WDR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197695 CVCL_Y705 GM09040 transformed cell line human CVCL_Y705 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197696 CVCL_XV05 HAP1 WDR45 (-) 1 cancer cell line human CVCL_XV05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28912; WDR45; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197697 CVCL_Y704 GM09039 transformed cell line human CVCL_Y704 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197698 CVCL_XV04 HAP1 WAS (-) 2 cancer cell line human CVCL_XV04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12731; WAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197699 CVCL_Y703 GM06902 finite cell line human CVCL_Y703 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21197700 CVCL_XV03 HAP1 VPS4B (-) cancer cell line human CVCL_XV03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10895; VPS4B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197701 CVCL_Y709 GM23389 transformed cell line human CVCL_Y709 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197702 CVCL_XV09 HAP1 WDR91 (-) 2 cancer cell line human CVCL_XV09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24997; WDR91; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197703 CVCL_Y708 GM23388 transformed cell line human CVCL_Y708 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197704 CVCL_XV08 HAP1 WDR6 (-) 4 cancer cell line human CVCL_XV08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12758; WDR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197705 CVCL_Y707 GM23387 transformed cell line human CVCL_Y707 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197706 CVCL_XV07 HAP1 WDR6 (-) 3 cancer cell line human CVCL_XV07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12758; WDR6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197707 CVCL_GC84 ND09555 transformed cell line human CVCL_GC84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197708 CVCL_GC83 ND09554 transformed cell line human CVCL_GC83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197709 CVCL_GC82 ND09523 transformed cell line human CVCL_GC82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197710 CVCL_GC81 ND09521 transformed cell line human CVCL_GC81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197711 CVCL_GC88 ND09611 transformed cell line human CVCL_GC88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197712 CVCL_GC87 ND09609 transformed cell line human CVCL_GC87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197713 CVCL_GC86 ND09604 transformed cell line human CVCL_GC86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197714 CVCL_GC85 ND09568 transformed cell line human CVCL_GC85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197715 CVCL_GC80 ND09485 transformed cell line human CVCL_GC80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197716 CVCL_GC79 ND09462 transformed cell line human CVCL_GC79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197717 CVCL_GC78 ND09461 transformed cell line human CVCL_GC78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197718 CVCL_GC95 ND09724 transformed cell line human CVCL_GC95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197719 CVCL_GC94 ND09723 transformed cell line human CVCL_GC94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197720 CVCL_GC93 ND09688 transformed cell line human CVCL_GC93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197721 CVCL_GC92 ND09686 transformed cell line human CVCL_GC92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197722 CVCL_GC99 ND09728 transformed cell line human CVCL_GC99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197723 CVCL_GC98 ND09727 transformed cell line human CVCL_GC98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197724 CVCL_GC97 ND09726 transformed cell line human CVCL_GC97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197725 CVCL_GC96 ND09725 transformed cell line human CVCL_GC96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197726 CVCL_GC91 ND09668 transformed cell line human CVCL_GC91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197727 CVCL_GC90 ND09658 transformed cell line human CVCL_GC90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197728 CVCL_GC89 ND09620 transformed cell line human CVCL_GC89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197729 CVCL_XU79 HAP1 TSPAN4 (-) cancer cell line human CVCL_XU79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11859; TSPAN4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197730 CVCL_Y679 Rama 704E spontaneously immortalized cell line Norway rat CVCL_Y679 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21197731 CVCL_XU78 HAP1 TSFM (-) cancer cell line human CVCL_XU78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12367; TSFM; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197732 CVCL_Y678 Rama 704 spontaneously immortalized cell line Norway rat CVCL_Y678 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21197733 CVCL_XU77 HAP1 TRPV6 (-) 3 cancer cell line human CVCL_XU77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14006; TRPV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197734 CVCL_Y677 Rama 25-I4 cancer cell line Norway rat CVCL_Y677 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21197735 CVCL_6031 SK-MEL-29 cancer cell line human CVCL_6031 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-525 21197736 CVCL_6030 SK-MEL-27 cancer cell line human CVCL_6030 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). Female 21197737 CVCL_6035 SK-MEL-36 cancer cell line human CVCL_6035 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197738 CVCL_6034 SK-MEL-35 cancer cell line human CVCL_6034 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197739 CVCL_6033 SK-MEL-33 cancer cell line human CVCL_6033 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp96Metfs*6 (c.286delG); Zygosity=Unspecified (PubMed=8432869) Derived from metastatic site: Axillary lymph node. Male 21197740 CVCL_6032 SK-MEL-32 cancer cell line human CVCL_6032 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Female 21197741 CVCL_6028 SK-MEL-25 cancer cell line human CVCL_6028 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Not specified. Discontinued: CLS; 300336; true Female 21197742 CVCL_6027 SK-MEL-23 cancer cell line human CVCL_6027 HLA typing: A*01,02:01; B*07,08 (PubMed=9670966); HLA typing: A*01:01,02:01; B*08:01,37:04; C*07:01,07:01 (PubMed=26589293) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=10766161; PubMed=15009714) Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq. Female Characteristics: Very highly pigmented 21197743 CVCL_6026 SK-MEL-22 cancer cell line human CVCL_6026 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Male 21197744 CVCL_6025 SK-MEL-19 cancer cell line human CVCL_6025 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=17260012); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=17260012; PubMed=21725359; PubMed=24576830; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn131Lys (c.393C>A); ClinVar=VCV000246429; Zygosity=Unspecified (DepMap) Omics: Array-based CGH; Omics: Deep exome analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Male Characteristics: Pigmented Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21197745 CVCL_6029 SK-MEL-26 cancer cell line human CVCL_6029 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Female Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-546 21197746 CVCL_XU83 HAP1 TXNIP (-) 2 cancer cell line human CVCL_XU83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16952; TXNIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197747 CVCL_Y683 Rama 37E cancer cell line Norway rat CVCL_Y683 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197748 CVCL_XU82 HAP1 TTL (-) cancer cell line human CVCL_XU82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21586; TTL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197749 CVCL_Y682 Rama 712 spontaneously immortalized cell line Norway rat CVCL_Y682 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21197750 CVCL_XU81 HAP1 TTC7A (-) 2 cancer cell line human CVCL_XU81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19750; TTC7A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197751 CVCL_Y681 Rama 711 spontaneously immortalized cell line Norway rat CVCL_Y681 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21197752 CVCL_XU80 HAP1 TTC38 (-) 2 cancer cell line human CVCL_XU80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26082; TTC38; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197753 CVCL_Y680 Rama 710 spontaneously immortalized cell line Norway rat CVCL_Y680 CL:0000010 Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21197754 CVCL_XU87 HAP1 UBE3A (-) 2 cancer cell line human CVCL_XU87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12496; UBE3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197755 CVCL_Y687 Rama 54 cancer cell line Norway rat CVCL_Y687 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197756 CVCL_XU86 HAP1 UBE2V1 (-) 2 cancer cell line human CVCL_XU86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12494; UBE2V1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197757 CVCL_Y686 Rama 53 cancer cell line Norway rat CVCL_Y686 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197758 CVCL_XU85 HAP1 UBE2V1 (-) 1 cancer cell line human CVCL_XU85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12494; UBE2V1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197759 CVCL_Y685 Rama 52 cancer cell line Norway rat CVCL_Y685 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197760 CVCL_XU84 HAP1 UBA6 (-) cancer cell line human CVCL_XU84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25581; UBA6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197761 CVCL_Y684 Rama 50 cancer cell line Norway rat CVCL_Y684 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197762 CVCL_XU69 HAP1 TRAK1 (-) 2 cancer cell line human CVCL_XU69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29947; TRAK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197763 CVCL_Y669 Rama 802 cancer cell line Norway rat CVCL_Y669 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21197764 CVCL_XU68 HAP1 TRA2A (-) 3 cancer cell line human CVCL_XU68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16645; TRA2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197765 CVCL_Y668 Rama 801 cancer cell line Norway rat CVCL_Y668 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21197766 CVCL_XU67 HAP1 TRA2A (-) 2 cancer cell line human CVCL_XU67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16645; TRA2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197767 CVCL_Y667 MT-100M cancer cell line Norway rat CVCL_Y667 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from metastatic site: Ascites; Breed/subspecies: Wistar Furth. Female 21197768 CVCL_XU66 HAP1 TPP1 (-) cancer cell line human CVCL_XU66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2073; TPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197769 CVCL_Y666 MT-100-TC cancer cell line Norway rat CVCL_Y666 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from metastatic site: Ascites; Breed/subspecies: Wistar Furth. Female 21197770 CVCL_6042 SK-MEL-55 cancer cell line human CVCL_6042 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197771 CVCL_6041 SK-MEL-51 cancer cell line human CVCL_6041 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197772 CVCL_6040 SK-MEL-44 cancer cell line human CVCL_6040 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197773 CVCL_6046 SK-MEL-56 cancer cell line human CVCL_6046 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197774 CVCL_6045 SK-MEL-63 cancer cell line human CVCL_6045 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714). 21197775 CVCL_6044 SK-MEL-61 cancer cell line human CVCL_6044 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197776 CVCL_6043 SK-MEL-57 cancer cell line human CVCL_6043 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197777 CVCL_6039 SK-MEL-42 cancer cell line human CVCL_6039 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197778 CVCL_6038 SK-MEL-41 cancer cell line human CVCL_6038 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Male 21197779 CVCL_6037 SK-MEL-40 cancer cell line human CVCL_6037 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Female 21197780 CVCL_6036 SK-MEL-39 cancer cell line human CVCL_6036 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Lys22Gln (c.64A>C); ClinVar=VCV000485487; Zygosity=Unspecified (PubMed=9692547); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys183fs*7 (c.546_547insA); Zygosity=Unspecified (PubMed=9692547; PubMed=10766161). Male 21197781 CVCL_XU72 HAP1 TRIP13 (-) 2 cancer cell line human CVCL_XU72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12307; TRIP13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197782 CVCL_Y672 Rama 805 cancer cell line Norway rat CVCL_Y672 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21197783 CVCL_XU71 HAP1 TRAPPC9 (-) cancer cell line human CVCL_XU71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30832; TRAPPC9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197784 CVCL_Y671 Rama 804 cancer cell line Norway rat CVCL_Y671 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21197785 CVCL_XU70 HAP1 TRAPPC10 (-) cancer cell line human CVCL_XU70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11868; TRAPPC10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197786 CVCL_Y670 Rama 803 cancer cell line Norway rat CVCL_Y670 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Wistar Furth. Female 21197787 CVCL_XU76 HAP1 TRPV6 (-) 2 cancer cell line human CVCL_XU76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14006; TRPV6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197788 CVCL_Y676 Rama 25-I2 cancer cell line Norway rat CVCL_Y676 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21197789 CVCL_XU75 HAP1 TRPV5 (-) cancer cell line human CVCL_XU75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3145; TRPV5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197790 CVCL_Y675 Rama 25-I1 cancer cell line Norway rat CVCL_Y675 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21197791 CVCL_XU74 HAP1 TRIP4 (-) 2 cancer cell line human CVCL_XU74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12310; TRIP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197792 CVCL_Y674 Rama 29 cancer cell line Norway rat CVCL_Y674 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21197793 CVCL_XU73 HAP1 TRIP13 (-) 3 cancer cell line human CVCL_XU73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12307; TRIP13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197794 CVCL_Y673 Rama 25 cancer cell line Norway rat CVCL_Y673 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: Sprague Dawley. Female 21197795 CVCL_XU58 HAP1 TNFRSF12A (-) 5 cancer cell line human CVCL_XU58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18152; TNFRSF12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197796 CVCL_Y658 R-3327-H cancer cell line Norway rat CVCL_Y658 CL:0000010 Miscellaneous: This is not a cell line but a xenograft, it is the parent tumor for many cell lines Breed/subspecies: Copenhagen. Male 21197797 CVCL_Y657 AT3B-2 cancer cell line Norway rat CVCL_Y657 CL:0000010 Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Breed/subspecies: Copenhagen. Male 21197798 CVCL_XU57 HAP1 TNFRSF12A (-) 4 cancer cell line human CVCL_XU57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18152; TNFRSF12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197799 CVCL_Y656 ALVA-38 cancer cell line human CVCL_Y656 CL:0000010 Derived from metastatic site: Lymph node. Male Doubling time: 23 hours (PubMed=8561862) 21197800 CVCL_XU56 HAP1 TNFRSF12A (-) 3 cancer cell line human CVCL_XU56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18152; TNFRSF12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197801 CVCL_XU55 HAP1 TNFRSF12A (-) 2 cancer cell line human CVCL_XU55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18152; TNFRSF12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197802 CVCL_Y655 IP15 transformed cell line human CVCL_Y655 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; cortex Cell type=Mesangial cell.. Male 21197803 CVCL_XU59 HAP1 TNFSF9 (-) 2 cancer cell line human CVCL_XU59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11939; TNFSF9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197804 CVCL_Y659 MAT-LyLu-B-1 cancer cell line Norway rat CVCL_Y659 CL:0000010 Breed/subspecies: Copenhagen. Male 21197805 CVCL_6013 NPC-TW06 cancer cell line human CVCL_6013 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Heterozygous (PubMed=9212825; PubMed=15448710) Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Female 21197806 CVCL_6012 NPC-TW05 cancer cell line human CVCL_6012 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Male 21197807 CVCL_6011 NPC-TW04 cancer cell line human CVCL_6011 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Female 21197808 CVCL_6010 NPC-TW03 cancer cell line human CVCL_6010 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Male Virology: EBV-negative, but was originally EBV-positive Doubling time: ~13-14 hours (PubMed=10744066) 21197809 CVCL_6006 NKC3 factor-dependent cell line house mouse CVCL_6006 CL:0000010 Derived from sampling site: Spleen Cell type=Natural killer cell.; Breed/subspecies: C3H/He. Male Characteristics: IL2 dependent Caution: It is unclear which of the clones described in PubMed=6600260 has been later renamed as NKC3 21197810 CVCL_6005 NIS-G cancer cell line human CVCL_6005 CL:0000010 Population: Caucasian. Unspecified 21197811 CVCL_6004 MML-1 [Human melanoma] cancer cell line human CVCL_6004 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS). Unspecified 21197812 CVCL_6003 MEL-CLS-4 cancer cell line human CVCL_6003 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS). Population: Caucasian Male Characteristics: Established from a xenograft (CLS) 21197813 CVCL_6009 NPC-TW02 cancer cell line human CVCL_6009 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Female Virology: EBV-negative, but was originally EBV-positive Doubling time: 10.8 hours (PubMed=2162997) 21197814 CVCL_6008 NPC-TW01 cancer cell line human CVCL_6008 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Male Virology: EBV-negative, but was originally EBV-positive Doubling time: 10.5 hours (PubMed=2162997) 21197815 CVCL_6007 NPC-BM1 cancer cell line human CVCL_6007 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from metastatic site: Bone marrow. Female Doubling time: 28.5 hours (PubMed=9595045) 21197816 CVCL_XU61 HAP1 TNKS2 (-) 2 cancer cell line human CVCL_XU61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15677; TNKS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197817 CVCL_Y661 R-3327-AT-5 cancer cell line Norway rat CVCL_Y661 CL:0000010 Breed/subspecies: Copenhagen. Male 21197818 CVCL_XU60 HAP1 TNFSF9 (-) 3 cancer cell line human CVCL_XU60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11939; TNFSF9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197819 CVCL_Y660 R-3327-AT-4 cancer cell line Norway rat CVCL_Y660 CL:0000010 Breed/subspecies: Copenhagen. Male 21197820 CVCL_XU65 HAP1 TP73 (-) 3 cancer cell line human CVCL_XU65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197821 CVCL_Y665 MT-W9B cancer cell line Norway rat CVCL_Y665 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar Furth. Female 21197822 CVCL_XU64 HAP1 TP73 (-) 2 cancer cell line human CVCL_XU64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197823 CVCL_Y664 TMT-50 cancer cell line Norway rat CVCL_Y664 CL:0000010 Breed/subspecies: Wistar Furth. Female 21197824 CVCL_XU63 HAP1 TNRC6A (-) 2 cancer cell line human CVCL_XU63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11969; TNRC6A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197825 CVCL_Y663 MeWo LNI 6I cancer cell line human CVCL_Y663 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6877; MAPK3; Simple; p.Pro246Ser (c.736C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Unspecified (from parent cell line) Derived from metastatic site: Lymph node. Male 21197826 CVCL_XU62 HAP1 TNPO1 (-) 4 cancer cell line human CVCL_XU62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6401; TNPO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197827 CVCL_Y662 MIM/8 cancer cell line human CVCL_Y662 CL:0000010 Derived from metastatic site: Inguinal lymph node. Male Characteristics: Pigmented 21197828 CVCL_Y647 hAFDC-iPS-35 induced pluripotent stem cell human CVCL_Y647 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197829 CVCL_XU47 HAP1 TMEM205 (-) 3 cancer cell line human CVCL_XU47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29631; TMEM205; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197830 CVCL_Y646 hAFDC-iPS-19 induced pluripotent stem cell human CVCL_Y646 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197831 CVCL_XU46 HAP1 TMEM205 (-) 2 cancer cell line human CVCL_XU46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29631; TMEM205; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197832 CVCL_Y645 hAFDC-iPS-16 induced pluripotent stem cell human CVCL_Y645 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197833 CVCL_XU45 HAP1 TMEM2 (-) 2 cancer cell line human CVCL_XU45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11869; CEMIP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197834 CVCL_Y644 hAFDC-iPS-15 induced pluripotent stem cell human CVCL_Y644 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197835 CVCL_XU44 HAP1 TMEM189 (-) 1 cancer cell line human CVCL_XU44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16735; PEDS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197836 CVCL_Y649 hAFDC-iPS-4 induced pluripotent stem cell human CVCL_Y649 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Omics: Transcriptome analysis by microarray Female 21197837 CVCL_XU49 HAP1 TMEM205 (-) 5 cancer cell line human CVCL_XU49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29631; TMEM205; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197838 CVCL_Y648 hAFDC-iPS-36 induced pluripotent stem cell human CVCL_Y648 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197839 CVCL_XU48 HAP1 TMEM205 (-) 4 cancer cell line human CVCL_XU48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29631; TMEM205; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197840 CVCL_6020 SK-MEL-10 cancer cell line human CVCL_6020 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 3689; FGFR2; Simple; FGFR2 p.Arg625Gln (c.1874G>A) (p.Arg626Gln, c.1877G>A); Zygosity=Unspecified (PubMed=27533468); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=27533468). 21197841 CVCL_6024 SK-MEL-17 cancer cell line human CVCL_6024 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197842 CVCL_6023 SK-MEL-14 cancer cell line human CVCL_6023 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21197843 CVCL_6022 SK-MEL-13 cancer cell line human CVCL_6022 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=9354451); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=24576830) Omics: Transcriptome analysis by microarray. Male 21197844 CVCL_6021 SK-MEL-12 cancer cell line human CVCL_6021 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197845 CVCL_6017 OCUT-1 cancer cell line human CVCL_6017 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040) Miscellaneous: Cell line has been lost (PubMed=24357248) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Female Doubling time: 34 hours (PubMed=12210034) 21197846 CVCL_6016 NPC-TW09 cancer cell line human CVCL_6016 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Male 21197847 CVCL_6015 NPC-TW08 cancer cell line human CVCL_6015 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pharynx; nasopharynx. Male 21197848 CVCL_6014 NPC-TW07 cancer cell line human CVCL_6014 CL:0000010 Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male 21197849 CVCL_6019 SK-Hep-1-NIS cancer cell line human CVCL_6019 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11040; SLC5A5 Population: Caucasian; Karyotypic information: Has lost chromosome Y (from parent cell line); Derived from metastatic site: Ascites Cell type=Endothelial cell.. Male Problematic cell line: Misclassified Parent cell line (SK-HEP-1) was originally described as originating from an adenocarcinoma of liver and thus classified as hepatocellular carcinoma. Later studies show that it most probably has arisen from endothelial cells. 21197850 CVCL_6018 Shay cancer cell line Norway rat CVCL_6018 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar. Doubling time: 49 hours (PubMed=6585112) 21197851 CVCL_Y650 hAFDC-iPS-7 induced pluripotent stem cell human CVCL_Y650 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Omics: Transcriptome analysis by microarray Female 21197852 CVCL_XU50 HAP1 TMEM30A (-) 2 cancer cell line human CVCL_XU50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16667; TMEM30A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197853 CVCL_XU54 HAP1 TMEM8A (-) 1 cancer cell line human CVCL_XU54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17205; PGAP6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197854 CVCL_Y654 PB-1 [Mouse mast cell] spontaneously immortalized cell line house mouse CVCL_Y654 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mast cell.; Breed/subspecies: DBA/2. Female 21197855 CVCL_Y653 GM10744 transformed cell line human CVCL_Y653 CL:0000010 Sequence variation: Mutation; HGNC; 7459; MT-ND4; Simple; p.Arg340His (m.11778G>A); ClinVar=VCV000009708; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21197856 CVCL_XU53 HAP1 TMEM69 (-) 1 cancer cell line human CVCL_XU53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28035; TMEM69; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197857 CVCL_Y652 GM10742 transformed cell line human CVCL_Y652 CL:0000010 Sequence variation: Mutation; HGNC; 7459; MT-ND4; Simple; p.Arg340His (m.11778G>A); ClinVar=VCV000009708; Zygosity=Unspecified (Coriell; PubMed=16120335) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Mitochondrial genome sequenced Male 21197858 CVCL_XU52 HAP1 TMEM39B (-) 1 cancer cell line human CVCL_XU52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25510; TMEM39B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197859 CVCL_Y651 hAFDC-iPS-9 induced pluripotent stem cell human CVCL_Y651 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197860 CVCL_XU51 HAP1 TMEM38B (-) 2 cancer cell line human CVCL_XU51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25535; TMEM38B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197861 CVCL_XU36 HAP1 TMED9 (-) 3 cancer cell line human CVCL_XU36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24878; TMED9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197862 CVCL_Y636 WB6a embryonic stem cell house mouse CVCL_Y636 CL:0000010 Breed/subspecies: C57BL/6. Male 21197863 CVCL_XU35 HAP1 TMED9 (-) 2 cancer cell line human CVCL_XU35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24878; TMED9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197864 CVCL_Y635 W5 embryonic stem cell house mouse CVCL_Y635 CL:0000010 Breed/subspecies: 129S9/SvEvH. Male 21197865 CVCL_XU34 HAP1 TMED7 (-) 2 cancer cell line human CVCL_XU34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24253; TMED7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197866 CVCL_Y634 W4 [Mouse ESC] embryonic stem cell house mouse CVCL_Y634 CL:0000010 Breed/subspecies: 129S6/SvEvTac. Omics: SNP array analysis Male 21197867 CVCL_XU33 HAP1 TMED5 (-) 2 cancer cell line human CVCL_XU33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24251; TMED5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197868 CVCL_Y633 W3 embryonic stem cell house mouse CVCL_Y633 CL:0000010 Breed/subspecies: 129S9/SvEvH. Male 21197869 CVCL_XU39 HAP1 TMEM126A (-) 2 cancer cell line human CVCL_XU39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25382; TMEM126A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197870 CVCL_Y639 MPI 65-3 embryonic stem cell house mouse CVCL_Y639 CL:0000010 Breed/subspecies: C57BL/6. Male 21197871 CVCL_XU38 HAP1 TMEM106B (-) 3 cancer cell line human CVCL_XU38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22407; TMEM106B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197872 CVCL_Y638 WB6d embryonic stem cell house mouse CVCL_Y638 CL:0000010 Breed/subspecies: C57BL/6. Male 21197873 CVCL_XU37 HAP1 TMEM106B (-) 2 cancer cell line human CVCL_XU37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22407; TMEM106B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197874 CVCL_Y637 WB6b embryonic stem cell house mouse CVCL_Y637 CL:0000010 Breed/subspecies: C57BL/6. Male 21197875 CVCL_Y643 hAFDC-iPS-14 induced pluripotent stem cell human CVCL_Y643 From: Shanghai Institutes for Biological Sciences; Shanghai; China CL:0000010 Derived from sampling site: Amniotic fluid. Female 21197876 CVCL_XU43 HAP1 TMEM175 (-) 3 cancer cell line human CVCL_XU43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28709; TMEM175; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197877 CVCL_XU42 HAP1 TMEM175 (-) 2 cancer cell line human CVCL_XU42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28709; TMEM175; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197878 CVCL_Y642 RC-20 embryonic stem cell human CVCL_Y642 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Unspecified Characteristics: Exists as early seed stock, not yet extensively characterized Not yet available (personal communication of De Sousa P.).. 21197879 CVCL_XU41 HAP1 TMEM126A (-) 4 cancer cell line human CVCL_XU41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25382; TMEM126A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197880 CVCL_Y641 RC-19 embryonic stem cell human CVCL_Y641 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Unspecified Characteristics: Exists as early seed stock, not yet extensively characterized Not yet available (personal communication of De Sousa P.).. Group: Clinical grade hESC cell line 21197881 CVCL_XU40 HAP1 TMEM126A (-) 3 cancer cell line human CVCL_XU40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25382; TMEM126A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197882 CVCL_Y640 RC-18 embryonic stem cell human CVCL_Y640 From: Roslin Cells, Ltd; Roslin; United Kingdom CL:0000010 Unspecified Characteristics: Exists as early seed stock, not yet extensively characterized Not yet available (personal communication of De Sousa P.).. Group: Clinical grade hESC cell line 21197883 CVCL_XU25 HAP1 TIMM8A (-) 3 cancer cell line human CVCL_XU25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11817; TIMM8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197884 CVCL_Y625 SR2 induced pluripotent stem cell human CVCL_Y625 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 21197885 CVCL_Y624 CM-9 embryonic stem cell human CVCL_Y624 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197886 CVCL_XU24 HAP1 TIMM8A (-) 2 cancer cell line human CVCL_XU24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11817; TIMM8A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197887 CVCL_Y623 CM-8 embryonic stem cell human CVCL_Y623 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197888 CVCL_XU23 HAP1 TIMM17B (-) cancer cell line human CVCL_XU23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17310; TIMM17B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197889 CVCL_Y622 CM-5 [Human ESC] embryonic stem cell human CVCL_Y622 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197890 CVCL_XU22 HAP1 TGFBR2 (-) 7 cancer cell line human CVCL_XU22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197891 CVCL_Y629 C2 [Mouse ESC] embryonic stem cell house mouse CVCL_Y629 CL:0000010 Breed/subspecies: C57BL/6NTac. Unspecified 21197892 CVCL_XU29 HAP1 TLR4 (-) 1 cancer cell line human CVCL_XU29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11850; TLR4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197893 CVCL_Y628 BL/6-III embryonic stem cell house mouse CVCL_Y628 CL:0000010 Breed/subspecies: C57BL/6J. Male 21197894 CVCL_XU28 HAP1 TJP1 (-) 2 cancer cell line human CVCL_XU28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11827; TJP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197895 CVCL_Y627 DSV2 induced pluripotent stem cell human CVCL_Y627 CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 21197896 CVCL_XU27 HAP1 TIMP2 (-) 2 cancer cell line human CVCL_XU27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11821; TIMP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197897 CVCL_Y626 DSS3 induced pluripotent stem cell human CVCL_Y626 CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Female 21197898 CVCL_XU26 HAP1 TIMP1 (-) 2 cancer cell line human CVCL_XU26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11820; TIMP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197899 CVCL_6002 MEL-CLS-3 cancer cell line human CVCL_6002 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Skin. Male 21197900 CVCL_6001 MEL-CLS-2 cancer cell line human CVCL_6001 HLA typing: A*02:06:01,20:02:01; B*39:01:01,53:01:01; C*03:04:01,04:01:01; DPB1*02:01,04:01; DQA1*03:03:01,05:01:01; DQB1*02:01:01,03:01:01; DRB1*03:01:01,04:01:01 (CLS=300283) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (CLS) Population: Caucasian; Derived from sampling site: Skin. Male Characteristics: Established from a xenograft (CLS) 21197901 CVCL_6000 ME17 [Mouse liver] transformed cell line house mouse CVCL_6000 CL:0000010 Transformant: Myc; Derived from sampling site: Embryonic liver Cell type=Erythroid lineage cell.; Breed/subspecies: CBA. Unspecified 21197902 CVCL_XU32 HAP1 TMCC3 (-) 3 cancer cell line human CVCL_XU32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29199; TMCC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197903 CVCL_Y632 W2 [Mouse ESC] embryonic stem cell house mouse CVCL_Y632 CL:0000010 Breed/subspecies: 129S9/SvEvH. Male 21197904 CVCL_XU31 HAP1 TMCC3 (-) 2 cancer cell line human CVCL_XU31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29199; TMCC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197905 CVCL_Y631 W12 [Mouse ESC] embryonic stem cell house mouse CVCL_Y631 CL:0000010 Breed/subspecies: 129S9/SvEvH. Male 21197906 CVCL_Y630 Dale1 embryonic stem cell house mouse CVCL_Y630 CL:0000010 Breed/subspecies: C57BL/6 tyrc-2J. Male 21197907 CVCL_XU30 HAP1 TM6SF1 (-) 2 cancer cell line human CVCL_XU30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11860; TM6SF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197908 CVCL_Y614 CM-10 embryonic stem cell human CVCL_Y614 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197909 CVCL_XU14 HAP1 TDP2 (-) cancer cell line human CVCL_XU14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17768; TDP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197910 CVCL_Y613 CM-1 [Human ESC] embryonic stem cell human CVCL_Y613 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197911 CVCL_XU13 HAP1 TDG (-) 3 cancer cell line human CVCL_XU13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11700; TDG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197912 CVCL_Y612 Chula5.hES embryonic stem cell human CVCL_Y612 From: Chulalongkorn University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai. Female 21197913 CVCL_XU12 HAP1 TDG (-) 2 cancer cell line human CVCL_XU12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11700; TDG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197914 CVCL_Y611 Chula4.hES embryonic stem cell human CVCL_Y611 From: Chulalongkorn University; Bangkok; Thailand CL:0000010 Population: Southeast Asian; Thai. Male 21197915 CVCL_XU11 HAP1 TCF7L2 (-) 2 cancer cell line human CVCL_XU11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11641; TCF7L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197916 CVCL_Y618 CM-14 embryonic stem cell human CVCL_Y618 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197917 CVCL_XU18 HAP1 TGFB1 (-) cancer cell line human CVCL_XU18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11766; TGFB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197918 CVCL_Y617 CM-13 embryonic stem cell human CVCL_Y617 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197919 CVCL_XU17 HAP1 TFG (-) 2 cancer cell line human CVCL_XU17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11758; TFG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197920 CVCL_Y616 CM-12 embryonic stem cell human CVCL_Y616 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197921 CVCL_XU16 HAP1 TEAD4 (-) 2 cancer cell line human CVCL_XU16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11717; TEAD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197922 CVCL_Y615 CM-11 embryonic stem cell human CVCL_Y615 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197923 CVCL_XU15 NEO217-luc cancer cell line human CVCL_XU15 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Chinese; Derived from sampling site: Bone; spine. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018179 21197924 CVCL_Y619 CM-16 embryonic stem cell human CVCL_Y619 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197925 CVCL_XU19 HAP1 TGFBR2 (-) 4 cancer cell line human CVCL_XU19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197926 CVCL_Y621 CM-4 [Human ESC] embryonic stem cell human CVCL_Y621 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197927 CVCL_XU21 HAP1 TGFBR2 (-) 6 cancer cell line human CVCL_XU21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197928 CVCL_Y620 CM-3 [Human ESC] embryonic stem cell human CVCL_Y620 From: Children's Memorial Hospital; Chicago; USA. CL:0000010 Unspecified 21197929 CVCL_XU20 HAP1 TGFBR2 (-) 5 cancer cell line human CVCL_XU20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11773; TGFBR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197930 CVCL_Y603 GM23929 transformed cell line human CVCL_Y603 CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Trp5885Ter (c.17654G>A) (p.Trp4184Ter, c.12551G>A); ClinVar=VCV001076162; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Phe8257Leufs*10 (c.24771delT) (p.Phe6366Leufs*10, c.19098delT); ClinVar=VCV000279999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197931 CVCL_XU03 HAP1 SUN2 (-) cancer cell line human CVCL_XU03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14210; SUN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197932 CVCL_Y602 GM13363 transformed cell line human CVCL_Y602 CL:0000010 Sequence variation: Mutation; HGNC; 7225; MPZ; Simple; p.Asp90Glu (c.270C>A); ClinVar=VCV000014167; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197933 CVCL_XU02 HAP1 STX17 (-) 3 cancer cell line human CVCL_XU02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11432; STX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197934 CVCL_XU01 HAP1 STX17 (-) 2 cancer cell line human CVCL_XU01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11432; STX17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197935 CVCL_Y601 STR-I-443-NF1 embryonic stem cell human CVCL_Y601 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE09-316-L1. 21197936 CVCL_XU00 HAP1 STK33 (-) 3 cancer cell line human CVCL_XU00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14568; STK33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197937 CVCL_Y600 STR-I-441-NF1 embryonic stem cell human CVCL_Y600 From: INSERM; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE09-315-L1. 21197938 CVCL_Y607 FiPS 5-7 induced pluripotent stem cell human CVCL_Y607 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21197939 CVCL_XU07 HAP1 TASP1 (-) 2 cancer cell line human CVCL_XU07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15859; TASP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197940 CVCL_Y606 GM21545 transformed cell line human CVCL_Y606 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21197941 CVCL_XU06 HAP1 TAGLN2 (-) 2 cancer cell line human CVCL_XU06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11554; TAGLN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197942 CVCL_Y605 GM13034 finite cell line human CVCL_Y605 CL:0000010 Sequence variation: Mutation; HGNC; 4451; GPC3; Simple; c.1292+1G>T (IVS5+1G>T); ClinVar=VCV000011688; Zygosity=Unspecified; Note=Splice donor mutation (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21197943 CVCL_XU05 HAP1 SYNCRIP (-) cancer cell line human CVCL_XU05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16918; SYNCRIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197944 CVCL_Y604 GM16389 finite cell line human CVCL_Y604 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21197945 CVCL_XU04 HAP1 SURF1 (-) cancer cell line human CVCL_XU04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11474; SURF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197946 CVCL_Y609 AB2.1 embryonic stem cell house mouse CVCL_Y609 CL:0000010 Breed/subspecies: 129S7/SvEvBrd-Hprt. Male 21197947 CVCL_XU09 HAP1 TBX21 (-) 2 cancer cell line human CVCL_XU09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11599; TBX21; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197948 CVCL_Y608 FiPS 6-14 induced pluripotent stem cell human CVCL_Y608 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21197949 CVCL_XU08 HAP1 TAZ (-) 3 cancer cell line human CVCL_XU08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11577; TAFAZZIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197950 CVCL_Y610 AC34 cancer cell line house mouse CVCL_Y610 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Ascites; Breed/subspecies: CBA. Female Doubling time: 19 hours (PubMed=1459729) 21197951 CVCL_XU10 HAP1 TCF19 (-) 2 cancer cell line human CVCL_XU10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11629; TCF19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197952 CVCL_6093 SK-MEL-178 cancer cell line human CVCL_6093 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197953 CVCL_6092 SK-MEL-176 cancer cell line human CVCL_6092 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197954 CVCL_6091 SK-MEL-174 cancer cell line human CVCL_6091 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197955 CVCL_6090 SK-MEL-173 cancer cell line human CVCL_6090 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp32Gly (c.95A>G); ClinVar=VCV000017578; Zygosity=Unspecified (PubMed=25645078); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830; PubMed=25645078) Omics: Protein expression by reverse-phase protein arrays; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. Part of: MD Anderson Cell Lines Project 21197956 CVCL_6097 SK-MEL-187 cancer cell line human CVCL_6097 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21197957 CVCL_6096 SK-MEL-186 cancer cell line human CVCL_6096 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197958 CVCL_6095 SK-MEL-182 cancer cell line human CVCL_6095 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197959 CVCL_6094 SK-MEL-181 cancer cell line human CVCL_6094 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197960 CVCL_6099 SK-MEL-190 cancer cell line human CVCL_6099 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197961 CVCL_6098 SK-MEL-188 cancer cell line human CVCL_6098 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). Characteristics: Pigmented 21197962 CVCL_6071 SK-MEL-106 cancer cell line human CVCL_6071 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197963 CVCL_6070 SK-MEL-105 cancer cell line human CVCL_6070 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197964 CVCL_6075 SK-MEL-117 cancer cell line human CVCL_6075 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197965 CVCL_6074 SK-MEL-113 cancer cell line human CVCL_6074 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197966 CVCL_6073 SK-MEL-109 cancer cell line human CVCL_6073 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197967 CVCL_6072 SK-MEL-108 cancer cell line human CVCL_6072 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197968 CVCL_6079 SK-MEL-128 cancer cell line human CVCL_6079 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197969 CVCL_6078 SK-MEL-127 cancer cell line human CVCL_6078 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197970 CVCL_6077 SK-MEL-119 cancer cell line human CVCL_6077 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=10766161; PubMed=15009714; PubMed=24576830) 21197971 CVCL_6076 SK-MEL-118 cancer cell line human CVCL_6076 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197972 CVCL_6069 SK-MEL-103 cancer cell line human CVCL_6069 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21197973 CVCL_6082 SK-MEL-133 cancer cell line human CVCL_6082 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197974 CVCL_6081 SK-MEL-131 cancer cell line human CVCL_6081 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15009714; PubMed=21725359; PubMed=24576830). 21197975 CVCL_6080 SK-MEL-130 cancer cell line human CVCL_6080 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197976 CVCL_6086 LyD9 K-GM factor-dependent cell line house mouse CVCL_6086 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: CSF2 dependent 21197977 CVCL_6085 SK-MEL-146 cancer cell line human CVCL_6085 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000012601; Zygosity=Unspecified (PubMed=24576830). 21197978 CVCL_6084 SK-MEL-144 cancer cell line human CVCL_6084 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197979 CVCL_6083 SK-MEL-135 cancer cell line human CVCL_6083 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197980 CVCL_6089 SK-MEL-170 cancer cell line human CVCL_6089 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197981 CVCL_6088 SK-MEL-161 cancer cell line human CVCL_6088 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197982 CVCL_6087 SK-MEL-153 cancer cell line human CVCL_6087 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197983 CVCL_XU99 HAP1 VDR (-) cancer cell line human CVCL_XU99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12679; VDR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197984 CVCL_Y699 HiPS-RIKEN-9B induced pluripotent stem cell human CVCL_Y699 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21197985 CVCL_6053 SK-MEL-73 cancer cell line human CVCL_6053 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197986 CVCL_6052 SK-MEL-72 cancer cell line human CVCL_6052 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197987 CVCL_6051 SK-MEL-68 cancer cell line human CVCL_6051 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197988 CVCL_6050 SK-MEL-65 cancer cell line human CVCL_6050 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197989 CVCL_6057 SK-MEL-80 cancer cell line human CVCL_6057 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197990 CVCL_6056 SK-MEL-78 cancer cell line human CVCL_6056 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197991 CVCL_6054 SK-MEL-75 cancer cell line human CVCL_6054 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197992 CVCL_6049 SK-MEL-88 cancer cell line human CVCL_6049 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197993 CVCL_6048 SK-MEL-64 cancer cell line human CVCL_6048 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21197994 CVCL_6047 SK-MEL-60 cancer cell line human CVCL_6047 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21197995 CVCL_XU89 HAP1 USP2 (-) 3 cancer cell line human CVCL_XU89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12618; USP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197996 CVCL_Y689 Rama 59 cancer cell line Norway rat CVCL_Y689 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197997 CVCL_XU88 HAP1 UCK2 (-) cancer cell line human CVCL_XU88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12562; UCK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21197998 CVCL_Y688 Rama 55 cancer cell line Norway rat CVCL_Y688 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21197999 CVCL_6060 SK-MEL-87 cancer cell line human CVCL_6060 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198000 CVCL_6064 SK-MEL-95 cancer cell line human CVCL_6064 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198001 CVCL_6063 LyD9 K-5 factor-dependent cell line house mouse CVCL_6063 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL5 dependent 21198002 CVCL_6061 LyD9 K-4 factor-dependent cell line house mouse CVCL_6061 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL4 dependent 21198003 CVCL_6068 SK-MEL-101 cancer cell line human CVCL_6068 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198004 CVCL_6067 SK-MEL-100 cancer cell line human CVCL_6067 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21198005 CVCL_6066 SK-MEL-98 cancer cell line human CVCL_6066 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198006 CVCL_6065 SK-MEL-97 cancer cell line human CVCL_6065 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198007 CVCL_6059 SK-MEL-83 cancer cell line human CVCL_6059 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198008 CVCL_6058 SK-MEL-69 cancer cell line human CVCL_6058 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198009 CVCL_XU90 HAP1 USP2 (-) 4 cancer cell line human CVCL_XU90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12618; USP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198010 CVCL_Y690 Rama 60 cancer cell line Norway rat CVCL_Y690 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Wistar Furth. Female 21198011 CVCL_XU94 HAP1 USP4 (-) 2 cancer cell line human CVCL_XU94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12627; USP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198012 CVCL_Y694 HiPS-RIKEN-7B induced pluripotent stem cell human CVCL_Y694 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198013 CVCL_XU93 HAP1 USP28 (-) 5 cancer cell line human CVCL_XU93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12625; USP28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198014 CVCL_Y693 HiPS-RIKEN-6B induced pluripotent stem cell human CVCL_Y693 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198015 CVCL_XU92 HAP1 USP28 (-) 4 cancer cell line human CVCL_XU92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12625; USP28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198016 CVCL_Y692 HiPS-RIKEN-6A induced pluripotent stem cell human CVCL_Y692 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198017 CVCL_XU91 HAP1 USP28 (-) 3 cancer cell line human CVCL_XU91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12625; USP28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198018 CVCL_Y691 HPS0155 induced pluripotent stem cell human CVCL_Y691 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198019 CVCL_XU98 HAP1 VDAC3 (-) 2 cancer cell line human CVCL_XU98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12674; VDAC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198020 CVCL_Y698 iCK10 induced pluripotent stem cell human CVCL_Y698 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198021 CVCL_XU97 HAP1 VDAC1 (-) 2 cancer cell line human CVCL_XU97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12669; VDAC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198022 CVCL_Y697 iCK8 induced pluripotent stem cell human CVCL_Y697 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198023 CVCL_XU96 HAP1 USP42 (-) cancer cell line human CVCL_XU96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20068; USP42; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198024 CVCL_Y696 iOTC6 induced pluripotent stem cell human CVCL_Y696 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198025 CVCL_XU95 HAP1 USP4 (-) 3 cancer cell line human CVCL_XU95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12627; USP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198026 CVCL_Y695 iOTC2 induced pluripotent stem cell human CVCL_Y695 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198027 CVCL_GD83 ND10410 transformed cell line human CVCL_GD83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198028 CVCL_GD82 ND10392 transformed cell line human CVCL_GD82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198029 CVCL_GD81 ND10391 transformed cell line human CVCL_GD81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198030 CVCL_GD80 ND10389 transformed cell line human CVCL_GD80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198031 CVCL_GD87 ND10426 transformed cell line human CVCL_GD87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198032 CVCL_GD86 ND10425 transformed cell line human CVCL_GD86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198033 CVCL_GD85 ND10423 transformed cell line human CVCL_GD85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198034 CVCL_GD84 ND10421 transformed cell line human CVCL_GD84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198035 CVCL_GD79 ND10383 transformed cell line human CVCL_GD79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198036 CVCL_GD78 ND10381 transformed cell line human CVCL_GD78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198037 CVCL_GD77 ND10364 transformed cell line human CVCL_GD77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198038 CVCL_GD94 ND10474 transformed cell line human CVCL_GD94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198039 CVCL_GD93 ND10472 transformed cell line human CVCL_GD93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198040 CVCL_GD92 ND10471 transformed cell line human CVCL_GD92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198041 CVCL_GD91 ND10466 transformed cell line human CVCL_GD91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198042 CVCL_GD98 ND10523 transformed cell line human CVCL_GD98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198043 CVCL_GD97 ND10499 transformed cell line human CVCL_GD97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198044 CVCL_GD96 ND10480 transformed cell line human CVCL_GD96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198045 CVCL_GD95 ND10478 transformed cell line human CVCL_GD95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198046 CVCL_GD90 ND10431 transformed cell line human CVCL_GD90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198047 CVCL_GD89 ND10429 transformed cell line human CVCL_GD89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198048 CVCL_GD88 ND10428 transformed cell line human CVCL_GD88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198049 CVCL_GD61 ND10306 transformed cell line human CVCL_GD61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198050 CVCL_GD60 ND10305 transformed cell line human CVCL_GD60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198051 CVCL_GD65 ND10333 transformed cell line human CVCL_GD65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198052 CVCL_GD64 ND10331 transformed cell line human CVCL_GD64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198053 CVCL_GD63 ND10325 transformed cell line human CVCL_GD63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198054 CVCL_GD62 ND10307 transformed cell line human CVCL_GD62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198055 CVCL_GD58 ND10303 transformed cell line human CVCL_GD58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198056 CVCL_GD57 ND10301 transformed cell line human CVCL_GD57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198057 CVCL_GD56 ND10300 transformed cell line human CVCL_GD56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198058 CVCL_GD55 ND10299 transformed cell line human CVCL_GD55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198059 CVCL_GD59 ND10304 transformed cell line human CVCL_GD59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198060 CVCL_GD72 ND10358 transformed cell line human CVCL_GD72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198061 CVCL_GD71 ND10348 transformed cell line human CVCL_GD71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198062 CVCL_GD70 ND10344 transformed cell line human CVCL_GD70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198063 CVCL_GD76 ND10363 transformed cell line human CVCL_GD76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198064 CVCL_GD75 ND10361 transformed cell line human CVCL_GD75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198065 CVCL_GD74 ND10360 transformed cell line human CVCL_GD74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198066 CVCL_GD73 ND10359 transformed cell line human CVCL_GD73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198067 CVCL_GD69 ND10343 transformed cell line human CVCL_GD69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198068 CVCL_GD68 ND10342 transformed cell line human CVCL_GD68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198069 CVCL_GD67 ND10337 transformed cell line human CVCL_GD67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198070 CVCL_GD66 ND10336 transformed cell line human CVCL_GD66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198071 CVCL_GD43 ND10180 transformed cell line human CVCL_GD43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198072 CVCL_GD42 ND10147 transformed cell line human CVCL_GD42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198073 CVCL_GD41 ND10128 transformed cell line human CVCL_GD41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198074 CVCL_GD40 ND10120 transformed cell line human CVCL_GD40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198075 CVCL_GD36 ND10058 transformed cell line human CVCL_GD36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198076 CVCL_GD35 ND10039 transformed cell line human CVCL_GD35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198077 CVCL_GD34 ND10019 transformed cell line human CVCL_GD34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198078 CVCL_GD33 ND10017 transformed cell line human CVCL_GD33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198079 CVCL_GD39 ND10102 transformed cell line human CVCL_GD39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198080 CVCL_GD38 ND10091 transformed cell line human CVCL_GD38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198081 CVCL_GD37 ND10090 transformed cell line human CVCL_GD37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198082 CVCL_GD50 ND10271 transformed cell line human CVCL_GD50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198083 CVCL_GD54 ND10293 transformed cell line human CVCL_GD54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198084 CVCL_GD53 ND10280 transformed cell line human CVCL_GD53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198085 CVCL_GD52 ND10279 transformed cell line human CVCL_GD52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198086 CVCL_GD51 ND10278 transformed cell line human CVCL_GD51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198087 CVCL_GD47 ND10234 transformed cell line human CVCL_GD47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198088 CVCL_GD46 ND10229 transformed cell line human CVCL_GD46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198089 CVCL_GD45 ND10225 transformed cell line human CVCL_GD45 CL:0000010 Population: Caucasian; Greek; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198090 CVCL_GD44 ND10187 transformed cell line human CVCL_GD44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198091 CVCL_GD49 ND10267 transformed cell line human CVCL_GD49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198092 CVCL_GD48 ND10253 transformed cell line human CVCL_GD48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198093 CVCL_GD21 ND09941 transformed cell line human CVCL_GD21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198094 CVCL_GD20 ND09938 transformed cell line human CVCL_GD20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198095 CVCL_GD19 ND09912 transformed cell line human CVCL_GD19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198096 CVCL_GD14 ND09893 transformed cell line human CVCL_GD14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198097 CVCL_GD13 ND09892 transformed cell line human CVCL_GD13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198098 CVCL_GD12 ND09882 transformed cell line human CVCL_GD12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198099 CVCL_GD11 ND09843 transformed cell line human CVCL_GD11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198100 CVCL_GD18 ND09908 transformed cell line human CVCL_GD18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198101 CVCL_GD17 ND09896 transformed cell line human CVCL_GD17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198102 CVCL_GD16 ND09895 transformed cell line human CVCL_GD16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198103 CVCL_GD15 ND09894 transformed cell line human CVCL_GD15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198104 CVCL_GD32 ND10008 transformed cell line human CVCL_GD32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198105 CVCL_GD31 ND09999 transformed cell line human CVCL_GD31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198106 CVCL_GD30 ND09991 transformed cell line human CVCL_GD30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198107 CVCL_GD25 ND09951 transformed cell line human CVCL_GD25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198108 CVCL_GD24 ND09949 transformed cell line human CVCL_GD24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198109 CVCL_GD23 ND09947 transformed cell line human CVCL_GD23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198110 CVCL_GD22 ND09942 transformed cell line human CVCL_GD22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198111 CVCL_GD29 ND09967 transformed cell line human CVCL_GD29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198112 CVCL_GD28 ND09964 transformed cell line human CVCL_GD28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198113 CVCL_GD27 ND09958 transformed cell line human CVCL_GD27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198114 CVCL_GD26 ND09952 transformed cell line human CVCL_GD26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198115 CVCL_XW34 HEK293 eGFP-ZNF34 transformed cell line human CVCL_XW34 CL:0000010 Transfected with: HGNC; 13098; ZNF34; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198116 CVCL_Y834 ND41656 induced pluripotent stem cell human CVCL_Y834 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[57] (c.52CAG(57)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41656; true Female 21198117 CVCL_XW33 HEK293 eGFP-ZNF331 transformed cell line human CVCL_XW33 CL:0000010 Transfected with: HGNC; 15489; ZNF331; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198118 CVCL_Y833 ND41654 induced pluripotent stem cell human CVCL_Y833 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41654; true Male 21198119 CVCL_XW32 HEK293 eGFP-ZNF311 transformed cell line human CVCL_XW32 CL:0000010 Transfected with: HGNC; 13847; ZNF311; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198120 CVCL_Y832 ND41114 induced pluripotent stem cell human CVCL_Y832 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; ND41114; true Female 21198121 CVCL_XW31 HEK293 eGFP-ZNF302 transformed cell line human CVCL_XW31 CL:0000010 Transfected with: HGNC; 13848; ZNF302; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198122 CVCL_Y831 ND40020 induced pluripotent stem cell human CVCL_Y831 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40020; true Male 21198123 CVCL_XW38 HEK293 eGFP-ZNF366 transformed cell line human CVCL_XW38 CL:0000010 Transfected with: HGNC; 18316; ZNF366; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198124 CVCL_Y838 ND41866 induced pluripotent stem cell human CVCL_Y838 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41866; true Male 21198125 CVCL_XW37 HEK293 eGFP-ZNF362 transformed cell line human CVCL_XW37 CL:0000010 Transfected with: HGNC; 18079; ZNF362; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198126 CVCL_Y837 ND41865 induced pluripotent stem cell human CVCL_Y837 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41865; true Male 21198127 CVCL_XW36 HEK293 eGFP-ZNF350 transformed cell line human CVCL_XW36 CL:0000010 Transfected with: HGNC; 16656; ZNF350; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198128 CVCL_Y836 ND41658 induced pluripotent stem cell human CVCL_Y836 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41658; true Male 21198129 CVCL_XW35 HEK293 eGFP-ZNF346 transformed cell line human CVCL_XW35 CL:0000010 Transfected with: HGNC; 16403; ZNF346; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198130 CVCL_Y835 ND41657 induced pluripotent stem cell human CVCL_Y835 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[57] (c.52CAG(57)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41657; true Female 21198131 CVCL_XW39 HEK293 eGFP-ZNF382 transformed cell line human CVCL_XW39 CL:0000010 Transfected with: HGNC; 17409; ZNF382; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198132 CVCL_Y839 ND41867 induced pluripotent stem cell human CVCL_Y839 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41867; true Male 21198133 CVCL_XW41 HEK293 eGFP-ZNF398 transformed cell line human CVCL_XW41 CL:0000010 Transfected with: HGNC; 18373; ZNF398; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198135 CVCL_XW40 HEK293 eGFP-ZNF394 transformed cell line human CVCL_XW40 CL:0000010 Transfected with: HGNC; 18832; ZNF394; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198136 CVCL_Y840 ND41869 induced pluripotent stem cell human CVCL_Y840 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41869; true Male 21198137 CVCL_XW23 HEK293 eGFP-ZNF23 transformed cell line human CVCL_XW23 CL:0000010 Transfected with: HGNC; 13023; ZNF23; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198138 CVCL_Y823 ND39030 induced pluripotent stem cell human CVCL_Y823 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Asp91Ala (c.272A>C) (D90A); ClinVar=VCV000014766; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39030; true Female 21198139 CVCL_XW22 HEK293 eGFP-ZNF223 transformed cell line human CVCL_XW22 CL:0000010 Transfected with: HGNC; 13016; ZNF223; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198140 CVCL_Y822 ND38555 induced pluripotent stem cell human CVCL_Y822 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38555; true Female 21198141 CVCL_XW21 HEK293 eGFP-ZNF221 transformed cell line human CVCL_XW21 CL:0000010 Transfected with: HGNC; 13014; ZNF221; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198142 CVCL_Y821 ND38554 induced pluripotent stem cell human CVCL_Y821 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38554; true Female 21198143 CVCL_XW20 HEK293 eGFP-ZNF214 transformed cell line human CVCL_XW20 CL:0000010 Transfected with: HGNC; 13006; ZNF214; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198144 CVCL_Y820 ND38552 induced pluripotent stem cell human CVCL_Y820 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49-50] (c.52CAG(49-50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38552; true Female 21198145 CVCL_XW27 HEK293 eGFP-ZNF274 transformed cell line human CVCL_XW27 CL:0000010 Transfected with: HGNC; 13068; ZNF274; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198146 CVCL_Y827 ND39037 induced pluripotent stem cell human CVCL_Y827 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39037; true Male 21198147 CVCL_XW26 HEK293 eGFP-ZNF266 transformed cell line human CVCL_XW26 CL:0000010 Transfected with: HGNC; 13059; ZNF266; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198148 CVCL_Y826 ND39036 induced pluripotent stem cell human CVCL_Y826 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Gly86Arg (c.256G>C) (G85R); ClinVar=VCV000014758; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39036; true Male 21198149 CVCL_XW25 HEK293 eGFP-ZNF26 transformed cell line human CVCL_XW25 CL:0000010 Transfected with: HGNC; 13053; ZNF26; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198150 CVCL_Y825 ND39034 induced pluripotent stem cell human CVCL_Y825 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg522Arg (c.1566G>A); ClinVar=VCV000540280; Zygosity=Unspecified; Note=Mislocalized protein (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39034; true Male 21198151 CVCL_XW24 HEK293 eGFP-ZNF248 transformed cell line human CVCL_XW24 CL:0000010 Transfected with: HGNC; 13041; ZNF248; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198152 CVCL_Y824 ND39032 induced pluripotent stem cell human CVCL_Y824 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39032; true Male Caution: SOD1 mutation wrongly indicated as L144P in NHCDR 21198153 CVCL_XW29 HEK293 eGFP-ZNF280D transformed cell line human CVCL_XW29 CL:0000010 Transfected with: HGNC; 25953; ZNF280D; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198154 CVCL_Y829 ND40018 induced pluripotent stem cell human CVCL_Y829 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40018; probable Female 21198155 CVCL_XW28 HEK293 eGFP-ZNF280C transformed cell line human CVCL_XW28 CL:0000010 Transfected with: HGNC; 25955; ZNF280C; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198156 CVCL_Y828 ND39896 induced pluripotent stem cell human CVCL_Y828 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39896; true Male 21198157 CVCL_5Q00 GM13482 transformed cell line human CVCL_5Q00 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198158 CVCL_6200 SK-RC-54 cancer cell line human CVCL_6200 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Lung. Male 21198159 CVCL_XW30 HEK293 eGFP-ZNF300 transformed cell line human CVCL_XW30 CL:0000010 Transfected with: HGNC; 13091; ZNF300; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198160 CVCL_Y830 ND40019 induced pluripotent stem cell human CVCL_Y830 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (NHCDR) Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND40019; true Male 21198161 CVCL_XW12 HEK293 eGFP-ZNF174 transformed cell line human CVCL_XW12 CL:0000010 Transfected with: HGNC; 12963; ZNF174; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198162 CVCL_Y812 ND38477 induced pluripotent stem cell human CVCL_Y812 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Asn52Metfs*29 (c.155delA) (255delA); ClinVar=VCV000536457; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38477; true Male 21198163 CVCL_XW11 HEK293 eGFP-ZNF169 transformed cell line human CVCL_XW11 CL:0000010 Transfected with: HGNC; 12957; ZNF169; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198164 CVCL_Y811 ND29543 finite cell line human CVCL_Y811 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Asn52Metfs*29 (c.155delA) (255delA); ClinVar=VCV000536457; Zygosity=Heterozygous (PubMed=22952635); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29543; true Male 21198165 CVCL_XW10 HEK293 eGFP-ZNF157 transformed cell line human CVCL_XW10 CL:0000010 Transfected with: HGNC; 12942; ZNF157; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198166 CVCL_Y810 ND07278 transformed cell line human CVCL_Y810 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Asn52Metfs*29 (c.155delA) (255delA); ClinVar=VCV000536457; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3-4del; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198167 CVCL_XW16 HEK293 eGFP-ZNF2 transformed cell line human CVCL_XW16 CL:0000010 Transfected with: HGNC; 12991; ZNF2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198168 CVCL_Y816 ND38547 induced pluripotent stem cell human CVCL_Y816 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell; NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38547; true Male 21198169 CVCL_XW15 HEK293 eGFP-ZNF195 transformed cell line human CVCL_XW15 CL:0000010 Transfected with: HGNC; 12986; ZNF195; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198170 CVCL_Y815 ND38546 induced pluripotent stem cell human CVCL_Y815 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38546; true Female 21198171 CVCL_XW14 HEK293 eGFP-ZNF19 transformed cell line human CVCL_XW14 CL:0000010 Transfected with: HGNC; 12981; ZNF19; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198172 CVCL_Y814 ND38545 induced pluripotent stem cell human CVCL_Y814 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[45] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Population: South American (Brazil, Guyana, Venezuela); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38545; true Female 21198173 CVCL_XW13 HEK293 eGFP-ZNF189 transformed cell line human CVCL_XW13 CL:0000010 Transfected with: HGNC; 12980; ZNF189; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198174 CVCL_Y813 ND29510 finite cell line human CVCL_Y813 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29510; true Female 21198175 CVCL_XW19 HEK293 eGFP-ZNF213 transformed cell line human CVCL_XW19 CL:0000010 Transfected with: HGNC; 13005; ZNF213; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198176 CVCL_Y819 ND38551 induced pluripotent stem cell human CVCL_Y819 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198177 CVCL_XW18 HEK293 eGFP-ZNF211 transformed cell line human CVCL_XW18 CL:0000010 Transfected with: HGNC; 13003; ZNF211; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198178 CVCL_Y818 ND38549 induced pluripotent stem cell human CVCL_Y818 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38549; true Female 21198179 CVCL_XW17 HEK293 eGFP-ZNF202 transformed cell line human CVCL_XW17 CL:0000010 Transfected with: HGNC; 12994; ZNF202; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198180 CVCL_Y817 ND38548 induced pluripotent stem cell human CVCL_Y817 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[42] (c.52CAG(42)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND38548; true Female 21198181 CVCL_Y801 GM24559 induced pluripotent stem cell human CVCL_Y801 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198182 CVCL_XW01 HEK293 eGFP-ZNF101 transformed cell line human CVCL_XW01 CL:0000010 Transfected with: HGNC; 12881; ZNF101; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198183 CVCL_Y800 GM06077 transformed cell line human CVCL_Y800 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (PubMed=32656337) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198184 CVCL_XW00 HEK293 eGFP-ZNF10 transformed cell line human CVCL_XW00 CL:0000010 Transfected with: HGNC; 12879; ZNF10; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198185 CVCL_XW05 HEK293 eGFP-ZNF132 transformed cell line human CVCL_XW05 CL:0000010 Transfected with: HGNC; 12916; ZNF132; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198186 CVCL_Y805 ND35673 induced pluripotent stem cell human CVCL_Y805 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35673; true Female 21198187 CVCL_XW04 HEK293 eGFP-ZNF121 transformed cell line human CVCL_XW04 CL:0000010 Transfected with: HGNC; 12904; ZNF121; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198188 CVCL_Y804 ND35670 induced pluripotent stem cell human CVCL_Y804 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Val149Gly (c.446T>G) (V148G); ClinVar=VCV000873204; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35670; true Male 21198189 CVCL_Y803 GM25256 induced pluripotent stem cell human CVCL_Y803 CL:0000010 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Omics: Genome sequenced Male 21198190 CVCL_XW03 HEK293 eGFP-ZNF114 transformed cell line human CVCL_XW03 CL:0000010 Transfected with: HGNC; 12894; ZNF114; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198191 CVCL_Y802 GM24683 induced pluripotent stem cell human CVCL_Y802 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198192 CVCL_XW02 HEK293 eGFP-ZNF112 transformed cell line human CVCL_XW02 CL:0000010 Transfected with: HGNC; 12892; ZNF112; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198193 CVCL_XW09 HEK293 eGFP-ZNF155 transformed cell line human CVCL_XW09 CL:0000010 Transfected with: HGNC; 12940; ZNF155; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198194 CVCL_Y809 ND41113 induced pluripotent stem cell human CVCL_Y809 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND41113; true Female 21198195 CVCL_XW08 HEK293 eGFP-ZNF148 transformed cell line human CVCL_XW08 CL:0000010 Transfected with: HGNC; 12933; ZNF148; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198196 CVCL_Y808 ND36997 induced pluripotent stem cell human CVCL_Y808 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND36997; true Female 21198197 CVCL_XW07 HEK293 eGFP-ZNF140 transformed cell line human CVCL_XW07 CL:0000010 Transfected with: HGNC; 12925; ZNF140; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198198 CVCL_Y807 ND36998 induced pluripotent stem cell human CVCL_Y807 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND36998; true Female 21198199 CVCL_XW06 HEK293 eGFP-ZNF133 transformed cell line human CVCL_XW06 CL:0000010 Transfected with: HGNC; 12917; ZNF133; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198200 CVCL_Y806 ND39023 finite cell line human CVCL_Y806 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Ala5Val (c.14C>T) (A4V); ClinVar=VCV000014763; Zygosity=Unspecified (NHCDR) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39023; true Female 21198201 CVCL_GD99 ND10525 transformed cell line human CVCL_GD99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198202 CVCL_Y799 GM06076 finite cell line human CVCL_Y799 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[66] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198203 CVCL_XV99 HEK293 eGFP-ZIK1 transformed cell line human CVCL_XV99 CL:0000010 Transfected with: HGNC; 33104; ZIK1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198204 CVCL_Y798 GM06075 transformed cell line human CVCL_Y798 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[66] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21198205 CVCL_XV98 HEK293 eGFP-ZIC2 transformed cell line human CVCL_XV98 CL:0000010 Transfected with: HGNC; 12873; ZIC2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198206 CVCL_5P52 GM11404 transformed cell line human CVCL_5P52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198207 CVCL_6152 SK-MEL-323 cancer cell line human CVCL_6152 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198208 CVCL_5P51 GM11403 finite cell line human CVCL_5P51 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM11403; probable Male 21198209 CVCL_6151 SK-MEL-316 cancer cell line human CVCL_6151 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198210 CVCL_5P50 GM11393 transformed cell line human CVCL_5P50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198211 CVCL_6150 SK-MEL-307 cancer cell line human CVCL_6150 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198212 CVCL_5P56 GM11518 transformed cell line human CVCL_5P56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198213 CVCL_6156 SK-MEL-334 cancer cell line human CVCL_6156 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198214 CVCL_5P55 GM11517 transformed cell line human CVCL_5P55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198215 CVCL_6155 SK-MEL-330 cancer cell line human CVCL_6155 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198216 CVCL_5P54 GM11516 transformed cell line human CVCL_5P54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198217 CVCL_6154 SK-MEL-326 cancer cell line human CVCL_6154 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198218 CVCL_5P53 GM11515 transformed cell line human CVCL_5P53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198219 CVCL_6153 SK-MEL-325 cancer cell line human CVCL_6153 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198220 CVCL_5P49 GM11392 transformed cell line human CVCL_5P49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198221 CVCL_6149 SK-MEL-306 cancer cell line human CVCL_6149 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198222 CVCL_5P48 GM11390 transformed cell line human CVCL_5P48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198223 CVCL_6148 SK-MEL-304 cancer cell line human CVCL_6148 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198224 CVCL_5P47 GM11389 transformed cell line human CVCL_5P47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198225 CVCL_6147 SK-MEL-301 cancer cell line human CVCL_6147 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198226 CVCL_5P46 GM11387 transformed cell line human CVCL_5P46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198227 CVCL_6146 SK-MEL-285 cancer cell line human CVCL_6146 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=24576830). 21198228 CVCL_Y789 GM24681 transformed cell line human CVCL_Y789 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu301Phe (c.903A>T); ClinVar=VCV000097350; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198229 CVCL_XV89 HEK293 eGFP-ZBTB21 transformed cell line human CVCL_XV89 CL:0000010 Transfected with: HGNC; 13083; ZBTB21; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198230 CVCL_Y788 GM24422 transformed cell line human CVCL_Y788 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ala208Thr (c.622G>A); ClinVar=VCV000097274; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198231 CVCL_XV88 HEK293 eGFP-ZBTB20 transformed cell line human CVCL_XV88 CL:0000010 Transfected with: HGNC; 13503; ZBTB20; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198232 CVCL_Y787 GM24389 transformed cell line human CVCL_Y787 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu82Ter (c.245T>A); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198233 CVCL_XV87 HEK293 eGFP-ZBTB17 transformed cell line human CVCL_XV87 CL:0000010 Transfected with: HGNC; 12936; ZBTB17; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21198234 CVCL_5P63 GM12074 transformed cell line human CVCL_5P63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198235 CVCL_6163 SK-MEL-366 cancer cell line human CVCL_6163 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198236 CVCL_5P62 GM12013 finite cell line human CVCL_5P62 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198237 CVCL_6162 SK-MEL-364 cancer cell line human CVCL_6162 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198238 CVCL_5P61 GM11949 transformed cell line human CVCL_5P61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198239 CVCL_6161 SK-MEL-359 cancer cell line human CVCL_6161 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198240 CVCL_5P60 GM11672 transformed cell line human CVCL_5P60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198241 CVCL_6160 SK-MEL-351 cancer cell line human CVCL_6160 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198242 CVCL_5P67 GM12662 transformed cell line human CVCL_5P67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198243 CVCL_6167 SK-MEL-381 cancer cell line human CVCL_6167 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198244 CVCL_5P66 GM12606 transformed cell line human CVCL_5P66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198245 CVCL_6166 SK-MEL-380 cancer cell line human CVCL_6166 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198246 CVCL_5P65 GM12590 finite cell line human CVCL_5P65 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Male 21198247 CVCL_6165 SK-MEL-369 cancer cell line human CVCL_6165 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198248 CVCL_5P64 GM12218 finite cell line human CVCL_5P64 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198249 CVCL_6164 SK-MEL-367 cancer cell line human CVCL_6164 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198250 CVCL_5P59 GM11571 transformed cell line human CVCL_5P59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198251 CVCL_6159 SK-MEL-346 cancer cell line human CVCL_6159 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198252 CVCL_5P58 GM11570 transformed cell line human CVCL_5P58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198253 CVCL_6158 SK-MEL-341 cancer cell line human CVCL_6158 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198254 CVCL_5P57 HHW1405 hybrid cell line human CVCL_5P57 CL:0000010 Group: Human/rodent somatic cell hybrid. 21198255 CVCL_6157 SK-MEL-339 cancer cell line human CVCL_6157 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198256 CVCL_Y793 GM04601 finite cell line human CVCL_Y793 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198257 CVCL_XV93 HEK293 eGFP-ZBTB6 transformed cell line human CVCL_XV93 CL:0000010 Transfected with: HGNC; 16764; ZBTB6; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198258 CVCL_XV92 HEK293 eGFP-ZBTB48 transformed cell line human CVCL_XV92 CL:0000010 Transfected with: HGNC; 4930; ZBTB48; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198259 CVCL_Y791 GM24721 transformed cell line human CVCL_Y791 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198260 CVCL_XV91 HEK293 eGFP-ZBTB33 transformed cell line human CVCL_XV91 CL:0000010 Transfected with: HGNC; 16682; ZBTB33; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198261 CVCL_Y790 GM24720 transformed cell line human CVCL_Y790 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198262 CVCL_XV90 HEK293 eGFP-ZBTB26 transformed cell line human CVCL_XV90 CL:0000010 Transfected with: HGNC; 23383; ZBTB26; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198263 CVCL_Y797 GM04608 finite cell line human CVCL_Y797 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21198264 CVCL_XV97 HEK293 eGFP-ZFP69B transformed cell line human CVCL_XV97 CL:0000010 Transfected with: HGNC; 28053; ZFP69B; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198265 CVCL_Y796 GM04604 transformed cell line human CVCL_Y796 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198266 CVCL_XV96 HEK293 eGFP-ZFP37 transformed cell line human CVCL_XV96 CL:0000010 Transfected with: HGNC; 12863; ZFP37; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198267 CVCL_Y795 GM04603 finite cell line human CVCL_Y795 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198268 CVCL_XV95 HEK293 eGFP-ZFP2 transformed cell line human CVCL_XV95 CL:0000010 Transfected with: HGNC; 26138; ZFP2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198269 CVCL_Y794 GM04602 finite cell line human CVCL_Y794 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1700] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Heterozygous (from autologous cell line GM06077) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198270 CVCL_XV94 HEK293 eGFP-ZFHX2 transformed cell line human CVCL_XV94 CL:0000010 Transfected with: HGNC; 20152; ZFHX2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198271 CVCL_Y779 GM24019 transformed cell line human CVCL_Y779 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198272 CVCL_XV79 HEK293 eGFP-SALL1 transformed cell line human CVCL_XV79 CL:0000010 Transfected with: HGNC; 10524; SALL1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198273 CVCL_Y778 GM24018 transformed cell line human CVCL_Y778 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198274 CVCL_XV78 HEK293 eGFP-RREB1 transformed cell line human CVCL_XV78 CL:0000010 Transfected with: HGNC; 10449; RREB1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198275 CVCL_Y777 GM24017 transformed cell line human CVCL_Y777 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198276 CVCL_XV77 HEK293 eGFP-REPIN1 transformed cell line human CVCL_XV77 CL:0000010 Transfected with: HGNC; 17922; REPIN1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198277 CVCL_Y776 GM24011 transformed cell line human CVCL_Y776 CL:0000010 Population: Caucasian; Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198278 CVCL_XV76 HEK293 eGFP-RBAK transformed cell line human CVCL_XV76 CL:0000010 Transfected with: HGNC; 17680; RBAK; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198279 CVCL_5P30 GM10951 finite cell line human CVCL_5P30 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(7)(pter->p15::p13->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198280 CVCL_6130 SK-MEL-263 cancer cell line human CVCL_6130 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198281 CVCL_5P34 GM11002 transformed cell line human CVCL_5P34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198282 CVCL_6134 SK-MEL-267 cancer cell line human CVCL_6134 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198283 CVCL_5P33 GM10994 transformed cell line human CVCL_5P33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198284 CVCL_6133 SK-MEL-266 cancer cell line human CVCL_6133 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198285 CVCL_5P32 GM10985 transformed cell line human CVCL_5P32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198286 CVCL_6132 SK-MEL-265 cancer cell line human CVCL_6132 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198287 CVCL_5P31 GM10954 finite cell line human CVCL_5P31 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM10954; probable Female 21198288 CVCL_6131 SK-MEL-264 cancer cell line human CVCL_6131 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Asp594Gly (c.1781A>G); ClinVar=VCV000013972; Zygosity=Unspecified (PubMed=24576830). 21198289 CVCL_5P27 GM10922 transformed cell line human CVCL_5P27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198290 CVCL_6127 SK-MEL-252 cancer cell line human CVCL_6127 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198291 CVCL_5P26 GM10918 transformed cell line human CVCL_5P26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198292 CVCL_6126 SK-MEL-246 cancer cell line human CVCL_6126 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ala (c.1406G>C); ClinVar=VCV000013971; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198293 CVCL_5P25 GM10800 transformed cell line human CVCL_5P25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198294 CVCL_6125 SK-MEL-245 cancer cell line human CVCL_6125 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198295 CVCL_5P24 GM10709 finite cell line human CVCL_5P24 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Male 21198296 CVCL_6124 SK-MEL-244 cancer cell line human CVCL_6124 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198297 CVCL_5P29 GM10933 finite cell line human CVCL_5P29 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198298 CVCL_6129 SK-MEL-258 cancer cell line human CVCL_6129 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198299 CVCL_5P28 GM10932 finite cell line human CVCL_5P28 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198300 CVCL_6128 SK-MEL-256 cancer cell line human CVCL_6128 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198301 CVCL_Y782 GM24053 transformed cell line human CVCL_Y782 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg129His (c.386G>A); ClinVar=VCV000011010; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198302 CVCL_XV82 HEK293 eGFP-SCRT2 transformed cell line human CVCL_XV82 CL:0000010 Transfected with: HGNC; 15952; SCRT2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198303 CVCL_Y781 GM24048 transformed cell line human CVCL_Y781 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198304 CVCL_XV81 HEK293 eGFP-SCRT1 transformed cell line human CVCL_XV81 CL:0000010 Transfected with: HGNC; 15950; SCRT1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198305 CVCL_Y780 GM24047 transformed cell line human CVCL_Y780 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Glu273fs (c.818delA); ClinVar=VCV000097338; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198306 CVCL_XV80 HEK293 eGFP-SALL2 transformed cell line human CVCL_XV80 CL:0000010 Transfected with: HGNC; 10526; SALL2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21198307 CVCL_Y786 GM24263 transformed cell line human CVCL_Y786 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198308 CVCL_XV86 HEK293 eGFP-ZBTB12 transformed cell line human CVCL_XV86 CL:0000010 Transfected with: HGNC; 19066; ZBTB12; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198309 CVCL_Y785 GM24215 transformed cell line human CVCL_Y785 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Gln (c.422G>A); ClinVar=VCV000010987; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198310 CVCL_XV85 HEK293 eGFP-ZBTB10 transformed cell line human CVCL_XV85 CL:0000010 Transfected with: HGNC; 30953; ZBTB10; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21198311 CVCL_Y784 GM24214 transformed cell line human CVCL_Y784 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21198312 CVCL_XV84 HEK293 eGFP-YY2 transformed cell line human CVCL_XV84 CL:0000010 Transfected with: HGNC; 31684; YY2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198313 CVCL_Y783 GM24054 transformed cell line human CVCL_Y783 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg129His (c.386G>A); ClinVar=VCV000011010; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198314 CVCL_XV83 HEK293 eGFP-YY1 transformed cell line human CVCL_XV83 CL:0000010 Transfected with: HGNC; 12856; YY1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198315 CVCL_Y768 GM23890 transformed cell line human CVCL_Y768 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198316 CVCL_XV68 HEK293 eGFP-KLF13 transformed cell line human CVCL_XV68 CL:0000010 Transfected with: HGNC; 13672; KLF13; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198317 CVCL_Y767 GM23875 transformed cell line human CVCL_Y767 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198318 CVCL_XV67 HEK293 eGFP-IKZF2 transformed cell line human CVCL_XV67 CL:0000010 Transfected with: HGNC; 13177; IKZF2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198319 CVCL_Y766 GM23866 transformed cell line human CVCL_Y766 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198320 CVCL_XV66 HEK293 eGFP-HIC1 transformed cell line human CVCL_XV66 CL:0000010 Transfected with: HGNC; 4909; HIC1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198321 CVCL_Y765 GM23864 transformed cell line human CVCL_Y765 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198322 CVCL_XV65 HEK293 eGFP-GLI2 transformed cell line human CVCL_XV65 CL:0000010 Transfected with: HGNC; 4318; GLI2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198323 CVCL_Y769 GM23891 transformed cell line human CVCL_Y769 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198324 CVCL_XV69 HEK293 eGFP-KLF14 transformed cell line human CVCL_XV69 CL:0000010 Transfected with: HGNC; 23025; KLF14; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198325 CVCL_5P41 GM11169 finite cell line human CVCL_5P41 CL:0000010 Population: African American; Derived from sampling site: Heart. Male 21198326 CVCL_6141 SK-MEL-279 cancer cell line human CVCL_6141 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198327 CVCL_5P40 GM11115 finite cell line human CVCL_5P40 CL:0000010 Population: African American; Karyotypic information: 47,XY,+9.arr(9)x3 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198328 CVCL_6140 SK-MEL-276 cancer cell line human CVCL_6140 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198329 CVCL_5P45 GM11386 transformed cell line human CVCL_5P45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198330 CVCL_6145 SK-MEL-284 cancer cell line human CVCL_6145 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198331 CVCL_5P44 GM11383 transformed cell line human CVCL_5P44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198332 CVCL_6144 SK-MEL-283 cancer cell line human CVCL_6144 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198333 CVCL_5P43 GM11382 transformed cell line human CVCL_5P43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198334 CVCL_6143 SK-MEL-282 cancer cell line human CVCL_6143 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198335 CVCL_5P42 GM11226 transformed cell line human CVCL_5P42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198336 CVCL_6142 SK-MEL-281 cancer cell line human CVCL_6142 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198337 CVCL_5P38 GM11006 transformed cell line human CVCL_5P38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198338 CVCL_6138 SK-MEL-272 cancer cell line human CVCL_6138 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198339 CVCL_5P37 GM11005 transformed cell line human CVCL_5P37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198340 CVCL_6137 SK-MEL-271 cancer cell line human CVCL_6137 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198341 CVCL_5P36 GM11004 transformed cell line human CVCL_5P36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198342 CVCL_6136 SK-MEL-269 cancer cell line human CVCL_6136 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198343 CVCL_5P35 GM11003 transformed cell line human CVCL_5P35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198344 CVCL_6135 SK-MEL-268 cancer cell line human CVCL_6135 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198345 CVCL_5P39 GM11034 finite cell line human CVCL_5P39 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198346 CVCL_6139 SK-MEL-275 cancer cell line human CVCL_6139 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198347 CVCL_Y771 GM23924 transformed cell line human CVCL_Y771 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198348 CVCL_XV71 HEK293 eGFP-MZF1 transformed cell line human CVCL_XV71 CL:0000010 Transfected with: HGNC; 13108; MZF1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198349 CVCL_Y770 GM23923 transformed cell line human CVCL_Y770 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198350 CVCL_XV70 HEK293 eGFP-KLF16 transformed cell line human CVCL_XV70 CL:0000010 Transfected with: HGNC; 16857; KLF16; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198351 CVCL_Y775 GM24010 transformed cell line human CVCL_Y775 CL:0000010 Population: Caucasian; Greek/Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198352 CVCL_XV75 HEK293 eGFP-PRDM6 transformed cell line human CVCL_XV75 CL:0000010 Transfected with: HGNC; 9350; PRDM6; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198353 CVCL_Y774 GM24007 transformed cell line human CVCL_Y774 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198354 CVCL_XV74 HEK293 eGFP-PRDM4 transformed cell line human CVCL_XV74 CL:0000010 Transfected with: HGNC; 9348; PRDM4; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198355 CVCL_Y773 GM23982 transformed cell line human CVCL_Y773 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg92Gln (c.275G>A); ClinVar=VCV000097152; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198356 CVCL_XV73 HEK293 eGFP-PRDM2 transformed cell line human CVCL_XV73 CL:0000010 Transfected with: HGNC; 9347; PRDM2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198357 CVCL_Y772 GM23981 transformed cell line human CVCL_Y772 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg92Gln (c.275G>A); ClinVar=VCV000097152; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198358 CVCL_XV72 HEK293 eGFP-PATZ1 transformed cell line human CVCL_XV72 CL:0000010 Transfected with: HGNC; 13071; PATZ1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198359 CVCL_Y757 GM23826 transformed cell line human CVCL_Y757 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Ter (c.421C>T); ClinVar=VCV000010988; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198360 CVCL_XV57 TS-IFNGamma-13 hybridoma house mouse CVCL_XV57 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; S5WI25; Tupaia belangeri IFNG. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016222 21198361 CVCL_Y756 GM23811 transformed cell line human CVCL_Y756 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198362 CVCL_XV56 TS-CD4-38 hybridoma house mouse CVCL_XV56 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G4L1; Tupaia belangeri CD4. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016221 21198363 CVCL_Y755 GM23808 transformed cell line human CVCL_Y755 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000097371; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198364 CVCL_XV55 PEAA-3B5 hybridoma house mouse CVCL_XV55 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: ChEBI; CHEBI:144925; 1-(4-methoxyphenyl)-2-\{[4-(4-nitrophenyl)butan-2-yl]amino\}ethanol (Phenylethylamine A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2014222 21198365 CVCL_Y754 GM23788 transformed cell line human CVCL_Y754 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198366 CVCL_XV54 NGAL-4F6 hybridoma house mouse CVCL_XV54 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80188; Human LCN2 Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016216 21198367 CVCL_Y759 GM23828 transformed cell line human CVCL_Y759 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Ter (c.421C>T); ClinVar=VCV000010988; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198368 CVCL_XV59 LYON-ES1 GFP embryonic stem cell CVCL_XV59 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Female Group: Non-human primate cell line 21198369 CVCL_Y758 GM23827 transformed cell line human CVCL_Y758 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198370 CVCL_XV58 TSd-1 hybridoma house mouse CVCL_XV58 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Tupaia glis spermatogenic cells antigen. 21198371 CVCL_5P12 GM10184 transformed cell line human CVCL_5P12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198372 CVCL_6112 SK-MEL-222 cancer cell line human CVCL_6112 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198373 CVCL_5P11 GM10160 transformed cell line human CVCL_5P11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198374 CVCL_6111 SK-MEL-217 cancer cell line human CVCL_6111 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198375 CVCL_5P10 GM10064 finite cell line human CVCL_5P10 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198376 CVCL_6110 SK-MEL-209 cancer cell line human CVCL_6110 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198377 CVCL_5P05 GM09892 finite cell line human CVCL_5P05 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM09892; probable Male 21198378 CVCL_6105 SK-MEL-200 cancer cell line human CVCL_6105 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198379 CVCL_5P04 GM09888 transformed cell line human CVCL_5P04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198380 CVCL_6104 SK-MEL-199 cancer cell line human CVCL_6104 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198381 CVCL_5P03 GM09711 transformed cell line human CVCL_5P03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198382 CVCL_6103 SK-MEL-198 cancer cell line human CVCL_6103 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198383 CVCL_5P02 GM09709 transformed cell line human CVCL_5P02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Ambiguous 21198384 CVCL_6102 SK-MEL-196 cancer cell line human CVCL_6102 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198385 CVCL_5P09 GM10020 finite cell line human CVCL_5P09 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198386 CVCL_6109 SK-MEL-208 cancer cell line human CVCL_6109 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Glu (c.1397G>A); ClinVar=VCV000376073; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198387 CVCL_5P08 GM09996 finite cell line human CVCL_5P08 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198388 CVCL_6108 SK-MEL-207 cancer cell line human CVCL_6108 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198389 CVCL_5P07 GM09982 transformed cell line human CVCL_5P07 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198390 CVCL_6107 SK-MEL-205 cancer cell line human CVCL_6107 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198391 CVCL_5P06 GM09981 transformed cell line human CVCL_5P06 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex2-4dup; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21198392 CVCL_6106 SK-MEL-202 cancer cell line human CVCL_6106 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198393 CVCL_XV60 5E08 hybridoma house mouse CVCL_XV60 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; O00478; Human BTN3A3. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.14723 21198394 CVCL_Y760 GM23829 transformed cell line human CVCL_Y760 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Ter (c.421C>T); ClinVar=VCV000010988; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198395 CVCL_Y764 GM23853 transformed cell line human CVCL_Y764 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg92Ter (c.274C>T); ClinVar=VCV000097151; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198396 CVCL_XV64 HEK293 eGFP-FEZF1 transformed cell line human CVCL_XV64 CL:0000010 Transfected with: HGNC; 22788; FEZF1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198397 CVCL_Y763 GM23850 transformed cell line human CVCL_Y763 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg40His (c.119G>A); ClinVar=VCV000011014; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198398 CVCL_XV63 HEK293 eGFP-BCL6B transformed cell line human CVCL_XV63 CL:0000010 Transfected with: HGNC; 1002; BCL6B; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21198399 CVCL_Y762 GM23847 transformed cell line human CVCL_Y762 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198400 CVCL_XV62 HEK293 eGFP-BCL11A transformed cell line human CVCL_XV62 CL:0000010 Transfected with: HGNC; 13221; BCL11A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Omics: ChIP-seq epigenome analysis Female 21198401 CVCL_Y761 GM23840 transformed cell line human CVCL_Y761 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Pro225Leu (c.674C>T); ClinVar=VCV000011000; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198402 CVCL_XV61 HeLa S3/HA-E2F1 cancer cell line human CVCL_XV61 CL:0000010 Transfected with: HGNC; 3113; E2F1 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with E2F1 fused at the N-terminus to an HA tag 21198403 CVCL_XV46 6H9 [Mouse hybridoma against fowl aviadenovirus 4 fiber-1 protein] hybridoma house mouse CVCL_XV46 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A1B1SLD1; Fowl aviadenovirus 4 (FAdV-4) fiber-1 protein (Note=Also reacts with FAdV-10). 21198404 CVCL_Y746 GM23730 transformed cell line human CVCL_Y746 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198405 CVCL_XV45 6F20 hybridoma house mouse CVCL_XV45 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016219 21198406 CVCL_Y745 GM23726 transformed cell line human CVCL_Y745 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198407 CVCL_XV44 3B5 [Mouse hybridoma against FAdV-4 fiber 1] hybridoma house mouse CVCL_XV44 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; A0A1B1SLD1; Fowl aviadenovirus 4 (FAdV-4) fiber-1 protein (Note=Also reacts with FAdV-10). 21198408 CVCL_Y744 GM23725 transformed cell line human CVCL_Y744 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu301Ser (c.901T>C); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198409 CVCL_XV43 35C8 hybridoma house mouse CVCL_XV43 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G6F6; Tupaia belangeri CD3E. 21198410 CVCL_Y743 GM23724 transformed cell line human CVCL_Y743 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu301Ser (c.901T>C); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198411 CVCL_XV49 87I hybridoma house mouse CVCL_XV49 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G6F6; Tupaia belangeri CD3E. 21198412 CVCL_Y749 GM23744 transformed cell line human CVCL_Y749 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg26Gln (c.77G>A); ClinVar=VCV000010993; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198413 CVCL_XV48 78I hybridoma house mouse CVCL_XV48 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G6F6; Tupaia belangeri CD3E. 21198414 CVCL_Y748 GM23743 transformed cell line human CVCL_Y748 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg26Gln (c.77G>A); ClinVar=VCV000010993; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198415 CVCL_XV47 75II hybridoma house mouse CVCL_XV47 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G6F6; Tupaia belangeri CD3E. 21198416 CVCL_Y747 GM23732 transformed cell line human CVCL_Y747 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; c.472dupT; Zygosity=Unspecified (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198417 CVCL_5P23 GM10636 transformed cell line human CVCL_5P23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198418 CVCL_6123 SK-MEL-243 cancer cell line human CVCL_6123 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198419 CVCL_5P22 GM10608 transformed cell line human CVCL_5P22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198420 CVCL_6122 SK-MEL-239 cancer cell line human CVCL_6122 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198421 CVCL_5P21 GM10606 finite cell line human CVCL_5P21 CL:0000010 Karyotypic information: 69,XXX,dup(20)(pter->q13.2::q11.2->qter).arr 3q21.3(129973405-130112434)x3,8p23.1(7242445-7825360)x1,20q11.21q13.2(29298697-54338231)x3 (Coriell); Derived from sampling site: Whole fetus Cell type=Fibroblast.. Omics: CNV analysis Female 21198422 CVCL_6121 SK-MEL-238 cancer cell line human CVCL_6121 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24576830). 21198423 CVCL_5P20 GM10568 finite cell line human CVCL_5P20 CL:0000010 Population: Pakistani; Derived from sampling site: Cell type=Fibroblast. Male 21198424 CVCL_6120 SK-MEL-237 cancer cell line human CVCL_6120 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198425 CVCL_5P16 GM10283 transformed cell line human CVCL_5P16 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex73-79del; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21198426 CVCL_6116 SK-MEL-230 cancer cell line human CVCL_6116 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198427 CVCL_5P15 GM10254 transformed cell line human CVCL_5P15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198428 CVCL_6115 SK-MEL-229 cancer cell line human CVCL_6115 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198429 CVCL_5P14 GM10207 transformed cell line human CVCL_5P14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198430 CVCL_6114 SK-MEL-228 cancer cell line human CVCL_6114 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198431 CVCL_5P13 GM10186 finite cell line human CVCL_5P13 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198432 CVCL_6113 SK-MEL-227 cancer cell line human CVCL_6113 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198433 CVCL_5P19 GM10565 transformed cell line human CVCL_5P19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198434 CVCL_6119 SK-MEL-234 cancer cell line human CVCL_6119 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198435 CVCL_5P18 GM10557 finite cell line human CVCL_5P18 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198436 CVCL_6118 SK-MEL-233 cancer cell line human CVCL_6118 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198437 CVCL_5P17 GM10401 finite cell line human CVCL_5P17 CL:0000010 Population: Caucasian; Karyotypic information: 47,XX,+2.arr(2p)x3 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198438 CVCL_6117 SK-MEL-232 cancer cell line human CVCL_6117 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198439 CVCL_Y753 GM23770 transformed cell line human CVCL_Y753 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu349Pro (c.1046T>C); Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198440 CVCL_XV53 NGAL-3B5 hybridoma house mouse CVCL_XV53 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80188; Human LCN2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016214 21198441 CVCL_Y752 GM23769 transformed cell line human CVCL_Y752 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu349Pro (c.1046T>C); Zygosity=Mosaic (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198442 CVCL_XV52 NGAL-2D8 hybridoma house mouse CVCL_XV52 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P80188; Human LCN2. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016215 21198443 CVCL_XV51 CRP2 hybridoma house mouse CVCL_XV51 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02741; Human CRP. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016218 21198444 CVCL_Y751 GM23767 transformed cell line human CVCL_Y751 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198445 CVCL_XV50 92D1 hybridoma house mouse CVCL_XV50 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; X2G6F6; Tupaia belangeri CD3E. 21198446 CVCL_Y750 GM23752 transformed cell line human CVCL_Y750 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198447 CVCL_Y735 GM23643 transformed cell line human CVCL_Y735 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Gln (c.422G>A); ClinVar=VCV000010987; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198448 CVCL_XV35 HAP1 ZNF646 (-) 3 cancer cell line human CVCL_XV35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29004; ZNF646; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198449 CVCL_Y734 GM23638 transformed cell line human CVCL_Y734 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg277Trp (c.829C>T); ClinVar=VCV000010999; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with OTC deficiency but at risk for disease; Derived from sampling site: Peripheral blood. Female 21198450 CVCL_XV34 HAP1 ZNF646 (-) 2 cancer cell line human CVCL_XV34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29004; ZNF646; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198451 CVCL_Y733 GM23636 transformed cell line human CVCL_Y733 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Gln180Pro (c.539_540AG>CC); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198452 CVCL_XV33 HAP1 ZNF536 (-) cancer cell line human CVCL_XV33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29025; ZNF536; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198453 CVCL_Y732 GM23632 transformed cell line human CVCL_Y732 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198454 CVCL_XV32 HAP1 ZNF367 (-) 2 cancer cell line human CVCL_XV32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18320; ZNF367; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198455 CVCL_XV39 E14Tg2aSc4TP6.3 embryonic stem cell house mouse CVCL_XV39 CL:0000010 Transfected with: VGNC; 57143; Bovine MAPT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr, p.Val163Leu, p.Ile167Thr and p.Ser175Gly = mGFP6); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Transfected with construct expressing a MAPT/Tau-GFP fusion protein 21198456 CVCL_Y739 GM23668 transformed cell line human CVCL_Y739 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ala208Thr (c.622G>A); ClinVar=VCV000097274; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198457 CVCL_Y738 GM23667 transformed cell line human CVCL_Y738 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; c.216+1G>T (IVS2+1G>T); ClinVar=VCV000097135; Zygosity=Hemizygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198458 CVCL_XV38 HAP1 ZNRF3 (-) 4 cancer cell line human CVCL_XV38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18126; ZNRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198459 CVCL_Y737 GM23657 transformed cell line human CVCL_Y737 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198460 CVCL_XV37 HAP1 ZNRF3 (-) 3 cancer cell line human CVCL_XV37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18126; ZNRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198461 CVCL_Y736 GM23656 transformed cell line human CVCL_Y736 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg92Gln (c.275G>A); ClinVar=VCV000097152; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198462 CVCL_XV36 HAP1 ZNRF3 (-) 2 cancer cell line human CVCL_XV36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18126; ZNRF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198463 CVCL_XV42 1F38 hybridoma house mouse CVCL_XV42 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P05413; Human FABP3. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016220 21198464 CVCL_Y742 GM23685 transformed cell line human CVCL_Y742 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ile160Thr (c.479T>C); ClinVar=VCV000097213; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198465 CVCL_Y741 GM23683 transformed cell line human CVCL_Y741 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg92Ter (c.274C>T); ClinVar=VCV000097151; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198466 CVCL_XV41 LYON-ES1 Tau-GFP embryonic stem cell CVCL_XV41 CL:0000010 Transfected with: VGNC; 57143; Bovine MAPT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr, p.Val163Leu, p.Ile167Thr and p.Ser175Gly = mGFP6); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Transfected with construct expressing a MAPT/Tau-GFP fusion protein Group: Non-human primate cell line 21198467 CVCL_Y740 GM23671 transformed cell line human CVCL_Y740 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Arg141Ter (c.421C>T); ClinVar=VCV000010988; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198468 CVCL_XV40 LYON-ES1 embryonic stem cell CVCL_XV40 CL:0000010 Female Group: Non-human primate cell line. 21198469 CVCL_Y724 GM23486 transformed cell line human CVCL_Y724 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu95Ser (c.284T>C); ClinVar=VCV000097156; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198470 CVCL_XV24 HAP1 ZADH2 (-) 4 cancer cell line human CVCL_XV24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28697; PTGR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198471 CVCL_Y723 GM23465 transformed cell line human CVCL_Y723 CL:0000010 Sequence variation: Gene deletion; HGNC; 8512; OTC; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198472 CVCL_XV23 HAP1 ZADH2 (-) 3 cancer cell line human CVCL_XV23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28697; PTGR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198473 CVCL_Y722 GM23464 transformed cell line human CVCL_Y722 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198474 CVCL_XV22 HAP1 ZADH2 (-) 2 cancer cell line human CVCL_XV22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28697; PTGR3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198475 CVCL_Y721 GM23457 transformed cell line human CVCL_Y721 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198476 CVCL_XV21 HAP1 YTHDF3 (-) cancer cell line human CVCL_XV21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26465; YTHDF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198477 CVCL_Y728 GM23502 transformed cell line human CVCL_Y728 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198478 CVCL_XV28 HAP1 ZEB1 (-) 4 cancer cell line human CVCL_XV28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198479 CVCL_Y727 GM23501 transformed cell line human CVCL_Y727 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198480 CVCL_XV27 HAP1 ZEB1 (-) 3 cancer cell line human CVCL_XV27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198481 CVCL_Y726 GM23500 transformed cell line human CVCL_Y726 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198482 CVCL_XV26 HAP1 ZEB1 (-) 2 cancer cell line human CVCL_XV26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11642; ZEB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198483 CVCL_Y725 GM23487 transformed cell line human CVCL_Y725 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Leu95Ser (c.284T>C); ClinVar=VCV000097156; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198484 CVCL_XV25 HAP1 ZC3H12A (-) 2 cancer cell line human CVCL_XV25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26259; ZC3H12A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198485 CVCL_Y729 GM23509 transformed cell line human CVCL_Y729 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Ala135Glu (c.404C>A); ClinVar=VCV000097191; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198486 CVCL_XV29 HAP1 ZEB2 (-) 2 cancer cell line human CVCL_XV29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198487 CVCL_5P01 GM09596 transformed cell line human CVCL_5P01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198488 CVCL_6101 SK-MEL-192 cancer cell line human CVCL_6101 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21198489 CVCL_5P00 GM09447 finite cell line human CVCL_5P00 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM09447; probable Female 21198490 CVCL_6100 SK-MEL-191 cancer cell line human CVCL_6100 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198491 CVCL_Y731 GM23631 transformed cell line human CVCL_Y731 CL:0000010 Sequence variation: Mutation; HGNC; 8512; OTC; Simple; p.Met335Ile (c.1005G>A); ClinVar=VCV000097091; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198492 CVCL_XV31 HAP1 ZNF143 (-) cancer cell line human CVCL_XV31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12928; ZNF143; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198493 CVCL_Y730 GM23627 transformed cell line human CVCL_Y730 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198494 CVCL_XV30 HAP1 ZFX (-) cancer cell line human CVCL_XV30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12869; ZFX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21198495 CVCL_GD10 ND09825 transformed cell line human CVCL_GD10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198496 CVCL_GD09 ND09824 transformed cell line human CVCL_GD09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198497 CVCL_GD08 ND09823 transformed cell line human CVCL_GD08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198498 CVCL_GD03 ND09771 transformed cell line human CVCL_GD03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198499 CVCL_GD02 ND09769 transformed cell line human CVCL_GD02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198500 CVCL_GD01 ND09733 transformed cell line human CVCL_GD01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; ND09733; probable Female 21198501 CVCL_GD00 ND09732 transformed cell line human CVCL_GD00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198502 CVCL_GD07 ND09819 transformed cell line human CVCL_GD07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198503 CVCL_GD06 ND09807 transformed cell line human CVCL_GD06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198504 CVCL_GD05 ND09790 transformed cell line human CVCL_GD05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198505 CVCL_GD04 ND09780 transformed cell line human CVCL_GD04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198506 CVCL_5P92 GM13473 transformed cell line human CVCL_5P92 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198507 CVCL_6192 SK-RC-42 cancer cell line human CVCL_6192 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Bone. Doubling time: 48 hours (PubMed=2386958) 21198508 CVCL_5P91 GM13472 transformed cell line human CVCL_5P91 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198509 CVCL_6191 SK-RC-41 cancer cell line human CVCL_6191 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21198510 CVCL_5P90 GM13471 transformed cell line human CVCL_5P90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198511 CVCL_6190 SK-RC-40 cancer cell line human CVCL_6190 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21198512 CVCL_5P96 GM13478 transformed cell line human CVCL_5P96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198513 CVCL_6196 SK-RC-49 cancer cell line human CVCL_6196 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Doubling time: 42 hours (PubMed=2386958) 21198514 CVCL_5P95 GM13477 transformed cell line human CVCL_5P95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198515 CVCL_6195 SK-RC-48 cancer cell line human CVCL_6195 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu135Tyrfs*24 (c.404delT); Zygosity=Unspecified (PubMed=7915601) Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21198516 CVCL_5P94 GM13475 transformed cell line human CVCL_5P94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198517 CVCL_6194 SK-RC-47 cancer cell line human CVCL_6194 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21198518 CVCL_5P93 GM13474 transformed cell line human CVCL_5P93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198519 CVCL_6193 SK-RC-46 cancer cell line human CVCL_6193 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, metastatic site and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Bone; shoulder. Female 21198520 CVCL_5P99 GM13481 transformed cell line human CVCL_5P99 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198521 CVCL_6199 SK-RC-53 cancer cell line human CVCL_6199 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21198522 CVCL_5P98 GM13480 transformed cell line human CVCL_5P98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198523 CVCL_6198 SK-RC-52 cancer cell line human CVCL_6198 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Mediastinum. Female Doubling time: 36 hours (PubMed=2386958) 21198524 CVCL_5P97 GM13479 transformed cell line human CVCL_5P97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198525 CVCL_6197 SK-RC-51 cancer cell line human CVCL_6197 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21198526 CVCL_5P70 GM12929 finite cell line human CVCL_5P70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21198527 CVCL_6170 SK-RC-3 cancer cell line human CVCL_6170 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Female 21198528 CVCL_5P74 GM13433 transformed cell line human CVCL_5P74 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro15Leu (c.44C>T) (P14L); ClinVar=VCV000011075; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198529 CVCL_6174 SK-RC-9 cancer cell line human CVCL_6174 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Leu89Arg (c.266T>G); Zygosity=Unspecified (PubMed=7915601) Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from metastatic site: Brain. Male 21198530 CVCL_5P73 GM13277 transformed cell line human CVCL_5P73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198531 CVCL_6173 SK-RC-8 cancer cell line human CVCL_6173 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Arg120Lysfs*39 (c.359del); Zygosity=Unspecified (PubMed=7915601) Miscellaneous: STR profile, metastatic site and exact cancer type from MSKCC antibody and bioresource core facility Derived from metastatic site: Adrenal gland. Male 21198532 CVCL_5P72 GM13031 transformed cell line human CVCL_5P72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198533 CVCL_6172 SK-RC-5 cancer cell line human CVCL_6172 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21198534 CVCL_5P71 GM12959 transformed cell line human CVCL_5P71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198535 CVCL_6171 SK-RC-4 cancer cell line human CVCL_6171 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and metastatic site from MSKCC antibody and bioresource core facility Derived from metastatic site: Bone; humerus. Male 21198536 CVCL_5P78 GM13437 transformed cell line human CVCL_5P78 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Thr116Lys (c.347C>A) (T115K); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198537 CVCL_6178 SK-RC-13 cancer cell line human CVCL_6178 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from metastatic site: Brain. Male Doubling time: 42 hours (PubMed=2386958) 21198538 CVCL_5P77 GM13436 transformed cell line human CVCL_5P77 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Thr43Ile (c.128C>T) (T42I); ClinVar=VCV000011086; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198539 CVCL_6177 SK-RC-12 cancer cell line human CVCL_6177 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and metastatic site from MSKCC antibody and bioresource core facility Derived from metastatic site: Adrenal gland. Male 21198540 CVCL_5P76 GM13435 transformed cell line human CVCL_5P76 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Gly128Gly (c.384C>G) (G127G); Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198541 CVCL_6176 SK-RC-11 cancer cell line human CVCL_6176 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility. Male 21198542 CVCL_5P75 GM13434 transformed cell line human CVCL_5P75 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Thr118_Val166del (c.352_499del); Zygosity=Hemizygous (PubMed=7539213) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198543 CVCL_6175 SK-RC-10 cancer cell line human CVCL_6175 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21198544 CVCL_5P69 GM12722 transformed cell line human CVCL_5P69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198545 CVCL_6169 SK-RC-2 cancer cell line human CVCL_6169 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Male Doubling time: 60 hours (PubMed=2386958) 21198546 CVCL_5P68 GM12721 transformed cell line human CVCL_5P68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198547 CVCL_6168 SK-MEL-390 cancer cell line human CVCL_6168 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198548 CVCL_5P81 GM13460 transformed cell line human CVCL_5P81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198549 CVCL_6181 SK-RC-18 cancer cell line human CVCL_6181 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, metastatic site and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Cervical lymph node. Male Doubling time: 42 hours (PubMed=2386958) 21198550 CVCL_5P80 GM13451 finite cell line human CVCL_5P80 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21198551 CVCL_6180 SK-RC-15 cancer cell line human CVCL_6180 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, exact cancer type and age/sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21198552 CVCL_5P85 GM13465 transformed cell line human CVCL_5P85 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198553 CVCL_6185 SK-RC-30 cancer cell line human CVCL_6185 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Female 21198554 CVCL_5P84 GM13464 transformed cell line human CVCL_5P84 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198555 CVCL_6184 SK-RC-28 cancer cell line human CVCL_6184 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Pro86His (c.257C>A); Zygosity=Unspecified (PubMed=7915601) Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Female 21198556 CVCL_5P83 GM13463 transformed cell line human CVCL_5P83 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198557 CVCL_6183 SK-RC-26A cancer cell line human CVCL_6183 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Lung. Male 21198558 CVCL_5P82 GM13461 transformed cell line human CVCL_5P82 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198559 CVCL_6182 SK-RC-21 cancer cell line human CVCL_6182 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile, metastatic site and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Bone; lumbar vertebra. Male Doubling time: 38 hours (PubMed=2386958) 21198560 CVCL_5P89 GM13470 transformed cell line human CVCL_5P89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198561 CVCL_6189 SK-RC-38 cancer cell line human CVCL_6189 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from metastatic site: Lung. 21198562 CVCL_5P88 GM13468 transformed cell line human CVCL_5P88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198563 CVCL_6188 SK-RC-37 cancer cell line human CVCL_6188 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male 21198564 CVCL_5P87 GM13467 transformed cell line human CVCL_5P87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198565 CVCL_6187 SK-RC-33 cancer cell line human CVCL_6187 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Female 21198566 CVCL_5P86 GM13466 transformed cell line human CVCL_5P86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198567 CVCL_6186 SK-RC-31 cancer cell line human CVCL_6186 Genome ancestry: African=3.19%; Native American=0.01%; East Asian, North=7.38%; East Asian, South=0%; South Asian=3.18%; European, North=19.72%; European, South=66.52% (PubMed=30894373) From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Lung. Male Doubling time: 120 hours (PubMed=25984343) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21198568 CVCL_5P79 GM13441 finite cell line human CVCL_5P79 CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Ser1481Gly (c.4441A>G); ClinVar=VCV000036074; Zygosity=Unspecified; Note=VUS (PubMed=22639450) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21198569 CVCL_6179 SK-RC-14 cancer cell line human CVCL_6179 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility. Male 21198570 CVCL_GE99 ND11143 transformed cell line human CVCL_GE99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198571 CVCL_GE98 ND11138 transformed cell line human CVCL_GE98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198572 CVCL_GE82 ND11065 transformed cell line human CVCL_GE82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198573 CVCL_GE81 ND11059 transformed cell line human CVCL_GE81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198574 CVCL_GE80 ND11057 transformed cell line human CVCL_GE80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198575 CVCL_GE86 ND11083 transformed cell line human CVCL_GE86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198576 CVCL_GE85 ND11082 transformed cell line human CVCL_GE85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198577 CVCL_GE84 ND11080 transformed cell line human CVCL_GE84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198578 CVCL_GE83 ND11066 transformed cell line human CVCL_GE83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198579 CVCL_GE79 ND11056 transformed cell line human CVCL_GE79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198580 CVCL_GE78 ND11055 transformed cell line human CVCL_GE78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198581 CVCL_GE77 ND11054 transformed cell line human CVCL_GE77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198582 CVCL_GE76 ND11053 transformed cell line human CVCL_GE76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198583 CVCL_GE93 ND11127 transformed cell line human CVCL_GE93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198584 CVCL_GE92 ND11126 transformed cell line human CVCL_GE92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198585 CVCL_GE91 ND11114 transformed cell line human CVCL_GE91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198586 CVCL_GE90 ND11108 transformed cell line human CVCL_GE90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198587 CVCL_GE97 ND11137 transformed cell line human CVCL_GE97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198588 CVCL_GE96 ND11136 transformed cell line human CVCL_GE96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198589 CVCL_GE95 ND11135 transformed cell line human CVCL_GE95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198590 CVCL_GE94 ND11128 transformed cell line human CVCL_GE94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198591 CVCL_GE89 ND11096 transformed cell line human CVCL_GE89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198592 CVCL_GE88 ND11088 transformed cell line human CVCL_GE88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198593 CVCL_GE87 ND11086 transformed cell line human CVCL_GE87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198594 CVCL_GE60 ND10980 transformed cell line human CVCL_GE60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198595 CVCL_GE64 ND11005 transformed cell line human CVCL_GE64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198596 CVCL_GE63 ND11004 transformed cell line human CVCL_GE63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198597 CVCL_GE62 ND11003 transformed cell line human CVCL_GE62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198598 CVCL_GE61 ND11002 transformed cell line human CVCL_GE61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198599 CVCL_GE57 ND10959 transformed cell line human CVCL_GE57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198600 CVCL_GE56 ND10956 transformed cell line human CVCL_GE56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198601 CVCL_GE55 ND10953 transformed cell line human CVCL_GE55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198602 CVCL_GE54 ND10932 transformed cell line human CVCL_GE54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198603 CVCL_GE59 ND10970 transformed cell line human CVCL_GE59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198604 CVCL_GE58 ND10962 transformed cell line human CVCL_GE58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198605 CVCL_GE71 ND11043 transformed cell line human CVCL_GE71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198606 CVCL_GE70 ND11039 transformed cell line human CVCL_GE70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198607 CVCL_GE75 ND11051 transformed cell line human CVCL_GE75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198608 CVCL_GE74 ND11050 transformed cell line human CVCL_GE74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198609 CVCL_GE73 ND11048 transformed cell line human CVCL_GE73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198610 CVCL_GE72 ND11047 transformed cell line human CVCL_GE72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198611 CVCL_GE68 ND11035 transformed cell line human CVCL_GE68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198612 CVCL_GE67 ND11034 transformed cell line human CVCL_GE67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198613 CVCL_GE66 ND11033 transformed cell line human CVCL_GE66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198614 CVCL_GE65 ND11010 transformed cell line human CVCL_GE65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198615 CVCL_GE69 ND11038 transformed cell line human CVCL_GE69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198616 CVCL_GE42 ND10873 transformed cell line human CVCL_GE42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198617 CVCL_GE41 ND10870 transformed cell line human CVCL_GE41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198618 CVCL_GE40 ND10867 transformed cell line human CVCL_GE40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198619 CVCL_GE35 ND10840 transformed cell line human CVCL_GE35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198620 CVCL_GE34 ND10836 transformed cell line human CVCL_GE34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198621 CVCL_GE33 ND10784 transformed cell line human CVCL_GE33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198622 CVCL_GE32 ND10771 transformed cell line human CVCL_GE32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198623 CVCL_GE39 ND10866 transformed cell line human CVCL_GE39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198624 CVCL_GE38 ND10863 transformed cell line human CVCL_GE38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198625 CVCL_GE37 ND10856 transformed cell line human CVCL_GE37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198626 CVCL_GE36 ND10850 transformed cell line human CVCL_GE36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198627 CVCL_GE53 ND10931 transformed cell line human CVCL_GE53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198628 CVCL_GE52 ND10929 transformed cell line human CVCL_GE52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198629 CVCL_GE51 ND10927 transformed cell line human CVCL_GE51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198630 CVCL_GE50 ND10891 transformed cell line human CVCL_GE50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198631 CVCL_GE46 ND10884 transformed cell line human CVCL_GE46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198632 CVCL_GE45 ND10883 transformed cell line human CVCL_GE45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198633 CVCL_GE44 ND10881 transformed cell line human CVCL_GE44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198634 CVCL_GE43 ND10878 transformed cell line human CVCL_GE43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198635 CVCL_GE49 ND10888 transformed cell line human CVCL_GE49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198636 CVCL_GE48 ND10887 transformed cell line human CVCL_GE48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198637 CVCL_GE47 ND10886 transformed cell line human CVCL_GE47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198638 CVCL_XX55 AT40RM transformed cell line human CVCL_XX55 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe1209Tyrfs*19 (c.3626_3627delTT) (3625delTT); ClinVar=VCV000187552; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198639 CVCL_Y955 CHARGE1-20 induced pluripotent stem cell human CVCL_Y955 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1391fs*13 (c.4171delC); Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198640 CVCL_XX54 AT14RM transformed cell line human CVCL_XX54 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.3109delG; Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Met2384fs*1 (c.7146delA); Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198641 CVCL_Y954 CHARGE1-13 induced pluripotent stem cell human CVCL_Y954 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1391fs*13 (c.4171delC); Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Okuno H Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198642 CVCL_XX53 AT79RM transformed cell line human CVCL_XX53 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.2718_2721delGGCC; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198643 CVCL_Y953 HPS0132 induced pluripotent stem cell human CVCL_Y953 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198644 CVCL_XX52 AT13RM transformed cell line human CVCL_XX52 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Tyr731Ter (c.2192dupA); ClinVar=VCV000633063; Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2849Ter (c.8545C>T); ClinVar=VCV000133637; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198645 CVCL_Y952 HPS0131 induced pluripotent stem cell human CVCL_Y952 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198646 CVCL_XX59 AT16RM transformed cell line human CVCL_XX59 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu43Pro (c.128T>C); Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4842delA; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198647 CVCL_Y959 iPSC carrier 2 line 1 induced pluripotent stem cell human CVCL_Y959 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=23836290) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198648 CVCL_XX58 AT81RM transformed cell line human CVCL_XX58 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Thr1743Thr (c.5229A>T); Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198649 CVCL_Y958 iPSC carrier 1 line 6 induced pluripotent stem cell human CVCL_Y958 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=23836290) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198650 CVCL_XX57 AT18RM transformed cell line human CVCL_XX57 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ala1299Cysfs*3 (c.3894dupT); ClinVar=VCV000141534; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198651 CVCL_Y957 iPSC carrier 1 line 5 induced pluripotent stem cell human CVCL_Y957 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=23836290) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198652 CVCL_XX56 AT4RM transformed cell line human CVCL_XX56 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1267_Val1268insTer (c.3802delG) (p.Val1268Terfs); ClinVar=VCV000127374; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198653 CVCL_Y956 CHARGE1-25 induced pluripotent stem cell human CVCL_Y956 From: Keio University School of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Gln1391fs*13 (c.4171delC); Zygosity=Heterozygous (PubMed=29179815) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198654 CVCL_5R10 GM20375 transformed cell line human CVCL_5R10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198655 CVCL_6310 MRO cancer cell line human CVCL_6310 From: Juillard G.J.-F.; University of California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00240 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland follicular carcinoma. 21198656 CVCL_5R03 GM20125 transformed cell line human CVCL_5R03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198657 CVCL_6303 KAT-18 cancer cell line human CVCL_6303 CL:0000010 Sequence variation: Mutation; HGNC; 7230; MRE11; Simple; p.Leu57Ter (c.170T>G); ClinVar=VCV000479719; Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly199Val (c.596G>T); ClinVar=VCV000451799; Zygosity=Homozygous (PubMed=19825993; PubMed=30737244) Omics: Transcriptome analysis by microarray. Unspecified 21198658 CVCL_5R02 GM20118 transformed cell line human CVCL_5R02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198659 CVCL_6302 KAT-10 cancer cell line human CVCL_6302 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00221 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma. 21198660 CVCL_5R01 GM20022 transformed cell line human CVCL_5R01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198661 CVCL_6301 KAK-1 cancer cell line human CVCL_6301 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00220 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland follicular carcinoma. 21198662 CVCL_5R00 GM19715 transformed cell line human CVCL_5R00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198663 CVCL_6300 KTC-1 cancer cell line human CVCL_6300 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=23833040; PubMed=29156680; PubMed=30737244); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Transcriptome analysis by microarray Male Doubling time: ~48 hours (PubMed=10946899) 21198664 CVCL_5R07 GM20304 transformed cell line human CVCL_5R07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198665 CVCL_6307 K7 [Human thyroid carcinoma] cancer cell line human CVCL_6307 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified Doubling time: 22 hours (PubMed=9054892) 21198666 CVCL_5R06 GM20220 transformed cell line human CVCL_5R06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198667 CVCL_6306 KAT-7 cancer cell line human CVCL_6306 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00225 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). 21198668 CVCL_5R05 GM20201 transformed cell line human CVCL_5R05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198669 CVCL_6305 KAT-50 cancer cell line human CVCL_6305 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00224 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). 21198670 CVCL_5R04 GM20200 transformed cell line human CVCL_5R04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198671 CVCL_6304 KAT-4 cancer cell line human CVCL_6304 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=14522906) Omics: Transcriptome analysis by microarray. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00222 Problematic cell line: Contaminated Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma. 21198672 CVCL_6309 A14 [Thyroid adenma] cancer cell line human CVCL_6309 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified Doubling time: 26 hours (PubMed=9054892) 21198673 CVCL_5R09 GM20366 transformed cell line human CVCL_5R09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198674 CVCL_5R08 GM20305 transformed cell line human CVCL_5R08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198675 CVCL_6308 K2 [Human thyroid carcinoma] cancer cell line human CVCL_6308 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Caucasian; Italian; Derived from metastatic site: Thyroid gland. Male Doubling time: 23 hours (PubMed=9054892) Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00219 Problematic cell line: Contaminated Shown to be a GLAG-66 derivative (PubMed=20143388). 21198676 CVCL_XX62 AT95RM transformed cell line human CVCL_XX62 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.1607+1G>T (IVS12+1G>T); ClinVar=VCV000220555; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198677 CVCL_Y962 HiPS-RIKEN-8A induced pluripotent stem cell human CVCL_Y962 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198678 CVCL_XX61 AT101RM transformed cell line human CVCL_XX61 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Trp488Ter (c.1463G>A); ClinVar=VCV000246090; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198679 CVCL_Y961 CiRA00021 induced pluripotent stem cell human CVCL_Y961 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gln343Arg (c.1028A>G); ClinVar=VCV000005235; Zygosity=Heterozygous (PubMed=22855461) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Discontinued: RCB; HPS0289; probable Male 21198680 CVCL_XX60 AT106RM transformed cell line human CVCL_XX60 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.His231Arg (c.692A>G); ClinVar=VCV000142096; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198681 CVCL_Y960 iPSC carrier 2 line 11 induced pluripotent stem cell human CVCL_Y960 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=23836290) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198682 CVCL_Y944 HPS0230 induced pluripotent stem cell human CVCL_Y944 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198683 CVCL_XX44 PHK-T transformed cell line human CVCL_XX44 CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified 21198684 CVCL_XX43 HEL 286 finite cell line human CVCL_XX43 CL:0000010 Population: African American; Derived from sampling site: Fetal lung. Female 21198685 CVCL_Y943 HPS0229 induced pluripotent stem cell human CVCL_Y943 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198686 CVCL_XX42 HEL 274 finite cell line human CVCL_XX42 CL:0000010 Population: African American; Derived from sampling site: Fetal lung. Unspecified 21198687 CVCL_Y942 HPS0237 induced pluripotent stem cell human CVCL_Y942 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198688 CVCL_XX41 HEL 241 finite cell line human CVCL_XX41 CL:0000010 Population: African American; Derived from sampling site: Fetal lung. Unspecified 21198689 CVCL_Y941 HPS0236 induced pluripotent stem cell human CVCL_Y941 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198690 CVCL_XX48 AT97RM transformed cell line human CVCL_XX48 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Phe239Leufs*15 (c.717_720delCCTC); ClinVar=VCV000142709; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198691 CVCL_Y948 HPS0200 induced pluripotent stem cell human CVCL_Y948 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198692 CVCL_Y947 HPS0199 induced pluripotent stem cell human CVCL_Y947 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198693 CVCL_XX47 RPMI-7466 transformed cell line human CVCL_XX47 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~40 hours (PubMed=4960081) Caution: We are not certain this is an EBV-transformed cell line This assignment is based on the description of this cell line in PubMed=4304349 and PubMed=4960081. 21198694 CVCL_Y946 HPS0198 induced pluripotent stem cell human CVCL_Y946 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198695 CVCL_XX46 MAMI-96 spontaneously immortalized cell line house mouse CVCL_XX46 CL:0000010 Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: BALB/c. Unspecified 21198696 CVCL_Y945 HPS0231 induced pluripotent stem cell human CVCL_Y945 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198697 CVCL_XX45 Led-106 finite cell line human CVCL_XX45 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified Senescence: Senesces at 30 PDL (PubMed=14207842) 21198698 CVCL_Y949 LA5 induced pluripotent stem cell human CVCL_Y949 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (PubMed=26056228) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21198699 CVCL_XX49 T24/MMC cancer cell line human CVCL_XX49 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Swedish; Selected for resistance to: ChEBI; CHEBI:27504; Mitomycin C (MMC; Derived from sampling site: Urinary bladder. Female 21198700 CVCL_5R21 GM20546 transformed cell line human CVCL_5R21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198701 CVCL_6321 HR/+ D.Sp finite cell line house mouse CVCL_6321 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6350; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21198702 CVCL_5R20 GM20545 transformed cell line human CVCL_5R20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198703 CVCL_6320 HR/+ C.Sp finite cell line house mouse CVCL_6320 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6349; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21198704 CVCL_6314 BW5147.3(Thy-1-e).10 cancer cell line house mouse CVCL_6314 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21198705 CVCL_5R14 GM20418 transformed cell line human CVCL_5R14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198706 CVCL_6313 BW5147(T200-a)5.2 cancer cell line house mouse CVCL_6313 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21198707 CVCL_5R13 GM20411 transformed cell line human CVCL_5R13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198708 CVCL_6312 AL/N spontaneously immortalized cell line house mouse CVCL_6312 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: AL/N. Discontinued: ATCC; CRL-6506; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21198709 CVCL_5R12 GM20410 transformed cell line human CVCL_5R12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198710 CVCL_6311 AB.9 spontaneously immortalized cell line zebrafish CVCL_6311 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: AB. Unspecified Group: Fish cell line 21198711 CVCL_5R11 GM20409 transformed cell line human CVCL_5R11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198712 CVCL_6318 F1B cancer cell line CVCL_6318 CL:0000010 Derived from sampling site: Submandibular lymph node. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21198713 CVCL_5R18 GM20437 transformed cell line human CVCL_5R18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198714 CVCL_6317 Cl. Ly1+2-/9 spontaneously immortalized cell line house mouse CVCL_6317 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: C57BL/6-TL+. Characteristics: Produces IL3 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8179 21198715 CVCL_5R17 GM20435 transformed cell line human CVCL_5R17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198716 CVCL_6316 C5B7 transformed cell line human CVCL_6316 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8753 21198717 CVCL_5R16 GM20434 transformed cell line human CVCL_5R16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198718 CVCL_6315 BW5147.G.1.4 cancer cell line house mouse CVCL_6315 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Group: Hybridoma fusion partner cell line; Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21198719 CVCL_5R15 GM20419 transformed cell line human CVCL_5R15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198720 CVCL_5R19 GM20501 transformed cell line human CVCL_5R19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198721 CVCL_6319 HR/+ A.Sp finite cell line house mouse CVCL_6319 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6347; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21198722 CVCL_XX51 AT73RM transformed cell line human CVCL_XX51 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys750Lys (c.2250G>A); ClinVar=VCV000003044; Zygosity=Heterozygous; Note=Causes skipping of exon 14 (p.Ile709_Lys750del, c.2125_2250del) (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg805Ter (c.2413C>T); ClinVar=VCV000216021; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198723 CVCL_Y951 LA11 induced pluripotent stem cell human CVCL_Y951 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (PubMed=26056228) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21198724 CVCL_XX50 AT26RM transformed cell line human CVCL_XX50 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln414Ter (c.1240C>T); ClinVar=VCV000236671; Zygosity=Heterozygous (PubMed=8845835; PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21198725 CVCL_Y950 LA8 induced pluripotent stem cell human CVCL_Y950 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (from autologous cell lines LA5 and LA11) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21198726 CVCL_Y933 HPS0210 induced pluripotent stem cell human CVCL_Y933 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198728 CVCL_Y932 HiPS-RIKEN-8B induced pluripotent stem cell human CVCL_Y932 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198729 CVCL_XX32 PM-LGSOC-01 cancer cell line human CVCL_XX32 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=32317693) Miscellaneous: Age of donor from personal communication of De Wever O Derived from metastatic site: Peritoneum. Female Characteristics: Established from a patient-derived xenograft Doubling time: 42 hours (at 5th passage), 23 hours (at 22th passage) (PubMed=32317693) 21198730 CVCL_XX31 CCH-FAHNSCC-2 cancer cell line human CVCL_XX31 CL:0000010 Omics: Genome sequenced (low read coverage). Female 21198731 CVCL_Y931 HPS0234 induced pluripotent stem cell human CVCL_Y931 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198732 CVCL_Y930 GM00007 finite cell line human CVCL_Y930 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198733 CVCL_XX30 VU1149+SV40+pcDNA transformed cell line human CVCL_XX30 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. 21198734 CVCL_XX37 FP5-3-1 clone M5 spontaneously immortalized cell line house mouse CVCL_XX37 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mammary placode. Female 21198735 CVCL_Y937 GM23687 transformed cell line human CVCL_Y937 CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=28284873; PubMed=33197628) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198736 CVCL_XX36 FP5-3-1 clone L3 spontaneously immortalized cell line house mouse CVCL_XX36 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mammary placode. Female 21198737 CVCL_Y936 PMD4-16 induced pluripotent stem cell human CVCL_Y936 CL:0000010 Male 21198738 CVCL_XX35 FP5-3-1 clone K1 spontaneously immortalized cell line house mouse CVCL_XX35 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mammary placode. Female 21198739 CVCL_Y935 PMD4-14 induced pluripotent stem cell human CVCL_Y935 CL:0000010 Male 21198740 CVCL_XX34 FP5-3-1 spontaneously immortalized cell line house mouse CVCL_XX34 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mammary placode. Female 21198741 CVCL_Y934 HPS0211 induced pluripotent stem cell human CVCL_Y934 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198742 CVCL_XX39 CrCB spontaneously immortalized cell line CVCL_XX39 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) Group: Fish cell line 21198743 CVCL_Y939 GM23689 transformed cell line human CVCL_Y939 CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=28284873) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198744 CVCL_XX38 FP5-3-1 clone O1 spontaneously immortalized cell line house mouse CVCL_XX38 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Mammary placode. Female 21198745 CVCL_Y938 GM23688 transformed cell line human CVCL_Y938 CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Heterozygous (PubMed=28284873) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198746 CVCL_XX40 GFB spontaneously immortalized cell line CVCL_XX40 CL:0000010 Derived from sampling site: Brain. Unspecified Virology: Susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) Group: Fish cell line 21198747 CVCL_Y940 HPS0235 induced pluripotent stem cell human CVCL_Y940 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198748 CVCL_Y922 HPS0153 induced pluripotent stem cell human CVCL_Y922 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198749 CVCL_XX22 VU-SCC-RO cancer cell line human CVCL_XX22 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927) Omics: Genome sequenced (low read coverage). Male Characteristics: Established from a xenograft Doubling time: 43 +- 4 hours (PubMed=9139877) 21198750 CVCL_Y921 HPS0152 induced pluripotent stem cell human CVCL_Y921 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198751 CVCL_XX21 VU-SCC-OE cancer cell line human CVCL_XX21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=31541927) Derived from metastatic site: Lymph node. Omics: Genome sequenced (low read coverage) Male Characteristics: Established from a xenograft Doubling time: 48 +- 3 hours (PubMed=9139877) 21198752 CVCL_Y920 HPS0173 induced pluripotent stem cell human CVCL_Y920 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21198753 CVCL_XX20 VU-SCC-1604 cancer cell line human CVCL_XX20 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg21Lys (c.62G>A); ClinVar=VCV000371974; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Asn (c.250G>A); ClinVar=VCV000229806; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Gln1455Ter (c.4363C>T); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Pro1131Leu (c.3392C>T); ClinVar=VCV000134672; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (PubMed=31541927) Omics: Genome sequenced (low read coverage). Female 21198754 CVCL_Y926 HPS0238 induced pluripotent stem cell human CVCL_Y926 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198755 CVCL_XX26 VU1199-F SV40 transformed cell line human CVCL_XX26 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Arg293Serfs*7 (c.877_878AG[1]) (c.877_878delAG); ClinVar=VCV000021251; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198756 CVCL_Y925 HPS0182 induced pluripotent stem cell human CVCL_Y925 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198757 CVCL_XX25 VU1199-F finite cell line human CVCL_XX25 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Arg293Serfs*7 (c.877_878AG[1]) (c.877_878delAG); ClinVar=VCV000021251; Zygosity=Homozygous (PubMed=19738907) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198758 CVCL_Y924 HPS0181 induced pluripotent stem cell human CVCL_Y924 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198759 CVCL_XX24 VU-SCC-9917 cancer cell line human CVCL_XX24 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=23613873). Female 21198760 CVCL_Y923 HPS0154 induced pluripotent stem cell human CVCL_Y923 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21198761 CVCL_XX23 OHSU-974 cancer cell line human CVCL_XX23 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser37fs (c.109delT); Zygosity=Unspecified (PubMed=23613873) Female Caution: TP53 mutation indicated to be at p.Asp41fs (c.121delT) in PubMed=15735012. 21198762 CVCL_Y929 HPS0232 induced pluripotent stem cell human CVCL_Y929 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198763 CVCL_XX29 VU1149+SV40+DDX11 transformed cell line human CVCL_XX29 CL:0000010 Transfected with: HGNC; 2736; DDX11; Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. 21198764 CVCL_Y928 HPS0240 induced pluripotent stem cell human CVCL_Y928 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198765 CVCL_XX28 VU1199-F SV40+V5-ESCO2 transformed cell line human CVCL_XX28 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Arg293Serfs*7 (c.877_878AG[1]) (c.877_878delAG); ClinVar=VCV000021251; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 27230; ESCO2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198766 CVCL_Y927 HPS0239 induced pluripotent stem cell human CVCL_Y927 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198767 CVCL_XX27 VU1199-F SV40+GFP-ESCO2 transformed cell line human CVCL_XX27 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Arg293Serfs*7 (c.877_878AG[1]) (c.877_878delAG); ClinVar=VCV000021251; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 27230; ESCO2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198768 CVCL_Y911 HKC-11 transformed cell line human CVCL_Y911 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 20 hours (PubMed=9042817) 21198769 CVCL_XX11 RVAb-1 hybridoma house mouse CVCL_XX11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Rotavirus group A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201743 21198770 CVCL_XX10 HEK293-DR-GFP-XRCC3-5/X3+ transformed cell line human CVCL_XX10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12830; XRCC3; Transfected with: HGNC; 12830; XRCC3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The parental XRCC3 KO cell line is functionally reconstituted by retroviral transfection of XRCC3; Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~20-30 hours (DSMZ=ACC-854) 21198771 CVCL_Y910 HKC-8 transformed cell line human CVCL_Y910 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Omics: Transcriptome analysis by RNAseq Unspecified Doubling time: 20 hours (PubMed=9042817) 21198772 CVCL_Y915 HiPS-RIKEN-10B induced pluripotent stem cell human CVCL_Y915 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198773 CVCL_XX15 VU-SCC-078 cancer cell line human CVCL_XX15 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala161Thr (c.481G>A); ClinVar=VCV000161518; Zygosity=Unspecified (PubMed=15735012). Female 21198774 CVCL_Y914 HiPS-RIKEN-10A induced pluripotent stem cell human CVCL_Y914 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21198775 CVCL_XX14 VU-SCC-041 cancer cell line human CVCL_XX14 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=15735012). Male 21198776 CVCL_XX13 EC/PC-DR-mESC embryonic stem cell house mouse CVCL_XX13 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP Miscellaneous: Cell line information from personal communication of Payne L.B Breed/subspecies: CD-1/129 x Flk1:eGFP/+;NG2:dsRed/+. Unspecified 21198777 CVCL_Y913 iMELA3 induced pluripotent stem cell human CVCL_Y913 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198778 CVCL_Y912 iMELA1 induced pluripotent stem cell human CVCL_Y912 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198779 CVCL_XX12 RVAb-2 hybridoma house mouse CVCL_XX12 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Rotavirus group A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201744 21198780 CVCL_Y919 HPS0172 induced pluripotent stem cell human CVCL_Y919 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21198781 CVCL_XX19 VU-SCC-1365 cancer cell line human CVCL_XX19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 1509; CASP8; Simple; p.Arg432Ter (c.1294C>T); Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Glu838Lys (c.2512G>A); Zygosity=Heterozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Homozygous (PubMed=15735012; PubMed=23613873; PubMed=31541927) Omics: Genome sequenced (low read coverage). Male 21198782 CVCL_Y918 HPS0206 induced pluripotent stem cell human CVCL_Y918 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198783 CVCL_XX18 VU-SCC-1131 cancer cell line human CVCL_XX18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=31541927); Sequence variation: Mutation; HGNC; 3584; FANCC; Simple; p.Asp23Ilefs*23 (c.67delG) (322delG); ClinVar=VCV000012049; Zygosity=Unspecified (PubMed=15735012); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; c.1252-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=31541927); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Leu (c.818G>T); ClinVar=VCV000376655; Zygosity=Homozygous (PubMed=15735012; PubMed=23613873; PubMed=31541927) Omics: Genome sequenced (low read coverage). Female 21198784 CVCL_Y917 HPS0205 induced pluripotent stem cell human CVCL_Y917 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198785 CVCL_XX17 VU-SCC-094 cancer cell line human CVCL_XX17 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.919+1G>A (IVS8+1G>A); ClinVar=VCV000633606; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=15735012; PubMed=23613873). Female 21198786 CVCL_Y916 HPS0204 induced pluripotent stem cell human CVCL_Y916 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198787 CVCL_XX16 VU-SCC-080 cancer cell line human CVCL_XX16 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Del300bp; Zygosity=Unspecified (PubMed=15735012). Male 21198788 CVCL_XX00 HEK293-DR-GFP transformed cell line human CVCL_XX00 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~24 hours (DSMZ=ACC-844) 21198789 CVCL_Y900 Rama 401 spontaneously immortalized cell line Norway rat CVCL_Y900 CL:0000010 Derived from sampling site: Mammary gland Cell type=Myoepithelial cell.; Breed/subspecies: ICRF-Wistar. Female 21198790 CVCL_XX04 HEK293-DR-GFP-XRCC2-13 transformed cell line human CVCL_XX04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12829; XRCC2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~50-70 hours (DSMZ=ACC-848) 21198791 CVCL_Y904 Rama 900 cancer cell line Norway rat CVCL_Y904 CL:0000010 Breed/subspecies: Wistar Furth. Female 21198792 CVCL_XX03 HEK293-DR-GFP-RAD51D-16 transformed cell line human CVCL_XX03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~40 hours (DSMZ=ACC-847) 21198793 CVCL_Y903 Rama 622 cancer cell line Norway rat CVCL_Y903 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: Fischer 344. Female 21198794 CVCL_XX02 HEK293-DR-GFP-RAD51C-2 transformed cell line human CVCL_XX02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9820; RAD51C; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~40 hours (DSMZ=ACC-846) 21198795 CVCL_Y902 Rama 600 cancer cell line Norway rat CVCL_Y902 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: Fischer 344. Female 21198796 CVCL_XX01 HEK293-DR-GFP-RAD51B-9 transformed cell line human CVCL_XX01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9822; RAD51B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~48 hours (DSMZ=ACC-845) 21198797 CVCL_Y901 LICR LON TR2CL cancer cell line Norway rat CVCL_Y901 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Breed/subspecies: Fischer 344. Female 21198798 CVCL_XX08 HEK293-DR-GFP-RAD51D-16/D+ transformed cell line human CVCL_XX08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9823; RAD51D; Transfected with: HGNC; 9823; RAD51D; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The parental RAD51D KO cell line is functionally reconstituted by retroviral transfection of RAD51D; Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~30 hours (DSMZ=ACC-852) 21198799 CVCL_Y908 SVE3 transformed cell line human CVCL_Y908 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female Doubling time: 12 hours (in routine medium), 12 hours (in growth medium) (PubMed=2478401) 21198800 CVCL_XX07 HEK293-DR-GFP-RAD51C-2/C+ transformed cell line human CVCL_XX07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9820; RAD51C; Transfected with: HGNC; 9820; RAD51C; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The parental RAD51C KO cell line is functionally reconstituted by retroviral transfection of RAD51C; Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~30 hours (after thawing), ~10-20 hours (later passages) (DSMZ=ACC-851) 21198801 CVCL_Y907 Huma 62 transformed cell line human CVCL_Y907 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female Doubling time: 68 hours (in routine medium), 17 hours (in growth medium) (PubMed=2478401) 21198802 CVCL_XX06 HEK293-DR-GFP-RAD51B-9/B+ transformed cell line human CVCL_XX06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9822; RAD51B; Transfected with: HGNC; 9822; RAD51B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The parental RAD51B KO cell line is functionally reconstituted by retroviral transfection of RAD51B; Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~24-36 hours (DSMZ=ACC-850) 21198803 CVCL_Y906 Huma 25 transformed cell line human CVCL_Y906 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female Doubling time: 53 hours (in routine medium), 68 hours (in growth medium) (PubMed=2478401) 21198804 CVCL_XX05 HEK293-DR-GFP-XRCC3-5 transformed cell line human CVCL_XX05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12830; XRCC3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~40-50 hours (DSMZ=ACC-849) 21198805 CVCL_Y905 Huma 7 transformed cell line human CVCL_Y905 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast; epithelium. Female Doubling time: 17 hours (in routine medium), 19 hours (in growth medium) (PubMed=2478401) 21198806 CVCL_XX09 HEK293-DR-GFP-XRCC2-13/X2+ transformed cell line human CVCL_XX09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12829; XRCC2; Transfected with: HGNC; 12829; XRCC2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: The parental XRCC2 KO cell line is functionally reconstituted by retroviral transfection of XRCC2; Characteristics: Transfected with the hprtDR-GFP reporter construct that targets the DR-GFP into the hprt locus and includes a dominant selectable puroR marker The DR-GFP construct which contains a tandem repeat of two inactive genes coding for EGFP. After transfection with an expression vector coding for the I-SceI enzyme, recombination induced by the cleavage of the I-SceI site recreates a functional EGFP.; Characteristics: Transfected with the tetracycline transactivator (tTA) protein, a fusion of tetR with the activation domain of HSV-1 VP16 Doubling time: ~40 hours (DSMZ=ACC-853) 21198807 CVCL_Y909 HKC-5 transformed cell line human CVCL_Y909 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Kidney; proximal tubule Cell type=Proximal tubule epithelial cell.. Unspecified Doubling time: 40 hours (PubMed=9042817) 21198808 CVCL_6273 eEnd.1 transformed cell line house mouse CVCL_6273 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Cell type=Endothelial cell. Unspecified 21198809 CVCL_5Q73 GM16595 transformed cell line human CVCL_5Q73 CL:0000010 Population: Cuban; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198810 CVCL_5Q72 GM16594 hybrid cell line human CVCL_5Q72 CL:0000010 Group: Human/rodent somatic cell hybrid. 21198811 CVCL_6272 tEnd.1 transformed cell line house mouse CVCL_6272 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Thymus Cell type=Endothelial cell.. Unspecified 21198812 CVCL_6271 AT-1 [Human ataxia telangiectasia] undefined cell line type human CVCL_6271 CL:0000010 Unspecified 21198813 CVCL_5Q71 GM16593 transformed cell line human CVCL_5Q71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198814 CVCL_5Q70 GM16589 hybrid cell line human CVCL_5Q70 CL:0000010 Group: Human/rodent somatic cell hybrid. 21198815 CVCL_6270 sEnd.1 transformed cell line house mouse CVCL_6270 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Skin Cell type=Endothelial cell.. Unspecified 21198816 CVCL_6277 B3Z hybridoma house mouse CVCL_6277 CL:0000010 Characteristics: T-cell hybridoma. 21198817 CVCL_5Q77 GM16736 transformed cell line human CVCL_5Q77 CL:0000010 Sequence variation: Gene fusion; HGNC; 1787; CDKN2A + HGNC; 45045; FAM230A; Name(s)=CDKN2A-FAM230A (PubMed=23661601) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198818 CVCL_6276 B157 transformed cell line human CVCL_6276 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21198819 CVCL_5Q76 GM16718 transformed cell line human CVCL_5Q76 CL:0000010 Population: Southeast Asian; Vietnamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198820 CVCL_6275 bEnd.4 transformed cell line house mouse CVCL_6275 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Brain Cell type=Endothelial cell.; Breed/subspecies: BALB/c. Unspecified 21198821 CVCL_5Q75 GM16599 hybrid cell line human CVCL_5Q75 CL:0000010 Group: Human/rodent somatic cell hybrid. 21198822 CVCL_6274 eEnd.2 transformed cell line house mouse CVCL_6274 CL:0000010 Transformant: Polyoma middle T antigen (PyMLV); Derived from sampling site: Cell type=Endothelial cell. 21198823 CVCL_5Q74 GM16598 transformed cell line human CVCL_5Q74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198824 CVCL_5Q69 GM16588 transformed cell line human CVCL_5Q69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198825 CVCL_6269 IMR-90-SV transformed cell line human CVCL_6269 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21198826 CVCL_5Q68 GM16580 transformed cell line human CVCL_5Q68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198827 CVCL_6268 ScN2a cancer cell line house mouse CVCL_6268 CL:0000010 Breed/subspecies: A/J. Male Characteristics: Infected with mouse RML strain prions 21198828 CVCL_5Q67 GM16363 transformed cell line human CVCL_5Q67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM16362 (Cellosaurus=CVCL_5Q66); Derived from sampling site: Peripheral blood. Male 21198829 CVCL_6267 ScGT1 transformed cell line house mouse CVCL_6267 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2. Characteristics: Infected with mouse scrapie prions 21198830 CVCL_6280 BHP 15-3 cancer cell line human CVCL_6280 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00555 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=28940260). Originally thought to originate from a thyroid gland papillary carcinoma. 21198831 CVCL_5Q80 GM16809 transformed cell line human CVCL_5Q80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198832 CVCL_6284 BHP 5-16 cancer cell line human CVCL_6284 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00183 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland papillary carcinoma. 21198833 CVCL_5Q84 GM18180 transformed cell line human CVCL_5Q84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198834 CVCL_6283 BHP 2-7 cancer cell line human CVCL_6283 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Mitochondrial genome sequenced Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00182 Problematic cell line: Contaminated Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). 21198835 CVCL_5Q83 GM17941 transformed cell line human CVCL_5Q83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM17941; probable Female 21198836 CVCL_6282 BHP 18-21 hybrid cell line human CVCL_6282 CL:0000010 Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00571. Problematic cell line: Contaminated Shown to be a mixture of M14 and TPC-1 cell lines (DOI=10.1016/j.yamp.2018.07.005). Originally thought to originate from a thyroid gland papillary carcinoma. 21198837 CVCL_5Q82 GM17938 transformed cell line human CVCL_5Q82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198838 CVCL_6281 BHP 17-10 cancer cell line human CVCL_6281 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00181 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma. 21198839 CVCL_5Q81 GM16810 transformed cell line human CVCL_5Q81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198840 CVCL_5Q88 GM18332 transformed cell line human CVCL_5Q88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198841 CVCL_6288 HTh74 cancer cell line human CVCL_6288 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu732fs (c.2195_2202delTGCCCAAC); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=30737244) Derived from sampling site: Thyroid gland Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female Characteristics: Established from a tumor implanted into a nude mice (PubMed=1655394) 21198842 CVCL_6287 FRO cancer cell line human CVCL_6287 CL:0000010 Omics: Transcriptome analysis by microarray. Male 21198843 CVCL_5Q87 GM18331 transformed cell line human CVCL_5Q87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198844 CVCL_6286 DRO cancer cell line human CVCL_6286 From: Juillard G.J.-F.; University of California, Los Angeles; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00188 Problematic cell line: Contaminated Shown to be a A-375 derivative (PubMed=18713817; PubMed=20143388; PubMed=21868764). Originally thought to originate from a thyroid gland anaplastic carcinoma. 21198845 CVCL_5Q86 GM18311 transformed cell line human CVCL_5Q86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198846 CVCL_6285 BHP 7-13 cancer cell line human CVCL_6285 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00184 Problematic cell line: Contaminated Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388). 21198847 CVCL_5Q85 GM18308 transformed cell line human CVCL_5Q85 CL:0000010 Sequence variation: Mutation; HGNC; 21317; DYM; Simple; p.Tyr16Ter (c.48C>G); ClinVar=VCV000003184; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198848 CVCL_6279 BHP 14-9 cancer cell line human CVCL_6279 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00180 Problematic cell line: Contaminated Shown to be a M14 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland papillary carcinoma. 21198849 CVCL_5Q79 GM16808 transformed cell line human CVCL_5Q79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198850 CVCL_6278 BHP 10-3 cancer cell line human CVCL_6278 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Derived from sampling site: Thyroid gland. Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00179 Problematic cell line: Contaminated Shown to be a TPC-1 derivative (PubMed=18713817; PubMed=20143388). 21198851 CVCL_5Q78 GM16792 finite cell line human CVCL_5Q78 CL:0000010 Sequence variation: Gene fusion; HGNC; 1787; CDKN2A + HGNC; 45045; FAM230A; Name(s)=CDKN2A-FAM230A (PubMed=23661601) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21198852 CVCL_XW99 5A9B8 hybridoma house mouse CVCL_XW99 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07307; Human ASGR2 (isoform sH2a). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201751 21198853 CVCL_Y899 ND30013 finite cell line human CVCL_Y899 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[43] (c.52CAG(43)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30013; true Male Caution: Patient indicated as not affected with HD in HQ01808, but as affected in ND30013 21198854 CVCL_XW98 1F2D2 hybridoma house mouse CVCL_XW98 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P07307; Human ASGR2 (isoform sH2a). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201750 21198855 CVCL_Y898 ND30014 finite cell line human CVCL_Y898 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30014; true Female 21198856 CVCL_XW97 K562 eGFP-ZNF507 cancer cell line human CVCL_XW97 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 23783; ZNF507; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21198857 CVCL_Y897 ND33392 finite cell line human CVCL_Y897 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[57] (c.52CAG(57)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND33392; true Female 21198858 CVCL_6251 ASZ001 cancer cell line house mouse CVCL_6251 CL:0000010 21198859 CVCL_5Q51 GM14291 transformed cell line human CVCL_5Q51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198860 CVCL_6250 Akata EG cancer cell line human CVCL_6250 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 21198861 CVCL_5Q50 GM14268 transformed cell line human CVCL_5Q50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198862 CVCL_6255 ES-5838 cancer cell line human CVCL_6255 CL:0000010 Derived from metastatic site: Pleural effusion. Male 21198863 CVCL_5Q55 GM14297 transformed cell line human CVCL_5Q55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198864 CVCL_6254 DHFR-G8 spontaneously immortalized cell line house mouse CVCL_6254 CL:0000010 Transfected with: RGD; 2561; Erbb2 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21198865 CVCL_5Q54 GM14296 transformed cell line human CVCL_5Q54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198866 CVCL_6253 CSZ1 cancer cell line house mouse CVCL_6253 CL:0000010 21198867 CVCL_5Q53 GM14295 transformed cell line human CVCL_5Q53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198868 CVCL_6252 BSZ2 cancer cell line house mouse CVCL_6252 CL:0000010 21198869 CVCL_5Q52 GM14292 transformed cell line human CVCL_5Q52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198870 CVCL_6248 Akata 2C1 cancer cell line human CVCL_6248 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative Treated with hydroxyurea which completely eliminated EBV episomes. 21198871 CVCL_5Q48 GM14258 transformed cell line human CVCL_5Q48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198872 CVCL_6247 Akata 2A8 cancer cell line human CVCL_6247 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Protein expression by reverse-phase protein arrays. Female Virology: EBV-negative Treated with hydroxyurea which completely eliminated EBV episomes. Part of: MD Anderson Cell Lines Project 21198873 CVCL_5Q47 GM14243 transformed cell line human CVCL_5Q47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198874 CVCL_6246 AGN2a cancer cell line house mouse CVCL_6246 CL:0000010 Breed/subspecies: A/J. Male 21198875 CVCL_5Q46 GM14238 transformed cell line human CVCL_5Q46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198876 CVCL_6245 A4573 cancer cell line human CVCL_6245 CL:0000010 Derived from metastatic site: Pleural effusion. Omics: Protein expression by reverse-phase protein arrays Female Part of: MD Anderson Cell Lines Project 21198877 CVCL_5Q45 GM14234 transformed cell line human CVCL_5Q45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198878 CVCL_6249 Akata 3F2 cancer cell line human CVCL_6249 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative Treated with hydroxyurea which completely eliminated EBV episomes. 21198879 CVCL_5Q49 GM14267 transformed cell line human CVCL_5Q49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198880 CVCL_Y889 GM05622 transformed cell line human CVCL_Y889 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198881 CVCL_XW89 HEK293 eGFP-ZNF843 transformed cell line human CVCL_XW89 CL:0000010 Transfected with: HGNC; 28710; ZNF843; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198882 CVCL_Y888 GM05621 finite cell line human CVCL_Y888 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05621; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21198883 CVCL_XW88 HEK293 eGFP-ZNF792 transformed cell line human CVCL_XW88 CL:0000010 Transfected with: HGNC; 24751; ZNF792; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198884 CVCL_Y887 GM04799 finite cell line human CVCL_Y887 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198885 CVCL_XW87 HEK293 eGFP-ZNF791 transformed cell line human CVCL_XW87 CL:0000010 Transfected with: HGNC; 26895; ZNF791; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198886 CVCL_Y886 GM04798 transformed cell line human CVCL_Y886 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198887 CVCL_XW86 HEK293 eGFP-ZNF788 transformed cell line human CVCL_XW86 CL:0000010 Transfected with: HGNC; 33112; ZNF788P; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198888 CVCL_5Q62 GM16098 finite cell line human CVCL_5Q62 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM16098; probable Female 21198889 CVCL_6262 LCL 721.22 transformed cell line human CVCL_6262 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198890 CVCL_5Q61 GM15913 transformed cell line human CVCL_5Q61 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198891 CVCL_6261 LCL 721.180 transformed cell line human CVCL_6261 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198892 CVCL_5Q60 GM15901 transformed cell line human CVCL_5Q60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198893 CVCL_6260 LCL 721.174 transformed cell line human CVCL_6260 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198894 CVCL_5Q66 GM16362 transformed cell line human CVCL_5Q66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: Established from monozygotic twin of GM16363 (Cellosaurus=CVCL_5Q67); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198895 CVCL_6266 RCC63 cancer cell line human CVCL_6266 CL:0000010 Transfected with: HGNC; 12687; VHL. 21198896 CVCL_5Q65 GM16268 transformed cell line human CVCL_5Q65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198897 CVCL_6265 RCC10 cancer cell line human CVCL_6265 CL:0000010 21198898 CVCL_5Q64 GM16158 transformed cell line human CVCL_5Q64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198899 CVCL_6264 OSA344 cancer cell line human CVCL_6264 CL:0000010 Derived from sampling site: Bone. 21198900 CVCL_5Q63 GM16156 transformed cell line human CVCL_5Q63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198901 CVCL_6263 LCL 721.221 transformed cell line human CVCL_6263 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Gamma radiation(NCIt; C44386); Derived from sampling site: Peripheral blood. Discontinued: ATCC; CRL-1855; true Female Characteristics: Does not express HLA-A, HLA-B and HLA-C The absence of class I HLA expression allows for functional analysis of individual classI antigens via transformation with individual HLA genes (Millipore). Part of: International Histocompatibility Workshop cell lines 21198902 CVCL_5Q59 GM15603 transformed cell line human CVCL_5Q59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198903 CVCL_6259 HM2-SV40 transformed cell line human CVCL_6259 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Unspecified 21198904 CVCL_5Q58 GM15099 transformed cell line human CVCL_5Q58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198905 CVCL_6258 HM1-SV40 transformed cell line human CVCL_6258 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Stromal cell.. Unspecified 21198906 CVCL_5Q57 GM14489 finite cell line human CVCL_5Q57 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21198907 CVCL_6257 HFB-1 cancer cell line human CVCL_6257 CL:0000010 21198908 CVCL_5Q56 GM14485 transformed cell line human CVCL_5Q56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198909 CVCL_6256 HCB1-SV40 transformed cell line human CVCL_6256 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical cord blood Cell type=Stromal cell.. Unspecified 21198910 CVCL_Y892 GM05739 finite cell line human CVCL_Y892 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05739; probable Male Part of: Venezuelan Huntington disease kindreds subcollection 21198911 CVCL_XW92 HEK293 eGFP-ZSCAN21 transformed cell line human CVCL_XW92 CL:0000010 Transfected with: HGNC; 13104; ZSCAN21; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198912 CVCL_Y891 GM05614 transformed cell line human CVCL_Y891 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198913 CVCL_XW91 HEK293 eGFP-ZSCAN20 transformed cell line human CVCL_XW91 CL:0000010 Transfected with: HGNC; 13093; ZSCAN20; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198914 CVCL_Y890 GM05613 finite cell line human CVCL_Y890 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05613; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21198915 CVCL_XW90 HEK293 eGFP-ZSCAN18 transformed cell line human CVCL_XW90 CL:0000010 Transfected with: HGNC; 21037; ZSCAN18; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198916 CVCL_XW96 K562 eGFP-ZNF354B cancer cell line human CVCL_XW96 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 17197; ZNF354B; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 21198917 CVCL_Y896 ND30626 finite cell line human CVCL_Y896 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[41] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=22952635) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30626; true Male Caution: Patient indicated as not affected with HD in HQ01462, but as affected in ND30626 21198918 CVCL_XW95 HEK293 eGFP-ZSCAN5C transformed cell line human CVCL_XW95 CL:0000010 Transfected with: HGNC; 34294; ZSCAN5C; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198919 CVCL_Y895 ND30625 finite cell line human CVCL_Y895 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND30625; true Male 21198920 CVCL_XW94 HEK293 eGFP-ZSCAN29 transformed cell line human CVCL_XW94 CL:0000010 Transfected with: HGNC; 26673; ZSCAN29; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198921 CVCL_Y894 ND29563 finite cell line human CVCL_Y894 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg522Arg (c.1566G>A); ClinVar=VCV000540280; Zygosity=Unspecified; Note=Mislocalized protein (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND29563; true Male 21198922 CVCL_Y893 GM05740 transformed cell line human CVCL_Y893 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198923 CVCL_XW93 HEK293 eGFP-ZSCAN26 transformed cell line human CVCL_XW93 CL:0000010 Transfected with: HGNC; 12978; ZSCAN26; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198924 CVCL_Y878 GM04693 finite cell line human CVCL_Y878 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198925 CVCL_XW78 HEK293 eGFP-ZNF704 transformed cell line human CVCL_XW78 CL:0000010 Transfected with: HGNC; 32291; ZNF704; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198926 CVCL_Y877 GM04791 finite cell line human CVCL_Y877 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198927 CVCL_XW77 HEK293 eGFP-ZNF701 transformed cell line human CVCL_XW77 CL:0000010 Transfected with: HGNC; 25597; ZNF701; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198928 CVCL_Y876 GM04790 transformed cell line human CVCL_Y876 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198929 CVCL_XW76 HEK293 eGFP-ZNF692 transformed cell line human CVCL_XW76 CL:0000010 Transfected with: HGNC; 26049; ZNF692; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198930 CVCL_Y875 GM04736 transformed cell line human CVCL_Y875 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198931 CVCL_XW75 HEK293 eGFP-ZNF670 transformed cell line human CVCL_XW75 CL:0000010 Transfected with: HGNC; 28167; ZNF670; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198932 CVCL_Y879 GM04694 transformed cell line human CVCL_Y879 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198933 CVCL_XW79 HEK293 eGFP-ZNF71 transformed cell line human CVCL_XW79 CL:0000010 Transfected with: HGNC; 13141; ZNF71; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198934 CVCL_6233 A375-P cancer cell line human CVCL_6233 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 21198935 CVCL_5Q33 GM14049 transformed cell line human CVCL_5Q33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198936 CVCL_5Q32 GM14043 transformed cell line human CVCL_5Q32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198937 CVCL_6232 LyB9 factor-dependent cell line house mouse CVCL_6232 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent 21198938 CVCL_5Q31 GM14033 transformed cell line human CVCL_5Q31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198939 CVCL_6231 LyH7 factor-dependent cell line house mouse CVCL_6231 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: IL3 dependent 21198940 CVCL_5Q30 GM14007 transformed cell line human CVCL_5Q30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198941 CVCL_6230 SW707 cancer cell line human CVCL_6230 From: Scott and White Clinic; Temple; USA CL:0000010 Derived from sampling site: Rectum. Discontinued: CLS; 300351; true Male Doubling time: 47 hours, at 43th passage (PubMed=1000501) 21198942 CVCL_5Q26 GM13952 transformed cell line human CVCL_5Q26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198943 CVCL_6226 SK-MEL-89 cancer cell line human CVCL_6226 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198944 CVCL_5Q25 GM13951 transformed cell line human CVCL_5Q25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198945 CVCL_6225 SK-MEL-86 cancer cell line human CVCL_6225 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198946 CVCL_5Q24 GM13950 transformed cell line human CVCL_5Q24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198947 CVCL_6224 SK-MEL-85 cancer cell line human CVCL_6224 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Ser (c.1405_1406delGGinsTC); ClinVar=VCV000376072; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830) Omics: SNP array analysis; Omics: Transcriptome analysis by microarray. 21198948 CVCL_5Q23 GM13949 transformed cell line human CVCL_5Q23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198949 CVCL_6223 SK-MEL-81 cancer cell line human CVCL_6223 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198950 CVCL_5Q29 GM14005 transformed cell line human CVCL_5Q29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21198951 CVCL_6229 SK-MEL-49 cancer cell line human CVCL_6229 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 Male 21198952 CVCL_5Q28 GM13988 transformed cell line human CVCL_5Q28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198953 CVCL_6228 SK-MEL-91 cancer cell line human CVCL_6228 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21198954 CVCL_5Q27 GM13959 transformed cell line human CVCL_5Q27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198955 CVCL_6227 SK-MEL-90 cancer cell line human CVCL_6227 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830). 21198956 CVCL_Y881 GM05562 finite cell line human CVCL_Y881 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM05562; probable Female Part of: Venezuelan Huntington disease kindreds subcollection 21198957 CVCL_XW81 HEK293 eGFP-ZNF768 transformed cell line human CVCL_XW81 CL:0000010 Transfected with: HGNC; 26273; ZNF768; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198958 CVCL_Y880 GM04818 transformed cell line human CVCL_Y880 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198959 CVCL_XW80 HEK293 eGFP-ZNF747 transformed cell line human CVCL_XW80 CL:0000010 Transfected with: HGNC; 28350; ZNF747; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198960 CVCL_Y885 GM04797 finite cell line human CVCL_Y885 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198961 CVCL_XW85 HEK293 eGFP-ZNF785 transformed cell line human CVCL_XW85 CL:0000010 Transfected with: HGNC; 26496; ZNF785; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198962 CVCL_Y884 GM04796 transformed cell line human CVCL_Y884 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198963 CVCL_XW84 HEK293 eGFP-ZNF777 transformed cell line human CVCL_XW84 CL:0000010 Transfected with: HGNC; 22213; ZNF777; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198964 CVCL_Y883 GM04730 transformed cell line human CVCL_Y883 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198965 CVCL_XW83 HEK293 eGFP-ZNF776 transformed cell line human CVCL_XW83 CL:0000010 Transfected with: HGNC; 26765; ZNF776; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198966 CVCL_Y882 GM04729 finite cell line human CVCL_Y882 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198967 CVCL_XW82 HEK293 eGFP-ZNF770 transformed cell line human CVCL_XW82 CL:0000010 Transfected with: HGNC; 26061; ZNF770; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198968 CVCL_Y867 GM04285 finite cell line human CVCL_Y867 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198969 CVCL_XW67 HEK293 eGFP-ZNF621 transformed cell line human CVCL_XW67 CL:0000010 Transfected with: HGNC; 24787; ZNF621; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198970 CVCL_Y866 GM04716 transformed cell line human CVCL_Y866 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198971 CVCL_XW66 HEK293 eGFP-ZNF577 transformed cell line human CVCL_XW66 CL:0000010 Transfected with: HGNC; 28673; ZNF577; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198972 CVCL_Y865 GM04715 finite cell line human CVCL_Y865 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198973 CVCL_XW65 HEK293 eGFP-ZNF571 transformed cell line human CVCL_XW65 CL:0000010 Transfected with: HGNC; 25000; ZNF571; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198974 CVCL_Y864 GM04710 transformed cell line human CVCL_Y864 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198975 CVCL_XW64 HEK293 eGFP-ZNF560 transformed cell line human CVCL_XW64 CL:0000010 Transfected with: HGNC; 26484; ZNF560; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198976 CVCL_Y869 GM04721 finite cell line human CVCL_Y869 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21198977 CVCL_XW69 HEK293 eGFP-ZNF626 transformed cell line human CVCL_XW69 CL:0000010 Transfected with: HGNC; 30461; ZNF626; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198978 CVCL_Y868 GM04286 transformed cell line human CVCL_Y868 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21198979 CVCL_XW68 HEK293 eGFP-ZNF624 transformed cell line human CVCL_XW68 CL:0000010 Transfected with: HGNC; 29254; ZNF624; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21198980 CVCL_6240 661W transformed cell line house mouse CVCL_6240 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; retina Cell type=Retinal cone cell.; Breed/subspecies: C57BL/6N transgenic. Omics: Proteome analysis by 2D-DE/MS; Omics: Transcriptome analysis by RNAseq Male Doubling time: ~24 hours (PubMed=12407171) 21198981 CVCL_5Q40 GM14182 transformed cell line human CVCL_5Q40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198982 CVCL_6244 CEM A3.01 cancer cell line human CVCL_6244 CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: CD4+/CXCR4+ 21198983 CVCL_5Q44 GM14230 transformed cell line human CVCL_5Q44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198984 CVCL_6243 A2.A2 undefined cell line type house mouse CVCL_6243 CL:0000010 21198985 CVCL_5Q43 GM14222 transformed cell line human CVCL_5Q43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21198986 CVCL_6242 720 undefined cell line type house mouse CVCL_6242 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:102688; H2ax; Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53. 21198987 CVCL_5Q42 GM14184 transformed cell line human CVCL_5Q42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198988 CVCL_6241 7-17 factor-dependent cell line house mouse CVCL_6241 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Dendritic epidermal T-cell.; Breed/subspecies: AKR/J. Characteristics: IL2 or IL7 dependent Caution: Erroneously indicated as originating from human in Lonza=1468 21198989 CVCL_5Q41 GM14183 transformed cell line human CVCL_5Q41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198990 CVCL_5Q37 GM14162 transformed cell line human CVCL_5Q37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198991 CVCL_6237 GT1-3 transformed cell line house mouse CVCL_6237 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 transgenic with rat Gnrh1 promoter-Tg(SV40). 21198992 CVCL_5Q36 GM14140 transformed cell line human CVCL_5Q36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198993 CVCL_6236 GT1-1 transformed cell line house mouse CVCL_6236 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 transgenic with rat Gnrh1 promoter-Tg(SV40). 21198994 CVCL_5Q35 GM14106 transformed cell line human CVCL_5Q35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21198995 CVCL_6235 GT1 transformed cell line house mouse CVCL_6235 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: (C57BL/6J x BALB/cJ) F2 transgenic with rat Gnrh1 promoter-Tg(SV40). 21198996 CVCL_6234 A375-R cancer cell line human CVCL_6234 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Derived from sampling site: Skin. Female 21198997 CVCL_5Q34 GM14055 transformed cell line human CVCL_5Q34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21198998 CVCL_6239 3A9 hybridoma house mouse CVCL_6239 CL:0000010 Characteristics: T-cell hybridoma; Monoclonal antibody target: UniProtKB; P00698; Chicken LYZ. 21198999 CVCL_5Q39 GM14171 transformed cell line human CVCL_5Q39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199000 CVCL_6238 300-19 cancer cell line house mouse CVCL_6238 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Breed/subspecies: NIH Swiss. 21199001 CVCL_5Q38 GM14163 transformed cell line human CVCL_5Q38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199002 CVCL_Y870 GM04722 transformed cell line human CVCL_Y870 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199003 CVCL_XW70 HEK293 eGFP-ZNF629 transformed cell line human CVCL_XW70 CL:0000010 Transfected with: HGNC; 29008; ZNF629; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199004 CVCL_Y874 GM04735 finite cell line human CVCL_Y874 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199005 CVCL_XW74 HEK293 eGFP-ZNF662 transformed cell line human CVCL_XW74 CL:0000010 Transfected with: HGNC; 31930; ZNF662; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199006 CVCL_Y873 GM04727 finite cell line human CVCL_Y873 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199007 CVCL_XW73 HEK293 eGFP-ZNF658 transformed cell line human CVCL_XW73 CL:0000010 Transfected with: HGNC; 25226; ZNF658; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199008 CVCL_Y872 GM04724 transformed cell line human CVCL_Y872 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199009 CVCL_XW72 HEK293 eGFP-ZNF645 transformed cell line human CVCL_XW72 CL:0000010 Transfected with: HGNC; 26371; CBLL2; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199010 CVCL_Y871 GM04723 finite cell line human CVCL_Y871 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199011 CVCL_XW71 HEK293 eGFP-ZNF641 transformed cell line human CVCL_XW71 CL:0000010 Transfected with: HGNC; 31834; ZNF641; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199012 CVCL_Y856 GM04738 transformed cell line human CVCL_Y856 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199013 CVCL_XW56 HEK293 eGFP-ZNF518A transformed cell line human CVCL_XW56 CL:0000010 Transfected with: HGNC; 29009; ZNF518A; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199014 CVCL_Y855 GM04737 finite cell line human CVCL_Y855 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199015 CVCL_XW55 HEK293 eGFP-ZNF514 transformed cell line human CVCL_XW55 CL:0000010 Transfected with: HGNC; 25894; ZNF514; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199016 CVCL_Y854 GM04777 finite cell line human CVCL_Y854 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199017 CVCL_XW54 HEK293 eGFP-ZNF510 transformed cell line human CVCL_XW54 CL:0000010 Transfected with: HGNC; 29161; ZNF510; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199018 CVCL_Y853 GM04776 transformed cell line human CVCL_Y853 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(45)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199019 CVCL_XW53 HEK293 eGFP-ZNF501 transformed cell line human CVCL_XW53 CL:0000010 Transfected with: HGNC; 23717; ZNF501; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199020 CVCL_Y859 GM04287 finite cell line human CVCL_Y859 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from child cell line ND38551) Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199021 CVCL_XW59 HEK293 eGFP-ZNF529 transformed cell line human CVCL_XW59 CL:0000010 Transfected with: HGNC; 29328; ZNF529; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199022 CVCL_Y858 GM04773 finite cell line human CVCL_Y858 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199023 CVCL_XW58 HEK293 eGFP-ZNF524 transformed cell line human CVCL_XW58 CL:0000010 Transfected with: HGNC; 28322; ZNF524; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199024 CVCL_Y857 GM04772 transformed cell line human CVCL_Y857 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199025 CVCL_XW57 HEK293 eGFP-ZNF521 transformed cell line human CVCL_XW57 CL:0000010 Transfected with: HGNC; 24605; ZNF521; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199026 CVCL_5Q11 GM13880 transformed cell line human CVCL_5Q11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199027 CVCL_6211 WS1-CLS cancer cell line human CVCL_6211 CL:0000010 Population: Caucasian; Derived from sampling site: Foot; skin. Male 21199028 CVCL_5Q10 GM13721 transformed cell line human CVCL_5Q10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199029 CVCL_6210 SNUOT-Rb1 cancer cell line human CVCL_6210 CL:0000010 Population: Korean; Derived from sampling site: Eye. Omics: Array-based CGH Unspecified Doubling time: 24 hours (PubMed=17671685) 21199030 CVCL_5Q04 GM13487 transformed cell line human CVCL_5Q04 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199031 CVCL_6204 SK-RC-57 cancer cell line human CVCL_6204 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Doubling time: 48 hours (PubMed=2386958) 21199032 CVCL_5Q03 GM13485 transformed cell line human CVCL_5Q03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199033 CVCL_6203 SK-RC-56 cancer cell line human CVCL_6203 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Miscellaneous: STR profile and age/sex of donor from MSKCC antibody and bioresource core facility Derived from sampling site: Kidney. Male Doubling time: 48 hours (PubMed=2386958) 21199034 CVCL_5Q02 GM13484 transformed cell line human CVCL_5Q02 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199035 CVCL_6202 SK-RC-55 cancer cell line human CVCL_6202 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21199036 CVCL_5Q01 GM13483 transformed cell line human CVCL_5Q01 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199037 CVCL_6201 SK-RC-54V cancer cell line human CVCL_6201 CL:0000010 Derived from metastatic site: Lung. Male 21199038 CVCL_5Q08 GM13554 transformed cell line human CVCL_5Q08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199039 CVCL_6208 SK-RC-61 cancer cell line human CVCL_6208 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Val130Leu (c.388G>C); ClinVar=VCV000002229; Zygosity=Unspecified (PubMed=7915601) Miscellaneous: STR profile, metastatic site and age/sex of donor from MSKCC antibody and bioresource core facility Derived from metastatic site: Adrenal gland. Male Doubling time: 48 hours (PubMed=2386958) 21199040 CVCL_5Q07 GM13540 transformed cell line human CVCL_5Q07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199041 CVCL_6207 SK-RC-60 cancer cell line human CVCL_6207 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. 21199042 CVCL_5Q06 GM13489 transformed cell line human CVCL_5Q06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199043 CVCL_6206 SK-RC-59 cancer cell line human CVCL_6206 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Doubling time: 36 hours (PubMed=2386958) 21199044 CVCL_5Q05 GM13488 transformed cell line human CVCL_5Q05 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199045 CVCL_6205 SK-RC-58 cancer cell line human CVCL_6205 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Derived from sampling site: Kidney. Doubling time: 36 hours (PubMed=2386958) 21199046 CVCL_5Q09 GM13590 transformed cell line human CVCL_5Q09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199047 CVCL_6209 SK-RC-62 cancer cell line human CVCL_6209 From: Memorial Sloan Kettering Cancer Center; New York; USA CL:0000010 Sequence variation: Mutation; HGNC; 12687; VHL; Simple; p.Cys162Tyr (c.485G>A); ClinVar=VCV000223225; Zygosity=Unspecified (PubMed=7915601) Derived from sampling site: Kidney. Doubling time: 96 hours (PubMed=2386958) 21199048 CVCL_Y863 GM04709 finite cell line human CVCL_Y863 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199049 CVCL_XW63 HEK293 eGFP-ZNF555 transformed cell line human CVCL_XW63 CL:0000010 Transfected with: HGNC; 28382; ZNF555; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199050 CVCL_Y862 GM04688 transformed cell line human CVCL_Y862 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49-50] (c.52CAG(49-50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199051 CVCL_XW62 HEK293 eGFP-ZNF548 transformed cell line human CVCL_XW62 CL:0000010 Transfected with: HGNC; 26561; ZNF548; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199052 CVCL_Y861 GM04687 finite cell line human CVCL_Y861 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49-50] (c.52CAG(49-50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199053 CVCL_XW61 HEK293 eGFP-ZNF544 transformed cell line human CVCL_XW61 CL:0000010 Transfected with: HGNC; 16759; ZNF544; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199054 CVCL_Y860 GM04288 transformed cell line human CVCL_Y860 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[50] (c.52CAG(50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from autologous cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Venezuelan Huntington disease kindreds subcollection 21199055 CVCL_XW60 HEK293 eGFP-ZNF530 transformed cell line human CVCL_XW60 CL:0000010 Transfected with: HGNC; 29297; ZNF530; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199056 CVCL_XW45 HEK293 eGFP-ZNF426 transformed cell line human CVCL_XW45 CL:0000010 Transfected with: HGNC; 20725; ZNF426; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199057 CVCL_Y845 ND42224 induced pluripotent stem cell human CVCL_Y845 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42224; true; Discontinued: NHCDR; ND42224; true Female 21199058 CVCL_XW44 HEK293 eGFP-ZNF416 transformed cell line human CVCL_XW44 CL:0000010 Transfected with: HGNC; 20645; ZNF416; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199059 CVCL_Y844 ND42222 induced pluripotent stem cell human CVCL_Y844 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42222; true; Discontinued: NHCDR; ND42222; true Female 21199060 CVCL_XW43 HEK293 eGFP-ZNF414 transformed cell line human CVCL_XW43 CL:0000010 Transfected with: HGNC; 20630; ZNF414; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199062 CVCL_XW42 HEK293 eGFP-ZNF404 transformed cell line human CVCL_XW42 CL:0000010 Transfected with: HGNC; 19417; ZNF404; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199064 CVCL_XW49 HEK293 eGFP-ZNF473 transformed cell line human CVCL_XW49 CL:0000010 Transfected with: HGNC; 23239; ZNF473; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199065 CVCL_Y849 ND42240 induced pluripotent stem cell human CVCL_Y849 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; ND42240; true Female 21199066 CVCL_XW48 HEK293 eGFP-ZNF449 transformed cell line human CVCL_XW48 CL:0000010 Transfected with: HGNC; 21039; ZNF449; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199067 CVCL_Y848 ND42235 induced pluripotent stem cell human CVCL_Y848 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49-50] (c.52CAG(49-50)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42235; true Female 21199068 CVCL_XW47 HEK293 eGFP-ZNF438 transformed cell line human CVCL_XW47 CL:0000010 Transfected with: HGNC; 21029; ZNF438; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199069 CVCL_Y847 ND42230 induced pluripotent stem cell human CVCL_Y847 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42230; true Female 21199070 CVCL_XW46 HEK293 eGFP-ZNF433 transformed cell line human CVCL_XW46 CL:0000010 Transfected with: HGNC; 20811; ZNF433; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199071 CVCL_Y846 ND42229 induced pluripotent stem cell human CVCL_Y846 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[71] (c.52CAG(71)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42229; true; Discontinued: NHCDR; ND42229; true Female 21199072 CVCL_5Q22 GM13948 transformed cell line human CVCL_5Q22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199073 CVCL_6222 SK-MEL-79 cancer cell line human CVCL_6222 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21199074 CVCL_5Q21 GM13947 transformed cell line human CVCL_5Q21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199075 CVCL_6221 SK-MEL-76 cancer cell line human CVCL_6221 From: Memorial Sloan Kettering Cancer Center; New York; USA. CL:0000010 21199076 CVCL_6220 Daudi-TG cancer cell line human CVCL_6220 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male 21199077 CVCL_5Q20 GM13946 transformed cell line human CVCL_5Q20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199078 CVCL_5Q15 GM13919 transformed cell line human CVCL_5Q15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199079 CVCL_6215 RT112/D21 cancer cell line human CVCL_6215 CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Urinary bladder. Female 21199080 CVCL_5Q14 GM13897 transformed cell line human CVCL_5Q14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199081 CVCL_6214 HB-CLS-2 cancer cell line human CVCL_6214 HLA typing: A*24:02:01,32:01:01; B*27:02:00,55:01:01; C*02:02:02,03:03:01; DPB1*02:01,03:01; DQA1*01:05:01,04:01:01; DQB1*04:02:01,05:01:01; DRB1*08:01:01,10:01:01 (CLS=300191) CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21199082 CVCL_5Q13 GM13895 transformed cell line human CVCL_5Q13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199083 CVCL_6213 HB-CLS-1 cancer cell line human CVCL_6213 CL:0000010 Population: Caucasian; Derived from sampling site: Urinary bladder. Omics: Protein expression by reverse-phase protein arrays Male Part of: MD Anderson Cell Lines Project 21199084 CVCL_5Q12 GM13893 transformed cell line human CVCL_5Q12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199085 CVCL_6212 LyD9 LS-1 factor-dependent cell line house mouse CVCL_6212 CL:0000010 Derived from sampling site: Bone marrow; Breed/subspecies: CBA/J. Characteristics: CSF2 dependent 21199086 CVCL_5Q19 GM13945 transformed cell line human CVCL_5Q19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199087 CVCL_6219 RUDPUT-2 hybrid cell line human CVCL_6219 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21199088 CVCL_5Q18 GM13944 transformed cell line human CVCL_5Q18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199089 CVCL_6218 RUDPICAT-1 hybrid cell line human CVCL_6218 CL:0000010 Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21199090 CVCL_6217 DUTKO-1 hybrid cell line human CVCL_6217 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21199091 CVCL_5Q17 GM13943 transformed cell line human CVCL_5Q17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199092 CVCL_6216 DITRUD-1 hybrid cell line human CVCL_6216 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 21199093 CVCL_5Q16 GM13940 transformed cell line human CVCL_5Q16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199094 CVCL_XW52 HEK293 eGFP-ZNF493 transformed cell line human CVCL_XW52 CL:0000010 Transfected with: HGNC; 23708; ZNF493; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199095 CVCL_Y852 ND42245 induced pluripotent stem cell human CVCL_Y852 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42245; true Male 21199096 CVCL_XW51 HEK293 eGFP-ZNF491 transformed cell line human CVCL_XW51 CL:0000010 Transfected with: HGNC; 23706; ZNF491; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199097 CVCL_Y851 ND42242 induced pluripotent stem cell human CVCL_Y851 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42242; true Female 21199098 CVCL_XW50 HEK293 eGFP-ZNF48 transformed cell line human CVCL_XW50 CL:0000010 Transfected with: HGNC; 13114; ZNF48; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21199099 CVCL_Y850 ND42241 induced pluripotent stem cell human CVCL_Y850 CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; ND42241; true Female 21199100 CVCL_GE20 ND10652 transformed cell line human CVCL_GE20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199101 CVCL_GE19 ND10637 transformed cell line human CVCL_GE19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199102 CVCL_GE18 ND10634 transformed cell line human CVCL_GE18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199103 CVCL_GE13 ND10612 transformed cell line human CVCL_GE13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199104 CVCL_GE12 ND10609 transformed cell line human CVCL_GE12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199105 CVCL_GE11 ND10607 transformed cell line human CVCL_GE11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199106 CVCL_GE10 ND10606 transformed cell line human CVCL_GE10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199107 CVCL_GE17 ND10633 transformed cell line human CVCL_GE17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199108 CVCL_GE16 ND10616 transformed cell line human CVCL_GE16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199109 CVCL_GE15 ND10615 transformed cell line human CVCL_GE15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199110 CVCL_GE14 ND10614 transformed cell line human CVCL_GE14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199111 CVCL_GE31 ND10770 transformed cell line human CVCL_GE31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199112 CVCL_GE30 ND10714 transformed cell line human CVCL_GE30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199113 CVCL_GE29 ND10713 transformed cell line human CVCL_GE29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199114 CVCL_GE24 ND10678 transformed cell line human CVCL_GE24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199115 CVCL_GE23 ND10677 transformed cell line human CVCL_GE23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199116 CVCL_GE22 ND10660 transformed cell line human CVCL_GE22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199117 CVCL_GE21 ND10654 transformed cell line human CVCL_GE21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199118 CVCL_GE28 ND10712 transformed cell line human CVCL_GE28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199119 CVCL_GE27 ND10682 transformed cell line human CVCL_GE27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199120 CVCL_GE26 ND10681 transformed cell line human CVCL_GE26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199121 CVCL_GE25 ND10680 transformed cell line human CVCL_GE25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199122 CVCL_GE09 ND10605 transformed cell line human CVCL_GE09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199123 CVCL_GE08 ND10598 transformed cell line human CVCL_GE08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199124 CVCL_GE07 ND10597 transformed cell line human CVCL_GE07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199125 CVCL_GE02 ND10558 transformed cell line human CVCL_GE02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199126 CVCL_GE01 ND10540 transformed cell line human CVCL_GE01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199127 CVCL_GE00 ND10526 transformed cell line human CVCL_GE00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199128 CVCL_GE06 ND10595 transformed cell line human CVCL_GE06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199129 CVCL_GE05 ND10574 transformed cell line human CVCL_GE05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199130 CVCL_GE04 ND10562 transformed cell line human CVCL_GE04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199131 CVCL_GE03 ND10560 transformed cell line human CVCL_GE03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199132 CVCL_6291 ACT-1 [Human thyroid carcinoma] cancer cell line human CVCL_6291 From: Ohata S.; Tokushima University; Tokushima; Japan CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Ser (c.725G>C); ClinVar=VCV000647334; Zygosity=Homozygous (PubMed=30737244) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Unspecified 21199133 CVCL_5Q91 GM18335 transformed cell line human CVCL_5Q91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199134 CVCL_6290 ACT-1 [Human adrenocortical carcinoma] cancer cell line human CVCL_6290 CL:0000010 Population: Japanese; Derived from sampling site: Adrenal gland. Male Doubling time: 24 hours, at 26th passage (PubMed=11168692) 21199135 CVCL_5Q90 GM18334 transformed cell line human CVCL_5Q90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199136 CVCL_5Q95 GM18339 transformed cell line human CVCL_5Q95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199137 CVCL_6295 SSL-1 transformed cell line CVCL_6295 CL:0000010 Transformant: Rous sarcoma virus (strain Schmidt-Ruppin)(NCBI-Taxonomy; 11889); Derived from sampling site: Embryonic spleen Cell type=Stromal cell.; Breed/subspecies: Australorp x White Leghorn. Unspecified Group: Bird cell line 21199138 CVCL_5Q94 GM18338 transformed cell line human CVCL_5Q94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199139 CVCL_6294 MI-4 [Human lung carcinoma] cancer cell line human CVCL_6294 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21199140 CVCL_5Q93 GM18337 transformed cell line human CVCL_5Q93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199141 CVCL_6293 KT-3 cancer cell line human CVCL_6293 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21199142 CVCL_5Q92 GM18336 transformed cell line human CVCL_5Q92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199143 CVCL_6292 K-119 cancer cell line human CVCL_6292 CL:0000010 Population: Japanese; Derived from sampling site: Thyroid gland. Female Characteristics: Produces and secretes large amount of CSF3 Doubling time: 26 hours (PubMed=7689076) 21199144 CVCL_5Q99 GM18381 transformed cell line human CVCL_5Q99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199145 CVCL_6299 T238 cancer cell line human CVCL_6299 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu63Arg (c.188T>G); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Homozygous (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21199146 CVCL_5Q98 GM18379 transformed cell line human CVCL_5Q98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199147 CVCL_6298 TPC-1 cancer cell line human CVCL_6298 CL:0000010 Sequence variation: Gene fusion; HGNC; 18782; CCDC6 + HGNC; 9967; RET; Name(s)=CCDC6-RET, RET/PTC1 (PubMed=7491517; PubMed=30737244); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68fs (c.204_208delGGAGC); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11355; STAG2; Simple; p.Gln1089Ter (c.3265C>T); Zygosity=Heterozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=23833040; PubMed=30737244) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Mitochondrial genome sequenced; Omics: Transcriptome analysis by microarray Female 21199148 CVCL_5Q97 GM18378 transformed cell line human CVCL_5Q97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199149 CVCL_6297 TTA-1 cancer cell line human CVCL_6297 CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Gly289fs (c.866delG); Zygosity=Homozygous (PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg158Leu (c.473G>T); ClinVar=VCV000528248; Zygosity=Homozygous (PubMed=30737244) Population: Japanese; Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male Doubling time: 28.8 hours (PubMed=8121182) Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-7523 21199150 CVCL_5Q96 GM18340 transformed cell line human CVCL_5Q96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199151 CVCL_6296 V79B spontaneously immortalized cell line CVCL_6296 CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 21199152 CVCL_5Q89 GM18333 transformed cell line human CVCL_5Q89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199153 CVCL_6289 HTh7 cancer cell line human CVCL_6289 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln4118Ter (c.12352C>T); Zygosity=Unspecified (PubMed=30737244); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Homozygous; Note=In promoter (PubMed=23833040; PubMed=30737244); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Unspecified (PubMed=30737244) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 21199154 CVCL_GF99 ND11432 transformed cell line human CVCL_GF99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199155 CVCL_GF98 ND11431 transformed cell line human CVCL_GF98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199156 CVCL_GF97 ND11430 transformed cell line human CVCL_GF97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199157 CVCL_GF81 ND11340 transformed cell line human CVCL_GF81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199158 CVCL_GF80 ND11338 transformed cell line human CVCL_GF80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199159 CVCL_GF85 ND11381 transformed cell line human CVCL_GF85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199160 CVCL_GF84 ND11358 transformed cell line human CVCL_GF84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199161 CVCL_GF83 ND11357 transformed cell line human CVCL_GF83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199162 CVCL_GF82 ND11344 transformed cell line human CVCL_GF82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199163 CVCL_GF78 ND11334 transformed cell line human CVCL_GF78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199164 CVCL_GF77 ND11333 transformed cell line human CVCL_GF77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199165 CVCL_GF76 ND11332 transformed cell line human CVCL_GF76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199166 CVCL_GF75 ND11331 transformed cell line human CVCL_GF75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199167 CVCL_GF79 ND11335 transformed cell line human CVCL_GF79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199168 CVCL_GF92 ND11419 transformed cell line human CVCL_GF92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199169 CVCL_GF91 ND11418 transformed cell line human CVCL_GF91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199170 CVCL_GF90 ND11414 transformed cell line human CVCL_GF90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199171 CVCL_GF96 ND11428 transformed cell line human CVCL_GF96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199172 CVCL_GF95 ND11426 transformed cell line human CVCL_GF95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199173 CVCL_GF94 ND11424 transformed cell line human CVCL_GF94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199174 CVCL_GF93 ND11420 transformed cell line human CVCL_GF93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199175 CVCL_GF89 ND11413 transformed cell line human CVCL_GF89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199176 CVCL_GF88 ND11412 transformed cell line human CVCL_GF88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199177 CVCL_GF87 ND11390 transformed cell line human CVCL_GF87 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199178 CVCL_GF86 ND11388 transformed cell line human CVCL_GF86 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199179 CVCL_GF63 ND11259 transformed cell line human CVCL_GF63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199180 CVCL_GF62 ND11255 transformed cell line human CVCL_GF62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199181 CVCL_GF61 ND11250 transformed cell line human CVCL_GF61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199182 CVCL_GF60 ND11248 transformed cell line human CVCL_GF60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199183 CVCL_GF56 ND11241 transformed cell line human CVCL_GF56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199184 CVCL_GF55 ND11240 transformed cell line human CVCL_GF55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199185 CVCL_GF54 ND11239 transformed cell line human CVCL_GF54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199186 CVCL_GF53 ND11238 transformed cell line human CVCL_GF53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199187 CVCL_GF59 ND11246 transformed cell line human CVCL_GF59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199188 CVCL_GF58 ND11245 transformed cell line human CVCL_GF58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199189 CVCL_GF57 ND11242 transformed cell line human CVCL_GF57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199190 CVCL_GF70 ND11325 transformed cell line human CVCL_GF70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199191 CVCL_GF74 ND11330 transformed cell line human CVCL_GF74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199192 CVCL_GF73 ND11329 transformed cell line human CVCL_GF73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199193 CVCL_GF72 ND11328 transformed cell line human CVCL_GF72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199194 CVCL_GF71 ND11327 transformed cell line human CVCL_GF71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199195 CVCL_GF67 ND11292 transformed cell line human CVCL_GF67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199196 CVCL_GF66 ND11290 transformed cell line human CVCL_GF66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199197 CVCL_GF65 ND11282 transformed cell line human CVCL_GF65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199198 CVCL_GF64 ND11262 transformed cell line human CVCL_GF64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199199 CVCL_GF69 ND11316 transformed cell line human CVCL_GF69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199200 CVCL_GF68 ND11300 transformed cell line human CVCL_GF68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199201 CVCL_XY76 RCPCMi004-A induced pluripotent stem cell human CVCL_XY76 From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex2del; Zygosity=Heterozygous (PubMed=32151951) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199202 CVCL_XY75 KOG-1 cancer cell line human CVCL_XY75 CL:0000010 Population: Japanese; Derived from sampling site: Ascites. Female Doubling time: 13.7 hours (PubMed=31583526) 21199203 CVCL_XY74 4/95 hybridoma house mouse CVCL_XY74 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q1ZXQ8; Dictyostelium discoideum mtaA. 21199204 CVCL_XY73 4/148 hybridoma house mouse CVCL_XY73 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q1ZXQ8; Dictyostelium discoideum mtaA. 21199205 CVCL_XY79 EDi024-A induced pluripotent stem cell human CVCL_XY79 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21199206 CVCL_XY78 EDi025-A induced pluripotent stem cell human CVCL_XY78 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA; From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Peripheral blood. Male Part of: Lothian Birth Cohort 1936 iPSC collection 21199207 CVCL_XY77 RCPCMi005-A induced pluripotent stem cell human CVCL_XY77 From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199208 CVCL_5S31 GM22927 transformed cell line human CVCL_5S31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199209 CVCL_6431 Peccary.K finite cell line CVCL_6431 CL:0000010 Derived from sampling site: Kidney. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199210 CVCL_5S30 GM22926 transformed cell line human CVCL_5S30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199211 CVCL_6430 P116.cl39 cancer cell line human CVCL_6430 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 12858; ZAP70 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21199212 CVCL_5S24 GM22908 transformed cell line human CVCL_5S24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199213 CVCL_6424 NMu3Li finite cell line house mouse CVCL_6424 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Namru. Omics: SNP array analysis Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199214 CVCL_5S23 GM22905 transformed cell line human CVCL_5S23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199215 CVCL_6423 NEF36.Sg undefined cell line type CVCL_6423 CL:0000010 Derived from sampling site: Fetal salivary gland; sublingual gland. Discontinued: ATCC; CRL-6176; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199216 CVCL_5S22 GM22904 transformed cell line human CVCL_5S22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199217 CVCL_6422 NEF26.Ov undefined cell line type CVCL_6422 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-6175; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199218 CVCL_5S21 GM22903 transformed cell line human CVCL_5S21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199219 CVCL_6421 MDA-kb2 cancer cell line human CVCL_6421 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gln868His (c.2604G>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Trp638Ter (c.1913G>A); ClinVar=VCV000599651; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu307Lys (c.919G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex10-11del; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pericardial effusion. Biotechnology: Can be used in an vitro assay to screen androgen agonist and antagonists and to characterize its specificity and sensitivity to endocrine disrupting chemicals Female Characteristics: Expresses luciferase under the control of a MMTV promoter that contains glucocorticoid receptor and androgen receptor response elements Group: Triple negative breast cancer (TNBC) cell line 21199220 CVCL_5S28 GM22923 transformed cell line human CVCL_5S28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199221 CVCL_6428 OSU1 finite cell line CVCL_6428 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-6178; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199222 CVCL_5S27 GM22916 transformed cell line human CVCL_5S27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199223 CVCL_6427 OML clone 13C transformed cell line CVCL_6427 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Female Group: Non-human primate cell line 21199224 CVCL_5S26 GM22910 transformed cell line human CVCL_5S26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199225 CVCL_6426 OA4.K/S1 finite cell line CVCL_6426 CL:0000010 Derived from sampling site: Fetal kidney. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199226 CVCL_5S25 GM22909 transformed cell line human CVCL_5S25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199227 CVCL_6425 NMuLi spontaneously immortalized cell line house mouse CVCL_6425 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Namru. Discontinued: ATCC; CRL-6591; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199228 CVCL_5S29 GM22925 transformed cell line human CVCL_5S29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199229 CVCL_6429 P116 cancer cell line human CVCL_6429 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: SNP array analysis Male 21199230 CVCL_XY83 293T cyno PDL1 transformed cell line human CVCL_XY83 CL:0000010 Transfected with: UniProtKB; G7PSE7; Macaca fascicularis CD274; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21199231 CVCL_XY82 293T cyno GITR transformed cell line human CVCL_XY82 CL:0000010 Transfected with: UniProtKB; A0A2K5WP38; Macaca fascicularis TNFRSF18; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21199232 CVCL_XY81 293T cyno CSF1R transformed cell line human CVCL_XY81 CL:0000010 Transfected with: UniProtKB; A0A2K5WG91; Macaca fascicularis CSF1R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21199233 CVCL_XY80 293T cyno CD40 transformed cell line human CVCL_XY80 CL:0000010 Transfected with: UniProtKB; G7PG38; Macaca fascicularis CD40; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Doubling time: ~30 hours (KYinno) 21199234 CVCL_XY65 232-238-10 hybridoma house mouse CVCL_XY65 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q550R2; Dictyostelium discoideum ctxB. 21199235 CVCL_XY64 221-135-1 hybridoma house mouse CVCL_XY64 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q86IA3; Dictyostelium discoideum pdi1. 21199236 CVCL_XY63 F1 2-1 embryonic stem cell CVCL_XY63 CL:0000010 Breed/subspecies: Cast/EiJ x 129SvJae. Female 21199237 CVCL_XY62 mSG-PAC1 spontaneously immortalized cell line house mouse CVCL_XY62 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.; Breed/subspecies: Itga3flx/flx-Trp53-/-. Female 21199238 CVCL_XY69 260-302-2 hybridoma house mouse CVCL_XY69 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24005; Dictyostelium discoideum abpB. 21199239 CVCL_XY68 252-234-2 hybridoma house mouse CVCL_XY68 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q23858; Dictyostelium discoideum crtA. 21199240 CVCL_XY67 241-438-1 hybridoma house mouse CVCL_XY67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q54HG2; Dictyostelium discoideum ctxA. 21199241 CVCL_XY66 241-36-2 hybridoma house mouse CVCL_XY66 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q54HG2; Dictyostelium discoideum ctxA. 21199242 CVCL_5S42 GM22953 transformed cell line human CVCL_5S42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199243 CVCL_6442 RW4 embryonic stem cell house mouse CVCL_6442 CL:0000010 Breed/subspecies: 129X1/SvJ. Male 21199244 CVCL_5S41 GM22952 transformed cell line human CVCL_5S41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199245 CVCL_6441 RTgill-W1 spontaneously immortalized cell line CVCL_6441 CL:0000010 Derived from sampling site: Gill Cell type=Epithelial cell.. Biotechnology: Used in the ISO 21115:2019 assay for the determination of acute toxicity of water samples; Biotechnology: Used in the Organisation for Economic Co-operation and Development (OECD) fish cell line acute toxicity test method 249 (DOI=10.1787/c66d5190-en) Discontinued: BCRJ; 0362; true Unspecified Characteristics: Used for acute toxicity tests on chemicals Doubling time: ~10-12 days (DSMZ=ACC-899) Group: Fish cell line 21199246 CVCL_5S40 GM22951 transformed cell line human CVCL_5S40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199247 CVCL_6440 RT101 transformed cell line house mouse CVCL_6440 CL:0000010 Transformant: 12-O-tetradecanoylphorbol-13-acetate (TPA)(ChEBI; CHEBI:37537); Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21199248 CVCL_5S35 GM22932 transformed cell line human CVCL_5S35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199249 CVCL_6435 Prost 410 hybridoma house mouse CVCL_6435 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11426 21199250 CVCL_5S34 GM22931 transformed cell line human CVCL_5S34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM22931; probable Male 21199251 CVCL_6434 PK-2a/CL 13 spontaneously immortalized cell line pig CVCL_6434 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Discontinued: ATCC; CRL-6492; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199252 CVCL_5S33 GM22930 transformed cell line human CVCL_5S33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199253 CVCL_6433 PK-13 spontaneously immortalized cell line pig CVCL_6433 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Virology: Can be used for isolation and growth of rubella virus Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199254 CVCL_5S32 GM22929 transformed cell line human CVCL_5S32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199255 CVCL_6432 PK(D1) finite cell line pig CVCL_6432 CL:0000010 Discontinued: ATCC; CRL-6490; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199256 CVCL_5S39 GM22948 transformed cell line human CVCL_5S39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199257 CVCL_6439 RSOI finite cell line human CVCL_6439 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199258 CVCL_5S38 GM22944 transformed cell line human CVCL_5S38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199259 CVCL_6438 Rn 5TES finite cell line Norway rat CVCL_6438 CL:0000010 Derived from sampling site: Testis. Discontinued: ATCC; CRL-6513; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199260 CVCL_5S37 GM22937 transformed cell line human CVCL_5S37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199261 CVCL_6437 RATV-NRK undefined cell line type Norway rat CVCL_6437 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6510; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199262 CVCL_5S36 GM22936 transformed cell line human CVCL_5S36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199263 CVCL_6436 PT-K75 spontaneously immortalized cell line pig CVCL_6436 CL:0000010 Derived from sampling site: Nose; nasal cavity; nasal turbinate. Unspecified 21199264 CVCL_XY72 3/121 hybridoma house mouse CVCL_XY72 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum antigen at distal end of fibrous linkage structure connecting the centrosome to the nucleus. 21199265 CVCL_XY71 2/165 hybridoma house mouse CVCL_XY71 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q1ZXQ8; Dictyostelium discoideum mtaA. 21199266 CVCL_XY70 270-01-3 hybridoma house mouse CVCL_XY70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P24005; Dictyostelium discoideum abpB. 21199267 CVCL_XY54 AT12RM transformed cell line human CVCL_XY54 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.8269del403; Zygosity=Homozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199268 CVCL_XY53 WG1101 finite cell line human CVCL_XY53 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ala2067Glnfs*10 (c.6199_6347del149); Zygosity=Heterozygous (PubMed=8845835) Miscellaneous: Cell line no longer available Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 21199269 CVCL_XY52 AT5RM transformed cell line human CVCL_XY52 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Tyr705Thrfs*30 (c.2113delT); Zygosity=Heterozygous (PubMed=8845835); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1993Argfs*23 (c.5979_5983delTAAAG) (5979delTAAAG); ClinVar=VCV000233016; Zygosity=Heterozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199270 CVCL_XY51 AT8RM transformed cell line human CVCL_XY51 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Heterozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199271 CVCL_XY58 Replic transformed cell line house mouse CVCL_XY58 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:95407; Epo; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Kidney; Breed/subspecies: ISAM-REC (EpoGFP/GFP:Rosa26CAG-LSL-tdTomato/WT:Tg3.3K-Epo:TgEpoCre) transgenic. Characteristics: Established from renal erythropoietin-producing (REP) cells 21199272 CVCL_XY57 PaF spontaneously immortalized cell line CVCL_XY57 CL:0000010 Derived from sampling site: Fin. Unspecified Characteristics: Grows stably in a range of temperatures from 20 to 32 Celsius with a maximum growth rate of 28 Celsius; Virology: Susceptible to infection by viral hemorrhagic septicemia virus (VHSV) Group: Fish cell line 21199273 CVCL_XY56 E10F10D5 hybridoma house mouse CVCL_XY56 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04134; Porcine transmissible gastroenteritis coronavirus (TGEV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200502 21199274 CVCL_XY55 WSSV-R hybridoma house mouse CVCL_XY55 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Penaeus China white spot syndrome virus receptor. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200418 21199275 CVCL_XY59 imHC-FVII telomerase immortalized cell line human CVCL_XY59 CL:0000010 Transfected with: HGNC; 3544; F7; Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell derived hepatocyte.. 21199276 CVCL_5S02 GM22666 transformed cell line human CVCL_5S02 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199277 CVCL_6402 Hs 212.M finite cell line human CVCL_6402 CL:0000010 Derived from sampling site: Fascia Cell type=Fibroblast.. Discontinued: ATCC; CRL-7173; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199278 CVCL_5S01 GM22664 transformed cell line human CVCL_5S01 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199279 CVCL_6401 HJ2.Lu finite cell line CVCL_6401 CL:0000010 Derived from sampling site: Fetal lung. Discontinued: ATCC; CRL-6277; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199280 CVCL_5S00 GM22663 transformed cell line human CVCL_5S00 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199281 CVCL_6400 HJ1.Ov finite cell line CVCL_6400 CL:0000010 Derived from sampling site: Ovary. Discontinued: ATCC; CRL-6274; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199282 CVCL_5S06 GM22682 transformed cell line human CVCL_5S06 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199283 CVCL_6406 I-11.15 factor-dependent cell line house mouse CVCL_6406 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21199284 CVCL_5S05 GM22669 transformed cell line human CVCL_5S05 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199285 CVCL_6405 HT-768.M finite cell line human CVCL_6405 CL:0000010 Discontinued: ATCC; CRL-7790; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199286 CVCL_5S04 GM22668 transformed cell line human CVCL_5S04 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199287 CVCL_6404 HT-297.T finite cell line human CVCL_6404 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199288 CVCL_5S03 GM22667 transformed cell line human CVCL_5S03 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199289 CVCL_6403 Hs 395.We finite cell line human CVCL_6403 CL:0000010 Derived from sampling site: Whole fetus Cell type=Fibroblast.. Discontinued: ATCC; CRL-7271; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199290 CVCL_5S09 GM22710 transformed cell line human CVCL_5S09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199291 CVCL_6409 ICR MEF finite cell line house mouse CVCL_6409 CL:0000010 Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: ICR. Discontinued: ATCC; SCRC-1046; true Mixed 21199292 CVCL_5S08 GM22709 transformed cell line human CVCL_5S08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199293 CVCL_6408 ICR-134 spontaneously immortalized cell line CVCL_6408 CL:0000010 Unspecified Doubling time: ~50 hours (DOI=10.1007/978-3-642-85791-1_7). Group: Amphibian cell line 21199294 CVCL_5S07 GM22684 transformed cell line human CVCL_5S07 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199295 CVCL_6407 I-13.35 factor-dependent cell line house mouse CVCL_6407 CL:0000010 Derived from sampling site: Spleen Cell type=Macrophage.; Breed/subspecies: C3H/HeJ. Female Characteristics: CSF1 dependent 21199296 CVCL_XY61 mSG-DUC1 spontaneously immortalized cell line house mouse CVCL_XY61 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:98834; Trp53 Derived from sampling site: Salivary gland; submandibular gland; Breed/subspecies: Itga3flx/flx-Trp53-/-. Unspecified 21199297 CVCL_XY60 C3948 cancer cell line human CVCL_XY60 CL:0000010 Sequence variation: Mutation; HGNC; 28648; DIS3L2; Simple; p.Trp361Leu (c.1082G>T); Zygosity=Unspecified (PubMed=31368081); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Ser216Phe (c.647C>T); ClinVar=VCV000376708; Zygosity=Unspecified (PubMed=31368081); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu346Ter (c.1036G>T); ClinVar=VCV000634697; Zygosity=Hemizygous (PubMed=31368081) Derived from sampling site: Thyroid gland. Omics: Transcriptome analysis by microarray Male Doubling time: 30 hours (PubMed=31368081) 21199298 CVCL_XY43 8.2 [Mouse hybridoma against human CD89] hybridoma house mouse CVCL_XY43 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24071; Human FCAR/CD89. 21199299 CVCL_XY42 7.4 hybridoma house mouse CVCL_XY42 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24071; Human FCAR/CD89. 21199300 CVCL_XY41 14.1 [Mouse hybridoma against human FCAR] hybridoma house mouse CVCL_XY41 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P24071; Human FCAR/CD89. 21199301 CVCL_XY40 4H84 hybridoma house mouse CVCL_XY40 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199302 CVCL_XY47 AT22RM transformed cell line human CVCL_XY47 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Homozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199303 CVCL_XY46 CGMCC-14697 hybridoma house mouse CVCL_XY46 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:4046; Cyproheptadine. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.14697 21199304 CVCL_XY45 ICGi015-B induced pluripotent stem cell human CVCL_XY45 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 30213; ATP13A2; Simple; p.Pro1172Pro (c.3516G>A) (p.Ala1072Thr, c.3214G>A); ClinVar=VCV000128475; Zygosity=Heterozygous (PubMed=31733442); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ala419Val (c.1256C>T); ClinVar=VCV000039131; Zygosity=Heterozygous (PubMed=31733442); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Met318Leu (c.952A>T); ClinVar=VCV000447942; Zygosity=Heterozygous (PubMed=31733442) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21199305 CVCL_XY44 ICGi015-A induced pluripotent stem cell human CVCL_XY44 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 30213; ATP13A2; Simple; p.Pro1172Pro (c.3516G>A) (p.Ala1072Thr, c.3214G>A); ClinVar=VCV000128475; Zygosity=Heterozygous (PubMed=31733442); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ala419Val (c.1256C>T); ClinVar=VCV000039131; Zygosity=Heterozygous (PubMed=31733442); Sequence variation: Mutation; HGNC; 14581; PINK1; Simple; p.Met318Leu (c.952A>T); ClinVar=VCV000447942; Zygosity=Heterozygous (PubMed=31733442) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21199306 CVCL_XY49 AT59RM transformed cell line human CVCL_XY49 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Homozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199307 CVCL_XY48 AT29RM transformed cell line human CVCL_XY48 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro1480Tyrfs*5 (c.4611_4611+9del10) (c.4437_4611del175); Zygosity=Homozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199308 CVCL_5S20 GM22902 transformed cell line human CVCL_5S20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199309 CVCL_6420 MD transformed cell line human CVCL_6420 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9850 21199310 CVCL_5S13 GM22770 transformed cell line human CVCL_5S13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199311 CVCL_6413 KMA transformed cell line human CVCL_6413 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9856 21199312 CVCL_5S12 GM22765 transformed cell line human CVCL_5S12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199313 CVCL_6412 J1 embryonic stem cell house mouse CVCL_6412 CL:0000010 Breed/subspecies: 129S4/SvJae. Omics: Cell surface proteome Male 21199314 CVCL_5S11 GM22712 transformed cell line human CVCL_5S11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199315 CVCL_6411 J.gamma1.WT cancer cell line human CVCL_6411 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 9065; PLCG1 Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 21199316 CVCL_5S10 GM22711 transformed cell line human CVCL_5S10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199317 CVCL_6410 J.gamma1 cancer cell line human CVCL_6410 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Deep phosphoproteome analysis; Omics: SNP array analysis Male 21199318 CVCL_5S17 GM22782 transformed cell line human CVCL_5S17 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199319 CVCL_6417 m5S spontaneously immortalized cell line house mouse CVCL_6417 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: ICR/Jcl. Male 21199320 CVCL_5S16 GM22777 transformed cell line human CVCL_5S16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199321 CVCL_6416 LTR228 transformed cell line human CVCL_6416 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>A); ClinVar=VCV000142714; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male Group: Hybridoma fusion partner cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8502 21199322 CVCL_5S15 GM22775 transformed cell line human CVCL_5S15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199323 CVCL_6415 LFC16.Ln finite cell line CVCL_6415 CL:0000010 Derived from sampling site: Lymph node. Discontinued: ATCC; CRL-6173; true Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199324 CVCL_5S14 GM22771 transformed cell line human CVCL_5S14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199325 CVCL_6414 L.N. 4159 transformed cell line house mouse CVCL_6414 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver. Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10998 21199326 CVCL_5S19 GM22899 transformed cell line human CVCL_5S19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199327 CVCL_6419 MCB3901 transformed cell line CVCL_6419 CL:0000010 Transformant: Adenovirus 12(NCBI-Taxonomy; 28282). Doubling time: 14-16 hours (ATCC=CRL-9595) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9595 21199328 CVCL_5S18 GM22894 transformed cell line human CVCL_5S18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199329 CVCL_6418 MC-SV-HUC T-2 transformed cell line human CVCL_6418 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ureter Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9519 21199330 CVCL_XY50 AT7RM transformed cell line human CVCL_XY50 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Heterozygous (PubMed=8845835); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5320del3556; Zygosity=Heterozygous (PubMed=8845835) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199331 CVCL_XY32 MEM-G/10 hybridoma house mouse CVCL_XY32 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199332 CVCL_XY31 MEM-G/09 hybridoma house mouse CVCL_XY31 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199333 CVCL_XY30 MEM-G/08 hybridoma house mouse CVCL_XY30 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199334 CVCL_XY36 MEM-G/14 hybridoma house mouse CVCL_XY36 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199335 CVCL_XY35 MEM-G/13 hybridoma house mouse CVCL_XY35 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199336 CVCL_XY34 MEM-G/12 hybridoma house mouse CVCL_XY34 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199337 CVCL_XY33 MEM-G/11 hybridoma house mouse CVCL_XY33 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199338 CVCL_XY39 HGY hybridoma house mouse CVCL_XY39 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200416 21199339 CVCL_XY38 MEM-E/06 hybridoma house mouse CVCL_XY38 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13747; Human HLA-E. 21199340 CVCL_XY37 MEM-E/02 hybridoma house mouse CVCL_XY37 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P13747; Human HLA-E. 21199341 CVCL_XY21 AT19RM transformed cell line human CVCL_XY21 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2993Ter (c.8977C>T); ClinVar=VCV000186330; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199342 CVCL_XY20 AT45RM transformed cell line human CVCL_XY20 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Leu2945Valfs*10 (c.8833_8834delCT); Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199343 CVCL_XY25 JAR-G1 cancer cell line human CVCL_XY25 CL:0000010 Transfected with: HGNC; 4964; HLA-G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male 21199344 CVCL_XY24 J26-G spontaneously immortalized cell line house mouse CVCL_XY24 CL:0000010 Transfected with: HGNC; 914; B2M; Transfected with: HGNC; 4964; HLA-G; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male 21199345 CVCL_XY23 BHK HL-1 spontaneously immortalized cell line CVCL_XY23 CL:0000010 Transfected with: HGNC; 3546; F8 Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200007 21199346 CVCL_XY22 FZ01 hybridoma house mouse CVCL_XY22 CL:0000010 Characteristics: This seems to be a tetradoma, a fusion of two hybridomas; Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human fibrin; Monoclonal antibody target: UniProtKB; P00749; Human PLAU Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200002 21199347 CVCL_XY29 MEM-G/04 hybridoma house mouse CVCL_XY29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199348 CVCL_XY28 MEM-G/01 hybridoma house mouse CVCL_XY28 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199349 CVCL_XY27 BFL.1 hybridoma house mouse CVCL_XY27 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17693; Human HLA-G. 21199350 CVCL_XY26 JAR-G1s cancer cell line human CVCL_XY26 CL:0000010 Transfected with: HGNC; 4964; HLA-G (soluble isoform); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male 21199351 CVCL_XY10 AT25RM transformed cell line human CVCL_XY10 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Val835Serfs*7 (c.2502dupA) (2501insA); ClinVar=VCV000127351; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199352 CVCL_XY14 AT105RM transformed cell line human CVCL_XY14 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1267_Val1268insTer (c.3802delG) (p.Val1268Terfs); ClinVar=VCV000127374; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199353 CVCL_XY13 AT85RM transformed cell line human CVCL_XY13 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199354 CVCL_XY12 AT3RM transformed cell line human CVCL_XY12 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Lys1192Lys (c.3576G>A) (3403del174) (Ex26del); ClinVar=VCV000003035; Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4842insCT; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199355 CVCL_XY11 AT96RM transformed cell line human CVCL_XY11 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1037Serfs*2 (c.3111delT); Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199356 CVCL_XY18 AT71RM transformed cell line human CVCL_XY18 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.7789-3T>G (IVS54-3T>G); ClinVar=VCV000219629; Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199357 CVCL_XY17 AT76RM transformed cell line human CVCL_XY17 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2506Thrfs (c.7517_7520delGAGA) (7517del4); Zygosity=Homozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199358 CVCL_XY16 AT61RM transformed cell line human CVCL_XY16 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser1993Argfs*23 (c.5979_5983delTAAAG) (5979delTAAAG); ClinVar=VCV000233016; Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2305Ter (c.6913C>T); ClinVar=VCV000482710; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199359 CVCL_XY15 AT50RM transformed cell line human CVCL_XY15 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5319+2T>C (IVS37+2T>C) (c.5178_5319del142); ClinVar=VCV000479006; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=8845835; PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg1898Ter (c.5692C>T); ClinVar=VCV000482526; Zygosity=Heterozygous (PubMed=8845835; PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199360 CVCL_XY19 AT90RM transformed cell line human CVCL_XY19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.6442delA; Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln2762Alafs*6 (c.8283_8284delTC); Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199361 CVCL_XY03 QAU-Ho-E-6-22 spontaneously immortalized cell line CVCL_XY03 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201866. 21199362 CVCL_XY02 DF4 hybridoma house mouse CVCL_XY02 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:29036; Copper(2+). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200907 21199363 CVCL_XY01 DV3-M11 hybridoma house mouse CVCL_XY01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99D35; Dengue virus type 3 non-structural protein 1 (NS1) (Note=Also reacts with dengue type 1 NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200857 21199364 CVCL_XY00 DV3-M24 hybridoma house mouse CVCL_XY00 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q99D35; Dengue virus type 3 non-structural protein 1 (NS1) (Note=Also reacts with dengue types 1, 2 and 4 NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200859 21199365 CVCL_XY07 WL-3C2 hybridoma house mouse CVCL_XY07 CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P20591; Human MX1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200916 21199366 CVCL_XY06 QB-CL-F spontaneously immortalized cell line CVCL_XY06 CL:0000010 Unspecified Characteristics: Adapted to growth in SF-900 III SFM. Group: Insect cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201327 21199367 CVCL_XY05 QAU-Tn-E-7 spontaneously immortalized cell line CVCL_XY05 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201865. 21199368 CVCL_XY04 QAU-Hp-E-9-2 spontaneously immortalized cell line CVCL_XY04 CL:0000010 Unspecified Group: Insect cell line; Group: Patented cell line. 21199369 CVCL_XY09 AT6RM transformed cell line human CVCL_XY09 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro795Thr (c.2385C>A); Zygosity=Heterozygous (PubMed=17124347); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu1978Ter (c.5932G>T); ClinVar=VCV000127414; Zygosity=Heterozygous (PubMed=17124347) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 21199370 CVCL_XY08 SCRV-G-1B2 hybridoma house mouse CVCL_XY08 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q06Z36; Siniperca chuatsi rhabdovirus glycoprotein (G). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200918 21199371 CVCL_6390 FL 62891 transformed cell line human CVCL_6390 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11005 21199372 CVCL_5R90 GM22598 transformed cell line human CVCL_5R90 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199373 CVCL_6394 F.thy 62891 transformed cell line human CVCL_6394 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal thymus. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10936 21199374 CVCL_5R94 GM22637 transformed cell line human CVCL_5R94 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199375 CVCL_6393 FO-4 undefined cell line type CVCL_6393 CL:0000010 Discontinued: ATCC; CRL-6171; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199376 CVCL_5R93 GM22634 transformed cell line human CVCL_5R93 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199377 CVCL_6392 FNS undefined cell line type CVCL_6392 CL:0000010 Discontinued: ATCC; CRL-6170; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199378 CVCL_5R92 GM22605 transformed cell line human CVCL_5R92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199379 CVCL_6391 FL-74-UCD-1 cancer cell line CVCL_6391 CL:0000010 Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768). Virology: Produces large amounts of feline leukemia virus (FeLV) strain KT-FeLV-UCD-1 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8012 21199380 CVCL_5R91 GM22602 transformed cell line human CVCL_5R91 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199381 CVCL_5R98 GM22656 transformed cell line human CVCL_5R98 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199382 CVCL_6398 GMMs transformed cell line CVCL_6398 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 21199383 CVCL_5R97 GM22655 transformed cell line human CVCL_5R97 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199384 CVCL_6397 GMMe transformed cell line CVCL_6397 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium Cell type=Epithelial cell.. Female 21199385 CVCL_6396 GH354 cancer cell line human CVCL_6396 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-3404 21199386 CVCL_5R96 GM22654 transformed cell line human CVCL_5R96 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199387 CVCL_6395 GH329 cancer cell line human CVCL_6395 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-803 21199388 CVCL_5R95 GM22639 transformed cell line human CVCL_5R95 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199389 CVCL_6389 Fcwf-4 spontaneously immortalized cell line CVCL_6389 CL:0000010 Derived from sampling site: Whole fetus Cell type=Macrophage.. Unspecified Virology: Susceptible to infection by feline coronavirus (FCoV) Doubling time: 31 hours (ATCC=CRL-2787) 21199390 CVCL_5R89 GM22597 transformed cell line human CVCL_5R89 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199391 CVCL_6388 F8 undefined cell line type CVCL_6388 CL:0000010 Discontinued: ATCC; CRL-6074; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199392 CVCL_5R88 GM22596 transformed cell line human CVCL_5R88 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199393 CVCL_5R99 GM22658 transformed cell line human CVCL_5R99 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199394 CVCL_6399 HIVS-125 finite cell line human CVCL_6399 CL:0000010 Derived from sampling site: Iliac vein; smooth muscle. Discontinued: ATCC; CRL-2482; true; Discontinued: Coriell; WC00105; probable Male Senescence: Capable of at least 40 PDL (ATCC=CRL-2482) Part of: Wistar Institute Special Collection vascular cell lines 21199395 CVCL_6372 BNL 1NG A.2 transformed cell line house mouse CVCL_6372 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21199396 CVCL_5R72 GM22517 transformed cell line human CVCL_5R72 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199397 CVCL_6371 BNL 1ME A.7R.1 transformed cell line house mouse CVCL_6371 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Embryonic liver; Breed/subspecies: BALB/c. Unspecified Characteristics: Tumorigenic; forms tumors in BALB/c mice and ATxFL mice (ATCC) Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21199398 CVCL_5R71 GM22516 transformed cell line human CVCL_5R71 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199399 CVCL_6370 BHK570 spontaneously immortalized cell line CVCL_6370 CL:0000010 Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10314 21199400 CVCL_5R70 GM22513 transformed cell line human CVCL_5R70 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199401 CVCL_6376 C5/MJ transformed cell line human CVCL_6376 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Umbilical cord blood Cell type=T-cell.. Male Virology: HTLV-1 producing cell line Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8293 21199402 CVCL_5R76 GM22527 transformed cell line human CVCL_5R76 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199403 CVCL_6375 C1R-sB7 transformed cell line human CVCL_6375 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*07) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199404 CVCL_5R75 GM22526 transformed cell line human CVCL_5R75 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199405 CVCL_6374 C1R-neo transformed cell line human CVCL_6374 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199406 CVCL_5R74 GM22524 transformed cell line human CVCL_5R74 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199407 CVCL_6373 C1R-B7 transformed cell line human CVCL_6373 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*07) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199408 CVCL_5R73 GM22523 transformed cell line human CVCL_5R73 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199409 CVCL_6369 BHK21-pcDNA3.1-HC spontaneously immortalized cell line CVCL_6369 CL:0000010 Transfected with: HGNC; 3415; EPO; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-419 21199410 CVCL_5R69 GM22511 transformed cell line human CVCL_5R69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199411 CVCL_6368 F4/B8/3 cancer cell line house mouse CVCL_6368 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. 21199412 CVCL_5R68 GM22502 transformed cell line human CVCL_5R68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199413 CVCL_6367 B-3 transformed cell line human CVCL_6367 CL:0000010 Transformant: Ad12-SV40 hybrid virus; Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11421 Problematic cell line: Possibly misidentified Presence of a Y chromosome in cell line that was thought to be of female origin (STR profile). 21199414 CVCL_5R67 GM22500 transformed cell line human CVCL_5R67 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199415 CVCL_6366 A68177 finite cell line human CVCL_6366 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-7714; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199416 CVCL_5R66 GM22397 transformed cell line human CVCL_5R66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199417 CVCL_6383 CGBQ spontaneously immortalized cell line CVCL_6383 CL:0000010 Derived from sampling site: Embryonic sternum Cell type=Fibroblast.. Unspecified Group: Bird cell line Problematic cell line: Misidentified Originally thought to be of Anser anser anser origin but found to be from Anser cygnoides (PubMed=34737324). 21199418 CVCL_5R83 GM22570 transformed cell line human CVCL_5R83 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199419 CVCL_6382 CCD-112CoN finite cell line human CVCL_6382 CL:0000010 Derived from sampling site: Fetal colon Cell type=Fibroblast.. Female Senescence: Senesces at ~76 PDL (ATCC=CRL-1541) 21199420 CVCL_5R82 GM22569 transformed cell line human CVCL_5R82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199421 CVCL_6381 C8-S spontaneously immortalized cell line house mouse CVCL_6381 CL:0000010 Derived from sampling site: Brain; cerebellum Cell type=Astrocyte.; Breed/subspecies: C57BL/6. Unspecified 21199422 CVCL_5R81 GM22559 transformed cell line human CVCL_5R81 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199423 CVCL_6380 C8-D30 spontaneously immortalized cell line house mouse CVCL_6380 CL:0000010 Derived from sampling site: Brain; cerebellum Cell type=Astrocyte.; Breed/subspecies: C57BL/6. Unspecified 21199424 CVCL_5R80 GM22558 transformed cell line human CVCL_5R80 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199425 CVCL_6387 F25 [Cat erythroleukemia] cancer cell line CVCL_6387 CL:0000010 Derived from sampling site: Bone marrow. Female Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199426 CVCL_5R87 GM22594 transformed cell line human CVCL_5R87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199427 CVCL_6386 DPSO 114/74 finite cell line CVCL_6386 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male Group: Non-human primate cell line 21199428 CVCL_5R86 GM22593 transformed cell line human CVCL_5R86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199429 CVCL_6385 CV-1/EBNA-1 transformed cell line CVCL_6385 CL:0000010 Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10478 21199430 CVCL_5R85 GM22588 transformed cell line human CVCL_5R85 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199431 CVCL_6384 CTLA4 Ig-24 spontaneously immortalized cell line CVCL_6384 CL:0000010 Transfected with: HGNC; 2505; CTLA4 (extracellular domain fused to the hinge, CH2 and CH3 regions of IgC.gamma.1 domain) Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10762 21199432 CVCL_5R84 GM22571 transformed cell line human CVCL_5R84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199433 CVCL_6379 C8-D1A spontaneously immortalized cell line house mouse CVCL_6379 CL:0000010 Derived from sampling site: Brain; cerebellum Cell type=Astrocyte.; Breed/subspecies: C57BL/6. Omics: Deep proteome analysis; Omics: Secretome proteome analysis Unspecified Characteristics: Susceptible to infection by mouse scrapie prion (PrPSc) strains 22L and RML (PubMed=32561641) 21199434 CVCL_5R79 GM22544 transformed cell line human CVCL_5R79 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199435 CVCL_6378 C8-B4 spontaneously immortalized cell line house mouse CVCL_6378 CL:0000010 Derived from sampling site: Brain; cerebellum Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Female 21199436 CVCL_5R78 GM22543 transformed cell line human CVCL_5R78 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199437 CVCL_6377 C57L/J.We finite cell line house mouse CVCL_6377 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: C57L/J. Discontinued: ATCC; CRL-6336; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199438 CVCL_5R77 GM22528 transformed cell line human CVCL_5R77 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199439 CVCL_XX99 5H11.H6 hybridoma house mouse CVCL_XX99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:28009; N-acetyl-beta-D-glucosamine (Note=In beta-O-glycosidic linkage to serine and threonine). 21199440 CVCL_Y999 CHA-hES33 embryonic stem cell human CVCL_Y999 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012004. 21199441 CVCL_XX98 1F5.D6 hybridoma house mouse CVCL_XX98 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: ChEBI; CHEBI:28009; N-acetyl-beta-D-glucosamine (Note=In beta-O-glycosidic linkage to serine and threonine). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9339 21199442 CVCL_Y998 CHA-hES32 embryonic stem cell human CVCL_Y998 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012003. 21199443 CVCL_XX97 18B10.C7 hybridoma house mouse CVCL_XX97 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:28009; N-acetyl-beta-D-glucosamine (Note=In beta-O-glycosidic linkage to serine and threonine). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9341 21199444 CVCL_Y997 CHA-hES31 embryonic stem cell human CVCL_Y997 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012002. 21199445 CVCL_Y996 CHA-hES30 embryonic stem cell human CVCL_Y996 From: CHA University; Seongnam; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012001. 21199446 CVCL_XX96 R3/1 spontaneously immortalized cell line Norway rat CVCL_XX96 CL:0000010 Derived from sampling site: Embryonic lung; Breed/subspecies: Wistar-Han. Male Characteristics: Alveolar epithelial type I-like Doubling time: ~38 hours, in RPMI 1640 + 10% FCS (PubMed=15221420) 21199447 CVCL_5R50 GM22032 transformed cell line human CVCL_5R50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199448 CVCL_6354 2B8 [Human Burkitt lymphoma] cancer cell line human CVCL_6354 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12569 21199449 CVCL_5R54 GM22219 transformed cell line human CVCL_5R54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199450 CVCL_6353 2A transformed cell line human CVCL_6353 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12013 21199451 CVCL_5R53 GM22122 finite cell line human CVCL_5R53 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Male 21199452 CVCL_6352 293/CHE-Fc transformed cell line human CVCL_6352 CL:0000010 Transfected with: UniProtKB; P03465; Influenza C virus isolate C/Cal/78 hemagglutinin-esterase-fusion glycoprotein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with CHE-Fc, a recombinant soluble chimeric protein fusion of influenza C hemagglutinin-esterase with human IgG1 Fc It is useful as a probe to detect 9-O-acetylated sialic acids (PubMed=8052660). 21199453 CVCL_5R52 GM22121 transformed cell line human CVCL_5R52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199454 CVCL_6351 293 EcR Shh transformed cell line human CVCL_6351 CL:0000010 Transfected with: MGI; MGI:98297; Shh Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-2782; true; Discontinued: ATCC; JHU-64; true Female Characteristics: Transfected with a construct that allows the expression of Shh under ecdysone-inducible control 21199455 CVCL_5R51 GM22049 transformed cell line human CVCL_5R51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199456 CVCL_6347 20B8 hybrid cell line human CVCL_6347 CL:0000010 Transfected with: HGNC; 3546; F8 (with p.Ser765_Asn1658del = BDD-FVIII). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12582 21199457 CVCL_5R47 GM21892 transformed cell line human CVCL_5R47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199458 CVCL_6346 2.040 pRSV-T transformed cell line human CVCL_6346 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767). Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11516 21199459 CVCL_5R46 GM21887 transformed cell line human CVCL_5R46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199460 CVCL_6345 1G2 hybrid cell line human CVCL_6345 CL:0000010 Transfected with: HGNC; 6014; IL4 (with p.Thr37Asp and p.Arg145Glu = IL-4SA) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-87 21199461 CVCL_5R45 GM21886 transformed cell line human CVCL_5R45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199462 CVCL_6344 5637 subclone 1A6 cancer cell line human CVCL_6344 CL:0000010 Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.Arg79Lys (c.236G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Tyr325Ter (c.975T>A); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Thr (c.839G>C); ClinVar=VCV000012368; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Urinary bladder. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2742; probable Male Group: Patented cell line; Part of: BLA-40 bladder carcinoma cell line panel; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-556 21199463 CVCL_5R44 GM21885 transformed cell line human CVCL_5R44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199464 CVCL_6349 2254-62.2 spontaneously immortalized cell line CVCL_6349 CL:0000010 Transfected with: HGNC; 3546; F8; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8544 21199465 CVCL_5R49 GM22031 transformed cell line human CVCL_5R49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199466 CVCL_6348 20H11 transformed cell line human CVCL_6348 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P72151; Pseudomonas aeruginosa B-type flagellin (fliC) Doubling time: 24-36 hours (ATCC=CRL-9300) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9300 21199467 CVCL_5R48 GM21893 transformed cell line human CVCL_5R48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199468 CVCL_XX88 6H7 hybridoma house mouse CVCL_XX88 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Azumapecten farreri granulocytes 155 kDa protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201042 21199469 CVCL_Y988 GM00910 finite cell line human CVCL_Y988 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Leu158Pro (c.473T>C); ClinVar=VCV000021439; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199470 CVCL_XX87 1F2 [Mouse hybridoma against phage 933W stxA2] hybridoma house mouse CVCL_XX87 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P09385; Bacteriophage 933W Shiga-like toxin 2 subunit A (stxA2). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200822 21199471 CVCL_Y987 GM00909 finite cell line human CVCL_Y987 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21199472 CVCL_XX86 140-2 hybridoma house mouse CVCL_XX86 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis C virus core protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200824 21199473 CVCL_Y986 GM00908 finite cell line human CVCL_Y986 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Leu158Pro (c.473T>C); ClinVar=VCV000021439; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Unexplicit; Ex1-10del (nsv1067862) (57-KB DEL); ClinVar=VCV000004445; Zygosity=Heterozygous (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199474 CVCL_XX85 140-1 hybridoma house mouse CVCL_XX85 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Hepatitis C virus core protein. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200823 21199475 CVCL_Y985 GM00489 finite cell line human CVCL_Y985 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199476 CVCL_XX89 AHT-C2-H12 hybridoma house mouse CVCL_XX89 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P14679; Human TYR. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4824 21199477 CVCL_Y989 CE-25 hybridoma house mouse CVCL_Y989 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-719 21199478 CVCL_6361 90.74 transformed cell line human CVCL_6361 CL:0000010 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Group: Patented cell line; Group: Retrovirus packaging cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11654 21199479 CVCL_5R61 GM22364 transformed cell line human CVCL_5R61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199480 CVCL_6360 8E7 [Human B-cell P.aeruginosa LPS mAB producing] transformed cell line human CVCL_6360 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 7 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8795 21199481 CVCL_5R60 GM22295 transformed cell line human CVCL_5R60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199482 CVCL_6365 A.P. finite cell line CVCL_6365 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199483 CVCL_5R65 GM22392 transformed cell line human CVCL_5R65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199484 CVCL_6364 9D10 transformed cell line human CVCL_6364 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Monoclonal antibody isotype: IgM; Monoclonal antibody target: Pseudomonas aeruginosa LPS Fisher immunotype 4 Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-8752 21199485 CVCL_5R64 GM22391 transformed cell line human CVCL_5R64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199486 CVCL_6363 92TAg transformed cell line house mouse CVCL_6363 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21199487 CVCL_5R63 GM22390 transformed cell line human CVCL_5R63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199488 CVCL_6362 90196B finite cell line human CVCL_6362 CL:0000010 Derived from sampling site: Spleen. Omics: Transcriptome analysis by microarray Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9853 21199489 CVCL_5R62 GM22389 transformed cell line human CVCL_5R62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199490 CVCL_6358 5/9 m a3-18 spontaneously immortalized cell line CVCL_6358 CL:0000010 Transfected with: HGNC; 2432; CSF1 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10154 21199491 CVCL_5R58 GM22281 transformed cell line human CVCL_5R58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199492 CVCL_6357 451Lu cancer cell line human CVCL_6357 HLA typing: A*24:02,24:02; B*07:02,07:02; DPB1*06:01,06:01; DQB1*06:04,06:04; DRB1*13:01,13:01 (PubMed=15592718); Genome ancestry: African=0%; Native American=1.32%; East Asian, North=0.06%; East Asian, South=0.98%; South Asian=0.7%; European, North=67.32%; European, South=29.61% (PubMed=30894373) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=17260012; PubMed=18632627; PubMed=21156289; PubMed=23851445; Cosmic-CLP; DepMap; Wistar); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61fs*59 (c.179dupC) (p.Gly75fs, c.222dupC); Zygosity=Heterozygous (PubMed=23851445; Cosmic-CLP; DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (PubMed=17260012; PubMed=21156289; PubMed=23851445; Cosmic-CLP; DepMap) Derived from metastatic site: Arm; skin. Omics: Array-based CGH; Omics: Deep exome analysis; Omics: Deep quantitative proteome analysis; Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Discontinued: ATCC; CRL-2813; true; Discontinued: Coriell; WC00059; probable Male Characteristics: Metastatic Established from the lung of a nude mouse after 4 sequential passages of the parent cell line (PubMed=2156614). Doubling time: 72 hours (PubMed=2253310); Microsatellite instability: Stable (MSS) (PubMed=31068700; Sanger) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: COSMIC cell lines project; Part of: Wistar Institute melanoma cell line collection Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018; The major changes were: CSF1PO 21199493 CVCL_5R57 GM22269 transformed cell line human CVCL_5R57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199494 CVCL_6356 35.6 spontaneously immortalized cell line CVCL_6356 CL:0000010 Transfected with: HGNC; 2334; CR1 Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10052 21199495 CVCL_5R56 GM22249 transformed cell line human CVCL_5R56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199496 CVCL_6355 2V6.11 transformed cell line human CVCL_6355 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q6VGT3; Adenovirus 5 E4 34kda protein Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-2784; true; Discontinued: ATCC; JHU-67; true Female 21199497 CVCL_5R55 GM22242 transformed cell line human CVCL_5R55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199498 CVCL_6359 80T finite cell line human CVCL_6359 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-7901; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199499 CVCL_5R59 GM22285 transformed cell line human CVCL_5R59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199500 CVCL_XX91 AVND-3C8 hybridoma house mouse CVCL_XX91 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Acute virus necrobiotic disease (AVND). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200835 21199501 CVCL_Y991 SNUhES39 embryonic stem cell human CVCL_Y991 From: Seoul National University; Seoul; South Korea CL:0000010 Male Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014001. 21199502 CVCL_XX90 AHT-C2-H31 hybridoma house mouse CVCL_XX90 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P14679; Human TYR. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-4801 21199503 CVCL_Y990 SNUhES36 embryonic stem cell human CVCL_Y990 From: Seoul National University; Seoul; South Korea CL:0000010 Unspecified Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12012009. 21199504 CVCL_Y995 CHA-hES29 embryonic stem cell human CVCL_Y995 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011008. 21199505 CVCL_XX95 whiov-P24C-MoAb hybridoma house mouse CVCL_XX95 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: HIV-1 capsid protein p24. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200818 21199506 CVCL_Y994 CHA-hES28 embryonic stem cell human CVCL_Y994 From: CHA University; Seongnam; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011007. 21199507 CVCL_XX94 T311 hybridoma house mouse CVCL_XX94 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P14679; Human TYR. 21199508 CVCL_Y993 CHA-hES27 embryonic stem cell human CVCL_Y993 From: CHA University; Seongnam; South Korea CL:0000010 Unspecified Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12011006. 21199509 CVCL_XX93 RME hybridoma house mouse CVCL_XX93 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:21891; N6-methyladenosine (m6A). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201619 21199510 CVCL_XX92 Jurkat-LTRGT cancer cell line human CVCL_XX92 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200821 21199511 CVCL_Y992 SNUhES40 embryonic stem cell human CVCL_Y992 From: Seoul National University; Seoul; South Korea CL:0000010 Female Registration: Korea Center for Disease Control and Prevention Stem Cell Registry; hES12014002. 21199512 CVCL_XX77 1/39 hybridoma house mouse CVCL_XX77 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum antigen in Golgi compartment. 21199513 CVCL_Y977 HPS0148 induced pluripotent stem cell human CVCL_Y977 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199514 CVCL_XX76 Ctrl 154 finite cell line human CVCL_XX76 CL:0000010 Miscellaneous: Cell line information from personal communication of Varcianna A Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199515 CVCL_Y976 HPS0147 induced pluripotent stem cell human CVCL_Y976 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199516 CVCL_XX75 H72 hybridoma house mouse CVCL_XX75 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum 25 kDa antigen at plasma membrane and endosomal compartments. 21199517 CVCL_Y975 HPS0136 induced pluripotent stem cell human CVCL_Y975 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199518 CVCL_XX74 H194 hybridoma house mouse CVCL_XX74 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum 23 kDa antigen at plasma membrane and intracellular compartments. 21199519 CVCL_Y974 HPS0135 induced pluripotent stem cell human CVCL_Y974 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199520 CVCL_XX79 AsPC1-R cancer cell line human CVCL_XX79 CL:0000010 Sequence variation: Gene deletion; HGNC; 6844; MAP2K4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Leu78Hisfs*41 (c.233_234delTC) (p.His93Profs*67, c.276_277delTC); ClinVar=VCV000977782; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg100Thr (c.299G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Alafs*35 (c.403delT); ClinVar=VCV001069265; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 21199521 CVCL_Y979 HPS0142 induced pluripotent stem cell human CVCL_Y979 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199522 CVCL_XX78 BxPC3-R cancer cell line human CVCL_XX78 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val487_Pro492delinsAla (c.1460_1474delGTGTAGGTGCTGTCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; None_reported; -; Zygosity=- (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Female 21199523 CVCL_Y978 HPS0141 induced pluripotent stem cell human CVCL_Y978 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199524 CVCL_5R32 GM20738 transformed cell line human CVCL_5R32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199525 CVCL_6332 S1A(Thy-1-b) cancer cell line house mouse CVCL_6332 CL:0000010 Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21199526 CVCL_5R31 GM20570 transformed cell line human CVCL_5R31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199527 CVCL_6331 LLC-PK1A spontaneously immortalized cell line pig CVCL_6331 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hampshire. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-101.1 21199528 CVCL_5R30 GM20569 transformed cell line human CVCL_5R30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199529 CVCL_6330 HR/HR 3.Sp finite cell line house mouse CVCL_6330 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6356; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199530 CVCL_5R25 GM20551 transformed cell line human CVCL_5R25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199531 CVCL_6325 HR/+ B.Sp finite cell line house mouse CVCL_6325 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6348; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199532 CVCL_5R24 GM20550 transformed cell line human CVCL_5R24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199533 CVCL_6324 HR/+ G.Sp finite cell line house mouse CVCL_6324 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6353; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199534 CVCL_5R23 GM20548 transformed cell line human CVCL_5R23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Ambiguous 21199535 CVCL_6323 HR/+ F.Sp finite cell line house mouse CVCL_6323 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6352; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199536 CVCL_5R22 GM20547 transformed cell line human CVCL_5R22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199537 CVCL_6322 HR/+ E.Sp finite cell line house mouse CVCL_6322 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6351; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199538 CVCL_5R29 GM20562 transformed cell line human CVCL_5R29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199539 CVCL_6329 HR/HR 2.Sp finite cell line house mouse CVCL_6329 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6355; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199540 CVCL_5R28 GM20560 transformed cell line human CVCL_5R28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199541 CVCL_6328 HR/HR 1.Sp finite cell line house mouse CVCL_6328 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6354; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199542 CVCL_5R27 GM20556 transformed cell line human CVCL_5R27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199543 CVCL_6327 HR/HRB.We finite cell line house mouse CVCL_6327 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6358; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199544 CVCL_5R26 GM20555 transformed cell line human CVCL_5R26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199545 CVCL_6326 HR/HRA.We finite cell line house mouse CVCL_6326 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: HRS/J. Discontinued: ATCC; CRL-6357; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199546 CVCL_XX80 DV3-M15 hybridoma house mouse CVCL_XX80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99D35; Dengue virus type 3 non-structural protein 1 (NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200820 21199547 CVCL_Y980 HPS0128 induced pluripotent stem cell human CVCL_Y980 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199548 CVCL_Y984 GM00379 finite cell line human CVCL_Y984 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Trp138Ter (c.414G>A); ClinVar=VCV000004443; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; c.970+2T>C (IVS11+2T>C); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199549 CVCL_XX84 THUEC transformed cell line human CVCL_XX84 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Urethra epithelium. Male 21199550 CVCL_XX83 DV4-M6 hybridoma house mouse CVCL_XX83 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P09866; Dengue virus type 4 non-structural protein 1 (NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200854 21199551 CVCL_Y983 GM00378 finite cell line human CVCL_Y983 CL:0000010 Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; p.Trp138Ter (c.414G>A); ClinVar=VCV000004443; Zygosity=Heterozygous (PubMed=28649545); Sequence variation: Mutation; HGNC; 2518; CTNS; Simple; c.970+2T>C (IVS11+2T>C); Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=28649545) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21199552 CVCL_XX82 DV4-M12 hybridoma house mouse CVCL_XX82 CL:0000010 Monoclonal antibody isotype: IgG1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200855 21199553 CVCL_Y982 GM00020 finite cell line human CVCL_Y982 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199554 CVCL_XX81 DV3-M3 hybridoma house mouse CVCL_XX81 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q99D35; Dengue virus type 3 non-structural protein 1 (NS1). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200819 21199555 CVCL_Y981 GM00018 finite cell line human CVCL_Y981 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21199556 CVCL_XX66 989RM transformed cell line human CVCL_XX66 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Simple; c.6106+3393c.7101-22del20648bp/ins25 (Ex16-23del); Zygosity=Heterozygous (PubMed=21112256) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199557 CVCL_Y966 GM23686 transformed cell line human CVCL_Y966 CL:0000010 Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=33197628) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199558 CVCL_XX65 655RM transformed cell line human CVCL_XX65 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Simple; c.7287+5G>A (IVS23+5G>A); Zygosity=Homozygous (PubMed=21112256) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199559 CVCL_Y965 GM00232 finite cell line human CVCL_Y965 CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199560 CVCL_XX64 654RM transformed cell line human CVCL_XX64 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Simple; c.7287+5G>A (IVS23+5G>A); Zygosity=Homozygous (PubMed=21112256) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199561 CVCL_Y964 GM04805 finite cell line human CVCL_Y964 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199562 CVCL_XX63 9D1.E4 hybridoma house mouse CVCL_XX63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:28009; N-acetyl-beta-D-glucosamine (Note=In beta-O-glycosidic linkage to serine and threonine). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9340 21199563 CVCL_Y963 GM04804 transformed cell line human CVCL_Y963 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Venezuelan Huntington disease kindreds subcollection 21199564 CVCL_Y969 HPS0245 induced pluripotent stem cell human CVCL_Y969 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21199565 CVCL_XX69 K117RM transformed cell line human CVCL_XX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199566 CVCL_XX68 FLEBV transformed cell line human CVCL_XX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199567 CVCL_Y968 HPS0208 induced pluripotent stem cell human CVCL_Y968 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199568 CVCL_XX67 990RM transformed cell line human CVCL_XX67 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Simple; c.6106+3393c.7101-22del20648bp/ins25 (Ex16-23del); Zygosity=Homozygous (PubMed=21112256) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199569 CVCL_Y967 HiPS-RIKEN-5B induced pluripotent stem cell human CVCL_Y967 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199570 CVCL_6343 151TAg transformed cell line house mouse CVCL_6343 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104288; Pms2; Knockout cell: Method=KO mouse; MGI; MGI:97740; Polb Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 21199571 CVCL_5R43 GM21884 transformed cell line human CVCL_5R43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199572 CVCL_6342 12MBr-6 finite cell line CVCL_6342 CL:0000010 Derived from sampling site: Bronchus; epithelium. Discontinued: IZSLER; BS CL 216; probable Male Senescence: Senesces at ~23 PDL (ATCC=CRL-1576) Group: Non-human primate cell line 21199573 CVCL_5R42 GM21883 transformed cell line human CVCL_5R42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199574 CVCL_6341 10.014 pRSV-T transformed cell line human CVCL_6341 CL:0000010 Transformant: Simian virus 40 (SV40) [pRSV-T](NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; cornea; epithelium Cell type=Epithelial cell.. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11515 21199575 CVCL_5R41 GM21878 finite cell line human CVCL_5R41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21199576 CVCL_5R40 GM21874 finite cell line human CVCL_5R40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21199577 CVCL_6340 NZP-46 finite cell line CVCL_6340 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Senescence: Capable of at least 17 PDL (ATCC=CRL-1926) 21199578 CVCL_6336 C6-SF2 cancer cell line Norway rat CVCL_6336 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male 21199579 CVCL_5R36 GM03125 finite cell line human CVCL_5R36 CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,del(2)(pter->q23::q32.2->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Male 21199580 CVCL_5R35 GM21681 transformed cell line human CVCL_5R35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199581 CVCL_6335 T36274 transformed cell line house mouse CVCL_6335 CL:0000010 Derived from sampling site: Skin; epidermis; Breed/subspecies: BALB/c. Unspecified 21199582 CVCL_5R34 GM21546 transformed cell line human CVCL_5R34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199583 CVCL_6334 T-AL/N spontaneously immortalized cell line house mouse CVCL_6334 CL:0000010 Derived from sampling site: Whole embryo; Breed/subspecies: AL/N. Discontinued: ATCC; CRL-6514; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21199584 CVCL_5R33 GM20916 transformed cell line human CVCL_5R33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199585 CVCL_6333 S1A.TB.4.8.2 cancer cell line house mouse CVCL_6333 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Breed/subspecies: BALB/c. Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981) 21199586 CVCL_6339 CHO 1-15 500 spontaneously immortalized cell line CVCL_6339 CL:0000010 Transfected with: HGNC; 9051; PLAT Derived from sampling site: Ovary. Female Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-9606 Caution: There seem to be two distinct cell lines which were assigned NCBI_Iran catalog number C527 21199587 CVCL_5R39 GM21871 transformed cell line human CVCL_5R39 CL:0000010 Sequence variation: Mutation; HGNC; 27230; ESCO2; Simple; p.Lys103Glufs*2 (c.307_311delAAAGA) (I102fs*1); ClinVar=VCV000021243; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM21871; probable Female 21199588 CVCL_6338 ARPE-19/HPV-16 transformed cell line human CVCL_6338 CL:0000010 Transformant: Human papillomavirus type 16 (HPV16)(NCBI-Taxonomy; 333760); Derived from sampling site: Eye; retina; retinal pigment epithelium. Male 21199589 CVCL_5R38 GM21729 transformed cell line human CVCL_5R38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199590 CVCL_6337 AML14.3D10/CCCKR3 Clone 16 cancer cell line human CVCL_6337 CL:0000010 Transfected with: HGNC; 1604; CCR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Peripheral blood. Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12079 21199591 CVCL_5R37 GM21715 transformed cell line human CVCL_5R37 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199592 CVCL_XX73 H161 hybridoma house mouse CVCL_XX73 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7YXD4; Dictyostelium discoideum p80. 21199593 CVCL_Y973 HPS0226 induced pluripotent stem cell human CVCL_Y973 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199594 CVCL_Y972 HPS0225 induced pluripotent stem cell human CVCL_Y972 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199595 CVCL_XX72 K138RM transformed cell line human CVCL_XX72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199596 CVCL_Y971 HPS0228 induced pluripotent stem cell human CVCL_Y971 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199597 CVCL_Y970 HPS0246 induced pluripotent stem cell human CVCL_Y970 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21199598 CVCL_XX70 K135RM transformed cell line human CVCL_XX70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 21199599 CVCL_GF41 ND11219 transformed cell line human CVCL_GF41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199600 CVCL_GF40 ND11218 transformed cell line human CVCL_GF40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199601 CVCL_GF39 ND11217 transformed cell line human CVCL_GF39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199602 CVCL_GF34 ND11212 transformed cell line human CVCL_GF34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199603 CVCL_GF33 ND11211 transformed cell line human CVCL_GF33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199604 CVCL_GF32 ND11210 transformed cell line human CVCL_GF32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199605 CVCL_GF31 ND11209 transformed cell line human CVCL_GF31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199606 CVCL_GF38 ND11216 transformed cell line human CVCL_GF38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199607 CVCL_GF37 ND11215 transformed cell line human CVCL_GF37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199608 CVCL_GF36 ND11214 transformed cell line human CVCL_GF36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199609 CVCL_GF35 ND11213 transformed cell line human CVCL_GF35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199610 CVCL_GF52 ND11237 transformed cell line human CVCL_GF52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199611 CVCL_GF51 ND11235 transformed cell line human CVCL_GF51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199612 CVCL_GF50 ND11233 transformed cell line human CVCL_GF50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199613 CVCL_GF45 ND11224 transformed cell line human CVCL_GF45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199614 CVCL_GF44 ND11223 transformed cell line human CVCL_GF44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199615 CVCL_GF43 ND11222 transformed cell line human CVCL_GF43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199616 CVCL_GF42 ND11221 transformed cell line human CVCL_GF42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199617 CVCL_GF49 ND11231 transformed cell line human CVCL_GF49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199618 CVCL_GF48 ND11229 transformed cell line human CVCL_GF48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199619 CVCL_GF47 ND11227 transformed cell line human CVCL_GF47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199620 CVCL_GF46 ND11226 transformed cell line human CVCL_GF46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199621 CVCL_GF19 ND11192 transformed cell line human CVCL_GF19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199622 CVCL_GF18 ND11190 transformed cell line human CVCL_GF18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199623 CVCL_GF17 ND11189 transformed cell line human CVCL_GF17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199624 CVCL_GF12 ND11183 transformed cell line human CVCL_GF12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199625 CVCL_GF11 ND11182 transformed cell line human CVCL_GF11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199626 CVCL_GF10 ND11181 transformed cell line human CVCL_GF10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199627 CVCL_GF16 ND11187 transformed cell line human CVCL_GF16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199628 CVCL_GF15 ND11186 transformed cell line human CVCL_GF15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199629 CVCL_GF14 ND11185 transformed cell line human CVCL_GF14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199630 CVCL_GF13 ND11184 transformed cell line human CVCL_GF13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199631 CVCL_GF30 ND11208 transformed cell line human CVCL_GF30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199632 CVCL_GF29 ND11207 transformed cell line human CVCL_GF29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199633 CVCL_GF28 ND11206 transformed cell line human CVCL_GF28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199634 CVCL_GF23 ND11199 transformed cell line human CVCL_GF23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199635 CVCL_GF22 ND11195 transformed cell line human CVCL_GF22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199636 CVCL_GF21 ND11194 transformed cell line human CVCL_GF21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199637 CVCL_GF20 ND11193 transformed cell line human CVCL_GF20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199638 CVCL_GF27 ND11203 transformed cell line human CVCL_GF27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199639 CVCL_GF26 ND11202 transformed cell line human CVCL_GF26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199640 CVCL_GF25 ND11201 transformed cell line human CVCL_GF25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199641 CVCL_GF24 ND11200 transformed cell line human CVCL_GF24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199642 CVCL_GF09 ND11179 transformed cell line human CVCL_GF09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199643 CVCL_GF08 ND11178 transformed cell line human CVCL_GF08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199644 CVCL_GF07 ND11177 transformed cell line human CVCL_GF07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199645 CVCL_GF06 ND11175 transformed cell line human CVCL_GF06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199646 CVCL_GF01 ND11153 transformed cell line human CVCL_GF01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199647 CVCL_GF00 ND11152 transformed cell line human CVCL_GF00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199648 CVCL_GF05 ND11174 transformed cell line human CVCL_GF05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199649 CVCL_GF04 ND11173 transformed cell line human CVCL_GF04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199650 CVCL_GF03 ND11172 transformed cell line human CVCL_GF03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199651 CVCL_GF02 ND11164 transformed cell line human CVCL_GF02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199652 CVCL_5K93 GM25379 transformed cell line human CVCL_5K93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199653 CVCL_5K92 GM25378 finite cell line human CVCL_5K92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199654 CVCL_5K91 GM25377 transformed cell line human CVCL_5K91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199655 CVCL_5K90 GM25375 transformed cell line human CVCL_5K90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199656 CVCL_5K97 SACK-Xs 12(3) somatic stem cell human CVCL_5K97 CL:0000010 Derived from sampling site: Liver. Male 21199657 CVCL_5K96 Adult/T315I cancer cell line human CVCL_5K96 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=21474579); Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (PubMed=21474579). Unspecified 21199658 CVCL_5K95 BV-173/E255K cancer cell line human CVCL_5K95 CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 76; ABL1; Simple; p.Glu255Lys (c.763G>A); ClinVar=VCV000376090; Zygosity=Unspecified (PubMed=21474579); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln4045Ter (c.12133C>T); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from sampling site: Peripheral blood. Male 21199659 CVCL_5K94 GM25380 transformed cell line human CVCL_5K94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199660 CVCL_5K99 SACK-Xs Lig-8 somatic stem cell Norway rat CVCL_5K99 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male Group: Patented cell line 21199661 CVCL_5K98 SACK-Xs Lig-13 somatic stem cell Norway rat CVCL_5K98 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Fischer 344. Male Group: Patented cell line 21199662 CVCL_5K71 GM24538 transformed cell line human CVCL_5K71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199663 CVCL_5K70 GM24527 transformed cell line human CVCL_5K70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199664 CVCL_5K75 GM25353 transformed cell line human CVCL_5K75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199665 CVCL_5K74 GM25352 transformed cell line human CVCL_5K74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199666 CVCL_5K73 GM25351 transformed cell line human CVCL_5K73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199667 CVCL_5K72 GM25350 finite cell line human CVCL_5K72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199668 CVCL_5K79 GM25361 transformed cell line human CVCL_5K79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199669 CVCL_5K78 GM25357 transformed cell line human CVCL_5K78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199670 CVCL_5K77 GM25355 transformed cell line human CVCL_5K77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199671 CVCL_5K76 GM25354 transformed cell line human CVCL_5K76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199672 CVCL_5K82 GM25364 transformed cell line human CVCL_5K82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199673 CVCL_5K81 GM25363 transformed cell line human CVCL_5K81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199674 CVCL_5K80 GM25362 transformed cell line human CVCL_5K80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199675 CVCL_5K86 GM25369 transformed cell line human CVCL_5K86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199676 CVCL_5K85 GM25368 transformed cell line human CVCL_5K85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199677 CVCL_5K84 GM25367 finite cell line human CVCL_5K84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199678 CVCL_5K83 GM25365 transformed cell line human CVCL_5K83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199679 CVCL_5K89 GM25374 finite cell line human CVCL_5K89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199680 CVCL_5K88 GM25373 transformed cell line human CVCL_5K88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199681 CVCL_5K87 GM25372 finite cell line human CVCL_5K87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199682 CVCL_5K53 GM24300 transformed cell line human CVCL_5K53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199683 CVCL_5K52 GM24299 transformed cell line human CVCL_5K52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199684 CVCL_5K51 GM24298 transformed cell line human CVCL_5K51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199685 CVCL_5K50 GM24297 transformed cell line human CVCL_5K50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199686 CVCL_5K57 GM24304 transformed cell line human CVCL_5K57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199687 CVCL_5K56 GM24303 transformed cell line human CVCL_5K56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199688 CVCL_5K55 GM24302 transformed cell line human CVCL_5K55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199689 CVCL_5K54 GM24301 transformed cell line human CVCL_5K54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199690 CVCL_5K59 GM24306 transformed cell line human CVCL_5K59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199691 CVCL_5K58 GM24305 transformed cell line human CVCL_5K58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199692 CVCL_5K60 GM24308 finite cell line human CVCL_5K60 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199693 CVCL_5K64 GM24312 finite cell line human CVCL_5K64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199694 CVCL_5K63 GM24311 finite cell line human CVCL_5K63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199695 CVCL_5K62 GM24310 finite cell line human CVCL_5K62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199696 CVCL_5K61 GM24309 finite cell line human CVCL_5K61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199697 CVCL_5K68 GM24322 transformed cell line human CVCL_5K68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199698 CVCL_5K67 GM24315 finite cell line human CVCL_5K67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21199699 CVCL_5K66 GM24314 finite cell line human CVCL_5K66 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199700 CVCL_5K65 GM24313 finite cell line human CVCL_5K65 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21199701 CVCL_5K69 GM24357 transformed cell line human CVCL_5K69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199702 CVCL_XQ90 HAP1 NEDD4L (-) 2 cancer cell line human CVCL_XQ90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7728; NEDD4L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199703 CVCL_Y290 NCI-H2850 cancer cell line human CVCL_Y290 CL:0000010 21199704 CVCL_XQ94 HAP1 NFE2L2 (-) cancer cell line human CVCL_XQ94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7782; NFE2L2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199705 CVCL_Y294 NCI-H3072 cancer cell line human CVCL_Y294 CL:0000010 21199706 CVCL_XQ93 HAP1 NFE2L1 (-) 2 cancer cell line human CVCL_XQ93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7781; NFE2L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199707 CVCL_Y293 NCI-H3030 cancer cell line human CVCL_Y293 CL:0000010 21199708 CVCL_XQ92 HAP1 NFATC1 (-) 2 cancer cell line human CVCL_XQ92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7775; NFATC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199709 CVCL_Y292 NCI-H3026 cancer cell line human CVCL_Y292 CL:0000010 21199710 CVCL_XQ91 HAP1 NES (-) 2 cancer cell line human CVCL_XQ91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7756; NES; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199711 CVCL_Y291 NCI-H2925 cancer cell line human CVCL_Y291 CL:0000010 21199712 CVCL_Y298 GLC-4/CDDP3 cancer cell line human CVCL_Y298 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21199713 CVCL_XQ98 HAP1 NIPSNAP3A (-) 4 cancer cell line human CVCL_XQ98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23619; NIPSNAP3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199714 CVCL_Y297 GLC-4/CDDP11 cancer cell line human CVCL_Y297 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21199715 CVCL_XQ97 HAP1 NIPSNAP3A (-) 3 cancer cell line human CVCL_XQ97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23619; NIPSNAP3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199716 CVCL_Y296 H273 cancer cell line human CVCL_Y296 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11998; TP53 (with p.Arg273His) Population: Caucasian; Derived from metastatic site: Lymph node. Male 21199717 CVCL_XQ96 HAP1 NIPSNAP3A (-) 2 cancer cell line human CVCL_XQ96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23619; NIPSNAP3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199718 CVCL_XQ95 HAP1 NFIL3 (-) cancer cell line human CVCL_XQ95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7787; NFIL3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199719 CVCL_Y295 NCI-H3123 cancer cell line human CVCL_Y295 CL:0000010 Unspecified 21199720 CVCL_Y299 GLC-4/AM3x cancer cell line human CVCL_Y299 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:2687; Amsacrine; Derived from metastatic site: Pleural effusion. Male Doubling time: 18.6 hours (PubMed=8980384) 21199721 CVCL_XQ99 HAP1 NMNAT3 (-) 2 cancer cell line human CVCL_XQ99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20989; NMNAT3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199722 CVCL_P909 HG00473 transformed cell line human CVCL_P909 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199723 CVCL_P908 HG00472 transformed cell line human CVCL_P908 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199724 CVCL_P907 HG00465 transformed cell line human CVCL_P907 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199725 CVCL_P906 HG00464 transformed cell line human CVCL_P906 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199726 CVCL_P905 HG00463 transformed cell line human CVCL_P905 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199727 CVCL_P904 HG00459 transformed cell line human CVCL_P904 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199728 CVCL_P903 HG00458 transformed cell line human CVCL_P903 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199729 CVCL_P902 HG00457 transformed cell line human CVCL_P902 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199730 CVCL_P901 HG00453 transformed cell line human CVCL_P901 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199731 CVCL_P900 HG00452 transformed cell line human CVCL_P900 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199732 CVCL_P859 HG00373 transformed cell line human CVCL_P859 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199733 CVCL_P858 HG00372 transformed cell line human CVCL_P858 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199734 CVCL_P857 HG00371 transformed cell line human CVCL_P857 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199735 CVCL_P856 HG00369 transformed cell line human CVCL_P856 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199736 CVCL_P855 HG00368 transformed cell line human CVCL_P855 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199737 CVCL_P854 HG00367 transformed cell line human CVCL_P854 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199738 CVCL_P853 HG00366 transformed cell line human CVCL_P853 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199739 CVCL_P852 HG00365 transformed cell line human CVCL_P852 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199740 CVCL_P851 HG00364 transformed cell line human CVCL_P851 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199741 CVCL_P850 HG00362 transformed cell line human CVCL_P850 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199742 CVCL_XQ03 HAP1 KRAS (-) 2 cancer cell line human CVCL_XQ03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6407; KRAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199743 CVCL_Y203 SK3/VP16 cancer cell line human CVCL_Y203 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Pericardial effusion. Male 21199744 CVCL_Y202 ACC-LC-172/CDDP cancer cell line human CVCL_Y202 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pericardial effusion. Male 21199745 CVCL_XQ02 HAP1 KIF18B (-) 2 cancer cell line human CVCL_XQ02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27102; KIF18B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199746 CVCL_XQ01 HAP1 KIAA1524 (-) 2 cancer cell line human CVCL_XQ01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29302; CIP2A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199747 CVCL_XQ00 HAP1 KIAA0319L (-) cancer cell line human CVCL_XQ00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30071; KIAA0319L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199748 CVCL_P869 HG00384 transformed cell line human CVCL_P869 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199749 CVCL_P868 HG00383 transformed cell line human CVCL_P868 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199750 CVCL_P867 HG00382 transformed cell line human CVCL_P867 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199751 CVCL_P866 HG00381 transformed cell line human CVCL_P866 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199752 CVCL_P865 HG00380 transformed cell line human CVCL_P865 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199753 CVCL_P864 HG00379 transformed cell line human CVCL_P864 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199754 CVCL_P863 HG00378 transformed cell line human CVCL_P863 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199755 CVCL_P862 HG00377 transformed cell line human CVCL_P862 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199756 CVCL_P861 HG00376 transformed cell line human CVCL_P861 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199757 CVCL_P860 HG00375 transformed cell line human CVCL_P860 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199758 CVCL_P839 HG00349 transformed cell line human CVCL_P839 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199759 CVCL_P838 HG00346 transformed cell line human CVCL_P838 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199760 CVCL_P837 HG00345 transformed cell line human CVCL_P837 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199761 CVCL_P836 HG00344 transformed cell line human CVCL_P836 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199762 CVCL_P835 HG00343 transformed cell line human CVCL_P835 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199763 CVCL_P834 HG00342 transformed cell line human CVCL_P834 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199764 CVCL_P833 HG00341 transformed cell line human CVCL_P833 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199765 CVCL_P832 HG00339 transformed cell line human CVCL_P832 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199766 CVCL_P831 HG00338 transformed cell line human CVCL_P831 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199767 CVCL_P830 HG00337 transformed cell line human CVCL_P830 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199768 CVCL_P849 HG00361 transformed cell line human CVCL_P849 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199769 CVCL_P848 HG00360 transformed cell line human CVCL_P848 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199770 CVCL_P847 HG00359 transformed cell line human CVCL_P847 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199771 CVCL_P846 HG00358 transformed cell line human CVCL_P846 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199772 CVCL_P845 HG00357 transformed cell line human CVCL_P845 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199773 CVCL_P844 HG00356 transformed cell line human CVCL_P844 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199774 CVCL_P843 HG00355 transformed cell line human CVCL_P843 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199775 CVCL_P842 HG00353 transformed cell line human CVCL_P842 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199776 CVCL_P841 HG00351 transformed cell line human CVCL_P841 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199777 CVCL_P840 HG00350 transformed cell line human CVCL_P840 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199778 CVCL_P819 HG00325 transformed cell line human CVCL_P819 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199779 CVCL_P818 HG00324 transformed cell line human CVCL_P818 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199780 CVCL_P817 HG00323 transformed cell line human CVCL_P817 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199781 CVCL_P816 HG00321 transformed cell line human CVCL_P816 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199782 CVCL_P815 HG00320 transformed cell line human CVCL_P815 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199783 CVCL_P814 HG00319 transformed cell line human CVCL_P814 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199784 CVCL_P813 HG00318 transformed cell line human CVCL_P813 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199785 CVCL_P812 HG00315 transformed cell line human CVCL_P812 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199786 CVCL_P811 HG00313 transformed cell line human CVCL_P811 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199787 CVCL_P810 HG00312 transformed cell line human CVCL_P810 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199788 CVCL_P829 HG00336 transformed cell line human CVCL_P829 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199789 CVCL_P828 HG00335 transformed cell line human CVCL_P828 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199790 CVCL_P827 HG00334 transformed cell line human CVCL_P827 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199791 CVCL_P826 HG00332 transformed cell line human CVCL_P826 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199792 CVCL_P825 HG00331 transformed cell line human CVCL_P825 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199793 CVCL_P824 HG00330 transformed cell line human CVCL_P824 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199794 CVCL_P823 HG00329 transformed cell line human CVCL_P823 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199795 CVCL_P822 HG00328 transformed cell line human CVCL_P822 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199796 CVCL_P821 HG00327 transformed cell line human CVCL_P821 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199797 CVCL_P820 HG00326 transformed cell line human CVCL_P820 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199798 CVCL_P809 HG00311 transformed cell line human CVCL_P809 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199799 CVCL_P808 HG00310 transformed cell line human CVCL_P808 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199800 CVCL_P807 HG00309 transformed cell line human CVCL_P807 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199801 CVCL_P806 HG00308 transformed cell line human CVCL_P806 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199802 CVCL_P805 HG00306 transformed cell line human CVCL_P805 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199803 CVCL_P804 HG00285 transformed cell line human CVCL_P804 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199804 CVCL_P803 HG00284 transformed cell line human CVCL_P803 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199805 CVCL_P802 HG00282 transformed cell line human CVCL_P802 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199806 CVCL_P801 HG00281 transformed cell line human CVCL_P801 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199807 CVCL_P800 HG00280 transformed cell line human CVCL_P800 CL:0000010 Population: Caucasian; Finnish in Finland (FIN); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199808 CVCL_5K31 GM24276 transformed cell line human CVCL_5K31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199809 CVCL_5K30 GM24274 transformed cell line human CVCL_5K30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199810 CVCL_5K35 GM24280 transformed cell line human CVCL_5K35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199811 CVCL_5K34 GM24279 transformed cell line human CVCL_5K34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199812 CVCL_5K33 GM24278 transformed cell line human CVCL_5K33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199813 CVCL_5K32 GM24277 transformed cell line human CVCL_5K32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199814 CVCL_5K39 GM24286 transformed cell line human CVCL_5K39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199815 CVCL_5K38 GM24284 transformed cell line human CVCL_5K38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199816 CVCL_5K37 GM24283 transformed cell line human CVCL_5K37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199817 CVCL_5K36 GM24281 transformed cell line human CVCL_5K36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199818 CVCL_5K29 GM24273 transformed cell line human CVCL_5K29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199819 CVCL_XQ83 HAP1 NAA30 (-) 2 cancer cell line human CVCL_XQ83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19844; NAA30; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199820 CVCL_Y283 ML10 transformed cell line human CVCL_Y283 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767) Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Female Doubling time: 2.0 +- 0.2 days (PubMed=9441775) 21199821 CVCL_XQ82 HAP1 MYO5B (-) 2 cancer cell line human CVCL_XQ82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7603; MYO5B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199822 CVCL_Y282 ML3 transformed cell line human CVCL_Y282 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female Doubling time: 1.7 +- 0.3 days (PubMed=9441775) 21199823 CVCL_Y281 BC215 cancer cell line house mouse CVCL_Y281 CL:0000010 Derived from sampling site: Lung; Breed/subspecies: C57BL/6. 21199824 CVCL_XQ81 HAP1 MYO18A (-) 1 cancer cell line human CVCL_XQ81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 31104; MYO18A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199825 CVCL_XQ80 HAP1 MYB (-) 2 cancer cell line human CVCL_XQ80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7545; MYB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199826 CVCL_Y280 SKOV3/VP cancer cell line human CVCL_Y280 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from metastatic site: Ascites. Female 21199827 CVCL_Y287 CHO-VV 3-2 spontaneously immortalized cell line CVCL_Y287 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from sampling site: Ovary. Female 21199828 CVCL_XQ87 HAP1 NDUFAF6 (-) cancer cell line human CVCL_XQ87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28625; NDUFAF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199829 CVCL_XQ86 HAP1 NAGK (-) 2 cancer cell line human CVCL_XQ86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17174; NAGK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199830 CVCL_Y286 HY595 transformed cell line human CVCL_Y286 HLA typing: DPB1*02:01,05:01; DQA1*01:03; DQB1*03:03; DRB1*09:01 (IPD-IMGT/HLA=10784) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Part of: International Histocompatibility Workshop cell lines 21199831 CVCL_XQ85 HAP1 NADK2 (-) cancer cell line human CVCL_XQ85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26404; NADK2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199832 CVCL_Y285 SL-15 transformed cell line human CVCL_Y285 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 36-48 hours (PubMed=16049984) 21199833 CVCL_XQ84 HAP1 NADK (-) cancer cell line human CVCL_XQ84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29831; NADK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199834 CVCL_Y284 ML8 transformed cell line human CVCL_Y284 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767). Female Doubling time: 1.7 +- 0.3 days (PubMed=9441775) 21199835 CVCL_XQ89 HAP1 NDUFS3 (-) 1 cancer cell line human CVCL_XQ89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7710; NDUFS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199836 CVCL_Y289 NCI-H2712 cancer cell line human CVCL_Y289 CL:0000010 21199837 CVCL_XQ88 HAP1 NDUFB8 (-) 2 cancer cell line human CVCL_XQ88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7703; NDUFB8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199838 CVCL_Y288 NCI-H2427 cancer cell line human CVCL_Y288 CL:0000010 21199839 CVCL_5K42 GM24289 transformed cell line human CVCL_5K42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199840 CVCL_5K41 GM24288 transformed cell line human CVCL_5K41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199841 CVCL_5K40 GM24287 transformed cell line human CVCL_5K40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199842 CVCL_5K46 GM24293 transformed cell line human CVCL_5K46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199843 CVCL_5K45 GM24292 transformed cell line human CVCL_5K45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199844 CVCL_5K44 GM24291 transformed cell line human CVCL_5K44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199845 CVCL_5K43 GM24290 transformed cell line human CVCL_5K43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199846 CVCL_5K49 GM24296 transformed cell line human CVCL_5K49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199847 CVCL_5K48 GM24295 transformed cell line human CVCL_5K48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199848 CVCL_5K47 GM24294 transformed cell line human CVCL_5K47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199849 CVCL_XQ72 HAP1 MTFR1L (-) 3 cancer cell line human CVCL_XQ72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28836; MTFR1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199850 CVCL_Y272 X63-omIL-2 cancer cell line house mouse CVCL_Y272 CL:0000010 Transfected with: MGI; MGI:96548; Il2 Breed/subspecies: BALB/c. Female 21199851 CVCL_Y271 CHEULL1F cancer cell line human CVCL_Y271 CL:0000010 Unspecified 21199852 CVCL_XQ71 HAP1 MTFR1L (-) 2 cancer cell line human CVCL_XQ71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28836; MTFR1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199853 CVCL_Y270 ESC/LCM9T-N cancer cell line human CVCL_Y270 CL:0000010 Unspecified 21199854 CVCL_XQ70 GAL-FR21 hybridoma house mouse CVCL_XQ70 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21802; Human FGFR2/CD332 (isoform IgIIIb/K-sam-II) (Note=Also reacts with mouse and monkeys). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9586 21199855 CVCL_XQ76 HAP1 MTHFD2 (-) 3 cancer cell line human CVCL_XQ76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7434; MTHFD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199856 CVCL_Y276 NB5-B2 cancer cell line human CVCL_Y276 CL:0000010 21199857 CVCL_XQ75 HAP1 MTHFD2 (-) 2 cancer cell line human CVCL_XQ75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7434; MTHFD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199858 CVCL_Y275 mEHE/CH5 cancer cell line house mouse CVCL_Y275 CL:0000010 Derived from sampling site: Thyroid gland. 21199859 CVCL_XQ74 HAP1 MTHFD1L (-) 2 cancer cell line human CVCL_XQ74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21055; MTHFD1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199860 CVCL_Y274 X63-omIL-5 cancer cell line house mouse CVCL_Y274 CL:0000010 Transfected with: MGI; MGI:96557; Il5 Breed/subspecies: BALB/c. Female 21199861 CVCL_XQ73 HAP1 MTFR1L (-) 4 cancer cell line human CVCL_XQ73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28836; MTFR1L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199862 CVCL_Y273 X63-omIL-4 cancer cell line house mouse CVCL_Y273 CL:0000010 Transfected with: MGI; MGI:96556; Il4 Breed/subspecies: BALB/c. Female 21199863 CVCL_Y279 ESC/LCM1T cancer cell line human CVCL_Y279 CL:0000010 Unspecified 21199864 CVCL_XQ79 HAP1 MX2 (-) 2 cancer cell line human CVCL_XQ79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7533; MX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199865 CVCL_XQ78 HAP1 MUM1 (-) cancer cell line human CVCL_XQ78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29641; PWWP3A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199866 CVCL_Y278 KYSE-2650 cancer cell line human CVCL_Y278 CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. 21199867 CVCL_XQ77 HAP1 MTO1 (-) cancer cell line human CVCL_XQ77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19261; MTO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199868 CVCL_Y277 KKS-2 cancer cell line human CVCL_Y277 CL:0000010 Unspecified 21199869 CVCL_Y259 ESC/LCM6T cancer cell line human CVCL_Y259 CL:0000010 Unspecified 21199870 CVCL_XQ59 HAP1 MPC1 (-) cancer cell line human CVCL_XQ59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21606; MPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199871 CVCL_5K13 GM18320 transformed cell line human CVCL_5K13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199872 CVCL_5K12 GM18319 transformed cell line human CVCL_5K12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199873 CVCL_5K11 GM13476 transformed cell line human CVCL_5K11 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199874 CVCL_5K10 M2-21-4.6 hybridoma house mouse CVCL_5K10 CL:0000010 Discontinued: Coriell; WC00028; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Influenza A virus matrix protein (M) 21199875 CVCL_5K17 GM18324 transformed cell line human CVCL_5K17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199876 CVCL_5K16 GM18323 transformed cell line human CVCL_5K16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199877 CVCL_5K15 GM18322 transformed cell line human CVCL_5K15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199878 CVCL_5K14 GM18321 transformed cell line human CVCL_5K14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199879 CVCL_5K09 H15-A13 hybridoma house mouse CVCL_5K09 CL:0000010 Discontinued: Coriell; WC00050; probable. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P03454; Influenza A virus isolate A/Wilson-Smith/1933 H1N1 hemagglutinin (HA) 21199880 CVCL_5K08 H2-6A1 hybridoma house mouse CVCL_5K08 CL:0000010 Discontinued: Coriell; WC00022; probable. Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21199881 CVCL_5K07 H2-4C2 hybridoma house mouse CVCL_5K07 CL:0000010 Discontinued: Coriell; WC00034; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21199882 CVCL_Y261 ESC/LCM61T-N cancer cell line human CVCL_Y261 CL:0000010 Unspecified 21199883 CVCL_XQ61 HAP1 MPV17 (-) 2 cancer cell line human CVCL_XQ61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7224; MPV17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199884 CVCL_Y260 ESC/LCM60T-N cancer cell line human CVCL_Y260 CL:0000010 Unspecified 21199885 CVCL_XQ60 HAP1 MPND (-) 3 cancer cell line human CVCL_XQ60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25934; MPND; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199886 CVCL_Y265 ESC/LCM69T-N cancer cell line human CVCL_Y265 CL:0000010 Unspecified 21199887 CVCL_XQ65 HAP1 MSI2 (-) 2 cancer cell line human CVCL_XQ65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18585; MSI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199888 CVCL_Y264 ESC/LCM67T-N cancer cell line human CVCL_Y264 CL:0000010 Unspecified 21199889 CVCL_XQ64 HAP1 MSI1 (-) 2 cancer cell line human CVCL_XQ64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7330; MSI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199890 CVCL_Y263 ESC/LCM66T-N cancer cell line human CVCL_Y263 CL:0000010 Unspecified 21199891 CVCL_XQ63 HAP1 MRPS22 (-) cancer cell line human CVCL_XQ63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14508; MRPS22; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199892 CVCL_Y262 ESC/LCM62T-N cancer cell line human CVCL_Y262 CL:0000010 Unspecified 21199893 CVCL_XQ62 HAP1 MPV17 (-) 3 cancer cell line human CVCL_XQ62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7224; MPV17; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199894 CVCL_Y269 ESC/LCM8T-N cancer cell line human CVCL_Y269 CL:0000010 Unspecified 21199895 CVCL_XQ69 HAP1 MTERFD3 (-) cancer cell line human CVCL_XQ69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30779; MTERF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199896 CVCL_Y268 ESC/LCM71T-N cancer cell line human CVCL_Y268 CL:0000010 Unspecified 21199897 CVCL_XQ68 HAP1 MTERFD1 (-) cancer cell line human CVCL_XQ68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24258; MTERF3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199898 CVCL_Y267 ESC/LCM70T-N cancer cell line human CVCL_Y267 CL:0000010 Unspecified 21199899 CVCL_XQ67 HAP1 MTERF (-) cancer cell line human CVCL_XQ67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21463; MTERF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199900 CVCL_Y266 ESC/LCM7T cancer cell line human CVCL_Y266 CL:0000010 Unspecified 21199901 CVCL_XQ66 HAP1 MSI2 (-) 3 cancer cell line human CVCL_XQ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18585; MSI2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199902 CVCL_Y249 ESC/LCM50T-N cancer cell line human CVCL_Y249 CL:0000010 Unspecified 21199903 CVCL_XQ49 HAP1 MFSD8 (-) 2 cancer cell line human CVCL_XQ49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28486; MFSD8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199904 CVCL_Y248 ESC/LCM5T cancer cell line human CVCL_Y248 CL:0000010 Unspecified 21199905 CVCL_XQ48 HAP1 MFN2 (-) cancer cell line human CVCL_XQ48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16877; MFN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199906 CVCL_5K20 GM20734 transformed cell line human CVCL_5K20 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Leu85fs*60 (c.253del19); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199907 CVCL_5K24 GM22766 transformed cell line human CVCL_5K24 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Ala75Ser (c.223G>T); ClinVar=VCV000588756; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199908 CVCL_5K23 GM20743 transformed cell line human CVCL_5K23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199909 CVCL_5K22 GM20742 transformed cell line human CVCL_5K22 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Val925fs*8 (c.2773del29); Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21199910 CVCL_5K21 GM20735 transformed cell line human CVCL_5K21 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Gln1562Arg (c.4685A>G); ClinVar=VCV000002950; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199911 CVCL_5K28 GM24271 transformed cell line human CVCL_5K28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199912 CVCL_5K27 GM24204 transformed cell line human CVCL_5K27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199913 CVCL_5K26 GM23786 transformed cell line human CVCL_5K26 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199914 CVCL_5K25 GM22767 transformed cell line human CVCL_5K25 CL:0000010 Sequence variation: Mutation; HGNC; 9834; RAI1; Simple; p.Ala75Ser (c.223G>T); ClinVar=VCV000588756; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21199915 CVCL_5K19 GM18326 transformed cell line human CVCL_5K19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21199916 CVCL_5K18 GM18325 transformed cell line human CVCL_5K18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21199917 CVCL_Y250 ESC/LCM51T-N cancer cell line human CVCL_Y250 CL:0000010 Unspecified 21199918 CVCL_XQ50 HAP1 MFSD9 (-) 2 cancer cell line human CVCL_XQ50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28158; MFSD9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199919 CVCL_Y254 ESC/LCM55T-N cancer cell line human CVCL_Y254 CL:0000010 Unspecified 21199920 CVCL_XQ54 HAP1 MIEN1 (-) cancer cell line human CVCL_XQ54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28230; MIEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199921 CVCL_Y253 ESC/LCM54T-N cancer cell line human CVCL_Y253 CL:0000010 Unspecified 21199922 CVCL_XQ53 HAP1 MGEA5 (-) 2 cancer cell line human CVCL_XQ53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7056; OGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199923 CVCL_Y252 ESC/LCM53T-N cancer cell line human CVCL_Y252 CL:0000010 Unspecified 21199924 CVCL_XQ52 HAP1 MGAT1 (-) 3 cancer cell line human CVCL_XQ52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7044; MGAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199925 CVCL_Y251 ESC/LCM52T-N cancer cell line human CVCL_Y251 CL:0000010 Unspecified 21199926 CVCL_XQ51 HAP1 MGAT1 (-) 2 cancer cell line human CVCL_XQ51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7044; MGAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199927 CVCL_Y258 ESC/LCM59T-N cancer cell line human CVCL_Y258 CL:0000010 Unspecified 21199928 CVCL_XQ58 HAP1 MMP2 (-) cancer cell line human CVCL_XQ58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7166; MMP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199929 CVCL_Y257 ESC/LCM58T-N cancer cell line human CVCL_Y257 CL:0000010 Unspecified 21199930 CVCL_XQ57 HAP1 MLXIP (-) 2 cancer cell line human CVCL_XQ57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17055; MLXIP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199931 CVCL_Y256 ESC/LCM57T-N cancer cell line human CVCL_Y256 CL:0000010 Unspecified 21199932 CVCL_XQ56 HAP1 MISP (-) cancer cell line human CVCL_XQ56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27000; MISP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199933 CVCL_Y255 ESC/LCM56T-N cancer cell line human CVCL_Y255 CL:0000010 Unspecified 21199934 CVCL_XQ55 HAP1 MIF (-) 2 cancer cell line human CVCL_XQ55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7097; MIF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199935 CVCL_Y239 ESC/LCM41T-N cancer cell line human CVCL_Y239 CL:0000010 Unspecified 21199936 CVCL_XQ39 HAP1 MECR (-) cancer cell line human CVCL_XQ39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19691; MECR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199937 CVCL_Y238 ESC/LCM40T cancer cell line human CVCL_Y238 CL:0000010 Unspecified 21199938 CVCL_XQ38 HAP1 ME2 (-) 2 cancer cell line human CVCL_XQ38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6984; ME2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199939 CVCL_Y237 ESC/LCM4T-N cancer cell line human CVCL_Y237 CL:0000010 Unspecified 21199940 CVCL_XQ37 HAP1 ME1 (-) 2 cancer cell line human CVCL_XQ37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6983; ME1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199941 CVCL_P899 HG00451 transformed cell line human CVCL_P899 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199942 CVCL_P898 HG00450 transformed cell line human CVCL_P898 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199943 CVCL_P897 HG00449 transformed cell line human CVCL_P897 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199944 CVCL_P896 HG00448 transformed cell line human CVCL_P896 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199945 CVCL_Y243 ESC/LCM45T-N cancer cell line human CVCL_Y243 CL:0000010 Unspecified 21199946 CVCL_XQ43 HAP1 METTL10 (-) 2 cancer cell line human CVCL_XQ43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 33787; EEF1AKMT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199947 CVCL_P895 HG00447 transformed cell line human CVCL_P895 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199948 CVCL_Y242 ESC/LCM44T-N cancer cell line human CVCL_Y242 CL:0000010 Unspecified 21199949 CVCL_XQ42 HAP1 MERTK (-) 4 cancer cell line human CVCL_XQ42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7027; MERTK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199950 CVCL_P894 HG00446 transformed cell line human CVCL_P894 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199951 CVCL_Y241 ESC/LCM43T-N cancer cell line human CVCL_Y241 CL:0000010 Unspecified 21199952 CVCL_XQ41 HAP1 MEIS1 (-) 3 cancer cell line human CVCL_XQ41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7000; MEIS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199953 CVCL_P893 HG00445 transformed cell line human CVCL_P893 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199954 CVCL_Y240 ESC/LCM42T-N cancer cell line human CVCL_Y240 CL:0000010 Unspecified 21199955 CVCL_XQ40 HAP1 MEIS1 (-) 2 cancer cell line human CVCL_XQ40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7000; MEIS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199956 CVCL_P892 HG00444 transformed cell line human CVCL_P892 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199957 CVCL_Y247 ESC/LCM49T-N cancer cell line human CVCL_Y247 CL:0000010 Unspecified 21199958 CVCL_XQ47 HAP1 MFF (-) cancer cell line human CVCL_XQ47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24858; MFF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199959 CVCL_P891 HG00443 transformed cell line human CVCL_P891 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199960 CVCL_Y246 ESC/LCM48T-N cancer cell line human CVCL_Y246 CL:0000010 Unspecified 21199961 CVCL_XQ46 HAP1 METTL4 (-) cancer cell line human CVCL_XQ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24726; METTL4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199962 CVCL_P890 HG00442 transformed cell line human CVCL_P890 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21199963 CVCL_Y245 ESC/LCM47T-N cancer cell line human CVCL_Y245 CL:0000010 Unspecified 21199964 CVCL_XQ45 HAP1 METTL20 (-) 2 cancer cell line human CVCL_XQ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28739; ETFBKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199965 CVCL_Y244 ESC/LCM46T-N cancer cell line human CVCL_Y244 CL:0000010 Unspecified 21199966 CVCL_XQ44 HAP1 METTL20 (-) 1 cancer cell line human CVCL_XQ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28739; ETFBKMT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199967 CVCL_Y229 ESC/LCM32T-N cancer cell line human CVCL_Y229 CL:0000010 Unspecified 21199968 CVCL_XQ29 HAP1 MAPKAPK5 (-) 3 cancer cell line human CVCL_XQ29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6889; MAPKAPK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199969 CVCL_Y228 ESC/LCM31T-N cancer cell line human CVCL_Y228 CL:0000010 Unspecified 21199970 CVCL_XQ28 HAP1 MAPKAPK5 (-) 2 cancer cell line human CVCL_XQ28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6889; MAPKAPK5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199971 CVCL_Y227 ESC/LCM3T-N cancer cell line human CVCL_Y227 CL:0000010 Unspecified 21199972 CVCL_XQ27 HAP1 MAGT1 (-) cancer cell line human CVCL_XQ27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28880; MAGT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199973 CVCL_Y226 ESC/LCM29T-N cancer cell line human CVCL_Y226 CL:0000010 Unspecified 21199974 CVCL_XQ26 HAP1 MAD2L1 (-) 2 cancer cell line human CVCL_XQ26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6763; MAD2L1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199975 CVCL_5K02 H18-S210 hybridoma house mouse CVCL_5K02 CL:0000010 Discontinued: Coriell; WC00029; probable. 21199976 CVCL_5K01 H19-S24-4 hybridoma house mouse CVCL_5K01 CL:0000010 Discontinued: Coriell; WC00018; probable. Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: Influenza A virus nucleoprotein (NP) 21199977 CVCL_5K00 H17-L8 hybridoma house mouse CVCL_5K00 CL:0000010 Discontinued: Coriell; WC00011; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21199978 CVCL_5K06 H2-4B3 hybridoma house mouse CVCL_5K06 CL:0000010 Discontinued: Coriell; WC00041; probable. Monoclonal antibody target: UniProtKB; P03452; Influenza A virus isolate A/Puerto Rico/8/1934 hemagglutinin (HA) 21199979 CVCL_5K05 M2-58 hybridoma house mouse CVCL_5K05 CL:0000010 Discontinued: Coriell; WC00043; probable. 21199980 CVCL_5K04 M2-40 hybridoma house mouse CVCL_5K04 CL:0000010 Discontinued: Coriell; WC00016; probable. 21199981 CVCL_5K03 H18-S415 hybridoma house mouse CVCL_5K03 CL:0000010 Discontinued: Coriell; WC00038; probable. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P03454; Influenza A virus isolate A/Wilson-Smith/1933 H1N1 hemagglutinin (HA) 21199982 CVCL_Y232 ESC/LCM35T-N cancer cell line human CVCL_Y232 CL:0000010 Unspecified 21199983 CVCL_XQ32 HAP1 MBP (-) 2 cancer cell line human CVCL_XQ32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6925; MBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199984 CVCL_Y231 ESC/LCM34T-N cancer cell line human CVCL_Y231 CL:0000010 Unspecified 21199985 CVCL_XQ31 HAP1 MBD2 (-) 3 cancer cell line human CVCL_XQ31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6917; MBD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199986 CVCL_Y230 ESC/LCM33T cancer cell line human CVCL_Y230 CL:0000010 Unspecified 21199987 CVCL_XQ30 HAP1 MAPKBP1 (-) cancer cell line human CVCL_XQ30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29536; MAPKBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199988 CVCL_Y236 ESC/LCM39T-N cancer cell line human CVCL_Y236 CL:0000010 Unspecified 21199989 CVCL_XQ36 HAP1 MDH2 (-) 1 cancer cell line human CVCL_XQ36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6971; MDH2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199990 CVCL_Y235 ESC/LCM38T-N cancer cell line human CVCL_Y235 CL:0000010 Unspecified 21199991 CVCL_XQ35 HAP1 MDH1 (-) cancer cell line human CVCL_XQ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6970; MDH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199992 CVCL_Y234 ESC/LCM37T-N cancer cell line human CVCL_Y234 CL:0000010 Unspecified 21199993 CVCL_XQ34 HAP1 MCUR1 (-) cancer cell line human CVCL_XQ34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21097; MCUR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199994 CVCL_Y233 ESC/LCM36T cancer cell line human CVCL_Y233 CL:0000010 Unspecified 21199995 CVCL_XQ33 HAP1 MCOLN3 (-) 2 cancer cell line human CVCL_XQ33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13358; MCOLN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199996 CVCL_Y218 ESC/LCM20T-N cancer cell line human CVCL_Y218 CL:0000010 Unspecified 21199997 CVCL_XQ18 HAP1 LIMCH1 (-) 3 cancer cell line human CVCL_XQ18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29191; LIMCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21199998 CVCL_Y217 ESC/LCM2T-N cancer cell line human CVCL_Y217 CL:0000010 Unspecified 21199999 CVCL_XQ17 HAP1 LIMCH1 (-) 2 cancer cell line human CVCL_XQ17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29191; LIMCH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200000 CVCL_Y216 ESC/LCM18T cancer cell line human CVCL_Y216 CL:0000010 Unspecified 21200001 CVCL_XQ16 HAP1 LIAS (-) cancer cell line human CVCL_XQ16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16429; LIAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200002 CVCL_Y215 ESC/LCM17T-N cancer cell line human CVCL_Y215 CL:0000010 Unspecified 21200003 CVCL_XQ15 HAP1 LGALS3 (-) 2 cancer cell line human CVCL_XQ15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6563; LGALS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200004 CVCL_Y219 ESC/LCM21T-N cancer cell line human CVCL_Y219 CL:0000010 Unspecified 21200005 CVCL_XQ19 HAP1 LMBRD1 (-) cancer cell line human CVCL_XQ19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23038; LMBRD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200006 CVCL_P879 HG00419 transformed cell line human CVCL_P879 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200007 CVCL_P878 HG00418 transformed cell line human CVCL_P878 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200008 CVCL_P877 HG00410 transformed cell line human CVCL_P877 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200009 CVCL_P876 HG00409 transformed cell line human CVCL_P876 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200010 CVCL_P875 HG00408 transformed cell line human CVCL_P875 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200011 CVCL_P874 HG00407 transformed cell line human CVCL_P874 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200012 CVCL_Y221 ESC/LCM23T cancer cell line human CVCL_Y221 CL:0000010 Unspecified 21200013 CVCL_XQ21 HAP1 LOX (-) 2 cancer cell line human CVCL_XQ21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6664; LOX; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200014 CVCL_P873 HG00406 transformed cell line human CVCL_P873 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200015 CVCL_Y220 ESC/LCM22T-N cancer cell line human CVCL_Y220 CL:0000010 Unspecified 21200016 CVCL_XQ20 HAP1 LMNB2 (-) 2 cancer cell line human CVCL_XQ20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6638; LMNB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200017 CVCL_P872 HG00405 transformed cell line human CVCL_P872 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200018 CVCL_P871 HG00404 transformed cell line human CVCL_P871 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200019 CVCL_P870 HG00403 transformed cell line human CVCL_P870 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200020 CVCL_Y225 ESC/LCM27T-N cancer cell line human CVCL_Y225 CL:0000010 Unspecified 21200021 CVCL_XQ25 HAP1 LYRM2 (-) 2 cancer cell line human CVCL_XQ25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25229; LYRM2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200022 CVCL_Y224 ESC/LCM26T-N cancer cell line human CVCL_Y224 CL:0000010 Unspecified 21200023 CVCL_XQ24 HAP1 LTF (-) cancer cell line human CVCL_XQ24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6720; LTF; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200024 CVCL_Y223 ESC/LCM25T-N cancer cell line human CVCL_Y223 CL:0000010 Unspecified 21200025 CVCL_XQ23 HAP1 LRRC16A (-) cancer cell line human CVCL_XQ23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21581; CARMIL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200026 CVCL_Y222 ESC/LCM24T-N cancer cell line human CVCL_Y222 CL:0000010 Unspecified 21200027 CVCL_XQ22 HAP1 LPIN1 (-) 1 cancer cell line human CVCL_XQ22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13345; LPIN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200028 CVCL_XQ07 HAP1 LAT (-) 2 cancer cell line human CVCL_XQ07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18874; LAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200029 CVCL_XQ06 HAP1 LARP1 (-) cancer cell line human CVCL_XQ06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29531; LARP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200030 CVCL_Y206 MOA2/CDDP cancer cell line human CVCL_Y206 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Pleural effusion. Male 21200031 CVCL_XQ05 HAP1 L2HGDH (-) cancer cell line human CVCL_XQ05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20499; L2HGDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200032 CVCL_Y205 MOA2 cancer cell line human CVCL_Y205 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21200033 CVCL_XQ04 HAP1 KRAS (-) 3 cancer cell line human CVCL_XQ04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6407; KRAS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200034 CVCL_Y204 MOA1 cancer cell line human CVCL_Y204 CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Male 21200035 CVCL_Y209 ESC/LCM10T-N cancer cell line human CVCL_Y209 CL:0000010 21200036 CVCL_XQ09 HAP1 LAT (-) 4 cancer cell line human CVCL_XQ09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18874; LAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200037 CVCL_Y208 ACC-LC-51 cancer cell line human CVCL_Y208 CL:0000010 Population: Japanese; Derived from metastatic site: Mesentery. Male 21200038 CVCL_XQ08 HAP1 LAT (-) 3 cancer cell line human CVCL_XQ08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18874; LAT; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200039 CVCL_P889 HG00438 transformed cell line human CVCL_P889 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200040 CVCL_P888 HG00437 transformed cell line human CVCL_P888 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200041 CVCL_P887 HG00436 transformed cell line human CVCL_P887 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200042 CVCL_P886 HG00429 transformed cell line human CVCL_P886 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200043 CVCL_P885 HG00428 transformed cell line human CVCL_P885 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200044 CVCL_Y210 ESC/LCM11T-N cancer cell line human CVCL_Y210 CL:0000010 Unspecified 21200045 CVCL_XQ10 HAP1 LEF1 (-) 2 cancer cell line human CVCL_XQ10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6551; LEF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200046 CVCL_P884 HG00427 transformed cell line human CVCL_P884 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200047 CVCL_P883 HG00423 transformed cell line human CVCL_P883 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200048 CVCL_P882 HG00422 transformed cell line human CVCL_P882 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200049 CVCL_P881 HG00421 transformed cell line human CVCL_P881 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200050 CVCL_Y214 ESC/LCM16T-N cancer cell line human CVCL_Y214 CL:0000010 Unspecified 21200051 CVCL_XQ14 HAP1 LGALS1 (-) 2 cancer cell line human CVCL_XQ14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6561; LGALS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200052 CVCL_P880 HG00420 transformed cell line human CVCL_P880 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200053 CVCL_Y213 ESC/LCM15T-N cancer cell line human CVCL_Y213 CL:0000010 Unspecified 21200054 CVCL_XQ13 HAP1 LETMD1 (-) 4 cancer cell line human CVCL_XQ13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24241; LETMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200055 CVCL_Y212 ESC/LCM14T-N cancer cell line human CVCL_Y212 CL:0000010 Unspecified 21200056 CVCL_XQ12 HAP1 LETMD1 (-) 3 cancer cell line human CVCL_XQ12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24241; LETMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200057 CVCL_Y211 ESC/LCM12T-N cancer cell line human CVCL_Y211 CL:0000010 Unspecified 21200058 CVCL_XQ11 HAP1 LETMD1 (-) 2 cancer cell line human CVCL_XQ11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24241; LETMD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200059 CVCL_5L92 GM09378 transformed cell line human CVCL_5L92 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200060 CVCL_5L91 GM09377 transformed cell line human CVCL_5L91 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200061 CVCL_5L90 GM09376 transformed cell line human CVCL_5L90 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200062 CVCL_5L96 GM09432 transformed cell line human CVCL_5L96 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200063 CVCL_5L95 GM09431 transformed cell line human CVCL_5L95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200064 CVCL_5L94 GM09380 transformed cell line human CVCL_5L94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200065 CVCL_5L93 GM09379 transformed cell line human CVCL_5L93 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200066 CVCL_5L99 GM09435 transformed cell line human CVCL_5L99 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200067 CVCL_5L98 GM09434 transformed cell line human CVCL_5L98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200068 CVCL_5L97 GM09433 transformed cell line human CVCL_5L97 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200069 CVCL_5L70 GM08584 transformed cell line human CVCL_5L70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200070 CVCL_5L74 GM09339 transformed cell line human CVCL_5L74 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200071 CVCL_5L73 GM09338 transformed cell line human CVCL_5L73 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200072 CVCL_5L72 GM09337 transformed cell line human CVCL_5L72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200073 CVCL_5L71 GM09335 transformed cell line human CVCL_5L71 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200074 CVCL_5L78 GM09343 transformed cell line human CVCL_5L78 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200075 CVCL_5L77 GM09342 transformed cell line human CVCL_5L77 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200076 CVCL_5L76 GM09341 transformed cell line human CVCL_5L76 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200077 CVCL_5L75 GM09340 transformed cell line human CVCL_5L75 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200078 CVCL_5L79 GM09344 transformed cell line human CVCL_5L79 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200079 CVCL_5L81 GM09349 transformed cell line human CVCL_5L81 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200080 CVCL_5L80 GM09348 transformed cell line human CVCL_5L80 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200081 CVCL_5L85 GM09359 transformed cell line human CVCL_5L85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200082 CVCL_5L84 GM09354 transformed cell line human CVCL_5L84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200083 CVCL_5L83 GM09353 transformed cell line human CVCL_5L83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200084 CVCL_5L82 GM09351 transformed cell line human CVCL_5L82 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200085 CVCL_5L89 GM09375 transformed cell line human CVCL_5L89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200086 CVCL_5L88 GM09374 transformed cell line human CVCL_5L88 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200087 CVCL_5L87 GM09373 transformed cell line human CVCL_5L87 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Ser1232Thrfs*92 (c.3693_3696delGTCT) (Leu1231fs*1323) (c.3693delGTCT); ClinVar=VCV000050013; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200088 CVCL_5L86 GM09366 transformed cell line human CVCL_5L86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200089 CVCL_Y317 GM17547 transformed cell line human CVCL_Y317 CL:0000010 Sequence variation: Mutation; HGNC; 1133; BTK; Simple; p.Cys506Arg (c.1516T>C); ClinVar=VCV000011376; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200090 CVCL_XR17 HAP1 NSUN5 (-) 2 cancer cell line human CVCL_XR17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16385; NSUN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200091 CVCL_Y316 GM00362 finite cell line human CVCL_Y316 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200092 CVCL_XR16 HAP1 NSUN2 (-) 2 cancer cell line human CVCL_XR16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25994; NSUN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200093 CVCL_XR15 HAP1 NRP2 (-) 2 cancer cell line human CVCL_XR15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8005; NRP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200094 CVCL_Y315 WIN-5 embryonic stem cell human CVCL_Y315 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0303. 21200095 CVCL_XR14 HAP1 NRP1 (-) 2 cancer cell line human CVCL_XR14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8004; NRP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200096 CVCL_Y314 WIN-4 embryonic stem cell human CVCL_Y314 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0302. 21200097 CVCL_Y319 GM11067 transformed cell line human CVCL_Y319 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200098 CVCL_XR19 HAP1 NSUN5 (-) 4 cancer cell line human CVCL_XR19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16385; NSUN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200099 CVCL_Y318 GM17566 transformed cell line human CVCL_Y318 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200100 CVCL_XR18 HAP1 NSUN5 (-) 3 cancer cell line human CVCL_XR18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16385; NSUN5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200101 CVCL_P979 HG00614 transformed cell line human CVCL_P979 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200102 CVCL_P978 HG00613 transformed cell line human CVCL_P978 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200103 CVCL_P977 HG00612 transformed cell line human CVCL_P977 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200104 CVCL_P976 HG00611 transformed cell line human CVCL_P976 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200105 CVCL_P975 HG00610 transformed cell line human CVCL_P975 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200106 CVCL_P974 HG00609 transformed cell line human CVCL_P974 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200107 CVCL_P973 HG00608 transformed cell line human CVCL_P973 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200108 CVCL_Y320 GM11068 transformed cell line human CVCL_Y320 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200109 CVCL_XR20 HAP1 NT5DC2 (-) 2 cancer cell line human CVCL_XR20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25717; NT5DC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200110 CVCL_P972 HG00607 transformed cell line human CVCL_P972 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200111 CVCL_P971 HG00599 transformed cell line human CVCL_P971 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200112 CVCL_P970 HG00598 transformed cell line human CVCL_P970 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200113 CVCL_XR24 HAP1 NUMB (-) 2 cancer cell line human CVCL_XR24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8060; NUMB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200114 CVCL_Y324 SZ-CIPA1 embryonic stem cell human CVCL_Y324 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 8031; NTRK1; Simple; p.Pro621Serfs*12 (c.1860_1861insT) (1926insT) (p.Pro585fs, c.1752_1753insT); ClinVar=VCV000021306; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0415 21200115 CVCL_XR23 HAP1 NUDT9 (-) 1 cancer cell line human CVCL_XR23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8056; NUDT9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200116 CVCL_Y323 SZ-BRCA1-4 embryonic stem cell human CVCL_Y323 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Gln1756Profs*74 (c.5266dupC) (5382insC); ClinVar=VCV000017677; Zygosity=Unspecified (PubMed=21585244) Miscellaneous: Identity of SZ-BRCA1-4 with SZ-BRCA1 of PubMed=21585244 from personal communication of Eiges R. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0455 21200117 CVCL_XR22 HAP1 NT5DC2 (-) 4 cancer cell line human CVCL_XR22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25717; NT5DC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200118 CVCL_Y322 SZ-BOR1 embryonic stem cell human CVCL_Y322 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3519; EYA1; Simple; c.433delG; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0436 21200119 CVCL_Y321 GM23079 transformed cell line human CVCL_Y321 CL:0000010 Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly588_Pro590delinsValSer (c.1763_1769delGTGCTCCinsTAAG); ClinVar=VCV000101208; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200120 CVCL_XR21 HAP1 NT5DC2 (-) 3 cancer cell line human CVCL_XR21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25717; NT5DC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200121 CVCL_XR06 HAP1 NPL (-) 3 cancer cell line human CVCL_XR06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16781; NPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200122 CVCL_Y306 Je Kin finite cell line human CVCL_Y306 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1232; true Male 21200123 CVCL_Y305 CCD-15Sk finite cell line human CVCL_Y305 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1457; true Female 21200124 CVCL_XR05 HAP1 NPL (-) 2 cancer cell line human CVCL_XR05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16781; NPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200125 CVCL_Y304 BLP spontaneously immortalized cell line house mouse CVCL_Y304 CL:0000010 Karyotypic information: Near tetraploid karotype (PubMed=190778); Breed/subspecies: BALB/c. Unspecified 21200126 CVCL_XR04 HAP1 NPC2 (-) cancer cell line human CVCL_XR04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14537; NPC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200127 CVCL_Y303 10E2 [Mouse embryo] spontaneously immortalized cell line house mouse CVCL_Y303 CL:0000010 Breed/subspecies: BALB/c. Unspecified 21200128 CVCL_XR03 HAP1 NPC1 (-) 2 cancer cell line human CVCL_XR03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7897; NPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200129 CVCL_Y309 34-1-4S hybridoma house mouse CVCL_Y309 CL:0000010 Discontinued: ATCC; HB-74; true. Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse MHC class II I-Ed 21200130 CVCL_XR09 HAP1 NR4A1 (-) 2 cancer cell line human CVCL_XR09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7980; NR4A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200131 CVCL_Y308 1-29-7 hybridoma house mouse CVCL_Y308 CL:0000010 Discontinued: ATCC; HB-63; true. Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human IgA 21200132 CVCL_XR08 HAP1 NR3C1 (-) cancer cell line human CVCL_XR08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7978; NR3C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200133 CVCL_Y307 CCD-1Sk finite cell line human CVCL_Y307 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1445; probable Male 21200134 CVCL_XR07 HAP1 NQO2 (-) 2 cancer cell line human CVCL_XR07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7856; NQO2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200135 CVCL_P989 HG00628 transformed cell line human CVCL_P989 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200136 CVCL_P988 HG00627 transformed cell line human CVCL_P988 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200137 CVCL_P987 HG00626 transformed cell line human CVCL_P987 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200138 CVCL_P986 HG00625 transformed cell line human CVCL_P986 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200139 CVCL_P985 HG00623 transformed cell line human CVCL_P985 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200140 CVCL_P984 HG00622 transformed cell line human CVCL_P984 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200141 CVCL_P983 HG00621 transformed cell line human CVCL_P983 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200142 CVCL_P982 HG00620 transformed cell line human CVCL_P982 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200143 CVCL_P981 HG00619 transformed cell line human CVCL_P981 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200144 CVCL_P980 HG00615 transformed cell line human CVCL_P980 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200145 CVCL_XR13 HAP1 NRBP1 (-) 4 cancer cell line human CVCL_XR13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7993; NRBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200146 CVCL_Y313 WIN-3 embryonic stem cell human CVCL_Y313 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0301. 21200147 CVCL_XR12 HAP1 NRBP1 (-) 3 cancer cell line human CVCL_XR12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7993; NRBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200148 CVCL_Y312 WIN-2 embryonic stem cell human CVCL_Y312 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0300. 21200149 CVCL_XR11 HAP1 NRBP1 (-) 2 cancer cell line human CVCL_XR11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7993; NRBP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200150 CVCL_Y311 WIN-1 embryonic stem cell human CVCL_Y311 From: Whitehead Institute for Biomedical Research; Boston; USA CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-14-0299; Registration: Swiss research registry; BAG-hES-IMP-0050. 21200151 CVCL_Y310 9A3M hybridoma house mouse CVCL_Y310 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Ser20 and p.Gly24) (Note=Recognizes M blood group antigen). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8160 21200152 CVCL_XR10 HAP1 NR5A2 (-) 1 cancer cell line human CVCL_XR10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7984; NR5A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200153 CVCL_P959 HG00584 transformed cell line human CVCL_P959 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200154 CVCL_P958 HG00583 transformed cell line human CVCL_P958 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200155 CVCL_P957 HG00582 transformed cell line human CVCL_P957 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200156 CVCL_P956 HG00581 transformed cell line human CVCL_P956 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200157 CVCL_P955 HG00580 transformed cell line human CVCL_P955 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200158 CVCL_P954 HG00579 transformed cell line human CVCL_P954 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200159 CVCL_P953 HG00578 transformed cell line human CVCL_P953 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200160 CVCL_P952 HG00577 transformed cell line human CVCL_P952 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200161 CVCL_P951 HG00567 transformed cell line human CVCL_P951 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200162 CVCL_P950 HG00566 transformed cell line human CVCL_P950 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200163 CVCL_Y302 CLCL finite cell line human CVCL_Y302 CL:0000010 Derived from sampling site: Fetal liver. Unspecified Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CL-99 21200164 CVCL_XR02 HAP1 NOTCH3 (-) 2 cancer cell line human CVCL_XR02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7883; NOTCH3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200165 CVCL_Y301 GLC-4/VM20x cancer cell line human CVCL_Y301 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Glu (c.394A>G); ClinVar=VCV000376626; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75988; Teniposide (VM-26); Derived from metastatic site: Pleural effusion. Male Doubling time: 22 hours (PubMed=8980384) 21200166 CVCL_XR01 HAP1 NMRK1 (-) 1 cancer cell line human CVCL_XR01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26057; NMRK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200167 CVCL_XR00 HAP1 NMRAL1 (-) 2 cancer cell line human CVCL_XR00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24987; NMRAL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200168 CVCL_P969 HG00597 transformed cell line human CVCL_P969 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200169 CVCL_P968 HG00596 transformed cell line human CVCL_P968 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200170 CVCL_P967 HG00595 transformed cell line human CVCL_P967 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200171 CVCL_P966 HG00594 transformed cell line human CVCL_P966 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200172 CVCL_P965 HG00593 transformed cell line human CVCL_P965 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200173 CVCL_P964 HG00592 transformed cell line human CVCL_P964 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200174 CVCL_P963 HG00591 transformed cell line human CVCL_P963 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200175 CVCL_P962 HG00590 transformed cell line human CVCL_P962 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200176 CVCL_P961 HG00589 transformed cell line human CVCL_P961 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200177 CVCL_P960 HG00585 transformed cell line human CVCL_P960 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200178 CVCL_P939 HG00552 transformed cell line human CVCL_P939 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200179 CVCL_P938 HG00551 transformed cell line human CVCL_P938 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200180 CVCL_P937 HG00544 transformed cell line human CVCL_P937 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200181 CVCL_P936 HG00543 transformed cell line human CVCL_P936 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200182 CVCL_P935 HG00542 transformed cell line human CVCL_P935 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200183 CVCL_P934 HG00538 transformed cell line human CVCL_P934 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200184 CVCL_P933 HG00537 transformed cell line human CVCL_P933 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200185 CVCL_P932 HG00536 transformed cell line human CVCL_P932 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200186 CVCL_P931 HG00535 transformed cell line human CVCL_P931 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200187 CVCL_P930 HG00534 transformed cell line human CVCL_P930 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200188 CVCL_P949 HG00565 transformed cell line human CVCL_P949 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200189 CVCL_P948 HG00561 transformed cell line human CVCL_P948 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200190 CVCL_P947 HG00560 transformed cell line human CVCL_P947 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200191 CVCL_P946 HG00559 transformed cell line human CVCL_P946 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200192 CVCL_P945 HG00558 transformed cell line human CVCL_P945 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200193 CVCL_P944 HG00557 transformed cell line human CVCL_P944 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200194 CVCL_P943 HG00556 transformed cell line human CVCL_P943 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200195 CVCL_P942 HG00555 transformed cell line human CVCL_P942 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200196 CVCL_P941 HG00554 transformed cell line human CVCL_P941 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200197 CVCL_P940 HG00553 transformed cell line human CVCL_P940 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200198 CVCL_P919 HG00502 transformed cell line human CVCL_P919 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200199 CVCL_P918 HG00501 transformed cell line human CVCL_P918 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200200 CVCL_P917 HG00500 transformed cell line human CVCL_P917 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200201 CVCL_P916 HG00480 transformed cell line human CVCL_P916 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200202 CVCL_P915 HG00479 transformed cell line human CVCL_P915 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200203 CVCL_P914 HG00478 transformed cell line human CVCL_P914 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200204 CVCL_P913 HG00477 transformed cell line human CVCL_P913 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200205 CVCL_P912 HG00476 transformed cell line human CVCL_P912 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200206 CVCL_P911 HG00475 transformed cell line human CVCL_P911 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200207 CVCL_P910 HG00474 transformed cell line human CVCL_P910 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200208 CVCL_P929 HG00533 transformed cell line human CVCL_P929 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200209 CVCL_P928 HG00532 transformed cell line human CVCL_P928 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200210 CVCL_P927 HG00531 transformed cell line human CVCL_P927 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200211 CVCL_P926 HG00530 transformed cell line human CVCL_P926 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200212 CVCL_P925 HG00526 transformed cell line human CVCL_P925 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200213 CVCL_P924 HG00525 transformed cell line human CVCL_P924 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200214 CVCL_P923 HG00524 transformed cell line human CVCL_P923 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200215 CVCL_P922 HG00514 transformed cell line human CVCL_P922 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200216 CVCL_P921 HG00513 transformed cell line human CVCL_P921 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200217 CVCL_P920 HG00512 transformed cell line human CVCL_P920 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200218 CVCL_5L52 GM06099 transformed cell line human CVCL_5L52 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; c.2743-1G>A; ClinVar=VCV000049560; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200219 CVCL_5L51 GM04520 finite cell line human CVCL_5L51 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Unexplicit; Ex1-14del; Zygosity=Unspecified (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21200220 CVCL_5L50 GM04519 transformed cell line human CVCL_5L50 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Unexplicit; Ex1-14del; Zygosity=Unspecified (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200221 CVCL_5L56 GM06146 transformed cell line human CVCL_5L56 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Trp750Ter (c.2249G>A); ClinVar=VCV000048922; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200222 CVCL_5L55 GM06121 finite cell line human CVCL_5L55 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200223 CVCL_5L54 GM06120 transformed cell line human CVCL_5L54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200224 CVCL_5L53 GM06100 finite cell line human CVCL_5L53 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; c.2743-1G>A; ClinVar=VCV000049560; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21200225 CVCL_5L59 GM06150 finite cell line human CVCL_5L59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200226 CVCL_5L58 GM06149 finite cell line human CVCL_5L58 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Trp750Ter (c.2249G>A); ClinVar=VCV000048922; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200227 CVCL_5L57 GM06148 finite cell line human CVCL_5L57 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200228 CVCL_5L63 GM07417 transformed cell line human CVCL_5L63 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200229 CVCL_5L62 GM07416 transformed cell line human CVCL_5L62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200230 CVCL_5L61 GM06194 transformed cell line human CVCL_5L61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200231 CVCL_5L60 GM06188 transformed cell line human CVCL_5L60 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Arg611Trp (c.1831C>T); ClinVar=VCV000049643; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200232 CVCL_5L67 GM07421 transformed cell line human CVCL_5L67 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200233 CVCL_5L66 GM07420 transformed cell line human CVCL_5L66 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200234 CVCL_5L65 GM07419 transformed cell line human CVCL_5L65 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200235 CVCL_5L64 GM07418 transformed cell line human CVCL_5L64 CL:0000010 Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Ser332Tyrfs*9 (c.994_995insA); ClinVar=VCV000049136; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200236 CVCL_5L69 GM08583 transformed cell line human CVCL_5L69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200237 CVCL_5L68 GM08298 transformed cell line human CVCL_5L68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200238 CVCL_Y393 293/hTLR4A transformed cell line human CVCL_Y393 CL:0000010 Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200239 CVCL_XR93 HAP1 PRPF40B (-) 2 cancer cell line human CVCL_XR93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25031; PRPF40B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200240 CVCL_Y392 293/hTLR3-HA transformed cell line human CVCL_Y392 CL:0000010 Transfected with: HGNC; 11849; TLR3 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200241 CVCL_XR92 HAP1 PROM1 (-) cancer cell line human CVCL_XR92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9454; PROM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200242 CVCL_Y391 293/hTLR3 transformed cell line human CVCL_Y391 CL:0000010 Transfected with: HGNC; 11849; TLR3; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200243 CVCL_XR91 HAP1 PRODH (-) 3 cancer cell line human CVCL_XR91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9453; PRODH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200244 CVCL_Y390 293/hTLR2-TLR6 transformed cell line human CVCL_Y390 CL:0000010 Transfected with: HGNC; 11848; TLR2; Transfected with: HGNC; 16711; TLR6; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200245 CVCL_XR90 HAP1 PRODH (-) 2 cancer cell line human CVCL_XR90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9453; PRODH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200246 CVCL_Y397 293/hTLR5-CD14 transformed cell line human CVCL_Y397 CL:0000010 Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11851; TLR5; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200247 CVCL_XR97 HAP1 PSEN1 (-) 2 cancer cell line human CVCL_XR97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200248 CVCL_Y396 293/hTLR5 transformed cell line human CVCL_Y396 CL:0000010 Transfected with: HGNC; 11851; TLR5; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200249 CVCL_XR96 HAP1 PSAT1 (-) 4 cancer cell line human CVCL_XR96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19129; PSAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200250 CVCL_Y395 293/hTLR4A-MD2-CD14 transformed cell line human CVCL_Y395 CL:0000010 Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 17156; LY96; Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200251 CVCL_XR95 HAP1 PSAT1 (-) 3 cancer cell line human CVCL_XR95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19129; PSAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200252 CVCL_Y394 293/hTLR4-HA transformed cell line human CVCL_Y394 CL:0000010 Transfected with: HGNC; 11850; TLR4 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200253 CVCL_XR94 HAP1 PSAT1 (-) 2 cancer cell line human CVCL_XR94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19129; PSAT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200254 CVCL_Y399 293/hTLR6-HA transformed cell line human CVCL_Y399 CL:0000010 Transfected with: HGNC; 16711; TLR6 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200255 CVCL_XR99 HAP1 PSEN1 (-) 4 cancer cell line human CVCL_XR99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200256 CVCL_Y398 293/hTLR5-HA transformed cell line human CVCL_Y398 CL:0000010 Transfected with: HGNC; 11851; TLR5 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200257 CVCL_XR98 HAP1 PSEN1 (-) 3 cancer cell line human CVCL_XR98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200258 CVCL_5L30 GM50165 transformed cell line human CVCL_5L30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200259 CVCL_5L34 GM50176 transformed cell line human CVCL_5L34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200260 CVCL_5L33 GM50175 transformed cell line human CVCL_5L33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200261 CVCL_5L32 GM50172 transformed cell line human CVCL_5L32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200262 CVCL_5L31 GM50168 transformed cell line human CVCL_5L31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200263 CVCL_5L38 GM50321 transformed cell line human CVCL_5L38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200264 CVCL_5L37 GM50292 transformed cell line human CVCL_5L37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200265 CVCL_5L36 GM50193 transformed cell line human CVCL_5L36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200266 CVCL_5L35 GM50180 transformed cell line human CVCL_5L35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200267 CVCL_5L29 GM50164 transformed cell line human CVCL_5L29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200268 CVCL_5L28 GM50160 transformed cell line human CVCL_5L28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200269 CVCL_XR82 HAP1 PRDX6 (-) 2 cancer cell line human CVCL_XR82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16753; PRDX6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200270 CVCL_Y382 OSU-CLL transformed cell line human CVCL_Y382 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Transcriptome analysis by microarray. Male Doubling time: ~50 hours (PubMed=24130782) 21200271 CVCL_Y381 293XL/null transformed cell line human CVCL_Y381 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200272 CVCL_XR81 HAP1 PQLC2 (-) 2 cancer cell line human CVCL_XR81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26001; SLC66A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200273 CVCL_Y380 A6ATL cancer cell line house mouse CVCL_Y380 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: AT.L. 21200274 CVCL_XR80 HAP1 PQLC1 (-) 2 cancer cell line human CVCL_XR80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26188; SLC66A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200275 CVCL_Y386 293/hTLR10-HA transformed cell line human CVCL_Y386 CL:0000010 Transfected with: HGNC; 15634; TLR10 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200276 CVCL_XR86 HAP1 PREP (-) 5 cancer cell line human CVCL_XR86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200277 CVCL_Y385 293/hTLR1-HA transformed cell line human CVCL_Y385 CL:0000010 Transfected with: HGNC; 11847; TLR1 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200278 CVCL_XR85 HAP1 PREP (-) 4 cancer cell line human CVCL_XR85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200279 CVCL_Y384 293/hMD2-CD14 transformed cell line human CVCL_Y384 CL:0000010 Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 17156; LY96; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200280 CVCL_XR84 HAP1 PREP (-) 3 cancer cell line human CVCL_XR84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200281 CVCL_XR83 HAP1 PREP (-) 2 cancer cell line human CVCL_XR83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9358; PREP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200282 CVCL_Y383 MO1043 cancer cell line human CVCL_Y383 CL:0000010 Derived from sampling site: Peripheral blood. Male 21200283 CVCL_Y389 293/hTLR2-HA transformed cell line human CVCL_Y389 CL:0000010 Transfected with: HGNC; 11848; TLR2 (with a C-terminal HA tag); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200284 CVCL_XR89 HAP1 PRMT6 (-) 2 cancer cell line human CVCL_XR89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18241; PRMT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200285 CVCL_Y388 293/hTLR2-CD14 transformed cell line human CVCL_Y388 CL:0000010 Transfected with: HGNC; 1628; CD14; Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: InVivoGen; Catalog number 293-htlr2cd14 Female 21200286 CVCL_XR88 HAP1 PREPL (-) 3 cancer cell line human CVCL_XR88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30228; PREPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200287 CVCL_Y387 293/hTLR2 transformed cell line human CVCL_Y387 CL:0000010 Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200288 CVCL_XR87 HAP1 PREPL (-) 2 cancer cell line human CVCL_XR87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30228; PREPL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200289 CVCL_XR69 HAP1 PNPLA2 (-) 2 cancer cell line human CVCL_XR69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30802; PNPLA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200290 CVCL_Y369 Lis43_Connexin3N embryonic stem cell human CVCL_Y369 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0315. 21200291 CVCL_5L41 GM01637 finite cell line human CVCL_5L41 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200292 CVCL_5L40 GM01636 transformed cell line human CVCL_5L40 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200293 CVCL_5L45 GM02332 finite cell line human CVCL_5L45 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200294 CVCL_5L44 GM01644 finite cell line human CVCL_5L44 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200295 CVCL_5L43 GM01643 finite cell line human CVCL_5L43 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200296 CVCL_5L42 GM01638 transformed cell line human CVCL_5L42 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200297 CVCL_5L49 GM03958 finite cell line human CVCL_5L49 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.His522Thrfs (c.1564delC); ClinVar=VCV000049640; Zygosity=Unspecified (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200298 CVCL_5L48 GM03933 transformed cell line human CVCL_5L48 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.His522Thrfs (c.1564delC); ClinVar=VCV000049640; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200299 CVCL_5L47 GM03549 transformed cell line human CVCL_5L47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200300 CVCL_5L46 GM02333 finite cell line human CVCL_5L46 CL:0000010 Population: Caucasian. Male 21200301 CVCL_5L39 GM01635 finite cell line human CVCL_5L39 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200302 CVCL_XR71 HAP1 PODXL (-) 3 cancer cell line human CVCL_XR71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200303 CVCL_Y371 Lis45_Ichthyosis1N embryonic stem cell human CVCL_Y371 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0314. 21200304 CVCL_XR70 HAP1 PODXL (-) 2 cancer cell line human CVCL_XR70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200305 CVCL_Y370 Lis44_t(13;14)2N embryonic stem cell human CVCL_Y370 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Unspecified 21200306 CVCL_XR75 HAP1 PPARG (-) cancer cell line human CVCL_XR75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9236; PPARG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200307 CVCL_Y375 Lis49_Hydrocephaly2N embryonic stem cell human CVCL_Y375 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0310. 21200308 CVCL_XR74 HAP1 POT1 (-) 2 cancer cell line human CVCL_XR74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17284; POT1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200309 CVCL_Y374 Lis48_DMD6N embryonic stem cell human CVCL_Y374 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0311. 21200310 CVCL_XR73 HAP1 POR (-) cancer cell line human CVCL_XR73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9208; POR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200311 CVCL_Y373 Lis47_NF1_2N embryonic stem cell human CVCL_Y373 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0312. 21200312 CVCL_XR72 HAP1 PODXL (-) 4 cancer cell line human CVCL_XR72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9171; PODXL; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200313 CVCL_Y372 Lis46_Ichthyosis2N embryonic stem cell human CVCL_Y372 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0313. 21200314 CVCL_Y379 A1ATH cancer cell line house mouse CVCL_Y379 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801); Breed/subspecies: AT.H. 21200315 CVCL_XR79 HAP1 PPIL1 (-) 2 cancer cell line human CVCL_XR79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9260; PPIL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200316 CVCL_XR78 HAP1 PPIB (-) 3 cancer cell line human CVCL_XR78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9255; PPIB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200317 CVCL_Y378 TENN cancer cell line human CVCL_Y378 CL:0000010 21200318 CVCL_XR77 HAP1 PPIB (-) 2 cancer cell line human CVCL_XR77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9255; PPIB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200319 CVCL_Y377 Lis51_FXS9N embryonic stem cell human CVCL_Y377 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0309. 21200320 CVCL_XR76 HAP1 PPARGC1A (-) 1 cancer cell line human CVCL_XR76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9237; PPARGC1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200321 CVCL_Y376 Lis50_Hydrocephaly3N embryonic stem cell human CVCL_Y376 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0308. 21200322 CVCL_XR59 HAP1 PHRF1 (-) cancer cell line human CVCL_XR59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24351; PHRF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200323 CVCL_Y359 Lis33_Norrie embryonic stem cell human CVCL_Y359 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Unspecified 21200324 CVCL_XR58 HAP1 PHF6 (-) 6 cancer cell line human CVCL_XR58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200325 CVCL_Y358 Lis32_DM4 embryonic stem cell human CVCL_Y358 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Unspecified 21200326 CVCL_5L12 GM11955 transformed cell line human CVCL_5L12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200327 CVCL_5L11 GM11954 transformed cell line human CVCL_5L11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200328 CVCL_5L10 GM11953 transformed cell line human CVCL_5L10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200329 CVCL_5L16 GM11963 transformed cell line human CVCL_5L16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200330 CVCL_5L15 GM11959 transformed cell line human CVCL_5L15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200331 CVCL_5L14 GM11958 transformed cell line human CVCL_5L14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200332 CVCL_5L13 GM11957 transformed cell line human CVCL_5L13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200333 CVCL_5L09 GM11952 transformed cell line human CVCL_5L09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200334 CVCL_5L08 GM11951 transformed cell line human CVCL_5L08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200335 CVCL_5L07 GM11950 transformed cell line human CVCL_5L07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200336 CVCL_5L06 GM11948 transformed cell line human CVCL_5L06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200337 CVCL_XR60 HAP1 PIH1D1 (-) cancer cell line human CVCL_XR60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26075; PIH1D1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200338 CVCL_Y360 Lis34_FAP3 embryonic stem cell human CVCL_Y360 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0324. 21200339 CVCL_XR64 HAP1 PLOD2 (-) 2 cancer cell line human CVCL_XR64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9082; PLOD2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200340 CVCL_Y364 Lis38_FXS7N embryonic stem cell human CVCL_Y364 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0320. 21200341 CVCL_XR63 HAP1 PLOD1 (-) cancer cell line human CVCL_XR63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9081; PLOD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200342 CVCL_Y363 Lis37_FXS10 embryonic stem cell human CVCL_Y363 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0321. 21200343 CVCL_XR62 HAP1 PLIN2 (-) 2 cancer cell line human CVCL_XR62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 248; PLIN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200344 CVCL_Y362 Lis36_t(11;20)N embryonic stem cell human CVCL_Y362 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0322. 21200345 CVCL_XR61 HAP1 PISD (-) cancer cell line human CVCL_XR61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8999; PISD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200346 CVCL_Y361 Lis35_Hydrocephaly1 embryonic stem cell human CVCL_Y361 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0323. 21200347 CVCL_XR68 HAP1 PMS1 (-) 1 cancer cell line human CVCL_XR68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9121; PMS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200348 CVCL_Y368 Lis42_NF1_1N embryonic stem cell human CVCL_Y368 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0316. 21200349 CVCL_XR67 HAP1 PML (-) 3 cancer cell line human CVCL_XR67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200350 CVCL_Y367 Lis41_LTBL_N embryonic stem cell human CVCL_Y367 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0317. 21200351 CVCL_XR66 HAP1 PML (-) 2 cancer cell line human CVCL_XR66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9113; PML; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200352 CVCL_Y366 Lis40_t(13;14)N embryonic stem cell human CVCL_Y366 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0318. 21200353 CVCL_XR65 HAP1 PMAIP1 (-) 2 cancer cell line human CVCL_XR65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9108; PMAIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200354 CVCL_Y365 Lis39_FXS8N embryonic stem cell human CVCL_Y365 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K27me3 ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: H3K4me3 ChIP-seq epigenome analysis; Omics: H3K9me3 ChIP-seq epigenome analysis. Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0319 21200355 CVCL_XR49 HAP1 PDIA3 (-) 2 cancer cell line human CVCL_XR49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4606; PDIA3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200356 CVCL_Y349 Lis23_DMD5 embryonic stem cell human CVCL_Y349 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg2870Ter (c.8608C>T); ClinVar=VCV000094810; Zygosity=Unspecified (PubMed=21585244). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0328 21200357 CVCL_XR48 HAP1 PDIA2 (-) 2 cancer cell line human CVCL_XR48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14180; PDIA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200358 CVCL_Y348 Lis22_DMD4 embryonic stem cell human CVCL_Y348 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg2870Ter (c.8608C>T); ClinVar=VCV000094810; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0347 21200359 CVCL_XR47 HAP1 PDE6D (-) 2 cancer cell line human CVCL_XR47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8788; PDE6D; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200360 CVCL_Y347 Lis21_Noonan1 embryonic stem cell human CVCL_Y347 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0346. 21200361 CVCL_5L23 GM16447 transformed cell line human CVCL_5L23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200362 CVCL_5L22 GM16445 transformed cell line human CVCL_5L22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200363 CVCL_5L21 GM12025 transformed cell line human CVCL_5L21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200364 CVCL_5L20 GM11968 transformed cell line human CVCL_5L20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200365 CVCL_5L27 GM50153 transformed cell line human CVCL_5L27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200366 CVCL_5L26 GM50152 transformed cell line human CVCL_5L26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200367 CVCL_5L25 GM50145 transformed cell line human CVCL_5L25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200368 CVCL_5L24 GM16457 transformed cell line human CVCL_5L24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200369 CVCL_5L19 GM11967 transformed cell line human CVCL_5L19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200370 CVCL_5L18 GM11965 transformed cell line human CVCL_5L18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200371 CVCL_5L17 GM11964 transformed cell line human CVCL_5L17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200372 CVCL_XR53 HAP1 PEX3 (-) 1 cancer cell line human CVCL_XR53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8858; PEX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200373 CVCL_Y353 Lis27_t(Y;14)1 embryonic stem cell human CVCL_Y353 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0351. 21200374 CVCL_XR52 HAP1 PEG10 (-) 2 cancer cell line human CVCL_XR52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14005; PEG10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200375 CVCL_Y352 Lis26_FXS6 embryonic stem cell human CVCL_Y352 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[50-600]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=27690107). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0350 21200376 CVCL_XR51 HAP1 PDXK (-) 2 cancer cell line human CVCL_XR51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8819; PDXK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200377 CVCL_Y351 Lis25_FAP1 embryonic stem cell human CVCL_Y351 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg332Ter (c.994C>T); ClinVar=VCV000184937; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0349 21200378 CVCL_XR50 HAP1 PDPN (-) 2 cancer cell line human CVCL_XR50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29602; PDPN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200379 CVCL_Y350 Lis24_FXS5 embryonic stem cell human CVCL_Y350 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0348. 21200380 CVCL_XR57 HAP1 PHF6 (-) 5 cancer cell line human CVCL_XR57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18145; PHF6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200381 CVCL_Y357 Lis31_DM3 embryonic stem cell human CVCL_Y357 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel. CL:0000010 Unspecified 21200382 CVCL_XR56 HAP1 PGR (-) cancer cell line human CVCL_XR56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8910; PGR; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200383 CVCL_Y356 Lis30_FAP2 embryonic stem cell human CVCL_Y356 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0325. 21200384 CVCL_XR55 HAP1 PFN2 (-) 2 cancer cell line human CVCL_XR55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8882; PFN2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200385 CVCL_Y355 Lis29_FXS7 embryonic stem cell human CVCL_Y355 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0326. 21200386 CVCL_XR54 HAP1 PFN1 (-) 2 cancer cell line human CVCL_XR54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8881; PFN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200387 CVCL_Y354 Lis28_t(Y;14)2 embryonic stem cell human CVCL_Y354 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0327. 21200388 CVCL_XR39 HAP1 PAX8 (-) 2 cancer cell line human CVCL_XR39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8622; PAX8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200389 CVCL_Y339 SZ-Rb2 embryonic stem cell human CVCL_Y339 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ala525Lysfs*7 (c.1572insAA); Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0418 21200390 CVCL_XR38 HAP1 PARP2 (-) 4 cancer cell line human CVCL_XR38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200391 CVCL_Y338 SZ-Rb18 embryonic stem cell human CVCL_Y338 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ala525Lysfs*7 (c.1572insAA); Zygosity=Unspecified (PubMed=21585244). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0417 21200392 CVCL_XR37 HAP1 PARP2 (-) 3 cancer cell line human CVCL_XR37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 272; PARP2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200393 CVCL_Y337 SZ-Hunter4 embryonic stem cell human CVCL_Y337 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 5389; IDS; Unexplicit; Ex4-7del; Zygosity=Unspecified (PubMed=21585244; PubMed=23320174). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0438 21200394 CVCL_XR36 HAP1 PARP16 (-) 2 cancer cell line human CVCL_XR36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26040; PARP16; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200395 CVCL_Y336 SZ-HED7 embryonic stem cell human CVCL_Y336 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Asp50Asn (c.148G>A); ClinVar=VCV000017020; Zygosity=Unspecified (PubMed=21585244). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0434 21200396 CVCL_P999 HG00639 transformed cell line human CVCL_P999 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200397 CVCL_P998 HG00638 transformed cell line human CVCL_P998 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200398 CVCL_P997 HG00637 transformed cell line human CVCL_P997 CL:0000010 Population: Puerto Rican in Puerto Rico (PUR); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200399 CVCL_P996 HG00636 transformed cell line human CVCL_P996 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200400 CVCL_P995 HG00635 transformed cell line human CVCL_P995 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200401 CVCL_XR42 HAP1 PBK (-) 5 cancer cell line human CVCL_XR42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200402 CVCL_P994 HG00634 transformed cell line human CVCL_P994 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200403 CVCL_Y342 Lis15_t(1;12) embryonic stem cell human CVCL_Y342 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0341. 21200404 CVCL_XR41 HAP1 PBK (-) 4 cancer cell line human CVCL_XR41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200405 CVCL_P993 HG00632 transformed cell line human CVCL_P993 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200406 CVCL_Y341 SZ-Kennedy embryonic stem cell human CVCL_Y341 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)>40 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Unspecified. Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0459 21200407 CVCL_XR40 HAP1 PBK (-) 3 cancer cell line human CVCL_XR40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18282; PBK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200408 CVCL_P992 HG00631 transformed cell line human CVCL_P992 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200409 CVCL_Y340 SZ-Rb26 embryonic stem cell human CVCL_Y340 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ala525Lysfs*7 (c.1572insAA); Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0416 21200410 CVCL_P991 HG00630 transformed cell line human CVCL_P991 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Male Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200411 CVCL_XR46 HAP1 PDCD5 (-) 2 cancer cell line human CVCL_XR46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8764; PDCD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200412 CVCL_P990 HG00629 transformed cell line human CVCL_P990 CL:0000010 Population: Chinese; Han in the South (CHS); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis; Omics: Genome sequenced Female Part of: International Genome Sample Resource (1000 genomes project) cell lines 21200413 CVCL_Y346 Lis20_DMD3 embryonic stem cell human CVCL_Y346 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg2870Ter (c.8608C>T); ClinVar=VCV000094810; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0345 21200414 CVCL_XR45 HAP1 PDCD1LG2 (-) 2 cancer cell line human CVCL_XR45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200415 CVCL_Y345 Lis19_DM2 embryonic stem cell human CVCL_Y345 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0344. 21200416 CVCL_XR44 HAP1 PDCD10 (-) 2 cancer cell line human CVCL_XR44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8761; PDCD10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200417 CVCL_Y344 Lis18_Connexin2 embryonic stem cell human CVCL_Y344 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0343. 21200418 CVCL_XR43 HAP1 PCCA (-) 2 cancer cell line human CVCL_XR43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8653; PCCA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200419 CVCL_Y343 Lis17_Connexin1 embryonic stem cell human CVCL_Y343 From: Tel-Aviv Sourasky Medical Center; Tel-Aviv; Israel CL:0000010 Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0342. 21200420 CVCL_XR28 HAP1 OCLN (-) 2 cancer cell line human CVCL_XR28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8104; OCLN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200421 CVCL_Y328 SZ-DM5 embryonic stem cell human CVCL_Y328 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~300] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female 21200422 CVCL_XR27 HAP1 OCIAD1 (-) 3 cancer cell line human CVCL_XR27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16074; OCIAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200423 CVCL_Y327 SZ-DM4 embryonic stem cell human CVCL_Y327 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~180] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0420 21200424 CVCL_XR26 HAP1 OCIAD1 (-) 2 cancer cell line human CVCL_XR26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16074; OCIAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200425 CVCL_Y326 SZ-DM2 embryonic stem cell human CVCL_Y326 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~430-1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0422 21200426 CVCL_XR25 HAP1 NUMB (-) 3 cancer cell line human CVCL_XR25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8060; NUMB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200427 CVCL_Y325 SZ-DM1 embryonic stem cell human CVCL_Y325 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~1000] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0421 21200428 CVCL_XR29 HAP1 OXNAD1 (-) 2 cancer cell line human CVCL_XR29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25128; OXNAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200429 CVCL_Y329 SZ-DM7 embryonic stem cell human CVCL_Y329 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[~300] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (PubMed=26190529). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0423 21200430 CVCL_5L01 SACK-Xn 5B8 somatic stem cell house mouse CVCL_5L01 CL:0000010 Breed/subspecies: FVB/NTac. Male 21200431 CVCL_5L00 SACK-Xn 3C5 somatic stem cell house mouse CVCL_5L00 CL:0000010 Breed/subspecies: FVB/NTac. Male 21200432 CVCL_5L05 JS2 TLR4-/- D299G/T399I transformed cell line house mouse CVCL_5L05 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4; Transfected with: HGNC; 11850; TLR4 (with p.Asp299Gly and p.Thr399Ile); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 21200433 CVCL_5L04 JS2 TLR4-/- T399I transformed cell line house mouse CVCL_5L04 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4; Transfected with: HGNC; 11850; TLR4 (with p.Thr399Ile); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 21200434 CVCL_5L03 JS2 TLR4-/- D299G transformed cell line house mouse CVCL_5L03 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4; Transfected with: HGNC; 11850; TLR4 (with p.Asp299Gly); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 21200435 CVCL_5L02 JS2 TLR4-/- WT transformed cell line house mouse CVCL_5L02 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4; Transfected with: HGNC; 11850; TLR4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 21200436 CVCL_XR31 HAP1 PACRG (-) 2 cancer cell line human CVCL_XR31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19152; PACRG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200437 CVCL_Y331 SZ-FX10 embryonic stem cell human CVCL_Y331 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0442 21200438 CVCL_XR30 HAP1 OXNAD1 (-) 3 cancer cell line human CVCL_XR30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25128; OXNAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200439 CVCL_Y330 SZ-FX1 embryonic stem cell human CVCL_Y330 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0440 21200440 CVCL_XR35 HAP1 PARP12 (-) 2 cancer cell line human CVCL_XR35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21919; PARP12; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200441 CVCL_Y335 SZ-FX6 embryonic stem cell human CVCL_Y335 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[170]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=21585244). Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0443 21200442 CVCL_XR34 HAP1 PARG (-) 2 cancer cell line human CVCL_XR34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8605; PARG; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200443 CVCL_Y334 SZ-FX5 embryonic stem cell human CVCL_Y334 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[75]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0441 21200444 CVCL_XR33 HAP1 PANX2 (-) cancer cell line human CVCL_XR33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8600; PANX2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200445 CVCL_Y333 SZ-FX3 embryonic stem cell human CVCL_Y333 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[100-300]; ClinVar=VCV000009972; Zygosity=Unspecified (PubMed=21585244). Female Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-20-0439 21200446 CVCL_XR32 HAP1 PAN3 (-) 1 cancer cell line human CVCL_XR32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29991; PAN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200447 CVCL_Y332 SZ-FX2 embryonic stem cell human CVCL_Y332 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[70]; ClinVar=VCV000009972; Zygosity=Hemizygous (PubMed=21585244) Miscellaneous: Information on contamination from personal communication of Eiges R. Male Problematic cell line: Contaminated Cell line withdrawn from distribution by the Shaare Zedek Medical Center. 21200448 CVCL_GA20 ND03958 transformed cell line human CVCL_GA20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200449 CVCL_GA24 ND00049 transformed cell line human CVCL_GA24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200450 CVCL_GA23 ND03986 transformed cell line human CVCL_GA23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200451 CVCL_GA22 ND03985 transformed cell line human CVCL_GA22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200452 CVCL_GA21 ND03984 transformed cell line human CVCL_GA21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200453 CVCL_GA17 ND03879 transformed cell line human CVCL_GA17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200454 CVCL_GA16 ND03845 transformed cell line human CVCL_GA16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200455 CVCL_GA15 ND03844 transformed cell line human CVCL_GA15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200456 CVCL_GA14 ND03838 transformed cell line human CVCL_GA14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200457 CVCL_GA19 ND03957 transformed cell line human CVCL_GA19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200458 CVCL_GA18 ND03941 transformed cell line human CVCL_GA18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200459 CVCL_GA31 ND00193 transformed cell line human CVCL_GA31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200460 CVCL_GA30 ND00191 transformed cell line human CVCL_GA30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200461 CVCL_GA35 ND00237 transformed cell line human CVCL_GA35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200462 CVCL_GA34 ND00233 transformed cell line human CVCL_GA34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200463 CVCL_GA33 ND00225 transformed cell line human CVCL_GA33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200464 CVCL_GA32 ND00203 transformed cell line human CVCL_GA32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200465 CVCL_GA28 ND00151 transformed cell line human CVCL_GA28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21200466 CVCL_GA27 ND00150 transformed cell line human CVCL_GA27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200467 CVCL_GA26 ND00141 transformed cell line human CVCL_GA26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200468 CVCL_GA25 ND00138 transformed cell line human CVCL_GA25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200469 CVCL_GA29 ND00152 transformed cell line human CVCL_GA29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200470 CVCL_GA02 ND31156 transformed cell line human CVCL_GA02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200471 CVCL_GA01 ND30801 transformed cell line human CVCL_GA01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200472 CVCL_GA00 ND30714 transformed cell line human CVCL_GA00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200473 CVCL_GA13 GM14951 transformed cell line human CVCL_GA13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200474 CVCL_GA12 Vero-SV2neo clone VN5 spontaneously immortalized cell line green monkey CVCL_GA12 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-2659 21200475 CVCL_GA11 Vero/PPRV H spontaneously immortalized cell line green monkey CVCL_GA11 CL:0000010 Transfected with: UniProtKB; Q6Q498; PPRV hemagglutinin (H) Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 21200476 CVCL_GA10 ND35947 transformed cell line human CVCL_GA10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200477 CVCL_GA06 ND34215 transformed cell line human CVCL_GA06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200478 CVCL_GA05 ND33916 transformed cell line human CVCL_GA05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200479 CVCL_GA04 ND32623 transformed cell line human CVCL_GA04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200480 CVCL_GA03 ND31691 transformed cell line human CVCL_GA03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200481 CVCL_GA09 ND35939 transformed cell line human CVCL_GA09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200482 CVCL_GA08 ND35393 transformed cell line human CVCL_GA08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200483 CVCL_GA07 ND35188 transformed cell line human CVCL_GA07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200484 CVCL_5M91 GM04297 transformed cell line human CVCL_5M91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200485 CVCL_5M90 GM04100 transformed cell line human CVCL_5M90 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200486 CVCL_5M95 GM04364 finite cell line human CVCL_5M95 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex51-55del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200487 CVCL_5M94 GM04363 finite cell line human CVCL_5M94 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex51-55del; Zygosity=Heterozygous (from familial inference of GM04364) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200488 CVCL_5M93 GM04327 finite cell line human CVCL_5M93 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex5-7dup; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200489 CVCL_5M92 GM04315 finite cell line human CVCL_5M92 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex44del; Zygosity=Heterozygous (PubMed=21354051) Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21200490 CVCL_5M99 GM04982 finite cell line human CVCL_5M99 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Female 21200491 CVCL_5M98 GM04978 finite cell line human CVCL_5M98 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln1973Ter (c.5917C>T) (p.Gln1965Ter, c.5893C>T); ClinVar=VCV000217206; Zygosity=Hemizygous (PubMed=21354051) Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200492 CVCL_5M97 GM04621 finite cell line human CVCL_5M97 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg2905Ter (c.8713C>T); ClinVar=VCV000011288; Zygosity=Heterozygous (from familial inference of GM04619) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200493 CVCL_5M96 GM04619 finite cell line human CVCL_5M96 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Arg2905Ter (c.8713C>T); ClinVar=VCV000011288; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200494 CVCL_GA86 ND01606 transformed cell line human CVCL_GA86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200495 CVCL_GA85 ND01575 transformed cell line human CVCL_GA85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200496 CVCL_GA84 ND01556 transformed cell line human CVCL_GA84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200497 CVCL_GA83 ND01427 transformed cell line human CVCL_GA83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200498 CVCL_GA89 ND01739 transformed cell line human CVCL_GA89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200499 CVCL_GA88 ND01736 transformed cell line human CVCL_GA88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200500 CVCL_GA87 ND01697 transformed cell line human CVCL_GA87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200501 CVCL_GA82 ND01405 transformed cell line human CVCL_GA82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200502 CVCL_GA81 ND01350 transformed cell line human CVCL_GA81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200503 CVCL_GA80 ND01333 transformed cell line human CVCL_GA80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200504 CVCL_GA97 ND02134 transformed cell line human CVCL_GA97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200505 CVCL_GA96 ND02128 transformed cell line human CVCL_GA96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200506 CVCL_GA95 ND02062 transformed cell line human CVCL_GA95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200507 CVCL_GA94 ND02059 transformed cell line human CVCL_GA94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200508 CVCL_GA99 ND02137 transformed cell line human CVCL_GA99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200509 CVCL_GA98 ND02136 transformed cell line human CVCL_GA98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200510 CVCL_GA93 ND01980 transformed cell line human CVCL_GA93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200511 CVCL_GA92 ND01884 transformed cell line human CVCL_GA92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200512 CVCL_GA91 ND01756 transformed cell line human CVCL_GA91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200513 CVCL_GA90 ND01740 transformed cell line human CVCL_GA90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200514 CVCL_GA64 ND00402 transformed cell line human CVCL_GA64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200515 CVCL_GA63 ND00392 transformed cell line human CVCL_GA63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200516 CVCL_GA62 ND00387 transformed cell line human CVCL_GA62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200517 CVCL_GA61 ND00377 transformed cell line human CVCL_GA61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200518 CVCL_GA68 ND00659 transformed cell line human CVCL_GA68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200519 CVCL_GA67 ND00500 transformed cell line human CVCL_GA67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200520 CVCL_GA66 ND00485 transformed cell line human CVCL_GA66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200521 CVCL_GA65 ND00450 transformed cell line human CVCL_GA65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200522 CVCL_GA60 ND00366 transformed cell line human CVCL_GA60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200523 CVCL_GA59 ND00362 transformed cell line human CVCL_GA59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200524 CVCL_GA58 ND00361 transformed cell line human CVCL_GA58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200525 CVCL_GA75 ND01087 transformed cell line human CVCL_GA75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200526 CVCL_GA74 ND00736 transformed cell line human CVCL_GA74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200527 CVCL_GA73 ND00717 transformed cell line human CVCL_GA73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200528 CVCL_GA72 ND00692 transformed cell line human CVCL_GA72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200529 CVCL_GA79 ND01283 transformed cell line human CVCL_GA79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200530 CVCL_GA78 ND01274 transformed cell line human CVCL_GA78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200531 CVCL_GA77 ND01254 transformed cell line human CVCL_GA77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200532 CVCL_GA76 ND01242 transformed cell line human CVCL_GA76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200533 CVCL_GA71 ND00685 transformed cell line human CVCL_GA71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200534 CVCL_GA70 ND00663 transformed cell line human CVCL_GA70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200535 CVCL_GA69 ND00662 transformed cell line human CVCL_GA69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200536 CVCL_GA42 ND00271 transformed cell line human CVCL_GA42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200537 CVCL_GA41 ND00270 transformed cell line human CVCL_GA41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200538 CVCL_GA40 ND00269 transformed cell line human CVCL_GA40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200539 CVCL_GA46 ND00284 transformed cell line human CVCL_GA46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200540 CVCL_GA45 ND00279 transformed cell line human CVCL_GA45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200541 CVCL_GA44 ND00276 transformed cell line human CVCL_GA44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200542 CVCL_GA43 ND00274 transformed cell line human CVCL_GA43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200543 CVCL_GA39 ND00268 transformed cell line human CVCL_GA39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 21200544 CVCL_GA38 ND00259 transformed cell line human CVCL_GA38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Female 21200545 CVCL_GA37 ND00253 transformed cell line human CVCL_GA37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200546 CVCL_GA36 ND00238 transformed cell line human CVCL_GA36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200547 CVCL_GA53 ND00332 transformed cell line human CVCL_GA53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200548 CVCL_GA52 ND00312 transformed cell line human CVCL_GA52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200549 CVCL_GA51 ND00311 transformed cell line human CVCL_GA51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200550 CVCL_GA50 ND00309 transformed cell line human CVCL_GA50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200551 CVCL_GA57 ND00358 transformed cell line human CVCL_GA57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200552 CVCL_GA56 ND00356 transformed cell line human CVCL_GA56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200553 CVCL_GA55 ND00352 transformed cell line human CVCL_GA55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200554 CVCL_GA54 ND00350 transformed cell line human CVCL_GA54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200555 CVCL_GA49 ND00307 transformed cell line human CVCL_GA49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200556 CVCL_GA48 ND00296 transformed cell line human CVCL_GA48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200557 CVCL_GA47 ND00294 transformed cell line human CVCL_GA47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200558 CVCL_XS38 HAP1 S100A10 (-) 2 cancer cell line human CVCL_XS38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10487; S100A10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200559 CVCL_Y438 WA-C3CD5+ transformed cell line human CVCL_Y438 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Doubling time: ~40-50 hours (DSMZ=ACC-769) 21200560 CVCL_XS37 HAP1 RYR2 (-) 2 cancer cell line human CVCL_XS37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10484; RYR2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200561 CVCL_Y437 I83-E95 transformed cell line human CVCL_Y437 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~30-60 hours (DSMZ=ACC-763) 21200562 CVCL_Y436 232-B4 transformed cell line human CVCL_Y436 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200563 CVCL_XS36 HAP1 RUNX3 (-) 3 cancer cell line human CVCL_XS36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10473; RUNX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200564 CVCL_XS35 HAP1 RUNX3 (-) 2 cancer cell line human CVCL_XS35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10473; RUNX3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200565 CVCL_Y435 LD cancer cell line human CVCL_Y435 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgA lambda Doubling time: ~10 days (PubMed=17760811) 21200566 CVCL_Y439 A375S1 cancer cell line human CVCL_Y439 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Miscellaneous: Not sure what is the relationship between A375.S2 and A375S1 Population: Caucasian; Derived from sampling site: Skin. Female 21200567 CVCL_XS39 HAP1 S100PBP (-) cancer cell line human CVCL_XS39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25768; S100PBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200568 CVCL_Y441 E3C/O undefined cell line type CVCL_Y441 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6179; true Unspecified Group: Bird cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200569 CVCL_XS41 HAP1 S1PR1 (-) 3 cancer cell line human CVCL_XS41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3165; S1PR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200570 CVCL_Y440 Bt Thd finite cell line CVCL_Y440 CL:0000010 Derived from sampling site: Thyroid gland. Discontinued: ATCC; CRL-6031; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200571 CVCL_XS40 HAP1 S1PR1 (-) 2 cancer cell line human CVCL_XS40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3165; S1PR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200572 CVCL_Y445 GT1.Thy finite cell line CVCL_Y445 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6269; probable Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200573 CVCL_XS45 HAP1 SAV1 (-) 3 cancer cell line human CVCL_XS45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17795; SAV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200574 CVCL_XS44 HAP1 SAV1 (-) 2 cancer cell line human CVCL_XS44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17795; SAV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200575 CVCL_Y444 HO(6) undefined cell line type CVCL_Y444 CL:0000010 Discontinued: ATCC; CRL-6267; true. Unspecified Group: Amphibian cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200576 CVCL_XS43 HAP1 SATB1 (-) 2 cancer cell line human CVCL_XS43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10541; SATB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200577 CVCL_Y443 NBE-5 finite cell line dog CVCL_Y443 CL:0000010 Breed/subspecies: Beagle. Discontinued: ATCC; CRL-6255; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200578 CVCL_Y442 CF2A.Thy finite cell line dog CVCL_Y442 CL:0000010 Derived from sampling site: Thymus. Discontinued: ATCC; CRL-6197; probable Unspecified 21200579 CVCL_XS42 HAP1 SAT2 (-) 2 cancer cell line human CVCL_XS42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23160; SAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200580 CVCL_Y427 41M:RD1694 cancer cell line human CVCL_Y427 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Argfs*18 (c.455delC); ClinVar=VCV000634779; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (41M) has been shown to be a OAW28 derivative. 21200581 CVCL_XS27 HAP1 RIPK3 (-) cancer cell line human CVCL_XS27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10021; RIPK3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200582 CVCL_Y426 CH1:RD1694 cancer cell line human CVCL_Y426 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Derived from metastatic site: Ascites. Female Problematic cell line: Contaminated Parent cell line (CH1) has been shown to be a PA-1 derivative. 21200583 CVCL_XS26 HAP1 RIC3 (-) cancer cell line human CVCL_XS26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30338; RIC3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200584 CVCL_XS25 HAP1 REXO4 (-) 2 cancer cell line human CVCL_XS25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12820; REXO4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200585 CVCL_Y425 WIL2:RD1694 transformed cell line human CVCL_Y425 CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Spleen. Male 21200586 CVCL_XS24 HAP1 REST (-) 2 cancer cell line human CVCL_XS24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9966; REST; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200587 CVCL_Y424 L1210:RD1694 cancer cell line house mouse CVCL_Y424 CL:0000010 Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200588 CVCL_Y429 DF15 cancer cell line human CVCL_Y429 CL:0000010 21200589 CVCL_XS29 HAP1 RRAGA (-) 2 cancer cell line human CVCL_XS29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16963; RRAGA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200590 CVCL_Y428 CL100 cancer cell line human CVCL_Y428 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Ser (c.421T>A); ClinVar=VCV000376567; Zygosity=Unspecified (PubMed=26202522) Omics: Deep membrane proteome analysis. Female 21200591 CVCL_XS28 HAP1 ROBO1 (-) 2 cancer cell line human CVCL_XS28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10249; ROBO1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200592 CVCL_5M00 GM09436 transformed cell line human CVCL_5M00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200593 CVCL_5M04 GM09569 transformed cell line human CVCL_5M04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200594 CVCL_5M03 GM09439 transformed cell line human CVCL_5M03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200595 CVCL_5M02 GM09438 transformed cell line human CVCL_5M02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200596 CVCL_5M01 GM09437 transformed cell line human CVCL_5M01 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200597 CVCL_Y430 DF15R cancer cell line human CVCL_Y430 CL:0000010 Selected for resistance to: ChEBI; CHEBI:72690; Pomalidomide (3-amino-thalidomide. 21200598 CVCL_XS30 HAP1 RRNAD1 (-) 2 cancer cell line human CVCL_XS30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24273; METTL25B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200599 CVCL_XS34 HAP1 RSAD1 (-) 4 cancer cell line human CVCL_XS34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25634; RSAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200600 CVCL_Y434 JB cancer cell line human CVCL_Y434 CL:0000010 Derived from sampling site: Bone marrow. Female Characteristics: Produces Ig lambda Doubling time: ~4-6 days (PubMed=17760811) 21200601 CVCL_Y433 CF [Human plasma cell myeloma] cancer cell line human CVCL_Y433 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG kappa Doubling time: ~4-6 days (PubMed=17760811) 21200602 CVCL_XS33 HAP1 RSAD1 (-) 3 cancer cell line human CVCL_XS33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25634; RSAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200603 CVCL_Y432 BN cancer cell line human CVCL_Y432 CL:0000010 Derived from sampling site: Bone marrow. Male Characteristics: Produces IgG lambda Doubling time: ~4-6 days (PubMed=17760811) 21200604 CVCL_XS32 HAP1 RSAD1 (-) 2 cancer cell line human CVCL_XS32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25634; RSAD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200605 CVCL_Y431 BW288 cancer cell line human CVCL_Y431 CL:0000010 21200606 CVCL_XS31 HAP1 RRNAD1 (-) 3 cancer cell line human CVCL_XS31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24273; METTL25B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200607 CVCL_Y416 293XL/mTLR7 transformed cell line human CVCL_Y416 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: MGI; MGI:2176882; Tlr7; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200608 CVCL_XS16 HAP1 RBKS (-) 3 cancer cell line human CVCL_XS16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30325; RBKS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200609 CVCL_Y415 293XL/hTLR9 transformed cell line human CVCL_Y415 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15633; TLR9; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200610 CVCL_XS15 HAP1 RBKS (-) 2 cancer cell line human CVCL_XS15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30325; RBKS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200611 CVCL_Y414 293XL/hTLR8 transformed cell line human CVCL_Y414 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15632; TLR8 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200612 CVCL_XS14 HAP1 RASSF4 (-) cancer cell line human CVCL_XS14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20793; RASSF4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200613 CVCL_Y413 293XL/hTLR7 transformed cell line human CVCL_Y413 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15631; TLR7; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200614 CVCL_XS13 HAP1 RAP1GAP (-) 2 cancer cell line human CVCL_XS13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9858; RAP1GAP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200615 CVCL_XS19 HAP1 RCBTB2 (-) 3 cancer cell line human CVCL_XS19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1914; RCBTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200616 CVCL_Y419 L1210/DACH cancer cell line house mouse CVCL_Y419 CL:0000010 Selected for resistance to: ChEBI; CHEBI:90269; Dichloro(1,2-diaminocyclohexane)platinum(II) (DACHPt); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200617 CVCL_XS18 HAP1 RCBTB2 (-) 2 cancer cell line human CVCL_XS18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1914; RCBTB2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200618 CVCL_Y418 L1210/0 cancer cell line house mouse CVCL_Y418 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200619 CVCL_Y417 293/hTLR1-TLR2 transformed cell line human CVCL_Y417 CL:0000010 Transfected with: HGNC; 11847; TLR1; Transfected with: HGNC; 11848; TLR2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: InVivoGen; Catalog number 293-htlr12 Female 21200620 CVCL_XS17 HAP1 RBKS (-) 4 cancer cell line human CVCL_XS17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30325; RBKS; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200621 CVCL_XS23 HAP1 RERE (-) 2 cancer cell line human CVCL_XS23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9965; RERE; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200622 CVCL_Y423 L1210/TGO cancer cell line house mouse CVCL_Y423 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200623 CVCL_XS22 HAP1 REPS1 (-) cancer cell line human CVCL_XS22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15578; REPS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200624 CVCL_Y422 L1210/DDP5 cancer cell line house mouse CVCL_Y422 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200625 CVCL_XS21 HAP1 RENBP (-) 2 cancer cell line human CVCL_XS21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9959; RENBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200626 CVCL_Y421 L1210/DDP2 cancer cell line house mouse CVCL_Y421 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200627 CVCL_XS20 HAP1 RDH13 (-) 2 cancer cell line human CVCL_XS20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19978; RDH13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200628 CVCL_Y420 L1210/DDP10 cancer cell line house mouse CVCL_Y420 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Ascites; Breed/subspecies: DBA/2. Female 21200629 CVCL_Y405 293/mTLR4 transformed cell line human CVCL_Y405 CL:0000010 Transfected with: MGI; MGI:96824; Tlr4; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200630 CVCL_XS05 HAP1 PUSL1 (-) 2 cancer cell line human CVCL_XS05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26914; PUSL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200631 CVCL_Y404 293/mTLR3 transformed cell line human CVCL_Y404 CL:0000010 Transfected with: MGI; MGI:2156367; Tlr3; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200632 CVCL_XS04 HAP1 PTPRJ (-) 2 cancer cell line human CVCL_XS04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9673; PTPRJ; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200633 CVCL_Y403 293/mTLR2-TLR6 transformed cell line human CVCL_Y403 CL:0000010 Transfected with: MGI; MGI:1346060; Tlr2; Transfected with: MGI; MGI:1341296; Tlr6; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200634 CVCL_XS03 HAP1 PTPRD (-) 2 cancer cell line human CVCL_XS03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9668; PTPRD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200635 CVCL_Y402 293/mTLR2 transformed cell line human CVCL_Y402 CL:0000010 Transfected with: MGI; MGI:1346060; Tlr2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200636 CVCL_XS02 HAP1 PSPC1 (-) 3 cancer cell line human CVCL_XS02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20320; PSPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200637 CVCL_Y409 293/mTLR9 transformed cell line human CVCL_Y409 CL:0000010 Transfected with: MGI; MGI:1932389; Tlr9; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200638 CVCL_XS09 HAP1 RAB1A (-) 1 cancer cell line human CVCL_XS09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9758; RAB1A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200639 CVCL_Y408 293/mTLR6 transformed cell line human CVCL_Y408 CL:0000010 Transfected with: MGI; MGI:1341296; Tlr6 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200640 CVCL_XS08 HAP1 RAB11B (-) 3 cancer cell line human CVCL_XS08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9761; RAB11B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200641 CVCL_Y407 293/mTLR5 transformed cell line human CVCL_Y407 CL:0000010 Transfected with: MGI; MGI:1858171; Tlr5; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200642 CVCL_XS07 HAP1 RAB11B (-) 2 cancer cell line human CVCL_XS07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9761; RAB11B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200643 CVCL_Y406 293/mTLR4-MD2-CD14 transformed cell line human CVCL_Y406 CL:0000010 Transfected with: MGI; MGI:88318; Cd14; Transfected with: MGI; MGI:1341909; Ly96; Transfected with: MGI; MGI:96824; Tlr4; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200644 CVCL_XS06 HAP1 QKI (-) 2 cancer cell line human CVCL_XS06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21100; QKI; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200645 CVCL_Y412 293XL/hTLR9-HA transformed cell line human CVCL_Y412 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15633; TLR9 (with a C-terminal HA tag) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200646 CVCL_XS12 HAP1 RAB35 (-) 4 cancer cell line human CVCL_XS12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9774; RAB35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200647 CVCL_Y411 293XL/hTLR8-HA transformed cell line human CVCL_Y411 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15632; TLR8 (with a C-terminal HA tag) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200648 CVCL_XS11 HAP1 RAB35 (-) 3 cancer cell line human CVCL_XS11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9774; RAB35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200649 CVCL_Y410 293XL/hTLR7-HA transformed cell line human CVCL_Y410 CL:0000010 Transfected with: HGNC; 992; BCL2L1; Transfected with: HGNC; 15631; TLR7 (with a C-terminal HA tag) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200650 CVCL_XS10 HAP1 RAB35 (-) 2 cancer cell line human CVCL_XS10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9774; RAB35; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200651 CVCL_Y401 293/mTLR1-TLR2 transformed cell line human CVCL_Y401 CL:0000010 Transfected with: MGI; MGI:1341295; Tlr1; Transfected with: MGI; MGI:1346060; Tlr2; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200652 CVCL_XS01 HAP1 PSPC1 (-) 2 cancer cell line human CVCL_XS01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20320; PSPC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200653 CVCL_Y400 293/mTLR1 transformed cell line human CVCL_Y400 CL:0000010 Transfected with: MGI; MGI:1341295; Tlr1; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21200654 CVCL_XS00 HAP1 PSENEN (-) cancer cell line human CVCL_XS00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30100; PSENEN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200655 CVCL_5M73 GM02437 finite cell line human CVCL_5M73 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21200656 CVCL_5M72 GM02339 finite cell line human CVCL_5M72 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex31-43del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200657 CVCL_5M71 GM02298 finite cell line human CVCL_5M71 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; None_reported; -; Zygosity=- (PubMed=21354051) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200658 CVCL_5M70 GM01889 finite cell line human CVCL_5M70 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX (Coriell); Derived from sampling site: Cell type=Fibroblast. Ambiguous 21200659 CVCL_5M77 GM02670 finite cell line human CVCL_5M77 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200660 CVCL_5M76 GM02626 finite cell line human CVCL_5M76 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200661 CVCL_5M75 GM02625 finite cell line human CVCL_5M75 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21200662 CVCL_5M74 GM02624 finite cell line human CVCL_5M74 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200663 CVCL_5M79 GM02672 finite cell line human CVCL_5M79 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200664 CVCL_5M78 GM02671 finite cell line human CVCL_5M78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: Transcriptome analysis by RNAseq Female 21200665 CVCL_5M80 GM02718 finite cell line human CVCL_5M80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Discontinued: Coriell; AG02718; probable Female 21200666 CVCL_5M84 GM03604 finite cell line human CVCL_5M84 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex18-41del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200667 CVCL_5M83 GM03503 finite cell line human CVCL_5M83 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200668 CVCL_5M82 GM03429 finite cell line human CVCL_5M82 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Male 21200669 CVCL_5M81 GM02971 finite cell line human CVCL_5M81 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,t(X;13)(p22jq12) (PubMed=10377420); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02971; probable Female 21200670 CVCL_5M88 GM03997 transformed cell line human CVCL_5M88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200671 CVCL_5M87 GM03929 transformed cell line human CVCL_5M87 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-50del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; AG03929; probable Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200672 CVCL_5M86 GM03783 finite cell line human CVCL_5M86 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-17del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Iberian; Derived from sampling site: Cell type=Fibroblast. Male 21200673 CVCL_5M85 GM03782 transformed cell line human CVCL_5M85 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-17del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Iberian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200674 CVCL_5M89 GM04099 transformed cell line human CVCL_5M89 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Heterozygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21200675 CVCL_5M51 GM12200 transformed cell line human CVCL_5M51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200676 CVCL_5M50 GM12212 finite cell line human CVCL_5M50 CL:0000010 Sequence variation: Mutation; HGNC; 8806; PDHA1; Simple; p.Arg263Gly (c.787C>G); ClinVar=VCV000010878; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200677 CVCL_5M55 GM12260 finite cell line human CVCL_5M55 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21200678 CVCL_5M54 GM12203 transformed cell line human CVCL_5M54 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200679 CVCL_5M53 GM12202 transformed cell line human CVCL_5M53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200680 CVCL_5M52 GM12201 transformed cell line human CVCL_5M52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200681 CVCL_5M59 GM18481 transformed cell line human CVCL_5M59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200682 CVCL_5M58 GM12318 transformed cell line human CVCL_5M58 CL:0000010 Sequence variation: Mutation; HGNC; 7678; NDP; Simple; p.Leu61Phe (c.181C>T); ClinVar=VCV000010690; Zygosity=Hemizygous (PubMed=9143918) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200683 CVCL_5M57 GM12316 transformed cell line human CVCL_5M57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200684 CVCL_5M56 GM12315 transformed cell line human CVCL_5M56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200685 CVCL_5M49 GM00583 finite cell line human CVCL_5M49 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21200686 CVCL_5M62 GM22475 transformed cell line human CVCL_5M62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200687 CVCL_5M61 GM22439 transformed cell line human CVCL_5M61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200688 CVCL_5M60 GM22421 transformed cell line human CVCL_5M60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200689 CVCL_5M66 HHW972 hybrid cell line human CVCL_5M66 CL:0000010 Group: Human/rodent somatic cell hybrid. 21200690 CVCL_5M65 RenCa/CA-IX cancer cell line house mouse CVCL_5M65 CL:0000010 Transfected with: HGNC; 1383; CA9 Breed/subspecies: BALB/c. Male 21200691 CVCL_5M64 GM00622 finite cell line human CVCL_5M64 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21200692 CVCL_5M63 GM22478 transformed cell line human CVCL_5M63 CL:0000010 Karyotypic information: 46,XX,del(11)(pter->q24.1) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200693 CVCL_5M69 GM01641 transformed cell line human CVCL_5M69 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200694 CVCL_5M68 GM01639 finite cell line human CVCL_5M68 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200695 CVCL_5M67 GM00914 finite cell line human CVCL_5M67 CL:0000010 Population: Caucasian; Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG00914; probable Male 21200696 CVCL_XS92 HAP1 SLC20A2 (-) 2 cancer cell line human CVCL_XS92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200697 CVCL_Y492 UTSW-ACC112 transformed cell line human CVCL_Y492 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; submandibular gland. Male Doubling time: 30 hours (PubMed=10328235) 21200698 CVCL_XS91 HAP1 SLC19A3 (-) 2 cancer cell line human CVCL_XS91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16266; SLC19A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200699 CVCL_Y491 UTSW-EMC23 transformed cell line human CVCL_Y491 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; submandibular gland. Male Doubling time: 26 hours (PubMed=10328235) 21200700 CVCL_XS90 HAP1 SLC18B1 (-) 2 cancer cell line human CVCL_XS90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21573; SLC18B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200701 CVCL_Y490 UTSW-CaPA79 transformed cell line human CVCL_Y490 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: 35 hours (PubMed=10328235) 21200702 CVCL_XS96 HAP1 SLC22A15 (-) 2 cancer cell line human CVCL_XS96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20301; SLC22A15; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200703 CVCL_Y496 SF1-3 embryonic stem cell CVCL_Y496 CL:0000010 Breed/subspecies: C57BL/6 x CBA/Ca. Male 21200704 CVCL_XS95 HAP1 SLC20A2 (-) 5 cancer cell line human CVCL_XS95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200705 CVCL_Y495 SF1-1 embryonic stem cell CVCL_Y495 CL:0000010 Breed/subspecies: C57BL/6 x CBA/Ca. Male 21200706 CVCL_XS94 HAP1 SLC20A2 (-) 4 cancer cell line human CVCL_XS94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200707 CVCL_Y494 Patski spontaneously immortalized cell line CVCL_Y494 CL:0000010 Omics: Transcriptome analysis by RNAseq. Female Part of: ENCODE project mouse cell lines 21200708 CVCL_XS93 HAP1 SLC20A2 (-) 3 cancer cell line human CVCL_XS93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10947; SLC20A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200709 CVCL_Y493 MCF-7R cancer cell line human CVCL_Y493 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female 21200710 CVCL_Y499 EpiSC-5 somatic stem cell house mouse CVCL_Y499 CL:0000010 Derived from sampling site: Cell type=Epiblast. Male Part of: ENCODE project mouse cell lines 21200711 CVCL_XS99 GAL-FR22 hybridoma house mouse CVCL_XS99 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21802; Human FGFR2/CD332 (isoform IgIIIb/K-sam-II). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9587 21200712 CVCL_XS98 HAP1 SLC23A2 (-) 2 cancer cell line human CVCL_XS98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10973; SLC23A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200713 CVCL_Y498 SF1-G embryonic stem cell CVCL_Y498 CL:0000010 Breed/subspecies: C57BL/6 x CBA/Ca. Female 21200714 CVCL_XS97 HAP1 SLC22A23 (-) 2 cancer cell line human CVCL_XS97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21106; SLC22A23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200715 CVCL_Y497 SF1-8 embryonic stem cell CVCL_Y497 CL:0000010 Breed/subspecies: C57BL/6 x CBA/Ca. Male 21200716 CVCL_XS79 HAP1 SHPRH (-) 1 cancer cell line human CVCL_XS79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19336; SHPRH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200717 CVCL_Y479 HepG3 cancer cell line human CVCL_Y479 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Miscellaneous: It is not clear if there is a single HepG3 cell line or many differents ones The one described in PubMed=22912842 is is said to be a Hep-G2 'derived stable cell line containing an integrated wild-type DHBV head-to-tail unit-length genomic DNA dimer', but there seem to be old papers (like PubMed=1828229) using this cell line as if it was obtained from ATCC. Population: Caucasian; Derived from sampling site: Liver. Male 21200718 CVCL_5M33 GM23677 transformed cell line human CVCL_5M33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200719 CVCL_5M32 GM23672 transformed cell line human CVCL_5M32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200720 CVCL_5M31 GM23661 transformed cell line human CVCL_5M31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200721 CVCL_5M30 GM23430 transformed cell line human CVCL_5M30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200722 CVCL_5M37 GM23825 transformed cell line human CVCL_5M37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200723 CVCL_5M36 GM23809 transformed cell line human CVCL_5M36 CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Arg344Ter (c.1030C>T); ClinVar=VCV000188885; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Arg363Trp (c.1087C>T); ClinVar=VCV000006328; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200724 CVCL_5M35 GM23706 transformed cell line human CVCL_5M35 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200725 CVCL_5M34 GM23705 transformed cell line human CVCL_5M34 CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Gly390Arg (c.1168G>A); ClinVar=VCV000006329; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200726 CVCL_5M29 GM23942 transformed cell line human CVCL_5M29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200727 CVCL_5M28 GM23867 transformed cell line human CVCL_5M28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200728 CVCL_5M27 GM23653 transformed cell line human CVCL_5M27 CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Arg304Trp (c.910C>T); ClinVar=VCV000006330; Zygosity=Homozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200729 CVCL_Y481 ES-E14TG2a.4 embryonic stem cell house mouse CVCL_Y481 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Feeder free 21200730 CVCL_XS81 HAP1 SIRPA (-) 2 cancer cell line human CVCL_XS81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9662; SIRPA; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200731 CVCL_XS80 HAP1 SIK1 (-) 2 cancer cell line human CVCL_XS80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11142; SIK1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200732 CVCL_Y480 MEL-GATA-1-ER cancer cell line house mouse CVCL_Y480 CL:0000010 Transfected with: HGNC; 4170; GATA1; Transfected with: HGNC; 3467; ESR1 (ligand-binding domain) Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: DBA/2. Characteristics: Transfected with a GATA-1-ER construct (GATA1 fused to the ligand-binding domains of ESR1) Part of: ENCODE project mouse cell lines 21200733 CVCL_XS85 HAP1 SLC10A7 (-) 2 cancer cell line human CVCL_XS85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23088; SLC10A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200734 CVCL_Y485 UTSW-PA116 transformed cell line human CVCL_Y485 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: 41 hours (PubMed=10328235) 21200735 CVCL_Y484 CEM 2cl cancer cell line human CVCL_Y484 CL:0000010 Female 21200736 CVCL_XS84 HAP1 SLC10A4 (-) 2 cancer cell line human CVCL_XS84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22980; SLC10A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200737 CVCL_XS83 HAP1 SKOR1 (-) 3 cancer cell line human CVCL_XS83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21326; SKOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200738 CVCL_Y483 hMSC-UC somatic stem cell human CVCL_Y483 CL:0000010 Derived from sampling site: Umbilical cord Cell type=Umbilical cord mesenchymal stem cell.. Female Part of: ENCODE project common cell types; tier 3 21200739 CVCL_Y482 46C embryonic stem cell house mouse CVCL_Y482 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Expresses eGFP under the control of the Sox-1 promoter Part of: ENCODE project mouse cell lines 21200740 CVCL_XS82 HAP1 SKOR1 (-) 2 cancer cell line human CVCL_XS82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21326; SKOR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200741 CVCL_XS89 HAP1 SLC16A9 (-) 2 cancer cell line human CVCL_XS89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23520; SLC16A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200742 CVCL_Y489 UTSW-ACC52 transformed cell line human CVCL_Y489 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; minor salivary gland. Male Doubling time: 32 hours (PubMed=10328235) 21200743 CVCL_XS88 HAP1 SLC16A2 (-) 2 cancer cell line human CVCL_XS88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10923; SLC16A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200744 CVCL_Y488 UTSW-MEC49 transformed cell line human CVCL_Y488 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; parotid gland. Male Doubling time: 46 hours (PubMed=10328235) 21200745 CVCL_XS87 HAP1 SLC10A7 (-) 4 cancer cell line human CVCL_XS87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23088; SLC10A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200746 CVCL_Y487 UTSW-PA37 transformed cell line human CVCL_Y487 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; parotid gland. Female Doubling time: 24 hours (PubMed=10328235) 21200747 CVCL_XS86 HAP1 SLC10A7 (-) 3 cancer cell line human CVCL_XS86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23088; SLC10A7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200748 CVCL_Y486 UTSW-PA125 transformed cell line human CVCL_Y486 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Salivary gland; parotid gland. Male Doubling time: 34 hours (PubMed=10328235) 21200749 CVCL_XS69 HAP1 SFXN3 (-) 3 cancer cell line human CVCL_XS69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16087; SFXN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200750 CVCL_Y469 SUM16LN finite cell line human CVCL_Y469 CL:0000010 Derived from metastatic site: Lymph node. Female Senescence: Has a finite life span Senesces at 15 to 20 PDL (PubMed=8018955). 21200751 CVCL_XS68 HAP1 SFXN3 (-) 2 cancer cell line human CVCL_XS68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16087; SFXN3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200752 CVCL_Y468 MEF (DR4) MITC finite cell line house mouse CVCL_Y468 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Mitomycin C (MMC(ChEBI; CHEBI:27504); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: DR4. Discontinued: ATCC; SCRC-1045.2; true Mixed Characteristics: Used as feeder cells to support the growth of stem cells in the undifferentiated state; Characteristics: Growth-arrested by mitomycin C; Characteristics: Expresses transgenes that make this cell line resistant to four different drugs: geneticin (G418), puromycin, hygromycin and 6-tioguanine 21200753 CVCL_5M40 GM08014 transformed cell line human CVCL_5M40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200754 CVCL_5M44 GM19292 transformed cell line human CVCL_5M44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200755 CVCL_5M43 GM19291 transformed cell line human CVCL_5M43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200756 CVCL_5M42 GM12787 finite cell line human CVCL_5M42 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(2)(pter->q35) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21200757 CVCL_5M41 GM08015 transformed cell line human CVCL_5M41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200758 CVCL_5M48 GM00444 finite cell line human CVCL_5M48 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200759 CVCL_5M47 GM14164 transformed cell line human CVCL_5M47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21200760 CVCL_5M46 GM09500 finite cell line human CVCL_5M46 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21200761 CVCL_5M45 GM09499 transformed cell line human CVCL_5M45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200762 CVCL_5M39 GM08010 transformed cell line human CVCL_5M39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200763 CVCL_5M38 GM23879 transformed cell line human CVCL_5M38 CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Thr389Ile (c.1166C>T); ClinVar=VCV000645842; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Gly390Arg (c.1168G>A); ClinVar=VCV000006329; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200764 CVCL_XS70 HAP1 SGCB (-) cancer cell line human CVCL_XS70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10806; SGCB; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200765 CVCL_Y470 SFT-R spontaneously immortalized cell line CVCL_Y470 CL:0000010 Derived from sampling site: Thymus. Unspecified 21200766 CVCL_XS74 HAP1 SH3BP5 (-) 2 cancer cell line human CVCL_XS74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10827; SH3BP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200767 CVCL_Y474 UM-HMC-2 cancer cell line human CVCL_Y474 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=24035723) Population: Caucasian; Derived from sampling site: Salivary gland; parotid gland. Female 21200768 CVCL_XS73 HAP1 SGSH (-) 1 cancer cell line human CVCL_XS73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10818; SGSH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200769 CVCL_Y473 UM-HMC-1 cancer cell line human CVCL_Y473 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=24035723) Population: African American; Derived from sampling site: Salivary gland; anterior buccal gland. Male 21200770 CVCL_XS72 HAP1 SGPL1 (-) 3 cancer cell line human CVCL_XS72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10817; SGPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200771 CVCL_Y472 UM-HMC-3B cancer cell line human CVCL_Y472 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=24035723) Population: Caucasian; Derived from metastatic site: Lymph node. Female 21200772 CVCL_XS71 HAP1 SGPL1 (-) 2 cancer cell line human CVCL_XS71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10817; SGPL1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200773 CVCL_Y471 UM-HMC-3A cancer cell line human CVCL_Y471 CL:0000010 Sequence variation: Gene fusion; HGNC; 16062; CRTC1 + HGNC; 16259; MAML2; Name(s)=CRTC1-MAML2, MECT1-MAML2 (PubMed=24035723) Population: Caucasian; Derived from sampling site: Oral cavity; hard palate. Female 21200774 CVCL_XS78 HAP1 SHC1 (-) 2 cancer cell line human CVCL_XS78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10840; SHC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200775 CVCL_Y478 TOC-2 cancer cell line human CVCL_Y478 HLA typing: A*26,33; B*07,44; C*07 (PubMed=7671230). From: Sato N.; Sapporo Medical College; Sapporo; Japan CL:0000010 Population: Japanese Female 21200776 CVCL_Y477 ABC-11 cancer cell line human CVCL_Y477 CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=25170107) Population: Japanese; Derived from metastatic site: Pleural effusion. Female 21200777 CVCL_XS77 HAP1 SHARPIN (-) 2 cancer cell line human CVCL_XS77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25321; SHARPIN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200778 CVCL_XS76 HAP1 SH3BP5L (-) 2 cancer cell line human CVCL_XS76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29360; SH3BP5L; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200779 CVCL_Y476 MKN45P cancer cell line human CVCL_Y476 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from metastatic site: Liver. Female Characteristics: High-potential peritoneal dissemination child line of MKN45 21200780 CVCL_XS75 HAP1 SH3BP5 (-) 3 cancer cell line human CVCL_XS75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10827; SH3BP5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200781 CVCL_Y475 UM-HPA-1 cancer cell line human CVCL_Y475 CL:0000010 Population: Caucasian; Derived from sampling site: Salivary gland; parotid gland. Male 21200782 CVCL_Y459 5HL2 hybrid cell line human CVCL_Y459 CL:0000010 Group: Human/rodent somatic cell hybrid. 21200783 CVCL_XS59 HAP1 SERPINH1 (-) 2 cancer cell line human CVCL_XS59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1546; SERPINH1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200784 CVCL_XS58 HAP1 SERPINF1 (-) 2 cancer cell line human CVCL_XS58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8824; SERPINF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200785 CVCL_Y458 RCH-ADD transformed cell line human CVCL_Y458 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200786 CVCL_Y457 3D5 [Human melanoma] cancer cell line human CVCL_Y457 CL:0000010 Unspecified 21200787 CVCL_XS57 HAP1 SEPT6 (-) 4 cancer cell line human CVCL_XS57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15848; SEPTIN6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200788 CVCL_5M11 GM09685 transformed cell line human CVCL_5M11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200789 CVCL_5M10 GM09684 transformed cell line human CVCL_5M10 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200790 CVCL_5M15 RPMI-2403 cancer cell line CVCL_5M15 CL:0000010 Unspecified 21200791 CVCL_5M14 RPMI-2298 cancer cell line CVCL_5M14 CL:0000010 Unspecified 21200792 CVCL_5M13 RPMI-3460 cancer cell line CVCL_5M13 CL:0000010 Male Characteristics: Pigmented. 21200793 CVCL_5M12 GM09686 transformed cell line human CVCL_5M12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200794 CVCL_5M08 GM09576 transformed cell line human CVCL_5M08 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200795 CVCL_5M07 GM09575 transformed cell line human CVCL_5M07 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200796 CVCL_5M06 GM09574 transformed cell line human CVCL_5M06 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200797 CVCL_5M05 GM09572 transformed cell line human CVCL_5M05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200798 CVCL_5M09 GM09683 transformed cell line human CVCL_5M09 CL:0000010 Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Gln1503Pro (c.4508A>C); ClinVar=VCV000012401; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200799 CVCL_Y463 DTK-E cancer cell line dog CVCL_Y463 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Doubling time: 24 hours (PubMed=25267010) 21200800 CVCL_XS63 HAP1 SFI1 (-) 2 cancer cell line human CVCL_XS63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29064; SFI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200801 CVCL_Y462 5HL9-4 hybrid cell line human CVCL_Y462 CL:0000010 Characteristics: Hybrid for chromosome 19 mapping Contains a complete copy of chromosome 19.. Group: Human/rodent somatic cell hybrid 21200802 CVCL_XS62 HAP1 SFI1 (-) 1 cancer cell line human CVCL_XS62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29064; SFI1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200803 CVCL_Y461 5HL2-B hybrid cell line human CVCL_Y461 CL:0000010 Group: Human/rodent somatic cell hybrid. 21200804 CVCL_XS61 HAP1 SETD8 (-) 2 cancer cell line human CVCL_XS61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29489; KMT5A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200805 CVCL_Y460 5HL9 hybrid cell line human CVCL_Y460 CL:0000010 Characteristics: Hybrid for chromosome 19 mapping Contains a complete copy of chromosome 19.. Group: Human/rodent somatic cell hybrid 21200806 CVCL_XS60 HAP1 SETD4 (-) 2 cancer cell line human CVCL_XS60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1258; SETD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200807 CVCL_Y467 C3H/MCA-58 transformed cell line house mouse CVCL_Y467 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: C3H. Unspecified 21200808 CVCL_XS67 HAP1 SFR1 (-) 5 cancer cell line human CVCL_XS67 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29574; SFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200809 CVCL_Y466 AKR-MCA transformed cell line house mouse CVCL_Y466 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Whole embryo Cell type=Epithelial cell.; Breed/subspecies: AKR. Unspecified 21200810 CVCL_XS66 HAP1 SFR1 (-) 4 cancer cell line human CVCL_XS66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29574; SFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200811 CVCL_XS65 HAP1 SFR1 (-) 3 cancer cell line human CVCL_XS65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29574; SFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200812 CVCL_Y465 RBHF-1 undefined cell line type CVCL_Y465 CL:0000010 Unspecified Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00155. Problematic cell line: Misidentified Originally thought to be a human hepatocellular carcinoma cell line but shown not to be of human origin (PubMed=10508494; PubMed=20143388). 21200813 CVCL_Y464 DTK-SME cancer cell line dog CVCL_Y464 CL:0000010 Derived from sampling site: Mammary gland; Breed/subspecies: Mixed breed. Female Doubling time: 18 hours (PubMed=25267010) 21200814 CVCL_XS64 HAP1 SFR1 (-) 2 cancer cell line human CVCL_XS64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29574; SFR1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200815 CVCL_Y449 EFK finite cell line CVCL_Y449 CL:0000010 Derived from sampling site: Fetal kidney. Discontinued: ATCC; CRL-6289; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200816 CVCL_XS49 HAP1 SCCPDH (-) 3 cancer cell line human CVCL_XS49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24275; SCCPDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200817 CVCL_Y448 066 undefined cell line type CVCL_Y448 CL:0000010 Discontinued: ATCC; CRL-6287; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200818 CVCL_XS48 HAP1 SCCPDH (-) 2 cancer cell line human CVCL_XS48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24275; SCCPDH; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200819 CVCL_XS47 HAP1 SCARB1 (-) 2 cancer cell line human CVCL_XS47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200820 CVCL_Y447 MBA-HE finite cell line CVCL_Y447 CL:0000010 Discontinued: ATCC; CRL-6286; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200821 CVCL_XS46 HAP1 SAV1 (-) 4 cancer cell line human CVCL_XS46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17795; SAV1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200822 CVCL_Y446 HT-1 [Hamster] cancer cell line CVCL_Y446 CL:0000010 Transformant: Moloney murine leukemia virus (MoMuLV)(NCBI-Taxonomy; 11801) Discontinued: ATCC; CRL-6283; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200823 CVCL_5M22 TD cancer cell line CVCL_5M22 CL:0000010 21200824 CVCL_5M21 MB cancer cell line CVCL_5M21 CL:0000010 21200825 CVCL_5M20 KF cancer cell line CVCL_5M20 CL:0000010 21200826 CVCL_5M26 GM23609 transformed cell line human CVCL_5M26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200827 CVCL_5M25 GM23851 transformed cell line human CVCL_5M25 CL:0000010 Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Val269Met (c.805G>A); ClinVar=VCV000193968; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 758; ASS1; Simple; p.Arg272Cys (c.814C>T); ClinVar=VCV000371132; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200828 CVCL_5M24 GM23865 transformed cell line human CVCL_5M24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200829 CVCL_5M23 WE cancer cell line CVCL_5M23 CL:0000010 21200830 CVCL_5M19 RPMI-8746 cancer cell line CVCL_5M19 CL:0000010 Unspecified 21200831 CVCL_5M18 RPMI-8113 cancer cell line CVCL_5M18 CL:0000010 Unspecified 21200832 CVCL_5M17 RPMI-7113 cancer cell line CVCL_5M17 CL:0000010 Male 21200833 CVCL_5M16 RPMI-2739 cancer cell line CVCL_5M16 CL:0000010 Unspecified 21200834 CVCL_Y452 BAB/BM cancer cell line CVCL_Y452 CL:0000010 Derived from sampling site: Bone marrow. Discontinued: ATCC; CRL-6298; true Male Group: Non-human primate cell line; Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200835 CVCL_XS52 HAP1 SDCBP (-) 2 cancer cell line human CVCL_XS52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10662; SDCBP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200836 CVCL_Y451 BD.SP. finite cell line CVCL_Y451 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-6296; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200837 CVCL_XS51 HAP1 SDC1 (-) 2 cancer cell line human CVCL_XS51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10658; SDC1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200838 CVCL_Y450 EK [Horse] finite cell line CVCL_Y450 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6290; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200839 CVCL_XS50 HAP1 SCML2 (-) 2 cancer cell line human CVCL_XS50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10581; SCML2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200840 CVCL_XS56 HAP1 SENP7 (-) cancer cell line human CVCL_XS56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30402; SENP7; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200841 CVCL_Y456 ST1 finite cell line CVCL_Y456 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: ATCC; CRL-6552; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200842 CVCL_XS55 HAP1 SEC31B (-) 1 cancer cell line human CVCL_XS55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23197; SEC31B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200843 CVCL_Y455 P72-9 finite cell line CVCL_Y455 CL:0000010 Derived from sampling site: Skin. Discontinued: ATCC; CRL-6525; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200844 CVCL_XS54 HAP1 SEC31A (-) cancer cell line human CVCL_XS54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17052; SEC31A; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200845 CVCL_Y454 PD(H39) undefined cell line type pig CVCL_Y454 CL:0000010 Discontinued: ATCC; CRL-6491; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200846 CVCL_XS53 HAP1 SDHAF2 (-) cancer cell line human CVCL_XS53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26034; SDHAF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200847 CVCL_Y453 MMM [Mus molossinus] finite cell line CVCL_Y453 CL:0000010 Derived from sampling site: Kidney. Discontinued: ATCC; CRL-6439; true Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 21200848 CVCL_GB41 ND03137 transformed cell line human CVCL_GB41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200849 CVCL_GB40 ND03136 transformed cell line human CVCL_GB40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200850 CVCL_GB45 ND03376 transformed cell line human CVCL_GB45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200851 CVCL_GB44 ND03338 transformed cell line human CVCL_GB44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200852 CVCL_GB43 ND03228 transformed cell line human CVCL_GB43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200853 CVCL_GB42 ND03215 transformed cell line human CVCL_GB42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200854 CVCL_GB38 ND02927 transformed cell line human CVCL_GB38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200855 CVCL_GB37 ND02855 transformed cell line human CVCL_GB37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200856 CVCL_GB36 ND02853 transformed cell line human CVCL_GB36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200857 CVCL_GB35 ND02808 transformed cell line human CVCL_GB35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200858 CVCL_GB39 ND03104 transformed cell line human CVCL_GB39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200859 CVCL_GB52 ND03555 transformed cell line human CVCL_GB52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200860 CVCL_GB51 ND03503 transformed cell line human CVCL_GB51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200861 CVCL_GB50 ND03497 transformed cell line human CVCL_GB50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200862 CVCL_GB56 ND03742 transformed cell line human CVCL_GB56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200863 CVCL_GB55 ND03638 transformed cell line human CVCL_GB55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200864 CVCL_GB54 ND03637 transformed cell line human CVCL_GB54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200865 CVCL_GB53 ND03636 transformed cell line human CVCL_GB53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200866 CVCL_GB49 ND03495 transformed cell line human CVCL_GB49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200867 CVCL_GB48 ND03494 transformed cell line human CVCL_GB48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200868 CVCL_GB47 ND03493 transformed cell line human CVCL_GB47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200869 CVCL_GB46 ND03471 transformed cell line human CVCL_GB46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200870 CVCL_GB23 ND02469 transformed cell line human CVCL_GB23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200871 CVCL_GB22 ND02467 transformed cell line human CVCL_GB22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200872 CVCL_GB21 ND02456 transformed cell line human CVCL_GB21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200873 CVCL_GB20 ND02455 transformed cell line human CVCL_GB20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200874 CVCL_GB16 ND02379 transformed cell line human CVCL_GB16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200875 CVCL_GB15 ND02378 transformed cell line human CVCL_GB15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200876 CVCL_GB14 ND02377 transformed cell line human CVCL_GB14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200877 CVCL_GB13 ND02373 transformed cell line human CVCL_GB13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200878 CVCL_GB19 ND02441 transformed cell line human CVCL_GB19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200879 CVCL_GB18 ND02401 transformed cell line human CVCL_GB18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200880 CVCL_GB17 ND02381 transformed cell line human CVCL_GB17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200881 CVCL_GB30 ND02541 transformed cell line human CVCL_GB30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200882 CVCL_GB34 ND02807 transformed cell line human CVCL_GB34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200883 CVCL_GB33 ND02801 transformed cell line human CVCL_GB33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200884 CVCL_GB32 ND02756 transformed cell line human CVCL_GB32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200885 CVCL_GB31 ND02559 transformed cell line human CVCL_GB31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200886 CVCL_GB27 ND02513 transformed cell line human CVCL_GB27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200887 CVCL_GB26 ND02482 transformed cell line human CVCL_GB26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200888 CVCL_GB25 ND02472 transformed cell line human CVCL_GB25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200889 CVCL_GB24 ND02470 transformed cell line human CVCL_GB24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200890 CVCL_GB29 ND02532 transformed cell line human CVCL_GB29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200891 CVCL_GB28 ND02531 transformed cell line human CVCL_GB28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200892 CVCL_GB01 ND02183 transformed cell line human CVCL_GB01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200893 CVCL_GB00 ND02172 transformed cell line human CVCL_GB00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200894 CVCL_GB12 ND02372 transformed cell line human CVCL_GB12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200895 CVCL_GB11 ND02365 transformed cell line human CVCL_GB11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200896 CVCL_GB10 ND02361 transformed cell line human CVCL_GB10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200897 CVCL_GB05 ND02219 transformed cell line human CVCL_GB05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200898 CVCL_GB04 ND02189 transformed cell line human CVCL_GB04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200899 CVCL_GB03 ND02188 transformed cell line human CVCL_GB03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200900 CVCL_GB02 ND02184 transformed cell line human CVCL_GB02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200901 CVCL_GB09 ND02340 transformed cell line human CVCL_GB09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200902 CVCL_GB08 ND02314 transformed cell line human CVCL_GB08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200903 CVCL_GB07 ND02222 transformed cell line human CVCL_GB07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200904 CVCL_GB06 ND02220 transformed cell line human CVCL_GB06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200905 CVCL_GB85 ND04515 transformed cell line human CVCL_GB85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200906 CVCL_GB84 ND04480 transformed cell line human CVCL_GB84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200907 CVCL_GB83 ND04479 transformed cell line human CVCL_GB83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200908 CVCL_GB82 ND04478 transformed cell line human CVCL_GB82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200909 CVCL_GB89 ND04679 transformed cell line human CVCL_GB89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200910 CVCL_GB88 ND04678 transformed cell line human CVCL_GB88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200911 CVCL_GB87 ND04632 transformed cell line human CVCL_GB87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200912 CVCL_GB86 ND04541 transformed cell line human CVCL_GB86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200913 CVCL_GB81 ND04402 transformed cell line human CVCL_GB81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200914 CVCL_GB80 ND04398 transformed cell line human CVCL_GB80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200915 CVCL_GB79 ND04385 transformed cell line human CVCL_GB79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200916 CVCL_GB96 ND05123 transformed cell line human CVCL_GB96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200917 CVCL_GB95 ND04990 transformed cell line human CVCL_GB95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200918 CVCL_GB94 ND04984 transformed cell line human CVCL_GB94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200919 CVCL_GB93 ND04981 transformed cell line human CVCL_GB93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200920 CVCL_GB99 ND05267 transformed cell line human CVCL_GB99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200921 CVCL_GB98 ND05233 transformed cell line human CVCL_GB98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200922 CVCL_GB97 ND05211 transformed cell line human CVCL_GB97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200923 CVCL_GB92 ND04978 transformed cell line human CVCL_GB92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200924 CVCL_GB91 ND04971 transformed cell line human CVCL_GB91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200925 CVCL_GB90 ND04691 transformed cell line human CVCL_GB90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200926 CVCL_GB63 ND04009 transformed cell line human CVCL_GB63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200927 CVCL_GB62 ND04000 transformed cell line human CVCL_GB62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200928 CVCL_GB61 ND03973 transformed cell line human CVCL_GB61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200929 CVCL_GB60 ND03968 transformed cell line human CVCL_GB60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200930 CVCL_GB67 ND04013 transformed cell line human CVCL_GB67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200931 CVCL_GB66 ND04012 transformed cell line human CVCL_GB66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200932 CVCL_GB65 ND04011 transformed cell line human CVCL_GB65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200933 CVCL_GB64 ND04010 transformed cell line human CVCL_GB64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200934 CVCL_GB59 ND03967 transformed cell line human CVCL_GB59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200935 CVCL_GB58 ND03876 transformed cell line human CVCL_GB58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200936 CVCL_GB57 ND03873 transformed cell line human CVCL_GB57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200937 CVCL_GB74 ND04311 transformed cell line human CVCL_GB74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200938 CVCL_GB73 ND04267 transformed cell line human CVCL_GB73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200939 CVCL_GB72 ND04225 transformed cell line human CVCL_GB72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200940 CVCL_GB71 ND04117 transformed cell line human CVCL_GB71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200941 CVCL_GB78 ND04384 transformed cell line human CVCL_GB78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200942 CVCL_GB77 ND04377 transformed cell line human CVCL_GB77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21200943 CVCL_GB76 ND04337 transformed cell line human CVCL_GB76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200944 CVCL_GB75 ND04313 transformed cell line human CVCL_GB75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200945 CVCL_GB70 ND04113 transformed cell line human CVCL_GB70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200946 CVCL_GB69 ND04030 transformed cell line human CVCL_GB69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200947 CVCL_GB68 ND04020 transformed cell line human CVCL_GB68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200948 CVCL_XT59 HAP1 SMYD3 (-) 2 cancer cell line human CVCL_XT59 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15513; SMYD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200949 CVCL_Y559 IGR-20 finite cell line human CVCL_Y559 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200950 CVCL_XT58 HAP1 SMURF2 (-) cancer cell line human CVCL_XT58 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16809; SMURF2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200951 CVCL_Y558 IGR-3 cancer cell line human CVCL_Y558 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533); Sequence variation: Mutation; HGNC; 3432; ERBB4; Simple; p.Glu452Lys (c.1354G>A); ClinVar=VCV000091898; Zygosity=Heterozygous (PubMed=22383533) Derived from sampling site: Skin. Male 21200952 CVCL_XT57 HAP1 SMURF1 (-) cancer cell line human CVCL_XT57 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16807; SMURF1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200953 CVCL_Y557 IGR-2 cancer cell line human CVCL_Y557 CL:0000010 Derived from metastatic site: Axillary lymph node. Female 21200954 CVCL_Y556 232-A4 transformed cell line human CVCL_Y556 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~30-40 hours (DSMZ=ACC-774) 21200955 CVCL_XT56 HAP1 SMTN (-) 2 cancer cell line human CVCL_XT56 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11126; SMTN; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200956 CVCL_5N10 GM05114 finite cell line human CVCL_5N10 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200957 CVCL_5N14 GM05118 finite cell line human CVCL_5N14 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200958 CVCL_5N13 GM05117 transformed cell line human CVCL_5N13 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Heterozygous (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21200959 CVCL_5N12 GM05116 finite cell line human CVCL_5N12 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200960 CVCL_5N11 GM05115 transformed cell line human CVCL_5N11 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200961 CVCL_5N07 GM05104 finite cell line human CVCL_5N07 CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200962 CVCL_5N06 GM05088 transformed cell line human CVCL_5N06 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21200963 CVCL_5N05 GM05087 finite cell line human CVCL_5N05 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200964 CVCL_5N04 GM05023 finite cell line human CVCL_5N04 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Heterozygous (from familial inference of GM05016 and GM05017) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21200965 CVCL_5N09 GM05113 transformed cell line human CVCL_5N09 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21200966 CVCL_5N08 GM05112 finite cell line human CVCL_5N08 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21200967 CVCL_Y562 CSO spontaneously immortalized cell line CVCL_Y562 CL:0000010 Derived from sampling site: Ovary. Female Group: Fish cell line 21200968 CVCL_XT62 HAP1 SNX10 (-) 4 cancer cell line human CVCL_XT62 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14974; SNX10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200969 CVCL_XT61 HAP1 SNX10 (-) 3 cancer cell line human CVCL_XT61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14974; SNX10; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200970 CVCL_Y561 IGR-36 cancer cell line human CVCL_Y561 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female 21200971 CVCL_XT60 HAP1 SMYD5 (-) 2 cancer cell line human CVCL_XT60 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16258; SMYD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200972 CVCL_Y560 IGR-22 cancer cell line human CVCL_Y560 CL:0000010 Population: Caucasian; Derived from sampling site: Skin. Female 21200973 CVCL_Y566 bmGH spontaneously immortalized cell line CVCL_Y566 CL:0000010 Derived from sampling site: Heart. Unspecified Doubling time: 40.3 hours (PubMed=20409167) Group: Fish cell line 21200974 CVCL_XT66 HAP1 SOCS3 (-) 3 cancer cell line human CVCL_XT66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200975 CVCL_Y565 bmGF-1 spontaneously immortalized cell line CVCL_Y565 CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 21200976 CVCL_XT65 HAP1 SOCS3 (-) 2 cancer cell line human CVCL_XT65 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200977 CVCL_XT64 HAP1 SOCS2 (-) cancer cell line human CVCL_XT64 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19382; SOCS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200978 CVCL_Y564 RMT1 spontaneously immortalized cell line CVCL_Y564 CL:0000010 Derived from sampling site: Testis. Male Doubling time: 24.4 hours (PubMed=23076971) Group: Endangered species/breed cell line; Group: Fish cell line 21200979 CVCL_XT63 HAP1 SNX19 (-) cancer cell line human CVCL_XT63 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21532; SNX19; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200980 CVCL_Y563 RMO1 spontaneously immortalized cell line CVCL_Y563 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 28.8 hours (PubMed=23076971) Group: Endangered species/breed cell line; Group: Fish cell line 21200981 CVCL_Y548 CI transformed cell line human CVCL_Y548 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female Doubling time: ~30-60 hours (DSMZ=ACC-770) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 21200982 CVCL_XT48 HAP1 SLCO5A1 (-) 3 cancer cell line human CVCL_XT48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19046; SLCO5A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200983 CVCL_XT47 HAP1 SLCO5A1 (-) 2 cancer cell line human CVCL_XT47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19046; SLCO5A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200984 CVCL_Y547 HG-3 transformed cell line human CVCL_Y547 HLA typing: A*11:01:01,31:01:02; B*07:02:01,15:01:01; C*03:03:01,07:02:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,04:01:01; DQA1*01:02:01,01:04:01; DQB1*05:03:01,06:02:01; DRA*01:01:01,01:02:03; DRB1*14:54:01,15:01:01 (DSMZCellDive=ACC-765) CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male Characteristics: Genetically heterogeneous, consists of 3 subclones (PubMed=27566572) Doubling time: ~50-70 hours (DSMZ=ACC-765) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21200985 CVCL_XT46 HAP1 SLCO4A1 (-) 3 cancer cell line human CVCL_XT46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10953; SLCO4A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200986 CVCL_Y546 I83-LCL transformed cell line human CVCL_Y546 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~40-50 hours (DSMZ=ACC-764) 21200987 CVCL_XT45 HAP1 SLCO4A1 (-) 2 cancer cell line human CVCL_XT45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10953; SLCO4A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200988 CVCL_Y545 PGA-1 cancer cell line human CVCL_Y545 HLA typing: A*02:01:01,03:01:01; B*35:03:01,39:01:01; C*07:02:01,12:03:01; DPA1*01:03:01,01:03:01; DPB1*04:02:01,02:01:02; DQA1*01:02:01,05:05:01; DQB1*03:01:01,06:09:01; DRA*01:02:02,01:02:02; DRB1*12:01:01,13:02:01 (DSMZCellDive=ACC-766) CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376) Omics: Deep exome analysis; Omics: Transcriptome analysis by RNAseq. Male Doubling time: ~50 hours (DSMZ=ACC-766) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: LL-100 blood cancer cell line panel 21200989 CVCL_XT49 HAP1 SLFN11 (-) 2 cancer cell line human CVCL_XT49 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21200990 CVCL_Y549 WA-OSEL transformed cell line human CVCL_Y549 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Male Doubling time: ~40 hours (DSMZ=ACC-767) 21200991 CVCL_5N21 GM05128 finite cell line human CVCL_5N21 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Glu1845Ter (c.5533G>T); ClinVar=VCV000545963; Zygosity=Hemizygous (from famililal inference of GM05127) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200992 CVCL_5N20 GM05127 finite cell line human CVCL_5N20 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Glu1845Ter (c.5533G>T); ClinVar=VCV000545963; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200993 CVCL_5N25 BFL-9 finite cell line CVCL_5N25 CL:0000010 Miscellaneous: Breed from personal communication of Talbot N.C Derived from sampling site: Fetal liver Cell type=Hepatocyte.; Breed/subspecies: Holstein. Unspecified Characteristics: Requires feeder cells Doubling time: 3-4 days (PubMed=26659396) 21200994 CVCL_5N24 BFL-6 finite cell line CVCL_5N24 CL:0000010 Miscellaneous: Breed from personal communication of Talbot N.C Derived from sampling site: Fetal liver Cell type=Hepatocyte.; Breed/subspecies: Holstein. Unspecified Characteristics: Requires feeder cells 21200995 CVCL_5N23 GM05159 transformed cell line human CVCL_5N23 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-50del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21200996 CVCL_5N22 GM05158 finite cell line human CVCL_5N22 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-50del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 21200997 CVCL_5N18 GM05125 finite cell line human CVCL_5N18 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-62del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21200998 CVCL_5N17 GM05124 transformed cell line human CVCL_5N17 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-62del; Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21200999 CVCL_5N16 GM05123 finite cell line human CVCL_5N16 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-62del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201000 CVCL_5N15 GM05119 transformed cell line human CVCL_5N15 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21201001 CVCL_5N19 GM05126 transformed cell line human CVCL_5N19 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-62del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201002 CVCL_Y551 Cor.At finite cell line house mouse CVCL_Y551 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Cardiomyocyte; Breed/subspecies: 129S2/SvPas. Male 21201003 CVCL_XT51 HAP1 SLIT2 (-) 3 cancer cell line human CVCL_XT51 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11086; SLIT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201004 CVCL_Y550 Cor.4U finite cell line human CVCL_Y550 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Derived from sampling site: Cell type=Cardiomyocyte. Female 21201005 CVCL_XT50 HAP1 SLIT2 (-) 2 cancer cell line human CVCL_XT50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11086; SLIT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201006 CVCL_XT55 HAP1 SMCHD1 (-) cancer cell line human CVCL_XT55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29090; SMCHD1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201007 CVCL_Y555 PG/B95-8 transformed cell line human CVCL_Y555 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: ~35 hours (DSMZ=ACC-776) 21201008 CVCL_XT54 HAP1 SMARCC2 (-) 2 cancer cell line human CVCL_XT54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11105; SMARCC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201009 CVCL_Y554 HCT116-SN6 cancer cell line human CVCL_Y554 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Arg621His (c.1862G>A); Zygosity=Heterozygous (PubMed=21619602); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Glu710Gly (c.2129A>G); Zygosity=Heterozygous (PubMed=21619602) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Omics: Transcriptome analysis by microarray Male Doubling time: 31.7 hours (PubMed=21619602) 21201010 CVCL_XT53 HAP1 SMAD4 (-) 3 cancer cell line human CVCL_XT53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201011 CVCL_Y553 HCT116-SN50 cancer cell line human CVCL_Y553 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11986; TOP1; Simple; p.Leu617Ile (c.1849C>A); Zygosity=Homozygous (PubMed=21619602) Selected for resistance to: ChEBI; CHEBI:8988; SN-38 (7-ethyl-10-hydroxy-camptothecin); Derived from sampling site: Colon. Male Doubling time: 23.2 hours (PubMed=21619602) 21201012 CVCL_Y552 Cor.At GFP finite cell line house mouse CVCL_Y552 From: Ncardia B.V (formerly Axiogenesis); Leiden; Netherlands. CL:0000010 Transfected with: UniProtKB; P42212; GFP Derived from sampling site: Cell type=Cardiomyocyte; Breed/subspecies: 129S2/SvPas. Male 21201013 CVCL_XT52 HAP1 SMAD4 (-) 2 cancer cell line human CVCL_XT52 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6770; SMAD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201014 CVCL_Y537 Edom-iPS-#r-23 induced pluripotent stem cell human CVCL_Y537 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201015 CVCL_XT37 HAP1 SLC7A8 (-) 3 cancer cell line human CVCL_XT37 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11066; SLC7A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201016 CVCL_Y536 Edom-iPS-#r-5 induced pluripotent stem cell human CVCL_Y536 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201017 CVCL_XT36 HAP1 SLC7A8 (-) 2 cancer cell line human CVCL_XT36 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11066; SLC7A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201018 CVCL_Y535 Edom-iPS-#S-31 induced pluripotent stem cell human CVCL_Y535 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201019 CVCL_XT35 HAP1 SLC7A5 (-) 2 cancer cell line human CVCL_XT35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11063; SLC7A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201020 CVCL_XT34 HAP1 SLC6A9 (-) 2 cancer cell line human CVCL_XT34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11056; SLC6A9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201021 CVCL_Y534 PMD2-6 induced pluripotent stem cell human CVCL_Y534 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201022 CVCL_Y539 Edom-iPS-#r35 induced pluripotent stem cell human CVCL_Y539 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201023 CVCL_XT39 HAP1 SLC8B1 (-) 3 cancer cell line human CVCL_XT39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26175; SLC8B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201024 CVCL_Y538 Edom-iPS-#r30 induced pluripotent stem cell human CVCL_Y538 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201025 CVCL_XT38 HAP1 SLC8B1 (-) 2 cancer cell line human CVCL_XT38 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26175; SLC8B1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201026 CVCL_Y540 Edom-iPS-#r49 induced pluripotent stem cell human CVCL_Y540 CL:0000010 Derived from sampling site: Menstrual blood Cell type=Mesenchymal stem cell.. Female 21201027 CVCL_XT40 HAP1 SLC9A1 (-) 2 cancer cell line human CVCL_XT40 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11071; SLC9A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201028 CVCL_Y544 C2 [Human iPSC] induced pluripotent stem cell human CVCL_Y544 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21201029 CVCL_XT44 HAP1 SLCO3A1 (-) 2 cancer cell line human CVCL_XT44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10952; SLCO3A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201030 CVCL_Y543 CRTDi001-A induced pluripotent stem cell human CVCL_Y543 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21201031 CVCL_XT43 HAP1 SLCO1A2 (-) cancer cell line human CVCL_XT43 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10956; SLCO1A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201032 CVCL_Y542 CiRA086Ai-w1 induced pluripotent stem cell human CVCL_Y542 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201033 CVCL_XT42 HAP1 SLC9A8 (-) 3 cancer cell line human CVCL_XT42 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20728; SLC9A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201034 CVCL_XT41 HAP1 SLC9A8 (-) 2 cancer cell line human CVCL_XT41 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20728; SLC9A8; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201035 CVCL_Y541 iPS-HHT induced pluripotent stem cell human CVCL_Y541 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21201036 CVCL_Y526 ATiPS-263 induced pluripotent stem cell human CVCL_Y526 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21201037 CVCL_XT26 HAP1 SLC35F5 (-) 2 cancer cell line human CVCL_XT26 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23617; SLC35F5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201038 CVCL_Y525 ATiPS-262 induced pluripotent stem cell human CVCL_Y525 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21201039 CVCL_XT25 HAP1 SLC35E4 (-) 2 cancer cell line human CVCL_XT25 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17058; SLC35E4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201040 CVCL_Y524 ATiPS-024 induced pluripotent stem cell human CVCL_Y524 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21201041 CVCL_XT24 HAP1 SLC35E3 (-) 2 cancer cell line human CVCL_XT24 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20864; SLC35E3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201042 CVCL_Y523 GM00151 finite cell line human CVCL_Y523 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201043 CVCL_XT23 HAP1 SLC35D2 (-) 2 cancer cell line human CVCL_XT23 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20799; SLC35D2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201044 CVCL_XT29 HAP1 SLC37A1 (-) 2 cancer cell line human CVCL_XT29 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11024; SLC37A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201045 CVCL_Y529 PMD1-15 induced pluripotent stem cell human CVCL_Y529 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Ser253Thr (c.757T>A); Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201046 CVCL_XT28 HAP1 SLC36A1 (-) 3 cancer cell line human CVCL_XT28 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18761; SLC36A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201047 CVCL_Y528 WD39 induced pluripotent stem cell human CVCL_Y528 CL:0000010 Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21201048 CVCL_Y527 ATiPS-264 induced pluripotent stem cell human CVCL_Y527 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Male 21201049 CVCL_XT27 HAP1 SLC36A1 (-) 2 cancer cell line human CVCL_XT27 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18761; SLC36A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201050 CVCL_5N03 GM05022 transformed cell line human CVCL_5N03 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Heterozygous (from familial inference of GM05016 and GM05017) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201051 CVCL_5N02 GM05017 finite cell line human CVCL_5N02 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21201052 CVCL_5N01 GM05016 transformed cell line human CVCL_5N01 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex45-50del; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201053 CVCL_5N00 GM04997 finite cell line human CVCL_5N00 CL:0000010 Population: Lebanese; Derived from sampling site: Cell type=Fibroblast. Male 21201054 CVCL_XT33 HAP1 SLC6A6 (-) 2 cancer cell line human CVCL_XT33 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11052; SLC6A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201055 CVCL_Y533 PMD2-22 induced pluripotent stem cell human CVCL_Y533 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201056 CVCL_XT32 HAP1 SLC46A1 (-) 2 cancer cell line human CVCL_XT32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30521; SLC46A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201057 CVCL_Y532 PMD2-10 induced pluripotent stem cell human CVCL_Y532 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201058 CVCL_XT31 HAP1 SLC44A3 (-) 2 cancer cell line human CVCL_XT31 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28689; SLC44A3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201059 CVCL_Y531 PMD1-7 induced pluripotent stem cell human CVCL_Y531 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Ser253Thr (c.757T>A); Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201060 CVCL_XT30 HAP1 SLC39A13 (-) 2 cancer cell line human CVCL_XT30 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20859; SLC39A13; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201061 CVCL_Y530 PMD1-27 induced pluripotent stem cell human CVCL_Y530 CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Ser253Thr (c.757T>A); Zygosity=Hemizygous (PubMed=24936452) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21201062 CVCL_XT15 HAP1 SLC30A5 (-) 2 cancer cell line human CVCL_XT15 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19089; SLC30A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201063 CVCL_Y515 Kif-5 finite cell line human CVCL_Y515 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 21201064 CVCL_XT14 HAP1 SLC2A6 (-) 2 cancer cell line human CVCL_XT14 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11011; SLC2A6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201065 CVCL_Y514 HH375 cancer cell line human CVCL_Y514 CL:0000010 Derived from metastatic site: Supraventricular lymph node. Female Doubling time: 72-96 hours, at 13th passage (PubMed=10777059) 21201066 CVCL_XT13 HAP1 SLC2A11 (-) 2 cancer cell line human CVCL_XT13 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14239; SLC2A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201067 CVCL_Y513 HH315 cancer cell line human CVCL_Y513 CL:0000010 Derived from metastatic site: Gastro-omental lymph node. Female Doubling time: 48-72 hours, at 18th passage (PubMed=10777059) 21201068 CVCL_XT12 HAP1 SLC2A11 (-) 1 cancer cell line human CVCL_XT12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14239; SLC2A11; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201069 CVCL_Y512 MOP-6 transformed cell line house mouse CVCL_Y512 CL:0000010 Transformant: Polyoma large T antigen (PyLT); Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 21201070 CVCL_XT19 HAP1 SLC35B2 (-) 2 cancer cell line human CVCL_XT19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16872; SLC35B2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201071 CVCL_Y519 HPS0157 induced pluripotent stem cell human CVCL_Y519 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201072 CVCL_XT18 HAP1 SLC35A4 (-) 2 cancer cell line human CVCL_XT18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20753; SLC35A4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201073 CVCL_Y518 HPS0130 induced pluripotent stem cell human CVCL_Y518 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201074 CVCL_XT17 HAP1 SLC31A2 (-) 2 cancer cell line human CVCL_XT17 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11017; SLC31A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201075 CVCL_Y517 HiPS-RIKEN-9A induced pluripotent stem cell human CVCL_Y517 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21201076 CVCL_XT16 HAP1 SLC30A5 (-) 3 cancer cell line human CVCL_XT16 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19089; SLC30A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201077 CVCL_Y516 HPS0227 induced pluripotent stem cell human CVCL_Y516 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21201078 CVCL_XT22 HAP1 SLC35C2 (-) 2 cancer cell line human CVCL_XT22 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17117; SLC35C2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201079 CVCL_Y522 HPS0207 induced pluripotent stem cell human CVCL_Y522 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201080 CVCL_XT21 HAP1 SLC35C1 (-) 2 cancer cell line human CVCL_XT21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20197; SLC35C1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201081 CVCL_Y521 HPS0244 induced pluripotent stem cell human CVCL_Y521 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 21201082 CVCL_XT20 HAP1 SLC35B3 (-) 2 cancer cell line human CVCL_XT20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21601; SLC35B3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201083 CVCL_Y520 HPS0233 induced pluripotent stem cell human CVCL_Y520 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201084 CVCL_Y504 CHO-AS52 spontaneously immortalized cell line CVCL_Y504 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Ovary. Female 21201085 CVCL_XT04 HAP1 SLC25A28 (-) 2 cancer cell line human CVCL_XT04 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23472; SLC25A28; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201086 CVCL_Y503 CHO-X3/5 spontaneously immortalized cell line CVCL_Y503 CL:0000010 Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Ovary. Female Characteristics: Established from parent cell line following X-irradiation with 500 rads and selection in 10 muM Tioguanine (PubMed=6095070) 21201087 CVCL_XT03 HAP1 SLC25A24 (-) 2 cancer cell line human CVCL_XT03 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20662; SLC25A24; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201088 CVCL_Y502 CHO-K1-BH4 spontaneously immortalized cell line CVCL_Y502 CL:0000010 Derived from sampling site: Ovary. Female 21201089 CVCL_XT02 HAP1 SLC25A23 (-) 3 cancer cell line human CVCL_XT02 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19375; SLC25A23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201090 CVCL_XT01 HAP1 SLC25A23 (-) 2 cancer cell line human CVCL_XT01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19375; SLC25A23; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201091 CVCL_Y501 J185a undefined cell line type house mouse CVCL_Y501 CL:0000010 Unspecified Part of: ENCODE project mouse cell lines. 21201092 CVCL_Y508 B140H cancer cell line house mouse CVCL_Y508 CL:0000010 21201093 CVCL_XT08 HAP1 SLC26A10 (-) 1 cancer cell line human CVCL_XT08 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14470; SLC26A10P; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201094 CVCL_Y507 B140p cancer cell line house mouse CVCL_Y507 CL:0000010 21201095 CVCL_XT07 HAP1 SLC25A44 (-) 2 cancer cell line human CVCL_XT07 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29036; SLC25A44; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201096 CVCL_Y506 B117H cancer cell line house mouse CVCL_Y506 CL:0000010 21201097 CVCL_XT06 HAP1 SLC25A43 (-) 2 cancer cell line human CVCL_XT06 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30557; SLC25A43; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201098 CVCL_Y505 B117p cancer cell line house mouse CVCL_Y505 CL:0000010 21201099 CVCL_XT05 HAP1 SLC25A42 (-) 2 cancer cell line human CVCL_XT05 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28380; SLC25A42; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201100 CVCL_XT09 HAP1 SLC26A10 (-) 2 cancer cell line human CVCL_XT09 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14470; SLC26A10P; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201101 CVCL_Y509 hMSC-AT somatic stem cell human CVCL_Y509 CL:0000010 Derived from sampling site: Adipose tissue Cell type=Adipose mesenchymal stem cell.. Female Part of: ENCODE project common cell types; tier 3 21201102 CVCL_XT11 HAP1 SLC29A2 (-) 2 cancer cell line human CVCL_XT11 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11004; SLC29A2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201103 CVCL_Y511 HFF-Myc finite cell line human CVCL_Y511 CL:0000010 Transfected with: VGNC; 43527; Dog MYC Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: H3K4me3 ChIP-seq epigenome analysis Male Part of: ENCODE project common cell types; tier 3 21201104 CVCL_XT10 HAP1 SLC27A5 (-) 2 cancer cell line human CVCL_XT10 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10999; SLC27A5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201105 CVCL_Y510 hMSC-BM somatic stem cell human CVCL_Y510 CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male Part of: ENCODE project common cell types; tier 3 21201106 CVCL_Y500 EpiSC-7 somatic stem cell house mouse CVCL_Y500 CL:0000010 Derived from sampling site: Cell type=Epiblast. Male Part of: ENCODE project mouse cell lines 21201107 CVCL_XT00 HAP1 SLC24A1 (-) 2 cancer cell line human CVCL_XT00 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10975; SLC24A1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201108 CVCL_5N90 GM08785 transformed cell line human CVCL_5N90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201109 CVCL_5N94 GM09101 transformed cell line human CVCL_5N94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201110 CVCL_5N93 GM08946 finite cell line human CVCL_5N93 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201111 CVCL_5N92 GM08944 finite cell line human CVCL_5N92 CL:0000010 Population: Caucasian; Karyotypic information: 46,X,i(X)(p11.4) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201112 CVCL_5N91 GM08808 finite cell line human CVCL_5N91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201113 CVCL_5N98 GM09332 transformed cell line human CVCL_5N98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201114 CVCL_5N97 GM09189 transformed cell line human CVCL_5N97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201115 CVCL_5N96 GM09133 transformed cell line human CVCL_5N96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201116 CVCL_5N95 GM09102 transformed cell line human CVCL_5N95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201117 CVCL_5N99 GM09367 transformed cell line human CVCL_5N99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201118 CVCL_5N72 GM07939 transformed cell line human CVCL_5N72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201119 CVCL_5N71 GM07873 finite cell line human CVCL_5N71 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201120 CVCL_5N70 GM07863 finite cell line human CVCL_5N70 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201121 CVCL_5N76 GM07985 finite cell line human CVCL_5N76 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201122 CVCL_5N75 GM07981 finite cell line human CVCL_5N75 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201123 CVCL_5N74 GM07947 transformed cell line human CVCL_5N74 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; 5'end-Ex19del; Zygosity=Hemizygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201124 CVCL_5N73 GM07945 transformed cell line human CVCL_5N73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201125 CVCL_5N79 GM08035 finite cell line human CVCL_5N79 CL:0000010 Population: Caucasian; Karyotypic information: 47,XY,+i(12)(pter->p10::p10->pter) (Coriell); Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Omics: CNV analysis Male 21201126 CVCL_5N78 GM07995 finite cell line human CVCL_5N78 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201127 CVCL_5N77 GM07993 transformed cell line human CVCL_5N77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Discontinued: Coriell; GM07993; probable Female 21201128 CVCL_5N83 GM08331 transformed cell line human CVCL_5N83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201129 CVCL_5N82 GM08146 transformed cell line human CVCL_5N82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201130 CVCL_5N81 GM08093 transformed cell line human CVCL_5N81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201131 CVCL_5N80 GM08039 finite cell line human CVCL_5N80 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201132 CVCL_5N87 GM08762 finite cell line human CVCL_5N87 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM08762; probable Male 21201133 CVCL_5N86 GM08696 finite cell line human CVCL_5N86 CL:0000010 Derived from sampling site: Fetal Achilles tendon. Omics: CNV analysis Male 21201134 CVCL_5N85 GM08618 transformed cell line human CVCL_5N85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201135 CVCL_5N84 GM08403 finite cell line human CVCL_5N84 CL:0000010 Population: African American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201136 CVCL_5N89 GM08778 finite cell line human CVCL_5N89 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201137 CVCL_5N88 GM08763 transformed cell line human CVCL_5N88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201138 CVCL_5N50 GM06936 transformed cell line human CVCL_5N50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201139 CVCL_5N54 GM06979 finite cell line human CVCL_5N54 CL:0000010 Population: Caucasian; Karyotypic information: 92,XXYY.arr(1-22)x2,(XY)x1 (Coriell); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201140 CVCL_5N53 GM06960 finite cell line human CVCL_5N53 CL:0000010 Population: African American; Karyotypic information: 46,X,i(X)(q22) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201141 CVCL_5N52 GM06938 finite cell line human CVCL_5N52 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male 21201142 CVCL_5N51 GM06937 finite cell line human CVCL_5N51 CL:0000010 Population: Caucasian; Karyotypic information: 46,XX,del(10)(p13->qter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21201143 CVCL_5N58 GM07212 finite cell line human CVCL_5N58 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM07212; probable Female 21201144 CVCL_5N57 GM07156 transformed cell line human CVCL_5N57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201145 CVCL_5N56 GM07148 finite cell line human CVCL_5N56 CL:0000010 Population: Native North American; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201146 CVCL_5N55 GM07106 finite cell line human CVCL_5N55 CL:0000010 Derived from sampling site: Chorionic villus. Omics: CNV analysis Male 21201147 CVCL_5N49 GM06918 finite cell line human CVCL_5N49 CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: CNV analysis Male 21201148 CVCL_5N48 GM06871 finite cell line human CVCL_5N48 CL:0000010 Karyotypic information: 47,XX,+i(18)(pter->p10::p10->pter) (Coriell); Derived from sampling site: Cell type=Fibroblast. Female 21201149 CVCL_Y589 CHCC-OU2 transformed cell line CVCL_Y589 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12302 21201150 CVCL_XT89 HAP1 SSBP4 (-) 3 cancer cell line human CVCL_XT89 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15676; SSBP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201151 CVCL_5N61 GM07408 finite cell line human CVCL_5N61 CL:0000010 Derived from sampling site: Chorionic villus. Omics: CNV analysis Female 21201152 CVCL_5N60 GM07323 transformed cell line human CVCL_5N60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201153 CVCL_5N65 GM07448 transformed cell line human CVCL_5N65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201154 CVCL_5N64 GM07446 transformed cell line human CVCL_5N64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201155 CVCL_5N63 GM07427 transformed cell line human CVCL_5N63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201156 CVCL_5N62 GM07412 finite cell line human CVCL_5N62 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Male 21201157 CVCL_5N69 GM07773 transformed cell line human CVCL_5N69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201158 CVCL_5N68 GM07736 transformed cell line human CVCL_5N68 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201159 CVCL_5N67 GM07692 transformed cell line human CVCL_5N67 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex1-18del; Zygosity=Heterozygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Genetic Testing Reference Material (GeT-RM) samples 21201160 CVCL_5N66 GM07691 transformed cell line human CVCL_5N66 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex1-18del; Zygosity=Hemizygous (PubMed=21354051) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21201161 CVCL_5N59 GM07216 finite cell line human CVCL_5N59 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201162 CVCL_XT91 HAP1 STAT2 (-) 3 cancer cell line human CVCL_XT91 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201163 CVCL_Y591 MDV OU2.1 transformed cell line CVCL_Y591 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Infected with Marek's disease virus (MDV) Group: Bird cell line 21201164 CVCL_XT90 HAP1 STAT2 (-) 2 cancer cell line human CVCL_XT90 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11363; STAT2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201165 CVCL_Y590 MDV OU2.2 transformed cell line CVCL_Y590 CL:0000010 Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from sampling site: Cell type=Fibroblast. Unspecified Virology: Infected with Marek's disease virus (MDV) Group: Bird cell line; Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-11985 21201166 CVCL_XT95 HAP1 STIM1 (-) 3 cancer cell line human CVCL_XT95 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11386; STIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201167 CVCL_Y595 HD129 embryonic stem cell human CVCL_Y595 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE08-005-L1. 21201168 CVCL_Y594 CL04 embryonic stem cell human CVCL_Y594 From: Universite Paris-Sud 11; Paris; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE10-151-L1. 21201169 CVCL_XT94 HAP1 STIM1 (-) 2 cancer cell line human CVCL_XT94 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11386; STIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201170 CVCL_XT93 HAP1 STIM1 (-) 1 cancer cell line human CVCL_XT93 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11386; STIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201171 CVCL_Y593 PB13 induced pluripotent stem cell human CVCL_Y593 From: Universite Paris-Sud 11; Paris; France CL:0000010 Derived from sampling site: Peripheral blood Cell type=Endothelial progenitor cell.. 21201172 CVCL_XT92 HAP1 STAT6 (-) 2 cancer cell line human CVCL_XT92 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11368; STAT6; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201173 CVCL_Y592 SOgE cancer cell line CVCL_Y592 CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Derived from sampling site: Muscle. Unspecified Group: Bird cell line; Group: Vaccine production cell line 21201174 CVCL_XT99 HAP1 STK33 (-) 2 cancer cell line human CVCL_XT99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14568; STK33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201175 CVCL_Y599 STR-I-437-NF1 embryonic stem cell human CVCL_Y599 From: INSERM; Paris; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE09-313-L1. 21201176 CVCL_XT98 HAP1 STK33 (-) 1 cancer cell line human CVCL_XT98 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14568; STK33; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201177 CVCL_Y598 HD83 embryonic stem cell human CVCL_Y598 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE07-135-L1. 21201178 CVCL_XT97 HAP1 STIP1 (-) 2 cancer cell line human CVCL_XT97 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11387; STIP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201179 CVCL_Y597 HD291 embryonic stem cell human CVCL_Y597 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Male Registration: French Agence de la Biomedecine; FE10-0162-L1. 21201180 CVCL_XT96 HAP1 STIM1 (-) 4 cancer cell line human CVCL_XT96 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11386; STIM1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201181 CVCL_Y596 HD287 embryonic stem cell human CVCL_Y596 From: University Hospital of Montpellier; Montpellier; France CL:0000010 Female Registration: French Agence de la Biomedecine; FE10-0158-L1. 21201182 CVCL_XT79 HAP1 SPP1 (-) 2 cancer cell line human CVCL_XT79 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201183 CVCL_Y579 YN cancer cell line human CVCL_Y579 CL:0000010 Population: Japanese Male Doubling time: 36.2 hours (at 8th passage), 21.6 hours (at 47th passage) (PubMed=3541491). 21201184 CVCL_XT78 HAP1 SPOP (-) cancer cell line human CVCL_XT78 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11254; SPOP; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201185 CVCL_Y578 VK [Human embryonal rhabdomyosarcoma] cancer cell line human CVCL_Y578 CL:0000010 Female Doubling time: 38 hours (PubMed=1322234). 21201186 CVCL_5N32 GM05264 finite cell line human CVCL_5N32 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln2632Serfs*6 (c.7893delC); Zygosity=Heterozygous (from familial inference of GM05263) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Female 21201187 CVCL_5N31 GM05263 finite cell line human CVCL_5N31 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gln2632Serfs*6 (c.7893delC); Zygosity=Hemizygous (PubMed=21354051) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: CNV analysis Male Part of: Genetic Testing Reference Material (GeT-RM) samples 21201188 CVCL_5N30 GM05174 transformed cell line human CVCL_5N30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201189 CVCL_5N36 GM05880 finite cell line human CVCL_5N36 CL:0000010 Population: Iraqi; Derived from sampling site: Cell type=Fibroblast. Female 21201190 CVCL_5N35 GM05835 finite cell line human CVCL_5N35 CL:0000010 Karyotypic information: 46,X,t(X;5)(p21.2;q35.3) (PubMed=10377420); Derived from sampling site: Cell type=Fibroblast. Female 21201191 CVCL_5N34 GM05753 finite cell line human CVCL_5N34 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Discontinued: Coriell; GM05753; probable Male 21201192 CVCL_5N33 GM05518 transformed cell line human CVCL_5N33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201193 CVCL_5N29 GM05173 finite cell line human CVCL_5N29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21201194 CVCL_5N28 GM05172 transformed cell line human CVCL_5N28 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21201195 CVCL_5N27 GM05171 finite cell line human CVCL_5N27 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201196 CVCL_5N26 GM05162 finite cell line human CVCL_5N26 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex46-50del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 21201197 CVCL_Y580 CB-NJR cancer cell line human CVCL_Y580 From: Reynolds C.P.; Children's Hospital of Los Angeles; Los Angeles; USA. CL:0000010 Unspecified 21201198 CVCL_XT80 HAP1 SPP1 (-) 3 cancer cell line human CVCL_XT80 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11255; SPP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201199 CVCL_XT84 HAP1 SPTLC2 (-) 2 cancer cell line human CVCL_XT84 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11278; SPTLC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201200 CVCL_Y584 Rh28/L-PAM cancer cell line human CVCL_Y584 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.237_238CC>TT) (c.237_238delinsTT) (p.Pro94Leu, c.280_281CC>TT); Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28876; Melphalan (L-phenylalanine mustard; Derived from metastatic site: Axillary lymph node. Male 21201201 CVCL_XT83 HAP1 SPRYD4 (-) 4 cancer cell line human CVCL_XT83 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27468; SPRYD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201202 CVCL_Y583 Rh7 cancer cell line human CVCL_Y583 CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (PubMed=8275086). Unspecified 21201203 CVCL_XT82 HAP1 SPRYD4 (-) 3 cancer cell line human CVCL_XT82 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27468; SPRYD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201204 CVCL_Y582 HS-RMS-2 cancer cell line human CVCL_Y582 CL:0000010 Population: Japanese; Derived from sampling site: Left gluteal muscle. Female 21201205 CVCL_XT81 HAP1 SPRYD4 (-) 2 cancer cell line human CVCL_XT81 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 27468; SPRYD4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201206 CVCL_Y581 UISO-RS-3 cancer cell line human CVCL_Y581 CL:0000010 Derived from metastatic site: Pleural effusion. Female Doubling time: 1.5-2 days, depending on growth conditions (PubMed=2243060) 21201207 CVCL_Y588 Garvin-1 cancer cell line human CVCL_Y588 CL:0000010 Miscellaneous: Cell line name is not official Was assigned by PubMed=23665679. Derived from sampling site: Pleural effusion. Female 21201208 CVCL_XT88 HAP1 SSBP4 (-) 2 cancer cell line human CVCL_XT88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15676; SSBP4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201209 CVCL_XT87 HAP1 SRXN1 (-) 3 cancer cell line human CVCL_XT87 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16132; SRXN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201210 CVCL_Y587 NOL-3 cancer cell line human CVCL_Y587 CL:0000010 Population: Japanese; Derived from sampling site: Pleural effusion. Female 21201211 CVCL_XT86 HAP1 SRXN1 (-) 2 cancer cell line human CVCL_XT86 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16132; SRXN1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201212 CVCL_Y586 RhRKM-T4 cancer cell line human CVCL_Y586 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified Characteristics: Established from parent cell line after a passage in the peritoneal cavity of an athymic nude mouse 21201213 CVCL_XT85 HAP1 SPTLC2 (-) 3 cancer cell line human CVCL_XT85 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11278; SPTLC2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201214 CVCL_Y585 RhRKM-P4 cancer cell line human CVCL_Y585 CL:0000010 Derived from sampling site: Pleural effusion. Unspecified 21201215 CVCL_XT69 HAP1 SPAG9 (-) cancer cell line human CVCL_XT69 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14524; SPAG9; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201216 CVCL_Y569 SG3 spontaneously immortalized cell line CVCL_Y569 CL:0000010 Derived from sampling site: Testis Cell type=Spermatogonium.; Breed/subspecies: Albino strain i3. Male Group: Fish cell line 21201217 CVCL_XT68 HAP1 SORD (-) 2 cancer cell line human CVCL_XT68 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11184; SORD; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201218 CVCL_Y568 SaBE-1c embryonic stem cell CVCL_Y568 CL:0000010 Unspecified Group: Fish cell line. 21201219 CVCL_XT67 GAL-FR23 hybridoma house mouse CVCL_XT67 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P21802; Human FGFR2/CD332 (isoform IgIIIb/K-sam-II). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-9408 21201220 CVCL_Y567 SaBE-1 embryonic stem cell CVCL_Y567 CL:0000010 Unspecified Group: Fish cell line. 21201221 CVCL_5N43 GM06473 finite cell line human CVCL_5N43 CL:0000010 Population: Hispanic; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201222 CVCL_5N42 GM06312 finite cell line human CVCL_5N42 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: CNV analysis Male 21201223 CVCL_5N41 GM06230 finite cell line human CVCL_5N41 CL:0000010 Population: Asian; Derived from sampling site: Cell type=Fibroblast. Omics: CNV analysis Female 21201224 CVCL_5N40 GM06007 transformed cell line human CVCL_5N40 CL:0000010 Karyotypic information: 46,X,t(X;9)(Xqter->Xp21.2::9p22->9pter;9qter->9p22::Xp21.2->Xpter) (Coriell); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201225 CVCL_5N47 GM06870 transformed cell line human CVCL_5N47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201226 CVCL_5N46 GM06803 transformed cell line human CVCL_5N46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201227 CVCL_5N45 GM06802 transformed cell line human CVCL_5N45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201228 CVCL_5N44 GM06801 transformed cell line human CVCL_5N44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201229 CVCL_5N39 GM05913 transformed cell line human CVCL_5N39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Male 21201230 CVCL_5N38 GM05912 transformed cell line human CVCL_5N38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21201231 CVCL_5N37 GM05881 transformed cell line human CVCL_5N37 CL:0000010 Population: Iraqi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CNV analysis Female 21201232 CVCL_Y573 GM06324 finite cell line human CVCL_Y573 CL:0000010 Population: Caucasian; Portuguese; Derived from sampling site: Cell type=Fibroblast. Male 21201233 CVCL_XT73 HAP1 SPATA20 (-) 4 cancer cell line human CVCL_XT73 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26125; SPATA20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201234 CVCL_XT72 HAP1 SPATA20 (-) 3 cancer cell line human CVCL_XT72 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26125; SPATA20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201235 CVCL_Y572 HUES 74 embryonic stem cell human CVCL_Y572 From: Harvard University; Boston; USA CL:0000010 Omics: Deep exome analysis; Omics: SNP array analysis. Male Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-15-0304 21201236 CVCL_XT71 HAP1 SPATA20 (-) 2 cancer cell line human CVCL_XT71 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26125; SPATA20; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201237 CVCL_Y571 S4 [Mouse spermatogonia] telomerase immortalized cell line house mouse CVCL_Y571 CL:0000010 Transfected with: MGI; MGI:1202709; Tert Derived from sampling site: Testis Cell type=Spermatogonium.; Breed/subspecies: BALB/c. Male 21201238 CVCL_XT70 HAP1 SPARC (-) 2 cancer cell line human CVCL_XT70 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11219; SPARC; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201239 CVCL_Y570 TB2 spontaneously immortalized cell line CVCL_Y570 CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 21201240 CVCL_XT77 HAP1 SPNS1 (-) 5 cancer cell line human CVCL_XT77 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30621; SPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201241 CVCL_Y577 RMS-GR cancer cell line human CVCL_Y577 CL:0000010 Male Doubling time: ~42 hours (PubMed=9685856). 21201242 CVCL_Y576 GM11530 finite cell line human CVCL_Y576 CL:0000010 Population: Hispanic; Derived from sampling site: Lung Cell type=Fibroblast.. Male 21201243 CVCL_XT76 HAP1 SPNS1 (-) 4 cancer cell line human CVCL_XT76 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30621; SPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201244 CVCL_Y575 GM11529 finite cell line human CVCL_Y575 CL:0000010 Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21201245 CVCL_XT75 HAP1 SPNS1 (-) 3 cancer cell line human CVCL_XT75 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30621; SPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21201246 CVCL_Y574 GM09154 finite cell line human CVCL_Y574 CL:0000010 Population: Hispanic; Derived from sampling site: Lung Cell type=Fibroblast.. Female 21201247 CVCL_XT74 HAP1 SPNS1 (-) 2 cancer cell line human CVCL_XT74 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30621; SPNS1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 21408597 CVCL_YJ30 CIPGC conditionally immortalized cell line pig CVCL_YJ30 CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Characteristics: Transfected with a P-TR3G-SV40largeT-T2A-mCherry-PhPGK-Pac-T2A-rTer-VP16 construct The expression of the SV40 largeT antigen is under the control of the Tet-On system and induced by doxycycline. 21408598 CVCL_YP93 BC-034 cancer cell line human CVCL_YP93 CL:0000010 Population: Chinese; Derived from sampling site: Breast. Female Doubling time: 33 hours, at 27th passage (PubMed=30662642) 21408599 CVCL_YP94 NH50214 induced pluripotent stem cell human CVCL_YP94 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly298Ser (c.892G>A); ClinVar=VCV000005232; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408600 CVCL_YP95 NH50215 induced pluripotent stem cell human CVCL_YP95 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly298Ser (c.892G>A); ClinVar=VCV000005232; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408601 CVCL_YP96 NH50216 induced pluripotent stem cell human CVCL_YP96 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Gly298Ser (c.892G>A); ClinVar=VCV000005232; Zygosity=Heterozygous (PubMed=22952635) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408602 CVCL_YP90 KURATOU cancer cell line human CVCL_YP90 CL:0000010 Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: ~10 days (PubMed=2584814) 21408603 CVCL_YP91 GM16733 finite cell line human CVCL_YP91 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM16733; probable Female 21408604 CVCL_YP92 GM16735 finite cell line human CVCL_YP92 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; GM16735; probable Male 21408605 CVCL_YP97 NH50217 induced pluripotent stem cell human CVCL_YP97 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408606 CVCL_YP98 NH50218 induced pluripotent stem cell human CVCL_YP98 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408607 CVCL_YP99 NH50219 induced pluripotent stem cell human CVCL_YP99 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408608 CVCL_YP82 NH50205 finite cell line human CVCL_YP82 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408609 CVCL_YP83 NH50206 finite cell line human CVCL_YP83 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408610 CVCL_YP84 NH50207 finite cell line human CVCL_YP84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408611 CVCL_YP85 NH50208 finite cell line human CVCL_YP85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408612 CVCL_YP80 NH50203 finite cell line human CVCL_YP80 CL:0000010 Population: African American; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408613 CVCL_YP81 NH50204 finite cell line human CVCL_YP81 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408614 CVCL_YP86 NH50209 finite cell line human CVCL_YP86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408615 CVCL_YP87 NH50211 induced pluripotent stem cell human CVCL_YP87 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Gly (c.1561C>G); ClinVar=VCV000016222; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408616 CVCL_YP88 NH50212 induced pluripotent stem cell human CVCL_YP88 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Gly (c.1561C>G); ClinVar=VCV000016222; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408617 CVCL_YP89 NH50213 induced pluripotent stem cell human CVCL_YP89 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Arg521Gly (c.1561C>G); ClinVar=VCV000016222; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408618 CVCL_YP71 GM26259 transformed cell line human CVCL_YP71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408619 CVCL_YP72 GM26260 transformed cell line human CVCL_YP72 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Trp5754Ter (c.17262G>A) (p.Trp4053Ter, c.12159G>A); ClinVar=VCV000373081; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Tyr8107Asnfs*74 (c.24318_24319insAA); ClinVar=VCV000422612; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21408620 CVCL_YP73 GM26261 finite cell line human CVCL_YP73 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Trp5754Ter (c.17262G>A) (p.Trp4053Ter, c.12159G>A); ClinVar=VCV000373081; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Tyr8107Asnfs*74 (c.24318_24319insAA); ClinVar=VCV000422612; Zygosity=Heterozygous (Coriell) Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 21408621 CVCL_YP74 GM26263 transformed cell line human CVCL_YP74 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Trp5754Ter (c.17262G>A) (p.Trp4053Ter, c.12159G>A); ClinVar=VCV000373081; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21408622 CVCL_YP70 GM26258 transformed cell line human CVCL_YP70 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg576Ter (c.1726C>T) (p.Arg572Ter, c.1714C>T); ClinVar=VCV000488988; Zygosity=Unspecified (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408623 CVCL_YP79 NH50202 finite cell line human CVCL_YP79 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408624 CVCL_YP75 NH50210 induced pluripotent stem cell human CVCL_YP75 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21408625 CVCL_YP76 NH50286 induced pluripotent stem cell human CVCL_YP76 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408626 CVCL_YP77 NH50200 finite cell line human CVCL_YP77 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408627 CVCL_YP78 NH50201 finite cell line human CVCL_YP78 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408628 CVCL_YP60 WG0544 finite cell line human CVCL_YP60 From: Montreal Children's Hospital cell repository; Montreal; Canada CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin Cell type=Fibroblast.. 21408629 CVCL_YP61 CS58iMCT8 induced pluripotent stem cell human CVCL_YP61 CL:0000010 Sequence variation: Mutation; HGNC; 10923; SLC16A2; Simple; p.Ala330fs*12; Zygosity=Hemizygous (PubMed=28526555) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408630 CVCL_YP62 CS01iMCT8 induced pluripotent stem cell human CVCL_YP62 CL:0000010 Sequence variation: Mutation; HGNC; 10923; SLC16A2; Simple; p.Pro247Leu (c.740C>T); Zygosity=Hemizygous (PubMed=28526555) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408631 CVCL_YP63 CS01iMCT8cor induced pluripotent stem cell human CVCL_YP63 CL:0000010 Sequence variation: Mutation; HGNC; 10923; SLC16A2; Simple_corrected; p.Pro247Leu (c.740C>T); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=28526555) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408632 CVCL_YP68 GM26201 transformed cell line human CVCL_YP68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408633 CVCL_YP69 GM26234 transformed cell line human CVCL_YP69 CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Phe354Ile (c.1060T>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408634 CVCL_YP64 CS03iCTR induced pluripotent stem cell human CVCL_YP64 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408635 CVCL_YP65 CS03iCTRmut induced pluripotent stem cell human CVCL_YP65 CL:0000010 Sequence variation: Mutation; HGNC; 10923; SLC16A2; Simple_edited; p.Pro247Leu (c.740C>T); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=28526555) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408636 CVCL_YP66 GM26087 transformed cell line human CVCL_YP66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21408637 CVCL_YP67 GM26188 transformed cell line human CVCL_YP67 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408638 CVCL_YP50 PJS22JTO finite cell line human CVCL_YP50 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408639 CVCL_YP51 PJS23JTO finite cell line human CVCL_YP51 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408640 CVCL_YP52 PJS5JTO hTERT-1 telomerase immortalized cell line human CVCL_YP52 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408641 CVCL_YP57 MK-6 finite cell line human CVCL_YP57 CL:0000010 Unspecified 21408642 CVCL_YP58 MK-7 finite cell line human CVCL_YP58 CL:0000010 Unspecified 21408643 CVCL_YP59 MK-8 finite cell line human CVCL_YP59 CL:0000010 Karyotypic information: 46,XY,mar+ (JCRB). Male 21408644 CVCL_YP53 PJS5JTO hTERT-2 telomerase immortalized cell line human CVCL_YP53 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408645 CVCL_YP54 MK-43 finite cell line human CVCL_YP54 CL:0000010 Population: Japanese; Karyotypic information: 46,XY,t(14;18)(q11.2;p11.31)mat (JCRB); Derived from sampling site: Amniotic fluid. Female 21408646 CVCL_YP55 MK-3 finite cell line human CVCL_YP55 CL:0000010 Population: Japanese. Female 21408647 CVCL_YP56 MK-5 finite cell line human CVCL_YP56 CL:0000010 Population: Japanese. Female 21408648 CVCL_YP39 NH50195 finite cell line human CVCL_YP39 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408649 CVCL_YP40 NH50194 finite cell line human CVCL_YP40 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408650 CVCL_YP41 NH50193 finite cell line human CVCL_YP41 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408651 CVCL_YP46 PJS2JTO finite cell line human CVCL_YP46 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408652 CVCL_YP47 PJS7JTO finite cell line human CVCL_YP47 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21408653 CVCL_YP48 PJS8JTO finite cell line human CVCL_YP48 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408654 CVCL_YP49 PJS21JTO finite cell line human CVCL_YP49 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408655 CVCL_YP42 NH50192 induced pluripotent stem cell human CVCL_YP42 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408656 CVCL_YP43 NH50256 induced pluripotent stem cell human CVCL_YP43 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[1150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408657 CVCL_YP44 NH50257 induced pluripotent stem cell human CVCL_YP44 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[1150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408658 CVCL_YP45 NH50259 induced pluripotent stem cell human CVCL_YP45 CL:0000010 Sequence variation: Mutation; HGNC; 2933; DMPK; Repeat_expansion; c.*224CTG[1150] (c.*224CTG[(51_?)]); ClinVar=VCV000005049; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408659 CVCL_YP28 iPS MS3 induced pluripotent stem cell human CVCL_YP28 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=18511599) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408660 CVCL_YP29 iPS ZK1 induced pluripotent stem cell human CVCL_YP29 CL:0000010 Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 21408661 CVCL_YP30 GM03667 transformed cell line human CVCL_YP30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03667; probable Male 21408662 CVCL_YP35 NH50199 finite cell line human CVCL_YP35 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408663 CVCL_YP36 NH50198 finite cell line human CVCL_YP36 CL:0000010 Sequence variation: Mutation; HGNC; 9438; PRKRA; Simple; p.Cys213Arg (c.637T>C); ClinVar=VCV000689778; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 9438; PRKRA; Simple; p.Pro222Leu (c.665C>T); ClinVar=VCV000006346; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408664 CVCL_YP37 NH50197 finite cell line human CVCL_YP37 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with autosomal dominant torsion dystonia 1 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408665 CVCL_YP38 NH50196 finite cell line human CVCL_YP38 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408666 CVCL_YP31 GM24528 transformed cell line human CVCL_YP31 CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Arg2578Ter (c.7732C>T); ClinVar=VCV000014296; Zygosity=Unspecified (Coriell) Population: Caucasian; Macedonian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21408667 CVCL_YP32 GM10595 transformed cell line human CVCL_YP32 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM10595; probable Male 21408668 CVCL_YP33 HL-60/5FU cancer cell line human CVCL_YP33 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Peripheral blood. Female 21408669 CVCL_YP34 H58 cancer cell line human CVCL_YP34 CL:0000010 Sequence variation: Gene fusion; HGNC; 22170; BCAR4 + HGNC; 30959; ZC3H7A; Name(s)=ZC3H7A-BCAR4 (PubMed=32005909); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1175Ter (c.3523C>T); ClinVar=VCV000537459; Zygosity=Unspecified (PubMed=32005909); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (PubMed=32005909); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Unspecified (PubMed=32005909) Omics: Deep exome analysis; Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq. Male Doubling time: 36 hours (PubMed=32005909) 21408670 CVCL_YP17 JTUi002-A induced pluripotent stem cell human CVCL_YP17 From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Heterozygous (PubMed=32199281); Sequence variation: Mutation; HGNC; 11190; SOX10; Simple; p.Tyr313Argfs*85 (c.937_947delTACTCAGCAGGC); Zygosity=Heterozygous (PubMed=32199281) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408671 CVCL_YP18 ARSA-/- immortalized MSC transformed cell line human CVCL_YP18 CL:0000010 Sequence variation: Mutation; HGNC; 713; ARSA; Simple; p.Arg246His (c.737G>A) (p.Arg244His, c.731G>A); ClinVar=VCV000068148; Zygosity=Heterozygous (PubMed=28762252); Sequence variation: Mutation; HGNC; 713; ARSA; Simple; p.Glu309Lys (c.925G>A) (p.Glu307Lys, c.919G>A); ClinVar=VCV000068162; Zygosity=Heterozygous (PubMed=28762252); Transfected with: UniProtKB; Q66PV6; CFP Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Unspecified 21408673 CVCL_YP24 XP15CA finite cell line human CVCL_YP24 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG04317; probable 21408674 CVCL_YP25 XP16CA finite cell line human CVCL_YP25 CL:0000010 Population: Egyptian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG04318; probable 21408675 CVCL_YP26 iPS MS1 induced pluripotent stem cell human CVCL_YP26 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=18511599) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408676 CVCL_YP27 iPS MS2 induced pluripotent stem cell human CVCL_YP27 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (PubMed=18511599) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408678 CVCL_YP21 NPM1 transformed cell line naked mole-rat CVCL_YP21 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Peritoneum Cell type=Peritoneal macrophage.. Unspecified 21408679 CVCL_YP22 PKU-UiPSC 3 induced pluripotent stem cell human CVCL_YP22 From: Key Laboratory for Rare Disease Research of Shandong Province; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21408680 CVCL_YP23 XP9CA finite cell line human CVCL_YP23 CL:0000010 Population: Egyptian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03960; probable 21408681 CVCL_YP06 FAT 2C1 cancer cell line Norway rat CVCL_YP06 CL:0000010 Transformant: Formaldehyde(ChEBI; CHEBI:16842); Derived from sampling site: Nose; nasal cavity; nasal vestibule; Breed/subspecies: Fischer 344. Male Doubling time: 18 hours (PubMed=8148052) 21408682 CVCL_YP07 FAT 3 cancer cell line Norway rat CVCL_YP07 CL:0000010 Sequence variation: Mutation; RGD; 3889; Tp53; Simple; p.Phe132Leu (c.396C>A); Zygosity=Unspecified (PubMed=8148052) Transformant: Formaldehyde(ChEBI; CHEBI:16842); Derived from sampling site: Nose; nasal cavity; nasal vestibule; Breed/subspecies: Fischer 344. Male Doubling time: 23 hours (PubMed=8148052) 21408683 CVCL_YP08 FAT 8 cancer cell line Norway rat CVCL_YP08 CL:0000010 Transformant: Formaldehyde(ChEBI; CHEBI:16842); Derived from sampling site: Nose; nasal cavity; nasal vestibule; Breed/subspecies: Fischer 344. Male Doubling time: 20 hours (PubMed=8148052) 21408684 CVCL_YP09 8C9E8 hybridoma house mouse CVCL_YP09 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. 21408685 CVCL_YP13 PDXPC1 cancer cell line human CVCL_YP13 CL:0000010 Sequence variation: Mutation; HGNC; 4392; GNAS; Simple; p.His69Asn (c.205C>A); Zygosity=Heterozygous (PubMed=32124956); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous (PubMed=32124956); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=32124956) Population: Chinese; Derived from sampling site: Pancreas. Omics: Deep exome analysis Female Characteristics: Established from a 3rd generation xenograft obtained by subcutaneously implantation into female BALB/c nude mice of the parent tumor cells Doubling time: 37.2 hours (PubMed=32124956) 21408686 CVCL_YP14 ZSSYe001-A embryonic stem cell human CVCL_YP14 From: Sun Yat-sen University Third Affiliated Hospital; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2674; DAPK1. Male 21408687 CVCL_YP15 PT [Pig] transformed cell line pig CVCL_YP15 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Oral cavity; palatine tonsil Cell type=Epithelial cell.. Unspecified Virology: Susceptible to infection by Japanese encephalitis virus (JEV) 21408688 CVCL_YP16 JTUi001-A induced pluripotent stem cell human CVCL_YP16 From: Sixth People's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Leu1151Glyfs*17 (c.3449_3450delTC); Zygosity=Heterozygous; Note=De novo mutation (PubMed=32247258) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408689 CVCL_YP10 LEPI spontaneously immortalized cell line human CVCL_YP10 CL:0000010 Derived from sampling site: Eye; retina; retinal pigment epithelium. Male Characteristics: Rapidly forms cobblestone morphology, clear microvilli and tight barrier in simple culture conditions (PubMed=31412689) Doubling time: ~20 hours (PubMed=31412689) 21408690 CVCL_YP11 Caco-2 Cu Pro-R cancer cell line human CVCL_YP11 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:29036; Copper(2+); Derived from sampling site: Colon. Omics: Deep proteome analysis Male 21408691 CVCL_YP12 Caco-2 CuSO4-R cancer cell line human CVCL_YP12 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1367Ter (c.4099C>T); ClinVar=VCV000376060; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly245Ala (c.734G>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp351His (c.1051G>C); ClinVar=VCV000375998; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu204Ter (c.610G>T); ClinVar=VCV000977783; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:23414; Copper(II) sulfate; Derived from sampling site: Colon. Omics: Deep proteome analysis Male 21408692 CVCL_YP02 FBT [Goat] transformed cell line CVCL_YP02 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ear; Breed/subspecies: Nubian. Male Virology: Susceptible to infection by ORFV 21408693 CVCL_YP03 GTT transformed cell line CVCL_YP03 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Testis; Breed/subspecies: Nubian. Male Virology: Susceptible to infection by ORFV 21408694 CVCL_YP04 EL spontaneously immortalized cell line CVCL_YP04 CL:0000010 Derived from sampling site: Liver. Unspecified Characteristics: Grows well from 15 to 32 Celsius, the optimal growth temperature is 27 Celsius Doubling time: 29.64 hours (PubMed=31814207) Group: Fish cell line 21408695 CVCL_YP05 SPC-A-1BM cancer cell line human CVCL_YP05 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Bone metastatic phenotype Obtained after 8 serial passages of the parent cell line by injection into the left cardiac ventricle of NIH-Beige-Nude-XID immunodeficient mice and retrieval of the bone metastatic lesions. Problematic cell line: Contaminated Parent cell line (SPC-A1) has been shown to be a HeLa derivative. 21408696 CVCL_YP00 BGA spontaneously immortalized cell line CVCL_YP00 CL:0000010 Derived from sampling site: Bone; vertebra. Unspecified Virology: Susceptible to infection by redspotted grouper nervous necrosis virus (RGNNV) and striped jack nervous necrosis virus (SJNNV) Group: Fish cell line 21408697 CVCL_YP01 hAKPC-P finite cell line human CVCL_YP01 CL:0000010 Derived from sampling site: Amniotic fluid. Omics: Transcriptome analysis by microarray Male Doubling time: ~28 hours (PubMed=24349133) 21408698 CVCL_YQ92 NUIGi048-C induced pluripotent stem cell human CVCL_YQ92 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408699 CVCL_YQ93 NUIGi049-A induced pluripotent stem cell human CVCL_YQ93 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408700 CVCL_YQ94 NUIGi049-B induced pluripotent stem cell human CVCL_YQ94 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408701 CVCL_YQ95 NUIGi049-C induced pluripotent stem cell human CVCL_YQ95 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408702 CVCL_YQ90 NUIGi048-A induced pluripotent stem cell human CVCL_YQ90 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408703 CVCL_YQ91 NUIGi048-B induced pluripotent stem cell human CVCL_YQ91 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408704 CVCL_YQ96 NUIGi042-A induced pluripotent stem cell human CVCL_YQ96 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408705 CVCL_YQ97 NUIGi042-B induced pluripotent stem cell human CVCL_YQ97 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408706 CVCL_YQ98 NUIGi041-A induced pluripotent stem cell human CVCL_YQ98 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=33578364) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408707 CVCL_YQ99 NUIGi041-B induced pluripotent stem cell human CVCL_YQ99 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 8008; NRXN1; Unexplicit; Ex1-5del; Zygosity=Heterozygous (PubMed=33578364) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408708 CVCL_YQ81 NUIGi051-A induced pluripotent stem cell human CVCL_YQ81 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408709 CVCL_YQ82 NUIGi051-B induced pluripotent stem cell human CVCL_YQ82 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408710 CVCL_YQ83 NUIGi051-C induced pluripotent stem cell human CVCL_YQ83 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408711 CVCL_YQ84 NUIGi046-A induced pluripotent stem cell human CVCL_YQ84 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408712 CVCL_YQ80 NUIGi050-C induced pluripotent stem cell human CVCL_YQ80 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408713 CVCL_YQ89 NUIGi047-C induced pluripotent stem cell human CVCL_YQ89 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408714 CVCL_YQ85 NUIGi046-B induced pluripotent stem cell human CVCL_YQ85 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408715 CVCL_YQ86 NUIGi046-C induced pluripotent stem cell human CVCL_YQ86 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408716 CVCL_YQ87 NUIGi047-A induced pluripotent stem cell human CVCL_YQ87 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408717 CVCL_YQ88 NUIGi047-B induced pluripotent stem cell human CVCL_YQ88 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408718 CVCL_YQ70 HPS1359 induced pluripotent stem cell human CVCL_YQ70 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408719 CVCL_YQ71 HPS1360 induced pluripotent stem cell human CVCL_YQ71 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408720 CVCL_YQ72 CS4PV finite cell line human CVCL_YQ72 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asn75Glnfs*9 (c.223_227del); ClinVar=VCV001455112; Zygosity=Homozygous (PubMed=29572252) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408721 CVCL_YQ73 CS6PV finite cell line human CVCL_YQ73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408722 CVCL_YQ78 NUIGi050-A induced pluripotent stem cell human CVCL_YQ78 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408723 CVCL_YQ79 NUIGi050-B induced pluripotent stem cell human CVCL_YQ79 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408724 CVCL_YQ74 CS7PV finite cell line human CVCL_YQ74 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; c.719-1G>A; dbSNP=rs1239745117; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=29572252) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408725 CVCL_YQ75 NUIGi052-A induced pluripotent stem cell human CVCL_YQ75 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Leu290Arg (c.869T>G); ClinVar=VCV000985630; Zygosity=Heterozygous (PubMed=32540721) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408726 CVCL_YQ76 NUIGi052-B induced pluripotent stem cell human CVCL_YQ76 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Leu290Arg (c.869T>G); ClinVar=VCV000985630; Zygosity=Heterozygous (PubMed=32540721) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408727 CVCL_YQ77 NUIGi052-C induced pluripotent stem cell human CVCL_YQ77 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Leu290Arg (c.869T>G); ClinVar=VCV000985630; Zygosity=Heterozygous (PubMed=32540721) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21408728 CVCL_YQ60 HPS1347 induced pluripotent stem cell human CVCL_YQ60 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408729 CVCL_YQ61 HPS1348 induced pluripotent stem cell human CVCL_YQ61 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408730 CVCL_YQ62 HPS1350 induced pluripotent stem cell human CVCL_YQ62 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408731 CVCL_YQ67 HPS1356 induced pluripotent stem cell human CVCL_YQ67 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408732 CVCL_YQ68 HPS1357 induced pluripotent stem cell human CVCL_YQ68 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408733 CVCL_YQ69 HPS1358 induced pluripotent stem cell human CVCL_YQ69 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408734 CVCL_YQ63 HPS1351 induced pluripotent stem cell human CVCL_YQ63 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408735 CVCL_YQ64 HPS1352 induced pluripotent stem cell human CVCL_YQ64 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408736 CVCL_YQ65 HPS1353 induced pluripotent stem cell human CVCL_YQ65 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408737 CVCL_YQ66 HPS1354 induced pluripotent stem cell human CVCL_YQ66 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408738 CVCL_YQ49 VeroE6/TMPRSS2 spontaneously immortalized cell line green monkey CVCL_YQ49 CL:0000010 Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Virology: Highly susceptible to infection by Middle East respiratory syndrome-related coronavirus (MERS-CoV), SARS coronavirus (SARS-CoV) and SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=32165541) Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 21408739 CVCL_YQ50 HPS1392 induced pluripotent stem cell human CVCL_YQ50 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408740 CVCL_YQ51 HPS1393 induced pluripotent stem cell human CVCL_YQ51 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408741 CVCL_YQ56 HPS1429 induced pluripotent stem cell human CVCL_YQ56 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408742 CVCL_YQ57 HPS1344 induced pluripotent stem cell human CVCL_YQ57 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408743 CVCL_YQ58 HPS1345 induced pluripotent stem cell human CVCL_YQ58 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408744 CVCL_YQ59 HPS1346 induced pluripotent stem cell human CVCL_YQ59 CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex49-50del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 21408745 CVCL_YQ52 HPS1394 induced pluripotent stem cell human CVCL_YQ52 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408746 CVCL_YQ53 HPS1395 induced pluripotent stem cell human CVCL_YQ53 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408747 CVCL_YQ54 HPS1396 induced pluripotent stem cell human CVCL_YQ54 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408748 CVCL_YQ55 HPS1428 induced pluripotent stem cell human CVCL_YQ55 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408749 CVCL_YQ38 NH50247 finite cell line human CVCL_YQ38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408750 CVCL_YQ39 NH50248 finite cell line human CVCL_YQ39 CL:0000010 Population: Caucasian; Scottish and Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408751 CVCL_YQ40 NH50249 finite cell line human CVCL_YQ40 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408752 CVCL_YQ45 NH50254 finite cell line human CVCL_YQ45 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with autosomal dominant torsion dystonia 1 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408753 CVCL_YQ46 NH50255 finite cell line human CVCL_YQ46 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408754 CVCL_YQ47 PEMf finite cell line CVCL_YQ47 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Piedmontese. Male Doubling time: ~24 hours (DOI=10.5897/AJB10.2616) 21408755 CVCL_YQ48 Vero/TMPRSS2 spontaneously immortalized cell line green monkey CVCL_YQ48 CL:0000010 Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 21408756 CVCL_YQ41 NH50250 finite cell line human CVCL_YQ41 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408757 CVCL_YQ42 NH50251 finite cell line human CVCL_YQ42 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408758 CVCL_YQ43 NH50252 finite cell line human CVCL_YQ43 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408759 CVCL_YQ44 NH50253 finite cell line human CVCL_YQ44 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408760 CVCL_YQ27 NH50236 finite cell line human CVCL_YQ27 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408761 CVCL_YQ28 NH50237 finite cell line human CVCL_YQ28 CL:0000010 Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408762 CVCL_YQ29 NH50238 finite cell line human CVCL_YQ29 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408763 CVCL_YQ34 NH50243 finite cell line human CVCL_YQ34 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with autosomal dominant torsion dystonia 1 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408764 CVCL_YQ35 NH50244 finite cell line human CVCL_YQ35 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408765 CVCL_YQ36 NH50245 finite cell line human CVCL_YQ36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408766 CVCL_YQ37 NH50246 finite cell line human CVCL_YQ37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408767 CVCL_YQ30 NH50239 finite cell line human CVCL_YQ30 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408768 CVCL_YQ31 NH50240 finite cell line human CVCL_YQ31 CL:0000010 Population: Southeast Asian; Filipino and Hispanic; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408769 CVCL_YQ32 NH50241 finite cell line human CVCL_YQ32 CL:0000010 Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; SINE-VNTR-Alu (SVA) retrotransposon insertion in intron 32; ClinVar=VCV000009862; Zygosity=Hemizygous (NHCDR); Sequence variation: Mutation; HGNC; 11535; TAF1; Unexplicit; 48-bp intronic deletion; Zygosity=Hemizygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408770 CVCL_YQ33 NH50242 finite cell line human CVCL_YQ33 CL:0000010 Sequence variation: Mutation; HGNC; 3098; TOR1A; Simple; p.Glu303del (c.907_909delGAG); ClinVar=VCV000005180; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408771 CVCL_YQ16 NH50224 finite cell line human CVCL_YQ16 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408772 CVCL_YQ17 NH50225 finite cell line human CVCL_YQ17 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408773 CVCL_YQ18 NH50227 finite cell line human CVCL_YQ18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408774 CVCL_YQ19 NH50228 finite cell line human CVCL_YQ19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408775 CVCL_YQ23 NH50232 induced pluripotent stem cell human CVCL_YQ23 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408776 CVCL_YQ24 NH50233 induced pluripotent stem cell human CVCL_YQ24 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408777 CVCL_YQ25 NH50234 induced pluripotent stem cell human CVCL_YQ25 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg42Pro (c.125G>C); ClinVar=VCV000644125; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex3del; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408778 CVCL_YQ26 NH50235 finite cell line human CVCL_YQ26 CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408779 CVCL_YQ20 NH50229 induced pluripotent stem cell human CVCL_YQ20 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg418Ter (c.1252C>T); ClinVar=VCV000098177; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408780 CVCL_YQ21 NH50230 induced pluripotent stem cell human CVCL_YQ21 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg418Ter (c.1252C>T); ClinVar=VCV000098177; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408781 CVCL_YQ22 NH50231 induced pluripotent stem cell human CVCL_YQ22 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg418Ter (c.1252C>T); ClinVar=VCV000098177; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408782 CVCL_YQ09 VP-6 cancer cell line human CVCL_YQ09 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21408783 CVCL_YQ05 JMW cancer cell line human CVCL_YQ05 CL:0000010 Omics: Transcriptome analysis by RNAseq. 21408784 CVCL_YQ06 LYMM cancer cell line human CVCL_YQ06 CL:0000010 21408785 CVCL_YQ07 MCG cancer cell line human CVCL_YQ07 CL:0000010 21408786 CVCL_YQ08 RM43 cancer cell line human CVCL_YQ08 CL:0000010 21408787 CVCL_YQ12 rSN-150 hybridoma house mouse CVCL_YQ12 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P59595; Human SARS coronavirus (SARS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10145 21408788 CVCL_YQ13 rSN-21-2 hybridoma house mouse CVCL_YQ13 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P59595; Human SARS coronavirus (SARS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10146 21408789 CVCL_YQ14 rSN-29 hybridoma house mouse CVCL_YQ14 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P59595; Human SARS coronavirus (SARS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10147 21408790 CVCL_YQ15 NH50223 finite cell line human CVCL_YQ15 CL:0000010 Population: Pacific; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408791 CVCL_YQ10 rSN-18 hybridoma house mouse CVCL_YQ10 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P59595; Human SARS coronavirus (SARS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10143 21408792 CVCL_YQ11 rSN-122 hybridoma house mouse CVCL_YQ11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P59595; Human SARS coronavirus (SARS-CoV) nucleoprotein (N). Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-10144 21408793 CVCL_YQ01 NH50221 induced pluripotent stem cell human CVCL_YQ01 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408794 CVCL_YQ02 NH50222 induced pluripotent stem cell human CVCL_YQ02 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408795 CVCL_YQ03 LEMf finite cell line pig CVCL_YQ03 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Landrace. Male Doubling time: ~24 hours (PubMed=20297920) 21408796 CVCL_YQ04 DT-6I cancer cell line human CVCL_YQ04 CL:0000010 21408797 CVCL_YQ00 NH50220 induced pluripotent stem cell human CVCL_YQ00 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21408798 CVCL_YR91 HPS2801 induced pluripotent stem cell human CVCL_YR91 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408799 CVCL_YR92 HPS2802 induced pluripotent stem cell human CVCL_YR92 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408800 CVCL_YR93 HPS2803 induced pluripotent stem cell human CVCL_YR93 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408801 CVCL_YR94 HPS2835 induced pluripotent stem cell human CVCL_YR94 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408802 CVCL_YR90 HPS2800 induced pluripotent stem cell human CVCL_YR90 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408803 CVCL_YR99 HPS2847 induced pluripotent stem cell human CVCL_YR99 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408804 CVCL_YR95 HPS2836 induced pluripotent stem cell human CVCL_YR95 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408805 CVCL_YR96 HPS2837 induced pluripotent stem cell human CVCL_YR96 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408806 CVCL_YR97 HPS2838 induced pluripotent stem cell human CVCL_YR97 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408807 CVCL_YR98 HPS2839 induced pluripotent stem cell human CVCL_YR98 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408808 CVCL_YR80 HPS2100 induced pluripotent stem cell human CVCL_YR80 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408809 CVCL_YR81 HPS2101 induced pluripotent stem cell human CVCL_YR81 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408810 CVCL_YR82 HPS2109 induced pluripotent stem cell human CVCL_YR82 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408811 CVCL_YR83 HPS2110 induced pluripotent stem cell human CVCL_YR83 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408812 CVCL_YR88 HPS2116 induced pluripotent stem cell human CVCL_YR88 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408813 CVCL_YR89 HPS2799 induced pluripotent stem cell human CVCL_YR89 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408814 CVCL_YR84 HPS2111 induced pluripotent stem cell human CVCL_YR84 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408815 CVCL_YR85 HPS2112 induced pluripotent stem cell human CVCL_YR85 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408816 CVCL_YR86 HPS2113 induced pluripotent stem cell human CVCL_YR86 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408817 CVCL_YR87 HPS2115 induced pluripotent stem cell human CVCL_YR87 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408818 CVCL_YR70 HPS2004 induced pluripotent stem cell human CVCL_YR70 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408819 CVCL_YR71 HPS2005 induced pluripotent stem cell human CVCL_YR71 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408820 CVCL_YR72 HPS2085 induced pluripotent stem cell human CVCL_YR72 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408821 CVCL_YR77 HPS2097 induced pluripotent stem cell human CVCL_YR77 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408822 CVCL_YR78 HPS2098 induced pluripotent stem cell human CVCL_YR78 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408823 CVCL_YR79 HPS2099 induced pluripotent stem cell human CVCL_YR79 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408824 CVCL_YR73 HPS2086 induced pluripotent stem cell human CVCL_YR73 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408825 CVCL_YR74 HPS2087 induced pluripotent stem cell human CVCL_YR74 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408826 CVCL_YR75 HPS2088 induced pluripotent stem cell human CVCL_YR75 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408827 CVCL_YR76 HPS2089 induced pluripotent stem cell human CVCL_YR76 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408828 CVCL_YR59 HPS1255 induced pluripotent stem cell human CVCL_YR59 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408829 CVCL_YR60 HPS1256 induced pluripotent stem cell human CVCL_YR60 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408830 CVCL_YR61 HPS1257 induced pluripotent stem cell human CVCL_YR61 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408831 CVCL_YR66 HPS1465 induced pluripotent stem cell human CVCL_YR66 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21408832 CVCL_YR67 HPS2001 induced pluripotent stem cell human CVCL_YR67 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408833 CVCL_YR68 HPS2002 induced pluripotent stem cell human CVCL_YR68 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408834 CVCL_YR69 HPS2003 induced pluripotent stem cell human CVCL_YR69 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 21408835 CVCL_YR62 HPS1461 induced pluripotent stem cell human CVCL_YR62 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21408836 CVCL_YR63 HPS1462 induced pluripotent stem cell human CVCL_YR63 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21408837 CVCL_YR64 HPS1463 induced pluripotent stem cell human CVCL_YR64 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21408838 CVCL_YR65 HPS1464 induced pluripotent stem cell human CVCL_YR65 CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Unexplicit; Not described; Zygosity=Heterozygous (RCB) Derived from sampling site: Peripheral blood. Female 21408839 CVCL_YR50 HPS1718 induced pluripotent stem cell human CVCL_YR50 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408840 CVCL_YR55 HPS1053 induced pluripotent stem cell human CVCL_YR55 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408841 CVCL_YR56 HPS1054 induced pluripotent stem cell human CVCL_YR56 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408842 CVCL_YR57 HPS1253 induced pluripotent stem cell human CVCL_YR57 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408843 CVCL_YR58 HPS1254 induced pluripotent stem cell human CVCL_YR58 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408844 CVCL_YR51 HPS1050 induced pluripotent stem cell human CVCL_YR51 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408845 CVCL_YR52 HPS1051 induced pluripotent stem cell human CVCL_YR52 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408846 CVCL_YR53 HPS1703 induced pluripotent stem cell human CVCL_YR53 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408847 CVCL_YR54 HPS1704 induced pluripotent stem cell human CVCL_YR54 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408848 CVCL_YR37 UUIGPi010-A induced pluripotent stem cell human CVCL_YR37 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden. CL:0000010 21408849 CVCL_YR38 UUIGPi011-A induced pluripotent stem cell human CVCL_YR38 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden. CL:0000010 21408850 CVCL_YR39 HPS0552 induced pluripotent stem cell human CVCL_YR39 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408851 CVCL_YR44 HPS0557 induced pluripotent stem cell human CVCL_YR44 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408852 CVCL_YR45 HPS1047 induced pluripotent stem cell human CVCL_YR45 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408853 CVCL_YR46 HPS1048 induced pluripotent stem cell human CVCL_YR46 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408854 CVCL_YR47 HPS1049 induced pluripotent stem cell human CVCL_YR47 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408855 CVCL_YR40 HPS0553 induced pluripotent stem cell human CVCL_YR40 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408856 CVCL_YR41 HPS0554 induced pluripotent stem cell human CVCL_YR41 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408857 CVCL_YR42 HPS0555 induced pluripotent stem cell human CVCL_YR42 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408858 CVCL_YR43 HPS0556 induced pluripotent stem cell human CVCL_YR43 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408859 CVCL_YR26 UNIPDi004-A induced pluripotent stem cell human CVCL_YR26 From: University of Padova; Padova; Italy CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21408860 CVCL_YR27 UNIPDi004-B induced pluripotent stem cell human CVCL_YR27 From: University of Padova; Padova; Italy CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 21408861 CVCL_YR28 UNEWi007-A induced pluripotent stem cell human CVCL_YR28 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21408862 CVCL_YR29 UNEWi008-A induced pluripotent stem cell human CVCL_YR29 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21408863 CVCL_YR33 INMi002-A-1 induced pluripotent stem cell human CVCL_YR33 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple_corrected; p.Glu767Serfs*21 (c.2299delG); ClinVar=VCV000002351; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31909088) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis Female 21408864 CVCL_YR34 CS02iCTR induced pluripotent stem cell human CVCL_YR34 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21408865 CVCL_YR35 ZIPi014-A induced pluripotent stem cell human CVCL_YR35 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany. CL:0000010 21408866 CVCL_YR36 UUIGPi009-A induced pluripotent stem cell human CVCL_YR36 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden. CL:0000010 21408867 CVCL_YR30 UNEWi009-A induced pluripotent stem cell human CVCL_YR30 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21408868 CVCL_YR31 UNEWi010-A induced pluripotent stem cell human CVCL_YR31 From: University of Newcastle; Newcastle; United Kingdom. CL:0000010 21408869 CVCL_YR32 INMi001-A-1 induced pluripotent stem cell human CVCL_YR32 From: Institute for Neurosciences of Montpellier; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple_corrected; p.Cys759Phe (c.2276G>T); ClinVar=VCV000002356; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31909088); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Glu767Serfs*21 (c.2299delG); ClinVar=VCV000002351; Zygosity=Heterozygous (PubMed=30453153) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Deep exome analysis Female 21408870 CVCL_YR19 ZIPi011-A induced pluripotent stem cell human CVCL_YR19 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany. CL:0000010 21408871 CVCL_YR15 QBRIi005-B induced pluripotent stem cell human CVCL_YR15 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408872 CVCL_YR16 QBRIi005-C induced pluripotent stem cell human CVCL_YR16 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408873 CVCL_YR17 SJTUi001-A induced pluripotent stem cell human CVCL_YR17 From: Shanghai Jiao Tong University School of Medicine; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 8980; PIK3R2; Simple; p.Arg89Cys (c.265C>T); ClinVar=VCV001534490; Zygosity=Heterozygous (PubMed=32155459) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21408874 CVCL_YR18 ZIPi010-A induced pluripotent stem cell human CVCL_YR18 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany. CL:0000010 21408875 CVCL_YR22 CRTDi003-B induced pluripotent stem cell human CVCL_YR22 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 21408876 CVCL_YR23 CRTDi004-A induced pluripotent stem cell human CVCL_YR23 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21408877 CVCL_YR24 CRTDi005-A induced pluripotent stem cell human CVCL_YR24 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21408878 CVCL_YR25 CRTDi005-B induced pluripotent stem cell human CVCL_YR25 From: Center for Regenerative Therapies Dresden (CRTD); Dresden; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21408879 CVCL_YR20 ZIPi012-A induced pluripotent stem cell human CVCL_YR20 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany. CL:0000010 21408880 CVCL_YR21 ZIPi001-B induced pluripotent stem cell human CVCL_YR21 From: Zentrum fur Integrative Psychiatrie; Kiel; Germany. CL:0000010 21408881 CVCL_YR08 QBRIi001-A induced pluripotent stem cell human CVCL_YR08 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21408882 CVCL_YR09 QBRIi001-B induced pluripotent stem cell human CVCL_YR09 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21408883 CVCL_YR04 HUSTi002-A induced pluripotent stem cell human CVCL_YR04 From: Huazhong University of Science and Technology Tongji Medicine College; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 17644; PIWIL2; Simple; p.His244Argfs (c.731_732delAT); Zygosity=Homozygous (PubMed=32006804) Population: Chinese; Han; Derived from sampling site: Scrotum; skin Cell type=Fibroblast.. Male 21408884 CVCL_YR05 QBRIi009-A induced pluripotent stem cell human CVCL_YR05 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Gene deletion; HGNC; 5022; FOXA2; Zygosity=Heterozygous (PubMed=31991389) Population: Bengali; Derived from sampling site: Peripheral blood. Male 21408885 CVCL_YR06 QBRIi008-A induced pluripotent stem cell human CVCL_YR06 From: Qatar Biomedical Research Institute; Doha; Quatar. CL:0000010 21408886 CVCL_YR07 QBRIi007-A induced pluripotent stem cell human CVCL_YR07 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 11006; SLC2A2; Simple; c.613-7T>G (IVS5-7T>G); ClinVar=VCV001339449; Zygosity=Homozygous (PubMed=32146263) Derived from sampling site: Peripheral blood. Female 21408887 CVCL_YR11 QBRIi002-A induced pluripotent stem cell human CVCL_YR11 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408888 CVCL_YR12 QBRIi002-B induced pluripotent stem cell human CVCL_YR12 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408889 CVCL_YR13 QBRIi002-C induced pluripotent stem cell human CVCL_YR13 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408890 CVCL_YR14 QBRIi005-A induced pluripotent stem cell human CVCL_YR14 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Female 21408891 CVCL_YR10 QBRIi001-C induced pluripotent stem cell human CVCL_YR10 From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Derived from sampling site: Peripheral blood. Male 21408892 CVCL_YR00 NUIGi040-A induced pluripotent stem cell human CVCL_YR00 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408893 CVCL_YR01 NUIGi040-A-1 induced pluripotent stem cell human CVCL_YR01 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408894 CVCL_YR02 HIHDNDi001-A induced pluripotent stem cell human CVCL_YR02 From: Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala30Pro (c.88G>C); ClinVar=VCV000014008; Zygosity=Heterozygous (PubMed=32798915) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408895 CVCL_YR03 HIHDNDi001-B induced pluripotent stem cell human CVCL_YR03 From: Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala30Pro (c.88G>C); ClinVar=VCV000014008; Zygosity=Heterozygous (PubMed=32798915) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21408896 CVCL_YS07 HPS3040 induced pluripotent stem cell human CVCL_YS07 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408897 CVCL_YS08 HPS3041 induced pluripotent stem cell human CVCL_YS08 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408898 CVCL_YS09 HPS3043 induced pluripotent stem cell human CVCL_YS09 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408899 CVCL_YS03 HPS2851 induced pluripotent stem cell human CVCL_YS03 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408900 CVCL_YS04 HPS3037 induced pluripotent stem cell human CVCL_YS04 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408901 CVCL_YS05 HPS3038 induced pluripotent stem cell human CVCL_YS05 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408902 CVCL_YS06 HPS3039 induced pluripotent stem cell human CVCL_YS06 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408903 CVCL_YS10 HPS3044 induced pluripotent stem cell human CVCL_YS10 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408904 CVCL_YS11 HPS3045 induced pluripotent stem cell human CVCL_YS11 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408905 CVCL_YS12 HPS3046 induced pluripotent stem cell human CVCL_YS12 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408906 CVCL_YS13 HPS3047 induced pluripotent stem cell human CVCL_YS13 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408907 CVCL_YS00 HPS2848 induced pluripotent stem cell human CVCL_YS00 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408908 CVCL_YS01 HPS2849 induced pluripotent stem cell human CVCL_YS01 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408909 CVCL_YS02 HPS2850 induced pluripotent stem cell human CVCL_YS02 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408910 CVCL_YS90 HPS3245 induced pluripotent stem cell human CVCL_YS90 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408911 CVCL_YS91 HPS3246 induced pluripotent stem cell human CVCL_YS91 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408912 CVCL_YS92 HPS3247 induced pluripotent stem cell human CVCL_YS92 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408913 CVCL_YS93 CHL-YN spontaneously immortalized cell line CVCL_YS93 CL:0000010 Derived from sampling site: Lung. Female Doubling time: 8.1 hours (PubMed=33077772) Group: Serum/protein free medium cell line 21408914 CVCL_YS98 HPS3926 induced pluripotent stem cell human CVCL_YS98 CL:0000010 Sequence variation: Mutation; HGNC; 4056; G6PC1; Simple; p.Leu216Leu (c.648G>T); ClinVar=VCV000012003; Zygosity=Homozygous; Note=Produces an aberrant transcript (PubMed=33291009) Population: Japanese; Derived from sampling site: Cell type=Fibroblast. Female 21408915 CVCL_YS99 MGEF finite cell line CVCL_YS99 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.; Breed/subspecies: Matou. Doubling time: ~36 hours (PubMed=19306575) 21408916 CVCL_YS94 CHK-Q spontaneously immortalized cell line CVCL_YS94 CL:0000010 Derived from sampling site: Kidney Cell type=Epithelial cell.. Omics: Transcriptome analysis by microarray Female 21408917 CVCL_YS95 CHO-MK spontaneously immortalized cell line CVCL_YS95 CL:0000010 Derived from sampling site: Ovary Cell type=Epithelial cell.. Female 21408918 CVCL_YS96 UNIPDi005-A induced pluripotent stem cell human CVCL_YS96 From: University of Padova; Padova; Italy CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 21408919 CVCL_YS97 KAISTe001-A embryonic stem cell human CVCL_YS97 From: Korea Advanced Institute of Science and Technology; Daejeon; South Korea. CL:0000010 Female 21408920 CVCL_YS80 HPS2948 induced pluripotent stem cell human CVCL_YS80 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408921 CVCL_YS81 HPS2949 induced pluripotent stem cell human CVCL_YS81 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408922 CVCL_YS82 HPS3001 induced pluripotent stem cell human CVCL_YS82 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408923 CVCL_YS87 HPS3242 induced pluripotent stem cell human CVCL_YS87 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408924 CVCL_YS88 HPS3243 induced pluripotent stem cell human CVCL_YS88 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408925 CVCL_YS89 HPS3244 induced pluripotent stem cell human CVCL_YS89 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408926 CVCL_YS83 HPS3002 induced pluripotent stem cell human CVCL_YS83 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408927 CVCL_YS84 HPS3003 induced pluripotent stem cell human CVCL_YS84 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408928 CVCL_YS85 HPS3004 induced pluripotent stem cell human CVCL_YS85 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408929 CVCL_YS86 HPS3005 induced pluripotent stem cell human CVCL_YS86 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408930 CVCL_YS69 HPS2749 induced pluripotent stem cell human CVCL_YS69 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408931 CVCL_YS70 HPS2804 induced pluripotent stem cell human CVCL_YS70 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408932 CVCL_YS71 HPS2805 induced pluripotent stem cell human CVCL_YS71 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408933 CVCL_YS76 HPS2944 induced pluripotent stem cell human CVCL_YS76 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408934 CVCL_YS77 HPS2945 induced pluripotent stem cell human CVCL_YS77 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408935 CVCL_YS78 HPS2946 induced pluripotent stem cell human CVCL_YS78 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408936 CVCL_YS79 HPS2947 induced pluripotent stem cell human CVCL_YS79 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408937 CVCL_YS72 HPS2806 induced pluripotent stem cell human CVCL_YS72 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408938 CVCL_YS73 HPS2807 induced pluripotent stem cell human CVCL_YS73 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408939 CVCL_YS74 HPS2808 induced pluripotent stem cell human CVCL_YS74 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408940 CVCL_YS75 HPS2809 induced pluripotent stem cell human CVCL_YS75 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408941 CVCL_YS58 HPS2636 induced pluripotent stem cell human CVCL_YS58 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408942 CVCL_YS59 HPS2637 induced pluripotent stem cell human CVCL_YS59 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408943 CVCL_YS60 HPS2638 induced pluripotent stem cell human CVCL_YS60 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408944 CVCL_YS65 HPS2745 induced pluripotent stem cell human CVCL_YS65 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408945 CVCL_YS66 HPS2746 induced pluripotent stem cell human CVCL_YS66 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408946 CVCL_YS67 HPS2747 induced pluripotent stem cell human CVCL_YS67 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408947 CVCL_YS68 HPS2748 induced pluripotent stem cell human CVCL_YS68 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408948 CVCL_YS61 HPS2639 induced pluripotent stem cell human CVCL_YS61 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408949 CVCL_YS62 HPS2640 induced pluripotent stem cell human CVCL_YS62 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408950 CVCL_YS63 HPS2641 induced pluripotent stem cell human CVCL_YS63 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408951 CVCL_YS64 HPS2744 induced pluripotent stem cell human CVCL_YS64 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408952 CVCL_YS47 HPS2192 induced pluripotent stem cell human CVCL_YS47 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408953 CVCL_YS48 HPS2193 induced pluripotent stem cell human CVCL_YS48 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408954 CVCL_YS49 HPS2194 induced pluripotent stem cell human CVCL_YS49 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408955 CVCL_YS54 HPS2297 induced pluripotent stem cell human CVCL_YS54 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408956 CVCL_YS55 HPS2298 induced pluripotent stem cell human CVCL_YS55 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408957 CVCL_YS56 HPS2299 induced pluripotent stem cell human CVCL_YS56 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408958 CVCL_YS57 HPS2300 induced pluripotent stem cell human CVCL_YS57 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408959 CVCL_YS50 HPS2195 induced pluripotent stem cell human CVCL_YS50 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408960 CVCL_YS51 HPS2196 induced pluripotent stem cell human CVCL_YS51 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408961 CVCL_YS52 HPS2197 induced pluripotent stem cell human CVCL_YS52 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408962 CVCL_YS53 HPS2296 induced pluripotent stem cell human CVCL_YS53 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 21408963 CVCL_YS36 HPS1627 induced pluripotent stem cell human CVCL_YS36 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408964 CVCL_YS37 HPS1628 induced pluripotent stem cell human CVCL_YS37 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408965 CVCL_YS38 HPS1629 induced pluripotent stem cell human CVCL_YS38 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408966 CVCL_YS39 HPS1630 induced pluripotent stem cell human CVCL_YS39 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408967 CVCL_YS43 HPS2140 induced pluripotent stem cell human CVCL_YS43 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408968 CVCL_YS44 HPS2141 induced pluripotent stem cell human CVCL_YS44 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408969 CVCL_YS45 HPS2142 induced pluripotent stem cell human CVCL_YS45 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408970 CVCL_YS46 HPS2143 induced pluripotent stem cell human CVCL_YS46 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408971 CVCL_YS40 HPS1631 induced pluripotent stem cell human CVCL_YS40 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408972 CVCL_YS41 HPS2138 induced pluripotent stem cell human CVCL_YS41 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408973 CVCL_YS42 HPS2139 induced pluripotent stem cell human CVCL_YS42 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408974 CVCL_YS29 HPS1269 induced pluripotent stem cell human CVCL_YS29 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408975 CVCL_YS25 HPS1265 induced pluripotent stem cell human CVCL_YS25 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408976 CVCL_YS26 HPS1266 induced pluripotent stem cell human CVCL_YS26 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408977 CVCL_YS27 HPS1267 induced pluripotent stem cell human CVCL_YS27 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408978 CVCL_YS28 HPS1268 induced pluripotent stem cell human CVCL_YS28 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408979 CVCL_YS32 HPS1423 induced pluripotent stem cell human CVCL_YS32 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408980 CVCL_YS33 HPS1424 induced pluripotent stem cell human CVCL_YS33 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408981 CVCL_YS34 HPS1425 induced pluripotent stem cell human CVCL_YS34 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408982 CVCL_YS35 HPS1426 induced pluripotent stem cell human CVCL_YS35 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408983 CVCL_YS30 HPS1421 induced pluripotent stem cell human CVCL_YS30 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408984 CVCL_YS31 HPS1422 induced pluripotent stem cell human CVCL_YS31 CL:0000010 Derived from sampling site: Peripheral blood. Female 21408985 CVCL_YS18 HPS3053 induced pluripotent stem cell human CVCL_YS18 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408986 CVCL_YS19 HPS3285 induced pluripotent stem cell human CVCL_YS19 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408987 CVCL_YS14 HPS3049 induced pluripotent stem cell human CVCL_YS14 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408988 CVCL_YS15 HPS3050 induced pluripotent stem cell human CVCL_YS15 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408989 CVCL_YS16 HPS3051 induced pluripotent stem cell human CVCL_YS16 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408990 CVCL_YS17 HPS3052 induced pluripotent stem cell human CVCL_YS17 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408991 CVCL_YS21 HPS3287 induced pluripotent stem cell human CVCL_YS21 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408992 CVCL_YS22 HPS3288 induced pluripotent stem cell human CVCL_YS22 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408993 CVCL_YS23 HPS3289 induced pluripotent stem cell human CVCL_YS23 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408994 CVCL_YS24 HPS1264 induced pluripotent stem cell human CVCL_YS24 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 21408995 CVCL_YS20 HPS3286 induced pluripotent stem cell human CVCL_YS20 CL:0000010 Derived from sampling site: Peripheral blood. Male 21408996 CVCL_YL32 RTT-1155del32 C18 induced pluripotent stem cell human CVCL_YL32 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Argfs*8 (c.1157_1188del32) (p.Leu398Argfs*8, c.1193_1224del32) (1155del32); ClinVar=VCV000143366; Zygosity=Unspecified (PubMed=21074045) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21408997 CVCL_YL33 RTT-Q244X C3 induced pluripotent stem cell human CVCL_YL33 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gln244Ter (c.730C>T); ClinVar=VCV000095200; Zygosity=Heterozygous (PubMed=21074045) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21408998 CVCL_YL21 WT-AG09319 C1 induced pluripotent stem cell human CVCL_YL21 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by microarray Female 21408999 CVCL_YL24 Hs578T-delta-hTfR1 cancer cell line human CVCL_YL24 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (3 of 3 alleles); HGNC; 11763; TFRC; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012612; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Breast. Female 21409000 CVCL_YL26 RTT-1155del32 C15 induced pluripotent stem cell human CVCL_YL26 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Leu386Argfs*8 (c.1157_1188del32) (p.Leu398Argfs*8, c.1193_1224del32) (1155del32); ClinVar=VCV000143366; Zygosity=Unspecified (PubMed=21074045) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 21409001 CVCL_YL10 hTERT-PNH telomerase immortalized cell line pig CVCL_YL10 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the transformation method, the species of origin and the primary cell type name Derived from sampling site: Liver Cell type=Hepatocyte.; Breed/subspecies: Miniature pig. Male 21409002 CVCL_YL15 WT-126 C5 induced pluripotent stem cell human CVCL_YL15 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21409003 CVCL_YL90 AG26866 transformed cell line human CVCL_YL90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409004 CVCL_YL91 AG26869 transformed cell line human CVCL_YL91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409005 CVCL_YL92 AG26871 transformed cell line human CVCL_YL92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409006 CVCL_YL97 AG26893 transformed cell line human CVCL_YL97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409007 CVCL_YL98 AG26896 transformed cell line human CVCL_YL98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409008 CVCL_YL99 AG26901 transformed cell line human CVCL_YL99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409009 CVCL_YL93 AG26875 transformed cell line human CVCL_YL93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409010 CVCL_YL94 AG26878 transformed cell line human CVCL_YL94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409011 CVCL_YL95 AG26882 transformed cell line human CVCL_YL95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409012 CVCL_YL96 AG26887 transformed cell line human CVCL_YL96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409013 CVCL_YL80 AG26677 transformed cell line human CVCL_YL80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409014 CVCL_YL81 AG26692 transformed cell line human CVCL_YL81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409015 CVCL_YL86 AG26834 transformed cell line human CVCL_YL86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409016 CVCL_YL87 AG26843 transformed cell line human CVCL_YL87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409017 CVCL_YL88 AG26855 transformed cell line human CVCL_YL88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409018 CVCL_YL89 AG26865 transformed cell line human CVCL_YL89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409019 CVCL_YL82 AG26743 transformed cell line human CVCL_YL82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409020 CVCL_YL83 AG26751 transformed cell line human CVCL_YL83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409021 CVCL_YL84 AG26826 transformed cell line human CVCL_YL84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409022 CVCL_YL85 AG26827 transformed cell line human CVCL_YL85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409023 CVCL_YL70 NCC-CDS2-C1 cancer cell line human CVCL_YL70 CL:0000010 Sequence variation: Gene fusion; HGNC; 14214; CIC + HGNC; 50800; DUX4; Name(s)=CIC-DUX4 (PubMed=31898195). Population: Japanese Female Doubling time: ~28 hours (PubMed=31898195) Part of: NCC sarcoma cell line panel 21409024 CVCL_YL75 POSC spontaneously immortalized cell line CVCL_YL75 CL:0000010 Derived from sampling site: Testis Cell type=Sertoli cell.. Male Doubling time: 30.1 +- 2.8 hours (DOI=10.1007/s00343-016-5091-4) Group: Fish cell line 21409025 CVCL_YL76 SCT1 spontaneously immortalized cell line CVCL_YL76 CL:0000010 Derived from sampling site: Testis. Male Group: Fish cell line 21409026 CVCL_YL77 CSK [Cynoglossus] spontaneously immortalized cell line CVCL_YL77 CL:0000010 Derived from sampling site: Kidney Cell type=Fibroblast.. Male Characteristics: Grows at temperatures ranging from 16 to 30 Celsius The highest growth rate is obtained at 25 Celsius. Group: Fish cell line 21409027 CVCL_YL78 AG26675 transformed cell line human CVCL_YL78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409028 CVCL_YL71 NHRI-HN1 cancer cell line house mouse CVCL_YL71 CL:0000010 Transformant: Arecoline(ChEBI; CHEBI:2814); Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: C57BL/6. Characteristics: Capable of generating orthotopic tumors in syngeneic mice 21409029 CVCL_YL72 NHRI-HN2 cancer cell line house mouse CVCL_YL72 CL:0000010 Transformant: Arecoline(ChEBI; CHEBI:2814); Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Breed/subspecies: C57BL/6. 21409030 CVCL_YL73 Jump-In T-REx CHO-K1 spontaneously immortalized cell line CVCL_YL73 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Generated by integration of an R4 acceptor site and a promoterless Geneticin antibiotic resistance gene (Neo) using the Jump-In cell engineering technology 21409031 CVCL_YL74 Jump-In T-REx HEK 293 transformed cell line human CVCL_YL74 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Generated by integration of an R4 acceptor site and a promoterless Geneticin antibiotic resistance gene (Neo) using the Jump-In cell engineering technology 21409032 CVCL_YL79 AG26676 transformed cell line human CVCL_YL79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409033 CVCL_YL54 NCC-CDS1-X1-C1 cancer cell line human CVCL_YL54 CL:0000010 Sequence variation: Gene fusion; HGNC; 14214; CIC + HGNC; 50800; DUX4; Name(s)=CIC-DUX4 (PubMed=28680140) Population: Japanese Omics: Deep proteome analysis. Female Characteristics: Established from a first generation xenograft established by subcutaneous injection in female NOD/Shi-scid IL-2Rgammanull mice Doubling time: ~40 hours (PubMed=28680140) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409034 CVCL_YL55 NCC-CDS1-X3-C1 cancer cell line human CVCL_YL55 CL:0000010 Sequence variation: Gene fusion; HGNC; 14214; CIC + HGNC; 50800; DUX4; Name(s)=CIC-DUX4 (PubMed=28680140) Population: Japanese Omics: Deep proteome analysis. Female Characteristics: Established from a third generation xenograft established by subcutaneous injection in female NOD/Shi-scid IL-2Rgammanull mice Doubling time: ~30 hours (PubMed=28680140) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409035 CVCL_YL50 U2OS#18-XRCC3-6A/X3+ cancer cell line human CVCL_YL50 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12830; XRCC3; Transfected with: HGNC; 12830; XRCC3; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The parental XRCC3 KO cell line is functionally reconstituted by retroviral transfection of XRCC3; Characteristics: Contains a 'nested intron' reporter construct HRsub that allows to study sister chromatid recombination (SCR) by positive selection of 'long tract' gene conversion events between sister chromatids Doubling time: ~50-60 hours (DSMZ=ACC-842) 21409036 CVCL_YL42 RTT-Q244X C4 induced pluripotent stem cell human CVCL_YL42 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gln244Ter (c.730C>T); ClinVar=VCV000095200; Zygosity=Heterozygous (PubMed=21074045) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409037 CVCL_YL44 RTT-R306C C1 induced pluripotent stem cell human CVCL_YL44 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Arg306Cys (c.916C>T) (p.Arg318Cys, c.952C>T); ClinVar=VCV000011824; Zygosity=Heterozygous (PubMed=21074045) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409038 CVCL_YL45 RTT-T158M C3 induced pluripotent stem cell human CVCL_YL45 CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Thr158Met (c.473C>T) (p.Thr170Met, c.509C>T); ClinVar=VCV000011811; Zygosity=Heterozygous (PubMed=21074045) Derived from sampling site: Oral cavity; tonsil Cell type=Fibroblast.. Female 21409039 CVCL_YM52 MMCi001-A induced pluripotent stem cell human CVCL_YM52 From: Mackay Medical College; New Taipei City; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Val37Ile (c.109G>A); ClinVar=VCV000017023; Zygosity=Homozygous (PubMed=31896484) Derived from sampling site: Peripheral blood. Male 21409040 CVCL_YM53 NHLBIi003-A-1 induced pluripotent stem cell human CVCL_YM53 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 tdTomato under the control of a CAG promoter was inserted into one allele of the AAVS1 safe harbor locus 21409041 CVCL_YM54 NHLBIi003-A-2 induced pluripotent stem cell human CVCL_YM54 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 tdTomato under the control of a CAG promoter was inserted into one allele of the AAVS1 safe harbor locus 21409042 CVCL_YM55 NMSUNLi001-A-1 induced pluripotent stem cell human CVCL_YM55 From: CEDOC, NOVA Medical School, Universidade Nova De Lisboa; Lisbon; Portugal CL:0000010 Sequence variation: Mutation; HGNC; 26780; DAND5; Simple_corrected; p.Arg152His (c.455G>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31869685) Population: Caucasian; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 21409043 CVCL_YM50 NCCSi008-B induced pluripotent stem cell human CVCL_YM50 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21409044 CVCL_YM51 NCCSi009-A induced pluripotent stem cell human CVCL_YM51 From: National Centre for Cell Science; Pune; India CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Ser10Valfs*14 (c.27dupG) (c.27_28insG) (cd8/9+G); ClinVar=VCV000036308; Zygosity=Homozygous (PubMed=32278313) Population: Indian; Derived from sampling site: Peripheral blood. Male 21409045 CVCL_YM56 Mo03 finite cell line house mouse CVCL_YM56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21409046 CVCL_YM57 Mo06 finite cell line house mouse CVCL_YM57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21409047 CVCL_YM58 Mo09 finite cell line house mouse CVCL_YM58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 21409048 CVCL_YM59 AG27099 transformed cell line human CVCL_YM59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409049 CVCL_YM41 JUFMDOi005-A induced pluripotent stem cell human CVCL_YM41 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Homozygous (PubMed=32745712) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21409050 CVCL_YM42 JUFMDOi006-A induced pluripotent stem cell human CVCL_YM42 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Leu79Cysfs*3 (c.235delC); ClinVar=VCV000017014; Zygosity=Homozygous (PubMed=32745712) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21409051 CVCL_YM43 REGUi004-A induced pluripotent stem cell human CVCL_YM43 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser706Leufs*11 (c.2116delT); Zygosity=Homozygous (PubMed=31918214) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21409052 CVCL_YM44 REGUi005-A induced pluripotent stem cell human CVCL_YM44 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; p.Gln757Ter (c.2269C>T); ClinVar=VCV000006063; Zygosity=Homozygous (CelloPub=CLPUB00552; PubMed=32416578) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409053 CVCL_YM40 JUFMDOi004-A induced pluripotent stem cell human CVCL_YM40 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Val37Ile (c.109G>A); ClinVar=VCV000017023; Zygosity=Homozygous (PubMed=31926383) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21409054 CVCL_YM49 NCCSi008-A induced pluripotent stem cell human CVCL_YM49 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21409055 CVCL_YM45 NCCDFWi001-A induced pluripotent stem cell human CVCL_YM45 From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Pro228fs (c.684_736+4del); Zygosity=Heterozygous (PubMed=31901832); Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Leu871Phe (c.2613A>C); ClinVar=VCV000667457; Zygosity=Heterozygous (PubMed=31901832) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409056 CVCL_YM46 NCCSi007-A induced pluripotent stem cell human CVCL_YM46 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21409057 CVCL_YM47 NCCSi007-B induced pluripotent stem cell human CVCL_YM47 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21409058 CVCL_YM48 NCCSi007-C induced pluripotent stem cell human CVCL_YM48 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 21409059 CVCL_YM30 6620c1 cancer cell line house mouse CVCL_YM30 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409060 CVCL_YM31 6694c2 cancer cell line house mouse CVCL_YM31 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409061 CVCL_YM32 7160c2 cancer cell line house mouse CVCL_YM32 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409062 CVCL_YM33 7160c5 cancer cell line house mouse CVCL_YM33 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409063 CVCL_YM38 JUFMDOi002-A induced pluripotent stem cell human CVCL_YM38 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly45Glu (c.134G>A); ClinVar=VCV000017033; Zygosity=Heterozygous (PubMed=33780732); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Tyr136Ter (c.408C>A); ClinVar=VCV000189092; Zygosity=Heterozygous (PubMed=33780732) Population: Japanese; Derived from sampling site: Peripheral blood. Female 21409064 CVCL_YM39 JUFMDOi003-A induced pluripotent stem cell human CVCL_YM39 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan. CL:0000010 21409065 CVCL_YM34 ZZUNEUi008-A induced pluripotent stem cell human CVCL_YM34 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3754; FLNA; Simple; p.Met28Ile (c.84G>A); ClinVar=VCV000641298; Zygosity=Hemizygous (PubMed=32592953) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409066 CVCL_YM35 ZZUNEUi009-A induced pluripotent stem cell human CVCL_YM35 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409067 CVCL_YM36 ZZUi018-A induced pluripotent stem cell human CVCL_YM36 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Repeat_expansion; p.Gln2313[25] (c.6937CAG[25]) (c.6937CAG[(21_30)]); ClinVar=VCV000562099; Zygosity=Heterozygous; Note=The non-expanded allele has p.Gln2313[14] (PubMed=32229428) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409068 CVCL_YM37 JUFMDOi001-A induced pluripotent stem cell human CVCL_YM37 From: Department of Otorhinolaryngology, Juntendo University Faculty of Medicine; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Gly45Glu (c.134G>A); ClinVar=VCV000017033; Zygosity=Homozygous (PubMed=33780732); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Tyr136Ter (c.408C>A); ClinVar=VCV000189092; Zygosity=Homozygous (PubMed=33780732) Population: Japanese; Derived from sampling site: Peripheral blood. Male 21409069 CVCL_YM20 6419c1 cancer cell line house mouse CVCL_YM20 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409070 CVCL_YM21 6419c5 cancer cell line house mouse CVCL_YM21 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409071 CVCL_YM22 6421c2 cancer cell line house mouse CVCL_YM22 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409072 CVCL_YM27 6555c3 cancer cell line house mouse CVCL_YM27 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409073 CVCL_YM28 6556c3 cancer cell line house mouse CVCL_YM28 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409074 CVCL_YM29 6556c4 cancer cell line house mouse CVCL_YM29 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409075 CVCL_YM23 6422c1 cancer cell line house mouse CVCL_YM23 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409076 CVCL_YM24 6422c5 cancer cell line house mouse CVCL_YM24 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409077 CVCL_YM25 6499c3 cancer cell line house mouse CVCL_YM25 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409078 CVCL_YM26 6499c4 cancer cell line house mouse CVCL_YM26 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409079 CVCL_YM09 A3C hybridoma house mouse CVCL_YM09 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27410; Rabbit hemorrhagic disease virus genome polyprotein (AA 1768-2344; Capsid protein VP60). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200921 21409080 CVCL_YM10 S-163-6 hybridoma house mouse CVCL_YM10 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08727; Human KRT19. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200925 21409081 CVCL_YM11 S-66-5 hybridoma house mouse CVCL_YM11 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08727; Human KRT19. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200923 21409082 CVCL_YM16 HEK293T GAPDH-KD transformed cell line human CVCL_YM16 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 4141; GAPDH; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 21409083 CVCL_YM17 2699c4 cancer cell line house mouse CVCL_YM17 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409084 CVCL_YM18 2838c3 cancer cell line house mouse CVCL_YM18 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). Omics: Transcriptome analysis by RNAseq 21409085 CVCL_YM19 5821c3 cancer cell line house mouse CVCL_YM19 CL:0000010 Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231) Breed/subspecies: KrasLSL-G12D/+;Trp53LSL-R172H/+;Pdx1-Cre;Rosa26YFP/YFP (KPCY). 21409086 CVCL_YM12 S-71-9 hybridoma house mouse CVCL_YM12 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P08727; Human KRT19. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200924 21409087 CVCL_YM13 HTK hybridoma house mouse CVCL_YM13 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06870; Human KLK1. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C200928 21409088 CVCL_YM14 PaKiS spontaneously immortalized cell line CVCL_YM14 CL:0000010 Miscellaneous: Cell line information from personal communication of Goh G Derived from sampling site: Kidney. Group: Bat cell line 21409089 CVCL_YM15 COX10 KO clone K19 transformed cell line house mouse CVCL_YM15 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1917633; Cox10; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; Breed/subspecies: 129X1/SvJ x C57BL/6J. 21409090 CVCL_YM00 AG26904 transformed cell line human CVCL_YM00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409091 CVCL_YM05 AG26958 transformed cell line human CVCL_YM05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409092 CVCL_YM06 hTERT-NBSC telomerase immortalized cell line CVCL_YM06 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Testis Cell type=Sertoli cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018201 21409093 CVCL_YM07 hTERT-LSC telomerase immortalized cell line CVCL_YM07 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Testis Cell type=Sertoli cell.. Male Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018202 21409094 CVCL_YM08 C8C37 spontaneously immortalized cell line CVCL_YM08 CL:0000010 Derived from sampling site: Spinal cord. Unspecified Group: Fish cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018204 21409095 CVCL_YM01 AG26910 transformed cell line human CVCL_YM01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409096 CVCL_YM02 AG26914 transformed cell line human CVCL_YM02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: Tulane University longevity study 21409097 CVCL_YM03 AG26937 transformed cell line human CVCL_YM03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409098 CVCL_YM04 AG26951 transformed cell line human CVCL_YM04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: Tulane University longevity study 21409099 CVCL_YM90 GZWWTi001-A [2019] induced pluripotent stem cell human CVCL_YM90 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Ala267Val (c.800C>T) (c.551C>T); Zygosity=Heterozygous (PubMed=31698190); Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Tyr398Ser (c.1193A>C) (c.944A>C); ClinVar=VCV001456043; Zygosity=Heterozygous (PubMed=31698190) Population: Chinese; Derived from sampling site: Peripheral blood. Female Caution: This group has named GZWWTi001-A two different iPSC cell lines 21409100 CVCL_YM91 GZWTZi001-A induced pluripotent stem cell human CVCL_YM91 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Ala267Val (c.800C>T) (c.551C>T); Zygosity=Heterozygous (PubMed=31698190); Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Tyr398Ser (c.1193A>C) (c.944A>C); ClinVar=VCV001456043; Zygosity=Heterozygous (PubMed=31698190) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409101 CVCL_YM96 UBi001-A-2 induced pluripotent stem cell human CVCL_YM96 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple_edited; p.Asn94Glyfs*15 (c.279_294del) (p.Asn66Glyfs*15, c.195_210del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31731183); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple_edited; p.Tyr98Ter (c.293delinsGAATG) (p.Tyr70Ter, c.209delinsGAATG); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31731183) Derived from sampling site: Cell type=Fibroblast. Male 21409102 CVCL_YM97 SFC6-iPS#3.1 induced pluripotent stem cell human CVCL_YM97 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.633+1G>A; dbSNP=rs528466699; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26411903); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; p.Leu473Pro (c.1418T>C) (p.Leu445Pro, c.1334T>C); Zygosity=Heterozygous (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409103 CVCL_YM98 SFC6-iPS#3.2 induced pluripotent stem cell human CVCL_YM98 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.633+1G>A; dbSNP=rs528466699; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26411903); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; p.Leu473Pro (c.1418T>C) (p.Leu445Pro, c.1334T>C); Zygosity=Heterozygous (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409104 CVCL_YM99 SFC7-iPS#3.1 induced pluripotent stem cell human CVCL_YM99 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.372-2A>G; ClinVar=VCV000001236; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409105 CVCL_YM92 GZWXDi001-A induced pluripotent stem cell human CVCL_YM92 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Ala267Val (c.800C>T) (c.551C>T); Zygosity=Heterozygous (PubMed=31698190) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409106 CVCL_YM93 GZWXYi001-A induced pluripotent stem cell human CVCL_YM93 From: The Third Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 753; ASNS; Simple; p.Tyr398Ser (c.1193A>C) (c.944A>C); ClinVar=VCV001456043; Zygosity=Heterozygous (PubMed=31698190) Population: Chinese; Derived from sampling site: Peripheral blood. Female 21409107 CVCL_YM94 UBi001-A induced pluripotent stem cell human CVCL_YM94 From: University of Barcelona; Barcelona; Spain CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 21409108 CVCL_YM95 UBi001-A-1 induced pluripotent stem cell human CVCL_YM95 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple_edited; p.Asn94Glyfs*15 (c.279_294del) (p.Asn66Glyfs*15, c.195_210del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31731183); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple_edited; p.Tyr98Hisfs*17 (c.291_292insCA) (p.Tyr70Hisfs*17, c.207_208insCA); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=31731183) Derived from sampling site: Cell type=Fibroblast. Male 21409109 CVCL_YM80 XACHi007-A induced pluripotent stem cell human CVCL_YM80 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Asp76Asn (c.226G>A); ClinVar=VCV000013477; Zygosity=Heterozygous (PubMed=32344329) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409110 CVCL_YM85 NIHTVBi013-A induced pluripotent stem cell human CVCL_YM85 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Val463del (c.1384_1386GTG[1]) (c.1387_1389delGTG); ClinVar=VCV000018303; Zygosity=Heterozygous (PubMed=31707214) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409111 CVCL_YM86 NIHTVBi006-A induced pluripotent stem cell human CVCL_YM86 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Cys233Gly (c.697T>G); Zygosity=Heterozygous (PubMed=32344328) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21409112 CVCL_YM87 NIHTVBi009-A induced pluripotent stem cell human CVCL_YM87 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA. CL:0000010 21409113 CVCL_YM88 NIHTVBi010-A induced pluripotent stem cell human CVCL_YM88 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA. CL:0000010 21409114 CVCL_YM81 XACHi008-A induced pluripotent stem cell human CVCL_YM81 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Asp76Asn (c.226G>A); ClinVar=VCV000013477; Zygosity=Heterozygous (PubMed=32344329) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409115 CVCL_YM82 XACHi009-A induced pluripotent stem cell human CVCL_YM82 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 6240; KCNE1; Simple; p.Asp76Asn (c.226G>A); ClinVar=VCV000013477; Zygosity=Heterozygous (PubMed=32344329) Population: Chinese; Derived from sampling site: Peripheral blood. Female 21409116 CVCL_YM83 NIHTVBi011-A induced pluripotent stem cell human CVCL_YM83 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Pro639Ala (c.1915C>G); ClinVar=VCV001429145; Zygosity=Heterozygous (PubMed=31707214) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409117 CVCL_YM84 NIHTVBi012-A induced pluripotent stem cell human CVCL_YM84 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Glu652Lys (c.1954G>A); Zygosity=Heterozygous (PubMed=31707214) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409118 CVCL_YM89 NIHTVBi014-A induced pluripotent stem cell human CVCL_YM89 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 25118; OTULIN; Simple; p.Leu272Pro (c.815T>C); ClinVar=VCV000254124; Zygosity=Homozygous (PubMed=32721894) Population: Pakistani; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409119 CVCL_YM74 KIOMi002-A induced pluripotent stem cell human CVCL_YM74 From: Korea Institute of Oriental Medicine; Daejeon; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By homologous recombination (PubMed=31731184) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409120 CVCL_YM75 XACHi002-A induced pluripotent stem cell human CVCL_YM75 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg608Ter (c.1822C>T); ClinVar=VCV000972803; Zygosity=Heterozygous (PubMed=31743840); Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu888Ter (c.2662G>T); ClinVar=VCV000578595; Zygosity=Heterozygous (PubMed=31743840) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409121 CVCL_YM76 XACHi003-A induced pluripotent stem cell human CVCL_YM76 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China. CL:0000010 21409122 CVCL_YM77 XACHi004-A induced pluripotent stem cell human CVCL_YM77 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Val4880Ile (c.14638G>A); ClinVar=VCV001439521; Zygosity=Heterozygous (PubMed=36335801) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409123 CVCL_YM70 IPTi004-A induced pluripotent stem cell human CVCL_YM70 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409124 CVCL_YM71 IPTi005-A induced pluripotent stem cell human CVCL_YM71 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409125 CVCL_YM72 IPTi006-A induced pluripotent stem cell human CVCL_YM72 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409126 CVCL_YM73 IPTi007-A induced pluripotent stem cell human CVCL_YM73 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409127 CVCL_YM78 XACHi005-A induced pluripotent stem cell human CVCL_YM78 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Glu888Ter (c.2662G>T); ClinVar=VCV000578595; Zygosity=Heterozygous (PubMed=36240644) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409128 CVCL_YM79 XACHi006-A induced pluripotent stem cell human CVCL_YM79 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 4065; GAA; Simple; p.Arg608Ter (c.1822C>T); ClinVar=VCV000972803; Zygosity=Heterozygous (PubMed=36240644) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409129 CVCL_YM63 PHAi002-A induced pluripotent stem cell human CVCL_YM63 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409130 CVCL_YM64 PHAi002-B induced pluripotent stem cell human CVCL_YM64 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409131 CVCL_YM65 PHAi003-A induced pluripotent stem cell human CVCL_YM65 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 11937; CD70; Simple; p.Ser84Profs*27 (c.250delT); ClinVar=VCV000599338; Zygosity=Homozygous (PubMed=31678777) Population: Iranian; Persian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409132 CVCL_YM66 PHAi003-B induced pluripotent stem cell human CVCL_YM66 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Sequence variation: Mutation; HGNC; 11937; CD70; Simple; p.Ser84Profs*27 (c.250delT); ClinVar=VCV000599338; Zygosity=Homozygous (PubMed=31678777) Population: Iranian; Persian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409133 CVCL_YM60 AG27590 induced pluripotent stem cell human CVCL_YM60 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (Coriell) Population: Caucasian; Derived from sampling site: Hip; skin Cell type=Fibroblast.. Female 21409134 CVCL_YM61 PHAi001-A induced pluripotent stem cell human CVCL_YM61 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409135 CVCL_YM62 PHAi001-B induced pluripotent stem cell human CVCL_YM62 From: Pan-Hammarstrom Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409136 CVCL_YM67 CBTCi003-A-1 induced pluripotent stem cell human CVCL_YM67 From: Centro de Biotecnologia e Terapia Celular, Hospital Sao Rafael; Salvador; Brazil CL:0000010 Population: Afro-Brazilian; Derived from sampling site: Peripheral blood. Male 21409137 CVCL_YM68 IPTi002-A induced pluripotent stem cell human CVCL_YM68 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=33799279) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409138 CVCL_YM69 IPTi003-A induced pluripotent stem cell human CVCL_YM69 From: Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409139 CVCL_YN73 HVRDe006-A-6 embryonic stem cell human CVCL_YN73 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple_edited; p.Gly691Glufs*6 (c.2072del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32682288). Female 21409140 CVCL_YN74 1F8 hybridoma house mouse CVCL_YN74 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. 21409141 CVCL_YN75 4B9 [Mouse hybridoma against human PDCD1] hybridoma house mouse CVCL_YN75 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. 21409142 CVCL_YN76 8F5 [Mouse hybridoma against human PDCD1] hybridoma house mouse CVCL_YN76 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. 21409143 CVCL_YN70 BIHi001-B induced pluripotent stem cell human CVCL_YN70 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21409144 CVCL_YN71 TVGH-iPSC-023-02 induced pluripotent stem cell human CVCL_YN71 From: Taipei Veterans General Hospital; Taipei; Taiwan CL:0000010 Derived from sampling site: Peripheral blood. Female 21409145 CVCL_YN72 HVRDe006-A-4 embryonic stem cell human CVCL_YN72 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple_edited; p.Gly647Ter (c.1939_1946del) (p.Gly660Ter, c.1978_1985del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32682288). Female 21409146 CVCL_YN77 9H1 hybridoma house mouse CVCL_YN77 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15116; Human PDCD1/PD1/CD279. 21409147 CVCL_YN78 5B7F5 hybridoma house mouse CVCL_YN78 CL:0000010 Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. 21409148 CVCL_YN79 5C6D5 hybridoma house mouse CVCL_YN79 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. 21409149 CVCL_YN62 GM27743 transformed cell line human CVCL_YN62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409150 CVCL_YN63 GM27848 finite cell line human CVCL_YN63 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln86Profs*35 (c.256dupC); ClinVar=VCV000189613; Zygosity=Heterozygous (Coriell) Population: Jewish; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 21409151 CVCL_YN64 GM27849 finite cell line human CVCL_YN64 CL:0000010 Population: Jewish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21409152 CVCL_YN65 GM27850 finite cell line human CVCL_YN65 CL:0000010 Population: Jewish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21409153 CVCL_YN60 GM27723 transformed cell line human CVCL_YN60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409154 CVCL_YN61 GM27724 transformed cell line human CVCL_YN61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409155 CVCL_YN66 GM27851 finite cell line human CVCL_YN66 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly169Alafs*23 (c.506delG); ClinVar=VCV000471470; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409156 CVCL_YN67 AG27607 induced pluripotent stem cell human CVCL_YN67 CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg176Cys (c.526C>T); ClinVar=VCV000017848; Zygosity=Heterozygous; Note=ApoE2 allele (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409157 CVCL_YN68 CHWi001-A induced pluripotent stem cell human CVCL_YN68 From: Center of Prenatal Diagnosis, The Central Hospital of Wenzhou; Wenzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409158 CVCL_YN69 BIHi250-A induced pluripotent stem cell human CVCL_YN69 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409159 CVCL_YN51 GM27651 finite cell line human CVCL_YN51 CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21409160 CVCL_YN52 GM27659 transformed cell line human CVCL_YN52 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Trp65Ter (c.195G>A); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409161 CVCL_YN53 GM27660 transformed cell line human CVCL_YN53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409162 CVCL_YN54 GM27661 transformed cell line human CVCL_YN54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409163 CVCL_YN50 GM27650 finite cell line human CVCL_YN50 CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21409164 CVCL_YN59 GM27699 transformed cell line human CVCL_YN59 CL:0000010 Population: Caucasian; Spanish (Chilean); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409165 CVCL_YN55 GM27667 transformed cell line human CVCL_YN55 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; c.680-11G>A; ClinVar=VCV000521457; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409166 CVCL_YN56 GM27668 transformed cell line human CVCL_YN56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409167 CVCL_YN57 GM27669 transformed cell line human CVCL_YN57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409168 CVCL_YN58 GM27698 transformed cell line human CVCL_YN58 CL:0000010 Population: Caucasian; Spanish (Chilean); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409169 CVCL_YN40 GM27299 transformed cell line human CVCL_YN40 CL:0000010 Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Gly219Arg (c.655G>A); ClinVar=VCV000140752; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409170 CVCL_YN41 GM27326 transformed cell line human CVCL_YN41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409171 CVCL_YN42 GM27389 finite cell line human CVCL_YN42 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409172 CVCL_YN43 GM27411 transformed cell line human CVCL_YN43 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Glu154Glyfs*301 (c.460dupG); ClinVar=VCV000095268; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409173 CVCL_YN48 GM27643 transformed cell line human CVCL_YN48 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Gln649Ter (c.1945C>T); ClinVar=VCV000217910; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4284; GJB2; Simple; p.Val91Serfs*11 (c.269dupT); ClinVar=VCV000177737; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409174 CVCL_YN49 GM27644 transformed cell line human CVCL_YN49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409175 CVCL_YN44 GM27600 finite cell line human CVCL_YN44 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Ile190Asn (c.569T>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Spanish (Chilean); Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409176 CVCL_YN45 GM27614 finite cell line human CVCL_YN45 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln86Profs*35 (c.256dupC); ClinVar=VCV000189613; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 21409177 CVCL_YN46 GM27622 induced pluripotent stem cell human CVCL_YN46 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln86Profs*35 (c.256dupC); ClinVar=VCV000189613; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409178 CVCL_YN47 GM27629 induced pluripotent stem cell human CVCL_YN47 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Asn232Ser (c.695A>G); ClinVar=VCV001698021; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409179 CVCL_YN30 GM27203 transformed cell line human CVCL_YN30 CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Arg157Glufs*77 (c.469delC); ClinVar=VCV000589268; Zygosity=Unspecified (Coriell) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409180 CVCL_YN31 GM27205 transformed cell line human CVCL_YN31 CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409181 CVCL_YN32 GM27206 finite cell line human CVCL_YN32 CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409182 CVCL_YN37 GM27288 transformed cell line human CVCL_YN37 CL:0000010 Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Gly219Arg (c.655G>A); ClinVar=VCV000140752; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Leu492Pro (c.1475T>C); ClinVar=VCV000375390; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409183 CVCL_YN38 GM27289 transformed cell line human CVCL_YN38 CL:0000010 Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Gly219Arg (c.655G>A); ClinVar=VCV000140752; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Leu492Pro (c.1475T>C); ClinVar=VCV000375390; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409184 CVCL_YN39 GM27290 transformed cell line human CVCL_YN39 CL:0000010 Sequence variation: Mutation; HGNC; 23089; SLC13A5; Simple; p.Leu492Pro (c.1475T>C); ClinVar=VCV000375390; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409185 CVCL_YN33 GM27207 transformed cell line human CVCL_YN33 CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409186 CVCL_YN34 GM27208 finite cell line human CVCL_YN34 CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409187 CVCL_YN35 GM27226 finite cell line human CVCL_YN35 CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Asn216Ile (c.647A>T); ClinVar=VCV000007707; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409188 CVCL_YN36 GM27243 transformed cell line human CVCL_YN36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409189 CVCL_YN19 UKERi313-R1 induced pluripotent stem cell human CVCL_YN19 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10582; SCN10A; Simple; p.Arg923His (c.2768G>A); ClinVar=VCV000936757; Zygosity=Unspecified (PubMed=30503201); Sequence variation: Mutation; HGNC; 10583; SCN11A; Simple; p.Asn1169Ser (c.3506A>G); ClinVar=VCV000474720; Zygosity=Unspecified (PubMed=30503201) Population: Caucasian; Norwegian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 21409190 CVCL_YN20 GM27393 finite cell line human CVCL_YN20 CL:0000010 Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Ala222Val (c.665C>T) (C677T); ClinVar=VCV000003520; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7436; MTHFR; Simple; p.Glu429Ala (c.1286A>C) (1298A>C); ClinVar=VCV000003521; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg141Cys (c.421C>T); ClinVar=VCV000447846; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409191 CVCL_YN21 GM27134 transformed cell line human CVCL_YN21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409192 CVCL_YN26 GM27140 transformed cell line human CVCL_YN26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409193 CVCL_YN27 GM27141 transformed cell line human CVCL_YN27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409194 CVCL_YN28 GM27142 transformed cell line human CVCL_YN28 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Trp453Cys (c.1359G>C); ClinVar=VCV000372502; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Glu474Aspfs*93 (c.1421_1422insC); ClinVar=VCV002100000; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409195 CVCL_YN29 GM27192 finite cell line human CVCL_YN29 CL:0000010 Sequence variation: Mutation; HGNC; 2745; DDX3X; Simple; p.Lys208Serfs*13 (c.623delA); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409196 CVCL_YN22 GM27135 transformed cell line human CVCL_YN22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409197 CVCL_YN23 GM27137 transformed cell line human CVCL_YN23 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Thr295Lys (c.884C>A); ClinVar=VCV001298419; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409198 CVCL_YN24 GM27138 transformed cell line human CVCL_YN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409199 CVCL_YN25 GM27139 transformed cell line human CVCL_YN25 CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Trp453Cys (c.1359G>C); ClinVar=VCV000372502; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Glu474Aspfs*93 (c.1421_1422insC); ClinVar=VCV002100000; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409200 CVCL_YN08 WAe001-A-33 embryonic stem cell human CVCL_YN08 From: Jilin University; Changchun; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3444; ERF. Male 21409201 CVCL_YN09 WAe001-A-34 embryonic stem cell human CVCL_YN09 From: Jilin University; Changchun; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3444; ERF. Male 21409202 CVCL_YN10 KSCBi002-A-1 induced pluripotent stem cell human CVCL_YN10 From: Daegu-Gyeongbuk Medical Innovation Foundation; Daegu; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4296; GLA Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409203 CVCL_YN15 HEK-293 hNav1.9 transformed cell line human CVCL_YN15 CL:0000010 Transfected with: HGNC; 10583; SCN11A; Transfected with: HGNC; 10586; SCN1B; Transfected with: HGNC; 10589; SCN2B Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21409204 CVCL_YN16 HEK-293 mNav1.9 transformed cell line human CVCL_YN16 CL:0000010 Transfected with: MGI; MGI:1345149; Scn11a; Transfected with: MGI; MGI:98247; Scn1b; Transfected with: MGI; MGI:106921; Scn2b Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21409205 CVCL_YN17 HEK-293 rNav1.9 transformed cell line human CVCL_YN17 CL:0000010 Transfected with: RGD; 3630; Scn11a; Transfected with: RGD; 3631; Scn1b; Transfected with: RGD; 3633; Scn2b Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 21409206 CVCL_YN18 UKERi006-B induced pluripotent stem cell human CVCL_YN18 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409207 CVCL_YN11 UBi001-A-3 induced pluripotent stem cell human CVCL_YN11 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple_edited; p.Phe288_Ile290del; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31825816) Derived from sampling site: Cell type=Fibroblast. Male 21409208 CVCL_YN12 UBi001-A-4 induced pluripotent stem cell human CVCL_YN12 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 7632; NAGLU; Simple_edited; p.Phe288Ilefs*27; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=31825816) Derived from sampling site: Cell type=Fibroblast. Male 21409209 CVCL_YN13 GM27325 transformed cell line human CVCL_YN13 CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Ser269Asn (c.806G>A); ClinVar=VCV000373714; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3791; FOLR1; Simple; c.493+2T>C (IVS4+2T>C); ClinVar=VCV000095750; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly224Ser (c.670G>A); ClinVar=VCV000167092; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Pro8Thr (c.22C>A); ClinVar=VCV000205598; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409210 CVCL_YN14 HVRDe006-A-1 embryonic stem cell human CVCL_YN14 From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple_edited; p.Gly647Metfs*4 (c.1939_1951del) (p.Gly660Metfs*4, c.1978_1990del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32682288). Female 21409211 CVCL_YN04 NDi002-A induced pluripotent stem cell human CVCL_YN04 From: University of Notre Dame; Notre Dame; USA CL:0000010 Derived from sampling site: Bone marrow. Male 21409212 CVCL_YN05 NDi002-B induced pluripotent stem cell human CVCL_YN05 From: University of Notre Dame; Notre Dame; USA CL:0000010 Derived from sampling site: Bone marrow. Male 21409213 CVCL_YN06 NDi003-A induced pluripotent stem cell human CVCL_YN06 From: University of Notre Dame; Notre Dame; USA. CL:0000010 21409214 CVCL_YN07 NDi003-B induced pluripotent stem cell human CVCL_YN07 From: University of Notre Dame; Notre Dame; USA. CL:0000010 21409215 CVCL_YN00 SFC7-iPS#3.2 induced pluripotent stem cell human CVCL_YN00 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.372-2A>G; ClinVar=VCV000001236; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409217 CVCL_YN02 NHLBIi002-A induced pluripotent stem cell human CVCL_YN02 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA. CL:0000010 21409218 CVCL_YN03 NDi001-A induced pluripotent stem cell human CVCL_YN03 From: University of Notre Dame; Notre Dame; USA CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21409219 CVCL_YN90 Hep-G2/C3A-hOTC cancer cell line human CVCL_YN90 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 8512; OTC Population: Caucasian; Derived from sampling site: Liver. Male 21409220 CVCL_YN95 Raji CD19 High cancer cell line human CVCL_YN95 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1633; CD19; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1633; CD19 Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Expresses CD19 at high level 21409221 CVCL_YN96 Raji CD19 Low cancer cell line human CVCL_YN96 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1633; CD19; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1633; CD19 Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male Characteristics: Expresses CD19 at low level 21409222 CVCL_YN97 Yazd1 embryonic stem cell human CVCL_YN97 From: Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences; Yazd; Iran. CL:0000010 Female 21409223 CVCL_YN98 Yazd2 embryonic stem cell human CVCL_YN98 From: Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences; Yazd; Iran. CL:0000010 Male 21409224 CVCL_YN91 IMhu transformed cell line human CVCL_YN91 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain Cell type=Microglial cell.. 21409225 CVCL_YN92 3A1-1D6 hybridoma CVCL_YN92 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q99470; Human SDF2. 21409226 CVCL_YN93 3A1-1H10 hybridoma CVCL_YN93 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q99470; Human SDF2. 21409227 CVCL_YN94 Raji CD19 Knockout cancer cell line human CVCL_YN94 CL:0000010 Knockout cell: Method=ZFN; HGNC; 1633; CD19; Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 21409228 CVCL_YN99 Yazd3 embryonic stem cell human CVCL_YN99 From: Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences; Yazd; Iran. CL:0000010 Ambiguous 21409229 CVCL_YN84 GENYOi006-A-2 induced pluripotent stem cell human CVCL_YN84 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Spanish; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21409230 CVCL_YN85 UWG01CTC cancer cell line human CVCL_YN85 CL:0000010 Miscellaneous: Age of donor and doubling time from personal communication of Brungs D Derived from metastatic site: Peripheral blood. Male Doubling time: 55 hours (Direct_author_submission) 21409231 CVCL_YN86 UWG02ASC cancer cell line human CVCL_YN86 CL:0000010 Miscellaneous: Age of donor from personal communication of Brungs D Derived from metastatic site: Ascites. Male 21409232 CVCL_YN87 UWG02CTC cancer cell line human CVCL_YN87 CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Arg1446Cys (c.4336C>T); ClinVar=VCV000095047; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Phe (c.98C>T); ClinVar=VCV000017583; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 4392; GNAS; Simple; p.Arg201His (c.602G>A); ClinVar=VCV000015934; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Thr992Ile (c.2975C>T) (p.Thr1010Ile, c.3029C>T); ClinVar=VCV000041624; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu418Lys (c.1252G>A); ClinVar=VCV000045464; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Gln (c.1624G>C); ClinVar=VCV000376244; Zygosity=Heterozygous (PubMed=31953491); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asp537His (c.1609G>C); Zygosity=Homozygous (PubMed=31953491) Miscellaneous: Age of donor, doubling time and zygosity of sequence variations from personal communication of Brungs D Derived from metastatic site: Peripheral blood. Male Doubling time: 18 hours (Direct_author_submission) 21409233 CVCL_YN80 7F5F3 hybridoma house mouse CVCL_YN80 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. 21409234 CVCL_YN81 8A7B4 hybridoma house mouse CVCL_YN81 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8NBJ4; Human GOLM1. 21409235 CVCL_YN82 WAe009-A-24 embryonic stem cell human CVCL_YN82 From: Monash University; Melbourne; Australia CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using CRISPR/Cas9 a IRES-tdTomato-T2A-NanoLuc-pA-FRT-neo-FRT was integrated in front of the stop codon of CX3CR1 21409236 CVCL_YN83 GENYOi006-A-1 induced pluripotent stem cell human CVCL_YN83 From: Centre for Genomics and Oncological Research (GENYO); Granada; Spain CL:0000010 Transfected with: HGNC; 1537; CBFA2T3 (CBFA2T3-GLIS2 fusion); Transfected with: HGNC; 29450; GLIS2 (CBFA2T3-GLIS2 fusion) Population: Caucasian; Spanish; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 21409237 CVCL_YN88 Hep-G2/C3A-hARG1 cancer cell line human CVCL_YN88 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 663; ARG1 Population: Caucasian; Derived from sampling site: Liver. Male 21409238 CVCL_YN89 Hep-G2/C3A-hARG1/hOTC cancer cell line human CVCL_YN89 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 663; ARG1; Transfected with: HGNC; 8512; OTC Population: Caucasian; Derived from sampling site: Liver. Male 21409239 CVCL_YY00 SZ-NF6 embryonic stem cell human CVCL_YY00 From: Shaare Zedek Medical Center, The Hebrew University; Jerusalem; Israel CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; c.4269+1G>C; Zygosity=Unspecified; Note=Splice donor mutation (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Eiges R. Unspecified 21409240 CVCL_YX97 PM1-Luc cancer cell line human CVCL_YX97 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The luciferase reporter gene expression is under the control of a Tat-inducible SIV LTR 21409241 CVCL_YX98 PM1-CCR5-Luc cancer cell line human CVCL_YX98 CL:0000010 Sequence variation: Gene deletion; HGNC; 7208; MPDZ; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: The luciferase reporter gene expression is under the control of a Tat-inducible SIV LTR 21409242 CVCL_YX99 RCSIi001-A induced pluripotent stem cell human CVCL_YX99 From: Royal College of Surgeons in Ireland; Dublin; Ireland CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21409243 CVCL_YX86 ZR75-LTED cancer cell line human CVCL_YX86 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361) 21409244 CVCL_YX87 MHHi011-A induced pluripotent stem cell human CVCL_YX87 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany. CL:0000010 21409245 CVCL_YX88 MHHi012-A induced pluripotent stem cell human CVCL_YX88 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11772; TGFBR1; Simple; p.Met253Ile (c.759G>A); Zygosity=Heterozygous (PubMed=32062130) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21409246 CVCL_YX89 MHHi013-A induced pluripotent stem cell human CVCL_YX89 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11772; TGFBR1; Simple; p.Met253Ile (c.759G>A); Zygosity=Heterozygous (PubMed=32062130) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 21409247 CVCL_YX93 CS08iFAD-nxx induced pluripotent stem cell human CVCL_YX93 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (CSMC) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21409248 CVCL_YX94 CS40iFAD-nxx induced pluripotent stem cell human CVCL_YX94 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Unspecified (CSMC) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 21409249 CVCL_YX95 CS2AW(SVT) transformed cell line human CVCL_YX95 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409250 CVCL_YX96 MKN45/CDDP/R1 cancer cell line human CVCL_YX96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Liver. Female 21409251 CVCL_YX90 MHHi014-A induced pluripotent stem cell human CVCL_YX90 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11772; TGFBR1; Simple; p.Met253Ile (c.759G>A); Zygosity=Heterozygous (PubMed=32062130) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 21409252 CVCL_YX91 MHHi018-A induced pluripotent stem cell human CVCL_YX91 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Asn1303Lys (c.3909C>G); ClinVar=VCV000007136; Zygosity=Homozygous (PubMed=32220772) Derived from sampling site: Peripheral blood. Male 21409253 CVCL_YX92 SZ-ATRX7 embryonic stem cell human CVCL_YX92 CL:0000010 Sequence variation: Mutation; HGNC; 886; ATRX; Simple; p.Arg37Ter (c.109C>T); ClinVar=VCV000011742; Zygosity=Unspecified (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Eiges R. Unspecified 21409254 CVCL_YX79 BT474 A3 cancer cell line human CVCL_YX79 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Breast. Female 21409255 CVCL_YX75 WMUi001-A induced pluripotent stem cell human CVCL_YX75 From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2203; COL4A2; Simple; p.Arg131Met (c.392G>T); Zygosity=Heterozygous (PubMed=32062133) Population: Chinese; Han; Derived from sampling site: Aorta; smooth muscle. Male 21409256 CVCL_YX76 WMUi002-A induced pluripotent stem cell human CVCL_YX76 From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Asp173Thrfs*11 (c.517delG); ClinVar=VCV001704478; Zygosity=Hemizygous (PubMed=32619718) Population: Chinese; Han; Derived from sampling site: Urine. Male 21409257 CVCL_YX77 AG07587 finite cell line human CVCL_YX77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG07587; probable Male 21409258 CVCL_YX78 AG10646 transformed cell line human CVCL_YX78 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG10646; probable Female 21409259 CVCL_YX82 ZR75.1 A3 cancer cell line human CVCL_YX82 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Ascites. Female 21409260 CVCL_YX83 HCC1428-LTED cancer cell line human CVCL_YX83 CL:0000010 Sequence variation: Gene fusion; HGNC; 73; ABCG1 + HGNC; 11024; SLC37A1; Name(s)=SLC37A1-ABCG1 (from parent cell line); Sequence variation: Mutation; HGNC; 3701; FHIT; Unexplicit; Ex4del; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361) 21409261 CVCL_YX84 MCF7-LTED cancer cell line human CVCL_YX84 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361) 21409262 CVCL_YX85 T47D-LTED cancer cell line human CVCL_YX85 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Female Characteristics: Derived from parent cell line by long-term culture in the presence of RPMI-1640 medium containing 10% dextran charcoal stripped serum (DCC) (PubMed=26116361) 21409263 CVCL_YX80 MCF-7 A2 cancer cell line human CVCL_YX80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21409264 CVCL_YX81 SKBR3 A3 cancer cell line human CVCL_YX81 CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 2594; CYP19A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Pleural effusion. Female 21409265 CVCL_YX68 AG24442 transformed cell line human CVCL_YX68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409266 CVCL_YX69 AG24445 transformed cell line human CVCL_YX69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409267 CVCL_YX64 AG24438 transformed cell line human CVCL_YX64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409268 CVCL_YX65 AG24439 transformed cell line human CVCL_YX65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409269 CVCL_YX66 AG24440 transformed cell line human CVCL_YX66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409270 CVCL_YX67 AG24441 transformed cell line human CVCL_YX67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409271 CVCL_YX71 AG24458 transformed cell line human CVCL_YX71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409272 CVCL_YX72 AG27711 induced pluripotent stem cell human CVCL_YX72 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409273 CVCL_YX73 AG24157 transformed cell line human CVCL_YX73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409274 CVCL_YX74 SHEHi002-A induced pluripotent stem cell human CVCL_YX74 From: Shanghai East Hospital; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 1390; CACNA1C; Simple; p.Arg858His (c.2573G>A); ClinVar=VCV000190653; Zygosity=Heterozygous (PubMed=32062134) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409275 CVCL_YX70 AG24454 transformed cell line human CVCL_YX70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409276 CVCL_YX57 AG24430 transformed cell line human CVCL_YX57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409277 CVCL_YX58 AG24432 transformed cell line human CVCL_YX58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409278 CVCL_YX59 AG24433 transformed cell line human CVCL_YX59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409279 CVCL_YX53 AG24426 transformed cell line human CVCL_YX53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409280 CVCL_YX54 AG24427 transformed cell line human CVCL_YX54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409281 CVCL_YX55 AG24428 transformed cell line human CVCL_YX55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409282 CVCL_YX56 AG24429 transformed cell line human CVCL_YX56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409283 CVCL_YX60 AG24434 transformed cell line human CVCL_YX60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409284 CVCL_YX61 AG24435 transformed cell line human CVCL_YX61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409285 CVCL_YX62 AG24436 transformed cell line human CVCL_YX62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409286 CVCL_YX63 AG24437 transformed cell line human CVCL_YX63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409287 CVCL_YX46 AG24417 transformed cell line human CVCL_YX46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409288 CVCL_YX47 AG24418 transformed cell line human CVCL_YX47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409289 CVCL_YX48 AG24420 transformed cell line human CVCL_YX48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409290 CVCL_YX49 AG24421 transformed cell line human CVCL_YX49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409291 CVCL_YX42 AG24413 transformed cell line human CVCL_YX42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409292 CVCL_YX43 AG24414 transformed cell line human CVCL_YX43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409293 CVCL_YX44 AG24415 transformed cell line human CVCL_YX44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409294 CVCL_YX45 AG24416 transformed cell line human CVCL_YX45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409295 CVCL_YX50 AG24423 transformed cell line human CVCL_YX50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409296 CVCL_YX51 AG24424 transformed cell line human CVCL_YX51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409297 CVCL_YX52 AG24425 transformed cell line human CVCL_YX52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409298 CVCL_YX35 AG24406 transformed cell line human CVCL_YX35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409299 CVCL_YX36 AG24407 transformed cell line human CVCL_YX36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409300 CVCL_YX37 AG24408 transformed cell line human CVCL_YX37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409301 CVCL_YX38 AG24409 transformed cell line human CVCL_YX38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409302 CVCL_YX31 AG24402 transformed cell line human CVCL_YX31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409303 CVCL_YX32 AG24403 transformed cell line human CVCL_YX32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409304 CVCL_YX33 AG24404 transformed cell line human CVCL_YX33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409305 CVCL_YX34 AG24405 transformed cell line human CVCL_YX34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409306 CVCL_YX39 AG24410 transformed cell line human CVCL_YX39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409307 CVCL_YX40 AG24411 transformed cell line human CVCL_YX40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409308 CVCL_YX41 AG24412 transformed cell line human CVCL_YX41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409309 CVCL_YT28 FHUi002-C induced pluripotent stem cell human CVCL_YT28 From: Fujita Health University; Toyoake; Japan CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409310 CVCL_YT29 IMBPASi001-A induced pluripotent stem cell human CVCL_YT29 From: Institute of Medical Biology of Polish Academy of Sciences; Lodz; Poland CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Arg611His (c.1832G>A); ClinVar=VCV000045442; Zygosity=Heterozygous (PubMed=32521500); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp648Ter (c.1944G>A); ClinVar=VCV000004511; Zygosity=Heterozygous (PubMed=32521500); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Gly695Val (c.2084G>T); ClinVar=VCV000004510; Zygosity=Heterozygous (PubMed=32521500) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409311 CVCL_YT24 FHUi001-B induced pluripotent stem cell human CVCL_YT24 From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg171_Val173del (c.512_520delGGGATGTCC); Zygosity=Heterozygous (PubMed=32460232) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409312 CVCL_YT25 FHUi001-C induced pluripotent stem cell human CVCL_YT25 From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg171_Val173del (c.512_520delGGGATGTCC); Zygosity=Heterozygous (PubMed=32460232) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409313 CVCL_YT26 FHUi002-A induced pluripotent stem cell human CVCL_YT26 From: Fujita Health University; Toyoake; Japan CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409314 CVCL_YT27 FHUi002-B induced pluripotent stem cell human CVCL_YT27 From: Fujita Health University; Toyoake; Japan CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409315 CVCL_YT31 JUCTCi001-A induced pluripotent stem cell human CVCL_YT31 From: Cell Therapy Center, University of Jordan; Amman; Jordan. CL:0000010 Male 21409316 CVCL_YT32 JUCTCi001-B induced pluripotent stem cell human CVCL_YT32 From: Cell Therapy Center, University of Jordan; Amman; Jordan. CL:0000010 Male 21409317 CVCL_YT33 JUCTCi001-C induced pluripotent stem cell human CVCL_YT33 From: Cell Therapy Center, University of Jordan; Amman; Jordan. CL:0000010 Male 21409318 CVCL_YT34 MRIi001-A induced pluripotent stem cell human CVCL_YT34 From: Klinikum rechts der Isar, Technical University of Munich; Munich; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409319 CVCL_YT30 ISFi001-A induced pluripotent stem cell human CVCL_YT30 From: Institute for Stem Cell Research, Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 21409320 CVCL_YT17 DCGi001-A induced pluripotent stem cell human CVCL_YT17 From: Division of Cancer and Genetics, School of Medicine, Cardiff University; Cardiff; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Glu154Glyfs*301 (c.460dupG); ClinVar=VCV000095268; Zygosity=Heterozygous (PubMed=33096386) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409321 CVCL_YT18 EHTJUi001-A induced pluripotent stem cell human CVCL_YT18 From: East Hospital Affiliated to Tongji University; Shanghai; China. CL:0000010 Female 21409322 CVCL_YT19 EHTJUi002-A induced pluripotent stem cell human CVCL_YT19 From: East Hospital Affiliated to Tongji University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 4042; FZD4; Simple; p.Trp226Ter (c.678G>A); ClinVar=VCV000940196; Zygosity=Heterozygous (PubMed=32889247) Population: Chinese; Han; Derived from sampling site: Umbilical cord blood. Male 21409323 CVCL_YT13 SYSUi004-A induced pluripotent stem cell human CVCL_YT13 From: Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 25598; TYW1; Simple; p.Arg206Cys (c.616C>T); Zygosity=Heterozygous (PubMed=32279010); Sequence variation: Mutation; HGNC; 25598; TYW1; Simple; p.Arg389Gln (c.1166G>A); Zygosity=Heterozygous (PubMed=32279010) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409324 CVCL_YT14 UKBi014-A induced pluripotent stem cell human CVCL_YT14 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 21409325 CVCL_YT15 BMSSDUi001-A induced pluripotent stem cell human CVCL_YT15 From: School of Basic Medical Sciences, Shandong University; Jinan; China. CL:0000010 21409326 CVCL_YT16 CCMBi001-A induced pluripotent stem cell human CVCL_YT16 From: Centre for Cellular and Molecular Biology; Hyderabad; India CL:0000010 Population: Indian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409327 CVCL_YT20 ERPLi001-A induced pluripotent stem cell human CVCL_YT20 From: Eyestem Research Private Ltd; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; c.5018+5G>A; ClinVar=VCV000438098; Zygosity=Heterozygous (PubMed=32278301) Population: Indian; Derived from sampling site: Peripheral blood. Female 21409328 CVCL_YT21 ERPLi002-A induced pluripotent stem cell human CVCL_YT21 From: Eyestem Research Private Ltd; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 19977; RDH12; Simple; p.Ser13Ter (c.38C>A); ClinVar=VCV000977812; Zygosity=Homozygous (PubMed=32278301) Population: Indian; Derived from sampling site: Peripheral blood. Male 21409329 CVCL_YT22 ERPLi003-A induced pluripotent stem cell human CVCL_YT22 From: Eyestem Research Private Ltd; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Cys91Tyr (c.272G>A); ClinVar=VCV000039977; Zygosity=Heterozygous (PubMed=32278301); Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg278Ter (c.832C>T); ClinVar=VCV000099583; Zygosity=Heterozygous (PubMed=32278301) Population: Indian; Derived from sampling site: Peripheral blood. Male 21409330 CVCL_YT23 FHUi001-A induced pluripotent stem cell human CVCL_YT23 From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Arg171_Val173del (c.512_520delGGGATGTCC); Zygosity=Heterozygous (PubMed=32460232) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409332 CVCL_YT07 LEIi012-A induced pluripotent stem cell human CVCL_YT07 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Val256Val (c.768G>T); ClinVar=VCV000099505; Zygosity=Heterozygous; Note=Affects splicing (PubMed=32810830); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Leu2027Phe (c.6079C>T); ClinVar=VCV000007882; Zygosity=Heterozygous (PubMed=32810830) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409333 CVCL_YT08 LEIi012-B induced pluripotent stem cell human CVCL_YT08 From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Val256Val (c.768G>T); ClinVar=VCV000099505; Zygosity=Heterozygous; Note=Affects splicing (PubMed=32810830); Sequence variation: Mutation; HGNC; 34; ABCA4; Simple; p.Leu2027Phe (c.6079C>T); ClinVar=VCV000007882; Zygosity=Heterozygous (PubMed=32810830) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 21409334 CVCL_YT09 DCM iPSC clone 1 induced pluripotent stem cell human CVCL_YT09 CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Ser14450fs*4 (c.43628insAT); Zygosity=Heterozygous (PubMed=25759365) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409335 CVCL_YT02 GIBHi004-A induced pluripotent stem cell human CVCL_YT02 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple; p.Leu10Pro (c.29T>C); Zygosity=Homozygous (PubMed=32534165) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409336 CVCL_YT03 GIBHi006-A induced pluripotent stem cell human CVCL_YT03 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys253Tyr (c.758G>A); ClinVar=VCV000645725; Zygosity=Homozygous (PubMed=32387897) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409337 CVCL_YT04 GIBHi006-B induced pluripotent stem cell human CVCL_YT04 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys253Tyr (c.758G>A); ClinVar=VCV000645725; Zygosity=Homozygous (PubMed=32387897) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409338 CVCL_YT05 GIBHi006-C induced pluripotent stem cell human CVCL_YT05 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys253Tyr (c.758G>A); ClinVar=VCV000645725; Zygosity=Homozygous (PubMed=32387897) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409339 CVCL_YT10 DCM iPSC clone 2 induced pluripotent stem cell human CVCL_YT10 CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Ser14450fs*4 (c.43628insAT); Zygosity=Heterozygous (PubMed=25759365) Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409340 CVCL_YT11 NUIGi003-B induced pluripotent stem cell human CVCL_YT11 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Val822Met (c.2464G>A); ClinVar=VCV000014424; Zygosity=Heterozygous (from autologous cell line NUIGi003-A) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409341 CVCL_YT12 PUMCHi001-A-1 induced pluripotent stem cell human CVCL_YT12 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple_corrected; p.Arg349Trp (c.1045C>T); ClinVar=VCV000066762; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32213461) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409342 CVCL_YT00 CIBi007-A induced pluripotent stem cell human CVCL_YT00 From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 14348; HTRA2; Simple; p.Pro143Ala (c.427C>G); ClinVar=VCV000030583; Zygosity=Heterozygous (PubMed=32688332); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys154Phe (c.461G>T); Zygosity=Heterozygous (PubMed=32688332); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Cys337Tyr (c.1010G>A); Zygosity=Heterozygous (PubMed=32688332) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409343 CVCL_YT01 CMUi002-A induced pluripotent stem cell human CVCL_YT01 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Cell type=Fibroblast. Male 21409344 CVCL_YT90 NH50276 induced pluripotent stem cell human CVCL_YT90 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409345 CVCL_YT91 NH50277 finite cell line human CVCL_YT91 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with torsion dystonia 6 but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409346 CVCL_YT92 NH50278 finite cell line human CVCL_YT92 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409347 CVCL_YT97 NH50283 induced pluripotent stem cell human CVCL_YT97 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu73Metfs*26 (c.217_218delGA); ClinVar=VCV000569567; Zygosity=Heterozygous (PubMed=26677768); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2598Ter (c.7792C>T); ClinVar=VCV000265383; Zygosity=Heterozygous (PubMed=26677768) Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male 21409348 CVCL_YT98 NH50284 induced pluripotent stem cell human CVCL_YT98 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Arg2598Ter (c.7792C>T); ClinVar=VCV000265383; Zygosity=Heterozygous (PubMed=26677768) Population: Asian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Characteristics: The ATM p.Glu73Metfs*26 (c.217_218delGA) present in the patient and in another iPSC from the same individual has been lost during the reprogramming process 21409349 CVCL_YT99 NH50287 finite cell line human CVCL_YT99 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409350 CVCL_YT93 NH50279 finite cell line human CVCL_YT93 CL:0000010 Population: Caucasian; Scottish and Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409351 CVCL_YT94 NH50280 finite cell line human CVCL_YT94 CL:0000010 Population: Caucasian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409352 CVCL_YT95 NH50281 induced pluripotent stem cell human CVCL_YT95 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu73Metfs*26 (c.217_218delGA); ClinVar=VCV000569567; Zygosity=Heterozygous (PubMed=26677768) Population: Asian; Derived from sampling site: Peripheral blood. Female 21409353 CVCL_YT96 NH50282 induced pluripotent stem cell human CVCL_YT96 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Glu522Ilefs (c.1564_1565delGA) (1563_1564delAG); Zygosity=Heterozygous (PubMed=26677768); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ser2394Leu (c.7181C>T); ClinVar=VCV000127437; Zygosity=Heterozygous (PubMed=26677768) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female 21409354 CVCL_YT79 NH50266 induced pluripotent stem cell human CVCL_YT79 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409355 CVCL_YT80 NH50267 induced pluripotent stem cell human CVCL_YT80 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409356 CVCL_YT81 NH50268 induced pluripotent stem cell human CVCL_YT81 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409357 CVCL_YT86 NH50273 induced pluripotent stem cell human CVCL_YT86 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409358 CVCL_YT87 NH50274 induced pluripotent stem cell human CVCL_YT87 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409359 CVCL_YT88 NH50275 induced pluripotent stem cell human CVCL_YT88 CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21409360 CVCL_YT89 NH50285 induced pluripotent stem cell human CVCL_YT89 CL:0000010 Derived from sampling site: Umbilical cord blood. Male 21409361 CVCL_YT82 NH50269 induced pluripotent stem cell human CVCL_YT82 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409362 CVCL_YT83 NH50270 induced pluripotent stem cell human CVCL_YT83 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409363 CVCL_YT84 NH50271 induced pluripotent stem cell human CVCL_YT84 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409364 CVCL_YT85 NH50272 induced pluripotent stem cell human CVCL_YT85 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409365 CVCL_YT68 WT 6-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT68 CL:0000010 Derived from sampling site: Peripheral blood. Male 21409366 CVCL_YT69 WT 7-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT69 CL:0000010 Derived from sampling site: Peripheral blood. Male 21409367 CVCL_YT70 WT 8-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT70 CL:0000010 Derived from sampling site: Peripheral blood. Male 21409368 CVCL_YT75 NH50262 induced pluripotent stem cell human CVCL_YT75 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409369 CVCL_YT76 NH50263 induced pluripotent stem cell human CVCL_YT76 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21409370 CVCL_YT77 NH50264 induced pluripotent stem cell human CVCL_YT77 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21409371 CVCL_YT78 NH50265 induced pluripotent stem cell human CVCL_YT78 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 21409372 CVCL_YT71 WT 9-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT71 CL:0000010 Derived from sampling site: Peripheral blood. Female 21409373 CVCL_YT72 NH50258 induced pluripotent stem cell human CVCL_YT72 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Repeat_expansion; (CAG)54 (c.172_174CAG(10_36)); ClinVar=VCV000009818; Zygosity=Hemizygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409374 CVCL_YT73 NH50260 induced pluripotent stem cell human CVCL_YT73 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409375 CVCL_YT74 NH50261 induced pluripotent stem cell human CVCL_YT74 CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 21409376 CVCL_YT57 HSC 20 transformed cell line human CVCL_YT57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 21409377 CVCL_YT58 HSC 22 transformed cell line human CVCL_YT58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 21409378 CVCL_YT59 ssHUDEP2 transformed cell line human CVCL_YT59 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple_edited; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous; Note=By CRISPR/Cas9 (DOI=10.1182/blood-2019-127330); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Population: Japanese; Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical cord blood Cell type=Erythroid progenitor cell.. Unspecified 21409379 CVCL_YT64 WT 2-DP-hiPSC induced pluripotent stem cell human CVCL_YT64 CL:0000010 Derived from sampling site: Tooth; dental pulp. Male Caution: Indicated as originating from a female donor in table 1 and from having an amelogenin X,Y marker in figure 8 21409380 CVCL_YT65 WT 3-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT65 CL:0000010 Derived from sampling site: Peripheral blood. Male 21409381 CVCL_YT66 WT 4-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT66 CL:0000010 Derived from sampling site: Peripheral blood. Male 21409382 CVCL_YT67 WT 5-PBMC-hiPSC induced pluripotent stem cell human CVCL_YT67 CL:0000010 Derived from sampling site: Peripheral blood. Female 21409383 CVCL_YT60 RenCares cancer cell line house mouse CVCL_YT60 CL:0000010 Selected for resistance to: ChEBI; CHEBI:68478; Everolimus (RAD001); Breed/subspecies: BALB/c. Male 21409384 CVCL_YT61 CNGBCCAC00007 finite cell line CVCL_YT61 CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Male Doubling time: 21.28 hours (PubMed=31898011) 21409385 CVCL_YT62 CCD-SeV-iPS1 induced pluripotent stem cell human CVCL_YT62 CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Simple; p.Arg225Gln (c.674G>A); ClinVar=VCV000009302; Zygosity=Heterozygous (PubMed=26559068) Derived from sampling site: Tooth; dental pulp. Female 21409386 CVCL_YT63 WT 1-DP-hiPSC induced pluripotent stem cell human CVCL_YT63 CL:0000010 Derived from sampling site: Tooth; dental pulp. Female 21409387 CVCL_YT46 STJUDEi003-A induced pluripotent stem cell human CVCL_YT46 From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Gly227Arg (c.679G>A); ClinVar=VCV000430342; Zygosity=Heterozygous (PubMed=32485644); Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.His399_Tyr400dup (c.1195_1200dup); Zygosity=Heterozygous (PubMed=32485644) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409388 CVCL_YT47 TYWHSTi001-A induced pluripotent stem cell human CVCL_YT47 From: Tianyou Hospital, Wuhan University of Science and Technology; Wuhan; China. CL:0000010 Female 21409389 CVCL_YT48 TYWHSTi002-A induced pluripotent stem cell human CVCL_YT48 From: Tianyou Hospital, Wuhan University of Science and Technology; Wuhan; China CL:0000010 Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; c.919-2A>G (IVS7AS,A-G,-2); ClinVar=VCV000004840; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=32717573); Sequence variation: Mutation; HGNC; 8818; SLC26A4; Simple; c.1614+1G>A; ClinVar=VCV000043516; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=32717573) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 21409390 CVCL_YT49 UKMi001-A induced pluripotent stem cell human CVCL_YT49 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2364; CRLF1; Simple; p.Pro238Argfs*6 (c.708_709delinsT); ClinVar=VCV000005712; Zygosity=Homozygous (PubMed=32492556) Population: Turkish; Derived from sampling site: Nose Cell type=Fibroblast.. Female 21409391 CVCL_YT53 CNE1 SRPK1 KO hybrid cell line human CVCL_YT53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Problematic cell line: Contaminated The parent cell line (CNE-1) seems to be a hybrid of HeLa and of cell line of unknown origin. 21409392 CVCL_YT54 CNE1 SRPK2 KO hybrid cell line human CVCL_YT54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11306; SRPK2; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Problematic cell line: Contaminated The parent cell line (CNE-1) seems to be a hybrid of HeLa and of cell line of unknown origin. 21409393 CVCL_YT55 CNE1 SRPK1/2 KO hybrid cell line human CVCL_YT55 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Knockout cell: Method=CRISPR/Cas9; HGNC; 11306; SRPK2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q9U6Y8; RFP. Problematic cell line: Contaminated The grand-parent cell line (CNE-1) seems to be a hybrid of HeLa and of cell line of unknown origin. 21409394 CVCL_YT56 HL-60R cancer cell line human CVCL_YT56 CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln411Ter (c.1231C>T); Zygosity=Heterozygous; Note=Responsible for retinoic acid resistance (PubMed=1327285) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:15367; All-trans-retinoic acid (ATRA; Derived from sampling site: Peripheral blood. Female 21409395 CVCL_YT50 UKMi001-B induced pluripotent stem cell human CVCL_YT50 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2364; CRLF1; Simple; p.Pro238Argfs*6 (c.708_709delinsT); ClinVar=VCV000005712; Zygosity=Homozygous (PubMed=32492556) Population: Turkish; Derived from sampling site: Nose Cell type=Fibroblast.. Female 21409396 CVCL_YT51 UKMi001-C induced pluripotent stem cell human CVCL_YT51 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2364; CRLF1; Simple; p.Pro238Argfs*6 (c.708_709delinsT); ClinVar=VCV000005712; Zygosity=Homozygous (PubMed=32492556) Population: Turkish; Derived from sampling site: Nose Cell type=Fibroblast.. Female 21409397 CVCL_YT52 UMi027-A induced pluripotent stem cell human CVCL_YT52 From: Miller School of Medicine, University of Miami; Miami; USA. CL:0000010 21409398 CVCL_YT39 SDUBMSi002-A induced pluripotent stem cell human CVCL_YT39 From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 2555; CUL4B; Simple; p.Arg388Ter (c.1162C>T) (c.1564C>T); ClinVar=VCV000011339; Zygosity=Hemizygous (PubMed=32078988) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409399 CVCL_YT35 NIMHi001-A induced pluripotent stem cell human CVCL_YT35 From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile1371Val (c.4111A>G); ClinVar=VCV000039176; Zygosity=Heterozygous (PubMed=32244201) Population: Indian; Derived from sampling site: Peripheral blood. Male 21409400 CVCL_YT36 RCMGi001-A induced pluripotent stem cell human CVCL_YT36 From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=32777768) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409401 CVCL_YT37 RCMGi002-A induced pluripotent stem cell human CVCL_YT37 From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=33684631) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 21409402 CVCL_YT38 SDUBMSi001-A induced pluripotent stem cell human CVCL_YT38 From: School of Basic Medical Sciences, Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Thr258Met (c.773C>T); ClinVar=VCV000464261; Zygosity=Heterozygous (PubMed=32045731) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409403 CVCL_YT42 SKLOi001-A induced pluripotent stem cell human CVCL_YT42 From: State Key Laboratory of Ophthalmology, Sun Yat-sen University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2020; CLCN2; Simple; p.Arg753Ter (c.2257C>T); Zygosity=Homozygous (PubMed=32278302) Population: Chinese; Han; Derived from sampling site: Urine. Female 21409404 CVCL_YT43 SKLRMi001-A induced pluripotent stem cell human CVCL_YT43 From: State Key Laboratory of Reproductive Medicine, Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Val904Met (c.2710G>A); Zygosity=Hemizygous (PubMed=32505105) Derived from sampling site: Peripheral blood. Male 21409405 CVCL_YT44 STJUDEi001-A induced pluripotent stem cell human CVCL_YT44 From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Leu215Pro (c.644T>C); ClinVar=VCV000393239; Zygosity=Heterozygous (PubMed=32485644); Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Val217Met (c.649G>A); ClinVar=VCV000002449; Zygosity=Heterozygous (PubMed=32485644) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409406 CVCL_YT45 STJUDEi002-A induced pluripotent stem cell human CVCL_YT45 From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 7758; NEU1; Simple; p.Tyr370Cys (c.1109A>G); ClinVar=VCV000986732; Zygosity=Homozygous (PubMed=32485644) Population: Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409407 CVCL_YT40 SHCDNi001-A induced pluripotent stem cell human CVCL_YT40 From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 13601; FBXL4; Simple; p.Leu332Thrfs*3 (c.993dupA); Zygosity=Homozygous (PubMed=32416579) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409408 CVCL_YT41 SJTUi002-A induced pluripotent stem cell human CVCL_YT41 From: Shanghai Jiao Tong University School of Medicine; Shanghai; China. CL:0000010 21409409 CVCL_YU49 AG24049 transformed cell line human CVCL_YU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409410 CVCL_YU45 PSFDFN388 finite cell line human CVCL_YU45 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21409411 CVCL_YU46 PSADFN423 finite cell line human CVCL_YU46 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+2T>A; ClinVar=VCV000162414; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27920058) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Doubling time: 28.8 days, at 8th passage (PubMed=27920058) Part of: Progeria Research Foundation cell lines 21409412 CVCL_YU47 AG24047 transformed cell line human CVCL_YU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409413 CVCL_YU48 AG24048 transformed cell line human CVCL_YU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409414 CVCL_YU52 AG24053 transformed cell line human CVCL_YU52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409415 CVCL_YU53 AG24054 transformed cell line human CVCL_YU53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409416 CVCL_YU54 AG24055 transformed cell line human CVCL_YU54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409417 CVCL_YU55 AG24056 transformed cell line human CVCL_YU55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409418 CVCL_YU50 AG24050 transformed cell line human CVCL_YU50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409419 CVCL_YU51 AG24051 transformed cell line human CVCL_YU51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409420 CVCL_YU38 HGADFN496 finite cell line human CVCL_YU38 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF) Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409421 CVCL_YU39 HGMDFN718 finite cell line human CVCL_YU39 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409422 CVCL_YU34 CS03iHD-53nxx induced pluripotent stem cell human CVCL_YU34 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[53] (c.52CAG(53)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Unspecified (CSMC) Derived from sampling site: Cell type=Fibroblast. Male 21409423 CVCL_YU35 CS06iCTR induced pluripotent stem cell human CVCL_YU35 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 21409424 CVCL_YU36 PSADFN485 finite cell line human CVCL_YU36 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Glu138Lys (c.412G>A); ClinVar=VCV000066897; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21409425 CVCL_YU37 HGMDFN717 finite cell line human CVCL_YU37 CL:0000010 Miscellaneous: Cell line no longer available Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409426 CVCL_YU41 PSFDFN714 finite cell line human CVCL_YU41 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Progeria Research Foundation cell lines 21409427 CVCL_YU42 PSMDFN713 finite cell line human CVCL_YU42 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409428 CVCL_YU43 PSADFN386 finite cell line human CVCL_YU43 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; c.1968+2T>C; ClinVar=VCV000162415; Zygosity=Mosaic; Note=Splice donor mutation In 100% of the skin fibroblast cells. The patient blood is mosaic for 4.7% c.1968+2T>C (causing mild HGPS) and 41.3% c.1968+2T>A (severe HGPS) (PubMed=27920058). Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409429 CVCL_YU44 PSMDFN387 finite cell line human CVCL_YU44 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409430 CVCL_YU40 PSADFN489 finite cell line human CVCL_YU40 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Gly608Gly (c.1824C>T); ClinVar=VCV000014500; Zygosity=Heterozygous; Note=Creates an exonic consensus splice donor sequence that leads to the activation of a cryptic splice site which in turn causes skipping of 150 bp of the LMNA mRNA leading to the deletion of 50 amino acids (PRF); Sequence variation: Mutation; HGNC; 2468; SMC3; Simple; p.Lys188Glu (c.562A>G); ClinVar=VCV000383548; Zygosity=Heterozygous (PRF) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Progeria Research Foundation cell lines 21409431 CVCL_YU27 Mu-9 hybridoma house mouse CVCL_YU27 CL:0000010 Characteristics: The produced mAB reacts strongly with >60% of colon carcinomas; Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q8WXI7; Human MUC16. 21409432 CVCL_YU28 CGMCC-14700 hybridoma house mouse CVCL_YU28 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:6741; Meloxicam. Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.14700 21409433 CVCL_YU29 WTC FBL-mEGFP/NPM1-mTagRFPT/CLYBL-dCas9-TagBFP-KRAB-cl61 induced pluripotent stem cell human CVCL_YU29 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Tyr66His and p.Tyr145Phe = BFP); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 (deactivated version with KRAB domain; dCas9-KRAB) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 FBL has been endogenously tagged in one allele at the C-terminus with mEGFP, NPM1 has been endogenously tagged in one allele at the C-terminus with mTagRFP-T and a dCas9-TagBFP-KRAB construct is expressed from a CAGGS promoter edited into the 2nd intron of the CLYBL safe harbor Part of: Allen Cell Collection 21409434 CVCL_YU23 CTLL-2 NF-kappaB transformed cell line house mouse CVCL_YU23 CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6. Characteristics: Reporter cell line for the measurement of the biological activity of a wide variety of cytokines; Characteristics: Activated by NF-kappaB through a NF-kappaB response element fused to a secNanoLuc-T2A-mCherry construct 21409435 CVCL_YU24 BSa2 spontaneously immortalized cell line CVCL_YU24 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Characteristics: Can differentiate into osteoblastic, chondroblastic and osteoclastic lineages Group: Fish cell line 21409436 CVCL_YU26 ClDuF spontaneously immortalized cell line CVCL_YU26 CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: ~24 hours (PubMed=31989626) Group: Endangered species/breed cell line; Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC059 21409437 CVCL_YU30 WTC-mEGFP-SON-cl24 induced pluripotent stem cell human CVCL_YU30 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 SON has been endogenously tagged in one allele at the N-terminus with mEGFP Part of: Allen Cell Collection 21409438 CVCL_YU31 MW10 finite cell line human CVCL_YU31 CL:0000010 Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Ala33Val (c.98C>T) (A16V, 274T); ClinVar=VCV000013667; Zygosity=Heterozygous (PubMed=1409720); Sequence variation: Mutation; HGNC; 438; ALPL; Simple; p.Tyr436His (c.1306T>C) (Y419H, 1482C); ClinVar=VCV000013668; Zygosity=Heterozygous (PubMed=1409720). Male 21409439 CVCL_YU32 CSUASOi003-A induced pluripotent stem cell human CVCL_YU32 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Gly750Asp (c.2249G>A); Zygosity=Heterozygous (PubMed=32244200); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Ala937Thr (c.2809G>A); ClinVar=VCV000285879; Zygosity=Heterozygous (PubMed=32244200) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 21409440 CVCL_YU33 hTERT-ATL3 Y192C telomerase immortalized cell line human CVCL_YU33 CL:0000010 Sequence variation: Mutation; HGNC; 24526; ATL3; Simple; p.Tyr192Cys (c.575A>G); ClinVar=VCV000097070; Zygosity=Heterozygous (PubMed=30666337); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Age/sex of donor from personal communication of Kaether C Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409441 CVCL_YU16 NCC-MPNST4-C1 cancer cell line human CVCL_YU16 CL:0000010 Sequence variation: Gene deletion; HGNC; 646; ARAF; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Gene deletion; HGNC; 12637; KDM6A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; c.5812+3delAGTA; Zygosity=Heterozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Gly (c.745A>G); ClinVar=VCV000376654; Zygosity=Homozygous (PubMed=32099531). Population: Japanese Male Doubling time: 70 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409442 CVCL_YU17 NCC-MPNST5-C1 cancer cell line human CVCL_YU17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Thr586Valfs*18 (c.1756_1759delACTA) (1756delACTA); ClinVar=VCV000186215; Zygosity=Heterozygous (PubMed=32099531). Population: Japanese Female Doubling time: 33 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409443 CVCL_YU18 CSUASOi004-A induced pluripotent stem cell human CVCL_YU18 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 15860; PRPF6; Simple; p.Arg900His (c.2699G>A); ClinVar=VCV000842292; Zygosity=Heterozygous (PubMed=32335390) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 21409444 CVCL_YU19 CSUASOi005-A induced pluripotent stem cell human CVCL_YU19 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 10457; RS1; Simple; p.Phe176Tyr (c.527T>A); ClinVar=VCV000540204; ClinVar=VCV000540204; Zygosity=Hemizygous (PubMed=32050117) Population: Chinese; Derived from sampling site: Peripheral blood. Male 21409445 CVCL_YU12 NCC-MPNST1-C1 cancer cell line human CVCL_YU12 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Gene deletion; HGNC; 12362; TSC1; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1872Ter (c.5614A>T); ClinVar=VCV000037979; Zygosity=Heterozygous (PubMed=32099531). Population: Japanese Female Doubling time: 28 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409446 CVCL_YU13 NCC-MPNST2-C1 cancer cell line human CVCL_YU13 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu179Tyrfs*11 (c.536_539del); Zygosity=Unspecified (PubMed=32099531). Population: Japanese Male Doubling time: 49 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409447 CVCL_YU14 NCC-MPNST3-C1 cancer cell line human CVCL_YU14 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Gene deletion; HGNC; 3942; MTOR; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg816Ter (c.2446C>T); ClinVar=VCV000280055; Zygosity=Heterozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=32099531). Population: Japanese Male Doubling time: 70 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409448 CVCL_YU15 NCC-MPNST3-X2-C1 cancer cell line human CVCL_YU15 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Arg816Ter (c.2446C>T); ClinVar=VCV000280055; Zygosity=Heterozygous (PubMed=32099531); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=32099531); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Trp (c.405C>G); ClinVar=VCV000376561; Zygosity=Heterozygous (PubMed=32099531). Population: Japanese Male Characteristics: Established from a second generation xenograft established by subcutaneous grafting of tumor tissue into the bilateral hind flanks of female NOD/Shi-scid IL-2Rgammanull mice Doubling time: 64 hours (PubMed=32099531) Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: NCC sarcoma cell line panel 21409449 CVCL_YU20 Huh7.5.1-8 cancer cell line human CVCL_YU20 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (PubMed=33193621); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Heterozygous (PubMed=33193621); Sequence variation: Mutation; HGNC; 11255; SPP1; Simple; p.Lys241Thr (c.722A>C); Zygosity=Heterozygous; Note=Newly acquired mutation (PubMed=33193621); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Omics: Genome sequenced Male Virology: Highly susceptible to infection by HCV 21409450 CVCL_YU21 Huh7.5.1-5 cancer cell line human CVCL_YU21 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 19102; RIGI; Simple; p.Thr55Ile (c.164C>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Liver. Omics: Genome sequenced Male Virology: CD81-defective clone not susceptible to infection by HCV 21409451 CVCL_YU22 A20 NF-kappaB cancer cell line house mouse CVCL_YU22 CL:0000010 Transfected with: NanoLuc, a 19 kDa ATP-independent bright luminescent protein derived from Oplophorus gracilirostris; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Breed/subspecies: BALB/cAnN. Unspecified Characteristics: Reporter cell line for the measurement of the biological activity of a wide variety of cytokines; Characteristics: Activated by NF-kappaB through a NF-kappaB response element fused to a secNanoLuc-T2A-mCherry construct 21409452 CVCL_YU05 HPSI1016i-eoxu_2 induced pluripotent stem cell human CVCL_YU05 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Male 21409453 CVCL_YU06 HPSI1016i-eoxu_6 induced pluripotent stem cell human CVCL_YU06 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Male 21409454 CVCL_YU07 HPSI1116i-zehh_3 induced pluripotent stem cell human CVCL_YU07 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Female 21409455 CVCL_YU08 HPSI1116i-zehh_4 induced pluripotent stem cell human CVCL_YU08 From: Cambridge BioResource; Cambridge; United Kingdom CL:0000010 Population: Caucasian; British; Donor information: Donor is said to be suffering from a 'rare genetic neurological disorder'; Derived from sampling site: Peripheral blood. Female 21409456 CVCL_YU01 NH50289 finite cell line human CVCL_YU01 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Arg245Lys (c.734G>A); Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 8607; PRKN; Simple; p.Gly430Asp (c.1289G>A); ClinVar=VCV000356016; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 21409457 CVCL_YU02 NH50290 induced pluripotent stem cell human CVCL_YU02 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Heterozygous (NHCDR); Sequence variation: Mutation; HGNC; 4010; FUS; Simple_corrected; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409458 CVCL_YU03 NH50291 induced pluripotent stem cell human CVCL_YU03 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple_corrected; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409459 CVCL_YU04 NH50292 induced pluripotent stem cell human CVCL_YU04 CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.His517Gln (c.1551C>G); ClinVar=VCV000016221; Zygosity=Homozygous (NHCDR) Population: Cape Verdian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Non-edited control for NH50290 (Cellosaurus=CVCL_YU02) and NH50291 (Cellosaurus=CVCL_YU03) 21409460 CVCL_YU09 WI-38 (HSV-2)Tr transformed cell line human CVCL_YU09 CL:0000010 Population: Caucasian; Swedish; Transformant: Human herpesvirus 2 (HHV-2)(NCBI-Taxonomy; 10310); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 21409461 CVCL_YU10 SK-OV-3-hCD271 cancer cell line human CVCL_YU10 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7809; NGFR; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Ascites. Female 21409462 CVCL_YU11 hCD271mAb#13 hybridoma house mouse CVCL_YU11 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08138; Human NGFR/CD271. 21409463 CVCL_YU00 NH50288 finite cell line human CVCL_YU00 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 21409464 CVCL_YU89 AG24112 transformed cell line human CVCL_YU89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409465 CVCL_YU90 AG24113 transformed cell line human CVCL_YU90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409466 CVCL_YU91 AG24114 transformed cell line human CVCL_YU91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409467 CVCL_YU96 AG24119 transformed cell line human CVCL_YU96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409468 CVCL_YU97 AG24120 transformed cell line human CVCL_YU97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409469 CVCL_YU98 AG24121 transformed cell line human CVCL_YU98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409470 CVCL_YU99 AG24122 transformed cell line human CVCL_YU99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409471 CVCL_YU92 AG24115 transformed cell line human CVCL_YU92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409472 CVCL_YU93 AG24116 transformed cell line human CVCL_YU93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409473 CVCL_YU94 AG24117 transformed cell line human CVCL_YU94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409474 CVCL_YU95 AG24118 transformed cell line human CVCL_YU95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409475 CVCL_YU78 AG24100 transformed cell line human CVCL_YU78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409476 CVCL_YU79 AG24101 transformed cell line human CVCL_YU79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409477 CVCL_YU80 AG24102 transformed cell line human CVCL_YU80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409478 CVCL_YU85 AG24107 transformed cell line human CVCL_YU85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409479 CVCL_YU86 AG24108 transformed cell line human CVCL_YU86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409480 CVCL_YU87 AG24109 transformed cell line human CVCL_YU87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409481 CVCL_YU88 AG24111 transformed cell line human CVCL_YU88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409482 CVCL_YU81 AG24103 transformed cell line human CVCL_YU81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409483 CVCL_YU82 AG24104 transformed cell line human CVCL_YU82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409484 CVCL_YU83 AG24105 transformed cell line human CVCL_YU83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409485 CVCL_YU84 AG24106 transformed cell line human CVCL_YU84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409486 CVCL_YU67 AG24083 transformed cell line human CVCL_YU67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409487 CVCL_YU68 AG24084 transformed cell line human CVCL_YU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409488 CVCL_YU69 AG24085 transformed cell line human CVCL_YU69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409489 CVCL_YU74 AG24092 transformed cell line human CVCL_YU74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409490 CVCL_YU75 AG24093 transformed cell line human CVCL_YU75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409491 CVCL_YU76 AG24096 transformed cell line human CVCL_YU76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409492 CVCL_YU77 AG24098 transformed cell line human CVCL_YU77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409493 CVCL_YU70 AG24086 transformed cell line human CVCL_YU70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409494 CVCL_YU71 AG24087 transformed cell line human CVCL_YU71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409495 CVCL_YU72 AG24090 transformed cell line human CVCL_YU72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409496 CVCL_YU73 AG24091 transformed cell line human CVCL_YU73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409497 CVCL_YU56 AG24057 transformed cell line human CVCL_YU56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409498 CVCL_YU57 AG24058 transformed cell line human CVCL_YU57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409499 CVCL_YU58 AG24059 transformed cell line human CVCL_YU58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409500 CVCL_YU59 AG24060 transformed cell line human CVCL_YU59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409501 CVCL_YU63 AG24065 transformed cell line human CVCL_YU63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409502 CVCL_YU64 AG24077 transformed cell line human CVCL_YU64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409503 CVCL_YU65 AG24078 transformed cell line human CVCL_YU65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409504 CVCL_YU66 AG24081 transformed cell line human CVCL_YU66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409505 CVCL_YU60 AG24062 transformed cell line human CVCL_YU60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409506 CVCL_YU61 AG24063 transformed cell line human CVCL_YU61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409507 CVCL_YU62 AG24064 transformed cell line human CVCL_YU62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409508 CVCL_YW03 AG24241 transformed cell line human CVCL_YW03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409509 CVCL_YW04 AG24242 transformed cell line human CVCL_YW04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409510 CVCL_YW05 AG24243 transformed cell line human CVCL_YW05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409511 CVCL_YW06 AG24244 transformed cell line human CVCL_YW06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409512 CVCL_YW00 AG24238 transformed cell line human CVCL_YW00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409513 CVCL_YW01 AG24239 transformed cell line human CVCL_YW01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409514 CVCL_YW02 AG24240 transformed cell line human CVCL_YW02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409515 CVCL_YW07 AG24245 transformed cell line human CVCL_YW07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409516 CVCL_YW08 AG24246 transformed cell line human CVCL_YW08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409517 CVCL_YW09 AG24247 transformed cell line human CVCL_YW09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409518 CVCL_YV66 AG24198 transformed cell line human CVCL_YV66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409519 CVCL_YV67 AG24199 transformed cell line human CVCL_YV67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409520 CVCL_YV68 AG24200 transformed cell line human CVCL_YV68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409521 CVCL_YV69 AG24202 transformed cell line human CVCL_YV69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409522 CVCL_YV73 AG24206 transformed cell line human CVCL_YV73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409523 CVCL_YV74 AG24207 transformed cell line human CVCL_YV74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409524 CVCL_YV75 AG24208 transformed cell line human CVCL_YV75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409525 CVCL_YV76 AG24209 transformed cell line human CVCL_YV76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409526 CVCL_YV70 AG24203 transformed cell line human CVCL_YV70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409527 CVCL_YV71 AG24204 transformed cell line human CVCL_YV71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409528 CVCL_YV72 AG24205 transformed cell line human CVCL_YV72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409529 CVCL_YV59 AG24191 transformed cell line human CVCL_YV59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409530 CVCL_YV55 AG24187 transformed cell line human CVCL_YV55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409531 CVCL_YV56 AG24188 transformed cell line human CVCL_YV56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409532 CVCL_YV57 AG24189 transformed cell line human CVCL_YV57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409533 CVCL_YV58 AG24190 transformed cell line human CVCL_YV58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409534 CVCL_YV62 AG24194 transformed cell line human CVCL_YV62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409535 CVCL_YV63 AG24195 transformed cell line human CVCL_YV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409536 CVCL_YV64 AG24196 transformed cell line human CVCL_YV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409537 CVCL_YV65 AG24197 transformed cell line human CVCL_YV65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409538 CVCL_YV60 AG24192 transformed cell line human CVCL_YV60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409539 CVCL_YV61 AG24193 transformed cell line human CVCL_YV61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409540 CVCL_YV48 AG24180 transformed cell line human CVCL_YV48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409541 CVCL_YV49 AG24181 transformed cell line human CVCL_YV49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409542 CVCL_YV44 AG24176 transformed cell line human CVCL_YV44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409543 CVCL_YV45 AG24177 transformed cell line human CVCL_YV45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409544 CVCL_YV46 AG24178 transformed cell line human CVCL_YV46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409545 CVCL_YV47 AG24179 transformed cell line human CVCL_YV47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409546 CVCL_YV51 AG24183 transformed cell line human CVCL_YV51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409547 CVCL_YV52 AG24184 transformed cell line human CVCL_YV52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409548 CVCL_YV53 AG24185 transformed cell line human CVCL_YV53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409549 CVCL_YV54 AG24186 transformed cell line human CVCL_YV54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409550 CVCL_YV50 AG24182 transformed cell line human CVCL_YV50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409551 CVCL_YV37 AG24165 transformed cell line human CVCL_YV37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409552 CVCL_YV38 AG24166 transformed cell line human CVCL_YV38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409553 CVCL_YV39 AG24167 transformed cell line human CVCL_YV39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409554 CVCL_YV33 AG24161 transformed cell line human CVCL_YV33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409555 CVCL_YV34 AG24162 transformed cell line human CVCL_YV34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409556 CVCL_YV35 AG24163 transformed cell line human CVCL_YV35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409557 CVCL_YV36 AG24164 transformed cell line human CVCL_YV36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409558 CVCL_YV40 AG24168 transformed cell line human CVCL_YV40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409559 CVCL_YV41 AG24170 transformed cell line human CVCL_YV41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409560 CVCL_YV42 AG24172 transformed cell line human CVCL_YV42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409561 CVCL_YV43 AG24174 transformed cell line human CVCL_YV43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409562 CVCL_YV26 AG24153 transformed cell line human CVCL_YV26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409563 CVCL_YV27 AG24154 transformed cell line human CVCL_YV27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409564 CVCL_YV28 AG24155 transformed cell line human CVCL_YV28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409565 CVCL_YV29 AG24156 transformed cell line human CVCL_YV29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409566 CVCL_YV22 AG24149 transformed cell line human CVCL_YV22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409567 CVCL_YV23 AG24150 transformed cell line human CVCL_YV23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409568 CVCL_YV24 AG24151 transformed cell line human CVCL_YV24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409569 CVCL_YV25 AG24152 transformed cell line human CVCL_YV25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409570 CVCL_YV30 AG24158 transformed cell line human CVCL_YV30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409571 CVCL_YV31 AG24159 transformed cell line human CVCL_YV31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409572 CVCL_YV32 AG24160 transformed cell line human CVCL_YV32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409573 CVCL_YV15 AG24139 transformed cell line human CVCL_YV15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409574 CVCL_YV16 AG24141 transformed cell line human CVCL_YV16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409575 CVCL_YV17 AG24142 transformed cell line human CVCL_YV17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409576 CVCL_YV18 AG24144 transformed cell line human CVCL_YV18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409577 CVCL_YV11 AG24135 transformed cell line human CVCL_YV11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409578 CVCL_YV12 AG24136 transformed cell line human CVCL_YV12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409579 CVCL_YV13 AG24137 transformed cell line human CVCL_YV13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409580 CVCL_YV14 AG24138 transformed cell line human CVCL_YV14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409581 CVCL_YV19 AG24146 transformed cell line human CVCL_YV19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409582 CVCL_YV20 AG24147 transformed cell line human CVCL_YV20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409583 CVCL_YV21 AG24148 transformed cell line human CVCL_YV21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409584 CVCL_YV04 AG24127 transformed cell line human CVCL_YV04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409585 CVCL_YV05 AG24128 transformed cell line human CVCL_YV05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409586 CVCL_YV06 AG24130 transformed cell line human CVCL_YV06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409587 CVCL_YV07 AG24131 transformed cell line human CVCL_YV07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409588 CVCL_YV00 AG24123 transformed cell line human CVCL_YV00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409589 CVCL_YV01 AG24124 transformed cell line human CVCL_YV01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409590 CVCL_YV02 AG24125 transformed cell line human CVCL_YV02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409591 CVCL_YV03 AG24126 transformed cell line human CVCL_YV03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409592 CVCL_YV08 AG24132 transformed cell line human CVCL_YV08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409593 CVCL_YV09 AG24133 transformed cell line human CVCL_YV09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409594 CVCL_YV10 AG24134 transformed cell line human CVCL_YV10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409595 CVCL_YV99 AG24237 transformed cell line human CVCL_YV99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409596 CVCL_YV88 AG24222 transformed cell line human CVCL_YV88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409597 CVCL_YV89 AG24223 transformed cell line human CVCL_YV89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409598 CVCL_YV90 AG24226 transformed cell line human CVCL_YV90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409599 CVCL_YV95 AG24233 transformed cell line human CVCL_YV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409600 CVCL_YV96 AG24234 transformed cell line human CVCL_YV96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409601 CVCL_YV97 AG24235 transformed cell line human CVCL_YV97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409602 CVCL_YV98 AG24236 transformed cell line human CVCL_YV98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409603 CVCL_YV91 AG24227 transformed cell line human CVCL_YV91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409604 CVCL_YV92 AG24228 transformed cell line human CVCL_YV92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409605 CVCL_YV93 AG24230 transformed cell line human CVCL_YV93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409606 CVCL_YV94 AG24232 transformed cell line human CVCL_YV94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409607 CVCL_YV77 AG24210 transformed cell line human CVCL_YV77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409608 CVCL_YV78 AG24211 transformed cell line human CVCL_YV78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409609 CVCL_YV79 AG24212 transformed cell line human CVCL_YV79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409610 CVCL_YV84 AG24218 transformed cell line human CVCL_YV84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409611 CVCL_YV85 AG24219 transformed cell line human CVCL_YV85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409612 CVCL_YV86 AG24220 transformed cell line human CVCL_YV86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409613 CVCL_YV87 AG24221 transformed cell line human CVCL_YV87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409614 CVCL_YV80 AG24213 transformed cell line human CVCL_YV80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409615 CVCL_YV81 AG24214 transformed cell line human CVCL_YV81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409616 CVCL_YV82 AG24215 transformed cell line human CVCL_YV82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409617 CVCL_YV83 AG24216 transformed cell line human CVCL_YV83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409618 CVCL_YX24 AG24395 transformed cell line human CVCL_YX24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409619 CVCL_YX25 AG24396 transformed cell line human CVCL_YX25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409620 CVCL_YX26 AG24397 transformed cell line human CVCL_YX26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409621 CVCL_YX27 AG24398 transformed cell line human CVCL_YX27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409622 CVCL_YX20 AG24390 transformed cell line human CVCL_YX20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409623 CVCL_YX21 AG24391 transformed cell line human CVCL_YX21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409624 CVCL_YX22 AG24393 transformed cell line human CVCL_YX22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409625 CVCL_YX23 AG24394 transformed cell line human CVCL_YX23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409626 CVCL_YX28 AG24399 transformed cell line human CVCL_YX28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409627 CVCL_YX29 AG24400 transformed cell line human CVCL_YX29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409628 CVCL_YX30 AG24401 transformed cell line human CVCL_YX30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409629 CVCL_YX13 AG24382 transformed cell line human CVCL_YX13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409630 CVCL_YX14 AG24383 transformed cell line human CVCL_YX14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409631 CVCL_YX15 AG24384 transformed cell line human CVCL_YX15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409632 CVCL_YX16 AG24385 transformed cell line human CVCL_YX16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409633 CVCL_YX10 AG24379 transformed cell line human CVCL_YX10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409634 CVCL_YX11 AG24380 transformed cell line human CVCL_YX11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409635 CVCL_YX12 AG24381 transformed cell line human CVCL_YX12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409636 CVCL_YX17 AG24386 transformed cell line human CVCL_YX17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409637 CVCL_YX18 AG24387 transformed cell line human CVCL_YX18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409638 CVCL_YX19 AG24388 transformed cell line human CVCL_YX19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409639 CVCL_YX02 AG24368 transformed cell line human CVCL_YX02 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409640 CVCL_YX03 AG24369 transformed cell line human CVCL_YX03 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409641 CVCL_YX04 AG24370 transformed cell line human CVCL_YX04 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409642 CVCL_YX05 AG24371 transformed cell line human CVCL_YX05 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409643 CVCL_YX00 AG24363 transformed cell line human CVCL_YX00 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409644 CVCL_YX01 AG24364 transformed cell line human CVCL_YX01 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409645 CVCL_YX06 AG24373 transformed cell line human CVCL_YX06 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409646 CVCL_YX07 AG24374 transformed cell line human CVCL_YX07 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409647 CVCL_YX08 AG24375 transformed cell line human CVCL_YX08 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409648 CVCL_YX09 AG24377 transformed cell line human CVCL_YX09 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409649 CVCL_YW87 AG24338 transformed cell line human CVCL_YW87 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409650 CVCL_YW88 AG24339 transformed cell line human CVCL_YW88 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409651 CVCL_YW89 AG24340 transformed cell line human CVCL_YW89 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409652 CVCL_YW94 AG24351 transformed cell line human CVCL_YW94 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409653 CVCL_YW95 AG24352 transformed cell line human CVCL_YW95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409654 CVCL_YW96 AG24354 transformed cell line human CVCL_YW96 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409655 CVCL_YW97 AG24357 transformed cell line human CVCL_YW97 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409656 CVCL_YW90 AG24341 transformed cell line human CVCL_YW90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409657 CVCL_YW91 AG24343 transformed cell line human CVCL_YW91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409658 CVCL_YW92 AG24345 transformed cell line human CVCL_YW92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409659 CVCL_YW93 AG24346 transformed cell line human CVCL_YW93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409660 CVCL_YW76 AG24324 transformed cell line human CVCL_YW76 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409661 CVCL_YW77 AG24325 transformed cell line human CVCL_YW77 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409662 CVCL_YW78 AG24326 transformed cell line human CVCL_YW78 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409663 CVCL_YW79 AG24327 transformed cell line human CVCL_YW79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409664 CVCL_YW83 AG24333 transformed cell line human CVCL_YW83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409665 CVCL_YW84 AG24335 transformed cell line human CVCL_YW84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409666 CVCL_YW85 AG24336 transformed cell line human CVCL_YW85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409667 CVCL_YW86 AG24337 transformed cell line human CVCL_YW86 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409668 CVCL_YW80 AG24329 transformed cell line human CVCL_YW80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409669 CVCL_YW81 AG24331 transformed cell line human CVCL_YW81 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409670 CVCL_YW82 AG24332 transformed cell line human CVCL_YW82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409671 CVCL_YW69 AG24315 transformed cell line human CVCL_YW69 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409672 CVCL_YW65 AG24310 transformed cell line human CVCL_YW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409673 CVCL_YW66 AG24311 transformed cell line human CVCL_YW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409674 CVCL_YW67 AG24313 transformed cell line human CVCL_YW67 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409675 CVCL_YW68 AG24314 transformed cell line human CVCL_YW68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409676 CVCL_YW72 AG24320 transformed cell line human CVCL_YW72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409677 CVCL_YW73 AG24321 transformed cell line human CVCL_YW73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409678 CVCL_YW74 AG24322 transformed cell line human CVCL_YW74 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409679 CVCL_YW75 AG24323 transformed cell line human CVCL_YW75 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409680 CVCL_YW70 AG24316 transformed cell line human CVCL_YW70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409681 CVCL_YW71 AG24318 transformed cell line human CVCL_YW71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409682 CVCL_YW58 AG24303 transformed cell line human CVCL_YW58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409683 CVCL_YW59 AG24304 transformed cell line human CVCL_YW59 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409684 CVCL_YW54 AG24298 transformed cell line human CVCL_YW54 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409685 CVCL_YW55 AG24300 transformed cell line human CVCL_YW55 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409686 CVCL_YW56 AG24301 transformed cell line human CVCL_YW56 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409687 CVCL_YW57 AG24302 transformed cell line human CVCL_YW57 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409688 CVCL_YW61 AG24306 transformed cell line human CVCL_YW61 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409689 CVCL_YW62 AG24307 transformed cell line human CVCL_YW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409690 CVCL_YW63 AG24308 transformed cell line human CVCL_YW63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409691 CVCL_YW64 AG24309 transformed cell line human CVCL_YW64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409692 CVCL_YW60 AG24305 transformed cell line human CVCL_YW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409693 CVCL_YW47 AG24290 transformed cell line human CVCL_YW47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409694 CVCL_YW48 AG24291 transformed cell line human CVCL_YW48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409695 CVCL_YW49 AG24292 transformed cell line human CVCL_YW49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409696 CVCL_YW43 AG24286 transformed cell line human CVCL_YW43 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409697 CVCL_YW44 AG24287 transformed cell line human CVCL_YW44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409698 CVCL_YW45 AG24288 transformed cell line human CVCL_YW45 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409699 CVCL_YW46 AG24289 transformed cell line human CVCL_YW46 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409700 CVCL_YW50 AG24293 transformed cell line human CVCL_YW50 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409701 CVCL_YW51 AG24295 transformed cell line human CVCL_YW51 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409702 CVCL_YW52 AG24296 transformed cell line human CVCL_YW52 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409703 CVCL_YW53 AG24297 transformed cell line human CVCL_YW53 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409704 CVCL_YW36 AG24278 transformed cell line human CVCL_YW36 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409705 CVCL_YW37 AG24279 transformed cell line human CVCL_YW37 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409706 CVCL_YW38 AG24280 transformed cell line human CVCL_YW38 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409707 CVCL_YW39 AG24281 transformed cell line human CVCL_YW39 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409708 CVCL_YW32 AG24274 transformed cell line human CVCL_YW32 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409709 CVCL_YW33 AG24275 transformed cell line human CVCL_YW33 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409710 CVCL_YW34 AG24276 transformed cell line human CVCL_YW34 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409711 CVCL_YW35 AG24277 transformed cell line human CVCL_YW35 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409712 CVCL_YW40 AG24282 transformed cell line human CVCL_YW40 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409713 CVCL_YW41 AG24283 transformed cell line human CVCL_YW41 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409714 CVCL_YW42 AG24285 transformed cell line human CVCL_YW42 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409715 CVCL_YW25 AG24266 transformed cell line human CVCL_YW25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409716 CVCL_YW26 AG24267 transformed cell line human CVCL_YW26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409717 CVCL_YW27 AG24268 transformed cell line human CVCL_YW27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409718 CVCL_YW28 AG24269 transformed cell line human CVCL_YW28 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409719 CVCL_YW21 AG24260 transformed cell line human CVCL_YW21 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409720 CVCL_YW22 AG24261 transformed cell line human CVCL_YW22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409721 CVCL_YW23 AG24262 transformed cell line human CVCL_YW23 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409722 CVCL_YW24 AG24263 transformed cell line human CVCL_YW24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409723 CVCL_YW29 AG24270 transformed cell line human CVCL_YW29 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409724 CVCL_YW30 AG24272 transformed cell line human CVCL_YW30 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409725 CVCL_YW31 AG24273 transformed cell line human CVCL_YW31 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409726 CVCL_YW14 AG24253 transformed cell line human CVCL_YW14 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409727 CVCL_YW15 AG24254 transformed cell line human CVCL_YW15 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409728 CVCL_YW16 AG24255 transformed cell line human CVCL_YW16 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409729 CVCL_YW17 AG24256 transformed cell line human CVCL_YW17 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409730 CVCL_YW10 AG24248 transformed cell line human CVCL_YW10 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409731 CVCL_YW11 AG24249 transformed cell line human CVCL_YW11 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409732 CVCL_YW12 AG24250 transformed cell line human CVCL_YW12 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409733 CVCL_YW13 AG24252 transformed cell line human CVCL_YW13 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409734 CVCL_YW18 AG24257 transformed cell line human CVCL_YW18 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409735 CVCL_YW19 AG24258 transformed cell line human CVCL_YW19 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409736 CVCL_YW20 AG24259 transformed cell line human CVCL_YW20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: 90+ study cell line collection 21409737 CVCL_YW98 AG24358 transformed cell line human CVCL_YW98 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409738 CVCL_YW99 AG24359 transformed cell line human CVCL_YW99 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: 90+ study cell line collection 21409739 CVCL_UD34 S2R+-Tnks-KO spontaneously immortalized cell line fruit fly CVCL_UD34 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0027508; Tnks Breed/subspecies: Oregon-R. Male Group: Insect cell line 21409740 CVCL_UD32 S2R+-CG8786-KO spontaneously immortalized cell line fruit fly CVCL_UD32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0036897; CG8786 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21409741 CVCL_XF50 S2R+-Lamin-mNeonGreen D6 spontaneously immortalized cell line fruit fly CVCL_XF50 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; A0A1S4NYF2; mNeonGreen (derivative of Branchiostoma lanceolatum blFP-Y3) Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of neonGreen into the Lam locus (FBgn0002525) Group: Insect cell line 21409742 CVCL_XF46 S2R+-Apc-KO-1G spontaneously immortalized cell line fruit fly CVCL_XF46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0015589; Apc; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21409743 CVCL_XF49 S2R+-His2Av-mNeonGreen B11 spontaneously immortalized cell line fruit fly CVCL_XF49 From: Drosophila RNAi Screening Center (DRSC), Harvard Medical School; Boston; USA CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; A0A1S4NYF2; mNeonGreen (derivative of Branchiostoma lanceolatum blFP-Y3) Breed/subspecies: Oregon-R. Male Characteristics: The constitutively Cas9-expressed parent cell line was modified with a knock-in of neonGreen into the His2AV locus (FBgn0001197) Group: Insect cell line 21409744 CVCL_XF48 S2R+-hairy-KO-BF3B spontaneously immortalized cell line fruit fly CVCL_XF48 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0001168; hairy Breed/subspecies: Oregon-R. Male Group: Insect cell line 21409745 CVCL_XF47 S2R+-Apc-KO-3E spontaneously immortalized cell line fruit fly CVCL_XF47 CL:0000010 Knockout cell: Method=CRISPR/Cas9; FlyBase_Gene; FBgn0015589; Apc; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Breed/subspecies: Oregon-R. Male Group: Insect cell line 21409746 CVCL_XH27 CDDP-R B16F10 cancer cell line house mouse CVCL_XH27 CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male 21409747 CVCL_XX71 2F3 [Mouse hybridoma against human GPC3] hybridoma house mouse CVCL_XX71 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P51654; Human GPC3. 288083509 CVCL_B5P3 KOLF2.1J induced pluripotent stem cell human CVCL_B5P3 CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple_corrected; p.Pro197Hisfs*12 (c.590_608delCTAAAATCATCACTTTACT); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36459969); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.3526-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly1176Ser (c.3526G>A); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced Male 288083510 CVCL_C6PS ESi098-A induced pluripotent stem cell human CVCL_C6PS HLA typing: A*30,30; B*18,18; C*03,03 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083511 CVCL_C6Q4 ISTEMi003-A induced pluripotent stem cell human CVCL_C6Q4 From: Institut from Stem cell Therapy and Exploration of Monogenic diseases; Corbeil-Essonnes; France CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083512 CVCL_C6PR ESi097-A induced pluripotent stem cell human CVCL_C6PR HLA typing: A*24,24; B*07,07; C*15,15 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083513 CVCL_C6Q3 ISTEMi002-A induced pluripotent stem cell human CVCL_C6Q3 From: Institut from Stem cell Therapy and Exploration of Monogenic diseases; Corbeil-Essonnes; France CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083514 CVCL_C6Q6 BJNhem20-OCIAD2-CRISPR-33 embryonic stem cell human CVCL_C6Q6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28685; OCIAD2. Population: Indian Female 288083515 CVCL_C6PU ESi092-A induced pluripotent stem cell human CVCL_C6PU HLA typing: A*23; B*03,44; C*04,01:09N (Spanish_Stem_Cell_Bank) From: Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Sevilla; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083516 CVCL_C6PT ESi099-A induced pluripotent stem cell human CVCL_C6PT HLA typing: A*33,33; B*14,14; C*01,01 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083517 CVCL_C6Q5 IUFi002-A induced pluripotent stem cell human CVCL_C6Q5 From: Leibniz Research Institute For Environmental Medicine; Dusseldorf; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7707; NDUFS1; Simple; p.Arg557Ter (c.1671C>T); ClinVar=VCV000050923; Zygosity=Heterozygous (PubMed=36403546); Sequence variation: Mutation; HGNC; 7707; NDUFS1; Simple; p.Asp618Asn (c.1854G>A); Zygosity=Heterozygous (PubMed=36403546) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288083518 CVCL_C6Q8 BJNhem20-OCIAD2-OV embryonic stem cell human CVCL_C6Q8 CL:0000010 Transfected with: HGNC; 28685; OCIAD2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Population: Indian Female 288083519 CVCL_C6PW ESi104-A induced pluripotent stem cell human CVCL_C6PW CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Pro213_Gly214ins23 (c.640-9T>G) (IVS7-9T>G); ClinVar=VCV000632945; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Thr237Met (c.710C>T); ClinVar=VCV000021145; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083520 CVCL_C6Q7 BJNhem20-OCIAD2-CRISPR-40 embryonic stem cell human CVCL_C6Q7 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 28685; OCIAD2. Population: Indian Female 288083521 CVCL_C6PV ESi093-A induced pluripotent stem cell human CVCL_C6PV CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083522 CVCL_C6PY MD FiPS3236-Sv4F-9 induced pluripotent stem cell human CVCL_C6PY From: University of Zaragoza; Zaragoza; Spain CL:0000010 Sequence variation: Mutation; HGNC; 32151; ATAD3C; Simple; c.152+1G>A; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank); Sequence variation: Mutation; HGNC; 32151; ATAD3C; Simple; c.692T>C; Zygosity=Heterozygous (Spanish_Stem_Cell_Bank) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083523 CVCL_C6PX ESi106-A induced pluripotent stem cell human CVCL_C6PX From: University of Zaragoza; Zaragoza; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083524 CVCL_C6Q9 KEIUi002-A induced pluripotent stem cell human CVCL_C6Q9 From: Keio University; Tokyo; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083525 CVCL_C6PK DRICUi032-A induced pluripotent stem cell human CVCL_C6PK From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083526 CVCL_C6PJ DRICUi031-A induced pluripotent stem cell human CVCL_C6PJ From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083527 CVCL_C6PM EDi046-A induced pluripotent stem cell human CVCL_C6PM From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 288083528 CVCL_C6PL DRICUi033-A induced pluripotent stem cell human CVCL_C6PL From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083529 CVCL_C6Q0 IAIi010-A induced pluripotent stem cell human CVCL_C6Q0 From: Istituto Auxologico Italiano (IAI)-IRCCS; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6323; KIF5A; Simple; p.Arg17Gln (c.50G>A); Zygosity=Heterozygous (PubMed=36565680) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288083530 CVCL_C6PN ESi094-A induced pluripotent stem cell human CVCL_C6PN HLA typing: A*01,01; B*08,08; C*03,03 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083531 CVCL_C6PQ ESi096-A induced pluripotent stem cell human CVCL_C6PQ HLA typing: A*11,11; B*27,27; C*01,01 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083532 CVCL_C6Q2 ISTEMi001-A induced pluripotent stem cell human CVCL_C6Q2 From: Institut from Stem cell Therapy and Exploration of Monogenic diseases; Corbeil-Essonnes; France CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 288083533 CVCL_C6PP ESi095-A induced pluripotent stem cell human CVCL_C6PP HLA typing: A*03,03; B*07,07; C*15,15 (Spanish_Stem_Cell_Bank) CL:0000010 Derived from sampling site: Umbilical cord blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083534 CVCL_C6Q1 ISCRMi001-A induced pluripotent stem cell human CVCL_C6Q1 From: University of Washington Institute for Stem Cell and Regenerative Medicine; Seattle; USA CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Leu463Serfs*22 (c.1386delT); ClinVar=VCV000922148; Zygosity=Heterozygous (PubMed=36481506) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083535 CVCL_C6PC DRICUi024-A induced pluripotent stem cell human CVCL_C6PC From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083536 CVCL_C6PB DRICUi023-A induced pluripotent stem cell human CVCL_C6PB From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083537 CVCL_C6PE DRICUi026-A induced pluripotent stem cell human CVCL_C6PE From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083538 CVCL_C6PD DRICUi025-A induced pluripotent stem cell human CVCL_C6PD From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083539 CVCL_C6PG DRICUi028-A induced pluripotent stem cell human CVCL_C6PG From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083540 CVCL_C6PF DRICUi027-A induced pluripotent stem cell human CVCL_C6PF From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083541 CVCL_C6PI DRICUi030-A induced pluripotent stem cell human CVCL_C6PI From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083542 CVCL_C6PH DRICUi029-A induced pluripotent stem cell human CVCL_C6PH From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083543 CVCL_C6PA DRICUi022-A induced pluripotent stem cell human CVCL_C6PA From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083544 CVCL_C6QT LBi006-B induced pluripotent stem cell human CVCL_C6QT From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083545 CVCL_C6R5 LBi012-B induced pluripotent stem cell human CVCL_C6R5 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083546 CVCL_C6QS LBi006-A induced pluripotent stem cell human CVCL_C6QS From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083547 CVCL_C6R4 LBi012-A induced pluripotent stem cell human CVCL_C6R4 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083548 CVCL_C6QV LBi007-B induced pluripotent stem cell human CVCL_C6QV From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083549 CVCL_C6R7 LBi014-A induced pluripotent stem cell human CVCL_C6R7 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083550 CVCL_C6QU LBi007-A induced pluripotent stem cell human CVCL_C6QU From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083551 CVCL_C6R6 LBi013-A induced pluripotent stem cell human CVCL_C6R6 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083552 CVCL_C6QX LBi008-B induced pluripotent stem cell human CVCL_C6QX From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083553 CVCL_C6R9 LBi015-A induced pluripotent stem cell human CVCL_C6R9 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083554 CVCL_C6QW LBi008-A induced pluripotent stem cell human CVCL_C6QW From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083555 CVCL_C6R8 LBi014-B induced pluripotent stem cell human CVCL_C6R8 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083556 CVCL_C6QZ LBi009-B induced pluripotent stem cell human CVCL_C6QZ From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083557 CVCL_C6QY LBi009-A induced pluripotent stem cell human CVCL_C6QY From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083558 CVCL_C6QL LBi003-A induced pluripotent stem cell human CVCL_C6QL From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083559 CVCL_C6QK LBi002-B induced pluripotent stem cell human CVCL_C6QK From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083560 CVCL_C6QN LBi004-A induced pluripotent stem cell human CVCL_C6QN From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083561 CVCL_C6QM LBi003-B induced pluripotent stem cell human CVCL_C6QM From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083562 CVCL_C6QP LBi004-B induced pluripotent stem cell human CVCL_C6QP From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083563 CVCL_C6R1 LBi010-B induced pluripotent stem cell human CVCL_C6R1 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083564 CVCL_C6R0 LBi010-A induced pluripotent stem cell human CVCL_C6R0 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083565 CVCL_C6QR LBi005-B induced pluripotent stem cell human CVCL_C6QR From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083566 CVCL_C6R3 LBi011-B induced pluripotent stem cell human CVCL_C6R3 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083567 CVCL_C6QQ LBi005-A induced pluripotent stem cell human CVCL_C6QQ From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083568 CVCL_C6R2 LBi011-A induced pluripotent stem cell human CVCL_C6R2 From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Homozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Homozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083569 CVCL_C6QD KRIBBi009-A induced pluripotent stem cell human CVCL_C6QD From: Korea Research Institute of Bioscience and Biotechnology; Daejeon; South Korea CL:0000010 Population: Korean; Donor information: Established from the normal breast tissue of a patient suffering from breast cancer; Derived from sampling site: Breast Cell type=Fibroblast.. Female 288083570 CVCL_C6QC KLRMMEi004-A induced pluripotent stem cell human CVCL_C6QC From: Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University; Guangzhou; China. CL:0000010 288083571 CVCL_C6QF KSCBi017-C induced pluripotent stem cell human CVCL_C6QF From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 288083572 CVCL_C6QE KSCBi017-B induced pluripotent stem cell human CVCL_C6QE From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 288083573 CVCL_C6QH LBi001-A induced pluripotent stem cell human CVCL_C6QH From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083574 CVCL_C6QG KSCBi017-D induced pluripotent stem cell human CVCL_C6QG From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Peripheral blood. Male 288083575 CVCL_C6QJ LBi002-A induced pluripotent stem cell human CVCL_C6QJ From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083576 CVCL_C6QI LBi001-B induced pluripotent stem cell human CVCL_C6QI From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 1659; CD33; Simple; chr19:g.51224706C>A; dbSNP=rs3865444; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 1659; CD33; Simple; p.Ala14Val (c.41C>T) (chr19:g.51225221C>T); ClinVar=VCV001275129; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083577 CVCL_C6PZ FDHPIi001-A induced pluripotent stem cell human CVCL_C6PZ CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; c.344+5G>T; Zygosity=Heterozygous (PubMed=36502619) Population: Asian; Derived from sampling site: Peripheral blood. Female 288083578 CVCL_C6QB KLRMMEi003-A induced pluripotent stem cell human CVCL_C6QB From: Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; c.8559-2A>G (p.Tyr2854_Arg2894del); ClinVar=VCV000048604; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=36863132) Population: Chinese; Derived from sampling site: Peripheral blood. Male 288083579 CVCL_C6QA KEIUi003-A induced pluripotent stem cell human CVCL_C6QA From: Keio University; Tokyo; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083580 CVCL_C6NQ STF3a transformed cell line human CVCL_C6NQ CL:0000010 Transfected with: MGI; MGI:98956; Wnt3a; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Stably express high levels of murine Wnt3a (PubMed=19022675); Characteristics: Responds to activation of the canonical Wnt signaling pathway by increasing expression of firefly luciferase Luciferase reporter gene expression is under the control of a promoter with 7 LEF/TCF binding sites (from parent cell line). 288083581 CVCL_C6NP D42.M1 cancer cell line human CVCL_C6NP CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Characteristics: Early passage culture 288083582 CVCL_C6NS UM314-2 PGD embryonic stem cell human CVCL_C6NS From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM314-1 PGD (Cellosaurus=CVCL_C6NR). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0499 288083583 CVCL_C6NR UM314-1 PGD embryonic stem cell human CVCL_C6NR From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM314-2 PGD (Cellosaurus=CVCL_C6NS). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-22-0500 288083584 CVCL_C6NU CDIi010-A induced pluripotent stem cell human CVCL_C6NU From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 288083585 CVCL_C6NT CDIi009-A induced pluripotent stem cell human CVCL_C6NT From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 288083586 CVCL_C6NW CDIi012-A induced pluripotent stem cell human CVCL_C6NW From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 288083587 CVCL_C6NV CDIi011-A induced pluripotent stem cell human CVCL_C6NV From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA. CL:0000010 288083588 CVCL_C6NK A03 cancer cell line human CVCL_C6NK CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Unspecified 288083589 CVCL_C6NJ A08 cancer cell line human CVCL_C6NJ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Unspecified 288083590 CVCL_C6NM C101 cancer cell line human CVCL_C6NM CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Characteristics: Early passage culture 288083591 CVCL_C6NL A14 [Human melanoma] cancer cell line human CVCL_C6NL CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533). Unspecified 288083592 CVCL_C6NN C108 [Human melanoma] cancer cell line human CVCL_C6NN CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (PubMed=22383533) Derived from metastatic site: Not specified. Characteristics: Early passage culture 288083593 CVCL_C6P3 CTGUi001-A induced pluripotent stem cell human CVCL_C6P3 From: China Three Gorges University; Yichang; China CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Cys52Ter (c.156C>A); Zygosity=Hemizygous (PubMed=36917862) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288083594 CVCL_C6P2 CIAUi003-A-1 induced pluripotent stem cell human CVCL_C6P2 From: Molecular Cardiology, Centenary Institute of Cancer Medicine and Cell Biology; Camperdown; Australia CL:0000010 Sequence variation: Mutation; HGNC; 1513; CASQ2; Simple_corrected; p.Lys180Arg (c.539A>G); ClinVar=VCV000265850; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288083595 CVCL_C6P5 DRICUi017-A induced pluripotent stem cell human CVCL_C6P5 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083596 CVCL_C6P4 DRICUi016-A induced pluripotent stem cell human CVCL_C6P4 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083597 CVCL_C6P7 DRICUi019-A induced pluripotent stem cell human CVCL_C6P7 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083598 CVCL_C6P6 DRICUi018-A induced pluripotent stem cell human CVCL_C6P6 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083599 CVCL_C6P9 DRICUi021-A induced pluripotent stem cell human CVCL_C6P9 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083600 CVCL_C6P8 DRICUi020-A induced pluripotent stem cell human CVCL_C6P8 From: UK Dementia Research Institute, Cardiff University; Cardiff; United Kingdom. CL:0000010 288083601 CVCL_C6P1 CHULAi001-A induced pluripotent stem cell human CVCL_C6P1 From: Faculty of Allied Health Sciences, Chulalongkorn University; Bangkok; Thailand CL:0000010 Sequence variation: Mutation; HGNC; 4057; G6PD; Simple; p.Val321Met (c.871G>A); ClinVar=VCV000010386; Zygosity=Hemizygous; Note=G6PD Viangchan (PubMed=36334578) Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Male 288083602 CVCL_C6P0 CBDTi001-A induced pluripotent stem cell human CVCL_C6P0 From: Institute for Stem Cell Science and Regenerative Medicine; Bangalore; India CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; c.3628-41_3628-17del25 (delta25); ClinVar=VCV000177677; Zygosity=Heterozygous (PubMed=36403549) Population: Indian; Donor information: At sampling donor was asymptomatic for cardiomyopathy; Derived from sampling site: Peripheral blood. Female 288083603 CVCL_C6NY ICGi044-B induced pluripotent stem cell human CVCL_C6NY From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4336; GLUD2; Simple; p.Ser498Ala (c.1492T>G); ClinVar=VCV000029936; Zygosity=Hemizygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083604 CVCL_C6NX ICGi044-A induced pluripotent stem cell human CVCL_C6NX From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4336; GLUD2; Simple; p.Ser498Ala (c.1492T>G); ClinVar=VCV000029936; Zygosity=Hemizygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083605 CVCL_C6NZ ICGi044-C induced pluripotent stem cell human CVCL_C6NZ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 4336; GLUD2; Simple; p.Ser498Ala (c.1492T>G); ClinVar=VCV000029936; Zygosity=Hemizygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083606 CVCL_C7JL SN5b hybridoma house mouse CVCL_C7JL CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 288083607 CVCL_C7JK SN5a hybridoma house mouse CVCL_C7JK CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 288083608 CVCL_C7JN SN6 hybridoma house mouse CVCL_C7JN CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P17813; Human ENG/CD105. 288083609 CVCL_C7JM SN5c hybridoma house mouse CVCL_C7JM CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 288083610 CVCL_C7K1 PR2D3 hybridoma house mouse CVCL_C7K1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human myofibroblasts. 288083611 CVCL_C7JP SN8 hybridoma house mouse CVCL_C7JP CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40259; Human CD79B. 288083612 CVCL_C7K0 PR1A3 hybridoma house mouse CVCL_C7K0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 288083613 CVCL_C7K3 PR3A5 hybridoma house mouse CVCL_C7K3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human goblet-cell mucus. 288083614 CVCL_C7JR SN8b hybridoma house mouse CVCL_C7JR CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40259; Human CD79B. 288083615 CVCL_C7K2 mbbm4 hybridoma house mouse CVCL_C7K2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:62265; Beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc (Lewis A). 288083616 CVCL_C7JQ SN8a hybridoma house mouse CVCL_C7JQ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P40259; Human CD79B. 288083617 CVCL_C7JD SN2a hybridoma house mouse CVCL_C7JD CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Gp37/CD165. 288083618 CVCL_C7JC SN2 hybridoma house mouse CVCL_C7JC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Gp37/CD165. 288083619 CVCL_C7JF SN3 hybridoma house mouse CVCL_C7JF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 288083620 CVCL_C7JE SN2b hybridoma house mouse CVCL_C7JE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Human Gp37/CD165. 288083621 CVCL_C7JH SN3b hybridoma house mouse CVCL_C7JH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 288083622 CVCL_C7JG SN3a hybridoma house mouse CVCL_C7JG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25063; Human CD24. 288083623 CVCL_C7JJ SN5 hybridoma house mouse CVCL_C7JJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P08473; Human MME/CD10. 288083624 CVCL_C7JI SN4 hybridoma house mouse CVCL_C7JI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P21926; Human CD9. 288083625 CVCL_C7IZ 11/32 hybridoma house mouse CVCL_C7IZ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; CHEBI:30154; 5beta-pregnane-3,20-dione. 288083626 CVCL_C7JB SN1b hybridoma house mouse CVCL_C7JB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P41732; Human TSPAN7/CD231. 288083627 CVCL_C7JA SN1a hybridoma house mouse CVCL_C7JA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P41732; Human TSPAN7/CD231. 288083628 CVCL_C7J4 Alpha-SN4-3 hybridoma house mouse CVCL_C7J4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes TNase-like domain 4). 288083629 CVCL_C7IS HCK1T-E7 telomerase immortalized cell line human CVCL_C7IS CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Female 288083630 CVCL_C7J3 Alpha-SN4-2 hybridoma house mouse CVCL_C7J3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes TNase-like domain 4). 288083631 CVCL_C7IR HCK1T-E6E7 telomerase immortalized cell line human CVCL_C7IR CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Female 288083632 CVCL_C7IU AA1 hybridoma house mouse CVCL_C7IU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; ChEBI:16076; 11alpha-hydroxyprogesterone. 288083633 CVCL_C7J6 Alpha-SN4-5 hybridoma house mouse CVCL_C7J6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes TNase-like domain 4 Also reacts with mouse).. 288083634 CVCL_C7J5 Alpha-SN4-4 hybridoma house mouse CVCL_C7J5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes TNase-like domain 4 Also reacts with mouse).. 288083635 CVCL_C7IT HeLa S3 ATG3 KO cancer cell line human CVCL_C7IT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20962; ATG3 Miscellaneous: Cell line information from personal communication of Skulsuppaisarn M Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 288083636 CVCL_C7J8 Alpha-TSN-2 hybridoma house mouse CVCL_C7J8 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes Tudor domain). 288083637 CVCL_C7IW III A4.1 hybridoma house mouse CVCL_C7IW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; ChEBI:16076; 11alpha-hydroxyprogesterone. 288083638 CVCL_C7J7 Alpha-TSN-1 hybridoma house mouse CVCL_C7J7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes Tudor domain). 288083639 CVCL_C7IV DB3 hybridoma house mouse CVCL_C7IV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; ChEBI:16076; 11alpha-hydroxyprogesterone. 288083640 CVCL_C7IY 10/8 hybridoma house mouse CVCL_C7IY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone. 288083641 CVCL_C7IX 10/16 hybridoma house mouse CVCL_C7IX CL:0000010 Monoclonal antibody isotype: IgG1. 288083642 CVCL_C7J9 SN1 hybridoma house mouse CVCL_C7J9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P41732; Human TSPAN7/CD231. 288083643 CVCL_C7KM alpha wheat HBZ#5-1 hybridoma house mouse CVCL_C7KM CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083644 CVCL_C7KL alpha wheat HBZ#2-1 hybridoma house mouse CVCL_C7KL CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083645 CVCL_C7L0 HT146F induced pluripotent stem cell human CVCL_C7L0 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000056193; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Tyr247His (c.739T>C); ClinVar=VCV000056214; Zygosity=Heterozygous (PubMed=29631617) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083646 CVCL_C7KN alpha wheat HBZ#6-1 hybridoma house mouse CVCL_C7KN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083647 CVCL_C7KQ alpha wheat HBZ#8-1 hybridoma house mouse CVCL_C7KQ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083648 CVCL_C7L2 HT264B induced pluripotent stem cell human CVCL_C7L2 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Gln (c.380G>A); ClinVar=VCV000068746; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=29631617) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083649 CVCL_C7KP alpha wheat HBZ#7-1 hybridoma house mouse CVCL_C7KP CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE ABP-01969 288083650 CVCL_C7L1 HT264A induced pluripotent stem cell human CVCL_C7L1 From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Gln (c.380G>A); ClinVar=VCV000068746; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; c.509-1G>C (IVS5-1G>C); ClinVar=VCV000002644; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=29631617) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083651 CVCL_C7KS alpha wheat HBZ#12-1 hybridoma house mouse CVCL_C7KS CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083652 CVCL_C7L4 GM27891 transformed cell line human CVCL_C7L4 CL:0000010 Sequence variation: Mutation; HGNC; 11164; SNRPN; Simple; p.Arg25Ter (c.73C>T); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288083653 CVCL_C7KR alpha wheat HBZ#10-1 hybridoma house mouse CVCL_C7KR CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083654 CVCL_C7L3 GM27620 induced pluripotent stem cell human CVCL_C7L3 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Glu154Glyfs*301 (c.460dupG); ClinVar=VCV000095268; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288083655 CVCL_C7KE pep#1 P6-A7 hybridoma house mouse CVCL_C7KE CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083656 CVCL_C7KD pep#1 P4-E12 hybridoma house mouse CVCL_C7KD CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083657 CVCL_C7KG pep#2 P1-A12 hybridoma house mouse CVCL_C7KG CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083658 CVCL_C7KF pep#2 #20-H12 hybridoma house mouse CVCL_C7KF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE ABP-01967 288083659 CVCL_C7KI pep#3 #21-1 hybridoma CVCL_C7KI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083660 CVCL_C7KH pep#2 P3-E3 hybridoma house mouse CVCL_C7KH CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083661 CVCL_C7KK alpha wheat HBZ#1-1 hybridoma house mouse CVCL_C7KK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288083662 CVCL_C7KJ pep#3 #91-1 hybridoma CVCL_C7KJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE ABP-01968 288083663 CVCL_C7KA PR5C5 hybridoma house mouse CVCL_C7KA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:62265; Beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc (Lewis A). 288083664 CVCL_C7KC PR6B5 hybridoma house mouse CVCL_C7KC CL:0000010 Monoclonal antibody isotype: IgG1. 288083665 CVCL_C7KB PR5D5 hybridoma house mouse CVCL_C7KB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human goblet-cell mucus. 288083666 CVCL_C7JT h1B1/OR transformed cell line human CVCL_C7JT CL:0000010 Transfected with: HGNC; 2597; CYP1B1; Transfected with: HGNC; 9208; POR; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288083667 CVCL_C7K5 PR4B10 hybridoma house mouse CVCL_C7K5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human epithelial cell membranes. 288083668 CVCL_C7JS BLMRL-HMFG-Mc16 hybridoma house mouse CVCL_C7JS CL:0000010 Monoclonal antibody target: UniProtKB; Q08431; Human MFGE8. 288083669 CVCL_C7K4 PR3B10 hybridoma house mouse CVCL_C7K4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 288083670 CVCL_C7K7 PR4D4 hybridoma house mouse CVCL_C7K7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human goblet-cell mucus. 288083671 CVCL_C7JV RT112 CP2 cancer cell line human CVCL_C7JV CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083672 CVCL_C7K6 PR4D1 hybridoma house mouse CVCL_C7K6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human goblet-cell mucus. 288083673 CVCL_C7JU RT112 CP1.5 cancer cell line human CVCL_C7JU CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083674 CVCL_C7K9 PR4D6 hybridoma house mouse CVCL_C7K9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human epithelial cell membranes. 288083675 CVCL_C7JX RT112 CP3 cancer cell line human CVCL_C7JX CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083676 CVCL_C7K8 PR4D2 hybridoma house mouse CVCL_C7K8 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: ChEBI; CHEBI:62265; Beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc (Lewis A). 288083677 CVCL_C7JW RT112 CP2.5 cancer cell line human CVCL_C7JW CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083678 CVCL_C7JZ RT112 CP1.5 K2 cancer cell line human CVCL_C7JZ CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083679 CVCL_C7JY RT112 CP1.5 K1 cancer cell line human CVCL_C7JY CL:0000010 Sequence variation: Gene fusion; HGNC; 3690; FGFR3 + HGNC; 11524; TACC3; Name(s)=FGFR3-TACC3 (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser183Ter (c.548C>G); ClinVar=VCV000634701; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Urinary bladder. Female 288083680 CVCL_C7HJ Dbt telomerase immortalized cell line human CVCL_C7HJ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Miscellaneous: Sex of donor and species used for Bmi1 transfection from personal communication of Cudre-Mauroux C Derived from sampling site: Skeletal muscle Cell type=Satellite cell.. Male 288083681 CVCL_C7HI HAP1 CHMP2B (-) 2 cancer cell line human CVCL_C7HI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24537; CHMP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288083682 CVCL_C7HL Dbt-MYCN/indP3F telomerase immortalized cell line human CVCL_C7HL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 7559; MYCN; Transfected with: HGNC; 3819; FOXO1 (PAX3-FOXO1 fusion); Transfected with: HGNC; 8617; PAX3 (PAX3-FOXO1 fusion); Transfected with: MGI; MGI:88174; Bmi1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skeletal muscle Cell type=Satellite cell.. Male Characteristics: Transduced with a retroviral construct expressing MYCN constitutively and a doxycycline-inducible PAX3-FOXO1 lentiviral expression construct (PubMed=28138962) 288083683 CVCL_C7HK Dbt-indP3F telomerase immortalized cell line human CVCL_C7HK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 3819; FOXO1 (PAX3-FOXO1 fusion); Transfected with: HGNC; 8617; PAX3 (PAX3-FOXO1 fusion); Transfected with: MGI; MGI:88174; Bmi1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skeletal muscle Cell type=Satellite cell.. Male Characteristics: Transduced with a doxycycline-inducible PAX3-FOXO1 lentiviral expression construct (PubMed=28138962) 288083684 CVCL_C7HN 2A2 HLA-A2 transformed cell line pig CVCL_C7HN CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*2); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Miniature boar (a/a haplotype). Unspecified 288083685 CVCL_C7HM 2A2 [Pig bone marrow] transformed cell line pig CVCL_C7HM CL:0000010 Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Miniature boar (a/a haplotype). Unspecified 288083686 CVCL_C7HP 2A2 HLA-B27 transformed cell line pig CVCL_C7HP CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*27); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Miniature boar (a/a haplotype). Unspecified 288083687 CVCL_C7I1 2D7 hybridoma house mouse CVCL_C7I1 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083688 CVCL_C7I0 2C7 [Mouse hybridoma against human CA9] hybridoma house mouse CVCL_C7I0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083689 CVCL_C7HB BLMRL-HMFG-Mc5 hybridoma house mouse CVCL_C7HB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. 288083690 CVCL_C7HA BLMRL-HMFG-Mc3 hybridoma house mouse CVCL_C7HA CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized Angiolix therapeutic antibody used against breast tumors Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08431; Human MFGE8. 288083691 CVCL_C7HD BLMRL-HMFG-Mc8 hybridoma house mouse CVCL_C7HD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q08431; Human MFGE8. 288083692 CVCL_C7HC BLMRL-HMFG-McR2 hybridoma CVCL_C7HC CL:0000010 288083693 CVCL_C7HF HAP1 ALS2 (-) 1 cancer cell line human CVCL_C7HF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 443; ALS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288083694 CVCL_C7HE iPSC72_3-AAVS1-CAG-GFP induced pluripotent stem cell human CVCL_C7HE CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 GFP under the control of a CAG promoter has been inserted at the safe harbor locus (AAVS1) 288083695 CVCL_C7HH HAP1 CHMP2B (-) 1 cancer cell line human CVCL_C7HH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24537; CHMP2B; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288083696 CVCL_C7HG HAP1 ALS2 (-) 2 cancer cell line human CVCL_C7HG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 443; ALS2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288083697 CVCL_C7GY B-LCL-HROG04 transformed cell line human CVCL_C7GY From: Linnebacher M.; University of Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288083698 CVCL_C7H9 BLMRL-HMFG-Mc1 hybridoma house mouse CVCL_C7H9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. 288083699 CVCL_C7GX hTERT-CSF telomerase immortalized cell line human CVCL_C7GX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288083700 CVCL_C7GZ CIBCgp185 hybridoma house mouse CVCL_C7GZ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P04626; Human ERBB2/CD340. 288083701 CVCL_C7H2 CIBCRGC1 hybridoma house mouse CVCL_C7H2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. 288083702 CVCL_C7GQ NK-92 clone 1 cancer cell line human CVCL_C7GQ CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: High cytotoxic activity (PubMed=36039429) 288083703 CVCL_C7GP CHA89 cancer cell line human CVCL_C7GP CL:0000010 Derived from sampling site: Urinary bladder; trigone. Female 288083704 CVCL_C7H1 CIBCNSH3 hybridoma house mouse CVCL_C7H1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P00533; Human EGFR. 288083705 CVCL_C7GS A549-IR3 cancer cell line human CVCL_C7GS CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: NCIt; C129640; Cobalt-60 gamma radiation; Derived from sampling site: Lung. Male Characteristics: Irradiated 3 times with 4 Gy and with at least a three-week interval between each two consecutive irradiations (PubMed=35976051) Doubling time: 23.07 hours (PubMed=35976051) 288083706 CVCL_C7H4 KU44.22B hybridoma house mouse CVCL_C7H4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. 288083707 CVCL_C7H3 KU44.13B hybridoma house mouse CVCL_C7H3 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083708 CVCL_C7GR NK-92 clone 2 cancer cell line human CVCL_C7GR CL:0000010 Derived from sampling site: Peripheral blood Cell type=Natural killer cell.. Male Characteristics: Low cytotoxic activity (PubMed=36039429) 288083709 CVCL_C7H6 BCA 227 hybridoma house mouse CVCL_C7H6 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Human 71 kDa protein expressed by tumor cells of epithelial origin. 288083710 CVCL_C7GU DKFZ-BT308 cancer cell line human CVCL_C7GU CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 22219; KIAA1549; Name(s)=KIAA1549-BRAF (PubMed=35977048); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Male Characteristics: Transduced with a doxycycline-inducible system coding for SV40 large T antigen and GFP (PubMed=35977048) Senescence: Withdrawal of doxycyclin leads to senescence (PubMed=35977048) 288083711 CVCL_C7GT A549-IR6 cancer cell line human CVCL_C7GT CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: NCIt; C129640; Cobalt-60 gamma radiation; Derived from sampling site: Lung. Male Characteristics: Irradiated 6 times with 4 Gy and with at least a three-week interval between each two consecutive irradiations (PubMed=35976051) Doubling time: 28.23 hours (PubMed=35976051) 288083712 CVCL_C7H5 SP1.D8 hybridoma house mouse CVCL_C7H5 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; W5P481; Sheep COL1A1 (Note=Also reacts with bovine, human and chicken). 288083713 CVCL_C7H8 3.15.C3 hybridoma house mouse CVCL_C7H8 CL:0000010 Monoclonal antibody isotype: Not determined. 288083714 CVCL_C7GW DKFZ-BT317 cancer cell line human CVCL_C7GW CL:0000010 Sequence variation: Gene fusion; HGNC; 1097; BRAF + HGNC; 22219; KIAA1549; Name(s)=KIAA1549-BRAF (PubMed=35977048); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Male Characteristics: Transduced with a doxycycline-inducible system coding for SV40 large T antigen and GFP (PubMed=35977048) Senescence: Withdrawal of doxycyclin leads to senescence (PubMed=35977048) 288083715 CVCL_C7GV DKFZ-BT314 cancer cell line human CVCL_C7GV CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=35977048); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; forebrain; optic chiasma. Female Characteristics: Transduced with a doxycycline-inducible system coding for SV40 large T antigen and GFP (PubMed=35977048) Senescence: Withdrawal of doxycyclin leads to senescence (PubMed=35977048) 288083716 CVCL_C7H7 HFMG1 hybridoma house mouse CVCL_C7H7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P15941; Human MUC1/CD227. 288083717 CVCL_C7IK Clone-275 hybridoma house mouse CVCL_C7IK CL:0000010 Monoclonal antibody isotype: Not determined; Monoclonal antibody target: UniProtKB; Q86UP6; Human CUZD1. 288083718 CVCL_C7IJ Clone-119 hybridoma house mouse CVCL_C7IJ CL:0000010 Monoclonal antibody isotype: Not determined; Monoclonal antibody target: UniProtKB; Q86UP6; Human CUZD1. 288083719 CVCL_C7IM K562-mb15-41BBL cancer cell line human CVCL_C7IM CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5977; IL15 (membrane bound, contains the signal peptide of CD8A, the mature part of IL15 and the transmembrane domain of CD8A); Transfected with: HGNC; 11939; TNFSF9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 288083720 CVCL_C7IL K562-mb15 cancer cell line human CVCL_C7IL CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5977; IL15 (membrane bound, contains the signal peptide of CD8A, the mature part of IL15 and the transmembrane domain of CD8A); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Caucasian; Derived from sampling site: Pleural effusion. Female 288083721 CVCL_C7J0 11/34 hybridoma house mouse CVCL_C7J0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; ChEBI:16076; 11alpha-hydroxyprogesterone. 288083722 CVCL_C7IN HCK1T telomerase immortalized cell line human CVCL_C7IN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Omics: Secretome proteome analysis by 2D-DE/MS Female 288083723 CVCL_C7J2 Alpha-SN4-1 hybridoma house mouse CVCL_C7J2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; Q7KZF4; Human SND1 (Note=Recognizes TNase-like domain 4 Also reacts with mouse).. 288083724 CVCL_C7IQ HCK1T-E6 telomerase immortalized cell line human CVCL_C7IQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Uterus; cervix Cell type=Keratinocyte.. Female 288083725 CVCL_C7J1 11/64 hybridoma house mouse CVCL_C7J1 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: ChEBI; ChEBI:17026; Progesterone; Monoclonal antibody target: ChEBI; CHEBI:30154; 5beta-pregnane-3,20-dione. 288083726 CVCL_C7IP HCK12-E6E7 transformed cell line human CVCL_C7IP CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pCLXSN-16E6E7](NCBI-Taxonomy; 333760). Female 288083727 CVCL_C7IC 12E3B hybridoma house mouse CVCL_C7IC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083728 CVCL_C7IB 11H9 [Mouse hybridoma against human DPP4] hybridoma house mouse CVCL_C7IB CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083729 CVCL_C7IE 16D4B hybridoma house mouse CVCL_C7IE CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083730 CVCL_C7ID 14D10 hybridoma house mouse CVCL_C7ID CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized YS110 (YSCMA) therapeutic antibody which is in clinical trials for the treatment of malignant mesothelioma Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083731 CVCL_C7IG 2F9 hybridoma house mouse CVCL_C7IG CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083732 CVCL_C7IF 18H3A hybridoma house mouse CVCL_C7IF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083733 CVCL_C7II 9C11 [Mouse hybridoma against human DPP4] hybridoma house mouse CVCL_C7II CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083734 CVCL_C7IH 4G8 [Mouse hybridoma against human DPP4] hybridoma house mouse CVCL_C7IH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083735 CVCL_C7HZ 12H8 hybridoma house mouse CVCL_C7HZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083736 CVCL_C7HY 11H9 [Mouse hybridoma against human CA9] hybridoma house mouse CVCL_C7HY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083737 CVCL_C7IA 10F8A hybridoma house mouse CVCL_C7IA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. 288083738 CVCL_C7I3 9B6 hybridoma house mouse CVCL_C7I3 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083739 CVCL_C7HR PEDNSV1.1 transformed cell line pig CVCL_C7HR CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium Cell type=Endothelial cell.; Breed/subspecies: Miniature boar (d/d haplotype). Unspecified 288083740 CVCL_C7HQ 2A2 HLA-Cw3 transformed cell line pig CVCL_C7HQ CL:0000010 Transfected with: HGNC; 4933; HLA-C (allele C*03); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow Cell type=Stromal cell.; Breed/subspecies: Miniature boar (a/a haplotype). Unspecified 288083741 CVCL_C7I2 4A2 [Mouse hybridoma against human CA9] hybridoma house mouse CVCL_C7I2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q16790; Human CA9. 288083742 CVCL_C7I5 2-2 [Mouse hybridoma against human IL26] hybridoma house mouse CVCL_C7I5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NPH9; Human IL26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE P-02580 288083743 CVCL_C7HT PEDSV.20 transformed cell line pig CVCL_C7HT CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium Cell type=Endothelial cell.; Breed/subspecies: Miniature boar (d/d haplotype). Unspecified 288083744 CVCL_C7I4 67-2 hybridoma house mouse CVCL_C7I4 CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized pepinemab (VX15/2503) therapeutic antibody which is used in clinical trials for the treatment of a number of neuroinflammatory/neurodegenerative diseases Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q92854; Human SEMA4D/CD100 (Note=Also reacts with mouse). 288083745 CVCL_C7HS PEDSV.15 transformed cell line pig CVCL_C7HS CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium Cell type=Endothelial cell.; Breed/subspecies: Miniature boar (d/d haplotype). Unspecified 288083746 CVCL_C7I7 31-4 hybridoma house mouse CVCL_C7I7 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NPH9; Human IL26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE P-02579 288083747 CVCL_C7HV PED GGTA1+/- transformed cell line pig CVCL_C7HV CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); UniProtKB; P50127; GGTA1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Aorta; endothelium Cell type=Endothelial cell.; Breed/subspecies: Miniature boar (d/d haplotype). Unspecified 288083748 CVCL_C7I6 20-3 hybridoma house mouse CVCL_C7I6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NPH9; Human IL26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE P-02578 288083749 CVCL_C7HU PEDSV.4 transformed cell line pig CVCL_C7HU CL:0000010 Derived from sampling site: Aorta; endothelium Cell type=Endothelial cell.; Breed/subspecies: Miniature boar (d/d haplotype). Unspecified 288083750 CVCL_C7I9 anti-1F7 hybridoma house mouse CVCL_C7I9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10297 288083751 CVCL_C7HX ST-IOWA GGTA1-/- spontaneously immortalized cell line pig CVCL_C7HX CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); UniProtKB; P50127; GGTA1; Knockout cell: Method=Spontanous mutation (1 of 2 alleles); UniProtKB; P50127; GGTA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal testis Cell type=Sertoli cell.. Male 288083752 CVCL_C7I8 69-10 hybridoma house mouse CVCL_C7I8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NPH9; Human IL26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE P-02577 288083753 CVCL_C7HW ST-IOWA GGTA1+/- spontaneously immortalized cell line pig CVCL_C7HW CL:0000010 Knockout cell: Method=Homologous recombination (1 of 2 alleles); UniProtKB; P50127; GGTA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal testis Cell type=Sertoli cell.. Male 288083754 CVCL_C7FH CCMi011-A induced pluripotent stem cell human CVCL_C7FH From: Centro Cardiologico Monzino; Milan; Italy CL:0000010 Population: Caucasian; Donor information: Established from a COVID-19 patient who displayed increased levels of high-sensitivity Troponin (hsTnI) during the acute phase of infection; Derived from sampling site: Peripheral blood. Female 288083755 CVCL_C7FG UKWi005-A-1 induced pluripotent stem cell human CVCL_C7FG From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083756 CVCL_C7FJ UKERe008-A-2 embryonic stem cell human CVCL_C7FJ From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 288083757 CVCL_C7FI UKERe008-A-1 embryonic stem cell human CVCL_C7FI From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 288083758 CVCL_C7FL UKERe008-A-4 embryonic stem cell human CVCL_C7FL From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083759 CVCL_C7FK UKERe008-A-3 embryonic stem cell human CVCL_C7FK From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 288083760 CVCL_C7FN UKERe008-A-6 embryonic stem cell human CVCL_C7FN From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083761 CVCL_C7FM UKERe008-A-5 embryonic stem cell human CVCL_C7FM From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083762 CVCL_C7FB UKWi003-A induced pluripotent stem cell human CVCL_C7FB From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20974; ADGRL3; Simple; c.2913C>G; dbSNP=rs1397547; Zygosity=Heterozygous (PubMed=36640473) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083763 CVCL_C7FA UKWi002-A-1 induced pluripotent stem cell human CVCL_C7FA From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083764 CVCL_C7FD UKWi004-A induced pluripotent stem cell human CVCL_C7FD From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20974; ADGRL3; Simple; c.2913C>G; dbSNP=rs1397547; Zygosity=Heterozygous (PubMed=36640473) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083765 CVCL_C7FC UKWi003-A-1 induced pluripotent stem cell human CVCL_C7FC From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20974; ADGRL3; Simple; c.2913C>G; dbSNP=rs1397547; Zygosity=Heterozygous (PubMed=36640473) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083766 CVCL_C7FF UKWi005-A induced pluripotent stem cell human CVCL_C7FF From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083767 CVCL_C7FE UKWi004-A-1 induced pluripotent stem cell human CVCL_C7FE From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 20974; ADGRL3; Simple; c.2913C>G; dbSNP=rs1397547; Zygosity=Heterozygous (PubMed=36640473) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083768 CVCL_C7EW F-25 hybridoma house mouse CVCL_C7EW CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. 288083769 CVCL_C7F8 GPK-SI spontaneously immortalized cell line CVCL_C7F8 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Hartley. Unspecified Virology: Susceptible to infection by classical swine fever virus (CSFV) strain GPE- (PubMed=36631081) Doubling time: 87.82 +- 12.49 hours, at 27th passage (PubMed=36631081) 288083770 CVCL_C7EV Abcam THP-1 TXNIP KO cancer cell line human CVCL_C7EV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16952; TXNIP; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083771 CVCL_C7F7 GPK-AI_F5 transformed cell line CVCL_C7F7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: Hartley. Unspecified Virology: Susceptible to infection by classical swine fever virus (CSFV) strain GPE- (PubMed=36631081) Doubling time: 61.28 +- 9.55 hours (PubMed=36631081) 288083772 CVCL_C7EY 863.D4 hybridoma house mouse CVCL_C7EY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P01133; Human EGF. 288083773 CVCL_C7EX F-26 hybridoma house mouse CVCL_C7EX CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P01579; Human IFNG. 288083774 CVCL_C7F9 UKWi002-A induced pluripotent stem cell human CVCL_C7F9 From: Division of Molecular Psychiatry, Center of Mental Health, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083775 CVCL_C7EZ IG10 hybridoma house mouse CVCL_C7EZ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03972; Bovine AMH. 288083776 CVCL_C7F0 IG8 hybridoma house mouse CVCL_C7F0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P03972; Bovine AMH. 288083777 CVCL_C7EN Abcam THP-1 RBL2 KO cancer cell line human CVCL_C7EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9894; RBL2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083778 CVCL_C7EQ Abcam THP-1 SKP2 KO cancer cell line human CVCL_C7EQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10901; SKP2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083779 CVCL_C7F2 EquiPSC Line K2 induced pluripotent stem cell CVCL_C7F2 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 288083780 CVCL_C7EP Abcam THP-1 ROCK1 KO cancer cell line human CVCL_C7EP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083781 CVCL_C7F1 EquiPSC Line K1 induced pluripotent stem cell CVCL_C7F1 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 288083782 CVCL_C7ES Abcam THP-1 TIMP2 KO cancer cell line human CVCL_C7ES CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11821; TIMP2; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083783 CVCL_C7F4 MciA conditionally immortalized cell line house mouse CVCL_C7F4 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; cerebral cortex Cell type=Astrocyte.; Breed/subspecies: (CBA/Ca x C57BL/10)Tg(H2Kb-tsA58) Immortomouse. Unspecified Doubling time: 36 hours (PubMed=19724901) 288083784 CVCL_C7ER Abcam THP-1 SMPD1 KO cancer cell line human CVCL_C7ER CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11120; SMPD1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083785 CVCL_C7F3 EquiPSC Line K3 induced pluripotent stem cell CVCL_C7F3 CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 288083786 CVCL_C7EU Abcam THP-1 TXNRD1 KO cancer cell line human CVCL_C7EU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12437; TXNRD1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083787 CVCL_C7F6 GPK-AI_D1 transformed cell line CVCL_C7F6 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney; Breed/subspecies: Hartley. Unspecified Virology: Susceptible to infection by classical swine fever virus (CSFV) strain GPE- (PubMed=36631081) Doubling time: 50.87 +- 5.24 hours (PubMed=36631081) 288083788 CVCL_C7ET Abcam THP-1 TRAP1 KO cancer cell line human CVCL_C7ET CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16264; TRAP1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083789 CVCL_C7F5 OFTu-hTERT telomerase immortalized cell line CVCL_C7F5 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Fetal nose; nasal cavity; nasal turbinate. Unspecified Virology: Susceptible to infection by Orf virus (ORFV) (PubMed=36619965) 288083790 CVCL_C7GI A375-NTP-R cancer cell line human CVCL_C7GI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: NCIt; C192869; Non-thermal plasma; Derived from sampling site: Skin. Female 288083791 CVCL_C7GH HAA-1 transformed cell line human CVCL_C7GH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [p16HHMo](NCBI-Taxonomy; 333760); Derived from sampling site: Adrenal gland; zona reticularis. Male 288083792 CVCL_C7GK AuxB1 DeltaP-gp B2 spontaneously immortalized cell line CVCL_C7GK CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; P21448; Abcb1 Derived from sampling site: Ovary. Female 288083793 CVCL_C7GJ AuxB1 DeltaP-gp B1 spontaneously immortalized cell line CVCL_C7GJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; P21448; Abcb1 Derived from sampling site: Ovary. Female 288083794 CVCL_C7GM CHORC5 DeltaP-gp A2 spontaneously immortalized cell line CVCL_C7GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; P21448; Abcb1 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female Characteristics: Shows complete reversal of the resistance to both colchicine and doxorubicin which exist in the parental cell line (PubMed=35381425) 288083795 CVCL_C7GL CHORC5 DeltaP-gp A1 spontaneously immortalized cell line CVCL_C7GL CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; P21448; Abcb1 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female Characteristics: Shows complete reversal of the resistance to both colchicine and doxorubicin which exist in the parental cell line (PubMed=35381425) 288083796 CVCL_C7H0 CIBCHTB1 hybridoma house mouse CVCL_C7H0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06731; Human CEACAM5/CEA/CD66e. 288083797 CVCL_C7GN CHORC5 DeltaP-gp A3 spontaneously immortalized cell line CVCL_C7GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; P21448; Abcb1 Selected for resistance to: ChEBI; CHEBI:23359; Colchicine; Derived from sampling site: Ovary. Female Characteristics: Shows complete reversal of the resistance to both colchicine and doxorubicin which exist in the parental cell line (PubMed=35381425) 288083798 CVCL_C7GA repo>Ras bratdsRNA-L6-Clone4 spontaneously immortalized cell line fruit fly CVCL_C7GA CL:0000010 Unspecified Characteristics: repo-Gal4 driving UAS-RasV12 and UAS-bratdsRNA (P\{y[+t7.7] v[+t1.8]=TRiP.HMS01121\}attP2). Group: Insect cell line 288083799 CVCL_C7GC Act5C-GS>Ras attP-LB-Clone6 spontaneously immortalized cell line fruit fly CVCL_C7GC CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Unspecified Characteristics: Expresses Act5C-GeneSwitch-Gal4; UAS-GFP; attP, UAS-RasV12 Group: Insect cell line 288083800 CVCL_C7GB repo>Ras bratdsRNA-L6-CloneF9 spontaneously immortalized cell line fruit fly CVCL_C7GB CL:0000010 Unspecified Characteristics: repo-Gal4 driving UAS-RasV12 and UAS-bratdsRNA (P\{y[+t7.7] v[+t1.8]=TRiP.HMS01121\}attP2). Group: Insect cell line 288083801 CVCL_C7GE Act5C-GS>Ras attP-GFP-LI-Clone3 spontaneously immortalized cell line fruit fly CVCL_C7GE CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Unspecified Characteristics: Expresses Act5C-GeneSwitch-Gal4; UAS-GFP; attP, UAS-RasV12 Group: Insect cell line 288083802 CVCL_C7GD Act5C-GS>Ras attP-GFP-LI-CloneI2 spontaneously immortalized cell line fruit fly CVCL_C7GD CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP). Unspecified Characteristics: Expresses Act5C-GeneSwitch-Gal4; UAS-GFP; attP, UAS-RasV12 Group: Insect cell line 288083803 CVCL_C7GG CMT-1 [Chihuahua] cancer cell line dog CVCL_C7GG CL:0000010 Derived from sampling site: Mammary gland Cell type=Myoepithelial cell.; Breed/subspecies: Chihuahua. Female Doubling time: 26.67 hours (PubMed=36717813) 288083804 CVCL_C7GF IM-FW11 hybridoma house mouse CVCL_C7GF CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 288083805 CVCL_C7FX DMBi006-A induced pluripotent stem cell human CVCL_C7FX From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Sequence variation: Mutation; HGNC; 5013; HMOX1; Unexplicit; (GT)>=29 promoter repeat; ClinVar=VCV000015897; Zygosity=Homozygous (PubMed=36565681) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083806 CVCL_C7G9 repo>Ras bratdsRNA-L6-Clone2 spontaneously immortalized cell line fruit fly CVCL_C7G9 CL:0000010 Unspecified Characteristics: repo-Gal4 driving UAS-RasV12 and UAS-bratdsRNA (P\{y[+t7.7] v[+t1.8]=TRiP.HMS01121\}attP2). Group: Insect cell line 288083807 CVCL_C7G8 24B>Ras attP-G1-CloneF3 spontaneously immortalized cell line fruit fly CVCL_C7G8 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic muscle. Unspecified Characteristics: how(24B)-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE and co-expression of GFP Group: Insect cell line 288083808 CVCL_C7FW DMBi005-A-1 induced pluripotent stem cell human CVCL_C7FW From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit_edited; Ex50del; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=36565681); Sequence variation: Mutation; HGNC; 5013; HMOX1; Unexplicit; (GT)>=29 promoter repeat; ClinVar=VCV000015897; Zygosity=Heterozygous (PubMed=36565681) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083809 CVCL_C7FZ SYSUe009-A embryonic stem cell human CVCL_C7FZ From: Sun Yat-sen University; Guangzhou; China CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Male Characteristics: Using CRISPR/Cas9 NANOS3 has been endogenously tagged at the C-terminus with mCherry (PubMed=36630838) 288083810 CVCL_C7FY DMBi006-A-1 induced pluripotent stem cell human CVCL_C7FY From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit_edited; Ex50del; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=36565681); Sequence variation: Mutation; HGNC; 5013; HMOX1; Unexplicit; (GT)>=29 promoter repeat; ClinVar=VCV000015897; Zygosity=Homozygous (PubMed=36565681) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083811 CVCL_C7G1 AF208 cancer cell line human CVCL_C7G1 From: Alman B.; The Hospital for Sick Children; Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Heterozygous (PubMed=35221159). 288083812 CVCL_C7FP UKERe008-A-7 embryonic stem cell human CVCL_C7FP From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083813 CVCL_C7G0 NCC-DSM1-C1 cancer cell line human CVCL_C7G0 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Heterozygous (PubMed=36629983) Population: Japanese; Derived from sampling site: Left thigh; hypodermis. Male Doubling time: 39 hours (PubMed=36629983) Part of: NCC sarcoma cell line panel 288083814 CVCL_C7G3 ML-DmBG3-c2-attP-25C6 spontaneously immortalized cell line fruit fly CVCL_C7G3 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 25C6 locus (PubMed=33963853) Group: Insect cell line 288083815 CVCL_C7FR UKERe008-A-9 embryonic stem cell human CVCL_C7FR From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083816 CVCL_C7G2 ML-DmBG2-c2-attP-25C6 spontaneously immortalized cell line fruit fly CVCL_C7G2 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 25C6 locus (PubMed=33963853) Group: Insect cell line 288083817 CVCL_C7FQ UKERe008-A-8 embryonic stem cell human CVCL_C7FQ From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2494; CTBP1; Simple_edited; p.Arg331Trp (c.991C>T); ClinVar=VCV000225758; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36610307). Female 288083818 CVCL_C7FT IGGi001-A induced pluripotent stem cell human CVCL_C7FT From: IRCCS Istituto Giannina Gaslini; Genova; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288083819 CVCL_C7G5 OSC:eFH-piwi spontaneously immortalized cell line fruit fly CVCL_C7G5 CL:0000010 Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female Characteristics: Using CRISPR/Cas9, Piwi was endogenously tagged with a Flag-HA-tag (PubMed=35639929) Group: Insect cell line 288083820 CVCL_C7G4 ML-DmBG3-c2 attP 99F8 spontaneously immortalized cell line fruit fly CVCL_C7G4 CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male Characteristics: Using CRISPR/Cas9, a Actin5C promoter-dsRed cassette flanked by attP sites was introduced in the 99F8 locus (PubMed=33963853) Group: Insect cell line 288083821 CVCL_C7FS SKLRMe004-A induced pluripotent stem cell human CVCL_C7FS From: State Key Laboratory of Reproductive Medicine, Nanjing Medical University; Nanjing; China CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Using CRISPR/Cas9 two constructs T2A-EGFP-PGK-PuroR and T2A-Tdtomato-EF1a-NeoR were respectively inserted at the C-terminus of NKX2.5 and TBX5 (PubMed=36608451) 288083822 CVCL_C7G7 24B>Ras attP-G1-CloneG1 spontaneously immortalized cell line fruit fly CVCL_C7G7 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Embryonic muscle. Unspecified Characteristics: how(24B)-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE and co-expression of GFP Group: Insect cell line 288083823 CVCL_C7FV DMBi005-A induced pluripotent stem cell human CVCL_C7FV From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Sequence variation: Mutation; HGNC; 5013; HMOX1; Unexplicit; (GT)>=29 promoter repeat; ClinVar=VCV000015897; Zygosity=Heterozygous (PubMed=36565681) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288083824 CVCL_C7G6 24B>Ras attP-L5-CloneB8 spontaneously immortalized cell line fruit fly CVCL_C7G6 CL:0000010 Derived from sampling site: Embryonic muscle. Unspecified Characteristics: how(24B)-Gal4 driving UAS-RasV12 with an attP flanked cassette for RMCE Group: Insect cell line 288083825 CVCL_C7FU IGGi001-B induced pluripotent stem cell human CVCL_C7FU From: IRCCS Istituto Giannina Gaslini; Genova; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288083826 CVCL_C7DF Abcam A-549 PRDX6 KO cancer cell line human CVCL_C7DF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16753; PRDX6; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083827 CVCL_C7DE Abcam A-549 PDE5A KO cancer cell line human CVCL_C7DE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8784; PDE5A; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083828 CVCL_C7DH Abcam A-549 PTHLH KO cancer cell line human CVCL_C7DH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9607; PTHLH; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083829 CVCL_C7DG Abcam A-549 PSMB9 KO cancer cell line human CVCL_C7DG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083830 CVCL_C7DJ Abcam A-549 ROCK1 KO cancer cell line human CVCL_C7DJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083831 CVCL_C7DI Abcam A-549 RBL2 KO cancer cell line human CVCL_C7DI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9894; RBL2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083832 CVCL_C7DL Abcam A-549 SLC2A3 KO cancer cell line human CVCL_C7DL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11007; SLC2A3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083833 CVCL_C7DK Abcam A-549 SLC25A4 KO cancer cell line human CVCL_C7DK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10990; SLC25A4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083834 CVCL_C7DB Abcam A-549 NEDD4L KO cancer cell line human CVCL_C7DB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7728; NEDD4L; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083835 CVCL_C7DA Abcam A-549 MST1R KO cancer cell line human CVCL_C7DA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7381; MST1R; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083836 CVCL_C7DD Abcam A-549 PCSK9 KO cancer cell line human CVCL_C7DD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20001; PCSK9; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083837 CVCL_C7DC Abcam A-549 NOD1 KO cancer cell line human CVCL_C7DC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16390; NOD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083838 CVCL_C7D6 Abcam A-549 GCLC KO cancer cell line human CVCL_C7D6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4311; GCLC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083839 CVCL_C7CU Abcam PC-3 ULBP3 KO cancer cell line human CVCL_C7CU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14895; ULBP3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083840 CVCL_C7D5 Abcam A-549 CASP4 KO cancer cell line human CVCL_C7D5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1505; CASP4; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083841 CVCL_C7CT Abcam PC-3 ULBP2 KO cancer cell line human CVCL_C7CT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14894; ULBP2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083842 CVCL_C7D8 Abcam A-549 ME1 KO cancer cell line human CVCL_C7D8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6983; ME1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083843 CVCL_C7CW Abcam PC-3 VCAN KO cancer cell line human CVCL_C7CW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2464; VCAN; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083844 CVCL_C7D7 Abcam A-549 MAD1L1 KO cancer cell line human CVCL_C7D7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6762; MAD1L1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083845 CVCL_C7CV Abcam PC-3 UVRAG KO cancer cell line human CVCL_C7CV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12640; UVRAG; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083846 CVCL_C7CY Abcam PC-3 WNT11 KO cancer cell line human CVCL_C7CY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12776; WNT11; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083847 CVCL_C7D9 Abcam A-549 MMP3 KO cancer cell line human CVCL_C7D9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7173; MMP3; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083848 CVCL_C7CX Abcam PC-3 WDR77 KO cancer cell line human CVCL_C7CX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29652; WDR77; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083849 CVCL_C7CZ Abcam PC-3 YTHDC2 KO cancer cell line human CVCL_C7CZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24721; YTHDC2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083850 CVCL_C7CM Abcam PC-3 TWIST1 KO cancer cell line human CVCL_C7CM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12428; TWIST1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083851 CVCL_C7CL Abcam PC-3 TRMT2A KO cancer cell line human CVCL_C7CL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24974; TRMT2A; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083852 CVCL_C7D0 Abcam PC-3 YTHDF1 KO cancer cell line human CVCL_C7D0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15867; YTHDF1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083853 CVCL_C7CN Abcam PC-3 TWIST2 KO cancer cell line human CVCL_C7CN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20670; TWIST2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083854 CVCL_C7CQ Abcam PC-3 UBA1 KO cancer cell line human CVCL_C7CQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12469; UBA1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083855 CVCL_C7D2 Abcam PC-3 YY1 KO cancer cell line human CVCL_C7D2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12856; YY1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083856 CVCL_C7CP Abcam PC-3 U2AF1 KO cancer cell line human CVCL_C7CP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12453; U2AF1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083857 CVCL_C7D1 Abcam PC-3 YTHDF3 KO cancer cell line human CVCL_C7D1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26465; YTHDF3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083858 CVCL_C7D4 Abcam A-549 APAF1 KO cancer cell line human CVCL_C7D4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083859 CVCL_C7CS Abcam PC-3 UCHL5 KO cancer cell line human CVCL_C7CS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19678; UCHL5; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083860 CVCL_C7CR Abcam PC-3 UBE2D2 KO cancer cell line human CVCL_C7CR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12475; UBE2D2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083861 CVCL_C7D3 Abcam PC-3 ZEB2 KO cancer cell line human CVCL_C7D3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14881; ZEB2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288083862 CVCL_C7EG Abcam HCT 116 TXNRD1 KO cancer cell line human CVCL_C7EG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12437; TXNRD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083863 CVCL_C7EF Abcam HCT 116 TRAP1 KO cancer cell line human CVCL_C7EF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16264; TRAP1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083864 CVCL_C7EI Abcam THP-1 APAF1 KO cancer cell line human CVCL_C7EI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083865 CVCL_C7EH Abcam HCT 116 TXNIP KO cancer cell line human CVCL_C7EH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16952; TXNIP; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083866 CVCL_C7EK Abcam THP-1 MAD1L1 KO cancer cell line human CVCL_C7EK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6762; MAD1L1; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083867 CVCL_C7EJ Abcam THP-1 CASP4 KO cancer cell line human CVCL_C7EJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1505; CASP4; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083868 CVCL_C7EM Abcam THP-1 PSMB9 KO cancer cell line human CVCL_C7EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083869 CVCL_C7EL Abcam THP-1 MMP3 KO cancer cell line human CVCL_C7EL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7173; MMP3; Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood. Male 288083870 CVCL_C7EA Abcam HCT 116 SKP2 KO cancer cell line human CVCL_C7EA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10901; SKP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083871 CVCL_C7EC Abcam HCT 116 SLC2A3 KO cancer cell line human CVCL_C7EC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11007; SLC2A3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083872 CVCL_C7EB Abcam HCT 116 SLC25A4 KO cancer cell line human CVCL_C7EB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10990; SLC25A4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083873 CVCL_C7EE Abcam HCT 116 TIMP2 KO cancer cell line human CVCL_C7EE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11821; TIMP2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083874 CVCL_C7ED Abcam HCT 116 SPARC KO cancer cell line human CVCL_C7ED CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11219; SPARC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083875 CVCL_C7DV Abcam HCT 116 CASP4 KO cancer cell line human CVCL_C7DV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1505; CASP4; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083876 CVCL_C7E7 Abcam HCT 116 PTHLH KO cancer cell line human CVCL_C7E7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9607; PTHLH; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083877 CVCL_C7DU Abcam HCT 116 APAF1 KO cancer cell line human CVCL_C7DU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 576; APAF1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083878 CVCL_C7E6 Abcam HCT 116 PSMB9 KO cancer cell line human CVCL_C7E6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9546; PSMB9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083879 CVCL_C7DX Abcam HCT 116 MAD1L1 KO cancer cell line human CVCL_C7DX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6762; MAD1L1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083880 CVCL_C7E9 Abcam HCT 116 ROCK1 KO cancer cell line human CVCL_C7E9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10251; ROCK1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083881 CVCL_C7DW Abcam HCT 116 GCLC KO cancer cell line human CVCL_C7DW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4311; GCLC; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083882 CVCL_C7E8 Abcam HCT 116 RBL2 KO cancer cell line human CVCL_C7E8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9894; RBL2; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083883 CVCL_C7DZ Abcam HCT 116 MMP3 KO cancer cell line human CVCL_C7DZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7173; MMP3; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083884 CVCL_C7DY Abcam HCT 116 ME1 KO cancer cell line human CVCL_C7DY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6983; ME1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083885 CVCL_C7DN Abcam A-549 SMPD1 KO cancer cell line human CVCL_C7DN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11120; SMPD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083886 CVCL_C7DM Abcam A-549 SKP2 KO cancer cell line human CVCL_C7DM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10901; SKP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083887 CVCL_C7DP Abcam A-549 SPARC KO cancer cell line human CVCL_C7DP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11219; SPARC; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083888 CVCL_C7E1 Abcam HCT 116 NEDD4L KO cancer cell line human CVCL_C7E1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7728; NEDD4L; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083889 CVCL_C7E0 Abcam HCT 116 MST1R KO cancer cell line human CVCL_C7E0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7381; MST1R; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083890 CVCL_C7DR Abcam A-549 TRAP1 KO cancer cell line human CVCL_C7DR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16264; TRAP1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083891 CVCL_C7E3 Abcam HCT 116 PCSK9 KO cancer cell line human CVCL_C7E3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20001; PCSK9; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083892 CVCL_C7DQ Abcam A-549 TIMP2 KO cancer cell line human CVCL_C7DQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11821; TIMP2; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083893 CVCL_C7E2 Abcam HCT 116 NOD1 KO cancer cell line human CVCL_C7E2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16390; NOD1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083894 CVCL_C7DT Abcam A-549 TXNIP KO cancer cell line human CVCL_C7DT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16952; TXNIP; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083895 CVCL_C7E5 Abcam HCT 116 PRDX6 KO cancer cell line human CVCL_C7E5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16753; PRDX6; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083896 CVCL_C7DS Abcam A-549 TXNRD1 KO cancer cell line human CVCL_C7DS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12437; TXNRD1; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 288083897 CVCL_C7E4 Abcam HCT 116 PDE5A KO cancer cell line human CVCL_C7E4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8784; PDE5A; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Male 288083898 CVCL_C7S5 54T [Human osteosarcoma] cancer cell line human CVCL_C7S5 CL:0000010 Derived from metastatic site: Popliteal fossa. Male 288083899 CVCL_C7RT NRM 4 spontaneously immortalized cell line Norway rat CVCL_C7RT CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male 288083900 CVCL_C7S4 54N finite cell line human CVCL_C7S4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083901 CVCL_C7RS NRM 3 spontaneously immortalized cell line Norway rat CVCL_C7RS CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male 288083902 CVCL_C7RV Me1 cancer cell line Norway rat CVCL_C7RV CL:0000010 Derived from sampling site: Testis; tunica vaginalis; Breed/subspecies: Fischer 344. Male 288083903 CVCL_C7S7 SASY-4 cancer cell line human CVCL_C7S7 CL:0000010 Population: Japanese; Derived from sampling site: Bone; proximal tibia. Male Doubling time: 54 hours (DOI=10.14930/jsma1939.53.537) 288083904 CVCL_C7S6 SASY-1 cancer cell line human CVCL_C7S6 CL:0000010 Population: Japanese; Derived from sampling site: Bone; proximal femur. Male 288083905 CVCL_C7RU SFM1 spontaneously immortalized cell line Norway rat CVCL_C7RU CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 38 hours (PubMed=9733279) Group: Serum/protein free medium cell line 288083906 CVCL_C7RX Me3 cancer cell line Norway rat CVCL_C7RX CL:0000010 Derived from sampling site: Testis; tunica vaginalis; Breed/subspecies: Fischer 344. Male 288083907 CVCL_C7S9 SI #2 cancer cell line human CVCL_C7S9 CL:0000010 Derived from sampling site: Bone; left leg. Unspecified 288083908 CVCL_C7RW Me1t cancer cell line Norway rat CVCL_C7RW CL:0000010 Derived from sampling site: Testis; tunica vaginalis; Breed/subspecies: Fischer 344. Male Characteristics: Recovered from the tumor formed upon injection of the parent cell line into the subcutis of nude mice (PubMed=7627973) 288083909 CVCL_C7S8 SI #1 cancer cell line human CVCL_C7S8 CL:0000010 Derived from metastatic site: Lung. Unspecified 288083910 CVCL_C7RZ II-45 cancer cell line Norway rat CVCL_C7RZ CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Peritoneum; Breed/subspecies: Fischer 344. Female Doubling time: 18.5 hours (PubMed=2827488) 288083911 CVCL_C7RY II-14 cancer cell line Norway rat CVCL_C7RY CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from sampling site: Peritoneum; Breed/subspecies: Fischer 344. Female Doubling time: 24.8 hours (PubMed=2827488) 288083912 CVCL_C7RL BCRTi011-A induced pluripotent stem cell human CVCL_C7RL From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 288083913 CVCL_C7RK BCRTi010-A induced pluripotent stem cell human CVCL_C7RK From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 288083914 CVCL_C7RN M12C1 spontaneously immortalized cell line Norway rat CVCL_C7RN CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 36 hours, at 15th passage (PubMed=1974862) Caution: It is possible that M12C1 and NRM 1 (Cellosaurus=CVCL_C7RQ) are the same cell line 288083915 CVCL_C7RM UMT42 cancer cell line human CVCL_C7RM CL:0000010 Derived from sampling site: Eye; uvea. Unspecified 288083916 CVCL_C7S1 DDT1-MF2 GR1 cancer cell line CVCL_C7S1 CL:0000010 Transformant: Diethylstilbestrol(ChEBI; CHEBI:41922); Derived from sampling site: Vas deferens; smooth muscle. Male Characteristics: Glucocorticold receptor-poor variant Growth of this cell line is completely resistant to the inhibitory action of glucocorticoids (PubMed=4058427; PubMed=8314862). 288083917 CVCL_C7RP M12C2 spontaneously immortalized cell line Norway rat CVCL_C7RP CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 33 hours, at 12th passage (PubMed=1974862) Caution: It is possible that M12C1 and NRM 2 (Cellosaurus=CVCL_C7RS) are the same cell line 288083918 CVCL_C7S0 III-2 cancer cell line Norway rat CVCL_C7S0 CL:0000010 Transformant: Chrysotile asbestos(ChEBI; CHEBI:46664); Derived from sampling site: Peritoneum; Breed/subspecies: Fischer 344. Female Doubling time: 26.4 hours (PubMed=2827488) 288083919 CVCL_C7S3 393T cancer cell line human CVCL_C7S3 HLA typing: A*01,08/10; B*w35,w40 (PubMed=77569) CL:0000010 Derived from sampling site: Bone. Unspecified 288083920 CVCL_C7RR NRM 2 spontaneously immortalized cell line Norway rat CVCL_C7RR CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male Doubling time: 40 hours (PubMed=9733279) Caution: It is possible that M12C2 (Cellosaurus=CVCL_C7RP) and NRM 2 are the same cell line 288083921 CVCL_C7S2 393S finite cell line human CVCL_C7S2 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 288083922 CVCL_C7RQ NRM 1 spontaneously immortalized cell line Norway rat CVCL_C7RQ CL:0000010 Derived from sampling site: Lung; parietal pleura Cell type=Mesothelial cell.; Breed/subspecies: Fischer 344. Male Caution: It is possible that M12C1 (Cellosaurus=CVCL_C7RN) and NRM 1 are the same cell line 288083923 CVCL_C7RD YCMi008-A induced pluripotent stem cell human CVCL_C7RD From: Yonsei University College of Medicine; Seoul; South Korea. CL:0000010 288083924 CVCL_C7RC IT 4 hybridoma house mouse CVCL_C7RC CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P9WMK1; Mycobacterium tuberculosis hspX. 288083925 CVCL_C7RF GDSRMi001-A induced pluripotent stem cell human CVCL_C7RF From: Guangdong Provincial People's Hospital; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 25636; MCTP2; Simple; p.Ter879Gluext (c.2635T>G); Zygosity=Homozygous (PubMed=36868039) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 288083926 CVCL_C7RE HEBHMUi013-A induced pluripotent stem cell human CVCL_C7RE From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Male 288083927 CVCL_C7RH BCRTi007-A induced pluripotent stem cell human CVCL_C7RH From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Derived from sampling site: Urine. Female 288083928 CVCL_C7RG ASGRCi008-A induced pluripotent stem cell human CVCL_C7RG From: Genomics Research Center, Academia Sinica; Taipei; Taiwan. CL:0000010 288083929 CVCL_C7RJ BCRTi009-A induced pluripotent stem cell human CVCL_C7RJ From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 288083930 CVCL_C7RI BCRTi008-A induced pluripotent stem cell human CVCL_C7RI From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany. CL:0000010 288083931 CVCL_C7QZ MCF10A-ERBB2m-11 spontaneously immortalized cell line human CVCL_C7QZ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Asp769Tyr) Derived from sampling site: Breast; epithelium. Female 288083932 CVCL_C7RB IT 1 hybridoma house mouse CVCL_C7RB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P9WMK1; Mycobacterium tuberculosis hspX. 288083933 CVCL_C7RA IT 20 hybridoma house mouse CVCL_C7RA CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P9WMK1; Mycobacterium tuberculosis hspX. 288083934 CVCL_C7SU HME50-5 spontaneously immortalized cell line human CVCL_C7SU CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083935 CVCL_C7T6 IISHDOi002-B induced pluripotent stem cell human CVCL_C7T6 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083936 CVCL_C7ST HME50-3 finite cell line human CVCL_C7ST CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083937 CVCL_C7T5 IISHDOi001-B induced pluripotent stem cell human CVCL_C7T5 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9726; PYGM; Simple; p.Arg50Ter (c.148C>T); ClinVar=VCV000002298; Zygosity=Homozygous (PubMed=36430443) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083938 CVCL_C7T8 C26C finite cell line human CVCL_C7T8 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1157Aspfs*7 (c.3471_3474delGAGA); ClinVar=VCV000186532; Zygosity=Heterozygous (PubMed=15153338) Derived from sampling site: Colon Cell type=Fibroblast.. Unspecified Senescence: Senesces at ~30 PDL (PubMed=15153338) 288083939 CVCL_C7SW HME50-7 finite cell line human CVCL_C7SW CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083940 CVCL_C7SV HME50-6 finite cell line human CVCL_C7SV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083941 CVCL_C7T7 IISHDOi001-A-1 induced pluripotent stem cell human CVCL_C7T7 From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9726; PYGM; Simple_edited; p.Pro49Pro (c.147A>T); Zygosity=Homozygous; Note=Introduces a XhoI restriction site (PubMed=36430443); Sequence variation: Mutation; HGNC; 9726; PYGM; Simple_corrected; p.Arg50Ter (c.148C>T); ClinVar=VCV000002298; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=36430443) Derived from sampling site: Skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 288083942 CVCL_C7SY HME50-9 spontaneously immortalized cell line human CVCL_C7SY CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (PubMed=7799951) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083943 CVCL_C7T9 C26Ci spontaneously immortalized cell line human CVCL_C7T9 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1157Aspfs*7 (c.3471_3474delGAGA); ClinVar=VCV000186532; Zygosity=Heterozygous (PubMed=15153338) Derived from sampling site: Colon Cell type=Fibroblast.. Unspecified 288083944 CVCL_C7SX HME50-8 spontaneously immortalized cell line human CVCL_C7SX CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female 288083945 CVCL_C7SZ HMS50-E6/E7-2 transformed cell line human CVCL_C7SZ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (PubMed=7799951); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 288083946 CVCL_C7SM HPC-92Y cancer cell line human CVCL_C7SM From: Yanoma S.; Yokohama Tsurugamine Hospital; Yokohama; Japan CL:0000010 Population: Japanese; Derived from sampling site: Pharynx; hypopharynx. 288083947 CVCL_C7SL LD-1 cancer cell line house mouse CVCL_C7SL CL:0000010 Transfected with: MGI; MGI:87986; Akt1; Transfected with: MGI; MGI:103262; Yap1 Transformant: Akt1 and Yap1; Derived from sampling site: Liver; Breed/subspecies: C57BL/6. Omics: Deep exome analysis 288083948 CVCL_C7T0 HMS50-E7-5 transformed cell line human CVCL_C7T0 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (PubMed=7799951); Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E7](NCBI-Taxonomy; 333760); Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female 288083949 CVCL_C7SN SK-N-FI ACE KO cancer cell line human CVCL_C7SN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2707; ACE; Sequence variation: Mutation; HGNC; 7765; NF1; Unexplicit; Partial deletion; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Arg (c.737T>G); ClinVar=VCV000127822; Zygosity=Homozygous (from parent cell line) Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from metastatic site: Bone marrow. Male 288083950 CVCL_C7T2 HMS50 finite cell line human CVCL_C7T2 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (PubMed=7799951) Derived from sampling site: Breast; interlobular stroma Cell type=Fibroblast.. Female Senescence: Capable of 40-50 PDL One clone senesced at 68 PDL (PubMed=7799951). 288083951 CVCL_C7SQ MiaPaCa(BCRP) cancer cell line human CVCL_C7SQ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:91367; Barasertib-HQPA (AZD1152-HQPA); Derived from sampling site: Pancreas. Omics: Transcriptome analysis by microarray Male 288083952 CVCL_C7T1 HME50 finite cell line human CVCL_C7T1 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (PubMed=7799951) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Female 288083953 CVCL_C7SP SW620(MDR1/3) cancer cell line human CVCL_C7SP CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:91367; Barasertib-HQPA (AZD1152-HQPA); Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by microarray Male 288083954 CVCL_C7SS HCT-116 TICCR-mClover cancer cell line human CVCL_C7SS CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Colon. Male Characteristics: Using CRISPR/Cas9 the fluorescent protein mClover was inserted at the C-terminus of TICRR (PubMed=34534348) 288083955 CVCL_C7T4 HME50-9R spontaneously immortalized cell line human CVCL_C7T4 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female Characteristics: Treated with resveratrol (PubMed=17968319) 288083956 CVCL_C7SR HCT-116 MTBP-mClover cancer cell line human CVCL_C7SR CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Ser65Gly, p.Gln69Ala, p.Phe99Ser, p.Asn105Phe, p.Tyr145Phe, p.Met153Thr, p.Val163Ala, p.Ile171Val, p.Thr203His = Clover GFP); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Colon. Male Characteristics: Using CRISPR/Cas9 the fluorescent protein mClover was inserted at the C-terminus of MTBP (PubMed=34534348) 288083957 CVCL_C7T3 HME50-8R spontaneously immortalized cell line human CVCL_C7T3 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Thr (c.398T>C); ClinVar=VCV000012357; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Breast; epithelium Cell type=Epithelial cell.. Female Characteristics: Treated with resveratrol (PubMed=17968319) 288083958 CVCL_C7SE Fe Mus #1 finite cell line human CVCL_C7SE CL:0000010 Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Unspecified 288083959 CVCL_C7SD LO #2 cancer cell line human CVCL_C7SD CL:0000010 Derived from metastatic site: Scapula; skin. Female Doubling time: 32 hours (at 32th passage), 29 hours (at 52th passage) (PubMed=994214) 288083960 CVCL_C7SG Fe Sk #1 finite cell line human CVCL_C7SG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 288083961 CVCL_C7SF Fe Mus #5 finite cell line human CVCL_C7SF CL:0000010 Derived from sampling site: Fetal muscle Cell type=Fibroblast.. Unspecified 288083962 CVCL_C7SI HOS-O cancer cell line human CVCL_C7SI CL:0000010 Population: Japanese; Derived from metastatic site: Lung. Female Doubling time: 12.0-16.8 hours (CelloPub=CLPUB00733) 288083963 CVCL_C7SH Fe Sk #5 finite cell line human CVCL_C7SH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 288083964 CVCL_C7SK YR-6 cancer cell line human CVCL_C7SK CL:0000010 Population: Japanese. Unspecified 288083965 CVCL_C7SJ YR-2 cancer cell line human CVCL_C7SJ From: Akira Yamaguchi; Department of Oral Pathology, Showa University School of Dentistry; Showa; Japan CL:0000010 Population: Japanese. Unspecified 288083966 CVCL_C7SA AL #1 cancer cell line human CVCL_C7SA CL:0000010 Derived from metastatic site: Inguinal lymph node. Male Doubling time: 28 hours, at 83th passage (PubMed=994214) 288083967 CVCL_C7SC KE #1 cancer cell line human CVCL_C7SC CL:0000010 Derived from metastatic site: Lung. Unspecified 288083968 CVCL_C7SB BOL #1 cancer cell line human CVCL_C7SB CL:0000010 Derived from metastatic site: Axillary lymph node. Male Doubling time: 36 hours, at 30th passage (PubMed=994214) 288083969 CVCL_C7Q3 MCF10A-EGFR1m-2 spontaneously immortalized cell line human CVCL_C7Q3 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del) Derived from sampling site: Breast; epithelium. Female 288083970 CVCL_C7PR WEHI-7.2 CAT2 cancer cell line house mouse CVCL_C7PR CL:0000010 Transfected with: RGD; 2279; Cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083971 CVCL_C7Q2 MCF10A-EGFR1m-1 spontaneously immortalized cell line human CVCL_C7Q2 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Leu858Arg) Derived from sampling site: Breast; epithelium. Female 288083972 CVCL_C7PQ WEHI-3B D+ P1 cancer cell line house mouse CVCL_C7PQ CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 288083973 CVCL_C7Q5 MCF10A-EGFR1m-4 spontaneously immortalized cell line human CVCL_C7Q5 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val769_Asp770insAlaSerVal) Derived from sampling site: Breast; epithelium. Female 288083974 CVCL_C7PT WEHI-7.2 Trx5 cancer cell line house mouse CVCL_C7PT CL:0000010 Transfected with: HGNC; 12435; TXN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083975 CVCL_C7Q4 MCF10A-EGFR1m-3 spontaneously immortalized cell line human CVCL_C7Q4 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Leu861Gln) Derived from sampling site: Breast; epithelium. Female 288083976 CVCL_C7PS WEHI-7.2 CAT38 cancer cell line house mouse CVCL_C7PS CL:0000010 Transfected with: RGD; 2279; Cat; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083977 CVCL_C7Q7 MCF10A-EGFR1m-6 spontaneously immortalized cell line human CVCL_C7Q7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.His773_Val774insAsnProHis) Derived from sampling site: Breast; epithelium. Female 288083978 CVCL_C7PV W.Hb12 cancer cell line house mouse CVCL_C7PV CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083979 CVCL_C7Q6 MCF10A-EGFR1m-5 spontaneously immortalized cell line human CVCL_C7Q6 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Asp770_Asn771insSerValAsp) Derived from sampling site: Breast; epithelium. Female 288083980 CVCL_C7PU WEHI-7.2 Trx6 cancer cell line house mouse CVCL_C7PU CL:0000010 Transfected with: HGNC; 12435; TXN; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083981 CVCL_C7Q9 MCF10A-EGFR1m-8 spontaneously immortalized cell line human CVCL_C7Q9 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.His773_Val774insHis) Derived from sampling site: Breast; epithelium. Female 288083982 CVCL_C7PX WEHI-7.2 100R cancer cell line house mouse CVCL_C7PX CL:0000010 Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Doubling time: 14.20 +- 0.49 hours (PubMed=11526450) 288083983 CVCL_C7Q8 MCF10A-EGFR1m-7 spontaneously immortalized cell line human CVCL_C7Q8 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Ala763_Tyr764insPheGlnGluAla) Derived from sampling site: Breast; epithelium. Female 288083984 CVCL_C7PW W.Hb13 cancer cell line house mouse CVCL_C7PW CL:0000010 Transfected with: HGNC; 990; BCL2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. 288083985 CVCL_C7PJ AG28869 induced pluripotent stem cell human CVCL_C7PJ CL:0000010 Population: Caucasian; Derived from sampling site: Toe; skin Cell type=Fibroblast.. Female 288083986 CVCL_C7PI AG28851 induced pluripotent stem cell human CVCL_C7PI CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 288083987 CVCL_C7PL JS1 transformed cell line house mouse CVCL_C7PL CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 288083988 CVCL_C7PK JS2 transformed cell line house mouse CVCL_C7PK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:96824; Tlr4; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 288083989 CVCL_C7PN Mu-mpl 32D factor-dependent cell line house mouse CVCL_C7PN CL:0000010 Transfected with: MGI; MGI:97076; Mpl; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent 288083990 CVCL_C7PM JS3 transformed cell line house mouse CVCL_C7PM CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:108005; Myd88; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatic stellate cell.; Breed/subspecies: C57BL/6. Unspecified 288083991 CVCL_C7Q1 MCF10A-AKTm-Control spontaneously immortalized cell line human CVCL_C7Q1 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 391; AKT1 Derived from sampling site: Breast; epithelium. Female 288083992 CVCL_C7PP WEHI-3B D+ F17 cancer cell line house mouse CVCL_C7PP CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Mineral oil(DrugBank; DB11057); Derived from sampling site: Peripheral blood; Breed/subspecies: BALB/c. Male 288083993 CVCL_C7Q0 MCF10A-AKTm-1 spontaneously immortalized cell line human CVCL_C7Q0 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 391; AKT1 (with p.Glu17Lys) Derived from sampling site: Breast; epithelium. Female 288083994 CVCL_C7PB AG28346 induced pluripotent stem cell human CVCL_C7PB CL:0000010 Population: African American; Donor information: Donor has history of diabetes mellitus; chronic renal failure; neurogenic bladder; fourniers gangrene and multiple ulcers; Derived from sampling site: Ischium; skin (Note=From a right ischial pressure wound); Cell type=Fibroblast. Male 288083995 CVCL_C7PA AG28336 induced pluripotent stem cell human CVCL_C7PA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288083996 CVCL_C7PD XP23BE iPSC induced pluripotent stem cell human CVCL_C7PD CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Native North American; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 288083997 CVCL_C7PC AG28369 induced pluripotent stem cell human CVCL_C7PC CL:0000010 Population: African American; Donor information: Donor was bedbound with bilateral ischial ulcers and multiple sclerosis; Derived from sampling site: Ischium; skin (Note=From a right ischial pressure ulcer); Cell type=Fibroblast. Male 288083998 CVCL_C7PF AG28585 induced pluripotent stem cell human CVCL_C7PF CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 288083999 CVCL_C7PE AG28462 induced pluripotent stem cell human CVCL_C7PE CL:0000010 Sequence variation: Mutation; HGNC; 9949; RECQL4; Simple; c.1483+25del11 (g.2746del11); Zygosity=Homozygous (Coriell) Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084000 CVCL_C7PH AG28801 induced pluripotent stem cell human CVCL_C7PH CL:0000010 Population: Caucasian; Derived from sampling site: Chest/abdomen; skin Cell type=Fibroblast.. Male 288084001 CVCL_C7PG AG28599 induced pluripotent stem cell human CVCL_C7PG CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 288084002 CVCL_C7P9 GM28862 induced pluripotent stem cell human CVCL_C7P9 CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg192Trp (c.574C>T); ClinVar=VCV000215235; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084003 CVCL_C7QS MCF10A-ERBB2m-4 spontaneously immortalized cell line human CVCL_C7QS CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Arg678Gln) Derived from sampling site: Breast; epithelium. Female 288084004 CVCL_C7R4 MCF10A-PTENm-2 spontaneously immortalized cell line human CVCL_C7R4 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN (with p.Arg130Gly) Derived from sampling site: Breast; epithelium. Female 288084005 CVCL_C7QR MCF10A-ERBB2m-3 spontaneously immortalized cell line human CVCL_C7QR CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Ser310Tyr) Derived from sampling site: Breast; epithelium. Female 288084006 CVCL_C7R3 MCF10A-PTENm-1 spontaneously immortalized cell line human CVCL_C7R3 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN (with p.Arg130Gln) Derived from sampling site: Breast; epithelium. Female 288084007 CVCL_C7QU MCF10A-ERBB2m-6 spontaneously immortalized cell line human CVCL_C7QU CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Leu755_Thr759del) Derived from sampling site: Breast; epithelium. Female 288084008 CVCL_C7R6 MCF10A-PTENm-4 spontaneously immortalized cell line human CVCL_C7R6 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN (with p.Arg130Ter) Derived from sampling site: Breast; epithelium. Female 288084009 CVCL_C7QT MCF10A-ERBB2m-5 spontaneously immortalized cell line human CVCL_C7QT CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Ala775_Gly776insTyrValMetAla) Derived from sampling site: Breast; epithelium. Female 288084010 CVCL_C7R5 MCF10A-PTENm-3 spontaneously immortalized cell line human CVCL_C7R5 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN (with p.Arg233Ter) Derived from sampling site: Breast; epithelium. Female 288084011 CVCL_C7QW MCF10A-ERBB2m-8 spontaneously immortalized cell line human CVCL_C7QW CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Gly776ValCys) Derived from sampling site: Breast; epithelium. Female 288084012 CVCL_C7R8 MCF10A-PTENm-Control spontaneously immortalized cell line human CVCL_C7R8 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN Derived from sampling site: Breast; epithelium. Female 288084013 CVCL_C7QV MCF10A-ERBB2m-7 spontaneously immortalized cell line human CVCL_C7QV CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Asp769His) Derived from sampling site: Breast; epithelium. Female 288084014 CVCL_C7R7 MCF10A-PTENm-5 spontaneously immortalized cell line human CVCL_C7R7 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 9588; PTEN (with p.Arg335Ter) Derived from sampling site: Breast; epithelium. Female 288084015 CVCL_C7QY MCF10A-ERBB2m-10 spontaneously immortalized cell line human CVCL_C7QY CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Val842Ile) Derived from sampling site: Breast; epithelium. Female 288084016 CVCL_C7QX MCF10A-ERBB2m-9 spontaneously immortalized cell line human CVCL_C7QX CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Val777Leu) Derived from sampling site: Breast; epithelium. Female 288084017 CVCL_C7R9 P6 hybridoma house mouse CVCL_C7R9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: Mycobacterium tuberculosis (Note=Reacts with strains H37Rv and 79112 but not with many other strains). 288084018 CVCL_C7QK MCF10A-EGFR1m-19 spontaneously immortalized cell line human CVCL_C7QK CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Thr790Met, p.Cys797Ser and p.Leu858Arg) Derived from sampling site: Breast; epithelium. Female 288084019 CVCL_C7QJ MCF10A-EGFR1m-18 spontaneously immortalized cell line human CVCL_C7QJ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Thr790Met and p.Leu858Arg) Derived from sampling site: Breast; epithelium. Female 288084020 CVCL_C7QM MCF10A-EGFR1m-21 spontaneously immortalized cell line human CVCL_C7QM CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Glu709Gly) Derived from sampling site: Breast; epithelium. Female 288084021 CVCL_C7QL MCF10A-EGFR1m-20 spontaneously immortalized cell line human CVCL_C7QL CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del, p.Thr790Met and Cys797Ser) Derived from sampling site: Breast; epithelium. Female 288084022 CVCL_C7R0 MCF10A-ERBB2m-12 spontaneously immortalized cell line human CVCL_C7R0 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Arg896Cys) Derived from sampling site: Breast; epithelium. Female 288084023 CVCL_C7QN MCF10A-EGFR1m-control spontaneously immortalized cell line human CVCL_C7QN CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR Derived from sampling site: Breast; epithelium. Female 288084024 CVCL_C7QQ MCF10A-ERBB2m-2 spontaneously immortalized cell line human CVCL_C7QQ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Ser310Phe) Derived from sampling site: Breast; epithelium. Female 288084025 CVCL_C7R2 MCF10A-ERRB2m-Control spontaneously immortalized cell line human CVCL_C7R2 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 Derived from sampling site: Breast; epithelium. Female 288084026 CVCL_C7QP MCF10A-ERBB2m-1 spontaneously immortalized cell line human CVCL_C7QP CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Gly309Ala) Derived from sampling site: Breast; epithelium. Female 288084027 CVCL_C7R1 MCF10A-ERBB2m-13 spontaneously immortalized cell line human CVCL_C7R1 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3430; ERBB2 (with p.Pro780_Tyr781insGlySerPro) Derived from sampling site: Breast; epithelium. Female 288084028 CVCL_C7QC MCF10A-EGFR1m-11 spontaneously immortalized cell line human CVCL_C7QC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Cys797Ser and p.Leu858Arg) Derived from sampling site: Breast; epithelium. Female 288084029 CVCL_C7QB MCF10A-EGFR1m-10 spontaneously immortalized cell line human CVCL_C7QB CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.His773_Val774insProHis) Derived from sampling site: Breast; epithelium. Female 288084030 CVCL_C7QE MCF10A-EGFR1m-13 spontaneously immortalized cell line human CVCL_C7QE CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del and p.Cys797Ser) Derived from sampling site: Breast; epithelium. Female 288084031 CVCL_C7QD MCF10A-EGFR1m-12 spontaneously immortalized cell line human CVCL_C7QD CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Glu746_Ala750del and p.Thr785Met) Derived from sampling site: Breast; epithelium. Female 288084032 CVCL_C7QG MCF10A-EGFR1m-15 spontaneously immortalized cell line human CVCL_C7QG CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Gly719Ser) Derived from sampling site: Breast; epithelium. Female 288084033 CVCL_C7QF MCF10A-EGFR1m-14 spontaneously immortalized cell line human CVCL_C7QF CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Gly719Ala) Derived from sampling site: Breast; epithelium. Female 288084034 CVCL_C7QI MCF10A-EGFR1m-17 spontaneously immortalized cell line human CVCL_C7QI CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Asp770_Asn771insGly) Derived from sampling site: Breast; epithelium. Female 288084035 CVCL_C7QH MCF10A-EGFR1m-16 spontaneously immortalized cell line human CVCL_C7QH CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Gly719Cys) Derived from sampling site: Breast; epithelium. Female 288084036 CVCL_C7PZ WEHI-7.2 50R cancer cell line house mouse CVCL_C7PZ CL:0000010 Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Doubling time: 14.62 +- 0.76 hours (PubMed=11526450) 288084037 CVCL_C7PY WEHI-7.2 200R cancer cell line house mouse CVCL_C7PY CL:0000010 Selected for resistance to: ChEBI; CHEBI:16240; Hydrogen peroxide; Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Thymus; Breed/subspecies: BALB/c. Doubling time: 14.63 +- 0.31 hours (PubMed=11526450) 288084038 CVCL_C7QA MCF10A-EGFR1m-9 spontaneously immortalized cell line human CVCL_C7QA CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 3236; EGFR (with p.Val774_Cys775insHisVal) Derived from sampling site: Breast; epithelium. Female 288084039 CVCL_C7NP GM28514 transformed cell line human CVCL_C7NP CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084040 CVCL_C7NR GM28517 transformed cell line human CVCL_C7NR CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084041 CVCL_C7NQ GM28515 transformed cell line human CVCL_C7NQ CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084042 CVCL_C7NT GM28519 transformed cell line human CVCL_C7NT CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084043 CVCL_C7NS GM28518 transformed cell line human CVCL_C7NS CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084044 CVCL_C7NV GM28521 transformed cell line human CVCL_C7NV CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084045 CVCL_C7NU GM28520 transformed cell line human CVCL_C7NU CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084046 CVCL_C7NH MKN1 NPTXR KO-2 cancer cell line human CVCL_C7NH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7954; NPTXR Population: Japanese; Derived from metastatic site: Lymph node. Male 288084047 CVCL_C7NG MKN1 NPTXR KO-1 cancer cell line human CVCL_C7NG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7954; NPTXR Population: Japanese; Derived from metastatic site: Lymph node. Male 288084048 CVCL_C7NJ MKN1 CHRNB2 KO-2 cancer cell line human CVCL_C7NJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1962; CHRNB2 Population: Japanese; Derived from metastatic site: Lymph node. Male 288084049 CVCL_C7NI MKN1 CHRNB2 KO-1 cancer cell line human CVCL_C7NI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1962; CHRNB2 Population: Japanese; Derived from metastatic site: Lymph node. Male 288084050 CVCL_C7NL Vero-furin spontaneously immortalized cell line green monkey CVCL_C7NL CL:0000010 Transfected with: HGNC; 8568; FURIN; Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Kidney; epithelium. Female Virology: Useful for the production of viruses with more effective furin cleavage (BEI Resources) Group: Non-human primate cell line 288084051 CVCL_C7NK Vero E6-TMPRSS2-T2A-ACE2 spontaneously immortalized cell line green monkey CVCL_C7NK CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: HGNC; 11876; TMPRSS2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; epithelium. Female Characteristics: Transfected with a PuroR-P2A-TMPRSS2-T2A-ACE2 plasmid under the control of a CAG promoter (BEI Resources) Group: Non-human primate cell line; Group: SARS-CoV-2 research cell line 288084052 CVCL_C7NN GM28513 transformed cell line human CVCL_C7NN CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084053 CVCL_C7NM GM28510 transformed cell line human CVCL_C7NM CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084054 CVCL_C7NB clone 16 hybridoma house mouse CVCL_C7NB CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-01644 288084055 CVCL_C7NA GM28507 transformed cell line human CVCL_C7NA CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084056 CVCL_C7ND clone 19 hybridoma house mouse CVCL_C7ND CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-01642 288084057 CVCL_C7NC clone 18 hybridoma house mouse CVCL_C7NC CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27487; Human DPP4/CD26. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-01643 288084058 CVCL_C7NF CH-01 hybridoma house mouse CVCL_C7NF CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P17787; Human CHRNB2. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-02857 288084059 CVCL_C7NE NP-01 hybridoma house mouse CVCL_C7NE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O95502; Human NPTXR. Group: Patented cell line; Registration: International Depositary Authority, Japanese National Institute of Technology and Evaluation; NITE BP-02856 288084060 CVCL_C7MW GM28490 transformed cell line human CVCL_C7MW CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084061 CVCL_C7N8 GM28505 transformed cell line human CVCL_C7N8 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084062 CVCL_C7MV GM28489 transformed cell line human CVCL_C7MV CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084063 CVCL_C7N7 GM28503 transformed cell line human CVCL_C7N7 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084064 CVCL_C7MY GM28493 transformed cell line human CVCL_C7MY CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084065 CVCL_C7MX GM28492 transformed cell line human CVCL_C7MX CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084066 CVCL_C7N9 GM28506 transformed cell line human CVCL_C7N9 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084067 CVCL_C7MZ GM28494 transformed cell line human CVCL_C7MZ CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084068 CVCL_C7P2 GM28610 finite cell line human CVCL_C7P2 CL:0000010 Sequence variation: Mutation; HGNC; 23794; PACS2; Simple; p.Glu209Lys (c.625G>A); ClinVar=VCV000495141; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Polish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 288084069 CVCL_C7P1 GM28529 transformed cell line human CVCL_C7P1 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084070 CVCL_C7P4 GM28623 transformed cell line human CVCL_C7P4 CL:0000010 Population: Caucasian; Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084071 CVCL_C7P3 GM28611 finite cell line human CVCL_C7P3 CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084072 CVCL_C7P6 GM28627 transformed cell line human CVCL_C7P6 CL:0000010 Sequence variation: Mutation; HGNC; 23794; PACS2; Simple; p.Glu209Lys (c.625G>A); ClinVar=VCV000495141; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084073 CVCL_C7P5 GM28624 finite cell line human CVCL_C7P5 CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084074 CVCL_C7P8 GM28629 finite cell line human CVCL_C7P8 CL:0000010 Population: Caucasian; Polish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084075 CVCL_C7P7 GM28628 transformed cell line human CVCL_C7P7 CL:0000010 Population: Caucasian; Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084076 CVCL_C7P0 GM28528 transformed cell line human CVCL_C7P0 CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084077 CVCL_C7NX GM28525 transformed cell line human CVCL_C7NX CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084078 CVCL_C7NW GM28524 transformed cell line human CVCL_C7NW CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084079 CVCL_C7NZ GM28527 transformed cell line human CVCL_C7NZ CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084080 CVCL_C7NY GM28526 transformed cell line human CVCL_C7NY CL:0000010 Population: Bedouin; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084081 CVCL_C7LN GM27991 transformed cell line human CVCL_C7LN CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084082 CVCL_C7LM GM27990 finite cell line human CVCL_C7LM CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084083 CVCL_C7LP GM27993 finite cell line human CVCL_C7LP CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084084 CVCL_C7M1 GM28028 transformed cell line human CVCL_C7M1 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe107del (c.318CTT[1]) (c.321_323delCTT); ClinVar=VCV000021448; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084085 CVCL_C7M0 GM28937 induced pluripotent stem cell human CVCL_C7M0 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe408del (c.1216_1218TTC[2]) (c.1222_1224delTTC); ClinVar=VCV000011698; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084086 CVCL_C7LR GM27995 finite cell line human CVCL_C7LR CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084087 CVCL_C7M3 GM28061 transformed cell line human CVCL_C7M3 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe107del (c.318CTT[1]) (c.321_323delCTT); ClinVar=VCV000021448; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084088 CVCL_C7LQ GM27994 transformed cell line human CVCL_C7LQ CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084089 CVCL_C7M2 GM28048 transformed cell line human CVCL_C7M2 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe107del (c.318CTT[1]) (c.321_323delCTT); ClinVar=VCV000021448; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084090 CVCL_C7LT GM27997 finite cell line human CVCL_C7LT CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084091 CVCL_C7M5 GM28096 finite cell line human CVCL_C7M5 CL:0000010 Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Lys109Lys (c.327G>A); ClinVar=VCV000021065; Zygosity=Heterozygous; Note=Affects splicing (Coriell); Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Trp174Ter (c.522G>A); ClinVar=VCV000205584; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084092 CVCL_C7LS GM27996 transformed cell line human CVCL_C7LS CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084093 CVCL_C7M4 GM28070 transformed cell line human CVCL_C7M4 CL:0000010 Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Lys109Lys (c.327G>A); ClinVar=VCV000021065; Zygosity=Heterozygous; Note=Affects splicing (Coriell); Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Trp174Ter (c.522G>A); ClinVar=VCV000205584; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084094 CVCL_C7LF GM27962 transformed cell line human CVCL_C7LF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084095 CVCL_C7LE GM27961 finite cell line human CVCL_C7LE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084096 CVCL_C7LH GM27967 transformed cell line human CVCL_C7LH CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ser181Cysfs*5 (c.542_543delCT); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084097 CVCL_C7LG GM27963 finite cell line human CVCL_C7LG CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Ser181Cysfs*5 (c.542_543delCT); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084098 CVCL_C7LJ GM27980 transformed cell line human CVCL_C7LJ CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Unspecified; Note=Factor V Leiden (Coriell) Population: Caucasian; Bosnian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084099 CVCL_C7LI GM27968 finite cell line human CVCL_C7LI CL:0000010 Sequence variation: Mutation; HGNC; 3542; F5; Simple; p.Arg534Gln (c.1601G>A) (R506Q); ClinVar=VCV000000642; Zygosity=Unspecified; Note=Factor V Leiden (Coriell) Population: Caucasian; Bosnian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084100 CVCL_C7LL GM27988 transformed cell line human CVCL_C7LL CL:0000010 Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Glu105Asnfs*2 (c.312delA); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 9440; THAP12; Simple; p.Pro277Thr (c.829C>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084101 CVCL_C7LK GM27987 finite cell line human CVCL_C7LK CL:0000010 Sequence variation: Mutation; HGNC; 7027; MERTK; Simple; p.Ala258Glu (c.773C>A); ClinVar=VCV000330747; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15446; PRPF31; Simple; p.Gln389Ter (c.1165C>T); ClinVar=VCV001297104; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 28396; TMEM67; Simple; p.Gly195Ilefs*13 (c.579_580delAG); ClinVar=VCV000056783; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084102 CVCL_C7LB GM27954 finite cell line human CVCL_C7LB CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Tyr335Cysfs*5 (c.1004_1005delAT (p.Tyr336Cysfs*5, c.1007_1008delAT); ClinVar=VCV000041911; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Latino or Hispanic; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 288084103 CVCL_C7LA GM27949 finite cell line human CVCL_C7LA CL:0000010 Population: Caucasian; Derived from sampling site: Oral cavity; tongue Cell type=Fibroblast.. Female 288084104 CVCL_C7LD GM28589 induced pluripotent stem cell human CVCL_C7LD CL:0000010 Sequence variation: Mutation; HGNC; 4175; GATM; Simple; p.Ala97Valfs*11 (c.484+1G>T); ClinVar=VCV000021299; Zygosity=Homozygous (Coriell) Population: Chinese; Taiwan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084105 CVCL_C7LC GM27955 transformed cell line human CVCL_C7LC CL:0000010 Sequence variation: Mutation; HGNC; 4175; GATM; Simple; p.Ala97Valfs*11 (c.484+1G>T); ClinVar=VCV000021299; Zygosity=Homozygous (Coriell) Population: Chinese; Taiwan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084106 CVCL_C7L6 GM27939 induced pluripotent stem cell human CVCL_C7L6 CL:0000010 Sequence variation: Mutation; HGNC; 19743; POMT2; Simple; p.Gly353Ser (c.1057G>A); ClinVar=VCV000003231; Zygosity=Homozygous (Coriell) Population: Caucasian; German/Irish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084107 CVCL_C7KU IPFLS transformed cell line CVCL_C7KU CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatic stem cell.. Unspecified Doubling time: ~6 days (PubMed=11904425) Group: Non-human primate cell line 288084108 CVCL_C7KT alpha wheat HBZ#14-1 hybridoma house mouse CVCL_C7KT CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q2Q067; Human T-cell leukemia virus 1 (HTLV-1) HBZ. 288084109 CVCL_C7L5 GM27914 finite cell line human CVCL_C7L5 CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; p.Phe221Leufs*67 (c.660delC); Zygosity=Heterozygous (Coriell) Population: Iranian; Derived from sampling site: Cell type=Fibroblast. Female 288084110 CVCL_C7KW GM27624 induced pluripotent stem cell human CVCL_C7KW CL:0000010 Sequence variation: Gene deletion; HGNC; 3811; FOXG1; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084111 CVCL_C7L8 GM27953 transformed cell line human CVCL_C7L8 CL:0000010 Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Glu64Lys (c.190G>A); ClinVar=VCV000128068; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084112 CVCL_C7L7 GM27948 finite cell line human CVCL_C7L7 CL:0000010 Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Glu64Lys (c.190G>A); ClinVar=VCV000128068; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084113 CVCL_C7KV MHPC transformed cell line CVCL_C7KV CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver Cell type=Hepatic stem cell.. Omics: Transcriptome analysis by RNAseq Male Doubling time: 2.3 days (PubMed=29796307) Group: Non-human primate cell line 288084114 CVCL_C7KY HT140E induced pluripotent stem cell human CVCL_C7KY From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Ter (c.379C>T); ClinVar=VCV000207569; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=29631617) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084115 CVCL_C7L9 GM28915 induced pluripotent stem cell human CVCL_C7L9 CL:0000010 Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Glu64Lys (c.190G>A); ClinVar=VCV000128068; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084116 CVCL_C7KX HT140A induced pluripotent stem cell human CVCL_C7KX From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg127Ter (c.379C>T); ClinVar=VCV000207569; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 2073; TPP1; Simple; p.Arg208Ter (c.622C>T); ClinVar=VCV000002643; Zygosity=Heterozygous (PubMed=29631617) Population: Latino or Hispanic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084117 CVCL_C7KZ HT146B induced pluripotent stem cell human CVCL_C7KZ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Met1Ile (c.3G>A); ClinVar=VCV000056193; Zygosity=Heterozygous (PubMed=29631617); Sequence variation: Mutation; HGNC; 9325; PPT1; Simple; p.Tyr247His (c.739T>C); ClinVar=VCV000056214; Zygosity=Heterozygous (PubMed=29631617) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084118 CVCL_C7N0 GM28495 transformed cell line human CVCL_C7N0 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084119 CVCL_C7MN GM28481 transformed cell line human CVCL_C7MN CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084120 CVCL_C7MQ GM28483 transformed cell line human CVCL_C7MQ CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084121 CVCL_C7N2 GM28497 transformed cell line human CVCL_C7N2 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084122 CVCL_C7MP GM28482 transformed cell line human CVCL_C7MP CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084123 CVCL_C7N1 GM28496 transformed cell line human CVCL_C7N1 CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084124 CVCL_C7MS GM28485 transformed cell line human CVCL_C7MS CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084125 CVCL_C7N4 GM28499 transformed cell line human CVCL_C7N4 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084126 CVCL_C7MR GM28484 transformed cell line human CVCL_C7MR CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084127 CVCL_C7N3 GM28498 transformed cell line human CVCL_C7N3 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084128 CVCL_C7MU GM28488 transformed cell line human CVCL_C7MU CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084129 CVCL_C7N6 GM28501 transformed cell line human CVCL_C7N6 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084130 CVCL_C7MT GM28487 transformed cell line human CVCL_C7MT CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084131 CVCL_C7N5 GM28500 transformed cell line human CVCL_C7N5 CL:0000010 Population: Palestinian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084132 CVCL_C7MG GM28361 finite cell line human CVCL_C7MG CL:0000010 Population: Caucasian; Dutch/Spanish; Derived from sampling site: Back; skin Cell type=Fibroblast.. Female 288084133 CVCL_C7MF GM28360 transformed cell line human CVCL_C7MF CL:0000010 Population: Caucasian; Dutch/Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084134 CVCL_C7MI GM28399 induced pluripotent stem cell human CVCL_C7MI CL:0000010 Sequence variation: Mutation; HGNC; 5959; ELP1; Simple; c.2204+6T>C (2507+6T>C) (IVS20+6T>C) (Ex20del); ClinVar=VCV000006085; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084135 CVCL_C7MH GM28378 transformed cell line human CVCL_C7MH CL:0000010 Sequence variation: Mutation; HGNC; 1388; CACNA1A; Simple; p.Gln1673Serfs*43 (c.5015dupG) (p.Gln1674Serfs*43, c.5018dupG); ClinVar=VCV001679533; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084136 CVCL_C7MK GM28476 finite cell line human CVCL_C7MK CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Gly159Valfs*68 (c.476delG); Zygosity=Heterozygous (from familial inference of GM28475) Population: Jewish; Syrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084137 CVCL_C7MJ GM28475 finite cell line human CVCL_C7MJ CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Gly159Valfs*68 (c.476delG); Zygosity=Homozygous (Coriell) Population: Jewish; Syrian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084138 CVCL_C7MM GM28480 transformed cell line human CVCL_C7MM CL:0000010 Population: Druze; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: National Laboratory for the Genetics of Israeli Populations (NLGIP) collection 288084139 CVCL_C7ML GM28477 finite cell line human CVCL_C7ML CL:0000010 Sequence variation: Mutation; HGNC; 9081; PLOD1; Simple; p.Gly159Valfs*68 (c.476delG); Zygosity=Heterozygous (from familial inference of GM28475) Population: Jewish; Syrian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084140 CVCL_C7MA GM28362 transformed cell line human CVCL_C7MA CL:0000010 Sequence variation: Mutation; HGNC; 24931; ZC4H2; Unexplicit; 244kb microdeletion; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Dutch/Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084141 CVCL_C7MC GM28603 induced pluripotent stem cell human CVCL_C7MC CL:0000010 Sequence variation: Mutation; HGNC; 24931; ZC4H2; Unexplicit; 244kb microdeletion; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Dutch/Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084142 CVCL_C7MB GM28363 finite cell line human CVCL_C7MB CL:0000010 Sequence variation: Mutation; HGNC; 24931; ZC4H2; Unexplicit; 244kb microdeletion; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Dutch/Spanish; Derived from sampling site: Hip; skin Cell type=Fibroblast.. Female 288084143 CVCL_C7ME GM28359 finite cell line human CVCL_C7ME CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 288084144 CVCL_C7MD GM28358 transformed cell line human CVCL_C7MD CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084145 CVCL_C7M7 GM28099 transformed cell line human CVCL_C7M7 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Unexplicit; Ex4-13del; Zygosity=Hemizygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 288084146 CVCL_C7LV GM28575 induced pluripotent stem cell human CVCL_C7LV CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly169Glyfs*23 (c.507del); Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Arg303His (c.908G>A); ClinVar=VCV000284411; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084147 CVCL_C7M6 GM28098 finite cell line human CVCL_C7M6 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Unexplicit; Ex4-13del; Zygosity=Hemizygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084148 CVCL_C7LU GM28322 finite cell line human CVCL_C7LU CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084149 CVCL_C7M9 GM28345 finite cell line human CVCL_C7M9 CL:0000010 Population: Caucasian; Dutch/Spanish; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 288084150 CVCL_C7LX GM28577 induced pluripotent stem cell human CVCL_C7LX CL:0000010 Sequence variation: Mutation; HGNC; 13830; CNTNAP2; Simple; p.Ser269Asn (c.806G>A); ClinVar=VCV000373714; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3791; FOLR1; Simple; c.493+2T>C (IVS4+2T>C); ClinVar=VCV000095750; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly224Ser (c.670G>A); ClinVar=VCV000167092; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Pro8Thr (c.22C>A); ClinVar=VCV000205598; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084151 CVCL_C7M8 GM28344 transformed cell line human CVCL_C7M8 CL:0000010 Population: Caucasian; Dutch/Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084152 CVCL_C7LW GM28576 induced pluripotent stem cell human CVCL_C7LW CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Trp308Ter (c.924G>A); ClinVar=VCV000013871; Zygosity=Unspecified; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 288084153 CVCL_C7LZ GM28910 induced pluripotent stem cell human CVCL_C7LZ CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Thr150Ala (c.448A>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 14888; DNAJB6; Simple; c.899-3T>G; Zygosity=Heterozygous (from parent cell line) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 288084154 CVCL_C7LY GM28578 induced pluripotent stem cell human CVCL_C7LY CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Ser326Glufs*129 (c.974_975insA); Zygosity=Heterozygous (Coriell) Population: Caucasian; French; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084155 CVCL_C6XZ MG87-TrkC spontaneously immortalized cell line house mouse CVCL_C6XZ CL:0000010 Transfected with: RGD; 3214; Ntrk3 (isoform TRKC) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 288084156 CVCL_C6YB Abcam PC-3 ABL1 KO cancer cell line human CVCL_C6YB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 76; ABL1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084157 CVCL_C6YA Abcam PC-3 ABCB1 KO cancer cell line human CVCL_C6YA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 40; ABCB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084158 CVCL_C6XS 6F6-1 hybridoma house mouse CVCL_C6XS CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084159 CVCL_C6Y4 HAP1 FASTKD3-sKO cancer cell line human CVCL_C6Y4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28758; FASTKD3; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084160 CVCL_C6XR 6B9-4 hybridoma house mouse CVCL_C6XR CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084161 CVCL_C6Y3 HAP1 CTAGE5 (-) cancer cell line human CVCL_C6Y3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18432; MIA2; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084162 CVCL_C6XU 8G6-5 hybridoma house mouse CVCL_C6XU CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084163 CVCL_C6Y6 HAP1 FASTKD5-sKO cancer cell line human CVCL_C6Y6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25790; FASTKD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084164 CVCL_C6XT 7E1-13 hybridoma house mouse CVCL_C6XT CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084165 CVCL_C6Y5 HAP1 FASTKD4-sKO cancer cell line human CVCL_C6Y5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17443; TBRG4; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084166 CVCL_C6XW 9C3-8 hybridoma house mouse CVCL_C6XW CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084167 CVCL_C6Y8 HAP1 FASTKD4&5-dKO cancer cell line human CVCL_C6Y8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17443; TBRG4; Knockout cell: Method=CRISPR/Cas9; HGNC; 25790; FASTKD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084168 CVCL_C6XV 9C11-14 hybridoma house mouse CVCL_C6XV CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084169 CVCL_C6Y7 HAP1 FASTKD3&4-dKO cancer cell line human CVCL_C6Y7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28758; FASTKD3; Knockout cell: Method=CRISPR/Cas9; HGNC; 17443; TBRG4; Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 25790; FASTKD5; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084170 CVCL_C6XY 9E4-20 hybridoma house mouse CVCL_C6XY CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084171 CVCL_C6XX 9D4-7 hybridoma house mouse CVCL_C6XX CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084172 CVCL_C6Y9 Abcam PC-3 AATF KO cancer cell line human CVCL_C6Y9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19235; AATF; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084173 CVCL_C6XK 10F2-13 hybridoma house mouse CVCL_C6XK CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084174 CVCL_C6XJ 10E3-17 hybridoma house mouse CVCL_C6XJ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084175 CVCL_C6XM 2C11-4 hybridoma house mouse CVCL_C6XM CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084176 CVCL_C6XL 2B7-7 hybridoma house mouse CVCL_C6XL CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084177 CVCL_C6Y0 MG87-TrkC.ki14 spontaneously immortalized cell line house mouse CVCL_C6Y0 CL:0000010 Transfected with: RGD; 3214; Ntrk3 (isoform KI14) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 288084178 CVCL_C6XN 3B9-10 hybridoma house mouse CVCL_C6XN CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084179 CVCL_C6XQ 5H2-17 hybridoma house mouse CVCL_C6XQ CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084180 CVCL_C6Y2 HAP1 MDK (-) cancer cell line human CVCL_C6Y2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6972; MDK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 288084181 CVCL_C6XP 3H7-6 hybridoma house mouse CVCL_C6XP CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084182 CVCL_C6Y1 MG87-TrkC.ki39 spontaneously immortalized cell line house mouse CVCL_C6Y1 CL:0000010 Transfected with: RGD; 3214; Ntrk3 (isoform KI39) Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 288084183 CVCL_C6XC 32Dcl3/HNP factor-dependent cell line house mouse CVCL_C6XC CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent 288084184 CVCL_C6XB 32D/HNP factor-dependent cell line house mouse CVCL_C6XB CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Bone marrow; Breed/subspecies: C3H/HeJ. Male Characteristics: IL3 dependent 288084185 CVCL_C6XE J774.1/HNP cancer cell line house mouse CVCL_C6XE CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Breed/subspecies: BALB/c. Female 288084186 CVCL_C6XD AtT-20/HNP cancer cell line house mouse CVCL_C6XD CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. 288084187 CVCL_C6XG RAW264.7/HNP cancer cell line house mouse CVCL_C6XG CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084188 CVCL_C6XF NIH 3T3/HNP spontaneously immortalized cell line house mouse CVCL_C6XF CL:0000010 Transfected with: HGNC; 2761; DEFA1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 288084189 CVCL_C6XI NS0-hCD20 cancer cell line house mouse CVCL_C6XI CL:0000010 Transfected with: HGNC; 7315; MS4A1 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female 288084190 CVCL_C6XH MG87/CD20 spontaneously immortalized cell line house mouse CVCL_C6XH CL:0000010 Transfected with: HGNC; 7315; MS4A1 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 288084191 CVCL_C6ZA Abcam PC-3 CTSB KO cancer cell line human CVCL_C6ZA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2527; CTSB; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084192 CVCL_C6ZC Abcam PC-3 CUL3 KO cancer cell line human CVCL_C6ZC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2553; CUL3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084193 CVCL_C6ZB Abcam PC-3 CUL2 KO cancer cell line human CVCL_C6ZB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2552; CUL2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084194 CVCL_C6YT Abcam PC-3 BRD9 KO cancer cell line human CVCL_C6YT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25818; BRD9; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084195 CVCL_C6Z5 Abcam PC-3 CLU KO cancer cell line human CVCL_C6Z5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2095; CLU; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084196 CVCL_C6YS Abcam PC-3 BRD2 KO cancer cell line human CVCL_C6YS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1103; BRD2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084197 CVCL_C6Z4 Abcam PC-3 CITED2 KO cancer cell line human CVCL_C6Z4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1987; CITED2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084198 CVCL_C6YV Abcam PC-3 BTK KO cancer cell line human CVCL_C6YV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1133; BTK; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084199 CVCL_C6Z7 Abcam PC-3 CMTM6 KO cancer cell line human CVCL_C6Z7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19177; CMTM6; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084200 CVCL_C6YU Abcam PC-3 BTG1 KO cancer cell line human CVCL_C6YU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1130; BTG1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084201 CVCL_C6Z6 Abcam PC-3 CMKLR1 KO cancer cell line human CVCL_C6Z6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2121; CMKLR1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084202 CVCL_C6YX Abcam PC-3 C3 KO cancer cell line human CVCL_C6YX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1318; C3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084203 CVCL_C6Z9 Abcam PC-3 CST3 KO cancer cell line human CVCL_C6Z9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2475; CST3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084204 CVCL_C6YW Abcam PC-3 BTRC KO cancer cell line human CVCL_C6YW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1144; BTRC; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084205 CVCL_C6Z8 Abcam PC-3 CNR2 KO cancer cell line human CVCL_C6Z8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2160; CNR2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084206 CVCL_C6YZ Abcam PC-3 CCRL2 KO cancer cell line human CVCL_C6YZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1612; CCRL2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084207 CVCL_C6YY Abcam PC-3 CASP3 KO cancer cell line human CVCL_C6YY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1504; CASP3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084208 CVCL_C6YL Abcam PC-3 ATF5 KO cancer cell line human CVCL_C6YL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 790; ATF5; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084209 CVCL_C6YK Abcam PC-3 ASAH1 KO cancer cell line human CVCL_C6YK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 735; ASAH1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084210 CVCL_C6YN Abcam PC-3 ATG9A KO cancer cell line human CVCL_C6YN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 22408; ATG9A; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084211 CVCL_C6YM Abcam PC-3 ATG3 KO cancer cell line human CVCL_C6YM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20962; ATG3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084212 CVCL_C6YP Abcam PC-3 BAK1 KO cancer cell line human CVCL_C6YP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 949; BAK1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084213 CVCL_C6Z1 Abcam PC-3 CD58 KO cancer cell line human CVCL_C6Z1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1688; CD58; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084214 CVCL_C6Z0 Abcam PC-3 CD36 KO cancer cell line human CVCL_C6Z0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1663; CD36; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084215 CVCL_C6YR Abcam PC-3 BRD1 KO cancer cell line human CVCL_C6YR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1102; BRD1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084216 CVCL_C6Z3 Abcam PC-3 CD81 KO cancer cell line human CVCL_C6Z3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1701; CD81; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084217 CVCL_C6YQ Abcam PC-3 BMPR2 KO cancer cell line human CVCL_C6YQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1078; BMPR2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084218 CVCL_C6Z2 Abcam PC-3 CD59 KO cancer cell line human CVCL_C6Z2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1689; CD59; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084219 CVCL_C6YD Abcam PC-3 AGTR1 KO cancer cell line human CVCL_C6YD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 336; AGTR1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084220 CVCL_C6YC Abcam PC-3 ADGRG1 KO cancer cell line human CVCL_C6YC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4512; ADGRG1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084221 CVCL_C6YF Abcam PC-3 AIM2 KO cancer cell line human CVCL_C6YF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 357; AIM2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084222 CVCL_C6YE Abcam PC-3 AHR KO cancer cell line human CVCL_C6YE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 348; AHR; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084223 CVCL_C6YH Abcam PC-3 ALKBH1 KO cancer cell line human CVCL_C6YH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17911; ALKBH1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084224 CVCL_C6YG Abcam PC-3 ALCAM KO cancer cell line human CVCL_C6YG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 400; ALCAM; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084225 CVCL_C6YJ Abcam PC-3 APOBEC3B KO cancer cell line human CVCL_C6YJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17352; APOBEC3B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084226 CVCL_C6YI Abcam PC-3 ALYREF KO cancer cell line human CVCL_C6YI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19071; ALYREF; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084227 CVCL_C6VY Alex1 induced pluripotent stem cell human CVCL_C6VY CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg239Cys (c.729C>T); ClinVar=VCV000016167; Zygosity=Heterozygous (PubMed=27402089) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084228 CVCL_C6W9 iPS-MEF3-6 induced pluripotent stem cell house mouse CVCL_C6W9 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084229 CVCL_C6VX MSOD-B telomerase immortalized cell line human CVCL_C6VX CL:0000010 Transfected with: HGNC; 1069; BMP2; Transfected with: HGNC; 1633; CD19 (with p.Lys324_Arg556del = CD19t); Transfected with: HGNC; 7809; NGFR (truncated); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female Characteristics: Capable of chondrogenesis and deposition of a morphogen-enriched ECM (PubMed=34486186); Characteristics: Can successfully undergo chondrogenic and osteogenic differentiation in vitro, forming mature hypertrophic cartilage and osteoid tissues, respectively Their subsequent ectopic implantation results in rapid humanized ossicles (hOss) formation and reconstitution of a cellular and molecular human mesenchymal niche (PubMed=36223446).; Characteristics: Transduced with a lentiviral vector containing hTERT and eGFP respectively under the control of the CMV and EF1a promoters and a retro-vector containing iCas9-2A-CD19t under the control of a CMV promoter (from parent cell line); Characteristics: Transduced with a lentiviral vector containing a PGK bidirectional promoter driving the expression of BMP2 and truncated LNGFR (PubMed=34486186); Characteristics: The suicide system of this cell line can be activated by addition of an homodimerizer that activates the apoptosis pathway through the dimerization of iCas9 (from parent cell line) 288084230 CVCL_C6VZ Alex2 induced pluripotent stem cell human CVCL_C6VZ CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Glu69Lys (c.205G>A); ClinVar=VCV000190333; Zygosity=Heterozygous (PubMed=27402089) Derived from sampling site: Peripheral blood. Female 288084231 CVCL_C6W2 HC2 induced pluripotent stem cell human CVCL_C6W2 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084232 CVCL_C6VQ OVTW59-P1 cancer cell line human CVCL_C6VQ CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Characteristics: Selected from parent cell line for invasion phenotype using Matrigel-coated transwell membranes P1 are P0-derived cells that had invaded through the Matrigel (PubMed=17952116). 288084233 CVCL_C6W1 HC1 induced pluripotent stem cell human CVCL_C6W1 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084234 CVCL_C6VP OVTW59-P0 cancer cell line human CVCL_C6VP CL:0000010 Miscellaneous: STR profile from personal communication of Yeh T.-C Population: Chinese; Taiwan; Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Doubling time: 26 hours (PubMed=17952116) 288084235 CVCL_C6W4 iPS-MEF3-1 induced pluripotent stem cell house mouse CVCL_C6W4 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57/BL6-129-ICR Fbx15bgeo/bgeo transgenic. 288084236 CVCL_C6VS OVTW59-P3 cancer cell line human CVCL_C6VS CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Characteristics: Selected from parent cell line for invasion phenotype using Matrigel-coated transwell membranes P3 are P2-derived cells that had invaded through the Matrigel (PubMed=17952116). 288084237 CVCL_C6W3 HC3 induced pluripotent stem cell human CVCL_C6W3 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084238 CVCL_C6VR OVTW59-P2 cancer cell line human CVCL_C6VR CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Characteristics: Selected from parent cell line for invasion phenotype using Matrigel-coated transwell membranes P2 are P1-derived cells that had invaded through the Matrigel (PubMed=17952116). 288084239 CVCL_C6W6 iPS-MEF3-3 induced pluripotent stem cell house mouse CVCL_C6W6 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084240 CVCL_C6VU OVTW59-P4-pBIG2i-hIGFBP3 cancer cell line human CVCL_C6VU CL:0000010 Transfected with: HGNC; 5472; IGFBP3 Population: Chinese; Taiwan; Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Characteristics: Transduced with a doxycycline-induced expression plasmid pBIG2i that drives the expression of hIGFPB3 288084241 CVCL_C6W5 iPS-MEF3-2 induced pluripotent stem cell house mouse CVCL_C6W5 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57/BL6-129-ICR Fbx15bgeo/bgeo transgenic. 288084242 CVCL_C6VT OVTW59-P4 cancer cell line human CVCL_C6VT CL:0000010 Population: Chinese; Taiwan; Karyotypic information: XXX,t(3;12),t(5;8),t(6;15),t(11;12),t(15;22),del(7)(q22),-4,+12,+14,+14,-18,-19,+21,-22,-22 (PubMed=17952116); Derived from sampling site: Ovary Cell type=Epithelial cell.. Female Characteristics: High invasive phenotype Selected from parent cell line for invasion phenotype using Matrigel-coated transwell membranes. P4 are P3-derived cells that had invaded through the Matrigel (PubMed=17952116). Doubling time: 19 hours (PubMed=17952116) 288084243 CVCL_C6W8 iPS-MEF3-5 induced pluripotent stem cell house mouse CVCL_C6W8 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084244 CVCL_C6VW MSOD telomerase immortalized cell line human CVCL_C6VW CL:0000010 Transfected with: HGNC; 1633; CD19 (with p.Lys324_Arg556del = CD19t); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female Characteristics: Capable to efficiently differentiate toward the osteogenic lineage (PubMed=24561906); Characteristics: Transduced with a lentiviral vector containing hTERT and eGFP respectively under the control of the CMV and EF1a promoters and a retro-vector containing iCas9-2A-CD19t under the control of a CMV promoter (PubMed=24561906); Characteristics: The suicide system of this cell line can be activated by addition of an homodimerizer that activates the apoptosis pathway through the dimerization of iCas9 (PubMed=24561906) Group: Patented cell line 288084245 CVCL_C6VV 196hT telomerase immortalized cell line human CVCL_C6VV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female Characteristics: Transduced with a lentiviral vector containing hTERT and eGFP respectively under the control of the CMV and EF1a promoters (PubMed=24561906) 288084246 CVCL_C6W7 iPS-MEF3-4 induced pluripotent stem cell house mouse CVCL_C6W7 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084247 CVCL_C6VI 3Ao cancer cell line human CVCL_C6VI CL:0000010 Female Doubling time: 24.9 +-0.1 hours (CelloPub=CLPUB00731). 288084248 CVCL_C6VH S3-iPS4 induced pluripotent stem cell human CVCL_C6VH CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084249 CVCL_C6VK HT94 cancer cell line human CVCL_C6VK CL:0000010 Population: Caucasian; Derived from sampling site: Thyroid gland. Female 288084250 CVCL_C6VJ 3Ao/cDDP cancer cell line human CVCL_C6VJ CL:0000010 Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female Doubling time: 23.8 +-0.3 hours (CelloPub=CLPUB00731) 288084251 CVCL_C6VM FS6-14.13 hybridoma house mouse CVCL_C6VM CL:0000010 Characteristics: T-cell hybridoma Produces IL2 when stimulated by concanavalin A (ConA) (PubMed=6968339).. 288084252 CVCL_C6VL Mel 364 cancer cell line human CVCL_C6VL CL:0000010 Population: Caucasian; Derived from metastatic site: Lymph node. Female Characteristics: Pigmented 288084253 CVCL_C6W0 Alex3 induced pluripotent stem cell human CVCL_C6W0 CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg276Leu (c.827G>T); ClinVar=VCV000016177; Zygosity=Heterozygous (PubMed=27402089) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084254 CVCL_C6VN FS6-14.13.AG2.OU8 hybridoma house mouse CVCL_C6VN CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain. Characteristics: T-cell hybridoma Produces IL2 when stimulated by concanavalin A (ConA) (from parent cell line). Group: Hybridoma fusion partner cell line 288084255 CVCL_C6VA Anti-ESAT-6 hybridoma house mouse CVCL_C6VA CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P9WNK7; Mycobacterium tuberculosis ESAT-6 (esxA). 288084256 CVCL_C6VC L1-iPS6 induced pluripotent stem cell human CVCL_C6VC CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084257 CVCL_C6VB L1-iPS1 induced pluripotent stem cell human CVCL_C6VB CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084258 CVCL_C6VE L2-iPS6 induced pluripotent stem cell human CVCL_C6VE CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084259 CVCL_C6VD L1-iPS13 induced pluripotent stem cell human CVCL_C6VD CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084260 CVCL_C6VG L2-iPS18 induced pluripotent stem cell human CVCL_C6VG CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084261 CVCL_C6VF L2-iPS16 induced pluripotent stem cell human CVCL_C6VF CL:0000010 Sequence variation: Mutation; HGNC; 9644; PTPN11; Simple; p.Thr468Met (c.1403C>T); ClinVar=VCV000013331; Zygosity=Heterozygous (PubMed=20535210) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084262 CVCL_C6WZ RAW264.7 clone C1 cancer cell line house mouse CVCL_C6WZ CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084263 CVCL_C6WY RAW264.7 clone J8 cancer cell line house mouse CVCL_C6WY CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Compared to parent cell line, does not form multinucleated TRAP-positive cells or exhibit other osteoclast-characteristics (PubMed=31947698) 288084264 CVCL_C6XA RAW264.7 clone C12 cancer cell line house mouse CVCL_C6XA CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084265 CVCL_C6WR AO-40.10 hybridoma house mouse CVCL_C6WR CL:0000010 Characteristics: Hybrid of the T-cell hybridoma FS6-14.13 Ag2.1 with T-cell blasts from chicken ovalbumin (cOVA)-immunized B10.A (H-2a) mice Produces IL-2 in response to antigen stimulation (ovalbumin) plus irradiated B10.A spleen cells (PubMed=6166712). Doubling time: ~12 hours (PubMed=6166712). 288084266 CVCL_C6X3 RAW264.7 clone C5 cancer cell line house mouse CVCL_C6X3 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084267 CVCL_C6WQ NB1-C cancer cell line human CVCL_C6WQ CL:0000010 Derived from metastatic site: Bone marrow. Male Characteristics: Established from the NB1 xenograft tumor in serum-free medium (PubMed=22028624) 288084268 CVCL_C6X2 RAW264.7 clone C4 cancer cell line house mouse CVCL_C6X2 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084269 CVCL_C6WT 33BTE-140.9 hybridoma house mouse CVCL_C6WT CL:0000010 Characteristics: T-cell hybridoma. 288084270 CVCL_C6X5 RAW264.7 clone C7 cancer cell line house mouse CVCL_C6X5 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084271 CVCL_C6WS 33BTE-140 hybridoma house mouse CVCL_C6WS CL:0000010 Characteristics: T-cell hybridoma. 288084272 CVCL_C6X4 RAW264.7 clone C6 cancer cell line house mouse CVCL_C6X4 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Differentiates well into osteoclast upon treatment with RANK (PubMed=16948499) 288084273 CVCL_C6WV 9H4-12 hybridoma house mouse CVCL_C6WV CL:0000010 Miscellaneous: As the immunized splenic B-cells are from VelocImmune mice the produced mAB is of human origin. Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20 288084274 CVCL_C6X7 RAW264.7 clone C9 cancer cell line house mouse CVCL_C6X7 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084275 CVCL_C6WU 4B12 spontaneously immortalized cell line house mouse CVCL_C6WU CL:0000010 Derived from sampling site: Bone; calvaria Cell type=Osteoclast.; Breed/subspecies: ddY. Unspecified Characteristics: Selected by FACS to be Mac-1+cFms+-RANK1+ Depend on Csf1 for both proliferation and osteoclast differentiation (PubMed=19492422). 288084276 CVCL_C6X6 RAW264.7 clone C8 cancer cell line house mouse CVCL_C6X6 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084277 CVCL_C6X9 RAW264.7 clone C11 cancer cell line house mouse CVCL_C6X9 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Differentiates well into osteoclast upon treatment with RANK (PubMed=16948499) 288084278 CVCL_C6WX RAW264.7 clone H9 cancer cell line house mouse CVCL_C6WX CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Forms osteoclast-like cells capable of bone resorption faster than the parent cell line Presents a higher expression of osteoclast markers in cultures without added RANKL compared to the parental cell line (PubMed=31947698). 288084279 CVCL_C6WW RAW-N cancer cell line house mouse CVCL_C6WW CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Incapable of differentiating into osteoclast-like multinucleated cells (PubMed=14709158) 288084280 CVCL_C6X8 RAW264.7 clone C10 cancer cell line house mouse CVCL_C6X8 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084281 CVCL_C6WJ iPS-TTFgfp4-5 induced pluripotent stem cell house mouse CVCL_C6WJ CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084282 CVCL_C6WI iPS-TTFgfp4-4 induced pluripotent stem cell house mouse CVCL_C6WI CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084283 CVCL_C6WL PoEFCI spontaneously immortalized cell line CVCL_C6WL CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Fish cell line 288084284 CVCL_C6WK iPS-TTFgfp4-7 induced pluripotent stem cell house mouse CVCL_C6WK CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084285 CVCL_C6WN PoEFCIII spontaneously immortalized cell line CVCL_C6WN CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Fish cell line 288084286 CVCL_C6WM PoEFCII spontaneously immortalized cell line CVCL_C6WM CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Fish cell line 288084287 CVCL_C6WP PoEFCIV spontaneously immortalized cell line CVCL_C6WP CL:0000010 Derived from sampling site: Cell type=Fibroblast. Unspecified Group: Fish cell line 288084288 CVCL_C6X1 RAW264.7 clone C3 cancer cell line house mouse CVCL_C6X1 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male Characteristics: Differentiates well into osteoclast upon treatment with RANK (PubMed=16948499) 288084289 CVCL_C6X0 RAW264.7 clone C2 cancer cell line house mouse CVCL_C6X0 CL:0000010 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.; Breed/subspecies: BALB/c. Male 288084290 CVCL_C6WB iPS-MEF4-7 induced pluripotent stem cell house mouse CVCL_C6WB CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084291 CVCL_C6WA iPS-MEF4-2 induced pluripotent stem cell house mouse CVCL_C6WA CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084292 CVCL_C6WD iPS-TTF4-1 induced pluripotent stem cell house mouse CVCL_C6WD CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129 Fbx15bgeo/bgeo transgenic. Male 288084293 CVCL_C6WC iPS-MEF4-10 induced pluripotent stem cell house mouse CVCL_C6WC CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. 288084294 CVCL_C6WF iPS-TTFgfp4-1 induced pluripotent stem cell house mouse CVCL_C6WF CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084295 CVCL_C6WE iPS-TTF4-3 induced pluripotent stem cell house mouse CVCL_C6WE CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129 Fbx15bgeo/bgeo transgenic. Male 288084296 CVCL_C6WH iPS-TTFgfp4-3 induced pluripotent stem cell house mouse CVCL_C6WH CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084297 CVCL_C6WG iPS-TTFgfp4-2 induced pluripotent stem cell house mouse CVCL_C6WG CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Miscellaneous: The transgenic mice used have a beta-geo cassette (a fusion of the beta-galactosidase and neo genes) inserted in the Fbx15 gene by homologous recombination Derived from sampling site: Tail Cell type=Fibroblast.; Breed/subspecies: C57BL/6-129-ICR Fbx15bgeo/bgeo transgenic. Female 288084298 CVCL_C6TW CJUHi001-A induced pluripotent stem cell human CVCL_C6TW From: China-Japan Union Hospital; Changchun City; China CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[44]; Zygosity=Heterozygous (PubMed=36459834) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 288084299 CVCL_C6U8 SCVI-116 induced pluripotent stem cell human CVCL_C6U8 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. 288084300 CVCL_C6TV MHHi001-A-10 induced pluripotent stem cell human CVCL_C6TV From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Transfected with: Arclight A242, a fluorescent voltage sensor; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female Characteristics: Using TALEN the voltage-sensor (GEVI) Arclight A242 and antibiotic resistance genes under the control of the cardiac-specific myosin heavy chain promoter (pCAG-Arclight-alphaMHC-NeoR-PGK-HygroR construct) were introduced in both alleles of the AAVS1 safe harbor locus (PubMed=36463634) 288084301 CVCL_C6U7 ZZUSAHi004-A induced pluripotent stem cell human CVCL_C6U7 From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 379; AKAP9; Simple; p.Gln1341Lys (c.4021C>A); Zygosity=Heterozygous (PubMed=36395689) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 288084302 CVCL_C6TY BIHi288-A induced pluripotent stem cell human CVCL_C6TY From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[58] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36434993) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084303 CVCL_C6TX GIBHe015-B embryonic stem cell human CVCL_C6TX From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21689; FIS1. Male 288084304 CVCL_C6U9 SCVI-111 induced pluripotent stem cell human CVCL_C6U9 From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. Male 288084305 CVCL_C6TZ BIHi033-A induced pluripotent stem cell human CVCL_C6TZ From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36434993) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084306 CVCL_C6U0 BIHi034-A induced pluripotent stem cell human CVCL_C6U0 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[44] (c.52CAG(41)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=36434993) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084307 CVCL_C6TN CNNDi001-A-1 induced pluripotent stem cell human CVCL_C6TN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 37; ABCA7 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 288084308 CVCL_C6TQ FD-1-TSP-1-/- induced pluripotent stem cell human CVCL_C6TQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11785; THBS1; Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Leu268fs*1 (c.803_806del); Zygosity=Hemizygous (PubMed=31981984) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084309 CVCL_C6U2 SDUCTi001-A induced pluripotent stem cell human CVCL_C6U2 From: Department of Clinical Research, University of Southern Denmark; Odense; Denmark CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084310 CVCL_C6U1 cmESF-iPS-C5 induced pluripotent stem cell CVCL_C6U1 From: National Primate Research Center, Korea Research Institute of Bioscience and Biotechnology; Cheongju; South Korea CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 288084311 CVCL_C6TP FD-1-iPSC induced pluripotent stem cell human CVCL_C6TP From: Korea Advanced Institute of Science and Technology; Daejeon; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Leu268fs*1 (c.803_806del); Zygosity=Hemizygous (PubMed=31981984) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084312 CVCL_C6TS FDCHi009-A induced pluripotent stem cell human CVCL_C6TS From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 20626; CHD7; Simple; p.Leu980Pro (c.2939T>C); Zygosity=Heterozygous (PubMed=36502621) Population: Chinese; Derived from sampling site: Peripheral blood. Male 288084313 CVCL_C6U4 SDUCTi005-A induced pluripotent stem cell human CVCL_C6U4 From: Department of Clinical Research, University of Southern Denmark; Odense; Denmark. CL:0000010 288084314 CVCL_C6TR FD-1-Cor induced pluripotent stem cell human CVCL_C6TR From: Korea Advanced Institute of Science and Technology; Daejeon; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple_corrected; p.Leu268fs*1 (c.803_806del); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=31981984; PubMed=36516658) Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084315 CVCL_C6U3 SDUCTi003-A induced pluripotent stem cell human CVCL_C6U3 From: Department of Clinical Research, University of Southern Denmark; Odense; Denmark. CL:0000010 288084316 CVCL_C6U6 WAe009-A-93 embryonic stem cell human CVCL_C6U6 From: National Center for Cardiovascular Diseases and Fuwai Hospital; Beijing; China CL:0000010 Transfected with: HGNC; 11040; SLC5A5; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Tranduced with a SLC5A5/NIS-P2A-eGFP-EF1a-Luc-T2A-PuroR construct (PubMed=36403548) 288084317 CVCL_C6TU WAe009-A-99 embryonic stem cell human CVCL_C6TU From: Korea Institute of Toxicology; Daejeon; South Korea CL:0000010 Transfected with: HGNC; 3373; EP300 (with p.Met1_Lys1047del and p.Arg1665_His2414del = catalytic domain); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female Characteristics: Transduced with a dCas9-p300-P2A-PuroR construct where the dCas9 is fused to the catalytic HAT core domain of p300 (PubMed=36493708) 288084318 CVCL_C6TT IPCASi001-A induced pluripotent stem cell human CVCL_C6TT From: Institute of Psychology, Chinese Academy of Sciences; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 288084319 CVCL_C6U5 SDUCTi006-A induced pluripotent stem cell human CVCL_C6U5 From: Department of Clinical Research, University of Southern Denmark; Odense; Denmark. CL:0000010 288084320 CVCL_C6TG WAe001-A-95 embryonic stem cell human CVCL_C6TG From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16950; STAMBP. Male 288084321 CVCL_C6TF USPi003-A induced pluripotent stem cell human CVCL_C6TF From: Laboratory of Human Genetics, Institute of Biosciences; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 25230; AHDC1; Simple; p.Lys494Serfs*22 (c.1481_1482delTT); ClinVar=VCV001320043; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 288084322 CVCL_C6TI ABi001-A induced pluripotent stem cell human CVCL_C6TI From: Moscow Institute of Physics and Technology, National Research University; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 19698; KCNV2; Simple; p.Ala259Thr (c.775G>A); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084323 CVCL_C6TH ATCi003-A induced pluripotent stem cell human CVCL_C6TH From: Aegicare (Shenzhen) Technology Co; Shenzhen; China. CL:0000010 288084324 CVCL_C6TK CIBi014-A induced pluripotent stem cell human CVCL_C6TK From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Leu1712Phe (c.5136A>T); Zygosity=Heterozygous (PubMed=36528012) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 288084325 CVCL_C6TJ ABi002-A induced pluripotent stem cell human CVCL_C6TJ From: Moscow Institute of Physics and Technology, National Research University; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 19698; KCNV2; Simple; c.754A>T; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 19698; KCNV2; Simple; p.Ala259Thr (c.775G>A); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084326 CVCL_C6TM CIBi012-A induced pluripotent stem cell human CVCL_C6TM From: Cell Inspire Biotechnology; Shenzhen; China. CL:0000010 288084327 CVCL_C6TL CIBi013-A induced pluripotent stem cell human CVCL_C6TL From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple; p.Leu122Val (c.334C>G); Zygosity=Homozygous (PubMed=36469984) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 288084328 CVCL_C6TA UKWNLi006-B induced pluripotent stem cell human CVCL_C6TA From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Asp170Asn (c.508G>A); Zygosity=Hemizygous (PubMed=36640471) Population: Caucasian; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 288084329 CVCL_C6TC UNIPVi001-A induced pluripotent stem cell human CVCL_C6TC From: Units of Biology and Genetics, University of Pavia; Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 21575; AHI1; Simple; p.Gln263Profs*8 (c.787dupC); Zygosity=Homozygous (PubMed=36521382) Population: Caucasian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 288084330 CVCL_C6TB UKWNLi007-B induced pluripotent stem cell human CVCL_C6TB From: Department of Neurology, University of Wurzburg; Wurzburg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Cys172Tyr (c.515G>A); ClinVar=VCV001323002; Zygosity=Hemizygous (PubMed=36640471) Population: Caucasian; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Male 288084331 CVCL_C6TE USPi002-A induced pluripotent stem cell human CVCL_C6TE From: Laboratory of Human Genetics, Institute of Biosciences; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 25230; AHDC1; Simple; p.Lys552Argfs*33 (c.1653del); Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 288084332 CVCL_C6TD USPi001-A induced pluripotent stem cell human CVCL_C6TD From: Laboratory of Human Genetics, Institute of Biosciences; Sao Paulo; Brazil CL:0000010 Sequence variation: Mutation; HGNC; 25230; AHDC1; Simple; p.Gln332Ter (c.994C>T); ClinVar=VCV000800800; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Male 288084333 CVCL_C6UX MG-63/DOXR8 cancer cell line human CVCL_C6UX CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Bone; left femur. Male 288084334 CVCL_C6V9 MPT64-A5B2 hybridoma house mouse CVCL_C6V9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P9WIN9; Mycobacterium tuberculosis MPT64 (mpt64). 288084335 CVCL_C6V8 B1C8 hybridoma house mouse CVCL_C6V8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P9WNK7; Mycobacterium tuberculosis ESAT-6 (esxA). 288084336 CVCL_C6UW MG-63/CISR8 cancer cell line human CVCL_C6UW CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Bone; left femur. Male 288084337 CVCL_C6UZ MG-63/TRIR8 cancer cell line human CVCL_C6UZ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from metastatic site: Bone; left femur. Male 288084338 CVCL_C6UY MG-63/MTXR8 cancer cell line human CVCL_C6UY CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from metastatic site: Bone; left femur. Male 288084339 CVCL_C6V1 HOS-143B/DOXR8 cancer cell line human CVCL_C6V1 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Bone; right femur. Female 288084340 CVCL_C6UP SBG6 finite cell line human CVCL_C6UP CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084341 CVCL_C6V0 HOS-143B/CISR8 cancer cell line human CVCL_C6V0 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from sampling site: Bone; right femur. Female 288084342 CVCL_C6V3 HOS-143B/TRIR8 cancer cell line human CVCL_C6V3 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Bone; right femur. Female 288084343 CVCL_C6UR SBG8 finite cell line human CVCL_C6UR CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10676_14868del; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084344 CVCL_C6V2 HOS-143B/MTXR8 cancer cell line human CVCL_C6V2 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Bone; right femur. Female 288084345 CVCL_C6UQ SBG7 finite cell line human CVCL_C6UQ CL:0000010 Sequence variation: Mutation; HGNC; 7479; MT-TE; Simple; m.14739G>A; ClinVar=VCV000690211; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084346 CVCL_C6V5 IT 15 hybridoma house mouse CVCL_C6V5 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P9WGU1; Mycobacterium tuberculosis pstS1. 288084347 CVCL_C6UT SBG10 finite cell line human CVCL_C6UT CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.10167_15568del; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084348 CVCL_C6V4 NRC-13810 hybridoma house mouse CVCL_C6V4 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P9WGE7; Mycobacterium tuberculosis sodB. 288084349 CVCL_C6US SBG9 finite cell line human CVCL_C6US CL:0000010 Sequence variation: Mutation; HGNC; Group_1972; MT-@; Unexplicit; m.7342_9916del; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084350 CVCL_C6UV IOR-C5 hybridoma house mouse CVCL_C6UV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human colorectal glycoprotein IOR-C2. Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 97061101 288084351 CVCL_C6V7 NRC-49680 hybridoma house mouse CVCL_C6V7 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P9WIE5; Mycobacterium tuberculosis katG. 288084352 CVCL_C6UU IOR-C2 hybridoma house mouse CVCL_C6UU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human colorectal glycoprotein IOR-C2. 288084353 CVCL_C6V6 IT 3 hybridoma house mouse CVCL_C6V6 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P9WPE5; Mycobacterium tuberculosis groES. 288084354 CVCL_C6UH SBG2-iPSC induced pluripotent stem cell human CVCL_C6UH CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Heteroplasmic (PubMed=34662843) Derived from sampling site: Cell type=Fibroblast. 288084355 CVCL_C6UG SBG2 finite cell line human CVCL_C6UG CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084356 CVCL_C6UJ SBG3-iPSC induced pluripotent stem cell human CVCL_C6UJ CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Heteroplasmic (PubMed=34662843) Derived from sampling site: Cell type=Fibroblast. 288084357 CVCL_C6UI SBG3 finite cell line human CVCL_C6UI CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu220Pro (m.9185T>C); ClinVar=VCV000009647; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084358 CVCL_C6UL SBG4-iPSC induced pluripotent stem cell human CVCL_C6UL CL:0000010 Sequence variation: Mutation; HGNC; 7458; MT-ND3; Simple; m.10158T>C; ClinVar=VCV000009714; Zygosity=Heteroplasmic (PubMed=34662843) Derived from sampling site: Cell type=Fibroblast. 288084359 CVCL_C6UK SBG4 finite cell line human CVCL_C6UK CL:0000010 Sequence variation: Mutation; HGNC; 7458; MT-ND3; Simple; m.10158T>C; ClinVar=VCV000009714; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084360 CVCL_C6UN SBG5-iPSC induced pluripotent stem cell human CVCL_C6UN CL:0000010 Sequence variation: Mutation; HGNC; 7461; MT-ND5; Simple; p.Phe124Leu (m.12706T>C); ClinVar=VCV000009698; Zygosity=Heteroplasmic (PubMed=34662843) Derived from sampling site: Cell type=Fibroblast. 288084361 CVCL_C6UM SBG5 finite cell line human CVCL_C6UM CL:0000010 Sequence variation: Mutation; HGNC; 7461; MT-ND5; Simple; p.Phe124Leu (m.12706T>C); ClinVar=VCV000009698; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084362 CVCL_C6UB SCVI-34 induced pluripotent stem cell human CVCL_C6UB From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. 288084363 CVCL_C6UA SCVI-202 induced pluripotent stem cell human CVCL_C6UA From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Derived from sampling site: Peripheral blood. Female 288084364 CVCL_C6UD LUMCi004-A-2 induced pluripotent stem cell human CVCL_C6UD From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Phe64Leu, p.Tyr66His, p.Ser72Ala, p.Asn105Thr, p.Ile128Val, p.Tyr145Phe, p.Val150Ile, p.Asp155Val, p.Ile171Val, p.Asn198Ser, p.Ala206Val, p.Val224Arg, p.His231Leu = EBFP2); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Contains a platform to precisely integrate DNA payloads into the cell genome Using TALEN a STRAIGHT-IN v2 construct (loxP-EBFP2-attP(bxb1)-BleoR-lox257) was introduced in one of the alleles of CLYBL (PubMed=36495703). 288084365 CVCL_C6UC LUMCi004-A-1 induced pluripotent stem cell human CVCL_C6UC From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser30Arg, p.Tyr39Asn, p.Phe64Leu, p.Tyr66His, p.Ser72Ala, p.Asn105Thr, p.Ile128Val, p.Tyr145Phe, p.Val150Ile, p.Asp155Val, p.Ile171Val, p.Asn198Ser, p.Ala206Val, p.Val224Arg, p.His231Leu = EBFP2); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Contains a platform to precisely integrate DNA payloads into the cell genome Using CRISPR/Cas9 a STRAIGHT-IN v2 construct (loxP-EBFP2-attP(bxb1)-BleoR-lox257) was introduced in one of the alleles of the AAVS1 safe harbor locus (PubMed=36495703). 288084366 CVCL_C6UF SBG1-iPSC induced pluripotent stem cell human CVCL_C6UF CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Heteroplasmic (PubMed=34662843) Derived from sampling site: Cell type=Fibroblast. 288084367 CVCL_C6UE SBG1 finite cell line human CVCL_C6UE CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Heteroplasmic (PubMed=34200828) Derived from sampling site: Cell type=Fibroblast. 288084368 CVCL_C6RU NUIGi059-B induced pluripotent stem cell human CVCL_C6RU From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 288084369 CVCL_C6S6 NUIGi063-B induced pluripotent stem cell human CVCL_C6S6 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084370 CVCL_C6RT NUIGi059-A induced pluripotent stem cell human CVCL_C6RT From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 288084371 CVCL_C6S5 NUIGi063-A induced pluripotent stem cell human CVCL_C6S5 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084372 CVCL_C6RW NUIGi060-A induced pluripotent stem cell human CVCL_C6RW From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Male 288084373 CVCL_C6S8 NUIGi064-A induced pluripotent stem cell human CVCL_C6S8 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084374 CVCL_C6RV NUIGi059-C induced pluripotent stem cell human CVCL_C6RV From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 288084375 CVCL_C6S7 NUIGi063-C induced pluripotent stem cell human CVCL_C6S7 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084376 CVCL_C6RY NUIGi060-C induced pluripotent stem cell human CVCL_C6RY From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Male 288084377 CVCL_C6RX NUIGi060-B induced pluripotent stem cell human CVCL_C6RX From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Male 288084378 CVCL_C6S9 NUIGi064-B induced pluripotent stem cell human CVCL_C6S9 From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084379 CVCL_C6RZ NUIGi061-A induced pluripotent stem cell human CVCL_C6RZ From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084380 CVCL_C6RM NUIGi057-A induced pluripotent stem cell human CVCL_C6RM From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084381 CVCL_C6RL NJUCMi001-A induced pluripotent stem cell human CVCL_C6RL From: Nanjing University of Chinese Medicine; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 6482; LAMA2; Simple; p.Lys1124Asnfs (c.3372delA) (c.3367delA); dbSNP=rs1361925574; Zygosity=Heterozygous (PubMed=36334577) Population: Chinese; Derived from sampling site: Peripheral blood. Male 288084382 CVCL_C6S0 NUIGi061-B induced pluripotent stem cell human CVCL_C6S0 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084383 CVCL_C6RN NUIGi057-B induced pluripotent stem cell human CVCL_C6RN From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084384 CVCL_C6RQ NUIGi058-A induced pluripotent stem cell human CVCL_C6RQ From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084385 CVCL_C6S2 NUIGi062-A induced pluripotent stem cell human CVCL_C6S2 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084386 CVCL_C6RP NUIGi057-C induced pluripotent stem cell human CVCL_C6RP From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084387 CVCL_C6S1 NUIGi061-C induced pluripotent stem cell human CVCL_C6S1 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084388 CVCL_C6RS NUIGi058-C induced pluripotent stem cell human CVCL_C6RS From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084389 CVCL_C6S4 NUIGi062-C induced pluripotent stem cell human CVCL_C6S4 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084390 CVCL_C6RR NUIGi058-B induced pluripotent stem cell human CVCL_C6RR From: National University of Ireland Galway; Galway; Ireland. CL:0000010 Female 288084391 CVCL_C6S3 NUIGi062-B induced pluripotent stem cell human CVCL_C6S3 From: National University of Ireland Galway; Galway; Ireland. CL:0000010 288084392 CVCL_C6RE LBi017-B induced pluripotent stem cell human CVCL_C6RE From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084393 CVCL_C6RD LBi017-A induced pluripotent stem cell human CVCL_C6RD From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084394 CVCL_C6RG LBi018-B induced pluripotent stem cell human CVCL_C6RG From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084395 CVCL_C6RF LBi018-A induced pluripotent stem cell human CVCL_C6RF From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084396 CVCL_C6RI LBi019-B induced pluripotent stem cell human CVCL_C6RI From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084397 CVCL_C6RH LBi019-A induced pluripotent stem cell human CVCL_C6RH From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084398 CVCL_C6RK NCHi009-A induced pluripotent stem cell human CVCL_C6RK From: Nationwide Children's Hospital; Columbus; USA CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Gly661Ser (c.1981G>A); ClinVar=VCV000264541; Zygosity=Heterozygous (PubMed=36599283) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084399 CVCL_C6RJ LBi020-A induced pluripotent stem cell human CVCL_C6RJ From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084400 CVCL_C6RA LBi015-B induced pluripotent stem cell human CVCL_C6RA From: Life & Brain GmbH; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084401 CVCL_C6RC LBi016-B induced pluripotent stem cell human CVCL_C6RC From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084402 CVCL_C6RB LBi016-A induced pluripotent stem cell human CVCL_C6RB From: Life & Brain GmbH; Bonn; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17761; TREM2; Simple; p.Arg47His (c.140G>A); ClinVar=VCV000195350; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084403 CVCL_C6SV STJUDEi005-A induced pluripotent stem cell human CVCL_C6SV From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 10402; RPS19; Simple; p.Arg62Trp (c.184C>T); ClinVar=VCV000006314; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Peripheral blood. Female 288084404 CVCL_C6T7 UKAi010-A induced pluripotent stem cell human CVCL_C6T7 From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 288084405 CVCL_C6SU STJUDEi004-A-1 induced pluripotent stem cell human CVCL_C6SU From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 10402; RPS19; Simple_corrected; p.Leu64Pro (c.191T>C); ClinVar=VCV001782649; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084406 CVCL_C6T6 UKAi009-A induced pluripotent stem cell human CVCL_C6T6 From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 288084407 CVCL_C6SX SZGJMSi001-A induced pluripotent stem cell human CVCL_C6SX From: Research Center of Biological Psychiatry, Suzhou Guangji Hospital; Suzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 288084408 CVCL_C6T9 UKAi012-A induced pluripotent stem cell human CVCL_C6T9 From: Universitatsklinikum Aachen; Aachen; Germany. CL:0000010 288084409 CVCL_C6SW STJUDEi005-A-1 induced pluripotent stem cell human CVCL_C6SW From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 10402; RPS19; Simple_corrected; p.Arg62Trp (c.184C>T); ClinVar=VCV000006314; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Derived from sampling site: Peripheral blood. Female 288084410 CVCL_C6T8 UKAi011-A induced pluripotent stem cell human CVCL_C6T8 From: Universitatsklinikum Aachen; Aachen; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 288084411 CVCL_C6SZ SZGJMSi003-A induced pluripotent stem cell human CVCL_C6SZ From: Research Center of Biological Psychiatry, Suzhou Guangji Hospital; Suzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 288084412 CVCL_C6SY SZGJMSi002-A induced pluripotent stem cell human CVCL_C6SY From: Research Center of Biological Psychiatry, Suzhou Guangji Hospital; Suzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 288084413 CVCL_C6SN SDQLCHi048-A induced pluripotent stem cell human CVCL_C6SN From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 288084414 CVCL_C6SM SDPHi002-A induced pluripotent stem cell human CVCL_C6SM From: Shandong Provincial Hospital Affiliated to Shandong First Medical University; Jinan; China. CL:0000010 288084415 CVCL_C6SP SDQLCHi049-A induced pluripotent stem cell human CVCL_C6SP From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 288084416 CVCL_C6T1 UCLi021-A induced pluripotent stem cell human CVCL_C6T1 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2076; CLN5; Simple; p.Arg63His (c.188G>A) (p.Arg112His, c.335G>A); ClinVar=VCV000002567; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 2076; CLN5; Simple; p.Trp158Arg (c.472T>C) (p.Trp207Arg, c.619T>C); ClinVar=VCV001302670; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; British; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 288084417 CVCL_C6T0 TMPi008-B induced pluripotent stem cell human CVCL_C6T0 From: Translational Molecular Psychiatry, Clinic for Child and Adolescent Psychiatry and Psychotherapy, University of Zurich; Zurich; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 288084418 CVCL_C6SR BCRTi006-A induced pluripotent stem cell human CVCL_C6SR From: Berlin-Brandenburg Center for Regenerative Therapies; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female 288084419 CVCL_C6T3 WTC-mEGFP-DCP1A-cl5 induced pluripotent stem cell human CVCL_C6T3 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 DCP1A has been endogenously tagged in both alleles with mEGFP Part of: Allen Cell Collection 288084420 CVCL_C6SQ SMUSHi002-A induced pluripotent stem cell human CVCL_C6SQ From: Southern Medical University, Shenzhen Hospital; Shenzhen; China. CL:0000010 288084421 CVCL_C6T2 UCLi022-A induced pluripotent stem cell human CVCL_C6T2 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 2076; CLN5; Simple; p.Leu309Alafs*4 (c.925_926delTT) (p.Leu358Alafs*4, c.1072_1073delTT); ClinVar=VCV000056527; Zygosity=Homozygous (hPSCreg) Population: Pakistani; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084422 CVCL_C6ST STJUDEi004-A induced pluripotent stem cell human CVCL_C6ST From: St Jude Children's Research Hospital; Memphis; USA. CL:0000010 Sequence variation: Mutation; HGNC; 10402; RPS19; Simple; p.Leu64Pro (c.191T>C); ClinVar=VCV001782649; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084423 CVCL_C6T5 UGENTi001-A induced pluripotent stem cell human CVCL_C6T5 From: Ghent University; Ghent; Belgium. CL:0000010 Male 288084424 CVCL_C6SS CHOPi012-A induced pluripotent stem cell human CVCL_C6SS From: Children's Hospital of Philadelphia; Philadelphia; USA. CL:0000010 288084425 CVCL_C6T4 WTC-mEGFP-DCP1A-cl124 induced pluripotent stem cell human CVCL_C6T4 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 DCP1A has been endogenously tagged in one allele with mEGFP Part of: Allen Cell Collection 288084426 CVCL_C6SF SCTCi019-B induced pluripotent stem cell human CVCL_C6SF From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands. CL:0000010 Male 288084427 CVCL_C6SE SCTCi019-A induced pluripotent stem cell human CVCL_C6SE From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands. CL:0000010 Male 288084428 CVCL_C6SH SCVIi070-A induced pluripotent stem cell human CVCL_C6SH From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 288084429 CVCL_C6SG SCVIi069-A induced pluripotent stem cell human CVCL_C6SG From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 Male 288084430 CVCL_C6SJ SCVIi072-A induced pluripotent stem cell human CVCL_C6SJ From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 288084431 CVCL_C6SI SCVIi071-A induced pluripotent stem cell human CVCL_C6SI From: Stanford Cardiovascular Institute; Palo Alto; USA. CL:0000010 288084432 CVCL_C6SL SCVIi074-A induced pluripotent stem cell human CVCL_C6SL From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 939; BAG3; Simple; p.Ser185Leu (c.554C>T); ClinVar=VCV000180282; Zygosity=Heterozygous (PubMed=36642055) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084433 CVCL_C6SK SCVIi073-A induced pluripotent stem cell human CVCL_C6SK From: Stanford Cardiovascular Institute; Palo Alto; USA CL:0000010 Sequence variation: Mutation; HGNC; 939; BAG3; Simple; p.Tyr233Ter (c.699C>A); ClinVar=VCV000234982; Zygosity=Homozygous (PubMed=36642055); Sequence variation: Mutation; HGNC; 939; BAG3; Simple; p.Ala262Thr (c.784G>A); ClinVar=VCV000234983; Zygosity=Heterozygous (PubMed=36642055); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Leu3729Thrfs*9 (c.11183dupG) (p.Leu3557Thrfs*9, c.10670dupG); ClinVar=VCV000202507; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084434 CVCL_C6SB PUMCi004-A induced pluripotent stem cell human CVCL_C6SB From: Peking Union Medical College; Beijing; China. CL:0000010 288084435 CVCL_C6SA NUIGi064-C induced pluripotent stem cell human CVCL_C6SA From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 288084436 CVCL_C6SD RCPCMi009-A-1 induced pluripotent stem cell human CVCL_C6SD From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084437 CVCL_C6SC RCPCMi009-A induced pluripotent stem cell human CVCL_C6SC From: Federal Research and Clinical Center of Physical-Chemical Medicine; Moscow; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084438 CVCL_C7BD Abcam PC-3 PTGER4 KO cancer cell line human CVCL_C7BD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9596; PTGER4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084439 CVCL_C7BC Abcam PC-3 PSEN1 KO cancer cell line human CVCL_C7BC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9508; PSEN1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084440 CVCL_C7BF Abcam PC-3 PTK2 KO cancer cell line human CVCL_C7BF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9611; PTK2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084441 CVCL_C7BE Abcam PC-3 PTGES2 KO cancer cell line human CVCL_C7BE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17822; PTGES2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084442 CVCL_C7BH Abcam PC-3 PTPN12 KO cancer cell line human CVCL_C7BH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9645; PTPN12; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084443 CVCL_C7BG Abcam PC-3 PTP4A3 KO cancer cell line human CVCL_C7BG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9636; PTP4A3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084444 CVCL_C7BJ Abcam PC-3 RAC2 KO cancer cell line human CVCL_C7BJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9802; RAC2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084445 CVCL_C7BI Abcam PC-3 PUS1 KO cancer cell line human CVCL_C7BI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15508; PUS1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084446 CVCL_C7AZ Abcam PC-3 NQO1 KO cancer cell line human CVCL_C7AZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2874; NQO1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084447 CVCL_C7BB Abcam PC-3 PRMT7 KO cancer cell line human CVCL_C7BB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 25557; PRMT7; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084448 CVCL_C7BA Abcam PC-3 PLCG1 KO cancer cell line human CVCL_C7BA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9065; PLCG1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084449 CVCL_C7AS Abcam PC-3 MTA3 KO cancer cell line human CVCL_C7AS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 23784; MTA3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084450 CVCL_C7B4 Abcam PC-3 PIK3CA KO cancer cell line human CVCL_C7B4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8975; PIK3CA; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084451 CVCL_C7AR Abcam PC-3 MMP8 KO cancer cell line human CVCL_C7AR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7175; MMP8; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084452 CVCL_C7B3 Abcam PC-3 PHF8 KO cancer cell line human CVCL_C7B3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20672; PHF8; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084453 CVCL_C7AU Abcam PC-3 NCR3LG1 KO cancer cell line human CVCL_C7AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 42400; NCR3LG1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084454 CVCL_C7B6 Abcam PC-3 PIK3R4 KO cancer cell line human CVCL_C7B6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8982; PIK3R4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084455 CVCL_C7AT Abcam PC-3 NBR1 KO cancer cell line human CVCL_C7AT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6746; NBR1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084456 CVCL_C7B5 Abcam PC-3 PIK3CD KO cancer cell line human CVCL_C7B5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8977; PIK3CD; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084457 CVCL_C7AW Abcam PC-3 NLRC4 KO cancer cell line human CVCL_C7AW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16412; NLRC4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084458 CVCL_C7B8 Abcam PC-3 PLAU KO cancer cell line human CVCL_C7B8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9052; PLAU; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084459 CVCL_C7AV Abcam PC-3 NFKB1 KO cancer cell line human CVCL_C7AV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7794; NFKB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084460 CVCL_C7B7 Abcam PC-3 PLA2G4A KO cancer cell line human CVCL_C7B7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9035; PLA2G4A; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084461 CVCL_C7AY Abcam PC-3 NOTCH4 KO cancer cell line human CVCL_C7AY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7884; NOTCH4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084462 CVCL_C7AX Abcam PC-3 NOTCH3 KO cancer cell line human CVCL_C7AX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7883; NOTCH3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084463 CVCL_C7B9 Abcam PC-3 PLCB3 KO cancer cell line human CVCL_C7B9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9056; PLCB3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084464 CVCL_C7AK Abcam PC-3 MAP2K3 KO cancer cell line human CVCL_C7AK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6843; MAP2K3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084465 CVCL_C7AJ Abcam PC-3 MAGEA3 KO cancer cell line human CVCL_C7AJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6801; MAGEA3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084466 CVCL_C7AM Abcam PC-3 MAPK7 KO cancer cell line human CVCL_C7AM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6880; MAPK7; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084467 CVCL_C7AL Abcam PC-3 MAP3K3 KO cancer cell line human CVCL_C7AL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6855; MAP3K3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084468 CVCL_C7B0 Abcam PC-3 NR1H4 KO cancer cell line human CVCL_C7B0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7967; NR1H4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084469 CVCL_C7AN Abcam PC-3 MBD1 KO cancer cell line human CVCL_C7AN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6916; MBD1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084470 CVCL_C7AQ Abcam PC-3 MMP13 KO cancer cell line human CVCL_C7AQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7159; MMP13; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084471 CVCL_C7B2 Abcam PC-3 PDCD1LG2 KO cancer cell line human CVCL_C7B2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18731; PDCD1LG2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084472 CVCL_C7AP Abcam PC-3 MBD3 KO cancer cell line human CVCL_C7AP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6918; MBD3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084473 CVCL_C7B1 Abcam PC-3 NR3C2 KO cancer cell line human CVCL_C7B1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7979; NR3C2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084474 CVCL_C7CE Abcam PC-3 TIMP3 KO cancer cell line human CVCL_C7CE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11822; TIMP3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084475 CVCL_C7CD Abcam PC-3 THBS1 KO cancer cell line human CVCL_C7CD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11785; THBS1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084476 CVCL_C7CG Abcam PC-3 TNFRSF10B KO cancer cell line human CVCL_C7CG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11905; TNFRSF10B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084477 CVCL_C7CF Abcam PC-3 TLN1 KO cancer cell line human CVCL_C7CF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11845; TLN1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084478 CVCL_C7CI Abcam PC-3 TP73 KO cancer cell line human CVCL_C7CI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12003; TP73; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084479 CVCL_C7CH Abcam PC-3 TNFRSF1B KO cancer cell line human CVCL_C7CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11917; TNFRSF1B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084480 CVCL_C7CK Abcam PC-3 TRAF2 KO cancer cell line human CVCL_C7CK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11562; TANK; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084481 CVCL_C7CJ Abcam PC-3 TRADD KO cancer cell line human CVCL_C7CJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 12030; TRADD; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084482 CVCL_C7CA Abcam PC-3 TBP KO cancer cell line human CVCL_C7CA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11588; TBP; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084483 CVCL_C7CC Abcam PC-3 TFDP1 KO cancer cell line human CVCL_C7CC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11749; TFDP1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084484 CVCL_C7CB Abcam PC-3 TCF7L2 KO cancer cell line human CVCL_C7CB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11641; TCF7L2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084485 CVCL_C7BT Abcam PC-3 SLFN11 KO cancer cell line human CVCL_C7BT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 26633; SLFN11; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084486 CVCL_C7C5 Abcam PC-3 STK4 KO cancer cell line human CVCL_C7C5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11408; STK4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084487 CVCL_C7BS Abcam PC-3 SETD2 KO cancer cell line human CVCL_C7BS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18420; SETD2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084488 CVCL_C7C4 Abcam PC-3 STAT5A KO cancer cell line human CVCL_C7C4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11366; STAT5A; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084489 CVCL_C7BV Abcam PC-3 SMARCC2 KO cancer cell line human CVCL_C7BV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11105; SMARCC2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084490 CVCL_C7C7 Abcam PC-3 SUZ12 KO cancer cell line human CVCL_C7C7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17101; SUZ12; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084491 CVCL_C7BU Abcam PC-3 SMARCAL1 KO cancer cell line human CVCL_C7BU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11102; SMARCAL1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084492 CVCL_C7C6 Abcam PC-3 SUV39H1 KO cancer cell line human CVCL_C7C6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11479; SUV39H1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084493 CVCL_C7BX Abcam PC-3 SMURF1 KO cancer cell line human CVCL_C7BX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16807; SMURF1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084494 CVCL_C7C9 Abcam PC-3 TBK1 KO cancer cell line human CVCL_C7C9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11584; TBK1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084495 CVCL_C7BW Abcam PC-3 SMARCE1 KO cancer cell line human CVCL_C7BW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11109; SMARCE1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084496 CVCL_C7C8 Abcam PC-3 TAPBP KO cancer cell line human CVCL_C7C8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11566; TAPBP; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084497 CVCL_C7BZ Abcam PC-3 SMYD3 KO cancer cell line human CVCL_C7BZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 15513; SMYD3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084498 CVCL_C7BY Abcam PC-3 SMYD2 KO cancer cell line human CVCL_C7BY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 20982; SMYD2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084499 CVCL_C7BL Abcam PC-3 ROCK2 KO cancer cell line human CVCL_C7BL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10252; ROCK2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084500 CVCL_C7BK Abcam PC-3 RING1 KO cancer cell line human CVCL_C7BK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10018; RING1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084501 CVCL_C7BN Abcam PC-3 RUNX2 KO cancer cell line human CVCL_C7BN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10472; RUNX2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084502 CVCL_C7BM Abcam PC-3 ROR2 KO cancer cell line human CVCL_C7BM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10257; ROR2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084503 CVCL_C7BP Abcam PC-3 RYBP KO cancer cell line human CVCL_C7BP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10480; RYBP; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084504 CVCL_C7C1 Abcam PC-3 SRF KO cancer cell line human CVCL_C7C1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11291; SRF; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084505 CVCL_C7C0 Abcam PC-3 SOCS3 KO cancer cell line human CVCL_C7C0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19391; SOCS3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084506 CVCL_C7BR Abcam PC-3 SDC4 KO cancer cell line human CVCL_C7BR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10661; SDC4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084507 CVCL_C7C3 Abcam PC-3 STAT4 KO cancer cell line human CVCL_C7C3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11365; STAT4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084508 CVCL_C7BQ Abcam PC-3 SCARB1 KO cancer cell line human CVCL_C7BQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1664; SCARB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084509 CVCL_C7C2 Abcam PC-3 SRPK1 KO cancer cell line human CVCL_C7C2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11305; SRPK1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084510 CVCL_C7AC Abcam PC-3 KDM6B KO cancer cell line human CVCL_C7AC CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 29012; KDM6B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084511 CVCL_C7AB Abcam PC-3 KDM1B KO cancer cell line human CVCL_C7AB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 21577; KDM1B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084512 CVCL_C7AE Abcam PC-3 LAIR1 KO cancer cell line human CVCL_C7AE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6477; LAIR1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084513 CVCL_C7AD Abcam PC-3 KPNA2 KO cancer cell line human CVCL_C7AD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6395; KPNA2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084514 CVCL_C7AG Abcam PC-3 LDHA KO cancer cell line human CVCL_C7AG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6535; LDHA; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084515 CVCL_C7AF Abcam PC-3 LAMP2 KO cancer cell line human CVCL_C7AF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6501; LAMP2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084516 CVCL_C7AI Abcam PC-3 LMNB1 KO cancer cell line human CVCL_C7AI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6637; LMNB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084517 CVCL_C7AH Abcam PC-3 LGR6 KO cancer cell line human CVCL_C7AH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19719; LGR6; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084518 CVCL_C7AA Abcam PC-3 KAT7 KO cancer cell line human CVCL_C7AA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17016; KAT7; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084519 CVCL_C7A3 Abcam PC-3 HNF1B KO cancer cell line human CVCL_C7A3 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11630; HNF1B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084520 CVCL_C7A2 Abcam PC-3 GZMA KO cancer cell line human CVCL_C7A2 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4708; GZMA; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084521 CVCL_C7A5 Abcam PC-3 ID2 KO cancer cell line human CVCL_C7A5 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5361; ID2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084522 CVCL_C7A4 Abcam PC-3 HSPG2 KO cancer cell line human CVCL_C7A4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5273; HSPG2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084523 CVCL_C7A7 Abcam PC-3 ITPR3 KO cancer cell line human CVCL_C7A7 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6182; ITPR3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084524 CVCL_C7A6 Abcam PC-3 IL17RB KO cancer cell line human CVCL_C7A6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18015; IL17RB; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084525 CVCL_C7A9 Abcam PC-3 JMJD6 KO cancer cell line human CVCL_C7A9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19355; JMJD6; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084526 CVCL_C7A8 Abcam PC-3 JAG1 KO cancer cell line human CVCL_C7A8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6188; JAG1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084527 CVCL_C7A1 Abcam PC-3 GPR132 KO cancer cell line human CVCL_C7A1 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17482; GPR132; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084528 CVCL_C7A0 Abcam PC-3 GLB1 KO cancer cell line human CVCL_C7A0 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4298; GLB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084529 CVCL_C6ZU Abcam PC-3 FOXO1 KO cancer cell line human CVCL_C6ZU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3819; FOXO1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084530 CVCL_C6ZT Abcam PC-3 FKBP5 KO cancer cell line human CVCL_C6ZT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3721; FKBP5; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084531 CVCL_C6ZW Abcam PC-3 FST KO cancer cell line human CVCL_C6ZW CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3971; FST; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084532 CVCL_C6ZV Abcam PC-3 FOXO3 KO cancer cell line human CVCL_C6ZV CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3821; FOXO3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084533 CVCL_C6ZY Abcam PC-3 FZD7 KO cancer cell line human CVCL_C6ZY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4045; FZD7; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084534 CVCL_C6ZX Abcam PC-3 FTL KO cancer cell line human CVCL_C6ZX CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3999; FTL; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084535 CVCL_C6ZZ Abcam PC-3 GAB1 KO cancer cell line human CVCL_C6ZZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4066; GAB1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084536 CVCL_C6ZM Abcam PC-3 EPHB4 KO cancer cell line human CVCL_C6ZM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3395; EPHB4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084537 CVCL_C6ZL Abcam PC-3 ENG KO cancer cell line human CVCL_C6ZL CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3349; ENG; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084538 CVCL_C6ZN Abcam PC-3 ERAP1 KO cancer cell line human CVCL_C6ZN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18173; ERAP1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084539 CVCL_C6ZQ Abcam PC-3 EXO1 KO cancer cell line human CVCL_C6ZQ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3511; EXO1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084540 CVCL_C6ZP Abcam PC-3 ETS2 KO cancer cell line human CVCL_C6ZP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3489; ETS2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084541 CVCL_C6ZS Abcam PC-3 FGF23 KO cancer cell line human CVCL_C6ZS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3680; FGF23; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084542 CVCL_C6ZR Abcam PC-3 FABP4 KO cancer cell line human CVCL_C6ZR CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3559; FABP4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084543 CVCL_C6ZE Abcam PC-3 CXXC1 KO cancer cell line human CVCL_C6ZE CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24343; CXXC1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084544 CVCL_C6ZD Abcam PC-3 CUL4B KO cancer cell line human CVCL_C6ZD CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2555; CUL4B; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084545 CVCL_C6ZG Abcam PC-3 DLL1 KO cancer cell line human CVCL_C6ZG CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2908; DLL1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084546 CVCL_C6ZF Abcam PC-3 DCP2 KO cancer cell line human CVCL_C6ZF CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 24452; DCP2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084547 CVCL_C6ZI Abcam PC-3 EGLN1 KO cancer cell line human CVCL_C6ZI CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1232; EGLN1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084548 CVCL_C6ZH Abcam PC-3 DVL3 KO cancer cell line human CVCL_C6ZH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3087; DVL3; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084549 CVCL_C6ZK Abcam PC-3 EIF2AK4 KO cancer cell line human CVCL_C6ZK CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19687; EIF2AK4; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084550 CVCL_C6ZJ Abcam PC-3 EHMT2 KO cancer cell line human CVCL_C6ZJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14129; EHMT2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from metastatic site: Bone. Male 288084551 CVCL_C7TV PNUSCRi003-A induced pluripotent stem cell human CVCL_C7TV From: Convergence Stem Cell Research Center, Pusan National University; Yangsan; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg87Cys (c.259C>T); ClinVar=VCV000004321; Zygosity=Unspecified (hPSCreg); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Arg296Gln (c.887G>A) (R247Q); ClinVar=VCV000004328; Zygosity=Unspecified (hPSCreg) Population: Korean; Derived from sampling site: Peripheral blood. Male 288084552 CVCL_C7TU EndoC-betaH5 conditionally immortalized cell line human CVCL_C7TU CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Characteristics: Displays robust GLP-1 and GIP receptor activity associated with insulin content and glucose stimulated insulin secretion levels, close to those of native human beta cells (Human_Cell_Design) 288084553 CVCL_C7TX HPSI0214i-kucg_3 induced pluripotent stem cell human CVCL_C7TX From: Cambridge BioResource; Cambridge; United Kingdom; From: Wellcome Trust Sanger Institute; Hinxton; United Kingdom CL:0000010 Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Genome sequenced Male 288084554 CVCL_C7TW PNUSCRi004-A induced pluripotent stem cell human CVCL_C7TW From: Convergence Stem Cell Research Center, Pusan National University; Yangsan; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Heterozygous (PubMed=36805467); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Ala495Pro (c.1483G>C) (A456P); ClinVar=VCV000093450; Zygosity=Heterozygous (PubMed=36805467); Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Val499Val (c.1497G>C) (V460V); ClinVar=VCV000093451; Zygosity=Heterozygous (PubMed=36805467) Population: Korean; Derived from sampling site: Peripheral blood. Female 288084555 CVCL_C7TZ HeLa HIV-1 LTR-FFL cancer cell line human CVCL_C7TZ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with a firefly luciferase reporter gene under the control of the HIV-1 LTR promoter (PubMed=20562857) 288084556 CVCL_C7TY KOLF2.1J PPM1H KO induced pluripotent stem cell human CVCL_C7TY CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18583; PPM1H; Sequence variation: Mutation; HGNC; 18037; ARID2; Simple_corrected; p.Pro197Hisfs*12 (c.590_608delCTAAAATCATCACTTTACT); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (from parent cell line); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; c.3526-1G>A; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 2201; COL3A1; Simple; p.Gly1176Ser (c.3526G>A); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 288084557 CVCL_C7TN CS-9 cancer cell line human CVCL_C7TN CL:0000010 Unspecified 288084558 CVCL_C7TM CS-8 cancer cell line human CVCL_C7TM CL:0000010 Derived from sampling site: Pelvis; cartilage Cell type=Chondrocyte.. Omics: Transcriptome analysis by serial analysis of gene expression (SAGE) Male 288084559 CVCL_C7TP Ma-Mel-86c cancer cell line human CVCL_C7TP HLA typing: A*01:01; B*08:01; C*07:01 (PubMed=27261508) CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; PTEN p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508) Derived from metastatic site: Lymph node. Omics: SNP array analysis Female 288084560 CVCL_C7TR IBMS-iPSC-073-01 induced pluripotent stem cell human CVCL_C7TR From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Ala684Val (c.2051C>T); ClinVar=VCV000030556; Zygosity=Heterozygous (PubMed=36933359) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 288084561 CVCL_C7TQ Ma-Mel-86f cancer cell line human CVCL_C7TQ CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Homozygous (PubMed=27261508); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 1773; CDK4; Simple; p.Arg24His (c.71G>A); ClinVar=VCV000016929; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 6840; MAP2K1; Simple; p.Pro193Ser (c.577C>T); dbSNP=rs1595884713; Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; PTEN p.Asn212fs (c.633_645delAGATCCTCAGTTT); Zygosity=Unspecified (PubMed=27261508); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.741_742delinsTT) (c.741_742CC>TT); ClinVar=VCV000437017; Zygosity=Unspecified (PubMed=27261508) Derived from metastatic site: Lymph node. Omics: SNP array analysis Female Characteristics: Has lost HLA class I surface expression due to the deletion of B2M (PubMed=27261508) 288084562 CVCL_C7TT GM-F finite cell line CVCL_C7TT CL:0000010 Derived from sampling site: Skin Cell type=Fiobroblast.; Breed/subspecies: Angora. Female 288084563 CVCL_C7TS GM-1 cancer cell line CVCL_C7TS CL:0000010 Derived from metastatic site: Parotid lymph node; Breed/subspecies: Angora. Female Characteristics: Amelanotic Tumorigenic in nude mice (PubMed=2101929). Doubling time: ~46 hours (PubMed=2101929) 288084564 CVCL_C7TF CS-13 cancer cell line human CVCL_C7TF CL:0000010 Unspecified 288084565 CVCL_C7TE CS-12 cancer cell line human CVCL_C7TE CL:0000010 Derived from sampling site: Pelvis; cartilage Cell type=Chondrocyte.. Male 288084566 CVCL_C7TH CS-3 cancer cell line human CVCL_C7TH CL:0000010 Unspecified 288084567 CVCL_C7TG CS-2 cancer cell line human CVCL_C7TG CL:0000010 Unspecified 288084568 CVCL_C7TJ CS-5 cancer cell line human CVCL_C7TJ CL:0000010 Unspecified 288084569 CVCL_C7TI CS-4 cancer cell line human CVCL_C7TI CL:0000010 Omics: Transcriptome analysis by serial analysis of gene expression (SAGE). Male 288084570 CVCL_C7TL CS-7 cancer cell line human CVCL_C7TL CL:0000010 Unspecified 288084571 CVCL_C7TK CS-6 cancer cell line human CVCL_C7TK CL:0000010 Unspecified 288084572 CVCL_C7TB EN-2 cancer cell line human CVCL_C7TB CL:0000010 Unspecified 288084573 CVCL_C7TA EN-1 cancer cell line human CVCL_C7TA CL:0000010 Unspecified 288084574 CVCL_C7TD CS-11 cancer cell line human CVCL_C7TD CL:0000010 Unspecified 288084575 CVCL_C7TC CS-10 cancer cell line human CVCL_C7TC CL:0000010 Unspecified 288084576 CVCL_C3RX ICGi043-B induced pluripotent stem cell human CVCL_C3RX From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084577 CVCL_C3RW ICGi043-A induced pluripotent stem cell human CVCL_C3RW From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 288084578 CVCL_C3RY ICGi043-C induced pluripotent stem cell human CVCL_C3RY From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35668866 CVCL_YR48 GeneBLAzer D1-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_YR48 CL:0000010 Transfected with: HGNC; 3020; DRD1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35668867 CVCL_YR49 GeneBLAzer D5-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_YR49 CL:0000010 Transfected with: HGNC; 3026; DRD5; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35668868 CVCL_YY45 FHS014i-sh1296E induced pluripotent stem cell human CVCL_YY45 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668869 CVCL_YY46 FHS015i-sh13352A induced pluripotent stem cell human CVCL_YY46 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668870 CVCL_YY47 FHS016i-sh13352E induced pluripotent stem cell human CVCL_YY47 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668871 CVCL_YY48 FHS017i-sh14157A induced pluripotent stem cell human CVCL_YY48 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668872 CVCL_YY41 FHS010i-sh12888B induced pluripotent stem cell human CVCL_YY41 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668873 CVCL_YY42 FHS011i-sh1293A induced pluripotent stem cell human CVCL_YY42 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668874 CVCL_YY43 FHS012i-sh1293B induced pluripotent stem cell human CVCL_YY43 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668875 CVCL_YY44 FHS013i-sh1296C induced pluripotent stem cell human CVCL_YY44 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668876 CVCL_YY49 FHS018i-sh14157C induced pluripotent stem cell human CVCL_YY49 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668877 CVCL_YY50 FHS019i-sh1441F induced pluripotent stem cell human CVCL_YY50 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668878 CVCL_YY51 FHS020i-sh1441G induced pluripotent stem cell human CVCL_YY51 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668879 CVCL_YY34 FHS003i-sh12022B induced pluripotent stem cell human CVCL_YY34 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668880 CVCL_YY35 FHS004i-sh12022C induced pluripotent stem cell human CVCL_YY35 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668881 CVCL_YY36 FHS005i-sh1236B induced pluripotent stem cell human CVCL_YY36 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668882 CVCL_YY37 FHS006i-sh1236C induced pluripotent stem cell human CVCL_YY37 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668883 CVCL_YY30 BJAB-L-YFP cancer cell line human CVCL_YY30 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; Q9QR71; Human herpesvirus 8 type P LANA1; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Transduced with a pLVx-AcYFP-C1-LANA-FLAG construct; Virology: EBV-negative 35668884 CVCL_YY31 BJAB-YFP cancer cell line human CVCL_YY31 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Arg (c.578A>G); ClinVar=VCV000184979; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: African; Kenyan; Derived from sampling site: Groin. Female Characteristics: Transduced with a pLVx-AcYFP-C1-FLAG construct; Virology: EBV-negative 35668885 CVCL_YY32 FHS001i-sh10950A induced pluripotent stem cell human CVCL_YY32 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668886 CVCL_YY33 FHS002i-sh10950C induced pluripotent stem cell human CVCL_YY33 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668887 CVCL_YY38 FHS007i-sh12569A induced pluripotent stem cell human CVCL_YY38 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668888 CVCL_YY39 FHS008i-sh12569B induced pluripotent stem cell human CVCL_YY39 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668889 CVCL_YY40 FHS009i-sh12888A induced pluripotent stem cell human CVCL_YY40 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668890 CVCL_YY23 CREM058i-BR43-1 induced pluripotent stem cell human CVCL_YY23 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668891 CVCL_YY24 CREM059i-BR45-1 induced pluripotent stem cell human CVCL_YY24 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668892 CVCL_YY25 CREM060i-BR51-1 induced pluripotent stem cell human CVCL_YY25 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668893 CVCL_YY26 CREM061i-BT1-1 induced pluripotent stem cell human CVCL_YY26 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+1G>T (IVS1,G>T,+1); ClinVar=VCV000015437; Zygosity=Unspecified; Note=Splice donor mutation (WiCell) Population: Southeast Asian; Cambodian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668894 CVCL_YY20 CREM055i-BR37-1 induced pluripotent stem cell human CVCL_YY20 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668895 CVCL_YY21 CREM056i-BR39-1 induced pluripotent stem cell human CVCL_YY21 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668896 CVCL_YY22 CREM057i-BR41-1 induced pluripotent stem cell human CVCL_YY22 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668897 CVCL_YY27 CREM062i-BT2 induced pluripotent stem cell human CVCL_YY27 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.92+6T>C (IVS1,T>C,+6) (IVS I-6 T>C); ClinVar=VCV000015450; Zygosity=Heterozygous (WiCell); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Gln40Ter (c.118C>T) (Q39*); ClinVar=VCV000015402; Zygosity=Heterozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668898 CVCL_YY28 HPDE-iKRASG12D transformed cell line human CVCL_YY28 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Asp); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from a cystadenocarcinoma in the tail of her pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Female Characteristics: Expression the KRAS gene is under the control of doxycycline 35668899 CVCL_YY29 HPDE-iKRASwt transformed cell line human CVCL_YY29 CL:0000010 Transfected with: HGNC; 6407; KRAS; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Donor information: Established from a patient suffering from a cystadenocarcinoma in the tail of her pancreas; Derived from sampling site: Pancreas Cell type=Ductal cell.. Female Characteristics: Expression the KRAS gene is under the control of doxycycline 35668900 CVCL_YY12 CREM005i-SS2-1GAG induced pluripotent stem cell human CVCL_YY12 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple_corrected; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=28111279) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668901 CVCL_YY13 CREM048i-BR3-1 induced pluripotent stem cell human CVCL_YY13 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668902 CVCL_YY14 CREM049i-BR21-1 induced pluripotent stem cell human CVCL_YY14 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668903 CVCL_YY15 CREM050i-BR23-1 induced pluripotent stem cell human CVCL_YY15 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668904 CVCL_YY10 B2M-/Etrimer Elf1 embryonic stem cell human CVCL_YY10 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 914; B2M. Female Characteristics: Using a rAAV, the second B2M allele has been edited to express the signal sequence of HLA-G followed by a flexible (G4S)3 linker followed by B2M covalently linked at the C-terminus to a flexible (G4S)4 linker followed by HLA-E 35668905 CVCL_YY11 CREM011i-SS12-1 induced pluripotent stem cell human CVCL_YY11 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: African American; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668906 CVCL_YY16 CREM051i-BR25-1 induced pluripotent stem cell human CVCL_YY16 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668907 CVCL_YY17 CREM052i-BR29-1 induced pluripotent stem cell human CVCL_YY17 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668908 CVCL_YY18 CREM053i-BR31-1 induced pluripotent stem cell human CVCL_YY18 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668909 CVCL_YY19 CREM054i-BR33-1 induced pluripotent stem cell human CVCL_YY19 CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu7Val (c.20A>T) (E6V); ClinVar=VCV000015333; Zygosity=Homozygous (WiCell) Population: Brazilian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668910 CVCL_YY01 FNB6 finite cell line human CVCL_YY01 CL:0000010 Derived from sampling site: Oral cavity; buccal mucosa Cell type=Keratinocyte.. Unspecified Senescence: Senesces at 11-12 PDL (PubMed=12183435) 35668911 CVCL_YY02 CHOmt17-0 spontaneously immortalized cell line CVCL_YY02 CL:0000010 Transfected with: HGNC; 10860; ST6GAL1; Transfected with: MGI; MGI:1354951; Gne; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Can produce a considerably large amount of sialyled glycoproteins 35668912 CVCL_YY03 CHOmt17-100 spontaneously immortalized cell line CVCL_YY03 CL:0000010 Transfected with: HGNC; 10860; ST6GAL1; Transfected with: MGI; MGI:1354951; Gne; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Ovary. Female Characteristics: Can produce a considerably large amount of sialyled glycoproteins 35668913 CVCL_YY04 CHOmt17-200 spontaneously immortalized cell line CVCL_YY04 CL:0000010 Transfected with: HGNC; 10860; ST6GAL1; Transfected with: MGI; MGI:1354951; Gne; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Ovary. Female Characteristics: Can produce a considerably large amount of sialyled glycoproteins 35668914 CVCL_YY09 B2M-/Edimer Elf1 embryonic stem cell human CVCL_YY09 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 914; B2M. Female Characteristics: Using a rAAV, the second B2M allele has been edited to express B2M covalently linked at the C-terminus to a flexible (G4S)4 linker followed by HLA-E 35668915 CVCL_YY05 CHOmt17-300 spontaneously immortalized cell line CVCL_YY05 CL:0000010 Transfected with: HGNC; 10860; ST6GAL1; Transfected with: MGI; MGI:1354951; Gne; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Ovary. Female Characteristics: Can produce a considerably large amount of sialyled glycoproteins 35668916 CVCL_YY06 3T3 rho-0#8 transformed cell line house mouse CVCL_YY06 CL:0000010 Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Cell line devoid of mitochondrial DNA (rho0) Produced by transient transfection with plasmid pMA4008 encoding HSV-1 UL12.5M185 protein, which damages mtDNA by an unknown mechanism. 35668917 CVCL_YY07 B2M-/- Elf1 embryonic stem cell human CVCL_YY07 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus; HGNC; 914; B2M. Female 35668918 CVCL_YY08 B2M-/Edimer(preCre)Elf1 embryonic stem cell human CVCL_YY08 CL:0000010 Knockout cell: Method=Recombinant Adeno-Associated Virus (1 of 2 alleles); HGNC; 914; B2M; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Female Characteristics: Using a rAAV, the second B2M allele has been edited to express B2M covalently linked at the C-terminus to a flexible (G4S)4 linker followed by HLA-E A HyTK-Neo selection cassette has not been removed by Cre-recombinase. 35668919 CVCL_YZ66 Vero E6/NPC1-KO cl.19 spontaneously immortalized cell line green monkey CVCL_YZ66 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9RYM1; NPC1 Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 35668920 CVCL_YZ67 BKT1 transformed cell line CVCL_YZ67 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 35668921 CVCL_YZ68 DemKT1 transformed cell line CVCL_YZ68 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 35668922 CVCL_YZ69 FBKT1 transformed cell line CVCL_YZ69 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Virology: Susceptible to infection by many filoviruses except Marburg virus (MARV) This is due to specific sequence changes in NPC1 that acts as a receptor for filoviruses (PubMed=31940478). Group: Bat cell line 35668923 CVCL_YZ62 EEC16-TERT-L telomerase immortalized cell line human CVCL_YZ62 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Endometrium. Female Doubling time: 28.5 +- 9.8 days (PubMed=24972189) 35668924 CVCL_YZ63 EEC16-TERT-R telomerase immortalized cell line human CVCL_YZ63 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Endometrium. Female Doubling time: 30.7 +- 4.1 days (PubMed=24972189) 35668925 CVCL_YZ64 iPS87 induced pluripotent stem cell human CVCL_YZ64 CL:0000010 Derived from sampling site: Prostate. Male Characteristics: Highly tumorigenic Established from prostate cancer stem cells. Doubling time: ~42 hours (PubMed=32256979) 35668926 CVCL_YZ65 293T/ACE2 [USA 2003] transformed cell line human CVCL_YZ65 CL:0000010 Transfected with: HGNC; 13557; ACE2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Group: SARS-CoV-2 research cell line 35668927 CVCL_YZ70 IndFSPT1 transformed cell line CVCL_YZ70 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen. Group: Bat cell line 35668928 CVCL_YZ71 SuBK12-08 transformed cell line CVCL_YZ71 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Virology: Highly susceptible to infection by Lloviu virus (LLOV) (PubMed=24131711) Group: Bat cell line 35668929 CVCL_YZ72 YubFKT1 transformed cell line CVCL_YZ72 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 35668930 CVCL_YZ55 IOSE19CMYC telomerase immortalized cell line human CVCL_YZ55 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668931 CVCL_YZ56 IOSE4CMYC telomerase immortalized cell line human CVCL_YZ56 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668932 CVCL_YZ57 IOSE11CMYC.BRAF telomerase immortalized cell line human CVCL_YZ57 CL:0000010 Transfected with: HGNC; 1097; BRAF (with p.Val600Glu); Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668933 CVCL_YZ58 IOSE11CMYC.KRAS telomerase immortalized cell line human CVCL_YZ58 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary. Female 35668934 CVCL_YZ51 EMosis-CC/TERT2 telomerase immortalized cell line human CVCL_YZ51 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Endometrium. Female 35668935 CVCL_YZ52 EMosis-E6/E7/TERT2 transformed cell line human CVCL_YZ52 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium. Female 35668936 CVCL_YZ53 Clo03 transformed cell line human CVCL_YZ53 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Endometrium. Female Doubling time: 29-32 hours (PubMed=10233862) 35668937 CVCL_YZ54 IOSE11CMYC telomerase immortalized cell line human CVCL_YZ54 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668938 CVCL_YZ59 IOSE19CMYC.BRAF telomerase immortalized cell line human CVCL_YZ59 CL:0000010 Transfected with: HGNC; 1097; BRAF (with p.Val600Glu); Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668939 CVCL_YZ60 IOSE19CMYC.KRAS telomerase immortalized cell line human CVCL_YZ60 CL:0000010 Transfected with: HGNC; 6407; KRAS (with p.Gly12Val); Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd) Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35668940 CVCL_YZ61 EEC16 finite cell line human CVCL_YZ61 CL:0000010 Derived from sampling site: Endometrium. Omics: H3K27ac ChIP-seq epigenome analysis; Omics: H3K4me1 ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq Female 35668941 CVCL_YZ44 MDCK.STAT1 KO spontaneously immortalized cell line dog CVCL_YZ44 CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; -; STAT1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Virology: Excellent cell model for virus propagation and viral vaccine production It exhibits significant increased viral titer and enhanced virus production capability when compared to its parental cell line (ATCC). Doubling time: ~22 hours (ATCC=CCL-34-VHG) Group: Vaccine production cell line 35668942 CVCL_YZ45 Vero.STAT1 KO spontaneously immortalized cell line green monkey CVCL_YZ45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; A0A0D9RIE1; STAT1 Derived from sampling site: Kidney; epithelium. Female Virology: Excellent cell model for virus propagation and viral vaccine production It exhibits significant increased viral titer and enhanced virus production capability when compared to its parental cell line (ATCC). Doubling time: ~28 hours (ATCC=CCL-81-VHG) Group: Non-human primate cell line; Group: Vaccine production cell line 35668943 CVCL_YZ46 A549 DHODH-/- cancer cell line human CVCL_YZ46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2867; DHODH; Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male 35668944 CVCL_YZ47 Calu-3 2B4 cancer cell line human CVCL_YZ47 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met237Ile (c.711G>T); ClinVar=VCV000634770; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Male Characteristics: Increased expression of ACE2; Virology: Highly susceptible to SARS coronavirus (SARS-CoV) infection (PubMed=20090954) 35668945 CVCL_YZ40 PACS1003i-GM27161 induced pluripotent stem cell human CVCL_YZ40 CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous; Note=De novo mutation (from parent cell line) Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Male 35668946 CVCL_YZ41 WC008i-C603-4 induced pluripotent stem cell human CVCL_YZ41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668947 CVCL_YZ42 AA-103A cancer cell line human CVCL_YZ42 CL:0000010 Population: African American; Derived from sampling site: Prostate. Male 35668948 CVCL_YZ43 AA-103B finite cell line human CVCL_YZ43 CL:0000010 Population: African American; Derived from sampling site: Prostate. Male 35668949 CVCL_YZ48 EMosis-CC/TERT1 telomerase immortalized cell line human CVCL_YZ48 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Endometrium. Female 35668950 CVCL_YZ49 EMosis-CC/TERT1/ER telomerase immortalized cell line human CVCL_YZ49 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 3467; ESR1 Derived from sampling site: Endometrium. Female 35668951 CVCL_YZ50 EMosis-E6/E7/TERT1 transformed cell line human CVCL_YZ50 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Endometrium. Female 35668952 CVCL_YZ33 LUEL8361i-2 induced pluripotent stem cell human CVCL_YZ33 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668953 CVCL_YZ34 LUEL8363i-2 induced pluripotent stem cell human CVCL_YZ34 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668954 CVCL_YZ35 LUEL8363i-3 induced pluripotent stem cell human CVCL_YZ35 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668955 CVCL_YZ36 LUEL8364i-1 induced pluripotent stem cell human CVCL_YZ36 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668956 CVCL_YZ30 LUEL8360i-2 induced pluripotent stem cell human CVCL_YZ30 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668957 CVCL_YZ31 LUEL8360i-5 induced pluripotent stem cell human CVCL_YZ31 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668958 CVCL_YZ32 LUEL8361i-1 induced pluripotent stem cell human CVCL_YZ32 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668959 CVCL_YZ37 LUEL8679i-4 induced pluripotent stem cell human CVCL_YZ37 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668960 CVCL_YZ38 PACS1001i-GM27160 induced pluripotent stem cell human CVCL_YZ38 CL:0000010 Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668961 CVCL_YZ39 PACS1002i-GM27159 induced pluripotent stem cell human CVCL_YZ39 CL:0000010 Sequence variation: Mutation; HGNC; 30032; PACS1; Simple; p.Arg203Trp (c.607C>T); ClinVar=VCV000039581; Zygosity=Heterozygous; Note=De novo mutation (from parent cell line) Population: Caucasian and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668962 CVCL_YZ22 LUEL7994i-1 induced pluripotent stem cell human CVCL_YZ22 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668963 CVCL_YZ23 LUEL7994i-2 induced pluripotent stem cell human CVCL_YZ23 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668964 CVCL_YZ24 LUEL7996i-10 induced pluripotent stem cell human CVCL_YZ24 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668965 CVCL_YZ25 LUEL7996i-2 induced pluripotent stem cell human CVCL_YZ25 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668966 CVCL_YZ20 LUEL7991i-1 induced pluripotent stem cell human CVCL_YZ20 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668967 CVCL_YZ21 LUEL7991i-4 induced pluripotent stem cell human CVCL_YZ21 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668968 CVCL_YZ26 LUEL8312i-1 induced pluripotent stem cell human CVCL_YZ26 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668969 CVCL_YZ27 LUEL8312i-4 induced pluripotent stem cell human CVCL_YZ27 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668970 CVCL_YZ28 LUEL8357i-2 induced pluripotent stem cell human CVCL_YZ28 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668971 CVCL_YZ29 LUEL8357i-3 induced pluripotent stem cell human CVCL_YZ29 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668972 CVCL_YZ11 LUEL5748i-2 induced pluripotent stem cell human CVCL_YZ11 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668973 CVCL_YZ12 LUEL7149i-1 induced pluripotent stem cell human CVCL_YZ12 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668974 CVCL_YZ13 LUEL7149i-2 induced pluripotent stem cell human CVCL_YZ13 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668975 CVCL_YZ14 LUEL7153i-1 induced pluripotent stem cell human CVCL_YZ14 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668976 CVCL_YZ10 F26G19 hybridoma house mouse CVCL_YZ10 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). 35668977 CVCL_YZ19 LUEL7756i-4 induced pluripotent stem cell human CVCL_YZ19 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668978 CVCL_YZ15 LUEL7159i-16 induced pluripotent stem cell human CVCL_YZ15 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668979 CVCL_YZ16 LUEL7159i-7 induced pluripotent stem cell human CVCL_YZ16 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35668980 CVCL_YZ17 LUEL7673i-3 induced pluripotent stem cell human CVCL_YZ17 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668981 CVCL_YZ18 LUEL7756i-2 induced pluripotent stem cell human CVCL_YZ18 CL:0000010 Population: Southeast Asian; Filipino; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35668982 CVCL_YZ00 FHS069i-sh14564C induced pluripotent stem cell human CVCL_YZ00 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668983 CVCL_YZ01 FHS070i-sh4670A induced pluripotent stem cell human CVCL_YZ01 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668984 CVCL_YZ02 STAN101i-110C3 induced pluripotent stem cell human CVCL_YZ02 CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668985 CVCL_YZ03 STAN215i-490C3 induced pluripotent stem cell human CVCL_YZ03 From: Quertermous T.; Stanford University; Stanford; USA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668986 CVCL_YZ08 F26G8 hybridoma house mouse CVCL_YZ08 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). 35668987 CVCL_YZ09 F26G18 hybridoma house mouse CVCL_YZ09 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). 35668988 CVCL_YZ04 RaKSM-2.5i transformed cell line CVCL_YZ04 CL:0000010 Miscellaneous: Doubling time and age of donor from personal communication of Letko M Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Doubling time: 1.5-2 days (Direct_author_submission) Group: Bat cell line 35668989 CVCL_YZ05 AJi transformed cell line CVCL_YZ05 CL:0000010 Miscellaneous: Doubling time and age of donor from personal communication of Letko M Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Unspecified Doubling time: 1.5-2 days (Direct_author_submission) Group: Bat cell line 35668990 CVCL_YZ06 F26G1 hybridoma house mouse CVCL_YZ06 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). 35668991 CVCL_YZ07 F26G6 hybridoma house mouse CVCL_YZ07 CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P59594; Human SARS coronavirus (SARS-CoV) spike protein (S). 35668992 CVCL_YY96 FHS065i-sh921B induced pluripotent stem cell human CVCL_YY96 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668993 CVCL_YY97 FHS066i-sh921C induced pluripotent stem cell human CVCL_YY97 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668994 CVCL_YY98 FHS067i-sh9462A induced pluripotent stem cell human CVCL_YY98 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668995 CVCL_YY99 FHS068i-sh9462B induced pluripotent stem cell human CVCL_YY99 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668996 CVCL_YY89 FHS058i-sh4105D induced pluripotent stem cell human CVCL_YY89 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668997 CVCL_YY85 FHS054i-sh3726B induced pluripotent stem cell human CVCL_YY85 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668998 CVCL_YY86 FHS055i-sh4064A induced pluripotent stem cell human CVCL_YY86 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35668999 CVCL_YY87 FHS056i-sh4064B induced pluripotent stem cell human CVCL_YY87 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669000 CVCL_YY88 FHS057i-sh4105B induced pluripotent stem cell human CVCL_YY88 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669001 CVCL_YY92 FHS061i-sh521C induced pluripotent stem cell human CVCL_YY92 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669002 CVCL_YY93 FHS062i-sh521E induced pluripotent stem cell human CVCL_YY93 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669003 CVCL_YY94 FHS063i-sh554A induced pluripotent stem cell human CVCL_YY94 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669004 CVCL_YY95 FHS064i-sh554D induced pluripotent stem cell human CVCL_YY95 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669005 CVCL_YY90 FHS059i-sh4756A induced pluripotent stem cell human CVCL_YY90 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669006 CVCL_YY91 FHS060i-sh4756B induced pluripotent stem cell human CVCL_YY91 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669007 CVCL_YY78 FHS047i-sh25727B induced pluripotent stem cell human CVCL_YY78 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669008 CVCL_YY79 FHS048i-sh25727G induced pluripotent stem cell human CVCL_YY79 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669009 CVCL_YY74 FHS043i-sh24472D induced pluripotent stem cell human CVCL_YY74 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669010 CVCL_YY75 FHS044i-sh24472K induced pluripotent stem cell human CVCL_YY75 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669011 CVCL_YY76 FHS045i-sh25642B induced pluripotent stem cell human CVCL_YY76 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669012 CVCL_YY77 FHS046i-sh25642C induced pluripotent stem cell human CVCL_YY77 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669013 CVCL_YY81 FHS050i-sh2633D induced pluripotent stem cell human CVCL_YY81 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669014 CVCL_YY82 FHS051i-sh2945A induced pluripotent stem cell human CVCL_YY82 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669015 CVCL_YY83 FHS052i-sh2945B induced pluripotent stem cell human CVCL_YY83 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669016 CVCL_YY84 FHS053i-sh3726A induced pluripotent stem cell human CVCL_YY84 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669017 CVCL_YY80 FHS049i-sh2633B induced pluripotent stem cell human CVCL_YY80 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669018 CVCL_YY67 FHS036i-sh18961C induced pluripotent stem cell human CVCL_YY67 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669019 CVCL_YY68 FHS037i-sh1998E induced pluripotent stem cell human CVCL_YY68 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669020 CVCL_YY69 FHS038i-sh1998G induced pluripotent stem cell human CVCL_YY69 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669021 CVCL_YY63 FHS032i-sh16939B induced pluripotent stem cell human CVCL_YY63 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669022 CVCL_YY64 FHS033i-sh18719B induced pluripotent stem cell human CVCL_YY64 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669023 CVCL_YY65 FHS034i-sh18719D induced pluripotent stem cell human CVCL_YY65 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669024 CVCL_YY66 FHS035i-sh18961A induced pluripotent stem cell human CVCL_YY66 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669025 CVCL_YY70 FHS039i-sh2098A induced pluripotent stem cell human CVCL_YY70 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669026 CVCL_YY71 FHS040i-sh2098B induced pluripotent stem cell human CVCL_YY71 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669027 CVCL_YY72 FHS041i-sh22512A induced pluripotent stem cell human CVCL_YY72 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669028 CVCL_YY73 FHS042i-sh22512D induced pluripotent stem cell human CVCL_YY73 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669029 CVCL_YY56 FHS025i-sh1649A induced pluripotent stem cell human CVCL_YY56 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669030 CVCL_YY57 FHS026i-sh1649B induced pluripotent stem cell human CVCL_YY57 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669031 CVCL_YY58 FHS027i-sh1660E induced pluripotent stem cell human CVCL_YY58 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669032 CVCL_YY59 FHS028i-sh1660F induced pluripotent stem cell human CVCL_YY59 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669033 CVCL_YY52 FHS021i-sh14685A induced pluripotent stem cell human CVCL_YY52 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669034 CVCL_YY53 FHS022i-sh14685B induced pluripotent stem cell human CVCL_YY53 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669035 CVCL_YY54 FHS023i-sh16126C induced pluripotent stem cell human CVCL_YY54 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669036 CVCL_YY55 FHS024i-sh16126E induced pluripotent stem cell human CVCL_YY55 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669037 CVCL_YY60 FHS029i-sh1673B induced pluripotent stem cell human CVCL_YY60 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669038 CVCL_YY61 FHS030i-sh1673F induced pluripotent stem cell human CVCL_YY61 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G; dbSNP=rs12740374; Zygosity=Homozygous; Note=Major haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669039 CVCL_YY62 FHS031i-sh16939A induced pluripotent stem cell human CVCL_YY62 CL:0000010 Sequence variation: Mutation; HGNC; 3231; CELSR2; Simple; c.*919G>T; dbSNP=rs12740374; Zygosity=Homozygous; Note=Minor haplotype (PubMed=28388431) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female Part of: Framingham Heart Study (FHS) collection; Part of: Next Generation Genetic Association studies (Next Gen) program cell lines 35669040 CVCL_YZ99 SHCDNi002-A induced pluripotent stem cell human CVCL_YZ99 From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 11957; MED12; Simple; c.1249-1G>C; ClinVar=VCV001210232; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=32505899) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669041 CVCL_YZ95 EMCi128-A induced pluripotent stem cell human CVCL_YZ95 From: Erasmus University Medical Center; Rotterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 3809; FOXF1; Simple; p.Phe85Ile (c.253T>A); Zygosity=Heterozygous (PubMed=32169823) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669042 CVCL_YZ96 0363M-1 induced pluripotent stem cell CVCL_YZ96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 35669043 CVCL_YZ97 0363M-2 induced pluripotent stem cell CVCL_YZ97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 35669044 CVCL_YZ98 ZZUNEUi010-A induced pluripotent stem cell human CVCL_YZ98 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 4010; FUS; Simple; p.Gly504Argfs*12 (c.1509dupA) (p.Arg503fs); ClinVar=VCV000933229; Zygosity=Heterozygous; Note=De novo mutation (PubMed=33093822) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669045 CVCL_YZ88 KICRi002-A-1 induced pluripotent stem cell human CVCL_YZ88 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 5961; IKBKG Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669046 CVCL_YZ89 KICRi002-A-2 induced pluripotent stem cell human CVCL_YZ89 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30677; GPKOW Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669047 CVCL_YZ84 LentiPro26-A59 transformed cell line human CVCL_YZ84 CL:0000010 Transfected with: UniProtKB; P12493; HIV-1 isolate NY5 gag; Transfected with: UniProtKB; P12497; HIV-1 isolate NY5 pol (with p.Thr514Ser); Transfected with: UniProtKB; P04325; HIV-1 isolate PCV12 rev; Transfected with: UniProtKB; Q89683; Murine leukemia virus isolate 4070A env; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the pGP(T26S)P-blast plasmid containing HIV-1 Gag-Pro(Thr514Ser)-Pol-bsr, the pREV-hygro-WPRE plasmid containing Rev-hph and a woodchuck hepatitis post-transcriptional regulatory element (WPRE), the pMONO-zeo-4070A plasmid containing a ferritin heavy chain promoter fused with SV40 enhancer followed by MLV 4070A env, IRES and ble and the pRRLSIN-mCP-GFP plasmid containing mCherry, pac, the human phosphoglycerate kinase promoter, GFP and WPRE 35669048 CVCL_YZ85 HEBHMUi003-A induced pluripotent stem cell human CVCL_YZ85 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Female 35669049 CVCL_YZ86 HEBHMUi005-A induced pluripotent stem cell human CVCL_YZ86 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669050 CVCL_YZ87 KICRi002-A-3 induced pluripotent stem cell human CVCL_YZ87 From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17597; NCDN Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669051 CVCL_YZ91 REGUi007-A induced pluripotent stem cell human CVCL_YZ91 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 35669052 CVCL_YZ92 REGUi008-A induced pluripotent stem cell human CVCL_YZ92 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 35669053 CVCL_YZ93 EMCi127-A induced pluripotent stem cell human CVCL_YZ93 From: Erasmus University Medical Center; Rotterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 3809; FOXF1; Simple; p.Leu56Val (c.166C>G); ClinVar=VCV000869491; Zygosity=Heterozygous (PubMed=32169823) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669054 CVCL_YZ94 EMCi127-B induced pluripotent stem cell human CVCL_YZ94 From: Erasmus University Medical Center; Rotterdam; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 3809; FOXF1; Simple; p.Leu56Val (c.166C>G); ClinVar=VCV000869491; Zygosity=Heterozygous (PubMed=32169823) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669055 CVCL_YZ90 REGUi006-A induced pluripotent stem cell human CVCL_YZ90 From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 35669056 CVCL_YZ77 ZFBS13-75A transformed cell line CVCL_YZ77 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Spleen. Group: Bat cell line 35669057 CVCL_YZ78 EMosis-CC/TERT1/PRA telomerase immortalized cell line human CVCL_YZ78 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 8910; PGR (isoform A) Derived from sampling site: Endometrium. Female 35669058 CVCL_YZ79 EMosis-CC/TERT1/PRA-/PRB+ telomerase immortalized cell line human CVCL_YZ79 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 8910; PGR (isoform B) Derived from sampling site: Endometrium. Female 35669059 CVCL_YZ73 YubFKT2 transformed cell line CVCL_YZ73 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 35669060 CVCL_YZ74 ZFBK11-97 transformed cell line CVCL_YZ74 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line Caution: Exact taxonomic provenance is not known On the basis of habitat and cyb sequence, it could be from Epomophorus anselli, Epomophorus crypturus, Epomophorus gambianus, Epomophorus minimus or Micropteropus pusillus (PubMed=30718752). 35669061 CVCL_YZ75 ZFBK13-76E transformed cell line CVCL_YZ75 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Virology: Susceptible to infection by many filoviruses except Ebola virus (EBOV) This is due to specific sequence changes in NPC1 that acts as a receptor for filoviruses (PubMed=31940478). Group: Bat cell line 35669062 CVCL_YZ76 ZFBK15-137RA transformed cell line CVCL_YZ76 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Group: Bat cell line 35669063 CVCL_YZ80 MDA-MB-231/Luciferase-2A-RFP cancer cell line human CVCL_YZ80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transduced by lentivirus with a suCMV-Luc-2A-RFP-RSV-Bsr construct Group: Triple negative breast cancer (TNBC) cell line 35669064 CVCL_YZ81 LentiPro26 transformed cell line human CVCL_YZ81 CL:0000010 Transfected with: UniProtKB; P12493; HIV-1 isolate NY5 gag; Transfected with: UniProtKB; P12497; HIV-1 isolate NY5 pol (with p.Thr514Ser); Transfected with: UniProtKB; P04325; HIV-1 isolate PCV12 rev; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the pGP(T26S)P-blast plasmid containing HIV-1 Gag-Pro(Thr514Ser)-Pol-bsr and the pREV-hygro-WPRE plasmid containing Rev-hph and a woodchuck hepatitis post-transcriptional regulatory element (WPRE) 35669065 CVCL_YZ82 LentiPro26-4070A transformed cell line human CVCL_YZ82 CL:0000010 Transfected with: UniProtKB; P12493; HIV-1 isolate NY5 gag; Transfected with: UniProtKB; P12497; HIV-1 isolate NY5 pol (with p.Thr514Ser); Transfected with: UniProtKB; P04325; HIV-1 isolate PCV12 rev; Transfected with: UniProtKB; Q89683; Murine leukemia virus isolate 4070A env; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the pGP(T26S)P-blast plasmid containing HIV-1 Gag-Pro(Thr514Ser)-Pol-bsr, the pREV-hygro-WPRE plasmid containing Rev-hph and a woodchuck hepatitis post-transcriptional regulatory element (WPRE) and the pMONO-zeo-4070A plasmid containing a ferritin heavy chain promoter fused with SV40 enhancer followed by MLV 4070A env, IRES and ble 35669066 CVCL_YZ83 LentiPro26-4070A-mCPGFP transformed cell line human CVCL_YZ83 CL:0000010 Transfected with: UniProtKB; P12493; HIV-1 isolate NY5 gag; Transfected with: UniProtKB; P12497; HIV-1 isolate NY5 pol (with p.Thr514Ser); Transfected with: UniProtKB; P04325; HIV-1 isolate PCV12 rev; Transfected with: UniProtKB; Q89683; Murine leukemia virus isolate 4070A env; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with the pGP(T26S)P-blast plasmid containing HIV-1 Gag-Pro(Thr514Ser)-Pol-bsr, the pREV-hygro-WPRE plasmid containing Rev-hph and a woodchuck hepatitis post-transcriptional regulatory element (WPRE), the pMONO-zeo-4070A plasmid containing a ferritin heavy chain promoter fused with SV40 enhancer followed by MLV 4070A env, IRES and ble and the pRRLSIN-mCP-GFP plasmid containing mCherry, pac, the human phosphoglycerate kinase promoter, GFP and WPRE 35669067 CVCL_YU25 GeneBLAzer EDNRB-NFAT-bla HEK 293T transformed cell line human CVCL_YU25 CL:0000010 Transfected with: HGNC; 3180; EDNRB; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669068 CVCL_ZB92 FRDA203 finite cell line human CVCL_ZB92 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[916]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1382]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669069 CVCL_ZB93 FRDA281 finite cell line human CVCL_ZB93 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[630]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[806]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669070 CVCL_ZB94 Cre4 transformed cell line house mouse CVCL_ZB94 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified 35669071 CVCL_ZB95 Cre4 rho-0#11 transformed cell line house mouse CVCL_ZB95 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: Cell line devoid of mitochondrial DNA (rho0) Produced by propagation for 3 weeks of the parent cell line in a medium containing 5 ug/ml EtBr. 35669072 CVCL_ZB90 FRDA156 finite cell line human CVCL_ZB90 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[495]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[505]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669073 CVCL_ZB91 FRDA188 finite cell line human CVCL_ZB91 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[490]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[680]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669074 CVCL_ZB96 FRDA4192 finite cell line human CVCL_ZB96 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[400]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[967]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669075 CVCL_ZB97 FRDA4194 finite cell line human CVCL_ZB97 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Simple; p.Gly130Val (c.389G>T); ClinVar=VCV000003982; Zygosity=Heterozygous (PubMed=27002638); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[540]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669076 CVCL_ZB98 FRDA4230 finite cell line human CVCL_ZB98 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[870]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1470]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669077 CVCL_ZB99 FRDA4259 finite cell line human CVCL_ZB99 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[404]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[920]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669078 CVCL_ZB81 MDCC-UD26 cancer cell line CVCL_ZB81 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Breed/subspecies: White Leghorn. Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669079 CVCL_ZB82 MDCC-UD27 cancer cell line CVCL_ZB82 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Kidney; Breed/subspecies: White Leghorn. Male Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669080 CVCL_ZB83 MDCC-UD28 cancer cell line CVCL_ZB83 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Testis; Breed/subspecies: White Leghorn. Male Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669081 CVCL_ZB84 MDCC-UD29 cancer cell line CVCL_ZB84 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from metastatic site: Not specified; Breed/subspecies: White Leghorn. Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669082 CVCL_ZB80 MDCC-UD25 cancer cell line CVCL_ZB80 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Testis; Breed/subspecies: White Leghorn. Male Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669083 CVCL_ZB89 FRDA130 finite cell line human CVCL_ZB89 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[136]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[540]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669084 CVCL_ZB85 MDCC-UD35 cancer cell line CVCL_ZB85 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Derived from metastatic site: Liver; Breed/subspecies: White Leghorn. Group: Bird cell line 35669085 CVCL_ZB86 MDCC-UD36 cancer cell line CVCL_ZB86 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain rMDV-1137)(NCBI-Taxonomy; 10390); Derived from metastatic site: Kidney; Breed/subspecies: White Leghorn. Group: Bird cell line 35669086 CVCL_ZB87 MDCC-UD37 cancer cell line CVCL_ZB87 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Derived from metastatic site: Kidney; Breed/subspecies: White Leghorn. Group: Bird cell line 35669087 CVCL_ZB88 MDCC-UD38 cancer cell line CVCL_ZB88 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain rMDV-1137)(NCBI-Taxonomy; 10390); Derived from metastatic site: Spleen; Breed/subspecies: White Leghorn. Group: Bird cell line 35669088 CVCL_ZB70 MDCC-UA23 cancer cell line CVCL_ZB70 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-pp38smGFP](NCBI-Taxonomy; 33707); Derived from sampling site: Testis; Breed/subspecies: White Leghorn. Male Characteristics: The MDV RB-1b virus has been modified by insertion of a soluble modified derivative of GFP (smGFP) downstream of the pp38 protein of MDV Thus the expression of GFP is induced during reactivation of the MDV from latency, therefore these cells are ideal for studying the early events of reactivation. Group: Bird cell line 35669089 CVCL_ZB71 MDCC-UA53 cancer cell line CVCL_ZB71 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain TK)(NCBI-Taxonomy; 10390); Derived from sampling site: Spleen; Breed/subspecies: White Leghorn. Group: Bird cell line 35669090 CVCL_ZB72 MDCC-UD01 cancer cell line CVCL_ZB72 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-Delta4.5lac](NCBI-Taxonomy; 33707); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Characteristics: The MDV RB-1b virus has been modified by deletion of six genes from the US region of the virus genome and replaced with a lacZ expression cassette Group: Bird cell line 35669091 CVCL_ZB73 MDCC-UD02 cancer cell line CVCL_ZB73 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-Delta4.5lac](NCBI-Taxonomy; 33707); Derived from sampling site: Spleen; Breed/subspecies: White Leghorn. Characteristics: The MDV RB-1b virus has been modified by deletion of six genes from the US region of the virus genome and replaced with a lacZ expression cassette Group: Bird cell line 35669092 CVCL_ZB78 MDCC-UD23 cancer cell line CVCL_ZB78 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669093 CVCL_ZB79 MDCC-UD24 cancer cell line CVCL_ZB79 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Liver; Breed/subspecies: White Leghorn. Male Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669094 CVCL_ZB74 MDCC-UD03 cancer cell line CVCL_ZB74 CL:0000010 Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-Delta4.5lac](NCBI-Taxonomy; 33707); Derived from sampling site: Liver; Breed/subspecies: White Leghorn. Characteristics: The MDV RB-1b virus has been modified by deletion of six genes from the US region of the virus genome and replaced with a lacZ expression cassette Group: Bird cell line 35669095 CVCL_ZB75 MDCC-UD13 cancer cell line CVCL_ZB75 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Derived from metastatic site: Not specified; Breed/subspecies: White Leghorn. Group: Bird cell line 35669096 CVCL_ZB76 MDCC-UD14 cancer cell line CVCL_ZB76 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Derived from sampling site: Kidney; Breed/subspecies: White Leghorn. Group: Bird cell line 35669097 CVCL_ZB77 MDCC-UD22 cancer cell line CVCL_ZB77 CL:0000010 Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00722; Escherichia coli lacZ Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US6lacgpt](NCBI-Taxonomy; 33707); Derived from sampling site: Kidney; Breed/subspecies: White Leghorn. Female Characteristics: The MDV RB-1b virus has been modified by an insertion of a lacZ-gpt cassette within the US6 gene Group: Bird cell line 35669098 CVCL_ZB60 C6 rho-0#14 cancer cell line Norway rat CVCL_ZB60 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Brain; Breed/subspecies: Wistar Furth. Male Characteristics: Cell line devoid of mitochondrial DNA (rho0) Produced by transient transfection with plasmid pMA4008 encoding HSV-1 UL12.5M185 protein, which damages mtDNA by an unknown mechanism. 35669099 CVCL_ZB61 DHSA-1426 cancer cell line dog CVCL_ZB61 CL:0000010 Derived from sampling site: Spleen; Breed/subspecies: Golden Retriever. Omics: Transcriptome analysis by RNAseq Male Characteristics: Forms hemangiosarcoma xenografts in immunodeficient mice when injected subcutaneously in Matrigel (Kerafast) Doubling time: ~24 hours (Kerafast) 35669100 CVCL_ZB62 AbC1 cancer cell line CVCL_ZB62 CL:0000010 Derived from sampling site: Skin. Male Characteristics: Produces melanin pigment when L-tyrosine or L-DOPA are added to the culture media - along with new organelle formation - melanosomes and increased expression of MSH receptors (Kerafast); Characteristics: Established from the transplantable Bomirski hamster amelanotic melanoma 35669101 CVCL_ZB67 MDCC-UA04 cancer cell line CVCL_ZB67 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-US2gfpDelta-1](NCBI-Taxonomy; 33707); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Characteristics: The MDV RB-1b virus has been modified by insertion of a soluble modified derivative of GFP (smGFP) in the US2 locus Group: Bird cell line 35669102 CVCL_ZB68 MDCC-UA20 cancer cell line CVCL_ZB68 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-vIL-8Delta-smGFP](NCBI-Taxonomy; 33707); Derived from sampling site: Ovary; Breed/subspecies: White Leghorn. Female Characteristics: The MDV RB-1b virus has been modified by replacement of the vIL-8 gene by a soluble modified derivative of GFP (smGFP) Group: Bird cell line 35669103 CVCL_ZB69 MDCC-UA22 cancer cell line CVCL_ZB69 CL:0000010 Transfected with: UniProtKB; P42212; GFP Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b) [RB-1B-pp38smGFP](NCBI-Taxonomy; 33707); Derived from sampling site: Kidney; Breed/subspecies: White Leghorn. Characteristics: The MDV RB-1b virus has been modified by insertion of a soluble modified derivative of GFP (smGFP) downstream of the pp38 protein of MDV Thus the expression of GFP is induced during reactivation of the MDV from latency, therefore these cells are ideal for studying the early events of reactivation. Group: Bird cell line 35669104 CVCL_ZB63 CH12F3 (APE1+/+/-) cancer cell line house mouse CVCL_ZB63 CL:0000010 Knockout cell: Method=Homologous recombination (1 of 3 alleles); MGI; MGI:88042; Apex1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 35669105 CVCL_ZB64 CH12F3 (APE1+/-/-) cancer cell line house mouse CVCL_ZB64 CL:0000010 Knockout cell: Method=Homologous recombination (2 of 3 alleles); MGI; MGI:88042; Apex1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 35669106 CVCL_ZB65 CH12F3 (APE1-/-/-) cancer cell line house mouse CVCL_ZB65 CL:0000010 Knockout cell: Method=Homologous recombination; MGI; MGI:88042; Apex1 Derived from sampling site: Lymph node; Breed/subspecies: B10.H-2aH-4bp/Wts. 35669107 CVCL_ZB66 MDCC-UA01 cancer cell line CVCL_ZB66 CL:0000010 Transformant: Gallid herpesvirus 2 (Marek's disease virus) (strain RB-1b)(NCBI-Taxonomy; 33707); Breed/subspecies: White Leghorn. Group: Bird cell line 35669108 CVCL_ZB50 HS970 embryonic stem cell human CVCL_ZB50 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669109 CVCL_ZB51 0138F-1 induced pluripotent stem cell CVCL_ZB51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 35669110 CVCL_ZB56 HPS0448 induced pluripotent stem cell human CVCL_ZB56 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (from autologous cell line HPS0447) Population: Japanese; Derived from sampling site: Peripheral blood. Female 35669111 CVCL_ZB57 LUMCi031-A induced pluripotent stem cell human CVCL_ZB57 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Dutch; Derived from sampling site: Peripheral blood. Male 35669112 CVCL_ZB58 KCLi004-A induced pluripotent stem cell human CVCL_ZB58 From: King's College London; London; United Kingdom. CL:0000010 35669113 CVCL_ZB59 HS659 embryonic stem cell human CVCL_ZB59 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669114 CVCL_ZB52 0274F-1 induced pluripotent stem cell CVCL_ZB52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 35669115 CVCL_ZB53 0274F-2 induced pluripotent stem cell CVCL_ZB53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 35669116 CVCL_ZB54 HPS0446 induced pluripotent stem cell human CVCL_ZB54 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (from autologous cell line HPS0447) Population: Japanese; Derived from sampling site: Peripheral blood. Female 35669117 CVCL_ZB55 HPS0447 induced pluripotent stem cell human CVCL_ZB55 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (PubMed=32361464) Population: Japanese; Derived from sampling site: Peripheral blood. Female 35669118 CVCL_ZB40 WAe009-A-22 embryonic stem cell human CVCL_ZB40 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India. CL:0000010 Female 35669119 CVCL_ZB45 WAe009-A-31 embryonic stem cell human CVCL_ZB45 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1. Female 35669120 CVCL_ZB46 WAe009-A-32 embryonic stem cell human CVCL_ZB46 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1. Female 35669121 CVCL_ZB47 WAe009-A-33 embryonic stem cell human CVCL_ZB47 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1. Female 35669122 CVCL_ZB48 WAe009-A-34 embryonic stem cell human CVCL_ZB48 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1. Female 35669123 CVCL_ZB41 WAe009-A-25 embryonic stem cell human CVCL_ZB41 From: Sun Yat-sen University Third Affiliated Hospital; Guangzhou; China. CL:0000010 Female 35669124 CVCL_ZB42 WAe009-A-28 embryonic stem cell human CVCL_ZB42 From: Institute for Stem Cell Biology and Regenerative Medicine; Bangalore; India. CL:0000010 Female 35669125 CVCL_ZB43 WAe009-A-29 embryonic stem cell human CVCL_ZB43 From: University of Wisconsin; Madison; USA CL:0000010 Transfected with: UniProtKB; Q8RUT8; Chlamydomonas reinhardtii channelrhodopsin-2 (cop4); Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Female 35669126 CVCL_ZB44 WAe009-A-30 embryonic stem cell human CVCL_ZB44 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 9884; RB1. Female 35669127 CVCL_ZB49 WAe009-A-35 embryonic stem cell human CVCL_ZB49 From: University Hospital Essen, University of Duisburg-Essen; Essen; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1. Female 35669128 CVCL_ZB34 WAe001-A-40 embryonic stem cell human CVCL_ZB34 From: University of Wisconsin; Madison; USA. CL:0000010 Male 35669129 CVCL_ZB35 WISCi015-A induced pluripotent stem cell human CVCL_ZB35 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg88Cys (c.262C>T); ClinVar=VCV000016172; Zygosity=Heterozygous (PubMed=30355500) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669130 CVCL_ZB36 WISCi015-A-1 induced pluripotent stem cell human CVCL_ZB36 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple_corrected; p.Arg88Cys (c.262C>T); ClinVar=VCV000016172; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30355500) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669131 CVCL_ZB37 WISCi016-A induced pluripotent stem cell human CVCL_ZB37 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg416Trp (c.1246C>T); ClinVar=VCV000016169; Zygosity=Heterozygous (PubMed=30355500) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669132 CVCL_ZB30 ZZUSAHi002-A induced pluripotent stem cell human CVCL_ZB30 From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669133 CVCL_ZB31 WAe001-A-41 embryonic stem cell human CVCL_ZB31 From: Nanfang Hospital, Southern Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2. Male 35669134 CVCL_ZB32 WAe001-A-42 embryonic stem cell human CVCL_ZB32 From: Nanfang Hospital, Southern Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10061; RNF2. Male 35669135 CVCL_ZB33 WAe001-A-43 embryonic stem cell human CVCL_ZB33 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China. CL:0000010 Male 35669136 CVCL_ZB38 WISCi016-A-1 induced pluripotent stem cell human CVCL_ZB38 From: University of Wisconsin; Madison; USA CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple_corrected; p.Arg416Trp (c.1246C>T); ClinVar=VCV000016169; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=30355500) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669137 CVCL_ZB39 WAe009-A-17 embryonic stem cell human CVCL_ZB39 From: Pennsylvania State University; State College; USA CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd). Female 35669138 CVCL_ZB23 VUi022-A induced pluripotent stem cell human CVCL_ZB23 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669139 CVCL_ZB24 VUi023-A induced pluripotent stem cell human CVCL_ZB24 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669140 CVCL_ZB25 VUi024-A induced pluripotent stem cell human CVCL_ZB25 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669141 CVCL_ZB26 XACHi010-A induced pluripotent stem cell human CVCL_ZB26 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 1243; C1QBP; Simple; p.Leu275Phe (c.823C>T); ClinVar=VCV000441245; Zygosity=Homozygous (PubMed=32707487) Population: Chinese; Derived from sampling site: Peripheral blood. Male 35669142 CVCL_ZB20 VUi019-A induced pluripotent stem cell human CVCL_ZB20 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669143 CVCL_ZB21 VUi020-A induced pluripotent stem cell human CVCL_ZB21 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669144 CVCL_ZB22 VUi021-A induced pluripotent stem cell human CVCL_ZB22 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669145 CVCL_ZB27 XACHi011-A induced pluripotent stem cell human CVCL_ZB27 From: Children's Research Institute of Shaanxi province, Xi'an Key Laboratory of Children's Health and Diseases; Xi'an; China CL:0000010 Sequence variation: Mutation; HGNC; 1243; C1QBP; Simple; p.Leu275Phe (c.823C>T); ClinVar=VCV000441245; Zygosity=Heterozygous (PubMed=32707487) Population: Chinese; Derived from sampling site: Peripheral blood. Female 35669146 CVCL_ZB28 YCMi001-A induced pluripotent stem cell human CVCL_ZB28 From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Unexplicit; Ex8-22del; Zygosity=Hemizygous (from autologous cell line YCMi001-B) Population: Korean; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 35669147 CVCL_ZB29 ZZUSAHi001-A induced pluripotent stem cell human CVCL_ZB29 From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6224; KCNA5; Simple; p.Val259Ile (c.775G>A); Zygosity=Heterozygous (PubMed=32721895) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669148 CVCL_ZB12 VUi011-A induced pluripotent stem cell human CVCL_ZB12 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669149 CVCL_ZB13 VUi012-A induced pluripotent stem cell human CVCL_ZB13 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669150 CVCL_ZB14 VUi013-A induced pluripotent stem cell human CVCL_ZB14 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669151 CVCL_ZB15 VUi014-A induced pluripotent stem cell human CVCL_ZB15 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669152 CVCL_ZB10 VUi009-A induced pluripotent stem cell human CVCL_ZB10 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669153 CVCL_ZB11 VUi010-A induced pluripotent stem cell human CVCL_ZB11 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669154 CVCL_ZB16 VUi015-A induced pluripotent stem cell human CVCL_ZB16 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669155 CVCL_ZB17 VUi016-A induced pluripotent stem cell human CVCL_ZB17 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669156 CVCL_ZB18 VUi017-A induced pluripotent stem cell human CVCL_ZB18 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669157 CVCL_ZB19 VUi018-A induced pluripotent stem cell human CVCL_ZB19 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669158 CVCL_ZB01 UMCGi008-A induced pluripotent stem cell human CVCL_ZB01 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669159 CVCL_ZB02 VUi001-A induced pluripotent stem cell human CVCL_ZB02 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669160 CVCL_ZB03 VUi002-A induced pluripotent stem cell human CVCL_ZB03 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 Male 35669161 CVCL_ZB04 VUi003-A induced pluripotent stem cell human CVCL_ZB04 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669162 CVCL_ZB00 UMCGi007-B induced pluripotent stem cell human CVCL_ZB00 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669163 CVCL_ZB09 VUi008-A induced pluripotent stem cell human CVCL_ZB09 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669164 CVCL_ZB05 VUi004-A induced pluripotent stem cell human CVCL_ZB05 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands. CL:0000010 35669165 CVCL_ZB06 VUi005-A induced pluripotent stem cell human CVCL_ZB06 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669166 CVCL_ZB07 VUi006-A induced pluripotent stem cell human CVCL_ZB07 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669167 CVCL_ZB08 VUi007-A induced pluripotent stem cell human CVCL_ZB08 From: Vrije Universiteit Amsterdam; Amsterdam; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669168 CVCL_ZC91 UNCN1T telomerase immortalized cell line human CVCL_ZC91 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Male 35669169 CVCL_ZC92 UNCN2T telomerase immortalized cell line human CVCL_ZC92 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Female 35669170 CVCL_ZC93 UNCN3T telomerase immortalized cell line human CVCL_ZC93 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Female 35669171 CVCL_ZC94 AALEB transformed cell line human CVCL_ZC94 CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. 35669172 CVCL_ZC90 UNCCF3T telomerase immortalized cell line human CVCL_ZC90 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=18978040); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Female 35669173 CVCL_ZC99 Lucky 1.2 hybridoma house mouse CVCL_ZC99 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q68285; Hepatitis C virus subtype 1b (Korean isolate) (AA 1192-1457; NS3 fragment). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10950 35669174 CVCL_ZC95 MLEC-Ext1f/f transformed cell line house mouse CVCL_ZC95 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ext1f/f x C57BL/6J. Omics: Deep quantitative phosphoproteome analysis Unspecified 35669175 CVCL_ZC96 MLEC-Ext1-/- transformed cell line house mouse CVCL_ZC96 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:894663; Ext1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ext1f/f x C57BL/6J. Omics: Deep quantitative phosphoproteome analysis Unspecified 35669176 CVCL_ZC97 NCC-SS3-C1 cancer cell line human CVCL_ZC97 CL:0000010 Sequence variation: Gene fusion; HGNC; 11340; SS18 + HGNC; 11335; SSX1; Name(s)=SS18-SSX1 (PubMed=32274656). Population: Japanese Female Doubling time: 60 hours (PubMed=32274656) Part of: NCC sarcoma cell line panel 35669177 CVCL_ZC98 Lucky 1.1 hybridoma house mouse CVCL_ZC98 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q68285; Hepatitis C virus subtype 1b (Korean isolate) (AA 1192-1457; NS3 fragment). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-10949 35669178 CVCL_ZC80 CS09iHD109-n4 induced pluripotent stem cell human CVCL_ZC80 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669179 CVCL_ZC81 CS09iHD109-n5 induced pluripotent stem cell human CVCL_ZC81 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669180 CVCL_ZC82 CS21iHD60-n5 induced pluripotent stem cell human CVCL_ZC82 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 35669181 CVCL_ZC83 CS21iHD60-n8 induced pluripotent stem cell human CVCL_ZC83 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[60] (c.52CAG(60)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669182 CVCL_ZC88 UNCCF1T telomerase immortalized cell line human CVCL_ZC88 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=18978040); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Male 35669183 CVCL_ZC89 UNCCF2T telomerase immortalized cell line human CVCL_ZC89 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous (PubMed=18978040); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88174; Bmi1 Population: Caucasian; Derived from sampling site: Bronchus; epithelium. Female 35669184 CVCL_ZC84 CS83iCTR33-n2 induced pluripotent stem cell human CVCL_ZC84 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[33] (c.52CAG(33)) (c.52CAG[(27_35)]); ClinVar=VCV000031915; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Donor information: At sampling donor was not affected with Huntington disease but at significant risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669185 CVCL_ZC85 CS14iCTR28-n5 induced pluripotent stem cell human CVCL_ZC85 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Extensive; Zygosity=Unspecified; Note=5 copies (from parent cell line); Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669186 CVCL_ZC86 CS00iCTR21-n1 induced pluripotent stem cell human CVCL_ZC86 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Population: African American; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 35669187 CVCL_ZC87 LNCaP-95 cancer cell line human CVCL_ZC87 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (PubMed=28928128); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 52.2 hours (PubMed=32954481) 35669188 CVCL_ZC70 FTD3678 finite cell line human CVCL_ZC70 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669189 CVCL_ZC71 FTD3682 finite cell line human CVCL_ZC71 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669190 CVCL_ZC72 CTL156 finite cell line human CVCL_ZC72 CL:0000010 Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669191 CVCL_ZC77 PRE3475 finite cell line human CVCL_ZC77 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Donor information: At sampling donor was not affected with frontotemporal dementia and/or amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669192 CVCL_ZC78 ND39258 finite cell line human CVCL_ZC78 CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39258; true Female 35669193 CVCL_ZC79 CS09iHD109-n1 induced pluripotent stem cell human CVCL_ZC79 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[109] (c.52CAG(109)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669194 CVCL_ZC73 CTL161 finite cell line human CVCL_ZC73 CL:0000010 Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669195 CVCL_ZC74 ALS3410v1 finite cell line human CVCL_ZC74 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669196 CVCL_ZC75 ALS3410v2 finite cell line human CVCL_ZC75 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669197 CVCL_ZC76 PRE3441 finite cell line human CVCL_ZC76 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Donor information: At sampling donor was not affected with frontotemporal dementia and/or amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669198 CVCL_ZC60 CWR-R1-AD1 cancer cell line human CVCL_ZC60 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Clone of CWR-R1 that harbors one intact AR gene copy, express full-length AR and exhibit growth stimulation in response to androgens and growth suppression in response to AR antagonists, including enzalutamide (PubMed=24101480) 35669199 CVCL_ZC61 CWR-R1-D567 cancer cell line human CVCL_ZC61 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Using TALEN AR introns 4-7 were deleted This cell line exclusively expresses the ARv567es isoform that skips exons 5 to 7 (PubMed=24101480). 35669200 CVCL_ZC66 22Rv1-undup3 cancer cell line human CVCL_ZC66 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: The 35Kb tandem duplication of exons 2b-3-CE1-3 of AR that drives the expression of AR variant 7 (ARv7) was corrected using TALEN (PubMed=28928128) 35669201 CVCL_ZC67 BL3 BM cancer cell line CVCL_ZC67 CL:0000010 Derived from sampling site: Spleen and thymus. Discontinued: ATCC; CRL-6026; true Male Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 35669202 CVCL_ZC68 FTD142 finite cell line human CVCL_ZC68 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669203 CVCL_ZC69 FTD3009 finite cell line human CVCL_ZC69 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Heterozygous (Direct_author_submission) Miscellaneous: Cell line information from personal communication of Shaw A.C Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669204 CVCL_ZC62 CWR-R1-I567 cancer cell line human CVCL_ZC62 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.His875Tyr (c.2623C>T); ClinVar=VCV000009834; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: Using TALEN AR introns 4-7 were inverted This cell line exclusively expresses the ARv567es isoform that skips exons 5 to 7 (PubMed=24101480). 35669205 CVCL_ZC63 PC-3 ML-Luc cancer cell line human CVCL_ZC63 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from metastatic site: Bone. Male 35669206 CVCL_ZC64 22Rv1-undup1 cancer cell line human CVCL_ZC64 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: The 35Kb tandem duplication of exons 2b-3-CE1-3 of AR that drives the expression of AR variant 7 (ARv7) was corrected using TALEN (PubMed=28928128) 35669207 CVCL_ZC65 22Rv1-undup2 cancer cell line human CVCL_ZC65 CL:0000010 Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Arg1252Ter (c.3754C>T); ClinVar=VCV000167228; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gln3158Ter (c.9472C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gln546Arg (c.1637A>G); ClinVar=VCV000045466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln331Arg (c.992A>G); ClinVar=VCV000421319; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Prostate. Male Characteristics: The 35Kb tandem duplication of exons 2b-3-CE1-3 of AR that drives the expression of AR variant 7 (ARv7) was corrected using TALEN (PubMed=28928128) 35669208 CVCL_ZC50 R1E4 hybridoma Norway rat CVCL_ZC50 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 35669209 CVCL_ZC55 HEK293-mCnr1 transformed cell line human CVCL_ZC55 CL:0000010 Transfected with: MGI; MGI:104615; Cnr1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669210 CVCL_ZC56 HEK293-mCnr2 transformed cell line human CVCL_ZC56 CL:0000010 Transfected with: MGI; MGI:104650; Cnr2 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669211 CVCL_ZC57 HEK293-rCnr1 transformed cell line human CVCL_ZC57 CL:0000010 Transfected with: RGD; 2369; Cnr1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Kerafast; EIU006; true Female 35669212 CVCL_ZC58 HEK293-rCnr2 transformed cell line human CVCL_ZC58 CL:0000010 Transfected with: RGD; 619713; Cnr2 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669213 CVCL_ZC51 U2OS-LacO-I-SceI-TetO cancer cell line human CVCL_ZC51 CL:0000010 Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Cell line designed to probe the role of chromatin condensation in DNA damage response (DDR) using a lac-repressor/operator-tethering system (Kerafast); Characteristics: Contains 2 integrated copies of a construct that consist of a I-Scel endonuclease cut site (I-SceIcs) sandwiched between 256 copies of the lac operator (lacO) and 96 copies of the tet operator (tetO) (Kerafast) 35669214 CVCL_ZC52 N1664A hybridoma house mouse CVCL_ZC52 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:149489; 5,5-dimethyl-1-pyrroline N-oxide (DMPO). 35669215 CVCL_ZC53 HEK293-hCNR1 transformed cell line human CVCL_ZC53 CL:0000010 Transfected with: HGNC; 2159; CNR1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Kerafast; EIU004; true Female 35669216 CVCL_ZC54 HEK293-hCNR2 transformed cell line human CVCL_ZC54 CL:0000010 Transfected with: HGNC; 2160; CNR2 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Kerafast; EIU007; true Female 35669217 CVCL_ZC59 AML14.eos cancer cell line human CVCL_ZC59 CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: Cytokine-induced fully differentiated eosinophilic myelocyte subline of AML14 Proliferates and maintains a differentiated phenotype only if supplemented with CSF2, IL3 and IL5 (Kerafast). 35669218 CVCL_ZC44 4B6/3598/3442#2/4011/4014C1-2 transformed cell line house mouse CVCL_ZC44 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109152; Lig3; Transfected with: UniProtKB; P15042; Escherichia coli ligA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: To generate this cell line the parental cells were transiently transfected with a plasmid pMA4014, which encodes mCherry and FLPo and flow sorted for transfected cells As a result of FLPo-mediated excision of the MTS in front of the bacterial ligA gene, mitochondrial import of ligA in this cell line is inefficient and mtDNA is maintained at a reduced copy number (Kerafast).; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669219 CVCL_ZC45 HEK293T SIRT1 KO transformed cell line human CVCL_ZC45 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 35669220 CVCL_ZC46 RKO SIRT1 KO cancer cell line human CVCL_ZC46 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1; Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Leu452Pro (c.1355T>C); ClinVar=VCV000930524; Zygosity=Heterozygous (from parent cell line). Unspecified 35669221 CVCL_ZC47 23G3 hybridoma Norway rat CVCL_ZC47 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 35669222 CVCL_ZC40 DMBi001-A induced pluripotent stem cell human CVCL_ZC40 From: Department of Medical Biotechnology, Jagiellonian University; Krakow; Poland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669223 CVCL_ZC41 4B6 [Mouse fibroblast] transformed cell line house mouse CVCL_ZC41 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669224 CVCL_ZC42 4B6/3598/3442#2 transformed cell line house mouse CVCL_ZC42 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109152; Lig3; Transfected with: UniProtKB; P15042; Escherichia coli ligA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: Inefficient mitochondrial import of ligA in the absence of Lig3 makes DNA ligase activity limiting for the mtDNA replication and leads to a reduced (10-100 fold) mtDNA copy number (Kerafast); Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669225 CVCL_ZC43 4B6/3598/3442#2/4011C1 transformed cell line house mouse CVCL_ZC43 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109152; Lig3; Transfected with: UniProtKB; P15042; Escherichia coli ligA; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: Unlike the parental cell line, this cell line maintains mtDNA at normal levels This was achieved by introducing into the parental cell line a ligA gene fused to an excisable (FRT/FLPo) mitochondrial targeting sequence (MTS) from human ornithine transcarbamylase.; The resulting cell line expresses two ligA variants: one without- and another with MTS The latter is efficiently imported into mitochondria and therefore normal mtDNA copy number is restored in the transduced cells (Kerafast).; Characteristics: Transfected with reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669226 CVCL_ZC48 B1E3 hybridoma Norway rat CVCL_ZC48 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 35669227 CVCL_ZC49 C12B9 hybridoma Norway rat CVCL_ZC49 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P06336; Mouse immunoglobulin heavy chain epsilon. 35669228 CVCL_ZC33 SDQLCHi025-A induced pluripotent stem cell human CVCL_ZC33 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Ser388Leu (c.1163C>T); ClinVar=VCV000579011; Zygosity=Heterozygous (PubMed=32272370); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Phe4808Asn (c.14422_14423inv) (c.14422_14423delTTinsAA); ClinVar=VCV000478199; Zygosity=Heterozygous (PubMed=32272370) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669229 CVCL_ZC34 SDQLCHi023-A induced pluripotent stem cell human CVCL_ZC34 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669230 CVCL_ZC35 SDQLCHi024-A induced pluripotent stem cell human CVCL_ZC35 From: Qilu Children's Hospital of Shandong University; Jinan; China. CL:0000010 35669231 CVCL_ZC36 SDQLCHi026-A induced pluripotent stem cell human CVCL_ZC36 From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Pro261Leu (c.782C>T); ClinVar=VCV000021058; Zygosity=Heterozygous (PubMed=33882394); Sequence variation: Mutation; HGNC; 3579; FAH; Simple; p.Trp234Leu (c.701G>T); Zygosity=Heterozygous (PubMed=33882394) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669232 CVCL_ZC30 HT TRAF6 KD cancer cell line human CVCL_ZC30 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 12036; TRAF6; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val216Met (c.646G>A); ClinVar=VCV000182965; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Ascites. Male 35669233 CVCL_ZC31 Cyct/Cycs KO transformed cell line house mouse CVCL_ZC31 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:88579; Cyct; Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:88578; Cycs; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung; Breed/subspecies: (cyt ct-/- x cyt cs-/-) x cyt cflox/o. Unspecified 35669234 CVCL_ZC32 UQCRFS1 KO clone 8.5 transformed cell line house mouse CVCL_ZC32 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1913944; Uqcrfs1; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung; Breed/subspecies: 129X1/SvJ x C57BL/6J. 35669235 CVCL_ZC37 WAe009-A-18 embryonic stem cell human CVCL_ZC37 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 15631; TLR7. Female 35669236 CVCL_ZC38 DSY127 embryonic stem cell CVCL_ZC38 CL:0000010 Omics: Transcriptome analysis by RNAseq. Male Group: Non-human primate cell line 35669237 CVCL_ZC39 DSY127-BV8VT1 embryonic stem cell CVCL_ZC39 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; F7GM67; PRDM1; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Male Group: Non-human primate cell line 35669238 CVCL_ZC22 LP [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC22 CL:0000010 35669239 CVCL_ZC23 LR cancer cell line human CVCL_ZC23 CL:0000010 35669240 CVCL_ZC24 LVP-03 cancer cell line human CVCL_ZC24 CL:0000010 35669241 CVCL_ZC25 MS [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC25 CL:0000010 35669242 CVCL_ZC20 HB [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC20 CL:0000010 35669243 CVCL_ZC21 JM [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC21 CL:0000010 35669244 CVCL_ZC26 MZ cancer cell line human CVCL_ZC26 CL:0000010 35669245 CVCL_ZC27 PL [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC27 CL:0000010 35669246 CVCL_ZC28 SF [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC28 CL:0000010 35669247 CVCL_ZC29 WP [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC29 CL:0000010 35669248 CVCL_ZC11 iPS FRDA68 Pi2 induced pluripotent stem cell human CVCL_ZC11 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[570]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1200]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669249 CVCL_ZC12 DLD-1 SIRT1 KO cancer cell line human CVCL_ZC12 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14929; SIRT1. Male 35669250 CVCL_ZC13 DLD-1 SIRT1 Het cancer cell line human CVCL_ZC13 CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 14929; SIRT1. Male 35669251 CVCL_ZC14 Cre4/2941#6 transformed cell line house mouse CVCL_ZC14 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109152; Lig3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: B6.Cg-Tg(CAG-cre/Esr1)5Amc/J x Lig3LoxP. Unspecified Characteristics: The deletion of Lig3 is accompanied by the loss of mitochondrial DNA 35669252 CVCL_ZC10 iPS FRDA68 Pi1 induced pluripotent stem cell human CVCL_ZC10 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[570]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1200]; ClinVar=VCV000561195; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669253 CVCL_ZC19 FN cancer cell line human CVCL_ZC19 CL:0000010 35669254 CVCL_ZC15 HEK293-hGPR55 transformed cell line human CVCL_ZC15 CL:0000010 Transfected with: HGNC; 4511; GPR55; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Discontinued: Kerafast; EIU003; true Female 35669255 CVCL_ZC16 HEK293-mGpr55 transformed cell line human CVCL_ZC16 CL:0000010 Transfected with: MGI; MGI:2685064; Gpr55; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669256 CVCL_ZC17 DBr cancer cell line human CVCL_ZC17 CL:0000010 35669257 CVCL_ZC18 EJ [Human diffuse large B-cell lymphoma] cancer cell line human CVCL_ZC18 CL:0000010 35669258 CVCL_ZC00 FRDA4491 finite cell line human CVCL_ZC00 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Simple; p.Gly130Val (c.389G>T); ClinVar=VCV000003982; Zygosity=Heterozygous (PubMed=27002638); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[559]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638) Derived from sampling site: Arm; skin Cell type=Fibroblast.. 35669259 CVCL_ZC01 FRDA4497 finite cell line human CVCL_ZC01 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[526]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[826]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669260 CVCL_ZC02 FRDA4509 finite cell line human CVCL_ZC02 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[211]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1428]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669261 CVCL_ZC03 FRDA4627 finite cell line human CVCL_ZC03 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[468]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[807]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669262 CVCL_ZC08 FRDA68 finite cell line human CVCL_ZC08 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[570]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1200]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638; PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669263 CVCL_ZC09 FRDA88 finite cell line human CVCL_ZC09 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[422]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[520]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Female 35669264 CVCL_ZC04 FRDA4654 finite cell line human CVCL_ZC04 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[190]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[500]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669265 CVCL_ZC05 FRDA4675 finite cell line human CVCL_ZC05 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[185]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[1130]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669266 CVCL_ZC06 FRDA50 finite cell line human CVCL_ZC06 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[353]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[616]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=27002638) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669267 CVCL_ZC07 FRDA66 finite cell line human CVCL_ZC07 CL:0000010 Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[110]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828); Sequence variation: Mutation; HGNC; 3951; FXN; Repeat_expansion; IVS1 GAA[590]; ClinVar=VCV000561195; Zygosity=Heterozygous (PubMed=29125828) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 35669268 CVCL_ZD90 1321N1-HA-P2Y1 cancer cell line human CVCL_ZD90 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8539; P2RY1 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669269 CVCL_ZD91 1321N1-HA-P2Y2 cancer cell line human CVCL_ZD91 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8541; P2RY2 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669270 CVCL_ZD92 1321N1-HA-P2Y4 cancer cell line human CVCL_ZD92 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8542; P2RY4 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669271 CVCL_ZD93 1321N1-HA-P2Y6 cancer cell line human CVCL_ZD93 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8543; P2RY6 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669272 CVCL_ZD98 FAMRCi008-A induced pluripotent stem cell human CVCL_ZD98 From: Federal Almazov North-West Medical Research Centre; St Petersburg; Russia. CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 35669273 CVCL_ZD99 ICGi021-A induced pluripotent stem cell human CVCL_ZD99 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Siberian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 35669274 CVCL_ZD94 1321N1-HA-P2Y11 cancer cell line human CVCL_ZD94 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 8540; P2RY11 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669275 CVCL_ZD95 1321N1-HA-P2Y12 cancer cell line human CVCL_ZD95 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 18124; P2RY12 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669276 CVCL_ZD96 1321N1-HA-P2Y13 cancer cell line human CVCL_ZD96 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 4537; P2RY13 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669277 CVCL_ZD97 1321N1-HA-P2Y14 cancer cell line human CVCL_ZD97 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; c.1026+1G>T (IVS8+1G>T); ClinVar=VCV000635377; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 16442; P2RY14 (with a N-terminal HA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Brain. Male Problematic cell line: Contaminated Ancestral cell line (U-118MG) has been shown to be a U-138MG derivative. 35669278 CVCL_ZD00 Lucky 1.3 hybridoma house mouse CVCL_ZD00 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q68285; Hepatitis C virus subtype 1b (Korean isolate) (AA 1192-1457; NS3 fragment). 35669279 CVCL_ZD01 Lucky 1.4 hybridoma house mouse CVCL_ZD01 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q68285; Hepatitis C virus subtype 1b (Korean isolate) (AA 1192-1457; NS3 fragment). 35669280 CVCL_ZD02 F09152 finite cell line human CVCL_ZD02 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: Indicated as originating from a 60 year old male donor in LINCS 35669281 CVCL_ZD07 Mel 00.08 cancer cell line human CVCL_ZD07 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455; PubMed=25538140) Omics: Transcriptome analysis by RNAseq. 35669282 CVCL_ZD08 Mel 04.07 cancer cell line human CVCL_ZD08 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455; PubMed=25538140). 35669283 CVCL_ZD09 Mel 93.03 cancer cell line human CVCL_ZD09 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455; PubMed=25538140). 35669284 CVCL_ZD03 Mel 04.01 cancer cell line human CVCL_ZD03 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455; PubMed=25538140); Sequence variation: Mutation; HGNC; 1424; CAD; Simple; p.Arg1854Gln (c.5561G>A); ClinVar=VCV001481207; Zygosity=Heterozygous (PubMed=27350335); Sequence variation: Mutation; HGNC; 3330; EML1; Simple; p.Arg64Trp (c.190C>T); Zygosity=Heterozygous (PubMed=27350335); Sequence variation: Mutation; HGNC; 8761; PDCD10; Simple; p.Pro28Ser (c.82C>T); Zygosity=Homozygous (PubMed=27350335); Sequence variation: Mutation; HGNC; 30400; SEMA3G; Simple; p.Arg300Cys (c.898C>T); Zygosity=Heterozygous (PubMed=27350335) Omics: Deep phosphoproteome analysis; Omics: Deep proteome analysis. Male 35669285 CVCL_ZD04 Mel 05.18 cancer cell line human CVCL_ZD04 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 29676; PUM3; Simple; p.Pro451Leu (c.1352C>T); Zygosity=Unspecified (PubMed=27350335); Sequence variation: Mutation; HGNC; 10330; RPL28; Simple; p.Ser76Phe (c.227C>T); Zygosity=Heterozygous (PubMed=27350335) Derived from metastatic site: Hypodermis. Male 35669286 CVCL_ZD05 Mel 06.07 cancer cell line human CVCL_ZD05 CL:0000010 Sequence variation: Mutation; HGNC; 29676; PUM3; Simple; p.Pro451Leu (c.1352C>T); Zygosity=Unspecified (PubMed=27350335) Derived from metastatic site: Brain. Male 35669287 CVCL_ZD06 Mel 12.07 cancer cell line human CVCL_ZD06 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1424; CAD; Simple; p.Arg1854Gln (c.5561G>A); ClinVar=VCV001481207; Zygosity=Heterozygous (PubMed=27350335); Sequence variation: Mutation; HGNC; 3330; EML1; Simple; p.Arg64Trp (c.190C>T); Zygosity=Heterozygous (PubMed=27350335); Sequence variation: Mutation; HGNC; 8761; PDCD10; Simple; p.Pro28Ser (c.82C>T); Zygosity=Homozygous (PubMed=27350335) Derived from metastatic site: Hypodermis. Male 35669288 CVCL_ZD80 MEF Actbf/f-Actg1f/f transformed cell line house mouse CVCL_ZD80 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Actb and Actg1 can be both knocked-out after exogenous expression of Cre recombinase via Cre-Lox recombination 35669289 CVCL_ZD81 MEF Actg1f/f transformed cell line house mouse CVCL_ZD81 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Actg1 can be knocked-out after exogenous expression of Cre recombinase via Cre-Lox recombination 35669290 CVCL_ZD82 CD36E transformed cell line human CVCL_ZD82 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Peripheral blood Cell type=Erythroid progenitor cell.. Discontinued: ABM; T0136; probable Male Characteristics: Potentially useful for culturing Plasmodium vivax and other species of malaria; useful for hematological disease applications involving red blood cells or red blood cell precursors (Kerafast) Doubling time: 3-4 days (PubMed=20696208) Caution: ABM T0136 wrongly indicated this cell line to originate from mouse 35669291 CVCL_ZD87 293T ERR reporter transformed cell line human CVCL_ZD87 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a construct with a pleiotropic nuclear receptor enhancer MHRE that controls the expression of GFP and luciferase (AAB-GFP-Luc) 35669292 CVCL_ZD88 293T PCC/ERR reporter transformed cell line human CVCL_ZD88 CL:0000010 Transfected with: HGNC; 3471; ESRRA; Transfected with: HGNC; 9237; PPARGC1A; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a construct with a pleiotropic nuclear receptor enhancer MHRE that controls the expression of GFP and luciferase (AAB-GFP-Luc) 35669293 CVCL_ZD89 RAW 264.7 shRNA-RSK2 cancer cell line house mouse CVCL_ZD89 CL:0000010 Knockout cell: Method=shRNA knockdown; MGI; MGI:104557; Rps6ka3 Transformant: Abelson mouse leukemia virus (AbMuLV)(NCBI-Taxonomy; 11788); Derived from sampling site: Ascites Cell type=Macrophage.. Male 35669294 CVCL_ZD83 imSVF transformed cell line house mouse CVCL_ZD83 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Inguinal fat pad; adipose tissue. Male Characteristics: Model cell line for adipocyte biology Can be used to study adipogenesis marker expression and trans-differentiation potential. Can develop both white and brown-like adipocyte (brite or beige cell) phenotypes (Kerafast). 35669295 CVCL_ZD84 207TAg transformed cell line house mouse CVCL_ZD84 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109352; Ung Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 35669296 CVCL_ZD85 210TAg transformed cell line house mouse CVCL_ZD85 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:109352; Ung Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767). Unspecified 35669297 CVCL_ZD86 293T-PGC transformed cell line human CVCL_ZD86 CL:0000010 Transfected with: HGNC; 9237; PPARGC1A; Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses a construct with a pleiotropic nuclear receptor enhancer MHRE that controls the expression of luciferase (AAB-Luc) 35669298 CVCL_ZD70 NIH 3T3 Met-H1104D spontaneously immortalized cell line house mouse CVCL_ZD70 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.His1104Asp); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669299 CVCL_ZD71 NIH 3T3 Met-L1193V spontaneously immortalized cell line house mouse CVCL_ZD71 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Leu1193Val); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669300 CVCL_ZD76 NIH 3T3 Met-V1218I spontaneously immortalized cell line house mouse CVCL_ZD76 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Val1218Ile); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669301 CVCL_ZD77 NIH 3T3 Met-Y1228D spontaneously immortalized cell line house mouse CVCL_ZD77 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Tyr1228Asp); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669302 CVCL_ZD78 NIH 3T3 Met-Y1228H spontaneously immortalized cell line house mouse CVCL_ZD78 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Tyr1228His); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669303 CVCL_ZD79 MEF Actbf/f transformed cell line house mouse CVCL_ZD79 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Cell type=Fibroblast. Unspecified Characteristics: Actb can be knocked-out after exogenous expression of Cre recombinase via Cre-Lox recombination 35669304 CVCL_ZD72 NIH 3T3 Met-M1129T spontaneously immortalized cell line house mouse CVCL_ZD72 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Met1129Thr); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669305 CVCL_ZD73 NIH 3T3 Met-M1248T spontaneously immortalized cell line house mouse CVCL_ZD73 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Met1248Thr); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669306 CVCL_ZD74 NIH 3T3 Met-V1090I spontaneously immortalized cell line house mouse CVCL_ZD74 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Val1090Ile); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669307 CVCL_ZD75 NIH 3T3 Met-V1186L spontaneously immortalized cell line house mouse CVCL_ZD75 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.Val1186Leu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669308 CVCL_ZD60 MS-68 transformed cell line human CVCL_ZD60 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1) [pHTLV-X1MT](NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 35669309 CVCL_ZD65 CS97iHD180-n2 induced pluripotent stem cell human CVCL_ZD65 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669310 CVCL_ZD66 CS97iHD180-n3 induced pluripotent stem cell human CVCL_ZD66 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669311 CVCL_ZD67 NIH 3T3 Met-WT spontaneously immortalized cell line house mouse CVCL_ZD67 CL:0000010 Transfected with: MGI; MGI:96969; Met; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669312 CVCL_ZD68 NIH 3T3 Met-H1092L spontaneously immortalized cell line house mouse CVCL_ZD68 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.His1092Leu); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669313 CVCL_ZD61 MS-74 transformed cell line human CVCL_ZD61 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1) [pHTLV-X1MT](NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 35669314 CVCL_ZD62 MS-9 transformed cell line human CVCL_ZD62 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1) [pHTLV-X1MT](NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified Characteristics: IL2 dependent 35669315 CVCL_ZD63 HEK293-CAGA transformed cell line human CVCL_ZD63 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Robustly responds to signaling by activin and TGF-beta class ligands and employed in an assay measuring inhibition of ligand activity (PubMed=23543431); Characteristics: Luciferase reporter gene expression is under the control of a promoter containing a Smad binding element (SBE) (CAGA(12)) 35669316 CVCL_ZD64 CS97iHD180-n1 induced pluripotent stem cell human CVCL_ZD64 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[179] (c.52CAG(179)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669317 CVCL_ZD69 NIH 3T3 Met-H1092Y spontaneously immortalized cell line house mouse CVCL_ZD69 CL:0000010 Transfected with: MGI; MGI:96969; Met (with p.His1092Tyr); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male 35669318 CVCL_ZD54 IR transformed cell line human CVCL_ZD54 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669319 CVCL_ZD55 Y03 transformed cell line human CVCL_ZD55 CL:0000010 Population: Mexican; Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669320 CVCL_ZD56 Y06 transformed cell line human CVCL_ZD56 CL:0000010 Population: Mexican; Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669321 CVCL_ZD57 Y17 transformed cell line human CVCL_ZD57 CL:0000010 Population: Mexican; Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669322 CVCL_ZD50 H1B transformed cell line human CVCL_ZD50 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669323 CVCL_ZD51 H1H transformed cell line human CVCL_ZD51 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669324 CVCL_ZD52 H2A transformed cell line human CVCL_ZD52 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669325 CVCL_ZD53 H2E transformed cell line human CVCL_ZD53 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669326 CVCL_ZD58 DCH-4 transformed cell line human CVCL_ZD58 CL:0000010 Transfected with: UniProtKB; P42212; EYFP (modified GFP at L-46, 64-LG-65, L-68, A-72, T-153, A-163, G-175, Y-203 and L-231) Transformant: Human T-lymphotropic virus 1 (HTLV-1) [Tax](NCBI-Taxonomy; 11908); Derived from sampling site: Cell type=CD4-positive helper T cell. Characteristics: Produced by lentivirus tranduction of a vector encoding an HTLV-1 Tax-EYFP fusion 35669327 CVCL_ZD59 MS-64 transformed cell line human CVCL_ZD59 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1) [pHTLV-X1MT](NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Unspecified 35669328 CVCL_ZD43 1996 transformed cell line human CVCL_ZD43 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669329 CVCL_ZD44 3614 transformed cell line human CVCL_ZD44 CL:0000010 Population: Peruvian; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669330 CVCL_ZD45 3669 transformed cell line human CVCL_ZD45 CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669331 CVCL_ZD46 A212 transformed cell line human CVCL_ZD46 CL:0000010 Population: Egyptian; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669332 CVCL_ZD40 Ms-19 cancer cell line human CVCL_ZD40 CL:0000010 Population: Japanese. Unspecified 35669333 CVCL_ZD41 1657 transformed cell line human CVCL_ZD41 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Donor information: Established from a patient suffering from adult T-cell leukemia/lymphoma (ATLL); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669334 CVCL_ZD42 1742 transformed cell line human CVCL_ZD42 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669335 CVCL_ZD47 EG [Human HTLV-1 transformed] transformed cell line human CVCL_ZD47 CL:0000010 Population: Caribbean; Jamaican; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 35669336 CVCL_ZD48 FS transformed cell line human CVCL_ZD48 CL:0000010 Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: IL2 dependent 35669338 CVCL_ZD32 MOC1 cancer cell line house mouse CVCL_ZD32 CL:0000010 Sequence variation: Mutation; MGI; MGI:96224; Hras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Unspecified (PubMed=22086849); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Val170Glu; Zygosity=Unspecified (PubMed=24668645) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Indolent growth phenotype 35669339 CVCL_ZD33 MOC2 cancer cell line house mouse CVCL_ZD33 CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>T); Zygosity=Unspecified (PubMed=22086849); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Glu225Ter; Zygosity=Unspecified (PubMed=24668645) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6 Cxcr3-/-. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Agressive growth phenotype 35669340 CVCL_ZD34 MOC2-7 cancer cell line house mouse CVCL_ZD34 CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>T); Zygosity=Unspecified (PubMed=22086849); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Glu225Ter; Zygosity=Unspecified (from parent cell line) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6 Cxcr3-/-. Omics: Transcriptome analysis by microarray Female Problematic cell line: Contaminated Shown to be a MOC2 derivative (PubMed=24668645). Originally (PubMed=22086849) thought to be independently derived and was named MOC7. Was renamed MOC2-7 when shown to be a derivative of MOC2. 35669341 CVCL_ZD35 MOC2-10 cancer cell line house mouse CVCL_ZD35 CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>T); Zygosity=Unspecified (PubMed=22086849); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Glu225Ter; Zygosity=Unspecified (PubMed=24668645) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6 Cxcr3-/-. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00594 Problematic cell line: Contaminated Shown to be a MOC2 derivative (PubMed=24668645). Originally (PubMed=22086849) thought to be independently derived and was named MOC10. Was renamed MOC2-10 when shown to be a derivative of MOC2. 35669342 CVCL_ZD30 MLEC-Sulf1f/f;Sulf2f/f transformed cell line house mouse CVCL_ZD30 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Sulf1f/f;Sulf2f/f x C57BL/6J. Unspecified 35669343 CVCL_ZD31 MLEC-Sulf1-/-;Sulf2-/- transformed cell line house mouse CVCL_ZD31 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:2138563; Sulf1; Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1919293; Sulf2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Sulf1f/f;Sulf2f/f x C57BL/6J. Unspecified 35669344 CVCL_ZD36 MOC22 cancer cell line house mouse CVCL_ZD36 CL:0000010 Sequence variation: Mutation; MGI; MGI:96224; Hras; Simple; p.Gln61Leu (c.182A>T); Zygosity=Unspecified (PubMed=22086849); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Thr122Pro; Zygosity=Unspecified (PubMed=24668645); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Lys384Ter; Zygosity=Unspecified (PubMed=24668645) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Characteristics: Indolent growth phenotype 35669345 CVCL_ZD37 MOC23 cancer cell line house mouse CVCL_ZD37 CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Breed/subspecies: C57BL/6. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female 35669346 CVCL_ZD38 MOC2LN cancer cell line house mouse CVCL_ZD38 CL:0000010 Sequence variation: Mutation; MGI; MGI:96680; Kras; Simple; p.Gln61His (c.183A>T); Zygosity=Unspecified (from autologous cell line MOC2); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Glu225Ter; Zygosity=Unspecified (from autologous cell line MOC2) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from metastatic site: Lymph node; Breed/subspecies: C57BL/6 Cxcr3-/-. Omics: Transcriptome analysis by microarray Female 35669347 CVCL_ZD39 Ms-10 cancer cell line human CVCL_ZD39 CL:0000010 Population: Japanese. Unspecified 35669348 CVCL_ZD21 MLEC-Hs3st4-/- transformed cell line house mouse CVCL_ZD21 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1333792; Hs3st4 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669349 CVCL_ZD22 MLEC-Hs6st1f/f transformed cell line house mouse CVCL_ZD22 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs6st1f/f x C57BL/6J. Unspecified 35669350 CVCL_ZD23 MLEC-Hs6st1f/f;Hs6st2-/- transformed cell line house mouse CVCL_ZD23 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:1354959; Hs6st2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs2st1f/f;Hs6st2-/- x C57BL/6J. Unspecified 35669351 CVCL_ZD24 MLEC-Hs6st1-/- transformed cell line house mouse CVCL_ZD24 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1354958; Hs6st1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs2st1f/f x C57BL/6J. Unspecified 35669352 CVCL_ZD20 MLEC-Hs3st1-/-;Hs3st4-/- transformed cell line house mouse CVCL_ZD20 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1201606; Hs3st1; Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1333792; Hs3st4 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669353 CVCL_ZD29 MLEC-Ndst1-/-;Ndst2-/- transformed cell line house mouse CVCL_ZD29 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:104719; Ndst1; Knockout cell: Method=KO mouse; MGI; MGI:97040; Ndst2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f;Ndst2-/- x C57BL/6J. Unspecified 35669354 CVCL_ZD25 MLEC-Hs6st1-/-;Hs6st2-/- transformed cell line house mouse CVCL_ZD25 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1354958; Hs6st1; Knockout cell: Method=KO mouse; MGI; MGI:1354959; Hs6st2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs2st1f/f;Hs6st2-/- x C57BL/6J. Unspecified 35669355 CVCL_ZD26 MLEC-Ndst1f/f transformed cell line house mouse CVCL_ZD26 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669356 CVCL_ZD27 MLEC-Ndst1f/f;Ndst2-/- transformed cell line house mouse CVCL_ZD27 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:97040; Ndst2 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f;Ndst2-/- x C57BL/6J. Unspecified 35669357 CVCL_ZD28 MLEC-Ndst1-/- transformed cell line house mouse CVCL_ZD28 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:104719; Ndst1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669358 CVCL_ZD10 Mel 06.04 cancer cell line human CVCL_ZD10 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455). 35669359 CVCL_ZD11 Mel 07.16 cancer cell line human CVCL_ZD11 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455). 35669360 CVCL_ZD12 Mel 93.15.2 cancer cell line human CVCL_ZD12 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23685455). 35669361 CVCL_ZD13 Mel 13.03 cancer cell line human CVCL_ZD13 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 35669362 CVCL_ZD18 MLEC-Glce-/- transformed cell line house mouse CVCL_ZD18 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:2136405; Glce Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669363 CVCL_ZD19 MLEC-Hs3st1-/- transformed cell line house mouse CVCL_ZD19 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:1201606; Hs3st1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Ndst1f/f x C57BL/6J. Unspecified 35669364 CVCL_ZD14 Mel 93.05 cancer cell line human CVCL_ZD14 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 35669365 CVCL_ZD15 Mel 95.23 cancer cell line human CVCL_ZD15 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Omics: Transcriptome analysis by RNAseq. 35669366 CVCL_ZD16 MLEC-Hs2st1f/f transformed cell line house mouse CVCL_ZD16 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs2st1f/f x C57BL/6J. Unspecified 35669367 CVCL_ZD17 MLEC-Hs2st1-/- transformed cell line house mouse CVCL_ZD17 CL:0000010 Knockout cell: Method=Floxing/Cre recombination; MGI; MGI:1346049; Hs2st1 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Lung Cell type=Lung endothelial cell.; Breed/subspecies: Hs2st1f/f x C57BL/6J. Unspecified 35669368 CVCL_ZE20 MUSIi012-A-2 induced pluripotent stem cell human CVCL_ZE20 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16262; YAP1 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 35669369 CVCL_ZE21 DRCF spontaneously immortalized cell line zebrafish CVCL_ZE21 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Wild strain from Brahmaputra river. Unspecified Characteristics: Grows at temperatures ranging from 20 to 32 Celsius The highest growth rate is obtained at 28 Celsius (PubMed=32232614). Doubling time: 36 hours, at 25th passage (PubMed=32232614) Group: Fish cell line 35669370 CVCL_ZE22 A2780-CBDCA-R cancer cell line human CVCL_ZE22 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from sampling site: Ovary. Omics: Transcriptome analysis by RNAseq Female 35669371 CVCL_ZE23 USTCi001-A induced pluripotent stem cell human CVCL_ZE23 From: School of Life Sciences, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Gln1923Arg (c.5768A>G); Zygosity=Heterozygous (PubMed=32335389) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669372 CVCL_ZE28 EB11 transformed cell line human CVCL_ZE28 CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Glu475Gly (c.1424A>G); ClinVar=VCV000014638; Zygosity=Heterozygous (PubMed=21490615); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 35669373 CVCL_ZE29 EB12 transformed cell line human CVCL_ZE29 CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Glu475Gly (c.1424A>G); ClinVar=VCV000014638; Zygosity=Heterozygous (PubMed=21490615); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 35669374 CVCL_ZE24 EB21 transformed cell line human CVCL_ZE24 CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Val186Leu (c.556G>T); ClinVar=VCV000014652; Zygosity=Heterozygous (PubMed=19157792); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 35669375 CVCL_ZE25 EB22 transformed cell line human CVCL_ZE25 CL:0000010 Sequence variation: Mutation; HGNC; 6442; KRT5; Simple; p.Val186Leu (c.556G>T); ClinVar=VCV000014652; Zygosity=Heterozygous (PubMed=19157792); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 35669376 CVCL_ZE26 NKc11 transformed cell line human CVCL_ZE26 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 35669377 CVCL_ZE27 NKc12 transformed cell line human CVCL_ZE27 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Male 35669378 CVCL_ZE10 FDC-P1 KIT N822K factor-dependent cell line house mouse CVCL_ZE10 CL:0000010 Transfected with: HGNC; 6342; KIT (with p.Asn822Lys); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Bone marrow; Breed/subspecies: DBA/2. Characteristics: IL3 dependent 35669379 CVCL_ZE11 IPAM 3D4/21/CD163 transformed cell line pig CVCL_ZE11 CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus type 2 (PRRSV-2) 35669380 CVCL_ZE12 mPAM-CD163-GFP transformed cell line pig CVCL_ZE12 CL:0000010 Transfected with: UniProtKB; E1AQW7; Pig CD163; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Lung; alveolus Cell type=Alveolar macrophage.; Breed/subspecies: Landrace. Unspecified Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus type 2 (PRRSV-2) strains JXA1 and SD1 (PubMed=32402349) 35669381 CVCL_ZE17 PUC-GBC3 cancer cell line human CVCL_ZE17 CL:0000010 Population: Chilean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Male Doubling time: 44 hours (PubMed=32293552) 35669382 CVCL_ZE18 CypCa-CaudalFin spontaneously immortalized cell line CVCL_ZE18 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the cell line description Derived from sampling site: Caudal fin. Unspecified Group: Fish cell line 35669383 CVCL_ZE19 CypCa-Gill spontaneously immortalized cell line CVCL_ZE19 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the cell line description Derived from sampling site: Gill. Unspecified Group: Fish cell line 35669384 CVCL_ZE13 NCC-ssRMS1-C1 cancer cell line human CVCL_ZE13 CL:0000010 Sequence variation: Mutation; HGNC; 7611; MYOD1; Simple; p.Leu122Arg (c.365T>G); Zygosity=Unspecified (PubMed=32300959) Population: Japanese; Derived from sampling site: Thigh; skeletal muscle. Omics: SNP array analysis Female Doubling time: ~40 hours (PubMed=32300959) Part of: NCC sarcoma cell line panel 35669385 CVCL_ZE14 HPS3887 induced pluripotent stem cell human CVCL_ZE14 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Duplication; Zygosity=Heterozygous (PubMed=32413791) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669386 CVCL_ZE15 PUC-GBC1 cancer cell line human CVCL_ZE15 CL:0000010 Population: Chilean; Karyotypic information: Has lost chromosome X; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Male Doubling time: 60 hours (PubMed=32293552) 35669387 CVCL_ZE16 PUC-GBC2 cancer cell line human CVCL_ZE16 CL:0000010 Population: Chilean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by RNAseq Male Doubling time: 36 hours (PubMed=32293552) 35669388 CVCL_ZE00 ICGi020-A induced pluripotent stem cell human CVCL_ZE00 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (PubMed=32738633) Miscellaneous: While Wilson disease is autosomal recessive no other ATP7B mutation was found in the donor of this cell line Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669389 CVCL_ZE01 ICGi020-B induced pluripotent stem cell human CVCL_ZE01 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Heterozygous (PubMed=32738633) Miscellaneous: While Wilson disease is autosomal recessive no other ATP7B mutation was found in the donor of this cell line Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669390 CVCL_ZE06 NIHTVBi005-A induced pluripotent stem cell human CVCL_ZE06 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg169Cys (c.505C>T); ClinVar=VCV000009219; Zygosity=Heterozygous (PubMed=32344328) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35669391 CVCL_ZE07 NIHTVBi007-A induced pluripotent stem cell human CVCL_ZE07 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Cys222Tyr (c.665G>A); ClinVar=VCV000447867; Zygosity=Heterozygous (PubMed=32344328) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35669392 CVCL_ZE08 NIHTVBi008-A induced pluripotent stem cell human CVCL_ZE08 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Cys455Tyr (c.1364G>A); ClinVar=VCV000447784; Zygosity=Heterozygous (PubMed=32344328) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669393 CVCL_ZE09 NIHTVBi015-A induced pluripotent stem cell human CVCL_ZE09 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple; p.Ala111Leufs*7 (c.331delG); Zygosity=Homozygous (PubMed=34419745) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 35669394 CVCL_ZE02 ICGi022-A induced pluripotent stem cell human CVCL_ZE02 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Siberian; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 35669395 CVCL_ZE03 GIBHi002-A-3 induced pluripotent stem cell human CVCL_ZE03 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Population: Caucasian; Derived from sampling site: Urine. Female 35669396 CVCL_ZE04 GIBHi002-A-4 induced pluripotent stem cell human CVCL_ZE04 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Population: Caucasian; Derived from sampling site: Urine. Female 35669397 CVCL_ZE05 NIHTVBi004-A induced pluripotent stem cell human CVCL_ZE05 From: National Heart, Lung, and Blood Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 7883; NOTCH3; Simple; p.Arg332Cys (c.994C>T); ClinVar=VCV000009224; Zygosity=Heterozygous (PubMed=32344328) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669399 CVCL_ZE91 hSG-Bmi1 finite cell line human CVCL_ZE91 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Larynx; subglottis. Male Caution: Stated to be immortalized but it is not clear from the paper if they are really immortal or have a extended life time 35669400 CVCL_ZE92 hV-Bmi1 finite cell line human CVCL_ZE92 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Larynx; ventricle. Male Caution: Stated to be immortalized but it is not clear from the paper if they are really immortal or have a extended life time 35669401 CVCL_ZE97 NARO-Lydi spontaneously immortalized cell line CVCL_ZE97 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 2.49 days (PubMed=32246241) Group: Insect cell line 35669402 CVCL_ZE98 NARO-Thol spontaneously immortalized cell line CVCL_ZE98 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 1.37 days (PubMed=32246241) Group: Insect cell line 35669403 CVCL_ZE99 CHO-K1 UA10 spontaneously immortalized cell line CVCL_ZE99 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3I1V4; Atic; Knockout cell: Method=CRISPR/Cas9; UniProtKB; G3GSP0; Umps Derived from sampling site: Ovary. Female Characteristics: Doubly auxotrophic; deficient in 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC) and uridine monophosphate synthetase (UMPS), respectively disrupting the purine and pyrimidine de novo synthesis pathways; Characteristics: Useful for the production of recombinant monoclonal antibodies as it rovides a rapid and efficient selection method for the serial or simultaneous transfer of genes for multiple polypeptides of choice into the cells using readily available purine- and pyrimidine-free commercial media 35669404 CVCL_ZE93 NARO-Cehy spontaneously immortalized cell line CVCL_ZE93 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 1.03 days (PubMed=32246241) Group: Insect cell line 35669405 CVCL_ZE94 NARO-Cyku spontaneously immortalized cell line CVCL_ZE94 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 1.53 days (PubMed=32246241) Group: Insect cell line 35669406 CVCL_ZE95 NARO-Haba spontaneously immortalized cell line CVCL_ZE95 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 1.92 days (PubMed=32246241) Group: Insect cell line 35669407 CVCL_ZE96 NARO-Hycu spontaneously immortalized cell line CVCL_ZE96 CL:0000010 Derived from sampling site: Fat body. Unspecified Doubling time: 1.61 days (PubMed=32246241) Group: Insect cell line 35669408 CVCL_ZE80 LuMa cancer cell line dog CVCL_ZE80 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Male Characteristics: Metastasizes to the appendicular and axial skeleton after injection into the left cardiac ventricle in mice and produce osteoblastic bone metastases Doubling time: 30.8 +- 1.4 hours (PubMed=32348616) 35669409 CVCL_ZE81 LuMa-Luc cancer cell line dog CVCL_ZE81 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Male 35669410 CVCL_ZE86 HNMUi001-A induced pluripotent stem cell human CVCL_ZE86 From: Hainan Medical University; Haikou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Chorionic villus. Female 35669411 CVCL_ZE87 IBMS-iPSC-014-C induced pluripotent stem cell human CVCL_ZE87 From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 9009; PKD2; Simple_corrected; p.Arg803Ter (c.2407C>T); ClinVar=VCV000618321; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32361310) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Female 35669412 CVCL_ZE88 46C-Dip2a KO embryonic stem cell house mouse CVCL_ZE88 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:2385920; Dip2a; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Breed/subspecies: 129P2/Ola. Male Characteristics: Using CRISPR/Cas9 exon 8 of Dip2a was replaced by a PGK-Puro-P2A-mCherry construct; Characteristics: Expresses GFP under the control of the Sox1 promoter 35669413 CVCL_ZE89 PM-LGSOC-01 luc-EGFP cancer cell line human CVCL_ZE89 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=32317693); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Peritoneum. Female 35669414 CVCL_ZE82 BMA19 cancer cell line human CVCL_ZE82 CL:0000010 Sequence variation: Gene fusion; HGNC; 591; BIRC3 + HGNC; 6819; MALT1; Name(s)=BIRC3-MALT1, API2-MALT1 (PubMed=32348592); Sequence variation: Mutation; HGNC; 17575; SPEN; Simple; p.Arg267Ser (c.801G>C); Zygosity=Unspecified (PubMed=32348592) Derived from metastatic site: Ascites. Omics: Deep exome analysis Male Doubling time: 30-40 hours (PubMed=32348592) 35669415 CVCL_ZE83 CT1258-FusionRed cancer cell line dog CVCL_ZE83 CL:0000010 Transfected with: FusionRed, a bright red fluorescent protein derived from eqFP578; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Briard. Male Doubling time: 28.6 hours (PubMed=32368185) 35669416 CVCL_ZE84 CT1258-mKate2C cancer cell line dog CVCL_ZE84 CL:0000010 Transfected with: mKate2, a bright red fluorescent protein derived from eqFP578; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Briard. Male Doubling time: 29.5 hours (PubMed=32368185) 35669417 CVCL_ZE85 CT1258-TurboFP650 cancer cell line dog CVCL_ZE85 CL:0000010 Transfected with: UniProtKB; J9PBR7; Entacmaea quadricolor far-red fluorescent protein eqFP650; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Prostate; Breed/subspecies: Briard. Male Doubling time: 27.2 hours (PubMed=32368185) 35669418 CVCL_ZE70 HPS0451 induced pluripotent stem cell human CVCL_ZE70 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (from autologous cell line HPS0450) Population: Japanese; Derived from sampling site: Peripheral blood. Male 35669419 CVCL_ZE75 HR-1 cancer cell line human CVCL_ZE75 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 17.6 hours (PubMed=3791243) 35669420 CVCL_ZE76 FU-SFT8611 cancer cell line human CVCL_ZE76 CL:0000010 Population: Japanese; Derived from metastatic site: Left axillary lymph node. Male Doubling time: ~50 hours (PubMed=17088980) 35669421 CVCL_ZE77 FU-SFT8710 cancer cell line human CVCL_ZE77 CL:0000010 Population: Japanese; Derived from sampling site: Peripheral nervous system; sciatic nerve. Female Doubling time: ~68 hours (PubMed=17088980) 35669422 CVCL_ZE78 FU-SFT9817 cancer cell line human CVCL_ZE78 CL:0000010 Population: Japanese; Derived from sampling site: Thigh. Female Doubling time: ~19 hours (PubMed=17088980) 35669423 CVCL_ZE71 UMGi145-A induced pluripotent stem cell human CVCL_ZE71 From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669424 CVCL_ZE72 UMGi146-A induced pluripotent stem cell human CVCL_ZE72 From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669425 CVCL_ZE73 MUSIi012-A-3 induced pluripotent stem cell human CVCL_ZE73 From: Faculty of Medicine Siriraj Hospital, Mahidol University; Bangkok; Thailand CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6514; LATS1 Population: Southeast Asian; Thai; Derived from sampling site: Peripheral blood. Female 35669426 CVCL_ZE74 HR cancer cell line human CVCL_ZE74 CL:0000010 Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: 13.2 hours (PubMed=3791243); 19 hours (PubMed=6541042) 35669427 CVCL_ZE79 NCC-DFSP3-C1 cancer cell line human CVCL_ZE79 CL:0000010 Sequence variation: Gene fusion; HGNC; 2197; COL1A1 + HGNC; 8800; PDGFB; Name(s)=COL1A1-PDGFB (PubMed=32356243) Population: Japanese; Derived from metastatic site: Thigh. Omics: SNP array analysis Female Doubling time: ~28 hours (PubMed=32356243) Part of: NCC sarcoma cell line panel 35669428 CVCL_ZE64 SNU-2621B cancer cell line human CVCL_ZE64 CL:0000010 Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Arg74Ter (c.220C>T); ClinVar=VCV000239891; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Arg800Alafs*16 (c.2398delC); ClinVar=VCV000156497; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (PubMed=32321971); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gly163Ser (c.487G>A); Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe328fs (c.980_981dupAT); Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from metastatic site: Ascites. Omics: Deep exome analysis Male Doubling time: 1.346 days (PubMed=32321971); Microsatellite instability: Instable (MSI) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669429 CVCL_ZE65 SNU-NCC-376 cancer cell line human CVCL_ZE65 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 3.147 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669430 CVCL_ZE66 SNU-NCC-377 cancer cell line human CVCL_ZE66 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 2.449 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669431 CVCL_ZE67 SNU-NCC-61 cancer cell line human CVCL_ZE67 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu11Gln (c.31G>C); ClinVar=VCV000041723; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 3.283 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669432 CVCL_ZE60 SNU-2431 cancer cell line human CVCL_ZE60 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln442Ter (c.1324C>T); ClinVar=VCV000529907; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 5.759 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669433 CVCL_ZE61 SNU-2465 cancer cell line human CVCL_ZE61 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Female Doubling time: 2.133 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669434 CVCL_ZE62 SNU-2493 cancer cell line human CVCL_ZE62 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser106Arg (c.318C>G); ClinVar=VCV000492752; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Female Doubling time: 2.113 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669435 CVCL_ZE63 SNU-2536C cancer cell line human CVCL_ZE63 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from metastatic site: Liver. Omics: Deep exome analysis Male Doubling time: 3.305 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669436 CVCL_ZE68 HPS0449 induced pluripotent stem cell human CVCL_ZE68 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (from autologous cell line HPS0450) Population: Japanese; Derived from sampling site: Peripheral blood. Male 35669437 CVCL_ZE69 HPS0450 induced pluripotent stem cell human CVCL_ZE69 CL:0000010 Sequence variation: Gene deletion; HGNC; 7905; NPHP1; Zygosity=Homozygous (PubMed=32361464) Population: Japanese; Derived from sampling site: Peripheral blood. Male 35669438 CVCL_ZE53 SNU-2297 cancer cell line human CVCL_ZE53 CL:0000010 Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gly386Asp (c.1157G>A); ClinVar=VCV000008545; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 1.721 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669439 CVCL_ZE54 SNU-2303 cancer cell line human CVCL_ZE54 CL:0000010 Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Leu574Pro (c.1721T>C); ClinVar=VCV000089846; Zygosity=Heterozygous (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 1.982 days (PubMed=32321971); Microsatellite instability: Instable (MSI) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669440 CVCL_ZE55 SNU-2353B cancer cell line human CVCL_ZE55 CL:0000010 Population: Korean; Derived from metastatic site: Lymph node. Omics: Deep exome analysis Male Doubling time: 3.157 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669441 CVCL_ZE56 SNU-2359 cancer cell line human CVCL_ZE56 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Phe (c.527G>T); ClinVar=VCV000376569; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 2.937 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669442 CVCL_ZE50 SNU-1566 cancer cell line human CVCL_ZE50 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Heterozygous (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 2.856 days (PubMed=32321971); Microsatellite instability: Instable (MSI) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669443 CVCL_ZE51 SNU-1983 cancer cell line human CVCL_ZE51 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Trp666Ter (c.1997G>A); ClinVar=VCV000265246; Zygosity=Heterozygous (PubMed=32321971); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys164Argfs*3 (c.491delA); ClinVar=VCV000189448; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Trp146Ter (c.437G>A); ClinVar=VCV000634785; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 1.474 days (PubMed=32321971); Microsatellite instability: Instable (MSI) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669444 CVCL_ZE52 SNU-2172 cancer cell line human CVCL_ZE52 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Colon. Omics: Deep exome analysis Male Doubling time: 2.122 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669445 CVCL_ZE57 SNU-2373B cancer cell line human CVCL_ZE57 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val147Asp (c.440T>A); ClinVar=VCV001351017; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from metastatic site: Liver. Omics: Deep exome analysis Male Doubling time: 2.335 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669446 CVCL_ZE58 SNU-2407 cancer cell line human CVCL_ZE58 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from sampling site: Rectum. Omics: Deep exome analysis Male Doubling time: 3.031 days (PubMed=32321971); Microsatellite instability: Stable (MSS) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669447 CVCL_ZE59 SNU-2423 cancer cell line human CVCL_ZE59 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (PubMed=32321971); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Leu574Pro (c.1721T>C); ClinVar=VCV000089846; Zygosity=Heterozygous (PubMed=32321971); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro72Arg (c.215C>G); ClinVar=VCV000012351; Zygosity=Unspecified (PubMed=32321971) Population: Korean; Derived from metastatic site: Colon; serosa. Omics: Deep exome analysis Female Doubling time: 2.296 days (PubMed=32321971); Microsatellite instability: Instable (MSI) (PubMed=32321971) Part of: Seoul National University (SNU) cell line collection 35669448 CVCL_ZE42 LIBDi005-A induced pluripotent stem cell human CVCL_ZE42 From: Lieber Institute for Brain Development; Baltimore; USA. CL:0000010 35669449 CVCL_ZE43 LIBDi006-A induced pluripotent stem cell human CVCL_ZE43 From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 35669450 CVCL_ZE44 LIBDi007-A induced pluripotent stem cell human CVCL_ZE44 From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 35669451 CVCL_ZE45 LIBDi008-A induced pluripotent stem cell human CVCL_ZE45 From: Lieber Institute for Brain Development; Baltimore; USA. CL:0000010 35669452 CVCL_ZE40 LIBDi003-A induced pluripotent stem cell human CVCL_ZE40 From: Lieber Institute for Brain Development; Baltimore; USA. CL:0000010 35669453 CVCL_ZE41 LIBDi004-A induced pluripotent stem cell human CVCL_ZE41 From: Lieber Institute for Brain Development; Baltimore; USA. CL:0000010 35669454 CVCL_ZE46 LIBDi009-A induced pluripotent stem cell human CVCL_ZE46 From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 35669455 CVCL_ZE47 ZJUi005-A induced pluripotent stem cell human CVCL_ZE47 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Leu146Pro (c.437T>C); Zygosity=Hemizygous (PubMed=32402715) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669456 CVCL_ZE48 201B7 PITX2-EGFP knockin hiPSC clone 8-2 induced pluripotent stem cell human CVCL_ZE48 CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Using TALEN an IRES2 (2A)-EGFP-SV40 poly(A)-neo cassette was inserted at the 3'end of PITX2 35669457 CVCL_ZE49 ORIONi001-A induced pluripotent stem cell human CVCL_ZE49 From: Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University; Martin; Slovakia CL:0000010 Population: Caucasian; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 35669458 CVCL_ZE31 EH21 transformed cell line human CVCL_ZE31 CL:0000010 Sequence variation: Mutation; HGNC; 6413; KRT10; Simple; p.Arg156Gly (c.466C>G); ClinVar=VCV000066969; Zygosity=Heterozygous (PubMed=20977447); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 35669459 CVCL_ZE32 EH31 transformed cell line human CVCL_ZE32 CL:0000010 Sequence variation: Mutation; HGNC; 6413; KRT10; Simple; p.Leu161_Asp162del (c.481_486delTTGGAC); ClinVar=VCV000066179; Zygosity=Heterozygous (PubMed=20977447); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 35669460 CVCL_ZE33 NKc21 transformed cell line human CVCL_ZE33 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Unspecified 35669461 CVCL_ZE34 MHHi010-A induced pluripotent stem cell human CVCL_ZE34 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11362; STAT1; Simple; p.Arg274Gln (c.821G>A); ClinVar=VCV000030085; Zygosity=Heterozygous (PubMed=32000109) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669462 CVCL_ZE30 EH11 transformed cell line human CVCL_ZE30 CL:0000010 Sequence variation: Mutation; HGNC; 6412; KRT1; Simple; p.Val176_Lys197del (c.591+1G>C); ClinVar=VCV000066656; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=20977447); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 35669463 CVCL_ZE39 LIBDi002-A induced pluripotent stem cell human CVCL_ZE39 From: Lieber Institute for Brain Development; Baltimore; USA CL:0000010 Population: Caucasian; Derived from sampling site: Brain; meningeal dura mater Cell type=Fibroblast.. Male 35669464 CVCL_ZE35 CRL-6440 undefined cell line type house mouse CVCL_ZE35 CL:0000010 Discontinued: ATCC; CRL-6440; true. Unspecified Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982) 35669465 CVCL_ZE36 UACC-2715 cancer cell line human CVCL_ZE36 CL:0000010 Discontinued: ATCC; CRL-3190; probable. Female 35669466 CVCL_ZE37 WAe001-A-44 embryonic stem cell human CVCL_ZE37 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=TALEN; HGNC; 10471; RUNX1; Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Male 35669467 CVCL_ZE38 LIBDi001-A induced pluripotent stem cell human CVCL_ZE38 From: Lieber Institute for Brain Development; Baltimore; USA. CL:0000010 35669468 CVCL_ZA93 UMCGi004-A induced pluripotent stem cell human CVCL_ZA93 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669469 CVCL_ZA94 UMCGi004-B induced pluripotent stem cell human CVCL_ZA94 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669470 CVCL_ZA95 UMCGi005-A induced pluripotent stem cell human CVCL_ZA95 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669471 CVCL_ZA96 UMCGi005-B induced pluripotent stem cell human CVCL_ZA96 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669472 CVCL_ZA90 UMCGi002-C induced pluripotent stem cell human CVCL_ZA90 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669473 CVCL_ZA91 UMCGi003-A induced pluripotent stem cell human CVCL_ZA91 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669474 CVCL_ZA92 UMCGi003-B induced pluripotent stem cell human CVCL_ZA92 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 35669475 CVCL_ZA97 UMCGi006-A induced pluripotent stem cell human CVCL_ZA97 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669476 CVCL_ZA98 UMCGi006-B induced pluripotent stem cell human CVCL_ZA98 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669477 CVCL_ZA99 UMCGi007-A induced pluripotent stem cell human CVCL_ZA99 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669478 CVCL_ZA82 UOMi002-A induced pluripotent stem cell human CVCL_ZA82 From: University of Manitoba; Winnipeg; Canada CL:0000010 Sequence variation: Mutation; HGNC; 7716; NDUFV1; Simple; p.Tyr177Leufs*1 (c.529dupT); Zygosity=Heterozygous (PubMed=32871395); Sequence variation: Mutation; HGNC; 7716; NDUFV1; Simple; p.Glu214Lys (c.640G>A); ClinVar=VCV000014059; Zygosity=Heterozygous (PubMed=32871395) Population: Caucasian; Mennonite; Derived from sampling site: Peripheral blood. Female 35669479 CVCL_ZA83 UOMi003-A induced pluripotent stem cell human CVCL_ZA83 From: University of Manitoba; Winnipeg; Canada CL:0000010 Derived from sampling site: Peripheral blood. Male Characteristics: This cell line does not harbor the sequence variation MT-TL1 m.3243A>G found in some mitochondria of the patient (PubMed=32777772) 35669480 CVCL_ZA84 UOMi004-A induced pluripotent stem cell human CVCL_ZA84 From: University of Manitoba; Winnipeg; Canada. CL:0000010 35669481 CVCL_ZA85 CSSi011-A induced pluripotent stem cell human CVCL_ZA85 From: Fondazione Casa Sollievo della Sofferenza IRCCS; San Giovanni Rotondo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Leu145Phe (c.435G>C) (L144F); ClinVar=VCV000586637; Zygosity=Unspecified (PubMed=32739880) Population: Caucasian; Albanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669482 CVCL_ZA80 UFRJi010-A induced pluripotent stem cell human CVCL_ZA80 From: Universidade Federal do Rio de Janeiro; Rio de Janeiro; Brazil. CL:0000010 35669483 CVCL_ZA81 UOMi001-A induced pluripotent stem cell human CVCL_ZA81 From: University of Manitoba; Winnipeg; Canada CL:0000010 Sequence variation: Mutation; HGNC; 3151; ECHS1; Simple; p.Ala173Val (c.518C>T); ClinVar=VCV000377257; Zygosity=Heterozygous (PubMed=32777769); Sequence variation: Mutation; HGNC; 3151; ECHS1; Simple; p.Lys284Profs*31 (c.849_852delAAAG); dbSNP=rs1414662857; Zygosity=Heterozygous (PubMed=32777769) Population: Caucasian; Mennonite; Derived from sampling site: Peripheral blood. Male 35669484 CVCL_ZA86 UMCGi001-A induced pluripotent stem cell human CVCL_ZA86 From: University Medical Center Groningen; Groningen; Netherlands. CL:0000010 Female 35669485 CVCL_ZA87 UMCGi001-B induced pluripotent stem cell human CVCL_ZA87 From: University Medical Center Groningen; Groningen; Netherlands. CL:0000010 Female 35669486 CVCL_ZA88 UMCGi002-A induced pluripotent stem cell human CVCL_ZA88 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669487 CVCL_ZA89 UMCGi002-B induced pluripotent stem cell human CVCL_ZA89 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669488 CVCL_ZA71 HS1041 embryonic stem cell human CVCL_ZA71 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669489 CVCL_ZA72 HS1042 embryonic stem cell human CVCL_ZA72 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669490 CVCL_ZA73 KISCOi001-A induced pluripotent stem cell human CVCL_ZA73 From: Stem Cell and Organoid Laboratory, Karolinska Institutet; Stockholm; Sweden CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35669491 CVCL_ZA74 MCRIi001-B induced pluripotent stem cell human CVCL_ZA74 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple_edited; p.Arg989Cys (c.2965C>T); ClinVar=VCV000017366; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32446218); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 SOX9 has been endogenously tagged at the C-terminus with TdTomato 35669492 CVCL_ZA70 HS1038 embryonic stem cell human CVCL_ZA70 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669493 CVCL_ZA79 UCLi013-A induced pluripotent stem cell human CVCL_ZA79 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 8620; PAX6; Simple; p.Asn124Lys (c.372C>A); Zygosity=Heterozygous (PubMed=33524672) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669494 CVCL_ZA75 NCCSi010-A induced pluripotent stem cell human CVCL_ZA75 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 35669495 CVCL_ZA76 NCCSi010-B induced pluripotent stem cell human CVCL_ZA76 From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 35669496 CVCL_ZA77 TAUi001-A induced pluripotent stem cell human CVCL_ZA77 From: University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 14202; JPH2; Simple; p.Thr161Lys (c.482C>A); ClinVar=VCV000155800; Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669497 CVCL_ZA78 TAUi001-A-1 induced pluripotent stem cell human CVCL_ZA78 From: University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 14202; JPH2; Simple_corrected; p.Thr161Lys (c.482C>A); Zygosity=Heterozygous (hPSCreg) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669498 CVCL_ZA60 HS795 embryonic stem cell human CVCL_ZA60 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669499 CVCL_ZA61 HS798 embryonic stem cell human CVCL_ZA61 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669500 CVCL_ZA62 HS800 embryonic stem cell human CVCL_ZA62 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669501 CVCL_ZA63 HS838 embryonic stem cell human CVCL_ZA63 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669502 CVCL_ZA68 HS1024 embryonic stem cell human CVCL_ZA68 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669503 CVCL_ZA69 HS1036 embryonic stem cell human CVCL_ZA69 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669504 CVCL_ZA64 HS839 embryonic stem cell human CVCL_ZA64 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669505 CVCL_ZA65 HS841 embryonic stem cell human CVCL_ZA65 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669506 CVCL_ZA66 HS842 embryonic stem cell human CVCL_ZA66 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669507 CVCL_ZA67 HS1023 embryonic stem cell human CVCL_ZA67 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669508 CVCL_ZA50 HKUi001-A induced pluripotent stem cell human CVCL_ZA50 From: Department of Paediatrics and Adolescent Medicine, University of Hong Kong; Hong Kong; China. CL:0000010 35669509 CVCL_ZA51 HKUi002-A induced pluripotent stem cell human CVCL_ZA51 From: Department of Paediatrics and Adolescent Medicine, University of Hong Kong; Hong Kong; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; c.31+1G>A; ClinVar=VCV001070319; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=33099108) Population: Chinese; Derived from sampling site: Peripheral blood. Male 35669510 CVCL_ZA52 ICGi019-A induced pluripotent stem cell human CVCL_ZA52 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Met659Ile (c.1977G>A); ClinVar=VCV001054170; Zygosity=Heterozygous (PubMed=32422568) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669511 CVCL_ZA57 HS700 embryonic stem cell human CVCL_ZA57 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669512 CVCL_ZA58 HS717 embryonic stem cell human CVCL_ZA58 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669513 CVCL_ZA59 HS719 embryonic stem cell human CVCL_ZA59 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669514 CVCL_ZA53 ICGi019-B induced pluripotent stem cell human CVCL_ZA53 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Met659Ile (c.1977G>A); ClinVar=VCV001054170; Zygosity=Heterozygous (PubMed=32422568) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35669515 CVCL_ZA54 HS660 embryonic stem cell human CVCL_ZA54 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669516 CVCL_ZA55 HS685 embryonic stem cell human CVCL_ZA55 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669517 CVCL_ZA56 HS699 embryonic stem cell human CVCL_ZA56 From: Karolinska Institutet; Stockholm; Sweden. CL:0000010 Unspecified 35669518 CVCL_ZA40 HMGUi001-A-2 induced pluripotent stem cell human CVCL_ZA40 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669519 CVCL_ZA41 CIRAi005-A induced pluripotent stem cell human CVCL_ZA41 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 29090; SMCHD1; Simple; p.Val1373_Lys1377del (c.4118_4132del); Zygosity=Heterozygous (hPSCreg) Population: Japanese; Derived from sampling site: Peripheral blood. Female 35669520 CVCL_ZA46 CSUXHi002-A induced pluripotent stem cell human CVCL_ZA46 From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 10548; ATXN1; Repeat_expansion; CAG[65]; Zygosity=Heterozygous (PubMed=32335388) Population: Chinese; Han; Derived from sampling site: Urine. Male 35669521 CVCL_ZA47 EDi001-B induced pluripotent stem cell human CVCL_ZA47 From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669522 CVCL_ZA48 FDZSi002-A induced pluripotent stem cell human CVCL_ZA48 From: Zhongshan Hospital of Fudan University; Shanghai; China. CL:0000010 35669523 CVCL_ZA49 HIHCNi005-A induced pluripotent stem cell human CVCL_ZA49 From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany. CL:0000010 35669524 CVCL_ZA42 CIRAi005-A-1 induced pluripotent stem cell human CVCL_ZA42 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 29090; SMCHD1; Simple_corrected; p.Val1373_Lys1377del (c.4118_4132del); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (hPSCreg) Population: Japanese; Derived from sampling site: Peripheral blood. Female 35669525 CVCL_ZA43 CIRAi006-A induced pluripotent stem cell human CVCL_ZA43 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 29090; SMCHD1; Simple; p.Lys607Ter (c.1819A>T); Zygosity=Heterozygous (PubMed=32711388) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669526 CVCL_ZA44 CIRAi006-A-1 induced pluripotent stem cell human CVCL_ZA44 From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 29090; SMCHD1; Simple_corrected; p.Lys607Ter (c.1819A>T); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32711388); Sequence variation: Mutation; HGNC; 29090; SMCHD1; Simple_edited; p.Gly612Gly (c.1835A>G); Zygosity=Heterozygous; Note=By CRISPR/Cas9; silent mutation (PubMed=32711388) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35669527 CVCL_ZA45 CMUi002-B induced pluripotent stem cell human CVCL_ZA45 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Cell type=Fibroblast. Discontinued: hPSCreg; CMUi002-B; true Male 35669528 CVCL_ZA30 SIAISi006-A induced pluripotent stem cell human CVCL_ZA30 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=33472125) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669529 CVCL_ZA35 SIAISi011-A induced pluripotent stem cell human CVCL_ZA35 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669530 CVCL_ZA36 SIAISi012-A induced pluripotent stem cell human CVCL_ZA36 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669531 CVCL_ZA37 SHCDNRi001-A induced pluripotent stem cell human CVCL_ZA37 From: Department of Nephrology and Rheumatology, Shanghai Children's Hospital; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly409Ser (c.1225G>A); ClinVar=VCV000975073; Zygosity=Heterozygous (PubMed=32416580) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669532 CVCL_ZA38 LUMCi030-A induced pluripotent stem cell human CVCL_ZA38 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple; p.Arg374_Glu379del (c.1120_1137del18) (c.1120del18); Zygosity=Heterozygous (PubMed=32485642) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669533 CVCL_ZA31 SIAISi007-A induced pluripotent stem cell human CVCL_ZA31 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (PubMed=33472125) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669534 CVCL_ZA32 SIAISi008-A induced pluripotent stem cell human CVCL_ZA32 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (PubMed=33472125) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669535 CVCL_ZA33 SIAISi009-A induced pluripotent stem cell human CVCL_ZA33 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=33524675) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669536 CVCL_ZA34 SIAISi010-A induced pluripotent stem cell human CVCL_ZA34 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669537 CVCL_ZA39 LUMCi030-B induced pluripotent stem cell human CVCL_ZA39 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple; p.Arg374_Glu379del (c.1120_1137del18) (c.1120del18); Zygosity=Heterozygous (PubMed=32485642) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669538 CVCL_ZA24 LUMCi026-A induced pluripotent stem cell human CVCL_ZA24 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Arg958Ter (c.2872C>T); dbSNP=rs779332260; Zygosity=Heterozygous (PubMed=34088003) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669539 CVCL_ZA25 LUMCi028-A induced pluripotent stem cell human CVCL_ZA25 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669540 CVCL_ZA26 ICGi003-A induced pluripotent stem cell human CVCL_ZA26 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Gene amplification; HGNC; 11118; SMN2; Triplication; Zygosity=Unspecified (PubMed=32795928); Sequence variation: Gene deletion; HGNC; 11117; SMN1; Zygosity=Homozygous (PubMed=32795928) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35669541 CVCL_ZA27 SIAISi003-A induced pluripotent stem cell human CVCL_ZA27 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Heterozygous; Note=ApoE4 allele (PubMed=32822964) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669542 CVCL_ZA20 LUMCi020-A induced pluripotent stem cell human CVCL_ZA20 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Arg4147Ser (c.12441G>T); Zygosity=Heterozygous (PubMed=32315959) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669543 CVCL_ZA21 LUMCi017-A induced pluripotent stem cell human CVCL_ZA21 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 35669544 CVCL_ZA22 LUMCi018-A induced pluripotent stem cell human CVCL_ZA22 From: Leiden University Medical Center; Leiden; Netherlands. CL:0000010 35669546 CVCL_ZA28 SIAISi004-A induced pluripotent stem cell human CVCL_ZA28 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=34450529) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669547 CVCL_ZA29 SIAISi005-A induced pluripotent stem cell human CVCL_ZA29 From: Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University; Shanghai; China. CL:0000010 35669548 CVCL_ZA13 LUMCi022-C induced pluripotent stem cell human CVCL_ZA13 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 35669549 CVCL_ZA14 LUMCi023-A induced pluripotent stem cell human CVCL_ZA14 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 35669550 CVCL_ZA15 LUMCi021-A induced pluripotent stem cell human CVCL_ZA15 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Tyr4962Cys (c.14885A>G); ClinVar=VCV000201405; Zygosity=Heterozygous (PubMed=32315959) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669551 CVCL_ZA16 LUMCi024-A induced pluripotent stem cell human CVCL_ZA16 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Arg592Trp (c.1774C>T); ClinVar=VCV000030940; Zygosity=Heterozygous (PubMed=34088003); Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Val730Met (c.2188G>A); ClinVar=VCV000136214; Zygosity=Heterozygous (PubMed=34088003); Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Arg958Ter (c.2872C>T); dbSNP=rs779332260; Zygosity=Heterozygous (PubMed=34088003) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669552 CVCL_ZA10 LUMCi029-B induced pluripotent stem cell human CVCL_ZA10 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669553 CVCL_ZA11 LUMCi022-A induced pluripotent stem cell human CVCL_ZA11 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 35669554 CVCL_ZA12 LUMCi022-B induced pluripotent stem cell human CVCL_ZA12 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 35669555 CVCL_ZA17 LUMCi025-A induced pluripotent stem cell human CVCL_ZA17 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Arg592Trp (c.1774C>T); ClinVar=VCV000030940; Zygosity=Heterozygous (PubMed=34088003); Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Val730Met (c.2188G>A); ClinVar=VCV000136214; Zygosity=Heterozygous (PubMed=34088003); Sequence variation: Mutation; HGNC; 21022; AARS2; Simple; p.Arg958Ter (c.2872C>T); dbSNP=rs779332260; Zygosity=Heterozygous (PubMed=34088003) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669556 CVCL_ZA18 LUMCi027-A induced pluripotent stem cell human CVCL_ZA18 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; p.Lys672Argfs*12 (c.2013delC); ClinVar=VCV000202022; Zygosity=Heterozygous (PubMed=32485643) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669557 CVCL_ZA19 LUMCi027-A-1 induced pluripotent stem cell human CVCL_ZA19 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple_corrected; p.Lys672Argfs*12 (c.2013delC); ClinVar=VCV000202022; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32485643) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669558 CVCL_ZA02 DS1-iPS induced pluripotent stem cell human CVCL_ZA02 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35669559 CVCL_ZA03 DS2-iPS induced pluripotent stem cell human CVCL_ZA03 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35669560 CVCL_ZA04 euDS-iPS induced pluripotent stem cell human CVCL_ZA04 CL:0000010 Population: Caucasian; Karyotypic information: Lost the third copy of chromosome 21 (PubMed=23225669); Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35669561 CVCL_ZA05 WT1-iPS induced pluripotent stem cell human CVCL_ZA05 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35669562 CVCL_ZA00 LUMCi004-B induced pluripotent stem cell human CVCL_ZA00 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669563 CVCL_ZA01 LUMCi004-C induced pluripotent stem cell human CVCL_ZA01 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Urine. Female 35669564 CVCL_ZA06 WT2-iPS induced pluripotent stem cell human CVCL_ZA06 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 35669565 CVCL_ZA07 WT3-iPS induced pluripotent stem cell human CVCL_ZA07 CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35669566 CVCL_ZA08 WT4-iPS induced pluripotent stem cell human CVCL_ZA08 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 35669567 CVCL_ZA09 LUMCi029-A induced pluripotent stem cell human CVCL_ZA09 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669568 CVCL_ZK60 GeneBLAzer P2RY6-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK60 CL:0000010 Transfected with: HGNC; 8543; P2RY6; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669569 CVCL_ZK61 GeneBLAzer NPSR1-A-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK61 CL:0000010 Transfected with: HGNC; 23631; NPSR1 (isoform A); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669570 CVCL_ZK66 GeneBLAzer GCGR-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK66 CL:0000010 Transfected with: HGNC; 4192; GCGR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669571 CVCL_ZK67 GeneBLAzer GIPR-CRE-bla HEK 293T transformed cell line human CVCL_ZK67 CL:0000010 Transfected with: HGNC; 4271; GIPR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669572 CVCL_ZK68 GeneBLAzer Gqo5-NFAT-bla FreeStyle 293F transformed cell line human CVCL_ZK68 CL:0000010 Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669573 CVCL_ZK69 GeneBLAzer CysLT2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK69 CL:0000010 Transfected with: HGNC; 18274; CYSLTR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669574 CVCL_ZK62 GeneBLAzer NTSR1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK62 CL:0000010 Transfected with: HGNC; 8039; NTSR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669575 CVCL_ZK63 GeneBLAzer PROKR2-Gqi5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK63 CL:0000010 Transfected with: HGNC; 15836; PROKR2; Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669576 CVCL_ZK64 GeneBLAzer NMUR1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK64 CL:0000010 Transfected with: HGNC; 4518; NMUR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female 35669577 CVCL_ZK65 GeneBLAzer OXTR-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK65 CL:0000010 Transfected with: HGNC; 8529; OXTR; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669578 CVCL_ZK50 GeneBLAzer CRHR1-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK50 CL:0000010 Transfected with: HGNC; 2357; CRHR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669579 CVCL_ZK55 SEES3-1V Emerald, clone2 embryonic stem cell human CVCL_ZK55 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected Emerald (EmGFP) gene and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-EmGFP-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669580 CVCL_ZK56 SEES3-1V Emerald, clone3 embryonic stem cell human CVCL_ZK56 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected Emerald (EmGFP) gene and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-EmGFP-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669581 CVCL_ZK57 GeneBLAzer FPRL-1-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK57 CL:0000010 Transfected with: HGNC; 3827; FPR2; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669582 CVCL_ZK58 GeneBLAzer P2RY2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK58 CL:0000010 Transfected with: HGNC; 8541; P2RY2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669583 CVCL_ZK51 GeneBLAzer CRHR2-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK51 CL:0000010 Transfected with: HGNC; 2358; CRHR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669584 CVCL_ZK52 GeneBLAzer CaSR-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK52 CL:0000010 Transfected with: HGNC; 1514; CASR; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669585 CVCL_ZK53 Tango ADORA1-bla U2OS cancer cell line human CVCL_ZK53 CL:0000010 Transfected with: HGNC; 262; ADORA1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669586 CVCL_ZK54 SEES3-1V Emerald, clone1 embryonic stem cell human CVCL_ZK54 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected Emerald (EmGFP) gene and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-EmGFP-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669587 CVCL_ZK59 GeneBLAzer P2RY4-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK59 CL:0000010 Transfected with: HGNC; 8542; P2RY4; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669588 CVCL_ZK44 GeneBLAzer CALCR-CRE-bla FreeStyle 293F transformed cell line human CVCL_ZK44 CL:0000010 Transfected with: HGNC; 1440; CALCR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669589 CVCL_ZK45 GeneBLAzer CALCRL:RAMP1-CRE-bla FreeStyle 293F transformed cell line human CVCL_ZK45 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9843; RAMP1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669590 CVCL_ZK46 GeneBLAzer CALCRL:RAMP2-CRE-bla FreeStyle 293F transformed cell line human CVCL_ZK46 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9843; RAMP1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669591 CVCL_ZK47 GeneBLAzer CALCRL:RAMP3-CRE-bla FreeStyle 293F transformed cell line human CVCL_ZK47 CL:0000010 Transfected with: HGNC; 16709; CALCRL; Transfected with: HGNC; 9843; RAMP1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669592 CVCL_ZK40 GeneBLAzer ADORA2B-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK40 CL:0000010 Transfected with: HGNC; 264; ADORA2B; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Discontinued: Thermofisher/Invitrogen; Catalog number K1780 Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669593 CVCL_ZK41 GeneBLAzer ADRB1-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK41 CL:0000010 Transfected with: HGNC; 285; ADRB1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669594 CVCL_ZK42 GeneBLAzer ADRB2-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK42 CL:0000010 Transfected with: HGNC; 286; ADRB2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669595 CVCL_ZK43 GeneBLAzer ADRB3-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK43 CL:0000010 Transfected with: HGNC; 288; ADRB3; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669596 CVCL_ZK48 GeneBLAzer CCKAR-NFAT-bla HEK 293T transformed cell line human CVCL_ZK48 CL:0000010 Transfected with: HGNC; 1570; CCKAR; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669597 CVCL_ZK49 GeneBLAzer CNR1-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK49 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669598 CVCL_ZK33 Tango EDG8-bla U2OS cancer cell line human CVCL_ZK33 CL:0000010 Transfected with: HGNC; 14299; S1PR5; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669599 CVCL_ZK34 Tango GPR23-bla U2OS cancer cell line human CVCL_ZK34 CL:0000010 Transfected with: HGNC; 4478; LPAR4; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669600 CVCL_ZK35 Tango GPR92-bla U2OS cancer cell line human CVCL_ZK35 CL:0000010 Transfected with: HGNC; 13307; LPAR5; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Discontinued: Thermofisher/Invitrogen; Catalog number K1843 Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669601 CVCL_ZK36 Tango GPR87-bla U2OS cancer cell line human CVCL_ZK36 CL:0000010 Transfected with: HGNC; 4538; GPR87; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669602 CVCL_ZK30 Tango EDG6-bla U2OS cancer cell line human CVCL_ZK30 CL:0000010 Transfected with: HGNC; 3170; S1PR4; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669603 CVCL_ZK31 Tango GPR120-bla U2OS cancer cell line human CVCL_ZK31 CL:0000010 Transfected with: HGNC; 19061; FFAR4; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669604 CVCL_ZK32 Tango EDG7-bla U2OS cancer cell line human CVCL_ZK32 CL:0000010 Transfected with: HGNC; 14298; LPAR3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669605 CVCL_ZK37 Tango EDG4-bla U2OS cancer cell line human CVCL_ZK37 CL:0000010 Transfected with: HGNC; 3168; LPAR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669606 CVCL_ZK38 Tango EDG5-bla U2OS cancer cell line human CVCL_ZK38 CL:0000010 Transfected with: HGNC; 3169; S1PR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669607 CVCL_ZK39 GeneBLAzer 5TH1A-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK39 CL:0000010 Transfected with: HGNC; 5286; HTR1A; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669608 CVCL_ZK22 Tango SSTR2-bla U2OS cancer cell line human CVCL_ZK22 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669609 CVCL_ZK23 Tango SSTR5-bla U2OS cancer cell line human CVCL_ZK23 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669610 CVCL_ZK24 Tango TACR1-bla U2OS cancer cell line human CVCL_ZK24 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669611 CVCL_ZK25 Tango TACR3-bla U2OS cancer cell line human CVCL_ZK25 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669612 CVCL_ZK20 Tango RLN3R1-bla U2OS cancer cell line human CVCL_ZK20 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669613 CVCL_ZK21 Tango SSTR1-bla U2OS cancer cell line human CVCL_ZK21 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669614 CVCL_ZK26 Tango TBXA2R-bla U2OS cancer cell line human CVCL_ZK26 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669615 CVCL_ZK27 T-REx Tango GHSR-bla U2OS cancer cell line human CVCL_ZK27 CL:0000010 Transfected with: HGNC; 4267; GHSR; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669616 CVCL_ZK28 T-REx Tango P2RY14-bla U2OS cancer cell line human CVCL_ZK28 CL:0000010 Transfected with: HGNC; 16442; P2RY14; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669617 CVCL_ZK29 Tango GPR8-bla U2OS cancer cell line human CVCL_ZK29 CL:0000010 Transfected with: HGNC; 4530; NPBWR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669618 CVCL_ZK11 Tango CXCR3-bla U2OS cancer cell line human CVCL_ZK11 CL:0000010 Transfected with: HGNC; 4540; CXCR3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669619 CVCL_ZK12 Tango CXCR4-bla U2OS cancer cell line human CVCL_ZK12 CL:0000010 Transfected with: HGNC; 2561; CXCR4; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669620 CVCL_ZK13 Tango CXCR6-bla U2OS cancer cell line human CVCL_ZK13 CL:0000010 Transfected with: HGNC; 16647; CXCR6; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669621 CVCL_ZK14 Tango CXCR7-bla U2OS cancer cell line human CVCL_ZK14 CL:0000010 Transfected with: HGNC; 23692; ACKR3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669622 CVCL_ZK10 Tango CXCR2-bla U2OS cancer cell line human CVCL_ZK10 CL:0000010 Transfected with: HGNC; 6027; CXCR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669623 CVCL_ZK19 Tango PTAFR-bla U2OS cancer cell line human CVCL_ZK19 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669624 CVCL_ZK15 Tango DRD1-bla U2OS cancer cell line human CVCL_ZK15 CL:0000010 Transfected with: HGNC; 3020; DRD1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669625 CVCL_ZK16 Tango EDG1-bla U2OS cancer cell line human CVCL_ZK16 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669626 CVCL_ZK17 Tango EDG2-bla U2OS cancer cell line human CVCL_ZK17 CL:0000010 Transfected with: HGNC; 3166; LPAR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669627 CVCL_ZK18 Tango EDG3-bla U2OS cancer cell line human CVCL_ZK18 CL:0000010 Transfected with: HGNC; 3167; S1PR3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669628 CVCL_ZK00 Tango CCR3-bla U2OS cancer cell line human CVCL_ZK00 CL:0000010 Transfected with: HGNC; 1604; CCR3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669629 CVCL_ZK01 Tango CCR4-bla U2OS cancer cell line human CVCL_ZK01 CL:0000010 Transfected with: HGNC; 1605; CCR4; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669630 CVCL_ZK02 Tango CCR5-bla U2OS cancer cell line human CVCL_ZK02 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669631 CVCL_ZK03 Tango CCR6-bla U2OS cancer cell line human CVCL_ZK03 CL:0000010 Transfected with: HGNC; 1607; CCR6; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669632 CVCL_ZK08 Tango CNR2-bla U2OS cancer cell line human CVCL_ZK08 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: HGNC; 2160; CNR2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669633 CVCL_ZK09 Tango CXCR1-bla U2OS cancer cell line human CVCL_ZK09 CL:0000010 Transfected with: HGNC; 6026; CXCR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669634 CVCL_ZK04 Tango CCR7-bla U2OS cancer cell line human CVCL_ZK04 CL:0000010 Transfected with: HGNC; 1608; CCR7; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669635 CVCL_ZK05 Tango CHRM2-bla U2OS cancer cell line human CVCL_ZK05 CL:0000010 Transfected with: HGNC; 1951; CHRM2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669636 CVCL_ZK06 Tango CMKLR1-bla U2OS cancer cell line human CVCL_ZK06 CL:0000010 Transfected with: HGNC; 2121; CMKLR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669637 CVCL_ZK07 Tango CNR1-bla U2OS cancer cell line human CVCL_ZK07 CL:0000010 Transfected with: HGNC; 2159; CNR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669638 CVCL_ZJ92 SEES3-5V embryonic stem cell human CVCL_ZJ92 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669639 CVCL_ZJ93 Tango GPCR-bla U2OS cancer cell line human CVCL_ZJ93 CL:0000010 Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: This is the parental cell line for all other ThermoFisher Tango cell lines It is not distributed.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669640 CVCL_ZJ94 Tango ADORA3-bla U2OS cancer cell line human CVCL_ZJ94 CL:0000010 Transfected with: HGNC; 268; ADORA3; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669641 CVCL_ZJ95 Tango ADRA2A-bla U2OS cancer cell line human CVCL_ZJ95 CL:0000010 Transfected with: HGNC; 281; ADRA2A; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669642 CVCL_ZJ90 SEES3-3L embryonic stem cell human CVCL_ZJ90 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669643 CVCL_ZJ91 SEES3-1V embryonic stem cell human CVCL_ZJ91 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669644 CVCL_ZJ96 Tango AGTR1-bla U2OS cancer cell line human CVCL_ZJ96 CL:0000010 Transfected with: HGNC; 336; AGTR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669645 CVCL_ZJ97 Tango AGTRL1-bla U2OS cancer cell line human CVCL_ZJ97 CL:0000010 Transfected with: HGNC; 339; APLNR; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669646 CVCL_ZJ98 Tango CCR1-bla U2OS cancer cell line human CVCL_ZJ98 CL:0000010 Transfected with: HGNC; 1602; CCR1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669647 CVCL_ZJ99 Tango CCR2-bla U2OS cancer cell line human CVCL_ZJ99 CL:0000010 Transfected with: HGNC; 1603; CCR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669648 CVCL_ZJ81 HT1080-MFAP4 W235F-MH cancer cell line human CVCL_ZJ81 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7035; MFAP4 (with p.Trp235Phe and a C-terminal mycHis6 tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 35669649 CVCL_ZJ82 Melan-a 2C spontaneously immortalized cell line house mouse CVCL_ZJ82 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 22 hours (PubMed=16611417) 35669650 CVCL_ZJ83 Melan-a 4C spontaneously immortalized cell line house mouse CVCL_ZJ83 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Doubling time: 20 hours (PubMed=16611417) 35669651 CVCL_ZJ84 Melan-a 4C3 spontaneously immortalized cell line house mouse CVCL_ZJ84 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified 35669652 CVCL_ZJ80 HT1080-MFAP4 wt-MH cancer cell line human CVCL_ZJ80 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 7035; MFAP4 (with a C-terminal mycHis6 tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; pelvis; acetabulum. Male 35669653 CVCL_ZJ89 SEES3-1L embryonic stem cell human CVCL_ZJ89 CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35669654 CVCL_ZJ85 Melan-a 4C11 spontaneously immortalized cell line house mouse CVCL_ZJ85 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified 35669655 CVCL_ZJ86 Melan-a S11 spontaneously immortalized cell line house mouse CVCL_ZJ86 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified 35669656 CVCL_ZJ87 Melan-a Tm1 spontaneously immortalized cell line house mouse CVCL_ZJ87 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Tumorigenic (PubMed=16611417) Doubling time: 18 hours (PubMed=16611417) 35669657 CVCL_ZJ88 Melan-a Tm5 spontaneously immortalized cell line house mouse CVCL_ZJ88 CL:0000010 Derived from sampling site: Trunk; skin Cell type=Melanocyte.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Tumorigenic (PubMed=16611417) Doubling time: 14 hours (PubMed=16611417) 35669658 CVCL_ZJ70 LR-416 transformed cell line human CVCL_ZJ70 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35669659 CVCL_ZJ71 KD-406 transformed cell line human CVCL_ZJ71 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669660 CVCL_ZJ72 KD-408 transformed cell line human CVCL_ZJ72 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35669661 CVCL_ZJ73 KD-417 transformed cell line human CVCL_ZJ73 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669662 CVCL_ZJ78 Wrh-f2 cancer cell line Norway rat CVCL_ZJ78 CL:0000010 Karyotypic information: Hypertetraploid karyotype (PubMed=32433581); Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Transformant: N-nitrosomorpholine (NMOR)(ChEBI; CHEBI:76326); Breed/subspecies: Wistar. Male Characteristics: Has a low degree of diferentiation, a high degree of malignancy and a high metastasis potential which can lead to typical pulmonary metastasis (PubMed=32433581) 35669663 CVCL_ZJ79 Wrh-s2 cancer cell line Norway rat CVCL_ZJ79 CL:0000010 Karyotypic information: Hyperdiploid karyotype (PubMed=32433581); Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Transformant: N-nitrosomorpholine (NMOR)(ChEBI; CHEBI:76326); Breed/subspecies: Wistar. Male Characteristics: Poorly diferentiated cell with a relatively low metastasis potential and a low incidence of pulmonary metastasis (PubMed=32433581) 35669664 CVCL_ZJ74 KD-420 transformed cell line human CVCL_ZJ74 CL:0000010 Population: Iranian; Kurd; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35669665 CVCL_ZJ75 PWS UPD 1.2 induced pluripotent stem cell human CVCL_ZJ75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669666 CVCL_ZJ76 GeneBLAzer HTR2C-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZJ76 CL:0000010 Transfected with: HGNC; 5295; HTR2C; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669667 CVCL_ZJ77 GeneBLAzer C5aR1-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZJ77 CL:0000010 Transfected with: HGNC; 1338; C5AR1; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669668 CVCL_ZJ60 CT-2A-Luc cancer cell line house mouse CVCL_ZJ60 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Breed/subspecies: C57BL/6J. Unspecified Characteristics: Transduced with a lentiviral vector containing a Fluc-IRES-GFP construct expressed under the control of the CMV promoter 35669669 CVCL_ZJ61 GL-400 transformed cell line human CVCL_ZJ61 CL:0000010 Population: Iranian; Gilaks; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669670 CVCL_ZJ62 LR-402 transformed cell line human CVCL_ZJ62 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669671 CVCL_ZJ67 LR-412 transformed cell line human CVCL_ZJ67 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669672 CVCL_ZJ68 LR-413 transformed cell line human CVCL_ZJ68 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669673 CVCL_ZJ69 LR-414 transformed cell line human CVCL_ZJ69 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669674 CVCL_ZJ63 LR-405 transformed cell line human CVCL_ZJ63 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669675 CVCL_ZJ64 LR-409 transformed cell line human CVCL_ZJ64 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669676 CVCL_ZJ65 LR-410 transformed cell line human CVCL_ZJ65 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669677 CVCL_ZJ66 LR-411 transformed cell line human CVCL_ZJ66 CL:0000010 Population: Iranian; Lurs; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669678 CVCL_ZJ50 PWS SD 2-4 iPSC induced pluripotent stem cell human CVCL_ZJ50 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669679 CVCL_ZJ51 PWS SD 2-5 iPSC induced pluripotent stem cell human CVCL_ZJ51 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669680 CVCL_ZJ56 N27-A transformed cell line Norway rat CVCL_ZJ56 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic brain; mesencephalon. Unspecified Characteristics: Improved in vitro model of dopamine neurons for research on Parkinson's disease Expresses TH and DAT at 4 times the level of the parent cell line. Also expresses VMAT2, dopaminergic transcription factors, dopaminergic storage protein (PubMed=27512998). Doubling time: ~36 hours (PubMed=27512998) 35669681 CVCL_ZJ57 BFAE-39g spontaneously immortalized cell line CVCL_ZJ57 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male Senescence: Senesces at 54 PDL (PubMed=2981236) Caution: Indicated to be of female origin in PubMed=2981236, but karyotype of parent cell line from Coriell shows X,Y 35669682 CVCL_ZJ58 BFAE-39h spontaneously immortalized cell line CVCL_ZJ58 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Male Senescence: Senesces at 48 PDL (PubMed=2981236) Caution: Indicated to be of female origin in PubMed=2981236, but karyotype of parent cell line from Coriell shows X,Y 35669683 CVCL_ZJ59 BFAE-12d spontaneously immortalized cell line CVCL_ZJ59 CL:0000010 Derived from sampling site: Fetal thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Holstein. Female Senescence: Senesces at 65 PDL (PubMed=2981236) 35669684 CVCL_ZJ52 PWS SD 2-6 iPSC induced pluripotent stem cell human CVCL_ZJ52 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669685 CVCL_ZJ53 PWS SD 2-7 iPSC induced pluripotent stem cell human CVCL_ZJ53 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35669686 CVCL_ZJ54 PWS SD 2-8 iPSC induced pluripotent stem cell human CVCL_ZJ54 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Characteristics: Has a high propensities to differentiate into neurons due to the robust expression of neural lineage markers and silencing of the pluripotency genes (PubMed=24363065) 35669687 CVCL_ZJ55 PWS SD 2-9 iPSC induced pluripotent stem cell human CVCL_ZJ55 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male Characteristics: Has a high propensities to differentiate into neurons due to the robust expression of neural lineage markers and silencing of the pluripotency genes (PubMed=24363065) 35669688 CVCL_ZL00 Tango MTNR1B-bla U2OS cancer cell line human CVCL_ZL00 CL:0000010 Transfected with: HGNC; 7464; MTNR1B; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669689 CVCL_ZL01 Tango NPY5R-bla U2OS cancer cell line human CVCL_ZL01 CL:0000010 Transfected with: HGNC; 7958; NPY5R; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669690 CVCL_ZL02 Tango NPY1R-bla U2OS cancer cell line human CVCL_ZL02 CL:0000010 Transfected with: HGNC; 7956; NPY1R; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669691 CVCL_ZL07 Tango OPRD1-bla U2OS cancer cell line human CVCL_ZL07 CL:0000010 Transfected with: HGNC; 8153; OPRD1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669692 CVCL_ZL08 Tango OPRL1-bla U2OS cancer cell line human CVCL_ZL08 CL:0000010 Transfected with: HGNC; 8155; OPRL1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669693 CVCL_ZL09 Tango F2RL1-bla U2OS cancer cell line human CVCL_ZL09 CL:0000010 Transfected with: HGNC; 3538; F2RL1; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669694 CVCL_ZL03 Tango GALR2-bla U2OS cancer cell line human CVCL_ZL03 CL:0000010 Transfected with: HGNC; 4133; GALR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669695 CVCL_ZL04 Tango M4-bla U2OS cancer cell line human CVCL_ZL04 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669696 CVCL_ZL05 Tango M1-bla U2OS cancer cell line human CVCL_ZL05 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669697 CVCL_ZL06 Tango HTR1A-bla U2OS cancer cell line human CVCL_ZL06 CL:0000010 Transfected with: HGNC; 5286; HTR1A; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669698 CVCL_ZL80 DM426 cancer cell line human CVCL_ZL80 From: Duke University Medical Center; Durham; USA. CL:0000010 35669699 CVCL_ZL81 DM434 cancer cell line human CVCL_ZL81 From: Duke University Medical Center; Durham; USA. CL:0000010 35669700 CVCL_ZL82 DM441 cancer cell line human CVCL_ZL82 From: Duke University Medical Center; Durham; USA. CL:0000010 35669701 CVCL_ZL87 PUMCHi003-A induced pluripotent stem cell human CVCL_ZL87 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9603; PTGIS; Simple; p.Arg252Glu (c.755G>A); Zygosity=Heterozygous (PubMed=32559633) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669702 CVCL_ZL88 ZJUi003-A induced pluripotent stem cell human CVCL_ZL88 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Thr61Serfs*16 (c.180_181del); Zygosity=Heterozygous (PubMed=32534167) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 35669703 CVCL_ZL89 ZJUi004-A induced pluripotent stem cell human CVCL_ZL89 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 9024; PKP2; Simple; c.2357+1G>A (c.2489+1G>A); ClinVar=VCV000006757; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=32916635) Population: Chinese; Han; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35669704 CVCL_ZL83 DM465 cancer cell line human CVCL_ZL83 From: Duke University Medical Center; Durham; USA. CL:0000010 35669705 CVCL_ZL84 UKMi002-A induced pluripotent stem cell human CVCL_ZL84 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17412; CLCF1; Simple; p.Tyr107Ter (c.321C>G); ClinVar=VCV000002930; Zygosity=Homozygous (PubMed=32512309) Population: Caucasian; Derived from sampling site: Nose Cell type=Fibroblast.. Male 35669706 CVCL_ZL85 UKMi002-B induced pluripotent stem cell human CVCL_ZL85 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17412; CLCF1; Simple; p.Tyr107Ter (c.321C>G); ClinVar=VCV000002930; Zygosity=Homozygous (PubMed=32512309) Population: Caucasian; Derived from sampling site: Nose Cell type=Fibroblast.. Male 35669707 CVCL_ZL86 UKMi002-C induced pluripotent stem cell human CVCL_ZL86 From: Muenster University Children's Hospital; Muenster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 17412; CLCF1; Simple; p.Tyr107Ter (c.321C>G); ClinVar=VCV000002930; Zygosity=Homozygous (PubMed=32512309) Population: Caucasian; Derived from sampling site: Nose Cell type=Fibroblast.. Male 35669708 CVCL_ZL70 MEL-SLM2 cancer cell line human CVCL_ZL70 CL:0000010 Omics: Transcriptome analysis by microarray. 35669709 CVCL_ZL71 DM277 cancer cell line human CVCL_ZL71 From: Duke University Medical Center; Durham; USA. CL:0000010 35669710 CVCL_ZL76 DM387 cancer cell line human CVCL_ZL76 From: Duke University Medical Center; Durham; USA. CL:0000010 35669711 CVCL_ZL77 DM390 cancer cell line human CVCL_ZL77 From: Duke University Medical Center; Durham; USA. CL:0000010 35669712 CVCL_ZL78 DM400 cancer cell line human CVCL_ZL78 From: Duke University Medical Center; Durham; USA. CL:0000010 35669713 CVCL_ZL79 DM406 cancer cell line human CVCL_ZL79 From: Duke University Medical Center; Durham; USA. CL:0000010 35669714 CVCL_ZL72 DM341 cancer cell line human CVCL_ZL72 From: Duke University Medical Center; Durham; USA. CL:0000010 35669715 CVCL_ZL73 DM343 cancer cell line human CVCL_ZL73 From: Duke University Medical Center; Durham; USA. CL:0000010 35669716 CVCL_ZL74 DM349 cancer cell line human CVCL_ZL74 From: Duke University Medical Center; Durham; USA. CL:0000010 35669717 CVCL_ZL75 DM385 cancer cell line human CVCL_ZL75 From: Duke University Medical Center; Durham; USA. CL:0000010 35669718 CVCL_ZL60 WLM-20 cancer cell line human CVCL_ZL60 CL:0000010 Sequence variation: Gene deletion; HGNC; 11103; SMARCB1; Zygosity=Homozygous (PubMed=11921280). Unspecified 35669719 CVCL_ZL65 DM141 cancer cell line human CVCL_ZL65 HLA typing: A*02,28; B*07 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669720 CVCL_ZL66 DM144 cancer cell line human CVCL_ZL66 HLA typing: A*01; B*03,15; C*03 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669721 CVCL_ZL67 DM13/B7-7 cancer cell line human CVCL_ZL67 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*07); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lymph node. 35669722 CVCL_ZL68 DM150/B7-8 cancer cell line human CVCL_ZL68 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*07); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lymph node. 35669723 CVCL_ZL61 IngWAT transformed cell line house mouse CVCL_ZL61 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: White adipose tissue. Characteristics: Versatile model for a broad spectrum of studies of beige adipocyte induction, maintenance and physiology (Millipore) 35669724 CVCL_ZL62 DM12 [Human melanoma] cancer cell line human CVCL_ZL62 HLA typing: A*03,31; B*05 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669725 CVCL_ZL63 DM49 cancer cell line human CVCL_ZL63 HLA typing: A*01,10; B*08,51; C*02,04 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669726 CVCL_ZL64 DM100 cancer cell line human CVCL_ZL64 HLA typing: A*29; B*44 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669727 CVCL_ZL69 DM93/B7-3 cancer cell line human CVCL_ZL69 CL:0000010 Transfected with: HGNC; 4932; HLA-B (allele B*07); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from metastatic site: Lymph node. 35669728 CVCL_ZL54 K562 NGLY1 KO c20 cancer cell line human CVCL_ZL54 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17646; NGLY1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 35669729 CVCL_ZL55 INS-1 832/3 cancer cell line Norway rat CVCL_ZL55 CL:0000010 Transfected with: HGNC; 6081; INS; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.; Breed/subspecies: NEDH. Male Characteristics: Shows robust glucose-stimulated insulin secretion (GSIS) (Millipore) 35669730 CVCL_ZL56 LIBUCi001-A induced pluripotent stem cell human CVCL_ZL56 From: Libin Cardiovascular Institute of Alberta, University of Calgary; Calgary; Canada CL:0000010 Sequence variation: Mutation; HGNC; 30528; DNAJC19; Simple; c.130-1G>C; ClinVar=VCV000001951; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=32521499) Population: Caucasian; Canadian Dariusleut Hutterite; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 35669731 CVCL_ZL57 LIBUCi002-A induced pluripotent stem cell human CVCL_ZL57 From: Libin Cardiovascular Institute of Alberta, University of Calgary; Calgary; Canada CL:0000010 Sequence variation: Mutation; HGNC; 30528; DNAJC19; Simple; c.130-1G>C; ClinVar=VCV000001951; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=32521499) Population: Caucasian; Canadian Dariusleut Hutterite; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 35669732 CVCL_ZL50 NOX1-HEK293 transformed cell line human CVCL_ZL50 CL:0000010 Transfected with: HGNC; 7889; NOX1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669733 CVCL_ZL51 NOX4-HEK293 transformed cell line human CVCL_ZL51 CL:0000010 Transfected with: HGNC; 7891; NOX4 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 35669734 CVCL_ZL52 143B rho-0 EtBr cancer cell line human CVCL_ZL52 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala59Thr (c.175G>A); ClinVar=VCV000012581; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Bone; right femur. Female Characteristics: Cell line devoid of mitochondrial DNA (rho0) Obtained by growth of parental cell line with ethidium bromide. 35669735 CVCL_ZL53 K562 NGLY1 KO c15 cancer cell line human CVCL_ZL53 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 17646; NGLY1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female 35669736 CVCL_ZL58 JMUi001-A induced pluripotent stem cell human CVCL_ZL58 From: Institute of Anatomy, University of Wurzburg; Wurzburg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35669737 CVCL_ZL59 JMUi001-A-1 induced pluripotent stem cell human CVCL_ZL59 From: Comprehensive Heart Failure Center, University Clinic Wurzburg; Wurzburg; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 30528; DNAJC19 Population: Caucasian; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35669738 CVCL_ZL43 UISO-MEL-29 cancer cell line human CVCL_ZL43 CL:0000010 35669739 CVCL_ZL44 UISO-CMN-1 spontaneously immortalized cell line human CVCL_ZL44 CL:0000010 Derived from sampling site: Skin; dermis; nevus. Female 35669740 CVCL_ZL45 UISO-MEL-4WP cancer cell line human CVCL_ZL45 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Skin. Male 35669741 CVCL_ZL46 BT474-J4 cancer cell line human CVCL_ZL46 CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (PubMed=19671800); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (PubMed=19671800) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female 35669742 CVCL_ZL40 UISO-MEL-6 cancer cell line human CVCL_ZL40 CL:0000010 Male Characteristics: Metastatic to lung and liver in nude mice. 35669743 CVCL_ZL41 UISO-MEL-7 cancer cell line human CVCL_ZL41 CL:0000010 Female 35669744 CVCL_ZL42 UISO-MEL-8 cancer cell line human CVCL_ZL42 CL:0000010 Female 35669745 CVCL_ZL47 LUMCi030-A-1 induced pluripotent stem cell human CVCL_ZL47 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple_corrected; p.Arg374_Glu379del (c.1120_1137del18); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32485642) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669746 CVCL_ZL48 LUMCi030-B-1 induced pluripotent stem cell human CVCL_ZL48 From: Leiden University Medical Center; Leiden; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 175; ACVRL1; Simple_corrected; p.Arg374_Glu379del (c.1120_1137del18); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32485642) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669747 CVCL_ZL49 SH-SY5Y/VCR cancer cell line human CVCL_ZL49 CL:0000010 Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from metastatic site: Bone marrow. Female 35669748 CVCL_ZL32 IHOSE-1431-SV40 transformed cell line human CVCL_ZL32 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.81 +- 1.55 hours (PubMed=30296284) 35669749 CVCL_ZL33 IHOSE-4138-SV40 transformed cell line human CVCL_ZL33 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 52.11 +- 2.47 hours (PubMed=30296284) 35669750 CVCL_ZL34 IHOSE-8695-SV40 transformed cell line human CVCL_ZL34 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 33.67 +- 2.21 hours (PubMed=30296284) 35669751 CVCL_ZL35 CSEC216 cancer cell line human CVCL_ZL35 CL:0000010 Population: Chinese; Derived from sampling site: Esophagus. Omics: Genome sequenced Male Doubling time: 29.7 hours (PubMed=32489320) 35669752 CVCL_ZL30 IHOSE-0160-SV40 transformed cell line human CVCL_ZL30 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA209](NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 42.92 +- 1.17 hours (PubMed=30296284) 35669753 CVCL_ZL31 IHOSE-1431-E6/E7 transformed cell line human CVCL_ZL31 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 90.20 +- 11.52 hours (PubMed=30296284) 35669754 CVCL_ZL36 UISO-MEL-11 cancer cell line human CVCL_ZL36 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile195Thr (c.584T>C); ClinVar=VCV000216077; Zygosity=Unspecified (PubMed=12894234). 35669755 CVCL_ZL37 UISO-MEL-16 cancer cell line human CVCL_ZL37 CL:0000010 Male 35669756 CVCL_ZL38 UISO-MEL-23 cancer cell line human CVCL_ZL38 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-12G>T; Zygosity=Unspecified (PubMed=7872667). Male 35669757 CVCL_ZL39 UISO-MEL-3 cancer cell line human CVCL_ZL39 CL:0000010 Female 35669758 CVCL_ZL21 JR#002105 embryonic stem cell house mouse CVCL_ZL21 CL:0000010 Breed/subspecies: NZO/HlLtJ. Male 35669759 CVCL_ZL22 JR#002448 embryonic stem cell house mouse CVCL_ZL22 CL:0000010 Breed/subspecies: 129S1/SvImJ. Male 35669760 CVCL_ZL23 UW-NLA-HC3 somatic stem cell human CVCL_ZL23 CL:0000010 Miscellaneous: Cell line name from personal communication of Hinman S Derived from sampling site: Colon. Male 35669761 CVCL_ZL24 GN10 transformed cell line house mouse CVCL_ZL24 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: Transgenic with human GNRH1 promoter-Tg(SV40). 35669762 CVCL_ZL20 JR#001145 embryonic stem cell house mouse CVCL_ZL20 CL:0000010 Breed/subspecies: WSB/EiJ. Male 35669763 CVCL_ZL29 OVCA832 cancer cell line human CVCL_ZL29 CL:0000010 Derived from sampling site: Ovary. Female 35669764 CVCL_ZL25 GN11 transformed cell line house mouse CVCL_ZL25 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: Transgenic with human GNRH1 promoter-Tg(SV40). 35669765 CVCL_ZL26 GN11-EGFP transformed cell line house mouse CVCL_ZL26 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: Transgenic with human GNRH1 promoter-Tg(SV40). 35669766 CVCL_ZL27 NLT transformed cell line house mouse CVCL_ZL27 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: Transgenic with human GNRH1 promoter-Tg(SV40). Characteristics: Secretes more GnRH1 than the autologous cell line GN11 (Cellosaurus=CVCL_ZL25) 35669767 CVCL_ZL28 HOSE2089 spontaneously immortalized cell line human CVCL_ZL28 CL:0000010 Derived from sampling site: Ovary; surface epithelium Cell type=Epithelial cell.. Female 35669768 CVCL_ZL10 Tango GPR35-bla U2OS cancer cell line human CVCL_ZL10 CL:0000010 Transfected with: HGNC; 4492; GPR35; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669769 CVCL_ZL11 Tango GPR109A-bla U2OS cancer cell line human CVCL_ZL11 CL:0000010 Transfected with: HGNC; 24827; HCAR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669770 CVCL_ZL12 Tango GPR1-bla U2OS cancer cell line human CVCL_ZL12 CL:0000010 Transfected with: HGNC; 4463; CMKLR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669771 CVCL_ZL13 Tango GPR119-bla U2OS cancer cell line human CVCL_ZL13 CL:0000010 Transfected with: HGNC; 19060; GPR119; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669772 CVCL_ZL18 JR#000928 embryonic stem cell CVCL_ZL18 CL:0000010 Breed/subspecies: CAST/EiJ. Male 35669773 CVCL_ZL19 GN transformed cell line house mouse CVCL_ZL19 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain; hypothalamus Cell type=GnRH neuron.; Breed/subspecies: Transgenic with human GNRH1 promoter-Tg(SV40). 35669774 CVCL_ZL14 Tango GPR44 (CRTH2)-bla U2OS cancer cell line human CVCL_ZL14 CL:0000010 Transfected with: HGNC; 4502; PTGDR2; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669775 CVCL_ZL15 JR#000646 embryonic stem cell house mouse CVCL_ZL15 CL:0000010 Breed/subspecies: A/J. Male 35669776 CVCL_ZL16 AC464 embryonic stem cell house mouse CVCL_ZL16 CL:0000010 Breed/subspecies: C57BL/6J-Chr 12A/J/NaJ. Male 35669777 CVCL_ZL17 JR#000664 embryonic stem cell house mouse CVCL_ZL17 CL:0000010 Breed/subspecies: C57BL/6J. Male 35669778 CVCL_ZK91 GeneBLAzer CMV-bla Jurkat cancer cell line human CVCL_ZK91 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CMV promoter 35669779 CVCL_ZK92 Tango NPY2R-bla U2OS cancer cell line human CVCL_ZK92 CL:0000010 Transfected with: HGNC; 7957; NPY2R; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669780 CVCL_ZK93 Tango OPRM1-bla U2OS cancer cell line human CVCL_ZK93 CL:0000010 Transfected with: HGNC; 8156; OPRM1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669781 CVCL_ZK94 Tango HTR1D-bla U2OS cancer cell line human CVCL_ZK94 CL:0000010 Transfected with: HGNC; 5289; HTR1D; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669782 CVCL_ZK90 GeneBLAzer T-Rex GPR119-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK90 CL:0000010 Transfected with: HGNC; 19060; GPR119; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669783 CVCL_ZK99 GeneBLAzer PPARgamma-UAS-bla HEK 293H transformed cell line human CVCL_ZK99 CL:0000010 Transfected with: HGNC; 9236; PPARG (ligand-binding domain); Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS) 35669784 CVCL_ZK95 Tango GLP2R-bla U2OS cancer cell line human CVCL_ZK95 CL:0000010 Transfected with: HGNC; 4325; GLP2R; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669785 CVCL_ZK96 Tango HTR2A-bla U2OS cancer cell line human CVCL_ZK96 CL:0000010 Transfected with: HGNC; 5293; HTR2A; Transfected with: HGNC; 712; ARRB2; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669786 CVCL_ZK97 Tango OPRK1-bla U2OS cancer cell line human CVCL_ZK97 CL:0000010 Transfected with: HGNC; 8154; OPRK1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del); Transfected with: UniProtKB; P04517; Tobacco etch virus (TEV) protease (AA 2038-2279); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: The target GPCR is linked to a TEV protease cleavage site and a GAL4-VP16 transcription factor When activated the GPCR recruits the beta-arrestin/TEV protease fusion protein, the TEV protease cleaves off the transcription factor that translocates to the nucleus to activate the expression of the bla gene.; Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS) 35669787 CVCL_ZK98 GeneBLAzer UAS-bla HEK 293H transformed cell line human CVCL_ZK98 CL:0000010 Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS) 35669788 CVCL_ZK80 GeneBLAzer PTGER1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK80 CL:0000010 Transfected with: HGNC; 9593; PTGER1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669789 CVCL_ZK81 GeneBLAzer PTGER2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK81 CL:0000010 Transfected with: HGNC; 9594; PTGER2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669790 CVCL_ZK82 GeneBLAzer PTGIR-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK82 CL:0000010 Transfected with: HGNC; 9602; PTGIR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669791 CVCL_ZK83 GeneBLAzer OPRK1-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK83 CL:0000010 Transfected with: HGNC; 8154; OPRK1; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669792 CVCL_ZK88 GeneBLAzer SCTR-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK88 CL:0000010 Transfected with: HGNC; 10608; SCTR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669793 CVCL_ZK89 GeneBLAzer TACR2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK89 CL:0000010 Transfected with: HGNC; 11527; TACR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669794 CVCL_ZK84 GeneBLAzer VPAC1-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK84 CL:0000010 Transfected with: HGNC; 12694; VIPR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669795 CVCL_ZK85 GeneBLAzer VPAC2-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK85 CL:0000010 Transfected with: HGNC; 12695; VIPR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669796 CVCL_ZK86 GeneBLAzer GRPR-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK86 CL:0000010 Transfected with: HGNC; 4609; GRPR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669797 CVCL_ZK87 GeneBLAzer MCHR2-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK87 CL:0000010 Transfected with: HGNC; 20867; MCHR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669798 CVCL_ZK70 GeneBLAzer H2-CRE-bla HEK 293T transformed cell line human CVCL_ZK70 CL:0000010 Transfected with: HGNC; 5183; HRH2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669799 CVCL_ZK71 GeneBLAzer HTR2B-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK71 CL:0000010 Transfected with: HGNC; 5294; HTR2B; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669800 CVCL_ZK72 GeneBLAzer LTB4R-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK72 CL:0000010 Transfected with: HGNC; 6713; LTB4R; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669801 CVCL_ZK77 GeneBLAzer MC1R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK77 CL:0000010 Transfected with: HGNC; 6929; MC1R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669802 CVCL_ZK78 GeneBLAzer M4-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK78 CL:0000010 Transfected with: HGNC; 1953; CHRM4; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669803 CVCL_ZK79 GeneBLAzer M5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK79 CL:0000010 Transfected with: HGNC; 1954; CHRM5; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669804 CVCL_ZK73 GeneBLAzer MC3R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK73 CL:0000010 Transfected with: HGNC; 6931; MC3R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669805 CVCL_ZK74 GeneBLAzer MC4R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK74 CL:0000010 Transfected with: HGNC; 6932; MC4R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669806 CVCL_ZK75 GeneBLAzer MC5R-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZK75 CL:0000010 Transfected with: HGNC; 6933; MC5R; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35669807 CVCL_ZK76 GeneBLAzer M1-NFAT-bla Jurkat cancer cell line human CVCL_ZK76 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35669808 CVCL_ZM20 XP101TO finite cell line human CVCL_ZM20 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669809 CVCL_ZM21 XP102TO finite cell line human CVCL_ZM21 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669810 CVCL_ZM22 XP103TO finite cell line human CVCL_ZM22 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669811 CVCL_ZM23 XP104TO finite cell line human CVCL_ZM23 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669812 CVCL_ZM28 XP26KO finite cell line human CVCL_ZM28 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669813 CVCL_ZM29 XP4KO finite cell line human CVCL_ZM29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669814 CVCL_ZM24 XP43KO finite cell line human CVCL_ZM24 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Asp234Asn (c.700G>A); Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg601Leu (c.1802G>T); Zygosity=Heterozygous (PubMed=9238033) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669815 CVCL_ZM25 XP25KO finite cell line human CVCL_ZM25 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669816 CVCL_ZM26 XP27KO finite cell line human CVCL_ZM26 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669817 CVCL_ZM27 XP28KO finite cell line human CVCL_ZM27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669818 CVCL_ZM10 N2A FLAG-Cdh1 cancer cell line house mouse CVCL_ZM10 CL:0000010 Transfected with: MGI; MGI:1926790; Fzr1 Breed/subspecies: A/J. Male 35669819 CVCL_ZM11 WT-AG09319 C2 induced pluripotent stem cell human CVCL_ZM11 CL:0000010 Derived from sampling site: Oral cavity; gingiva. Omics: Transcriptome analysis by microarray Female 35669820 CVCL_ZM12 XP20PV finite cell line human CVCL_ZM12 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35669821 CVCL_ZM17 XP93TO finite cell line human CVCL_ZM17 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669822 CVCL_ZM18 XP14TO finite cell line human CVCL_ZM18 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669823 CVCL_ZM19 XP10TO finite cell line human CVCL_ZM19 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669824 CVCL_ZM13 XP25PV finite cell line human CVCL_ZM13 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Asp307Tyr (c.919G>T); ClinVar=VCV000008790; Zygosity=Homozygous (PubMed=12812979) Derived from sampling site: Skin Cell type=Fibroblast.. 35669825 CVCL_ZM14 XP27PV finite cell line human CVCL_ZM14 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Lys244Terfs (c.901_904delAAAG); Zygosity=Homozygous (PubMed=12812979) Derived from sampling site: Skin Cell type=Fibroblast.. 35669826 CVCL_ZM15 XP43TO finite cell line human CVCL_ZM15 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669827 CVCL_ZM16 XP89TO finite cell line human CVCL_ZM16 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669828 CVCL_ZM00 YUMM1.7D5 cancer cell line house mouse CVCL_ZM00 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Breed/subspecies: C57BL/6. Male 35669829 CVCL_ZM01 HeLa FLAG-SNAP-hTERT cancer cell line human CVCL_ZM01 CL:0000010 Transfected with: HGNC; 7059; MGMT (with p.Gly180_Asn_207del and 19 mutations = SNAP-tag) Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Using CRISPR/Cas9 a FLAG-SNAP-tag was fused to the N-terminus of TERT The SNAP-tag may be used to visualize subcellular localization of the low abundant endogenous TERT protein. 35669830 CVCL_ZM06 HEK293T Control-PEROXO transformed cell line human CVCL_ZM06 CL:0000010 Transfected with: HGNC; 22965; PEX26 (with Met1_Val236del); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Expresses Control-PEROXO-Tag, a chimeric protein consisting of three Myc epitopes attached to the N-terminus of mEGFP and a segment of PEX26 fused to the EGFP C-terminus 35669831 CVCL_ZM07 HEK293T HA-PEROXO transformed cell line human CVCL_ZM07 CL:0000010 Transfected with: HGNC; 22965; PEX26 (with Met1_Val236del); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Omics: Quantitative peroxisome proteome analysis by proteomics Female Characteristics: Expresses PEROXO-Tag, a chimeric protein consisting of three HA epitopes attached to the N-terminus of mEGFP and a segment of PEX26 fused to the EGFP C-terminus This tag allows for localization to and insertion into the peroxisomal membrane. 35669832 CVCL_ZM08 T-47D Control-PEROXO cancer cell line human CVCL_ZM08 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 22965; PEX26 (with Met1_Val236del); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Pleural effusion. Female Characteristics: Expresses Control-PEROXO-Tag, a chimeric protein consisting of three Myc epitopes attached to the N-terminus of mEGFP and a segment of PEX26 fused to the EGFP C-terminus 35669833 CVCL_ZM09 T-47D HA-PEROXO cancer cell line human CVCL_ZM09 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 22965; PEX26 (with Met1_Val236del); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from metastatic site: Pleural effusion. Female Characteristics: Expresses PEROXO-Tag, a chimeric protein consisting of three HA epitopes attached to the N-terminus of mEGFP and a segment of PEX26 fused to the EGFP C-terminus This tag allows for localization to and insertion into the peroxisomal membrane. 35669834 CVCL_ZM02 HeLa H2B-GFP cancer cell line human CVCL_ZM02 CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: The H2B-EGFP fusion protein is expressed under the control of the EF1a promoter 35669835 CVCL_ZM03 ZZUNEUi011-A induced pluripotent stem cell human CVCL_ZM03 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669836 CVCL_ZM04 ZZUNEUi012-A induced pluripotent stem cell human CVCL_ZM04 From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35669837 CVCL_ZM05 DM165 cancer cell line human CVCL_ZM05 HLA typing: A*02; B*12,44 (PubMed=2785141) From: Duke University Medical Center; Durham; USA CL:0000010 Derived from metastatic site: Lymph node. 35669838 CVCL_ZM90 XP16OS finite cell line human CVCL_ZM90 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669839 CVCL_ZM91 XP17OS finite cell line human CVCL_ZM91 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669840 CVCL_ZM92 XP19OS finite cell line human CVCL_ZM92 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669841 CVCL_ZM97 XP25OS finite cell line human CVCL_ZM97 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669842 CVCL_ZM98 XP26OS finite cell line human CVCL_ZM98 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669843 CVCL_ZM99 XP28OS finite cell line human CVCL_ZM99 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669844 CVCL_ZM93 XP20OS finite cell line human CVCL_ZM93 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669845 CVCL_ZM94 XP21OS finite cell line human CVCL_ZM94 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669846 CVCL_ZM95 XP22OS finite cell line human CVCL_ZM95 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7947212) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669847 CVCL_ZM96 XP24OS finite cell line human CVCL_ZM96 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669848 CVCL_ZM80 XP4OS finite cell line human CVCL_ZM80 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669849 CVCL_ZM81 XP5OS finite cell line human CVCL_ZM81 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669850 CVCL_ZM86 XP11OS finite cell line human CVCL_ZM86 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669851 CVCL_ZM87 XP12OS finite cell line human CVCL_ZM87 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669852 CVCL_ZM88 XP13OS finite cell line human CVCL_ZM88 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669853 CVCL_ZM89 XP14OS finite cell line human CVCL_ZM89 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669854 CVCL_ZM82 XP6OS finite cell line human CVCL_ZM82 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669855 CVCL_ZM83 XP7OS finite cell line human CVCL_ZM83 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669856 CVCL_ZM84 XP8OS finite cell line human CVCL_ZM84 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669857 CVCL_ZM85 XP9OS finite cell line human CVCL_ZM85 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669858 CVCL_ZM70 XP10SE finite cell line human CVCL_ZM70 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669859 CVCL_ZM75 EB-BS-AkSak transformed cell line human CVCL_ZM75 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser186_Lys187delinsTer (c.557_559delCAA) (S186*); ClinVar=VCV000005455; Zygosity=Heterozygous (PubMed=17407155); Sequence variation: Mutation; HGNC; 1058; BLM; Simple; c.2074+1G>T; ClinVar=VCV000042066; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=17407155) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 78(AkSak) (BSR78); Derived from sampling site: Peripheral blood. Male 35669860 CVCL_ZM76 XP18BR finite cell line human CVCL_ZM76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35669861 CVCL_ZM77 XP8TO finite cell line human CVCL_ZM77 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669862 CVCL_ZM78 XP9TO finite cell line human CVCL_ZM78 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669863 CVCL_ZM71 XP11SE finite cell line human CVCL_ZM71 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669864 CVCL_ZM72 XP13SE finite cell line human CVCL_ZM72 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669865 CVCL_ZM73 XP14SE finite cell line human CVCL_ZM73 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669866 CVCL_ZM74 XP16SE finite cell line human CVCL_ZM74 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669867 CVCL_ZM79 XP1OS finite cell line human CVCL_ZM79 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669868 CVCL_ZM64 XP3SE finite cell line human CVCL_ZM64 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669869 CVCL_ZM65 XP4SE finite cell line human CVCL_ZM65 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669870 CVCL_ZM66 XP6SE finite cell line human CVCL_ZM66 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669871 CVCL_ZM67 XP7SE finite cell line human CVCL_ZM67 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669872 CVCL_ZM60 XP4SA finite cell line human CVCL_ZM60 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669873 CVCL_ZM61 XP5SA finite cell line human CVCL_ZM61 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669874 CVCL_ZM62 XP1SE [Sendai] finite cell line human CVCL_ZM62 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669875 CVCL_ZM63 XP2SE finite cell line human CVCL_ZM63 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669876 CVCL_ZM68 XP8SE finite cell line human CVCL_ZM68 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669877 CVCL_ZM69 XP9SE finite cell line human CVCL_ZM69 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669878 CVCL_ZM53 XP4KA finite cell line human CVCL_ZM53 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669879 CVCL_ZM54 XP40KO finite cell line human CVCL_ZM54 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669880 CVCL_ZM55 XP115KO finite cell line human CVCL_ZM55 CL:0000010 Sequence variation: Mutation; HGNC; 47; ABCB6; Simple; p.Asn467Ser (c.1400A>G); Zygosity=Heterozygous (PubMed=29330851); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg579Ter (c.1735C>T); ClinVar=VCV000000259; Zygosity=Homozygous (PubMed=29330851) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669881 CVCL_ZM56 XP18OSHM finite cell line human CVCL_ZM56 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Tyr116Ter (c.348T>A); ClinVar=VCV000000997; Zygosity=Heterozygous (from familial inference of XP18OS) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669882 CVCL_ZM50 XP4JTO-II finite cell line human CVCL_ZM50 CL:0000010 Population: Japanese; Derived from sampling site: Elbow; skin Cell type=Fibroblast.. Female 35669883 CVCL_ZM51 XP5JTO finite cell line human CVCL_ZM51 CL:0000010 Population: Japanese; Derived from sampling site: Elbow; skin Cell type=Fibroblast.. Female 35669884 CVCL_ZM52 XP38KO finite cell line human CVCL_ZM52 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669885 CVCL_ZM57 XP1AS finite cell line human CVCL_ZM57 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669886 CVCL_ZM58 XP2AS finite cell line human CVCL_ZM58 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669887 CVCL_ZM59 XP3SA finite cell line human CVCL_ZM59 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669888 CVCL_ZM42 XP21KO finite cell line human CVCL_ZM42 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669889 CVCL_ZM43 XP22KO finite cell line human CVCL_ZM43 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669890 CVCL_ZM44 XP16KO-II finite cell line human CVCL_ZM44 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669891 CVCL_ZM45 NHSF3 finite cell line human CVCL_ZM45 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669892 CVCL_ZM40 XP19KO finite cell line human CVCL_ZM40 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669893 CVCL_ZM41 XP20KO finite cell line human CVCL_ZM41 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669894 CVCL_ZM46 NHSF6 finite cell line human CVCL_ZM46 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 56 PDL (PubMed=4083160) 35669895 CVCL_ZM47 NHSF40 finite cell line human CVCL_ZM47 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669896 CVCL_ZM48 HeLa S3 9IV cancer cell line human CVCL_ZM48 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 35669897 CVCL_ZM49 XP4JTO-I finite cell line human CVCL_ZM49 CL:0000010 Population: Japanese; Derived from sampling site: Elbow; skin Cell type=Fibroblast.. Female 35669898 CVCL_ZM31 XP6KO finite cell line human CVCL_ZM31 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669899 CVCL_ZM32 XP5KO finite cell line human CVCL_ZM32 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669900 CVCL_ZM33 XP11KO finite cell line human CVCL_ZM33 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669901 CVCL_ZM34 XP3KO finite cell line human CVCL_ZM34 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669902 CVCL_ZM30 XP59TO finite cell line human CVCL_ZM30 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669903 CVCL_ZM39 XP17KO finite cell line human CVCL_ZM39 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35669904 CVCL_ZM35 XP8KO finite cell line human CVCL_ZM35 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669905 CVCL_ZM36 XP9KO finite cell line human CVCL_ZM36 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669906 CVCL_ZM37 XP12KO finite cell line human CVCL_ZM37 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669907 CVCL_ZM38 XP16KO-I finite cell line human CVCL_ZM38 CL:0000010 Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35669908 CVCL_ZL90 ZJUi001-A induced pluripotent stem cell human CVCL_ZL90 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Hemizygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 35669909 CVCL_ZL91 ZJUi001-B induced pluripotent stem cell human CVCL_ZL91 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Hemizygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 35669910 CVCL_ZL92 ZJUi001-C induced pluripotent stem cell human CVCL_ZL92 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Hemizygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Male 35669911 CVCL_ZL93 ZJUi002-A induced pluripotent stem cell human CVCL_ZL93 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Heterozygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Female 35669912 CVCL_ZL98 SMBCi005-A induced pluripotent stem cell human CVCL_ZL98 From: Shandong Medical Biotechnological Center; Jinan; China. CL:0000010 35669913 CVCL_ZL99 YUMM1.7D4 cancer cell line house mouse CVCL_ZL99 CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Breed/subspecies: C57BL/6. Male 35669914 CVCL_ZL94 ZJUi002-B induced pluripotent stem cell human CVCL_ZL94 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Heterozygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Female 35669915 CVCL_ZL95 ZJUi002-C induced pluripotent stem cell human CVCL_ZL95 From: Women's Hospital, Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Simple; p.Gly166Val (c.497G>T); ClinVar=VCV000448900; Zygosity=Heterozygous (PubMed=33039804) Population: Chinese; Han; Derived from sampling site: Urine Cell type=Epithelial cell.. Female 35669916 CVCL_ZL96 SHCDNi003-A induced pluripotent stem cell human CVCL_ZL96 From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 10923; SLC16A2; Simple; c.1026+1G>A; Zygosity=Hemizygous; Note=Splice donor mutation (PubMed=32603881) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35669917 CVCL_ZL97 SMBCi004-A induced pluripotent stem cell human CVCL_ZL97 From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Leu483Pro (c.1448T>C) (L444P); ClinVar=VCV000004288; Zygosity=Homozygous (PubMed=32977293) Population: Chinese; Han; Derived from sampling site: Urine. Female 35669918 CVCL_ZN41 XP9MA finite cell line human CVCL_ZN41 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Homozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669919 CVCL_ZN42 XPLA-Be finite cell line human CVCL_ZN42 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Tyr542Cys (c.1625A>G); Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669920 CVCL_ZN43 XP22VI finite cell line human CVCL_ZN43 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669921 CVCL_ZN44 XP23VI finite cell line human CVCL_ZN44 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669922 CVCL_ZN40 XPJCLO finite cell line human CVCL_ZN40 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033; PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gln645fs (c.1933_1934delCA); Zygosity=Heterozygous (PubMed=9238033; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669923 CVCL_ZN49 205BR finite cell line human CVCL_ZN49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669924 CVCL_ZN45 XP26VI finite cell line human CVCL_ZN45 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669925 CVCL_ZN46 XP233VI finite cell line human CVCL_ZN46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669926 CVCL_ZN47 AT6BR finite cell line human CVCL_ZN47 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5763-1050A>G (5762ins137); ClinVar=VCV000003021; Zygosity=Unspecified (PubMed=12082606) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669927 CVCL_ZN48 AT25BI finite cell line human CVCL_ZN48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669928 CVCL_ZN30 XP34BR finite cell line human CVCL_ZN30 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala818Val (c.2453C>T); ClinVar=VCV000996657; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Thr863fs (c.2586_2587delTA); Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669929 CVCL_ZN31 XP1DU finite cell line human CVCL_ZN31 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Trp (c.1846C>T); ClinVar=VCV000016788; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669930 CVCL_ZN32 XP2DU finite cell line human CVCL_ZN32 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys70fs (c.207delG); ClinVar=VCV000005892; Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669931 CVCL_ZN33 XP101LO finite cell line human CVCL_ZN33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669932 CVCL_ZN38 XP130LO finite cell line human CVCL_ZN38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669933 CVCL_ZN39 XP135LO finite cell line human CVCL_ZN39 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Homozygous (PubMed=9238033; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669934 CVCL_ZN34 XP106LO finite cell line human CVCL_ZN34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669935 CVCL_ZN35 XP107LO finite cell line human CVCL_ZN35 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669936 CVCL_ZN36 XP111LO finite cell line human CVCL_ZN36 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=9238033); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669937 CVCL_ZN37 XP124LO finite cell line human CVCL_ZN37 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala792Val (c.2375C>T) (2572C>T); ClinVar=VCV000016567; Zygosity=Heterozygous (from autologous cell line XP124LO LCL); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu960Ter (c.2878G>T) (3075G>T); ClinVar=VCV000016566; Zygosity=Heterozygous (from autologous cell line XP124LO LCL) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669938 CVCL_ZN20 AT4JTOM(SV) finite cell line human CVCL_ZN20 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669939 CVCL_ZN21 250BR finite cell line human CVCL_ZN21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669940 CVCL_ZN22 251BR finite cell line human CVCL_ZN22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669941 CVCL_ZN27 XP58TO finite cell line human CVCL_ZN27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669942 CVCL_ZN28 XP15BR finite cell line human CVCL_ZN28 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Val90Lysfs*15 (c.266_267dupAA); ClinVar=VCV000524023; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669943 CVCL_ZN29 XP16BR finite cell line human CVCL_ZN29 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=9238033; PubMed=26184184; PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=9238033; PubMed=26184184; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669944 CVCL_ZN23 XP14BR.1 finite cell line human CVCL_ZN23 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg718Ter (c.2152C>T); ClinVar=VCV000551486; Zygosity=Unspecified (from autologous cell line XP14BR.2) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669945 CVCL_ZN24 LB146 transformed cell line human CVCL_ZN24 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35669946 CVCL_ZN25 LB102 transformed cell line human CVCL_ZN25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 35669947 CVCL_ZN26 142BRneo finite cell line human CVCL_ZN26 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669948 CVCL_ZN09 XP41OS finite cell line human CVCL_ZN09 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669949 CVCL_ZN10 XP42OS finite cell line human CVCL_ZN10 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669950 CVCL_ZN11 XP43OS finite cell line human CVCL_ZN11 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669951 CVCL_ZN16 XP2NA finite cell line human CVCL_ZN16 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669952 CVCL_ZN17 XP3NA finite cell line human CVCL_ZN17 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669953 CVCL_ZN18 XP4NA finite cell line human CVCL_ZN18 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669954 CVCL_ZN19 AT4JTO(SV) finite cell line human CVCL_ZN19 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669955 CVCL_ZN12 XP44OS finite cell line human CVCL_ZN12 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669956 CVCL_ZN13 XP1KO finite cell line human CVCL_ZN13 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669957 CVCL_ZN14 XP1YO finite cell line human CVCL_ZN14 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669958 CVCL_ZN15 XP1NA finite cell line human CVCL_ZN15 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669959 CVCL_ZN00 XP29OS finite cell line human CVCL_ZN00 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669960 CVCL_ZN05 XP34OS finite cell line human CVCL_ZN05 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7947212) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669961 CVCL_ZN06 XP36OS finite cell line human CVCL_ZN06 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from familial inference of XP35OS) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669962 CVCL_ZN07 XP37OS finite cell line human CVCL_ZN07 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669963 CVCL_ZN08 XP38OS finite cell line human CVCL_ZN08 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669964 CVCL_ZN01 XP30OS finite cell line human CVCL_ZN01 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669965 CVCL_ZN02 XP31OS finite cell line human CVCL_ZN02 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669966 CVCL_ZN03 XP32OS finite cell line human CVCL_ZN03 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669967 CVCL_ZN04 XP33OS finite cell line human CVCL_ZN04 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669968 CVCL_ZN90 XP96TO finite cell line human CVCL_ZN90 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669969 CVCL_ZN91 XP84TO finite cell line human CVCL_ZN91 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669970 CVCL_ZN96 XP91TMA finite cell line human CVCL_ZN96 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM15700; probable Male 35669971 CVCL_ZN97 XP38BE finite cell line human CVCL_ZN97 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asp360Glyfs*32 (c.1078dupG) (c.1078_1079dupG); ClinVar=VCV001696282; Zygosity=Homozygous (PubMed=18368133) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02592; probable Male 35669972 CVCL_ZN98 XP39BE finite cell line human CVCL_ZN98 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asp360Glyfs*32 (c.1078dupG) (c.1078_1079dupG); ClinVar=VCV001696282; Zygosity=Homozygous (PubMed=18368133) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669973 CVCL_ZN99 XP161BE finite cell line human CVCL_ZN99 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asp360Glyfs*32 (c.1078dupG) (c.1078_1079dupG); ClinVar=VCV001696282; Zygosity=Homozygous (PubMed=18368133) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669974 CVCL_ZN92 XP87TO finite cell line human CVCL_ZN92 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669975 CVCL_ZN93 Ed Leb finite cell line human CVCL_ZN93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1372; true Unspecified 35669976 CVCL_ZN94 XP92TMA finite cell line human CVCL_ZN94 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln152Ter (c.454C>T); Zygosity=Homozygous (PubMed=18368133) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM15713; probable Male 35669977 CVCL_ZN95 XP1SE [Seoul] finite cell line human CVCL_ZN95 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=18368133) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669978 CVCL_ZN80 XP2OS SV40-transformed transformed cell line human CVCL_ZN80 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (Coriell) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Could be identical to XP2OS(SV) (Cellosaurus=CVCL_3242) 35669979 CVCL_ZN85 XP75TO finite cell line human CVCL_ZN85 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1372102; PubMed=1702221); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Heterozygous (PubMed=1372102; PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669980 CVCL_ZN86 XP67TO finite cell line human CVCL_ZN86 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Tyr116Ter (c.348T>A); ClinVar=VCV000000997; Zygosity=Heterozygous (PubMed=1372102; PubMed=1702221); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=1372102; PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669981 CVCL_ZN87 XP8LO finite cell line human CVCL_ZN87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1376; true Female 35669982 CVCL_ZN88 Me Leb finite cell line human CVCL_ZN88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: ATCC; CRL-1371; true Unspecified 35669983 CVCL_ZN81 14B2 hybridoma house mouse CVCL_ZN81 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04062; Human GBA. 35669984 CVCL_ZN82 16B3 hybridoma house mouse CVCL_ZN82 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04062; Human GBA. 35669985 CVCL_ZN83 B6D4 hybridoma house mouse CVCL_ZN83 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04062; Human GBA. 35669986 CVCL_ZN84 B8B3 hybridoma house mouse CVCL_ZN84 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P04062; Human GBA. 35669987 CVCL_ZN89 XP78TO finite cell line human CVCL_ZN89 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Tyr116Ter (c.348T>A); ClinVar=VCV000000997; Zygosity=Heterozygous (PubMed=1372102); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669988 CVCL_ZN74 CS1MA finite cell line human CVCL_ZN74 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Phe665_Gln723del (c.1993_2169del177); Zygosity=Homozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669989 CVCL_ZN75 XP32TO finite cell line human CVCL_ZN75 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669990 CVCL_ZN76 XP35TO finite cell line human CVCL_ZN76 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669991 CVCL_ZN77 XP54TO finite cell line human CVCL_ZN77 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35669992 CVCL_ZN70 CS2BI finite cell line human CVCL_ZN70 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg670Trp (c.2008C>T) (C2087T); ClinVar=VCV000190158; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Pro1042Leu (c.3125C>T) (C3204T); Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669993 CVCL_ZN71 CS3TAN finite cell line human CVCL_ZN71 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Trp851Arg (c.2551T>A) (T2630A); ClinVar=VCV000522698; Zygosity=Homozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669994 CVCL_ZN72 CS7TAN finite cell line human CVCL_ZN72 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg1213Gly (c.3637A>G) (A3716G); ClinVar=VCV000129017; Zygosity=Homozygous (PubMed=9443879) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669995 CVCL_ZN73 CS1IAF finite cell line human CVCL_ZN73 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Val957Gly (c.2870T>G) (T2949G); ClinVar=VCV001704479; Zygosity=Homozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Jewish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669996 CVCL_ZN78 CS5BR finite cell line human CVCL_ZN78 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Unexplicit; Mutation in splice donor site of intron 9; Zygosity=Homozygous (PubMed=7664335) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35669997 CVCL_ZN79 CS6BR finite cell line human CVCL_ZN79 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Unexplicit; Mutation in splice donor site of intron 9; Zygosity=Homozygous (PubMed=7664335) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35669998 CVCL_ZN63 CS3BR finite cell line human CVCL_ZN63 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Leu271Pro (c.812T>C); ClinVar=VCV000354015; Zygosity=Homozygous (PubMed=29572252) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35669999 CVCL_ZN64 CS2SE finite cell line human CVCL_ZN64 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Heterozygous (PubMed=12655141); Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Gln106Pro (c.317A>C); Zygosity=Heterozygous (PubMed=12655141) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670000 CVCL_ZN65 CS8BR finite cell line human CVCL_ZN65 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Gln854Ter (c.2560C>T) (C2639T); ClinVar=VCV000557733; Zygosity=Homozygous (PubMed=9443879) Population: Indo Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670001 CVCL_ZN66 XP31TO finite cell line human CVCL_ZN66 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=1702221) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670002 CVCL_ZN60 CS3LO finite cell line human CVCL_ZN60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670003 CVCL_ZN61 CS1BR finite cell line human CVCL_ZN61 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Val161Ile (c.481G>A); ClinVar=VCV000645783; Zygosity=Homozygous (PubMed=29572252) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670004 CVCL_ZN62 CS2BR finite cell line human CVCL_ZN62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670005 CVCL_ZN67 CS10BR finite cell line human CVCL_ZN67 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys1203fs (c.3607_3608insGGGCTGGCTGCTTAAGGTCCACCTTA) (3686ins26); ClinVar=VCV000190168; Zygosity=Homozygous (PubMed=9443879) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670006 CVCL_ZN68 CS1ABR finite cell line human CVCL_ZN68 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys1203fs (c.3607_3608insGGGCTGGCTGCTTAAGGTCCACCTTA) (3686ins26); ClinVar=VCV000190168; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; DOI=10.1086/302394); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; c.2599-26A>G; ClinVar=VCV000190162; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e; DOI=10.1086/302394) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670007 CVCL_ZN69 CS10LO finite cell line human CVCL_ZN69 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Ser429Lysfs*7 (c.1280dupT); ClinVar=VCV000190146; Zygosity=Homozygous (PubMed=9443879) Population: African; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670008 CVCL_ZN52 XP7NE finite cell line human CVCL_ZN52 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Pro379Ser (c.1135C>T); ClinVar=VCV000134148; Zygosity=Heterozygous (PubMed=20221251) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670009 CVCL_ZN53 XP26PV finite cell line human CVCL_ZN53 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Homozygous (PubMed=10766188) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670010 CVCL_ZN54 TTD3VI finite cell line human CVCL_ZN54 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg658His (c.1973G>A); ClinVar=VCV001499293; Zygosity=Heterozygous (PubMed=8571952); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=8571952) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670011 CVCL_ZN55 XP22BE finite cell line human CVCL_ZN55 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2033+2T>G (IVS9+2T>G); ClinVar=VCV000000257; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=9804340) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670012 CVCL_ZN50 128BR finite cell line human CVCL_ZN50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670013 CVCL_ZN51 XP6BR finite cell line human CVCL_ZN51 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Thr808Valfs*48 (c.2421_2604del184); Zygosity=Heterozygous (PubMed=10766188) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670014 CVCL_ZN56 XP10BR finite cell line human CVCL_ZN56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670015 CVCL_ZN57 XP9BR finite cell line human CVCL_ZN57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670016 CVCL_ZN58 CS2TAN finite cell line human CVCL_ZN58 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Trp517Ter (c.1550G>A); ClinVar=VCV000001700; Zygosity=Homozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670017 CVCL_ZN59 CS1TAN finite cell line human CVCL_ZN59 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg735Ter (c.2203C>T) (C2282T); ClinVar=VCV000001701; Zygosity=Homozygous (DOI=10.21954/ou.ro.0000e27e; PubMed=9443879) Population: Turkish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670018 CVCL_ZF41 NSC-HyCu15B spontaneously immortalized cell line CVCL_ZF41 CL:0000010 Derived from sampling site: Fat body. Unspecified Group: Insect cell line 35670019 CVCL_ZF42 BCIRL-HZ-AM3-F9 spontaneously immortalized cell line CVCL_ZF42 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 35670020 CVCL_ZF43 BCIRL-HZ-AM1-A4 spontaneously immortalized cell line CVCL_ZF43 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 35670021 CVCL_ZF44 BCIRL-HZ-AM1-A7 spontaneously immortalized cell line CVCL_ZF44 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 34 hours (PubMed=2022870) Group: Insect cell line 35670022 CVCL_ZF40 RML12.wMelPopCLA spontaneously immortalized cell line CVCL_ZF40 CL:0000010 Unspecified Characteristics: Infected by Wolbachia pipientis strain wMelPop-CLA. Group: Insect cell line Problematic cell line: Misidentified Parent cell line (RML-12) was originally thought to be of Aedes aegypti origin but found to be from Aedes albopictus. 35670023 CVCL_ZF49 PFAT cancer cell line human CVCL_ZF49 CL:0000010 Unspecified 35670024 CVCL_ZF45 BCIRL-HZ-AM1-B3 spontaneously immortalized cell line CVCL_ZF45 CL:0000010 Derived from sampling site: Ovary. Female Doubling time: 24 hours (PubMed=2022870) Group: Insect cell line 35670025 CVCL_ZF46 PR-57 spontaneously immortalized cell line CVCL_ZF46 CL:0000010 Derived from sampling site: Ovary. Female Group: Insect cell line 35670026 CVCL_ZF47 JBSA cancer cell line human CVCL_ZF47 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9499454) Karyotypic information: Hypotriploid karyotype; Derived from sampling site: Brain. Male Doubling time: 26 hours (PubMed=7621407) 35670027 CVCL_ZF48 PFGC cancer cell line human CVCL_ZF48 CL:0000010 Unspecified 35670028 CVCL_ZF30 HIRO-305 hybridoma CVCL_ZF30 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P02724; Human GYPA/CD235a (with p.Thr31Pro) (Note=Recognizes SUMI blood group antigen). 35670029 CVCL_ZF31 PBDEP-4 transformed cell line human CVCL_ZF31 CL:0000010 Transfected with: HGNC; 992; BCL2L1 (isoform Bcl-xL); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Peripheral blood. Unspecified 35670030 CVCL_ZF32 PBDEP-4-dGYPA transformed cell line human CVCL_ZF32 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4702; GYPA; Transfected with: HGNC; 992; BCL2L1 (isoform Bcl-xL); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Peripheral blood. Unspecified 35670031 CVCL_ZF33 NIAS-Bm-F1 spontaneously immortalized cell line CVCL_ZF33 CL:0000010 Breed/subspecies: Sex limited black egg. Female Doubling time: ~3 days (PubMed=17967886) Group: Insect cell line 35670032 CVCL_ZF38 Pr-E-HNU9(C) spontaneously immortalized cell line CVCL_ZF38 CL:0000010 Unspecified Group: Insect cell line. 35670033 CVCL_ZF39 RB1442 cancer cell line human CVCL_ZF39 CL:0000010 35670034 CVCL_ZF34 NIAS-Bm-M1 spontaneously immortalized cell line CVCL_ZF34 CL:0000010 Breed/subspecies: Sex limited black egg. Male Doubling time: ~3 days (PubMed=17967886) Group: Insect cell line 35670035 CVCL_ZF35 SYSU-OfHe-C spontaneously immortalized cell line CVCL_ZF35 CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Doubling time: 2.37 days (PubMed=24513271) Group: Insect cell line 35670036 CVCL_ZF36 Pr-E-HNU9(A) spontaneously immortalized cell line CVCL_ZF36 CL:0000010 Unspecified Group: Insect cell line. 35670037 CVCL_ZF37 Pr-E-HNU9(B) spontaneously immortalized cell line CVCL_ZF37 CL:0000010 Unspecified Group: Insect cell line. 35670038 CVCL_ZF20 RB1224 cancer cell line human CVCL_ZF20 CL:0000010 35670039 CVCL_ZF21 RB1335 cancer cell line human CVCL_ZF21 CL:0000010 35670040 CVCL_ZF22 RB1355 cancer cell line human CVCL_ZF22 CL:0000010 35670041 CVCL_ZF27 JMS-3 hybrid cell line CVCL_ZF27 CL:0000010 Group: Hybridoma fusion partner cell line. 35670042 CVCL_ZF28 OSK43 hybridoma CVCL_ZF28 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q9NP58; Human ABCB6. 35670043 CVCL_ZF29 HIRO-294 hybridoma CVCL_ZF29 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q13336; Human SLC14A1 (Note=Recognizes the Jka/Jkb polymorphic site). 35670044 CVCL_ZF23 RB1518 cancer cell line human CVCL_ZF23 CL:0000010 35670045 CVCL_ZF24 RB(E)-3 cancer cell line human CVCL_ZF24 CL:0000010 35670046 CVCL_ZF25 RB(E)-5 cancer cell line human CVCL_ZF25 CL:0000010 35670047 CVCL_ZF26 HMR0921 hybridoma CVCL_ZF26 CL:0000010 Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: UniProtKB; Q9UNQ0; Human ABCG2/CD338. 35670048 CVCL_ZF10 Beta-9-F10 hybridoma house mouse CVCL_ZF10 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Pig beta-crystallin. 35670049 CVCL_ZF11 Gamma-4-A4 hybridoma house mouse CVCL_ZF11 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Pig gamma-crystallin. 35670050 CVCL_ZF16 RB893 cancer cell line human CVCL_ZF16 CL:0000010 35670051 CVCL_ZF17 RB1037 cancer cell line human CVCL_ZF17 CL:0000010 35670052 CVCL_ZF18 RB898 cancer cell line human CVCL_ZF18 CL:0000010 35670053 CVCL_ZF19 RB1210 cancer cell line human CVCL_ZF19 CL:0000010 35670054 CVCL_ZF12 HeLa E cancer cell line human CVCL_ZF12 CL:0000010 Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female 35670055 CVCL_ZF13 T101 [Human retinoblastoma] cancer cell line human CVCL_ZF13 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; None_reported; -; Zygosity=- (PubMed=23498719). 35670056 CVCL_ZF14 RB778 cancer cell line human CVCL_ZF14 CL:0000010 35670057 CVCL_ZF15 RB805 cancer cell line human CVCL_ZF15 CL:0000010 35670058 CVCL_ZF00 BCIRL-HZ-FB33 spontaneously immortalized cell line CVCL_ZF00 CL:0000010 Derived from sampling site: Fat body. Unspecified Virology: Susceptible to infection by Providence virus (PubMed=12642108) Group: Insect cell line 35670059 CVCL_ZF05 CHLA-215-Luc cancer cell line human CVCL_ZF05 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase. Characteristics: Expression of luciferase is under the control of the CMV promoter 35670060 CVCL_ZF06 Y79-Luc cancer cell line human CVCL_ZF06 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; Ex2-6del; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Unexplicit; IVS20+1G>A; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Eye; globe. Female Characteristics: Expression of luciferase is under the control of the CMV promoter 35670061 CVCL_ZF07 RB3823 cancer cell line human CVCL_ZF07 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; None_reported; -; Zygosity=- (PubMed=30584916) Miscellaneous: STR profile from personal communication of Bremner R. 35670062 CVCL_ZF08 TOTL-86 spontaneously immortalized cell line CVCL_ZF08 CL:0000010 Derived from sampling site: Eye; ocular lens; epithelium Cell type=Epithelial cell.. Unspecified Doubling time: 40 hours (PubMed=3295341) 35670063 CVCL_ZF01 BCIRL-HZ-MG8 spontaneously immortalized cell line CVCL_ZF01 CL:0000010 Derived from sampling site: Midgut. Unspecified Virology: Persistently infected by Providence virus (PubMed=12642108; PubMed=20702652) Group: Insect cell line 35670064 CVCL_ZF02 BCIRL-PX-EM1 spontaneously immortalized cell line CVCL_ZF02 CL:0000010 Unspecified Group: Insect cell line. 35670065 CVCL_ZF03 VUMC-RB-26 cancer cell line human CVCL_ZF03 CL:0000010 Omics: Transcriptome analysis by microarray. 35670066 CVCL_ZF04 RB522 cancer cell line human CVCL_ZF04 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; None_reported; -; Zygosity=- (PubMed=30584916). 35670067 CVCL_ZF09 Alpha-8-D5 hybridoma house mouse CVCL_ZF09 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P02475; Pig CRYAA. 35670068 CVCL_ZF90 CLC3 cancer cell line human CVCL_ZF90 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Pro865Glnfs*50 (c.2594_2597delCAGC); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Ile (c.839G>T); ClinVar=VCV000161517; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 17.72 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670069 CVCL_ZF91 CLC30 cancer cell line human CVCL_ZF91 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Glu158Lysfs*24 (c.472delG); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 34.06 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670070 CVCL_ZF96 CLC35 cancer cell line human CVCL_ZF96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Serfs*5 (c.798_799insT); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670071 CVCL_ZF97 CLC36 cancer cell line human CVCL_ZF97 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670072 CVCL_ZF98 CLC37 cancer cell line human CVCL_ZF98 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala276Phe (c.826_827GC>TT); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670073 CVCL_ZF99 CLC38 cancer cell line human CVCL_ZF99 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Part of: Liver Cancer Model Repository (LIMORE) 35670074 CVCL_ZF92 CLC31 cancer cell line human CVCL_ZF92 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Leu449Ter (c.1346T>A); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Cys (c.809T>G); ClinVar=VCV000376597; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 32.21 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670075 CVCL_ZF93 CLC32 cancer cell line human CVCL_ZF93 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27.1 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670076 CVCL_ZF94 CLC33 cancer cell line human CVCL_ZF94 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn329Lysfs*14 (c.987_990delTAAA); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln165Ter (c.493C>T); ClinVar=VCV000182930; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26.97 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670077 CVCL_ZF95 CLC34 cancer cell line human CVCL_ZF95 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro250His (c.749C>A); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 37.44 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670078 CVCL_ZF80 CLC20 cancer cell line human CVCL_ZF80 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Val (c.302G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31.58 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670079 CVCL_ZF85 CLC25 cancer cell line human CVCL_ZF85 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28.62 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670080 CVCL_ZF86 CLC26 cancer cell line human CVCL_ZF86 CL:0000010 Sequence variation: Mutation; HGNC; 14085; RTN4; Simple; p.Glu299Ter (c.895G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 49.16 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670081 CVCL_ZF87 CLC27 cancer cell line human CVCL_ZF87 CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Pro605Serfs*13 (c.1813_1835delCCACTTCCCATTCAGATGTACTA); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 40.13 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670082 CVCL_ZF88 CLC28 cancer cell line human CVCL_ZF88 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: 35.3 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670083 CVCL_ZF81 CLC21 cancer cell line human CVCL_ZF81 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 36.15 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670084 CVCL_ZF82 CLC22 cancer cell line human CVCL_ZF82 CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Arg368Ter (c.1102A>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Thr79Profs*5 (c.234delC); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.673-2A>T (IVS6-2A>T); ClinVar=VCV000635388; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25.39 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670085 CVCL_ZF83 CLC23 cancer cell line human CVCL_ZF83 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu14Serfs*15 (c.38dupC); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 31.57 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670086 CVCL_ZF84 CLC24 cancer cell line human CVCL_ZF84 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Gln176Leu (c.527A>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly334Val (c.1001G>T); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 37.57 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670087 CVCL_ZF89 CLC29 cancer cell line human CVCL_ZF89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Ala (c.721T>G); ClinVar=VCV000376665; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 27.78 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670088 CVCL_ZF74 CLC12 cancer cell line human CVCL_ZF74 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asp1850Glyfs*4 (c.5548dupG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Glu245Ter (c.733G>T); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 26.97 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670089 CVCL_ZF75 CLC14 cancer cell line human CVCL_ZF75 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 28.11 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670090 CVCL_ZF76 CLC15 cancer cell line human CVCL_ZF76 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Arg582Ter (c.1744A>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Glu843Glyfs*6 (c.2528delA); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 41.22 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670091 CVCL_ZF77 CLC17 cancer cell line human CVCL_ZF77 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 41.36 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670092 CVCL_ZF70 OVC-FRT cancer cell line Norway rat CVCL_ZF70 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Derived from sampling site: Muscle; Breed/subspecies: Fischer 344. 35670093 CVCL_ZF71 Ra-SLN transformed cell line CVCL_ZF71 CL:0000010 Transformant: Human T-lymphotropic virus 2 (HTLV-2)(NCBI-Taxonomy; 11909); Breed/subspecies: Japanese white. Male 35670094 CVCL_ZF72 NPC-TW03 EBV(+) cancer cell line human CVCL_ZF72 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Pharynx; nasopharynx. Male Characteristics: Compared to the parent cell line, shows increased tumorigenicity; Virology: In vitro infected with EBV isolate Akata with a neomycin-resistance gene (neo-Akata) Doubling time: ~13-14 hours (PubMed=10744066) 35670095 CVCL_ZF73 CLC10 cancer cell line human CVCL_ZF73 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Gly381Ter (c.1141G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female Doubling time: 52.18 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670096 CVCL_ZF78 CLC18 cancer cell line human CVCL_ZF78 CL:0000010 Sequence variation: Mutation; HGNC; 14310; BRD7; Simple; p.Glu277Glyfs*18 (c.830_831delAG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 1577; CCNA1; Simple; c.1098+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=31378681); Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Tyr373Ter (c.1119C>G); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 25.7 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670097 CVCL_ZF79 CLC19 cancer cell line human CVCL_ZF79 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Gly101Val (c.302G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670098 CVCL_ZF63 MIO-M4 spontaneously immortalized cell line human CVCL_ZF63 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Omics: Deep proteome analysis 35670099 CVCL_ZF64 MIO-M5 spontaneously immortalized cell line human CVCL_ZF64 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Omics: Deep proteome analysis 35670100 CVCL_ZF65 MIO-M6 spontaneously immortalized cell line human CVCL_ZF65 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. 35670101 CVCL_ZF66 MIO-M7 spontaneously immortalized cell line human CVCL_ZF66 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. Omics: Deep proteome analysis 35670102 CVCL_ZF60 AQH-hET-GBE1-Y34* corrected finite cell line CVCL_ZF60 CL:0000010 Sequence variation: Mutation; VGNC; 18263; GBE1; Simple_corrected; p.Tyr34Ter (c.102C>A); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32366884); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: American Quarter Horse. Male 35670103 CVCL_ZF61 MIO-M2 spontaneously immortalized cell line human CVCL_ZF61 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. 35670104 CVCL_ZF62 MIO-M3 spontaneously immortalized cell line human CVCL_ZF62 CL:0000010 Derived from sampling site: Eye; retina Cell type=Muller glia.. 35670105 CVCL_ZF67 B16-R1 cancer cell line house mouse CVCL_ZF67 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Established from lymph nodes metastatic cells obtained by intradermal injection of the parent cell line in the backskin of C57BL/6 mice 35670106 CVCL_ZF68 B16-R2 cancer cell line house mouse CVCL_ZF68 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Established from lymph nodes metastatic cells obtained by intradermal injection of the parent cell line in the backskin of C57BL/6 mice 35670107 CVCL_ZF69 B16-R2L cancer cell line house mouse CVCL_ZF69 CL:0000010 Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Established from lung metastatic cells obtained by intradermal injection of the parent cell line in the backskin of C57BL/6 mice 35670108 CVCL_ZF52 Ts-B-9 transformed cell line CVCL_ZF52 CL:0000010 Transformant: Cynomolgus Epstein-Barr Virus TsB-B6(NCBI-Taxonomy; 104240); Derived from sampling site: Axillary lymph node. Male Group: Non-human primate cell line 35670109 CVCL_ZF53 A388.6TG.c2 cancer cell line human CVCL_ZF53 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg832Cys (c.2494C>T); ClinVar=VCV000936373; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 35670110 CVCL_ZF54 A388.6TG.c2.neoc1 cancer cell line human CVCL_ZF54 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg832Cys (c.2494C>T); ClinVar=VCV000936373; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(ChEBI; CHEBI:21759); Derived from metastatic site: Lymph node. Male 35670111 CVCL_ZF55 BC31ad cancer cell line Norway rat CVCL_ZF55 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 35670112 CVCL_ZF50 Ts-B transformed cell line CVCL_ZF50 CL:0000010 Transformant: Cynomolgus Epstein-Barr Virus TsB-B6(NCBI-Taxonomy; 104240); Derived from sampling site: Axillary lymph node. Male Doubling time: ~4 days (PubMed=2160013) Group: Non-human primate cell line 35670113 CVCL_ZF51 Ts-B-6 transformed cell line CVCL_ZF51 CL:0000010 Transformant: Cynomolgus Epstein-Barr Virus TsB-B6(NCBI-Taxonomy; 104240); Derived from sampling site: Axillary lymph node. Male Group: Non-human primate cell line 35670114 CVCL_ZF56 BC31nonad cancer cell line Norway rat CVCL_ZF56 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 35670115 CVCL_ZF57 BC31ad clone C19 cancer cell line Norway rat CVCL_ZF57 CL:0000010 Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Derived from sampling site: Urinary bladder; Breed/subspecies: ACI/N. Male 35670116 CVCL_ZF58 Rat-BBN-BC cancer cell line Norway rat CVCL_ZF58 CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the cell line description Transformant: N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN)(ChEBI; CHEBI:91275); Breed/subspecies: Wistar. Male Doubling time: ~30 hours (PubMed=151485) 35670117 CVCL_ZF59 AQH-hET-GBE1-Y34* finite cell line CVCL_ZF59 CL:0000010 Sequence variation: Mutation; VGNC; 18263; GBE1; Simple; p.Tyr34Ter (c.102C>A); Zygosity=Heterozygous (PubMed=32366884) Derived from sampling site: Skin Cell type=Fibroblast.; Breed/subspecies: American Quarter Horse. Male 35670118 CVCL_ZH03 GM27533 transformed cell line human CVCL_ZH03 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670119 CVCL_ZH04 GM27534 transformed cell line human CVCL_ZH04 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670120 CVCL_ZH05 GM27535 transformed cell line human CVCL_ZH05 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670121 CVCL_ZH06 GM27536 transformed cell line human CVCL_ZH06 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670122 CVCL_ZH00 GM27530 transformed cell line human CVCL_ZH00 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670123 CVCL_ZH01 GM27531 transformed cell line human CVCL_ZH01 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670124 CVCL_ZH02 GM27532 transformed cell line human CVCL_ZH02 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670125 CVCL_ZH07 GM27537 transformed cell line human CVCL_ZH07 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670126 CVCL_ZH08 GM27538 transformed cell line human CVCL_ZH08 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670127 CVCL_ZH09 GM27539 transformed cell line human CVCL_ZH09 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670128 CVCL_ZG62 GM27492 transformed cell line human CVCL_ZG62 CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670129 CVCL_ZG63 GM27493 transformed cell line human CVCL_ZG63 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670130 CVCL_ZG64 GM27494 transformed cell line human CVCL_ZG64 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670131 CVCL_ZG65 GM27495 transformed cell line human CVCL_ZG65 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670132 CVCL_ZG60 GM27490 transformed cell line human CVCL_ZG60 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670133 CVCL_ZG61 GM27491 transformed cell line human CVCL_ZG61 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670134 CVCL_ZG66 GM27496 transformed cell line human CVCL_ZG66 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670135 CVCL_ZG67 GM27497 transformed cell line human CVCL_ZG67 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670136 CVCL_ZG68 GM27498 transformed cell line human CVCL_ZG68 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670137 CVCL_ZG69 GM27499 transformed cell line human CVCL_ZG69 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670138 CVCL_ZG51 GM27481 transformed cell line human CVCL_ZG51 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670139 CVCL_ZG52 GM27482 transformed cell line human CVCL_ZG52 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670140 CVCL_ZG53 GM27483 transformed cell line human CVCL_ZG53 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670141 CVCL_ZG54 GM27484 transformed cell line human CVCL_ZG54 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670142 CVCL_ZG50 GM27480 transformed cell line human CVCL_ZG50 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670143 CVCL_ZG59 GM27489 transformed cell line human CVCL_ZG59 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670144 CVCL_ZG55 GM27485 transformed cell line human CVCL_ZG55 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670145 CVCL_ZG56 GM27486 transformed cell line human CVCL_ZG56 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670146 CVCL_ZG57 GM27487 transformed cell line human CVCL_ZG57 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670147 CVCL_ZG58 GM27488 transformed cell line human CVCL_ZG58 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670148 CVCL_ZG40 GM27470 transformed cell line human CVCL_ZG40 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670149 CVCL_ZG41 GM27471 transformed cell line human CVCL_ZG41 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670150 CVCL_ZG42 GM27472 transformed cell line human CVCL_ZG42 CL:0000010 Population: Indian; Gujarati; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670151 CVCL_ZG43 GM27473 transformed cell line human CVCL_ZG43 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670152 CVCL_ZG48 GM27478 transformed cell line human CVCL_ZG48 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670153 CVCL_ZG49 GM27479 transformed cell line human CVCL_ZG49 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670154 CVCL_ZG44 GM27474 transformed cell line human CVCL_ZG44 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670155 CVCL_ZG45 GM27475 transformed cell line human CVCL_ZG45 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670156 CVCL_ZG46 GM27476 transformed cell line human CVCL_ZG46 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670157 CVCL_ZG47 GM27477 transformed cell line human CVCL_ZG47 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670158 CVCL_ZG30 LB3080-MELA cancer cell line human CVCL_ZG30 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Brain. Female 35670159 CVCL_ZG31 LB3110-MEL cancer cell line human CVCL_ZG31 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Male 35670160 CVCL_ZG32 LB3129-MELA cancer cell line human CVCL_ZG32 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Skin. Female 35670161 CVCL_ZG37 HepaFH3 finite cell line human CVCL_ZG37 CL:0000010 Derived from sampling site: Liver Cell type=Hepatocyte.. Female Characteristics: Has an extended lifespan due to the lentiviral transfer of Upcyte(R) proliferation genes Doubling time: ~28 hours (PubMed=26715207) 35670162 CVCL_ZG38 GM27468 transformed cell line human CVCL_ZG38 CL:0000010 Population: Indian; Gujarati; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670163 CVCL_ZG39 GM27469 transformed cell line human CVCL_ZG39 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670164 CVCL_ZG33 LB3129-MELB cancer cell line human CVCL_ZG33 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Female 35670165 CVCL_ZG34 LB33-MELC cancer cell line human CVCL_ZG34 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Hypodermis. Female 35670166 CVCL_ZG35 LB33-MELD cancer cell line human CVCL_ZG35 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Female 35670167 CVCL_ZG36 HAF-SRK01 finite cell line human CVCL_ZG36 CL:0000010 Miscellaneous: Doubling time from personal communication of Kunzel S.R Derived from sampling site: Heart; atrium Cell type=Fibroblast.. Male Characteristics: Has an extended lifespan due to the lentiviral transfer of Upcyte(R) proliferation genes Doubling time: ~3-4 days (Direct author submission) 35670168 CVCL_ZG20 LB2077-MELB cancer cell line human CVCL_ZG20 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Breast. Female 35670169 CVCL_ZG21 LB2077-MELC cancer cell line human CVCL_ZG21 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Heart. Female 35670170 CVCL_ZG26 LB2687-MEL cancer cell line human CVCL_ZG26 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Male 35670171 CVCL_ZG27 LB2870-MEL cancer cell line human CVCL_ZG27 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Female 35670172 CVCL_ZG28 LB2901-MEL cancer cell line human CVCL_ZG28 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Lymph node. Male 35670173 CVCL_ZG29 LB2929-MEL cancer cell line human CVCL_ZG29 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Derived from metastatic site: Lymph node. Male 35670174 CVCL_ZG22 LB2784-MEL cancer cell line human CVCL_ZG22 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Male 35670175 CVCL_ZG23 LB2805-MEL cancer cell line human CVCL_ZG23 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Female 35670176 CVCL_ZG24 LB2813-MEL cancer cell line human CVCL_ZG24 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Female 35670177 CVCL_ZG25 LB2840-MEL cancer cell line human CVCL_ZG25 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Lymph node. Male 35670178 CVCL_ZG10 CLC49 cancer cell line human CVCL_ZG10 CL:0000010 Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Gly944Ter (c.2830G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys176Tyr (c.527G>A); ClinVar=VCV000186451; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670179 CVCL_ZG15 GM27102 induced pluripotent stem cell human CVCL_ZG15 CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple_corrected; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Homozygous; Note=By CRISPR/Cas9 (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670180 CVCL_ZG16 GM27173 induced pluripotent stem cell human CVCL_ZG16 CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple_corrected; p.Ala422Thr (c.1264G>A); ClinVar=VCV000067174; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (Coriell) Population: Chinese; Derived from sampling site: Leg; skin; dermis Cell type=Fibroblast.. Female 35670181 CVCL_ZG17 GM27195 finite cell line human CVCL_ZG17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670182 CVCL_ZG18 GM27443 transformed cell line human CVCL_ZG18 CL:0000010 Population: Southeast Asian; Thai; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670183 CVCL_ZG11 CLC50 cancer cell line human CVCL_ZG11 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670184 CVCL_ZG12 CLC8 cancer cell line human CVCL_ZG12 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu51Ter (c.151G>T); ClinVar=VCV000568781; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Doubling time: 21.96 hours (PubMed=31378681) Part of: Liver Cancer Model Repository (LIMORE) 35670185 CVCL_ZG13 CLC9 cancer cell line human CVCL_ZG13 CL:0000010 Sequence variation: Mutation; HGNC; 1577; CCNA1; Simple; p.Leu276His (c.827T>A); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670186 CVCL_ZG14 H256 C6 induced pluripotent stem cell human CVCL_ZG14 From: Bioneer A/S; Horsholm; Denmark CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670187 CVCL_ZG19 LB2077-MELA cancer cell line human CVCL_ZG19 From: Ludwig Institute for Cancer Research, Brussels Branch; Brussels; Belgium CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=28636941) Derived from metastatic site: Hypodermis. Female 35670188 CVCL_ZG04 CLC43 cancer cell line human CVCL_ZG04 CL:0000010 Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670189 CVCL_ZG05 CLC44 cancer cell line human CVCL_ZG05 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Ser579Ter (c.1736C>A); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 12363; TSC2; Simple; p.Glu366Ter (c.1096G>T); ClinVar=VCV000012400; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670190 CVCL_ZG06 CLC45 cancer cell line human CVCL_ZG06 CL:0000010 Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670191 CVCL_ZG07 CLC46 cancer cell line human CVCL_ZG07 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Ser1990Cysfs*5 (c.5968_5978delAGCCTGTCATT); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser315Leufs*30 (c.943delT); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670192 CVCL_ZG00 CLC39 cancer cell line human CVCL_ZG00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu17Lysfs*27 (c.49delG); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670193 CVCL_ZG01 CLC40 cancer cell line human CVCL_ZG01 CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Leu2258Hisfs*4 (c.6773_6788delTGTTGGACATCTCGGT); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Cys (c.733G>T); ClinVar=VCV000012349; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670194 CVCL_ZG02 CLC41 cancer cell line human CVCL_ZG02 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670195 CVCL_ZG03 CLC42 cancer cell line human CVCL_ZG03 CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; c.1421+1G>T; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=31378681); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Glu (c.843C>G); ClinVar=VCV000376587; Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670196 CVCL_ZG08 CLC47 cancer cell line human CVCL_ZG08 CL:0000010 Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Glu188Ter (c.562G>T); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670197 CVCL_ZG09 CLC48 cancer cell line human CVCL_ZG09 CL:0000010 Sequence variation: Mutation; HGNC; 172; ACVR1B; Simple; p.Trp518Cysfs*9 (c.1554delG); Zygosity=Unspecified (PubMed=31378681); Sequence variation: Mutation; HGNC; 903; AXIN1; Simple; p.Gly508Valfs*197 (c.1523delG); Zygosity=Unspecified (PubMed=31378681) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male Part of: Liver Cancer Model Repository (LIMORE) 35670198 CVCL_ZG90 GM27520 transformed cell line human CVCL_ZG90 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670199 CVCL_ZG95 GM27525 transformed cell line human CVCL_ZG95 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670200 CVCL_ZG96 GM27526 transformed cell line human CVCL_ZG96 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670201 CVCL_ZG97 GM27527 transformed cell line human CVCL_ZG97 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670202 CVCL_ZG98 GM27528 transformed cell line human CVCL_ZG98 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670203 CVCL_ZG91 GM27521 transformed cell line human CVCL_ZG91 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670204 CVCL_ZG92 GM27522 transformed cell line human CVCL_ZG92 CL:0000010 Population: Indian; Sindhi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670205 CVCL_ZG93 GM27523 transformed cell line human CVCL_ZG93 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670206 CVCL_ZG94 GM27524 transformed cell line human CVCL_ZG94 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670207 CVCL_ZG99 GM27529 transformed cell line human CVCL_ZG99 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670208 CVCL_ZG84 GM27514 transformed cell line human CVCL_ZG84 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670209 CVCL_ZG85 GM27515 transformed cell line human CVCL_ZG85 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670210 CVCL_ZG86 GM27516 transformed cell line human CVCL_ZG86 CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670211 CVCL_ZG87 GM27517 transformed cell line human CVCL_ZG87 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670212 CVCL_ZG80 GM27510 transformed cell line human CVCL_ZG80 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670213 CVCL_ZG81 GM27511 transformed cell line human CVCL_ZG81 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670214 CVCL_ZG82 GM27512 transformed cell line human CVCL_ZG82 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670215 CVCL_ZG83 GM27513 transformed cell line human CVCL_ZG83 CL:0000010 Population: Indian; Marathi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670216 CVCL_ZG88 GM27518 transformed cell line human CVCL_ZG88 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670217 CVCL_ZG89 GM27519 transformed cell line human CVCL_ZG89 CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670218 CVCL_ZG73 GM27503 transformed cell line human CVCL_ZG73 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670219 CVCL_ZG74 GM27504 transformed cell line human CVCL_ZG74 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670220 CVCL_ZG75 GM27505 transformed cell line human CVCL_ZG75 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670221 CVCL_ZG76 GM27506 transformed cell line human CVCL_ZG76 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670222 CVCL_ZG70 GM27500 transformed cell line human CVCL_ZG70 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670223 CVCL_ZG71 GM27501 transformed cell line human CVCL_ZG71 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670224 CVCL_ZG72 GM27502 transformed cell line human CVCL_ZG72 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670225 CVCL_ZG77 GM27507 transformed cell line human CVCL_ZG77 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670226 CVCL_ZG78 GM27508 transformed cell line human CVCL_ZG78 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670227 CVCL_ZG79 GM27509 transformed cell line human CVCL_ZG79 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670228 CVCL_ZI24 BL-92 cancer cell line human CVCL_ZI24 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Male Virology: EBV-negative. 35670229 CVCL_ZI25 4F2 [Mouse hybridoma against fenitrothion] hybridoma house mouse CVCL_ZI25 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: ChEBI; CHEBI:34757; Fenitrothion. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201511 35670230 CVCL_ZI26 DA01693 transformed cell line human CVCL_ZI26 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01693; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670231 CVCL_ZI27 DA01802 transformed cell line human CVCL_ZI27 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670232 CVCL_ZI20 Mwanzia cancer cell line human CVCL_ZI20 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 35670233 CVCL_ZI21 Salim Mwalin cancer cell line human CVCL_ZI21 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670234 CVCL_ZI22 AK-Caren cancer cell line human CVCL_ZI22 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 35670235 CVCL_ZI23 BL-14B cancer cell line human CVCL_ZI23 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Turkish; Derived from sampling site: Bone marrow. Female Virology: EBV-negative 35670236 CVCL_ZI28 DA01288 transformed cell line human CVCL_ZI28 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA01288; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670237 CVCL_ZI29 DA02057 transformed cell line human CVCL_ZI29 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02057; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670238 CVCL_ZI13 RUD cancer cell line human CVCL_ZI13 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234His (c.700T>C); ClinVar=VCV000376691; Zygosity=Heterozygous (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 35670239 CVCL_ZI14 PICAT cancer cell line human CVCL_ZI14 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ascites. Male 35670240 CVCL_ZI15 PICATPO-1 hybrid cell line human CVCL_ZI15 CL:0000010 Selected for resistance to: ChEBI; CHEBI:17698; Chloramphenicol; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 35670241 CVCL_ZI16 DUT cancer cell line human CVCL_ZI16 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Met1Ile (c.3G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala5_Ala80del (c.14_241del228); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Population: African; Kenyan; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Male 35670242 CVCL_ZI10 HEK293 Flp-In T-Rex GLUT1 transformed cell line human CVCL_ZI10 CL:0000010 Transfected with: HGNC; 11005; SLC2A1; Transfected with: UniProtKB; P06709; Escherichia coli birA; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a BirA-FLAG-SLC2A1 construct 35670243 CVCL_ZI11 HEK293 Flp-In T-Rex GLUT1_P485L transformed cell line human CVCL_ZI11 CL:0000010 Transfected with: HGNC; 11005; SLC2A1 (with p.Pro485Leu); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a BirA-FLAG-SLC2A1(P485L) construct 35670244 CVCL_ZI12 PUT cancer cell line human CVCL_ZI12 CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line) Population: African; Nigerian; Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Ethyl methanesulfonate (Methylsulfonic acid ethyl ester(ChEBI; CHEBI:23994); Derived from sampling site: Ascites. Male 35670245 CVCL_ZI17 PUTRAL hybrid cell line human CVCL_ZI17 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 35670246 CVCL_ZI18 NAMPUT hybrid cell line human CVCL_ZI18 CL:0000010 Selected for resistance to: ChEBI; CHEBI:472805; Ouabain; Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine. 35670247 CVCL_ZI19 Peter cancer cell line human CVCL_ZI19 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670248 CVCL_ZI02 GM27897 finite cell line human CVCL_ZI02 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670249 CVCL_ZI03 GM27898 finite cell line human CVCL_ZI03 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Trp865Ter (c.2595G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Leu1067Tyrfs*10 (c.3200delT); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 13890; ITCH; Simple; c.337+2T>C; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670250 CVCL_ZI04 GM27900 transformed cell line human CVCL_ZI04 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Trp865Ter (c.2595G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Leu1067Tyrfs*10 (c.3200delT); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 13890; ITCH; Simple; c.337+2T>C; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670251 CVCL_ZI05 BIHi037-A finite cell line human CVCL_ZI05 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (PubMed=30197081) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670252 CVCL_ZI00 GM27895 finite cell line human CVCL_ZI00 CL:0000010 Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670254 CVCL_ZI06 BIHi037-B finite cell line human CVCL_ZI06 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (PubMed=30197081) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670255 CVCL_ZI07 BIHi037-C finite cell line human CVCL_ZI07 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (PubMed=30197081) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670256 CVCL_ZI08 BIHi037-D finite cell line human CVCL_ZI08 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (PubMed=30197081) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670257 CVCL_ZI09 BIHi037-E finite cell line human CVCL_ZI09 From: Berlin Institute of Health; Berlin; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Pro485Leu (c.1454C>T); ClinVar=VCV000871442; Zygosity=Heterozygous (PubMed=30197081) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670258 CVCL_ZH83 GM27799 transformed cell line human CVCL_ZH83 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670259 CVCL_ZH84 GM27800 transformed cell line human CVCL_ZH84 CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670260 CVCL_ZH85 GM27801 transformed cell line human CVCL_ZH85 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670261 CVCL_ZH86 GM27802 transformed cell line human CVCL_ZH86 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670262 CVCL_ZH80 GM27796 transformed cell line human CVCL_ZH80 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670263 CVCL_ZH81 GM27797 transformed cell line human CVCL_ZH81 CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670264 CVCL_ZH82 GM27798 transformed cell line human CVCL_ZH82 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670265 CVCL_ZH87 GM27805 transformed cell line human CVCL_ZH87 CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670266 CVCL_ZH88 GM27806 transformed cell line human CVCL_ZH88 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670267 CVCL_ZH89 GM27807 transformed cell line human CVCL_ZH89 CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670268 CVCL_ZH72 GM27788 transformed cell line human CVCL_ZH72 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670269 CVCL_ZH73 GM27789 transformed cell line human CVCL_ZH73 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670270 CVCL_ZH74 GM27790 transformed cell line human CVCL_ZH74 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670271 CVCL_ZH75 GM27791 transformed cell line human CVCL_ZH75 CL:0000010 Population: Indian; Tulu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670272 CVCL_ZH70 GM27786 transformed cell line human CVCL_ZH70 CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670273 CVCL_ZH71 GM27787 transformed cell line human CVCL_ZH71 CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670274 CVCL_ZH76 GM27792 transformed cell line human CVCL_ZH76 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670275 CVCL_ZH77 GM27793 transformed cell line human CVCL_ZH77 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670276 CVCL_ZH78 GM27794 transformed cell line human CVCL_ZH78 CL:0000010 Population: Indian; Dogri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670277 CVCL_ZH79 GM27795 transformed cell line human CVCL_ZH79 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670278 CVCL_ZH61 GM27777 transformed cell line human CVCL_ZH61 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670279 CVCL_ZH62 GM27778 transformed cell line human CVCL_ZH62 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670280 CVCL_ZH63 GM27779 transformed cell line human CVCL_ZH63 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670281 CVCL_ZH64 GM27780 transformed cell line human CVCL_ZH64 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670282 CVCL_ZH60 GM27776 transformed cell line human CVCL_ZH60 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670283 CVCL_ZH69 GM27785 transformed cell line human CVCL_ZH69 CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670284 CVCL_ZH65 GM27781 transformed cell line human CVCL_ZH65 CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670285 CVCL_ZH66 GM27782 transformed cell line human CVCL_ZH66 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670286 CVCL_ZH67 GM27783 transformed cell line human CVCL_ZH67 CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670287 CVCL_ZH68 GM27784 transformed cell line human CVCL_ZH68 CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670288 CVCL_ZH50 GM27763 transformed cell line human CVCL_ZH50 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670289 CVCL_ZH51 GM27764 transformed cell line human CVCL_ZH51 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670290 CVCL_ZH52 GM27765 transformed cell line human CVCL_ZH52 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670291 CVCL_ZH53 GM27766 transformed cell line human CVCL_ZH53 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670292 CVCL_ZH58 GM27773 transformed cell line human CVCL_ZH58 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670293 CVCL_ZH59 GM27775 transformed cell line human CVCL_ZH59 CL:0000010 Population: Indian; Bengali; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670294 CVCL_ZH54 GM27767 transformed cell line human CVCL_ZH54 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670295 CVCL_ZH55 GM27768 transformed cell line human CVCL_ZH55 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670296 CVCL_ZH56 GM27770 transformed cell line human CVCL_ZH56 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670297 CVCL_ZH57 GM27771 transformed cell line human CVCL_ZH57 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670298 CVCL_ZH40 GM27752 transformed cell line human CVCL_ZH40 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670299 CVCL_ZH41 GM27754 transformed cell line human CVCL_ZH41 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670300 CVCL_ZH42 GM27755 transformed cell line human CVCL_ZH42 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670301 CVCL_ZH47 GM27760 transformed cell line human CVCL_ZH47 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670302 CVCL_ZH48 GM27761 transformed cell line human CVCL_ZH48 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670303 CVCL_ZH49 GM27762 transformed cell line human CVCL_ZH49 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670304 CVCL_ZH43 GM27756 transformed cell line human CVCL_ZH43 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670305 CVCL_ZH44 GM27757 transformed cell line human CVCL_ZH44 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670306 CVCL_ZH45 GM27758 transformed cell line human CVCL_ZH45 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670307 CVCL_ZH46 GM27759 transformed cell line human CVCL_ZH46 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670308 CVCL_ZH30 GM27562 transformed cell line human CVCL_ZH30 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670309 CVCL_ZH31 GM27563 transformed cell line human CVCL_ZH31 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670310 CVCL_ZH36 GM27748 transformed cell line human CVCL_ZH36 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670311 CVCL_ZH37 GM27749 transformed cell line human CVCL_ZH37 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670312 CVCL_ZH38 GM27750 transformed cell line human CVCL_ZH38 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670313 CVCL_ZH39 GM27751 transformed cell line human CVCL_ZH39 CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670314 CVCL_ZH32 GM27564 transformed cell line human CVCL_ZH32 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670315 CVCL_ZH33 GM27565 transformed cell line human CVCL_ZH33 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670316 CVCL_ZH34 GM27566 transformed cell line human CVCL_ZH34 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670317 CVCL_ZH35 GM27567 transformed cell line human CVCL_ZH35 CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670318 CVCL_ZH20 GM27552 transformed cell line human CVCL_ZH20 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670319 CVCL_ZH25 GM27557 transformed cell line human CVCL_ZH25 CL:0000010 Population: Indian; Tulu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670320 CVCL_ZH26 GM27558 transformed cell line human CVCL_ZH26 CL:0000010 Population: Indian; Tulu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670321 CVCL_ZH27 GM27559 transformed cell line human CVCL_ZH27 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670322 CVCL_ZH28 GM27560 transformed cell line human CVCL_ZH28 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670323 CVCL_ZH21 GM27553 transformed cell line human CVCL_ZH21 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670324 CVCL_ZH22 GM27554 transformed cell line human CVCL_ZH22 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670325 CVCL_ZH23 GM27555 transformed cell line human CVCL_ZH23 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670326 CVCL_ZH24 GM27556 transformed cell line human CVCL_ZH24 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670327 CVCL_ZH29 GM27561 transformed cell line human CVCL_ZH29 CL:0000010 Population: Indian; Konkani; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670328 CVCL_ZH14 GM27546 transformed cell line human CVCL_ZH14 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670329 CVCL_ZH15 GM27547 transformed cell line human CVCL_ZH15 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670330 CVCL_ZH16 GM27548 transformed cell line human CVCL_ZH16 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670331 CVCL_ZH17 GM27549 transformed cell line human CVCL_ZH17 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670332 CVCL_ZH10 GM27541 transformed cell line human CVCL_ZH10 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670333 CVCL_ZH11 GM27543 transformed cell line human CVCL_ZH11 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670334 CVCL_ZH12 GM27544 transformed cell line human CVCL_ZH12 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670335 CVCL_ZH13 GM27545 transformed cell line human CVCL_ZH13 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670336 CVCL_ZH18 GM27550 transformed cell line human CVCL_ZH18 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670337 CVCL_ZH19 GM27551 transformed cell line human CVCL_ZH19 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670338 CVCL_ZH94 GM27730 induced pluripotent stem cell human CVCL_ZH94 CL:0000010 Derived from sampling site: Peripheral blood. Male Part of: Personal Genome Project (PGP) cell line collection 35670339 CVCL_ZH95 GM27852 transformed cell line human CVCL_ZH95 CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly169Alafs*23 (c.506delG); ClinVar=VCV000471470; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670340 CVCL_ZH96 GM27853 transformed cell line human CVCL_ZH96 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670341 CVCL_ZH97 GM27854 transformed cell line human CVCL_ZH97 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Thr221Asnfs*3 (c.661dupA); ClinVar=VCV000827777; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670342 CVCL_ZH90 GM27630 transformed cell line human CVCL_ZH90 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Tyr709Ter (c.2127T>G); ClinVar=VCV000523879; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670343 CVCL_ZH91 GM27638 transformed cell line human CVCL_ZH91 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Tyr709Ter (c.2127T>G); ClinVar=VCV000523879; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670344 CVCL_ZH92 GM27639 transformed cell line human CVCL_ZH92 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670345 CVCL_ZH93 GM27640 transformed cell line human CVCL_ZH93 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670346 CVCL_ZH98 GM27860 induced pluripotent stem cell human CVCL_ZH98 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Arg497Ter (c.1489C>T); ClinVar=VCV000210050; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670347 CVCL_ZH99 GM27864 transformed cell line human CVCL_ZH99 CL:0000010 Population: Caucasian; Spanish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670348 CVCL_ZJ40 C9-1B induced pluripotent stem cell human CVCL_ZJ40 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=33837088) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670349 CVCL_ZJ45 40L cancer cell line house mouse CVCL_ZJ45 CL:0000010 Transformant: Crocidolite asbestos(ChEBI; CHEBI:46666); Derived from metastatic site: Peritoneum; Breed/subspecies: C57BL/6. Male Characteristics: Established from lung micro-metastases in a C57BL/6 mouse subcutaneous injected with the parent cell line (PubMed=21505561) 35670350 CVCL_ZJ46 PWS SD fibroblast finite cell line human CVCL_ZJ46 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35670351 CVCL_ZJ47 PWS SD 2-1 iPSC induced pluripotent stem cell human CVCL_ZJ47 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35670352 CVCL_ZJ48 PWS SD 2-2 iPSC induced pluripotent stem cell human CVCL_ZJ48 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35670353 CVCL_ZJ41 C9-2B induced pluripotent stem cell human CVCL_ZJ41 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=33837088) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670354 CVCL_ZJ42 C9-3B induced pluripotent stem cell human CVCL_ZJ42 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=33837088) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670355 CVCL_ZJ43 C9-4B induced pluripotent stem cell human CVCL_ZJ43 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified (PubMed=33837088) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670356 CVCL_ZJ44 CT-2A cancer cell line house mouse CVCL_ZJ44 CL:0000010 Breed/subspecies: C57BL/6J. Unspecified Characteristics: Mouse model for therapeutic research on brain malignancies (Millipore); Characteristics: Established from a tumor maintained through serial intracranial transplants 35670357 CVCL_ZJ49 PWS SD 2-3 iPSC induced pluripotent stem cell human CVCL_ZJ49 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 35670358 CVCL_ZJ34 38.13 hybridoma CVCL_ZJ34 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:18313; Alpha-D-galactosyl-(1->4)-beta-D-galactosyl-(1->4)-beta-D-glucosylceramide (Globotriaosylceramide; Ceramide trihexoside; CD77). 35670359 CVCL_ZJ35 BV-2 PU.1 KO transformed cell line house mouse CVCL_ZJ35 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:98282; Spi1 Transformant: Recombinant retrovirus J2; Derived from sampling site: Brain Cell type=Microglial cell.; Breed/subspecies: C57BL/6. Omics: Transcriptome analysis by RNAseq Female 35670360 CVCL_ZJ36 Murtaugh001 cancer cell line pig CVCL_ZJ36 CL:0000010 Anecdotal: Named in homage to the last author of the paper PubMed=32240660, Michael P Murtaugh, who passed away during the time when these cell lines were established.; Miscellaneous: Sex assignment derived from RNAseq analysis Derived from sampling site: Spleen. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~16 hours (PubMed=32240660) 35670361 CVCL_ZJ37 Murtaugh002 cancer cell line pig CVCL_ZJ37 CL:0000010 Anecdotal: Named in homage to the last author of the paper PubMed=32240660, Michael P Murtaugh, who passed away during the time when these cell lines were established.; Miscellaneous: Sex assignment derived from RNAseq analysis Derived from sampling site: Subiliac lymph node. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~16 hours (PubMed=32240660) 35670362 CVCL_ZJ30 IARC-370 transformed cell line human CVCL_ZJ30 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 35670363 CVCL_ZJ31 IARC-443B transformed cell line human CVCL_ZJ31 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670364 CVCL_ZJ32 IARC-435B transformed cell line human CVCL_ZJ32 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670365 CVCL_ZJ33 IARC-503 transformed cell line human CVCL_ZJ33 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670366 CVCL_ZJ38 Murtaugh003 cancer cell line pig CVCL_ZJ38 CL:0000010 Anecdotal: Named in homage to the last author of the paper PubMed=32240660, Michael P Murtaugh, who passed away during the time when these cell lines were established.; Miscellaneous: Sex assignment derived from RNAseq analysis Derived from sampling site: Subiliac lymph node. Omics: Transcriptome analysis by RNAseq Female Doubling time: ~16 hours (PubMed=32240660) 35670367 CVCL_ZJ39 1196a induced pluripotent stem cell human CVCL_ZJ39 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670368 CVCL_ZJ23 BL-123 cancer cell line human CVCL_ZJ23 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670369 CVCL_ZJ24 BL-81 cancer cell line human CVCL_ZJ24 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 35670370 CVCL_ZJ25 BL-86 cancer cell line human CVCL_ZJ25 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Male Virology: EBV-negative. 35670371 CVCL_ZJ26 IARC-693 transformed cell line human CVCL_ZJ26 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670372 CVCL_ZJ20 MHHi016-A induced pluripotent stem cell human CVCL_ZJ20 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18576; CCNO; Simple; p.Gly85Cysfs*11 (c.248_252dupCAGGG); ClinVar=VCV000139599; Zygosity=Homozygous (PubMed=32464346) Derived from sampling site: Peripheral blood. Male 35670373 CVCL_ZJ21 MHHi016-B induced pluripotent stem cell human CVCL_ZJ21 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 18576; CCNO; Simple; p.Gly85Cysfs*11 (c.248_252dupCAGGG); ClinVar=VCV000139599; Zygosity=Homozygous (PubMed=32464346) Derived from sampling site: Peripheral blood. Male 35670374 CVCL_ZJ22 BL-103 cancer cell line human CVCL_ZJ22 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Male Virology: EBV-negative. 35670375 CVCL_ZJ27 IARC-594 transformed cell line human CVCL_ZJ27 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670376 CVCL_ZJ28 IARC-661 transformed cell line human CVCL_ZJ28 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670377 CVCL_ZJ29 IARC-837 transformed cell line human CVCL_ZJ29 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 35670378 CVCL_ZJ12 SDUKIi001-A induced pluripotent stem cell human CVCL_ZJ12 From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark. CL:0000010 35670379 CVCL_ZJ13 SDUKIi002-A induced pluripotent stem cell human CVCL_ZJ13 From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670380 CVCL_ZJ14 MPIi001-A induced pluripotent stem cell human CVCL_ZJ14 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670381 CVCL_ZJ15 MPIi005-A induced pluripotent stem cell human CVCL_ZJ15 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670382 CVCL_ZJ10 LanthaScreen STAT5 (JAK2 V617F) U2OS cancer cell line human CVCL_ZJ10 CL:0000010 Transfected with: HGNC; 6192; JAK2 (with p.Val617Phe); Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with both a emGFP-STAT5A and a GST-JAK2(V617F) constructs whose expression are under the control of a CMV promoter 35670383 CVCL_ZJ11 LanthaScreen STAT5 TF-1 cancer cell line human CVCL_ZJ11 CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Transfected with an emGFP-STAT5A construct whose expression is under the control of a CMV promoter 35670384 CVCL_ZJ16 MPIi006-A induced pluripotent stem cell human CVCL_ZJ16 From: Max Planck Institute for Molecular Biomedicine; Munster; Germany CL:0000010 Sequence variation: Mutation; HGNC; 9086; PLP1; Simple; p.Pro216Ser (c.646C>T) (P215S); ClinVar=VCV000011073; Zygosity=Hemizygous (PubMed=32446239) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670385 CVCL_ZJ17 HEBHMUi004-A induced pluripotent stem cell human CVCL_ZJ17 From: Hebei Medical University; Shijiazhuang; China CL:0000010 Derived from sampling site: Peripheral blood. Female 35670386 CVCL_ZJ18 MHHi017-A induced pluripotent stem cell human CVCL_ZJ18 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2950; DNAH5; Simple; p.Arg2639Ter (c.7915C>T); ClinVar=VCV000520775; Zygosity=Homozygous (PubMed=32470793) Derived from sampling site: Peripheral blood. Female 35670387 CVCL_ZJ19 MHHi017-B induced pluripotent stem cell human CVCL_ZJ19 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2950; DNAH5; Simple; p.Arg2639Ter (c.7915C>T); ClinVar=VCV000520775; Zygosity=Homozygous (PubMed=32470793) Derived from sampling site: Peripheral blood. Female 35670388 CVCL_ZJ01 GM27717 induced pluripotent stem cell human CVCL_ZJ01 CL:0000010 Population: African American; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Female 35670389 CVCL_ZJ02 GM27540 transformed cell line human CVCL_ZJ02 CL:0000010 Population: Indian; Telugu; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670390 CVCL_ZJ03 LanthaScreen IGF-1R GripTite transformed cell line human CVCL_ZJ03 CL:0000010 Transfected with: HGNC; 5465; IGF1R; Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P42212; YFP (modified GFP at G-65, L-68, A-72, Y-203 and L-231); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an IGF1R-YFP construct whose expression is under the control of a CMV promoter 35670391 CVCL_ZJ04 LanthaScreen STAT1 U2OS cancer cell line human CVCL_ZJ04 CL:0000010 Transfected with: HGNC; 11362; STAT1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with an emGFP-STAT1 construct whose expression is under the control of a CMV promoter 35670392 CVCL_ZJ00 LanthaScreen ERK2 U2OS cancer cell line human CVCL_ZJ00 CL:0000010 Transfected with: HGNC; 6871; MAPK1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Transfected with an emGFP-MAPK1/ERK2 construct whose expression is under the control of a CMV promoter 35670393 CVCL_ZJ09 LanthaScreen c-Jun (1-79) HeLa cancer cell line human CVCL_ZJ09 CL:0000010 Transfected with: HGNC; 6204; JUN (with p.Ile80_Phe331del); Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Discontinued: Thermofisher/Invitrogen; Catalog number K1425 Female Characteristics: Transfected with an emGFP-JUN(1-79) construct whose expression is under the control of a CMV promoter 35670394 CVCL_ZJ05 LanthaScreen ERK2 A375 cancer cell line human CVCL_ZJ05 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 6871; MAPK1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Skin. Female Characteristics: Transfected with an emGFP-MAPK1/ERK2 construct whose expression is under the control of a CMV promoter 35670395 CVCL_ZJ06 LanthaScreen PDCD4 HEK 293E transformed cell line human CVCL_ZJ06 CL:0000010 Transfected with: HGNC; 8763; PDCD4; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an emGFP-PDCD4 construct whose expression is under the control of a CMV promoter 35670396 CVCL_ZJ07 LanthaScreen Akt HEK 293E transformed cell line human CVCL_ZJ07 CL:0000010 Transfected with: HGNC; 391; AKT1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an emGFP-AKT1 construct whose expression is under the control of a CMV promoter 35670397 CVCL_ZJ08 LanthaScreen PRAS40 HEK 293E transformed cell line human CVCL_ZJ08 CL:0000010 Transfected with: HGNC; 28426; AKT1S1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P03211; EBV EBNA1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an emGFP-AKT1S1/PRAS40 construct whose expression is under the control of a CMV promoter 35670398 CVCL_ZI93 MDCi011-B induced pluripotent stem cell human CVCL_ZI93 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35670399 CVCL_ZI94 GeneBLAzer AR-UAS-bla Griptite 293 transformed cell line human CVCL_ZI94 CL:0000010 Transfected with: RGD; 2147; Ar (ligand-binding domain); Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of rat AR fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 35670400 CVCL_ZI95 GeneBLAzer ERalpha-UAS-bla GripTite 293 transformed cell line human CVCL_ZI95 CL:0000010 Transfected with: HGNC; 3467; ESR1 (ligand-binding domain); Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of ESR1 fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 35670401 CVCL_ZI96 GeneBLAzer ERbeta-UAS-bla GripTite 293 transformed cell line human CVCL_ZI96 CL:0000010 Transfected with: HGNC; 3468; ESR2 (ligand-binding domain); Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P04386; Yeast GAL4 (DNA-binding domain); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS); Characteristics: Transfected with the ligand-binding domain (LBD) of ESR2 fused to the DNA-binding domain (DBD) of GAL4 When an agonist binds to the LBD of the DBD-LBD fusion protein, the protein binds to the UAS, resulting in expression of the beta-lactamase. 35670402 CVCL_ZI90 MDCi012-A induced pluripotent stem cell human CVCL_ZI90 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Female 35670403 CVCL_ZI91 MDCi012-B induced pluripotent stem cell human CVCL_ZI91 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35670404 CVCL_ZI92 MDCi011-A induced pluripotent stem cell human CVCL_ZI92 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Female 35670405 CVCL_ZI97 LanthaScreen IkB alpha GripTite transformed cell line human CVCL_ZI97 CL:0000010 Transfected with: HGNC; 7797; NFKBIA; Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an emGFP-NFKBIA construct whose expression is under the control of a CMV promoter 35670406 CVCL_ZI98 LanthaScreen STAT3 GripTite transformed cell line human CVCL_ZI98 CL:0000010 Transfected with: HGNC; 11364; STAT3; Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with an emGFP-STAT3 construct whose expression is under the control of a CMV promoter 35670407 CVCL_ZI99 LanthaScreen ATF2 (19-106) A549 cancer cell line human CVCL_ZI99 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 784; ATF2 (with p.Met1_Asn18del and p.Met107_Ser505del); Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Transfected with an emGFP-ATF2(19-106) construct whose expression is under the control of a CMV promoter 35670408 CVCL_ZI82 GeneBLAzer D2-Gqo5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI82 CL:0000010 Transfected with: HGNC; 3023; DRD2; Transfected with: HGNC; 4390; GNAQ (Gqo5, with 355-GCGLY-359 from GNAO1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670409 CVCL_ZI83 GeneBLAzer UAS-bla GripTite 293 transformed cell line human CVCL_ZI83 CL:0000010 Transfected with: HGNC; 7376; MSR1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of an upstream activator sequence (UAS) 35670410 CVCL_ZI84 SHUPLi001-A induced pluripotent stem cell human CVCL_ZI84 From: Shanghai University of Political Science and Law; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 35670411 CVCL_ZI85 PUMCHi002-A induced pluripotent stem cell human CVCL_ZI85 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 35670412 CVCL_ZI80 GeneBLAzer PTGDR-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI80 CL:0000010 Transfected with: HGNC; 9591; PTGDR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35670413 CVCL_ZI81 GeneBLAzer AVPR2-CRE-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI81 CL:0000010 Transfected with: HGNC; 897; AVPR2; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the CRE response element 35670414 CVCL_ZI86 MDCi013-A induced pluripotent stem cell human CVCL_ZI86 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Female 35670415 CVCL_ZI87 MDCi013-B induced pluripotent stem cell human CVCL_ZI87 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 35670416 CVCL_ZI88 MDCi014-A induced pluripotent stem cell human CVCL_ZI88 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Muscle; vastus lateralis Cell type=Myoblast.. Male 35670417 CVCL_ZI89 MDCi014-B induced pluripotent stem cell human CVCL_ZI89 From: Max Delbruck Center Berlin Buch; Berlin; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 35670418 CVCL_ZI71 GeneBLAzer M1-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI71 CL:0000010 Transfected with: HGNC; 1950; CHRM1; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670419 CVCL_ZI72 GeneBLAzer HCRTR2-Galpha15-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI72 CL:0000010 Transfected with: HGNC; 4849; HCRTR2; Transfected with: HGNC; 4383; GNA15; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670420 CVCL_ZI73 GeneBLAzer P2RY11-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI73 CL:0000010 Transfected with: HGNC; 8540; P2RY11; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670421 CVCL_ZI74 GeneBLAzer GPR24-Gqi5-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI74 CL:0000010 Transfected with: HGNC; 4479; MCHR1; Transfected with: HGNC; 4390; GNAQ (Gqi5, with 355-DCGLF-359 from GNAI1); Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670422 CVCL_ZI70 GeneBLAzer GnRHR-NFAT-bla CHO-K1 spontaneously immortalized cell line CVCL_ZI70 CL:0000010 Transfected with: HGNC; 4421; GNRHR; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Derived from sampling site: Ovary. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670423 CVCL_ZI79 GeneBLAzer EDG3-Galpha15-NFAT-bla HEK 293T transformed cell line human CVCL_ZI79 CL:0000010 Transfected with: HGNC; 3167; S1PR3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P62593; Escherichia coli beta-lactamase bla (with p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female Characteristics: Transfected with a plasmid containing a beta-lactamase reporter gene under control of the NFAT response element 35670424 CVCL_ZI75 FTD1#1-iPSC induced pluripotent stem cell human CVCL_ZI75 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; c.-8+5G>C (IVS1+5G>C) (g-3826G>C); ClinVar=VCV000098119; Zygosity=Unspecified (PubMed=25556567) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH 35670425 CVCL_ZI76 FTD2#5-iPSC induced pluripotent stem cell human CVCL_ZI76 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; c.-8+5G>C (IVS1+5G>C) (g-3826G>C); ClinVar=VCV000098119; Zygosity=Unspecified (PubMed=25556567) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH 35670426 CVCL_ZI77 FTD3#6-iPSC induced pluripotent stem cell human CVCL_ZI77 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; c.-8+5G>C (IVS1+5G>C) (g-3826G>C); ClinVar=VCV000098119; Zygosity=Unspecified (PubMed=25556567) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Transcriptome analysis by RNAseq 35670427 CVCL_ZI78 FTD3#6-PGRN induced pluripotent stem cell human CVCL_ZI78 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; c.-8+5G>C (IVS1+5G>C) (g-3826G>C); ClinVar=VCV000098119; Zygosity=Unspecified (PubMed=25556567); Transfected with: HGNC; 4601; GRN Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Characteristics: Using ZFN GRN was introduced in the AAVS1 safe harbor locus 35670428 CVCL_ZI60 DA02618 transformed cell line human CVCL_ZI60 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02618; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670429 CVCL_ZI61 DA02631 transformed cell line human CVCL_ZI61 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02631; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670430 CVCL_ZI62 DA02634 transformed cell line human CVCL_ZI62 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02634; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670431 CVCL_ZI63 DA02652 transformed cell line human CVCL_ZI63 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02652; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670432 CVCL_ZI68 DA02747 transformed cell line human CVCL_ZI68 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02747; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670433 CVCL_ZI69 CTRL-iPSC induced pluripotent stem cell human CVCL_ZI69 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670434 CVCL_ZI64 DA02673 transformed cell line human CVCL_ZI64 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02673; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670435 CVCL_ZI65 DA02674 transformed cell line human CVCL_ZI65 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02674; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670436 CVCL_ZI66 DA02723 transformed cell line human CVCL_ZI66 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02723; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670437 CVCL_ZI67 DA02724 transformed cell line human CVCL_ZI67 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02724; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670438 CVCL_ZI50 DA02483 transformed cell line human CVCL_ZI50 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02483; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670439 CVCL_ZI51 DA02484 transformed cell line human CVCL_ZI51 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02484; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670440 CVCL_ZI52 DA02485 transformed cell line human CVCL_ZI52 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02485; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670441 CVCL_ZI57 DA02574 transformed cell line human CVCL_ZI57 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02574; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670442 CVCL_ZI58 DA02575 transformed cell line human CVCL_ZI58 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02575; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670443 CVCL_ZI59 DA02598 transformed cell line human CVCL_ZI59 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02598; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670444 CVCL_ZI53 DA02486 transformed cell line human CVCL_ZI53 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02486; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670445 CVCL_ZI54 DA02503 transformed cell line human CVCL_ZI54 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02503; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670446 CVCL_ZI55 DA02509 transformed cell line human CVCL_ZI55 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02509; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670447 CVCL_ZI56 DA02531 transformed cell line human CVCL_ZI56 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02531; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670448 CVCL_ZI40 DA02354 transformed cell line human CVCL_ZI40 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02354; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670449 CVCL_ZI41 DA02355 transformed cell line human CVCL_ZI41 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02355; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670450 CVCL_ZI46 DA02377 transformed cell line human CVCL_ZI46 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02377; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670451 CVCL_ZI47 DA02386 transformed cell line human CVCL_ZI47 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02386; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670452 CVCL_ZI48 DA02389 transformed cell line human CVCL_ZI48 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02389; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670453 CVCL_ZI49 DA02464 transformed cell line human CVCL_ZI49 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02464; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670454 CVCL_ZI42 DA02356 transformed cell line human CVCL_ZI42 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02356; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670455 CVCL_ZI43 DA02367 transformed cell line human CVCL_ZI43 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02367; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670456 CVCL_ZI44 DA02369 transformed cell line human CVCL_ZI44 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02369; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670457 CVCL_ZI45 DA02371 transformed cell line human CVCL_ZI45 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02371; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670458 CVCL_ZI30 DA02190 transformed cell line human CVCL_ZI30 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02190; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670459 CVCL_ZI35 DA02274 transformed cell line human CVCL_ZI35 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02274; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670460 CVCL_ZI36 DA02275 transformed cell line human CVCL_ZI36 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02275; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670461 CVCL_ZI37 DA02331 transformed cell line human CVCL_ZI37 CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02331; probable Male Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670462 CVCL_ZI38 DA02348 transformed cell line human CVCL_ZI38 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02348; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670463 CVCL_ZI31 DA02243 transformed cell line human CVCL_ZI31 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02243; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670464 CVCL_ZI32 DA02244 transformed cell line human CVCL_ZI32 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02244; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670465 CVCL_ZI33 DA02259 transformed cell line human CVCL_ZI33 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02259; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670466 CVCL_ZI34 DA02273 transformed cell line human CVCL_ZI34 CL:0000010 Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02273; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670467 CVCL_ZI39 DA02351 transformed cell line human CVCL_ZI39 CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; DA02351; probable Female Part of: American Diabetes Association (ADA) GENNID study cell line collection 35670468 CVCL_ZS91 NL-Ha transformed cell line human CVCL_ZS91 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female Doubling time: 36 hours (PubMed=1900268) 35670469 CVCL_ZS92 NL-Mu transformed cell line human CVCL_ZS92 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 35670470 CVCL_ZS93 NL-Sh transformed cell line human CVCL_ZS93 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 35670471 CVCL_ZS94 XP31KO finite cell line human CVCL_ZS94 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670472 CVCL_ZS90 NL-Ch transformed cell line human CVCL_ZS90 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male Doubling time: 48 hours (PubMed=1900268) 35670473 CVCL_ZS99 3DD finite cell line human CVCL_ZS99 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 35670474 CVCL_ZS95 XP3HM [XP-G] finite cell line human CVCL_ZS95 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu65Pro (c.194T>C); Zygosity=Homozygous (PubMed=22417308) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: Two different patients and fibroblast cell lines seem to have been given the same designation: XPH3M, one is a XP-A (Cellosaurus=CVCL_ZQ56) the other a XP-G (Cellosaurus=CVCL_ZS95) 35670475 CVCL_ZS96 XP52HM finite cell line human CVCL_ZS96 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670476 CVCL_ZS97 405VI finite cell line human CVCL_ZS97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670477 CVCL_ZS98 2DD finite cell line human CVCL_ZS98 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Unspecified 35670478 CVCL_ZS80 NFS812 finite cell line human CVCL_ZS80 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670479 CVCL_ZS81 NFS70.226 cancer cell line house mouse CVCL_ZS81 CL:0000010 Transformant: Murine leukemia virus [Isolate CAS-NS-7](NCBI-Taxonomy; 11786); Derived from sampling site: Peripheral blood; Breed/subspecies: NFS/N. Characteristics: Subclone of NFS-70 that does not produce IgMu chains 35670480 CVCL_ZS82 NFS70.255 cancer cell line house mouse CVCL_ZS82 CL:0000010 Transformant: Murine leukemia virus [Isolate CAS-NS-7](NCBI-Taxonomy; 11786); Derived from sampling site: Peripheral blood; Breed/subspecies: NFS/N. 35670481 CVCL_ZS83 NFS70.255.23 cancer cell line house mouse CVCL_ZS83 CL:0000010 Transformant: Murine leukemia virus [Isolate CAS-NS-7](NCBI-Taxonomy; 11786); Derived from sampling site: Peripheral blood; Breed/subspecies: NFS/N. Characteristics: Subclone of NFS-70 that produce IgMu chains Contains one productively rearranged allele and one nonproductively rearranged allele. 35670482 CVCL_ZS88 N7KA finite cell line human CVCL_ZS88 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670483 CVCL_ZS89 N9OS finite cell line human CVCL_ZS89 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670484 CVCL_ZS84 EB-BS-NoKi-1 transformed cell line human CVCL_ZS84 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (from autologous cell lines BS1KA and HG1805) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 86(NoKi) (BSR86); Derived from sampling site: Peripheral blood. Female 35670485 CVCL_ZS85 EB-BS-NoKi-2 transformed cell line human CVCL_ZS85 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Asn515Lysfs*2 (c.1544dupA) (1610insA); ClinVar=VCV000042064; Zygosity=Homozygous (from autologous cell lines BS1KA and HG1805) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: From Bloom Syndrome Registry patient 86(NoKi) (BSR86); Derived from sampling site: Peripheral blood. Female 35670486 CVCL_ZS86 N4KA finite cell line human CVCL_ZS86 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670487 CVCL_ZS87 N6KA finite cell line human CVCL_ZS87 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670488 CVCL_ZS70 hTERT-WRN2 telomerase immortalized cell line human CVCL_ZS70 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Male 35670489 CVCL_ZS71 XP5KA finite cell line human CVCL_ZS71 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670490 CVCL_ZS72 VE45 finite cell line human CVCL_ZS72 CL:0000010 Derived from sampling site: Skin. Male 35670491 CVCL_ZS77 NFSL66 finite cell line human CVCL_ZS77 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670492 CVCL_ZS78 NFSL68 finite cell line human CVCL_ZS78 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670493 CVCL_ZS79 NFSL70 finite cell line human CVCL_ZS79 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670494 CVCL_ZS73 XP1KA finite cell line human CVCL_ZS73 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670495 CVCL_ZS74 MIZ-2 finite cell line human CVCL_ZS74 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670496 CVCL_ZS75 N1KY finite cell line human CVCL_ZS75 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670497 CVCL_ZS76 NTU finite cell line human CVCL_ZS76 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670498 CVCL_ZS59 XP6BI finite cell line human CVCL_ZS59 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670499 CVCL_ZS60 XP73BR finite cell line human CVCL_ZS60 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670500 CVCL_ZS61 XP76BR finite cell line human CVCL_ZS61 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670501 CVCL_ZS66 hTERT-GM01389 telomerase immortalized cell line human CVCL_ZS66 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Asn349del (c.1045_1047del); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Leu350Pro (c.1049T>C); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670502 CVCL_ZS67 XP115LO 2 hTERT telomerase immortalized cell line human CVCL_ZS67 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln373Ter (c.1117C>T); ClinVar=VCV000005890; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670503 CVCL_ZS68 hTERT-BLM telomerase immortalized cell line human CVCL_ZS68 CL:0000010 Sequence variation: Mutation; HGNC; 1058; BLM; Simple; p.Ser595Ter (c.1784C>A); ClinVar=VCV000820081; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; French Canadian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670504 CVCL_ZS69 hTERT-WRN1 telomerase immortalized cell line human CVCL_ZS69 CL:0000010 Sequence variation: Mutation; HGNC; 12791; WRN; Simple; p.Gln748Ter (c.2242C>T) (2476C>T); ClinVar=VCV000835212; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670505 CVCL_ZS62 XP77BR finite cell line human CVCL_ZS62 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670506 CVCL_ZS63 XP78BR finite cell line human CVCL_ZS63 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670507 CVCL_ZS64 XP83BR finite cell line human CVCL_ZS64 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670508 CVCL_ZS65 XP93BR finite cell line human CVCL_ZS65 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670509 CVCL_ZS48 HSPH 14 finite cell line human CVCL_ZS48 CL:0000010 Male 35670510 CVCL_ZS49 XP20SE finite cell line human CVCL_ZS49 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670511 CVCL_ZS50 XP21SE LCL transformed cell line human CVCL_ZS50 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670512 CVCL_ZS55 XP59BR finite cell line human CVCL_ZS55 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670513 CVCL_ZS56 XP3LE [Leeds] finite cell line human CVCL_ZS56 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670514 CVCL_ZS57 XP58BR finite cell line human CVCL_ZS57 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670515 CVCL_ZS58 XP62BR finite cell line human CVCL_ZS58 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670516 CVCL_ZS51 XP22SE LCL transformed cell line human CVCL_ZS51 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670517 CVCL_ZS52 XP23SE LCL transformed cell line human CVCL_ZS52 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670518 CVCL_ZS53 XP25SE LCL transformed cell line human CVCL_ZS53 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670519 CVCL_ZS54 XP26SE LCL transformed cell line human CVCL_ZS54 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670520 CVCL_ZS37 XP13NA finite cell line human CVCL_ZS37 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670521 CVCL_ZS38 MSU-1 finite cell line human CVCL_ZS38 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670522 CVCL_ZS39 MSU-2 finite cell line human CVCL_ZS39 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 35670523 CVCL_ZS44 XP107LO LCL transformed cell line human CVCL_ZS44 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from autologous cell line XP107LO); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP107LO) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670524 CVCL_ZS45 XP1NE LCL transformed cell line human CVCL_ZS45 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Gly47Arg (c.139G>A); ClinVar=VCV001176084; Zygosity=Heterozygous (from autologous cell line XP1NE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from autologous cell line XP1NE); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (from autologous cell line XP1NE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670525 CVCL_ZS46 XP38BE LCL transformed cell line human CVCL_ZS46 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asp360Glyfs*32 (c.1078dupG) (c.1078_1079dupG); ClinVar=VCV001696282; Zygosity=Homozygous (from autologous cell line XP38BE) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG02593; probable Male 35670526 CVCL_ZS47 AG03499 finite cell line human CVCL_ZS47 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03499; probable Female 35670527 CVCL_ZS40 XP6EH finite cell line human CVCL_ZS40 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670528 CVCL_ZS41 XP377BE finite cell line human CVCL_ZS41 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; IVS6-13_-21del9; Zygosity=Homozygous (CelloPub=CLPUB00565) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670529 CVCL_ZS42 XP7NE LCL transformed cell line human CVCL_ZS42 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Pro379Ser (c.1135C>T); ClinVar=VCV000134148; Zygosity=Heterozygous (from autologous cell line XP7NE) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670530 CVCL_ZS43 XP1DU LCL transformed cell line human CVCL_ZS43 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Trp (c.1846C>T); ClinVar=VCV000016788; Zygosity=Heterozygous (from autologous cell line XP1DU); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (from autologous cell line XP1DU) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670531 CVCL_ZS26 XP2MY finite cell line human CVCL_ZS26 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670532 CVCL_ZS27 XP3MY finite cell line human CVCL_ZS27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670533 CVCL_ZS28 XP4MY finite cell line human CVCL_ZS28 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670534 CVCL_ZS29 XP5MY finite cell line human CVCL_ZS29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670535 CVCL_ZS33 XP1CBJ finite cell line human CVCL_ZS33 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670536 CVCL_ZS34 XP1CNX finite cell line human CVCL_ZS34 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670537 CVCL_ZS35 XP2CNX finite cell line human CVCL_ZS35 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670538 CVCL_ZS36 XP3CNX finite cell line human CVCL_ZS36 CL:0000010 Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670539 CVCL_ZS30 XP6MY finite cell line human CVCL_ZS30 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670540 CVCL_ZS31 XP7MY finite cell line human CVCL_ZS31 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670541 CVCL_ZS32 XP1CTA finite cell line human CVCL_ZS32 CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670542 CVCL_ZS19 XP3TUF finite cell line human CVCL_ZS19 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670543 CVCL_ZS15 XP5TUF finite cell line human CVCL_ZS15 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670544 CVCL_ZS16 XP1TUF finite cell line human CVCL_ZS16 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gly95Arg (c.283G>A); Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670545 CVCL_ZS17 XP6TUF finite cell line human CVCL_ZS17 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670546 CVCL_ZS18 XP8TUF finite cell line human CVCL_ZS18 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670547 CVCL_ZS22 XP2TUF finite cell line human CVCL_ZS22 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670548 CVCL_ZS23 XP4TUF finite cell line human CVCL_ZS23 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670549 CVCL_ZS24 N17OS finite cell line human CVCL_ZS24 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670550 CVCL_ZS25 XP1MY finite cell line human CVCL_ZS25 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670551 CVCL_ZS20 XP7TUF finite cell line human CVCL_ZS20 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670552 CVCL_ZS21 XP9TUF finite cell line human CVCL_ZS21 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=18567921) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. 35670553 CVCL_ZS08 CS697CTO finite cell line human CVCL_ZS08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670554 CVCL_ZS09 CS698CTO finite cell line human CVCL_ZS09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670555 CVCL_ZS04 CS3AN finite cell line human CVCL_ZS04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670556 CVCL_ZS05 CS4AN finite cell line human CVCL_ZS05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670557 CVCL_ZS06 CS6MO finite cell line human CVCL_ZS06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670558 CVCL_ZS07 CS8SE finite cell line human CVCL_ZS07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670559 CVCL_ZS11 CSH696CTO finite cell line human CVCL_ZS11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670560 CVCL_ZS12 AT1LO finite cell line human CVCL_ZS12 CL:0000010 Male 35670561 CVCL_ZS13 AT181TO finite cell line human CVCL_ZS13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670562 CVCL_ZS14 XP1HEF finite cell line human CVCL_ZS14 CL:0000010 Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670563 CVCL_ZS10 CSH695CTO finite cell line human CVCL_ZS10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670564 CVCL_ZS00 CS15PV finite cell line human CVCL_ZS00 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Glu13Ter (c.37G>T); ClinVar=VCV000001716; Zygosity=Homozygous (PubMed=29572252) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670565 CVCL_ZS01 CSH1AN finite cell line human CVCL_ZS01 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670566 CVCL_ZS02 CSH2AN finite cell line human CVCL_ZS02 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670567 CVCL_ZS03 CS2AN finite cell line human CVCL_ZS03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670568 CVCL_ZT90 1387T finite cell line human CVCL_ZT90 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670569 CVCL_ZT91 1461T finite cell line human CVCL_ZT91 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670570 CVCL_ZT92 1872T finite cell line human CVCL_ZT92 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670571 CVCL_ZT93 1873T finite cell line human CVCL_ZT93 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (PubMed=7779715) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670572 CVCL_ZT98 105MA finite cell line human CVCL_ZT98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 34 PDL (PubMed=9649131) 35670573 CVCL_ZT99 109MA finite cell line human CVCL_ZT99 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Lys (c.538G>A); ClinVar=VCV000245711; Zygosity=Heterozygous (PubMed=9649131) Donor information: At sampling donor was not affected with Li-Fraumeni syndrome; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 64 PDL (PubMed=9649131) 35670574 CVCL_ZT94 2525T finite cell line human CVCL_ZT94 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670575 CVCL_ZT95 2674T finite cell line human CVCL_ZT95 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (PubMed=2259385; PubMed=7779715) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670576 CVCL_ZT96 2675T finite cell line human CVCL_ZT96 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Asp (c.734G>A); ClinVar=VCV000012355; Zygosity=Heterozygous (PubMed=2259385; PubMed=7779715) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670577 CVCL_ZT97 2800T finite cell line human CVCL_ZT97 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr234Cys (c.701A>G); ClinVar=VCV000127820; Zygosity=Heterozygous (PubMed=7779715) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670578 CVCL_ZT00 NB1 [Human skin fibroblast] finite cell line human CVCL_ZT00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670579 CVCL_ZT01 2599T finite cell line human CVCL_ZT01 CL:0000010 Derived from sampling site: Skin. Male 35670580 CVCL_ZT02 3012T finite cell line human CVCL_ZT02 CL:0000010 Derived from sampling site: Skin. Male 35670581 CVCL_ZT80 L991 transformed cell line human CVCL_ZT80 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 35670582 CVCL_ZT81 HO11 finite cell line human CVCL_ZT81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 63 PDL (PubMed=9649131) 35670583 CVCL_ZT82 FH1 finite cell line human CVCL_ZT82 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=8794843; PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 55 PDL (PubMed=9649131) 35670584 CVCL_ZT87 138MA finite cell line human CVCL_ZT87 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=8794843; PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 47 PDL (PubMed=9649131) 35670585 CVCL_ZT88 IVBF finite cell line human CVCL_ZT88 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Heterozygous; Note=Impairs TP53 splicing dramatically (PubMed=1467311) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670586 CVCL_ZT89 IIICF finite cell line human CVCL_ZT89 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Thr125Thr (c.375G>A); ClinVar=VCV000177825; Zygosity=Heterozygous; Note=Impairs TP53 splicing dramatically (PubMed=1467311) Derived from sampling site: Breast; stroma. Female 35670587 CVCL_ZT83 160MA finite cell line human CVCL_ZT83 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu344Pro (c.1031T>C); ClinVar=VCV000012375; Zygosity=Heterozygous (PubMed=9649131) Population: Indian; Derived from sampling site: Kidney. Male Senescence: Senesces at 17 PDL (PubMed=9649131) 35670588 CVCL_ZT84 161MA-F finite cell line human CVCL_ZT84 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu344Pro (c.1031T>C); ClinVar=VCV000012375; Zygosity=Hemizygous (PubMed=8649785; PubMed=9649131) Population: Indian; Derived from sampling site: Mesentery. Male Senescence: Senesces at 19 PDL (PubMed=9649131) 35670589 CVCL_ZT85 161MA-M finite cell line human CVCL_ZT85 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu344Pro (c.1031T>C); ClinVar=VCV000012375; Zygosity=Heterozygous (PubMed=8649785) Population: Indian; Derived from metastatic site: Retroperitoneal space. Male 35670590 CVCL_ZT86 21MA finite cell line human CVCL_ZT86 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 44 PDL (PubMed=9649131) 35670591 CVCL_ZT69 FG4003 finite cell line human CVCL_ZT69 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Glu232Glyfs*38 (c.689dupT) (167insT) (689insT); ClinVar=VCV000004425; Zygosity=Heterozygous (PubMed=15044383); Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Ser281Leufs*8 (c.841delT) (318delT) (840delT); ClinVar=VCV000004427; Zygosity=Heterozygous (PubMed=15044383) Derived from sampling site: Cell type=Fibroblast. 35670592 CVCL_ZT70 FD104 telomerase immortalized cell line human CVCL_ZT70 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (PubMed=15380105); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 35670593 CVCL_ZT71 FD104-m21 telomerase immortalized cell line human CVCL_ZT71 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 15984; APTX; Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 35670594 CVCL_ZT76 L136 transformed cell line human CVCL_ZT76 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Glu232Glyfs*38 (c.689dupT) (167insT) (689insT); ClinVar=VCV000004425; Zygosity=Heterozygous (PubMed=15044383); Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Ser281Leufs*8 (c.841delT) (318delT) (840delT); ClinVar=VCV000004427; Zygosity=Heterozygous (PubMed=15044383) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 35670595 CVCL_ZT77 L938 transformed cell line human CVCL_ZT77 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Pro206Leu (c.617C>T); ClinVar=VCV000004426; Zygosity=Homozygous (PubMed=15044383) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670596 CVCL_ZT78 L939 transformed cell line human CVCL_ZT78 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Pro206Leu (c.617C>T); ClinVar=VCV000004426; Zygosity=Heterozygous (PubMed=15044383); Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Val263Gly (c.788T>G); ClinVar=VCV000004428; Zygosity=Heterozygous (PubMed=15044383) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670597 CVCL_ZT79 L990 transformed cell line human CVCL_ZT79 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 35670598 CVCL_ZT72 FD105 telomerase immortalized cell line human CVCL_ZT72 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (PubMed=15380105); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 35670599 CVCL_ZT73 FD105-m20 telomerase immortalized cell line human CVCL_ZT73 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. Characteristics: Transfected with an empty vector Control line for FD105-m21. 35670600 CVCL_ZT74 FD105-m21 telomerase immortalized cell line human CVCL_ZT74 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 15984; APTX; Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 35670601 CVCL_ZT75 FD106 telomerase immortalized cell line human CVCL_ZT75 CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (PubMed=15380105); Transfected with: HGNC; 11730; TERT Derived from sampling site: Cell type=Fibroblast. 35670602 CVCL_ZT58 170BR finite cell line human CVCL_ZT58 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670603 CVCL_ZT59 212BR finite cell line human CVCL_ZT59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670604 CVCL_ZT60 214BR finite cell line human CVCL_ZT60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670605 CVCL_ZT65 AT3BR LCL transformed cell line human CVCL_ZT65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670606 CVCL_ZT66 SETX-1RM finite cell line human CVCL_ZT66 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Unexplicit; Ex14-21del; Zygosity=Homozygous (PubMed=17562789) Derived from sampling site: Cell type=Fibroblast. Unspecified 35670607 CVCL_ZT67 SETX-2RM transformed cell line human CVCL_ZT67 CL:0000010 Sequence variation: Mutation; HGNC; 445; SETX; Simple; c.7287+5G>A (IVS23+5G>A); Zygosity=Homozygous (PubMed=17562789) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 35670608 CVCL_ZT68 ATL2ABR transformed cell line human CVCL_ZT68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 35670609 CVCL_ZT61 215BR finite cell line human CVCL_ZT61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670610 CVCL_ZT62 228BR finite cell line human CVCL_ZT62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670611 CVCL_ZT63 AT4BR finite cell line human CVCL_ZT63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670612 CVCL_ZT64 AT4BR LCL transformed cell line human CVCL_ZT64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670613 CVCL_ZT47 141BR finite cell line human CVCL_ZT47 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670614 CVCL_ZT48 143BR finite cell line human CVCL_ZT48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670615 CVCL_ZT49 145BR finite cell line human CVCL_ZT49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670616 CVCL_ZT54 159BR finite cell line human CVCL_ZT54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670617 CVCL_ZT55 160BR finite cell line human CVCL_ZT55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670618 CVCL_ZT56 164BR finite cell line human CVCL_ZT56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670619 CVCL_ZT57 165BR finite cell line human CVCL_ZT57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670620 CVCL_ZT50 146BR finite cell line human CVCL_ZT50 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670621 CVCL_ZT51 151BR finite cell line human CVCL_ZT51 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670622 CVCL_ZT52 152BR finite cell line human CVCL_ZT52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670623 CVCL_ZT53 156BR finite cell line human CVCL_ZT53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670624 CVCL_ZT36 129BR finite cell line human CVCL_ZT36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670625 CVCL_ZT37 130BR finite cell line human CVCL_ZT37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670626 CVCL_ZT38 131BR finite cell line human CVCL_ZT38 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670627 CVCL_ZT39 132BR finite cell line human CVCL_ZT39 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670628 CVCL_ZT43 137BR finite cell line human CVCL_ZT43 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670629 CVCL_ZT44 138BR finite cell line human CVCL_ZT44 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670630 CVCL_ZT45 139BR finite cell line human CVCL_ZT45 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670631 CVCL_ZT46 140BR finite cell line human CVCL_ZT46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670632 CVCL_ZT40 133BR finite cell line human CVCL_ZT40 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670633 CVCL_ZT41 134BR finite cell line human CVCL_ZT41 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670634 CVCL_ZT42 135BR finite cell line human CVCL_ZT42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670635 CVCL_ZT29 70BR finite cell line human CVCL_ZT29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670636 CVCL_ZT25 AT1BR LCL transformed cell line human CVCL_ZT25 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670637 CVCL_ZT26 AT7BI LCL transformed cell line human CVCL_ZT26 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670638 CVCL_ZT27 AT25BI LCL transformed cell line human CVCL_ZT27 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670639 CVCL_ZT28 71BR finite cell line human CVCL_ZT28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670640 CVCL_ZT32 267BR finite cell line human CVCL_ZT32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670641 CVCL_ZT33 124BR finite cell line human CVCL_ZT33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670642 CVCL_ZT34 126BR finite cell line human CVCL_ZT34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670643 CVCL_ZT35 127BR finite cell line human CVCL_ZT35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670644 CVCL_ZT30 287BR finite cell line human CVCL_ZT30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670645 CVCL_ZT31 266BR finite cell line human CVCL_ZT31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670646 CVCL_ZT18 CS4IAF finite cell line human CVCL_ZT18 CL:0000010 Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670647 CVCL_ZT19 CS5IAF finite cell line human CVCL_ZT19 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Tyr322Ter (c.966C>A); ClinVar=VCV000001715; Zygosity=Homozygous (PubMed=29572252) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670648 CVCL_ZT14 CS2GO finite cell line human CVCL_ZT14 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Leu45Pro (c.134C>T) (C213T); Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Trp851Arg (c.2551T>A) (T2630A); ClinVar=VCV000522698; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg1213Gly (c.3637A>G) (A3716G); ClinVar=VCV000129017; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: CS2GO (Cellosaurus=CVCL_ZT14) and CS3GO (Cellosaurus=CVCL_ZT15) originate from 2 siblings, however their mutation profile is different, different hypothesis are proposed about this issue (DOI=10.21954/ou.ro.0000e27e) 35670649 CVCL_ZT15 CS3GO finite cell line human CVCL_ZT15 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg1213Gly (c.3637A>G) (A3716G); ClinVar=VCV000129017; Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; c.3779_4574del (3858-4653del); Zygosity=Heterozygous (DOI=10.21954/ou.ro.0000e27e) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: CS2GO (Cellosaurus=CVCL_ZT14) and CS3GO (Cellosaurus=CVCL_ZT15) originate from 2 siblings, however their mutation profile is different, different hypothesis are proposed about this issue (DOI=10.21954/ou.ro.0000e27e) 35670650 CVCL_ZT16 CS2IAF finite cell line human CVCL_ZT16 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Tyr322Ter (c.966C>A); ClinVar=VCV000001715; Zygosity=Homozygous (PubMed=9338586) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670651 CVCL_ZT17 CS3IAF finite cell line human CVCL_ZT17 CL:0000010 Derived from sampling site: Amniotic fluid. Unspecified 35670652 CVCL_ZT21 CS5LO finite cell line human CVCL_ZT21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670653 CVCL_ZT22 CS7LO finite cell line human CVCL_ZT22 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670654 CVCL_ZT23 CS8LO finite cell line human CVCL_ZT23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670655 CVCL_ZT24 AT5BR LCL transformed cell line human CVCL_ZT24 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.5763-1050A>G (5762ins137); ClinVar=VCV000003021; Zygosity=Unspecified (from autologous cell line AT5BR) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670656 CVCL_ZT20 CS9IAF finite cell line human CVCL_ZT20 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Tyr322Ter (c.966C>A); ClinVar=VCV000001715; Zygosity=Homozygous (PubMed=29572252) Population: Arab; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670657 CVCL_ZT07 Kps23F finite cell line human CVCL_ZT07 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Heterozygous (from familial inference of Kps2 and Kps3) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670658 CVCL_ZT08 Kps23M finite cell line human CVCL_ZT08 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Heterozygous (from familial inference of Kps2 and Kps3) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670659 CVCL_ZT09 Kps4 finite cell line human CVCL_ZT09 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670660 CVCL_ZT03 3072T finite cell line human CVCL_ZT03 CL:0000010 Derived from sampling site: Skin. Female 35670661 CVCL_ZT04 3190T finite cell line human CVCL_ZT04 CL:0000010 Derived from sampling site: Skin. Male 35670662 CVCL_ZT05 3191T finite cell line human CVCL_ZT05 CL:0000010 Derived from sampling site: Skin. Female 35670663 CVCL_ZT06 3248T finite cell line human CVCL_ZT06 CL:0000010 Derived from sampling site: Skin. Male 35670664 CVCL_ZT10 Kps1 finite cell line human CVCL_ZT10 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670665 CVCL_ZT11 NB1-Tert telomerase immortalized cell line human CVCL_ZT11 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670666 CVCL_ZT12 TTD12PV finite cell line human CVCL_ZT12 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Cys259Tyr (c.776G>A); ClinVar=VCV000329522; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670667 CVCL_ZT13 TTD15PV finite cell line human CVCL_ZT13 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Cys259Tyr (c.776G>A); ClinVar=VCV000329522; Zygosity=Heterozygous (PubMed=9758621); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg722Trp (c.2164C>T); ClinVar=VCV000016792; Zygosity=Heterozygous (PubMed=9758621) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670668 CVCL_ZU17 162MA finite cell line human CVCL_ZU17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 26 PDL (PubMed=9649131) 35670669 CVCL_ZU18 163MA finite cell line human CVCL_ZU18 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Heterozygous (PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 70 PDL (PubMed=9649131) 35670670 CVCL_ZU19 164MA finite cell line human CVCL_ZU19 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Ser (c.733G>A); ClinVar=VCV000012365; Zygosity=Heterozygous (PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 58 PDL (PubMed=9649131) 35670671 CVCL_ZU13 155MA finite cell line human CVCL_ZU13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 14 PDL (PubMed=9649131) 35670672 CVCL_ZU14 156MA finite cell line human CVCL_ZU14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (PubMed=9649131) 35670673 CVCL_ZU15 157MA finite cell line human CVCL_ZU15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 9 PDL (PubMed=9649131) 35670674 CVCL_ZU16 159MA finite cell line human CVCL_ZU16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 19 PDL (PubMed=9649131) 35670675 CVCL_ZU20 169MA finite cell line human CVCL_ZU20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 11 PDL (PubMed=9649131) 35670676 CVCL_ZU21 170MA finite cell line human CVCL_ZU21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (PubMed=9649131) 35670677 CVCL_ZU22 172MA finite cell line human CVCL_ZU22 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg337Cys (c.1009C>T); ClinVar=VCV000142536; Zygosity=Hemizygous (PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 26 PDL (PubMed=9649131) 35670678 CVCL_ZU23 Mps1 finite cell line human CVCL_ZU23 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Unexplicit; Ex1del; Zygosity=Homozygous (PubMed=12655141) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670679 CVCL_ZU06 130MA finite cell line human CVCL_ZU06 CL:0000010 Donor information: Established from an unaffected member of a Li-Fraumeni syndrome family; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 18 PDL (PubMed=9649131) 35670680 CVCL_ZU07 131MA finite cell line human CVCL_ZU07 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 23 PDL (PubMed=9649131) 35670681 CVCL_ZU08 135MA finite cell line human CVCL_ZU08 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 74 PDL (PubMed=9649131) 35670682 CVCL_ZU09 136MA finite cell line human CVCL_ZU09 CL:0000010 Donor information: Established from an unaffected member of a Li-Fraumeni syndrome family; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 24 PDL (PubMed=9649131) 35670683 CVCL_ZU02 123MA finite cell line human CVCL_ZU02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 14 PDL (PubMed=9649131) 35670684 CVCL_ZU03 124MA finite cell line human CVCL_ZU03 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Heterozygous (PubMed=8794843; PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 27 PDL (PubMed=9649131) 35670685 CVCL_ZU04 125MA finite cell line human CVCL_ZU04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 15 PDL (PubMed=9649131) 35670686 CVCL_ZU05 126MA finite cell line human CVCL_ZU05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 53 PDL (PubMed=9649131) 35670687 CVCL_ZU10 141MA finite cell line human CVCL_ZU10 CL:0000010 Donor information: Established from an unaffected member of a Li-Fraumeni syndrome family; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 17 PDL (PubMed=9649131) 35670688 CVCL_ZU11 146MA finite cell line human CVCL_ZU11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 13 PDL (PubMed=9649131) 35670689 CVCL_ZU12 154MA finite cell line human CVCL_ZU12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 35 PDL (PubMed=9649131) 35670690 CVCL_ZU00 110MA finite cell line human CVCL_ZU00 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180Lys (c.538G>A); ClinVar=VCV000245711; Zygosity=Heterozygous (PubMed=8794843; PubMed=9018113; PubMed=9649131) Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 53 PDL (PubMed=9649131) 35670691 CVCL_ZU01 120MA finite cell line human CVCL_ZU01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 33 PDL (PubMed=9649131) 35670692 CVCL_ZU90 XP100BR finite cell line human CVCL_ZU90 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; c.457-2A>C; ClinVar=VCV000872377; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670693 CVCL_ZU91 XP101BR finite cell line human CVCL_ZU91 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ile290Asn (c.869T>A); Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670694 CVCL_ZU92 XP102BR finite cell line human CVCL_ZU92 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Thr371fs (c.1111delA); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; Ex1del; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670695 CVCL_ZU97 XP109BR finite cell line human CVCL_ZU97 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670696 CVCL_ZU98 XP112BR finite cell line human CVCL_ZU98 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Trp603Ter (c.1808G>A); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2420+2T>C; ClinVar=VCV000963704; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670697 CVCL_ZU99 XP115BR finite cell line human CVCL_ZU99 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Met383fs (c.1149delG); Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670698 CVCL_ZU93 XP104BR finite cell line human CVCL_ZU93 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.His46Metfs*5 (c.136delC); ClinVar=VCV001322832; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670699 CVCL_ZU94 XP104LO finite cell line human CVCL_ZU94 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; c.718+1C>A; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670700 CVCL_ZU95 XP105BR finite cell line human CVCL_ZU95 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Arg239Ile (c.716G>T); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Pro357Leu (c.1070C>T); ClinVar=VCV000304927; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670701 CVCL_ZU96 XP107BR finite cell line human CVCL_ZU96 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Tyr585Cys (c.1754A>G); Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670702 CVCL_ZU79 Ramos/B95-8 cancer cell line human CVCL_ZU79 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV strain B95-8 Caution: Ramos B7 (Cellosaurus=CVCL_JL65) and Ramos/B95-8 could be identical 35670703 CVCL_ZU80 Ramos/NPC cancer cell line human CVCL_ZU80 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile254Asp (c.760_761AT>GA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Ascites. Male Virology: EBV-negative cell line infected with EBV from NPC-KT cell line (Cellosaurus=CVCL_X204) 35670704 CVCL_ZU81 Ly11 cancer cell line human CVCL_ZU81 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670705 CVCL_ZU86 ABADRL-Cs-W8A spontaneously immortalized cell line CVCL_ZU86 CL:0000010 Unspecified Doubling time: ~14 hours (PubMed=12943114). Group: Insect cell line 35670706 CVCL_ZU87 CNE/LULS44 spontaneously immortalized cell line CVCL_ZU87 CL:0000010 Unspecified Group: Insect cell line. 35670707 CVCL_ZU88 CNE/LULS47 spontaneously immortalized cell line CVCL_ZU88 CL:0000010 Unspecified Group: Insect cell line. 35670708 CVCL_ZU89 XPCS1BD finite cell line human CVCL_ZU89 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; c.673-1G>A (G870A); dbSNP=rs1256618339; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=15572672); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Cys529Ser (c.1586G>C) (G1783C); ClinVar=VCV000129010; Zygosity=Homozygous (PubMed=15572672) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670709 CVCL_ZU82 Ly28 cancer cell line human CVCL_ZU82 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670710 CVCL_ZU83 Ly1 cancer cell line human CVCL_ZU83 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670711 CVCL_ZU84 Ly2 cancer cell line human CVCL_ZU84 CL:0000010 Population: Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male 35670712 CVCL_ZU85 ABADRL-Cs-W3 spontaneously immortalized cell line CVCL_ZU85 CL:0000010 Unspecified Doubling time: ~14 hours (PubMed=12943114). Group: Insect cell line 35670713 CVCL_ZU68 ROS-16 cancer cell line human CVCL_ZU68 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 35670714 CVCL_ZU69 BL-137 cancer cell line human CVCL_ZU69 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Virology: Contains an integrated EBV genome and also from 5 to 10 episomal copies of EBV (PubMed=8382295) 35670715 CVCL_ZU70 CHEV cancer cell line human CVCL_ZU70 CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=6806672) Population: Caucasian; Derived from sampling site: Ascites. Male Virology: EBV-negative Doubling time: 27-28 hours (PubMed=6289490) 35670716 CVCL_ZU75 Nelson cancer cell line human CVCL_ZU75 CL:0000010 Population: African; Kenyan; Derived from sampling site: Bone; jaw; maxilla. Male 35670717 CVCL_ZU76 Wilkister cancer cell line human CVCL_ZU76 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Female 35670718 CVCL_ZU77 Opasa cancer cell line human CVCL_ZU77 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone; jaw; maxilla. Male 35670719 CVCL_ZU78 FL-SJC cancer cell line human CVCL_ZU78 CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=32459397); Sequence variation: Gene fusion; HGNC; 5853; IGL + HGNC; 7553; MYC; Name(s)=MYC-IGL (PubMed=32459397); Sequence variation: Mutation; HGNC; 2348; CREBBP; Simple; p.Ser1680del (c.5036_5038CCT[1]) (c.5039_5041delCCT) (p.Ser1642del, c.4922_4924CCT[1]); ClinVar=VCV000158384; Zygosity=Unspecified (PubMed=32459397); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Met1379Valfs*52 (c.4135_4136delAT); ClinVar=VCV000094216; Zygosity=Unspecified (PubMed=32459397) Population: Chinese; Derived from sampling site: Pleural effusion. Male Doubling time: 24 hours (PubMed=32459397) 35670720 CVCL_ZU71 Awia-BL cancer cell line human CVCL_ZU71 CL:0000010 Population: African; Ugandan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Ovary. Female 35670721 CVCL_ZU72 Annah cancer cell line human CVCL_ZU72 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 35670722 CVCL_ZU73 Dalmas cancer cell line human CVCL_ZU73 CL:0000010 Population: African; Kenyan; Derived from sampling site: Bone; jaw; mandible. Male 35670723 CVCL_ZU74 Juma cancer cell line human CVCL_ZU74 CL:0000010 Population: African; Kenyan; Derived from sampling site: Bone; jaw; mandible. Male 35670724 CVCL_ZU57 XP211BA LCL transformed cell line human CVCL_ZU57 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg314Glyfs*10 (c.940delC) (C940del-1); Zygosity=Heterozygous (PubMed=16990803) Population: Guatemalan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670725 CVCL_ZU58 XP212BA LCL transformed cell line human CVCL_ZU58 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg314Glyfs*10 (c.940delC) (C940del-1); Zygosity=Heterozygous (PubMed=16990803) Population: Guatemalan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670726 CVCL_ZU59 TTD1GL finite cell line human CVCL_ZU59 CL:0000010 Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670727 CVCL_ZU64 IARC-602 transformed cell line human CVCL_ZU64 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). 35670728 CVCL_ZU65 IARC-822 transformed cell line human CVCL_ZU65 From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female 35670729 CVCL_ZU66 Wan-LCL transformed cell line human CVCL_ZU66 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670730 CVCL_ZU67 Mutu-LCL transformed cell line human CVCL_ZU67 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670731 CVCL_ZU60 USTCi001-A-1 induced pluripotent stem cell human CVCL_ZU60 From: School of Life Sciences, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple_corrected; p.Gln1923Arg (c.5768A>G); Zygosity=Heterozygous; Note=By TALEN (PubMed=32544858) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670732 CVCL_ZU61 RIG-I(-/-) 293T transformed cell line human CVCL_ZU61 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19102; RIGI; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 35670733 CVCL_ZU62 XGC-1 cancer cell line human CVCL_ZU62 CL:0000010 Population: Chinese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Stomach; fundus. Male Doubling time: ~48 hours (PubMed=32943986) 35670734 CVCL_ZU63 50D10 hybridoma house mouse CVCL_ZU63 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: ChEBI; CHEBI:2955; Azithromycin. 35670735 CVCL_ZU46 LCL M2-2 transformed cell line human CVCL_ZU46 CL:0000010 Karyotypic information: Has a marker chromosome present (der(8)); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670736 CVCL_ZU47 LCL N1 transformed cell line human CVCL_ZU47 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670737 CVCL_ZU48 LCL N2 transformed cell line human CVCL_ZU48 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670738 CVCL_ZU49 LCL N3 transformed cell line human CVCL_ZU49 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670739 CVCL_ZU53 XP226BA finite cell line human CVCL_ZU53 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg314Glyfs*10 (c.940delC) (C940del-1); Zygosity=Homozygous (PubMed=27543334) Population: Guatemalan; Derived from sampling site: Skin Cell type=Fibroblast.. 35670740 CVCL_ZU54 XP207SF finite cell line human CVCL_ZU54 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Asp121Alafs*26 (c.362delA) (A362del-1); Zygosity=Heterozygous (from autologous cell line XP207SF LCL); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu149Lysfs*18 (c.441_442GA[2]) (c.444_445delAG) (c.445_446delGA) (GA444,445 del-2); ClinVar=VCV000557065; Zygosity=Heterozygous (from autologous cell line XP207SF LCL) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670741 CVCL_ZU55 XP207SF LCL transformed cell line human CVCL_ZU55 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Asp121Alafs*26 (c.362delA) (A362del-1); Zygosity=Heterozygous (PubMed=16990803); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu149Lysfs*18 (c.441_442GA[2]) (c.444_445delAG) (c.445_446delGA) (GA444,445 del-2); ClinVar=VCV000557065; Zygosity=Heterozygous (PubMed=16990803) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670742 CVCL_ZU56 XP202BA LCL transformed cell line human CVCL_ZU56 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg314Glyfs*10 (c.940delC) (C940del-1); Zygosity=Homozygous (PubMed=16990803) Population: Guatemalan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670743 CVCL_ZU50 Nps2 finite cell line human CVCL_ZU50 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (PubMed=12655141) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35670744 CVCL_ZU51 GM05659T telomerase immortalized cell line human CVCL_ZU51 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 35670745 CVCL_ZU52 CS7SE hTERT telomerase immortalized cell line human CVCL_ZU52 CL:0000010 Transfected with: HGNC; 11730; TERT Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670746 CVCL_ZU39 JHH_ONB_1904 cancer cell line human CVCL_ZU39 CL:0000010 Derived from sampling site: Brain; cranial cavity. 35670747 CVCL_ZU35 86MA finite cell line human CVCL_ZU35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 17 PDL (PubMed=9649131) 35670748 CVCL_ZU36 89MA finite cell line human CVCL_ZU36 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 24 PDL (PubMed=9649131) 35670749 CVCL_ZU37 93MA finite cell line human CVCL_ZU37 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 64 PDL (PubMed=9649131) 35670750 CVCL_ZU38 JHH_ONB_1903 cancer cell line human CVCL_ZU38 CL:0000010 Derived from sampling site: Nose. 35670751 CVCL_ZU42 LCL A2 transformed cell line human CVCL_ZU42 CL:0000010 Karyotypic information: Aberrant karyotype, 47,XY,t(13;14)(q31;q21),+12 (PubMed=32108534); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670752 CVCL_ZU43 LCL A3 transformed cell line human CVCL_ZU43 CL:0000010 Karyotypic information: Aberrant karyotype, 47,X,i(Y)(q11.21),+12 (PubMed=32108534); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670753 CVCL_ZU44 LCL M1 transformed cell line human CVCL_ZU44 CL:0000010 Karyotypic information: Has a marker chromosome present (der(22)); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670754 CVCL_ZU45 LCL M2-1 transformed cell line human CVCL_ZU45 CL:0000010 Karyotypic information: Has a marker chromosome present (der(8)); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670755 CVCL_ZU40 LCL A1-1 transformed cell line human CVCL_ZU40 CL:0000010 Karyotypic information: Aberrant karyotype, 50,XX,+5,+10,+12,+12,add(15)(p11.2) (PubMed=32108534); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670756 CVCL_ZU41 LCL A1-2 transformed cell line human CVCL_ZU41 CL:0000010 Karyotypic information: Aberrant karyotype; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 35670757 CVCL_ZU28 66MA finite cell line human CVCL_ZU28 CL:0000010 Donor information: Established from an unaffected member of a Li-Fraumeni syndrome family; Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 28 PDL (PubMed=9649131) 35670758 CVCL_ZU29 79MA finite cell line human CVCL_ZU29 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 38 PDL (PubMed=9649131) 35670759 CVCL_ZU24 174MA finite cell line human CVCL_ZU24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 6 PDL (PubMed=9649131) 35670760 CVCL_ZU25 176MA finite cell line human CVCL_ZU25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 38 PDL (PubMed=9649131) 35670761 CVCL_ZU26 22MA finite cell line human CVCL_ZU26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 22 PDL (PubMed=9649131) 35670762 CVCL_ZU27 25MA finite cell line human CVCL_ZU27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 7 PDL (PubMed=9649131) 35670763 CVCL_ZU31 81MA finite cell line human CVCL_ZU31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 55 PDL (PubMed=9649131) 35670764 CVCL_ZU32 83MA finite cell line human CVCL_ZU32 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 36 PDL (PubMed=9649131) 35670765 CVCL_ZU33 84MA finite cell line human CVCL_ZU33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Senescence: Senesces at 26 PDL (PubMed=9649131) 35670766 CVCL_ZU34 85MA finite cell line human CVCL_ZU34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 36 PDL (PubMed=9649131) 35670767 CVCL_ZU30 80MA finite cell line human CVCL_ZU30 CL:0000010 Donor information: Established from an unaffected member of a Li-Fraumeni syndrome family; Derived from sampling site: Skin Cell type=Fibroblast.. Male Senescence: Senesces at 39 PDL (PubMed=9649131) 35670768 CVCL_ZV38 JUCTCi010-C induced pluripotent stem cell human CVCL_ZV38 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670769 CVCL_ZV39 ANGM5 cancer cell line human CVCL_ZV39 CL:0000010 Population: Iraqi Male Doubling time: 22 hours (PubMed=26300657). 35670770 CVCL_ZV34 XP98BR finite cell line human CVCL_ZV34 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Trp54Ter (c.161G>A); Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670771 CVCL_ZV35 CAM spontaneously immortalized cell line CVCL_ZV35 CL:0000010 Derived from sampling site: Muscle. Unspecified Characteristics: Maximum growth rate at 28 Celsius Group: Fish cell line 35670772 CVCL_ZV36 JUCTCi010-A induced pluripotent stem cell human CVCL_ZV36 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670773 CVCL_ZV37 JUCTCi010-B induced pluripotent stem cell human CVCL_ZV37 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670774 CVCL_ZV41 UCD4 cancer cell line human CVCL_ZV41 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Lys585Asnfs*3 (c.1755_1759delGAAAA); ClinVar=VCV000037754; Zygosity=Unspecified (PubMed=32576280); Sequence variation: Mutation; HGNC; 3467; ESR1; Simple; p.Asp538Gly (c.1613A>G); Zygosity=Unspecified (PubMed=32576280) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft; Characteristics: ER/PR-positive and ERBB2-negative Doubling time: 95.9 hours, 89.3 hours (with 17-beta-estradiol) (PubMed=32576280) 35670775 CVCL_ZV42 UCD12 cancer cell line human CVCL_ZV42 CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ala1648Glufs*22 (c.4943delC); ClinVar=VCV001458405; Zygosity=Unspecified (PubMed=32576280); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Leu (c.3140A>T); ClinVar=VCV000013653; Zygosity=Unspecified (PubMed=32576280) Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft; Characteristics: ER-positive, PR-negative and ERBB2-negative Doubling time: 110.1 hours, 94.6 hours (with 17-beta-estradiol) (PubMed=32576280) 35670776 CVCL_ZV43 UCD46 cancer cell line human CVCL_ZV43 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser94Ter (c.281C>G); Zygosity=Unspecified (PubMed=32576280) Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft Doubling time: 81.5 hours, 89.4 hours (with 17-beta-estradiol) (PubMed=32576280) Group: Triple negative breast cancer (TNBC) cell line 35670777 CVCL_ZV44 UCD65 cancer cell line human CVCL_ZV44 CL:0000010 Sequence variation: Mutation; HGNC; 7765; NF1; Simple; p.Leu792fs*2 (c.2372dupT); Zygosity=Unspecified (PubMed=32576280); Sequence variation: Mutation; HGNC; 7882; NOTCH2; Simple; p.Leu2135Glufs*2 (c.6403_6404delCT); ClinVar=VCV000946387; Zygosity=Unspecified (PubMed=32576280) Derived from metastatic site: Lymph node. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft; Characteristics: ER/PR-positive and ERBB2-negative Doubling time: 132.8 hours, 109.3 (with 17-beta-estradiol) (PubMed=32576280) 35670778 CVCL_ZV40 HCAM cancer cell line house mouse CVCL_ZV40 CL:0000010 Derived from sampling site: Liver; Breed/subspecies: Swiss albino. Male 35670779 CVCL_ZV27 XP82BR finite cell line human CVCL_ZV27 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Asp132fs (c.395_398delATTG); ClinVar=VCV000916576; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Unexplicit; Ex14-15del; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670780 CVCL_ZV28 XP84BR finite cell line human CVCL_ZV28 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670781 CVCL_ZV29 XP85BR finite cell line human CVCL_ZV29 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; c.490+3A>G; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ala264Pro (c.790G>C); Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670782 CVCL_ZV23 XP67BR finite cell line human CVCL_ZV23 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg511Gln (c.1532G>A); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670783 CVCL_ZV24 XP70BR finite cell line human CVCL_ZV24 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; c.816-2A>G; ClinVar=VCV000631814; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670784 CVCL_ZV25 XP71BR finite cell line human CVCL_ZV25 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; c.816-2A>G; ClinVar=VCV000631814; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670785 CVCL_ZV26 XP72BR finite cell line human CVCL_ZV26 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Pro379Ser (c.1135C>T); ClinVar=VCV000134148; Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670786 CVCL_ZV30 XP87BR finite cell line human CVCL_ZV30 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Val623Glyfs*26 (c.1867dupG); dbSNP=rs756630156; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670787 CVCL_ZV31 XP94BR finite cell line human CVCL_ZV31 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg293Ter (c.877C>T); ClinVar=VCV000554485; Zygosity=Homozygous (PubMed=26884178) Population: Sri Lankan; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670788 CVCL_ZV32 XP95BR finite cell line human CVCL_ZV32 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2033+5G>A; ClinVar=VCV000554256; Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670789 CVCL_ZV33 XP97BR finite cell line human CVCL_ZV33 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; c.1378-26_1383del32; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Heterozygous (PubMed=26884178) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670790 CVCL_ZV16 XP51BR finite cell line human CVCL_ZV16 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2251-1G>C; ClinVar=VCV000190213; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26884178) Population: Middle Eastern; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670791 CVCL_ZV17 XP54PV finite cell line human CVCL_ZV17 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Lys217fs (c.648_649delGA); ClinVar=VCV000374933; Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670792 CVCL_ZV18 XP55BR finite cell line human CVCL_ZV18 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; c.264+1delG; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=26884178) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670793 CVCL_ZV19 XP56BR finite cell line human CVCL_ZV19 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; c.264+1delG; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=26884178) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670794 CVCL_ZV12 XP30BR finite cell line human CVCL_ZV12 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Phe610Leufs*90 (c.1827delC); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Gln (c.2048G>A); ClinVar=VCV000264679; Zygosity=Heterozygous (PubMed=26884178) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670795 CVCL_ZV13 XP35BR finite cell line human CVCL_ZV13 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu726Profs*67 (c.2176_2192del17); Zygosity=Homozygous (PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670796 CVCL_ZV14 XP39BR finite cell line human CVCL_ZV14 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu726Profs*67 (c.2176_2192del17); Zygosity=Homozygous (PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670797 CVCL_ZV15 XP4LE finite cell line human CVCL_ZV15 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu726Profs*67 (c.2176_2192del17); Zygosity=Homozygous (PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670798 CVCL_ZV20 XP63BR finite cell line human CVCL_ZV20 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys70fs (c.207delG); ClinVar=VCV000005892; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670799 CVCL_ZV21 XP64BR finite cell line human CVCL_ZV21 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Tyr146Ter (c.437dupA); Zygosity=Homozygous (PubMed=26884178) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670800 CVCL_ZV22 XP66TU finite cell line human CVCL_ZV22 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Leu309_313del (c.924_938del15); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Ala341Ser (c.1021G>T); Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670801 CVCL_ZV05 XP17BR finite cell line human CVCL_ZV05 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg616Pro (c.1847G>C); ClinVar=VCV000329508; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670802 CVCL_ZV06 XP1NO finite cell line human CVCL_ZV06 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser51Glufs*3 (c.149dupT); ClinVar=VCV000631984; Zygosity=Homozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670803 CVCL_ZV07 XP1SH finite cell line human CVCL_ZV07 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu149Lysfs*18 (c.441_442GA[2]) (c.444_445delAG) (c.445_446delGA) (GA444,445 del-2); ClinVar=VCV000557065; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Leu779fs (c.2336delT); Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670804 CVCL_ZV08 XP21BR finite cell line human CVCL_ZV08 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000550020; Zygosity=Homozygous (PubMed=26884178) Population: Middle Eastern; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670805 CVCL_ZV01 XP118BR finite cell line human CVCL_ZV01 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu615fs (c.1842delT); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala795Thr (c.2383G>A); ClinVar=VCV000883461; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670806 CVCL_ZV02 XP119BR finite cell line human CVCL_ZV02 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu585Ter (c.1753G>T); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala818Val (c.2453C>T); ClinVar=VCV000996657; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670807 CVCL_ZV03 XP120BR finite cell line human CVCL_ZV03 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu585Ter (c.1753G>T); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala818Val (c.2453C>T); ClinVar=VCV000996657; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670808 CVCL_ZV04 XP136LO finite cell line human CVCL_ZV04 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Val9Phe (c.25G>T); ClinVar=VCV000910499; Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; c.490+3A>G; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670809 CVCL_ZV09 XP22BR finite cell line human CVCL_ZV09 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg220Ter (c.658C>T); ClinVar=VCV000550020; Zygosity=Homozygous (PubMed=26884178) Population: Middle Eastern; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670810 CVCL_ZV10 XP28BR finite cell line human CVCL_ZV10 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Glu726Profs*67 (c.2176_2192del17); Zygosity=Homozygous (PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670811 CVCL_ZV11 XP29BR finite cell line human CVCL_ZV11 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.2033+5G>A; ClinVar=VCV000554256; Zygosity=Homozygous (PubMed=26884178) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670812 CVCL_ZV00 XP117BR finite cell line human CVCL_ZV00 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.299+2delT; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26884178); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gly810Alafs*9 (c.2429_2441del13); Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670813 CVCL_ZV89 HEK293 Actinin-M-cpstFRET transformed cell line human CVCL_ZV89 CL:0000010 Transfected with: HGNC; 163; ACTN1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Used to report forces in actinin in living cells Has one actinin molecule with the cpstFRET sensor incorporated between spectrin repeat domains 3 and 4 toward the middle of actinin. The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670814 CVCL_ZV90 MDCK cpstFRET-Actin spontaneously immortalized cell line dog CVCL_ZV90 CL:0000010 Transfected with: HGNC; 132; ACTB Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Has one actin molecule attached to the C-terminal of cpstFRET, leaving the other end of the probe dangling free and the probe devoid of tension (force-free control) The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670815 CVCL_ZV91 MDCK Actin-cpstFRET-Actin spontaneously immortalized cell line dog CVCL_ZV91 CL:0000010 Transfected with: HGNC; 132; ACTB Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Used to report forces in actin in living cells Has one actin molecule attached on each end of cpstFRET. The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670816 CVCL_ZV92 MDCK Actinin-C-cpstFRET spontaneously immortalized cell line dog CVCL_ZV92 CL:0000010 Transfected with: HGNC; 163; ACTN1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Has one actinin molecule attached to the C-terminal of cpstFRET, leaving the other end of the probe dangling free and the probe devoid of tension (force-free control) The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670817 CVCL_ZV93 MDCK Actinin-M-cpstFRET spontaneously immortalized cell line dog CVCL_ZV93 CL:0000010 Transfected with: HGNC; 163; ACTN1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Characteristics: Used to report forces in actinin in living cells Has one actinin molecule with the cpstFRET sensor incorporated between spectrin repeat domains 3 and 4 toward the middle of actinin. The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670818 CVCL_ZV94 OSA 1777 cancer cell line human CVCL_ZV94 CL:0000010 Derived from sampling site: Bone; proximal femur. Female Doubling time: ~60 hours (PubMed=31736134) 35670819 CVCL_ZV78 XPCS1RO hTERT telomerase immortalized cell line human CVCL_ZV78 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gly926Profs (c.2775delT) (2972delT); ClinVar=VCV000016568; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Caucasian; Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670820 CVCL_ZV79 VMM13 cancer cell line human CVCL_ZV79 HLA typing: A*01,02; B*53 (PubMed=10752474). CL:0000010 Unspecified 35670821 CVCL_ZV80 VMM6 cancer cell line human CVCL_ZV80 HLA typing: A*0201,33; B*14,44 (PubMed=10752474). CL:0000010 Unspecified 35670822 CVCL_ZV85 VMM64 cancer cell line human CVCL_ZV85 CL:0000010 Unspecified 35670823 CVCL_ZV86 HEK293 cpstFRET-Actin transformed cell line human CVCL_ZV86 CL:0000010 Transfected with: HGNC; 132; ACTB Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Has one actin molecule attached to the C-terminal of cpstFRET, leaving the other end of the probe dangling free and the probe devoid of tension (force-free control) The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670824 CVCL_ZV87 HEK293 Actin-cpstFRET-Actin transformed cell line human CVCL_ZV87 CL:0000010 Transfected with: HGNC; 132; ACTB Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Used to report forces in actin in living cells Has one actin molecule attached on each end of cpstFRET. The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670825 CVCL_ZV88 HEK293 Actinin-C-cpstFRET transformed cell line human CVCL_ZV88 CL:0000010 Transfected with: HGNC; 163; ACTN1 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Has one actinin molecule attached to the C-terminal of cpstFRET, leaving the other end of the probe dangling free and the probe devoid of tension (force-free control) The cpstFRET (circularly permuted stretch sensitive FRET) sensor consists of a pair of tandemly connected circularly permutated CFP/YFPs (cpCerulean/cpVenus). Mechanical loading twists the dipole orientation from near parallel to diagonal, decreasing FRET efficiency. 35670826 CVCL_ZV81 VMM105 cancer cell line human CVCL_ZV81 CL:0000010 Unspecified 35670827 CVCL_ZV82 VMM273 cancer cell line human CVCL_ZV82 CL:0000010 Unspecified 35670828 CVCL_ZV83 VMM330 cancer cell line human CVCL_ZV83 CL:0000010 Unspecified 35670829 CVCL_ZV84 VMM34 cancer cell line human CVCL_ZV84 CL:0000010 Unspecified 35670830 CVCL_ZV67 LK1D cancer cell line human CVCL_ZV67 CL:0000010 Derived from sampling site: Peripheral blood. Female 35670831 CVCL_ZV68 LK57 cancer cell line human CVCL_ZV68 CL:0000010 Derived from sampling site: Peripheral blood. Female 35670832 CVCL_ZV69 LK60 cancer cell line human CVCL_ZV69 CL:0000010 Derived from sampling site: Peripheral blood. Female 35670833 CVCL_ZV74 N1KA finite cell line human CVCL_ZV74 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670834 CVCL_ZV75 N2KA finite cell line human CVCL_ZV75 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670836 CVCL_ZV77 F02/98 hTERT telomerase immortalized cell line human CVCL_ZV77 CL:0000010 Sequence variation: Mutation; HGNC; 882; ATR; Simple; p.Gly674Gly (c.2022A>G) (2101A>G); ClinVar=VCV000008307; Zygosity=Homozygous; Note=Silent mutation that causes increased levels of skipping exon 9 and activation of two cryptic splicing events from sites in exon 9 leading to termination in exon 10 (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Pakistani; Derived from sampling site: Cell type=Fibroblast. Male 35670837 CVCL_ZV70 LK63 [Philadelphia] cancer cell line human CVCL_ZV70 CL:0000010 Derived from sampling site: Peripheral blood. Female 35670838 CVCL_ZV71 LK87A cancer cell line human CVCL_ZV71 CL:0000010 Derived from sampling site: Peripheral blood. 35670839 CVCL_ZV72 LK91 cancer cell line human CVCL_ZV72 CL:0000010 Derived from sampling site: Peripheral blood. Female 35670840 CVCL_ZV73 C1ABR transformed cell line human CVCL_ZV73 From: Queensland Institute of Medical Research; Brisbane; Australia CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 35670841 CVCL_ZV56 TihoDProAdcarc1511.1 cancer cell line dog CVCL_ZV56 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Doberman Pinscher. Omics: Transcriptome analysis by RNAseq Male Doubling time: 27.9 hours (PubMed=32168360) 35670842 CVCL_ZV57 TihoDProMetadcarc1511.2 cancer cell line dog CVCL_ZV57 CL:0000010 Derived from metastatic site: Sublumbar lymph node; Breed/subspecies: Doberman Pinscher. Omics: Transcriptome analysis by RNAseq Male Doubling time: 37.9 hours (PubMed=32168360) 35670843 CVCL_ZV58 TihoDProMetadcarc1511.3 cancer cell line dog CVCL_ZV58 CL:0000010 Derived from metastatic site: Sublumbar lymph node; Breed/subspecies: Doberman Pinscher. Omics: Transcriptome analysis by RNAseq Male Doubling time: 38.5 hours (PubMed=32168360) 35670844 CVCL_ZV59 TihoDProCarc/TCC0840 cancer cell line dog CVCL_ZV59 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Pitbull Terrier. Omics: Transcriptome analysis by RNAseq Male Doubling time: 28.6 hours (PubMed=32168360) 35670845 CVCL_ZV63 RPMI-7216 transformed cell line human CVCL_ZV63 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670846 CVCL_ZV64 RPMI-7206 transformed cell line human CVCL_ZV64 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670847 CVCL_ZV65 LK63/A3KD cancer cell line human CVCL_ZV65 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 3387; EPHA3 Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Unspecified 35670848 CVCL_ZV66 Reh/EphA3 cancer cell line human CVCL_ZV66 CL:0000010 Sequence variation: Gene fusion; HGNC; 3495; ETV6 + HGNC; 10471; RUNX1; Name(s)=ETV6-RUNX1; TEL-AML1 (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg181Cys (c.541C>T); ClinVar=VCV000142624; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3387; EPHA3 Derived from sampling site: Peripheral blood. Female 35670849 CVCL_ZV60 TihoDProTCC1509 cancer cell line dog CVCL_ZV60 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Bolonka Zwetna. Omics: Transcriptome analysis by RNAseq Male Doubling time: 19.9 hours (PubMed=32168360) 35670850 CVCL_ZV61 TihoDUrtTCC1506 cancer cell line dog CVCL_ZV61 CL:0000010 Derived from sampling site: Urinary bladder; Breed/subspecies: Labrador Retriever. Omics: Transcriptome analysis by RNAseq Female Doubling time: 21.3 hours (PubMed=32168360) 35670851 CVCL_ZV62 TC587 cancer cell line human CVCL_ZV62 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp816Tyr (c.2446G>T); ClinVar=VCV000013860; Zygosity=Unspecified (PubMed=32014918); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000013901; Zygosity=Unspecified (PubMed=32014918); Sequence variation: Mutation; HGNC; 18118; RSF1; Simple; p.Pro1133Leu (c.3398C>T); Zygosity=Unspecified (PubMed=32014918); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala347Asp (c.1040C>A); ClinVar=VCV000043587; Zygosity=Unspecified (PubMed=32014918) Population: Japanese; Derived from sampling site: Ovary. Female Doubling time: ~36 hours (PubMed=32014918) 35670852 CVCL_ZV49 EFC-2 cancer cell line human CVCL_ZV49 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9090379). 35670853 CVCL_ZV45 UCD115 cancer cell line human CVCL_ZV45 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys305fs*47 (c.892_911dupGAGCTGCCCCCAGGGAGCAC); Zygosity=Unspecified (PubMed=32576280) Derived from sampling site: Breast. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft Doubling time: 65.4 hours, 67.7 hours (with 17-beta-estradiol) (PubMed=32576280) Group: Triple negative breast cancer (TNBC) cell line 35670854 CVCL_ZV46 UCD178 cancer cell line human CVCL_ZV46 CL:0000010 Sequence variation: Gene fusion; HGNC; 7881; NOTCH1 + HGNC; 29006; SEC16A; Name(s)=SEC16A-NOTCH1 (PubMed=32576280) Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Female Characteristics: Established from a patient-derived xenograft Doubling time: 54.1 hours, 55.8 hours (with 17-beta-estradiol) (PubMed=32576280) Group: Triple negative breast cancer (TNBC) cell line 35670855 CVCL_ZV47 MDCK-A3-15 spontaneously immortalized cell line dog CVCL_ZV47 CL:0000010 Transfected with: HGNC; 1706; CD8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 35670856 CVCL_ZV48 LG-11 cancer cell line human CVCL_ZV48 CL:0000010 Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=9090379). 35670857 CVCL_ZV52 KE cancer cell line human CVCL_ZV52 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; c.(2062_3114)ins?; Zygosity=Unspecified (PubMed=10698499); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gly36Glu (c.107G>A); ClinVar=VCV000486972; Zygosity=Unspecified (PubMed=9090379). 35670858 CVCL_ZV53 PH-2 [Human glioblastoma] cancer cell line human CVCL_ZV53 CL:0000010 35670859 CVCL_ZV54 TihoDProAdcarc0846 cancer cell line dog CVCL_ZV54 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: German Rough-haired Pointer. Omics: Transcriptome analysis by RNAseq Male Doubling time: 26.2 hours (PubMed=32168360) 35670860 CVCL_ZV55 TihoDProAdcarc1508 cancer cell line dog CVCL_ZV55 CL:0000010 Derived from sampling site: Prostate; Breed/subspecies: Mixed breed. Omics: Transcriptome analysis by RNAseq Male Doubling time: 18.2 hours (PubMed=32168360) 35670861 CVCL_ZV50 D77 cancer cell line human CVCL_ZV50 CL:0000010 35670862 CVCL_ZV51 F60 cancer cell line human CVCL_ZV51 CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg335Ter (c.1003C>T); ClinVar=VCV000007833; Zygosity=Unspecified (PubMed=9090379). 35670863 CVCL_ZP83 XP1UTSW finite cell line human CVCL_ZP83 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; c.622-2A>C (IVS5.1-2A>C); ClinVar=VCV000190209; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=17079196; PubMed=17084680); Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Gly810Alafs*9 (c.2429_2441del13); Zygosity=Heterozygous (PubMed=17079196; PubMed=17084680) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670864 CVCL_ZP84 XP01RJ finite cell line human CVCL_ZP84 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala28Asp (c.83C>A); ClinVar=VCV000041495; Zygosity=Heterozygous (PubMed=23255472); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Trp968Cys (c.2904G>C); ClinVar=VCV000041496; Zygosity=Heterozygous (PubMed=23255472) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670865 CVCL_ZP85 XP02RJ finite cell line human CVCL_ZP85 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala28Asp (c.83C>A); ClinVar=VCV000041495; Zygosity=Heterozygous (PubMed=23255472); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Trp968Cys (c.2904G>C); ClinVar=VCV000041496; Zygosity=Heterozygous (PubMed=23255472) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670866 CVCL_ZP86 XPHF01RJ finite cell line human CVCL_ZP86 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Trp968Cys (c.2904G>C); ClinVar=VCV000041496; Zygosity=Heterozygous (PubMed=23255472) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670867 CVCL_ZP80 XP3EH finite cell line human CVCL_ZP80 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670868 CVCL_ZP81 XP4EH finite cell line human CVCL_ZP81 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670869 CVCL_ZP82 XP5EH finite cell line human CVCL_ZP82 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670870 CVCL_ZP87 XP115LO 1 finite cell line human CVCL_ZP87 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln373Ter (c.1117C>T); ClinVar=VCV000005890; Zygosity=Homozygous (from autologous cell line XP115LO 2) Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM02111; probable Male 35670871 CVCL_ZP88 XP1CH [XP-V Caucasian] finite cell line human CVCL_ZP88 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Phe247fs (c.738delC); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg356Ter (c.1066C>T); ClinVar=VCV001459259; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670872 CVCL_ZP89 XP110BR finite cell line human CVCL_ZP89 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Phe247fs (c.738delC); Zygosity=Heterozygous (PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg356Ter (c.1066C>T); ClinVar=VCV001459259; Zygosity=Heterozygous (PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670873 CVCL_ZP72 GM06059 transformed cell line human CVCL_ZP72 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM06059; probable Unspecified 35670874 CVCL_ZP73 GM06060 transformed cell line human CVCL_ZP73 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM06060; probable Unspecified 35670875 CVCL_ZP74 XP329BE finite cell line human CVCL_ZP74 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Met1Arg (c.2T>G); ClinVar=VCV001066146; Zygosity=Homozygous (PubMed=18955168) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670876 CVCL_ZP75 XPH395BE finite cell line human CVCL_ZP75 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Met1Arg (c.2T>G); ClinVar=VCV001066146; Zygosity=Heterozygous (PubMed=18955168) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670877 CVCL_ZP70 GM06057 transformed cell line human CVCL_ZP70 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM06057; probable Unspecified 35670878 CVCL_ZP71 GM06058 transformed cell line human CVCL_ZP71 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM06058; probable Unspecified 35670879 CVCL_ZP76 XPH396BE finite cell line human CVCL_ZP76 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Met1Arg (c.2T>G); ClinVar=VCV001066146; Zygosity=Heterozygous (PubMed=18955168) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670880 CVCL_ZP77 XP5GO finite cell line human CVCL_ZP77 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys642Ilefs*20 (c.1923_1934delins25); Zygosity=Homozygous (PubMed=16794584) Population: Iraqi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670881 CVCL_ZP78 XP6GO finite cell line human CVCL_ZP78 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Lys642Ilefs*20 (c.1923_1934delins25); Zygosity=Homozygous (PubMed=16794584) Population: Iraqi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670882 CVCL_ZP79 XP1EH finite cell line human CVCL_ZP79 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670883 CVCL_ZP61 Kirkman insulinoma clone 27 cancer cell line CVCL_ZP61 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Tumorigenic Does not produces insulin when grown in culture but does so when grown in tumors. 35670884 CVCL_ZP62 Kirkman insulinoma clone 30 cancer cell line CVCL_ZP62 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Tumorigenic Does not produces insulin when grown in culture but does so when grown in tumors. 35670885 CVCL_ZP63 Kirkman insulinoma clone 35 cancer cell line CVCL_ZP63 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Tumorigenic Does not produces insulin when grown in culture but does so when grown in tumors. 35670886 CVCL_ZP64 XP124LO LCL transformed cell line human CVCL_ZP64 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Ala792Val (c.2375C>T) (2572C>T); ClinVar=VCV000016567; Zygosity=Heterozygous (PubMed=9096355); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Glu960Ter (c.2878G>T) (3075G>T); ClinVar=VCV000016566; Zygosity=Heterozygous (PubMed=9096355) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670887 CVCL_ZP60 Kirkman insulinoma clone 13 cancer cell line CVCL_ZP60 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Tumorigenic Does not produces insulin when grown in culture but does so when grown in tumors. 35670888 CVCL_ZP69 XP3BR LCL transformed cell line human CVCL_ZP69 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Asp499Ilefs*23 (c.1494delA); ClinVar=VCV000016575; Zygosity=Heterozygous (PubMed=11841555); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Lys917Asnfs*64 (c.2751delA); ClinVar=VCV000016576; Zygosity=Heterozygous (PubMed=11841555) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35670889 CVCL_ZP65 CS1USAU finite cell line human CVCL_ZP65 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Cys236Arg (c.706T>C); ClinVar=VCV000055827; Zygosity=Heterozygous (PubMed=23623389); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Tyr577Ter (c.1730dupA); ClinVar=VCV000055828; Zygosity=Heterozygous (PubMed=23623389) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670890 CVCL_ZP66 XPCS1CD finite cell line human CVCL_ZP66 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Cys236Arg (c.706T>C); ClinVar=VCV000055827; Zygosity=Heterozygous (PubMed=23623389); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg589Trp (c.1765C>T); ClinVar=VCV000055829; Zygosity=Heterozygous (PubMed=23623389) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670891 CVCL_ZP67 CS20LO finite cell line human CVCL_ZP67 CL:0000010 Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Phe231Leu (c.693C>G); ClinVar=VCV000016778; Zygosity=Homozygous (PubMed=23623389) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670892 CVCL_ZP68 XPCS1RO finite cell line human CVCL_ZP68 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Gly926Profs (c.2775delT) (2972delT); ClinVar=VCV000016568; Zygosity=Unspecified (PubMed=9096355) Population: Caucasian; Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670893 CVCL_ZP50 95RD28 finite cell line human CVCL_ZP50 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Heterozygous (PubMed=9579555) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670894 CVCL_ZP51 XP24BR finite cell line human CVCL_ZP51 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg589Trp (c.1765C>T); ClinVar=VCV000055829; Zygosity=Heterozygous (PubMed=20221251; PubMed=26884178); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Heterozygous (PubMed=20221251; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670895 CVCL_ZP52 XP26BR finite cell line human CVCL_ZP52 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Homozygous (PubMed=20221251) Derived from sampling site: Skin Cell type=Fibroblast.. 35670896 CVCL_ZP53 XP32BR finite cell line human CVCL_ZP53 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Pro379Ser (c.1135C>T); ClinVar=VCV000134148; Zygosity=Heterozygous (PubMed=20221251; PubMed=26884178); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg589Trp (c.1765C>T); ClinVar=VCV000055829; Zygosity=Heterozygous (PubMed=20221251; PubMed=26884178) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670897 CVCL_ZP58 XP42RO-hTERT telomerase immortalized cell line human CVCL_ZP58 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670898 CVCL_ZP59 Kirkman insulinoma clone 10 cancer cell line CVCL_ZP59 CL:0000010 Derived from sampling site: Pancreas; islets of Langerhans. Unspecified Characteristics: Tumorigenic Does not produces insulin when grown in culture but does so when grown in tumors. 35670899 CVCL_ZP54 XP62RO finite cell line human CVCL_ZP54 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Homozygous (PubMed=20221251) Derived from sampling site: Skin Cell type=Fibroblast.. 35670900 CVCL_ZP55 XP51RO finite cell line human CVCL_ZP55 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg153Pro (c.458G>C); ClinVar=VCV000016581; Zygosity=Homozygous (PubMed=17183314; PubMed=20221251) Population: Afghan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670901 CVCL_ZP56 XP51RO-hTERT telomerase immortalized cell line human CVCL_ZP56 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg153Pro (c.458G>C); ClinVar=VCV000016581; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Afghan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670902 CVCL_ZP57 TTD1BI finite cell line human CVCL_ZP57 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Glu731Argfs*14 (c.2190delG) (730fs); Zygosity=Heterozygous (PubMed=7920640) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670903 CVCL_ZP40 XPCS2BASV Cl-14 transformed cell line human CVCL_ZP40 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670904 CVCL_ZP41 XPCS2BASV Cl-19 transformed cell line human CVCL_ZP41 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670905 CVCL_ZP42 GM02060 finite cell line human CVCL_ZP42 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM02060; probable Unspecified Senescence: Senesces at 22 PDL (PubMed=6492896) 35670906 CVCL_ZP47 STUC finite cell line human CVCL_ZP47 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Glu55Ter (c.163G>T); ClinVar=VCV000975158; Zygosity=Homozygous (PubMed=24986372) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670907 CVCL_ZP48 C4RO finite cell line human CVCL_ZP48 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670908 CVCL_ZP49 TTD18PV finite cell line human CVCL_ZP49 From: Istituto di Genetica Biochimica ed Evoluzionistica (IGBE); Pavia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 11572; TARS1; Simple; p.Lys276Glu (c.826A>G); ClinVar=VCV000689398; Zygosity=Heterozygous (PubMed=31374204); Sequence variation: Mutation; HGNC; 11572; TARS1; Simple; p.Arg638Ter (c.1912C>T); ClinVar=VCV000689397; Zygosity=Heterozygous (PubMed=31374204) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis 35670909 CVCL_ZP43 TTD9VI finite cell line human CVCL_ZP43 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (PubMed=18676829) Derived from sampling site: Skin Cell type=Fibroblast.. 35670910 CVCL_ZP44 TTD9VILas transformed cell line human CVCL_ZP44 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg112His (c.335G>A); ClinVar=VCV000016784; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 35670911 CVCL_ZP45 TTD1BRSV transformed cell line human CVCL_ZP45 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Leu21Pro (c.62T>C); ClinVar=VCV000002104; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Arg56Ter (c.166C>T); ClinVar=VCV000002103; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670912 CVCL_ZP46 TTD99RO finite cell line human CVCL_ZP46 CL:0000010 Sequence variation: Mutation; HGNC; 21157; GTF2H5; Simple; p.Arg56Ter (c.166C>T); ClinVar=VCV000002103; Zygosity=Homozygous (PubMed=15220921) Derived from sampling site: Skin Cell type=Fibroblast.. 35670913 CVCL_ZP29 XPCS1BA(SV) finite cell line human CVCL_ZP29 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (from parent cell line) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670914 CVCL_ZP30 TTD4VI finite cell line human CVCL_ZP30 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Thr119Pro (c.355A>C); ClinVar=VCV000016584; Zygosity=Homozygous (PubMed=9012405) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670915 CVCL_ZP31 TTD4VILas finite cell line human CVCL_ZP31 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Thr119Pro (c.355A>C); ClinVar=VCV000016584; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670916 CVCL_ZP36 C5ROLas transformed cell line human CVCL_ZP36 CL:0000010 Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670917 CVCL_ZP37 C5RO-hTERT telomerase immortalized cell line human CVCL_ZP37 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670918 CVCL_ZP38 XPCS2BASV transformed cell line human CVCL_ZP38 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670919 CVCL_ZP39 XPCS2BASV Cl-5 transformed cell line human CVCL_ZP39 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Lys157insThrSerAspSerTer (c.471+1G>A); ClinVar=VCV000016589; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 3435; ERCC3 (with p.Thr119Pro); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670920 CVCL_ZP32 XP4PA finite cell line human CVCL_ZP32 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from child cell line XP4PA(SV)) Derived from sampling site: Amniotic fluid. Male 35670921 CVCL_ZP33 AS3 finite cell line human CVCL_ZP33 CL:0000010 Derived from sampling site: Amniotic fluid. Unspecified 35670922 CVCL_ZP34 AS3-SVwt transformed cell line human CVCL_ZP34 CL:0000010 Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Amniotic fluid. Unspecified 35670923 CVCL_ZP35 C5RO finite cell line human CVCL_ZP35 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670924 CVCL_ZP18 CSHM1MO finite cell line human CVCL_ZP18 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670925 CVCL_ZP19 XP126LO finite cell line human CVCL_ZP19 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Thr770Profs*46 (c.2304_2307delTCTC) (2281del4); ClinVar=VCV000016579; Zygosity=Heterozygous (PubMed=8797827); Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Heterozygous (PubMed=8797827) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670926 CVCL_ZP20 XP42RO finite cell line human CVCL_ZP20 CL:0000010 Sequence variation: Mutation; HGNC; 3436; ERCC4; Simple; p.Arg799Trp (c.2395C>T) (R788W); ClinVar=VCV000016580; Zygosity=Homozygous (PubMed=9579555) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670927 CVCL_ZP25 TTD5VI finite cell line human CVCL_ZP25 CL:0000010 Sequence variation: Mutation; HGNC; 11572; TARS1; Simple; p.Leu227Pro (c.680T>C); ClinVar=VCV000689399; Zygosity=Homozygous (PubMed=31374204) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 35670928 CVCL_ZP26 TTD6VI finite cell line human CVCL_ZP26 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Thr119Pro (c.355A>C); ClinVar=VCV000016584; Zygosity=Homozygous (PubMed=9012405) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670929 CVCL_ZP27 TTD6VILas transformed cell line human CVCL_ZP27 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Thr119Pro (c.355A>C); ClinVar=VCV000016584; Zygosity=Homozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670930 CVCL_ZP28 TTD8VI finite cell line human CVCL_ZP28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35670931 CVCL_ZP21 165TOR finite cell line human CVCL_ZP21 CL:0000010 Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Gln158Ter (c.472C>T); ClinVar=VCV000016777; Zygosity=Heterozygous (PubMed=17273966); Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Phe231Leu (c.693C>G); ClinVar=VCV000016778; Zygosity=Heterozygous (PubMed=17273966) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 35670932 CVCL_ZP22 XP202DC finite cell line human CVCL_ZP22 CL:0000010 Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; c.604-26G>A; Zygosity=Heterozygous (CelloPub=CLPUB00562); Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Lys226Ter (c.676A>T); ClinVar=VCV000264678; Zygosity=Heterozygous (CelloPub=CLPUB00562) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670933 CVCL_ZP23 174TOR finite cell line human CVCL_ZP23 CL:0000010 Sequence variation: Mutation; HGNC; 3433; ERCC1; Simple; p.Gln158Ter (c.472C>T); ClinVar=VCV000016777; Zygosity=Heterozygous (PubMed=17273966) Population: Caucasian; Italian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 35670934 CVCL_ZP24 TTD3VILas transformed cell line human CVCL_ZP24 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Leu461Val (c.1381C>G); ClinVar=VCV000016779; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg658His (c.1973G>A); ClinVar=VCV001499293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ala717Gly (c.2150C>G) (p.Val716_Arg730del); ClinVar=VCV000134102; Zygosity=Heterozygous; Note=Creates a cryptic donor splice site (from parent cell line) Transformant: Simian virus 40 (SV40) [pLASwt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670935 CVCL_ZP07 UVs1KO finite cell line human CVCL_ZP07 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg77Ter (c.229C>T) (C308T); ClinVar=VCV000001708; Zygosity=Homozygous (PubMed=15486090) Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35670936 CVCL_ZP08 UVs1KOSV transformed cell line human CVCL_ZP08 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg77Ter (c.229C>T) (C308T); ClinVar=VCV000001708; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 35670937 CVCL_ZP09 CS3AM finite cell line human CVCL_ZP09 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg77Ter (c.229C>T) (C308T); ClinVar=VCV000001708; Zygosity=Homozygous (PubMed=21143350) Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35670938 CVCL_ZP14 CS1MO finite cell line human CVCL_ZP14 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670939 CVCL_ZP15 Kps3 finite cell line human CVCL_ZP15 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Homozygous (PubMed=22466610) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Deep exome analysis Female 35670940 CVCL_ZP16 Kps2 finite cell line human CVCL_ZP16 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Lys123Ter (c.367A>T); ClinVar=VCV000031569; Zygosity=Homozygous (PubMed=22466610) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670941 CVCL_ZP17 CS2MO finite cell line human CVCL_ZP17 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670942 CVCL_ZP10 XP12BR finite cell line human CVCL_ZP10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35670943 CVCL_ZP11 XP13BR finite cell line human CVCL_ZP11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35670944 CVCL_ZP12 UVSS1VI finite cell line human CVCL_ZP12 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Trp361Cys (c.1083G>T); ClinVar=VCV000068752; Zygosity=Homozygous (PubMed=19329487) Population: Caucasian; Derived from sampling site: Buttock; skin Cell type=Fibroblast.. Female 35670945 CVCL_ZP13 UVSS24TA finite cell line human CVCL_ZP13 CL:0000010 Sequence variation: Mutation; HGNC; 29304; UVSSA; Simple; p.Ile31Phefs*9 (c.87delG); ClinVar=VCV000031570; Zygosity=Homozygous (PubMed=22466610) Population: Israeli; Derived from sampling site: Skin Cell type=Fibroblast.. 35670946 CVCL_ZP94 XP37RO finite cell line human CVCL_ZP94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35670947 CVCL_ZP95 XP1RO finite cell line human CVCL_ZP95 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Trp297Ter (c.890G>A); ClinVar=VCV000005888; Zygosity=Heterozygous (PubMed=10385124); Sequence variation: Mutation; HGNC; 9181; POLH; Unexplicit; Large deletion; Zygosity=Heterozygous (PubMed=10385124) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670948 CVCL_ZP96 XP62VI finite cell line human CVCL_ZP96 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Homozygous (PubMed=11773631) Population: Algerian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670949 CVCL_ZP97 XP75VI finite cell line human CVCL_ZP97 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Homozygous (PubMed=11773631) Population: Algerian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670950 CVCL_ZP90 XP7TA finite cell line human CVCL_ZP90 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu178Profs*2 (c.533_534delTT) (del 770-771); ClinVar=VCV000005886; Zygosity=Unspecified (PubMed=10385124) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670951 CVCL_ZP91 XP1NY finite cell line human CVCL_ZP91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35670952 CVCL_ZP92 19BR finite cell line human CVCL_ZP92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670953 CVCL_ZP93 XP3DU finite cell line human CVCL_ZP93 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys70fs (c.207delG); ClinVar=VCV000005892; Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670954 CVCL_ZP98 XP28VI finite cell line human CVCL_ZP98 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr364fs (c.1091dupC) (Fs364); Zygosity=Heterozygous (PubMed=11773631) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670955 CVCL_ZP99 XP127VI finite cell line human CVCL_ZP99 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Homozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr364fs (c.1091dupC) (Fs364); Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670956 CVCL_ZP03 XP224BE finite cell line human CVCL_ZP03 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser51Glufs*3 (c.149dupT); ClinVar=VCV000631984; Zygosity=Heterozygous (PubMed=18368133); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys220Glu (c.658A>G); Zygosity=Heterozygous (PubMed=18368133) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM16818; probable Female 35670957 CVCL_ZP04 XP139DC finite cell line human CVCL_ZP04 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Heterozygous (PubMed=18368133); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr569Argfs*10 (c.1706_1707delCA); Zygosity=Heterozygous (PubMed=18368133) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670958 CVCL_ZP05 UVsH-F finite cell line human CVCL_ZP05 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg77Ter (c.229C>T) (C308T); ClinVar=VCV000001708; Zygosity=Heterozygous (PubMed=15486090) Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 35670959 CVCL_ZP06 UVsH-M finite cell line human CVCL_ZP06 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Arg77Ter (c.229C>T) (C308T); ClinVar=VCV000001708; Zygosity=Heterozygous (PubMed=15486090) Population: Japanese; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 35670960 CVCL_ZP00 XP164BE finite cell line human CVCL_ZP00 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asp360Glyfs*32 (c.1078dupG) (c.1078_1079dupG); ClinVar=VCV001696282; Zygosity=Homozygous (PubMed=18368133) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670961 CVCL_ZP01 XP10TA finite cell line human CVCL_ZP01 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Trp174Cys (c.522G>T); Zygosity=Homozygous (PubMed=18368133) Population: Jewish; Iraqi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670962 CVCL_ZP02 XP3GO finite cell line human CVCL_ZP02 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Val221Profs*2 (c.661_764del104) (Ex6del); Zygosity=Homozygous (PubMed=18368133) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670963 CVCL_ZQ93 XP98MA finite cell line human CVCL_ZQ93 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670964 CVCL_ZQ94 XP99MA finite cell line human CVCL_ZQ94 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670965 CVCL_ZQ95 XP100MA finite cell line human CVCL_ZQ95 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670966 CVCL_ZQ96 XP102MA finite cell line human CVCL_ZQ96 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670967 CVCL_ZQ90 XP4MA finite cell line human CVCL_ZQ90 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670968 CVCL_ZQ91 XP52MA finite cell line human CVCL_ZQ91 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670969 CVCL_ZQ92 XP95MA finite cell line human CVCL_ZQ92 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670970 CVCL_ZQ97 XP107MA finite cell line human CVCL_ZQ97 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670971 CVCL_ZQ98 XP112MA finite cell line human CVCL_ZQ98 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670972 CVCL_ZQ99 XP114MA finite cell line human CVCL_ZQ99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670973 CVCL_ZQ82 198VI finite cell line human CVCL_ZQ82 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35670974 CVCL_ZQ83 XP28MA finite cell line human CVCL_ZQ83 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670975 CVCL_ZQ84 XP43MA finite cell line human CVCL_ZQ84 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670976 CVCL_ZQ85 XP44MA finite cell line human CVCL_ZQ85 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670977 CVCL_ZQ80 XP15MA finite cell line human CVCL_ZQ80 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670978 CVCL_ZQ81 XP16MA finite cell line human CVCL_ZQ81 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Said to originate from a female patient in PubMed=2054785 and from a male patient in PubMed=7165374 35670979 CVCL_ZQ86 XP70MA finite cell line human CVCL_ZQ86 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670980 CVCL_ZQ87 XP74MA finite cell line human CVCL_ZQ87 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670981 CVCL_ZQ88 XP77MA finite cell line human CVCL_ZQ88 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670982 CVCL_ZQ89 XP79MA finite cell line human CVCL_ZQ89 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670983 CVCL_ZQ71 XP24HM finite cell line human CVCL_ZQ71 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=20574439; PubMed=27603812) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670984 CVCL_ZQ72 XP31MA finite cell line human CVCL_ZQ72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670985 CVCL_ZQ73 XP32MA finite cell line human CVCL_ZQ73 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670986 CVCL_ZQ74 XP54MA finite cell line human CVCL_ZQ74 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670987 CVCL_ZQ70 XP12HM finite cell line human CVCL_ZQ70 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=20574439; PubMed=27603812) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670988 CVCL_ZQ79 XP11MA finite cell line human CVCL_ZQ79 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670989 CVCL_ZQ75 XP2MA finite cell line human CVCL_ZQ75 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670990 CVCL_ZQ76 XP3MA finite cell line human CVCL_ZQ76 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Said to originate from a female patient in PubMed=2054785 and from a male patient in PubMed=7165374 35670991 CVCL_ZQ77 XP7MA finite cell line human CVCL_ZQ77 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670992 CVCL_ZQ78 XP8MA finite cell line human CVCL_ZQ78 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670993 CVCL_ZQ60 XP4KY finite cell line human CVCL_ZQ60 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670994 CVCL_ZQ61 XP5KY finite cell line human CVCL_ZQ61 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670995 CVCL_ZQ62 XP8MY finite cell line human CVCL_ZQ62 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670996 CVCL_ZQ63 XP9KY finite cell line human CVCL_ZQ63 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670997 CVCL_ZQ68 XP42HM finite cell line human CVCL_ZQ68 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=20574439); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Thr260Ilefs*8 (c.779delCinsTTCTT) (779insTT) (780insTT); Zygosity=Heterozygous (PubMed=20574439) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35670998 CVCL_ZQ69 XP43HM finite cell line human CVCL_ZQ69 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=20574439); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Thr260Ilefs*8 (c.779delCinsTTCTT) (779insTT) (780insTT); Zygosity=Heterozygous (PubMed=20574439) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35670999 CVCL_ZQ64 XP46HM finite cell line human CVCL_ZQ64 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gly176Aspfs*6 (c.529G>A); Zygosity=Homozygous; Note=Causes aberrant splicing (PubMed=27603812) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671000 CVCL_ZQ65 XP1Ni(EB-L) transformed cell line human CVCL_ZQ65 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from autologous cell line XP1NI) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35671001 CVCL_ZQ66 XP17HM finite cell line human CVCL_ZQ66 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=20574439); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg231Lysfs*15 (c.689dupT) (690insT); ClinVar=VCV001457431; Zygosity=Heterozygous (PubMed=20574439) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671002 CVCL_ZQ67 XP21HM finite cell line human CVCL_ZQ67 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=20574439); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Thr260Ilefs*8 (c.779delCinsTTCTT) (779insTT) (780insTT); Zygosity=Heterozygous (PubMed=20574439) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671003 CVCL_ZQ50 XP1KG finite cell line human CVCL_ZQ50 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671004 CVCL_ZQ51 XP1KN finite cell line human CVCL_ZQ51 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671005 CVCL_ZQ52 XP1NI finite cell line human CVCL_ZQ52 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671006 CVCL_ZQ57 XP3KG finite cell line human CVCL_ZQ57 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671007 CVCL_ZQ58 XP3KY finite cell line human CVCL_ZQ58 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671008 CVCL_ZQ59 XP4KG finite cell line human CVCL_ZQ59 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671009 CVCL_ZQ53 XP22KY finite cell line human CVCL_ZQ53 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671010 CVCL_ZQ54 XP26KY finite cell line human CVCL_ZQ54 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671011 CVCL_ZQ55 XP2KY finite cell line human CVCL_ZQ55 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671012 CVCL_ZQ56 XP3HM [XP-A] finite cell line human CVCL_ZQ56 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Caution: Two different patients and fibroblast cell lines seem to have been given the same designation: XPH3M, one is a XP-A (Cellosaurus=CVCL_ZQ56) the other a XP-G (Cellosaurus=CVCL_ZS95) 35671013 CVCL_ZQ39 KOWA finite cell line human CVCL_ZQ39 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671014 CVCL_ZQ40 XP11KY finite cell line human CVCL_ZQ40 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671015 CVCL_ZQ41 XP13KY finite cell line human CVCL_ZQ41 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671016 CVCL_ZQ46 XP1BP finite cell line human CVCL_ZQ46 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671017 CVCL_ZQ47 XP2NI finite cell line human CVCL_ZQ47 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=7905727; PubMed=8596539); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Glu225Gln (c.673G>C); Zygosity=Heterozygous (PubMed=7905727; PubMed=8596539) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671018 CVCL_ZQ48 XP1FI finite cell line human CVCL_ZQ48 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671019 CVCL_ZQ49 XP1HM finite cell line human CVCL_ZQ49 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671020 CVCL_ZQ42 XP15KY finite cell line human CVCL_ZQ42 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671021 CVCL_ZQ43 XP16NA finite cell line human CVCL_ZQ43 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671022 CVCL_ZQ44 XP18KY finite cell line human CVCL_ZQ44 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671023 CVCL_ZQ45 XP19KY finite cell line human CVCL_ZQ45 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671024 CVCL_ZQ28 XP14NA finite cell line human CVCL_ZQ28 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671025 CVCL_ZQ29 XP15NA finite cell line human CVCL_ZQ29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35671026 CVCL_ZQ30 XPL1KM transformed cell line human CVCL_ZQ30 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 35671027 CVCL_ZQ35 XP12TU finite cell line human CVCL_ZQ35 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671028 CVCL_ZQ36 XP13TU finite cell line human CVCL_ZQ36 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671029 CVCL_ZQ37 XP27TU finite cell line human CVCL_ZQ37 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671030 CVCL_ZQ38 XP33TU finite cell line human CVCL_ZQ38 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671031 CVCL_ZQ31 XP1KR finite cell line human CVCL_ZQ31 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. 35671032 CVCL_ZQ32 XP5TU finite cell line human CVCL_ZQ32 CL:0000010 Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671033 CVCL_ZQ33 XP8TU finite cell line human CVCL_ZQ33 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671034 CVCL_ZQ34 XP11TU finite cell line human CVCL_ZQ34 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=8105686) Population: Tunisian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671035 CVCL_ZQ17 XPVAR-1 transformed cell line human CVCL_ZQ17 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln373Ter (c.1117C>T); ClinVar=VCV000005890; Zygosity=Homozygous (from parent cell line) Population: Iranian; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671036 CVCL_ZQ18 CS1BI finite cell line human CVCL_ZQ18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671037 CVCL_ZQ19 CS1BO finite cell line human CVCL_ZQ19 CL:0000010 Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Lys506Asnfs*37 (c.1518delG) (1597delG); ClinVar=VCV000190150; Zygosity=Heterozygous (PubMed=9443879); Sequence variation: Mutation; HGNC; 3438; ERCC6; Simple; p.Pro1095Arg (c.3284C4G) (G3363C); ClinVar=VCV000001707; Zygosity=Heterozygous (PubMed=9443879) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671038 CVCL_ZQ24 XP6NA finite cell line human CVCL_ZQ24 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671039 CVCL_ZQ25 XP7NA finite cell line human CVCL_ZQ25 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671040 CVCL_ZQ26 XP8NA finite cell line human CVCL_ZQ26 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671041 CVCL_ZQ27 XP9NA finite cell line human CVCL_ZQ27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671042 CVCL_ZQ20 XP1TA finite cell line human CVCL_ZQ20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35671043 CVCL_ZQ21 XP3TA finite cell line human CVCL_ZQ21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35671044 CVCL_ZQ22 XP4KR finite cell line human CVCL_ZQ22 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=7905727); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Heterozygous (PubMed=7905727) Population: Japanese; Donor information: Established from monozygotic twin of XP3KR (Cellosaurus=CVCL_L777); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671045 CVCL_ZQ23 XP2HM finite cell line human CVCL_ZQ23 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Tyr116Ter (c.348T>A); ClinVar=VCV000000997; Zygosity=Heterozygous (PubMed=7905727); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=7905727) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671046 CVCL_ZQ06 XP37BR finite cell line human CVCL_ZQ06 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Pro556fs (c.1668dupC) (Fs556); Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671047 CVCL_ZQ07 XP51VI finite cell line human CVCL_ZQ07 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys163fs (Ex5del) (Fs163); Zygosity=Homozygous (PubMed=11773631) Population: Algerian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671048 CVCL_ZQ08 XP52RO finite cell line human CVCL_ZQ08 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg356Ter (c.1066C>T); ClinVar=VCV001459259; Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671049 CVCL_ZQ09 XP53RO finite cell line human CVCL_ZQ09 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys163fs (Ex5del) (Fs163); Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gly295fs (c.882dupT) (Fs294); Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg356Ter (c.1066C>T); ClinVar=VCV001459259; Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671050 CVCL_ZQ13 XP59RO finite cell line human CVCL_ZQ13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35671051 CVCL_ZQ14 XPA7A3A transformed cell line human CVCL_ZQ14 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys108Phe (c.323G>T); ClinVar=VCV000000993; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Leu117Glufs*4 (c.349_353delCTTAT) (349del5); ClinVar=VCV000000994; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671052 CVCL_ZQ15 XPA7A6B transformed cell line human CVCL_ZQ15 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys108Phe (c.323G>T); ClinVar=VCV000000993; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Leu117Glufs*4 (c.349_353delCTTAT) (349del5); ClinVar=VCV000000994; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671053 CVCL_ZQ16 XPG415A transformed cell line human CVCL_ZQ16 CL:0000010 Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Arg372Thrfs*5 (c.1115_1118delGGAA); ClinVar=VCV000016574; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3437; ERCC5; Simple; p.Leu858Pro (c.2573T>C); ClinVar=VCV000016573; Zygosity=Heterozygous (from parent cell line) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671054 CVCL_ZQ10 XP56RO finite cell line human CVCL_ZQ10 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys163fs (Ex5del) (Fs163); Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Trp297Ter (c.890G>A); ClinVar=VCV000005888; Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671055 CVCL_ZQ11 XP57RO finite cell line human CVCL_ZQ11 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg361Ser (c.1083G>T) (G1083T); Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671056 CVCL_ZQ12 XP58RO finite cell line human CVCL_ZQ12 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Homozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671057 CVCL_ZQ02 XP36BR finite cell line human CVCL_ZQ02 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg111His (c.332G>A); ClinVar=VCV001331405; Zygosity=Heterozygous (PubMed=11773631; PubMed=26884178); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr408fs (c.1222_1225delACTT) (Fs407); Zygosity=Heterozygous (PubMed=11773631; PubMed=26884178) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671058 CVCL_ZQ03 XP5BI finite cell line human CVCL_ZQ03 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr122Pro (p.364A>C); Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr408fs (c.1222_1225delACTT) (Fs407); Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671059 CVCL_ZQ04 XP86VI finite cell line human CVCL_ZQ04 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln521Ter (c.1561C>T); ClinVar=VCV001333587; Zygosity=Homozygous (PubMed=11773631) Population: Algerian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671060 CVCL_ZQ05 XP1AB finite cell line human CVCL_ZQ05 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser548Ter (c.1643C>A); Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified Caution: The p.Ser548Ter (c.1643C>A) variant is incorrectly reported as p.Thr548Ter (c.1543C>A) in PubMed=11773631 35671061 CVCL_ZQ00 XP7DU finite cell line human CVCL_ZQ00 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Thr408fs (c.1222_1225delACTT) (Fs407); Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Scottish; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671062 CVCL_ZQ01 XP7BR finite cell line human CVCL_ZQ01 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Leu77del (c.222_224TCT[1]) (c.225_227delTCT) (L75del); ClinVar=VCV000005893; Zygosity=Heterozygous (PubMed=11773631); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ile255fs (Fs255); Zygosity=Heterozygous (PubMed=11773631) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671063 CVCL_ZR92 XP57BR finite cell line human CVCL_ZR92 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Met214Asnfs*7 (c.640dupA); ClinVar=VCV001805601; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671064 CVCL_ZR93 XP80BR finite cell line human CVCL_ZR93 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys105Tyr (c.314G>A); Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671065 CVCL_ZR94 XP81BR finite cell line human CVCL_ZR94 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Cys105Tyr (c.314G>A); Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: African; Somali; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671066 CVCL_ZR95 XP88BR finite cell line human CVCL_ZR95 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671067 CVCL_ZR90 XP49BR finite cell line human CVCL_ZR90 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599) Population: Afghan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671068 CVCL_ZR91 XP53BR finite cell line human CVCL_ZR91 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671069 CVCL_ZR96 XP89BR finite cell line human CVCL_ZR96 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671070 CVCL_ZR97 XP89BR-S finite cell line human CVCL_ZR97 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671071 CVCL_ZR98 XP1CB finite cell line human CVCL_ZR98 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671072 CVCL_ZR99 XPH8RO finite cell line human CVCL_ZR99 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671073 CVCL_ZR81 XP1PR finite cell line human CVCL_ZR81 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671074 CVCL_ZR82 XP2PR finite cell line human CVCL_ZR82 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671075 CVCL_ZR83 XP9BI finite cell line human CVCL_ZR83 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671076 CVCL_ZR84 XP103BR finite cell line human CVCL_ZR84 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671077 CVCL_ZR80 XP1SA [Salisbury] finite cell line human CVCL_ZR80 CL:0000010 Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Phe99Ser (c.296T>C); ClinVar=VCV000016583; Zygosity=Heterozygous (PubMed=16947863); Sequence variation: Mutation; HGNC; 3435; ERCC3; Simple; p.Arg425Ter (c.1273C>T); ClinVar=VCV000016585; Zygosity=Heterozygous (PubMed=16947863) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671078 CVCL_ZR89 XP20BR finite cell line human CVCL_ZR89 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg228Ter (c.682C>T); ClinVar=VCV000000995; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671079 CVCL_ZR85 XP111BR finite cell line human CVCL_ZR85 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Gln85Ter (c.253C>T); ClinVar=VCV001193397; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Bangladeshi; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671080 CVCL_ZR86 XP116BR finite cell line human CVCL_ZR86 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599; PubMed=26884178) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671081 CVCL_ZR87 XP121BR finite cell line human CVCL_ZR87 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.555+8A>G; ClinVar=VCV000852033; Zygosity=Homozygous (PubMed=26743599) Population: Pakistani; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671082 CVCL_ZR88 SHFDi001-A induced pluripotent stem cell human CVCL_ZR88 From: Shanghai Stomatological Hospital, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Omics: Deep exome analysis Female 35671083 CVCL_ZR70 AS552 finite cell line human CVCL_ZR70 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile456del (c.1361_1363TCA[2]) (1439_1441delTCA); ClinVar=VCV000620626; Zygosity=Heterozygous (PubMed=19934020); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=19934020) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671084 CVCL_ZR71 AS553 finite cell line human CVCL_ZR71 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile456del (c.1361_1363TCA[2]) (1439_1441delTCA); ClinVar=VCV000620626; Zygosity=Heterozygous (PubMed=19934020); Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=19934020) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671085 CVCL_ZR72 XP45TA finite cell line human CVCL_ZR72 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35671086 CVCL_ZR73 XP1KU finite cell line human CVCL_ZR73 CL:0000010 Population: Japanese; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 35671087 CVCL_ZR78 XP1KUHM finite cell line human CVCL_ZR78 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671088 CVCL_ZR79 XP1KUHF finite cell line human CVCL_ZR79 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671089 CVCL_ZR74 XP1KU clone-14 finite cell line human CVCL_ZR74 CL:0000010 Population: Japanese; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female Characteristics: UV-resistant 35671090 CVCL_ZR75 XP1KU clone-2 finite cell line human CVCL_ZR75 CL:0000010 Population: Japanese; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female Characteristics: UV-sensitive 35671091 CVCL_ZR76 XP1KU-14(SV) finite cell line human CVCL_ZR76 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 35671092 CVCL_ZR77 XP1KU-2(SV) finite cell line human CVCL_ZR77 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 35671093 CVCL_ZR60 XP6RO finite cell line human CVCL_ZR60 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671094 CVCL_ZR61 XP7RO finite cell line human CVCL_ZR61 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671095 CVCL_ZR62 XP9RO finite cell line human CVCL_ZR62 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671096 CVCL_ZR67 XP14VI finite cell line human CVCL_ZR67 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 35671097 CVCL_ZR68 AS550 finite cell line human CVCL_ZR68 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Arg683Trp (c.2047C>T); ClinVar=VCV000016793; Zygosity=Heterozygous (PubMed=19934020) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671098 CVCL_ZR69 AS551 finite cell line human CVCL_ZR69 CL:0000010 Sequence variation: Mutation; HGNC; 3434; ERCC2; Simple; p.Ile456del (c.1361_1363TCA[2]) (1439_1441delTCA); ClinVar=VCV000620626; Zygosity=Heterozygous (PubMed=19934020) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671099 CVCL_ZR63 2498 finite cell line human CVCL_ZR63 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671100 CVCL_ZR64 ANA-1 [Human fibroblast] finite cell line human CVCL_ZR64 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671101 CVCL_ZR65 XP2OS(SV)neo transformed cell line human CVCL_ZR65 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671102 CVCL_ZR66 PX1 hybrid cell line CVCL_ZR66 CL:0000010 35671103 CVCL_ZR49 XPH17RO finite cell line human CVCL_ZR49 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671104 CVCL_ZR50 XPH27RO finite cell line human CVCL_ZR50 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Heterozygous (from familial inference of XP25RO) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671105 CVCL_ZR51 XPH28RO finite cell line human CVCL_ZR51 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Heterozygous (from familial inference of XP25RO) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671106 CVCL_ZR56 XP19HO finite cell line human CVCL_ZR56 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671107 CVCL_ZR57 XP20RO finite cell line human CVCL_ZR57 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671108 CVCL_ZR58 XP3RO finite cell line human CVCL_ZR58 CL:0000010 Sequence variation: Mutation; HGNC; 2718; DDB2; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000008788; Zygosity=Homozygous (PubMed=8798680; PubMed=10777490) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671109 CVCL_ZR59 XP5RO finite cell line human CVCL_ZR59 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671110 CVCL_ZR52 XP11RO finite cell line human CVCL_ZR52 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671111 CVCL_ZR53 XP12SF finite cell line human CVCL_ZR53 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671112 CVCL_ZR54 XP16RO finite cell line human CVCL_ZR54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671113 CVCL_ZR55 XP17SF finite cell line human CVCL_ZR55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671114 CVCL_ZR38 XPHF662VI finite cell line human CVCL_ZR38 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from familial inference of XP664VI and XP665VI) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671115 CVCL_ZR39 XPHM663VI finite cell line human CVCL_ZR39 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Heterozygous (from familial inference of XP664VI and XP665VI) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671116 CVCL_ZR40 UW-NLA-HSI1 somatic stem cell human CVCL_ZR40 CL:0000010 Miscellaneous: Cell line name from personal communication of Hinman S Derived from sampling site: Small intestine; jejunum. Female 35671117 CVCL_ZR45 UW-NLA-D5 somatic stem cell human CVCL_ZR45 CL:0000010 Miscellaneous: Cell line information from personal communication of Hinman S Derived from sampling site: Intestine. Male 35671118 CVCL_ZR46 XPH10RO finite cell line human CVCL_ZR46 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671119 CVCL_ZR47 XPH14RO finite cell line human CVCL_ZR47 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Heterozygous (from familial inference of XP12RO) Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671120 CVCL_ZR48 XPH15RO finite cell line human CVCL_ZR48 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; p.Arg207Ter (c.619C>T); ClinVar=VCV000000996; Zygosity=Heterozygous (from familial inference of XP12RO) Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671121 CVCL_ZR41 UW-NLA-D1 somatic stem cell human CVCL_ZR41 CL:0000010 Miscellaneous: Cell line name from personal communication of Hinman S Derived from sampling site: Intestine. Male 35671122 CVCL_ZR42 UW-NLA-D2 somatic stem cell human CVCL_ZR42 CL:0000010 Miscellaneous: Cell line information from personal communication of Hinman S Derived from sampling site: Intestine. Female 35671123 CVCL_ZR43 UW-NLA-D3 somatic stem cell human CVCL_ZR43 CL:0000010 Miscellaneous: Cell line information from personal communication of Hinman S Derived from sampling site: Intestine. Male 35671124 CVCL_ZR44 UW-NLA-D4 somatic stem cell human CVCL_ZR44 CL:0000010 Miscellaneous: Cell line information from personal communication of Hinman S Derived from sampling site: Intestine. Female 35671125 CVCL_ZR27 XP22MA finite cell line human CVCL_ZR27 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671126 CVCL_ZR28 XP23MA finite cell line human CVCL_ZR28 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671127 CVCL_ZR29 XP24MA finite cell line human CVCL_ZR29 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys220fs (c.661_764del); Zygosity=Homozygous (PubMed=14705792) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671128 CVCL_ZR34 XP30VI finite cell line human CVCL_ZR34 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671129 CVCL_ZR35 XP314VI finite cell line human CVCL_ZR35 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Arg415Ter (c.1243C>T) (C1348T); ClinVar=VCV000438623; Zygosity=Heterozygous (PubMed=16081512) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671130 CVCL_ZR36 XP664VI finite cell line human CVCL_ZR36 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Homozygous (PubMed=16081512) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671131 CVCL_ZR37 XP665VI finite cell line human CVCL_ZR37 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Homozygous (from familial inference of XP664VI) Population: Moroccan; Derived from sampling site: Skin Cell type=Fibroblast.. 35671132 CVCL_ZR30 XP26MA finite cell line human CVCL_ZR30 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671133 CVCL_ZR31 XP10MA finite cell line human CVCL_ZR31 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671134 CVCL_ZR32 XP16VI finite cell line human CVCL_ZR32 CL:0000010 Sequence variation: Mutation; HGNC; 12816; XPC; Simple; p.Val548Alafs*25 (c.1639_1640TG[2]) (c.1643_1644delTG) (1744_1745delTG); ClinVar=VCV000000262; Zygosity=Homozygous (PubMed=16081512) Population: Algerian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671135 CVCL_ZR33 XP24VI finite cell line human CVCL_ZR33 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 35671136 CVCL_ZR16 XP34MA finite cell line human CVCL_ZR16 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671137 CVCL_ZR17 XP35MA finite cell line human CVCL_ZR17 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671138 CVCL_ZR18 XP41MA finite cell line human CVCL_ZR18 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671139 CVCL_ZR19 XP29MA finite cell line human CVCL_ZR19 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671140 CVCL_ZR23 XP6MA finite cell line human CVCL_ZR23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671141 CVCL_ZR24 XP13MA finite cell line human CVCL_ZR24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671142 CVCL_ZR25 XP14MA finite cell line human CVCL_ZR25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671143 CVCL_ZR26 XP21MA finite cell line human CVCL_ZR26 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671144 CVCL_ZR20 XP30MA finite cell line human CVCL_ZR20 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671145 CVCL_ZR21 XP27MA finite cell line human CVCL_ZR21 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671146 CVCL_ZR22 XP1MA finite cell line human CVCL_ZR22 CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Asn359Valfs*32 (c.1075_1244del170) (Ex10del); Zygosity=Homozygous (PubMed=14705792) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671147 CVCL_ZR09 XP46MA finite cell line human CVCL_ZR09 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671148 CVCL_ZR05 XP33MA finite cell line human CVCL_ZR05 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671149 CVCL_ZR06 XP36MA finite cell line human CVCL_ZR06 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671150 CVCL_ZR07 XP39MA finite cell line human CVCL_ZR07 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671151 CVCL_ZR08 XP40MA finite cell line human CVCL_ZR08 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671152 CVCL_ZR12 XP90MA finite cell line human CVCL_ZR12 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671153 CVCL_ZR13 XP42MA finite cell line human CVCL_ZR13 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671154 CVCL_ZR14 XP89MA finite cell line human CVCL_ZR14 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671155 CVCL_ZR15 XP103MA finite cell line human CVCL_ZR15 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671156 CVCL_ZR10 XP47MA finite cell line human CVCL_ZR10 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671157 CVCL_ZR11 XP55MA finite cell line human CVCL_ZR11 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671158 CVCL_ZR01 XP12MA finite cell line human CVCL_ZR01 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671159 CVCL_ZR02 XP17MA finite cell line human CVCL_ZR02 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671160 CVCL_ZR03 XP18MA finite cell line human CVCL_ZR03 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671161 CVCL_ZR04 XP19MA finite cell line human CVCL_ZR04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 35671162 CVCL_ZR00 XP115MA finite cell line human CVCL_ZR00 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 35671163 CVCL_A0C0 SEES3-1V human AR, clone3 embryonic stem cell human CVCL_A0C0 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671164 CVCL_A0B8 SEES3-1V human AR, clone1 embryonic stem cell human CVCL_A0B8 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671165 CVCL_A0B9 SEES3-1V human AR, clone2 embryonic stem cell human CVCL_A0B9 CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671166 CVCL_A0B0 SEES3-1V human ALX3, clone2 embryonic stem cell human CVCL_A0B0 CL:0000010 Transfected with: HGNC; 449; ALX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671167 CVCL_A0B1 SEES3-1V human ALX3, clone3 embryonic stem cell human CVCL_A0B1 CL:0000010 Transfected with: HGNC; 449; ALX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671168 CVCL_A0B2 SEES3-1V human ALX4, clone1 embryonic stem cell human CVCL_A0B2 CL:0000010 Transfected with: HGNC; 450; ALX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671169 CVCL_A0B3 SEES3-1V human ALX4, clone2 embryonic stem cell human CVCL_A0B3 CL:0000010 Transfected with: HGNC; 450; ALX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671170 CVCL_A0B4 SEES3-1V human ALX4, clone3 embryonic stem cell human CVCL_A0B4 CL:0000010 Transfected with: HGNC; 450; ALX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671171 CVCL_A0B5 SEES3-1V human ANKRD22, clone1 embryonic stem cell human CVCL_A0B5 CL:0000010 Transfected with: HGNC; 28321; ANKRD22; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671172 CVCL_A0B6 SEES3-1V human ANKRD22, clone2 embryonic stem cell human CVCL_A0B6 CL:0000010 Transfected with: HGNC; 28321; ANKRD22; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671173 CVCL_A0B7 SEES3-1V human ANKRD22, clone3 embryonic stem cell human CVCL_A0B7 CL:0000010 Transfected with: HGNC; 28321; ANKRD22; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671174 CVCL_A0D0 SEES3-1V human ASCL1, clone1 embryonic stem cell human CVCL_A0D0 CL:0000010 Transfected with: HGNC; 738; ASCL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671175 CVCL_A0D1 SEES3-1V human ASCL1, clone2 embryonic stem cell human CVCL_A0D1 CL:0000010 Transfected with: HGNC; 738; ASCL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671176 CVCL_A0C9 SEES3-1V human ARNT2, clone3 embryonic stem cell human CVCL_A0C9 CL:0000010 Transfected with: HGNC; 16876; ARNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671177 CVCL_A0C1 SEES3-1V human ARID3A, clone1 embryonic stem cell human CVCL_A0C1 CL:0000010 Transfected with: HGNC; 3031; ARID3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671178 CVCL_A0C2 SEES3-1V human ARID3A, clone2 embryonic stem cell human CVCL_A0C2 CL:0000010 Transfected with: HGNC; 3031; ARID3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671179 CVCL_A0C3 SEES3-1V human ARID3A, clone3 embryonic stem cell human CVCL_A0C3 CL:0000010 Transfected with: HGNC; 3031; ARID3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671180 CVCL_A0C4 SEES3-1V human ARID3B, clone1 embryonic stem cell human CVCL_A0C4 CL:0000010 Transfected with: HGNC; 14350; ARID3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671181 CVCL_A0C5 SEES3-1V human ARID3B, clone2 embryonic stem cell human CVCL_A0C5 CL:0000010 Transfected with: HGNC; 14350; ARID3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671182 CVCL_A0C6 SEES3-1V human ARID3B, clone3 embryonic stem cell human CVCL_A0C6 CL:0000010 Transfected with: HGNC; 14350; ARID3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671183 CVCL_A0C7 SEES3-1V human ARNT2, clone1 embryonic stem cell human CVCL_A0C7 CL:0000010 Transfected with: HGNC; 16876; ARNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671184 CVCL_A0C8 SEES3-1V human ARNT2, clone2 embryonic stem cell human CVCL_A0C8 CL:0000010 Transfected with: HGNC; 16876; ARNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671185 CVCL_A0A7 SEES3-1V human ALX1, clone2 embryonic stem cell human CVCL_A0A7 CL:0000010 Transfected with: HGNC; 1494; ALX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671186 CVCL_A0A8 SEES3-1V human ALX1, clone3 embryonic stem cell human CVCL_A0A8 CL:0000010 Transfected with: HGNC; 1494; ALX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671187 CVCL_A0A9 SEES3-1V human ALX3, clone1 embryonic stem cell human CVCL_A0A9 CL:0000010 Transfected with: HGNC; 449; ALX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671188 CVCL_A0A0 SEES3-1V human AATF, clone1 embryonic stem cell human CVCL_A0A0 CL:0000010 Transfected with: HGNC; 19235; AATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671189 CVCL_A0A1 SEES3-1V human AATF, clone2 embryonic stem cell human CVCL_A0A1 CL:0000010 Transfected with: HGNC; 19235; AATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671190 CVCL_A0A2 SEES3-1V human AATF, clone3 embryonic stem cell human CVCL_A0A2 CL:0000010 Transfected with: HGNC; 19235; AATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671191 CVCL_A0A3 SEES3-1V human AES, clone1 embryonic stem cell human CVCL_A0A3 CL:0000010 Transfected with: HGNC; 307; TLE5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671192 CVCL_A0A4 SEES3-1V human AES, clone2 embryonic stem cell human CVCL_A0A4 CL:0000010 Transfected with: HGNC; 307; TLE5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671193 CVCL_A0A5 SEES3-1V human AES, clone3 embryonic stem cell human CVCL_A0A5 CL:0000010 Transfected with: HGNC; 307; TLE5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671194 CVCL_A0A6 SEES3-1V human ALX1, clone1 embryonic stem cell human CVCL_A0A6 CL:0000010 Transfected with: HGNC; 1494; ALX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671195 CVCL_A0K1 SEES3-1V human BRF2, clone1 embryonic stem cell human CVCL_A0K1 CL:0000010 Transfected with: HGNC; 17298; BRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671196 CVCL_A0K2 SEES3-1V human BRF2, clone2 embryonic stem cell human CVCL_A0K2 CL:0000010 Transfected with: HGNC; 17298; BRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671197 CVCL_A0K3 SEES3-1V human BRF2, clone3 embryonic stem cell human CVCL_A0K3 CL:0000010 Transfected with: HGNC; 17298; BRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671198 CVCL_A0K4 SEES3-1V human CARM1, clone1 embryonic stem cell human CVCL_A0K4 CL:0000010 Transfected with: HGNC; 23393; CARM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671199 CVCL_A0K5 SEES3-1V human CARM1, clone2 embryonic stem cell human CVCL_A0K5 CL:0000010 Transfected with: HGNC; 23393; CARM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671200 CVCL_A0K6 SEES3-1V human CARM1, clone3 embryonic stem cell human CVCL_A0K6 CL:0000010 Transfected with: HGNC; 23393; CARM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671201 CVCL_A0K7 SEES3-1V human CBFB, clone1 embryonic stem cell human CVCL_A0K7 CL:0000010 Transfected with: HGNC; 1539; CBFB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671202 CVCL_A0K8 SEES3-1V human CBFB, clone2 embryonic stem cell human CVCL_A0K8 CL:0000010 Transfected with: HGNC; 1539; CBFB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671203 CVCL_A0K0 SEES3-1V human BRF1, clone3 embryonic stem cell human CVCL_A0K0 CL:0000010 Transfected with: HGNC; 11551; BRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671204 CVCL_A0J8 SEES3-1V human BRF1, clone1 embryonic stem cell human CVCL_A0J8 CL:0000010 Transfected with: HGNC; 11551; BRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671205 CVCL_A0J9 SEES3-1V human BRF1, clone2 embryonic stem cell human CVCL_A0J9 CL:0000010 Transfected with: HGNC; 11551; BRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671206 CVCL_A0L2 SEES3-1V human CBX2, clone3 embryonic stem cell human CVCL_A0L2 CL:0000010 Transfected with: HGNC; 1552; CBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671207 CVCL_A0L3 SEES3-1V human CBX3, clone1 embryonic stem cell human CVCL_A0L3 CL:0000010 Transfected with: HGNC; 1553; CBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671208 CVCL_A0L4 SEES3-1V human CBX3, clone2 embryonic stem cell human CVCL_A0L4 CL:0000010 Transfected with: HGNC; 1553; CBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671209 CVCL_A0L5 SEES3-1V human CBX3, clone3 embryonic stem cell human CVCL_A0L5 CL:0000010 Transfected with: HGNC; 1553; CBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671210 CVCL_A0L6 SEES3-1V human CBX8, clone1 embryonic stem cell human CVCL_A0L6 CL:0000010 Transfected with: HGNC; 15962; CBX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671211 CVCL_A0L7 SEES3-1V human CBX8, clone2 embryonic stem cell human CVCL_A0L7 CL:0000010 Transfected with: HGNC; 15962; CBX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671212 CVCL_A0L8 SEES3-1V human CBX8, clone3 embryonic stem cell human CVCL_A0L8 CL:0000010 Transfected with: HGNC; 15962; CBX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671213 CVCL_A0L9 SEES3-1V human CCNE1, clone1 embryonic stem cell human CVCL_A0L9 CL:0000010 Transfected with: HGNC; 1589; CCNE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671214 CVCL_A0L0 SEES3-1V human CBX2, clone1 embryonic stem cell human CVCL_A0L0 CL:0000010 Transfected with: HGNC; 1552; CBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671215 CVCL_A0L1 SEES3-1V human CBX2, clone2 embryonic stem cell human CVCL_A0L1 CL:0000010 Transfected with: HGNC; 1552; CBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671216 CVCL_A0K9 SEES3-1V human CBFB, clone3 embryonic stem cell human CVCL_A0K9 CL:0000010 Transfected with: HGNC; 1539; CBFB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671217 CVCL_A0I0 SEES3-1V human BCL6, clone3 embryonic stem cell human CVCL_A0I0 CL:0000010 Transfected with: HGNC; 1001; BCL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671218 CVCL_A0I1 SEES3-1V human BHLHE40, clone1 embryonic stem cell human CVCL_A0I1 CL:0000010 Transfected with: HGNC; 1046; BHLHE40; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671219 CVCL_A0I2 SEES3-1V human BHLHE40, clone2 embryonic stem cell human CVCL_A0I2 CL:0000010 Transfected with: HGNC; 1046; BHLHE40; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671220 CVCL_A0I3 SEES3-1V human BHLHE40, clone3 embryonic stem cell human CVCL_A0I3 CL:0000010 Transfected with: HGNC; 1046; BHLHE40; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671221 CVCL_A0I4 SEES3-1V human BLZF1, clone1 embryonic stem cell human CVCL_A0I4 CL:0000010 Transfected with: HGNC; 1065; BLZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671222 CVCL_A0I5 SEES3-1V human BLZF1, clone2 embryonic stem cell human CVCL_A0I5 CL:0000010 Transfected with: HGNC; 1065; BLZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671223 CVCL_A0I6 SEES3-1V human BLZF1, clone3 embryonic stem cell human CVCL_A0I6 CL:0000010 Transfected with: HGNC; 1065; BLZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671224 CVCL_A0H6 SEES3-1V human BCL11A, clone2 embryonic stem cell human CVCL_A0H6 CL:0000010 Transfected with: HGNC; 13221; BCL11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671225 CVCL_A0H7 SEES3-1V human BCL11A, clone3 embryonic stem cell human CVCL_A0H7 CL:0000010 Transfected with: HGNC; 13221; BCL11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671226 CVCL_A0H8 SEES3-1V human BCL6, clone1 embryonic stem cell human CVCL_A0H8 CL:0000010 Transfected with: HGNC; 1001; BCL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671227 CVCL_A0H9 SEES3-1V human BCL6, clone2 embryonic stem cell human CVCL_A0H9 CL:0000010 Transfected with: HGNC; 1001; BCL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671228 CVCL_A0J0 SEES3-1V human BMP2, clone2 embryonic stem cell human CVCL_A0J0 CL:0000010 Transfected with: HGNC; 1069; BMP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671229 CVCL_A0J1 SEES3-1V human BMP2, clone3 embryonic stem cell human CVCL_A0J1 CL:0000010 Transfected with: HGNC; 1069; BMP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671230 CVCL_A0J2 SEES3-1V human BMP4, clone1 embryonic stem cell human CVCL_A0J2 CL:0000010 Transfected with: HGNC; 1071; BMP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671231 CVCL_A0J3 SEES3-1V human BMP4, clone2 embryonic stem cell human CVCL_A0J3 CL:0000010 Transfected with: HGNC; 1071; BMP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671232 CVCL_A0J4 SEES3-1V human BMP4, clone3 embryonic stem cell human CVCL_A0J4 CL:0000010 Transfected with: HGNC; 1071; BMP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671233 CVCL_A0J5 SEES3-1V human BMP7, clone1 embryonic stem cell human CVCL_A0J5 CL:0000010 Transfected with: HGNC; 1074; BMP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671234 CVCL_A0J6 SEES3-1V human BMP7, clone2 embryonic stem cell human CVCL_A0J6 CL:0000010 Transfected with: HGNC; 1074; BMP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671235 CVCL_A0J7 SEES3-1V human BMP7, clone3 embryonic stem cell human CVCL_A0J7 CL:0000010 Transfected with: HGNC; 1074; BMP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671236 CVCL_A0I7 SEES3-1V human BMI1, clone1 embryonic stem cell human CVCL_A0I7 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671237 CVCL_A0I8 SEES3-1V human BMI1, clone3 embryonic stem cell human CVCL_A0I8 CL:0000010 Transfected with: HGNC; 1066; BMI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671238 CVCL_A0I9 SEES3-1V human BMP2, clone1 embryonic stem cell human CVCL_A0I9 CL:0000010 Transfected with: HGNC; 1069; BMP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671239 CVCL_A0G0 SEES3-1V human BANP, clone1 embryonic stem cell human CVCL_A0G0 CL:0000010 Transfected with: HGNC; 13450; BANP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671240 CVCL_A0G1 SEES3-1V human BANP, clone2 embryonic stem cell human CVCL_A0G1 CL:0000010 Transfected with: HGNC; 13450; BANP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671241 CVCL_A0G2 SEES3-1V human BANP, clone3 embryonic stem cell human CVCL_A0G2 CL:0000010 Transfected with: HGNC; 13450; BANP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671242 CVCL_A0G3 SEES3-1V human BARHL2, clone1 embryonic stem cell human CVCL_A0G3 CL:0000010 Transfected with: HGNC; 954; BARHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671243 CVCL_A0G4 SEES3-1V human BARHL2, clone2 embryonic stem cell human CVCL_A0G4 CL:0000010 Transfected with: HGNC; 954; BARHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671244 CVCL_A0F4 SEES3-1V human ATOH7, clone1 embryonic stem cell human CVCL_A0F4 CL:0000010 Transfected with: HGNC; 13907; ATOH7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671245 CVCL_A0F5 SEES3-1V human ATOH7, clone2 embryonic stem cell human CVCL_A0F5 CL:0000010 Transfected with: HGNC; 13907; ATOH7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671246 CVCL_A0F6 SEES3-1V human ATOH7, clone3 embryonic stem cell human CVCL_A0F6 CL:0000010 Transfected with: HGNC; 13907; ATOH7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671247 CVCL_A0F7 SEES3-1V human BACH1, clone1 embryonic stem cell human CVCL_A0F7 CL:0000010 Transfected with: HGNC; 935; BACH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671248 CVCL_A0F8 SEES3-1V human BACH1, clone2 embryonic stem cell human CVCL_A0F8 CL:0000010 Transfected with: HGNC; 935; BACH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671249 CVCL_A0F9 SEES3-1V human BACH1, clone3 embryonic stem cell human CVCL_A0F9 CL:0000010 Transfected with: HGNC; 935; BACH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671250 CVCL_A0H0 SEES3-1V human BATF, clone2 embryonic stem cell human CVCL_A0H0 CL:0000010 Transfected with: HGNC; 958; BATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671251 CVCL_A0H1 SEES3-1V human BATF, clone3 embryonic stem cell human CVCL_A0H1 CL:0000010 Transfected with: HGNC; 958; BATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671252 CVCL_A0H2 SEES3-1V human BATF3, clone1 embryonic stem cell human CVCL_A0H2 CL:0000010 Transfected with: HGNC; 28915; BATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671253 CVCL_A0H3 SEES3-1V human BATF3, clone2 embryonic stem cell human CVCL_A0H3 CL:0000010 Transfected with: HGNC; 28915; BATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671254 CVCL_A0H4 SEES3-1V human BATF3, clone3 embryonic stem cell human CVCL_A0H4 CL:0000010 Transfected with: HGNC; 28915; BATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671255 CVCL_A0H5 SEES3-1V human BCL11A, clone1 embryonic stem cell human CVCL_A0H5 CL:0000010 Transfected with: HGNC; 13221; BCL11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671256 CVCL_A0G5 SEES3-1V human BARHL2, clone3 embryonic stem cell human CVCL_A0G5 CL:0000010 Transfected with: HGNC; 954; BARHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671257 CVCL_A0G6 SEES3-1V human BARX2, clone1 embryonic stem cell human CVCL_A0G6 CL:0000010 Transfected with: HGNC; 956; BARX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671258 CVCL_A0G7 SEES3-1V human BARX2, clone2 embryonic stem cell human CVCL_A0G7 CL:0000010 Transfected with: HGNC; 956; BARX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671259 CVCL_A0G8 SEES3-1V human BARX2, clone3 embryonic stem cell human CVCL_A0G8 CL:0000010 Transfected with: HGNC; 956; BARX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671260 CVCL_A0G9 SEES3-1V human BATF, clone1 embryonic stem cell human CVCL_A0G9 CL:0000010 Transfected with: HGNC; 958; BATF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671261 CVCL_A0E0 SEES3-1V human ATF1, clone2 embryonic stem cell human CVCL_A0E0 CL:0000010 Transfected with: HGNC; 783; ATF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671262 CVCL_A0E1 SEES3-1V human ATF1, clone3 embryonic stem cell human CVCL_A0E1 CL:0000010 Transfected with: HGNC; 783; ATF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671263 CVCL_A0E2 SEES3-1V human ATF2, clone1 embryonic stem cell human CVCL_A0E2 CL:0000010 Transfected with: HGNC; 784; ATF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671264 CVCL_A0D2 SEES3-1V human ASCL1, clone3 embryonic stem cell human CVCL_A0D2 CL:0000010 Transfected with: HGNC; 738; ASCL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671265 CVCL_A0D3 SEES3-1V human ASCL2, clone1 embryonic stem cell human CVCL_A0D3 CL:0000010 Transfected with: HGNC; 739; ASCL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671266 CVCL_A0D4 SEES3-1V human ASCL2, clone2 embryonic stem cell human CVCL_A0D4 CL:0000010 Transfected with: HGNC; 739; ASCL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671267 CVCL_A0D5 SEES3-1V human ASCL2, clone3 embryonic stem cell human CVCL_A0D5 CL:0000010 Transfected with: HGNC; 739; ASCL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671268 CVCL_A0D6 SEES3-1V human ASH2L, clone1 embryonic stem cell human CVCL_A0D6 CL:0000010 Transfected with: HGNC; 744; ASH2L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671269 CVCL_A0D7 SEES3-1V human ASH2L, clone2 embryonic stem cell human CVCL_A0D7 CL:0000010 Transfected with: HGNC; 744; ASH2L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671270 CVCL_A0D8 SEES3-1V human ASH2L, clone3 embryonic stem cell human CVCL_A0D8 CL:0000010 Transfected with: HGNC; 744; ASH2L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671271 CVCL_A0D9 SEES3-1V human ATF1, clone1 embryonic stem cell human CVCL_A0D9 CL:0000010 Transfected with: HGNC; 783; ATF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671272 CVCL_A0F0 SEES3-1V human ATF4, clone3 embryonic stem cell human CVCL_A0F0 CL:0000010 Transfected with: HGNC; 786; ATF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671273 CVCL_A0F1 SEES3-1V human ATOH1, clone1 embryonic stem cell human CVCL_A0F1 CL:0000010 Transfected with: HGNC; 797; ATOH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671274 CVCL_A0F2 SEES3-1V human ATOH1, clone2 embryonic stem cell human CVCL_A0F2 CL:0000010 Transfected with: HGNC; 797; ATOH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671275 CVCL_A0F3 SEES3-1V human ATOH1, clone3 embryonic stem cell human CVCL_A0F3 CL:0000010 Transfected with: HGNC; 797; ATOH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671276 CVCL_A0E3 SEES3-1V human ATF2, clone2 embryonic stem cell human CVCL_A0E3 CL:0000010 Transfected with: HGNC; 784; ATF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671277 CVCL_A0E4 SEES3-1V human ATF2, clone3 embryonic stem cell human CVCL_A0E4 CL:0000010 Transfected with: HGNC; 784; ATF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671278 CVCL_A0E5 SEES3-1V human ATF3, clone1 embryonic stem cell human CVCL_A0E5 CL:0000010 Transfected with: HGNC; 785; ATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671279 CVCL_A0E6 SEES3-1V human ATF3, clone2 embryonic stem cell human CVCL_A0E6 CL:0000010 Transfected with: HGNC; 785; ATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671280 CVCL_A0E7 SEES3-1V human ATF3, clone3 embryonic stem cell human CVCL_A0E7 CL:0000010 Transfected with: HGNC; 785; ATF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671281 CVCL_A0E8 SEES3-1V human ATF4, clone1 embryonic stem cell human CVCL_A0E8 CL:0000010 Transfected with: HGNC; 786; ATF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671282 CVCL_A0E9 SEES3-1V human ATF4, clone2 embryonic stem cell human CVCL_A0E9 CL:0000010 Transfected with: HGNC; 786; ATF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671283 CVCL_A1E0 SEES3-1V human EDF1, clone2 embryonic stem cell human CVCL_A1E0 CL:0000010 Transfected with: HGNC; 3164; EDF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671284 CVCL_A1E1 SEES3-1V human EDF1, clone3 embryonic stem cell human CVCL_A1E1 CL:0000010 Transfected with: HGNC; 3164; EDF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671285 CVCL_A1D9 SEES3-1V human EDF1, clone1 embryonic stem cell human CVCL_A1D9 CL:0000010 Transfected with: HGNC; 3164; EDF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671286 CVCL_A1D1 SEES3-1V human E2F6, clone2 embryonic stem cell human CVCL_A1D1 CL:0000010 Transfected with: HGNC; 3120; E2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671287 CVCL_A1D2 SEES3-1V human E2F6, clone3 embryonic stem cell human CVCL_A1D2 CL:0000010 Transfected with: HGNC; 3120; E2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671288 CVCL_A1D3 SEES3-1V human E2F7, clone1 embryonic stem cell human CVCL_A1D3 CL:0000010 Transfected with: HGNC; 23820; E2F7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671289 CVCL_A1D4 SEES3-1V human E2F7, clone2 embryonic stem cell human CVCL_A1D4 CL:0000010 Transfected with: HGNC; 23820; E2F7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671290 CVCL_A1D5 SEES3-1V human E2F7, clone3 embryonic stem cell human CVCL_A1D5 CL:0000010 Transfected with: HGNC; 23820; E2F7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671291 CVCL_A1D6 SEES3-1V human EBF1, clone1 embryonic stem cell human CVCL_A1D6 CL:0000010 Transfected with: HGNC; 3126; EBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671292 CVCL_A1D7 SEES3-1V human EBF1, clone2 embryonic stem cell human CVCL_A1D7 CL:0000010 Transfected with: HGNC; 3126; EBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671293 CVCL_A1D8 SEES3-1V human EBF1, clone3 embryonic stem cell human CVCL_A1D8 CL:0000010 Transfected with: HGNC; 3126; EBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671294 CVCL_A1F0 SEES3-1V human EEF1A1, clone3 embryonic stem cell human CVCL_A1F0 CL:0000010 Transfected with: HGNC; 3189; EEF1A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671295 CVCL_A1F1 SEES3-1V human EGFLAM, clone1 embryonic stem cell human CVCL_A1F1 CL:0000010 Transfected with: HGNC; 26810; EGFLAM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671296 CVCL_A1F2 SEES3-1V human EGFLAM, clone2 embryonic stem cell human CVCL_A1F2 CL:0000010 Transfected with: HGNC; 26810; EGFLAM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671297 CVCL_A1E2 SEES3-1V human EDN3, clone1 embryonic stem cell human CVCL_A1E2 CL:0000010 Transfected with: HGNC; 3178; EDN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671298 CVCL_A1E3 SEES3-1V human EDN3, clone2 embryonic stem cell human CVCL_A1E3 CL:0000010 Transfected with: HGNC; 3178; EDN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671299 CVCL_A1E4 SEES3-1V human EDN3, clone3 embryonic stem cell human CVCL_A1E4 CL:0000010 Transfected with: HGNC; 3178; EDN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671300 CVCL_A1E5 SEES3-1V human EED, clone1 embryonic stem cell human CVCL_A1E5 CL:0000010 Transfected with: HGNC; 3188; EED; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671301 CVCL_A1E6 SEES3-1V human EED, clone2 embryonic stem cell human CVCL_A1E6 CL:0000010 Transfected with: HGNC; 3188; EED; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671302 CVCL_A1E7 SEES3-1V human EED, clone3 embryonic stem cell human CVCL_A1E7 CL:0000010 Transfected with: HGNC; 3188; EED; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671303 CVCL_A1E8 SEES3-1V human EEF1A1, clone1 embryonic stem cell human CVCL_A1E8 CL:0000010 Transfected with: HGNC; 3189; EEF1A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671304 CVCL_A1E9 SEES3-1V human EEF1A1, clone2 embryonic stem cell human CVCL_A1E9 CL:0000010 Transfected with: HGNC; 3189; EEF1A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671305 CVCL_A1B7 SEES3-1V human DVL2, clone3 embryonic stem cell human CVCL_A1B7 CL:0000010 Transfected with: HGNC; 3086; DVL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671306 CVCL_A1B8 SEES3-1V human E2F1, clone1 embryonic stem cell human CVCL_A1B8 CL:0000010 Transfected with: HGNC; 3113; E2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671307 CVCL_A1B9 SEES3-1V human E2F1, clone2 embryonic stem cell human CVCL_A1B9 CL:0000010 Transfected with: HGNC; 3113; E2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671308 CVCL_A1B0 SEES3-1V human DPF1, clone2 embryonic stem cell human CVCL_A1B0 CL:0000010 Transfected with: HGNC; 20225; DPF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671309 CVCL_A1B1 SEES3-1V human DPF1, clone3 embryonic stem cell human CVCL_A1B1 CL:0000010 Transfected with: HGNC; 20225; DPF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671310 CVCL_A1B2 SEES3-1V human DUX4, clone1 embryonic stem cell human CVCL_A1B2 CL:0000010 Transfected with: HGNC; 50800; DUX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671311 CVCL_A1B3 SEES3-1V human DUX4, clone2 embryonic stem cell human CVCL_A1B3 CL:0000010 Transfected with: HGNC; 50800; DUX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671312 CVCL_A1B4 SEES3-1V human DUX4, clone3 embryonic stem cell human CVCL_A1B4 CL:0000010 Transfected with: HGNC; 50800; DUX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671313 CVCL_A1B5 SEES3-1V human DVL2, clone1 embryonic stem cell human CVCL_A1B5 CL:0000010 Transfected with: HGNC; 3086; DVL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671314 CVCL_A1B6 SEES3-1V human DVL2, clone2 embryonic stem cell human CVCL_A1B6 CL:0000010 Transfected with: HGNC; 3086; DVL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671315 CVCL_A1D0 SEES3-1V human E2F6, clone1 embryonic stem cell human CVCL_A1D0 CL:0000010 Transfected with: HGNC; 3120; E2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671316 CVCL_A1C8 SEES3-1V human E2F5, clone2 embryonic stem cell human CVCL_A1C8 CL:0000010 Transfected with: HGNC; 3119; E2F5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671317 CVCL_A1C9 SEES3-1V human E2F5, clone3 embryonic stem cell human CVCL_A1C9 CL:0000010 Transfected with: HGNC; 3119; E2F5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671318 CVCL_A1C0 SEES3-1V human E2F1, clone3 embryonic stem cell human CVCL_A1C0 CL:0000010 Transfected with: HGNC; 3113; E2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671319 CVCL_A1C1 SEES3-1V human E2F3, clone1 embryonic stem cell human CVCL_A1C1 CL:0000010 Transfected with: HGNC; 3115; E2F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671320 CVCL_A1C2 SEES3-1V human E2F3, clone2 embryonic stem cell human CVCL_A1C2 CL:0000010 Transfected with: HGNC; 3115; E2F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671321 CVCL_A1C3 SEES3-1V human E2F3, clone3 embryonic stem cell human CVCL_A1C3 CL:0000010 Transfected with: HGNC; 3115; E2F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671322 CVCL_A1C4 SEES3-1V human E2F4, clone1 embryonic stem cell human CVCL_A1C4 CL:0000010 Transfected with: HGNC; 3118; E2F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671323 CVCL_A1C5 SEES3-1V human E2F4, clone2 embryonic stem cell human CVCL_A1C5 CL:0000010 Transfected with: HGNC; 3118; E2F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671324 CVCL_A1C6 SEES3-1V human E2F4, clone3 embryonic stem cell human CVCL_A1C6 CL:0000010 Transfected with: HGNC; 3118; E2F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671325 CVCL_A1C7 SEES3-1V human E2F5, clone1 embryonic stem cell human CVCL_A1C7 CL:0000010 Transfected with: HGNC; 3119; E2F5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671326 CVCL_A1A6 SEES3-1V human DNMT3L, clone1 embryonic stem cell human CVCL_A1A6 CL:0000010 Transfected with: HGNC; 2980; DNMT3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671327 CVCL_A1A7 SEES3-1V human DNMT3L, clone2 embryonic stem cell human CVCL_A1A7 CL:0000010 Transfected with: HGNC; 2980; DNMT3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671328 CVCL_A1A8 SEES3-1V human DNMT3L, clone3 embryonic stem cell human CVCL_A1A8 CL:0000010 Transfected with: HGNC; 2980; DNMT3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671329 CVCL_A1A9 SEES3-1V human DPF1, clone1 embryonic stem cell human CVCL_A1A9 CL:0000010 Transfected with: HGNC; 20225; DPF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671330 CVCL_A1A0 SEES3-1V human DMRT2, clone3 embryonic stem cell human CVCL_A1A0 CL:0000010 Transfected with: HGNC; 2935; DMRT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671331 CVCL_A1A1 SEES3-1V human DMRTC2, clone1 embryonic stem cell human CVCL_A1A1 CL:0000010 Transfected with: HGNC; 13911; DMRTC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671332 CVCL_A1A2 SEES3-1V human DMRTC2, clone2 embryonic stem cell human CVCL_A1A2 CL:0000010 Transfected with: HGNC; 13911; DMRTC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671333 CVCL_A1A3 SEES3-1V human DNMT3B, clone1 embryonic stem cell human CVCL_A1A3 CL:0000010 Transfected with: HGNC; 2979; DNMT3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671334 CVCL_A1A4 SEES3-1V human DNMT3B, clone2 embryonic stem cell human CVCL_A1A4 CL:0000010 Transfected with: HGNC; 2979; DNMT3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671335 CVCL_A1A5 SEES3-1V human DNMT3B, clone3 embryonic stem cell human CVCL_A1A5 CL:0000010 Transfected with: HGNC; 2979; DNMT3B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671336 CVCL_A1M2 SEES3-1V human ETS1, clone1 embryonic stem cell human CVCL_A1M2 CL:0000010 Transfected with: HGNC; 3488; ETS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671337 CVCL_A1M3 SEES3-1V human ETS1, clone2 embryonic stem cell human CVCL_A1M3 CL:0000010 Transfected with: HGNC; 3488; ETS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671338 CVCL_A1M4 SEES3-1V human ETS1, clone3 embryonic stem cell human CVCL_A1M4 CL:0000010 Transfected with: HGNC; 3488; ETS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671339 CVCL_A1M5 SEES3-1V human ETS2, clone1 embryonic stem cell human CVCL_A1M5 CL:0000010 Transfected with: HGNC; 3489; ETS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671340 CVCL_A1M6 SEES3-1V human ETS2, clone2 embryonic stem cell human CVCL_A1M6 CL:0000010 Transfected with: HGNC; 3489; ETS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671341 CVCL_A1M7 SEES3-1V human ETS2, clone3 embryonic stem cell human CVCL_A1M7 CL:0000010 Transfected with: HGNC; 3489; ETS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671342 CVCL_A1M8 SEES3-1V human ETV1, clone1 embryonic stem cell human CVCL_A1M8 CL:0000010 Transfected with: HGNC; 3490; ETV1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671343 CVCL_A1M9 SEES3-1V human ETV1, clone2 embryonic stem cell human CVCL_A1M9 CL:0000010 Transfected with: HGNC; 3490; ETV1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671344 CVCL_A1M0 SEES3-1V human ESX1, clone2 embryonic stem cell human CVCL_A1M0 CL:0000010 Transfected with: HGNC; 14865; ESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671345 CVCL_A1M1 SEES3-1V human ESX1, clone3 embryonic stem cell human CVCL_A1M1 CL:0000010 Transfected with: HGNC; 14865; ESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671346 CVCL_A1L9 SEES3-1V human ESX1, clone1 embryonic stem cell human CVCL_A1L9 CL:0000010 Transfected with: HGNC; 14865; ESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671347 CVCL_A1N3 SEES3-1V human ETV2, clone3 embryonic stem cell human CVCL_A1N3 CL:0000010 Transfected with: HGNC; 3491; ETV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671348 CVCL_A1N4 SEES3-1V human ETV3, clone1 embryonic stem cell human CVCL_A1N4 CL:0000010 Transfected with: HGNC; 3492; ETV3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671349 CVCL_A1N5 SEES3-1V human ETV3, clone2 embryonic stem cell human CVCL_A1N5 CL:0000010 Transfected with: HGNC; 3492; ETV3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671350 CVCL_A1N6 SEES3-1V human ETV3, clone3 embryonic stem cell human CVCL_A1N6 CL:0000010 Transfected with: HGNC; 3492; ETV3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671351 CVCL_A1N7 SEES3-1V human ETV4, clone1 embryonic stem cell human CVCL_A1N7 CL:0000010 Transfected with: HGNC; 3493; ETV4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671352 CVCL_A1N8 SEES3-1V human ETV4, clone2 embryonic stem cell human CVCL_A1N8 CL:0000010 Transfected with: HGNC; 3493; ETV4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671353 CVCL_A1N9 SEES3-1V human ETV4, clone3 embryonic stem cell human CVCL_A1N9 CL:0000010 Transfected with: HGNC; 3493; ETV4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671354 CVCL_A1N0 SEES3-1V human ETV1, clone3 embryonic stem cell human CVCL_A1N0 CL:0000010 Transfected with: HGNC; 3490; ETV1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671355 CVCL_A1N1 SEES3-1V human ETV2, clone1 embryonic stem cell human CVCL_A1N1 CL:0000010 Transfected with: HGNC; 3491; ETV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671356 CVCL_A1N2 SEES3-1V human ETV2, clone2 embryonic stem cell human CVCL_A1N2 CL:0000010 Transfected with: HGNC; 3491; ETV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671357 CVCL_A1K0 SEES3-1V human EOMES, clone3 embryonic stem cell human CVCL_A1K0 CL:0000010 Transfected with: HGNC; 3372; EOMES; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671358 CVCL_A1K1 SEES3-1V human ERG, clone1 embryonic stem cell human CVCL_A1K1 CL:0000010 Transfected with: HGNC; 3446; ERG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671359 CVCL_A1K2 SEES3-1V human ERG, clone2 embryonic stem cell human CVCL_A1K2 CL:0000010 Transfected with: HGNC; 3446; ERG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671360 CVCL_A1K3 SEES3-1V human ERG, clone3 embryonic stem cell human CVCL_A1K3 CL:0000010 Transfected with: HGNC; 3446; ERG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671361 CVCL_A1K4 SEES3-1V human ESR1, clone1 embryonic stem cell human CVCL_A1K4 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671362 CVCL_A1K5 SEES3-1V human ESR1, clone2 embryonic stem cell human CVCL_A1K5 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671363 CVCL_A1K6 SEES3-1V human ESR1, clone3 embryonic stem cell human CVCL_A1K6 CL:0000010 Transfected with: HGNC; 3467; ESR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671364 CVCL_A1K7 SEES3-1V human ESR2, clone1 embryonic stem cell human CVCL_A1K7 CL:0000010 Transfected with: HGNC; 3468; ESR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671365 CVCL_A1J7 SEES3-1V human EN1, clone3 embryonic stem cell human CVCL_A1J7 CL:0000010 Transfected with: HGNC; 3342; EN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671366 CVCL_A1J8 SEES3-1V human EOMES, clone1 embryonic stem cell human CVCL_A1J8 CL:0000010 Transfected with: HGNC; 3372; EOMES; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671367 CVCL_A1J9 SEES3-1V human EOMES, clone2 embryonic stem cell human CVCL_A1J9 CL:0000010 Transfected with: HGNC; 3372; EOMES; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671368 CVCL_A1L1 SEES3-1V human ESRRA, clone2 embryonic stem cell human CVCL_A1L1 CL:0000010 Transfected with: HGNC; 3471; ESRRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671369 CVCL_A1L2 SEES3-1V human ESRRA, clone3 embryonic stem cell human CVCL_A1L2 CL:0000010 Transfected with: HGNC; 3471; ESRRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671370 CVCL_A1L3 SEES3-1V human ESRRB, clone1 embryonic stem cell human CVCL_A1L3 CL:0000010 Transfected with: HGNC; 3473; ESRRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671371 CVCL_A1L4 SEES3-1V human ESRRB, clone2 embryonic stem cell human CVCL_A1L4 CL:0000010 Transfected with: HGNC; 3473; ESRRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671372 CVCL_A1L5 SEES3-1V human ESRRB, clone3 embryonic stem cell human CVCL_A1L5 CL:0000010 Transfected with: HGNC; 3473; ESRRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671373 CVCL_A1L6 SEES3-1V human ESRRG, clone1 embryonic stem cell human CVCL_A1L6 CL:0000010 Transfected with: HGNC; 3474; ESRRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671374 CVCL_A1L7 SEES3-1V human ESRRG, clone2 embryonic stem cell human CVCL_A1L7 CL:0000010 Transfected with: HGNC; 3474; ESRRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671375 CVCL_A1L8 SEES3-1V human ESRRG, clone3 embryonic stem cell human CVCL_A1L8 CL:0000010 Transfected with: HGNC; 3474; ESRRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671376 CVCL_A1L0 SEES3-1V human ESRRA, clone1 embryonic stem cell human CVCL_A1L0 CL:0000010 Transfected with: HGNC; 3471; ESRRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671377 CVCL_A1K8 SEES3-1V human ESR2, clone2 embryonic stem cell human CVCL_A1K8 CL:0000010 Transfected with: HGNC; 3468; ESR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671378 CVCL_A1K9 SEES3-1V human ESR2, clone3 embryonic stem cell human CVCL_A1K9 CL:0000010 Transfected with: HGNC; 3468; ESR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671379 CVCL_A1I0 SEES3-1V human ELF5, clone3 embryonic stem cell human CVCL_A1I0 CL:0000010 Transfected with: HGNC; 3320; ELF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671380 CVCL_A1I1 SEES3-1V human ELF5, clone4 embryonic stem cell human CVCL_A1I1 CL:0000010 Transfected with: HGNC; 3320; ELF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671381 CVCL_A1I2 SEES3-1V human ELF5, clone5 embryonic stem cell human CVCL_A1I2 CL:0000010 Transfected with: HGNC; 3320; ELF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671382 CVCL_A1I3 SEES3-1V human ELK1, clone1 embryonic stem cell human CVCL_A1I3 CL:0000010 Transfected with: HGNC; 3321; ELK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671383 CVCL_A1I4 SEES3-1V human ELK1, clone2 embryonic stem cell human CVCL_A1I4 CL:0000010 Transfected with: HGNC; 3321; ELK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671384 CVCL_A1I5 SEES3-1V human ELK1, clone3 embryonic stem cell human CVCL_A1I5 CL:0000010 Transfected with: HGNC; 3321; ELK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671385 CVCL_A1H5 SEES3-1V human ELF4, clone1 embryonic stem cell human CVCL_A1H5 CL:0000010 Transfected with: HGNC; 3319; ELF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671386 CVCL_A1H6 SEES3-1V human ELF4, clone2 embryonic stem cell human CVCL_A1H6 CL:0000010 Transfected with: HGNC; 3319; ELF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671387 CVCL_A1H7 SEES3-1V human ELF4, clone3 embryonic stem cell human CVCL_A1H7 CL:0000010 Transfected with: HGNC; 3319; ELF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671388 CVCL_A1H8 SEES3-1V human ELF5, clone1 embryonic stem cell human CVCL_A1H8 CL:0000010 Transfected with: HGNC; 3320; ELF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671389 CVCL_A1H9 SEES3-1V human ELF5, clone2 embryonic stem cell human CVCL_A1H9 CL:0000010 Transfected with: HGNC; 3320; ELF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671390 CVCL_A1J0 SEES3-1V human ELL2, clone2 embryonic stem cell human CVCL_A1J0 CL:0000010 Transfected with: HGNC; 17064; ELL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671391 CVCL_A1J1 SEES3-1V human ELL2, clone3 embryonic stem cell human CVCL_A1J1 CL:0000010 Transfected with: HGNC; 17064; ELL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671392 CVCL_A1J2 SEES3-1V human EMX2, clone1 embryonic stem cell human CVCL_A1J2 CL:0000010 Transfected with: HGNC; 3341; EMX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671393 CVCL_A1J3 SEES3-1V human EMX2, clone2 embryonic stem cell human CVCL_A1J3 CL:0000010 Transfected with: HGNC; 3341; EMX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671394 CVCL_A1J4 SEES3-1V human EMX2, clone3 embryonic stem cell human CVCL_A1J4 CL:0000010 Transfected with: HGNC; 3341; EMX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671395 CVCL_A1J5 SEES3-1V human EN1, clone1 embryonic stem cell human CVCL_A1J5 CL:0000010 Transfected with: HGNC; 3342; EN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671396 CVCL_A1J6 SEES3-1V human EN1, clone2 embryonic stem cell human CVCL_A1J6 CL:0000010 Transfected with: HGNC; 3342; EN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671397 CVCL_A1I6 SEES3-1V human ELK3, clone1 embryonic stem cell human CVCL_A1I6 CL:0000010 Transfected with: HGNC; 3325; ELK3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671398 CVCL_A1I7 SEES3-1V human ELK3, clone2 embryonic stem cell human CVCL_A1I7 CL:0000010 Transfected with: HGNC; 3325; ELK3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671399 CVCL_A1I8 SEES3-1V human ELK3, clone3 embryonic stem cell human CVCL_A1I8 CL:0000010 Transfected with: HGNC; 3325; ELK3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671400 CVCL_A1I9 SEES3-1V human ELL2, clone1 embryonic stem cell human CVCL_A1I9 CL:0000010 Transfected with: HGNC; 17064; ELL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671401 CVCL_A1G0 SEES3-1V human EHF, clone1 embryonic stem cell human CVCL_A1G0 CL:0000010 Transfected with: HGNC; 3246; EHF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671402 CVCL_A1G1 SEES3-1V human EHF, clone2 embryonic stem cell human CVCL_A1G1 CL:0000010 Transfected with: HGNC; 3246; EHF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671403 CVCL_A1G2 SEES3-1V human EHF, clone3 embryonic stem cell human CVCL_A1G2 CL:0000010 Transfected with: HGNC; 3246; EHF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671404 CVCL_A1G3 SEES3-1V human EIF4E, clone1 embryonic stem cell human CVCL_A1G3 CL:0000010 Transfected with: HGNC; 3287; EIF4E; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671405 CVCL_A1F3 SEES3-1V human EGFLAM, clone3 embryonic stem cell human CVCL_A1F3 CL:0000010 Transfected with: HGNC; 26810; EGFLAM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671406 CVCL_A1F4 SEES3-1V human EGR1, clone1 embryonic stem cell human CVCL_A1F4 CL:0000010 Transfected with: HGNC; 3238; EGR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671407 CVCL_A1F5 SEES3-1V human EGR1, clone2 embryonic stem cell human CVCL_A1F5 CL:0000010 Transfected with: HGNC; 3238; EGR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671408 CVCL_A1F6 SEES3-1V human EGR1, clone3 embryonic stem cell human CVCL_A1F6 CL:0000010 Transfected with: HGNC; 3238; EGR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671409 CVCL_A1F7 SEES3-1V human EGR2, clone1 embryonic stem cell human CVCL_A1F7 CL:0000010 Transfected with: HGNC; 3239; EGR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671410 CVCL_A1F8 SEES3-1V human EGR2, clone2 embryonic stem cell human CVCL_A1F8 CL:0000010 Transfected with: HGNC; 3239; EGR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671411 CVCL_A1F9 SEES3-1V human EGR2, clone3 embryonic stem cell human CVCL_A1F9 CL:0000010 Transfected with: HGNC; 3239; EGR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671412 CVCL_A1H0 SEES3-1V human ELF2, clone2 embryonic stem cell human CVCL_A1H0 CL:0000010 Transfected with: HGNC; 3317; ELF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671413 CVCL_A1H1 SEES3-1V human ELF2, clone3 embryonic stem cell human CVCL_A1H1 CL:0000010 Transfected with: HGNC; 3317; ELF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671414 CVCL_A1H2 SEES3-1V human ELF3, clone1 embryonic stem cell human CVCL_A1H2 CL:0000010 Transfected with: HGNC; 3318; ELF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671415 CVCL_A1H3 SEES3-1V human ELF3, clone2 embryonic stem cell human CVCL_A1H3 CL:0000010 Transfected with: HGNC; 3318; ELF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671416 CVCL_A1H4 SEES3-1V human ELF3, clone3 embryonic stem cell human CVCL_A1H4 CL:0000010 Transfected with: HGNC; 3318; ELF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671417 CVCL_A1G4 SEES3-1V human EIF4E, clone2 embryonic stem cell human CVCL_A1G4 CL:0000010 Transfected with: HGNC; 3287; EIF4E; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671418 CVCL_A1G5 SEES3-1V human EIF4E, clone3 embryonic stem cell human CVCL_A1G5 CL:0000010 Transfected with: HGNC; 3287; EIF4E; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671419 CVCL_A1G6 SEES3-1V human ELF1, clone1 embryonic stem cell human CVCL_A1G6 CL:0000010 Transfected with: HGNC; 3316; ELF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671420 CVCL_A1G7 SEES3-1V human ELF1, clone2 embryonic stem cell human CVCL_A1G7 CL:0000010 Transfected with: HGNC; 3316; ELF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671421 CVCL_A1G8 SEES3-1V human ELF1, clone3 embryonic stem cell human CVCL_A1G8 CL:0000010 Transfected with: HGNC; 3316; ELF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671422 CVCL_A1G9 SEES3-1V human ELF2, clone1 embryonic stem cell human CVCL_A1G9 CL:0000010 Transfected with: HGNC; 3317; ELF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671423 CVCL_A0S9 SEES3-1V human CRY1, clone1 embryonic stem cell human CVCL_A0S9 CL:0000010 Transfected with: HGNC; 2384; CRY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671424 CVCL_A0S1 SEES3-1V human CREB1, clone2 embryonic stem cell human CVCL_A0S1 CL:0000010 Transfected with: HGNC; 2345; CREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671425 CVCL_A0S2 SEES3-1V human CREB1, clone3 embryonic stem cell human CVCL_A0S2 CL:0000010 Transfected with: HGNC; 2345; CREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671426 CVCL_A0S3 SEES3-1V human CREB3, clone1 embryonic stem cell human CVCL_A0S3 CL:0000010 Transfected with: HGNC; 2347; CREB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671427 CVCL_A0S4 SEES3-1V human CREB3, clone2 embryonic stem cell human CVCL_A0S4 CL:0000010 Transfected with: HGNC; 2347; CREB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671428 CVCL_A0S5 SEES3-1V human CREB3, clone3 embryonic stem cell human CVCL_A0S5 CL:0000010 Transfected with: HGNC; 2347; CREB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671429 CVCL_A0S6 SEES3-1V human CRX, clone1 embryonic stem cell human CVCL_A0S6 CL:0000010 Transfected with: HGNC; 2383; CRX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671430 CVCL_A0S7 SEES3-1V human CRX, clone2 embryonic stem cell human CVCL_A0S7 CL:0000010 Transfected with: HGNC; 2383; CRX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671431 CVCL_A0S8 SEES3-1V human CRX, clone3 embryonic stem cell human CVCL_A0S8 CL:0000010 Transfected with: HGNC; 2383; CRX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671432 CVCL_A0S0 SEES3-1V human CREB1, clone1 embryonic stem cell human CVCL_A0S0 CL:0000010 Transfected with: HGNC; 2345; CREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671433 CVCL_A0T2 SEES3-1V human CRY2, clone1 embryonic stem cell human CVCL_A0T2 CL:0000010 Transfected with: HGNC; 2385; CRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671434 CVCL_A0T3 SEES3-1V human CRY2, clone2 embryonic stem cell human CVCL_A0T3 CL:0000010 Transfected with: HGNC; 2385; CRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671435 CVCL_A0T4 SEES3-1V human CRY2, clone3 embryonic stem cell human CVCL_A0T4 CL:0000010 Transfected with: HGNC; 2385; CRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671436 CVCL_A0T5 SEES3-1V human CTBP1, clone1 embryonic stem cell human CVCL_A0T5 CL:0000010 Transfected with: HGNC; 2494; CTBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671437 CVCL_A0T6 SEES3-1V human CTBP1, clone2 embryonic stem cell human CVCL_A0T6 CL:0000010 Transfected with: HGNC; 2494; CTBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671438 CVCL_A0T7 SEES3-1V human CTBP1, clone3 embryonic stem cell human CVCL_A0T7 CL:0000010 Transfected with: HGNC; 2494; CTBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671439 CVCL_A0T8 SEES3-1V human CTBP2, clone1 embryonic stem cell human CVCL_A0T8 CL:0000010 Transfected with: HGNC; 2495; CTBP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671440 CVCL_A0T9 SEES3-1V human CTBP2, clone2 embryonic stem cell human CVCL_A0T9 CL:0000010 Transfected with: HGNC; 2495; CTBP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671441 CVCL_A0T0 SEES3-1V human CRY1, clone2 embryonic stem cell human CVCL_A0T0 CL:0000010 Transfected with: HGNC; 2384; CRY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671442 CVCL_A0T1 SEES3-1V human CRY1, clone3 embryonic stem cell human CVCL_A0T1 CL:0000010 Transfected with: HGNC; 2384; CRY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671443 CVCL_A0Q7 SEES3-1V human CERS2, clone3 embryonic stem cell human CVCL_A0Q7 CL:0000010 Transfected with: HGNC; 14076; CERS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671444 CVCL_A0Q8 SEES3-1V human CHD1, clone1 embryonic stem cell human CVCL_A0Q8 CL:0000010 Transfected with: HGNC; 1915; CHD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671445 CVCL_A0Q9 SEES3-1V human CHD1, clone2 embryonic stem cell human CVCL_A0Q9 CL:0000010 Transfected with: HGNC; 1915; CHD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671446 CVCL_A0Q0 SEES3-1V human CEBPE, clone2 embryonic stem cell human CVCL_A0Q0 CL:0000010 Transfected with: HGNC; 1836; CEBPE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671447 CVCL_A0Q1 SEES3-1V human CEBPE, clone3 embryonic stem cell human CVCL_A0Q1 CL:0000010 Transfected with: HGNC; 1836; CEBPE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671448 CVCL_A0Q2 SEES3-1V human CEBPG, clone1 embryonic stem cell human CVCL_A0Q2 CL:0000010 Transfected with: HGNC; 1837; CEBPG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671449 CVCL_A0Q3 SEES3-1V human CEBPG, clone2 embryonic stem cell human CVCL_A0Q3 CL:0000010 Transfected with: HGNC; 1837; CEBPG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671450 CVCL_A0Q4 SEES3-1V human CEBPG, clone3 embryonic stem cell human CVCL_A0Q4 CL:0000010 Transfected with: HGNC; 1837; CEBPG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671451 CVCL_A0Q5 SEES3-1V human CERS2, clone1 embryonic stem cell human CVCL_A0Q5 CL:0000010 Transfected with: HGNC; 14076; CERS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671452 CVCL_A0Q6 SEES3-1V human CERS2, clone2 embryonic stem cell human CVCL_A0Q6 CL:0000010 Transfected with: HGNC; 14076; CERS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671453 CVCL_A0R8 SEES3-1V human CITED1, clone2 embryonic stem cell human CVCL_A0R8 CL:0000010 Transfected with: HGNC; 1986; CITED1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671454 CVCL_A0R9 SEES3-1V human CITED1, clone3 embryonic stem cell human CVCL_A0R9 CL:0000010 Transfected with: HGNC; 1986; CITED1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671455 CVCL_A0R0 SEES3-1V human CHD1, clone3 embryonic stem cell human CVCL_A0R0 CL:0000010 Transfected with: HGNC; 1915; CHD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671456 CVCL_A0R1 SEES3-1V human CHD4, clone1 embryonic stem cell human CVCL_A0R1 CL:0000010 Transfected with: HGNC; 1919; CHD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671457 CVCL_A0R2 SEES3-1V human CHD4, clone2 embryonic stem cell human CVCL_A0R2 CL:0000010 Transfected with: HGNC; 1919; CHD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671458 CVCL_A0R3 SEES3-1V human CHD4, clone3 embryonic stem cell human CVCL_A0R3 CL:0000010 Transfected with: HGNC; 1919; CHD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671459 CVCL_A0R4 SEES3-1V human CHD5, clone1 embryonic stem cell human CVCL_A0R4 CL:0000010 Transfected with: HGNC; 16816; CHD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671460 CVCL_A0R5 SEES3-1V human CHD5, clone2 embryonic stem cell human CVCL_A0R5 CL:0000010 Transfected with: HGNC; 16816; CHD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671461 CVCL_A0R6 SEES3-1V human CHD5, clone3 embryonic stem cell human CVCL_A0R6 CL:0000010 Transfected with: HGNC; 16816; CHD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671462 CVCL_A0R7 SEES3-1V human CITED1, clone1 embryonic stem cell human CVCL_A0R7 CL:0000010 Transfected with: HGNC; 1986; CITED1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671463 CVCL_A0P6 SEES3-1V human CEBPD, clone1 embryonic stem cell human CVCL_A0P6 CL:0000010 Transfected with: HGNC; 1835; CEBPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671464 CVCL_A0P7 SEES3-1V human CEBPD, clone2 embryonic stem cell human CVCL_A0P7 CL:0000010 Transfected with: HGNC; 1835; CEBPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671465 CVCL_A0P8 SEES3-1V human CEBPD, clone3 embryonic stem cell human CVCL_A0P8 CL:0000010 Transfected with: HGNC; 1835; CEBPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671466 CVCL_A0P9 SEES3-1V human CEBPE, clone1 embryonic stem cell human CVCL_A0P9 CL:0000010 Transfected with: HGNC; 1836; CEBPE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671467 CVCL_A0P0 SEES3-1V human CEBPA, clone1 embryonic stem cell human CVCL_A0P0 CL:0000010 Transfected with: HGNC; 1833; CEBPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671468 CVCL_A0P1 SEES3-1V human CEBPA, clone2 embryonic stem cell human CVCL_A0P1 CL:0000010 Transfected with: HGNC; 1833; CEBPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671469 CVCL_A0P2 SEES3-1V human CEBPA, clone3 embryonic stem cell human CVCL_A0P2 CL:0000010 Transfected with: HGNC; 1833; CEBPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671470 CVCL_A0P3 SEES3-1V human CEBPB, clone1 embryonic stem cell human CVCL_A0P3 CL:0000010 Transfected with: HGNC; 1834; CEBPB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671471 CVCL_A0P4 SEES3-1V human CEBPB, clone2 embryonic stem cell human CVCL_A0P4 CL:0000010 Transfected with: HGNC; 1834; CEBPB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671472 CVCL_A0P5 SEES3-1V human CEBPB, clone3 embryonic stem cell human CVCL_A0P5 CL:0000010 Transfected with: HGNC; 1834; CEBPB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671473 CVCL_A0M3 SEES3-1V human CDK9, clone2 embryonic stem cell human CVCL_A0M3 CL:0000010 Transfected with: HGNC; 1780; CDK9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671474 CVCL_A0M4 SEES3-1V human CDK9, clone3 embryonic stem cell human CVCL_A0M4 CL:0000010 Transfected with: HGNC; 1780; CDK9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671475 CVCL_A0M5 SEES3-1V human CDKN1B, clone1 embryonic stem cell human CVCL_A0M5 CL:0000010 Transfected with: HGNC; 1785; CDKN1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671476 CVCL_A0M6 SEES3-1V human CDKN1B, clone2 embryonic stem cell human CVCL_A0M6 CL:0000010 Transfected with: HGNC; 1785; CDKN1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671477 CVCL_A0M7 SEES3-1V human CDKN1B, clone3 embryonic stem cell human CVCL_A0M7 CL:0000010 Transfected with: HGNC; 1785; CDKN1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671478 CVCL_A0M8 SEES3-1V human CDKN2D, clone1 embryonic stem cell human CVCL_A0M8 CL:0000010 Transfected with: HGNC; 1790; CDKN2D; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671479 CVCL_A0M9 SEES3-1V human CDKN2D, clone2 embryonic stem cell human CVCL_A0M9 CL:0000010 Transfected with: HGNC; 1790; CDKN2D; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671480 CVCL_A0M0 SEES3-1V human CCNE1, clone2 embryonic stem cell human CVCL_A0M0 CL:0000010 Transfected with: HGNC; 1589; CCNE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671481 CVCL_A0M1 SEES3-1V human CCNE1, clone3 embryonic stem cell human CVCL_A0M1 CL:0000010 Transfected with: HGNC; 1589; CCNE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671482 CVCL_A0M2 SEES3-1V human CDK9, clone1 embryonic stem cell human CVCL_A0M2 CL:0000010 Transfected with: HGNC; 1780; CDK9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671483 CVCL_A0N4 SEES3-1V human CDYL, clone1 embryonic stem cell human CVCL_A0N4 CL:0000010 Transfected with: HGNC; 1811; CDYL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671484 CVCL_A0N5 SEES3-1V human CDYL, clone2 embryonic stem cell human CVCL_A0N5 CL:0000010 Transfected with: HGNC; 1811; CDYL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671485 CVCL_A0N6 SEES3-1V human CDYL, clone3 embryonic stem cell human CVCL_A0N6 CL:0000010 Transfected with: HGNC; 1811; CDYL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671486 CVCL_A0N7 SEES3-1V human CDYL2, clone1 embryonic stem cell human CVCL_A0N7 CL:0000010 Transfected with: HGNC; 23030; CDYL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671487 CVCL_A0N8 SEES3-1V human CDYL2, clone2 embryonic stem cell human CVCL_A0N8 CL:0000010 Transfected with: HGNC; 23030; CDYL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671488 CVCL_A0N9 SEES3-1V human CDYL2, clone3 embryonic stem cell human CVCL_A0N9 CL:0000010 Transfected with: HGNC; 23030; CDYL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671489 CVCL_A0N0 SEES3-1V human CDKN2D, clone3 embryonic stem cell human CVCL_A0N0 CL:0000010 Transfected with: HGNC; 1790; CDKN2D; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671490 CVCL_A0N1 SEES3-1V human CDX2, clone1 embryonic stem cell human CVCL_A0N1 CL:0000010 Transfected with: HGNC; 1806; CDX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671491 CVCL_A0N2 SEES3-1V human CDX2, clone2 embryonic stem cell human CVCL_A0N2 CL:0000010 Transfected with: HGNC; 1806; CDX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671492 CVCL_A0N3 SEES3-1V human CDX2, clone3 embryonic stem cell human CVCL_A0N3 CL:0000010 Transfected with: HGNC; 1806; CDX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671493 CVCL_A0Y7 SEES3-1V human DLX4, clone2 embryonic stem cell human CVCL_A0Y7 CL:0000010 Transfected with: HGNC; 2917; DLX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671494 CVCL_A0Y8 SEES3-1V human DLX4, clone3 embryonic stem cell human CVCL_A0Y8 CL:0000010 Transfected with: HGNC; 2917; DLX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671495 CVCL_A0Y9 SEES3-1V human DLX5, clone1 embryonic stem cell human CVCL_A0Y9 CL:0000010 Transfected with: HGNC; 2918; DLX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671496 CVCL_A0Y0 SEES3-1V human DLX2, clone1 embryonic stem cell human CVCL_A0Y0 CL:0000010 Transfected with: HGNC; 2915; DLX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671497 CVCL_A0Y1 SEES3-1V human DLX2, clone2 embryonic stem cell human CVCL_A0Y1 CL:0000010 Transfected with: HGNC; 2915; DLX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671498 CVCL_A0Y2 SEES3-1V human DLX2, clone3 embryonic stem cell human CVCL_A0Y2 CL:0000010 Transfected with: HGNC; 2915; DLX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671499 CVCL_A0Y3 SEES3-1V human DLX3, clone1 embryonic stem cell human CVCL_A0Y3 CL:0000010 Transfected with: HGNC; 2916; DLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671500 CVCL_A0Y4 SEES3-1V human DLX3, clone2 embryonic stem cell human CVCL_A0Y4 CL:0000010 Transfected with: HGNC; 2916; DLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671501 CVCL_A0Y5 SEES3-1V human DLX3, clone3 embryonic stem cell human CVCL_A0Y5 CL:0000010 Transfected with: HGNC; 2916; DLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671502 CVCL_A0Y6 SEES3-1V human DLX4, clone1 embryonic stem cell human CVCL_A0Y6 CL:0000010 Transfected with: HGNC; 2917; DLX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671503 CVCL_A0Z8 SEES3-1V human DMRT2, clone1 embryonic stem cell human CVCL_A0Z8 CL:0000010 Transfected with: HGNC; 2935; DMRT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671504 CVCL_A0Z9 SEES3-1V human DMRT2, clone2 embryonic stem cell human CVCL_A0Z9 CL:0000010 Transfected with: HGNC; 2935; DMRT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671505 CVCL_A0Z0 SEES3-1V human DLX5, clone2 embryonic stem cell human CVCL_A0Z0 CL:0000010 Transfected with: HGNC; 2918; DLX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671506 CVCL_A0Z1 SEES3-1V human DLX5, clone3 embryonic stem cell human CVCL_A0Z1 CL:0000010 Transfected with: HGNC; 2918; DLX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671507 CVCL_A0Z2 SEES3-1V human DLX6, clone1 embryonic stem cell human CVCL_A0Z2 CL:0000010 Transfected with: HGNC; 2919; DLX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671508 CVCL_A0Z3 SEES3-1V human DLX6, clone2 embryonic stem cell human CVCL_A0Z3 CL:0000010 Transfected with: HGNC; 2919; DLX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671509 CVCL_A0Z4 SEES3-1V human DLX6, clone3 embryonic stem cell human CVCL_A0Z4 CL:0000010 Transfected with: HGNC; 2919; DLX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671510 CVCL_A0Z5 SEES3-1V human DMRT1, clone1 embryonic stem cell human CVCL_A0Z5 CL:0000010 Transfected with: HGNC; 2934; DMRT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671511 CVCL_A0Z6 SEES3-1V human DMRT1, clone2 embryonic stem cell human CVCL_A0Z6 CL:0000010 Transfected with: HGNC; 2934; DMRT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671512 CVCL_A0Z7 SEES3-1V human DMRT1, clone3 embryonic stem cell human CVCL_A0Z7 CL:0000010 Transfected with: HGNC; 2934; DMRT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671513 CVCL_A0W5 SEES3-1V human DCP1A, clone1 embryonic stem cell human CVCL_A0W5 CL:0000010 Transfected with: HGNC; 18714; DCP1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671514 CVCL_A0W6 SEES3-1V human DCP1A, clone2 embryonic stem cell human CVCL_A0W6 CL:0000010 Transfected with: HGNC; 18714; DCP1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671515 CVCL_A0W7 SEES3-1V human DCP1A, clone3 embryonic stem cell human CVCL_A0W7 CL:0000010 Transfected with: HGNC; 18714; DCP1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671516 CVCL_A0W8 SEES3-1V human DCT, clone1 embryonic stem cell human CVCL_A0W8 CL:0000010 Transfected with: HGNC; 2709; DCT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671517 CVCL_A0W9 SEES3-1V human DCT, clone2 embryonic stem cell human CVCL_A0W9 CL:0000010 Transfected with: HGNC; 2709; DCT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671518 CVCL_A0W0 SEES3-1V human DBX1, clone2 embryonic stem cell human CVCL_A0W0 CL:0000010 Transfected with: HGNC; 33185; DBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671519 CVCL_A0W1 SEES3-1V human DBX1, clone3 embryonic stem cell human CVCL_A0W1 CL:0000010 Transfected with: HGNC; 33185; DBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671520 CVCL_A0W2 SEES3-1V human DBX2, clone1 embryonic stem cell human CVCL_A0W2 CL:0000010 Transfected with: HGNC; 33186; DBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671521 CVCL_A0W3 SEES3-1V human DBX2, clone2 embryonic stem cell human CVCL_A0W3 CL:0000010 Transfected with: HGNC; 33186; DBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671522 CVCL_A0W4 SEES3-1V human DBX2, clone3 embryonic stem cell human CVCL_A0W4 CL:0000010 Transfected with: HGNC; 33186; DBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671523 CVCL_A0X6 SEES3-1V human DLK1, clone3 embryonic stem cell human CVCL_A0X6 CL:0000010 Transfected with: HGNC; 2907; DLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671524 CVCL_A0X7 SEES3-1V human DLX1, clone1 embryonic stem cell human CVCL_A0X7 CL:0000010 Transfected with: HGNC; 2914; DLX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671525 CVCL_A0X8 SEES3-1V human DLX1, clone2 embryonic stem cell human CVCL_A0X8 CL:0000010 Transfected with: HGNC; 2914; DLX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671526 CVCL_A0X9 SEES3-1V human DLX1, clone3 embryonic stem cell human CVCL_A0X9 CL:0000010 Transfected with: HGNC; 2914; DLX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671527 CVCL_A0X0 SEES3-1V human DCT, clone3 embryonic stem cell human CVCL_A0X0 CL:0000010 Transfected with: HGNC; 2709; DCT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671528 CVCL_A0X1 SEES3-1V human DEDD2, clone1 embryonic stem cell human CVCL_A0X1 CL:0000010 Transfected with: HGNC; 24450; DEDD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671529 CVCL_A0X2 SEES3-1V human DEDD2, clone2 embryonic stem cell human CVCL_A0X2 CL:0000010 Transfected with: HGNC; 24450; DEDD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671530 CVCL_A0X3 SEES3-1V human DEDD2, clone3 embryonic stem cell human CVCL_A0X3 CL:0000010 Transfected with: HGNC; 24450; DEDD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671531 CVCL_A0X4 SEES3-1V human DLK1, clone1 embryonic stem cell human CVCL_A0X4 CL:0000010 Transfected with: HGNC; 2907; DLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671532 CVCL_A0X5 SEES3-1V human DLK1, clone2 embryonic stem cell human CVCL_A0X5 CL:0000010 Transfected with: HGNC; 2907; DLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671533 CVCL_A0U3 SEES3-1V human CTCF, clone3 embryonic stem cell human CVCL_A0U3 CL:0000010 Transfected with: HGNC; 13723; CTCF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671534 CVCL_A0U4 SEES3-1V human CTCFL, clone1 embryonic stem cell human CVCL_A0U4 CL:0000010 Transfected with: HGNC; 16234; CTCFL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671535 CVCL_A0U5 SEES3-1V human CTCFL, clone2 embryonic stem cell human CVCL_A0U5 CL:0000010 Transfected with: HGNC; 16234; CTCFL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671536 CVCL_A0U6 SEES3-1V human CTCFL, clone3 embryonic stem cell human CVCL_A0U6 CL:0000010 Transfected with: HGNC; 16234; CTCFL; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671537 CVCL_A0U7 SEES3-1V human CTGF, clone1 embryonic stem cell human CVCL_A0U7 CL:0000010 Transfected with: HGNC; 2500; CCN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671538 CVCL_A0U8 SEES3-1V human CTGF, clone2 embryonic stem cell human CVCL_A0U8 CL:0000010 Transfected with: HGNC; 2500; CCN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671539 CVCL_A0U9 SEES3-1V human CTGF, clone3 embryonic stem cell human CVCL_A0U9 CL:0000010 Transfected with: HGNC; 2500; CCN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671540 CVCL_A0U0 SEES3-1V human CTBP2, clone3 embryonic stem cell human CVCL_A0U0 CL:0000010 Transfected with: HGNC; 2495; CTBP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671541 CVCL_A0U1 SEES3-1V human CTCF, clone1 embryonic stem cell human CVCL_A0U1 CL:0000010 Transfected with: HGNC; 13723; CTCF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671542 CVCL_A0U2 SEES3-1V human CTCF, clone2 embryonic stem cell human CVCL_A0U2 CL:0000010 Transfected with: HGNC; 13723; CTCF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671543 CVCL_A0V4 SEES3-1V human CUX1, clone2 embryonic stem cell human CVCL_A0V4 CL:0000010 Transfected with: HGNC; 2557; CUX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671544 CVCL_A0V5 SEES3-1V human CUX1, clone3 embryonic stem cell human CVCL_A0V5 CL:0000010 Transfected with: HGNC; 2557; CUX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671545 CVCL_A0V6 SEES3-1V human CXXC5, clone1 embryonic stem cell human CVCL_A0V6 CL:0000010 Transfected with: HGNC; 26943; CXXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671546 CVCL_A0V7 SEES3-1V human CXXC5, clone2 embryonic stem cell human CVCL_A0V7 CL:0000010 Transfected with: HGNC; 26943; CXXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671547 CVCL_A0V8 SEES3-1V human CXXC5, clone3 embryonic stem cell human CVCL_A0V8 CL:0000010 Transfected with: HGNC; 26943; CXXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671548 CVCL_A0V9 SEES3-1V human DBX1, clone1 embryonic stem cell human CVCL_A0V9 CL:0000010 Transfected with: HGNC; 33185; DBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671549 CVCL_A0V0 SEES3-1V human CTNNB1, clone1 embryonic stem cell human CVCL_A0V0 CL:0000010 Transfected with: HGNC; 2514; CTNNB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671550 CVCL_A0V1 SEES3-1V human CTNNB1, clone2 embryonic stem cell human CVCL_A0V1 CL:0000010 Transfected with: HGNC; 2514; CTNNB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671551 CVCL_A0V2 SEES3-1V human CTNNB1, clone3 embryonic stem cell human CVCL_A0V2 CL:0000010 Transfected with: HGNC; 2514; CTNNB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671552 CVCL_A0V3 SEES3-1V human CUX1, clone1 embryonic stem cell human CVCL_A0V3 CL:0000010 Transfected with: HGNC; 2557; CUX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671553 CVCL_A2G0 SEES3-1V human GATA6, clone1 embryonic stem cell human CVCL_A2G0 CL:0000010 Transfected with: HGNC; 4174; GATA6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671554 CVCL_A2G1 SEES3-1V human GATA6, clone2 embryonic stem cell human CVCL_A2G1 CL:0000010 Transfected with: HGNC; 4174; GATA6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671555 CVCL_A2G2 SEES3-1V human GATA6, clone3 embryonic stem cell human CVCL_A2G2 CL:0000010 Transfected with: HGNC; 4174; GATA6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671556 CVCL_A2F2 SEES3-1V human GATA1, clone2 embryonic stem cell human CVCL_A2F2 CL:0000010 Transfected with: HGNC; 4170; GATA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671557 CVCL_A2F3 SEES3-1V human GATA1, clone3 embryonic stem cell human CVCL_A2F3 CL:0000010 Transfected with: HGNC; 4170; GATA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671558 CVCL_A2F4 SEES3-1V human GATA2, clone1 embryonic stem cell human CVCL_A2F4 CL:0000010 Transfected with: HGNC; 4171; GATA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671559 CVCL_A2F5 SEES3-1V human GATA2, clone2 embryonic stem cell human CVCL_A2F5 CL:0000010 Transfected with: HGNC; 4171; GATA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671560 CVCL_A2F6 SEES3-1V human GATA2, clone3 embryonic stem cell human CVCL_A2F6 CL:0000010 Transfected with: HGNC; 4171; GATA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671561 CVCL_A2F7 SEES3-1V human GATA3, clone1 embryonic stem cell human CVCL_A2F7 CL:0000010 Transfected with: HGNC; 4172; GATA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671562 CVCL_A2F8 SEES3-1V human GATA3, clone2 embryonic stem cell human CVCL_A2F8 CL:0000010 Transfected with: HGNC; 4172; GATA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671563 CVCL_A2F9 SEES3-1V human GATA3, clone3 embryonic stem cell human CVCL_A2F9 CL:0000010 Transfected with: HGNC; 4172; GATA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671564 CVCL_A2H0 SEES3-1V human GLI4, clone2 embryonic stem cell human CVCL_A2H0 CL:0000010 Transfected with: HGNC; 4320; GLI4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671565 CVCL_A2H1 SEES3-1V human GLI4, clone3 embryonic stem cell human CVCL_A2H1 CL:0000010 Transfected with: HGNC; 4320; GLI4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671566 CVCL_A2H2 SEES3-1V human GLIS2, clone1 embryonic stem cell human CVCL_A2H2 CL:0000010 Transfected with: HGNC; 29450; GLIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671567 CVCL_A2H3 SEES3-1V human GLIS2, clone2 embryonic stem cell human CVCL_A2H3 CL:0000010 Transfected with: HGNC; 29450; GLIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671568 CVCL_A2G3 SEES3-1V human GBX2, clone1 embryonic stem cell human CVCL_A2G3 CL:0000010 Transfected with: HGNC; 4186; GBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671569 CVCL_A2G4 SEES3-1V human GBX2, clone2 embryonic stem cell human CVCL_A2G4 CL:0000010 Transfected with: HGNC; 4186; GBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671570 CVCL_A2G5 SEES3-1V human GBX2, clone3 embryonic stem cell human CVCL_A2G5 CL:0000010 Transfected with: HGNC; 4186; GBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671571 CVCL_A2G6 SEES3-1V human GLI1, clone1 embryonic stem cell human CVCL_A2G6 CL:0000010 Transfected with: HGNC; 4317; GLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671572 CVCL_A2G7 SEES3-1V human GLI1, clone2 embryonic stem cell human CVCL_A2G7 CL:0000010 Transfected with: HGNC; 4317; GLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671573 CVCL_A2G8 SEES3-1V human GLI1, clone3 embryonic stem cell human CVCL_A2G8 CL:0000010 Transfected with: HGNC; 4317; GLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671574 CVCL_A2G9 SEES3-1V human GLI4, clone1 embryonic stem cell human CVCL_A2G9 CL:0000010 Transfected with: HGNC; 4320; GLI4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671575 CVCL_A2E0 SEES3-1V human FUBP1, clone2 embryonic stem cell human CVCL_A2E0 CL:0000010 Transfected with: HGNC; 4004; FUBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671576 CVCL_A2D8 SEES3-1V human FOXS1, clone3 embryonic stem cell human CVCL_A2D8 CL:0000010 Transfected with: HGNC; 3735; FOXS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671577 CVCL_A2D9 SEES3-1V human FUBP1, clone1 embryonic stem cell human CVCL_A2D9 CL:0000010 Transfected with: HGNC; 4004; FUBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671578 CVCL_A2D0 SEES3-1V human FOXP1, clone1 embryonic stem cell human CVCL_A2D0 CL:0000010 Transfected with: HGNC; 3823; FOXP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671579 CVCL_A2D1 SEES3-1V human FOXP1, clone2 embryonic stem cell human CVCL_A2D1 CL:0000010 Transfected with: HGNC; 3823; FOXP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671580 CVCL_A2D2 SEES3-1V human FOXP1, clone3 embryonic stem cell human CVCL_A2D2 CL:0000010 Transfected with: HGNC; 3823; FOXP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671581 CVCL_A2D3 SEES3-1V human FOXP3, clone1 embryonic stem cell human CVCL_A2D3 CL:0000010 Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671582 CVCL_A2D4 SEES3-1V human FOXP3, clone2 embryonic stem cell human CVCL_A2D4 CL:0000010 Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671583 CVCL_A2D5 SEES3-1V human FOXP3, clone3 embryonic stem cell human CVCL_A2D5 CL:0000010 Transfected with: HGNC; 6106; FOXP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671584 CVCL_A2D6 SEES3-1V human FOXS1, clone1 embryonic stem cell human CVCL_A2D6 CL:0000010 Transfected with: HGNC; 3735; FOXS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671585 CVCL_A2D7 SEES3-1V human FOXS1, clone2 embryonic stem cell human CVCL_A2D7 CL:0000010 Transfected with: HGNC; 3735; FOXS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671586 CVCL_A2F0 SEES3-1V human GADD45A, clone3 embryonic stem cell human CVCL_A2F0 CL:0000010 Transfected with: HGNC; 4095; GADD45A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671587 CVCL_A2F1 SEES3-1V human GATA1, clone1 embryonic stem cell human CVCL_A2F1 CL:0000010 Transfected with: HGNC; 4170; GATA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671588 CVCL_A2E9 SEES3-1V human GADD45A, clone2 embryonic stem cell human CVCL_A2E9 CL:0000010 Transfected with: HGNC; 4095; GADD45A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671589 CVCL_A2E1 SEES3-1V human FUBP1, clone3 embryonic stem cell human CVCL_A2E1 CL:0000010 Transfected with: HGNC; 4004; FUBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671590 CVCL_A2E2 SEES3-1V human FXR1, clone1 embryonic stem cell human CVCL_A2E2 CL:0000010 Transfected with: HGNC; 4023; FXR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671591 CVCL_A2E3 SEES3-1V human FXR1, clone2 embryonic stem cell human CVCL_A2E3 CL:0000010 Transfected with: HGNC; 4023; FXR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671592 CVCL_A2E4 SEES3-1V human FXR1, clone3 embryonic stem cell human CVCL_A2E4 CL:0000010 Transfected with: HGNC; 4023; FXR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671593 CVCL_A2E5 SEES3-1V human GABPA, clone1 embryonic stem cell human CVCL_A2E5 CL:0000010 Transfected with: HGNC; 4071; GABPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671594 CVCL_A2E6 SEES3-1V human GABPA, clone2 embryonic stem cell human CVCL_A2E6 CL:0000010 Transfected with: HGNC; 4071; GABPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671595 CVCL_A2E7 SEES3-1V human GABPA, clone3 embryonic stem cell human CVCL_A2E7 CL:0000010 Transfected with: HGNC; 4071; GABPA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671596 CVCL_A2E8 SEES3-1V human GADD45A, clone1 embryonic stem cell human CVCL_A2E8 CL:0000010 Transfected with: HGNC; 4095; GADD45A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671597 CVCL_A2B6 SEES3-1V human FOXL2, clone2 embryonic stem cell human CVCL_A2B6 CL:0000010 Transfected with: HGNC; 1092; FOXL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671598 CVCL_A2B7 SEES3-1V human FOXL2, clone3 embryonic stem cell human CVCL_A2B7 CL:0000010 Transfected with: HGNC; 1092; FOXL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671599 CVCL_A2B8 SEES3-1V human FOXM1, clone1 embryonic stem cell human CVCL_A2B8 CL:0000010 Transfected with: HGNC; 3818; FOXM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671600 CVCL_A2B9 SEES3-1V human FOXM1, clone2 embryonic stem cell human CVCL_A2B9 CL:0000010 Transfected with: HGNC; 3818; FOXM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671601 CVCL_A2B0 SEES3-1V human FOXJ2, clone2 embryonic stem cell human CVCL_A2B0 CL:0000010 Transfected with: HGNC; 24818; FOXJ2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671602 CVCL_A2B1 SEES3-1V human FOXJ2, clone3 embryonic stem cell human CVCL_A2B1 CL:0000010 Transfected with: HGNC; 24818; FOXJ2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671603 CVCL_A2B2 SEES3-1V human FOXL1, clone1 embryonic stem cell human CVCL_A2B2 CL:0000010 Transfected with: HGNC; 3817; FOXL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671604 CVCL_A2B3 SEES3-1V human FOXL1, clone2 embryonic stem cell human CVCL_A2B3 CL:0000010 Transfected with: HGNC; 3817; FOXL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671605 CVCL_A2B4 SEES3-1V human FOXL1, clone3 embryonic stem cell human CVCL_A2B4 CL:0000010 Transfected with: HGNC; 3817; FOXL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671606 CVCL_A2B5 SEES3-1V human FOXL2, clone1 embryonic stem cell human CVCL_A2B5 CL:0000010 Transfected with: HGNC; 1092; FOXL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671607 CVCL_A2C7 SEES3-1V human FOXO3, clone1 embryonic stem cell human CVCL_A2C7 CL:0000010 Transfected with: HGNC; 3821; FOXO3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671608 CVCL_A2C8 SEES3-1V human FOXO3, clone2 embryonic stem cell human CVCL_A2C8 CL:0000010 Transfected with: HGNC; 3821; FOXO3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671609 CVCL_A2C9 SEES3-1V human FOXO3, clone3 embryonic stem cell human CVCL_A2C9 CL:0000010 Transfected with: HGNC; 3821; FOXO3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671610 CVCL_A2C0 SEES3-1V human FOXM1, clone3 embryonic stem cell human CVCL_A2C0 CL:0000010 Transfected with: HGNC; 3818; FOXM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671611 CVCL_A2C1 SEES3-1V human FOXN1, clone1 embryonic stem cell human CVCL_A2C1 CL:0000010 Transfected with: HGNC; 12765; FOXN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671612 CVCL_A2C2 SEES3-1V human FOXN1, clone2 embryonic stem cell human CVCL_A2C2 CL:0000010 Transfected with: HGNC; 12765; FOXN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671613 CVCL_A2C3 SEES3-1V human FOXN1, clone3 embryonic stem cell human CVCL_A2C3 CL:0000010 Transfected with: HGNC; 12765; FOXN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671614 CVCL_A2C4 SEES3-1V human FOXN3, clone1 embryonic stem cell human CVCL_A2C4 CL:0000010 Transfected with: HGNC; 1928; FOXN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671615 CVCL_A2C5 SEES3-1V human FOXN3, clone2 embryonic stem cell human CVCL_A2C5 CL:0000010 Transfected with: HGNC; 1928; FOXN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671616 CVCL_A2C6 SEES3-1V human FOXN3, clone3 embryonic stem cell human CVCL_A2C6 CL:0000010 Transfected with: HGNC; 1928; FOXN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671617 CVCL_A2A5 SEES3-1V human FOXH1, clone3 embryonic stem cell human CVCL_A2A5 CL:0000010 Transfected with: HGNC; 3814; FOXH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671618 CVCL_A2A6 SEES3-1V human FOXJ1, clone1 embryonic stem cell human CVCL_A2A6 CL:0000010 Transfected with: HGNC; 3816; FOXJ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671619 CVCL_A2A7 SEES3-1V human FOXJ1, clone2 embryonic stem cell human CVCL_A2A7 CL:0000010 Transfected with: HGNC; 3816; FOXJ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671620 CVCL_A2A8 SEES3-1V human FOXJ1, clone3 embryonic stem cell human CVCL_A2A8 CL:0000010 Transfected with: HGNC; 3816; FOXJ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671621 CVCL_A2A9 SEES3-1V human FOXJ2, clone1 embryonic stem cell human CVCL_A2A9 CL:0000010 Transfected with: HGNC; 24818; FOXJ2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671622 CVCL_A2A0 SEES3-1V human FOXG1, clone1 embryonic stem cell human CVCL_A2A0 CL:0000010 Transfected with: HGNC; 3811; FOXG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671623 CVCL_A2A1 SEES3-1V human FOXG1, clone2 embryonic stem cell human CVCL_A2A1 CL:0000010 Transfected with: HGNC; 3811; FOXG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671624 CVCL_A2A2 SEES3-1V human FOXG1, clone3 embryonic stem cell human CVCL_A2A2 CL:0000010 Transfected with: HGNC; 3811; FOXG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671625 CVCL_A2A3 SEES3-1V human FOXH1, clone1 embryonic stem cell human CVCL_A2A3 CL:0000010 Transfected with: HGNC; 3814; FOXH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671626 CVCL_A2A4 SEES3-1V human FOXH1, clone2 embryonic stem cell human CVCL_A2A4 CL:0000010 Transfected with: HGNC; 3814; FOXH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671627 CVCL_A2P4 SEES3-1V human HEY1, clone2 embryonic stem cell human CVCL_A2P4 CL:0000010 Transfected with: HGNC; 4880; HEY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671628 CVCL_A2P5 SEES3-1V human HEY1, clone3 embryonic stem cell human CVCL_A2P5 CL:0000010 Transfected with: HGNC; 4880; HEY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671629 CVCL_A2P6 SEES3-1V human HEY2, clone1 embryonic stem cell human CVCL_A2P6 CL:0000010 Transfected with: HGNC; 4881; HEY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671630 CVCL_A2P7 SEES3-1V human HEY2, clone2 embryonic stem cell human CVCL_A2P7 CL:0000010 Transfected with: HGNC; 4881; HEY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671631 CVCL_A2P8 SEES3-1V human HEY2, clone3 embryonic stem cell human CVCL_A2P8 CL:0000010 Transfected with: HGNC; 4881; HEY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671632 CVCL_A2P9 SEES3-1V human HGF, clone1 embryonic stem cell human CVCL_A2P9 CL:0000010 Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671633 CVCL_A2P0 SEES3-1V human HESX1, clone1 embryonic stem cell human CVCL_A2P0 CL:0000010 Transfected with: HGNC; 4877; HESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671634 CVCL_A2P1 SEES3-1V human HESX1, clone2 embryonic stem cell human CVCL_A2P1 CL:0000010 Transfected with: HGNC; 4877; HESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671635 CVCL_A2P2 SEES3-1V human HESX1, clone3 embryonic stem cell human CVCL_A2P2 CL:0000010 Transfected with: HGNC; 4877; HESX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671636 CVCL_A2P3 SEES3-1V human HEY1, clone1 embryonic stem cell human CVCL_A2P3 CL:0000010 Transfected with: HGNC; 4880; HEY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671637 CVCL_A2M1 SEES3-1V human HDAC2, clone2 embryonic stem cell human CVCL_A2M1 CL:0000010 Transfected with: HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671638 CVCL_A2M2 SEES3-1V human HDAC2, clone3 embryonic stem cell human CVCL_A2M2 CL:0000010 Transfected with: HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671639 CVCL_A2M3 SEES3-1V human HDAC3, clone1 embryonic stem cell human CVCL_A2M3 CL:0000010 Transfected with: HGNC; 4854; HDAC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671640 CVCL_A2M4 SEES3-1V human HDAC3, clone2 embryonic stem cell human CVCL_A2M4 CL:0000010 Transfected with: HGNC; 4854; HDAC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671641 CVCL_A2M5 SEES3-1V human HDAC6, clone1 embryonic stem cell human CVCL_A2M5 CL:0000010 Transfected with: HGNC; 14064; HDAC6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671642 CVCL_A2M6 SEES3-1V human HDAC6, clone2 embryonic stem cell human CVCL_A2M6 CL:0000010 Transfected with: HGNC; 14064; HDAC6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671643 CVCL_A2M7 SEES3-1V human HDAC6, clone3 embryonic stem cell human CVCL_A2M7 CL:0000010 Transfected with: HGNC; 14064; HDAC6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671644 CVCL_A2M8 SEES3-1V human HDAC8, clone1 embryonic stem cell human CVCL_A2M8 CL:0000010 Transfected with: HGNC; 13315; HDAC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671645 CVCL_A2M0 SEES3-1V human HDAC2, clone1 embryonic stem cell human CVCL_A2M0 CL:0000010 Transfected with: HGNC; 4853; HDAC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671646 CVCL_A2L8 SEES3-1V human HDAC1, clone2 embryonic stem cell human CVCL_A2L8 CL:0000010 Transfected with: HGNC; 4852; HDAC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671647 CVCL_A2L9 SEES3-1V human HDAC1, clone3 embryonic stem cell human CVCL_A2L9 CL:0000010 Transfected with: HGNC; 4852; HDAC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671648 CVCL_A2N2 SEES3-1V human HDGF, clone2 embryonic stem cell human CVCL_A2N2 CL:0000010 Transfected with: HGNC; 4856; HDGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671649 CVCL_A2N3 SEES3-1V human HDGF, clone3 embryonic stem cell human CVCL_A2N3 CL:0000010 Transfected with: HGNC; 4856; HDGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671650 CVCL_A2N4 SEES3-1V human HES1, clone1 embryonic stem cell human CVCL_A2N4 CL:0000010 Transfected with: HGNC; 5192; HES1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671651 CVCL_A2N5 SEES3-1V human HES1, clone2 embryonic stem cell human CVCL_A2N5 CL:0000010 Transfected with: HGNC; 5192; HES1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671652 CVCL_A2N6 SEES3-1V human HES1, clone3 embryonic stem cell human CVCL_A2N6 CL:0000010 Transfected with: HGNC; 5192; HES1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671653 CVCL_A2N7 SEES3-1V human HES6, clone1 embryonic stem cell human CVCL_A2N7 CL:0000010 Transfected with: HGNC; 18254; HES6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671654 CVCL_A2N8 SEES3-1V human HES6, clone2 embryonic stem cell human CVCL_A2N8 CL:0000010 Transfected with: HGNC; 18254; HES6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671655 CVCL_A2N9 SEES3-1V human HES6, clone3 embryonic stem cell human CVCL_A2N9 CL:0000010 Transfected with: HGNC; 18254; HES6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671656 CVCL_A2N0 SEES3-1V human HDAC8, clone3 embryonic stem cell human CVCL_A2N0 CL:0000010 Transfected with: HGNC; 13315; HDAC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671657 CVCL_A2N1 SEES3-1V human HDGF, clone1 embryonic stem cell human CVCL_A2N1 CL:0000010 Transfected with: HGNC; 4856; HDGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671658 CVCL_A2M9 SEES3-1V human HDAC8, clone2 embryonic stem cell human CVCL_A2M9 CL:0000010 Transfected with: HGNC; 13315; HDAC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671659 CVCL_A2K0 SEES3-1V human H2AFX, clone2 embryonic stem cell human CVCL_A2K0 CL:0000010 Transfected with: HGNC; 4739; H2AX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671660 CVCL_A2K1 SEES3-1V human H2AFX, clone3 embryonic stem cell human CVCL_A2K1 CL:0000010 Transfected with: HGNC; 4739; H2AX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671661 CVCL_A2K2 SEES3-1V human H2AFY, clone1 embryonic stem cell human CVCL_A2K2 CL:0000010 Transfected with: HGNC; 4740; MACROH2A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671662 CVCL_A2K3 SEES3-1V human H2AFY, clone2 embryonic stem cell human CVCL_A2K3 CL:0000010 Transfected with: HGNC; 4740; MACROH2A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671663 CVCL_A2K4 SEES3-1V human H2AFY, clone3 embryonic stem cell human CVCL_A2K4 CL:0000010 Transfected with: HGNC; 4740; MACROH2A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671664 CVCL_A2K5 SEES3-1V human H2AFY2, clone1 embryonic stem cell human CVCL_A2K5 CL:0000010 Transfected with: HGNC; 14453; MACROH2A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671665 CVCL_A2K6 SEES3-1V human H2AFY2, clone2 embryonic stem cell human CVCL_A2K6 CL:0000010 Transfected with: HGNC; 14453; MACROH2A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671666 CVCL_A2J6 SEES3-1V human GTF3C5, clone1 embryonic stem cell human CVCL_A2J6 CL:0000010 Transfected with: HGNC; 4668; GTF3C5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671667 CVCL_A2J7 SEES3-1V human GTF3C5, clone2 embryonic stem cell human CVCL_A2J7 CL:0000010 Transfected with: HGNC; 4668; GTF3C5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671668 CVCL_A2J8 SEES3-1V human GTF3C5, clone3 embryonic stem cell human CVCL_A2J8 CL:0000010 Transfected with: HGNC; 4668; GTF3C5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671669 CVCL_A2J9 SEES3-1V human H2AFX, clone1 embryonic stem cell human CVCL_A2J9 CL:0000010 Transfected with: HGNC; 4739; H2AX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671670 CVCL_A2L0 SEES3-1V human H2AFZ, clone3 embryonic stem cell human CVCL_A2L0 CL:0000010 Transfected with: HGNC; 4741; H2AZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671671 CVCL_A2L1 SEES3-1V human H3F3A, clone1 embryonic stem cell human CVCL_A2L1 CL:0000010 Transfected with: HGNC; 4764; H3-3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671672 CVCL_A2L2 SEES3-1V human H3F3A, clone2 embryonic stem cell human CVCL_A2L2 CL:0000010 Transfected with: HGNC; 4764; H3-3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671673 CVCL_A2L3 SEES3-1V human H3F3A, clone3 embryonic stem cell human CVCL_A2L3 CL:0000010 Transfected with: HGNC; 4764; H3-3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671674 CVCL_A2L4 SEES3-1V human HCFC1, clone1 embryonic stem cell human CVCL_A2L4 CL:0000010 Transfected with: HGNC; 4839; HCFC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671675 CVCL_A2L5 SEES3-1V human HCFC1, clone2 embryonic stem cell human CVCL_A2L5 CL:0000010 Transfected with: HGNC; 4839; HCFC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671676 CVCL_A2L6 SEES3-1V human HCFC1, clone3 embryonic stem cell human CVCL_A2L6 CL:0000010 Transfected with: HGNC; 4839; HCFC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671677 CVCL_A2L7 SEES3-1V human HDAC1, clone1 embryonic stem cell human CVCL_A2L7 CL:0000010 Transfected with: HGNC; 4852; HDAC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671678 CVCL_A2K7 SEES3-1V human H2AFY2, clone3 embryonic stem cell human CVCL_A2K7 CL:0000010 Transfected with: HGNC; 14453; MACROH2A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671679 CVCL_A2K8 SEES3-1V human H2AFZ, clone1 embryonic stem cell human CVCL_A2K8 CL:0000010 Transfected with: HGNC; 4741; H2AZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671680 CVCL_A2K9 SEES3-1V human H2AFZ, clone2 embryonic stem cell human CVCL_A2K9 CL:0000010 Transfected with: HGNC; 4741; H2AZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671681 CVCL_A2I0 SEES3-1V human GRHL2, clone3 embryonic stem cell human CVCL_A2I0 CL:0000010 Transfected with: HGNC; 2799; GRHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671682 CVCL_A2I1 SEES3-1V human GSC, clone1 embryonic stem cell human CVCL_A2I1 CL:0000010 Transfected with: HGNC; 4612; GSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671683 CVCL_A2I2 SEES3-1V human GSC, clone2 embryonic stem cell human CVCL_A2I2 CL:0000010 Transfected with: HGNC; 4612; GSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671684 CVCL_A2I3 SEES3-1V human GSC, clone3 embryonic stem cell human CVCL_A2I3 CL:0000010 Transfected with: HGNC; 4612; GSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671685 CVCL_A2I4 SEES3-1V human GTF2B, clone1 embryonic stem cell human CVCL_A2I4 CL:0000010 Transfected with: HGNC; 4648; GTF2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671686 CVCL_A2H4 SEES3-1V human GLIS2, clone3 embryonic stem cell human CVCL_A2H4 CL:0000010 Transfected with: HGNC; 29450; GLIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671687 CVCL_A2H5 SEES3-1V human GPBP1L1, clone1 embryonic stem cell human CVCL_A2H5 CL:0000010 Transfected with: HGNC; 28843; GPBP1L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671688 CVCL_A2H6 SEES3-1V human GPBP1L1, clone2 embryonic stem cell human CVCL_A2H6 CL:0000010 Transfected with: HGNC; 28843; GPBP1L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671689 CVCL_A2H7 SEES3-1V human GPBP1L1, clone3 embryonic stem cell human CVCL_A2H7 CL:0000010 Transfected with: HGNC; 28843; GPBP1L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671690 CVCL_A2H8 SEES3-1V human GRHL2, clone1 embryonic stem cell human CVCL_A2H8 CL:0000010 Transfected with: HGNC; 2799; GRHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671691 CVCL_A2H9 SEES3-1V human GRHL2, clone2 embryonic stem cell human CVCL_A2H9 CL:0000010 Transfected with: HGNC; 2799; GRHL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671692 CVCL_A2J0 SEES3-1V human GTF2H4, clone1 embryonic stem cell human CVCL_A2J0 CL:0000010 Transfected with: HGNC; 4658; GTF2H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671693 CVCL_A2J1 SEES3-1V human GTF2H4, clone2 embryonic stem cell human CVCL_A2J1 CL:0000010 Transfected with: HGNC; 4658; GTF2H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671694 CVCL_A2J2 SEES3-1V human GTF2H4, clone3 embryonic stem cell human CVCL_A2J2 CL:0000010 Transfected with: HGNC; 4658; GTF2H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671695 CVCL_A2J3 SEES3-1V human GTF3C2, clone1 embryonic stem cell human CVCL_A2J3 CL:0000010 Transfected with: HGNC; 4665; GTF3C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671696 CVCL_A2J4 SEES3-1V human GTF3C2, clone2 embryonic stem cell human CVCL_A2J4 CL:0000010 Transfected with: HGNC; 4665; GTF3C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671697 CVCL_A2J5 SEES3-1V human GTF3C2, clone3 embryonic stem cell human CVCL_A2J5 CL:0000010 Transfected with: HGNC; 4665; GTF3C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671698 CVCL_A2I5 SEES3-1V human GTF2B, clone2 embryonic stem cell human CVCL_A2I5 CL:0000010 Transfected with: HGNC; 4648; GTF2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671699 CVCL_A2I6 SEES3-1V human GTF2B, clone3 embryonic stem cell human CVCL_A2I6 CL:0000010 Transfected with: HGNC; 4648; GTF2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671700 CVCL_A2I7 SEES3-1V human GTF2F1, clone1 embryonic stem cell human CVCL_A2I7 CL:0000010 Transfected with: HGNC; 4652; GTF2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671701 CVCL_A2I8 SEES3-1V human GTF2F1, clone2 embryonic stem cell human CVCL_A2I8 CL:0000010 Transfected with: HGNC; 4652; GTF2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671702 CVCL_A2I9 SEES3-1V human GTF2F1, clone3 embryonic stem cell human CVCL_A2I9 CL:0000010 Transfected with: HGNC; 4652; GTF2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671703 CVCL_A1U2 SEES3-1V human FGR, clone2 embryonic stem cell human CVCL_A1U2 CL:0000010 Transfected with: HGNC; 3697; FGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671704 CVCL_A1U3 SEES3-1V human FGR, clone3 embryonic stem cell human CVCL_A1U3 CL:0000010 Transfected with: HGNC; 3697; FGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671705 CVCL_A1U4 SEES3-1V human FIGLA, clone1 embryonic stem cell human CVCL_A1U4 CL:0000010 Transfected with: HGNC; 24669; FIGLA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671706 CVCL_A1U5 SEES3-1V human FIGLA, clone2 embryonic stem cell human CVCL_A1U5 CL:0000010 Transfected with: HGNC; 24669; FIGLA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671707 CVCL_A1U6 SEES3-1V human FIGLA, clone3 embryonic stem cell human CVCL_A1U6 CL:0000010 Transfected with: HGNC; 24669; FIGLA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671708 CVCL_A1U7 SEES3-1V human FLI1, clone1 embryonic stem cell human CVCL_A1U7 CL:0000010 Transfected with: HGNC; 3749; FLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671709 CVCL_A1U8 SEES3-1V human FLI1, clone2 embryonic stem cell human CVCL_A1U8 CL:0000010 Transfected with: HGNC; 3749; FLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671710 CVCL_A1U9 SEES3-1V human FLI1, clone3 embryonic stem cell human CVCL_A1U9 CL:0000010 Transfected with: HGNC; 3749; FLI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671711 CVCL_A1U0 SEES3-1V human FGFBP1, clone3 embryonic stem cell human CVCL_A1U0 CL:0000010 Transfected with: HGNC; 19695; FGFBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671712 CVCL_A1U1 SEES3-1V human FGR, clone1 embryonic stem cell human CVCL_A1U1 CL:0000010 Transfected with: HGNC; 3697; FGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671713 CVCL_A1V3 SEES3-1V human FOSB, clone1 embryonic stem cell human CVCL_A1V3 CL:0000010 Transfected with: HGNC; 3797; FOSB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671714 CVCL_A1V4 SEES3-1V human FOSB, clone2 embryonic stem cell human CVCL_A1V4 CL:0000010 Transfected with: HGNC; 3797; FOSB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671715 CVCL_A1V5 SEES3-1V human FOSB, clone3 embryonic stem cell human CVCL_A1V5 CL:0000010 Transfected with: HGNC; 3797; FOSB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671716 CVCL_A1V6 SEES3-1V human FOSL1, clone1 embryonic stem cell human CVCL_A1V6 CL:0000010 Transfected with: HGNC; 13718; FOSL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671717 CVCL_A1V7 SEES3-1V human FOSL1, clone2 embryonic stem cell human CVCL_A1V7 CL:0000010 Transfected with: HGNC; 13718; FOSL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671718 CVCL_A1V8 SEES3-1V human FOSL1, clone3 embryonic stem cell human CVCL_A1V8 CL:0000010 Transfected with: HGNC; 13718; FOSL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671719 CVCL_A1V9 SEES3-1V human FOSL2, clone1 embryonic stem cell human CVCL_A1V9 CL:0000010 Transfected with: HGNC; 3798; FOSL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671720 CVCL_A1V0 SEES3-1V human FOS, clone1 embryonic stem cell human CVCL_A1V0 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671721 CVCL_A1V1 SEES3-1V human FOS, clone2 embryonic stem cell human CVCL_A1V1 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671722 CVCL_A1V2 SEES3-1V human FOS, clone3 embryonic stem cell human CVCL_A1V2 CL:0000010 Transfected with: HGNC; 3796; FOS; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671723 CVCL_A1S8 SEES3-1V human FGF18, clone3 embryonic stem cell human CVCL_A1S8 CL:0000010 Transfected with: HGNC; 3674; FGF18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671724 CVCL_A1S9 SEES3-1V human FGF21, clone1 embryonic stem cell human CVCL_A1S9 CL:0000010 Transfected with: HGNC; 3678; FGF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671725 CVCL_A1S0 SEES3-1V human FGF1, clone1 embryonic stem cell human CVCL_A1S0 CL:0000010 Transfected with: HGNC; 3665; FGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671726 CVCL_A1S1 SEES3-1V human FGF1, clone2 embryonic stem cell human CVCL_A1S1 CL:0000010 Transfected with: HGNC; 3665; FGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671727 CVCL_A1S2 SEES3-1V human FGF1, clone3 embryonic stem cell human CVCL_A1S2 CL:0000010 Transfected with: HGNC; 3665; FGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671728 CVCL_A1S3 SEES3-1V human FGF10, clone1 embryonic stem cell human CVCL_A1S3 CL:0000010 Transfected with: HGNC; 3666; FGF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671729 CVCL_A1S4 SEES3-1V human FGF10, clone2 embryonic stem cell human CVCL_A1S4 CL:0000010 Transfected with: HGNC; 3666; FGF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671730 CVCL_A1S5 SEES3-1V human FGF10, clone3 embryonic stem cell human CVCL_A1S5 CL:0000010 Transfected with: HGNC; 3666; FGF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671731 CVCL_A1S6 SEES3-1V human FGF18, clone1 embryonic stem cell human CVCL_A1S6 CL:0000010 Transfected with: HGNC; 3674; FGF18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671732 CVCL_A1S7 SEES3-1V human FGF18, clone2 embryonic stem cell human CVCL_A1S7 CL:0000010 Transfected with: HGNC; 3674; FGF18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671733 CVCL_A1T9 SEES3-1V human FGFBP1, clone2 embryonic stem cell human CVCL_A1T9 CL:0000010 Transfected with: HGNC; 19695; FGFBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671734 CVCL_A1T1 SEES3-1V human FGF21, clone3 embryonic stem cell human CVCL_A1T1 CL:0000010 Transfected with: HGNC; 3678; FGF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671735 CVCL_A1T2 SEES3-1V human FGF4, clone1 embryonic stem cell human CVCL_A1T2 CL:0000010 Transfected with: HGNC; 3682; FGF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671736 CVCL_A1T3 SEES3-1V human FGF4, clone2 embryonic stem cell human CVCL_A1T3 CL:0000010 Transfected with: HGNC; 3682; FGF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671737 CVCL_A1T4 SEES3-1V human FGF4, clone3 embryonic stem cell human CVCL_A1T4 CL:0000010 Transfected with: HGNC; 3682; FGF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671738 CVCL_A1T5 SEES3-1V human FGF7, clone1 embryonic stem cell human CVCL_A1T5 CL:0000010 Transfected with: HGNC; 3685; FGF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671739 CVCL_A1T6 SEES3-1V human FGF7, clone2 embryonic stem cell human CVCL_A1T6 CL:0000010 Transfected with: HGNC; 3685; FGF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671740 CVCL_A1T7 SEES3-1V human FGF7, clone3 embryonic stem cell human CVCL_A1T7 CL:0000010 Transfected with: HGNC; 3685; FGF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671741 CVCL_A1T8 SEES3-1V human FGFBP1, clone1 embryonic stem cell human CVCL_A1T8 CL:0000010 Transfected with: HGNC; 19695; FGFBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671742 CVCL_A1T0 SEES3-1V human FGF21, clone2 embryonic stem cell human CVCL_A1T0 CL:0000010 Transfected with: HGNC; 3678; FGF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671743 CVCL_A1Q6 SEES3-1V human FAM48A, clone2 embryonic stem cell human CVCL_A1Q6 CL:0000010 Transfected with: HGNC; 20596; SUPT20H; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671744 CVCL_A1Q7 SEES3-1V human FAM48A, clone3 embryonic stem cell human CVCL_A1Q7 CL:0000010 Transfected with: HGNC; 20596; SUPT20H; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671745 CVCL_A1Q8 SEES3-1V human FBXO15, clone1 embryonic stem cell human CVCL_A1Q8 CL:0000010 Transfected with: HGNC; 13617; FBXO15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671746 CVCL_A1Q9 SEES3-1V human FBXO15, clone2 embryonic stem cell human CVCL_A1Q9 CL:0000010 Transfected with: HGNC; 13617; FBXO15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671747 CVCL_A1Q0 SEES3-1V human EYA1, clone2 embryonic stem cell human CVCL_A1Q0 CL:0000010 Transfected with: HGNC; 3519; EYA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671748 CVCL_A1Q1 SEES3-1V human EYA1, clone3 embryonic stem cell human CVCL_A1Q1 CL:0000010 Transfected with: HGNC; 3519; EYA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671749 CVCL_A1Q2 SEES3-1V human EZH2, clone1 embryonic stem cell human CVCL_A1Q2 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671750 CVCL_A1Q3 SEES3-1V human EZH2, clone2 embryonic stem cell human CVCL_A1Q3 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671751 CVCL_A1Q4 SEES3-1V human EZH2, clone3 embryonic stem cell human CVCL_A1Q4 CL:0000010 Transfected with: HGNC; 3527; EZH2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671752 CVCL_A1Q5 SEES3-1V human FAM48A, clone1 embryonic stem cell human CVCL_A1Q5 CL:0000010 Transfected with: HGNC; 20596; SUPT20H; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671753 CVCL_A1R7 SEES3-1V human FEV, clone1 embryonic stem cell human CVCL_A1R7 CL:0000010 Transfected with: HGNC; 18562; FEV; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671754 CVCL_A1R8 SEES3-1V human FEV, clone2 embryonic stem cell human CVCL_A1R8 CL:0000010 Transfected with: HGNC; 18562; FEV; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671755 CVCL_A1R9 SEES3-1V human FEV, clone3 embryonic stem cell human CVCL_A1R9 CL:0000010 Transfected with: HGNC; 18562; FEV; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671756 CVCL_A1R0 SEES3-1V human FBXO15, clone3 embryonic stem cell human CVCL_A1R0 CL:0000010 Transfected with: HGNC; 13617; FBXO15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671757 CVCL_A1R1 SEES3-1V human FEM1B, clone1 embryonic stem cell human CVCL_A1R1 CL:0000010 Transfected with: HGNC; 3649; FEM1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671758 CVCL_A1R2 SEES3-1V human FEM1B, clone2 embryonic stem cell human CVCL_A1R2 CL:0000010 Transfected with: HGNC; 3649; FEM1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671759 CVCL_A1R3 SEES3-1V human FEM1B, clone3 embryonic stem cell human CVCL_A1R3 CL:0000010 Transfected with: HGNC; 3649; FEM1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671760 CVCL_A1R4 SEES3-1V human FERD3L, clone1 embryonic stem cell human CVCL_A1R4 CL:0000010 Transfected with: HGNC; 16660; FERD3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671761 CVCL_A1R5 SEES3-1V human FERD3L, clone2 embryonic stem cell human CVCL_A1R5 CL:0000010 Transfected with: HGNC; 16660; FERD3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671762 CVCL_A1R6 SEES3-1V human FERD3L, clone3 embryonic stem cell human CVCL_A1R6 CL:0000010 Transfected with: HGNC; 16660; FERD3L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671763 CVCL_A1P5 SEES3-1V human ETV6, clone3 embryonic stem cell human CVCL_A1P5 CL:0000010 Transfected with: HGNC; 3495; ETV6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671764 CVCL_A1P6 SEES3-1V human EVX1, clone1 embryonic stem cell human CVCL_A1P6 CL:0000010 Transfected with: HGNC; 3506; EVX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671765 CVCL_A1P7 SEES3-1V human EVX1, clone2 embryonic stem cell human CVCL_A1P7 CL:0000010 Transfected with: HGNC; 3506; EVX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671766 CVCL_A1P8 SEES3-1V human EVX1, clone3 embryonic stem cell human CVCL_A1P8 CL:0000010 Transfected with: HGNC; 3506; EVX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671767 CVCL_A1P9 SEES3-1V human EYA1, clone1 embryonic stem cell human CVCL_A1P9 CL:0000010 Transfected with: HGNC; 3519; EYA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671768 CVCL_A1P0 SEES3-1V human ETV5, clone1 embryonic stem cell human CVCL_A1P0 CL:0000010 Transfected with: HGNC; 3494; ETV5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671769 CVCL_A1P1 SEES3-1V human ETV5, clone2 embryonic stem cell human CVCL_A1P1 CL:0000010 Transfected with: HGNC; 3494; ETV5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671770 CVCL_A1P2 SEES3-1V human ETV5, clone3 embryonic stem cell human CVCL_A1P2 CL:0000010 Transfected with: HGNC; 3494; ETV5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671771 CVCL_A1P3 SEES3-1V human ETV6, clone1 embryonic stem cell human CVCL_A1P3 CL:0000010 Transfected with: HGNC; 3495; ETV6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671772 CVCL_A1P4 SEES3-1V human ETV6, clone2 embryonic stem cell human CVCL_A1P4 CL:0000010 Transfected with: HGNC; 3495; ETV6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671773 CVCL_A1Y6 SEES3-1V human FOXD4L3, clone2 embryonic stem cell human CVCL_A1Y6 CL:0000010 Transfected with: HGNC; 18523; FOXD4L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671774 CVCL_A1Y7 SEES3-1V human FOXD4L3, clone3 embryonic stem cell human CVCL_A1Y7 CL:0000010 Transfected with: HGNC; 18523; FOXD4L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671775 CVCL_A1Y8 SEES3-1V human FOXD4L4, clone1 embryonic stem cell human CVCL_A1Y8 CL:0000010 Transfected with: HGNC; 23762; FOXD4L4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671776 CVCL_A1Y9 SEES3-1V human FOXD4L4, clone2 embryonic stem cell human CVCL_A1Y9 CL:0000010 Transfected with: HGNC; 23762; FOXD4L4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671777 CVCL_A1Y0 SEES3-1V human FOXD3, clone1 embryonic stem cell human CVCL_A1Y0 CL:0000010 Transfected with: HGNC; 3804; FOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671778 CVCL_A1Y1 SEES3-1V human FOXD3, clone2 embryonic stem cell human CVCL_A1Y1 CL:0000010 Transfected with: HGNC; 3804; FOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671779 CVCL_A1Y2 SEES3-1V human FOXD3, clone3 embryonic stem cell human CVCL_A1Y2 CL:0000010 Transfected with: HGNC; 3804; FOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671780 CVCL_A1Y3 SEES3-1V human FOXD4L1, clone1 embryonic stem cell human CVCL_A1Y3 CL:0000010 Transfected with: HGNC; 18521; FOXD4L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671781 CVCL_A1Y4 SEES3-1V human FOXD4L1, clone2 embryonic stem cell human CVCL_A1Y4 CL:0000010 Transfected with: HGNC; 18521; FOXD4L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671782 CVCL_A1Y5 SEES3-1V human FOXD4L3, clone1 embryonic stem cell human CVCL_A1Y5 CL:0000010 Transfected with: HGNC; 18523; FOXD4L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671783 CVCL_A1Z7 SEES3-1V human FOXF1, clone1 embryonic stem cell human CVCL_A1Z7 CL:0000010 Transfected with: HGNC; 3809; FOXF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671784 CVCL_A1Z8 SEES3-1V human FOXF1, clone2 embryonic stem cell human CVCL_A1Z8 CL:0000010 Transfected with: HGNC; 3809; FOXF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671785 CVCL_A1Z9 SEES3-1V human FOXF1, clone3 embryonic stem cell human CVCL_A1Z9 CL:0000010 Transfected with: HGNC; 3809; FOXF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671786 CVCL_A1Z0 SEES3-1V human FOXD4L4, clone3 embryonic stem cell human CVCL_A1Z0 CL:0000010 Transfected with: HGNC; 23762; FOXD4L4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671787 CVCL_A1Z1 SEES3-1V human FOXE1, clone1 embryonic stem cell human CVCL_A1Z1 CL:0000010 Transfected with: HGNC; 3806; FOXE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671788 CVCL_A1Z2 SEES3-1V human FOXE1, clone2 embryonic stem cell human CVCL_A1Z2 CL:0000010 Transfected with: HGNC; 3806; FOXE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671789 CVCL_A1Z3 SEES3-1V human FOXE1, clone3 embryonic stem cell human CVCL_A1Z3 CL:0000010 Transfected with: HGNC; 3806; FOXE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671790 CVCL_A1Z4 SEES3-1V human FOXE3, clone1 embryonic stem cell human CVCL_A1Z4 CL:0000010 Transfected with: HGNC; 3808; FOXE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671791 CVCL_A1Z5 SEES3-1V human FOXE3, clone2 embryonic stem cell human CVCL_A1Z5 CL:0000010 Transfected with: HGNC; 3808; FOXE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671792 CVCL_A1Z6 SEES3-1V human FOXE3, clone3 embryonic stem cell human CVCL_A1Z6 CL:0000010 Transfected with: HGNC; 3808; FOXE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671793 CVCL_A1W4 SEES3-1V human FOXA1, clone3 embryonic stem cell human CVCL_A1W4 CL:0000010 Transfected with: HGNC; 5021; FOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671794 CVCL_A1W5 SEES3-1V human FOXA2, clone1 embryonic stem cell human CVCL_A1W5 CL:0000010 Transfected with: HGNC; 5022; FOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671795 CVCL_A1W6 SEES3-1V human FOXA2, clone2 embryonic stem cell human CVCL_A1W6 CL:0000010 Transfected with: HGNC; 5022; FOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671796 CVCL_A1W7 SEES3-1V human FOXA2, clone3 embryonic stem cell human CVCL_A1W7 CL:0000010 Transfected with: HGNC; 5022; FOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671797 CVCL_A1W8 SEES3-1V human FOXB1, clone1 embryonic stem cell human CVCL_A1W8 CL:0000010 Transfected with: HGNC; 3799; FOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671798 CVCL_A1W9 SEES3-1V human FOXB1, clone2 embryonic stem cell human CVCL_A1W9 CL:0000010 Transfected with: HGNC; 3799; FOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671799 CVCL_A1W0 SEES3-1V human FOSL2, clone2 embryonic stem cell human CVCL_A1W0 CL:0000010 Transfected with: HGNC; 3798; FOSL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671800 CVCL_A1W1 SEES3-1V human FOSL2, clone3 embryonic stem cell human CVCL_A1W1 CL:0000010 Transfected with: HGNC; 3798; FOSL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671801 CVCL_A1W2 SEES3-1V human FOXA1, clone1 embryonic stem cell human CVCL_A1W2 CL:0000010 Transfected with: HGNC; 5021; FOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671802 CVCL_A1W3 SEES3-1V human FOXA1, clone2 embryonic stem cell human CVCL_A1W3 CL:0000010 Transfected with: HGNC; 5021; FOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671803 CVCL_A1X5 SEES3-1V human FOXC2, clone2 embryonic stem cell human CVCL_A1X5 CL:0000010 Transfected with: HGNC; 3801; FOXC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671804 CVCL_A1X6 SEES3-1V human FOXC2, clone3 embryonic stem cell human CVCL_A1X6 CL:0000010 Transfected with: HGNC; 3801; FOXC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671805 CVCL_A1X7 SEES3-1V human FOXD1, clone1 embryonic stem cell human CVCL_A1X7 CL:0000010 Transfected with: HGNC; 3802; FOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671806 CVCL_A1X8 SEES3-1V human FOXD1, clone2 embryonic stem cell human CVCL_A1X8 CL:0000010 Transfected with: HGNC; 3802; FOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671807 CVCL_A1X9 SEES3-1V human FOXD1, clone3 embryonic stem cell human CVCL_A1X9 CL:0000010 Transfected with: HGNC; 3802; FOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671808 CVCL_A1X0 SEES3-1V human FOXB1, clone3 embryonic stem cell human CVCL_A1X0 CL:0000010 Transfected with: HGNC; 3799; FOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671809 CVCL_A1X1 SEES3-1V human FOXC1, clone1 embryonic stem cell human CVCL_A1X1 CL:0000010 Transfected with: HGNC; 3800; FOXC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671810 CVCL_A1X2 SEES3-1V human FOXC1, clone2 embryonic stem cell human CVCL_A1X2 CL:0000010 Transfected with: HGNC; 3800; FOXC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671811 CVCL_A1X3 SEES3-1V human FOXC1, clone3 embryonic stem cell human CVCL_A1X3 CL:0000010 Transfected with: HGNC; 3800; FOXC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671812 CVCL_A1X4 SEES3-1V human FOXC2, clone1 embryonic stem cell human CVCL_A1X4 CL:0000010 Transfected with: HGNC; 3801; FOXC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671813 CVCL_A3I0 SEES3-1V human IRX2, clone1 embryonic stem cell human CVCL_A3I0 CL:0000010 Transfected with: HGNC; 14359; IRX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671814 CVCL_A3I1 SEES3-1V human IRX2, clone2 embryonic stem cell human CVCL_A3I1 CL:0000010 Transfected with: HGNC; 14359; IRX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671815 CVCL_A3I2 SEES3-1V human IRX2, clone3 embryonic stem cell human CVCL_A3I2 CL:0000010 Transfected with: HGNC; 14359; IRX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671816 CVCL_A3I3 SEES3-1V human ISL1, clone1 embryonic stem cell human CVCL_A3I3 CL:0000010 Transfected with: HGNC; 6132; ISL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671817 CVCL_A3H3 SEES3-1V human IRF8, clone3 embryonic stem cell human CVCL_A3H3 CL:0000010 Transfected with: HGNC; 5358; IRF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671818 CVCL_A3H4 SEES3-1V human IRF9, clone1 embryonic stem cell human CVCL_A3H4 CL:0000010 Transfected with: HGNC; 6131; IRF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671819 CVCL_A3H5 SEES3-1V human IRF9, clone2 embryonic stem cell human CVCL_A3H5 CL:0000010 Transfected with: HGNC; 6131; IRF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671820 CVCL_A3H6 SEES3-1V human IRF9, clone3 embryonic stem cell human CVCL_A3H6 CL:0000010 Transfected with: HGNC; 6131; IRF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671821 CVCL_A3H7 SEES3-1V human IRX1, clone1 embryonic stem cell human CVCL_A3H7 CL:0000010 Transfected with: HGNC; 14358; IRX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671822 CVCL_A3H8 SEES3-1V human IRX1, clone2 embryonic stem cell human CVCL_A3H8 CL:0000010 Transfected with: HGNC; 14358; IRX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671823 CVCL_A3H9 SEES3-1V human IRX1, clone3 embryonic stem cell human CVCL_A3H9 CL:0000010 Transfected with: HGNC; 14358; IRX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671824 CVCL_A3J0 SEES3-1V human JAG1, clone2 embryonic stem cell human CVCL_A3J0 CL:0000010 Transfected with: HGNC; 6188; JAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671825 CVCL_A3J1 SEES3-1V human JAG1, clone3 embryonic stem cell human CVCL_A3J1 CL:0000010 Transfected with: HGNC; 6188; JAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671826 CVCL_A3J2 SEES3-1V human JARID2, clone1 embryonic stem cell human CVCL_A3J2 CL:0000010 Transfected with: HGNC; 6196; JARID2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671827 CVCL_A3J3 SEES3-1V human JARID2, clone2 embryonic stem cell human CVCL_A3J3 CL:0000010 Transfected with: HGNC; 6196; JARID2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671828 CVCL_A3J4 SEES3-1V human JARID2, clone3 embryonic stem cell human CVCL_A3J4 CL:0000010 Transfected with: HGNC; 6196; JARID2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671829 CVCL_A3I4 SEES3-1V human ISL1, clone2 embryonic stem cell human CVCL_A3I4 CL:0000010 Transfected with: HGNC; 6132; ISL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671830 CVCL_A3I5 SEES3-1V human ISL1, clone3 embryonic stem cell human CVCL_A3I5 CL:0000010 Transfected with: HGNC; 6132; ISL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671831 CVCL_A3I6 SEES3-1V human ISL2, clone1 embryonic stem cell human CVCL_A3I6 CL:0000010 Transfected with: HGNC; 18524; ISL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671832 CVCL_A3I7 SEES3-1V human ISL2, clone2 embryonic stem cell human CVCL_A3I7 CL:0000010 Transfected with: HGNC; 18524; ISL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671833 CVCL_A3I8 SEES3-1V human ISL2, clone3 embryonic stem cell human CVCL_A3I8 CL:0000010 Transfected with: HGNC; 18524; ISL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671834 CVCL_A3I9 SEES3-1V human JAG1, clone1 embryonic stem cell human CVCL_A3I9 CL:0000010 Transfected with: HGNC; 6188; JAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671835 CVCL_A3G0 SEES3-1V human IRF4, clone2 embryonic stem cell human CVCL_A3G0 CL:0000010 Transfected with: HGNC; 6119; IRF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671836 CVCL_A3G1 SEES3-1V human IRF4, clone3 embryonic stem cell human CVCL_A3G1 CL:0000010 Transfected with: HGNC; 6119; IRF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671837 CVCL_A3F9 SEES3-1V human IRF4, clone1 embryonic stem cell human CVCL_A3F9 CL:0000010 Transfected with: HGNC; 6119; IRF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671838 CVCL_A3F1 SEES3-1V human IRF2, clone2 embryonic stem cell human CVCL_A3F1 CL:0000010 Transfected with: HGNC; 6117; IRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671839 CVCL_A3F2 SEES3-1V human IRF2, clone3 embryonic stem cell human CVCL_A3F2 CL:0000010 Transfected with: HGNC; 6117; IRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671840 CVCL_A3F3 SEES3-1V human IRF2BP2, clone1 embryonic stem cell human CVCL_A3F3 CL:0000010 Transfected with: HGNC; 21729; IRF2BP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671841 CVCL_A3F4 SEES3-1V human IRF2BP2, clone2 embryonic stem cell human CVCL_A3F4 CL:0000010 Transfected with: HGNC; 21729; IRF2BP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671842 CVCL_A3F5 SEES3-1V human IRF2BP2, clone3 embryonic stem cell human CVCL_A3F5 CL:0000010 Transfected with: HGNC; 21729; IRF2BP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671843 CVCL_A3F6 SEES3-1V human IRF3, clone1 embryonic stem cell human CVCL_A3F6 CL:0000010 Transfected with: HGNC; 6118; IRF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671844 CVCL_A3F7 SEES3-1V human IRF3, clone2 embryonic stem cell human CVCL_A3F7 CL:0000010 Transfected with: HGNC; 6118; IRF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671845 CVCL_A3F8 SEES3-1V human IRF3, clone3 embryonic stem cell human CVCL_A3F8 CL:0000010 Transfected with: HGNC; 6118; IRF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671846 CVCL_A3H0 SEES3-1V human IRF7, clone3 embryonic stem cell human CVCL_A3H0 CL:0000010 Transfected with: HGNC; 6122; IRF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671847 CVCL_A3H1 SEES3-1V human IRF8, clone1 embryonic stem cell human CVCL_A3H1 CL:0000010 Transfected with: HGNC; 5358; IRF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671848 CVCL_A3H2 SEES3-1V human IRF8, clone2 embryonic stem cell human CVCL_A3H2 CL:0000010 Transfected with: HGNC; 5358; IRF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671849 CVCL_A3G2 SEES3-1V human IRF5, clone1 embryonic stem cell human CVCL_A3G2 CL:0000010 Transfected with: HGNC; 6120; IRF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671850 CVCL_A3G3 SEES3-1V human IRF5, clone2 embryonic stem cell human CVCL_A3G3 CL:0000010 Transfected with: HGNC; 6120; IRF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671851 CVCL_A3G4 SEES3-1V human IRF5, clone3 embryonic stem cell human CVCL_A3G4 CL:0000010 Transfected with: HGNC; 6120; IRF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671852 CVCL_A3G5 SEES3-1V human IRF6, clone1 embryonic stem cell human CVCL_A3G5 CL:0000010 Transfected with: HGNC; 6121; IRF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671853 CVCL_A3G6 SEES3-1V human IRF6, clone2 embryonic stem cell human CVCL_A3G6 CL:0000010 Transfected with: HGNC; 6121; IRF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671854 CVCL_A3G7 SEES3-1V human IRF6, clone3 embryonic stem cell human CVCL_A3G7 CL:0000010 Transfected with: HGNC; 6121; IRF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671855 CVCL_A3G8 SEES3-1V human IRF7, clone1 embryonic stem cell human CVCL_A3G8 CL:0000010 Transfected with: HGNC; 6122; IRF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671856 CVCL_A3G9 SEES3-1V human IRF7, clone2 embryonic stem cell human CVCL_A3G9 CL:0000010 Transfected with: HGNC; 6122; IRF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671857 CVCL_A3D7 SEES3-1V human IGF1, clone3 embryonic stem cell human CVCL_A3D7 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671858 CVCL_A3D8 SEES3-1V human IKZF1, clone1 embryonic stem cell human CVCL_A3D8 CL:0000010 Transfected with: HGNC; 13176; IKZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671859 CVCL_A3D9 SEES3-1V human IKZF1, clone2 embryonic stem cell human CVCL_A3D9 CL:0000010 Transfected with: HGNC; 13176; IKZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671860 CVCL_A3D0 SEES3-1V human ID1, clone2 embryonic stem cell human CVCL_A3D0 CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671861 CVCL_A3D1 SEES3-1V human ID1, clone3 embryonic stem cell human CVCL_A3D1 CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671862 CVCL_A3D2 SEES3-1V human ID3, clone1 embryonic stem cell human CVCL_A3D2 CL:0000010 Transfected with: HGNC; 5362; ID3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671863 CVCL_A3D3 SEES3-1V human ID3, clone2 embryonic stem cell human CVCL_A3D3 CL:0000010 Transfected with: HGNC; 5362; ID3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671864 CVCL_A3D4 SEES3-1V human ID3, clone3 embryonic stem cell human CVCL_A3D4 CL:0000010 Transfected with: HGNC; 5362; ID3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671865 CVCL_A3D5 SEES3-1V human IGF1, clone1 embryonic stem cell human CVCL_A3D5 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671866 CVCL_A3D6 SEES3-1V human IGF1, clone2 embryonic stem cell human CVCL_A3D6 CL:0000010 Transfected with: HGNC; 5464; IGF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671867 CVCL_A3F0 SEES3-1V human IRF2, clone1 embryonic stem cell human CVCL_A3F0 CL:0000010 Transfected with: HGNC; 6117; IRF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671868 CVCL_A3E8 SEES3-1V human IRF1, clone2 embryonic stem cell human CVCL_A3E8 CL:0000010 Transfected with: HGNC; 6116; IRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671869 CVCL_A3E9 SEES3-1V human IRF1, clone3 embryonic stem cell human CVCL_A3E9 CL:0000010 Transfected with: HGNC; 6116; IRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671870 CVCL_A3E0 SEES3-1V human IKZF1, clone3 embryonic stem cell human CVCL_A3E0 CL:0000010 Transfected with: HGNC; 13176; IKZF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671871 CVCL_A3E1 SEES3-1V human IKZF5, clone1 embryonic stem cell human CVCL_A3E1 CL:0000010 Transfected with: HGNC; 14283; IKZF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671872 CVCL_A3E2 SEES3-1V human IKZF5, clone2 embryonic stem cell human CVCL_A3E2 CL:0000010 Transfected with: HGNC; 14283; IKZF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671873 CVCL_A3E3 SEES3-1V human IKZF5, clone3 embryonic stem cell human CVCL_A3E3 CL:0000010 Transfected with: HGNC; 14283; IKZF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671874 CVCL_A3E4 SEES3-1V human ILF2, clone1 embryonic stem cell human CVCL_A3E4 CL:0000010 Transfected with: HGNC; 6037; ILF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671875 CVCL_A3E5 SEES3-1V human ILF2, clone2 embryonic stem cell human CVCL_A3E5 CL:0000010 Transfected with: HGNC; 6037; ILF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671876 CVCL_A3E6 SEES3-1V human ILF2, clone3 embryonic stem cell human CVCL_A3E6 CL:0000010 Transfected with: HGNC; 6037; ILF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671877 CVCL_A3E7 SEES3-1V human IRF1, clone1 embryonic stem cell human CVCL_A3E7 CL:0000010 Transfected with: HGNC; 6116; IRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671878 CVCL_A3B5 SEES3-1V human HOXD3, clone2 embryonic stem cell human CVCL_A3B5 CL:0000010 Transfected with: HGNC; 5137; HOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671879 CVCL_A3B6 SEES3-1V human HOXD3, clone3 embryonic stem cell human CVCL_A3B6 CL:0000010 Transfected with: HGNC; 5137; HOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671880 CVCL_A3B7 SEES3-1V human HSF1, clone1 embryonic stem cell human CVCL_A3B7 CL:0000010 Transfected with: HGNC; 5224; HSF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671881 CVCL_A3B8 SEES3-1V human HSF1, clone2 embryonic stem cell human CVCL_A3B8 CL:0000010 Transfected with: HGNC; 5224; HSF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671882 CVCL_A3B9 SEES3-1V human HSF1, clone3 embryonic stem cell human CVCL_A3B9 CL:0000010 Transfected with: HGNC; 5224; HSF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671883 CVCL_A3B0 SEES3-1V human HOXD10, clone3 embryonic stem cell human CVCL_A3B0 CL:0000010 Transfected with: HGNC; 5133; HOXD10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671884 CVCL_A3B1 SEES3-1V human HOXD13, clone1 embryonic stem cell human CVCL_A3B1 CL:0000010 Transfected with: HGNC; 5136; HOXD13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671885 CVCL_A3B2 SEES3-1V human HOXD13, clone2 embryonic stem cell human CVCL_A3B2 CL:0000010 Transfected with: HGNC; 5136; HOXD13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671886 CVCL_A3B3 SEES3-1V human HOXD13, clone3 embryonic stem cell human CVCL_A3B3 CL:0000010 Transfected with: HGNC; 5136; HOXD13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671887 CVCL_A3B4 SEES3-1V human HOXD3, clone1 embryonic stem cell human CVCL_A3B4 CL:0000010 Transfected with: HGNC; 5137; HOXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671888 CVCL_A3C6 SEES3-1V human HSFY2, clone1 embryonic stem cell human CVCL_A3C6 CL:0000010 Transfected with: HGNC; 23950; HSFY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671889 CVCL_A3C7 SEES3-1V human HSFY2, clone2 embryonic stem cell human CVCL_A3C7 CL:0000010 Transfected with: HGNC; 23950; HSFY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671890 CVCL_A3C8 SEES3-1V human HSFY2, clone3 embryonic stem cell human CVCL_A3C8 CL:0000010 Transfected with: HGNC; 23950; HSFY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671891 CVCL_A3C9 SEES3-1V human ID1, clone1 embryonic stem cell human CVCL_A3C9 CL:0000010 Transfected with: HGNC; 5360; ID1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671892 CVCL_A3C0 SEES3-1V human HSF4, clone1 embryonic stem cell human CVCL_A3C0 CL:0000010 Transfected with: HGNC; 5227; HSF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671893 CVCL_A3C1 SEES3-1V human HSF4, clone2 embryonic stem cell human CVCL_A3C1 CL:0000010 Transfected with: HGNC; 5227; HSF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671894 CVCL_A3C2 SEES3-1V human HSF4, clone3 embryonic stem cell human CVCL_A3C2 CL:0000010 Transfected with: HGNC; 5227; HSF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671895 CVCL_A3C3 SEES3-1V human HSFX1, clone1 embryonic stem cell human CVCL_A3C3 CL:0000010 Transfected with: HGNC; 29603; HSFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671896 CVCL_A3C4 SEES3-1V human HSFX1, clone2 embryonic stem cell human CVCL_A3C4 CL:0000010 Transfected with: HGNC; 29603; HSFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671897 CVCL_A3C5 SEES3-1V human HSFX1, clone3 embryonic stem cell human CVCL_A3C5 CL:0000010 Transfected with: HGNC; 29603; HSFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671898 CVCL_A3Q4 SEES3-1V human KLF2, clone3 embryonic stem cell human CVCL_A3Q4 CL:0000010 Transfected with: HGNC; 6347; KLF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671899 CVCL_A3Q5 SEES3-1V human KLF3, clone1 embryonic stem cell human CVCL_A3Q5 CL:0000010 Transfected with: HGNC; 16516; KLF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671900 CVCL_A3Q6 SEES3-1V human KLF3, clone2 embryonic stem cell human CVCL_A3Q6 CL:0000010 Transfected with: HGNC; 16516; KLF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671901 CVCL_A3Q7 SEES3-1V human KLF3, clone3 embryonic stem cell human CVCL_A3Q7 CL:0000010 Transfected with: HGNC; 16516; KLF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671902 CVCL_A3Q8 SEES3-1V human KLF4, clone1 embryonic stem cell human CVCL_A3Q8 CL:0000010 Transfected with: HGNC; 6348; KLF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671903 CVCL_A3Q9 SEES3-1V human KLF4, clone2 embryonic stem cell human CVCL_A3Q9 CL:0000010 Transfected with: HGNC; 6348; KLF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671904 CVCL_A3Q0 SEES3-1V human KLF16, clone2 embryonic stem cell human CVCL_A3Q0 CL:0000010 Transfected with: HGNC; 16857; KLF16; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671905 CVCL_A3Q1 SEES3-1V human KLF16, clone3 embryonic stem cell human CVCL_A3Q1 CL:0000010 Transfected with: HGNC; 16857; KLF16; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671906 CVCL_A3Q2 SEES3-1V human KLF2, clone1 embryonic stem cell human CVCL_A3Q2 CL:0000010 Transfected with: HGNC; 6347; KLF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671907 CVCL_A3Q3 SEES3-1V human KLF2, clone2 embryonic stem cell human CVCL_A3Q3 CL:0000010 Transfected with: HGNC; 6347; KLF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671908 CVCL_A3R5 SEES3-1V human KLF6, clone2 embryonic stem cell human CVCL_A3R5 CL:0000010 Transfected with: HGNC; 2235; KLF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671909 CVCL_A3R6 SEES3-1V human KLF6, clone3 embryonic stem cell human CVCL_A3R6 CL:0000010 Transfected with: HGNC; 2235; KLF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671910 CVCL_A3R7 SEES3-1V human KLF7, clone1 embryonic stem cell human CVCL_A3R7 CL:0000010 Transfected with: HGNC; 6350; KLF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671911 CVCL_A3R8 SEES3-1V human KLF7, clone2 embryonic stem cell human CVCL_A3R8 CL:0000010 Transfected with: HGNC; 6350; KLF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671912 CVCL_A3R9 SEES3-1V human KLF7, clone3 embryonic stem cell human CVCL_A3R9 CL:0000010 Transfected with: HGNC; 6350; KLF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671913 CVCL_A3R0 SEES3-1V human KLF4, clone3 embryonic stem cell human CVCL_A3R0 CL:0000010 Transfected with: HGNC; 6348; KLF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671914 CVCL_A3R1 SEES3-1V human KLF5, clone1 embryonic stem cell human CVCL_A3R1 CL:0000010 Transfected with: HGNC; 6349; KLF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671915 CVCL_A3R2 SEES3-1V human KLF5, clone2 embryonic stem cell human CVCL_A3R2 CL:0000010 Transfected with: HGNC; 6349; KLF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671916 CVCL_A3R3 SEES3-1V human KLF5, clone3 embryonic stem cell human CVCL_A3R3 CL:0000010 Transfected with: HGNC; 6349; KLF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671917 CVCL_A3R4 SEES3-1V human KLF6, clone1 embryonic stem cell human CVCL_A3R4 CL:0000010 Transfected with: HGNC; 2235; KLF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671918 CVCL_A3N9 SEES3-1V human KLF11, clone3 embryonic stem cell human CVCL_A3N9 CL:0000010 Transfected with: HGNC; 11811; KLF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671919 CVCL_A3P3 SEES3-1V human KLF14, clone1 embryonic stem cell human CVCL_A3P3 CL:0000010 Transfected with: HGNC; 23025; KLF14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671920 CVCL_A3P4 SEES3-1V human KLF14, clone2 embryonic stem cell human CVCL_A3P4 CL:0000010 Transfected with: HGNC; 23025; KLF14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671921 CVCL_A3P5 SEES3-1V human KLF14, clone3 embryonic stem cell human CVCL_A3P5 CL:0000010 Transfected with: HGNC; 23025; KLF14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671922 CVCL_A3P6 SEES3-1V human KLF15, clone1 embryonic stem cell human CVCL_A3P6 CL:0000010 Transfected with: HGNC; 14536; KLF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671923 CVCL_A3P7 SEES3-1V human KLF15, clone2 embryonic stem cell human CVCL_A3P7 CL:0000010 Transfected with: HGNC; 14536; KLF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671924 CVCL_A3P8 SEES3-1V human KLF15, clone3 embryonic stem cell human CVCL_A3P8 CL:0000010 Transfected with: HGNC; 14536; KLF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671925 CVCL_A3P9 SEES3-1V human KLF16, clone1 embryonic stem cell human CVCL_A3P9 CL:0000010 Transfected with: HGNC; 16857; KLF16; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671926 CVCL_A3P0 SEES3-1V human KLF12, clone1 embryonic stem cell human CVCL_A3P0 CL:0000010 Transfected with: HGNC; 6346; KLF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671927 CVCL_A3P1 SEES3-1V human KLF12, clone2 embryonic stem cell human CVCL_A3P1 CL:0000010 Transfected with: HGNC; 6346; KLF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671928 CVCL_A3P2 SEES3-1V human KLF12, clone3 embryonic stem cell human CVCL_A3P2 CL:0000010 Transfected with: HGNC; 6346; KLF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671929 CVCL_A3M0 SEES3-1V human KDM4C, clone2 embryonic stem cell human CVCL_A3M0 CL:0000010 Transfected with: HGNC; 17071; KDM4C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671930 CVCL_A3M1 SEES3-1V human KDM4C, clone3 embryonic stem cell human CVCL_A3M1 CL:0000010 Transfected with: HGNC; 17071; KDM4C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671931 CVCL_A3M2 SEES3-1V human KDM5A, clone1 embryonic stem cell human CVCL_A3M2 CL:0000010 Transfected with: HGNC; 9886; KDM5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671932 CVCL_A3M3 SEES3-1V human KDM5A, clone2 embryonic stem cell human CVCL_A3M3 CL:0000010 Transfected with: HGNC; 9886; KDM5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671933 CVCL_A3M4 SEES3-1V human KDM5A, clone3 embryonic stem cell human CVCL_A3M4 CL:0000010 Transfected with: HGNC; 9886; KDM5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671934 CVCL_A3M5 SEES3-1V human KDM5B, clone1 embryonic stem cell human CVCL_A3M5 CL:0000010 Transfected with: HGNC; 18039; KDM5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671935 CVCL_A3M6 SEES3-1V human KDM5B, clone2 embryonic stem cell human CVCL_A3M6 CL:0000010 Transfected with: HGNC; 18039; KDM5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671936 CVCL_A3M7 SEES3-1V human KDM5B, clone3 embryonic stem cell human CVCL_A3M7 CL:0000010 Transfected with: HGNC; 18039; KDM5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671937 CVCL_A3L7 SEES3-1V human KDM3A, clone2 embryonic stem cell human CVCL_A3L7 CL:0000010 Transfected with: HGNC; 20815; KDM3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671938 CVCL_A3L8 SEES3-1V human KDM3A, clone3 embryonic stem cell human CVCL_A3L8 CL:0000010 Transfected with: HGNC; 20815; KDM3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671939 CVCL_A3L9 SEES3-1V human KDM4C, clone1 embryonic stem cell human CVCL_A3L9 CL:0000010 Transfected with: HGNC; 17071; KDM4C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671940 CVCL_A3N1 SEES3-1V human KLF1, clone1 embryonic stem cell human CVCL_A3N1 CL:0000010 Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671941 CVCL_A3N2 SEES3-1V human KLF1, clone2 embryonic stem cell human CVCL_A3N2 CL:0000010 Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671942 CVCL_A3N3 SEES3-1V human KLF1, clone3 embryonic stem cell human CVCL_A3N3 CL:0000010 Transfected with: HGNC; 6345; KLF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671943 CVCL_A3N4 SEES3-1V human KLF10, clone1 embryonic stem cell human CVCL_A3N4 CL:0000010 Transfected with: HGNC; 11810; KLF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671944 CVCL_A3N5 SEES3-1V human KLF10, clone2 embryonic stem cell human CVCL_A3N5 CL:0000010 Transfected with: HGNC; 11810; KLF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671945 CVCL_A3N6 SEES3-1V human KLF10, clone3 embryonic stem cell human CVCL_A3N6 CL:0000010 Transfected with: HGNC; 11810; KLF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671946 CVCL_A3N7 SEES3-1V human KLF11, clone1 embryonic stem cell human CVCL_A3N7 CL:0000010 Transfected with: HGNC; 11811; KLF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671947 CVCL_A3N8 SEES3-1V human KLF11, clone2 embryonic stem cell human CVCL_A3N8 CL:0000010 Transfected with: HGNC; 11811; KLF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671948 CVCL_A3N0 SEES3-1V human KITLG, clone3 embryonic stem cell human CVCL_A3N0 CL:0000010 Transfected with: HGNC; 6343; KITLG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671949 CVCL_A3M8 SEES3-1V human KITLG, clone1 embryonic stem cell human CVCL_A3M8 CL:0000010 Transfected with: HGNC; 6343; KITLG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671950 CVCL_A3M9 SEES3-1V human KITLG, clone2 embryonic stem cell human CVCL_A3M9 CL:0000010 Transfected with: HGNC; 6343; KITLG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671951 CVCL_A3K0 SEES3-1V human JUNB, clone3 embryonic stem cell human CVCL_A3K0 CL:0000010 Transfected with: HGNC; 6205; JUNB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671952 CVCL_A3K1 SEES3-1V human JUND, clone1 embryonic stem cell human CVCL_A3K1 CL:0000010 Transfected with: HGNC; 6206; JUND; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671953 CVCL_A3K2 SEES3-1V human JUND, clone2 embryonic stem cell human CVCL_A3K2 CL:0000010 Transfected with: HGNC; 6206; JUND; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671954 CVCL_A3K3 SEES3-1V human JUND, clone3 embryonic stem cell human CVCL_A3K3 CL:0000010 Transfected with: HGNC; 6206; JUND; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671955 CVCL_A3K4 SEES3-1V human KAT2A, clone1 embryonic stem cell human CVCL_A3K4 CL:0000010 Transfected with: HGNC; 4201; KAT2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671956 CVCL_A3K5 SEES3-1V human KAT2A, clone2 embryonic stem cell human CVCL_A3K5 CL:0000010 Transfected with: HGNC; 4201; KAT2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671957 CVCL_A3J5 SEES3-1V human JUN, clone1 embryonic stem cell human CVCL_A3J5 CL:0000010 Transfected with: HGNC; 6204; JUN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671958 CVCL_A3J6 SEES3-1V human JUN, clone2 embryonic stem cell human CVCL_A3J6 CL:0000010 Transfected with: HGNC; 6204; JUN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671959 CVCL_A3J7 SEES3-1V human JUN, clone3 embryonic stem cell human CVCL_A3J7 CL:0000010 Transfected with: HGNC; 6204; JUN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671960 CVCL_A3J8 SEES3-1V human JUNB, clone1 embryonic stem cell human CVCL_A3J8 CL:0000010 Transfected with: HGNC; 6205; JUNB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671961 CVCL_A3J9 SEES3-1V human JUNB, clone2 embryonic stem cell human CVCL_A3J9 CL:0000010 Transfected with: HGNC; 6205; JUNB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671962 CVCL_A3L0 SEES3-1V human KAT8, clone1 embryonic stem cell human CVCL_A3L0 CL:0000010 Transfected with: HGNC; 17933; KAT8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671963 CVCL_A3L1 SEES3-1V human KAT8, clone2 embryonic stem cell human CVCL_A3L1 CL:0000010 Transfected with: HGNC; 17933; KAT8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671964 CVCL_A3L2 SEES3-1V human KAT8, clone3 embryonic stem cell human CVCL_A3L2 CL:0000010 Transfected with: HGNC; 17933; KAT8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671965 CVCL_A3L3 SEES3-1V human KDM1A, clone1 embryonic stem cell human CVCL_A3L3 CL:0000010 Transfected with: HGNC; 29079; KDM1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671966 CVCL_A3L4 SEES3-1V human KDM1A, clone2 embryonic stem cell human CVCL_A3L4 CL:0000010 Transfected with: HGNC; 29079; KDM1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671967 CVCL_A3L5 SEES3-1V human KDM1A, clone3 embryonic stem cell human CVCL_A3L5 CL:0000010 Transfected with: HGNC; 29079; KDM1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671968 CVCL_A3L6 SEES3-1V human KDM3A, clone1 embryonic stem cell human CVCL_A3L6 CL:0000010 Transfected with: HGNC; 20815; KDM3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671969 CVCL_A3K6 SEES3-1V human KAT2A, clone3 embryonic stem cell human CVCL_A3K6 CL:0000010 Transfected with: HGNC; 4201; KAT2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671970 CVCL_A3K7 SEES3-1V human KAT6A, clone1 embryonic stem cell human CVCL_A3K7 CL:0000010 Transfected with: HGNC; 13013; KAT6A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671971 CVCL_A3K8 SEES3-1V human KAT6A, clone2 embryonic stem cell human CVCL_A3K8 CL:0000010 Transfected with: HGNC; 13013; KAT6A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671972 CVCL_A3K9 SEES3-1V human KAT6A, clone3 embryonic stem cell human CVCL_A3K9 CL:0000010 Transfected with: HGNC; 13013; KAT6A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671973 CVCL_A2W3 SEES3-1V human HOXA1, clone3 embryonic stem cell human CVCL_A2W3 CL:0000010 Transfected with: HGNC; 5099; HOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671974 CVCL_A2W4 SEES3-1V human HOXA10, clone1 embryonic stem cell human CVCL_A2W4 CL:0000010 Transfected with: HGNC; 5100; HOXA10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671975 CVCL_A2W5 SEES3-1V human HOXA10, clone2 embryonic stem cell human CVCL_A2W5 CL:0000010 Transfected with: HGNC; 5100; HOXA10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671976 CVCL_A2W6 SEES3-1V human HOXA10, clone3 embryonic stem cell human CVCL_A2W6 CL:0000010 Transfected with: HGNC; 5100; HOXA10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671977 CVCL_A2W7 SEES3-1V human HOXA2, clone1 embryonic stem cell human CVCL_A2W7 CL:0000010 Transfected with: HGNC; 5103; HOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671978 CVCL_A2W8 SEES3-1V human HOXA2, clone2 embryonic stem cell human CVCL_A2W8 CL:0000010 Transfected with: HGNC; 5103; HOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671979 CVCL_A2W9 SEES3-1V human HOXA2, clone3 embryonic stem cell human CVCL_A2W9 CL:0000010 Transfected with: HGNC; 5103; HOXA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671980 CVCL_A2W0 SEES3-1V human HOPX, clone3 embryonic stem cell human CVCL_A2W0 CL:0000010 Transfected with: HGNC; 24961; HOPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671981 CVCL_A2W1 SEES3-1V human HOXA1, clone1 embryonic stem cell human CVCL_A2W1 CL:0000010 Transfected with: HGNC; 5099; HOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671982 CVCL_A2W2 SEES3-1V human HOXA1, clone2 embryonic stem cell human CVCL_A2W2 CL:0000010 Transfected with: HGNC; 5099; HOXA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671983 CVCL_A2X4 SEES3-1V human HOXA5, clone2 embryonic stem cell human CVCL_A2X4 CL:0000010 Transfected with: HGNC; 5106; HOXA5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671984 CVCL_A2X5 SEES3-1V human HOXA5, clone3 embryonic stem cell human CVCL_A2X5 CL:0000010 Transfected with: HGNC; 5106; HOXA5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671985 CVCL_A2X6 SEES3-1V human HOXA7, clone1 embryonic stem cell human CVCL_A2X6 CL:0000010 Transfected with: HGNC; 5108; HOXA7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671986 CVCL_A2X7 SEES3-1V human HOXA7, clone2 embryonic stem cell human CVCL_A2X7 CL:0000010 Transfected with: HGNC; 5108; HOXA7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671987 CVCL_A2X8 SEES3-1V human HOXA7, clone3 embryonic stem cell human CVCL_A2X8 CL:0000010 Transfected with: HGNC; 5108; HOXA7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671988 CVCL_A2X9 SEES3-1V human HOXA9, clone1 embryonic stem cell human CVCL_A2X9 CL:0000010 Transfected with: HGNC; 5109; HOXA9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671989 CVCL_A2X0 SEES3-1V human HOXA3, clone1 embryonic stem cell human CVCL_A2X0 CL:0000010 Transfected with: HGNC; 5104; HOXA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671990 CVCL_A2X1 SEES3-1V human HOXA3, clone2 embryonic stem cell human CVCL_A2X1 CL:0000010 Transfected with: HGNC; 5104; HOXA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671991 CVCL_A2X2 SEES3-1V human HOXA3, clone3 embryonic stem cell human CVCL_A2X2 CL:0000010 Transfected with: HGNC; 5104; HOXA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671992 CVCL_A2X3 SEES3-1V human HOXA5, clone1 embryonic stem cell human CVCL_A2X3 CL:0000010 Transfected with: HGNC; 5106; HOXA5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671993 CVCL_A2U9 SEES3-1V human HNF4A, clone1 embryonic stem cell human CVCL_A2U9 CL:0000010 Transfected with: HGNC; 5024; HNF4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671994 CVCL_A2U1 SEES3-1V human HMX1, clone1 embryonic stem cell human CVCL_A2U1 CL:0000010 Transfected with: HGNC; 5017; HMX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671995 CVCL_A2U2 SEES3-1V human HMX1, clone2 embryonic stem cell human CVCL_A2U2 CL:0000010 Transfected with: HGNC; 5017; HMX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671996 CVCL_A2U3 SEES3-1V human HMX1, clone3 embryonic stem cell human CVCL_A2U3 CL:0000010 Transfected with: HGNC; 5017; HMX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671997 CVCL_A2U4 SEES3-1V human HMX2, clone1 embryonic stem cell human CVCL_A2U4 CL:0000010 Transfected with: HGNC; 5018; HMX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671998 CVCL_A2U5 SEES3-1V human HMX2, clone2 embryonic stem cell human CVCL_A2U5 CL:0000010 Transfected with: HGNC; 5018; HMX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35671999 CVCL_A2U6 SEES3-1V human HNF1A, clone1 embryonic stem cell human CVCL_A2U6 CL:0000010 Transfected with: HGNC; 11621; HNF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672000 CVCL_A2U7 SEES3-1V human HNF1A, clone2 embryonic stem cell human CVCL_A2U7 CL:0000010 Transfected with: HGNC; 11621; HNF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672001 CVCL_A2U8 SEES3-1V human HNF1A, clone3 embryonic stem cell human CVCL_A2U8 CL:0000010 Transfected with: HGNC; 11621; HNF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672002 CVCL_A2U0 SEES3-1V human HMGN3, clone3 embryonic stem cell human CVCL_A2U0 CL:0000010 Transfected with: HGNC; 12312; HMGN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672003 CVCL_A2V2 SEES3-1V human HNF4G, clone1 embryonic stem cell human CVCL_A2V2 CL:0000010 Transfected with: HGNC; 5026; HNF4G; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672004 CVCL_A2V3 SEES3-1V human HNF4G, clone2 embryonic stem cell human CVCL_A2V3 CL:0000010 Transfected with: HGNC; 5026; HNF4G; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672005 CVCL_A2V4 SEES3-1V human HNF4G, clone3 embryonic stem cell human CVCL_A2V4 CL:0000010 Transfected with: HGNC; 5026; HNF4G; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672006 CVCL_A2V5 SEES3-1V human HNRNPD, clone1 embryonic stem cell human CVCL_A2V5 CL:0000010 Transfected with: HGNC; 5036; HNRNPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672007 CVCL_A2V6 SEES3-1V human HNRNPD, clone2 embryonic stem cell human CVCL_A2V6 CL:0000010 Transfected with: HGNC; 5036; HNRNPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672008 CVCL_A2V7 SEES3-1V human HNRNPD, clone3 embryonic stem cell human CVCL_A2V7 CL:0000010 Transfected with: HGNC; 5036; HNRNPD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672009 CVCL_A2V8 SEES3-1V human HOPX, clone1 embryonic stem cell human CVCL_A2V8 CL:0000010 Transfected with: HGNC; 24961; HOPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672010 CVCL_A2V9 SEES3-1V human HOPX, clone2 embryonic stem cell human CVCL_A2V9 CL:0000010 Transfected with: HGNC; 24961; HOPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672011 CVCL_A2V0 SEES3-1V human HNF4A, clone2 embryonic stem cell human CVCL_A2V0 CL:0000010 Transfected with: HGNC; 5024; HNF4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672012 CVCL_A2V1 SEES3-1V human HNF4A, clone3 embryonic stem cell human CVCL_A2V1 CL:0000010 Transfected with: HGNC; 5024; HNF4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672013 CVCL_A2S7 SEES3-1V human HMGA2, clone2 embryonic stem cell human CVCL_A2S7 CL:0000010 Transfected with: HGNC; 5009; HMGA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672014 CVCL_A2S8 SEES3-1V human HMGA2, clone3 embryonic stem cell human CVCL_A2S8 CL:0000010 Transfected with: HGNC; 5009; HMGA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672015 CVCL_A2S9 SEES3-1V human HMGB1, clone1 embryonic stem cell human CVCL_A2S9 CL:0000010 Transfected with: HGNC; 4983; HMGB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672016 CVCL_A2S0 SEES3-1V human HMG2L1, clone1 embryonic stem cell human CVCL_A2S0 CL:0000010 Transfected with: HGNC; 5003; HMGXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672017 CVCL_A2S1 SEES3-1V human HMG2L1, clone2 embryonic stem cell human CVCL_A2S1 CL:0000010 Transfected with: HGNC; 5003; HMGXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672018 CVCL_A2S2 SEES3-1V human HMG2L1, clone3 embryonic stem cell human CVCL_A2S2 CL:0000010 Transfected with: HGNC; 5003; HMGXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672019 CVCL_A2S3 SEES3-1V human HMGA1, clone1 embryonic stem cell human CVCL_A2S3 CL:0000010 Transfected with: HGNC; 5010; HMGA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672020 CVCL_A2S4 SEES3-1V human HMGA1, clone2 embryonic stem cell human CVCL_A2S4 CL:0000010 Transfected with: HGNC; 5010; HMGA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672021 CVCL_A2S5 SEES3-1V human HMGA1, clone3 embryonic stem cell human CVCL_A2S5 CL:0000010 Transfected with: HGNC; 5010; HMGA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672022 CVCL_A2S6 SEES3-1V human HMGA2, clone1 embryonic stem cell human CVCL_A2S6 CL:0000010 Transfected with: HGNC; 5009; HMGA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672023 CVCL_A2T8 SEES3-1V human HMGN3, clone1 embryonic stem cell human CVCL_A2T8 CL:0000010 Transfected with: HGNC; 12312; HMGN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672024 CVCL_A2T9 SEES3-1V human HMGN3, clone2 embryonic stem cell human CVCL_A2T9 CL:0000010 Transfected with: HGNC; 12312; HMGN3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672025 CVCL_A2T0 SEES3-1V human HMGB1, clone2 embryonic stem cell human CVCL_A2T0 CL:0000010 Transfected with: HGNC; 4983; HMGB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672026 CVCL_A2T1 SEES3-1V human HMGB1, clone3 embryonic stem cell human CVCL_A2T1 CL:0000010 Transfected with: HGNC; 4983; HMGB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672027 CVCL_A2T2 SEES3-1V human HMGB2, clone1 embryonic stem cell human CVCL_A2T2 CL:0000010 Transfected with: HGNC; 5000; HMGB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672028 CVCL_A2T3 SEES3-1V human HMGB2, clone2 embryonic stem cell human CVCL_A2T3 CL:0000010 Transfected with: HGNC; 5000; HMGB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672029 CVCL_A2T4 SEES3-1V human HMGB2, clone3 embryonic stem cell human CVCL_A2T4 CL:0000010 Transfected with: HGNC; 5000; HMGB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672030 CVCL_A2T5 SEES3-1V human HMGN1, clone1 embryonic stem cell human CVCL_A2T5 CL:0000010 Transfected with: HGNC; 4984; HMGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672031 CVCL_A2T6 SEES3-1V human HMGN1, clone2 embryonic stem cell human CVCL_A2T6 CL:0000010 Transfected with: HGNC; 4984; HMGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672032 CVCL_A2T7 SEES3-1V human HMGN1, clone3 embryonic stem cell human CVCL_A2T7 CL:0000010 Transfected with: HGNC; 4984; HMGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672033 CVCL_A2Q5 SEES3-1V human HIC2, clone1 embryonic stem cell human CVCL_A2Q5 CL:0000010 Transfected with: HGNC; 18595; HIC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672034 CVCL_A2Q6 SEES3-1V human HIC2, clone2 embryonic stem cell human CVCL_A2Q6 CL:0000010 Transfected with: HGNC; 18595; HIC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672035 CVCL_A2Q7 SEES3-1V human HIC2, clone3 embryonic stem cell human CVCL_A2Q7 CL:0000010 Transfected with: HGNC; 18595; HIC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672036 CVCL_A2Q8 SEES3-1V human HIST2H2AC, clone1 embryonic stem cell human CVCL_A2Q8 CL:0000010 Transfected with: HGNC; 4738; H2AC20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672037 CVCL_A2Q9 SEES3-1V human HIST2H2AC, clone2 embryonic stem cell human CVCL_A2Q9 CL:0000010 Transfected with: HGNC; 4738; H2AC20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672038 CVCL_A2Q0 SEES3-1V human HGF, clone2 embryonic stem cell human CVCL_A2Q0 CL:0000010 Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672039 CVCL_A2Q1 SEES3-1V human HGF, clone3 embryonic stem cell human CVCL_A2Q1 CL:0000010 Transfected with: HGNC; 4893; HGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672040 CVCL_A2Q2 SEES3-1V human HHEX, clone1 embryonic stem cell human CVCL_A2Q2 CL:0000010 Transfected with: HGNC; 4901; HHEX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672041 CVCL_A2Q3 SEES3-1V human HHEX, clone2 embryonic stem cell human CVCL_A2Q3 CL:0000010 Transfected with: HGNC; 4901; HHEX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672042 CVCL_A2Q4 SEES3-1V human HHEX, clone3 embryonic stem cell human CVCL_A2Q4 CL:0000010 Transfected with: HGNC; 4901; HHEX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672043 CVCL_A2R6 SEES3-1V human HIST2H4A, clone3 embryonic stem cell human CVCL_A2R6 CL:0000010 Transfected with: HGNC; 4794; H4C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672044 CVCL_A2R7 SEES3-1V human HLX, clone1 embryonic stem cell human CVCL_A2R7 CL:0000010 Transfected with: HGNC; 4978; HLX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672045 CVCL_A2R8 SEES3-1V human HLX, clone2 embryonic stem cell human CVCL_A2R8 CL:0000010 Transfected with: HGNC; 4978; HLX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672046 CVCL_A2R9 SEES3-1V human HLX, clone3 embryonic stem cell human CVCL_A2R9 CL:0000010 Transfected with: HGNC; 4978; HLX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672047 CVCL_A2R0 SEES3-1V human HIST2H2AC, clone3 embryonic stem cell human CVCL_A2R0 CL:0000010 Transfected with: HGNC; 4738; H2AC20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672048 CVCL_A2R1 SEES3-1V human HIST2H3C, clone1 embryonic stem cell human CVCL_A2R1 CL:0000010 Transfected with: HGNC; 20503; H3C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672049 CVCL_A2R2 SEES3-1V human HIST2H3C, clone2 embryonic stem cell human CVCL_A2R2 CL:0000010 Transfected with: HGNC; 20503; H3C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672050 CVCL_A2R3 SEES3-1V human HIST2H3C, clone3 embryonic stem cell human CVCL_A2R3 CL:0000010 Transfected with: HGNC; 20503; H3C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672051 CVCL_A2R4 SEES3-1V human HIST2H4A, clone1 embryonic stem cell human CVCL_A2R4 CL:0000010 Transfected with: HGNC; 4794; H4C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672052 CVCL_A2R5 SEES3-1V human HIST2H4A, clone2 embryonic stem cell human CVCL_A2R5 CL:0000010 Transfected with: HGNC; 4794; H4C14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672053 CVCL_A3A4 SEES3-1V human HOXC9, clone3 embryonic stem cell human CVCL_A3A4 CL:0000010 Transfected with: HGNC; 5130; HOXC9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672054 CVCL_A3A5 SEES3-1V human HOXD1, clone1 embryonic stem cell human CVCL_A3A5 CL:0000010 Transfected with: HGNC; 5132; HOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672055 CVCL_A3A6 SEES3-1V human HOXD1, clone2 embryonic stem cell human CVCL_A3A6 CL:0000010 Transfected with: HGNC; 5132; HOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672056 CVCL_A3A7 SEES3-1V human HOXD1, clone3 embryonic stem cell human CVCL_A3A7 CL:0000010 Transfected with: HGNC; 5132; HOXD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672057 CVCL_A3A8 SEES3-1V human HOXD10, clone1 embryonic stem cell human CVCL_A3A8 CL:0000010 Transfected with: HGNC; 5133; HOXD10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672058 CVCL_A3A9 SEES3-1V human HOXD10, clone2 embryonic stem cell human CVCL_A3A9 CL:0000010 Transfected with: HGNC; 5133; HOXD10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672059 CVCL_A3A0 SEES3-1V human HOXC8, clone2 embryonic stem cell human CVCL_A3A0 CL:0000010 Transfected with: HGNC; 5129; HOXC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672060 CVCL_A3A1 SEES3-1V human HOXC8, clone3 embryonic stem cell human CVCL_A3A1 CL:0000010 Transfected with: HGNC; 5129; HOXC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672061 CVCL_A3A2 SEES3-1V human HOXC9, clone1 embryonic stem cell human CVCL_A3A2 CL:0000010 Transfected with: HGNC; 5130; HOXC9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672062 CVCL_A3A3 SEES3-1V human HOXC9, clone2 embryonic stem cell human CVCL_A3A3 CL:0000010 Transfected with: HGNC; 5130; HOXC9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672063 CVCL_A2Y5 SEES3-1V human HOXB3, clone2 embryonic stem cell human CVCL_A2Y5 CL:0000010 Transfected with: HGNC; 5114; HOXB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672064 CVCL_A2Y6 SEES3-1V human HOXB3, clone3 embryonic stem cell human CVCL_A2Y6 CL:0000010 Transfected with: HGNC; 5114; HOXB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672065 CVCL_A2Y7 SEES3-1V human HOXB4, clone1 embryonic stem cell human CVCL_A2Y7 CL:0000010 Transfected with: HGNC; 5115; HOXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672066 CVCL_A2Y8 SEES3-1V human HOXB4, clone2 embryonic stem cell human CVCL_A2Y8 CL:0000010 Transfected with: HGNC; 5115; HOXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672067 CVCL_A2Y9 SEES3-1V human HOXB4, clone3 embryonic stem cell human CVCL_A2Y9 CL:0000010 Transfected with: HGNC; 5115; HOXB4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672068 CVCL_A2Y0 SEES3-1V human HOXA9, clone2 embryonic stem cell human CVCL_A2Y0 CL:0000010 Transfected with: HGNC; 5109; HOXA9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672069 CVCL_A2Y1 SEES3-1V human HOXB1, clone1 embryonic stem cell human CVCL_A2Y1 CL:0000010 Transfected with: HGNC; 5111; HOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672070 CVCL_A2Y2 SEES3-1V human HOXB1, clone2 embryonic stem cell human CVCL_A2Y2 CL:0000010 Transfected with: HGNC; 5111; HOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672071 CVCL_A2Y3 SEES3-1V human HOXB1, clone3 embryonic stem cell human CVCL_A2Y3 CL:0000010 Transfected with: HGNC; 5111; HOXB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672072 CVCL_A2Y4 SEES3-1V human HOXB3, clone1 embryonic stem cell human CVCL_A2Y4 CL:0000010 Transfected with: HGNC; 5114; HOXB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672073 CVCL_A2Z6 SEES3-1V human HOXC5, clone1 embryonic stem cell human CVCL_A2Z6 CL:0000010 Transfected with: HGNC; 5127; HOXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672074 CVCL_A2Z7 SEES3-1V human HOXC5, clone2 embryonic stem cell human CVCL_A2Z7 CL:0000010 Transfected with: HGNC; 5127; HOXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672075 CVCL_A2Z8 SEES3-1V human HOXC5, clone3 embryonic stem cell human CVCL_A2Z8 CL:0000010 Transfected with: HGNC; 5127; HOXC5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672076 CVCL_A2Z9 SEES3-1V human HOXC8, clone1 embryonic stem cell human CVCL_A2Z9 CL:0000010 Transfected with: HGNC; 5129; HOXC8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672077 CVCL_A2Z0 SEES3-1V human HOXB6, clone1 embryonic stem cell human CVCL_A2Z0 CL:0000010 Transfected with: HGNC; 5117; HOXB6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672078 CVCL_A2Z1 SEES3-1V human HOXB6, clone2 embryonic stem cell human CVCL_A2Z1 CL:0000010 Transfected with: HGNC; 5117; HOXB6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672079 CVCL_A2Z2 SEES3-1V human HOXB6, clone3 embryonic stem cell human CVCL_A2Z2 CL:0000010 Transfected with: HGNC; 5117; HOXB6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672080 CVCL_A2Z3 SEES3-1V human HOXC13, clone1 embryonic stem cell human CVCL_A2Z3 CL:0000010 Transfected with: HGNC; 5125; HOXC13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672081 CVCL_A2Z4 SEES3-1V human HOXC13, clone2 embryonic stem cell human CVCL_A2Z4 CL:0000010 Transfected with: HGNC; 5125; HOXC13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672082 CVCL_A2Z5 SEES3-1V human HOXC13, clone3 embryonic stem cell human CVCL_A2Z5 CL:0000010 Transfected with: HGNC; 5125; HOXC13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672083 CVCL_A8M0 SEES3-1V human TBX5, clone2 embryonic stem cell human CVCL_A8M0 CL:0000010 Transfected with: HGNC; 11604; TBX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672084 CVCL_A8M2 SEES3-1V human TBX6, clone1 embryonic stem cell human CVCL_A8M2 CL:0000010 Transfected with: HGNC; 11605; TBX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672085 CVCL_A8M1 SEES3-1V human TBX5, clone3 embryonic stem cell human CVCL_A8M1 CL:0000010 Transfected with: HGNC; 11604; TBX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672086 CVCL_A8L3 SEES3-1V human ZSCAN5A, clone2 embryonic stem cell human CVCL_A8L3 CL:0000010 Transfected with: HGNC; 23710; ZSCAN5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672087 CVCL_A8L2 SEES3-1V human ZSCAN5A, clone1 embryonic stem cell human CVCL_A8L2 CL:0000010 Transfected with: HGNC; 23710; ZSCAN5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672088 CVCL_A8L5 SEES3-1V human TBX3, clone3 embryonic stem cell human CVCL_A8L5 CL:0000010 Transfected with: HGNC; 11602; TBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672089 CVCL_A8L4 SEES3-1V human ZSCAN5A, clone3 embryonic stem cell human CVCL_A8L4 CL:0000010 Transfected with: HGNC; 23710; ZSCAN5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P06492; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672090 CVCL_A8L7 SEES3-1V human TBX4, clone2 embryonic stem cell human CVCL_A8L7 CL:0000010 Transfected with: HGNC; 11603; TBX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672091 CVCL_A8L6 SEES3-1V human TBX4, clone1 embryonic stem cell human CVCL_A8L6 CL:0000010 Transfected with: HGNC; 11603; TBX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672092 CVCL_A8L9 SEES3-1V human TBX5, clone1 embryonic stem cell human CVCL_A8L9 CL:0000010 Transfected with: HGNC; 11604; TBX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672093 CVCL_A8L8 SEES3-1V human TBX4, clone3 embryonic stem cell human CVCL_A8L8 CL:0000010 Transfected with: HGNC; 11603; TBX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672094 CVCL_A8M4 SEES3-1V human TBX6, clone3 embryonic stem cell human CVCL_A8M4 CL:0000010 Transfected with: HGNC; 11605; TBX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672095 CVCL_A8M3 SEES3-1V human TBX6, clone2 embryonic stem cell human CVCL_A8M3 CL:0000010 Transfected with: HGNC; 11605; TBX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672096 CVCL_A8B9 SEES3-1V human ZFAND3, clone3 embryonic stem cell human CVCL_A8B9 CL:0000010 Transfected with: HGNC; 18019; ZFAND3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672097 CVCL_A8B8 SEES3-1V human ZFAND3, clone2 embryonic stem cell human CVCL_A8B8 CL:0000010 Transfected with: HGNC; 18019; ZFAND3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672098 CVCL_A8B1 SEES3-1V human ZBTB7A, clone1 embryonic stem cell human CVCL_A8B1 CL:0000010 Transfected with: HGNC; 18078; ZBTB7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672099 CVCL_A8B0 SEES3-1V human ZBTB45, clone3 embryonic stem cell human CVCL_A8B0 CL:0000010 Transfected with: HGNC; 23715; ZBTB45; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672100 CVCL_A8B3 SEES3-1V human ZBTB7A, clone3 embryonic stem cell human CVCL_A8B3 CL:0000010 Transfected with: HGNC; 18078; ZBTB7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672101 CVCL_A8B2 SEES3-1V human ZBTB7A, clone2 embryonic stem cell human CVCL_A8B2 CL:0000010 Transfected with: HGNC; 18078; ZBTB7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672102 CVCL_A8B5 SEES3-1V human ZC3H11A, clone2 embryonic stem cell human CVCL_A8B5 CL:0000010 Transfected with: HGNC; 29093; ZC3H11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672103 CVCL_A8B4 SEES3-1V human ZC3H11A, clone1 embryonic stem cell human CVCL_A8B4 CL:0000010 Transfected with: HGNC; 29093; ZC3H11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672104 CVCL_A8B7 SEES3-1V human ZFAND3, clone1 embryonic stem cell human CVCL_A8B7 CL:0000010 Transfected with: HGNC; 18019; ZFAND3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672105 CVCL_A8B6 SEES3-1V human ZC3H11A, clone3 embryonic stem cell human CVCL_A8B6 CL:0000010 Transfected with: HGNC; 29093; ZC3H11A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672106 CVCL_A8C9 SEES3-1V human ZKSCAN1, clone1 embryonic stem cell human CVCL_A8C9 CL:0000010 Transfected with: HGNC; 13101; ZKSCAN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672107 CVCL_A8C2 SEES3-1V human ZFP57, clone3 embryonic stem cell human CVCL_A8C2 CL:0000010 Transfected with: HGNC; 18791; ZFP57; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672108 CVCL_A8C1 SEES3-1V human ZFP57, clone2 embryonic stem cell human CVCL_A8C1 CL:0000010 Transfected with: HGNC; 18791; ZFP57; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672109 CVCL_A8C4 SEES3-1V human ZIC1, clone2 embryonic stem cell human CVCL_A8C4 CL:0000010 Transfected with: HGNC; 12872; ZIC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672110 CVCL_A8C3 SEES3-1V human ZIC1, clone1 embryonic stem cell human CVCL_A8C3 CL:0000010 Transfected with: HGNC; 12872; ZIC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672111 CVCL_A8C6 SEES3-1V human ZIC3, clone1 embryonic stem cell human CVCL_A8C6 CL:0000010 Transfected with: HGNC; 12874; ZIC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672112 CVCL_A8C5 SEES3-1V human ZIC1, clone3 embryonic stem cell human CVCL_A8C5 CL:0000010 Transfected with: HGNC; 12872; ZIC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672113 CVCL_A8C8 SEES3-1V human ZIC3, clone3 embryonic stem cell human CVCL_A8C8 CL:0000010 Transfected with: HGNC; 12874; ZIC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672114 CVCL_A8C7 SEES3-1V human ZIC3, clone2 embryonic stem cell human CVCL_A8C7 CL:0000010 Transfected with: HGNC; 12874; ZIC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672115 CVCL_A8C0 SEES3-1V human ZFP57, clone1 embryonic stem cell human CVCL_A8C0 CL:0000010 Transfected with: HGNC; 18791; ZFP57; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672116 CVCL_A8A8 SEES3-1V human ZBTB45, clone1 embryonic stem cell human CVCL_A8A8 CL:0000010 Transfected with: HGNC; 23715; ZBTB45; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672117 CVCL_A8A7 SEES3-1V human ZBTB44, clone3 embryonic stem cell human CVCL_A8A7 CL:0000010 Transfected with: HGNC; 25001; ZBTB44; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672118 CVCL_A8A9 SEES3-1V human ZBTB45, clone2 embryonic stem cell human CVCL_A8A9 CL:0000010 Transfected with: HGNC; 23715; ZBTB45; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672119 CVCL_A8A0 SEES3-1V human ZBTB3, clone2 embryonic stem cell human CVCL_A8A0 CL:0000010 Transfected with: HGNC; 22918; ZBTB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672120 CVCL_A8A2 SEES3-1V human ZBTB33, clone1 embryonic stem cell human CVCL_A8A2 CL:0000010 Transfected with: HGNC; 16682; ZBTB33; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672121 CVCL_A8A1 SEES3-1V human ZBTB3, clone3 embryonic stem cell human CVCL_A8A1 CL:0000010 Transfected with: HGNC; 22918; ZBTB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672122 CVCL_A8A4 SEES3-1V human ZBTB33, clone3 embryonic stem cell human CVCL_A8A4 CL:0000010 Transfected with: HGNC; 16682; ZBTB33; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672123 CVCL_A8A3 SEES3-1V human ZBTB33, clone2 embryonic stem cell human CVCL_A8A3 CL:0000010 Transfected with: HGNC; 16682; ZBTB33; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672124 CVCL_A8A6 SEES3-1V human ZBTB44, clone2 embryonic stem cell human CVCL_A8A6 CL:0000010 Transfected with: HGNC; 25001; ZBTB44; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672125 CVCL_A8A5 SEES3-1V human ZBTB44, clone1 embryonic stem cell human CVCL_A8A5 CL:0000010 Transfected with: HGNC; 25001; ZBTB44; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672126 CVCL_A8K0 SEES3-1V human ZNF713, clone1 embryonic stem cell human CVCL_A8K0 CL:0000010 Transfected with: HGNC; 22043; ZNF713; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672127 CVCL_A8J9 SEES3-1V human ZNF706, clone3 embryonic stem cell human CVCL_A8J9 CL:0000010 Transfected with: HGNC; 24992; ZNF706; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672128 CVCL_A8J8 SEES3-1V human ZNF706, clone2 embryonic stem cell human CVCL_A8J8 CL:0000010 Transfected with: HGNC; 24992; ZNF706; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672129 CVCL_A8J1 SEES3-1V human ZNF646, clone1 embryonic stem cell human CVCL_A8J1 CL:0000010 Transfected with: HGNC; 29004; ZNF646; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672130 CVCL_A8J0 SEES3-1V human ZNF559, clone2 embryonic stem cell human CVCL_A8J0 CL:0000010 Transfected with: HGNC; 28197; ZNF559; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672131 CVCL_A8J3 SEES3-1V human ZNF646, clone3 embryonic stem cell human CVCL_A8J3 CL:0000010 Transfected with: HGNC; 29004; ZNF646; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672132 CVCL_A8J2 SEES3-1V human ZNF646, clone2 embryonic stem cell human CVCL_A8J2 CL:0000010 Transfected with: HGNC; 29004; ZNF646; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672133 CVCL_A8J5 SEES3-1V human ZNF70, clone2 embryonic stem cell human CVCL_A8J5 CL:0000010 Transfected with: HGNC; 13140; ZNF70; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672134 CVCL_A8J4 SEES3-1V human ZNF70, clone1 embryonic stem cell human CVCL_A8J4 CL:0000010 Transfected with: HGNC; 13140; ZNF70; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672135 CVCL_A8J7 SEES3-1V human ZNF706, clone1 embryonic stem cell human CVCL_A8J7 CL:0000010 Transfected with: HGNC; 24992; ZNF706; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672136 CVCL_A8J6 SEES3-1V human ZNF70, clone3 embryonic stem cell human CVCL_A8J6 CL:0000010 Transfected with: HGNC; 13140; ZNF70; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672137 CVCL_A8L1 SEES3-1V human ZSCAN4, clone3 embryonic stem cell human CVCL_A8L1 CL:0000010 Transfected with: HGNC; 23709; ZSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672138 CVCL_A8L0 SEES3-1V human ZSCAN4, clone2 embryonic stem cell human CVCL_A8L0 CL:0000010 Transfected with: HGNC; 23709; ZSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672139 CVCL_A8K9 SEES3-1V human ZSCAN4, clone1 embryonic stem cell human CVCL_A8K9 CL:0000010 Transfected with: HGNC; 23709; ZSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672140 CVCL_A8K2 SEES3-1V human ZNF713, clone3 embryonic stem cell human CVCL_A8K2 CL:0000010 Transfected with: HGNC; 22043; ZNF713; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672141 CVCL_A8K1 SEES3-1V human ZNF713, clone2 embryonic stem cell human CVCL_A8K1 CL:0000010 Transfected with: HGNC; 22043; ZNF713; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672142 CVCL_A8K4 SEES3-1V human ZNF74, clone2 embryonic stem cell human CVCL_A8K4 CL:0000010 Transfected with: HGNC; 13144; ZNF74; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672143 CVCL_A8K3 SEES3-1V human ZNF74, clone1 embryonic stem cell human CVCL_A8K3 CL:0000010 Transfected with: HGNC; 13144; ZNF74; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672144 CVCL_A8K6 SEES3-1V human ZNF780A, clone1 embryonic stem cell human CVCL_A8K6 CL:0000010 Transfected with: HGNC; 27603; ZNF780A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672145 CVCL_A8K5 SEES3-1V human ZNF74, clone3 embryonic stem cell human CVCL_A8K5 CL:0000010 Transfected with: HGNC; 13144; ZNF74; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672146 CVCL_A8K8 SEES3-1V human ZNF780A, clone3 embryonic stem cell human CVCL_A8K8 CL:0000010 Transfected with: HGNC; 27603; ZNF780A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672147 CVCL_A8K7 SEES3-1V human ZNF780A, clone2 embryonic stem cell human CVCL_A8K7 CL:0000010 Transfected with: HGNC; 27603; ZNF780A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672148 CVCL_A8H7 SEES3-1V human ZNF462, clone1 embryonic stem cell human CVCL_A8H7 CL:0000010 Transfected with: HGNC; 21684; ZNF462; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672149 CVCL_A8H6 SEES3-1V human ZNF426, clone3 embryonic stem cell human CVCL_A8H6 CL:0000010 Transfected with: HGNC; 20725; ZNF426; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672150 CVCL_A8H9 SEES3-1V human ZNF462, clone3 embryonic stem cell human CVCL_A8H9 CL:0000010 Transfected with: HGNC; 21684; ZNF462; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672151 CVCL_A8H8 SEES3-1V human ZNF462, clone2 embryonic stem cell human CVCL_A8H8 CL:0000010 Transfected with: HGNC; 21684; ZNF462; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672152 CVCL_A8H1 SEES3-1V human ZNF384, clone1 embryonic stem cell human CVCL_A8H1 CL:0000010 Transfected with: HGNC; 11955; ZNF384; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672153 CVCL_A8H0 SEES3-1V human ZNF382, clone3 embryonic stem cell human CVCL_A8H0 CL:0000010 Transfected with: HGNC; 17409; ZNF382; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672154 CVCL_A8H3 SEES3-1V human ZNF384, clone3 embryonic stem cell human CVCL_A8H3 CL:0000010 Transfected with: HGNC; 11955; ZNF384; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672155 CVCL_A8H2 SEES3-1V human ZNF384, clone2 embryonic stem cell human CVCL_A8H2 CL:0000010 Transfected with: HGNC; 11955; ZNF384; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672156 CVCL_A8H5 SEES3-1V human ZNF426, clone2 embryonic stem cell human CVCL_A8H5 CL:0000010 Transfected with: HGNC; 20725; ZNF426; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672157 CVCL_A8H4 SEES3-1V human ZNF426, clone1 embryonic stem cell human CVCL_A8H4 CL:0000010 Transfected with: HGNC; 20725; ZNF426; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672158 CVCL_A8I8 SEES3-1V human ZNF521, clone3 embryonic stem cell human CVCL_A8I8 CL:0000010 Transfected with: HGNC; 24605; ZNF521; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672159 CVCL_A8I7 SEES3-1V human ZNF521, clone2 embryonic stem cell human CVCL_A8I7 CL:0000010 Transfected with: HGNC; 24605; ZNF521; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672160 CVCL_A8I9 SEES3-1V human ZNF559, clone1 embryonic stem cell human CVCL_A8I9 CL:0000010 Transfected with: HGNC; 28197; ZNF559; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672161 CVCL_A8I0 SEES3-1V human ZNF480, clone1 embryonic stem cell human CVCL_A8I0 CL:0000010 Transfected with: HGNC; 23305; ZNF480; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672162 CVCL_A8I2 SEES3-1V human ZNF480, clone3 embryonic stem cell human CVCL_A8I2 CL:0000010 Transfected with: HGNC; 23305; ZNF480; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672163 CVCL_A8I1 SEES3-1V human ZNF480, clone2 embryonic stem cell human CVCL_A8I1 CL:0000010 Transfected with: HGNC; 23305; ZNF480; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672164 CVCL_A8I4 SEES3-1V human ZNF496, clone2 embryonic stem cell human CVCL_A8I4 CL:0000010 Transfected with: HGNC; 23713; ZNF496; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672165 CVCL_A8I3 SEES3-1V human ZNF496, clone1 embryonic stem cell human CVCL_A8I3 CL:0000010 Transfected with: HGNC; 23713; ZNF496; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672166 CVCL_A8I6 SEES3-1V human ZNF521, clone1 embryonic stem cell human CVCL_A8I6 CL:0000010 Transfected with: HGNC; 24605; ZNF521; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672167 CVCL_A8I5 SEES3-1V human ZNF496, clone3 embryonic stem cell human CVCL_A8I5 CL:0000010 Transfected with: HGNC; 23713; ZNF496; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672168 CVCL_A8F5 SEES3-1V human ZNF217, clone3 embryonic stem cell human CVCL_A8F5 CL:0000010 Transfected with: HGNC; 13009; ZNF217; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672169 CVCL_A8F4 SEES3-1V human ZNF217, clone2 embryonic stem cell human CVCL_A8F4 CL:0000010 Transfected with: HGNC; 13009; ZNF217; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672170 CVCL_A8F7 SEES3-1V human ZNF263, clone2 embryonic stem cell human CVCL_A8F7 CL:0000010 Transfected with: HGNC; 13056; ZNF263; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672171 CVCL_A8F6 SEES3-1V human ZNF263, clone1 embryonic stem cell human CVCL_A8F6 CL:0000010 Transfected with: HGNC; 13056; ZNF263; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672172 CVCL_A8F9 SEES3-1V human ZNF274, clone1 embryonic stem cell human CVCL_A8F9 CL:0000010 Transfected with: HGNC; 13068; ZNF274; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672173 CVCL_A8F8 SEES3-1V human ZNF263, clone3 embryonic stem cell human CVCL_A8F8 CL:0000010 Transfected with: HGNC; 13056; ZNF263; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672174 CVCL_A8F1 SEES3-1V human ZNF121, clone2 embryonic stem cell human CVCL_A8F1 CL:0000010 Transfected with: HGNC; 12904; ZNF121; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672175 CVCL_A8F0 SEES3-1V human ZNF121, clone1 embryonic stem cell human CVCL_A8F0 CL:0000010 Transfected with: HGNC; 12904; ZNF121; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672176 CVCL_A8F3 SEES3-1V human ZNF217, clone1 embryonic stem cell human CVCL_A8F3 CL:0000010 Transfected with: HGNC; 13009; ZNF217; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672177 CVCL_A8F2 SEES3-1V human ZNF121, clone3 embryonic stem cell human CVCL_A8F2 CL:0000010 Transfected with: HGNC; 12904; ZNF121; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672178 CVCL_A8G6 SEES3-1V human ZNF281, clone2 embryonic stem cell human CVCL_A8G6 CL:0000010 Transfected with: HGNC; 13075; ZNF281; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672179 CVCL_A8G5 SEES3-1V human ZNF281, clone1 embryonic stem cell human CVCL_A8G5 CL:0000010 Transfected with: HGNC; 13075; ZNF281; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672180 CVCL_A8G8 SEES3-1V human ZNF382, clone1 embryonic stem cell human CVCL_A8G8 CL:0000010 Transfected with: HGNC; 17409; ZNF382; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672181 CVCL_A8G7 SEES3-1V human ZNF281, clone3 embryonic stem cell human CVCL_A8G7 CL:0000010 Transfected with: HGNC; 13075; ZNF281; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672182 CVCL_A8G9 SEES3-1V human ZNF382, clone2 embryonic stem cell human CVCL_A8G9 CL:0000010 Transfected with: HGNC; 17409; ZNF382; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672183 CVCL_A8G0 SEES3-1V human ZNF274, clone2 embryonic stem cell human CVCL_A8G0 CL:0000010 Transfected with: HGNC; 13068; ZNF274; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672184 CVCL_A8G2 SEES3-1V human ZNF280B, clone1 embryonic stem cell human CVCL_A8G2 CL:0000010 Transfected with: HGNC; 23022; ZNF280B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672185 CVCL_A8G1 SEES3-1V human ZNF274, clone3 embryonic stem cell human CVCL_A8G1 CL:0000010 Transfected with: HGNC; 13068; ZNF274; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672186 CVCL_A8G4 SEES3-1V human ZNF280B, clone3 embryonic stem cell human CVCL_A8G4 CL:0000010 Transfected with: HGNC; 23022; ZNF280B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672187 CVCL_A8G3 SEES3-1V human ZNF280B, clone2 embryonic stem cell human CVCL_A8G3 CL:0000010 Transfected with: HGNC; 23022; ZNF280B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672188 CVCL_A8D3 SEES3-1V human ZKSCAN4, clone2 embryonic stem cell human CVCL_A8D3 CL:0000010 Transfected with: HGNC; 13854; ZKSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672189 CVCL_A8D2 SEES3-1V human ZKSCAN4, clone1 embryonic stem cell human CVCL_A8D2 CL:0000010 Transfected with: HGNC; 13854; ZKSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672190 CVCL_A8D5 SEES3-1V human ZMAT4, clone1 embryonic stem cell human CVCL_A8D5 CL:0000010 Transfected with: HGNC; 25844; ZMAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672191 CVCL_A8D4 SEES3-1V human ZKSCAN4, clone3 embryonic stem cell human CVCL_A8D4 CL:0000010 Transfected with: HGNC; 13854; ZKSCAN4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672192 CVCL_A8D7 SEES3-1V human ZMAT4, clone3 embryonic stem cell human CVCL_A8D7 CL:0000010 Transfected with: HGNC; 25844; ZMAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672193 CVCL_A8D6 SEES3-1V human ZMAT4, clone2 embryonic stem cell human CVCL_A8D6 CL:0000010 Transfected with: HGNC; 25844; ZMAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672194 CVCL_A8D9 SEES3-1V human ZMAT5, clone2 embryonic stem cell human CVCL_A8D9 CL:0000010 Transfected with: HGNC; 28046; ZMAT5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672195 CVCL_A8D8 SEES3-1V human ZMAT5, clone1 embryonic stem cell human CVCL_A8D8 CL:0000010 Transfected with: HGNC; 28046; ZMAT5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672196 CVCL_A8D1 SEES3-1V human ZKSCAN1, clone3 embryonic stem cell human CVCL_A8D1 CL:0000010 Transfected with: HGNC; 13101; ZKSCAN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672197 CVCL_A8D0 SEES3-1V human ZKSCAN1, clone2 embryonic stem cell human CVCL_A8D0 CL:0000010 Transfected with: HGNC; 13101; ZKSCAN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672198 CVCL_A8E4 SEES3-1V human ZMYND11, clone1 embryonic stem cell human CVCL_A8E4 CL:0000010 Transfected with: HGNC; 16966; ZMYND11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672199 CVCL_A8E3 SEES3-1V human ZMYND10, clone3 embryonic stem cell human CVCL_A8E3 CL:0000010 Transfected with: HGNC; 19412; ZMYND10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672200 CVCL_A8E6 SEES3-1V human ZMYND11, clone3 embryonic stem cell human CVCL_A8E6 CL:0000010 Transfected with: HGNC; 16966; ZMYND11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672201 CVCL_A8E5 SEES3-1V human ZMYND11, clone2 embryonic stem cell human CVCL_A8E5 CL:0000010 Transfected with: HGNC; 16966; ZMYND11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672202 CVCL_A8E8 SEES3-1V human ZMYND12, clone2 embryonic stem cell human CVCL_A8E8 CL:0000010 Transfected with: HGNC; 21192; ZMYND12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672203 CVCL_A8E7 SEES3-1V human ZMYND12, clone1 embryonic stem cell human CVCL_A8E7 CL:0000010 Transfected with: HGNC; 21192; ZMYND12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672204 CVCL_A8E9 SEES3-1V human ZMYND12, clone3 embryonic stem cell human CVCL_A8E9 CL:0000010 Transfected with: HGNC; 21192; ZMYND12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672205 CVCL_A8E0 SEES3-1V human ZMAT5, clone3 embryonic stem cell human CVCL_A8E0 CL:0000010 Transfected with: HGNC; 28046; ZMAT5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672206 CVCL_A8E2 SEES3-1V human ZMYND10, clone2 embryonic stem cell human CVCL_A8E2 CL:0000010 Transfected with: HGNC; 19412; ZMYND10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672207 CVCL_A8E1 SEES3-1V human ZMYND10, clone1 embryonic stem cell human CVCL_A8E1 CL:0000010 Transfected with: HGNC; 19412; ZMYND10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672208 CVCL_A4K0 SEES3-1V human NEUROD1, clone1 embryonic stem cell human CVCL_A4K0 CL:0000010 Transfected with: HGNC; 7762; NEUROD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672209 CVCL_A4K2 SEES3-1V human NEUROD1, clone3 embryonic stem cell human CVCL_A4K2 CL:0000010 Transfected with: HGNC; 7762; NEUROD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672210 CVCL_A4K1 SEES3-1V human NEUROD1, clone2 embryonic stem cell human CVCL_A4K1 CL:0000010 Transfected with: HGNC; 7762; NEUROD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672211 CVCL_A4K4 SEES3-1V human NEUROD2, clone2 embryonic stem cell human CVCL_A4K4 CL:0000010 Transfected with: HGNC; 7763; NEUROD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672212 CVCL_A4K3 SEES3-1V human NEUROD2, clone1 embryonic stem cell human CVCL_A4K3 CL:0000010 Transfected with: HGNC; 7763; NEUROD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672213 CVCL_A4J5 SEES3-1V human MYT1L, clone2 embryonic stem cell human CVCL_A4J5 CL:0000010 Transfected with: HGNC; 7623; MYT1L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672214 CVCL_A4J4 SEES3-1V human MYT1L, clone1 embryonic stem cell human CVCL_A4J4 CL:0000010 Transfected with: HGNC; 7623; MYT1L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672215 CVCL_A4J7 SEES3-1V human NANOG, clone1 embryonic stem cell human CVCL_A4J7 CL:0000010 Transfected with: HGNC; 20857; NANOG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672216 CVCL_A4J6 SEES3-1V human MYT1L, clone3 embryonic stem cell human CVCL_A4J6 CL:0000010 Transfected with: HGNC; 7623; MYT1L; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672217 CVCL_A4J9 SEES3-1V human NANOG, clone3 embryonic stem cell human CVCL_A4J9 CL:0000010 Transfected with: HGNC; 20857; NANOG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672218 CVCL_A4J8 SEES3-1V human NANOG, clone2 embryonic stem cell human CVCL_A4J8 CL:0000010 Transfected with: HGNC; 20857; NANOG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672219 CVCL_A4L1 SEES3-1V human NEUROD6, clone3 embryonic stem cell human CVCL_A4L1 CL:0000010 Transfected with: HGNC; 13804; NEUROD6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672220 CVCL_A4L0 SEES3-1V human NEUROD6, clone2 embryonic stem cell human CVCL_A4L0 CL:0000010 Transfected with: HGNC; 13804; NEUROD6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672221 CVCL_A4L3 SEES3-1V human NEUROG1, clone2 embryonic stem cell human CVCL_A4L3 CL:0000010 Transfected with: HGNC; 7764; NEUROG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672222 CVCL_A4L2 SEES3-1V human NEUROG1, clone1 embryonic stem cell human CVCL_A4L2 CL:0000010 Transfected with: HGNC; 7764; NEUROG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672223 CVCL_A4L5 SEES3-1V human NEUROG2, clone1 embryonic stem cell human CVCL_A4L5 CL:0000010 Transfected with: HGNC; 13805; NEUROG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672224 CVCL_A4L4 SEES3-1V human NEUROG1, clone3 embryonic stem cell human CVCL_A4L4 CL:0000010 Transfected with: HGNC; 7764; NEUROG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672225 CVCL_A4K6 SEES3-1V human NEUROD4, clone1 embryonic stem cell human CVCL_A4K6 CL:0000010 Transfected with: HGNC; 13802; NEUROD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672226 CVCL_A4K5 SEES3-1V human NEUROD2, clone3 embryonic stem cell human CVCL_A4K5 CL:0000010 Transfected with: HGNC; 7763; NEUROD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672227 CVCL_A4K8 SEES3-1V human NEUROD4, clone3 embryonic stem cell human CVCL_A4K8 CL:0000010 Transfected with: HGNC; 13802; NEUROD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672228 CVCL_A4K7 SEES3-1V human NEUROD4, clone2 embryonic stem cell human CVCL_A4K7 CL:0000010 Transfected with: HGNC; 13802; NEUROD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672229 CVCL_A4K9 SEES3-1V human NEUROD6, clone1 embryonic stem cell human CVCL_A4K9 CL:0000010 Transfected with: HGNC; 13804; NEUROD6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672230 CVCL_A4I0 SEES3-1V human MYCN, clone2 embryonic stem cell human CVCL_A4I0 CL:0000010 Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672231 CVCL_A4I2 SEES3-1V human MYF5, clone1 embryonic stem cell human CVCL_A4I2 CL:0000010 Transfected with: HGNC; 7565; MYF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672232 CVCL_A4I1 SEES3-1V human MYCN, clone3 embryonic stem cell human CVCL_A4I1 CL:0000010 Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672233 CVCL_A4H3 SEES3-1V human MYBL2, clone1 embryonic stem cell human CVCL_A4H3 CL:0000010 Transfected with: HGNC; 7548; MYBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672234 CVCL_A4H2 SEES3-1V human MYB, clone3 embryonic stem cell human CVCL_A4H2 CL:0000010 Transfected with: HGNC; 7545; MYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672235 CVCL_A4H5 SEES3-1V human MYBL2, clone3 embryonic stem cell human CVCL_A4H5 CL:0000010 Transfected with: HGNC; 7548; MYBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672236 CVCL_A4H4 SEES3-1V human MYBL2, clone2 embryonic stem cell human CVCL_A4H4 CL:0000010 Transfected with: HGNC; 7548; MYBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672237 CVCL_A4H7 SEES3-1V human MYC, clone2 embryonic stem cell human CVCL_A4H7 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672238 CVCL_A4H6 SEES3-1V human MYC, clone1 embryonic stem cell human CVCL_A4H6 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672239 CVCL_A4H9 SEES3-1V human MYCN, clone1 embryonic stem cell human CVCL_A4H9 CL:0000010 Transfected with: HGNC; 7559; MYCN; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672240 CVCL_A4H8 SEES3-1V human MYC, clone3 embryonic stem cell human CVCL_A4H8 CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672241 CVCL_A4J1 SEES3-1V human MYT1, clone1 embryonic stem cell human CVCL_A4J1 CL:0000010 Transfected with: HGNC; 7622; MYT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672242 CVCL_A4J0 SEES3-1V human MYOD1, clone3 embryonic stem cell human CVCL_A4J0 CL:0000010 Transfected with: HGNC; 7611; MYOD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672243 CVCL_A4J3 SEES3-1V human MYT1, clone3 embryonic stem cell human CVCL_A4J3 CL:0000010 Transfected with: HGNC; 7622; MYT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672244 CVCL_A4J2 SEES3-1V human MYT1, clone2 embryonic stem cell human CVCL_A4J2 CL:0000010 Transfected with: HGNC; 7622; MYT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672245 CVCL_A4I4 SEES3-1V human MYF5, clone3 embryonic stem cell human CVCL_A4I4 CL:0000010 Transfected with: HGNC; 7565; MYF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672246 CVCL_A4I3 SEES3-1V human MYF5, clone2 embryonic stem cell human CVCL_A4I3 CL:0000010 Transfected with: HGNC; 7565; MYF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672247 CVCL_A4I6 SEES3-1V human MYF6, clone2 embryonic stem cell human CVCL_A4I6 CL:0000010 Transfected with: HGNC; 7566; MYF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672248 CVCL_A4I5 SEES3-1V human MYF6, clone1 embryonic stem cell human CVCL_A4I5 CL:0000010 Transfected with: HGNC; 7566; MYF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672249 CVCL_A4I8 SEES3-1V human MYOD1, clone1 embryonic stem cell human CVCL_A4I8 CL:0000010 Transfected with: HGNC; 7611; MYOD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672250 CVCL_A4I7 SEES3-1V human MYF6, clone3 embryonic stem cell human CVCL_A4I7 CL:0000010 Transfected with: HGNC; 7566; MYF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672251 CVCL_A4I9 SEES3-1V human MYOD1, clone2 embryonic stem cell human CVCL_A4I9 CL:0000010 Transfected with: HGNC; 7611; MYOD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672252 CVCL_A4G0 SEES3-1V human MSL3L1, clone3 embryonic stem cell human CVCL_A4G0 CL:0000010 Transfected with: HGNC; 7370; MSL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672253 CVCL_A4F9 SEES3-1V human MSL3L1, clone2 embryonic stem cell human CVCL_A4F9 CL:0000010 Transfected with: HGNC; 7370; MSL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672254 CVCL_A4F8 SEES3-1V human MSL3L1, clone1 embryonic stem cell human CVCL_A4F8 CL:0000010 Transfected with: HGNC; 7370; MSL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672255 CVCL_A4F1 SEES3-1V human MSC, clone3 embryonic stem cell human CVCL_A4F1 CL:0000010 Transfected with: HGNC; 7321; MSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672256 CVCL_A4F0 SEES3-1V human MSC, clone2 embryonic stem cell human CVCL_A4F0 CL:0000010 Transfected with: HGNC; 7321; MSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672257 CVCL_A4F3 SEES3-1V human MSGN1, clone2 embryonic stem cell human CVCL_A4F3 CL:0000010 Transfected with: HGNC; 14907; MSGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672258 CVCL_A4F2 SEES3-1V human MSGN1, clone1 embryonic stem cell human CVCL_A4F2 CL:0000010 Transfected with: HGNC; 14907; MSGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672259 CVCL_A4F5 SEES3-1V human MSI1, clone1 embryonic stem cell human CVCL_A4F5 CL:0000010 Transfected with: HGNC; 7330; MSI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672260 CVCL_A4F4 SEES3-1V human MSGN1, clone3 embryonic stem cell human CVCL_A4F4 CL:0000010 Transfected with: HGNC; 14907; MSGN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672261 CVCL_A4F7 SEES3-1V human MSI1, clone3 embryonic stem cell human CVCL_A4F7 CL:0000010 Transfected with: HGNC; 7330; MSI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672262 CVCL_A4F6 SEES3-1V human MSI1, clone2 embryonic stem cell human CVCL_A4F6 CL:0000010 Transfected with: HGNC; 7330; MSI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672263 CVCL_A4H1 SEES3-1V human MYB, clone2 embryonic stem cell human CVCL_A4H1 CL:0000010 Transfected with: HGNC; 7545; MYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672264 CVCL_A4H0 SEES3-1V human MYB, clone1 embryonic stem cell human CVCL_A4H0 CL:0000010 Transfected with: HGNC; 7545; MYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672265 CVCL_A4G9 SEES3-1V human MXI1, clone3 embryonic stem cell human CVCL_A4G9 CL:0000010 Transfected with: HGNC; 7534; MXI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672266 CVCL_A4G2 SEES3-1V human MSX2, clone2 embryonic stem cell human CVCL_A4G2 CL:0000010 Transfected with: HGNC; 7392; MSX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672267 CVCL_A4G1 SEES3-1V human MSX2, clone1 embryonic stem cell human CVCL_A4G1 CL:0000010 Transfected with: HGNC; 7392; MSX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672268 CVCL_A4G4 SEES3-1V human MXD3, clone1 embryonic stem cell human CVCL_A4G4 CL:0000010 Transfected with: HGNC; 14008; MXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672269 CVCL_A4G3 SEES3-1V human MSX2, clone3 embryonic stem cell human CVCL_A4G3 CL:0000010 Transfected with: HGNC; 7392; MSX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672270 CVCL_A4G6 SEES3-1V human MXD3, clone3 embryonic stem cell human CVCL_A4G6 CL:0000010 Transfected with: HGNC; 14008; MXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672271 CVCL_A4G5 SEES3-1V human MXD3, clone2 embryonic stem cell human CVCL_A4G5 CL:0000010 Transfected with: HGNC; 14008; MXD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672272 CVCL_A4G8 SEES3-1V human MXI1, clone2 embryonic stem cell human CVCL_A4G8 CL:0000010 Transfected with: HGNC; 7534; MXI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672273 CVCL_A4G7 SEES3-1V human MXI1, clone1 embryonic stem cell human CVCL_A4G7 CL:0000010 Transfected with: HGNC; 7534; MXI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672274 CVCL_A4D7 SEES3-1V human MITF, clone1 embryonic stem cell human CVCL_A4D7 CL:0000010 Transfected with: HGNC; 7105; MITF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672275 CVCL_A4D6 SEES3-1V human MIF4GD, clone3 embryonic stem cell human CVCL_A4D6 CL:0000010 Transfected with: HGNC; 24030; MIF4GD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672276 CVCL_A4D9 SEES3-1V human MITF, clone3 embryonic stem cell human CVCL_A4D9 CL:0000010 Transfected with: HGNC; 7105; MITF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672277 CVCL_A4D8 SEES3-1V human MITF, clone2 embryonic stem cell human CVCL_A4D8 CL:0000010 Transfected with: HGNC; 7105; MITF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672278 CVCL_A4D1 SEES3-1V human METTL5, clone1 embryonic stem cell human CVCL_A4D1 CL:0000010 Transfected with: HGNC; 25006; METTL5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672279 CVCL_A4D0 SEES3-1V human MEIS2, clone3 embryonic stem cell human CVCL_A4D0 CL:0000010 Transfected with: HGNC; 7001; MEIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672280 CVCL_A4D3 SEES3-1V human METTL5, clone3 embryonic stem cell human CVCL_A4D3 CL:0000010 Transfected with: HGNC; 25006; METTL5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672281 CVCL_A4D2 SEES3-1V human METTL5, clone2 embryonic stem cell human CVCL_A4D2 CL:0000010 Transfected with: HGNC; 25006; METTL5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672282 CVCL_A4D5 SEES3-1V human MIF4GD, clone2 embryonic stem cell human CVCL_A4D5 CL:0000010 Transfected with: HGNC; 24030; MIF4GD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672283 CVCL_A4D4 SEES3-1V human MIF4GD, clone1 embryonic stem cell human CVCL_A4D4 CL:0000010 Transfected with: HGNC; 24030; MIF4GD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672284 CVCL_A4E8 SEES3-1V human MNX1, clone3 embryonic stem cell human CVCL_A4E8 CL:0000010 Transfected with: HGNC; 4979; MNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672285 CVCL_A4E7 SEES3-1V human MNX1, clone2 embryonic stem cell human CVCL_A4E7 CL:0000010 Transfected with: HGNC; 4979; MNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672286 CVCL_A4E9 SEES3-1V human MSC, clone1 embryonic stem cell human CVCL_A4E9 CL:0000010 Transfected with: HGNC; 7321; MSC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672287 CVCL_A4E0 SEES3-1V human MKRN1, clone1 embryonic stem cell human CVCL_A4E0 CL:0000010 Transfected with: HGNC; 7112; MKRN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672288 CVCL_A4E2 SEES3-1V human MKRN1, clone3 embryonic stem cell human CVCL_A4E2 CL:0000010 Transfected with: HGNC; 7112; MKRN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672289 CVCL_A4E1 SEES3-1V human MKRN1, clone2 embryonic stem cell human CVCL_A4E1 CL:0000010 Transfected with: HGNC; 7112; MKRN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672290 CVCL_A4E4 SEES3-1V human MLLT1, clone2 embryonic stem cell human CVCL_A4E4 CL:0000010 Transfected with: HGNC; 7134; MLLT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672291 CVCL_A4E3 SEES3-1V human MLLT1, clone1 embryonic stem cell human CVCL_A4E3 CL:0000010 Transfected with: HGNC; 7134; MLLT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672292 CVCL_A4E6 SEES3-1V human MNX1, clone1 embryonic stem cell human CVCL_A4E6 CL:0000010 Transfected with: HGNC; 4979; MNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672293 CVCL_A4E5 SEES3-1V human MLLT1, clone3 embryonic stem cell human CVCL_A4E5 CL:0000010 Transfected with: HGNC; 7134; MLLT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672294 CVCL_A4S6 SEES3-1V human NR1D1, clone3 embryonic stem cell human CVCL_A4S6 CL:0000010 Transfected with: HGNC; 7962; NR1D1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672295 CVCL_A4S5 SEES3-1V human NR1D1, clone2 embryonic stem cell human CVCL_A4S5 CL:0000010 Transfected with: HGNC; 7962; NR1D1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672296 CVCL_A4S8 SEES3-1V human NR1D2, clone2 embryonic stem cell human CVCL_A4S8 CL:0000010 Transfected with: HGNC; 7963; NR1D2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672297 CVCL_A4S7 SEES3-1V human NR1D2, clone1 embryonic stem cell human CVCL_A4S7 CL:0000010 Transfected with: HGNC; 7963; NR1D2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672298 CVCL_A4S9 SEES3-1V human NR1D2, clone3 embryonic stem cell human CVCL_A4S9 CL:0000010 Transfected with: HGNC; 7963; NR1D2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672299 CVCL_A4S0 SEES3-1V human NPAS2, clone3 embryonic stem cell human CVCL_A4S0 CL:0000010 Transfected with: HGNC; 7895; NPAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672300 CVCL_A4S2 SEES3-1V human NR0B2, clone2 embryonic stem cell human CVCL_A4S2 CL:0000010 Transfected with: HGNC; 7961; NR0B2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672301 CVCL_A4S1 SEES3-1V human NR0B2, clone1 embryonic stem cell human CVCL_A4S1 CL:0000010 Transfected with: HGNC; 7961; NR0B2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672302 CVCL_A4S4 SEES3-1V human NR1D1, clone1 embryonic stem cell human CVCL_A4S4 CL:0000010 Transfected with: HGNC; 7962; NR1D1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672303 CVCL_A4S3 SEES3-1V human NR0B2, clone3 embryonic stem cell human CVCL_A4S3 CL:0000010 Transfected with: HGNC; 7961; NR0B2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672304 CVCL_A4T7 SEES3-1V human NR1H4, clone2 embryonic stem cell human CVCL_A4T7 CL:0000010 Transfected with: HGNC; 7967; NR1H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672305 CVCL_A4T6 SEES3-1V human NR1H4, clone1 embryonic stem cell human CVCL_A4T6 CL:0000010 Transfected with: HGNC; 7967; NR1H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672306 CVCL_A4T9 SEES3-1V human NR1I2, clone1 embryonic stem cell human CVCL_A4T9 CL:0000010 Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672307 CVCL_A4T8 SEES3-1V human NR1H4, clone3 embryonic stem cell human CVCL_A4T8 CL:0000010 Transfected with: HGNC; 7967; NR1H4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672308 CVCL_A4T1 SEES3-1V human NR1H2, clone2 embryonic stem cell human CVCL_A4T1 CL:0000010 Transfected with: HGNC; 7965; NR1H2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672309 CVCL_A4T0 SEES3-1V human NR1H2, clone1 embryonic stem cell human CVCL_A4T0 CL:0000010 Transfected with: HGNC; 7965; NR1H2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672310 CVCL_A4T3 SEES3-1V human NR1H3, clone1 embryonic stem cell human CVCL_A4T3 CL:0000010 Transfected with: HGNC; 7966; NR1H3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672311 CVCL_A4T2 SEES3-1V human NR1H2, clone3 embryonic stem cell human CVCL_A4T2 CL:0000010 Transfected with: HGNC; 7965; NR1H2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672312 CVCL_A4T5 SEES3-1V human NR1H3, clone3 embryonic stem cell human CVCL_A4T5 CL:0000010 Transfected with: HGNC; 7966; NR1H3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672313 CVCL_A4T4 SEES3-1V human NR1H3, clone2 embryonic stem cell human CVCL_A4T4 CL:0000010 Transfected with: HGNC; 7966; NR1H3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672314 CVCL_A4Q4 SEES3-1V human NKX2-2, clone2 embryonic stem cell human CVCL_A4Q4 CL:0000010 Transfected with: HGNC; 7835; NKX2-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672315 CVCL_A4Q3 SEES3-1V human NKX2-2, clone1 embryonic stem cell human CVCL_A4Q3 CL:0000010 Transfected with: HGNC; 7835; NKX2-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672316 CVCL_A4Q6 SEES3-1V human NKX2-5, clone1 embryonic stem cell human CVCL_A4Q6 CL:0000010 Transfected with: HGNC; 2488; NKX2-5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672317 CVCL_A4Q5 SEES3-1V human NKX2-2, clone3 embryonic stem cell human CVCL_A4Q5 CL:0000010 Transfected with: HGNC; 7835; NKX2-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672318 CVCL_A4Q8 SEES3-1V human NKX2-5, clone3 embryonic stem cell human CVCL_A4Q8 CL:0000010 Transfected with: HGNC; 2488; NKX2-5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672319 CVCL_A4Q7 SEES3-1V human NKX2-5, clone2 embryonic stem cell human CVCL_A4Q7 CL:0000010 Transfected with: HGNC; 2488; NKX2-5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672320 CVCL_A4Q9 SEES3-1V human NKX6-1, clone1 embryonic stem cell human CVCL_A4Q9 CL:0000010 Transfected with: HGNC; 7839; NKX6-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672321 CVCL_A4Q0 SEES3-1V human NKX2-1, clone1 embryonic stem cell human CVCL_A4Q0 CL:0000010 Transfected with: HGNC; 11825; NKX2-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672322 CVCL_A4Q2 SEES3-1V human NKX2-1, clone3 embryonic stem cell human CVCL_A4Q2 CL:0000010 Transfected with: HGNC; 11825; NKX2-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672323 CVCL_A4Q1 SEES3-1V human NKX2-1, clone2 embryonic stem cell human CVCL_A4Q1 CL:0000010 Transfected with: HGNC; 11825; NKX2-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672324 CVCL_A4R5 SEES3-1V human NKX6-3, clone1 embryonic stem cell human CVCL_A4R5 CL:0000010 Transfected with: HGNC; 26328; NKX6-3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672325 CVCL_A4R4 SEES3-1V human NKX6-2, clone3 embryonic stem cell human CVCL_A4R4 CL:0000010 Transfected with: HGNC; 19321; NKX6-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672326 CVCL_A4R7 SEES3-1V human NKX6-3, clone3 embryonic stem cell human CVCL_A4R7 CL:0000010 Transfected with: HGNC; 26328; NKX6-3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672327 CVCL_A4R6 SEES3-1V human NKX6-3, clone2 embryonic stem cell human CVCL_A4R6 CL:0000010 Transfected with: HGNC; 26328; NKX6-3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672328 CVCL_A4R9 SEES3-1V human NPAS2, clone2 embryonic stem cell human CVCL_A4R9 CL:0000010 Transfected with: HGNC; 7895; NPAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672329 CVCL_A4R8 SEES3-1V human NPAS2, clone1 embryonic stem cell human CVCL_A4R8 CL:0000010 Transfected with: HGNC; 7895; NPAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672330 CVCL_A4R1 SEES3-1V human NKX6-1, clone3 embryonic stem cell human CVCL_A4R1 CL:0000010 Transfected with: HGNC; 7839; NKX6-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672331 CVCL_A4R0 SEES3-1V human NKX6-1, clone2 embryonic stem cell human CVCL_A4R0 CL:0000010 Transfected with: HGNC; 7839; NKX6-1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672332 CVCL_A4R3 SEES3-1V human NKX6-2, clone2 embryonic stem cell human CVCL_A4R3 CL:0000010 Transfected with: HGNC; 19321; NKX6-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672333 CVCL_A4R2 SEES3-1V human NKX6-2, clone1 embryonic stem cell human CVCL_A4R2 CL:0000010 Transfected with: HGNC; 19321; NKX6-2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672334 CVCL_A4N9 SEES3-1V human NFX1, clone2 embryonic stem cell human CVCL_A4N9 CL:0000010 Transfected with: HGNC; 7803; NFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672335 CVCL_A4N8 SEES3-1V human NFX1, clone1 embryonic stem cell human CVCL_A4N8 CL:0000010 Transfected with: HGNC; 7803; NFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672336 CVCL_A4P3 SEES3-1V human NFYA, clone3 embryonic stem cell human CVCL_A4P3 CL:0000010 Transfected with: HGNC; 7804; NFYA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672337 CVCL_A4P2 SEES3-1V human NFYA, clone2 embryonic stem cell human CVCL_A4P2 CL:0000010 Transfected with: HGNC; 7804; NFYA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672338 CVCL_A4P5 SEES3-1V human NFYB, clone2 embryonic stem cell human CVCL_A4P5 CL:0000010 Transfected with: HGNC; 7805; NFYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672339 CVCL_A4P4 SEES3-1V human NFYB, clone1 embryonic stem cell human CVCL_A4P4 CL:0000010 Transfected with: HGNC; 7805; NFYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672340 CVCL_A4P7 SEES3-1V human NGF, clone1 embryonic stem cell human CVCL_A4P7 CL:0000010 Transfected with: HGNC; 7808; NGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672341 CVCL_A4P6 SEES3-1V human NFYB, clone3 embryonic stem cell human CVCL_A4P6 CL:0000010 Transfected with: HGNC; 7805; NFYB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672342 CVCL_A4P9 SEES3-1V human NGF, clone3 embryonic stem cell human CVCL_A4P9 CL:0000010 Transfected with: HGNC; 7808; NGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672343 CVCL_A4P8 SEES3-1V human NGF, clone2 embryonic stem cell human CVCL_A4P8 CL:0000010 Transfected with: HGNC; 7808; NGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672344 CVCL_A4P1 SEES3-1V human NFYA, clone1 embryonic stem cell human CVCL_A4P1 CL:0000010 Transfected with: HGNC; 7804; NFYA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672345 CVCL_A4P0 SEES3-1V human NFX1, clone3 embryonic stem cell human CVCL_A4P0 CL:0000010 Transfected with: HGNC; 7803; NFX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672346 CVCL_A4M0 SEES3-1V human NEUROG3, clone3 embryonic stem cell human CVCL_A4M0 CL:0000010 Transfected with: HGNC; 13806; NEUROG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672347 CVCL_A4M2 SEES3-1V human NFATC1, clone2 embryonic stem cell human CVCL_A4M2 CL:0000010 Transfected with: HGNC; 7775; NFATC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672348 CVCL_A4M1 SEES3-1V human NFATC1, clone1 embryonic stem cell human CVCL_A4M1 CL:0000010 Transfected with: HGNC; 7775; NFATC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672349 CVCL_A4M4 SEES3-1V human NFE2L1, clone1 embryonic stem cell human CVCL_A4M4 CL:0000010 Transfected with: HGNC; 7781; NFE2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672350 CVCL_A4M3 SEES3-1V human NFATC1, clone3 embryonic stem cell human CVCL_A4M3 CL:0000010 Transfected with: HGNC; 7775; NFATC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672351 CVCL_A4M6 SEES3-1V human NFE2L1, clone3 embryonic stem cell human CVCL_A4M6 CL:0000010 Transfected with: HGNC; 7781; NFE2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672352 CVCL_A4M5 SEES3-1V human NFE2L1, clone2 embryonic stem cell human CVCL_A4M5 CL:0000010 Transfected with: HGNC; 7781; NFE2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672353 CVCL_A4L7 SEES3-1V human NEUROG2, clone3 embryonic stem cell human CVCL_A4L7 CL:0000010 Transfected with: HGNC; 13805; NEUROG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672354 CVCL_A4L6 SEES3-1V human NEUROG2, clone2 embryonic stem cell human CVCL_A4L6 CL:0000010 Transfected with: HGNC; 13805; NEUROG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672355 CVCL_A4L9 SEES3-1V human NEUROG3, clone2 embryonic stem cell human CVCL_A4L9 CL:0000010 Transfected with: HGNC; 13806; NEUROG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672356 CVCL_A4L8 SEES3-1V human NEUROG3, clone1 embryonic stem cell human CVCL_A4L8 CL:0000010 Transfected with: HGNC; 13806; NEUROG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672357 CVCL_A4N1 SEES3-1V human NFIB, clone2 embryonic stem cell human CVCL_A4N1 CL:0000010 Transfected with: HGNC; 7785; NFIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672358 CVCL_A4N0 SEES3-1V human NFIB, clone1 embryonic stem cell human CVCL_A4N0 CL:0000010 Transfected with: HGNC; 7785; NFIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672359 CVCL_A4N3 SEES3-1V human NFIC, clone1 embryonic stem cell human CVCL_A4N3 CL:0000010 Transfected with: HGNC; 7786; NFIC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672360 CVCL_A4N2 SEES3-1V human NFIB, clone3 embryonic stem cell human CVCL_A4N2 CL:0000010 Transfected with: HGNC; 7785; NFIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672361 CVCL_A4N5 SEES3-1V human NFIL3, clone1 embryonic stem cell human CVCL_A4N5 CL:0000010 Transfected with: HGNC; 7787; NFIL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672362 CVCL_A4N4 SEES3-1V human NFIC, clone2 embryonic stem cell human CVCL_A4N4 CL:0000010 Transfected with: HGNC; 7786; NFIC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672363 CVCL_A4N7 SEES3-1V human NFIL3, clone3 embryonic stem cell human CVCL_A4N7 CL:0000010 Transfected with: HGNC; 7787; NFIL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672364 CVCL_A4N6 SEES3-1V human NFIL3, clone2 embryonic stem cell human CVCL_A4N6 CL:0000010 Transfected with: HGNC; 7787; NFIL3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672365 CVCL_A4M8 SEES3-1V human NFIA, clone2 embryonic stem cell human CVCL_A4M8 CL:0000010 Transfected with: HGNC; 7784; NFIA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672366 CVCL_A4M7 SEES3-1V human NFIA, clone1 embryonic stem cell human CVCL_A4M7 CL:0000010 Transfected with: HGNC; 7784; NFIA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672367 CVCL_A4M9 SEES3-1V human NFIA, clone3 embryonic stem cell human CVCL_A4M9 CL:0000010 Transfected with: HGNC; 7784; NFIA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672368 CVCL_A3Y5 SEES3-1V human LMX1A, clone3 embryonic stem cell human CVCL_A3Y5 CL:0000010 Transfected with: HGNC; 6653; LMX1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672369 CVCL_A3Y4 SEES3-1V human LMX1A, clone2 embryonic stem cell human CVCL_A3Y4 CL:0000010 Transfected with: HGNC; 6653; LMX1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672370 CVCL_A3Y7 SEES3-1V human LMX1B, clone2 embryonic stem cell human CVCL_A3Y7 CL:0000010 Transfected with: HGNC; 6654; LMX1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672371 CVCL_A3Y6 SEES3-1V human LMX1B, clone1 embryonic stem cell human CVCL_A3Y6 CL:0000010 Transfected with: HGNC; 6654; LMX1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672372 CVCL_A3Y9 SEES3-1V human MAB21L1, clone1 embryonic stem cell human CVCL_A3Y9 CL:0000010 Transfected with: HGNC; 6757; MAB21L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672373 CVCL_A3Y8 SEES3-1V human LMX1B, clone3 embryonic stem cell human CVCL_A3Y8 CL:0000010 Transfected with: HGNC; 6654; LMX1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672374 CVCL_A3Y1 SEES3-1V human LMO2, clone2 embryonic stem cell human CVCL_A3Y1 CL:0000010 Transfected with: HGNC; 6642; LMO2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672375 CVCL_A3Y0 SEES3-1V human LMO2, clone1 embryonic stem cell human CVCL_A3Y0 CL:0000010 Transfected with: HGNC; 6642; LMO2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672376 CVCL_A3Y3 SEES3-1V human LMX1A, clone1 embryonic stem cell human CVCL_A3Y3 CL:0000010 Transfected with: HGNC; 6653; LMX1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672377 CVCL_A3Y2 SEES3-1V human LMO2, clone3 embryonic stem cell human CVCL_A3Y2 CL:0000010 Transfected with: HGNC; 6642; LMO2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672378 CVCL_A3Z6 SEES3-1V human MAB21L3, clone2 embryonic stem cell human CVCL_A3Z6 CL:0000010 Transfected with: HGNC; 26787; MAB21L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672379 CVCL_A3Z5 SEES3-1V human MAB21L3, clone1 embryonic stem cell human CVCL_A3Z5 CL:0000010 Transfected with: HGNC; 26787; MAB21L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672380 CVCL_A3Z8 SEES3-1V human MAFA, clone1 embryonic stem cell human CVCL_A3Z8 CL:0000010 Transfected with: HGNC; 23145; MAFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672381 CVCL_A3Z7 SEES3-1V human MAB21L3, clone3 embryonic stem cell human CVCL_A3Z7 CL:0000010 Transfected with: HGNC; 26787; MAB21L3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672382 CVCL_A3Z9 SEES3-1V human MAFA, clone2 embryonic stem cell human CVCL_A3Z9 CL:0000010 Transfected with: HGNC; 23145; MAFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672383 CVCL_A3Z0 SEES3-1V human MAB21L1, clone2 embryonic stem cell human CVCL_A3Z0 CL:0000010 Transfected with: HGNC; 6757; MAB21L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672384 CVCL_A3Z2 SEES3-1V human MAB21L2, clone1 embryonic stem cell human CVCL_A3Z2 CL:0000010 Transfected with: HGNC; 6758; MAB21L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672385 CVCL_A3Z1 SEES3-1V human MAB21L1, clone3 embryonic stem cell human CVCL_A3Z1 CL:0000010 Transfected with: HGNC; 6757; MAB21L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672386 CVCL_A3Z4 SEES3-1V human MAB21L2, clone3 embryonic stem cell human CVCL_A3Z4 CL:0000010 Transfected with: HGNC; 6758; MAB21L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672387 CVCL_A3Z3 SEES3-1V human MAB21L2, clone2 embryonic stem cell human CVCL_A3Z3 CL:0000010 Transfected with: HGNC; 6758; MAB21L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672388 CVCL_A3W3 SEES3-1V human LHX6, clone2 embryonic stem cell human CVCL_A3W3 CL:0000010 Transfected with: HGNC; 21735; LHX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672389 CVCL_A3W2 SEES3-1V human LHX6, clone1 embryonic stem cell human CVCL_A3W2 CL:0000010 Transfected with: HGNC; 21735; LHX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672390 CVCL_A3W5 SEES3-1V human LHX8, clone1 embryonic stem cell human CVCL_A3W5 CL:0000010 Transfected with: HGNC; 28838; LHX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672391 CVCL_A3W4 SEES3-1V human LHX6, clone3 embryonic stem cell human CVCL_A3W4 CL:0000010 Transfected with: HGNC; 21735; LHX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672392 CVCL_A3W7 SEES3-1V human LHX8, clone3 embryonic stem cell human CVCL_A3W7 CL:0000010 Transfected with: HGNC; 28838; LHX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672393 CVCL_A3W6 SEES3-1V human LHX8, clone2 embryonic stem cell human CVCL_A3W6 CL:0000010 Transfected with: HGNC; 28838; LHX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672394 CVCL_A3W9 SEES3-1V human LHX9, clone2 embryonic stem cell human CVCL_A3W9 CL:0000010 Transfected with: HGNC; 14222; LHX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672395 CVCL_A3W8 SEES3-1V human LHX9, clone1 embryonic stem cell human CVCL_A3W8 CL:0000010 Transfected with: HGNC; 14222; LHX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672396 CVCL_A3W1 SEES3-1V human LHX5, clone3 embryonic stem cell human CVCL_A3W1 CL:0000010 Transfected with: HGNC; 14216; LHX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672397 CVCL_A3W0 SEES3-1V human LHX5, clone2 embryonic stem cell human CVCL_A3W0 CL:0000010 Transfected with: HGNC; 14216; LHX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672398 CVCL_A3X4 SEES3-1V human LIN28, clone1 embryonic stem cell human CVCL_A3X4 CL:0000010 Transfected with: HGNC; 15986; LIN28A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672399 CVCL_A3X3 SEES3-1V human LIF, clone3 embryonic stem cell human CVCL_A3X3 CL:0000010 Transfected with: HGNC; 6596; LIF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672400 CVCL_A3X6 SEES3-1V human LIN28, clone3 embryonic stem cell human CVCL_A3X6 CL:0000010 Transfected with: HGNC; 15986; LIN28A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672401 CVCL_A3X5 SEES3-1V human LIN28, clone2 embryonic stem cell human CVCL_A3X5 CL:0000010 Transfected with: HGNC; 15986; LIN28A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672402 CVCL_A3X8 SEES3-1V human LMO1, clone2 embryonic stem cell human CVCL_A3X8 CL:0000010 Transfected with: HGNC; 6641; LMO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672403 CVCL_A3X7 SEES3-1V human LMO1, clone1 embryonic stem cell human CVCL_A3X7 CL:0000010 Transfected with: HGNC; 6641; LMO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672404 CVCL_A3X9 SEES3-1V human LMO1, clone3 embryonic stem cell human CVCL_A3X9 CL:0000010 Transfected with: HGNC; 6641; LMO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672405 CVCL_A3X0 SEES3-1V human LHX9, clone3 embryonic stem cell human CVCL_A3X0 CL:0000010 Transfected with: HGNC; 14222; LHX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672406 CVCL_A3X2 SEES3-1V human LIF, clone2 embryonic stem cell human CVCL_A3X2 CL:0000010 Transfected with: HGNC; 6596; LIF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672407 CVCL_A3X1 SEES3-1V human LIF, clone1 embryonic stem cell human CVCL_A3X1 CL:0000010 Transfected with: HGNC; 6596; LIF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672408 CVCL_A3U9 SEES3-1V human LHX1, clone3 embryonic stem cell human CVCL_A3U9 CL:0000010 Transfected with: HGNC; 6593; LHX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672409 CVCL_A3U8 SEES3-1V human LHX1, clone2 embryonic stem cell human CVCL_A3U8 CL:0000010 Transfected with: HGNC; 6593; LHX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672410 CVCL_A3U1 SEES3-1V human LFNG, clone1 embryonic stem cell human CVCL_A3U1 CL:0000010 Transfected with: HGNC; 6560; LFNG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672411 CVCL_A3U0 SEES3-1V human LEF1, clone3 embryonic stem cell human CVCL_A3U0 CL:0000010 Transfected with: HGNC; 6551; LEF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672412 CVCL_A3U3 SEES3-1V human LFNG, clone3 embryonic stem cell human CVCL_A3U3 CL:0000010 Transfected with: HGNC; 6560; LFNG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672413 CVCL_A3U2 SEES3-1V human LFNG, clone2 embryonic stem cell human CVCL_A3U2 CL:0000010 Transfected with: HGNC; 6560; LFNG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672414 CVCL_A3U5 SEES3-1V human LHFP, clone2 embryonic stem cell human CVCL_A3U5 CL:0000010 Transfected with: HGNC; 6586; LHFPL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672415 CVCL_A3U4 SEES3-1V human LHFP, clone1 embryonic stem cell human CVCL_A3U4 CL:0000010 Transfected with: HGNC; 6586; LHFPL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672416 CVCL_A3U7 SEES3-1V human LHX1, clone1 embryonic stem cell human CVCL_A3U7 CL:0000010 Transfected with: HGNC; 6593; LHX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672417 CVCL_A3U6 SEES3-1V human LHFP, clone3 embryonic stem cell human CVCL_A3U6 CL:0000010 Transfected with: HGNC; 6586; LHFPL6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672418 CVCL_A3V9 SEES3-1V human LHX5, clone1 embryonic stem cell human CVCL_A3V9 CL:0000010 Transfected with: HGNC; 14216; LHX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672419 CVCL_A3V2 SEES3-1V human LHX2, clone3 embryonic stem cell human CVCL_A3V2 CL:0000010 Transfected with: HGNC; 6594; LHX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672420 CVCL_A3V1 SEES3-1V human LHX2, clone2 embryonic stem cell human CVCL_A3V1 CL:0000010 Transfected with: HGNC; 6594; LHX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672421 CVCL_A3V4 SEES3-1V human LHX3, clone2 embryonic stem cell human CVCL_A3V4 CL:0000010 Transfected with: HGNC; 6595; LHX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672422 CVCL_A3V3 SEES3-1V human LHX3, clone1 embryonic stem cell human CVCL_A3V3 CL:0000010 Transfected with: HGNC; 6595; LHX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672423 CVCL_A3V6 SEES3-1V human LHX4, clone1 embryonic stem cell human CVCL_A3V6 CL:0000010 Transfected with: HGNC; 21734; LHX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672424 CVCL_A3V5 SEES3-1V human LHX3, clone3 embryonic stem cell human CVCL_A3V5 CL:0000010 Transfected with: HGNC; 6595; LHX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672425 CVCL_A3V8 SEES3-1V human LHX4, clone3 embryonic stem cell human CVCL_A3V8 CL:0000010 Transfected with: HGNC; 21734; LHX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672426 CVCL_A3V7 SEES3-1V human LHX4, clone2 embryonic stem cell human CVCL_A3V7 CL:0000010 Transfected with: HGNC; 21734; LHX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672427 CVCL_A3V0 SEES3-1V human LHX2, clone1 embryonic stem cell human CVCL_A3V0 CL:0000010 Transfected with: HGNC; 6594; LHX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672428 CVCL_A3S7 SEES3-1V human KLRG1, clone2 embryonic stem cell human CVCL_A3S7 CL:0000010 Transfected with: HGNC; 6380; KLRG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672429 CVCL_A3S6 SEES3-1V human KLRG1, clone1 embryonic stem cell human CVCL_A3S6 CL:0000010 Transfected with: HGNC; 6380; KLRG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672430 CVCL_A3S9 SEES3-1V human KRBA2, clone1 embryonic stem cell human CVCL_A3S9 CL:0000010 Transfected with: HGNC; 26989; KRBA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672431 CVCL_A3S8 SEES3-1V human KLRG1, clone3 embryonic stem cell human CVCL_A3S8 CL:0000010 Transfected with: HGNC; 6380; KLRG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672432 CVCL_A3S1 SEES3-1V human KLF8, clone2 embryonic stem cell human CVCL_A3S1 CL:0000010 Transfected with: HGNC; 6351; KLF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672433 CVCL_A3S0 SEES3-1V human KLF8, clone1 embryonic stem cell human CVCL_A3S0 CL:0000010 Transfected with: HGNC; 6351; KLF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672434 CVCL_A3S3 SEES3-1V human KLF9, clone1 embryonic stem cell human CVCL_A3S3 CL:0000010 Transfected with: HGNC; 1123; KLF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672435 CVCL_A3S2 SEES3-1V human KLF8, clone3 embryonic stem cell human CVCL_A3S2 CL:0000010 Transfected with: HGNC; 6351; KLF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672436 CVCL_A3S5 SEES3-1V human KLF9, clone3 embryonic stem cell human CVCL_A3S5 CL:0000010 Transfected with: HGNC; 1123; KLF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672437 CVCL_A3S4 SEES3-1V human KLF9, clone2 embryonic stem cell human CVCL_A3S4 CL:0000010 Transfected with: HGNC; 1123; KLF9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672438 CVCL_A3T8 SEES3-1V human LEF1, clone1 embryonic stem cell human CVCL_A3T8 CL:0000010 Transfected with: HGNC; 6551; LEF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672439 CVCL_A3T7 SEES3-1V human LBX2, clone3 embryonic stem cell human CVCL_A3T7 CL:0000010 Transfected with: HGNC; 15525; LBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672440 CVCL_A3T9 SEES3-1V human LEF1, clone2 embryonic stem cell human CVCL_A3T9 CL:0000010 Transfected with: HGNC; 6551; LEF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672441 CVCL_A3T0 SEES3-1V human KRBA2, clone2 embryonic stem cell human CVCL_A3T0 CL:0000010 Transfected with: HGNC; 26989; KRBA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672442 CVCL_A3T2 SEES3-1V human L3MBTL2, clone1 embryonic stem cell human CVCL_A3T2 CL:0000010 Transfected with: HGNC; 18594; L3MBTL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672443 CVCL_A3T1 SEES3-1V human KRBA2, clone3 embryonic stem cell human CVCL_A3T1 CL:0000010 Transfected with: HGNC; 26989; KRBA2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672444 CVCL_A3T4 SEES3-1V human L3MBTL2, clone3 embryonic stem cell human CVCL_A3T4 CL:0000010 Transfected with: HGNC; 18594; L3MBTL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672445 CVCL_A3T3 SEES3-1V human L3MBTL2, clone2 embryonic stem cell human CVCL_A3T3 CL:0000010 Transfected with: HGNC; 18594; L3MBTL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672446 CVCL_A3T6 SEES3-1V human LBX2, clone2 embryonic stem cell human CVCL_A3T6 CL:0000010 Transfected with: HGNC; 15525; LBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672447 CVCL_A3T5 SEES3-1V human LBX2, clone1 embryonic stem cell human CVCL_A3T5 CL:0000010 Transfected with: HGNC; 15525; LBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672448 CVCL_A4B5 SEES3-1V human MECOM, clone3 embryonic stem cell human CVCL_A4B5 CL:0000010 Transfected with: HGNC; 3498; MECOM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672449 CVCL_A4B4 SEES3-1V human MECOM, clone2 embryonic stem cell human CVCL_A4B4 CL:0000010 Transfected with: HGNC; 3498; MECOM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672450 CVCL_A4B7 SEES3-1V human MED12, clone2 embryonic stem cell human CVCL_A4B7 CL:0000010 Transfected with: HGNC; 11957; MED12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672451 CVCL_A4B6 SEES3-1V human MED12, clone1 embryonic stem cell human CVCL_A4B6 CL:0000010 Transfected with: HGNC; 11957; MED12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672452 CVCL_A4B9 SEES3-1V human MEF2A, clone1 embryonic stem cell human CVCL_A4B9 CL:0000010 Transfected with: HGNC; 6993; MEF2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672453 CVCL_A4B8 SEES3-1V human MED12, clone3 embryonic stem cell human CVCL_A4B8 CL:0000010 Transfected with: HGNC; 11957; MED12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672454 CVCL_A4B1 SEES3-1V human MBD3, clone2 embryonic stem cell human CVCL_A4B1 CL:0000010 Transfected with: HGNC; 6918; MBD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672455 CVCL_A4B0 SEES3-1V human MBD3, clone1 embryonic stem cell human CVCL_A4B0 CL:0000010 Transfected with: HGNC; 6918; MBD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672456 CVCL_A4B3 SEES3-1V human MECOM, clone1 embryonic stem cell human CVCL_A4B3 CL:0000010 Transfected with: HGNC; 3498; MECOM; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672457 CVCL_A4B2 SEES3-1V human MBD3, clone3 embryonic stem cell human CVCL_A4B2 CL:0000010 Transfected with: HGNC; 6918; MBD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672458 CVCL_A4C6 SEES3-1V human MEIS1, clone2 embryonic stem cell human CVCL_A4C6 CL:0000010 Transfected with: HGNC; 7000; MEIS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672459 CVCL_A4C5 SEES3-1V human MEIS1, clone1 embryonic stem cell human CVCL_A4C5 CL:0000010 Transfected with: HGNC; 7000; MEIS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672460 CVCL_A4C8 SEES3-1V human MEIS2, clone1 embryonic stem cell human CVCL_A4C8 CL:0000010 Transfected with: HGNC; 7001; MEIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672461 CVCL_A4C7 SEES3-1V human MEIS1, clone3 embryonic stem cell human CVCL_A4C7 CL:0000010 Transfected with: HGNC; 7000; MEIS1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672462 CVCL_A4C9 SEES3-1V human MEIS2, clone2 embryonic stem cell human CVCL_A4C9 CL:0000010 Transfected with: HGNC; 7001; MEIS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672463 CVCL_A4C0 SEES3-1V human MEF2A, clone2 embryonic stem cell human CVCL_A4C0 CL:0000010 Transfected with: HGNC; 6993; MEF2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672464 CVCL_A4C2 SEES3-1V human MEF2C, clone1 embryonic stem cell human CVCL_A4C2 CL:0000010 Transfected with: HGNC; 6996; MEF2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672465 CVCL_A4C1 SEES3-1V human MEF2A, clone3 embryonic stem cell human CVCL_A4C1 CL:0000010 Transfected with: HGNC; 6993; MEF2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672466 CVCL_A4C4 SEES3-1V human MEF2C, clone3 embryonic stem cell human CVCL_A4C4 CL:0000010 Transfected with: HGNC; 6996; MEF2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672467 CVCL_A4C3 SEES3-1V human MEF2C, clone2 embryonic stem cell human CVCL_A4C3 CL:0000010 Transfected with: HGNC; 6996; MEF2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672468 CVCL_A4A4 SEES3-1V human MAX, clone1 embryonic stem cell human CVCL_A4A4 CL:0000010 Transfected with: HGNC; 6913; MAX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672469 CVCL_A4A3 SEES3-1V human MAFK, clone3 embryonic stem cell human CVCL_A4A3 CL:0000010 Transfected with: HGNC; 6782; MAFK; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672470 CVCL_A4A6 SEES3-1V human MAX, clone3 embryonic stem cell human CVCL_A4A6 CL:0000010 Transfected with: HGNC; 6913; MAX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672471 CVCL_A4A5 SEES3-1V human MAX, clone2 embryonic stem cell human CVCL_A4A5 CL:0000010 Transfected with: HGNC; 6913; MAX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672472 CVCL_A4A8 SEES3-1V human MAZ, clone2 embryonic stem cell human CVCL_A4A8 CL:0000010 Transfected with: HGNC; 6914; MAZ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672473 CVCL_A4A7 SEES3-1V human MAZ, clone1 embryonic stem cell human CVCL_A4A7 CL:0000010 Transfected with: HGNC; 6914; MAZ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672474 CVCL_A4A9 SEES3-1V human MAZ, clone3 embryonic stem cell human CVCL_A4A9 CL:0000010 Transfected with: HGNC; 6914; MAZ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672475 CVCL_A4A0 SEES3-1V human MAFA, clone3 embryonic stem cell human CVCL_A4A0 CL:0000010 Transfected with: HGNC; 23145; MAFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672476 CVCL_A4A2 SEES3-1V human MAFK, clone2 embryonic stem cell human CVCL_A4A2 CL:0000010 Transfected with: HGNC; 6782; MAFK; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672477 CVCL_A4A1 SEES3-1V human MAFK, clone1 embryonic stem cell human CVCL_A4A1 CL:0000010 Transfected with: HGNC; 6782; MAFK; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672478 CVCL_A5M1 SEES3-1V human POU3F2, clone3 embryonic stem cell human CVCL_A5M1 CL:0000010 Transfected with: HGNC; 9215; POU3F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672479 CVCL_A5M0 SEES3-1V human POU3F2, clone2 embryonic stem cell human CVCL_A5M0 CL:0000010 Transfected with: HGNC; 9215; POU3F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672480 CVCL_A5M3 SEES3-1V human POU3F4, clone2 embryonic stem cell human CVCL_A5M3 CL:0000010 Transfected with: HGNC; 9217; POU3F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672481 CVCL_A5M2 SEES3-1V human POU3F4, clone1 embryonic stem cell human CVCL_A5M2 CL:0000010 Transfected with: HGNC; 9217; POU3F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672482 CVCL_A5M5 SEES3-1V human POU4F1, clone1 embryonic stem cell human CVCL_A5M5 CL:0000010 Transfected with: HGNC; 9218; POU4F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672483 CVCL_A5M4 SEES3-1V human POU3F4, clone3 embryonic stem cell human CVCL_A5M4 CL:0000010 Transfected with: HGNC; 9217; POU3F4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672484 CVCL_A5L6 SEES3-1V human POU2F2, clone1 embryonic stem cell human CVCL_A5L6 CL:0000010 Transfected with: HGNC; 9213; POU2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672485 CVCL_A5L5 SEES3-1V human POU2AF1, clone3 embryonic stem cell human CVCL_A5L5 CL:0000010 Transfected with: HGNC; 9211; POU2AF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672486 CVCL_A5L8 SEES3-1V human POU2F2, clone3 embryonic stem cell human CVCL_A5L8 CL:0000010 Transfected with: HGNC; 9213; POU2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672487 CVCL_A5L7 SEES3-1V human POU2F2, clone2 embryonic stem cell human CVCL_A5L7 CL:0000010 Transfected with: HGNC; 9213; POU2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672488 CVCL_A5L9 SEES3-1V human POU3F2, clone1 embryonic stem cell human CVCL_A5L9 CL:0000010 Transfected with: HGNC; 9215; POU3F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672489 CVCL_A5N0 SEES3-1V human POU4F3, clone3 embryonic stem cell human CVCL_A5N0 CL:0000010 Transfected with: HGNC; 9220; POU4F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672490 CVCL_A5N2 SEES3-1V human POU5F1, clone2 embryonic stem cell human CVCL_A5N2 CL:0000010 Transfected with: HGNC; 9221; POU5F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672491 CVCL_A5N1 SEES3-1V human POU5F1, clone1 embryonic stem cell human CVCL_A5N1 CL:0000010 Transfected with: HGNC; 9221; POU5F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672492 CVCL_A5N4 SEES3-1V human PPARA, clone1 embryonic stem cell human CVCL_A5N4 CL:0000010 Transfected with: HGNC; 9232; PPARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672493 CVCL_A5N3 SEES3-1V human POU5F1, clone3 embryonic stem cell human CVCL_A5N3 CL:0000010 Transfected with: HGNC; 9221; POU5F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672494 CVCL_A5N6 SEES3-1V human PPARA, clone3 embryonic stem cell human CVCL_A5N6 CL:0000010 Transfected with: HGNC; 9232; PPARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672495 CVCL_A5N5 SEES3-1V human PPARA, clone2 embryonic stem cell human CVCL_A5N5 CL:0000010 Transfected with: HGNC; 9232; PPARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672496 CVCL_A5M7 SEES3-1V human POU4F1, clone3 embryonic stem cell human CVCL_A5M7 CL:0000010 Transfected with: HGNC; 9218; POU4F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672497 CVCL_A5M6 SEES3-1V human POU4F1, clone2 embryonic stem cell human CVCL_A5M6 CL:0000010 Transfected with: HGNC; 9218; POU4F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672498 CVCL_A5M9 SEES3-1V human POU4F3, clone2 embryonic stem cell human CVCL_A5M9 CL:0000010 Transfected with: HGNC; 9220; POU4F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672499 CVCL_A5M8 SEES3-1V human POU4F3, clone1 embryonic stem cell human CVCL_A5M8 CL:0000010 Transfected with: HGNC; 9220; POU4F3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672500 CVCL_A5K1 SEES3-1V human PLAGL1, clone1 embryonic stem cell human CVCL_A5K1 CL:0000010 Transfected with: HGNC; 9046; PLAGL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672501 CVCL_A5K0 SEES3-1V human PKNOX2, clone3 embryonic stem cell human CVCL_A5K0 CL:0000010 Transfected with: HGNC; 16714; PKNOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672502 CVCL_A5K3 SEES3-1V human PLAGL1, clone3 embryonic stem cell human CVCL_A5K3 CL:0000010 Transfected with: HGNC; 9046; PLAGL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672503 CVCL_A5K2 SEES3-1V human PLAGL1, clone2 embryonic stem cell human CVCL_A5K2 CL:0000010 Transfected with: HGNC; 9046; PLAGL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672504 CVCL_A5J4 SEES3-1V human PITX2, clone3 embryonic stem cell human CVCL_A5J4 CL:0000010 Transfected with: HGNC; 9005; PITX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672505 CVCL_A5J3 SEES3-1V human PITX2, clone2 embryonic stem cell human CVCL_A5J3 CL:0000010 Transfected with: HGNC; 9005; PITX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672506 CVCL_A5J6 SEES3-1V human PITX3, clone2 embryonic stem cell human CVCL_A5J6 CL:0000010 Transfected with: HGNC; 9006; PITX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672507 CVCL_A5J5 SEES3-1V human PITX3, clone1 embryonic stem cell human CVCL_A5J5 CL:0000010 Transfected with: HGNC; 9006; PITX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672508 CVCL_A5J8 SEES3-1V human PKNOX2, clone1 embryonic stem cell human CVCL_A5J8 CL:0000010 Transfected with: HGNC; 16714; PKNOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672509 CVCL_A5J7 SEES3-1V human PITX3, clone3 embryonic stem cell human CVCL_A5J7 CL:0000010 Transfected with: HGNC; 9006; PITX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672510 CVCL_A5J9 SEES3-1V human PKNOX2, clone2 embryonic stem cell human CVCL_A5J9 CL:0000010 Transfected with: HGNC; 16714; PKNOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672511 CVCL_A5L0 SEES3-1V human POLR3A, clone1 embryonic stem cell human CVCL_A5L0 CL:0000010 Transfected with: HGNC; 30074; POLR3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672512 CVCL_A5L2 SEES3-1V human POLR3A, clone3 embryonic stem cell human CVCL_A5L2 CL:0000010 Transfected with: HGNC; 30074; POLR3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672513 CVCL_A5L1 SEES3-1V human POLR3A, clone2 embryonic stem cell human CVCL_A5L1 CL:0000010 Transfected with: HGNC; 30074; POLR3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672514 CVCL_A5L4 SEES3-1V human POU2AF1, clone2 embryonic stem cell human CVCL_A5L4 CL:0000010 Transfected with: HGNC; 9211; POU2AF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672515 CVCL_A5L3 SEES3-1V human POU2AF1, clone1 embryonic stem cell human CVCL_A5L3 CL:0000010 Transfected with: HGNC; 9211; POU2AF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672516 CVCL_A5K5 SEES3-1V human PLXNB3, clone2 embryonic stem cell human CVCL_A5K5 CL:0000010 Transfected with: HGNC; 9105; PLXNB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672517 CVCL_A5K4 SEES3-1V human PLXNB3, clone1 embryonic stem cell human CVCL_A5K4 CL:0000010 Transfected with: HGNC; 9105; PLXNB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672518 CVCL_A5K7 SEES3-1V human PML, clone1 embryonic stem cell human CVCL_A5K7 CL:0000010 Transfected with: HGNC; 9113; PML; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672519 CVCL_A5K6 SEES3-1V human PLXNB3, clone3 embryonic stem cell human CVCL_A5K6 CL:0000010 Transfected with: HGNC; 9105; PLXNB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672520 CVCL_A5K9 SEES3-1V human PML, clone3 embryonic stem cell human CVCL_A5K9 CL:0000010 Transfected with: HGNC; 9113; PML; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672521 CVCL_A5K8 SEES3-1V human PML, clone2 embryonic stem cell human CVCL_A5K8 CL:0000010 Transfected with: HGNC; 9113; PML; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672522 CVCL_A5I1 SEES3-1V human PHF8, clone2 embryonic stem cell human CVCL_A5I1 CL:0000010 Transfected with: HGNC; 20672; PHF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672523 CVCL_A5I0 SEES3-1V human PHF8, clone1 embryonic stem cell human CVCL_A5I0 CL:0000010 Transfected with: HGNC; 20672; PHF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672524 CVCL_A5H9 SEES3-1V human PHF2, clone3 embryonic stem cell human CVCL_A5H9 CL:0000010 Transfected with: HGNC; 8920; PHF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672525 CVCL_A5H2 SEES3-1V human PGF, clone2 embryonic stem cell human CVCL_A5H2 CL:0000010 Transfected with: HGNC; 8893; PGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672526 CVCL_A5H1 SEES3-1V human PGF, clone1 embryonic stem cell human CVCL_A5H1 CL:0000010 Transfected with: HGNC; 8893; PGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672527 CVCL_A5H4 SEES3-1V human PGR, clone1 embryonic stem cell human CVCL_A5H4 CL:0000010 Transfected with: HGNC; 8910; PGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672528 CVCL_A5H3 SEES3-1V human PGF, clone3 embryonic stem cell human CVCL_A5H3 CL:0000010 Transfected with: HGNC; 8893; PGF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672529 CVCL_A5H6 SEES3-1V human PGR, clone3 embryonic stem cell human CVCL_A5H6 CL:0000010 Transfected with: HGNC; 8910; PGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672530 CVCL_A5H5 SEES3-1V human PGR, clone2 embryonic stem cell human CVCL_A5H5 CL:0000010 Transfected with: HGNC; 8910; PGR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672531 CVCL_A5H8 SEES3-1V human PHF2, clone2 embryonic stem cell human CVCL_A5H8 CL:0000010 Transfected with: HGNC; 8920; PHF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672532 CVCL_A5H7 SEES3-1V human PHF2, clone1 embryonic stem cell human CVCL_A5H7 CL:0000010 Transfected with: HGNC; 8920; PHF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672533 CVCL_A5J0 SEES3-1V human PITX1, clone2 embryonic stem cell human CVCL_A5J0 CL:0000010 Transfected with: HGNC; 9004; PITX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672534 CVCL_A5J2 SEES3-1V human PITX2, clone1 embryonic stem cell human CVCL_A5J2 CL:0000010 Transfected with: HGNC; 9005; PITX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672535 CVCL_A5J1 SEES3-1V human PITX1, clone3 embryonic stem cell human CVCL_A5J1 CL:0000010 Transfected with: HGNC; 9004; PITX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672536 CVCL_A5I3 SEES3-1V human PHOX2B, clone1 embryonic stem cell human CVCL_A5I3 CL:0000010 Transfected with: HGNC; 9143; PHOX2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672537 CVCL_A5I2 SEES3-1V human PHF8, clone3 embryonic stem cell human CVCL_A5I2 CL:0000010 Transfected with: HGNC; 20672; PHF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672538 CVCL_A5I5 SEES3-1V human PHOX2B, clone3 embryonic stem cell human CVCL_A5I5 CL:0000010 Transfected with: HGNC; 9143; PHOX2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672539 CVCL_A5I4 SEES3-1V human PHOX2B, clone2 embryonic stem cell human CVCL_A5I4 CL:0000010 Transfected with: HGNC; 9143; PHOX2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672540 CVCL_A5I7 SEES3-1V human PIAS2, clone2 embryonic stem cell human CVCL_A5I7 CL:0000010 Transfected with: HGNC; 17311; PIAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672541 CVCL_A5I6 SEES3-1V human PIAS2, clone1 embryonic stem cell human CVCL_A5I6 CL:0000010 Transfected with: HGNC; 17311; PIAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672542 CVCL_A5I9 SEES3-1V human PITX1, clone1 embryonic stem cell human CVCL_A5I9 CL:0000010 Transfected with: HGNC; 9004; PITX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672543 CVCL_A5I8 SEES3-1V human PIAS2, clone3 embryonic stem cell human CVCL_A5I8 CL:0000010 Transfected with: HGNC; 17311; PIAS2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672544 CVCL_A5F8 SEES3-1V human PCDH1, clone3 embryonic stem cell human CVCL_A5F8 CL:0000010 Transfected with: HGNC; 8655; PCDH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672545 CVCL_A5F7 SEES3-1V human PCDH1, clone2 embryonic stem cell human CVCL_A5F7 CL:0000010 Transfected with: HGNC; 8655; PCDH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672546 CVCL_A5F9 SEES3-1V human PDE4A, clone1 embryonic stem cell human CVCL_A5F9 CL:0000010 Transfected with: HGNC; 8780; PDE4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672547 CVCL_A5F0 SEES3-1V human PBX1, clone1 embryonic stem cell human CVCL_A5F0 CL:0000010 Transfected with: HGNC; 8632; PBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672548 CVCL_A5F2 SEES3-1V human PBX1, clone3 embryonic stem cell human CVCL_A5F2 CL:0000010 Transfected with: HGNC; 8632; PBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672549 CVCL_A5F1 SEES3-1V human PBX1, clone2 embryonic stem cell human CVCL_A5F1 CL:0000010 Transfected with: HGNC; 8632; PBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672550 CVCL_A5F4 SEES3-1V human PBX3, clone2 embryonic stem cell human CVCL_A5F4 CL:0000010 Transfected with: HGNC; 8634; PBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672551 CVCL_A5F3 SEES3-1V human PBX3, clone1 embryonic stem cell human CVCL_A5F3 CL:0000010 Transfected with: HGNC; 8634; PBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672552 CVCL_A5F6 SEES3-1V human PCDH1, clone1 embryonic stem cell human CVCL_A5F6 CL:0000010 Transfected with: HGNC; 8655; PCDH1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672553 CVCL_A5F5 SEES3-1V human PBX3, clone3 embryonic stem cell human CVCL_A5F5 CL:0000010 Transfected with: HGNC; 8634; PBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672554 CVCL_A5H0 SEES3-1V human PDX1, clone3 embryonic stem cell human CVCL_A5H0 CL:0000010 Transfected with: HGNC; 6107; PDX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672555 CVCL_A5G9 SEES3-1V human PDX1, clone2 embryonic stem cell human CVCL_A5G9 CL:0000010 Transfected with: HGNC; 6107; PDX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672556 CVCL_A5G8 SEES3-1V human PDX1, clone1 embryonic stem cell human CVCL_A5G8 CL:0000010 Transfected with: HGNC; 6107; PDX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672557 CVCL_A5G1 SEES3-1V human PDE4A, clone3 embryonic stem cell human CVCL_A5G1 CL:0000010 Transfected with: HGNC; 8780; PDE4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672558 CVCL_A5G0 SEES3-1V human PDE4A, clone2 embryonic stem cell human CVCL_A5G0 CL:0000010 Transfected with: HGNC; 8780; PDE4A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672559 CVCL_A5G3 SEES3-1V human PDGFA, clone2 embryonic stem cell human CVCL_A5G3 CL:0000010 Transfected with: HGNC; 8799; PDGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672560 CVCL_A5G2 SEES3-1V human PDGFA, clone1 embryonic stem cell human CVCL_A5G2 CL:0000010 Transfected with: HGNC; 8799; PDGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672561 CVCL_A5G5 SEES3-1V human PDLIM1, clone1 embryonic stem cell human CVCL_A5G5 CL:0000010 Transfected with: HGNC; 2067; PDLIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672562 CVCL_A5G4 SEES3-1V human PDGFA, clone3 embryonic stem cell human CVCL_A5G4 CL:0000010 Transfected with: HGNC; 8799; PDGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672563 CVCL_A5G7 SEES3-1V human PDLIM1, clone3 embryonic stem cell human CVCL_A5G7 CL:0000010 Transfected with: HGNC; 2067; PDLIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672564 CVCL_A5G6 SEES3-1V human PDLIM1, clone2 embryonic stem cell human CVCL_A5G6 CL:0000010 Transfected with: HGNC; 2067; PDLIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672565 CVCL_A5U7 SEES3-1V human REPIN1, clone1 embryonic stem cell human CVCL_A5U7 CL:0000010 Transfected with: HGNC; 17922; REPIN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672566 CVCL_A5U6 SEES3-1V human RDBP, clone3 embryonic stem cell human CVCL_A5U6 CL:0000010 Transfected with: HGNC; 13974; NELFE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672567 CVCL_A5U9 SEES3-1V human REPIN1, clone3 embryonic stem cell human CVCL_A5U9 CL:0000010 Transfected with: HGNC; 17922; REPIN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672568 CVCL_A5U8 SEES3-1V human REPIN1, clone2 embryonic stem cell human CVCL_A5U8 CL:0000010 Transfected with: HGNC; 17922; REPIN1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672569 CVCL_A5U1 SEES3-1V human RCOR1, clone1 embryonic stem cell human CVCL_A5U1 CL:0000010 Transfected with: HGNC; 17441; RCOR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672570 CVCL_A5U0 SEES3-1V human RBPJ, clone3 embryonic stem cell human CVCL_A5U0 CL:0000010 Transfected with: HGNC; 5724; RBPJ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672571 CVCL_A5U3 SEES3-1V human RCOR1, clone3 embryonic stem cell human CVCL_A5U3 CL:0000010 Transfected with: HGNC; 17441; RCOR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672572 CVCL_A5U2 SEES3-1V human RCOR1, clone2 embryonic stem cell human CVCL_A5U2 CL:0000010 Transfected with: HGNC; 17441; RCOR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672573 CVCL_A5U5 SEES3-1V human RDBP, clone2 embryonic stem cell human CVCL_A5U5 CL:0000010 Transfected with: HGNC; 13974; NELFE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672574 CVCL_A5U4 SEES3-1V human RDBP, clone1 embryonic stem cell human CVCL_A5U4 CL:0000010 Transfected with: HGNC; 13974; NELFE; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672575 CVCL_A5V8 SEES3-1V human RFX5, clone3 embryonic stem cell human CVCL_A5V8 CL:0000010 Transfected with: HGNC; 9986; RFX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672576 CVCL_A5V7 SEES3-1V human RFX5, clone2 embryonic stem cell human CVCL_A5V7 CL:0000010 Transfected with: HGNC; 9986; RFX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672577 CVCL_A5V9 SEES3-1V human RFXAP, clone1 embryonic stem cell human CVCL_A5V9 CL:0000010 Transfected with: HGNC; 9988; RFXAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672578 CVCL_A5V0 SEES3-1V human REST, clone1 embryonic stem cell human CVCL_A5V0 CL:0000010 Transfected with: HGNC; 9966; REST; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672579 CVCL_A5V2 SEES3-1V human REST, clone3 embryonic stem cell human CVCL_A5V2 CL:0000010 Transfected with: HGNC; 9966; REST; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672580 CVCL_A5V1 SEES3-1V human REST, clone2 embryonic stem cell human CVCL_A5V1 CL:0000010 Transfected with: HGNC; 9966; REST; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672581 CVCL_A5V4 SEES3-1V human RFX2, clone2 embryonic stem cell human CVCL_A5V4 CL:0000010 Transfected with: HGNC; 9983; RFX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672582 CVCL_A5V3 SEES3-1V human RFX2, clone1 embryonic stem cell human CVCL_A5V3 CL:0000010 Transfected with: HGNC; 9983; RFX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672583 CVCL_A5V6 SEES3-1V human RFX5, clone1 embryonic stem cell human CVCL_A5V6 CL:0000010 Transfected with: HGNC; 9986; RFX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672584 CVCL_A5V5 SEES3-1V human RFX2, clone3 embryonic stem cell human CVCL_A5V5 CL:0000010 Transfected with: HGNC; 9983; RFX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672585 CVCL_A5S5 SEES3-1V human RARA, clone3 embryonic stem cell human CVCL_A5S5 CL:0000010 Transfected with: HGNC; 9864; RARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672586 CVCL_A5S4 SEES3-1V human RARA, clone2 embryonic stem cell human CVCL_A5S4 CL:0000010 Transfected with: HGNC; 9864; RARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672587 CVCL_A5S7 SEES3-1V human RARB, clone2 embryonic stem cell human CVCL_A5S7 CL:0000010 Transfected with: HGNC; 9865; RARB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672588 CVCL_A5S6 SEES3-1V human RARB, clone1 embryonic stem cell human CVCL_A5S6 CL:0000010 Transfected with: HGNC; 9865; RARB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672589 CVCL_A5S9 SEES3-1V human RARG, clone1 embryonic stem cell human CVCL_A5S9 CL:0000010 Transfected with: HGNC; 9866; RARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672590 CVCL_A5S8 SEES3-1V human RARB, clone3 embryonic stem cell human CVCL_A5S8 CL:0000010 Transfected with: HGNC; 9865; RARB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672591 CVCL_A5S1 SEES3-1V human RAD21, clone2 embryonic stem cell human CVCL_A5S1 CL:0000010 Transfected with: HGNC; 9811; RAD21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672592 CVCL_A5S0 SEES3-1V human RAD21, clone1 embryonic stem cell human CVCL_A5S0 CL:0000010 Transfected with: HGNC; 9811; RAD21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672593 CVCL_A5S3 SEES3-1V human RARA, clone1 embryonic stem cell human CVCL_A5S3 CL:0000010 Transfected with: HGNC; 9864; RARA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672594 CVCL_A5S2 SEES3-1V human RAD21, clone3 embryonic stem cell human CVCL_A5S2 CL:0000010 Transfected with: HGNC; 9811; RAD21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672595 CVCL_A5T6 SEES3-1V human RBBP6, clone2 embryonic stem cell human CVCL_A5T6 CL:0000010 Transfected with: HGNC; 9889; RBBP6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672596 CVCL_A5T5 SEES3-1V human RBBP6, clone1 embryonic stem cell human CVCL_A5T5 CL:0000010 Transfected with: HGNC; 9889; RBBP6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672597 CVCL_A5T8 SEES3-1V human RBPJ, clone1 embryonic stem cell human CVCL_A5T8 CL:0000010 Transfected with: HGNC; 5724; RBPJ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672598 CVCL_A5T7 SEES3-1V human RBBP6, clone3 embryonic stem cell human CVCL_A5T7 CL:0000010 Transfected with: HGNC; 9889; RBBP6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672599 CVCL_A5T9 SEES3-1V human RBPJ, clone2 embryonic stem cell human CVCL_A5T9 CL:0000010 Transfected with: HGNC; 5724; RBPJ; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672600 CVCL_A5T0 SEES3-1V human RARG, clone2 embryonic stem cell human CVCL_A5T0 CL:0000010 Transfected with: HGNC; 9866; RARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672601 CVCL_A5T2 SEES3-1V human RBBP5, clone1 embryonic stem cell human CVCL_A5T2 CL:0000010 Transfected with: HGNC; 9888; RBBP5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672602 CVCL_A5T1 SEES3-1V human RARG, clone3 embryonic stem cell human CVCL_A5T1 CL:0000010 Transfected with: HGNC; 9866; RARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672603 CVCL_A5T4 SEES3-1V human RBBP5, clone3 embryonic stem cell human CVCL_A5T4 CL:0000010 Transfected with: HGNC; 9888; RBBP5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672604 CVCL_A5T3 SEES3-1V human RBBP5, clone2 embryonic stem cell human CVCL_A5T3 CL:0000010 Transfected with: HGNC; 9888; RBBP5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672605 CVCL_A5Q3 SEES3-1V human PRDM2, clone2 embryonic stem cell human CVCL_A5Q3 CL:0000010 Transfected with: HGNC; 9347; PRDM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672606 CVCL_A5Q2 SEES3-1V human PRDM2, clone1 embryonic stem cell human CVCL_A5Q2 CL:0000010 Transfected with: HGNC; 9347; PRDM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672607 CVCL_A5Q5 SEES3-1V human PRDM4, clone1 embryonic stem cell human CVCL_A5Q5 CL:0000010 Transfected with: HGNC; 9348; PRDM4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672608 CVCL_A5Q4 SEES3-1V human PRDM2, clone3 embryonic stem cell human CVCL_A5Q4 CL:0000010 Transfected with: HGNC; 9347; PRDM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672609 CVCL_A5Q7 SEES3-1V human PRDM4, clone3 embryonic stem cell human CVCL_A5Q7 CL:0000010 Transfected with: HGNC; 9348; PRDM4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672610 CVCL_A5Q6 SEES3-1V human PRDM4, clone2 embryonic stem cell human CVCL_A5Q6 CL:0000010 Transfected with: HGNC; 9348; PRDM4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672611 CVCL_A5Q9 SEES3-1V human PREB, clone2 embryonic stem cell human CVCL_A5Q9 CL:0000010 Transfected with: HGNC; 9356; PREB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672612 CVCL_A5Q8 SEES3-1V human PREB, clone1 embryonic stem cell human CVCL_A5Q8 CL:0000010 Transfected with: HGNC; 9356; PREB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672613 CVCL_A5Q1 SEES3-1V human PRDM13, clone3 embryonic stem cell human CVCL_A5Q1 CL:0000010 Transfected with: HGNC; 13998; PRDM13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672614 CVCL_A5Q0 SEES3-1V human PRDM13, clone2 embryonic stem cell human CVCL_A5Q0 CL:0000010 Transfected with: HGNC; 13998; PRDM13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672615 CVCL_A5P9 SEES3-1V human PRDM13, clone1 embryonic stem cell human CVCL_A5P9 CL:0000010 Transfected with: HGNC; 13998; PRDM13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672616 CVCL_A5R4 SEES3-1V human PTAFR, clone1 embryonic stem cell human CVCL_A5R4 CL:0000010 Transfected with: HGNC; 9582; PTAFR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672617 CVCL_A5R3 SEES3-1V human PRICKLE1, clone3 embryonic stem cell human CVCL_A5R3 CL:0000010 Transfected with: HGNC; 17019; PRICKLE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672618 CVCL_A5R6 SEES3-1V human PTAFR, clone3 embryonic stem cell human CVCL_A5R6 CL:0000010 Transfected with: HGNC; 9582; PTAFR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672619 CVCL_A5R5 SEES3-1V human PTAFR, clone2 embryonic stem cell human CVCL_A5R5 CL:0000010 Transfected with: HGNC; 9582; PTAFR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672620 CVCL_A5R8 SEES3-1V human PTF1A, clone2 embryonic stem cell human CVCL_A5R8 CL:0000010 Transfected with: HGNC; 23734; PTF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672621 CVCL_A5R7 SEES3-1V human PTF1A, clone1 embryonic stem cell human CVCL_A5R7 CL:0000010 Transfected with: HGNC; 23734; PTF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672622 CVCL_A5R9 SEES3-1V human PTF1A, clone3 embryonic stem cell human CVCL_A5R9 CL:0000010 Transfected with: HGNC; 23734; PTF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672623 CVCL_A5R0 SEES3-1V human PREB, clone3 embryonic stem cell human CVCL_A5R0 CL:0000010 Transfected with: HGNC; 9356; PREB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672624 CVCL_A5R2 SEES3-1V human PRICKLE1, clone2 embryonic stem cell human CVCL_A5R2 CL:0000010 Transfected with: HGNC; 17019; PRICKLE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672625 CVCL_A5R1 SEES3-1V human PRICKLE1, clone1 embryonic stem cell human CVCL_A5R1 CL:0000010 Transfected with: HGNC; 17019; PRICKLE1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672626 CVCL_A5N8 SEES3-1V human PPARD, clone2 embryonic stem cell human CVCL_A5N8 CL:0000010 Transfected with: HGNC; 9235; PPARD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672627 CVCL_A5N7 SEES3-1V human PPARD, clone1 embryonic stem cell human CVCL_A5N7 CL:0000010 Transfected with: HGNC; 9235; PPARD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672628 CVCL_A5N9 SEES3-1V human PPARD, clone3 embryonic stem cell human CVCL_A5N9 CL:0000010 Transfected with: HGNC; 9235; PPARD; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672629 CVCL_A5P2 SEES3-1V human PPARG, clone3 embryonic stem cell human CVCL_A5P2 CL:0000010 Transfected with: HGNC; 9236; PPARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672630 CVCL_A5P1 SEES3-1V human PPARG, clone2 embryonic stem cell human CVCL_A5P1 CL:0000010 Transfected with: HGNC; 9236; PPARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672631 CVCL_A5P4 SEES3-1V human PPARGC1A, clone2 embryonic stem cell human CVCL_A5P4 CL:0000010 Transfected with: HGNC; 9237; PPARGC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672632 CVCL_A5P3 SEES3-1V human PPARGC1A, clone1 embryonic stem cell human CVCL_A5P3 CL:0000010 Transfected with: HGNC; 9237; PPARGC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672633 CVCL_A5P6 SEES3-1V human PRDM1, clone1 embryonic stem cell human CVCL_A5P6 CL:0000010 Transfected with: HGNC; 9346; PRDM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672634 CVCL_A5P5 SEES3-1V human PPARGC1A, clone3 embryonic stem cell human CVCL_A5P5 CL:0000010 Transfected with: HGNC; 9237; PPARGC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672635 CVCL_A5P8 SEES3-1V human PRDM1, clone3 embryonic stem cell human CVCL_A5P8 CL:0000010 Transfected with: HGNC; 9346; PRDM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672636 CVCL_A5P7 SEES3-1V human PRDM1, clone2 embryonic stem cell human CVCL_A5P7 CL:0000010 Transfected with: HGNC; 9346; PRDM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672637 CVCL_A5P0 SEES3-1V human PPARG, clone1 embryonic stem cell human CVCL_A5P0 CL:0000010 Transfected with: HGNC; 9236; PPARG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672638 CVCL_A4Y4 SEES3-1V human NSBP1, clone1 embryonic stem cell human CVCL_A4Y4 CL:0000010 Transfected with: HGNC; 8013; HMGN5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672639 CVCL_A4Y3 SEES3-1V human NRF1, clone3 embryonic stem cell human CVCL_A4Y3 CL:0000010 Transfected with: HGNC; 7996; NRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672640 CVCL_A4Y6 SEES3-1V human NSBP1, clone3 embryonic stem cell human CVCL_A4Y6 CL:0000010 Transfected with: HGNC; 8013; HMGN5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672641 CVCL_A4Y5 SEES3-1V human NSBP1, clone2 embryonic stem cell human CVCL_A4Y5 CL:0000010 Transfected with: HGNC; 8013; HMGN5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672642 CVCL_A4Y8 SEES3-1V human NUPR1, clone2 embryonic stem cell human CVCL_A4Y8 CL:0000010 Transfected with: HGNC; 29990; NUPR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672643 CVCL_A4Y7 SEES3-1V human NUPR1, clone1 embryonic stem cell human CVCL_A4Y7 CL:0000010 Transfected with: HGNC; 29990; NUPR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672644 CVCL_A4Y9 SEES3-1V human NUPR1, clone3 embryonic stem cell human CVCL_A4Y9 CL:0000010 Transfected with: HGNC; 29990; NUPR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672645 CVCL_A4Y0 SEES3-1V human NR6A1, clone3 embryonic stem cell human CVCL_A4Y0 CL:0000010 Transfected with: HGNC; 7985; NR6A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672646 CVCL_A4Y2 SEES3-1V human NRF1, clone2 embryonic stem cell human CVCL_A4Y2 CL:0000010 Transfected with: HGNC; 7996; NRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672647 CVCL_A4Y1 SEES3-1V human NRF1, clone1 embryonic stem cell human CVCL_A4Y1 CL:0000010 Transfected with: HGNC; 7996; NRF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672648 CVCL_A4Z5 SEES3-1V human OLIG2, clone3 embryonic stem cell human CVCL_A4Z5 CL:0000010 Transfected with: HGNC; 9398; OLIG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672649 CVCL_A4Z4 SEES3-1V human OLIG2, clone2 embryonic stem cell human CVCL_A4Z4 CL:0000010 Transfected with: HGNC; 9398; OLIG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672650 CVCL_A4Z7 SEES3-1V human OLIG3, clone2 embryonic stem cell human CVCL_A4Z7 CL:0000010 Transfected with: HGNC; 18003; OLIG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672651 CVCL_A4Z6 SEES3-1V human OLIG3, clone1 embryonic stem cell human CVCL_A4Z6 CL:0000010 Transfected with: HGNC; 18003; OLIG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672652 CVCL_A4Z9 SEES3-1V human ONECUT1, clone1 embryonic stem cell human CVCL_A4Z9 CL:0000010 Transfected with: HGNC; 8138; ONECUT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672653 CVCL_A4Z8 SEES3-1V human OLIG3, clone3 embryonic stem cell human CVCL_A4Z8 CL:0000010 Transfected with: HGNC; 18003; OLIG3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672654 CVCL_A4Z1 SEES3-1V human OLIG1, clone2 embryonic stem cell human CVCL_A4Z1 CL:0000010 Transfected with: HGNC; 16983; OLIG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672655 CVCL_A4Z0 SEES3-1V human OLIG1, clone1 embryonic stem cell human CVCL_A4Z0 CL:0000010 Transfected with: HGNC; 16983; OLIG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672656 CVCL_A4Z3 SEES3-1V human OLIG2, clone1 embryonic stem cell human CVCL_A4Z3 CL:0000010 Transfected with: HGNC; 9398; OLIG2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672657 CVCL_A4Z2 SEES3-1V human OLIG1, clone3 embryonic stem cell human CVCL_A4Z2 CL:0000010 Transfected with: HGNC; 16983; OLIG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672658 CVCL_A4W9 SEES3-1V human NR4A2, clone1 embryonic stem cell human CVCL_A4W9 CL:0000010 Transfected with: HGNC; 7981; NR4A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672659 CVCL_A4W2 SEES3-1V human NR2F6, clone3 embryonic stem cell human CVCL_A4W2 CL:0000010 Transfected with: HGNC; 7977; NR2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672660 CVCL_A4W1 SEES3-1V human NR2F6, clone2 embryonic stem cell human CVCL_A4W1 CL:0000010 Transfected with: HGNC; 7977; NR2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672661 CVCL_A4W4 SEES3-1V human NR3C1, clone2 embryonic stem cell human CVCL_A4W4 CL:0000010 Transfected with: HGNC; 7978; NR3C1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672662 CVCL_A4W3 SEES3-1V human NR3C1, clone1 embryonic stem cell human CVCL_A4W3 CL:0000010 Transfected with: HGNC; 7978; NR3C1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672663 CVCL_A4W6 SEES3-1V human NR4A1, clone1 embryonic stem cell human CVCL_A4W6 CL:0000010 Transfected with: HGNC; 7980; NR4A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672664 CVCL_A4W5 SEES3-1V human NR3C1, clone3 embryonic stem cell human CVCL_A4W5 CL:0000010 Transfected with: HGNC; 7978; NR3C1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672665 CVCL_A4W8 SEES3-1V human NR4A1, clone3 embryonic stem cell human CVCL_A4W8 CL:0000010 Transfected with: HGNC; 7980; NR4A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672666 CVCL_A4W7 SEES3-1V human NR4A1, clone2 embryonic stem cell human CVCL_A4W7 CL:0000010 Transfected with: HGNC; 7980; NR4A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672667 CVCL_A4W0 SEES3-1V human NR2F6, clone1 embryonic stem cell human CVCL_A4W0 CL:0000010 Transfected with: HGNC; 7977; NR2F6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672668 CVCL_A4X3 SEES3-1V human NR4A3, clone3 embryonic stem cell human CVCL_A4X3 CL:0000010 Transfected with: HGNC; 7982; NR4A3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672669 CVCL_A4X2 SEES3-1V human NR4A3, clone2 embryonic stem cell human CVCL_A4X2 CL:0000010 Transfected with: HGNC; 7982; NR4A3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672670 CVCL_A4X5 SEES3-1V human NR5A1, clone2 embryonic stem cell human CVCL_A4X5 CL:0000010 Transfected with: HGNC; 7983; NR5A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672671 CVCL_A4X4 SEES3-1V human NR5A1, clone1 embryonic stem cell human CVCL_A4X4 CL:0000010 Transfected with: HGNC; 7983; NR5A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672672 CVCL_A4X7 SEES3-1V human NR5A2, clone1 embryonic stem cell human CVCL_A4X7 CL:0000010 Transfected with: HGNC; 7984; NR5A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672673 CVCL_A4X6 SEES3-1V human NR5A1, clone3 embryonic stem cell human CVCL_A4X6 CL:0000010 Transfected with: HGNC; 7983; NR5A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672674 CVCL_A4X9 SEES3-1V human NR6A1, clone2 embryonic stem cell human CVCL_A4X9 CL:0000010 Transfected with: HGNC; 7985; NR6A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672675 CVCL_A4X8 SEES3-1V human NR6A1, clone1 embryonic stem cell human CVCL_A4X8 CL:0000010 Transfected with: HGNC; 7985; NR6A1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672676 CVCL_A4X1 SEES3-1V human NR4A3, clone1 embryonic stem cell human CVCL_A4X1 CL:0000010 Transfected with: HGNC; 7981; NR4A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672677 CVCL_A4X0 SEES3-1V human NR4A2, clone2 embryonic stem cell human CVCL_A4X0 CL:0000010 Transfected with: HGNC; 7981; NR4A2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672678 CVCL_A4U8 SEES3-1V human NR2E1, clone1 embryonic stem cell human CVCL_A4U8 CL:0000010 Transfected with: HGNC; 7973; NR2E1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672679 CVCL_A4U7 SEES3-1V human NR2C2, clone3 embryonic stem cell human CVCL_A4U7 CL:0000010 Transfected with: HGNC; 7972; NR2C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672680 CVCL_A4U9 SEES3-1V human NR2E1, clone2 embryonic stem cell human CVCL_A4U9 CL:0000010 Transfected with: HGNC; 7973; NR2E1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672681 CVCL_A4U0 SEES3-1V human NR1I2, clone2 embryonic stem cell human CVCL_A4U0 CL:0000010 Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672682 CVCL_A4U2 SEES3-1V human NR1I3, clone1 embryonic stem cell human CVCL_A4U2 CL:0000010 Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672683 CVCL_A4U1 SEES3-1V human NR1I2, clone3 embryonic stem cell human CVCL_A4U1 CL:0000010 Transfected with: HGNC; 7968; NR1I2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672684 CVCL_A4U4 SEES3-1V human NR1I3, clone3 embryonic stem cell human CVCL_A4U4 CL:0000010 Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672685 CVCL_A4U3 SEES3-1V human NR1I3, clone2 embryonic stem cell human CVCL_A4U3 CL:0000010 Transfected with: HGNC; 7969; NR1I3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672686 CVCL_A4U6 SEES3-1V human NR2C2, clone2 embryonic stem cell human CVCL_A4U6 CL:0000010 Transfected with: HGNC; 7972; NR2C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672687 CVCL_A4U5 SEES3-1V human NR2C2, clone1 embryonic stem cell human CVCL_A4U5 CL:0000010 Transfected with: HGNC; 7972; NR2C2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672688 CVCL_A4V9 SEES3-1V human NR2F2, clone3 embryonic stem cell human CVCL_A4V9 CL:0000010 Transfected with: HGNC; 7976; NR2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672689 CVCL_A4V8 SEES3-1V human NR2F2, clone2 embryonic stem cell human CVCL_A4V8 CL:0000010 Transfected with: HGNC; 7976; NR2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672690 CVCL_A4V1 SEES3-1V human NR2E3, clone1 embryonic stem cell human CVCL_A4V1 CL:0000010 Transfected with: HGNC; 7974; NR2E3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672691 CVCL_A4V0 SEES3-1V human NR2E1, clone3 embryonic stem cell human CVCL_A4V0 CL:0000010 Transfected with: HGNC; 7973; NR2E1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672692 CVCL_A4V3 SEES3-1V human NR2E3, clone3 embryonic stem cell human CVCL_A4V3 CL:0000010 Transfected with: HGNC; 7974; NR2E3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672693 CVCL_A4V2 SEES3-1V human NR2E3, clone2 embryonic stem cell human CVCL_A4V2 CL:0000010 Transfected with: HGNC; 7974; NR2E3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672694 CVCL_A4V5 SEES3-1V human NR2F1, clone2 embryonic stem cell human CVCL_A4V5 CL:0000010 Transfected with: HGNC; 7975; NR2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672695 CVCL_A4V4 SEES3-1V human NR2F1, clone1 embryonic stem cell human CVCL_A4V4 CL:0000010 Transfected with: HGNC; 7975; NR2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672696 CVCL_A4V7 SEES3-1V human NR2F2, clone1 embryonic stem cell human CVCL_A4V7 CL:0000010 Transfected with: HGNC; 7976; NR2F2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672697 CVCL_A4V6 SEES3-1V human NR2F1, clone3 embryonic stem cell human CVCL_A4V6 CL:0000010 Transfected with: HGNC; 7975; NR2F1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672698 CVCL_A5D6 SEES3-1V human PAX4, clone2 embryonic stem cell human CVCL_A5D6 CL:0000010 Transfected with: HGNC; 8618; PAX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672699 CVCL_A5D5 SEES3-1V human PAX4, clone1 embryonic stem cell human CVCL_A5D5 CL:0000010 Transfected with: HGNC; 8618; PAX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672700 CVCL_A5D8 SEES3-1V human PAX5, clone1 embryonic stem cell human CVCL_A5D8 CL:0000010 Transfected with: HGNC; 8619; PAX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672701 CVCL_A5D7 SEES3-1V human PAX4, clone3 embryonic stem cell human CVCL_A5D7 CL:0000010 Transfected with: HGNC; 8618; PAX4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672702 CVCL_A5D9 SEES3-1V human PAX5, clone2 embryonic stem cell human CVCL_A5D9 CL:0000010 Transfected with: HGNC; 8619; PAX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672703 CVCL_A5D0 SEES3-1V human PAX2, clone2 embryonic stem cell human CVCL_A5D0 CL:0000010 Transfected with: HGNC; 8616; PAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672704 CVCL_A5D2 SEES3-1V human PAX3, clone1 embryonic stem cell human CVCL_A5D2 CL:0000010 Transfected with: HGNC; 8617; PAX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672705 CVCL_A5D1 SEES3-1V human PAX2, clone3 embryonic stem cell human CVCL_A5D1 CL:0000010 Transfected with: HGNC; 8616; PAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672706 CVCL_A5D4 SEES3-1V human PAX3, clone3 embryonic stem cell human CVCL_A5D4 CL:0000010 Transfected with: HGNC; 8617; PAX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672707 CVCL_A5D3 SEES3-1V human PAX3, clone2 embryonic stem cell human CVCL_A5D3 CL:0000010 Transfected with: HGNC; 8617; PAX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672708 CVCL_A5E7 SEES3-1V human PAX9, clone1 embryonic stem cell human CVCL_A5E7 CL:0000010 Transfected with: HGNC; 8623; PAX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672709 CVCL_A5E6 SEES3-1V human PAX8, clone3 embryonic stem cell human CVCL_A5E6 CL:0000010 Transfected with: HGNC; 8622; PAX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672710 CVCL_A5E9 SEES3-1V human PAX9, clone3 embryonic stem cell human CVCL_A5E9 CL:0000010 Transfected with: HGNC; 8623; PAX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672711 CVCL_A5E8 SEES3-1V human PAX9, clone2 embryonic stem cell human CVCL_A5E8 CL:0000010 Transfected with: HGNC; 8623; PAX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672712 CVCL_A5E1 SEES3-1V human PAX6, clone1 embryonic stem cell human CVCL_A5E1 CL:0000010 Transfected with: HGNC; 8620; PAX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672713 CVCL_A5E0 SEES3-1V human PAX5, clone3 embryonic stem cell human CVCL_A5E0 CL:0000010 Transfected with: HGNC; 8619; PAX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672714 CVCL_A5E3 SEES3-1V human PAX6, clone3 embryonic stem cell human CVCL_A5E3 CL:0000010 Transfected with: HGNC; 8620; PAX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672715 CVCL_A5E2 SEES3-1V human PAX6, clone2 embryonic stem cell human CVCL_A5E2 CL:0000010 Transfected with: HGNC; 8620; PAX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672716 CVCL_A5E5 SEES3-1V human PAX8, clone2 embryonic stem cell human CVCL_A5E5 CL:0000010 Transfected with: HGNC; 8622; PAX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672717 CVCL_A5E4 SEES3-1V human PAX8, clone1 embryonic stem cell human CVCL_A5E4 CL:0000010 Transfected with: HGNC; 8622; PAX8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672718 CVCL_A5B4 SEES3-1V human OTX2, clone1 embryonic stem cell human CVCL_A5B4 CL:0000010 Transfected with: HGNC; 8522; OTX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672719 CVCL_A5B3 SEES3-1V human OTX1, clone3 embryonic stem cell human CVCL_A5B3 CL:0000010 Transfected with: HGNC; 8521; OTX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672720 CVCL_A5B6 SEES3-1V human OTX2, clone3 embryonic stem cell human CVCL_A5B6 CL:0000010 Transfected with: HGNC; 8522; OTX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672721 CVCL_A5B5 SEES3-1V human OTX2, clone2 embryonic stem cell human CVCL_A5B5 CL:0000010 Transfected with: HGNC; 8522; OTX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672722 CVCL_A5B8 SEES3-1V human OVOL2, clone2 embryonic stem cell human CVCL_A5B8 CL:0000010 Transfected with: HGNC; 15804; OVOL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672723 CVCL_A5B7 SEES3-1V human OVOL2, clone1 embryonic stem cell human CVCL_A5B7 CL:0000010 Transfected with: HGNC; 15804; OVOL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672724 CVCL_A5B9 SEES3-1V human OVOL2, clone3 embryonic stem cell human CVCL_A5B9 CL:0000010 Transfected with: HGNC; 15804; OVOL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672725 CVCL_A5B0 SEES3-1V human OTP, clone3 embryonic stem cell human CVCL_A5B0 CL:0000010 Transfected with: HGNC; 8518; OTP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672726 CVCL_A5B2 SEES3-1V human OTX1, clone2 embryonic stem cell human CVCL_A5B2 CL:0000010 Transfected with: HGNC; 8521; OTX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672727 CVCL_A5B1 SEES3-1V human OTX1, clone1 embryonic stem cell human CVCL_A5B1 CL:0000010 Transfected with: HGNC; 8521; OTX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672728 CVCL_A5C5 SEES3-1V human PABPC1, clone3 embryonic stem cell human CVCL_A5C5 CL:0000010 Transfected with: HGNC; 8554; PABPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672729 CVCL_A5C4 SEES3-1V human PABPC1, clone2 embryonic stem cell human CVCL_A5C4 CL:0000010 Transfected with: HGNC; 8554; PABPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672730 CVCL_A5C7 SEES3-1V human PATZ1, clone2 embryonic stem cell human CVCL_A5C7 CL:0000010 Transfected with: HGNC; 13071; PATZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672731 CVCL_A5C6 SEES3-1V human PATZ1, clone1 embryonic stem cell human CVCL_A5C6 CL:0000010 Transfected with: HGNC; 13071; PATZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672732 CVCL_A5C9 SEES3-1V human PAX2, clone1 embryonic stem cell human CVCL_A5C9 CL:0000010 Transfected with: HGNC; 8616; PAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672733 CVCL_A5C8 SEES3-1V human PATZ1, clone3 embryonic stem cell human CVCL_A5C8 CL:0000010 Transfected with: HGNC; 13071; PATZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672734 CVCL_A5C1 SEES3-1V human PA2G4, clone2 embryonic stem cell human CVCL_A5C1 CL:0000010 Transfected with: HGNC; 8550; PA2G4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672735 CVCL_A5C0 SEES3-1V human PA2G4, clone1 embryonic stem cell human CVCL_A5C0 CL:0000010 Transfected with: HGNC; 8550; PA2G4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672736 CVCL_A5C3 SEES3-1V human PABPC1, clone1 embryonic stem cell human CVCL_A5C3 CL:0000010 Transfected with: HGNC; 8554; PABPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672737 CVCL_A5C2 SEES3-1V human PA2G4, clone3 embryonic stem cell human CVCL_A5C2 CL:0000010 Transfected with: HGNC; 8550; PA2G4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672738 CVCL_A5A3 SEES3-1V human OSR1, clone2 embryonic stem cell human CVCL_A5A3 CL:0000010 Transfected with: HGNC; 8111; OSR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672739 CVCL_A5A2 SEES3-1V human OSR1, clone1 embryonic stem cell human CVCL_A5A2 CL:0000010 Transfected with: HGNC; 8111; OSR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672740 CVCL_A5A5 SEES3-1V human OSTF1, clone1 embryonic stem cell human CVCL_A5A5 CL:0000010 Transfected with: HGNC; 8510; OSTF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672741 CVCL_A5A4 SEES3-1V human OSR1, clone3 embryonic stem cell human CVCL_A5A4 CL:0000010 Transfected with: HGNC; 8111; OSR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672742 CVCL_A5A7 SEES3-1V human OSTF1, clone3 embryonic stem cell human CVCL_A5A7 CL:0000010 Transfected with: HGNC; 8510; OSTF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672743 CVCL_A5A6 SEES3-1V human OSTF1, clone2 embryonic stem cell human CVCL_A5A6 CL:0000010 Transfected with: HGNC; 8510; OSTF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672744 CVCL_A5A9 SEES3-1V human OTP, clone2 embryonic stem cell human CVCL_A5A9 CL:0000010 Transfected with: HGNC; 8518; OTP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672745 CVCL_A5A8 SEES3-1V human OTP, clone1 embryonic stem cell human CVCL_A5A8 CL:0000010 Transfected with: HGNC; 8518; OTP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672746 CVCL_A5A1 SEES3-1V human ONECUT1, clone3 embryonic stem cell human CVCL_A5A1 CL:0000010 Transfected with: HGNC; 8138; ONECUT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672747 CVCL_A5A0 SEES3-1V human ONECUT1, clone2 embryonic stem cell human CVCL_A5A0 CL:0000010 Transfected with: HGNC; 8138; ONECUT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672748 CVCL_A6N7 SEES3-1V human SOX7, clone3 embryonic stem cell human CVCL_A6N7 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672749 CVCL_A6N6 SEES3-1V human SOX7, clone2 embryonic stem cell human CVCL_A6N6 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672750 CVCL_A6N9 SEES3-1V human SOX9, clone2 embryonic stem cell human CVCL_A6N9 CL:0000010 Transfected with: HGNC; 11204; SOX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672751 CVCL_A6N8 SEES3-1V human SOX9, clone1 embryonic stem cell human CVCL_A6N8 CL:0000010 Transfected with: HGNC; 11204; SOX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672752 CVCL_A6P1 SEES3-1V human SP4, clone1 embryonic stem cell human CVCL_A6P1 CL:0000010 Transfected with: HGNC; 11209; SP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672753 CVCL_A6P0 SEES3-1V human SOX9, clone3 embryonic stem cell human CVCL_A6P0 CL:0000010 Transfected with: HGNC; 11204; SOX9; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672754 CVCL_A6P3 SEES3-1V human SP4, clone3 embryonic stem cell human CVCL_A6P3 CL:0000010 Transfected with: HGNC; 11209; SP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672755 CVCL_A6P2 SEES3-1V human SP4, clone2 embryonic stem cell human CVCL_A6P2 CL:0000010 Transfected with: HGNC; 11209; SP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672756 CVCL_A6P5 SEES3-1V human SP8, clone2 embryonic stem cell human CVCL_A6P5 CL:0000010 Transfected with: HGNC; 19196; SP8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672757 CVCL_A6P4 SEES3-1V human SP8, clone1 embryonic stem cell human CVCL_A6P4 CL:0000010 Transfected with: HGNC; 19196; SP8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672758 CVCL_A6P7 SEES3-1V human SPI1, clone1 embryonic stem cell human CVCL_A6P7 CL:0000010 Transfected with: HGNC; 11241; SPI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672759 CVCL_A6P6 SEES3-1V human SP8, clone3 embryonic stem cell human CVCL_A6P6 CL:0000010 Transfected with: HGNC; 19196; SP8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672760 CVCL_A6M0 SEES3-1V human SOX15, clone1 embryonic stem cell human CVCL_A6M0 CL:0000010 Transfected with: HGNC; 11196; SOX15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672761 CVCL_A6M2 SEES3-1V human SOX15, clone3 embryonic stem cell human CVCL_A6M2 CL:0000010 Transfected with: HGNC; 11196; SOX15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672762 CVCL_A6M1 SEES3-1V human SOX15, clone2 embryonic stem cell human CVCL_A6M1 CL:0000010 Transfected with: HGNC; 11196; SOX15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672763 CVCL_A6M4 SEES3-1V human SOX17, clone2 embryonic stem cell human CVCL_A6M4 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672764 CVCL_A6M3 SEES3-1V human SOX17, clone1 embryonic stem cell human CVCL_A6M3 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672765 CVCL_A6L5 SEES3-1V human SOX11, clone2 embryonic stem cell human CVCL_A6L5 CL:0000010 Transfected with: HGNC; 11191; SOX11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672766 CVCL_A6L4 SEES3-1V human SOX11, clone1 embryonic stem cell human CVCL_A6L4 CL:0000010 Transfected with: HGNC; 11191; SOX11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672767 CVCL_A6L7 SEES3-1V human SOX14, clone1 embryonic stem cell human CVCL_A6L7 CL:0000010 Transfected with: HGNC; 11193; SOX14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672768 CVCL_A6L6 SEES3-1V human SOX11, clone3 embryonic stem cell human CVCL_A6L6 CL:0000010 Transfected with: HGNC; 11191; SOX11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672769 CVCL_A6L9 SEES3-1V human SOX14, clone3 embryonic stem cell human CVCL_A6L9 CL:0000010 Transfected with: HGNC; 11193; SOX14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672770 CVCL_A6L8 SEES3-1V human SOX14, clone2 embryonic stem cell human CVCL_A6L8 CL:0000010 Transfected with: HGNC; 11193; SOX14; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672771 CVCL_A6N1 SEES3-1V human SOX5, clone3 embryonic stem cell human CVCL_A6N1 CL:0000010 Transfected with: HGNC; 11201; SOX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672772 CVCL_A6N0 SEES3-1V human SOX5, clone2 embryonic stem cell human CVCL_A6N0 CL:0000010 Transfected with: HGNC; 11201; SOX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672773 CVCL_A6N3 SEES3-1V human SOX6, clone2 embryonic stem cell human CVCL_A6N3 CL:0000010 Transfected with: HGNC; 16421; SOX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672774 CVCL_A6N2 SEES3-1V human SOX6, clone1 embryonic stem cell human CVCL_A6N2 CL:0000010 Transfected with: HGNC; 16421; SOX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672775 CVCL_A6N5 SEES3-1V human SOX7, clone1 embryonic stem cell human CVCL_A6N5 CL:0000010 Transfected with: HGNC; 18196; SOX7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672776 CVCL_A6N4 SEES3-1V human SOX6, clone3 embryonic stem cell human CVCL_A6N4 CL:0000010 Transfected with: HGNC; 16421; SOX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672777 CVCL_A6M6 SEES3-1V human SOX2, clone1 embryonic stem cell human CVCL_A6M6 CL:0000010 Transfected with: HGNC; 11195; SOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672778 CVCL_A6M5 SEES3-1V human SOX17, clone3 embryonic stem cell human CVCL_A6M5 CL:0000010 Transfected with: HGNC; 18122; SOX17; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672779 CVCL_A6M8 SEES3-1V human SOX2, clone3 embryonic stem cell human CVCL_A6M8 CL:0000010 Transfected with: HGNC; 11195; SOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672780 CVCL_A6M7 SEES3-1V human SOX2, clone2 embryonic stem cell human CVCL_A6M7 CL:0000010 Transfected with: HGNC; 11195; SOX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672781 CVCL_A6M9 SEES3-1V human SOX5, clone1 embryonic stem cell human CVCL_A6M9 CL:0000010 Transfected with: HGNC; 11201; SOX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672782 CVCL_A6K0 SEES3-1V human SNAI2, clone2 embryonic stem cell human CVCL_A6K0 CL:0000010 Transfected with: HGNC; 11094; SNAI2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672783 CVCL_A6K2 SEES3-1V human SNAI3, clone1 embryonic stem cell human CVCL_A6K2 CL:0000010 Transfected with: HGNC; 18411; SNAI3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672784 CVCL_A6K1 SEES3-1V human SNAI2, clone3 embryonic stem cell human CVCL_A6K1 CL:0000010 Transfected with: HGNC; 11094; SNAI2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672785 CVCL_A6J3 SEES3-1V human SMC3, clone1 embryonic stem cell human CVCL_A6J3 CL:0000010 Transfected with: HGNC; 2468; SMC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672786 CVCL_A6J2 SEES3-1V human SMC1A, clone3 embryonic stem cell human CVCL_A6J2 CL:0000010 Transfected with: HGNC; 11111; SMC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672787 CVCL_A6J5 SEES3-1V human SMC3, clone3 embryonic stem cell human CVCL_A6J5 CL:0000010 Transfected with: HGNC; 2468; SMC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672788 CVCL_A6J4 SEES3-1V human SMC3, clone2 embryonic stem cell human CVCL_A6J4 CL:0000010 Transfected with: HGNC; 2468; SMC3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672789 CVCL_A6J7 SEES3-1V human SNAI1, clone2 embryonic stem cell human CVCL_A6J7 CL:0000010 Transfected with: HGNC; 11128; SNAI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672790 CVCL_A6J6 SEES3-1V human SNAI1, clone1 embryonic stem cell human CVCL_A6J6 CL:0000010 Transfected with: HGNC; 11128; SNAI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672791 CVCL_A6J9 SEES3-1V human SNAI2, clone1 embryonic stem cell human CVCL_A6J9 CL:0000010 Transfected with: HGNC; 11094; SNAI2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672792 CVCL_A6J8 SEES3-1V human SNAI1, clone3 embryonic stem cell human CVCL_A6J8 CL:0000010 Transfected with: HGNC; 11128; SNAI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672793 CVCL_A6L1 SEES3-1V human SOX10, clone1 embryonic stem cell human CVCL_A6L1 CL:0000010 Transfected with: HGNC; 11190; SOX10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672794 CVCL_A6L0 SEES3-1V human SNAPC4, clone3 embryonic stem cell human CVCL_A6L0 CL:0000010 Transfected with: HGNC; 11137; SNAPC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672795 CVCL_A6L3 SEES3-1V human SOX10, clone3 embryonic stem cell human CVCL_A6L3 CL:0000010 Transfected with: HGNC; 11190; SOX10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672796 CVCL_A6L2 SEES3-1V human SOX10, clone2 embryonic stem cell human CVCL_A6L2 CL:0000010 Transfected with: HGNC; 11190; SOX10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672797 CVCL_A6K4 SEES3-1V human SNAI3, clone3 embryonic stem cell human CVCL_A6K4 CL:0000010 Transfected with: HGNC; 18411; SNAI3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672798 CVCL_A6K3 SEES3-1V human SNAI3, clone2 embryonic stem cell human CVCL_A6K3 CL:0000010 Transfected with: HGNC; 18411; SNAI3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672799 CVCL_A6K6 SEES3-1V human SNAPC1, clone2 embryonic stem cell human CVCL_A6K6 CL:0000010 Transfected with: HGNC; 11134; SNAPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672800 CVCL_A6K5 SEES3-1V human SNAPC1, clone1 embryonic stem cell human CVCL_A6K5 CL:0000010 Transfected with: HGNC; 11134; SNAPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672801 CVCL_A6K8 SEES3-1V human SNAPC4, clone1 embryonic stem cell human CVCL_A6K8 CL:0000010 Transfected with: HGNC; 11137; SNAPC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672802 CVCL_A6K7 SEES3-1V human SNAPC1, clone3 embryonic stem cell human CVCL_A6K7 CL:0000010 Transfected with: HGNC; 11134; SNAPC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672803 CVCL_A6K9 SEES3-1V human SNAPC4, clone2 embryonic stem cell human CVCL_A6K9 CL:0000010 Transfected with: HGNC; 11137; SNAPC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672804 CVCL_A6I0 SEES3-1V human SMARCA4, clone3 embryonic stem cell human CVCL_A6I0 CL:0000010 Transfected with: HGNC; 11100; SMARCA4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672805 CVCL_A6H9 SEES3-1V human SMARCA4, clone2 embryonic stem cell human CVCL_A6H9 CL:0000010 Transfected with: HGNC; 11100; SMARCA4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672806 CVCL_A6H8 SEES3-1V human SMARCA4, clone1 embryonic stem cell human CVCL_A6H8 CL:0000010 Transfected with: HGNC; 11100; SMARCA4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672807 CVCL_A6H1 SEES3-1V human SMAD4, clone3 embryonic stem cell human CVCL_A6H1 CL:0000010 Transfected with: HGNC; 6770; SMAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672808 CVCL_A6H0 SEES3-1V human SMAD4, clone2 embryonic stem cell human CVCL_A6H0 CL:0000010 Transfected with: HGNC; 6770; SMAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672809 CVCL_A6H3 SEES3-1V human SMAD5, clone2 embryonic stem cell human CVCL_A6H3 CL:0000010 Transfected with: HGNC; 6771; SMAD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672810 CVCL_A6H2 SEES3-1V human SMAD5, clone1 embryonic stem cell human CVCL_A6H2 CL:0000010 Transfected with: HGNC; 6771; SMAD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672811 CVCL_A6H5 SEES3-1V human SMAD7, clone1 embryonic stem cell human CVCL_A6H5 CL:0000010 Transfected with: HGNC; 6773; SMAD7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672812 CVCL_A6H4 SEES3-1V human SMAD5, clone3 embryonic stem cell human CVCL_A6H4 CL:0000010 Transfected with: HGNC; 6771; SMAD5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672813 CVCL_A6H7 SEES3-1V human SMAD7, clone3 embryonic stem cell human CVCL_A6H7 CL:0000010 Transfected with: HGNC; 6773; SMAD7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672814 CVCL_A6H6 SEES3-1V human SMAD7, clone2 embryonic stem cell human CVCL_A6H6 CL:0000010 Transfected with: HGNC; 6773; SMAD7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672815 CVCL_A6J1 SEES3-1V human SMC1A, clone2 embryonic stem cell human CVCL_A6J1 CL:0000010 Transfected with: HGNC; 11111; SMC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672816 CVCL_A6J0 SEES3-1V human SMC1A, clone1 embryonic stem cell human CVCL_A6J0 CL:0000010 Transfected with: HGNC; 11111; SMC1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672817 CVCL_A6I9 SEES3-1V human SMARCC2, clone3 embryonic stem cell human CVCL_A6I9 CL:0000010 Transfected with: HGNC; 11105; SMARCC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672818 CVCL_A6I2 SEES3-1V human SMARCB1, clone2 embryonic stem cell human CVCL_A6I2 CL:0000010 Transfected with: HGNC; 11103; SMARCB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672819 CVCL_A6I1 SEES3-1V human SMARCB1, clone1 embryonic stem cell human CVCL_A6I1 CL:0000010 Transfected with: HGNC; 11103; SMARCB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672820 CVCL_A6I4 SEES3-1V human SMARCC1, clone1 embryonic stem cell human CVCL_A6I4 CL:0000010 Transfected with: HGNC; 11104; SMARCC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672821 CVCL_A6I3 SEES3-1V human SMARCB1, clone3 embryonic stem cell human CVCL_A6I3 CL:0000010 Transfected with: HGNC; 11103; SMARCB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672822 CVCL_A6I6 SEES3-1V human SMARCC1, clone3 embryonic stem cell human CVCL_A6I6 CL:0000010 Transfected with: HGNC; 11104; SMARCC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672823 CVCL_A6I5 SEES3-1V human SMARCC1, clone2 embryonic stem cell human CVCL_A6I5 CL:0000010 Transfected with: HGNC; 11104; SMARCC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672824 CVCL_A6I8 SEES3-1V human SMARCC2, clone2 embryonic stem cell human CVCL_A6I8 CL:0000010 Transfected with: HGNC; 11105; SMARCC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672825 CVCL_A6I7 SEES3-1V human SMARCC2, clone1 embryonic stem cell human CVCL_A6I7 CL:0000010 Transfected with: HGNC; 11105; SMARCC2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672826 CVCL_A6W8 SEES3-1V human TAB1, clone3 embryonic stem cell human CVCL_A6W8 CL:0000010 Transfected with: HGNC; 18157; TAB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672827 CVCL_A6W7 SEES3-1V human TAB1, clone2 embryonic stem cell human CVCL_A6W7 CL:0000010 Transfected with: HGNC; 18157; TAB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672828 CVCL_A6W9 SEES3-1V human TAF10, clone1 embryonic stem cell human CVCL_A6W9 CL:0000010 Transfected with: HGNC; 11543; TAF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672829 CVCL_A6W0 SEES3-1V human SUZ12, clone1 embryonic stem cell human CVCL_A6W0 CL:0000010 Transfected with: HGNC; 17101; SUZ12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672830 CVCL_A6W2 SEES3-1V human SUZ12, clone3 embryonic stem cell human CVCL_A6W2 CL:0000010 Transfected with: HGNC; 17101; SUZ12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672831 CVCL_A6W1 SEES3-1V human SUZ12, clone2 embryonic stem cell human CVCL_A6W1 CL:0000010 Transfected with: HGNC; 17101; SUZ12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672832 CVCL_A6W4 SEES3-1V human T, clone2 embryonic stem cell human CVCL_A6W4 CL:0000010 Transfected with: HGNC; 11515; TBXT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672833 CVCL_A6W3 SEES3-1V human T, clone1 embryonic stem cell human CVCL_A6W3 CL:0000010 Transfected with: HGNC; 11515; TBXT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672834 CVCL_A6W6 SEES3-1V human TAB1, clone1 embryonic stem cell human CVCL_A6W6 CL:0000010 Transfected with: HGNC; 18157; TAB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672835 CVCL_A6W5 SEES3-1V human T, clone3 embryonic stem cell human CVCL_A6W5 CL:0000010 Transfected with: HGNC; 11515; TBXT; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672836 CVCL_A6X9 SEES3-1V human TAF13, clone2 embryonic stem cell human CVCL_A6X9 CL:0000010 Transfected with: HGNC; 11546; TAF13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672837 CVCL_A6X8 SEES3-1V human TAF13, clone1 embryonic stem cell human CVCL_A6X8 CL:0000010 Transfected with: HGNC; 11546; TAF13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672838 CVCL_A6X1 SEES3-1V human TAF10, clone3 embryonic stem cell human CVCL_A6X1 CL:0000010 Transfected with: HGNC; 11543; TAF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672839 CVCL_A6X0 SEES3-1V human TAF10, clone2 embryonic stem cell human CVCL_A6X0 CL:0000010 Transfected with: HGNC; 11543; TAF10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672840 CVCL_A6X3 SEES3-1V human TAF11, clone2 embryonic stem cell human CVCL_A6X3 CL:0000010 Transfected with: HGNC; 11544; TAF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672841 CVCL_A6X2 SEES3-1V human TAF11, clone1 embryonic stem cell human CVCL_A6X2 CL:0000010 Transfected with: HGNC; 11544; TAF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672842 CVCL_A6X5 SEES3-1V human TAF12, clone1 embryonic stem cell human CVCL_A6X5 CL:0000010 Transfected with: HGNC; 11545; TAF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672843 CVCL_A6X4 SEES3-1V human TAF11, clone3 embryonic stem cell human CVCL_A6X4 CL:0000010 Transfected with: HGNC; 11544; TAF11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672844 CVCL_A6X7 SEES3-1V human TAF12, clone3 embryonic stem cell human CVCL_A6X7 CL:0000010 Transfected with: HGNC; 11545; TAF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672845 CVCL_A6X6 SEES3-1V human TAF12, clone2 embryonic stem cell human CVCL_A6X6 CL:0000010 Transfected with: HGNC; 11545; TAF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672846 CVCL_A6U6 SEES3-1V human STAT4, clone2 embryonic stem cell human CVCL_A6U6 CL:0000010 Transfected with: HGNC; 11365; STAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672847 CVCL_A6U5 SEES3-1V human STAT4, clone1 embryonic stem cell human CVCL_A6U5 CL:0000010 Transfected with: HGNC; 11365; STAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672848 CVCL_A6U8 SEES3-1V human STAT5A, clone1 embryonic stem cell human CVCL_A6U8 CL:0000010 Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672849 CVCL_A6U7 SEES3-1V human STAT4, clone3 embryonic stem cell human CVCL_A6U7 CL:0000010 Transfected with: HGNC; 11365; STAT4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672850 CVCL_A6U9 SEES3-1V human STAT5A, clone2 embryonic stem cell human CVCL_A6U9 CL:0000010 Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672851 CVCL_A6U0 SEES3-1V human STAG1, clone2 embryonic stem cell human CVCL_A6U0 CL:0000010 Transfected with: HGNC; 11354; STAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672852 CVCL_A6U2 SEES3-1V human STAT3, clone1 embryonic stem cell human CVCL_A6U2 CL:0000010 Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672853 CVCL_A6U1 SEES3-1V human STAG1, clone3 embryonic stem cell human CVCL_A6U1 CL:0000010 Transfected with: HGNC; 11354; STAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672854 CVCL_A6U4 SEES3-1V human STAT3, clone3 embryonic stem cell human CVCL_A6U4 CL:0000010 Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672855 CVCL_A6U3 SEES3-1V human STAT3, clone2 embryonic stem cell human CVCL_A6U3 CL:0000010 Transfected with: HGNC; 11364; STAT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672856 CVCL_A6V7 SEES3-1V human SUB1, clone1 embryonic stem cell human CVCL_A6V7 CL:0000010 Transfected with: HGNC; 19985; SUB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672857 CVCL_A6V6 SEES3-1V human STRA8, clone3 embryonic stem cell human CVCL_A6V6 CL:0000010 Transfected with: HGNC; 30653; STRA8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672858 CVCL_A6V9 SEES3-1V human SUB1, clone3 embryonic stem cell human CVCL_A6V9 CL:0000010 Transfected with: HGNC; 19985; SUB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672859 CVCL_A6V8 SEES3-1V human SUB1, clone2 embryonic stem cell human CVCL_A6V8 CL:0000010 Transfected with: HGNC; 19985; SUB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672860 CVCL_A6V1 SEES3-1V human STRA13, clone1 embryonic stem cell human CVCL_A6V1 CL:0000010 Transfected with: HGNC; 11422; CENPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672861 CVCL_A6V0 SEES3-1V human STAT5A, clone3 embryonic stem cell human CVCL_A6V0 CL:0000010 Transfected with: HGNC; 11366; STAT5A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672862 CVCL_A6V3 SEES3-1V human STRA13, clone3 embryonic stem cell human CVCL_A6V3 CL:0000010 Transfected with: HGNC; 11422; CENPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672863 CVCL_A6V2 SEES3-1V human STRA13, clone2 embryonic stem cell human CVCL_A6V2 CL:0000010 Transfected with: HGNC; 11422; CENPX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672864 CVCL_A6V5 SEES3-1V human STRA8, clone2 embryonic stem cell human CVCL_A6V5 CL:0000010 Transfected with: HGNC; 30653; STRA8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672865 CVCL_A6V4 SEES3-1V human STRA8, clone1 embryonic stem cell human CVCL_A6V4 CL:0000010 Transfected with: HGNC; 30653; STRA8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672866 CVCL_A6S4 SEES3-1V human SRF, clone1 embryonic stem cell human CVCL_A6S4 CL:0000010 Transfected with: HGNC; 11291; SRF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672867 CVCL_A6S3 SEES3-1V human SREBF2, clone3 embryonic stem cell human CVCL_A6S3 CL:0000010 Transfected with: HGNC; 11290; SREBF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672868 CVCL_A6S6 SEES3-1V human SRF, clone3 embryonic stem cell human CVCL_A6S6 CL:0000010 Transfected with: HGNC; 11291; SRF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672869 CVCL_A6S5 SEES3-1V human SRF, clone2 embryonic stem cell human CVCL_A6S5 CL:0000010 Transfected with: HGNC; 11291; SRF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672870 CVCL_A6S8 SEES3-1V human SSX1, clone2 embryonic stem cell human CVCL_A6S8 CL:0000010 Transfected with: HGNC; 11335; SSX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672871 CVCL_A6S7 SEES3-1V human SSX1, clone1 embryonic stem cell human CVCL_A6S7 CL:0000010 Transfected with: HGNC; 11335; SSX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672872 CVCL_A6S9 SEES3-1V human SSX1, clone3 embryonic stem cell human CVCL_A6S9 CL:0000010 Transfected with: HGNC; 11335; SSX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672873 CVCL_A6S0 SEES3-1V human SREBF1, clone3 embryonic stem cell human CVCL_A6S0 CL:0000010 Transfected with: HGNC; 11289; SREBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672874 CVCL_A6S2 SEES3-1V human SREBF2, clone2 embryonic stem cell human CVCL_A6S2 CL:0000010 Transfected with: HGNC; 11290; SREBF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672875 CVCL_A6S1 SEES3-1V human SREBF2, clone1 embryonic stem cell human CVCL_A6S1 CL:0000010 Transfected with: HGNC; 11290; SREBF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672876 CVCL_A6T5 SEES3-1V human SSX6, clone3 embryonic stem cell human CVCL_A6T5 CL:0000010 Transfected with: HGNC; 19652; SSX6P; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672877 CVCL_A6T4 SEES3-1V human SSX6, clone2 embryonic stem cell human CVCL_A6T4 CL:0000010 Transfected with: HGNC; 19652; SSX6P; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672878 CVCL_A6T7 SEES3-1V human ST18, clone2 embryonic stem cell human CVCL_A6T7 CL:0000010 Transfected with: HGNC; 18695; ST18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672879 CVCL_A6T6 SEES3-1V human ST18, clone1 embryonic stem cell human CVCL_A6T6 CL:0000010 Transfected with: HGNC; 18695; ST18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672880 CVCL_A6T9 SEES3-1V human STAG1, clone1 embryonic stem cell human CVCL_A6T9 CL:0000010 Transfected with: HGNC; 11354; STAG1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672881 CVCL_A6T8 SEES3-1V human ST18, clone3 embryonic stem cell human CVCL_A6T8 CL:0000010 Transfected with: HGNC; 18695; ST18; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672882 CVCL_A6T1 SEES3-1V human SSX4B, clone2 embryonic stem cell human CVCL_A6T1 CL:0000010 Transfected with: HGNC; 16880; SSX4B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672883 CVCL_A6T0 SEES3-1V human SSX4B, clone1 embryonic stem cell human CVCL_A6T0 CL:0000010 Transfected with: HGNC; 16880; SSX4B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672884 CVCL_A6T3 SEES3-1V human SSX6, clone1 embryonic stem cell human CVCL_A6T3 CL:0000010 Transfected with: HGNC; 19652; SSX6P; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672885 CVCL_A6T2 SEES3-1V human SSX4B, clone3 embryonic stem cell human CVCL_A6T2 CL:0000010 Transfected with: HGNC; 16880; SSX4B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672886 CVCL_A6Q2 SEES3-1V human SPIB, clone3 embryonic stem cell human CVCL_A6Q2 CL:0000010 Transfected with: HGNC; 11242; SPIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672887 CVCL_A6Q1 SEES3-1V human SPIB, clone2 embryonic stem cell human CVCL_A6Q1 CL:0000010 Transfected with: HGNC; 11242; SPIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672888 CVCL_A6Q4 SEES3-1V human SPIC, clone2 embryonic stem cell human CVCL_A6Q4 CL:0000010 Transfected with: HGNC; 29549; SPIC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672889 CVCL_A6Q3 SEES3-1V human SPIC, clone1 embryonic stem cell human CVCL_A6Q3 CL:0000010 Transfected with: HGNC; 29549; SPIC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672890 CVCL_A6Q6 SEES3-1V human SPINT1, clone1 embryonic stem cell human CVCL_A6Q6 CL:0000010 Transfected with: HGNC; 11246; SPINT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672891 CVCL_A6Q5 SEES3-1V human SPIC, clone3 embryonic stem cell human CVCL_A6Q5 CL:0000010 Transfected with: HGNC; 29549; SPIC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672892 CVCL_A6Q8 SEES3-1V human SPINT1, clone3 embryonic stem cell human CVCL_A6Q8 CL:0000010 Transfected with: HGNC; 11246; SPINT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672893 CVCL_A6Q7 SEES3-1V human SPINT1, clone2 embryonic stem cell human CVCL_A6Q7 CL:0000010 Transfected with: HGNC; 11246; SPINT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672894 CVCL_A6Q0 SEES3-1V human SPIB, clone1 embryonic stem cell human CVCL_A6Q0 CL:0000010 Transfected with: HGNC; 11242; SPIB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672895 CVCL_A6P9 SEES3-1V human SPI1, clone3 embryonic stem cell human CVCL_A6P9 CL:0000010 Transfected with: HGNC; 11241; SPI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672896 CVCL_A6P8 SEES3-1V human SPI1, clone2 embryonic stem cell human CVCL_A6P8 CL:0000010 Transfected with: HGNC; 11241; SPI1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672897 CVCL_A6R3 SEES3-1V human SPZ1, clone2 embryonic stem cell human CVCL_A6R3 CL:0000010 Transfected with: HGNC; 30721; SPZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672898 CVCL_A6R2 SEES3-1V human SPZ1, clone1 embryonic stem cell human CVCL_A6R2 CL:0000010 Transfected with: HGNC; 30721; SPZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672899 CVCL_A6R5 SEES3-1V human SRCAP, clone1 embryonic stem cell human CVCL_A6R5 CL:0000010 Transfected with: HGNC; 16974; SRCAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672900 CVCL_A6R4 SEES3-1V human SPZ1, clone3 embryonic stem cell human CVCL_A6R4 CL:0000010 Transfected with: HGNC; 30721; SPZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672901 CVCL_A6R7 SEES3-1V human SRCAP, clone3 embryonic stem cell human CVCL_A6R7 CL:0000010 Transfected with: HGNC; 16974; SRCAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672902 CVCL_A6R6 SEES3-1V human SRCAP, clone2 embryonic stem cell human CVCL_A6R6 CL:0000010 Transfected with: HGNC; 16974; SRCAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672903 CVCL_A6R9 SEES3-1V human SREBF1, clone2 embryonic stem cell human CVCL_A6R9 CL:0000010 Transfected with: HGNC; 11289; SREBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672904 CVCL_A6R8 SEES3-1V human SREBF1, clone1 embryonic stem cell human CVCL_A6R8 CL:0000010 Transfected with: HGNC; 11289; SREBF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672905 CVCL_A6R1 SEES3-1V human SPRY2, clone3 embryonic stem cell human CVCL_A6R1 CL:0000010 Transfected with: HGNC; 11270; SPRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672906 CVCL_A6R0 SEES3-1V human SPRY2, clone2 embryonic stem cell human CVCL_A6R0 CL:0000010 Transfected with: HGNC; 11270; SPRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672907 CVCL_A6Q9 SEES3-1V human SPRY2, clone1 embryonic stem cell human CVCL_A6Q9 CL:0000010 Transfected with: HGNC; 11270; SPRY2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672908 CVCL_A5Y3 SEES3-1V human RUNX1, clone2 embryonic stem cell human CVCL_A5Y3 CL:0000010 Transfected with: HGNC; 10471; RUNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672909 CVCL_A5Y2 SEES3-1V human RUNX1, clone1 embryonic stem cell human CVCL_A5Y2 CL:0000010 Transfected with: HGNC; 10471; RUNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672910 CVCL_A5Y5 SEES3-1V human RUNX2, clone1 embryonic stem cell human CVCL_A5Y5 CL:0000010 Transfected with: HGNC; 10472; RUNX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672911 CVCL_A5Y4 SEES3-1V human RUNX1, clone3 embryonic stem cell human CVCL_A5Y4 CL:0000010 Transfected with: HGNC; 10471; RUNX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672912 CVCL_A5Y7 SEES3-1V human RUNX2, clone3 embryonic stem cell human CVCL_A5Y7 CL:0000010 Transfected with: HGNC; 10472; RUNX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672913 CVCL_A5Y6 SEES3-1V human RUNX2, clone2 embryonic stem cell human CVCL_A5Y6 CL:0000010 Transfected with: HGNC; 10472; RUNX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672914 CVCL_A5Y9 SEES3-1V human RUNX3, clone2 embryonic stem cell human CVCL_A5Y9 CL:0000010 Transfected with: HGNC; 10473; RUNX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672915 CVCL_A5Y8 SEES3-1V human RUNX3, clone1 embryonic stem cell human CVCL_A5Y8 CL:0000010 Transfected with: HGNC; 10473; RUNX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672916 CVCL_A5Y1 SEES3-1V human RSPO1, clone3 embryonic stem cell human CVCL_A5Y1 CL:0000010 Transfected with: HGNC; 21679; RSPO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672917 CVCL_A5Y0 SEES3-1V human RSPO1, clone2 embryonic stem cell human CVCL_A5Y0 CL:0000010 Transfected with: HGNC; 21679; RSPO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672918 CVCL_A5Z4 SEES3-1V human RXRA, clone1 embryonic stem cell human CVCL_A5Z4 CL:0000010 Transfected with: HGNC; 10477; RXRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672919 CVCL_A5Z3 SEES3-1V human RUVBL2, clone3 embryonic stem cell human CVCL_A5Z3 CL:0000010 Transfected with: HGNC; 10475; RUVBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672920 CVCL_A5Z6 SEES3-1V human RXRA, clone3 embryonic stem cell human CVCL_A5Z6 CL:0000010 Transfected with: HGNC; 10477; RXRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672921 CVCL_A5Z5 SEES3-1V human RXRA, clone2 embryonic stem cell human CVCL_A5Z5 CL:0000010 Transfected with: HGNC; 10477; RXRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672922 CVCL_A5Z8 SEES3-1V human RXRB, clone2 embryonic stem cell human CVCL_A5Z8 CL:0000010 Transfected with: HGNC; 10478; RXRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672923 CVCL_A5Z7 SEES3-1V human RXRB, clone1 embryonic stem cell human CVCL_A5Z7 CL:0000010 Transfected with: HGNC; 10478; RXRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672924 CVCL_A5Z9 SEES3-1V human RXRB, clone3 embryonic stem cell human CVCL_A5Z9 CL:0000010 Transfected with: HGNC; 10478; RXRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672925 CVCL_A5Z0 SEES3-1V human RUNX3, clone3 embryonic stem cell human CVCL_A5Z0 CL:0000010 Transfected with: HGNC; 10473; RUNX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672926 CVCL_A5Z2 SEES3-1V human RUVBL2, clone2 embryonic stem cell human CVCL_A5Z2 CL:0000010 Transfected with: HGNC; 10475; RUVBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672927 CVCL_A5Z1 SEES3-1V human RUVBL2, clone1 embryonic stem cell human CVCL_A5Z1 CL:0000010 Transfected with: HGNC; 10475; RUVBL2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672928 CVCL_A5W9 SEES3-1V human RORB, clone2 embryonic stem cell human CVCL_A5W9 CL:0000010 Transfected with: HGNC; 10259; RORB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672929 CVCL_A5W8 SEES3-1V human RORB, clone1 embryonic stem cell human CVCL_A5W8 CL:0000010 Transfected with: HGNC; 10259; RORB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672930 CVCL_A5W1 SEES3-1V human RFXAP, clone3 embryonic stem cell human CVCL_A5W1 CL:0000010 Transfected with: HGNC; 9988; RFXAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672931 CVCL_A5W0 SEES3-1V human RFXAP, clone2 embryonic stem cell human CVCL_A5W0 CL:0000010 Transfected with: HGNC; 9988; RFXAP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672932 CVCL_A5W3 SEES3-1V human RHOXF2, clone2 embryonic stem cell human CVCL_A5W3 CL:0000010 Transfected with: HGNC; 30011; RHOXF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672933 CVCL_A5W2 SEES3-1V human RHOXF2, clone1 embryonic stem cell human CVCL_A5W2 CL:0000010 Transfected with: HGNC; 30011; RHOXF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672934 CVCL_A5W5 SEES3-1V human RNF2, clone1 embryonic stem cell human CVCL_A5W5 CL:0000010 Transfected with: HGNC; 10061; RNF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672935 CVCL_A5W4 SEES3-1V human RHOXF2, clone3 embryonic stem cell human CVCL_A5W4 CL:0000010 Transfected with: HGNC; 30011; RHOXF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672936 CVCL_A5W7 SEES3-1V human RNF2, clone3 embryonic stem cell human CVCL_A5W7 CL:0000010 Transfected with: HGNC; 10061; RNF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672937 CVCL_A5W6 SEES3-1V human RNF2, clone2 embryonic stem cell human CVCL_A5W6 CL:0000010 Transfected with: HGNC; 10061; RNF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672938 CVCL_A5X9 SEES3-1V human RSPO1, clone1 embryonic stem cell human CVCL_A5X9 CL:0000010 Transfected with: HGNC; 21679; RSPO1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672939 CVCL_A5X2 SEES3-1V human RORC, clone2 embryonic stem cell human CVCL_A5X2 CL:0000010 Transfected with: HGNC; 10260; RORC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672940 CVCL_A5X1 SEES3-1V human RORC, clone1 embryonic stem cell human CVCL_A5X1 CL:0000010 Transfected with: HGNC; 10260; RORC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672941 CVCL_A5X4 SEES3-1V human RPS6KA1, clone1 embryonic stem cell human CVCL_A5X4 CL:0000010 Transfected with: HGNC; 10430; RPS6KA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672942 CVCL_A5X3 SEES3-1V human RORC, clone3 embryonic stem cell human CVCL_A5X3 CL:0000010 Transfected with: HGNC; 10260; RORC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672943 CVCL_A5X6 SEES3-1V human RREB1, clone1 embryonic stem cell human CVCL_A5X6 CL:0000010 Transfected with: HGNC; 10449; RREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672944 CVCL_A5X5 SEES3-1V human RPS6KA1, clone2 embryonic stem cell human CVCL_A5X5 CL:0000010 Transfected with: HGNC; 10430; RPS6KA1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672945 CVCL_A5X8 SEES3-1V human RREB1, clone3 embryonic stem cell human CVCL_A5X8 CL:0000010 Transfected with: HGNC; 10449; RREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672946 CVCL_A5X7 SEES3-1V human RREB1, clone2 embryonic stem cell human CVCL_A5X7 CL:0000010 Transfected with: HGNC; 10449; RREB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672947 CVCL_A5X0 SEES3-1V human RORB, clone3 embryonic stem cell human CVCL_A5X0 CL:0000010 Transfected with: HGNC; 10259; RORB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672948 CVCL_A6F7 SEES3-1V human SLBP, clone1 embryonic stem cell human CVCL_A6F7 CL:0000010 Transfected with: HGNC; 10904; SLBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672949 CVCL_A6F6 SEES3-1V human SIX6, clone3 embryonic stem cell human CVCL_A6F6 CL:0000010 Transfected with: HGNC; 10892; SIX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672950 CVCL_A6F9 SEES3-1V human SLBP, clone3 embryonic stem cell human CVCL_A6F9 CL:0000010 Transfected with: HGNC; 10904; SLBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672951 CVCL_A6F8 SEES3-1V human SLBP, clone2 embryonic stem cell human CVCL_A6F8 CL:0000010 Transfected with: HGNC; 10904; SLBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672952 CVCL_A6F1 SEES3-1V human SIX5, clone1 embryonic stem cell human CVCL_A6F1 CL:0000010 Transfected with: HGNC; 10891; SIX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672953 CVCL_A6F0 SEES3-1V human SIX2, clone3 embryonic stem cell human CVCL_A6F0 CL:0000010 Transfected with: HGNC; 10888; SIX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672954 CVCL_A6F3 SEES3-1V human SIX5, clone3 embryonic stem cell human CVCL_A6F3 CL:0000010 Transfected with: HGNC; 10891; SIX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672955 CVCL_A6F2 SEES3-1V human SIX5, clone2 embryonic stem cell human CVCL_A6F2 CL:0000010 Transfected with: HGNC; 10891; SIX5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672956 CVCL_A6F5 SEES3-1V human SIX6, clone2 embryonic stem cell human CVCL_A6F5 CL:0000010 Transfected with: HGNC; 10892; SIX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672957 CVCL_A6F4 SEES3-1V human SIX6, clone1 embryonic stem cell human CVCL_A6F4 CL:0000010 Transfected with: HGNC; 10892; SIX6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672958 CVCL_A6G8 SEES3-1V human SMAD3, clone3 embryonic stem cell human CVCL_A6G8 CL:0000010 Transfected with: HGNC; 6769; SMAD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672959 CVCL_A6G7 SEES3-1V human SMAD3, clone2 embryonic stem cell human CVCL_A6G7 CL:0000010 Transfected with: HGNC; 6769; SMAD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672960 CVCL_A6G9 SEES3-1V human SMAD4, clone1 embryonic stem cell human CVCL_A6G9 CL:0000010 Transfected with: HGNC; 6770; SMAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672961 CVCL_A6G0 SEES3-1V human SMAD1, clone1 embryonic stem cell human CVCL_A6G0 CL:0000010 Transfected with: HGNC; 6767; SMAD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672962 CVCL_A6G2 SEES3-1V human SMAD1, clone3 embryonic stem cell human CVCL_A6G2 CL:0000010 Transfected with: HGNC; 6767; SMAD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672963 CVCL_A6G1 SEES3-1V human SMAD1, clone2 embryonic stem cell human CVCL_A6G1 CL:0000010 Transfected with: HGNC; 6767; SMAD1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672964 CVCL_A6G4 SEES3-1V human SMAD2, clone2 embryonic stem cell human CVCL_A6G4 CL:0000010 Transfected with: HGNC; 6768; SMAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672965 CVCL_A6G3 SEES3-1V human SMAD2, clone1 embryonic stem cell human CVCL_A6G3 CL:0000010 Transfected with: HGNC; 6768; SMAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672966 CVCL_A6G6 SEES3-1V human SMAD3, clone1 embryonic stem cell human CVCL_A6G6 CL:0000010 Transfected with: HGNC; 6769; SMAD3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672967 CVCL_A6G5 SEES3-1V human SMAD2, clone3 embryonic stem cell human CVCL_A6G5 CL:0000010 Transfected with: HGNC; 6768; SMAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672968 CVCL_A6D5 SEES3-1V human SIN3A, clone3 embryonic stem cell human CVCL_A6D5 CL:0000010 Transfected with: HGNC; 19353; SIN3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672969 CVCL_A6D4 SEES3-1V human SIN3A, clone2 embryonic stem cell human CVCL_A6D4 CL:0000010 Transfected with: HGNC; 19353; SIN3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672970 CVCL_A6D7 SEES3-1V human S1PR1, clone2 embryonic stem cell human CVCL_A6D7 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672971 CVCL_A6D6 SEES3-1V human S1PR1, clone1 embryonic stem cell human CVCL_A6D6 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672972 CVCL_A6D9 SEES3-1V human SIRT3, clone1 embryonic stem cell human CVCL_A6D9 CL:0000010 Transfected with: HGNC; 14931; SIRT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672973 CVCL_A6D8 SEES3-1V human S1PR1, clone3 embryonic stem cell human CVCL_A6D8 CL:0000010 Transfected with: HGNC; 3165; S1PR1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672974 CVCL_A6D1 SEES3-1V human SIM1, clone2 embryonic stem cell human CVCL_A6D1 CL:0000010 Transfected with: HGNC; 10882; SIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672975 CVCL_A6D0 SEES3-1V human SIM1, clone1 embryonic stem cell human CVCL_A6D0 CL:0000010 Transfected with: HGNC; 10882; SIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672976 CVCL_A6D3 SEES3-1V human SIN3A, clone1 embryonic stem cell human CVCL_A6D3 CL:0000010 Transfected with: HGNC; 19353; SIN3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672977 CVCL_A6D2 SEES3-1V human SIM1, clone3 embryonic stem cell human CVCL_A6D2 CL:0000010 Transfected with: HGNC; 10882; SIM1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672978 CVCL_A6E6 SEES3-1V human SIX1, clone2 embryonic stem cell human CVCL_A6E6 CL:0000010 Transfected with: HGNC; 10887; SIX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672979 CVCL_A6E5 SEES3-1V human SIX1, clone1 embryonic stem cell human CVCL_A6E5 CL:0000010 Transfected with: HGNC; 10887; SIX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672980 CVCL_A6E8 SEES3-1V human SIX2, clone1 embryonic stem cell human CVCL_A6E8 CL:0000010 Transfected with: HGNC; 10888; SIX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672981 CVCL_A6E7 SEES3-1V human SIX1, clone3 embryonic stem cell human CVCL_A6E7 CL:0000010 Transfected with: HGNC; 10887; SIX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672982 CVCL_A6E9 SEES3-1V human SIX2, clone2 embryonic stem cell human CVCL_A6E9 CL:0000010 Transfected with: HGNC; 10888; SIX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672983 CVCL_A6E0 SEES3-1V human SIRT3, clone2 embryonic stem cell human CVCL_A6E0 CL:0000010 Transfected with: HGNC; 14931; SIRT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672984 CVCL_A6E2 SEES3-1V human SIRT6, clone1 embryonic stem cell human CVCL_A6E2 CL:0000010 Transfected with: HGNC; 14934; SIRT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672985 CVCL_A6E1 SEES3-1V human SIRT3, clone3 embryonic stem cell human CVCL_A6E1 CL:0000010 Transfected with: HGNC; 14931; SIRT3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672986 CVCL_A6E4 SEES3-1V human SIRT6, clone3 embryonic stem cell human CVCL_A6E4 CL:0000010 Transfected with: HGNC; 14934; SIRT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672987 CVCL_A6E3 SEES3-1V human SIRT6, clone2 embryonic stem cell human CVCL_A6E3 CL:0000010 Transfected with: HGNC; 14934; SIRT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672988 CVCL_A6B3 SEES3-1V human SAP30, clone2 embryonic stem cell human CVCL_A6B3 CL:0000010 Transfected with: HGNC; 10532; SAP30; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672989 CVCL_A6B2 SEES3-1V human SAP30, clone1 embryonic stem cell human CVCL_A6B2 CL:0000010 Transfected with: HGNC; 10532; SAP30; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672990 CVCL_A6B5 SEES3-1V human SATB1, clone1 embryonic stem cell human CVCL_A6B5 CL:0000010 Transfected with: HGNC; 10541; SATB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672991 CVCL_A6B4 SEES3-1V human SAP30, clone3 embryonic stem cell human CVCL_A6B4 CL:0000010 Transfected with: HGNC; 10532; SAP30; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672992 CVCL_A6B7 SEES3-1V human SATB1, clone3 embryonic stem cell human CVCL_A6B7 CL:0000010 Transfected with: HGNC; 10541; SATB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672993 CVCL_A6B6 SEES3-1V human SATB1, clone2 embryonic stem cell human CVCL_A6B6 CL:0000010 Transfected with: HGNC; 10541; SATB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672994 CVCL_A6B9 SEES3-1V human SETDB1, clone2 embryonic stem cell human CVCL_A6B9 CL:0000010 Transfected with: HGNC; 10761; SETDB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672995 CVCL_A6B8 SEES3-1V human SETDB1, clone1 embryonic stem cell human CVCL_A6B8 CL:0000010 Transfected with: HGNC; 10761; SETDB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672996 CVCL_A6B1 SEES3-1V human SALL4, clone3 embryonic stem cell human CVCL_A6B1 CL:0000010 Transfected with: HGNC; 15924; SALL4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672997 CVCL_A6B0 SEES3-1V human SALL4, clone2 embryonic stem cell human CVCL_A6B0 CL:0000010 Transfected with: HGNC; 15924; SALL4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672998 CVCL_A6C4 SEES3-1V human SHH, clone1 embryonic stem cell human CVCL_A6C4 CL:0000010 Transfected with: HGNC; 10848; SHH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35672999 CVCL_A6C3 SEES3-1V human SFRS6, clone3 embryonic stem cell human CVCL_A6C3 CL:0000010 Transfected with: HGNC; 10788; SRSF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673000 CVCL_A6C6 SEES3-1V human SHH, clone3 embryonic stem cell human CVCL_A6C6 CL:0000010 Transfected with: HGNC; 10848; SHH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673001 CVCL_A6C5 SEES3-1V human SHH, clone2 embryonic stem cell human CVCL_A6C5 CL:0000010 Transfected with: HGNC; 10848; SHH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673002 CVCL_A6C8 SEES3-1V human SHOX, clone2 embryonic stem cell human CVCL_A6C8 CL:0000010 Transfected with: HGNC; 10853; SHOX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673003 CVCL_A6C7 SEES3-1V human SHOX, clone1 embryonic stem cell human CVCL_A6C7 CL:0000010 Transfected with: HGNC; 10853; SHOX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673004 CVCL_A6C9 SEES3-1V human SHOX, clone3 embryonic stem cell human CVCL_A6C9 CL:0000010 Transfected with: HGNC; 10853; SHOX; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673005 CVCL_A6C0 SEES3-1V human SETDB1, clone3 embryonic stem cell human CVCL_A6C0 CL:0000010 Transfected with: HGNC; 10761; SETDB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673006 CVCL_A6C2 SEES3-1V human SFRS6, clone2 embryonic stem cell human CVCL_A6C2 CL:0000010 Transfected with: HGNC; 10788; SRSF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673007 CVCL_A6C1 SEES3-1V human SFRS6, clone1 embryonic stem cell human CVCL_A6C1 CL:0000010 Transfected with: HGNC; 10788; SRSF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673008 CVCL_A6A9 SEES3-1V human SALL4, clone1 embryonic stem cell human CVCL_A6A9 CL:0000010 Transfected with: HGNC; 15924; SALL4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673009 CVCL_A6A2 SEES3-1V human RXRG, clone3 embryonic stem cell human CVCL_A6A2 CL:0000010 Transfected with: HGNC; 10479; RXRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673010 CVCL_A6A1 SEES3-1V human RXRG, clone2 embryonic stem cell human CVCL_A6A1 CL:0000010 Transfected with: HGNC; 10479; RXRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673011 CVCL_A6A4 SEES3-1V human RYBP, clone2 embryonic stem cell human CVCL_A6A4 CL:0000010 Transfected with: HGNC; 10480; RYBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673012 CVCL_A6A3 SEES3-1V human RYBP, clone1 embryonic stem cell human CVCL_A6A3 CL:0000010 Transfected with: HGNC; 10480; RYBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673013 CVCL_A6A6 SEES3-1V human SALL1, clone1 embryonic stem cell human CVCL_A6A6 CL:0000010 Transfected with: HGNC; 10524; SALL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673014 CVCL_A6A5 SEES3-1V human RYBP, clone3 embryonic stem cell human CVCL_A6A5 CL:0000010 Transfected with: HGNC; 10480; RYBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673015 CVCL_A6A8 SEES3-1V human SALL1, clone3 embryonic stem cell human CVCL_A6A8 CL:0000010 Transfected with: HGNC; 10524; SALL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673016 CVCL_A6A7 SEES3-1V human SALL1, clone2 embryonic stem cell human CVCL_A6A7 CL:0000010 Transfected with: HGNC; 10524; SALL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673017 CVCL_A6A0 SEES3-1V human RXRG, clone1 embryonic stem cell human CVCL_A6A0 CL:0000010 Transfected with: HGNC; 10479; RXRG; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673018 CVCL_A7Q1 SEES3-1V human TRIM28, clone2 embryonic stem cell human CVCL_A7Q1 CL:0000010 Transfected with: HGNC; 16384; TRIM28; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673019 CVCL_A7Q0 SEES3-1V human TRIM28, clone1 embryonic stem cell human CVCL_A7Q0 CL:0000010 Transfected with: HGNC; 16384; TRIM28; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673020 CVCL_A7Q3 SEES3-1V human TRPV2, clone1 embryonic stem cell human CVCL_A7Q3 CL:0000010 Transfected with: HGNC; 18082; TRPV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673021 CVCL_A7Q2 SEES3-1V human TRIM28, clone3 embryonic stem cell human CVCL_A7Q2 CL:0000010 Transfected with: HGNC; 16384; TRIM28; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673022 CVCL_A7Q5 SEES3-1V human TRPV2, clone3 embryonic stem cell human CVCL_A7Q5 CL:0000010 Transfected with: HGNC; 18082; TRPV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673023 CVCL_A7Q4 SEES3-1V human TRPV2, clone2 embryonic stem cell human CVCL_A7Q4 CL:0000010 Transfected with: HGNC; 18082; TRPV2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673024 CVCL_A7Q7 SEES3-1V human TSHZ1, clone2 embryonic stem cell human CVCL_A7Q7 CL:0000010 Transfected with: HGNC; 10669; TSHZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673025 CVCL_A7Q6 SEES3-1V human TSHZ1, clone1 embryonic stem cell human CVCL_A7Q6 CL:0000010 Transfected with: HGNC; 10669; TSHZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673026 CVCL_A7P8 SEES3-1V human TRIB2, clone2 embryonic stem cell human CVCL_A7P8 CL:0000010 Transfected with: HGNC; 30809; TRIB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673027 CVCL_A7P7 SEES3-1V human TRIB2, clone1 embryonic stem cell human CVCL_A7P7 CL:0000010 Transfected with: HGNC; 30809; TRIB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673028 CVCL_A7P9 SEES3-1V human TRIB2, clone3 embryonic stem cell human CVCL_A7P9 CL:0000010 Transfected with: HGNC; 30809; TRIB2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673029 CVCL_A7R2 SEES3-1V human TYR, clone1 embryonic stem cell human CVCL_A7R2 CL:0000010 Transfected with: HGNC; 12442; TYR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673030 CVCL_A7R1 SEES3-1V human TWIST2, clone3 embryonic stem cell human CVCL_A7R1 CL:0000010 Transfected with: HGNC; 20670; TWIST2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673031 CVCL_A7R4 SEES3-1V human TYR, clone3 embryonic stem cell human CVCL_A7R4 CL:0000010 Transfected with: HGNC; 12442; TYR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673032 CVCL_A7R3 SEES3-1V human TYR, clone2 embryonic stem cell human CVCL_A7R3 CL:0000010 Transfected with: HGNC; 12442; TYR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673033 CVCL_A7R6 SEES3-1V human TYRP1, clone2 embryonic stem cell human CVCL_A7R6 CL:0000010 Transfected with: HGNC; 12450; TYRP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673034 CVCL_A7R5 SEES3-1V human TYRP1, clone1 embryonic stem cell human CVCL_A7R5 CL:0000010 Transfected with: HGNC; 12450; TYRP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673035 CVCL_A7R8 SEES3-1V human UBTF, clone1 embryonic stem cell human CVCL_A7R8 CL:0000010 Transfected with: HGNC; 12511; UBTF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673036 CVCL_A7R7 SEES3-1V human TYRP1, clone3 embryonic stem cell human CVCL_A7R7 CL:0000010 Transfected with: HGNC; 12450; TYRP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673037 CVCL_A7R0 SEES3-1V human TWIST2, clone2 embryonic stem cell human CVCL_A7R0 CL:0000010 Transfected with: HGNC; 20670; TWIST2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673038 CVCL_A7Q9 SEES3-1V human TWIST2, clone1 embryonic stem cell human CVCL_A7Q9 CL:0000010 Transfected with: HGNC; 20670; TWIST2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673039 CVCL_A7Q8 SEES3-1V human TSHZ1, clone3 embryonic stem cell human CVCL_A7Q8 CL:0000010 Transfected with: HGNC; 10669; TSHZ1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673040 CVCL_A7N6 SEES3-1V human TNF, clone2 embryonic stem cell human CVCL_A7N6 CL:0000010 Transfected with: HGNC; 11892; TNF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673041 CVCL_A7N5 SEES3-1V human TNF, clone1 embryonic stem cell human CVCL_A7N5 CL:0000010 Transfected with: HGNC; 11892; TNF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673042 CVCL_A7N8 SEES3-1V human TP53, clone1 embryonic stem cell human CVCL_A7N8 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673043 CVCL_A7N7 SEES3-1V human TNF, clone3 embryonic stem cell human CVCL_A7N7 CL:0000010 Transfected with: HGNC; 11892; TNF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673044 CVCL_A7N9 SEES3-1V human TP53, clone2 embryonic stem cell human CVCL_A7N9 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673045 CVCL_A7P0 SEES3-1V human TP53, clone3 embryonic stem cell human CVCL_A7P0 CL:0000010 Transfected with: HGNC; 11998; TP53; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673046 CVCL_A7P2 SEES3-1V human TP73, clone2 embryonic stem cell human CVCL_A7P2 CL:0000010 Transfected with: HGNC; 12003; TP73; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673047 CVCL_A7P1 SEES3-1V human TP73, clone1 embryonic stem cell human CVCL_A7P1 CL:0000010 Transfected with: HGNC; 12003; TP73; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673048 CVCL_A7P4 SEES3-1V human TRAF4, clone1 embryonic stem cell human CVCL_A7P4 CL:0000010 Transfected with: HGNC; 12034; TRAF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673049 CVCL_A7P3 SEES3-1V human TP73, clone3 embryonic stem cell human CVCL_A7P3 CL:0000010 Transfected with: HGNC; 12003; TP73; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673050 CVCL_A7P6 SEES3-1V human TRAF4, clone3 embryonic stem cell human CVCL_A7P6 CL:0000010 Transfected with: HGNC; 12034; TRAF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673051 CVCL_A7P5 SEES3-1V human TRAF4, clone2 embryonic stem cell human CVCL_A7P5 CL:0000010 Transfected with: HGNC; 12034; TRAF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673052 CVCL_A7M1 SEES3-1V human THOC1, clone2 embryonic stem cell human CVCL_A7M1 CL:0000010 Transfected with: HGNC; 19070; THOC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673053 CVCL_A7M0 SEES3-1V human THOC1, clone1 embryonic stem cell human CVCL_A7M0 CL:0000010 Transfected with: HGNC; 19070; THOC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673054 CVCL_A7M3 SEES3-1V human THRA, clone1 embryonic stem cell human CVCL_A7M3 CL:0000010 Transfected with: HGNC; 11796; THRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673055 CVCL_A7M2 SEES3-1V human THOC1, clone3 embryonic stem cell human CVCL_A7M2 CL:0000010 Transfected with: HGNC; 19070; THOC1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673056 CVCL_A7L4 SEES3-1V human THAP3, clone1 embryonic stem cell human CVCL_A7L4 CL:0000010 Transfected with: HGNC; 20855; THAP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673057 CVCL_A7L3 SEES3-1V human THAP11, clone3 embryonic stem cell human CVCL_A7L3 CL:0000010 Transfected with: HGNC; 23194; THAP11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673058 CVCL_A7L6 SEES3-1V human THAP3, clone3 embryonic stem cell human CVCL_A7L6 CL:0000010 Transfected with: HGNC; 20855; THAP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673059 CVCL_A7L5 SEES3-1V human THAP3, clone2 embryonic stem cell human CVCL_A7L5 CL:0000010 Transfected with: HGNC; 20855; THAP3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673060 CVCL_A7L8 SEES3-1V human THAP7, clone2 embryonic stem cell human CVCL_A7L8 CL:0000010 Transfected with: HGNC; 23190; THAP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673061 CVCL_A7L7 SEES3-1V human THAP7, clone1 embryonic stem cell human CVCL_A7L7 CL:0000010 Transfected with: HGNC; 23190; THAP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673062 CVCL_A7L9 SEES3-1V human THAP7, clone3 embryonic stem cell human CVCL_A7L9 CL:0000010 Transfected with: HGNC; 23190; THAP7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673063 CVCL_A7N0 SEES3-1V human TLK1, clone2 embryonic stem cell human CVCL_A7N0 CL:0000010 Transfected with: HGNC; 11841; TLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673064 CVCL_A7N2 SEES3-1V human TLX3, clone1 embryonic stem cell human CVCL_A7N2 CL:0000010 Transfected with: HGNC; 13532; TLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673065 CVCL_A7N1 SEES3-1V human TLK1, clone3 embryonic stem cell human CVCL_A7N1 CL:0000010 Transfected with: HGNC; 11841; TLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673066 CVCL_A7N4 SEES3-1V human TLX3, clone3 embryonic stem cell human CVCL_A7N4 CL:0000010 Transfected with: HGNC; 13532; TLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673067 CVCL_A7N3 SEES3-1V human TLX3, clone2 embryonic stem cell human CVCL_A7N3 CL:0000010 Transfected with: HGNC; 13532; TLX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673068 CVCL_A7M5 SEES3-1V human THRA, clone3 embryonic stem cell human CVCL_A7M5 CL:0000010 Transfected with: HGNC; 11796; THRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673069 CVCL_A7M4 SEES3-1V human THRA, clone2 embryonic stem cell human CVCL_A7M4 CL:0000010 Transfected with: HGNC; 11796; THRA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673070 CVCL_A7M7 SEES3-1V human THRB, clone2 embryonic stem cell human CVCL_A7M7 CL:0000010 Transfected with: HGNC; 11799; THRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673071 CVCL_A7M6 SEES3-1V human THRB, clone1 embryonic stem cell human CVCL_A7M6 CL:0000010 Transfected with: HGNC; 11799; THRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673072 CVCL_A7M9 SEES3-1V human TLK1, clone1 embryonic stem cell human CVCL_A7M9 CL:0000010 Transfected with: HGNC; 11841; TLK1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673073 CVCL_A7M8 SEES3-1V human THRB, clone3 embryonic stem cell human CVCL_A7M8 CL:0000010 Transfected with: HGNC; 11799; THRB; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673074 CVCL_A7K1 SEES3-1V human TGIF2, clone3 embryonic stem cell human CVCL_A7K1 CL:0000010 Transfected with: HGNC; 15764; TGIF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673075 CVCL_A7K0 SEES3-1V human TGIF2, clone2 embryonic stem cell human CVCL_A7K0 CL:0000010 Transfected with: HGNC; 15764; TGIF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673076 CVCL_A7J9 SEES3-1V human TGIF2, clone1 embryonic stem cell human CVCL_A7J9 CL:0000010 Transfected with: HGNC; 15764; TGIF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673077 CVCL_A7J2 SEES3-1V human TGFB1, clone3 embryonic stem cell human CVCL_A7J2 CL:0000010 Transfected with: HGNC; 11766; TGFB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673078 CVCL_A7J1 SEES3-1V human TGFB1, clone2 embryonic stem cell human CVCL_A7J1 CL:0000010 Transfected with: HGNC; 11766; TGFB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673079 CVCL_A7J4 SEES3-1V human TGFBR2, clone2 embryonic stem cell human CVCL_A7J4 CL:0000010 Transfected with: HGNC; 11773; TGFBR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673080 CVCL_A7J3 SEES3-1V human TGFBR2, clone1 embryonic stem cell human CVCL_A7J3 CL:0000010 Transfected with: HGNC; 11773; TGFBR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673081 CVCL_A7J6 SEES3-1V human TGIF1, clone1 embryonic stem cell human CVCL_A7J6 CL:0000010 Transfected with: HGNC; 11776; TGIF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673082 CVCL_A7J5 SEES3-1V human TGFBR2, clone3 embryonic stem cell human CVCL_A7J5 CL:0000010 Transfected with: HGNC; 11773; TGFBR2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673083 CVCL_A7J8 SEES3-1V human TGIF1, clone3 embryonic stem cell human CVCL_A7J8 CL:0000010 Transfected with: HGNC; 11776; TGIF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673084 CVCL_A7J7 SEES3-1V human TGIF1, clone2 embryonic stem cell human CVCL_A7J7 CL:0000010 Transfected with: HGNC; 11776; TGIF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673085 CVCL_A7L0 SEES3-1V human THAP10, clone3 embryonic stem cell human CVCL_A7L0 CL:0000010 Transfected with: HGNC; 23193; THAP10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673086 CVCL_A7L2 SEES3-1V human THAP11, clone2 embryonic stem cell human CVCL_A7L2 CL:0000010 Transfected with: HGNC; 23194; THAP11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673087 CVCL_A7L1 SEES3-1V human THAP11, clone1 embryonic stem cell human CVCL_A7L1 CL:0000010 Transfected with: HGNC; 23194; THAP11; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673088 CVCL_A7K3 SEES3-1V human TGM2, clone2 embryonic stem cell human CVCL_A7K3 CL:0000010 Transfected with: HGNC; 11778; TGM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673089 CVCL_A7K2 SEES3-1V human TGM2, clone1 embryonic stem cell human CVCL_A7K2 CL:0000010 Transfected with: HGNC; 11778; TGM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673090 CVCL_A7K5 SEES3-1V human THAP1, clone1 embryonic stem cell human CVCL_A7K5 CL:0000010 Transfected with: HGNC; 20856; THAP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673091 CVCL_A7K4 SEES3-1V human TGM2, clone3 embryonic stem cell human CVCL_A7K4 CL:0000010 Transfected with: HGNC; 11778; TGM2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673092 CVCL_A7K7 SEES3-1V human THAP1, clone3 embryonic stem cell human CVCL_A7K7 CL:0000010 Transfected with: HGNC; 20856; THAP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673093 CVCL_A7K6 SEES3-1V human THAP1, clone2 embryonic stem cell human CVCL_A7K6 CL:0000010 Transfected with: HGNC; 20856; THAP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673094 CVCL_A7K9 SEES3-1V human THAP10, clone2 embryonic stem cell human CVCL_A7K9 CL:0000010 Transfected with: HGNC; 23193; THAP10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673095 CVCL_A7K8 SEES3-1V human THAP10, clone1 embryonic stem cell human CVCL_A7K8 CL:0000010 Transfected with: HGNC; 23193; THAP10; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673096 CVCL_A7Y9 SEES3-1V human XRN2, clone3 embryonic stem cell human CVCL_A7Y9 CL:0000010 Transfected with: HGNC; 12836; XRN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673097 CVCL_A7Y8 SEES3-1V human XRN2, clone2 embryonic stem cell human CVCL_A7Y8 CL:0000010 Transfected with: HGNC; 12836; XRN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673098 CVCL_A7Y1 SEES3-1V human XDH, clone1 embryonic stem cell human CVCL_A7Y1 CL:0000010 Transfected with: HGNC; 12805; XDH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673099 CVCL_A7Y0 SEES3-1V human XBP1, clone3 embryonic stem cell human CVCL_A7Y0 CL:0000010 Transfected with: HGNC; 12801; XBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673100 CVCL_A7Y3 SEES3-1V human XDH, clone3 embryonic stem cell human CVCL_A7Y3 CL:0000010 Transfected with: HGNC; 12805; XDH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673101 CVCL_A7Y2 SEES3-1V human XDH, clone2 embryonic stem cell human CVCL_A7Y2 CL:0000010 Transfected with: HGNC; 12805; XDH; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673102 CVCL_A7Y5 SEES3-1V human XRCC4, clone2 embryonic stem cell human CVCL_A7Y5 CL:0000010 Transfected with: HGNC; 12831; XRCC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673103 CVCL_A7Y4 SEES3-1V human XRCC4, clone1 embryonic stem cell human CVCL_A7Y4 CL:0000010 Transfected with: HGNC; 12831; XRCC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673104 CVCL_A7Y7 SEES3-1V human XRN2, clone1 embryonic stem cell human CVCL_A7Y7 CL:0000010 Transfected with: HGNC; 12836; XRN2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673105 CVCL_A7Y6 SEES3-1V human XRCC4, clone3 embryonic stem cell human CVCL_A7Y6 CL:0000010 Transfected with: HGNC; 12831; XRCC4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673106 CVCL_A7Z9 SEES3-1V human ZBTB3, clone1 embryonic stem cell human CVCL_A7Z9 CL:0000010 Transfected with: HGNC; 22918; ZBTB3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673107 CVCL_A7Z2 SEES3-1V human YBX1, clone3 embryonic stem cell human CVCL_A7Z2 CL:0000010 Transfected with: HGNC; 8014; YBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673108 CVCL_A7Z1 SEES3-1V human YBX1, clone2 embryonic stem cell human CVCL_A7Z1 CL:0000010 Transfected with: HGNC; 8014; YBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673109 CVCL_A7Z4 SEES3-1V human YY1, clone2 embryonic stem cell human CVCL_A7Z4 CL:0000010 Transfected with: HGNC; 12856; YY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673110 CVCL_A7Z3 SEES3-1V human YY1, clone1 embryonic stem cell human CVCL_A7Z3 CL:0000010 Transfected with: HGNC; 12856; YY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673111 CVCL_A7Z6 SEES3-1V human ZBED4, clone1 embryonic stem cell human CVCL_A7Z6 CL:0000010 Transfected with: HGNC; 20721; ZBED4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673112 CVCL_A7Z5 SEES3-1V human YY1, clone3 embryonic stem cell human CVCL_A7Z5 CL:0000010 Transfected with: HGNC; 12856; YY1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673113 CVCL_A7Z8 SEES3-1V human ZBED4, clone3 embryonic stem cell human CVCL_A7Z8 CL:0000010 Transfected with: HGNC; 20721; ZBED4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673114 CVCL_A7Z7 SEES3-1V human ZBED4, clone2 embryonic stem cell human CVCL_A7Z7 CL:0000010 Transfected with: HGNC; 20721; ZBED4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673115 CVCL_A7Z0 SEES3-1V human YBX1, clone1 embryonic stem cell human CVCL_A7Z0 CL:0000010 Transfected with: HGNC; 8014; YBX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673116 CVCL_A7W7 SEES3-1V human WNT7A, clone2 embryonic stem cell human CVCL_A7W7 CL:0000010 Transfected with: HGNC; 12786; WNT7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673117 CVCL_A7W6 SEES3-1V human WNT7A, clone1 embryonic stem cell human CVCL_A7W6 CL:0000010 Transfected with: HGNC; 12786; WNT7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673118 CVCL_A7W9 SEES3-1V human WNT8B, clone1 embryonic stem cell human CVCL_A7W9 CL:0000010 Transfected with: HGNC; 12789; WNT8B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673119 CVCL_A7W8 SEES3-1V human WNT7A, clone3 embryonic stem cell human CVCL_A7W8 CL:0000010 Transfected with: HGNC; 12786; WNT7A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673120 CVCL_A7W1 SEES3-1V human WNT5B, clone2 embryonic stem cell human CVCL_A7W1 CL:0000010 Transfected with: HGNC; 16265; WNT5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673121 CVCL_A7W0 SEES3-1V human WNT5B, clone1 embryonic stem cell human CVCL_A7W0 CL:0000010 Transfected with: HGNC; 16265; WNT5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673122 CVCL_A7W3 SEES3-1V human WNT6, clone1 embryonic stem cell human CVCL_A7W3 CL:0000010 Transfected with: HGNC; 12785; WNT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673123 CVCL_A7W2 SEES3-1V human WNT5B, clone3 embryonic stem cell human CVCL_A7W2 CL:0000010 Transfected with: HGNC; 16265; WNT5B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673124 CVCL_A7W5 SEES3-1V human WNT6, clone3 embryonic stem cell human CVCL_A7W5 CL:0000010 Transfected with: HGNC; 12785; WNT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673125 CVCL_A7W4 SEES3-1V human WNT6, clone2 embryonic stem cell human CVCL_A7W4 CL:0000010 Transfected with: HGNC; 12785; WNT6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673126 CVCL_A7X8 SEES3-1V human XBP1, clone1 embryonic stem cell human CVCL_A7X8 CL:0000010 Transfected with: HGNC; 12801; XBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673127 CVCL_A7X7 SEES3-1V human WT1, clone3 embryonic stem cell human CVCL_A7X7 CL:0000010 Transfected with: HGNC; 12796; WT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673128 CVCL_A7X9 SEES3-1V human XBP1, clone2 embryonic stem cell human CVCL_A7X9 CL:0000010 Transfected with: HGNC; 12801; XBP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673129 CVCL_A7X0 SEES3-1V human WNT8B, clone2 embryonic stem cell human CVCL_A7X0 CL:0000010 Transfected with: HGNC; 12789; WNT8B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673130 CVCL_A7X2 SEES3-1V human WRNIP1, clone1 embryonic stem cell human CVCL_A7X2 CL:0000010 Transfected with: HGNC; 20876; WRNIP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673131 CVCL_A7X1 SEES3-1V human WNT8B, clone3 embryonic stem cell human CVCL_A7X1 CL:0000010 Transfected with: HGNC; 12789; WNT8B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673132 CVCL_A7X4 SEES3-1V human WRNIP1, clone3 embryonic stem cell human CVCL_A7X4 CL:0000010 Transfected with: HGNC; 20876; WRNIP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673133 CVCL_A7X3 SEES3-1V human WRNIP1, clone2 embryonic stem cell human CVCL_A7X3 CL:0000010 Transfected with: HGNC; 20876; WRNIP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673134 CVCL_A7X6 SEES3-1V human WT1, clone2 embryonic stem cell human CVCL_A7X6 CL:0000010 Transfected with: HGNC; 12796; WT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673135 CVCL_A7X5 SEES3-1V human WT1, clone1 embryonic stem cell human CVCL_A7X5 CL:0000010 Transfected with: HGNC; 12796; WT1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673136 CVCL_A7U5 SEES3-1V human VPS72, clone1 embryonic stem cell human CVCL_A7U5 CL:0000010 Transfected with: HGNC; 11644; VPS72; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673137 CVCL_A7U4 SEES3-1V human VEGFC, clone3 embryonic stem cell human CVCL_A7U4 CL:0000010 Transfected with: HGNC; 12682; VEGFC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673138 CVCL_A7U7 SEES3-1V human VPS72, clone3 embryonic stem cell human CVCL_A7U7 CL:0000010 Transfected with: HGNC; 11644; VPS72; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673139 CVCL_A7U6 SEES3-1V human VPS72, clone2 embryonic stem cell human CVCL_A7U6 CL:0000010 Transfected with: HGNC; 11644; VPS72; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673140 CVCL_A7U9 SEES3-1V human WHSC1, clone2 embryonic stem cell human CVCL_A7U9 CL:0000010 Transfected with: HGNC; 12766; NSD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673141 CVCL_A7U8 SEES3-1V human WHSC1, clone1 embryonic stem cell human CVCL_A7U8 CL:0000010 Transfected with: HGNC; 12766; NSD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673142 CVCL_A7U1 SEES3-1V human VEGFA, clone3 embryonic stem cell human CVCL_A7U1 CL:0000010 Transfected with: HGNC; 12680; VEGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673143 CVCL_A7U0 SEES3-1V human VEGFA, clone2 embryonic stem cell human CVCL_A7U0 CL:0000010 Transfected with: HGNC; 12680; VEGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673144 CVCL_A7U3 SEES3-1V human VEGFC, clone2 embryonic stem cell human CVCL_A7U3 CL:0000010 Transfected with: HGNC; 12682; VEGFC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673145 CVCL_A7U2 SEES3-1V human VEGFC, clone1 embryonic stem cell human CVCL_A7U2 CL:0000010 Transfected with: HGNC; 12682; VEGFC; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673146 CVCL_A7V6 SEES3-1V human WNT2, clone3 embryonic stem cell human CVCL_A7V6 CL:0000010 Transfected with: HGNC; 12780; WNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673147 CVCL_A7V5 SEES3-1V human WNT2, clone2 embryonic stem cell human CVCL_A7V5 CL:0000010 Transfected with: HGNC; 12780; WNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673148 CVCL_A7V8 SEES3-1V human WNT3A, clone2 embryonic stem cell human CVCL_A7V8 CL:0000010 Transfected with: HGNC; 15983; WNT3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673149 CVCL_A7V7 SEES3-1V human WNT3A, clone1 embryonic stem cell human CVCL_A7V7 CL:0000010 Transfected with: HGNC; 15983; WNT3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673150 CVCL_A7V9 SEES3-1V human WNT3A, clone3 embryonic stem cell human CVCL_A7V9 CL:0000010 Transfected with: HGNC; 15983; WNT3A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673151 CVCL_A7V0 SEES3-1V human WHSC1, clone3 embryonic stem cell human CVCL_A7V0 CL:0000010 Transfected with: HGNC; 12766; NSD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673152 CVCL_A7V2 SEES3-1V human WHSC2, clone2 embryonic stem cell human CVCL_A7V2 CL:0000010 Transfected with: HGNC; 12768; NELFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673153 CVCL_A7V1 SEES3-1V human WHSC2, clone1 embryonic stem cell human CVCL_A7V1 CL:0000010 Transfected with: HGNC; 12768; NELFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673154 CVCL_A7V4 SEES3-1V human WNT2, clone1 embryonic stem cell human CVCL_A7V4 CL:0000010 Transfected with: HGNC; 12780; WNT2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673155 CVCL_A7V3 SEES3-1V human WHSC2, clone3 embryonic stem cell human CVCL_A7V3 CL:0000010 Transfected with: HGNC; 12768; NELFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673156 CVCL_A7S3 SEES3-1V human UGP2, clone3 embryonic stem cell human CVCL_A7S3 CL:0000010 Transfected with: HGNC; 12527; UGP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673157 CVCL_A7S2 SEES3-1V human UGP2, clone2 embryonic stem cell human CVCL_A7S2 CL:0000010 Transfected with: HGNC; 12527; UGP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673158 CVCL_A7S5 SEES3-1V human USF1, clone2 embryonic stem cell human CVCL_A7S5 CL:0000010 Transfected with: HGNC; 12593; USF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673159 CVCL_A7S4 SEES3-1V human USF1, clone1 embryonic stem cell human CVCL_A7S4 CL:0000010 Transfected with: HGNC; 12593; USF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673160 CVCL_A7S7 SEES3-1V human USF2, clone1 embryonic stem cell human CVCL_A7S7 CL:0000010 Transfected with: HGNC; 12594; USF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673161 CVCL_A7S6 SEES3-1V human USF1, clone3 embryonic stem cell human CVCL_A7S6 CL:0000010 Transfected with: HGNC; 12593; USF1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673162 CVCL_A7S9 SEES3-1V human USF2, clone3 embryonic stem cell human CVCL_A7S9 CL:0000010 Transfected with: HGNC; 12594; USF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673163 CVCL_A7S8 SEES3-1V human USF2, clone2 embryonic stem cell human CVCL_A7S8 CL:0000010 Transfected with: HGNC; 12594; USF2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673164 CVCL_A7S1 SEES3-1V human UGP2, clone1 embryonic stem cell human CVCL_A7S1 CL:0000010 Transfected with: HGNC; 12527; UGP2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673165 CVCL_A7S0 SEES3-1V human UBTF, clone3 embryonic stem cell human CVCL_A7S0 CL:0000010 Transfected with: HGNC; 12511; UBTF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673166 CVCL_A7R9 SEES3-1V human UBTF, clone2 embryonic stem cell human CVCL_A7R9 CL:0000010 Transfected with: HGNC; 12511; UBTF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673167 CVCL_A7T4 SEES3-1V human VAX2, clone2 embryonic stem cell human CVCL_A7T4 CL:0000010 Transfected with: HGNC; 12661; VAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673168 CVCL_A7T3 SEES3-1V human VAX2, clone1 embryonic stem cell human CVCL_A7T3 CL:0000010 Transfected with: HGNC; 12661; VAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673169 CVCL_A7T6 SEES3-1V human VDR, clone1 embryonic stem cell human CVCL_A7T6 CL:0000010 Transfected with: HGNC; 12679; VDR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673170 CVCL_A7T5 SEES3-1V human VAX2, clone3 embryonic stem cell human CVCL_A7T5 CL:0000010 Transfected with: HGNC; 12661; VAX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673171 CVCL_A7T8 SEES3-1V human VDR, clone3 embryonic stem cell human CVCL_A7T8 CL:0000010 Transfected with: HGNC; 12679; VDR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673172 CVCL_A7T7 SEES3-1V human VDR, clone2 embryonic stem cell human CVCL_A7T7 CL:0000010 Transfected with: HGNC; 12679; VDR; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673173 CVCL_A7T9 SEES3-1V human VEGFA, clone1 embryonic stem cell human CVCL_A7T9 CL:0000010 Transfected with: HGNC; 12680; VEGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673174 CVCL_A7T0 SEES3-1V human VAX1, clone1 embryonic stem cell human CVCL_A7T0 CL:0000010 Transfected with: HGNC; 12660; VAX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673175 CVCL_A7T2 SEES3-1V human VAX1, clone3 embryonic stem cell human CVCL_A7T2 CL:0000010 Transfected with: HGNC; 12660; VAX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673176 CVCL_A7T1 SEES3-1V human VAX1, clone2 embryonic stem cell human CVCL_A7T1 CL:0000010 Transfected with: HGNC; 12660; VAX1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673177 CVCL_A7A9 SEES3-1V human TBX3, clone2 embryonic stem cell human CVCL_A7A9 CL:0000010 Transfected with: HGNC; 11602; TBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673178 CVCL_A7A8 SEES3-1V human TBX3, clone1 embryonic stem cell human CVCL_A7A8 CL:0000010 Transfected with: HGNC; 11602; TBX3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673179 CVCL_A7A1 SEES3-1V human TAL1, clone3 embryonic stem cell human CVCL_A7A1 CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673180 CVCL_A7A0 SEES3-1V human TAL1, clone2 embryonic stem cell human CVCL_A7A0 CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673181 CVCL_A7A3 SEES3-1V human TBP, clone2 embryonic stem cell human CVCL_A7A3 CL:0000010 Transfected with: HGNC; 11588; TBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673182 CVCL_A7A2 SEES3-1V human TBP, clone1 embryonic stem cell human CVCL_A7A2 CL:0000010 Transfected with: HGNC; 11588; TBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673183 CVCL_A7A5 SEES3-1V human TBX2, clone1 embryonic stem cell human CVCL_A7A5 CL:0000010 Transfected with: HGNC; 11597; TBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673184 CVCL_A7A4 SEES3-1V human TBP, clone3 embryonic stem cell human CVCL_A7A4 CL:0000010 Transfected with: HGNC; 11588; TBP; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673185 CVCL_A7A7 SEES3-1V human TBX2, clone3 embryonic stem cell human CVCL_A7A7 CL:0000010 Transfected with: HGNC; 11597; TBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673186 CVCL_A7A6 SEES3-1V human TBX2, clone2 embryonic stem cell human CVCL_A7A6 CL:0000010 Transfected with: HGNC; 11597; TBX2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673187 CVCL_A6Y9 SEES3-1V human TAF5, clone3 embryonic stem cell human CVCL_A6Y9 CL:0000010 Transfected with: HGNC; 11539; TAF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673188 CVCL_A6Y2 SEES3-1V human TAF1A, clone2 embryonic stem cell human CVCL_A6Y2 CL:0000010 Transfected with: HGNC; 11532; TAF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673189 CVCL_A6Y1 SEES3-1V human TAF1A, clone1 embryonic stem cell human CVCL_A6Y1 CL:0000010 Transfected with: HGNC; 11532; TAF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673190 CVCL_A6Y4 SEES3-1V human TAF3, clone1 embryonic stem cell human CVCL_A6Y4 CL:0000010 Transfected with: HGNC; 17303; TAF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673191 CVCL_A6Y3 SEES3-1V human TAF1A, clone3 embryonic stem cell human CVCL_A6Y3 CL:0000010 Transfected with: HGNC; 11532; TAF1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673192 CVCL_A6Y6 SEES3-1V human TAF3, clone3 embryonic stem cell human CVCL_A6Y6 CL:0000010 Transfected with: HGNC; 17303; TAF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673193 CVCL_A6Y5 SEES3-1V human TAF3, clone2 embryonic stem cell human CVCL_A6Y5 CL:0000010 Transfected with: HGNC; 17303; TAF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673194 CVCL_A6Y8 SEES3-1V human TAF5, clone2 embryonic stem cell human CVCL_A6Y8 CL:0000010 Transfected with: HGNC; 11539; TAF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673195 CVCL_A6Y7 SEES3-1V human TAF5, clone1 embryonic stem cell human CVCL_A6Y7 CL:0000010 Transfected with: HGNC; 11539; TAF5; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673196 CVCL_A6Y0 SEES3-1V human TAF13, clone3 embryonic stem cell human CVCL_A6Y0 CL:0000010 Transfected with: HGNC; 11546; TAF13; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673197 CVCL_A6Z3 SEES3-1V human TAF7, clone1 embryonic stem cell human CVCL_A6Z3 CL:0000010 Transfected with: HGNC; 11541; TAF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673198 CVCL_A6Z2 SEES3-1V human TAF6, clone3 embryonic stem cell human CVCL_A6Z2 CL:0000010 Transfected with: HGNC; 11540; TAF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673199 CVCL_A6Z5 SEES3-1V human TAF7, clone3 embryonic stem cell human CVCL_A6Z5 CL:0000010 Transfected with: HGNC; 11541; TAF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673200 CVCL_A6Z4 SEES3-1V human TAF7, clone2 embryonic stem cell human CVCL_A6Z4 CL:0000010 Transfected with: HGNC; 11541; TAF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673201 CVCL_A6Z7 SEES3-1V human TAF8, clone2 embryonic stem cell human CVCL_A6Z7 CL:0000010 Transfected with: HGNC; 17300; TAF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673202 CVCL_A6Z6 SEES3-1V human TAF8, clone1 embryonic stem cell human CVCL_A6Z6 CL:0000010 Transfected with: HGNC; 17300; TAF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673203 CVCL_A6Z9 SEES3-1V human TAL1, clone1 embryonic stem cell human CVCL_A6Z9 CL:0000010 Transfected with: HGNC; 11556; TAL1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673204 CVCL_A6Z8 SEES3-1V human TAF8, clone3 embryonic stem cell human CVCL_A6Z8 CL:0000010 Transfected with: HGNC; 17300; TAF8; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673205 CVCL_A6Z1 SEES3-1V human TAF6, clone2 embryonic stem cell human CVCL_A6Z1 CL:0000010 Transfected with: HGNC; 11540; TAF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673206 CVCL_A6Z0 SEES3-1V human TAF6, clone1 embryonic stem cell human CVCL_A6Z0 CL:0000010 Transfected with: HGNC; 11540; TAF6; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673207 CVCL_A7H8 SEES3-1V human TFCP2L1, clone3 embryonic stem cell human CVCL_A7H8 CL:0000010 Transfected with: HGNC; 17925; TFCP2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673208 CVCL_A7H7 SEES3-1V human TFCP2L1, clone2 embryonic stem cell human CVCL_A7H7 CL:0000010 Transfected with: HGNC; 17925; TFCP2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673209 CVCL_A7H9 SEES3-1V human TFCP2L1, clone4 embryonic stem cell human CVCL_A7H9 CL:0000010 Transfected with: HGNC; 17925; TFCP2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673210 CVCL_A7H0 SEES3-1V human TFAP2C, clone1 embryonic stem cell human CVCL_A7H0 CL:0000010 Transfected with: HGNC; 11744; TFAP2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673211 CVCL_A7H2 SEES3-1V human TFAP2C, clone3 embryonic stem cell human CVCL_A7H2 CL:0000010 Transfected with: HGNC; 11744; TFAP2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673212 CVCL_A7H1 SEES3-1V human TFAP2C, clone2 embryonic stem cell human CVCL_A7H1 CL:0000010 Transfected with: HGNC; 11744; TFAP2C; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673213 CVCL_A7H4 SEES3-1V human TFAP4, clone2 embryonic stem cell human CVCL_A7H4 CL:0000010 Transfected with: HGNC; 11745; TFAP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673214 CVCL_A7H3 SEES3-1V human TFAP4, clone1 embryonic stem cell human CVCL_A7H3 CL:0000010 Transfected with: HGNC; 11745; TFAP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673215 CVCL_A7H6 SEES3-1V human TFCP2L1, clone1 embryonic stem cell human CVCL_A7H6 CL:0000010 Transfected with: HGNC; 17925; TFCP2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673216 CVCL_A7H5 SEES3-1V human TFAP4, clone3 embryonic stem cell human CVCL_A7H5 CL:0000010 Transfected with: HGNC; 11745; TFAP4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673217 CVCL_A7J0 SEES3-1V human TGFB1, clone1 embryonic stem cell human CVCL_A7J0 CL:0000010 Transfected with: HGNC; 11766; TGFB1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673218 CVCL_A7I9 SEES3-1V human TGFA, clone3 embryonic stem cell human CVCL_A7I9 CL:0000010 Transfected with: HGNC; 11765; TGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673219 CVCL_A7I8 SEES3-1V human TGFA, clone2 embryonic stem cell human CVCL_A7I8 CL:0000010 Transfected with: HGNC; 11765; TGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673220 CVCL_A7I1 SEES3-1V human TFDP1, clone1 embryonic stem cell human CVCL_A7I1 CL:0000010 Transfected with: HGNC; 11749; TFDP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673221 CVCL_A7I0 SEES3-1V human TFCP2L1, clone5 embryonic stem cell human CVCL_A7I0 CL:0000010 Transfected with: HGNC; 17925; TFCP2L1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673222 CVCL_A7I3 SEES3-1V human TFDP1, clone3 embryonic stem cell human CVCL_A7I3 CL:0000010 Transfected with: HGNC; 11749; TFDP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673223 CVCL_A7I2 SEES3-1V human TFDP1, clone2 embryonic stem cell human CVCL_A7I2 CL:0000010 Transfected with: HGNC; 11749; TFDP1; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673224 CVCL_A7I5 SEES3-1V human TFE3, clone2 embryonic stem cell human CVCL_A7I5 CL:0000010 Transfected with: HGNC; 11752; TFE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673225 CVCL_A7I4 SEES3-1V human TFE3, clone1 embryonic stem cell human CVCL_A7I4 CL:0000010 Transfected with: HGNC; 11752; TFE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673226 CVCL_A7I7 SEES3-1V human TGFA, clone1 embryonic stem cell human CVCL_A7I7 CL:0000010 Transfected with: HGNC; 11765; TGFA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673227 CVCL_A7I6 SEES3-1V human TFE3, clone3 embryonic stem cell human CVCL_A7I6 CL:0000010 Transfected with: HGNC; 11752; TFE3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673228 CVCL_A7F6 SEES3-1V human TEAD2, clone2 embryonic stem cell human CVCL_A7F6 CL:0000010 Transfected with: HGNC; 11715; TEAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673229 CVCL_A7F5 SEES3-1V human TEAD2, clone1 embryonic stem cell human CVCL_A7F5 CL:0000010 Transfected with: HGNC; 11715; TEAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673230 CVCL_A7F8 SEES3-1V human TEAD4, clone1 embryonic stem cell human CVCL_A7F8 CL:0000010 Transfected with: HGNC; 11717; TEAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673231 CVCL_A7F7 SEES3-1V human TEAD2, clone3 embryonic stem cell human CVCL_A7F7 CL:0000010 Transfected with: HGNC; 11715; TEAD2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673232 CVCL_A7F9 SEES3-1V human TEAD4, clone2 embryonic stem cell human CVCL_A7F9 CL:0000010 Transfected with: HGNC; 11717; TEAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673233 CVCL_A7F0 SEES3-1V human TCF7L2, clone2 embryonic stem cell human CVCL_A7F0 CL:0000010 Transfected with: HGNC; 11641; TCF7L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673234 CVCL_A7F2 SEES3-1V human TCL1A, clone1 embryonic stem cell human CVCL_A7F2 CL:0000010 Transfected with: HGNC; 11648; TCL1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673235 CVCL_A7F1 SEES3-1V human TCF7L2, clone3 embryonic stem cell human CVCL_A7F1 CL:0000010 Transfected with: HGNC; 11641; TCF7L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673236 CVCL_A7F4 SEES3-1V human TCL1A, clone3 embryonic stem cell human CVCL_A7F4 CL:0000010 Transfected with: HGNC; 11648; TCL1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673237 CVCL_A7F3 SEES3-1V human TCL1A, clone2 embryonic stem cell human CVCL_A7F3 CL:0000010 Transfected with: HGNC; 11648; TCL1A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673238 CVCL_A7G7 SEES3-1V human TFAP2B, clone1 embryonic stem cell human CVCL_A7G7 CL:0000010 Transfected with: HGNC; 11743; TFAP2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673239 CVCL_A7G6 SEES3-1V human TFAP2A, clone3 embryonic stem cell human CVCL_A7G6 CL:0000010 Transfected with: HGNC; 11742; TFAP2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673240 CVCL_A7G9 SEES3-1V human TFAP2B, clone3 embryonic stem cell human CVCL_A7G9 CL:0000010 Transfected with: HGNC; 11743; TFAP2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673241 CVCL_A7G8 SEES3-1V human TFAP2B, clone2 embryonic stem cell human CVCL_A7G8 CL:0000010 Transfected with: HGNC; 11743; TFAP2B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673242 CVCL_A7G1 SEES3-1V human TEF, clone1 embryonic stem cell human CVCL_A7G1 CL:0000010 Transfected with: HGNC; 11722; TEF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673243 CVCL_A7G0 SEES3-1V human TEAD4, clone3 embryonic stem cell human CVCL_A7G0 CL:0000010 Transfected with: HGNC; 11717; TEAD4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673244 CVCL_A7G3 SEES3-1V human TEF, clone3 embryonic stem cell human CVCL_A7G3 CL:0000010 Transfected with: HGNC; 11722; TEF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673245 CVCL_A7G2 SEES3-1V human TEF, clone2 embryonic stem cell human CVCL_A7G2 CL:0000010 Transfected with: HGNC; 11722; TEF; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673246 CVCL_A7G5 SEES3-1V human TFAP2A, clone2 embryonic stem cell human CVCL_A7G5 CL:0000010 Transfected with: HGNC; 11742; TFAP2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673247 CVCL_A7G4 SEES3-1V human TFAP2A, clone1 embryonic stem cell human CVCL_A7G4 CL:0000010 Transfected with: HGNC; 11742; TFAP2A; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673248 CVCL_A7D4 SEES3-1V human TCF23, clone1 embryonic stem cell human CVCL_A7D4 CL:0000010 Transfected with: HGNC; 18602; TCF23; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673249 CVCL_A7D3 SEES3-1V human TCF21, clone3 embryonic stem cell human CVCL_A7D3 CL:0000010 Transfected with: HGNC; 11632; TCF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673250 CVCL_A7D6 SEES3-1V human TCF23, clone3 embryonic stem cell human CVCL_A7D6 CL:0000010 Transfected with: HGNC; 18602; TCF23; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673251 CVCL_A7D5 SEES3-1V human TCF23, clone2 embryonic stem cell human CVCL_A7D5 CL:0000010 Transfected with: HGNC; 18602; TCF23; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673252 CVCL_A7D8 SEES3-1V human TCF25, clone2 embryonic stem cell human CVCL_A7D8 CL:0000010 Transfected with: HGNC; 29181; TCF25; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673253 CVCL_A7D7 SEES3-1V human TCF25, clone1 embryonic stem cell human CVCL_A7D7 CL:0000010 Transfected with: HGNC; 29181; TCF25; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673254 CVCL_A7D9 SEES3-1V human TCF25, clone3 embryonic stem cell human CVCL_A7D9 CL:0000010 Transfected with: HGNC; 29181; TCF25; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673255 CVCL_A7D0 SEES3-1V human TCF20, clone3 embryonic stem cell human CVCL_A7D0 CL:0000010 Transfected with: HGNC; 11631; TCF20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673256 CVCL_A7D2 SEES3-1V human TCF21, clone2 embryonic stem cell human CVCL_A7D2 CL:0000010 Transfected with: HGNC; 11632; TCF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673257 CVCL_A7D1 SEES3-1V human TCF21, clone1 embryonic stem cell human CVCL_A7D1 CL:0000010 Transfected with: HGNC; 11632; TCF21; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673258 CVCL_A7E5 SEES3-1V human TCF4, clone3 embryonic stem cell human CVCL_A7E5 CL:0000010 Transfected with: HGNC; 11634; TCF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673259 CVCL_A7E4 SEES3-1V human TCF4, clone2 embryonic stem cell human CVCL_A7E4 CL:0000010 Transfected with: HGNC; 11634; TCF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673260 CVCL_A7E7 SEES3-1V human TCF7, clone2 embryonic stem cell human CVCL_A7E7 CL:0000010 Transfected with: HGNC; 11639; TCF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673261 CVCL_A7E6 SEES3-1V human TCF7, clone1 embryonic stem cell human CVCL_A7E6 CL:0000010 Transfected with: HGNC; 11639; TCF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673262 CVCL_A7E9 SEES3-1V human TCF7L2, clone1 embryonic stem cell human CVCL_A7E9 CL:0000010 Transfected with: HGNC; 11641; TCF7L2; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673263 CVCL_A7E8 SEES3-1V human TCF7, clone3 embryonic stem cell human CVCL_A7E8 CL:0000010 Transfected with: HGNC; 11639; TCF7; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673264 CVCL_A7E1 SEES3-1V human TCF3, clone2 embryonic stem cell human CVCL_A7E1 CL:0000010 Transfected with: HGNC; 11633; TCF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673265 CVCL_A7E0 SEES3-1V human TCF3, clone1 embryonic stem cell human CVCL_A7E0 CL:0000010 Transfected with: HGNC; 11633; TCF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673266 CVCL_A7E3 SEES3-1V human TCF4, clone1 embryonic stem cell human CVCL_A7E3 CL:0000010 Transfected with: HGNC; 11634; TCF4; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673267 CVCL_A7E2 SEES3-1V human TCF3, clone3 embryonic stem cell human CVCL_A7E2 CL:0000010 Transfected with: HGNC; 11633; TCF3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673268 CVCL_A7B9 SEES3-1V human TCF15, clone1 embryonic stem cell human CVCL_A7B9 CL:0000010 Transfected with: HGNC; 11627; TCF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673269 CVCL_A7B2 SEES3-1V human TCEA3, clone3 embryonic stem cell human CVCL_A7B2 CL:0000010 Transfected with: HGNC; 11615; TCEA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673270 CVCL_A7B1 SEES3-1V human TCEA3, clone2 embryonic stem cell human CVCL_A7B1 CL:0000010 Transfected with: HGNC; 11615; TCEA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673271 CVCL_A7B4 SEES3-1V human TCEB3, clone2 embryonic stem cell human CVCL_A7B4 CL:0000010 Transfected with: HGNC; 11620; ELOA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673272 CVCL_A7B3 SEES3-1V human TCEB3, clone1 embryonic stem cell human CVCL_A7B3 CL:0000010 Transfected with: HGNC; 11620; ELOA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673273 CVCL_A7B6 SEES3-1V human TCF12, clone1 embryonic stem cell human CVCL_A7B6 CL:0000010 Transfected with: HGNC; 11623; TCF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673274 CVCL_A7B5 SEES3-1V human TCEB3, clone3 embryonic stem cell human CVCL_A7B5 CL:0000010 Transfected with: HGNC; 11620; ELOA; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673275 CVCL_A7B8 SEES3-1V human TCF12, clone3 embryonic stem cell human CVCL_A7B8 CL:0000010 Transfected with: HGNC; 11623; TCF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673276 CVCL_A7B7 SEES3-1V human TCF12, clone2 embryonic stem cell human CVCL_A7B7 CL:0000010 Transfected with: HGNC; 11623; TCF12; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673277 CVCL_A7B0 SEES3-1V human TCEA3, clone1 embryonic stem cell human CVCL_A7B0 CL:0000010 Transfected with: HGNC; 11615; TCEA3; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673278 CVCL_A7C3 SEES3-1V human TCF19, clone2 embryonic stem cell human CVCL_A7C3 CL:0000010 Transfected with: HGNC; 11629; TCF19; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673279 CVCL_A7C2 SEES3-1V human TCF19, clone1 embryonic stem cell human CVCL_A7C2 CL:0000010 Transfected with: HGNC; 11629; TCF19; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673280 CVCL_A7C5 SEES3-1V human TCF2, clone1 embryonic stem cell human CVCL_A7C5 CL:0000010 Transfected with: HGNC; 11630; HNF1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673281 CVCL_A7C4 SEES3-1V human TCF19, clone3 embryonic stem cell human CVCL_A7C4 CL:0000010 Transfected with: HGNC; 11629; TCF19; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673282 CVCL_A7C7 SEES3-1V human TCF2, clone3 embryonic stem cell human CVCL_A7C7 CL:0000010 Transfected with: HGNC; 11630; HNF1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673283 CVCL_A7C6 SEES3-1V human TCF2, clone2 embryonic stem cell human CVCL_A7C6 CL:0000010 Transfected with: HGNC; 11630; HNF1B; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673284 CVCL_A7C9 SEES3-1V human TCF20, clone2 embryonic stem cell human CVCL_A7C9 CL:0000010 Transfected with: HGNC; 11631; TCF20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673285 CVCL_A7C8 SEES3-1V human TCF20, clone1 embryonic stem cell human CVCL_A7C8 CL:0000010 Transfected with: HGNC; 11631; TCF20; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673286 CVCL_A7C1 SEES3-1V human TCF15, clone3 embryonic stem cell human CVCL_A7C1 CL:0000010 Transfected with: HGNC; 11627; TCF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 35673287 CVCL_A7C0 SEES3-1V human TCF15, clone2 embryonic stem cell human CVCL_A7C0 CL:0000010 Transfected with: HGNC; 11627; TCF15; Transfected with: UniProtKB; P00722; Escherichia coli lacZ; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P04486; Human herpesvirus 1 VP16 (UL28) (with p.Met1_Arg360del). Male Characteristics: When doxycycline is added the transfected human gene (ORF) and lacZ are expressed; Characteristics: Transfected with a PB-PuroR-Ins-tetO2-ORF-IRES-bgeo-PB where PB is a PiggyBac sequence, Ins is a chicken HS4 insulator, ORF is the transfected human gene and bgeo is a neo-LacZ fusion protein; Characteristics: Transfected with a pG-flox-CAGrtTA3G-IRES-Hyg-pA construct that contains a reverse tetracycline-controlled transactivator (rtTA), a fusion between a mutated version of E.coli TetR and the activating domain of HSV-1 VP16 40818437 CVCL_ZV96 gMEC finite cell line CVCL_ZV96 CL:0000010 Miscellaneous: Doubling time from personal communication of Singh M Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: American Saanen. Female Doubling time: ~3 days (Direct_author_submission) 40818438 CVCL_ZV97 HPA [Human pituitary adenoma] cancer cell line human CVCL_ZV97 CL:0000010 Population: Japanese; Derived from sampling site: Pituitary gland. Unspecified Characteristics: Secretes prolactin Doubling time: 14 hours (PubMed=4053045) 40818439 CVCL_ZV98 YK cancer cell line human CVCL_ZV98 CL:0000010 Population: Japanese. Female 40818440 CVCL_ZV99 GX cancer cell line human CVCL_ZV99 CL:0000010 Derived from sampling site: Pituitary gland. Male 40818441 CVCL_ZV95 AKU-MY01 cancer cell line human CVCL_ZV95 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male Doubling time: 48-53 hours (DOI=10.1182/blood-2019-132238) 40818442 CVCL_A1DI PCIi022-A induced pluripotent stem cell human CVCL_A1DI From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40818443 CVCL_A1DJ NIMHi002-A induced pluripotent stem cell human CVCL_A1DJ From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 40818444 CVCL_A1DK NIMHi003-A induced pluripotent stem cell human CVCL_A1DK From: National Institute of Mental Health and Neurosciences; Bengaluru; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 40818445 CVCL_A1DL SHAMUi001-A induced pluripotent stem cell human CVCL_A1DL From: The Second Affiliated Hospital of Army Medical University; Chongqing; China CL:0000010 Sequence variation: Mutation; HGNC; 29186; ANKRD26; Simple; c.-128G>T; ClinVar=VCV000812728; Zygosity=Heterozygous (PubMed=32979630) Population: Chinese; Han; Derived from sampling site: Bone marrow. Female 40818446 CVCL_A1DM 501-EBV transformed cell line human CVCL_A1DM HLA typing: A*02:01,24 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818447 CVCL_A1DN 888-EBV transformed cell line human CVCL_A1DN HLA typing: A*01,24; B*52,55; C*01:02,12:01 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818448 CVCL_A1DP 697-EBV transformed cell line human CVCL_A1DP From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 40818449 CVCL_A1DA HMGUi001-A-8 induced pluripotent stem cell human CVCL_A1DA From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a mCherry construct was fused to the C-terminus of INS C-peptide in one allele (PubMed=33373890) 40818450 CVCL_A1DB Liver iPS A induced pluripotent stem cell CVCL_A1DB CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 40818451 CVCL_A1DC Liver iPS B induced pluripotent stem cell CVCL_A1DC CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 40818452 CVCL_A1DD Liver iPS 1 induced pluripotent stem cell CVCL_A1DD CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 40818453 CVCL_A1DE Liver iPS 7 induced pluripotent stem cell CVCL_A1DE CL:0000010 Derived from sampling site: Fetal liver. Female Group: Non-human primate cell line 40818454 CVCL_A1DF FDCHi003-A induced pluripotent stem cell human CVCL_A1DF From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 428; ALMS1; Simple; p.Ser1301Ter (c.3902C>A); ClinVar=VCV000264657; Zygosity=Heterozygous (PubMed=33264725); Sequence variation: Mutation; HGNC; 428; ALMS1; Simple; p.Arg2146Ter (c.6436C>T); ClinVar=VCV000210129; Zygosity=Heterozygous (PubMed=33264725) Population: Chinese; Derived from sampling site: Peripheral blood. Male 40818455 CVCL_A1DG FDCHi003-A-1 induced pluripotent stem cell human CVCL_A1DG From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 428; ALMS1; Simple_corrected; p.Ser1301Ter (c.3902C>A); ClinVar=VCV000264657; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33264725); Sequence variation: Mutation; HGNC; 428; ALMS1; Simple; p.Arg2146Ter (c.6436C>T); ClinVar=VCV000210129; Zygosity=Heterozygous (PubMed=33264725) Population: Chinese; Derived from sampling site: Peripheral blood. Male 40818456 CVCL_A1DH PCIi021-A induced pluripotent stem cell human CVCL_A1DH From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818457 CVCL_A1CX COLO 591 cancer cell line human CVCL_A1CX CL:0000010 Miscellaneous: Cell line information from archive documents of Moore G.E Derived from metastatic site: Ascites. Female 40818458 CVCL_A1CY GWCMCi001-A induced pluripotent stem cell human CVCL_A1CY From: Guangzhou Women and Children's Medical Center; Guangzhou; China CL:0000010 Derived from sampling site: Peripheral blood. Male 40818459 CVCL_A1CZ GWCMCi004-A induced pluripotent stem cell human CVCL_A1CZ From: Guangzhou Women and Children's Medical Center; Guangzhou; China. CL:0000010 40818460 CVCL_A1CP FUmEC transformed cell line CVCL_A1CP CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4252 40818461 CVCL_A1CQ FPPMEC transformed cell line CVCL_A1CQ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal intestine; Peyer's patch Cell type=Endothelial cell of Peyer's patch.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4255 40818462 CVCL_A1CR FSkMEC transformed cell line CVCL_A1CR CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4254 40818463 CVCL_A1CS MDA-T187 cancer cell line human CVCL_A1CS CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (PubMed=34147031); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>C); ClinVar=VCV000376624; Zygosity=Homozygous (PubMed=34147031) Miscellaneous: Age of donor from personal communication of Henderson Y.C Derived from sampling site: Thyroid gland. Female Doubling time: 32.6 hours (PubMed=34147031) 40818464 CVCL_A1CT MDA-T248 cancer cell line human CVCL_A1CT CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=34147031); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp74Asn (c.220G>A); ClinVar=VCV000483340; Zygosity=Homozygous (PubMed=34147031); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.994-1G>C; ClinVar=VCV000232659; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=34147031) Miscellaneous: Age of donor from personal communication of Henderson Y.C Derived from sampling site: Thyroid gland. Female Doubling time: 25.6 hours (PubMed=34147031) 40818465 CVCL_A1CU MDA-T269 cancer cell line human CVCL_A1CU CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly13Arg (c.37G>C); ClinVar=VCV000035554; Zygosity=Heterozygous (PubMed=34147031); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=34147031) Miscellaneous: Age of donor from personal communication of Henderson Y.C Derived from sampling site: Thyroid gland. Male Doubling time: 97.4 hours (PubMed=34147031) 40818466 CVCL_A1CV MDA-T273 cancer cell line human CVCL_A1CV CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Homozygous (PubMed=34147031); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (PubMed=34147031); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (PubMed=34147031) Miscellaneous: Age of donor from personal communication of Henderson Y.C Derived from sampling site: Thyroid gland. Female Doubling time: 33.9 hours (PubMed=34147031) 40818467 CVCL_A1CW COLO 719 cancer cell line human CVCL_A1CW CL:0000010 Miscellaneous: Cell line information from archive documents of Moore G.E Derived from sampling site: Peripheral blood. Male 40818468 CVCL_A1EJ JC-33 cancer cell line human CVCL_A1EJ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1303Ter (c.3907C>T); ClinVar=VCV001076263; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818469 CVCL_A1EK JC-35 cancer cell line human CVCL_A1EK CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1164fs; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818470 CVCL_A1EL JC-36 cancer cell line human CVCL_A1EL CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg805Ter (c.2413C>T); ClinVar=VCV000127281; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818471 CVCL_A1EM JC-37 cancer cell line human CVCL_A1EM CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818472 CVCL_A1EN JC-39 cancer cell line human CVCL_A1EN CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg216Ter (c.646C>T); ClinVar=VCV000127312; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818473 CVCL_A1EP JC-47 cancer cell line human CVCL_A1EP CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Phe1491fs; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818474 CVCL_A1EQ JC-49 cancer cell line human CVCL_A1EQ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg302Ter (c.904C>T) (R284*); ClinVar=VCV000000798; Zygosity=Unspecified (PubMed=28179481); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1345Ter (c.4033G>T); ClinVar=VCV000449334; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818475 CVCL_A1EB 1685M cancer cell line human CVCL_A1EB CL:0000010 Derived from metastatic site: Not specified. Male 40818476 CVCL_A1EC CSSTH1 spontaneously immortalized cell line CVCL_A1EC CL:0000010 Derived from sampling site: Heart. Group: Reptilian cell line 40818477 CVCL_A1ED CSSTL1 spontaneously immortalized cell line CVCL_A1ED CL:0000010 Derived from sampling site: Lung. Group: Reptilian cell line 40818478 CVCL_A1EE CSSTSP1 spontaneously immortalized cell line CVCL_A1EE CL:0000010 Derived from sampling site: Spleen. Group: Reptilian cell line 40818479 CVCL_A1EF ABC-14 cancer cell line human CVCL_A1EF CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=31374369) Population: Japanese; Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by RNAseq Male Characteristics: Sensitive to crizotinib and resistant to alectinib 40818480 CVCL_A1EG ABC-17 cancer cell line human CVCL_A1EG CL:0000010 Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=31374369); Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Gly1202Arg (c.3604G>A); ClinVar=VCV000376134; Zygosity=Unspecified (PubMed=31374369) Population: Japanese; Derived from metastatic site: Liver. Omics: Transcriptome analysis by RNAseq Male Characteristics: Established from a xenograft produced by subcutaneous injection of tumor cells into NOG (NOD/Shi-scid, IL-2RgammaKO Jic) mice; Characteristics: Resistant to alectinib and crizotinib 40818481 CVCL_A1EH JC-20 cancer cell line human CVCL_A1EH CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Pro1483fs; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818482 CVCL_A1EI JC-32 cancer cell line human CVCL_A1EI CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Trp553Ter (c.1659G>A); ClinVar=VCV000092340; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818483 CVCL_A1DY Ma-Mel-100b cancer cell line human CVCL_A1DY CL:0000010 Sequence variation: Gene deletion; HGNC; 914; B2M; Zygosity=Heterozygous (PubMed=25294904); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Leu60_Glu64delinsGln (c.179_190del); Zygosity=Heterozygous (PubMed=25294904) Derived from metastatic site: Lymph node. Omics: SNP array analysis Male 40818484 CVCL_A1DZ BL-78 cancer cell line human CVCL_A1DZ From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Sequence variation: Mutation; HGNC; 7553; MYC; Simple; p.Thr73Ile (c.218C>T); ClinVar=VCV000376300; Zygosity=Unspecified (PubMed=8108117) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Female 40818485 CVCL_A1EA 1777N Pr cancer cell line human CVCL_A1EA CL:0000010 Derived from sampling site: Testis. Male 40818486 CVCL_A1DQ 1308-mel cancer cell line human CVCL_A1DQ HLA typing: A*11,24 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 40818487 CVCL_A1DR 1338-mel cancer cell line human CVCL_A1DR HLA typing: A*24,31 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 40818488 CVCL_A1DS 1351-mel cancer cell line human CVCL_A1DS HLA typing: A*01,03; B*08,47; C*06,07 (PubMed=9670966) From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 40818489 CVCL_A1DT 1173-mel cancer cell line human CVCL_A1DT From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Derived from metastatic site: Not specified. Unspecified 40818490 CVCL_A1DU NHEM680 finite cell line human CVCL_A1DU CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Melanocyte.. Male 40818491 CVCL_A1DV 624-mel/A31 cancer cell line human CVCL_A1DV From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Transfected with: HGNC; 4931; HLA-A (allele A*31) Derived from metastatic site: Not specified. Male 40818492 CVCL_A1DW 397-mel/A31 cancer cell line human CVCL_A1DW From: Rosenberg S.A.; Surgery Branch, National Cancer Institute, National Institutes of Health; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 4931; HLA-A (allele A*31) Derived from metastatic site: Skin. Unspecified 40818493 CVCL_A1DX 1510-EBV transformed cell line human CVCL_A1DX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818494 CVCL_A1BG BLuMEC transformed cell line CVCL_A1BG CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung; endothelium Cell type=Lung microvascular endothelial cell.; Breed/subspecies: Montbeliarde. Female Doubling time: 36 hours (PubMed=32722052) 40818495 CVCL_A1BH BMLNMEC transformed cell line CVCL_A1BH CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal mesenteric lymph node; microvascular endothelium; Breed/subspecies: Montbeliarde. Female Virology: Highly susceptible to infection by foot-and-mouth disease virus (PubMed=32722052) Doubling time: 24 hours (PubMed=32722052) 40818496 CVCL_A1BI BOvMEC transformed cell line CVCL_A1BI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal ovary; microvascular endothelium; Breed/subspecies: Montbeliarde. Female Doubling time: 30 hours (PubMed=32722052) 40818497 CVCL_A1BJ BSkMEC transformed cell line CVCL_A1BJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium Cell type=Microvascular endothelial cell.; Breed/subspecies: Montbeliarde. Female Doubling time: 24 hours (PubMed=32722052) 40818498 CVCL_A1BK BUcEC transformed cell line CVCL_A1BK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Umbilical cord Cell type=Endothelial cell.; Breed/subspecies: Montbeliarde. Female Doubling time: 36 hours (PubMed=32722052) 40818499 CVCL_A1BL LNCaP AR-V7/pLenti cancer cell line human CVCL_A1BL CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 644; AR (isoform ARv7); Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Inducibly expresses AR variant 7 (ARv7) Developed with the T-REx lentiviral Gateway expression system. Addition of doxycycline (Dox) relieves repression by tetR thus permitting ARv7 induction. 40818500 CVCL_A1BM LNCaP AR-V7/pHage cancer cell line human CVCL_A1BM CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 644; AR (isoform ARv7); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Inducibly expresses AR variant 7 (ARv7) 40818501 CVCL_A1BN LNCaP AR-NTD/pHage cancer cell line human CVCL_A1BN CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 644; AR (with p.Thr661_Gln920del = AR-NTD); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Inducibly expresses AR N-terminal domain (AR-NTD) 40818502 CVCL_A1BA CEM/P cancer cell line human CVCL_A1BA CL:0000010 Sequence variation: Gene fusion; HGNC; 13222; BCL11B + HGNC; 2488; NKX2-5; Name(s)=NKX2.5-BCL11B (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3765; FLT3; Simple; p.Ala627Thr (c.1879G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1593_Arg1594insProArgLeuProHisAsnSerSerPheHisPheLeu (c.4780_4781ins36); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2412Thr (c.7234C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:71223; Pralatrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Female 40818503 CVCL_A1BB MOLT4/P cancer cell line human CVCL_A1BB CL:0000010 Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Leu1600Pro (c.4799T>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Pro2514Argfs*4 (c.7541_7542delCT); ClinVar=VCV000581973; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000040468; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln214Ter (c.640C>T); ClinVar=VCV000428759; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:71223; Pralatrexate; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 40818504 CVCL_A1BC CHO Pro-5-Esel spontaneously immortalized cell line CVCL_A1BC CL:0000010 Transfected with: HGNC; 10718; SELE; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 40818505 CVCL_A1BD HSkMEC.2 transformed cell line human CVCL_A1BD CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin; microvascular endothelium. 40818506 CVCL_A1BE BBrMEC transformed cell line CVCL_A1BE CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; endothelium Cell type=Brain microvascular endothelial cell.; Breed/subspecies: Montbeliarde. Female Doubling time: 48 hours (PubMed=32722052) 40818507 CVCL_A1BF BIntMEC transformed cell line CVCL_A1BF CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal intestine; microvascular endothelium Cell type=Microvascular endothelial cell.; Breed/subspecies: Montbeliarde. Female Doubling time: 30 hours (PubMed=32722052) 40818508 CVCL_A1AV HEPC-CB.1 telomerase immortalized cell line human CVCL_A1AV CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Sex of donor from personal communication of Kieda C Derived from sampling site: Umbilical cord blood Cell type=Endothelial progenitor cell.. Female Characteristics: Expresses CD133 and CD271, markers specific for early stem/progenitor cells Can undergo an in vitro pre-angiogenic process, forms pseudovessel structures and presents an accelerated angiogenesis in hypoxic conditions (PubMed=21710642). Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4220 40818509 CVCL_A1AW HEPC-CB.2 telomerase immortalized cell line human CVCL_A1AW CL:0000010 Transfected with: HGNC; 11730; TERT Miscellaneous: Sex of donor from personal communication of Kieda C Derived from sampling site: Umbilical cord blood Cell type=Endothelial progenitor cell.. Female Characteristics: Expresses CD133 and CD271, markers specific for early stem/progenitor cells Can undergo an in vitro pre-angiogenic process, forms pseudovessel structures and presents an accelerated angiogenesis in hypoxic conditions (PubMed=21710642). Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4221 40818510 CVCL_A1AX MAgEC 10.5 transformed cell line house mouse CVCL_A1AX CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: FVB. Characteristics: Displays progenitor endothelial characteristics (PubMed=26577811) Doubling time: ~24 hours (PubMed=26577811) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4222 40818511 CVCL_A1AY MAgEC 11.5 transformed cell line house mouse CVCL_A1AY CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Embryonic aorta-gonad-mesonephros; Breed/subspecies: FVB. Characteristics: Displays progenitor endothelial characteristics Is more differentiated than MAgEC 10.5 (Cellosaurus=CVCL_A1AY) and displays faster angiogenesis in vitro, different response to hypoxia and chemokines (PubMed=26577811). Doubling time: ~24 hours (PubMed=26577811) Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4223 40818512 CVCL_A1AZ CPGHi002-A induced pluripotent stem cell human CVCL_A1AZ From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 854; ATP6V1B2; Simple; p.Arg506Ter (c.1516C>T); ClinVar=VCV000203442; Zygosity=Heterozygous (PubMed=32961450) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 40818513 CVCL_A1AN KB10460 finite cell line CVCL_A1AN From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 40818514 CVCL_A1AP KB10973 finite cell line CVCL_A1AP From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Group: Non-human primate cell line 40818515 CVCL_A1AQ LPC43 cancer cell line human CVCL_A1AQ CL:0000010 Characteristics: Established from the patient-derived xenograft PHLC178/ADC6. 40818516 CVCL_A1AR HeLa-SHMT2-shSHMT2 cancer cell line human CVCL_A1AR CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 10852; SHMT2; Transfected with: MGI; MGI:1277989; Shmt2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Allows both a Tet-inducible over-expression of mouse Shmt2 and isopropyl beta-D-1-thiogalactopyranoside (IPTG)-inducible shRNA against SHMT2 40818517 CVCL_A1AS B1 [Human hepatocellular carcinoma] cancer cell line human CVCL_A1AS From: Grasl-Kraupp B.; Medical University of Vienna; Vienna; Austria CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro152Leu (c.455C>T); ClinVar=VCV000142766; Zygosity=Unspecified (PubMed=31063779) Population: Caucasian Omics: Deep exome analysis; Omics: miRNA expression profiling; Omics: Protein expression by reverse-phase protein arrays. Unspecified 40818518 CVCL_A1AT CSUe011-A embryonic stem cell human CVCL_A1AT From: Central South University; Changsha; China CL:0000010 Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed). Female Characteristics: Using CRISPR/Cas9 a construct containing the ESRG promoter followed by tdTomato was introduced in the AAVS1 safe harbor locus 40818519 CVCL_A1AU BON1-MEN1-KO cancer cell line human CVCL_A1AU CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7010; MEN1; Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Omics: Deep quantitative proteome analysis Male Doubling time: 36 +- 0.48 hours (PubMed=32884006) 40818520 CVCL_A1CH HAP1 POMK/LARGE1 (-) cancer cell line human CVCL_A1CH CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6511; LARGE1; Knockout cell: Method=CRISPR/Cas9; HGNC; 26267; POMK; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 40818521 CVCL_A1CI FBrMEC transformed cell line CVCL_A1CI CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; endothelium Cell type=Brain microvascular endothelial cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4257 40818522 CVCL_A1CJ FHeMEC transformed cell line CVCL_A1CJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal heart; microvascular endothelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4256 40818523 CVCL_A1CK FIntMEC transformed cell line CVCL_A1CK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal intestine; microvascular endothelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4250 40818524 CVCL_A1CL FLiMEC transformed cell line CVCL_A1CL CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal liver; microvascular endothelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4253 40818525 CVCL_A1CM FLuMEC transformed cell line CVCL_A1CM CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung; endothelium Cell type=Lung microvascular endothelial cell.. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4258 40818526 CVCL_A1CN FPLNMEC transformed cell line CVCL_A1CN CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal peripheral lymph node; microvascular endothelium. Unspecified Group: Patented cell line; Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4251 40818527 CVCL_A1CA HNMUi004-A induced pluripotent stem cell human CVCL_A1CA From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Unexplicit; 4.2 kb deletion (alpha4.2 del); ClinVar=VCV000375752; Zygosity=Heterozygous (PubMed=33039806); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Amniotic fluid. Male 40818528 CVCL_A1CB HNMUi005-A induced pluripotent stem cell human CVCL_A1CB From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Simple; g.223300_227103del (3.7 kb deletion) (alpha3.7 del); ClinVar=VCV000038636; Zygosity=Heterozygous (PubMed=33039806); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Urine. Male 40818529 CVCL_A1CC HNMUi006-A induced pluripotent stem cell human CVCL_A1CC From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Urine. Female 40818530 CVCL_A1CD HNMUi007-A induced pluripotent stem cell human CVCL_A1CD From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Simple; g.223300_227103del (3.7 kb deletion) (alpha3.7 del); ClinVar=VCV000038636; Zygosity=Heterozygous (PubMed=33039806); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Amniotic fluid. Male 40818531 CVCL_A1CE HNMUi008-A induced pluripotent stem cell human CVCL_A1CE From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Han; Derived from sampling site: Urine. Male 40818532 CVCL_A1CF HNMUi009-A induced pluripotent stem cell human CVCL_A1CF From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Han; Derived from sampling site: Urine. Female 40818533 CVCL_A1CG HNMUi010-A induced pluripotent stem cell human CVCL_A1CG From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=33039806) Population: Chinese; Han; Derived from sampling site: Amniotic fluid. Female 40818534 CVCL_A1BW iPSC 72.3 induced pluripotent stem cell human CVCL_A1BW From: Cincinnati Children's Hospital Medical Center; Cincinnati; USA CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 40818535 CVCL_A1BX iPSC 72.3-NEUROG3 induced pluripotent stem cell human CVCL_A1BX CL:0000010 Transfected with: HGNC; 13806; NEUROG3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Dox-induced expression (using rtTA) of NEUROG3 40818536 CVCL_A1BY HNMUi002-A induced pluripotent stem cell human CVCL_A1BY From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4824; HBA2; Unexplicit; 4.2 kb deletion (alpha4.2 del); ClinVar=VCV000375752; Zygosity=Heterozygous (PubMed=33039806); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Urine. Male 40818537 CVCL_A1BZ HNMUi003-A induced pluripotent stem cell human CVCL_A1BZ From: Hainan Medical University; Haikou; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Heterozygous (PubMed=33039806) Population: Chinese; Derived from sampling site: Urine. Female 40818538 CVCL_A1BP VCaP AR-V7/pHag cancer cell line human CVCL_A1BP CL:0000010 Sequence variation: Gene fusion; HGNC; 3446; ERG + HGNC; 11876; TMPRSS2; Name(s)=TMPRSS2-ERG (from parent cell line); Sequence variation: Mutation; HGNC; 7127; MLH1; Simple; p.Ile219Val (c.655A>G); ClinVar=VCV000036557; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 644; AR (isoform ARv7); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from metastatic site: Bone; vertebra. Male Characteristics: Inducibly expresses AR variant 7 (ARv7); Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 40818539 CVCL_A1BQ COLO 251 cancer cell line human CVCL_A1BQ CL:0000010 Population: Caucasian; Derived from metastatic site: Lymph node. Male 40818540 CVCL_A1BR COLO 59 transformed cell line human CVCL_A1BR CL:0000010 Miscellaneous: Age of donor from archive documents of Moore G.E Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818541 CVCL_A1BS COLO 660 cancer cell line human CVCL_A1BS CL:0000010 Miscellaneous: Cell line information from archive documents of Moore G.E Derived from metastatic site: Lymph node. Female 40818542 CVCL_A1BT COLO 742 cancer cell line human CVCL_A1BT CL:0000010 Miscellaneous: Cell line information from personal communication of Shaw A.C. Female 40818543 CVCL_A1BU COLO 716 cancer cell line human CVCL_A1BU CL:0000010 Miscellaneous: Cell line information from archive documents of Moore G.E Derived from metastatic site: Ascites. Female 40818544 CVCL_A1BV NCC-DDLPS1-C1 cancer cell line human CVCL_A1BV CL:0000010 Population: Japanese; Derived from metastatic site: Retroperitoneal space. Male Doubling time: ~50 hours (PubMed=32949334) Part of: NCC sarcoma cell line panel 40818545 CVCL_A1AF KB6268 finite cell line CVCL_A1AF From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.0 days (PubMed=12840040) Group: Non-human primate cell line 40818546 CVCL_A1AG KB5047 finite cell line CVCL_A1AG From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.0 days (PubMed=12840040) Group: Non-human primate cell line 40818547 CVCL_A1AH KB7500 finite cell line CVCL_A1AH From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.8 days (PubMed=12840040) Group: Non-human primate cell line 40818548 CVCL_A1AI KB7801 finite cell line CVCL_A1AI From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.9 days (PubMed=12840040) Group: Non-human primate cell line 40818549 CVCL_A1AJ KB8021 finite cell line CVCL_A1AJ From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.4 days (PubMed=12840040) Group: Non-human primate cell line 40818550 CVCL_A1AK KB7621 finite cell line CVCL_A1AK From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.3 days (PubMed=12840040) Group: Non-human primate cell line 40818551 CVCL_A1AL KB8594 finite cell line CVCL_A1AL From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 1.6 days (PubMed=12840040) Group: Non-human primate cell line 40818552 CVCL_A1AM KB6278 finite cell line CVCL_A1AM From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 1.9 days (PubMed=12840040) Group: Non-human primate cell line 40818553 CVCL_A1AA KB8024 finite cell line bonobo/pygmy chimpanzee CVCL_A1AA From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.3 days (PubMed=12840040) Group: Non-human primate cell line 40818554 CVCL_A1AB KB7189 finite cell line bonobo/pygmy chimpanzee CVCL_A1AB From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.8 days (PubMed=12840040) Group: Non-human primate cell line 40818555 CVCL_A1AC KB8840 finite cell line CVCL_A1AC From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.5 days (PubMed=12840040) Group: Non-human primate cell line 40818556 CVCL_A1AD KB9047 finite cell line CVCL_A1AD From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.4 days (PubMed=12840040) Group: Non-human primate cell line 40818557 CVCL_A1AE KB8592 finite cell line CVCL_A1AE From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 1.9 days (PubMed=12840040) Group: Non-human primate cell line 40818558 CVCL_A1LQ ITK-3 hybridoma house mouse CVCL_A1LQ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cluster-1 antigen on small cell lung cancer. 40818559 CVCL_A1LR LAL-B transformed cell line human CVCL_A1LR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Omics: Transcriptome analysis by RNAseq Unspecified 40818560 CVCL_A1LS LAL-B#2 transformed cell line human CVCL_A1LS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 40818561 CVCL_A1LT LAL-B#3 transformed cell line human CVCL_A1LT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Unspecified 40818562 CVCL_A1LU AeAe-GH98 spontaneously immortalized cell line CVCL_A1LU CL:0000010 Breed/subspecies: Strain GH98. Unspecified Virology: Susceptible to infection by yellow fever virus (YFV) and Zika virus (ZIKV) Not susceptible to infection by dengue virus types 1 and 2. Doubling time: ~1.3 days (PubMed=33000384) Group: Insect cell line 40818563 CVCL_A1LV HaSKpw spontaneously immortalized cell line human CVCL_A1LV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln317Ter (c.949C>T); ClinVar=VCV000450344; Zygosity=Heterozygous (PubMed=32938951) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female Doubling time: 43.4 hours (PubMed=32938951) 40818564 CVCL_A1LW NIKS spontaneously immortalized cell line human CVCL_A1LW CL:0000010 Miscellaneous: STR profile from personal communication of Lee D Derived from sampling site: Foreskin; skin; epidermis Cell type=Keratinocyte.. Biotechnology: Can be used to construct a living bioengineered skin substitute (StrataGraft) intended to provide immediate wound coverage and promote wound healaling through sustained expression by living cells of wound healing factors (PubMed=24527287); Biotechnology: Can be used to construct a human skin model (Stratatest) that can be used to assess tissue damage caused by chemical or physical agents and for the identification and characterization of agents formulated to mitigate this damage (PubMed=20688150); Omics: Transcriptome analysis by microarray Male Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12191 40818565 CVCL_A1LX CT/BCIRL-DvWL1-0619-KZ spontaneously immortalized cell line CVCL_A1LX CL:0000010 Unspecified Doubling time: 102 hours (PubMed=32409954). Group: Insect cell line 40818566 CVCL_A1LI Eveline transformed cell line house mouse CVCL_A1LI CL:0000010 Anecdotal: Cell line name corresponds to the first name of the person who established it (Eveline Seifert) Transformant: Friend murine leukemia virus (FrMLV)(NCBI-Taxonomy; 11795); Breed/subspecies: STU. Unspecified Virology: Produces high yields of Friend murine leukemia virus (FrMLV), up to 6.1 mg of virus protein per liter of cell supernatant (PubMed=4371954) 40818567 CVCL_A1LJ RTE [Carp eye] spontaneously immortalized cell line CVCL_A1LJ CL:0000010 Derived from sampling site: Eye. Unspecified Virology: Susceptible to infection by striped jack nervous necrosis virus (SJNNV), Tilapia lake virus (TiLV) Resistant to infection by Cyprinid herpes virus 2 (CyHV-2) (DOI=10.1016/j.aquaculture.2020.736027). Doubling time: ~33 hours, at 61th passage (DOI=10.1016/j.aquaculture.2020.736027) Group: Fish cell line 40818568 CVCL_A1LK RTK [Carp] spontaneously immortalized cell line CVCL_A1LK CL:0000010 Derived from sampling site: Kidney. Unspecified Virology: Susceptible to infection by striped jack nervous necrosis virus (SJNNV), Tilapia lake virus (TiLV) Resistant to infection by Cyprinid herpes virus 2 (CyHV-2) (DOI=10.1016/j.aquaculture.2020.736027). Doubling time: ~39 hours, at 57th passage (DOI=10.1016/j.aquaculture.2020.736027) Group: Fish cell line 40818569 CVCL_A1LL RTS spontaneously immortalized cell line CVCL_A1LL CL:0000010 Derived from sampling site: Spleen. Unspecified Virology: Susceptible to infection by striped jack nervous necrosis virus (SJNNV), Tilapia lake virus (TiLV) Resistant to infection by Cyprinid herpes virus 2 (CyHV-2) (DOI=10.1016/j.aquaculture.2020.736027). Doubling time: ~28 hours, at 55th passage (DOI=10.1016/j.aquaculture.2020.736027) Group: Fish cell line 40818570 CVCL_A1LM OS2-RA-R cancer cell line human CVCL_A1LM CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female Characteristics: Resistant to the cytostatic activity of lymphokine-activated killer (LAK) cells 40818571 CVCL_A1LN OS1-F finite cell line human CVCL_A1LN CL:0000010 Population: Japanese; Derived from sampling site: Lung Cell type=Fibroblast.. Male 40818572 CVCL_A1LP ITK-2 hybridoma house mouse CVCL_A1LP CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human cluster-1 antigen on small cell lung cancer. 40818573 CVCL_A1LA MOG-G-ATA cancer cell line human CVCL_A1LA CL:0000010 Derived from sampling site: Brain. Unspecified 40818574 CVCL_A1LB MOG-G-RAT cancer cell line human CVCL_A1LB CL:0000010 Derived from sampling site: Brain. Unspecified 40818575 CVCL_A1LC MZ-NKC-1790 finite cell line human CVCL_A1LC CL:0000010 Derived from sampling site: Kidney. Unspecified 40818576 CVCL_A1LD MZ-NKC-1795 finite cell line human CVCL_A1LD CL:0000010 Derived from sampling site: Kidney. Unspecified 40818579 CVCL_A1LG MZ-MEL-12 cancer cell line human CVCL_A1LG CL:0000010 Unspecified 40818580 CVCL_A1LH DU-ALL-1 hybridoma house mouse CVCL_A1LH CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P21926; Human CD9 Caution: Isotype indicated as IgG2a in PubMed=6958929 but IgG1 in sites distributing the produced mAB. 40818581 CVCL_A1KX EHC4 transformed cell line human CVCL_A1KX CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 7989; NRAS (with p.Gln61Leu) Karyotypic information: 47,XY,t(14;18)(q32;q21),+12 (PubMed=8652393); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818582 CVCL_A1KY SA4 [Human leukemia] transformed cell line human CVCL_A1KY CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 7989; NRAS (with p.Gln61Leu) Karyotypic information: 46,XY (PubMed=8652393); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818583 CVCL_A1KZ SA4-2 transformed cell line human CVCL_A1KZ CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 7989; NRAS (with p.Gln61Leu) Karyotypic information: 45,XY,-20 (PubMed=8652393); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818584 CVCL_A1MR KthES14 embryonic stem cell human CVCL_A1MR From: Kyoto University; Kyoto; Japan. CL:0000010 Female Group: Clinical grade hESC cell line 40818585 CVCL_A1MS PCIi023-A induced pluripotent stem cell human CVCL_A1MS From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40818586 CVCL_A1MT PCIi024-A induced pluripotent stem cell human CVCL_A1MT From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818587 CVCL_A1MU CSUXHi003-A induced pluripotent stem cell human CVCL_A1MU From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 7105; MITF; Simple; p.His316Leu (c.947A>T) (p.His209Leu, c.626A>T); Zygosity=Heterozygous (PubMed=33454628) Population: Chinese; Han; Derived from sampling site: Scalp; skin; dermis Cell type=Fibroblast.. Male 40818588 CVCL_A1MV AHQUi001-A-1 induced pluripotent stem cell human CVCL_A1MV From: Affiliated Hospital of Qingdao University; Qingdao; China CL:0000010 Sequence variation: Mutation; HGNC; 6677; LPL; Simple_corrected; p.Cys310Arg (c.928T>C); ClinVar=VCV000226449; Zygosity=Heterozygous (PubMed=33592566) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40818589 CVCL_A1MW LUEi013-A induced pluripotent stem cell human CVCL_A1MW From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818590 CVCL_A1MX WAe001-A-53 embryonic stem cell human CVCL_A1MX From: Nanfang Hospital, Southern Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 13233; ANP32A. Male 40818591 CVCL_A1MY WAe009-A-45 embryonic stem cell human CVCL_A1MY From: Gynaecology and Obstetrics, Anzhen Hospital; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11604; TBX5. Female 40818592 CVCL_A1MJ ICGi026-A induced pluripotent stem cell human CVCL_A1MJ From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[27]; ClinVar=VCV000009972; Zygosity=Mosaic (PubMed=33189043); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[60]; ClinVar=VCV000009972; Zygosity=Mosaic (PubMed=33189043); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[110]; ClinVar=VCV000009972; Zygosity=Mosaic (PubMed=33189043); Sequence variation: Mutation; HGNC; 3775; FMR1; Repeat_expansion; CGG[410]; ClinVar=VCV000009972; Zygosity=Mosaic (PubMed=33189043) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818593 CVCL_A1MK SDUKIi004-A induced pluripotent stem cell human CVCL_A1MK From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818594 CVCL_A1ML SDUKIi005-A induced pluripotent stem cell human CVCL_A1ML From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark. CL:0000010 40818595 CVCL_A1MM SDUKIi006-A induced pluripotent stem cell human CVCL_A1MM From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818596 CVCL_A1MN PLAFMCi002-A induced pluripotent stem cell human CVCL_A1MN From: Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Ser843Pro (c.2527T>C); ClinVar=VCV000997278; Zygosity=Heterozygous (PubMed=33068887); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Met3091Arg (c.9272T>G); Zygosity=Heterozygous (PubMed=33068887) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40818597 CVCL_A1MP KthES12 embryonic stem cell human CVCL_A1MP From: Kyoto University; Kyoto; Japan. CL:0000010 Female Group: Clinical grade hESC cell line 40818598 CVCL_A1MQ KthES13 embryonic stem cell human CVCL_A1MQ From: Kyoto University; Kyoto; Japan. CL:0000010 Female Group: Clinical grade hESC cell line 40818599 CVCL_A1MB IBMS-iPSC-060-04 induced pluripotent stem cell human CVCL_A1MB From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 25443; C19orf12; Simple; p.Pro92Thrfs*9 (c.273_274insA); Zygosity=Heterozygous (PubMed=33068888) Population: Chinese; Derived from sampling site: Peripheral blood. Female 40818600 CVCL_A1MC IBMS-iPSC-063-06 induced pluripotent stem cell human CVCL_A1MC From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 967; BBS2; Simple; c.534+1G>T; ClinVar=VCV000553927; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=34364070) Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 40818601 CVCL_A1MD MCRIi020-A induced pluripotent stem cell human CVCL_A1MD From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40818602 CVCL_A1ME MCRIi021-A induced pluripotent stem cell human CVCL_A1ME From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818603 CVCL_A1MF MCRIi022-A induced pluripotent stem cell human CVCL_A1MF From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818604 CVCL_A1MG MCRIi023-A induced pluripotent stem cell human CVCL_A1MG From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40818605 CVCL_A1MH UMi028-A induced pluripotent stem cell human CVCL_A1MH From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40818606 CVCL_A1MI UMi028-A-1 induced pluripotent stem cell human CVCL_A1MI From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 15459; P2RX2; Simple_edited; p.Val60Leu (c.178G>T); ClinVar=VCV000155762; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33038743) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40818607 CVCL_A1LY CT/BCIRL-DvWL2-0619-KZ spontaneously immortalized cell line CVCL_A1LY CL:0000010 Unspecified Doubling time: 51 hours (PubMed=32409954). Group: Insect cell line 40818608 CVCL_A1LZ CT/BCIRL-DvWL3-0619-KZ spontaneously immortalized cell line CVCL_A1LZ CL:0000010 Unspecified Doubling time: 67 hours (PubMed=32409954). Group: Insect cell line 40818609 CVCL_A1MA IBMS-iPSC-057-05 induced pluripotent stem cell human CVCL_A1MA From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Sequence variation: Mutation; HGNC; 12585; UQCRC1; Simple; p.Tyr314Ser (c.941A>C); ClinVar=VCV001064663; Zygosity=Heterozygous (PubMed=33070102) Population: Chinese; Derived from sampling site: Peripheral blood. Male 40818610 CVCL_A1JP YTC3 cancer cell line human CVCL_A1JP CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion Cell type=Natural killer cell.. Male 40818611 CVCL_A1JQ RB1KY finite cell line human CVCL_A1JQ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818612 CVCL_A1JR RB1KYF finite cell line human CVCL_A1JR CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818613 CVCL_A1JS RB1KYM finite cell line human CVCL_A1JS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818614 CVCL_A1JT KPUM-MS3 cancer cell line human CVCL_A1JT CL:0000010 Sequence variation: Gene fusion; HGNC; 990; BCL2 + HGNC; 5477; IGH; Name(s)=IGH-BCL2 (PubMed=21640157) Population: Japanese; Derived from sampling site: Pleural effusion. Male 40818615 CVCL_A1JU KPUM-UH1 cancer cell line human CVCL_A1JU CL:0000010 Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=21640157) Population: Japanese; Derived from sampling site: Pleural effusion. Female 40818616 CVCL_A1JV TCO-3 cancer cell line human CVCL_A1JV CL:0000010 Population: Japanese. Unspecified 40818617 CVCL_A1JG Sq-1979 233-11 cancer cell line house mouse CVCL_A1JG CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the primary tumor of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 16.0 +- 4.8 hours (PubMed=29435078) 40818618 CVCL_A1JH Sq-1979 L2-3 cancer cell line house mouse CVCL_A1JH CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the metastastic lymph nodes of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 12.1 +- 0.3 hours (PubMed=29435078) 40818619 CVCL_A1JI Sq-1979 L3-5 cancer cell line house mouse CVCL_A1JI CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the metastastic lymph nodes of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 11.6 +- 1.1 hours (PubMed=29435078) 40818620 CVCL_A1JJ Sq-1979 L5-11 cancer cell line house mouse CVCL_A1JJ CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the metastastic lymph nodes of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 15.4 +- 1.2 hours (PubMed=29435078) 40818621 CVCL_A1JK Sq-1979 L6-8 cancer cell line house mouse CVCL_A1JK CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the metastastic lymph nodes of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 14.1 +- 0.4 hours (PubMed=29435078) 40818622 CVCL_A1JL Sq-1979 L6-9 cancer cell line house mouse CVCL_A1JL CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the metastastic lymph nodes of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 18.6 +- 2.5 hours (PubMed=29435078) 40818623 CVCL_A1JM MK2 cancer cell line human CVCL_A1JM CL:0000010 Population: Japanese Unspecified Doubling time: 52-53 hours (CelloPub=CLPUB00584). 40818624 CVCL_A1JN YT clone 2C2 cancer cell line human CVCL_A1JN CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Pericardial effusion Cell type=Natural killer cell.. Male 40818625 CVCL_A1JA OS3-R5-GFP cancer cell line human CVCL_A1JA CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Unspecified 40818626 CVCL_A1JB OS3-R5-GFP-CD9 cancer cell line human CVCL_A1JB CL:0000010 Transfected with: HGNC; 1709; CD9; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Japanese; Derived from sampling site: Lung. Unspecified Characteristics: Transfected with CD9 fused to the C-terminal of GFP 40818627 CVCL_A1JC Sq-1979-1 cancer cell line house mouse CVCL_A1JC CL:0000010 Breed/subspecies: C3H. Doubling time: 11.0 +- 3.3 hours (PubMed=29435078) 40818628 CVCL_A1JD Sq-1979-2 cancer cell line house mouse CVCL_A1JD CL:0000010 Breed/subspecies: C3H. Doubling time: 11.8 +- 1.0 hours (PubMed=29435078) 40818629 CVCL_A1JE Sq-1979-3 cancer cell line house mouse CVCL_A1JE CL:0000010 Breed/subspecies: C3H. Doubling time: 11.6 +- 0.8 hours (PubMed=29435078) 40818630 CVCL_A1JF Sq-1979 233-1 cancer cell line house mouse CVCL_A1JF CL:0000010 Breed/subspecies: C3H. Characteristics: Established from the primary tumor of male C3H/HeN mice subcutaneously injected with the parent cell line into the posterior neck area Doubling time: 12.7 +- 0.5 hours (PubMed=29435078) 40818631 CVCL_A1IV SNB-3 cancer cell line human CVCL_A1IV CL:0000010 40818632 CVCL_A1IW SNB-4 cancer cell line human CVCL_A1IW CL:0000010 40818633 CVCL_A1IX NN [Human astrocytoma Bethesda] cancer cell line human CVCL_A1IX CL:0000010 Derived from sampling site: Brain. Female 40818634 CVCL_A1IY Ch-4 transformed cell line human CVCL_A1IY CL:0000010 Population: Japanese; Transformant: Ad-SV40 hybrid virus; Derived from sampling site: Femoral head; cartilage. Unspecified 40818635 CVCL_A1IZ KMK-2 cancer cell line human CVCL_A1IZ CL:0000010 Population: Japanese; Derived from metastatic site: Peritoneal effusion. Female 40818636 CVCL_A1KP KMG-9 cancer cell line human CVCL_A1KP CL:0000010 Population: Japanese. Unspecified 40818637 CVCL_A1KQ KMG-14 cancer cell line human CVCL_A1KQ CL:0000010 Population: Japanese. Unspecified 40818638 CVCL_A1KR KMG-15 cancer cell line human CVCL_A1KR CL:0000010 Population: Japanese. Unspecified 40818639 CVCL_A1KS KMG-16 cancer cell line human CVCL_A1KS CL:0000010 Population: Japanese. Unspecified 40818640 CVCL_A1KT KMG-17 cancer cell line human CVCL_A1KT CL:0000010 Population: Japanese. Unspecified 40818641 CVCL_A1KU LC-65A cancer cell line human CVCL_A1KU HLA typing: A*11:01,24:02; B*40:02; C*03:04 (PubMed=9023415). CL:0000010 Population: Japanese Unspecified 40818642 CVCL_A1KV LC-99A cancer cell line human CVCL_A1KV HLA typing: A*24:02; B*52:01,54:01; C*01:02,12:02 (PubMed=9023415). CL:0000010 Population: Japanese Unspecified 40818643 CVCL_A1KW RK4 transformed cell line human CVCL_A1KW CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 7989; NRAS (with p.Gln61Leu) Karyotypic information: 48,XY,+12,+5 (PubMed=8652393); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818644 CVCL_A1KH HOC119PF cancer cell line human CVCL_A1KH CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Group: Serum/protein free medium cell line 40818645 CVCL_A1KI KMS II cancer cell line human CVCL_A1KI CL:0000010 Population: Japanese; Derived from sampling site: Brain; fourth ventricle. Male Doubling time: 24 hours, at 117th passage (CelloPub=CLPUB00587) 40818646 CVCL_A1KJ Ep-C4 hybridoma house mouse CVCL_A1KJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human surface antigen on ependymoma cells. 40818647 CVCL_A1KK KMG-2 cancer cell line human CVCL_A1KK CL:0000010 Population: Japanese; Derived from sampling site: Brain; frontal lobe. Male Doubling time: 38 hours, at 72th passage (CelloPub=CLPUB00587) 40818648 CVCL_A1KL KMG-3 cancer cell line human CVCL_A1KL CL:0000010 Population: Japanese; Derived from sampling site: Brain; frontal lobe. Female Doubling time: 48 hours, at 39th passage (CelloPub=CLPUB00587) 40818649 CVCL_A1KM KMG-5 cancer cell line human CVCL_A1KM CL:0000010 Population: Japanese; Derived from sampling site: Brain; fronto-temporal lobe. Male Doubling time: 100 hours, at 31th passage (CelloPub=CLPUB00587) 40818650 CVCL_A1KN KMG-8 cancer cell line human CVCL_A1KN CL:0000010 Population: Japanese. Unspecified 40818651 CVCL_A1KA Y-MESO-26C cancer cell line human CVCL_A1KA CL:0000010 Population: Japanese. Male 40818652 CVCL_A1KB YDOV-139 cancer cell line human CVCL_A1KB HLA typing: A*24,31; B*07,35; C*03,07; DRB1*01,15 (PubMed=20596667) CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Proteome analysis by 2D-DE; Omics: Transcriptome analysis by microarray Female Doubling time: 120 hours (PubMed=20596667) 40818653 CVCL_A1KC YDOV-151 cancer cell line human CVCL_A1KC HLA typing: A*38,38; B*58,58; C*03,03; DRB1*03,04 (PubMed=19478469) CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female Doubling time: 19 hours (PubMed=19478469) 40818654 CVCL_A1KD YDOV-161 cancer cell line human CVCL_A1KD CL:0000010 Population: Korean; Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female 40818655 CVCL_A1KE YDOV-105 cancer cell line human CVCL_A1KE CL:0000010 Population: Korean; Derived from sampling site: Ovary. Omics: Transcriptome analysis by microarray Female 40818656 CVCL_A1KF YDOV-13 cancer cell line human CVCL_A1KF CL:0000010 Population: Korean; Derived from metastatic site: Ascites. Omics: Transcriptome analysis by microarray Female 40818657 CVCL_A1KG HOC519PF cancer cell line human CVCL_A1KG CL:0000010 Population: Japanese; Derived from metastatic site: Cervical lymph node. Group: Serum/protein free medium cell line 40818658 CVCL_A1JW TCO-5 cancer cell line human CVCL_A1JW CL:0000010 Population: Japanese. Unspecified 40818659 CVCL_A1JX AT2EM finite cell line human CVCL_A1JX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Doubling time: 90 hours (PubMed=8609460) 40818660 CVCL_A1JY Y-MESO-11B cancer cell line human CVCL_A1JY CL:0000010 Population: Japanese. Male 40818661 CVCL_A1JZ Y-MESO-38 cancer cell line human CVCL_A1JZ CL:0000010 Population: Japanese. Male 40818662 CVCL_A1GT LUEi019-B induced pluripotent stem cell human CVCL_A1GT From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818663 CVCL_A1GU MN-1A cancer cell line human CVCL_A1GU CL:0000010 Population: Japanese Female Doubling time: 40.0 hours, at 22th passage (DOI=10.5795/jjscc.32.1). 40818664 CVCL_A1GV MN-1B cancer cell line human CVCL_A1GV CL:0000010 Population: Japanese Female Doubling time: 32.0 hours, at 9th passage (DOI=10.5795/jjscc.32.1). 40818665 CVCL_A1GW BB [Human ovarian carcinoma] cancer cell line human CVCL_A1GW CL:0000010 Derived from metastatic site: Ascites. Female 40818666 CVCL_A1GX HB [Human ovarian carcinoma] cancer cell line human CVCL_A1GX From: Kaul S.; Frauenklinik der Universitat Heidelberg; Heidelberg; Germany CL:0000010 Derived from metastatic site: Ascites. Female 40818667 CVCL_A1GY HI cancer cell line human CVCL_A1GY From: Kaul S.; Frauenklinik der Universitat Heidelberg; Heidelberg; Germany CL:0000010 Derived from metastatic site: Ascites. Female 40818668 CVCL_A1GZ OC cancer cell line human CVCL_A1GZ From: Kaul S.; Frauenklinik der Universitat Heidelberg; Heidelberg; Germany CL:0000010 Derived from metastatic site: Ascites. Female 40818669 CVCL_A1IN EMTOKA 117 cancer cell line human CVCL_A1IN CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818670 CVCL_A1IP EMTOKA 124 cancer cell line human CVCL_A1IP CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818671 CVCL_A1IQ EMTOKA 2B10 cancer cell line human CVCL_A1IQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818672 CVCL_A1IR EMTOKA 5D9 cancer cell line human CVCL_A1IR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818673 CVCL_A1IS EMTOKA 5E4 cancer cell line human CVCL_A1IS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818674 CVCL_A1IT SNB-2 cancer cell line human CVCL_A1IT CL:0000010 40818675 CVCL_A1IU SNB-1 cancer cell line human CVCL_A1IU CL:0000010 Derived from sampling site: Brain; right temporo-parietal junction. Male 40818676 CVCL_A1IF KP 1 cancer cell line human CVCL_A1IF CL:0000010 Population: Japanese; Derived from sampling site: Kidney; renal pelvis. Female Doubling time: 45 hours (PubMed=7200272) 40818677 CVCL_A1IG BCNS1KO(SVT)-1 transformed cell line human CVCL_A1IG CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818678 CVCL_A1IH BCNS1KO(SVT)-2 transformed cell line human CVCL_A1IH CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818679 CVCL_A1II Pan2M cancer cell line human CVCL_A1II CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>A (IVS9+1G>A); ClinVar=VCV000528261; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Derived from metastatic site: Ascites. Female Characteristics: Metastatic Established from the orthopical implementation of the parent cell line in BALB/c nu/nu nude mice. 40818680 CVCL_A1IJ Pan2MmLuc cancer cell line human CVCL_A1IJ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=30747829); Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (PubMed=30747829); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Arg (c.34G>C); ClinVar=VCV000012579; Zygosity=Heterozygous (PubMed=30747829); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.993+1G>A (IVS9+1G>A); ClinVar=VCV000528261; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=30747829); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Ascites. Female Characteristics: Metastatic Established from the orthopical implementation of the TCC-pan2 cell line in BALB/c nu/nu nude mice. Doubling time: ~24 hours (PubMed=30747829) 40818681 CVCL_A1IK HOGT spontaneously immortalized cell line human CVCL_A1IK CL:0000010 Population: Japanese; Derived from sampling site: Stomach. Male Doubling time: 48 hours (at 5th passage), 40 hours (at 24th passage), 38 hours (at 40th passage) (PubMed=2408913) 40818682 CVCL_A1IL EMTOKA 107 cancer cell line human CVCL_A1IL CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818683 CVCL_A1IM EMTOKA 107-D1 cancer cell line human CVCL_A1IM CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Uterus. Female 40818684 CVCL_A1IA DW cancer cell line human CVCL_A1IA From: Kaul S.; Frauenklinik der Universitat Heidelberg; Heidelberg; Germany CL:0000010 Derived from metastatic site: Ascites. Female 40818685 CVCL_A1IB GG cancer cell line human CVCL_A1IB From: Kaul S.; Frauenklinik der Universitat Heidelberg; Heidelberg; Germany CL:0000010 Derived from metastatic site: Abdominal wall. Female 40818686 CVCL_A1IC HD-10 cancer cell line human CVCL_A1IC CL:0000010 Population: Japanese; Derived from sampling site: Lymph node. Doubling time: 17.5 hours (PubMed=6991350) 40818687 CVCL_A1ID JFCR-OCCA-1 cancer cell line human CVCL_A1ID CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the originating institute (Japanese Foundation for Cancer Research) and cell line description (ovarian clear cell adenocarcinoma) Population: Japanese; Derived from metastatic site: Ascites. Female Doubling time: ~53 hours (DOI=10.5795/jjscc.30.473) 40818688 CVCL_A1IE PC-5 [Human lung carcinoma] cancer cell line human CVCL_A1IE From: Immuno-Biological Laboratories (IBL); Tokyo; Japan CL:0000010 Population: Japanese. Unspecified 40818689 CVCL_A1FK IARC-591 transformed cell line human CVCL_A1FK From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Unspecified 40818690 CVCL_A1FL Evsa-T GDC-0941-resistant clone 1 cancer cell line human CVCL_A1FL CL:0000010 Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Tyr (c.3199G>T); Zygosity=Heterozygous; Note=Responsible for pictrelisib resistance (PubMed=26759240); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; c.687+1_687+2delGT; ClinVar=VCV000483268; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.951_954delACTT) (p.VL317fs) (V317fs*3); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Cys (c.722C>G); ClinVar=VCV000177791; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; Derived from metastatic site: Ascites. Omics: Deep exome analysis Female 40818691 CVCL_A1FM SUM52PE GDC-0941_resistant cancer cell line human CVCL_A1FM CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala68Val (c.203C>T); ClinVar=VCV000406701; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Ter (c.637C>T); ClinVar=VCV000043590; Zygosity=Unspecified (from parent cell line) Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; Derived from metastatic site: Pleural effusion. Female 40818692 CVCL_A1FN ZR-75-1 GDC-0941-resistant cancer cell line human CVCL_A1FN CL:0000010 Sequence variation: Mutation; HGNC; 8976; PIK3CB; Simple; p.Asp1067Tyr (c.3199G>T); Zygosity=Heterozygous; Note=Responsible for pictrelisib resistance (PubMed=26759240); Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; Derived from metastatic site: Ascites. Female 40818693 CVCL_A1FP HCC1569 GDC-0941_resistant cancer cell line human CVCL_A1FP CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1100Thr (c.3299A>C); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Val1862fs*1 (c.5578delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3701; FHIT; Simple; p.Val97Phe (c.289G>T) (651G>T); dbSNP=rs139666727; Zygosity=Heterozygous; Note=Genomic (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu294Ter (c.880G>T); ClinVar=VCV000379471; Zygosity=Heterozygous (from parent cell line) Population: African American; Selected for resistance to: ChEBI; CHEBI:65326; Pictrelisib (Pictilisib; Derived from sampling site: Breast. Female 40818694 CVCL_A1FQ RERF-LC-MK cancer cell line human CVCL_A1FQ CL:0000010 Population: Japanese. Unspecified 40818695 CVCL_A1FR HWL cancer cell line human CVCL_A1FR CL:0000010 Doubling time: 23 hours (PubMed=8402660). 40818696 CVCL_A1FC COLO 38R cancer cell line human CVCL_A1FC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=24732172); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Right buttock; hypodermis. Male Problematic cell line: Contaminated Parent cell line (COLO 38) has been shown to be a M14 derivative. 40818697 CVCL_A1FD TPF-10-741 cancer cell line human CVCL_A1FD CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24732172) Derived from metastatic site: Cutaneous. 40818698 CVCL_A1FE M13 cancer cell line human CVCL_A1FE CL:0000010 Derived from metastatic site: Cutaneous. Female 40818699 CVCL_A1FF M7 [Human melanoma Berlin] cancer cell line human CVCL_A1FF CL:0000010 Derived from metastatic site: Cutaneous. Male 40818700 CVCL_A1FG DF-15 cancer cell line human CVCL_A1FG CL:0000010 Female 40818701 CVCL_A1FH DF-22 cancer cell line human CVCL_A1FH CL:0000010 Female 40818702 CVCL_A1FI DF-23 cancer cell line human CVCL_A1FI CL:0000010 Female 40818703 CVCL_A1FJ BYH transformed cell line CVCL_A1FJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Group: Non-human primate cell line 40818704 CVCL_A1EZ TLBR-3 cancer cell line human CVCL_A1EZ CL:0000010 Derived from sampling site: Breast Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 77 hours (PubMed=22791880); ~20-50 hours (DSMZ=ACC-906) 40818705 CVCL_A1FA TLBR-4 cancer cell line human CVCL_A1FA CL:0000010 Derived from sampling site: Breast Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Female 40818706 CVCL_A1FB M21R cancer cell line human CVCL_A1FB CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=24732172) Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Not specified. Female 40818707 CVCL_A1ER JC-52 cancer cell line human CVCL_A1ER CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu1342Ter (c.4025T>G); ClinVar=VCV000645602; Zygosity=Unspecified (PubMed=28179481); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1343Phefs*10 (c.4028_4029delCT); ClinVar=VCV000824521; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818708 CVCL_A1ES JC-54 cancer cell line human CVCL_A1ES CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg876Ter (c.2626C>T); ClinVar=VCV000216014; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818709 CVCL_A1ET JC-55 cancer cell line human CVCL_A1ET CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1306Ter (c.3916G>T) (E1288*, c.3862G>T); ClinVar=VCV000376059; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818710 CVCL_A1EU JC-56 cancer cell line human CVCL_A1EU CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1023Asnfs*6 (c.3067dupA); ClinVar=VCV000230713; Zygosity=Unspecified (PubMed=28179481); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1554Ter (c.4660G>T); ClinVar=VCV000433664; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818711 CVCL_A1EV JC-58 cancer cell line human CVCL_A1EV CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1295Ter (c.3883G>T); Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818712 CVCL_A1EW JC-61 cancer cell line human CVCL_A1EW CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu941Ter (c.2821G>T); Zygosity=Unspecified (PubMed=28179481); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1459fs; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818713 CVCL_A1EX JC-7 cancer cell line human CVCL_A1EX CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg232Ter (c.694C>T); ClinVar=VCV000042248; Zygosity=Unspecified (PubMed=28179481). Population: Japanese 40818714 CVCL_A1EY TLBR-2 cancer cell line human CVCL_A1EY CL:0000010 Sequence variation: Mutation; HGNC; 11364; STAT3; Simple; p.Asp661Tyr (c.1981G>T); ClinVar=VCV000928790; Zygosity=Unspecified (PubMed=28356514) Derived from sampling site: Breast Cell type=T-cell.. Omics: Transcriptome analysis by RNAseq Female Doubling time: 37 hours (PubMed=22791880); ~24-30 hours (DSMZ=ACC-905) 40818715 CVCL_A1GL U3189MG cancer cell line human CVCL_A1GL CL:0000010 Derived from sampling site: Brain. Male 40818716 CVCL_A1GM U3198MG cancer cell line human CVCL_A1GM CL:0000010 Derived from sampling site: Brain. Male 40818717 CVCL_A1GN U3202MG cancer cell line human CVCL_A1GN CL:0000010 Derived from sampling site: Brain. Male 40818718 CVCL_A1GP Ma-Mel-36-EBV transformed cell line human CVCL_A1GP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: SNP array analysis Female 40818719 CVCL_A1GQ ACC-LC-319/bone2 cancer cell line human CVCL_A1GQ CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000045116; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro71fs (c.211delC); Zygosity=Unspecified (from parent cell line). Population: Japanese Unspecified Characteristics: Highly metastatic to bone Obtained after 2 cycles of intravenous injection of parental cells into NK cell-depleted SCID mice and harvesting of the bone metastases. 40818720 CVCL_A1GR OCGH_ATRT cancer cell line human CVCL_A1GR CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg53Ter (c.157C>T); ClinVar=VCV000944246; Zygosity=Unspecified (PubMed=32997328) Population: Japanese; Derived from sampling site: Brain; pineal gland. Male Doubling time: 19.3 hours (PubMed=32997328) 40818721 CVCL_A1GS LUEi019-A induced pluripotent stem cell human CVCL_A1GS From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818722 CVCL_A1GD U3155MG cancer cell line human CVCL_A1GD CL:0000010 Derived from sampling site: Brain. Female 40818723 CVCL_A1GE U3164MG cancer cell line human CVCL_A1GE CL:0000010 Derived from sampling site: Brain. Male 40818724 CVCL_A1GF U3167MG cancer cell line human CVCL_A1GF CL:0000010 Derived from sampling site: Brain. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Female 40818725 CVCL_A1GG U3169MG cancer cell line human CVCL_A1GG CL:0000010 Derived from sampling site: Brain. Female 40818726 CVCL_A1GH U3172MG cancer cell line human CVCL_A1GH CL:0000010 Derived from sampling site: Brain. Male 40818727 CVCL_A1GI U3173MG cancer cell line human CVCL_A1GI CL:0000010 Derived from sampling site: Brain. Female 40818728 CVCL_A1GJ U3175MG cancer cell line human CVCL_A1GJ CL:0000010 Derived from sampling site: Brain. Male 40818729 CVCL_A1GK U3180MG cancer cell line human CVCL_A1GK CL:0000010 Derived from sampling site: Brain. Male 40818730 CVCL_A1GA U3137MG cancer cell line human CVCL_A1GA CL:0000010 Derived from sampling site: Brain. Male 40818731 CVCL_A1GB U3140MG cancer cell line human CVCL_A1GB CL:0000010 Derived from sampling site: Brain. Female 40818732 CVCL_A1GC U3146MG cancer cell line human CVCL_A1GC CL:0000010 Derived from sampling site: Brain. Male 40818733 CVCL_A1FS TE110 cancer cell line human CVCL_A1FS CL:0000010 40818734 CVCL_A1FT WMN cancer cell line human CVCL_A1FT CL:0000010 Doubling time: 24 hours (PubMed=8402660). 40818735 CVCL_A1FU COLO 736 cancer cell line human CVCL_A1FU CL:0000010 Miscellaneous: Cell line information from archive documents of Moore G.E Derived from metastatic site: Pericardial effusion. Male 40818736 CVCL_A1FV HRI cancer cell line human CVCL_A1FV CL:0000010 40818737 CVCL_A1FW UM-SCC-118 cancer cell line human CVCL_A1FW CL:0000010 Omics: CNV analysis. Female 40818738 CVCL_A1FX U3093MG cancer cell line human CVCL_A1FX CL:0000010 Derived from sampling site: Brain. Female 40818739 CVCL_A1FY U3102MG cancer cell line human CVCL_A1FY CL:0000010 Derived from sampling site: Brain. Female 40818740 CVCL_A1FZ U3104MG cancer cell line human CVCL_A1FZ CL:0000010 Derived from sampling site: Brain. Male 40818741 CVCL_A1PU JUCTCi016-C induced pluripotent stem cell human CVCL_A1PU From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. Female Caution: Indicated as originating from a 35 year old female donor, but as this is an umbilical cord-derived cell line this is not possible 40818742 CVCL_A1PV UNIBSi011-A induced pluripotent stem cell human CVCL_A1PV From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Ser1290Pro (c.3868T>C); Zygosity=Heterozygous (PubMed=33010677); Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Arg2493Ter (c.7477C>A); ClinVar=VCV000031223; Zygosity=Heterozygous (PubMed=33010677) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818743 CVCL_A1PW UNIBSi011-B induced pluripotent stem cell human CVCL_A1PW From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Ser1290Pro (c.3868T>C); Zygosity=Heterozygous (PubMed=33010677); Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Arg2493Ter (c.7477C>A); ClinVar=VCV000031223; Zygosity=Heterozygous (PubMed=33010677) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818744 CVCL_A1PX UNIBSi011-C induced pluripotent stem cell human CVCL_A1PX From: University of Brescia; Brescia; Italy CL:0000010 Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Ser1290Pro (c.3868T>C); Zygosity=Heterozygous (PubMed=33010677); Sequence variation: Mutation; HGNC; 25801; CPLANE1; Simple; p.Arg2493Ter (c.7477C>A); ClinVar=VCV000031223; Zygosity=Heterozygous (PubMed=33010677) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818745 CVCL_A1PY NUIGi038-A induced pluripotent stem cell human CVCL_A1PY From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40818746 CVCL_A1PZ NUIGi038-B induced pluripotent stem cell human CVCL_A1PZ From: National University of Ireland Galway; Galway; Ireland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40818747 CVCL_A1PM JUCTCi014-B induced pluripotent stem cell human CVCL_A1PM From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40818748 CVCL_A1PN JUCTCi014-C induced pluripotent stem cell human CVCL_A1PN From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40818749 CVCL_A1PP JUCTCi015-A induced pluripotent stem cell human CVCL_A1PP From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 40818750 CVCL_A1PQ JUCTCi015-B induced pluripotent stem cell human CVCL_A1PQ From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 40818751 CVCL_A1PR JUCTCi015-C induced pluripotent stem cell human CVCL_A1PR From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 40818752 CVCL_A1PS JUCTCi016-A induced pluripotent stem cell human CVCL_A1PS From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. Female Caution: Indicated as originating from a 35 year old female donor, but as this is an umbilical cord-derived cell line this is not possible 40818753 CVCL_A1PT JUCTCi016-B induced pluripotent stem cell human CVCL_A1PT From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Umbilical cord; Wharton's jelly Cell type=Umbilical cord mesenchymal stem cell.. Female Caution: Indicated as originating from a 35 year old female donor, but as this is an umbilical cord-derived cell line this is not possible 40818754 CVCL_A1PE CHAi006-A induced pluripotent stem cell human CVCL_A1PE HLA typing: A*30:01,30:01; B*13:02,13:02; C*06:02,06:02; DPB1*17:01,17:01; DQB1*02:02,02:02; DRB1*07:01,07:01 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 40818755 CVCL_A1PF CHAi007-A induced pluripotent stem cell human CVCL_A1PF HLA typing: A*11:01,11:01; B*15:01,15:01; C*04:01,04:01; DPB1*02:01,05:01; DQB1*03:02,03:02; DRB1*04:06,04:06 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 40818756 CVCL_A1PG CHAi008-A induced pluripotent stem cell human CVCL_A1PG HLA typing: A*33:03,33:03; B*58:01,58:01; C*03:02,03:02; DPB1*02:01,04:01; DQB1*02:01,02:01; DRB1*03:01,03:01 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 40818757 CVCL_A1PH CHAi009-A induced pluripotent stem cell human CVCL_A1PH HLA typing: A*02:07,02:07; B*46:01,46:01; C*01:02,01:02; DPB1*02:02,04:01; DQB1*06:01,06:01; DRB1*08:03,08:03 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Male 40818758 CVCL_A1PI CHAi010-A induced pluripotent stem cell human CVCL_A1PI HLA typing: A*24:02,24:02; B*54:01,54:01; C*01:02,01:02; DPB1*05:01,05:01; DQB1*04:01,04:01; DRB1*04:05,04:05 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Male 40818759 CVCL_A1PJ WAe009-A-37 embryonic stem cell human CVCL_A1PJ From: University of Milan; Milan; Italy CL:0000010 Transfected with: UniProtKB; Q6WV12; Pontellina plumata GFP2 (with p.Lys5Glu, p.Val117Met, p.Val149Asp, p.Val151Asp, p.Ala155Thr, p.Phe168Ser and p.Leu200Asp = TurboGFP). Female Characteristics: Using CRISPR/Cas9 a tTA-turbo GFP construct was integrated in front of the stop codon of GSX2 (PubMed=33039807) 40818760 CVCL_A1PK RUCDRi002-A-5 induced pluripotent stem cell human CVCL_A1PK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Hispanic; Derived from sampling site: Umbilical cord blood. Male Characteristics: Using CRISPR/Cas9 two constructs one containing CAGpromoter-dCas9-VPR-2A-tdTomato-gGH and the other EF1alpha-promoter-Pac-SV40polyA were introduced in the AAVS1 safe harbor locus (PubMed=33038615) 40818761 CVCL_A1PL JUCTCi014-A induced pluripotent stem cell human CVCL_A1PL From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40818762 CVCL_A1PA CHAi002-A induced pluripotent stem cell human CVCL_A1PA HLA typing: A*33:03,33:03; B*58:01,58:01; C*03:02,03:02; DPB1*02:01,02:01; DQB1*06:09,06:09; DRB1*13:02,13:02 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Male 40818763 CVCL_A1PB CHAi003-A induced pluripotent stem cell human CVCL_A1PB HLA typing: A*33:03,33:03; B*44:03,44:03; C*07:01,07:01; DPB1*13:01,13:01; DQB1*02:02,02:02; DRB1*07:01,07:01 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Male 40818764 CVCL_A1PC CHAi004-A induced pluripotent stem cell human CVCL_A1PC HLA typing: A*24:02,24:02; B*07:02,07:02; C*07:02,07:02; DPB1*04:02,04:02; DQB1*05:01,05:01; DRB1*01:01,01:01 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Male 40818765 CVCL_A1PD CHAi005-A induced pluripotent stem cell human CVCL_A1PD HLA typing: A*24:02,24:02; B*52:01,52:01; C*12:02,12:02; DPB1*09:01,09:01; DQB1*06:01,06:01; DRB1*15:02,15:02 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 40818767 CVCL_A1QP MCRIi019-A-7 induced pluripotent stem cell human CVCL_A1QP From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple_edited; p.Gly1113Cys (c.3337G>T); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=34543885) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818768 CVCL_A1QQ USTCi001-A-2 induced pluripotent stem cell human CVCL_A1QQ From: School of Life Sciences, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Gln1923Arg (c.5768A>G); Zygosity=Heterozygous (PubMed=32335389); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Asian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 a tdTomato gene was introduced into the first exon of the GAD67 gene (PubMed=32977294) 40818769 CVCL_A1QR DLEC-NNV spontaneously immortalized cell line CVCL_A1QR CL:0000010 Transfected with: UniProtKB; G8GVZ5; Dicentrarchus labrax betanodavirus capsid protein alpha; Transfected with: UniProtKB; P00552; Transposon Tn5 neo. Unspecified Group: Fish cell line 40818770 CVCL_A1QF UKHGi001-B induced pluripotent stem cell human CVCL_A1QF From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818771 CVCL_A1QG UKHGi002-A induced pluripotent stem cell human CVCL_A1QG From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818772 CVCL_A1QH UKHGi002-B induced pluripotent stem cell human CVCL_A1QH From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818773 CVCL_A1QI UKHGi003-A induced pluripotent stem cell human CVCL_A1QI From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 14295; SHANK2; Unexplicit; 120 kb deletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=33002717) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818774 CVCL_A1QJ UKHGi003-B induced pluripotent stem cell human CVCL_A1QJ From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 14295; SHANK2; Unexplicit; 120 kb deletion; Zygosity=Unspecified; Note=De novo mutation (PubMed=33002717) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818775 CVCL_A1QK ECMA-1 cancer cell line human CVCL_A1QK CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val157Phe (c.469G>T); ClinVar=VCV000012353; Zygosity=Heterozygous (PubMed=33087752) Population: Caucasian; Derived from metastatic site: Liver. Omics: Array-based CGH Male Doubling time: 87 hours (PubMed=33087752) 40818776 CVCL_A1QL MCC-38 cancer cell line human CVCL_A1QL CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (PubMed=33087752) Population: Caucasian; Derived from sampling site: Rectum. Omics: Array-based CGH Male Doubling time: 22 hours (PubMed=33087752) 40818778 CVCL_A1QA OSRi002-A induced pluripotent stem cell human CVCL_A1QA From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Gly488Arg (c.1462G>A); ClinVar=VCV000447893; Zygosity=Heterozygous (hPSCreg). 40818779 CVCL_A1QB OSRi003-A induced pluripotent stem cell human CVCL_A1QB From: Ospedale San Raffaele; Milan; Italy CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Gly488Arg (c.1462G>A); ClinVar=VCV000447893; Zygosity=Heterozygous (hPSCreg). 40818780 CVCL_A1QC CVTTHi001-A induced pluripotent stem cell human CVCL_A1QC From: Centro Vasco de Transfusion y Tejidos Humanos; Galdakao; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1425+2delT; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33221676) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 40818781 CVCL_A1QD REGUi009-A induced pluripotent stem cell human CVCL_A1QD From: Institute for Regenerative Medecine and Biotherapy; Montpellier; France CL:0000010 Sequence variation: Mutation; HGNC; 2226; COLQ; Simple; p.Cys427Cys (c.1281C>T); ClinVar=VCV000536241; Zygosity=Homozygous; Note=Activates a cryptic splice site (PubMed=33370874) Population: Turkish; Derived from sampling site: Peripheral blood. Male 40818782 CVCL_A1QE UKHGi001-A induced pluripotent stem cell human CVCL_A1QE From: Institute of Human Genetics Heidelberg; Heidelberg; Germany CL:0000010 Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818783 CVCL_A1NS TRNDi024-D induced pluripotent stem cell human CVCL_A1NS From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818784 CVCL_A1NT TRNDi025-A induced pluripotent stem cell human CVCL_A1NT From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818785 CVCL_A1NU TRNDi025-B induced pluripotent stem cell human CVCL_A1NU From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818786 CVCL_A1NV TRNDi025-C induced pluripotent stem cell human CVCL_A1NV From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818787 CVCL_A1NW TRNDi025-D induced pluripotent stem cell human CVCL_A1NW From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818788 CVCL_A1NX UHOMi002-A induced pluripotent stem cell human CVCL_A1NX From: University Hospital of Montpellier; Montpellier; France CL:0000010 Derived from sampling site: Peripheral blood. Male 40818789 CVCL_A1NY CAMi014-A induced pluripotent stem cell human CVCL_A1NY From: University of Cambridge; Cambridge; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 8941; SERPINA1; Simple; p.Glu366Lys (c.1096G>A); ClinVar=VCV000017967; Zygosity=Homozygous; Note=Z allele (PubMed=21993621) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40818790 CVCL_A1NZ CHAi001-A induced pluripotent stem cell human CVCL_A1NZ HLA typing: A*33:03,33:03; B*44:03,44:03; C*14:03,14:03; DPB1*02:02,04:02; DQB1*06:04,06:04; DRB1*13:02,13:02 (PubMed=30004605) From: CHA University; Seongnam; South Korea CL:0000010 Population: Korean; Derived from sampling site: Umbilical cord blood. Omics: Array-based CGH Female 40818791 CVCL_A1NK TRNDi023-A induced pluripotent stem cell human CVCL_A1NK From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 40818792 CVCL_A1NL TRNDi023-B induced pluripotent stem cell human CVCL_A1NL From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 40818793 CVCL_A1NM TRNDi023-C induced pluripotent stem cell human CVCL_A1NM From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 40818794 CVCL_A1NN TRNDi023-D induced pluripotent stem cell human CVCL_A1NN From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Thr408Met (c.1223C>T) (T369M); ClinVar=VCV000093447; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Male 40818795 CVCL_A1NP TRNDi024-A induced pluripotent stem cell human CVCL_A1NP From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818796 CVCL_A1NQ TRNDi024-B induced pluripotent stem cell human CVCL_A1NQ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818797 CVCL_A1NR TRNDi024-C induced pluripotent stem cell human CVCL_A1NR From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 40818798 CVCL_A1NC SMBCi010-A induced pluripotent stem cell human CVCL_A1NC From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 3512; EXT1; Simple; c.1883+1G>T; ClinVar=VCV000961767; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=33360848) Population: Chinese; Han; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40818799 CVCL_A1ND YCMi002-A induced pluripotent stem cell human CVCL_A1ND From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 3544; F7; Simple; p.Cys115Ter (c.345C>A); Zygosity=Heterozygous (PubMed=33038747); Sequence variation: Mutation; HGNC; 3544; F7; Simple; p.Gln426Ter (c.1276C>T); Zygosity=Heterozygous (PubMed=33038747) Population: Korean; Derived from sampling site: Cell type=Fibroblast. Female 40818800 CVCL_A1NE NJDTHi001-A induced pluripotent stem cell human CVCL_A1NE From: Department of Cardio-Thoracic Surgery, Nanjing Drum Tower Hospital; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 6501; LAMP2; Simple; p.Leu156Ter (c.467T>G); ClinVar=VCV001323203; Zygosity=Hemizygous (PubMed=33038746) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40818801 CVCL_A1NF UNCi001-A induced pluripotent stem cell human CVCL_A1NF From: University of North Carolina at Chapel Hill; Chapel Hill; USA CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40818802 CVCL_A1NG TRNDi021-A induced pluripotent stem cell human CVCL_A1NG From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818803 CVCL_A1NH TRNDi021-B induced pluripotent stem cell human CVCL_A1NH From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818804 CVCL_A1NI TRNDi021-C induced pluripotent stem cell human CVCL_A1NI From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818805 CVCL_A1NJ TRNDi021-D induced pluripotent stem cell human CVCL_A1NJ From: NIH-NCATS-TRND Branch; Rockville; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818806 CVCL_A1MZ SMBCi006-A induced pluripotent stem cell human CVCL_A1MZ From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 40818807 CVCL_A1NA SMBCi006-B induced pluripotent stem cell human CVCL_A1NA From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 40818808 CVCL_A1NB SMBCi006-C induced pluripotent stem cell human CVCL_A1NB From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Urine. Male 40818809 CVCL_ZW59 GM27632 transformed cell line human CVCL_ZW59 CL:0000010 Population: El Salvadoran; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818810 CVCL_ZW55 GM27889 finite cell line human CVCL_ZW55 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818811 CVCL_ZW56 GM27892 transformed cell line human CVCL_ZW56 CL:0000010 Sequence variation: Mutation; HGNC; 4136; GAMT; Simple; p.Glu142del (c.424_426delGAG); dbSNP=rs1736323141; Zygosity=Homozygous (Coriell) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818812 CVCL_ZW57 GM27894 finite cell line human CVCL_ZW57 CL:0000010 Sequence variation: Mutation; HGNC; 29331; EPG5; Simple; p.Gln336Arg (c.1007A>G); ClinVar=VCV000192333; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818813 CVCL_ZW58 GM27631 transformed cell line human CVCL_ZW58 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818814 CVCL_ZW62 GM27642 transformed cell line human CVCL_ZW62 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818815 CVCL_ZW63 GM27648 transformed cell line human CVCL_ZW63 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Lys618Glufs*13 (c.1850dupA); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818816 CVCL_ZW64 GM27664 transformed cell line human CVCL_ZW64 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Arg212Leufs*24 (c.628_629delAG); Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818817 CVCL_ZW65 GM27665 transformed cell line human CVCL_ZW65 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818818 CVCL_ZW60 GM27633 transformed cell line human CVCL_ZW60 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818819 CVCL_ZW61 GM27641 transformed cell line human CVCL_ZW61 CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Arg398Ter (c.1192C>T); ClinVar=VCV000208415; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818820 CVCL_ZW48 GM27863 transformed cell line human CVCL_ZW48 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe408del (c.1216_1218TTC[2]) (c.1222_1224delTTC); ClinVar=VCV000011698; Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818821 CVCL_ZW49 GM27874 finite cell line human CVCL_ZW49 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe408del (c.1216_1218TTC[2]) (c.1222_1224delTTC); ClinVar=VCV000011698; Zygosity=Hemizygous (Coriell) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40818822 CVCL_ZW44 GM09938 hybrid cell line CVCL_ZW44 CL:0000010 Discontinued: Coriell; GM09938; probable. Group: Human/rodent somatic cell hybrid 40818823 CVCL_ZW45 GM09940 hybrid cell line CVCL_ZW45 CL:0000010 Discontinued: Coriell; GM09940; probable. Group: Human/rodent somatic cell hybrid 40818824 CVCL_ZW46 GM27909 finite cell line human CVCL_ZW46 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Val277_Leu281dup (c.829_843dup15); ClinVar=VCV000810773; Zygosity=Hemizygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818825 CVCL_ZW47 GM27910 transformed cell line human CVCL_ZW47 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Asn125Tyr (c.373A>T); Zygosity=Hemizygous (Coriell) Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818826 CVCL_ZW51 GM27866 transformed cell line human CVCL_ZW51 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Trp556Ter (c.1667G>A); ClinVar=VCV000546017; Zygosity=Hemizygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818827 CVCL_ZW52 GM27867 finite cell line human CVCL_ZW52 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Trp556Ter (c.1667G>A); ClinVar=VCV000546017; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818828 CVCL_ZW53 GM27868 transformed cell line human CVCL_ZW53 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Trp556Ter (c.1667G>A); ClinVar=VCV000546017; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818829 CVCL_ZW54 GM27888 finite cell line human CVCL_ZW54 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818830 CVCL_ZW50 GM27865 finite cell line human CVCL_ZW50 CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Trp556Ter (c.1667G>A); ClinVar=VCV000546017; Zygosity=Hemizygous (Coriell) Population: Caucasian; German; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818831 CVCL_ZW37 GM09931 hybrid cell line CVCL_ZW37 CL:0000010 Discontinued: Coriell; GM09931; probable. Group: Human/rodent somatic cell hybrid 40818832 CVCL_ZW38 GM09932 hybrid cell line CVCL_ZW38 CL:0000010 Discontinued: Coriell; GM09932; probable. Group: Human/rodent somatic cell hybrid 40818833 CVCL_ZW39 GM09933 hybrid cell line CVCL_ZW39 CL:0000010 Discontinued: Coriell; GM09933; probable. Group: Human/rodent somatic cell hybrid 40818834 CVCL_ZW33 GM09927 hybrid cell line CVCL_ZW33 CL:0000010 Discontinued: Coriell; GM09927; probable. Group: Human/rodent somatic cell hybrid 40818835 CVCL_ZW34 GM09928 hybrid cell line CVCL_ZW34 CL:0000010 Discontinued: Coriell; GM09928; probable. Group: Human/rodent somatic cell hybrid 40818836 CVCL_ZW35 GM09929 hybrid cell line CVCL_ZW35 CL:0000010 Discontinued: Coriell; GM09929; probable. Group: Human/rodent somatic cell hybrid 40818837 CVCL_ZW36 GM09930 hybrid cell line CVCL_ZW36 CL:0000010 Discontinued: Coriell; GM09930; probable. Group: Human/rodent somatic cell hybrid 40818838 CVCL_ZW40 GM09934 hybrid cell line CVCL_ZW40 CL:0000010 Discontinued: Coriell; GM09934; probable. Group: Human/rodent somatic cell hybrid 40818839 CVCL_ZW41 GM09935 hybrid cell line CVCL_ZW41 CL:0000010 Discontinued: Coriell; GM09935; probable. Group: Human/rodent somatic cell hybrid 40818840 CVCL_ZW42 GM09936 hybrid cell line CVCL_ZW42 CL:0000010 Discontinued: Coriell; GM09936; probable. Group: Human/rodent somatic cell hybrid 40818841 CVCL_ZW43 GM09937 hybrid cell line CVCL_ZW43 CL:0000010 Discontinued: Coriell; GM09937; probable. Group: Human/rodent somatic cell hybrid 40818842 CVCL_ZW26 XP6EHF finite cell line human CVCL_ZW26 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP6EH) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818843 CVCL_ZW27 XP6EHM finite cell line human CVCL_ZW27 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP6EH) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818844 CVCL_ZW28 XP1EHF finite cell line human CVCL_ZW28 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP1EH) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818845 CVCL_ZW29 XP1EHM finite cell line human CVCL_ZW29 CL:0000010 Sequence variation: Mutation; HGNC; 12814; XPA; Simple; c.390-1G>C (IVS3-1G>C); ClinVar=VCV000264684; Zygosity=Heterozygous; Note=Splice acceptor mutation (from familial inference of XP1EH) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818846 CVCL_ZW22 XP107TO finite cell line human CVCL_ZW22 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818847 CVCL_ZW23 XP2DF finite cell line human CVCL_ZW23 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 40818848 CVCL_ZW24 XP4DF finite cell line human CVCL_ZW24 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 40818849 CVCL_ZW25 XP19BR finite cell line human CVCL_ZW25 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 40818850 CVCL_ZW30 LCD3 hybrid cell line human CVCL_ZW30 CL:0000010 Characteristics: Hybrid for chromosome X mapping Contains a complete copy of chromosome X.. Group: Human/rodent somatic cell hybrid 40818851 CVCL_ZW31 GM09925 hybrid cell line CVCL_ZW31 CL:0000010 Discontinued: Coriell; GM09925; probable. Group: Human/rodent somatic cell hybrid 40818852 CVCL_ZW32 GM09926 hybrid cell line CVCL_ZW32 CL:0000010 Discontinued: Coriell; GM09926; probable. Group: Human/rodent somatic cell hybrid 40818853 CVCL_ZW15 HDZi001-A induced pluripotent stem cell human CVCL_ZW15 From: Heart and Diabetes Center North Rhine Westphalia; Bad Oeynhausen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 28472; TMEM43; Simple; p.Ser358Leu (c.1073C>T); ClinVar=VCV000000734; Zygosity=Heterozygous (PubMed=32858485) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 40818854 CVCL_ZW16 BTH-C induced pluripotent stem cell human CVCL_ZW16 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Ser110Pro (c.328T>C); ClinVar=VCV000042255; Zygosity=Hemizygous (PubMed=24813252) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818855 CVCL_ZW17 BTH-H induced pluripotent stem cell human CVCL_ZW17 CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Asp173Thrfs*11 (c.517delG); ClinVar=VCV001704478; Zygosity=Hemizygous (PubMed=24813252) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818856 CVCL_ZW18 CHD-26 induced pluripotent stem cell human CVCL_ZW18 From: National Human Genome Research Institute; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Arg503Ter (c.1507C>T); ClinVar=VCV000620096; Zygosity=Heterozygous (PubMed=32619719); Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Gly3309Ser (c.9925G>A); Zygosity=Heterozygous (PubMed=32619719) Derived from sampling site: Peripheral blood. Male 40818857 CVCL_ZW11 FUi003-A1 induced pluripotent stem cell human CVCL_ZW11 From: Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University; Fukuoka; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Tyr1102Ter (c.3306C>A); ClinVar=VCV000217243; Zygosity=Heterozygous (PubMed=32599563) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818858 CVCL_ZW12 FUi003-A2 induced pluripotent stem cell human CVCL_ZW12 From: Central Research Institute for the Pathomechanisms of Epilepsy, Fukuoka University; Fukuoka; Japan CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Tyr1102Ter (c.3306C>A); ClinVar=VCV000217243; Zygosity=Heterozygous (PubMed=32599563) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818859 CVCL_ZW13 HMGUi001-A-5 induced pluripotent stem cell human CVCL_ZW13 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a large non-coding genomic DNA at INK4 locus was homozygously deleted (PubMed=32739881) 40818860 CVCL_ZW14 ASGRCi007-A induced pluripotent stem cell human CVCL_ZW14 From: Genomics Research Center, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Chinese; Taiwan; Derived from sampling site: Peripheral blood. Male 40818861 CVCL_ZW19 CHD-19 induced pluripotent stem cell human CVCL_ZW19 From: National Human Genome Research Institute; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Arg1104Ter (c.3310C>T); ClinVar=VCV000003809; Zygosity=Heterozygous (PubMed=32619719); Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Gly3408Arg (c.10222G>A); Zygosity=Heterozygous (PubMed=32619719) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818862 CVCL_ZW20 CHD-39 induced pluripotent stem cell human CVCL_ZW20 From: National Human Genome Research Institute; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Val1564_Arg1621del (c.4862+1G>A) (c.4689_4862del); Zygosity=Heterozygous (PubMed=32619719); Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.His3236Tyr (c.9706C>T); Zygosity=Heterozygous (PubMed=32619719) Derived from sampling site: Peripheral blood. Female 40818863 CVCL_ZW21 CHD-5 induced pluripotent stem cell human CVCL_ZW21 From: National Human Genome Research Institute; Bethesda; USA CL:0000010 Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Val2651Phe (c.7951G>T); Zygosity=Heterozygous (PubMed=32619719); Sequence variation: Mutation; HGNC; 1968; LYST; Simple; p.Ala3680Glyfs*8 (c.11039_11195del); Zygosity=Heterozygous (PubMed=32619719) Derived from sampling site: Peripheral blood. Female 40818864 CVCL_ZW04 PSF [Human AOA3 fibroblast] finite cell line human CVCL_ZW04 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. 40818865 CVCL_ZW05 PSF-hTERT telomerase immortalized cell line human CVCL_ZW05 CL:0000010 Transfected with: HGNC; 11730; TERT Derived from sampling site: Skin Cell type=Fibroblast.. 40818866 CVCL_ZW06 PSF-SV transformed cell line human CVCL_ZW06 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. 40818867 CVCL_ZW07 AtT20PL cancer cell line house mouse CVCL_ZW07 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pituitary gland; Breed/subspecies: LAF1. Characteristics: Expression of luciferase is under the control of the rat POMC promoter 40818868 CVCL_ZW00 MDCK-A3-10 spontaneously immortalized cell line dog CVCL_ZW00 CL:0000010 Transfected with: HGNC; 1706; CD8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 40818869 CVCL_ZW01 MDCK-A3-14 spontaneously immortalized cell line dog CVCL_ZW01 CL:0000010 Transfected with: HGNC; 1706; CD8A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female 40818870 CVCL_ZW02 1182-4D spontaneously immortalized cell line fruit fly CVCL_ZW02 CL:0000010 Karyotypic information: Diploid karyotype. Female Characteristics: Constitutively lacks centrioles (CelloPub=CLPUB00568; PubMed=3084259) Group: Insect cell line 40818871 CVCL_ZW03 GM07166VA7-NBS1 transformed cell line human CVCL_ZW03 CL:0000010 Sequence variation: Mutation; HGNC; 7652; NBN; Simple; p.Lys219Asnfs*16 (c.657_661delACAAA) (657del5); ClinVar=VCV000006940; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7652; NBN Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818872 CVCL_ZW08 P11 cancer cell line Norway rat CVCL_ZW08 CL:0000010 Transformant: 2,4,6-trimethylaniline (TMA)(ChEBI; CHEBI:82545); Derived from sampling site: Pituitary gland; Breed/subspecies: Buffalo. Female Characteristics: Established from the transplantable tumor 7315a Doubling time: ~25 hours (PubMed=2160057) 40818873 CVCL_ZW09 SUP1 cancer cell line Norway rat CVCL_ZW09 CL:0000010 Transformant: 2,4,6-trimethylaniline (TMA)(ChEBI; CHEBI:82545); Derived from sampling site: Pituitary gland; Breed/subspecies: Buffalo. Female Characteristics: Established from the transplantable tumor 7315a 40818874 CVCL_ZW10 44-3A6 hybridoma house mouse CVCL_ZW10 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Human labyrinthin. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8986 40818875 CVCL_ZW99 TC-1/A9 transformed cell line house mouse CVCL_ZW99 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Lacks MHC class I expression Established from tumors produced by subcutaneous injection of parent cell line (PubMed=12559790). Doubling time: 17.5 hours (PubMed=12559790); 16.2 hours (PubMed=31638243) 40818876 CVCL_ZW88 017-PC-M finite cell line human CVCL_ZW88 CL:0000010 Female Characteristics: hESC-derived pericyte-like cell. 40818877 CVCL_ZW89 017-PC-O finite cell line human CVCL_ZW89 CL:0000010 Female Characteristics: hESC-derived osteogenic progenitor. 40818878 CVCL_ZW90 HuH-7-END cancer cell line human CVCL_ZW90 CL:0000010 Sequence variation: Mutation; HGNC; 6307; KDR; Simple; p.Gln472His (c.1416A>T); ClinVar=VCV000134603; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 20932; POLD3; Simple; p.Lys109Arg (c.326A>G) (p.Lys70Arg, c.209A>G); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr220Cys (c.659A>G); ClinVar=VCV000127819; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 10905; SLC10A1; Transfected with: UniProtKB; P03138; Hepatitis B virus genotype D subtype ayw envelope protein (HBsAg); Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from sampling site: Liver. Male Characteristics: Transfected with pJC126, a plasmid harboring a 1.1-fold cDNA copy of the HDV antigenome; Virology: Persistently replicates and secretes hepatitis delta virus (HDV) 40818879 CVCL_ZW95 SW1990-GZ cancer cell line human CVCL_ZW95 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 40818880 CVCL_ZW96 SW1990/ADM cancer cell line human CVCL_ZW96 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from sampling site: Pancreas. Male 40818881 CVCL_ZW97 SW1990/FU cancer cell line human CVCL_ZW97 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from sampling site: Pancreas. Male 40818882 CVCL_ZW98 SW1990/GEM cancer cell line human CVCL_ZW98 CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.Gln533Ter (c.1597C>T); ClinVar=VCV000096480; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro191del (c.569_571CTC[1]) (c.572_574delCTC); ClinVar=VCV000458551; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Pancreas. Male 40818883 CVCL_ZW91 HBE-1A1 transformed cell line human CVCL_ZW91 CL:0000010 Transfected with: HGNC; 2595; CYP1A1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Bronchus; epithelium. Male 40818884 CVCL_ZW92 HEK293 Nav1.7 transformed cell line human CVCL_ZW92 CL:0000010 Transfected with: HGNC; 10597; SCN9A; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Ruhlmann A Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 40818885 CVCL_ZW93 Vero-pA104R spontaneously immortalized cell line green monkey CVCL_ZW93 CL:0000010 Transfected with: UniProtKB; P68742; African swine fever virus (AFSV) isolate Ba71V pA104R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line 40818886 CVCL_ZW94 COS-1-pA104R transformed cell line CVCL_ZW94 CL:0000010 Transfected with: UniProtKB; P68742; African swine fever virus (AFSV) isolate Ba71V pA104R; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV6-1](NCBI-Taxonomy; 1891767); Derived from sampling site: Kidney. Male Group: Non-human primate cell line 40818887 CVCL_ZW77 VeroS spontaneously immortalized cell line green monkey CVCL_ZW77 CL:0000010 Derived from sampling site: Kidney; epithelium. Female Characteristics: Adapted to suspension growth Group: Non-human primate cell line; Group: Vaccine production cell line 40818888 CVCL_ZW78 2.12.1 hybridoma house mouse CVCL_ZW78 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2792 40818889 CVCL_ZW79 2.13.2 hybridoma house mouse CVCL_ZW79 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2788 40818890 CVCL_ZW84 120816CT somatic stem cell human CVCL_ZW84 CL:0000010 Derived from sampling site: Umbilical cord. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-124321 40818891 CVCL_ZW85 GEAMP cancer cell line human CVCL_ZW85 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser836Ter (c.2507C>A); ClinVar=VCV001072880; Zygosity=Unspecified (PubMed=31292541); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly154Alafs*16 (c.459delG); Zygosity=Unspecified (PubMed=31292541) Derived from metastatic site: Pleural effusion. Male 40818892 CVCL_ZW86 iPS-DF19-9 MYF5-2A-GFP clone 5 induced pluripotent stem cell human CVCL_ZW86 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 MYF5 has been endogenously tagged in both alleles at the C-terminus with a 2A-GFP reporter 40818893 CVCL_ZW87 017-PC-A finite cell line human CVCL_ZW87 CL:0000010 Female Characteristics: hESC-derived mesenchymal progenitor. 40818894 CVCL_ZW80 2.14.3 hybridoma house mouse CVCL_ZW80 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2790 40818895 CVCL_ZW81 3.1.1 hybridoma house mouse CVCL_ZW81 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2791 40818896 CVCL_ZW82 4.17.3 hybridoma house mouse CVCL_ZW82 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2793 40818897 CVCL_ZW83 4.9.2 hybridoma house mouse CVCL_ZW83 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P08069; Human IGF1R/CD221. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2789 40818898 CVCL_ZW66 GM27666 transformed cell line human CVCL_ZW66 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818899 CVCL_ZW67 GM27682 transformed cell line human CVCL_ZW67 CL:0000010 Sequence variation: Mutation; HGNC; 11005; SLC2A1; Simple; p.Arg212His (c.635G>A); ClinVar=VCV000265386; Zygosity=Heterozygous (Coriell) Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818900 CVCL_ZW68 GM27683 transformed cell line human CVCL_ZW68 CL:0000010 Population: Indian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818901 CVCL_ZW69 HaCaT-shNeg spontaneously immortalized cell line human CVCL_ZW69 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Control cell line for the HaCaT-shNrf2 cell lines 40818902 CVCL_ZW73 iHFK-shNeg transformed cell line human CVCL_ZW73 CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male Characteristics: Control cell line for the iHFK-shNrf2 cell lines 40818903 CVCL_ZW74 iHFK-shNrf2#1 transformed cell line human CVCL_ZW74 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 40818904 CVCL_ZW75 iHFK-shNrf2#2 transformed cell line human CVCL_ZW75 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 40818905 CVCL_ZW76 iHFK-shNrf2#3 transformed cell line human CVCL_ZW76 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Foreskin; skin Cell type=Keratinocyte.. Male 40818906 CVCL_ZW70 HaCaT-shNrf2#1 spontaneously immortalized cell line human CVCL_ZW70 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 40818907 CVCL_ZW71 HaCaT-shNrf2#2 spontaneously immortalized cell line human CVCL_ZW71 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 40818908 CVCL_ZW72 HaCaT-shNrf2#3 spontaneously immortalized cell line human CVCL_ZW72 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 7782; NFE2L2; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His179Tyr (c.535C>T); ClinVar=VCV000127815; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.843_844CC>TT); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male 40818909 CVCL_ZY13 AP66P(L) transformed cell line human CVCL_ZY13 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from autologous cell line AP66P) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818910 CVCL_ZY14 AP66P(SVT) transformed cell line human CVCL_ZY14 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818911 CVCL_ZY15 AP66S finite cell line human CVCL_ZY15 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818912 CVCL_ZY16 AP66S(L) transformed cell line human CVCL_ZY16 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818913 CVCL_ZY10 AP66M(L) transformed cell line human CVCL_ZY10 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from autologous cell line AP66M) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40818914 CVCL_ZY11 AP66M(SVT) transformed cell line human CVCL_ZY11 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818915 CVCL_ZY12 AP66P finite cell line human CVCL_ZY12 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818916 CVCL_ZY17 AP66S(SVT) transformed cell line human CVCL_ZY17 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818917 CVCL_ZY18 AP66S hTERT telomerase immortalized cell line human CVCL_ZY18 CL:0000010 Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818918 CVCL_ZY19 AP2P finite cell line human CVCL_ZY19 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10807541); Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Heterozygous (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818919 CVCL_ZY02 HUF8 finite cell line human CVCL_ZY02 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 40818920 CVCL_ZY03 HUF9 finite cell line human CVCL_ZY03 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 40818921 CVCL_ZY04 PIS-1 cancer cell line human CVCL_ZY04 CL:0000010 Population: Japanese; Derived from sampling site: Lung. Female 40818922 CVCL_ZY05 Mutu- cancer cell line human CVCL_ZY05 CL:0000010 Population: African; Kenyan; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Male Virology: EBV-negative 40818923 CVCL_ZY00 HUF6 finite cell line human CVCL_ZY00 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (PubMed=19774082) Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 40818924 CVCL_ZY01 HUF7 finite cell line human CVCL_ZY01 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=19774082) Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 40818925 CVCL_ZY06 AP66F finite cell line human CVCL_ZY06 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818926 CVCL_ZY07 AP66F(L) transformed cell line human CVCL_ZY07 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from autologous cell line AP66F) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818927 CVCL_ZY08 AP66F(SVT) transformed cell line human CVCL_ZY08 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40818928 CVCL_ZY09 AP66M finite cell line human CVCL_ZY09 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818929 CVCL_ZX76 CPA-Yang5 cancer cell line human CVCL_ZX76 CL:0000010 Population: Chinese; Derived from metastatic site: Pericardial effusion. Male Characteristics: Metastatic to bone Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.3139 40818930 CVCL_ZX77 12G5 hybridoma house mouse CVCL_ZX77 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P61073; Human CXCR4/CD184. 40818931 CVCL_ZX78 ATAP120 hybridoma house mouse CVCL_ZX78 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25116; Human F2R (Note=Recognizes N-terminal region). 40818932 CVCL_ZX79 ATAP138 hybridoma house mouse CVCL_ZX79 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25116; Human F2R (Note=Recognizes N-terminal region). 40818933 CVCL_ZX83 LKA29 induced pluripotent stem cell human CVCL_ZX83 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40818934 CVCL_ZX84 LKA36 induced pluripotent stem cell human CVCL_ZX84 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40818935 CVCL_ZX85 KA(LCL) transformed cell line human CVCL_ZX85 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40818936 CVCL_ZX86 KA(DF) finite cell line human CVCL_ZX86 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40818937 CVCL_ZX80 ATAP2 hybridoma house mouse CVCL_ZX80 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P25116; Human F2R (Note=Recognizes N-terminal region). 40818938 CVCL_ZX81 BC7/CCR5 cancer cell line human CVCL_ZX81 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Cys251Tyr (c.752G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Arg177His (c.530G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7029; MET; Simple; p.Arg191Trp (c.571C>T); ClinVar=VCV000568557; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Asp (c.1635G>T); ClinVar=VCV000217293; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Lys (c.2908G>A); ClinVar=VCV001057635; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9585; PTCH1; Simple; p.Arg682Cys (c.2044C>T); ClinVar=VCV000237466; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 15533; SPRY4; Simple; p.Arg25Trp (c.73C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg267Leu (c.800G>T); ClinVar=VCV000852206; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 1606; CCR5 Derived from sampling site: Pleural effusion Cell type=T-cell.. Male Characteristics: CD4 negative 40818939 CVCL_ZX82 LKA10 induced pluripotent stem cell human CVCL_ZX82 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40818940 CVCL_ZX69 Hs 750.M finite cell line human CVCL_ZX69 CL:0000010 Derived from sampling site: Muscle. Male 40818941 CVCL_ZX65 UMCGi009-A induced pluripotent stem cell human CVCL_ZX65 From: University Medical Center Groningen; Groningen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 9080; PLN; Simple; p.Arg14del (c.37_39AGA[1]) (c.40_42delAGA) (R14del); ClinVar=VCV000044580; Zygosity=Heterozygous (hPSCreg) Derived from sampling site: Cell type=Fibroblast. Unspecified 40818942 CVCL_ZX66 SPan-1 hybridoma house mouse CVCL_ZX66 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human mucin-like antigen. 40818943 CVCL_ZX67 Ypan1 hybridoma house mouse CVCL_ZX67 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Human mucin-like antigen. 40818944 CVCL_ZX68 Ypan2 hybridoma house mouse CVCL_ZX68 CL:0000010 Monoclonal antibody isotype: IgM. 40818945 CVCL_ZX72 A-427F finite cell line human CVCL_ZX72 CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40818946 CVCL_ZX73 A549L0 cancer cell line human CVCL_ZX73 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Male 40818947 CVCL_ZX74 A549L6 cancer cell line human CVCL_ZX74 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Highly metastatic to spine Established after 3 rounds of intracardial injection of the parent cell line in nude mice and extraction of the metastatic cells from spine tumors. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201346 40818948 CVCL_ZX75 CPA-Yang6 cancer cell line human CVCL_ZX75 CL:0000010 Population: Chinese; Derived from metastatic site: Pleural effusion. Female Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.5404 40818949 CVCL_ZX70 IMR90-830 transformed cell line human CVCL_ZX70 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 40818950 CVCL_ZX71 IMR90-890 transformed cell line human CVCL_ZX71 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 40818951 CVCL_ZX58 KCLi006-A induced pluripotent stem cell human CVCL_ZX58 From: King's College London; London; United Kingdom. CL:0000010 40818952 CVCL_ZX59 MUSCSDi001-A-1 induced pluripotent stem cell human CVCL_ZX59 From: Medical University of South Carolina; Charleston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8654; PCCB Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 40818953 CVCL_ZX54 STBCi321-A induced pluripotent stem cell human CVCL_ZX54 From: StemBANCC; Oxford; United Kingdom. CL:0000010 Male 40818954 CVCL_ZX55 STBCi322-A induced pluripotent stem cell human CVCL_ZX55 From: StemBANCC; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40818955 CVCL_ZX56 STBCi323-A induced pluripotent stem cell human CVCL_ZX56 From: StemBANCC; Oxford; United Kingdom. CL:0000010 Male 40818956 CVCL_ZX57 UNIGEi003-A induced pluripotent stem cell human CVCL_ZX57 From: University of Geneva; Geneva; Switzerland CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Array-based CGH Male 40818957 CVCL_ZX61 UTA.11505.WTsb induced pluripotent stem cell human CVCL_ZX61 From: University of Tampere; Tampere; Finland CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818958 CVCL_ZX62 UTA.14511.CPVT induced pluripotent stem cell human CVCL_ZX62 From: University of Tampere; Tampere; Finland CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Pro2328Ser (c.6982C>T); ClinVar=VCV000012960; Zygosity=Unspecified (hPSCreg) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40818959 CVCL_ZX63 WAe009-A-36 embryonic stem cell human CVCL_ZX63 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14202; JPH2. Female 40818960 CVCL_ZX64 KUMCi001-A induced pluripotent stem cell human CVCL_ZX64 From: Korea University College of Medicine; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow. Female 40818961 CVCL_ZX60 MUSCSDi001-A-2 induced pluripotent stem cell human CVCL_ZX60 From: Medical University of South Carolina; Charleston; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 8654; PCCB Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 40818962 CVCL_ZX47 GZHMCi001-A induced pluripotent stem cell human CVCL_ZX47 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6233; KCNC1; Simple; p.Arg320His (c.959G>A); ClinVar=VCV000162519; Zygosity=Heterozygous (PubMed=32712483) Population: Chinese; Derived from sampling site: Peripheral blood. Male 40818963 CVCL_ZX48 GZHMCi001-B induced pluripotent stem cell human CVCL_ZX48 From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6233; KCNC1; Simple; p.Arg320His (c.959G>A); ClinVar=VCV000162519; Zygosity=Heterozygous (PubMed=32712483) Population: Chinese; Derived from sampling site: Peripheral blood. Male 40818964 CVCL_ZX49 ICGi023-A induced pluripotent stem cell human CVCL_ZX49 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818965 CVCL_ZX43 FM7-H11 hybrid cell line CVCL_ZX43 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767). Characteristics: Contains human chromosome 11 Group: Patented cell line 40818966 CVCL_ZX44 CIBi008-A induced pluripotent stem cell human CVCL_ZX44 From: Cell Inspire Biotechnology; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.-78A>G (-28A>G); ClinVar=VCV000015471; Zygosity=Heterozygous (PubMed=33157391); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-197C>T (IVS2-654C>T); ClinVar=VCV000015458; Zygosity=Heterozygous (PubMed=33157391) Derived from sampling site: Amniotic fluid. Male 40818967 CVCL_ZX45 CMCi001-A induced pluripotent stem cell human CVCL_ZX45 From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 29170; FAN1; Simple; p.Gly663Ilefs*54 (c.1985_1994del10); Zygosity=Homozygous (PubMed=32563974) Population: Asian; Derived from sampling site: Peripheral blood. Female 40818968 CVCL_ZX46 CSUASOi006-A induced pluripotent stem cell human CVCL_ZX46 From: Central South University, Aier School of Ophthalmology; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 17340; PRPF8; Simple; p.Thr1931Met (c.5792C>T); ClinVar=VCV000867014; Zygosity=Unspecified (PubMed=33157387) Population: Chinese; Han; Derived from sampling site: Urine. Male 40818969 CVCL_ZX50 ICGi023-B induced pluripotent stem cell human CVCL_ZX50 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40818970 CVCL_ZX51 ICGi024-A induced pluripotent stem cell human CVCL_ZX51 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(18) [50]; 45,XY,-18 [6]; 47,XY,r(18),r(18) [1] (PubMed=33212351); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male 40818971 CVCL_ZX52 ICGi025-A induced pluripotent stem cell human CVCL_ZX52 From: The Federal Research Center Institute of Cytology and Genetics; Novosibirsk; Russia CL:0000010 Population: Caucasian; Karyotypic information: 46,XY,r(8)(p23;q24.3) [88]; 45,XY,-8 [11] (PubMed=33070101); Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: SNP array analysis Male 40818972 CVCL_ZX53 PUMCHi004-A induced pluripotent stem cell human CVCL_ZX53 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 12405; TTR; Simple; p.Asp38Asn (c.112G>A); ClinVar=VCV000571867; Zygosity=Heterozygous (PubMed=33038745) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40818973 CVCL_ZX36 BBANTWi004-C induced pluripotent stem cell human CVCL_ZX36 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818974 CVCL_ZX37 BBANTWi005-A induced pluripotent stem cell human CVCL_ZX37 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818975 CVCL_ZX38 BBANTWi005-B induced pluripotent stem cell human CVCL_ZX38 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818976 CVCL_ZX39 BBANTWi005-C induced pluripotent stem cell human CVCL_ZX39 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818977 CVCL_ZX32 BBANTWi003-B induced pluripotent stem cell human CVCL_ZX32 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Female 40818978 CVCL_ZX33 BBANTWi003-C induced pluripotent stem cell human CVCL_ZX33 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Female 40818979 CVCL_ZX34 BBANTWi004-A induced pluripotent stem cell human CVCL_ZX34 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818980 CVCL_ZX35 BBANTWi004-B induced pluripotent stem cell human CVCL_ZX35 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818981 CVCL_ZX40 FDCHi004-A induced pluripotent stem cell human CVCL_ZX40 From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2198; COL1A2; Simple; p.Gly328Ser (c.982G>A); ClinVar=VCV000456848; Zygosity=Heterozygous (PubMed=32659730) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 40818982 CVCL_ZX41 CMUi002-A-1 induced pluripotent stem cell human CVCL_ZX41 From: Anzhen Hospital, Capital Medical University; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 7871; NONO; Simple_edited; p.Glu234Argfs*31 (c.966insA); Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=32717574) Population: Chinese; Han; Derived from sampling site: Cell type=Fibroblast. Male 40818983 CVCL_ZX42 FM7 transformed cell line CVCL_ZX42 CL:0000010 Transformant: Simian virus 40 (SV40) [pSV3-gpt](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Patented cell line 40818984 CVCL_ZX25 BBANTWi001-A induced pluripotent stem cell human CVCL_ZX25 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Population: Caucasian; Belgian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis Male 40818985 CVCL_ZX26 BBANTWi001-B induced pluripotent stem cell human CVCL_ZX26 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Population: Caucasian; Belgian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis Male 40818986 CVCL_ZX27 BBANTWi001-C induced pluripotent stem cell human CVCL_ZX27 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Population: Caucasian; Belgian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: SNP array analysis Male 40818987 CVCL_ZX28 BBANTWi002-A induced pluripotent stem cell human CVCL_ZX28 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818988 CVCL_ZX21 WTC-mTagRFPT-LMNB1-cl62 induced pluripotent stem cell human CVCL_ZX21 CL:0000010 Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 LMNB1 has been endogenously tagged in one allele at the N-terminus with mTagRFP-T Part of: Allen Cell Collection 40818989 CVCL_ZX22 WTC-TFAM-mEGFP-cl31 induced pluripotent stem cell human CVCL_ZX22 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 TFAM has been endogenously tagged in one allele at the C-terminus with mTagRFP-T Part of: Allen Cell Collection 40818990 CVCL_ZX23 MHHi015-A induced pluripotent stem cell human CVCL_ZX23 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 40818991 CVCL_ZX24 MHHi015-B induced pluripotent stem cell human CVCL_ZX24 From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 40818992 CVCL_ZX29 BBANTWi002-B induced pluripotent stem cell human CVCL_ZX29 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818993 CVCL_ZX30 BBANTWi002-C induced pluripotent stem cell human CVCL_ZX30 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Male 40818994 CVCL_ZX31 BBANTWi003-A induced pluripotent stem cell human CVCL_ZX31 From: Biobank Antwerpen; Antwerp; Belgium CL:0000010 Derived from sampling site: Peripheral blood. Female 40818995 CVCL_ZX14 NS-A cancer cell line house mouse CVCL_ZX14 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Breed/subspecies: C3H. Female 40818996 CVCL_ZX15 NS-D cancer cell line house mouse CVCL_ZX15 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Breed/subspecies: C3H. Female 40818997 CVCL_ZX16 NS-E cancer cell line house mouse CVCL_ZX16 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Breed/subspecies: C3H. Female 40818998 CVCL_ZX17 NS-G cancer cell line house mouse CVCL_ZX17 CL:0000010 Transformant: Nickel subsulfide(ChEBI; CHEBI:144804); Breed/subspecies: C3H. Female 40818999 CVCL_ZX10 AP63P finite cell line human CVCL_ZX10 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10807541); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Leu1082Pro (c.3245C>T); Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819000 CVCL_ZX11 AP63P(SVT) transformed cell line human CVCL_ZX11 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Leu1082Pro (c.3245C>T); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819001 CVCL_ZX12 AP48P(SVT)-1 transformed cell line human CVCL_ZX12 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg435Cys (c.1303C>T); ClinVar=VCV000555603; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819002 CVCL_ZX13 AP48P(SVT)-2 transformed cell line human CVCL_ZX13 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg435Cys (c.1303C>T); ClinVar=VCV000555603; Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819003 CVCL_ZX18 IMR-32rCARBO1000 cancer cell line human CVCL_ZX18 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:31355; Carboplatin (CBP; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 40819004 CVCL_ZX19 IMR-5rDACARB40 cancer cell line human CVCL_ZX19 CL:0000010 Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4305; Dacarbazine (DTIC; Derived from metastatic site: Abdomen. Male Part of: Resistant Cancer Cell Line (RCCL) collection 40819005 CVCL_ZX20 WTC FBL-mEGFP/NPM1-mTagRFP-T/UBTF-HaloTag-cl147 induced pluripotent stem cell human CVCL_ZX20 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; H3JQU7; Entacmaea quadricolor red fluorescent protein eqFP578 (mutated to obtain mTagRFP-T); Transfected with: UniProtKB; P0A3G2; Rhodococcus rhodochrous dhaA (mutated = Halo-Tag) Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 FBL has been endogenously tagged in one allele at the C-terminus with mEGFP, NPM1 has been endogenously tagged in one allele at the C-terminus with mTagRFP-T and UBTF has been endogenously tagged in one allele at the N-terminus with a Halo-Tag Part of: Allen Cell Collection 40819006 CVCL_ZX03 DU145-TxR cancer cell line human CVCL_ZX03 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Brain. Omics: Transcriptome analysis by microarray Male 40819007 CVCL_ZX04 DU145-TxR/CxR cancer cell line human CVCL_ZX04 CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Asp84Tyr (c.250G>T) (p.Arg98Leu, c.293G>T); ClinVar=VCV000376306; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Lys715Ter (c.2143A>T); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Lys178fs*86 (c.532_536delAAGCC); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223Leu (c.668C>T); ClinVar=VCV000234214; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val274Phe (c.820G>T); ClinVar=VCV000376674; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Brain. Male 40819008 CVCL_ZX05 PC-3-TxR cancer cell line human CVCL_ZX05 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone. Omics: Transcriptome analysis by microarray Male 40819009 CVCL_ZX06 PC-3-TxR/CxR cancer cell line human CVCL_ZX06 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63584; Cabazitaxel; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Bone. Male 40819010 CVCL_ZX00 TC-1/D11 transformed cell line house mouse CVCL_ZX00 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Has reduced MHC class I expression Established from tumors produced by subcutaneous injection of parent cell line (PubMed=12559790). Doubling time: 16.5 hours (PubMed=12559790) 40819011 CVCL_ZX01 TC-1/dB2m transformed cell line house mouse CVCL_ZX01 CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:88127; B2m; Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Lung Cell type=Epithelial cell.; Breed/subspecies: C57BL/6. Unspecified Characteristics: Irreversible MHC class I downregulation and has a reduced proliferation rate and tumor growth (PubMed=31638243) Doubling time: 27.9 hours (PubMed=31638243) 40819012 CVCL_ZX02 Vero-CD4/CCR5 spontaneously immortalized cell line green monkey CVCL_ZX02 CL:0000010 Transfected with: HGNC; 1606; CCR5; Transfected with: HGNC; 1678; CD4; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; epithelium. Female Group: Non-human primate cell line; Group: Patented cell line 40819013 CVCL_ZX07 LNCAP-AAR cancer cell line human CVCL_ZX07 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:68639; Abiraterone acetate; Derived from metastatic site: Left supraclavicular lymph node. Male 40819014 CVCL_ZX08 AP68P finite cell line human CVCL_ZX08 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg435Cys (c.1303C>T); ClinVar=VCV000555603; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10807541); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (DOI=10.1007/0-387-33776-8_11; PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819015 CVCL_ZX09 AP68P(SVT) transformed cell line human CVCL_ZX09 CL:0000010 Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Arg435Cys (c.1303C>T); ClinVar=VCV000555603; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3582; FANCA; Simple; p.Ser849Phefs*40 (c.2546delC); ClinVar=VCV000408166; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819016 CVCL_ZX98 HUF4 finite cell line human CVCL_ZX98 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=19774082) Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 40819017 CVCL_ZX99 HUF5 finite cell line human CVCL_ZX99 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 40819018 CVCL_ZX87 KA(T-cell) finite cell line human CVCL_ZX87 CL:0000010 Derived from sampling site: Peripheral blood Cell type=T-cell.. Omics: Transcriptome analysis by microarray Male 40819019 CVCL_ZX88 PB(LCL) transformed cell line human CVCL_ZX88 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from autologous cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40819020 CVCL_ZX89 PB(DF) finite cell line human CVCL_ZX89 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from autologous cell line) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819021 CVCL_ZX94 LPB8 induced pluripotent stem cell human CVCL_ZX94 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40819022 CVCL_ZX95 HUF1 finite cell line human CVCL_ZX95 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 40819023 CVCL_ZX96 HUF2 finite cell line human CVCL_ZX96 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 40819024 CVCL_ZX97 HUF3 finite cell line human CVCL_ZX97 CL:0000010 Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 40819025 CVCL_ZX90 PB(T-cell) finite cell line human CVCL_ZX90 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from autologous cell line) Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 40819026 CVCL_ZX91 LPB1 induced pluripotent stem cell human CVCL_ZX91 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40819027 CVCL_ZX92 LPB7 induced pluripotent stem cell human CVCL_ZX92 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40819028 CVCL_ZX93 LPB3 induced pluripotent stem cell human CVCL_ZX93 CL:0000010 Sequence variation: Mutation; HGNC; 8607; PRKN; Unexplicit; Ex6-7del; Zygosity=Homozygous (from parent cell line) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by microarray Male 40819029 CVCL_ZZ34 MK1-OSU spontaneously immortalized cell line pig CVCL_ZZ34 CL:0000010 Miscellaneous: Doubling time and sex non-determination from personal communication of Khatri M Derived from sampling site: Trachea and lung. Unspecified Virology: Susceptible to infection by swine influenza viruses (PubMed=29880757) Doubling time: <24 hours (Direct_author_submission) 40819030 CVCL_ZZ35 SD-PJEC spontaneously immortalized cell line pig CVCL_ZZ35 CL:0000010 Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Unspecified Virology: Susceptible to infection by human and avian influenza viruses (PubMed=22739061) 40819031 CVCL_ZZ36 KKUi001-A induced pluripotent stem cell human CVCL_ZZ36 From: School of Medicine, Konkuk University; Seoul; South Korea CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male Characteristics: Using CRISPR/Cas9 EGFP and tdTomato reporter genes were inserted repsectively before the stop codon of OCT4 and NANOG 40819032 CVCL_ZZ37 C8 [Human HEK293 derivative] transformed cell line human CVCL_ZZ37 CL:0000010 Transfected with: MGI; MGI:1347098; Slc27a1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 40819033 CVCL_ZZ30 ZR75B Vb10 cancer cell line human CVCL_ZZ30 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Ascites. Female Doubling time: 38.2 hours (PubMed=9815641) 40819034 CVCL_ZZ31 MK-DIEC spontaneously immortalized cell line CVCL_ZZ31 CL:0000010 Miscellaneous: Doubling time and sex non-determination from personal communication of Khatri M Derived from sampling site: Embryonic intestine; Breed/subspecies: American Pekin. Unspecified Virology: Susceptible to infection by porcine epidemic diarrhea virus (PEDV) Doubling time: <24 hours (Direct_author_submission) Group: Bird cell line 40819035 CVCL_ZZ32 DEF-TA transformed cell line CVCL_ZZ32 CL:0000010 Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Whole embryo Cell type=Fibroblast.. Unspecified Virology: Susceptible to infection by duck hepatitis virus type 1 (DHV-1) (PubMed=22633926) Doubling time: 30-48 hours (PubMed=22633926) Group: Bird cell line 40819036 CVCL_ZZ33 BC25B11.2C hybridoma house mouse CVCL_ZZ33 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Bovine coronavirus DB2. 40819037 CVCL_ZZ38 ETCC cancer cell line CVCL_ZZ38 CL:0000010 Derived from sampling site: Kidney; Breed/subspecies: Thoroughbred. Female Virology: Susceptible to infection by equine herpesvirus type 3 (EHV-3) (PubMed=558280) Doubling time: 16 hours (PubMed=4421147) 40819038 CVCL_ZZ39 SW620/AD300 cancer cell line human CVCL_ZZ39 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Lymph node. Male 40819039 CVCL_ZZ40 MCF-7/BCRP cancer cell line human CVCL_ZZ40 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 74; ABCG2 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Myc-tagged ABCG2/BCRP 40819040 CVCL_ZZ23 MDA-MB-453 Ad15 cancer cell line human CVCL_ZZ23 CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Gln868His (c.2604G>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 1748; CDH1; Simple; p.Trp638Ter (c.1913G>A); ClinVar=VCV000599651; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Glu307Lys (c.919G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex10-11del; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pericardial effusion. Female Doubling time: 120.5 hours (PubMed=9815641) Group: Triple negative breast cancer (TNBC) cell line 40819041 CVCL_ZZ24 T47D Ad12 cancer cell line human CVCL_ZZ24 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Doubling time: 68.2 hours (PubMed=8562478; PubMed=9815641) 40819042 CVCL_ZZ25 T47D Ad60 cancer cell line human CVCL_ZZ25 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Doubling time: 86.0 hours (PubMed=8562478; PubMed=9815641) 40819043 CVCL_ZZ26 ZR75B Ad120 cancer cell line human CVCL_ZZ26 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female Doubling time: 47.8 hours (PubMed=8562478; PubMed=9815641) 40819044 CVCL_ZZ20 MCF-7 Tx200 cancer cell line human CVCL_ZZ20 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Doubling time: 79.3 hours (PubMed=8562478; PubMed=9815641) 40819045 CVCL_ZZ21 MCF-7 Tx8 cancer cell line human CVCL_ZZ21 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Pleural effusion. Female Doubling time: 54.7 hours (PubMed=8562478) 40819046 CVCL_ZZ22 MDA-MB-231 Vb100 cancer cell line human CVCL_ZZ22 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:27375; Vincaleukoblastine (Vinblastine); Derived from metastatic site: Pleural effusion. Female Doubling time: 33.5 hours (PubMed=9815641) Group: Triple negative breast cancer (TNBC) cell line 40819047 CVCL_ZZ27 ZR75B Ad24 cancer cell line human CVCL_ZZ27 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Ascites. Female Doubling time: 41.3 hours (PubMed=8562478; PubMed=9815641) 40819048 CVCL_ZZ28 ZR75B Tx10 cancer cell line human CVCL_ZZ28 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female Doubling time: 34.1 hours (PubMed=8562478; PubMed=9815641) 40819049 CVCL_ZZ29 ZR75B Tx40 cancer cell line human CVCL_ZZ29 CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:45863; Paclitaxel (Taxol); Derived from metastatic site: Ascites. Female Doubling time: 43.5 hours (PubMed=8562478; PubMed=9815641) 40819050 CVCL_ZZ12 SALS-29 induced pluripotent stem cell human CVCL_ZZ12 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819051 CVCL_ZZ13 SALS-30 induced pluripotent stem cell human CVCL_ZZ13 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819052 CVCL_ZZ14 SALS-31 induced pluripotent stem cell human CVCL_ZZ14 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819053 CVCL_ZZ15 SALS-32 induced pluripotent stem cell human CVCL_ZZ15 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819054 CVCL_ZZ10 SALS-27 induced pluripotent stem cell human CVCL_ZZ10 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819055 CVCL_ZZ11 SALS-28 induced pluripotent stem cell human CVCL_ZZ11 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819056 CVCL_ZZ16 MCF-7 TH cancer cell line human CVCL_ZZ16 CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gln26Arg (c.77A>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Gly776Val (c.2327G>T); ClinVar=VCV000163410; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Pro121His (c.362C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=8562478). Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin Female Doubling time: 50.6 hours (PubMed=8562478; PubMed=9815641) Problematic cell line: Contaminated Shown to be a OVCAR-8 derivative (PubMed=10995814). Originally thought to be a derivative of MCF-7. 40819057 CVCL_ZZ17 MCF-7 Ad75 cancer cell line human CVCL_ZZ17 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female Doubling time: 77.3 hours (PubMed=9815641) 40819058 CVCL_ZZ18 MCF-7 AdP500 cancer cell line human CVCL_ZZ18 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Derived from metastatic site: Pleural effusion. Female 40819059 CVCL_ZZ19 MCF-7 Ida6 cancer cell line human CVCL_ZZ19 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:42068; Idarubicin; Derived from metastatic site: Pleural effusion. Female 40819060 CVCL_ZZ01 SALS-18 induced pluripotent stem cell human CVCL_ZZ01 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819061 CVCL_ZZ02 SALS-19 induced pluripotent stem cell human CVCL_ZZ02 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819062 CVCL_ZZ03 SALS-20 induced pluripotent stem cell human CVCL_ZZ03 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819063 CVCL_ZZ04 SALS-21 induced pluripotent stem cell human CVCL_ZZ04 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819064 CVCL_ZZ00 SALS-17 induced pluripotent stem cell human CVCL_ZZ00 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819065 CVCL_ZZ09 SALS-26 induced pluripotent stem cell human CVCL_ZZ09 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819066 CVCL_ZZ05 SALS-22 induced pluripotent stem cell human CVCL_ZZ05 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819067 CVCL_ZZ06 SALS-23 induced pluripotent stem cell human CVCL_ZZ06 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819068 CVCL_ZZ07 SALS-24 induced pluripotent stem cell human CVCL_ZZ07 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819069 CVCL_ZZ08 SALS-25 induced pluripotent stem cell human CVCL_ZZ08 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819070 CVCL_ZY97 SALS-14 induced pluripotent stem cell human CVCL_ZY97 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819071 CVCL_ZY98 SALS-15 induced pluripotent stem cell human CVCL_ZY98 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819072 CVCL_ZY99 SALS-16 induced pluripotent stem cell human CVCL_ZY99 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819073 CVCL_ZY86 SALS-3 induced pluripotent stem cell human CVCL_ZY86 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819074 CVCL_ZY87 SALS-4 induced pluripotent stem cell human CVCL_ZY87 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819075 CVCL_ZY88 SALS-5 induced pluripotent stem cell human CVCL_ZY88 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819076 CVCL_ZY89 SALS-6 induced pluripotent stem cell human CVCL_ZY89 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819077 CVCL_ZY93 SALS-10 induced pluripotent stem cell human CVCL_ZY93 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819078 CVCL_ZY94 SALS-11 induced pluripotent stem cell human CVCL_ZY94 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819079 CVCL_ZY95 SALS-12 induced pluripotent stem cell human CVCL_ZY95 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819080 CVCL_ZY96 SALS-13 induced pluripotent stem cell human CVCL_ZY96 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819081 CVCL_ZY90 SALS-7 induced pluripotent stem cell human CVCL_ZY90 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819082 CVCL_ZY91 SALS-8 induced pluripotent stem cell human CVCL_ZY91 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819083 CVCL_ZY92 SALS-9 induced pluripotent stem cell human CVCL_ZY92 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819084 CVCL_ZY79 JaCALS LCL 023-0108 transformed cell line human CVCL_ZY79 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819085 CVCL_ZY75 JaCALS LCL 001-0358 transformed cell line human CVCL_ZY75 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819086 CVCL_ZY76 JaCALS LCL 001-0460 transformed cell line human CVCL_ZY76 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819087 CVCL_ZY77 JaCALS LCL 023-0089 transformed cell line human CVCL_ZY77 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819088 CVCL_ZY78 JaCALS LCL 001-0482 transformed cell line human CVCL_ZY78 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819089 CVCL_ZY82 JaCALS LCL 023-0100 transformed cell line human CVCL_ZY82 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819090 CVCL_ZY83 JaCALS LCL 023-0104 transformed cell line human CVCL_ZY83 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819091 CVCL_ZY84 SALS-1 induced pluripotent stem cell human CVCL_ZY84 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819092 CVCL_ZY85 SALS-2 induced pluripotent stem cell human CVCL_ZY85 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819093 CVCL_ZY80 JaCALS LCL 023-0009 transformed cell line human CVCL_ZY80 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819094 CVCL_ZY81 JaCALS LCL 001-0426 transformed cell line human CVCL_ZY81 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819095 CVCL_ZY68 JaCALS LCL 001-0459 transformed cell line human CVCL_ZY68 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819096 CVCL_ZY69 JaCALS LCL 001-0218 transformed cell line human CVCL_ZY69 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819097 CVCL_ZY64 JaCALS LCL 001-0058 transformed cell line human CVCL_ZY64 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819098 CVCL_ZY65 JaCALS LCL 023-0084 transformed cell line human CVCL_ZY65 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819099 CVCL_ZY66 JaCALS LCL 023-0083 transformed cell line human CVCL_ZY66 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819100 CVCL_ZY67 JaCALS LCL 023-0086 transformed cell line human CVCL_ZY67 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819101 CVCL_ZY71 JaCALS LCL 001-0478 transformed cell line human CVCL_ZY71 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819102 CVCL_ZY72 JaCALS LCL 001-0126 transformed cell line human CVCL_ZY72 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819103 CVCL_ZY73 JaCALS LCL 001-0361 transformed cell line human CVCL_ZY73 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819104 CVCL_ZY74 JaCALS LCL 001-0481 transformed cell line human CVCL_ZY74 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819105 CVCL_ZY70 JaCALS LCL 001-0431 transformed cell line human CVCL_ZY70 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819106 CVCL_ZY57 JaCALS LCL 001-0363 transformed cell line human CVCL_ZY57 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819107 CVCL_ZY58 JaCALS LCL 001-0352 transformed cell line human CVCL_ZY58 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819108 CVCL_ZY59 JaCALS LCL 001-0351 transformed cell line human CVCL_ZY59 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819109 CVCL_ZY53 JaCALS LCL 023-0052 transformed cell line human CVCL_ZY53 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819110 CVCL_ZY54 JaCALS LCL 001-0040 transformed cell line human CVCL_ZY54 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819111 CVCL_ZY55 JaCALS LCL 001-0010 transformed cell line human CVCL_ZY55 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819112 CVCL_ZY56 JaCALS LCL 001-0068 transformed cell line human CVCL_ZY56 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819113 CVCL_ZY60 JaCALS LCL 023-0081 transformed cell line human CVCL_ZY60 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819114 CVCL_ZY61 JaCALS LCL 001-0347 transformed cell line human CVCL_ZY61 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819115 CVCL_ZY62 JaCALS LCL 001-0009 transformed cell line human CVCL_ZY62 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819116 CVCL_ZY63 JaCALS LCL 001-0223 transformed cell line human CVCL_ZY63 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819117 CVCL_ZY46 1SOD1-6 induced pluripotent stem cell human CVCL_ZY46 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His47Arg (c.140A>G) (H46R); ClinVar=VCV000014764; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819118 CVCL_ZY47 2SOD1-1 induced pluripotent stem cell human CVCL_ZY47 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His47Arg (c.140A>G) (H46R); ClinVar=VCV000014764; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819119 CVCL_ZY48 2SOD1-4 induced pluripotent stem cell human CVCL_ZY48 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His47Arg (c.140A>G) (H46R); ClinVar=VCV000014764; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819120 CVCL_ZY49 3SOD1-1 induced pluripotent stem cell human CVCL_ZY49 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819121 CVCL_ZY42 Hep-2017 telomerase immortalized cell line human CVCL_ZY42 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver. 40819122 CVCL_ZY43 Hep-2022D telomerase immortalized cell line human CVCL_ZY43 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. 40819123 CVCL_ZY44 RPMI-7022 transformed cell line human CVCL_ZY44 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819124 CVCL_ZY45 1SOD1-4 induced pluripotent stem cell human CVCL_ZY45 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His47Arg (c.140A>G) (H46R); ClinVar=VCV000014764; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819125 CVCL_ZY50 3SOD1-4 induced pluripotent stem cell human CVCL_ZY50 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819126 CVCL_ZY51 3SOD1-7 induced pluripotent stem cell human CVCL_ZY51 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.His44Arg (c.131A>G) (H43R); ClinVar=VCV000014756; Zygosity=Unspecified (PubMed=30127392) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819127 CVCL_ZY52 JaCALS LCL 001-0006 transformed cell line human CVCL_ZY52 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819128 CVCL_ZY35 AT1OS SV transformed cell line human CVCL_ZY35 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; c.4612del165 (Ex33del); Zygosity=Homozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819129 CVCL_ZY36 Hep-2004 telomerase immortalized cell line human CVCL_ZY36 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. 40819130 CVCL_ZY37 KCLi005-A induced pluripotent stem cell human CVCL_ZY37 From: King's College London; London; United Kingdom. CL:0000010 40819131 CVCL_ZY38 KEIOi001-A induced pluripotent stem cell human CVCL_ZY38 From: Keio University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Asn345Lys (c.1035C>G); Zygosity=Heterozygous (PubMed=32659732) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819132 CVCL_ZY31 AP65P(SVT) transformed cell line human CVCL_ZY31 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819133 CVCL_ZY32 CS1AW(SV) transformed cell line human CVCL_ZY32 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from familial inference) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819134 CVCL_ZY33 CS2OS hTERT-1 telomerase immortalized cell line human CVCL_ZY33 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819135 CVCL_ZY34 CS2OS hTERT-2 telomerase immortalized cell line human CVCL_ZY34 CL:0000010 Sequence variation: Mutation; HGNC; 3439; ERCC8; Simple; p.Asp93Leufs*26 (Ex4del); Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 11730; TERT Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819136 CVCL_ZY39 Hep-2039D telomerase immortalized cell line human CVCL_ZY39 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. 40819137 CVCL_ZY40 Hep-2044 telomerase immortalized cell line human CVCL_ZY40 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. 40819138 CVCL_ZY41 Hep-2045 telomerase immortalized cell line human CVCL_ZY41 CL:0000010 Transfected with: HGNC; 1582; CCND1; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Liver Cell type=Hepatocyte.. 40819139 CVCL_ZY24 AP2M(SVT) transformed cell line human CVCL_ZY24 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819140 CVCL_ZY25 AP65F finite cell line human CVCL_ZY25 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819141 CVCL_ZY26 AP65F(SVT) transformed cell line human CVCL_ZY26 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819142 CVCL_ZY27 AP65M finite cell line human CVCL_ZY27 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819143 CVCL_ZY20 AP2P(SVT) transformed cell line human CVCL_ZY20 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819144 CVCL_ZY21 AP2F finite cell line human CVCL_ZY21 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Heterozygous (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819145 CVCL_ZY22 AP2F(SVT) transformed cell line human CVCL_ZY22 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; p.Gln356Ter (c.1066C>T); ClinVar=VCV000006715; Zygosity=Heterozygous (from children cell line) Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819146 CVCL_ZY23 AP2M finite cell line human CVCL_ZY23 CL:0000010 Sequence variation: Mutation; HGNC; 3588; FANCG; Simple; c.307+1G>C (IVS3+1G>C); ClinVar=VCV000006714; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=10807541) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819147 CVCL_ZY28 AP65M(SVT) transformed cell line human CVCL_ZY28 CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819148 CVCL_ZY29 AP65P finite cell line human CVCL_ZY29 CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819149 CVCL_ZY30 AP65P(L) transformed cell line human CVCL_ZY30 CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819150 CVCL_ZZ96 FNLE2 transformed cell line human CVCL_ZZ96 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube. Female 40819151 CVCL_ZZ97 FNLER2 transformed cell line human CVCL_ZZ97 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube. Female 40819152 CVCL_ZZ98 OCE2 telomerase immortalized cell line human CVCL_ZZ98 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Ovary. Female 40819153 CVCL_ZZ99 OCLE2 transformed cell line human CVCL_ZZ99 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary. Female 40819154 CVCL_ZZ89 FNE1 telomerase immortalized cell line human CVCL_ZZ89 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Fallopian tube. Female 40819155 CVCL_ZZ85 WAe001-A-46 embryonic stem cell human CVCL_ZZ85 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=TALEN; HGNC; 7545; MYB. Male 40819156 CVCL_ZZ86 T7CC transformed cell line CVCL_ZZ86 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 40819157 CVCL_ZZ87 TD3 transformed cell line CVCL_ZZ87 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 40819158 CVCL_ZZ88 TE4 [Macaca LCL] transformed cell line CVCL_ZZ88 CL:0000010 Transformant: Simian T-lymphotropic virus 1 (STLV-1)(NCBI-Taxonomy; 33747); Derived from sampling site: Peripheral blood. Female Group: Non-human primate cell line 40819159 CVCL_ZZ92 OCE1 telomerase immortalized cell line human CVCL_ZZ92 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Ovary. Female 40819160 CVCL_ZZ93 OCLE1 transformed cell line human CVCL_ZZ93 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary. Female 40819161 CVCL_ZZ94 OCLER1 transformed cell line human CVCL_ZZ94 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Ovary. Female 40819162 CVCL_ZZ95 FNE2 telomerase immortalized cell line human CVCL_ZZ95 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Fallopian tube. Female 40819163 CVCL_ZZ90 FNLE1 transformed cell line human CVCL_ZZ90 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube. Female 40819164 CVCL_ZZ91 FNLER1 transformed cell line human CVCL_ZZ91 CL:0000010 Transfected with: HGNC; 5173; HRAS (with p.Gly12Val); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube. Female 40819165 CVCL_ZZ78 PC-6/VP1-1 cancer cell line human CVCL_ZZ78 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16). Unspecified 40819166 CVCL_ZZ79 PC-6/AMR-OH cancer cell line human CVCL_ZZ79 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:156204; Amrubicinol. Unspecified Doubling time: ~24 hours (PubMed=21128075) 40819167 CVCL_ZZ74 PC-6/ADM2-1 cancer cell line human CVCL_ZZ74 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin. Unspecified 40819168 CVCL_ZZ75 PC-6/CDDP2-7 cancer cell line human CVCL_ZZ75 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Unspecified 40819169 CVCL_ZZ76 PC-6/CPT2-2 cancer cell line human CVCL_ZZ76 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:80630; Irinotecan (Camptothecin-11. Unspecified 40819170 CVCL_ZZ77 PC-6/VCR29-9 cancer cell line human CVCL_ZZ77 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR). Unspecified 40819171 CVCL_ZZ81 NCC-ASPS1-C1 cancer cell line human CVCL_ZZ81 CL:0000010 Sequence variation: Gene fusion; HGNC; 13825; ASPSCR1 + HGNC; 11752; TFE3; Name(s)=ASPSCR1-TFE3, ASPL-TFE3 (PubMed=32648033) Population: Japanese; Derived from sampling site: Thigh. Female Doubling time: 6 days (PubMed=32648033) Part of: NCC sarcoma cell line panel 40819172 CVCL_ZZ82 HMGUi001-A-4 induced pluripotent stem cell human CVCL_ZZ82 From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Transfected with: HGNC; 4761; H2BC11; Transfected with: UniProtKB; Q66PV6; CFP Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Using CRISPR/Cas9 a T2A-H2B-CFP-FLAG construct was inserted at the C-terminus of both alleles of ARX (PubMed=32544857) 40819173 CVCL_ZZ83 IMAGINi007-A induced pluripotent stem cell human CVCL_ZZ83 From: Imagine Institute; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 13394; NPHS2; Simple; p.Arg138Gln (c.413G>A); ClinVar=VCV000005360; Zygosity=Homozygous (PubMed=32585588) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819174 CVCL_ZZ84 WAe001-A-45 embryonic stem cell human CVCL_ZZ84 From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=TALEN; HGNC; 7545; MYB. Male 40819175 CVCL_ZZ80 NCI-H23/GEM-R cancer cell line human CVCL_ZZ80 CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Gln1919Pro (c.5756A>C); ClinVar=VCV000580726; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Trp332Ter (c.996G>A); ClinVar=VCV000376339; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met246Ile (c.738G>C); Zygosity=Homozygous (from parent cell line) Population: African American; Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar); Derived from sampling site: Lung. Male 40819176 CVCL_ZZ67 3F3.5F hybridoma CVCL_ZZ67 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse activated macrophages. 40819177 CVCL_ZZ68 MUM-4 hybridoma Norway rat CVCL_ZZ68 CL:0000010 Monoclonal antibody isotype: IgG2c, kappa; Monoclonal antibody target: Mouse resident peritoneal macrophages. 40819178 CVCL_ZZ69 A-2394 cancer cell line human CVCL_ZZ69 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819179 CVCL_ZZ63 JUCTCi007-B induced pluripotent stem cell human CVCL_ZZ63 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 1966; CHRNE; Simple; p.Arg331Trp (c.991C>T); ClinVar=VCV000018358; Zygosity=Homozygous (from autologous cell line JUCTCi007-A) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819180 CVCL_ZZ64 JUCTCi007-C induced pluripotent stem cell human CVCL_ZZ64 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 1966; CHRNE; Simple; p.Arg331Trp (c.991C>T); ClinVar=VCV000018358; Zygosity=Homozygous (from autologous cell line JUCTCi007-A) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819181 CVCL_ZZ65 HUi001-A induced pluripotent stem cell human CVCL_ZZ65 From: Hanyang Biomedical Research Institute, Hanyang University; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=32623353) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 40819182 CVCL_ZZ66 9.2.27 hybridoma house mouse CVCL_ZZ66 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q6UVK1; Human CSPG4. 40819183 CVCL_ZZ70 A-1095 cancer cell line human CVCL_ZZ70 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819184 CVCL_ZZ71 M14-CDM cancer cell line human CVCL_ZZ71 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.150+2T>C (IVS1+2T>C); ClinVar=VCV000406712; Zygosity=Heterozygous; Note=Splice donor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.455insCdel26; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly266Glu (c.797G>A); ClinVar=VCV000161516; Zygosity=Heterozygous (from parent cell line) Derived from metastatic site: Right buttock; hypodermis. Male Group: Serum/protein free medium cell line 40819185 CVCL_ZZ72 PC-9/CDDP cancer cell line human CVCL_ZZ72 CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Glu746_Ala750del (c.2235_2249del15); ClinVar=VCV000163343; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP); Derived from metastatic site: Lymph node. Male 40819186 CVCL_ZZ73 PC-6/FU23-26 cancer cell line human CVCL_ZZ73 CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU). Unspecified 40819187 CVCL_ZZ56 A-3243 cancer cell line human CVCL_ZZ56 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819188 CVCL_ZZ57 A-2095 cancer cell line human CVCL_ZZ57 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819189 CVCL_ZZ58 A-2984 cancer cell line human CVCL_ZZ58 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819190 CVCL_ZZ59 A-3008 cancer cell line human CVCL_ZZ59 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819191 CVCL_ZZ52 A-1617 cancer cell line human CVCL_ZZ52 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819192 CVCL_ZZ53 A-1632 cancer cell line human CVCL_ZZ53 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819193 CVCL_ZZ54 A-1673 cancer cell line human CVCL_ZZ54 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819194 CVCL_ZZ55 A-1690 cancer cell line human CVCL_ZZ55 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819195 CVCL_ZZ60 Am1010-GFP cancer cell line human CVCL_ZZ60 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Population: Chinese; Derived from metastatic site: Upper arm; skeletal muscle. Female 40819196 CVCL_ZZ61 Am1010-RFP cancer cell line human CVCL_ZZ61 CL:0000010 Transfected with: DsRed2, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Chinese; Derived from metastatic site: Upper arm; skeletal muscle. Female 40819197 CVCL_ZZ62 JUCTCi007-A induced pluripotent stem cell human CVCL_ZZ62 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 1966; CHRNE; Simple; p.Arg331Trp (c.991C>T); ClinVar=VCV000018358; Zygosity=Homozygous (PubMed=32645605) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819198 CVCL_ZZ45 FNR-85-Cl 2 cancer cell line human CVCL_ZZ45 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768); Derived from sampling site: Bone; right femur. Female 40819199 CVCL_ZZ46 FNR-85-Cl 3 cancer cell line human CVCL_ZZ46 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768); Derived from sampling site: Bone; right femur. Female 40819200 CVCL_ZZ47 FNR-85-Cl 5 cancer cell line human CVCL_ZZ47 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768); Derived from sampling site: Bone; right femur. Female 40819201 CVCL_ZZ48 A-1306 cancer cell line human CVCL_ZZ48 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819202 CVCL_ZZ41 MDA-MB-231/BCRP cancer cell line human CVCL_ZZ41 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 74; ABCG2 Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Myc-tagged ABCG2/BCRP Group: Triple negative breast cancer (TNBC) cell line 40819203 CVCL_ZZ42 SKOV-3/BCRP cancer cell line human CVCL_ZZ42 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Leufs*9 (c.4666delA); ClinVar=VCV000156477; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Leu (c.1514G>T); ClinVar=VCV000376424; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser90Profs*33 (c.267delC); ClinVar=VCV000156515; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 74; ABCG2 Population: Caucasian; Derived from metastatic site: Ascites. Female Characteristics: Transfected with a Myc-tagged ABCG2/BCRP 40819204 CVCL_ZZ43 T-47D/BCRP cancer cell line human CVCL_ZZ43 CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 74; ABCG2 Derived from metastatic site: Pleural effusion. Female Characteristics: Transfected with a Myc-tagged ABCG2/BCRP 40819205 CVCL_ZZ44 FNR-85-Cl 1 cancer cell line human CVCL_ZZ44 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Transformant: Feline leukemia virus(NCBI-Taxonomy; 11768); Derived from sampling site: Bone; right femur. Female 40819206 CVCL_ZZ49 A-1336 cancer cell line human CVCL_ZZ49 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Female 40819207 CVCL_ZZ50 A-1383 cancer cell line human CVCL_ZZ50 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819208 CVCL_ZZ51 A-1498 cancer cell line human CVCL_ZZ51 From: Aaronson S.A.; Mt Sinai Medical Center; New York; USA.. CL:0000010 Unspecified 40819209 CVCL_A8S2 COS-33 cancer cell line human CVCL_A8S2 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Unexplicit; Ex8-9del; Zygosity=Homozygous (PubMed=32676162) Population: Caucasian; Derived from sampling site: Bone; humerus. Female Characteristics: Established from a patient-derived xenograft in its third passage (OS-33) 40819210 CVCL_A8S1 BCPAP-R cancer cell line human CVCL_A8S1 CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Heterozygous; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp259Tyr (c.775G>T); ClinVar=VCV000634680; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Thyroid gland. Female 40819211 CVCL_A8S4 HAS3 hybridoma house mouse CVCL_A8S4 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819212 CVCL_A8S3 FtGF spontaneously immortalized cell line CVCL_A8S3 CL:0000010 Derived from sampling site: Caudal fin; Breed/subspecies: Fantail. Unspecified Virology: Highly susceptible to infection by cyprinid herpesvirus 2 (CyHV-2) (PubMed=33005480) Doubling time: 33.9 hours, at 25th passage (PubMed=33005480) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC058 40819213 CVCL_A8S6 HAS6 hybridoma house mouse CVCL_A8S6 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819214 CVCL_A8S5 HAS4 hybridoma house mouse CVCL_A8S5 CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819215 CVCL_A8S8 P1D6 hybridoma house mouse CVCL_A8S8 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P08648; Human ITGA5/CD49e. 40819216 CVCL_A8S7 P1B5 hybridoma house mouse CVCL_A8S7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. 40819217 CVCL_A8S0 MTSV1-7 HB2-neo transformed cell line human CVCL_A8S0 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female Characteristics: Control cell line for MTSV1-7 HB2-Erb-B2 (Cellosaurus=CVCL_A8R8) and MTSV1-7 HB2-Ras (Cellosaurus=CVCL_A8R9) 40819218 CVCL_A8R9 MTSV1-7 HB2-Ras transformed cell line human CVCL_A8R9 CL:0000010 Transfected with: UniProtKB; P01115; Harvey murine sarcoma virus H-Ras (V-Ha-ras); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 40819219 CVCL_A8R8 MTSV1-7 HB2-Erb-B2 transformed cell line human CVCL_A8R8 CL:0000010 Transfected with: HGNC; 3430; ERBB2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female 40819220 CVCL_A8T3 P1G12 hybridoma house mouse CVCL_A8T3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 40819221 CVCL_A8T2 P1F8 hybridoma house mouse CVCL_A8T2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08648; Human ITGA5/CD49e. 40819222 CVCL_A8T5 P1H6 hybridoma house mouse CVCL_A8T5 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819223 CVCL_A8T4 P1H5 hybridoma house mouse CVCL_A8T4 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819224 CVCL_A8T7 P2B1 hybridoma house mouse CVCL_A8T7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P16284; Human PECAM1/CD31 (Note=Also reacts with mouse, rat and dog). 40819225 CVCL_A8T6 P2A4 hybridoma house mouse CVCL_A8T6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05362; Human ICAM1/CD54. 40819226 CVCL_A8T9 P3G2 hybridoma house mouse CVCL_A8T9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51; Monoclonal antibody target: UniProtKB; P18084; Human ITGB5. 40819227 CVCL_A8T8 P3E3 hybridoma house mouse CVCL_A8T8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P13612; Human ITGA4/CD49d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10212 40819228 CVCL_A8T1 P1F6 hybridoma house mouse CVCL_A8T1 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51; Monoclonal antibody target: UniProtKB; P18084; Human ITGB5. 40819229 CVCL_A8T0 P1F2 hybridoma house mouse CVCL_A8T0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P26006; Human ITGA3/CD49c. 40819230 CVCL_A8S9 P1E6 hybridoma house mouse CVCL_A8S9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819231 CVCL_A8Q0 HT29-5M21 cancer cell line human CVCL_A8Q0 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female Characteristics: Mucus-secreting clone of HT-29 which forms a monolayer of polarized cells with strong anti-gastric mucin immunoreactivity and mainly expresses MUC5AC and MUC5B Resistant to methotrexate and sensitive to 5-fluorouracil. 40819232 CVCL_A8Q2 CIOV2 cancer cell line human CVCL_A8Q2 CL:0000010 Derived from sampling site: Ovary. Female 40819233 CVCL_A8Q1 CIOV1 cancer cell line human CVCL_A8Q1 CL:0000010 Derived from sampling site: Ovary. Female 40819234 CVCL_A8Q4 JHUEM-14 Prex2a shRNA type 1 cancer cell line human CVCL_A8Q4 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 22950; PREX2 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 40819235 CVCL_A8Q3 CIOV3 cancer cell line human CVCL_A8Q3 CL:0000010 Derived from sampling site: Ovary. Female 40819236 CVCL_A8Q6 OMC-2 Prex2a shRNA type 1 cancer cell line human CVCL_A8Q6 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 22950; PREX2 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 40819237 CVCL_A8Q5 JHUEM-14 Prex2a shRNA type 2 cancer cell line human CVCL_A8Q5 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 22950; PREX2 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 40819238 CVCL_A8P7 HT29-5F12 cancer cell line human CVCL_A8P7 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female Characteristics: Mucus-secreting clone of HT-29 Consists of unpolarized cells with mucus secretions that have anti-colonic mucin immunoreactivity and mainly expresses MUC2. Resistant to 5-fluorouracil and sensitive to methotrexate. 40819239 CVCL_A8P6 HT29-5FU resistant (10 microMolar) cancer cell line human CVCL_A8P6 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female Characteristics: Resistant to 10 muM of 5-fluorouracil 40819240 CVCL_A8P9 HT29-5M12 cancer cell line human CVCL_A8P9 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX) Female Characteristics: Has an enterocyte-like phenotype Resistant to both 5-fluorouracil and methotrexate. 40819241 CVCL_A8P8 HT29-5F7 cancer cell line human CVCL_A8P8 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female Characteristics: Has an enterocyte-like phenotype Resistant to both 5-fluorouracil and methotrexate. 40819242 CVCL_A8R1 ALC 2.1 finite cell line human CVCL_A8R1 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819243 CVCL_A8R0 ALC 10.2 finite cell line human CVCL_A8R0 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819244 CVCL_A8R3 ALC 4.1 finite cell line human CVCL_A8R3 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819245 CVCL_A8R2 ALC 2.2 finite cell line human CVCL_A8R2 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819246 CVCL_A8R5 BER 5 finite cell line human CVCL_A8R5 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819247 CVCL_A8R4 ALC 4.2 finite cell line human CVCL_A8R4 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819248 CVCL_A8R7 MTSV1-7 neo transformed cell line human CVCL_A8R7 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Breast Cell type=Luminal epithelial cell.. Female Characteristics: Control cell line for MTSV1-7 ce1 (Cellosaurus=CVCL_3033) 40819249 CVCL_A8R6 BER 5(SV40) transformed cell line human CVCL_A8R6 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819250 CVCL_A8Q8 MSN-1 hybridoma house mouse CVCL_A8Q8 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: ChEBI; CHEBI:59440; Alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcNAc (Lewis B). 40819251 CVCL_A8Q7 OMC-2 Prex2a shRNA type 2 cancer cell line human CVCL_A8Q7 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 22950; PREX2 Population: Japanese; Derived from sampling site: Endometrium. Omics: Transcriptome analysis by microarray Female 40819252 CVCL_A8Q9 ALC 10.1 finite cell line human CVCL_A8Q9 CL:0000010 Derived from sampling site: Eye; trabecular meshwork. Unspecified 40819253 CVCL_A8N5 NIMP-R13 hybridoma Norway rat CVCL_A8N5 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse eosinophils. 40819254 CVCL_A8N4 NIMP-R12 hybridoma Norway rat CVCL_A8N4 CL:0000010 Monoclonal antibody isotype: IgG2b. 40819255 CVCL_A8N7 NIMP-R16 hybridoma Norway rat CVCL_A8N7 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: Mouse granulocyte-macrophages. 40819256 CVCL_A8N6 NIMP-R14 hybridoma Norway rat CVCL_A8N6 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse neutrophils. 40819257 CVCL_A8N9 L13D6 hybridoma house mouse CVCL_A8N9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22225; Trypanosoma brucei PFRA/PFRB. 40819258 CVCL_A8N8 L1C6 hybridoma house mouse CVCL_A8N8 CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: Trypanosoma brucei nucleolar-specific antigen. 40819259 CVCL_A8P1 L6B3 hybridoma house mouse CVCL_A8P1 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; Q585H6; Trypanosoma brucei FAZ1. 40819260 CVCL_A8P0 L3B2 hybridoma house mouse CVCL_A8P0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; Q585H6; Trypanosoma brucei FAZ1. 40819261 CVCL_A8P3 CDIB4 hybridoma house mouse CVCL_A8P3 CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; W5PK89; Sheep ODF2 (Note=Also reacts with human, mouse and rat). 40819262 CVCL_A8P2 L8C4 hybridoma house mouse CVCL_A8P2 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P22225; Trypanosoma brucei PFRA/PFRB. 40819263 CVCL_A8P5 MCF-7 TTE-MBD2 cancer cell line human CVCL_A8P5 CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 6917; MBD2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from metastatic site: Pleural effusion. Omics: MBD2 ChIP-seq epigenome analysis; Omics: Pol2 ChIP-seq epigenome analysis Female Characteristics: The transfected human MBD2 gene is N-terminally tagged with a Ty1-Ty1-ER (TTE) epitope tag 40819264 CVCL_A8P4 BB2 hybridoma house mouse CVCL_A8P4 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P0CX57; Saccharomyces cerevisiae TY1A-A (AA 25-34, EVHTNQDPLD, the Ty1 Tag). 40819265 CVCL_A8N1 NIMP-R9 hybridoma Norway rat CVCL_A8N1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse granulocyte-macrophages. 40819266 CVCL_A8N0 NIMP-R6 hybridoma Norway rat CVCL_A8N0 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Mouse eosinophils. 40819267 CVCL_A8N3 NIMP-R11 hybridoma Norway rat CVCL_A8N3 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Mouse eosinophils. 40819268 CVCL_A8N2 NIMP-R10 hybridoma Norway rat CVCL_A8N2 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: UniProtKB; P05555; Mouse Itgam/Cd11b. 40819269 CVCL_A8M6 Aag2-AF319 spontaneously immortalized cell line CVCL_A8M6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; UniProtKB; Q49LL4; Dcr2 Derived from sampling site: Whole embryo. Unspecified Group: Insect cell line 40819270 CVCL_A8M5 Aag2-AF5 spontaneously immortalized cell line CVCL_A8M5 CL:0000010 Derived from sampling site: Whole embryo. Unspecified Characteristics: Immunocompetent for RNAi (siRNA and piRNA pathways) and NF-kappaB signalling Group: Insect cell line 40819271 CVCL_A8M8 NIMP-R4 hybridoma Norway rat CVCL_A8M8 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Mouse eosinophils. 40819272 CVCL_A8M7 NIMP-R3 hybridoma Norway rat CVCL_A8M7 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Mouse eosinophils. 40819273 CVCL_A8M9 NIMP-R5 hybridoma Norway rat CVCL_A8M9 CL:0000010 Monoclonal antibody isotype: IgG2c; Monoclonal antibody target: Mouse granulocyte-macrophages. 40819274 CVCL_A8Y8 MK082 finite cell line human CVCL_A8Y8 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from child cell line UOXFi002-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819275 CVCL_A8Y7 OX1 finite cell line human CVCL_A8Y7 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 40819276 CVCL_A8Y9 MK088 finite cell line human CVCL_A8Y9 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from child cell line UOXFi003-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 40819277 CVCL_A8Y0 LUCC7EBV transformed cell line human CVCL_A8Y0 CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 40819278 CVCL_A8Y2 SF856 finite cell line human CVCL_A8Y2 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819279 CVCL_A8Y1 SF831 finite cell line human CVCL_A8Y1 CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819280 CVCL_A8Y4 MK144 finite cell line human CVCL_A8Y4 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819281 CVCL_A8Y3 MK002 finite cell line human CVCL_A8Y3 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819282 CVCL_A8Y6 iPS-JR036-1 induced pluripotent stem cell human CVCL_A8Y6 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819283 CVCL_A8Y5 JR036 finite cell line human CVCL_A8Y5 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=28096185) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819284 CVCL_A8Z9 STBCi026-A-2 induced pluripotent stem cell human CVCL_A8Z9 From: StemBANCC; Oxford; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819285 CVCL_A8Z8 STBCi026-A-1 induced pluripotent stem cell human CVCL_A8Z8 From: StemBANCC; Oxford; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18618; LRRK2 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819286 CVCL_A8Z1 JR053 finite cell line human CVCL_A8Z1 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819287 CVCL_A8Z0 OX2 finite cell line human CVCL_A8Z0 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819288 CVCL_A8Z3 SF848 finite cell line human CVCL_A8Z3 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (from child cell line STBCi042-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819289 CVCL_A8Z2 SF871 finite cell line human CVCL_A8Z2 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Unspecified (from child cell line STBCi084-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819290 CVCL_A8Z5 MK024 finite cell line human CVCL_A8Z5 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Female 40819291 CVCL_A8Z4 AH016-6 induced pluripotent stem cell human CVCL_A8Z4 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819292 CVCL_A8Z7 MRRL-CH1 clone GV1 spontaneously immortalized cell line CVCL_A8Z7 CL:0000010 Unspecified Group: Insect cell line. 40819293 CVCL_A8Z6 MK071 finite cell line human CVCL_A8Z6 CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Simple; p.Asn409Ser (c.1226A>G) (N370S); ClinVar=VCV000004290; Zygosity=Heterozygous (from child cell line UOXFi001-A) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Female 40819294 CVCL_A8W6 TEC1C8 spontaneously immortalized cell line house mouse CVCL_A8W6 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819295 CVCL_A8W5 TEC1C6 spontaneously immortalized cell line house mouse CVCL_A8W5 CL:0000010 Derived from sampling site: Thymus Cell type=Medullary thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819296 CVCL_A8W8 TEC2-3 spontaneously immortalized cell line house mouse CVCL_A8W8 CL:0000010 Derived from sampling site: Thymus Cell type=Medullary thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819297 CVCL_A8W7 TEC1C9 spontaneously immortalized cell line house mouse CVCL_A8W7 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819298 CVCL_A8W9 TEC3-10 spontaneously immortalized cell line house mouse CVCL_A8W9 CL:0000010 Derived from sampling site: Thymus Cell type=Medullary thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819299 CVCL_A8W0 TEC1-2C2 spontaneously immortalized cell line house mouse CVCL_A8W0 CL:0000010 Derived from sampling site: Thymus Cell type=Medullary thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819300 CVCL_A8W2 TEC1-4 spontaneously immortalized cell line house mouse CVCL_A8W2 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819301 CVCL_A8W1 TEC1-3 spontaneously immortalized cell line house mouse CVCL_A8W1 CL:0000010 Derived from sampling site: Thymus Cell type=Medullary thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819302 CVCL_A8W4 TEC1C5 spontaneously immortalized cell line house mouse CVCL_A8W4 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: C57BL/6. Unspecified 40819303 CVCL_A8W3 TEC1-4C18 spontaneously immortalized cell line house mouse CVCL_A8W3 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819304 CVCL_A8X7 SF828 finite cell line human CVCL_A8X7 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819305 CVCL_A8X6 SF180 finite cell line human CVCL_A8X6 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 40819306 CVCL_A8X9 SF830 finite cell line human CVCL_A8X9 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819307 CVCL_A8X8 SF829 finite cell line human CVCL_A8X8 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (PubMed=28827786) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819308 CVCL_A8X1 STBCi004-B-1 induced pluripotent stem cell human CVCL_A8X1 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32359446) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819309 CVCL_A8X0 BL2-5-8 factor-dependent cell line house mouse CVCL_A8X0 CL:0000010 Transfected with: HGNC; 1639; CD2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Bone marrow; Breed/subspecies: C3H. Characteristics: Transfected with a LexA-hCD2 reporter that consists of 8 tandem copies of a LexA binding element, a minimal promoter from mouse Ifnb and human CD2 (PubMed=15225556) Doubling time: 12 hours (RCB=RCB4495) Caution: The parent cell line was originally thought to originate from a BALB/c mouse but is in fact from a C3H mouse 40819310 CVCL_A8X3 JME/Nl 13 transformed cell line human CVCL_A8X3 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified 40819311 CVCL_A8X2 JME/Nl 7 transformed cell line human CVCL_A8X2 CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified 40819312 CVCL_A8X5 AH016-3 induced pluripotent stem cell human CVCL_A8X5 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819313 CVCL_A8X4 AH016 finite cell line human CVCL_A8X4 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819314 CVCL_A8U4 P4C2 hybridoma house mouse CVCL_A8U4 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P13612; Human ITGA4/CD49d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10215 40819315 CVCL_A8U3 P4C10 hybridoma house mouse CVCL_A8U3 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10214 40819316 CVCL_A8U6 P4G11 hybridoma house mouse CVCL_A8U6 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. 40819317 CVCL_A8U5 P4E7 hybridoma house mouse CVCL_A8U5 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819318 CVCL_A8U8 P4H9 hybridoma house mouse CVCL_A8U8 CL:0000010 Monoclonal antibody isotype: IgG3; Monoclonal antibody target: UniProtKB; P05107; Human ITGB2/CD18. 40819319 CVCL_A8U7 P4G9 hybridoma house mouse CVCL_A8U7 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P13612; Human ITGA4/CD49d. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10213 40819320 CVCL_A8U9 P5D2 hybridoma house mouse CVCL_A8U9 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05556; Human ITGB1/CD29. 40819321 CVCL_A8U0 P3G8 hybridoma house mouse CVCL_A8U0 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51. 40819322 CVCL_A8U2 P4B4 hybridoma house mouse CVCL_A8U2 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P17301; Human ITGA2/CD49b. 40819323 CVCL_A8U1 P3H9 hybridoma house mouse CVCL_A8U1 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P16070; Human CD44. 40819324 CVCL_A8V5 LN229/CD20 cancer cell line human CVCL_A8V5 CL:0000010 Sequence variation: Mutation; HGNC; 6597; LIFR; Simple; p.Pro1060Ala (c.3178C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9811; RAD21; Simple; p.Gln132Ter (c.394C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro98Leu (c.293C>T); ClinVar=VCV000528236; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 7315; MS4A1 (with a N-terminal PA tag); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Brain; right frontal parieto-occipital cortex. Female 40819325 CVCL_A8V4 CHO/CD20 spontaneously immortalized cell line CVCL_A8V4 CL:0000010 Transfected with: HGNC; 7315; MS4A1 (with a N-terminal PA tag); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 40819326 CVCL_A8V7 BHK/T7-9 spontaneously immortalized cell line CVCL_A8V7 CL:0000010 Transfected with: UniProtKB; P00573; Bacteriophage T7 DNA-directed RNA polymerase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney. Male Characteristics: Expression of the T7 RNA polymerase gene is under control of the strong chicken beta-actin promoter (PubMed=14524622) 40819327 CVCL_A8V6 BALL-1/CD20-KO cancer cell line human CVCL_A8V6 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7315; MS4A1; Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Gly (c.842A>G); ClinVar=VCV000141141; Zygosity=Homozygous (from parent cell line) Population: Japanese; Derived from sampling site: Peripheral blood Cell type=B-cell.. Male 40819328 CVCL_A8V9 TEC1-2C1 spontaneously immortalized cell line house mouse CVCL_A8V9 CL:0000010 Derived from sampling site: Thymus Cell type=Cortical thymic epithelial cell.; Breed/subspecies: C57BL/6. Unspecified 40819329 CVCL_A8V8 TEC1-2 spontaneously immortalized cell line house mouse CVCL_A8V8 CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: C57BL/6. Unspecified 40819330 CVCL_A8V1 sHPT-1/TET1 cancer cell line human CVCL_A8V1 CL:0000010 Transfected with: HGNC; 29484; TET1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Parathyroid gland. Unspecified 40819331 CVCL_A8V0 P5H9 hybridoma house mouse CVCL_A8V0 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P06756; Human ITGAV/CD51; Monoclonal antibody target: UniProtKB; P18084; Human ITGB5. 40819332 CVCL_A8V3 C20Mab-60 hybridoma house mouse CVCL_A8V3 CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20. 40819333 CVCL_A8V2 C20Mab-11 hybridoma house mouse CVCL_A8V2 CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P11836; Human MS4A1/CD20. 40819334 CVCL_A9TR GSC#147 cancer cell line human CVCL_A9TR From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819335 CVCL_A9U3 GSC#195 cancer cell line human CVCL_A9U3 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819336 CVCL_A9TQ GSC#142 cancer cell line human CVCL_A9TQ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819337 CVCL_A9U2 GSC#191 cancer cell line human CVCL_A9U2 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819338 CVCL_A9TT GSC#151 cancer cell line human CVCL_A9TT From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819339 CVCL_A9U5 GSC#196 cancer cell line human CVCL_A9U5 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819340 CVCL_A9TS GSC#148 cancer cell line human CVCL_A9TS From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819341 CVCL_A9U4 GSC#195V cancer cell line human CVCL_A9U4 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819342 CVCL_A9TV GSC#169 cancer cell line human CVCL_A9TV From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819343 CVCL_A9U7 GSC#206 cancer cell line human CVCL_A9U7 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819344 CVCL_A9TU GSC#163 cancer cell line human CVCL_A9TU From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819345 CVCL_A9U6 GSC#204 cancer cell line human CVCL_A9U6 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819346 CVCL_A9TX GSC#171 cancer cell line human CVCL_A9TX From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819347 CVCL_A9U9 GSC#209 cancer cell line human CVCL_A9U9 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Female Group: Cancer stem cell line 40819348 CVCL_A9TW GSC#170 cancer cell line human CVCL_A9TW From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819349 CVCL_A9U8 GSC#208 cancer cell line human CVCL_A9U8 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819350 CVCL_A9TJ GSC#74 cancer cell line human CVCL_A9TJ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819351 CVCL_A9TI GSC#70 cancer cell line human CVCL_A9TI From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819352 CVCL_A9TL GSC#83 cancer cell line human CVCL_A9TL From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819353 CVCL_A9TK GSC#76 cancer cell line human CVCL_A9TK From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819354 CVCL_A9TN GSC#112 cancer cell line human CVCL_A9TN From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819355 CVCL_A9TM GSC#83.2 cancer cell line human CVCL_A9TM From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819356 CVCL_A9TP GSC#120 cancer cell line human CVCL_A9TP From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819357 CVCL_A9U1 GSC#188 cancer cell line human CVCL_A9U1 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819358 CVCL_A9U0 GSC#184 cancer cell line human CVCL_A9U0 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819359 CVCL_A9TB GSC#28 cancer cell line human CVCL_A9TB From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819360 CVCL_A9TA GSC#23P cancer cell line human CVCL_A9TA From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819361 CVCL_A9TD GSC#30PT cancer cell line human CVCL_A9TD From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819362 CVCL_A9TC GSC#30P cancer cell line human CVCL_A9TC From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819363 CVCL_A9TF GSC#62 cancer cell line human CVCL_A9TF From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819364 CVCL_A9TE GSC#61 cancer cell line human CVCL_A9TE From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819365 CVCL_A9TH GSC#68 cancer cell line human CVCL_A9TH From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819366 CVCL_A9TG GSC#67 cancer cell line human CVCL_A9TG From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819367 CVCL_A9SY IMAGINi022-A induced pluripotent stem cell human CVCL_A9SY From: Imagine Institute; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 11190; SOX10; Simple; p.Pro175Ala (c.523C>G); Zygosity=Heterozygous (PubMed=32795927) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819368 CVCL_A9SX BL1391 cancer cell line human CVCL_A9SX CL:0000010 Sequence variation: Gene fusion; HGNC; 6974; MDM4 + HGNC; 29945; TENM4; Name(s)=TENM4-MDM4; Note=In frame (PubMed=32856169); Sequence variation: Gene fusion; HGNC; 29314; CACHD1 + HGNC; 16262; YAP1; Name(s)=YAP1-CACHD1; Note=In frame (PubMed=32856169) Miscellaneous: Donor ethnicity from personal communication of Storlazzi C.T Population: Caucasian; Swedish; Karyotypic information: Contains a giant rod-shaped marker (RGM) chromosome composed of high copy number amplifications of regions from chromosomes 1 and 11, arrayed in a complex fashion, with additional 8q sequences at both ends (PubMed=32856169); Derived from sampling site: Thigh; quadriceps skeletal muscle. Omics: ChIP-seq epigenome analysis; Omics: SNP array analysis Female Doubling time: ~48 hours (PubMed=32856169) 40819369 CVCL_A9T9 GSC#23C cancer cell line human CVCL_A9T9 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819370 CVCL_A9SZ IMAGINi013-A induced pluripotent stem cell human CVCL_A9SZ From: Imagine Institute; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819371 CVCL_A9US GSC#315 cancer cell line human CVCL_A9US From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819372 CVCL_A9V4 GSC#384 cancer cell line human CVCL_A9V4 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819373 CVCL_A9UR GSC#314P cancer cell line human CVCL_A9UR From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819374 CVCL_A9V3 GSC#381 cancer cell line human CVCL_A9V3 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819375 CVCL_A9UU GSC#323 cancer cell line human CVCL_A9UU From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819376 CVCL_A9V6 GSC#391 cancer cell line human CVCL_A9V6 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819377 CVCL_A9UT GSC#318 cancer cell line human CVCL_A9UT From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819378 CVCL_A9V5 GSC#389 cancer cell line human CVCL_A9V5 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819379 CVCL_A9UW GSC#327 cancer cell line human CVCL_A9UW From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819380 CVCL_A9V8 GSC#394 cancer cell line human CVCL_A9V8 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819381 CVCL_A9UV GSC#326 cancer cell line human CVCL_A9UV From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819382 CVCL_A9V7 GSC#393 cancer cell line human CVCL_A9V7 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819383 CVCL_A9UY GSC#352 cancer cell line human CVCL_A9UY From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819384 CVCL_A9UX GSC#329 cancer cell line human CVCL_A9UX From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819385 CVCL_A9V9 GSC#394bis cancer cell line human CVCL_A9V9 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819386 CVCL_A9UK GSC#284 cancer cell line human CVCL_A9UK From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819387 CVCL_A9UJ GSC#277 cancer cell line human CVCL_A9UJ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819388 CVCL_A9UM GSC#291 cancer cell line human CVCL_A9UM From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819389 CVCL_A9UL GSC#290 cancer cell line human CVCL_A9UL From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; cerebellum. Male Group: Cancer stem cell line 40819390 CVCL_A9V0 GSC#365 cancer cell line human CVCL_A9V0 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819391 CVCL_A9UN GSC#298 cancer cell line human CVCL_A9UN From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819392 CVCL_A9UQ GSC#314C cancer cell line human CVCL_A9UQ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819393 CVCL_A9V2 GSC#369 cancer cell line human CVCL_A9V2 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819394 CVCL_A9UP GSC#309S cancer cell line human CVCL_A9UP From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819395 CVCL_A9V1 GSC#366 cancer cell line human CVCL_A9V1 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819396 CVCL_A9UC GSC#220C cancer cell line human CVCL_A9UC From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819397 CVCL_A9UB GSC#213 cancer cell line human CVCL_A9UB From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819398 CVCL_A9UE GSC#242 cancer cell line human CVCL_A9UE From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819399 CVCL_A9UD GSC#221 cancer cell line human CVCL_A9UD From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819400 CVCL_A9UG GSC#262 cancer cell line human CVCL_A9UG From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819401 CVCL_A9UF GSC#257 cancer cell line human CVCL_A9UF From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 40819402 CVCL_A9UI GSC#275bis cancer cell line human CVCL_A9UI From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819403 CVCL_A9UH GSC#275 cancer cell line human CVCL_A9UH From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819404 CVCL_A9TZ GSC#181 cancer cell line human CVCL_A9TZ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Female Group: Cancer stem cell line 40819405 CVCL_A9TY GSC#172 cancer cell line human CVCL_A9TY From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819406 CVCL_A9UA GSC#210 cancer cell line human CVCL_A9UA From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819407 CVCL_A9RP NH50294 finite cell line human CVCL_A9RP CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819408 CVCL_A9S1 NH50306 induced pluripotent stem cell human CVCL_A9S1 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Non-edited control for NH50305 (Cellosaurus=CVCL_A9S0) 40819409 CVCL_A9S0 NH50305 induced pluripotent stem cell human CVCL_A9S0 CL:0000010 Sequence variation: Mutation; HGNC; 11571; TARDBP; Simple_corrected; p.Ala382Thr (c.1144G>A); ClinVar=VCV000021474; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (NHCDR) Population: Caucasian; Italian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819410 CVCL_A9RR NH50296 finite cell line human CVCL_A9RR CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819411 CVCL_A9S3 RIRI-PaDe-1-C1 spontaneously immortalized cell line CVCL_A9S3 CL:0000010 Unspecified Characteristics: Can be adapted to growth in serum-free culture conditions. Group: Insect cell line 40819412 CVCL_A9RQ NH50295 finite cell line human CVCL_A9RQ CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819413 CVCL_A9S2 NH50307 finite cell line human CVCL_A9S2 CL:0000010 Population: Asian; Donor information: At sampling donor was not affected with dystonia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819414 CVCL_A9RT NH50298 induced pluripotent stem cell human CVCL_A9RT CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819415 CVCL_A9S5 RIRI-PaDe-1-C3 spontaneously immortalized cell line CVCL_A9S5 CL:0000010 Unspecified Group: Insect cell line. 40819416 CVCL_A9RS NH50297 induced pluripotent stem cell human CVCL_A9RS CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819417 CVCL_A9S4 RIRI-PaDe-1-C2 spontaneously immortalized cell line CVCL_A9S4 CL:0000010 Unspecified Group: Insect cell line. 40819418 CVCL_A9RV NH50300 induced pluripotent stem cell human CVCL_A9RV CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819419 CVCL_A9S7 RIRI-PaDe-1-C5 spontaneously immortalized cell line CVCL_A9S7 CL:0000010 Unspecified Group: Insect cell line. 40819420 CVCL_A9RU NH50299 induced pluripotent stem cell human CVCL_A9RU CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819421 CVCL_A9S6 RIRI-PaDe-1-C4 spontaneously immortalized cell line CVCL_A9S6 CL:0000010 Unspecified Group: Insect cell line. 40819422 CVCL_A9RH TP4 hybridoma house mouse CVCL_A9RH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19821; Thermus aquaticus polA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11126 40819423 CVCL_A9RG 6-914-518 hybridoma house mouse CVCL_A9RG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1191-1457; Serine protease NS3) Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10600 40819424 CVCL_A9RJ TP1 hybridoma house mouse CVCL_A9RJ CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19821; Thermus aquaticus polA. 40819425 CVCL_A9RI TP9 hybridoma house mouse CVCL_A9RI CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19821; Thermus aquaticus polA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11127 40819426 CVCL_A9RL TP4-9.2 hybridoma house mouse CVCL_A9RL CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P19821; Thermus aquaticus polA. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11807 40819427 CVCL_A9RK TP1-12.2 hybridoma house mouse CVCL_A9RK CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P19821; Thermus aquaticus polA. Group: Patented cell line 40819428 CVCL_A9RN NH50293 induced pluripotent stem cell human CVCL_A9RN CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Ala9Asp (c.26C>A); ClinVar=VCV000016013; Zygosity=Heterozygous (NHCDR) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819429 CVCL_A9RM DPCP2 finite cell line human CVCL_A9RM CL:0000010 Derived from sampling site: Tooth; dental pulp Cell type=Fibroblast.. Male 40819430 CVCL_A9RB H1C46 hybridoma house mouse CVCL_A9RB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1191-1457; Serine protease NS3). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10594 40819431 CVCL_A9RA H11C130 hybridoma house mouse CVCL_A9RA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1191-1457; Serine protease NS3). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10589 40819432 CVCL_A9RD 14-153-234 hybridoma house mouse CVCL_A9RD CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1-150; Core protein p21). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10604 40819433 CVCL_A9RC 13-975-157 hybridoma house mouse CVCL_A9RC CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1-150; Core protein p21). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10608 40819434 CVCL_A9RF 6-296-534 hybridoma house mouse CVCL_A9RF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1191-1457; Serine protease NS3). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10607 40819435 CVCL_A9RE 14-1350-210 hybridoma house mouse CVCL_A9RE CL:0000010 Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1-150; Core protein p21). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10602 40819436 CVCL_A9R8 H28C110 hybridoma house mouse CVCL_A9R8 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1569-1930; Non-structural protein 4A/4B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10587 40819437 CVCL_A9QW HPT-8 spontaneously immortalized cell line human CVCL_A9QW CL:0000010 Population: Chinese; Derived from sampling site: Trophoblast. Unspecified 40819438 CVCL_A9R7 H35C54 hybridoma house mouse CVCL_A9R7 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1-150; Core protein p21). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10592 40819439 CVCL_A9QV PCI-KER_CAU induced pluripotent stem cell human CVCL_A9QV From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 40819440 CVCL_A9QY GM27616 finite cell line human CVCL_A9QY CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Asn232Ser (c.695A>G); ClinVar=VCV001698021; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819441 CVCL_A9R9 H4C20 hybridoma house mouse CVCL_A9R9 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1569-1930; Non-structural protein 4A/4B). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10593 40819442 CVCL_A9QX HPT-8-HBV spontaneously immortalized cell line human CVCL_A9QX CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Chinese; Derived from sampling site: Trophoblast. Unspecified Virology: Transfected with a hepatitis B virus (HBV) subtype adr genome 40819443 CVCL_A9QZ Q201 spontaneously immortalized cell line CVCL_A9QZ CL:0000010 Derived from sampling site: Peripheral blood. Unspecified Characteristics: IL2 dependent 40819444 CVCL_A9T2 IMAGINi021-A induced pluripotent stem cell human CVCL_A9T2 From: Imagine Institute; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819445 CVCL_A9SQ NP5 telomerase immortalized cell line human CVCL_A9SQ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Male 40819446 CVCL_A9T1 IMAGINi005-A induced pluripotent stem cell human CVCL_A9T1 From: Imagine Institute; Paris; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819447 CVCL_A9SP NP4 telomerase immortalized cell line human CVCL_A9SP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Male 40819448 CVCL_A9SS CS24iALS-SOD1E50Kn9 induced pluripotent stem cell human CVCL_A9SS From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Glu50Lys (c.148G>A) (E49K); ClinVar=VCV000658902; Zygosity=Unspecified (CSMC) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819449 CVCL_A9T4 ND42499 finite cell line human CVCL_A9T4 CL:0000010 Sequence variation: Mutation; HGNC; 4601; GRN; Simple; p.Arg493Ter (c.1477C>T); ClinVar=VCV000016014; Zygosity=Unspecified (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND42499; true Male 40819450 CVCL_A9SR F09229 finite cell line human CVCL_A9SR CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819451 CVCL_A9T3 PUMCHi005-A induced pluripotent stem cell human CVCL_A9T3 From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 12405; TTR; Simple; p.Phe53Val (c.157T>G); Zygosity=Heterozygous (PubMed=32858486) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40819452 CVCL_A9T6 CS84iSMA-n12B induced pluripotent stem cell human CVCL_A9T6 From: Cedars-Sinai Medical Center iPSC Core Facility; Los Angeles; USA CL:0000010 Sequence variation: Mutation; HGNC; 11117; SMN1; Unexplicit; Ex7-8del; Zygosity=Homozygous (CSMC) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819453 CVCL_A9SU KAUSTi006-A induced pluripotent stem cell human CVCL_A9SU From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Karyotypic information: 46-XY from a mosaic patient which has both 46-XY and 47-XXY cells (Cellosaurus=CVCL_A9SV); Derived from sampling site: Cell type=Fibroblast. Male 40819454 CVCL_A9T5 F09128 finite cell line human CVCL_A9T5 CL:0000010 Sequence variation: Mutation; HGNC; 28337; C9orf72; Repeat_expansion; c.-45+163GGGGCC[>24] (GGGGCC repeat expansion); ClinVar=VCV000031151; Zygosity=Unspecified Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819455 CVCL_A9ST NFH-46 finite cell line human CVCL_A9ST HLA typing: A*01:01,03:01; B*08,35; C*04:01,07:01; DRB1*03:01,11:01 (PubMed=25765079) CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819456 CVCL_A9T8 GSC#10 cancer cell line human CVCL_A9T8 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819457 CVCL_A9SW KAUSTi005-C induced pluripotent stem cell human CVCL_A9SW From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40819458 CVCL_A9T7 GSC#1 cancer cell line human CVCL_A9T7 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819459 CVCL_A9SV KAUSTi006-B induced pluripotent stem cell human CVCL_A9SV From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Karyotypic information: 47-XXY from a mosaic patient which has both 46-XY (Cellosaurus=CVCL_A9SU) and 47-XXY cells; Derived from sampling site: Cell type=Fibroblast. Male 40819460 CVCL_A9SI RIRI-PaDe-3-C48 spontaneously immortalized cell line CVCL_A9SI CL:0000010 Unspecified Group: Insect cell line. 40819461 CVCL_A9SH RIRI-PaDe-3-C47 spontaneously immortalized cell line CVCL_A9SH CL:0000010 Unspecified Group: Insect cell line. 40819462 CVCL_A9SK RIRI-PaDe-3-C53 spontaneously immortalized cell line CVCL_A9SK CL:0000010 Unspecified Group: Insect cell line. 40819463 CVCL_A9SJ RIRI-PaDe-3-C52 spontaneously immortalized cell line CVCL_A9SJ CL:0000010 Unspecified Characteristics: Can be adapted to growth in serum-free culture conditions Doubling time: 75.79 hours (before serum-free medium adaptation), 108.34 hours (in serum-free Ex-Cell 405 medium), 38.22 hours (in serum-free Express Five SFM medium) (PubMed=32737835). Group: Insect cell line 40819464 CVCL_A9SM NP2 [Human lung] telomerase immortalized cell line human CVCL_A9SM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Unspecified 40819465 CVCL_A9SL NP1 telomerase immortalized cell line human CVCL_A9SL CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Female 40819466 CVCL_A9T0 IMAGINi004-A induced pluripotent stem cell human CVCL_A9T0 From: Imagine Institute; Paris; France CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Male 40819467 CVCL_A9SN NP3 [Human lung] telomerase immortalized cell line human CVCL_A9SN CL:0000010 Sequence variation: Mutation; HGNC; 950; BAP1; Simple; p.Lys286Glnfs*21 (c.855dupC); ClinVar=VCV000545892; Zygosity=Heterozygous (PubMed=32726133); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Donor information: Established from a patient suffering from an early stage malignant pleural mesothelioma; Derived from sampling site: Lung; pleura Cell type=Mesothelial cell.. Unspecified 40819468 CVCL_A9SA RIRI-PaDe-2-C6 spontaneously immortalized cell line CVCL_A9SA CL:0000010 Unspecified Characteristics: Can be adapted to growth in serum-free culture conditions Doubling time: 66.92 hours (before serum-free medium adaptation), 87.59 hours (in serum-free mediium) (PubMed=32737835). Group: Insect cell line 40819469 CVCL_A9SC RIRI-PaDe-2-C8 spontaneously immortalized cell line CVCL_A9SC CL:0000010 Unspecified Group: Insect cell line. 40819470 CVCL_A9SB RIRI-PaDe-2-C7 spontaneously immortalized cell line CVCL_A9SB CL:0000010 Unspecified Group: Insect cell line. 40819471 CVCL_A9SE RIRI-PaDe-2-C19 spontaneously immortalized cell line CVCL_A9SE CL:0000010 Unspecified Group: Insect cell line. 40819472 CVCL_A9SD RIRI-PaDe-2-C18 spontaneously immortalized cell line CVCL_A9SD CL:0000010 Unspecified Group: Insect cell line. 40819473 CVCL_A9SG RIRI-PaDe-3-C42 spontaneously immortalized cell line CVCL_A9SG CL:0000010 Unspecified Group: Insect cell line. 40819474 CVCL_A9SF NH50226 finite cell line human CVCL_A9SF CL:0000010 Population: Southeast Asian; Filipino; Donor information: At sampling donor was not affected with X-linked dystonia parkinsonism but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819475 CVCL_A9RX NH50302 induced pluripotent stem cell human CVCL_A9RX CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 40819476 CVCL_A9S9 RIRI-PaDe-2-C5 spontaneously immortalized cell line CVCL_A9S9 CL:0000010 Unspecified Group: Insect cell line. 40819477 CVCL_A9RW NH50301 induced pluripotent stem cell human CVCL_A9RW CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819478 CVCL_A9S8 RIRI-PaDe-1-C6 spontaneously immortalized cell line CVCL_A9S8 CL:0000010 Unspecified Group: Insect cell line. 40819479 CVCL_A9RZ NH50304 induced pluripotent stem cell human CVCL_A9RZ CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 40819480 CVCL_A9RY NH50303 induced pluripotent stem cell human CVCL_A9RY CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 40819481 CVCL_A9PN iLB-C-50-s9 induced pluripotent stem cell human CVCL_A9PN From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Umbilical cord blood. Unspecified 40819482 CVCL_A9PM ND35665 induced pluripotent stem cell human CVCL_A9PM CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND35665; true Male 40819483 CVCL_A9PP AR1034ZIMA finite cell line human CVCL_A9PP CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819484 CVCL_A9Q1 TAF5 finite cell line human CVCL_A9Q1 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Female 40819485 CVCL_A9Q0 FFF-031 finite cell line human CVCL_A9Q0 CL:0000010 Sequence variation: Mutation; HGNC; 11138; SNCA; Simple; p.Ala53Thr (c.157G>A); ClinVar=VCV000014007; Zygosity=Heterozygous (from child cell line ESi039-A) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819486 CVCL_A9PR del-AR1034ZIMA clone 1.2 induced pluripotent stem cell human CVCL_A9PR CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819487 CVCL_A9Q3 KCLi007-A induced pluripotent stem cell human CVCL_A9Q3 From: King's College London; London; United Kingdom. CL:0000010 40819488 CVCL_A9PQ fl-AR1034ZIMA clone 1 induced pluripotent stem cell human CVCL_A9PQ CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Characteristics: Contains a loxP flanked STEMCCA polycistronic (OSKM) vector 40819489 CVCL_A9Q2 TAF6 finite cell line human CVCL_A9Q2 CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Array-based CGH Male 40819490 CVCL_A9Q5 Ha168 spontaneously immortalized cell line CVCL_A9Q5 CL:0000010 Unspecified Doubling time: 58 hours, at 25th passage (PubMed=32827128). Group: Insect cell line 40819491 CVCL_A9PT KAUSTi001-A induced pluripotent stem cell human CVCL_A9PT From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819492 CVCL_A9PS del-AR1034ZIMA clone 1.4 induced pluripotent stem cell human CVCL_A9PS CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 40819493 CVCL_A9Q4 KSCBi012-A induced pluripotent stem cell human CVCL_A9Q4 From: National Institute of Health, Korea-National Stem Cell Bank (KSCB); Cheongwon-gun; South Korea CL:0000010 Population: Korean; Derived from sampling site: Urine. Omics: SNP array analysis Male 40819494 CVCL_A9PF iP-MSC D2 cC induced pluripotent stem cell human CVCL_A9PF From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40819495 CVCL_A9PE iP-MSC D2 cB induced pluripotent stem cell human CVCL_A9PE From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40819496 CVCL_A9PH iP-MSC D5 cB induced pluripotent stem cell human CVCL_A9PH From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 40819497 CVCL_A9PG iP-MSC D5 cA induced pluripotent stem cell human CVCL_A9PG From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 40819498 CVCL_A9PJ iP-MSC D4 cA induced pluripotent stem cell human CVCL_A9PJ From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 40819499 CVCL_A9PI iP-MSC D5 cC induced pluripotent stem cell human CVCL_A9PI From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 40819500 CVCL_A9PL UKKi014-A induced pluripotent stem cell human CVCL_A9PL From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany. CL:0000010 40819501 CVCL_A9PK iP-MSC D4 cC induced pluripotent stem cell human CVCL_A9PK From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Female 40819502 CVCL_A9PB 4E1-7 hybridoma CVCL_A9PB CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; Q3C2E2; Dog MS4A1/CD20. 40819503 CVCL_A9PA CLBL-1/luc cancer cell line dog CVCL_A9PA CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lymph node; Breed/subspecies: Bernese mountain dog. Male 40819504 CVCL_A9PD iP-MSC D2 cA induced pluripotent stem cell human CVCL_A9PD From: Institute for Neurophysiology, Medical Faculty, University of Cologne; Cologne; Germany CL:0000010 Derived from sampling site: Bone marrow Cell type=Mesenchymal stem cell.. Male 40819505 CVCL_A9PC NRK/cCD20 spontaneously immortalized cell line Norway rat CVCL_A9PC CL:0000010 Transfected with: VGNC; 52268; Dog MS4A1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney; Breed/subspecies: Osborne-Mendel. 40819506 CVCL_A9P6 Foxp3 reporter (Luc)-Jurkat cancer cell line human CVCL_A9P6 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expression of the luciferase reporter gene is driven by a CPG-island enhancer followed by a FOXP3 promoter 40819507 CVCL_A9P5 LIGHT-CHO spontaneously immortalized cell line CVCL_A9P5 CL:0000010 Transfected with: HGNC; 11930; TNFSF14; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female 40819508 CVCL_A9P8 FFF-028 finite cell line human CVCL_A9P8 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (PubMed=22666358) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819509 CVCL_A9P7 FFF-022 finite cell line human CVCL_A9P7 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (PubMed=22666358) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819510 CVCL_A9P9 ND39028 finite cell line human CVCL_A9P9 CL:0000010 Sequence variation: Mutation; HGNC; 11179; SOD1; Simple; p.Gly86Arg (c.256G>C) (G85R); ClinVar=VCV000014758; Zygosity=Unspecified (Coriell) Population: Caucasian; Donor information: At sampling donor was not affected with amyotrophic lateral sclerosis but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND39028; true Male 40819511 CVCL_A9R0 ND32948 finite cell line human CVCL_A9R0 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND32948; probable Male 40819512 CVCL_A9QN PCIi020-A induced pluripotent stem cell human CVCL_A9QN From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819513 CVCL_A9R2 FTDP-17-1-I induced pluripotent stem cell human CVCL_A9R2 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (PubMed=26143746) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819514 CVCL_A9QQ PCIi016-A induced pluripotent stem cell human CVCL_A9QQ From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819515 CVCL_A9R1 ND34392 induced pluripotent stem cell human CVCL_A9R1 CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Homozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; ND34392; probable Male 40819516 CVCL_A9QP PCIi015-A induced pluripotent stem cell human CVCL_A9QP From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819517 CVCL_A9R4 FTDP-17-2-I induced pluripotent stem cell human CVCL_A9R4 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (PubMed=26143746) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819518 CVCL_A9QS PCIi018-A induced pluripotent stem cell human CVCL_A9QS From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819519 CVCL_A9R3 FTDP-17-1-II induced pluripotent stem cell human CVCL_A9R3 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Unspecified (PubMed=26143746) Population: Caucasian; Donor information: At sampling donor was not affected with frontotemporal dementia but at risk for disease; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819520 CVCL_A9QR PCIi017-A induced pluripotent stem cell human CVCL_A9QR From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819521 CVCL_A9R6 H81C17 hybridoma house mouse CVCL_A9R6 CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 1-150; Core protein p21). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10588 40819522 CVCL_A9QU PCI-KER_ASI induced pluripotent stem cell human CVCL_A9QU From: Phenocell SAS; Grasse; France CL:0000010 Population: Asian; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 40819523 CVCL_A9R5 FTDP-17-2-II induced pluripotent stem cell human CVCL_A9R5 CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Val337Met (c.1009G>A) (V654M, c.1960G>A or V672M, c.2014G>A); ClinVar=VCV000014252; Zygosity=Unspecified (PubMed=26143746) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819524 CVCL_A9QT PCI-KER_AFR induced pluripotent stem cell human CVCL_A9QT From: Phenocell SAS; Grasse; France CL:0000010 Population: African; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. 40819525 CVCL_A9QG PCIi007-A induced pluripotent stem cell human CVCL_A9QG From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819526 CVCL_A9QF PCi-ASI2 induced pluripotent stem cell human CVCL_A9QF From: Phenocell SAS; Grasse; France CL:0000010 Population: Chinese. Female 40819527 CVCL_A9QI PCIi009-A induced pluripotent stem cell human CVCL_A9QI From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819528 CVCL_A9QH PCIi008-A induced pluripotent stem cell human CVCL_A9QH From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819529 CVCL_A9QK PCIi011-A induced pluripotent stem cell human CVCL_A9QK From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819530 CVCL_A9QJ PCIi010-A induced pluripotent stem cell human CVCL_A9QJ From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819531 CVCL_A9QM PCIi019-A induced pluripotent stem cell human CVCL_A9QM From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819532 CVCL_A9QL PCIi012-A induced pluripotent stem cell human CVCL_A9QL From: Phenocell SAS; Grasse; France CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819533 CVCL_A9QA UEFi003-A induced pluripotent stem cell human CVCL_A9QA From: University of Eastern Finland; Kuopio; Finland CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Ala673Thr (c.2017G>A); ClinVar=VCV000037145; Zygosity=Heterozygous (PubMed=32911327) Population: Caucasian; Finnish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819534 CVCL_A9QC NCC-GCTB1-C1 cancer cell line human CVCL_A9QC CL:0000010 Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=32815117) Population: Japanese; Derived from sampling site: Bone; right distal radius. Male Doubling time: 13 hours (PubMed=32815117) Part of: NCC sarcoma cell line panel 40819535 CVCL_A9QB JAM-ICR cancer cell line human CVCL_A9QB CL:0000010 Population: Iranian; Derived from sampling site: Urinary bladder. Male Doubling time: 23.9 hours (PubMed=33165868) 40819536 CVCL_A9QE PCi-AFR2 induced pluripotent stem cell human CVCL_A9QE From: Phenocell SAS; Grasse; France CL:0000010 Population: African. Female 40819538 CVCL_A9PV KAUSTi003-A induced pluripotent stem cell human CVCL_A9PV From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819539 CVCL_A9Q7 UCLi008-A induced pluripotent stem cell human CVCL_A9Q7 From: University College London; London; United Kingdom. CL:0000010 40819540 CVCL_A9PU KAUSTi001-B induced pluripotent stem cell human CVCL_A9PU From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819541 CVCL_A9Q6 UCLi003-B induced pluripotent stem cell human CVCL_A9Q6 From: University College London; London; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; c.1866+16C>T (IVS10+16C>T) (c.915+16C>T) (g.123819C>T); ClinVar=VCV000098222; Zygosity=Unspecified (from autologous cell line UCLi003-A) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819542 CVCL_A9PX KAUSTi004-B induced pluripotent stem cell human CVCL_A9PX From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 40819543 CVCL_A9Q9 UKBi016-A induced pluripotent stem cell human CVCL_A9Q9 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819544 CVCL_A9PW KAUSTi004-A induced pluripotent stem cell human CVCL_A9PW From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 40819545 CVCL_A9Q8 UKBi015-A induced pluripotent stem cell human CVCL_A9Q8 From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Derived from sampling site: Peripheral blood. Male 40819546 CVCL_A9PZ KAUSTi005-B induced pluripotent stem cell human CVCL_A9PZ From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40819547 CVCL_A9PY KAUSTi005-A induced pluripotent stem cell human CVCL_A9PY From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Sardinian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40819548 CVCL_A9N4 GIST-R2m cancer cell line human CVCL_A9N4 CL:0000010 Population: Korean. 40819549 CVCL_A9N3 GIST-R1 cancer cell line human CVCL_A9N3 CL:0000010 Population: Korean. 40819550 CVCL_A9N6 GIST-R4ma cancer cell line human CVCL_A9N6 CL:0000010 Population: Korean. 40819551 CVCL_A9N5 GIST-R3 cancer cell line human CVCL_A9N5 CL:0000010 Population: Korean. 40819552 CVCL_A9N8 WTC11_RB1KO#1 induced pluripotent stem cell human CVCL_A9N8 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 40819553 CVCL_A9N7 GIST-R5 cancer cell line human CVCL_A9N7 CL:0000010 Sequence variation: Gene fusion; HGNC; 20091; AK7 + HGNC; 24968; EXOC2; Name(s)=EXOC2-AK7; Note=In frame (PubMed=32736695). Population: Korean 40819554 CVCL_A9N9 WTC11_RB1KO#4 induced pluripotent stem cell human CVCL_A9N9 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9884; RB1 Population: Japanese; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 40819555 CVCL_A9P0 NF-KappaB reporter (Luc)-A549 cancer cell line human CVCL_A9P0 CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Expression of the luciferase reporter gene is driven by four copies of the NF-kappaB response element located upstream of a minimal TATA promoter 40819556 CVCL_A9P2 NF-KappaB reporter (Luc)-HCT-116 cancer cell line human CVCL_A9P2 CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ile2675Aspfs*6 (c.8021dupA) (c.8021_8022insA); ClinVar=VCV000267050; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg24Serfs*20 (c.68dupG) (c.68_69insG) (p.G23fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45del (c.133_135delTCT); ClinVar=VCV000017576; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Met1470Cysfs*22 (c.4408delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 3373; EP300; Simple; p.Asn1700Thrfs*9 (c.5099delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Colon. Male Characteristics: Expression of the luciferase reporter gene is driven by four copies of the NF-kappaB response element located upstream of a minimal TATA promoter 40819557 CVCL_A9P1 NF-KappaB reporter (Luc)-CHO-K1 spontaneously immortalized cell line CVCL_A9P1 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Ovary. Female Characteristics: Expression of the luciferase reporter gene is driven by four copies of the NF-kappaB response element located upstream of a minimal TATA promoter 40819558 CVCL_A9P4 NF-kappaB reporter (Luc)-Jurkat cancer cell line human CVCL_A9P4 CL:0000010 Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male Characteristics: Expression of the luciferase reporter gene is driven by four copies of the NF-kappaB response element located upstream of a minimal TATA promoter 40819559 CVCL_A9P3 NF-KappaB reporter (Luc)-HEK293 transformed cell line human CVCL_A9P3 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female Characteristics: Expression of the luciferase reporter gene is driven by four copies of the NF-kappaB response element located upstream of a minimal TATA promoter 40819560 CVCL_A9ZX KB5828 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZX From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.7 days (PubMed=12840040) Group: Non-human primate cell line 40819561 CVCL_A9ZW KB4512 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZW From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.6 days (PubMed=12840040) Group: Non-human primate cell line 40819562 CVCL_A9ZZ KB8025 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZZ From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.0 days (PubMed=12840040) Group: Non-human primate cell line 40819563 CVCL_A9ZY KB7998 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZY From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.0 days (PubMed=12840040) Group: Non-human primate cell line 40819564 CVCL_A9ZP FDCHDPi001-A induced pluripotent stem cell human CVCL_A9ZP From: Children's Hospital of Fudan University; Shanghai; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40819565 CVCL_A9ZR AG27605 induced pluripotent stem cell human CVCL_A9ZR CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=30699343) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40819566 CVCL_A9ZQ AG27602 induced pluripotent stem cell human CVCL_A9ZQ CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 40819567 CVCL_A9ZT KB5275 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZT From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.4 days (PubMed=12840040) Group: Non-human primate cell line 40819568 CVCL_A9ZS KB6884 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZS From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.0 days (PubMed=12840040) Group: Non-human primate cell line 40819569 CVCL_A9ZV KB7033 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZV From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female Doubling time: 2.1 days (PubMed=12840040) Group: Non-human primate cell line 40819570 CVCL_A9ZU KB10025 finite cell line bonobo/pygmy chimpanzee CVCL_A9ZU From: Center for Reproduction of Endangered Species, Zoological Society of San Diego; San Diego; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male Doubling time: 2.4 days (PubMed=12840040) Group: Non-human primate cell line 40819571 CVCL_A9ZH GM27930 induced pluripotent stem cell human CVCL_A9ZH CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; c.726-1G>A (c.729-1G>A) (IVS9-1G>A); ClinVar=VCV001803675; Zygosity=Heterozygous; Note=De novo mutation Splice acceptor mutation (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819572 CVCL_A9ZG TNGB-78816 finite cell line human CVCL_A9ZG CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819573 CVCL_A9ZJ GM27912 transformed cell line human CVCL_A9ZJ CL:0000010 Sequence variation: Mutation; HGNC; 20311; CHAMP1; Simple; p.Gln657Ter (c.1969C>T); ClinVar=VCV000217916; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819574 CVCL_A9ZI GM27913 finite cell line human CVCL_A9ZI CL:0000010 Sequence variation: Mutation; HGNC; 2212; COL6A2; Simple; p.Arg468Ter (c.1402C>T); ClinVar=VCV000565700; Zygosity=Homozygous (Coriell) Population: Jewish; Sephardic; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819575 CVCL_A9ZL KPC3-TRP1 cancer cell line house mouse CVCL_A9ZL CL:0000010 Transfected with: MGI; MGI:98881; Tyrp1 (with p.Gln512_Val537del); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Pancreas; Breed/subspecies: LSL-KrasG12D:LSL-Trp53R270H:Pdx1-Cre (KPC). Female 40819576 CVCL_A9ZK KPC3 cancer cell line house mouse CVCL_A9ZK CL:0000010 Derived from sampling site: Pancreas; Breed/subspecies: LSL-KrasG12D:LSL-Trp53R270H:Pdx1-Cre (KPC). Female 40819577 CVCL_A9ZN BIPTi002-A induced pluripotent stem cell human CVCL_A9ZN From: Beijing Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 40819578 CVCL_A9ZM BIPTi001-A induced pluripotent stem cell human CVCL_A9ZM From: Beijing Institute of Pharmacology and Toxicology; Beijing; China CL:0000010 Population: Chinese; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Female 40819579 CVCL_A9ZB KAUSTi009-A induced pluripotent stem cell human CVCL_A9ZB From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819580 CVCL_A9ZA NCL2 [Human umbilical cord] induced pluripotent stem cell human CVCL_A9ZA From: NxCell, Inc.; Novato; USA CL:0000010 Derived from sampling site: Umbilical cord blood. 40819581 CVCL_A9ZD TNGB-66257 finite cell line human CVCL_A9ZD CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819582 CVCL_A9ZC KAUSTi009-B induced pluripotent stem cell human CVCL_A9ZC From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819583 CVCL_A9ZF KAUSTi010-B induced pluripotent stem cell human CVCL_A9ZF From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819584 CVCL_A9ZE KAUSTi010-A induced pluripotent stem cell human CVCL_A9ZE From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819585 CVCL_A9XV FHUi004-A induced pluripotent stem cell human CVCL_A9XV From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 894; AVP; Simple; p.Cys105Ser (c.314G>C); Zygosity=Heterozygous (PubMed=32927425) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819586 CVCL_A9Y7 KAUSTi008-B induced pluripotent stem cell human CVCL_A9Y7 From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XY cell line originating from the 47,XXY patient fibroblast (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819587 CVCL_A9XU FHUi003-B induced pluripotent stem cell human CVCL_A9XU From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 894; AVP; Simple; p.Cys105Ser (c.314G>C); Zygosity=Heterozygous (PubMed=32927425) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819588 CVCL_A9Y6 KAUSTi008-A induced pluripotent stem cell human CVCL_A9Y6 From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XY cell line originating from the 47,XXY patient fibroblast (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819589 CVCL_A9Y9 KAUSTi008-D induced pluripotent stem cell human CVCL_A9Y9 From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XXY (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819590 CVCL_A9XX WAe009-A-43 embryonic stem cell human CVCL_A9XX From: The First Affiliated Hospital of Guangxi Medical University; Guangxi; China CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Tyr475Cys (c.1424A>G); ClinVar=VCV000067199; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32911324). Female 40819591 CVCL_A9XW FHUi004-B induced pluripotent stem cell human CVCL_A9XW From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 894; AVP; Simple; p.Cys105Ser (c.314G>C); Zygosity=Heterozygous (PubMed=32927425) Population: Japanese; Derived from sampling site: Peripheral blood. Female 40819592 CVCL_A9Y8 KAUSTi008-C induced pluripotent stem cell human CVCL_A9Y8 From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XXY (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819593 CVCL_A9XZ MCRIi019-A-2 induced pluripotent stem cell human CVCL_A9XZ From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 2200; COL2A1; Simple_edited; p.Gly1170Ser (c.3508_3510GGT>TCA); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=33002832) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819594 CVCL_A9XY MCRIi019-A induced pluripotent stem cell human CVCL_A9XY From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819595 CVCL_A9XN NMIi002-B induced pluripotent stem cell human CVCL_A9XN From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819596 CVCL_A9XM NMIi002-A induced pluripotent stem cell human CVCL_A9XM From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819597 CVCL_A9Y1 B-LCL-CDG2 transformed cell line human CVCL_A9Y1 HLA typing: A*02:01:01,31:01:02; B*40:01:02,44:02:01; C*03:04:01,05:01:01; DPB1*04:02:01,06:01:01; DQA1*03:01:01,03:02:01; DQB1*03:02:01,03:03:02; DRB1*04:04:01,09:01:02 (CLS=302013) CL:0000010 Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Arg141His (c.422G>A); ClinVar=VCV000007706; Zygosity=Heterozygous (PubMed=34420056); Sequence variation: Mutation; HGNC; 9115; PMM2; Simple; p.Asp188Gly (c.563A>G); ClinVar=VCV000007712; Zygosity=Heterozygous (PubMed=34420056) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819598 CVCL_A9XP NMIi004-A induced pluripotent stem cell human CVCL_A9XP From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819599 CVCL_A9Y0 HC84S cancer cell line human CVCL_A9Y0 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Leu1488Phefs*19 (c.4464delA); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Lys340Asn (c.1020G>C); Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.560-1G>T; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line) Population: Caucasian; Derived from metastatic site: Lung. Male Doubling time: 6-7 days (PubMed=6932031) Group: Serum/protein free medium cell line 40819600 CVCL_A9Y3 B-LCL-CDG7 transformed cell line human CVCL_A9Y3 CL:0000010 Sequence variation: Mutation; HGNC; 10702; SEC23B; Unexplicit; Not described; Zygosity=Homozygous (CLS) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819601 CVCL_A9XR NMIi006-A induced pluripotent stem cell human CVCL_A9XR From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819602 CVCL_A9Y2 B-LCL-CDG4 transformed cell line human CVCL_A9Y2 HLA typing: A*01:01:01,24:02:01; B*08:01:01,18:01:01; C*07:01:01,12:03:01; DPB1*03:01:01,04:02:01; DQA1*01:02:01,05:01:01; DQB1*02:01:01,06:02:01; DRB1*03:01:01,15:01:01 (CLS=302015) CL:0000010 Sequence variation: Mutation; HGNC; 10702; SEC23B; Unexplicit; Not described; Zygosity=Homozygous (CLS) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819603 CVCL_A9XQ NMIi005-A induced pluripotent stem cell human CVCL_A9XQ From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819604 CVCL_A9XT FHUi003-A induced pluripotent stem cell human CVCL_A9XT From: Fujita Health University; Toyoake; Japan CL:0000010 Sequence variation: Mutation; HGNC; 894; AVP; Simple; p.Cys105Ser (c.314G>C); Zygosity=Heterozygous (PubMed=32927425) Population: Japanese; Derived from sampling site: Peripheral blood. Male 40819605 CVCL_A9Y5 TNGB-64135 finite cell line human CVCL_A9Y5 CL:0000010 Derived from sampling site: Amniotic fluid. Male 40819606 CVCL_A9XS NMIi006-B induced pluripotent stem cell human CVCL_A9XS From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819607 CVCL_A9Y4 TNGB-64137 finite cell line human CVCL_A9Y4 CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 40819608 CVCL_A9XF CPGHi001-A induced pluripotent stem cell human CVCL_A9XF From: Chinese PLA Institute of Otolaryngology, Chinese PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 16513; TMC1; Simple; p.Met418Lys (c.1253T>A); ClinVar=VCV000183668; Zygosity=Heterozygous (PubMed=33217648) Population: Chinese; Han; Derived from sampling site: Urine. Male 40819609 CVCL_A9XE BGUi003-A induced pluripotent stem cell human CVCL_A9XE From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9208; POR; Simple; p.Gly536Arg (c.1606G>A) (p.Gly539Arg, c.1615G>A) (1697G>A); ClinVar=VCV000016915; Zygosity=Homozygous (PubMed=32905996) Population: Bedouin; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819610 CVCL_A9XH SDUKIi003-A induced pluripotent stem cell human CVCL_A9XH From: Institute of Clinical Research, University of Southern Denmark; Odense; Denmark CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819611 CVCL_A9XG JHUi002-A induced pluripotent stem cell human CVCL_A9XG From: Johns Hopkins University; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=32916633) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819612 CVCL_A9XJ JUCTCi012-B induced pluripotent stem cell human CVCL_A9XJ From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Homozygous (from autologous cell line JUCTCi012-A) Population: Jordanian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819613 CVCL_A9XI JUCTCi012-A induced pluripotent stem cell human CVCL_A9XI From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Homozygous (PubMed=32916636) Population: Jordanian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819614 CVCL_A9XL NMIi001-A induced pluripotent stem cell human CVCL_A9XL From: Natural and Medical Sciences Institute, University of Tubingen; Tubingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819615 CVCL_A9XK JUCTCi012-C induced pluripotent stem cell human CVCL_A9XK From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 16877; MFN2; Simple; p.Arg707Trp (c.2119C>T); ClinVar=VCV000002280; Zygosity=Homozygous (from autologous cell line JUCTCi012-A) Population: Jordanian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819616 CVCL_A9XB BGUi005-A induced pluripotent stem cell human CVCL_A9XB From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9143; PHOX2B; Simple; p.Ala260(5_9) (c.765_779dup); ClinVar=VCV000006008; Zygosity=Heterozygous (PubMed=32822965) Population: Jewish; Ashkenazi; Donor information: Established from monozygotic twin of BGUi004-A (Cellosaurus=CVCL_A9XA); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819617 CVCL_A9XA BGUi004-A induced pluripotent stem cell human CVCL_A9XA From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9143; PHOX2B; Simple; p.Ala260(5_9) (c.765_779dup); ClinVar=VCV000006008; Zygosity=Heterozygous (PubMed=32822965) Population: Jewish; Ashkenazi; Donor information: Established from monozygotic twin of BGUi005-A (Cellosaurus=CVCL_A9XB); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819618 CVCL_A9XD BGUi002-A induced pluripotent stem cell human CVCL_A9XD From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9208; POR; Simple; p.Gly536Arg (c.1606G>A) (p.Gly539Arg, c.1615G>A) (1697G>A); ClinVar=VCV000016915; Zygosity=Homozygous (PubMed=32905996) Population: Bedouin; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819619 CVCL_A9XC BGUi001-A induced pluripotent stem cell human CVCL_A9XC From: Ben Gurion University of the Negev; Beer Sheva; Israel CL:0000010 Sequence variation: Mutation; HGNC; 9208; POR; Simple; p.Gly536Arg (c.1606G>A) (p.Gly539Arg, c.1615G>A) (1697G>A); ClinVar=VCV000016915; Zygosity=Heterozygous (PubMed=32905996) Population: Bedouin; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819620 CVCL_A9Z8 FAP 6888-1 induced pluripotent stem cell human CVCL_A9Z8 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (PubMed=30024920) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819621 CVCL_A9YW PUMCi002-A induced pluripotent stem cell human CVCL_A9YW From: Peking Union Medical College; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Simple; p.Pro154His (c.461C>A); ClinVar=VCV001457103; Zygosity=Heterozygous (PubMed=36270068) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819622 CVCL_A9Z7 FAP 3954-1 induced pluripotent stem cell human CVCL_A9Z7 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (PubMed=30024920) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819623 CVCL_A9YV PUMCi001-A induced pluripotent stem cell human CVCL_A9YV From: Peking Union Medical College; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4115; GALC; Simple; p.Pro154His (c.461C>A); ClinVar=VCV001457103; Zygosity=Heterozygous (PubMed=32763824); Sequence variation: Mutation; HGNC; 4115; GALC; Simple; p.Gly415Glu (c.1244G>A); ClinVar=VCV001334157; Zygosity=Heterozygous (PubMed=32763824) Population: Asian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819624 CVCL_A9YY YCMi001-B-1 induced pluripotent stem cell human CVCL_A9YY From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Unexplicit_corrected; Ex8-22del; Zygosity=Hemizygous; Note=By CRISPR/Cas9 (PubMed=32798916) Population: Korean; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 40819625 CVCL_A9Z9 FAP 6965-1 induced pluripotent stem cell human CVCL_A9Z9 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1538Ilefs*5 (c.4612_4613delAG) (P1542X); ClinVar=VCV000000823; Zygosity=Unspecified (PubMed=30024920) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819626 CVCL_A9YX YCMi001-B induced pluripotent stem cell human CVCL_A9YX From: Yonsei University College of Medicine; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Unexplicit; Ex8-22del; Zygosity=Hemizygous (PubMed=31105049; PubMed=32798916) Population: Korean; Derived from sampling site: Cell type=Adipose mesenchymal stem cell. Male 40819627 CVCL_A9YZ NCC-TGCT1-C1 cancer cell line human CVCL_A9YZ CL:0000010 Sequence variation: Gene fusion; HGNC; 2213; COL6A3 + HGNC; 2432; CSF1; Name(s)=COL6A3-CSF1 (PubMed=32886306) Population: Japanese; Derived from sampling site: Hip; tendon sheath. Female Doubling time: 30 hours (PubMed=32886306) Part of: NCC sarcoma cell line panel 40819628 CVCL_A9Z0 GBM8902 cancer cell line human CVCL_A9Z0 CL:0000010 Population: Chinese; Derived from sampling site: Brain. Male 40819629 CVCL_A9YN IRFMNi003-A-3 induced pluripotent stem cell human CVCL_A9YN From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple_edited; p.Pro3582Glyfs*44 (c.10744_10745delCC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32592954) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819630 CVCL_A9Z2 HHT3 telomerase immortalized cell line human CVCL_A9Z2 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Hepatocyte.. Omics: Transcriptome analysis by microarray Male 40819631 CVCL_A9YQ UMGi144-A induced pluripotent stem cell human CVCL_A9YQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 27424; RBM20; Simple; p.Arg634Trp (c.1900C>T); ClinVar=VCV000411653; Zygosity=Heterozygous (PubMed=32674065) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819632 CVCL_A9Z1 HHT4 telomerase immortalized cell line human CVCL_A9Z1 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Liver Cell type=Hepatocyte.. Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 40819633 CVCL_A9YP IRFMNi003-A-4 induced pluripotent stem cell human CVCL_A9YP From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple_edited; p.Pro3582Glyfs*3 (c.10745delC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32592954); Sequence variation: Mutation; HGNC; 9008; PKD1; Simple_edited; p.Pro3582Glyfs*44 (c.10744_10745delCC); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32592954) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 40819634 CVCL_A9Z4 MCRIi001-A-4 induced pluripotent stem cell human CVCL_A9Z4 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 18083; TRPV4; Simple_edited; p.Pro799Leu (c.2396C>T); ClinVar=VCV000004998; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32771907); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 SOX9 has been endogenously tagged at the C-terminus with TdTomato 40819635 CVCL_A9YS UKERe006-B embryonic stem cell human CVCL_A9YS From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 40819636 CVCL_A9Z3 MCRIi001-A-3 induced pluripotent stem cell human CVCL_A9Z3 From: Murdoch Children's Research Institute; Melbourne; Australia CL:0000010 Sequence variation: Mutation; HGNC; 18083; TRPV4; Simple_edited; p.Phe273Leu (c.819C>G); ClinVar=VCV000035511; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32771907); Transfected with: tdTomato, a bright red fluorescent protein derived from drFP583 (DsRed) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Characteristics: Using CRISPR/Cas9 SOX9 has been endogenously tagged at the C-terminus with TdTomato 40819637 CVCL_A9YR UMGi144-A-1 induced pluripotent stem cell human CVCL_A9YR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 27424; RBM20; Simple_corrected; p.Arg634Trp (c.1900C>T); ClinVar=VCV000411653; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32674065) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819638 CVCL_A9Z6 FAP 3948-1 induced pluripotent stem cell human CVCL_A9Z6 CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln541Ter (c.1621C>T); ClinVar=VCV000000806; Zygosity=Heterozygous (PubMed=30024920) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819639 CVCL_A9YU UKERe006-D embryonic stem cell human CVCL_A9YU From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 40819640 CVCL_A9YT UKERe006-C embryonic stem cell human CVCL_A9YT From: Universitatsklinikum Erlangen (UKER); Erlangen; Germany. CL:0000010 Female 40819641 CVCL_A9Z5 ZJSHi001-A induced pluripotent stem cell human CVCL_A9Z5 From: Department of Pediatrics, The Second Affiliated Hospital of Zhejiang University School of Medicine; Hangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6231; KCNB1; Simple; p.Glu330Asp (c.990G>T); Zygosity=Heterozygous (PubMed=33607466) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 40819642 CVCL_A9YG KUMCi002-A induced pluripotent stem cell human CVCL_A9YG From: Korea University College of Medicine; Seoul; South Korea CL:0000010 Population: Korean; Derived from sampling site: Bone marrow. Female 40819643 CVCL_A9YF KAUSTi008-G induced pluripotent stem cell human CVCL_A9YF From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XXY (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819644 CVCL_A9YI IMEDEAi008-A induced pluripotent stem cell human CVCL_A9YI From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Sequence variation: Mutation; HGNC; 1606; CCR5; Simple; p.Ser185Ilefs (c.554_585del32) (CCR5del32); ClinVar=VCV000008184; Zygosity=Homozygous (PubMed=32702648) Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 40819645 CVCL_A9YH IMEDEAi007-A induced pluripotent stem cell human CVCL_A9YH From: Instituto Mediterraneo de Estudios Avanzados; Esporles; Spain CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 40819646 CVCL_A9YK MNDINSi001-A induced pluripotent stem cell human CVCL_A9YK From: Endocrinology Research Centre; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 6081; INS; Simple; c.188-31G>A; ClinVar=VCV000211186; Zygosity=Heterozygous (PubMed=32739878) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819647 CVCL_A9YJ HMGUi001-A-3 induced pluripotent stem cell human CVCL_A9YJ From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819648 CVCL_A9YM ZZUNEUi014-A induced pluripotent stem cell human CVCL_A9YM From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 775; SERPINC1; Simple; p.Trp27Ter (c.80G>A); Zygosity=Heterozygous (PubMed=34973562) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 40819649 CVCL_A9YL ZZUNEUi013-A induced pluripotent stem cell human CVCL_A9YL From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7576; MYH6; Simple; p.Arg1252Gln (c.3755G>A); dbSNP=rs759454361; Zygosity=Heterozygous (PubMed=33385793) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 40819650 CVCL_A9YA KAUSTi008-E induced pluripotent stem cell human CVCL_A9YA From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XXY (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819651 CVCL_A9YC KAUSTi007-A induced pluripotent stem cell human CVCL_A9YC From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819652 CVCL_A9YB KAUSTi008-F induced pluripotent stem cell human CVCL_A9YB From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Karyotypic information: 46,XXY (PubMed=33333453); Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819653 CVCL_A9YE KAUSTi007-B induced pluripotent stem cell human CVCL_A9YE From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819654 CVCL_A9YD FFF0312002 finite cell line human CVCL_A9YD CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Male 40819655 CVCL_A9VT GSC#440 cancer cell line human CVCL_A9VT From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819656 CVCL_A9W5 SFC6-iPS#4.6 induced pluripotent stem cell human CVCL_A9W5 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.633+1G>A; dbSNP=rs528466699; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26411903); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; p.Leu473Pro (c.1418T>C) (p.Leu445Pro, c.1334T>C); Zygosity=Heterozygous (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819657 CVCL_A9VS GSC#433 cancer cell line human CVCL_A9VS From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819658 CVCL_A9W4 GSC#455 cancer cell line human CVCL_A9W4 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819659 CVCL_A9VV GSC#442 cancer cell line human CVCL_A9VV From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819660 CVCL_A9W7 SFC7-iPS#4.8 induced pluripotent stem cell human CVCL_A9W7 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.372-2A>G; ClinVar=VCV000001236; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819661 CVCL_A9VU GSC#441 cancer cell line human CVCL_A9VU From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819662 CVCL_A9W6 SFC6-iPS#4.7 induced pluripotent stem cell human CVCL_A9W6 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.633+1G>A; dbSNP=rs528466699; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=26411903); Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; p.Leu473Pro (c.1418T>C) (p.Leu445Pro, c.1334T>C); Zygosity=Heterozygous (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819663 CVCL_A9VX GSC#447P cancer cell line human CVCL_A9VX From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819664 CVCL_A9W9 nr-HaCat spontaneously immortalized cell line human CVCL_A9W9 CL:0000010 Population: Caucasian; Derived from sampling site: Back; skin; epidermis Cell type=Keratinocyte.. Male Characteristics: Unable to undergo UVR-induced apoptosis 40819665 CVCL_A9VW GSC#445 cancer cell line human CVCL_A9VW From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819666 CVCL_A9W8 SFC7-iPS#4.9 induced pluripotent stem cell human CVCL_A9W8 From: University of Barcelona; Barcelona; Spain CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Simple; c.372-2A>G; ClinVar=VCV000001236; Zygosity=Homozygous; Note=Splice acceptor mutation (PubMed=26411903) Population: Caucasian; Spanish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819667 CVCL_A9VZ GSC#449 cancer cell line human CVCL_A9VZ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819668 CVCL_A9VY GSC#448 cancer cell line human CVCL_A9VY From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819669 CVCL_A9VL GSC#420 cancer cell line human CVCL_A9VL From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819670 CVCL_A9VK GSC#416 cancer cell line human CVCL_A9VK From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819671 CVCL_A9VN GSC#426 cancer cell line human CVCL_A9VN From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819672 CVCL_A9VM GSC#421 cancer cell line human CVCL_A9VM From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819673 CVCL_A9VP GSC#429 cancer cell line human CVCL_A9VP From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819674 CVCL_A9W1 GSC#452C cancer cell line human CVCL_A9W1 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819675 CVCL_A9W0 GSC#450 cancer cell line human CVCL_A9W0 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819676 CVCL_A9VR GSC#432 cancer cell line human CVCL_A9VR From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Male Group: Cancer stem cell line 40819677 CVCL_A9W3 GSC#454 cancer cell line human CVCL_A9W3 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819678 CVCL_A9VQ GSC#431 cancer cell line human CVCL_A9VQ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819679 CVCL_A9W2 GSC#452P cancer cell line human CVCL_A9W2 From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Female Group: Cancer stem cell line 40819680 CVCL_A9VD GSC#401 cancer cell line human CVCL_A9VD From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; occipital lobe. Male Group: Cancer stem cell line 40819681 CVCL_A9VC GSC#399 cancer cell line human CVCL_A9VC From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819682 CVCL_A9VF GSC#406 cancer cell line human CVCL_A9VF From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819683 CVCL_A9VE GSC#403 cancer cell line human CVCL_A9VE From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819684 CVCL_A9VH GSC#411 cancer cell line human CVCL_A9VH From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819685 CVCL_A9VG GSC#407 cancer cell line human CVCL_A9VG From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Female Group: Cancer stem cell line 40819686 CVCL_A9VJ GSC#415 cancer cell line human CVCL_A9VJ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819687 CVCL_A9VI GSC#413 cancer cell line human CVCL_A9VI From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819688 CVCL_A9UZ GSC#361 cancer cell line human CVCL_A9UZ From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; frontal lobe. Male Group: Cancer stem cell line 40819689 CVCL_A9VB GSC#397 cancer cell line human CVCL_A9VB From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; parietal lobe. Female Group: Cancer stem cell line 40819690 CVCL_A9VA GSC#395 cancer cell line human CVCL_A9VA From: Institute of Neurosurgery, Catholic University School of Medicine; Rome; Italy CL:0000010 Derived from sampling site: Brain; temporal lobe. Male Group: Cancer stem cell line 40819691 CVCL_A9WU CTSC#432 cancer cell line human CVCL_A9WU From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Arg486His (c.1457G>A); ClinVar=VCV000809472; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Pro300Leu (c.899C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Leu (c.814G>T); ClinVar=VCV000012358; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; distal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819692 CVCL_A9X6 MOC-L4 cancer cell line house mouse CVCL_A9X6 CL:0000010 Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6 K14-EGFP-miR-211 transgenic. Unspecified Characteristics: Compared to other MOC-L cell lines, MOC-L4 is the least aggressive, has the lowest proliferation rate, invasion ability and colony formation ability It has high migration competence and the highest tolerance to CDDP treatment (PubMed=30922255). Doubling time: 29.3 hours (PubMed=30922255) 40819693 CVCL_A9WT CTSC#430 cancer cell line human CVCL_A9WT From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly97Arg (c.289G>A); ClinVar=VCV001697514; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1465Trpfs*3 (c.4385_4386AG[4]); ClinVar=VCV000000811; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.His104Tyr (c.310C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg179Cys (c.535C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Gly248Ser (c.742G>A); ClinVar=VCV000523491; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu563Lys (c.1687G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu57Trpfs*42 (c.166delT); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys267Argfs*9 (c.800delA) (p.Leu265fs, c.795delA); ClinVar=VCV000092828; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Thr34Lys (c.101C>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.His287Gln (c.861T>G); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819694 CVCL_A9X5 MOC-L3 cancer cell line house mouse CVCL_A9X5 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Gly241Glu (c.722G>A); Zygosity=Unspecified (PubMed=30922255); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6 K14-EGFP-miR-211 transgenic. Unspecified Doubling time: 20.3 hours (PubMed=30922255) 40819695 CVCL_A9WW CTSC#446 cancer cell line human CVCL_A9WW From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 172; ACVR1B; Simple; p.Met361Leu (c.1081A>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 172; ACVR1B; Simple; p.Glu482Gly (c.1445A>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Asp412Gly (c.1235A>G); ClinVar=VCV001498964; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Arg717His (c.2150G>A); dbSNP=rs753246841; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Ser142Arg (c.424A>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Ser678Ter (c.2033C>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp105Val (c.314A>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Cys186Tyr (c.557G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.His93Arg (c.278A>G); ClinVar=VCV000007848; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu182Ser (c.545T>C); ClinVar=VCV000187827; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Asn34Asp (c.100A>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Leu254Phe (c.760C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Pro108His (c.323C>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Gln263Arg (c.788A>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ala189Profs*58 (c.565delG); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Phe270Cys (c.809T>G); ClinVar=VCV000376597; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819696 CVCL_A9X8 IA-1g1 spontaneously immortalized cell line Norway rat CVCL_A9X8 CL:0000010 Derived from sampling site: Brain Cell type=Astrocyte.. Unspecified Characteristics: Type-1 astrocyte 40819697 CVCL_A9X7 3E8 [Mouse hybridoma against EBV BHRF1] hybridoma house mouse CVCL_A9X7 CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P03182; Epstein-Barr virus apoptosis regulator BHRF1. 40819698 CVCL_A9WV CTSC#438 cancer cell line human CVCL_A9WV From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Leu443Ser (c.1328T>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Arg182Ter (c.544C>T); ClinVar=VCV001187876; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Thr243Profs*10 (c.723delC); ClinVar=VCV000817191; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819699 CVCL_A9WY CTSC#510 cancer cell line human CVCL_A9WY From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1752Ter (c.5254C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ile (c.122C>T); ClinVar=VCV000017587; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Asn107Metfs*3 (c.320delA) (c.316delA); ClinVar=VCV001728912; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg361His (c.1082G>A); ClinVar=VCV000024832; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Asp91Val (c.272A>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Met411Thr (c.1232T>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu388Lys (c.1162G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser392Ter (c.1175C>A); dbSNP=rs769664911; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ter394Aspext*28 (c.1180_1182insGAC); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819700 CVCL_A9WX CTSC#482 cancer cell line human CVCL_A9WX From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asn436Ilefs*18 (c.1307delA); ClinVar=VCV000487058; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1465Trpfs*3 (c.4385_4386AG[4]); ClinVar=VCV000000811; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Asp1636Metfs*14 (c.4906dupG); ClinVar=VCV000469982; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465His (c.1394G>A); ClinVar=VCV000376415; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro3Thr (c.7C>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Gln368Lys (c.1102C>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Leu382Gln (c.1145T>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu201Ter (c.602T>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg213Gln (c.638G>A); ClinVar=VCV000135359; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819701 CVCL_A9X9 ESC 9 embryonic stem cell house mouse CVCL_A9X9 From: Agricultural Technology Research Institute (ATRI); Hsinchu; Taiwan CL:0000010 Breed/subspecies: BALB/c. Male 40819702 CVCL_A9WZ CTSC#553 cancer cell line human CVCL_A9WZ From: Sant Andrea Hospital; Rome; Italy CL:0000010 Derived from sampling site: Colon; proximal. Female Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819703 CVCL_A9WM CTSC#383 cancer cell line human CVCL_A9WM From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg564Ter (c.1690C>T); ClinVar=VCV000000808; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala612Hisfs*18 (c.1834delG); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Trp690Arg (c.2068T>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Asp54Tyr (c.160G>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Glu326Lys (c.976G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; distal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819704 CVCL_A9WL CTSC#85 cancer cell line human CVCL_A9WL From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg283Ter (c.847C>T); ClinVar=VCV000184999; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ser1415Argfs*4 (c.4245delT); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Ala146Thr (c.436G>A); ClinVar=VCV000197243; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val54Ala (c.161T>C); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg361Cys (c.1081C>T); ClinVar=VCV000008543; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819705 CVCL_A9X0 MTCQ1 cancer cell line house mouse CVCL_A9X0 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Val214Leu (c.640G>T); Zygosity=Unspecified (PubMed=31345390); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Ile329_Asp390delins13; Zygosity=Unspecified (PubMed=31345390) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6. Unspecified 40819706 CVCL_A9WN CTSC#389 cancer cell line human CVCL_A9WN From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Ala626Val (c.1877C>T); ClinVar=VCV001698991; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln366Ter (c.1096C>T); ClinVar=VCV000405490; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg497His (c.1490G>A); ClinVar=VCV000959550; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Gly461Cys (c.1381G>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Male Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819707 CVCL_A9WQ CTSC#398 cancer cell line human CVCL_A9WQ From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met314Ile (c.942G>T); ClinVar=VCV000517186; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu991Ter (c.2971G>T); ClinVar=VCV000186494; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>C); ClinVar=VCV000177881; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Lys (c.1571G>A); ClinVar=VCV000132954; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg361Cys (c.1081C>T); ClinVar=VCV000008543; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; distal. Female Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819708 CVCL_A9X2 MTCQ1-GFP cancer cell line house mouse CVCL_A9X2 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Val214Leu (c.640G>T); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Ile329_Asp390delins13; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6. Unspecified 40819709 CVCL_A9WP CTSC#393 cancer cell line human CVCL_A9WP From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala440Thr (c.1318G>A); ClinVar=VCV000418008; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala759Asnfs*2 (c.2273_2285delAAGCCCTAGAAGC); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Val325Ile (c.973G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Glu110Lys (c.328G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Gln277Ter (c.829C>T); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu970Val (c.2909A>T); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819710 CVCL_A9X1 MTCQ2 cancer cell line house mouse CVCL_A9X1 CL:0000010 Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6. Unspecified 40819711 CVCL_A9WS CTSC#417 cancer cell line human CVCL_A9WS From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Met438Thr (c.1313T>C); ClinVar=VCV000630112; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg876Ter (c.2626C>T); ClinVar=VCV000216014; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg524Lys (c.1571G>A); ClinVar=VCV000132954; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg282Trp (c.844C>T); ClinVar=VCV000012364; Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-low) (PubMed=33128777) Group: Cancer stem cell line 40819712 CVCL_A9X4 MOC-L2 cancer cell line house mouse CVCL_A9X4 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Ala156Pro (c.466G>C); Zygosity=Unspecified (PubMed=30922255); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6 K14-EGFP-miR-211 transgenic. Unspecified Characteristics: Tumorigenic in syngeneic mice Doubling time: 20.4 hours (PubMed=30922255) 40819713 CVCL_A9WR CTSC#416 cancer cell line human CVCL_A9WR From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 6768; SMAD2; Simple; p.Arg462His (c.1385G>A); ClinVar=VCV001308032; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11204; SOX9; Simple; p.Ala481Val (c.1442C>T); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Male Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819714 CVCL_A9X3 MOC-L1 cancer cell line house mouse CVCL_A9X3 CL:0000010 Sequence variation: Mutation; MGI; MGI:98834; Trp53; Simple; p.Thr122Asn (c.365_366CG>AT); Zygosity=Unspecified (PubMed=30922255); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: 4-nitroquinoline N-oxide (4NQO)(ChEBI; CHEBI:16907); Derived from sampling site: Oral cavity; tongue; Breed/subspecies: C57BL/6 K14-EGFP-miR-211 transgenic. Unspecified Characteristics: Tumorigenic in syngeneic mice and also possesses a competence for neck dissemination Doubling time: 24.7 hours (PubMed=30922255) 40819715 CVCL_A9WE IBMS-iPSC-052-01 induced pluripotent stem cell human CVCL_A9WE From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Male 40819716 CVCL_A9WD IBMS-iPSC-051-05 induced pluripotent stem cell human CVCL_A9WD From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819717 CVCL_A9WG IBMS-iPSC-053-05 induced pluripotent stem cell human CVCL_A9WG From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819718 CVCL_A9WF IBMS-iPSC-053-02 induced pluripotent stem cell human CVCL_A9WF From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819719 CVCL_A9WI CTSC#1.2 cancer cell line human CVCL_A9WI From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr182Ilefs*2 (c.543_546delACAA); ClinVar=VCV000470005; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg259Trp (c.775C>T); ClinVar=VCV000411556; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1284Ter (c.3850G>T); ClinVar=VCV000946474; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Pro606Ala (c.1816C>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg361Cys (c.1081C>T); ClinVar=VCV000008543; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Leu200Profs*10 (c.593_594insC); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; distal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819720 CVCL_A9WH CTSC#1.1 cancer cell line human CVCL_A9WH From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr182Ilefs*2 (c.543_546delACAA); ClinVar=VCV000470005; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg259Trp (c.775C>T); ClinVar=VCV000411556; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1284Ter (c.3850G>T); ClinVar=VCV000946474; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu542Lys (c.1624G>A); ClinVar=VCV000031944; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Arg361Cys (c.1081C>T); ClinVar=VCV000008543; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Leu200Profs*10 (c.593_594insC); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; distal. Male Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819721 CVCL_A9WK CTSC#CRO cancer cell line human CVCL_A9WK From: Sant Andrea Hospital; Rome; Italy CL:0000010 Derived from sampling site: Colon; proximal. Female Microsatellite instability: Stable (MSS) (PubMed=33128777) Group: Cancer stem cell line 40819722 CVCL_A9WJ CTSC#18 cancer cell line human CVCL_A9WJ From: Sant Andrea Hospital; Rome; Italy CL:0000010 Sequence variation: Mutation; HGNC; 172; ACVR1B; Simple; p.Trp501Ter (c.1503G>A); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala199Val (c.596C>T); ClinVar=VCV000246301; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gly2250Asp (c.6749G>A); ClinVar=VCV001502413; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Lys647Glu (c.1939A>G); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Asn323Metfs*21 (c.968delA); ClinVar=VCV000653412; Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11641; TCF7L2; Simple; p.Ser569Profs*33 (c.1700delC); Zygosity=Unspecified (PubMed=33128777); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp148Ter (c.441dupT); Zygosity=Unspecified (PubMed=33128777) Derived from sampling site: Colon; proximal. Female Microsatellite instability: Instable (MSI-high) (PubMed=33128777) Group: Cancer stem cell line 40819723 CVCL_A9WA IBMS-iPSC-050-04 induced pluripotent stem cell human CVCL_A9WA From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819724 CVCL_A9WC IBMS-iPSC-051-02 induced pluripotent stem cell human CVCL_A9WC From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819725 CVCL_A9WB IBMS-iPSC-050-05 induced pluripotent stem cell human CVCL_A9WB From: Institute of Biomedical Sciences, Academia Sinica; Taipei; Taiwan CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 40819726 CVCL_A9D9 LRB finite cell line human CVCL_A9D9 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 40819727 CVCL_A9D2 CM16 finite cell line human CVCL_A9D2 CL:0000010 Donor information: Established from a patient suffering from a breast adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819728 CVCL_A9D1 CM11 finite cell line human CVCL_A9D1 CL:0000010 Donor information: Established from a patient suffering from a breast polymorphic adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819729 CVCL_A9D4 CM3 finite cell line human CVCL_A9D4 CL:0000010 Donor information: Established from a patient suffering from a breast intracanacular adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819730 CVCL_A9D3 CM19 finite cell line human CVCL_A9D3 CL:0000010 Donor information: Established from a patient suffering from a breast adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819731 CVCL_A9D6 CM8 finite cell line human CVCL_A9D6 CL:0000010 Donor information: Established from a patient suffering from a breast atypic adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819732 CVCL_A9D5 CM5 finite cell line human CVCL_A9D5 CL:0000010 Donor information: Established from a patient suffering from a breast polymorphic adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819733 CVCL_A9D8 LBB finite cell line human CVCL_A9D8 CL:0000010 Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 40819734 CVCL_A9D7 CMV finite cell line human CVCL_A9D7 CL:0000010 Donor information: Established from a patient suffering from a breast carcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819735 CVCL_A9D0 CM10 finite cell line human CVCL_A9D0 CL:0000010 Donor information: Established from a patient suffering from a breast atypic adenocarcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819736 CVCL_A9E3 ICIG-7-SV40 transformed cell line human CVCL_A9E3 CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 40819737 CVCL_A9E2 ICIG-7 finite cell line human CVCL_A9E2 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Male 40819738 CVCL_A9E5 ICIG-9 finite cell line human CVCL_A9E5 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 40819739 CVCL_A9E4 ICIG-8 finite cell line human CVCL_A9E4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 40819740 CVCL_A9E7 HP PER.C6 transformed cell line human CVCL_A9E7 CL:0000010 Transformant: Adenovirus 5 [E1](NCBI-Taxonomy; 28285); Derived from sampling site: Fetal eye; retina Cell type=Retinoblast.. Unspecified Characteristics: Has a greater capacity for adenovirus production than the parent cell line and is better adapted to suspension culture growth (PubMed=18052336) Group: Vaccine production cell line 40819741 CVCL_A9E6 PT12 cancer cell line human CVCL_A9E6 CL:0000010 Derived from sampling site: Breast. Female Characteristics: ER/PR-positive and ERBB2-negative Established from a mouse xenograft. 40819742 CVCL_A9E9 MCI7885 finite cell line human CVCL_A9E9 CL:0000010 Population: Japanese; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 40819743 CVCL_A9E8 TRI8-iPS-C8 induced pluripotent stem cell human CVCL_A9E8 CL:0000010 Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819744 CVCL_A9E1 NMS-1 finite cell line human CVCL_A9E1 CL:0000010 Donor information: Established from a patient suffering from a mammary gland ptosis; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819745 CVCL_A9E0 RDF finite cell line human CVCL_A9E0 CL:0000010 Donor information: Established from a patient suffering from renal failure; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819746 CVCL_A9B8 RLD-23(8) transformed cell line Norway rat CVCL_A9B8 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819747 CVCL_A9B7 RLD-20(12) transformed cell line Norway rat CVCL_A9B7 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819748 CVCL_A9B9 RLM-22(12) transformed cell line Norway rat CVCL_A9B9 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819749 CVCL_A9B0 RLD-17 transformed cell line Norway rat CVCL_A9B0 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819750 CVCL_A9B2 RLM-39(12) transformed cell line Norway rat CVCL_A9B2 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819751 CVCL_A9B1 RLM-39(4) transformed cell line Norway rat CVCL_A9B1 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819752 CVCL_A9B4 RLM-22(4) transformed cell line Norway rat CVCL_A9B4 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819753 CVCL_A9B3 RLM-39(24) transformed cell line Norway rat CVCL_A9B3 CL:0000010 Transformant: 3'-methyl-4-dimethylaminoazobenzene (3'-Me-DAB)(ChEBI; CHEBI:76329); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819754 CVCL_A9B6 RLD-20(8) transformed cell line Norway rat CVCL_A9B6 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819755 CVCL_A9B5 RLD-22 transformed cell line Norway rat CVCL_A9B5 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819756 CVCL_A9C9 BMS-7 finite cell line human CVCL_A9C9 CL:0000010 Donor information: Established from a patient suffering from a mammary gland cystic papillary adenoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819757 CVCL_A9C8 BMS-6 finite cell line human CVCL_A9C8 CL:0000010 Donor information: Established from a patient suffering from a mammary gland diffuse adenosis; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819758 CVCL_A9C1 RLD-36(2) spontaneously immortalized cell line Norway rat CVCL_A9C1 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819759 CVCL_A9C0 RLD-35 spontaneously immortalized cell line Norway rat CVCL_A9C0 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Unspecified 40819760 CVCL_A9C3 964 Lung finite cell line human CVCL_A9C3 CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Unspecified 40819761 CVCL_A9C2 dRLh-82 cancer cell line Norway rat CVCL_A9C2 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: Donryu. Female 40819762 CVCL_A9C5 BMS-2 finite cell line human CVCL_A9C5 CL:0000010 Donor information: Established from a patient suffering from a mammary gland nodular sclerocystic dystrophy; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819763 CVCL_A9C4 964 Skin finite cell line human CVCL_A9C4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 40819764 CVCL_A9C7 BMS-5 finite cell line human CVCL_A9C7 CL:0000010 Donor information: Established from a patient operated for a benign breast lesion who later developed breast carcinoma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819765 CVCL_A9C6 BMS-4 finite cell line human CVCL_A9C6 CL:0000010 Donor information: Established from a patient suffering from a mammary gland adenofibroma; Derived from sampling site: Breast; skin Cell type=Fibroblast.. Female 40819766 CVCL_A9A7 Hsa/TR/OPN1 cancer cell line human CVCL_A9A7 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11255; SPP1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from metastatic site: Thoracic lymph duct. Unspecified 40819767 CVCL_A9A6 Hsa/TR/mock cancer cell line human CVCL_A9A6 CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from metastatic site: Thoracic lymph duct. Unspecified Characteristics: Control cell line for Hsa/TR/OPN1 (Cellosaurus=CVCL_A9A7) and Hsa/TR/OPN2 (Cellosaurus=CVCL_A9A8) 40819768 CVCL_A9A9 RLD-14 transformed cell line Norway rat CVCL_A9A9 CL:0000010 Transformant: 4-(dimethylamino)azobenzene (DAB(ChEBI; CHEBI:17903); Derived from sampling site: Liver; Breed/subspecies: JAR. Unspecified 40819769 CVCL_A9A8 Hsa/TR/OPN2 cancer cell line human CVCL_A9A8 CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11255; SPP1; Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; P33967; B.cereus Bsr; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Japanese; Derived from metastatic site: Thoracic lymph duct. Unspecified 40819770 CVCL_A9A1 TMC16 transformed cell line house mouse CVCL_A9A1 CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow Cell type=Macrophage.; Breed/subspecies: C57BL/6 SV40-tsA58 transgenic. Unspecified 40819771 CVCL_A9A0 STBCi026-A-3 induced pluripotent stem cell human CVCL_A9A0 From: StemBANCC; Oxford; United Kingdom CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_edited; p.Arg1441Cys (c.4321C>T); ClinVar=VCV000001938; Zygosity=Heterozygous; Note=By CRISPR/Cas9 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819772 CVCL_A9A3 JR023 finite cell line human CVCL_A9A3 CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis Male 40819773 CVCL_A9A2 CMG14-12 spontaneously immortalized cell line house mouse CVCL_A9A2 CL:0000010 Transfected with: MGI; MGI:1339753; Csf1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Selected for resistance to: ChEBI; CHEBI:472552; 5-bromo-2'-deoxyuridine (Bromodeoxyuridine; Derived from sampling site: Connective tissue Cell type=Fibroblast.; Breed/subspecies: C3H/An. Male Characteristics: Expression of the Csf1 gene is driven by the chicken beta-actin promoter and the human cytomegalovirus enhancer (PubMed=10934646) Doubling time: 20 hours (RCB=RCB5036) 40819774 CVCL_A9A5 BCK4 cancer cell line human CVCL_A9A5 CL:0000010 Miscellaneous: STR profile from personal communication of Xavier J.M Derived from metastatic site: Pleural effusion. Omics: Transcriptome analysis by microarray Female Characteristics: ER-positive, PR-positive and ERBB2-negative Has mucinous features. Established from a mouse xenograft. Doubling time: ~120 hours (PubMed=23247610) 40819775 CVCL_A9A4 UOXFi004-C induced pluripotent stem cell human CVCL_A9A4 From: University of Oxford; Oxford; United Kingdom CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Omics: SNP array analysis; Omics: Transcriptome analysis by microarray Male 40819776 CVCL_A9M1 Wolf-2012-13-FA induced pluripotent stem cell human CVCL_A9M1 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819777 CVCL_A9M0 Wolf-2010-9-MO induced pluripotent stem cell human CVCL_A9M0 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819778 CVCL_A9L9 Wolf-2010-5-MO induced pluripotent stem cell human CVCL_A9L9 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819779 CVCL_A9L2 1024-4F-A-DiPS induced pluripotent stem cell human CVCL_A9L2 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819780 CVCL_A9L1 1021-4F-B DiPS induced pluripotent stem cell human CVCL_A9L1 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819781 CVCL_A9L4 1026-3F-C MODY iPS induced pluripotent stem cell human CVCL_A9L4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819782 CVCL_A9L3 1026-3F-A MODY iPS induced pluripotent stem cell human CVCL_A9L3 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819783 CVCL_A9L6 1028-3F-A-DiPS induced pluripotent stem cell human CVCL_A9L6 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819784 CVCL_A9L5 1027-3F-C-DiPS induced pluripotent stem cell human CVCL_A9L5 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819785 CVCL_A9L8 Wolf-2010-5 induced pluripotent stem cell human CVCL_A9L8 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.His313Tyr (c.937C>T); ClinVar=VCV000290817; Zygosity=Heterozygous (PubMed=25422446) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819786 CVCL_A9L7 Wolf-2010-11 induced pluripotent stem cell human CVCL_A9L7 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Ala126Thr (c.376G>A); ClinVar=VCV000372583; Zygosity=Heterozygous (PubMed=25422446); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp613Ter (c.1839G>A); ClinVar=VCV000349320; Zygosity=Heterozygous (PubMed=25422446) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819787 CVCL_A9N0 GIST-T1/816 cancer cell line human CVCL_A9N0 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=25239608); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Asp820Glu (c.2460T>A) (D816E); ClinVar=VCV000375929; Zygosity=Heterozygous (PubMed=25239608) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Omics: H3K27ac ChIP-seq epigenome analysis Female 40819788 CVCL_A9N2 GIST882IMR cancer cell line human CVCL_A9N2 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys642Glu (c.1924A>G); ClinVar=VCV000013866; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec Characteristics: Has lost KIT protein expression (PubMed=30488756) 40819789 CVCL_A9N1 GIST430B cancer cell line human CVCL_A9N1 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Leu576del (c.1678_1728del); ClinVar=VCV000523644; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val654Ala (c.1961T>C); ClinVar=VCV000375921; Zygosity=Heterozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec Omics: H3K27ac ChIP-seq epigenome analysis. Characteristics: Has lost KIT protein expression (PubMed=30488756) 40819790 CVCL_A9M3 1019SeVF induced pluripotent stem cell human CVCL_A9M3 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819791 CVCL_A9M2 1031SeVA induced pluripotent stem cell human CVCL_A9M2 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819792 CVCL_A9M5 1013-4FA induced pluripotent stem cell human CVCL_A9M5 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819793 CVCL_A9M4 1041SeVF induced pluripotent stem cell human CVCL_A9M4 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819794 CVCL_A9M7 IPEC-J2 rMDR1a spontaneously immortalized cell line pig CVCL_A9M7 CL:0000010 Transfected with: RGD; 619951; Abcb1a; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Small intestine; jejunum Cell type=Enterocyte.. Unspecified Characteristics: Can be used to screen drug compounds for interactions with rat efflux pump P-glycoprotein (P-gp) 40819795 CVCL_A9M6 1023SevF induced pluripotent stem cell human CVCL_A9M6 CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819796 CVCL_A9M9 GIST-T1/670 cancer cell line human CVCL_A9M9 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Val560_Tyr578del (c.1679_1735del); Zygosity=Heterozygous (PubMed=25239608); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Thr670Ile (c.2009C>T); ClinVar=VCV000376058; Zygosity=Heterozygous (PubMed=25239608) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:45783; Imatinib (Gleevec; Derived from metastatic site: Pleural effusion. Female 40819797 CVCL_A9M8 GIST226 cancer cell line human CVCL_A9M8 CL:0000010 Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Lys550_Trp557del (c.1648_1671del); Zygosity=Heterozygous (PubMed=29866822); Sequence variation: Mutation; HGNC; 6342; KIT; Simple; p.Tyr823Asp (c.2467T>G); ClinVar=VCV000376101; Zygosity=Heterozygous (PubMed=29866822) Omics: H3K27ac ChIP-seq epigenome analysis; Omics: Transcriptome analysis by RNAseq. 40819798 CVCL_A9J8 iEc-ESC telomerase immortalized cell line human CVCL_A9J8 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Derived from sampling site: Endometrium Cell type=Endometrial stromal cell.. Female 40819799 CVCL_A9J7 MKN45/DR cancer cell line human CVCL_A9J7 CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU); Derived from metastatic site: Liver. Female 40819800 CVCL_A9J9 F3-B2 hybridoma CVCL_A9J9 CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; P33706; Dog CD8A. 40819801 CVCL_A9J0 IMR-32/CMV-Luc cancer cell line human CVCL_A9J0 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Caucasian; Derived from metastatic site: Abdomen. Discontinued: JCRB; NIHS1296; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 40819802 CVCL_A9J2 PK565C CMV-Luc#7 cancer cell line human CVCL_A9J2 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Discontinued: JCRB; NIHS1297; true. Unspecified Characteristics: Expression of luciferase is under the control of the CMV promoter 40819803 CVCL_A9J1 PK565C cancer cell line human CVCL_A9J1 CL:0000010 Unspecified 40819804 CVCL_A9J4 60As6Luc cancer cell line human CVCL_A9J4 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS1336; true Male 40819805 CVCL_A9J3 PK565C CMV-Luc/EF-1a/RFP-Pur#1 cancer cell line human CVCL_A9J3 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase; Transfected with: UniProtKB; Q9U6Y8; RFP; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Discontinued: JCRB; NIHS1298; true. Unspecified Characteristics: Expression of luciferase is under the control of the CMV promoter 40819806 CVCL_A9J6 KCMC-2060 finite cell line human CVCL_A9J6 CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Simple; p.Arg239Cys (c.729C>T); ClinVar=VCV000016167; Zygosity=Unspecified (JCRB) Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: JCRB; NIHS1042; true Female 40819807 CVCL_A9J5 Neuro-2a/CMV-Luc cancer cell line house mouse CVCL_A9J5 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Breed/subspecies: A/J. Discontinued: JCRB; NIHS1295; true Male Characteristics: Expression of luciferase is under the control of the CMV promoter 40819808 CVCL_A9L0 WS13corr induced pluripotent stem cell human CVCL_A9L0 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple_corrected; p.Leu200Argfs*87 (c.599delT); ClinVar=VCV002203514; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Glu752Ter (c.2254G>T); ClinVar=VCV000215399; Zygosity=Heterozygous (PubMed=25422446; PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819809 CVCL_A9K9 WS13unedit induced pluripotent stem cell human CVCL_A9K9 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Leu200Argfs*87 (c.599delT); ClinVar=VCV002203514; Zygosity=Heterozygous (PubMed=25422446; PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Glu752Ter (c.2254G>T); ClinVar=VCV000215399; Zygosity=Heterozygous (PubMed=25422446; PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819810 CVCL_A9K8 WS9unedit induced pluripotent stem cell human CVCL_A9K8 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Ala126Thr (c.376G>A); ClinVar=VCV000372583; Zygosity=Heterozygous (PubMed=25422446; PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp613Ter (c.1839G>A); ClinVar=VCV000349320; Zygosity=Heterozygous (PubMed=25422446; PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819811 CVCL_A9K1 58As1mLuc cancer cell line human CVCL_A9K1 CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase Population: Japanese; Derived from metastatic site: Ascites. Discontinued: JCRB; NIHS1333; true Male 40819812 CVCL_A9K0 T-MNU-1 cancer cell line Norway rat CVCL_A9K0 CL:0000010 Transformant: N-methyl-N-nitrosourea (NMU)(ChEBI; CHEBI:50102); Derived from sampling site: Urinary bladder; Breed/subspecies: Fischer 344. Female 40819813 CVCL_A9K3 AN1.1 induced pluripotent stem cell human CVCL_A9K3 CL:0000010 Miscellaneous: Cell line information from personal communication of Maxwell K.G Derived from sampling site: Kidney; epithelium. Female 40819814 CVCL_A9K2 HS27-iPS induced pluripotent stem cell human CVCL_A9K2 CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 40819815 CVCL_A9K5 WS4unedit induced pluripotent stem cell human CVCL_A9K5 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp371Ter (c.1112G>A); ClinVar=VCV001709531; Zygosity=Heterozygous (PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Arg629Trp (c.1885C>T); ClinVar=VCV001071979; Zygosity=Heterozygous (PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819816 CVCL_A9K4 T2D001A induced pluripotent stem cell human CVCL_A9K4 CL:0000010 Miscellaneous: Cell line information from personal communication of Maxwell K.G Derived from sampling site: Pancreas; islets of Langerhans. Male 40819817 CVCL_A9K7 WS4corr-B induced pluripotent stem cell human CVCL_A9K7 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp371Ter (c.1112G>A); ClinVar=VCV001709531; Zygosity=Heterozygous (PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple_corrected; p.Arg629Trp (c.1885C>T); ClinVar=VCV001071979; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819818 CVCL_A9K6 WS4corr induced pluripotent stem cell human CVCL_A9K6 CL:0000010 Sequence variation: Mutation; HGNC; 12762; WFS1; Simple; p.Trp371Ter (c.1112G>A); ClinVar=VCV001709531; Zygosity=Heterozygous (PubMed=32321868); Sequence variation: Mutation; HGNC; 12762; WFS1; Simple_corrected; p.Arg629Trp (c.1885C>T); ClinVar=VCV001071979; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32321868) Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819819 CVCL_A9H6 H191 [Mouse hybridoma against D.discoideum p80] hybridoma house mouse CVCL_A9H6 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q7YXD4; Dictyostelium discoideum p80. 40819820 CVCL_A9H5 H9 [Mouse hybridoma against D.discoideum 23 kda antigen] hybridoma house mouse CVCL_A9H5 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum 23 kDa antigen at plasma membrane and intracellular compartments. 40819821 CVCL_A9H8 RCMGi003-A induced pluripotent stem cell human CVCL_A9H8 From: Research Centre for Medical Genetics; Moscow; Russia. CL:0000010 40819822 CVCL_A9H7 SaB-1 spontaneously immortalized cell line CVCL_A9H7 CL:0000010 Derived from sampling site: Brain. Unspecified Characteristics: Neural stem cells, have a neuron-like morphology and show a rapid growth in culture (PubMed=32771610); Virology: Susceptible to infection by nervous necrosis virus (NNV), spring viremia carp virus (SVCV), infectious pancreatic necrosis virus (IPNV) and viral hemorrhagic septicemia virus (VHSV) (PubMed=32771610) Doubling time: 35.5 hours (PubMed=32771610) Group: Fish cell line 40819823 CVCL_A9H9 RCMGi004-A induced pluripotent stem cell human CVCL_A9H9 From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=33607467); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (PubMed=33607467) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819824 CVCL_A9H0 194-62-7 hybridoma house mouse CVCL_A9H0 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P27133; Dictyostelium discoideum corA. 40819825 CVCL_A9H2 221-42-1 hybridoma house mouse CVCL_A9H2 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q86IA3; Dictyostelium discoideum pdi1. 40819826 CVCL_A9H1 21-96-3 hybridoma house mouse CVCL_A9H1 CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P08799; Dictyostelium discoideum mhcA. 40819827 CVCL_A9H4 HAP1 TRAP1 (-) 1 cancer cell line human CVCL_A9H4 CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 16264; TRAP1; Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Gly (c.643A>G); ClinVar=VCV000265337; Zygosity=Hemizygous (from parent cell line) Derived from sampling site: Bone marrow. Male Group: Haploid karyotype cell line 40819828 CVCL_A9H3 HeLap121G cancer cell line human CVCL_A9H3 CL:0000010 Transfected with: HGNC; 19702; POM121; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with POM121 C-terminally tagged with GFP 40819829 CVCL_A9I7 OVNIS 5H spontaneously immortalized cell line CVCL_A9I7 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 40819830 CVCL_A9I6 HeLa POM121-mCherry cancer cell line human CVCL_A9I6 CL:0000010 Transfected with: HGNC; 19702; POM121; Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Tingey M Population: African American; Transformant: Human papillomavirus type 18 (HPV18)(NCBI-Taxonomy; 333761); Derived from sampling site: Uterus; cervix. Female Characteristics: Transfected with POM121 C-terminally tagged with mCherry 40819831 CVCL_A9I9 OVNIS 6H clone 2 spontaneously immortalized cell line CVCL_A9I9 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 40819832 CVCL_A9I8 OVNIS 6H clone 1 spontaneously immortalized cell line CVCL_A9I8 CL:0000010 Derived from sampling site: Thyroid gland. Unspecified 40819833 CVCL_A9I1 JUCTCi011-B induced pluripotent stem cell human CVCL_A9I1 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819834 CVCL_A9I0 JUCTCi011-A induced pluripotent stem cell human CVCL_A9I0 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819835 CVCL_A9I3 JUCTCi002-A induced pluripotent stem cell human CVCL_A9I3 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (PubMed=32769066) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819836 CVCL_A9I2 JUCTCi011-C induced pluripotent stem cell human CVCL_A9I2 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 40819837 CVCL_A9I5 JUCTCi002-C induced pluripotent stem cell human CVCL_A9I5 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (from autologous cell line JUCTCi002-A) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819838 CVCL_A9I4 JUCTCi002-B induced pluripotent stem cell human CVCL_A9I4 From: Cell Therapy Center, University of Jordan; Amman; Jordan CL:0000010 Sequence variation: Mutation; HGNC; 15984; APTX; Simple; p.Trp279Ter (c.837G>A); ClinVar=VCV000004431; Zygosity=Homozygous (from autologous cell line JUCTCi002-A) Population: Jordanian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 40819839 CVCL_A9F4 IRAN1010 fibroblast finite cell line human CVCL_A9F4 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Ala57Pro (c.169G>C); ClinVar=VCV000014506; Zygosity=Heterozygous (PubMed=12927431) Population: Iranian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819840 CVCL_A9F3 ATLAN1010 LCL transformed cell line human CVCL_A9F3 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Leu (c.398G>T); ClinVar=VCV000014488; Zygosity=Heterozygous (PubMed=12927431) Population: African American; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819841 CVCL_A9F6 NORWAY1010 fibroblast finite cell line human CVCL_A9F6 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Leu140Arg (c.419T>G); ClinVar=VCV000014507; Zygosity=Heterozygous (PubMed=12927431; PubMed=23847654) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 40819842 CVCL_A9F5 IRAN1010 LCL transformed cell line human CVCL_A9F5 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Ala57Pro (c.169G>C); ClinVar=VCV000014506; Zygosity=Heterozygous (PubMed=12927431) Population: Iranian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819843 CVCL_A9F8 NORWAY1010 LCL transformed cell line human CVCL_A9F8 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Leu140Arg (c.419T>G); ClinVar=VCV000014507; Zygosity=Heterozygous (PubMed=12927431) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 40819844 CVCL_A9F7 NORWAY1010 fibroblast hTERT finite cell line human CVCL_A9F7 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Leu140Arg (c.419T>G); ClinVar=VCV000014507; Zygosity=Heterozygous (PubMed=23847654); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Transduced with a lentiviral vector containing a LTR-loxP-hTERT-SV40p-hisD-Pac-LTR construct 40819845 CVCL_A9F9 PORTU8010 fibroblast finite cell line human CVCL_A9F9 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Leu (c.398G>T); ClinVar=VCV000014488; Zygosity=Heterozygous; Note=De novo mutation (PubMed=12927431; PubMed=23847654) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819846 CVCL_A9F0 MCI7326 finite cell line human CVCL_A9F0 CL:0000010 Population: Japanese; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 40819847 CVCL_A9F2 ATLAN1010 fibroblast finite cell line human CVCL_A9F2 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Leu (c.398G>T); ClinVar=VCV000014488; Zygosity=Heterozygous (PubMed=12927431) Population: African American; Derived from sampling site: Skin Cell type=Fibroblast.. Female 40819848 CVCL_A9F1 CTA60001 finite cell line human CVCL_A9F1 CL:0000010 Population: Indian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 40819849 CVCL_A9G5 88-6 finite cell line human CVCL_A9G5 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Male 40819850 CVCL_A9G4 88-1 hTERT finite cell line human CVCL_A9G4 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female Characteristics: Transduced with a lentiviral vector containing a LTR-loxP-hTERT-SV40p-hisD-Pac-LTR construct 40819851 CVCL_A9G7 NIH 3T3 IFT20-GFP spontaneously immortalized cell line house mouse CVCL_A9G7 CL:0000010 Transfected with: MGI; MGI:1915585; Ift20; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Whole embryo Cell type=Fibroblast.; Breed/subspecies: NIH Swiss. Male Characteristics: Transfected with mouse Ift20 C-terminally tagged with GFP 40819852 CVCL_A9G6 hT-MECs telomerase immortalized cell line CVCL_A9G6 CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Mammary gland Cell type=Epithelial cell.; Breed/subspecies: Xinong Saanen. Female 40819853 CVCL_A9G9 41-71-21 hybridoma house mouse CVCL_A9G9 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P08796; Dictyostelium discoideum csaA. 40819854 CVCL_A9G8 173-185-1 hybridoma house mouse CVCL_A9G8 CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Dictyostelium discoideum common antigen 1 (CA1), a sulfated carbohydrate epitope. 40819855 CVCL_A9G1 PORTU8010 LCL transformed cell line human CVCL_A9G1 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Leu (c.398G>T); ClinVar=VCV000014488; Zygosity=Heterozygous; Note=De novo mutation (PubMed=12927431) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 40819856 CVCL_A9G0 PORTU8010 fibroblast hTERT telomerase immortalized cell line human CVCL_A9G0 CL:0000010 Sequence variation: Mutation; HGNC; 6636; LMNA; Simple; p.Arg133Leu (c.398G>T); ClinVar=VCV000014488; Zygosity=Heterozygous; Note=De novo mutation (PubMed=23847654); Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Transduced with a lentiviral vector containing a LTR-loxP-hTERT-SV40p-hisD-Pac-LTR construct 40819857 CVCL_A9G3 88-1 finite cell line human CVCL_A9G3 CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 40819858 CVCL_A9G2 UH607902 finite cell line human CVCL_A9G2 CL:0000010 Population: Caucasian; Derived from sampling site: Chest; skin Cell type=Fibroblast.. Female 41408342 CVCL_A2FJ GA28 transformed cell line CVCL_A2FJ CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; hypothalamus; arcuate nucleus Cell type=KNDy neuron.; Breed/subspecies: Shiba. Female Characteristics: Expresses KISS1, PDYN, PGR and TACR3 and weakly expresses OPRK1 (PubMed=32432378) 41408343 CVCL_A2FK GP11 transformed cell line CVCL_A2FK CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; hypothalamus; preoptic area Cell type=GnRH neuron.; Breed/subspecies: Shiba. Female Characteristics: Expresses GNRH1, GPR54 and ESR2, but not ESR1 Secretes GnRH peptides and responds to kisspeptin (PubMed=32432378). 41408344 CVCL_A2FL GP31 transformed cell line CVCL_A2FL CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; hypothalamus; preoptic area Cell type=GnRH neuron.; Breed/subspecies: Shiba. Female Characteristics: Expresses GNRH1, GPR54 and ESR2, but not ESR1 Secretes GnRH peptides and responds to kisspeptin (PubMed=32432378). 41408345 CVCL_A2FM GP64 transformed cell line CVCL_A2FM CL:0000010 Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal brain; hypothalamus; preoptic area Cell type=Kisspeptin neuron.; Breed/subspecies: Shiba. Female Characteristics: Expresses kisspeptin and ER-alpha both at the mRNA and protein levels and responds to estrogen, similar to endogenous preoptic area kisspeptin neurons, which mediate estrogen positive feedback and regulate GnRH/LH surge (PubMed=33100283) 41408346 CVCL_A2FN KP-MRT-KS cancer cell line human CVCL_A2FN CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg53Ter (c.157C>T); ClinVar=VCV000944246; Zygosity=Heterozygous (PubMed=33109553); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg190Profs*27 (c.551_569dup19); Zygosity=Heterozygous (PubMed=33109553) Population: Japanese; Karyotypic information: Has a hypo-tetraploid karyotype (PubMed=33109553); Derived from sampling site: Neck. Omics: DNA methylation analysis Female Doubling time: ~48 hours (PubMed=33109553) 41408347 CVCL_A2FP KP-MRT-KSa cancer cell line human CVCL_A2FP CL:0000010 Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg53Ter (c.157C>T); ClinVar=VCV000944246; Zygosity=Heterozygous (PubMed=33109553); Sequence variation: Mutation; HGNC; 11103; SMARCB1; Simple; p.Arg190Profs*27 (c.551_569dup19); Zygosity=Heterozygous (PubMed=33109553) Population: Japanese; Karyotypic information: Has a diploid karyotype with a few chromosomal abnormalities (PubMed=33109553); Derived from metastatic site: Ascites. Omics: DNA methylation analysis Female Doubling time: ~48 hours (PubMed=33109553) 41408348 CVCL_A2FQ KP-MRT-HS cancer cell line human CVCL_A2FQ CL:0000010 Population: Japanese. Unspecified 41408349 CVCL_A2FB PoBf spontaneously immortalized cell line CVCL_A2FB CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 41408350 CVCL_A2FC PoBh spontaneously immortalized cell line CVCL_A2FC CL:0000010 Derived from sampling site: Brain; hypothalamus. Unspecified Group: Fish cell line 41408351 CVCL_A2FD PC-3/DTX cancer cell line human CVCL_A2FD CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere); Derived from metastatic site: Bone. Male Doubling time: 28.87 +- 0.75 hours (PubMed=32968452) 41408352 CVCL_A2FE SKBR-3-OE cancer cell line human CVCL_A2FE CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line); Transfected with: HGNC; 5467; IGF2R Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Using CRISPR/Cas9 a construct containing a CAG promoter-driven IGF2R gene was introduced in the AAVS1 safe harbor locus 41408353 CVCL_A2FF SEB-1 transformed cell line human CVCL_A2FF CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Face; skin; sebaceous gland Cell type=Sebocyte.. Omics: Transcriptome analysis by microarray Male Doubling time: 36 hours (PubMed=12787114) 41408354 CVCL_A2FG Seb-E6E7 transformed cell line human CVCL_A2FG CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Face; skin; sebaceous gland Cell type=Sebocyte.. Male 41408355 CVCL_A2FH SEBO662 transformed cell line human CVCL_A2FH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Face; skin; sebaceous gland Cell type=Sebocyte.. Male 41408356 CVCL_A2FI SEBO662 AR+ transformed cell line human CVCL_A2FI CL:0000010 Transfected with: HGNC; 644; AR; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7 Transformant: Human papillomavirus type 16 (HPV16) [E6/E7](NCBI-Taxonomy; 333760); Derived from sampling site: Face; skin; sebaceous gland Cell type=Sebocyte.. Male 41408357 CVCL_A2EY hTERT-PTECs telomerase immortalized cell line pig CVCL_A2EY CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.; Breed/subspecies: Large Yorkshire. Male 41408358 CVCL_A2EZ PoB1 spontaneously immortalized cell line CVCL_A2EZ CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 41408359 CVCL_A2FA PoB2 spontaneously immortalized cell line CVCL_A2FA CL:0000010 Derived from sampling site: Brain. Unspecified Group: Fish cell line 41408360 CVCL_A2EQ A-253 clone B4 cancer cell line human CVCL_A2EQ CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland. Male Characteristics: Clone is presumably a mixture of acinar and ductal origin (PubMed=32842479) 41408361 CVCL_A2ER A-253 clone B9 cancer cell line human CVCL_A2ER CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.. Male Characteristics: Clone of acinar origin (PubMed=32842479) 41408362 CVCL_A2ES A-253 clone D3 cancer cell line human CVCL_A2ES CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland Cell type=Salivary gland acinar cell.. Male Characteristics: Clone of acinar origin (PubMed=32842479) 41408363 CVCL_A2ET A-253 clone F11 cancer cell line human CVCL_A2ET CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland. Male Characteristics: Clone of myoepithelial origin (PubMed=32842479) 41408364 CVCL_A2EU ITH6.1 transformed cell line CVCL_A2EU CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Liver Cell type=Hepatocyte.. Omics: Transcriptome analysis by RNAseq Male Virology: Susceptible to infection by enterovirus type 71 (EV71), but not by hepatitis C virus Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201740 41408365 CVCL_A2EV hSS-005R cancer cell line human CVCL_A2EV CL:0000010 Population: Chinese. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C201911 41408366 CVCL_A2EW YSCF spontaneously immortalized cell line CVCL_A2EW CL:0000010 Derived from sampling site: Caudal fin Cell type=Fibroblast.. Unspecified Group: Fish cell line; Group: Endangered species/breed cell line 41408367 CVCL_A2EX AS-FPH0 cancer cell line CVCL_A2EX CL:0000010 Derived from sampling site: Skin; Breed/subspecies: American shorthair. Female Doubling time: 57.6 hours (PubMed=32885737) 41408368 CVCL_A2GK siTEC transformed cell line pig CVCL_A2GK CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Trachea; epithelium Cell type=Epithelial cell.. Unspecified Doubling time: ~50 hours (PubMed=32967961) 41408369 CVCL_A2GL Nips-B2 GNAS R201H/+ clone 1 induced pluripotent stem cell human CVCL_A2GL CL:0000010 Sequence variation: Mutation; HGNC; 4392; GNAS; Simple_edited; p.Arg201His (c.602G>A); ClinVar=VCV000015934; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32996421) Population: Japanese; Derived from sampling site: Nose; nasal cavity; epithelium. Female 41408370 CVCL_A2GM Nips-B2 GNAS R201H/+ clone 2 induced pluripotent stem cell human CVCL_A2GM CL:0000010 Sequence variation: Mutation; HGNC; 4392; GNAS; Simple_edited; p.Arg201His (c.602G>A); ClinVar=VCV000015934; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=32996421) Population: Japanese; Derived from sampling site: Nose; nasal cavity; epithelium. Female 41408371 CVCL_A2GN GCN-01 telomerase immortalized cell line human CVCL_A2GN CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: Doubling time and info on hygromycin vector from personal communication of Nasimian A Population: Iranian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 86 hours (Direct_author_submission) 41408372 CVCL_A2GP GCP-01 telomerase immortalized cell line human CVCL_A2GP CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: Doubling time and info on hygromycin vector from personal communication of Nasimian A Population: Iranian; Derived from sampling site: Ovary; ovarian follicle; granulosa cell layer. Female Doubling time: 75 hours (Direct_author_submission) 41408373 CVCL_A2GQ K-21 transformed cell line human CVCL_A2GQ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408374 CVCL_A2GR K-22 [Human leukemia] transformed cell line human CVCL_A2GR CL:0000010 Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408375 CVCL_A2GC NCCSi011-B induced pluripotent stem cell human CVCL_A2GC From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 41408376 CVCL_A2GD CMCi002-A induced pluripotent stem cell human CVCL_A2GD From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 10912; SLC12A3; Simple; p.Cys16Glnfs*13 (c.46_47delTG); ClinVar=VCV001459093; Zygosity=Heterozygous (PubMed=33370877); Sequence variation: Mutation; HGNC; 10912; SLC12A3; Simple; p.Ile988Thr (c.2963T>C) (p.Ile979Thr, c.2936T>C); Zygosity=Heterozygous (PubMed=33370877) Population: Asian; Derived from sampling site: Peripheral blood. Male 41408377 CVCL_A2GE BCEC-1 finite cell line CVCL_A2GE CL:0000010 Derived from sampling site: Placenta; caruncle Cell type=Epithelial cell.. Female Characteristics: Susceptible to infection by Neospora caninum isolates Nc-Spain7 and Nc-Spain1H (PubMed=29017582) 41408378 CVCL_A2GF F3 finite cell line CVCL_A2GF CL:0000010 Derived from sampling site: Trophoblast. Omics: Deep proteome analysis Unspecified Characteristics: Susceptible to infection by Neospora caninum isolates Nc-Spain7 and Nc-Spain1H (PubMed=29017582) Doubling time: ~24 hours, in FSM medium (PubMed=19914712) 41408379 CVCL_A2GG YCU-AML1 cancer cell line human CVCL_A2GG CL:0000010 Population: Japanese; Karyotypic information: Monosomy of chromosome 7 (PubMed=33163905); Derived from sampling site: Bone marrow. Male 41408380 CVCL_A2GH LR-BT474 cancer cell line human CVCL_A2GH CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from sampling site: Breast. Omics: Transcriptome analysis by microarray Female 41408381 CVCL_A2GI LR-SKBR3 cancer cell line human CVCL_A2GI CL:0000010 Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Derived from metastatic site: Pleural effusion. Female 41408382 CVCL_A2GJ siNEC transformed cell line pig CVCL_A2GJ CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Nose; nasal cavity; epithelium. Unspecified Doubling time: ~50 hours (PubMed=32967961) 41408383 CVCL_A2FZ MBA72R cancer cell line human CVCL_A2FZ CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (from parent cell line) Miscellaneous: Age/sex of donor and metastatic site from personal communication of Guida G Selected for resistance to: ChEBI; CHEBI:91367; Barasertib-HQPA (AZD1152-HQPA); Derived from metastatic site: Right temple. Male 41408384 CVCL_A2GA hmel1R cancer cell line human CVCL_A2GA CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Trp383Cys (c.1149G>T); Zygosity=Unspecified (from parent cell line) Population: Caucasian; Italian; Selected for resistance to: ChEBI; CHEBI:91367; Barasertib-HQPA (AZD1152-HQPA); Derived from metastatic site: Skin. Male 41408385 CVCL_A2GB NCCSi011-A induced pluripotent stem cell human CVCL_A2GB From: National Centre for Cell Science; Pune; India CL:0000010 Population: Indian; Derived from sampling site: Peripheral blood. Male 41408386 CVCL_A2FR KP-EW-AK cancer cell line human CVCL_A2FR CL:0000010 Population: Japanese; Derived from sampling site: Bone; scapula. Male 41408387 CVCL_A2FS KP-RMS-DH cancer cell line human CVCL_A2FS CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8617; PAX3; Name(s)=PAX3-FOXO1, PAX3-FKHR (CelloPub=CLPUB00599) Population: Japanese; Derived from metastatic site: Bone marrow. Male 41408388 CVCL_A2FT KP-RMS-KH cancer cell line human CVCL_A2FT CL:0000010 Population: Japanese; Derived from sampling site: Perineum. Female 41408389 CVCL_A2FU KP-PNET-TO cancer cell line human CVCL_A2FU CL:0000010 Population: Japanese; Derived from metastatic site: Bone; iliac spine. Male 41408390 CVCL_A2FV BKZ-2 cancer cell line human CVCL_A2FV CL:0000010 Population: Caucasian; Derived from sampling site: Rectum. Male Characteristics: Contains subpopulations with potential stem-like properties Forms spheres under serum-free conditions and supplementation with heparin (PubMed=32927768). Doubling time: 40.12 +- 1.56 hours (PubMed=32927768) 41408391 CVCL_A2FW BKZ-3 cancer cell line human CVCL_A2FW CL:0000010 Population: Caucasian; Derived from sampling site: Colon. Male Characteristics: Contains subpopulations with potential stem-like properties Forms spheres under serum-free conditions and supplementation with heparin (PubMed=32927768). Doubling time: 21.88 +- 1.19 hours (PubMed=32927768) 41408392 CVCL_A2FX CMG-1 cancer cell line dog CVCL_A2FX CL:0000010 Derived from sampling site: Eye lid; sebaceous gland. Unspecified Doubling time: 11.8 +- 1.2 hours (PubMed=32921644) 41408393 CVCL_A2FY MBA72 cancer cell line human CVCL_A2FY CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=25623468); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Val92Met (c.274G>A); ClinVar=VCV000014308; Zygosity=Heterozygous (PubMed=27540956); Sequence variation: Mutation; HGNC; 6929; MC1R; Simple; p.Asp294His (c.880G>C); ClinVar=VCV000014307; Zygosity=Heterozygous (PubMed=27540956) Miscellaneous: Age/sex of donor and metastatic site from personal communication of Guida G Derived from metastatic site: Right temple. Male 41408394 CVCL_A2DH B59.2 hybridoma house mouse CVCL_A2DH CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 41408395 CVCL_A2DI GG013 transformed cell line CVCL_A2DI From: Tyler-Smith C.; Wellcome Trust Sanger Institute; Cambridge; United Kingdom CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Unspecified Group: Non-human primate cell line 41408396 CVCL_A2DJ Mm 71-2006 transformed cell line CVCL_A2DJ From: New England Primate Research Center (NEPRC), Harvard Medical School; Boston; USA CL:0000010 Transformant: Papiine herpesvirus 1 (Herpesvirus papio)(NCBI-Taxonomy; 106332); Derived from sampling site: Peripheral blood. Omics: CTCF ChIP-seq epigenome analysis; Omics: YY1 ChIP-seq epigenome analysis Group: Non-human primate cell line 41408397 CVCL_A2DK AG12502 finite cell line human CVCL_A2DK CL:0000010 Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Discontinued: Coriell; AG12502; probable Female 41408398 CVCL_A2DL AG12209 finite cell line human CVCL_A2DL CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: Coriell; AG12209; probable Male 41408399 CVCL_A2DM AG12206 finite cell line human CVCL_A2DM CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: Coriell; AG12206; probable Male 41408400 CVCL_A2DN OCF [Amphiprion] spontaneously immortalized cell line CVCL_A2DN CL:0000010 Derived from sampling site: Caudal fin. Unspecified Doubling time: 40 hours, at 25th passage (PubMed=33208823) Group: Fish cell line 41408401 CVCL_A2DA HUVE-12M finite cell line human CVCL_A2DA CL:0000010 Derived from sampling site: Fetal umbilical vein Cell type=Endothelial cell of umbilical vein.. Male 41408402 CVCL_A2DB HAAE-1F finite cell line human CVCL_A2DB CL:0000010 Derived from sampling site: Abdomen; aorta Cell type=Aortic endothelial cell.. Male 41408403 CVCL_A2DC HIVCE-17 finite cell line human CVCL_A2DC CL:0000010 Derived from sampling site: Inferior vena cava; endothelium. Part of: Wistar Institute Special Collection vascular cell lines 41408404 CVCL_A2DD B1.12 hybridoma house mouse CVCL_A2DD CL:0000010 Monoclonal antibody isotype: IgG1. 41408405 CVCL_A2DE B2.10 hybridoma house mouse CVCL_A2DE CL:0000010 Monoclonal antibody isotype: IgM. 41408406 CVCL_A2DF B2.12 hybridoma house mouse CVCL_A2DF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P05106; Human ITGB3/CD61. 41408407 CVCL_A2DG B37.3 hybridoma house mouse CVCL_A2DG CL:0000010 Monoclonal antibody isotype: IgM. 41408408 CVCL_A2CW AG13014 finite cell line human CVCL_A2CW CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG13014; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 41408409 CVCL_A2CX AG05187 finite cell line human CVCL_A2CX CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05187; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 41408410 CVCL_A2CY AG06303 finite cell line human CVCL_A2CY CL:0000010 Population: Caucasian; Karyotypic information: 46,XY [18%]; 46,XY,t(8;13) [82%] (Coriell); Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG06303; probable Male Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 41408411 CVCL_A2CZ HIAE-25 finite cell line human CVCL_A2CZ CL:0000010 Derived from sampling site: Iliac artery; endothelium. Discontinued: Coriell; AG10504; probable Male Part of: Wistar Institute Special Collection vascular cell lines 41408412 CVCL_A2CP SBA-6 cancer cell line human CVCL_A2CP CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Val842Ile (c.2524G>A); ClinVar=VCV000375994; Zygosity=Unspecified (PubMed=30352910). 41408413 CVCL_A2CQ 471L cancer cell line human CVCL_A2CQ CL:0000010 Derived from sampling site: Lung. Characteristics: Established from a second generation nude mouse xenograft 41408414 CVCL_A2CR A375-R1 cancer cell line human CVCL_A2CR CL:0000010 Sequence variation: Mutation; HGNC; 25657; BCORL1; Simple; p.Gln1076His (c.3228G>T); Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=29605720); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val47_Asp380del (c.139_1140del1002); Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=29605720); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29605720); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from sampling site: Skin. Female 41408415 CVCL_A2CS KTC1res.1 cancer cell line human CVCL_A2CS CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple; p.Lys443Glu (c.1327A>G); Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=29156680); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29156680); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis Male 41408416 CVCL_A2CT KTC1res.2 cancer cell line human CVCL_A2CT CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (PubMed=29156680); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=29156680); Sequence variation: Mutation; HGNC; 9801; RAC1; Simple; p.Asp63Val (c.188A>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Heterozygous; Note=In promoter (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:63637; Vemurafenib (Zelboraf; Derived from metastatic site: Pleural effusion. Omics: Array-based CGH; Omics: Deep exome analysis Male 41408417 CVCL_A2CU AG07304 finite cell line human CVCL_A2CU CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07304; probable Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 41408418 CVCL_A2CV AG11794 finite cell line human CVCL_A2CV CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG11794; probable Female Part of: Baltimore Longitudinal Study of Aging (BLSA) cell line collection 41408419 CVCL_A2EI NCC-MFS2-C1 cancer cell line human CVCL_A2EI CL:0000010 Population: Japanese; Derived from sampling site: Thigh; hypodermis. Omics: SNP array analysis Male Doubling time: 13 hours (PubMed=32870449) Part of: NCC sarcoma cell line panel 41408420 CVCL_A2EJ HUBUi001-A induced pluripotent stem cell human CVCL_A2EJ From: Hubei University; Hubei; China CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Gly35Val (c.104G>T); Zygosity=Heterozygous (PubMed=32942234); Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Arg1873Cys (c.5617C>T); ClinVar=VCV000222581; Zygosity=Heterozygous (PubMed=32942234) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female Caution: Indicated to be of female origin in PubMed=32942234, but karyotype from the same paper shows X,Y 41408421 CVCL_A2EK HUBUi002-A induced pluripotent stem cell human CVCL_A2EK From: Hubei University; Hubei; China CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Gly35Val (c.104G>T); Zygosity=Heterozygous (PubMed=32942234) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408422 CVCL_A2EL HUBUi003-A induced pluripotent stem cell human CVCL_A2EL From: Hubei University; Hubei; China CL:0000010 Sequence variation: Mutation; HGNC; 3052; DSP; Simple; p.Arg1873Cys (c.5617C>T); ClinVar=VCV000222581; Zygosity=Heterozygous (PubMed=32942234) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 41408423 CVCL_A2EM hPrEC-T-deltaN2A, clone 1 telomerase immortalized cell line human CVCL_A2EM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 41408424 CVCL_A2EN hPrEC-T-deltaN2A, clone 2 telomerase immortalized cell line human CVCL_A2EN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 1787; CDKN2A; Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Prostate; epithelium Cell type=Epithelial cell.. Male 41408425 CVCL_A2EP A-253 clone B2 cancer cell line human CVCL_A2EP CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Ala17fs*5 (c.49_61delGCCACGGCCGCGG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7133; KMT2D; Simple; p.Gly3092Ter (c.9274G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu152Pro (c.455T>C); ClinVar=VCV000536551; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu180fs*67 (c.539delA); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Salivary gland; submandibular gland. Male Characteristics: Clone of ductal origin Particularly suitable for transport studies in biomarker research (PubMed=32842479). 41408426 CVCL_A2EA AG02493 finite cell line human CVCL_A2EA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02493; probable Female 41408427 CVCL_A2EB AG02494 finite cell line human CVCL_A2EB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02494; probable Male 41408428 CVCL_A2EC AG03758 finite cell line human CVCL_A2EC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03758; probable Female 41408429 CVCL_A2ED AG03532 finite cell line human CVCL_A2ED CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Discontinued: Coriell; AG03532; probable Unspecified 41408430 CVCL_A2EE AG03533 finite cell line human CVCL_A2EE CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Discontinued: Coriell; AG03533; probable Unspecified 41408431 CVCL_A2EF AG03354 finite cell line human CVCL_A2EF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03354; probable Unspecified 41408432 CVCL_A2EG AG03574 finite cell line human CVCL_A2EG CL:0000010 Derived from sampling site: Chest; skin Cell type=Fibroblast.. Discontinued: Coriell; AG03574; probable Unspecified 41408433 CVCL_A2EH AG03556 finite cell line human CVCL_A2EH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03556; probable Unspecified 41408434 CVCL_A2DX AG06311 finite cell line human CVCL_A2DX CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG06311; probable Male 41408435 CVCL_A2DY AG12796 finite cell line human CVCL_A2DY CL:0000010 Population: Japanese; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG12796; probable Female 41408436 CVCL_A2DZ AG05230 finite cell line human CVCL_A2DZ CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG05230; probable Female 41408437 CVCL_A2DP AG12983 transformed cell line human CVCL_A2DP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG12983; probable Male 41408438 CVCL_A2DQ AG12962 transformed cell line human CVCL_A2DQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG12962; probable Female 41408439 CVCL_A2DR AG12963 transformed cell line human CVCL_A2DR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG12963; probable Female 41408440 CVCL_A2DS AG12986 transformed cell line human CVCL_A2DS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG12986; probable Male 41408441 CVCL_A2DT AG12987 transformed cell line human CVCL_A2DT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Donor information: At sampling donor was not affected with Alzheimer disease but has a 50% risk; Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG12987; probable Male 41408442 CVCL_A2DU AG09371 transformed cell line human CVCL_A2DU CL:0000010 Population: Jewish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG09371; probable Male 41408443 CVCL_A2DV AG09370 transformed cell line human CVCL_A2DV CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG09370; probable Male 41408444 CVCL_A2DW AG08508 transformed cell line human CVCL_A2DW CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (from autologous cell line AG08509) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG08508; probable Male Part of: German Alzheimer disease kindred subcollection 41408445 CVCL_A2BF HMOS-1 cancer cell line human CVCL_A2BF CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male Doubling time: 18 hours (PubMed=9307724) 41408446 CVCL_A2BG IGR-N-331 cancer cell line human CVCL_A2BG CL:0000010 Derived from metastatic site: Bone marrow. Female 41408447 CVCL_A2BH IGR-N-337 cancer cell line human CVCL_A2BH CL:0000010 Derived from metastatic site: Bone marrow. Female 41408448 CVCL_A2BI HOSM-1 cancer cell line human CVCL_A2BI CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male 41408449 CVCL_A2BJ HOSM-2 cancer cell line human CVCL_A2BJ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg306Ter (c.916C>T); ClinVar=VCV000142144; Zygosity=Unspecified (PubMed=15172645) Population: Japanese; Karyotypic information: Has lost chromosome Y; Derived from sampling site: Bone; jaw; mandible. Male Doubling time: 74.8 hours (CelloPub=CLPUB00596); 70.6 hours (PubMed=15172645) 41408450 CVCL_A2BK HOSMN-1C cancer cell line human CVCL_A2BK CL:0000010 Population: Japanese; Derived from sampling site: Bone; jaw; mandible. Male Characteristics: Established from a nude mouse xenograft (HOSMN-1) Doubling time: 30.75 hours (DOI=10.11277/stomatology1952.38.1007) 41408451 CVCL_A2BL YAMCL-95 cancer cell line human CVCL_A2BL CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136His (c.408A>T); ClinVar=VCV000482213; Zygosity=Unspecified (PubMed=20575032). Population: Japanese Unspecified 41408452 CVCL_A2BM Endo-kun cancer cell line human CVCL_A2BM CL:0000010 Sequence variation: Gene fusion; HGNC; 4977; HLF + HGNC; 11633; TCF3; Name(s)=TCF3-HLF, E2A-HLF (PubMed=20147975). Population: Japanese Female 41408453 CVCL_A2BA IGR-HEU cancer cell line human CVCL_A2BA CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Asn (c.396G>T); ClinVar=VCV000634773; Zygosity=Unspecified (PubMed=15634909) Derived from sampling site: Lung. Male 41408454 CVCL_A2BB IGR-PUB cancer cell line human CVCL_A2BB CL:0000010 Derived from sampling site: Lung. Male 41408455 CVCL_A2BC YUMMER1.7D5 cancer cell line house mouse CVCL_A2BC CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6. Male Characteristics: Diploid clone of parent cell line 41408456 CVCL_A2BD YUMMER1.7D4 cancer cell line house mouse CVCL_A2BD CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6. Male Characteristics: Diploid clone of parent cell line 41408457 CVCL_A2BE GC-006-03 cancer cell line human CVCL_A2BE CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu33Argfs*20 (c.97delG); Zygosity=Unspecified (PubMed=30271482); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Gly (c.1634A>G); ClinVar=VCV000013656; Zygosity=Unspecified (PubMed=30271482) Population: Chinese; Derived from metastatic site: Ascites. Omics: Genome sequenced Female Doubling time: 36 hours (PubMed=30271482) Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2016152 41408458 CVCL_A2AU 936T cancer cell line human CVCL_A2AU From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408459 CVCL_A2AV 94T cancer cell line human CVCL_A2AV From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408460 CVCL_A2AW 98T cancer cell line human CVCL_A2AW From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408461 CVCL_A2AX YUMMER1.7 cancer cell line house mouse CVCL_A2AX CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6. Male Characteristics: The parent cell line was exposed to three rounds of UVB radiation at 1,500 J/m2 to generate a cell line with an increased number of somatic mutations (PubMed=28379630) 41408462 CVCL_A2AY YUMMER1.7 H2B-GFP5 cancer cell line house mouse CVCL_A2AY CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:104738; Cdkn2a; Knockout cell: Method=KO mouse; MGI; MGI:109583; Pten; Sequence variation: Mutation; MGI; MGI:88190; Braf; Simple; p.Val637Glu (c.1910T>A); Zygosity=Heterozygous (from parent cell line); Transfected with: HGNC; 4761; H2BC11 (with p.Gly26Asp and p.Ile119Val and fused in frame with eGFP); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Transformant: Ultraviolet radiation(NCIt; C17231); Breed/subspecies: C57BL/6. Male 41408463 CVCL_A2AZ IGR-BLA cancer cell line human CVCL_A2AZ CL:0000010 Derived from sampling site: Lung. Female 41408464 CVCL_A2AM 54T [Human lung carcinoma] cancer cell line human CVCL_A2AM From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Female 41408465 CVCL_A2AN 7-90T cancer cell line human CVCL_A2AN From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Female 41408466 CVCL_A2AP 76T cancer cell line human CVCL_A2AP From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408467 CVCL_A2AQ 784T cancer cell line human CVCL_A2AQ From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408468 CVCL_A2AR 81-86T cancer cell line human CVCL_A2AR From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Unspecified 41408469 CVCL_A2AS 84T cancer cell line human CVCL_A2AS From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor and lung cancer type (incorrect in PubMed=10545285) from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408470 CVCL_A2AT 91T cancer cell line human CVCL_A2AT From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (PubMed=18645002) Miscellaneous: Age of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408471 CVCL_A2CG NCI-H508 R2 Cetux cancer cell line human CVCL_A2CG CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly596Arg (c.1786G>C); ClinVar=VCV000375943; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Abdominal wall. Male 41408472 CVCL_A2CH OX-CO-2 R1 Cetux cancer cell line human CVCL_A2CH CL:0000010 Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux). Male 41408473 CVCL_A2CI OX-CO-2 R2 Cetux cancer cell line human CVCL_A2CI CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ile491Met (c.1473A>G); ClinVar=VCV001404733; Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215). Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux) Male 41408474 CVCL_A2CJ OXCO-2 R3 Cetux cancer cell line human CVCL_A2CJ CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ser464Leu (c.1391C>T); Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215). Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux) Male 41408475 CVCL_A2CK HO1 cancer cell line human CVCL_A2CK CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. 41408476 CVCL_A2CL RSO4 cancer cell line human CVCL_A2CL CL:0000010 Sequence variation: Mutation; HGNC; 11920; FAS; Simple; p.His60Arg (c.179A>G); ClinVar=VCV001439236; Zygosity=Heterozygous (PubMed=12207908); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro223His (c.668C>A); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 41408477 CVCL_A2CM RST1 cancer cell line human CVCL_A2CM CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Characteristics: IL2 dependent 41408478 CVCL_A2CN SBA-16 cancer cell line human CVCL_A2CN CL:0000010 Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Tyr803His (c.2407T>C); Zygosity=Unspecified (PubMed=30352910). 41408479 CVCL_A2CA LIM1215 R1 Cetux cancer cell line human CVCL_A2CA CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ile491Met (c.1473A>G); ClinVar=VCV001404733; Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Omentum. Male 41408480 CVCL_A2CB LIM1215 R2 Cetux cancer cell line human CVCL_A2CB CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Omentum. Male 41408481 CVCL_A2CC LIM1215 R3 Cetux cancer cell line human CVCL_A2CC CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Omentum. Male 41408482 CVCL_A2CD LIM1215 R4 Cetux cancer cell line human CVCL_A2CD CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Omentum. Male 41408483 CVCL_A2CE LIM1215 R5 Cetux cancer cell line human CVCL_A2CE CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Gly465Arg (c.1393G>A); Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Omentum. Male 41408484 CVCL_A2CF NCI-H508 R1 Cetux cancer cell line human CVCL_A2CF CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly596Arg (c.1786G>C); ClinVar=VCV000375943; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Abdominal wall. Male 41408485 CVCL_A2BV CCK-81 R3 Cetux cancer cell line human CVCL_A2BV CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278His (c.833C>A); ClinVar=VCV000376646; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Lymph node. Female 41408486 CVCL_A2BW DiFi R1 Cetux cancer cell line human CVCL_A2BW CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu443fs*16 (c.1328_1329delAA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1151Ter (c.3451G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Ascites. Female 41408487 CVCL_A2BX DiFi R2 Cetux cancer cell line human CVCL_A2BX CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu443fs*16 (c.1328_1329delAA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu1151Ter (c.3451G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Homozygous (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Ascites. Female 41408488 CVCL_A2BY HCA46 R1 Cetux cancer cell line human CVCL_A2BY CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala183Ser (c.547G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Alafs*33 (c.815_816delTG); Zygosity=Unspecified (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Colon; sigmoid. Female 41408489 CVCL_A2BZ HCA46 R2 Cetux cancer cell line human CVCL_A2BZ CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ala183Ser (c.547G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Val272Alafs*33 (c.815_816delTG); Zygosity=Unspecified (from parent cell line) Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from sampling site: Colon; sigmoid. Female 41408490 CVCL_A2BN HOT-1 cancer cell line human CVCL_A2BN CL:0000010 Population: Japanese; Derived from sampling site: Oral cavity; tongue. Male Doubling time: ~31.2 hours, at 20th passage (DOI=10.11277/stomatology1952.42.48) 41408491 CVCL_A2BP HSD-10 transformed cell line human CVCL_A2BP CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; minor salivary gland. Female 41408492 CVCL_A2BQ Simplicon induced pluripotent stem cell human CVCL_A2BQ CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 41408493 CVCL_A2BR NCC-PLPS1-C1 cancer cell line human CVCL_A2BR CL:0000010 Population: Japanese; Derived from sampling site: Adipose tissue; hypodermis. Male Doubling time: 11 hours (PubMed=33205363) Part of: NCC sarcoma cell line panel 41408494 CVCL_A2BS FT-MZ-1 cancer cell line human CVCL_A2BS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=7926016) Derived from sampling site: Fallopian tube. Female Doubling time: 14 days (PubMed=7926016) 41408495 CVCL_A2BT CCK-81 R1 Cetux cancer cell line human CVCL_A2BT CL:0000010 Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Ser464Leu (c.1391C>T); Zygosity=Heterozygous; Note=Acquired during resistance selection process (PubMed=25623215); Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278His (c.833C>A); ClinVar=VCV000376646; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Lymph node. Female 41408496 CVCL_A2BU CCK-81 R2 Cetux cancer cell line human CVCL_A2BU CL:0000010 Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg465Cys (c.1393C>T); ClinVar=VCV000376414; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Cys420Arg (c.1258T>C); ClinVar=VCV000031945; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278His (c.833C>A); ClinVar=VCV000376646; Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux); Derived from metastatic site: Lymph node. Female 41408497 CVCL_A2AE 119-87T cancer cell line human CVCL_A2AE From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor and lung cancer type from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408498 CVCL_A2AF 166T cancer cell line human CVCL_A2AF From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor and lung cancer type from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408499 CVCL_A2AG 128-88T cancer cell line human CVCL_A2AG From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age at sampling from personal communication of Siegfried J.M Derived from sampling site: Lung. Female 41408500 CVCL_A2AH 180T cancer cell line human CVCL_A2AH From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor and lung cancer type from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408501 CVCL_A2AI 239T cancer cell line human CVCL_A2AI From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408502 CVCL_A2AJ 390T cancer cell line human CVCL_A2AJ From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408503 CVCL_A2AK 343T cancer cell line human CVCL_A2AK From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Unspecified (PubMed=18645002) Miscellaneous: Age/sex of donor and lung cancer type from personal communication of Siegfried J.M Derived from sampling site: Lung. Female 41408504 CVCL_A2AL 399T cancer cell line human CVCL_A2AL From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408505 CVCL_A2AA 101-87T cancer cell line human CVCL_A2AA From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Female 41408506 CVCL_A2AB 109-87T cancer cell line human CVCL_A2AB From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408507 CVCL_A2AC 110-87T cancer cell line human CVCL_A2AC From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408508 CVCL_A2AD 114-87T cancer cell line human CVCL_A2AD From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from sampling site: Lung. Male 41408509 CVCL_A2NR AG10104 transformed cell line human CVCL_A2NR CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG10104; probable Male 41408510 CVCL_A2NS AG10326 transformed cell line human CVCL_A2NS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG10326; probable Male 41408511 CVCL_A2NT AG11670 finite cell line pig CVCL_A2NT CL:0000010 Derived from sampling site: Thoracic aorta Cell type=Thoracic aorta endothelial cell.; Breed/subspecies: Yorkshire. Discontinued: Coriell; AG11670; probable Female 41408512 CVCL_A2NU AG11673 finite cell line pig CVCL_A2NU CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.; Breed/subspecies: Yorkshire. Discontinued: Coriell; AG11673; probable Female 41408513 CVCL_A2NV AG11855 finite cell line CVCL_A2NV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG11855; probable Female Group: Non-human primate cell line 41408514 CVCL_A2NW AG11856 finite cell line CVCL_A2NW CL:0000010 Derived from sampling site: Lung Cell type=Fibroblast.. Discontinued: Coriell; AG11856; probable Female Group: Non-human primate cell line 41408515 CVCL_A2NX AG05357 finite cell line CVCL_A2NX CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05357; probable Male Group: Non-human primate cell line 41408516 CVCL_A2NY AG07130 finite cell line CVCL_A2NY CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Discontinued: Coriell; AG07130; probable Female Group: Non-human primate cell line 41408517 CVCL_A2NJ RB 5204 transformed cell line human CVCL_A2NJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408518 CVCL_A2NK RB 5207 transformed cell line human CVCL_A2NK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408519 CVCL_A2NL RB 5333 transformed cell line human CVCL_A2NL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408520 CVCL_A2NM RB 5360 transformed cell line human CVCL_A2NM CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408521 CVCL_A2NN RB 5014 transformed cell line human CVCL_A2NN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408522 CVCL_A2NP RB 6044 finite cell line human CVCL_A2NP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408523 CVCL_A2NQ AG07988 transformed cell line human CVCL_A2NQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG07988; probable Male 41408524 CVCL_A2NB RB 5175 finite cell line human CVCL_A2NB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408525 CVCL_A2NC RB 5061 finite cell line human CVCL_A2NC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408526 CVCL_A2ND RB 5065 finite cell line human CVCL_A2ND CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408527 CVCL_A2NE RB 5205 finite cell line human CVCL_A2NE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408528 CVCL_A2NF RB 5206 finite cell line human CVCL_A2NF CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408529 CVCL_A2NG RB 4361 transformed cell line human CVCL_A2NG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408530 CVCL_A2NH RB 5062 transformed cell line human CVCL_A2NH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408531 CVCL_A2NI RB 5064 transformed cell line human CVCL_A2NI CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41408532 CVCL_A2MY RB 4582 finite cell line human CVCL_A2MY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408533 CVCL_A2MZ RB 4963 finite cell line human CVCL_A2MZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408534 CVCL_A2NA RB 5053 finite cell line human CVCL_A2NA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408535 CVCL_A2NZ AG12255 finite cell line CVCL_A2NZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG12255; probable Female Group: Non-human primate cell line 41408536 CVCL_A2LP AG02647 finite cell line human CVCL_A2LP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02647; probable Male 41408537 CVCL_A2LQ AG02648 transformed cell line human CVCL_A2LQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG02648; probable Male 41408538 CVCL_A2LR AG02649 finite cell line human CVCL_A2LR CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02649; probable Male 41408539 CVCL_A2LS AG02650 transformed cell line human CVCL_A2LS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG02650; probable Male 41408540 CVCL_A2LT AG02651 finite cell line human CVCL_A2LT CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02651; probable Male 41408541 CVCL_A2LU AG02653 finite cell line human CVCL_A2LU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02653; probable Female 41408542 CVCL_A2LV AG02655 finite cell line human CVCL_A2LV CL:0000010 Donor information: Established from a patient suffering from acute myelogenous leukemia; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02655; probable Female 41408543 CVCL_A2LW AG03000 finite cell line human CVCL_A2LW CL:0000010 Donor information: Established from a patient suffering from medulloblastoma; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03000; probable Male 41408544 CVCL_A2LH AG02514 finite cell line human CVCL_A2LH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02514; probable Female 41408545 CVCL_A2LI AG02508 finite cell line human CVCL_A2LI CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02508; probable Female 41408546 CVCL_A2LJ AG02510 finite cell line human CVCL_A2LJ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02510; probable Female 41408547 CVCL_A2LK AG02511 finite cell line human CVCL_A2LK CL:0000010 Derived from sampling site: Kidney. Discontinued: Coriell; AG02511; probable Male 41408548 CVCL_A2LL AG02512 finite cell line human CVCL_A2LL CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02512; probable Male 41408549 CVCL_A2LM AG02611 finite cell line human CVCL_A2LM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02611; probable Female 41408550 CVCL_A2LN AG02646 transformed cell line human CVCL_A2LN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG02646; probable Male 41408551 CVCL_A2LA AG03515 finite cell line human CVCL_A2LA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03515; probable Female 41408552 CVCL_A2LB AG03516 finite cell line human CVCL_A2LB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03516; probable Male 41408553 CVCL_A2LC AG02308 finite cell line human CVCL_A2LC CL:0000010 Donor information: Established from the irradiated skin of an osteogenic sarcoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02308; probable Female 41408554 CVCL_A2LD AG02309 finite cell line human CVCL_A2LD CL:0000010 Donor information: Established from the non-irradiated skin of an osteogenic sarcoma patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02309; probable Female 41408555 CVCL_A2LE AG02310 finite cell line human CVCL_A2LE CL:0000010 Donor information: Established from the irradiated skin of a Wilm's tumor patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02310; probable Male 41408556 CVCL_A2LF AG02311 finite cell line human CVCL_A2LF CL:0000010 Donor information: Established from the non-irradiated skin of a Wilm's tumor patient; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02311; probable Male 41408557 CVCL_A2LG AG02360 finite cell line human CVCL_A2LG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG02360; probable Female 41408558 CVCL_A2KW AG03308 finite cell line human CVCL_A2KW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03308; probable Male 41408559 CVCL_A2KX AG03309 finite cell line human CVCL_A2KX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03309; probable Female 41408560 CVCL_A2KY AG03310 finite cell line human CVCL_A2KY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03310; probable Female 41408561 CVCL_A2KZ AG03311 finite cell line human CVCL_A2KZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03311; probable Female 41408562 CVCL_A2MQ AG03820 finite cell line human CVCL_A2MQ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03820; probable Female 41408563 CVCL_A2MR RB 4087 finite cell line human CVCL_A2MR CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408564 CVCL_A2MS RB 4436 finite cell line human CVCL_A2MS CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408565 CVCL_A2MT RB 4468 finite cell line human CVCL_A2MT CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408566 CVCL_A2MU RB 4470 finite cell line human CVCL_A2MU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408567 CVCL_A2MV RB 4492 finite cell line human CVCL_A2MV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408568 CVCL_A2MW RB 4494 finite cell line human CVCL_A2MW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408569 CVCL_A2MX RB 4581 finite cell line human CVCL_A2MX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408570 CVCL_A2MI AG03730 finite cell line human CVCL_A2MI CL:0000010 Derived from sampling site: Cell type=Fibroblast. Discontinued: Coriell; AG03730; probable Male 41408571 CVCL_A2MJ AG03805 finite cell line human CVCL_A2MJ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03805; probable Male 41408572 CVCL_A2MK AG03818 finite cell line human CVCL_A2MK CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03818; probable Female 41408573 CVCL_A2ML AG03819 finite cell line human CVCL_A2ML CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03819; probable Female 41408574 CVCL_A2MM AG03848 finite cell line human CVCL_A2MM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03848; probable Male 41408575 CVCL_A2MN AG03849 finite cell line human CVCL_A2MN CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03849; probable Female 41408576 CVCL_A2MP AG03927 transformed cell line human CVCL_A2MP CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03927; probable Female 41408577 CVCL_A2MA AG03664 finite cell line human CVCL_A2MA CL:0000010 Derived from metastatic site: Spinal cord. Discontinued: Coriell; AG03664; probable Female 41408578 CVCL_A2MB AG03436 transformed cell line human CVCL_A2MB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03436; probable Male 41408579 CVCL_A2MC AG03593 finite cell line human CVCL_A2MC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03593; probable Male 41408580 CVCL_A2MD AG03594 finite cell line human CVCL_A2MD CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03594; probable Male 41408581 CVCL_A2ME AG03607 finite cell line human CVCL_A2ME CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03607; probable Female 41408582 CVCL_A2MF AG03674 transformed cell line human CVCL_A2MF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03674; probable Male 41408583 CVCL_A2MG AG03678 finite cell line human CVCL_A2MG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03678; probable Male 41408584 CVCL_A2MH AG03690 finite cell line human CVCL_A2MH CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03690; probable Female 41408585 CVCL_A2LX AG03001 finite cell line human CVCL_A2LX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03001; probable Female 41408586 CVCL_A2LY AG03002 finite cell line human CVCL_A2LY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03002; probable Male 41408587 CVCL_A2LZ AG03376 finite cell line human CVCL_A2LZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03376; probable Female 41408588 CVCL_A2JN hMSC-hTERT telomerase immortalized cell line human CVCL_A2JN CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Cell type=Mesenchymal stem cell. Unspecified 41408589 CVCL_A2JP hMSC-hTERT-E6/E7 transformed cell line human CVCL_A2JP CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Cell type=Mesenchymal stem cell. Unspecified 41408590 CVCL_A2JQ SPF [Lateolabrax] spontaneously immortalized cell line CVCL_A2JQ CL:0000010 Unspecified Virology: Susceptible to infection by sea perch iridovirus (SPIV), Singapore grouper iridovirus (SGIV), and red-spotted grouper nervous necrosis virus (RGNNV). Group: Fish cell line 41408591 CVCL_A2JR GS70JTO(SVT)-1 transformed cell line human CVCL_A2JR CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408592 CVCL_A2JS GS70JTO(SVT)-2 transformed cell line human CVCL_A2JS CL:0000010 Population: Japanese; Transformant: Simian virus 40 (SV40) [pSVori-](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408593 CVCL_A2JT TR-1 spontaneously immortalized cell line Norway rat CVCL_A2JT CL:0000010 Derived from sampling site: Testis Cell type=Endothelial cell.; Breed/subspecies: Sprague Dawley. Male Doubling time: 24 hours (PubMed=7046561) 41408594 CVCL_A2JU TR-M spontaneously immortalized cell line Norway rat CVCL_A2JU CL:0000010 Derived from sampling site: Testis Cell type=Peritubular myoid cell.; Breed/subspecies: Long-Evans. Male Doubling time: 36 hours (PubMed=7046561) 41408595 CVCL_A2JF HER4.10H1.1A1 hybridoma house mouse CVCL_A2JF CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2828 41408596 CVCL_A2JG HER4.1A6.5B3 hybridoma house mouse CVCL_A2JG CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2827 41408597 CVCL_A2JH HER4.1C6.A11 hybridoma house mouse CVCL_A2JH CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2829 41408598 CVCL_A2JI HER4.3B9.2C9 hybridoma house mouse CVCL_A2JI CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2826 41408599 CVCL_A2JJ HER4.8B1.2H2 hybridoma house mouse CVCL_A2JJ CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q15303; Human ERBB4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-2825 41408600 CVCL_A2JK iSGEC-nSS1 transformed cell line human CVCL_A2JK CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; labial gland Cell type=Epithelial cell.. Female Characteristics: Has a heterologous mesenchymal phenotype Exhibits high expression of both VIM and CST3, and the low expression of KRT19 (PubMed=33255850). 41408601 CVCL_A2JL iSGEC-nSS2 transformed cell line human CVCL_A2JL CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; labial gland Cell type=Epithelial cell.. Female Characteristics: Has an undifferentiated ductal cell phenotype Has a high mRNA expression of KRT5 and relatively spotty distribution of KRT19 protein (PubMed=33255850). 41408602 CVCL_A2JM iSGEC-pSS1 transformed cell line human CVCL_A2JM CL:0000010 Population: Caucasian; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Salivary gland; labial gland Cell type=Epithelial cell.. Female 41408603 CVCL_A2JA TG-4 hybridoma house mouse CVCL_A2JA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11745 41408604 CVCL_A2JB TG-5 hybridoma house mouse CVCL_A2JB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11746 41408605 CVCL_A2IU MC-5 hybridoma house mouse CVCL_A2IU CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11739 41408606 CVCL_A2IV MC-6 hybridoma house mouse CVCL_A2IV CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11740 41408607 CVCL_A2IW MC-15 hybridoma house mouse CVCL_A2IW CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11741 41408608 CVCL_A2IX MC-16 hybridoma house mouse CVCL_A2IX CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11742 41408609 CVCL_A2IY PHF-1 hybridoma house mouse CVCL_A2IY CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P10636; Human MAPT (Note=Phosphorylated on p.Ser396 and p.Ser404). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11743 41408610 CVCL_A2IZ TG-3 hybridoma house mouse CVCL_A2IZ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11744 41408611 CVCL_A2KP AG03634 finite cell line human CVCL_A2KP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03634; probable Unspecified 41408612 CVCL_A2KQ AG03635 transformed cell line human CVCL_A2KQ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03635; probable Unspecified 41408613 CVCL_A2KR AG01231 finite cell line human CVCL_A2KR CL:0000010 Derived from sampling site: Eye; conjunctiva Cell type=Fibroblast.. Discontinued: Coriell; AG01231; probable Female 41408614 CVCL_A2KS AG01517 finite cell line human CVCL_A2KS CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG01517; probable Female 41408615 CVCL_A2KT AG02120 finite cell line CVCL_A2KT CL:0000010 Derived from sampling site: Ear; skin Cell type=Fibroblast.. Discontinued: Coriell; AG02120; probable 41408616 CVCL_A2KU AG03302 finite cell line human CVCL_A2KU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03302; probable Male 41408617 CVCL_A2KV AG03307 finite cell line human CVCL_A2KV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03307; probable Female 41408618 CVCL_A2KG E710.2 cancer cell line house mouse CVCL_A2KG CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Has an immature phenotype (CD4-CD8-) (PubMed=1828825); Characteristics: Proliferates in response to thymocytes or phorbol 12-myristate 13-acetate (PMA) when cultured at low density Proliferates spontaneously when grown at high density (PubMed=1828825). 41408619 CVCL_A2KH E710.2.3 cancer cell line house mouse CVCL_A2KH CL:0000010 Derived from sampling site: Thymus; Breed/subspecies: AKR/J. Characteristics: Has an immature phenotype (CD4-CD8-) (PubMed=10415028); Characteristics: Proliferates in response to thymocytes or phorbol 12-myristate 13-acetate (PMA) when cultured at low density Proliferates spontaneously when grown at high density (PubMed=10415028). 41408620 CVCL_A2KI AG02409 finite cell line CVCL_A2KI CL:0000010 Derived from sampling site: Smooth muscle. Discontinued: Coriell; AG02409; probable Male 41408621 CVCL_A2KJ AG02410 finite cell line CVCL_A2KJ CL:0000010 Derived from sampling site: Smooth muscle. Discontinued: Coriell; AG02410; probable Male 41408622 CVCL_A2KK AG02411 finite cell line CVCL_A2KK CL:0000010 Derived from sampling site: Smooth muscle. Discontinued: Coriell; AG02411; probable Male 41408623 CVCL_A2KL AG02791 finite cell line CVCL_A2KL CL:0000010 Derived from sampling site: Lung; artery; endothelium. Discontinued: Coriell; AG02791; probable Unspecified 41408624 CVCL_A2KM AG03692 finite cell line human CVCL_A2KM CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03692; probable Male 41408625 CVCL_A2KN AG03633 transformed cell line human CVCL_A2KN CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; AG03633; probable 41408626 CVCL_A2KA MDCK-hMDR1 cMDR1-KO spontaneously immortalized cell line dog CVCL_A2KA CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 37431; ABCB1; Transfected with: HGNC; 40; ABCB1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Deep quantitative proteome analysis Female 41408627 CVCL_A2KB HEK-OCT3 transformed cell line human CVCL_A2KB CL:0000010 Transfected with: HGNC; 10967; SLC22A3; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 41408628 CVCL_A2KC MDCK-hBCRP cMDR1-KO. spontaneously immortalized cell line dog CVCL_A2KC CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 37431; ABCB1; Transfected with: HGNC; 74; ABCG2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Deep quantitative proteome analysis Female 41408629 CVCL_A2KD DMF10.167.4 hybridoma house mouse CVCL_A2KD CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-405 41408630 CVCL_A2KE DMF10.62.3 hybridoma house mouse CVCL_A2KE CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-377 41408631 CVCL_A2KF DMF10.34.36 hybridoma house mouse CVCL_A2KF CL:0000010 Monoclonal antibody isotype: IgG; Monoclonal antibody target: ChEBI; CHEBI:60327; Ganglioside GM2. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-404 41408632 CVCL_A2JV TR-ST cancer cell line Norway rat CVCL_A2JV CL:0000010 Derived from sampling site: Testis Cell type=Sertoli cell.; Breed/subspecies: Long-Evans. Male Characteristics: Tumorigenic in BALB/c nu/nu mice Doubling time: 10 hours (PubMed=7046561) 41408633 CVCL_A2JW TSL spontaneously immortalized cell line CVCL_A2JW CL:0000010 Derived from sampling site: Testis Cell type=Leydig stem cell.. Male Characteristics: Capable of 11- ketotestosterone (11-KT) production Group: Fish cell line 41408634 CVCL_A2JX MDCK cMDR1-KO spontaneously immortalized cell line dog CVCL_A2JX CL:0000010 Knockout cell: Method=CRISPR/Cas9; VGNC; 37431; ABCB1 Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Omics: Deep quantitative proteome analysis Female Caution: Incorrectly indicated as originating from MDCK-II while it seems to be derived from MDCK.2 41408635 CVCL_A2JY MDCK2-ABCC2 spontaneously immortalized cell line dog CVCL_A2JY CL:0000010 Transfected with: HGNC; 53; ABCC2; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Caution: There is another MDCK-II cell line with transfected human ABCC2: MDCK-MRP2 (Cellosaurus=CVCL_X022) 41408636 CVCL_A2JZ MDCK2-ABCB1 spontaneously immortalized cell line dog CVCL_A2JZ CL:0000010 Transfected with: HGNC; 40; ABCB1; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Kidney; Breed/subspecies: Cocker Spaniel. Female Caution: There is another MDCK-II cell line with transfected human ABCB1: MDCK-MDR1 (Cellosaurus=CVCL_S586) 41408637 CVCL_A2HL KO288 cancer cell line house mouse CVCL_A2HL CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:103076; Vdr Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6J Vdrtm1Mbd. Female Doubling time: 23.1 hours (non-treated), 24.1 hours (1,25D3 treated) (PubMed=12644300) 41408638 CVCL_A2HM WT145 cancer cell line house mouse CVCL_A2HM CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6J. Female Doubling time: 15.8 hours (non-treated), 45.9 hours (1,25D3 treated) (PubMed=12644300) 41408639 CVCL_A2HN WT276 cancer cell line house mouse CVCL_A2HN CL:0000010 Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6J. Female Doubling time: 13.3 hours (non-treated), 17.5 hours (1,25D3 treated) (PubMed=12644300) 41408640 CVCL_A2HP SiBBE transformed cell line human CVCL_A2HP CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.His3His (c.9T>C); ClinVar=VCV000193106; Zygosity=Heterozygous (PubMed=33033327); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Glu27Lys (c.79G>A) (E26K); ClinVar=VCV000015161; Zygosity=Heterozygous (PubMed=33033327); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.315+16G>C; ClinVar=VCV000256345; Zygosity=Heterozygous (PubMed=33033327); Sequence variation: Mutation; HGNC; 4827; HBB; Simple; c.316-185C>T; ClinVar=VCV000036316; Zygosity=Homozygous (PubMed=33033327); Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Southeast Asian; Thai; Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Peripheral blood Cell type=Mononuclear cell.. Female Doubling time: 17 hours (PubMed=33033327) 41408641 CVCL_A2HQ RD/VCR-F3 cancer cell line human CVCL_A2HQ CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000373003; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR); Derived from sampling site: Pelvis; muscle. Female 41408642 CVCL_A2HR Akata (-) EBV-neoR cancer cell line human CVCL_A2HR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leufs*57 (c.569delC); Zygosity=Unspecified (from parent cell line) Population: Japanese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Female Virology: EBV-negative cell line re-infected with recombinant EBV whose genome contains a neoR gene 41408643 CVCL_A2HS UM217-1 PGD embryonic stem cell human CVCL_A2HS From: University of Michigan; Ann Arbor; USA CL:0000010 Donor information: Embryo is sibling to that giving rise to UM217-2 PGD (Cellosaurus=CVCL_C3F4). Unspecified Registration: NIH Human Embryonic Stem Cell Registry; NIHhESC-21-0485 41408644 CVCL_A2HD Hep G2-C34 cancer cell line human CVCL_A2HD CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Control cell line for Hep G2-E43 and Hep G2-E47 41408645 CVCL_A2HE Hep G2-C37 cancer cell line human CVCL_A2HE CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Control cell line for Hep G2-E43 and Hep G2-E47 41408646 CVCL_A2HF Hep G2-E43 cancer cell line human CVCL_A2HF CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Overexpresses CYP2E1 41408647 CVCL_A2HG Hep G2-E47 cancer cell line human CVCL_A2HG CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Overexpresses CYP2E1 41408648 CVCL_A2HH HepG2-CYP2E1 cancer cell line human CVCL_A2HH CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 41408649 CVCL_A2HI EO-NY cancer cell line house mouse CVCL_A2HI CL:0000010 Transfected with: HGNC; 17234; ANKRD30A; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6. Female 41408650 CVCL_A2HJ EO-NY/PX458/#1 cancer cell line house mouse CVCL_A2HJ CL:0000010 Knockout cell: Method=CRISPR/Cas9; MGI; MGI:88127; B2m; Transfected with: HGNC; 17234; ANKRD30A; Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR); Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP) Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6. Female 41408651 CVCL_A2HK KO240 cancer cell line house mouse CVCL_A2HK CL:0000010 Knockout cell: Method=KO mouse; MGI; MGI:103076; Vdr Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Mammary gland; Breed/subspecies: C57BL/6J Vdrtm1Mbd. Female Doubling time: 15.8 hours (non-treated), 16.1 hours (1,25D3 treated) (PubMed=12644300) 41408652 CVCL_A2HA V79-hCYP1A2-hNAT2 spontaneously immortalized cell line CVCL_A2HA CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7646; NAT2; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408653 CVCL_A2HB Hep G2-MV2E1-9 cancer cell line human CVCL_A2HB CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male 41408654 CVCL_A2HC Hep G2-MV-5 cancer cell line human CVCL_A2HC CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Derived from sampling site: Liver. Male Characteristics: Control cell line for Hep G2-MV2E1-9 41408655 CVCL_A2GS K-23-L transformed cell line human CVCL_A2GS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41408656 CVCL_A2GT OnH spontaneously immortalized cell line CVCL_A2GT CL:0000010 Derived from sampling site: Heart. Unspecified Characteristics: Grows optimally in the temperature from 24 to 32 Celsius; Virology: Susceptible to infection by Tilapia lake virus (TiLV) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC071 41408657 CVCL_A2GU V79-hCYP2E1 spontaneously immortalized cell line CVCL_A2GU CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2631; CYP2E1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408658 CVCL_A2GV V79-hSULT2A1 spontaneously immortalized cell line CVCL_A2GV CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11458; SULT2A1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408659 CVCL_A2GW V79-hSULT1A1 spontaneously immortalized cell line CVCL_A2GW CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11453; SULT1A1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408660 CVCL_A2GX V79-hSULT1A3 spontaneously immortalized cell line CVCL_A2GX CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 11455; SULT1A3; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408661 CVCL_A2GY V79-hCYP1A2-hSULT1A1 spontaneously immortalized cell line CVCL_A2GY CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 11453; SULT1A1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408662 CVCL_A2GZ V79-hCYP1A2-hNAT1 spontaneously immortalized cell line CVCL_A2GZ CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 2596; CYP1A2; Transfected with: HGNC; 7645; NAT1; Transfected with: UniProtKB; P00552; Transposon Tn5 neo; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41408663 CVCL_A2IM Sf9-HT spontaneously immortalized cell line CVCL_A2IM CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Able to grow at 37 Celsius Doubling time: 33.6 hours (at 28 Celsius), 21.4 +- 2.5 hours (at 37 Celsius) (PubMed=10718368) Group: Insect cell line; Group: Recombinant protein production insect cell line 41408664 CVCL_A2IN Sf21-HT spontaneously immortalized cell line CVCL_A2IN CL:0000010 Derived from sampling site: Ovary. Female Characteristics: Able to grow at 37 Celsius Group: Insect cell line; Group: Recombinant protein production insect cell line 41408665 CVCL_A2IP ATS8 hybridoma house mouse CVCL_A2IP CL:0000010 Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: UniProtKB; P10636; Human MAPT (Note=Phosphorylated on p.Ser199 and/or p.Ser202). Group: Patented cell line; Registration: International Depositary Authority, European Collection of Cell Cultures (ECACC); 91100806 41408666 CVCL_A2IQ ALZ-50 hybridoma house mouse CVCL_A2IQ CL:0000010 Monoclonal antibody isotype: IgM; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9205 41408667 CVCL_A2IR MC-1 [Mouse hybridoma against human MAPT] hybridoma house mouse CVCL_A2IR CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11736 41408668 CVCL_A2IS MC-2 hybridoma house mouse CVCL_A2IS CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11737 41408669 CVCL_A2IT MC-3 hybridoma house mouse CVCL_A2IT CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P10636; Human MAPT. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-11738 41408670 CVCL_A2IE V82G12-R1G1 hybridoma house mouse CVCL_A2IE CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408671 CVCL_A2IF V82B1-R2D4 hybridoma house mouse CVCL_A2IF CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408672 CVCL_A2IG I101C9-R1A5 hybridoma house mouse CVCL_A2IG CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408673 CVCL_A2IH I101D4-R1D8 hybridoma house mouse CVCL_A2IH CL:0000010 Monoclonal antibody isotype: IgG1+IgM, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408674 CVCL_A2II I101F8-R1G5 hybridoma house mouse CVCL_A2II CL:0000010 Monoclonal antibody isotype: IgG1+IgG2b, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408675 CVCL_A2IJ I101H12-R1GB hybridoma house mouse CVCL_A2IJ CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. 41408676 CVCL_A2IK I101F5-R1G2 hybridoma house mouse CVCL_A2IK CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. 41408677 CVCL_A2IL HL130C2.3C5 hybridoma house mouse CVCL_A2IL CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8746 41408678 CVCL_A2IA V81C6-R1B6 hybridoma house mouse CVCL_A2IA CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408679 CVCL_A2IB V82A6-R1C4 hybridoma house mouse CVCL_A2IB CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-8742 41408680 CVCL_A2IC V82B2-R1F6 hybridoma house mouse CVCL_A2IC CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408681 CVCL_A2ID V82G3-R1D6 hybridoma house mouse CVCL_A2ID CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P04114; Human APOB. 41408682 CVCL_A2HT H91H4.2H8 hybridoma house mouse CVCL_A2HT CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9200 41408683 CVCL_A2HU H103D8.1D11 hybridoma house mouse CVCL_A2HU CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9201 41408684 CVCL_A2HV H105C7.1C10 hybridoma house mouse CVCL_A2HV CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9202 41408685 CVCL_A2HW H105F4.1B4 hybridoma house mouse CVCL_A2HW CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9203 41408686 CVCL_A2HX H114D12.2D8 hybridoma house mouse CVCL_A2HX CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9204 41408687 CVCL_A2HY H135D3 hybridoma house mouse CVCL_A2HY CL:0000010 Monoclonal antibody isotype: IgG1, kappa; Monoclonal antibody target: UniProtKB; P02647; Human APOA1. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-9570 41408688 CVCL_A2HZ P3X63Ag8.653.1 cancer cell line house mouse CVCL_A2HZ CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine; Breed/subspecies: BALB/c. Female Group: Hybridoma fusion partner cell line 41408689 CVCL_A1TY 411BRneo finite cell line human CVCL_A1TY CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Ala3Val (c.8C>T); ClinVar=VCV000007676; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Thr9Ile (c.26C>T); ClinVar=VCV000007677; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg278His (c.833G>A); ClinVar=VCV000007675; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Simian virus 40 (SV40) [pSV3-neo](NCBI-Taxonomy; 1891767); Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41408690 CVCL_A1TZ FB2303 finite cell line human CVCL_A1TZ CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg580Ter (c.1738C>T); ClinVar=VCV000007672; Zygosity=Heterozygous (PubMed=11779494); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg814Ter (c.2440C>T); ClinVar=VCV000007673; Zygosity=Heterozygous (PubMed=11779494) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41408691 CVCL_A1UA LB2304 transformed cell line human CVCL_A1UA CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg580Ter (c.1738C>T); ClinVar=VCV000007672; Zygosity=Heterozygous (PubMed=11779494); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg814Ter (c.2440C>T); ClinVar=VCV000007673; Zygosity=Heterozygous (PubMed=11779494) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 41408692 CVCL_A1TQ Nakajima cancer cell line human CVCL_A1TQ CL:0000010 Population: Japanese. Female 41408693 CVCL_A1TR Nakajima-S1 cancer cell line human CVCL_A1TR CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female 41408694 CVCL_A1TS Nakajima-S2 cancer cell line human CVCL_A1TS CL:0000010 Population: Japanese; Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Female 41408695 CVCL_A1TT JIL-2266 cancer cell line human CVCL_A1TT CL:0000010 Sequence variation: Mutation; HGNC; 7527; MUTYH; Simple; p.Arg106Trp (c.316C>T) (p.Arg81Trp, c.241C>T); ClinVar=VCV000183896; Zygosity=Heterozygous; Note=Germline (PubMed=33830941); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Hemizygous (DOI=10.1530/endoabs.70.AEP83; PubMed=33830941) Derived from sampling site: Adrenal gland. Female Doubling time: ~39 hours (DOI=10.1530/endoabs.70.AEP83); 41 hours (PubMed=33830941) 41408696 CVCL_A1TU EndoC-betaH2-OFP-GFZ conditionally immortalized cell line human CVCL_A1TU CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: Cre-ERT2, Cre recombinase fused with ligand-binding domain of ESR mutated to only bind tamoxifen; Transfected with: UniProtKB; Q60I24; Galaxea fascicularis monomeric Azami-Green; Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR); Transfected with: UniProtKB; P17493; Streptoalloteichus hindustanus ble (BleoR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Unspecified Characteristics: The lentiviral vector insert containing the SV40 LT and hTERT can be excised by the Cre recombinase upon addition of tamixofen Following excision of immortalizing transgenes, cell proliferation sharply decreases and in parallel there is a massive enhancement of beta cell-specific features such as increased INS gene expression.; Characteristics: Transduced with the Fucci probe which consist of the fusion of monomeric Kusabira-Orange 2 (mKO2) to the ubiquitination domain of human CDT1 (AA 30-120) and monomeric Azami-Green (mAG) to the ubiquitination domain of human geminin (AA 1-110); Characteristics: In this cell line the Fucci probe was produced by transducing two different constructs: LTR-mKO2/CDT1-IRES-PuroR-LTR and LTR-mAG/GMNN-IRES-ZeoR-LTR; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 41408697 CVCL_A1TV EndoC-betaH21-PGF2AOF conditionally immortalized cell line human CVCL_A1TV CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: HGNC; 24576; CDT1 (with p.Met1_Thr29del and p.Ser121_Leu546del); Transfected with: HGNC; 17493; GMNN (with p.Tyr111_Ile209del); Transfected with: Cre-ERT2, Cre recombinase fused with ligand-binding domain of ESR mutated to only bind tamoxifen; Transfected with: UniProtKB; Q60I24; Galaxea fascicularis monomeric Azami-Green; Transfected with: UniProtKB; Q6I7B2; Fungia concinna monomeric Kusabira-Orange (with p.Lys49Glu, p.Pro70Val, p.Phe176Met, p.Lys185Glu, P.Lys188Glu, p.Ser192Asp, p.Ser196Gly and p.Leu210Gln = mKO2); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Pancreas; islets of Langerhans Cell type=Beta cell.. Unspecified Characteristics: The lentiviral vector insert containing the SV40 LT and hTERT can be excised by the Cre recombinase upon addition of tamixofen Following excision of immortalizing transgenes, cell proliferation sharply decreases and in parallel there is a massive enhancement of beta cell-specific features such as increased INS gene expression.; Characteristics: Transduced with the Fucci probe which consist of the fusion of monomeric Kusabira-Orange 2 (mKO2) to the ubiquitination domain of human CDT1 (AA 30-120) and monomeric Azami-Green (mAG) to the ubiquitination domain of human geminin (AA 1-110); Characteristics: In this cell line the Fucci probe was produced by transducing with a construct LTR-PuroR-IRES-mAG/GMNN-2A-mKO2/CDT1-LTR; Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (from parent cell line) 41408698 CVCL_A1TW CZ2 cancer cell line human CVCL_A1TW CL:0000010 Population: Chinese; Derived from sampling site: Pleural effusion. Male Characteristics: Does not secrete immunoglobulins Doubling time: ~48 hours (DOI=10.21203/rs.3.rs-94742/v1) 41408699 CVCL_A1TX 411BR finite cell line human CVCL_A1TX CL:0000010 Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Ala3Val (c.8C>T); ClinVar=VCV000007676; Zygosity=Homozygous (PubMed=11779494); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Thr9Ile (c.26C>T); ClinVar=VCV000007677; Zygosity=Homozygous (PubMed=11779494); Sequence variation: Mutation; HGNC; 6601; LIG4; Simple; p.Arg278His (c.833G>A); ClinVar=VCV000007675; Zygosity=Homozygous (PubMed=11779494) Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41408700 CVCL_A1TI HN-6n2 cancer cell line human CVCL_A1TI CL:0000010 Derived from metastatic site: Cervical lymph node. Male Doubling time: 72 hours (PubMed=7284233) 41408701 CVCL_A1TJ HN-6Rr cancer cell line human CVCL_A1TJ CL:0000010 Derived from sampling site: Oral cavity; tongue. Male Doubling time: 30 hours (PubMed=7284233) 41408702 CVCL_A1TK H13C113 hybridoma house mouse CVCL_A1TK CL:0000010 Monoclonal antibody isotype: IgG3, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 643-683; Envelope glycoprotein E2). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10857 41408703 CVCL_A1TL H23C163 hybridoma house mouse CVCL_A1TL CL:0000010 Monoclonal antibody isotype: IgG2b, kappa; Monoclonal antibody target: UniProtKB; P26664; Hepatitis C virus genotype 1a (isolate 1) genome polyprotein (AA 643-683; Envelope glycoprotein E2). Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); HB-10856 41408704 CVCL_A1TM AL07 telomerase immortalized cell line human CVCL_A1TM CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Derived from sampling site: Trophoblast. Unspecified 41408705 CVCL_A1TN DFT2.JV cancer cell line CVCL_A1TN CL:0000010 Male Group: Marsupial cell line. 41408706 CVCL_A1TA HPS1709 induced pluripotent stem cell human CVCL_A1TA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408707 CVCL_A1TB HPS1038 induced pluripotent stem cell human CVCL_A1TB CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408708 CVCL_A1TC HPS1710 induced pluripotent stem cell human CVCL_A1TC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408709 CVCL_A1TD HPS1711 induced pluripotent stem cell human CVCL_A1TD CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408710 CVCL_A1TE SHETi002-A induced pluripotent stem cell human CVCL_A1TE From: Department of Cardiology, Shanghai Children's Hospital, Shanghai Jiaotong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 2511; CTNNA3; Simple; p.Met737Ile (c.2211G>C); ClinVar=VCV000643288; Zygosity=Heterozygous (PubMed=33497884) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 41408711 CVCL_A1TF SHETi001-A induced pluripotent stem cell human CVCL_A1TF From: Department of Cardiology, Shanghai Children's Hospital, Shanghai Jiaotong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 16974; SRCAP; Simple; p.Phe151Cysfs*71 (c.452_453del); Zygosity=Heterozygous (PubMed=33517121) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408712 CVCL_A1TG LUEi014-A induced pluripotent stem cell human CVCL_A1TG From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408713 CVCL_A1TH LUEi012-A induced pluripotent stem cell human CVCL_A1TH From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408714 CVCL_A1UZ ICC10-6 cancer cell line human CVCL_A1UZ CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln219Ter (c.655C>T); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35Cysfs*9 (c.102delC); ClinVar=VCV001072141; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408715 CVCL_A1VA ICC10-8 cancer cell line human CVCL_A1VA CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln219Ter (c.655C>T); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35Cysfs*9 (c.102delC); ClinVar=VCV001072141; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408716 CVCL_A1VB ICC10 cancer cell line human CVCL_A1VB CL:0000010 Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Gln219Ter (c.655C>T); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu35Cysfs*9 (c.102delC); ClinVar=VCV001072141; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408717 CVCL_A1UR GM27324 transformed cell line human CVCL_A1UR CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408718 CVCL_A1US GM27323 transformed cell line human CVCL_A1US CL:0000010 Population: Caucasian; Italian/Portuguese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408719 CVCL_A1UT GM27373 transformed cell line human CVCL_A1UT CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Asn232Ser (c.695A>G); ClinVar=VCV001698021; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408720 CVCL_A1UU GM27374 transformed cell line human CVCL_A1UU CL:0000010 Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408721 CVCL_A1UV GM27376 transformed cell line human CVCL_A1UV CL:0000010 Population: Caucasian; British; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408722 CVCL_A1UW GM27379 transformed cell line human CVCL_A1UW CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Tyr208Cys (c.623A>G); Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408723 CVCL_A1UX C396 cancer cell line human CVCL_A1UX CL:0000010 Derived from metastatic site: Not specified. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408724 CVCL_A1UY LPS067 cancer cell line human CVCL_A1UY CL:0000010 Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). 41408725 CVCL_A1UJ GM27315 transformed cell line human CVCL_A1UJ CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Phe215Ser (c.644T>C); Zygosity=Heterozygous (Coriell) Population: Southeast Asian; Thai and Chinese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408726 CVCL_A1UK GM27308 transformed cell line human CVCL_A1UK CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408727 CVCL_A1UL GM27318 transformed cell line human CVCL_A1UL CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408728 CVCL_A1UM GM27319 transformed cell line human CVCL_A1UM CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408729 CVCL_A1UN GM27320 transformed cell line human CVCL_A1UN CL:0000010 Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408730 CVCL_A1UP GM27321 transformed cell line human CVCL_A1UP CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Arg230Leu (c.689G>T); ClinVar=VCV000288531; Zygosity=Heterozygous (Coriell) Population: Caucasian; Hungarian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408731 CVCL_A1UQ GM27322 transformed cell line human CVCL_A1UQ CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gln29Argfs*90 (c.85_90delCAGAACinsA); Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408732 CVCL_A1UB TMBL-1 cancer cell line human CVCL_A1UB CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Unspecified (PubMed=12802925) Population: Japanese; Derived from sampling site: Bone marrow. Male Doubling time: 96 hours (PubMed=12802925) 41408733 CVCL_A1UC UOK156 cancer cell line human CVCL_A1UC CL:0000010 Unspecified 41408734 CVCL_A1UD UOK157 cancer cell line human CVCL_A1UD CL:0000010 Unspecified 41408735 CVCL_A1UE M140325 cancer cell line human CVCL_A1UE CL:0000010 Derived from sampling site: Skin. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408736 CVCL_A1UF M040416 cancer cell line human CVCL_A1UF CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap) Derived from metastatic site: Not specified. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408737 CVCL_A1UG WM4235 cancer cell line human CVCL_A1UG CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (DepMap) Derived from metastatic site: Not specified. Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE); Part of: Wistar Institute melanoma cell line collection 41408738 CVCL_A1UH 950-5-BIK cancer cell line human CVCL_A1UH CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Unspecified (DepMap) Derived from sampling site: Pancreas. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408739 CVCL_A1UI ECC2 cancer cell line human CVCL_A1UI CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln104Ter (c.310C>T); ClinVar=VCV000566924; Zygosity=Unspecified (DepMap) Derived from sampling site: Bile duct. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408740 CVCL_A1RW SGF-5 cancer cell line human CVCL_A1RW CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Doubling time: 30 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) Caution: Indicated as originating from a 78 year old male patient in DOI=10.5833/jjgs.28.615 and from a 71 year old male patient in PubMed=10937344 41408741 CVCL_A1RX SGF-7 cancer cell line human CVCL_A1RX CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 35 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) Caution: Indicated as originating from a 78 year old male patient in DOI=10.5833/jjgs.28.615 and from a 71 year old male patient in PubMed=10937344 41408742 CVCL_A1RY SGF-8 cancer cell line human CVCL_A1RY CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Male Characteristics: Established from a xenograft transplanted into BALB/c,nu/nu mice Doubling time: 38.5 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) Caution: Indicated as originating from a 56 year old male patient in DOI=10.5833/jjgs.28.615 and from a 52 year old male patient in PubMed=10937344 41408743 CVCL_A1RZ SGF-9 cancer cell line human CVCL_A1RZ CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Characteristics: Established from a xenograft transplanted into BALB/c,nu/nu mice Doubling time: 28 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) 41408744 CVCL_A1RP TM-1 [Human melanoma] cancer cell line human CVCL_A1RP CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Female Doubling time: ~72 hours (PubMed=494244) 41408745 CVCL_A1RQ PK [Human penis carcinoma] cancer cell line human CVCL_A1RQ CL:0000010 Population: Japanese; Derived from sampling site: Penis. Male 41408746 CVCL_A1RR Hep-11 cancer cell line human CVCL_A1RR CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=19897602) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH Male Doubling time: 44 hours (PubMed=19929456) Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.3203 41408747 CVCL_A1RS Hep-12 cancer cell line human CVCL_A1RS CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Ser (c.747G>T); ClinVar=VCV000012352; Zygosity=Unspecified (PubMed=19897602) Population: Chinese; Transformant: Hepatitis B virus (HBV)(NCBI-Taxonomy; 10407); Derived from sampling site: Liver. Omics: Array-based CGH Male Doubling time: 53 hours (PubMed=19929456) Group: Patented cell line; Registration: International Depositary Authority, China General Microbiological Culture Collection Center; CGMCC No.3204 41408748 CVCL_A1RT THP-1/E cancer cell line human CVCL_A1RT CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line) Population: Japanese; Selected for resistance to: ChEBI; CHEBI:4911; Etoposide (VP-16); Derived from sampling site: Peripheral blood. Male 41408749 CVCL_A1RU SGF-3 cancer cell line human CVCL_A1RU CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 33 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) 41408750 CVCL_A1RV SGF-4 cancer cell line human CVCL_A1RV CL:0000010 Population: Japanese; Derived from sampling site: Esophagus. Male Doubling time: 26 hours (DOI=10.5833/jjgs.28.615; PubMed=10937344) Caution: Indicated as originating from a 66 year old male patient in DOI=10.5833/jjgs.28.615 and from a 64 year old male patient in PubMed=10937344 41408751 CVCL_A1RG MC-1 [Rat fibrosarcoma] cancer cell line Norway rat CVCL_A1RG CL:0000010 Transformant: 3-methylcholanthrene (3-MC(ChEBI; CHEBI:34342); Breed/subspecies: Wistar. Male Doubling time: ~36 hours, at 48th passage (PubMed=5027480) 41408752 CVCL_A1RH Yana-1 cancer cell line human CVCL_A1RH CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: IL2 dependent 41408753 CVCL_A1RI Yana-2 cancer cell line human CVCL_A1RI CL:0000010 Population: Japanese; Transformant: Human T-lymphotropic virus 1 (HTLV-1)(NCBI-Taxonomy; 11908); Derived from sampling site: Peripheral blood Cell type=T-cell.. Female Characteristics: Not IL2 dependent 41408754 CVCL_A1RJ TK-SA cancer cell line human CVCL_A1RJ CL:0000010 Population: Japanese; Derived from metastatic site: Pleural effusion. Female Doubling time: 100.4 hours (PubMed=7570584) 41408755 CVCL_A1RK TKB-11 cancer cell line human CVCL_A1RK CL:0000010 Population: Japanese. Unspecified 41408756 CVCL_A1RL TKB-13 cancer cell line human CVCL_A1RL CL:0000010 Population: Japanese. Unspecified 41408757 CVCL_A1RM TKB-101 cancer cell line human CVCL_A1RM CL:0000010 Population: Japanese. Unspecified 41408758 CVCL_A1RN TKB-102 cancer cell line human CVCL_A1RN CL:0000010 Population: Japanese. Female 41408759 CVCL_A1RA UM-SCC-64 cancer cell line human CVCL_A1RA CL:0000010 Derived from sampling site: Salivary gland; parotid gland. Female 41408760 CVCL_A1RB HSC 89 transformed cell line human CVCL_A1RB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408761 CVCL_A1RC HSC 49 transformed cell line human CVCL_A1RC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41408762 CVCL_A1RD HSC 50 transformed cell line human CVCL_A1RD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408763 CVCL_A1RE HSC 55 transformed cell line human CVCL_A1RE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41408764 CVCL_A1RF NH32 transformed cell line human CVCL_A1RF CL:0000010 Knockout cell: Method=Promoterless gene targeting; HGNC; 11998; TP53; Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=26774668); Transfected with: UniProtKB; P06988; Escherichia coli hisD; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Omics: Transcriptome analysis by RNAseq Male 41408765 CVCL_A1SX HPS1705 induced pluripotent stem cell human CVCL_A1SX CL:0000010 Sequence variation: Mutation; HGNC; 10947; SLC20A2; Simple; p.Trp616Ter (c.1848G>A); Zygosity=Heterozygous (from autologous cell line CIRAi003-A) Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408766 CVCL_A1SY HPS1037 induced pluripotent stem cell human CVCL_A1SY CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408767 CVCL_A1SZ HPS1708 induced pluripotent stem cell human CVCL_A1SZ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408768 CVCL_A1SP OV-3291 cancer cell line human CVCL_A1SP CL:0000010 Sequence variation: Mutation; HGNC; 24224; CDK12; Simple; c.3095+1G>A; Zygosity=Unspecified; Note=Splice donor mutation (PubMed=32784519); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg249Trp (c.745A>T); ClinVar=VCV000141881; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 4.4 +- 0.6 days (PubMed=32784519) 41408769 CVCL_A1SQ OV-3331 cancer cell line human CVCL_A1SQ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn210Lysfs*37 (c.630del); Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 2.7 +- 0.3 days (PubMed=32784519) 41408770 CVCL_A1SR TOV-2414 cancer cell line human CVCL_A1SR CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 1.3 +- 0.2 days (PubMed=32784519) 41408771 CVCL_A1SS TOV-3392D cancer cell line human CVCL_A1SS CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 2.1 +- 0.4 days (PubMed=32784519) 41408772 CVCL_A1ST NCC-aRMS1-C1 cancer cell line human CVCL_A1ST CL:0000010 Sequence variation: Gene fusion; HGNC; 3819; FOXO1 + HGNC; 8621; PAX7; Name(s)=PAX7-FOXO1 (PubMed=32715445) Population: Japanese; Derived from sampling site: Thigh. Male Doubling time: 61 hours (PubMed=32715445) Part of: NCC sarcoma cell line panel 41408773 CVCL_A1SU m5S/1M spontaneously immortalized cell line house mouse CVCL_A1SU CL:0000010 Derived from sampling site: Skin; Breed/subspecies: ICR/Jcl. Male 41408774 CVCL_A1SV m5S/1M cl.4103 transformed cell line house mouse CVCL_A1SV CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; Breed/subspecies: ICR/Jcl. Male 41408775 CVCL_A1SW m5S/1M cl.6310 transformed cell line house mouse CVCL_A1SW CL:0000010 Transformant: X-Ray(NCIt; C17262); Derived from sampling site: Skin; Breed/subspecies: ICR/Jcl. Male 41408776 CVCL_A1SH TX545 transformed cell line human CVCL_A1SH CL:0000010 Sequence variation: Mutation; HGNC; 11272; SPTA1; Simple; p.Ser1163Ala (c.3487T>G); ClinVar=VCV000258929; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Ala78Argfs*27 (c.231insC); Zygosity=Heterozygous (PubMed=7859358); Sequence variation: Mutation; HGNC; 11830; TK1; Simple; p.Thr163Lys (c.488_489CC>AG); Zygosity=Heterozygous (PubMed=7859358) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Spleen. Male 41408777 CVCL_A1SI OV-2085 cancer cell line human CVCL_A1SI CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Arg (c.395A>G); ClinVar=VCV000376625; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 6.2 +- 2.2 days (PubMed=32784519) 41408778 CVCL_A1SJ TOV-2835EP cancer cell line human CVCL_A1SJ CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asp281Tyr (c.841G>T); ClinVar=VCV000376585; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 2.4 +- 0.3 days (PubMed=32784519) 41408779 CVCL_A1SK TOV-2881EP cancer cell line human CVCL_A1SK CL:0000010 Sequence variation: Mutation; HGNC; 23112; FAT3; Simple; p.Gly90Ala (c.286G>C); Zygosity=Unspecified (PubMed=32784519); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg156Pro (c.467G>C); ClinVar=VCV000634768; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 6.1 +- 1.7 days (PubMed=32784519) 41408780 CVCL_A1SL TOV-2929D cancer cell line human CVCL_A1SL CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys242Tyr (c.725G>A); ClinVar=VCV000012354; Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from sampling site: Ovary. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 6.0 +- 1.1 days (PubMed=32784519) 41408781 CVCL_A1SM OV-2978 cancer cell line human CVCL_A1SM CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.920-2A>G (IVS8-2A>G); ClinVar=VCV000043595; Zygosity=Unspecified; Note=Splice acceptor mutation (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Ascites. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 3.8 +- 0.03 days (PubMed=32784519) 41408782 CVCL_A1SN TOV-3121EP cancer cell line human CVCL_A1SN CL:0000010 Sequence variation: Mutation; HGNC; 19291; CSMD3; Simple; p.Asn563Ser (c.1688A>G); Zygosity=Unspecified (PubMed=32784519); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His214Leufs*33 (c.641delA); Zygosity=Unspecified (PubMed=32784519) Miscellaneous: STR profile from personal communication of Mes-Masson A.-M Derived from metastatic site: Omentum. Omics: Deep exome analysis; Omics: Transcriptome analysis by microarray Female Doubling time: 3.0 +- 0.5 days (PubMed=32784519) 41408783 CVCL_A1SA HM4KO cancer cell line human CVCL_A1SA CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 41408784 CVCL_A1SB HM5KO cancer cell line human CVCL_A1SB CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 41408785 CVCL_A1SC HM6KO cancer cell line human CVCL_A1SC CL:0000010 Population: Japanese; Derived from metastatic site: Lymph node. Unspecified 41408786 CVCL_A1SD CY-6 cancer cell line human CVCL_A1SD CL:0000010 Sequence variation: Mutation; HGNC; 9065; PLCG1; Simple; p.Glu650Ter (c.1948G>T); Zygosity=Heterozygous (CelloPub=CLPUB00592). 41408787 CVCL_A1SE S6B45 cancer cell line human CVCL_A1SE CL:0000010 Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Unspecified (from parent cell line); Transfected with: HGNC; 6018; IL6 Population: Japanese; Derived from sampling site: Pleural effusion. Female 41408788 CVCL_A1SF VOA1066 cancer cell line human CVCL_A1SF CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Asp1503fs (c.4509_4510insATGACCT); Zygosity=Unspecified (PubMed=33052929); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gly2087Ter (c.6259G>T); Zygosity=Unspecified (PubMed=33052929); Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Trp1109Ter (c.3327G>A); Zygosity=Unspecified (PubMed=33052929); Sequence variation: Mutation; HGNC; 18040; ARID1B; Simple; p.Ile1778fs (c.5334dupA); Zygosity=Unspecified (PubMed=33052929); Sequence variation: Mutation; HGNC; 17098; DICER1; Simple; p.Asp1810Tyr (c.5428G>T); ClinVar=VCV000933084; Zygosity=Heterozygous (PubMed=33052929) Derived from sampling site: Endometrium. Omics: Deep exome analysis Female Doubling time: ~35 hours (PubMed=33052929) 41408789 CVCL_A1SG ME1042 cancer cell line human CVCL_A1SG CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22383533; PubMed=23455323). 41408790 CVCL_A1QV UT-OC-1 cancer cell line human CVCL_A1QV CL:0000010 Derived from sampling site: Ovary. Female 41408791 CVCL_A1QW UT-OC-2 cancer cell line human CVCL_A1QW CL:0000010 Derived from sampling site: Ovary. Female 41408792 CVCL_A1QX UT-OC-3 cancer cell line human CVCL_A1QX CL:0000010 Derived from sampling site: Ovary. Female 41408793 CVCL_A1QY UT-OC-4 cancer cell line human CVCL_A1QY CL:0000010 Derived from sampling site: Ovary. Female 41408794 CVCL_A1QZ UT-OC-5 cancer cell line human CVCL_A1QZ CL:0000010 Derived from metastatic site: Omentum. Female 41408795 CVCL_A1QS TRA-1-60 hybridoma house mouse CVCL_A1QS CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma along with that produced by TRA-1-81 (Cellosaurus=CVCL_A1QT) are widely used in human stem cell research as positive indicators of a true pluripotent human stem cell Monoclonal antibody isotype: IgM; Monoclonal antibody target: Type 1 lactosamine minimal epitope Galbeta1-3GlcNAcbeta1-3Galbeta1-4GlcNAc (Note=Recognizes human podocalyxin). 41408796 CVCL_A1QT TRA-1-81 hybridoma house mouse CVCL_A1QT CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma along with that produced by TRA-1-60 (Cellosaurus=CVCL_A1QS) are widely used in human stem cell research as positive indicators of a true pluripotent human stem cell Monoclonal antibody isotype: IgM; Monoclonal antibody target: Type 1 lactosamine minimal epitope Galbeta1-3GlcNAcbeta1-3Galbeta1-4GlcNAc (Note=Recognizes human podocalyxin). 41408797 CVCL_A1QU U-348MG cancer cell line human CVCL_A1QU CL:0000010 Derived from sampling site: Brain; temporal lobe. Male 41408798 CVCL_A1ZW A549-1 cancer cell line human CVCL_A1ZW CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Characteristics: Selected to grow at low density 41408799 CVCL_A1ZX A549-R0 cancer cell line human CVCL_A1ZX CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11389; STK11; Simple; p.Gln37Ter (c.109C>T); ClinVar=VCV000376334; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Lung. Male Doubling time: 8-10 days (PubMed=8132585) Group: Serum/protein free medium cell line 41408800 CVCL_A1ZY 1000T cancer cell line human CVCL_A1ZY From: Siegfried J.M.; University of Pittsburgh; Pittsburgh; USA CL:0000010 Miscellaneous: Age/sex of donor from personal communication of Siegfried J.M Derived from metastatic site: Bone marrow. Male 41408801 CVCL_A1ZZ LA10-1 cancer cell line human CVCL_A1ZZ From: Repasky E.; Roswell Park Cancer Center; Buffalo; USA. CL:0000010 Unspecified 41408802 CVCL_A1ZP XPV4KO finite cell line human CVCL_A1ZP CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser242Ter (c.725C>G); ClinVar=VCV000264680; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408803 CVCL_A1ZQ XPV5KO finite cell line human CVCL_A1ZQ CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408804 CVCL_A1ZR XPV6KO finite cell line human CVCL_A1ZR CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu306Ter (c.916G>T); ClinVar=VCV000005887; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408805 CVCL_A1ZS XPV7KO finite cell line human CVCL_A1ZS CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408806 CVCL_A1ZT SHO cancer cell line human CVCL_A1ZT CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376). Doubling time: 21 hours (PubMed=8402660) 41408807 CVCL_A1ZU SG568 cancer cell line human CVCL_A1ZU CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.522_523ins3; Zygosity=Unspecified (PubMed=8402660). Doubling time: 23 hours (PubMed=8402660) 41408808 CVCL_A1ZV XMDYYYi001-A induced pluripotent stem cell human CVCL_A1ZV From: Department of Neurology, The First Affiliated Hospital of Xiamen University; Xiamen; China CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex2-19dup; Zygosity=Hemizygous (PubMed=33799273) Population: Asian; Derived from sampling site: Peripheral blood. Male 41408809 CVCL_A1ZG XPV7HM finite cell line human CVCL_A1ZG CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408810 CVCL_A1ZH XPV8HM finite cell line human CVCL_A1ZH CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser242Ter (c.725C>G); ClinVar=VCV000264680; Zygosity=Heterozygous (PubMed=17344931); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Lys589Thr (c.1766A>C); ClinVar=VCV000005895; Zygosity=Heterozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408811 CVCL_A1ZI XPV10HM finite cell line human CVCL_A1ZI CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408812 CVCL_A1ZJ XPV11HM finite cell line human CVCL_A1ZJ CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu306Ter (c.916G>T); ClinVar=VCV000005887; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408813 CVCL_A1ZK XPV12HM finite cell line human CVCL_A1ZK CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Gln554fs*31 (c.1661delA); Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408814 CVCL_A1ZL XPV1KO finite cell line human CVCL_A1ZL CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Heterozygous (PubMed=17344931); Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu306Ter (c.916G>T); ClinVar=VCV000005887; Zygosity=Heterozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408815 CVCL_A1ZM XPV2KO finite cell line human CVCL_A1ZM CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408816 CVCL_A1ZN XPV3KO finite cell line human CVCL_A1ZN CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ala117Pro (c.349G>C); Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408817 CVCL_A1YA MIN30i-33109.2G induced pluripotent stem cell human CVCL_A1YA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408818 CVCL_A1YB WAe001-A-35 embryonic stem cell human CVCL_A1YB From: Sun Yat-sen University Third Affiliated Hospital; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 14261; RGS18. Male 41408819 CVCL_A1YC KEIUi001-A induced pluripotent stem cell human CVCL_A1YC From: Keio University; Tokyo; Japan CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple_corrected; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous; Note=By TALEN (PubMed=33181472) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408820 CVCL_A1YD LB16 induced pluripotent stem cell human CVCL_A1YD CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (PubMed=26056228) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408821 CVCL_A1YE LB21 induced pluripotent stem cell human CVCL_A1YE CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Ile2020Thr (c.6059C>T); ClinVar=VCV000001941; Zygosity=Heterozygous (PubMed=26056228) Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408822 CVCL_A1XU MIN24i-35613.B induced pluripotent stem cell human CVCL_A1XU CL:0000010 41408823 CVCL_A1XV MIN25i-35613.SF-1 induced pluripotent stem cell human CVCL_A1XV CL:0000010 41408824 CVCL_A1XW MIN26i-35326.I induced pluripotent stem cell human CVCL_A1XW CL:0000010 41408825 CVCL_A1XX MIN27i-35326.K induced pluripotent stem cell human CVCL_A1XX CL:0000010 41408826 CVCL_A1XY MIN28i-35833.A induced pluripotent stem cell human CVCL_A1XY CL:0000010 41408827 CVCL_A1XZ MIN29i-35833.B induced pluripotent stem cell human CVCL_A1XZ CL:0000010 41408828 CVCL_A1XM WMUi004-A induced pluripotent stem cell human CVCL_A1XM From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 29326; SLC7A14; Simple; p.Gly330Arg (c.988G>A); ClinVar=VCV000126446; Zygosity=Heterozygous (PubMed=33207307) Population: Chinese; Derived from sampling site: Peripheral blood. Male 41408829 CVCL_A1XN WMUi005-A induced pluripotent stem cell human CVCL_A1XN From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 29326; SLC7A14; Simple; p.Gly330Arg (c.988G>A); ClinVar=VCV000126446; Zygosity=Heterozygous (PubMed=33207307) Population: Chinese; Derived from sampling site: Peripheral blood. Female 41408830 CVCL_A1XP EDi001-B-1 induced pluripotent stem cell human CVCL_A1XP From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408831 CVCL_A1XQ EDi001-B-2 induced pluripotent stem cell human CVCL_A1XQ From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408832 CVCL_A1XR EDi001-B-3 induced pluripotent stem cell human CVCL_A1XR From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408833 CVCL_A1XS EDi001-B-4 induced pluripotent stem cell human CVCL_A1XS From: University of Edinburgh; Edinburgh; United Kingdom CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11138; SNCA Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41408834 CVCL_A1XT WMUi015-A induced pluripotent stem cell human CVCL_A1XT From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly1433Val (c.4298G>T); ClinVar=VCV000024724; Zygosity=Hemizygous (PubMed=33202306) Population: Chinese; Han; Derived from sampling site: Urine. Male 41408835 CVCL_A1XE UKBi017-A induced pluripotent stem cell human CVCL_A1XE From: Institut fur Rekonstruktive Neurobiologie, University Clinic of Bonn; Bonn; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41408836 CVCL_A1XF UMGWi001-B induced pluripotent stem cell human CVCL_A1XF From: Department of Functional Genomics - Human Molecular Genetics, University Medicine Greifswald; Greifswald; Germany CL:0000010 Sequence variation: Mutation; HGNC; 16974; SRCAP; Simple; p.Arg2444Ter (c.7330C>T); ClinVar=VCV000030908; Zygosity=Heterozygous (PubMed=33099107) Derived from sampling site: Oral cavity; gingiva Cell type=Fibroblast.. Male 41408837 CVCL_A1XG UMi029-A induced pluripotent stem cell human CVCL_A1XG From: Miller School of Medicine, University of Miami; Miami; USA CL:0000010 Sequence variation: Mutation; HGNC; 11122; SMPX; Simple; p.Gly45Valfs*36 (c.133-1G>A); ClinVar=VCV000417903; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=34052664) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41408838 CVCL_A1XH UNIMGi001-A induced pluripotent stem cell human CVCL_A1XH From: Universita degli Studi Magna Graecia di Catanzaro; Catanzaro; Italy CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Met145Thr (c.434T>C); ClinVar=VCV000012896; Zygosity=Heterozygous (PubMed=33370868) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408839 CVCL_A1XI UNIMGi002-A induced pluripotent stem cell human CVCL_A1XI From: Universita degli Studi Magna Graecia di Catanzaro; Catanzaro; Italy CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Met145Thr (c.434T>C); ClinVar=VCV000012896; Zygosity=Heterozygous (PubMed=33370868) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408840 CVCL_A1XJ UUIGPi013-A induced pluripotent stem cell human CVCL_A1XJ From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41408841 CVCL_A1XK UUIGPi014-A induced pluripotent stem cell human CVCL_A1XK From: Department of Immunology, Genetics and Pathology, Uppsala University; Uppsala; Sweden CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41408842 CVCL_A1XL WMUi003-A induced pluripotent stem cell human CVCL_A1XL From: Wenzhou Medical University; Wenzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 29326; SLC7A14; Simple; p.Gly330Arg (c.988G>A); ClinVar=VCV000126446; Zygosity=Homozygous (PubMed=33207307) Population: Chinese; Derived from sampling site: Peripheral blood. Male 41408843 CVCL_A1ZA ESi082-A induced pluripotent stem cell human CVCL_A1ZA CL:0000010 Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Ile205Aspfs*13 (c.613_619delATAGGAA); ClinVar=VCV000099913; Zygosity=Heterozygous (PubMed=33773389); Sequence variation: Mutation; HGNC; 2343; CRB1; Simple; p.Ile167_Gly169del (c.498_506delAATTGATGG); ClinVar=VCV000096659; Zygosity=Heterozygous (PubMed=33773389) Population: Caucasian; Derived from sampling site: Peripheral blood. Male Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 41408844 CVCL_A1ZB ICC3 cancer cell line human CVCL_A1ZB CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Ala615fs (c.1843_1844insC); Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Pro (c.97T>C); ClinVar=VCV000376391; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408845 CVCL_A1ZC XPV1HM finite cell line human CVCL_A1ZC CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Glu164Ter (c.490G>T); ClinVar=VCV000225444; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408846 CVCL_A1ZD XPV2HM finite cell line human CVCL_A1ZD CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Arg356Ter (c.1066C>T); ClinVar=VCV001459259; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408847 CVCL_A1ZE XPV3HM finite cell line human CVCL_A1ZE CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408848 CVCL_A1ZF XPV6HM finite cell line human CVCL_A1ZF CL:0000010 Sequence variation: Mutation; HGNC; 9181; POLH; Simple; p.Ser242Ter (c.725C>G); ClinVar=VCV000264680; Zygosity=Homozygous (PubMed=17344931) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408849 CVCL_A1YV UMGi055-A.4 induced pluripotent stem cell human CVCL_A1YV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi055-A) for a series of distinct clones 41408850 CVCL_A1YW UMGi056-A.1 induced pluripotent stem cell human CVCL_A1YW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Arg57Leu (c.170G>T); Zygosity=Hemizygous (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi056-A) for a series of distinct clones 41408851 CVCL_A1YX UMGi056-A.5 induced pluripotent stem cell human CVCL_A1YX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Arg57Leu (c.170G>T); Zygosity=Hemizygous (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi056-A) for a series of distinct clones 41408852 CVCL_A1YY UMGi056-A.8 induced pluripotent stem cell human CVCL_A1YY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Arg57Leu (c.170G>T); Zygosity=Hemizygous (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi056-A) for a series of distinct clones 41408853 CVCL_A1YZ SMBCi009-A induced pluripotent stem cell human CVCL_A1YZ From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.His583Tyr (c.1747C>T); ClinVar=VCV000200921; Zygosity=Heterozygous (PubMed=34974203); Sequence variation: Mutation; HGNC; 6547; LDLR; Simple; p.Glu650Argfs*15 (c.1948delG); Zygosity=Heterozygous (PubMed=34974203) Population: Chinese; Han; Derived from sampling site: Urine. Male 41408854 CVCL_A1YN DR177 cancer cell line human CVCL_A1YN CL:0000010 Population: Caucasian; Derived from sampling site: Brain. Female Doubling time: 32.9 hours (PubMed=24443327) 41408855 CVCL_A1YP MPM176 cancer cell line human CVCL_A1YP CL:0000010 Derived from sampling site: Brain. Doubling time: 31.5 hours (PubMed=24443327) Group: Cancer stem cell line 41408856 CVCL_A1YQ PERU cancer cell line human CVCL_A1YQ CL:0000010 Derived from sampling site: Brain. Male Doubling time: 58.9 hours (PubMed=24443327) Group: Cancer stem cell line 41408857 CVCL_A1YR VIPI cancer cell line human CVCL_A1YR CL:0000010 Derived from sampling site: Brain. Doubling time: 18 hours (PubMed=24443327) Group: Cancer stem cell line 41408858 CVCL_A1YS UMGi054-A.3 induced pluripotent stem cell human CVCL_A1YS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Gly197Val (c.590G>T); Zygosity=Hemizygous (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi054-A) for a series of distinct clones 41408859 CVCL_A1YT UMGi054-A.4 induced pluripotent stem cell human CVCL_A1YT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; p.Gly197Val (c.590G>T); Zygosity=Hemizygous (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi054-A) for a series of distinct clones 41408860 CVCL_A1YU UMGi055-A.3 induced pluripotent stem cell human CVCL_A1YU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 11577; TAFAZZIN; Simple; c.110-1G>C; Zygosity=Hemizygous; Note=Splice acceptor mutation (PubMed=23792436) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi055-A) for a series of distinct clones 41408861 CVCL_A1YF WAe009-A-26 embryonic stem cell human CVCL_A1YF From: Sun Yat-sen University Third Affiliated Hospital; Guangzhou; China. CL:0000010 Female 41408862 CVCL_A1YG WAe009-A-41 embryonic stem cell human CVCL_A1YG From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2472; CSRP3. Female 41408863 CVCL_A1YH DFT2.SN cancer cell line CVCL_A1YH CL:0000010 Male Group: Marsupial cell line. 41408864 CVCL_A1YI iPCP transformed cell line human CVCL_A1YI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=33044631) Population: Chinese; Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Brain. Male Doubling time: 23.5 hours (PubMed=33044631) 41408865 CVCL_A1YJ 2/11 cancer cell line human CVCL_A1YJ CL:0000010 Derived from sampling site: Brain. Male Doubling time: 63.5 hours (PubMed=24443327) Group: Cancer stem cell line 41408866 CVCL_A1YK BORRU cancer cell line human CVCL_A1YK CL:0000010 Derived from sampling site: Brain. Male Doubling time: 53.9 hours (PubMed=24443327) Group: Cancer stem cell line 41408867 CVCL_A1YL COMI cancer cell line human CVCL_A1YL CL:0000010 Derived from sampling site: Brain. Male Doubling time: 60 hours (PubMed=24443327) Group: Cancer stem cell line 41408868 CVCL_A1YM DEMI cancer cell line human CVCL_A1YM CL:0000010 Derived from sampling site: Brain. Male Doubling time: 56.5 hours (PubMed=24443327) Group: Cancer stem cell line 41408869 CVCL_A1WA FJMUUHi001-A induced pluripotent stem cell human CVCL_A1WA From: Fujian Medical University Union Hospital; Fuzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 16369; PARK7; Simple; p.Glu64Argfs (c.189dupA); ClinVar=VCV000623671; Zygosity=Homozygous (PubMed=33485186) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408870 CVCL_A1WB GZHMCi002-A induced pluripotent stem cell human CVCL_A1WB From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 603; APOB; Simple; p.Arg3527Trp (c.10579C>T); ClinVar=VCV000040223; Zygosity=Heterozygous (PubMed=33128957) Derived from sampling site: Peripheral blood. Female 41408871 CVCL_A1WC GZHMCi003-A induced pluripotent stem cell human CVCL_A1WC From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 10472; RUNX2; Unexplicit; Ex3del; Zygosity=Heterozygous (PubMed=33477036) Derived from sampling site: Umbilical cord blood. Female 41408872 CVCL_A1VS NCC-MLPS1-C1 cancer cell line human CVCL_A1VS CL:0000010 Sequence variation: Gene fusion; HGNC; 2726; DDIT3 + HGNC; 4010; FUS; Name(s)=FUS-DDIT3, TLS-CHOP (PubMed=33146842) Population: Japanese; Derived from sampling site: Thigh. Male Doubling time: 98 hours (PubMed=33146842) Part of: NCC sarcoma cell line panel 41408873 CVCL_A1VT SoMG spontaneously immortalized cell line CVCL_A1VT CL:0000010 Derived from sampling site: Midgut. Male Doubling time: 72.3 +- 4.3 hours (PubMed=33146860) Group: Insect cell line 41408874 CVCL_A1VU 150057 cancer cell line human CVCL_A1VU CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Gln1330Ter (c.3988C>T); Zygosity=Heterozygous (PubMed=33143664); Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Ala281Thr (c.841G>A); Zygosity=Heterozygous (PubMed=33143664) Population: Chinese; Derived from sampling site: Endometrium. Female Doubling time: 91.7 +- 12.7 hours (at 10th passage), 76.2 +- 6.7 hours (at 26th passage), 70.4 +- 14.0 hours (at 41th passage) (PubMed=33143664) 41408875 CVCL_A1VV AKOSi009-A induced pluripotent stem cell human CVCL_A1VV From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41408876 CVCL_A1VW AKOSi008-A induced pluripotent stem cell human CVCL_A1VW From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.His1069Gln (c.3207C>A); ClinVar=VCV000003848; Zygosity=Homozygous (PubMed=33197697) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408877 CVCL_A1VX CDIi007-A induced pluripotent stem cell human CVCL_A1VX From: Fujifilm Cellular Dynamics International, Inc.; Madison; USA CL:0000010 Discontinued: hPSCreg; CDIi007-A; true. Male 41408878 CVCL_A1VY CHOPi004-A induced pluripotent stem cell human CVCL_A1VY From: Children's Hospital of Philadelphia; Philadelphia; USA CL:0000010 Population: African American; Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 41408879 CVCL_A1VZ CRFi001-A induced pluripotent stem cell human CVCL_A1VZ From: Choroideremia Research Foundation; Springfield; USA CL:0000010 Sequence variation: Mutation; HGNC; 1940; CHM; Simple; p.Arg270Ter (c.808C>T); ClinVar=VCV000143078; Zygosity=Hemizygous (from parent cell line) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408880 CVCL_A1VK HT-144 Dab-R/Rox-R cancer cell line human CVCL_A1VK CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Selected for resistance to: ChEBI; CHEBI:132774; Roxadustat (FG4592); Derived from metastatic site: Hypodermis. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408881 CVCL_A1VL HT-144 Dab-R/Tram-R cancer cell line human CVCL_A1VL CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; Derived from metastatic site: Hypodermis. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408882 CVCL_A1VM RVH-421 Dab-R cancer cell line human CVCL_A1VM CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln52fs*71 (c.154delC); Zygosity=Heterozygous (DepMap) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Brain. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408883 CVCL_A1VN UACC62-RMR cancer cell line human CVCL_A1VN CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Pro248Thrfs*5 (c.741dupA) (c.741_742insA); ClinVar=VCV000142259; Zygosity=Homozygous (DepMap). Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist Unspecified Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408884 CVCL_A1VP A375-RMR cancer cell line human CVCL_A1VP CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Selected for resistance to: ChEBI; CHEBI:75998; Trametinib (Mekinist; Derived from sampling site: Skin. Female Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408885 CVCL_A1VQ LPS27 cancer cell line human CVCL_A1VQ CL:0000010 Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). 41408886 CVCL_A1VR LPS6 cancer cell line human CVCL_A1VR CL:0000010 Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). 41408887 CVCL_A1VC ICC12 cancer cell line human CVCL_A1VC CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro190Leu (c.569C>T); ClinVar=VCV000418517; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408888 CVCL_A1VD ICC13-7 cancer cell line human CVCL_A1VD CL:0000010 Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE). 41408889 CVCL_A1VE ICC15 cancer cell line human CVCL_A1VE CL:0000010 Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1718His (c.5152A>C); Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Trp2788Ter (c.8363G>A); ClinVar=VCV000052564; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys141Tyr (c.422G>A); ClinVar=VCV000140801; Zygosity=Unspecified (DepMap). Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408890 CVCL_A1VF ICC6 cancer cell line human CVCL_A1VF CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys132Thr (c.395A>C); ClinVar=VCV000376627; Zygosity=Unspecified (DepMap); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408891 CVCL_A1VG ICC8 cancer cell line human CVCL_A1VG CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (DepMap). Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408892 CVCL_A1VH ICC9 cancer cell line human CVCL_A1VH CL:0000010 Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Unspecified (DepMap). Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408893 CVCL_A1VI ICC4 cancer cell line human CVCL_A1VI CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu137Gln (c.410T>A); Zygosity=Unspecified (DepMap). Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408894 CVCL_A1VJ HT-144 Dab-R cancer cell line human CVCL_A1VJ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (DepMap); Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line) Selected for resistance to: ChEBI; CHEBI:75045; Dabrafenib (Tafinlar; Derived from metastatic site: Hypodermis. Male Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE) 41408895 CVCL_A1XA PG-ES-8 embryonic stem cell pig CVCL_A1XA CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 41408896 CVCL_A1XB IVF-ES-12 embryonic stem cell pig CVCL_A1XB CL:0000010 Male 41408897 CVCL_A1XC THSJTUi001-A induced pluripotent stem cell human CVCL_A1XC CL:0000010 Sequence variation: Mutation; HGNC; 870; ATP7B; Simple; p.Arg778Leu (c.2333G>T); ClinVar=VCV000003852; Zygosity=Homozygous (PubMed=33096383) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408898 CVCL_A1XD UAMi004-A-1 induced pluripotent stem cell human CVCL_A1XD From: Centro de Biologia Molecular Severo Ochoa, Universidad Autonoma de Madrid; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 8654; PCCB; Simple_corrected; p.Gly407Argfs*14 (c.1218_1231delGGGCATCATCCGGCinsTAGAGCACAGGA) (c.1218_1231del14ins12); ClinVar=VCV000038875; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33128956) Population: Caucasian; Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 41408899 CVCL_A1WT RCNSi002-B induced pluripotent stem cell human CVCL_A1WT From: RCNS-Institute of Enzymology; Budapest; Hungary CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of RCNSi001-A (Cellosaurus=CVCL_A1WQ) and RCNSi001-B (Cellosaurus=CVCL_A1WR); Derived from sampling site: Peripheral blood. Female 41408900 CVCL_A1WU SAHGMUi001-A induced pluripotent stem cell human CVCL_A1WU From: The Second Affiliated Hospital of Guangzhou Medical University; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 15464; SPINK5; Simple; p.Lys754Ter (c.2260A>T); ClinVar=VCV001379542; Zygosity=Heterozygous (PubMed=33556917); Sequence variation: Mutation; HGNC; 15464; SPINK5; Simple; p.Thr808Ile (c.2423C>T); ClinVar=VCV000848986; Zygosity=Heterozygous (PubMed=33556917) Population: Chinese; Han; Derived from sampling site: Urine. Male 41408901 CVCL_A1WV SHCDNi004-A induced pluripotent stem cell human CVCL_A1WV From: Shanghai Children's Hospital, Shanghai Jiao Tong University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 5996; IL1RAPL1; Simple; p.Leu349Serfs*7 (c.1043_1044dup); Zygosity=Hemizygous; Note=De novo mutation (PubMed=33774333) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408902 CVCL_A1WW SMCPGHi001-A induced pluripotent stem cell human CVCL_A1WW From: The Seven Medical Center of PLA General Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 33; ABCA3; Simple; p.Arg1333Glyfs*24 (c.3997_3998del); ClinVar=VCV001317554; Zygosity=Heterozygous (PubMed=33839547); Sequence variation: Mutation; HGNC; 33; ABCA3; Simple; p.Ala1046Val (c.3137C>T); Zygosity=Heterozygous (PubMed=33839547) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408903 CVCL_A1WX PG-ES-7 embryonic stem cell pig CVCL_A1WX CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 41408904 CVCL_A1WY IVF-ES-11 embryonic stem cell pig CVCL_A1WY CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 41408905 CVCL_A1WZ PG-ES-3 embryonic stem cell pig CVCL_A1WZ CL:0000010 Omics: Transcriptome analysis by RNAseq. Female 41408906 CVCL_A1WL LUEi018-A induced pluripotent stem cell human CVCL_A1WL From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408907 CVCL_A1WM NCKDi001-A induced pluripotent stem cell human CVCL_A1WM From: National Center of Kidney Diseases; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 2207; COL4A5; Simple; p.Gly896Ala (c.2687G>C); Zygosity=Hemizygous (PubMed=33128955) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41408908 CVCL_A1WN PCIi025-A induced pluripotent stem cell human CVCL_A1WN From: Phenocell SAS; Grasse; France CL:0000010 Derived from sampling site: Peripheral blood. Female 41408909 CVCL_A1WP RCMGi004-B induced pluripotent stem cell human CVCL_A1WP From: Research Centre for Medical Genetics; Moscow; Russia CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (PubMed=33607467); Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Trp1282Ter (c.3846G>A); ClinVar=VCV000007129; Zygosity=Heterozygous (PubMed=33607467) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408910 CVCL_A1WQ RCNSi001-A induced pluripotent stem cell human CVCL_A1WQ From: RCNS-Institute of Enzymology; Budapest; Hungary CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of RCNSi002-A (Cellosaurus=CVCL_A1WS) and RCNSi002-B (Cellosaurus=CVCL_A1WT); Derived from sampling site: Peripheral blood. Female 41408911 CVCL_A1WR RCNSi001-B induced pluripotent stem cell human CVCL_A1WR From: RCNS-Institute of Enzymology; Budapest; Hungary CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of RCNSi002-A (Cellosaurus=CVCL_A1WS) and RCNSi002-B (Cellosaurus=CVCL_A1WT); Derived from sampling site: Peripheral blood. Female 41408912 CVCL_A1WS RCNSi002-A induced pluripotent stem cell human CVCL_A1WS From: RCNS-Institute of Enzymology; Budapest; Hungary CL:0000010 Population: Caucasian; Donor information: Established from monozygotic twin of RCNSi001-A (Cellosaurus=CVCL_A1WQ) and RCNSi001-B (Cellosaurus=CVCL_A1WR); Derived from sampling site: Peripheral blood. Female 41408913 CVCL_A1WD GZHMCi004-A induced pluripotent stem cell human CVCL_A1WD From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3690; FGFR3; Simple; p.Gly380Arg (c.1138G>A); ClinVar=VCV000016327; Zygosity=Heterozygous (PubMed=33848795) Derived from sampling site: Umbilical cord blood. Female 41408914 CVCL_A1WE IMAGINi011-A induced pluripotent stem cell human CVCL_A1WE From: Imagine Institute; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 27962; STING1; Simple; p.Val155Met (c.463G>A); ClinVar=VCV000143862; Zygosity=Heterozygous (PubMed=33340797) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41408915 CVCL_A1WF IRFMNi001-B induced pluripotent stem cell human CVCL_A1WF From: Istituto di Ricerche Farmacologiche Mario Negri (IRCCS); Bergamo; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Male 41408916 CVCL_A1WG KAUSTi011-A induced pluripotent stem cell human CVCL_A1WG From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Sequence variation: Mutation; HGNC; 4324; GLP1R; Simple; c.402+3delG (p.Val95Glufs*72) (Ex4del); Zygosity=Homozygous (PubMed=33421754) Population: Saudi Arabian; Derived from sampling site: Cell type=Fibroblast. Male 41408917 CVCL_A1WH KAUSTi011-B induced pluripotent stem cell human CVCL_A1WH From: King Abdullah University of Science and Technology; Thuwal; Saudi Arabia CL:0000010 Sequence variation: Mutation; HGNC; 4324; GLP1R; Simple; c.402+3delG (p.Val95Glufs*72) (Ex4del); Zygosity=Homozygous (PubMed=33421754) Population: Saudi Arabian; Derived from sampling site: Cell type=Fibroblast. Male 41408918 CVCL_A1WI LUEi015-A induced pluripotent stem cell human CVCL_A1WI From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41408919 CVCL_A1WJ LUEi016-A induced pluripotent stem cell human CVCL_A1WJ From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany. CL:0000010 41408920 CVCL_A1WK LUEi017-A induced pluripotent stem cell human CVCL_A1WK From: Institute of Neurogenetics, University of Lubeck; Lubeck; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41408921 CVCL_A3HK HPS2037 induced pluripotent stem cell human CVCL_A3HK CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408922 CVCL_A3HL HPS2038 induced pluripotent stem cell human CVCL_A3HL CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408923 CVCL_A3HM HPS2039 induced pluripotent stem cell human CVCL_A3HM CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408924 CVCL_A3HN HPS2040 induced pluripotent stem cell human CVCL_A3HN CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408925 CVCL_A3HP HPS2041 induced pluripotent stem cell human CVCL_A3HP CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408926 CVCL_A3HQ HPS2054 induced pluripotent stem cell human CVCL_A3HQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408927 CVCL_A3HR HPS2055 induced pluripotent stem cell human CVCL_A3HR CL:0000010 Derived from sampling site: Peripheral blood. Male 41408928 CVCL_A3HC HPS3748 induced pluripotent stem cell human CVCL_A3HC CL:0000010 Derived from sampling site: Peripheral blood. Male 41408929 CVCL_A3HD HPS2012 induced pluripotent stem cell human CVCL_A3HD CL:0000010 Derived from sampling site: Peripheral blood. Male 41408930 CVCL_A3HE HPS2013 induced pluripotent stem cell human CVCL_A3HE CL:0000010 Derived from sampling site: Peripheral blood. Male 41408931 CVCL_A3HF HPS2014 induced pluripotent stem cell human CVCL_A3HF CL:0000010 Derived from sampling site: Peripheral blood. Male 41408932 CVCL_A3HG HPS2015 induced pluripotent stem cell human CVCL_A3HG CL:0000010 Derived from sampling site: Peripheral blood. Male 41408933 CVCL_A3HH HPS2016 induced pluripotent stem cell human CVCL_A3HH CL:0000010 Derived from sampling site: Peripheral blood. Male 41408934 CVCL_A3HI HPS2017 induced pluripotent stem cell human CVCL_A3HI CL:0000010 Derived from sampling site: Peripheral blood. Male 41408935 CVCL_A3HJ HPS2036 induced pluripotent stem cell human CVCL_A3HJ CL:0000010 Sequence variation: Mutation; HGNC; 1037; CFB; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41408936 CVCL_A3GZ HPS3384 induced pluripotent stem cell human CVCL_A3GZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408937 CVCL_A3HA HPS3385 induced pluripotent stem cell human CVCL_A3HA CL:0000010 Derived from sampling site: Peripheral blood. Male 41408938 CVCL_A3HB HPS3747 induced pluripotent stem cell human CVCL_A3HB CL:0000010 Derived from sampling site: Peripheral blood. Male 41408939 CVCL_A3GR HPS1608 induced pluripotent stem cell human CVCL_A3GR CL:0000010 Derived from sampling site: Peripheral blood. Male 41408940 CVCL_A3GS HPS1706 induced pluripotent stem cell human CVCL_A3GS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408941 CVCL_A3GT HPS1707 induced pluripotent stem cell human CVCL_A3GT CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408942 CVCL_A3GU HPS1899 induced pluripotent stem cell human CVCL_A3GU CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41408943 CVCL_A3GV HPS1729 induced pluripotent stem cell human CVCL_A3GV CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408944 CVCL_A3GW HPS1730 induced pluripotent stem cell human CVCL_A3GW CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408945 CVCL_A3GX HPS3382 induced pluripotent stem cell human CVCL_A3GX HLA typing: A*01:01:01:01New,26:01:01:01; B*37:01:01,40:02:01:01; C*03:04:01,06:02:01:01; DPB1*02:01:02,05:01:01; DQB1*03:03:02,05:01:01New; DRB1*09:01:02,10:01:01:03 (RCB=HPS3382) CL:0000010 Derived from sampling site: Peripheral blood. Male 41408946 CVCL_A3GY HPS3383 induced pluripotent stem cell human CVCL_A3GY CL:0000010 Derived from sampling site: Peripheral blood. Male 41408947 CVCL_A3IL HPS2411 induced pluripotent stem cell human CVCL_A3IL CL:0000010 Derived from sampling site: Peripheral blood. Male 41408948 CVCL_A3IM HPS2412 induced pluripotent stem cell human CVCL_A3IM CL:0000010 Derived from sampling site: Peripheral blood. Male 41408949 CVCL_A3IN HPS3007 induced pluripotent stem cell human CVCL_A3IN CL:0000010 Derived from sampling site: Peripheral blood. Male 41408950 CVCL_A3IP HPS3008 induced pluripotent stem cell human CVCL_A3IP CL:0000010 Derived from sampling site: Peripheral blood. Male 41408951 CVCL_A3IQ HPS3009 induced pluripotent stem cell human CVCL_A3IQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408952 CVCL_A3IR HPS3010 induced pluripotent stem cell human CVCL_A3IR CL:0000010 Derived from sampling site: Peripheral blood. Male 41408953 CVCL_A3IS HPS3011 induced pluripotent stem cell human CVCL_A3IS CL:0000010 Derived from sampling site: Peripheral blood. Male 41408954 CVCL_A3ID HPS2396 induced pluripotent stem cell human CVCL_A3ID CL:0000010 Derived from sampling site: Peripheral blood. Male 41408955 CVCL_A3IE HPS2397 induced pluripotent stem cell human CVCL_A3IE CL:0000010 Derived from sampling site: Peripheral blood. Male 41408956 CVCL_A3IF HPS2398 induced pluripotent stem cell human CVCL_A3IF CL:0000010 Derived from sampling site: Peripheral blood. Male 41408957 CVCL_A3IG HPS2399 induced pluripotent stem cell human CVCL_A3IG CL:0000010 Derived from sampling site: Peripheral blood. Male 41408958 CVCL_A3IH HPS2400 induced pluripotent stem cell human CVCL_A3IH CL:0000010 Derived from sampling site: Peripheral blood. Male 41408959 CVCL_A3II HPS2408 induced pluripotent stem cell human CVCL_A3II CL:0000010 Derived from sampling site: Peripheral blood. Male 41408960 CVCL_A3IJ HPS2409 induced pluripotent stem cell human CVCL_A3IJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408961 CVCL_A3IK HPS2410 induced pluripotent stem cell human CVCL_A3IK CL:0000010 Derived from sampling site: Peripheral blood. Male 41408962 CVCL_A3IA HPS2124 induced pluripotent stem cell human CVCL_A3IA CL:0000010 Derived from sampling site: Peripheral blood. Male 41408963 CVCL_A3IB HPS2125 induced pluripotent stem cell human CVCL_A3IB CL:0000010 Derived from sampling site: Peripheral blood. Male 41408964 CVCL_A3IC HPS2395 induced pluripotent stem cell human CVCL_A3IC CL:0000010 Derived from sampling site: Peripheral blood. Male 41408965 CVCL_A3HS HPS2056 induced pluripotent stem cell human CVCL_A3HS CL:0000010 Derived from sampling site: Peripheral blood. Male 41408966 CVCL_A3HT HPS2057 induced pluripotent stem cell human CVCL_A3HT CL:0000010 Derived from sampling site: Peripheral blood. Male 41408967 CVCL_A3HU HPS2058 induced pluripotent stem cell human CVCL_A3HU CL:0000010 Derived from sampling site: Peripheral blood. Male 41408968 CVCL_A3HV HPS2059 induced pluripotent stem cell human CVCL_A3HV CL:0000010 Derived from sampling site: Peripheral blood. Male 41408969 CVCL_A3HW HPS2120 induced pluripotent stem cell human CVCL_A3HW CL:0000010 Derived from sampling site: Peripheral blood. Male 41408970 CVCL_A3HX HPS2121 induced pluripotent stem cell human CVCL_A3HX CL:0000010 Derived from sampling site: Peripheral blood. Male 41408971 CVCL_A3HY HPS2122 induced pluripotent stem cell human CVCL_A3HY CL:0000010 Derived from sampling site: Peripheral blood. Male 41408972 CVCL_A3HZ HPS2123 induced pluripotent stem cell human CVCL_A3HZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408973 CVCL_A3FI SCD36-2 induced pluripotent stem cell human CVCL_A3FI CL:0000010 Sequence variation: Mutation; HGNC; 15911; NOP56; Simple; c.3+71_3+75[(16_?)] (IVS1 GGCCTG repeat expansion); ClinVar=VCV000031106; Zygosity=Unspecified (PubMed=28918022) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Male 41408974 CVCL_A3FJ SCD36-3 induced pluripotent stem cell human CVCL_A3FJ CL:0000010 Sequence variation: Mutation; HGNC; 15911; NOP56; Simple; c.3+71_3+75[(16_?)] (IVS1 GGCCTG repeat expansion); ClinVar=VCV000031106; Zygosity=Unspecified (PubMed=28918022) Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female 41408975 CVCL_A3FK HPS0424 induced pluripotent stem cell human CVCL_A3FK CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408976 CVCL_A3FL HPS0425 induced pluripotent stem cell human CVCL_A3FL CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408977 CVCL_A3FM HPS1204 induced pluripotent stem cell human CVCL_A3FM CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408978 CVCL_A3FN HPS1205 induced pluripotent stem cell human CVCL_A3FN CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408979 CVCL_A3FP HPS1206 induced pluripotent stem cell human CVCL_A3FP CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41408980 CVCL_A3FA HPS3776 induced pluripotent stem cell human CVCL_A3FA CL:0000010 Derived from sampling site: Peripheral blood. Male 41408981 CVCL_A3FB HPS3777 induced pluripotent stem cell human CVCL_A3FB CL:0000010 Derived from sampling site: Peripheral blood. Male 41408982 CVCL_A3FC 2fTGH-U1A cancer cell line human CVCL_A3FC CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 5382; IDH1; Simple; p.Arg132Cys (c.394C>T); ClinVar=VCV000375891; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P0A9M5; Escherichia coli gpt; Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Population: Caucasian; Transformant: Acridine half-mustard dihydrochloride (6-chloro-9-[3-(2-chloroethylamino)propylamino]-2-methoxyacridine dihydrochloride(ChEBI; CHEBI:132982); Derived from sampling site: Bone; pelvis; acetabulum. Male Characteristics: 2fTGH was derived from a HPRT negative subline of HT-1080 Expression of gpt is under the control of a IFN-alpha inducible IFI6 (6-16) promoter and is thus only expressed when IFN-alpha is present in the growth medium. 41408983 CVCL_A3FD HX011-1D9 hybridoma house mouse CVCL_A3FD CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P43489; Human TNFRSF4/CD134. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018198 41408984 CVCL_A3FE HX011-9C12 hybridoma house mouse CVCL_A3FE CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; P43489; Human TNFRSF4/CD134. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C2018197 41408985 CVCL_A3FF LMH serum-free suspension cancer cell line CVCL_A3FF CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: White Leghorn L-M. Male Group: Bird cell line; Group: Patented cell line; Group: Serum/protein free medium cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202072 41408986 CVCL_A3FG HPS1044 induced pluripotent stem cell human CVCL_A3FG CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Omics: Transcriptome analysis by RNAseq Female 41408987 CVCL_A3FH SCD36-1 induced pluripotent stem cell human CVCL_A3FH CL:0000010 Sequence variation: Mutation; HGNC; 15911; NOP56; Simple; c.3+71_3+75[(16_?)] (IVS1 GGCCTG repeat expansion); ClinVar=VCV000031106; Zygosity=Unspecified (PubMed=28918022) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male 41408988 CVCL_A3EX HPS3426 induced pluripotent stem cell human CVCL_A3EX CL:0000010 Derived from sampling site: Peripheral blood. Male 41408989 CVCL_A3EY HPS3427 induced pluripotent stem cell human CVCL_A3EY CL:0000010 Derived from sampling site: Peripheral blood. Male 41408990 CVCL_A3EZ HPS3428 induced pluripotent stem cell human CVCL_A3EZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41408991 CVCL_A3EP HPS3775 induced pluripotent stem cell human CVCL_A3EP CL:0000010 Derived from sampling site: Peripheral blood. Male 41408992 CVCL_A3EQ HPS3419 induced pluripotent stem cell human CVCL_A3EQ HLA typing: A*02:01:01:01,02:06:01:04; B*39:01:03,40:02:01:01; C*01:02:01New,07:02:01:01; DPB1*02:01:02,05:01:01; DQB1*04:02,06:03:01:01; DRB1*08:02:01,13:01:01:01 (RCB=HPS3419) CL:0000010 Derived from sampling site: Peripheral blood. Male 41408993 CVCL_A3ER HPS3420 induced pluripotent stem cell human CVCL_A3ER CL:0000010 Derived from sampling site: Peripheral blood. Male 41408994 CVCL_A3ES HPS3421 induced pluripotent stem cell human CVCL_A3ES CL:0000010 Derived from sampling site: Peripheral blood. Male 41408995 CVCL_A3ET HPS3422 induced pluripotent stem cell human CVCL_A3ET CL:0000010 Derived from sampling site: Peripheral blood. Male 41408996 CVCL_A3EU HPS3423 induced pluripotent stem cell human CVCL_A3EU CL:0000010 Derived from sampling site: Peripheral blood. Male 41408997 CVCL_A3EV HPS3424 induced pluripotent stem cell human CVCL_A3EV CL:0000010 Derived from sampling site: Peripheral blood. Male 41408998 CVCL_A3EW HPS3425 induced pluripotent stem cell human CVCL_A3EW HLA typing: A*24:02:01:01,26:03:01; B*35:01:01:02NEW,52:01:01:02; C*03:03:01,12:02:02:01; DPB1*05:01:01,09:01:01; DQB1*03:02:01,06:01; DRB1*04:03:01,15:02:01:01 (RCB=HPS3425) CL:0000010 Derived from sampling site: Peripheral blood. Male 41408999 CVCL_A3GJ HPS1601 induced pluripotent stem cell human CVCL_A3GJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409000 CVCL_A3GK HPS1602 induced pluripotent stem cell human CVCL_A3GK CL:0000010 Derived from sampling site: Peripheral blood. Female 41409001 CVCL_A3GL HPS1603 induced pluripotent stem cell human CVCL_A3GL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409002 CVCL_A3GM HPS1604 induced pluripotent stem cell human CVCL_A3GM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409003 CVCL_A3GN HPS1605 induced pluripotent stem cell human CVCL_A3GN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409004 CVCL_A3GP HPS1606 induced pluripotent stem cell human CVCL_A3GP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409005 CVCL_A3GQ HPS1607 induced pluripotent stem cell human CVCL_A3GQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409006 CVCL_A3GB HPS1510 induced pluripotent stem cell human CVCL_A3GB CL:0000010 Derived from sampling site: Peripheral blood. Male 41409007 CVCL_A3GC HPS1511 induced pluripotent stem cell human CVCL_A3GC CL:0000010 Derived from sampling site: Peripheral blood. Male 41409008 CVCL_A3GD HPS1512 induced pluripotent stem cell human CVCL_A3GD CL:0000010 Derived from sampling site: Peripheral blood. Male 41409009 CVCL_A3GE HPS1513 induced pluripotent stem cell human CVCL_A3GE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409010 CVCL_A3GF HPS1597 induced pluripotent stem cell human CVCL_A3GF CL:0000010 Derived from sampling site: Peripheral blood. Female 41409011 CVCL_A3GG HPS1598 induced pluripotent stem cell human CVCL_A3GG CL:0000010 Derived from sampling site: Peripheral blood. Female 41409012 CVCL_A3GH HPS1599 induced pluripotent stem cell human CVCL_A3GH CL:0000010 Derived from sampling site: Peripheral blood. Female 41409013 CVCL_A3GI HPS1600 induced pluripotent stem cell human CVCL_A3GI CL:0000010 Derived from sampling site: Peripheral blood. Female 41409014 CVCL_A3FY HPS1441 induced pluripotent stem cell human CVCL_A3FY CL:0000010 Derived from sampling site: Peripheral blood. Male 41409015 CVCL_A3FZ HPS1508 induced pluripotent stem cell human CVCL_A3FZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409016 CVCL_A3GA HPS1509 induced pluripotent stem cell human CVCL_A3GA CL:0000010 Derived from sampling site: Peripheral blood. Male 41409017 CVCL_A3FQ HPS1207 induced pluripotent stem cell human CVCL_A3FQ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409018 CVCL_A3FR HPS1208 induced pluripotent stem cell human CVCL_A3FR CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409019 CVCL_A3FS HPS1209 induced pluripotent stem cell human CVCL_A3FS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409020 CVCL_A3FT HPS1436 induced pluripotent stem cell human CVCL_A3FT CL:0000010 Derived from sampling site: Peripheral blood. Male 41409021 CVCL_A3FU HPS1437 induced pluripotent stem cell human CVCL_A3FU CL:0000010 Derived from sampling site: Peripheral blood. Male 41409022 CVCL_A3FV HPS1438 induced pluripotent stem cell human CVCL_A3FV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409023 CVCL_A3FW HPS1439 induced pluripotent stem cell human CVCL_A3FW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409024 CVCL_A3FX HPS1440 induced pluripotent stem cell human CVCL_A3FX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409025 CVCL_A3DG HPS3690 induced pluripotent stem cell human CVCL_A3DG CL:0000010 Derived from sampling site: Peripheral blood. Female 41409026 CVCL_A3DH HPS3691 induced pluripotent stem cell human CVCL_A3DH CL:0000010 Derived from sampling site: Peripheral blood. Female 41409027 CVCL_A3DI HPS3681 induced pluripotent stem cell human CVCL_A3DI HLA typing: A*02:06:01:01,24:02:01:01; B*40:02:01:01,54:01:01; C*01:02:01,03:04:01; DPB1*02:01:02,02:01:02:11; DQB1*06:01,06:02:01:01; DRB1*08:03:02,15:01:01 (RCB=HPS3681) CL:0000010 Derived from sampling site: Peripheral blood. Female 41409028 CVCL_A3DJ HPS3682 induced pluripotent stem cell human CVCL_A3DJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409029 CVCL_A3DK HPS3683 induced pluripotent stem cell human CVCL_A3DK CL:0000010 Derived from sampling site: Peripheral blood. Female 41409030 CVCL_A3DL HPS3684 induced pluripotent stem cell human CVCL_A3DL CL:0000010 Derived from sampling site: Peripheral blood. Female 41409031 CVCL_A3DM HPS3685 induced pluripotent stem cell human CVCL_A3DM CL:0000010 Derived from sampling site: Peripheral blood. Female 41409032 CVCL_A3DN HPS3800 induced pluripotent stem cell human CVCL_A3DN CL:0000010 Derived from sampling site: Peripheral blood. Female 41409033 CVCL_A3DA HPS3801 induced pluripotent stem cell human CVCL_A3DA CL:0000010 Derived from sampling site: Peripheral blood. Female 41409034 CVCL_A3DB HPS3802 induced pluripotent stem cell human CVCL_A3DB CL:0000010 Derived from sampling site: Peripheral blood. Female 41409035 CVCL_A3DC HPS3686 induced pluripotent stem cell human CVCL_A3DC HLA typing: A*11:01:01:01,26:01:01:01; B*15:01:01:01,40:02:01:01; C*01:02:01,03:04:01; DPB1*05:01:01,09:01:01; DQB1*05:03:01,06:01; DRB1*14:05:01:01,15:02:01:01 (RCB=HPS3686) CL:0000010 Derived from sampling site: Peripheral blood. Female 41409036 CVCL_A3DD HPS3687 induced pluripotent stem cell human CVCL_A3DD CL:0000010 Derived from sampling site: Peripheral blood. Female 41409037 CVCL_A3DE HPS3688 induced pluripotent stem cell human CVCL_A3DE CL:0000010 Derived from sampling site: Peripheral blood. Female 41409038 CVCL_A3DF HPS3689 induced pluripotent stem cell human CVCL_A3DF CL:0000010 Derived from sampling site: Peripheral blood. Female 41409039 CVCL_A3CV HPS3697 induced pluripotent stem cell human CVCL_A3CV CL:0000010 Derived from sampling site: Peripheral blood. Female 41409040 CVCL_A3CW HPS3698 induced pluripotent stem cell human CVCL_A3CW CL:0000010 Derived from sampling site: Peripheral blood. Female 41409041 CVCL_A3CX HPS3699 induced pluripotent stem cell human CVCL_A3CX CL:0000010 Derived from sampling site: Peripheral blood. Female 41409042 CVCL_A3CY HPS3700 induced pluripotent stem cell human CVCL_A3CY CL:0000010 Derived from sampling site: Peripheral blood. Female 41409043 CVCL_A3CZ HPS3701 induced pluripotent stem cell human CVCL_A3CZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409044 CVCL_A3CN GSK6F05 hybridoma house mouse CVCL_A3CN CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: UniProtKB; P20393; Human NR1D1 (AA 281-614). 41409045 CVCL_A3CP HT29-5FU resistant (1 microMolar) cancer cell line human CVCL_A3CP CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). Selected for resistance to: ChEBI; CHEBI:46345; 5-fluorouracil (5-FU) Female Characteristics: Resistant to 1 muM of 5-fluorouracil 41409046 CVCL_A3CQ HPS3692 induced pluripotent stem cell human CVCL_A3CQ HLA typing: A*24:02:01:01,31:01:02:01; B*51:01:01:03,52:01:01:02; C*12:02:02:01,14:02:01; DPB1*02:01:02,09:01:01; DQB1*03:01:01,06:01; DRB1*11:01:01:03,15:02:01:01 (RCB=HPS3692) CL:0000010 Derived from sampling site: Peripheral blood. Female 41409047 CVCL_A3CR HPS3693 induced pluripotent stem cell human CVCL_A3CR CL:0000010 Derived from sampling site: Peripheral blood. Female 41409048 CVCL_A3CS HPS3694 induced pluripotent stem cell human CVCL_A3CS CL:0000010 Derived from sampling site: Peripheral blood. Female 41409049 CVCL_A3CT HPS3695 induced pluripotent stem cell human CVCL_A3CT CL:0000010 Derived from sampling site: Peripheral blood. Female 41409050 CVCL_A3CU HPS3696 induced pluripotent stem cell human CVCL_A3CU HLA typing: A*11:01:01:01; B*39:04,48:01:01; C*07:02:01:01,08:01:01:01; DPB1*02:01:02; DQB1*03:01:01,03:03:02; DRB1*09:01:02,11:01:01:04 (RCB=HPS3696) CL:0000010 Derived from sampling site: Peripheral blood. Female 41409051 CVCL_A3EH HPS3770 induced pluripotent stem cell human CVCL_A3EH CL:0000010 Derived from sampling site: Peripheral blood. Male 41409052 CVCL_A3EI HPS3771 induced pluripotent stem cell human CVCL_A3EI CL:0000010 Derived from sampling site: Peripheral blood. Male 41409053 CVCL_A3EJ HPS3417 induced pluripotent stem cell human CVCL_A3EJ HLA typing: A*24:02:01:01,26:01:01:01; B*40:02:01:01,54:01:01; C*01:02:01:05,03:29; DPB1*02:01:02,04:02:01; DQB1*05:02:01:01,06:01; DRB1*08:03:02,14:54:01:02New (RCB=HPS3417) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409054 CVCL_A3EK HPS3418 induced pluripotent stem cell human CVCL_A3EK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409055 CVCL_A3EL HPS3772 induced pluripotent stem cell human CVCL_A3EL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409056 CVCL_A3EM HPS3773 induced pluripotent stem cell human CVCL_A3EM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409057 CVCL_A3EN HPS3774 induced pluripotent stem cell human CVCL_A3EN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409058 CVCL_A3EA HPS3814 induced pluripotent stem cell human CVCL_A3EA CL:0000010 Derived from sampling site: Peripheral blood. Female 41409059 CVCL_A3EB HPS4016 induced pluripotent stem cell human CVCL_A3EB CL:0000010 Derived from sampling site: Peripheral blood. Male 41409060 CVCL_A3EC HPS4115 induced pluripotent stem cell human CVCL_A3EC CL:0000010 Derived from sampling site: Peripheral blood. Female 41409061 CVCL_A3ED HPS3410 induced pluripotent stem cell human CVCL_A3ED HLA typing: A*02:01:01:01,24:02:01:01; B*15:01:01:01New,40:01:02; C*03:04:01,08:03:01; DPB1*02:01:02,05:01:01; DQB1*03:01:01,05:03:01; DRB1*14:06:01,14:54:01:02 (RCB=HPS3410) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409062 CVCL_A3EE HPS3767 induced pluripotent stem cell human CVCL_A3EE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409063 CVCL_A3EF HPS3768 induced pluripotent stem cell human CVCL_A3EF CL:0000010 Derived from sampling site: Peripheral blood. Male 41409064 CVCL_A3EG HPS3769 induced pluripotent stem cell human CVCL_A3EG CL:0000010 Derived from sampling site: Peripheral blood. Male 41409065 CVCL_A3DW HPS3810 induced pluripotent stem cell human CVCL_A3DW CL:0000010 Derived from sampling site: Peripheral blood. Female 41409066 CVCL_A3DX HPS3811 induced pluripotent stem cell human CVCL_A3DX CL:0000010 Derived from sampling site: Peripheral blood. Female 41409067 CVCL_A3DY HPS3812 induced pluripotent stem cell human CVCL_A3DY CL:0000010 Derived from sampling site: Peripheral blood. Female 41409068 CVCL_A3DZ HPS3813 induced pluripotent stem cell human CVCL_A3DZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409069 CVCL_A3DP HPS3676 induced pluripotent stem cell human CVCL_A3DP HLA typing: A*24:02:01:01; B*40:06:01:01,52:01:01:02; C*03:03:01,12:02:02:01; DPB1*05:01:01,09:01:01; DQB1*06:01New,06:04; DRB1*13:02:01:02,15:02:01:01 (RCB=HPS3676) CL:0000010 Derived from sampling site: Peripheral blood. Female 41409070 CVCL_A3DQ 1205D1 induced pluripotent stem cell human CVCL_A3DQ From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: African American; Derived from sampling site: Peripheral blood. Female 41409071 CVCL_A3DR HPS3678 induced pluripotent stem cell human CVCL_A3DR CL:0000010 Derived from sampling site: Peripheral blood. Female 41409072 CVCL_A3DS HPS3679 induced pluripotent stem cell human CVCL_A3DS CL:0000010 Derived from sampling site: Peripheral blood. Female 41409073 CVCL_A3DT HPS3680 induced pluripotent stem cell human CVCL_A3DT CL:0000010 Derived from sampling site: Peripheral blood. Female 41409074 CVCL_A3DU HPS3799 induced pluripotent stem cell human CVCL_A3DU CL:0000010 Derived from sampling site: Peripheral blood. Female 41409075 CVCL_A3DV HPS3702 induced pluripotent stem cell human CVCL_A3DV CL:0000010 Derived from sampling site: Peripheral blood. Female 41409076 CVCL_A3BE GOS-2 cancer cell line human CVCL_A3BE CL:0000010 Male Doubling time: 30 hours (PubMed=9760066). 41409077 CVCL_A3BF Hu70 cancer cell line human CVCL_A3BF CL:0000010 Derived from sampling site: Brain. Unspecified 41409078 CVCL_A3BG Hu104 cancer cell line human CVCL_A3BG CL:0000010 Derived from sampling site: Brain. Unspecified 41409079 CVCL_A3BH Hu112 cancer cell line human CVCL_A3BH CL:0000010 Derived from sampling site: Brain. Unspecified 41409080 CVCL_A3BI Hu195 cancer cell line human CVCL_A3BI CL:0000010 Derived from sampling site: Brain. Unspecified 41409081 CVCL_A3BJ Hu197 cancer cell line human CVCL_A3BJ CL:0000010 Derived from sampling site: Brain. Unspecified 41409082 CVCL_A3BK SA134 cancer cell line human CVCL_A3BK CL:0000010 41409083 CVCL_A3BL SA137 cancer cell line human CVCL_A3BL CL:0000010 41409084 CVCL_A3BA Ast812 cancer cell line human CVCL_A3BA CL:0000010 Derived from sampling site: Brain. Unspecified 41409085 CVCL_A3BB Ast718 cancer cell line human CVCL_A3BB CL:0000010 Derived from sampling site: Brain. Unspecified 41409086 CVCL_A3BC UW18 cancer cell line human CVCL_A3BC CL:0000010 Male 41409087 CVCL_A3BD GOS-1 cancer cell line human CVCL_A3BD CL:0000010 Male Doubling time: 25 hours (PubMed=9760066). 41409088 CVCL_A3AT ENL-2 finite cell line CVCL_A3AT CL:0000010 Derived from sampling site: Cell type=Fibroblast. 41409089 CVCL_A3AU APH-R finite cell line CVCL_A3AU CL:0000010 Derived from sampling site: Skin. 41409090 CVCL_A3AV E42/02 cancer cell line CVCL_A3AV CL:0000010 41409091 CVCL_A3AW GBK finite cell line CVCL_A3AW From: Solarzano R.F.; College of Veterinary Medicine, University of Missouri; Columbia; USA CL:0000010 Derived from sampling site: Kidney. 41409092 CVCL_A3AX MTH-R spontaneously immortalized cell line house mouse CVCL_A3AX CL:0000010 Derived from sampling site: Thymus. 41409093 CVCL_A3AY EFH-12 finite cell line pig CVCL_A3AY CL:0000010 Derived from sampling site: Testis. Male 41409094 CVCL_A3AZ TF [Scophthalmus fin UK] spontaneously immortalized cell line CVCL_A3AZ From: Hill B.; MAFF Fish Diseases Laboratory; Weymouth; United Kingdom CL:0000010 Derived from sampling site: Fin. Unspecified Characteristics: Optimal growth temperature is 25 Celsius (DOI=10.1046/j.1365-2761.2002.00371.x) Group: Fish cell line Caution: There are two turbot fin cell lines that were established and that were given the same name, TF, one by UK group in the 1980's (Cellosaurus=CVCL_A3AZ) and one from a Chines lab in 2010 (Cellosaurus=CVCL_8274) 41409095 CVCL_A3AL RPS-R finite cell line CVCL_A3AL CL:0000010 Derived from sampling site: Fetal rumen; mucosa. 41409096 CVCL_A3AM CCLV-RIE270 finite cell line pig CVCL_A3AM CL:0000010 Derived from sampling site: Oviduct epithelium. Female 41409097 CVCL_A3AN SGW-R finite cell line pig CVCL_A3AN CL:0000010 Derived from sampling site: Brainstem. 41409098 CVCL_A3AP SPLW-R finite cell line CVCL_A3AP CL:0000010 Derived from sampling site: Brain; choroid plexus. 41409099 CVCL_A3AQ T34 [Rabbit spleen] finite cell line CVCL_A3AQ CL:0000010 Derived from sampling site: Spleen. 41409100 CVCL_A3AR ZLI-R finite cell line CVCL_A3AR CL:0000010 Derived from sampling site: Fetal oral cavity; lip. 41409101 CVCL_A3AS KLU-2-R finite cell line CVCL_A3AS CL:0000010 Derived from sampling site: Fetal lung. Male 41409102 CVCL_A3CF 2H9 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CF CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409103 CVCL_A3CG 1C7 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CG CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409104 CVCL_A3CH 2D12 [Mouse hybridoma against canine distemper virus protein H] hybridoma house mouse CVCL_A3CH CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: Canine distemper virus isolate CDV851 hemagglutinin glycoprotein (H). Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202062 41409105 CVCL_A3CI B1-23 hybridoma house mouse CVCL_A3CI CL:0000010 Monoclonal antibody isotype: IgG2a, kappa; Monoclonal antibody target: UniProtKB; Q99988; Human GDF15. Group: Patented cell line; Registration: International Depositary Authority, Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ); ACC-3142 41409106 CVCL_A3CJ KT50 hybridoma CVCL_A3CJ CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse T cell receptor (TcR) V-alpha-8. 41409107 CVCL_A3CK KT65 hybridoma CVCL_A3CK CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: Mouse T cell receptor (TcR) V-alpha-8. 41409108 CVCL_A3CL KT15 hybridoma CVCL_A3CL CL:0000010 Monoclonal antibody isotype: IgG2a, lambda; Monoclonal antibody target: UniProtKB; P01731; Mouse Cd8a. 41409109 CVCL_A3CM KT112 hybridoma CVCL_A3CM CL:0000010 Monoclonal antibody isotype: IgG2a; Monoclonal antibody target: UniProtKB; P10300; Mouse Cd8b. 41409110 CVCL_A3CA 4G6F3 hybridoma house mouse CVCL_A3CA CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00755; Human WNT7A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202096 41409111 CVCL_A3CB 3H11 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CB CL:0000010 Monoclonal antibody isotype: IgG2b; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409112 CVCL_A3CC 3B9 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CC CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409113 CVCL_A3CD 1A5 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CD CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409114 CVCL_A3CE 3G6 [Mouse hybridoma against CDV hemagglutinin] hybridoma house mouse CVCL_A3CE CL:0000010 Monoclonal antibody isotype: IgG1; Monoclonal antibody target: Canine distemper virus isolate NJ01 hemagglutinin glycoprotein (H). 41409115 CVCL_A3BU Marmoset iPSC #A10 induced pluripotent stem cell CVCL_A3BU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409116 CVCL_A3BV Marmoset iPSC #A18 induced pluripotent stem cell CVCL_A3BV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409117 CVCL_A3BW Marmoset iPSC #B8 induced pluripotent stem cell CVCL_A3BW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409118 CVCL_A3BX SHEHDNi002-A induced pluripotent stem cell human CVCL_A3BX From: Department of Neurology, Shanghai East Hospital; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 15469; DNAJC6; Simple; p.Asn526Ser (c.1577A>G); ClinVar=VCV000706821; Zygosity=Heterozygous (hPSCreg); Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; p.Gly2385Arg (c.7153G>A); ClinVar=VCV000001943; Zygosity=Heterozygous (hPSCreg) Population: Chinese; Han; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409119 CVCL_A3BY 1B8A2 hybridoma house mouse CVCL_A3BY CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00755; Human WNT7A. Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202095 41409120 CVCL_A3BZ 3G5G2 hybridoma house mouse CVCL_A3BZ CL:0000010 Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; O00755; Human WNT7A. 41409121 CVCL_A3BM SA146 I cancer cell line human CVCL_A3BM CL:0000010 Derived from sampling site: Brain. Male Doubling time: 63 hours (at 7th passage), 97 hours (at 28th passage) (PubMed=9341940) 41409122 CVCL_A3BN SA146 II cancer cell line human CVCL_A3BN CL:0000010 Derived from sampling site: Brain. Male Characteristics: Established from a xenograft (SA146 XT) obtained from the parent cell line after subcutaneous injection into the thorax of nude mice 41409123 CVCL_A3BP Marmoset iPSC #15 induced pluripotent stem cell CVCL_A3BP CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409124 CVCL_A3BQ Marmoset iPSC #36 induced pluripotent stem cell CVCL_A3BQ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409125 CVCL_A3BR Marmoset iPSC #37 induced pluripotent stem cell CVCL_A3BR CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409126 CVCL_A3BS Marmoset iPSC #81 induced pluripotent stem cell CVCL_A3BS CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409127 CVCL_A3BT Marmoset iPSC #88 induced pluripotent stem cell CVCL_A3BT CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Group: Non-human primate cell line 41409128 CVCL_A3PS HPS1477 induced pluripotent stem cell human CVCL_A3PS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409129 CVCL_A3PT HPS1479 induced pluripotent stem cell human CVCL_A3PT CL:0000010 Derived from sampling site: Peripheral blood. Male 41409130 CVCL_A3PU HPS1480 induced pluripotent stem cell human CVCL_A3PU CL:0000010 Derived from sampling site: Peripheral blood. Male 41409131 CVCL_A3PV HPS1481 induced pluripotent stem cell human CVCL_A3PV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409132 CVCL_A3PW HPS1482 induced pluripotent stem cell human CVCL_A3PW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409133 CVCL_A3PX HPS1483 induced pluripotent stem cell human CVCL_A3PX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409134 CVCL_A3PY HPS2215 induced pluripotent stem cell human CVCL_A3PY CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409135 CVCL_A3PZ HPS2216 induced pluripotent stem cell human CVCL_A3PZ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409136 CVCL_A3PK HPS1469 induced pluripotent stem cell human CVCL_A3PK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409137 CVCL_A3PL HPS1470 induced pluripotent stem cell human CVCL_A3PL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409138 CVCL_A3PM HPS1471 induced pluripotent stem cell human CVCL_A3PM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409139 CVCL_A3PN HPS1473 induced pluripotent stem cell human CVCL_A3PN CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409140 CVCL_A3PP HPS1474 induced pluripotent stem cell human CVCL_A3PP CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409141 CVCL_A3PQ HPS1475 induced pluripotent stem cell human CVCL_A3PQ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409142 CVCL_A3PR HPS1476 induced pluripotent stem cell human CVCL_A3PR CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409143 CVCL_A3PC HPS3136 induced pluripotent stem cell human CVCL_A3PC CL:0000010 Derived from sampling site: Peripheral blood. Female 41409144 CVCL_A3PD HPS3144 induced pluripotent stem cell human CVCL_A3PD CL:0000010 Derived from sampling site: Peripheral blood. Female 41409145 CVCL_A3PE HPS3145 induced pluripotent stem cell human CVCL_A3PE CL:0000010 Derived from sampling site: Peripheral blood. Female 41409146 CVCL_A3PF HPS3146 induced pluripotent stem cell human CVCL_A3PF CL:0000010 Derived from sampling site: Peripheral blood. Female 41409147 CVCL_A3PG HPS3147 induced pluripotent stem cell human CVCL_A3PG CL:0000010 Derived from sampling site: Peripheral blood. Female 41409148 CVCL_A3PH HPS3148 induced pluripotent stem cell human CVCL_A3PH CL:0000010 Derived from sampling site: Peripheral blood. Female 41409149 CVCL_A3PI HPS1467 induced pluripotent stem cell human CVCL_A3PI CL:0000010 Derived from sampling site: Peripheral blood. Male 41409150 CVCL_A3PJ HPS1468 induced pluripotent stem cell human CVCL_A3PJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409151 CVCL_A3PA HPS3134 induced pluripotent stem cell human CVCL_A3PA CL:0000010 Derived from sampling site: Peripheral blood. Female 41409152 CVCL_A3PB HPS3135 induced pluripotent stem cell human CVCL_A3PB CL:0000010 Derived from sampling site: Peripheral blood. Female 41409153 CVCL_A3QT HPS2338 induced pluripotent stem cell human CVCL_A3QT CL:0000010 Derived from sampling site: Peripheral blood. Female 41409154 CVCL_A3QU HPS2339 induced pluripotent stem cell human CVCL_A3QU CL:0000010 Derived from sampling site: Peripheral blood. Female 41409155 CVCL_A3QV HPS2340 induced pluripotent stem cell human CVCL_A3QV CL:0000010 Derived from sampling site: Peripheral blood. Female 41409156 CVCL_A3QW HPS2384 induced pluripotent stem cell human CVCL_A3QW CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409157 CVCL_A3QX HPS2385 induced pluripotent stem cell human CVCL_A3QX CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409158 CVCL_A3QY HPS2386 induced pluripotent stem cell human CVCL_A3QY CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409159 CVCL_A3QZ HPS2387 induced pluripotent stem cell human CVCL_A3QZ CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409160 CVCL_A3QL HPS2230 induced pluripotent stem cell human CVCL_A3QL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409161 CVCL_A3QM HPS2231 induced pluripotent stem cell human CVCL_A3QM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409162 CVCL_A3QN HPS1533 induced pluripotent stem cell human CVCL_A3QN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409163 CVCL_A3QP HPS1534 induced pluripotent stem cell human CVCL_A3QP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409164 CVCL_A3QQ HPS1535 induced pluripotent stem cell human CVCL_A3QQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409165 CVCL_A3QR HPS1536 induced pluripotent stem cell human CVCL_A3QR CL:0000010 Derived from sampling site: Peripheral blood. Male 41409166 CVCL_A3QS HPS1537 induced pluripotent stem cell human CVCL_A3QS CL:0000010 Derived from sampling site: Peripheral blood. Male 41409167 CVCL_A3QD HPS2221 induced pluripotent stem cell human CVCL_A3QD CL:0000010 Derived from sampling site: Peripheral blood. Female 41409168 CVCL_A3QE HPS2222 induced pluripotent stem cell human CVCL_A3QE CL:0000010 Derived from sampling site: Peripheral blood. Female 41409169 CVCL_A3QF HPS2223 induced pluripotent stem cell human CVCL_A3QF CL:0000010 Derived from sampling site: Peripheral blood. Female 41409170 CVCL_A3QG HPS2224 induced pluripotent stem cell human CVCL_A3QG CL:0000010 Derived from sampling site: Peripheral blood. Female 41409171 CVCL_A3QH HPS2225 induced pluripotent stem cell human CVCL_A3QH CL:0000010 Derived from sampling site: Peripheral blood. Female 41409172 CVCL_A3QI HPS2227 induced pluripotent stem cell human CVCL_A3QI CL:0000010 Derived from sampling site: Peripheral blood. Male 41409173 CVCL_A3QJ HPS2228 induced pluripotent stem cell human CVCL_A3QJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409174 CVCL_A3QK HPS2229 induced pluripotent stem cell human CVCL_A3QK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409175 CVCL_A3QA HPS2217 induced pluripotent stem cell human CVCL_A3QA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409176 CVCL_A3QB HPS2218 induced pluripotent stem cell human CVCL_A3QB CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409177 CVCL_A3QC HPS2219 induced pluripotent stem cell human CVCL_A3QC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409178 CVCL_A3NQ HPS2511 induced pluripotent stem cell human CVCL_A3NQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409179 CVCL_A3NR HPS2512 induced pluripotent stem cell human CVCL_A3NR CL:0000010 Derived from sampling site: Peripheral blood. Female 41409180 CVCL_A3NS HPS2513 induced pluripotent stem cell human CVCL_A3NS CL:0000010 Derived from sampling site: Peripheral blood. Female 41409181 CVCL_A3NT HPS3126 induced pluripotent stem cell human CVCL_A3NT CL:0000010 Derived from sampling site: Peripheral blood. Male 41409182 CVCL_A3NU HPS3127 induced pluripotent stem cell human CVCL_A3NU CL:0000010 Derived from sampling site: Peripheral blood. Male 41409183 CVCL_A3NV HPS3128 induced pluripotent stem cell human CVCL_A3NV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409184 CVCL_A3NW HPS3129 induced pluripotent stem cell human CVCL_A3NW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409185 CVCL_A3NX HPS3130 induced pluripotent stem cell human CVCL_A3NX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409186 CVCL_A3NI HPS2479 induced pluripotent stem cell human CVCL_A3NI CL:0000010 Derived from sampling site: Peripheral blood. Female 41409187 CVCL_A3NJ HPS2480 induced pluripotent stem cell human CVCL_A3NJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409188 CVCL_A3NK HPS2481 induced pluripotent stem cell human CVCL_A3NK CL:0000010 Derived from sampling site: Peripheral blood. Female 41409189 CVCL_A3NL HPS2482 induced pluripotent stem cell human CVCL_A3NL CL:0000010 Derived from sampling site: Peripheral blood. Female 41409190 CVCL_A3NM HPS2483 induced pluripotent stem cell human CVCL_A3NM CL:0000010 Derived from sampling site: Peripheral blood. Female 41409191 CVCL_A3NN HPS2509 induced pluripotent stem cell human CVCL_A3NN CL:0000010 Derived from sampling site: Peripheral blood. Female 41409192 CVCL_A3NP HPS2510 induced pluripotent stem cell human CVCL_A3NP CL:0000010 Derived from sampling site: Peripheral blood. Female 41409193 CVCL_A3NA HPS2873 induced pluripotent stem cell human CVCL_A3NA CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409194 CVCL_A3NB HPS2874 induced pluripotent stem cell human CVCL_A3NB CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409195 CVCL_A3NC HPS2875 induced pluripotent stem cell human CVCL_A3NC CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409196 CVCL_A3ND HPS2485 induced pluripotent stem cell human CVCL_A3ND CL:0000010 Derived from sampling site: Peripheral blood. Male 41409197 CVCL_A3NE HPS2486 induced pluripotent stem cell human CVCL_A3NE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409198 CVCL_A3NF HPS2487 induced pluripotent stem cell human CVCL_A3NF CL:0000010 Derived from sampling site: Peripheral blood. Male 41409199 CVCL_A3NG HPS2488 induced pluripotent stem cell human CVCL_A3NG CL:0000010 Derived from sampling site: Peripheral blood. Male 41409200 CVCL_A3NH HPS2489 induced pluripotent stem cell human CVCL_A3NH CL:0000010 Derived from sampling site: Peripheral blood. Male 41409201 CVCL_A3MX HPS2364 induced pluripotent stem cell human CVCL_A3MX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409202 CVCL_A3MY HPS2871 induced pluripotent stem cell human CVCL_A3MY CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409203 CVCL_A3MZ HPS2872 induced pluripotent stem cell human CVCL_A3MZ CL:0000010 Sequence variation: Mutation; HGNC; 26527; HGSNAT; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409204 CVCL_A3NY HPS3132 induced pluripotent stem cell human CVCL_A3NY CL:0000010 Derived from sampling site: Peripheral blood. Female 41409205 CVCL_A3NZ HPS3133 induced pluripotent stem cell human CVCL_A3NZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409206 CVCL_A3LP HPS2909 induced pluripotent stem cell human CVCL_A3LP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409207 CVCL_A3LQ HPS2910 induced pluripotent stem cell human CVCL_A3LQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409208 CVCL_A3LR HPS2911 induced pluripotent stem cell human CVCL_A3LR CL:0000010 Derived from sampling site: Peripheral blood. Male 41409209 CVCL_A3LS HPS3842 induced pluripotent stem cell human CVCL_A3LS CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41409210 CVCL_A3LT HPS3843 induced pluripotent stem cell human CVCL_A3LT CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41409211 CVCL_A3LU HPS3844 induced pluripotent stem cell human CVCL_A3LU CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409212 CVCL_A3LV HPS3845 induced pluripotent stem cell human CVCL_A3LV CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409213 CVCL_A3LG HPS3386 induced pluripotent stem cell human CVCL_A3LG HLA typing: A*24:02:01:01; B*52:01:01:02,54:01:01; C*01:02:01,12:02:02:01; DPB1*05:01:01,09:01:01; DQB1*04:01:01:01,06:01; DRB1*04:05:01:02,15:02:01:01 (RCB=HPS3386) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409214 CVCL_A3LH HPS3387 induced pluripotent stem cell human CVCL_A3LH CL:0000010 Derived from sampling site: Peripheral blood. Male 41409215 CVCL_A3LI HPS3388 induced pluripotent stem cell human CVCL_A3LI CL:0000010 Derived from sampling site: Peripheral blood. Male 41409216 CVCL_A3LJ HPS3389 induced pluripotent stem cell human CVCL_A3LJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409217 CVCL_A3LK HPS3390 induced pluripotent stem cell human CVCL_A3LK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409218 CVCL_A3LL HPS3391 induced pluripotent stem cell human CVCL_A3LL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409219 CVCL_A3LM HPS2907 induced pluripotent stem cell human CVCL_A3LM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409220 CVCL_A3LN HPS2908 induced pluripotent stem cell human CVCL_A3LN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409221 CVCL_A3LA HPS3354 induced pluripotent stem cell human CVCL_A3LA HLA typing: A*02:06:01:01,24:20:01:01New; B*35:01:01:02,39:01:01:03; C*03:03:01:01,03:04:01:02; DPB1*02:01:02,05:01:01; DQB1*03:01:01,06:02:01:01; DRB1*11:01:01:01,15:01:01New (RCB=HPS3354) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409222 CVCL_A3LB HPS3355 induced pluripotent stem cell human CVCL_A3LB CL:0000010 Derived from sampling site: Peripheral blood. Male 41409223 CVCL_A3LC HPS3356 induced pluripotent stem cell human CVCL_A3LC CL:0000010 Derived from sampling site: Peripheral blood. Male 41409224 CVCL_A3LD HPS3357 induced pluripotent stem cell human CVCL_A3LD CL:0000010 Derived from sampling site: Peripheral blood. Male 41409225 CVCL_A3LE HPS3358 induced pluripotent stem cell human CVCL_A3LE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409226 CVCL_A3LF HPS3359 induced pluripotent stem cell human CVCL_A3LF CL:0000010 Derived from sampling site: Peripheral blood. Male 41409227 CVCL_A3KV HPS3349 induced pluripotent stem cell human CVCL_A3KV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409228 CVCL_A3KW HPS3350 induced pluripotent stem cell human CVCL_A3KW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409229 CVCL_A3KX HPS3351 induced pluripotent stem cell human CVCL_A3KX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409230 CVCL_A3KY HPS3352 induced pluripotent stem cell human CVCL_A3KY CL:0000010 Derived from sampling site: Peripheral blood. Male 41409231 CVCL_A3KZ HPS3353 induced pluripotent stem cell human CVCL_A3KZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409232 CVCL_A3MP HPS2391 induced pluripotent stem cell human CVCL_A3MP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409233 CVCL_A3MQ HPS2392 induced pluripotent stem cell human CVCL_A3MQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409234 CVCL_A3MR HPS2393 induced pluripotent stem cell human CVCL_A3MR CL:0000010 Derived from sampling site: Peripheral blood. Male 41409235 CVCL_A3MS HPS2394 induced pluripotent stem cell human CVCL_A3MS CL:0000010 Derived from sampling site: Peripheral blood. Male 41409236 CVCL_A3MT HPS2360 induced pluripotent stem cell human CVCL_A3MT CL:0000010 Derived from sampling site: Peripheral blood. Male 41409237 CVCL_A3MU HPS2361 induced pluripotent stem cell human CVCL_A3MU CL:0000010 Derived from sampling site: Peripheral blood. Male 41409238 CVCL_A3MV HPS2362 induced pluripotent stem cell human CVCL_A3MV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409239 CVCL_A3MW HPS2363 induced pluripotent stem cell human CVCL_A3MW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409240 CVCL_A3MH HPS1443 induced pluripotent stem cell human CVCL_A3MH CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409241 CVCL_A3MI HPS1444 induced pluripotent stem cell human CVCL_A3MI CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409242 CVCL_A3MJ HPS1445 induced pluripotent stem cell human CVCL_A3MJ CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409243 CVCL_A3MK HPS1446 induced pluripotent stem cell human CVCL_A3MK CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409244 CVCL_A3ML HPS1447 induced pluripotent stem cell human CVCL_A3ML CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409245 CVCL_A3MM HPS2389 induced pluripotent stem cell human CVCL_A3MM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409246 CVCL_A3MN HPS2390 induced pluripotent stem cell human CVCL_A3MN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409247 CVCL_A3MA HPS1572 induced pluripotent stem cell human CVCL_A3MA CL:0000010 Derived from sampling site: Peripheral blood. Female 41409248 CVCL_A3MB HPS1907 induced pluripotent stem cell human CVCL_A3MB CL:0000010 Derived from sampling site: Peripheral blood. Male 41409249 CVCL_A3MC HPS1908 induced pluripotent stem cell human CVCL_A3MC CL:0000010 Derived from sampling site: Peripheral blood. Male 41409250 CVCL_A3MD HPS1909 induced pluripotent stem cell human CVCL_A3MD CL:0000010 Derived from sampling site: Peripheral blood. Male 41409251 CVCL_A3ME HPS1910 induced pluripotent stem cell human CVCL_A3ME CL:0000010 Derived from sampling site: Peripheral blood. Male 41409252 CVCL_A3MF HPS1911 induced pluripotent stem cell human CVCL_A3MF CL:0000010 Derived from sampling site: Peripheral blood. Male 41409253 CVCL_A3MG HPS1442 induced pluripotent stem cell human CVCL_A3MG CL:0000010 Sequence variation: Mutation; HGNC; 4235; GFAP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. 41409254 CVCL_A3LW HPS3846 induced pluripotent stem cell human CVCL_A3LW CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409255 CVCL_A3LX HPS1569 induced pluripotent stem cell human CVCL_A3LX CL:0000010 Derived from sampling site: Peripheral blood. Female 41409256 CVCL_A3LY HPS1570 induced pluripotent stem cell human CVCL_A3LY CL:0000010 Derived from sampling site: Peripheral blood. Female 41409257 CVCL_A3LZ HPS1571 induced pluripotent stem cell human CVCL_A3LZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409258 CVCL_A3JM HPS2817 induced pluripotent stem cell human CVCL_A3JM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409259 CVCL_A3JN HPS2818 induced pluripotent stem cell human CVCL_A3JN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409260 CVCL_A3JP HPS2819 induced pluripotent stem cell human CVCL_A3JP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409261 CVCL_A3JQ HPS2820 induced pluripotent stem cell human CVCL_A3JQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409262 CVCL_A3JR HPS2821 induced pluripotent stem cell human CVCL_A3JR CL:0000010 Derived from sampling site: Peripheral blood. Male 41409263 CVCL_A3JS HPS2876 induced pluripotent stem cell human CVCL_A3JS CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409264 CVCL_A3JT HPS2877 induced pluripotent stem cell human CVCL_A3JT CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409265 CVCL_A3JE HPS2501 induced pluripotent stem cell human CVCL_A3JE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409266 CVCL_A3JF HPS2556 induced pluripotent stem cell human CVCL_A3JF CL:0000010 Derived from sampling site: Peripheral blood. Female 41409267 CVCL_A3JG HPS2557 induced pluripotent stem cell human CVCL_A3JG CL:0000010 Derived from sampling site: Peripheral blood. Female 41409268 CVCL_A3JH HPS2558 induced pluripotent stem cell human CVCL_A3JH CL:0000010 Derived from sampling site: Peripheral blood. Female 41409269 CVCL_A3JI HPS2559 induced pluripotent stem cell human CVCL_A3JI CL:0000010 Derived from sampling site: Peripheral blood. Female 41409270 CVCL_A3JJ HPS2560 induced pluripotent stem cell human CVCL_A3JJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41409271 CVCL_A3JK HPS2561 induced pluripotent stem cell human CVCL_A3JK CL:0000010 Derived from sampling site: Peripheral blood. Female 41409272 CVCL_A3JL HPS2816 induced pluripotent stem cell human CVCL_A3JL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409273 CVCL_A3JA HPS2497 induced pluripotent stem cell human CVCL_A3JA CL:0000010 Derived from sampling site: Peripheral blood. Male 41409274 CVCL_A3JB HPS2498 induced pluripotent stem cell human CVCL_A3JB CL:0000010 Derived from sampling site: Peripheral blood. Male 41409275 CVCL_A3JC HPS2499 induced pluripotent stem cell human CVCL_A3JC CL:0000010 Derived from sampling site: Peripheral blood. Male 41409276 CVCL_A3JD HPS2500 induced pluripotent stem cell human CVCL_A3JD CL:0000010 Derived from sampling site: Peripheral blood. Male 41409277 CVCL_A3IT HPS2490 induced pluripotent stem cell human CVCL_A3IT HLA typing: A*11:01:01:01,24:02:01:01; B*40:02:01:01,51:01:01; C*03:04:01:02,15:02:01:01; DPB1*04:02:01,09:01:01; DQB1*03:01:01,06:01; DRB1*04:01:01:01,08:03:02 (RCB=HPS2490) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409278 CVCL_A3IU HPS2491 induced pluripotent stem cell human CVCL_A3IU CL:0000010 Derived from sampling site: Peripheral blood. Male 41409279 CVCL_A3IV HPS2492 induced pluripotent stem cell human CVCL_A3IV CL:0000010 Derived from sampling site: Peripheral blood. Male 41409280 CVCL_A3IW HPS2493 induced pluripotent stem cell human CVCL_A3IW CL:0000010 Derived from sampling site: Peripheral blood. Male 41409281 CVCL_A3IX HPS2494 induced pluripotent stem cell human CVCL_A3IX CL:0000010 Derived from sampling site: Peripheral blood. Male 41409282 CVCL_A3IY HPS2495 induced pluripotent stem cell human CVCL_A3IY CL:0000010 Derived from sampling site: Peripheral blood. Male 41409283 CVCL_A3IZ HPS2496 induced pluripotent stem cell human CVCL_A3IZ HLA typing: A*11:01:01:01,24:02:01:01; B*15:01:01:01,52:01:01:02; C*03:03:01:01,12:02:02:01; DPB1*05:01:01,09:01:01; DQB1*04:01:01:02,06:01; DRB1*04:05:01:02,15:02:01:01 (RCB=HPS2496) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409284 CVCL_A3KN HPS3227 induced pluripotent stem cell human CVCL_A3KN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409285 CVCL_A3KP HPS3228 induced pluripotent stem cell human CVCL_A3KP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409286 CVCL_A3KQ HPS3229 induced pluripotent stem cell human CVCL_A3KQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409287 CVCL_A3KR HEK293 C9orf72+/- transformed cell line human CVCL_A3KR CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 28337; C9orf72 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 41409288 CVCL_A3KS HEK293 C9orf72-/- A transformed cell line human CVCL_A3KS CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 41409289 CVCL_A3KT HEK293 C9orf72-/- B transformed cell line human CVCL_A3KT CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72 Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Derived from sampling site: Fetal kidney. Female 41409290 CVCL_A3KU HPS3348 induced pluripotent stem cell human CVCL_A3KU HLA typing: A*24:02:01:01,26:03:01; B*07:02:01:01,15:01:01:01; C*03:03:01:01,07:02:01:03; DPB1*02:01:02New,04:02:01New; DQB1*03:03:02,05:01:01; DRB1*01:01:01,09:01:02 (RCB=HPS3348) CL:0000010 Derived from sampling site: Peripheral blood. Male 41409291 CVCL_A3KF HPS3180 induced pluripotent stem cell human CVCL_A3KF CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409292 CVCL_A3KG HPS3181 induced pluripotent stem cell human CVCL_A3KG CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409293 CVCL_A3KH HPS3182 induced pluripotent stem cell human CVCL_A3KH CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409294 CVCL_A3KI HPS3183 induced pluripotent stem cell human CVCL_A3KI CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409295 CVCL_A3KJ HPS3184 induced pluripotent stem cell human CVCL_A3KJ CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409296 CVCL_A3KK HPS3224 induced pluripotent stem cell human CVCL_A3KK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409297 CVCL_A3KL HPS3225 induced pluripotent stem cell human CVCL_A3KL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409298 CVCL_A3KM HPS3226 induced pluripotent stem cell human CVCL_A3KM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409299 CVCL_A3KA HPS2884 induced pluripotent stem cell human CVCL_A3KA CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409300 CVCL_A3KB HPS2885 induced pluripotent stem cell human CVCL_A3KB CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409301 CVCL_A3KC HPS2886 induced pluripotent stem cell human CVCL_A3KC CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409302 CVCL_A3KD HPS2887 induced pluripotent stem cell human CVCL_A3KD CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409303 CVCL_A3KE HPS3179 induced pluripotent stem cell human CVCL_A3KE CL:0000010 Sequence variation: Mutation; HGNC; 11444; STXBP1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41409304 CVCL_A3JU HPS2878 induced pluripotent stem cell human CVCL_A3JU CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409305 CVCL_A3JV HPS2879 induced pluripotent stem cell human CVCL_A3JV CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409306 CVCL_A3JW HPS2880 induced pluripotent stem cell human CVCL_A3JW CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409307 CVCL_A3JX HPS2881 induced pluripotent stem cell human CVCL_A3JX CL:0000010 Sequence variation: Mutation; HGNC; 2348; CREBBP; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Female 41409308 CVCL_A3JY HPS2882 induced pluripotent stem cell human CVCL_A3JY CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409309 CVCL_A3JZ HPS2883 induced pluripotent stem cell human CVCL_A3JZ CL:0000010 Sequence variation: Mutation; HGNC; 7448; MTM1; Unexplicit; Not described; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41409310 CVCL_A2VZ GM26165 transformed cell line human CVCL_A2VZ CL:0000010 Population: Caucasian; Hungarian/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409311 CVCL_A2WA GM26179 transformed cell line human CVCL_A2WA CL:0000010 Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Val178Met (c.532G>A); ClinVar=VCV000002402; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 746; ASL; Simple; p.Arg193Gln (c.578G>A); ClinVar=VCV000372306; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409312 CVCL_A2WB GM26181 transformed cell line human CVCL_A2WB CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; c.5238+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Tyr8107Cysfs*75 (c.24313_24317dupGTGTT); ClinVar=VCV000553170; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409313 CVCL_A2VR GM26137 transformed cell line human CVCL_A2VR CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Asn4575Thr (c.13724A>C); ClinVar=VCV000590436; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch/German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409314 CVCL_A2VS GM26147 transformed cell line human CVCL_A2VS CL:0000010 Sequence variation: Mutation; HGNC; 3754; FLNA; Simple; p.Pro680Leu (c.2039C>T); Zygosity=Hemizygous (Coriell); Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; p.Val1360Ile (c.4078G>A); ClinVar=VCV000042991; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Gln1589Pro (c.4766A>C); ClinVar=VCV000544377; Zygosity=Heterozygous (Coriell) Population: Caucasian; British/Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409315 CVCL_A2VT GM26153 transformed cell line human CVCL_A2VT CL:0000010 Sequence variation: Mutation; HGNC; 90; ACADS; Simple; p.Arg171Trp (c.511C>T) (R147W); ClinVar=VCV000003830; Zygosity=Homozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Lys3867Thr (c.11600A>C); ClinVar=VCV000544409; Zygosity=Heterozygous (Coriell) Population: Caucasian; British/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409316 CVCL_A2VU GM26154 transformed cell line human CVCL_A2VU CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409317 CVCL_A2VV GM26155 transformed cell line human CVCL_A2VV CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Gly4444_Gly4450dup (c.13331_13351dup); ClinVar=VCV000478183; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Arg4861His (c.14582G>A); ClinVar=VCV000012982; Zygosity=Heterozygous (Coriell) Population: Caucasian; German; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409318 CVCL_A2VW GM26156 transformed cell line human CVCL_A2VW CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409319 CVCL_A2VX GM26163 transformed cell line human CVCL_A2VX CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409320 CVCL_A2VY GM26164 transformed cell line human CVCL_A2VY CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409321 CVCL_A2VJ GM26193 finite cell line human CVCL_A2VJ CL:0000010 Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; p.Val283Ala (c.848T>C); ClinVar=VCV000021025; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; p.Ile420Leu (c.1258A>C); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409322 CVCL_A2VK GM26194 finite cell line human CVCL_A2VK CL:0000010 Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; p.Ile373Thr (c.1118T>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 92; ACADVL; Simple; p.Arg453Gln (c.1358G>A); ClinVar=VCV000374123; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409323 CVCL_A2VL GM26130 transformed cell line human CVCL_A2VL CL:0000010 Sequence variation: Mutation; HGNC; 7577; MYH7; Simple; c.3337-4dupC (c.3337-3dupC); ClinVar=VCV000042956; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Gly334Val (c.1001G>T); ClinVar=VCV000159825; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; c.1186_1187delinsTC; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Pro2496Arg (c.7487C>G); ClinVar=VCV000159859; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Arg3113His (c.9338G>A); ClinVar=VCV000130688; Zygosity=Heterozygous (Coriell) Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409324 CVCL_A2VM GM26131 transformed cell line human CVCL_A2VM CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409325 CVCL_A2VN GM26132 transformed cell line human CVCL_A2VN CL:0000010 Population: Korean; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409326 CVCL_A2VP GM26135 transformed cell line human CVCL_A2VP CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Asn4575Thr (c.13724A>C); ClinVar=VCV000590436; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409327 CVCL_A2VQ GM26136 transformed cell line human CVCL_A2VQ CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Asn4575Thr (c.13724A>C); ClinVar=VCV000590436; Zygosity=Heterozygous (Coriell) Population: Caucasian; German/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409328 CVCL_A2VB GM26091 finite cell line human CVCL_A2VB CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409329 CVCL_A2VC GM26094 transformed cell line human CVCL_A2VC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409330 CVCL_A2VD GM26112 transformed cell line human CVCL_A2VD CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Gly48Cys (c.142C>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Irish/Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409331 CVCL_A2VE GM26113 finite cell line human CVCL_A2VE CL:0000010 Sequence variation: Mutation; HGNC; 8967; PIGN; Simple; c.1434_c.1434+1delGGinsAA; ClinVar=VCV000280280; Zygosity=Homozygous; Note=Causes abnormal splicing (Coriell); Sequence variation: Mutation; HGNC; 10485; RYR3; Simple; p.Arg1521Ser (c.4562G>C); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10485; RYR3; Simple; p.Glu4130Ala (c.12389A>C); Zygosity=Heterozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409332 CVCL_A2VF GM26114 transformed cell line human CVCL_A2VF CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Asp27Asn (c.79G>A); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Arg1894Gly (c.5680A>G); ClinVar=VCV000465617; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Pro4678Arg (c.14033C>G) (p.Pro3751Arg, c.11252C>G) (p.Pro4995Arg, c.14984C>G); ClinVar=VCV000046595; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12403; TTN; Simple; p.Val5118Met (c.15352G>A) (p.Val4191Met, c.12571G>A) (p.Val5435Met, c.16303G>A); ClinVar=VCV000046614; Zygosity=Heterozygous (Coriell) Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409333 CVCL_A2VG GM26115 transformed cell line human CVCL_A2VG CL:0000010 Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409334 CVCL_A2VH GM26116 transformed cell line human CVCL_A2VH CL:0000010 Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409335 CVCL_A2VI GM26117 transformed cell line human CVCL_A2VI CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Asn94Lys (c.282C>A); ClinVar=VCV000948238; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Ile382Met (c.1146A>G); ClinVar=VCV000050866; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Glu3212Gly (c.9635A>G); ClinVar=VCV000329090; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11831; TK2; Simple; p.Arg183Trp (c.547C>T); ClinVar=VCV000038992; Zygosity=Heterozygous (Coriell) Population: Caucasian; Lithuanian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409336 CVCL_A2XA KKN 122 transformed cell line human CVCL_A2XA CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human neurons and neurofibrillary tangles 41409337 CVCL_A2XB JGR 29 transformed cell line human CVCL_A2XB CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human neurons and neurofibrillary tangles 41409338 CVCL_A2XC JGR 38 transformed cell line human CVCL_A2XC CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human neurons, glia and neurofibrillary tangles 41409339 CVCL_A2WS Eckert transformed cell line human CVCL_A2WS CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified 41409340 CVCL_A2WT IFAR-847 transformed cell line human CVCL_A2WT CL:0000010 Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Arg753Ter (c.2257C>T); ClinVar=VCV000142403; Zygosity=Heterozygous (PubMed=17200671); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Tyr1183Ter (c.3549C>A); ClinVar=VCV000128144; Zygosity=Heterozygous (PubMed=17200671) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41409341 CVCL_A2WU IFAR-849 transformed cell line human CVCL_A2WU CL:0000010 Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Asn1039Ilefs*2 (c.3116delA); ClinVar=VCV000126715; Zygosity=Heterozygous (PubMed=17200671); Sequence variation: Mutation; HGNC; 26144; PALB2; Simple; p.Tyr1183Ter (c.3549C>G); ClinVar=VCV000001245; Zygosity=Heterozygous (PubMed=17200671) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. 41409342 CVCL_A2WV 98-4.9 transformed cell line human CVCL_A2WV CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG3, lambda; Monoclonal antibody target: HIV-1 p24 41409343 CVCL_A2WW 126-50 transformed cell line human CVCL_A2WW CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG2, kappa; Monoclonal antibody target: HIV-1 gp41 41409344 CVCL_A2WX 91-6 transformed cell line human CVCL_A2WX CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Unspecified Monoclonal antibody isotype: IgG1, lambda; Monoclonal antibody target: HIV-1 p24 41409345 CVCL_A2WY KKN 7 transformed cell line human CVCL_A2WY CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa; Monoclonal antibody target: Human neurons and neurofibrillary tangles 41409346 CVCL_A2WZ KKN 92 transformed cell line human CVCL_A2WZ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, lambda; Monoclonal antibody target: Human astrocytes and neurofibrillary tangles 41409347 CVCL_A2WK GM26642 transformed cell line human CVCL_A2WK CL:0000010 Sequence variation: Mutation; HGNC; 2209; COL5A1; Simple; p.Thr1008Met (c.3023C>T); ClinVar=VCV000213047; Zygosity=Heterozygous (Coriell) Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409348 CVCL_A2WL GM26643 transformed cell line human CVCL_A2WL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409349 CVCL_A2WM BKZ-1 cancer cell line human CVCL_A2WM CL:0000010 Derived from sampling site: Lung. Female Group: Cancer stem cell line 41409350 CVCL_A2WN IDG3.2 embryonic stem cell house mouse CVCL_A2WN CL:0000010 Breed/subspecies: C57BL/6J x 129S6/SvEvTac. 41409351 CVCL_A2WP IDG26.10-3 embryonic stem cell house mouse CVCL_A2WP CL:0000010 Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Breed/subspecies: C57BL/6J x 129S6/SvEvTac. Characteristics: Contains a recombinase-mediated cassette exchange (RMCE) acceptor vector pRosa26.10 (PubMed=17586814) 41409352 CVCL_A2WQ GS-iPSC1 induced pluripotent stem cell thirteen-lined ground squirrel CVCL_A2WQ CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.. Female 41409353 CVCL_A2WR GS-iPSC3 induced pluripotent stem cell thirteen-lined ground squirrel CVCL_A2WR CL:0000010 Derived from sampling site: Brain; cerebral cortex Cell type=Neuron.. Female 41409354 CVCL_A2WC GM26182 transformed cell line human CVCL_A2WC CL:0000010 Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409355 CVCL_A2WD GM26183 transformed cell line human CVCL_A2WD CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409356 CVCL_A2WE GM26184 finite cell line human CVCL_A2WE CL:0000010 Sequence variation: Mutation; HGNC; 12340; TRPS1; Simple; c.-9dupT; ClinVar=VCV000260329; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12340; TRPS1; Simple; p.Ser1067Argfs*3 (c.3198_3199delAT); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Nose; cartilage. Male 41409357 CVCL_A2WF GM26186 transformed cell line human CVCL_A2WF CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Ile4898Thr (c.14693T>C); ClinVar=VCV000012975; Zygosity=Heterozygous (Coriell) Population: Mexican; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409358 CVCL_A2WG GM26199 transformed cell line human CVCL_A2WG CL:0000010 Sequence variation: Mutation; HGNC; 10483; RYR1; Simple; p.Ile4898Thr (c.14693T>C); ClinVar=VCV000012975; Zygosity=Heterozygous (Coriell) Population: Caucasian; Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409359 CVCL_A2WH GM26216 transformed cell line human CVCL_A2WH CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409360 CVCL_A2WI GM26264 transformed cell line human CVCL_A2WI CL:0000010 Sequence variation: Mutation; HGNC; 7720; NEB; Simple; p.Ser8228Ser (c.24684G>A) (p.Ser8193Ser, c.24579G>A) (p.Ser6337Ser, c.19011G>A); ClinVar=VCV000521691; Zygosity=Unspecified (Coriell) Population: Caucasian; Polish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409361 CVCL_A2WJ GM26577 transformed cell line human CVCL_A2WJ CL:0000010 Sequence variation: Mutation; HGNC; 9118; PMP22; Unexplicit; Ex1-5del; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409362 CVCL_A2TX S1123-01 iPS #2 induced pluripotent stem cell human CVCL_A2TX CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409363 CVCL_A2TY S1123-01 iPS #3 induced pluripotent stem cell human CVCL_A2TY CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409364 CVCL_A2TZ S1123-01 iPS #4 induced pluripotent stem cell human CVCL_A2TZ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409365 CVCL_A2TP GM27934 induced pluripotent stem cell human CVCL_A2TP CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Glu253Lys (c.757G>A); ClinVar=VCV000162059; Zygosity=Heterozygous (Coriell) Derived from sampling site: Peripheral blood. Male 41409366 CVCL_A2TQ GM27935 induced pluripotent stem cell human CVCL_A2TQ CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Cys151Tyr (c.452G>A); ClinVar=VCV000451648; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409367 CVCL_A2TR GM27936 induced pluripotent stem cell human CVCL_A2TR CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Arg316Trp (c.946C>T); ClinVar=VCV000162060; Zygosity=Heterozygous (Coriell) Derived from sampling site: Peripheral blood. Male 41409368 CVCL_A2TS GM27973 finite cell line human CVCL_A2TS CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Gly169Glyfs*23 (c.507del); Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Arg303His (c.908G>A); ClinVar=VCV000284411; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409369 CVCL_A2TT GM27904 transformed cell line human CVCL_A2TT CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409370 CVCL_A2TU GM27903 transformed cell line human CVCL_A2TU CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Simple; p.Phe365Leufs*105 (c.1094_1095insGGAGCGTGGGCTTCTC); Zygosity=Hemizygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409371 CVCL_A2TV GM27899 finite cell line human CVCL_A2TV CL:0000010 Sequence variation: Mutation; HGNC; 11042; SLC6A1; Simple; p.Ala288Val (c.863C>T); ClinVar=VCV000192372; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 12303; TRIO; Simple; p.Arg2707Ter (c.8119C>T); ClinVar=VCV000936994; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409372 CVCL_A2TW S1123-01 iPS #1 induced pluripotent stem cell human CVCL_A2TW CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409373 CVCL_A2TH S1123-02 fibroblast finite cell line human CVCL_A2TH CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 41409374 CVCL_A2TI S1123-03 fibroblast finite cell line human CVCL_A2TI CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409375 CVCL_A2TJ 03-01 fibroblast finite cell line human CVCL_A2TJ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409376 CVCL_A2TK 03-02 fibroblast finite cell line human CVCL_A2TK CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Female 41409377 CVCL_A2TL 03-03 fibroblast finite cell line human CVCL_A2TL CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409378 CVCL_A2TM 03-04 fibroblast finite cell line human CVCL_A2TM CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409379 CVCL_A2TN GM27933 induced pluripotent stem cell human CVCL_A2TN CL:0000010 Sequence variation: Mutation; HGNC; 888; KIF1A; Simple; p.Pro305Leu (c.914C>T); ClinVar=VCV000428604; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409380 CVCL_A2TA GM27879 finite cell line human CVCL_A2TA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409381 CVCL_A2TB GM27880 induced pluripotent stem cell human CVCL_A2TB CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple_edited; p.Ser19Glnfs*120 (c.53_54insT); Zygosity=Homozygous; Note=By CRISPR/Cas9 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409382 CVCL_A2TC GM27881 induced pluripotent stem cell human CVCL_A2TC CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple_edited; p.Phe18Thrfs*188 (c.49_58delTCGTTCAGCA); Zygosity=Homozygous; Note=By CRISPR/Cas9 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409383 CVCL_A2TD GM27882 induced pluripotent stem cell human CVCL_A2TD CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple_edited; p.Ser19Glnfs*120 (c.53_54insT); Zygosity=Heterozygous; Note=By CRISPR/Cas9 (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409384 CVCL_A2TE GM27885 induced pluripotent stem cell human CVCL_A2TE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: Control cell line for the edited cell lines GM27880 (Cellosaurus=CVCL_A2TB), GM27881 (Cellosaurus=CVCL_A2TC) and GM27882 (Cellosaurus=CVCL_A2TD) 41409385 CVCL_A2TF GM27890 transformed cell line human CVCL_A2TF CL:0000010 Sequence variation: Mutation; HGNC; 129; ACTA1; Simple; p.Thr150Ala (c.448A>G); Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 14888; DNAJB6; Simple; c.899-3T>G; Zygosity=Heterozygous (Coriell) Population: Jewish; Ashkenazi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409386 CVCL_A2TG S1123-01 fibroblast finite cell line human CVCL_A2TG CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409387 CVCL_A2UY GM26227 finite cell line human CVCL_A2UY CL:0000010 Sequence variation: Mutation; HGNC; 12840; YARS1; Simple; p.Pro167Thr (c.499C>A); ClinVar=VCV000662296; Zygosity=Homozygous (Coriell) Anecdotal: Established from the skin fibroblast of Grace Miller, the seventh member of a Dover Amish family to be diagnosed with what is known now as YARSopathy Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409388 CVCL_A2UZ GM26228 finite cell line human CVCL_A2UZ CL:0000010 Sequence variation: Mutation; HGNC; 12840; YARS1; Simple; p.Pro167Thr (c.499C>A); ClinVar=VCV000662296; Zygosity=Heterozygous (Coriell) Population: Caucasian; Amish; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409389 CVCL_A2VA GM26023 finite cell line human CVCL_A2VA CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Ala614Val (c.1841C>T) (p.Ala610Val, c.1829C>T); ClinVar=VCV000581714; Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Derived from sampling site: Back; skin Cell type=Fibroblast.. Male 41409390 CVCL_A2UQ 03-02 iPS #9 induced pluripotent stem cell human CVCL_A2UQ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409391 CVCL_A2UR 03-03 iPS #2 induced pluripotent stem cell human CVCL_A2UR CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409392 CVCL_A2US 03-03 iPS #3 induced pluripotent stem cell human CVCL_A2US CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409393 CVCL_A2UT 03-03 iPS #4 induced pluripotent stem cell human CVCL_A2UT CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409394 CVCL_A2UU 03-04 iPS #1 induced pluripotent stem cell human CVCL_A2UU CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409395 CVCL_A2UV 03-04 iPS #3 induced pluripotent stem cell human CVCL_A2UV CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409396 CVCL_A2UW 03-04 iPS #5 induced pluripotent stem cell human CVCL_A2UW CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409397 CVCL_A2UX 03-04 iPS #6 induced pluripotent stem cell human CVCL_A2UX CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409398 CVCL_A2UI 03-01 iPS #2 induced pluripotent stem cell human CVCL_A2UI CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409399 CVCL_A2UJ 03-01 iPS #3 induced pluripotent stem cell human CVCL_A2UJ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409400 CVCL_A2UK 03-01 iPS #4 induced pluripotent stem cell human CVCL_A2UK CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409401 CVCL_A2UL 03-01 iPS #9 induced pluripotent stem cell human CVCL_A2UL CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409402 CVCL_A2UM 03-02 iPS #2B induced pluripotent stem cell human CVCL_A2UM CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 41409403 CVCL_A2UN 03-02 iPS #5 induced pluripotent stem cell human CVCL_A2UN CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409404 CVCL_A2UP 03-02 iPS #8 induced pluripotent stem cell human CVCL_A2UP CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409405 CVCL_A2UA S1123-02 iPS #2 induced pluripotent stem cell human CVCL_A2UA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409406 CVCL_A2UB S1123-02 iPS #5 induced pluripotent stem cell human CVCL_A2UB CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Female 41409407 CVCL_A2UC S1123-02 iPS #11 induced pluripotent stem cell human CVCL_A2UC CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409408 CVCL_A2UD S1123-02 iPS #17 induced pluripotent stem cell human CVCL_A2UD CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Female 41409409 CVCL_A2UE S1123-03 iPS #1 induced pluripotent stem cell human CVCL_A2UE CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409410 CVCL_A2UF S1123-03 iPS #2 induced pluripotent stem cell human CVCL_A2UF CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409411 CVCL_A2UG S1123-03 iPS #8 induced pluripotent stem cell human CVCL_A2UG CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409412 CVCL_A2UH S1123-03 iPS #9 induced pluripotent stem cell human CVCL_A2UH CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Array-based CGH; Omics: Genome sequenced; Omics: Transcriptome analysis by microarray; Omics: Transcriptome analysis by RNAseq Male 41409413 CVCL_A2RV GM27830 transformed cell line human CVCL_A2RV CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409414 CVCL_A2RW GM27831 transformed cell line human CVCL_A2RW CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409415 CVCL_A2RX GM27832 transformed cell line human CVCL_A2RX CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409416 CVCL_A2RY GM27833 transformed cell line human CVCL_A2RY CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409417 CVCL_A2RZ GM27834 transformed cell line human CVCL_A2RZ CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409418 CVCL_A2RN GM27823 transformed cell line human CVCL_A2RN CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409419 CVCL_A2RP GM27824 transformed cell line human CVCL_A2RP CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409420 CVCL_A2RQ GM27825 transformed cell line human CVCL_A2RQ CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409421 CVCL_A2RR GM27826 transformed cell line human CVCL_A2RR CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409422 CVCL_A2RS GM27827 transformed cell line human CVCL_A2RS CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409423 CVCL_A2RT GM27828 transformed cell line human CVCL_A2RT CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409424 CVCL_A2RU GM27829 transformed cell line human CVCL_A2RU CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409425 CVCL_A2RF GM27815 transformed cell line human CVCL_A2RF CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409426 CVCL_A2RG GM27816 transformed cell line human CVCL_A2RG CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409427 CVCL_A2RH GM27817 transformed cell line human CVCL_A2RH CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409428 CVCL_A2RI GM27818 transformed cell line human CVCL_A2RI CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409429 CVCL_A2RJ GM27819 transformed cell line human CVCL_A2RJ CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409430 CVCL_A2RK GM27820 transformed cell line human CVCL_A2RK CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409431 CVCL_A2RL GM27821 transformed cell line human CVCL_A2RL CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409432 CVCL_A2RM GM27822 transformed cell line human CVCL_A2RM CL:0000010 Population: Indian; Kannada; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409433 CVCL_A2RA GM27809 transformed cell line human CVCL_A2RA CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409434 CVCL_A2RB GM27810 transformed cell line human CVCL_A2RB CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409435 CVCL_A2RC GM27811 transformed cell line human CVCL_A2RC CL:0000010 Population: Indian; Punjabi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409436 CVCL_A2RD GM27812 transformed cell line human CVCL_A2RD CL:0000010 Population: Indian; Hindi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409437 CVCL_A2RE GM27813 transformed cell line human CVCL_A2RE CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409438 CVCL_A2SW SSF-3 spontaneously immortalized cell line CVCL_A2SW CL:0000010 Derived from sampling site: Fin. Unspecified Group: Fish cell line 41409439 CVCL_A2SX STLE spontaneously immortalized cell line CVCL_A2SX CL:0000010 Unspecified Group: Fish cell line. 41409440 CVCL_A2SY SPC-PL-65 P1 spontaneously immortalized cell line CVCL_A2SY CL:0000010 Derived from sampling site: Hemolymph Cell type=Hemocyte.. Unspecified Virology: Susceptible to infection by deformed wing virus (DWV) Doubling time: ~40 hours (PubMed=32659903) Group: Insect cell line 41409441 CVCL_A2SZ bKEC finite cell line CVCL_A2SZ CL:0000010 Derived from sampling site: Kidney; epithelium. Male Characteristics: Susceptible to infection by Listeria monocytogenes strain EGDe (PubMed=33105852); Virology: Susceptible to infection by bluetongue virus (BTV); Rift Valley fever virus (RVFV) and lumpy skin disease (LSDV) (PubMed=33683063) Group: Bat cell line 41409442 CVCL_A2SP GM27869 transformed cell line human CVCL_A2SP CL:0000010 Sequence variation: Mutation; HGNC; 28912; WDR45; Simple; c.726-1G>A (c.729-1G>A) (IVS9-1G>A); ClinVar=VCV001803675; Zygosity=Heterozygous; Note=De novo mutation Splice acceptor mutation (Coriell). Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409443 CVCL_A2SQ GM27871 transformed cell line human CVCL_A2SQ CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Ile190Asn (c.569T>A); Zygosity=Heterozygous; Note=De novo mutation (Coriell) Population: Caucasian; Spanish (Chilean); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409444 CVCL_A2SR GM27872 transformed cell line human CVCL_A2SR CL:0000010 Population: Caucasian; Spanish (Chilean); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409445 CVCL_A2SS GM27873 transformed cell line human CVCL_A2SS CL:0000010 Population: Caucasian; Spanish (Chilean); Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409446 CVCL_A2ST Vero-TB spontaneously immortalized cell line green monkey CVCL_A2ST CL:0000010 Derived from sampling site: Kidney; epithelium. Female Virology: Highly susceptible to infection by porcine reproductive and respiratory syndrome virus (PRRSV) Group: Non-human primate cell line; Group: Patented cell line; Registration: International Depositary Authority, China Center for Type Culture Collection; CCTCC C202054 41409447 CVCL_A2SU 793 OsSar RVV cancer cell line human CVCL_A2SU CL:0000010 Derived from metastatic site: Lung. Female Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 789D 41409448 CVCL_A2SV OMG spontaneously immortalized cell line CVCL_A2SV CL:0000010 Derived from sampling site: Ovary. Female Virology: Susceptible to infection by infectious pancreatic necrosis virus (IPNV), viral hemorrhagic septicemia virus (VHSV) and infectious haematopoetic necrosis virus (IHNV) Group: Fish cell line; Group: Patented cell line; Registration: Non-internationally recognized Depositary Authority, Russian Cell Culture Collection (RCCC); 75 41409449 CVCL_A2SG GM27842 transformed cell line human CVCL_A2SG CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409450 CVCL_A2SH GM27843 transformed cell line human CVCL_A2SH CL:0000010 Population: Indian; Parsi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409451 CVCL_A2SI GM27844 transformed cell line human CVCL_A2SI CL:0000010 Population: Indian; Parsi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409452 CVCL_A2SJ GM27845 transformed cell line human CVCL_A2SJ CL:0000010 Population: Indian; Parsi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409453 CVCL_A2SK GM27846 transformed cell line human CVCL_A2SK CL:0000010 Population: Indian; Parsi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409454 CVCL_A2SL GM27847 transformed cell line human CVCL_A2SL CL:0000010 Population: Indian; Parsi; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409455 CVCL_A2SM GM27838 transformed cell line human CVCL_A2SM CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409456 CVCL_A2SN GM27857 induced pluripotent stem cell human CVCL_A2SN CL:0000010 Sequence variation: Mutation; HGNC; 11055; SLC6A8; Unexplicit; Ex10-11del; Zygosity=Hemizygous (Coriell) Population: Caucasian; Romanian and Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409457 CVCL_A2SA GM27835 transformed cell line human CVCL_A2SA CL:0000010 Population: Indian; Assamese; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409458 CVCL_A2SB GM27836 transformed cell line human CVCL_A2SB CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409459 CVCL_A2SC GM27837 transformed cell line human CVCL_A2SC CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409460 CVCL_A2SD GM27839 transformed cell line human CVCL_A2SD CL:0000010 Population: Indian; Marwari; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409461 CVCL_A2SE GM27840 transformed cell line human CVCL_A2SE CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Ambiguous 41409462 CVCL_A2SF GM27841 transformed cell line human CVCL_A2SF CL:0000010 Population: Indian; Kashmiri; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409463 CVCL_A2PT MCF-10A BRCA1 (185delAG/+) spontaneously immortalized cell line human CVCL_A2PT CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1100; BRCA1; Simple_edited; p.Glu23Valfs*17 (c.68_69delAG) (c.66_67AG[1]) (185delAG); ClinVar=VCV000017662; Zygosity=Heterozygous; Note=By homologous recombination (PubMed=21987798) Derived from sampling site: Breast; epithelium. Female 41409464 CVCL_A2PU MCF-10A CTNNB1 (T41A/+/+) spontaneously immortalized cell line human CVCL_A2PU CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple_edited; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Heterozygous knockin of a CTNNB1 activating mutation 41409465 CVCL_A2PV MCF-10A ARID1A (Q456*/Q456*) spontaneously immortalized cell line human CVCL_A2PV CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple_edited; p.Gln456Ter (c.1366C>T); Zygosity=Homozygous; Note=By method not specified (Horizon Discovery) Derived from sampling site: Breast; epithelium. Female Characteristics: Homozygous knockin of an ARID1A nonsense mutation 41409466 CVCL_A2PW GM27120 transformed cell line human CVCL_A2PW CL:0000010 Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Asn238Lysfs*63 (c.713dupA) (c.713_714insA); ClinVar=VCV000004494; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 15999; SELENON; Simple; p.Arg466Gln (c.1397G>A); ClinVar=VCV000004492; Zygosity=Heterozygous (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409467 CVCL_A2PX GM27123 transformed cell line human CVCL_A2PX CL:0000010 Sequence variation: Mutation; HGNC; 2211; COL6A1; Simple; c.1003-1G>A; ClinVar=VCV000286179; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Swiss; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409468 CVCL_A2PY GM27125 transformed cell line human CVCL_A2PY CL:0000010 Sequence variation: Mutation; HGNC; 12403; TTN; Simple; c.39893-1G>A (IVS192-1G>A) (c.37112-1G>A, IVS191-1G>A); ClinVar=VCV000202368; Zygosity=Heterozygous; Note=Splice acceptor mutation (Coriell) Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409469 CVCL_A2PZ GM27131 transformed cell line human CVCL_A2PZ CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Cys528Thrfs*4 (c.1577_1580dupCACT); ClinVar=VCV000181148; Zygosity=Heterozygous (Coriell) Population: Caucasian; German/Irish; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409470 CVCL_A2PL ATH19BE LCL transformed cell line human CVCL_A2PL CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02930; probable Female 41409471 CVCL_A2PM ATH20BE LCL transformed cell line human CVCL_A2PM CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM03227; probable Male 41409472 CVCL_A2PN V79-B310H spontaneously immortalized cell line CVCL_A2PN CL:0000010 Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Leu133Gln (c.398T>A); Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; UniProtKB; O09185; Tp53; Simple; p.Cys135Trp (c.405C>G); Zygosity=Unspecified (from parent cell line) Derived from sampling site: Lung Cell type=Fibroblast.. Male 41409473 CVCL_A2PP SW48 NRAS (G12V/+) cancer cell line human CVCL_A2PP CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2714Cys (c.8140C>T); ClinVar=VCV000231255; Zygosity=Unspecified (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Ser14fs*29 (c.41_44delCTCT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Glu67fs (c.200delA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser33Tyr (c.98C>A); ClinVar=VCV000017577; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000040470; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Colon. Female Characteristics: Heterozygous knockin of a NRAS activating mutation 41409474 CVCL_A2PQ DLD-1 AKT3(-/-) cancer cell line human CVCL_A2PQ CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 393; AKT3. Male 41409475 CVCL_A2PR BPH22 spontaneously immortalized cell line CVCL_A2PR CL:0000010 Derived from sampling site: Midgut. Unspecified Characteristics: Optimal growth temperature is 24 Celsius (PubMed=20927604) Group: Insect cell line 41409476 CVCL_A2PS RPW-1 spontaneously immortalized cell line CVCL_A2PS CL:0000010 Derived from sampling site: Midgut Cell type=Epithelial cell.. Characteristics: Optimal growth temperature is 27 Celsius in Grace's and Schneider's media was, 24 Celsius in TNM-FH medium and 21 Celsius in Medium-199 (PubMed=24197670) Group: Insect cell line 41409477 CVCL_A2PD AG10999 finite cell line CVCL_A2PD CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG10999; probable Male 41409478 CVCL_A2PE AG03675 finite cell line human CVCL_A2PE CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG03675; probable Male 41409479 CVCL_A2PF AG01232 finite cell line human CVCL_A2PF CL:0000010 Discontinued: Coriell; AG01232; probable. Female 41409480 CVCL_A2PG GM03017 finite cell line human CVCL_A2PG CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03017; probable Male 41409481 CVCL_A2PH GM03526 finite cell line human CVCL_A2PH CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03526; probable Male 41409482 CVCL_A2PI GM03528 finite cell line human CVCL_A2PI CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; GM03528; probable Female 41409483 CVCL_A2PJ AT5BE LCL transformed cell line human CVCL_A2PJ CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02928; probable Male 41409484 CVCL_A2PK AT6BE LCL transformed cell line human CVCL_A2PK CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Discontinued: Coriell; GM02929; probable Female 41409485 CVCL_A2PA AG05307 finite cell line CVCL_A2PA CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG05307; probable Female Group: Non-human primate cell line 41409486 CVCL_A2PB AG06211 finite cell line CVCL_A2PB CL:0000010 Derived from sampling site: Thigh; skin Cell type=Fibroblast.. Discontinued: Coriell; AG06211; probable Female 41409487 CVCL_A2PC AG10998 finite cell line CVCL_A2PC CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Discontinued: Coriell; AG10998; probable Female 41409488 CVCL_A2QU GM27769 transformed cell line human CVCL_A2QU CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409489 CVCL_A2QV GM27772 transformed cell line human CVCL_A2QV CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409490 CVCL_A2QW GM27774 transformed cell line human CVCL_A2QW CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409491 CVCL_A2QX GM27803 transformed cell line human CVCL_A2QX CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409492 CVCL_A2QY GM27804 transformed cell line human CVCL_A2QY CL:0000010 Population: Indian; Tamil; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409493 CVCL_A2QZ GM27808 transformed cell line human CVCL_A2QZ CL:0000010 Population: Indian; Malayalam; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409494 CVCL_A2QM GM27574 transformed cell line human CVCL_A2QM CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; c.922+1G>A; ClinVar=VCV001711453; Zygosity=Mosaic; Note=Splice donor mutation Mutation found in 3% of the cells (Coriell). Population: Caucasian and Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409495 CVCL_A2QN GM27575 transformed cell line human CVCL_A2QN CL:0000010 Population: Caucasian and Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409496 CVCL_A2QP GM27576 transformed cell line human CVCL_A2QP CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409497 CVCL_A2QQ GM27612 finite cell line human CVCL_A2QQ CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Glu154Glyfs*301 (c.460dupG); ClinVar=VCV000095268; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409498 CVCL_A2QR GM27613 finite cell line human CVCL_A2QR CL:0000010 Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Glu154Glyfs*301 (c.460dupG); ClinVar=VCV000095268; Zygosity=Heterozygous (Coriell) Population: Caucasian; British; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409499 CVCL_A2QS GM27615 finite cell line human CVCL_A2QS CL:0000010 Sequence variation: Gene deletion; HGNC; 3811; FOXG1; Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409500 CVCL_A2QT GM27753 transformed cell line human CVCL_A2QT CL:0000010 Population: Indian; Oriya; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409501 CVCL_A2QE GM27262 transformed cell line human CVCL_A2QE CL:0000010 Population: Caucasian; Italian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409502 CVCL_A2QF GM27264 transformed cell line human CVCL_A2QF CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409503 CVCL_A2QG GM27265 finite cell line human CVCL_A2QG CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409504 CVCL_A2QH GM27434 transformed cell line human CVCL_A2QH CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 3811; FOXG1; Simple; p.Leu257Arg (c.770T>G); Zygosity=Heterozygous; Note=De novo mutation (Coriell); Sequence variation: Mutation; HGNC; 8656; PCDH11X; Simple; p.Asp1111Asn (c.3331G>A); Zygosity=Hemizygous (Coriell) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409505 CVCL_A2QI GM27435 transformed cell line human CVCL_A2QI CL:0000010 Sequence variation: Mutation; HGNC; 8656; PCDH11X; Simple; p.Asp1111Asn (c.3331G>A); Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409506 CVCL_A2QJ GM27436 transformed cell line human CVCL_A2QJ CL:0000010 Sequence variation: Mutation; HGNC; 1884; CFTR; Simple; p.Phe508del (c.1521_1523delCTT); ClinVar=VCV000007105; Zygosity=Heterozygous (Coriell) Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409507 CVCL_A2QK GM27572 transformed cell line human CVCL_A2QK CL:0000010 Population: Caucasian and Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409508 CVCL_A2QL GM27573 transformed cell line human CVCL_A2QL CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; c.922+1G>A; ClinVar=VCV001711453; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian and Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409509 CVCL_A2QA GM27186 finite cell line human CVCL_A2QA CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; p.Lys171Argfs*63 (c.512delA); Zygosity=Heterozygous (Coriell) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409510 CVCL_A2QB GM27239 transformed cell line human CVCL_A2QB CL:0000010 Sequence variation: Mutation; HGNC; 11634; TCF4; Simple; c.922+1G>A; ClinVar=VCV001711453; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian and Pacific; Hawaiian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Female 41409511 CVCL_A2QC GM27260 transformed cell line human CVCL_A2QC CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409512 CVCL_A2QD GM27261 finite cell line human CVCL_A2QD CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409513 CVCL_A3AD GRE-R finite cell line CVCL_A3AD CL:0000010 Derived from sampling site: Fetal brain. Unspecified 41409514 CVCL_A3AE JKM finite cell line CVCL_A3AE CL:0000010 Derived from sampling site: Spleen. 41409515 CVCL_A3AF KHY finite cell line CVCL_A3AF CL:0000010 Derived from sampling site: Pituitary gland. 41409516 CVCL_A3AG KM-2-R finite cell line CVCL_A3AG CL:0000010 Derived from sampling site: Fetal spleen. 41409517 CVCL_A3AH KNN-R finite cell line CVCL_A3AH CL:0000010 Derived from sampling site: Fetal adrenal gland. 41409518 CVCL_A3AI OFC finite cell line CVCL_A3AI CL:0000010 Derived from sampling site: Fetal eye; cornea. 41409519 CVCL_A3AJ Oligo finite cell line human CVCL_A3AJ CL:0000010 Derived from sampling site: Fetal brain Cell type=Oligodendrocyte.. Unspecified 41409520 CVCL_A3AK RLI-R transformed cell line CVCL_A3AK CL:0000010 Derived from sampling site: Liver. 41409521 CVCL_A3AA FKD-1-R finite cell line CVCL_A3AA CL:0000010 Derived from sampling site: Fetal intestine. Unspecified 41409522 CVCL_A3AB FP-R finite cell line CVCL_A3AB CL:0000010 Derived from sampling site: Fetal rumen. Unspecified 41409523 CVCL_A3AC FRD-R finite cell line CVCL_A3AC CL:0000010 Derived from sampling site: Fetal gut. Unspecified 41409524 CVCL_A2ZV A9-PM hybrid cell line CVCL_A2ZV CL:0000010 Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine. Characteristics: Contains human chromosome X with the 80-85 CGG repeats in the FMR1 gene Group: Human/rodent somatic cell hybrid 41409525 CVCL_A2ZW MDBK-N4 spontaneously immortalized cell line CVCL_A2ZW CL:0000010 Transfected with: VGNC; 43719; Dog NECTIN4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male Virology: Susceptible to infection by canine parvovirus (CPV) and canine distemper virus (CDV) 41409526 CVCL_A2ZX MDBK-TfR spontaneously immortalized cell line CVCL_A2ZX CL:0000010 Transfected with: VGNC; 47305; Dog TRFC; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Kidney. Male Virology: Susceptible to infection by canine parvovirus (CPV) and canine distemper virus (CDV) 41409527 CVCL_A2ZY DWM-R finite cell line CVCL_A2ZY CL:0000010 Derived from sampling site: Fetal stomach. Unspecified 41409528 CVCL_A2ZZ ESP finite cell line CVCL_A2ZZ CL:0000010 Derived from sampling site: Fetal brain; choroid plexus. Unspecified 41409529 CVCL_A2ZN S1120-03 iPS #5 induced pluripotent stem cell human CVCL_A2ZN CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409530 CVCL_A2ZP CMP [Cirrhinus] spontaneously immortalized cell line CVCL_A2ZP CL:0000010 Derived from sampling site: Peritoneal effusion. Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC056 41409531 CVCL_A2ZQ CST spontaneously immortalized cell line CVCL_A2ZQ CL:0000010 Derived from sampling site: Thymus. Unspecified Characteristics: Grows well from 28 to 32 Celsius, the optimal growth temperature is 28 Celsius (PubMed=25877070) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC055 41409532 CVCL_A2ZR CMgT-1 spontaneously immortalized cell line CVCL_A2ZR CL:0000010 Derived from sampling site: Testis. Male Doubling time: 51 hours (DOI=10.1007/s13237-020-00345-w) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC062 41409533 CVCL_A2ZS CMgM-1 spontaneously immortalized cell line CVCL_A2ZS CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC066 41409534 CVCL_A2ZT CMgB-1 spontaneously immortalized cell line CVCL_A2ZT CL:0000010 Derived from sampling site: Barbel. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC067 41409535 CVCL_A2ZU ZFiM-1 spontaneously immortalized cell line zebrafish CVCL_A2ZU CL:0000010 Derived from sampling site: Muscle. Unspecified Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC069 41409536 CVCL_A2ZF S1120-01 fibroblast finite cell line human CVCL_A2ZF CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409537 CVCL_A2ZG S1120-03 fibroblast finite cell line human CVCL_A2ZG CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409538 CVCL_A2ZH S1120-01 iPS #2 induced pluripotent stem cell human CVCL_A2ZH CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409539 CVCL_A2ZI S1120-01 iPS #4 induced pluripotent stem cell human CVCL_A2ZI CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409540 CVCL_A2ZJ S1120-01 iPS #6 induced pluripotent stem cell human CVCL_A2ZJ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409541 CVCL_A2ZK S1120-01 iPS #9 induced pluripotent stem cell human CVCL_A2ZK CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409542 CVCL_A2ZL S1120-03 iPS #1 induced pluripotent stem cell human CVCL_A2ZL CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409543 CVCL_A2ZM S1120-03 iPS #3 induced pluripotent stem cell human CVCL_A2ZM CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409544 CVCL_A2YA LCL-U-DCS transformed cell line human CVCL_A2YA CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409545 CVCL_A2YB WAe001-A-59 embryonic stem cell human CVCL_A2YB From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4095; GADD45A. Male 41409546 CVCL_A2YC CSUXHi004-A induced pluripotent stem cell human CVCL_A2YC From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 8617; PAX3; Simple; c.452-2A>G; Zygosity=Heterozygous; Note=Splice acceptor mutation (PubMed=33774334) Population: Chinese; Han; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409547 CVCL_A2YD SCTCi009-A induced pluripotent stem cell human CVCL_A2YD From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 41409548 CVCL_A2XT UNIBSi013-A induced pluripotent stem cell human CVCL_A2XT From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409549 CVCL_A2XU SBWCHi001-A induced pluripotent stem cell human CVCL_A2XU From: Shenzhen Baoan Women's and Children's Hospital, Jinan University; Shenzhen; China CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Tyr333Ter (c.999C>A); ClinVar=VCV000450550; Zygosity=Heterozygous (PubMed=33264726) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41409550 CVCL_A2XV INSRMi008-A induced pluripotent stem cell human CVCL_A2XV From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex1del; Zygosity=Hemizygous (PubMed=33246213) Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 41409551 CVCL_A2XW INSRMi009-A induced pluripotent stem cell human CVCL_A2XW From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex52del; Zygosity=Hemizygous (PubMed=33246213) Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 41409552 CVCL_A2XX INSRMi010-A induced pluripotent stem cell human CVCL_A2XX From: INSERM; Paris; France CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex55del; Zygosity=Hemizygous (PubMed=33246213) Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 41409553 CVCL_A2XY PUFHi001-A induced pluripotent stem cell human CVCL_A2XY From: Peking University First Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 6220; KCNA2; Simple; p.Pro405Leu (c.1214C>T); ClinVar=VCV000190325; Zygosity=Heterozygous (PubMed=33232902) Population: Chinese; Derived from sampling site: Peripheral blood. Female 41409554 CVCL_A2XZ U-DCS cancer cell line human CVCL_A2XZ HLA typing: A*11:01,24:02; B*15:01,35:01; C*03:03,04:01; DQB1*05:01,06:04; DRB1*01:01,13:02 (PubMed=33277516) CL:0000010 Population: Caucasian; Karyotypic information: More than tetraploid karyotype with approximately 130 chromosomes and multiple aberrations (PubMed=33277516); Derived from metastatic site: Lung. Male Doubling time: ~2 days (PubMed=33277516) 41409555 CVCL_A2XL MYN9 transformed cell line CVCL_A2XL CL:0000010 Transfected with: HGNC; 7553; MYC; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Myc. Unspecified Virology: Seems to be infected with deformed wing virus (DWV) (PubMed=21688083) Group: Insect cell line 41409556 CVCL_A2XM GSNM-F finite cell line CVCL_A2XM CL:0000010 Miscellaneous: As no cell line name was provided in the paper, we assigned the name based on the abbreviation of the cell line description Derived from sampling site: Ear; skin Cell type=Fibroblast.. Omics: Transcriptome analysis by RNAseq Male Group: Endangered species/breed cell line; Group: Non-human primate cell line 41409557 CVCL_A2XN KCB 200004 finite cell line CVCL_A2XN CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 41409558 CVCL_A2XP KCB 88003 finite cell line CVCL_A2XP CL:0000010 Derived from sampling site: Cell type=Fibroblast. Female 41409559 CVCL_A2XQ KCB 91001 finite cell line CVCL_A2XQ CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 41409560 CVCL_A2XR KCB 91006 finite cell line CVCL_A2XR CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 41409561 CVCL_A2XS UNIBSi012-A induced pluripotent stem cell human CVCL_A2XS From: University of Brescia; Brescia; Italy CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409562 CVCL_A2XD MHI 16 transformed cell line human CVCL_A2XD CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa 41409563 CVCL_A2XE BRH 17 transformed cell line human CVCL_A2XE CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, lambda 41409564 CVCL_A2XF CAN 19 transformed cell line human CVCL_A2XF CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgG, lambda; Monoclonal antibody target: Human neurons and glia 41409565 CVCL_A2XG CNE 19 transformed cell line human CVCL_A2XG CL:0000010 Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood Cell type=B-cell.. Unspecified Monoclonal antibody isotype: IgM, kappa 41409566 CVCL_A2XH IARC-303B transformed cell line human CVCL_A2XH From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Bone marrow. Male 41409567 CVCL_A2XI IARC-176B transformed cell line human CVCL_A2XI From: International Agency of Research on Cancer (IARC); Lyon; France CL:0000010 Population: Caucasian; French; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409568 CVCL_A2XJ YK6 telomerase immortalized cell line human CVCL_A2XJ CL:0000010 Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Miscellaneous: Sex assignment derived from omics analysis from personal communication of Hodson D Population: Korean; Derived from sampling site: Oral cavity; tonsil Cell type=Follicular dendritic cell.. Male 41409569 CVCL_A2XK YK6-CD40Lg-IL21 telomerase immortalized cell line human CVCL_A2XK CL:0000010 Transfected with: HGNC; 11935; CD40LG; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 6005; IL21; Transfected with: HGNC; 11730; TERT; Transfected with: MGI; MGI:88346; Cd8a; Transfected with: MGI; MGI:98834; Trp53 (with p.Leu14_Lys302del = p53DD); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Miscellaneous: Sex assignment derived from omics analysis from personal communication of Hodson D Population: Korean; Derived from sampling site: Oral cavity; tonsil Cell type=Follicular dendritic cell.. Male Characteristics: Used as a feeder line to co-culture with human B cells 41409570 CVCL_A2ZA 07-01 iPS #4 induced pluripotent stem cell human CVCL_A2ZA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409571 CVCL_A2ZB 07-03 fibroblast finite cell line human CVCL_A2ZB CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409572 CVCL_A2ZC 07-03 iPS #3 induced pluripotent stem cell human CVCL_A2ZC CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409573 CVCL_A2ZD 07-03 iPS #7 induced pluripotent stem cell human CVCL_A2ZD CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409574 CVCL_A2ZE 07-03 iPS #9 induced pluripotent stem cell human CVCL_A2ZE CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 41409575 CVCL_A2YU GM28016 finite cell line human CVCL_A2YU CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Gly124Arg (c.370G>A); dbSNP=rs782033035; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; c.751+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 41409576 CVCL_A2YV GM28017 finite cell line human CVCL_A2YV CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; c.751+1G>A; Zygosity=Heterozygous; Note=Splice donor mutation (Coriell) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409577 CVCL_A2YW SREM-1 spontaneously immortalized cell line CVCL_A2YW CL:0000010 Derived from sampling site: Eye; muscle. Unspecified Characteristics: Can grow at temperatures ranging from 20 to 32 Celsius with an optimum temperature of 28 Celsius (DOI=10.4194/1303-2712-v21_2_05) Doubling time: ~34 hours (DOI=10.4194/1303-2712-v21_2_05) Group: Fish cell line; Registration: National Repository of Fish Cell Line (NRFC), National Bureau of Fish Genetic Resources, India; NRFC060 41409578 CVCL_A2YX 07-01 fibroblast finite cell line human CVCL_A2YX CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409579 CVCL_A2YY 07-01 iPS #1 induced pluripotent stem cell human CVCL_A2YY CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409580 CVCL_A2YZ 07-01 iPS #2 induced pluripotent stem cell human CVCL_A2YZ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Omics: Genome sequenced; Omics: Transcriptome analysis by RNAseq Male 41409581 CVCL_A2YM GM24645 transformed cell line human CVCL_A2YM CL:0000010 Population: Latino or Hispanic; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Male 41409582 CVCL_A2YN GM28009 finite cell line human CVCL_A2YN CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409583 CVCL_A2YP GM28010 finite cell line human CVCL_A2YP CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg192Trp (c.574C>T); ClinVar=VCV000215235; Zygosity=Heterozygous (Coriell) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409584 CVCL_A2YQ GM28011 finite cell line human CVCL_A2YQ CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409585 CVCL_A2YR GM28012 finite cell line human CVCL_A2YR CL:0000010 Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Leu105Ter (c.312_321del10insAT) (p.Pro104_Leu105insTer); ClinVar=VCV000215237; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Arg192Profs*8 (c.574_575insCTGC); ClinVar=VCV000419973; Zygosity=Heterozygous (Coriell) Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409586 CVCL_A2YS GM28013 finite cell line human CVCL_A2YS CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Ile143Val (m.8953A>G); ClinVar=VCV000693034; Zygosity=Homoplasmic (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Gln251Ter (c.751C>T); ClinVar=VCV000012762; Zygosity=Heterozygous (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Thr266Asnfs*26 (c.796dupA); ClinVar=VCV000524066; Zygosity=Heterozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409587 CVCL_A2YT GM28014 finite cell line human CVCL_A2YT CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Ile143Val (m.8953A>G); ClinVar=VCV000693034; Zygosity=Unspecified (Coriell); Sequence variation: Mutation; HGNC; 11474; SURF1; Simple; p.Thr266Asnfs*26 (c.796dupA); ClinVar=VCV000524066; Zygosity=Heterozygous (Coriell) Population: Indian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409588 CVCL_A2YE SCTCi010-A induced pluripotent stem cell human CVCL_A2YE From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 41409589 CVCL_A2YF SCTCi011-A induced pluripotent stem cell human CVCL_A2YF From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Lys204Thrfs*26 (c.607_610dupCCAA); Zygosity=Heterozygous (PubMed=35063911) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 41409590 CVCL_A2YG SCTCi012-A induced pluripotent stem cell human CVCL_A2YG From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Ile184Leufs*33 (c.550delA); Zygosity=Heterozygous (PubMed=35063911) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 41409591 CVCL_A2YH SCTCi013-A induced pluripotent stem cell human CVCL_A2YH From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Sequence variation: Mutation; HGNC; 4883; CFH; Simple; p.Arg175Gln (c.524G>A); Zygosity=Heterozygous (PubMed=35063911) Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Male 41409592 CVCL_A2YI SCTCi008-A induced pluripotent stem cell human CVCL_A2YI From: Radboudumc Stem Cell Technology Center; Nijmegen; Netherlands CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Omics: Array-based CGH Female 41409593 CVCL_A2YJ BIOi002-A induced pluripotent stem cell human CVCL_A2YJ From: Beijing Institute of Ophthalmology; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Val903Glyfs*3 (c.2708_2711delTTAG); ClinVar=VCV000005082; Zygosity=Heterozygous (PubMed=33752025) Population: Chinese; Derived from sampling site: Peripheral blood. Male 41409594 CVCL_A2YK GM24609 transformed cell line human CVCL_A2YK CL:0000010 Population: Caucasian; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Female Part of: Personal Genome Project (PGP) cell line collection 41409595 CVCL_A2YL GM24610 transformed cell line human CVCL_A2YL CL:0000010 Population: Caucasian; Dutch; Transformant: Epstein-Barr virus (EBV)(NCBI-Taxonomy; 10376); Derived from sampling site: Peripheral blood. Omics: Genome sequenced Male Part of: Personal Genome Project (PGP) cell line collection 41409596 CVCL_A4JM UMGi047-A induced pluripotent stem cell human CVCL_A4JM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409597 CVCL_A4JL UMGi046-A induced pluripotent stem cell human CVCL_A4JL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409598 CVCL_A4JN UMGi120-A.7 induced pluripotent stem cell human CVCL_A4JN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Asn588Lys (c.1764C>G); ClinVar=VCV000014436; Zygosity=Heterozygous (PubMed=29574456) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi120-A) for a series of distinct clones 41409599 CVCL_A4JQ UMGi120-A.15 induced pluripotent stem cell human CVCL_A4JQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Asn588Lys (c.1764C>G); ClinVar=VCV000014436; Zygosity=Heterozygous (PubMed=29574456) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi120-A) for a series of distinct clones 41409600 CVCL_A4JP UMGi120-A.8 induced pluripotent stem cell human CVCL_A4JP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6251; KCNH2; Simple; p.Asn588Lys (c.1764C>G); ClinVar=VCV000014436; Zygosity=Heterozygous (PubMed=29574456) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi120-A) for a series of distinct clones 41409601 CVCL_A4JS UMGi121-A.3 induced pluripotent stem cell human CVCL_A4JS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3049; DSG2; Simple; p.Gly638Arg (c.1912G>A); ClinVar=VCV000161224; Zygosity=Heterozygous (PubMed=29566126) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi121-A) for a series of distinct clones 41409602 CVCL_A4JR UMGi121-A.2 induced pluripotent stem cell human CVCL_A4JR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3049; DSG2; Simple; p.Gly638Arg (c.1912G>A); ClinVar=VCV000161224; Zygosity=Heterozygous (PubMed=29566126) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi121-A) for a series of distinct clones 41409603 CVCL_A4JE UMGi010-A induced pluripotent stem cell human CVCL_A4JE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Female 41409604 CVCL_A4JD UMGi009-A induced pluripotent stem cell human CVCL_A4JD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 41409605 CVCL_A4JG UMGi012-A induced pluripotent stem cell human CVCL_A4JG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409606 CVCL_A4JF UMGi011-A induced pluripotent stem cell human CVCL_A4JF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 41409607 CVCL_A4JI UMGi014-B.1 induced pluripotent stem cell human CVCL_A4JI From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi014-B) for a series of distinct clones 41409608 CVCL_A4JH UMGi014-A induced pluripotent stem cell human CVCL_A4JH From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409609 CVCL_A4JK UMGi014-B.6 induced pluripotent stem cell human CVCL_A4JK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi014-B) for a series of distinct clones 41409610 CVCL_A4JJ UMGi014-B.3 induced pluripotent stem cell human CVCL_A4JJ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi014-B) for a series of distinct clones 41409611 CVCL_A4JA UMGi006-A induced pluripotent stem cell human CVCL_A4JA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 41409612 CVCL_A4JC UMGi008-A induced pluripotent stem cell human CVCL_A4JC From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Male 41409613 CVCL_A4JB UMGi007-A induced pluripotent stem cell human CVCL_A4JB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Hair Cell type=Keratinocyte.. Female 41409614 CVCL_A4IT Blau2-corrected-iPSC induced pluripotent stem cell human CVCL_A4IT From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 5331; NOD2; Simple_corrected; p.Arg334Trp (c.1000C>T); ClinVar=VCV000004696; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28587749) Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409615 CVCL_A4IS Blau1-corrected-iPSC induced pluripotent stem cell human CVCL_A4IS From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 5331; NOD2; Simple_corrected; p.Arg334Trp (c.1000C>T); ClinVar=VCV000004696; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28587749) Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409616 CVCL_A4IV UMGi001-A induced pluripotent stem cell human CVCL_A4IV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409617 CVCL_A4IU BF15#2 induced pluripotent stem cell human CVCL_A4IU From: Delia D.; National Cancer Institute; Milan; Italy CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409618 CVCL_A4IX UMGi003-A induced pluripotent stem cell human CVCL_A4IX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Bone marrow. Unspecified 41409619 CVCL_A4IW UMGi002-A induced pluripotent stem cell human CVCL_A4IW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409620 CVCL_A4IZ UMGi005-A induced pluripotent stem cell human CVCL_A4IZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Bone marrow. Female 41409621 CVCL_A4IY UMGi004-A induced pluripotent stem cell human CVCL_A4IY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Bone marrow. Unspecified 41409622 CVCL_A4KN UMGi031-A induced pluripotent stem cell human CVCL_A4KN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409623 CVCL_A4KM UMGi030-A induced pluripotent stem cell human CVCL_A4KM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409624 CVCL_A4KP UMGi032-A induced pluripotent stem cell human CVCL_A4KP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409625 CVCL_A4KR UMGi034-A induced pluripotent stem cell human CVCL_A4KR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409626 CVCL_A4KQ UMGi033-A induced pluripotent stem cell human CVCL_A4KQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409627 CVCL_A4KT UMGi036-A induced pluripotent stem cell human CVCL_A4KT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409628 CVCL_A4KS UMGi035-A induced pluripotent stem cell human CVCL_A4KS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409629 CVCL_A4KF UMGi024-A induced pluripotent stem cell human CVCL_A4KF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409630 CVCL_A4KE UMGi023-A induced pluripotent stem cell human CVCL_A4KE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409631 CVCL_A4KH UMGi026-A induced pluripotent stem cell human CVCL_A4KH From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409632 CVCL_A4KG UMGi025-A induced pluripotent stem cell human CVCL_A4KG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409633 CVCL_A4KJ UMGi028-A induced pluripotent stem cell human CVCL_A4KJ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409634 CVCL_A4KI UMGi027-A induced pluripotent stem cell human CVCL_A4KI From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409635 CVCL_A4KL UMGi029-B induced pluripotent stem cell human CVCL_A4KL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409636 CVCL_A4KK UMGi029-A induced pluripotent stem cell human CVCL_A4KK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409637 CVCL_A4KB UMGi020-B induced pluripotent stem cell human CVCL_A4KB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409638 CVCL_A4KA UMGi020-A induced pluripotent stem cell human CVCL_A4KA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409639 CVCL_A4KD UMGi022-A induced pluripotent stem cell human CVCL_A4KD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409640 CVCL_A4KC UMGi021-A induced pluripotent stem cell human CVCL_A4KC From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409641 CVCL_A4JU UMGi013-A induced pluripotent stem cell human CVCL_A4JU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409642 CVCL_A4JT UMGi121-A.4 induced pluripotent stem cell human CVCL_A4JT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 3049; DSG2; Simple; p.Gly638Arg (c.1912G>A); ClinVar=VCV000161224; Zygosity=Heterozygous (PubMed=29566126) Derived from sampling site: Skin Cell type=Fibroblast.. Male Caution: The University Medical Center Goettingen is not following the guidelines of hPSCreg regarding the naming of their cell lines: they are assigning a single name (here UMGi121-A) for a series of distinct clones 41409643 CVCL_A4JW UMGi016-A induced pluripotent stem cell human CVCL_A4JW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409644 CVCL_A4JV UMGi015-A induced pluripotent stem cell human CVCL_A4JV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 41409645 CVCL_A4JY UMGi018-A induced pluripotent stem cell human CVCL_A4JY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409646 CVCL_A4JX UMGi017-A induced pluripotent stem cell human CVCL_A4JX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409647 CVCL_A4JZ UMGi019-A induced pluripotent stem cell human CVCL_A4JZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409648 CVCL_A4HK WT-2-hiPSC induced pluripotent stem cell human CVCL_A4HK From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409649 CVCL_A4HJ ZJ-C-hiPSC induced pluripotent stem cell human CVCL_A4HJ From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple_corrected; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409650 CVCL_A4HM HAX1corrected-iPSC#1 induced pluripotent stem cell human CVCL_A4HM From: Department of Pediatric Hematology and Oncology, Hannover Medical School; Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 16915; HAX1; Simple_corrected; p.Trp44Ter (c.130_131insA); ClinVar=VCV000004651; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=29296734) Derived from sampling site: Skin Cell type=Fibroblast.. 41409651 CVCL_A4HL HAX1W44X-iPSC induced pluripotent stem cell human CVCL_A4HL CL:0000010 Sequence variation: Mutation; HGNC; 16915; HAX1; Simple; p.Trp44Ter (c.130_131insA); ClinVar=VCV000004651; Zygosity=Homozygous (PubMed=29296734) Derived from sampling site: Skin Cell type=Fibroblast.. 41409652 CVCL_A4HN HAX1corrected-iPSC#2 induced pluripotent stem cell human CVCL_A4HN From: Department of Pediatric Hematology and Oncology, Hannover Medical School; Hannover; Germany CL:0000010 Sequence variation: Mutation; HGNC; 16915; HAX1; Simple_corrected; p.Trp44Ter (c.130_131insA); ClinVar=VCV000004651; Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=29296734) Derived from sampling site: Skin Cell type=Fibroblast.. 41409653 CVCL_A4HQ BTISi001-A induced pluripotent stem cell human CVCL_A4HQ From: Stem Cell Group, Bioprocessing Technology Institute, A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. 41409654 CVCL_A4HP U2OS C9orf72-/- cancer cell line human CVCL_A4HP CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 28337; C9orf72 Population: Caucasian; Derived from sampling site: Bone; tibia. Female 41409655 CVCL_A4HC ZJ-hiPSC 3 induced pluripotent stem cell human CVCL_A4HC From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409656 CVCL_A4HB ZW-hiPSC 12 induced pluripotent stem cell human CVCL_A4HB From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409657 CVCL_A4HE ZJ-hiPSC 11 induced pluripotent stem cell human CVCL_A4HE From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409658 CVCL_A4HD ZJ-hiPSC 6 induced pluripotent stem cell human CVCL_A4HD From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409659 CVCL_A4HG WT-hiPSC 2 induced pluripotent stem cell human CVCL_A4HG From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409660 CVCL_A4HF WT-hiPSC 1 induced pluripotent stem cell human CVCL_A4HF From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409661 CVCL_A4HI ZW-C-hiPSC induced pluripotent stem cell human CVCL_A4HI From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple_corrected; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409662 CVCL_A4HH WT-hiPSC 3 induced pluripotent stem cell human CVCL_A4HH From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409663 CVCL_A4GZ ZW-hiPSC 6 induced pluripotent stem cell human CVCL_A4GZ From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409664 CVCL_A4GY SAM iPSC clone 2 induced pluripotent stem cell human CVCL_A4GY CL:0000010 Transfected with: HGNC; 5224; HSF1; Transfected with: HGNC; 9955; RELA; Transfected with: UniProtKB; P03612; Escherichia phage MS2 capsid protein (with p.Asn56Lys); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Stably expresses dCas9-VP64, a nuclease-deficient mutant of SpCas9 (dCas9) under the control of a promoter containing 4 copies of the activating domain of HSV-1 VP16 (termed VP64) and EF1a-MS2-P65-HSF1-2A-HygR where the coat protein of MS2 fused to the transactivation domain of p65(RELA) and of heat shock factor 1 (HSF1) (PubMed=27934604) 41409665 CVCL_A4HA ZW-hiPSC 9 induced pluripotent stem cell human CVCL_A4HA From: Department of Physiology and Pathophysiology, School of Basic Medical Sciences, Fudan University; Shanghai; China CL:0000010 Sequence variation: Mutation; HGNC; 9386; PRKAG2; Simple; p.Arg302Gln (c.905G>A); ClinVar=VCV000006846; Zygosity=Heterozygous (PubMed=29452156) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409666 CVCL_A4GR Abcc8-A4 embryonic stem cell human CVCL_A4GR From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 59; ABCC8. Male 41409667 CVCL_A4GQ chHES-468 embryonic stem cell human CVCL_A4GQ From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Glu3509Aspfs*117 (c.10526_10527delAG); Zygosity=Heterozygous (PubMed=27934598). Male 41409668 CVCL_A4GT chHES-355 embryonic stem cell human CVCL_A4GT From: National Engineering Research Center of Human Stem Cells; Changsha; China. CL:0000010 41409669 CVCL_A4GS chHES-478 embryonic stem cell human CVCL_A4GS From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Arg299His (c.896G>A); ClinVar=VCV000003796; Zygosity=Heterozygous (PubMed=27934600); Sequence variation: Mutation; HGNC; 12442; TYR; Simple; p.Pro310Glnfs*9 (c.929_930insC) (p.Arg311Leufs*7); Zygosity=Heterozygous (PubMed=27934600). Female 41409670 CVCL_A4GV iPAI-026-C-K induced pluripotent stem cell human CVCL_A4GV From: Department of Medicine and Cardiovascular Center, Medical College of Wisconsin; Milwaukee; USA CL:0000010 Sequence variation: Mutation; HGNC; 8583; SERPINE1; Simple; c.4977insTA (2-BP INS,4977TA); ClinVar=VCV000013571; Zygosity=Homozygous (PubMed=27934602) Derived from sampling site: Urine. Female 41409671 CVCL_A4GU chHES-3XISTa embryonic stem cell human CVCL_A4GU From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Karyotypic information: Has 8 derivatives chromosomes. Female Characteristics: Constitutively expresses XIST (PubMed=27934601) 41409672 CVCL_A4GX SAM iPSC clone 1 induced pluripotent stem cell human CVCL_A4GX CL:0000010 Transfected with: HGNC; 5224; HSF1; Transfected with: HGNC; 9955; RELA; Transfected with: UniProtKB; P03612; Escherichia phage MS2 capsid protein (with p.Asn56Lys); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P0C2P0; Aspergillus terreus blasticidin-S deaminase (Bsd); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female Characteristics: Stably expresses dCas9-VP64, a nuclease-deficient mutant of SpCas9 (dCas9) under the control of a promoter containing 4 copies of the activating domain of HSV-1 VP16 (termed VP64) and EF1a-MS2-P65-HSF1-2A-HygR where the coat protein of MS2 fused to the transactivation domain of p65(RELA) and of heat shock factor 1 (HSF1) (PubMed=27934604) 41409673 CVCL_A4GW Abcc8-A2 embryonic stem cell human CVCL_A4GW From: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 59; ABCC8. Male 41409674 CVCL_A4IL NCI-H838 KRAS (G12V/+9n) cancer cell line human CVCL_A4IL CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male Characteristics: Heterozygous knockin of a KRAS activating mutation in 10 copies 41409675 CVCL_A4IK NCI-H838 KRAS (G12D/+9n) cancer cell line human CVCL_A4IK CL:0000010 Sequence variation: Mutation; HGNC; 11110; ARID1A; Simple; p.Pro1876Serfs*22 (c.5625_5632del) (p.CPP1657fs) (c.5621_5628delGCCCACCA); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu62Ter (c.184G>T); ClinVar=VCV000617472; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Lymph node. Male Characteristics: Heterozygous knockin of a KRAS activating mutation in 10 copies 41409676 CVCL_A4IN VACO 432 MAP2K2 (-/-) cancer cell line human CVCL_A4IN CL:0000010 Knockout cell: Method=Not specified; HGNC; 6842; MAP2K2; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Male 41409677 CVCL_A4IM VACO 432 MAP2K1 (-/-) cancer cell line human CVCL_A4IM CL:0000010 Knockout cell: Method=Not specified; HGNC; 6840; MAP2K1; Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (from parent cell line) Derived from sampling site: Colon. Male 41409678 CVCL_A4IP 201B7-R334W induced pluripotent stem cell human CVCL_A4IP CL:0000010 Sequence variation: Mutation; HGNC; 5331; NOD2; Simple_edited; p.Arg334Trp (c.1000C>T); ClinVar=VCV000004696; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=28587749) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409679 CVCL_A4IR Blau2-R334W-iPSC induced pluripotent stem cell human CVCL_A4IR From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 5331; NOD2; Simple; p.Arg334Trp (c.1000C>T); ClinVar=VCV000004696; Zygosity=Heterozygous (PubMed=28587749) Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409680 CVCL_A4IQ Blau1-R334W-iPSC induced pluripotent stem cell human CVCL_A4IQ From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Sequence variation: Mutation; HGNC; 5331; NOD2; Simple; p.Arg334Trp (c.1000C>T); ClinVar=VCV000004696; Zygosity=Heterozygous (PubMed=28587749) Population: Japanese; Derived from sampling site: Peripheral blood. Male 41409681 CVCL_A4ID piPS13 induced pluripotent stem cell human CVCL_A4ID From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409682 CVCL_A4IC piPS10 induced pluripotent stem cell human CVCL_A4IC From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409683 CVCL_A4IF ciPS9 induced pluripotent stem cell human CVCL_A4IF From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple_corrected; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous; Note=By homologous recombination (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409684 CVCL_A4IE ciPS5 induced pluripotent stem cell human CVCL_A4IE From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple_corrected; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous; Note=By homologous recombination (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409685 CVCL_A4IH LIM1215 PIK3CA (E545K/+) cancer cell line human CVCL_A4IH CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male 41409686 CVCL_A4IG LIM1215 PIK3CA (H1047R/+) cancer cell line human CVCL_A4IG CL:0000010 Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Pro423Gln (c.1268C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 173; ACVR2A; Simple; p.Lys437Argfs*5 (c.1310delA); dbSNP=rs764719749; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Thr41Ala (c.121A>G); ClinVar=VCV000017580; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple_edited; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11773; TGFBR2; Simple; p.Lys128Serfs*35 (c.383delA); ClinVar=VCV000477546; Zygosity=Homozygous (from parent cell line) Derived from metastatic site: Omentum. Male 41409687 CVCL_A4IJ NALM-6 POLB (-/-) cancer cell line human CVCL_A4IJ CL:0000010 Knockout cell: Method=Homologous recombination; HGNC; 9174; POLB; Sequence variation: Mutation; HGNC; 3236; EGFR; Simple; p.Arg1068Ter (c.3202C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Ala146Thr (c.436G>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9864; RARA; Simple; p.Gln45Ter (c.133C>T); ClinVar=VCV000393019; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409688 CVCL_A4II CAL-12T KRAS (G12C/+) cancer cell line human CVCL_A4II CL:0000010 Sequence variation: Mutation; HGNC; 18037; ARID2; Simple; p.Gly1291Glufs*4 (c.3872del) (p.Val1290fs, c.3870delG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly466Val (c.1397G>T); ClinVar=VCV000013967; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple_edited; p.Gly12Cys (c.34G>T); ClinVar=VCV000012578; Zygosity=Heterozygous; Note=By method not specified (Horizon Discovery); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys135Phe (c.404G>T); ClinVar=VCV000376559; Zygosity=Homozygous (from parent cell line) Derived from sampling site: Lung. Male Characteristics: Heterozygous knockin of a KRAS activating mutation 41409689 CVCL_A4HZ NHEK-iPSCs #2 induced pluripotent stem cell human CVCL_A4HZ CL:0000010 Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 41409690 CVCL_A4IB piPS7 induced pluripotent stem cell human CVCL_A4IB From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Omics: Transcriptome analysis by microarray Male 41409691 CVCL_A4IA piPS2 induced pluripotent stem cell human CVCL_A4IA From: National Institute of Biological Sciences; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 4827; HBB; Simple; p.Phe42Leufs*19 (c.126_129delCTTT) (c.125_128delTCTT) (CD 41/42); ClinVar=VCV000015417; Zygosity=Homozygous (PubMed=22310243) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409692 CVCL_A4HS BTISi003-A induced pluripotent stem cell human CVCL_A4HS From: Stem Cell Group, Bioprocessing Technology Institute, A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. 41409693 CVCL_A4HR BTISi002-A induced pluripotent stem cell human CVCL_A4HR From: Stem Cell Group, Bioprocessing Technology Institute, A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. 41409694 CVCL_A4HU EBKC-iPSCs case1 #1 induced pluripotent stem cell human CVCL_A4HU CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly2575Arg (c.7723G>A); ClinVar=VCV000265078; Zygosity=Heterozygous (PubMed=29229433); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Glu2857Ter (c.8569G>T); ClinVar=VCV001339053; Zygosity=Heterozygous (PubMed=29229433) Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 41409695 CVCL_A4HT BTISi004-A induced pluripotent stem cell human CVCL_A4HT From: Stem Cell Group, Bioprocessing Technology Institute, A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. 41409696 CVCL_A4HW EBKC-iPSCs case2 #1 induced pluripotent stem cell human CVCL_A4HW CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly1815Arg (c.5444G>A); Zygosity=Heterozygous (PubMed=29229433); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Pro1940Argfs*65 (c.5819delC); ClinVar=VCV000017428; Zygosity=Heterozygous (PubMed=29229433) Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 41409697 CVCL_A4HV EBKC-iPSCs case1 #2 induced pluripotent stem cell human CVCL_A4HV CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly2575Arg (c.7723G>A); ClinVar=VCV000265078; Zygosity=Heterozygous (PubMed=29229433); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Glu2857Ter (c.8569G>T); ClinVar=VCV001339053; Zygosity=Heterozygous (PubMed=29229433) Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Male 41409698 CVCL_A4HY NHEK-iPSCs #1 induced pluripotent stem cell human CVCL_A4HY CL:0000010 Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 41409699 CVCL_A4HX EBKC-iPSCs case2 #2 induced pluripotent stem cell human CVCL_A4HX CL:0000010 Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Gly1815Arg (c.5444G>A); Zygosity=Heterozygous (PubMed=29229433); Sequence variation: Mutation; HGNC; 2214; COL7A1; Simple; p.Pro1940Argfs*65 (c.5819delC); ClinVar=VCV000017428; Zygosity=Heterozygous (PubMed=29229433) Population: Japanese; Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Female 41409700 CVCL_A4FI WFS2_1#3 induced pluripotent stem cell human CVCL_A4FI CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409701 CVCL_A4FH WFS2_1#2 induced pluripotent stem cell human CVCL_A4FH CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409702 CVCL_A4FK WFS2_1#11 induced pluripotent stem cell human CVCL_A4FK CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409703 CVCL_A4FJ WFS2_1#10 induced pluripotent stem cell human CVCL_A4FJ CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409704 CVCL_A4FM WFS2_3#1 induced pluripotent stem cell human CVCL_A4FM CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 41409705 CVCL_A4FL WFS2_1#24 induced pluripotent stem cell human CVCL_A4FL CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Homozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Female 41409706 CVCL_A4FN WFS2_3#6 induced pluripotent stem cell human CVCL_A4FN CL:0000010 Sequence variation: Mutation; HGNC; 24212; CISD2; Simple; c.103+1G>A; ClinVar=VCV000638297; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=29239282) Population: Caucasian; Italian; Derived from sampling site: Arm; skin; dermis Cell type=Fibroblast.. Male 41409707 CVCL_A4FA CMT1A-1-hiPSCs 3 induced pluripotent stem cell human CVCL_A4FA From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409708 CVCL_A4FC CMT1A-2-hiPSCs 2 induced pluripotent stem cell human CVCL_A4FC From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409709 CVCL_A4FB CMT1A-2-hiPSCs 1 induced pluripotent stem cell human CVCL_A4FB From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409710 CVCL_A4FE SB-iPS#34 induced pluripotent stem cell human CVCL_A4FE CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409711 CVCL_A4FD CMT1A-2-hiPSCs 3 induced pluripotent stem cell human CVCL_A4FD From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409712 CVCL_A4FG SB-iPS#8 induced pluripotent stem cell human CVCL_A4FG CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409713 CVCL_A4FF SB-iPS#3 induced pluripotent stem cell human CVCL_A4FF CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409714 CVCL_A4EX ihVFE-E67T4 telomerase immortalized cell line human CVCL_A4EX CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: STR profile and cell line name from personal communication of Thibeault S.L Karyotypic information: Shows trisomy 7, trisomy 20, loss of one copy of chromosome 11, and gain of two marker chromosomes of unknown origin (PubMed=33428261); Derived from sampling site: Larynx; vocal fold Cell type=Epithelial cell.. Female 41409715 CVCL_A4EW UMNi001-A induced pluripotent stem cell human CVCL_A4EW From: University of Minnesota; Minneapolis; USA CL:0000010 Derived from sampling site: Foreskin; skin; dermis Cell type=Fibroblast.. Omics: DNA methylation analysis; Omics: SNP array analysis; Omics: Transcriptome analysis by RNAseq Male Part of: NHBLI Progenitor Cell Biology Consortium (PCBC) collection 41409716 CVCL_A4EZ CMT1A-1-hiPSCs 2 induced pluripotent stem cell human CVCL_A4EZ From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409717 CVCL_A4EY CMT1A-1-hiPSCs 1 induced pluripotent stem cell human CVCL_A4EY From: Sun Yat-sen University First Affiliated Hospital; Guangzhou; China CL:0000010 Sequence variation: Gene amplification; HGNC; 9118; PMP22; Duplication; Zygosity=Unspecified (PubMed=29276154) Population: Chinese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409718 CVCL_A4EP CMCi007-A induced pluripotent stem cell human CVCL_A4EP From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Leu324Trpfs*24 (c.969delC); ClinVar=VCV001050825; Zygosity=Heterozygous (PubMed=33545641) Population: Korean; Derived from sampling site: Peripheral blood. Female 41409719 CVCL_A4ER CMCi003-A induced pluripotent stem cell human CVCL_A4ER From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409720 CVCL_A4EQ CMCi006-A induced pluripotent stem cell human CVCL_A4EQ From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 4296; GLA; Simple; p.Leu324Trpfs*24 (c.969delC); ClinVar=VCV001050825; Zygosity=Hemizygous (PubMed=33545641) Population: Korean; Derived from sampling site: Peripheral blood. Male 41409721 CVCL_A4ET CMCi005-A induced pluripotent stem cell human CVCL_A4ET From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409722 CVCL_A4ES CMCi004-A induced pluripotent stem cell human CVCL_A4ES From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409723 CVCL_A4EV CMCi010-A induced pluripotent stem cell human CVCL_A4EV From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 41409724 CVCL_A4EU CMCi008-A induced pluripotent stem cell human CVCL_A4EU From: The Catholic University of Korea; Seoul; South Korea. CL:0000010 41409725 CVCL_A4GJ hTERT-VFF E7 telomerase immortalized cell line human CVCL_A4GJ CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Female 41409726 CVCL_A4GI hTERT-VFF E6 telomerase immortalized cell line human CVCL_A4GI CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Female 41409727 CVCL_A4GL chHES-480 embryonic stem cell human CVCL_A4GL From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Glu609Lys (c.1825G>A); ClinVar=VCV000166626; Zygosity=Hemizygous (PubMed=27934597). Male 41409728 CVCL_A4GK hTERT-VFF E10 telomerase immortalized cell line human CVCL_A4GK CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Female 41409729 CVCL_A4GN U2OS PRDX1 KO cancer cell line human CVCL_A4GN CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9352; PRDX1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 41409730 CVCL_A4GM U2OS PLEC KO cancer cell line human CVCL_A4GM CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 9069; PLEC Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 41409731 CVCL_A4GP CSUXHi005-A induced pluripotent stem cell human CVCL_A4GP From: Department of Neurology, Xiangya Hospital of Central South University; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[76]; Zygosity=Heterozygous; Note=The other allele has 26 repeats (PubMed=33761381) Population: Chinese; Han; Derived from sampling site: Urine. Female 41409732 CVCL_A4GB iMERRF-C7 induced pluripotent stem cell human CVCL_A4GB From: Obstetrics and Gynecology Hospital, Nanjing Medical University; Nanjing; China CL:0000010 Sequence variation: Mutation; HGNC; 7489; MT-TK; Simple; m.8344A>G; ClinVar=VCV000009579; Zygosity=Heteroplasmic (PubMed=27934592) Population: Chinese; Derived from sampling site: Peripheral blood. Female 41409733 CVCL_A4GA H236 C6 GC induced pluripotent stem cell human CVCL_A4GA From: Bioneer A/S; Horsholm; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple_corrected; p.Arg406Trp (c.1216C>T); ClinVar=VCV000014247; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=27934590) Donor information: At sampling donor was pre-symptomatic for frontotemporal dementia; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409734 CVCL_A4GD MMD ISCH#6 induced pluripotent stem cell human CVCL_A4GD From: CIBIO, University of Trento; Trento; Italy CL:0000010 Derived from sampling site: Peripheral blood. Female 41409735 CVCL_A4GC MMD HEM#30 induced pluripotent stem cell human CVCL_A4GC From: CIBIO, University of Trento; Trento; Italy CL:0000010 Derived from sampling site: Peripheral blood. Male 41409736 CVCL_A4GF hTERT-VFF A2 telomerase immortalized cell line human CVCL_A4GF CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Male 41409737 CVCL_A4GE chHES-458 embryonic stem cell human CVCL_A4GE From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[52] (c.52CAG(52)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=27934595). Female 41409738 CVCL_A4GH hTERT-VFF A10 telomerase immortalized cell line human CVCL_A4GH CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Male 41409739 CVCL_A4GG hTERT-VFF A8 telomerase immortalized cell line human CVCL_A4GG CL:0000010 Transfected with: HGNC; 11730; TERT; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Derived from sampling site: Larynx; vocal fold; lamina propria Cell type=Fibroblast.. Male 41409740 CVCL_A4FY 6686 hIPSC induced pluripotent stem cell human CVCL_A4FY CL:0000010 Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Female 41409741 CVCL_A4FX 6679 hIPSC induced pluripotent stem cell human CVCL_A4FX CL:0000010 Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Female 41409742 CVCL_A4FZ 6688 hIPSC induced pluripotent stem cell human CVCL_A4FZ CL:0000010 Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Male 41409743 CVCL_A4FQ N1-iPS-2 induced pluripotent stem cell human CVCL_A4FQ From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409744 CVCL_A4FP N1-iPS-1 induced pluripotent stem cell human CVCL_A4FP From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Population: Mexican; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409745 CVCL_A4FS N2-iPS-2 induced pluripotent stem cell human CVCL_A4FS From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409746 CVCL_A4FR N2-iPS-1 induced pluripotent stem cell human CVCL_A4FR From: A*STAR Institute of Medical Biology; Singapore; Singapore CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409747 CVCL_A4FU NYSCF-10005-687-687-Skin-mR-iPS induced pluripotent stem cell human CVCL_A4FU From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409748 CVCL_A4FT CL-49VIII cancer cell line Norway rat CVCL_A4FT CL:0000010 Transformant: N-nitrosodiethylamine (Diethylnitrosamine(ChEBI; CHEBI:34873); Derived from sampling site: Liver; Breed/subspecies: Wistar-AF/Han. Male 41409749 CVCL_A4FW 6661 hIPSC induced pluripotent stem cell human CVCL_A4FW CL:0000010 Derived from sampling site: Brain; leptomeninges Cell type=Leptomeningeal cell.. Female 41409750 CVCL_A4FV NYSCF-DE-1018-1018-Skin-MR1 induced pluripotent stem cell human CVCL_A4FV From: New York Stem Cell Foundation; New York; USA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409751 CVCL_A4DG AKOSi006-A induced pluripotent stem cell human CVCL_A4DG From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Ile1061Thr (c.3182T>C); ClinVar=VCV000002967; Zygosity=Homozygous (PubMed=33099109) Derived from sampling site: Cell type=Fibroblast. Male 41409752 CVCL_A4DF NUIGi053-A induced pluripotent stem cell human CVCL_A4DF From: National University of Ireland Galway; Galway; Ireland. CL:0000010 41409753 CVCL_A4DI AKOSi004-A induced pluripotent stem cell human CVCL_A4DI From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Gly992Arg (c.2974G>C); ClinVar=VCV000002969; Zygosity=Heterozygous (PubMed=33360098); Sequence variation: Mutation; HGNC; 7897; NPC1; Simple; p.Val1023Serfs*15 (c.3066_3073delinsT); Zygosity=Heterozygous (PubMed=33360098) Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 41409754 CVCL_A4DH AKOSi007-A induced pluripotent stem cell human CVCL_A4DH From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Groin; skin Cell type=Fibroblast.. Male 41409755 CVCL_A4DK UCLi016-A induced pluripotent stem cell human CVCL_A4DK From: University College London; London; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409756 CVCL_A4DJ AKOSi005-A induced pluripotent stem cell human CVCL_A4DJ From: Albrecht-Kossel Institute for Neuroregeneration, University Medicine Rostock; Rostock; Germany CL:0000010 Population: Caucasian; Derived from sampling site: Cell type=Fibroblast. Female 41409757 CVCL_A4DM UCLi018-A induced pluripotent stem cell human CVCL_A4DM From: University College London; London; United Kingdom CL:0000010 Discontinued: hPSCreg; UCLi018-A; true. 41409758 CVCL_A4DL UCLi017-A induced pluripotent stem cell human CVCL_A4DL From: University College London; London; United Kingdom CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409759 CVCL_A4DA PRMT6-KO-24 embryonic stem cell human CVCL_A4DA From: School of Biomedical Sciences, LKS Faculty of Medicine, University of Hong Kong; Hong Kong; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18241; PRMT6. Male 41409760 CVCL_A4DC NUIGi055-A induced pluripotent stem cell human CVCL_A4DC From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409761 CVCL_A4DB IISHDOi007-A induced pluripotent stem cell human CVCL_A4DB From: Instituto de Investigacion Sanitaria Hospital 12 de Octubre; Madrid; Spain CL:0000010 Sequence variation: Mutation; HGNC; 9726; PYGM; Simple; p.Trp798Arg (c.2392T>C); ClinVar=VCV000002312; Zygosity=Homozygous (PubMed=33370875) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Part of: Spanish Stem Cell Bank (Banco Nacional de Lineas Celulares) collection 41409762 CVCL_A4DE NUIGi055-C induced pluripotent stem cell human CVCL_A4DE From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409763 CVCL_A4DD NUIGi055-B induced pluripotent stem cell human CVCL_A4DD From: National University of Ireland Galway; Galway; Ireland CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409764 CVCL_A4CV SPPHIi001-A induced pluripotent stem cell human CVCL_A4CV From: Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[49] (c.52CAG(49)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=33429129) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41409765 CVCL_A4CU BNIi001-B induced pluripotent stem cell human CVCL_A4CU From: Barrow Neurological Institute; Phoenix; USA CL:0000010 Sequence variation: Mutation; HGNC; 6323; KIF5A; Simple; c.2993-14G>T; Zygosity=Heterozygous (PubMed=33388707); Sequence variation: Mutation; HGNC; 6912; MATR3; Simple; p.Phe115Cys (c.344T>G); ClinVar=VCV000126561; Zygosity=Heterozygous (PubMed=33388707) Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 41409766 CVCL_A4CX MHHi001-A-3 induced pluripotent stem cell human CVCL_A4CX From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4053; ISG15 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female 41409767 CVCL_A4CW SPPHIi002-A induced pluripotent stem cell human CVCL_A4CW From: Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital; Chengdu; China CL:0000010 Sequence variation: Mutation; HGNC; 4851; HTT; Repeat_expansion; p.Gln18[59] (c.52CAG(59)) (c.52CAG[(40_?)]); ClinVar=VCV000000409; Zygosity=Heterozygous (PubMed=33429129) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41409768 CVCL_A4CZ PRMT6-KO-10 embryonic stem cell human CVCL_A4CZ From: School of Biomedical Sciences, LKS Faculty of Medicine, University of Hong Kong; Hong Kong; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 18241; PRMT6. Male 41409769 CVCL_A4CY MHHi001-A-4 induced pluripotent stem cell human CVCL_A4CY From: Hannover Medical School, LEBAO (MHH); Hannover; Germany CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4053; ISG15 Population: Caucasian; Derived from sampling site: Umbilical cord blood. Female 41409770 CVCL_A4CN LEIi015-A induced pluripotent stem cell human CVCL_A4CN From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 30859; SNRNP200; Simple; p.Arg598Cys (c.1792C>T); ClinVar=VCV000839536; Zygosity=Heterozygous (PubMed=33429167); Sequence variation: Mutation; HGNC; 30859; SNRNP200; Simple; p.Leu1114Pro (c.3341T>C); Zygosity=Heterozygous (PubMed=33429167) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409771 CVCL_A4CM LL/2-Luc2 cancer cell line house mouse CVCL_A4CM CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P33967; B.cereus Bsr Derived from sampling site: Lung; Breed/subspecies: C57BL/6. Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~13 hours (ATCC=CRL-1642-LUC2) 41409772 CVCL_A4CP LEIi015-B induced pluripotent stem cell human CVCL_A4CP From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 30859; SNRNP200; Simple; p.Arg598Cys (c.1792C>T); ClinVar=VCV000839536; Zygosity=Heterozygous (PubMed=33429167); Sequence variation: Mutation; HGNC; 30859; SNRNP200; Simple; p.Leu1114Pro (c.3341T>C); Zygosity=Heterozygous (PubMed=33429167) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409773 CVCL_A4CR LEIi014-B induced pluripotent stem cell human CVCL_A4CR From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr318Cysfs*17 (c.949C>A); Zygosity=Heterozygous (PubMed=33360097); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys419Phe (c.1256G>T); ClinVar=VCV000002359; Zygosity=Heterozygous (PubMed=33360097) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409774 CVCL_A4CQ LEIi014-A induced pluripotent stem cell human CVCL_A4CQ From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr318Cysfs*17 (c.949C>A); Zygosity=Heterozygous (PubMed=33360097); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys419Phe (c.1256G>T); ClinVar=VCV000002359; Zygosity=Heterozygous (PubMed=33360097) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409775 CVCL_A4CT BNIi001-A induced pluripotent stem cell human CVCL_A4CT From: Barrow Neurological Institute; Phoenix; USA CL:0000010 Sequence variation: Mutation; HGNC; 6323; KIF5A; Simple; c.2993-14G>T; dbSNP=rs1356799960; Zygosity=Heterozygous (PubMed=33388707); Sequence variation: Mutation; HGNC; 6912; MATR3; Simple; p.Phe115Cys (c.344T>G); ClinVar=VCV000126561; Zygosity=Heterozygous (PubMed=33388707) Population: Caucasian; Derived from sampling site: Forearm; skin Cell type=Fibroblast.. Male 41409776 CVCL_A4CS LEIi014-C induced pluripotent stem cell human CVCL_A4CS From: Lions Eye Institute, University of Western Australia; Nedlands; Australia CL:0000010 Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Tyr318Cysfs*17 (c.949C>A); Zygosity=Heterozygous (PubMed=33360097); Sequence variation: Mutation; HGNC; 12601; USH2A; Simple; p.Cys419Phe (c.1256G>T); ClinVar=VCV000002359; Zygosity=Heterozygous (PubMed=33360097) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409777 CVCL_A4EH WAe001-A-49 embryonic stem cell human CVCL_A4EH From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 7000; MEIS1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR). Male Characteristics: Using CRISPR/Cas9 EF-1A-puroR-polyA was inserted in both alleles of MEIS1 exon 2 (PubMed=33157390) 41409778 CVCL_A4EG NCCSEDi001-A-1 induced pluripotent stem cell human CVCL_A4EG From: National Chengdu Center for Safety Evaluation of Drugs; Chengdu; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 19237; NANS; Transfected with: UniProtKB; P42212; GFP (with p.Phe64Leu, p.Ser65Thr and p.His231Leu = EGFP); Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Han; Derived from sampling site: Cell type=Fibroblast. Male Characteristics: Using CRISPR/Cas9 GFP-P2A-Puro was inserted in both alleles of NANS exon 1 (PubMed=33130469) 41409779 CVCL_A4EJ HIHRSi003-A-1 induced pluripotent stem cell human CVCL_A4EJ From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6317; KIF1C; Simple_edited; p.Asp53Alafs*83 (c.158_227del); Zygosity=Homozygous; Note=By CRISPR/Cas9 (PubMed=33161238) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409780 CVCL_A4EI HIHRSi003-A induced pluripotent stem cell human CVCL_A4EI From: Hertie-Institut fur Klinische Hirnforschung; Tubingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409781 CVCL_A4EL PUMCHi006-A induced pluripotent stem cell human CVCL_A4EL From: Peking Union Medical College Hospital; Beijing; China CL:0000010 Sequence variation: Mutation; HGNC; 9603; PTGIS; Simple; p.Ala447Thr (c.1339G>A); dbSNP=rs146531327; Zygosity=Heterozygous (PubMed=33221675) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 41409782 CVCL_A4EK GZLSL-i001-A induced pluripotent stem cell human CVCL_A4EK From: The Third Affiliated Hospital of Guangzhou Medical College; Guangzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3546; F8; Unexplicit; Inv22 (IVS22 INV); ClinVar=VCV000010150; Zygosity=Hemizygous (PubMed=33212352) Derived from sampling site: Urine. Male 41409783 CVCL_A4EN CMCi009-A induced pluripotent stem cell human CVCL_A4EN From: The Catholic University of Korea; Seoul; South Korea CL:0000010 Sequence variation: Mutation; HGNC; 27310; FLCN; Simple; p.His429Thrfs*39 (c.1285delC); ClinVar=VCV000003364; Zygosity=Heterozygous (PubMed=33540282) Population: Asian; Derived from sampling site: Peripheral blood. Female 41409784 CVCL_A4EM WMUi013-A induced pluripotent stem cell human CVCL_A4EM From: Wenzhou Medical University; Wenzhou; China CL:0000010 Transfected with: UniProtKB; P04483; Escherichia coli Tn10 tetR; Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Population: Chinese; Han; Derived from sampling site: Urine. Male Characteristics: Using CRISPR/Cas9 a HA/L-TetOn-Cas9-CMV-PuroR-2A-HA/R construct was introduced in the AAVS1 safe harbor locus (PubMed=33207306) 41409785 CVCL_A4EB LNCaP95 clone D3 cancer cell line human CVCL_A4EB CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 55.7 hours (PubMed=32954481) 41409786 CVCL_A4EA LNCaP95 clone D2 cancer cell line human CVCL_A4EA CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 68.6 hours (PubMed=32954481) 41409787 CVCL_A4ED LNCaP95 clone F2 cancer cell line human CVCL_A4ED CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 85.3 hours (PubMed=32954481) 41409788 CVCL_A4EC LNCaP95 clone E2 cancer cell line human CVCL_A4EC CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 64.1 hours (PubMed=32954481) 41409789 CVCL_A4EF NCCSEDi001-A induced pluripotent stem cell human CVCL_A4EF From: National Chengdu Center for Safety Evaluation of Drugs; Chengdu; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Cell type=Fibroblast. Male 41409790 CVCL_A4EE NCC-LMS2-C1 cancer cell line human CVCL_A4EE CL:0000010 Population: Japanese; Derived from metastatic site: Thigh. Female Doubling time: 46 hours (PubMed=33001379) Part of: NCC sarcoma cell line panel 41409791 CVCL_A4DW WAe009-A-42 embryonic stem cell human CVCL_A4DW From: Nanfang Hospital, Southern Medical University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 3814; FOXH1. Female 41409792 CVCL_A4DV WAe009-A-38 embryonic stem cell human CVCL_A4DV From: Zhongshan Ophthalmic Center, Sun Yat-sen University; Guangzhou; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2343; CRB1. Female 41409793 CVCL_A4DY LNCaP95 clone 2-D3 cancer cell line human CVCL_A4DY CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 52.9 hours (PubMed=32954481) 41409794 CVCL_A4DX LNCaP95 clone 2-C6 cancer cell line human CVCL_A4DX CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 57.6 hours (PubMed=32954481) 41409795 CVCL_A4DZ LNCaP95 clone A7 cancer cell line human CVCL_A4DZ CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Androgen-independent Doubling time: 71.0 hours (PubMed=32954481) 41409797 CVCL_A4DQ WAe001-A-52 embryonic stem cell human CVCL_A4DQ From: Shandong Medical Biotechnological Center; Jinan; China CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 6954; MCPH1. Male 41409799 CVCL_A4DS USTCi002-A induced pluripotent stem cell human CVCL_A4DS From: School of Life Sciences, University of Science and Technology of China; Hefei; China CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple_edited; p.Gln1923Arg (c.5768A>G); Zygosity=Heterozygous; Note=By TALEN (PubMed=33189042) Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 41409800 CVCL_A4DR HVRDe009-A-1 embryonic stem cell human CVCL_A4DR CL:0000010 Knockout cell: Method=CRISPR/Cas9 (1 of 2 alleles); HGNC; 2847; DGCR8. Female 41409801 CVCL_A4DU cIEC conditionally immortalized cell line dog CVCL_A4DU CL:0000010 Transformant: Simian virus 40 (SV40) [tsA58](NCBI-Taxonomy; 1891767); Derived from sampling site: Small intestine; jejunum Cell type=Epithelial cell.; Breed/subspecies: Beagle. Unspecified 41409802 CVCL_A4DT Nor-iPSC induced pluripotent stem cell human CVCL_A4DT CL:0000010 Derived from sampling site: Fetal lung Cell type=Fibroblast.. Female 41409803 CVCL_A4RU Mt2-1 induced pluripotent stem cell human CVCL_A4RU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409804 CVCL_A4RT Mt1-4 induced pluripotent stem cell human CVCL_A4RT CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Increased level of mutation compared to the parent skin fibroblast (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409805 CVCL_A4RW Mt2-3 induced pluripotent stem cell human CVCL_A4RW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409806 CVCL_A4RV Mt2-2 induced pluripotent stem cell human CVCL_A4RV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409807 CVCL_A4RY Mt2-5 induced pluripotent stem cell human CVCL_A4RY CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409808 CVCL_A4RX Mt2-4 induced pluripotent stem cell human CVCL_A4RX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409809 CVCL_A4RZ Mt2-6 induced pluripotent stem cell human CVCL_A4RZ CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Increased level of mutation compared to the parent skin fibroblast (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409810 CVCL_A4RM UMGi068-B induced pluripotent stem cell human CVCL_A4RM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Female 41409811 CVCL_A4RL UMGi068-A induced pluripotent stem cell human CVCL_A4RL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409812 CVCL_A4RN UMGi069-A induced pluripotent stem cell human CVCL_A4RN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409813 CVCL_A4RQ Mt1-1 induced pluripotent stem cell human CVCL_A4RQ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409814 CVCL_A4RP UMGi069-B induced pluripotent stem cell human CVCL_A4RP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Hair Cell type=Keratinocyte.. Male 41409815 CVCL_A4RS Mt1-3 induced pluripotent stem cell human CVCL_A4RS CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Increased level of mutation compared to the parent skin fibroblast (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409816 CVCL_A4RR Mt1-2 induced pluripotent stem cell human CVCL_A4RR CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409817 CVCL_A4RE MiPSC5 induced pluripotent stem cell human CVCL_A4RE CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=In >80% (PubMed=29318513) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409818 CVCL_A4RD S1120-03 iPS #2 induced pluripotent stem cell human CVCL_A4RD CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 41409819 CVCL_A4RG MiPSC5-T3 induced pluripotent stem cell human CVCL_A4RG CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple_corrected; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=By TALEN (PubMed=29318513) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409820 CVCL_A4RF MiPSC5-T1 induced pluripotent stem cell human CVCL_A4RF CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple_edited; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Using TALEN the percentage of heteroplasmy was reduced from >80% to 27% (PubMed=29318513) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409821 CVCL_A4RI Mt1-fibro finite cell line human CVCL_A4RI CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409822 CVCL_A4RH MiPSC5-T7 induced pluripotent stem cell human CVCL_A4RH CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple_corrected; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=By TALEN (PubMed=29318513) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409823 CVCL_A4RK UMGi062-A induced pluripotent stem cell human CVCL_A4RK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409824 CVCL_A4RJ Mt2-fibro finite cell line human CVCL_A4RJ CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409825 CVCL_A4RA 07-02 iPS #5 induced pluripotent stem cell human CVCL_A4RA CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409826 CVCL_A4RC S1120-01 iPS #7 induced pluripotent stem cell human CVCL_A4RC CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 41409827 CVCL_A4RB 07-02 iPS #10 induced pluripotent stem cell human CVCL_A4RB CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409828 CVCL_A4SB Mt2-8 induced pluripotent stem cell human CVCL_A4SB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409829 CVCL_A4SA Mt2-7 induced pluripotent stem cell human CVCL_A4SA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: The MT-TL1 m.3243A>G mutation of the donor is undetectable in this cell line (PubMed=22396012) 41409830 CVCL_A4SD Mt2-10 induced pluripotent stem cell human CVCL_A4SD CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Increased level of mutation compared to the parent skin fibroblast (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409831 CVCL_A4SC Mt2-9 induced pluripotent stem cell human CVCL_A4SC CL:0000010 Sequence variation: Mutation; HGNC; 7490; MT-TL1; Simple; m.3243A>G; ClinVar=VCV000009589; Zygosity=Heteroplasmic; Note=Increased level of mutation compared to the parent skin fibroblast (PubMed=22396012) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409832 CVCL_A4PS NMR-iPSC clone 4 induced pluripotent stem cell naked mole-rat CVCL_A4PS CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409833 CVCL_A4PR biPSC induced pluripotent stem cell CVCL_A4PR CL:0000010 Derived from sampling site: Peripheral blood. Male Group: Non-human primate cell line 41409834 CVCL_A4PU NMR-iPSC clone 10 induced pluripotent stem cell naked mole-rat CVCL_A4PU CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409835 CVCL_A4PT NMR-iPSC clone 8 induced pluripotent stem cell naked mole-rat CVCL_A4PT CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409836 CVCL_A4PW NMR-iPSC clone 12 induced pluripotent stem cell naked mole-rat CVCL_A4PW CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409837 CVCL_A4PV NMR-iPSC clone 11 induced pluripotent stem cell naked mole-rat CVCL_A4PV CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409838 CVCL_A4PY NMR-iPSC clone 14 induced pluripotent stem cell naked mole-rat CVCL_A4PY CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409839 CVCL_A4PX NMR-iPSC clone 13 induced pluripotent stem cell naked mole-rat CVCL_A4PX CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409840 CVCL_A4PK MUNIi012-A induced pluripotent stem cell human CVCL_A4PK From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409841 CVCL_A4PJ MUNIi011-A induced pluripotent stem cell human CVCL_A4PJ From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409842 CVCL_A4PM MUNIi014-A induced pluripotent stem cell human CVCL_A4PM From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Cys130Arg (c.388T>C); ClinVar=VCV000017864; Zygosity=Homozygous; Note=ApoE4 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409843 CVCL_A4PL MUNIi013-A induced pluripotent stem cell human CVCL_A4PL From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409844 CVCL_A4PN MUNIi015-A induced pluripotent stem cell human CVCL_A4PN From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409845 CVCL_A4PQ MUNIi017-A induced pluripotent stem cell human CVCL_A4PQ From: Masaryk University; Brno; Czech Republic CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409846 CVCL_A4PP MUNIi016-A induced pluripotent stem cell human CVCL_A4PP From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 613; APOE; Simple; p.Arg130Cys (c.388C>T); Zygosity=Homozygous; Note=ApoE3 allele (PubMed=34088007) Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409847 CVCL_A4PC TLE1-464-G04 embryonic stem cell human CVCL_A4PC From: Broad Institute of MIT and Harvard; Cambridge; USA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 11837; TLE1. Male 41409848 CVCL_A4PB HEK293T SLC25A11 KO transformed cell line human CVCL_A4PB CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 10981; SLC25A11; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Miscellaneous: Cell line information from personal communication of Laflamme C Transformant: Adenovirus 5(NCBI-Taxonomy; 28285); Transformant: Simian virus 40 (SV40) [tsA](NCBI-Taxonomy; 1891767); Derived from sampling site: Fetal kidney. Female 41409849 CVCL_A4PE MUNIi006-A induced pluripotent stem cell human CVCL_A4PE From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Heterozygous (PubMed=34088008) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409850 CVCL_A4PD MUNIi005-A induced pluripotent stem cell human CVCL_A4PD From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple; p.Ala246Glu (c.737C>A); ClinVar=VCV000018125; Zygosity=Heterozygous (PubMed=34088008) Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Male 41409851 CVCL_A4PG MUNIi008-A induced pluripotent stem cell human CVCL_A4PG From: Masaryk University; Brno; Czech Republic CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409852 CVCL_A4PF MUNIi007-A induced pluripotent stem cell human CVCL_A4PF From: Masaryk University; Brno; Czech Republic CL:0000010 Sequence variation: Mutation; HGNC; 9509; PSEN2; Simple; p.Asn141Ile (c.422A>T); ClinVar=VCV000008845; Zygosity=Heterozygous (PubMed=34088008) Population: Caucasian; German; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409853 CVCL_A4PI MUNIi010-A induced pluripotent stem cell human CVCL_A4PI From: Masaryk University; Brno; Czech Republic CL:0000010 Population: Caucasian; Derived from sampling site: Abdomen; skin Cell type=Fibroblast.. Female 41409854 CVCL_A4PH MUNIi009-A induced pluripotent stem cell human CVCL_A4PH From: Masaryk University; Brno; Czech Republic CL:0000010 Population: Caucasian; Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409855 CVCL_A4PA U2OS GSN KO cancer cell line human CVCL_A4PA CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 4620; GSN Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 41409856 CVCL_A4QT RTTe1-hiPSC #96 induced pluripotent stem cell human CVCL_A4QT From: The Hospital for Sick Children; Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly16Glufs*22 (c.47_57delGCGAGGAGGAG); ClinVar=VCV000189770; Zygosity=Heterozygous (PubMed=25644311) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409857 CVCL_A4QS RTTe1-hiPSC #48 induced pluripotent stem cell human CVCL_A4QS From: The Hospital for Sick Children; Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly16Glufs*22 (c.47_57delGCGAGGAGGAG); ClinVar=VCV000189770; Zygosity=Heterozygous (PubMed=25644311) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409858 CVCL_A4QV Trpl17 induced pluripotent stem cell human CVCL_A4QV CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=22110584) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409859 CVCL_A4QU Trpl8 induced pluripotent stem cell human CVCL_A4QU CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=22110584) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409860 CVCL_A4QX WIS2-NANOS3-mCherry embryonic stem cell human CVCL_A4QX From: Weizmann Institute of Science; Rehovot; Israel CL:0000010 Transfected with: UniProtKB; X5DSL3; Anaplasma marginale mCherry fluorescent protein. Population: Jewish Male Characteristics: Using TALEN a P2A-mCherry construct was integrated at the C-terminus of NANOS3 (PubMed=25543152) 41409861 CVCL_A4QW Trpl43 induced pluripotent stem cell human CVCL_A4QW CL:0000010 Sequence variation: Gene amplification; HGNC; 11138; SNCA; Triplication; Zygosity=Unspecified (PubMed=22110584) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409862 CVCL_A4QZ 07-02 iPS #3 induced pluripotent stem cell human CVCL_A4QZ CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409863 CVCL_A4QY 07-02 fibroblast finite cell line human CVCL_A4QY CL:0000010 Derived from sampling site: Arm; skin Cell type=Fibroblast.. Female 41409864 CVCL_A4QL T8993G iPSC clone 3 induced pluripotent stem cell human CVCL_A4QL CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Unspecified (PubMed=27008180) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409865 CVCL_A4QK T8993G iPSC clone 2 induced pluripotent stem cell human CVCL_A4QK CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Unspecified (PubMed=27008180) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409866 CVCL_A4QN BJ iPSC clone 2 induced pluripotent stem cell human CVCL_A4QN CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 41409867 CVCL_A4QM BJ iPSC clone 1 induced pluripotent stem cell human CVCL_A4QM CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 41409868 CVCL_A4QP BJ iPSC clone 3 induced pluripotent stem cell human CVCL_A4QP CL:0000010 Derived from sampling site: Foreskin; skin Cell type=Fibroblast.. Male 41409869 CVCL_A4QR RTTe1-hiPSC #39 induced pluripotent stem cell human CVCL_A4QR From: The Hospital for Sick Children; Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly16Glufs*22 (c.47_57delGCGAGGAGGAG); ClinVar=VCV000189770; Zygosity=Heterozygous (PubMed=25644311) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409870 CVCL_A4QQ RTTe1-hiPSC #27 induced pluripotent stem cell human CVCL_A4QQ From: The Hospital for Sick Children; Toronto; Canada CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly16Glufs*22 (c.47_57delGCGAGGAGGAG); ClinVar=VCV000189770; Zygosity=Heterozygous (PubMed=25644311) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409871 CVCL_A4QD WT#5J induced pluripotent stem cell human CVCL_A4QD CL:0000010 Derived from sampling site: Skin; dermis Cell type=Keratinocyte.. Unspecified 41409872 CVCL_A4QC 24HM induced pluripotent stem cell human CVCL_A4QC From: Okano H.; Keio University; Tokyo; Japan CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood Cell type=T-cell.. Male 41409873 CVCL_A4QF ADPKD#10D induced pluripotent stem cell human CVCL_A4QF CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Trp3842Ter (c.11525G>A); ClinVar=VCV000805142; Zygosity=Heterozygous (PubMed=22142803) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Unspecified 41409874 CVCL_A4QE WT#20G induced pluripotent stem cell human CVCL_A4QE CL:0000010 Derived from sampling site: Skin; dermis Cell type=Keratinocyte.. Unspecified 41409875 CVCL_A4QH SLE#100H induced pluripotent stem cell human CVCL_A4QH CL:0000010 Derived from sampling site: Skin; dermis Cell type=Keratinocyte.. Unspecified 41409876 CVCL_A4QG ADPKD#50B induced pluripotent stem cell human CVCL_A4QG CL:0000010 Sequence variation: Mutation; HGNC; 9008; PKD1; Simple; p.Trp3842Ter (c.11525G>A); ClinVar=VCV000805142; Zygosity=Heterozygous (PubMed=22142803) Derived from sampling site: Skin; epidermis Cell type=Keratinocyte.. Unspecified 41409877 CVCL_A4QJ T8993G iPSC clone 1 induced pluripotent stem cell human CVCL_A4QJ CL:0000010 Sequence variation: Mutation; HGNC; 7414; MT-ATP6; Simple; p.Leu156Arg (m.8993T>G); ClinVar=VCV000009641; Zygosity=Unspecified (PubMed=27008180) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409878 CVCL_A4QI SLE#20J induced pluripotent stem cell human CVCL_A4QI CL:0000010 Derived from sampling site: Skin; dermis Cell type=Keratinocyte.. Unspecified 41409879 CVCL_A4PZ NMR-iPSC clone 24 induced pluripotent stem cell naked mole-rat CVCL_A4PZ CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409880 CVCL_A4QB NMR-iPSC clone 27 induced pluripotent stem cell naked mole-rat CVCL_A4QB CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409881 CVCL_A4QA NMR-iPSC clone 26 induced pluripotent stem cell naked mole-rat CVCL_A4QA CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409882 CVCL_A4NQ TSD-01-hiPSC induced pluripotent stem cell human CVCL_A4NQ From: University of Alabama at Birmingham; Birmingham; USA CL:0000010 Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; p.Tyr427Ilefs*5 (c.1274_1277dupTATC) (c.1278insTATC); ClinVar=VCV000003889; Zygosity=Heterozygous (PubMed=27879213); Sequence variation: Mutation; HGNC; 4878; HEXA; Simple; c.1421+1G>C (IVS12+1G>C); ClinVar=VCV000003890; Zygosity=Heterozygous; Note=Splice donor mutation (PubMed=27879213) Population: Jewish; Ashkenazi; Derived from sampling site: Cell type=Fibroblast. Male 41409883 CVCL_A4NP NH50321 induced pluripotent stem cell human CVCL_A4NP CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 41409884 CVCL_A4NS iPS-OPA1-BEHR induced pluripotent stem cell human CVCL_A4NS From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; c.557-668G>A (c.610+364G>A); ClinVar=VCV000496968; Zygosity=Heterozygous (PubMed=27879217); Sequence variation: Mutation; HGNC; 8140; OPA1; Simple; p.Ile382Met (c.1146A>G); ClinVar=VCV000050866; Zygosity=Heterozygous (PubMed=27879217) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409885 CVCL_A4NR iPS-SPG5-R486C induced pluripotent stem cell human CVCL_A4NR From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2652; CYP7B1; Simple; p.Arg486Cys (c.1456C>T); ClinVar=VCV000006107; Zygosity=Homozygous (PubMed=27879216) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409886 CVCL_A4NU QBRIi007-C induced pluripotent stem cell human CVCL_A4NU From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 11006; SLC2A2; Simple; c.613-7T>G (IVS5-7T>G); ClinVar=VCV001339449; Zygosity=Homozygous (from autologous cell line QBRIi007-A) Derived from sampling site: Peripheral blood. Female 41409887 CVCL_A4NT QBRIi007-B induced pluripotent stem cell human CVCL_A4NT From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 11006; SLC2A2; Simple; c.613-7T>G (IVS5-7T>G); ClinVar=VCV001339449; Zygosity=Homozygous (from autologous cell line QBRIi007-A) Derived from sampling site: Peripheral blood. Female 41409888 CVCL_A4NW QBRIi011-A induced pluripotent stem cell human CVCL_A4NW From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 4195; GCK; Simple; p.Leu146Pro (c.437T>C); Zygosity=Homozygous (PubMed=32971462) Population: Egyptian; Derived from sampling site: Peripheral blood. Male 41409889 CVCL_A4NV QBRIi010-A induced pluripotent stem cell human CVCL_A4NV From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 4195; GCK; Simple; p.Leu146Pro (c.437T>C); Zygosity=Heterozygous (PubMed=32971462) Population: Egyptian; Derived from sampling site: Peripheral blood. Male 41409890 CVCL_A4NI NH50315 induced pluripotent stem cell human CVCL_A4NI CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409891 CVCL_A4NH NH50314 induced pluripotent stem cell human CVCL_A4NH CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409892 CVCL_A4NK NH50317 induced pluripotent stem cell human CVCL_A4NK CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409893 CVCL_A4NJ NH50316 induced pluripotent stem cell human CVCL_A4NJ CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409894 CVCL_A4NM NH50319 induced pluripotent stem cell human CVCL_A4NM CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Male 41409895 CVCL_A4NL NH50318 induced pluripotent stem cell human CVCL_A4NL CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood. Female 41409896 CVCL_A4NN NH50320 induced pluripotent stem cell human CVCL_A4NN CL:0000010 Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 41409897 CVCL_A4NA MAPT N279K-2 induced pluripotent stem cell human CVCL_A4NA CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (PubMed=26373282) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409898 CVCL_A4NC NH50309 induced pluripotent stem cell human CVCL_A4NC CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 41409899 CVCL_A4NB NH50308 induced pluripotent stem cell human CVCL_A4NB CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 41409900 CVCL_A4NE NH50311 induced pluripotent stem cell human CVCL_A4NE CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409901 CVCL_A4ND NH50310 induced pluripotent stem cell human CVCL_A4ND CL:0000010 Population: Caucasian; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Female 41409902 CVCL_A4NG NH50313 induced pluripotent stem cell human CVCL_A4NG CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409903 CVCL_A4NF NH50312 induced pluripotent stem cell human CVCL_A4NF CL:0000010 Population: African American; Derived from sampling site: Peripheral blood Cell type=Erythroblast.. Male 41409904 CVCL_A4MX PDX1 C18R iPSC1 induced pluripotent stem cell human CVCL_A4MX From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6107; PDX1; Simple; p.Cys18Arg (c.52T>C); ClinVar=VCV000008862; Zygosity=Heterozygous (PubMed=27879214) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409905 CVCL_A4MW PDX1 P33T iPSC1 induced pluripotent stem cell human CVCL_A4MW From: Helmholtz Zentrum Munchen; Neuherberg; Germany CL:0000010 Sequence variation: Mutation; HGNC; 6107; PDX1; Simple; p.Pro33Thr (c.97C>T); ClinVar=VCV000036414; Zygosity=Heterozygous (PubMed=27879211) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409906 CVCL_A4MZ MAPT N279K-1 induced pluripotent stem cell human CVCL_A4MZ CL:0000010 Sequence variation: Mutation; HGNC; 6893; MAPT; Simple; p.Asn279Lys (c.837T>G) (N596K, c.1788T>G or N614K, c.1842T>G); ClinVar=VCV000014253; Zygosity=Heterozygous (PubMed=26373282) Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409907 CVCL_A4MY A79V-GC-hiPSC induced pluripotent stem cell human CVCL_A4MY From: University of Copenhagen; Copenhagen; Denmark CL:0000010 Sequence variation: Mutation; HGNC; 9508; PSEN1; Simple_corrected; p.Ala79Val (c.236C>T); ClinVar=VCV000018157; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=27879212) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409908 CVCL_A4NY QBRIi010-C induced pluripotent stem cell human CVCL_A4NY From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 4195; GCK; Simple; p.Leu146Pro (c.437T>C); Zygosity=Heterozygous (from autologous cell line QBRIi010-A) Population: Egyptian; Derived from sampling site: Peripheral blood. Male 41409909 CVCL_A4NX QBRIi010-B induced pluripotent stem cell human CVCL_A4NX From: Qatar Biomedical Research Institute; Doha; Quatar CL:0000010 Sequence variation: Mutation; HGNC; 4195; GCK; Simple; p.Leu146Pro (c.437T>C); Zygosity=Heterozygous (from autologous cell line QBRIi010-A) Population: Egyptian; Derived from sampling site: Peripheral blood. Male 41409910 CVCL_A4NZ U2OS DNM1 KO cancer cell line human CVCL_A4NZ CL:0000010 Knockout cell: Method=CRISPR/Cas9; HGNC; 2972; DNM1 Miscellaneous: Cell line information from personal communication of Laflamme C Population: Caucasian; Derived from sampling site: Bone; tibia. Female 41409911 CVCL_A4LN UMGi057-A induced pluripotent stem cell human CVCL_A4LN From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409912 CVCL_A4LQ UMGi059-A induced pluripotent stem cell human CVCL_A4LQ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409913 CVCL_A4LP UMGi058-A induced pluripotent stem cell human CVCL_A4LP From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409914 CVCL_A4LS UMGi061-A induced pluripotent stem cell human CVCL_A4LS From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409915 CVCL_A4LR UMGi060-A induced pluripotent stem cell human CVCL_A4LR From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409916 CVCL_A4LU UMGi064-A induced pluripotent stem cell human CVCL_A4LU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409917 CVCL_A4LT UMGi063-A induced pluripotent stem cell human CVCL_A4LT From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409918 CVCL_A4LG UMGi048-A induced pluripotent stem cell human CVCL_A4LG From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409919 CVCL_A4LF UMGi045-A induced pluripotent stem cell human CVCL_A4LF From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Bone marrow. Male 41409920 CVCL_A4LI UMGi049-A induced pluripotent stem cell human CVCL_A4LI From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409921 CVCL_A4LH iSCN5A induced pluripotent stem cell human CVCL_A4LH CL:0000010 Sequence variation: Mutation; HGNC; 10593; SCN5A; Simple; p.Glu1795_Ile1796insAsp (c.5382_5384dupTGA) (1795insD); ClinVar=VCV000009382; Zygosity=Unspecified (PubMed=22647976) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. 41409922 CVCL_A4LK UMGi051-A induced pluripotent stem cell human CVCL_A4LK From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 41409923 CVCL_A4LJ UMGi050-A induced pluripotent stem cell human CVCL_A4LJ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Peripheral blood. Female 41409924 CVCL_A4LM UMGi053-A induced pluripotent stem cell human CVCL_A4LM From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409925 CVCL_A4LL UMGi052-A induced pluripotent stem cell human CVCL_A4LL From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409926 CVCL_A4LA UMGi042-A induced pluripotent stem cell human CVCL_A4LA From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409927 CVCL_A4LC UMGi043-A induced pluripotent stem cell human CVCL_A4LC From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409928 CVCL_A4LB UMGi042-B induced pluripotent stem cell human CVCL_A4LB From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409929 CVCL_A4LE UMGi044-A induced pluripotent stem cell human CVCL_A4LE From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409930 CVCL_A4LD UMGi043-B induced pluripotent stem cell human CVCL_A4LD From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409931 CVCL_A4KV UMGi038-A induced pluripotent stem cell human CVCL_A4KV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409932 CVCL_A4KU UMGi037-A induced pluripotent stem cell human CVCL_A4KU From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409933 CVCL_A4KX UMGi040-A induced pluripotent stem cell human CVCL_A4KX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409934 CVCL_A4KW UMGi039-A induced pluripotent stem cell human CVCL_A4KW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409935 CVCL_A4KZ UMGi041-B.2 induced pluripotent stem cell human CVCL_A4KZ From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Ala2254Val (c.6761C>T); Zygosity=Heterozygous (PubMed=33640691) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409936 CVCL_A4KY UMGi041-A induced pluripotent stem cell human CVCL_A4KY From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 10484; RYR2; Simple; p.Ala2254Val (c.6761C>T); Zygosity=Heterozygous (from autologous cell lines UMGi041-B.2 and UMGi041-B.3) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409937 CVCL_A4MP iPD-T2 induced pluripotent stem cell human CVCL_A4MP CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; g.chr12:40197315A; dbSNP=rs1491923; Zygosity=Unspecified (PubMed=29513666) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409938 CVCL_A4MR iPD-C2 induced pluripotent stem cell human CVCL_A4MR CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; g.chr12:40197315A>G; dbSNP=rs1491923; Zygosity=Unspecified (PubMed=29513666) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409939 CVCL_A4MQ iPD-C1 induced pluripotent stem cell human CVCL_A4MQ CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; g.chr12:40197315A>G; dbSNP=rs1491923; Zygosity=Unspecified (PubMed=29513666) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409940 CVCL_A4MT SF-003 induced pluripotent stem cell human CVCL_A4MT From: Johns Hopkins University School of Medicine; Baltimore; USA CL:0000010 Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Tyr1124Thrfs*4 (c.3369delA); ClinVar=VCV000141444; Zygosity=Heterozygous (PubMed=27879207); Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Tyr1252Glnfs*4 (c.3754_3756delTATinsCA); ClinVar=VCV000185042; Zygosity=Heterozygous (PubMed=27879207) Derived from sampling site: Peripheral blood. Male 41409941 CVCL_A4MS iPS-SPG5-Y275X induced pluripotent stem cell human CVCL_A4MS From: Hertie Institute for Clinical Brain Research and German Center for Neurodegenerative Diseases, University of Tubingen; Tubingen; Germany CL:0000010 Sequence variation: Mutation; HGNC; 2652; CYP7B1; Simple; p.Tyr275Ter (c.825T>A); ClinVar=VCV000006105; Zygosity=Homozygous (PubMed=27879220) Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409942 CVCL_A4MV RB-iPS-2 induced pluripotent stem cell human CVCL_A4MV From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser888Asn (c.2663G>A); ClinVar=VCV000527935; Zygosity=Heterozygous (PubMed=27879208) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409943 CVCL_A4MU RB-iPS-1 induced pluripotent stem cell human CVCL_A4MU From: National Engineering Research Center of Human Stem Cells; Changsha; China CL:0000010 Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Ser888Asn (c.2663G>A); ClinVar=VCV000527935; Zygosity=Heterozygous (PubMed=27879208) Population: Chinese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409944 CVCL_A4MH FPAH-3 UMC induced pluripotent stem cell human CVCL_A4MH CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys117Tyr (c.350G>A); ClinVar=VCV000425766; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409945 CVCL_A4MG FPAH-2-P induced pluripotent stem cell human CVCL_A4MG CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Thr835Lysfs*4 (c.2504delC); ClinVar=VCV000425991; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409946 CVCL_A4MJ ID 11599 iPSC induced pluripotent stem cell human CVCL_A4MJ CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409947 CVCL_A4MI FPAH-3-P induced pluripotent stem cell human CVCL_A4MI CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys117Tyr (c.350G>A); ClinVar=VCV000425766; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409948 CVCL_A4ML ID 16423 iPSC induced pluripotent stem cell human CVCL_A4ML CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409949 CVCL_A4MK ID 16421 iPSC induced pluripotent stem cell human CVCL_A4MK CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409950 CVCL_A4MN iPD-T1 induced pluripotent stem cell human CVCL_A4MN CL:0000010 Sequence variation: Mutation; HGNC; 18618; LRRK2; Simple; g.chr12:40197315A; dbSNP=rs1491923; Zygosity=Unspecified (PubMed=29513666) Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409951 CVCL_A4MM ID 16424 iPSC induced pluripotent stem cell human CVCL_A4MM CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409952 CVCL_A4MB FPAH-1-UMC induced pluripotent stem cell human CVCL_A4MB CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409953 CVCL_A4MA FPAH-control-3 induced pluripotent stem cell human CVCL_A4MA CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409954 CVCL_A4MD FPAH-1-P2 induced pluripotent stem cell human CVCL_A4MD CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409955 CVCL_A4MC FPAH-1-P1 induced pluripotent stem cell human CVCL_A4MC CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409956 CVCL_A4MF FPAH-2 UMC induced pluripotent stem cell human CVCL_A4MF CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Thr835Lysfs*4 (c.2504delC); ClinVar=VCV000425991; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409957 CVCL_A4ME FPAH-1-P3 induced pluripotent stem cell human CVCL_A4ME CL:0000010 Sequence variation: Mutation; HGNC; 1078; BMPR2; Simple; p.Cys118Trp (c.354T>G) (T354G); ClinVar=VCV000008799; Zygosity=Unspecified (PubMed=28017794) Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409958 CVCL_A4LW UMGi066-A induced pluripotent stem cell human CVCL_A4LW From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Unspecified 41409959 CVCL_A4LV UMGi065-A induced pluripotent stem cell human CVCL_A4LV From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409960 CVCL_A4LY FPAH-control-1 induced pluripotent stem cell human CVCL_A4LY CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41409961 CVCL_A4LX UMGi067-A induced pluripotent stem cell human CVCL_A4LX From: University Medical Center Goettingen; Goettingen; Germany CL:0000010 Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409962 CVCL_A4LZ FPAH-control-2 induced pluripotent stem cell human CVCL_A4LZ CL:0000010 Population: Caucasian; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409963 CVCL_A3YA HDF1375 finite cell line human CVCL_A3YA From: Cell Applications, Inc.; San Diego; USA CL:0000010 Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409964 CVCL_A3YC HPS0284 induced pluripotent stem cell human CVCL_A3YC CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409965 CVCL_A3YB HPS0193 induced pluripotent stem cell human CVCL_A3YB CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409966 CVCL_A3XT HPS3709 induced pluripotent stem cell human CVCL_A3XT CL:0000010 Derived from sampling site: Peripheral blood. Male 41409967 CVCL_A3XS HPS3708 induced pluripotent stem cell human CVCL_A3XS CL:0000010 Derived from sampling site: Peripheral blood. Male 41409968 CVCL_A3XV HDF1503 finite cell line human CVCL_A3XV From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409969 CVCL_A3XU 297L1 induced pluripotent stem cell human CVCL_A3XU From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409970 CVCL_A3XX HDF1488 finite cell line human CVCL_A3XX From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409971 CVCL_A3XW HDF1392 finite cell line human CVCL_A3XW From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Male 41409972 CVCL_A3XZ HDF1377 finite cell line human CVCL_A3XZ From: Cell Applications, Inc.; San Diego; USA CL:0000010 Population: Caucasian; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409973 CVCL_A3XY HDF1616 finite cell line human CVCL_A3XY CL:0000010 Population: Japanese; Derived from sampling site: Skin; dermis Cell type=Fibroblast.. Female 41409974 CVCL_A3XL HPS3347 induced pluripotent stem cell human CVCL_A3XL CL:0000010 Derived from sampling site: Peripheral blood. Male 41409975 CVCL_A3XK HPS3346 induced pluripotent stem cell human CVCL_A3XK CL:0000010 Derived from sampling site: Peripheral blood. Male 41409976 CVCL_A3XN HPS3721 induced pluripotent stem cell human CVCL_A3XN CL:0000010 Derived from sampling site: Peripheral blood. Male 41409977 CVCL_A3XM HPS3720 induced pluripotent stem cell human CVCL_A3XM CL:0000010 Derived from sampling site: Peripheral blood. Male 41409978 CVCL_A3XP HPS3705 induced pluripotent stem cell human CVCL_A3XP CL:0000010 Derived from sampling site: Peripheral blood. Male 41409979 CVCL_A3XR HPS3707 induced pluripotent stem cell human CVCL_A3XR CL:0000010 Derived from sampling site: Peripheral blood. Male 41409980 CVCL_A3XQ HPS3706 induced pluripotent stem cell human CVCL_A3XQ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409981 CVCL_A3XD HPS3124 induced pluripotent stem cell human CVCL_A3XD CL:0000010 Derived from sampling site: Peripheral blood. Male 41409982 CVCL_A3XC HPS3123 induced pluripotent stem cell human CVCL_A3XC CL:0000010 Derived from sampling site: Peripheral blood. Male 41409983 CVCL_A3XF HPS3340 induced pluripotent stem cell human CVCL_A3XF CL:0000010 Derived from sampling site: Peripheral blood. Male 41409984 CVCL_A3XE HPS3339 induced pluripotent stem cell human CVCL_A3XE CL:0000010 Derived from sampling site: Peripheral blood. Male 41409985 CVCL_A3XH HPS3342 induced pluripotent stem cell human CVCL_A3XH CL:0000010 Derived from sampling site: Peripheral blood. Male 41409986 CVCL_A3XG HPS3341 induced pluripotent stem cell human CVCL_A3XG CL:0000010 Derived from sampling site: Peripheral blood. Male 41409987 CVCL_A3XJ HPS3345 induced pluripotent stem cell human CVCL_A3XJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41409988 CVCL_A3XI HPS3343 induced pluripotent stem cell human CVCL_A3XI CL:0000010 Derived from sampling site: Peripheral blood. Male 41409989 CVCL_A3ZB DS-1-iPSC induced pluripotent stem cell human CVCL_A3ZB CL:0000010 Sequence variation: Mutation; HGNC; 4976; HLCS; Simple; p.Gly261Valfs*20 (c.782delG); ClinVar=VCV000203777; Zygosity=Heterozygous (PubMed=29295803); Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Gly1410Trp (c.4261G>T); Zygosity=Heterozygous (PubMed=29295803) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409990 CVCL_A3ZA GM1T#27 induced pluripotent stem cell human CVCL_A3ZA CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 41409991 CVCL_A3ZD SDQLCHi033-A induced pluripotent stem cell human CVCL_A3ZD From: Qilu Children's Hospital of Shandong University; Jinan; China CL:0000010 Sequence variation: Mutation; HGNC; 987; BCKDHB; Simple; p.Pro366Gln (c.1097C>A); Zygosity=Homozygous (PubMed=33388706) Derived from sampling site: Peripheral blood. Female 41409992 CVCL_A3ZC DS-2-iPSC induced pluripotent stem cell human CVCL_A3ZC CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Ile1183Cysfs*21 (c.3576_3580delTCAAA); Zygosity=Heterozygous (PubMed=29295803) Population: Korean; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409993 CVCL_A3YU RS2-62P induced pluripotent stem cell human CVCL_A3YU CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=26012557) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409994 CVCL_A3YT RS1-61P induced pluripotent stem cell human CVCL_A3YT CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=26012557) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41409995 CVCL_A3YW RS1 fibroblast finite cell line human CVCL_A3YW CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=23805272) Population: Japanese; Donor information: Established from monozygotic twin of RS2 fibroblast (Cellosaurus=CVCL_A3YX) The donor of RS1 suffers from typical Rett syndrome while the donor of RS2 suffers from an atypical form of Rett syndrome.; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis Female 41409996 CVCL_A3YV RS2-65M induced pluripotent stem cell human CVCL_A3YV CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=26012557) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 41409997 CVCL_A3YY GM1T#17 induced pluripotent stem cell human CVCL_A3YY CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 41409998 CVCL_A3YX RS2 fibroblast finite cell line human CVCL_A3YX CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=23805272) Population: Japanese; Donor information: Established from monozygotic twin of RS1 fibroblast (Cellosaurus=CVCL_A3YW) The donor of RS1 suffers from typical Rett syndrome while the donor of RS2 suffers from an atypical form of Rett syndrome.; Derived from sampling site: Skin Cell type=Fibroblast.. Omics: DNA methylation analysis Female 41409999 CVCL_A3YZ GM1T#26 induced pluripotent stem cell human CVCL_A3YZ CL:0000010 Population: Asian; Derived from sampling site: Peripheral blood. Female 41410000 CVCL_A3YM TC11-3782 finite cell line human CVCL_A3YM CL:0000010 Derived from sampling site: Cell type=Fibroblast. Male 41410001 CVCL_A3YL HPS2406 induced pluripotent stem cell human CVCL_A3YL CL:0000010 Derived from sampling site: Peripheral blood. Male 41410002 CVCL_A3YN TC86-1530 finite cell line human CVCL_A3YN CL:0000010 Female 41410003 CVCL_A3YQ D2 [Human Dravet fibroblast] finite cell line human CVCL_A3YQ CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Tyr1102Ter (c.3306C>A); ClinVar=VCV000217243; Zygosity=Heterozygous (PubMed=25732146) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41410004 CVCL_A3YP D1 [Human Dravet fibroblast] finite cell line human CVCL_A3YP CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Arg862Ter (c.2584C>T); ClinVar=VCV000189857; Zygosity=Heterozygous (PubMed=25732146) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410005 CVCL_A3YS RS1-52M induced pluripotent stem cell human CVCL_A3YS CL:0000010 Sequence variation: Mutation; HGNC; 6990; MECP2; Simple; p.Gly269Alafs*20 (c.806delG) (p.Gly281Alafs*20, c.842delG) (V288X); ClinVar=VCV000095202; Zygosity=Heterozygous; Note=De novo mutation (PubMed=26012557) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female Characteristics: Due to X chromosome inactivation does not express the mutated allele 41410006 CVCL_A3YR D3 [Human Dravet fibroblast] finite cell line human CVCL_A3YR CL:0000010 Sequence variation: Mutation; HGNC; 10585; SCN1A; Simple; p.Asp43Metfs*49 (c.126delA) (p.Lys42fs*50); ClinVar=VCV000496115; Zygosity=Heterozygous (PubMed=25732146) Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410007 CVCL_A3YE HPS0268 induced pluripotent stem cell human CVCL_A3YE CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male 41410008 CVCL_A3YD HPS0285 induced pluripotent stem cell human CVCL_A3YD CL:0000010 Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41410009 CVCL_A3YG HPS0112 induced pluripotent stem cell human CVCL_A3YG CL:0000010 Male 41410010 CVCL_A3YF HPS0269 induced pluripotent stem cell human CVCL_A3YF CL:0000010 Population: Japanese; Derived from sampling site: Bone marrow; stroma. Male 41410011 CVCL_A3YI HPS2403 induced pluripotent stem cell human CVCL_A3YI CL:0000010 Derived from sampling site: Peripheral blood. Male 41410012 CVCL_A3YH HPS2402 induced pluripotent stem cell human CVCL_A3YH CL:0000010 Derived from sampling site: Peripheral blood. Male 41410013 CVCL_A3YK HPS2405 induced pluripotent stem cell human CVCL_A3YK CL:0000010 Derived from sampling site: Peripheral blood. Male 41410014 CVCL_A3YJ HPS2404 induced pluripotent stem cell human CVCL_A3YJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410015 CVCL_A3VZ HPS2154 induced pluripotent stem cell human CVCL_A3VZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410016 CVCL_A3VY HPS2153 induced pluripotent stem cell human CVCL_A3VY CL:0000010 Derived from sampling site: Peripheral blood. Female 41410017 CVCL_A3WA HPS2155 induced pluripotent stem cell human CVCL_A3WA CL:0000010 Derived from sampling site: Peripheral blood. Female 41410018 CVCL_A3VR HPS2187 induced pluripotent stem cell human CVCL_A3VR CL:0000010 Derived from sampling site: Peripheral blood. Female 41410019 CVCL_A3VQ HPS2119 induced pluripotent stem cell human CVCL_A3VQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410020 CVCL_A3VT HPS2189 induced pluripotent stem cell human CVCL_A3VT CL:0000010 Derived from sampling site: Peripheral blood. Female 41410021 CVCL_A3VS HPS2188 induced pluripotent stem cell human CVCL_A3VS CL:0000010 Derived from sampling site: Peripheral blood. Female 41410022 CVCL_A3VV HPS2191 induced pluripotent stem cell human CVCL_A3VV CL:0000010 Derived from sampling site: Peripheral blood. Female 41410023 CVCL_A3VU HPS2190 induced pluripotent stem cell human CVCL_A3VU CL:0000010 Derived from sampling site: Peripheral blood. Female 41410024 CVCL_A3VX HPS2152 induced pluripotent stem cell human CVCL_A3VX CL:0000010 Derived from sampling site: Peripheral blood. Female 41410025 CVCL_A3VW HPS2151 induced pluripotent stem cell human CVCL_A3VW CL:0000010 Derived from sampling site: Peripheral blood. Female 41410026 CVCL_A3VJ HPS1990 induced pluripotent stem cell human CVCL_A3VJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410027 CVCL_A3VI HPS1989 induced pluripotent stem cell human CVCL_A3VI CL:0000010 Derived from sampling site: Peripheral blood. Male 41410028 CVCL_A3VL HPS1992 induced pluripotent stem cell human CVCL_A3VL CL:0000010 Derived from sampling site: Peripheral blood. Male 41410029 CVCL_A3VK HPS1991 induced pluripotent stem cell human CVCL_A3VK CL:0000010 Derived from sampling site: Peripheral blood. Male 41410030 CVCL_A3VN HPS2117 induced pluripotent stem cell human CVCL_A3VN CL:0000010 Derived from sampling site: Peripheral blood. Female 41410031 CVCL_A3VM HPS1993 induced pluripotent stem cell human CVCL_A3VM CL:0000010 Derived from sampling site: Peripheral blood. Male 41410032 CVCL_A3VP HPS2118 induced pluripotent stem cell human CVCL_A3VP CL:0000010 Derived from sampling site: Peripheral blood. Female 41410033 CVCL_A3VB HPS1531 induced pluripotent stem cell human CVCL_A3VB CL:0000010 Derived from sampling site: Peripheral blood. Female 41410034 CVCL_A3VA HPS1530 induced pluripotent stem cell human CVCL_A3VA CL:0000010 Derived from sampling site: Peripheral blood. Female 41410035 CVCL_A3VD HPS1937 induced pluripotent stem cell human CVCL_A3VD CL:0000010 Derived from sampling site: Peripheral blood. Female 41410036 CVCL_A3VC HPS1898 induced pluripotent stem cell human CVCL_A3VC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41410037 CVCL_A3VF HPS1939 induced pluripotent stem cell human CVCL_A3VF CL:0000010 Derived from sampling site: Peripheral blood. Female 41410038 CVCL_A3VE HPS1938 induced pluripotent stem cell human CVCL_A3VE CL:0000010 Derived from sampling site: Peripheral blood. Female 41410039 CVCL_A3VH HPS1941 induced pluripotent stem cell human CVCL_A3VH CL:0000010 Derived from sampling site: Peripheral blood. Female 41410040 CVCL_A3VG HPS1940 induced pluripotent stem cell human CVCL_A3VG CL:0000010 Derived from sampling site: Peripheral blood. Female 41410041 CVCL_A3WZ HPS3120 induced pluripotent stem cell human CVCL_A3WZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410042 CVCL_A3XB HPS3122 induced pluripotent stem cell human CVCL_A3XB CL:0000010 Derived from sampling site: Peripheral blood. Male 41410043 CVCL_A3XA HPS3121 induced pluripotent stem cell human CVCL_A3XA CL:0000010 Derived from sampling site: Peripheral blood. Male 41410044 CVCL_A3WS HPS2898 induced pluripotent stem cell human CVCL_A3WS CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410045 CVCL_A3WR HPS2897 induced pluripotent stem cell human CVCL_A3WR CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410046 CVCL_A3WU HPS2913 induced pluripotent stem cell human CVCL_A3WU CL:0000010 Derived from sampling site: Peripheral blood. Female 41410047 CVCL_A3WT HPS2899 induced pluripotent stem cell human CVCL_A3WT CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410048 CVCL_A3WW HPS2915 induced pluripotent stem cell human CVCL_A3WW CL:0000010 Derived from sampling site: Peripheral blood. Female 41410049 CVCL_A3WV HPS2914 induced pluripotent stem cell human CVCL_A3WV CL:0000010 Derived from sampling site: Peripheral blood. Female 41410050 CVCL_A3WY HPS2917 induced pluripotent stem cell human CVCL_A3WY CL:0000010 Derived from sampling site: Peripheral blood. Female 41410051 CVCL_A3WX HPS2916 induced pluripotent stem cell human CVCL_A3WX CL:0000010 Derived from sampling site: Peripheral blood. Female 41410052 CVCL_A3WK HPS2866 induced pluripotent stem cell human CVCL_A3WK CL:0000010 Derived from sampling site: Peripheral blood. Male 41410053 CVCL_A3WJ HPS2865 induced pluripotent stem cell human CVCL_A3WJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410054 CVCL_A3WM HPS2868 induced pluripotent stem cell human CVCL_A3WM CL:0000010 Derived from sampling site: Peripheral blood. Male 41410055 CVCL_A3WL HPS2867 induced pluripotent stem cell human CVCL_A3WL CL:0000010 Derived from sampling site: Peripheral blood. Male 41410056 CVCL_A3WN HPS2869 induced pluripotent stem cell human CVCL_A3WN CL:0000010 Derived from sampling site: Peripheral blood. Male 41410057 CVCL_A3WQ HPS2896 induced pluripotent stem cell human CVCL_A3WQ CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410058 CVCL_A3WP HPS2895 induced pluripotent stem cell human CVCL_A3WP CL:0000010 Sequence variation: Mutation; HGNC; 4241; GFPT1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410059 CVCL_A3WC HPS2694 induced pluripotent stem cell human CVCL_A3WC CL:0000010 Derived from sampling site: Peripheral blood. Female 41410060 CVCL_A3WB HPS2693 induced pluripotent stem cell human CVCL_A3WB CL:0000010 Derived from sampling site: Peripheral blood. Female 41410061 CVCL_A3WE HPS2829 induced pluripotent stem cell human CVCL_A3WE CL:0000010 Derived from sampling site: Peripheral blood. Female 41410062 CVCL_A3WD HPS2695 induced pluripotent stem cell human CVCL_A3WD CL:0000010 Derived from sampling site: Peripheral blood. Female 41410063 CVCL_A3WG HPS2831 induced pluripotent stem cell human CVCL_A3WG CL:0000010 Derived from sampling site: Peripheral blood. Female 41410064 CVCL_A3WF HPS2830 induced pluripotent stem cell human CVCL_A3WF CL:0000010 Derived from sampling site: Peripheral blood. Female 41410065 CVCL_A3WI HPS2833 induced pluripotent stem cell human CVCL_A3WI CL:0000010 Derived from sampling site: Peripheral blood. Female 41410066 CVCL_A3WH HPS2832 induced pluripotent stem cell human CVCL_A3WH CL:0000010 Derived from sampling site: Peripheral blood. Female 41410067 CVCL_A3TX HPS1215 induced pluripotent stem cell human CVCL_A3TX CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410068 CVCL_A3TW HPS1214 induced pluripotent stem cell human CVCL_A3TW CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410069 CVCL_A3TZ HPS1230 induced pluripotent stem cell human CVCL_A3TZ CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410070 CVCL_A3TY HPS1229 induced pluripotent stem cell human CVCL_A3TY CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410071 CVCL_A3TP HPS1387 induced pluripotent stem cell human CVCL_A3TP CL:0000010 Derived from sampling site: Peripheral blood. Female 41410072 CVCL_A3TR HPS1389 induced pluripotent stem cell human CVCL_A3TR CL:0000010 Derived from sampling site: Peripheral blood. Female 41410073 CVCL_A3TQ HPS1388 induced pluripotent stem cell human CVCL_A3TQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410074 CVCL_A3TT HPS1211 induced pluripotent stem cell human CVCL_A3TT CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410075 CVCL_A3TS HPS1390 induced pluripotent stem cell human CVCL_A3TS CL:0000010 Derived from sampling site: Peripheral blood. Female 41410076 CVCL_A3TV HPS1213 induced pluripotent stem cell human CVCL_A3TV CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410077 CVCL_A3TU HPS1212 induced pluripotent stem cell human CVCL_A3TU CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410078 CVCL_A3TH HPS1372 induced pluripotent stem cell human CVCL_A3TH CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410079 CVCL_A3TG HPS1371 induced pluripotent stem cell human CVCL_A3TG CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410080 CVCL_A3TJ HPS1375 induced pluripotent stem cell human CVCL_A3TJ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410081 CVCL_A3TI HPS1374 induced pluripotent stem cell human CVCL_A3TI CL:0000010 Derived from sampling site: Peripheral blood. Male 41410082 CVCL_A3TL HPS1377 induced pluripotent stem cell human CVCL_A3TL CL:0000010 Derived from sampling site: Peripheral blood. Male 41410083 CVCL_A3TK HPS1376 induced pluripotent stem cell human CVCL_A3TK CL:0000010 Derived from sampling site: Peripheral blood. Male 41410084 CVCL_A3TN HPS1386 induced pluripotent stem cell human CVCL_A3TN CL:0000010 Derived from sampling site: Peripheral blood. Female 41410085 CVCL_A3TM HPS1378 induced pluripotent stem cell human CVCL_A3TM CL:0000010 Derived from sampling site: Peripheral blood. Male 41410086 CVCL_A3TB HPS1101 induced pluripotent stem cell human CVCL_A3TB CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (from autologous cell line HPS1096) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410087 CVCL_A3TA HPS1100 induced pluripotent stem cell human CVCL_A3TA CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (from autologous cell line HPS1096) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410088 CVCL_A3TD HPS1368 induced pluripotent stem cell human CVCL_A3TD CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410089 CVCL_A3TC HPS1756 induced pluripotent stem cell human CVCL_A3TC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410090 CVCL_A3TF HPS1370 induced pluripotent stem cell human CVCL_A3TF CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410091 CVCL_A3TE HPS1369 induced pluripotent stem cell human CVCL_A3TE CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex3-7del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410092 CVCL_A3UY HPS1528 induced pluripotent stem cell human CVCL_A3UY CL:0000010 Derived from sampling site: Peripheral blood. Female 41410093 CVCL_A3UX HPS1527 induced pluripotent stem cell human CVCL_A3UX CL:0000010 Derived from sampling site: Peripheral blood. Female 41410094 CVCL_A3UZ HPS1529 induced pluripotent stem cell human CVCL_A3UZ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410095 CVCL_A3UQ HPS1407 induced pluripotent stem cell human CVCL_A3UQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410096 CVCL_A3UP HPS1406 induced pluripotent stem cell human CVCL_A3UP CL:0000010 Derived from sampling site: Peripheral blood. Female 41410097 CVCL_A3US HPS1455 induced pluripotent stem cell human CVCL_A3US CL:0000010 Derived from sampling site: Peripheral blood. Female 41410098 CVCL_A3UR HPS1408 induced pluripotent stem cell human CVCL_A3UR CL:0000010 Derived from sampling site: Peripheral blood. Female 41410099 CVCL_A3UU HPS1457 induced pluripotent stem cell human CVCL_A3UU CL:0000010 Derived from sampling site: Peripheral blood. Female 41410100 CVCL_A3UT HPS1456 induced pluripotent stem cell human CVCL_A3UT CL:0000010 Derived from sampling site: Peripheral blood. Female 41410101 CVCL_A3UW HPS1459 induced pluripotent stem cell human CVCL_A3UW CL:0000010 Derived from sampling site: Peripheral blood. Female 41410102 CVCL_A3UV HPS1458 induced pluripotent stem cell human CVCL_A3UV CL:0000010 Derived from sampling site: Peripheral blood. Female 41410103 CVCL_A3UI HPS1321 induced pluripotent stem cell human CVCL_A3UI CL:0000010 Derived from sampling site: Peripheral blood. Female 41410104 CVCL_A3UH HPS1317 induced pluripotent stem cell human CVCL_A3UH CL:0000010 Derived from sampling site: Peripheral blood. Female 41410105 CVCL_A3UK HPS1323 induced pluripotent stem cell human CVCL_A3UK CL:0000010 Derived from sampling site: Peripheral blood. Female 41410106 CVCL_A3UJ HPS1322 induced pluripotent stem cell human CVCL_A3UJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410107 CVCL_A3UM HPS1404 induced pluripotent stem cell human CVCL_A3UM CL:0000010 Derived from sampling site: Peripheral blood. Female 41410108 CVCL_A3UL HPS1772 induced pluripotent stem cell human CVCL_A3UL CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Female 41410109 CVCL_A3UN HPS1405 induced pluripotent stem cell human CVCL_A3UN CL:0000010 Derived from sampling site: Peripheral blood. Female 41410110 CVCL_A3UA HPS1231 induced pluripotent stem cell human CVCL_A3UA CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410111 CVCL_A3UC HPS1233 induced pluripotent stem cell human CVCL_A3UC CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410112 CVCL_A3UB HPS1232 induced pluripotent stem cell human CVCL_A3UB CL:0000010 Population: Japanese; Derived from sampling site: Peripheral blood. Male 41410113 CVCL_A3UE HPS1314 induced pluripotent stem cell human CVCL_A3UE CL:0000010 Derived from sampling site: Peripheral blood. Female 41410114 CVCL_A3UD HPS1313 induced pluripotent stem cell human CVCL_A3UD CL:0000010 Derived from sampling site: Peripheral blood. Female 41410115 CVCL_A3UG HPS1316 induced pluripotent stem cell human CVCL_A3UG CL:0000010 Derived from sampling site: Peripheral blood. Female 41410116 CVCL_A3UF HPS1315 induced pluripotent stem cell human CVCL_A3UF CL:0000010 Derived from sampling site: Peripheral blood. Female 41410117 CVCL_A3RV HPS2311 induced pluripotent stem cell human CVCL_A3RV CL:0000010 Derived from sampling site: Peripheral blood. Male 41410118 CVCL_A3RU HPS2310 induced pluripotent stem cell human CVCL_A3RU CL:0000010 Derived from sampling site: Peripheral blood. Male 41410119 CVCL_A3RX HPS1633 induced pluripotent stem cell human CVCL_A3RX CL:0000010 Derived from sampling site: Peripheral blood. Male 41410120 CVCL_A3RW HPS2312 induced pluripotent stem cell human CVCL_A3RW CL:0000010 Derived from sampling site: Peripheral blood. Male 41410121 CVCL_A3RZ HPS1635 induced pluripotent stem cell human CVCL_A3RZ CL:0000010 Derived from sampling site: Peripheral blood. Male 41410122 CVCL_A3RY HPS1634 induced pluripotent stem cell human CVCL_A3RY CL:0000010 Derived from sampling site: Peripheral blood. Male 41410123 CVCL_A3RN HPS2253 induced pluripotent stem cell human CVCL_A3RN CL:0000010 Derived from sampling site: Peripheral blood. Female 41410124 CVCL_A3RM HPS2252 induced pluripotent stem cell human CVCL_A3RM CL:0000010 Derived from sampling site: Peripheral blood. Female 41410125 CVCL_A3RP HPS2254 induced pluripotent stem cell human CVCL_A3RP CL:0000010 Derived from sampling site: Peripheral blood. Female 41410126 CVCL_A3RR HPS2199 induced pluripotent stem cell human CVCL_A3RR CL:0000010 Derived from sampling site: Peripheral blood. Female 41410127 CVCL_A3RQ HPS2255 induced pluripotent stem cell human CVCL_A3RQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410128 CVCL_A3RT HPS2201 induced pluripotent stem cell human CVCL_A3RT CL:0000010 Derived from sampling site: Peripheral blood. Female 41410129 CVCL_A3RS HPS2200 induced pluripotent stem cell human CVCL_A3RS CL:0000010 Derived from sampling site: Peripheral blood. Female 41410130 CVCL_A3RF HPS2382 induced pluripotent stem cell human CVCL_A3RF CL:0000010 Derived from sampling site: Peripheral blood. Male 41410131 CVCL_A3RE HPS2381 induced pluripotent stem cell human CVCL_A3RE CL:0000010 Derived from sampling site: Peripheral blood. Male 41410132 CVCL_A3RH HPS2276 induced pluripotent stem cell human CVCL_A3RH CL:0000010 Derived from sampling site: Peripheral blood. Female 41410133 CVCL_A3RG HPS2275 induced pluripotent stem cell human CVCL_A3RG CL:0000010 Derived from sampling site: Peripheral blood. Female 41410134 CVCL_A3RJ HPS2278 induced pluripotent stem cell human CVCL_A3RJ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410135 CVCL_A3RI HPS2277 induced pluripotent stem cell human CVCL_A3RI CL:0000010 Derived from sampling site: Peripheral blood. Female 41410136 CVCL_A3RL HPS2251 induced pluripotent stem cell human CVCL_A3RL CL:0000010 Derived from sampling site: Peripheral blood. Female 41410137 CVCL_A3RK HPS2279 induced pluripotent stem cell human CVCL_A3RK CL:0000010 Derived from sampling site: Peripheral blood. Female 41410138 CVCL_A3RB HPS2378 induced pluripotent stem cell human CVCL_A3RB CL:0000010 Derived from sampling site: Peripheral blood. Male 41410139 CVCL_A3RA HPS2388 induced pluripotent stem cell human CVCL_A3RA CL:0000010 Sequence variation: Mutation; HGNC; 4177; GBA1; Unexplicit; Not described; Zygosity=Unspecified (RCB) Derived from sampling site: Peripheral blood. Male 41410140 CVCL_A3RD HPS2380 induced pluripotent stem cell human CVCL_A3RD CL:0000010 Derived from sampling site: Peripheral blood. Male 41410141 CVCL_A3RC HPS2379 induced pluripotent stem cell human CVCL_A3RC CL:0000010 Derived from sampling site: Peripheral blood. Male 41410142 CVCL_A3SW HPS1095 induced pluripotent stem cell human CVCL_A3SW CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (from autologous cell line HPS1090) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410143 CVCL_A3SV HPS1094 induced pluripotent stem cell human CVCL_A3SV CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (from autologous cell line HPS1090) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410144 CVCL_A3SY HPS1098 induced pluripotent stem cell human CVCL_A3SY CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (from autologous cell line HPS1096) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410145 CVCL_A3SX HPS1097 induced pluripotent stem cell human CVCL_A3SX CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (from autologous cell line HPS1096) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410146 CVCL_A3SZ HPS1099 induced pluripotent stem cell human CVCL_A3SZ CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Leu670Phefs*63 (c.2010_2014delinsTAT); Zygosity=Hemizygous (from autologous cell line HPS1096) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410147 CVCL_A3SN HPS1327 induced pluripotent stem cell human CVCL_A3SN CL:0000010 Derived from sampling site: Peripheral blood. Female 41410148 CVCL_A3SQ HPS1329 induced pluripotent stem cell human CVCL_A3SQ CL:0000010 Derived from sampling site: Peripheral blood. Female 41410149 CVCL_A3SP HPS1328 induced pluripotent stem cell human CVCL_A3SP CL:0000010 Derived from sampling site: Peripheral blood. Female 41410150 CVCL_A3SS HPS1091 induced pluripotent stem cell human CVCL_A3SS CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (from autologous cell line HPS1090) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410151 CVCL_A3SR HPS1330 induced pluripotent stem cell human CVCL_A3SR CL:0000010 Derived from sampling site: Peripheral blood. Female 41410152 CVCL_A3SU HPS1093 induced pluripotent stem cell human CVCL_A3SU CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (from autologous cell line HPS1090) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410153 CVCL_A3ST HPS1092 induced pluripotent stem cell human CVCL_A3ST CL:0000010 Sequence variation: Mutation; HGNC; 61; ABCD1; Simple; p.Arg401Trp (c.1201C>T); ClinVar=VCV000488393; Zygosity=Hemizygous (from autologous cell line HPS1090) Population: Japanese; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410154 CVCL_A3SG HPS1684 induced pluripotent stem cell human CVCL_A3SG CL:0000010 Derived from sampling site: Peripheral blood. Female 41410155 CVCL_A3SF HPS1683 induced pluripotent stem cell human CVCL_A3SF CL:0000010 Derived from sampling site: Peripheral blood. Female 41410156 CVCL_A3SI HPS1339 induced pluripotent stem cell human CVCL_A3SI CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410157 CVCL_A3SH HPS1338 induced pluripotent stem cell human CVCL_A3SH CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410158 CVCL_A3SK HPS1341 induced pluripotent stem cell human CVCL_A3SK CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410159 CVCL_A3SJ HPS1340 induced pluripotent stem cell human CVCL_A3SJ CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410160 CVCL_A3SM HPS1326 induced pluripotent stem cell human CVCL_A3SM CL:0000010 Derived from sampling site: Peripheral blood. Female 41410161 CVCL_A3SL HPS1342 induced pluripotent stem cell human CVCL_A3SL CL:0000010 Sequence variation: Mutation; HGNC; 2928; DMD; Unexplicit; Ex47-52del; Zygosity=Hemizygous (RCB) Derived from sampling site: Peripheral blood. Male 41410162 CVCL_A3SA HPS1636 induced pluripotent stem cell human CVCL_A3SA CL:0000010 Derived from sampling site: Peripheral blood. Male 41410163 CVCL_A3SC HPS1680 induced pluripotent stem cell human CVCL_A3SC CL:0000010 Derived from sampling site: Peripheral blood. Female 41410164 CVCL_A3SB HPS1637 induced pluripotent stem cell human CVCL_A3SB CL:0000010 Derived from sampling site: Peripheral blood. Male 41410165 CVCL_A3SE HPS1682 induced pluripotent stem cell human CVCL_A3SE CL:0000010 Derived from sampling site: Peripheral blood. Female 41410166 CVCL_A3SD HPS1681 induced pluripotent stem cell human CVCL_A3SD CL:0000010 Derived from sampling site: Peripheral blood. Female 41410167 CVCL_A4BE HBMEC-27 transformed cell line human CVCL_A4BE CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Endothelial cell.. Unspecified 41410168 CVCL_A4BD HUVEC-96 transformed cell line human CVCL_A4BD CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified 41410169 CVCL_A4BG HBMEC-33 transformed cell line human CVCL_A4BG CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Endothelial cell.. Unspecified 41410170 CVCL_A4BF HBMEC-28 transformed cell line human CVCL_A4BF CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Endothelial cell.. Unspecified 41410171 CVCL_A4BI OHRI-MEL-13 cancer cell line human CVCL_A4BI CL:0000010 Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Lys601Asn (c.1803A>T); ClinVar=VCV000376285; Zygosity=Unspecified (ATCC) Population: Caucasian; Derived from metastatic site: Pelvic lymph node. Male Doubling time: ~42 hours (ATCC=CRL-3427) 41410172 CVCL_A4BH HBMEC-60 transformed cell line human CVCL_A4BH CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Bone marrow Cell type=Endothelial cell.. Unspecified 41410173 CVCL_A4BK 21M18 hybridoma house mouse CVCL_A4BK CL:0000010 Biotechnology: The monoclonal antibody produced by this hybridoma was used to prepare the humanized demcizumab (OMP-21M18) therapeutic antibody Monoclonal antibody isotype: Not specified; Monoclonal antibody target: UniProtKB; Q9NR61; Human DLL4. Group: Patented cell line; Registration: International Depositary Authority, American Type Culture Collection (ATCC); PTA-8670 41410174 CVCL_A4BJ BECK-1 cancer cell line human CVCL_A4BJ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Unspecified (ATCC); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Unspecified (ATCC); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000177778; Zygosity=Unspecified (ATCC) Derived from sampling site: Bone marrow. Female 41410175 CVCL_A4BA BMEC-1 transformed cell line human CVCL_A4BA CL:0000010 Transformant: Simian virus 40 (SV40) [pSVT](NCBI-Taxonomy; 1891767); Derived from sampling site: Bone marrow; blood microvessel Cell type=Microvascular endothelial cell.. Male Senescence: According to ATCC it senesces at ~27 PDL (ATCC=CRL-3421), but this is not what is described in PubMed=8954864 41410176 CVCL_A4BC HUVEC-95 transformed cell line human CVCL_A4BC CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified 41410177 CVCL_A4BB HUVEC-94 transformed cell line human CVCL_A4BB CL:0000010 Transfected with: UniProtKB; P03126; Human papillomavirus type 16 protein E6; Transfected with: UniProtKB; P03129; Human papillomavirus type 16 protein E7; Transfected with: UniProtKB; P00552; Transposon Tn5 neo Transformant: Human papillomavirus type 16 (HPV16) [pLXSN16E6E7](NCBI-Taxonomy; 333760); Derived from sampling site: Umbilical vein Cell type=Endothelial cell of umbilical vein.. Unspecified 41410178 CVCL_A4AT M28N2 transformed cell line house mouse CVCL_A4AT CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland; Breed/subspecies: FVB/N Tg(C3-1-TAg)cJeg C3(1)/Tag transgenic. Female Characteristics: Weakly tumorigenic (PubMed=12602905) Doubling time: 37 hours (PubMed=12602905) 41410179 CVCL_A4AS M27H4 transformed cell line house mouse CVCL_A4AS CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland; Breed/subspecies: FVB/N Tg(C3-1-TAg)cJeg C3(1)/Tag transgenic. Female Characteristics: Weakly tumorigenic (PubMed=12602905) Doubling time: 25 hours (PubMed=12602905) 41410180 CVCL_A4AV M6C cancer cell line house mouse CVCL_A4AV CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland; Breed/subspecies: FVB/N Tg(C3-1-TAg)cJeg C3(1)/Tag transgenic. Female Characteristics: Metastatic Established from a nude mice lung metastasis obtained by subcutaneous injection of the parent cell line (PubMed=12602905). Doubling time: 15 hours (PubMed=12602905) 41410181 CVCL_A4AU M6 cancer cell line house mouse CVCL_A4AU CL:0000010 Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Mammary gland; Breed/subspecies: FVB/N Tg(C3-1-TAg)cJeg C3(1)/Tag transgenic. Female Doubling time: 18 hours (PubMed=12602905) 41410182 CVCL_A4AX hTERT FT282 telomerase immortalized cell line human CVCL_A4AX CL:0000010 Knockout cell: Method=shRNA knockdown; HGNC; 11998; TP53; Transfected with: HGNC; 1773; CDK4 (with p.Arg24Cys); Transfected with: HGNC; 11730; TERT Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female Doubling time: ~32 hours (ATCC=CRL-3449) 41410183 CVCL_A4AW hTERT FT194 transformed cell line human CVCL_A4AW CL:0000010 Transfected with: HGNC; 11730; TERT Transformant: Simian virus 40 (SV40)(NCBI-Taxonomy; 1891767); Derived from sampling site: Fallopian tube Cell type=Fallopian tube secretory epithelial cell.. Female Doubling time: ~32 hours (ATCC=CRL-3445) 41410184 CVCL_A4AZ BT301 cancer cell line human CVCL_A4AZ CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 41410185 CVCL_A4AY BT238 cancer cell line human CVCL_A4AY CL:0000010 Derived from sampling site: Brain. Male Group: Cancer stem cell line 41410186 CVCL_A4AL ZR-75-1 Tam1 cancer cell line human CVCL_A4AL CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Ascites. Omics: Deep exome analysis Female 41410187 CVCL_A4AK BT-474 Tam2 cancer cell line human CVCL_A4AK CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from sampling site: Breast. Omics: Deep exome analysis Female 41410188 CVCL_A4AN T-47D Tam1 cancer cell line human CVCL_A4AN CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Female 41410189 CVCL_A4AM ZR-75-1 Tam2 cancer cell line human CVCL_A4AM CL:0000010 Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Ascites. Omics: Deep exome analysis Female 41410190 CVCL_A4AP T-47D Tam2 cancer cell line human CVCL_A4AP CL:0000010 Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu194Phe (c.580C>T); ClinVar=VCV000127817; Zygosity=Homozygous (from parent cell line) Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Female 41410191 CVCL_A4AR Agarabi CHO spontaneously immortalized cell line CVCL_A4AR CL:0000010 Selected for resistance to: ChEBI; CHEBI:44185; Methotrexate (MTX); Derived from sampling site: Ovary. Female Characteristics: Parent cell line was stably transfected with a two-vector system expressing a model mouse-human chimeric IgG1 antibody Doubling time: 22-28 hours (ATCC=CRL-3440) 41410192 CVCL_A4AQ MCF-7 Tam1 cancer cell line human CVCL_A4AQ CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line) Population: Caucasian; Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen; Derived from metastatic site: Pleural effusion. Omics: Deep exome analysis Female Doubling time: ~1-2 weeks (ATCC=CRL-3435) 41410193 CVCL_A4CF U-2 OS-Luc2 cancer cell line human CVCL_A4CF CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Bone; tibia. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~19 hours (ATCC=HTB-96-LUC2) 41410194 CVCL_A4CE THP-1 NF-kB-Luc2 cancer cell line human CVCL_A4CE CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses firefly luciferase under the control of the NF-kappaB response element Doubling time: ~72 hours (ATCC=TIB-202-NFkB-LUC2) 41410195 CVCL_A4CH MCF7 dCas9-KRAB cancer cell line human CVCL_A4CH CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph); Transfected with: UniProtKB; Q99ZW2; Streptomyces pyogenes Cas9; Transfected with: UniProtKB; Q9U6Y8; RFP Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Using CRISPR/Cas9 a construct containing KRAB-dCas9-2A-hph-2A-RFP-PA was introduced in the AAVS1 safe harbor locus 41410196 CVCL_A4CG FaDu-Luc2 cancer cell line human CVCL_A4CG CL:0000010 Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; c.151-1G>T; ClinVar=VCV000422058; Zygosity=Homozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 3595; FAT1; Simple; p.Lys3277Asnfs*4 (c.9828delG) (p.Gly3276fs); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21); ClinVar=VCV000481003; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Leu (c.743G>T); ClinVar=VCV000230253; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Indian; Derived from sampling site: Pharynx; hypopharynx. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~30 hours (ATCC=HTB-43-LUC2) 41410197 CVCL_A4CJ B16-F10-Luc2 [ATCC] cancer cell line house mouse CVCL_A4CJ CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~12 hours (ATCC=CRL-6475-LUC2) 41410198 CVCL_A4CI MCF7-Luc2 cancer cell line human CVCL_A4CI CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Pleural effusion. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~57 hours (ATCC=HTB-22-LUC2) 41410199 CVCL_A4CL BT-474 Ecadherin EmGFP cancer cell line human CVCL_A4CL CL:0000010 Sequence variation: Gene fusion; HGNC; 24618; AHCTF1 + HGNC; 736; NAAA; Name(s)=AHCTF1-NAAA (from parent cell line); Sequence variation: Gene fusion; HGNC; 7609; MYO9B + HGNC; 9764; RAB22A; Name(s)=RAB22A-MYO9B (from parent cell line); Sequence variation: Gene fusion; HGNC; 16173; DOK5 + HGNC; 17579; STARD3; Name(s)=STARD3-DOK5 (from parent cell line); Sequence variation: Gene fusion; HGNC; 16651; MRPL45 + HGNC; 16181; TRPC4AP; Name(s)=TRPC4AP-MRPL45 (from parent cell line); Sequence variation: Gene fusion; HGNC; 13178; IKZF3 + HGNC; 12649; VAPB; Name(s)=VAPB-IKZF3 (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Ser3094Ter (c.9281C>A); ClinVar=VCV000188440; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11621; HNF1A; Simple; p.Gln495Ter (c.1483C>T); ClinVar=VCV000586785; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6871; MAPK1; Simple; p.His61Gln (c.183C>G); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Lys111Asn (c.333G>C); ClinVar=VCV000376483; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu285Lys (c.853G>A); ClinVar=VCV000420133; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP) Population: Caucasian; Derived from sampling site: Breast. Female Characteristics: Using CRISPR/Cas9 CDH1 has been tagged in one allele at the C-terminus with EmGFP Allows to monitor the epithelial-to-mesenchymal transition (EMT) status of cells in vitro by monitoring EmGFP expression. 41410200 CVCL_A4CK B16-F1-Luc2 cancer cell line house mouse CVCL_A4CK CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Skin; Breed/subspecies: C57BL/6. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~11 hours (ATCC=CRL-6322-LUC2) 41410201 CVCL_A4CB THP-1 CRE-Luc2 cancer cell line human CVCL_A4CB CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses firefly luciferase under the control of the cAMP response element (CRE) Doubling time: ~72 hours (ATCC=TIB-202-CRE-LUC2) 41410202 CVCL_A4CA THP-1 AP1-Luc2 cancer cell line human CVCL_A4CA CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses firefly luciferase under the control of the AP-1 promoter Doubling time: ~72 hours (ATCC=TIB-202-AP1-LUC2) 41410203 CVCL_A4CD THP-1 GAS-Luc2 cancer cell line human CVCL_A4CD CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses firefly luciferase under the control of the gamma-activated site (GAS) promoter Doubling time: ~72 hours (ATCC=TIB-202-GAS-LUC2) 41410204 CVCL_A4CC THP-1 ISRE-Luc2 cancer cell line human CVCL_A4CC CL:0000010 Sequence variation: Gene fusion; HGNC; 2457; CSNK2A1 + HGNC; 13917; DDX39B; Name(s)=CSNK2A1-DDX39B (from parent cell line); Sequence variation: Gene fusion; HGNC; 7132; KMT2A + HGNC; 7136; MLLT3; Name(s)=KMT2A-MLLT3, MLL-MLLT3, MLL-AF9 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg174fs*3 (c.520_545del26); Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Peripheral blood. Male Characteristics: Stably expresses firefly luciferase under the control of the interferon-sensitive response element (ISRE) Doubling time: ~72 hours (ATCC=TIB-202-ISRE-LUC2) 41410205 CVCL_A4BU PANC-1-Luc2 cancer cell line human CVCL_A4BU CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~23 hours (ATCC=CRL-1469-LUC2) 41410206 CVCL_A4BT PANC-1 Ecadherin EmGFP cancer cell line human CVCL_A4BT CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP) Population: Caucasian; Derived from sampling site: Pancreas. Male Characteristics: Using CRISPR/Cas9 CDH1 has been tagged in one allele at the C-terminus with EmGFP Allows to monitor the epithelial-to-mesenchymal transition (EMT) status of cells in vitro by monitoring EmGFP expression. 41410207 CVCL_A4BW MCF 10A Ecadherin EmGFP spontaneously immortalized cell line human CVCL_A4BW CL:0000010 Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line); Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P42212; GFP (with p.Ser65Thr, p.Ser72Ala, p.Asn149Lys, p.Met153Thr, p.Ile167Thr and p.His231Leu = EmGFP) Derived from sampling site: Breast; epithelium. Female Characteristics: Using CRISPR/Cas9 CDH1 has been tagged in one allele at the C-terminus with EmGFP Allows to monitor the epithelial-to-mesenchymal transition (EMT) status of cells in vitro by monitoring EmGFP expression. 41410208 CVCL_A4BV PC-3-Luc2 cancer cell line human CVCL_A4BV CL:0000010 Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Lys139Argfs*31 (c.414delC) (413delC); ClinVar=VCV000133281; Zygosity=Homozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression); Transfected with: UniProtKB; P33967; B.cereus Bsr Population: Caucasian; Derived from metastatic site: Bone. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~16 hours (ATCC=CRL-1435-LUC2) 41410209 CVCL_A4BY HL-60-Luc2 cancer cell line human CVCL_A4BY CL:0000010 Sequence variation: Gene deletion; HGNC; 11998; TP53; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg80Ter (c.238C>T) (p.Pro94Leu, c.281C>T); ClinVar=VCV000009409; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Peripheral blood. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~19 hours (ATCC=CCL-240-LUC2) 41410210 CVCL_A4BX SW480-Luc2 cancer cell line human CVCL_A4BX CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Colon. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~55 hours (ATCC=CCL-228-LUC2) 41410211 CVCL_A4BZ HCT-15-Luc2 cancer cell line human CVCL_A4BZ CL:0000010 Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg727Met (c.2180G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Lys993Asn (c.2979G>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ile1417Leufs*2 (c.4248delC); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg2166Ter (c.6496C>T); ClinVar=VCV000438883; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; c.68-1G>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Tyr30Ter (c.90C>A); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Cys1200Terfs (c.3599_3600delGT) (3827delGT); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 1101; BRCA2; Simple; p.Asn1784Hisfs*7 (c.5350_5351delAA); ClinVar=VCV000037959; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 16627; CHEK2; Simple; p.Arg145Trp (c.433C>T); ClinVar=VCV000005592; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Asp549Asn (c.1645G>A); ClinVar=VCV000375900; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; c.1101-2A>C; ClinVar=VCV000635383; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression). Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~34 hours (ATCC=CCL-225-LUC2) 41410212 CVCL_A4BM 4T1-Luc2 [ATCC] cancer cell line house mouse CVCL_A4BM CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; Derived from sampling site: Mammary gland; Breed/subspecies: BALB/cfC3H. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: 12.3 hours (ATCC=CRL-2539-LUC2) 41410213 CVCL_A4BL TF-1 IDH2 p.R140Q-Luc2 cancer cell line human CVCL_A4BL CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 5383; IDH2; Simple_edited; p.Arg140Gln (c.419G>A); ClinVar=VCV000014716; Zygosity=Homozygous; Note=By CRISPR/Cas9 (ATCC); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~30 hours (ATCC=CRL-2003IG-LUC2) 41410214 CVCL_A4BN EL4-Luc2 [ATCC] cancer cell line house mouse CVCL_A4BN CL:0000010 Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Transformant: 7,12-dimethyltetraphene (DMBA(ChEBI; CHEBI:59032); Derived from sampling site: Cell type=T-cell; Breed/subspecies: C57BL/6N. Unspecified Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~19 hours (ATCC=TIB-39-LUC2) 41410215 CVCL_A4BQ LNCaP clone FGC-Luc2 cancer cell line human CVCL_A4BQ CL:0000010 Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line); Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from metastatic site: Left supraclavicular lymph node. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: 40.8 hours (ATCC=CRL-1740-LUC2) 41410216 CVCL_A4BP TF-1-Luc2 cancer cell line human CVCL_A4BP CL:0000010 Sequence variation: Gene fusion; HGNC; 15868; ABHD12 + HGNC; 1537; CBFA2T3; Name(s)=CBFA2T3-ABHD12 (from parent cell line); Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Pro (c.182A>C); ClinVar=VCV000280409; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ile251Thrfs*94 (c.752delT); Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Japanese; Derived from sampling site: Bone marrow. Male Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~19 hours (ATCC=CRL-2003-LUC2) 41410217 CVCL_A4BS A-431-Luc2 cancer cell line human CVCL_A4BS CL:0000010 Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (from parent cell line); Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Derived from sampling site: Skin; epidermis. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~22 hours (ATCC=CRL-1555-LUC2) 41410218 CVCL_A4BR AGS-Luc2 cancer cell line human CVCL_A4BR CL:0000010 Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Gly34Glu (c.101G>A); ClinVar=VCV000017584; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu453Lys (c.1357G>A); ClinVar=VCV000376470; Zygosity=Heterozygous (from parent cell line); Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Ala (c.1634A>C); ClinVar=VCV000013659; Zygosity=Heterozygous (from parent cell line); Transfected with: UniProtKB; P08659; Firefly luciferase (with optimized codon usage for mammalian expression) Population: Caucasian; Derived from sampling site: Stomach. Female Characteristics: Stably expresses firefly luciferase under the control of the human EF-1 alpha promoter Doubling time: ~24 hours (ATCC=CRL-1739-LUC2) 41410219 CVCL_A4AD CML-iPSCs Pt2-No.4 induced pluripotent stem cell human CVCL_A4AD CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410220 CVCL_A4AC CML-iPSCs Pt2-No.3 induced pluripotent stem cell human CVCL_A4AC CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410221 CVCL_A4AF CML-iPSCs Pt2-No.8 induced pluripotent stem cell human CVCL_A4AF CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410222 CVCL_A4AE CML-iPSCs Pt2-No.6 induced pluripotent stem cell human CVCL_A4AE CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410223 CVCL_A4AH DF-1 O/E-ST3T2 spontaneously immortalized cell line CVCL_A4AH CL:0000010 Transfected with: UniProtKB; Q11200; Chicken ST3GAL1; Transfected with: UniProtKB; F1NY88; Chicken TMPRSS2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Virology: Allows efficient propagation of influenza virus in the absence of exogenous trypsin (PubMed=33413322) Group: Bird cell line 41410224 CVCL_A4AG DF-1 O/E-ST3 spontaneously immortalized cell line CVCL_A4AG CL:0000010 Transfected with: UniProtKB; Q11200; Chicken ST3GAL1; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 41410225 CVCL_A4AJ DF-1 O/E-T4 spontaneously immortalized cell line CVCL_A4AJ CL:0000010 Transfected with: UniProtKB; F1N9M8; Chicken TMPRSS4; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 41410226 CVCL_A4AI DF-1 O/E-T2 spontaneously immortalized cell line CVCL_A4AI CL:0000010 Transfected with: UniProtKB; F1NY88; Chicken TMPRSS2; Transfected with: UniProtKB; P13249; S.alboniger pac (PuroR) Derived from sampling site: Cell type=Fibroblast; Breed/subspecies: East Lansing Line 0 (ELL-0). Unspecified Group: Bird cell line 41410227 CVCL_A4AB CML-iPSCs Pt2-No.2 induced pluripotent stem cell human CVCL_A4AB CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410228 CVCL_A4AA CML-iPSCs Pt2-No.1 induced pluripotent stem cell human CVCL_A4AA CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410229 CVCL_A3ZV CML-iPSCs Pt1-No.10 induced pluripotent stem cell human CVCL_A3ZV CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410230 CVCL_A3ZU CML-iPSCs Pt1-No.9 induced pluripotent stem cell human CVCL_A3ZU CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410231 CVCL_A3ZX CML-iPSCs Pt1-No.12 induced pluripotent stem cell human CVCL_A3ZX CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410232 CVCL_A3ZW CML-iPSCs Pt1-No.11 induced pluripotent stem cell human CVCL_A3ZW CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410233 CVCL_A3ZZ CML-iPSCs Pt1-No.14 induced pluripotent stem cell human CVCL_A3ZZ CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410234 CVCL_A3ZY CML-iPSCs Pt1-No.13 induced pluripotent stem cell human CVCL_A3ZY CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410235 CVCL_A3ZN CML-iPSCs Pt1-No.3 induced pluripotent stem cell human CVCL_A3ZN CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410236 CVCL_A3ZM ZZUi026-A induced pluripotent stem cell human CVCL_A3ZM From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7106; ATXN3; Repeat_expansion; c.892CAG[80]; Zygosity=Heterozygous (PubMed=34087977) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410237 CVCL_A3ZP CML-iPSCs Pt1-No.4 induced pluripotent stem cell human CVCL_A3ZP CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410238 CVCL_A3ZR CML-iPSCs Pt1-No.6 induced pluripotent stem cell human CVCL_A3ZR CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410239 CVCL_A3ZQ CML-iPSCs Pt1-No.5 induced pluripotent stem cell human CVCL_A3ZQ CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410240 CVCL_A3ZT CML-iPSCs Pt1-No.8 induced pluripotent stem cell human CVCL_A3ZT CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410241 CVCL_A3ZS CML-iPSCs Pt1-No.7 induced pluripotent stem cell human CVCL_A3ZS CL:0000010 Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (PubMed=29429960) Derived from sampling site: Bone marrow. Male 41410242 CVCL_A3ZF ZZUSAHi003-A induced pluripotent stem cell human CVCL_A3ZF From: Zhengzhou University Second Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 3603; FBN1; Simple; p.Cys980Tyr (c.2939G>A); Zygosity=Heterozygous (PubMed=33450697) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Female 41410243 CVCL_A3ZE FJMA0001i-HCM induced pluripotent stem cell human CVCL_A3ZE From: Fujian Academy of Medical Sciences; Fuzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 7551; MYBPC3; Simple; p.Cys1124Leufs*25 (c.3369_3370insC); Zygosity=Heterozygous (PubMed=33388705) Population: Chinese; Han; Derived from sampling site: Peripheral blood. Male 41410244 CVCL_A3ZH ZZUi020-A induced pluripotent stem cell human CVCL_A3ZH From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 53924; NOTCH2NLC; Simple; c.-164GGC[(66_517)]; ClinVar=VCV000691867; Zygosity=Heterozygous; Note=51 GGC repeats (PubMed=33626493) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41410245 CVCL_A3ZG ZZUi019-A induced pluripotent stem cell human CVCL_A3ZG From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Population: Chinese; Han; Derived from sampling site: Leg; skin Cell type=Fibroblast.. Male 41410246 CVCL_A3ZJ ZZUi022-A induced pluripotent stem cell human CVCL_A3ZJ From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 30500; PRRT2; Simple; p.Gln179Ter (c.535C>T); ClinVar=VCV001352762; Zygosity=Heterozygous (PubMed=33550051) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410247 CVCL_A3ZI ZZUi021-A induced pluripotent stem cell human CVCL_A3ZI From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 6239; KCND3; Simple; p.Thr377Met (c.1130C>T); ClinVar=VCV000626319; Zygosity=Heterozygous (PubMed=34087979) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Male 41410248 CVCL_A3ZL ZZUi024-A induced pluripotent stem cell human CVCL_A3ZL From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China CL:0000010 Sequence variation: Mutation; HGNC; 620; APP; Simple; p.Val717Ile (c.2149G>A); ClinVar=VCV000018088; Zygosity=Heterozygous (PubMed=33652304) Population: Chinese; Han; Derived from sampling site: Skin Cell type=Fibroblast.. Female 41410249 CVCL_A3ZK ZZUi023-A induced pluripotent stem cell human CVCL_A3ZK From: Zhengzhou University First Affiliated Hospital; Zhengzhou; China. CL:0000010 8655619 F344-Tg(UBC-EGFP)F455Rrrc-ES4011/Rrrc embryonic stem cell Norway rat These cells are homozygous for the EGFP gene which is inserted on Chromosome 5 Rat Resource and Research Center CL:0000010 Embryonic stem cell line made from F344-Tg(UBC-EGFP)F455Rrrc carrying an EGFP transgene with a ubiquitin C promoter and the woodchuck hepatitis virus posttranscriptional regulatory element (WRE) has germ-line transmission; used for making targeted mutations Cryopreserved Male This cell line has been used to produce chimeric offspring and it has been shown to have germ-line transmission. This ES cell line has ubiquitous EGFP expression. This ES cell line has a normal male karyotype. Yes 8655621 SD-Tg(GFP)2BalRrrc-ES1/Rrrc embryonic stem cell Norway rat Rat Resource and Research Center CL:0000010 This ES cell line was made from blastocyst produced from the mating of a wild type Sprague Dawley female with a SD-Tg(GFP)2BalRrrc (RRRC Stock # 0065) male. The transgene carried by the RRRC:0065 male consists of an EGFP gene under the control of the Ubiquitin C promoter. The transgene is integrated into a single loci on Chromosome 14. has germ-line transmission; used for making targeted mutations Cryopreserved Male This cell line has produced chimeric offspring and been shown to have germ-line transmission. This ES cell line has ubiquitous EGFP expression. This ES cell line has a normal male karyotype. Yes 8655624 DA/OlaHsd-ES2/Qly embryonic stem cell Norway rat Rat Resource and Research Center CL:0000010 Embryonic stem cell line made from DA/OlaHsd embryos has germ-line transmission; used for making targeted mutations Cryopreserved Female This ES cell line has a normal female karyotype and has been shown to have germline transmission Yes 8655626 F344/NHsd-ES6/Qly embryonic stem cell Norway rat Rat Resource and Research Center CL:0000010 Embryonic stem cell line made from F344/NHsd embryos used for making targeted mutations Cryopreserved Female This is a F344 female cell line with a normal karyotype. Unknown 8655628 DA/OlaHsd-ES11/Qly embryonic stem cell Norway rat Rat Resource and Research Center CL:0000010 Embryonic stem cell line made from DA/OlaHsd embryos used for making targeted mutations Cryopreserved Male Unknown 8655630 DA/OlaHsd-ES8/Qly embryonic stem cell Norway rat Rat Resource and Research Center CL:0000010 Embryonic stem cell line made from DA/OlaHsd embryos has germ-line transmission; used for making targeted mutations Cryopreserved Male This ES cell line has a normal male karyotype and has been shown to have germline transmission Yes